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Background: Malignant pleural mesothelioma (MPM) incidence 
is increasing and has no known cure. Non randomised studies 
suggest that video assisted thoracoscopic (VAT) pleurectomy is 
effective in controlling pleural effusion and may be associated with 
increased survival compared to talc pleurodesis.
Methods: A multicentre randomised controlled trial of VAT pleu-
rectomy versus talc pleurodesis was undertaken for patients > 
18 years with any sub-type confirmed or suspected MPM with a 
pleural effusion who were fit enough to undergo VAT pleurectomy. 
Exclusion criteria included previous pleurodesis by any approach. 
Previous malignancy was permitted if there was no evidence of 
active disease and MPM had been confirmed. Participants were 
risk stratified using a modified EORTC prognostic scoring system. 
Talc pleurodesis was performed via tube thoracostomy or by pou-
drage at thoracoscopy. VAT pleurectomy involved partial parietal 
pleurectomy and decortication of the visceral pleura, where ap-
propriate, to achieve lung re-expansion. A total of 196 patients was 
required to show a survival difference at 1 year of 59% (VAT pleu-
rectomy) versus 37% (talc pleurodesis). Ethical approval was gran-
ted by Huntingdon, Cambridge (UK) Research Ethics committee: 
H02/809; ISRCTN: 34321019; ClinicalTrials.gov NCT00821860. 
Results: Between 2003 and 2012, 196 patients (120 confirmed, 76 
suspected) were randomised across 9 UK centres. 21 cases sus-
pected MPM were subsequently found not to have MPM and ex-
cluded (pre-planned in protocol), leaving 87 VAT pleurectomy and 
88 talc pleurodesis for the main analysis. Baseline characteristics 
were similar between the two groups; overall mean age 69 years, 
86% men and 75% had known asbestos exposure. Eighty four per 
cent showed epithelioid disease, 78% were IMIG stage 3/4 and 
49% were high risk as per EORTC criteria. The allocated procedure 
was completed for 73 (83%) talc and 78 (90%) VAT pleurectomy 
patients. 
One year survival rates (primary outcome measure) were 57% for 
the talc group and 52% in the pleurectomy group (hazard ratio 
1.03 (95% CI: 0.76, 1.42), p=0.83). 
Of the secondary outcome measures, pleural effusion was cont-
rolled in 37% of talc and 59% pleurectomy patients at one month 
(p=0.008) and in 57% of talc and 76% pleurectomy patients at 6 
months (p=0.04). At 9 and 12 months control of pleural effusion 
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PL03.01 LUNG CANCER PROBABILITY IN SUBJECTS 
WITH CT-DETECTED PULMONARY NODULES
Nanda Horeweg1, Joost Van Rosmalen2, Marjolein Heuvelmans3, 
Carlijn M. Van Der Aalst4, Rozemarijn Vliegenthart3, Ernst T. 
Scholten5, Kevin Ten Haaf4, Kristiaan Nackaerts6, Jan-Willem 
Lammers7, Harry J.M. Groen8, Carla Weenink9, Erik Thunnissen10, 
Peter Van Ooijen3, Pim A. De Jongh11, Truuske De Bock12, Willem 
Mali11, Harry J. De Koning4, Matthijs Oudkerk3
1Public Health / Pulmonology, Erasmus Mc/Netherlands, 2Biostatistics, 
Erasmus Mc/Netherlands, 3Radiology, UMC Groningen/Netherlands, 
4Public Health, Erasmus Mc/Netherlands, 5Radiology, Kennemer Gast-
huis/Netherlands, 6Pulmonology, UZ Gasthuisberg/Belgium, 7Pulmono-
logy, Umc Utrecht/Netherlands, 8Pulmonology, UMC Groningen/Nether-
lands, 9Pulmonology, Kennemer Gasthuis/Netherlands, 10Pathology, 
Vumc/Netherlands, 11Radiology, Umc Utrecht/Netherlands, 12Epidemio-
logy, UMC Groningen/Netherlands
Background: The main challenge in computed tomography (CT) 
screening for lung cancer is the high prevalence of pulmonary no-
dules and the relatively low incidence of lung cancer. Thresholds 
for nodule size and growth rate, which determine which nodules 
require additional diagnostic procedures, should be based on the 
lung cancer probability of the individual.
Methods: Diameter, volume and volume-doubling time (VDT) of 
9,681 non-calcified nodules detected by CT screening in 7,155 
subjects were used to quantify lung cancer probability. Complete 
coverage on all lung cancer diagnoses was obtained by linkages 
with the national cancer registry. The nodule management algo-
rithm recommended by the ACCP was evaluated and an improved 
algorithm, based on lung cancer probability, was proposed.
Results: Lung cancer probability was low in subjects with a nodule 
volume <100mm³ (≤0.7%) or maximum transverse diameter <5mm 
(≤0.6%) Moreover, probability in these subjects was not signifi-
cantly different from that in subjects without nodules (0.4%). Lung 
cancer probability was 0.9-5.8% for nodules with a volume 100-
300mm³ or a diameter 5-10mm; the VDT further stratified the pro-
bability: 0.0-0.9% for VDTs>600days, 4.0% for VDTs 400-600days 
and 6.7-25.0% for VDTs<400days. Lung cancer probability was 
high for participants with nodule volumes ≥300mm³ (8.9-26.1%) or 
diameters ≥10mm (11.1-26.2%), even with long VDTs. Finally, raising 
the thresholds for nodule size recommended by the ACCP for an 
indeterminate result from 4mm to 5mm and for a positive result 
from 8mm to 10mm, would yield fewer follow-up CT examinations 
(from 29.8% to 22.2%) and fewer additional diagnostic procedures 
(from 8.9% to 5.3%) while maintaining the sensitivity at 94.2%.
Conclusion: Small nodules (volume <100mm³ or diameter <5mm) 
are not predictive for lung cancer. Immediate diagnostic evaluation 
is necessary for subjects with large nodules (volume ≥300mm³ or 
diameter ≥10mm) and only for subjects with nodules of intermedia-
te size is VDT assessment advocated.
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a 400 mg/m2 loading dose on Day 1 followed by weekly doses of 
250 mg/m2. All pts were to receive 2 cycles of consolidation CT. 
This is the initial report of survival outcome based on cetux. The 
trial was designed for 450 evaluable patients with 80% power and 
a 1-sided alpha of 0.0125 to detect a 29% reduction in OS failure 
for each comparison (RT and cetux). 
Results: 544 pts were accrued, and 419 and 465 are eligible for 
RT and cetux analyses. Median follow up is 18.7 months. Cetux 
delivery was acceptable in both the concurrent and consolidati-
on phases. Therapy related ≥Grade 3 non-hematologic toxicity 
was higher in the cetux group; 70.5% vs 50.7% (p<.0001). Grade 
4 and 5 events were 35.8% and 28.2%, respectively. Median sur-
vival was 23.1 vs 23.5 months, & 18-month OS rates were 60.8% 
vs 60.2% on the cetux vs non-cetux arms, respectively (p=0.484, 
HR=0.99), which crossed a protocol-specified futility boundary for 
early reporting. As previously reported, median survival times and 
18-month OS rates for SD and HD arms were 28.7 vs 19.5 months, 
and 66.9% vs 53.9% respectively (p=0.0007, HR=1.56). There was 
no significant interaction between RT dose and the use of cetux. 
The OS rates for the 4 arms of this trial are shown in Table. An H-
score analysis, a measure EFGR positivity, is forthcoming. 
Table: Overall Survival Rates with 95% CI (pts accrued while all 4 
arms were open) 
Time 60 Gy 74 Gy 
60 Gy + 
Cetux 
74 Gy + 
Cetux 
12m 
78.4% (68.9, 
85.4) 
62.6% (51.7, 
71.6) 
80.0% (70.8, 
86.6) 
74.7% (64.9, 
82.2) 
18m 
67.9% (57.6, 
76.2) 
52.3% (41.5, 
62.0) 
67.1% (56.8, 
75.5) 
58.0% (47.6, 
67.1) 
Conclusion: In pts receiving CRT for Stage III NSCLC, 74 Gy is not 
superior to and may be worse than 60 Gy in terms of OS. Cetux 
provides no survival benefit in the setting of CRT for Stage III NS-
CLC.
Keyword: RTOG0617, cetuximab, Stage III
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was similar between groups. Median hospital stay was longer 
in pleurectomy patients (8 days (range 1-31) vs. 6 (range 1-15), 
p<0.001) and this group had significantly more complications, pre-
dominantly prolonged air leak (26% vs. 8%, p=0.009). 
Based on patients with complete data there was a significant bene-
fit in EQ5D quality of life at 6 months (mean difference 0.08 (95%CI 
0.003,0.16), p=0.042) and 12 months (mean difference 0.19 (95%CI 
0.05,0.32), p=0.006) in favour of the pleurectomy group. Adjusting 
for bias due to missing data prior to death reduced the difference 
in 12 month EQ5D to 0.09 (95%CI -0.04,0.22), p=0.16. 
Conclusion: MesoVATS showed that VAT pleurectomy significantly 
improved control of pleural effusion versus talc pleurodesis and 
improved quality of life. However, overall survival was not increa-
sed and the pleurectomy group experienced more complications. 
Subgroup analyses will investigate which patients benefit most 
from which intervention. 
Funded by the BUPA Foundation 
Keywords: malignant pleural mesothelioma, Randomised Cont-
rolled Trial, Talc pleurodesis, Video assisted thoracoscopic surgery
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Background: The two primary objectives of RTOG 0617 were 
to compare the overall survival(OS) differences of 1) standard-
dose(SD)(60Gy) versus high-dose(HD)(74Gy) radiotherapy (RT) with 
concurrent chemotherapy(CT); and 2) the addition of cetux to stan-
dard CRT. Cetux is a monoclonal Ab targeting EGFR with activity 
when combined with CT in metastatic NSCLC and head and neck 
cancer (HNC), and with RT in locally advanced HNC.
Methods: This Phase III Intergroup trial randomized pts in a 2 x 
2 factorial design. Concurrent CRT included weekly paclitaxel(45 
mg/m2) & carboplatin(AUC=2). Pts randomized to cetux received 
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PL02.2 DARK MATTER: DEFINING ONCOGENIC DRIVERS 
IN THE EPIGENOME
Charles M. Rudin
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Abstract: The single most important advance in the approach to 
lung cancer treatment in the past decade has been the iterative 
identification and targeting of subsets of lung cancer defined by 
distinct oncogenic driver mutations. This has changed the way we 
think about these diseases, and is accelerating the development of 
driver-targeted therapies that are improving multiple measures of 
clinical outcome, most dramatically documented by waterfall plots 
of tumor response, for patients with advanced lung cancer. Despite 
the clinically meaningful benefits provided by selective inhibition 
of mutated oncogenic drivers, however, none of these treatments 
have changed the fundamental incurability of metastatic lung can-
cer. Hence the impetus for this series of talks: we have markedly 
improved the short-term prognosis for select subsets of our pati-
ents, but the survival curves even for these subsets go to ground. 
This observation, entirely consistent with the clinical experience of 
targeted inhibitor development in other malignancies, has promp-
ted focused research in a number of directions, including inhibiting 
secondary mutations and escape pathways implicated in acquired 
resistance, priming the immune system to effectively respond 
to advanced cancer, and defining and targeting non-mutational 
(epigenetic) mechanisms contributing to oncogenesis and disease 
persistence. Epigenetics refers to the somatically heritable diffe-
rences in gene expression not attributable to intrinsic alterations 
in the primary sequence of DNA. In general, the cells that compri-
se an individual have identical genomes, but have many entirely 
different epigenomes that dictate tissue specificity and cellular 
function. The past decade has seen remarkable expansion of our 
understanding of how epigenetic control influences the patterns of 
gene expression, how these controls can be manipulated, and how 
such manipulation can influence cell fate. These emerging insights 
have clear translational implications for therapeutic targeting epi-
genetic abnormalities in cancer. Cancers of all types demonstrate 
extensive and biologically significant changes in the epigenetic 
code; these changes collectively can be termed the “cancer epi-
genome.” Clonally heritable alterations in the cancer epigenome 
include important oncogenic drivers, entirely analogous to somatic 
mutations in the cancer genome. One nice example demonstrating 
the complementary nature of genetic and epigenetic alterations in 
cancer has emerged from The Cancer Genome Atlas sequencing 
efforts in lung cancer, revealing key tumor suppressors affected by 
mutational inactivation or epigenetic silencing in non-overlapping 
sets of cases. There is a key difference between genetic and epi-
genetic changes in cancer-causing genes. Mutation is in general 
irreversible, while epigenetic changes are not: these could be 
reversed with appropriately directed therapy. This plasticity may 
represent both an opportunity and a limitation for epigenetic 
therapy approaches. The existence of intermediate states of gene 
silencing or activation can further complicate identification of epi-
genetically dysregulated “driver” and “passenger” genes in can-
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Background: Detecting and targeting the oncogenic drivers EGFR 
and ALK have transformed the care of patients with lung adenocar-
cinomas. The LCMC was established to use multiplexed assays 
to test tumors for alterations in 10 genes and provide the results 
to clinicians to select treatments and clinical trials matched to the 
driver detected.
Methods: Fourteen LCMC sites enrolled patients with metastatic 
lung adenocarcinomas and tested their tumors in CLIA laboratories 
for activating mutations in 10 oncogenic driver genes.
Results: Tumors were tested from 1,007 patients for at least one 
gene and 733 for all 10 genes. An oncogenic driver was found in 
466 (64%) of fully-genotyped cases. Among these 733 tumors, dri-
vers found were: KRAS 182 (25%), sensitizing EGFR 122 (17%), ALK 
rearrangements 57 (8%), “other” EGFR 29 (4%), two genes 24 (3%), 
HER2 19 (3%), BRAF 16 (2%), PIK3CA 6 (1%), MET amplification 5 
(1%), NRAS 5 (1%), MEK1 1 (<1%), AKT1 0. For cases with any geno-
typing, we used results to select a targeted therapy or trial in 275 
(28%). Among 938 patients with follow-up, the median survivals 
were 3.5 years for the 264 with an oncogenic driver treated with 
genotype-directed therapy, 2.4 years for the 318 with an oncoge-
nic driver with no genotype-directed therapy, and 2.1 years for the 
360 with no driver identified (p<0.0001).
Conclusion: Individuals with lung cancers with oncogenic drivers 
receiving a corresponding targeted agent lived longer than similar 
patients who did not. An actionable driver was detected in 64% of 
tumors from patients with lung adenocarcinomas; more than one 
was present in 3%. Multiplexed testing aided physicians in choo-
sing therapies and targeted trials in 28% of patients. This paradigm 
for care and research will expand as genotyping becomes more 
efficient with Next-Gen platforms, additional drivers are identified 
(i.e.ROS1 and RET), and more targeted drugs become available in 
the pharmacy and through clinical trials. Supported by HSS NIH 
NCI 1RC2CA148394-01. Trial Registered with Clinicaltrials.gov: 
NCT01014286.
Keywords: targeted therapies, Adenocarcinoma, oncogenes, ge-
notyping
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PL02.3 TUMOUR HETEROGENEITY AS AN OBSTACLE TO 
CURE
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Abstract: Despite advances in cancer genomics, most advanced 
solid tumors remain incurable and drug resistance is almost ine-
vitable. Two important lessons have emerged, which may provi-
de an explanation for difficulties that have been encountered in 
improving cancer survival outcomes. First, each tumor contains 
an individual assortment of multiple genomic aberrations, few 
of which are shared between patients with the same histopatho-
logical tumor subtype. Second, evidence suggests that these 
anomalies appear to vary within individual tumors, both spatially 
and temporally during the disease course, indicating substantial 
intratumor heterogeneity. Branched evolutionary growth and in-
tratumor heterogeneity results in coexisting cancer cell subclones 
with variegated genotypes and phenotypes that may be regionally 
separated within the same tumor and alter in dominance over 
time. Variegated phenotypes, resulting from intratumoral genetic 
heterogeneity and the emergence of new subclones at relapse, are 
likely to have important implications for developing novel targeted 
therapies and for preventing the emergence of drug resistance. 
Intratumor heterogeneity and sampling bias, resulting from single 
biopsy-driven biomarker discovery and validation approaches, 
may also contribute to the recently reported failures in implemen-
tation of robust biomarkers in the clinical setting. In this talk, the 
two fundamental principles of Darwinian Evolution, diversity and 
selection, will be discussed in relation to achieving better cancer 
survival outcomes.
Keywords: Intratumor heterogeneity, Genome instability, Persona-
lised cancer medicine, drug resistance
cer. I will review our recent progress in epigenetic profiling of small 
cell lung cancer. The development of epigenetically targeted anti-
cancer drugs has lagged behind the recent explosive expansion 
of mutant kinase inhibitors. In part, this may be because many key 
components of epigenetic dysregulation in cancer are only now 
being described. Currently available epigenetically targeted drugs 
include the DNA methyltransferase inhibitors azacitidine and deci-
tabine and the histone deacetylase inhibitors romidepsin and vor-
inostat; a much larger portfolio of both of these classes of drugs, 
particularly the HDAC inhibitors, are now in development. These 
classes of drugs both induce broad changes in gene expression. 
Our experience in combining azacitidine with the HDAC inhibitor 
entinostat in patients with advanced lung cancer will be discussed 
in another presentation at this meeting. An additional develop-
ment with translational implications for drug development that has 
emerged from recent genomic sequencing efforts is the recogniti-
on that virtually all tumors harbor mutations in critical regulators of 
the epigenome. Novel agents targeting other epigenetic factors, 
including multiple chromatin modifiers, are now in development. 
Bromodomain inhibitors targeting the BET family proteins may be 
of particular interest in blocking activation of MYC target genes, of 
central relevance in small cell lung cancer. If cancer-specific epi-
genetic alterations were just an alternative to mutation in heritably 
affecting specific oncogenic drivers, one might not expect epige-
netically directed therapy to lead to durable responses. However, 
several preclinical observations that suggest that effective epige-
netic therapy could have very different, and potentially comple-
mentary, effects. One set of observations, first noted by the Settle-
man laboratory, suggests a strategy to convert excellent responses 
to targeted therapy to durable responses. These investigators de-
fine drug-tolerant “persisters” among driver-oncogene dependent 
tumor cells treated with supratherapeutic doses of tyrosine kinase 
inhibitors – these persisters are clonogenic but are dependent on 
a particular histone demethylase (KDM5A) and can be eliminated 
by exposure to any of multiple HDAC inhibitors. A second set of 
observations, from the Baylin laboratory and others, demonstrates 
that low dose exposure to demethylating agents alone, below the 
level of substantial cytotoxicity, can alter the long-term clonogenic 
and tumorigenic potential of cancer cells. A final set of observa-
tions concerns the extensive array of cancer-relevant pathways and 
processes that can be concomitantly affected by epigenetically 
targeted therapy; of particular note are multiple immunologically 
relevant pathways in both tumor cells and immunologic effectors. 
Induced re-expression of silenced tumor antigens together with 
stimulation of immune response pathways may enhance tumor 
susceptibility to immunotherapy. These recent observations define 
clinically testable hypotheses using currently available investigatio-
nal agents that could affect the long-term survival of patients with 
lung cancer.
Keyword: epigenetics
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PL04.4 BIOMARKER-DRIVEN PROGRAMS FOR LUNG 
CANCER SCREENING
Pierre Massion
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Abstract: The purpose of this presentation is to define a potential 
role for biomarkers 1) in the risk assessment of lung cancer among 
individuals considered for screening and 2) in the diagnostic evalu-
ation of screening detected lung nodules. We will distinguish ty-
pes of biomarkers design for the screening of lung cancer and their 
desired performance characteristics. We will describe current front 
runner candidates biomarkers and discuss how one could envision 
using those in the clinic. Suggested reading: The state of molecu-
lar biomarkers for the early detection of lung cancer. Hassanein M, 
Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. 
Cancer Prev Res (Phila). 2012 Aug;5(8):992-1006.
Keywords: performance, biomarker, screening, Design
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PL04.1 RISK REDUCTION BY STOPPING SMOKING
Valerie Beral1, Kirstin Pirie1, Richard Peto2
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2Clinical Trial Service Unit & Epidemiological Studies Unit (ctsu), Uni-
versity Of Oxford/United Kingdom
Abstract: Smoking is the most important cause of lung cancer and 
of death and morbidity from a wide range of causes. In most of 
Europe, North America and Australia recent results show that two-
thirds of all deaths among male and female smokers in their 50s, 
60s and 70s are caused by smoking. Smokers lose at least 10 years 
of lifespan. 
It takes decades for the full effects of smoking to emerge in a 
population. The hazards of smoking have been well described in 
men, but only recently have sufficiently large numbers of women 
in western countries been smoking for long enough for the full 
effects to be evident. For example, in the Million Women Study, a 
prospective study of 1.3 million UK women, lung cancer death ra-
tes in smokers were 20 times higher than in never smoker. Even in 
women who smoked fewer than 10 cigarettes per day, lung cancer 
rates were increased 10 fold, whereas among women who smoked 
about 25 cigarettes per day the risk was increased almost 40 fold. 
Risks were greater the younger women were when they started 
smoking.
In western countries women began smoking in large numbers 
more than 50 years ago, and it is only now that results show clearly 
that when women smoke as much as men their risk of lung cancer 
and other conditions are similar. In Asia the full effects of smoking 
are still not evident, since large proportions of the population smo-
king began only a few decades ago.
Stopping smoking substantially reduces the risks of lung cancer 
and of other conditions that would have occurred with continued 
smoking. Stopping at any age is beneficial. In the Million Women 
Study stopping at age 40 years was associated with a 3 fold incre-
ase in lung cancer, thus avoiding about 90% of the 20-fold excess 
mortality from lung cancer caused by continued smoking. Stop-
ping smoking at around age 30 avoided about 97% of the excess 
risk of lung cancer. Similar findings have been reported from the 
USA and elsewhere.
The avoidance of most of the excess risk of lung cancer and other 
adverse effects of continuing smoking by quitting before about 
age 40 years has major public health implications. It is estimated 
that during the 20th century smoking caused about 100 million 
deaths worldwide, but that it will cause ten times as many - 1000 
million deaths - in the 21st century if current smoking patterns 
continue. If current smoking patterns continue almost all the 
smoking-related excess lung cancers and deaths in the next 50 or 
so years will occur in people who are already smoking. Much of the 
predicted epidemic of smoking-related deaths in the next 50 could 
be avoided if people who now smoke stopped, preferably before 
age 40.
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Abstract: Introduction Lung cancer is a major health problem 
with no improvement in survival over the last decades. At time 
of diagnosis, lung cancer is often already in advanced stage, 
with 5-year survival of no more than 15%. Currently, several lung 
cancer screening trials investigating whether early detection 
of lung cancer in high-risk individuals will reduce lung cancer 
mortality are ongoing. In 2011, the National Lung Screening Trial 
(NLST), was the first and to date only reporting a 20% decrease 
in lung cancer mortality when three rounds of annual low-dose 
computed tomography (CT) were compared with three annual 
rounds of chest X-ray screening. A major challenge, however, is 
the high rate of positive test results reported by the NLST (24.2%). 
No less than 96.2% of these comprised false-positive test results, 
causing unnecessary patient anxiety, radiation exposure and cost. 
The Dutch-Belgian lung cancer screening trial (Dutch acronym: 
NELSON study) was launched in September 2003. The NELSON 
study is an ongoing multicentre randomized controlled multi-
detector low-dose CT lung cancer screening trial. The primary 
object is to investigate whether chest CT screening in year 1, 2, 
4 and 6.5 will decrease lung cancer mortality by at least 25% in 
high-risk (ex-)smokers between 50 and 75 years of age compared 
to a control group receiving no screening. The NELSON study is 
the first lung cancer screening trial in which nodule management 
is based on nodule volume, instead of transverse cross-sectional 
nodule diameter for new nodules, and nodule growth in terms of 
volume doubling time (VDT) for existing ones. In this presentation, 
different aspects of nodule management in the NELSON 
study will be discussed. Volume detection thresholds Sensitive 
pulmonary nodule detection is crucial not to miss any lung cancer 
in a screening setting. The sensitivity of nodule detection was 
investigated by scanning a Lungman phantom according to the 
standard NELSON protocol. Nodules of five different volumes 
(range 14–905mm3) were randomly positioned in the phantom. 
A sensitivity of 100% was found for nodules with a volume equal 
to or larger than 65mm3 (5mm), and a sensitivity of 60–80% was 
found for solid nodules with a volume of 14mm3 (3mm). Since the 
lung cancer probability of lung nodules smaller than 50mm3 or 
4mm is neglectable, the sensitivity of nodule detection using the 
NELSON protocol is sufficient for accurate detection of malignant 
lung nodules. Measurement reproducibility For accurate decision 
making in serial CT studies, nodule measurement reproducibility is 
essential. A sub-study of the NELSON trial showed a difference in 
repeatability among three reconstruction settings, demonstrating 
that the use of consistent reconstruction parameters is important. 
Volume measurements of pulmonary nodules obtained at 1mm 
section thickness combined with a soft kernel were found to be 
most repeatable. Another sub-study showed that variability on 
volume measurements is related to nodule size, morphology and 
location. Besides image reproducibility, interobserver variability 
in performing semi-automated volume measurements is of major 
importance in the classification of lung nodules. Gietema et al. 
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Abstract: Although EGFR mutations and fusions involving ALK and 
ROS1 are targetable by currently approved agents, these altera-
tions are present in less than a fifth of patients with non-squamous 
NSCLC. Treatment options for the majority of patients remain lar-
gely empirical. The urgent need to develop therapies capable of 
targeting cancers without these alterations can only occur with a 
better understanding of the molecular biology and cytogenetic al-
terations. Recently, the lung cancer mutation consortium reported 
longer survival in patients with adenocarcinoma who underwent 
multiplexed genomic testing for the detection of alterations in 10 
genes, and subsequently received matched targeted treatments. 
[Johnson et al J Clin Oncol 31, 2013 (suppl; abstr 8019)]. A total of 
1,007 patients were screened for at-least one genetic alteration, 
and an actionable alteration that led to the use of targeted thera-
pies was detected in 28% of these patients. The median survival in 
these patients was 3.5 years, while patients whose tumors did not 
harbor actionable alterations had a median survival of 2.1 years. It 
would be reasonable to assume that adapting NGS technologies, 
which allow comprehensive screening of the entire genome at 
a higher resolution, will result in improved outcomes in patients 
whose tumors do not harbor targetable mutations identifiable by 
commercially available assays. NGS has allowed a better charac-
terization of lung cancer, with the identification of novel mutations 
and copy number alterations. Preliminary results from TCGA 
demonstrated that a significant percentage of patients with lung 
cancer harbor a targetable abnormality. It is still possible that ad-
ditional less common mutations or alterations will be discovered 
once the sequencing of 1000 lung cancer samples is completed 
by TCGA. The next challenge is the development of novel drugs 
based on specific targetable abnormalities. Although this strategy 
may require extensive evaluation and multiple trials targeting dis-
tinct molecular subtypes of tumors, this departure from the empi-
rical treatment of lung cancer, probably represents the best hope 
towards achieving meaningful progress.
Keywords: small cell lung cancer, Clinical challenge, MANAGE-
MENT
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Abstract: In patients receiving radiation for a diversity of diagno-
ses (e.g. Hodgkin’s Disease, breast cancer, seminoma), multiple 
studies demonstrate that incidental irradiation of the heart can 
increase the cardiac morbidity and mortality. While there is limited 
data in patients irradiated for lung cancer, RT-induced heart di-
sease is likely clinically important and care should be taken to mini-
mize incidental cardiac irradiation. Breast Cancer: Dose-response 
and evolution of techniques: In patients irradiated for breast can-
cer, there is a fairly well-defined dose/volume response for radia-
tion-induced cardiac injury. The radiation techniques used to treat 
patients with breast cancer have evolved over the last several de-
cades with a corresponding marked reduction in incidental cardiac 
doses (and corresponding decreased cardiac risks). For example, it 
has been estimated that mean heart doses were in the range of 10-
15 Gy with anterior photon fields (directed to the internal mamma-
ry nodes), ≈5 Gy with tangents and medial IMN electrons, 1-2 Gy 
with partly-wide tangents, and <1 Gy with conformal cardiac blo-
cking and breath hold. The cardiac implications for patients with 
breast cancer can be large. In some older studies the detrimental 
cardiac effects of radiation totally off-set the improvements in can-
cer-specific survival provided by RT. More modern radiation tech-
niques clearly reduce the cardiac exposure and appear to reduce 
the frequency or RT-induced heart disease. However, the follow-up 
duration in the studies utilizing these modern techniques is not as 
long as are the follow-up durations in the studies using the older 
techniques. Thus, the long-term safety of “modern” RT can still be 
questioned. Timing of RT-associated heart injury in patients irra-
diated for breast cancer: In a classic meta-analysis (Cuzick; Recent 
Results Cancer Research 111:108-129, 1988; and JCO 12:452, 1994), 
post-mastectomy RT was associated with a reduction in overall 
survival at follow-up times >15 years post-RT. This observation 
helped fuel the traditional belief (recently being challenged) is that 
RT-induced cardiac injury is manifest at only extended follow-up 
intervals. This led our group and others to look for more short-
term subclinical surrogates for RT-induced cardiac injury. Summary 
of our prospective study: We prospectively assessed RT-induced 
changes in regional myocardial perfusion in patients being treated 
for left-sided breast cancer using modern CT-based techniques. 
We noted a volume-dependent new perfusion abnormalities 6-24 
months post-RT. These perfusion defects largely persist up to 6 
years post-RT. The distribution of the perfusion defects follows 
the path of the tangential radiation field, and not the territory of a 
coronary artery, and thus represent microvasculature (rather than 
named coronary artery) injury. In patients with greater than 5% of 
the left ventricle within the tangential field, the incidence of new 
perfusion abnormalities si >50%. The functional consequences of 
these perfusion defects are uncertain. At short follow-up times, 
they are associated with a slightly increased rate of regional wall 
motion abnormalities. These wall motion abnormalities, however, 
do not always persist long-term. There are minimal, if any chan-
ges in ejection fraction noted in patients with perfusion defects. 
However, in patients with "severe“ perfusion defects (scored by 
found that interobserver correlation was very high (r=0.99) in 
small-to-intermediate size (15-500mm3) nodules. Volume criteria 
for nodule stratification For solid nodules, and solid components 
of part-solid nodules, volume was calculated by 3-dimensional 
volumetric computer assessment, using LungCare software 
(version Somaris/5:VA70C-W; Siemens Medical Solutions). The 
final screen result was based on the nodule with largest volume 
or fasted growth. In the NELSON study, nodules were classified 
as negative if volume was <50mm3 (4.6mm diameter if the nodule 
would have been perfectly spherical), leading to an invitation 
for the regular next-round CT, as positive if nodule volume was 
>500mm3 (>9.8mm diameter), leading to direct referral to a 
pulmonologist for further workup, and as indeterminate in case 
of volume of 50-500mm3. Indeterminate nodules underwent a 
6-week to 3-month follow-up low-dose CT for growth assessment. 
Volumetric growth assessment of pulmonary nodules After a 
nodule has been selected by a radiologist, the LungCare software 
automatically calculates nodule volume. Information is saved in the 
NELSON Management System (NMS), which calculates the growth 
in case of a pre-existing nodule. Growth is defined as a change 
in volume of ≥25% between two subsequent scans according to 
the formula: Percentage volume change (%) = (V2-V1)/V1)*100 V2 
= volume at last CT, and V1 = volume at previous examination. 
Determination of the volume-doubling time For solid nodules, 
or solid components of partial-solid nodules with PVC≥25%, the 
VDT is semi-automatically calculated by the NMS according to 
the formula: VDT (days) = (ln(2)*Δt)/(ln(V2/V1)) The VDT is used to 
distinguish between positive screens (VDT<400days), requiring 
additional diagnostic procedures, indeterminate screens (VDT 
400-600days), requiring an extra follow-up CT 12 months after the 
regular round CT and negative screens (VDT>600days). Using this 
two-step approach of volume and growth assessment, 2.6% of 
NELSON baseline screens were positive, and compared to other 
screening trials, a higher proportion (34.6% at baseline) were true-
positive. The NELSON study reported a baseline screen sensitivity 
of 94.6% and a negative predictive value of 99.9%. Comparison 
between volumetric and diameter assessment of pulmonary 
nodules For determining pulmonary nodule size, the use of volume 
measurements has been found to be more reliable than diameter 
measurements. In the previously mentioned phantom study, 
measurements of the manually measured maximal transverse 
diameter and semi-automated measurements of diameter and 
nodule volume were compared with actual properties. In both 
methods, diameter and volume of the spherical nodules were 
significantly underestimated. In diameter evaluation, the overall 
underestimation for solid nodules was about 10% using the 
manual method, compared with less than 4% using the semi-
automated method. In volumetry, the overall underestimation 
for solid nodules was about 25% (translates into 8% diameter 
underestimation) using the manual method, compared with less 
than 8% (translates into 2.5% diameter underestimation) using the 
semi-automated method. It is important to keep in mind that a 
small change in diameter already corresponds to a considerably 
higher change in volume. Thus, in lung cancer screening we 
suggest nodule measurements by semi-automated volumetry 
should be used. Differences between volume and diameter 
based nodule management protocol in terms of early lung cancer 
detection, morbidity, mortality, radiation exposure and costs 
remain to be demonstrated.
Keyword: lung cancer screening, volumetry, CT
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Abstract: Introduction The improved survival in locally advanced 
non-small cell lung cancer (NSCLC) patients treated with con-
current chemo-radiation (CCRT) comes at a price of increased 
esophagus toxicity. Acute esophagus toxicity (AET) occurs within 
3 months after CCRT and late esophagus toxicity (LET) consists of 
symptoms persisting or occurring >3 months after treatment. AET 
is treated with dietary changes, proton pump inhibitors, analge-
sics, promotility agents, intravenous fluids, and/or nasogastric- or 
gastrostomy tube insertion. Patients who develop stenosis, perfo-
ration or fistula are categorized as severe LET (grade 3-5). Patients 
with stenosis are treated by dilatation. Some patients will develop 
a fistula, which can be treated with intraluminal stenting. However 
the prognosis for patients with a fistula is grim. Estimation of the 
probability and severity of radiation esophagitis after CCRT treat-
ment is crucial. This allows the individual prescription of tumor 
doses. Several prediction models have been reported to estimate 
the risk of AET based on the planned dose distributions. Currently 
used models to predict acute esophageal toxicity (AET) in lung 
cancer patients after Intensity Modulated Radiotherapy (IMRT) and 
concurrent chemotherapy were derived from patients treated with 
3D-conformal-radiotherapy (3DCRT). These models first reduce 
the dose-volume histograms to a single parameter like the volume 
of esophagus receiving more than a certain threshold dose (Vx). 
In a large multi-Institutional study on 1082 patients treated with 
3DCRT, or IMRT concurrent with chemotherapy, the high-dose vo-
lumes were the most important predictors for radiation esophagitis 
[ref 1]. The V60 emerged as the best predictor for both moderate 
and severe esophagus toxicity. A low-risk subgroup was identified 
with a very low V60 of <0.07%, an intermediate-risk subgroup with 
a V60 of 0.07%-16.99%, and a high-risk subgroup with a V60 of 
≥17%. Severe LET seriously affects the patients’ quality of life or 
even leads to death. For LET predicting models are lacking. With 
improved survival in patients treated with CCRT, it is important and 
feasible to analyze LET. This abstract is a summary from a series of 
studies conducted at NKI on esophagus toxicity in a large NSCLC 
patient cohort. The patients were all treated with hypofractionated 
radiotherapy, 66 Gy in 24 fractions, and concurrent daily low dose 
cisplatin. The following items were investigated:  
1) Comparison of AET incidence in patients treated with 3DCRT 
and CCRT to sequential chemoradiation and RT only.¨ 2) Compare 
incidence of AET with 3DCRT to IMRT. 3) Analysis of prognostic 
factors for AET using IMRT. 4) Correlation of radiotherapy dose to 
the oesophagus wall and AET by means of post-RT 18FDG-PET 
scans acquired after CCRT.  
5) Relations between severe LET and the clinical and dosimetric 
variables. Material and methods The dose-effect relation of AET 
(185 patients) [ref 3] and LET ≥grade 3 (171 patients) [ref 6] and 
dose-volume parameters of the esophagus after hypofractiona-
ted IMRT (66 Gy/24 fractions) and concurrent low dose cisplatin 
were investigated. The dose distributions were first converted to 
Normalized Total Doses to account for fractionation effects with 
an α/β-ratio of 10 Gy (AET) or 3 Gy (LET). Equivalent Uniform Dose 
(EUD) to the esophagus and the volume percentage receiving 
more than x Gy (Vx) were evaluated by Lyman-Kutcher-Burman 
model. The association between AET and severe LET (grade ≥3 
RTOG/EORTC) was tested through Cox-proportional-hazards mo-
del Clinical parameters, onset and recovery times were analyzed 
as well. Results Acute Esophagus Toxicity -For NSCLC patients 
treated with 3DCRT and concurrent chemotherapy, the incidence 
of AET grade ≥ 2 was 27% and significantly higher compared to 
patients treated with sequential chemoradiation or radiotherapy 
only regimens [ref 2]. -The AET incidences were not significantly 
different between 3DCRT based and IMRT based CCRT patients. 
In order to illustrate the differences between 3DCRT and IMRT we 
show the Vx (α/β-ratio=10) in steps of 5 Gy derived from the AET 
study by Kwint et al, and also for 36 CCRT patients treated in the 
EORTC 08972 trial. From Figure 1 it can be appreciated that with 
the summed rest score, SRS), there is suggestion that there might 
be a more meaningful reduction in ejection fraction (Marks 63:214, 
2005, Lind IJROBP 55:914, 2003, Prosnitz Cancer, 110:1840, 2007). 
The clinical relevance of these perfusion defects remains uncer-
tain. Perfusion defects may represent a reduction in collateral cir-
culation making the patient more prone to develop ischemia when 
they (at a much later date) develop coronary artery disease. There-
fore, care should be taken to minimize cardiac exposure for pati-
ents receiving left-sided RT. The use of conformal blocking (heart 
block), respiratory gating, and electron beam techniques are often 
useful to reduce cardiac exposure. Reconsideration of the timing 
of RT-induced cardiac injury in light of the recent analysis by Darby 
et al (NEJM 368:11, 2013): Darby’s report suggests that RT-induced 
cardiac injury in patients with breast cancer is clinically manifest 
relatively soon post-RT (i.e. within a few years), and that the cu-
mulative risk increases continually up to 20 years post-RT. This 
suggests that the microvascular changes seen in our study (noted 
above) might have a clinical relevance in the short post-RT interval. 
Therefore, an alternative interpretation Cuzick et al (cited above) is 
that there is a clinically-meaningful increase in cardiac mortality in 
the 1-15 year post-RT interval, but that this is offset by the reduc-
tion in breast-cancer specific mortality during that time (resulting 
in a no net change in overall survival vs. the control group). At 
>15 years, the excess cardiac events exceed the cumulative anti-
cancer effects, leading to the reduced overall survival noted. Lung 
Cancer: In patients early-stage lung cancer (N0-1), post-operative 
RT (PORT) is associated with an excess mortality within 0-5 years 
(Lancet 352:257; ’98). While the causes of the excess deaths are 
not noted in most studies, at least one study has noted increased 
cardiac deaths in this setting (Dautzenberg Cancer 86:265, ‘99). 
Two more-recent studies of “smaller field-PORT” (Mayer: Chest 
112:954, ’97; Tradella Radio Oncol 62:11, 2002) demonstrate an 
improvement in overall survival with PORT, again suggesting 
that there is a delicate balance between RT-induced reductions 
in cancer-specific death and normal tissue-induced injury (Miles, 
IJROBP 68:1047, ‘07), totally analogous to the situation with breast 
cancer (Marks & Prosnitz, IJROBP 48:625, 2000). With definitive RT 
for lung cancer, RT-induced cardiac injury is not often reported. 
However, this might be under-reported as the symptoms of cardiac 
dysfunction (e.g. dyspnea) might be ascribed to lung disease. Bet-
ter sparing of the heart during definitive RT for lung cancer is likely 
to improve the overall outcome. There are no clear dose/volume 
limits for the heart in patients with lung cancer (Gagliardi IJROBP 
2010). Non-axial beams are often useful in reducing cardiac expo-
sure, especially in patients with lower lobe tumors (Quaranta Jour-
nal Applied Clinical Medical Physics, 11:3010, 2010). Some portions 
of the heart might be particularly important in the genesis of RT-
induced cardiac injury (e.g. pericardium, coronary arteries, left ven-
tricle) and thus sophisticated techniques to redistribute incidental 
cardiac dose might be helpful. Dr Marks’s department receives 
grants from, or has relations with, from Elekta, Siemens, Accuray, 
Morphormics. Supported by NIH CA069579.
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Abstract: Treatment toxicity not only reduces quality of life, but 
also may be life threatening (and can be unidentified) when it is 
severe. Radiation induced lung toxicity (RILT) is among the most 
important dose limiting toxicity in the treatment of lung cancer, 
particularly locally advanced non-small cell lung cancer (NSCLC) 
or small cell lung cancer (SCLC). The current standard of RT tech-
niques considers the whole lung as a uniform organ and uses 
the same dose limit for all patients with the assumption that all 
have a SAME sensitivity to radiation damage. However, patients 
with NSCLC frequently have a respiratory comorbidity such as 
chronic obstructive pulmonary disease (COPD) that results in he-
terogeneous function within different lung regions. Patients often 
respond remarkably differently to the same amount of radiation 
dose. Furthermore, the presence of the tumor itself often affects 
local vascular supply and ventilation, and changes function level. 
In this presentation, I will review the current functional imaging 
for lung and predictive biomarkers for RILT with an emphasis on 
recent advances regarding 1) ventilation/perfusion single photon 
emission tomography (V/Q SPECT) for treatment planning and RILT 
prediction, and 2) blood markers and its integration with physical 
and functional dosimetric factors for RILT prediction. Ultimately, we 
would like to generate Functional Imaging and Biophysical Model 
(FunBipM) to guide individualized treatment planning to minimize 
treatment toxicity 
 
V/Q SPECT is a commonly available technique in most hospitals to 
image the perfusion (Q) and ventilation (V) of the lung. It has been 
proposed that Q-SPECT images can be used to guide RT planning 
so that radiation is directed to the non-functional lung regions 1-4. 
It was known to us that the Q-SPECT-guided plans produced more 
favorable functional dose volume histograms (DfVHs) compared to 
IMRT the volume of esophagus receiving a dose from 5-40 Gy was 
significantly smaller, while at 70 Gy it was increased. Moreover, the 
LKB model based on the V50 was not significantly different bet-
ween IMRT and 3DCRT [ref 3]. -A total of 22% NSCLC patients de-
veloped AET toxicity ≥ grade 3 after IMRT to 66 Gy in 24 fractions 
and concurrent daily low dose cisplatin. The V50 was identified as 
most accurate predictor of grade ≥ 3 AET [ref 3]. -The median time 
to AET grade 3 was 30 days, with a median duration of >80 days. 
Higher grade of AET was also associated with a lower recovery 
rate [ref 4]. -Post-CCRT esophageal FDG uptake on 18FDG-PET is 
associated with AET grade. SUV predictability of grade 2-3 AET 
was significantly improved by using the derived relation between 
RT dose and PETpost [ref 5]. Results Late Esophagus Toxicity A 
total of 6% patients developed LET ≥ grade 3 at a median follow-
up of 33 months (95% CI 29~37) with a median overall survival of 
24 months (95% CI 16~32) [ref 6]. The median onset time was 5 
months (range 3~12). Patients with un-recovered AET had a signifi-
cantly (p<0.001) higher risk of developing severe LET, compared to 
patients without AET or with a recovered AET. In the EUD; n=0.03 
model, all severe LET patients had an NTD >70 Gy on the esopha-
gus. In the EUDn-LKB model, the fitted values and 95% confidence 
intervals were TD50=76.1 Gy (73.2~78.6), m=0.03 (0.02~0.06) and 
n=0.03 (0~0.08). In the Vx-LKB model, the fitted values and 95% 
CIs were Tx50=23.5% (16.4~46.6), m=0.44 (0.32~0.60) and x=76.7 
Gy (74.7~77.5). Conclusions In routine clinical practice it is possible 
to provide insight in the probability and severity of esophagus 
toxicity for each individual lung cancer patient treated with CCRT. 
Both the maximum grade and the recovery rate of AET were signi-
ficantly associated with severe LET. In clinical practice, NTD correc-
ted esophagus EUD<70 Gy could be a dose constraint to minimize 
severe LET. AET was not changed with the use of IMRT.  
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was positively associated with RILT 21. We also demonstrated that 
SNPs of TGFβ1 genes may be associated with overall risk of other 
organs’ toxicity, including esophagus or heart/pericardium 23. This 
finding is also very important because after limiting lung toxicity to 
less than certain level (such as 15-17%), increased dose to the most 
resistant tumors may increase toxicity of other organs. This is com-
plicated but should be taken into consideration. 
 
In summary, we may generate a FunBipM through the combination 
of pre- and during-RT V/Q functional dosimetric parameters and 
blood biomarker data to predict the risk of lung toxicity for each 
individual patient: i.e. using a FunBipM that integrates biologic 
markers into the existing dosimetry-based model. By identify-
ing high-risk patients, adjusting lung dose limit according to the 
threshold of tolerance, and applying the FunBipM to optimize radi-
ation planning for dose and dose arrangement, we may anticipate 
a significant reduction of the incidence of toxicity without compro-
mised tumor control.
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non-SPECT guided plans, with the fV20 and fV30 values reduced 
by an average of 13.6% ± 5.2% and 10.5% ± 5.8%, respectively 2. 
We have further demonstrated that 1) NSCLC often presents with 
defect regions on V/Q SPECT, some of which are from tumor com-
pression that improves with tumor shrinkage during- RT; 2) SPECT 
defect regions are more resistant to post-RT function reduction; 3) 
V/Q SPECT guided radiation therapy can reduce dose to functional 
lung without increasing doses to the total physical lung; 4) V/Q 
SPECT based DfVHs from during-RT may predict clinical significant 
RILT more accurately than anatomic CT lung based DVH. From 
treatment planning point of view, I will use example cases to de-
monstrate that we can avoid V/Q SPECT functional regions in pre- 
and during- RT to minimize damage to functional lung, particularly 
by the combined use of pre- and during-. V/Q SPECT adds lung 
ventilation mapping on top of the Q-SPECT, providing more in-
formation (including the mechanism for lung function defects and 
their potential for recovery). During-RT V/Q SPECT allows adapti-
ve-RT because lung function changes globally and locally during 
RT, largely due to RT-induced tumor volume reduction improving 
the vascular supply and ventilation5. The combination of pre- and 
during- V/Q SPECT can classify the lung into different functional 
regions and strategize to differentially prioritize certain regions, a 
technique our group developed to minimize lung damage. Additi-
onally, we can compute DfVHs from both pre- during- SPECT scans 
to predict post-treatment functional loss and clinically significant 
RILT. 
 
Patients with the same dosimetric parameters have shown very 
different levels of toxicity largely due to their biologically different 
intrinsic sensitivity to radiation damage 6. Many studies have been 
conducted to understand the correlation between pro-inflammato-
ry and pro-fibrogenic cytokines, including TGF-ß1, IL-1ß, IL-6, IL-8, 
and TNF-α and radiation-induced normal tissue injury 7. TGFß1, a 
fibrogenic and radiation-inducible cytokine, has been known to 
play a key role in this process. Animal studies demonstrated signi-
ficantly elevated TGFß1 mRNA and protein expression within type 
II pneumocytes and fibroblasts in radiation-sensitive mice after 
thorax radiation 8-11, which subsequently contributed to increased 
TGFß1 levels in circulation. The Duke University group reported 
that plasma TGFß1 levels at the end of radiation are correlated 
with the later onset of symptomatic RILT in patients treated with 
definitive radiation therapy 9,12,13. Though the result was not con-
sistently reproduced by others 14, possibly due to technique issues 
15, end-of-treatment TGFβ1 correlation nevertheless has limited 
value. We have demonstrated that TGFß1 elevation in the middle 
of treatment (2-4 weeks during-treatment) relative to pre-treatment 
is highly correlated with late-onset grade >2 RILT in NSCLC pati-
ents 16,17 . Most recently, we have demonstrated that combining 
baseline IL-8, during-treatment TGF-ß1, and mean lung dose into 
a single model yielded an improved predictive ability (P<.001) for 
RILT compared to either variable alone 16. The findings on base-
line and during-treatment markers are more important than end-
treatment markers, as they provide us an opportunity to adjust 
treatment accordingly. 
 
More importantly, an individual’s susceptibility to radiation nor-
mal tissue toxicity may be genetically determined, which can be 
measured pre-RT. Germ-line genetic variations, most often single 
nucleotide polymorphisms (SNPs), may play an important role in 
radiation damage pathogenesis. SNPs associated with molecules 
involved in radiation damage pathways, such as DNA double-
strand break repair (ATM, XRCC1) and inflammation (TGF β1 and 
cytokines) have been studied for their association with clinical toxi-
city 18,19. It was reported that SNPs in TGFβ1 and NOS3 were asso-
ciated with a lower risk for radiation pneumonitis 20,21 whereas SNPs 
in ATM, IL1A, IL8, TNFa, TNFRSF1B and MIF were associated with 
an increased risk of radiation pneumonitis 20,22. TGFβ1 rs1800470 
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there is limited data available regarding the effects of BI on NCF in 
patients with lung cancer. This is due to the lack of intensive NCF 
testing in lung cancer trials. Mechanisms of injury The pathophy-
siology of late radiotherapy injury is a dynamic and complex inter-
action between the vasculature and the parenchyma. The vascular 
hypothesis of radiation-induced injury describes a process of acce-
lerated atherosclerosis causing vascular insufficiency, resulting in a 
picture similar to small vessel disease seen with vascular dementia. 
For this reason there is interest in studying vascular dementia treat-
ments to prevent or reduce radiation-induced NCF decline. Glu-
tamate is the principle excitatory amino acid neurotransmitter in 
cortical and hippocampal neurons. One of the receptors activated 
by glutamate is the N-methyl-D-aspartate (NMDA) receptor, which 
is involved in learning and memory. Ischemia can induce excessi-
ve NMDA stimulation and lead to excitotoxicity, suggesting that 
agents that block pathologic stimulation of NMDA receptors may 
protect against further damage in patients with vascular dementia. 
Memantine, an NMDA receptor antagonist, has been shown to be 
neuroprotective in preclinical models. Additionally, two placebo-
controlled phase III trials found memantine to be well-tolerated 
and effective in treatment for vascular dementia. On these basis, 
RTOG launched a placebo-controlled, double-blind, randomized 
trial to evaluate the potential protective effect of memantine on 
NCF in patients receiving whole brain radiation (WBRT). The re-
sults of this study (RTOG 0614) were recently reported. Predispo-
sing factors It is the therapeutic ratio of benefits vs. risks that helps 
determine the advisability of a treatment such as BI. Clinical trials 
of prophylactic cranial irradiation (PCI) can enable us to develop 
strategies that can potentially increase the benefits and decrease 
the risks. Potential strategies that can increase the benefits of BI 
may require better ways of identifying a subgroup of patients with 
the highest risk of developing BM such as those with small cell 
lung cancer (SCLC), adenocarcinoma, young age, high volume of 
disease and predictive markers. These are the patients most likely 
to benefit from PCI. In order to develop strategies to decrease the 
risks, we must identify and understand those risks. Identifying a 
subgroup of patients with the highest risk of developing NCF toxi-
cities, such as older age or other patient factors such as hyperten-
sion and diabetes, may also improve the therapeutic ratio. Dose 
volume determinants Due to the concerns with NCF with WBRT, 
stereotactic radiosurgery (SRS) approaches are being actively stu-
died. Combined therapy (SRS+WBRT) for BM are favored based on 
Phase III findings that brain control with combined therapy is sig-
nificantly better than with SRS alone or WBRT alone. On the other 
hand, a phase III study found that the risk of neurocognitive deficit 
is doubled with the addition of WBRT to SRS. The published data 
demonstrate continued evolution of clinical trials and different 
management strategies are currently being evaluated in prospec-
tive clinical trials to minimize the likelihood of cognitive decline 
following BI. To reduce cognitive injury of conventional WBRT, 
several groups are exploring modified WBRT approaches, such 
as hippocampal-avoidance WBRT (HA-WBRT). In this approach, 
complex planning techniques are used to reduce dose to bilateral 
hippocampal structures while treating the rest of the brain. Hip-
pocampal-dependent functions of learning, memory, and spatial 
information processing seem to be preferentially affected by RT. 
It is argued that since <5% of BM occur within 5 mm of the hippo-
campus, reducing dose to the hippocampus is safe and feasible. 
The feasibility of this approach has been studied prospectively in 
a multi-Institutional setting by the RTOG study 0933. Clinical fea-
tures and diagnosis Publications on radiation-induced neurotoxi-
city have used different assessment methods, time to assessment, 
and definition of impairment, thus making it difficult to accurately 
assess the rate and magnitude of the NCF decline that can be 
expected. There is a paucity of data on neurocognitive impairment 
after BI, which has previously been assessed using various different 
neuropsychological tests, as well as different definitions of neuro-
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Abstract: Overview of acute and late toxicities of brain irradiation 
Acute side effects of brain irradiation (BI) include common effects 
such as scalp erythema, alopecia, and fatigue and less common 
effects such as otitis externa, impaired sense of taste, nausea, and 
headache. Early delayed and late side effects from BI may include 
hyperpigmentation of the scalp, alopecia, hearing loss, behavioral 
changes, somnolence syndrome, radiation necrosis and neuroco-
gnitive decline. Brain Metastases (BM) often have a devastating 
impact on neurocognitive function (NCF). BI has been shown to 
treat, prevent or delay the incidence of BM in lung cancer. Howe-
ver, it can also cause toxicity resulting in a decline in NCF. To date 
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E03.1 MAXIMISING THE BENEFIT OF CHEMOTHERAPY 
FOR ADVANCED NSCLC
Giuseppe Giaccone
Oncology, Georgetown University, Lombardi Comprehensive Cancer 
Center/United States Of America
Abstract: Chemotherapy is still standard treatment for the majo-
rity of patients with advanced NSCLC, who do not have specific 
molecular markers (i.e. EGF mutations, ALK translocations). Plati-
num based doublets remain standard treatment for most patients 
and the choice of regimen is based mainly on side effect profile. 
There is a preference for pemetrexed based therapies for patients 
with adenocarcinoma histologies, based on one randomized study. 
Benefit of chemotherapy can be extented by maintenance chemo-
therapy (pemetrexed), in terms of increased progression-free sur-
vival and overall survival. Maintenance with erlotinib has also been 
approved, although the largest effects are really seen in EGFR 
mutant patients. 
 
Very few chemotherapy doublet regimens have been improved 
by addition of a third agent, chemotherapy or biological. Beva-
cizumab was shown to increase response rate, progression-free 
survival as well as overall survival in one study where carboplatin-
paclitaxel was the backbone. Bevacizumab is continued as main-
tenance. Cetuximab improved survival in addition to cisplatin-
vinorelbine, and again cetuximab was continued after the end of 
chemotherapy. Unfortunately most of the other combinations of 
biologicals with chemotherapy have been disappointing. 
 
Novel agents with different mechanisms of action from the classi-
cal tyrosine kinase inhibitors might obtain better results (e.g. PD-1/
PD-L1 antibodies). Results of randomzied studies are awaited. The 
HSP-90 inhibitor gatenespib, in combination with docetaxel gave 
promising results in a relatively large randomized phase II study, 
and a phase III study is now underway.
Keywords: chemotherapy, maintenance, Overall Survival
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E03.3 OPTIMAL ADJUVANT CHEMOTHERAPY:  
SELECTION OF PATIENTS AND AGENTS
Karen Kelly
UC Davis Comprehensive Cancer Center/United States Of America
Abstract: Optimal adjuvant chemotherapy: selection of patients 
and agents Patients with early stage, resectable non-small cell 
lung cancer (NSCLC) have the best chance to be cured with 5 year 
survival rates ranging from 73% for patients with pathological 
stage IA disease to 24% for patients with pathological stage IIIA 
disease. However, the presence of micro-metastases will lead to 
cognitive impairment. It must be remembered that NCF is affected 
by a number of factors (i.e. BM volume, disease progression (intra 
and/or extra-cranial progression), chemotherapy, hormonotherapy, 
surgery, radiation, prior neurologic disease, medications, paraneo-
plastic effects, etc.) which should be considered when evaluating 
of the actual neurocognitive effect of treatments such as BI. In 
addition, a challenge that plagues most studies in patients with 
advanced cancers, is the decline in compliance with NCF testing 
over time. Nevertheless, many studies have been completed and 
will be presented. Prevention and treatment. Because treatment 
of NCF decline after radiation is limited, treatments ideally would 
be developed to prevent the detrimental cognitive effects of BI 
as discussed above. Determining the impact of BI on NCF would 
provide support for therapeutic decision making for an individual 
patient, for which we need to use sensitive cognitive assessments 
to elucidate the incidence, time course, intensity, domains of NCF 
changes following BI and their actual impact on patient quality of 
life (QOL). Selected References Sun A, et al. Phase III trial of pro-
phylactic cranial irradiation compared with observation in patients 
with locally advanced non-small-cell lung cancer: Neurocognitive 
and quality-of-life analysis. J Clin Oncol 2011;29:279-286. Chang 
EL, et al. Neurocognition in patients with brain metastases treated 
with radiosurgery or radiosurgery plus whole-brain irradiation: 
A randomised controlled trial. Lancet Oncol 2009;10:1037-1044. 
Wolfson AH, et al. Primary analysis of a phase III randomized trial 
radiation therapy oncology group (RTOG) 0212: Impact of different 
total doses and schedules of prophylactic cranial irradiation on 
chronic neurotoxicity and quality of life for patients with LD-SCLC. 
IJROBP 2011;81:77-84.
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the two groups (HR 0.83; 95% CI 0.64-1.08; P=0.12). No significant 
improvement in DFS was observed. In an unplanned subgroup 
analysis based on tumor size a survival advantage for paclitaxel 
and carboplatin was seen in patients who had tumors >4 cm (HR, 
0.69; 95% CI 0.48-0.99; P = .043). In support of this finding, a 
retrospective analysis of patients with stage IB disease on JBR 10 
was conducted according to tumor size of < or > 4 cms. Patients 
with smaller tumors did not benefit from adjuvant therapy while 
treated patients with tumors > 4 cm had a favorable 5 year OS rate 
of 79% compared to 59% for untreated patients (HR .66; 95% CI 
0.39-1.14; P=0.13). It is important to remember that in the 7th TNM 
staging system, patients with tumors of > 4 cm could be Stage IB, 
IIA or IIB. Chemotherapy regimen In the clinical trials described 
above vinorelbine plus cisplatin was the most commonly used 
regimen. In a subgroup analysis of LACE, adjuvant cisplatin plus 
vinorelbine improved survival at 5 years by 8.9% in the vinorelbine 
cohort and this outcome was superior to the “other” cohort. Today 
more modern regimens are frequently used based on their activity 
in advanced disease including cisplatin and gemcitabine, cisplatin 
and docetaxel and cisplatin and pemetrexed. In summary, adjuvant 
cisplatin based chemotherapy is the standard of care for patients 
with resectable Stage II-III NSCLC with a good performance status 
and should be considered for patients with tumor size > 4 cm. 
Current strategies to improve outcome of adjuvant chemotherapy 
focuses on the integration of targeted therapies, tumor vaccines 
and the identification of prognostic and predictive biomarkers.
Keywords: Non small cell lung cancer, adjuvant chemotherapy
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E03.4 LUNG CANCER IN WOMEN
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Abstract: At the beginning of 20th century only a few hundred 
cases of lung cancer were diagnosed annually, but the progressive 
huge spread of tobacco consumption caused a dramatic increase 
of the incidence of this disease among men and later on among 
female smokers. US data shows that the prevalence of smoking 
in American women peaked in 1965 at 33% and remained at that 
level throughout the 1970s, before beginning to slowly decrease in 
1980. In contrast, more than half of American men smoked before 
1965, but the prevalence dramatically decreased during the sub-
sequent 20 years. Currently, 18% of American women smoke com-
pared with 23% of men, reflecting the earlier and more marked 
decline in the prevalence of tobacco use in men. Nowadays, more 
women in United States die from lung cancer each year than from 
breast, ovarian and uterine cancer combined: lung cancer is the 
leading cause of cancer death with more than 110,000 new cases 
and more than 72,000 estimated deaths in 2013. In European 
countries there are more than 79,000 new cases of lung cancer in 
female sex per year and 82,000 is the estimated death number 
in 2013, that means 9,024 more than what was reported in 2009. 
Approximately 80% - 85% of lung cancers in women are caused by 
cigarette smoking. Wang et al. investigated the association of both 
active and passive smoking on lung cancer risk in a prospective 
cohort of more than 90,000 post-menopausal women: the results 
of the Women’s Health Initiative Observational Study (WHI-OS) 
have been presented at 2013 ASCO annual meeting and evi-
denced an higher lung cancer incidence, particularly small cell lung 
cancers and squamous lung cancers, in current smokers (Hazard 
the development of systemic relapse and death in the majority 
of patients. To improve survival of these patients adjuvant 
chemotherapy following complete tumor resection has been 
studied. Three phase III trials with cisplatin-based regimens and 
the LACE meta-analysis demonstrated increased cure rates by 
adjuvant chemotherapy and established adjuvant chemotherapy 
as the standard of care. Randomized Trials The first trial to 
demonstrate a survival advantage for adjuvant chemotherapy was 
the International Adjuvant Lung Cancer Trial Cooperative Group 
(IALT) study. This trial enrolled 1867 patients; 932 patients were 
randomized to receive chemotherapy (cisplatin plus etoposide, 
vinorelbine, vinblastine, or vindesine for 3-4 cycles) and 935 
patients were randomized to observation. The 5 year overall 
survival rate significantly favored the chemotherapy arm (Hazard 
Ratio [HR] 0.86; 95% CI 0.76-0.98; P <0.03). Disease free survival 
(DFS) was also superior in the treated arm (HR 0.83; 95% CI 0.74-
0.94; P=0.003). With longer follow up of 8 years, the HR for overall 
survival was not significant (HR 91; 95% CI 0.81-1.02; P=0.10) while 
the HR for DFS retained significance (HR 0.88; 95% CI 0.78-0.98; 
P=0.02). In 2005, the National Cancer Institute of Canada Cancer 
Treatment Group (NCIC CTG) reported the results of JBR10. 
Patients with completely resected stage IB or stage II NSCLC were 
randomized to receive cisplatin plus vinorelbine (242 patients) or 
observation (240 patients). An impressive overall survival benefit 
was observed for the treated group (HR 0.69; 95% CI 0.52-0.91; 
P=0.04) corresponding to an absolute survival improvement of 
15%. In a subgroup analysis, the survival benefit was restricted 
to patients with Stage II disease. An update of this study, with > 
9 years of follow up continued to show a survival benefit for the 
treated group with an absolute improvement in the 5 year overall 
survival (OS) rate of 11% (67% versus 56%, respectively) with a HR 
of .78; 95% CI 0.62-0.99; P=0.04 (11). Subsequently, the results 
from the ANITA trial (Adjuvant Navelbine International Trialist 
Association) solidify the role of adjuvant systemic treatment. 
A total of 840 patients with Stage IB, II, and IIIA NSCLC were 
randomized to cisplatin plus vinorelbine versus observation. The 
HR for death was significantly lower for the chemotherapy group 
(HR= 0.80, 95% CI 0.66-0.96; P=0.017). The 5 and 7 year overall 
survival was improved by 8.6% and 8.4% in the chemotherapy 
group, respectively. No benefit was seen in the subset of patients 
with Stage IB disease (HR 1.10; 95% CI 0.76-1.57; P=NS). To identify 
which patients might have the greatest benefit from adjuvant 
chemotherapy, the LACE (Lung Adjuvant Cisplatin Evaluation) 
meta-analysis was conducted. Individual patient data was collected 
and pooled from 4,584 patients in 5 trials (BLT, ALPI, IALT, JBR10 
and ANITA). The HR of death was 0.89; 95% CI 0.82-0.96; P=0.005, 
which corresponded to a 5-year absolute survival benefit of 5.4% 
with chemotherapy. This benefit varied with stage of disease and 
was not seen for stage IA patients. A positive chemotherapy effect 
was seen in patients with performance status (PS) 0-1 whereas 
chemotherapy was potentially harmful for patients with a PS of 
2. Other subgroups analyzed including age, sex, histology, type 
of surgical resection, planned radiation, dose of cisplatin or the 
second agent used did not affect overall or disease free survival. 
Elderly patients Since the majority of patients diagnosed with 
lung cancer are 70 years old or greater, an additional analysis 
of the LACE data set by age was conducted. Elderly patients 
(age > 70 years) accounted for 9% of the patients. Their HR of 
death was better with treatment at .90 (95% CI 0.74-1.16) and 
was similar to the HR of death for treated patients < 65 years 
old at .86 (95% CI 0.78-.94). Elderly patients achieved a survival 
benefit despite having received lower cisplatin doses and fewer 
number of chemotherapy cycles than their younger counterparts. 
Tumor size The Cancer and Leukemia Group B (CALGB) trial 9633 
evaluated four cycles of adjuvant paclitaxel and carboplatin versus 
observation in stage IB patients. With mature follow up of 74 
months, overall survival was not significantly different between 
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subgroups (HR 2.19; 95% CI, 1.05-4.55). All these findings provide 
multiple evidence for the specificities of lung cancer in women. 
The different expression of specific biomarkers, which could be 
targeted by therapy, will improve research towards personalized 
sex-based investigations, stimulating the development of further 
gender-based approaches in thoracic oncology.
Keyword: women, lung cancer, epidemiology, molecular biology
Ratio, HR 13.44, 95%, CI 10.80-16.75) and former smokers (HR 4.20, 
95% CI 3.48-5.08) compared to never smokers. In the same study, 
among never smoking women, passive exposure, as an adult at 
home for > 30 years, was associated with a trend of increased risk 
(HR 1.61, 95% CI 1.00-2.58) for lung cancer, confirming findings of 
previous prospective cohort studies. In recent times, an increased 
proportion of non-smoking female patients, with earlier age at 
diagnosis and a majority of adenocarcinoma has been observed, 
particularly in Asian countries. Prevalence of lung cancer in fema-
les without history of tobacco smoking is estimated to represent 
19% compared with 9% of male lung carcinoma in the United 
States. Freedman et al. reported, on a cohort of nearly 500,000 
individuals, aged from 50 to 71 years, a significant increase in the 
rate of lung cancer for women who did not smoke, compared with 
male non-smokers, whereas no increased risk was described in 
current and former female smokers compared with matched males. 
Hormonal status is one of the potential explanations for gender 
differences. Estrogens are involved in lung tumorigenesis and pro-
gesterone receptor expression has been described in non small 
cell lung cancers (NSCLC). Combination of estrogen and progeste-
rone works synergistically in vitro to promote vascular endothelial 
growth factor secretion increasing tumor-associated angiogenesis. 
Chlebowski et al. examined estrogen plus progestin (E+P) associa-
tion with lung cancer incidence and outcome evaluating more than 
30,000 postmenopausal women. Results have been presented at 
2013 ASCO annual meeting: in non users of E+P, lung cancer inci-
dence and deaths from lung cancer were significantly and substan-
tially greater in current smokers versus never smokers (p< 0.0001 
for both comparisons). In current smokers, lung cancer incidence 
and deaths from lung cancer were significantly and substantially 
greater in E+P users versus non-users (p=0.0021 and 0.0005, re-
spectively), nearly doubling a smoker’s already high risk of death 
from lung cancer. Conversely, the role of androgens remains unc-
lear. Harlos et al. evaluated more than 3,000 men with lung cancer 
evidencing that exposure to androgen deprivation therapy (ADT) 
is associated with significantly better survival when compared with 
no exposure. Patients exposed to ADT after their diagnosis were 
found to have a significantly better survival than those not expo-
sed (HR 0.36 p=0.0007). This effect was also seen in those who 
received ADT before and after diagnosis (HR 0.53 p<0.0001). With 
regard to specific gene alterations there are relevant differences 
in men and women. The most widely recognized is the epidermal 
growth factor receptor (EGFR) mutation, that is found at a much 
higher frequency in adenocarcinomas, women, Asians and never 
smokers. Mutations in HER2 gene, although much rarer, target 
the same subpopulations. Mutations in EGFR (and HER2) are mu-
tually exclusive of K-ras mutations: these are primarily observed 
in smokers and historically associated with male sex, but there 
are also publications demonstrating an higher frequency in wo-
men of “non-classical” type of K-ras mutations even if these data 
need further validations. The echinoderm microtubule associated 
protein-like 4-anaplastic lymphoma kinase (EML4-ALK) transloca-
tion has been evidenced to occur more frequently in young pati-
ents, light or never smokers, while no major differences have been 
clearly stated between genders. B-Raf (V600) is described in 2% of 
patients with lung adenocarcinoma in western countries, related 
with worse prognosis and it is noted more frequently in women. 
An analysis of the p53 mutation databases indicated that the 
different spectra of p53 mutational patterns among smoker and 
never smoker cancers were almost entirely a result of differences 
between lung cancers in women, whereas male tumours did not 
show significant differences. Finally, recent studies investigated the 
role of telomere shortening in lung cancer. Kim et al. hypothesized 
that relative telomere length may be associated with recurrence in 
early stage NSCLC after curative resection. Longer telomeres were 
significantly associated with higher risk of developing recurrence in 
female (HR 2.25; 95% CI, 1.02-4.96, P= 0.044) and adenocarcinoma 
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characteristics of MIA in more detail. Invasive adenocarcinomas 
are classified by predominant pattern after using comprehensive 
histologic subtyping with lepidic, acinar, papillary, micropapillary, 
and solid patterns. Among the subtypes, lepidic growth repre-
sents in situ growth or spreading of invasive adenocarcinoma and 
the region showing lepidic growth does not influence the patient’s 
outcome. Therefore, it is very important to report the percentage 
of the lepidic subtype in the invasive adenocarcinoma. In order to 
verify the utility of invasive adenocarcinoma classification, inter-
observer agreement (kappa value) of the diagnostic criteria was 
assessed (6). Eight Japanese pathologists used the 2011 IASLC 
classification to independently evaluate the histologic grade of 
122 adenocarcinoma cases resected in the National Cancer Center 
Hospital (Tokyo). The mean (±SD) value of the kappa statistic for 
the 2011 IASLC classification was 0.46±0.09 (range: 0.24 to 0.61) 
and the value was not enough for practical use. But, if we modified 
the classification into low grade (lepidic, acinar, and papillary) and 
high grade (solid and micropapillary), the mean (±SD) value rose to 
0.66±0.09 (range: 0.47 to 0.85) reaching the level of practical use 
(Figure). Therefore, the modified 2011 IASLC classification shows 
the clinical outcome of the invasive adenocarcinoma. References 
(1) Travis WD, Elisabeth B, Noguchi M, et al. International associa-
tion for the study of lung cancer/American thoracic society/Euro-
pean respiratory society international multidisciplinary classifica-
tion of lung adenocarcinoma. J Thoracic Oncol 6:244-285, 2011. (2) 
Noguchi M. Stepwise progression of pulmonary adenocarcinoma. 
Clinical and molecular implications. Cancer Metastasis Rev 29:15-
21, 2010. (3) Yatabe Y, Kosaka T, Takaashi T, et al. EGFR mutation 
is specific for terminal respiratory unit type adenocarcinoma. Am J 
Surg Pathol 29:633-9, 2005. (4) Noguchi M, Morikawa A, Kawasaki 
M, et al. Small adenocarcinoma of the lung. Histologic characte-
ristics and prognosis. Cancer 75:2844-2852, 1995. (5) Minami Y, 
Matsuno Y, Iijima T, et al. Prognistication of small-sized primary 
pulmonary adenocarcinomas by hitopathlogical and karyometric 
analyasis. Lung Cancer 48:339-348, 2005. (6) Nakazato Y, Maeshi-
ma AM, Ishikawa Y, et al. Interobserver agreement in the nuclear 
grading of primary pulmonary adenocarcinoma. J Thoracic Oncol 
8:736-743, 2013  
IASLC/ATS/ERS Classification of Lung Adenocarcinoma
Preinvasive lesions Atypical adenomatous hyperplasia (AAH) 
Adenocarcinoma in situ (<3cm formerly BAC) 
Minimally invasive adenocarcinoma (MIA) (<3cm lepidic predo-
minant tumor with <5mm invasion) 
Invasive adenocarcinoma Lepidic predominant Acinar predomi-
nant Papillary predominant Micropapillary predominant Solid 
predominant with mucin production 
Variants (Invasive mucinous ad., Collid, Fetal, Enteric
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E04.1 ADENOCARCINOMA
Masayuki Noguchi
Faculty Of Medicine, University Of Tsukuba/Japan
Abstract: In 2011, an international multidisciplinary classification of 
adenocarcinoma was published (2011 IASLC classification) (1) (Ta-
ble). Pathologists, oncologists, radiologists, and basic scientists in 
the field of lung cancer are involved in this project. The new con-
cepts of adenocarcinoma in situ (AIS) and minimally invasive ade-
nocarcinoma (MIA) in this classification are based on the multistep 
carcinogenesis of adenocarcinoma (2). Pulmonary adenocarcinoma 
develops to invasive adenocarcinoma through atypical adenoma-
tous hyperplasia (AAH), AIS, and MIA. The diagnostic criteria for 
AIS and MIA were first defined in this new classification. AAH is a 
localized proliferation of mildly to moderately atypical cells lining 
involved alveoli and, sometimes, respiratory bronchioles. AAH 
is usually less than 5 mm in diameter and lacks any underlying 
interstitial inflammation or fibrosis. Before, AAH was detected as 
incidental findings in the adjacent lung parenchyma in resected 
lung adenocarcinoma, but recently it is found by thin-slice CT 
scan examination and shows characteristic ground glass opacity 
(GGO), similar to AIS. AAH shows positivity for TTF-1 antigen and 
is a preinvasive lesion of peripheral-type adenocarcinoma, espe-
cially the terminal respiratory unit (TRU) type (3). Adenocarcinoma 
with pure lepidic growth is a special subtype, because it mimics 
AAH, which is a preinvasive form of adenocarcinoma and has an 
extremely favorable prognosis. Among the pure lepidic adenocar-
cinomas, “adenocarcinoma in situ” is defined as localized small (< 
3 cm) adenocarcinoma with growth restricted to neoplastic cells 
along preexisting alveolar structures (lepidic growth), lacking stro-
mal, vascular, or pleural invasion. Differential diagnosis between 
AAH and AIS is sometimes very difficult. AIS corresponds to type 
A and B adenocarcinoma according to the 1995 Noguchi classifi-
cation (4). AIS is usually nonmucinous but rarely may be mucinous. 
MIA is a small, solitary adenocarcinoma (< 3 cm), with a predomi-
nantly lepidic pattern and < 5 mm invasion in greatest dimension 
in any one focus. By definition, the invasive component is com-
posed of histological subtypes other than the lepidic pattern (i.e. 
acinar, papillary, micropapillary, and/or solid) or tumor cells infiltra-
ting myofibroblastic stroma (malignant stroma). MIA is excluded if 
the tumor invades lymphatics, blood vessels, or pleura, or contains 
tumor necrosis. If the tumor is larger than 2 cm, diagnosis should 
be done with caution, and the tumor needs to be extensively 
sampled, especially the solid component. On thin-slice CT exami-
nation, MIA reveals pure GGO or a partly solid appearance. MIA 
corresponds to type C’ adenocarcinoma according to the modified 
Noguchi classification (5). We believe that the 5-year survival of 
patients with localized resected MIA is more than 95%, but there 
are no actual data on the clinical outcome of MIA. In Japan, lea-
ding radiologists and pathologists have just started a joint project 
to clarify the natural history of MIA, supported by the Ministry of 
Health, Labor and Welfare. First, they are defining the radiological 
diagnostic criteria for MIA. Then, based on the criteria, they will 
follow up cases for more than 5 years. In the course of follow-up, 
the growing cases will be surgically resected and examined histo-
logically. Finally we will understand the radiological and biological 
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Abstract: Squamous cell carcinoma is one of the four common 
types of lung cancer, and is defined as a malignant epithelial tu-
mour showing evidence of squamous differentiation in the form 
of keratinisation, intercellular bridging or both. The main purpose 
of a pathological classification is to produce clinically relevant 
subgroups, in addition being reproducible, thorough, dynamic, 
and globally applicable, and this talk summarises the current WHO 
classification and potential new parameters. Current morpholo-
gical classification: Since the 1999 classification, the recognised 
variants have been being papillary, clear cell, small cell and basa-
loid. Pure primary basaloid carcinomas of the lung are rare and the 
current WHO (2004) classification classifies basaloid carcinomas as 
variants of large cell carcinoma when they lack evidence of squa-
mous differentiation. When squamous differentiation is present, 
they are classified as basaloid variants of squamous cell carcinoma. 
Basaloid morphology has been shown to carry a poorer prognosis 
than poorly differentiated squamous cell carcinomas for stage 
I and II disease. Papillary squamous cell carcinomas tend to be 
endobronchial and most are staged as T1N0 with a 5year survival 
of over 60 percent, which may be due to early presentation at this 
location rather than the architectural pattern itself. With regard to 
small cell and clear cell variants, the last decade has seen virtually 
no publications. Indeed, the primary reason for recognising these 
variants is to avoid misdiagnosis as metastases or other subtypes 
of lung carcinoma. Therefore, with the exception of the basaloid 
variant that appears to carry a worse prognosis, especially given 
small cell and clear cell variants are cytological parameters, con-
sideration should be given to their removal from the next WHO 
classification, as well as the papillary variant. Also, given the incre-
ased knowledge in relation to immunophenotyping, basaloid and 
basaloid variant of squamous cell carcinoma could potentially be 
collapsed into a single subgroup of squamous cell carcinoma. Po-
tential new morphological subgroups: The last decade has seen 
publications suggesting an architectural classification termed "al-
veolar filling“ pattern. One paper has shown 100% survival when 
this pattern is present, although the number of cases showing this 
as a pure pattern is very low, around 1-2%. A more recent paper 
has suggested that the percentage of alveolar filling (greater than 
70%) was significantly associated with a better prognosis, arguing 
that in tumours less than 30 mm in maximum diameter, a minimally 
invasive category might be appropriate. Tumours with this pre-
dominance would likely be sufficiently frequent (near 25%) to be 
clinically useful, and more data are required to support its inclu-
sion. Other histological parameters such as extent of background 
of lymphocytic infiltration and keratinisation do not seem to carry 
prognostic significance. Classification according to presentati-
on and/or aetiological factors: Publications in the last decade 
have suggested that the frequency of peripheral squamous cell 
carcinomas is increasing, with a greater number of stage 1 patients 
having peripheral presentation, although there was no difference 
in survival in N0 disease when compared to central tumours in one 
paper (Funai K et al Am J Surg Pathol 2003:27;978-984) . Indeed, 
survival was better in N1 disease in central presenting tumours. 
The alveolar pattern of growth was seen within the peripheral 
group only. However, unlike adenocarcinomas where those that 
present peripherally may be never-smokers, nearly all peripheral 
squamous carcinomas appear to be either current or ex-smokers. 
Keywords: atypical adenomatous hyperplasia (AAH), adenocar-
cinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), 
Prognosis
S18 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
gically resected cases since tumour definitions mandate a feature 
be excluded from or present in at least 10% of the whole lesion. 
Although features suggesting a large cell variant or sarcomatoid 
tumour may be recognised in a small biopsy or cytology sample, 
these diagnoses are inappropriate in such samples. Large cell 
carcinoma (LCC) is morphologically defined as comprising large 
undifferentiated tumour cells lacking any evidence of squamous, 
glandular or small cell carcinoma (SCLC). Epidemiologically these 
cases are no different from most other non-small cell carcinomas 
(NSCLC). They favour a more peripheral location in the lung and 
necrosis is common. Cells are generally large, with open nuclei, 
prominent nucleoli and abundant cytoplasm, but some cases show 
hyperchromatic, granular nuclei, inconspicuous nucleoli and less 
cytoplasm. In the classical case, the cells show no organisation, just 
sheets of cells with little intervening vascular stroma, but some ca-
ses show cellular stratification with more abundant fibrous stroma. 
Several variants of large cell carcinoma are described. 
• Large cell neuroendocrine carcinoma (LCNEC) additionally re-
quires demonstration of neuroendocrine differentiation, usually 
by immunohistochemistry. These are often large, necrotic tumours 
and share many epidemiological and molecular features with 
small cell lung carcinoma. Organoid morphology with trabeculae 
and rosettes are common. A significant proportion of LCNEC are 
combined with other tumour types in the same lesion, most often 
adenocarcinoma. These cases would more logically reside in a 
separate category with other NE tumours.
• The basaloid variant of LCC largely meets the above definition, 
but tends to have rather smaller cells, peripheral nuclear palisa-
ding around discrete nests/sheets of cells, frequent intercellular 
basement membrane material, like basaloid carcinomas at other 
sites. An infrequent and unusual form of small keratin pearl may be 
seen but basaloid carcinomas lack the larger cells with eosinophilic 
cytoplasm and intercellular bridges of squamous cell carcinomas 
(SCC). They share immunohistochemical features (p63, p40, CK5/6, 
desmocollin3) with SCC and could represent de-differentiated 
SCC. Defining basaloid carcinoma apart from SCC remains a cont-
roversial issue.
• Lymphoepithelioma-like lung carcinoma (LELC) comprises a syn-
cytium of large undifferentiated cells with indistinct cell borders 
and a heavy lymphoplasmacytic infiltrate. Commoner in East Asian 
countries, this tumour is still rare and is closely associated with EBV 
genome. Distinction from other poorly differentiated carcinomas 
with a heavy immune cell infiltrate may be impossible in the ab-
sence of evidence of EBV infection and the latter should, perhaps, 
be incorporated into the tumour definition.
• Clear cell carcinoma of the lung features large cells with clear 
cytoplasm. This histological feature is, however, seen in a range of 
other NSCLC and as such, serves little useful purpose, apart from 
awareness of potential confusion with metastatic renal cell carcino-
ma. This would be better used as a descriptor rather than defining 
a separate tumour category.
• Large cell carcinoma with rhabdoid phenotype is rather ill-defi-
ned and extremely rare. A few cases reports or small series reflect 
the heterogeneity of so-called cases with no clear definition. One 
common impression is that of an aggressive tumour but again, this 
terminology is better used as a descriptor rather than defining a 
separate subtype.
Emerging immunohistochemical and molecular data have questi-
oned the nature of large cell carcinoma and our current classifica-
tion. Many cases share a molecular and/or immunohistochemical 
phenotype with either squamous cell or adenocarcinoma, sug-
gesting that they should be classified by their molecular profile, 
The frequency of HPV being present in squamous cell carcinoma 
of the lung varies extensively in the literature. The same ‘high-
risk’ subtypes of HPV for cervical carcinoma are found in invasive 
bronchial carcinomas. However, although data from oropharyngeal 
squamous cell carcinomas suggest HPV infection is associated 
with better prognosis, data in the lung are conflicting. There is also 
likely synergism between smoking and infection as the preferred 
site of entry for HPV is at squamo-columnar junctions, and the 
presence or absence of HPV is unlikely to be recommended as a 
parameter for subclassification. Pre-invasive lesions: Squamous 
lesions arising in the airways have been regarded as progenitors 
of squamous carcinoma for decades and basal cell hyperplasia 
and squamous metaplasia also likely represent earlier phases in 
the development of squamous carcinomas. The current WHO/
IASLC classification tabulates methodology for such gradation, and 
the system is sufficiently reproducible for diagnostic usage. The 
sequence progresses from basal cell hyperplasia through squa-
mous metaplasia and squamous dysplasia to carcinoma-in-situ. 
Immunohistochemistry and small biopsies: The past decade has 
seen increasing usage of immunohistochemistry to refine the dia-
gnosis of non-small cell carcinoma, driven by the needs for more 
accurate subclassification in relation to chemotherapeutic agents. 
This is not part of the current (WHO 2004) classification, although 
is recommended for use in biopsies by the IASLC as well as the 
ATS and ERS in relation subclassifying biopsies hitherto called 
non-small cell carcinoma, not otherwise specified (NSCLC-NOS) 
(Travis et al. J. Thor. Oncol. 2011;6:244-85). Therefore, any biopsy 
with NSCLC showing keratinisation and/or intercellular bridges 
should be classified as squamous cell carcinoma and, in NSCLCs 
lacking these or other disciminating morphological features on 
biopsy, but showing immunohistochemical evidence of squamous 
differentiation (one or two of CK 5/6, P63, and P40 being the most 
commonly used antibodies for this purpose) should be classified as 
NSCLC, favouring squamous cell carcinoma on immunohistoche-
mistry. Similar investigation should also be considered in resected 
large cell undifferentiated carcinomas. Molecular subtypes: There 
is a vast literature on the carcinogenesis of squamous carcinoma, 
in particular preinvasive lesions. However none have yet become 
part of pathology classification. In relation to targeted therapy for 
invasive squamous cell carcinoma, data are still primarily related to 
clinical trials, with low frequencies of identification. Therefore, alt-
hough targets such as DDR2 show some promise, at present, there 
is insufficient data to warrant pathological classification of invasive 
squamous carcinoma in relation to specific genetic abnormalities. 
Conclusion: Unlike adenocarcinomas, there has not been much 
advance in the morphogical subtyping of squamous cell carcino-
ma. There has however been advance in immunophenotyping, 
especially in relation to NSCLC-NOS, and it is hoped that molecu-
lar classification may have a role to play in the next decade.
Keywords: basaloid, squamous cell carcinoma, Pathology, classifi-
cation 
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Abstract: Large cell and sarcomatoid carcinomas account for 
approximately 10% of all lung cancers. For all practical purposes, 
each of these diagnoses can only be made with accuracy in sur-
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tial fibrosis, or infections. 
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 
(DIPNECH) consists of widespread peripheral airway NE cell hyper-
plasia and/or multiple tumorlets. These patients are thought to re-
present a preinvasive lesion for carcinoid tumors because a subset 
of these patients has one or more carcinoid tumors.1 DIPNECH may 
present as multiple pulmonary nodules often mistaken for metasta-
tic cancer or as a form of interstitial lung disease with airway obst-
ruction. Histologically DIPNECH is characterized by prominent NE 
cell hyperplasia and tumorlets. Some patients also have carcinoid 
tumors. Tumorlets may cause airway narrowing and/or obliteration. 
The surrounding lung parenchyma is generally normal. 
 
 
CARCINOID TUMORS 
Carcinoid tumors most commonly show an organoid growth pat-
tern. The tumor cells show uniform cytologic features with a mode-
rate amount of eosinophilic cytoplasm and finely granular nuclear 
chromatin. AC are separated from TC by the presence of mitoses 
between 2 and 10 per 2mm2 area or the presence of necrosis. Ne-
crosis is usually in the form small punctate foci. Other histologic 
features such as pleomorphism, vascular invasion and increased 
cellularity are not as helpful in separating TC from AC. 
Chromogranin, CD56 and synaptophysin are the most helpful NE 
immunohistochemical markers. A clear role for Ki-67 in separating 
TC from AC is not established. However, a low proliferation rate 
(≤5%) is typically seen in TC compared to AC where it is usually 
between 5 and 20%. Ki-67 is most useful in addressing the prob-
lem of over diagnosis of a high grade tumor in carcinoid tumors 
where diagnostic criteria are obscured in small crushed biopsies. 
In this setting a high proliferation rate (>59%) will be found in the 
high grade LCNEC or SCLC where TC or AC show a much lower 
proliferation rate. 
 
 
LARGE CELL NEUROENDOCRINE CARCINOMA 
LCNEC is a high grade NE carcinoma with cytologic features of a 
non-small cell carcinoma. It was classified as a variant of large cell 
carcinoma in the 2004 WHO classification.1 
LCNEC are diagnosed according to the following criteria: 1) NE 
morphology with organoid nesting, palisading or rosette-like 
structures, 2) high mitotic rate greater than 10 mitoses per 2 mm2 
(average 60-80 mitoses per 2 mm2), 3) non-small cell cytologic 
features including large cell size, low nuclear/cytoplasmic ratio, 
nucleoli, or vesicular chromatin, and 4) NE differentiation by immu-
nohistochemistry with antibodies such as chromogranin, CD56 or 
synaptophysin or electron microscopy. 
The diagnosis of LCNEC is difficult to establish based on small 
biopsies or cytology. This is because the NE pattern is difficult to 
see morphologically in small tissue samples or cytology. Also NE 
differentiation can be difficult to demonstrate by immunohistoche-
mistry in small pieces of tissue. For these reasons the diagnosis of 
LCNEC requires a surgical lung biopsy.  
When a LCNEC has components of adenocarcinoma, squamous 
cell carcinoma, giant cell carcinoma and/or spindle cell carcinoma 
it is called combined LCNEC. The most common component is 
adenocarcinoma, but squamous cell, giant cell or spindle cell car-
cinoma can also occur. If the second component is SCLC the tumor 
becomes a combined SCLC and LCNEC. 
NE differentiation must be demonstrated by immunohistoche-
mistry or electron microscopy to diagnose LCNEC. NE immunohis-
tochemical markers are usually best performed as a panel of chro-
mogranin, CD56/NCAM, and synaptophysin. In 41-75% of cases, 
TTF-1 will be positive. The proliferation index by Ki-67 staining is 
very with staining of 50-100% of tumor cells . 
effectively deleting the LCC category. This approach has several 
problems including the following: (a) Not all cases can be so re-
classified as squamous cell or adenocarcinoma, (b) these immune/
molecular profiles are not specific for either diagnosis, and (c) the 
definition of these differentiated tumours is based on H&E mor-
phology, not immune/molecular findings. Further confusion stems 
from the inappropriate use of the term ‘large cell carcinoma’ in the 
small biopsy/cytology setting. Any sample containing large undif-
ferentiated cells lacking features of small cell carcinoma should be 
referred to as NSCLC, not otherwise specified (NOS) and not ‘large 
cell carcinoma’. Most of these cases, if resected, derived from dif-
ferentiated adeno- or squamous cell carcinomas. The legitimate, 
recommended use of IHC to predict tumour subtype in small sam-
ples is neither validated nor justified in resected tumours under 
the current classification. However, it may be useful to characterise 
resected LCC cases by immunophenotype since this may correlate 
with some targetable mutations but it should not lead to a major 
change in diagnosis. Mutations of EGFR or KRAS are rarer than in 
adenocarcinoma but correlate with TTF1 positivity. Sarcomatoid 
carcinomas show pleomorphic, spindle or giant cells comprising at 
least 10% of the tumour. Usually all three cell types are seen. They 
account for 3-4% of resected tumours and are usually large, invasi-
ve, necrotic tumours. They are clinically aggressive and frequently 
chemorefractory, justifying their separation in our classification. 
Most lesions also show differentiated squamous cell or adenocarci-
noma components. As for LCC, this diagnosis should not be made 
in the small biopsy/cytology setting but if these cell types are 
present in the sample they should be described in the report. Im-
munohistochemical and/or molecular studies are few. Most cases 
show an immunoprofile in the sarcomatoid component consistent 
with the differentiated tumour also present. Pure sarcomatoid 
cases may also show a ‘differentiation-associated’ immunoprofile 
but often it is inconclusive or IHC is negative. KRAS mutations have 
been consistently reported in a few case series. Carcinosarcoma is 
an exceptionally rare tumour, defined in the lung as a lesion show-
ing carcinoma plus differentiated, heterologous sarcomatous ele-
ments, such as rhabdomyo, osteo or chondrosarcoma. Pulmonary 
Blastoma is a biphasic lesion combining primitive mesenchymal tu-
mour and well-differentiated adenocarcinoma, the latter described 
as endometrioid or ‘fetal’ in pattern. Regarding the more typical 
cases of LCC, sarcomatoid and basaloid carcinoma, the molecular 
evidence supports the concept that these tumours may represent 
dedifferentiated carcinomas of the lung. How this emerging con-
cept is reflected in our classification is a matter of ongoing debate.
Keywords: sarcomatoid carcinoma, classification, diagnosis, large 
cell carcinoma
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Abstract: TUMORLETS AND DIFFUSE IDIOPATHIC PULMONA-
RY NE CELL HYPERPLASIA (DIPNECH) 
 
Tumorlets are defined as nodular proliferations of NE cells that 
measure less than 0.5 cm in greatest diameter. Tumorlets typically 
represent incidental histologic findings found in lung tissues with 
inflammatory and/or fibrotic lesions such as bronchiectasis, intersti-
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E06.1 OPTIMAL CHEMOTHERAPY IN COMBINED MODA-
LITY THERAPY FOR NSCLC
Everett Vokes
University Of Chicago Medical Center/United States Of America
Abstract: Over the last decade, combined modality therapy has 
been established as standard of care for patients with locoregio-
nally advanced unresectable non-small cell lung cancer (1). Both 
induction chemotherapy followed by radiation as well as conco-
mitant chemoradiotherapy have been shown to be superior to 
radiotherapy alone and both approaches extend progression-free 
and overall survival. In direct comparison, concomitant chemora-
diotherapy has been shown to be superior to induction in several 
randomized phase III trials as well as meta-analyses, likely due to 
enhanced locoregional control due to the chemotherapy radiation 
sensitization effect (2, 3). Currently about 20 to 30% of patients can 
be cured. While there are established clinical prognostic factors, 
very little information exists to more precisely guide prognosis or 
therapeutic approach for individual patients. In trying to improve 
survival outcomes induction chemotherapy was added to conco-
mitant chemoradiotherapy but failed to result in superior outcome 
compared to concomitant chemoradiotherapy alone.(4). Similarly, 
consolidation chemotherapy or maintenance therapy with erlotinib 
in patients unselected for molecular characteristics did not impro-
ve survival compared with concomitant chemoradiotherapy alone 
(5,6). Several chemotherapy regimens have been investigated 
in the concomitant setting including the mitomycin/vinblastine/
cisplatin (MVP) regimen, carboplatin/paclitaxel given weekly (and 
this regimen has consolidation chemotherapy for two cycles built 
in) and cisplatin/etoposide. The latter two are frequently used 
standards in control arms for current randomized trials. There has 
also been interest in the combination of carboplatin and pemet-
rexed given the superior single modality activity of the platinum/
pemetrexed regimen in non-squamous cell tumors (7). It has been 
demonstrated that this drug combination can be given at full sys-
temic doses in combination with radiation, thus providing good 
systemic coverage to eradicate micro-metastases as well as locore-
gional radiation enhancement. Whether any of these regimens is 
superior to another is not clear and few direct comparisons have 
been completed. Japanese investigators compared carboplatin/ta-
xol with carboplatin/irinotecan and the MVP regimen in combinati-
on with concomitant radiation and reported equivalent outcomes 
with these regimens(8). In a small trial comparing carboplatin/taxol 
with cisplatin/etoposide and radiotherapy, the platinum/etoposide 
regimen appeared to be superior; however, the number of pati-
ents was very limited at approximately 30 per arm (9). Cisplatin/
pemetrexed vs. carboplatin/pemetrexed has also been compared 
in a randomized phase II format supporting a trend for superiority 
of cisplatin-based therapy as has been shown for other stages of 
non-small cell lung cancer as well (10). A large randomized phase 
III trial comparing cisplatin/etoposide with cisplatin/pemetrexed 
each with concomitant radiotherapy to 66 Gy has been completed. 
This study was closed after a futility analysis at near completion 
of planned accrual and a full analysis of this trial is awaited for the 
future. Targeted therapies have also been of interest. While they 
have matured to be standard therapy for many patients with stage 
SMALL CELL CARCINOMA 
The diagnosis of SCLC is established based on small specimens 
such as bronchoscopic biopsies, fine needle aspirates, core biop-
sies, and cytology in most all cases, because of the presentation 
in advanced stages. Fortunately these specimens are diagnostic in 
most all cases. 
The diagnosis is based primarily based on light microscopy. Tu-
mor cells appear round to fusiform, growing in sheets and nests. 
Necrosis is common and is often extensive. Tumor cell cytoplasm 
is scant and nuclear chromatin is finely granular. Tumor cell size is 
usually less than the diameter of three small resting lymphocytes. 
Nucleoli are inconspicuous or absent. A high mitotic rate averages 
60-80 per 2 mm2, however, mitoses can difficult to identify in small 
biopsy specimens.  
Combined SCLC is diagnosed when there is also a component of 
NSCLC such as adenocarcinoma, squamous cell carcinoma, large 
cell carcinoma, spindle cell carcinoma and giant cell carcinoma. 
In this setting each of the non-small cell components should be 
mentioned in the diagnosis. Combined SCLC can be seen in 25% 
of surgically resected tumors. At least 10% large cells should be 
present for the diagnosis of combined SCLC/large cell carcinoma; 
however, for the components of adenocarcinoma, squamous cell 
or spindle cell carcinoma the amount does not matter. 
Diagnostic challenges occur in the settings of crush artifact and 
surgically resected specimens. Crush artifact is common in small 
biopsy specimens. This can create a problem in separating SCLC 
from a variety of tumors including non-small cell lung cancer (NS-
CLC), lymphoma, carcinoid and chronic inflammation. Immunohis-
tochemistry can be very helpful in this setting. In well fixed speci-
mens such as resected specimens the tumor cells of SCLC appear 
larger than in small biopsies. This often results in over diagnosis of 
LCNEC. 
The most important special stain for the diagnosis of SCLC is a 
good quality H&E stain. However, a panel of immunohistochemical 
stains is often helpful in the diagnosis. The most common cause of 
problems in interpretation of biopsies for the diagnosis of SCLC re-
sult from sections that are too thick or poorly stained. If the histo-
logic features are classic, it may not be needed. The stains that are 
useful for the diagnosis of SCLC include a pancytokeratin antibody 
such as AE1/AE3, CD56, chromogranin and synaptophysin, TTF-1 
and Ki-67. If keratin is negative, In 70-80% of SCLC TTF-1 is posi-
tive. The main role of Ki-67 is to distinguish SCLC from carcinoids 
because the proliferation is very high (50-100%) in SCLC.
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Abstract: For years radiation oncologists have dreamed of being 
able to dynamically adapt treatment to the response of normal and 
tumor tissues observed during a protracted course of radiothera-
py. An obvious goal is to adjust the PTV as the GTV shrinks during 
treatment, which may improve dose volume metrics in the organs 
at risk, especially lung. Reinflation of atelectatic lung in response to 
tumour size reduction may require adjustment of PTV size and po-
sition to avoid geographic miss. Cone beam CT (CBCT) has revolu-
tionised the ability to regularly image soft tissue, although it is less 
useful for targets within the mediastinum or those defined primari-
ly by FDG PET. The main limiting step is the time required to deve-
lop an adaptive treatment plan without interrupting treatment. Ex-
perience suggests that tumor reduction needs to be substantial to 
have a meaningful impact on the dose volume metrics. The use of 
serial FDG PET during treatment to detect residual activity and to 
use this as a surrogate for persistent disease for adaptive radiothe-
rapy is under investigation. This is however based on an unproven 
assumption that such FDG activity is due to tumor and not inflam-
mation. Tumor motion adds further uncertainty, affecting both SUV 
and intrafraction location of the residual FDG uptake. CBCT may 
also detect tumor progression. This seems to be uncommon.(1) 
When it occurs, apart from discontinuing futile treatment to avoid 
unnecessary toxicity, can anything else be done? Our group has 
investigated the use of PET tracers to detect functional changes in 
tumour during treatment, including FDG and the thymidine based 
tracer FLT which we hypothesise images tumour proliferation. Pre-
liminary results indicate that FLT detects functional changes in the 
tumour earlier than FDG, but the clinical implications of this are 
unknown.(2) One patient with clinical progression had increased 
uptake of FLT detected at 20 Gy, suggesting accelerated repo-
pulation. The rate of treatment was accelerated with twice daily 
fractionation, resulting in a reduction in FLT uptake, providing an-
ecdotal proof of principle. Accelerated repopulation has also been 
indirectly observed with induction chemotherapy.(3) Imaging with 
FLT may present an opportunity to detect altered proliferation pre-
radiotherapy which may benefit from accelerated fractionation.(4) 
A further change that may occur during fractionated treatment is 
reoxygenation. We have observed changes in uptake of the hypo-
xia PET tracer FAZA during a course of radiotherapy,(5) indicating 
that hypoxia is present in some tumors pre-treatment, although 
surprisingly little use is made of this knowledge in clinical practice. 
Changes observed in normal tissue response may also present 
opportunities for adaptive treatment. The patient can be used as a 
biological dosemeter, and the occasional patient will require trun-
cation of treatment because of esophagitis. Is this increased sen-
sitivity a surrogate for inherently increased radiosensitivity within 
the tumor, indicating that a higher tumor dose is unnecessary for 
such patients? Our group has observed changes in normal lung 
during treatment using ventilation/perfusion imaging, opening 
up prospects of avoiding functioning (as opposed to anatomical) 
lung with beam redirection.(6) Conclusions: A number of tools 
are now available to detect tumor and normal tissue response to 
radiotherapy during treatment. These changes may be anatomic 
or functional, including changes in tumor kinetics or the micro-
environment. The challenge now is to turn these observations into 
clinically useful patient benefits. References 1. Lim G, Bezjak A, 
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F18-fluoro-deoxy-glucose (FDG) and F18-fluoro-deoxy-l-thymidine 
(FLT) Detected by Serial PET/CT Imaging During Radical Chemora-
diation for Non-Small Cell Lung Cancer (NSCLC). . J Thorac Oncol 
2012;7:S238. 3. El Sharouni SY, Kal HB, Battermann JJ. Accelerated 
regrowth of non-small-cell lung tumours after induction chemo-
therapy. Br J Cancer. 2003;89:2184-9. 4. Baumann M, Herrmann T, 
Koch R, Matthiessen W, Appold S, Wahlers B, et al. Final results of 
IV disease their role in earlier stages remains under-investigated. 
In a number of uncontrolled trial, the addition of erlotinib or gefi-
tinib to radiation therapy with or without additional chemotherapy 
has been shown to be feasible. In the Alliance Cooperative Group 
(formerly CALGB), a recent trial looking at induction chemothe-
rapy with carboplatin and albumin-bound paclitaxel followed by 
erlotinib and concomitant radiotherapy for patients with poor-
risk stage III non-small cell lung cancer was completed. Median 
progression-free and overall survival times of 11 months and 16 
months respectively were encouraging. However, no compara-
tive arm of radiotherapy alone was included in the trial design 
(11). Similarly, cetuximab has been integrated into this treatment 
approach. RTOG 0324 reported encouraging pilot data from the 
addition of cetuximab to carboplatin/paclitaxel-based concurrent 
chemoradiation and consolidation chemotherapy(12). A rando-
mized trial comparing the base regimen vs. the base regimen plus 
cetuximab in this setting has been completed and mature results 
are expected in the near future. It should be cautioned however, 
that the larger clinical experience with the addition of cetuximab 
to concurrent chemoradiotherapy regimens to date has been dis-
appointing. A randomized phase II study conducted by the CALGB 
(CALGB#30407) found no obvious clinically significant benefit from 
the addition of cetuximab to carboplatin/pemetrexed radiotherapy 
(7). Median survival times were 21.2 and 22.4 months respectively 
for the two study arms. Similarly, controlled trials investigating the 
addition of cetuximab in patients with esophageal or head and 
neck cancer to concomitant chemoradiotherapy have not shown 
a statistically significant benefit compared to chemoradiotherapy 
alone. Current research interest is focused on the treatment of 
patients with molecular abnormalities, in particular EGFR muta-
tions or EML/alk translocation. For these patients, a study investi-
gating induction chemotherapy with either erlotinib or crizotinib, 
respectively followed by standard concurrent chemoradiation vs 
concurrent chemoradiation alone is about to be activated. Similar-
ly, immunological approaches are of interest. At present, no data 
from studies investigating CTLA-4 or PD1 inhibitors are available. 
However, a randomized trial investigating the BLP25 vaccine, a 
liposome MUC1-based vaccine, has recently been reported. This 
vaccine attempts to induce a proliferative T-cell response to the 
MUC1 antigen which is frequently overexpressed and hyper-
glycosylated in non-small cell lung cancer. In this trial, patients 
completed standard combined modality therapy (either induction 
or concomitant chemoradiotherapy) and were then randomized to 
either a placebo or the active vaccine. For the overall study cohort 
a trend in survival was observed which was more pronounced in a 
planned subset analysis of patients receiving concomitant chemo-
radiotherapy (13). This study adds support to further investigations 
to vaccine-based approaches. While current standard therapy ap-
proaches do result in consistent cure rates of 20-30% of patients, 
further progress will depend on the development of more specific 
combined modality approaches. Immunological and molecularly 
driven clinical trials will be of particular interest in this regard.
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E06.4 TREATING THE ‚BORDERLINE‘ PATIENT  
(MODERATE PS, LARGE TUMOUR, ETC.)
Laurie Gaspar
Radiation Oncology, University Of Colorado Denver/United States Of 
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Abstract: There is no general agreement on the definition of 
the “borderline” patient with stage III non-small cell lung cancer 
(NSCLC). Patients judged to be unsuitable for standard treatment 
could be of advanced age, unable to undergo cisplatin-based 
chemotherapy, poor performance status, poor pulmonary func-
tion and/or bulky tumors requiring large radiation fields. Since 
the combination of chemotherapy and radiation therapy (RT) has 
been adopted as the standard of care, there has been an incre-
ased portion of elderly patients who receive it. [1]. Cooperative 
group studies have demonstrated that the elderly have more to-
xicity then their younger counterparts and that age is a negative 
prognostic factor for survival. [2, 3, 4] However, the elderly with 
good PF still have improved survival with combined chemoRT as 
opposed to radiation only. Prospective studies in the “borderline” 
patient by cooperative groups in North America and Asia have 
had various eligibility criteria. [5, 6, 7, 8]. Those studies accrued 
slowly or poorly, perhaps due to the 6-7 week RT required in most 
studies. One RTOG study combining celecoxib and RT did allow 
either 60 Gy in 6 weeks or 45 Gy in 3 weeks but few patients were 
treated with the short course. [8] A short of course of RT may be 
more acceptable to patients who are elderly or have a poor per-
formance status. A retrospective study of patients who did not 
receive concurrent chemoRT showed that similar survival was seen 
in patients treated with 45 Gy in 3 weeks as in patients treated with 
>60 Gy in 6 weeks. [9] Few prospective studies have been done 
in patients with poor pulmonary function. A retrospective study 
found that pre-treatment FEV1 was not statistically correlated with 
symptomatic lung toxicity following concurrent chemoradiation.
[10] However, the combination of poor FEV1, advanced age and 
high mean lung dose correlated positively with pulmonary toxicity. 
Prospective studies are also lacking in patients with bulky disease 
for whom large radiation fields are required. Retrospective studies 
suggest that bulky disease is associated with a higher risk for the 
early development of metastases and death. [11] Future efforts 
to improve the therapeutic ratio for borderline patients likely in-
volve the improved ability to predict both benefit and risk for an 
individual patient. Studies are ongoing using molecular methods 
to better predict distant metastases-free survival and pulmonary 
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accessible via EUS, and may require transvascular FNA.. Results. 
EUS is especially useful in staging of the posterior mediastinum. 
Multiple publications and a meta-analysis on EUS-FNA have shown 
a high sensitivity and specificity. Even in patients without medias-
tinal lymph node enlargement on CT, EUS-FNA has been able to 
demonstrate metastases in 25% of lung cancer patients. Also, the 
left adrenal can be reached and identified in 97% of cases. It has a 
so-called ‘seagull’ shape on ultrasound and is particularly well vi-
sualised in cases of metastatic enlargement. Furthermore, the left 
lobe of liver can also be reached. The hilar and pre-carinal lymph 
nodes cannot be reached. EUS is also more accurate and has a 
higher predictive value than either PET scan or CT for posterior 
mediastinal lymph nodes. The procedure carries only a very small 
risk of mediastinitis or bleeding. . For both techniques it´s impor-
tant to remember, however, that with EBUS and EUS the negative 
predictive value is limited and therefore samples which do not 
contain tumour cells require follow up with a more definitive proce-
dure such as mediastinoscopy or VATS. Combining EBUS and EUS 
For tissue sampling of mediastinal lymph nodes after conventional 
TBNA, the present authors prefer minimally invasive methods such 
as EBUS-TBNA and EUS-FNA to more invasive procedures such as 
mediastinoscopy and VATS. EUS-FNA and EBUS-TBNA have been 
shown to prevent mediastinoscopies to a large extent. EBUS-TBNA 
and EUS-FNA have a complementary reach in analysing mediasti-
nal nodes whereby EBUS has access to the paratracheal, subcarinal 
and hilar regions and EUS to the lower mediastinum and aortopul-
monary window. As shown above, EUS and EBUS provide access 
to different areas of the mediastinum. In combining techniques, 
most lymph node stations as well as the left adrenal gland can be 
reached (apart from stations 5 and 6). In six recent series the ac-
curacy of EUS-FNA and EBUS-TBNA used in combination for the 
diagnosis of mediastinal cancer was 95% . Using the EBUS-Scope 
for both endobronchial as well as endoesophagel sampling, the 
sensitivity for cancer detection could be shown to be as high as 
96% (EUS 89%, EBUS 91%), specificity 100% and negative predic-
tive value of 96% (EUS 82%, EBUS 92%). CONCLUSION Overall, 
EBUS and EUS are safe and effective techniques for the staging of 
the mediastinum. They are minimally invasive and reduce the num-
ber of invasive staging procedures. Currently, the main limitation 
for EBUS and EUS are that they are predominantly performed at 
centres of excellence and hence only on selected patients. Training 
of physicians and surgeons remains the issue and performance 
of an adequate amount of procedures per year is required in or-
der to maintain competency. Reimbursement remains an issue in 
some countries as well as the actual implementation into cancer 
guidelines within the hospitals. Increasingly both techniques are 
being used in hospitals across the world improving the diagnostic 
yield. Combined EBUS and EUS ought to be regarded as the “first 
techniques into the mediastinum”, called “complete endo-echo 
staging”.
Keyword: Endobronchial ultrasound, endoesophageal ultrasound, 
lung cancer, staging
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Abstract: ENDOBRONCHIAL ULTRASOUND The integration 
of ultrasound technology and flexible fiberbronchoscopy enab-
les imaging of lymph nodes, lesions and vessels located beyond 
the tracheobronchial mucosa. Developed in 2002, the EBUS-
bronchoscope looks similar to a normal bronchovideoscope, but is 
6.9mm wide and has a 2mm instrument channel and a 30 degree 
side viewing optic. Furthermore, a curved linear array ultrasonic 
transducer sits on the distal end and can be used either with direct 
contact to the mucosal surface or via an inflatable balloon which 
can be attached at the tip. This allows a conventional endosco-
pic picture side-by-side with the ultrasonic view. US scanning is 
performed at a frequency of 7.5-12 MHz with tissue penetration 
of 20 – 50mm. An ultrasound processor processes the US image. 
Procedure: The actual TBNA is performed by direct transducer 
contact with the wall of the trachea or bronchus. When a lesion is 
outlined, a needle of 21 gauge (NA-201SX-4022; Olympus Cor-
poration, Tokyo, Japan) can be advanced through the working 
channel and lymph nodes can be punctured under real-time ultra-
sound visualisation. At the same time colour Doppler can be used 
to identify surrounding vascular structures. Once the target lymph 
node or mass has been clearly identified with EBUS, the needle 
is inserted under real-time US guidance. Suction is applied with a 
syringe, and the needle is moved back and forth inside the lesion. 
Lymph node stations that can be reached via EBUS are the highest 
mediastinal (station 1), the upper paratracheal (2L and 2R), lower 
paratracheal (4R and 4L), the subcarinal (station 7), the hilar (station 
10) as well as the interlobar (station 11) and the lobar nodes (sta-
tion 12). The highest staging N should be biopsied first otherwise 
the needle needs to be changed each time. Results: In recently 
published meta-analysis EBUS-TBNA has been shown to have a 
high-pooled sensitivity of 93% and specificity of 100% . Multiple 
publications have shown that even in patients with lymph nodes 
under 1cm (which had been termed N0 by CT criteria), with the 
use of EBUS-TBNA a large percentage could still be shown to have 
N2/N3 disease (some despite also being negative on PET-CT). 
Complications such as bleeding or infection are very rare and have 
only been reported as case reports. Endoesophageal ultrasound 
Gastroenterologists have been using this technique for many 
years in the investigation of oesophageal and pancreatic malig-
nancies. Mediastinal EUS-FNAs were first used in the early 1990s 
and have subsequently become a popular method to diagnose 
a variety of intra-abdominal and intrathoracic masses, including 
mediastinal lesion. Procedure The linear EUS-Scope (has the same 
basic architecture as the EBUS and uses a scanner of between 5 
and 10 MHz. The penetrating ultrasound depth can be up to 8cm. 
Needles used for biopsy are 19 or 21gauge, again equipped with a 
stylet. The procedure is usually performed on an outpatient basis 
and takes approx 30min. However, EUS-FNA has limited access as 
only lymph node stations 2L, 4L, 7, 8 and 9 are accessible through 
a transesophageal approach. Lymph node station 5 is not routinely 
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that transgress the boundaries of individual nodal stations. Further 
improvements in stage discrimination and management of lung 
cancer could be expected in the future, as more robust data rela-
ted to genetic make-up and biological behavior affecting survival 
of tumors becomes available.
Keywords: TNM staging, 2011 new adenocarcinoma classification, 
AJCC7 staging, lung adenocarcinoma
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Abstract: Background The origin of the International Association 
for the Study of Lung Cancer (IASLC) Lung Cancer Staging Pro-
ject took place during an international workshop on intrathoracic 
staging organized at the Royal Brompton Hospital, London, UK, 
in 1996. (1) At that time, the 6th edition of the tumour, node and 
metastasis (TNM) classification was in press, but its limitations 
and weaknesses were discussed in an international and multi-
disciplinary forum. The main conclusion was the need for a large 
international database that could be used to refine and update the 
TNM classification of lung cancer. Two years later, the IASLC Board 
approved the creation of an International Staging Committee 
(ISC), whose first co-chairs were Mr. Peter Goldstraw and the late 
Dr. Robert Ginsberg. An international call was made to promote 
participation and data sharing, and potential participants were 
summoned to subsequent meetings and workshops. Data on lung 
cancer patients diagnosed from 1990 to 2000 were collected from 
46 different sources in 20 countries around the world. Data were 
stored, managed and analysed at Cancer Research And Biostatis-
tics (CRAB), a biostatistics agency based in Seattle, WA, USA. By 
the end of 2005, 100,869 cases had been registered and 81,495 
were analyzable: 68,463 non-small cell lung cancers (NSCLC) and 
13,032 small cell lung cancers (SCLC). (2) The analyses of these 
cases allowed the IASLC to issue recommendations for changes 
to the 6th edition of the TNM classification. The recommendations 
were accepted by the Union for International Cancer Control 
(UICC) and by the American Joint Committee on Cancer (AJCC), 
and were introduced in the 7th edition of the TNM classification. (3, 
4, 5) With the revision undertaken for the 7th edition, a new period 
of data-based revisions started, with the IASLC leading the revisi-
on process and informing the UICC and the AJCC of the potential 
changes in the classification based on the analyses of its growing 
international databases. The analyses of the retrospective IASLC 
database showed that a more detailed database, containing spe-
cific information on T, N and M descriptors, would be necessary to 
continue the revision process. Therefore, in 2009, a call was made 
for international participation in the prospective collection of data 
to inform the 8th edition of the TNM classification of lung cancer, 
due to be published in 2016. (6) The IASLC Prospective Phase of 
the Lung Cancer Staging Project This prospective phase of the 
project included a new retrospective collection of data from 1999 
to 2010. 94,684 patients were collected: 78,640 analyzable cases 
of NSCLC and 5,912 analyzable cases of SCLC. These cases will 
be used to inform the 8th edition of the TNM classification and are 
now being analysed at CRAB. Expansion to Other Thoracic Mali-
gnancies The ISC incorporated mesothelioma in 2008 and thymic 
malignancies and oesophageal cancer in 2009. The structure of the 
ISC was modified to accommodate more tumours and members. 
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Abstract: There is a widely divergent clinical, radiologic, molecular 
and pathologic spectrum within lung adenocarcinoma. Remar-
kable advances in understanding of the genetic mechanisms that 
underlie lung adenocarcinoma have altered the diagnostic criteria 
that determine subsequent treatment. The use of the term bron-
chioloalveolar carcinoma (BAC) encompassed a broad spectrum 
of tumors ranging from solitary small peripheral lung tumors with 
a 100% 5-year survival to widespread advanced disease with a 
10% 3-5 year survivals, with widely varying use of terminology 
even after publication of the 2004 WHO Classification. There are 
also clinical, radiologic, immunohistochemical, and molecular 
differences that are distinguishable among the subsets of muci-
nous and non-mucinous types of adenocarcinoma. In 2011, a new 
Classification of Lung Adenocarcinoma was therefore proposed 
by the International Association for the Study of Lung Cancer/
American Thoracic Society/European Respiratory Society. The 
2011 classification addressed three important weaknesses in the 
previous classification. First, it eliminated the term BAC. Second, 
it added new terminologies of carcinoma-in-situ, and minimally 
invasive adenocarcinoma to recognize that minimal invasion (< 
5mm). Third, it replaced the terminology of mixed adenocarcino-
ma. The widespread availability of MDCT and abundance of new 
information obtained especially from low-dose CT lung cancer 
screening programs, have increased our understanding of the 
types and management of small peripheral lung nodules encoun-
tered in daily clinical practice, in particular, the importance and 
prevalence of subsolid pulmonary nodules (atypical adenomatous 
hyperplasia (AAH), ground glass nodules (GGN) and part-solid no-
dules). Thin section CT has emerged as a new biomarker for lung 
adenocarcinoma subtypes. The staging system is based solely on 
the anatomic extent of the disease. Other factors, such as clinical 
symptoms or molecular biological characterization of the tumor 
or attenuation of nodules on CT are not factored in the new TNM 
classification. Increasing T status reflects tumors that are larger or 
invasive. In lung cancer nodal staging depends on the location of 
involved nodes (as opposed to the number of nodes). The M de-
scriptor defines the presence or absence of distant metastatic di-
sease. In 2007, The International Association for the Study of Lung 
Cancer (IASLC) revised the lung cancer stage groupings based on 
newer survival data. In the 7th edition of TNM classification of lung 
cancer, following modifications were made: (a) Size cut points, in 
addition to the 3 cm cut point that traditionally separated T1 and 
T2 tumors, was introduced at 2, 5, and 7 cm. T1 tumors were now 
subdivided into T1a and T1b around the 2 cm cut point. T2 tumors 
were subdivided into T2a and T2b around the 5 cm cut point, and 
tumors larger than 7 cm. were classified as T3. (b) Cases in which 
additional tumor nodules are found were reclassified. Those in the 
same lobe as the primary tumor are now classified as T3, those in 
the other ipsilateral lobes are T4 and those in the opposite lung 
are now M1a. (c) Cases associated with pleural or pericardial nodu-
les or effusions were reclassified from T4 to M1a. M1 disease due 
to distant metastasis was reclassified as M1b. A new IASLC nodal 
chart, with precise definitions was also agreed, reconciling the 
previous differences between the Japanese and Mountain-Dresler 
charts. The concept of nodal zones was introduced to make such 
classification relevant to those dealing with bulky nodal deposits 
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Abstract: Tumor diagnosis, tumor staging, and patient treatment 
in clinical oncology depend on morphological and molecular 
imaging procedures, such as magnetic resonance imaging (MRI), 
computed tomography (CT), and positron emission tomography 
(PET). Radiological and functional imaging studies, however, have 
well-known, inherent limitations that limit their diagnostic accuracy 
in assessing tumor stage and therapeutic response. Both CT and 
MRI provide mainly morphological information on the tumor and 
potential metastasis. However, the lack of functional information 
frequently limits the value of these studies when assessing lymph 
nodes metastasis. Accurate staging of patients with non-small cell 
lung cancer (NSCLC) is of paramount importance because stage 
significantly affects both treatment options and prognosis. The 
management of NSCLC often requires a multimodality approach 
for accurate diagnosis and staging and for patient treatment. Some 
of the most important advances in the treatment of lung cancer 
have been the development and implementation of accurate and 
functional imaging. In numerous studies the diagnostic capability 
of whole-body MRI, PET and PET/CT for cancer staging has been 
evaluated and compared. In the primary evaluation of pulmo-
nary lesions, fluorodeoxyglucose (FDG)-PET scans are useful for 
distinguishing benign from malignant etiologies. Several studies 
investigating the accuracy of FDG-PET in diagnosing malignant 
pulmonary lesions have estimated its sensitivity and specificity to 
be 96.8% and 77.8%, respectively. In the same analysis, FDG-PET 
was found to be superior to CT for evaluating nodal and distant 
metastases and changed therapeutic management in 18% of the 
cases studied. However, PET has been shown to be less sensitive 
for characterizing smaller lung lesions. The positive predictive va-
lue (PPV) of FDG-PET is significantly lower for lesions smaller than 
1 cm than for larger lesions (0.36 vs 0.90, p=0.015). The lower PPV 
for smaller lesions reflects a higher rate of false-positive FDG-PET 
scans. A comparison of the characteristics of PET-negative and 
PET-positive tumors has shown significant differences in lesion size 
(p < 0.001), histopathological type (p < 0.001), and pathological 
stage (p = 0.028). Both lesion size (p < 0.001) and histopathologi-
cal tumor type (p < 0.001) were significant factors for determining 
whether PET results were negative or positive. This study establis-
hed that negative PET findings were likely for lesions 2 cm or smal-
ler and for adenocarcinomas (i.e., adenocarcinoma in situ and well-
differentiated adenocarcinomas). A meta-analysis of 59 studies has 
shown that PET/CT is useful for detecting lymph node metastasis 
and extrathoracic metastasis. PET/CT is significantly more sensitive 
and specific than conventional CT alone and more sensitive than 
PET alone for staging NSCLC. Furthermore, PET/CT demonstrates 
excellent sensitivity (0.91) and specificity (0.98) for bone metas-
tasis. However, PET/CT has high specificity but low sensitivity for 
detecting brain metastasis. The question of bone metastasis was 
most thoroughly answered by a recent meta-analysis of 17 studies 
comparing FDG-PET/CT, FDG-PET, MRI, and bone scintigraphy. 
The pooled sensitivity of each of the modalities in the detection 
of metastasis was 92%, 87%, 77%, and 86%, respectively, and the 
specificity was 98%, 94%, 92%, and 88%, respectively. When com-
pared with other imaging modalities, FDG-PET appears to offer 
no additional information regarding the presence of metastatic 
disease in the brain. The current standard of care is to evaluate 
the brain metastasis with MRI in all patients, except those with 
Four domains were created: lung cancer domain (chaired by this 
writer), mesothelioma domain (chaired by Dr. Valerie Rusch), thymic 
malignancies domain (chaired by Dr. Frank Detterbeck) and oeso-
phageal cancer domain (chaired by Dr. Tom Rice). To increase the 
participation of more specialists without increasing the number of 
ISC members and the budget, advisory boards for mesothelioma, 
thymic malignancies and oesophageal cancer were created. The 
retrospective database of mesothelioma contains 3,101 surgically 
treated patients, and its first analysis has been already published. 
(7) The International Mesothelioma Interest Group (IMIG) and the 
Mesothelioma Applied Research Foundation (MARF) collaborate 
with the IASLC Mesothelioma Staging Project. The prospective 
collection of cases is now ongoing, includes surgically and non-sur-
gically treated patients, and is intended to inform the 8th edition of 
the TNM classification. A side-project on volumetric computerized 
tomography for clinical staging is also underway. The retrospective 
database of thymic malignancies has data on more than 10,000 
cases, and the prospective collection of data is ongoing. The ISC 
works closely with the International Thymic Malignancies Interest 
Group (ITMIG) (8) and with thymic working groups of scientific 
societies, such as the European Society of Thoracic Surgeons, the 
European Association for Cardiothoracic Surgery, etc. The main 
objective is to device a data-driven, internationally acceptable 
TNM classification for thymic malignancies, both thymomas and 
thymic carinomas. The retrospective database of the oesophageal 
cancer is kept at the Cleveland Clinic, Cleveland, OH, USA, and 
contains data on more than 10,000 patients. Cases are provided 
by members of the Worldwide Esophageal Cancer Collaboration 
(WECC). (9) The revised 7th edition of the TNM classification of 
oesophageal cancer was based on the analyses of the surgically 
treated patients of this database. (10) Expansion to Prognostic 
Factors Given the importance of more precise prognostication, 
besides that provided by the TNM classification and staging sys-
tem, the IASLC Board decided to expand the activities of the Com-
mittee to prognostic factors. To make this activity more patent, the 
name of the Committee was changed to Staging and Prognostic 
Factors Committee in February 2013. References 1. Goldstraw P. 
Report on the international workshop on intrathoracic staging, 
London, October 1996. Lung Cancer 1997;18:107-111. 2. Goldstraw 
P, Crowley JJ . The International Association for the Study of Lung 
Cancer international staging project on lung cancer. J Thorac On-
col 2006;1:281-286 3. Goldstraw P, ed. Staging manual in thoracic 
oncology. Orange Park, FL: Editorial Rx Press; 2009. 4. Sobin L, et 
al., eds. TNM classification of malignant tumours. 7th edition. Ox-
ford: Wiley-Blackwell; 2009;138-146. 5. Edge SB et al., eds. Cancer 
staging manual. 7th edition. New York: Springer; 2010;253-270. 6. 
Giroux DJ et al. The IASLC lung cancer staging project. Data ele-
ments for the prospective project. J Thorac Oncol 2009;4:679-683. 
7. Rusch VW et al. Initial analysis of the International Association for 
the Study of Lung Cancer mesothelioma database. J Thorac Oncol 
2012;7:1631-1639. 8. Detterbeck FC, Huang J. Overview. J Thorac 
Oncol 2011;6(Suppl 3):s1689-1690. 9. Rice TW et al. Worldwide eso-
phageal cancer collaboration. Dis Esophagus 2009;22:1-8. 10. Rice 
TW et al. 7th edition of the AJCC Cancer Staging Manual: esopha-
geal and esophagogastric junction. Ann Surg Oncol 2010;17:1721-
1724.
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S26 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Session E08: Early Endobronchial 
Tumours 
Tuesday, October 29, 2013
EARLY ENDOBRONCHIAL TUMOURS  
TUESDAY, OCTOBER 29, 2013 - 14:00-15:30
E08.1 SCREENING / EARLY DETECTION OF CENTRAL 
MALIGNANCY
Annette Mcwilliams
Respiratory Medicine, Sir Charles Gairdner Hospital/Australia
Abstract: Introduction: Excellent cure rates for central lung can-
cer can be achieved with local endobronchial therapy if lesions 
can be detected at a pre-invasive stage. Flexible white light bron-
choscopy is the most commonly used imaging tool to evaluate 
the central airways but it has a limited ability to detect small pre-
invasive central lung cancers. Screening with low dose thoracic CT 
(LDCT) has been shown to be useful in the early detection of lung 
cancer, but it largely detects peripheral lesions. Despite advances 
in CT technology, LDCT cannot detect early pre-invasive central 
lung cancers due to limitation of resolution. Method: Optical ima-
ging modalities that are both established and in development will 
be reviewed and discussed. These include techniques such as au-
tofluorescence bronchoscopy, narrow band imaging, optical cohe-
rence tomography, confocal microendoscopy, endocystoscopy and 
raman spectroscopy. Results: Autofluoresence imaging is the most 
well proven imaging tool to be used in conjunction with white light 
bronchoscopy to rapidly detect small preinvasive lesions. Narrow 
band imaging may also be useful but further comparative studies 
are needed. Optical coherence tomography and raman spectro-
scopy are promising techniques that can be easily applied via small 
probes during flexible bronchoscopy to further evaluate abnormal 
lesions. Further development of in-vivo microscopic evaluation of 
abnormal lesions is ongoing using confocal microendoscopy and 
endocystoscopy although tissue staining and direct contact is 
currently required. Conclusion: The detection of early central lung 
cancers requires more sophisticated tools than conventional white 
light bronchoscopy. The future utilisation of other imaging tools 
as part of a minimally invasive flexible bronchoscopic procedure 
appears promising. A multimodality approach will enable the rapid 
detection and diagnosis of early curable central lung cancers in 
selected high-risk populations.
Keyword: bronchoscopy, autofluorescence, early detection, cen-
tral lung cancer
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Abstract: Stereotactic ablative radiotherapy (SABR) is an establis-
hed treatment modality in the curative treatment of early stage pe-
ripheral non-small cell lung cancer (NSCLC). The local control rates 
clinical stage IA disease. A recent study of 1122 patients with PET-
CT–determined stage I (T1-2N0) NSCLC suggests that invasive 
staging is not indicated for such patients, especially if a PET scan 
of the mediastinum is negative. Several studies have assessed the 
prognostic implications of mediastinal PET findings in patients 
undergoing curative resection of NSCLC. The rates of locoregional 
and distant recurrence are higher in patients with positive medi-
astinal PET findings than in patients with negative findings for the 
N0/N1 subset. The higher rate of locoregional failure in patients 
with positive preoperative PET findings in the mediastinum might 
lead to postoperative radiation therapy. Although chemotherapy 
is recommended for most patients with N1 disease, chemotherapy 
is generally not recommended for patients with N0 disease. The 
higher rate of distant failure in patients with positive preoperati-
ve mediastinal PET findings might lead to chemotherapy being 
recommended. On the other hand, pathologic confirmation with 
invasive mediastinal staging, either by mediastinoscopy alone or 
by mediastinoscopy combined with thoracotomy, is recommended 
if mediastinal lymph node abnormalities are detected with PET-CT. 
Several recent studies have shown that diffusion-weighted magne-
tic resonance imaging (DWI) has a higher specificity for N staging 
of NSCLC than does FDG PET/CT and has the potential to be a 
reliable alternative noninvasive imaging method for the preopera-
tive staging of mediastinal and hilar lymph nodes in patients with 
NSCLC. Short inversion time inversion-recovery (STIR) turbo spin-
echo (SE) MRI may be useful for distinguishing metastatic lymph 
nodes from nonmetastatic lymph nodes in patients with NSCLC. 
This imaging method might be more sensitive and accurate than 
CT, conventional T1-weighted MRI, FDG PET, or FDG PET/CT. We 
can prospectively compare the diagnostic capabilities of STIR 
turbo SE imaging, DWI, and FDG PET/CT for N staging in patients 
with NSCLC. In patients with NSCLC, quantitative and qualitative 
assessments of N staging obtained with STIR turbo SE MR imaging 
are more sensitive and more accurate than those obtained with 
DWI or FDG PET/CT. A new technology, PET-MRI, is now being 
established. To guarantee the clinically valuable, time- and cost-
efficient use of PET/MRI, it is essential that appropriate indications 
be chosen, that cross-modality training be performed, that the ac-
quisition protocols be optimized, and that the images be carefully 
reviewed, taking into account potential artifacts. Additional studies 
are needed to determine how PET/MRI might best be used clini-
cally and to prospectively verify its clinical abilities. The increased 
use of FDG-PET will help clinicians to select the most appropriate 
treatments for each patient and thereby improve outcomes and 
avoid toxic therapies that are unlikely to be beneficial.
Keywords: computed tomography, positron emission tomogra-
phy, Magnetic resonance imaging, non-small cell lung cancer
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Abstract: Lung cancer risk models and screening protocols are 
becoming more precise and, consequently, there is an increasing 
interest in developing new chemoprevention strategies for lung 
cancer. A number of compounds, among them several phyto-
chemicals, have been proposed as potential lung cancer chemo-
preventive agents based on studies using rodent models. New 
preclinical studies involving novel chemopreventive compounds or 
more efficacious dosing strategies are required and their success 
will depend in part on the quality of the experimental models. In 
our presentation we will give an update of the available and newly 
emerging rodent models for the preclinical study of potential che-
mopreventive interventions for lung cancer. In order to fully reca-
pitulate the complexities of human lung cancer, different animal 
models have been developed. These models can be divided into 
chemically-induced lung cancer and genetically engineered mouse 
models (GEMMs). Most chemoprevention studies have been per-
formed on mouse models of lung adenocarcinoma (ADC) induced 
by a number of chemical carcinogens found in tobacco combusti-
on products. The A/J mouse strain has been utilized primarily for 
these studies since these mice develop lung tumors rapidly after 
treatment with certain carcinogens such as anthracene, urethane, 
nicotine-derived nitrosamine ketone (NNK), other nitrosamines, 
benzo(a)pyrene (BaP), or vinyl carbamate. There are several well 
established chemically induced mouse ADC models which have 
been most frequently used in the assessment of the preventive 
potential of various types of agents: Genetic differences between 
ADC and squamous cell carcinoma (SCC) are also paralleled in 
the development of animal models. Skin painting with nitroso-tris-
chloroethylurea (NTCU) is the best established protocol to produ-
ce lung SCC in susceptible mice and it has already been used for 
chemoprevention studies. In our lab, we have studied some phe-
notypic and genetic traits of the NTCU induced SCC, and we have 
used this model to analyse SCC-specific drug efficacy. GEMMs of 
lung cancer, mainly leading to adenomas or ADCs have also been 
used in chemopreventive preclinical studies. A plethora of GEMMs 
for lung carcinogenesis are available with single or combined 
genetic alterations in oncogenes or tumor suppressors. Several 
mouse models of lung cancer have been developed with mutation 
of Kras as the initiating oncogenic event. In the KrasLSLG12D/+ knock-in 
mouse model, expression of oncogenic Kras is achieved by intra-
tracheal inoculation with adenoviruses carrying Cre-recombinase 
The KrasLSLG12D/+ model represents a highly relevant GEMM as it 
recapitulates many aspects of human ADC oncogenesis, including 
the full spectrum of lesions from early atypical adenomatous hy-
perplasia (AAH) to adenocarcinoma, and expresses human NSCLC 
of SABR in many publications have exceeded 90% when tumors of 
up to 5 cm were treated, with corresponding regional nodal failure 
rates of approximately 10%. SABR has been reported in many se-
ries to have only modest early and late toxicity, generally maintai-
ning pulmonary function and preserving health-related quality of 
life. Following the publication of an phase II study, which showed 
an 11-fold increase in severe toxicity in the subgroup of patients 
with centrally located lung tumors that had been treated with a 
high dose per fraction, these central locations had been conside-
red to be a ‘no fly zone’ for SABR [Timmerman 2006]. Although se-
veral subsequent single center studies have shown that SABR per-
formed with an adapted fractionation scheme using daily fractions 
of 6.0–7.5 Gy to total doses of 48–60 Gy has been both effective 
and safe, the results of the ongoing Radiation Therapy Oncology 
Group (RTOG) phase II trial (0813) for SABR in central tumors, have 
to be awaited to determine the maximum tolerated dose which 
can be delivered in five fractions. A recently published systematic 
review of the literature identified a total of 20 studies reporting on 
the outcome of SABR in 315 patients with centrally located early 
stage NSCLC, including two phase II studies [Senthi 2013]. The 
overall survival rates reported for centrally located tumors ap-
peared to be similar to those of peripheral tumors. Similar to what 
has been described for peripheral lesions, central tumors showed 
a dose–response relationship for local control, with four studies re-
porting improved outcomes with a biological effective dose of 100 
Gy10 or higher compared to lower doses. In those studies where 
fractionation schedules with a biological effective dose of 100 Gy10 
or higher were used, the local control rates exceeded 85%. Post-
SABR grade 3 or 4 toxicity occurred in 8.6% of central tumors trea-
ted with SABR, and the risk of treatment-related mortality was less 
than 1% if the biological effective dose for late responding tissues 
(BED Gy3) remained below 210 Gy3. In conclusion, SABR for central 
tumors has been shown to be both effective and safe, provided 
that appropriate risk-adapted fractionation schemes are used and 
careful contouring of organs at risk with quality assurance of all 
aspects of treatment planning and delivery are taken into account. 
The results of the RTOG dose-finding phase II study 0813, in which 
already 120 patients are entered, will further strengthen the data 
on the use of SABR for centrally located tumors.
Keyword: SABR, central tumors
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fluctuation in expression. Although no intermediate endpoints 
have been validated as replacements for cancer incidence thus 
far, the assessment of a variety of such markers can significantly 
inform drug development and help make decisions regarding sub-
sequent phase III trials. Lung cancer consists of a heterogeneous 
set of malignancies that presents with diverse molecular and his-
tologic characteristics. The molecular evolution of tobacco related 
carcinogenesis is not well understood, but histologic evolution 
of squamous carcinogenesis, with progression from metaplasia 
through increasing grades of dysplasia and carcinoma in situ, is 
well described. This allows for a clinical trial design based on pre- 
and post-treatment bronchial biopsies to assess the response to 
chemopreventive interventions. Since the rate of progression of 
dysplasia to invasive cancer is variable, with higher progression 
rates associated with higher grades of dysplasia, studies assessing 
dysplasia as an endpoint need to be randomized such that the 
“spontaneous” reversion rate in the placebo arm can be used as 
a comparison to account for the effects of the biopsies and for 
true biologic reversion. This model has been successfully used to 
study a variety of interventions, including a recent trial of the pros-
tacyclin analogue iloprost that showed improvement in bronchial 
histology after 6 months of treatment (Keith R et al., Cancer Prev 
Res 2011;4:793-802). In contrast, the study of the development of 
adenocarcinomas has been more difficult due to the inability to 
access tissues from the peripheral lung. The demonstration that 
helical CT screening reduces lung cancer mortality opens the op-
portunity to assess the peripheral lung for adenocarcinoma pre-
cursor lesions. Veronesi and colleagues (Veronesi G et al., Cancer 
Prev Res 2011;4;34-42) examined the effect of an inhaled steroid, 
budesonide, on CT-detected lung nodules, showing nonsignifi-
cant modulation of nonsolid lesions only. As persistent nonsolid 
(ground glass) lesions are more likely to represent lung cancer 
precursor lesions such as atypical adenomatous hyperplasia or 
early cancers than solid nodules, future studies should focus on 
nonsolid lesions only. Alternative designs for trials include a focus 
on individual biomarkers, panels of biomarkers, or pathways that 
are deregulated during carcinogenesis. As an example, Gustafson 
et al. demonstrated that the PI3K pathway is upregulated early 
during lung carcinogenesis and that an intervention with the drug 
myo-inositol that resulted in regression of bronchial dysplasia also 
inhibited PI3K activation in the bronchial epithelium (Gustafson 
AM et al., Science Trans Med 2010;2:26ra25). These data suggest 
that upregulated PI3K signaling could potentially identify smokers 
at increased risk for lung cancer and that pathway inhibition could 
serve as an endpoint for assessing treatment effect, a hypothesis 
that requires further testing. The rapidly increasing understanding 
of the pathogenesis of lung cancer provides an unprecedented 
opportunity to intervene in the process. Optimization of clinical 
trial design is required to translate the basic knowledge into clini-
cal realities.
Keywords: atypical adenomatous hyperplasia, chemoprevention, 
bronchial dysplasia
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gene signatures. Interestingly, combined mutant KRAS expression 
with additional genetic alterations such as p53, PTEN or LKB1 loss 
results in advanced stages of lung cancer including metastasis. To 
date, there is only one GEMM leading to pure squamous histology 
with many human SCC traits, recently developed in kinase-dead 
IKKα knock-in mice. Some years ago a mouse model for SCLC was 
developed by conditional inactivation of Rb1 and Trp53 in mouse 
lung epithelial cells. A newly developed model of SCLC incorpo-
rates p130 knockout and accelerates the formation of SCLC. Finally, 
mouse models for inflammation-driven lung carcinogenesis are 
helping to understand the role of smoking induced inflammation 
in lung cancer. We recently found that silica-induced chronic lung 
inflammation markedly increases the incidence and multiplicity 
of mouse lung adenomas and ADCs following N-nitrosodime-
thylamine (NDMA) treatment. These results are in concordance 
with other animal models that explore the effects of different in-
flammatory agents in chemically-induced lung tumor promotion. 
One of the key practical points regarding the relevance of these 
animal models in developing new chemoprevention strategies is 
the extent to which they recapitulate human lung cancer multistep 
progression at the cellular and molecular levels.. The pathological 
and molecular likes and dislikes between human lung cancer and 
the most frequently used animal models will be discussed during 
the presentation. The quantitative assessment of tumor volume 
progression in cancers affecting internal organs such the lung is 
more difficult than the assessment of lesions that are superficial 
(for example, breast or skin). New imaging technologies such as 
respiratory-gated micro-CT scans for small animals allow perfor-
ming longitudinal studies on animal models of lung cancer. Micro-
CT has been mainly used to monitor tumor growth and to assess 
the response or the resistance to therapeutic drugs. The potential 
of micro-CT imaging in lung cancer chemoprevention studies has 
been already highlighted. Standardization of protocols, improved 
resolution, more robust and faster image acquisition and, fully 
automatic and properly validated quantification algorithms need to 
be implemented before micro-CT imaging can show its full poten-
tial in the assessment of chemoprevention therapies.
Keywords: imaging (animal models), mouse models, chemopre-
vention, carcinogenesis
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Abstract: The goal of lung cancer chemoprevention is to prevent 
the development of invasive cancer, but designing early phase 
intermediate efficacy clinical trials to demonstrate that a strategy 
is effective remains a “work in progress”. Phase III prevention trials 
focus on individuals at high risk for cancer and have a lung can-
cer endpoint. By contrast, phase II trials depend on intermediate 
endpoints that are surrogates for cancer incidence, in a fashion 
analogous to shrinkage in tumor size being a surrogate for survival 
in phase II cancer treatment trials. Examples of such endpoints 
include premalignant lesions, proliferative indices, and various 
biomarkers of risk or malignant potential. To be useful, intermedi-
ate endpoints should be integrally involved in the process of carci-
nogenesis, differentially expressed in at-risk vs. normal epithelium, 
and modulated by effective interventions with little spontaneous 
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could allow the discovery of new targets for chemoprevention and 
the possibility of customized lung cancer chemoprevention, by 
selecting the agents based on the different molecular profile of the 
individuals at high risk. Thus future chemoprevention trials should 
be undertaken based on the biological drivers and pathways of 
lung carcinogenesis. The chemoprevention trials should include 
the collection of biological samples to allow testing biomarker for 
their role as surrogate intermediate endpoint, for the selection of 
the patients who are at higher risk and for the personalization of 
the chemoprevention approach, with the purpose of optimizing 
the benefit and avoiding useless toxicity in high-risk but cancer-
free individuals.
Keywords: MicroRNAs, chemoprevention, biomarker, customized
Abstract: Smoking exposes the respiratory mucosa to carcinogens 
in a “field cancerization” process. Smokers develop bronchial le-
sions, at the pre-invasive stages, preceding the development of 
invasive lung cancer. Because of the field of cancerization, these 
lesions are multiple and occur throughout the bronchial airways, 
which make complete resection of bronchial premalignant lesions 
impractical. Chemoprevention aims to prevent the development 
of lung cancer. The administration of chemopreventive agents 
may be effective, alone or in association with local treatment, in 
reducing the risk of developing lung cancer. So far no phase III 
trial testing chemopreventive agents for lung cancer has shown a 
consistent and reproducible benefit. Therefore no agent can be 
recommended currently for the chemoprevention of lung cancer 
(Szabo et al, Chest, 143 (5), Supplement, 2013, e40S-e60S). Future 
chemoprevention trials should be conducted based on the know-
ledge of lung carcinogenesis drivers and pathways (Keith et al, 
Nature Reviews, 10, 2013, 334-343). This would allow the choice 
of drugs with a better chance of benefit and the customization of 
the chemoprevention agents. Personalized approaches based on 
prediction of response to therapy by biomarkers are integrated in 
lung cancer treatment, with much higher success rate and reduced 
useless toxicity. In the context of chemoprevention, no or minimal 
sides effect must be obtained in the high risk population receiving 
the drug because of the absence of active disease, the fact that 
the treatment might have to be taken for many years by a large po-
pulation at high-risk and consequently, the potential huge impact 
on public health. Therefore biomarkers could play crucial roles as 
surrogate intermediate endpoint and as predictors of response to 
targeted treatment. Lung cancers express lower levels of prosta-
cyclin than normal lung tissues. Prostacyclin prevents lung cancer 
in a variety of mouse models. A randomized phase II trial compa-
ring oral iloprost (a prostacyclin analogue) to placebo in high-risk 
subjects demonstrated improvement in bronchial histology but 
only in former smokers (Keith et al, Cancer Prev Res, 4 (6), 2011, 
793-802). This placebo-controlled study offered the opportunity 
for investigation of other potential intermediate endpoints and 
predictive biomarkers to incorporate into chemoprevention trials. 
Matched biopsies (baseline-BL and the same site at follow-up-FU 
after 6 months of Iloprost or placebo) were obtained in 125 high-
risk individuals who completed the trial: 40/35 and 25/25 current/
former smokers in the Iloprost and placebo arm, respectively. 
We analyzed 496 biopsies including 4 matched biopsy pairs per 
patient: the best and the worst histology at BL and the 2 biopsies 
from same site at FU. Total RNA was extracted from formalin fixed 
paraffin embedded sections adjacent to the diagnostic section 
and 14 selected miRNA previously identified in high-grade bron-
chial preneoplasia were analyzed by qRT-PCR (Mascaux et al, Eur 
Respir J, 33, 2009, 352-359). The expression of seven miRNAs was 
significantly correlated with histology at BL. The expression of 
miR-34c was inversely correlated with histology at BL (p<0.0001) 
and with change in histology at FU (p=0.0003), independent of 
treatment or smoking status. Several miRNAs were also found to 
be differentially expressed in current smokers as compared with 
former smokers. In current smokers, miR-375 was up-regulated at 
BL (p<0.0001) and down-regulated after treatment with iloprost 
(p=0.0023). No miRNA at baseline reliably predicted a response 
to iloprost. Thus, miR-34c was inversely correlated with BL histo-
logy and with histology changes. Mir-34c changes at FU could be 
used as a quantitative biomarker to assess histological response in 
formalin-fixed bronchial biopsies in future lung cancer chemopre-
vention studies (Mascaux et al, Canc Prev Res, 6 (2), 2013, 100-108). 
This utility of miR-34c to assess the histological response to che-
moprevention needs to be further demonstrated prospectively in 
other chemoprevention trials. The high-throughput gene expres-
sion profiling of bronchial epithelium (Gustafson et al, Sci Transl 
Med, 2 (26), 2010, 26ra25) and in lung preneoplasia (Mascaux et 
al, J Thor Oncol, 4 (suppl to 9), 2009, abstract PRS.2, page S282) 
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of KRAS mutations in smokers are either G12C (GGT-TGT) or G12V 
(GGT-GTT), while those in never smokers are G12D (GGT-GAT). It 
is thought that not all the KRAS mutations are created equal. The-
re is a report that G12V has a weaker GTPase activity than G12D, 
suggesting stronger oncogenic activity of G12D. It is also generally 
believed that KRAS codon 13 mutation is weaker oncogene than 
codon 12 mutation. In terms of effect of cetuximab in colon cancer, 
tumors with G13D behaves like those with WT KRAS. Prognostic 
impact of KRAS mutations in lung cancer are variably reported, but 
in general it is thought to be a weak negative prognostic factor. 
Whether there is a difference in prognostic impact among different 
KRAS mutations remains to be elucidated. In terms of histologic 
types, KRAS mutations are associated with lung adenocarcinoma 
with mucus production / goblet cell morphology. Lung cancer with 
KRAS mutations often accompanies with CK20 and CDX2. These 
phenotypes are commonly observed in colorectal, pancreato-bi-
liary, and ovarian mucinous carcinomas. How to cope with KRAS 
mutated lung cancer Although KRAS mutations occur in mutually 
exclusionary fashion with activation of other driver oncogenes such 
as EGFR, ALK, ROS1, RET, etc, it appears that not all cancers with 
KRAS mutations are dependent on mutant KRAS. Upon treatment 
of shRNAs to deplete KRAS in lung cancer cell lines harboring 
KRAS mutations, half of the cell lines maintained viability without 
expressing KRAS. This makes it difficult to develop treatment stra-
tegy against KRAS mutated tumors.. Although MEK-ERK signaling 
is an essential downstream of mutant KRAS, single treatment of 
MEK inhibitor exhibits variable responses and PI3K pathway acti-
vation strongly influences its sensitivity. Therefore, simultaneous 
downregulation of MEK-ERK and PI3K-AKT may have potential the-
rapeutic value. Recent approach is to identify synthetic lethal inter-
actions in cancer cells harboring KRAS mutation. In other words, 
it is to find which genes, when silenced, kill cells harboring mutant 
RAS gene but not cells without this mutation. However, the list of 
genes with synthetic lethal activity against RAS mutated tumors 
are expandingand includes THOC1, eNOS, Myc, Survivin, STK33, 
PLK1, SYK, RON, integrin b6, TBK1, NFkB, WT1, PKC delta, CDK4, 
JNK, ATR, GATA2. However, a subsequent and comprehensive 
study could not reproduce the synthetic lethal activity of STK33, 
throwing out the caveat that one should be cautious to interpret 
the RNAi data because individual shRNA can downregulate tens 
or hundreds of off-target genes . Above-mentioned experimental 
evidence suggests that RAS collaborate with many different mo-
lecules depending on cellular contexts to have oncogenic activity. 
This is why the development of RAS-targeted therapy is difficult 
and suggests that it would be necessary to develop combination 
therapy depending on different cellular context.
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Abstract: KRAS mutations are found in ~30% of adenocarcinomas 
and ~5% of squamous NSCLC. They are more common in current 
or former smokers. Most KRAS mutations in NSCLC occur on co-
don 12 and less frequently codons 13 and 61. Prognostic Value of 
KRAS The prognostic significance of KRAS has been investigated 
extensively. Results have been inconsistent with heterogeneity 
among studies including differing endpoints and patient popu-
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Abstract: Biological function of RAS An activity that transforms 
mouse NH 3T3 cells in DNA from human cancers turned out to be 
present in human homologues of retroviral oncogenes found ear-
lier. These genes were named as HRAS or KRAS according to the 
names of corresponding viruses; Harvey- or Kirsten- ratsarcoma 
viruses. The difference between RAS gene present in normal tissue 
and that in cancer tissue was a single missense point mutation eit-
her at codon 12 , and less frequently at codons 13 or 61. The third 
member of the RAS family gene, NRAS was identified one year 
later from a human neuroblastoma cell line, although its viral ho-
mologue was not identified. There is a tendency that a certain type 
of cancer uses a particular type of RAS gene; e.g. most RAS muta-
tions in lung or pancreas cancer occur in KRAS gene, whereas most 
RAS mutations in bladder cancer occur in HRAS gene . RAS gene 
encodes for a 21kDa protein that toggles guanosine diphosphate 
(GDP)-bound inactive form to and from guanosine triphosphate 
(GTP)-bound active form because RAS has a GTPase activity. Gu-
anine nucleotide-exchange factors (GNEFs) and RAS GTPase acti-
vating proteins (RAS-GAPs) positively and negatively regulate the 
amount of GTP bound RAS, respectively. Oncogenic point muta-
tions either at codon 12,or less frequently at codons 13 or 61 make 
RAS impair its intrinsic GTPase activity and confer resistance to 
GAPs, thereby causing RAS to accumulate in its active GTP-bound 
state and sustained activation of RAS signaling. It is known that 
GTP-bound, active RAS interacts with more than 20 effector prote-
ins and stimulates downstream signaling cascades. These effectors 
and corresponding functional outcomes include RAF (proliferati-
on), RIN1 (endocytosis), PI3K (survival), PLCe (second messenger 
signaling), RalGEF (endocytosis). Rather paradoxically, oncogenic 
RAS has been shown to cause senescence in primary cell culture 
through the activation of the WAFp21-p53 or p16-Rb pathways. It 
is also known that, to acquire its biological and transforming activi-
ties, RAS proteins should be bound to inner surface of the plasma 
membranes by appropriate post-translational modification. This 
process includes farnesyltation, proteolytic cleavage of AAX motif, 
carboxymethylation of the terminal Cys and palmitoylation. This 
process was initially thought to be a target of therapeutic interven-
tion. However, inhibition of farnesyl transferase results in alternati-
ve geranylgeranylation of RAS which supports membrane binding. 
RAS gene activation in lung cancer Frequent somatic mutation of 
the RAS gene in lung cancer was first identified in 1987. RAS muta-
tion in lung cancer usually occurs in KRAS, although rare instances 
of HRAS or NRAS mutations are reported. Mutation of the KRAS 
gene usually occurs in adenocarcinoma, rarely in squamous cell 
carcinoma and almost never occurs in small cell lung cancer. KRAS 
mutations predominantly occur in Caucasian patients (~30%) rather 
than East Asians (~10%). Association between KRAS mutation and 
smoking exposure has been reported back in 1991. KRAS mutation 
at codon 12 in lung cancer is characterized by the frequent a G to 
a T transversion in contrast to the frequent a G to a A transitions 
found in colorectal cancer. Even within lung cancer, more than half 
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for bevacizumab+erlotinib (HR 0.93, p=0.7697), while in wild-type 
KRAS, there appeared to be some benefit for the combination (HR 
0.67, p=0.01).14 In the SATURN trial, stable and responding patients 
were randomized to receive maintenance erlotinib or placebo. 
KRAS mutation was detected in 18%. Modest PFS benefit from er-
lotinib was seen both in patients with mutant KRAS and wild-type 
tumors (interaction p=0.95). Data are limited regarding KRAS mu-
tation subtype and response to EGFR-TKIs in NSCLC. One recent 
investigation of KRAS mutation status and response to EGFR-TKI 
in EGFR wild-type advanced NSCLC demonstrated that patients 
with codon 13 KRAS mutations had worse PFS (p=0.04) and OS 
(p=0.005) than patients with codon 12 mutations. However, there 
were only 14 and four patients having mutations in codons 12 and 
13, respectively. Two meta-analyses have evaluated the association 
between KRAS and EGFR TKIs in NSCLC. Linardou et al. assessed 
17 trials (1008 patients, 165 with KRAS mutation). Mutation was 
significantly associated with lack of response to TKIs. Mao et al. in-
cluded 22 studies; 16% (231/1470) had KRAS mutations. ORRs were 
higher for KRAS wild-type compared to mutation (26% and 3%, re-
spectively). The pooled relative risk for response was 0.29 (p<0.01). 
In Asians, relative risk was 0.22 (p=0.01), and 0.31 (p<0.01) in Cau-
casians. In BMS-099, advanced NSCLC patients were randomized 
to receive taxane/carboplatin +/- cetuximab. KRAS mutations 
were found in 17% of assessable samples. There was no significant 
association between KRAS status and response, PFS or OS. The 
FLEX study compared cisplatin/vinorelbine +/- cetuximab in EGFR-
expressing NSCLC. KRAS mutations were detected in 19% of as-
sessable samples. The addition of cetuximab to chemotherapy did 
not significantly affect survival, PFS or response in patients with 
KRAS wild-type or mutated tumors. Summary KRAS is at most, a 
weak prognostic marker in NSCLC. It should not be considered a 
tool to select patients for treatment at this time.
lations studied. A large meta-analysis of 28 studies reported that 
KRAS mutation was a negative prognostic factor for OS (p=0.01) 
when all cancers were considered, in adenocarcinoma (HR 1.52, 
CI 1.30-1.78, p=0.02) but not squamous histology (HR 1.49, CI 
95%: 0.88–2.52; p=0.48). The International Agency for Research 
on Cancer assessed KRAS in 762 patients with resected NSCLC. 
Mutations were detected in 18.5%; KRAS was not prognostic for 
PFS (p=0.26). The LACE-Bio group performed a pooled analysis 
of 1,543 patients from four randomized trials of adjuvant chemo-
therapy vs observation. KRAS mutations were present in tumors 
of 300 patients (codon 12 275, codon 13 24, and 1 codon-14). This 
was the first study to assess the prognostic effect of different KRAS 
mutations. In observation patients, there was no prognostic dif-
ference for OS for codon-12 (HR=1.04) or codon-13 (HR=1.01) mu-
tations, nor for specific codon-12 amino acid substitutions. KRAS 
was not prognostic in the adenocarcinoma subgroup (HR=1.0, 
p=0.97). This group was the first to report that OBS patients with 
KRAS-mutated tumors were more likely to develop second primary 
cancers (HR=2.76, p=0.005). This observation requires validation. 
Predictive Value of KRAS Mutation for Chemotherapy Several 
studies have assessed the predictive value of KRAS in NSCLC 
patients treated with chemotherapy, but few have had untreated 
control arms to be able to isolate the predictive from the prog-
nostic effects of mutation status. Rodenhuis et al. assessed KRAS 
in 83 patients with advanced adenocarcinoma treated with ifosfa-
mide/carboplatin/etoposide; 26% had mutations.10 The presence 
of KRAS mutation was not significantly associated with response 
rate, PFS or OS (p=0.486, p=0.22 and p=0.29, respectively). The 
TRIBUTE trial in advanced NSCLC compared first-line carboplatin/
paclitaxel +/- erlotinib. KRAS mutations were present in 21% of 
samples tested. Response rates in the chemotherapy-alone arm 
were 26% and 23% for patients with wild-type and mutated KRAS, 
respectively, with no significant survival difference (median OS 
13.5 and 11.3 months, respectively). In a neo-adjuvant chemothe-
rapy study, Boermann et al12 reported ORRs of 80% and 77% in 
patients with KRAS wild-type and mutated tumors, respectively. 
PFS was longer in patients with wild-type tumors compared to 
those with mutations (PFS 21 vs 9 mo, p=0.003) although there 
was no difference in OS (p=0.07). The LACE-BIO pooled ana-
lysis revealed no significant effect of KRAS mutation on benefit 
from adjuvant chemotherapy with respect to OS or DFS, even in 
adenocarcinoma (interaction p=0.99). Analysis by KRAS subty-
pe revealed a non-significant benefit from ACT in patients with 
wild-type KRAS (HR=0.89, p=0.15) but not codon-12 mutations 
(HR=0.95, p=0.77); with codon-13 mutations, ACT was deleteri-
ous (HR=5.78, p=0.001, interaction p=0.002). There was a trend 
towards benefit from ACT for codon-12 G12A or G12R (HR=0.66 
p=0.48) but not G12C or G12V (HR=0.94 p=0.77) or G12D or G12S 
(HR=1.39 p=0.48), (comparison of 4 HRs, including WT p=0.76). 
Predictive Value of KRAS Mutation for Epidermal Growth 
Factor Receptor Inhibitors In TRIBUTE, patients with KRAS mu-
tant tumors who received chemotherapy+erlotinib had shorter 
median TTP than those treated with chemotherapy+placebo (3.4 
vs 6 months, p=0.03). OS also was significantly shorter in the 
KRAS mutant subgroup treated with chemotherapy+erlotinib 
than those treated with chemotherapy+placebo (4.4 vs 13.5 
months, p=0.019). In the NCIC CTG BR.21 trial of erlotinib vs 
placebo in advanced NSCLC, KRAS mutations were found in 15% 
of response-evaluable patients in the erlotinib arm. Response 
rates were 10% and 5% for patients with wild-type and mutated 
KRAS, respectively (p=0.69). There was no significant difference 
in survival benefit from erlotinib based on KRAS status (interac-
tion p=0.09) on multivariable analysis (p=0.13), despite a trend in 
univariate analyses (KRAS mutant HR 1.67, p=0.31; KRAS wild-type 
HR 0.69, p=0.03). In the ATLAS trial that compared maintenance 
bevacizumab+placebo to bevacizumab+erlotinib, 93 patients had 
tumors with KRAS mutations. There was no significant PFS benefit 
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effects thus can develop during EGFR TKI treatment. Acneiform 
rash and diarrhea are the most common adverse effects reported 
in the clinical trials. Although most adverse effects of EGFR TKIs 
can be well managed without treatment discontinuation, some 
uncommon adverse effects, such as hepatotoxicity and intersti-
tial pneumonitis, can be serious and life threatening. Therefore, 
cautious monitoring for adverse effects is important to NSCLC 
patients receiving EGFR TKI treatment. Management of Skin To-
xicity Various cutaneous adverse effects can occur during EGFR 
TKI treatment, including acneiform rash, dry skin (xerosis), pruritus, 
nail or periungual alternations, and hair changes. Acneiform rash 
usually involves the upper torso, and appears within 2 weeks of 
treatment initiation. Topical steroids (such as 2.5% hydrocortisone 
acetate cream), tacrolimus, or antibiotics (such as clindamycin 1% 
to 2%) are effective treatments for patients with mild acneiform 
rash. Oral doxycycline (100 mg twice daily) or minocycline (100 
mg twice daily) can be used for those with moderate to severe 
eruptions. When purulent discharge or painful eruptions occurs, 
secondary infection should be suspected. Broad-spectrum empi-
rical antibiotics are recommended for initial treatment of bacterial 
super-infection, and appropriate skin swab for culture is required 
for identification of the causative bacteria. For patients with pruri-
tus during treatment with EGFR TKIs, topical steroid with moderate 
strength or anti-pruritics (such as 5% doxepin cream) can be used 
for symptomatic relief. Oral antihistamines may be required for 
those with more severe symptoms. Topical moisturizing cream or 
ointment and 12% ammonium lactate cream can help relieving 
xerosis associated with EGFR TKI treatment. For patients with pa-
ronychia associated with EGFR TKI treatment, topical antibiotics 
and ultrapotent steroids are recommended, and topical silver 
nitrate application can be used for more severe cases. Although 
cutaneous toxicities are frequent during EGFR TKI treatment, most 
of these cutaneous toxicities are mild to moderate in severity, and 
can be adequately treated without dose reduction or treatment 
discontinuation. Management of Liver Toxicity Hepatoxicity asso-
ciated with EGFR TKIs is less commonly reported in clinical trials. 
However, recent two phase III Japanese clinical trials reported that 
severe hepatotoxicity (defined as serum hepatic aminotrasferase 
levels above five times the upper limit of normal) developed in 16% 
to 28% of patients receiving gefitinib treatment. Furthermore, pa-
tients with lethal hepatotoxicity associated with Erlotinib treatment 
were also reported. Therefore, it is important to regularly monitor 
serum levels of hepatic aminotransferases in NSCLC patients recei-
ving EGFR TKI treatment. Once severe hepatitis develops during 
EGFR TKI treatment, timely discontinuation of EGFR TKIs is requi-
red, with thorough evaluation of other potential etiologies, such 
as acute viral hepatitis. It is not recommended to re-challenge the 
patients with the same EGFR TKIs, which may induce more severe 
hepatic damage even after dose reduction. The efficacy of steroids 
in preventing hepatotoxicity is unknown and is not consistent in 
different reports. Routine steroid treatment is thus not suggested 
in patients with hepatotoxicity associated with EGFR TKIs. Suc-
cessful Erlotinib or Gefitinib treatment has been reported in some 
patients recovering from severe Gefitinib- or Erlottinib-associated 
hepatotoxicity, respectively. Since different CYP450 enzymes are 
involved in the metabolism of different EGFR TKIs, trials of diffe-
rent EGFR TKIs may be considered after recovery from hepatitis, 
especially in responders to EGFR TKI treatment. References: 1. 
Hirsh V. Managing treatment-related adverse events associated 
with egfr tyrosine kinase inhibitors in advanced non-small-cell lung 
cancer. Curr Oncol 2011;18:126-138. 2. Lacouture ME. Mechanisms 
of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 
803-12. 3. Wang SH, Yang CH, Chiu HC, Hu FC, Chan CC, Liao YH, 
Chen HC, Chu CY. Skin manifestations of gefitinib and the associa-
tion with survival of advanced non-small cell lung cancer in Taiwan. 
Dermatologica Sinica 2011; 29: 13-18. 4. Lacouture ME, Schaden-
dorf D, Chu CY, Uttenreuther-Fischer M, Stammberger U, O’Brien 
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Abstract: MANAGING TARGETED THERAPY PATIENTS IN A 
NURSE LED CLINIC Numbers of lung cancer patients on targeted 
therapies are growing as testing becomes more widely available 
and cost effective. Lung cancer Clinical Nurse Specialists and Nur-
se Practitioners are in an ideal position to manage these patients 
for a number of reasons. Patients on Targeted Therapies present 
with unique toxicity profiles which CNS’s and NP’s are developing 
a growing level of expertise in managing. Toxicity profiles include 
rash, nausea, fatigue, cachexia, diarrhoea, deranged liver function 
tests, and shortness of breath. Nurses tend to be the most fre-
quently contacted person between clinic visits, triaging and mana-
ging toxicities. They are ideally placed to proactively monitor pa-
tients, aiding continuity of care and reducing hospital admissions. 
Patients report improved communication, education around ma-
nagement, and continuity, with reduced treatment related anxiety, 
in nurse led clinics. Many CNS and NPs can provide a prescription 
service adding to continuity of care. Support for nurse led clinics 
is essential to ensure patient safety and should be run alongside 
the oncologist’s clinics. Competency of the nurse leading the clinic 
must be maintained through identified supervisors. Utilisation of 
evidence based tools help to ensure best practice is maintained.
Keyword: nurse led targeted therapy
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Abstract: Managing Toxicities of Epidermal Growth Factor 
Receptor Tyrosine Kinase Inhibitors in Non-small-cell Lung 
Cancer Treatment: Focus on Skin and Liver Toxicities Pan-Chyr 
Yang MD, PhD. Department of Internal Medicine, National 
Taiwan University College of Medicine, Taipei, Taiwan. Several 
recent prospective randomized controlled studies have confirmed 
the efficacy of epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs), including Gefitinib, Erlotinib and Afatinib, 
in the treatment of non-small-cell lung cancer (NSCLC) harboring 
EGFR activating mutations (such as L858R or deletions in exon 19). 
Due to less systematic toxicity, treatment with EGFR TKIs is better 
tolerated, compared to platinum-based chemotherapy. However, 
signaling pathways downstream to EGFR are also important to the 
integrity and function of normal epithelium, and specific adverse 
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Abstract: Pain in lung cancer 
Lung cancer is the most common cancer globally with 1.6 million 
people diagnosed with the disease during 2008; over half of them 
in the developing world. Nearly 90% are due to smoking, or pas-
sively smoking, tobacco. The mortality to incidence ratio is 0.86, 
reflecting dismal survival [http//:globocan.iarc.fr/factsheet.asp] . 
Therefore, the focus of care remains one of palliation despite in-
creased options for cancer directed treatment. Optimal symptom 
relief must play a central role. 
A systematic review of pain in people in with lung cancer found 
an overall weighted mean prevalence of pain in 47% patients (6 – 
100%); the wide variation reflecting the different patient settings 
(1). However, for studies in general hospitals, just over one third of 
lung cancer patients had pain, and the weighted mean prevalence 
in a cancer treatment centre was 65%. 
Most pain is attributed to the cancer, either directly, or due to 
treatment (weighted mean prevalence; 13%). Pain is most common 
in the chest, then, pain in the spine. Patients may have multiple 
sites of pain, with other symptoms such as breathlessness, cough, 
and fatigue; pain considered to be one of the top three most dist-
ressing. Severe pain is associated with reduced survival, and inter-
feres with function, enjoyment of life, mood and work(2). According 
to surviving relatives, of the 85% patients who had pain in the last 
year of life, over 50% found it very distressing(3). Management 
Assessment. All symptom management should start with a full 
assessment which extends beyond physical concerns into psycho-
social and spiritual domains, and treatments (and involvement of 
relevant team members) tailored to the needs of the individual, 
remembering the effect on their family and friends. There are 
many extensive pain assessment tools which are not easy to use 
in daily clinical practice. Systematic assessment of every patient 
attending clinic, or admitted to hospital is often overlooked, but 
simple aide memoirs for the busy clinician are available and effec-
tive(4), or simple screening patient report scales. Where patient 
reported symptoms have been embedded in oncology clinical 
practice and linked to symptom management protocols, outcomes 
have improved(5-7). Symptom monitoring should be related to 
factors that patients rate as important such as effect on function 
and relationships with family and friends rather than a score(8). 
The liNKIng of assessment to education (clinician and patient) and 
clinical guidance is important and shown to be more effective than 
education alone(9). 
 
Interventions for pain control 
Radiotherapy. Most pain is from the primary tumour, often with 
haemoptysis and cough. Palliative radiotherapy is effective but not 
extensively documented. One RCT study in non-small cell lung 
cancer shows improvement in pain in three quarters. Other symp-
toms also improved, along with function and wellbeing(10). 
Bony metastases are common in lung cancer, if present over 55% 
lead to one or more skeletal related events. Palliative radiothe-
rapy is the most effective treatment. Onset of relief is between a 
D, Hauschild A. Dermatologic adverse events associated with afa-
tinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013; 
13: 721-8. 5. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N 
Engl J Med 2006;354:731-739. 6. Takeda M, Okamoto I, Tsurutani 
J, Oiso N, Kawada A, Nakagawa K. Clinical impact of switching to 
a second EGFR-TKI after a severe AE related to a first EGFR-TKI 
in EGFR-mutated NSCLC. Japanese journal of clinical oncology 
2012;42:528-533.
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Abstract: Cancer-related fatigue (CRF) is a well-acknowledged, 
very common, phenomena arising from treatment of cancer. It is 
defined as ‘a distressing, persistent, subjective sense of physical, 
emotional, and/or cognitive tiredness or exhaustion related to 
cancer treatment that is not proportional to recent activity and 
interferes with usual functioning’ [1]. In particular, the characte-
ristics of CRF are different to those of fatigue experienced in the 
general population. In persons with lung cancer, the prevalence 
of CRF is very high, with 75 - 100% presenting with this symptom, 
and ≥50% reporting severity to be moderate to marked [2, 3]. The 
mechanisms underpinning CRF are multi-dimensional. These me-
chanisms include both central and peripheral components resul-
ting from disturbances occurring across several systems, including 
physiological, biochemical, and psychological systems [4]. Factors 
that may contribute to CRF include side-effects of treatment such 
as anaemia, nutrition and fluid imbalance, sleep disturbances and 
systemic reactions to tissue injury induced by the disease and/or 
the treatment [5]. In addition, psychological factors can trigger or 
exacerbate CRF. Examples of psychological factors include anxiety 
and depression and difficulty in coping with treatments. Physical 
fatigue, often expressed as a feeling of weakness, lack of energy, 
or exhaustion associated with conducting activities of daily living, 
is thought to be due to a peripheral component. It is postulated 
that these sensations are a consequence of muscles having re-
duced capacity for a contractile response [4]. Several factors can 
conspire during cancer treatment to affect the contractile response 
of muscles, including insufficient oxygen transport and insufficient 
blood pumping to muscles, and severe impairment of skeletal-mu-
scle function [5]. In persons with physical fatigue, sedentary habits 
reinforce fatigue, resulting in a vicious cycle. Exercise has the 
capacity to interrupt this downward decline. There is compelling 
evidence that exercise can address cancer-related physical fatigue. 
A recent Cochrane Review on the role of exercise for management 
of cancer-related fatigue identified 56 randomised controlled trials 
(RCTs); however, the majority were carried out in women with early 
breast cancer [6]. Not surprisingly, timing of interventions varied, 
with some occurring during treatment and others after cessation 
of adjuvant therapies. Mode and intensity of exercise also differed 
across studies: some interventions occurred in the home, while 
others were supervised at institutions or used a combined super-
vised/home based intervention. The major finding from this review 
was that aerobic exercise, including walking programs, or statio-
nary arm or leg cycling significantly reduced fatigue both during 
and following cancer therapy. In addition, approximately half of 
the studies that included quality of life measures (n=17/35 studies) 
reported beneficial effects from exercise. In contrast, no consistent 
benefit from exercise was observed for anxiety or depression. Per-
sons living with lung cancer, from Stage I to IV, appear to have the 
capacity to be physically active. In a systematic review on exercise 
interventions to improve exercise capacity and health-related qua-
lity of life in patients with non-small cell lung cancer, it was conclu-
ded that exercise is safe before and after treatments [7]. However, 
it was also noted that the studies reviewed were either case re-
ports or small RCTs. Well-designed, appropriately powered RCT’s 
are required in this area. Two such studies are currently under way: 
Jones et al [8] are currently recruiting Stage I-IIIA non-small cell 
lung cancer patients treated surgically to participate in a study in 
which participants are randomised to one of four 16 week condi-
few days and 1 month, and lasts between 3 to 6 months(11;12). A 
Cochrane review in 2000 calculated a number needed to treat to 
give complete relief in one patient at one month as 4.2 (95% CI 3.7 
– 4.7)(13). A single fraction of 8Gy is as effective as higher multi-
fractionated doses for the acute relief of pain, although of shorter 
duration(14). Opioids and other analgesics. The WHO analgesic 
ladder remains the standard approach to analgesic use in cancer 
pain with morphine still the most cost-effective first line strong 
opioid; cheaper than the equally effective oxycodone(15;16). In the 
presence of significant renal dysfunction, fentanyl, alfentanil and 
methadone are the least likely to cause harm (17). A systematic 
review confirms a small further benefit with the addition of a non-
steroidal anti-inflammatory drug (NSAID), although the contributo-
ry studies were too small to comment on toxicity(18). Given the re-
cent data on cardiovascular toxicity of NSAIDS, naproxen and low 
dose ibuprofen appear to be the safest in this group(19). Incident 
pain due to bone metastases is difficult to manage with analgesics 
alone because the direct relationship to periods of activity; the 
average duration of incident pain is 60 minutes and so may be 
improving before oral morphine may be fully absorbed. The newer 
transmucosal fentanyl preparations may be more helpful, with an 
onset of action of 10 minutes(20). 
Neuropathic pain often contributes to difficult to manage cancer 
pain. Opioids may provide benefit and a trial should be given. 
Standard adjuvant analgesics such as tricyclic antidepressants 
(duloxetine, amitriptyline) and anticonvulsants (gabapentin and 
pregabalin) and topical agents (capsaicin and lidocaine) may help 
but good quality trials in cancer pain are lacking(21). A recent RCT 
of ketamine for the palliation of refractory cancer pain found no 
benefit with ketamine(22). Another in patients with better perfor-
mance status and where neuropathic pain is deemed to be the 
primary aetiology is almost closed to recruitment [ClinicalTrials.
gov Identifier: NCT01316744]. Corticosteroids are commonly used 
for cancer pain although the evidence base is scant; a systematic 
review only found “low level evidence” for benefit (23). 
Bisphosphonates. Bisphosphonates are not routinely used for pati-
ents with lung cancer. A recent systematic review of bisphosphona-
te use in small cell lung cancer demonstrated improved pain con-
trol (RR 1.18; 95% CI 1.0 – 1.4), reduced skeletal related events (RR 
0.81; 95% CIs 0.67 – 0.97) (24). However, many of the studies were 
of poor quality. Toxicity is usually restricted to transient flu-like or 
gastro-intestinal symptoms, but 15% of those with zoledronic acid 
developed renal dysfunction and 5% the distressing side-effect of 
osteonecrosis of the jaw. Newer agents such as denosumab may 
be tolerated better, but comparative trials in lung cancer are awai-
ted. For the future 
In spite of these options, cancer pain, in general, is under-treated 
even where there is good access. Barriers include fear of, and poor 
education about, opioids in both patients and clinicians with con-
sequent respective poor compliance and prescribing, and a lack of 
systematic screening of patient symptoms with full assessment if 
needed. Until assessment and management of pain is embedded 
into daily clinical practice, this feared symptom will remain a prob-
lem.
Keyword: Pain, lung cancer, assessment, management
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Abstract: Salvage surgery after Radiation: Residual Tumor and 
Complications Definitive chemoradiotherapy is increasingly used in 
the treatment of patients with stage III non-small-cell lung cancer. 
Historically, local control and overall survival rates have been poor. 
To improve local control higher doses of radiotherapy are being 
investigated, with or without new chemotherapeutic agents. Dose-
escalation appears to provide a modest benefit in terms of pre-
venting local failure and improving overall survival, but the benefit 
comes at a price: The risk of both early and late toxicity appears to 
increase as well. 
Despite improved treatment remnants of vital tumor often persist. 
In many patients this has no clinical significance because prognosis 
is determined by the occurrence of distant metastases. However, 
some tumors do not metastasize and local recurrence becomes 
a problem. These patients are then referred for possible surgical 
resection. Because of this possibility of isolated local recurrence, 
doctors Increasingly perform early re-staging procedures after de-
finitive chemoradiotherapy. In case of persistent tumor patients are 
referred for resection as “late-induction cases”. Another category 
consists of patients presenting with complications caused by high-
dose irradiation. These late sequalae of radiotherapy are: bronchial 
stenosis, fatal haemoptysis, esophageal stenosis, fistula’s, cardiac 
complications and the occurrence of 2nd primary tumors. They 
may occur as early as 3 months, but an interval of one or more 
years is not uncommon (1) 
Some of these complications, such as fistula’s or bronchial stenosis 
, require urgent surgical correction, due to their severe symptoms. 
Late surgical resection in irradiated patients has been described 
with good success (2). However, the impaired wound healing ca-
pacity of irradiated tissue makes surgery hazardous and the liberal 
use of non-irradiated tissue flaps is recommended. We describe 
our experience of surgical correction of late complications after 
concurrent chemoradiotherapy: 
Fistulae: A tracheo-esophageal fistula or broncho-esophageal 
fistula is best treated by esophageal resection and tube-stomach 
replacement, because the esophagus is often stenotic and mere 
interposition of a muscle flap between airway and esophagus will 
not suffice.  
Stenosis: Bronchial stenosis requires resection, but re-anastomosis 
carries a high risk of dehiscence. We have seen two cases of dehi-
scence after 6 and 8 weeks, after the sutures had been absorbed, 
in spite of wrapping the suture line with an intercostal muscle flap. 
Tracheomalacia requiring temporary stenting has also occurred 
following partial tracheal resection. 
Hemoptysis: Necrosis and cavitation of an irradiated area may be 
complicated by a fungal infection (aspergillus), causing haemop-
tysis. These patients, who are often weak and malnourished, are 
treated by a staged procedure: First thoracic wall fenestration for 
adequate drainage of the infectied area together with insertion of 
a gastrostomy or jejunostomy catheter for nutritional support. We 
try to avoid nasogastric tubes in these patients, to avoid aspiration. 
tions: aerobic training alone; resistance training alone; combination 
of aerobic and resistance training; and attentioncontrol; and Vardy 
et al [9] are currently exploring the role of supervised aerobic phy-
sical activity with behavioural support specifically on fatigue. One 
finding from the systematic review [7] was that lung cancer patients 
who exercised following surgery, chemotherapy, or radiotherapy 
consistently reported improvements in fatigue. In addition, other 
symptoms such as dyspnoea, pain and cough were also reduced 
with exercise. The interventions were predominantly supervised 
aerobic training, lasting from 10 to 45 minutes, performed at 
moderate to high intensity, 3 times per week over a set period of 
weeks. Interval training of 3 – 5 minutes duration, repeated several 
times per day, is a common feature of exercise programs designed 
for lung cancer. In contrast, and similar to the findings from the 
Cochrane Review on exercise and fatigue [6], progressive resis-
tance training was not effective in reducing fatigue in lung cancer 
patients who had completed 10 weeks of resistance training (n=17). 
Further clarity on the role of resistance training for management 
of fatigue in patients living with lung cancer will be determined 
from the study currently underway by Jones et al [8]. In conclusion, 
exercise is likely to be effective in reducing fatigue for persons 
living with Stage 1 – IV non-small cell lung cancer. However, it is 
important to recognise the support and supervision used in the 
interventions that demonstrated a significant reduction in fatigue. 
References: 1. Mock V. Evidence-based treatment for cancer-rela-
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2004:112-8 2. Iyer S, et al. The symptom burden of non-small cell 
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Exercise for the management of cancer-related fatigue in adults. 
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al. Exercise intervention to improve exercise capacity and health 
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The data should be periodically checked for discrepancies, incon-
sistencies, missing values, in order to ensure a high quality databa-
se. In fact no model or predictive equation can be better than the 
data upon which it is based. If any underperformance in data coll-
ection would be detected this should be reported to all persons 
involved in the process of data recording with the final objective 
of continuously improving the quality of the database. The Euro-
pean Society of Thoracic Surgeons (ESTS) appointed a Database 
Committee responsible to develop and maintain an online clinical 
Database with the aim to collect clinical data from thoracic surgery 
units across Europe. The ESTS Database is an online database, 
which is free to members and directly accessible from the link on 
the ESTS homepage.  
The main purpose of the ESTS database is for quality monitoring 
and improving activities. 
Several outcome and process indicators are included in the data-
set. These indicators have been used to construct a Composite 
Performance Score, which is used as one of the parameters neces-
sary for the European Institutional Accreditation System (EIAS). 
The EIAS is a process aimed at standardization of thoracic surgery 
practice across European units. It is currently based on the infor-
mation submitted to the ESTS Database and focused on major 
lung resections for lung cancer, the prevalent activity in our spe-
cialty. 
In the construction of the CPS, indicators covering all three tempo-
ral domains of our practice (preoperative, intraoperative and post-
operative) were selected. These indicators included risk-adjusted 
hospital mortality and morbidity (outcomes) and 3 process mea-
sures derived from published guidelines: the proportion of lung 
resection candidates with measured DLCO, the proportion of can-
didates to lung resection for NSCLC with clinically suspicious nodal 
disease submitted to preoperative invasive mediastinal staging 
and the proportion of patients with a intraoperative mediastinal 
staging according to the ESTS published guidelines. 
The final composite score combined 3 processes and 2 outcomes 
indicators into a single comprehensive quality score which was 
able to discriminate between the units entering in the compari-
son process. Units eligible for the accreditation process are then 
inspected by a team of auditors appointed by the ESTS to verify 
a sample of data submitted to the ESTS database and the struc-
tural, procedural and qualification characteristics of the unit and 
surgeons working in that unit. Most recently the ESTS Executive 
Committee revised the structural characteristics of general thora-
cic surgery unit in Europe with the aim to provide a comprehensive 
document in line with the quality initiatives of the Society and 
serving as a guide for harmonizing the general thoracic surgical 
practice in Europe. That document will be used as a reference for 
future quality initiatives and educational activities of the society 
Keywords: quality of care, guidelines, Thoracic surgery
At a second stage the cavity is filled with a pedicled muscle flap. 
Depending on the size and location of the cavity, a partial thoraco-
plasty is also performed. The interval between the two operations 
should be limited if the cavity extends towards the hilum, because 
erosion of a vessel wall may cause fatal hemorrhage. 
New treatments for lung cancer create new situations for the thora-
cic surgeon. Good skill, knowledge of old techniques such as tho-
racoplasty and the use of muscle flaps, and emphasis on nutritional 
support are mandatory to solve these problems. 
Keyword: complications radiotherapy surgery
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Abstract: Managed care system, public accountability, cost con-
tainment, pay-for-performance and raNKIng culture demand Qua-
lity of care to be monitored through appropriate instruments. 
Outcome endpoints (i.e. morbidity and mortality) are still the most 
widely used quality indicators in thoracic surgery. 
Outcomes however should be reported in the most correct way to 
prevent risk-averse behaviours and misleading information. 
They need risk-adjustment, as different case-mixes at different ins-
titutions may influence outcome and those units operating on ol-
der and sicker patients would be penalized without an appropriate 
risk-adjustment. Therefore, risk-modelling must become the logical 
and necessary approach for provider profiling and comparative 
audit. The most important tool of any quality assessment endea-
vour is a database that is made up of a representative sample of 
the study group of interest. 
The gold standard for data should be a specialty-specific, proce-
dure-specific, prospectively maintained, periodically audited, elec-
tronic database that contain, at the minimum, a core set of variab-
les that has been demonstrated to be associated with outcome.  
The practical steps that should be planned and possibly recorded 
to construct a solid clinical database are a clear definition of the 
data sources and the creation of a list of variables (and their defini-
tions) that will constitute the database. These steps will permit that 
1) the database can be used even by subjects that did not parti-
cipate to its construction, 2) the database can be audited by ex-
ternal data managers to assess quality of data, 3) changes in data 
collection or variables recording may be adequately planned. 
The importance of the source and the quality of data cannot be 
overemphasized enough. Most of the data that are of clinical in-
terest derive from clinical records or other attached documents, 
such as laboratory exams or PFTs. One of the most critical aspects 
of the database construction is the extraction of the data from the 
medical record to the database. Wherever possible, data should 
be entered in real time, at the point of capture; to this end a net-
worked database should be accessible in the operating theatre, 
the ward, the clinic and the multidisciplinary team meeting room.  
When possible this data should be used to generate documents 
such as operation notes, MDT report, correspondence, so that 
data capture becomes integral to routine patient care. The person 
in charge of capturing or transferring data into a database should 
be properly qualified and adequately trained. 
A Clinical Audit Lead should be selected within each unit who will 
be responsible for the accuracy and quality of data collection. 
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managing these cases will need to consider these matters when 
developing their investigative algorithms. 
Keywords: staging, prognostic factors, Lung cancer, multimodality 
care
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Abstract: The 7th edition of TNM for Lung Cancer, introduced in 
January 2010, was based entirely upon recommendations from the 
IASLC Staging and Prognostic Factors Committee. The enormous 
size of the data base, its international accrual of cases diagnosed 
over a relatively short time period and its inclusion of cases treated 
by all modalities of care, coupled with detailed analysis and inten-
sive validation ensured that this version aligned stage with progno-
sis more accurately than ever before. This was achieved by introdu-
cing new size cut-points for tumour size, re-assigning some T and 
M descriptors and moving some T, N, and M combinations to new 
stage groupings. Inevitably there are questions as to whether the-
re should be consequent changes to established treatment algo-
rithms. These discussions will focus upon the following scenarios: 
a) Larger node negative tumours, > 5cms, are now included in 
stage II. In the past 10 years we have seen data showing that stage 
II cases benefit from adjuvant chemotherapy after complete resec-
tion. Do these "new“ stage II cases benefit from adjuvant therapy? 
b) Cases in which there are additional tumour nodules in the 
tumour-bearing lobe and other ipsilateral lobes have with certain 
combinations of N category, been down-staged to IIIA. Selected 
cases of stage IIIA disease have benefitted from resection, usually 
in a multi-modality setting. Should these cases, now included in 
stage IIIA be treated with regimens including surgery? 
c) Tumours invading certain mediastinal structures that were clas-
sified as T4 in previous editions of TNM have not been re-assigned 
but when associated with N0 or N1 disease these cases have been 
down-staged to stage IIIA. Should they also be considered for 
surgery in a multi-modality setting? 
Whilst it is impossible to give dogmatic and unequivocal advice 
on the right answer to these questions the speaker hopes to give 
some insights into the factors which might influence the decisions 
made by the Multi-Disciplinary Team in such situations. 
Other issues raised by the 7th edition include: 
a) The distinction between pulmonary metastases and synchro-
nous primary tumours has been clarified and the opinion of the 
pathologist has been emphasised in this distinction. Thus in cases 
in which there is more than one malignant nodule biopsy of addi-
tional lesions may be required if such a distinction would alter the 
treatment advised in any case. 
b) The IASLC nodal map and definitions of nodal stations and 
zones are now the recommended means of describing regional 
lymph node involvement in lung cancer. All members of the MDT 
should be familiar with this nomenclature. 
c) The definition of an R0 resection now requires that a defined 
minimum of lymph nodes/stations be removed by the surgeon and 
examined by the pathologist. Surgeons and pathologists need to 
comply with this requirement and other members of the MDT need 
to understand this expanded definition. 
d) The 7th edition of TNM and the new IASLC/ATS/ERS classifi-
cation of Adenocarcinomas may influence the management of 
screen-detected lesions. The new T category of T1a tumours no 
larger than 2cms and the fall in prognosis seen in lesions above 
this threshold may influence the choice of approach to lesions 
around this watershed, one‘s policy of structured surveillance and 
the extent of surgical resection for lesions confirmed to be malig-
nant. As LDCT screening becomes more widely available the MDT 
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Abstract: Hypoxia as a cause of treatment failure in NSCLC Odd 
Terje Brustugun, MD PhD Senior Consultant, The Norwegian Ra-
dium Hospital, Oslo, Norway & Assoc. professor, Faculty of Me-
dicine, University of Oslo, Oslo, Norway Well-oxygenated tumors 
respond better to various therapies than hypoxic tumors. Hypoxia 
is therefore a predictive factor. However, emerging knowledge has 
underscored that hypoxia is also a prognostic factor, independent-
ly of therapy, and that hypoxia in a tumor’s microenvironment in-
duces a more aggressive tumor phenotype. Here, factors involved 
in hypoxia-mediated therapeutic failures will be discussed both 
in the context of therapy resistance and as a tumor biology phe-
nomenon per se. Most tumors (including lung cancer) have a low 
pO2 of 0-7.5 mmHg which can be measured indirectly using tracers 
as 18F-FAZA PET imaging, or via MR-based techniques. However, 
due to the heterogenous distribution and temporal instability of 
hypoxia, such methods are limited by lack of resolution. Oxygen 
molecules diffuse freely in normal tissues, with a diffusion range of 
ca 200 um. However, all solid tumors over 1 cm3 contain hypoxic 
regions due to several factors: abnormal microvessel structure and 
function leading to increased diffusion distance from vessel to cell, 
increased oxygen demand due to increased cellular proliferation, 
reduced oxygen supply due to vascular constriction and increa-
sed interstitial pressure. Anemia, frequently observed in cancer 
patients, adds to the reduced oxygen supply (1). Radiation kills 
cells mainly via production of free radicals that bind to DNA and 
induce strand breaks. Oxygen stabilizes the chemical bond breaks 
in DNA, and makes the damage permanent. Therefore, in oxygen 
absence, DNA is less vulnerable to permanent damage, leading to 
relative radioresistance, and the dose has to be increased substan-
tially to induce the same cell kill. Hypoxia-inducible factor-1 (HIF-1) 
is an intracellular protein whose transcriptional activity is increa-
sed as a response to cellular stresses, including hypoxia (2). HIF-1 
consists of a labile unit (HIF-1α) and a stable unit (HIF-1β), which 
heterodimerize to become transcriptionally active. In normoxia, 
HIF-1α undergoes proteolysis, resulting in a very low level of HIF-
hetereodimers. In hypoxia, degradation of the α-unit is reduced 
leading to an increased level of the functional heterodimer which 
via binding to hypoxia response elements (HRE) induces expres-
sion of genes. Notably, HIF-1 is also regulated by other factors 
apart from, or in concert with molecular oxygen. HRE-elements 
are found in promoter or enhancement regions of various tumor-
promoting families of genes, involved in anaerobic metabolism (3), 
angiogenesis (4), anti-apoptosis (5) and invasion and metastasizing 
(6). Lysyl oxidase, LOX, is upregulated in hypoxia via HIF-1 and is 
shown to be an independent prognostic marker also in lung cancer 
(7). LOX exerts its effect both locally by stimulating migration and 
invasive behavior, and far away from its secretory origin, preparing 
the metastatic niche (8). Blockade of LOX is shown experimentally 
to reduce the metastatic propensity of tumors. HIF-1-mediated 
signaling regulates virtually every step of the metastatic cascade, 
from migration towards blood vessels and intravasation through 
HIF-induced leaky endothelial cells. Further, HIF-1 inhibits anoio-
kis of circulating tumor cells, and hypoxic primary tumors secrete 
factors that permeabilize the endothelium at distant premetastatic 
sites (9). Every element of the stromal compartment is also influ-
enced by hypoxia, including fibroblasts, immune, lymph and blood 
cells, each playing important roles in tumor progression (10) Of 
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Abstract: Non-small cell lung cancer (NSCLC) is a highly lethal 
disease. Despite dose escalation with conformal radiotherapy (RT) 
in combination with modern chemotherapy, there is still a signifi-
cantly high rate of intrathoracic failure and poor overall survival in 
patients with locally advanced disease. Recently, clinical studies 
have shown that blocking the immune check points such as CTLA4 
and PD1 is effective in patients with metastatic NSCLC, resulting 
in a high response rate and improved both progression-free and 
overall survival. This generates enthusiasm for further studying 
the effect of immunomodulation with radiation therapy in earlier 
stage tumors. However, radiation can cause lymphodepletion, and 
persistently profound radiation-associated lymphopenia has been 
linked to poorer tumor control and survival in several solid tumors, 
including NSCLC. Radiation-induce lymphopenia can potentially 
counteract the effect of immunotherapy, making it less effective in 
patients treated with radiotherapy. Unfortunately the mechanism 
of radiation-induced lymphopenia is poorly understood, and un-
less we can overcome such effect, it will be difficult to integrate 
immunotherapy with radiotherapy. Galectin-1 (Gal-1) is a secreted 
carbohydrate binding lectin that is well known for its role in mo-
dulating T-cell homeostasis. More recently, it has been shown to 
play a major role in cancer progression. It is expressed in many 
cancers, including NSCLC, where increased Gal-1 expression is 
closely associated with larger tumors, more nodal metastasis and 
lower overall survival. In human head and neck cancer, expression 
of Galectin-1 was inversely related to intratumoral T-cell level and 
correlated with prognosis. We have previously showed that Gal-1’s 
secretion is enhanced by both hypoxia and radiation in NSCLC. 
Using an immunocompetent mouse model, we have also shown 
that tumor-derived Gal-1 is important for promoting tumor growth 
and spontaneous metastasis in NSCLC. Further mechanistic stu-
dies suggested that Gal-1 mediates its tumor promoting function 
by enhancing intratumoral T-cell death while protecting hypoxic 
tumor cells from apoptosis. More recently, using the same mouse 
model, we found that circulating plasma tumor Gal-1, which is ele-
vated after tumor irradiation, appears to mediate the phenomenon 
of lymphopenia in mice. In addition, in vitro and in vivo studies 
indicate that down regulation of Gal-1 expression or blocking its 
function result in enhanced radiation sensitivity in NSCLC, resul-
ting in more cell kill and tumor shrinkage. Based on these data, we 
believe that the poor outcome associated with radiation-induced 
lymphopenia is due to Gal-1’s effect on tumor infiltrating lympho-
cytes, and it is therefore logical to target Gal-1 in combination with 
radiation in NSCLC.
Keyword: radiation, immunotherapy, galectin 1, lymphopenia
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technique in the diagnosis and characterisation of NSCLC is 18Fluo-
ro-deoxy-glucose (FDG) position emission tomography (PET). PET 
acquired with CT on the same scanner (PET/CT) has been shown 
to be superior to CT alone in the staging of NSCLC. When PET 
is used to select patients for curative therapy an improvement in 
overall survival is seen. Many clinical studies describe an impact 
on the use of PET for target volume delineation (TVD) in NSCLC 
but none describe an improvement in clinical outcomes. Sever-
al staging studies clearly demonstrated the superiority of PET/
CT over CT for identification of involved mediastinal nodes. PET 
based TVD was also shown to improve the identification of invol-
ved mediastinal lymph nodes. In areas of atelectasis, PET can help 
discriminate between areas of collapsed lung and areas of tumour. 
A number of studies have sought to measure the impact of PET/CT 
based TVD on inter-observer variation or against a gold standard. 
When PET/CT is used for target volume delineation alone, and the 
baseline staging issues are removed, PET/CT reduces the undesi-
rable impact of inter-observer variation. Considering the impact 
on the resultant radiotherapy plan, PET/CT based target volume 
delineation has been shown to reduce the dose to normal struc-
tures and this may open the possibility of dose escalation. When 
used in its most basic form, images from the staging PET/CT scan 
can be visually correlated with the radiotherapy planning (RTP) CT 
image to identify areas of disease for inclusion within the treatment 
volume. To improve the accuracy of correlation a staging PET/CT 
scan can be registered with the planning CT and rigid registration 
is recommended to undertake this. One option is to acquire a PET/
CT exclusively for the purpose of RTP after a staging PET has been 
acquired and the patient is deemed suitable for radical radiothe-
rapy, requiring a separate PET scan, but removing any staging or 
patient selection issues. Another approach is to acquire a PET/
CT in the radiotherapy treatment position both for the purposes 
of staging and TVD and this represents a more cost effective ap-
proach. Given the nature of PET images a number of investigations 
have examined the use of automated methods to define the edge 
of the tumour. These methods include: i) Fixed thresholding based 
on absolute values were areas of disease above a given value are 
included within the target volume (e.g. SUVmax >2.5); ii) A contour 
based on the a percentage of the SUVmax (e.g.40% of SUVmax); 
iii) The use of the ratio of the SUVmax to the average SUV within a 
background structure to define the SUV level to generate the auto-
contour; iv) More complicated analytical methods such as the wa-
tershed method. Auto contours provide consistent contours, but 
have difficulty dealing with normal tissue adjacent to the tumour 
with high SUV uptake such as the heart. There is no clear consen-
sus on which method most closely approximates to the tumour 
position and tumour edge and pathological correlation has proven 
difficult. Another difficulty with PET based auto-contouring is the 
variability of SUV values due to factors other than tumour activity 
such patient biological factors and scanning technical factors. At 
present it is recommended that any PET based contouring outside 
of a clinical trial should be based on a visual assessment method. 
As PET images are acquired over a number of minutes at each 
table position, it has been suggested that PET could define the en-
tire motion trajectory of a lung tumour also known as the internal 
target volume (ITV) of a moving lung tumour. It has been demonst-
rated that a 4D PET/CT generated ITV based on the 4D PET image 
approximates to a 4DCT ITV. A number of studies have shown 
sizeable differences in SUV calculation between 3D PET/CT and 4D 
PET/CT and it is suggested that 4DCT provides a more accurate 
SUV quantification. This has implications for auto-contouring and 
may lead to new exciting new methods of PET based TVD based 
on 4DCT. FDG is the most commonly used tracer owing to its high 
tumour specificity and the relatively long half-life of 18F. Other fluo-
rine based tracers have been used to quantify tumour proliferation 
uisng 18 deoxy-fluoro-l-thymidine (FLT) and tumour hypoxia using 
Fluoroazomycin Arabinoside (F-FAZA). It has been suggested that 
special interest in lung cancer, epidermal growth factor receptor 
(EGFR) is involved in several aspects of hypoxia. Recently, hypoxia 
was shown to stimulate invasion via EGFR-activation (11). EGFR is 
also shown to suppress specific tumor-suppressing microRNAs in 
response to hypoxic stress through post-translational regulation 
of a Dicer-regulator, AGO2 (12). A number of HIF-1-upregulated 
genes contribute to radioresistance, perhaps most important is the 
shift from glucose metabolism to a glycolytic phenotype (13). This 
effect increases the cell’s antioxidant capacity via accumulation of 
redox-buffers, thereby reducing the level of free oxygen radicals 
produced by radiation and thus protects the DNA from damage. 
Hypoxic tumors reoxygenate after radiation therapy, as a result of 
reduced demand because of cell death, and due to increased per-
fusion in tissues (14). Based on this, one would expect HIF-1α levels 
to decline after radiation, but the opposite is observed. This phe-
nomenon is primarily caused by 1) increased level of free radicals, 
and 2) liberation of “stress granula” content, both leading to stabi-
lization of the HIF-1α subunit (15). The initial HIF-1-increase occurs 
within hours of radiation. A few days thereafter, increased NO pro-
duced by infiltrating macrophages induces a second peak of HIF-1 
stabilization, via NO-mediated prevention of HIF-degradation (16). 
Both the initial and the later increase of HIF-levels may contribu-
te to a more aggressive phenotype and ultimately to treatment 
failure as cells become more prone to invade and metastasize. 
Several hypoxia sensitizers are in clinical trials, but so far, none are 
in routine use in lung cancer (17). Both HIF-1-inhbitors, as well as 
drugs targeting glucose metabolism should be further examined 
in the context of radiation therapy (13). These studies should not 
only be confined to fractionated therapy, but may likely also have 
positive impact on stereotactic ablative radiotherapy. In conclu-
sion, tumor hypoxia is a major cause of therapy failure and tumor 
aggressiveness, involving a multitude of factors. As knowledge 
emerges, the opportunities of therapeutic interventions should be 
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Abstract: Radiotherapy planning and target volume delineation 
in lung cancer is largely based on x-ray based imaging such as CT 
scanning or fluoroscopy. The most widely used functional imaging 
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Abstract: The cellular hierarchy of the lung is quite complex and 
it is believed that different progenitor cells and stem cell popu-
lations residing within distinct spatial regions of the lung are re-
sponsible for orchestrating lung development, regeneration and 
repair. These different stem cell populations are also likely to be 
instrumental in the development of the various cancers in lung as 
particular lung tumour subtypes are almost exclusively found in 
distinct compartments within the lung. Squamous cell carcinomas 
are thought to arise from the proximal airways, small cell lung can-
cer are predominantly located in the bronchioles while adenocar-
cinomas are more frequently detected the in the distal part of the 
lung. To investigate the cellular origin of lung cancer, we utilized 
Cre-loxP recombination technology, which is an effective method 
for expressing or deleting a target gene in Cre-expressing cells. 
We generated a series of recombinant adenoviruses expressing 
Cre recombinase from specific lung epithelial gene promoters. For 
these studies we chose to target Clara cells, alveolar type 2 (AT2) 
cells and neuroendocrine (NE) cells. Comprehensive experiments 
performed in Rosa26R-lacZ and mT/mG reporter animals showed 
that these viruses exhibit a high level of cell selectivity in the adult 
mouse lung. To address the cellular origins of small cell lung can-
cer (SCLC) we have utilised a sporadic mouse model of small cell 
lung cancer based on the conditional inactivation of the tumour 
suppressor genes Tp53 and Rb1. We infected Tp53F/F;Rb1F/F ani-
mals with our cell type-restricted Adeno-Cre viruses: Ad5-CC10-
Cre, Ad5-SPC-Cre and Ad5-CGRP-Cre. Results from these studies 
show that inactivation of Trp53 and Rb1 can efficiently transform 
neuroendocrine (CGRP-positive) and to a lesser extent, alveolar 
type 2 (SPC-positive) cells leading to SCLC. In contrast, CC10-ex-
pressing cells were largely resistant to transformation. The results 
clearly indicate that neuroendocrine cells serve as the predominant 
cell-of-origin of SCLC in this model. Interestingly a different, cell 
type specificity was observed when a K-rasG12D oncogene-driven 
non-small cell lung cancer (NSCLC) model was used to reveal the 
cell of origin of NSCLC (mostly of adenomas and adenocarcino-
mas). In this case we noted a difference between K-rasLSL-G12D/+ 
and K-rasLSL-G12D/+;Trp53F/F animals following infection with 
our cell type-restricted adenoviruses. In K-rasLSL-G12D/+ mice 
alveolar type 2 cells appeared to be the most effective target cell 
for inducing adenomas, whereas in K-rasLSL-G12D/+;Trp53F/F 
mice multiple cell types had the capacity to give rise to adenomas 
and adenocarcinomas. Moreover, preliminary data from these 
experiments indicates that the cell-of-origin may also influence 
the characteristics and behaviour of the resulting tumours. Taken 
together, our data show that both cell specific features and the 
nature of the genetic lesion(s) are critical factors in determining the 
tumour initiating capacity of lung (progenitor) cells to give rise to 
various lung cancer subtypes.
these may be used for IMRT based dose painting Work is on-going 
to optimise dual tracer PET acquisition. A number of recent pub-
lications have examined the utility of PET for predicting outcome 
after stereotactic ablative radiotherapy (SABR) and demonstrated 
a clear association with SUVmax and poorer outcome. This might 
help identify those patients who might benefit from adjuvant the-
rapy after SABR treatment. PET may have increased accuracy in 
detecting recurrence following SABR and should be used in the 
re-staging process. There is growing evidence of a similar clinical 
utility for PET in the management of patients with SCLC. PET has 
been shown to select patients with SCLC appropriately for radical 
therapy, to be predictive for outcome following therapy and for 
TVD. In conclusion, functional imaging is an essential part of the 
radiotherapy planning process for both NSCLC and SCLC. For 
both disease sites PET is critical for baseline staging and patient 
selection for radical therapy. PET should be used to inform TVD 
in NSCLC and to guide TVD in SCLC. PET is useful for identify re-
lapse in patients treated with radiotherapy. It may also be useful 
as predictor of response and for adaptive radiotherapy. On-going 
research is still required particularly in the era of 4D PET/CT, given 
the promise 4D PET/CT has for improved accuracy in quantification 
and volume delineation.
Keywords: radiotherapy, PET/CT, Image guided radiotherapy, 
Functional Imaging
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of these tumours in vivo. One major controversy surrounding the 
role Hh signaling in cancer relates to the role of tumour stroma as 
a target of Shh signaling. To exclude this as a potential mechanism, 
we used two approaches. First, we crossed the mouse genetic 
model of SCLC referred to above with a reporter mouse in which 
LacZ activity can be used to measure Hh pathway activation. In this 
model, heterogeneous LacZ expression was clearly seen in tumour 
cells, but not stromal cells. Second, we recreated the carboplatin 
regeneration model of human SCLC in vitro using a three dimen-
sional, stroma-free clonogenic assay. Transient manipulation of Hh 
signaling at all levels of the pathway by antibody blockade, siRNA, 
transfection or small molecule treatment dramatically affected 
long term cloning capacity in SCLC cells. Moreover, SCLC cells that 
survived an LD95 treatment with carboplatin in vitro demonstrated 
a marked increase in clonal capacity that was even more sensitive 
to Hh pathway blockade. Confocal immunofluoresence imaging 
of these cells revealed expression of Smo in the tips of numerous 
primary cilia, demonstrating that cell autonomous Hh pathway ac-
tivation could be observed in a subset of innately chemoresistant, 
stem-like cells. In the last 5 years, targeted deletion of different 
components of the primary cilium in mice has dramatically expan-
ded our understanding of the role of these structures in cell sig-
naling. Once considered vestigial, cilia are now recognised as key 
signaling nodes for Hh, WNT, Notch, PDGF and mTOR signaling. In 
addition, we have identified heterogeneous expression of primary 
cilia in several other tumour models, most strikingly in osteosar-
coma. More recently, we have shown that knockdown of KIF3a, an 
essential component of cilia assembly, causes a more dramatic loss 
of cloning capacity than inhibition of Hh signaling alone. These 
data suggest that in a subset of self-renewing tumour cells, cilia-
dependent signaling pathways in addition to Hh are of importance, 
and may represent novel therapeutic targets. We are currently 
using genetically modified mouse models of cancer in which we 
can conditionally knockout Kif3a to address this question.
Keyword: SCLC, Hedgehog, Cilia, Stem Cells
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Abstract: Lung cancer, for its high incidence and mortality, is the 
most common cause of death from cancer in many developed 
countries. In contrast to other cancers, there has been almost no 
improvement in the 5-year survival rates of lung cancer in the past 
30 years, rate just above 10% in Europe, primarily because lung 
cancer is detected in most cases in an advanced stage. 
Detecting lung cancer at an earlier stage and, ideally, predicting 
who will develop the disease and particularly the most aggressive 
forms of cancer are the biggest challenge. 
Imaging via low-dose computed tomography (LDCT) scanning is 
being actively evaluated as a screening tool for early detection of 
lung cancer in high risk patients but, although the positive results 
in mortality reduction reported in the large NLST trial (1) were 
very promising, at present, the real efficacy of LDCT lung cancer 
screening in heavy smokers remains a controversial issue (2). No-
netheless, the high false positive rates of LDCT, leading to multiple 
Keywords: Cell-of-origin, Adeno-Cre viruses, small cell lung can-
cer, non-small cell lung cancer
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Abstract: Small cell lung cancer (SCLC) is a malignant neuroen-
docrine tumour responsible for 20% of all lung cancer deaths. 
Despite the effectiveness of platinum-based chemotherapy, the 
overwhelming majority of patients succumb to a chemoresistant 
recurrence within 2 years of diagnosis. Therefore, the discovery of 
novel strategies to prevent disease recurrence may have a signi-
ficant impact on outcome. Many groups, including our own, have 
identified the importance of embryonic signaling pathways in pro-
moting tumor-regeneration through the regulation of self-renewal. 
Activation of self-renewal pathways such as Notch, Hedgehog (Hh) 
and WNT is also thought to contribute to the survival of cancer 
cells with innate resistance to chemotherapeutic agents. Since the 
naturally occurring Hh inhibitor cyclopamine can block self-renewal 
in SCLC cells in vitro, we postulated that this pathway might be tar-
getable following platinum-based chemotherapy. The Hh pathway 
is a highly conserved signaling system that specifies cell fate and 
self-renewal in development and homeostasis. The Hh ligand Sonic 
Hh (Shh) binds to, and inactivates, the receptor Patched (Ptch). This 
prevents Ptch from inhibiting Smoothened (Smo), the molecular 
target of the small molecule Hh inhibitors. Smo activation requires 
translocation to the tip of the primary cilium, a single, immotile, 
tubulin-based organelle present on most vertebrate cells. The 
ciliary motor protein Kif3a is essential for Smo translocation to the 
ciliary tip, and is required for Smo signaling in development. The 
importance of primary cilia in cancer is poorly understood. In addi-
tion, the formation of cilia is normally restricted to cells in the G0 of 
G1 phases of the cell cycle. In order to better understand how Hh 
signaling is regulated in SCLC, we investigated pathway activation 
in the context of cilia formation, and the expression of Smo protein 
in these cilia. Using a genetic mouse model of SCLC, we observed 
that approximately 25% of tumour cells express primary cilia, with 
a variable number expressing Smo at the cilia tip. Clonal growth of 
these tumour cells could be inhibited by blocking the Shh ligand 
with a monoclonal antibody, or by inactivating Smo with the small 
molecule LDE225 (Novartis). These data suggest that activation 
of Smo by Hh ligand at the level of the primary cilium is a crucial 
step in the initiation and self-renewal of SCLC. By contrast, cilia 
were rarely observed in human SCLC cells, both in vitro and in vivo. 
Based on our hypothesis that Hh signaling may be important in the 
regeneration of SCLC stem-like cells following chemotherapy, we 
employed a primary xenograft model in which we could identify 
minimal residual disease following treatment with single-agent car-
boplatin. Following chemotherapy, more than 50% of the residual 
tumour cells expressed primary cilia, and in the majority of these, 
Smo could be detected in the tip. In addition, marked upregulati-
on of Shh ligand expression was observed. However, when these 
tumours were allowed to regrow to their original size, expression of 
Shh and cilia returned to the same pattern as seen in the treatment 
naive tumour, once again supporting a role for cilia-dependent ac-
tivation of Smo by Hh ligand in SCLC stem-like cells. Furthermore, 
treatment of mice following chemotherapy with several small mole-
cule inhibitors of Smo, including LDE225, delayed the regeneration 
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Abstract: The process of carcinogenesis is driven by clonally 
maintained genetic and epigenetic events that lead to aberrant 
cell proliferation, inhibit cell death, promote cell dissemination, 
and affect other key pathways. Research in the past decade has 
led to new insights into the epigenetic mechanisms controlling 
gene expression, and into the multiple ways in which these me-
chanisms are specifically disrupted in cancer. Epigenetic control of 
gene expression is dependent on modifications of the DNA itself, 
primarily methylation at CpG dinucleotides, and also by a host of 
site-specific protein modifications of histones, histone modifiers, 
and transcriptional machinery. Progress in understanding the mul-
tiple layers of epigenetic control is leading to the development 
and clinical testing of anti-cancer agents specifically targeting 
these aberrant pathways. DNA methylation and histone acetyla-
tion are two well established epigenetic control mechanisms that 
are known to be aberrantly regulated in essentially all cancers, 
including lung cancer. We conducted an exploratory phase I/II 
trial combining an inhibitor of DNA methyltransferase, azacitidine, 
and an inhibitor of histone deacetylase, entinostat, in patients with 
recurrent metastatic non-small cell lung cancer. DNA methylation 
of gene promoters, and loss of histone acetylation, are coordi-
nately regulated processes that can lead to selective silencing of 
gene expression: this mechanism has been implicated in silencing 
key tumor suppressor genes in cancer. Treatment with the com-
bination of azacitidine and entinostat led to rare but impressive 
objective responses, including a complete response in a patient 
with extensively pretreated disease. In addition, a surprising frac-
tion of patients experienced objective responses to the immediate 
subsequent therapy, including standard cytotoxic agents and in-
vestigational agents targeting the PD-1/PD-L1 immune checkpoint 
pathway. Preclinical data offer some potential explanations for this 
screening rounds, the issue of over-diagnosis, the unnecessary and 
sometimes harmful diagnostic follow-up and the costs underscore 
the need for non-invasive complementary biomarkers for standar-
dized use. 
MicroRNAs are small, non coding, endogenous single–stranded 
ribonucleic acids with regulatory functions that are involved in 
tuning of many important pathways, including developmental and 
oncogenic pathways. Because of their fundamental role in deve-
lopment and differentiation, their involvement in the biological 
mechanisms underlying tumorigenesis, as well as their low comple-
xity, stability and easily detection, they represent a promising class 
of tissue and blood-based biomarkers of cancer (3). 
We explored miRNA expression profiles of lung tumors and nor-
mal lung tissues from cases with variable prognosis identified in a 
completed spiral-CT screening trial with extensive follow-up (4). 
We found a panel of deregulated miRNAs discriminating normal 
lung tissue versus lung cancer and significant association of miRNA 
expression profiles in both tumor and non-involved lung tissue 
with clinical-pathological characteristics of the patients such as 
tumor histotype, tumor growth rate, disease free survival. miRNA 
expression profile in tumor and normal lung tissues from patients 
identifed in the first two years of the screening, including mainly 
Stage Ia ADC with excellent survival, was found to be significantly 
different from the profile of subjects with more aggressive tumors 
appearing in later years of screening, independently from tumor 
Stage. Overall these results indicate that, both in tumors and in 
non involved lung tissues, miRNA signatures are able to discrimi-
nate patients according to tumor aggressiveness, independently 
from Stage and type. 
We have then investigated mirRNA profiles in plasma samples from 
cases and controls belonging to two independent LDCT screening 
trials with extensive follow-up where multiple plasma samples, coll-
ected before and at time of disease detection were available. We 
reported that miRNA profiling in plasma samples collected 1–2 yrs 
before the onset of disease, at the time of lung cancer detection 
by LDCT and in disease-free smokers, resulted in the generation 
of four miRNA signatures with strong predictive, diagnostic, and 
prognostic potential (4). Overall, these results suggest that plasma 
miRNA profiles might be helpful in pinpointing those early stage 
tumors at high risk of aggressive evolution that would need additi-
onal treatments. 
We recently completed a large validation study where the dia-
gnostic performance of the plasma-based miRNA test was ret-
rospectively evaluated in samples prospectively collected from 
smoker subjects within the MILD trial. In this study, 1,000 con-
secutive MILD plasma samples collected from June 2009 to July 
2010 among lung cancer-free individuals enrolled in the trial and 
all patients with lung cancer diagnosed by September 2012 (n=85) 
were obtained. 
In patients we analyzed plasma samples collected both pre-di-
sease (four to 35 months before lung cancer detection, median lag 
time of 15 months) and at the time of diagnosis. 
Custom-made microfluidic cards containing the 24 microRNAs 
composing the signatures identified in the exploratory study were 
created, and on each card eight plasma samples were analyzed 
per time. Since the goal of this study was to combine the plasma 
miRNA assay with LDCT results, in order to have a clinical useful 
tool to classify plasma samples, we developed a three-level miRNA 
signature classifier (MSC) of Low, Intermediate, or High risk of di-
sease with subject categorization to one of these three risk groups 
based on pre-defined cut-points of positivity for the four different 
expression signatures of the 24 miRNAs previously identified. 
The results of this large validation study indicates that MSC is a 
significant diagnostic instrument for lung cancer detection with 
prognostic performance and support the combined use of MSC 
and LDCT to improve the efficacy of lung cancer screening (5).  
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Abstract: I will discuss recent results from genomic sequencing 
studies on small cell lung cancer. In particular, results related to 
possible therapeutic opportunities will be a focus of my talk.
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Abstract: Lung squamous cell carcinoma (lung SqCC) is the se-
cond most common histology of non-small cell lung cancer (NS-
CLC). While the treatment of lung adenocarcinoma has developed 
substantially over the past decade due to the discovery of a host 
of therapeutic biomarkers progress in lung SqCC has been more 
modest. However, large scale genomic studies of lung SqCC as 
well as early biomarker directed trials suggest that treatment op-
tions are likely to improve in the near future for lung SqCC given 
the rapid expansion in our knowledge of the molecular basis of this 
disease. There is now an opportunity for substantial improvement 
in outcomes for patients with lung SqCC and my presentation will 
focus on the opportunities and challenges that face our commu-
nity as we try to make progress in treating this disease. Here, I will 
discuss several recent studies which have defined the genomic 
landscape of lung SqCC in multiple patient cohorts and discuss 
the results of these studies in contrast to lung adenocarcinoma. I 
will review the predictive and prognostic biomarkers identified to 
date for lung SqCC and present pre-clinical and early clinical data 
on several therapeutic biomarkers with an emphasis on Fibroblast 
Growth Factor Receptor alterations. I will note clinical trials in pro-
gress and those which are likely to begin soon as well as diagnostic 
testing for patients with lung SqCC. I will also discuss pre-clinical 
data which have shed light on the development of lung SqCCs and 
discuss opportunities for further development in this field.
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observation: many relevant immunoregulatory pathways in both tu-
mor cells and immune effectors are markedly affected by azacitidi-
ne. We are now following up on the priming hypotheses suggested 
by these data, in randomized phase II studies assessing whether 
limited duration epigenetic therapy can enhance subsequent che-
motherapy or immunotherapy efficacy in patients with advanced 
non-small cell lung cancer. This study represents an initial foray 
into combinatorial epigenetic strategy in lung cancer: many other 
strategies are now possible and are being pursued. “Second ge-
neration” agents targeting DNA methyltransferase, including an 
oral formulation of azacitidine and a prodrug, SG-110, are in early 
phase clinical development. So too are newer histone deacetylase 
inhibitors differing in specificity, selectivity, route of administration, 
and pharmacokinetics. Among the exciting new horizons in epige-
netic therapy are new agents targeting more recently defined mo-
difiers of epigenetic control, including many of the readers, writers, 
and erasers of histone modification. The recent remarkable expan-
sion in knowledge about epigenetic regulatory pathways, and how 
they become dysregulated in cancer, is opening new therapeutic 
opportunities in lung cancer and other diseases.
Keyword: epigenetics
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(e.g. due to ethnicity) has still to be determined. A third recent 
study, with a separate cohort of 52 pleural MM, reported absence 
of BAP1 IHC staining in 60% of pleural MM, confirming previous 
results (Arzt et al). The Authors also confirmed the absence of a 
correlation between BAP1 expression and asbestos exposure, and 
suggested that expression of BAP1 in tumor samples is inversely 
correlated to survival. The discovery of BAP1 germline and somatic 
mutations has renewed after decades the interest in MM genetics. 
Because germline BAP1 mutations predispose to multiple cancers 
and because BAP1 loss of heterozygosity is frequent in different 
tumor types, BAP1 would appear to act as a classical tumor sup-
pressor. However, this definition is unsatisfactory because mani-
pulation in vitro of BAP1 expression has often given unexpected 
and paradoxical results, complicating our understanding of its 
mechanisms of action. BAP1 absence (due to genetic, genomic, 
epigenomic or post-translational causes) was reported in about 
60% of pleural MM. No studies so far have thoroughly investigated 
BAP1 expression in MMs arising from other sites. BAP1 expression 
is not associated to asbestos exposure, suggesting that its role in 
MM pathogenesis may be independent from the known asbestos-
related pathways. Other clinicopathological associations are at 
this moment too weak to be conclusive, possibly due to limited 
tumor sample sizes, methodological differences in the studies or 
finally ethical differences of the analyzed populations. It appears, 
but remains unproven, that patients with germline BAP1 mutations 
have less aggressive MMs compared to sporadic MMs in which 
BAP1 mutations do not appear to influence prognosis. More ex-
periments are urgently required to see whether BAP1 expression 
could be use in diagnostic, prognostic, or therapeutic settings. In 
fact, defining a therapeutically accessible synthetic lethal target 
in the setting of BAP1 loss could eventually benefit the approxi-
mately 40-60% of patients with BAP1 negative MMs. Even more 
speculatively, the same synthetic lethal target could be studied as 
chemoprevention drug targets in individuals with germline BAP1 
mutations. The impact of this work obviously extends to other 
cancers with BAP1 mutations.
Keywords: BAP1, mesothelioma, pathogenesis
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Abstract: Malignant mesothelioma (MM) is a lethal cancer whose 
pathogenesis results from complex interactions between host 
genetics and environmental carcinogens, such as asbestos and eri-
onite fibers. Recently, BAP1 (BRCA associated protein 1) has been 
identified as a novel MM tumor suppressor gene. BAP1 is located 
at the 3p21, a region frequently deleted in MM, and encodes for a 
deubiquitinase enzyme known to target histones and other prote-
ins. Originally discovered as a BRCA1 interacting protein, BAP1 ap-
pears to exert its anti-tumor activities mainly in a BRCA-indepen-
dent manner, through its association in multi-protein complexes 
with diverse functions. For example, when associated to the Poly-
comb protein ASXL1, BAP1 is important for the regulation of the 
cell epigenome, via modulation of histone H2A ubiquitination and 
thus chromatin accessibility. In complex with other proteins (e.g. 
HCF-1, OGT, and YY1), BAP1 is also important in the transcriptional 
regulation of several genes and in the stability of target proteins 
such as PGC-1α. Recent reports also suggest a possible involve-
ment of BAP1 in DNA repair pathways. However, the relevance 
of BAP1 to the biology of normal and cancer cells remains largely 
unexplained, in fact manipulation of BAP1 in cancer cells has often 
yielded unexpected or even contradictory results. For example, 
silencing of BAP1 in MM and uveal melanoma cell lines resulted in 
reduced cell growth (Bott et al; Matatall et al). We discovered that 
germline BAP1 mutations cause a novel cancer syndrome charac-
terized by a significant excess of both pleural and peritoneal MM, 
uveal and cutaneous melanoma and possibly other tumors. In the 
same study, we reported that 22% sporadic MM tumors harbored 
somatic BAP1 mutations (Testa et al). In a separate study using 53 
primary pleural MM collected in the USA, 42% of tumors harbored 
either BAP1 loss, BAP1 somatic mutations (detected in 23% of the 
samples), or both. Moreover, another 25% of tumors showed no 
BAP1 staining by immunohistochemistry (IHC) despite apparently 
normal BAP1 status, raising the possibility of post-translational 
deregulation of BAP1 in a subset of cases. In this MM cohort, there 
was a significant association between BAP1 status and patients’ 
age (66.7 years in mutant BAP1 compared to 58.6 years in wild-
type BAP1), but there was no significant correlation with other vari-
ables such as sex, overall survival, histological subtype or asbestos 
exposure (Bott et al). In a recent meeting, using a bigger sample 
size, the same group confirmed that somatic BAP1 mutations occur 
in about 20% of pleural MM. They reported that the only clinical 
variable significantly different among those with and without BAP1 
mutations was smoking (former or current), with BAP1 mutations 
more prevalent among smokers (75% vs. 42%). A Japanese study 
reported BAP1 gene alterations (either deletions or sequence-level 
mutations) in 61% of their 23 MM samples (Yoshikawa et al). Their 
data, but not those reported by Bott et al, also suggested an as-
sociation between BAP1 mutations and the epithelioid histological 
MM subtype. Whether this discrepancy results from the different 
methodologies in sample preparation and detection of BAP1 mu-
tations or it is an intrinsic difference between the two populations 
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Therefore, some investigators have advocated limited resection in 
patients with carcinoid 9, 10) . Some reports revealed that sublobar 
resection was noninferior to lobectomy for survival in patients with 
carcinoid tumor 10) . However, other reports advised that radical 
oncologic surgery with radical node dissection was needed, and 
segmental and other limited procedures had to be avoided be-
cause of the high frequency of lymph node involvement and multi-
centric forms11,12) . A randomized controlled trial is the best method 
to compare surgical efficacies. However, it may be impractical due 
to the rarity of carcinoid tumors. Moreover, AC has a poorer prog-
nosis and a higher frequency of lymph node metastases than TC, 
and preoperative diagnoses and/or diagnoses of intraoperative 
frozen sections are often difficult for differentiating AC from TC 
because small amounts of necrosis or few mitoses are sometimes 
unclear in those specimens. Therefore, sublobar resection for TC 
might be the optimal surgical method because of lung preservati-
on and lower mortality than lobectomy; however, limited resection 
for TC remains an area of controversy. References 
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Abstract: In the 1970s, pulmonary neuroendocrine tumors were 
classified into three histologically defined categories: typical car-
cinoid (TC), atypical carcinoid (AC) and small cell lung carcinoma 
(SCLC) 1) . Later, a fourth high-grade neuroendocrine tumor of 
the lung, large cell neuroendocrine carcinoma (LCNEC) was re-
cognized 2) , and in 1999, the World Health Organization (WHO) 
classified LCNEC as a variant of large cell carcinoma 3) . To date, 
in neuroendocrine tumors of the lung, the major categories of 
morphologically identifiable neuroendocrine tumors are TC, AC, 
LCNEC, and SCLC. 
Lung tumors with neuroendocrine morphology by light microscopy 
encompass a three-grade spectrum of low grade TC, intermedi-
ate-grade AC, and high-grade LCNEC and SCLC. WHO criteria 
show that the mitotic range for TC was less than two mitoses per 2 
mm2 (10 high-power field [10 HPF]), and that for AC was between 
two and ten mitoses per 10 HPF. 
A mitotic count of eleven or more mitoses per 10 HPF is the main 
criterion for distinguishing LCNEC and SCLC from AC. A criterion 
for distinguishing AC from TC is necrosis. Therefore, we classify TC 
as a tumor with carcinoid morphology, lacking necrosis with less 
than two mitoses per 2 mm2. Tumors with carcinoid morphology, 
areas of necrosis and/or 2-10 mitoses per 2 mm2 are classified as 
AC 4) . 
Immunohistochemically, neuroendocrine markers such as chro-
mogranin, synaptophysin, and N-CAM are typically positive in 
TC 4) . Analyses of molecular markers revealed that low-grade TC 
and intermediate-grade AC exhibit a low proliferative rate com-
pared with high-grade LCNEC and SCLC 5) , and TC and AC have 
different genetic alterations from high-grade LCNEC and SCLC 6) 
. Analyses of their genetic alterations show that neuroendocrine 
lung tumors may represent a spectrum ranging from low-grade TC 
and intermediate-grade AC to highly malignant LCNEC and SCLC 
tumors 6) . 
Carcinoid tumors can be diagnosed by cytology of bronchoscopic 
fine needle aspiration or bronchoscopic biopsy specimens. Distin-
guishing TC from AC requires examination of a surgical specimen, 
unless mitoses between two and ten per 10 HPF and/or necrosis 
are seen on a bronchoscopic biopsy 4) . Preoperative FDG-PET 
imaging is frequently positive in carcinoid tumors 7) . 
TC and AC occur equally in males and females, and patients with 
TC and AC are younger than those with LCNEC and SCLC. TC is 
classified as a malignant epithelial tumor of the lung 3,4) . However, 
the overall survival rate is better for TC than for AC 4,8) , and the 
frequency of lymph node metastases in TC is lower than in high-
grade LCNEC and SCLC 8) . 
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pendents DFS predictors were: age > 50 (p= 0.02), paraneoplastic 
syndromes (p=0.02), symptoms at presentation (p= 0.01) and poor 
differentiated histology (p= 0.04). CONCLUSIONS We have confir-
med that Thymic NETs are rare mediastinal tumors presenting with 
an aggressive biological behavior; surgery remains the mainstay of 
treatment and it should be proposed whenever possible, even in 
case of advanced diseases. Recurrences are frequent, especially in 
the first years after operation. Survival is statistically related to the 
tumor size and to the presence of recurrences, whereas, surprisin-
gly, it is not influenced by induction/adjuvant treatment. A global 
International effort is needed to collect larger series and to confirm 
these conclusions. 
 
Figure 1: Thymic NETs overall survival curve 
 
 
 
Figure 2: Thymic NETs: cumulative incidence of tumor recurren-
ces 
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Abstract: INTRODUCTION Mediastinal Neuroendocrine Tumors 
occur most frequently in the thymus. Primary Thymic Neuroendo-
crine Tumors (NETs) are rare and highly aggressive neoplasms; a 
little more than 350 cases have been described in the literature, 
many of which are single case reports. We collected one of the 
largest series ever reported through a multicenter International 
study, with the aim to evaluate factors influencing survival and 
recurrence development in patients with Thymic NETs. MATERIAL 
AND METHODS A multicenter retrospective study of patients 
operated for NETs between 1989 and 2012 in 9 high-volume Inter-
national Thoracic Surgery Institutions, was conducted. According 
to the International Thymic Malignancy Interest Group (ITMIG) 
outcome measures, primary and secondary outcome were Cause 
Specific Survival (CSS) and Disease Free Survival (DFS). Compe-
ting-risks regression models (Fine and Gray method), taking into 
account death by any causes as competing event, were used to 
identify the association between individual factors and tumor 
related death. Cox proportional hazards regression models were 
used to define association between individual factors and DFS, 
considering R0 cases only. Univariate and multivariate analyses 
were also performed. RESULTS There were 52 patients (41 males 
–79%-, median age 49 years). The tumor was asymptomatic in 22 
cases (42%). Endocrine paraneoplastic syndromes were observed 
in 23 cases (44%): 13 Cushing’s syndrome and 10 MEN-1 syndro-
me. Well differentiated neuroendocrine carcinoma (Typical and 
Atypical Carcinoid) was the commonest histological subtype (30 
cases –58%-). Eight patients (15%) received induction therapy (3 
chemotherapy, 2 chemo+radiotherapy, 2 biological therapy and 
1 chemo+radio+biological therapy), because of their radiological 
invasiveness. Median sternotomy was the commonest surgical 
approach (29 cases). The median tumor size was 8 cm (range 
1 – 31 cm); a complete resection (R0) was achieved in 48 cases 
(92%). Advanced Masaoka-Koga stage (III-IV) was observed in 35 
patients (67%). Postoperative treatment was offered to 26 (50%): 
radiotherapy in 17, chemotherapy in 1, chemo+radiotherapy in 5 
and chemo+radio+biological therapy in 3 patient, respectively. 
Three, 5 and 10-year survival rates were 89%, 76% and 51% (Figure 
1). Recurrences were observed in 32 cases (62%): 11 local, 10 in-
trathoracic and 11 distant. Cumulative incidence of recurrence was 
41% at 2 years and 70% at 3 years (Figure 2). Variables influencing 
survival were: tumor size (p< 0.00) and recurrences (p=0.01). Inde-
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teristics of the databases to assess if they are useful for the project 
prior to submission. This is, indeed, the easiest way to contribute: 
to submit your database. CRAB accepts databases on lung cancer 
and mesothelioma. Databases of thymic malignancies can be sub-
mitted either to CRAB or to the International Thymic Malignancies 
Interest Group (ITMIG). ITMIG will assess the data and will forward 
the specific staging data to CRAB for analysis. Those wishing to 
contribute oesophageal cancer cases should get in touch with the 
chair of the Oesophageal Cancer Domain of the SPFC, Dr. Tom 
Rice, at the Cleveland Clinic, Cleveland, OH, USA. Contribution 
is best through the Worldwide Esophageal Cancer Collaboration 
(WECC). Those who want to contribute prospective cases can use 
the on-line registration system that CRAB has established for lung 
cancer and mesothelioma. There also is an on-line registration 
system for thymic tumours provided by the ITMIG. Submitting ret-
rospective databases and on-line registration of prospective cases 
take time and may cost money. In order to facilitate grant applica-
tion to those who need the assistance of a data manager, CRAB 
has prepared a document describing the project that can be used 
to complete the grant application forms. This document can be 
accessed through the IASLC website at www.iaslc.org. Go to ‘Sta-
ging’ and there you will find all the necessary information about 
the IASLC Staging Projects. Those who cannot participate submit-
ting cases can participate analysing data not directly related to the 
main staging projects. An outline of the research project has to be 
sent to the Chair of the IASLC SPFC stating the objectives and the 
variables needed for the study. Approval will be granted based 
on the availability of data, the relevance of the project and the 
willingness of the applicant to pay for the CRAB statisticians’ work 
required for the extraction and analysis of data. (9) References 1. 
Goldstraw P. Report on the international workshop on intrathora-
cic staging, London, October 1996. Lung Cancer 1997;18:107-111. 
2. Goldstraw P, Crowley JJ. The International Association for the 
Study of Lung Cancer international staging project on lung cancer. 
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Association for the Study of Lung Cancer mesothelioma databa-
se. J Thorac Oncol 2012;7:1631-1639. 7. Detterbeck FC, Huang J. 
Overview. J Thorac Oncol 2011;6(Suppl 3):s1689-1690. 8. Rice TW 
et al. 7th edition of the AJCC Cancer Staging Manual: esophageal 
and esophagogastric junction. Ann Surg Oncol 2010;17:1721-1724. 
9. Goldstraw P et al. We probably have the answer: now what is the 
question? J Thorac Oncol 2009:4:939-940.
Keywords: thymoma, IASLC staging projects, Lung cancer, meso-
thelioma
SURGEONS AS DRIVERS OF NSCLC RESEARCH  
MONDAY, OCTOBER 28, 2013 - 14:00-15:30
MS06.2 CLINICAL TRIAL AND RESEARCH  
COOPERATION
Wen Zhao Zhong, Yi-Long Wu
Guangdong Lung Cancer Institute, Guangdong General Hospital &  
Guangdong Academy Of Medical Sciences/China
Abstract: Clinical research in non-small-cell lung cancer is a rapid-
ly evolving field. We conducted a survey of lung cancer surgical 
clinical trials listed on clinicaltrials.gov. 658 records were found, 
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Abstract: The IASLC Staging Projects The International Associ-
ation for the Study of Lung Cancer (IASLC) now has four staging 
projects. The first one, for lung cancer, originated during an inter-
national workshop on intrathoracic staging organized at the Royal 
Brompton Hospital, London, UK, in 1996. (1) It is an ongoing pro-
ject with two phases: a retrospective phase, during which 81,495 
analyzable lung cancer patients diagnosed between 1990 and 
2000 were registered: 68,463 non-small cell lung cancers (NSCLC) 
and 13,032 small cell lung cancers (SCLC) (2); and a prospective 
phase, that includes 78,640 analyzable cases of NSCLC and 5,912 
cases of SCLC diagnosed between 1999 and 2010. The retros-
pective database was used to revise the 6th edition of the tumour, 
node and metastases (TNM) classification and prepare for the 7th 
edition; (3, 4, 5) the data of the prospective phase will be used to 
inform the 8th edition of the TNM classification due to be published 
in 2016. This writer chairs the Lung Cancer Domain. In 2008, meso-
thelioma was incorporated into the activities of the IASLC Staging 
Project lead by Dr. Valerie Rusch as chair of the Mesothelioma 
Domain. As with lung cancer, a call was made to collect retrospec-
tive series from around the world and, at the same time, an online 
registration system was created for prospective collection of data. 
The retrospective mesothelioma database contains 3,101 surgically 
treated patients. This population was first analysed to assess the 
existing TNM classification and staging system for mesothelioma. 
(6) These analyses showed that more data are needed to refine the 
classification beyond what the retrospective database can do. In 
essence, more detailed data on the T, N and M descritpors is nee-
ded. The prospective collection of data is an ongoing project that 
collects surgically and non-surgically treated patients and is in-
tended to inform the 8th edition of the TNM classification. In 2009, 
thymic malignancies were incorporated into the IASLC Staging and 
Prognostic Factors Committee (SPFC). So far, more than 10,000 re-
trospective cases have been collected and are now being analysed 
by the statistitians at Cancer Research And Biostatistics (CRAB), in 
Seattle, WA, USA. The main objective of these analyses is to es-
tablish a TNM classification for thymomas and thymic carcinomas. 
The Thymic Domain of the Committee is chaired by Dr. Frank Det-
terbeck. (7) Finally, also in 2009, oesophageal cancer was incorpo-
rated into the activities of the IASLC SPFC under the leadership of 
Dr. Tom Rice, who is the chair of the Oesophageal Cancer Domain 
of the SPFC. More than 10,000 cases are registered in a database 
stored and analysed at the Cleveland Clinic, Cleveland, OH, USA. 
The surgical cases were used to inform the 7th edition. Plans are 
made to analyse the non-surgical series and validate data to inform 
the 8th edition of the TNM classification. How to contribute Indivi-
duals, institutions, cooperative groups and proprietors of registries 
can contribute by submitting their databases directly to CRAB, 
provided their databases include the information that is essential 
for the IASLC Staging Projects, i.e. clinical and pathological data 
on the different T, N and M descriptors, treatment modality and 
survival. CRAB statisticians have to be informed about the charac-
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symphysis; ③Central tumors; ④Inability to tolerate single-lung 
ventilation; ⑤Previous thoracotomy or high-dose radiation on 
the chest ; ⑥Pregnant or lactating female patients; ⑦Inability to 
sign the informed consent form because of psychological, family 
and society factors; ⑧History of other malignancies in the past 5 
years except for non-melanoma skin cancer, cervix cancer in situ 
or early-stage prostate cancer; ⑨Other uncontrolled factors (like 
intra-operative conversion to thoracotomy). Surgery criteria would 
be a radical lobectomy plus hilar and mediastinal lymph node diss-
ection. Also, the VATS lobectomy was defined by the avoidance of 
rib-spreading and use of the thoracoscope for visualization. The 
total number of ports is not relevant in this definition, but is typi-
cally 3 and 4. Five-year overall survival (OS) and disease-free sur-
vival (DFS), as the primary endpoints will be evaluated. Peri-ope-
rative parameters, including post-operative chest pain, cytokines 
response, post-operative respiratory reserve, Karnofsky perfor-
mance status and QOL would be explored. In addition, operation 
time, intra-operative blood loss, chest tube drainage, indwelling 
period of chest tube, etc. would be documented and compared 
between two groups. Lung Cancer Symptom Scale (LCSS) was ad-
opted to estimate the QOL before operation and at post-operative 
standpoints of 1, 3, 6, 9 and 12 months. Post-operative respiratory 
function would be measured in first three months, while Karnofsky 
performance status and chest pain at the standpoint of 1 year after 
surgery. Cytokines response, to be exact, serum levels of IL-2, IL-4, 
IL-6, IL-10, TNF and IFN-r, would be analyzed in first 48 hours after 
surgery. Randomization was done via an interactive web response 
system with computer-generated randomization codes. This study 
has been registered in Clinicaltrials.gov (NCT01102517) and spon-
sored by Sun Yat-Sen University Clinical Research 5010 plan as well 
as Guangdong provincial high-tech projects. Result: Five leading 
hospitals throughout China contributed to this RCT. 425 patients 
was recruited up to May 2013; nonetheless, 336 patients were 
finally analyzed in the study. The latest DMC review happened on 
May 2013 and our RCT was regarded to be strictly adhering to the 
protocol with good quality control. No surgery-related mortality 
was documented in both VATS and axillary thoracotomy groups. 
Unfortunately, four patients in the study group were excluded be-
cause of intra-operative conversion to axillary thoracotomy. The 
conversion rate was 0.94% (4/425) in our study. Another fact needs 
to be clarified that the remaining 85 patients were excluded due 
to a variety of reasons, which included extensive pleura symphysis 
(9 patients), benign pulmonary lesions (35 patients), small cell lung 
cancer (3 patients), accidental pleural metastasis (2 patients), Age 
> 75 years old (2 patients), invalid case report forms (13 patients), 
and inability to adhere to the randomized surgical approaches (21 
patients). As a result, 175 patients in VATS group and 161 patients 
in axillary thoracotomy group were finalized and analyzed by the 
database. No significant difference between the two groups in 
terms of the anatomical location of the tumors, histological sub-
types and clinical stages. Impressively, the operation time for the 
VATS lobectomy group was significantly shorter than that of the 
control group (150 min vs. 170 min, P<0.05). There was also remar-
kably less intra-operative blood loss in the study group (100 ml vs. 
150 ml, P<0.001). Another important finding was that no signifi-
cant differences were identified regarding the number of cleared 
lymph nodes and number of lymph node regions (10 vs 12; 5 vs 5, 
respectively). The peri-operative complication rates, once again, 
showed no significant difference between the two groups. Patients 
who undertook VATS lobectomy experienced significantly better 
post-operative QOL, and the superiority was showed in all the 
aspects of LCSS. When looking at cytokines response which may 
reflect the acute surgical injuries or trauma, IL-2, IL-4, IL-6, IL-10, 
TNF and IFN-r consistently demonstrated lower expression levels 
throughout the time in the VATS group. However, only the patients 
who recruited in Sun Yat-Sen University Cancer Center underwent 
which were mainly consisted of trials studying the surgical proce-
dure and (neo) adjuvant therapy. Phase III trials account for 15.5%. 
Only 34.9 %( 230 records) trials were completed, and 43 studies 
present results in clinicaltrials.gov. The median time to completion 
(MTC) of Ph III surgical procedure trials was 9.4 years. The MTC of 
Ph III neo-adjuvant and adjuvant trials had not been reached but 
are longer than 10 years. In comparison, the MTC of Ph III trials in 
first line setting were only 4.5 years. We summarized the characte-
ristics of these trials with real-world case examples. Our analyses 
reveal that it is critically needed for regulatory authorities, clinical 
trial sponsors, collaborative research groups, and academic insti-
tutions to work together to build the infrastructure and research 
cooperation for clinical trials with surgical components. In 2007, 
a national collaborative clinical research group, Chinese Thoracic 
Oncology Group (CTONG), was established. CTONG is a network 
of researchers, physicians and healthcare professionals in public 
institutions across China. Currently, there are 22 member hospitals 
in the group. A CTONG-sponsored trial (CTONG1104) is discussed 
to illustrate our experience with surgical clinical trials. In summary, 
to expedite clinical research in early stage lung cancer, it is neces-
sary for investigators to collaborate in cooperative clinical trials. 
As cancer treatment is multidisciplinary, while retaining a surgical 
focus, surgical trials require multidisciplinary collaboration.
Keywords: clinical trial, surgery, Cooperation
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Abstract: Background: Since video-assisted thoracoscopic surge-
ry (VATS) was first reported in the 1990s, this approach has been 
rapidly gaining popularity worldwide because of its less morbidity 
and expedited patient recovery. As a milestone, VATS lobectomy 
was first introduced into NCCN Guidelines in 2006, and then has 
been recommended as a reasonable and acceptable alternative 
in the treatment of non-small cell lung cancer (NSCLC) since 2007. 
However, whether VATS’s superiority really exists in the domain of 
NSCLC has raised unprecedented dispute in the past two decades, 
especially when compared to other minimally invasive approaches 
like axillary thoracotomy. Major debates have involved surgical 
trauma, post-operative neuralgia, shoulder dysfunction, influence 
on respiratory function/quality of life (QOL), and finally oncolo-
gic outcomes. So far, strong evidence demonstrating decreased 
morbidity and equivalent long-term survival of the new technique 
is lacking. In an attempt to obtain a better answer, we designed 
and initiated this multicenter randomized controlled trial (RCT) in 
China, which compared VATS and axillary approaches in terms of 
various surgical and oncologic outcomes for early stage NSCLC. 
Methods: 400 patients were planned to be recruited in this study 
since 2008, and then randomized into VATS group (Experimental 
group) and axillary thoracotomy group (Control group). The Inclu-
sion Criteria include: ①Clinical early stage NSCLC, no hilar and 
mediastinal lymphadenopathy (short diameter ≤ 1 cm assessed on 
computed tomography scan); ②No medical contraindications to 
lung resection; ③Age ≤ 75 years old and ≥18 years old; ④Ability 
to give informed consent. And the Exclusion Criteria are: ①Evi-
dence of invasion into neighboring organs; ②Extensive pleura 
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with researchers in other specialties, resulting in synergies for both 
groups. This may be the way to acquire part time bench space, 
for example. After determining what capabilities are required to 
conduct the projected range of research, funding will be the next 
concern. It is not usually possible to get large project and infra-
structure support without a track record and without the funds it 
is difficult to get a good track record. Therefore preliminary work 
needs to be funded from a range of more modest resources to pay 
for direct research costs and services outside any collaborative 
effort. Local organizations such as Rotary, Apex etc. are often keen 
to donate to research with a potential impact on their community. 
This could, for example, fund the construction of tissue microarrays 
or purchase of essential equipment. Anything that a name can be 
attached to is usually fair game for such donors. Hospital research 
foundations are the easiest target for competitive grants. Specialist 
societies commonly have foundations for distributing grants-in-aid. 
Participation in capitation-funded clinical trials may provide the 
salary for a research coordinator, allowing their spare time to be 
dedicated to translational projects. An Example of Surgeon Driven 
Translational Research After several years of building relationships, 
collaborations, infrastructure and funding, our group was able to 
assess our core research advantages. Figure 1 plots the gradual 
ascent to critical mass for research funding in our thoracic unit.
 
Our example project investigated the genomic/transcriptomic 
landscape of the recently classified subtypes of lung adenocar-
cinoma.1 Other than one gene expression study2 using outdated 
array-based platforms and subtype classifications, no molecular si-
gnature has been reported to correlate to the morphology seen by 
the pathologist under the microscope. It is debated whether these 
subtypes are genetically different or just a spectrum of the same 
tumour. Inter-observer differences in classifying these subtypes are 
particularly problematic for the new micropapillary subtype; there-
fore a molecular marker is an important goal. To investigate these 
new subtypes (table 1), we carefully selected tumors with classical 
morphological regions of the differing subtypes. From this group, 
29 tumours were selected with known mutations in one or more of 
EGFR, KRAS, BRAF and TP53. These would be the most likely cases 
to prove our hypothesis that there are differential genomic aberra-
tions within subtypes of the same tumor.  
Table 1. Subtypes of lung adenocarcinoma investigated, as clas-
sified in the 2011 IASLC/ATS/ERS pathological classification of 
lung adenocarcinoma.
Subtype Description
Lepidic Minimal metastatic potential. Malignant 
cells growing along but not invading 
airway walls 
the evaluation of cytokines response (180 patients). Regarding the 
primary endpoints, although longer follow-up is still needed befo-
re drawing a clear conclusion, initial analyze did show no significant 
difference was seen between the two groups regarding OS and 
DFS. We considered these results were premature, but we also 
believed current data tended to demonstrate a statistical non-infe-
riority result. Conclusions: Our multicenter RCT has illustrated that 
VATS approach is a safe approach for the treatment of early stage 
NSCLC, and may be superior to axillary thoracotomy approach 
in terms of intra-operative blood loss, acute surgical injuries and 
post-operative QOL. However, we also realized that longer follow-
up is necessary to determine its oncologic equivalency.
Keywords: video-assisted thoracoscopic surgery, Minimal incision 
thoracotomy, Lung neoplasm, lobectomy
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Abstract: Introduction Building translational research capacity is 
a daunting task if a thoracic surgeon has not inherited a fully set 
up laboratory. It is possible, however, for a thoracic surgeon to 
be involved in and even drive translational research. Given that 
surgeons are the major procurers of tissue and data in lung can-
cer, it should actually be more commonplace. It requires passion, 
organization, the understanding and assistance of colleagues, and 
the ability to seize what opportunities exist and create new ones 
with strategic collaboration. Creating this capacity also involves 
modifying surgical practice to facilitate research then building 
the relationships, funding and infrastructure. In this article, these 
building blocks are explored. A translational research project is 
presented as a successful application of this formula. Building 
Blocks As a principle, the pillars research capacity-building are: ~ 
Research-Based Surgical Practice ~ Relationships ~ Infrastructure 
~ Funding Sources For individual surgeons and circumstances, 
these may differ. Some components may already exist and some 
may seem unattainable. It is often overlooked that simple chan-
ges to standard practice can make research a natural activity. For 
example, focusing audits on the procedures that are the subject 
of potential research, aligning timing of routine follow-up so that 
outcome assessment becomes automatic, or a policy that all tissue 
excess to diagnostic needs is routinely stored in a tissue bank. A 
research coordinator, at least part-time, is essential for any susta-
inable research activity. Beyond that, key relationships may differ. 
For me, the most important initial relationship is an anatomical 
pathologist with a keen interest in lung. Without such a person to 
review and precisely classify tumors, the power and applicability 
of any study is seriously diminished. However, a relationship with a 
laboratory-based clinician or scientist is necessary in order to have 
access, training and conduct of the benchtop component of re-
search. The surgeon should be active in these endeavours (at least 
initially) to promote goodwill and a free-flowing exchange of ideas. 
Other clinicians or specialist scientists may then need to be invol-
ved depending on the scope of the potential research projects. 
Whatever infrastructure is available for research will often need to 
be augmented. Many useful research tests are already available in 
a diagnostic pathology laboratory (e.g. advanced immunohisto-
chemistry, mutation screening, PCR). Some facilities may be shared 
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Table 1. Subtypes of lung adenocarcinoma investigated, as clas-
sified in the 2011 IASLC/ATS/ERS pathological classification of 
lung adenocarcinoma.
Subtype Description
Acinar
Moderate metastatic potential. Glandu-
lar structures in invasive stroma 
Papillary Moderate metastatic potential. Bran-
ching structures with fibrovascular stro-
mal cores covered by malignant cells. 
Solid with/ 
without mucin 
High metastatic potential. Sheets or 
nests of malignant cells with or without 
intracellular mucin. 
Micropapillary 
High metastatic potential. Papillary 
tufts of tumor cells without fibrovascu-
lar cores either lying apparently free in 
alveolar spaces or surrounded by thin 
fibrous septa, often at a tumor’s edge. 
 
After marking the subtypes in areas of tumor purity > 50%, pun-
ches of formalin-fixed paraffin embedded tumor were deparaffi-
nized and DNA was extracted. High resolution melting was then 
used to screen for mutations in all selected subtypes of each tu-
mor. In 3 out of 11 KRAS mutant tumors and 2 out of 4 BRAF mu-
tant tumors, heterogeneity was found in mutation status between 
subtypes of lesser and higher metastatic potential. No differences 
were seen between subtypes for EGFR mutant tumors, however 
we did find a single case of very high copy number of the EGFR 
mutant allele mapping only to the micropapillary subtype in the 
tumor. The significance of this finding is far-reaching. It provides 
a genetic basis to support the new pathological classification and 
may inform its next revision. It also brings into question the accu-
racy of small biopsies in detecting mutations other than EGFR. It 
has the potential to unravel the biological evolution of lung ade-
nocarcinoma, with EGFR apparently an early event, whereas KRAS 
and BRAF may be acquired later and result in a transition to a more 
malignant subtype phenotype within a given tumor. Conclusion 
This example demonstrates that surgeons can drive important 
translational research as well as advancing other researchers’ 
goals. Although it takes years to develop such programs, once 
critical mass is achieved the results create further opportunities to 
sustain future research and incorporate advances in sequencing 
platforms and knowledge in lung cancer biology.  
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add to impairment of lung function [15]. The finding that over 90% 
of lung cancer patients have contributing causes of death, sug-
gests the possibility that saving a patient from one cause may only 
allow another disease process to become the immediate cause of 
death [15]. Conclusions The majority of patients with lung cancer 
also have serious comorbidity, especially other smoking-related 
diseases as cardiovascular diseases and COPD. Besides making 
treatment complex, comorbid conditions may also serve as com-
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Abstract: Background Over fifty percent of all newly diagnosed 
lung cancer patients are aged over 65 years at the time of lung 
cancer diagnosis, and about 30% are aged over 70. Since lung 
cancer is a disease that mainly occurs in elderly, and smoking is 
the most important risk factor [1], many patients have (smoking-
related) comorbidity at the time of lung cancer diagnosis. This 
may complicate the management of lung cancer and may also 
serve as a competing cause of death. Methods An overview of 
literature concerning the prevalence and prognostic influence of 
comorbidity in lung cancer patients as well as competing causes 
of death. Results Prevalence of comorbidity Previous studies have 
shown that over 70% of patients suffered from at least one serious 
comorbid condition at the time of lung cancer diagnosis [2, 3]. The 
prevalence of (especially tobacco-related) comorbidity was higher 
among lung cancer patients as compared to patients with other 
major tumour types or the general population [2, 4]. The most 
frequent concomitant diseases among lung cancer patients were 
tobacco-related, such as cardiovascular diseases (25-30%), chronic 
obstructive pulmonary diseases (COPD, 25-30%) and previous 
malignancies (about 20%) [2, 3]. Prognostic influence of comorbidi-
ty Since in most cancer trials significant comorbidity is an exclusion 
criteria, limited information is available on the prognostic influence 
of comorbidity (which is important information for everyday clini-
cal practice). Previous studies have shown that comorbidity only 
had a significant influence on survival in case of a localized lung 
tumour or in case of severe comorbidity [2, 3, 5-7]. A poorer overall 
survival in patients with comorbidity might be explained by death 
due to complications of treatment, death from cancer due to less 
aggressive treatment, or an increased risk of mortality due to co-
morbid conditions (competing causes of death). Comorbidity may 
increase the risk of peroperative and postoperative complications, 
especially those of the cardiorespiratory system [8]. A previous 
population-based publication has also shown that up to 75% of 
elderly SCLC patients receiving chemotherapy developed grade 
3-5 toxicity, and two thirds of these patients receiving chemothe-
rapy were unable to complete the treatment [9]. Elderly patients 
with localized non-small cell lung cancer (NSCLC) underwent less 
surgery than younger patients, older patients with non-localized 
NSCLC received less chemotherapy or chemoradiation, and elderly 
with small cell lung cancer (SCLC) received less chemotherapy and 
chemoradiation [5, 9, 10]. Competing causes of death Increased 
mortality due to comorbidity is probably of less importance in 
case of a lethal disease as non-localized NSCLC or SCLC [2, 10, 11]. 
Most patients probably die of lung cancer before they become 
at risk of dying of the comorbid condition. Previous studies have 
shown that 80-90% of all lung cancer patients died of lung cancer. 
The most common other causes of death were other tobacco-
related conditions as cancers and cardiovascular causes [12-14]. 
Respiratory failure is the most common immediate cause of death 
for patients with lung cancer, probably because most of them have 
lung disease besides cancer and therapy for lung cancer may also 
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criteria. Kovalchik et al. subsequently showed that 88% of LDCT-
prevented lung cancer deaths occurred among the 60% of NLST 
participants with highest pre-screening risk, while just 1% occurred 
among the 20% at lowest risk. This finding reinforces the role for 
risk-based screening. Maisonneuve et al. incorporated lung nodule 
characteristics and CT diagnosed emphysema into the Bach mo-
del. Presence of nonsolid nodules (RR = 10.1), nodule size > 8 mm 
(RR = 9.89), and emphysema (RR = 2.36) at baseline CT were all 
significant predictors of subsequent lung cancers. Incorporation of 
these variables into the Bach model increased the predictive value 
of the model (c-index = 0.759). Hoggart et al used prospective 
data from the European EPIC cohort. Using smoking information 
alone gave good predictive accuracy: the AUC and 95% CI in 
ever smokers was 0.843 (0.810-0.875). Adding other risk factors 
(10 occupational/environmental exposures previously implicated 
with lung cancer, and SNPs at two loci identified by GWAS of lung 
cancer) had a negligible effect on the AUC. An extended model 
was constructed incorporating two markers of DNA repair capacity 
that have been shown in case-control analyses to be associated 
with increased lung cancer risk. Addition of the biomarker assays 
improved the sensitivity of the models over epidemiologic and 
clinical data alone. These in vitro lymphocyte culture assays, how-
ever, are time-consuming and require technical expertise, and are 
not applicable for widespread population-based implementation. 
Spitz et al. added 3 SNPS that were most significant in their GWAS 
data – rs1051730 from 15q25 and two SNPs from the 5p15.33 locus 
(rs2736100 and rs401681 that were not in strong LD) to the base-
line model. The AUC for the baseline epidemiologic/clinical model 
including 1016 cases and 1111 controls (all ever smokers) was 0.59. 
There was evidence of a gene dosage effect with an odds ratio 
over threefold elevated in the highest genetic risk score (GRS) 
stratum. With addition of the GRS to the model, the AUC showed 
modest improvement, to 0.61, although this was significantly im-
proved over the baseline model, (P< 0.001). Current lung cancer 
risk prediction models are hampered by a restricted number of 
potential predictors, generally low overall predictive performance, 
and methodological limitations. To date, one can argue that the 
Tammemagi 2013 model exhibits the highest AUC among all the 
prediction models. It is important to conduct additional external 
validations of all models in diverse populations.
Keyword: risk prediction; multivariate models
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Abstract: Results from the National Lung Screening Trial (NLST) 
showing a 20% reduction in lung cancer mortality in the screened 
arm have heightened awareness of the need for reliable risk pre-
diction tools for estimating the probability of lung cancer. A key 
issue of uncertainty is which smokers should be targeted for low-
dose computed tomography (LDCT) screening. The NLST used 
55 - 74 years, ≥30 pack-years of smoking and up to 15 years since 
quitting as selection criteria. 7 million U.S. adults meet these entry 
criteria, and an estimated 94 million U.S. adults are current or for-
mer smokers. Validated risk prediction models could improve the 
outcomes of screening efforts. Such models have substantial pub-
lic health implications and value in clinical decision making as well. 
Further, risk prediction tools could be incorporated into the design 
of smaller, more powerful, and “smarter” prevention trials. The 
first lung cancer risk prediction model was developed by Bach et 
al. using data from the Carotene and Retinol Efficacy Trial (CARET) 
of 14,000 heavy smokers and over 4,000 asbestos-exposed men. 
Variables included in the final model were age, gender, asbestos 
exposure, smoking history, cigarettes per day, duration of smoking 
and duration of cessation. Cronin et al. externally validated the 
Bach model in the Alpha-Tocopherol, Beta-Carotene Cancer Pre-
vention Study control arm (c statistic of 0.69). Spitz et al. expanded 
on this model adding epidemiologic and clinical data derived from 
an ongoing lung cancer case-control study. Their model included 
environmental tobacco smoke (for never and former smokers), fa-
mily cancer history, asbestos and dust exposures, prior respiratory 
disease, history of hay fever, and smoking history variables. These 
variables have strong biologically plausibility and are relatively 
easy to ascertain through patient interview. However, the validated 
area under the curve (AUC) statistics for former and current smoker 
models were modest (0.63 and 0.58, respectively), although con-
sistent with those from other risk prediction models. The LLP mo-
del based on data from the Liverpool Lung Project included age, 
sex and smoking, as well as family history of lung cancer, exposure 
to asbestos, prior diagnosis of pneumonia and of a malignancy 
other than lung cancer. Prior diagnoses of emphysema and lung 
cancer lost significance in the multivariate model. Young et al. de-
veloped a risk model using a 20-single nucleotide polymorphism 
(SNP) panel including cell-cycle control, oxidant response, apopto-
sis, and inflammation genes, as well as age, history of COPD, family 
history of lung cancer, and gender. When numeric scores were 
assigned to both the SNP and demographic data, and sequentially 
combined by a simple algorithm in a risk model, the composite 
score was linearly related to risk with a bimodal distribution. These 
data have not been well replicated. In 2011,Tammemagi published 
a carefully constructed risk prediction model based on data from 
70,962 control subjects in the Prostate, Lung, Colorectal, Ovarian 
cancer screening trial (PLCO). Model 1 included age, education, 
body mass index (BMI), family history of lung cancer, chronic ob-
structive pulmonary disease (COPD), recent chest x-ray, smoking 
status (never, former, current), pack-years smoked, and smoking 
duration. Model 2 also included time in years since ever-smokers 
permanently quit smoking. In external validation, performed with 
44,223 PLCO intervention arm participants, Models 1 and 2 had 
area under the curves of 0.84 and 0.78, respectively. Tammema-
gi and colleagues also showed that their risk prediction model 
for lung cancer incidence was a more sensitive indicator of pre-
screening risk of developing lung cancer than were NLST eligibility 
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Abstract: Tumors evade immune system attack through various 
different mechanisms. One such mechanism is through coopting 
inhibitory immune checkpoints.(1) These inhibitory checkpoints 
cause compromised T cell activation and effector function. The 
two immune checkpoints best known are CTLA-4 and PD-1.(2) 
CTLA-4 is the receptor that is expressed earlier on in T cell acti-
vation and whose ligands are B7.1 and B7.2. Tumor cells have not 
been known to express the CTLA-4 ligands which are only known 
to be expressed on antigen presenting cells (APC). CTLA-4 defi-
cient mice die early on of massive lymphoproliferative disorders.
(3) Alternatively, the PD-1 receptor is expressed later on in T cell 
activation in the periphery and binds to two ligands, PD-L1(B7-H1) 
and PD-L2 (B7-DC). Both ligands are known to be expressed in 
peripheral tissues on APCs as well as tumor cells. Both ligands are 
upregulated by type 1 and 2 interferons, particularly gamma inter-
feron.(4) PD-1 deficient mice develop strain specific autoimmune 
diseases later on in life.(5) 
Antibodies developed to block the binding between co-inhibitory 
receptor and its ligands cause T cell activation. While CTLA-4 blo-
ckade via the antibody, ipilimumab, has yielded an improvement 
in survival in patients with melanoma, PD-1 blockade is earlier on 
its development.(6,7) Several antibodies are in various stages of 
development. Of the antibodies designed to bind to the PD-1 
receptor, Nivolumab (BMS-936558) is furthest along in develop-
ment. In the first in human, single dose study of nivolumab, no 
maximum tolerated dose was found.(8) The pharmacokinetics 
of the antibody revealed a 14 day half-life, but the antibody was 
found to occupy T cell receptors for up to 3 months after treatment 
leading to prolonged pharmacodynamic effects. The toxicities 
were relatively mild and consistent with the immune mechanism 
of action. Early signs of clinical activity were seen in patients with 
melanoma, colon cancer, non-small cell lung cancer (NSCLC), and 
renal cell cancer (RCC).(9) Two patients remain in a complete re-
sponse even up to almost 5 years after their last treatment. One 
patient’s response was maintained up to 18 months after stopping 
treatment and when the cancer progressed, the patient was retre-
ated with nivolumab resulting again in a response. More recently, 
a multidose phase I study of Nivolumab was performed.(10) Again, 
no maximum tolerated dose was found up to 10 mg/kg every two 
weeks. Toxicities again tended to be manageable and consistent 
with the immune mechanism of action. Because of initial signs of 
significant clinical activity, expansion cohorts in NSCCLC, RCC, and 
melanoma were enrolled. Exciting responses in NSCLC (17%) were 
seen. These responses were durable with a median duration of 
response of 17 months. Based on these results, two phase III trials 
have been initiated in the second line treatment setting comparing 
nivolumab to docetaxel in both squamous cell and non-squamous 
cell carcinomas. Another anti-PD-1 antibody, MK-3475, recently 
reported similar toxicities consistent with the immune mechanism 
of action as well as initial clinical activity in melanoma (47% respon-
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Abstract: There has been an explosion of studies, reports and 
clinical experience with Stereotactic Ablative Body Radiotherapy 
(SABR) for lung lesions (both primary and metastatic). Most of the 
experience and published literature focuses on peripheral lesions; 
the published and used SBRT dose/fractions are safe, associated 
with virtually no acute toxitxity and very low rates of subacute and 
late RT toxicity and high rates of local control. There is an emer-
ging experience in treating central lesions, previous described 
as a "no-fly zone“ . There is also an emerging appreciation about 
the multitude of organs at risk -- the intiial focus was on bronchi 
and spinal cord, but clinicians and researchers need to be midful 
of esophagus, great vessels, heart and brachial plexus as well. 
The presentation will review the current state of knowledge and 
highlight the methodological challenges of interpreting the current 
literature, and emphasize the importance of careful followup of 
patients with more centrally located lesions, treated with SABR.
Keyword: SBRT, lung cancer, toxicity
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Abstract: Surgical resection is the standard therapy for early 
stage NSCLC, but about half of the patients still develop a relapse 
and die of their cancer. In case of unresectable locally advanced 
disease, the combination of chemo- and radiotherapy may cure 
some patients, but the majority will relapse. Targeted agents have 
brought progress for patients with advanced NSCLC selected 
based on molecular factors such as EGFR or ALK mutation, but 
other novel approaches are needed. One is therapeutic cancer 
vaccination (TCV), which may become an important part in our 
future treatment armamentarium, especially for patients with 
local or locally advanced NSCLC. Cancer immunotherapy in a 
broad sense is any interaction with the immune system to treat 
cancer. A first approach is non-antigen-specific modulation of 
the immune system. Historical experience (BCG, C. parvum, 
interferon, interleukins, thymosin, etc.) was disappointing. 
Promising response rates in heavily pre-treated NSCLC patients 
were reported in recent phase I trials with agents acting on the 
interaction between antigen presenting cells, T-lymphocytes 
and tumor cells. Examples are antibodies against Cytotoxic 
T-lymphocyte Antigen 4 (CTLA-4) or against Programmed Death 
1 receptor or its ligands. Antigen-specific immunotherapy aims 
at specific priming of immune system to recognize the tumor as 
foreign, thereby generating specific antibodies and/or cytotoxic 
T cells. This is “therapeutic cancer vaccination”. Conditions for 
optimal TCV are: 1/ specificity (well-defined target antigen in the 
tumor, not in other tissues); 2/ selectivity (use in the population 
expressing the target); 3/ immunogenicity (interaction with 
antigen leads to effective humoral and/or cellular response); 4/ 
tumor sensitive to immune kill in order to obtain improvement 
in patients’ outcome. Although the historical results of TCV for 
NSCLC were disappointing, knowledge from the last decades 
about the molecular pathology of tumors, of the immune system 
in general, and of tumor immunity in particular, has led to the 
introduction of several modern and more sophisticated TCVs. 
These vaccine formulations have shown encouraging data in 
phase II randomized clinical trials, and are now being studies in 
large phase III studies. Important examples are the MAGE-A3 
vaccine in resected early stage NSCLC, the BLP-25 vaccine in 
locally advanced NSCLC after chemoradiotherapy, and e.g. 
belagenpumatucel-L and the TG4010 vaccine in advanced stage 
NSCLC. The MAGE-A3 protein is totally tumor-specific and present 
in about 35% of early stage NSCLC. In the hypothesis generating 
double-blind, randomized, placebo-controlled phase II study, 182 
patients with completely resected MAGE-A3-positive stage IB-II 
NSCLC received recombinant MAGE-A3 protein combined with 
an immunostimulant (13 doses over 27 months) or placebo 1. No 
significant toxicity was observed. There was a 24% - non-significant 
- improvement in disease-free survival (HR 0.76; 95% CI 0.48 to 
1.21). Moreover, a predictive gene signature, initially described in 
advanced melanoma patients could be confirmed in early stage 
NSCLC 2.A large phase III study (n=2270) with MAGE-A3 vaccine 
is recruited and awaiting results (MAGRIT, NCT00480025). Mucins 
like the MUC1 protein are present in many epithelia, but MUC1 
expression is altered (mainly by aberrant glycosylation) in many 
cancer types, including NSCLC. The tandem repeat MUC1-peptide 
liposomal vaccine BLP-25 has been studied in patients with stage 
IIIB-IV NSCLC 3. Patients in disease control after conventional 
se rate).(11) Further expansion cohorts were enrolled in NSCLC and 
information is forthcoming. 
Antibodies blocking the ligand, PD-L1, have also been developed. 
Theoretically there may be differences in activity and toxicities 
between the two groups of antibodies. By blocking the PD-L1, the 
interaction between PD-1 and PD-L2 remains intact. It remains to 
be seen if this is meaningful, clinically. The first in human study of 
once every two week dosing of BMS-936559 reported initial tumor 
activity in several tumor types including NSCLC (10%) as well as a 
tolerable safety profile.(12) Another PD-L1 antibody, MPDL3280A, 
initial phase I trial was reported at ASCO in 2013. Toxicities were 
mild, no MTD was reached, and initial clinical activity was seen in 
multiple tumor type including NSCLC (22%).(13) These trials de-
monstrate that the PD-1 pathway is important in tumor immune 
evasion, and by blocking this pathway, immune activation occurs 
which in turn can cause durable tumor control. 
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MS10.3 PLEURAL NEOPLASMS
Sonja Klebe, Douglas W. Henderson
Department Of Anatomical Pathology, Flinders University And Sa Pa-
thology/Australia
Abstract: Pleural neoplasms may be difficult to diagnose because 
they must be distinguished from metastatic malignancy involving 
the pleura, and from benign reactive processes causing pleural 
thickening. In contrast to primary lung neoplasms, primary pleural 
neoplasms are uncommon, with secondary involvement being 
more frequent. A correct diagnosis is important, so that approp-
riate therapy can be delivered. Also, the diagnosis may affect the 
pateint’s prospects for compensation. The most common primary 
pleural neoplasm is mesothelioma, but compared to lung tumours 
even mesotheliomas are relatively rare. Mesotheliomas exhibit a 
wide variety of histologic patterns, which may be confused with 
other neoplasms. Here we consider those other pleural lesions that 
must be differentiated from mesothelioma. Secondary Malignant 
Neoplasms Affecting the Pleura Secondary neoplasms represent 
the most common malignancy affecting the pleura, with lung carci-
noma being the most common, followed by metastatic breast can-
cer, malignant lymphoma, (including Hodgkin and non-Hodgkin 
malignant lymphomas). Metastatic carcinomas of ovarian or gastric 
origin, malignant melanoma and sarcomas account for only a small 
percentage of cancer-associated pleural disease (about 5%). Some 
of these may show diffuse infiltration of the pleura in a pattern in-
distinguishable from pleural malignant mesothelioma macroscopi-
cally and radiologically. The majority of such so-called pseudome-
sotheliomatous neoplasms originate from the lung, but metastases 
from kidney, thyroid gland, larynx, stomach and cutaneous mali-
gnant melanoma as well as various sarcomas, including malignant 
phyllodes tumor, have also been described. Renal cell carcinoma 
(RCC) and amelanotic malignant melanoma may also metastasize 
to the pleura. RCCs with a sarcomatoid pattern can present a dia-
gnostic problem. Labelling for RCC-related markers such as CD10 
can also be seen in mesotheliomas and in sarcomatoid RCCs, the 
other RCC markers may be negative: correlation with imaging stu-
dies is imperative. Rare cases of sarcoma metastatic to the pleura 
may mascerade as mesothelioma and comprehensive clinical 
history is of highest imprtance. Other Neoplasms Arising in the 
Pleura Thymoma Affecting the Pleura Thymoma may spread 
into the pleura from an anterior mediastinal thymoma, but prima-
ry pleural thymomas are described and can present as localised 
masses or with diffuse pleural thickening. The concept of primary 
pleural thymoma has become accepted, but only about 25–30 
cases have been reported to date. Spindle Cell Neoplasms Syno-
vial sarcoma of the pleura Both biphasic and monophasic synovial 
sarcomas (SySa) are characterized by a distinctive t(X;18) chromo-
somal translocation and the production of the resultant alternative 
fusion genes, SYT-SSX1 or SYT-SSX2. SySa are well recognised as 
primary intrathoracic neoplasms in the pleura, where they can be 
confused with biphasic or sarcomatoid mesothelioma, carcinosar-
coma /spindle cell carcinoma, or a biphasic pulmonary blastoma. 
treatment with chemo(-radio)therapy were randomly assigned to 
BLP25 (8 weekly s.c. immunizations, followed by administration 
at 6-week intervals) plus BSC or BSC alone. While overall survival 
(OS) was not significantly different in the total group, a challenging 
effect was observed in stage IIIB patients (HR 0.524; 95%CI 0.261-
1.052). No significant toxicity was observed. At the 2013 ASCO 
meeting, the double-blind, randomized, placebo-controlled phase 
III study was presented (START, NCT00409188) 4. Patients not 
progressing after primary chemoradiotherapy for unresectable 
stage III NSCLC were randomized to BLP25 or placebo. In the 
primary analysis population (n=1239), OS was better with the 
vaccine (HR 0.88, 95%CI 0.75-1.03). In the predefined subgroup 
analysis in patients after concurrent chemoradiotherapy (n=806) 
there was a median OS difference of 10.2 months (HR 0.78, 95%CI 
0.64-0.95). While the most obvious role for TCV is for patients with 
small residual disease after treatment, several compound are in 
phase III testing in advanced NSCLC as well. Belagenpumatucel-L 
is a vaccine based on a mixture of allogeneic tumor cells with 
TGF-β2 antisense blockade as adjuvant. In a phase II open trial, 
survival was related to the dose administered 5. A phase III trial 
in patients with stage III-IV NSCLC in disease control after first-
line therapy is now fully recruited (STOP, NCT00676507). TG4010 
is a vaccine based on a recombinant viral vector (attenuated 
strain of vaccinia virus) expressing both the tumor-associated 
antigen MUC1 and interleukin-2. In a phase II randomized 
study, 148 patients with advanced NSCLC expressing MUC1 by 
immunohistochemistry received either up to 6 cycles of cisplatin-
gemcitabine plus TG4010, or the same chemotherapy alone 6. 
The primary endpoint, a 6-month progression-free survival more 
than 40% in the experimental arm was met. A confirmatory phase 
IIB-III trial is ongoing (TIME, NCT01383148). 1. Vansteenkiste J, 
Zielinski M, Linder A, et al. Adjuvant MAGE-A3 immunotherapy 
in resected non-small cell lung cancer: Phase II randomized study 
results. J Clin Oncol 2013; 31: 2396-2403. 2. Ulloa-Montoya F, 
Louahed J, Dizier B, et al. Predictive gene signature in MAGEA3 
antigen-specific cancer immunotherapy. J Clin Oncol 2013; 31: 
2388-2395. 3. Butts C, Murray N, Maksymiuk A, et al. Randomized 
phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV 
non-small cell lung cancer. J Clin Oncol 2005; 23: 6674-6681. 4. 
Butts CA, Socinski MA, Mitchell P et al. START: A phase III study 
of L-BLP25 cancer immunotherapy for unresectable stage III non-
small cell lung cancer. J Clin Oncol 31 Suppl, abstract 7500. 2013. 
5. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase 
II study of belagenpumatucel-L, a transforming growth factor 
beta-2 antisense gene-modified allogeneic tumor cell vaccine in 
non-small cell lung cancer. J Clin Oncol 2006; 24: 4721-4730. 6. 
Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with 
TG4010 and first-line chemotherapy in advanced non-small cell 
lung cancer: a controlled phase 2B trial. Lancet Oncol 2011; 12: 
1125-1133.
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MS11.2 VALIDATING PLATFORMS FOR ROUTINE CLINI-
CAL USE
Paul Waring
Department Of Pathology, Melbourne University/Australia
Abstract: In this presentation, we describe the process that our 
laboratory followed that led to successful accreditation, by the 
Australian National Association of Testing Authorities (NATA), for 
medical use of NGS in clinical practice. 
 
First, we evaluated three different amplicon –based MPS technolo-
gies in order to choose the platform of choice for clinical use. We 
compared the performance of two commercial somatic mutation 
panels (Life Technology’s AmpliSeq cancer panel and Illumina’s 
TruSeq amplicon panel) and a customized panel (Agilent’s Halo-
Plex). The panels shared 31 genes in common. The AmpliSeq panel 
was sequenced using the Ion Torrent platform and the TruSeq and 
HaloPlex panels were sequenced using the Illumina MiSeq plat-
form. In-house bioinformatics and variant annotation and reporting 
pipeline were developed to allow data from all three panels to be 
compared. A training set of 28 FFPET samples with known mis-
sense or deletion mutations in EGFR, KRAS, BRAF, NRAS, PIK3CA 
and KIT were tested by all three panels. These samples, previously 
tested using NATA - accredited Sanger sequencing, SNaPshot and 
fragment analysis performed on an ABI3730, were used to empi-
rically determine the parameters required for accurate mutation 
detection by MPS. Sample acceptance criteria included samples 
with at least 1mg of extractable DNA following macrodissection 
from tumour areas with at least 70% purity. Library quality was 
assessed by BioAnalyser and libraries were sequenced to a median 
depth of 2000x. 
 
The panels and platforms were compared for % aligned reads, % 
on - target reads, median and range of coverage, input DNA quan-
tity and quality requirements, data quality and variability, cost, 
turn around time, ease of use, and accuracy of mutation detection. 
There was marked variation in the number and types of variants 
identified across the three panels. With minimum variant calling 
criteria of depth >50x, variant depth >20x, variant frequency >5% 
and base quality >15, we identified 18557 variants with AmpliSeq, 
15064 variants with TruSeq and 3326 variants with Haloplex. 14229 
of the TruSeq variants were SNPs (9319 were C>T), indicating DNA 
polymerase errors, while 12370 of the AmpliSeq variants were 
small indels (mostly in homopolymeric tracts) indicating errors in 
calling repetitive sequences. In total, 59 variants were identified 
by all three panels. The TruSeq and Ampliseq panels detected all 
31 known somatic mutations, where as the HaloPex panel missed 
four mutations due to patchy on - target coverage. In panels with 
adequate coverage of regions of interest, the assay sensitivity was 
100%. The TruSeq panel was chosen for clinical use, despite the 
requirement for higher DNA input (150ng compared to 10ng for 
AmpliSeq), primarily due to ease of use and less hands - on time by 
laboratory staff. 
Clinical features, immunohistochemistry and electron microscopsy 
are of limited usefulness and it is the detection of the t(X;18) chro-
mosomal translocation and expression of the resultant SYT-SSX1 or 
SYT-SSX2 that is diagnostic of SySa. This can be done by FISH, but 
PCR is more sensitive and we consider molecular analysis of t(X;18) 
to be mandatory for discrimination between a genuine pleural 
SySa versus a biphasic or monophasic mesothelioma with histolo-
gical appearances that mimic SySa. Solitary Fibrous Tumors (SFTs) 
Of Pleura Solitary fibrous tumors (SFTs) are uncommon localized 
spindle-cell fibroblastoid neoplasms. They most commonly arise 
in relation to the visceral pleura (~80%) or the parietal pleura, but 
they can occur in the mediastinum, lung parenchyma or related to 
pericardium or diaphragm. Terms such as submesothelial fibroma, 
fibrous mesothelioma and localized fibrous tumor have been used 
as synonyms in the past. Localized fibrous tumor might be the best 
term, because multiple simultaneous tumours have been descri-
bed but ‚SFT‘ is well established. Thoracic SFTs can vary greatly 
in size abd have a peak incidence between the 4th and 6th decade. 
SFTs are often incidental findings in asymptomatic patients, and 
the radiologic appearances may suggest the diagnosis, but a bi-
opsy is always required. Symptoms can be related to the size and 
site of the tumor with compression of surrounding tissues. The 
histology ranges from the ‚patternless pattern‘ of Stout to ‚herring-
bone‘, cellular, myxoid and hemangiopericytic or angiofibromatoid 
areas. The mitotic index may be useful to predict malignant beha-
viour. Desmoid Tumors of the Pleura Desmoid tumors in the region 
of the chest wall are well recognized and can impinge upon the 
parietal pleura, but primary desmoid tumors of the pleura and lung 
are extremely rare. Benign and Malignant Nerve Sheath Tumors 
Neoplasms that have histologic and immunohistochemical features 
of nerve sheath tumors can occur as primary tumours in the pleural 
cavity. Benign ones typically show Verocay bodies and Antoni A 
and B areas. When malignant, these cells can cause major diag-
nostic confusion. Immunohistochemical staining with neural mar-
kers such as S100 protein is helpful to confirm a neurogenic origin. 
Inflammatory Myofibroblastic Tumors Inflammatory pseudotumors 
(plasma cell granuloma; inflammatory myofibroblastic tumor) may 
occasionally involve the pleura. They consist of of a proliferation 
of spindle cells with varying numbers of inflammatory cells, with 
prominene of plasma cells. Current thiNKIng favours the concept 
that these are neoplastic lesions with the capacity in some cases 
for multicentricity, angioinvasion and metastasis (especially in ol-
der patients in whom IHC for anaplastic lymphoma kinsae (ALK) 
is negative). Epithelioid Hemangioendothelioma of the Pleura 
Epithelioid hemangioendothelioma is a malignant angioformative 
neoplasm, where the neoplastic endothelial cells are epithelioid 
and sometimes quite bland in appearance. The pattern in H&E-
stained sections may be virtually indistinguishable from mesothe-
lioma, and both may label for thrombomodulin and in some cases, 
cytokeratins. Labelling for endothelial markers such as CD31, 
CD34 or factor VIII-RAG aids in the diagnosis. Pleuropulmonary 
Blastoma Pleuropulmonary blastomas are rare in the pleura and 
mostly occur in early childhood. Tumours consist of primitive cells 
underneath an epithelium with a cambium layer-like appearance 
as seen in sarcoma botryoides. Rhabdomyoblasts may be found 
and anaplastic sarcomatous elements, such as embrynal rhabdo-
myosarcoma, fibrous sarcoma, chondrosarcoma and undifferentia-
ted sarcoma, may be present. Pleural Lymphomas Primary pleural 
lymphomas are rare, with primary effusion lymphoma (PEL) and 
pyothorax-associated lymphoma being the most common. In our 
experience, most cases of pleural lymphoma represent secondary 
spread in cases of previously-diagnosed extrapleural lymphoma.
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MS11.3 THE ROLE OF CURRENT PATHOLOGIC TECH-
NIQUES IN THE NEXT GEN WORLD
Ignacio Wistuba
Translational Molecular Pathology, The University Of Texas MD Ander-
son Cancer Center/United States Of America
Abstract: Over the past decade, significant progress has been 
made in the characterization of molecular and genetic abnorma-
lities tumors from patients with non-small cell carcinoma (NSCLC) 
that are being used as molecular targets and predictive biomarkers 
to select patients for targeted therapy. Recent advances in expan-
ding the available NSCLC targeted therapies require the analysis 
of a broad panel of molecular abnormalities in tumor specimens, 
including gene mutations, gene amplifications, gene fusions and 
protein expression by applying different methodologies to tumor 
tissue (biopsy) and cell (cytology) samples. The rapid development 
of technologies for large-scale sequencing (next-generation se-
quencing, NGS) has facilitated high-throughput molecular analysis 
holding various advantages over traditionally sequencing including 
the ability to fully sequence large numbers of genes in a single test 
and simultaneously detect deletions, insertions, copy number alte-
rations, translocations, and exome-wide base substitutions (inclu-
ding known hot-spot mutations) in all known cancer-related genes 
1,2. Currently, NGS platforms, including whole genome, whole 
exome and targeted gene sequencing, represent emerging diag-
nostic methodologies for the detection of oncogenes fusions and 
mutations in tumor tissue specimens, including formalin-fixed and 
paraffin-embedded (FFPE) samples 3. Technical challenges include 
sequencing samples of low quality and/or quality, reliable identifi-
cation of structural and copy number variation, and assessment of 
intratumoral heterogeneity. In addition, the clinical use of the NGS 
sequencing data is not straightforward and there are several chal-
lenges related to data analysis, data storage and report generation 
4. There is growing consensus that tumor tissue specimens must 
represent the setting of the disease to be treated, and increasingly, 
more tissue samples are being obtained for molecular testing of 
advanced, metastatic and chemo-refractory NSCLC tumors (e.g., 
MD Anderson BATTLE Lung Cancer Program) 5. However, the bio-
psy and cytology samples available for molecular testing in those 
metastatic refractory NSCLC tumors are likely to be more chal-
lenging samples for molecular testing, including NGS platforms. 
The role of the pathologist is becoming increasingly important to 
adequately integrate routine histopathology assessments and mo-
lecular testing, including NGS, with clinical pathology for the most 
accurate tumor diagnosis and subsequent selection of the most 
appropriate therapy. References: 1. Meyerson M, Gabriel S, Getz 
G: Advances in understanding cancer genomes through second-
generation sequencing. Nat Rev Genet 11:685-96, 2010 2. Mweni-
fumbo JC, Marra MA: Cancer genome-sequencing study design. 
Nat Rev Genet 14:321-32, 2013 3. Ross JS, Cronin M: Whole cancer 
genome sequencing by next-generation methods. Am J Clin Pa-
thol 136:527-39, 2011 4. Ulahannan D, Kovac MB, Mulholland PJ, et 
al: Technical and implementation issues in using next-generation 
sequencing of cancers in clinical practice. Br J Cancer 109:827-35, 
2013 5. Kim ES, Herbst RS, Wistuba, II, et al: The BATTLE trial: per-
sonalizing therapy for lung cancer. Cancer Discov 1:44-53, 2011
Keywords: next-generation of sequencing, molecular profiling, 
molecular diagnosis, molecular pathology
We then performed reproducibility, repeatability, robustness and 
limit of detection experiments using the TruSeq panel. Initially, 
there was poor reproducibility of all variants, particularly SNVs, 
especially in samples with low input DNA (<50ng) or poor quality 
DNA (fragment size <250 bp). Most of the identified variants were 
random and present at low frequency, most being present at <1-
2% allele frequency. These showed characteristics suggestive 
sequencing and polymerase errors, formalin – induced artifacts 
and misaligned repetitive sequences. To reduced the great excess 
of false positives, we restricted variant calling by establishing mi-
nimum allele frequencies, by eliminating unreported variants and 
by limiting alignment to clinically- relevant or actionable mutations. 
Variant reproducibility was increased to 38% by only calling SNVS 
>5% and indels >1% allele frequency that were contained within 
the COSMIC database. This was further increased to 92% by re-
stricting variant calling to known clinically - relevant mutations 
listed on the www.mycancergenome web site. Reproducibility was 
increased further by strict adherence to sample and library quality 
control criteria (DNA amount 150ng DNA fragment size at least 
250bp, minimum library concentration of 1nM, and minimum of 
400,000 reads per sample) and by only calling mutations if present 
with allele frequency above 5% for FFPET samples and 1% for AML 
samples. Notabily, non - reproducible “mutations” in clinically 
relevant genes (eg KRAS G12A) were not infrequently encountered 
below these cut off values.  
 
A second independent test set of 82 FFPET samples with known 
missense and deletion mutations in EGFR, KRAS, BRAF, NRAS, 
PIK3CA, KIT and PDGFRA were analysed by the TruSeq panel. 
By strict adherence to the above criteria and restricting variant 
calling to clinically relevant mutations, 100% sensitivity and 100% 
specificity was achieved in the samples that met the criteria. In all, 
only 71% of the samples tested passed all quality control criteria. 
12% of the samples failed the library preparation and were not 
processed. 17% of the samples passed the library QC criteria but 
failed the sample QC criteria. In each case the known mutation was 
identified. 
 
In conclusion, by strict adherence to sample and library QC and by 
restricting analysis to clinically-relevant mutations, the TruSeq am-
plicon cancer panel was able to detect common somatic missense 
and deletion mutations with an allele frequency >5% in FFPET 
samples with 100% specificity and sensitivity without the need for 
confirmation by an orthogonal method. However, confirmation by 
an orthogonal methods would be required for suspected muta-
tions present at an allele frequency <5%, for mutations not known 
to be of clinical – relevance and for samples with low tumour puri-
ty, low DNA input or poor quality DNA.  
 
This study showed that deep sequencing of tumour tissue from 
FFPETs generated many low frequency artifacts due to sequen-
cing, polymerase, formalin – induced chemical modifications and 
well as frequent mapping and variant calling errors. These artifacts 
and errors mostly occur at low allele frequency and can be difficult 
to distinguish from low frequency somatic mutations. Strict adhe-
rence to sample and library quality control criteria, allele frequency 
thresholds and clinically relevant mutations allows highly accurate 
mutation calling without the need for confirmation by an orthogo-
nal method.
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patient prognosis. In this context, especially if there are a number 
of genetic changes being reported (as example with NGS); it may 
be useful if the aberrations (often called variants) are classified into 
categories, which reflect their clinical utility. Although there is as 
yet no universally acceptable classification framework for reporting 
genomic aberrations identified by NGS platforms, broad catego-
ries that establish prognostic, biological or treatment relevance to 
the aberrations have been proposed or used. These variants have 
been classified into several “Levels” or “Tiers”, depending on the 
level of evidence for their predictiveness of response to specific 
drug. These levels have been derived from widely accepted clas-
sification schemes, such as those published by the American Col-
lege of Medial Genetics (ACMG) for use in diseases such as Breast 
Cancer. The “actionable” aberrations are those demonstrating 
proven evidence for their association with high response rates to 
a specific drug or treatment strategy. The “potentially actionable” 
alterations are those with strong rationale but as yet proven clini-
cal evidence for being associated high response rate to a specific 
drug. This group also include aberrations that have demonstrated 
evidence for response to a specific drug in one type of cancer, yet 
of unproven response pattern in a different tumor being studied. 
However, as NGS enables the discovery of a large number of ge-
netic aberrations that typically occur in sporadic adult cancers, 
many aberrations fall into the category of “unknown therapeutic 
or biological significance”. While some of these could potentially 
be predictive markers of drugs that are already available for other 
reasons, most may not even be pharmacologically targetable. An 
important risk of conducting comprehensive genomic profiling in 
patient samples is the identification of “incidental” aberrations, 
which require clinical management that is not originally planned or 
anticipated (2). These aberrations could involve genes/mutations 
with known hereditary roles in cancer or non-cancer conditions, 
with potentially significant implication on patient and/or other 
family members. For these reasons, the ACMG recently conve-
ned a working group of experts to publish recommendations for 
reporting of incidental findings in clinical exome and genome 
sequencing. While these recommendations have been provided 
primarily as educational resources for medical geneticists and 
other health care providers (and are still quite controversial), the 
issues discussed should be considered when deciding upon the re-
porting strategy for profiling cancer samples using NGS technolo-
gy. References: 1. Rehm HL, Bale SJ, et al. ACMG clinical laborato-
ry standards for next-generation sequencing. Genet Med. 2013 Jul 
25. doi: 10.1038/gim.2013.92. [Epub ahead of print] 2. Green RC, 
Berg JS, et al. ACMG recommendations for reporting of incidental 
findings in clinical exome and genome sequencing. Genet Med. 
2013 Jul;15(7):565-74. doi: 10.1038/gim.2013.73. Epub 2013 Jun 20.
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MS11.4 REPORTING AND INTERPRETING MOLECULAR 
RESULTS
Ming S. Tsao
Department Of Pathology, Princess Margaret Cancer Centre/Canada
Abstract: As molecular biomarkers are becoming routine in the 
clinical management of lung cancer patients, there is an increa-
sing need to establish standards or guidelines for the reporting of 
molecular results. In the most ideal situation, reporting of tissue 
based molecular biomarker results should be integrated into the 
histopathology report of the tissue sample, to provide a more 
complete genotype-phenotype characterization of the tumor. This 
is particularly important for lung cancer as molecular profiling to 
date has clearly shown that many “driver” genomic aberrations are 
often closely associated with specific tumor histology. In fact, the 
current CAP/IASLC/AMP guideline on molecular testing in lung 
cancer recommends the use of histology (adenocarcinoma contai-
ning tumors) as a primary criterion to select lung cancer samples 
for EGFR and ALK testing. However, until reflex molecular testing 
becomes routine in pathology practice, molecular testing is often 
conducted at a laboratory that is separate from the one where 
the original tissue histopathological diagnosis was made. In such 
cases, it is important that the stand alone molecular report should 
also include some histopathological data that may be highly rele-
vant to the interpretation of the results, or at the very least, refer 
to the relevant Pathology report. In the Pathology report, the data 
should include: (a) type of sample, whether it is paraffin embed-
ded or fresh (e.g. fluid), (b) tumor diagnosis, subtypes and variants 
when applicable, (c) essential immunohistochemical markers that 
were assessed to support the diagnosis, (d) use of tissue proces-
sing solution or fixative that could adversely affect the quality of 
DNA for sequencing, e.g. acid and Bouin’s solution, (e) the appro-
ximate size of the tissue, (f) whether a tumor cell enrichment strat-
egy was used, and (g) estimated tumor cellularity in the tissue area 
marked for isolation of DNA for testing. It is of utmost important 
that molecular reports are written in language that can be under-
stood by the treating physicians and the pathologists, who are the 
end-users of the report. Typical laboratory reports should include 
patient identification codes, the date the sample was acquired 
(biopsy or resection) from the patient, the date the sample is recei-
ved in the molecular testing laboratory, and the date the report is 
signed out. All this information provides not only important sample 
identification information, but also the real turnaround time of the 
reported results. Aside from a summary of the molecular results 
themselves, the report should include a concise but reasonable 
detailed methodological section, which also provides the perfor-
mance features of the assay platform being used. It should specify 
the list of genes included in the assay, the type of aberrations that 
can be reliably detected, e.g. single nucleotide mutations, deleti-
ons, insertions, rearrangements, copy number changes, etc, and 
the sensitivity and specificity of the assay. The methodology sec-
tion should also include the analytical software used for processing 
the data and identifying the genomic aberrations and the version 
of the normal reference sequence used for comparison with the 
sequence in question. If the methodology used is fairly new or 
represent emerging technology, such as next generation sequenci-
ng (NGS), then information about mutation verification technology 
or process may also be required (1). While molecular aberrations 
are integral to the complete pathological diagnosis of a tumor, 
in lung cancer their main clinical relevance is for their ability to 
predict patient response to a specific therapeutic agent, or for 
S59Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
be at relatively low dose to the port sites, of questionable benefit 
since 2 randomised trials have shown no effect from this interven-
tion at the time of diagnosis12, 13. The MARS group also plan to look 
at the benefits of pleurectomy, but radiotherapy is not currently 
included in the trial outline. Currently this is an area in which virtu-
ally no data exist to support decision making. Radiotherapy is likely 
to remain part of the trimodality recipe for those who continue to 
believe in EPP, at least until the postulated trial of 670 participants 
is completed14, and single centre reports on small numbers of pati-
ents with more complex treatment techniques likely to continue. If 
the next generation of larger trials of radiotherapy looking at port 
site prophylaxis confirm the lack of utility of this intervention, it is 
difficult to see that there will be a role for radiotherapy after pleu-
rectomy. Rather than assume such a role, it is to be hoped, but not 
expected, that randomised trials of the benefits of radiotherapy be 
instituted. 1. Treasure T et al, Lancet Oncol. 2011 Aug;12(8):763-72. 
2. Cao CQ et al, J Thorac Oncol. 2010 Oct;5(10):1692-703. 3. Cao 
CQ et al, Lung Cancer. 2013 Jun 12. doi:pii: S0169-5002(13)00212-
2. 4. http://clinicaltrials.gov/show/NCT00334594 5. Allen AM et al., 
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5. 6. Patel PR et 
al., Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):362-8. 7. Buduh-
an G et al., Ann Thorac Surg. 2009 Sep;88(3):870-5. 8. Van Schil PE 
et al., Eur Respir J. 2010 Dec;36(6):1362-9. 9. Scorsetti M et al., Int 
J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):942-9. 10. Krug, LM et al., 
J Clin Oncol. 2009 Jun 20;27(18):3007-13. 11. Rosenzweig KE et al., 
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1278-83. 12. Bydder 
S et al., Br J Cancer. 2004 Jul 5;91(1):9-10. 13. O’Rourke N et al., 
Radiother Oncol. 2007 Jul;84(1):18-22. 14. Weder W et al, Lancet 
Oncol. 2011 Nov;12(12):1093-4.
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MS12.4 ADJUVANT INTRACAVITARY TREATMENTS IN 
MESOTHELIOMA
Joseph Friedberg
University Of Pennsylvania/United States Of America
Abstract: Mesothelioma remains an incurable disease. Although 
there is compelling evidence that some patients can benefit from 
radical surgery, this modality remains surrounded by controversy 
and true Level I evidence in the form of a randomized prospective 
trial has yet to establish surgery as the standard of care. The dri-
ving principles behind utilizing surgery-based treatments for this 
cancer are that: these tumors are not curable with other modali-
ties, they can reach enormous volumes where surgery is the only 
current modality that has expectation of achieving a significant 
response, as a general rule these cancers tend to progress locally 
to the point of patient demise without extrahemithoracic disease 
being present or of clinical significance. Because it is not possible 
to achieve completely negative margins in the overwhelming ma-
jority of pleural cancers, the realistic goal of any radical surgical 
procedure is to achieve a macroscopic complete resection. It is 
logical, therefore, to employ intraoperative adjuvant therapies in 
an effort to control the microscopic disease that remains after sur-
gery. To date there are several different intraoperative adjuvants 
that have been employed with any regularity in the treatment of 
pleural mesothelioma: intraoperative radiation, heated perfusion 
with either chemotherapy or povidone iodine and photodyna-
mic therapy. Each has its own advantages and disadvantages, 
from both oncologic and technical perspectives. Intraoperative 
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MS12.3 PERI-OPERATIVE RADIOTHERAPY: CURRENT 
DATA AND STATE OF THE ART
Allan Price
Edinburgh Cancer Centre/United Kingdom
Abstract: Formal prospective evidence of benefit from cancer 
treatments for patients with mesothelioma exists only for the small 
survival increment obtained from combinations of cisplatin and 
anti-folate agents in those with inoperable disease. Despite this 
absence of evidence of benefit, and some evidence of detriment, 
trimodality therapy including neoadjuvant chemotherapy, surgery 
and adjuvant radiotherapy continues to be regarded as a wides-
pread standard of care in early disease. Only one very small ran-
domised trial has addressed this question1, and the evidence from 
that trial suggesting a substantial increase in mortality has been 
disputed by many believers in trimodality therapy. The surgical 
literature has recently been extensively reviewed, revealing the 
paucity of high level evidence for these treatments2-3. One Swiss 
trial investigated the role of radiotherapy in this combination, but 
closed last year because of poor accrual due to changes in surgical 
fashion (NCT00334594) 4. The two major surgical approaches to 
early mesothelioma have been extrapleural pneumonectomy (EPP), 
first described over 30 years ago, and presented in 16 published 
reports of which 5 were prospective and only 1 randomised2. None 
of these studies directly compare radiation doses or techniques, 
and no firm conclusions are possible regarding dose response, 
or the superiority of techniques as variable as a simple opposed 
pair with or without electrons to intensity modulated radiotherapy 
(IMRT) or protons. It seems extremely unlikely that such data will 
ever exist, and what radiotherapy is used will continue to depend 
mainly on the expertise, technology and time available locally. 
There have been publications5,6, reporting an unexpectedly high 
morbidity and mortality following IMRT and there may be an 
argument that simplest is best given the general lack of fatal out-
comes with conventional radiotherapy, although dose coverage 
of certain areas is poor. One report suggested lower local failure 
with IMRT7, but this may have related to the higher dose given 
(50.4 Gy vs 30 Gy) and it was unclear why the slightly higher dose 
(54 Gy) 8 normally used postoperatively was not possible. If IMRT 
is to be used then treatment times may be shorter with volumetric 
modulated arc therapy9. Whether as a result of the MARS trial, or 
the disappointing outcomes from prospective trials conducted 
by the EORTC and in the US8, 10, surgical fashion has moved in the 
last few years from EPP to various extents of pleurectomy, where 
the underlying lung is preserved. This is not a conventional cancer 
operation involving en bloc resection of tumour with a defined 
margin, and adjuvant radiotherapy is rendered more difficult, if 
not impossible, by the residual lung. Attempts to spare the lung 
at least partially must of necessity involve sparing the pleura over-
lying the fissures, and significant rates of pneumonitis have been 
reported, albeit less than in the early reports of IMRT11. The doses 
achievable by these techniques remain relatively low by cancero-
cidal standards in the context of a disease believed to relatively 
radioresistant. Cao has also reviewed the 34 publications on pleu-
rectomy, none of which are randomised and very few prospective3. 
Radiotherapy in most series, when it is described at all, seems to 
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MS13.1 A REVIEW OF RANDOMISED TRIALS IN LUNG 
CANCER
Richard Stephens
Mrc Clinical Trials Unit/United Kingdom
Abstract: There is a long and distinguished history of clinical tri-
als investigating the treatment of lung cancer dating back to the 
1950’s. One of the first such trials to be published looked at the 
use of nitrogen mustard and DON (6-diazo-5-oxo-L-norleucine) in 
patients with various cancers including bronchogenic carcinoma1, 
and probably the first published randomized trial specifically for 
lung cancer patients compared surgery and supervoltage radio-
therapy2. Continued progress in treatment relies on randomized 
clinical trials and meta-analyses, and a review was undertaken in 
2003 to assess the quality and quantity of all published rando-
mized lung cancer treatment trials3. This showed that, of nearly 
1000 trials, only 4 accrued more than 1000 patients, and that 
clinicians (and patients) could only rely on a few meta-analyses to 
guide treatment decision making. The review called for greater 
global collaboration to design and run large trials to improve the 
survival rates and quality of life of lung cancer patients. Ten years 
on, an update and extension of the 2003 review has been under-
taken, to see what changes have occurred, what patterns have 
emerged, and whether the data will help the design of future trials. 
The Cochrane Library was used as the e-library, as it contains some 
abstracts from major meetings, as Song et al4 estimate that up to 
50% of all trials are not fully published. In addition to sample size, 
information was collected regarding the histological subgroup 
studied, the treatment modality investigated, the trial design, the 
outcome and the country of affiliation of the first author. A search 
of ‘(lung OR bronchus) AND (cancer OR carcinoma)’ in Sept 2012 
produced 7130 reports (5218 full papers and 1912 meeting abs-
tracts) classified by the Cochrane Library as ‘trials’. However, as the 
inclusion of meeting abstracts was found to be inconsistent, the re-
sults presented here are based only on the full publications. A total 
of 1792 randomized clinical trials of lung cancer were identified, of 
which 1677 included the sample size in the title or abstract, 49 did 
not, and in the remaining 66 the abstract could be accessed. An 
analysis of the 1677 trials with sample size stated showed that: 
• There was an increasing number of randomized trials, mainly due 
to an increasing number of randomized phase II trials5
• Only 20 trials included >1000 patients, and 48% had less than 
100.
• The median sample size has remained unchanged for 40 years 
(~100 patients) although the median sample size for those designa-
ted as randomized phase III trials has increased from ~200 to ~400 
patients over the last 10 years
• In nearly half of the trials the primary research question 
addressed chemotherapy, 15% supportive care, 8% radiotherapy 
and only 1% surgery
• Of those that indicated the histology, trials of NSCLC cancer 
radiation does not appear to be in active use at this time. The ad-
vantages of radiation are the established track record in treating 
mesothelioma and the penetrating nature of the modality with 
the disadvantages being damage to normal tissue, from the same 
penetrating nature. Employment of intraoperative radiation is 
likely the most expensive and logistically complicated of the intra-
operative adjuvants. The technique that has been employed with 
heated povidone iodine has the advantages of logistical simplicity, 
with the treatment being delivered as sequential dwells, and low 
expense. In addition, there is the advantage of povidone iodine 
being an easy and safe material with which to work, with a high sa-
fety profile for both the patient and health care staff delivering the 
treatment. The disadvantages of this technique include the unclear 
benefit of povidone iodine as a therapeutic agent against this can-
cer and the certainty that unifom hyperthermia is not maintained 
during a dwell, working under the assumption that hyperthermia 
is an effective modality in and of itself. There is recent evidence, 
however, that mesothelioma may be resistant to hyperthermia. The 
common technique utilized for heated chemotherapy perfusion, 
typically platin-based, is significantly more involved than the dwell 
technique. In this situation a perfusion pump is employed. Disad-
vantages include increased expense and logistical complexity and 
utilization of an agent with a significant toxicity profile for both the 
patient and health care staff delivering the treatment. Advantages 
include assurance that hyperthermia is maintained, along with 
control of the temperature, and application of a perfusion agent 
that has an established track record in treating malignant pleural 
mesothelioma. With inflow and outflow catheters, this technique 
has the ability to simultaneously perfuse both the chest cavity and 
the abdomen, theoretically of benefit to treating occult peritoneal 
metastases or cells that are disseminated during surgery. Both 
perfusion techniques have the additional limitation that they are 
likely purely surface treatments, without any depth of penetration 
for the treating agent. Photodynamic therapy is a unique treatment 
modality and, as such, has unique advantages and limitations. 
Although it is simple to perform, it is likely the most logistically 
complex of the currently employed modalities. It requires delivery 
of visible laser light, pretreatment with a photosensitizing drug and 
employment of special “light precautions” for some period of time 
before, during and after surgery. Although the cost and availability 
of lasers has dropped dramatically, it is still a treatment that cur-
rently comes with a significant cost. The advantages are that the 
treatment works by a unique set of mechanisms, delivers treatment 
at and below the surface for short distance and is known to incite 
a significant immune response against treated cancers. Whether 
or not that tumor-directed immune response occurs with pleural 
mesothelioma is under investigation. Currently it is not possible to 
rigorously determine which, if any of these treatments is superior. 
Factors contributing to this dilemma are among the same that 
limit comparison of any surgery-based treatments. These include: 
small numbers of patients, colossal variability in patients not only 
between series but within series, lack of a highly effective staging 
system to allow rigorous analyses and comparisons, enormous 
variability in surgical techniques, lack of prospective randomized 
trials and the fact that essentially all patients suffer recurrence and 
overall survival may be greatly affected by subsequent treatments. 
This presentation will review the different intraoperative modali-
ties, present current results and speculate about future directions.
Keyword: intraoperative, adjuvant, mesothelioma, pleural
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MS14.1 SLIDING SLOPE BETWEEN CURE AND PALLIATI-
ON: LOCAL CURE IN DISSEMINATED DISEASE
Ben Slotman
Radiation Oncology, VU University Medical Center/Netherlands
Abstract: For a long time, radiotherapy for lung cancer were 
considered in terms of being either curative, palliative or radical. 
Conventional radiotherapy for early stage NSCLC was general 
considered ‘ curative’, but the more modest expectation in pa-
tients with locally advanced NSCLC led to it being referred to 
as ‘radical’, as disease recurrences was considered very likely. In 
metastatic NSCLC, the role of radiotherapy was considered only 
in a palliative context, since it was generally accepted that in dis-
seminated disease, local therapies could never be curative. These 
classifications have been reappraised in the light of recent data. In 
small cell lung cancer (SCLC), which has a very high risk of distant 
spread, recent studies have established that local treatments can 
extent survival and contribute to cure. This is not only the case for 
thoracic radiotherapy, but also for prophylactic radiotherapy to the 
brain (PCI; prophylactic cranial irradiation). Studies in patients with 
limited disease SCLC have shown a survival benefit of about 5% at 
3 years,a benefit of similar magnitude to that for thoracic radiothe-
rapy in this patient group. Even in patients with proven dissemina-
ted SCLC (extensive stage), the use of PCI has improved survival. In 
a randomized trial, patients who received PCI had a 1 year survival 
of 27% compared to 13% for patients who did not receive PCI [1]. 
A study on the use of thoracic radiotherapy after the completion of 
chemotherapy in patients with ES-SCLC has recently been closed 
and the results are awaited next year. With the advancements in 
radiotherapy techniques, we can now ablate tumors with very high 
doses, and with great precision using stereotactic techniques. 
Local control rates in excess of 90% are obtained and in fit, poten-
tially operable patients, 5-year survival rates above 60 % are achie-
ved [2,3]. These ablative radiation doses may also exert a benefical 
immunological effect both locally and systemically. The same prin-
ciples of high-dose high-precision radiotherapy are being applied 
in patients with a limited number of metastases (oligometastases). 
This patient group is increasingly being identified due to improved 
imaging techniques, and interest is growing due to the availabi-
lity of more effectivity of systemic therapy in subgroups of lung 
cancer. Aggressive treatment of metastases by surgery or ablative 
therapy, such as SBRT, might offer a real chance of cure for these 
patients. We have initiated a clinical study to evaluate the benefit 
of this approach [4]. References 1. Slotman BJ et al., New Engl J 
Med 357, 664-72, 2007. 2. Onishi H et al., Int J Radiat Oncol Biol 
Phys 75, 243-247, 2011. 3. Lagerwaard FJ et al., Int J Radiat Oncol 
Biol Phys 83, 348-53, 2012 [updated]. 4. Palma D et al., BMC Can-
cer 12, 305, 2012.
Keyword: sclc, nsclc, radiotherapy, oligometastases
accounted for 73%
• The country producing the most trials (397) was the USA, but 
China is now the second country, and published the most trials 
over the last 10 years.
Although there are limitations of this review (it is necessarily se-
veral years out of date, is only looking at the title and abstract of 
trials on the Cochrane Library, is complicated by multiple reporting 
of trials, etc), its strengths are the longitudinal overview and com-
prehensive inclusion criteria which substantially extend the results 
reported by Subramanian et al6 who compared ongoing trials of 
medical treatment for NSCLC in 2012 with those in 2009. The need 
to improve the quantity and quality of trials in lung cancer has 
been highlighted for more than 20 years7-10 as trials have not been 
sufficiently large, or poorly designed, or unnecessarily duplicated 
previous work11-12. In contrast, well designed trials make best use 
of researchers’ time, funders’ money and patients’ goodwill13, and 
may inform future work. The results of the current review suggest 
that greater global collaboration is still required to run large trials 
that will produce reliable results and influence practice worldwide. 
Updated and more detailed results will be presented. References 
1. Krantz S, et al for the Veterans Administration Cancer Chemo-
therapy Study Group. A Clinical Study of the Comparative Effect 
of Nitrogen Mustard and DON in Patients With Bronchogenic 
Carcinoma, Hodgkin‘s Disease, Lymphosarcoma, and Melanoma. 
JNCI 1959, 22, 433-9 2. Morrison R. The treatment of carcinoma 
of the bronchus. A clinical trial to compare surgery and supervol-
tage radiotherapy. Lancet 1963, 1, 683-4 3. Stephens R. The need 
for a world strategy for clinical trials. Lung Ca 2003, 41 (suppl 3), 
S96 (abs E-77) 4. Song F, et al. Dissemination and publication of 
research findings: an updated review of related biases. Health 
technology Assessment 2010, 14, No. 8 5. Turrisi AT. Creeping 
phase II-ism and the Medical Pharmaceutical Complex: Weapons 
of Mass Distraction in the War against Lung Cancer. JCO 2005, 23, 
4827-9 6. Subramanian J, et al. Review of Ongoing Clinical Trials 
in NSCLC - a status report from the CinicalTrials.gov Web Site. J 
Thorac Oncol 2013, 8, 860-5 7. Nicolucci A, et al. Quality, evolu-
tion, and clinical implications of randomized, controlled trials on 
the treatment of lung cancer. A lost opportunity for meta-analysis. 
JAMA 1989, 262, 2101-7 8. Brundage MD, Mackillop WJ. Locally 
advanced non-small cell lung cancer: Do we know the questions? A 
survey of randomized trials from 1966-1993. J Clin Epidemiol 1996, 
49, 183-92 9. Breathnach OS, et al. Twenty-two Years of Phase III 
trials for Patients With Advanced Non-Small Cell Lung Cancer: 
Sobering Results. J Clin Oncol 2001, 19, 1734-42 10. Macbeth F, et 
al. An open letter to all members of the IASLC. Lung Cancer 2004, 
45, 119-20 11. Chalmers I. The lethal consequences of failing to 
make full use of all relevant evidence about the effects of medical 
treatments: the importance of systematic reviews. Rothwell P, ed. 
Treating individuals: from randomised trials to personalised medi-
cine. London: Lancet, 2007: 37-58. 12. Young C, Horton R. Putting 
clinical trials into context. Lancet 2005, 366, 107-8 13. Chalmers 
I, Glasziou P. Avoidable waste in the production and reporting of 
research evidence. Lancet 2009, 374, 86-9
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case of non-squamous histology), erlotinib and gefitinib (in tumors 
expressing activating EGFR-mutations) (13-16). Crizotinib has re-
cently been registered for second-line therapy in ALK-positive 
tumors (17). Maintenance therapy: The prolongation of induction 
therapy represents an evidence based new option to improve out-
come in advanced NSCLC, in general and with strong implications 
for second line therapy, in particular. Three randomized studies 
investigated pemetrexed and erlotinib as maintenance therapy 
following 4 cycles of chemotherapy (18-21). In these trials switch-
early second-line- (pemetrexed, erlotinib) or continuation-true- 
(pemetrexed) maintenance therapy has significantly increased PFS 
and OS. Based on this given evidence these two compounds have 
been registered for maintenance therapy in patients with advan-
ced NSCLC, not progressing following 4 cycles of first-line stan-
dard platinum-based therapy. According to the European Medici-
nes Agency (EMA) pemetrexed is indicated as monotherapy for 
maintenance treatment of locally advanced or metastatic NSCLC 
other than predominantly squamous cell histology in patients 
who’s disease has not progressed immediately following platinum-
based chemotherapy, including platinum-pemetrexed combina-
tions, and erlotinib is indicated as monotherapy for maintenance 
treatment in patients with locally advanced or metastatic NSCLC 
with stable disease after 4 cycles of standard platinum-based first-
line therapy. When prescribing erlotinib, clinical factors associate 
with prolonged survival should be taken into account. There is 
clearly more which must be considered and which would lead to 
stop or even not to initiate a modern medical therapy. Even if nati-
onal and international treatment recommendations undoubtedly 
represent the backbone of the decision making process, the ma-
nagement of patients with advanced non-small cell lung cancer 
often clinically requires modification for a number of reasons not 
necessarily considered by guidelines.This refers to first and subse-
quent-line treatment as well. The majority of lung cancer patients 
are older patients and often express specific age related treatment 
expectations. Other relevant factors for decision making in a non-
curative setting are patient social environment and patient psycho-
logical status, regulations of national health care providers and 
reimbursement systems, drug availability, diagnostic and health 
care infrastructure. These circumstances modify decision making 
and lead to the use of older agents and regimens, to changes in 
dosing and scheduling of newer agents and regimens, to single 
agent therapy, to a reduction of treatment cycles and to a more 
free indication of best supportive care measures. Our increased 
understanding of the molecular biology of lung cancer and the 
change of its epidemiology has opened up venues for more ratio-
nal treatment strategies and at the same time has challenged the 
additional diagnostic algorithms, the established health care finan-
cing and the complex process of drug development. Customized 
therapy and therapeutic targeting were made possible through the 
identification of new treatment predictors and the development of 
a number of antineoplastic agents which have shown clinical evi-
dence for being more beneficial then the treatment standard in 
selected patients. Consequently, therapy individualization by his-
tology and molecular markers has significantly influence the work 
of pathologists around the globe and the process of obtaining a 
therapeutically relevant tumor diagnosis. Not only histological 
sub-typing becomes clinical relevant but molecular information is 
also of increasing importance for treatment selection. Routine 
molecular testing in certified laboratories must be established, and 
this diagnostic process should ideally performed under the 
guidance of evidence based recommendation such as the recently 
published guidelines from the College of American Pathologists, 
the International Association for the Study of Lung Cancer, and the 
Association for Molecular Pathology for the molecular testing to 
select patients for EGFR-ALK-thyrosine kinase inhibitors (22). This 
process requires advanced diagnostic techniques and expertise. 
Investigating and implementing medical targeting in lung cancer 
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MS14.2 DECISION MAKING; WHEN TO STOP DISEASE 
MODIFYING TREATMENT
Christian Manegold
Universitatsmedizin, Medizinische Fakultat, Mannheim Der Universitat 
Heidelberg/Germany
Abstract: Decision making in advanced NSCLC undoubtedly 
should primarily consider evidence based treatment standards 
recommended by international guidelines (1, 2) 
According to international guidelines, decision making in 2013 is 
characterized by customizing therapy in advanced non-small cell 
lung cancer, by selecting a specific therapeutic regimen based on 
tumor histology and molecular biology. This refers to first-line the-
rapy in patients with good performance status, but also to subse-
quent lines of therapy since antineoplastic drugs and regimens 
used in induction therapy directly influence the selection of 
agents/regimens considered for second/third-line treatment. The 
availability of antineoplastic monoclonal antibodies, small molecu-
les and newer cytotoxic such as pemetrexed, the antiangiogenic 
bevacizumab as well as the tyrosine kinase inhibitors erlotinib, 
gefitinib and crizotinib has recently changed the treatment algo-
rithm of advanced NSCLC. Therapy optimization by modern medi-
cal therapy is characterized by treatment individualization based 
on predictive factors. This process seems to continue since other 
products holding considerable promise for the near future such as 
tumor vaccines and other immunotherapeutic approaches, anti-
angeniogenic agents, and newer EGFR-targeting monoclonal anti-
bodies have already reached the level of phase III-testing or the 
registration process. Today’s recommendation can be summarized 
as follows: 
First-line therapy: In patients with good performance status with 
non-squamous tumors haboring an activating EGFR-mutation, an 
EGFR tyrosine kinase inhibitor may be the leading option, not only 
because of being active but also because of its feasibility and im-
proved toxicity profile (3-5). In patients with non-squamous cell 
tumors not expressing EGFR-mutations, combination therapy re-
mains standard with pemetrexed as the preferred partner of cispla-
tin (6). Furthermore, it has been demonstrated that in non-squa-
mous NSCLC the addition of bevacizumab to standard doublet 
therapy improves survival (7, 8). With regard to patients with squa-
mous cell tumors gemcitabine, vinorelbine or taxanes in combina-
tion with platinum-based agents remain the chemotherapeutic 
standards. Bevacizumab and pemetrexed are not recommended in 
squamous cell tumors either because of the agents toxicity profile 
(bevacizumab) or because of being less effective in this particular 
histological subtype (pemetrexed). For elderly patients not being 
fit for standard doublet chemotherapy medical treatment requires 
modification. Here single agent therapy is widely considered to be 
the preferred option for maintaining quality of life, reducing tumor 
association symptoms and improving survival (9). Fit elderly pati-
ents benefit from combination chemotherapy as much as younger 
patients and platinum-based chemotherapy is recommended as 
well (10, 11). Combination therapy remains investigational in pati-
ents with poor performance status (≥ PS 2), and single agent che-
motherapy is the preferred option (12). Second-line therapy: In 
patients with disease progression during or after completion of 
induction (first-line) chemotherapy second-line therapy is indicated 
if the patient remains in good clinical condition. Selection of drugs 
for second-line therapy is based on whether the drug has been 
used earlier, the toxicity profile or the patients wish. The approved 
options for second-line therapy are docetaxel and pemetrexed (in 
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MS14.3 END OF LIFE DISCUSSIONS - EVIDENCE-BASED 
COMMUNICATION
Josephine Clayton
Palliative & Supportive Care Service, Hammondcare & University Of 
Sydney/Australia
Abstract: Advance care planning refers to a “process of discus-
sion, reflection, understanding and communication between a 
patient, their family and health providers for the purpose of clarify-
ing values, treatment preferences and goals of end of life care” (1). 
Advance care planning provides a formal means of ensuring health 
professionals and family members are aware of the patient’s wishes 
for care if they were to become too unwell to speak for themselves 
in the future. This process may include the patient completing an 
Advance Care Directive, which documents their wishes and/or the 
appointment of a substitute decision maker. Advance care plan-
ning is a patient-centred initiative that promotes shared-decision 
making and supports substitute decision-making, where appro-
priate, and aims to achieve good end of life care. The potential 
benefits of advance care planning for patients with advanced 
lung cancer have been highlighted in recent literature and clinical 
practice guidelines (2-4). However, there are many barriers to im-
plementing advance care planning in this setting including patient, 
family, health professional and system related factors. In particular 
doctors and nurses caring for patients with lung cancer may be 
reluctant to raise the topic of advance care planning for fear of 
upsetting patients or they may lack confidence in knowing how to 
discuss it. This talk will focus on evidence-based strategies and 
practical tips for health professionals when having advance care 
planning discussions with patients with advanced lung cancer and 
their families. Recommendations from Australian “Clinical practice 
guidelines for communicating prognosis and end-of-life issues with 
adults in the advanced stages of a life-limiting illness, and their 
caregivers” will be described (5). The key recommendations are for 
health professionals to: Prepare for the discussion, where possible; 
Relate to the person; Elicit patient/caregiver understanding and 
information preferences; Provide information, tailored to the indivi-
dual needs of both patients and their families; Acknowledge emo-
tions and concerns; (foster) Realistic hope; Encourage questions 
and further discussions; and Document what had been discussed. 
(PREPARED). Sample phrases and useful questions for facilitating 
advance care planning discussions will be presented. Further re-
sources regarding advance care planning will be provided (6-9). 
References: (1) Royal Australasian College of General Practitioners 
Advance Care Planning Definition http://www.racgp.org.au/your-
practice/business/tools/support/acp/ (2) Mack JW, Cronin A, Kea-
ting NL et al. Associations between end-of-life discussion charac-
teristics and care received near death: a prospective cohort study. 
Journal of Clinical Oncology 2012; 35: 4387-4395 (3) (USA) National 
Comprehensive Cancer Network: Practice guidelines in oncology: 
Palliative care. http://www.nccn.org/professionals/physician_gls/f_
guidelines.asp (4) Smith, T, Clayton, J, Michael, N. What is the role 
of advance care planning and timing of referral for patients with 
lung cancer? [Version URL: http://wiki.cancer.org.au/australiawiki/
index.php?oldid=47787, cited 2013 Aug 26]. Available from http://
wiki.cancer.org.au/australia/Clinical_question:What_is_the_role_
of_advance_care_planning_and_timing_of_referral_for_patients_
with_lung_cancer%3F. In: Cancer Council Australia Lung Cancer 
Guidelines Working Party. Clinical practice guidelines for the treat-
ment of lung cancer. Sydney: Cancer Council Australia. Available 
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because of its large dimension is costly and characterize by the 
limitation of financial and clinical resources, and currently not every 
where available. Since the majority of large randomized phase III 
trials during the last decade turned out negative in their primary 
endpoints, the time of conducting trials on large unselected pati-
ent population seems definitely over and the classical investigatio-
nal strategy must probably be replaced by smaller trials in selected 
patients, and trials using study endpoints which can function as 
substitutes for the traditional overall survival endpoints (23). This 
inevitable change in the altitude of conducting clinical trials will 
increase the need for patients treated in clinical trials and, therefo-
re, has a significant impact in decision making in advanced NSCLC. 
Another hurdle for making promising therapies difficult to be ge-
nerally prescribed are that clinical evidence of being beneficial and 
the scientific rational do not necessarily equal clinical practicability 
and reimbursement in a given cultural and economic system. For 
Europe and specifically Germany it is important that an agent has 
reached a positive vote by the registration agency EMA and that it 
find acceptance by the national health care providers responsible 
for reimbursement. For this reasons the clinical evidence of being 
beneficial must be well documented and strong. Information about 
treatment selection by predictive factors and treatment restriction 
to patients who benefit the most is very welcome. In addition, if 
the treatment selection requires advanced diagnostic testing ge-
nerally accepted and validated methods should easy to be reached 
and should provide reliable and reproducible results by at the 
same time being cost effective.  
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termining when this transition to palliative care should commence, 
including extent of cancer, weight loss, serum albumin, white cell 
count, neutrophil to lymphocyte ratio, lactate dehydrogenase and 
measures of critical organ function (cerebral, pulmonary, liver and 
renal). The synthesis of all of this information, a global assessment 
of the patient and knowledge of all the available treatment options 
is required to determine the timing of transition to ‘end-of-life’ 
care. The transition is usually handled through a multidisciplina-
ry approach, with potential involvement of multiple health care 
professionals including the general practitioner, palliative care 
physician, medical oncologist, radiation oncologist and surgeon. 
Additional input from health care professionals in the fields of psy-
chology, psychiatry, dietetics, social work and physiotherapy can 
enhance the quality of care in this transition period, depending on 
the degrees of distress and disability. Expert counseling is requi-
red. Involvement of the primary carers and family in discussions 
and decision-making is also important. Optimising care for pati-
ents during the late stages of cancer should focus on alleviating 
symptoms, allow planning for death, facilitate arrangements and 
enable personal commitments before death, dealing with grief and 
supporting the caregivers. These measures can improve quality of 
life, reduce anxiety and permit a more peaceful death. Ongoing 
active cancer therapies may introduce adverse events, require 
additional hospital visits and expose patients to invasive procedu-
res. This can delay the introduction and implementation of optimal 
palliative care in the ‘end-of life’ period. The transition to end of 
life care should also be an opportunity to consider advanced di-
rectives. This issue needs to be discussed in a sensitive manner. 
Decisions around intensive medical intervention and confirmation 
of ‘not-for-resuscitation’ status will allow for patient wishes to be 
respected and permit patient autonomy at this difficult stage. An 
appreciation and acceptance of ‘end’-of-life’ care, when the prog-
nosis is clearly very poor and death from an advancing lung cancer 
inevitable, will improve the prospect of allowing a comfortable 
death, a ‘good death’. This should be a goal that every cancer spe-
cialist seeks for patients with incurable cancer.
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Abstract: Metastatic lung cancer remains an incurable condition 
despite recent advances in medical therapy. New treatments can 
prolong survival and enhance quality of life for patients. Lung can-
cers can shrink and impressive responses may divert attention from 
the inevitable reality that the cancer will eventually acquire resis-
tance to therapy. In the current era, patients are guided through 
multiple lines of therapy; first line, maintenance, second-line and 
so on. Such ‘lines of therapy’ extend the time on active therapeutic 
measures designed to alter the biological behavior of advanced 
lung cancer. Cancer centres that conduct clinical trials may offer 
potential active intervention beyond the proven ‘lines of therapy’, 
thereby extending time on active therapy. This may delay the tran-
sition to end-of-life care, but the likelihood of benefit with thera-
pies beyond 2nd line is low. Whilst oncologists have a greater arma-
mentarium in the fight against lung cancer, there comes a time for 
every patient when the medical advice will be to stop ‘active thera-
py’ as there is no prospect of benefit. The focus of care will be on 
symptom control with acceptance of palliative care. This is the time 
when patients accept that medical intervention will not prolong 
survival time, cannot alter the growth and spread of the cancer and 
will not influence the harmful effect of the cancer on the body. The 
body will fail, and in the process a functional decline will become 
obvious. This transition to ‘end-of-life’ care is not a clearly defined 
time point. Complex decision-making and emotional discussions 
are usually required. Several issues should be taken into account 
in determining when anti-cancer therapies should continue to be 
utilised or when such measures should be abandoned. These issu-
es include: 
• The likelihood of a beneficial response to a proposed therapy
• The safety and toxicity of the proposed intervention
• The patient’s ‘performance status’ – an overall measure of func-
tional capacity
• Comorbidity and organ dysfunction
• Patient preference
There are validated measures of prognosis that may assist in de-
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2010]. 3. After radiation doses of 74 Gy and 86 Gy delivered after 
chemotherapy, the incidence of bronchial stenosis was 4 and 25%, 
respectively, (Millar KL, 2005]. This complication may increase in 
incidence if higher doses of radiation are administered concurrent 
with chemotherapy. 4. When evaluating the results dose escalation 
studies, one must also consider the impact of tumor volume on 
survival in stage III NSCLC. For example, planning target volumes 
(PTV) correlated significantly with overall survival, with PTV values 
<350cc, 350-700cc, >700-1050cc and >1050cc having correspon-
ding median overall survivals of 35.6 months (95% CI=0-71.3), 24.2 
months (95% CI=18.3-30.2), 15.7 months (95% CI=10.5-20.9) and 
10.3 months (95% CI=6.0-14.7), respectively [van Reij E, 2013]. Sur-
vival for tumors measuring 350-700cc differed significantly from 
the groups 700-1050 and >1050 cc (p=0.039 and p=0.002, respec-
tively). In addition, larger tumor volumes are also associated with 
an increased risk of dying in the first 18 months, independently of 
T and N stage, but not beyond that time point [Ball D, 2012]. The 
latter finding suggests that a better characterization of tumor cha-
racteristics that correlate with radiocurability should be a research 
priority. 5. In RTOG 0617, the dose of 74 Gy arm was delivered in 
7.5 weeks. A recent meta-analysis suggested that the accelerated 
delivery of radiation, i.e. delivering a higher higher dose in a shor-
ter overall time, led to superior tumor control [Mauguen 2013]. 
Such accelerated delivery can be delivered using multiple fractions 
per day, or larger doses/fraction, both approaches which can incre-
ase the toxicity of concurrent CT-RT. For some subgroups of stage 
III-N2 disease, e.g. large volume tumors, where the benefits of 
concurrent CT-RT are modest [Wiersma T, 2013], sequential delive-
ry may be a less toxic manner for investigating dose escalation. 6. 
Tumor volumes not infrequently regress during a course of CT-RT, 
and may also shift in position during the course of treatment [Lim 
G, 2011]. Volumetric imaging on modern treatment machines can 
allow for such changes to be detected, and treatment plans be ad-
apted when required. Many recent clinical studies have not studied 
this aspect of treatment delivery. With dose escalation in fractions 
of 2 Gy falling out of favor, some groups are exploring the ‘dose 
painting’ hypothesis [Bentzen S, 2011]. Briefly, the former assumes 
that local recurrences arise from relatively radiation-resistant sub-
regions; that reliable spatio-temporal mapping of such sub-regions 
is possible (e.g. using FDG-PET); that boosting radiation delivery 
to these egions improves local tumor control with acceptable side 
effects. Others groups are exploring the use of protons to improve 
local control in stage III NSCLC. A critical evaluation of the results 
emerging from ongoing trials is required, even if early outcomes 
from pioneering centers appear promising. Quality assurance data 
from radiotherapy trials, in which a broad range of institutions par-
ticipate, reveals that a failure to comply with protocol requirements 
is associated lead to decreased survival, poorer local control and 
potentially increased toxicity [Weber DC, 2012].
Keywords: locally advanced NSCLC, chemo-radiotherapy, dose 
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Abstract: Chemo-radiotherapy (CT-RT) is the presently the stan-
dard of care in patients presenting with a stage III-N2 NSCLC, with 
surgery being considered an option in selected patient subgroups 
[ESMO Guidelines 2013]. Improved local disease control in stage III 
disease translated into improved overall survival [Auperin A, 2010; 
Machtay M, 2012]. The best median survival reported to date in a 
randomized phase III trial of concurrent CT-RT is 28.7 months in 
RTOG 0617, when concurrent carboplatin-paclitaxel was combined 
with delivery of 60 Gy in once-daily fractions of 2 Gy [Bradley J, 
2013]. At this dose, 25% of patients developed a local failure at 18 
months follow-up. Therefore, both the optimization of radiation 
delivery and dose escalation are areas of active research. Evidence 
supporting radiation dose escalation comes from retrospective 
analyses and pooled studies. The randomized RTOG 0617 study 
compared 60 Gy (in 6 weeks) versus 74 Gy (in 7.5 weeks), in a 2x2 
design where patients were also randomized to receive additional 
cetuximab or none [Bradley J, ASCO 2013]. Analysis of the impact 
of cetuximab has yet to be reported, but a difference in favor of 
the 60 Gy arm was seen for progression-free survival (36.6% vs. 
26.3% at 18 months), median overall survival (28.7 vs. 19.5 months). 
A higher incidence of grade 3 esophagitis in the 74 Gy arm (21% 
vs. 7%, p=0.0003) was not unexpected, but the higher rates of 
local disease progression (34.3% vs. 25.1%, HR = 1.37, p = 0.0319) 
was a surprise. The latter raises the possibility of unsafe planning 
practices being applied when higher (and more toxic) doses have 
to be delivered. On multivariate analysis, factors predictive of a 
poorer overall survival were higher radiation doses, higher eso-
phagitis/dysphagia grade, greater gross tumor volume, and heart 
volumes receiving >5 Gy. While publication of full data from the 
RTOG 0617 study is awaited, some issues related to toxicity and 
techniques should considered (below). 1. Improved radiotherapy 
planning using intensity modulated radiotherapy (IMRT) has per-
mitted some parameters for lung toxicity (V20, mean lung dose) to 
be improved. However, not all recent or ongoing studies have ap-
plied constraints for lung volumes undergoing low-dose irradiation 
(V5). Furthermore, the choice of chemotherapy may increase lung 
toxicity, as reported by a recent meta-analysis showing that the 
risk of radiation pneumonitis is highest after concurrent CT-RT in 
patients aged >65 years, who also received carboplatin-paclitaxel 
[Palma D, 2012]. This meta-analysis revealed that predictors of fatal 
pneumonitis were use of daily dose fractions exceeding 2 Gy, the 
V20 parameter, and lower-lobe tumor locations. 2. Cardiac doses 
exceeding 5 Gy correlated with poorer survival in RTOG 0617 trial, 
and future studies must pay more attention to cardiac toxicity. 
Following concurrent CT-RT, cardiac doses of 45 Gy or higher cor-
related with myocardial hypoperfusion [Gayed 2006], and a higher 
risk of ischemic heart disease and cardiac dysfunction was seen 
patients undergoing CT-RT for left-sided lung cancer [Hardy D, 
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outcomes. Although an optimal disease-free interval (DFI) to de-
fine synchronous and metachronous disease has not been agreed 
upon, synchronous oligometastasis is generally associated with 
poorer survival outcomes. Patients receiving adrenalectomy for 
oligometastatic NSCLC with DFI ≤6 months had median OS of 12 
months versus 31 months for DFI >6 months. Similar results were 
reported for isolated brain metastasis. Oligometastatic NSCLC is a 
stage IV cancer and as a guiding principle therapy should be simp-
le and minimally invasive. Furthermore, given the diffuse nature of 
this disease state, management should ideally involve a multidisci-
plinary team as the primary and metastatic cancer must be treated, 
requiring a wide range of expertise. Surgery and radiosurgery 
(stereotactic radiosurgery [SRS] in the brain and stereotactic body 
radiotherapy [SBRT] in extracranial sites) are the two most com-
mon methods of tumour ablation. In general, radiosurgery is less 
invasive than surgery and is therefore useful for patients ineligible 
for surgery. Additionally, evidence suggests SBRT may be more 
applicable to limited extracranial metastasis to multiple organs 
compared with surgery. The treatment of limited brain metasta-
ses has been evaluated through several randomised clinical trials. 
Surgical resection plus whole brain radiotherapy (WBRT) of oligo-
metastasis in the brain led to significantly prolonged OS compared 
with WBRT alone – as high as 40 weeks in one trial, compared with 
15 weeks for WBRT (P<0.01). Further, a study of SRS with WBRT 
in patients with 1–4 brain metastases showed improved survival 
outcomes for patients with solitary brain metastases and improved 
clinical outcomes for patients with >1 site of metastatic disease, 
compared with WBRT alone. Overall, SRS plus WBRT is considered 
an acceptable choice for those patients with limited brain metasta-
sis who are not suitable for surgery. Adrenalectomy is the standard 
of care for adrenal gland metastases, with OS ranging from 11–31 
months. There have been no randomised trials of the use of SBRT 
in the adrenal gland setting, although one retrospective study 
reported OS of 23 months for isolated adrenal metastases treated 
with SBRT. Further, a recent review article of extracranial oligome-
tastatic disease from various primary cancers suggests that survival 
following SBRT compares favourably to surgery. One of the key 
challenges for the management of oligometastatic NSCLC is con-
tinuing to improve diagnosis and prognostic factors to more accu-
rately identify those patients with oligometastatic NSCLC who are 
likely to benefit from ablative treatment, as well as distinguish truly 
isolated metastatic disease from early-stage metastasis that later 
develops into widely disseminated disease. Continuing advances 
in imaging technology will play a role in refining diagnosis and 
prognosis. From a treatment perspective, challenges include cog-
nitive problems associated with WBRT and the current lack of ran-
domised trial data comparing surgery, radiosurgery and standard 
of care. To this end, there are several ongoing clinical trials, such 
as the randomized SABR-COMET study, which compares palliative 
radiation with stereotactic ablative radiation for ≤3 metastatic tu-
mours to any single organ.
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Abstract: For the past decade, the standard first-line therapy for 
stage IV non-small-cell lung cancer (NSCLC) patients with adequa-
te ECOG performance status (<2) has been platinum-based dou-
blet chemotherapy with a reported median overall survival (OS) of 
8–10 months, which has slightly improved to 12 months with the 
addition of bevacizumab. More recently, tyrosine kinase inhibitors 
of epidermal growth factor receptor, gefitinib and erlotinib, and 
anaplastic lymphoma kinase, crizotinib, have been shown to pro-
vide longer progression-free survival (PFS) and fewer side effects 
as first-line therapy, compared with chemotherapy in patients with 
certain histological subtypes and activating mutations. However, 
despite therapeutic developments, palliative treatment is standard 
for many stage IV NSCLC patients and the prognosis remains poor, 
with relative 5-year survival rates ≤4%, compared with an average 
of approximately 17% for all patients with NSCLC. Oligometastatic 
NSCLC is a subgroup of stage IV NSCLC with a limited number/
number of sites of metastatic disease, usually 1–5 metastatic lesi-
ons. While only a small subset of patients present with such limited 
metastases (brain metastasis <50%, adrenal gland metastasis 
~7%), they may be suitable for, and achieve long-term survival 
following, eradication of both the primary and metastatic tumours. 
For example, reported 5-year survival rates for NSCLC patients 
with solitary brain or adrenal metastasis who underwent surgical 
removal of both primary lung and metastatic disease ranged from 
7–24% and 25–34%, respectively, which is higher than the average 
of ≤4% for all stage IV NSCLC patients. In addition to having an 
adequate performance status, there are additional key prognostic 
factors for identifying oligometastatic NSCLC patients likely to 
benefit from aggressive therapy; staging of the metastatic lesions, 
lymph node involvement and status of the primary lung tumour. 
A lower number of metastatic sites is predictive of good clinical 
outcome, with >2 metastatic sites associated with shorter PFS. The 
organ involved in metastatic spread may also impact clinical out-
come as, for instance, patients with brain and adrenal gland me-
tastases are more suitable for surgical intervention compared with 
bone or liver. Given the importance of number and site of metasta-
tic lesions, positron emission tomography and magnetic resonance 
imaging are vital for accurate staging of oligometastatic disease. 
An association between N0 disease and increased long-term sur-
vival compared with N1/N2 disease has been observed. For ex-
ample, following surgical treatment of one cohort of patients with 
solitary NSCLC adrenal gland metastasis, those with N2 disease 
had 0% median 5-year survival rate, compared with 52% for N0/N1 
patients (P=0.001). Pathologic staging of lymph nodes is therefore 
critical. The status of the primary lung tumour also impacts clinical 
outcome, as the primary tumour must itself be resectable. Stage 
III primary disease is associated with worse survival outcome than 
stage I or II in patients undergoing surgical excision of brain and 
adrenal gland metastases, with a reported 5-year survival rate of 
0% for stage III, compared with 63% and 77% for stage I and II, 
respectively. Similarly, patients with oligometastatic disease and a 
controlled primary site, or ‘oligorecurrance’, have better progno-
sis than those with an uncontrolled primary tumour. Histological 
subtype of NSCLC may also impact prognosis in oligometastatic 
NSCLC, with adenocarcinoma associated with the most favourable 
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thymoma and thymic carcinoma. Thymic epithelial cells stain for 
epithelial markers such as keratin and squamous markers such as 
p63 or p40 while thymic lymphocytes stain for T-cell markers such 
as TdT and CD3. Type A thymomas tend to have fewer immature 
(CD1a+) lymphocytes and more mature (CD1a-) lymphocytes, while 
the type B thymomas have many CD1a+ lymphocytes. PAX8 has 
been reported to be positive in tumor cells of thymomas. Con-
fusion between histologic classification and grading has led to 
proposals to collapse the classification into a smaller number of 
entities. One meta-analysis suggested that the current WHO clas-
sification scheme of thymomas could be simplified into three types 
with significant prognostic value: A/AB/B1, B2, and B3. However, 
what these authors propose is more of a grading system based 
on clinical behavior rather than histologic typing. The proposal 
suggests combining two tumors that are completely different mor-
phologically and genetically (type A and B1) both of which are low 
grade tumors with indolent clinical behavior. Genetic studies have 
shown distinct gene expression profiles that support the WHO 
subclassification of thymomas, as far as the subdivision in type A 
and B thymomas is concerned. Type AB thymomas are genetically 
heterogeneous, being more closely related to type B thymomas. 
Expression of the autoimmune regulator AIRE is lost in approxi-
mately 95% of thymomas. Genetic alterations in thymomas are 
most frequent on chromosome 6p23.3 (major histocompatibility 
complex locus) and 6q25.2 to 25.3. Thymic carcinoma has a dis-
tinctive morphology and biology. It is composed of highly atypical 
cells with cytoarchitectural features of carcinoma similar to those 
seen in other organs. Although many lymphocytes can be seen in 
its stroma, they are of B cell type and mature T cell type. Thymic 
carcinoma lacks the immature T cell lymphocytes that are present 
in thymoma. Thymic carcinomas are cytologically malignant.{Tra-
vis, 2004 #21463} While a certain amount of necrosis, atypia, and 
mitoses can be encountered in occasional epithelial thymomas, 
these findings are common in thymic carcinomas. An infiltrative 
growth pattern associated with desmoplastic stroma is often seen, 
without evidence of immature T lymphocytes. Thymic carcinomas 
display a variety of histologic subtypes, emphasizing the ability of 
thymic epithelium to differentiate toward different cells: squamous 
cell carcinoma, basaloid carcinoma, mucoepidermoid carcinoma, 
lymphoepithelial-like carcinoma, sarcomatoid carcinoma, clear 
cell carcinoma, adenocarcinoma, and NUT carcinoma with t(15:19) 
translocation. Several immunohistochemical studies have been 
employed in an attempt to confirm the diagnosis of thymic carci-
noma. Several studies have found that CD5 will stain the epithelial 
cells of some thymic carcinomas. C-kit (CD117) also frequently 
stains thymic carcinomas. However, neither of these markers are 
found in all thymic carcinomas and uncommonly they can be po-
sitive in B3 thymomas or carcinomas from other sites such as the 
lung. Comprehensive genomic analysis using comparative geno-
mic hybridization has shown thymic carcinomas are molecularly 
distinct from thymomas and squamous cell carcinomas of the lung. 
While c-Kit expression is common in thymic carcinomas mutations 
are rare. Despite multiple trials of molecular targeted therapies for 
the EGFR pathway, angiogenesis inhibition, c-kit pathway, histone 
deacetylase inhibition, octreotide, an IGF-1 receptor pathway, the-
re are no validated targeted therapies that can be recommended 
at this time. With some of these approaches in early therapeutic 
trials, and active molecular investigation of these rare tumors, 
hopefully, in the near future, new treatment options for patients 
with advanced disease will become available. So far, molecular 
studies have provided useful insights into the histologic subtypes 
of thymic epithelial tumors and provide genetic validation of the 
existing classification, but they have not demonstrated superiority 
over morphology in classifying these tumors. Hopefully molecular 
markers can be identified that will aid in refining the existing classi-
fication or in separating the existing subtypes.
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Abstract: Thymomas are epithelial neoplasms arising in the thy-
mus with a spectrum of morphology, genetic characteristics and 
clinical behavior. Thymomas are composed of a mixture of neo-
plastic epithelial cells and non-neoplastic T lymphocytes, admixed 
in varying proportions. Much of the controversy about classifica-
tion of thymic epithelial tumors can be attributed to confusion 
about differences in histologic classification versus grading. While 
genetic studies have provided some insights into the biology of 
these tumors and classification, a major hurdle is how to identify 
molecular abnormalities specific to the epithelial cells of B1 and B2 
tumors because the genetic findings are dominated by the nu-
merous lymphocytes in the tumor stroma. Thymic epithelial tumors 
are classified into thymomas and thymic carcinomas according to 
the 2004 World Health Organization (WHO). Thymomas are clas-
sified into Type A and Type B tumors with the latter being divided 
into B1, B2 and B3 with an increasing percentage and degree of 
atypia of epithelial cells and decreasing numbers of lymphocytes. 
THYMOMA 
• Type A thymoma, is composed of bland spindle or oval shaped 
and few lymphocytes.
• Type AB thymoma, , is composed of two components, one re-
sembling the type A thymoma and one with plump cells and pre-
dominant lymphocytic infiltrate.
• Type B1 thymoma, is composed of a prominent lymphocyte 
population with a minor component of epithelial tumor cells with 
vesicular nuclei and small nucleoli.
• Type B2 thymoma, is a thymoma with relatively even mixtures of 
lymphocytes and plump epithelial cells with vesicular nuclei.
• Type B3, is predominantly composed of polygonal or round epi-
thelial cells with mild atypia. This category shows variable degree 
of cytologic atypia.
THYMIC CARCINOMA Thymic carcinoma was previously classified 
as Type C thymoma, but in the 2004 classification this term was 
dropped. These tumors show much greater degree of cytologic 
atypia than thymoma. CLASSIFICATION ISSUES Histologic he-
terogeneity is common, with more than one histologic subtype 
frequently present in a given tumor, making histologic subclassi-
fication difficult. The clinical relevance of the WHO classification 
system has been validated by many studies. In general the classi-
fication from type A to AB, B1, B2 and B3, then thymic carcinoma 
represent an increasing histologic grade that corresponds to 
increasing aggressiveness of clinical behavior. Increasing mole-
cular alterations are also found along this spectrum from A to B3 
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its members collecting patients with thymic tumors submitted to 
surgical resection between 1990 and 2010. Methods: A total of 
2151 patients were collected from 35 Institutions, including 1798 
thymomas, 191 thymic carcinomas (TC), and 41 Neuroendocrine 
Thymic Tumors (NETT)). 1709 patients (89%) received a complete 
resection. Myasthenia Gravis (MG) was present in 629 patients 
(35%). Different clinical-pathologic characteristics were analyzed 
for their impact on survival and recurrence. Primary outcome was 
overall survival (OS); secondary outcomes were the proportion of 
incomplete resections, disease-free survival (DFS) and the cumu-
lative incidence of recurrence (CIR). Results: Ten-year OS and DFS 
rates were 73% and 70%. The risk of mortality increased with age 
and with the stage. It also increased in the presence of TC, NETT 
and incomplete resection. Ten-year CIR was 12%. Predictors of 
incomplete resection included male gender, tumor size, the ab-
sence of MG, non-thymoma categories (TC and NETT) and high-
risk thymomas (B2-B3). The risk of recurrence increased with tumor 
size, increased stage and NETT. Finally, our analysis indicates that 
the overall effect of adjuvant therapy after complete resection on 
OS was significantly beneficial (p=0.05) using a propensity score. 
Conclusions: Masaoka stages III-IV, incomplete resection and 
non-thymoma histology showed a significant impact in increasing 
recurrence and in worsening survival. The administration of adju-
vant therapy after complete resection is associated with improved 
survival.
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MS16.4 CHEMOTHERAPY FOR THYMIC TUMOURS
Nicolas Girard
Respiratory Medicine Service, Louis Pradel Hospital, Hospices Civils De 
Lyon/France
Abstract: Thymic epithelial tumors represent a wide range of 
anatomical, clinical, histological, and molecular malignant entities, 
which may be aggressive and difficult to treat. The histopathologi-
cal classification distinguishes thymomas from thymic carcinomas. 
Chemotherapy may be used in two clinical scenarios in thymic 
epithelial tumors: 1) chemotherapy may constitute primary part 
of the multimodal curative-intent treatment of locally-advanced 
tumors, and is subsequently combined with surgery or radiothe-
rapy; the main objective is to achieve long-term survival with no 
evidence of tumor recurrence; 2) chemotherapy may be delivered 
as the sole treatment modality in unresectable, advanced, meta-
static, or recurrent tumors; then a palliative-intent treatment, the 
aim is to improve tumor-related symptoms through achievement of 
tumor response, while no prolonged survival is expected. Several 
chemotherapy regimens have been used in the curative-intent 
setting, mostly consisting of adriamycin- and/or platin-based multi-
agent combinations. Usually 2-4 cycles of chemotherapy are ad-
ministered before imaging reassessment. Aiming at increasing the 
response rate to primary treatment, and thus complete resection 
rate, chemotherapy may be combined with radiotherapy; howe-
ver, retrospective data available do not provide with interpretable 
figures to compare chemotherapy to chemo-radiotherapy in the 
pre-operative setting. Response rates to curative-intent chemo-
therapy ranged from 70% to 80% in the largest studies. Patients 
for whom R0 resection was thought to be feasible undergo sur-
gery, and complete resection is achieved in about 50% of cases. 
Postoperative radiotherapy is then frequently delivered. When the 
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MS16.2 TOWARDS A TNM-BASED PROGNOSTIC CLASSI-
FICATION FOR THYMIC TUMOURS
Frank Detterbeck
Yale Thoracic Surgery/United States Of America
Abstract: There are many impediments to achieving scientific 
progress in thymic malignancies, starting with the fact that these 
are relatively rare tumors. Another problem is the fact that the-
re is no official stage classification system. At least 15 different 
systems have been proposed, all of which have been based on a 
limited number of patients, and none of which has been universally 
adopted with clear definitions that are consistently interpreted. 
This lack of a common basic language is a crucial fundamental 
building block for scientific advancement. The International Thymic 
Malignancies Interest Group (ITMIG) is an academic organization 
devoted to promoting the scientific advancement in thymic and 
other mediastinal malignancies. ITMIG has partnered with IASLC 
to develop proposals to the AJCC/UICC for the 8th edition of the 
stage classification system. This process began in 2010 and is now 
in full swing. ITMIG has pulled together an international database 
of approximately 9,000 patients. This involves 77 centers and 16 
countries, with a notable major contribution from the Japanese 
Association for Research in the Thymus (JART). This data, together 
with an additional approximately 1,800 patients provided by the 
ESTS have been made available to CRAB, the statistical center for 
IASLC stage classification analyses. The Thymic Domain of the Sta-
ging and Prognostic Factors Committee (SPFC) is currently analy-
zing this data. The committee is considering multiple factors, st-
arting with an analysis of the prognostic value of the Masaoka and 
Masaoka-Koga stage classification systems. Subcommittees of the 
thymic domain are also looking specifically at T, N, M factors, the 
impact of tumor size, invasion into particular structures and clinical 
stage. Internal validation will be performed, considering treatment 
factors, clinical stage, histologic subtypes, geographic regions 
and taking into account both survival and recurrence. Potentially 
useful factors will be compared to assess the relative impact, and 
to select the best factors to propose for use in the 8th edition stage 
classification system.
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MS16.3 SURGERY FOR THYMIC TUMOURS: OUTCOMES 
FROM THE ESTS DATA BASE
Enrico Ruffini
Thoracic Surgery, University Of Torino/Italy
Abstract: Introduction: Thymic tumors are rare malignancies and 
most of the current literature is composed of single-Institutional 
series collecting small number of patients spanned over short 
time periods. The European Society of Thoracic Surgeons (ESTS) 
thymic working group developed a retrospective database among 
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a histone deacetylase inhibitor was evaluated in thymic malignan-
cies in a recently completed phase II trial enrolling 41 patients (25 
thymomas and 16 thymic carcinomas). Response and 2-year survi-
val rates were 8% and 77% in thymomas. mTOR inhibitors, in the 
setting of phase I trials, have been reported to produce significant 
control rates in thymoma and thymic carcinoma. Along with the 
large variety of questions relative to the treatment strategy, thymic 
epithelial tumors represent a model of therapeutic implementation 
and achievement in orphan thoracic oncology, showing how the 
advent of new results induces new questions, as well as diversifies 
further clinical research directions; in this setting, regional and in-
ternational collaborative initiatives are mandatory to progress both 
in the understanding of the biological mechanisms underlying the 
development of thymic malignancies, and in the identification and 
validation of new targets with prognostic and predictive value.
Keywords: Targeted therapy, thymoma, chemotherapy, Thymic 
carcinoma
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MS16.5 RADIOTHERAPY FOR THYMIC TUMOURS:  
INDUCTION, ADJUVANT AND DEFINITIVE
Ritsuko Komaki
University Of Texas MD Anderson Cancer Center/United States Of 
America
Abstract: Although the predominant approach in the treatment of 
thymoma and thymic carcinoma is surgery, radiation therapy also 
has an important role, either as postoperative therapy to reduce 
the risk of mediastinal recurrence or as part of definitive treatment 
for patients that who cannot undergo surgery. We present here 
a review of radiation therapy for thymic malignancies and briefly 
discuss the potential benefits from novel technologies for such 
treatment. Thymic carcinoma is a rare but more aggressive tumor 
which has a tendency to fail locally and distantly. Thymic carcinoma 
has more frequent EGFR and/or HER2 abnormalities compared to 
thymoma., and the outcome of thymic carcinoma is usually wor-
se than invasive thymoma. Postoperative Radiation Therapy: 
Indications R0 (Completely Resected) Thymic Malignancies In 
general, radiation should be considered more strongly as the risk 
of recurrence increases. Therefore, for patients with the lowest 
likelihood of recurrence (i.e. completely resected Masaoka stage I 
thymoma), radiation can be safely omitted. For those at intermedi-
ate risk of local recurrence after complete resection, i.e. those with 
aggressive tumor histologies (such as thymic carcinoma) or Ma-
saoka stage II and stage III disease, retrospective evidence exists 
both to support and contradict claims of benefit from adjuvant 
radiotherapy after complete resection. In general, our institutional 
practice includes postoperative radiation for completely resected 
Masaoka-Koga stage III thymoma and stage II or III thymic carcino-
ma. Risk assessment and stratification is usually done in a multidis-
ciplinary setting and drives the choice of adjuvant treatment. The 
International Thymic Malignancy Interest Group (ITMIG) published 
a set of definitions and reporting guidelines for the use of radiation 
therapy for thymic malignancies in 2011. Pertinent recommen-
dations for postoperative therapy are as follows. First, the term 
“postoperative” should be used for situations in which the tumor 
is resected and no residual disease is evident on imaging. If gross 
disease is present on postoperative imaging, then the disease 
should be defined as “recurrent” and the intent as “radiation for 
postoperative disease.” Second, the minimum acceptable dose for 
patient is not deemed to be a surgical candidate - either because 
R0 resection is not thought to be achievable or because of poor 
performance status or co-existent medical condition, definite ra-
diotherapy, as reported above, is delivered. If radiotherapy is not 
feasible, either because of a large tumor burden that precludes 
safe delivery of appropriate doses or because of co-morbidities 
increasing the risks of radiation-induced toxicity, treatment is 
chemotherapy alone, in a strategy that may ultimately be conside-
red palliative. In the reported literature, 10-21% of patients with 
locally-advanced thymic tumors receiving upfront chemotherapy 
did not receive either surgery or radiation therapy or other local 
treatment. Survival of these patients is frequently limited. Overall, 
the major challenge in interpreting data about pre-operative che-
motherapy in thymic malignancies is the wide variation in the num-
ber of patients subsequently treated with surgery, radiotherapy, or 
chemotherapy alone, which suggests significant heterogeneity in 
the inclusion criteria among series. Response has been evaluated 
based on elusive criteria in some studies published before CT scan 
was largely available. In most studies, thymomas and thymic carci-
nomas, as well as newly diagnosed and recurrent tumors, were not 
analyzed separately. Ultimately, the majority of studies are retro-
spective, with uncontrolled design. Finally, one should consider 
the potential effect of corticosteroids, that have been known for a 
long time to have a “lympholytic” effect. Palliative chemotherapy 
is given as the sole treatment modality for thymic tumors, usually in 
the setting of stage IV, unresectable, recurrent disease. Prolonged 
disease control is possible, but tumor eradication is not expected. 
Several studies - both prospective and retrospective - described 
several regimens for definite chemotherapy, but because there are 
no randomized studies, it is unclear which are best; multi-agent 
combination regimens and anthracycline-based regimens appear 
to have improved response rates compared to others, especially 
the etoposide, ifosfamide and cisplatin combination. In general, 
combination regimen is recommended, for at least 3 and no more 
than 6 cycles. Overall, response rates are 20-40%, lower than that 
observed in the preoperative setting. Progression-free and over-
all survival of patients ranges from 12 to 66 months, and 37 to 72 
months, respectively; such variability may be related to the various 
settings in which chemotherapy was delivered in those studies. In 
the palliative-intent setting, several consecutive lines of chemothe-
rapy may be administered when the patient presents with tumor 
progression. It is estimated that 50-70% of patients with thymoma 
recurrence are eligible to chemotherapy. Strategy may consist of 
the re-administration of a previously effective regimen, especially 
in case of previous response, late occurring recurrence, and for 
anthracyclins, a patient in a good medical condition and not ha-
ving received cumulative doses precluding the safe delivery of at 
least 3 additional cycles. In case of recurrence, the strategy may 
actually primarily consist of a similar multimodal management to 
that conducted at time of first diagnosis, with surgery and radio-
therapy in eligible cases. Complete re-resection remains a major 
prognostic factor in this setting. In patients not eligible to receive 
additional chemotherapy, octreotide may represent a valuable 
option; as a single agent, octreotide produced objective tumor 
responses rates, and of more relevance in this setting, disease 
control rates. Novel treatment strategies are needed, especially for 
refractory, recurrent tumors, and thymic carcinomas, which carry 
a poor prognosis despite multimodal treatment. Potentially drug-
gable targets are emerging, laying the foundations to implement 
personalized medicine for patients. Given the currently available 
targeted agents outside of a clinical trial, the signaling pathways 
that are relevant in the clinical care of patients, are the KIT and the 
Vascular Endothelial Growth Factor (VEGF)-R (Receptor) pathways. 
Promising new targets in thymoma and thymic carcinoma include 
IGF-1R and histone-deacetylase. Cixutumumab, an IGF1-R directed 
monoclonal antibody was recently reported to produce a promi-
sing 90%-disease control rate in refractory thymomas. Belinostat, 
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postoperative R0 disease is 50 Gy in 5 weeks. Finally, radiation to 
elective nodal regions not recommended, and the extent of malig-
nancy before surgery should be used as a guide for designing the 
treatment fields. Microscopic Positive Margins (R1) and Gross 
Disease (R2) Radiation for R1 or R2 thymic malignancies should 
be started within 3 months of surgical resection. Doses between 
40 Gy and 64 Gy are most appropriate for microscopically positi-
ve margins, whereas doses of 54 Gy or higher should be used for 
gross disease; both given in standard fractions of 1.8- to 2.0-Gy. 
Patients with positive margins should be considered for concurrent 
chemotherapy and radiotherapy, especially among patients with 
thymic carcinoma. Definitive Radiation Therapy Definitive radia-
tion therapy is generally used for patients who are not candidates 
for surgery because of either the extent of disease at diagnosis or 
medical comorbidities. Because chemotherapy is a known radia-
tion sensitizer, the combination of chemotherapy and radiation is 
considered most likely to control disease in these circumstances. 
In this setting, which is analogous to recurrent disease after surgi-
cal resection, we recommend radiation doses of 60 Gy -66 Gy to 
encompass gross disease plus a margin for microscopic regions 
at risk. Thymic carcinoma behaves more like non-small cell lung 
cancer arising from the thymus. Therefore, unresectable thymic 
carcinoma needs to be treated based on the histology or mole-
cular biomarkers of expression e.g. EGFR, HER2 c-KIT and BCL-2. 
Approximately 50% of thymic carcinoma has squamous histology 
which can be treated with cisplatin based chemotherapy and ra-
diotherapy. If unresectable thymic carcinoma has atypical carcinoid 
histology, etoposide and cisplatin plus radiotherapy might be the 
best option. For recurrent thymic carcinoma, molecular targeted 
agents e.g EGFR-TKI, c-KIT inhibitors and VEGFR inhibitors can 
be delivered in the protocol setting with or without radiotherapy. 
Techniques Because of the central location of thymic malignancies 
and the relatively high doses used in radiation therapy, we strongly 
recommend the use of conformal techniques, such as three-dimen-
sional conformal radiation therapy (3D-CRT), intensity-modulated 
radiation therapy (IMRT), or, if available, proton beam therapy 
owing to the physical properties of the particles (i.e., the Bragg 
peak) which produce lower doses both proximal and distal to the 
target volume. In addition, because tumors can show substantial 
changes in shape or size over the course of several weeks of radi-
ation therapy, we recommend that when radiation is to be used as 
definitive therapy, adaptive planning should be considered. Long-
Term Consequences of Radiation on the Heart and Vasculature 
An abundance of evidence exists to show that long-term survivors 
of mediastinal radiation therapy can develop both acute and chro-
nic cardiac sequelae. With regard to acute effects, the dose and 
fractionation of the radiation and the volume of heart irradiated 
all affect the risk of pericarditis and pericardial effusion. Given the 
close physiologic association between perfusion and ventilation, 
one might expect that radiation to the heart could affect lung 
function and vice versa. In a clinical study, investigators found that 
several heart dose-volume variables predicted radiation pneu-
monitis and that the fit of a model predicting pneumonitis was 
improved by the incorporation of heart variables. In conclusion, 
considerable evidence has shown that irradiation of the heart and 
vasculature can lead to increased acute and long-term toxicity and 
that these side effects are related to the dose, volume, and exact 
location of the irradiated field. Short-term surrogates of long-term 
toxicity such as findings on cardiovascular imaging or biomarker 
correlates would be helpful for identifying which patients at gre-
atest risk for cardiac events. In the meantime, we recommend the 
continued use of advanced radiation therapy technologies such as 
IMRT, proton beam therapy, 4D imaging and treatment planning, 
and adaptive planning whenever possible to minimize the dose to 
mediastinal structures for patients with thymic disease, many of 
whom will survive for several decades and thus will live to see the 
long-term consequences of irradiation of these vital organs.
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free text can better capture the uncertainties within a radiological 
examination, as often findings cannot be simply categorized into 
negative or positive. Unlike standardized reporting, the subject 
of standardized protocols in lung cancer imaging is perhaps less 
controversial, but no less important. The protocols used for the 
imaging of lung cancer can have a significant impact on the accu-
rate staging and treatment planning of lung cancer. Furthermore, 
the successful implementation of future lung cancer screening 
programmes will require consistent adherence to low-dose CT 
acquisition protocols. In the staging of patients with lung cancer, 
protocols such as the routine reconstruction of multi-planar refor-
mats to better identify tumour invasion are becoming widely adop-
ted. Less agreement exists on imaging pathways. For example, the 
role of routine brain MRI in lung cancer staging or the possible use 
of contrast-enhanced PET/CT as a “one-stop shop”.
Keywords: standardized reporting, lung cancer imaging protocols
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MS17.2 STANDARDIZED REPORTING; GUIDELINES FOR 
IMAGING PROTOCOLS / INTERPRETATION
Anand Devaraj
St George‘s Hospital/United Kingdom
Abstract: The radiology report forms an essential component of 
any radiological examination, and an accurate radiology report 
requires two key components: the detection of abnormalities (if 
any), and subsequently their interpretation. However, for radiolo-
gy reports to be useful to the clinician and patient, a third crucial 
factor is successful communication. In the setting of lung cancer 
reporting, radiologists rely on their perceptive ability to detect 
nodules or masses, while interpretation requires knowledge and 
experience of the appearances, staging and behaviour of lung 
carcinomas. Improvements in both of the factors have been achie-
ved by developments such as the use of computer aided detection 
software or maximum intensity projections (MIPs), for example, to 
detect lung cancer; and the use of internationally recognized do-
cuments such as the IASLC lung cancer staging classification which 
aids radiological interpretation. By comparison, the communica-
tion of the radiology report has changed little over the years, and 
it could be argued that efforts to improve lung cancer detection 
and staging are diminished without satisfactory communication. 
Standardized reporting (SR) has been advocated as a tool that can 
improve the communication of radiology reports, and which may 
also have benefits in the detection and interpretation of radiolo-
gical abnormalities. This presentation will review the definitions of 
SR, and examine its purported benefits and disadvantages. Stu-
dies investigating the impact of SR will be reviewed. In particular, 
its relevance to lung cancer imaging will be highlighted. There 
is no single definition of what a standardized report should look 
like, but a key principle is that standardized reports (SRs) follow a 
pre-defined format. At the most basic level this includes the use 
of brief headings within a report, such as “clinical information” or 
“impression”, each of which contains free-text. At the other ext-
reme is the mandatory use of a check-list of itemised headings, 
and the selection from a list of only pre-defined terms (using 
standardized language) within these headings, rather than free-
text. Itemised headings in a CT structured report of a patient with 
lung cancer might include tumour morphology, tumour location, 
tri-dimensional measurements, presence or absence of invasion of 
structures such as pleura or chest wall, the presence or absence of 
enlarged lymph nodes recorded for all of the nodal stations, and 
the presence or absence of metastatic disease in each of the body 
organs. The hypothesized advantages of SR is that it produces: i) 
reports that are more accurate, ii) reports that are easier to read 
and understand, and iii) reports from which it is straightforward 
to retrieve data for research purposes. It has also been suggested 
that SRs allow radiologists to better convey uncertainties and like-
lihoods to clinicians. This is standard practice in mammographic 
reporting, where abnormalities are given a score between 1(nega-
tive) and 5 (highly suggestive of malignancy) and could in theory 
be extrapolated to the description of lung nodules in a clinical or 
lung cancer screening setting. The main disadvantages of SR that 
are put forward include its negative impact on workflow and the 
interpretation process. Additionally, it is suggested that, in fact, 
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year approximately 25 % of the patients having grade 3 or more 
toxicities. It comes as no surprise that the median overall survival 
after re-irradiation is low, ranging from 6-15 months. Because 
apart from one prospective trial with 23 patients only small, 
retrospective studies have been presented, it is not clear what 
the prognostic factors for survival are. Thorough staging, a good 
performance status, a small GTV and the possibility to give a high 
dose of radiotherapy seem obvious. In view of all uncertainties 
and the observation a significant proportion of patients with 
important toxicity, the time is right to launch prospective studies, 
randomised or not. These studies should focus on prognostic 
factors both for survival and toxicity, in order to ultimately be able 
to identify a subgroup of patients with truly curable disease or 
in which systemic treatment can be delayed significantly without 
undue toxicity. In the meantime, an individual patient should 
clearly understand the limitations and doubts of re-irradiation with 
regard to survival and toxicity. In case of a limited recurrence in an 
otherwise good performance patient, SBRT is reasonable if central 
structures can be avoided and 2 Gy per day, 5 days per week in 
other cases. A biological dose of at least 60 Gy should be given, 
taking into account the OARs. Probably the most suited patients 
are those with a long delay, possibly of more than one year, 
between the first irradiation and the recurrence.
Keywords: re-irradiation, radiotherapy, Recurrence
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MS18.3 RE-IRRADIATION FOLLOWING RADICAL RADIO-
THERAPY
Dirk De Ruysscher
Radiation Oncology, University Hospitals Leuven/ KU Leuven/Belgium
Abstract: As the prognosis of cancer patients gets better, more 
individuals are at risk to develop a local recurrence or a new 
primary tumour in previously irradiated organs. New radiation 
techniques, better imaging and more knowledge of dose volume 
relationships have fuelled re-irradiation to high doses. The aim of 
high-dose re-irradiation is to give the patient a chance for long-
term disease-free survival and even cure. Re-irradiation is only 
expected to be beneficial when a high-dose can be delivered. 
In order to do this safely, knowledge about the dose-response 
relation for the organs at risk (OAR) is needed. Here, the first 
problem starts. Even in patients that have never been irradiated, 
in-depth individual knowledge about dose-response relations for 
all AORs is lacking. As is clear from e.g. the QUANTEC reviews, 
even for widely used parameters such as the mean lung dose 
(MLD) or the V20, the accuracy of the model to predict subsequent 
development of radiation pneumonitis is very moderate, with 
AUC values under the ROC curve of 0.60-0.65. For other organs 
like the heart, current models score even worse. Functional, 
imaging and genetic parameters are an area of intensive research, 
but not usable in standard practice yet. In case of re-irradiation, 
only limited data coming from retrospective studies with small 
numbers at risk for late complications are available. Keeping all 
caveats in mind, it seems that the aorta can tolerate cumulative 
physical doses of up to 120 Gy (given in 2 Gy fractions), above 
which dose level lethal bleeding may occur (Evans et al. Radiother 
Oncol 2013). In other retrospective series, grade 4-5 stenosis, 
fistula and bleeding occurred only when re-irradiation included 
central structures (Peulen et al. Radiother Oncol 2011). Even when 
stereotactic body radiotherapy (SBRT) is used for re-irradiation, 
the risk for radiation pneumonitis seems to be more than 20 % 
with cumulative V20 values over 30 % (Liu et al. Int J Radiat Oncol 
Biol Phys 2012). This points to the importance to obtain composite 
plans, which should include non-rigid deformation. Whether alpha/
beta values that are used for primary irradiation are safe in the 
re-irradiation setting is not investigated thoroughly, as is the repair 
of OARs over time, the influence of co-morbidities, medication and 
anti-cancer drugs. Nevertheless, one prospective ( Wu et al. Int 
J Radiat Oncol Biol Phys 2003) and several retrospective studies 
(Okamoto et al. Int J Radiat Oncol Biol Phys 2002; Kruser et al. Am 
J Clin Oncol 2013; Tada et al. Int J Clin Oncol 2005; Ebara et al. 
Anticancer Res 2007; Peulen et al. Radiother Oncol 2011; Meijneke 
et al. Radiother Oncol 2013) have been published. In most series, 
the median radiation dose of the first treatment was about 60 
Gy and that of the second 40-50 Gy in 4-5 fractions in case of re-
treatment with SBRT or 60 Gy in 2 Gy daily fractions. The median 
interval between the first treatment and the second was in most 
studies between 12 and 24 months. All series indicate that re-
irradiation is “feasible”, with after a median follow-up of about one 
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sult in in unsafe margins and poorer local control? This problem 
can be partly addressed by careful and well planned prospective 
follow up studies. Secondly these innovations come with a real 
cost in capital investment, staff time and, often, longer individual 
treatment times and lower throughput. How much is that cost and 
could that money be used in another area to deliver more health 
benefit? In other words are these innovations cost effective? There 
are increasing concerns everywhere about the escalating costs of 
healthcare and whether the payer is the state, an insurance system, 
a health maintenance organisation or an individual, health profes-
sionals have a responsibility to deliver cost effective care. Given 
the difficulty of carrying out RCTs in this area, what can be done to 
help those deciding on the best use of resources? One option is 
to undertake modelling studies not only of dosimetric and clinical 
consequences but also of costs and consequences. It may then be 
possible to make to some high level decisions about whether the 
benefits are likely to large enough and the costs low enough to 
justify introduction into routine clinical practice, whether compa-
rative research (ideally an RCT) is needed or whether further eva-
luation of efficacy and safety is needed in institutions experienced 
in such research. I would therefore argue for better coordinated 
efforts, preferably at an international level, to address this difficult 
problem and provide more information about how best to use 
these new and important resources.
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Abstract: Resource Constraints is an important barrier to Lung 
Cancer Management. In order to understand this issue in De-
veloping Nations, the questionnaires was set up and send to an 
experts in Asian countries to find out the fact about this issues. 
Data gather from the questionnaires will be present at the mee-
ting. Specific information in the questionnaires are Drug lagging 
period, time to get new cancer drug approval, the important of 
economic analysis during the approval of new anticancer drug. The 
other information related to man power including specialist in all 
related subspecialties and the availability and accessibilty to diag-
nostic and treatment will be captured by questionnaires. Pattern of 
Health Insurance and other cost was also the information gathered 
at the same time.
Keywords: man power, heath care cost/ insurance, drug lag, wai-
ting time
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Kingdom
Abstract: The past 15 years has seen dramatic developments in 
radiotherapy (RT) technology and techniques many of which are 
being applied to patients with lung cancer. The most important 
of these are PET imaging for RT planning, 3D conformal RT, In-
tensity Modulated RT, stereotactic body RT (SBR), Image Guided 
RT and techniques to compensate for respiratory movement such 
as gating. These are now in widespread use and becoming the 
‘standard of care’ in developed countries. But significant questions 
remain about how fully they have been evaluated and whether or 
not they have actually led to improvements in clinical outcomes, 
let alone whether they are in fact cost effective innovations. In this 
presentation I will address the following questions: · Why are new 
RT technologies difficult to evaluate for anything beyond efficacy 
and safety? · Should they be subjected to the same rigorous eva-
luations as new pharmaceuticals through randomised controlled 
trials (RCTs) before entering wide clinical practice? · What strate-
gies could be used to assess ‘value for money’ in the absence of 
high quality evidence? The model for assessing new technologies 
is derived from pharmaceutics where the new drug is first evalu-
ated for safety and dosage (Phase I), then for efficacy (Phase II) 
and finally for clinical effectiveness compared to standard therapy 
(Phase III) before (in some health systems) being assessed for cost 
effectiveness. New non-pharmacological technologies are not 
subject to the same regulatory regime and, other than meeting 
routine requirements for radiation safety, RT technologies can be 
introduced into routine practice without evidence of clinical effec-
tiveness – improving outcomes. Novel RT technologies are difficult 
to evaluate formally because: · They often develop incrementally 
over time with new refinements, especially in associated computer 
software. · There may be competing manufacturers with slightly 
different products. · There is often a ‘learning curve’ before they 
are used most effectively. · There are demonstrable improvements 
in planned dose distributions, imaging and accurate dose delivery 
which lead to a reasonable belief that clinical outcomes will be 
better. · There is always a need for capital investment, sometimes 
substantial, which means that only centres that already have the 
technology can participate in comparative clinical trials and those 
clinicians may be reluctant because they may already be convinced 
that their new technology is better. · The important clinical out-
comes, local control, survival, late radiation toxicity take years to 
evaluate. · Funding for such research may be hard to find. Does 
this really matter? It can be argued that demonstration of better-
looking computerised plans and apparently more accurate and 
consistent delivery of radiation dose is a good in itself and one 
should always try to use the best tools available. That is true – up 
to a point. But there are two important considerations. First does 
this apparent improved ‘accuracy’ give false reassurance and re-
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efforts are required to communicate best practices to providers, 
(including primary care physicians), to improve the efficiency of 
clinic processes and to arrange patient transportation. For abori-
ginal and immigrant populations, culture and language are known 
barriers. Resources to lower language barriers, to assist patients 
in health system navigation and to educate health providers in the 
provision of culturally sensitive care may be necessary to ensure 
equitable access to appropriate care. 
Some developed countries have experienced resource constraints 
that have delayed access to cancer surgery and to radiation treat-
ment. Excessive wait times result from inadequate capacity and/
or inefficiencies in the health system. To resolve these issues first 
requires recognition of the problem, the development of a plan 
of action, appropriate funding to address capacity issues, process 
improvements to increase efficiency and incentives to providers to 
prioritize cancer treatments.  
In a recent review of access to cancer care services in Canada, 
Maddison et al. noted that inequity of access occurs across the 
continuum of care for different disease sites (4). The review sug-
gested that access to cancer services is most inequitable at the 
beginning (i.e. screening) and at the end (i.e. end-of-life care). 
Income level appeared to have the most influence on screening 
while age and geography were most influential on access to end-
of-life services. As the results of the NLST are implemented as 
population-based screening programs, low dose CT will compete 
for diagnostic service resources and other services. Smokers at risk 
from lower socioeconomic levels, in particular, may encounter bar-
riers to access. At the other end of the cancer spectrum, access to 
palliative care resources varies widely in developed countries. 
Conclusions: 
Access to optimal lung cancer care across the continuum from 
screening and early detection through treatment and end-of-life 
care can encounter numerous resource barriers, which are not all 
monetary in nature. Although the cost of new drugs is the most 
significant potential resource barrier, numerous other barriers can 
exist in developed countries related to the resources available for 
screening or diagnosis, radiation and surgery, access to knowledge 
specialists, supportive care services and accessible end-of-life care 
in the home or community. 
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LUNG CANCER MANAGEMENT: DEVELOPED NATIONS
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Abstract: The chronic disease burden of developed countries is 
increasing as the postwar “baby boomers” enter their senior years. 
The cost of managing these chronic diseases is compounded by 
the increasing availability and use of expensive technologies. Can-
cer drug costs are a key driver of health care costs and the expen-
diture on cancer drugs is rising faster than spending in most other 
areas of healthcare. Because of this and the fiscal constraint most 
developed countries have put in place a rigorous drug review pro-
cess. The United Kingdom’s National Institute for Health and Care 
Excellence (NICE), amongst others has led the way in establishing 
drug review processes. These reviews are generally viewed by the 
pharmaceutical industry, healthcare providers and the public itself 
as a barrier to access. The pan-Canadian Oncology Drug Review 
(pCODR) evaluates the clinical benefits and safety of new cancer 
drugs, as well as their cost-effectiveness and alignment with pati-
ent values using a standardized clinical and economic review pro-
cess, an expert panel, a deliberative framework and broad public 
engagement (1). Commonly, recommendations are conditional on 
the drug price being lowered because the drug is not felt to be 
cost-effective. The determination of incremental cost-effectiveness 
or cost-utility is critical to drug funding approval in most jurisdic-
tions except the United States. This is determined by assessing the 
incremental cost of the new drug or regimen over the standard 
treatment and dividing by the incremental benefit usually measu-
red as years of life gained. In Canada, $50,000 per life year gained 
or less was generally accepted as cost-effective. As drug costs 
have increased, this "threshold“ has crept higher and $100,000 per 
LYG is increasingly accepted as “reasonable”. To take account of 
morbidity from the disease and its treatment, the quantity of life 
gained is weighted by the quality of that life into a single multidi-
mensional measure (i.e. the quantity adjusted life year or QALY). 
The availability of other resources, not related to the cost of drugs, 
can be a barrier to access. In 2008, Cancer Care Ontario began 
to measure concordance with guidelines developed through its 
Program in Evidence-based Care and to report this information 
through a Cancer System Quality Index (CSQI) (3). In 2010- 2011, it 
was noted that only 41% of resected stage II/IIIA patients received 
guideline recommended adjuvant chemotherapy (AC) at Ontario’s 
regional cancer centres. There was also substantial variation in gui-
deline adherence between centers ranging from 42.9% to 72.1%. 
Men were significantly less likely to be treated with AC (38.2% 
compared to 52.7% for women) (p=0001), as were patients over 
age 65 (65% < 65 yrs. vs. 34% > 65 yrs.)(p=.0001). Patients from 
regions with the highest tercile of immigrants were significantly 
less likely to be treated: 14.3% for the highest, 46% for the middle 
and 51% for the lowest tercile. Similar variations were seen for the 
uptake of the guideline recommendation for the use of combined 
modality therapy in the treatment of stage III NSCLC. 
To better understand the reasons for these variances, a survey 
and key informant interviews were undertaken with clinicians and 
administrators. The perception of respondents was that the most 
common barriers to implementing practice guidelines were the 
slow referral process of patients to the treatment centers, lack of 
support from the organization’s leadership to implement the re-
commended regimens and the difficulties that patients had in get-
ting to the treatment centers. These results suggested that greater 
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MS20.3 OPTIMAL RADIOTHERAPY FOR SCLC
Corinne Faivre-Finn
The Christie NHS Foundation Trust/United Kingdom
Abstract: Whilst the incidence of small cell lung cancer (SCLC) has re-
duced over the last 20 years, the prognosis of the disease remains poor. 
Major advances in SCLC include improvements in radiotherapy (RT) 
techniques, the use of prophylactic cranial irradiation (PCI) for all stages 
of SCLC and the improved integration of chemotherapy and RT. It is 
unlikely that future advances in the treatment of SCLC will relate to stan-
dard chemotherapy. The role of thoracic RT is well established in the 
management of stage I-III SCLC 1,2,3,4. There is increasing evidence in 
the literature in favour of early concurrent chemo-radiotherapy (CTRT), 
and a gold standard of care for patients with a good performance 
status is twice-daily thoracic RT (45 Gy in 3 weeks) with concurrent 
cisplatin and etoposide 5. Although current clinical trials are exploring 
the efficacy of new chemotherapeutic strategies, essential questions 
related to the optimisation of thoracic RT remain unanswered. These 
questions include i) optimal total dose, ii) fractionation, iii) timing and 
sequencing of radiation, iv) volume of irradiation, v) concurrent che-
motherapy/targeted therapy combinations, and vi) the importance of 
the time between the start of any treatment to end of RT. PCI reduces 
the incidence of brain metastases and improves survival in all stages of 
SCLC 6,7. As a result of the implementation of best standard of care the 
5 year survival of stage I-III SCLC patients has increased from less than 
10% with chemotherapy alone to 25-30% with early concurrent CTRT 
and PCI. It is crucial that patients with SCLC are given the opportunity 
to participate in clinical research in order to continue to improve the 
survival of this disease. Clinical trials aiming to establish a standard 
dose/fractionation in the stage I-III setting include the European/
Canadian CONVERT and the US intergroup (CALGB 30610/RTOG 
0538) studies. The results of the CREST study investigating the role of 
thoracic RT in stage IV SCLC are eagerly awaited. Molecular studies are 
ongoing aiming to gain improved insight into the molecular biology 
of SCLC, discover and/or validate candidate biomarkers for response, 
resistance to or toxicity of systemic treatment and radiation. There is 
now a concerted effort within the research community to understand 
the molecular mechanisms that underpin the molecular pathways in 
cancer. It is hoped that this understanding will lead to the development 
of targeted therapies that will not only prove efficacious, but also less 
toxic than more conventional treatments. In combination with newer 
techniques such as conformal RT and better imaging, it is hoped that 
the rates of long term survivors will increase significantly in the future. 
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1Medicine, Penn State Hershey Medical Center/United States Of Ameri-
ca, 2Penn State Hershey Cancer Institute/United States Of America
Abstract: Small cell lung cancer represents about 12% of new case 
of lung cancer in the USA. It has a unique presentation and natural 
history compared to other types of lung cancer and is highly res-
ponsive to first-line treatment. Unfortunately, the cancer typically 
relapses after a short period of time and exhibits resistance to 
cytotoxic and targeted therapeutic agents with a poor median sur-
vival. The last 2 decades witnessed significant improvement in our 
understanding of the molecular basis of small cell lung cancer with 
identification of several potential therapeutic targets leading to ap-
plication and evaluation of novel chemotherapeutic, targeted and 
immunotherapeutic agents in a large number of clinical trials. In 
this presentation, we will summarize the data from the recent and 
ongoing clinical trials in this disease and understand the challenge 
that it poses. However, the results have overall been disappointing 
and the combination of a platinum compound with etoposide re-
mains the most effective treatment for this patient population. De-
spite the advent of new cytotoxic and targeted agents, which have 
shown significant activity in other types of cancer including non-
small cell lung cancer, their use in SCLC has not had any impact on 
survival. The differences in efficacy observed with agents such as 
amrubicin and irinotecan in patients from different ethnic or racial 
groups indicate the importance of the understanding the tumor 
genetic makeup and individualizing treatment regimens. The land-
scape of genetic alterations of SCLC is more complex than in other 
types of cancer. To date, no specific mutation, abnormal fusion 
protein secondary to chromosomal translocation or aberrant signal 
transduction pathway has been validated and proven to be critical 
for the continuation of the carcinogenesis process and survival of 
the SCLC tumor cells. SCLC remains one of the most challenging 
tumors to treat with our current standard of care. The recent ad-
vances in sequencing and high throughput technologies have star-
ted to yield useful information about the molecular abnormalities 
of SCLC. We need to refine the recently acquired knowledge of 
SCLC biology and apply that knowledge in innovative clinical trials 
to have a breakthrough in the treatment of SCLC.
Keywords: small cell lung cancer, clincial challenge, MANAGE-
MENT
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MS21.2 MOLECULAR DIAGNOSIS IN CYTOLOGY AND 
ITS PLACE IN THE NEW CLASSIFICATION
Sandra A. O‘Toole
Department Of Tissue Pathology, Royal Prince Alfred Hospital/Austra-
lia
Abstract: There has been very little improvement in outcome 
from lung cancer over the last two decades but the identification 
of actionable mutations and structural rearrangements in subsets 
of patients with lung adenocarcinoma holds hope for the near 
future, particularly if these agents successfully move into the ad-
juvant setting. Detection of key molecular targets is central to this 
new understanding of lung adenocarcinoma and targeted therapy 
but poses significant challenges for implementation into routine 
clinical diagnostics. The importance of molecular testing in lung 
adenocarcinoma has been emphasized not only in the updated 
classification of adenocarcinoma but also in the recently released 
molecular testing guidelines for selection of lung cancer patients 
for EGFR and ALK Tyrosine Kinase Inhibitors produced by the Col-
lege of American Pathologists, the International Association for the 
Study of Lung Cancer and the Association for Molecular Pathology 
this year with a central recommendation that tissue should be pri-
oritized for EGFR and ALK testing. Recent molecular and genomic 
studies of lung adenocarcinoma in particular has resulted in the 
identification of other low incidence, novel driver mutations inclu-
ding structural rearrangements in ROS1 and RET-KIF5B as well as 
recognition of point mutations in BRAF and HER2 among others. It 
is apparent that “profiling” lung cancers for a range of important 
and potentially treatable driver mutations may offer significant 
advantages such as cost effective, rapid identification of actiona-
ble changes and efficient triage for clinical trials of novel agents. 
However performing molecular testing in lung cancer can be 
challenging given the majority of patients present with inoperable 
disease. This means histological and molecular diagnosis is gene-
rally performed on small biopsies including cytological specimens 
often with very limited material for testing. Furthermore much of 
this tissue has undergone formalin fixation and paraffin processing 
with subsequent DNA cross-linkage and fragmentation. There are 
additional problems of contamination with non-malignant tissue 
elements including stroma and inflammatory cells. There are also 
time pressures with the need for rapid results with current recom-
mendations for results to be available within 10 working to allow 
appropriate triage for therapy. It is important to direct testing to 
appropriate clinical groups likely to benefit. While there are strong 
demongraphic associations of actionable mutations in lung ade-
nocarcinoma, including non-smoking status, younger age, female 
sex and Asian ethnicity, these criteria are insufficiently robust to 
exclude patients without these characteristics from testing. Cur-
rent recommendations in limited specimens are that molecular 
testing for EGFR or ALK gene changes be primarily undertaken in 
adenocarcinoma or cases with a component of adenocarcinoma. 
Fortunately cytology is emerging as a robust method for classifi-
cation of lung cancer and these specimens are increasingly utilized 
for mutation testing. Large cell or histologically undifferentiated 
carcinomas with features suggestive of adenocarcinoma differen-
tiation eg TTF-1 expression are also suitable for molecular testing. 
Molecular testing of limited biopsies may also be considered in 
cases showing squamous or small cell histology guided by clini-
cal features such as ethnic background and non-smoking status 
among others. There is good concordance between primary and 
metastatic sites for EGFR mutational status and specimens from 
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MS21.1 CYTOLOGICAL DIAGNOSIS
Kim Geisinger
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pel Hill/United States Of America
Abstract: Whenever a major alteration in histopathologic classi-
fication occurs, important ramifications for cytopathology follow. 
Furthermore, the recent recognition that associations of specific 
types of epithelial malignancies of the lung are associated with diffe-
rent prognoses and therapeutic complications also directly impacts 
diagnostic cytology. One important question is: how well can we 
distinguish adenocarcinoma, squamous cell carcinoma, and other 
nonsmall cell carcinomas (NSCLC) from each other in cytologic pre-
parations? The answer is very well, with most recent data emanating 
from aspiration samples. Based purely on routine cytomorphology, 
approximately 90% of all specimens with NSCLC can be rendered 
by strict adherence to classic well indoctrinated cellular features. 
When the distinction cannot be rendered by morphology alone, the 
addtion of a small battery of immunochemical reactions raises the 
proportion of correct cell typing to nearlly 100%. Recommendations 
emphasize using a limited array of antibodies, eg. targets such as 
TTF-1, cytokeratin 5/6, and synaptophysin. In the infrequent case in 
which this does not make clear the cell type, a diagnosis of NSCLC, 
NOS is preferred over large cell carcinoma. Once a tumor is inter-
preted as adenocarcinoma, how well do we do in determining the 
predominant histologic subtype from the 2011 classification? The 
answer is poorly. This is related to both the small sample size with 
the recognition of the histologic heterogeneity within a sizeable tu-
mor mass and the concept that the rather uniform manners in which 
neoplastic cells aggregate and present themselves in aspiration and 
exfoliative smears is typical of all types of adenocarcinomas and 
thus not representative of the histologic subtype. Current data sup-
ports the general notion that the predominant histologic subtype 
correlates with prognosis, and thus may serve as a morphologic gra-
ding surrogate. As just stated, it does not appear that cytology will 
permit such a parallel assessment. However, there is some evidence 
that certain nuclear attributes of adenocarcinoma cells in cytologic 
specimens are associated with prognosis and, hence, nuclear gra-
ding may be of value in this regard. Features which include nuclear 
contour, chromatin pattern, and the prominence of nucleoli can be 
used to formulate a meaningful nuclear grading system. This is likely 
better performed with alcohol-fixed Papanicolaou stained specim-
nes compared to air-dried Romanowsky stained samples. Note that 
mitotic figure counting is not a component of this proposal. It is 
crucial to recognize that cytologic samples provide a substrate for 
the molecular testing of therapeutically important mutations in ade-
nocarcinoma cells which seem to be equal to histologic specimens. 
Thus, it is very relevant that sufficient cytologic material be collected 
at the very time of sampling and that it be utlized in an extremely 
judicious manner.
Keyword: cytomorphology, subtyping, grading
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CLASSIFICATION
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Abstract: Most lung cancers are readily diagnosed by using light 
microscope without attaining special stains 1, but at least 30% of 
NSCLC could benefit from immunohistochemistry (IHC) to unveil 
the cell differentiation lineages, especially when dealing with 
cytology and biopsy specimens 2. Molecular methods, including 
micro-RNA expression analysis 3, are cumbersome and unlikely to 
be directly transferred into the everyday diagnostic workflow 2, 4. 
IHC is not a perfect mathematic model, since there is a small (<5%) 
subset of NSCLC with ambiguous co-expression of glandular and 
squamous cell differentiation markers or negative reaction for any 
marker 5, 6. a) What is the best combination of biomarkers to 
use? The coordinated expression for TTF-1 for adenocarcinoma 
and p40 for squamous carcinoma is currently emerging as the 
most reasonable and reliable biomarker duet in terms of sensitivity 
and specificity 2, 7-9. Other promising biomarkers include napsin A 
for adenocarcinoma 10 and desmocollin-3 for squamous carcinoma 
11, 12. While TTF1 is the best marker for adenocarcinoma and p40 
equivalent to p63 for squamous carcinoma, p40 is by far superior 
in terms of specificity since only rare adenocarcinomas are focally 
positive in comparison with p63 2, 7-9. b) Be aware of antibody 
clones and other technical issues. The monoclonal antibody 
8G7G3/1 for TTF1 seems to be more specific for adenocarcinoma 
than other clones (such as SPT24) 8, 13, but it has also been recorded 
in gynecologic 14 and breast 15 carcinomas. Monoclonal antibody 
to napsin A for adenocarcinoma is less sensitive, but more specific 
than polyclonal antiserum 16. The single best marker for squamous 
carcinoma is a polyclonal rabbit antiserum against p40 7-9,17, but 
very recently a monoclonal antibody has been made commercially 
available. c) Practical hints to surgical pathologists. NSCLC-NOS 
upon morphology with negativity for p40 and some TTF-1 positi-
vity should be equated to poorly differentiated adenocarcinomas, 
once large cell neuroendocrine carcinoma (LCNEC) by relevant 
markers (e.g., synaptophysin) has been excluded. NSCLC-NOS 
upon morphology showing double negativity or with only erratic 
labeling for p40 in < 5% tumor cells in absence of TTF-1 should be 
considered as poorly differentiated non-squamous carcinomas cor-
responding, in most instances, to poorly differentiated adenocarci-
noma once metastatic cancer has been reasonably excluded, kee-
ping in mind however that the same immunoprofile may be shared 
by sarcomatoid carcinomas (excludible by morphology and vimen-
tin IHC) 17 and LCNEC (excludible by synaptophysin IHC). Poorly 
differentiated squamous carcinomas are instead highlighted by 
strong and diffuse p40 expression and TTF-1 negativity, hence lack 
of p40 exclude by definition this tumor according to the axiom “no 
p40, no squamous” 9. When morphology fails to conclusively sub-
type NSCLC, it is recommended specifying in the pathology report 
the real contribution of IHC to render the final diagnosis according 
to the relevant cell differentiation lineages (e.g., NSCLC-NOS, fa-
vor adenocarcinoma or squamous carcinoma by IHC) 6. References 
1. Travis W, Brambilla E, Muller-Hermelink H, Harris C. Tumours 
of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. 2. 
Rossi G, Pelosi G, Barbareschi M, et al. Subtyping non-small cell 
lung cancer: relevant issues and operative recommendations for 
either site are acceptable for testing with choice based on mor-
phological assessment of optimal specimens for molecular testing 
There are a wide variety of molecular techniques available to 
assess for the presence of key driver mutations in lung adenocarci-
noma, each with their own limitations and advantages, but there is 
no perfect technology that fulfills all clinical and laboratory needs, 
especially on the limited material usually available in lung cancer 
mutation testing. Virtually all techniques for EGFR testing depend 
on PCR amplification, which is a major issue where limited DNA 
template is present raising the possibility of both false negative 
(due to sensitivity issues) and false positive results (eg due to am-
plification of formalin artifacts). In our own practice we have found 
that standard methods for DNA quantification such as spectropho-
tometry significantly overestimates the amount of DNA available 
for testing in comparison to more specific methods such as DNA 
fluorometry or estimates of amplifiable DNA copy number. We 
currently perform routine diagnostic mutation testing via multige-
ne mutation profiling using a commercial panel, Oncocarta v1.0, on 
the massARRAY Sequenom platform in combination with fragment 
analysis for EGFR exon 19 and 20 insertions and deletions. This 
allows simultaneous determination of key mutations in EGFR and 
KRAS status as well as identifying rare but potentially actionable 
changes in BRAF, PIK3CA and HER2. In parallel, we perform immu-
nohistochemistry for ALK and ROS1 to allow rapid triage for FISH 
testing if mutation profiling is negative. However not all cases have 
sufficient material for this approach and we are currently validating 
a new custom panel which can be performed reliably with less 
DNA. While cytological specimens are problematic in the generally 
small amount of tumour material available for testing, they have 
the advantage of often containing a relatively pure population of 
tumour cells, with a marked reduction in stromal contamination 
especially in FNAB specimen. Earlier studies suggested cytolo-
gical specimen were less preferred to small tissue biopsies but a 
number of more recent publications have highlighted the suitabi-
lity of these specimens. While the most recent recommendations 
suggest that cell block specimens allowing pretest morphological 
assessment are preferred to fresh smears, fresh material offers 
generally better quality and quantity of DNA. FISH testing for ALK 
gene rearrangement on cytological specimens is feasible and in-
creasingly widely performed. Generally FISH testing requires less 
cellular material than mutation testing and the direct visualization 
of the molecular assay in tumor cells gives greater confidence that 
a negative result is far less likely to reflect problems with sensitivity 
as for EGFR testing. Expert morphological assessment is critical 
to ensure malignant cells are being assessed in this setting. In 
summary, cytology specimens are a commonly tested lung cancer 
diagnostic specimen and offer a number of advantages over more 
invasive small biopsies. Expert cytological assessment of speci-
mens should be undertaken prior to molecular testing to maximize 
the quality and accuracy of testing.
Keywords: Cytology, molecular testing, EGFR & ALK
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MS21.4 AIS AND THE WELL DIFFERENTIATED SPECT-
RUM
Yasushi Yatabe
Dept. Of Pathology And Molecular Diagnostics, Aichi Cancer Center/
Japan
Abstract: According to the recent trend of increased frequency of 
CT screening for lung cancer, earlier stage of lung cancer is being 
detected and removed surgically. In applying the new classification 
to such lesions, it always becomes problematic to make a differen-
tial diagnosis among the three categories: adenocarcinoma in situ 
(AIS), minimally invasive adenocarcinoma (MIA) and lepidic predo-
minant adenocarcinoma. AIS is defined by a pure lepidic growth 
pattern with a continuous growth of neoplastic cells along the 
alveolar septa without disruption of the alveolar structures. MIA is 
defined as an adenocarcinoma with predominant lepidic growth 
with less than or equal to 0.5 cm area of sromal invasion. The de-
finitions are summarized in Table. When the invasive area is more 
than 0.5 cm and lepidic growth is predominant, the tumor is diag-
nosed as lepidic predominant adenocarcinoma. The distinction is 
clinically important because AIS and MIA have been shown to have 
100%5 year recurrence free-survival, whereas lepidic predominant 
adenocarcinoma can recur. However, the major difficulty for the 
differential diagnosis has in roots in the identification of stromal in-
vasion and measurement of the invasive area. Histological stromal 
invasion is determined by tumor cell and stromal factors. Because 
the area where the tumor cells show invasive structure is regarded 
as an invasive area, it is important to recognize the differentiation 
of lepidic pattern from papillary or acinic pattern. However, the di-
stinction is often difficult in practice. In terms of the stromal factor, 
it is also difficult to differentiate an invasive scar (myofibroblastic 
stroma) from a scar due to collapse. Physicians should know this 
room for discussion, and practical solutions should be shared with 
pathologists. 
Keywords: minimally invasive adenocarcinoma, lepidic predomi-
nant adenocarcinoma, early stage adenocarcinoma, adenocarcino-
ma in situ
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in squamous cell carcinoma is in practice. Conclusions: Molecular 
approaches to classification of multiple lung tumors have not been 
standardized, and their performance in routine clinical practice re-
main to be established. Testing for common activating oncogenic 
mutations and translocations is likely to provide information about 
clonal relationship between multifocal lung tumors. Implementa-
tion of molecular information to current histologic staging could 
improve the accuracy of staging in patients with multifocal tumors 
and improve therapeutic decision making.
Keyword: lung cancer-multiple nodules-staging-molecular
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MS21.5 MOLECULAR ANALYSIS FOR DISTINCTION SE-
COND PRIMARY OF THE LUNG VS LUNG METASTASIS?
Sanja Dacic
Pathology, University Of Pittsburgh/United States Of America
Abstract: Background: The development of high-resolution chest 
imaging techniques and screening of smokers for lung cancer re-
sulted in increased detection of multiple lung cancers. The challen-
ge for pathologists and treating physicians is to determine whether 
multiple lung cancers represent separate primary tumors or meta-
stasis, as this affects the stage, treatment and prognosis. The cli-
nical and pathological criteria used to define multiple lung tumors 
were initially published by Martini and Melamed in 1975. These 
criteria are based on tumor morphology and location and may not 
predict prognosis. The AJCC 7th edition staging of lung adenocar-
cinoma recognized shortcomings of this proposal and incorpora-
ted changes in the staging of multiple lung cancer, but molecular 
genetic analysis was not recommended as a standard approach. 
Methods: PubMed available peer-reviewed original articles and 
experience of the author. Results: Distinction between primary 
tumors and intrapulmonary metastasis becomes challenging when 
tumors are morphologically similar. Since the original Martini 
and Melamed proposal, many molecular approaches have been 
utilized in the evaluation of clonal relationships between multiple 
lung nodules including DNA microsatellite analysis, PCR assays for 
common somatic mutations, aCHG, and gene expression analysis. 
Molecular classification of multiple lung cancers is concordant with 
pathological classification in about two-thirds of the cases. It is dif-
ficult to determine the precise percentage because of the relatively 
small number of analyzed cases, mixed analysis of synchronous 
and metachronous tumors, and use of different methods and inter-
pretation criteria. Early studies used two types of clonality assays: 
a panel of variable number of polymorphic microsatellite markers 
and X-chromosome inactivation analysis (Am J Surg Pathol 2005; 
29(7):897;Ann Diagn Pathol 2001;5(6):321; Clin Cancer Res 2000; 
6(10):3994; J Natl Cancer Inst 2009;101:560) . Tumors with largely 
concordant results were considered clonal in origin (metastases), 
and those with discordant findings were considered to be inde-
pendent primary tumors. The main weakness of earlier studies was 
a limited number of analyzed genes. Recently, more comprehensi-
ve approaches analyzing a large number of single nucleotide po-
lymorphic loci in a single assay or large-scale DNA sequencing of 
tumors were used (Clin Cancer Res 2009; 15(16):5184; Lung Cancer 
2012;77:281). Although more comprehensive molecular approaches 
were used, a proportion of cases with discordant molecular and 
morphological results remained similar. Furthermore, molecular 
profiling only slightly improved prognostic classification of multiple 
lung tumors. Standard practice is to test non-resectable adenocar-
cinomas for common actionable somatic mutations (e.g. EGFR) 
and gene rearrangements (e.g. ALK) as predictors of response to 
targeted therapies. This information can also be used for improved 
staging of multiple lung nodules (Eur Resp J 2012; 39:1437; Lung 
Cancer 2012; 77:281). Based on similar or different mutational profi-
le synchronous tumors may be classified as independent primaries 
or intrapulmonary metastases. It is very likely that surgically non-
resectable tumors with different mutational profiles such as EGFR 
and KRAS will show different treatment responses, further empha-
sizing the need for separate analysis of multifocal tumors. In cont-
rast to morphologic classification, molecular profiling can be per-
formed on the cytology specimens. This approach can be used in 
adenocarcinoma only, and currently no standard molecular testing 
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nal (#7) lymph node is often visible medial to the oesophagus. 
• Ultrasound imaging of mediastinal and hilar lymph nodes for 
EBUS-TBNA by the Convex Bronchoscope
•#7 LN: Subcarinal lymph node
For approaching #7 LN, the convex bronchoscope is inserted into 
right main bronchus. While scanning at 9 o’clock direction, we can 
confirm the largest area of the #7 LN. While rotating right handed 
and scanning at 11 o’clock direction, we can watch the right main 
pulmonary artery. 
• 11R LN: right intralobar lymph node (between right lower lobe 
bronchus and right middle lobe bronchus)
For approaching #11R LN, the convex bronchoscope is inserted 
into right basal bronchus. While scanning at 12 o’clock direction, 
we can confirm the largest area of the #11R LN. While rotating right 
handed and scanning at 3 o’clock direction, we can watch the right 
pulmonary artery. 
• 11R LN: right intralobar lymph node (between right intermediate 
trunk and right upper lobe bronchus)
For approaching #11R LN, the convex bronchoscope is inserted 
into right intermediate trunk. On the bronchoscopic findings, right 
upper bronchus is locates at 12 o’clock direction from the interme-
diate trunk. While scanning at 12 o’clock direction, we can confirm 
the largest area of the #11R LN. While rotating left handed and 
scanning at 9 o’clock direction, we can watch the right main pul-
monary artery. 
• 11L LN: left intralobar lymph node
For approaching #11R LN, the convex bronchoscope is inserted 
into left basal bronchus. On the bronchoscopic findings, left upper 
lobe bronchus is locates at 12 o’clock direction from left lower lobe 
bronchus. While scanning at 12 o’clock direction, we can confirm 
the largest area of the #11L LN. While rotating left handed and 
scanning at 10 o’clock direction, we can watch the right pulmonary 
artery. 
• 4L LN
For approaching #4L LN, the convex bronchoscope is inserted to 
the distal site of the trachea. On the bronchoscopic findings, the 
left side of the trachea is locates at 12 o’clock direction. While 
scanning at 12 o’clock direction, we can confirm the largest area of 
the #4L LN. While pushing the scope to distal site about 1-2cm, we 
can watch the left main pulmonary artery. While pushing the scope 
to proximal site about 1-2cm, we can watch aortic arch. 
• 4R LN
For approaching #4R LN, the convex bronchoscope is inserted 
to the distal site of the trachea. On the bronchoscopic findings, 
the membranous portion of the trachea is locates at 6 o’clock di-
rection. While scanning at 2 o’clock direction, we can confirm the 
largest area of the #4R LN. While scanning 4R LN, we can watch 
superior vena cava (SVC) just below. While pushing the scope to 
proximal site about 1-2cm, we can watch aortic arch #4R LN.
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MS22.1 THE ANATOMY OF THE MEDIASTINUM / CT 
IMAGING
Noriaki Kurimoto
St Marianna University/Japan
Abstract: Overview of ultrasound imaging of the right and left 
bronchi using the radial probe
The positional relationship between the peribronchial organs in 
EBUS images taken from the trachea corresponds to those in a 
reversed CT image (CT scans are cross-sectional images looking 
from the caudal direction). EBUS images taken distal to the bifurca-
tion of the left and right main bronchi, however, are cross-sectional 
images of planes perpendicular to the long axis of the bronchus, 
and therefore have different positional relationship between the 
peribronchial organs to the CT images. To fully understand EBUS, 
it is essential to understand the positional relationship between 
the peribronchial organs during visualisation while the probe is 
being pulled out. 1. Right bronchi 1) Right lower lobe bronchi 
When the balloon is inflated in the right basal bronchus, the inferi-
or pulmonary vein (V6) passes on the dorsal side of the bronchus, 
whereas anterior to the bronchus the pulmonary artery divides into 
A8, A9 and A10 positioned between 9 o’clock and 2 o’clock. As the 
probe is pulled back, A8, A9 and A10 meet at the 12 o’clock direc-
tion and the direction of the pulmonary artery changes gradually 
to the 3 o’clock direction. When the probe is pulled further back, 
it approaches the bifurcation of B6. Pulling the probe back further, 
the opening of the middle lobe bronchus, indicated by reflection 
of the ultrasound pulse, appears at 12 o’clock. The pulmonary ar-
tery has gradually moved round to the 2 o’clock position. 2) From 
the right intermediate bronchus to the right main bronchus As the 
probe is pulled from the distal intermediate bronchus to a point 
immediately below the origin of the upper lobe bronchus, the 
pulmonary artery crosses the bronchus from the right to the left. In 
the central section of the intermediate bronchus, the superior pul-
monary vein can sometimes be seen anterior to the pulmonary ar-
tery. When the probe is pulled further back, the origin of the upper 
lobe bronchus is indicated by reflection of the ultrasound pulse at 
3 o’clock. Pulling the probe back further, A1+3, originating from 
the pulmonary trunk, can be seen crossing horizontally anterior to 
the right main bronchus. Retracting the probe further, the origin 
of the left main bronchus at the carina is indicated by reflection of 
the ultrasound pulse at 9 o’clock. 2. Left bronchi 1) Left lower lobe 
bronchi When the balloon is inflated in the left basal bronchus, the 
inferior pulmonary vein (V6) passes on the dorsal side of the bron-
chus, whereas the A8, A9 and A10 branches of the pulmonary arte-
ry meet at 9 o’clock. As the probe is pulled back, it approaches the 
bifurcation of B6. Pulling the probe back further, the opening of 
the upper lobe bronchus, indicated by reflection of the ultrasound 
pulse, appears at 11 o’clock. The pulmonary artery is located 
below the origin of the upper lobe bronchus. 2) Left main bron-
chus The distal section of the left main bronchus is characterised 
by the left pulmonary artery at 10 o’clock, the descending aorta 
at 7 o’clock, and the left atrium from 1 o’clock to 3 o’clock. As we 
enter the central section of the left main bronchus, the left atrium 
disappears, and the oesophagus appears at 6 o’clock. The subcari-
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important factors. False positive findings are often due to infection 
or inflammation. Common causes include sarcoidosis, silicosis, 
reactive changes, fungal or mycobacterial infections. In summary, 
it is important to confirm N2 and N3 disease with tissue sampling 
to avoid delay or missing potentially curative surgery. In the pre-
sence of negative of PET and CT findings in the mediastinum, that 
the decision to operate or to have invasive tissue sampling requi-
res careful consideration and clinical judgement. Combined with 
invasive mediastinal staging techniques Transbronchial biopsy 
has shown a median sensitivity of 78% and specificity of 100% in a 
systemic review. The sensitivity has been reported to be high in 
patients with positive CT or PET/CT findings. Occasional false posi-
tive results have been reported to be approximately 7%. The me-
dian negative predictive value in this systemic review is 77%. En-
dobronchial ultrasound with needle aspiration can achieve a 
median negative predicted value of 91%. This is further improved 
with combined EBUS and EUS which have a median negative pre-
dictive value is 96%[3]. For most patients undergoing PET/CT sta-
ging, the need of invasive mediastinal staging is not eliminated. It 
is important to confirm the presence of N2 or N3 disease in pati-
ents without evidence of metastatic disease to avoid withholding 
potentially curative surgery. FDG PET/CT can guide needle biopsy 
as to which nodal stations are considered high risk. Targeting 
lymph nodes with a higher pretest probability further decreases 
the inherent false negative rate of needle biopsy. The location of 
FDG avid nodal stations is important as to which technique will be 
most appropriate. For example, the identification of an FDG supra-
clavicular node (N3) can lead to ultrasound guided percutaneous 
biopsy. An FDG avid aortopulmonary lymph node may be sampled 
by using Chamberlain procedure, CT guided fine needle aspirati-
on, or extended cervical mediastinoscopy. In cases with enlarged 
mediastinal lymph node with negative PET, confirmation by invasi-
ve techniques is also advised, as up to 21% of these can still have 
nodal involvement[4, 6]. There are two exceptions to the rule. First, 
it is known that in a patient with a peripheral T1 tumour (<3 cm), 
negative FDG uptake and no enlarged lymph node in the mediasti-
num carries a high negative predicted value with false negative 
rate being only 4%[3]. Therefore invasive staging is not recommen-
ded in these patients given the similar negative predicted value in 
a combined EBUS and EUS needle biopsy. Secondly, in lung cancer 
patients with infiltrative mediastinal mass on CT or PET/CT either 
from overt T4 disease or bulky nodal disease would not require 
invasive mediastinal staging. MRI and emerging Techniques MR 
imaging has mainly been used to evaluate non-small cell lung car-
cinoma when there is possible involvement of superior sulcus or 
brachial plexus. It is currently not a routine clinical tool in mediasti-
nal nodal staging. New studies albeit with relatively smaller patient 
sample size have shown that MRI can detect nodal metastasis par-
ticularly using STIR and diffusion weighted imaging (DWI) [7, 8]. 
Several studies have shown comparable efficacy in relation to the 
PET/CT staging techniques[9]. Diffusion weighted imaging detect 
random thermal motion of water molecules, known as Brownian 
motion. Tissues with restricted diffusion will have a lower apparent 
diffusion coefficient (ADC) values. Hypercellular density, larger 
cellular nuclei and dense tumour cell membranes are known to 
cause restricted diffusion in malignant tissue. A study has confir-
med the negative relationship between the SUV on FDG PET/CT 
scans and the lower ADC values on MRI[10]. Furthermore, MRI has 
the ability to differentiate tumour tissue from vasculature and me-
diastinal fat. It is therefore potentially useful to delineate direct 
tumour invasion of the mediastinum, chest wall, diaphragm or spi-
nal column. More research is required in this field of MR mediasti-
nal staging. The latest development in PET/MR imaging technique 
[11]using hybrid scanner will provide a fertile ground for future 
research in the use of non-invasive mediastinal staging. Referen-
ces 1. Silvestri, G.A., M.K. Gould, M.L. Margolis, et al., Noninvasive 
staging of non-small cell lung cancer: ACCP evidenced-based clini-
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Abstract: PET and PET/CT FDG PET scans have shown high 
sensitivity and specificity in detecting mediastinal nodal 
involvement. It works by detecting increased accumulation of F-18 
fluorodeoxyglucose (FDG) in the neoplastic cells which have a 
deranged glucose metabolism. FDG undergoes similar uptake and 
metabolic pathway glucose molecules. The accumulation of 
positron emitting F-18 isotope can then be used to localise these 
hypermetabolic neoplastic tissue. Both 2003 and 2007 guidelines 
of the American College of Chest Physicians (ACCP) endorsed the 
use of PET imaging as a non-invasive staging tool for non-small cell 
lung cancer[1, 2]. FDG PET scan has become the standard of care 
in staging primary lung cancer. It is recognised as the most 
accurate non-invasive tool in the staging of lung cancer. It is also 
widely accepted that PET scanning improves detection of distant 
metastatic disease as well as unsuspected N2 or N3 disease 
particularly in the high-risk patients. Therefore, several series have 
shown that the use of PET imaging reduces unnecessary or futile 
surgical resection. Traditionally, a standard uptake value (SUVmax) 
of 2.5 or above is used as a threshold for malignancy, but this was 
initially based on the uptake of peripheral lung masses with 
diameter >2cm. Whether this can be applied to mediastinal nodes 
is questionable. The special resolution of a current generation PET 
scanner is approximately 7mm. Nonetheless, small or non-
enlarged lymph nodes with highly aggressive tumour metastasis 
may be detected based on the higher intensity of uptake 
compared to the background. While FDG PET is clinically useful, it 
is an imperfect technique. The meta-analysis carried out by 
Silvestri et al [3]in the third edition of ACCP guideline 
demonstrated that the median sensitivity and specificity for 
detecting mediastinal metastases were 80% and 88% respectively. 
The findings demonstrate that PET is more accurate than CT 
scanning (median sensitivity 55% and median specificity 81%) [3]. 
However, it is important to know that neither technique is perfect. 
Interestingly, an increasing number of recent studies were perfor-
med using integrated PET/CT scanner. The meta-analysis by the 
ACCP showed a median sensitivity of 62% and median specificity 
of 90%[3]. The specificity is slightly higher although the sensitivity 
is lower. The reason for this observation remains unclear. No-
netheless, PET/CT hybrid cameras have superseded the role of 
stand alone PET scanners in nowadays. False negative results are 
more often seen with adenocarcinoma in situ, well-differentiated 
invasive adenocarcinoma, and typical carcinoid tumours. Small 
volume or micrometastasis can also be missed due to the finite 
spatial resolution of PET and perhaps by all imaging techniques. 
Studies have demonstrated that PET scanning is less sensitive for 
lymph nodes measuring <7-10mm diameter, and micrometastases 
have been detected in non enlarged lymph nodes without abnor-
mal FDG uptake by invasive sampling[4]. Furthermore, in the pre-
sence of a central FDG avid lung cancer, N1 disease can be missed 
by FDG PET imaging in up to 25% of cases[5]. In the evolution of a 
peripheral T1A lesion particularly if the density of the nodule is 
ground glass or sub-solid. It is well known that these types of neo-
plasms have low incidence of mediastinal metastasis though the 
risk is not nil. It is important that the interpretation of a negative 
PET scan to be combined with clinical judgement as well as the 
pre-test likelihood of mediastinal metastasis. Furthermore the local 
availability and expertise in invasive biopsy procedures are also 
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Abstract: With the recent popularization of computed tomogra-
phy (CT) screening, small malignant nodules are increasingly de-
tected. In Japanese cases of lung cancer surgery, tumors in more 
than 60% of lung cancer patients were under 3cm in diameter. Ste-
reotactic ablative radiotherapy (SABR) is a new treatment modality 
where narrow beams from several directions focus on the target 
while sparing the adjacent normal tissues with high accuracy. By 
SABR, the biological effect of radiation on tumors was increased 
and the overall treatment time was shortened. SABR has emerged 
as one of the radical treatment options for stage I non-small cell 
lung cancer (NSCLC), mainly in medically inoperable patients. First 
of all, Uematsu et al reported in 2001, that 3-year local control and 
overall survival rates of SABR (50-60Gy in 10 fractions) were 94% 
and 66%, respectively. Then Nagata et al reported in 2005, that 
3-year overall survival rate of SABR (48Gy in 4 fractions) was 83% 
in stage IA and 72% in stage IB. In Japanese multi-centers large 
database of more than 2000 patients treated with SABR for stage I 
NSCLC, overall survival rate at three year (OS-3y) and disease-spe-
cific survival rate at three year of total patients was 72% and 85%, 
respectively. Locally progression free rate at three year of T1 and 
T2 tumors were 87% and 72%, respectively. In USA, Timmerman et 
al reported in 2010, that 3-year overall survival rate of SABR (54Gy 
in 3 fractions) was 55.8%. In Europe, Bauman et al reported in 
2009, that 3-year overall survival rate of SABR (45Gy in 3 fractions) 
was 60%. According to a lot of previous studies demonstrating 
better results of SABR compared with conventional radiotherapy, a 
consensus that SABR is a standard radical treatment for inoperable 
patients with stage I NSCLC has been generally accepted. The 
overall survival rate for subgroup of medically operable patients 
who rejected surgery in retrospective and prospective studies was 
almost comparative to that of surgical series considering the same 
age range though its evidence level is not high. Onishi et al repor-
ted five-year overall survival of 87 patients with stage I NSCLC was 
69% according to the multicenter retrospective study,. In the phase 
II trial of SABR with 48Gy in 4 fractions for stage IA (JCOG0403), 
Nagata et al reported three-year overall of 65 operable patients 
was 76%. For patients with stage I NSCLC, resection of full lobe 
and systemic lymph nodes represents standard treatment but 
can be associated with significant morbidity and even mortality, 
particularly because patients suffering from lung cancer are often 
elderly with high comorbidity rates. For such high-risk operable 
patients, SABR is considered as an alternative option of radical 
treatment. According to American College of Chest Physicians 
Evidence-Based Clinical Practice Guidelines, SABR and surgical 
wedge resection are suggested over no therapy for patients with 
clinical stage I NSCLC who cannot tolerate a lobectomy or seg-
mentectomy (Grade 2C), but surgical resection has the potential 
benefit of definitive histologic analysis and pathologic nodal in-
formation. In compromised patients for whom such information 
would not change management and also in patients for whom 
an adequate margin in unlikely with a surgical wedge resection, 
cal practice guidelines (2nd edition). Chest, 2007. 132(3 Suppl): p. 
178S-201S. 2. Physicians, A.C.o.C. and H.a.S.P. Committee, Diagno-
sis and management of lung cancer: ACCP evidence-based guideli-
nes. American College of Chest Physicians. Chest, 2003. 123(1 
Suppl): p. D-G, 1S-337S. 3. Silvestri, G.A., A.V. Gonzalez, M.A. 
Jantz, et al., Methods for staging non-small cell lung cancer: Diag-
nosis and management of lung cancer, 3rd ed: American College of 
Chest Physicians evidence-based clinical practice guidelines. Chest, 
2013. 143(5 Suppl): p. e211S-250S. 4. de Langen, A.J., P. Raijma-
kers, I. Riphagen, et al., The size of mediastinal lymph nodes and its 
relation with metastatic involvement: a meta-analysis. European 
journal of cardio-thoracic surgery : official journal of the European 
Association for Cardio-thoracic Surgery, 2006. 29(1): p. 26-29. 5. 
Pozo-Rodríguez, F., J.L. Martín de Nicolás, M.A. Sánchez-Nistal, et 
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deoxyglucose positron emission tomography for identifying lymph 
node mediastinal metastases in potentially resectable non-small-
cell lung cancer. J Clin Oncol, 2005. 23(33): p. 8348-8356. 6. De 
Leyn, P., D. Lardinois, P.E. Van Schil, et al., ESTS guidelines for pre-
operative lymph node staging for non-small cell lung cancer. Euro-
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turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative 
and qualitative assessment of N-stage in non-small-cell lung cancer 
patients. J Magn Reson Imaging, 2007. 26(4): p. 1071-1080. 9. 
Pauls, S., S.A. Schmidt, M.S. Juchems, et al., Diffusion-weighted 
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gy, 2012. 81(1): p. 178-182. 10. Heusch, P., C. Buchbender, J. Köh-
ler, et al., Correlation of the Apparent Diffusion Coefficient (ADC) 
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ro, et al., N staging of lung cancer patients with PET/MRI using a 
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Abstract: Very recently, the revised international multidisciplinary 
classification of lung adenocarcinoma was published by the Inter-
national Association for the Study of Lung Cancer (IASLC), Ame-
rican Thoracic Society, and European Respiratory Society.1,2 This 
new classification is characterized by the creation/abandonment 
of some terminology for early and advanced adenocarcinomas 
and by a multidisciplinary approach for the application of the new 
classification in a clinical setting. In particular, the term "bronchio-
loalveolar carcinoma (BAC)“ is no longer used and, instead, new 
concepts are introduced, such as “adenocarcinoma in situ (AIS)” 
and “minimally invasive adenocarcinoma (MIA)”. Invasive ade-
nocarcinomas are classified according to the predominant pattern 
after comprehensive histologic subtyping with lepidic, acinar, pa-
pillary, micropapillary, and solid patterns. The term of mixed subty-
pe adenocarcinoma is no longer used. The gold standard surgery 
for documented lung cancer has been lobectomy with lymph node 
sampling/dissection. The randomized, prospective study was per-
formed between lobectomy and sublobar, limited resection in 
1980’s by North American Lung Cancer Study Group (LCSG) and 
the results of this study justified the lobectomy as the standard 
surgical mode. 3 However, looking back this study from the present 
view point, it is obvious that the earlier forms of lung cancer, as 
mentioned above as adenocarcinomas of AIS or MIA, were not in-
volved in the LCSG study, and its conclusion could not be applied 
for these tumors. The present-day issue of lung cancer surgery is 
to define the role of lobectomy or limited, sublobar resection in 
relation to newly defined pathological entities. The Japan Clinical 
Oncology Group (JCOG) has been focusing upon defining the 
most appropriate surgical approach for tumors of relatively early 
stages in recent series of clinical trials. 
• JCOG 0201 was intended to define the radiological non-invasi-
ve lung cancer on the high-resolution CT image, and it has shown 
that a consolidation/tumor ratio (C/T ratio) on thin-section compu-
ted tomography (TSCT) ≤0.25 in cT1a (≤2.0 cm) could be used as 
a radiological criterion for a noninvasive pathology.4 Further prog-
nostic analyses have also indicated that according to this radiologi-
cal definition of non-invasive lung cancer the 5-year overall survival 
rate at 97.1% could be achieved.5
• JCOG 0804 is a prospective phase II trial, targeting the radiolo-
gical non-invasive lung cancers of a diameter of 2.0 cm.6 Again, the 
radiological criteria of non-invasive lung cancer were defined as 
those with a consolidation/tumor ratio (C/T ratio) on thin-section 
computed tomography (TSCT) ≤0.25. For these tumors, the wide 
wedge resection or segmentectomy was performed. Targeted 
number of accrual is 340 patients, and accrual has been already 
over, awaiting the data maturation.
• JCOG 0802 is a prospective, randomized phase III trial between 
lobectomy and segmentectomy for peripheral lung cancers with a 
diameter of 2 cm or less in a non-inferiority setting.6 The endpoints 
are overall survival (primary) and postoperative pulmonary function 
(secondary), and the targeted accrual is 1,100 patients. As of June, 
2013, more than 800 patients were registered. In case that the 
prognosis of patients undergoing segmentectomy was not signifi-
cantly inferior to that of those undergoing lobectomy and that the 
SABR is a preferred option. According to good results of these 
retrospective or prospective studies, some phase III prospective 
trials comparing SABR versus surgery (lobar resection) have been 
started, but the patient accrual seems to be difficult. Patient accru-
al of a trial exploring the efficacy and safety of sublobar resection 
for patients with smaller tumors has been completed by surgeon 
recently. SABR is a just local therapy, therefore it essentially should 
be compared with sublobar resection in high-risk operable pati-
ents for lobar resection with such small peripheral tumors. In the 
meantime, SABR represents a recent trend in radiation oncology 
also for oligometastases. Local aggressive therapy for oligometa-
stases may improve outcomes, including survival in some cases. 
SABR has emerged as one option for local therapy against oligo-
metastases in various body sites, most commonly in the lungs and 
liver. According to published papers of SABR for lung metastases, 
local control with SABR distributed from 70 to 90% with very low 
rates of serious toxicities. Although further investigation should 
be undertaken to clarify the benefits of SABR for the treatment of 
oligometastases, SABR may be worthwhile for patients who hope 
for treatment to acquire better local control and possible longer 
survival. Concerning toxicities, SABR for peripheral tumors is an 
almost safe and comfortable treatment. Rib fracture is a common 
adverse effect after SABR but the symptom is generally mild. But 
severe radiation-related pneumonitis occurs occasionally in the 
patients having pulmonary fibrosis. As the clear dose-constraint for 
mediastinal organs has not been demonstrated, the safety of SABR 
for cases with a central lesion has not been assured. When the 
tumor recurred only locally after SABR in operable patients, salva-
ge radical surgery was mostly operated safely. Primary radiation 
therapy remains the primary curative intent approach generally for 
patients who refuse surgical resection or are determined by a mul-
tidisciplinary team to be inoperable or high-risk operable. Howe-
ver, good tumor control, less toxicity, and fewer treatment courses 
of SABR decrease the indirect costs of cancer care, including lost 
time and economic productivity secondary to treatment-related 
and cancer-related illness and death. On the other hand of promi-
sing results and advantages of SABR, it is imperative to assess its 
cost-effectiveness as well as its efficacy because SABR is becoming 
used in more clinical situations. SABR employing image guidance, 
high-precision dose delivery, more accurate target definition with 
better anatomical and biological imaging, and the possibility of 
dose verification during treatment via dose-adaptive radiation 
therapy permits a higher probability of tumor control. Such major 
technological progress certainly comes at a higher cost, and there 
are many concerns regarding the value of that progress. In the 
symposium, we will discuss what the benefits and disadvantages 
of SABR compared to surgical treatment in high or low risk surgical 
patients with early-stage NSCLC or pulmonary oligometastases 
are, and how we can decide best to proceed with treatment.
Keywords: stage I lung cancer, pulmonary oligometastases, ste-
reotactic ablative radiotherapy (SABR), Stereotactic body radiothe-
rapy (SBRT)
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NSCLC are not eligible for surgery due to comorbidities, usually 
poor cardio-respiratory reserve. This number doubles in the pa-
tient population 75y and older. Approximately 30% of patients 
dying of malignancy have pulmonary metastases at autopsy with 
some primary cancers metastasising exclusively to the lungs. In 
the setting of primary cancer site being under control, reasonably 
long disease free interval (DFI) and oligometastatic lung disease 
with metastases of reasonable size and in amenable positions, 
data shows a survival benefit for metastasectomy in a selected 
patient population. Metastasectomies, even if performed as sub-
lobar or wedge resections, often carry a substantial morbidity and 
have a major impact on quality of life. Thermal ablations can be 
performed in an outpatient setting, they spare healthy tissue, are 
repeatable and are extremely well tolerated. Thermal ablation has 
been applied to lung tumours for over a decade and has managed 
to become an established minimally invasive therapy option for 
a selected patient population. It is used as a therapeutic means 
in primary and secondary lung cancer, both with a curative and 
palliative intent. Combination of thermal ablation with radiothe-
rapy for NSCLC should be a viable consideration in the therapy 
planning pathway, with available radiofrequency ablation (RFA)/
external radiation therapy (XRT) data showing convincing 5y 
cumulative survival rates of 39% at no additional toxicity. Micro-
wave ablation (MWA) represents the most recent addition to the 
growing armamentarium of minimally invasive thermal ablation 
therapies. Advantages of microwave over RF energy are perceived 
to be many. RF heating requires an electrical conduction path and 
is therefore less effective in areas of low electrical conductivity 
and high baseline impedance such as lung parenchyma. Unlike RF 
and laser, microwaves can even penetrate through the charred or 
desiccated tissues that build up around all hyperthermic ablation 
applicators, resulting in limited power delivery for non-microwave 
energy systems. Further advantages of MWA over RFA are that the 
system does not require grounding pads, thus avoiding pad site 
burns, that implanted cardiac devices are less prone to malfunc-
tion during MWA than during RFA and that heating occurs faster 
with is less susceptibility to heat sink, allowing for larger and more 
homogenous ablation volumes. Multiple microwave antennas can 
be powered simultaneously to maximise the ablation volume when 
placed in close proximity to each other, or when widely spaced, to 
ablate several tumours simultaneously, particularly helpful in the 
case of multiple metastatic ablations. This presentation will focus 
on the indications for pulmonary thermal ablation, the limitations 
of the procedure and the advantages of MWA over RFA.
Keyword: lung cancer, thermal ablation, RFA, MWA
postoperative pulmonary function is significantly better for those 
undergoing segmentectomy, it can be definitively concluded that 
standard surgical mode for these early tumors are segmentectomy.
The similar randomized trial is also underway in US (CALGB), and 
the sooner launch of these data is expected to change the daily 
practice of lung cancer surgery. Oligometastases are the state in 
which the patients show distant relapse in only a limited number 
of organs/sites. These distant, metastatic lesions are found both 
before and immediately after surgery, and obviously these indicate 
the systemic spread of the cancer cells as stage IV disease. The 
gold standard treatment for systemic disease has been systemic 
therapy (chemotherapy). However, it has been anecdotally repor-
ted that local treatment modality such as surgery for both primary 
and metastatic sites cure the patients. The present-day issue for 
patients with oligometastatic disease is the proper selection of 
surgical candidate who might benefit from such aggressive treat-
ment in lung cancer. REFERENCES 1. Travis WD, Brambilla E, 
Noguchi M, et al. International Association for the Study of Lung 
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Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus 
limited resection for T1 N0 non-small cell lung cancer. Lung Cancer 
Study Group. Ann Thorac Surg 1995;60:615-22. 4. Suzuki K, Koike 
T, Asakawa T, et al. A prospective radiological study of thin-section 
computed tomography to predict pathological noninvasiveness in 
peripheral clinical IA lung cancer (Japan Clinical Oncology Group 
0201). J Thorac Oncol 2011;6:751-6. 5. Asamura H, Hishida T, Su-
zuki K, Japan Clinical Oncology Group Lung Cancer Surgical Study 
Group. Radiographically determined noninvasive adenocarcinoma 
of the lung: Survival outcomes of Japan Clinical Oncology Group 
0201. J Thorac Cardiovasc Surg. 2013 [Epub ahead of print]. 6. 
Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata 
T, et al. A phase III randomized trial of lobectomy versus limited 
resection for small-sized peripheral non-small cell lung cancer 
(JCOG0802/WJOG4607L). Jpn J Clin Oncol 2010;40:271-4. 7. Ni-
ibe Y, Hayakawa K. Oligometastases and oligorecurrence: the new 
era of cancer therapy. Jpn J Clin Oncol 2010;40:107-11.
Keywords: surgery, early stage, oligometastasis, limited resection
TREATMENT OF THE SMALL MALIGNANT NODULE  
WEDNESDAY, OCTOBER 30, 2013 - 14:00-15:30
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CANCER AND OLIGOMETASTASES
Karin Steinke
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tal/Australia
Abstract: Lung cancer is the number one cancer killer worldwide 
accounting for more cancer deaths than colorectal cancer, breast 
cancer and prostate cancer combined. While the outlook is dismal 
in advanced lung cancer, when patients are diagnosed once they 
have become symptomatic, the prognosis is more favourable in 
early stage node-negative disease. Small lung cancers are increa-
singly diagnosed as incidental findings on cross-sectional imaging 
such as CT-coronary angiogram (CTCA), CT-pulmonary angiogram 
(CTPA), CT angiograms for vascular conditions or CT -intravenous 
pyelogram (CT-IVP). As many as 15% of patients with early stage 
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asbestos exposure because they are not dependent on deletion 
of p16 for tumourigenesis. Robinson, C., I. van Bruggen, A. Segal, 
M. Dunham, A. Sherwood, F. Koentgen, B.W. Robinson, and R.A. 
Lake. 2006. A novel SV40 TAg transgenic model of asbestos-
induced mesothelioma: malignant transformation is dose depen-
dent. Cancer Res 66:10786-10794. Robinson, C., A. Walsh, I. Larma, 
S. O‘Halloran, A.K. Nowak, and R.A. Lake. 2011. MexTAg mice 
exposed to asbestos develop cancer that faithfully replicates key 
features of the pathogenesis of human mesothelioma. Eur J Cancer 
47:151-161. Robinson, C., S. Woo, A. Walsh, A.K. Nowak, and R.A. 
Lake. 2012. The antioxidants vitamins A and E and selenium do not 
reduce the incidence of asbestos-induced disease in a mouse mo-
del of mesothelioma. Nutrition and cancer 64:315-322.
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Abstract: Malignant mesothelioma (MM) represents a significant 
clinical challenge. Not only can this tumour be difficult to diagno-
se but treatment options are limited. There is a desperate clinical 
need for biomarkers that can aid the diagnosis of MM, and/or 
predict survival and measure disease response to treatment. MM 
diagnosis is challenging as phenotypic differentiation of malignant 
mesothelial cells from benign reactive ones is notoriously difficult. 
No immunohistochemical marker(s) can uniformly define the cancer 
either. Invasive pleural tissue sampling for MM is more frequently 
negative than in any other cancer type 1. A reliable diagnostic mar-
ker will present a major aid to clinicians. The median survival for 
the MM population is less than 12 months, however about 5% of 
patients live for several years and unusually long survivals of over 
10 years have also been seen. But no reliable prognostic algorithm 
exists to predict survival in individual cases – a question of utmost 
concern for patients and their families. There is no cure for MM. 
Chemotherapy may improve survival, but only 30 to 40% of pati-
ents respond 2. Thus finding a biomarker that may reflect disease 
burden and response to therapy, and hence prognosis, will be a 
significant advance. It has been nearly a decade since mesothelin 
3 and MPF 4,5were reported as candidate biomarkers for MM, both 
providing similar diagnostic accuracy 6. A recent meta-analysis of 
serum mesothelin in the diagnosis of MM determined that having 
a sensitivity of 32% at a 95% specificity was too low for diagnostic 
use and highlighted the need for ongoing research for better 
biomarker(s) 7. However, studies world-wide on a range of soluble 
markers including osteopontin, hyaluronic acid, CA125, CA15-3 
and others have failed to improve upon diagnostic accuracy. More 
potential biomarkers such as fibulin-3 and the SOMamer panel 
have recently been identified 8,9and the search to discover novel 
biomarker(s) for this disease using a variety of genomic, proteomic 
and immunologic approaches continues. For these candidate MM 
biomarkers to attain their professed clinical potential, indepen-
dent externally validated studies with large, representative patient 
cohorts will be required. The next stage will then need studies to 
determine how to integrate promising markers into clinical diag-
nostic and/or management algorithms, a process essential to im-
prove outcomes for MM patients. 1 Davies, H. E. et al. Outcome of 
patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural 
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MS24.1 A TRACTABLE ANIMAL MODEL OF  
MESOTHELIOMA
Richard Lake
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Abstract: We have developed a novel transgenic mouse (Mex-
TAg) where cellular transformation is driven by the SV40 (simian 
virus 40) large T antigen (TAg). In these mice, TAg is specifically 
targeted to the mesothelial compartment because it is expressed 
under the control of a tissue specific promoter. MexTAg mice uni-
formly develop mesothelioma after exposure to asbestos, with 
no spontaneous formation of other tumours. The key differences 
between MexTAg and wild type animals are the higher incidence 
and the shorter latency of the disease. Survival after diagnosis is 
not different suggesting that TAg does not drive a more aggres-
sive disease. The model is comparable to human mesothelioma 
because of the eliciting carcinogen and because the location, 
pathology, molecular lesions and tumour response to therapy are 
similar (Robinson et al., 2006; Robinson et al., 2011). It is thought 
that asbestos fibres drive cellular transformation via the produc-
tion of reactive oxygen species and the induction of chronic local 
inflammation. Accordingly, we have begun to test antioxidants and 
anti-inflammatory drugs as potential cancer prevention agents. We 
have reported that dietary supplementation with the antioxidants, 
vitamins A, E and selenium does not affect overall survival nor the 
time to progression of asbestos-induced mesothelioma in MexTAg 
mice (Robinson et al., 2012). We have extended our analysis to 
vitamin D and compared survival of asbestos-exposed MexTAg 
mice provided with diets supplemented (4500 IU/kg feed) or defi-
cient in vitamin D (cholecalciferol). Survival of supplemented mice 
was significantly shorter than mice given standard diet (median 
survival, 29 and 32.5 weeks respectively). Mice deficient in vitamin 
D developed mesothelioma at the same rate as control mice. We 
conclude that vitamin D is unlikely to moderate the incidence of 
disease in asbestos exposed populations or to ameliorate the pa-
thology in patients with established mesothelioma. Mesotheliomas 
in MexTAg mice respond to cytotoxic chemotherapy. Gemcitabine 
treatment from week 16 prolonged survival of asbestos-exposed 
MexTAg mice increasing the median survival from 33 weeks to 48 
weeks. Interestingly, latency was not significantly prolonged, but 
animals survived for longer after the first signs of disease were 
noted. To understand the importance of the immune system in 
the pathogenesis of mesothelioma, we crossed MexTAg mice with 
immune deficient RAG KO mice. Perhaps surprisingly, MexTAg 
mice with no acquired immunity lived longer with a more indolent 
disease than their immunocompetent sibs. We compared cell lines 
derived from mesotheliomas from MexTAg mice and cell lines from 
wild type mice with human mesothelioma cell lines by expression 
array. TAg expressing mouse tumours were 90% identical to wild 
type mouse tumours. The key pathway that was different was cell 
cycle-associated. Human mesotheliomas commonly have a deleti-
on of the cdkN2 locus, encoding the tumour suppressor genes p16 
and p15. While wild type mouse tumours carried a homologous 
p16 deletion, TAg tumours did not. We hypothesize that TAg ex-
pressing mice develop tumours in an accelerated way following 
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MS25.1 DEFINING THE GOLD STANDARD: PFS V OS
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Abstract: Approval of most new agents for advanced non-small-
cell lung cancer (NSCLC) has been based on prolongation of OS, 
representing a direct measure of clinical benefit, in randomized 
clinical trials. Recently, however, as we have more opportunity to 
obtain trial results showing “significant improvement in PFS wit-
hout any OS benefit”, most investigators feel that the assessment 
of OS may become of limited use and that PFS must be surrogate 
endpoint for assessing the efficacy of an experimental agent in 
NSCLC. Originally, PFS is quite different from OS since it is sub-
jective, but not a direct measure of clinical benefit. Progression 
is often asymptomatic, and it is not always clinically relevant. To 
use PFS as surrogate endpoint, its validity should be statistically 
evaluated. In the pooled analysis using individual patient data of 
randomized trials comparing first-line docetaxel with vinca-alkalo-
ids, Buyse et al. showed relatively weak PFS-OS correlation [BMJ 
open 2013;3:e001802]. So far, there seem no other large-scaled 
validation studies investigating the surrogacy of PFS for OS end-
point with formal statistical approach. Thus, PFS has not yet been 
a statistically acceptable surrogate endpoint for OS in patients 
with metastatic NSCLC. Now, what could we interpret “significant 
improvement in PFS without any OS benefit”? Also, what would be 
the clinically meaningful endpoint in advanced NSCLC? The litera-
ture-based study was conducted to assess the PFS-OS relationship 
with the data of the phase III trials investigating molecular-targeted 
agents in advanced NSCLC [Lung Cancer 2013;79:20]. It showed a 
strong PFS-OS correlation only in trials where subsequent therapy 
was conducted less frequently, whilst trials with a higher propor-
tion of use of subsequent therapy had weaker association. The 
study concluded that 1) the relationship between PFS and OS is 
originally strong enough to support potential surrogacy of PFS, but 
that 2) given the observation that increasing use of effective sal-
vage therapies could affect the PFS-OS association, improvement 
in PFS without any OS benefit does not mean the experimental 
agent fails to have a true clinical benefit. That is, a potentially true 
OS benefit by an experimental agent would have been seen wit-
hout any confounding if no subsequent therapy had been given. 
This theory is called “explanatory approach”, supporting the use 
of PFS as a clinically meaningful outcome. Rather, there is an op-
posite opinion, suggesting the observed difference in OS would 
be considered the measure of clinical benefit, regardless of sub-
sequent therapies, provided that they follow the current standard 
of care. This is the pragmatic approach [JCO 2011;29:2439]. The 
observed difference in OS, of course, will be expected smaller by 
the subsequent therapy than one would see if it was not available, 
leading to the need of a large sample size to detect such differen-
ces. But, according to the pragmatic approach, such potentially 
attenuated but actually observed OS difference should be used for 
assessing the true clinical benefit of the experimental agent in the 
given clinical setting under reflecting the clinical reality of available 
subsequent treatments. Recently, ASCO discussed what would be 
clinical meaningful outcome in advanced NSCLC without EGFR 
biopsies. Eur J Cardiothorac Surg 38, 472-477, (2010). 2 Nowak, 
A. & Bydder, S. Management of malignant pleural mesothelioma: 
a review. Asia Pacific J clin Oncol (2007). 3 Robinson, B. W. et al. 
Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 
362, 4 Onda, M. et al. Megakaryocyte potentiation factor cleaved 
from mesothelin precursor is a useful tumor marker in the serum 
of patients with mesothelioma. Clin Cancer Res 12, 4225-4231 
(2006). 5 Shiomi, K. et al. Novel ELISA system for detection of N-
ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 
97, 928-932 (2006). 6 Hollevoet, K. et al. Diagnostic performance 
of soluble mesothelin and megakaryocyte potentiating factor in 
mesothelioma. Am J Respir Crit Care Med 181, 620-625, (2010). 
7 Hollevoet, K. et al. Serum mesothelin for diagnosing malignant 
pleural mesothelioma: an individual patient data meta-analysis. J 
Clin Oncol 30, 1541-1549, (2012). 8 Ostroff, R. M. et al. Early de-
tection of malignant pleural mesothelioma in asbestos-exposed 
individuals with a noninvasive proteomics-based surveillance tool. 
PLoS One 7, e46091, (2012). 9 Pass, H. I. et al. Fibulin-3 as a blood 
and effusion biomarker for pleural mesothelioma. N Engl J Med 
367, 1417-1427, (2012).
Keywords: biomarker, mesothelin, mesothelioma
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Abstract: A screening programme is a set of procedures that can be 
applied to an asymptomatic population to enable early detection and 
treatment of disease. The success of the programme is dependent 
on this early intervention reducing morbidity and mortality associa-
ted with the disease. There has been much research to develop and 
assess potential screening programmes for lung cancer. In particular, 
there are a number of major clinical trials such as the National Lung 
Screening Trial in the United States, the United Kingdom Lung Can-
cer Screening Trial and the Dutch-Belgian NELSON trial, that assess 
the effectiveness of screening a high risk population with low dose 
computed tomography scans to reduce mortality from lung cancer. 
The key elements of any screening programme are: (i) identification 
of the target population for screening, (ii) the screening test that will 
be used to classify patients as likely or unlikely to have the disease, 
(iii) the frequency of applying the screening test, (iv) the diagnostic 
test that will be used to determine whether people are truly diseased 
or not, (v) the treatment that will be available for those diagnosed 
early. These choices will impact on the statistical design. The research 
question may be whether to introduce screening, to determine the 
frequency of screening, to identify the appropriate target population 
for screening or whether to add an additional screening tool to an 
existing screening modality. Randomised controlled trials are the gold 
standard for assessing a screening programme as they overcome 
major biases specific to screening namely lead-time bias, length bias, 
over-diagnosis bias and selection bias. The usual trial design para-
meters are important but special statistical issues arise in relation to 
screening trials. Statistical inferences should only be made back to 
the eligible population defined for the trial so the choice of eligibi-
lity criteria is important. Screening interventions can cause harm to 
individuals that are potentially disease-free so the target population 
is usually those who are at high risk of disease. Interventions such as 
CT scans which have both a relatively high risk and high level of harm 
should be targeted at a high risk population whilst those that are low 
risk to the individual such as sputum cytology could be targeted at 
a wider population. Harms also include the inconvenience and psy-
chological effects of a false positive result. A high risk population is 
usually defined in terms of pack-years of smoking and time since quit-
ting and simple patient characteristics such as age. Statistical models 
that predict risk of disease could enhance the identification of a high 
risk population but the accuracy of prediction should be considered 
in relation to its impact on the trial. The primary outcome measure to 
assess benefit of a lung cancer screening programme should be lung 
cancer specific mortality. Duration of follow-up is an important de-
sign parameter. It needs to be long enough to allow for the time lag 
before the impact of screening becomes apparent and not so long 
after the cessation of screening as to include a period of time when 
screening would have lost its impact. Appropriate statistical analysis 
of the primary outcome measure is essential to properly evaluate 
the benefits of screening. Typically the screening intervention will be 
compared to the control arm in terms of its ability to reduce cumula-
tive mortality. If this is calculated over the entire period of screening 
and follow-up then the benefit may be underestimated. Comparing 
time-specific mortality rates is the recommended approach [1]. The 
analysis is also complicated by the problems of non-attendance and 
contamination but methods have been proposed to adjust for these 
[2]. Sample size calculations involve key design parameters including 
or EML4-ALK mutations, and provided draft recommendations 
as follows: 1) survival after first line therapy is relatively short, and 
OS is a feasible endpoint although the effects of the experimental 
agent on OS can be clouded by treatments administered after the 
period of therapy, and 2) clinical trials should aim to improve OS 
by a minimum of 25% as compared with standard therapy. ASCO 
seems to support the importance of measuring OS rather PFS, in 
favor of the pragmatic approach. Even in the first-line metastatic 
colorectal cancer, though PFS has already been established as a 
surrogate for OS in the 90’s, its surrogacy was reappraised using 
individual patient data between 1997 and 2006 because of the ad-
vance in the treatment during the last decade and recent improve-
ment of OS [JCO 2013 (suppl;abstr 3533)]. Surprisingly, the PFS-OS 
relationship was not as strong as was seen in the 90’s. The study 
concluded that in modern metastatic colorectal cancer trials where 
SPP exceeds time to first progression, the treatment effects on 
PFS do not reliably predict those on OS. It seems that even though 
PFS was once accepted as a suitable surrogate for OS, its validity 
should be assessed repeatedly along with the advances especially 
in the post-progression treatment, which also supports the con-
cept of the pragmatic approach. Regarding the regulatory consi-
derations, the FDA stated OS should be considered the standard 
clinical benefit endpoint and that it should be used to establish the 
efficacy of a treatment in metastatic NSCLC, although it can also 
consider PFS for regulatory decision of drug approval based on 
the population. Some of the abovementioned findings potentially 
support the rationale of the pragmatic approach, stressing the 
importance of a possibly attenuated, but actually observed OS 
difference. However, this theory is unlikely to be applied in more 
recent trials investigating specific targeted therapies including 
EGFR-TKIs or ALK inhibitors, because no OS difference would be 
arguably obtained due to a quite high level of crossover inevitably 
for the ethical reason. Thus, under the special situation where i) an 
experimental agent has theoretically been considered to target 
specific molecules, and ii) the earlier trials showed dramatic effect, 
this possibly high proportion of crossover can compromise the 
ability to assess clinical benefit, and also lead to the unrealistic 
sample size to detect significant OS difference. Rather, in this con-
dition, whether both large magnitude of PFS advantage and great 
OS advantage compared with historical control can be obtained 
would be more important than the conventional assessment of OS 
difference between the arms. In conclusion, the goals of any new 
cancer treatment are to offer patients a true clinical benefit. PFS 
has not yet been formally accepted as a valid surrogate for the OS 
endpoint in advanced NSCLC, and its surrogacy will be addressed 
by each drug mechanism of action and patient population. Finally, 
OS remains the primary endpoint of clinical trials, except in a si-
tuation where agents targeting specifically driver oncogenes are 
being evaluated with anticipation of high level of crossover.
Keyword: PFS; OS; endpoint; clinical benefit
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testing) may be more affordable compared to more labor-intensive 
methods used in initial clinical trials. For example, immunohistochemi-
cal techniques may replace more expensive methods, allowing more 
jurisdictions to take up testing and treatment of new therapies.
Keywords: Targeted therapy, cost effectiveness
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MS25.4 ASSESSING NEW TREATMENTS FOR LUNG 
CANCER - REGULATORY AND COST-EFFECTIVENESS 
IMPLICATIONS
Suzanne R. Hill
Pharmaceutical Benefits Advisory Committee/Australia
Abstract: Over the last several years, there have been a number of 
new classes of drugs approved for the management of lung cancer. 
Regulatory pathways are evolving in many ways – for example, to 
recognize that targeted therapies, such as the EGFR inhibitors, will 
require evaluation of the drug alongside a diagnostic test; or that the 
increasing specificity of targets may result in smaller and shorter trials 
with different endpoints; or that regulatory authorities might identify 
potential significant advances in therapy by the use of special evalu-
ation pathways, such as the ‘breakthrough’ therapy designation from 
the US FDA. Sometimes the trials now also measure quality of life out-
comes or patient preferences. But these trials are still fundamentally 
designed to ask the ‘regulatory’ question – can the new product work 
– as well as assessing the risk-benefit ratio. But where does this chan-
ging regulatory environment leave payers? The information set that 
is available to guide assessments of value of money generally seems 
to becomes more limited as the regulators increase the pace of their 
decision-making. Trials are truncated or treatment groups are crossed 
over to the new treatment at the earliest possible opportunity, often 
before there is a confident estimate of the effect size in terms of final 
clinical outcomes. The ethical imperative to offer access to possibly 
effective treatments outweighs ensuring adequate trial design to be 
confident in the estimate of effect. Statistical techniques to ‘adjust’ 
for limitations in design become more and more complex, and more 
prone to uncertainty. And at the same time, most countries are still 
struggling with faltering economies and diminishing health budgets. 
Patients still want access to the latest treatments, but are less and less 
willing to pay increasing prices. Payers then have to compare the limi-
ted information set available for new drugs with what is known about 
current treatments. Arguments over the value of differences such as a 
1.4 months gain in overall survival compared to existing treatment be-
come conflated with the cost of this gain. That is assuming, of course, 
that there is a gain in overall survival, which has not been often shown 
to date in the trials of the new drugs for lung cancer. When high prices 
and high prevalence are combined, the value-for-money question is 
rightly raised – why pay so much more for so much uncertainty? Argu-
ments about incremental advances in therapy, innovation and techno-
logical developments then dominate the discussion, rather than the 
appropriate focus on health gain for communities and individuals. So 
what is the solution? Options suggested include ‘managed entry’ of 
new products with additional data collection as a condition of price 
negotiation, ‘paying for performance’ with outcome data collection, 
or ‘value-based pricing’ that allows a premium for ‘innovation’. Howe-
ver, given the high clinical need for effective treatments, the emphasis 
should be on getting the best health outcomes for an affordable 
price, to the community and for individuals.
Keywords: cost-effectiveness, regulatory approval, trial design
hypothesised mortality reductions, expected compliance and con-
tamination, number of screening rounds and length of follow-up [3]. 
The accuracy of the screening test to predict disease in asymptomatic 
people is not only important for the feasibility and ethics but will also 
impact on sample size as inaccurate predictions will dilute the poten-
tial benefit of screening. Screening tests, such as those that involve 
biomarkers measured on a continuous measurement scale, should 
be rigorously developed and validated before assessing their clinical 
utility within a randomised controlled trial environment. References [1] 
Hanley JA; Measuring mortality reductions in cancer screening trials; 
Epidemiologic Reviews 2011; 33: 36-45. [2] Baker SG, Kramer BS, 
Prorok PC; Statistical issues in randomised trials of cancer screening; 
BMC Medical Research Methodology 2002; 2: 11. [3] Prorok PC, Mar-
cus PM; Cancer screening trials: nuts and bolts; Seminars in Oncology 
2010; 37(3): 216-223.
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MS25.3 COST-EFFECTIVENESS OF MODERN THERAPIES
Natasha Leighl
Dept. Med. Oncology, Princess Margaret Cancer Centre/Canada
Abstract: The growing number and rising costs of modern lung can-
cer therapies have brought the issue of cost and cost effectiveness 
to the forefront of clinical practice. While personalized medicine im-
proves outcomes in specific subgroups, sparing others from ineffec-
tive costly treatment and toxicity, it can be challenging to incorporate 
into economic analyses. Defining the target population for the new 
treatment is key, and then evaluating the costs and benefits of the 
new intervention compared to the previous standard. However, the 
definition of molecular populations for targeted therapies has emer-
ged as an important consideration when considering whether or not 
to adopt a new targeted therapy. The cost of biomarker testing can 
have a major impact on healthcare costs, and many countries are 
struggling with how to best incorporate the "hidden“ costs of per-
sonalized medicine into adopting new targeted therapies. Focusing 
only on the target population, comparing the new treatment with 
standard comparators does not incorporate the costs of biomarker 
testing, or need for repeat biopsies for successful testing, but will be 
a better reflection of the benefit of the new treatment in that popula-
tion. Comparing a test-and-treat strategy to a strategy without testing 
or the new therapy allows incorporation of the costs of testing, but 
has some important challenges. Biomarker frequency is a key driver 
in these analyses, with smaller populations as a particular challenge, 
such as ALK positive nonsmall cell lung cancer. Presenting the cost 
of both a test-and-treat strategy alongside an evaluation of the cost 
effectiveness of therapy in the target population may be a better way 
to illustrate the impact of a novel treatment, especially when the tar-
get population is small, while acknowledging the incremental financial 
burden of biomarker testing in cancer. This may allow new therapies 
to compete with current alternatives on a comparable footing, and 
not underestimate the impact of a new treatment in a small subgroup. 
It would also permit the development of more effective and cost-
efficient screening methods for the desired target population. It is 
important to recall that technological methods and costs involved in 
biomarker testing and molecular analysis are rapidly changing, and 
should be revisited over time. The technological methods used to 
identify molecular abnormalities in cancer, such as sequencing and 
antibody development, are changing rapidly along with associated 
costs. Thus less expensive or more efficient methods (e.g. multiplex 
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distress. How do we improve the symptom cluster experience? 
We need to develop symptom interventions that are moving from 
a reductionist model of focusing on a single symptom to under-
standing the clinical usefulness and relationships of symptoms 
through symptom clusters and developing interventions that affect 
all symptoms in the cluster. This area is still in its infancy and there 
are only a couple of ongoing trials with such more ‘complex’ inter-
ventions. How do these broader interventions look like? Comple-
mentary therapies may be good ‘candidates’ for such an approach; 
indeed, we have carried out a trial using acupuncture to manage 
cancer-related fatigue in breast cancer patients, and we have seen 
that many patients reported also reductions in hot flushes and 
joint pains too. Mindfulness therapy may be a good option for the 
common mood-related symptom cluster. Educational interventions 
could also be appropriate approaches. However, how one structu-
res and develops a new intervention to attend to clusters of symp-
toms needs significant thiNKIng and energy. 
Our team is currently testing a new such intervention focusing on 
the respiratory distress symptom cluster. However, to ‘shape’ the 
intervention we followed several steps: Through patient and care-
giver interviews (Ellis et al, 2012) important implications for patient 
participation and adherence to the intervention were identified, 
including the perceived relevance of potential techniques; appreci-
able benefits in the short-term; convenience; patient preferences; 
timing of the intervention; venue; caregiver involvement; the pro-
vider of the intervention, and contact with other patients. Through 
health care professionals’ focus group interviews (Wagland et al, 
2012) it was clear that to have a successful intervention we had to 
consider also staffing time and space, and there was a recognition 
that the preference of most patients to make as few hospital visits 
as possible also complicated the teaching of such interventions. 
Moreover, it was recognized that there may only be a small window 
of opportunity in which to effectively teach lung cancer patients 
a novel non-pharmacological intervention as the period between 
diagnosis and the onset of severe symptoms is often short. Finally, 
we assessed patient preferences for the intervention components 
through a discrete choices experiment (Molassiotis et al, 2012). 
After this work, we developed the intervention that includes pri-
marily diaphragmatic breathing exercises, cough suppression exer-
cises, and acupressure (main intervention) together with anxiety 
management, vocal hygiene, and energy conservation techniques, 
delivered through two educational sessions as a self-management 
strategy that involves both patients and caregivers. Currently we 
are testing this intervention in a pilot trial aiming to explore the 
impact of this novel non-pharmacological supportive intervention 
on symptom distress, coping and service utilisation in patients 
with lung cancer and their caregivers, and to test the feasibility of 
carrying out a trial using this intervention, including practical and 
logistical issues of providing the intervention in practice. The trial 
has currently recruited 60/100 patients and is envisaged to com-
plete recruitment by the end of 2013. Preliminary findings from the 
trial will be presented.
Keyword: symptom clusters, respiratory symptoms, lung cancer, 
intervention
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MS26.1 SYMPTOM CLUSTERS
Alex Molassiotis
 Hong Kong Polytechnic University, School Of Nursing/Hong Kong
Abstract: Symptom clusters is a relatively new field of study, re-
cognizing that patients are often experience multiple concurrent 
symptoms and some of them may be interlinked. Understanding 
these clusters may improve the management of unrelieved sym-
ptoms in patients with lung cancer. A symptom cluster is defined 
as two or more symptoms that are related to each other and that 
occur together (Kim et al, 2005; Molassiotis et al, 2010). A small 
amount of research has highlighted over the past decade the dif-
ferent symptom clusters that are reported by patients with lung 
cancer. Brown et al (2011) have shown a five-symptom cluster that 
includes fatigue, breathlessness, cough, pain and anorexia, present 
in 64% of women with lung cancer. Henoch et al (2009) identified 
three clusters, including a pain cluster (pain, nausea, bowel issues, 
appetite loss, fatigue); a mood cluster (mood, outlook, concentra-
tion, insomnia), and a respiratory cluster (breathing, cough). The 
latter respiratory cluster has also been shown with our own work 
and it was stable at various assessments over the first 12 months 
from diagnosis (Molassiotis et al, 2010). Depression, fatigue and 
pain is another one (Fox & Lyon, 2006) as is pain, fatigue and 
insomnia (Hoffman et al, 2007). On the clinical level, it is sugges-
ted that physicians and oncology nurses should think in terms of 
these naturally clustering symptoms when recommending plans 
for symptom management, in order to be more effective in the 
overall management of a larger spectrum of symptoms. However, 
all these studies have some methodological shortcoming, as many 
of the identified clusters reflect the measurement symptom tool 
used each time, some have small sample sizes and are often se-
condary analyses. Patients who experience symptom clusters are 
more distressed and have more severe symptom-reporting than 
those who experience single symptoms, and they form a particu-
lar group of patients in need of more careful intervention. More 
recently we have carried out a qualitative study with 19 patients 
and their caregivers assessed at diagnosis, and 3, 6 and 12 months 
post-diagnosis. We have identified, for a first time using such me-
thodology and the patients experience, a consistent and stable 
symptom cluster of fatigue, breathlessness and cough, which we 
called it ‘respiratory distress’ symptom cluster (Molassiotis et al, 
2011). Two other messages came out clearly from this study: a) that 
the patients’ symptom experiences and coping efforts need to be 
understood within the context of a panorama of symptoms which 
frequently co-occur and which may interact in complex ways. This 
suggests that it may therefore be potentially problematic within 
the lung cancer population to determine a patient‘s experience of 
a single symptom in isolation given the complex array of symptoms 
that patients may experience. b) cough, which is under-represen-
ted in research within this population, may play an important role 
in shaping the patients‘ symptom experience, and may be linked 
with breathlessness more strongly than we currently think. Also 
both breathlessness and cough lead to anxiety and emotional 
S90 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
ted QOL, however, did not demonstrate improvement. Spruit et al 
(2006) conducted a non-randomized clinical trial in patients who 
had a history of surgery, chemotherapy and/or radiotherapy eva-
luating an inpatient rehabilitation program on pulmonary function, 
6MWD and peak cycling load. Patients were trained in daily cyc-
ling, walking, weight training, and gymnastics (focusing on flexibi-
lity and mobility). No change was seen in pulmonary function post 
intervention. However, significant improvements were seen in the 
6MWD and peak cycling load. Symptom scores for dyspnea and 
fatigue also improved significantly. In focusing on patients with 
newly diagnosed advanced NSCLC with good performance status, 
Temel et al conducted a study to determine feasibility of imple-
menting a twice weekly physical therapy (PT) run program using 
aerobic exercise (bicycle and treadmill) and weight training. Func-
tional capacity as measured by the 6-minute walk test (6MWT), 
muscle strength, QOL and lung cancer symptoms and fatigue were 
evaluated. Results included no significant post intervention impro-
vement in QOL or fatigue. Lung cancer symptoms, though, were 
significantly improved. Additionally, no deterioration in the 6MWT 
or muscle strength were reported. Lastly, Jones et al (2008) stu-
died the effects of aerobic cycle training on changes in VO2peak 
and QOL among post surgery NSCLC patients. Results included 
increased VO2peak, improved QOL and decreased fatigue. Exer-
cise therapy is becoming increasingly acknowledged as an integral 
component of cancer rehabilitation. The limited literature focu-
sing on lung cancer survivors at different stages post diagnosis 
support exercise training as safe and well tolerated (Jones 2009). 
Adherence and ability to complete prescribed programs remains 
an issue, not surprisingly, for this patient population. While studies 
thus far have other limitations, they illustrate the need for large 
randomized trials to better determine the timing, support and spe-
cific interventions that will optimally benefit lung cancer survivors. 
References Available as a separate document
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MS26.3 EXERCISE AND LUNG CANCER SURVIVORSHIP
Stacie Corcoran
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States Of America
Abstract: An estimated 225,000 men and woman will be diag-
nosed with lung cancer in 2013 (NCI-SEER Data). Approximately 
80% of lung cancer patients will be diagnosed with non-small cell 
lung cancer (NSCLC), and an estimated 25% will present with early-
stage or operable disease (Jones 2009). The overall 5 year survival 
rate for lung cancer is 16%. However, if detected early the survival 
rate is 53% (ACS 2010). Improvements in surgical techniques, 
coupled with more effective chemotherapy regimens, have led to 
significant survival gains for patients with operable disease (Jones 
2009). With improved survival rates, long-term treatment sequelae 
and quality of life (QOL) are gaining increasing attention in terms 
of post-treatment management of early stage patients. For pati-
ents with inoperable or more advanced disease, measures to im-
prove symptoms and QOL are also being evaluated. An individual 
is considered a cancer survivor from the time of diagnosis, through 
the balance of his or her life (NCI- Survivorship Definitions 2004). 
Lung cancer survivors may experience a myriad of long-term and 
late effects related to their diagnosis and treatment exposures. 
Symptoms may include dyspnea, fatigue, decreased physical 
endurance, depression, inability to sleep and weight loss (An-
derson 2011). Anticipated age-related losses in physical function 
and comorbidities such as chronic obstructive pulmonary disease 
(COPD), ischemic heart disease and hypertension can add to post 
treatment complications, long term effects and overall recovery. 
Exercise therapy continues to gain recognition as an effective 
intervention in cancer rehabilitation. While early studies mainly 
focused on breast cancer survivors, a growing number of studies 
have been conducted over the past several years evaluating exer-
cise following a lung cancer diagnosis in the post treatment set-
ting. A review of literature suggests lung cancer patients are good 
candidates for pulmonary rehabilitation following treatment. Pedd-
le-McIntyre et al describe progressive resistance exercise training, 
or PRET, as an intervention that has been successful in improving 
muscular strength, body composition, physical fitness, physical 
function and QOL in some cancer survivor groups citing, however, 
that no studies have focused solely on lung cancer survivors. Their 
prospective study including early stage NSCLS survivors who had 
undergone surgical resection preliminarily revealed significant 
improvement in muscle strength, muscular endurance and peak in-
spiratory pressure. The 6-minute walk distance (6MWD), regarded 
as a prognostic indicator in certain chronic illnesses, also demons-
trated improvements suspected to correlate with preserving body 
function and delaying onset of mobility limitations. Several studies 
have demonstrated the benefits of exercise in COPD patients, who 
are known to experience respiratory symptoms comparable to 
lung cancer patients. A prospective study conducted by Anderson 
et al utilized an established COPD rehabilitation program in lung 
cancer patients to evaluate impact on fitness and QOL. Patients 
who had undergone pulmonary surgery as well as those who were 
surgically ineligible (comprising the majority of participants) were 
included in the study. Interventions included supervised exercise 
in the clinic setting and instruction on home exercising. Walking 
was the main element. Results showed improved physical fitness 
and performance as measured by the Incremental Shuttle Walk 
Test (ISWT), Endurance Shuttle Walk Test (ESWT) and spirometry 
after the exercise intervention. Pulmonary function and self repor-
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been observed in patient samples or in cell lines with induced drug 
resistance. Indeed, in the first case of published crizotinib resis-
tance, the tumor harbored two separate ALK mutations (6). This 
pattern stands in contrast to EGFR mutant lung cancer, where the 
observed rate of resistance mutations is 50-60% and the majority 
of resistance mutations occur at the gatekeeper position, T790M 
(7). Also in contrast to EGFR mutant lung cancer, resistance muta-
tions in ALK do not appear to confer a fitness disadvantage to the 
tumor cell (3). Mutations induce resistance by allowing persistent 
ALK signaling despite the presence of crizotinib. Copy number 
gain of the ALK fusion has also been observed in both cell line mo-
dels and in patient tumor samples following crizotinib resistance (3, 
4). It is hypothesized that that a fraction of ALK fusion proteins are 
not inhibited by clinically achievable doses of crizotinib and that 
increased expression may allow sufficient downstream signaling 
for tumor cell survival. Collectively, we have termed resistance 
mutations and copy number gain as ‘ALK-dominant’ mechanisms 
of resistance, because the tumor cells are still predicted to be ‘ad-
dicted’ to ALK signaling. Multiple mechanisms of ‘bypass’ signaling 
have been observed in both cell line models and post-progression 
tumor biopsies. These include activating mutations in EGFR and 
KRAS, and ligand dependent activation of EGFR or KIT (3, 4). In 
some cases the ALK gene rearrangement is no longer observed 
in post-crizotinib biopsy, also suggestive of an alternate or bypass 
signaling pathway. We have termed these bypass signaling me-
chanisms as ‘ALK non-dominant’ resistance as the tumor cells may 
no longer be dependent on ALK signaling. Approximately 50% 
of patients have been shown to harbor each class (dominant vs. 
non-dominant) resistance and this may have implications for post-
progression therapy in these patients (1). Next generation ALK 
inhibitors such as LDK378, AP26113, and CH/RO5424802 which 
potently inhibit the ALK kinase and have activity against many of 
the resistance mutations in vitro, may be the favored post-progres-
sion therapy for patients with ALK dominant resistance. All of these 
drugs have also demonstrated anecdotal evidence of activity in 
the CNS. Although not ALK-specific, HSP90 inhibitors, such as ga-
netespib, IPI-504, and AUY-922, can inhibit ALK signaling by decre-
asing proper folding of the chimeric ALK fusion proteins and may 
also overcome ALK dominant resistance (8). ALK non-dominant 
resistance may require dual inhibition of ALK and a bypass signa-
ling pathway to overcome resistance and the selection of drugs 
would be dependent on the alternate signaling pathway. Currently, 
no post-crizotinib therapies are approved in ALK+ lung cancer, 
but systemic chemotherapy remains as useful treatment strategy 
and some evidence suggests that pemetrexed-based regimens 
may be an optimal initial choice in the absence of a clinical trial 
(9). References 1. Camidge DR, Doebele RC. Treating ALK-positive 
lung cancer--early successes and future challenges. Nat Rev Clin 
Oncol. 2012;9:268-77. 2. Costa DB, Kobayashi S, Pandya SS, Yeo 
WL, Shen Z, Tan W, et al. CSF concentration of the anaplastic 
lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29:e443-
5. 3. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, 
Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in 
patients with ALK gene rearranged non-small cell lung cancer. 
Clin Cancer Res. 2012;18:1472-82. 4. Katayama R, Shaw AT, Khan 
TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms 
of acquired crizotinib resistance in ALK-rearranged lung Cancers. 
Sci Transl Med. 2012;4:120ra17. 5. Huang D, Kim DW, Kotsakis A, 
Deng S, Lira P, Ho SN, et al. Multiplexed deep sequencing analysis 
of ALK kinase domain identifies resistance mutations in relapsed 
patients following crizotinib treatment. Genomics. 2013. 6. Choi 
YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. 
EML4-ALK mutations in lung cancer that confer resistance to ALK 
inhibitors. N Engl J Med. 2010;363:1734-9. 7. Yu HA, Arcila ME, 
Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor 
specimens at the time of acquired resistance to EGFR-TKI therapy 
in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 
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MS27.1 RESISTANCE TO EGFR TKIS
Seiji Yano
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University/Japan
Abstract: Dramatic response has been achieved by EGFR inhibi-
tors in lung cancer expressing EGFR activating mutations. Howe-
ver, cancer cells show either intrinsic or acquire resistance to EGFR 
tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib, and 
cause disease progression. Known major mechanisms for acquired 
resistance to EGFR-TKI include T790M gatekeeper mutation in the 
EGFR gene and activation of bypass survival signal via receptors 
other than EGFR. The latter mechanism can involve Met gene amp-
lification and ligand-triggered receptor activation as well. For ex-
ample, HGF, the ligand of a tyrosine kinase receptor Met, activates 
Met and the downstream PI3K/Akt pathway and triggers resistance 
to EGFR inhibitors in EGFR mutant cancer cells. Moreover, com-
mon polymorphism in BIM gene was recently reported to be found 
specifically in East Asian and confer intrinsic resistance to EGFR-
TKI. These accumulating evidences suggest that mechanisms of 
EGFR-TKI resistance are complicated and heterogenous even in 
one individual. In this session, the resistance mechanisms will be 
introduced and therapeutic strategies will be discussed.
Keywords: drug resistance, gatekeeper mutation, bypass signal, 
BIM polymorphism
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MS27.2 RESISTANCE TO ALK INHIBITORS
Robert C. Doebele
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Abstract: ALK gene rearrangements occur in approximately 5% 
of lung adenocarcinomas and less frequently in other histologic 
subtypes. Crizotinib is currently the standard of care for ALK+ 
NSCLC (1). Treatment with crizotinib leads to remarkable objective 
response rates, durable progression free-survival and superiority 
over standard second line chemotherapy. Unfortunately, patients 
eventually experience disease progression on crizotinib. Disease 
progression may occur primarily in the central nervous system 
(CNS) alone, likely because of poor penetration of crizotinib into 
this space, or simultaneously with systemic progression outside of 
the CNS (2). Systemic disease progression likely occurs via cellular 
resistance that occurs by multiple mechanisms, which have been 
observed in vitro or in patient tumor samples derived following 
progression on crizotinib. Mutations in the kinase domain of ALK 
currently account for approximately 25% of observed drug resis-
tance (3-5). Resistance mutations occur at the ‘gatekeeper’ positi-
on, L1196M, but multiple other ALK kinase domain mutations have 
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Abstract: The United States Preventive Services Task Force 
(USPSTF) has released a draft recommendation, a “B”, for lung 
cancer screening. This means that the USPSTF concluded with 
moderate certainty that there was substantial net benefit for scree-
ning healthy individuals (i.e. those able to withstand surgical inter-
vention) with a 30 pack-year of more history of smoking, ages 55 
to 79 years of age who have smoked within the past 15 years. This 
recommendation is based primarily upon the results of the Nati-
onal Lung Screening Trial (NLST)with some consideration of the 
emerging results from much smaller trials in Europe. While this “B” 
isreasonable, the criteria for whom to screen may need revision. 
Tammemagi et al (NEJM 2013; 368:728-736) have serially refined an 
incidence-based risk model. In the most recent model, PLCOM2012, 
lung cancer risk increases with age, African American race/ethnici-
ty versus white, lower socioeconomic status (education), lower BMI, 
self-reported history of COPD, personal history of cancer, family 
history of lung cancer, being a current smoker, increased smoking 
intensity and duration, and shorter quit-time in former smokers. 
Applying the NLST criteria to the PLCO intervention arm smokers, 
14,144 of 37,332 (37.9%) were eligible. To obtain an equal number 
of individuals using the PLCOM2012, individuals with a lung cancer 
risk >1.3455% were regarded as positive. Overall the PLCOM2012 risk 
method identified 81 more of the 678 lung cancers (11.9%) than 
did the NLST criteria (41.3% fewer lung cancers were missed: 115 
versus 196). To include 80% of lung cancers in the PLCO control 
smokers, a PLCOM2012 risk probability of 0.016082 or higher would 
be used (specificity = 67.3%; PPV = 4.1%) and the proportion of 
smokers to be screened would be 33.6%. A spreadsheet calculator 
is available online, which calculates lung cancer risk according to 
PLCOM2012 given an individual’s predictor levels. http://www.brocku.
ca/lung-cancer-risk-calculator An alternative approach looking 
at lung cancer mortality was developed by Kovalchik et al (NEJM 
2013; 369:245-254). This analysis was limited to individuals who 
met the NLST entry criteria and used the NLST data for risk deve-
lopment with similar factors as Tammemagi et al. Five-year risk of 
lung cancer mortality ranged from 0.15-0.55% in the lowest risk 
group (Q1) to greater than 2% in the highest risk group (Q5). Sixty 
percent of NLST participants with the highest risk of lung can-
cer mortality accounted for 88% of LDCT-prevented lung cancer 
deaths. Sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of LDCT screening across rounds 
have now been reported. There is little variation across the rounds. 
At T0, the sensitivity and specificity were 93.8% and 73.4% for 
LDCT. In the LDCT arm, the PPV was 52.9% (265/501) for any positi-
ve finding that led to a biopsy procedure but only 3.8% (270/7,181) 
for positive findings overall Overall NPV was 99.9% (19,043/19,061). 
Among LDCT positive screenees undergoing thoracotomy at T1 
and T2, 18.9% and 15.9% did not result in a lung cancer diagnosis, 
respectively. The frequent need for evaluation of positive screens 
increases the burdens of LDCT screening. Increasing the minimum 
size threshold for screen positivity can reduce the frequency of 
2013;19:2240-7. 8. Normant E, Paez G, West KA, Lim AR, Slocum 
KL, Tunkey C, et al. The Hsp90 inhibitor IPI-504 rapidly lowers 
EML4-ALK levels and induces tumor regression in ALK-driven NS-
CLC models. Oncogene. 2011;30:2581-6. 9. Camidge DR, Kono SA, 
Lu X, Okuyama S, Baron AE, Oton AB, et al. Anaplastic lymphoma 
kinase gene rearrangements in non-small cell lung cancer are asso-
ciated with prolonged progression-free survival on pemetrexed. J 
Thorac Oncol. 2011;6:774-80.
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Abstract: Lung cancer therapy in the metastatic setting is invariab-
ly characterized by the emergence of resistance. This applies both 
to conventional chemotherapy and molecular targeted agents. 
This presentation will focus on the biological background and 
subsequent trial designs as it applies to resistance regarding mo-
lecular targeted agents (MTA). In the clinical setting when a patient 
develops progressive disease while exposed to a MTA some key 
basic considerations should be taken into account before consi-
dering acquired biological resistance. Compliance of the patient 
to the prescribed therapy is an obvious one. Indeed chronic ex-
posure to tyrosine kinase inhibitors (TKI) exposes the patient to 
chronic toxicities. Some of these toxicities can become intolerable 
for the patient, thus leading to patient-driven therapeutic breaks 
that are frequently not specified to the clinician. This is notably 
true for week-end breaks as well holiday breaks. Honest dialogue 
with the patient is necessary to identify compliance issues and 
pharmacological (PK) dosage in the blood of the relevant TKI is an 
approach to be discussed. Further pharmacokinetic interactions 
represent a real issue with TKI: many TKI are metabolized by the 
liver and can have CYP liabilities (ie erlotinib, gefitinib are susbtra-
ted of CYP3A4). Inter-individual PK variability due to genotypic 
background (polymorphisms in genes encoding drug metabolizing 
enzymes), inflammatory and nutritional status, may result in sub-
optimal drug concentrations and decreased efficacy. Significant 
decrease in drug exposure over time have also been described for 
and may result in secondary progression despite preserved sen-
sitivity to these agents, with a potential role for subsequent dose 
escalation. From a biological perspective, 3 main mechanisms have 
been described to explain resistance to TKI: a) mutation/amplifi-
cation in the target (ie T790M for EGFR or ALK L1196M), bypass 
mechanism (ie Met amplification, PI3K mutation, HER 3 activation,) 
and growth survival/apoptosis resistance (ie loss of BIM, SCLC, 
EMT). Stronger kinase inhibitors and use of combinations appear 
as potential solutions to deal with these resistance mechanisms. 
Some of the potential designs to address acquired resistance in-
clude: a) upfront combinations, b) use of third generation inhibitors 
or mutant-specific inhibitors, c) rolling trials (ie the use of sequen-
tial TKI therapies), c) alternating therapeutic approaches (TKI follo-
wed by chemotherapy or TKI followed by immunotherapy).
Keywords: TKI, resistance, trial design, NSCLC
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Abstract: Neuroendocrine Tumours of the Lung encompass low 
grade tumors (typical and atypical carcinoids) and high grade 
carcinomas (large cell neuroendocrine lung carcinoma and small 
cell lung carcinoma). Typical carcinoids (TC) and atypical carcino-
ids (AC) are usually diagnosed in front of symptoms (bleeding or 
pneumonia) or abnormal chest Xray or CT scan. Patients with TC 
are younger. Association with MEN1 syndrom is rare. Bronchial 
endoscopy often shows the tumor and biopsies made with caution 
usually confirms the diagnosis of carcinoid. However, the patholo-
gical analysis of the whole tumour is necessary to distinguish TC 
and AC, according to WHO criteria based on mitotic count (less or 
more than 2 per 2mm2) and necrosis. Staging differs from that of 
other lung cancers, including somatostatin receptor scintigraphy 
(SRS), hepatic MRI and bone MRI. Treatment of typical or atypical 
bronchial carcinoid is implemented in the multidisciplinary setting 
after an in depth characterization of host and tumor presentations. 
Goals of the treatment are both to control hormone-related sym-
ptoms if they exist, and tumor growth. Surgery remains the gold 
standard of treatment of bronchial carcinoids. Thoracic surgery 
should not differ from that of lung cancer, while it should be con-
servative for young patients, with complete resection and lymph 
node dissection. In case of lymph node involvement, there is no 
consensus about adjuvant treatment, which is not recommended 
by ENETS. Prognostic heterogeneity and absence of cure at the 
metastatic stage make quality of life a key issue of advanced bron-
chial carcinoid management. Advanced atypical carcinoids are 
more aggressive than typical carcinoids. The spontaneous slope 
without treatment, the number of tumor organs including the 
primary, SRS grade of uptake and quality of control of hormone-
related symptoms are key parameters to be characterized before 
any therapeutic decision. Based on the limited number of studies 
available in patients with bronchial primary, recommendations of 
treatment also take into account data established from the field of 
digestive NET. Treatment is based on locoregional therapies for 
bone and liver metastasis, and/or systemic treatment (somatostatin 
analogues, everolimus, chemotherapy, Peptide receptor radio-
nuclide therapy). Large cell neuroendocrine carcinomas (LCNEC) 
are high grade malignant tumours. Their behavior is very different 
from that of bronchial carcinoids. Patients are usually male and 
smokers. Locally advanced or metastatic stages are usual at pre-
sentation. Brain metastases are frequent. Surgery is possible only 
in one third of patients. Adjuvant chemotherapy with platinum-eto-
poside based chemotherapy is recommended. For more advanced 
LCNEC, prognosis is poor and treatment does not differ from that 
of SCLC, without any significant progress made these last years.
Keywords: lung tumors, carcinoid, chemotherapy, neuroendocrine
diagnostic work-up. Nodules 4-6 mm diameter accounted for 
roughly half of LDCT positive screens at T1 and T2, but were asso-
ciated with lung cancer in less than 1% of cases. The variability in 
radiologists‘ interpretations of computed tomography (CT) studies 
in the NLST (including assessment of false-positive rates [FPRs] 
and sensitivity), was characterized and factors that contributed 
to variability, and trade-offs between FPRs and sensitivity among 
different groups of radiologists were evaluated. One hundred 
twelve radiologists at 32 screening centers each interpreted 100 
or more NLST CT studies, interpreting 72 160 of 75 126 total NLST 
CT studies in aggregate. The mean FPR for radiologists was 28.7% 
± 13.7 (standard deviation), with a range of 3.8%-69.0%. Aggregate 
sensitivity was 96.5% for radiologists with FPRs higher than the me-
dian (27.1%), compared with 91.9% for those with FPRs lower than 
the median (P = .02). In adjusted analyses, smoking cessation was 
strongly associated with the amount of abnormality observed in 
the previous year’s screening (P<0.0001). Compared to those with 
a normal screen, individuals were less likely to be smokers if their 
previous year’s screen had a major abnormality that was not suspi-
cious for lung cancer (odds ratio (OR) = 0.790, P<0.001), was suspi-
cious for lung cancer but stable from previous screens (OR = 0.777, 
P<0.001), or was suspicious for lung cancer and was new or chan-
ged from the previous screen (OR 0.593, P<0.001). Integration of 
effective smoking cessation programs within screening programs 
should lead to further reduction in smoking-related morbidity and 
mortality. Estimates suggest that the risk of radiation-induced 
lung cancer from three annual lung CT screens (average lung dose 
from a single LDCT estimates at 4 mGY) for older current smokers 
is likely to be in the range 1-10 deaths per 10,000 screened. How-
ever, because of the high probability of a positive screen (>20%) 
the follow-up procedures could double the risk of radiation-related 
lung cancer. The observed reduction in lung cancer mortality in 
the trial due to lung CT screening was 31 deaths prevented per 
10,000 screened. The estimated radiation-related risks are therefo-
re considerably smaller than the observed benefit. However, when 
the follow-up scans are included the benefit for current smokers is 
reduced by about 30% from 31 to about 20 lung cancer deaths per 
10,000 screened. The impact on life-expectancy will be smaller, 
however, because the lung cancer deaths prevented occur at a 
younger age than the radiation-related cancer deaths. Estimates 
of the reduction in life-expectancy from radiation-related cancer 
were on average only 1-5 days. The advent of improved risk mo-
dels demonstrates that more efficient criteria for selection of indi-
viduals for lung cancer screening than the NLST are feasible and 
effective. The various medical groups that have developed recom-
mendations for lung cancer screening have primarily settled upon 
the NLST criteria. These groups should re-evaluate their criteria in 
light of the findings of these new risk models. This would have the 
salutary effect of making lung cancer screening more efficient and 
save more lives.
Keyword: NLST; low-dose CT screening; lung cancer; risk models
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days, excluding those over holidays, with 80% reported within 7 
days. Prolonged reporting times were mainly due to those refer-
ring not sending blocks or unstained slides, necessitating further 
despatch of material. There is also additional delay when cases 
require molecular analysis. With the advance of digital pathology, 
this has potential to facilitate and speed up external opinions, alt-
hough is still in its infancy. This is because referrals often comprise 
numerous slides which are still quicker to send and review via the 
microscope than scan and then go through remotely. However, for 
single or small numbers of slides, the technology has greater po-
tential. Finally, the question is often asked what happens when the 
putative specialists are unable to make a diagnosis. In the author’s 
experience, some are undiagnosable for practical reasons, such 
as poor fixation, whilst some are sufficiently complex and unusual 
that a further collective opinion from fellow specialists is obtained 
and fed back to the referring pathologist. This is often after much 
emailing and debate!
Keywords: lung, referral, rare tumour, multidisciplinary
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Abstract: The purpose of this session is to allow delegates to 
bring cases for discussion in relation to unusual thoracic tumours, 
primarily related to the pathology but also in relation to clinical 
management of complex pathological cases. Respiratory medici-
ne does not provide a huge volume of material for the diagnostic 
pathologist, but much of this is related to thoracic cancers and 
their differential diagnoses. This sometimes leads to a lack of 
experience in managing rare and complex cases and most patho-
logists will have an, albeit informal, link for specialist opinion to 
help in this instance. Indeed, it is now a recommendation in the 
United Kingdom that a pathway of referral is part of the multidis-
ciplinary management of lung cancer patients. In the speaker’s 
experience, around 60% of referrals for complex cases relate to 
tumour pathology, and this is perhaps increasing with the relative 
decrease in biopsy for non-neoplastic diseases and increased in-
terest in the subtyping of more common tumours. Cases referred 
for specialist opinion tend to breakdown into small lung biopsies, 
in particular asking the question, "is there enough evidence to call 
the biopsy definitively malignant?“ This is, in particular, in relati-
on to adenocarcinoma. Another common area is the differential 
diagnosis of mesothelioma, in particular in relation to spindle cell 
rather than epithelioid proliferations in the pleura. The third com-
mon area for referral is the "rare“ tumour, where cases will often 
be sent because the referring pathologist has been no previous 
experience of the particular neoplasm. This process is not only of 
benefit to the referrer but also for the specialist as it allows accrual 
of potential new entities, an example being primary pulmonary 
myxoid sarcomas with EWSR1-CREB1 fusion where cases were 
collected over a period of 12 years from first sighting. Even within 
these groups, the pattern of referral has changed over the last two 
decades. Between 1995 and 2000, there were frequent referrals 
in relation to the differential diagnosis of pulmonary marginal 
zone lymphoma of MALT origin and reactive pulmonary lymphoid 
hyperplasia. Now that distinguishing criteria are much more esta-
blished, these referrals are much rarer. However the last two years 
has seen an increase in referrals of non-small cell carcinoma, in 
relation to the need for further subtyping, with many of the cases 
being those with diverging immunophenotype. Little has been 
done to assess the value of specialist referral. However a review of 
personal experience of 50 cases affirmed diagnoses in 26/50 (52%) 
cases, revised in 16/50 (32%) and favoured diagnoses in 8/50. 80% 
of reports were deemed to have major clinical significance. Ave-
rage (laboratory and pathologist) coast was £130.47 respectively 
(in 2009), excluding lymphoma investigations and corporate costs 
and current charges in the UK vary between £150 and £250 per 
case for slide/block reviews. The author would argue that the cost 
of referral appears is offset by a high level of definitive diagnosis, 
negating further investigation. Average turnaround time was 5 
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is being developed. Smoking cessation pharmacotherapy appro-
ximately doubles the success rate of a quit attempt. Three cate-
gories of first-line treatment are approved in the U.S. and many 
other countries: nicotine replacement therapy (NRT), bupropion 
(an atypical antidepressant), and varenicline (a selective nicotine 
receptor partial agonist). NRT, the most widely used product, is 
available in multiple forms including skin patch, gum, lozenge or 
sublingual tablet, oral inhaler, mouth spray and nasal spray. Com-
bining NRT products (patch plus a shorter acting form) is the most 
effective way to administer NRT and is recommended by U.S. and 
U.K. clinical guidelines. Varenicline, the newest product to market, 
is effective but enthusiasm has been tempered by post-marketing 
concerns about psychiatric side effects and a possible increased 
risk of cardiovascular events. Current evidence does not suggest 
a large adverse effect but studies are ongoing. Cytisine, a partial 
nicotinic receptor agonist that is less selective for the α4β2 nicoti-
nic receptor than varenicline, is inexpensive and sold in some Eas-
tern European countries. It showed efficacy for smoking cessation 
in a recent double-blind randomized controlled trial although quit 
rates were low. If replicated, its low cost could make pharmacothe-
rapy affordable in settings where cost limits medication availability. 
Nortriptyline, a tricyclic antidepressant, has evidence of efficacy in 
systematic reviews but is supported by a smaller body of evidence. 
No other antidepressant and no anti-anxiety medication has de-
monstrated efficacy for smoking cessation. To date there are few 
trials of smoking cessation interventions specifically targeted to 
patients with cancer. However, there is substantial evidence about 
what works in ambulatory and inpatient medical practice, and this 
is likely to be generalizable to lung cancer patients. Physicians who 
routinely deliver brief advice to quit to all smokers increase smo-
kers’ odds of quitting. Providing a brief counselling intervention 
during an office visit is more effective than advice alone at promo-
ting smoking cessation. Clinicians in ambulatory practice can pro-
mote smoking cessation by encouraging a smoker to make a quit 
attempt and connecting the smoker to evidence-based medication 
and behavioural treatments available in the health care system 
or community. Caring for hospitalized smokers provides another 
opportunity to encourage smoking cessation. Hospital-initiated 
smoking cessation counselling interventions increase cessation 
rates after discharge. A system-wide approach to promoting and 
supporting smoking cessation should be part of standard care in 
cancer centers and other sites that deliver health care to cancer pa-
tients. This would include the systematic identification and docu-
mentation of smoking status throughout cancer treatment, routine 
and repeated offers of tobacco cessation treatment during cancer 
treatment, and coordination of care among various types of spe-
cialists who deliver the cancer care. In our institution, we conduc-
ted a pilot trial in newly diagnosed patients with early stage lung 
cancer to identify smoking status and routinely offer treatment. We 
compared 12 weeks of varenicline plus counselling with usual care. 
At end of treatment, quit rates were higher with treatment (34% vs. 
14%), and a full-scale randomized trial is underway.
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Abstract: Tobacco use is the leading preventable cause of death 
worldwide, responsible for over 5 million deaths per year. By 2030 
there will be more than 8 million tobacco-attributable deaths annu-
ally, if present trends continue, and 80% of them will occur in low 
and middle-income countries. Approximately half of regular smo-
kers will die of a tobacco-related disease, losing an average of ten 
years of life compared to never smokers. Tobacco use is the major 
cause of lung cancer, increasing the risk 15-20 fold, and accounts 
a substantial fraction of the burden of tobacco-attributable mor-
tality. In the U.S., for example, lung cancer is responsible for 29% 
of tobacco-attributable deaths. Lung cancer risk extends beyond 
tobacco users to nonsmokers who are exposed to secondhand 
smoke, who have a 30% higher risk of lung cancer than other non-
smokers. Reducing tobacco smoking is central to the prevention 
and treatment of lung cancer. The risk of lung cancer declines pro-
gressively with time after a smoker quits, reaching an asymptote 
at 15-20 years after quitting. Most cancer prevention efforts focus 
on preventing lung cancer by promotion smoking cessation among 
smokers and preventing smoking initiation by youths. A strong evi-
dence base exists to guide efforts to reduce the harms of tobacco 
use. Offering tobacco cessation treatment is a core component of 
the World Health Organization’s Framework Convention on Tobac-
co Control, the world’s first global health treaty. It complements 
policy efforts such as increasing tobacco excise taxes, expanding 
smoke-free areas, conducting public education campaigns, and 
restricting tobacco promotion. However, there is an important 
gap. Reducing tobacco use among smokers with diagnosed lung 
cancer has received far less attention in cancer care than it de-
serves, despite a small but growing body of evidence to indicate 
that continuing to smoke after a lung cancer diagnosis increases 
all-cause mortality, impairs the response to treatment and worsens 
the toxicity of treatment, whether surgery, radiation, or chemo-
therapy. Stopping smoking also improves lung cancer patients’ 
quality of life by reducing symptoms such as dyspnea and fatigue. 
A majority of patients diagnosed with lung cancer try to quit after 
the diagnosis, and effective treatments are available. However, 
clinicians caring for smokers with lung cancer often neglect to 
address this issue and to connect smokers to treatment to help 
them sustain tobacco abstinence. The randomized controlled clini-
cal trial evidence supporting the efficacy of treatments for tobacco 
use is strong. Systematic reviews agree that effective smoking 
cessation treatments exist and help many smokers to quit. Proven 
treatment methods fall into two major categories: psychosocial 
counseling (also called behavioral support) and pharmacotherapy. 
Each of these modalities is effective, but combining behavioral 
support and pharmacotherapy enhances success because the 
treatments are complementary. Pharmacotherapy primarily relieves 
nicotine withdrawal symptoms, while counseling aims to improve a 
smoker’s motivation and confidence to quit and teaches practical 
coping skills for quitting. Counseling can be delivered in person or 
by telephone (either voice or text messaging). The evidence base 
for the efficacy of delivery via the web or smart phone applications 
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Abstract: RECIST AND PERCIST CRITERIA FOR RESPONSE TO 
THERAPY Background We need to accurately assess response 
to therapy for our patients with cancer, early in their treatment. 
Because modern treatments are costly (up to $10,000 per month), 
it is important to determine whether the current regimen is being 
effective and whether the patient will respond well with this treat-
ment. If judged effective, stay the course. If current treatment is 
not being effective, then one could change management early, 
thus saving costs, avoiding unnecessary toxicities and improving 
quality of life. Anatomic Methods Tumor shrinkage has long been 
the standard for judging response to therapy since Moertel et al. 
published studies in 1976, comparing measurements of palpab-
le tumors. WHO: In 1979 the World Health Organization (WHO) 
Handbook established imaging criteria for following solid tumors 
during therapy. Response was judged by tumor shrinkage. Com-
plete response (CR), partial response (PR), stable disease (SD) and 
progressive disease (PD) were defined. Time to tumor progression 
(TTP), and progression free survival (PFS) defined when the di-
sease recurred or progressed, including death in PFS. Measurable 
disease was defined with bidimensional tumor measurements, 
utilizing the product of longest diameter (LD) and short axis (SAX). 
RECIST 1.0: In 2000 the European Organization for Research and 
Treatment of Cancer (EORTC) and the National Cancer Institute 
(NCI) task force published imaging criteria as the Response Eva-
luation Criteria In Solid Tumors (RECIST) Guidelines. Measurable 
disease was defined unidimensionally, utilizing the LD. The LD of 
the target lesions was summed. CR: complete disappearance of 
all lesions. PR: ≥30% decrease of the sum. PD: ≥20% increase of 
the sum. For nontarget lesions, CR: complete resolution of all lesi-
ons; PD: unequivocal progression, or appearance of new lesions; 
SD: essentially stable, nontarget lesions such as pleural effusion. 
RECIST 1.1: Revised in 2009. Measurable disease defined unidi-
mensionally, with the LD, except for lymph nodes in which the SAX 
is measured and must be ≥15mm at baseline. Normal lymph nodes 
defined as ≤10mm SAX. The SAX of the target lymph nodes is ad-
ded to the sum of the LD of other target lesions. With conventional 
techniques (such as CXR or palpable lesions), target lesions need 
to be ≥20mm at baseline, or ≥10mm for spiral CT. CR: complete 
resolution. PR: ≥30% decrease of the sum. PD: ≥20% increase 
of the sum. For nontarget lesions, CR: complete disappearance, 
such as effusions or lymphangietic tumor. PD: “unequivocal” pro-
gression, or appearance of new lesions. PD can also be new “PET 
positive” lesions. Biomarkers We currently have several clinically 
accepted biomarkers for evaluating active tumors: serum thyro-
globulin (TG) for thyroid cancer, prostate specific antigen (PSA) for 
prostate cancer, and CA-125 for ovarian cancer. With the advent of 
personalized medicine, other individual biomarkers, cell markers 
and genetic makers for a tumor are increasingly utilized and may 
require biopsy to evaluate evolving tumor mutations and chemo-
resistance. New biomarkers include (HER2) for breast cancer, and 
KRAS gene mutations for epidermal growth factor receptor (EGFR) 
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Abstract: Background The National Lung Screening Trial (NLST) 
demonstrated that screening with low-dose CT compared to 
screening with chest radiography reduced lung cancer mortality. 
Several cost-effectiveness analyses of lung cancer screening have 
been performed and will be reviewed in the presentation. A team 
of investigators from the NLST developed detailed data collection 
instruments to prospectively collect information about the entire 
screening process and cost expenditures while the trial was ongo-
ing with the specific intention of performing a cost-effectiveness 
analysis after conclusion of the study. The team has concluded 
this research and now reports the cost-effectiveness of CT scree-
ning within the setting of the NLST. Methods Mean life-years, 
quality-adjusted life-years (QALYs), and mean costs per person and 
incremental cost effectiveness ratios for three alternative scree-
ning strategies using the societal perspective were estimated. CT 
screening was compared to chest radiographic and no screening, 
assuming that chest radiographic screening was ineffective and 
only contributed costs directly related to screening, not lung can-
cer treatment. Life-years were based on all observed deaths within 
the trial and projected survival of those alive at the end. Quality 
adjustments were derived from a subset of participants selected 
for quality of life surveys. Costs were based on utilization rates, 
derived from a subset of participants selected for medical record 
abstraction, and Medicare reimbursements. Life-years, QALYs, and 
costs were discounted at 3% per year. Uncertainty was assessed 
using bootstrap sampling of participants, subset analyses based 
on age, gender, smoking history, and lung cancer risk, and one-
way sensitivity analyses on several assumptions. Results In the 
base case, the CXR screening strategy was dominated. Compared 
to no screening, CT screening costs $1441 per person and provi-
ded an additional 0.0217 QALYs per person; the incremental cost 
effectiveness ratio was $67,000 per QALY gained. Conclusions 
CT screening for lung cancer as performed in the NLST appears 
to be cost effective under a wide range of assumptions. Whether 
screening outside the trial will be cost effective will depend on 
who is selected for screening, how screening is performed, and 
how screenees are subsequently managed. As the United States 
Preventive Services Task Force has given a draft recommendation 
of “B” for lung cancer screening, it will need to be covered without 
a deductible by insurance companies upon implementation of the 
Patient Protection and Affordable Care Act. Therefore, appropriate 
implementation of screening is critical. (Funded by the National 
Cancer Institute; National Lung Screening Trial ClinicalTrials.gov 
number, NCT00047385.)
Keyword: Low-dose CT; cost-effectiveness analysis
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Abstract: Patient-derived xenotransplant (PDX) models are gene-
rated by engrafting human tumor material directly from surgery 
or biopsy into an immune-compromised mouse without any inter-
vening in vitro culturing. Previous efforts to accomplish this were 
hampered by poor tumor “take rates” of all but the highest grade 
tumors, limiting the spectrum of cancer types available for study. 
Several technical advances have led to improved model formation, 
including the advent of the NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) 
mouse by The Jackson Laboratories: a new immunodeficient strain 
that, in addition to a compromised complement system, have de-
fective dendritic cell and macrophage activity, lack mature T and B 
cells, and have no functional NK cells. This strain has demonstrated 
high rates of engraftment of a wide variety of tumor types, with 
the resulting xenografts retaining the tumor heterogeneity and 
oncogenic driver activity of the patient’s tumor; thus providing a 
model system that more closely reflects what is seen in the clinic. 
The University of California, Davis Comprehensive Cancer Center 
and The Jackson Laboratory have collaborated to establish over 50 
fully functional NSCLC PDX models. Testing to date has demons-
trated a high fidelity between the contributing patient tumor and 
the resultant PDX model (at passages 1 and 2) in terms of driving 
mutations, histology and treatment response. Models developed 
from tumors known to harbor alterations in EGFR, KRAS or ALK 
all retain the exact mutational characteristics of the donor tumor. 
Additionally, these models clearly recapitulate the tumor histologic 
characteristics and grade of their donors. Squamous cell carcino-
ma PDX models in this panel have a high incidence of p53 muta-
tions, with several models harboring PIK3CA or PTEN mutations, 
amplification of PIK3CA and FGFR1. KRAS-mutant models have 
a high incidence of KRAS and MYC amplification. EGFR-mutant 
positive adenocarcinomas include models derived from patient 
tumors prior to or following acquisition of resistance to erlotinib, 
and in models tested to date recapitulate the clinical results of the 
contributing patient when treated with the matching therapy. By 
the third passage, a large number of matched sister models can be 
generated, sufficient for multi-armed therapeutic testing with an n 
of 10 or more per arm. Additionally, short-term molecular effects 
of targeted agents, particularly kinase inhibitors, can easily be 
measured. Inhibition of drug target and the resultant downstream 
effects on kinase pathways have already been documented in on-
going studies (Mack et al, WCLC 2013), granting unique insight into 
drug activity, resistance and cellular compensatory effects. Such 
studies provide a rational basis for determining appropriate thera-
peutic combinations of signal transduction inhibitors and receptor 
tyrosine kinase inhibitors to achieve complete signaling blockade. 
Similarly, PDX models should aid in identification of targeted stra-
tegies to improve activity of chemotherapy. The use of early pas-
sage (or passage 0) PDX models as “avatars” for patient response 
to therapy is also under investigation, although the parameters in 
which models can be treated in a time-frame sufficient for patients 
with advanced NSCLC need to be determined. In summary, the 
in colorectal cancer and lung cancer. PET-CT with FDG has also 
become an established imaging biomarker for hypermetabolic 
tumor activity. Functional Methods Functional methods for jud-
ging tumor response include dynamic contrast enhancement (DCE) 
with CT or MRI, MR spectroscopy (MRS), MR diffusion weighted 
imaging (DWI), ultrasound contrast enhancement, and optical 
coherence techniques. DCE is well accepted for GIST tumors and 
is being studied for lung cancer and breast cancer at UC Davis. 
Molecular Methods As early as 1990, gallium-67 was utilized with 
gamma cameras and then SPECT, for judging tumor response in 
lymphomas and Hodgkin’s disease, and to determine tumor ac-
tivity if CT showed residual masses. In 2007, the Harmonization 
Criteria were established for judging tumor response with CT and 
PET-CT in malignant lymphomas and essentially replaced gallium. 
PET-CT with flourine-18 fluorodeoxyglucose (FDG) has become 
clinical standard-of-care in the staging and follow-up of many 
tumors, including lung cancer, esophageal cancer, head and neck 
cancers, brain tumors, lymphomas, GIST tumors (Choi criteria, 
2007), colorectal cancer, melanoma, cervical and ovarian cancers. 
PET-CT is a quantitative technology but is often used with quali-
tative evaluation, comparing tumor uptake to background, liver 
or blood pool activity. Viewing the whole body MIP (Maximum 
Intensity Projection) images can often quickly determine whether 
the primary lesion and metastatic lesions have greatly increased or 
decreased in number or metabolic activity. However, quantitative 
techniques are more objective and likely more precise in judging 
response to therapy. Quantitative techniques include measuring 
various forms of Standard Uptake Value (SUV) and total glycolytic 
volume (TGV). The same acquisition principles of PET-CT with 
FDG are also being studied for other radiopharmaceuticals such as 
F-18-fluorothymidine (FLT) for DNA synthesis, F-18-fluoroethyltyro-
sine (FET) for amino acid metabolism, F-18-fluoromisonidazole for 
hypoxia imaging, and numerous other PET radiotracers. PERCIST: 
In 2009, Wahl et al. published a landmark article for PET-CT, “From 
RECIST to PERCIST: Evolving Considerations for PET Response 
Criteria in Solid Tumors”. PERCIST (Positron Emission tomography 
Response Criteria In Solid Tumors) is a set of recommendations 
to help make PET-CT even more quantitative and more precise. 
Current recommendations involve stringent quality control for 
equipment, software standardization, standard dosing, consistent 
timing from injection to acquisition, SUV peak rather than SUV 
max, SUL (SUV with lean body mass) and standardized ROI shape 
and size. Current recommendation is for a 1 cm3, spherical ROI 
placed within the most hypermetabolic area of the tumor (SUV 
peak). Setting the required number of lesions and judging the 
summed response are still being evaluated. Conclusions RECIST 
1.1 criteria and anatomic measurements will continue to play an 
important central role in clinical trials and for individual patients. 
PERCIST criteria are evolving and will slowly be introduced in ca-
refully planned clinical trials. PET-CT with FDG has been proven 
to judge tumor response sooner than anatomic techniques alone, 
and it is thought that PERCIST criteria will help decrease the costs 
and duration of clinical trials, as well as improve the quality of life 
by decreasing prolonged exposures to ineffective treatments and 
associated toxicities.
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Abstract: Most patients affected by malignant pleural mesothelio-
ma (MPM) are candidates for chemotherapy during the course of 
the disease, as single modality treatment or within the context of 
a multimodality approach. Following the results of a large phase 
III trial, the combination of cisplatin and pemetrexed has become 
the preferred first-line chemotherapy, although there is also evi-
dence for the activity of the combination with carboplatin. Unfor-
tunately, nearly all MPM patients progress during or after first-line 
treatment. Second-line therapies are being increasingly used in 
the clinical practice because patients are frequently still in good 
clinical conditions at the time of disease progression. However, 
the role of these treatments in MPM is unproven, and the optimal 
regimens still remain to be defined. In pemetrexed-naïve patients, 
data from a randomized trial vs. best supportive care suggest the 
use of single-agent pemetrexed as a standard second-line treat-
ment. This evidence is supported also by the results of the Expan-
ded Access Programs. To date, there is no standard approach for 
pemetrexed-pre-treated patients. Several phase II and a few phase 
III trials have been performed or are ongoing, and this remains a 
field of active research. Unfortunately, studies available until now 
have frequently severe limitations, due to the small number and 
to the heterogeneity of patients included, and often to the design 
of the studies themselves. In selected cases with a prolonged res-
ponse to first-line pemetrexed-containing chemotherapy (less than 
25% of the whole population of MPM patients treated in first-line), 
re-treatment with a pemetrexed-based regimen should be consi-
dered, based on preliminary evidence reported in small case se-
ries. Clinicians should be aware of the risk of hypersensitivity reac-
tions when carboplatin is used in combination with pemetrexed in 
the re-treatment setting. For the remaining patients the evidence 
is still limited. Targeted therapies with agents such as EGFR and 
PDGFR inhibitors, anti-angiogenic compounds, and histone-deace-
tylase inhibitors have so far achieved disappointing results. Trials 
with small molecules or monoclonal antibodies that target different 
molecular pathways are ongoing. Patients should be encouraged 
to participate in these trials. When a trial is not available or pati-
ents are not eligible for an experimental approach, second-line 
chemotherapy can be a reasonable option for palliation. Gemcita-
bine and vinorelbine are the most commonly administered agents. 
However, prospective studies in this setting are sparse, and most 
evidence comes from retrospective reports. Gemcitabine has been 
studied mainly in combination with other compounds in small 
studies. Overall, all these studies showed a modest activity, with a 
response rate of 10% or less and a disease control (including also 
stable disease) in about half of patients. The incidence of severe 
toxicity was low, and mainly related to hematological adverse 
events. Vinorelbine has been studied in the second-line setting 
mainly as a single agent. There are at least 4 studies available, 2 
PDX platform, with its high degree of fidelity to patient tumors and 
minimized culture-induced artifacts, should significantly improve 
the predictive ability of preclinical modeling in the era of persona-
lized therapy.
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Abstract: Although recent development of minimally invasive 
procedures contributed significantly to reduce of postoperative 
complications, as the population continues to age, as more pati-
ents receive induction therapies, and as more patients are immu-
nocompromised, complications will continue to increase. Although 
many complications can be treated medically, some complications 
require another round of surgery. Postoperative complications af-
ter lung cancer surgery can take place both in early and late post-
operative periods. As a matter of fact, major surgical errors during 
the surgery can result in mortality or major morbidity. Hence, the 
surgery for complications of surgery should begin with prevention 
of the intraoperative event during the initial surgery. Intraoperative 
complications During the major lung resection, various kinds of 
errors can take place. Poor surgical technique can cause injuries 
of the pulmonary vasculature as well as of the bronchus. The risk 
of intraoperative technical complication can occur either during 
VATS or thoracotomy procedures. However, it is more difficult to 
control in VATS. Minor bleeding can be easily controlled trough 
VATS. However, once a major vascular injury occurs, the bleeding 
focus should be compressed, and a prompt thoracotomy should 
be made. Any bronchial injuries should be detected during the 
surgery and appropriately fixed. Bleeding can also occur from 
the pulmonary parenchyma, especially after wedge resection in 
patients whose pulmonary arterial pressure is increased. For such 
patients, the staple lines should be oversewed meticulously as the 
elevated pulmonary arterial pressure may cause postoperative 
bleeding. Sometimes, lack of understanding of variations of in-
trathoracic anatomy can cause serious complications. Such structu-
ral variations should be acknowledged preoperatively by carefully 
reviewing the CT scans. According to a report from a dedicated 
thoracic surgical center, the catastrophic complications took place 
in 1% of patients, including main pulmonary arterial and main pul-
monary venous transection requiring reanastomosis, unplanned 
pneumonectomies, unplanned bilobectomy, tracheoesophageal 
fistula, membranous airway injury to the bronchus intermedius, 
complete staple line disruption of the inferior pulmonary vein, 
injury to the azygos/superior vena cava junction, and splenectomy. 
The third and perhaps the most important cause of intraoperative 
complication is negligence. Thus, establishment of standardized 
surgical protocol is mandatory in training hospital. Postoperative 
complications Common postoperative complications such as pro-
longed air leak, atrial fibrillation, aspiration and pneumonia can 
be treated by medical methods. The early postoperative course is 
often compromised by chylothorax. The initial treatment is to give 
nothing by mouth and wait until the chest tube drainage decre-
ases. However, if the chylothorax persists, reoperation with duct 
ligation should be considered. Empyema is an uncommon com-
plication after pulmonary resection. The key treatment principle is 
control of the pleural space, which can be established by lung ex-
pansion. If there is any question of a BPF, repeat thoracotomy with 
muscle or omental harvesting is mandatory to drain the empyema 
of them with a retrospective design. These studies are difficult to 
compare, because of different patient selection and drug sche-
dules. In the largest study patients were pretreated with various 
chemotherapy regimens, including pemetrexed-based regimens, 
while in the other studies all patients were pemetrexed-pretreated. 
Two studies included also patients treated beyond second line, 
while the others were pure second-line trials. Treatment schedules 
were different, and this was reflected by the higher hematologi-
cal toxicity in studies with the higher vinorelbine dose-intensity. 
Overall, response rate ranged from 0 to 15%, with disease control 
rates variable according to patient selection. When gemcitabine 
and vinorelbine were used in combination, no survival benefit 
was observed as compared to single-agent chemotherapy, with a 
higher (mainly hematological) toxicity. In conclusion, evidence for 
a benefit of second-line chemotherapy in MPM patients is weak, 
and should be confirmed in prospective studies. A few trials with 
new chemotherapeutic compounds (e.g. trabectedin) are ongoing. 
Ideally, future second-line trials in MPM should be designed as at 
least randomized phase II trial and according to strict eligibility 
criteria, mainly as far as pre-treatment is concerned (prior regimens 
and numbers of treatment lines). Patients should be stratified 
according to the outcome of first-line therapy and to known prog-
nostic factors (like EORTC prognostic score). Time-related events 
(median PFS or 3-month PFS) should be the primary endpoints. 
Finally, second-line setting is the ideal field for high-quality corre-
lative studies aimed to identify the patients who will benefit from 
treatment, and to improve the knowledge of MPM biology.
Keyword: mesothelioma, chemotherapy, second-line
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Abstract: According to Facebook executives, the social network 
reports 1.06 billion monthly active users. This number has been 
steadily increasing with a 25% increase in monthly users from 
last year and a rise of 28% in daily users. Now that we know the 
numbers what is happening in the world of patients. Though 
the premise exists that Facebook is strictly for social media 
networking, I wouldn’t hesitate to guess that patients, especially 
those who are home bound, spend an enormous amount of time 
on the web. Patients with rare diseases, in particular, have found 
Facebook to be a useful tool in finding others facing similar 
circumstances. PatientsLikeMe.com, launched in 2004, uses a 
number of tools to collect data and derives a hefty profit from 
selling this data to pharmaceutical companies as well as research 
institutions. It reports over 200K users on the site covering 1800 
diseases. It uses sophisticated questionnaires to gather data about 
its users. Another active social media network, 23andme.com 
promotes the selling of an at-home saliva kit to map out genetic 
codes. They provide users with interactive tools meant “to shed 
new light on your distant ancestors, your close family and most 
of all, yourself.” In 2013, this company spent up to $5 million in 
advertising, further demonstrating that healthcare on the web is a 
lucrative field. Law firms representing mesothelioma patients spent 
over $50 million in goggle keyword advertising in 2012, making 
mesothelioma the most expensive word in Google advertising. 
Many of the larger firms representing victims of asbestos have 
now also launched Facebook pages and groups. These are 
usually marketed as patient support and advocacy sites providing 
patients with support and referrals to both medical and legal 
professionals. To the unsuspecting patient, these sites appear to 
be either VA sponsored or true advocacy sites which could not be 
further from the truth. Do you really want your patients to receive 
medical advice and referrals from representatives of legal entities 
or other for-profit operations with secondary motives? Nurses are 
the most trusted professionals valued by the public according 
to numerous surveys. Who is better equipped to engage with 
patients in social media and help them to understand the “rules 
of engagement”? The median age for the diagnosis of lung 
cancer is 72 and for mesothelioma 70. People in their 70s are 
less likely to be knowledgeable about the risks vs. the benefits 
of engaging in social media networking. We are all too familiar 
with the patient or family members who present to the office 
armed with paperwork obtained during web searches. Some of 
the information is valuable, but much is not applicable to their 
current situation and some is entirely misleading. An inordinate 
amount of time is consumed by those affected by the disease and 
the practitioner sorting through and commenting on relevancy of 
such information. I would suggest that if a nurse could guide their 
navigation of the web and provide accurate medical information 
and to decorticate the lung, and to buttress the open bronchus. 
Superficial wound infections are managed with antibiotics, drai-
nage, and local wound care. Management options of deep sternal 
infection include sternal debridement or sternectomy, prolonged 
open wound care or irrigation, muscle flap reconstruction, or some 
combination of these. Postpneumonectomy bronchopleural fistula 
(BPF) is difficult-to-manage. Management is determined by the 
timing of complication, the condition of the patient, and the pre-
sence or absence of empyema. Patients should be positioned with 
their operated side down. Chest tube drainage of the empyema 
should be performed. For repair of the bronchus, a long stump can 
be resected and closed primarily if the BPF took place in the early 
postoperative period. In some cases, primary closure of postpneu-
monectomy BPF may not be tenable. In such situations, the bron-
chial leak point can be closed with a vascularized flap. Sterile or mi-
nimally contaminated cavities can be irrigated, filled with antibiotic 
solution, and then closed. Eloesser flaps are ideal for long-term 
open drainage and irrigation. Alternatively, after the pleural cavity 
is granulating and healthy, it can be filled with antibiotic solution 
and closed. Rarely, BPFs have been managed nonoperatively with 
endoscopic techniques combined with antibiotics. Residual space 
after lobectomy can also occur. Intraoperative maneuvers to lessen 
the risk for space problems include pleural tents, phrenic nerve 
crush, muscle or omental transposition, thoracoplasty, and pneu-
moperitoneum. If a patient is clinically well, continued observation 
and antibiotics are appropriate while the space fills. Lobar torsion 
is one of the most serious complications and commonly affects the 
right middle lobe after right upper lobectomy. Visual confirmation 
of anatomic position and proper lung inflation allows detection of 
twisted or ischemic lung before closure. The lung may be salva-
geable if the torsion is recognized early, before infarction occurs. 
However, usually the diagnosis is late, and resection is required. 
Postpneumonectomy syndrome is caused by displacement and ro-
tation of the mediastinum into the operated chest. The remaining 
main stem bronchus is stretched and compressed over the spine or 
aorta. Surgical treatment principle is to reposition the mediastinum 
by placing intrathoracic prosthetic implants, which will relieve the 
airway compromise. Sleeve lobectomy or other bronchoplastic 
procedures may result in late airway stenosis. Repeated dilations 
sometimes stabilize strictures but usually the effect is temporarily. 
In some cases, reoperation is necessary. If the stenosis resulted 
from Kinking of the anastomosis, resection and re-anastomosis 
may fix the problem. Usually, a completion pneumonectomy may 
be necessary. A fistula between the airway and pulmonary artery 
occur after bronchoplasty or tracheal resection. If a fistula is appa-
rent, emergency surgery should be performed. The mortality rate 
of bronchovascular fistulas is high. Tracheoesophageal fistula can 
develop with prolonged intubation and mechanical ventilation. 
Surgical repair should be attempted after the patient‘s condition is 
optimized, and the patient is breathing spontaneously. Chest wall 
graft infection can happen even several years after chest wall re-
section and reconstruction. When chronic, often times, soft tissue 
flap support may be sufficient to obviate skeletal reconstruction. 
Conclusions An appropriate patient selection and meticulous sur-
gery are the best prophylaxis against postoperative surgical com-
plications. When complications arise, they require an experienced 
surgeon for identification and correction. Furthermore, training of 
surgical techniques, sound knowledge of anatomical variations, as 
well as stringent observances of surgical principle are mandatory 
to overcome intraoperative complications.
Keywords: surgery, Complication, morbidity, Mortality
S101Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
NURSING GOES GLOBAL - MEETING THE CHALLENGES POSED BY 
MESOTHELIOMA  
TUESDAY, OCTOBER 29, 2013 - 07:00-08:00
MTE17.3 SURGICAL OPTIONS AND GLOBAL  
DIFFERENCES
Jocelyn Mclean
Royal Prince Alfred Hospital/Australia
Abstract: Malignant Pleural Mesothelioma is a global challenge for 
heath professionals, and the role of surgery is key to that challen-
ge. Surgery has a palliative function and a curative function. The 
palliative function is to drain the fluid, take a biopsy, optimise lung 
re-expansion, and prevent fluid recurrence by pleurodesis. Video 
assisted thoracoscopy (VAT) is the palliative operation of choice 
because it is less painful, has a reduced hospital stay, and the sur-
geon can assess the chest cavity for suitability for more aggressive 
treatment. An important predictor for a successful VAT pleurode-
sis is lung re-expansion after initial pleural drainage assessed by 
radiology and a patient response of “I can breath now.” If pleu-
rodesis is ineffective and the fluid recurs, or if lung entrapment 
prevents lung re-expansion, then open surgery via thoracotomy 
with partial or subtotal pleurectomy / decortication should be 
considered, providing the patient is medically fit and has a reaso-
nable life expectancy. Partial pleurectomy /decortication is more 
invasive, has an increased potential for prolonged air-leak, is more 
painful and has a longer recovery period, however the patient may 
benefit from an improved quality of life, living without symptoms 
related to lung entrapment. Brancatisano (1991) reported our ex-
perience of 50 patients having partial pleurectomy / decortication. 
The median survival was 16 months with a range of 3 to 54 months 
and 21% of patients survived more than two years. The curative 
role is less defined. Surgical resection is the curative treatment 
option for most solid malignant tumours and this ideal underpins 
the practice of surgeons treating MPM. Cytoreductive surgery, to 
reduce the burden of disease and prolong disease free living by 
complete macroscopic surgical resection is offered to patients with 
early disease in some centers. Here lies the key challenge. There 
are differing operative techniques aiming for the same outcome: 
extrapleural pneumonectomy, EPP, and lung sparing pleurectomy/
decortication, EPD EPP, offered since the 1970s, involves complete 
resection en bloc of the lung, parietal pleura, ipsilateral pericardi-
um, and ipsilateral hemi-diaphragm, along with complete excision 
of thoracic lymph nodes. Defects of the pericardium and hemi-
diaphragm are repaired with Gortex mesh to prevent cardiac and 
visceral herniation. An early publication reported an unacceptable 
morbidity and mortality of 45% and 31%respecively (Butchart, 
1976). David Sugarbaker, determined to improve patient survival, 
continued offering EPP but high recurrence rates proved surgery 
alone provided little benefit to survival. With persistence, his team 
offered EPP in combination with chemotherapy (prior to pemetrex-
ed) and radiotherapy. In 1991 Sugarbaker reported survival rates 
of 70% at one year and 48% at two years. Morbidity and mortality 
rates were 19% and 6% respectively. This multimodality treatment 
required surgery to reduce tumour bulk, while chemotherapy and 
radiotherapy treated micro-metastatic disease. In 1996, Sugar-
baker again reported similar results but added that epithelial cell 
types had better survival rates compared to sarcomatoid or mixed 
histology tumours. Other centres around the world reported indi-
vidual surgical series each contributing to a collection of experi-
ences. Weder (2007) reported on 45 EPP trimodality patients and 
found epithelial cell type had better survival. Cao (2010), attemp-
ted to evaluate the safety and efficacy of EPP found an overall sur-
vival of 13 – 23.9 months and concluded/confirmed that selected 
patients might benefit from EPP especially when combined with 
and accurate interpretation of this information, the patient and 
their representatives as well as the provider could have a more 
focused discussion. Social media provides a unique opportunity to 
capture large numbers of patients and their advocates which can 
be used as a tool for both education and support. It would be the 
role of the nurse to explain the workings of the platform and to set 
guidelines to assist in protecting privacy to the degree possible 
when engaging on these sites. Patients need to understand the 
potential consequences of engaging in online health-related 
discussions and must be willing to accept the risks associated with 
membership in a group. It is fairly common for potential employers 
to peruse Facebook pages to gather additional background 
information on future employees. It could certainly be feasible 
that health insurance companies, especially if a dispute arises, 
might also turn to social media for information. Patients should be 
encouraged to read the privacy policy on these sites and an open 
dialogue about privacy within the group should be an ongoing. 
Patients themselves are the driving force in this healthcare-
related online movement. As a result, hundreds of groups run 
by patients are available for others to join and this is where this 
trend can become problematic. Patients with the loudest voice 
on Facebook, or perhaps the miracle responders, can sway a 
captive patient group into potential risky decisions with the best 
of intentions. Groups starting off as support groups can quickly 
and unexpectedly have their conversations shift toward sharing of 
medical information and practice. As nurses, we know that patients 
need to be fully informed without bias to be able to practice good 
decision-making. Nurse-led groups can promote support and 
can help to guide the conversation to avoid misinformation or 
“cyber opinion bullying” by the strongest patient leader. Nurses 
can designate a peer group leader but promote their role within 
the group as the medical monitor. This provides an opportunity 
to gently correct misinformation and present new medical 
information to the group thus maintaining professionalism and the 
integrity of the group. Patients with rare diseases are often isolated 
and local support groups may not be applicable to their particular 
situation. Patients in these groups often express relief that they 
are able to connect with others in similar circumstances. However, 
connecting with others in this manner can be bittersweet. The 
group can celebrate the victories but will also mourn setbacks 
and death of group members. Having a nursing professional in 
the group provides access to a trained individual who can assist in 
emotional healing as well as recognize and refer if group members 
need one on one counseling. In cancer, less than 10% of all 
patients enroll in clinical trials. As nurses we can educate patients 
about clinical trials and promote participation in such trials. Cancer 
patients are seeking knowledge on the web, and as educators, it is 
our role to see that this need is met. 
Keywords: social media nursing role, Risks and Benefits of Social 
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Abstract: Staging: Positron emission tomography (PET) using the 
radiopharmaceutical, 18F-2-deoxy-D-glucose (FDG), a D-glucose 
analog, is useful in the detection of nodal (N) and extrathoracic 
metastases (M1b) in patients with non-small cell lung (NSCLC). 
FDG-PET has a higher sensitivity (83%) and specificity (92%) than 
CT in the detection of nodal metastases. However, a commonly 
encountered dilemma occurs when nodal imaging is discordant i.e. 
in patients with NSCLC and small nodes on CT and a positive PET, 
the predicted post-test probability of N2 malignancy is 62% and 
when the nodes are >16-mm and the PET is negative, the post-
test probability of N2 malignancy is 21%. When the findings are 
concordant (enlarged nodes on CT and positive PET) the post-test 
probability of N2 malignancy is 90%. Accordingly, FDG-PET is usu-
ally used to direct invasive nodal staging. Metastatic disease (addi-
tional nodule/s in the contralateral lung, pleural nodules, malignant 
pleural or pericardial effusion (M1a) and extrathoracic metastasis 
(M1b)) are common in patients with NSCLC at presentation. Whole-
body FDG-PET imaging improves the accuracy of staging and has 
a higher sensitivity and specificity than CT in detecting extratho-
racic metastases although many solitary FDG-avid extrathoracic 
lesions are unrelated to the NSCLC. The American College of Sur-
geons Oncology Trial reports PET sensitivity, specificity, positive 
predictive value and negative predictive values of 83%, 90%, 36% 
and 99%, respectively for M1 disease. Importantly, whole-body 
PET imaging is useful in the detection of occult extrathoracic meta-
stases in patients considered resectable by standard imaging and 
clinical evaluation and prevents inappropriate resection in up to 
20% of these patients. Response: PET is being evaluated in the as-
sessment of therapeutic response and may allow an early and sen-
sitive assessment of the effectiveness of anticancer chemotherapy 
as FDG uptake is not only a function of proliferative activity but is 
also related to viable tumor cell number. FDG-PET/CT can predict 
early response to therapy in patients with stage IIIB-IV NSCLC who 
receive standard chemotherapy or molecular-targeted therapy. 
Early metabolic response (after one cycle of systemic therapy) 
has a significant correlation with best overall response. FDG-PET 
has also been reported to be useful in the assessment of therapy 
response and preoperative re-evaluation after neoadjuvant radio-
chemotherapy in stage III non-small cell lung cancer. Additionally, 
in patients with advanced NSCLC, FDG-PET can potentially be 
useful in identifying a subgroup of patients that would benefit from 
maintenance treatment after completion of first-line chemothera-
py. Furthermore, FDG-PET can be useful in the assessment of early 
response during radiotherapy with respect to overall survival in 
patients with NSCLC. While FDG-PET/CT assessment may be use-
ful in the prediction of early treatment response, progression-free 
survival and overall survival in NSCLC, the response to therapy and 
neoadjuvant chemo and adjuvant radiotherapy. Controversy about 
the ability of EPP to affect a cure or contribute to improved survi-
val was to be sorted by the UK Mesothelioma and Radical Surgery 
feasibility study known as the MARS trial. This randomised control 
trial concluded that EPP offers no benefit and possibly harms pa-
tients. Surgeons, skilled at performing EPP and who had reported 
their results vehemently opposed this conclusion. The only centre 
in Australia offering trimodality therapy reported 70 patients ha-
ving EPP between 1994 and 2008, having a median survival of 20 
months, and morbidity and mortality of 37% and 5.7% respectively 
(Yan, 2009). Pleurectomy / decortication or P/D was the other 
preferred operation as some surgeons questioned the morbidity 
and mortality of EPP. Valarie Rusch (1993) pioneered P/D in order 
remove all visible and palpable tumours and achieve macroscopic 
complete resection. Other surgeons varied this procedure ma-
king comparing results difficult so specific terminology was used 
to describe 3 approaches. 1) Extended or radical pleurectomy/
decortication (EPD); parietal and visceral pleura is resected along 
WITH diaphragm and pericardium. 2) Pleurectomy/decortication 
(PD); parietal and visceral pleura is resected WITHOUT diaphragm 
and pericardium. 3) Partial pleurectomy/visceral decortication as a 
palliative procedure. Individual cancer centers have reported case 
series. Flores (2008) compared EPP to pleurectomy / decortication. 
Nerangi-Miandoab (2008) reported epithelial cell type was a pre-
dictor of survival in patients having pleurectomy / decortication 
compared to no surgery. Nakas (2008) concluded patients not sui-
table for EPP should be offered radical P/D. Zahid (2011) found P/D 
may improve survival but at the expense of increased morbidity 
and is best offered to patients enrolled in prospective trials. Global 
differences related to the role of surgery in cytoreductive therapy 
relate to what radical surgical procedure provides the best chance 
of extended disease free survival. Is it EPP, lung sparing EPD, or 
P/D? What is certain is that EPP and EPD should be offered as part 
of trimodality therapy. Furthermore, the procedure must be per-
formed by an experienced surgeon, and supported by a team with 
proven expertise and experience to care for these patients. Rusch 
(2012) reminds us that the role of surgery in the management of 
MPM remains controversial but it also remains a treatment option 
because of the limited benefits of radiotherapy and chemotherapy. 
Surgery is offered either as a palliative procedure or with curative 
intent. There is little need for debate about the palliative option 
but debate about curative intent continues. Finally, while global 
differences are important, what is learnt from collective experien-
ces is more important. There is an urgent need to identify patients 
with favourable prognostic factors, suitable for cytoreductive the-
rapy. We need to provide support, hopeful encouragement, and 
equitable access to multi modality treatment because there is a 
growing number of well living long-term survivors. 
Keyword: mesothelioma, surgery,
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Abstract: Thymic epithelial tumors represent a wide range of 
anatomical, clinical, histological, and molecular malignant entities, 
which may be aggressive and difficult to treat. The histopathologi-
cal classification distinguishes thymomas from thymic carcinomas. 
Our current understanding of the carcinogenesis of these tumors 
remains limited; only few well-characterized preclinical models 
- mostly consisting of thymic carcinoma cell lines -, have been es-
tablished. Several biomarkers studies have been reported; while 
tumor stage, completion of surgical resection, and - to a lesser 
extent – histology have been shown to significantly predict the 
outcome of patients, the expression of EGFR, KIT, or IGF1-R by 
immunohistochemistry failed to consistently demonstrate a prog-
nostic value on the survival of patients. More recently, expression 
signatures have been reported, both for thymomas and thymic car-
cinomas, to correlate with metastasis-free survival; these results re-
main to be validated in separate cohorts, while prospective study 
to understand the clinical significance of these results will be requi-
red. The management of thymic epithelial tumors is a paradigm of 
cooperation between clinicians, surgeons, and pathologists from 
establishing the diagnosis to organizing the multimodal therapeu-
tic strategy. Chemotherapy may be used in two clinical scenarios in 
thymic epithelial tumors: 1) chemotherapy may constitute primary 
part of the multimodal curative-intent treatment of locally-advan-
ced tumors, and is subsequently combined with surgery or radio-
therapy; the main objective is to achieve long-term survival with no 
evidence of tumor recurrence; 2) chemotherapy may be delivered 
as the sole treatment modality in unresectable, advanced, meta-
static, or recurrent tumors; then a palliative-intent treatment, the 
aim is to improve tumor-related symptoms through achievement 
of tumor response, while no prolonged survival is expected. Novel 
treatment strategies are needed, especially for refractory, recur-
rent tumors, and thymic carcinomas, which carry a poor prognosis 
despite multimodal treatment. Potentially druggable targets are 
emerging, laying the foundations to implement personalized me-
dicine for patients. Given the currently available targeted agents 
outside of a clinical trial, the signaling pathways that are relevant in 
the clinical care of patients are the KIT and the Vascular Endothelial 
Growth Factor (VEGF)-R (Receptor) pathways. Several tyrosine ki-
nase inhibitors targeting KIT have been developed - including ima-
tinib (Novartis, Basel, Switzerland), sunitinib (Pfizer, New-York, NY), 
and sorafenib (Bayer, West Haven, CT) - , most of which also po-
tently inhibiting other kinases, including VEGFRs and Platelet-De-
rived Growth Factor Receptors. Collectively, KIT is overexpressed 
in 80% of thymic carcinomas, while KIT gene mutations are found 
only in 9% of cases. Clinically, KIT-mutant thymic carcinomas then 
represent a small molecular subset of thymic tumors. The clinical 
relevance of KIT mutations is more limited in thymic carcinoma 
than in other cancers like gastro-intestinal stromal tumor (GIST), as 
1) KIT mutations are far less frequent; 2) KIT expression does not 
survival is multifactorial with stage at presentation, performance 
status and genomic patterns influencing outcome. It is not certain 
whether FDG-PET in patients with NSCLC will provide reliable and 
routinely applicable clinical information in terms of therapeutic 
response. Restaging: In patients with recurrent malignancy after 
attempted curative treatment of NSCLC, repeat resection, salvage 
chemotherapy, or radiotherapy are therapeutic options. FDG-PET 
can detect local recurrence of tumor after definitive treatment with 
surgery, chemotherapy, or radiotherapy before conventional ima-
ging and has been reported to have a sensitivity of 98-100% and 
specificity of 62-92%. In one recent prospective study of patients 
with NSCLC who had undergone surgical resection, PET was able 
to detect tumor recurrence (sensitivity 93%, specificity 89%, and 
accuracy 92%) and predict which patients would benefit most from 
surgical retreatment. Additionally, in patients with NSCLC treated 
with radical radiotherapy, FDG-PET performed a median of 70 
after completion of radical radiotherapy was useful in the assess-
ment of therapeutic response.
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Abstract: Malignant mesothelioma is an uncommon malignancy 
that may involve the pleura, peritoneum or pericardium. Mesothe-
lioma may assume a variety of histological appearances ranging 
from epithelial to sarcomatoid to mixed. Because of its histologic 
similarity to a variety of other malignancies and because other 
malignancies may metastasize to serosal membranes, the diagno-
sis of mesothelioma may be challenging. A variety of immunohis-
tochemical stains have been developed to aid in the distinction 
between mesothelioma and other malignancies with which it may 
be confused. It is currently recommended that at least two positive 
(mesothelial) and two negative (carcinomatous) markers should be 
used. The differential diagnosis may differ depending on the parti-
cular histologic pattern under consideration and the location of the 
tumor. This will in turn affect what immunohistochemical panel is 
chosen. It is also recommended that the markers used should have 
a specificity and sensitivity of at least 80%. For epithelial pleural 
mesothelioma, the main differential diagnostic consideration is 
adenocarcinoma of the lung. For such cases the author uses a 
panel of four positive markers and two negative markers. Positive 
markers include calretinin, cytokeratins 5/6, WT-1 and D2-40. Ne-
gative markers include carcinoembryonic antigen (CEA) and TTF-1. 
The author has used this panel since 2004 and has had experience 
with more than 500 mesotheliomas to date. Epithelial pleural me-
sotheliomas were positive for calretinin in 98% of cases, and this 
was the most sensitive mesothelial marker. Cytokeratins 5/6 and 
D2-40 were each positive in 92% of cases, and WT-1 was positive 
in 91% (nuclear staining only counted). For the negative markers, 
pCEA was positive in 10% and TTF-1 in 0.5% (nuclear staining only 
counted). More recently we have used mCEA and thus far have 
not identified any positive cases. We have seen some cases where 
mesothelioma was confused with squamous cell carcinoma. Cy-
tokeratins 5/6 are not useful in this scenario since nearly all squa-
mous cell carcinomas are positive for this marker. Similarly, TTF-1 
is not useful since squamous cell carcinomas are expected to be 
negative. For this differential diagnosis, WT-1 and p63 (or p40) are 
a good pair of nuclear markers to use. Biphasic pleural mesothelio-
mas are more poorly differentiated so it is not surprising that one 
often observes a drop-out of one or more of the positive meso-
thelial markers in these tumors. We find calretinin positivity in 92% 
with positive staining for D2-40 in 83%. The corresponding values 
for WT-1 and cytokeratins 5/6 are 80% and 78%, respectively. CEA 
was positive in only 4% and none was positive for TTF-1. If one 
grades the intensity of staining, the epithelial tumors show higher 
scores on average than the biphasic. Peritoneal mesotheliomas 
usually involve a different set of diagnostic considerations. Since 
lung cancer is unlikely to be in the differential, TTF-1 has limited 
usefulness in this setting. Similarly, many of the tumors in the ab-
domen with which mesothelioma may be confused are negative for 
CEA. Therefore our panel for peritoneal tumors includes the same 
four positive markers noted above, and we substitute B72.3 and 
BerEP4 as negative markers. Epithelial peritoneal mesotheliomas 
correlate with the presence of KIT mutation; and 3) non-pretreated 
KIT mutants are not uniformly sensitive to imatinib, based on the 
clinical and/or the preclinical evidence in thymic carcinoma and/
or other KIT-mutant tumors. These findings may explain why the 2 
reported phase II trials with imatinib, where patients were not se-
lected, or selected based upon histologic type (B3 thymomas and 
thymic carcinomas) or KIT staining by immunohistochemistry, and 
not upon KIT genotyping, were negative. Multi-kinase inhibitors 
may also be of interest to target neoangiogenesis. The most po-
tent pro-angiogenic molecules are those of the VEGF/VEGFR sig-
naling pathway. VEGF-A and VEGFR-1 and -2 are overexpressed in 
thymomas and thymic carcinomas. Micro-vessel density and VEGF 
expression levels have been shown to correlate with tumor invasi-
on, aggressive histology and clinical stage. In a phase II trial, beva-
cizumab was tested in combination with erlotinib in thymomas and 
thymic carcinomas. No tumor response was observed. Interestin-
gly, despite the large tumor burden of thymic tumors and the fre-
quent abutment to mediastinal vascular structures, no hemorrhagic 
side effect has been reported with the use of these drugs in these 
studies. Beyond the inhibition of KIT, sunitinib and sorafenib also 
inhibit VEGFR-1, VEGFR-2, VEGFR-3 at the nanomolar range. The 
effect of these drugs, especially in KIT-wild-type thymic carcinoma 
tumors may then be partially related to an anti-angiogenic effect. 
Promising new targets in thymoma and thymic carcinoma include 
IGF-1R and histone-deacetylase. Cixutumumab, an IGF1-R directed 
monoclonal antibody was recently reported to produce a promi-
sing 90%-disease control rate in refractory thymomas. Belinostat, a 
histone deacetylase inhibitor was evaluated in thymic malignancies 
in a recently completed phase II trial enrolling 41 patients (25 thy-
momas and 16 thymic carcinomas). Response and 2-year survival 
rates were 8% and 77% in thymomas. Given the rarity of the tumor, 
translation of pre-clinical findings to the clinic may be quick; seve-
ral strategies have been implemented. A pragmatic approach is 
the recommendation for KIT genotyping in clinical practice, what 
represents a model of n-of-one trial approach in the field. Ano-
ther approach to validate the concept of personalized medicine 
in thymic malignancies includes the development of open-label 
multicentric phase II trials, using high throughput genome analysis 
(CGH array, next generation sequencing) as a therapeutic decisi-
on tool, to compare a medical treatment administered according 
to the identified molecular anomaly of the tumor with a medical 
treatment administered without considering the genome analysis; 
thymic tumors have been integrated in some ongoing trials using 
such methodology. A third approach is to promote the enrollment 
of patients with refractory thymic tumor in phase I trials, what may 
lead to identify new molecular pathways of therapeutic interest; 
mTOR is emerging as a potential target, following tumor responses 
observed in phase I trials, with recent data from several groups. 
Along with the large variety of questions relative to the treatment 
strategy, thymic epithelial tumors represent a model of therapeutic 
implementation and achievement; in this setting, regional and in-
ternational collaborative initiatives are mandatory to progress both 
in the understanding of the biological mechanisms underlying the 
development of thymic malignancies, and in the identification and 
validation of new targets with prognostic and predictive value.
Keywords: thymoma, Thymic carcinoma, chemotherapy, Targeted 
therapy
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Abstract: Novel therapeutic targets have been revealed in lung 
cancer through the use of systematic large-scale sequencing ap-
proaches. While some of these are already part of routine clinical 
care, others still await confirmation in clinical trials. I will discuss 
basics of lung cancer genomics, differences in targets and target 
candidates in lung adenocarcinoma, squamous cell lung cancer 
and small cell lung cancer and problems arising during the path of 
translating basic discoveries into clinical practice.
are positive for calretinin in 98% of cases, identical to pleurals. Po-
sitive staining for WT-1 and D240 is seen in 91% of cases, and 89% 
are positive for cytokeratins 5/6. BerEP4 was focally positive in 9% 
of peritoneal mesotheliomas but B72.3 was uniformly negative. For 
biphasic peritoneal mesothelioma, calretinin is positive in 80% and 
cytokeratins 5/6 positive in 75%. Only 60% were positive for D2-
40 and 50% for WT-1. None of the biphasic peritoneal cases was 
positive for B72.3 or BerEP4. Peritoneal mesotheliomas in women 
present a special diagnostic problem since many of the malignan-
cies involving the peritoneal cavity in women stain for one or more 
of the mesothelial specific markers. For this reason, we add estro-
gen and progesterone receptor immunohistochemical staining to 
the panel for peritoneal mesothelioma in women. Strong diffuse 
nuclear staining for these markers would favor a diagnosis of ova-
rian carcinoma over mesothelioma. Also, histochemical staining 
for PASD is useful in this setting. We also use a broad spectrum 
cytokeratin marker in our panel, with cytokeratins positive in 100% 
of our epithelial or biphasic pleural and peritoneal mesotheliomas. 
The intensity of staining for these broad spectrum cytokeratins was 
a little greater for epithelial as compared to biphasic mesothelio-
mas. Complete absence of staining for cytokeratins in an epithe-
lioid serosal based malignancy should alert the pathologist to the 
possibility of melanoma, lymphoma or epithelioid hemangioen-
dothelioma and appropriate follow-up immunostains examined to 
rule out these considerations. Sarcomatoid mesotheliomas account 
for 16.5% of our cases, and these are the least differentiated form. 
This is reflected in their immunohistochemical profile, which is typi-
cally negative for mesothelial specific markers. For example, in 76 
cases of sarcomatoid mesothelioma, we found positivity for calre-
tinin in only 47% and D2-40 in 55%. The other two markers we use 
in the sarcomatoid panel are vimentin (95%) and broad spectrum 
cytokeratins (92%). Vimentin is important as an antigenic preser-
vation marker: if vimentin is negative in a sarcomatoid tumor, then 
one should suspect poor tissue preservation with less concern for 
a negative keratin stain. Strong diffuse staining for cytokeratins is 
the most useful marker for sarcomatoid mesotheliomas. However, 
sarcomatoid carcinomas may be similarly positive, so one should 
pay close attention to the gross distribution of tumor in these 
cases. Although diffuse and moderate to strong staining for cyto-
keratins was seen in more than 70% of our sarcomatoid mesothe-
liomas, it should be noted that focal staining or less intense stai-
ning may also be seen in some cases. REFERENCES: Husain AN, 
Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of 
mesothelioma: 2012 update of the consensus statement from the 
International Mesothelioma Interest Group. Arch Pathol Lab Med 
137: 647, 2013. Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid 
mesothelioma: a clinical-pathologic correlation of 326 cases. Mod 
Pathol 23: 470, 2010. Churg A, Cagle PT, Roggli VL. Tumors of the 
Serosal Membranes, AFIP Atlas of Tumor Pathology, Series IV, Fas-
cicle 3, American Registry of Pathology: Washington, DC, 2006.
Keyword: Mesothelioma, immunohistochemistry, differential dia-
gnosis
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and identifies elevated metabolic activity. Nodule enhancement is 
an indication that a nodule is more likely malignant than benign, 
and absence of enhancement is a strong predictor that a nodule 
is benign. In a multicenter prospective study reported that FDG-
PET had an overall sensitivity of 92% and a specificity of 90% for 
detecting malignant nodules, yet the sensitivity fell to only 80% 
when nodules of 15 mm or smaller were analyzed. A meta-analysis 
of pulmonary nodules showed that PET had a sensitivity of 94% 
and a specificity of 86%. The lower limit of solid nodule size for 
PET applicability using current techniques is about 8-10 mm. A 
growing nodule that shows no enhancement on PET should still be 
considered suspicious for malignancy and prompt needle biopsy 
or resection. If multiple nodules are present, then evaluation is 
dictated by the largest nodule. Observation may be appropriate 
for patients with nodules that are larger than 8-10 mm and have a 
low likelihood of malignancy based lack of enhancement. Whether 
or not an indeterminate nodule > 8-10 mm should be biopsied is 
the subject of considerable debate and practices vary. The two 
biopsy techniques for assessment of nodules are bronchoscopy 
and transthoracic needle aspiration (TTNA). Bronchoscopy with 
fluoroscopy alone has a yield of less than 20% in the setting of 
malignant nodules less than 2 centimeters and in the range of 40-
60% when the nodule is 3-4 cm. Studies of guided bronchoscopy 
using endobronchial ultrasound and/or electromagnetic guidance 
have shown marked improvements in diagnostic yield over stan-
dard fluoroscopic guidance. Studies using one or more of these 
techniques have shown yields of 60 to 80% of peripheral nodules 
of a mean diameter of 2- to 25 mm. Yields remain highest with 
TTNA; multiple studies report yields of 90% and above for nodules 
< 2 cm and 95% for nodules > 2 cm. Pneumothorax is the most 
frequent complication of TTNA. Likelihood of obtaining a specific 
diagnosis in the setting of a benign lesion is problematic for both 
bronchoscopy and TTNA. Decision as to the method of biopsy 
involves lesion size, location, presence of a bronchus leading to the 
lesion, and comorbidities. Preoperative diagnosis may not be nee-
ded for lesions that show growth or are nearing 3cm and are PET 
avid due to the high likelihood of malignancy and low likelihood a 
biopsy is going to provide a specific benign diagnosis. An excepti-
on would be in countries where there is a high prevalence of tuber-
culosis where sampling may remain appropriate. Resection is the 
ultimate management for many lesions that remain indeterminate 
after imaging evaluation especially in a high risk individual. There 
are currently too many benign nodules removed surgically. Series 
of video assisted thoracic surgery (VATS) have reported benign no-
dules representing as high as 50-86% of nodules resected. Reduc-
tion in benign nodule resections may be achieved by observing 
smaller nodules, by utilizing PET-CT, and by performing biopsy by 
TTNA or bronchoscopy when information is discordant.
Keywords: Pulmonary nodule, ground glass nodule, Lung cancer
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Abstract: A Practical Approach to the Incidental Pulmonary No-
dule David Midthun, M.D. David Milne, M.D. The finding of a pul-
monary nodule (or multiple nodules) on an imaging study presents 
a decision point for the patient and physician. In the absence of a 
completely sensitive and specific non-invasive test for malignancy, 
the physician and patient must weigh the options for management. 
The vast majority of such nodules are benign; however the detec-
tion of a nodule may be the first and only point in time of a chance 
of cure in the patient with lung cancer. Guidelines for nodule evalu-
ation by the American college of Chest physicians (ACCP) and the 
Fleischner Society may help guide the decision making. Studies of 
lung cancer screening have shown high rates of nodule detection 
and that the rate is related to the CT slice thickness (collimation) 
used. Screening with 10 mm collimation results in detection of 
one or more nodules in approximately 20-25% of participants, 5 
mm collimation increases this to 40-50% of participants, and 1.25 
mm collimation raises detection to as high as 60%. A review of 
the data from 8 CT studies in high risk patients (current or former 
smokers, age 50 or above) reported that likelihood of malignancy 
was 0 to 1% for nodules < 5 mm, 6 to 28% for nodules 5 to 10 mm, 
33 to 60% for nodules > 11-20 mm, and 64 to 82% for nodules 
> 20-30 mm. The finding of a nodule on CT should first prompt 
review of any available old images that might include the nodule 
for comparison. Review of old images may show that the nodule is 
growing or, alternatively, establish that it has been stable for 2 or 
more years. Stability in size over a two-year period has been esta-
blished as an excellent indicator of benignancy for a solid nodule. 
If old images are not available, nodules < 8 mm may be observed 
with follow-up CT at an interval determined by the nodule size. 
Evidence for nodule growth is a hallmark of malignancy and should 
lead to a staging PET-CT scan (in those who are candidates for 
surgery) and consideration of prompt resection. Calcification in a 
benign pattern is an excellent indicator that a nodule is a granu-
loma and needs no further pursuit. Eccentric calcification should 
maintain concern for malignancy. Ground-glass nodules (GGN) are 
nodules of low density (attenuation) that are generally only visible 
by CT scan. They deserve special mention as they may represent 
low-grade adenocarcinomas which behave differently than most 
malignancies presenting as solid nodules. Malignant GGNs typi-
cally exhibit slow growth with doubling times on average over 400 
days and, for this reason, the 2-year stability rule for solid nodules 
doesn’t apply and a longer period of follow-up is needed. PET 
scanning is not helpful to distinguish malignancy due to the low 
density of the lesions, and needle biopsy is often nondiagnostic. 
GGNs may show growth or stay the same size yet develop a solid 
component in the process of progression. PET scanning uses the 
injection of the glucose analog 18F-2-fluorodeoxyglucose (FDG) 
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because of large intergroup inconsistencies. An individual patient 
data meta-analysis was performed, yielding an AUC of 0.77 re-
presenting the overall SM diagnostic performance. When SM was 
used to rule in or rule out diagnosis, the specificities and sensitivi-
ties were respectively 95% and 32% and 22% and 95%. SM has low 
specificity and is only selective for epithelioid and biphasic MPM, 
hampering its use as a stand-alone marker and possible replace-
ment of the current gold standard of invasive histopathologic dia-
gnosis. Hence a combination of several tumor markers might im-
prove the diagnostic performance. However, combining SM, OPN 
and MPF did not outperform the accuracy of SM alone and it is 
necessary to take GFR, BMI and age into account as confounding 
effects because they influence the biomarker levels. New markers 
like HMGB1 and fibulin-3 were investigated and were found upre-
gulated in patients sera compared to sera from healthy controls. 
Although both are promising, a long and cumbersome validation 
process will need to be executed comparing the accuracy of both 
biomarkers with serum SM. In the past, several programs have 
been conducted to screen asbestos-exposed individuals for lung 
disease with annual chest X-rays. Besides demonstrating the pre-
sence of benign asbestos-related diseases, these modalities have 
not proven to be effective at detecting early malignancies. CT has 
a superior sensitivity, and its use in screening has been examined 
in several large-scale studies (Table). Results predominantly illust-
rate the low prevalence of mesothelioma, and the high background 
noise (non-calcified nodules) in asbestos-exposed populations. 
In addition, the standardization of reading both chest X-ray and 
CT has proven to be difficult, while the cost and radiation doses 
represent other problematic issues. PET and MRI are currently not 
applied in screening, and their cost is likely to be prohibitive. Al-
together, it is now generally accepted that the use of imaging has 
not made any impact on the early detection of mesothelioma, and 
their use is not recommended by the different (inter)national gui-
delines. In the future, the ‘Holy Grail’ could be sniffed out thanks 
to the innovative field of exhaled breath analysis. Volatile organic 
compounds (VOCs) arise from the cells’ metabolism and are re-
leased in exhaled breath, making these promising diagnostic MPM 
markers obtained via high-throughput non-invasive techniques. 
Electronic nose (eNose) analysis has shown promising results for 
diagnosing MPM with diagnostic accuracies ranging from 80.8% to 
95% in discriminating MPM patients from asbestos-exposed and 
healthy individuals. However, eNoses work as blackboxes and do 
not identify VOCs as possible biomarkers. GC-MS analysis iden-
tified cyclohexane to discriminate MPM patients from asbestos-
exposed and healthy persons. Although this research field opens 
new perspectives for biomarker discovery, a lot of small-sized stu-
dies were performed in order to identify new biomarkers for scree-
ning, urging the need for large-scale validation studies. Although 
different routes of discovering biomarkers for early screening have 
been paved, the way to a validated and clinically useful screening 
biomarker panel still has to be constructed. Table: Prospective 
screening studies using chest CT in asbestos-exposed cohorts to 
detect asbestos-related malignancies.  
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Abstract: Malignant pleural mesothelioma (MPM) is an asbestos-
related disease with a very poor prognosis because of late-stage 
diagnosis due to unspecific imaging techniques and non-specific 
symptoms resembling pleural effusions such as chest pain and 
dyspnea. Early diagnosis could improve the disease’s outcome by 
reducing the diagnostic delay. Serum tumor biomarkers for early 
MPM screening are attractive because of their non-invasive and 
low-cost nature. Nevertheless, MPM is a heterogeneous disease 
suggesting an ideal biomarker should be capable of capturing all 
the MPM subtypes and to distinguish MPM from benign or me-
tastatic pleural conditions. To have a clinical impact, biomarkers 
should predict the development of the disease in which a positive 
test could enrich the at-risk population eligible for further scree-
ning and reduce the economical burden of wild screening. In order 
rule in MPM, a biomarker should have a positive predictive value of 
minimally 10%, and the low MPM prevalence urges the need for a 
high test specificity. Many candidate blood biomarkers have been 
studied such as hyaluronic acid, carcinoembryonic antigen, CYFRA 
21.1 and cancer antigen 125. Nonetheless, their accuracy is insuf-
ficient and based upon small-sized retrospective studies without 
further validation. Hence, they are of little use in clinical practice. 
More recently, the cell adhesion proteins soluble mesothelin (SM), 
megakaryocyte potentiating factor (MPF) and osteopontin (OPN) 
were investigated. OPN functions in cancer progression, bone 
matrix formation and immunologic responses. Despite 78% sensiti-
vity and 88% specificity found by Pass et al., subsequent validation 
studies revealed contradictory accuracy findings with AUCs ran-
ging from 0.64 to 0.89. Furthermore, OPN lacks specificity because 
it is overexpressed in other tumor types, limiting its use as a diag-
nostic mesothelioma marker. SM has been found the best available 
serum marker for MPM. It is derived from a mesothelin gene-
encoded precursor protein, which is cleaved into a soluble fraction 
(MPF) and a membrane-bound fraction (mesothelin) involved in 
cancerous growth, proliferation and migration and present on the 
pleural, peritoneal and pericardial mesothelial cells. SM enters the 
circulation by shedding of the membrane-bound mesothelin or 
frameshift mutations and is highly expressed in mesothelioma and 
other malignancies. The first determined serum MPF levels diffe-
rentiated MPM from healthy controls with 91% sensitivity and 100% 
specificity. Subsequent studies resulted in diagnostic accuracies 
with AUCs between 0.79 and 0.88. MPF and SM are highly correla-
ted and have equal diagnostic performances. SM was elevated in 
MPM patients compared to controls and had discriminative power 
with 84% sensitivity and 100% specificity. A commercial Meso-
MarkTM ELISA assay for SM was developed and evaluated by dif-
ferent groups gaining diagnostic accuracies with AUCs from 0.72 
to 0.81. The use of SM as diagnostic marker is still under debate 
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Abstract: Treatment of Cancer Cachexia over the next 5 years. 
The focus of this session will be on the emerging evidence for 
therapeutic approaches, outside anti-cancer treatments, that help 
clinicians care for patients and their families with anorexia cache-
xia syndrome. An overview of the basic pathophysiology will be 
presented to enable understanding of the diverse interventions 
studied as well as those that are currently under investigation. 
The challenge and importance of defining the syndrome will be 
discussed. It will also be important to discuss the drivers that are 
moving the sector towards the concept of categorising patients 
into pre-cachexia, established cachexia and refractory cachexia. 
This has implications about when to intervene and how the goals 
of interventions may change over time. This may help design bet-
ter matched cohorts for clinical trials, influence design of service 
models and alert us to the possibility of previous false negative 
studies. There will be a review of the prevalence of anorexia cache-
xia in various tumour streams and at different time points over the 
illness trajectory. The scope and scale of the clinical impact will be 
discussed in detail including the potential importance of symptom 
clusters, association with total symptom burden, links to fatigue 
and the evolving picture of the psycho-social distress that is com-
mon for suffers and their families or carers. Significant time will be 
dedicated to summarising the evidence base for pharmacological, 
nutritional and exercise approaches. The author will share his own 
experience in leading a dedicated inter-disciplinary cancer cache-
xia clinic over the last 9 years in Victoria and why he feels a multi-
modality approach should be adopted. Lastly an outline of what 
might represent best practice for the management of this syndro-
me over the next five years will be presented for open discussion.
Keyword: Cachexia, palliative care, anorexia,
Reference Total (n) Lung cancer (n) 
Mesothelioma 
(n) 
Tiitola et al. 602 5 1 peritoneal 
Vierikko et al. 633 5 1 pleural 
Fasola et al. 1045 9 - 
Mastrangelo 
et al. 
1119 5 - 
Roberts et al. 516 6 
2 pleural/2 
peritoneal 
Total 3915 30 (0.7%) 6 (0.2%) 
Keywords: mesothelioma, screening, CT scan, volatile organic 
compounds
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than early phase. Thus ideal radiation dose would be 60 to 66Gy, 
and lobectomy rather than pneumonectomy should be performed 
in trimodal treatment for stage IIIA N2 NSCLC. In this setting sur-
gery is performed following definitive CRT, and called as “salvage 
surgery.” There are few reports on the significance and feasibility 
of salvage surgery for lung cancer, and the indications should be 
limited. On the other hand, definitive CRT can control local disease 
at most 40% resulting in approximately 20% of long-term survival. 
Not a few patients die due to local disease without distant metas-
tasis. Recent randomized study on the feasibility of very high dose 
radiotherapy, RTOG 0617, showed inferiority of 74Gy to 66Gy, and 
better local control should be obtained only with additional surgi-
cal resection, i.e. salvage surgery. Methods Comprehensive review 
of the literature will be presented. Experience of salvage surgery 
at Juntendo Hospital was investigated and presented. Between 
February of 2008 and July of 2013, 1240 patients with lung cancer 
underwent surgical resection, which includes 20 salvage surgeries. 
Salvage surgery was performed in 10 patients following chemothe-
rapy, and 10 CRT. Majority of the mode of surgery was 6 pulmona-
ry lobectomies, including 3 sleeve resection, and 3 pneumonec-
tomies, including 1 sleeve pneumonectomy. The dose of radiation 
was 60Gy in 8 patients, 45Gy in 1 patient, and 140Gy in 1 patient 
who underwent proton and heavy particle radiotherapy. All cases 
underwent irradiation to the primary tumor and hilar and mediasti-
nal region. Surgical outcome was investigated. Results There were 
no surgical mortality. There were 3 postoperative morbidity inclu-
ding empyema, pneumonia and bronchopleural fistula (BPF). BPF 
developed following right side pneumonectomy following proton 
and heavy particle radiation for the primary and hilar region. This 
patient underwent open window and remain alive without evi-
dence of disease for 19 months. Sleeve bilobectomy of right midd-
le and lower lobectomy following 45Gy radiation was performed in 
1 patient, sleeve right upper lobectomy combined resection of the 
superior vena cava following concurrent CRT with 60Gy was per-
formed in 2 patients. Postoperative course for those patients were 
no problems at all. Postoperative bronchial healing was excellent. 
Conclusion Salvage lobectomy following high dose radiation could 
be feasible even performing radical resection of the superior vena 
cava or pulmonary artery.  
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Abstract: Background Standard treatment for stage IIIA or IIIB 
non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT). 
In patients with infiltrative stage III (N2) NSCLC and PS 0-1 being 
considered for curative-intent treatment, platinum-based chemo-
therapy and radiotherapy (60-66 Gy) are recommended based on 
the revised American College of Chest Physicians (ACCP) guideli-
nes for lung cancer. This guideline adopted new criteria for clinical 
N2 status, discrete and infiltrative N2 status. Infiltrative N2 means 
no radiolucency between nodes and surrounding organs, and usu-
ally considered to be unresectable unless combined resection not 
performed. Discrete N2 was defined as nodes having surrounding 
radiolucency on computerized axial tomogram (CAT). Surgery 
alone is not recommended for both clinical N2 diseases, based on 
several retrospective studies reported in 1990’s. Some cases would 
be candidates for upfront surgery followed by adjuvant chemothe-
rapy, but approximately 40% of patients with resected lung cancer 
cannot tolerate postoperative adjuvant chemotherapy. ACCP gui-
deline does not recommend surgery followed by chemotherapy, if 
N2 was verified preoperatively, which is reasonable for considering 
Thus preoperative treatment should be suitable for most clinical 
N2 NSCLC, if trimodal treatment is taken into consideration. As 
to a suitable preoperative treatment, induction chemotherapy is 
generally preferred to CRT, for pulmonary resection following CRT 
is believed to be more difficult and higher complication rate. How-
ever one of the major disadvantages for induction chemotherapy 
should be incomplete resection, which means losing local control 
for patients with N2 disease. In this respect induction treatment 
should include radiotherapy for infiltrative or discrete N2 NSCLC. 
The significance of surgery in N2 NSCLC is controversial. Rando-
mized controlled trial definitive CRT vs induction CRT followed by 
surgery, i.e. “Intergroup 0139 trial”, resulted in negative. Overall 
survival was not improved for surgery group. While in subset ana-
lysis lobectomy appeared to improve survival, pneumonectomy 
did not. This is partly due to a high mortality rate in pneumonec-
tomy group, which is a matter of debate. Some authors insisted 
that pneumonectomy is feasible following CRT with a low surgical 
mortality rate. Lessons from “Intergroup 0139 trial) were described 
in the recent ACCP guidelines as follows; 1) patients preferences 
and characteristics should be considered; 2) highlight the impor-
tance of minimizing harms, and surgery should be undertaken in 
a center with experience; 3) if there are reasons to be concerned 
about the ability of radiotherapy to achieve local control, surgery 
may have a benefit provided R0 resection is likely to be achieved; 
4) lobectomy is preferred to pneumonectomy following induction 
CRT. Dose of irradiation in surgery group is 45Gy, and in the other 
side of definitive CRT group 61Gy. Considering tumor biology un-
der radiotherapy, the difference of the doses cannot be negligible. 
Cancer cells tend to response in the late phase of radiation rather 
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Age/Gender Regimen 
Rt 
(Gy) 
Stage 
& Hist-
ology 
Discrete? Timing Operation Complications 
73 M 
CBDCA+PAC×3 
(CBDCA+GEM ×5 
60 IIIB Sq infiltrative 12 months Rt. Sleeve pneumonectomy No 
68 M 
CBDCA+PAC×3 
(DOC×4 PEM×13 
60 IIIA Ad infiltrative 11 months WWR No 
74 M CDDP+VNR×2 60 
IIIA NS-
CLC 
discrete 7 months RUL & S6 segmentectomy Pneumonia 
63 M CBDCA+PAC×5 60 IIIB Sq Infiltrative 9 months RULobectomy Non 
56 M 
CDDP+PEM×3 
(PEM×2 
60 IIIA Ad Discrete 12 months Rt pneumonectomy Non 
40 M 
CDDP+PEM×5 
CDDP+DOC×2 
VNR+Bev×2 
140 IV Ad Infiltrative 4 months Rt pneumonectomy BPF 
72 F CDDP+VNR×2 60 IIIA Ad Discrete 84 months RULobectomy Empyema 
61 M CDDP+VNR×3 60 IIIA Ad Infiltrative 15 months Sleeve RUL SVC replacement None 
61 M CDDP+VNR 60 
IIIA NS-
CLC 
Discrete 2 months Sleeve RUL SVC PA plasty None 
60 F CDDP+DTx 45 IIIA Ad Discrete 3 months Sleeve Middle and lower lobectomy None 
 
Keyword: salvage, combined resection, lobectomy, pneumonec-
tomy
S111Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
between open and VATS procedures were being performed. The 
trend toward the minimally invasive surgery is now generalized 
in the thoracic surgical community. The future directions in lung 
cancer surgery include the development of less invasive technique 
such as robotics, the improvement of the adjuvant treatment 
with new active drugs, the definition of the role of surgery in 
the multimodality treatment for advanced lung cancer, and the 
comparison between surgery and other local modalities (SBRT, 
ablation) as the treatment for pathologically early lung cancer.  
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Abstract: Staging is an objective measurement of the extent of 
cancer to allow logical grouping of patients with similar prognosis 
and pathobiological characteristics. Actually, the stage is 
expressed as combination of three factors: the size and invasion 
of the primary tumor (T), metastasis to the locoregional lymph 
nodes (N), and distant disease (M). Nowadays, any planning of the 
treatment is not possible without accurate staging. Moutain, who 
took the great leadership in the revision of TNM staging system, 
described staging as “assigning a simple coded designation 
to be a patient in accordance with an established set of rules”. 
Traditionally, UICC and AJCC have taken an initiative for the 
revision of the classification rules of TNM system. Since 7th edition 
which was published in 2009, IASLC was principally involved in 
the creation of proposals for revision to UICC and AJCC based 
upon the world-wide database. This process was known as “IASLC 
Lung Cancer Staging Project” lead by Goldstraw, and it is still 
underway for 8th edition. Although TNM staging system covers the 
malignant tumors of most organs, such aggressive intervention 
of international academic societies has been rarely seen except 
IASLC. The advent of mediastinoscopy, PET, and EBUS technique 
contrubuted to better staging. The IASLC Staging Project is now 
extended to cover not only lung cancer but also mesothelioma, 
thymic tumors, and esophageal cancer. As of 2013, surgery is still 
playing a principal role in the treatment of lung cancer especially 
for the relatively early stages of the disease with curative intent. 
Surgery is respected as the integration of two different parts: 
"art (surgical skill)“ and "science“. Therefore, we should realize 
that the evolution of lung cancer surgery has been achieved by 
the refinement of surgeons’ skills and advent of new technique 
(technology) as well as the accumulation of novel scientific 
evidence given by the well planned clinical trials. Surgery for lung 
cancer began as pneumonectomy as early as in 1930. However, 
the present-day gold standard surgery for lung cancer is defined 
as at least lobectomy and lymph node sampling/dissection. Series 
of clinical trials in 1980’s, mainly focusing upon the prognostic 
evaluation of adjuvant chemotherapy, were performed by Lung 
Cancer Study Group. The technically challenging surgery, such as 
those for superior sulcus tumor, has been also improved greatly. 
Even tumors located at the difficult potion of the thoracic inlet 
could be resected by refined method as shown by Grunenwald. 
How to manage the metastasis to the locoregional lymph nodes is 
also an important issue. Owing to the lymph node map originally 
drawn by Naruke and colleagues in 1970’s, the precise location of 
the metastatic nodes could be documented, and further analyses 
and comparison of the resected lung cancer with node metastasis 
became possible. The prognostic impact of the lymph node 
dissection was evaluated by the recent ACOSG study. In 1990’s, 
the minimally invasive technique (video-assisted thoracic surgery) 
was introduced in the surgery for lung cancer, and the comparison 
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scope virtually every lymph node adjacent to the bronchial tree 
can be reached (16). In combination with the ultrasound from in-
side the oesophagus (17) this results in a sensitivity of > 90% (18). 
In a RCT it was demonstrated that combining these techniques 
should be done before thiNKIng of a mediastinoscopy as their 
yield is comparable to mediastinoscopy (19). Bronchoscopy be-
came important for treatment as well, ranging from palliative to 
really curative. Stenting the airway but should be used with great 
caution as migration is common, it seriously affects mucus clea-
rance and narrowing of the airways through granulation tissue 
might develop (20). A desobstruction technique such as Nd-YAG 
laser, electrocautery or argon plasma coagulation can be used if 
intraluminal tumor gives obstruction (20). In specific situations with 
very limited cancer within the bronchial wall endobronchial treat-
ment might even lead to cure, an example of this is photodynamic 
therapy (21). Radiology Within the last 40 years imaging techniques 
have improved considerably. With the introduction of computed 
tomography, it became possible to visualize the primary tumor as 
well as mediastinal lymphnodes in a much better way. A further 
technical improvement, the Positron Emission Tomography (PET) 
and the use of 18-fluorodeoxyglucose (18-FDG) improved this (22). 
Further developments of imaging may lead to decision making on 
treatment (23). References 1 Tobacco policy recommendations of 
the International Association for the Study of Lung Cancer (IASLC): 
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Abstract: Etiology and epidemiology Awareness that lung cancer 
is for many patients a self-inflicted disease has become common 
knowledge and its incidence can only be reduced by an active 
fight against smoking . The IASLC has always considered this as 
very important (1). The last decade much attention was given the 
non-smokers who developed lung cancer. These patients have 
specific characteristics, of which EGFR mutation is one (2). What is 
responsible for this class of lung cancer is unknown. With an esti-
mated number of 300,000/year, it is far from an orphan disease (3). 
Early detection Lung cancer cure rates are far from impressive (4). 
For those diagnosed with symptoms the outcome is grim, cure is 
extremely rare, palliative needs are common (5). The 5 year survival 
rates in patients with resectable tumors is decreasing with increa-
sing stage (6). Finding early stage lung cancer with state-of -the-art 
CT technology resulted in an impressive 10 yr survival rate of 88% 
(7). This modern CT technologywas evaluated in the largest lung 
cancer screening study ever performed (8). For the first time it was 
demonstrated that screening is effective and results in a relative 
reduction in mortality from lung cancer of 20.0%, and death from 
any cause by 6.7% (95% CI, 1.2 to 13.6; P = 0.02). Still many ques-
tions remain unanswered and confirmation is needed (9)? How to 
treat these lesions with minimal invasive surgery (10) or stereotactic 
radiotherapy (11). Pulmonology Autofluorescence bronchoscopy 
improves the detection of mucosal abnormalities (12) such as pre-
invasive lesions (13), carcinoma in situ (14) and radiologically occult 
lung cancer (15). Through the EBUS (endobronchialultrasound) 
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mous cancers (19). Three and 4 drug combinations were not supe-
rior to 2 drug combinations. These 2 drug combinations were su-
perior in patients with PS 0-1 but benefitted elderly as well as 
younger patients (20). There is evidence that the paclitaxel/carbo-
platin combination may benefit PS2 patients (21). Thus, histology 
and performance status are key factors in therapy selection. 
 
Since the 1990’s, docetaxel, erlotinib, and pemetrexed have been 
shown to prolong survival when used in the 2nd line setting (22-24). 
For pemetrexed this improvement was limited to non-squamous 
histology (24). 
 
Since 2000 the use of targeted therapy began with the studies of 
inhibitors of VEGFR and EGFR signaling. Angiogenesis inhibitors 
were widely studied. Bevacizumab, a monoclonal antibody to 
VEGF, was shown to produce promising results in a randomized 
phase II trial (25). However, patients with squamous cell carcinoma 
had excess bleeding on this study and were excluded from all 
further trials. An ECOG randomized trial (4599) showed that beva-
cizumab improved survival in non-squamous histologies when 
combined with platinum doublets (26). However, the survival ad-
vantage is small and is less striking in elderly patients. The survival 
advantage was not observed in a randomized trial from Europe 
using gemcitabine/cisplatin as the chemotherapy backbone (27). 
 
As noted above, the EGFR TKI erlotinib was shown to prolong 
survival in unselected patients failing 1 or 2 chemotherapy regi-
mens (23). 
 
In 2004 an association between mutations in the EGFR and res-
ponse to EGFR TKIs was established (28,29). Subsequent rando-
mized trials showed that EGFR TKIs were superior to chemothera-
py in 1st line therapy of EGFR mutant patients but chemotherapy 
was preferred for those without mutations (30-35). 
 
In 2007, it was shown that EML4/ALK fusions could serve as driver 
molecular changes in up to 5% of NSCLC’s (36). Crizotinib, an ALK 
TKI was shown to produce high response rates and long PFS and 
was superior to chemotherapy in the second line setting (37-39). 
Patients with ALK fusions nearly always have adenocarcinoma his-
tology, more often are younger and female sex and are light or 
never smokers (40) but clinical features should not be used to de-
termine who should be tested (41). These and other molecular 
drivers may be present in more than 50% of lung adenocarcinomas 
(42). Molecular analyses of squamous and small cell cancers have 
recently been described (43-46). 
 
Checkpoint inhibitors such as PD1 and PDL1 were shown to be 
therapeutic targets since 2010. Antibodies to PD1 and PDL1 have 
produced responses in about 20% of patients who had failed mul-
tiple lines of chemotherapy and many of these were durable 
(46,47). PDL1 expression is being evaluated as a biomarker and 
many trials are in progress. 
 
Maintenance therapy with continuation of the original platinum 
doublet was shown in many trials to be associated with an increase 
in the PFS, an increase in toxicity but no increase in survival and 
therefore this approach was not adopted (48) . In 2009, Fidias et al 
reported that maintenance docetaxel could increase survival as 
well as PFS (49). This trial was followed by a trial showing that erlo-
tinib could improve PFS and survival as maintenance after a plati-
num doublet (50). PFS and survival were improved in all histologies 
but the improvement in PFS and OS was most striking in patients 
with EGFR mutations. Pemetrexed was shown to improve PFS and 
survival as switch maintenance after a platinum doublet that did 
not contain pemetrexed (51). A subsequent trial showed that pe-
metrexed continuation maintenance also improved PFS and OS 
with immediate effect: laser electrocautery, argon plasma coalgu-
lation and stents. EurRespir J 2006; 27: 1258-1271. 21 Cortese DA, 
et al. Photodynamic therapy for early stage squamous cel carcino-
ma of the lung. Mayo ClinProc 1997; 72: 595-602. 22 Silvestri GA, 
et al Methods for staging lung cancer. Chest 2013; 143: 211S-250S. 
23 Bahce I, et al. Development of [(11)C]erlotinib positron emission 
tomography for in vivo evaluation of EGF receptor mutational sta-
tus. Clin Cancer Res. 2013; 19: 183-193.
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Abstract: Systemic Therapy of Early Stage NSCLC 
The addition of chemotherapy to surgery before or after surgery 
was studied because trials in the 1970’s demonstrated that cure 
rates were lower than in other cancers and because the majority of 
relapses were in distant sites (1). Initial adjuvant studies showed no 
survival advantage for single agent chemotherapy. Subsequent 
trials in the 1980’s and 1990’s established that cisplatin based 
2-drug combinations produced a modest (4-5%) improvement in 5 
year survival rates but only in stages II and IIIa (2). Adjuvant therapy 
has not been shown to improve outcomes in Stage I with the possi-
ble exception of Stage IB tumors larger than 4 cm (3). Neoadjuvant 
chemotherapy produces similar improvement compared to adju-
vant therapy as demonstrated by randomized trials and metaanaly-
ses (4,5). Post-operative radiotherapy has not shown benefits in 
stage I and II where it may be harmful and it role in stage IIIa after 
surgery is under evaluation as there are conflicting data on its role 
in this setting (6,7). 
 
Systemic Therapy of Stage III NSCLC 
Combinations of radiotherapy with chemotherapy were shown to 
produce superior survival compared to either alone based on ran-
domized trials conducted in the 1990’s (8). Subsequent studies 
indicated that concurrent chemo-radiotherapy was superior to 
sequential therapy (9,10). There are conflicting data on whether 
two or four cycles of chemotherapy is best (11). There are also con-
flicting data on whether triple modality therapy is superior to two 
modalities for Stage IIIA N2 disease (12). 
 
Systemic Therapy of Stage IV NSCLC 
Chemotherapeutic agents and chemotherapy combinations were 
tested in the 1970’s and early 1980’s but failed to show any survival 
advantage. Two drug combinations combining cisplatin with vin-
desine or vinorelbine were shown to prolong survival compared to 
best supportive care in the 1980’s and 1990’s (13,14). Subsequent 
studies showed that 2-drug platinum based combinations were 
superior to a single active drugs (13,15,16). The survival advantage 
increased median survival times from 4-5 months to 8-12 months. 
Two-drug combinations with a platinum combined with gemcitabi-
ne, paclitaxel, docetaxel or pemetrexed were shown to produce 
equivalent survival in randomized trials conducted in the 1990’s 
and in the 2000’s (17,18). An exception to the equivalence was the 
finding that the pemetrexed/cisplatin combination was superior to 
gemcitabine/cisplatin in non-squamous cancer but inferior in squa-
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G02.1 PUBLIC AWARENESS OF LUNG CANCER SYMP-
TOMS - THE GLCC/IPSOS MORI 2013 INTERNATIONAL 
CONSUMER POLL
Jessica Elgood
Ipsos Mori/Australia
Abstract: Introduction Ipsos MORI were commissioned by the 
Global Lung Cancer Coalition to explore the prevalence of smo-
king within countries; and awareness of the symptoms of lung can-
cer. Two questions were asked: 1. Can I just check, do you consider 
yourself to be: a) A current smoker – i.e. someone who is a regular 
smoker at the present time; b) A former smoker – i.e. someone who 
used to smoke regularly but has quit; c) Someone who has never 
smoked – i.e. someone who has never smoked at all, or only very 
occasionally in the past (less than 100 cigarettes in your lifetime); 
d) Don’t know. 2. There are many warning signs and symptoms 
of lung cancer. Please name as many symptoms of lung cancer as 
you can think of.[1] A quantitative survey was conducted across: 
Argentina, Australia, Bulgaria, Canada, Denmark, Egypt, France, 
Germany, Great Britain, Ireland, Italy, Japan, Mexico, Norway, Por-
tugal, Slovenia, Spain, Sweden, Switzerland, the Netherlands, and 
the USA. This abstract outlines the headline findings[2]. Methodo-
logy A nationally representative quota sample for each country of 
500–1,204 adults was interviewed from 2 June – 16 August 2013[3], 
using Omnibus services (please note the lowest age varied slightly 
between countries)[4]. Face-to-face in-home interviewing was used 
in Bulgaria, France, Germany, Great Britain, Portugal and Spain, 
and telephone (CATI[5]) interviewing elsewhere (in Argentina, 
Australia, Canada, Denmark, Egypt, Ireland, Italy, Japan, Mexico, 
Norway, Slovenia, Sweden, Switzerland, the Netherlands, and the 
USA). Data have been weighted to the known adult population 
profile of each country. Please also note that booster surveys took 
place in Mexico, Norway, Sweden and Slovenia to boost the num-
ber of smokers in order to allow robust comparisons. In each coun-
try, data were weighted back to the original profile of smokers and 
non-smokers to ensure that smokers were not over-represented. 
Discussion of findings: where is smoking prevalence highest? 
Of all the 21 countries surveyed, people in Bulgaria are most likely 
to be current smokers (41%), followed by Spain (33%) and France 
(30%). The lowest proportions of current smokers are found in 
Sweden (12%) and Australia (13%). Egypt, however, has the highest 
proportion of people who have never smoked at all (70%). 
after induction therapy with a pemetrexed/platinum doublet in-
duction (52). An unpublished trial, (POINTBREAK), comparing pe-
metrexed/carboplatin/bevacizumab with pemetrexed/bevaci-
zumab maintenance compared to paclitaxel/carboplatin/
bevacizumab followed by bevacizumab, showed no difference in 
survival. Thus, there is no evidence at presence that maintenance 
should contain two drugs although the ECOG is comparing peme-
trexed with bevacizumab or the combination after induction thera-
py with paclitaxel/carboplatin/bevacizumab. 
 
Systemic Therapy of Early Stage SCLC 
Patients with Stage I and IIA SCLC, although infrequent, benefit 
from resection and adjuvant chemotherapy and the IASLC TNM 
classification is more accurate than the old VA classification (53). 
SCLC patients with stage IIB and III (limited stage SCLC) were 
shown to have prolonged survival when treated with chemothera-
py and radiotherapy compared to either alone (54,55). An ECOG 
randomized trial showed that chest RT with BID radiation to 45 Gy 
was superior to once daily chest RT to the same dose when com-
bined with etoposide/cisplatin (56). However, similar results were 
obtained with higher total doses of once daily RT and both once 
daily and twice daily are in routine practice. Concurrent chemora-
diotherapy is superior to sequential therapy but results with radio-
therapy starting at either cycle 1 or cycle 3 are similar. The combi-
nation of etoposide/cisplatin is the most frequent chemotherapy 
regimen because of reduced toxicities compared to Adriamycin or 
other combinations. Prophylactic cranial irradiation in good res-
ponders reduces brain relapse and prolongs survival (57). 25 Gy is 
the preferred dose (58). 
 
Systemic Therapy for Stage IV SCLC 
Both cisplatin and etoposide were first tested and shown to be 
active in the 1970’s. Studies in the 1980’s showed that the combi-
nation of etoposide and cisplatin produced high response rates 
(80%) with some complete responses (10-15% (59, 60). These re-
sults lead to randomized trials comparing etoposide/cisplatin to 
CAV, CAE or alternating combinations. Etoposide/cisplatin (EP) 
produced equivalent efficacy with less toxicity (60,61) and thus 
became the standard combination in the 1990’s. Pemetrexed/
carboplatin was compared to etoposide/carboplatin and was infe-
rior (62). Several trials have shown that irinotecan combined with 
cisplatin or carboplatin is equivalent to etoposide with cisplatin or 
carboplatin (63, 64). Thus EP remains the standard today. Topote-
can is approved for used in the second line setting albeit at a dose 
and schedule rarely used due to toxicity (65,66). Both oral and 
intravenous topotecan produce similar results. Topotecan impro-
ved PFS as maintenance but did not improve survival and increa-
sed toxicity (67). Thus, use in the maintenance setting was not wi-
dely adopted. Retreatment with EP for those with late relapse has 
been the most successful retreatment approach and is standard in 
this setting (68). After 2000, randomized trials showed that PCI 
after induction response could prolong survival in extensive stage 
as well as limited stage SCLC and as now used routinely in this 
setting (69). There has been little change in chemotherapy options 
for SCLC over the past 20 years but there is some hope that the 
immune checkpoint inhibitors could improve outcomes (70).
S115Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Spontaneous awareness varies significantly by country. For examp-
le, fewer than one in four Japanese adults mention breathlessness 
(22%), compared to a high of 56% in Ireland. Likewise, whilst 27% 
state tiredness or a lack of energy to be a symptom of lung cancer 
in Bulgaria, only 5% of Australians do the same. The following table 
shows the most frequently mentioned symptoms in each country. 
Breathlessness is the symptom respondents are most commonly 
aware of in fifteen countries, with general or unspecified coughing 
emerging more frequently in the other six.  
Spontaneous awareness of the symptoms of lung cancer The 
combined results from all countries show that breathlessness (40%) 
and coughing (39%) are the most frequently recognised symptoms 
of lung cancer. Other symptoms relating to coughing, as well as 
general or unspecified coughing, are also commonly mentioned: 
coughing blood (17%), a cough that doesn’t go away (14%), and 
a cough that gets worse (8%). Tiredness or a lack of energy (13%) 
and an ache or pain when coughing or breathing (11%), are spon-
taneously mentioned by more than one in ten people as well. It 
should also be recognised that approaching one in four could not 
name any symptoms, instead stating that they didn’t know (23%). 
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When analysing the mean number of potential symptoms of 
lung cancer mentioned in each country depending on whether 
respondents are current smokers, former smokers, or have never 
smoked at all, awareness appears to be fairly consistent. Please 
note that people who said that they did not know any symptoms 
have been excluded from this analysis. The following table 
highlights within each country which of the three groups has the 
highest mean score (i.e. the most mentions of symptoms per 
respondent). The key finding from this is that current smokers 
often mention fewer symptoms of lung cancer than former smokers 
or people who have never smoked. In three countries (France, 
Ireland and Portugal), current smokers do appear to have a greater 
awareness of potential symptoms, whilst in Sweden, current and 
former smokers have the same mean score. 
Mean number of mentions of symptoms of lung cancer 
per respondent (who named at least one symptom) 
Country Current  smokers 
Former  
smokers 
Never  
smokers 
Argentina 1.97 1.97 2.11 
Australia 2.04 2.47 2.28 
Bulgaria 3.63 4.18 3.97 
Canada 2.57 2.53 2.77 
Denmark 2.39 2.34 2.43 
Egypt 3.09 3.32 3.32 
France 2.54 2.53 2.40 
Germany 3.02 3.66 3.69 
Great Britain 2.77 2.89 2.75 
Ireland 3.21 2.99 2.94 
Italy 2.46 2.53 2.43 
Japan 2.41 2.55 2.67 
Mexico 1.98 1.84 2.00 
Netherlands 1.99 2.19 2.24 
Norway 1.86 2.14 2.18 
Portugal 2.61 2.54 2.43 
Slovenia 2.35 2.46 2.16 
Spain 2.13 2.30 2.13 
Sweden 1.98 1.98 1.89 
Switzerland 1.94 2.31 2.23 
USA 1.93 1.97 2.01 
 
 
[1] A pre-coded list was provided for interviewers to code respon-
ses. Respondents were able to code multiple responses. [2] Please 
note that at this stage the findings are based on interim data. [3] 
The base sizes in each country were as follows: Argentina (500), 
Australia (1,000), Bulgaria (1,148), Canada (1,005), Denmark (650), 
Egypt (1,009), France (953), Germany (1,073), Great Britain (957), 
Ireland (1,000), Italy (510), Japan (1,204), Mexico (600), Norway 
(529), Portugal (1,203), Slovenia (580), Spain (500), Sweden (550), 
Switzerland (510), the Netherlands (1,004), and the USA (1,000) [4] 
The lowest age for each country is as follows: Germany: 14 years; 
Australia, Ireland, Mexico and Norway: 15 years; Sweden: 17 years; 
Egypt and Japan: 20 years; all other countries: 18 years. [5] Com-
puter Assisted Telephone Interviewing
Keyword: Poll Lung Cancer Smoking
Country
Most  
frequently 
mentioned
Second most 
frequently 
mentioned
Third most  
frequently  
mentioned
Argentina
Breathlessness 
(31%)
A cough (26%)
Tiredness or lack 
of energy (12%) 
Australia
Breathlessness 
(53%)
A cough (37%)
Coughing blood 
(32%)
Bulgaria
Breathlessness 
(50%)
Coughing 
blood (37%)
A cough that gets 
worse (30%)
Canada
Breathlessness 
(49%)
A cough (45%)
Coughing blood 
(20%)
Denmark
Breathlessness 
(51%)
A cough 
(48%)
An ache or pain 
when coughing or 
breathing (20%)
Egypt
Breathlessness 
(25%)
Persistent 
chest infec-
tions (23%)
A cough (15%)
France A cough (54%)
Breathless-
ness (37%)
A cough that 
doesn’t go away 
(25%)
Germany
Breathlessness 
(36%)
Coughing 
blood (34%)
A cough that 
doesn’t go away 
(31%)
Great 
Britain
Breathlessness 
(46%)
A cough 
(43%)
Coughing blood 
(27%)
Ireland
Breathlessness 
(56%)
A cough (56%)
Coughing blood 
(27%)
Italy
Breathlessness 
(42%)
A cough that 
doesn’t go 
away (32%)
A cough (29%)
Japan A cough (50%)
Breathless-
ness (22%)
A cough that 
doesn’t go away 
(21%)
Mexico A cough (33%)
Breathless-
ness (27%)
An ache or pain 
when coughing or 
breathing (10%)
Nether-
lands
Breathlessness 
(45%)
A cough (45%)
Tiredness or lack 
of energy (13%)
Norway
Breathlessness 
(47%)
A cough 
(40%)
Chest and/or 
shoulder pains 
(9%)
Portugal
Breathlessness 
(35%)
A cough 
(33%)
Tiredness or lack 
of energy (18%)
Slovenia A cough (52%)
Breathless-
ness (31%)
Coughing blood 
(10%)
Spain A cough (29%)
Breathless-
ness (25%)
Tiredness or lack 
of energy (20%)
Sweden A cough (46%)
Breathless-
ness (42%)
Tiredness or lack 
of energy (10%)
Switzer-
land
A cough (53%)
Breathless-
ness (43%)
An ache or pain 
when coughing or 
breathing (12%)
USA
Breathlessness 
(38%)
A cough (37%)
Coughing blood 
(14%)
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[8] – in the 11 GP surgeries studied, after its first year (2008), noted, 
19% of lung cancers diagnosed in Stage I and II, an increase from 
11% in the previous year. We have also seen centrally, government 
funded campaigns. In England, the Department of Health, in 2012, 
funded the national ‘Be Clear on Cancer – Lung Cancer’ campaign 
[9]. This campaign, focusing on ‘’persistent cough’’ and results from 
the pilot study noted a 22% increase in the number of patients 
who visited their General Practitioner with relevant symptoms and 
also noted an increase in Chest CTscans being performed. This 
campaign has been repeated in the summer of 2013. In Scotland, 
the ‘Detect Cancer Early’ campaign is developing a national lung 
cancer component.  
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G02.2 OUTCOMES FROM PUBLIC INFORMATION  
CAMPAIGNS
Jesme Fox
Medical Directorate, Roy Castle Lung Cancer Foundation/United King-
dom
Abstract: Background Despite recent advances, lung cancer 
remains a disease characterized by late diagnosis and poor 
outcomes. Diagnosing more lung cancer patients, at an early 
stage, when curative treatments are an option, will save lives. In 
recent years, there has been a focus on lung cancer screening. 
In countries where lung cancer screening is available, high risk 
individuals are being directed to these services. In other counties, 
advocates are calling for further research to evaluate the benefit 
of screening tools. Raising general public awareness of the signs 
and symptoms associated with lung cancer is of importance 
in the pursuit of earlier diagnosis. It is a key function of many 
advocacy groups working in the lung cancer field. With the variety 
of associated signs and symptoms, this is a difficult area. Using 
nationally agreed guidelines, advocacy groups have produced 
information, such as the GLCC awareness raising leaflets, available 
for download, in 13 languages [1]. As noted in a 2013 survey, 
undertaken by Public Health England, [2], 40% of people surveyed 
were unaware that a persistent cough could be a symptom of 
lung cancer.. Challenges Much negativity surrounds lung cancer 
and impacts on effective campaigning. Lung cancer is seen as a 
‘depressing story’ and it is often difficult to engage the media. 
The notion of ‘self infliction’ surrounding this disease, adds to this 
difficulty. Furthermore, the stigma and blame associated with lung 
cancer is in itself, a contributing factor to late presentation in this 
disease [3, 4, 5,]. Stigmatisation has a very negative impact on the 
disease and on advocacy initiatives. Central to the lung cancer 
advocacy community is its focus on reducing the stigma associated 
with this disease. Many diseases are life style related, yet are 
not impacted in this way. It is important that whilst undertaking 
awareness campaigns, the messages of ‘no one deserves lung 
cancer’ and ‘smoker, former smoker or never smoker – anyone can 
get lung cancer’ are distributed widely. Public awareness raising 
campaigns in lung cancer Much of the awareness campaigning to 
date has come from the emerging Lung Cancer Patient Advocacy 
movement. Sadly, with poor survival, the number of lung cancer 
advocates and advocacy groups is relatively small, as compared 
with other common cancers. However, a key focus has been the 
November, ‘Lung Cancer Awareness Month’ initiative, initially 
developed in the US, by the Alliance for Lung Cancer Advocacy, 
Support and Education (now the Lung Cancer Alliance) and 
adopted by the global community, through the Global Lung 
Cancer Coalition, in 2001. The campaign aims to raise awareness 
of the signs and symptoms associated with lung cancer, change 
public perceptions and help to de-stigmatize this disease. An early 
example of this was the 2002 general public and media campaign, 
organized in the UK by the Roy Castle Lung Cancer Foundation 
and Macmillan Cancer Relief [6]. In recent years, the cross country 
initiative, involving Australia, Egypt and the US, being the ‘Shine 
a Light on Lung Cancer’ campaign, originally developed by Lung 
Cancer Alliance [7]. Other campaigns, from across the globe, will 
be described. In the UK, we have seen a number of general public 
lung cancer awareness raising initiatives, through the National 
Awareness and Early Diagnosis Initiative (NAEDI). We have also 
seen local campaigns such as the ‘’Doncaster Cough Campaign’’ 
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patient advocacy is developed to be more popular through open 
lecture, newspaper, web site and guideline book even in Japan. 
This method may be one of the ways to raise public awareness of 
lung cancer in Asian countries. 
Keywords: Oncologist, Patient advocacy, Lung cancer, Clinical 
study group
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G02.4 SURVIVORS AS ADVOCATES: WHAT IS POSSIBLE? 
- THE LUNG CANCER ALLIANCE EXPERIENCE
Kay Cofrancesco
Lung Cancer Alliance/United States Of America
Abstract: Working with survivors is the foundation for every one of 
our programs at Lung Cancer Alliance. We examined the past nine 
years and the varying degrees of success of each of our initiatives 
based on the engagement of survivors to accomplish our goals. 
We will discuss the ways in which survivors join our movement and 
the various ways in which advocacy can help them during their 
journey with lung cancer.
Keyword: survivors, advocacy, involvement, mission success
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G02.5 HOW CLINICIANS AND PATIENTS CAN BENEFIT 
FROM BETTER DATA ON LUNG CANCER
Michael D. Peake
Royal College Of Physicians/United Kingdom
Abstract: Background: There is evidence from a variety of sources 
that lung cancer outcomes in the UK are worse than in many other 
parts of the developed world [1,2]. Part of this ‘survival gap’ can be 
explained by late diagnosis as evidenced by an excess of deaths 
within the first few months of diagnosis [3] and a high rate of 
patients (~40%) being first diagnosed during emergency hospital 
admissions [4]. However stage-for-stage survival is also worse 
in the UK [2], surgical resection rates are [5] and there is a clear 
relationship between these rates and survival [6]. Methods: 
The National Lung Cancer Audit (NLCA) had its first full year of 
data collection in 2005. Its aim was to collect a core dataset of 
around 140 items on all patients newly diagnosed and with lung 
cancer and mesothelioma in all hospitals in England expanding 
to cover the entire UK from 2008. Data is collected by the Multi-
disciplinary teams and entered onto a secure national database. 
As of May 2013 there are almost 220,000 patient records for 
England alone in the database and all hospitals in the UK regularly 
report data for their patients. Annual reports contain a wide 
range of indicators including: numbers of patients diagnosed; 
treatment rates for surgery, chemotherapy and radiotherapy, case 
mix factors such as age, stage, performance status, co-morbidity 
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G02.3 CLINICIANS AS ADVOCATES: RAISING PUBLIC 
AWARENESS OF LUNG CANCER - THE WEST JAPAN ON-
COLOGY GROUP EXPERIENCE
Toshiyuki Sawa1, Kenji Eguchi2, Yasuo Iwamoto3, Hiroshi Semba4, 
Hidehiko Yamamoto5, Tatsuhiko Kashii6, Takashi Seto7, Shin-
Ichiroh Nakamura8, Yoichi Nakanishi9
1Division Of Respiratory Medicine And Medical Oncology, Gifu Muni-
cipal Hospital/Japan, 2Department Of Medical Oncology, Teikyo Uni-
versity School Of Medicine/Japan, 3Medical Oncology, Hiroshima City 
Hospital/Japan, 4Division Of Respiratory Disease, Kumamoto Regional 
Medical Center/Japan, 5Respiratory Medicine, Aso-iizuka Hospital/
Japan, 6Department Of Medical Oncology, Toyama University Hpspi-
tal/Japan, 7Thoracic Oncology, National Kyushu Cancer Center/Japan, 
8West Japan Oncology Group/Japan, 9Research Institute For Diseases Of 
The Chest, Kyushu University/Japan
Abstract: Background: In Japan and Asian countries, patient 
advocacy has not been popular to citizens and government, es-
pecially in patients with lung cancer compared to USA and EU 
countries. Therefore, a few clinicians had played a role as advocate 
instead of cancer survivors group or governments. Clinicians as 
advocates have a certain advantage to give professional informa-
tion by themselves, with trained communication skill about bad 
news, and to use medical resources which is involved to medical 
society for lung cancer or hospital. West Japan Oncology Group 
(WJOG), non-profit organization which was established in 2000 
by volunteer oncologists, has the mission to conduct and support 
multi-center clinical co-operative study for cancer and to provide 
the information about lung cancer, the importance and necessity 
of clinical study for standard treatment widely, therefore to contri-
bute improving social welfare. Methods: To achieve the mission 
of WJOG, we carried out open lecture in city hall in major city 
every year and published lecture recordings in newspaper as well 
DVD video distribution. In another way, we planed to publish the 
guideline book for the patients with lung cancer and revised in 
five years interval. The board of directors determined the plan and 
the guideline editors committee was organized by WJOG mem-
ber in March, 2006. The committee edited constitution, drafting, 
plan, writing as an enterprise in 2006, and 2011. Questions and 
answers style was adopted in accordance to previous US guide-
book. Results: In these 12 years, 27 times of open lecture were 
held and medical specialists for oncology, novelists with cancer, 
representative or president of organization for patients advocacy, 
and etc gave lecture and discussed with patients. Nearly two to 
eight hundred people had participated in each meeting, occupied 
by most women and senior citizens. The questionnaire survey to 
participant revealed satisfaction for lecture and expectation for 
next meeting. The contents of lecture appeared full page in the 
Asahi which has a large circulation of almost 8 million (the second 
position in the world) as well as DVD-video was distributed widely 
to institute participating to our study and patients for the purpose 
of providing larger citizens with useful information. Furthermore 
WJOG official web site show the detail of each lecture in Japanese 
because Japanese patients with lung cancer are old and difficult to 
read English web site. Last year, second edition guideline book for 
patients was edited which consists of 118 questions and answers 
with full color 200 pages, as well posted to the WJOG website. 
GLCC international quantitative survey in 2010 showed that Japan 
is one of the countries with the greatest proportion of adults who 
think lung cancer is the biggest killer. Conclusions: It seems that 
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and socio-economic status. Median and one-year survival rates 
are also reported. Data are presented both in terms of crude 
percentages and case-mix adjusted odds ratios. These reports, 
including the identification of hospitals, are available to the public. 
The programme has been backed up by a series of meetings 
with hospital teams to identify their particular strengths and 
weaknesses, to support them in service improvement and to share 
examples of best practice.  
 
Results: The table below shows some examples of data 
completeness and the ‘headline indicators’ from England and 
Wales between 2005 and 2011 (the latest period for which data are 
available). It will be seen that data quality and completeness has 
improved as have all the process and outcome indicators. 
 
 
 
We have demonstrated that there is wide variation in treatment 
and survival within the UK [7,8]. One of the most dramatic and 
important impacts of the audit has been the realisation of just how 
low surgical resection rates were in some parts of the UK and that 
this was related to a serious shortage of specialist thoracic surge-
ons in many areas [9]. The number of thoracic surgeons has almost 
doubled since the publication of the first audit report and the 
overall resection rate has increased by almost 50%. In addition, we 
have many examples of where local practice and service configu-
ration have been significantly improved as a result of this process. 
We are now assessing the extent to which these changes have 
been translated into improvements in survival. 
The Roy Castle Lung Cancer Foundation has developed a web-
based system called the ‘Lung Cancer Smart Map’ [10] which 
allows patients to search how treatment in their area compares 
both with other hospitals and against national standards. Patient 
empowerment of this sort is potentially one of the most effective 
ways to drive up standards of care.  
 
Conclusions: In summary, we have demonstrated that population-
based data collection is feasible and as a result, the NLCA 
database is one of the largest and most detailed lung cancer 
databases in the world. The regular feedback and support that we 
have given to clinical teams and to patients has had a significant 
impact on the quality of care for patients in the UK and is now 
incorporated into our Cancer registration systems, with its 
potential value being enhanced by linkage to a wide variety of 
other data sources. 
S120 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Session GR01: Surgery and  
the New Stage IIIA 
Tuesday, October 29, 2013
SURGERY AND THE NEW STAGE IIIA  
TUESDAY, OCTOBER 29, 2013 - 14:00-15:30
GR01.3 ROLE OF NEOADJUVANT AND ADJUVANT THE-
RAPIES
Shun-Ichi Watanabe
National Cancer Center Hospital/Japan
Abstract: 1. Introduction Lung cancer has remained to be the 
leading cause of cancer-related death in many countries. Most 
patients are diagnosed at an advanced stage, stage III or IV. A 
way to improve surgical outcome would be the administration of 
chemotherapy before or after the surgical procedure. 2. Neoad-
juvant therapy The preoperative induction therapy offers several 
benefits: (1) an increased percentage of patients completing the 
planned dose of chemotherapy, (2) the probability to treat micro-
metastatic tumor dissemination preoperatively, (3) the ability to 
assess response to the chemotherapy as a prognostic indicator, 
and (4) the probability to increase resectability by the tumor re-
gression. 2.1. Induction chemotherapy Numbers of phase II trial 
using induction chemotherapy can be found in the previous litera-
tures. Phase III neoadjuvant trial results including stage IIIA disease 
are summarized in Table1. Two studies reported by Roth (1994) 
and Rosell (1994) suggested that induction therapy followed by 
surgery could lead to improved outcomes, however, recent large 
scale studies did not show the improvement of survival in stage 
IIIA patients received neoadjuvant chemotherapy. ( 2.2. Induction 
chemotherapy with third-generation agents Results of previous 
studies, all of them are phase II study, evaluating the efficacy of 
induction chemotherapy with third-generation agents are shown 
in the table 2. These trials showed the feasibility and potential 
benefit of induction chemotherapy with combination or cisplatin 
and third-generation agents for stage III patients. Since the data 
of phase III trial with large sample size are lacking, the adequate 
regimen of induction chemotherapy has yet to be defined. 2.3. 
Induction chemotherapy or induction chemoradiotherapy? 
Whether induction radiotherapy adds benefit when surgery is pl-
anned is an important clinical question, because the addition of 
each modality increase the possibility of morbidity and mortality of 
treatment. To investigate the benefit of neoadjuvant radiation the-
rapy, Shah (2012) conducted systematic review and meta-analysis. 
None of the studies demonstrated a survival benefit to adding 
induction radiotherapy to induction chemotherapy versus induc-
tion chemotherapy alone. The meta-analysis performed on ran-
domized studies demonstrated no benefit in survival from adding 
radiation (HR: 0.93; p=0.81), nor did the meta-analysis performed 
on retrospective studies (HR: 0.77; p=0.24). The most promising 
use of induction chemoradiotherapy is to treat the superior sulcus 
tumor (SST) where preoperative local tumor regression is a key to 
achieving complete resection. Rush (2007) reported the results of 
SWOG 9416 (Intergroup 0160) phase II trial, which tested the feasi-
bility of induction chemoradiotherapy for SST, on the basis of im-
proved outcomes in other subsets of stage III NSCLC. Pathologic 
complete response (CR) or minimal microscopic disease was seen 
in 61 (56%) resection specimens. Five-year survival was 44% for 
all patients and 54% after complete resection, with no difference 
between T3 and T4 tumors. Kunitoh (2008) reported the similar re-
sults of Japan Clinical Oncology Group (JCOG) phase II trial (JCOG 
9806), which was conducted for testing the feasibility of induction 
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Peter Goldstraw
Academic Depart Of Thoracic Surgery, National Heart And Lung Insti-
tute, Imperial College, London/United Kingdom
Abstract: At its strategic review in September 2011 the IASLC 
undertook a thorough overall of its existing committee structure. 
As the membership of the organisation expanded and its influence 
globally was increasing it was felt that it was appropriate for the 
organisation to move beyond its traditional scientific and educa-
tional roles to embrace fundamentally important aspects of care 
such as advocacy, the involvement of nurses and allied professio-
nals and tackling the scourge of tobacco dependency. There were 
already several established advocacy organisations, especially in 
North America, the UK and Australia. Our aim was not to compete 
but to network with these bodies to ensure that advocacy issues 
were included in the discussions of every one of our other commit-
tees and at every educational activity organised by the IASLC and 
its partners. We are thus delighted that at this World Conference, 
the first since our committee was established, we have high profile 
sessions such as this, in collaboration with the Global Lung Cancer 
Coalition, and those held yesterday, organised by the Australian 
Lung Foundation and other partners. 
From 2015 our World Conferences will be held annually and our 
programme of regional meetings in Europe, Asia, North and South 
America will continue. We hope that the IASLC meetings and our 
journal, the Journal of Thoracic Oncology, will be seen as the ap-
propriate platform for issues such as patient advocacy, specialist 
nurse care, smoking cessation and tobacco control to be aired. 
The members of the IASLC are specialists in every research and 
clinical care aspect of thoracic oncology, working to improve the 
outcomes for lung cancer and other thoracic malignancies. You, 
the advocates, are our link to patients who need, deserve and de-
mand better care. Let us work together to the benefit our patients. 
 
Keywords: IASLC, Advocacy, smoking cessation, Tobacco Control
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from 55% to 48% after resection. Subgroup analysis suggested 
that the adverse effect on overall survival was most notable for 
patients with stage I/II (N0-N1) tumors, whereas there was no clear 
evidence of either adverse effect or benefit for stage III disease. 
The results of the PORT meta-analysis, however, are probably not 
applicable to current therapy because of recent major improve-
ments in radiation treatment planning and delivery. 4. Neoadju-
vant or adjuvant chemotherapy? Which is the better treatment, 
induction or adjuvant chemotherapy? Some concern has also ari-
sen regarding adjuvant chemotherapy compliance, with most trials 
using cisplatin doublets reporting delivery of only 60% of planned 
treatment. Induction chemotherapy seems better tolerated, more 
than 80% of the patients received the full planned treatment at the 
difference of adjuvant chemotherapy. In the LACE meta-analysis, 
33% of patients in the chemotherapy arm did not start or finish 
the planned chemotherapy regimen, reflecting the difficulty of 
adjuvant chemotherapy administering such taxing therapies to 
a postoperative population. 6. Conclusions Although definitive 
chemoradiation remains a standard of care for stage IIIA NSCLC, 
alternative approaches such as induction chemotherapy and sur-
gery for a selective group of patients can be considered. When 
surgical resection after induction therapy can be performed with 
low risk and a good chance of complete resection, it might provide 
an optimal outcome. The decision to proceed with resection after 
induction therapy must include a detailed preoperative pulmonary 
function evaluation as well as a critical intraoperative assessment 
of the feasibility of complete resection. 
Keywords: non-small cell lung cancer, stage III, Neoadjuvant the-
rapy, adjuvant therapy
chemoradiotherapy for NSCLC-SST patients. There were 12 pati-
ents with pathologic CR. The disease-free and overall survival rates 
at 3 years were 49% and 61%, respectively; at 5 years, they were 
45% and 56%, respectively. They concluded that the trimodality 
approach was safe and effective for the treatment of patients 
with SST 3. Adjuvant therapy 3.1. Adjuvant chemotherapy The 
NSCLC Collaborative Group (1995) reported a meta-analysis of 14 
clinical trials addressing the role of adjuvant chemotherapy for re-
sected NSCLC. There was no statistically significant survival benefit 
in group of patients received adjuvant chemotherapy, but a trend 
toward better survival prompted further studies. Subsequently, the 
Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis based 
on individual patient data collected from the 5 largest trials (4,584 
patients) of cisplatin-based adjuvant chemotherapy in completely 
resected patients with NSCLC was performed. This analysis also 
showed a significant survival benefit with adjuvant chemothe-
rapy, with an overall hazard ratio (HR) of 0.89, translating into a 
5-year absolute survival benefit of 5.4%. Then in 2010, the NSCLC 
Meta-analyses Collaborative Group reported a meta-analysis of 
34 clinical trials with 8,447 patients (3,323 deaths) addressing the 
benefit of adjuvant chemotherapy for resected NSCLC. Among 
those, the overall hazard ratio to survival in patients received 
cisplatinum-based adjuvant chemotherapy by stage suggests ab-
solute improvements in 5-year survival of 5% for stage III disease 
(from 30% to 35%). 3.2. Adjuvant radiotherapy In 1988, postop-
rative radiotherapy (PORT) Meta-analysis Trialists Group collected 
individual data on 2,128 patients from nine available randomized 
trials of PORT versus surgery alone. They reported a 21% relative 
increase in the risk of death, which was equivalent to an absolute 
detriment of 7% at 2 years, with PORT reducing overall survival 
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potential to improve both the quality and quantity of their lives and 
potentially help others with the same barriers in the future. Ano-
ther significant barrier is the real and perceived conflict that exists 
between the need for palliative and/or Hospice levels of care for 
advanced stage lung cancer patients. The need for Hospice bene-
fits and palliative care can and does have a significant impact on 
the decision to participate in early stage clinical trials to the point 
that participation may not even be an option. Funding and other 
system related issues act as barriers to participation in early sta-
ge clinical trials as well as the philosophical basis of the hospice/
palliative care approach to treatment/care. Over the past decade 
the availability of symptom management and palliative care clinical 
trials has increased the awareness of this barrier and in many res-
pects further clouded the issue for patients, their families and their 
healthcare providers. The primary ethical concern is does enroll-
ment into clinical trials interfere with the spirit of hospice care or 
does it offer hope to a dying patient? Identifying issues that exist 
globally may help to increase enrollment by advance stage pati-
ents while at the same time moving early phase clinical trials for-
ward and onto the phase II/III stage of study. Phase I trials are not 
designed with curative intent and phase I agents are not likely to 
prolong life or change the course of a disease. The life expectancy 
of phase I cancer patients’ averages between 5-6.5 months. Hospi-
ce providers and research investigators are in agreement that pha-
se I clinical trials should be open and available to advanced stage 
lung cancer patients who are concurrently enrolled in hospice care. 
Overcoming the barriers and obstacles for advanced stage lung 
cancer patients to participate in early stage clinical trials can only 
happen in the setting of a committed multidisciplinary research 
team.Methods to utilize in an effort to move toward that goal inclu-
de: (1) recognizing the importance of patient and family education, 
(2) recognizing the importance of healthcare provider education 
and awareness, (3) careful review and reinforcement of the infor-
med consent process, (4) identifying and recognizing the potential 
benefit of phase I clinical trial enrollment for advanced stage lung 
cancer patients – clinical and altruistic, (5) recognizing and assis-
ting patients and families with individual barriers and obstacles to 
participation and (6) employing effective marketing, recruiting and 
screening methods that are multidisciplinary in approach. Thoracic 
Oncology Nurses are well suited to serve as educators, advocates, 
resources, facilitators, and intermediaries. Nurses traditionally 
spend a greater amount of time in direct patient care and family 
interaction. Expanding and clarifying clinical information patients 
receive from their treating physicians is a vital role nurses play in 
ensuring patients are well informed and compliant with their plan 
of care. This is a model that can and has been extended into the 
realm of clinical trial work.Studies have shown that nurses play an 
important role in educating and recruiting cancer patients in clini-
cal trials.A randomized clinical trial compared nurses with surgeons 
recruitment of patients into a clinical trial for prostate cancer and 
the results indicated that surgeons and nurses were equally as 
effective in their recruiting and educating abilities and effectiven-
ess. With the proper education about early stage clinical trials, the 
conduct of clinical research, knowledge of the disease process of 
advance stage lung cancer and a high degree of self-motivation, 
thoracic oncology nurses are well suited to improve access and 
enrollment of advanced stage lung cancer patients into early pha-
se clinical trials.
Keywords: advanced stage lung cancer, clinical trials, phase I clini-
cal trials, thoracic oncology nursing
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Abstract: Cancer is the leading cause of death in the world, ac-
counting for approximately 7.6 million deaths in 2008. Lung cancer 
accounted for 1.37 million of those deaths.Identification of molecu-
lar markers in lung cancer has lead to the development of targeted 
therapies resulting in improved survival in selected groups of lung 
cancer patients. Despite the advancements in treatments, the 
survival for patients with lung cancer, particularly in the metastatic 
or locally advanced patients (stage IIIb/IV), is generally poor with 
a 5-year survival of only 6%. The current poor prognosis and latest 
advances made in the field of lung cancer highlight the importance 
of clinical trial development, participation and analysis. Partici-
pation in clinical trials for the general cancer patient’s is low, bet-
ween 5-9%. This low percentage is similar to those seen for lung 
cancer patients. Early stage clinical trials have a smaller number of 
participants by design and are aimed at establishing a maximum 
tolerated dose of a drug or treatment, not establishing efficacy.
These clinical trials are not designed with curative intent but rather 
are designed to evaluate drug absorption, distribution, metabo-
lism, excretion and mechanism of action. Only a small number of 
cancer patients and even a smaller number of advanced stage lung 
cancer patients enroll into phase I clinical trials. The number of 
international clinical trials has seen a rapid increase over the past 
decade. Recently the Office of Inspector General (OIG) reported 
that as of 2008, 80% of marketing applications for drugs and bio-
logics approved by the US Food and Drug Administration (FDA) 
contained data from US clinical trials conducted outside of the 
USA. Despite the importance and availability of clinical trials for 
lung cancer, participation in early stage clinical trials by advanced 
stage lung cancer patients remains very low. There are multiple 
barriers that contribute to these low numbers of participants, some 
of which include: (1) fear of unknown benefit from the investigati-
onal treatment, (2) negative family and family physician influence, 
(3) logistical and attitudinal constraints – too cumbersome to par-
ticipate and not willing to be the subject of “experiments”, (4) lack 
of knowledge, understanding and fear of the complexities of the 
clinical trial, (5) risk of inability to tolerate related investigational 
drug / treatment toxicity due to more weaken condition and (7) 
financial and insurance barriers.Identifying and overcoming the 
barriers that exist for each patient early in their diagnosis has the 
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Abstract: In lung cancer field, the direction of treatment strategy 
is in the midst of great change since molecular-targeted-drug was 
introduced. One of the revolutionary drugs is EGFR-TKI for EGFR 
positive lung cancer. It contributes to the treatment not only of 
advanced lung cancer, but also resectable early lung cancer in 
stage II and III. Although it is common to conduct surgery as the 
standard of care for early-stage lung cancer treatment, Stage II 
and III cases show poor prognosis even though complete resection 
is done. According to Asamura et al, 5-year survival of stage IIA, 
IIB and IIIA Japanese patients are 61%, 47% and 32% respectively. 
In response to these results, many investigators have been trying 
neoadjuvant and adjuvant chemotherapy in combination with 
surgery. In many cases, relapse after standard resection is distant 
metastasis, thus it is suspected that in order to achieve better 
prognosis, possible micrometastasis in whole body needs to be 
eradicated. Currently combination therapy with platinum-doublet 
is commonly chosen as the strong treatment regimen for control-
ling the micrometastasis in advanced cancer cases. Gefitinib is an 
EGFR-TKI (tyrosine kinase inhibitor) approved for the treatment of 
unresectable or recurrent NSCLC. Since its approval in Japan in 
July 2002, it has been approved in about 70 countries and used as 
the therapeutic medication for advanced recurrent NSCLC (at the 
point of August 2010). When Gefitinib was initially released, 3 to 
5% of drug-related ILD (Interstitial Lung Disease) and deaths were 
reported in Japan. After cohort study, it has been reported that 
those who are male, smoker, have the past illness of ILD and have 
low PS showed the higher ILD incidence rate than other cohorts. 
In 2004, it has been reported that Gefitinib shows the remarkably 
high response rate for EGFR positive patients, and subsequent 
studies demonstrated that EGFR mutation is an efficacy predictive 
biomarker.It is commonly known that Gefitinib induces apoptosis in 
EGFR positive patients. In fact, some clear anti-tumor effect have 
been observed in many clinical studies targeting on EGFR positive 
advanced NSCLC patients. The result of post-marketing Phase III 
clinical trial targeting on Asian patients untreated with chemothe-
rapy (IPASS trial)was reported in September 2008. According to 
pre-planned subgroup analysis based on biomarker, in EGFR posi-
tive patient group Gefitinib cohort showed the significant prolon-
gation of PFS (Progression Free Survival) compared to Carboplatin 
plus Paclitaxel cohort (HR 0.48, 95% CI 0.36~0.64, p<0.0001). In 
addition, Gefitinib cohort showed better efficacy, QOL, safety and 
tolerability. However, in terms of OS (Overall Survival), the diffe-
rence was not observed in two cohorts (HR 1.00, 95% CI 0.76~1.33, 
p=0.990). On the other hand, in EGFR negative patient group, Car-
boplatin plus Paclitaxel cohort significantly prolonged PFS compa-
red to Gefitinib cohort (HR 2.85, 95% CI 2.05~3.98, p<0.0001). It 
was reported from Japan that in the two Phase III controlled study 
targeting on EGFR positive advanced lung cancer patients untre-
ated with chemotherapy, Gefitinibcohort showed better PFS (Ha-
zard Ratio of less than 0.5) than standard chemotherapy cohort of 
Cisplatin plus Docetaxel (HR 0.489, 95% CI 0.336~0.710, p<0.0001) 
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Abstract: Adaptive clinical trials designs are sometimes claimed 
to have many benefits over conventional group sequential designs. 
Such claims are generally unfounded, though adaptive designs 
may be quite useful in specific situations. Adaptive designs can be 
quite useful in early phase dose finding trials, where the purpose 
is to minimize the number of patients exposed to inefficacious or 
overly toxic doses. Adaptive designs can also be useful in later 
phase trials when a biomarker (or baseline patient characteristic) is 
suspected to be strongly predictive of the effect of the treatment 
under investigation; in this case, an adaptive enrichment of the trial 
can greatly improve its power. Adaptive designs can also prove 
useful when the assumptions underlying a trial design are subse-
quently found to be grossly inadequate, but this is an undesirable 
as well as uncommon situation. Adaptive randomization, which 
consists of allocating more patients to the treatment that appears 
to have more efficacy ("play-the-winner“), is justified neither stati-
stically nor ethically. This strategy may produce slight reductions 
in the number of patients exposed to the inferior treatment, but it 
may increase the total sample size of the trial as compared to using 
a fixed allocation ratio (e.g. 1:1). More importantly, this adaptive 
strategy conveys the misealding impression that one treatment is 
known to be better than the other, a situation in which equipoise is 
not maintained and randomization no longer ethical.
Keywords: adaptive designs, clinical trials
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Abstract: Adjuvant therapies are required to prevent disease re-
currence and improve patient survival after surgery in early stage 
(stage I–IIIA) non-small cell lung cancer (NSCLC). In advanced 
disease, patients whose tumours have activating EGFR mutations 
have an approximately 60%-75% response rate to EGFR tyrosi-
ne kinase inhibitors (TKIs) treatment as first-line therapy and a 
progression-free survival that is significantly superior to standard 
chemotherapy. Although adjuvant TKI therapy is an appealing 
treatment strategy, can the remarkable efficacy of EGFR TKI in 
advanced EGFR-mutant NSCLC be extrapolated to stage I-IIIA 
disease? While adjuvant cisplatin-based chemotherapy prolongs 
survival with just 3-4 months of treatment, no trial to date has stu-
died the value of a few months of adjuvant EGFR TKI. The phase III 
BR.19 trial by the National Cancer Institute of Canada designed to 
study 1,160 patients with fully resected stage IB, II and IIIA NSCLC 
randomised to receive 2 years of adjuvant gefitinib at 250 mg daily 
or 2 years of adjuvant placebo was greatly underpowered because 
enrolment was stopped prematurely when, in 2008, the SWOG 
0023 investigators reported a worse overall median survival with 
maintenance gefitinib after definitive chemoradiation in a patient 
population not enriched for the presence of EGFR mutations with 
inoperable stage III NSCLC. EGFR mutation status was tested post-
hoc in two thirds of 537 patients enrolled. There was no overall sur-
vival (OS) benefit for adjuvant gefitinib over placebo (HR 1.58; 95% 
CI, 0.83 - 3.0; P = 0.16) in 76 patients with EGFR mutant tumours. 
Despite an underpowered study, the negative finding should cau-
tion us about recommending adjuvant EGFR TKI therapy outside 
of a protocol setting. The phase III Randomized, Double-Blind Trial 
in Adjuvant NSCLC with Tarceva (RADIANT) compares 2 years of 
adjuvant erlotinib, at 150 mg orally per day, to 2 years of placebo 
following complete resection of stage I-IIIA NSCLC in 945 patients 
who were selected based on having either EGFR protein expressi-
on by immunohistochemistry or increased EGFR gene copy num-
ber by FISH. At the 2009 ASCO meeting, the RADIANT investiga-
tors presented the results of the biomarker analyses from the first 
655 patients enrolled which showed an EGFR mutation-positive 
rate of 12%, which suggests that in the final result there will be 
approximately 38 EGFR mutation-positive patients on the placebo 
arm and about 76 on the erlotinib arm. This study is unlikely to 
provide sufficient power to a draw a firm conclusion about geno-
type-directed adjuvant therapy for patients with EGFR mutations. 
Investigators from the Memorial-Sloan Kettering Cancer Center 
reported a retrospective series of 167 patients at their centre with 
resected stages I-III NSCLC which were EGFR mutation-positive, 
among whom 32% received adjuvant EGFR TKI therapy. An im-
proved 2-year disease-free survival (DFS) was observed in patients 
who received adjuvant TKI therapy compared to those who did 
not (89% vs 72%) (HR, 0.53; 95% CI, 0.28 - 1.03; P = 0.06). A trend 
toward more favorable 2-year OS in recipients of EGFR TKI therapy 
was also seen (96% vs 90%; HR 0.62, CI0.26-1.51, P = 0.296). When 
the number of patients with resected EGFR mutant lung cancers 
was increased to 222, the same investigators in a more recent pu-
blication, showed treatment with adjuvant erlotinib or gefitinib was 
associated with a lower risk of recurrence or death, DFS HR 0.43 
(95% CI: 0.26-0.72, P = 0.001), and a trend toward improved OS. 
The phase II SELECT (Surgically resected EGFR-mutant Lung can-
or Carboplatin plus Paclitaxel (HR 0.357, 95% CI 0.252~0.507, 
p<0.001) in both studies. However, the comparison of 2-year sur-
vival in the controlled study of Carboplatin plus Paclitaxel, there 
was no statistically significant difference (Gefitinib: 61.4%, Standard 
Chemotherapy of CBDCA plus PTX: 46.7%) (P=0.31). In addition, 
in two cohorts (Gefitinibvs CDDP plus DOC) there was no statis-
tically significant difference in OS among them (HR 1.638, 95％CI 
0.749~3.582, p=0.21), thus the superiority of Gefitinib was not 
demonstrated in terms of OS. In the above-mentioned three pros-
pective controlled trial, it was demonstrated that Gefitinib drama-
tically prolongs PFS in EGFR positive NSCLC patients compared 
to standard chemotherapy, and shows high anti-tumor effect and 
improvement of QOL, but not in terms of OS. It is suspected this 
is partially because of the fact that in chemotherapy cohort many 
patients received Gefitinib after relapse. To sum up, Gefitinib 
shows higher anti-tumor effect than standard chemotherapy if the 
target patients are EGFR positive, and thus is an appropriate opti-
on as the adjuvant treatment regimen after complete resection. It 
was impliedfrom Phase I trial that Gefitinib shows anti-tumor effect 
for the solid tumor patients who did not benefit from standard 
of care or have no other treatment options and thus effective for 
various types of cancer. In Phase II monotherapy trial, Gefitinib 
showed clinically significant and continuous anti-tumor effect in 
locally-advanced or metastatic NSCLC patients previously treated 
with chemotherapy. Additionally, it improved the cancer symptoms 
in these patients. Orally administering 250mg or 500mg once per 
day showed the same level of efficacy. Although in Phase III mo-
notherapy trial targeting on advanced NSCLC patients the efficacy 
of Gefitinib was demonstrated, there was no statistically significant 
difference in terms of OS, which is the primary endpoint. However, 
the response rate of Gefitinib cohort was higher than that of place-
bo cohort. In Phase III combination chemotherapy trial, standard 
chemotherapy (Gemcitabine/Cisplatin, Paclitaxel/Carboplatin) and 
Gefitinib 250mg per day or 500mg per day were evaluated. In this 
study however, statistically or clinically significant data superior 
to combination of standard chemotherapy with placebo was not 
observed. In conclusion, there are three reasons why patients with 
EGFR mutations should receive adjuvant EGFR-TKIs. Firstly, EGFR-
TKI induces apoptosis and its exposition to EGFR positive patients 
potentially induces eradication of micrometastasis remaining after 
surgery. Secondly, for the EGFR positive patients, EGFR-TKI is 
superior to standard platinum-doublet in terms of safety and to-
lerability. Lastly, EGFR-TKI is the most potent anti-cancer drug for 
EGFR positive patients at the moment, which shows remarkable 
anti-tumor effect, prolongs PFS and improves QOL compared to 
platinum-doublet. Therefore, despite the issue of ILD remains, 
EGFR-TKI is to be considered as an appropriate treatment option 
in adjuvant setting for the EGFR positive patients. In order to prove 
this point, West Japan Oncology Group (WJOG) is currently con-
ducting IMPACT trial, which is a prospective Phase III study.
Keyword: EGFR, TKI, NSCLC
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Abstract: The Cochrane Collaboration is an international, inde-
pendent, not-for-profit organisation of over 28,000 contributors 
from more than 100 countries, dedicated to making up-to-date, 
accurate information about the effects of health care readily avail-
able worldwide.
Cochrane contributors work together to produce systematic re-
views of healthcare interventions, known as Cochrane Reviews, 
which are published online in The Cochrane Library. Cochrane 
Reviews are intended to help providers, practitioners and patients 
make informed decisions about health care, and are the most com-
prehensive, reliable and relevant source of evidence on which to 
base these decisions.
Over 5,000 Cochrane Reviews have been published so far, online 
in the Cochrane Database of Systematic Reviews, part of The Co-
chrane Library. The Collaboration also prepares the largest collec-
tion of records of randomised controlled trials in the world, called 
CENTRAL, published as part of The Cochrane Library. Work from 
the Cochrane Collaboration is internationally recognised as the 
benchmark for high quality information about the effectiveness of 
health care. 
 
The Collaboration believes that effective health care is created 
through equal partnerships between researcher, provider, prac-
titioner and patient. Cochrane Reviews are unique because they 
are both produced by, and are relevant to, everyone interested 
in the effects of human health care. Based on the best available 
evidence, healthcare providers can decide if they should fund pro-
duction of a particular drug. Practitioners can find out if an inter-
vention is effective in a specific clinical context. Patients and other 
healthcare consumers can assess the potential risks and benefits of 
their treatment. 
 
The Cochrane Collaboration’s contributors are a mix of volunteers 
and paid staff who are affiliated to the organisation through Co-
chrane entities: healthcare subject-related review groups, thematic 
networks (called ‘fields’), groups concerned with the methodology 
of systematic reviews, and regional centres. Many are world lead-
ers in their field of medicine, health policy, research methodology 
or consumer advocacy, and our entities are situated in some of the 
world’s finest academic and medical institutions. The Cochrane 
Collaboration is named after Archie Cochrane (1909-1988), a British 
epidemiologist, who advocated the use of randomised controlled 
trials as a means of reliably informing healthcare practice. The Col-
cer with adjuvant Erlotinib Cancer Treatment) trial is a single-arm, 
prospective study of two years of adjuvant erlotinib in 100 patients 
with resected, state IA to IIIA EGFR mutation positive NSCLC. Pre-
liminary results presented at the 2012 ASCO meeting for the first 
36 patients showed a DFS of 94% compared to a historical control 
of 70% with a median follow-up of 2.7 months. The answer provi-
ded by the SELECT trial is also unlikely to be definitive. The phase 
II/III Tailored Post-Surgical Therapy in Early Stage NSCLC (TASTE) 
trial by the French Collaborative Intergroup compares 4 cycles of 
standard cisplatin/pemetrexed (CP) adjuvant chemotherapy (arm 
A, n= 74) with customised adjuvant treatment (arm B, n = 76) based 
on EGFR and ERCC1 status in patients with completely resected 
stage IIA, IIB or IIIA (non-N2) (6th TNM edition) nonsquamous NS-
CLC. In the experimentalarm, EGFR mutated patients received 
erlotinib 150 mg for one year. ERCC1 negative pts received four 
cycles of CP. EGFR mutation was identified in only 10 patients (3 
in arm A, 7 in arm B). All 7 patients with EGFR mutation in arm B 
received erlotinib for a median duration of 276 days. The phase III 
was cancelled due to the unexpected unreliability of the ERCC1 
immunohistochemistry read-out. Two randomised studies compa-
ring gefitinib 250 mg daily for 2 years with adjuvant chemotherapy 
(4 cycles of cisplatin/vinorelbine) in patients with surgically resec-
ted stage IIA, IIB and IIIA EGFR mutation-positive adenocarcinoma 
are ongoing in Japan and in China (ADJUVANT CTONG 1104). In 
conclusion, it remains unclear whether targeted therapies improve 
outcomes over traditional chemotherapy in the adjuvant setting 
in NSCLC, and it is premature to recommend adjuvant EGFR TKI 
therapy outside well-designed clinical trials as there is currently no 
conclusive data on its role in early- and locally advanced NSCLC 
harbouring EGFR mutations. Given the consistent development of 
acquired resistance to EGFR TKI therapy in patients with metasta-
tic NSCLC, there is good reason to question whether it is advisable 
to use EGFR TKI for adjuvant therapy in patients who have no evi-
dence of disease and who can develop resistance to an otherwise 
effective treatment. Furthermore, the optimal duration of adjuvant 
therapy is yet to be defined and it is unknown whether EGFR TKI 
is merely by suppressing the growth of residual disease after sur-
gery rather than eradicating minimal residual disease. Given the 
fact that adjuvant therapy needs to be given post-operatively for 
a prolonged period, the quality of life of patients while on therapy 
and the financial cost involved also need to be considered.
Keyword: EGFR mutant NSCLC, adjuvant EGFR TKI
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Abstracts of Reviews of Effects (DARE), the Cochrane Central Re-
gister of Controlled Trials (CENTRAL), the Cochrane Methodology 
Register (Methodology Register), the Health Technology Assess-
ment Database (HTA), and the NHS Economic Evaluation Database 
(NHS EED). The CDSR now contains over 5520 systematic reviews 
and it impact factor was 5.912 in 2011. Although the great majority 
of reviews address questions of therapy based on evidence from 
controlled trials, there are also reviews of diagnostic interventions. 
The Cochrane Lung Cancer Group (LCG) is one of over 50 Cochra-
ne Review Groups and is dedicated to conducting systematic 
reviews on all aspects of primary prevention, therapy, supportive 
care, psychological interventions, biological therapy, and comple-
mentary therapy for the prevention, treatment and care of people 
with lung cancer and other intra-thoracic tumours. Established in 
1998 it was originally hosted by the Ibero American Cochrane Cen-
tre (IACC) in Barcelona but has recently moved to the University of 
Besançon, France. Prof Virginie Westeel and Dr Fergus Macbeth 
are the Coordinating Editors, supported by an international group 
of clinical and methodological editors. There are currently 37 lung 
cancer reviews either published or being worked on, with topics 
ranging from screening to chemotherapy and palliative radiothera-
py. The authors of new reviews have to submit a title proposal and 
a protocol to the Managing Editor. These are peer reviewed, for-
mally approved, and published in The Cochrane Library allowing 
opportunity for anyone interested to comment on the proposed 
content and methods. The review process requires: · a thorough 
literature search · careful selection of the relevant publications · 
assessing each publication’s Methods for any sources of bias and 
completing a ‘Risk of Bias’ table · extracting the key data · carry-
ing out a meta-analysis if appropriate · summarising the findings · 
writing conclusions including a summary in non-technical language 
for patients and public After the draft review is submitted, it is re-
fereed by three editors with the appropriate expertise. An external 
peer review is also obtained. This process is designed to maintain 
the rigour and quality of the reviews to the level expected by The 
Cochrane Library. Before publication, there is a second review for 
language, style, and clarity. Carrying out a systematic review to the 
required standards is therefore a demanding and rigorous process 
and should be regarded as a research project in itself. This sessi-
on explains the process in more detail and will I hope engender 
enthusiasm and lead to the recruitment of new authors. 1. http://
www.thecochranelibrary.com
Keyword: Cochrane Library, lung cancer, systematic review
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C.02 WRITING A PROTOCOL
Noelle O‘Rourke
Cochrane Collaboration Lung Cancer Group, Beatson Cancer Centre/
United Kingdom
Abstract: The Cochrane Collaboration is an international network 
of more than 28,000 dedicated people in over 100 countries. Our 
vision is that healthcare decision-making throughout the world 
will be informed by high-quality, timely research evidence. We 
prepare, update and promote the accessibility of Cochrane Sys-
tematic Reviews. The Lung Cancer Group editorial team oversees 
the process of review development from title registration through 
publishing a protocol to completion of the final systematic review. 
The scope of topics covered includes prevention, early detection, 
diagnostic test, all modalities of treatment for both lung cancer 
laboration is an independent, not-for-profit organisation, funded 
by a variety of sources including governments, universities, hospi-
tal trusts, charities and personal donations.
The Collaboration is registered as a charity in the United Kingdom. 
To tie the organisation together, there are a number of overarch-
ing structures, led by the Steering Group, which provides policy 
and strategic leadership for the organisation. Members of this 
group are democratically elected from, and by, contributors. The 
Cochrane Operations Unit, is based in Oxford, UK, which man-
ages the financial, legal and administrative work of the organisa-
tion, led by the Chief Executive Officer of the Collaboration; and 
a Cochrane Editorial Unit, based in London, UK, which supports 
Cochrane Review production, editorial processes, and training and 
methods development, led by the Editor in Chief of The Cochrane 
Library. There are annual conferences, known as “Colloquia”, which 
are open to everyone. Colloquia are designed to bring people 
together in one place to discuss, develop and promote our work, 
and to shape the organisation’s future direction.
In addition to the core mission of producing Cochrane Reviews, 
contributors are involved in a number of related activities, includ-
ing advocacy for evidence-based decision-making, providing train-
ing in Cochrane Review preparation, developing the methodology 
for preparing reviews, and translating them from English into a 
variety of different languages. 
 
This session includes providing an introduction to developing a 
Cochrane Review and is kindly supported by the Cochrane Lung 
Cancer Review Group, based in Barcelona Spain (website ) and 
uses high quality training materials developed by the Cochrane 
Collaboration (grateful acknowledgement of for allowing the use 
of the training materials) delivered by volunteer Cochrane Col-
laborators. The session will address topics including; Introduction 
to systematic reviews, Writing a Cochrane protocol, Searching for 
studies, Collecting data, Risk of bias, Meta-analysis, Types of data, 
Heterogeneity, Analysing data and Interpreting results 
 
Other training resources include Online Learning Modules as part 
of a self-directed learning initiative of The Cochrane Collabora-
tion. They provide an introduction to the core skills and methods 
required for new authors of Cochrane systematic reviews of inter-
ventions. The modules are intended to complement other learning 
opportunities such as face-to-face workshops and webinars, and 
the guidance provided in the Cochrane Handbook for Systematic 
Reviews of Interventions. 
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C.01 INTRODUCTION TO WRITING A COCHRANE RE-
VIEW
Fergus Macbeth
Cardiff University, School Of Medicine, Wales Cancer Trials Unit/United 
Kingdom
Abstract: The Cochrane Collaboration was set up in 1993 with 
the aim of providing a library of high quality systematic reviews of 
healthcare interventions. Over the past 20 years it has grown and 
now involves more than 28,000 people from around the world in 
its work. The Cochrane Library 1 is now published by Wiley as part 
of their Online system and includes the following databases: the 
Cochrane Database of Systematic Reviews (CDSR), the Database of 
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with similar characteristics to those of the patients included in the 
reviewed studies. (5) Many questions need to be answer in lung 
cancer therapy. However, randomized clinical trials are relatively 
few, especially in my specific field: thoracic surgery. We all should 
feel the responsibility to participate and include patients in clinical 
trials. No doubt, participation demands an extra effort from us: se-
lecting patients, taking the time to explain the trial to the patients, 
abiding by randomization rules, sticking to the protocol and so 
on. But the effort pays off, because the conclusions we draw from 
randomized clinical trials are the most reliable and solid we can 
now have on therapeutic interventions. I would like to encourage 
the audience to participate in clinical trials. The more randomized 
clinical trials we complete, the more systematic reviews and grea-
ter the level of evidence on specific issues of lung cancer and other 
health-related problems. References 1. Friedrich MJ. The Cochrane 
Collaboration turns 20: assessing the evidence to inform clinical 
care. JAMA 2013;309:1881-1882. 2. Tovey D, Maclehose H, Clarke 
M. The Cochrane Collaboration, its mission and the value of syste-
matic reviews. Cancer Control 2013;155-159. http://globalhealthdy-
namics.co.uk/cc2013/wp-content/uploads/2013/04/155-159-David-
Tovey_2012.pdf Accessed on 27th July 2013. 3. The Cochrane 
Library. http://www.thecochranelibrary.com/view/0/browse.
html Accessed on 27th July 2013. 4. OCEBM Levels of Evidence 
Working Group. “The Oxford 2011 Levels of Evidence”. Oxford 
Centre for Evidence-Based Medicine. http://www.cebm.net/index.
aspx?o=5653. Accessed on 27th July 2013. 5. Cochrane Consumer 
Network. http://consumers.cochrane.org/what-systematic-review 
Accessed on 27th July 2013.
Keywords: Cochrane Collaboration, Systematic reviews, Rando-
mised clinical trials, Meta-analysis
and mesothelioma and complementary therapies. 
 
The first stage in preparing a review is to identify the topic and 
register this as a title with the Cochrane group. From this point 
the authors have a six month time frame to develop a protocol 
which is essentially the outline plan for the full review. The protocol 
defines the question to be addressed and specifies the process 
for identifying, assessing and analysing studies in the review. This 
will include the inclusion criteria for studies, the search strategy 
used, the comparisons to be made, any sub-group analyses and 
their justification and the outcomes to be reported. Once the pro-
tocol has been reviewed by the editorial team and confirmed as 
appropriate for development to a full systematic review, it will be 
published by Cochrane as a public record of an intended review. 
This registration helps to minimize bias in the subsequent conduct 
and reporting of the review and also reduces duplication of effort 
between groups. This presentation will describe the process of 
protocol development for a Cochrane review.
Keywords: Cochrane Collaboration, Protocol
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C.13 FEEDBACK AND CLOSING REMARKS
Ramon Rami-Porta
Thoracic Surgery, Hospital Universitari Mutua Terrassa/Spain
Abstract: The Cochrane Collaboration celebrates its 20th anni-
versary this year. (1, 2) With around 28,000 people involved in 53 
Cochrane Review Groups in about 100 countries and more than 
5,000 systematic reviews, the Cochrane Collaboration has assisted 
clinicians, patients, researchers, policy makers and other health 
professionals to make decisions on a large number of health-
related topics. Around 400 systematic reviews are on screening, 
prevention or treatment of different cancers, and they collectively 
analyse nearly 5,000 studies. (2) Forty-one systematic reviews are 
on lung cancer and mesothelioma: 21 of them deal with non-small 
cell lung cancer and 8, on small cell lung cancer; 7 are related to 
general aspects of treatment; 3 are about prevention and early de-
tection; and 2 are about mesothelioma. (3) A Cochrane systematic 
review is the final product of a highly elaborated process. Today’s 
Workshop has gone through all this process starting with the de-
finition of a question that needs to be answered with the highest 
certainty. The question is reflected in the TITLE of the review, the 
first submission to the review group editors that the potential au-
thors do. Once the title has been approved, potential authors have 
to write and submit a PROTOCOL, a larger document that includes 
the background of the topic, the methodology to be used, with 
inclusion and exclusion criteria of studies and patients, the thera-
peutic interventions that will be included, the search strategy, and 
relevant references. After approval of this second phase of the 
process by the review group editors, the authors have to write the 
final document, the SYSTEMATIC REVIEW, which is internally and 
externally reviewed. Most systematic reviews analyse randomised 
clinical trials only, because this is the best research instrument 
we have in clinical practice. The conclusions derived from these 
reviews have a high level of evidence - that can even be increased 
if meta-analyses can be done combining data from the different 
studies. (4) The meticulous search of published and unpublished 
data, the careful identification of biases and the sound methodo-
logy provide reliable information on the effectiveness of a certain 
therapeutic intervention, that can be recommended to patients 
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zing data from10 cancer registries, the crude incidence rate of lung 
cancer in China was estimated to be 49.35 per 100,000 population 
(63.7 per 100,000 men and 35.0 per 100,000 women) in 2005 [29]. 
Compared to lifelong non-smokers, the mortality rate of lung can-
cer was found to be approximately 23 times and 13 times higher 
in current male smokers and current female smokers respectively 
[30]. As prevalence of smoking rose during the past 3 decades, 
lung cancer mortality also increased by 464.84% [31]. Since 2008, 
lung cancer has surpassed other malignant tumors to become the 
most common cause of death in Chinese cancer patients [32]. At 
present, the mortality rate of lung cancer is 600,000 per year [33]. 
If the current trend continues, it may reach 1 million by 2025 [33]. 
With an increased prevalence of lung cancer and more advanced 
technology, the total number of lung cancer inpatients increased 
from 174,066 to 364,484 while medical costs increased from 2.16 
billion yuan to 6.33 billion yuan between 1999 to 2005 as illustra-
ted in the China Statistical Yearbook. Nonetheless, such dedication 
did not effectively prove its worth since the 5-year survival rate 
of lung cancer remained relatively low (10% - 14%) [34]. To relieve 
the socioeconomic burden, measures should be taken to reduce 
the incidence of lung cancer and relevant medical costs. CAD and 
Smoking Smoking has been associated with increased risk of coro-
nary artery disease (CAD). In China, the reported crude odd ratio 
varied between 1.37 - 5.19 in former and current smokers [35-38]. 
In a study about risk ratio for CAD mortality, former smokers and 
current smokers had a risk ratio of 0.68 and 1.81 respectively when 
compared to never smokers [37]. Nonetheless, such figures bore 
no significant difference if stratified by co-morbidity of diabetes. 
Perhaps not surprisingly, passive smoking was verified to indepen-
dently increase the risk of cardiovascular heart disease (CHD) by 
25% - 30% [39,40]. While the prevalence of coronary artery disease 
(CAD) have fallen in developed countries through control of pre-
ventable risk factors, China witnessed an opposite trend as CAD 
climbed from the fifth most common heart disease in 1948-1957 
to the most common in 1980-1989 [41]. As reported, CAD caused 
51.4% and 32.8% of mortality related to cardiovascular disease 
(CVD) in urban and rural areas respectively. Projected from 1990, 
72.7 million Chinese male and 72.1 million Chinese female will 
have been diagnosed with CAD in 2020 [42]. Smoking, one of the 
modifiable risk factors of CAD, should be tightly controlled in Chi-
na if the socioeconomic burden has to be alleviated. Conclusion 
COPD, lung cancer and CAD are common smoking related chronic 
diseases which occupy a large share of medical resources yet cost 
a massive number of lives in China. In order to improve the current 
situation, smoking cessation should be reinforced in China through 
introduction of effective measures supported by favorable poli-
cy. Reference 1. Wang H. Tobacco control in China: the dilemma 
between economic development and health improvement. Salud 
Publica Mex. 2006; 48(Suppl. 1): S140–7.
Keyword: Smoking, COPD, Lung Cancer, CAD
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CALC.02 KEYNOTE: EPIDEMIOLOGY AND BURDEN OF 
SMOKING RELATED DISEASES IN CHINA
Chunxue Bai
Department Of Pulmonary Medicine, Zhongshan Hospital, Fudan Uni-
versity/China
Abstract: Being the largest producer and consumer of tobacco ac-
ross the globe, China produces one-third (2.66 million tons/year) of 
the global tobacco leaves [1] and consumes 30% of the world’s ci-
garettes [2]. According to the Global Adult Tobacco Survey (GATS) 
Collaborative Group, China had the highest number of tobacco 
users (300.8 million) and a low quit ratio compared to 16 countries 
[3]. The International Collaborative Study of Cardiovascular Disease 
in Asia showed that 147,358,000 Chinese male and 15,895,000 
Chinese female aged 35–74 years had been current cigarette 
smokers [4]. Regardless of gender difference, such prevalence was 
higher in the rural population compared to the urban population 
(male 61.6% vs 54.5% P <0.001; female 7.8% vs. 3.4% P<0.001) [4]. 
A growing prevalence of smoking was also observed in women [5], 
adolescents and young adults [2,6-8]. Even among non-smokers, 
the threat of tobacco smoke remained because airborne nicotine 
had been detected in 91% of the 273 public locations sampled 
in rural and urban China [9]. Specifically, an estimated 50-72% of 
Chinese non-smokers had been exposed to secondhand tobacco 
smoke [10,11]. Considering active and passive smoking altogether, 
72% of the Chinese population were tobacco exposed [12]. Such 
common exposure has aggravated tobacco-related morbidity and 
mortality which create a direct economic burden accounting for 
42.31 billion yuan [13]. By increasing mortality from cancer, respira-
tory disease and cardiovascular disease [14-18], smoking currently 
costs over 1 million Chinese lives per year. If the trend continues, 
a predicted sum of 2 million Chinese may die of tobacco-related 
diseases in 2025 [19]. COPD and Smoking Chronic obstructive 
pulmonary disease (COPD) had an estimated prevalence of 8.2% 
(>43 million) in the Chinese population > 40 years old [20] and was 
ranked the fourth/third leading cause of death in urban/rural area 
respectively [21]. Prompted by the causative roles of active [22-24] 
and passive smoking [25], a yet increasing prevalence of COPD 
would be expected in the Chinese population. In the meantime, 
the expensive treatments and compromised productivity of COPD 
patients had already created an enormous economic burden equa-
ling to 110% and 34% of the annual incomes in rural areas and ur-
ban areas respectively [26]. Even so, the situation might have been 
undermined due to premature mortality and impaired working 
capabilities within affected families. Anti-smoking measures could 
be the best solution since the absolute risks of COPD would fall 
by 56% in Chinese male and 63% in Chinese female 5 years after 
smoking cessation [27]. Lung Cancer and Smoking Smoking is the 
main risk factor for lung cancer regardless of smoking experience 
(ever, current and ex smoking), tobacco product variety (pipes, 
cigars and cigarettes) and histological subtypes [28].\\Lee et al. 
demonstrated the dose-response relationship between smoking 
and lung cancer pathogenesis [28]. Specifically, risk of lung cancer 
decreased with duration of smoking cessation but increased with 
an earlier age of smoking and elevations in (i) the amount and frac-
tion of smoking; (ii) duration of smoking; and (iii) tar level. Analy-
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Y.1 PLANNING AN ACADEMIC CAREER IN LUNG  
CANCER
Natasha Leighl
Dept. Med. Oncology, Princess Margaret Cancer Centre/Canada
Abstract: There are many academic career opportunities for 
the young oncologist. Examples of career tracks include basic, 
translational and clinical research, education and administration. 
Finding a niche, or an unique area of contribution, is essential. Key 
elements for success include: 1. Finding a mentor - you can have 
more than one, and s/he doesn‘t need to be at your institution; 2. 
Spending time in academic training, such as pursuing formal re-
search methodology training, administration or education training 
(e.g. Masters of Public Health, Business Administration or Educa-
tion, and higher); 3. Developing a team to support you - include 
clinical support, research support or the personnel you need to 
achieve your career goals; 4. Build strategic partnerships and build 
a collaborative network - for example if you‘re not a scientist and 
wish to do translational research, partner with scientists. Engage 
statisticians, methods experts, and remember that collaboration is 
a two-way street; 5. Challenge yourself to ask important questions 
in your area of study, and focus on key issues - aim high and trust 
yourself; 6. Be a mentor to junior trainees - this is your best invest-
ment; 7. Publish your work; 8. Apply for grants (and don‘t give up 
- you will get some!); 9. Focus on your areas of interest - your areas 
of priority may not be where you spend most of your time, but they 
should be; 10. Keep your passion for your career alive - have a life 
outside academic oncology, enjoy your work and keep it fun. 11. 
Take advantage of opportunities for development - presentation 
skills, teaching skills, grant writing, paper writing, research me-
thods - essential for a successful career, and not taught in medical 
school. 12. If you pursue a career in clinical research, join a coope-
rative group. Accrual is one way that young investigators can get 
themselves noticed, in addition to new ideas.
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Y.4 HOW TO GET YOUR PAPERS PUBLISHED
James R. Jett
National Jewish Health/United States Of America
Abstract: Scientific writing is not something that comes easily 
to most of us. I personally struggled with my own publications 
for the first five years of my academic career. However, I advise 
young colleagues that they should aim for three to five publica-
tions per year. If this is accomplished, then at the end of ten years, 
you would have 30-50 publications on your curriculum vitae. This 
would be enough to result in promotion from Assistant Professor 
to Associate Professor in most institutions. How does one get star-
ted with publishing articles? Before starting, I would suggest that 
you read about publishing scientific articles. An excellent book 
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CALC.06 DIAGNOSIS OF LUNG NODULES BY CT- 
GUIDED LUNG BIOPSY
Yong Song 
NanJing JinLing Hospital, Nanjing/China
Abstract: CT-guided percutaneous needle biopsy(CT-guided 
PTNB) of the lung, with its high sensitivity, specificity, and accura-
cy, is an important diagnostic tool in the evaluation of pulmonary 
lesion, especially in malignant disease . And it’s specificity can 
reach 95 percent to 100 percent in malignant disease. Although 
PTNB of the lung is a mature technique, careful case selection is 
necessary to increase diagnostic yield and avoid unnecessary com-
plications. It is indicated for indeterminate pulmonary nodules or 
masses, particularly those that will likely require chemotherapy or 
radiation rather than surgery. Pneumothorax and pulmonary he-
morrhage are the most common complications of PTNB, whereas 
air embolism and tumor seeding are extremely rare. Attention to 
biopsy planning and technique and postprocedural care help to 
prevent or minimize most potential complications. A retrospective 
investigation of patients with CT-guided PTNB in Jinling Hospital 
between January 2000 to October 2010 was performed. The risk 
factors for complications were determined by multivariate analysis 
of variables related to patients’ demographics, lung lesions, biopsy 
procedures, and individual radiological features.1014 biopsy prce-
dures were enrolled. The total complication rate was 18.5 percent 
with pneumothorax 12.9 percent (131/1014), hemoptysis 5.6 per-
cent (57/1014), and with no mortality. The diagnosis was cofirmed 
by PTNB in 961 patients (94.8 percent) with 639 patients as malig-
nant disease (63 percent) and 322 patients as benign diease (31.8 
percent). Taken into all the evidence, CT-guided percutaneous 
needle biopsy is a safe and effective means in the diagnosis of 
pulmonary occupying lesions.
Keywords: CT-guided, percutaneous needle biopsy, diagnosis, 
Lung cancer
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another journal. The majority of my own peer-reviewed publica-
tions were not accepted in the first journal where they were sub-
mitted. I have personally been rejected by many of the best medi-
cal journals. Do not take rejection personally. Try, try again!!!
Keyword: scientific writing; abstract; publishing articles
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Y.6 MAKING THE MOST OF THE WCLC: A GUIDE FOR 
FIRST TIME ATTENDEES
Primo Lara
Division Of Hematology And Oncology, UC Davis Comprehensive 
Cancer Center/United States Of America
Abstract: The 15th World Conference on Lung Cancer (WCLC) is a 
highly interactive, collaborative, and intellectually enriching forum 
that focuses on the biology, diagnosis, and management of tho-
racic malignancies. For first-time attendees, the sheer scope and 
depth of the WCLC can be quite daunting. This educational sessi-
on is designed for the young investigator or first time attendee. It 
aims to provide practical tools that will help the attendee navigate 
the 15th WCLC. This year, the Core Program Committee has orga-
nized a scientific program that includes more than 250 internatio-
nally renowned speakers and chairs participating in more than 100 
sessions. The program can essentially be categorized as a compo-
nent of either the Education Program or Scientific Program. The 
Education Program includes Invited Sessions wherein key faculty 
present state-of-the-art talks on relevant topics, as well as “Meet 
The Expert Sessions” that provide opportunities for attendees 
to directly interact with faculty . The Scientific Program includes 
cutting-edge and late-breaking research presented in oral, mini-
oral, and poster formats. The Scientific Program also includes the 
Plenary Sessions, the Presidential Symposium (where the top rated 
abstracts are presented), and Highlights of the Day (where expert 
faculty summarize the past day’s most outstanding presentations), 
among others. There are also additional educational sessions such 
as Industry-Sponsored Symposia, a Patient Advocacy session, a 
Cochrane Workshop, and new to the 2013 meeting, a Chinese Alli-
ance Against Lung Cancer session. First timers must carefully note 
that WCLC sessions can either be stand-alone (i.e, with no compe-
ting sessions such as the Plenary Sessions) or concurrent (e.g., oral 
and mini-abstract sessions). The organizers have developed a co-
lor-coded “session at a glance” diagram that clearly denotes each 
session’s schedule relative to others. (An online “virtual WCLC” will 
soon be developed to provide attendees access to concurrent ses-
sions that they may miss because of a competing session.) There 
are also social events such as the Welcome Reception and the Gala 
Dinner that provide additional opportunities for first time attende-
es to interact with colleagues and faculty. It is thus anticipated that 
the 15th WCLC will provide young investigators and first time atten-
dees a unique framework on which to build new collaborations that 
will ultimately have an impact on the future care of the patient with 
thoracic cancer.
Keywords: WCLC, First time attendees, Young investigator
that covers all aspects of scientific writing is “How to Write and 
Publish a Scientific Paper” by Robert Day and Barbara Gastel. This 
book has individual chapters on preparing Abstract, Introduction, 
Methods, Results, Discussion, and References. This text is an ex-
cellent source on “how to do it”. There are also chapters on writing 
review papers, editorials, book chapters, and writing for the public. 
Additional chapters address ethics in publication, use and misuse 
of English, use of abbreviations. Especially useful to authors whose 
first language is not English is the chapter, “How to Write Science 
in English as a Foreign Language”. Another good source, available 
on the internet, is the International Committee of Medical Journal 
Editors (ICMJE) web site. Just type those initials into your web 
browser and review the “Uniform Requirements for Manuscript 
Submitted to Biomedical Journals: Preparing a Manuscript for 
Submission to a Biomedical Journal.” Major ethical issues include 
simultaneous submission to two journals, duplicate publication of 
the same data, plagiarism, and ghost writing. Violation of any of 
these issues will likely result in significant damage to your reputa-
tion and potential punishment by your institution. Violations often 
result in authors being banned from publishing in journals for se-
veral years. It can destroy your academic career. Needless to say, it 
will make your boss very unhappy! Before you submit a manuscript 
to any journal, it is mandatory that you review the “Instructions to 
Authors” for the specific journal. When I was Editor of Journal of 
Thoracic Oncology, one of the most common reasons for rejection 
was that authors did not follow the instructions. It is also advisable 
that you should read several articles, in the journal where you wish 
to publish, to be sure that you follow a similar style to articles that 
the journal has published. I also recommend searching for articles 
on the same topic in the journal for which you are planning the 
submission. If they have published several articles in the past year 
or two on this same topic, then you may want to consider a dif-
ferent journal, unless your article contains new and original infor-
mation. The following are some of the most common reasons for 
articles to be rejected: 
• Failure to read and follow instructions to authors
• Poor quality of English
• Non-structured Abstract
• Lack of novelty (me too articles)
• Dataset too small; flawed statistics
The title and the abstract are extremely important. Often they 
are the only part of the article that is read. Readers decide, after 
reviewing these, if they wish to read the entire article. The words in 
the title should be carefully chosen. Pay careful attention to syntax. 
Avoid the temptation to be “too clever” in the title. Titles are used 
by indexing and abstracting services and help readers find your 
article in the morass of the medical literature. Write the abstract 
last. It should be a condensed version of the manuscript. Readers 
look at the abstract to see if they wish to read more. Sometimes an 
editor will read only the abstract and make a decision on rejection. 
I have done this many times. A poor abstract frequently means a 
poor manuscript. Most journals have a word limit for the abstract, 
frequently 250 words or fewer, and require a four-part structured 
abstract. Make sure that all of the numbers in the abstract match 
the numbers in the results section. This is a common error and 
reflects poorly on the author. Be concise! Remember that the ab-
stract is your chance to get the attention of the reader (reviewer). 
Lastly, do not let a rejection discourage you. Pay careful attention 
to the critique that you have received and consider revising your 
article accordingly. Remember that the “peer review” process is 
not perfect. Reviewers can make mistakes and not recognize the 
merits of your manuscript. Revise your manuscript and send it to 
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genetic variants linked to TNF and IL6 were significantly associated 
with outcome (each using wild-type genotype as reference) (Table 
1). For pneumonitis, the final models adjusted for V20 and smo-
king status. Eight genetic variants found within four genes (ATM, 
BRCA2, IL1alpha, IL1RN) were associated with significant pneumo-
nitis (Table 1).  
ESOPHAGITIS 
Function /  
Pathway Gene refSNP OR 
95% 
CI 
P 
value 
pro-inflammatory 
cytokine 
TNF rs3093662 3.54 
1.9-
10.6 
0.02 
pro-inflammatory 
cytokine 
TNF rs3093664 3.42 
1.2-
10.2 
0.03 
pro-inflammatory 
cytokine 
TNF rs3093665 4.95 
1.2-
21.1 
0.03 
anti-inflammatory 
cytokine 
IL6 rs1800797 2.53 
1.0-
6.2 
0.04 
anti-inflammatory 
cytokine 
IL6 rs1800795 2.45 1.0-5.9 0.046 
PNEUMONITIS 
Function /  
Pathway Gene refSNP OR 
95% 
CI 
P 
value 
double-strand 
break repair 
ATM rs664143 2.67 1.3-5.6 0.01 
double-strand 
break repair 
ATM rs664677 2.37 1.2-4.7 0.01 
homology-direc-
ted repair 
BRCA2 rs1799955 2.59 1.3-5.3 0.01 
homology-direc-
ted repair 
BRCA2 rs1801406 2.42 1.2-4.8 0.01 
homology-direc-
ted repair 
BRCA2 rs1799943 2.09 
1.0-
4.2 
0.04 
anti-inflammatory 
cytokine 
IL1al-
pha 
rs17561 2.63 1.2-5.7 0.01 
anti-inflammatory 
cytokine 
IL1al-
pha 
rs2856863 2.60 1.1-5.9 0.02 
anti-inflammatory 
cytokine 
IL1RN rs3087263 0.17 
0.04-
0.8 
0.04 
Conclusion: In our 92 patient training set, genetic variations in 
TNF and IL6 are associated with radiation esophagitis, while ge-
netic variations in ATM, BRCA2, IL1alpha and IL1RN are associated 
with pneumonitis. Results from the 209 patients in the validation 
dataset will be presented at the meeting (A.H. and G. L are co-
senior authors).
Keywords: esophagitis, pneumonitis, Polymorphisms, SNP
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O01.01 GENETIC POLYMORPHISMS OF INFLAMMATORY 
AND DNA REPAIR PATHWAYS, RADIATION-RELATED 
ESOPHAGITIS AND PNEUMONITIS IN DEFINITIVE CHE-
MORADIATION TREATED NON-SMALL CELL LUNG CAN-
CER PATIENTS.
Katherine Barrett1, Jingxiong Xu2, Kim Su Woon3, Kevin Boyd2, 
Dangxiao Cheng2, Zhuo Chen4, Andrea Bezjak1, Alexander Sun1, 
Andrew Hope1, John Cho1, Elantholi Parameswaran Saibishku-
mar1, Natasha Leighl4, Frances Shepherd4, Wei Xu2, Geoffrey Liu4
1Department Of Radiation Oncology, Princess Margaret Hospital/Ca-
nada, 2Department Of Biostatistics, Ontario Cancer Institute, Princess 
Margaret Hospital/Canada, 3National Cancer Center Sinapore/Singapo-
re, 4Department Of Medical Oncology, Princess Margaret Cancer Centre, 
University Health Network, University Of Toronto/Canada
Background: The benefits of concurrent chemoradiotherapy in 
locally advanced non-small cell lung cancer (NSCLC) are tempered 
by treatment toxicity. Germline genetic variants have been associa-
ted with intrinsic radiosensitivity and radiotoxicity in various cancer 
settings. We investigated whether variants in genes involved in 
inflammation response and DNA repair pathways independently 
influence radiation-induced phenotypes of esophagitis and pneu-
monitis. From 19 candidate genes, 52 polymorphisms, directed by 
literature and by tagging procedures, were systematically selected 
for assessment. The candidate genes were involved in DNA repair 
(double-strand breaks, homology directed, nucleotide excision) 
and pro/anti-inflammatory signaling. The this investigation sought 
to evaluate the association of genetic sequence markers for two 
clinically significant radiation-induced toxicities - esophagitis and 
pneumonitis – seen in NSCLC patients treated with a curative in-
tent.
Methods: From 312 patients treated at PMCC between 2005-12, a 
training cohort was defined consisting of 92 definitive concurrent 
chemoradiation/radiation-treated NSCLC patients with genotype 
information on the 52 polymorphisms. A second, validation cohort 
consisted of 209 patients. Multivariate logistic regression was 
performed for each polymorphism of interest, adjusting for known 
clinical and dosimetric prognostic factors on the dichotomized 
outcomes of radiation esophagitis (Grades 0-2 vs 3-5) and pneu-
monitis (Grades 0-1 vs 2-5). The CTCAEv4.03 grading criteria were 
used. Additive genetic models were used for genetic association 
analysis. In the training set, genetic variants, genotyped by Illumi-
naGoldenGate, with p<=0.05 were identified for validation; HWE 
was set at p>0.01, a criteria met by all polymorphisms with statisti-
cal significance.
Results: In the combined training and validation datasets, 63% 
were males, with median age of 65 years. Specifically in the trai-
ning dataset, 65% were male, with median age of 62, median mean 
lung doses of 15.9, median max esophageal dose of 67.1 and me-
dian V20 of 27.6. For esophagitis, the final models were adjusted 
for concurrent chemotherapy, V20 and max esophageal dose. Five 
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further validate our findings.
Keywords: Prognosis, SCLC, miR-886-3p, miR-150
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O01.03 BRM PROMOTER VARIANTS AND SURVIVAL 
OUTCOMES OF ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC) PATIENTS: A VALIDATION STUDY IN 
THE NCIC CLINICAL TRIALS GROUP (NCIC-CTG) BR24 
CLINICAL TRIAL
Sinead Cuffe1, Lu Cheng1, Abul K. Azad1, Yonathan Brhane1, 
Dangxiao Cheng1, Zhuo Chen1, Xin Qiu1, Kevin Boyd1, Natasha 
Leighl1, Wei Xu1, Bingshu E. Chen2, Penelope Bradbury2, Frances 
A. Shepherd1, Lesley Seymour2, Ming S. Tsao1, David N. Reisman3, 
Geoffrey Liu1
1Princess Margaret Cancer Centre/university Of Toronto/Canada, 2Ncic 
Clinical Trials Group/Canada, 3University Of Florida/United States Of 
America
Background: BRM, an ATPase subunit of the SWI/SNF chromatin 
remodeling complex, is a putative tumor susceptibility gene in 
NSCLC. Loss of BRM expression occurs in 15% of NSCLC, and has 
been linked to adverse outcome. Two BRM promoter insertion 
variants (BRM-741 and BRM-1321) result in epigenetic silencing of 
BRM through recruitment of histone deacetylases. The presence of 
double homozygous BRM variants is linked to loss of BRM expres-
sion and function in lung tumors, and double the risk of lung can-
cer. Pharmacological reversal of the epigenetic changes of BRM 
is feasible. In this study we evaluated the association between the 
BRM promoter variants and survival outcomes of advanced NSCLC 
patients.
Methods: The training cohort consisted of 564 stage III-IV NSCLC 
patients treated at the Princess Margaret Cancer Centre, Toron-
to 2006-2010. The validation cohort comprised 219 stage IIIb-IV 
NSCLC patients from the NCIC-CTG BR24 clinical trial, a phase II/
III double-blind randomized trial of cediranib versus placebo in 
patients receiving carboplatin/paclitaxel for the treatment of ad-
vanced or metastatic NSCLC. Genotyping for the BRM promoter 
variants was performed using Taqman. Associations of BRM pro-
moter variants and overall (OS) and progression free survival (PFS) 
were assessed using Cox proportional hazard models adjusted for 
clinically relevant variables, and in the case of the BR24 population, 
stratified by treatment arm.
Results: Among the training cohort, 73% were Caucasian, 52% 
male, median age 63 yrs, 55% stage IV disease, and 67% ade-
nocarcinoma. Median OS was 1.6yrs; median follow up, 3.6yrs. 
The frequency of homozygosity was BRM-741, 23%; BRM-1321, 
21%; both 12%. Homozygous variants of BRM-741 were strongly 
associated with worse OS (adjusted HR [aHR] 2.5 [95% CI: 1.9-3.3; 
p=6x10E-10]) and PFS (aHR 2.0 [95% CI: 1.6-2.6; p=9x10E-8]) com-
pared to the wild types. Similar findings were observed for the 
BRM-1321 homozygous variants (aHR for OS of 2.0 [95% CI: 1.5-2.6; 
p=2x10E-6]; aHR for PFS of 1.8 [95% CI: 1.4-2.4; p=3x10E-6]). The 
presence of double homozygous BRM-741 and BRM-1321 variants 
was strongly associated with worse OS (aHR 2.8 [95% CI: 1.9-4.0; 
p=7x10E-8]) and PFS (aHR 2.7 [95% CI: 1.9-3.8; p=1x10E-8]). Geno-
typing was possible for 219/296 BR24 participants. Of these, 59% 
were male, median age 59 yrs, 83% stage IV, 46% adenocarcinoma, 
with 50% receiving cediranib. Individuals carrying the homozygous 
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O01.02 MICRORNA SIGNATURE PREDICTS SURVIVAL IN 
RESECTABLE SMALL-CELL LUNG CANCER
Nan Bi1, Jianzhong Cao1, Yongmei Song2, Jing Fan2, Jie He3, Yuankai 
Shi4, Xun Zhang5, Ning Lu5, Luhua Wang1, Qimin Zhan2
1Radiation Oncology, Cancer Hospital (institute),chinese Academy Of 
Medical Sciences & Peking Union Medical College/China, 2State Key 
Laboratory Of Molecular Oncology, Cancer Hospital (institute),chinese 
Academy Of Medical Sciences & Peking Union Medical College/China, 
3Thoracic Surgery, Cancer Hospital (institute), Chinese Academy Of 
Medical Sciences/China, 4Medical Oncology, Cancer Hospital (institute), 
Chinese Academy Of Medical Sciences & Peking Union Medical College/
China, 5Pathology, Cancer Hospital (institute), Chinese Academy Of 
Medical Sciences & Peking Union Medical College/China
Background: Small-cell lung cancer (SCLC) is one of the most ag-
gressive types of cancer, yet the molecular mechanisms underlying 
its devastating clinic outcome remain elusive. In this study, we 
investigated whether microRNA (miRNA) expression profiles can 
predict clinical outcomes of SCLC patients.
Methods: A total of 82 patients with very limited SCLC, who re-
ceived surgical resection followed by adjuvant chemotherapy ac-
cording to the standard of care, were enrolled in this study. All the 
tumor samples used for miRNA profiling were required to contain 
at least 60% tumor cells and RNA was isolated from formalin-fixed 
paraffin-embedded specimens. First, we surveyed 924 miRNAs 
for their expressions from 42 SCLC patients to discover survival 
relevant miRNAs and develop prognostic models, which were then 
validated in an independent cohort of 40 cases. A risk score of 
miRNA signature for survival prediction was calculated according 
to a combination of expression level of the miRNA weighted by the 
regression coefficient derived by univariate Cox regression analy-
sis. Kaplan-Meier overall survival curves were compared using the 
log-rank test and multivariate Cox regression model was used to 
test if the miRNA signature was an independent prognostic factor.
Results: For all the patients, the median follow up time was 57.2 
months. Forty-four patients (53.7%) are still alive. Forty-two pati-
ents (51.2%) had recurrent disease and the median time to diag-
nosis of relapse was 12.3 months. In the training set, we identified 
that two miRNAs, miR-150 and miR-886-3p, were significantly 
associated with poor OS. The results compared between NL and 
SCLC tissues also verified that the miR-150 and miR-886-3p expres-
sion levels in SCLC were much lower than in normal lung samples 
(884±126 vs 2954±1652 for miR-150 and 1873±256 vs 3154±448 for 
miR-150 ). We then derived a miRNA signature 0.545×miR-150 + 
0.617 ×miR-886-3p. Compared with patients with low-risk miRNA 
signature, patients with high-risk signature had significantly shorter 
median OS (12.6 months versus not reached, P=0.02). This signa-
ture was also demonstrated to be a significant predictor of survi-
val in the validation set. Patients with high risk miRNA signatures 
had poor overall survival (P=0.005) and progression-free survival 
(P=0.017) compared to those with low-risk scores. It retained statis-
tical significance in a model adjusting for age, gender and smoking 
status (HR 0.27, 95% CI 0.10-0.72, P=0.008), which suggesting that 
the miRNA signature may be an independent predictor of survival.
Conclusion: In this study, we developed a prognostic miR-150/
miR-886-3p signature and validated in an independent dataset for 
resectable SCLC. Our results indicated that microRNAs may serve 
as promising molecular prognostic markers as well as new thera-
peutic targets for SCLC. Larger sample size studies are needed to 
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level) as cut-off value (3.95m vs. 1.60m, P=0.015). The objective 
response rate (ORR) was 7% in the EGFR wild-type cohort, and 
patients with high miR-200c expression level had better ORR than 
those with low level (12.5% and 3.0%, P=0.3). In Cox regression 
analysis, miR-200c expression also present the same trend for 
benefit from EGFR-TKIs in EGFR-negative NSCLC (HR= 0.375, 
95%CI: 0.198-0.712, P= 0.003).
Conclusion: miR-200c appears to act as a critical role in EGFR-TKIs 
sensitivity in NSCLC patients with wild-type EGFR. Up-expression 
of miR-200c can trigger MET and suppress PI3K/AKT, MEK/ERK 
pathway, which can also partially overcome EGFR-TKIs resistance. 
miR-200c might be a predictive biomarker of clinical response to 
EGFR-TKIs and assist in selecting the subpopulation in patients 
with wild-type EGFR to benefit from targeted therapy.
Keywords: EGFR-TKI, NSCLC, drug resistance, miR-200c
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O01.06 DYNAMIC CHANGE IN PLASMA EGFR MUTATI-
ON DNA IN RESPONSE TO FIRST LINE THERAPY FOR 
ADVANCED STAGE NON-SMALL CELL LUNG CANCER 
(NSCLC)
Tony Mok1, Yi-Long Wu2, Jin Soo Lee3, Chong-Jen Yu4, Virotw 
Sriuanpong5, Wei Wen6, Julie Tsai6, Matt Trueman7, Barbara Klug-
hammer8, Lin Wu6
1Department Of Clinical Oncology, The Chinese University Of Hong 
Kong/Hong Kong, 2Guangdong Lung Cancer Institute, Guangdong 
General Hospital/China, 3Lung Cancer Branch Research Institute And 
Hospital, National Cancer Center/Korea, 4National Taiwan University 
Hospital/Taiwan, 5The King Chulalongkorn Memorial Hospital & Chul-
alongkorn University/Thailand, 6Genomics And Onoclogy Department 
Research, Roche Molecular Systems, Inc./United States Of America, 
7Roche Products Ltd/Australia, 8Hoffmann-la Roche Ltd,/Switzerland
Background: Diagnostic utility study of EGFR mutation analysis 
of tumor and plasma from FASTACT 2 confirmed that the plasma 
EGFR mutation DNA (pEGFRmut) is a sensitive and specific bio-
marker. (Wu et al, Lancet Oncology 2013; T. Mok, ASCO 2013). Pri-
mary objective of this study is to investigate the dynamic change 
in pEGFRmut during course of treatment. Secondary objective is 
to study the diagnostic utility of pEGFRmut in patients with distant 
organ metastasis whom we assumed to have higher level of plasma 
DNA.
Methods: Retrospective EGFR mutation testing of FFPET and 
plasma from FASTACT 2 were performed with two allele-specific 
assays, cobas® 4800 EGFR_FFPET test and cobas® EGFR_blood 
test (in Development). Both tests are designed to detect one or 
more of the 42 known EGFR mut. One FFPET section was used for 
tissue test and 2-ml plasma was used for blood test. We studied 
the plasma samples collected at baseline, post cycle 3 (C3) and at 
tumor progression according to RECIST criteria (PD).
Results: Complete analysis of plasma samples at baseline, C3 and 
PD was available in 305 of 451 pts(67.6%). Incidence of pEGFRmut 
positive at baseline, C3 and PD was 35% (106/305),15% (47/305)
and 27% (81/305), respectively. 98 of 106 pEGFRmut patients har-
bor the Exon 19 deletion or L858R at baseline. (C arm 51; CE arm 
47). At C3, 21 (41%) pts lose pEGFRmut positivity in C arm compa-
ring to 39 (83%) in CE arm. At PD, 8 of the 21pts in C arm and 18 of 
variants of both BRM-741 and BRM-1321 (13% of cases) had a sub-
stantially worse OS (aHR 9.0 [95% CI: 4.3-18.5; p=1x10E-9]) and PFS 
(aHR 3.8 [95% CI: 1.9-7.3; p=3x10E-5]) compared to the wild types, 
irrespective of whether they were treated with cediranib (aHR for 
OS of 6.4; p=1x10E-4; aHR for PFS of 2.1; p=0.02) or placebo (aHR 
for OS of 16.8; p=2x10E-7; aHR for PFS of 8.3; p=1x10E-4).
Conclusion: The same two homozygous BRM promoter variants 
that are associated with increased risk of NSCLC are also strongly 
associated with adverse OS and PFS in this study of advanced 
NSCLC patients. We are completing additional studies focusing 
on the relationship between the BRM promoter variants and BRM 
protein expression; results will be presented at the meeting.
Keyword: non-small cell lung cancer, BRM, polymorphisms,  
survival
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O01.05 EGFR WILD-TYPE NSCLC PATIENTS WITH HIGH 
MIR-200C EXPRESSION CAN BENEFIT FROM EGFR-TKI
Jiayu Li, Xuefei Li, Shengxiang Ren, Xiaoxia Chen, Caicun Zhou
Department Of Medical Oncology; Lung Cancer And Immunology Labo-
ratory, Shanghai Pulmonary Hospital, Tongji University; Tongji Univer-
sity Medical School Cancer Institute/China
Background: EGFR mutation is a strong positive predictive factor 
of EGFR-TKIs therapy. However, at least 10% of patients with wild-
type EGFR are responsive to TKIs, suggesting that other determi-
nants of outcome besides mutant EGFR might exist. miR-200c is 
an important regulator of epithelial-to-mesenchymal transition and 
might be associated with drug-resistance. Our objective was to 
characterize miR-200c expression in NSCLC and its role in TKI sen-
sitivity in EGFR wild-type NSCLC.
Methods: miR-200c levels in 7 NSCLC cell lines were measured by 
real-time quantitative reverse transcription-PCR (qRT-PCR). Direct 
target of miR-200c was identified through the TargetScan databa-
se and was validated through qRT-PCR and Western blot analysis. 
The precursor of miR-200c was up-expressed in H1975 and A549 
cells using a lentivirus construct, and miRNA inhibitor was used to 
down-regulate the expression of miR-200c in PC9 cell line. Effects 
of miR-200c on cell proliferation and sensitivity to EGFR-TKIs were 
evaluated by MTT assay in vitro. The expression of proteins corre-
lating with signaling pathway was determined by western blot ana-
lysis. 141 FFPE samples of advanced NSCLC patients were enrolled 
in this study, and miR-200c expression and EGFR mutations were 
detected by qRT-PCR and amplification refractory mutation system 
(ARMS), respectively.
Results: We identified a tight association between the expression 
of miR-200c, epithelial phenotype, and sensitivity to TKIs in NSCLC 
cell lines. Up-expression of miR-200c in A549 and H1975 cells 
up-regulated E-cadherin levels, down-regulated expression of 
ZEB1, vimentin, pERK and pAKT. Up-regulated miR-200c increased 
sensitivity to gefitinib in the primary resistant cell line A549. 
Analysis of 141 NSCLC specimens indicated that median PFS of 
EGFR wild-type (n=57) and EGFR mutant NSCLC patients (n=73) 
treated with second/third line targeted therapy was 1.8m vs. 12.0m 
respectively (P<0.0001). Patients with high expression level of miR-
200c had a positive association towards a longer PFS in NSCLC 
harboring EGFR wild-type when considering 2-ΔCt=0.01128 (median 
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sification and has demonstrated prognostic and predictive utility 
in retrospective studies. PROSE is the first completed multicenter 
prospective randomized biomarker validation trial, designed to 
evaluate the ability of VS to predict survival in 2nd- line NSCLC pts 
treated with E or CT. As reported at 2013 ASCO1, VSG pts derived 
similar overall survival (OS) benefit from both agents (hazard ratio 
(HR) for E=1.06; p=0.71) whereas CT was the superior option for 
VSP pts (HR for E=1.72; p=0.02). PROSE met its primary endpoint 
of demonstrating significant treatment*VS interaction with a p-
value of 0.031. The present report discusses the results for the 
secondary endpoints, PFS.
Methods: 285 pts, stratified by ECOG-PS, smoking, and blinded 
pre-treatment VS classification, were randomized 1:1 to receive E 
or CT at standard doses. Primary endpoint was overall survival (OS) 
and the primary hypothesis was a significant interaction between 
VS status and treatment. Sample size was calculated based on an 
estimated 65%/35% VSG:VSP ratio and hazard ratio (HR) for inter-
action of 2.35, with a 2-sided α=0.05 and 90% power.
Results: 263 pts (129 CT, 134 E) were included in the per protocol 
primary analysis. 68% of pts in CT arm and 72% in E arm were clas-
sified as VSG, and analysis was performed at 226 survival events.
VSP classification was significantly correlated with worse PFS as 
compared to VSG, in overall comparison (HR=1.75, 95%CI: 1.34-
2.95, P <0.001) , in the CT (HR = 1.69, 95%CI: 1.15-2.48, P <0.007) 
and the E (HR = 1.91, 95%CI: 1.340-2.80, P<0.001) arms, demonst-
rating its prognostic value also in PFS. In VSG median PFS was 4.8 
months (m) on CT, and 2.5 m on E (HR = 1.26, 95% CI: 0.94-1.69, 
P =0.129); in VSP median PFS was 2.8 m on CT and 1.7 m on E 
(HR=1.51, 95% CI: 0.96-2.38, P =0.078). No statistical significant 
interaction was detected (p=0.44)
Conclusion: The analysis of PFS and OS indicates that the differen-
tial treatment benefit in OS related to VS classification is determi-
ned by the combination of prognostic and predictive properties of 
the test.
Keywords: NSCLC, VeriStrat, Proteomic profile, predictive  
biomarker
the 39 in CE arm regained pEGFRmut positivity. Table 1 summa-
rized the median pEGFRmut copies/PCR. There was a considerable 
decline at C3 in both C and CE arm. However, pEGFRmut copies/
PCR rebounded to high level at PD in C arm only and remained 
low in CE arm. Correlation of dynamic change in pEGFRmut co-
pies/PCR with clinical tumor response and PFS will be presented at 
the meeting. We have also identified 93 (out of 224 matched tissue 
and plasma samples) patients with known distant organ metastasis. 
Sensitivity of pEGFRmut in this patient subgroup is 91% (41/45), 
specificity at 98% (47/48) and overall concordance at 95% (88/93). 
Table 1  
Median pEGFRmut copies/PCR Baseline C3 PD 
C (Exon 19) 27.6 2.3 35.8 
CE (Exon 19) 43.2 0 2.7 
C(Exon 21) 40.9 2.6 63.9 
CE (Exon 21) 87.1 0 3.5 
Conclusion: This is the first study demonstrating the quantitative 
dynamic change in pEGFRmut in pts who received C or CE for ad-
vanced NSCLC. At RECIST progression, pEGFRmut remained low 
in patients who received erlotinib but not in patients who received 
chemotherapy only. pEGFRmut is a potential biomarker for monito-
ring tumor response.
Keyword: EGFR, mutation, plasma DNA, allele-specific PCR,
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O01.07 RANDOMIZED PROTEOMIC STRATIFIED PHA-
SE III STUDY OF SECOND LINE ERLOTINIB (E) VERSUS 
CHEMOTHERAPY (CT) IN PATIENTS WITH INOPERABLE 
NON-SMALL CELL LUNG CANCER (PROSE): SECONDARY 
ENDPOINT ANALYSIS
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Valter Torri10, Fred Hirsch11, Heinrich Roder12, Julia Grigorieva12, 
Joanna Roder12, Alessandra Bulotta1, Silvia Foti1, Mariagrazia Vi-
ganò1, Matteo Giaj Levra2, Angela Bachi13
1Department Of Oncology, Ospedale San Raffaele/Italy, 2Department Of 
Oncology, University Of Turin/Italy, 3Department Of Oncology, Azien-
da Ospedaliera Treviglio/Italy, 4Division Of Medical Oncology, Centro 
Di Riferimento Oncologico Di Basilicata/Italy, 5Medical Oncology Unit, 
National Institute For Cancer Research/Italy, 6Oncologia Malattie Respi-
ratorie, Istituto Europeo Di Oncologia/Italy, 7High Specialization Hospi-
tals , Oncological Pulmonary 1st Unit, San Camillo-forlanini/Italy, 8Di-
partimento Di Oncologia, Ao Villa Scassi/Italy, 9Department Of Medical 
Oncology, National Institute For Cancer Research/Italy, 10Department 
Of Oncology, Mario Negri Institute/Italy, 11University Of Colorado Can-
cer Center/United States Of America, 12Biodesix Inc/United States Of 
America, 13Division Of Mass Spectrometry, Ospedale San Raffaele/Italy
Background: EGFR-TKis are more effective in NSCLC patients 
with EGFR activating mutations. However, about 90% of non-Asian 
patients are EGFR wild type, and a test for optimizing treatment in 
pts with wild-type or in patients with undetectable EGFR mutation 
status or squamous histology is of clinical value. VeriStrat (VS) is a 
serum protein test that assigns "good“ (VSG) or "poor“ (VSP) clas-
S135Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
chemo- and radiotherapy, and chemotherapy agents used will be 
presented.  
Proportion of patients (%) with:
Use of concur-
rent chemo/RT
N-status deter-
mined with PET 
or PET/CT
N-status de-
termined with 
mediastino-
scopy
Australia 
(n=43)
100 74.4 2.3
North 
America 
(n=330)
92.7 37.9 18.5
Asia 
(n=51)
66.7 21.5 2.0
Latin 
America 
(n=86)
65.1 7.0 5.8
Western 
Europe 
(n=609)
67.2 32.2 6.9
Eastern 
Europe 
(n=394)
28.9 7.3 3.6
Conclusion: Baseline data from the START trial suggest substantial 
variations in the management of unresectable stage III NSCLC bet-
ween different regions of the world. While recruited patients from 
North American and Australian centers mostly received concurrent 
chemo/RT in accordance with current recommendations, a subs-
tantial proportion of patients in Europe, Latin America and Asia 
received sequential chemo/RT. More frequent use of concurrent 
chemo/RT as the recommended standard of care should be made 
across geographic regions.
Keywords: tecemotide, non-small cell lung cancer, immunothera-
py, START
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O02.02 TECEMOTIDE (L-BLP25) IN UNRESECTABLE STA-
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O02.01 GEOGRAPHIC DIFFERENCES IN THE COM-
BINED-MODALITY TREATMENT OF STAGE III UNRE-
SECTABLE NON-SMALL CELL LUNG CANCER: RESULTS 
FROM A GLOBAL PHASE III TRIAL OF TECEMOTIDE (L-
BLP25)
Nicholas Thatcher1, Frances A. Shepherd2, Paul Mitchell3, Mark 
A. Socinski4, Alfredo Paredes5, Marc Lambrechts6, Michael Tho-
mas7, Jens Kollmeier8, Milada Zemanova9, Parvis Sadjadian10, Nili 
Peylan-Ramu11, Christoph Helwig12, Andreas Schröder12, Charles 
A. Butts13
1Christie Hospital NHS Trust/United Kingdom, 2University Health Net-
work, Princess Margaret Hospital/Canada, 3Austin Hospital/Australia, 
4Upmc Cancer Pavilion/United States Of America, 5Medical Oncology, 
Hospital Donostia/Spain, 6Algemeen Ziekenhuis Sint Maarten/Germa-
ny, 7Universitätsklinikum Heidelberg/Germany, 8Helios Klinikum Emil 
Von Behring/Germany, 9Charles University And General University 
Hospital/Czech Republic, 10Johannes Wesling Klinikum Minden/Germa-
ny, 11Sharet Institute Of Oncology, Hadassah Ein Karem Medical Cen-
ter/Israel, 12Merck Kgaa/Germany, 13Cross Cancer Institute/Canada
Background: Chemo-radiotherapy (chemo/RT) is the standard of 
care for patients with unresectable stage III non-small cell lung 
cancer (NSCLC), but little is known about differences in clinical 
practice between regions of the world. The START trial is a global 
phase III trial of the MUC1-specific cancer immunotherapy tece-
motide (L-BLP25), for which key efficacy and safety results have 
been reported previously. Here we report regional differences in 
diagnostic procedures and treatment of stage III NSCLC prior to 
enrolment in START.
Methods: The START trial recruited patients (performance status 
0/1) with unresectable stage III NSCLC who had not progressed 
within 28–84 days of completing ≥2 cycles of platinum-based che-
motherapy with concurrent or sequential radiotherapy (≥50 Gy). 
Baseline characteristics, diagnostic procedures and the initial che-
mo/RT administered of those recruited were compared between 
centers in different regions.
Results: From Jan 2007 to Nov 2011, 1513 patients were recruited 
at >250 centers in 33 countries: Western Europe 40.3%, Eastern 
Europe 26.0%, North America 21.8%, Latin America 5.7%, Asia 
3.4%, Australia 2.8%. The majority of patients (92.1%) were Cauca-
sian and median age was 61 years. Overall, 6.3% of patients were 
never-smokers with little inter-regional variation except for Asia 
(31.4%). The proportion of current smokers upon entry into the 
trial was highest in Eastern Europe (36.3%) and lowest in Australia 
(11.6%). Median tobacco consumption by region ranged from 36.2 
(Eastern Europe) to 53.6 (Latin America) pack-years. The propor-
tion of patients considered for the START trial who received con-
current rather than sequential chemo/RT varied widely between 
regions and was highest in North America and Australia, lower in 
Western Europe, Latin America and Asia, and lowest in Eastern 
Europe. There were also substantial variations in the diagnostic 
procedures between the regions, although pathological confirma-
tion of N-status was infrequent in all regions. Detailed results by 
region for the time from diagnosis to randomization, duration of 
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O02.03 VALUE OF ADDING ERLOTINIB TO THORACIC 
RADIATION THERAPY WITH CHEMOTHERAPY FOR STA-
GE III NON-SMALL CELL LUNG CANCER: A PROSPECTI-
VE PHASE II STUDY
Ritsuko Komaki1, Pamela Allen1, Xiong Wei1, George Blumen-
schein2, Xi Ming Tang3, J Lee J. Lee4, James W. Welsh1, Ignacio Ivan 
Wistuba5, Diane D. Liu4, Waun K. Hong6
1Radiation Oncology, The University Of Texas MD Anderson Cancer 
Center/United States Of America, 2Thoracic/head And Neck Medical 
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3Translational Molecular Pathology, The University Of Texas MD An-
derson Cancer Cenrter/United States Of America, 4Biostatistics, The 
University Of Texas MD Anderson Cancer Center/United States Of 
America, 5Translational Molecular Pathology, The University Of Texas 
MD Anderson Cancer Center/United States Of America, 6Vice Provost, 
Clinical Research, The University Of Texas MD Anderson Cancer Cen-
ter/United States Of America
Background: The molecular basis for radiation resistance seems to 
involve an enhanced survival response with increased capacity for 
DNA repair and suppressed apoptosis. Both properties are cont-
rolled in part by upstream signal transduction pathways triggered 
by activation of the epidermal growth factor receptor (EGFR). 
Hypothesizing that the response of non-small cell lung cancer 
(NSCLC) to current standard chemoradiotherapy can be improved 
through the addition of therapy targeted to the epidermal growth 
factor receptor (EGFR), we undertook a single-Institution phase II 
trial to test whether adding the EGFR tyrosine kinase inhibitor (TKI) 
erlotinib to concurrent chemoradiation therapy for previously unt-
reated, locally advanced, inoperable NSCLC would improve survi-
val and response rates without increasing toxicity.
Methods: Forty-eight patients with previously untreated NSCLC 
received radiation (63 Gy/35 fractions) on  
Monday‒Friday, with chemotherapy (paclitaxel 45 mg/m², carbo-
platin AUC=2) given every  
Monday and erlotinib (150 mg orally 1/d)  
Tuesday–Sunday for 7 weeks, followed by two cycles of consoli-
dation paclitaxel-carboplatin. The primary endpoint was time to 
progression; secondary endpoints were toxicity; response, overall 
survival (OS), and disease control rates; and whether any endpoint 
differed by EGFR mutation status.
Results: Of 46 patients (96%) evaluable for response, 40 were for-
mer or never smokers; 23 had adenocarcinoma; and 41 were eva-
luable for EGFR mutations (37 wild-type [wt] and 4 mutations [all 
adenocarcinomas]). Median time to progression was 14.5 months 
and did not differ according to EGFR status. Toxicity was accep-
table (no grade 5, one grade 4, and eleven grade 3). Fourteen 
patients (31%) had complete responses (3 mutations and 11 wt), 
24 (52%) partial (20 wt and 4 unknown EGFR mutation status), and 
8 (18%) had stable or progressive disease (6 wt, 1 mutation and 1 
unknown EGFR mutation status); 3 patients with mutations (75%) 
had complete response vs. 11 wt (30%) (p=0.07 for EGFR mutation 
vs wt groups). For alive patients, the median follow-up was 44.7 
months’ follow-up (range, 29.3–54.6 months). OS rates were 82.6% 
at 1 year, 67.4% at 2 years, 48.5% at 3 years, and 32.2% at 4 years 
and did not differ by mutation status (wt vs mutation, p=0.17). For 
all patients the median follow-up was 30.6 months’ follow-up (ran-
ge, 3.4–54.6 months). 14 patients were free from progression and 
32 had local failure, distant failure, or both. Eleven of the 27 distant 
failures were in the brain (7 wt, 3 mutation, 1 unknown; P=0.04); 
Leczenia Chorób Płuc I Gruźlicy/Poland, 12Merck Kgaa/Germany, 13Uni-
versity Health Network, Princess Margaret Hospital/Canada
Background: The phase III START study evaluated the mucin 
1 (MUC1) antigen-specific cancer immunotherapy tecemotide 
(L-BLP25) vs. placebo in patients with stage III unresectable non-
small cell lung cancer (NSCLC) who did not progress following initi-
al chemo-radiotherapy (chemo/RT). The primary objective of ove-
rall survival (OS) prolongation was not met, however, pre-defined 
subgroup analyses revealed a clinically meaningful prolongation of 
survival with tecemotide in patients previously treated with concur-
rent chemo/RT (p=0.016). Sensitivity analyses suggested the ob-
served treatment effect may have been under-estimated due to a 
clinical hold, which resulted in a median suspension of recruitment 
and investigational treatment of about 4.4 months. Tecemotide 
was well tolerated and no safety concerns were identified.
Methods: From January 2007 to November 2011, 1513 patients 
with unresectable stage III NSCLC and stable disease or objec-
tive response following initial chemo/RT were randomized (2:1, 
double-blind) to subcutaneous tecemotide (806 µg lipopeptide) 
or placebo, weekly for 8 weeks and then 6-weekly until disease 
progression or withdrawal. A single dose of cyclophosphamide 
(300 mg/m2) or saline was given 3 days prior to first tecemotide/
placebo dose. Primary endpoint, OS, and secondary endpoints 
progression-free-survival (PFS) and time-to-treatment-failure (TTF) 
used a Cox proportional hazards regression model adjusting for 
randomization strata. While RECIST 1.0 had to be observed for 
determination of disease progression, there was no formal imaging 
schedule to determine disease progression; this was done accor-
ding to institutional practice. Exploratory analyses were done for 
treatment interaction for HLA-A02, -DRB4 and -B08. Baseline peri-
pheral blood anti-nuclear antibodies (ANA), serum MUC1 (sMUC1), 
lymphocyte count and neutrophil:lymphocyte ratio (NLR) currently 
are being explored.
Results: The primary analysis population (N=1239) was defined 
prospectively to account for the clinical hold and prospectively 
excluded 274 patients randomized within 6 months prior to onset 
of the hold. Median PFS was 9.6 months with tecemotide vs. 7.7 
months with placebo (HR 0.865, 95%CI 0.755–0.990, p=0.036). In 
keeping with OS data, tecemotide treatment effects on PFS were 
more pronounced in patients treated with concurrent chemo/RT 
(N=806; HR 0.826, 95%CI 0.696–0.980, p=0.029) vs. sequential 
chemo/RT (N=433; HR 0.947, 95%CI 0.756–1.187, p=0.638). Median 
TTF was 8.9 months with tecemotide vs. 7.2 months with placebo 
(HR 0.887, 95%CI 0.777–1.012, p=0.075). A prolongation of TTF 
with tecemotide was seen in patients with prior concurrent chemo/
RT (HR 0.844, 95%CI 0.715–0.996, p=0.045), which was absent in 
the subgroup with prior sequential chemo/RT (HR 0.977, 95%CI 
0.784–1.217, p=0.835). Detailed biomarker results will be presen-
ted.
Conclusion: While the primary endpoint of prolongation of OS 
was not met, secondary endpoints PFS and TTF support the pre-
viously-reported finding of a more favorable effect of tecemotide 
in patients treated with concurrent but not sequential chemo/RT. 
Any potential further clinical investigation of tecemotide in locally 
advanced NSCLC should focus on patients following concurrent 
chemo/RT therapy.
Keywords: non-small cell lung cancer, tecemotide, immunothera-
py, START
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(N=69) and including only those who underwent resection, only 
MPR significantly associated with overall survival. The table below 
details findings from the population who had complete cancer 
resection.
Endpoint 
(N=46) 
Yes 
(A) 
No 
(B) 
NA 
(C) 
HR (95% CI) 
ITT (A vs 
B+C) 
HR (95% CI) 
Resected(A 
vs B) 
Nodal 
downsta-
ging 
16 30 23 0.68 (0.32-1.56) 0.73 (0.24-2.10) 
Nodal 
clearance 
14 32 23 0.57 (0.27-1.36) 0.96 (0.32-2.81) 
MPR 5 41 23 0.28 (0.1-0.78) 0.26 (0.07-0.95) 
 
NA = not assessable; ITT = intention to treat
Conclusion: MPR (≤10% viable tumor) effectively identifies pati-
ents with good clinical outcomes after neoadjuvant chemotherapy 
and can serve as a surrogate endpoint for overall survival. Further-
more, lack of MPR identifies a patient population at high risk of 
recurrence. Neither nodal downstaging nor nodal clearance effec-
tively discriminated those with improved survival. Adaptive clinical 
trials designed to target those not achieving MPR are encouraged 
in attempt to improve the rate of cure in this disease.
Keywords: neoadjuvant chemotherapy, pathologic response, no-
dal downstaging, surrogate endpoint
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O02.06 PREDICTORS OF TRIMODALITY THERAPY USE 
AND OVERALL SURVIVAL IN PATIENTS WITH STAGE III 
NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NATI-
ONAL CANCER DATABASE
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Background: The optimal locoregional therapy for stage III non-
small cell lung cancer is controversial, with definitive chemora-
diotherapy (CRT) and trimodality therapy (chemoradiotherapy 
followed by surgery, TMT) serving as competing strategies. The 
implementation of TMT and resultant survival outcomes in routi-
ne United States clinical practice has not been closely examined. 
In this study, we used the National Cancer Database (NCDB) to 
determine predictors of TMT and compare overall survival (OS) 
among a large cohort of stage III NSCLC patients treated with CRT 
or TMT.
Methods: Patients included were stage III NSCLC patients who 
received concurrent CRT with or without subsequent surgical re-
section at Commission on Cancer-accredited programs between 
1998 and 2010; survival data were available for patients treated 
through 2005. High-volume (HV) center was defined as the upper 
decile. Per NCDB coding, treatment centers were stratified into 
academic, comprehensive, and non-comprehensive community 
cancer center (CCC). Logistic regression was used for univariable 
analyses, and multivariable models were prepared using stepwise 
selection to determine demographic, clinical and non-clinical pre-
dictors of TMT use and overall survival. Propensity score matching 
the local control rate was 75% among the 4 patients with EGFR 
mutations. Median time to progression was 13.6 months (95% con-
fidence interval 10.2-20) and did not differ by EGFR status (wt vs 
mutation p=0.39).
Conclusion: Overall survival was promising, but time to progressi-
on was disappointing. Toxicity was acceptable. The prevalence of 
distant failures underscores the need for more effective systemic 
therapy, perhaps including maintenance EGFR-TKI for patients with 
mutated EGFR.
Keyword: Erlotinib, Stage III Non-Small Cell Lung Cancer, Radiati-
on Treatment, Chemotherapy
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O02.05 MAJOR PATHOLOGIC RESPONSE (≤10% VIABLE 
TUMOR) FOLLOWING NEOADJUVANT CHEMOTHERAPY 
AS A SURROGATE FOR OVERALL SURVIVAL IN PATIENTS 
WITH PATHOLOGICALLY DOCUMENTED STAGE IIIA (N2) 
LUNG ADENOCARCINOMAS
Jamie E. Chaft1, Matthew D. Hellmann1, Valerie W. Rusch2, Wil-
liam D. Travis3, Mark G. Kris1
1Medical Oncology, Memorial Sloan-Kettering Cancer Center/United 
States Of America, 2Thoracic Surgery, Memorial Sloan-Kettering Cancer 
Center/United States Of America, 3Pathology, Memorial Sloan-Kettering 
Cancer Center/United States Of America
Background: Neoadjuvant chemotherapy improves overall survival 
in patients with resectable stage IIIA lung adenocarcinomas. The 
gold-standard endpoint for clinical trials evaluating curative thera-
pies is overall survival. Unfortunately, these trials take nearly a de-
cade to complete and this prolonged timeline hinders the approval 
of promising therapies in the curative realm. Alternative endpoints 
that can act as a surrogate for overall survival have been evaluated, 
including nodal downstaging, nodal clearance, and pathologic 
response. We evaluated the degree to which these endpoints as-
sociate with overall survival in patients with pathologically proven 
stage IIIA(N2) lung adenocarcinoma treated with neoadjuvant che-
motherapy.
Methods: An electronic database search engine was used to 
identify all patients with resectable stage IIIA(N2) lung adenocar-
cinoma treated with neoadjuvant chemotherapy at Memorial 
Sloan-Kettering Cancer Center between 1/2007-8/2012. Nodal 
downstaging was defined as no residual tumor tissue in the N2 
nodes. Nodal clearance was defined as no residual tumor tissue in 
N1 and N2 nodes. Pathologic response was systemically assessed 
by a dedicated thoracic pathologist (WDT) who reviewed at least 1 
section per centimeter of greatest gross tumor diameter. The per-
cent viable tumor tissue in each slide was estimated to the nearest 
10%. Major pathologic response (MPR) was defined as ≤10% viable 
tumor tissue. All pathologic analyses were performed by a dedica-
ted thoracic pathologist (WDT). Patients with residual N2 disease 
at resection were offered post-operative radiation and routinely 
monitored thereafter. Survival proportions were estimated by the 
Kaplan-Meier method and compared using the log-rank test.
Results: 69 patients with pathologically confirmed IIIA(N2) disease 
were identified and 46 (67%) ultimately underwent R0 resection. 
Among these patients, 16 had nodal downstaging, 14 had nodal 
clearance and 5 had a MPR. In both intention to treat analyses 
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ferred Reporting Items for Systematic Reviews and Meta-Analyses) 
standards.
Results: The comparison contained two components. In the com-
parison of neoadjuvant therapy followed by surgery and radical 
chemoradiotherapy/radiotherapy, a fine homogeneity (Χ2=2.26, 
p=0.52, I2=0.0%) between four studies with a total of 803 selected 
cases was detected between the overall survival (OS), and the 
combined hazard ratio (HR) was 0.95 (95% confidence interval [CI]: 
0.81-1.10; p=0.47). Progression-free survival (PFS) was investigated 
in two studies and there was also no significant difference for the 
combined HR was 0.90 (95% CI: 0.77-1.05; p=0.19). In the compa-
rison of neoadjuvant chemoradiotherapy (Neo-ChRT) and neoad-
juvant chemotherapy(Neo-ChT) alone, three studies with a total of 
229 selected cases were detected, with the combined HR of OS 
and PFS 0.79 (95% CI: 0.57–1.09; p=0.15) and 0.67 (95% CI: 0.39-
1.15; p=0.15) respectively, but it did not reach the statistical signifi-
cance. Observing the short-term therapeutic effect, these studies 
revealed that Neo-ChRT had increased the rate of mediastinal pCR 
by 15.48% (OR: 3.61, 95%CI: 1.07–12.15; P = 0.04). Comparing the 
incidence of main complications and mortality, there was no sig-
nificant difference between neoadjuvant therapy followed by sur-
gery and radical chemoradiotherapy /radiotherapy alone. Neoad-
juvant chemoradiotherapy followed by surgery achievered higher 
response rates and similar postoperative mortality as compared to 
neoadjuvant chemotherapy followed by operation, without adding 
significant adverse events.
Conclusion: Neoadjuvant chemotherapy and/or radiotherapy 
followed by surgery is not superior to that followed by definitive 
radiotherapy. Neoadjuvant chemoradiotherapy dose not improve 
survival compared to neoadjuvant chemotherapy alone. But it can 
increase the rate of downstaging and mediastinal pCR which were 
correlated with the better PFS and OS. Neoadjuvant treatment has 
not increased the incidence of postoperative complication and 
motality. Further studies should be conducted to determine the 
patients who will benefit from various administrations.
Keywords: non-small cell lung cancer, Neoadjuvant therapy, neo-
adjuvant chemotherapy, neoadjuvant chemoradiotherapy
was used to estimate treatment effect and to minimize the effect 
of confounding variables.
Results: The overall cohort consisted of 49,534 patients, 25,679 of 
whom also had available survival data. Trimodality therapy was de-
livered in 7.8% of patients. Multivariable clinical predictors of TMT 
included: white race (OR 1.36), younger age (lowest [LQ] vs highest 
[HQ] quartile, OR 4.31), high school education or higher (HQ vs 
LQ, OR 1.37), stage IIIA vs IIIB, (OR 3.02) and squamous histology 
(OR 1.26). Non-clinical variables associated with TMT included: 
early treatment era (first vs last 3 years, OR 1.30), private insurance 
(OR 1.53), increasing distance from the treatment center (HQ vs 
LQ, OR 1.81), geography (Northeast vs. other, OR 1.35), treatment 
at academic research programs (ARP) over comprehensive CCC 
or non-comprehensive CCC (OR 1.53 and 2.01, respectively), and 
HV institution (OR 1.26). The median, 3- and 5-year OS were 12.3 
months, 17% and 9.6%, respectively. Univariable comparison bet-
ween CRT and TMT showed OS benefit with TMT (median 26.1 vs 
11.7 months, log rank p<0.001). On MVA, stage IIIA (hazard ratio, 
HR, 0.85), squamous histology (HR 0.97), young age (HR 0.74) , 
female gender (HR 0.86), non-white race (HR 0.90), higher income 
(HQ vs LQ HR 0.76), farther distance from treatment center (HR 
0.93), more recent treatment era (HR 0.80 vs. first 2 time periods) 
and TMT (HR 0.49) were significantly associated with improved OS. 
ARP was significantly associated with superior OS (HR 0.92 vs. CCP) 
if TMT was not in the Cox model. After propensity matching, TMT 
was still associated with improved OS (HR 0.62, p<0.001).
Conclusion: The use of TMT was strongly associated with markers 
of higher socioeconomic status and treatment at high-volume and 
academic centers. These data further support a significant survival 
benefit in patients undergoing TMT, and treatment at academic 
centers may improve OS via increased use of TMT.
Keyword: trimodality thearpy, chemoradiation, population charac-
teristics
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O02.07 IS THERE A SURVIVAL BENEFIT IN PATIENTS 
WITH STAGE IIIA(N2) NON-SMALL CELL LUNG CANCER 
UNDER NEOADJUVANT CHEMOTHERAPY AND/OR RA-
DIOTHERAPY FOLLOWED BY SURGERY ADMINISTRATI-
ON: A SYSTEMATIC REVIEW AND META-ANALYSIS
Yaping Xu1, Bo Li2, Xiaoling Xu2, Qixun Chen1, Xinmin Yu1, Weimin 
Mao1
1Zhejiang Cancer Hospital/China, 2Zhejiang Cancer Research Institute/
China
Background: Optimal management of clinical stage IIIA (N2) non-
small cell lung cancer (NSCLC) is controversial despite the conduct 
of several randomized controlled trials (RCTs). This article contribu-
tes to this problem by conducting a systematic review and meta-
analysis of published RCTs.
Methods: A comprehensive literature search was performed in 
the Pubmed, Embase, Medline database (last search updated 
in May 2013) for relevant studies comparing patients with stage 
IIIA (N2)NSCLC undergoing surgery alone, chemotherapy and/
or radiotherapy alone, or resection after neoadjuvant treatment 
with chemotherapy and/or radiotherapy. A systematic review and 
meta-analysis of available data were conducted using PRISMA (Pre-
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6 and 4 for D+G and D, respectively. Grade 3/4 adverse events 
for the D+G and D alone arms were: neutropenia 37% vs. 38%; 
fatigue 6% vs. 3%; anemia 8% vs. 2%; diarrhea 3% vs. 0; fever with 
neutropenia 11% vs. 2%. A pre-specified analysis was conducted 
in May 2013. PFS HR for eLDH population (N=76) was 0.88 (90% CI: 
0.57, 1.36, p=0.310); OS HR was 0.63 (90% CI: 0.40, 0.99, p=0.046). 
PFS HR for mKRAS population (N=63) was 0.83 (90% CI: 0.51, 
1.37, p=0.271); and OS HR was 0.85 (90% CI: 0.48, 1.50, p=0.313). 
OS HR in the all adenocarcinoma population was 0.82 (90% CI: 
0.62, 1.09, p=0.082), and the PFS HR was 0.84 (90% CI: 0.65, 1.07, 
p=0.038). For patients that were enrolled >6 months after diagno-
sis of advanced NSCLC (N=176), a pre-specified stratification fac-
tor, the OS HR was 0.61 (90% CI: 0.43, 0.87, p=0.0093), and the PFS 
HR was 0.61 (90% CI: 0.45, 0.83, p=0.0041). Final data analysis is 
expected by end of September 2013. Updated PFS and OS results 
for all populations will be presented at the meeting.
Conclusion: Survival improvement was noted in all adenocarci-
noma patients with the addition of ganetespib to docetaxel. The 
maximal benefit was achieved in patients with eLDH and those 
diagnosed with advanced NSCLC >6 months prior to study entry.
Keyword: heat shock protein, ganetespib, NSCLC, docetaxel
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O03.02 RANDOMIZED PHASE-3 TRIAL (INSPIRE) OF 
NECITUMUMAB PLUS CISPLATIN-PEMETREXED VERSUS 
CISPLATIN-PEMETREXED ALONE AS FIRST-LINE THERA-
PY IN STAGE IV NON-SQUAMOUS NSCLC
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Background: Necitumumab is a human IgG1 anti-EGFR1 mono-
clonal antibody that competes for the binding of natural ligands to 
this receptor and prevents receptor activation. EGFR1 is detecta-
ble in approximately 85% of advanced NSCLC tumors. This phase 
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O03.01 GALAXY-1: RANDOMIZED PHASE II STUDY OF 
DOCETAXEL WITH OR WITHOUT GANETESPIB IN AD-
VANCED LUNG ADENOCARCINOMA: RESULTS IN BIO-
MARKER SUB-GROUPS AND ALL ADENOCARCINOMA 
PATIENTS.
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Background: Ganetespib (G) is a highly potent 2nd-generation 
Hsp90 inhibitor showing synergistic activity with docetaxel (D) in 
NSCLC xenografts. G has a favorable clinical safety profile and has 
shown single-agent clinical activity in NSCLC patients with tumors 
harboring EML4-ALK translocations and KRAS mutations (mKRAS).
Methods: We conducted a randomized, international open-label 
Phase 2 study of D with or without G in patients with advanced 
lung adenocarcinoma, one prior systemic therapy, and ECOG PS 
0/1. D was given at 75 mg/m2 on Day 1 of a three-week cycle in 
both arms. In the combination arm, G was given at 150 mg/m2 on 
Days 1 and 15. The co-primary endpoints were PFS in patients with 
elevated LDH (eLDH) levels, or tumors harboring KRAS mutation. 
Key secondary endpoints were OS and PFS in all adenocarcinoma 
patients. Target enrollment was 240 adenocarcinoma patients, 
including 120 eLDH and 80 mKRAS patients. The study was initia-
ted in all NSCLC patients and amended to include only those with 
adenocarcinoma histology.
Results: Enrollment of 252 adenocarcinoma patients completed 
in November 2012; enrollment of eLDH (total N=112) and mKRAS 
(total N= 86) patients completed in May 2013. In all adenocarci-
noma patients (N=252), baseline characteristics were balanced 
between the two arms (median age 60 years, males 56%, PS 0 41% 
and never-smokers 25%). Median numbers of cycles delivered were 
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Background: With recent successes of targeted therapeutics, the-
re has been increased enthusiasm to enroll patients with NSCLC 
into phase I trials. Most phase I prognostic indices have been deri-
ved from patient populations where NSCLC is underrepresented.
Methods: Retrospective review of NSCLC patients enrolled bet-
ween 2005-2012 at National Cancer Centre Singapore was perfor-
med, collating data on demographics, molecular profiles, trial cha-
racteristics and clinical outcomes (using RECIST criteria) to identify 
prognostic factors to improve patient selection.
Results: 167 patients were treated on 20 phase I trials. Median 
(range) age 60.7 years (22.7–84.7), 58% male, adenocarcinoma/
squamous/NOS/others (75.4%/9.6%/12.6%/2.4%). 13% were 
at high risk of nutritional deficiency (BMI<18.5), and ECOG 
0(21%)/1(77%)/2(2.4%). Median (range) prior chemotherapy was 2 
(0-6) and 99% received at least one treatment line. Class of agents 
include anti-angiogenics (50.3%), signal transduction pathway inhi-
bitors (STPi) 46%. Only 4.2% received cytotoxics alone. 86.2% were 
on combination regimens, of which two-thirds on combinations of 
chemotherapy and small molecule. Between 2008-2012, proporti-
on of patient tumors with molecular alterations identified increased 
from 5.5% to 62.5%, facilitating enrolment into trials designed 
for a specific genotype (or “matched” trials). 35% and 7.8% of 
patients participated on trials targeting EGFR and ALK alterations 
respectively. With a median follow up of 8.7 months, progression 
free survival was 3.9m (95%CI:3.4–5.8), overall survival (OS) 10.4m 
(95%CI:8.0–11.7). Among evaluable patients, 24.8% (95%CI:18.2–
32.5) had complete/partial response; clinical benefit rate (CBR) 
75.8% (95%CI:68.2–82.4). 90-day mortality (90DM) was 15%. Pa-
tients participating in “matched” trials had a lower risk of death 
(HR 0.55 [95%CI:0.38-0.78] p<0.001) compared to those on unse-
lected or “unmatched” trials (median OS 11.9 v 7.6). On univariate 
analysis, low BMI<18.5, ECOG>0, ≥3 metastatic sites, presence of 
bone metastasis, low albumin (<35), low Hb (<12), ≥ 3 prior lines 
of chemotherapy and non-participation in a "matched“ trial were 
significant negative prognostic factors for OS. On multivariate 
analysis, ECOG, number of metastatic sites, albumin and trial type 
(targeting EGFR/ALK/others), emerged as independent variables. 
These factors were used to construct a prognostic nomogram to 
predict OS at 3, 6 and 12m. Of 12 published prognostic indices, 
8 models were validated in our patient cohort, with the highest 
c-index being 0.66. Pairwise comparison against these 8 (7 tumor 
agnostic; 1 NSCLC) prognostic indices, found the nomogram to be 
superior in predicting OS, with a c-index of 0.74.
Conclusion: This is the largest analysis of phase I NSCLC patients 
using individual patient data. Outcome of NSCLC patients in pha-
se I trials is promising with CBR 76% and median OS 10.8m. Our 
nomogram – comprising of ECOG, albumin, number of metastatic 
sites, participation in a “matched” trial – is uniquely derived from 
NSCLC patients and was a better predictor of OS compared to 8 
published phase I prognostic scores.
Keywords: non-small cell lung cancer, Phase I, Molecular Selec-
tion, Prognostic Index
3 study investigated necitumumab in combination with first-line 
chemotherapy in advanced non-squamous NSCLC.
Methods: Patients with histologically or cytologically proven sta-
ge IV non-squamous NSCLC were randomized 1:1 to either Arm 
A: cisplatin 75mg/m2 i.v.-pemetrexed 500mg/m2 i.v. (Cis + PEM) 
on Day 1+ necitumumab 800mg i.v. on Days 1 and 8 of a 21-day 
cycle or Arm B: Cis+PEM alone. Patients received these regimens 
for up to six cycles. For patients in Arm A with at least stable di-
sease, necitumumab continued until PD or intolerable toxicity. The 
primary endpoint was overall survival (OS). Secondary endpoints 
included progression-free survival (PFS), objective response rate 
(ORR), safety, and EGFR protein expression level by immunohisto-
chemistry (H-score) utilizing archived tumor tissue based on a man-
datory tissue collection. The planned sample size of this study was 
947 patients (assuming a hazard ratio [HR] of 0.8 would allow 85% 
power at 2-sided alpha level of 0.05). After 633 patients, enroll-
ment was stopped (after Feb 2011) following an Independent Data 
Monitoring Committee (IDMC) recommendation.
Results: Between Nov 2009 and Feb 2011 633 patients were ran-
domized (315 Arm A; 318 Arm B). Baseline characteristics were 
balanced between the arms; 67.0% were male and 33.0% female; 
ECOG-PS 0/1 94.2 % and PS 2 5.7 %. No difference between treat-
ment arms was observed for OS (median 11.3 vs 11.5 months; HR 
1.01 95%-CI [0.84, 1.21]), PFS (median 5.6 vs 5.6 months, HR 0.96 
95%-CI [0.80, 1.16]) and ORR (31.1 vs 32.1%; Odds ratio 0.96 95%-
CI [0.68, 1.34]). The exploratory analysis in 490 patients assessable 
for H-score revealed no association between H-score and diffe-
rences in efficacy between treatment arms (H-score < 200: mOS 
8.97 vs 9.72 months, HR 1.07, mPFS 4.90 vs 4.76 months, HR 0.95, 
ORR 27.1 vs 26.0%; H-score > 200: mOS 15.01 vs 13.34 months, HR 
1.03, mPFS 5.59 vs 5.62 months, HR 0.94, ORR 39.6 vs 39.4%). Gra-
de > 3 treatment-emergent adverse events (AEs) occurring more 
frequently in Arm A included skin or subcutaneous disorders (14.1 
vs 0.3%), thromboembolic events (9.5 vs 6.4%), hypomagnesaemia 
(7.6 vs 2.2%), asthenia (6.9 vs 1.9%), vomiting (6.6 vs 3.2%), dyspnea 
(5.3 vs 2.6%) and diarrhea (4.3 vs 2.2%). The frequency of study 
drug related deaths was 4.9% and 2.9% in Arms A and B, respec-
tively.
Conclusion: In this study, the addition of necitumumab did not 
improve the efficacy outcome over cisplatin plus pemetrexed 
alone in advanced non-squamous-NSCLC. The EGFR H-score 
did not seem to predict the efficacy outcomes of necitumumab 
in combination with cisplatin plus pemetrexed. The addition of 
necitumumab resulted in a higher frequency of grade ≥ 3 AE (skin 
reaction, GI, asthenia and other) and an imbalance of grade ≥ 3 
thromboembolic events. Further biomarker studies are ongoing. 
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O03.03 OUTCOMES OF NSCLC PATIENTS ON PHASE I 
TRIALS: THE IMPORTANCE OF MOLECULAR AND PATI-
ENT SELECTION
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Conclusion: Afatinib was active in lung tumours harbouring un-
common EGFR mutations, such as G719X, L861Q, S768I. Rate 
and duration of response was comparable with that previously 
observed in patients with common mutations in these trials. The 
response rate was low in tumours with de novo T790M mutations 
and insertions in exon 20 but durable tumour control was achieved 
in some patients. To date this is the largest analysis of data for 
prospectively identified patients with uncommon EGFR mutations; 
treatment options in this heterogeneous group of tumours will be 
discussed.
Keywords: Uncommon EGFR mutations, afatinib, NSCLC, T790M 
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Background: EGFR (ErbB1) mutations define a lung cancer sub-
type with exquisite sensitivity to EGFR tyrosine kinase inhibitors 
(TKIs). While in-frame deletion in exon 19 (Del19) and a point muta-
tion (L858R) in exon 21 are the two most common sensitizing EGFR 
mutations in non-small cell lung cancer (NSCLC), approximately 
10% of EGFR mutation-positive tumours harbour uncommon mu-
tations. These mutations represent a heterogeneous group of rare 
molecular alterations (or combinations) within exons 18–21, whose 
oncogenicity and sensitivity to EGFR TKIs may vary and has not 
been prospectively studied. Here we present the first prospecti-
ve data series on activity of afatinib, the irreversible ErbB Family 
Blocker, in patients with tumours harbouring uncommon EGFR 
mutations.
Methods: This analysis is based on data from EGFR mutation-posi-
tive patients included in the LUX-Lung 2 (Phase II), LUX-Lung 3 and 
LUX-Lung 6 (both Phase III) studies. EGFR mutations were identi-
fied prospectively by direct sequencing in LUX-Lung 2 and by cen-
tral testing with TheraScreen EGFR RGQ PCR kit (TheraScreen29) 
in LUX-Lung 3 and 6. Patients were classified as having common 
(Del19 or L858R) or uncommon (all other single or complex) muta-
tions. Uncommon mutations were categorized into three groups: 
de novo T790M (alone or in combination with other mutations); 
exon 20 insertions; and other. Objective response rate (ORR), di-
sease control (DCR), duration of response and progression-free 
survival (PFS) were assessed by independent review.
Results: Seventy-five patients (LUX-Lung 2: n=23; LUX-Lung 3: 
n=26; and LUX-Lung 6: n=26) had uncommon mutations, accoun-
ting for 12.5% of all afatinib patients in these studies. The majority 
of patients received afatinib first line; 13 patients from LUX-Lung 
2 received afatinib after chemotherapy. Breakdown into the three 
groups was T790M: n=14; Exon 20 insertions: n=23; other: n=38 
(most frequent types were L861Q: n=12; G719X: n=8; G719X+S768I: 
n= 5; G719X+L861Q: n=3). Efficacy results for each group are 
shown below. Further details by mutation status will be presented.  
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further explore its potential for improved activity and better tolera-
bility over other existing EGFR TKIs.
Keywords: T790M, EGFR TKI, NSCLC, CO-1686
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O03.07 INVESTIGATION OF RISK FACTORS FOR DEVE-
LOPING INTERSTITIAL LUNG DISEASE (ILD) AND POOR 
PROGNOSTIC FACTORS FOR ILD DEATH IN JAPANESE 
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Background: A large-scale surveillance study (POLARSTAR) was 
implemented to investigate erlotinib safety and efficacy in Japa-
nese patients, focusing on the pattern of occurrence of interstitial 
lung disease (ILD) and specific factors that may contribute to the 
onset of ILD in patients receiving erlotinib. The following risk 
factors for erlotinib-induced ILD have been previously reported: 
concurrent/previous ILD (adjusted hazard ratio [HR] =3.2), exis-
ting emphysema/chronic obstructive pulmonary disease (COPD) 
(HR=1.9) or lung infection (HR=1.6), smoking status (HR=2.2) and 
ECOG performance status 2–4 (HR=1.4). These were identified as 
the primary risk factors for ILD by multivariate analysis. The current 
Background: Efficacy of existing EGFR tyrosine kinase inhibitors 
(TKIs) in NSCLC is limited by emergence of the T790M mutation 
in approximately 60% of patients, and significant skin rash and 
diarrhea, caused by wild-type (WT)-EGFR inhibition. CO-1686 is an 
oral, covalent TKI that targets common activating EGFR mutations 
and T790M, while sparing WT-EGFR. Animal models suggest gre-
atest efficacy when plasma concentrations exceed 200ng/ml for 
>16hrs/day.
Methods: This is an ongoing first-in-human dose finding study 
(3+3) of oral CO-1686 administered continuously in 21-day cycles. 
To be eligible, patients must have EGFR-mutant NSCLC and prior 
therapy with an EGFR TKI. All patients must undergo tumor tissue 
biopsy within 28 days before study drug dosing for central EGFR 
genotyping. Endpoints include safety, pharmacokinetics (PK), and 
efficacy.
Results: As of 12 June 2013, 45 patients have been treated with 
CO-1686. 31/42 (74%) were T790M+; data for three patients is pen-
ding. The median age is 58 years, 82% are female, 75% are white, 
and 73% ECOG 1. The median number of previous therapies was 
4 (range: 1- 6), with a median of 1 (range: 1- 4) previous EGFR TKI 
therapies. Dosing started at 150mg QD and escalated to 900mg 
QD, 900mg BID and 400mg TID, with a maximum tolerated dose 
not yet reached. Treatment-related AEs (all grades) occurring in > 
5% patients were: fatigue (19%), diarrhea (15%), nausea (14%), ane-
mia (10%), arthralgia (7%), muscle spasms (10%), myalgia (7%), hea-
dache (7%). The majority of events were mild or moderate. Unlike 
other EGFR inhibitors, rash and diarrhea were not commonly seen. 
This AE profile is consistent with the expected lack of wild type 
EGFR inhibition with CO-1686. The PFS for T790M+ patients with 
CO-1686 plasma concentrations > 200ng/mL for > 16 hours was 
194 days compared with 72.5 days for those that achieved these 
concentrations for < 16 hours (Figure 1). At the highest evaluated 
dose, 900mg BID, four T790M+ patients were evaluable for res-
ponse; 3 of the 4 achieved PRs, one achieved SD. One patient at a 
lower dose cohort also achieved a PR. Further safety and efficacy 
data will be presented at the meeting. 
Conclusion: CO-1686 has demonstrated good tolerability and ef-
ficacy against proven T790M+ EGFR mutant NSCLC with a strong 
suggestion of a dose-response relationship. Additional evaluation 
of the optimal dose and formulation of CO-1686 are underway to 
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Background: Lung adenocarcinoma (AD) of patients who have 
never smoked frequently bear targetable genome kinase altera-
tions, such as EGFR mutations and translocations affecting ALK, 
ROS1, and RET genes. These mutations correlate with kinase in-
hibitor sensitivity in mouse models or in patients. Unfortunately, 
therapeutically relevant kinase alterations are not present in all 
lung cancer specimens. Thus, additional genome alterations need 
to be discovered in order to provide a therapeutic opportunity for 
the remaining patients.
Methods: We collected a cohort of 25 AD specimens of never 
smokers lacking mutations in KRAS or EGFR, in which we perfor-
med transcriptome sequencing with the aim of identifying new 
oncogenic driver genes.
Results: We were able to identify known kinase fusions affec-
analysis was carried out to identify factors linked with poor prog-
nosis in terms of ILD-related death within the POLARSTAR surveil-
lance study.
Methods: Enrolment of all patients in Japan receiving erlotinib for 
NSCLC took place between December 2007 and October 2009; 
the observation period was 12 months. All ILD-like events were as-
sessed by an independent ILD review committee. ILD was defined 
as all ILD-like events excluding those events deemed non-ILD by 
the independent ILD review committee. Risk factors for poor prog-
nosis concerning ILD death were analyzed by multivariate analysis 
using a logistic regression model.
Results: A total of 10,708 patients were enrolled by the data cut-
off of 12 October 2009, with data available for 9,909 patients. The 
majority of ILD cases were reported within 4 weeks of receiving 
erlotinib. Among the 491 patients who experienced ‘ILD-like’ 
events, 93 could not be evaluated by the independent ILD review 
committee due to lack of imaging data; the remaining 398 pati-
ents were referred to the committee for evaluation. A total of 310 
patients had confirmed ILD by the ILD review committee, based 
on image evaluation or clinical investigation; 125 had died as a 
result of ILD. These patients were assessed by multivariate analy-
sis. Sixty-two events were deemed non-ILD and 26 events could 
not be evaluated due to a lack of clear clinical evidence (e.g. ILD 
could not be distinguished from progression or pneumonitis, or 
insufficient imaging data were available). The multivariate analysis 
identified ECOG performance status 2–4 (adjusted odds ratio [OR] 
=2.45 [95% CI 1.41–4.27]; p=0.0016), <50% remaining normal lung 
area (OR=3.12 [1.48–6.58]; p=0.0029) and interstitial pneumonia 
with concomitant honeycomb lung (OR=6.67 [1.35–32.94]; p=0.02) 
as poor prognostic factors for ILD death. However, pre-existing in-
terstitial pneumonia by grade of severity was not identified as one 
of these factors. This result could be attributed to practical bias in 
this surveillance study, such as selection or treatment bias for pati-
ents with pre-existing interstitial pneumonia within the condition of 
careful dosage specified in the erlotinib label.
Conclusion: These final data from this large surveillance study in 
Japanese patients with recurrent and advanced NSCLC provide 
further information on the risk factors for poor prognosis with ILD, 
identifying those patients at greatest risk of ILD-related death. 
Improved awareness of these prognostic factors will help clinicians 
in monitoring those patients at highest risk.
Keywords: Interstitial lung disease (ILD), Prognosis, NSCLC,  
erlotinib
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increasingly important to accurately characterize mutation status 
in lung cancer patients to provide personalized care that define 
prognosis and predict response to therapy. The advent of next 
generation sequencing (NGS) platforms in the realm of clinical 
molecular diagnostics has made multi-gene mutational profiling an 
affordable and highly successful methodology for massively paral-
lel sequencing using small quantities of DNA.
Methods: Tumor specimens from 262 distinct samples of primary 
lung carcinoma including adenocarcinoma (n=228), squamous 
cell carcinoma (n=15), non small cell cancer not otherwise spe-
cified (NSC-NOS) (n=8), poorly differentiated carcinoma (n=4), 
neuroendocrine carcinoma (n=2), small cell carcinoma (n=1) and 
pleomorphic carcinoma (n=4) were tested by NGS. Tumor samples 
included formalin-fixed paraffin-embedded surgical core needle 
biopsies, resection specimens, cytopathology cell blocks, as well 
as cytopathology direct smears. Ten ng of DNA from each sample 
was tested for mutations in hotspot regions of 46 cancer related 
genes (Ion AmpliSeq Cancer Panel) using either a 316 chip or a 318 
chip on an Ion Torrent Personal Genome Machine (PGM) Sequen-
cer (Life Technologies, CA).
Results: Mutations were detected in 222/240 (93%) patients with 
a histologic diagnosis of adenocarcinoma, NSC-NOS or PDC. 
EGFR mutations were detected in 47 (20%) of these patients and 
double EGFR mutations identified in 13 cases, including acquired 
resistance mutations T790M (n=6) and S768I (n=3). KRAS mutations 
were detected in 61 (25%) cases, most commonly involving codons 
12 and 13 (n= 58) and less frequently involving codons 61 and 146 
(n= 3). TP53 was most frequently mutated (n=65; 27%) and was of-
ten seen in conjunction with EGFR mutations (n=14; 5%) and KRAS 
mutations (n=15; 6%). Mutations were detected in 10/15 (67%) 
squamous cell carcinomas with mutations in TP53 (n=5), CDKN2A 
(n=3) and PIK3CA (n=2) most frequently seen. Additional mutations 
detected at a lower frequency from the entire dataset were STK11, 
ATM, BRAF, PIK3CA, CTNNB1, IDH1, NRAS, CDKN2A, KDR, RET, 
MET, FBXW7, APC, RB1, FLT3, GNAS, ABL1, HRAS, PTPN11, JAK3, 
NOTCH1, SMAD4, SMARCB1, SMO, MLH1, AKT1, and ERBB4.
Conclusion: In summary, our results show that NGS-based mu-
tational profiling using small amounts of DNA derived from FFPE 
as well as cytology smears can provide important information 
regarding mutation status of genes that play key roles in growth 
and progression of tumor in lung cancer patients and can provide 
insight into directing personalized cancer therapy.
Keyword: Mutations, NSCLC, Adenocarcinoma, EGFR, KRAS, p53.
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Background: Lung adenocarcinoma from never smoker repre-
ting ALK, ROS1 and RET genes in 3 cases each. Moreover, we 
detected one sample carrying a novel chimeric transcript fusing 
the first six exons of CD74 to the EGF-like domain of the NRG1 
III-β3 isoform, leading to the expression of its EGF-like domain in 
an otherwise NRG1-negative tumor tissue. The fusion gene was 
further detected in four additional cases out of 94 pan-negative* 
ADs of never smokers. In total, all 5 cases were identified in stage 
I invasive mucinous lung adenocarcinomas (IMA) of never smo-
ker females. This tumor type frequently presents with multifocal 
unresectable disease, for which no effective treatment has been 
yet established. IMA is highly associated with KRAS mutations; 
indeed, out of 15 IMA analysed, 6 carried a KRAS mutation (40%), 
and 4 the CD74-NRG1 fusion (27%). Given the fact that NRG1 sig-
nals through ERBB3 and ERBB4 receptors, we aimed to determine 
which receptor CD74-NRG1 provides the ligand for. We observed 
that ERBB4 was not expressed in the index case, while ERBB3 was 
relatively highly expressed and this expression also correlated 
with a positive phospho-ERBB3 (p-ERBB3) signal in the tumoral 
tissue of all 5 CD74-NRG1 positive cases. In order to test if this 
phosphorylation of ERBB3 was statistically significant, we stained 
a cohort of 241 ADs and found that p-ERBB3 was only positive in 
6 of them (p-value<0.0001). Additionally, although both EGFR and 
ERBB2 were expressed in the index case, only ERBB2 expression 
correlated with a p-ERBB2 positive signal. These data suggest that 
CD74-NRG1 might provide the ligand for ERBB3, which may form 
heterodimers with ERBB2, since ERBB3 is devoid of intrinsic kinase 
activity and cannot support linear signaling in isolation. This is in 
line with previous studies showing that NRG1 induces an oncoge-
nic signal through ERBB2-ERBB3 heterodimers engaging the PI3K-
AKT pathway. This was further supported by the activation of the 
PI3K-AKT, but not the MAPK pathway, in CD74-NRG1 transduced 
H2052 lung cells, after 24h starvation. 
 
*pan-negative: EGFR, KRAS, ALK, HER2, BRAF, ROS1 and RET wild-
type
Conclusion: Altogether, these data shows that CD74-NRG1 is a 
new recurrent oncogenic fusion gene, highly associated with IMA 
of never smokers. It also suggests that CD74-NRG1 fusion protein 
signals through the ERBB2-ERBB3 receptors complex leading to 
the activation of the PI3K-AKT pathway, providing a therapeutic 
opportunity for a tumor type with, so far, no effective treatment.
Keywords: NRG1, fusion gene, lung adenocarcinomas, transcrip-
tomis
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O04.02 USING NGS FOR MUTATIONAL PROFILING OF 
NSCLC IN THE CLINICAL SETTING
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Background: Recent advances in molecular characterization of 
lung cancer have led to the identification of potential therapeutic 
targets that play key roles in regulating cell growth and prolifera-
tion. With the introduction of new targeted therapies, it becomes 
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Background: Buparlisib (BKM120) is an oral PI3K inhibitor 
that inhibits all four isoforms of class I PI3K (α, β, γ, Δ) and has 
demonstrated antiproliferative, proapoptotic, and antiangiogenic 
activity in multiple preclinical cancer models. NSCLC cell lines with 
PIK3CA mutations (muts) have demonstrated increased sensitivity 
to buparlisib in vitro. BASALT-1 – an ongoing, multicenter, open-
label, two-stage Phase ll study (NCT01297491) – evaluates the 
safety and efficacy of single-agent buparlisib in patients (pts) with 
NSCLC and an activated PI3K pathway. Here we report data on 
the prevalence of PI3K pathway alterations in pts with squamous 
(sq) or non-squamous (non-sq) NSCLC prescreened for entry into 
BASALT-1.
Methods: Pts prescreened for BASALT-1 were ≥18 years of age 
with previously treated metastatic NSCLC of sq or non-sq histolo-
gy. PI3K pathway activation (defined as PIK3CA mut and/or PTEN 
mut and/or PTEN negative [neg; <10% protein expression at 1+ 
by immunohistochemistry]) was measured in archival or newly ac-
quired tumor tissue collected at prescreening. PIK3CA (exons 1, 5, 
7, 9, and 20) and PTEN (exons 1–9) muts were detected primarily 
using Sanger sequencing in a centralized fashion. Local analysis 
was permitted at selected sites where a SnapShot approach was 
most commonly used.
Results: As of April 10, 2013, 1183 pts had submitted tumor 
samples to be assayed (1179 tumors had known histology). PI3K 
pathway activation was detected in 16.0% of sq and 11.3% of non-
sq tumors. In sq tumors (N=612), loss of PTEN protein expression 
(8.2%) was the most common single alteration observed, followed 
by PIK3CA mut only (3.1%) and PTEN mut only (2.9%). In non-sq 
tumors (N=567), PTEN mut only was the most common alteration 
(4.9%), followed by PIK3CA mut only (2.6%) and PTEN neg only 
(2.1%). Frequencies of co-existing genetic alterations were: PTEN 
mut + PTEN neg only (1.0% sq vs 0.4% non-sq), PIK3CA mut + 
PTEN neg only (0.7% sq vs 0.4% non-sq), PIK3CA mut + PTEN mut 
only (0% sq vs 0.9% non-sq), and PIK3CA mut + PTEN mut + PTEN 
neg (0.2% sq vs 0% non-sq). No clear gender, age or ethnicity 
effects were observed (Table). 
sents a unique disease entity in that they often involve females of 
younger age and have a distinct mutation spectrum compared to 
those of smoker population. Mutations from the tumors of these 
patients often involve oncogenes that can be targeted for therapy 
by small molecule kinase inhibitors. We surveyed for tumor specific 
genetic changes in lung adenocarcinomas from never smokers for 
common oncogene mutations and transcript fusions.
Methods: We first developed a multiplex assay detecting187 
mutations in 10 actionable oncogenes frequently affected in lung 
cancer. We used this assay to examine 89 lung adenocarcinomas 
from never smokers identified through the Mayo Clinic Epidemio-
logy and Genetics of Lung Cancer Program. NextGen sequencing 
(RNASeq) was used to identify transcript fusions affecting either 
a known kinase or an oncogene in 20 of 89 tumors. RT-PCR, FISH 
and IHC were used to verify the novel fusion identified in this stu-
dy.
Results: Sixty-four tumors had mutation in at least one of the 
tested oncogenes involving EGFR (49 cases, 55%), k-RAS (5 cases, 
6%), MET (9 cases, 10%), BRAF (4 cases, 5%), PIK3CA (2 cases, 2%), 
and ERBB2 (4 cases, 5%). RNAseq identified five transcript fusions 
among the 20 tested tumors, involving known fusions of EZR- 
ROS1 or KIF5B-RET and three novel fusions involving SND1-BRAF, 
EML4-BIRC6, and GMEB2-TERT genes. We used RT-PCR to confirm 
the presence of the SND1-BRAF fusion transcript that involved 
exons 1-9 of SND1 with exon 2 to 3’ end of the BRAF on chromo-
some 7. Screening all 89 tumors by RT-PCR identified a total of 
three tumors with the identical fusion. Interestingly, two of these 
three tumors with a BRAF fusion also had a concurrent mutation in 
EGFR gene (S768I) and a third tumor had an additional mutation 
in the ERBB2 gene (M774_A775ins). Four additional samples were 
positive for EML4-ALK fusion by IHC and FISH.
Conclusion: In our study of a primarily Caucasian population, a 
majority of lung adenocarcinomas from never smokers (70/89, or 
78.6%) carry at least one genetic mutation in a targetable gene. 
For the first time, we report the presence of a transcript fusion 
involving SND1-BRAF in lung adenocarcinoma and that these fu-
sions are present in tumors also having EGFR or ERBB2 mutations. 
Combined together, activation of BRAF by either point mutation 
or transcript fusion is one of the most frequent events in our study 
accounting for 7/89 (8%) cases. These findings support a rapid and 
targeted gene mutation testing strategy for lung adenocarcinoma 
from never smokers, as the knowledge of these mutations can be 
readily used to augment therapeutic management.
Keywords: Targeted therapy, oncogene mutations, transcript fusi-
on, NGS sequencing
MOLECULAR PATHOLOGY I  
MONDAY, OCTOBER 28, 2013 - 10:30-12:00
O04.05 EPIDEMIOLOGY OF PI3K PATHWAY ALTERA-
TIONS IN PATIENTS WITH METASTATIC NON-SMALL 
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standardized ALK IHC assay.
Methods: Archival NSCLC tumor specimens (n=103) previously 
tested for ALK rearrangement by FISH were provided by the inter-
national collaborators. These specimens were stained by IHC with 
the anti-ALK (D5F3) primary antibody (Ventana Medical Systems, 
Inc) combined with OptiView DAB IHC detection and OptiView 
amplification (Ventana Medical Systems, Inc). The evaluators went 
through an interpretation training session and scored the speci-
mens as positive, if strong granular cytoplasmic brown staining was 
present in tumor cells, or negative. IHC results were compared to 
the FISH results and inter-evaluator agreement comparisons made.
Results: Overall for the 100 evaluable cases the ALK IHC assay was 
highly sensitive (90%), specific (95%) and accurate (93%) relative to 
the ALK FISH results. Similar results were observed using a majori-
ty score. For the discrepant cases IHC negativity was scored by 7/7 
on 3 FISH positive cases and 6/7 evaluators on 2 additional FISH 
positive cases. IHC positivity was scored on 2 FISH negative cases 
by 7/7 readers. There was agreement among 7/7 and 6/7 readers 
on 88% and 96%% of the cases before a consensus review, respec-
tively, and following a review there was agreement among 7/7 and 
6/7 on 95% and 97% of the cases, respectively.
Conclusion: Based on expert evaluation the ALK IHC assay using 
the D5F3 antibody combined with Optiview Detction and Optiview 
amplification is sensitive, specific and accurate, relative to FISH, 
and a majority score of multiple readers does not improve these 
results over an individual reader’s score. Excellent inter-reader 
agreement was observed for the IHC assay. These data support 
the algorithmic use of ALK IHC as a screening procedure for ALK 
protein expression in NSCLC.
Keywords: Crizotinib, predictive biomarker, companion diag-
nostic, ALK immunohistochemistry
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Background: Owing to use of high-resolution computed tomogra-
phy (CT) scan for lung cancers, small nodules could be detected, 
so that more patients are identified carrying more than one lesion 
in lung synchronously at the time of diagnosis. Under this circum-
stance, precisely distinguish multiple primary lung cancers from 
intrapulmonary metastasis has important significance on clinical 
staging and appropriate therapy design.
Methods: We comprehensively compared genomic aberration 
profiles of each tumor in the patients with multifocal pulmonary 
lesions, assuming that metastasis shared a certain portion of gene-
Conclusion: The findings from our large dataset indicate that ge-
netic alterations in the PI3K pathway occur in a clinically significant 
proportion of pts with sq and non-sq relapsed NSCLC. An accurate 
characterization of PI3K pathway alteration frequencies in NSCLC 
will help guide the design of future clinical trials of PI3K inhibitors.
Keywords: biomarker, buparlisib, PI3K/Akt/mTOR pathway, non-
small cell lung cancer
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Background: The goal of personalized medicine is treating pa-
tients with a therapy predicted to be efficacious based on the 
molecular characteristics of the tumor, thereby sparing the patient 
futile or detrimental therapy. Anaplastic lymphoma kinase (ALK) 
inhibitors are effective against ALK positive non-small cell lung 
cancer (NSCLC) tumors, but to date the only US Food and Drug 
Administration approved companion diagnostic is a break-apart 
fluorescence in situ hybridization (FISH) assay. Immunohistoche-
mistry (IHC) is a clinically applicable cost-effective test that is sen-
sitive and specific for ALK protein expression. The purpose of this 
study was to assemble an international team of expert pathologists 
to evaluate and standardize the interpretation of a new automated 
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Background: The purpose of this study was to explore the effect 
of screening with spiral CT on lung cancer mortality in comparison 
with no screening in a high-risk population. Secondary endpoints 
were incidence, stage and resectability.
Methods: Male subjects, aged 60-75, smokers of 20+ pack-years 
were randomized to screening with low-dose spiral CT or control. 
Prospective participants were pre-assessed for eligibility and 
randomized during a telephone interview, while formal enrolment 
took place at a later date. All enrolled participants underwent a 
structured medical interview and physical examination, a baseline, 
once-only chest X-ray (CXR) and sputum cytology examination. 
Screening-arm subjects had a LDCT upon accrual, which was re-
peated every year for four additional years (5 rounds), while con-
trols had a yearly clinical review only, with further testing only if 
needed.
Results: Between March 2001 and February 2006, 2811 sub-
jects were pre-assessed and randomized (CT arm: 1403, control 
arm:1408). 20 cases of double registration and two test records 
have been identified in the database, and 2540 subjects actually 
appeared for assessment (1229 CTR arm, 1299 CT arm), of whom 
2450 (1264 CT arm and 1186 Controls) were eligible and enrolled. 
The two study groups are comparable for age, smoking exposure, 
and comorbid conditions. As per inclusion criteria, all subjects are 
males and 99.8 % are 60 or older. As of December 2012, median 
follow-up was 73.1 months in the control arm and 75.5 months in 
the screening arm. Altogether, 152 patients were detected during 
active follow-up with 161 lung cancers: 92 CT-arm subjects (7.27%) 
versus 60 controls (5.05%), p< 0,0237. 82% of CT-arm lung cancers 
were detected at scheduled CT examinations, and 55% were stage 
I disease at the time of diagnosis compared with 27% in the Con-
trol arm. The absolute number of lung cancer cases with stage II-IV 
disease was virtually the same as in the control arm. Resectability 
rate was similar in the two groups. After linkage with population 
registries, vital status information is now available for 2528 subjects 
(99.5%). Overall, 370 subjects have died, for 104 of whom we are 
currently investigating mortality causes.
Conclusion: While the number of participants is relatively small, 
tic aberrations with the lesion it was originated. Therefore, whole-
genome/exome sequencing were applied on 15 intrapulmonary 
tumors that had highly similar histological diagnosis, and 1 lymph 
node metastasis derived from six patients with synchronous multi-
focal lung cancers. The somatic nucleotide variations (SNVs) detec-
ted by whole-genome/exome sequencing were validated by either 
mass spectrometry or the Sanger sequencing.
Results: A total of 344 non-synonymous somatic point mutations 
were detected in whole genome sequencing analysis (3 lesions 
and 1 lymph node metastasis in 1 patient), corresponding to 306 
unique mutation sites. Among the 70 mutations detected in the 
lymph node metastasis, 36 (51.4%) were also found in lesion 1 of 
the 3 intrapulmonary lesions, whereas no shared mutation were 
detected between the metastasis and either of the other two le-
sions. Meanwhile, there was only 1 common mutation between 
lesion 2 and 3, while no shared mutations were observed between 
lesion 1 and 2 or lesion 1 and 3. These results suggested that the 
metastasis was originated from lesion 1 and the 3 lesions were 
independent primary tumors. In whole exome sequencing analysis 
(12 lesions from 5 patient), among the 389 somatic non-syno-
nymous mutations detected, we observed a similarity between 
each pair of tumors within one patient ranged from 0% to 5.3%, 
suggesting that all the lesions were independent primary tumors 
rather than intrapulmonary metastasis. We also reached a same 
conclusion when we included all somatic mutations found across 
the genome/exome in the analysis. These genomic abnormality 
profile-based diagnosis were consistent with the diagnosis based 
on histological examination except one lesion in patient 5, which 
had been considered as an intrapulmonary metastasis by histolo-
gical judgment. At the same time, EGFR or KRAS mutations, which 
are therapy targets for adenocarcinoma in lung were detected in 
7 or 3 out of the 15 tumors in 3 or 2 patients, respectively. Hetero-
geneity was also observed in mutation status of these two genes 
among different lesions in a single patient.
Conclusion: Comprehensive genomic aberration profiling is pow-
erful for identification of multiple primary lung cancers. The lymph 
node metastasis in the study stands as a positive control, compa-
red with which we could tell that lesions from multifocal primary 
lung cancers shared too few somatic mutations to be intrapulmo-
nary metastasis. Considering the heterogeneous mutation status 
of EGFR or KRAS among different tumors derived from a single 
patient with multifocal primary lung cancer, molecular diagnosis 
should be taken for each accessible lesion when targeted adjuvant 
therapy is under consideration.
Keywords: Synchronous multiple primary lung cancers, Genome 
sequencing, Somatic mutation spectrum, Clinical staging
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Conclusion: Preliminary findings indicate features from both the 
nodule and the surrounding parenchyma have value in distingu-
ishing benign and malignant lesions. This is particularly valuable in 
the analysis of early detected, small pulmonary lesions (<10mm). In 
these small lesions, standard CAD approaches are hindered by few 
CT data voxels contained within the lesion. By incorporating local, 
surrounding and global features, more information is included 
and augmented CAD performance may be achieved. Finally, many 
significant features were identified despite diversity in the CT data 
acquisition parameters which indicates the suitability of the ap-
proach to broad clinical application. We are currently working on 
applying the CAD tool to a larger dataset. 
Keyword: computed tomography, computer aided diagnosis, 
screening,parenchymal features
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O05.03 SCREENING OF LUNG CANCER BY LOW-DOSE 
CT (LDCT), DIGITAL TOMOSYNTHESIS (DT) AND CHEST 
RADIOGRAPHY (CR) IN A HIGH RISK POPULATION: A 
COMPARISON OF DETECTION METHODS
Natthaya Triphuridet1, Sutida Singharuksa2, Thaniya Sricharun-
rat3
1Medical Pulmonology, Chulabhorn Hospital/Thailand, 2Radiology, 
Chulabhorn Hospital/Thailand, 3Pathology, Chulabhorn Hospital/Thai-
land
Background: LDCT has recently been recommended as a scree-
ning tool for lung cancer in a high risk population, provided a 20% 
reduction in lung-cancer specific mortality. Nevertheless, LDCT 
has some limitations with respect to its high false positive rate, 
accumulated radiation exposure and relatively high cost. Digital 
tomosynthesis (DT) is a multisection imaging technique which can 
improve detection ability of small lung nodules and renders much 
lower radiation dosage and operation costs.
Methods: Thai heavy smokers (>30 pack-years) were enrolled in 
a prospective study starting from July 2012 to April 2013 (n=580). 
LDCT, DT and CR were utilized as a screening tool for lung cancer 
screening. All participants underwent imaging studies on the same 
day and the results were independently reviewed within a 1-week 
interval. Abnormal findings were categorized into 3 groups: ne-
gative, indeterminate (maximum diameter of pulmonary nodule 
>5- 9.9 mm), and suspicious for malignancy (maximum diameter of 
pulmonary nodule > 10 mm, consolidation, obstructive atelectasis, 
pleural effusion or mediastinal lymphadenopathy).
Results: At baseline, LDCT and DT classified 16/580 cases as sus-
picious for primary lung cancer while CR detected 15/580 cases. 
Seven cases with positive LDCT and DT findings were tissue-pro-
ven primary lung cancer including 3 - stage I cancers, 1 - stage III 
cancer and 3 - stage IV cancers. CR detected only 3 proven cases 
of primary lung cancer and all of them were stage IV cancer. The 
lung cancer detection rate for pulmonary nodule > 10 mm and 
other suspicious findings was 1.2%, 1.2%, and 0.5% by LDCT, DT, 
and CR, respectively. LDCT classified 67 cases as indeterminate 
while DT and CR classified 21 and 11 as such cases, respectively. 
Two additional primary lung cancer cases were detected at a 
3-month follow-up LDCT of the indeterminate group by LDCT (2 
cases), DT (1 case) and CR (0 case), respectively. The lung cancer 
detection rate for pulmonary nodule > 5 mm and other suspicious 
smoking exposure and average age of participants are higher than 
in similar trials. A comparatively high number of events has been 
observed. To date, 28% of such events cannot yet be attributed to 
a specific cause. Health registry data necessary to complete mor-
tality comparisons is expected to become available in the next few 
weeks. Merging of all European trials may yield robust data about 
this strategy in the future.
Keywords: early detection, spiral CT, Lung cancer, randomized 
trial
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O05.02 LOCAL, SURROUNDING AND GLOBAL FEA-
TURES FOR IMPROVED COMPUTER AIDED DIAGNOSIS 
OF LUNG CANCER
Jessica C. Sieren, Samantha Dilger
Radiology, University Of Iowa/United States Of America
Background: The National Lung Screening Trial reported a 20% 
reduction in lung cancer mortality achieved through low dose 
computed tomography (CT) screening of the at risk population, 
compared to screening with chest x-ray. Challenges with clini-
cal implementation of CT screening for lung cancer include the 
high number of lesions detected that require further follow-up, 
approximately 97% of which are ultimately diagnosed as benign. 
A computer-aided diagnosis (CAD) tool can be designed to de-
termine the probability of malignancy of a lung nodule based on 
objective measurements. While current CAD tools examine the 
pulmonary nodule’s shape, density, and border, analyzing the lung 
parenchyma surrounding the nodule is an area that has been mi-
nimally explored. By quantifying characteristics, or features, of the 
surrounding tissue, this study explores the hypothesis that textural 
differences in both the nodule and surrounding parenchyma exist 
between malignant and benign cases, which can be utilized to 
improve CAD performance. 
Methods: From CT data, several novel feature extraction tech-
niques were developed, including a three-dimensional application 
of Laws’ Texture Energy Measures to quantify the textures of the 
parenchyma as well as the nodule. In addition, the densities of the 
nodule and parenchyma were summarized through metrics such as 
mean, variance, and entropy of the intensities. The margins of the 
nodule were characterized following ray casting and rubber-band 
straightening to analyze mean and variance of border irregularity. 
Basic demographics and risk factor data were also included. The 
large feature set was reduced by statistical testing and stepwise 
forward selection to a few independent features that best summa-
rize the dataset. A neural network was used to classify the cases in 
a leave-one-out method. 
Results: To illustrate proof of concept, the CAD tool was applied 
to 27 lung nodule cases: 10 malignant and 17 benign. These data 
were diverse with regards to data acquisition protocol, reconstruc-
tion kernel and slice thickness – all of which can pose challenges 
to CAD. Through statistical testing, 36 features were found to be 
significant predictors of malignancy (p < 0.05), including many tex-
tural and parenchymal features. Two of these significant features, 
selected through stepwise forward selection, were utilized to clas-
sify the data: nodule variance (p = 0.0003) and parenchyma medi-
an intensity (p = 0.0028). CAD performance achieved a sensitivity 
of 90%, specificity of 100%, and an accuracy of 96.3%. 
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of $60,900. Increasing age of eligibility to 55-79 cost $2.25 billion 
at an ICER of $58,700 per QALY while requiring a 40 p-y smoking 
history reduced cost to $1.3 billion at an ICER of $49,800 per 
QALY. Table 1. 
Year 
Stage 
Shift 
Scenario 
Sens/ 
Spec 
1 2 3 4 5 
0 T0 T0 T0 T0 T0 
0.9/ 
0.73 
1 CD PS PS PS CD - 
2 T0 T0 T0/T1 T1 T1 
0.89/ 
0.84 
3* CD PS PS PS CD - 
4** T0 T0 T0/T1 T1 T1 
0.89/ 
0.84 
ICER $275,000 $65,000 $56,200 $49,300 $104,00 
 
T0, T1 refer to the NLST stage shift at specified time, where T0 
equals shift at time zero screen, T1 shift at 12 month screen. T0/T1 
indicates an average. CD: the unscreened Canadian stage distribu-
tion. PS: NLST post-screening stage shift. *Represents 3rd year and 
all future odd years. **Represents 4th year and all future even years. 
Hyphens indicate years without screening.
Conclusion: Compared to annual lung cancer screening, biennial 
screening reduces net cost but may have a similar ICER. Stage shift 
assumptions have a significant impact on ICER values. Minor ad-
justments in Sens/Spec modestly change the ICER. Widening the 
age range increases but increasing the p-y requirement reduces 
system costs.
Keywords: Lung cancer, simulation, screening, cost-effectiveness
findings was 1.6%, 1.4%, and 0.5% by LDCT, DT, and CR, respec-
tively. The positive predictive value (PPV) for pulmonary nodule 
>10 mm and other suspicious findings by LDCT, DT and CR was 
43.8%, 43.8%, and 20.0%, respectively, while the PPV for pulmona-
ry nodules of> 5 mm and other suspicious for malignancy findings 
by LDCT, DT and CR were 10.8%, 21.6%, and 11.5%, respectively. 
The sensitivity and specificity was 100% and 87%, respectively, for 
LDCT, and 88.9% and 94.9%, respectively, for DT, and 33.3% and 
96%, respectively, for CR.
Conclusion: DT is a lung cancer screening modality that is com-
parable to LDCT, particularly for pulmonary lesions that are larger 
than 10 mm. and other suspicious for malignancy findings while CR 
was far inferior to DT and LDCT.
Keyword: Lung Cancer Screening, Low-Dose CT (LDCT), Digital 
Tomosynthesis (DT), Chest Radiography (CR)
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O05.05 BIENNIAL LUNG CANCER SCREENING BY LOW-
DOSE CT SCAN - A SIMULATION OF COST EFFECTIVEN-
ESS IN CANADA
John R. Goffin1, William M. Flanagan2, Anthony B. Miller3, Fei Fei 
Liu4, Sonya Cressman5, Natalie Fitzgerald4, Sharon Fung4, Michael 
C. Wolfson6, William Evans1
1Mcmaster University/Canada, 2Statistics Canada/Canada, 3Dalla 
Lana School Of Public Health/Canada, 4Canadian Partnership Against 
Cancer/Canada, 5The Canadian Centre For Applied Research In Cancer 
Control, The British Columbia Cancer Agency/Canada, 6University Of 
Ottawa/Canada
Background: Randomized data support annual screening for lung 
cancer among smokers using low-dose CT scans. To compare 
the resource implications of annual versus biennial screening, a 
cost-effectiveness analysis was undertaken using the Cancer Risk 
Management Model (CRMM version 2.0.1) in the context of the 
Canadian publicly funded healthcare system.
Methods: The CRMM performs simulations at an individual level 
and incorporates demographic data, cancer risk factors, cancer 
registry data, diagnostic and treatment algorithms and health uti-
lities. Outputs are aggregated and costs (in 2008 Cdn dollars) and 
life-years are discounted at 3% annually. Simulations were perfor-
med with a cohort 55-74 years and a ≥30 pack-year (p-y) smoking 
history recruited from 2012-2032. CT scan sensitivity (Sens) and 
specificity (Spec) and cohort outcomes were based on NLST and 
Canadian data. It was assumed 60% of the eligible population 
participates by 10 years, 70% adhere to the screening regimen, 
and smoking cessation rates are unchanged. Sensitivity analysis 
was undertaken.
Results: An annual screening program incurs net costs of $2.97 
billion and saves 55,000 quality-adjusted life-years (QALYs) at an 
incremental cost-effectiveness ratio (ICER) of $53,700 per QALY. 
Under default biennial screening assumptions (Table 1, scenario 
3), biennial screening costs are $1.81 billion, saving 32,000 QALYs 
and producing an ICER of $56,200. In the least favourable stage 
shift scenario (1) tested, the ICER is $275,000, whereas the most 
favourable shift (4) results in $49,300. Using Sens/Spec 0.90/0.73 
for all scans in scenario 3 produces an ICER of $61,400, whereas 
changing all incidence scan Sens/Spec to 0.87/0.73 gives an ICER 
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O05.07 COPD-BASED ELIGIBILITY INCREASES LUNG 
CANCER DETECTION RATE AND LOWERS OVER-DIAG-
NOSIS IN CT SCREENING STUDIES
Robert P. Young1, Fenghai Duan2, Raewyn J. Hopkins3, Xuan Deng2, 
Caroline Chiles4, Greg D. Gamble5, Castantine Gatsonis2, Denise 
Aberle6
1School Of Biological Sciences And Faculty Of Medical And Health Sci-
ences, University Of Auckland/New Zealand, 2Brown University/United 
States Of America, 3Faculty Of Medical And Health Sciences, University 
Of Auckland/New Zealand, 4Wake Forest University Baptist Medical 
Centre/United States Of America, 5University Of Auckland/New Zeal-
and, 6University Of California, Los Angeles/United States Of America
Background: Based on a 20% reduction in lung cancer deaths in 
the CT screening arm of the National Lung Screening Trial (NLST), 
yearly CT screening for lung cancer is now widely recommended. 
Eligibility for the NLST was based on age and smoking history 
only. However, we and others propose that multivariate risk models 
of lung cancer that incorporate variables for chronic obstructive 
pulmonary disease (COPD), improve risk prediction for lung can-
cer. The aim of this study was to examine recently published CT 
screening studies for lung cancer and the effect of having COPD 
on outcome.
Methods: We searched the literature for CT screening studies 
of lung cancer where spirometry had been done at baseline to 
assess the effects of spirometry-defined COPD on outcomes. We 
identified six studies where there was published data reporting 
spirometry results in lung cancer screening studies. Using this data 
we objectively measured outcomes stratified or pre-selected on 
spirometry-defined COPD.
Results: By comparing outcomes in these single arm and rando-
mized studies we found the following 
• lung cancer detection rates were between 1.5 to 6 fold higher in 
current and former smokers eligible for screening with spirometry-
defined COPD compared to those with no airflow limitation or 
normal lungs (Table 1).
• Only 15% of those screened had advanced stage COPD (GOLD 
3-4)
• The proportion of eligible current or former smokers with COPD 
had less indolent lung cancers with long doubling times (Table 2), 
and
• Survival after surgical resection of early stage CT-detected lung 
cancers was no different between those with or without COPD at 
baseline screening.
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O05.06 RESOURCE UTILIZATION AND COSTS OF SCREE-
NING HIGH-RISK INDIVIDUALS FOR LUNG CANCER IN 
CANADA
Sonya Cressman, Stuart J. Peacock, Ian Cromwell
The Canadian Centre For Applied Research In Cancer Control, The Bri-
tish Columbia Cancer Agency/Canada
Background: In September 2008 the Pan-Canadian early lung de-
tection of lung cancer study recruited 2537 current or former smo-
kers who were determined to have a high risk of developing lung 
cancer. An economic analysis was conducted to estimate the po-
tential costs and benefits of screening with the aim of knowledge 
translation and decision aid for provincial screening programs. An 
analysis of prospectively collected resource utilization and cost 
data is presented.
Methods: Screening costs have been determined, accounting for 
the cost of all resources utilized to confirm true negative and false 
positive screen tests as well as early stage treatment costs for re-
sources applied to obtain diagnostic confirmation of true positive 
and false negative results for screened individuals, treat the pri-
mary disease and any subsequent lung cancer within three years. 
All costs have been calculated from the Canadian public payer’s 
perspective. The average CT-screening cost over a fixed period 
of 18 months for the pan-Canadian study participants who did not 
have cancer was determined and compared with the phase specific 
costs of true positive and false negative lung cancer screening par-
ticipants who had a lung cancer diagnosis proven prior to Dec. 31, 
2012. The costs for early-detected lung cancer were determined 
and presented by diagnosis, treatment and surveillance phases of 
care.
Results: The average cost per screened individuals who did not 
end up having cancer in the first two years of the study was $456 
(95%CI: $385-$570) per-person. The average rate of non-invasive 
investigations to pursue suspicious CT findings was 49% (CI: 45%-
54%); depending significantly on the follow-up protocol observed 
in different participating sites. The rate of invasive investigations 
for individuals who had true negative or false positive results was 
low (<0.4%) as was the rate of complication (<0.004%). 85 indivi-
duals had lung cancer detected and diagnosed prior to December 
31, 2012. The average cost of screening and the subsequent diag-
nostic workup for the most common detected lung cancer (stage 
IA and IB non-small cell lung cancer) was $4,233 (95%CI: $3,643-
$4,822) per person. Per-person treatment and surveillance costs 
are presented by stage and mode of treatment for 84 lung cancers 
found in the early detection study.
Conclusion: This information indicates that screening costs are 
low on average, as are the rates of complications in the screened 
individuals that do not receive a cancer diagnosis in the first two 
years of screening. These numbers arrive while Canadian and other 
national healthcare systems must manage the impacts of several 
private, opportunistic, lung-screening clinics that are already ope-
rational. This study is sponsored by the Terry Fox Research Institu-
te and the Canadian Partnership against Cancer
Keyword: Health economics, cost analysis, screening
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O06.00 NATIONWIDE QUALITY IMPROVEMENT IN 
LUNG CANCER CARE: THE ROLE OF THE DANISH LUNG 
CANCER GROUP AND REGISTRY.
Erik Jakobsen1, Anders Green2, Kell Oesterlind3, Torben Riis Ras-
mussen4, Maria Iachina5, Torben Palshof6
1Thoracic Surgery, Odense University Hospital/Denmark, 2Odense Pa-
tient Data Exploratory Network (open), Institute Of Clinical Research, 
University Of Southern Denmark/Denmark, 3Department Of Oncology, 
Copenhagen University Hospital At Rigshospitalet/Denmark, 4Depart-
ment Of Pulmonary Medicine, Aarhus University Hospital/Denmark, 
5Center For Clinical Epidemiology, Odense University Hospital/Den-
mark, 6Department Of Oncology, Aarhus University Hospital/Denmark
Background: In order to improve prognosis and quality of lung 
cancer care the Danish Lung Cancer Group has developed a stra-
tegy consisting of national clinical guidelines and a clinical quality 
and research database. In 1998 the first edition of guidelines was 
published and a registry was opened for registrations in the year 
2000. This abstract describes the methods used and the result 
obtained through the collaborative work and discusses how to 
improve the quality of lung cancer care through the development 
and monitoring of indicators.
Methods: A wide range of indicators was established, validated 
and monitored. By registration of all lung cancer patients since the 
year 2000, more than 40.000 patients have been included in the 
database. Results are reported periodically and submitted to for-
mal auditing on an annual basis.
Results: Improvements in all outcome indicators are documented 
and statistical significant. Thus the one year overall survival has 
between 2003 and 2011increased from 36.6 % to 42.7 %; the 2 
year survival from 19.8 % to 24.3 % and the 5 year survival from 9.8 
% to 12.1 %. 5 year survival after surgery has increased from 39.5 
% to 48.1 %. Improvements in waiting times, accordance between 
cTNM and pTNM and in resection rates are documented. 
Conclusion: The Danish experience shows that a national quality 
management system including national guidelines, a database 
with a high degree of data quality, frequent reports, audit and 
commitment from all stakeholders can contribute to improve 
clinical practice, improve core results and reduce regional / 
geographic differences.
Keywords: quality of care, indicators, outcome measurement, 
survival
 
Conclusion: We conclude that a COPD-centric approach to lung 
cancer screening offers a more efficient means of identifying lung 
cancer (higher lung cancer detection rate), with less over-diagnosis 
and comparable outcomes to screening those without COPD.
Keyword: lung cancer, CT, screening, risk prediction
S152 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
CANCER CONTROL AND EPIDEMIOLOGY I  
MONDAY, OCTOBER 28, 2013 - 10:30-12:00
O06.01 LUNG CANCER RISKS, BELIEFS, AND HEALTH-
CARE ACCESS AMONG THE UNDERPRIVILEGED
Jean-Francois Morere1, Jérôme Viguier2, Chantal Touboul3, Xavier 
Pivot4, Jean-Yves Blay5, Yvan Coscas6, Christine Lhomel7, François 
Eisinger8
1Oncology, Hôpital Paul Brousse/France, 2Chru Trousseau/France, 3Kan-
tarhealth/France, 4Chu De Besançon/France, 5Department Of Medicine, 
Leon Bérard Cancer Center/France, 6Clinique De La Porte De Saint-
cloud/France, 7Roche Sas/France, 8Institut Paoli-calmettes/France
Background: One goal of the current French National Cancer Plan 
is to reduce health inequities in cancer control. In this study, an un-
derprivileged population was investigated to analyze exposure to 
lung cancer risk factors and health care access in order to highlight 
ways to improve lung cancer control in that population.
Methods: Within the nationwide observational study EDIFICE 3, 
conducted by phone interviews among a representative sample 
of 1603 subjects aged between 40 and 75 years old, we used 
the “EPICES” validated questionnaire to examine the association 
of underserved status with lung cancer risk factors, beliefs, and 
health care access.
Results: Based on the EPICES score, underserved subjects repre-
sented 33% of the sample. These subjects subjectively perceived a 
higher risk of cancer compared to subjects in the served populati-
on (21% vs. 14% respectively, p<0.01). Among people with cancer, 
underserved subjects have a higher rate of lung cancer (10% of 
cancers vs. 1%, p<0.05). They also have more cancer risk factors: a 
high BMI (26.0 vs. 24.8, p<0.01), are active smokers (38% vs. 23%, 
p<0.01) with a higher consumption of cigarettes (16.0 cigarettes/
day vs. 10.1, p<0.01) and for a longer period (29.4 years vs. 26.3, 
p<0.01), and also practice less sport (42% vs. 77%, p<0.01). They 
No Indicator 
Threshold 
(%) 
2003 
(%) 
2004 
(%) 
2005 
(%) 
2006 
(%) 
2007 
(%) 
2008 
(%) 
2009 
(%) 
2010 
(%) 
2011 
(%) 
2012 
(%) 
Ia 
Patients surviving 1 year from date 
of diagnosis 
42 36,6 37,4 37,3 37,2 39,3 38,2 38,3 40,2 42,7 
Ib 
Patients surviving 2 years from date 
of diagnosis 
22 19,8 20,5 20,7 20,9 22,9 21,8 23,0 24,3 
Ic 
Patients surviving 5 years from date 
of diagnosis 
12 9,8 9,6 10,4 10,5 12,1 
IIa 
Patients surviving 30 days from date 
of operation 
97 93,7 98,4 96,9 96,7 96,8 97,5 97,8 98,0 99,0 99,0 
IIb 
Patients surviving 1 year from date 
of operation 
75 73,8 76,4 79,7 80,7 83,8 82,2 86,1 85,9 88,6 
IIc 
Patients surviving 2 years from date 
of operation 
65 60,5 58,9 64,3 67,2 70,6 66,6 73,6 75,5 
IId 
Patients surviving 5 years from date 
of operation 
40 39,5 38,8 44,5 46,9 48,1 
IIIc 
Rate of patients starting chemo 
within 42 days after referral 
85 62,9 51,1 50,3 56,0 59,8 73,4 72,7 74,7 80,8 82,9 
IV 
Rate of patients with accordance 
between cTNM and pTNM 
85 68,2 70,2 77,0 72,7 79,8 77,6 80,1 83,3 86,4 91,3 
V 
Rate of patients with NSCLC who had 
a resection 
20 18,7 18,9 19,8 20,4 19,8 
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Conclusion: We conclude that the reduction in cancer mortality 
attributed to statin therapy by Nielsen et al. is seen almost exclu-
sively in cancers where smoking and/or systemic inflammation is 
thought to be of significant pathogenic importance. Significantly, 
the single largest reduction can be attributed to lung cancer where 
both smoking and systemic inflammation are strongly implicated. 
We suggest that a reduction in systemic inflammation by statins 
may be one mechanism underlying the reduction in mortality re-
ported by Nielsen and colleagues.
Keyword: Lung cancer, inflammation, statins, mortality
have more comorbidities: on average (2.2 vs. 1.8, p<0.01), at least 
one (76% vs. 65%, p<0.01), hypertension (24% vs. 19%, p<0.05), 
cardiovascular disease (13% vs. 9%, p<0.05) and respiratory di-
sease (13% vs. 7%, p<0.01). Access to healthcare is not an issue 
(consultations with a general practitioner are more frequent for 
the underserved group: 5.4 vs. 3.7 per year, p<0.01). They trust 
the national health system less (an average score from 1 to 10; 6.0 
vs. 6.3, p <0.05). However, 85% of underserved subjects think that 
lung cancer can be efficiently screened vs. 78% of the served po-
pulation (p<0.01).
Conclusion: In order to reduce inequities in lung cancer control, 
the effort of upstream interventions should be focused on pre-
vention, as healthcare access does not discriminate. Underserved 
subjects have a high level of trust in lung cancer screening but a 
riskier behavior in terms of smoking. This constitutes new targets 
for specific communication campaigns and Health authorities’ in-
terventions.
Keywords: EDIFICE, screening, Underprivileged, Lung cancer
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O06.02 STATIN USE AND REDUCED LUNG CANCER-
RELATED MORTALITY
Robert P. Young, Raewyn J. Hopkins, Greg D. Gamble
University Of Auckland/New Zealand
Background: Lung cancer results from the combined effects of 
smoking exposure and genetic predisposition. Recent studies have 
shown that susceptibility to chronic obstructive pulmonary disease 
(COPD) is also relevant to a predisposition to lung cancer. The lat-
ter may be mediated in part through exaggerated systemic inflam-
mation secondary to smoking exposure and the innate response to 
smoking in genetically susceptible people. Recently a large popu-
lation based study reported that statin therapy was associated with 
a reduction in mortality from cancer (Nielsen et al. Statin Use and 
Reduced Cancer-Related Mortality, NEJM 2012; 367: 1792-1802). 
The aim of this study was to examine the cancer specific effect of 
statins on mortality.
Methods: Using the raw data from the Nielsen study, we calcula-
ted the estimated number of lives saved from statin therapy use 
according to type of cancer and then estimated the absolute num-
bers of lives saved.
Results: When we examined the raw data showing hazard ratios 
according to statin use in each of the cancers described, we found 
that except for lymphoma, the mortality reductions were signi-
ficant for smoking related cancers (lung, pharynx, oesophagus, 
urinary) and obesity-related cancers (colon, prostate, breast - see 
Figure 1). When we calculated the number of lives saved according 
to specific cancer type, we found that of all lives saved, 43% could 
be attributed to a reduction in lung cancer deaths (Table 1). Impor-
tantly, mortality for many of these cancers (lung, colon, breast and 
prostate) has been associated, in large prospective studies, to ele-
vation of the C-reactive protein, a marker of systemic inflammation. 
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Table 1: Characteristics of California Health Interview Survey 
participants, 2009
Characteristics Unweighted sample size 
Weighted percen-
tages (95% CI) 
Smoking Status 
Current smokers 5,528 13.6 (12.8-14.4) 
Former Smokers 14,487 23.0 (22.1-23.8) 
Never smokers 27,317 63.4 (62.5-64.3) 
Family Cancer 
History 
Yes 22,286 35.0 (34.1-35.8) 
No 25,045 65.0 (64.1-65.8) 
Age 
18-25 2,826 16.0 (15.6-16.4) 
26-34 3,446 15.6 (15.0-16.0) 
35-49 10,484 30.2 (29.7-30.5) 
50+ 30,575 38.2 (38.1-38.2) 
Gender 
Male 19,280 49.0 (49.0-49.1) 
Female 28,051 51.0 (50.0-51.0) 
Race/Ethnicity 
Hispanic 8,281 32.5 (32.4-32.5) 
Non-Hispanic 
White 
30,951 46.4(46.4-46.5) 
Non-Hispanic Black 1,839 5.6 (5.6-5.7) 
Non-Hispanic Asian 4,833 12.8 (12.8-13.0) 
Non-Hispanic 
Other 
1,427 2.6 (2.5-2.6) 
Marital Status 
Married 27,079 61.3 (60.5-62.2) 
Not-married 20,252 38.6 (37.8-39.5) 
Federal Poverty 
Level (FPL) 
< 100% FPL 5,747 16.0 (15.3-16.8) 
100-199 % FPL 7,950 18.0 (17.2-18.7) 
200-299 % FPL 6,478 13.7 (13.0-14.5) 
≥ 300% FPL 27,156 52.2 (51.3-53.1) 
Education Level 
< High-school 4,795 16.3 (16.1-16.4) 
High-school gra-
duate 
10,345 26.0 (25.8-26.0) 
Some college 12,858 23.7 (23.0-24.5) 
College or more 19,333 34.0 (33.3-34.7) 
Health Insurance 
Currently insured 42,186 82.0 (81.0-82.8) 
Not insured 5,145 18.0 (17.1-19.0) 
General Health 
Excellent/Very 
Good 
24,554 52.0 (51.0-52.8) 
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O06.04 THE ASSOCIATION BETWEEN HAVING A FIRST-
DEGREE FAMILY HISTORY OF CANCER AND SMOKING 
STATUS
Hermine Poghosyan1, Jill G. Joseph2, Janice Bell2, Mary E. Cooley3
1College Of Nursing And Health Science, University Of Massachusetts 
Boston/United States Of America, 2Betty Irene Moore School Of Nur-
sing, University Of California Davis/United States Of America, 3Phyllis 
F. Cantor Center For Research In Nursing And Patient Care Services, 
Dana-Farber Cancer Institute/United States Of America
Background: Smokers with a family history of cancer are at higher 
risk for developing cancer. A diagnosis of cancer within the family 
may provide an opportunity for smokers to adopt health-promo-
ting behavior. This study examined associations between having a 
first-degree family history of cancer and smoking status.
Methods: Data from the 2009 California Health Interview Survey 
(CHIS) on 47,331 adults were used in this cross-sectional study. 
Sample weights were applied to account for the complex survey 
design with results generalizable to non-Institutionalized adults 
in California (27.4 million). Smoking status was classified as cur-
rent, former, or never-smoker. Family cancer history was defined 
as blood relatives that include biological father or mother, full 
brothers or sisters, or biological sons or daughters. Demographic 
characteristics included age, gender, race/ethnicity, marital status, 
poverty level, education level and health insurance coverage. Ge-
neral health status, physical activity, body weight status and binge 
driNKIng status were also included. CHIS defined binge driNKIng 
status as ≥5 alcoholic drinks for males or ≥4 alcoholic drinks for fe-
males in a single episode in the past year. Body weight status was 
defined by body mass index as underweight <18.5 kg/m2, normal 
= 18.5–24.9 kg/m2, overweight = 25.0–29.9 kg/m2, and obesity 
≥30.0 kg/m2. Multinomial logistic regression was used to analyze 
the association between first-degree family history of cancer and 
smoking status.
Results: In 2009, 13.6% (3.7 million) of the 27.4 million adults were 
current-smokers, 23.0% (6.3 million) former-smokers and 63.4% 
(17.4 million) never-smokers. Thirty-five percent (9.6 million) had a 
first-degree family history of cancer (Table 1). Among those with 
a first-degree family history of cancer, 13.5% (1.3million) were 
current-smokers, 29.7% (2.8 million) were former-smokers and 
56.8% (5.4 million) were never-smokers. Adults with a first-degree 
family history of cancer were more likely to be former-smokers 
compared with adults without a first-degree family history of 
cancer (29.7% vs. 19.3%, p<.001). Controlling for demographic 
factors and other risk characteristics (binge driNKIng, obesity, 
physical activity), having a first-degree family history of cancer 
was significantly related to being a current-smoker (OR=1.16; 95% 
CI=1.01-1.34) and former-smoker (OR=1.17; 95% CI 1.05-1.30). 
Conclusion: In California, many adults with a first-degree family 
history of cancer still smoke which places them at higher risk for 
poor health outcomes. Smokers with a first-degree family history 
of cancer may be an important target population for smoking 
cessation interventions.
Keywords: health promotion, smoking-cessation, family cancer 
history
S155Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
family members are recruited to the program via a multidiscipli-
nary referral system and have access to nurse led counselling and 
behaviour modification consultations as well as provision of free 
pharmacological smoking cessation aids. Evaluation of the pro-
gram was undertaken through and audit of medical and pharmacy 
records for all patients who participated in the program (n=312) 
and by phone interviews with a subset of patients (n=30) and com-
pared to data from a previously published study at our institution1.
Results: 50% (n=10,401) of patients newly registered to the hos-
pital identified as having ever smoked with 12% (n=2448) current 
smokers. Recruitment of self-identified active smokers into the 
smoking cessation program was low (7.3%). 43% (n=134) of patients 
enrolled into the program had not disclosed their smoking status 
at hospital registration. Magnitude of smoking was high; average 
pack-years of patients who have ever smoked was 22.6 and for 
current smokers was 27.8; 155 patients reported smoking magni-
tude as greater than 100 pack years. Provision of free pharmaco-
therapy equated to a net expenditure of AUD$22,042. Point preva-
lence smoking cessation rate among patients who participated in 
follow-up interviews (n=30) was similar to that previously reported 
following participation in our multidisciplinary smoking cessation 
program, 33% compared to 37%1. 66% of patients reported suc-
cessful outcomes (cessation or reduction in consumption).
Conclusion: Patient-reported smoking behaviours were grossly un-
derreported impacting on the ability to actively enrol patients into 
established interventional cessation programs. Despite low recruit-
ment rates and high magnitude of smoking, the multidisciplinary 
model was able to achieve successful outcomes at minimal cost 
in this vulnerable patient cohort. Improving disclosure practices 
may enable future targeted recruitment of patients by health-care 
professionals and increase the participation of smokers in proven 
healthcare interventions.
Keywords: cancer patients, smoking behaviours, smoking cessati-
on, multidisciplinary
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O06.06 FACTORS ASSOCIATED WITH SMOKING CESSA-
TION IN PARTICIPANTS OF THE PAN CANADIAN EARLY 
LUNG CANCER STUDY
Grzegorz J. Korpanty1, Stephen Lam2, Lawson Eng1, Peter Selby3, 
Susie Su1, Wei Xu1, Annette Mcwilliams2, Sukhinder Atkar-Khat-
tra2, John Mayo4, Ken Evans4, Richard Finley4, John Yee4, John C. 
English4, Heidi Roberts1, Ming Tsao1, Frances A. Shepherd1, Kam 
Soghrati1, Kazuhiro Yasufuku1, Simon Martel5, Francis Laberge5, 
John R. Goffin5, Michel Gingras5, Lori Stewart6, Serge Puksa6, Scott 
Tsai7, Daria Manos8, Michael Johnston8, Garth Nicholas9, Glen-
wood Goss9, Jean Seely9, Kayvan Amjadi9, Alain Tremblay10, Paul 
Burrowes10, Paul Maceachern10, Rick Bhatia11, Martin Tammema-
gi12, Geoffrey Liu1
1Princess Margaret Cancer Centre/Canada, 2British Columbia Cancer 
Agency/Canada, 3Centre For Addiction And Mental Health, University 
Of Toronto, Toronto, Ontario, Canada, University Of Toronto/Canada, 
4Vancouver General Hospital/Canada, 5Institut Universitaire De Cardi-
ologie Et De Pneumologie De Quebec/Canada, 6Mcmaster University/
Canada, 7Juravinski Hospital And Cancer Center/Canada, 8Dalhousie 
University/Canada, 9Ottawa Hospital Centre/Canada, 10University Of 
Calgary/Canada, 11Memorial University/Canada, 12Brock University/
Canada
Table 1: Characteristics of California Health Interview Survey 
participants, 2009
Characteristics Unweighted sample size 
Weighted percen-
tages (95% CI) 
Good 13,588 29.8 (28.4-30.8) 
Fair/Poor 9,189 18.2 (17.4-19.0) 
Body Weight 
Status 
Underweight 1,051 2.2 (2.0-2.5) 
Normal 19,689 41.3 (40.4-42.3) 
Overweight 16,078 33.7 (32.8-34.5) 
Obese 10,513 22.7 (21.8-23.5) 
Physical Activity 
Sedentary 16,936 34.6 (33.6-35.7) 
Some activity 20,838 43.4 (42.3-44.5) 
Regular activity 9,557 21.8 (21.0-22.7) 
Binge drinking 
status 
Yes 11,049 31.4 (30.5-32.3) 
No 36,282 68.5 (67.6-69.4) 
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O06.05 MULTIDISCIPLINARY SMOKING CESSATION 
MODEL IN A SPECIALIST ONCOLOGY HOSPITAL - OUR 5 
YEAR EXPERIENCE
Marliese Alexander, Ingrid Plueckhahn, James D. Mellor, Suzanne 
W. Kirsa
Peter MacCallum Cancer Centre/Australia
Background: Australia established its first national quitline ser-
vice in 1997 as part of the Australian National Tobacco Campaign 
(NTC). In 2005 our hospital, an Australian tertiary specialist cancer 
centre, commenced a multidisciplinary smoking cessation program 
which included the provision of counselling and behaviour tech-
niques as well as free access to pharmacological smoking cessation 
agents. In 2007 the hospital went totally smoke free and in 2009 
all new patient registrations included collection of information 
pertaining to smoking behaviours. Cancer patients are known to 
withhold and underreport details regarding current and previous 
smoking behaviours however there is limited data on the impact of 
non-disclosure on the ability to implement interventional smoking 
cessation programs in the oncology setting. Five years after initi-
ation of an interventional smoking cessation program we present 
previously uncollected and unreported hospital wide smoking 
behaviour data (prevalence, magnitude and willingness to report) 
of cancer patients. We also evaluate our multidisciplinary smoking 
cessation model including recruitment and quit rates for cancer 
patients at a specialist oncology centre.
Methods: For the two year period 2009-2011 self-reported smo-
king behaviors were obtained from hospital registration datasets. 
A retrospective single arm cohort study, including patients with a 
cancer diagnosis who accessed the smoking cessation program 
within the same two year period, was also conducted. Patients and 
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O07.01 RANDOMIZED PHASE III TRIAL OF APREPITANT 
COMPARED WITH DEXAMETHASONE FOR EMESIS IN-
DUCED BY CARBOPLATIN
Koji Takeda1, Haruko Daga1, Hideaki Okada1, Asuka Tsuya1, Shinya 
Tokubaga1, Koichi Taira1, Utae Katsushima1, Manabu Tsuda1, Shiro 
Kimbara1, Yumi Shibata1, Tetsuya Yoshida2, Masahiko Nakao2
1Department Of Clinical Oncology, Osaka City General Hospital/Japan, 
2Department Of Pharmacy, Osaka City General Hospital/Japan
Background: Carboplatin (CBDCA) is used widely against various 
tumors,including non-small cell lung cancer, small cell lung can-
cer, which is classified a moderate emetic risk. 5-HT3 antagonist 
and corticosteroid had a great efficacy in patients (pts) treated 
with CBDCA containing chemotherapy. This randomized trial was 
conducted to evaluate the efficacy and safety of aprepitant (APR) 
compared with corticosteroid, based on granisetron (GRA) plus 
corticosteroid at the first day, in pts treated with CBDCA contai-
ning chemotherapy.
Methods: Pts treated with CBDCA (AUC 5 or 6) containing chemo-
therapy were entered on this trial. Major eligible criteria included 
more than 20 years old, and ECOG PS 0-2. Patients were rando-
mized either A group (GRA 3 mg, iv, day 1, dexamethasone [DEX] 
3.3 mg, iv, day 1, APR 125 mg , po, day 1, and APR 80 mg, po, days 
2,3) or D group (GRA 3 mg, iv, day 1, D EX 6.6 mg, iv, day 1, and 
DEX 8 mg, po, days 2, 3). Randomization was stratified by gender 
and CBDCA AUC 5 or 6. Study period was 120 hours from adminis-
tration of CBDCA. During this period, pts recorded the time and 
date of emetic episodes and severity of nausea by themselves in a 
survey form. Primary endpoint was complete response rate (CRR), 
defined as no emetic episodes and no rescue medications during 
the overall study period. Secondary endpoints included CRR du-
ring the acute (0-24 h) and the delayed (24-120 h) phases, no nau-
sea rate, severity of nausea and safety. The planned sample size of 
128 provided 80% power to detect a 20% improvement in the CRR 
at overall period with two-sided α of 0.1. This study was approved 
by the institutional review board in our institution. All pts provided 
written informed consent prior to enrollment.
Results: From October 2010 to August 2012, 128 pts were entered 
in this phase III trial. Three quarters of entered pts were male, and 
63% were received CBDCA AUC 6. Baseline factors, such as age, 
gender, AUC of CBDCA, chemotherapy regimen, and PS, were 
well balanced between the two groups. The CRR during overall 
study period were 61.3% and 68.8% in A and D group, respectively 
(p=0.3799). There was no difference of CRR during both the acute 
phase (98.4% vs 98.4%) and the delayed (61.3% vs 68.8%). There 
was no adverse event due to the antiemetic therapy in both groups 
during the overall study period.
Conclusion: This randomized phase III trial failed to demonstrate 
that APR was superior to DEX for emesis induced by CBDCA con-
taining chemotherapy which was classified a moderate emetic risk. 
Combination APR with DEX on days 2 and 3, or more was likely to 
increase an antiemetic efficacy during delayed phase. Further stu-
dy was warranted.
Background: Lung cancer screening programs provide unique 
opportunities to facilitate smoking cessation in smokers who par-
ticipate in these programs. However, the effects of screening on 
motivation to quit might be mediated or modified by other variab-
les. Identifying the participants more likely to quit will allow rapid 
application of smoking cessation resources to these participants, 
while those least likely to quit can be afforded experimental inter-
ventions. The aim of our study was to assess the impact of lung 
cancer screening on smoking cessation in current smokers at the 
time of enrollment and to identify factors that were associated with 
quitting smoking in this screening population.
Methods: Using data collected from the Pan-Canadian Study of 
Early Detection of Lung Cancer, both univariate and multivariab-
le logistic regression analysis was used to identify predictors of 
smoking cessation among current smokers at enrolment. Smoking 
cessation was defined as quitting for at least a 6 month period, 
occurring anytime after enrolment.
Results: We analyzed baseline and follow-up questionnaires of 
2320 participants, of which 1419 were current smokers. Of these 
1419 patients, 392 (27.8%) met the definition of smoking cessation 
during a median of two annual follow-up visits. In both univariate 
and multivariable (MV) analysis, greater smoking cessation was 
associated with four factors: (i) having a diagnosis of lung cancer at 
any time during the screening process, with a MV Odds ratio (OR) 
of quitting of 2.4 (95%CI: 1.1-5.0); (ii) lower and medium nicotine 
addiction as assessed by the Fagerström Nicotine Dependence 
Scale Score, with MV-ORs of 3.2 (95%CI: 2.2-4.6) and 1.4 (95%CI: 
0.9-2.0), respectively; (iii) having higher education, with MV-OR: 1.4 
(95%CI: 1.1-1.9); and (iv) having an earlier age of onset of regular 
alcohol intake, with MV-OR of 1.11 (95%CI: 1.02-1.21) per 5 year 
decrease in age. Smoking cessation was also associated with (i) 
previous attempts of quitting [UV-OR 1.8 (95%CI: 1.2-2.7)], willing-
ness to quit smoking within the next month (at baseline screening) 
[UV-OR 2.2 (95%CI: 1.8-2.9)] or within the next 6 months after 
baseline screening [UV-OR 1.8 (95%CI: 1.3.-2.4)]. Second-hand 
smoking exposure, including exposure as a child, or as an adult 
at work, at home, privately with friends, or in public settings, or a 
cumulative index of these different exposures, was not associated 
with smoking cessation. Presence of potential index symptoms for 
lung disease, including shortness of breath, cough (both dry and 
productive), hoarseness, audible wheezing or even chest pain, was 
not associated with an increased chance of smoking cessation.
Conclusion: The diagnosis of a new lung cancer had a major po-
sitive impact on screening participants quitting smoking, as were 
factors such as lower nicotine dependence, higher education, ear-
lier starting alcohol driNKIng age, and willingness to quit. Whether 
a new lung cancer diagnosis triggered additional efforts by clinici-
ans to help the person quit will be explored further. Individual lung 
symptoms and secondhand smoke exposure were not associated 
with smoking cessation. (Geoffrey Liu and Martin Tamemmagi are 
co-senior authors)
Keyword: "Lung Cancer Screening“, "Smoking Cessation“
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preferred roles in decision-making about ACT with most patients 
preferring a collaborative role. Their preferences were stable over 
time, and were concordant with their perceived actual role in 
decision-making at baseline. Preferences for an active role in deci-
sion-making were associated with judging larger survival benefits 
necessary to make ACT worthwhile. Clinicians should elicit and 
consider patients’ preferences for involvement in decision-making 
when discussing ACT for NSCLC.
Keywords: non-small-cell lung cancer, adjuvant chemotherapy, 
patients‘ preferences, decision-making
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O07.03 QUANTIFYING THE HUMANISTIC BURDEN OF 
CAREGIVING FOR PATIENTS WITH LUNG CANCER IN 
EUROPE
Jacek Jassem1, Isabelle Gilloteau2, John R. Penrod2, Amir Goren3
1Department Of Oncology And Radiotherapy, Medical University Of 
Gdańsk/Poland, 2Global Health Economics & Outcomes, Bristol-Myers 
Squibb/United States Of America, 3Health Sciences Practice, Kantar 
Health/United States Of America
Background: Lung cancer, the leading cause of cancer-related 
death, is associated with poor survival, painful, life-threatening 
disease attributes, and greater associated economic burden com-
pared with other cancers. The disease also presents multiple chal-
lenges for the caregivers of patients with lung cancer, including 
increased distress, significant impact on social and health-related 
quality of life (HRQoL), and costs associated with loss of income 
and time spent on patient care. Little information exists on the ex-
tent of this caregiver burden. The current study aims to investigate 
the HRQoL and the comorbidity burden of caregivers of patients 
with lung cancer in several European (EU) countries.
Methods: Data were provided from the 2010 and 2011 EU Nati-
onal Health and Wellness Survey (NHWS), an annual, stratified, 
random, cross-sectional, self-administered Internet-based survey 
of healthcare attitudes and behaviors among adults in France, 
Germany, Italy, Spain, and the United Kingdom (n=114,962). Res-
pondents who reported providing care for a patient with lung can-
cer ("caregivers“) were compared with respondents not providing 
care ("non-caregivers“) on measures of HRQoL and self-reports of 
diagnosis with conditions known to be caused or exacerbated by 
psychological stress. HRQoL was assessed using the 12-Item Short 
Form Survey (SF)-12v2, which included Mental (MCS) and Physical 
(PCS) Component Summary scores; mental and physical functio-
ning subscales; and SF-6D health state utilities (with higher scores 
indicating better health status and minimally important differences 
[MIDs] of 3 points in PCS/MCS scores, and 0.03 points in health 
utilities).The self-reported diagnoses of interest included depressi-
on, anxiety, insomnia, headache, migraine, and gastrointestinal (GI) 
illnesses (ie, gastroesophageal reflux disease, heartburn, and/or 
irritable bowel syndrome). Regression models were used to predict 
health outcomes as a function of caregiving vs non-caregiving, 
controlling for demographics (age, gender, education, income, 
marital status, employment, body mass index category), health risk 
behaviors (exercise, smoking), and the Charlson Comorbidity Index 
(reflecting mortality risk).
Results: No significant differences between caregivers (n=107) and 
non-caregivers (n=103,868) on sociodemographic and health cha-
Keywords: Carboplatin, aprepitant, dexamethasone, moderate 
risk
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O07.02 THE PREFERRED AND ACTUAL LEVELS OF IN-
VOLVEMENT IN DECISION-MAKING AMONG PATIENTS 
CONSIDERING ADJUVANT CHEMOTHERAPY (ACT) FOR 
NON-SMALL-CELL LUNG CANCER (NSCLC).
Prunella Blinman1, Sue-Anne Mclachlan2, Anne-Sophie Veillard3, 
Nick Muljadi3, Malcolm Hudson3, Martin Stockler3
1Concord Cancer Centre, Concord Repatriation General Hosptal/Aus-
tralia, 2Medical Oncology, St Vincent‘s Hospital Melbourne/Australia, 
3Nhmrc Clinical Trials Centre/Australia
Background: Patients with cancer have varying preferences for 
involvement in decision-making between active, collaborative and 
passive roles. Previous studies suggest that many patients prefer 
a more active role than they experienced, and a more active role 
over time[MSA(1] . We sought the preferred and actual level of 
involvement in decision-making among patients considering ACT 
after resection of early NSCLC.
Methods: 98 patients completed a self-administered questi-
onnaire at baseline (before ACT, if they were having it) and at 6 
months (after ACT, if they had it). Preferred and actual level of in-
volvement in decision-making were assessed by the Control Prefe-
rences Scale (CPS) and trichotomised into active, collaborative, and 
passive roles. Health-related quality of life (HRQL) data were as-
sessed by the Patient DATA Form. Differences on the original CPS 
scale between preferred and actual roles and between preferred 
roles over time were assessed with the Wilcoxon signed-rank test. 
Determinants of preference for an active role were assessed with 
chi-square tests of association in 2x2 tables, summarising by odds 
ratios (ORs). Wilcoxon rank-sum (WRS) tests were used to assess 
differences in survival benefits required to make ACT worthwhile 
between patients preferring active and less active roles.
Results: Most patients were male (55%) with a median age of 64 
years (range, 43-79 years), married (74%) and previous smokers 
(82%). The majority had had a lobectomy (85%), adenocarcinoma 
histology (63%), and half (46%) had stage II disease. 83 patients 
decided to have ACT (85%), 15 declined ACT (15%). ACT was most 
commonly 4 cycles (71%) of cisplatin/ vinorelbine (73%). Preferred 
role in decision-making at baseline (n=98) was active in 26 (27%), 
collaborative in 46 (47%), and passive in 26 (27%); and at 6 months 
(n=73) was active in 15 (21%), collaborative in 37 (51%) and passive 
in 21 (29%). Preferred decision-making roles were stable over time 
(p=0.5). Actual decision-making roles at baseline (n=98) were ac-
tive in 24 (24%), collaborative in 47 (48%), and passive in 27 (28%). 
There was concordance between preferred and actual decision-
making roles at baseline (p=0.4). Preferring a more active role was 
associated with university education (p=0.02, OR 2.9) and worse 
HRQL during ACT: physical well-being (p=0.05, OR 4.4), overall 
well-being (p=0.02, OR 5.5), sleep (p=0.03, OR 8.4) and short-
ness of breath (p=0.01, OR 7.6). Patients who preferred an active 
decision-making role judged larger survival benefits to make ACT 
worthwhile than patients who preferred a passive role (eg extra 
survival time of 1 year v 6 months, WRS p=0.03; extra survival rate 
of 17.5% v 2.5%, WRS p <0.01).
Conclusion: Patients with recently resected NSCLC varied in their 
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• patients who receive a multi-disciplinary rehabilitation and early 
mobilisation achieve earlier discharge from hospital and signifi-
cantly reduce in hospital morbidities and complication rates 
• patient’s satisfaction regarding pain management significantly 
correlates to the preoperative information they have received 
• good quality patient information is vital in reducing patient’s 
anxiety and improving the overall patient experience 
Results: The Guideline was developed to support any health pro-
fessional involved in the provision of care for patients who are un-
dergoing thoracic surgery. The Guideline includes information for 
health professionals providing examples of current best practice 
and information for patients. The aim of the Guideline is to support 
self management, support patients through the surgical pathway, 
and improve patient outcomes and patient experience. 
The full guideline can be found at http://www.nlcfn.org.uk/editori-
mages/Guidelines%20to%20Prepare%20etc.pdf 
Conclusion: The Guideline is relevant to all patients who are 
undergoing a lung resection. The Guideline includes a series of 
broad statements and where necessary local procedures should 
be developed to complement the guidelines in each clinical area. 
The Guideline compliments the Surgical Follow Up Guideline also 
produced by the NLCFN Thoracic Surgical Group. 
Keywords: nursing, guideline, Lung cancer, Thoracic surgery
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O07.06 EARLY POST-OPERATIVE AMBULATION IS FEASI-
BLE AND SAFE
Sandeep J. Khandhar1, Daniel L. Fortes1, Christy Schatz2, Sally 
Schermer2, Paul D. Kiernan1
1Thoracic Surgery, Cvtsa / Inova Health System/United States Of Ame-
rica, 2Surgery, Inova Health System/United States Of America
Background: The goal of any intervention in medicine is to return 
the patient to the “pre-clinical state”. Thoracic surgical interven-
tion remains the most effective way to manage early stage lung 
cancer. Minimally invasive techniques have substantially reduced 
the morbidity associated with traditional open procedures and 
have returned patients to health faster. This has been achieved 
without compromising the oncologic validity of the operation and 
when done appropriately, has even proved superior. Our health 
system instituted a minimally invasive thoracic surgical program 5 
years ago to realize these benefits. This was accomplished through 
the recruitment of minimally invasive trained, dedicated thoracic 
surgeons; service line focused team development; rigorous trai-
ning of the team; systematic community awareness; and invest-
ment in technology and equipment. Seeing tremendous success in 
volumetric growth with our minimally invasive program, we began 
to focus on strategies to return patients to their pre-operative 
functional state more swiftly. We believed inherently that early 
post-operative ambulation had several clear benefits: 1) clearance 
of pulmonary secretions and reduction of atelectasis thereby pre-
venting pneumonia, 2) avoidance of deep venous thromboses and 
subsequent pulmonary emboli, 3) reduced third space fluid shifts 
therefore reducing the risk of atrial fibrillation and myocardial in-
farction, 4) better pain control without narcotics, and 5) a general 
racteristics were observed. Caregivers and non-caregivers were 
on average 44.1 and 46.3 years old, respectively, and employed 
(55.1% and 57.4%, respectively), suggesting care given by children 
rather than by spouse/partner. Adjusting for covariates, caregivers 
reported significantly worse HRQoL than non-caregivers, including 
PCS (-1.91 points, P=.017), MCS (-3.52 points, P <.001, exceeding 
MID), health utilities (-0.049 points, P <.001, exceeding MID), and 
all subscales, except vitality (-1.83 to -4.87, all P <.03). In addition, 
caregivers had about twice the odds of non-caregivers of diag-
nosis with depression (OR=1.885, P =.018), insomnia (OR=2.190, P 
=.002), headache (OR=1.997, P =.008), and GI problems (OR=1.970, 
P =.002).
Conclusion: Adjusting for confounders, caregivers for patients 
with lung cancer reported significantly lower mental and physical 
health status, lower health utilities, and higher depression, insom-
nia, headache, and GI problems than non-caregivers. In addition 
to confirming and extending knowledge of the caregiver burden 
of lung cancer in EU, this study highlights a need for increased 
personalized support for caregivers. Research on other aspects of 
caregiver burden, such as healthcare resource utilization and work 
productivity, will help refine estimation of the financial impact of 
lung cancer on society.
Keyword: lung cancer, caregiver, caregiving, quality of life, comor-
bidity
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O07.05 GUIDELINES TO PREPARE AND SUPPORT PATI-
ENTS UNDERGOING A LUNG RESECTION
John White1, Sandra Dixon1, Vanessa Beattie2
1St James`s Institute Of Oncology, Leeds Teaching Hospitals NHS Trust/
United Kingdom, 2Aintree Chest Centre, University Hospital Aintree/
United Kingdom
Background: Lung cancer affects nearly 40,000 patients per year 
in the UK of which 5000 (12%) will undergo major lung resection 
for primary lung cancer. Approximately 15% of patients will have 
complications post operatively. Once the patient develops a post 
surgical pulmonary complication mortality increases from 0.5% 
to 12%, ITU admission rate increases from 1.5% to 26% and the 
length of stay increases from 5 to 14 days. A Lack of preparedness 
prevents patients immediately engaging in post operative activi-
ties successfully and can result in an increase in patient’s anxiety, 
post operative complications and length of stay in hospital. 
The United Kingdom National Lung Cancer Forum for Nurses 
Thoracic Surgical Group (TSG) has produced this Guideline to aid 
health care professionals in the preparation and support of pati-
ents undergoing a lung resection with an aim to promote patient 
self management.
Methods: Following a literature review and discussion amongst 
this specialist group the Guideline was developed focusing on key 
topic areas and interventions which included: 
• poor nutrition, before and during the healing process is associa-
ted with poor wound healing 
• risks of hospital death and pulmonary complications after lung 
cancer resection are increased by smoking 
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chosen, to facilitate a convenient route for response and to mini-
mise costs. A custom excel database was built for the purposes of 
data collection and analysis. The audit was pilot tested by 10 LCNS 
prior to distribution.
Results: 138 (50%) responses received. Results support that LCNS 
have a good understanding of CT availability (92%). Research nur-
ses were regarded as key team members by all respondents, and 
81% were dedicated to lung cancer CT. 85% of LCNS discussed 
CT in the course of treatment option consultations. The vast ma-
jority of technical aspects of CT recruitment, was deferred to the 
Research nurses. Benefits of CT participation identified by the 
LCNS‘s included: access to new drugs, closer follow up,benefit for 
future patients, additional support from Research nurses, a level 
of decision making regarding treatment. Disadvantages included: 
excessive time commitment, additional requirement for hospital 
appointments, travel distance to trial centre, patients deriving false 
hope, delays commencing therapy due to protocol requirements, 
increased number of invasive procedures, feeling they will let the 
doctor down by non-participation, psychological harm if they don’t 
responsed to therapy. 17% of respondents suggested that CT 
participation may be unethical. On further analysis concerns were 
information, selection and appropriate support levels. Responses 
confirmed that there is uncertainty in relation to the LCNS role in 
CT management generally. Little reference was made regarding 
non drug CT, such as radiotherapy or supportive care.
Conclusion: The LCNS community understand and supports the 
value of CT. This include patients in the advanced stages of the 
disease. The role of the LCNS is not clearly defined in relation to 
CT. Most LCNS are comfortable speaking to patients regarding CT 
and have a good working knowledge of CT availability. The finer 
detail in terms of recruitment and clinical trial management is seen 
as the remit of the research nurse. No expressions of serious con-
cern in relation to trial participation or ethical concerns where de-
rived from responses. LCNS’s have reported understanding of CT 
philosophy in the UK, and the requirement for CT to continue in 
this patient group, while at the same time demonstrating a strong 
advocacy role. LCNS’s in the UK support clinical trial recruitment in 
patients with lung cancer and regard them as ethical.
Keyword: nursing, trials, recruirment, support
sense of well being. Therefore, we hypothesized that prompt initia-
tion of ambulation should reduce morbidity and return patients to 
the pre-operative state expeditiously and with greater predictabi-
lity.
Methods: Our limitations were pain, nursing motivation and cul-
ture. Pain is substantially reduced in minimally invasive approa-
ches. Ambulation inherently reduces pain as the upright position 
takes tension off the intercostal spaces. Nursing motivation and 
culture proved to be a bigger challenge given limitations in the 
time available for “bedside nursing”. However, perhaps more re-
levant was the skepticism related to the safety of this endeavor. 
Given these realities, we created an environment to test our hy-
pothesis seeking first to demonstrate safety and feasibility of an 
endeavor that we believed to be so pivotal. In July of 2010, with 
the support of nursing leadership, administration and our thoracic 
oncology team, we began a program of aggressive post-operative 
ambulation with one simple mandate: every patient must walk 250 
feet within 1 hour of extubation.
Results: For this analysis we included all patients recovered in our 
dedicated unit after VATS, thoracotomy, robotic or laparoscopic 
interventions. We excluded patients undergoing bronchoscopy 
or mediastinoscopy as they were routinely discharged within two 
hours of extubation. From July 2010 through May 2013, a total of 
720 patients were recovered in our unit. 553 (77%) were able to 
walk 250 feet or more. Of these, 328 (59%) were successful within 
1 hour of extubation. 74 patients (10%) were unable to ambulate 
largely due to weakness and hypotension. There have been no 
adverse events since implementation (0% complication rate).
Conclusion: We conclude that early post-operative ambulation 
is feasible and safe. We have observed favorable responses from 
patients and families and have enjoyed a considerable decrement 
in our overall post-operative length of stay. Further investigation 
will be necessary to quantify these endpoints.
Keywords: post-operative, thoracic, VATS, ambulation
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O07.07 LUNG CANCER CLINICAL TRIALS AND THE IN-
VOLVEMENT OF THE LUNG CANCER NURSE SPECIALIST
John Mcphelim1, Sharon Hughes2
1Cancer Division, Hairmyres Hospital/United Kingdom, 2Nhs Lanark-
shire/United Kingdom
Background: Clinical trials (CT) are fundamental to improving 
outcomes in lung cancer. Recruitment to CT in the UK is poor. The 
National Cancer Research Interest Group, Clinical Studies Group 
(UK), identified that Lung Cancer Nurse Specialist (LCNS) may have 
a role in improving recruitment to CT. The National Lung Cancer 
Audit (England) 2010-2012 identified that patients who access a 
LCNS are more likely to recieve anti cancer treatment. Therefore 
could this correlation be applicable to the CT setting? A survey 
was conducted to understand the role of LCNS in relation to CT, 
and to investigate the views of LCNS regarding CT involvement of 
advanced stage patients.
Methods: A questionnaire was emailed to all registered members 
of the National Lung Cancer Nurses Forum NLCFN(UK) with an 
explanatory letter,during the month of April 2013. An e-survey was 
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dies demonstrate that the vaccine remains stable for 23 months. 
The vaccine contains at least nine NCI-prioritized cancer antigens 
and agonists for 5 TLRs. Gene expression profiles of the 13 NSCLC 
cell lines identified 46 commonly overexpressed genes, all of which 
are expressed in the DPV-001 vaccine.
Conclusion: The DPV-001 vaccine provides a source of broad-
spectrum relevant NSCLC antigens. We are conducting a multicen-
ter, randomized, phase II trial of adjuvant DPV-001 vaccine in pa-
tients with definitively treated stage IIIA/B NSCLC. T-cell immune 
responses will be monitored using HLA matched cell lines from the 
indicator panel of 13 NSCLC cell lines. NIH grants R21 CA123864 
(WJU) and R43/44 CA121612 (SA, TH), Kuni Foundation (WJU), 
Murdoch Trust, Robert Franz, Wes and Nancy Lematta, Lyn and 
Jack Loacker, and the Chiles Foundation. Clinicaltrials.gov study 
identifier pending
Keyword: Lung cancer vaccines, T-cell immune response, auto-
phagosome, clinical trial
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O08.02 CRITICAL ROLE OF CD28 COSTIMULATION IN 
TUMOR-TARGETED T-CELL THERAPY CLINICAL TRIAL 
FOR PLEURAL MALIGNANCIES
Jonathan Villena-Vargas, Leonid Cherkassky, Christos Colovos,  
Elliot Servais, Luis A. Rodriguez, Valerie W. Rusch, Michel  
Sadelain, Prasad S. Adusumilli
Memorial Sloan-Kettering Cancer Center/United States Of America
Background: Successful translation of adoptive T-cell therapy for 
solid cancers is predicated on the ability to generate a potent anti-
tumor immune response and establish T-cell persistence. Thoracic 
malignancies typically lack expression of costimulatory ligands but 
do express negative regulators of T- cell function—factors that 
may impede T-cell therapy. We hypothesized that cancer antigen–
targeted T cells engineered with activating CD28 costimulatory 
signaling would eradicate tumor and establish long-term functio-
nal persistence.
Methods: Mesothelin-specific chimeric antigen receptors (CARs) 
were engineered without (Mz) or with (M28z) a CD28 costimulatory 
domain. CAR-transduced human T cells were evaluated in vitro 
for cytotoxicity (51Cr-release assay), cytokine release (Luminex 
cytokine-release assay), and proliferation (cell-counting assay). 
In vivo assessment included monitoring of tumor progression by 
bioluminescence imaging (BLI), flow cytometric analysis of splenic/
peripheral blood T-cell phenotypes, and Kaplan-Meier analysis of 
median survival, in NOD-scid IL-2Rγ-null mice bearing orthotopi-
cally implanted mesothelin-expressing mesothelioma cells (MSTO-
211H: CD80/86-, TGF-β+, PD-L1+) and treated with human T cells 
transduced to express either Mz, M28z, or a control vector.
Results: In vitro, M28z CAR–transduced T cells exhibited equiva-
lent cytotoxicity but enhanced Th1 cytokine secretion and antigen-
specific proliferation, compared with Mz transduced T cells. In vivo, 
mice treated with a single low dose of M28z CAR–transduced T 
cells achieved tumor eradication and prolonged survival (median 
survival not reached; p=0.01), compared with mice treated with 
an equal dose of Mz-transduced (median survival, 63 days; tumor 
eradication in 20% of mice) or control CAR–transduced (median 
survival, 36 days) T cells (Figure 1A, 1B). Furthermore, CD28 costi-
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O08.01 A NOVEL AUTOPHAGOSOME NON-SMALL CELL 
LUNG CANCER VACCINE (DRIBBLES) CONTAINS SHORT-
LIVED PROTEINS, DEFECTIVE RIBOSOMAL PRODUCTS, 
AT LEAST NINE NCI-PRIORITIZED ANTIGENS, AND AGO-
NISTS FOR TLR 2, 3, 4, 7, AND 9.
Helen J. Ross1, Traci Hilton2, Sachin Puri3, Bharat Joshi4, Jing Han4, 
Bhaskar Bhattacharya4, Tarsem Moudgil3, Christopher Dubay3, 
Rachel E. Sanborn3, Hong-Ming Hu3, Reineke Van De Ven3, Walter 
Urba3, Sandra Aung2, Raj Puri4, Bernard A. Fox3
1Medicine - Hematology & Medical Oncology, Mayo Clinic/United Sta-
tes Of America, 2Ubivac/United States Of America, 3Earle A Chiles 
Research Institute, Robert W. Franz Cancer Center/United States Of 
America, 4Tumor Vaccine & Biotechnology Branch, Division Of Cellular 
& Gene Therapies, Center For Biologics Evaluation & Research, Us Food 
& Drug Administration/United States Of America
Background: Tumor-derived autophagosomes, referred to as 
DRibbles, are novel cancer vaccines that have been shown to be 
effective against 5 preclinical models of established tumors. We 
hypothesize that DRibbles’ efficacy stems from their ability to pre-
sent stabilized tumor-derived short-lived proteins (SLiPs) and de-
fective ribosomal products (DRiPs) that are, due to their short-lived 
nature, normally not processed and presented by professional 
antigen presenting cells. These SLiPs and DRiPs represent a poten-
tial pool of tumor antigens against which the host is not tolerant. A 
pilot clinical trial of an autologous DRibble vaccine demonstrated 
feasibility and suggested immune effects in 4 patients with ad-
vanced NSCLC (WCLC 2013, submitted). In order to expand the 
DRibble strategy to patients without an autologous tumor source, 
we have produced an allogeneic DRibble vaccine (DPV-001) from 
two NSCLC cell lines and developed a panel of 13 NSCLC cell lines 
expressing relevant antigenic targets that will be used to monitor 
induction of tumor-specific immunity.
Methods: The two NSCLC cell lines used to produce the DPV-001 
vaccine (UbiLT3 and 6) were cultured with bortezomib and am-
monium chloride to block the proteasome and prevent lysosomal 
degradation of SLiPs and DRiPs. Gene expression profiles were 
performed for each lot produced (Human Gene 1.0 ST arrays). 
Stability of indicator tumor antigens was assessed by Western 
blots. Toll-like receptor (TLR) agonist activity was assessed using 
HEK blue cells transfected with specific TLRs. After informed con-
sent, a panel of NSCLC cell lines was established from 13 patients 
(tumor tissue or pleural fluid). These cell lines were HLA-typed for 
use in immunologic monitoring studies. cDNA was synthesized in 
triplicate from total RNA extracted from each cell line in log phase 
growth. Samples were then analyzed using human microarrays 
containing approximately 17,000 oligonucleotides (CBER array). 
Data files were uploaded into the mAdb database and analyzed 
by software provided by the Center for Information Technology 
(CIT), NIH. Group t-test was used to compare gene expression 
differences between NSCLC and normal lung tissues and between 
cell lines.
Results: Analyses confirm reproducible gene expression profiles 
from both cell lines during DPV-001 manufacture, and stability stu-
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mulation enhanced CD62L-CD45RA- effector memory T-cell persis-
tence (Figure 1C), leading to a robust T-cell proliferative response 
and superior control of tumor burden on tumor rechallenge 87 
days after T-cell administration (Figure 1D, 1E). 
Conclusion: CD28 costimulation plays an important role in achie-
ving long-term antitumor efficacy and functional persistence in 
mesothelin-targeted T-cell therapy. These data provide the scienti-
fic rationale for our upcoming clinical trial for pleural malignancies.
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number of photons per second in the region of interest. PET ima-
ging with 18F-FEAU was performed in a 3-dimensional microPET 
scanner. T-cell imaging results were validated by flow cytometric 
and immunohistochemical analysis of harvested tissue.
Results: Quantification studies showed a linear relationship bet-
ween photon emission and T-cell number both in vitro and in vivo. 
In vivo, evaluation of T-cell biodistribution kinetics, by intravenous 
administration of effLuc-M28z T cells into mice bearing flank tu-
mors, demonstrated initial accumulation of T cells in the lungs, 
liver, and spleen and progressive accumulation in the tumor (Fi-
gure 1A). Pleurally administered effLuc-M28z+ T cells displayed 
an increasing BLI signal (5-fold; p<0.01) in response to antigen 72 
hours after administration, compared with pleurally administered 
effLuc+ T cells alone (control) (Figure 1B). T-cell accumulation in 
pleural tumor and extrathoracic sites (spleen) was confirmed by 
flow cytometric analysis of tissues harvested at serial time points 
(Figure 1C). These results were reproduced with clinical-grade 
vector TK-M28z+ T cells administered intrapleurally in mice bea-
ring pleural tumor. Serial 18F-FEAU PET imaging showed antigen-
specific T-cell accumulation with decreasing tumor burden, as seen 
by corresponding tumor BLI (Figure 1D). 
Conclusion: We provide an optimized method for monitoring of 
T-cell trafficking, localization and proliferation in thoracic mali-
gnancies. Our findings—derived using a clinical-grade imaging 
construct and substrate—provide convincing evidence for the use 
of noninvasive T-cell monitoring in our upcoming adoptive T-cell 
therapy clinical trial.
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O08.03 T-CELL IMAGING TO NONINVASIVELY  
MONITOR ADOPTIVE T-CELL THERAPY FOR THORACIC 
MALIGNANCIES
Jonathan Villena-Vargas, Luis A. Rodriguez, Maxim Moroz, Leonid 
Cherkassky, Valerie W. Rusch, Michel Sadelain, Vladimir Ponoma-
rev, Prasad S. Adusumilli
Memorial Sloan-Kettering Cancer Center/United States Of America
Background: Noninvasive T-cell imaging technology allows moni-
toring of adoptive T-cell responses without the need for invasive 
biopsies. Herein, we report dynamic imaging of tumor-targeted T 
cells in preclinical models by use of luminescent-enhanced firefly 
luciferase vector, and we further demonstrate the successful use 
of a clinical-grade herpes simplex virus type 1 thymidine kinase 
(HSV1-tk)–incorporated vector for monitoring of T-cell trafficking, 
antigen-specific proliferation, and biodistribution.
Methods: T cells transduced with mesothelin-targeted chimeric 
antigen receptors (M28z) were either cotransduced with an en-
hanced firefly luciferase vector (effLuc-M28z) or singly transduced 
with HSV1-tk-M28z (TK-M28z). To simultaneously visualize tumor 
during T-cell PET imaging, cancer-cell imaging was performed 
using MSTO-GFP/ffLuc+ (MSTO-211H cells transduced to express 
mesothelin and the green fluorescent protein/firefly luciferase 
fusion protein). In vitro, uptake of 18F-FEAU radiotracer by T cells 
was measured by 3H channel counting. In vivo studies used either 
SCID-beige or NSG mice bearing pleural or flank tumors. Biolumi-
nescence imaging (BLI) quantification was determined by the mean 
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potential in ALK-positive NSCLC and that, furthermore, upfront 
combination of the two agents could extend the duration of  
response.
Keywords: ALK, Crizotinib, HSP90, AT13387
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O08.07 PATIENT-DERIVED PRIMARY NON-SMALL CELL 
LUNG CARCINOMA (NSCLC) XENOGRAFT MODELS FOR 
MECHANISTIC STUDIES OF RESISTANCE TO EGFR  
TYROSINE KINASE INHIBITOR THERAPY
Celine Mascaux1, Petra Martin1, Erin Stewart2, Devang Panchal3, 
Lucia Kim3, Shingo Sakashita3, Dennis Wang3, Ming Li3, Nhu-An 
Pham3, Natasha Leighl1, Geoffrey Liu1, Frances A. Shepherd1, Ming-
Sound Tsao4
1Department Of Medical Oncology, Princess Margaret Cancer Centre, 
University Health Network, University Of Toronto/Canada, 2Depart-
ment Of Medical Biophysics, University Of Toronto/Canada, 3Ontario 
Cancer Institute, University Health Network, University Of Toronto/
Canada, 4Department Of Pathology, University Health Network, Uni-
versity Of Toronto/Canada
Background: Non-small cell lung cancer (NSCLC) patients with 
tumors bearing “driver” mutations in the epidermal growth factor 
receptor (EGFR) tyrosine kinase (TK) domain have very high res-
ponse rates to small molecule EGFR TK inhibitors (TKIs). However, 
all patients eventually develop resistance to the TKIs, and more 
recent reports have shown that patients who have stopped TKI 
therapy may be sensitive again upon re-treatment. While several 
genetic mechanisms of resistance have been documented, in-
cluding the gate keeper T790M mutation and Met amplification, 
cell line studies in vitro have also implicated alternate epigenetic 
mechanisms that may explain the clinical progression observed in 
patients with EGFR mutations treated by TKIs. Studies in vivo using 
patient-derived primary lung tumor xenograft models have not 
been reported.
Methods: Patient-derived primary tumor xenografts were esta-
blished from surgically resected early stage NSCLC implanted 
subcutaneously in non-obese diabetic severe combined immune 
deficient (NOD-SCID) mice. Tumors were passaged after reaching 
the humane endpoint 1.5 cm maximum diameter. EGFR TKI thera-
py was initiated when tumors reached ~6 mm diameter. Treatment 
included daily oral gavage for erlotinib (50 mg/Kg) and dacomitinib 
(3 mg/Kg). Cetuximab was administered weekly intraperitoneally 
(50 mg/Kg).
Results: Among 33 tumors with EGFR mutations engrafted into 
the mice, only 6 (18.2 %) formed tumors that could be propagated 
beyond first passage. Three models have been studied for their 
responses to EGFR TKIs. Model 148 with L858R mutation showed 
intrinsic pan-resistance to erlotinib and dacomitinib, as well as to 
cetuximab. This model was derived from a patient who received 
pre-operative erlotinib in a window of opportunity trial and did not 
respond. The patient relapsed after surgery and did not receive 
additional TKI therapy. Model 137 with exon19 E746-A750 deletion 
mutation demonstrated complete response to both erlotinib and 
dacomitinib. However, microscopic examination of tissue from 
the implantation site revealed viable tumor cells, consistent with 
the inability of TKI to completely eradicate tumor cells even when 
complete response is observed clinically. The patient subsequently 
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O08.06 COMBINING THE HSP90 INHIBITOR, AT13387, 
WITH CRIZOTINIB IMPROVES RESPONSE IN AN ALK-
POSITIVE MODEL OF NSCLC.
Tomoko Smyth1, Joanne Munck1, Ana Rodriguez-Lopez1, Rachel 
Mcmenamin1, Neil Thompson1, Mohammad Azab2, John Lyons1, 
Nicola G. Wallis1
1Astex Pharmaceuticals/United Kingdom, 2Astex Pharmaceuticals/Uni-
ted States Of America
Background: Activation of anaplastic lymphoma kinase (ALK) via 
the EML4 translocation occurs in a proportion of non-small cell 
lung cancers (NSCLC). Whilst inhibitors of ALK such as crizotinib 
have been successful in the clinic, most patients ultimately relapse 
due to resistance via a number of different mechanisms. EML4-
ALK and many critical components of signalling pathways involved 
in resistance are clients for the chaperone HSP90. This offers an 
alternative approach for targeting both ALK inhibitor-sensitive and 
-resistant disease through inhibition of HSP90 alone or in combina-
tion with an ALK inhibitor. AT13387 is a potent second-generation 
HSP90 inhibitor currently being clinically tested in a number of 
indications, including ALK-positive NSCLC as single-agent and in 
combination with the ALK inhibitor, crizotinib. Here we describe its 
activity in preclinical models of ALK-positive NSCLC and investiga-
te its potential in combination with crizotinib.
Methods: The activity of AT13387 was investigated in vitro in the 
EML4-ALK translocated H2228 cell line. Protein levels were deter-
mined by western blotting. In vivo, AT13387 was evaluated in an 
H2228 tumor xenograft and an EML4-ALK translocated patient-
derived xenograft model by measuring inhibition of tumor growth.
Results: AT13387 potently inhibited the proliferation of the cri-
zotinib-sensitive EML4-ALK NSCLC cell line, H2228, in vitro with 
an IC50 value of 69 nM. The HSP90 client proteins, EML4-ALK and 
AKT, along with their phospho-forms, were depleted on treatment 
of these cells with AT13387. A simultaneous reduction in levels 
of phospho-ERK, phospho-AKT and phospho-S6 indicated that 
ALK signalling was inhibited, whilst induction of HSP70 confir-
med HSP90 inhibition. In vivo, AT13387 demonstrated activity in 
ALK-dependent xenograft models, including an ALK-dependent 
patient-derived xenograft model. When mice bearing H2228 tu-
mor xenografts were treated with AT13387 (70 mg/kg or 55 mg/
kg ip once weekly), significant inhibition of tumor growth was 
observed. As expected, treatment with crizotinib (50 mg/kg po 
daily) caused partial tumor regression in this model (75% regres-
sion after 8 weeks of treatment). However, when AT13387 (55mg/
kg weekly) was combined with the crizotinib treatment, a further 
enhancement of the inhibition of tumor growth over either of the 
monotherapies (88 % regression after 8 weeks) was observed, with 
5 out of 7 tumors achieving complete regression, suggesting that 
the upfront addition of AT13387 to crizotinib treatment could lead 
to an improved response and potentially delay the emergence of 
resistance. In addition, this combination was well-tolerated.
Conclusion: AT13387 was shown to be effective in models of ALK-
positive NSCLC as monotherapy or in combination with crizotinib, 
supporting the ongoing Phase II trial of AT13387 in ALK-positive 
NSCLC as single agent and in combination with crizotinib. The-
se data suggest that treatment with an HSP90 inhibitor such as 
AT13387, alone or in combination with crizotinib, has therapeutic 
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O09.01 SITES, SYMPTOMS, CT SCAN FINDINGS AND 
SURVIVAL IN PATIENTS WITH RECURRENCE AFTER 
CURATIVE-INTENT SURGICAL RESECTION FOR STAGE I 
LUNG ADENOCARCINOMA
Hideki Ujiie, Daniel Buitrago, Kyuichi Kadota, James Huang, Wil-
liam D. Travis, Valerie W. Rusch, Prasad S. Adusumilli, Nabil P. 
Rizk
Memorial Sloan-Kettering Cancer Center/United States Of America
Background: The purpose of this study is to examine the patterns 
of recurrence for stage I lung adenocarcinoma and to identify 
clinicopathologic factors associated with post-recurrence survival 
(PRS).
Methods: We performed a retrospective review of 1027 patients 
with stage I lung adenocarcinoma who underwent a surgical re-
section between 1999 and 2009 (median follow-up 35 months). 
The manner of recurrence detection, either by scheduled CT scan, 
presentation with new symptoms, or by other means, was noted. 
Tumors were classified using the new IASLC/ATS/ERS nomencla-
ture and grading as low (adenocarcinoma in situ, minimally invasive 
adenocarcinoma, or lepidic-predominant), intermediate (papillary-
predominant or acinar-predominant), and high (micropapillary-
predominant, solid-predominant, colloid-predominant, or invasive 
mucinous) grade. The Kaplan-Meier method was used to analyze 
recurrence-free survival (RFS). Log-rank tests and Cox proportional 
hazard models were used to analyze the association between pre-
dictive factors and PRS.
Results: Of the 1027 patients with follow-up data available, 
151(15%) had recurrent disease (table), five-year RFS was 80%. Of 
the 151 patients with recurrence, 80 (52%) were detected by a 
scheduled CT scan (51 locoregional and 29 distant). Symptomatic 
recurrences were seen in 70 (46%) patients (9 locoregional and 61 
distant). Overall, 5-year PRS was 27.8%. On multivariate analysis, 
recurrences identified by new symptoms (HR, 2.15; 95% CI, 1.36- 
3.40; p=0.001), a recurrence free interval ≤ 24 months (HR, 2.52; 
95% CI, 1.31- 4.84; p=0.006), and tumors with high architectural 
grade (HR, 1.69; 95% CI, 1.07- 2.67; p=0.024) and vascular invasion 
(HR, 1.79; 95% CI, 1.14- 2.81; p=0.012) were significantly associated 
with a worse PRS (Figure).
developed disease recurrence and responded to third line gefiti-
nib treatment. Model 164 has double exon19 L747-T751 deletion/
T790M mutations. As anticipated, the xenograft failed to respond 
to erlotinib but responded dramatically to cetuximab alone. Impor-
tantly, model 164 xenograft showed transient stabilization of the 
tumor growth when treated by dacomitinib, but eventually deve-
loped progressive growth after 2 weeks of treatment. Resistance 
was reversible each time the dacomitinib-resistant tumor was pro-
pagated, without drug in new mice. The reversibility of resistance 
observed upon re-initiation of dacomitinib treatment suggests an 
epigenetic mechanism for TKI resistance. This patient developed 
recurrence after surgery and failed to respond to second line erlo-
tinib treatment.
Conclusion: Patient-derived primary lung cancer xenografts may 
provide important patient-like models to study mechanisms of 
resistance to targeted therapies, and to test novel treatment stra-
tegies that may improve further treatment efficacy.
Keywords: Patient-derived xenograft, EGFR TKIs, EGFR mutations, 
Targeted therapy
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Conclusion: Our study demonstrates the recurrence patterns in 
patients who underwent surgical resection for stage I lung ade-
nocarcinoma. We identify a symptomatic recurrence, a recurrence-
free interval ≤ 24 months, high architectural grade, and vascular 
invasion, as independent factors associated with worse post recur-
rence survival.
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Conclusion: The postoperative survival in lung cancer patients 
aged up to 50 years was better than that in patients older than 50 
years.
Keywords: surgery, young patient, survival, Lung cancer
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O09.03 QUALITY INDICATORS IN THORACIC SURGERY: 
THE IMPORTANCE OF PROCESS INDICATORS IN LUNG 
CANCER
Gail E. Darling1, John Dickie2, Richard Malthaner3, Leigh Mck-
night4, Yasmin Sallay4, Amber Hunter4, Yingzi Li4, Robin Mcleod4
1Division Of Thoracic Surgery, Toronto General Hospital, University 
Health Network, University Of Toronto/Canada, 2Surgery, Lakeridge 
Health Centre/Canada, 3Surgery, London Health Sciences Centre/Cana-
da, 4Surgical Oncology, Cancer Care Ontario/Canada
Background: Outcome after surgery is the result of many com-
ponents of the care pathway.. The Thoracic Surgery Community 
of Practice of Cancer Care Ontario developed quality indicators 
which reflected processes of care as well as outcomes.
Methods: A systematic review of the literature identified potential 
indicators in the care of lung cancer patients which were relevant 
to thoracic surgery. These were then evaluated using a modified 
Delphi process. Seventeen indicators were chosen from seven 
domains: pre-operative assessment, staging, surgery, pathology, 
adjuvant therapy, surgical outcomes and miscellaneous based on 
actionability, validity, usefulness, discriminability, and feasibility. 
Data obtained from administrative databases is reported for 4 
process indicators and 3 outcome indicators.
Results: Of the 3242 patients diagnosed with Stage I and Stage II 
non-small cell lung cancer in 2009 and 2010, 2172 (67%) received 
a surgical consultation and 1524 (47%) underwent resection within 
3 months of diagnosis. For the 1075 Stage I and Stage II patients 
over age 75 only 634 (59%) received a surgical consultation and 
322 ( 32%) underwent resection. Of the 2302 patients resec-
ted in total (all stages), only 736 (32%) had invasive mediastinal 
staging(IMS) prior to resection:15% for sublobar resections; 30% 
for stage I; and 42% for stage II. Surprisingly only 42% of patients 
with stage III disease had IMS. IMS was also performed in an ad-
ditional 23% of patients for whom stage data was unavailable. In a 
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O09.02 CLINICOPATHOLOGICAL CHARACTERISTICS 
AND SURGICAL RESULTS OF LUNG CANCER PATIENTS 
AGED UP TO 50 YEARS: THE JAPANESE LUNG CANCER 
REGISTRY STUDY 2004
Masayoshi Inoue1, Meinoshin Okumura1, Noriyoshi Sawabata1, 
Etsuo Miyaoka2, Hisao Asamura3, Ichiro Yoshino4, Hirohito Tada5, 
Yoshitaka Fujii6, Yoichi Nakanishi7, Kenji Eguchi8, Masaki Mori9, 
Hideo Kobayashi10, Kohei Yokoi11
1Department Of General Thoracic Surgery, Osaka University Graduate 
School Of Medicine/Japan, 2Department Of Mathematics, Science Uni-
versity Of Tokyo/Japan, 3Division Of Thoracic Surgery, National Cancer 
Center Hospital/Japan, 4Department Of General Thoracic Surgery, Chi-
ba University Graduate School Of Medicine/Japan, 5Division Of Gene-
ral Thoracic Surgery, Osaka City General Hospital/Japan, 6Oncology, 
Immunology And Surgery, Nagoya City University Graduate School Of 
Medical Sciences/Japan, 7Department Of Clinical Medicine, Research In-
stitute For Diseases Of The Chest, Faculty Of Medical Sciences, Kyushu 
University/Japan, 8Department Of Medical Oncology, Teikyo University 
School Of Medicine/Japan, 9Department Of Pulmonary Medicine, Sap-
poro-Kosei General Hospital/Japan, 10Division Of Respiratory Disease, 
National Defense Medical College/Japan, 11Department Of Thoracic 
Surgery, Nagoya University Graduate School Of Medicine/Japan
Background: Since the incidence of lung cancer death increases 
from 50 years-old, the surgical results of young lung cancer pati-
ents remains unclear.
Methods: Seven hundred and four patients with lung cancer, aged 
up to 50 years, were enrolled from among the 11,663 patients 
registered in the Japanese Lung Cancer Registry Study 2004, and 
their clinical data were compared with those of 10959 patients 
older than 50 years.
Results: In the young/old groups, pneumonectomy was perfor-
med in 5.7%/3.2%; adjuvant therapies were given preoperatively 
in 10.4%/4.7% (p<0.001) and postoperatively in 31.4%/24.5% 
(p<0.001). The proportions of patients with p-stage IIIA and 
adenocarcinoma histology were higher in the young group. The 
5-year overall survival rate (5Y-OS) was 94.8%/86.2% for p-stage 
IA (p<0.001), 87.0%/73.2% for p-stage IB (p=0.001), 61.0%/61.6% 
for p-stage IIA (p=0.595), 71.0%/48.4% for p-stage IIB (p=0.003), 
49.6%/39.4% for p-stage IIIA (p=0.020), and 80.0%/24.8% for p-
stage IIIB (p=0.012); it was 83.5%/80.7% for females (p=0.106) and 
75.1%/62.3% for males (p<0.001) in the young/old groups. The 
postoperative survival was significantly better with all operative 
procedures in the young group. The 5Y-OS after recurrence was 
better in the young group (17.9%, p=0.016). In the young group, 
the 5Y-OS was better in females (83.5%) than in males (75.1%, 
p=0.002), and for patients with adenocarcinoma (80.3%) than for 
those with squamous cell carcinoma (68.5%, p=0.013). Age up to 
50 years was identified as an independent prognostic factor on 
multivariate analysis. 
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Results: The median age of the 271 patients at surgery was 67 ye-
ars (range: 31−92 years). The median size of the 319 lesions was 1.4 
cm (range: 0.4−3.5 cm), and there were 149 primary lung cancers 
and 170 pulmonary metastatic tumors (primary site: 116 colorectal 
and 54 others). Twenty-two lesions (7%) showed positive cytology 
results (11 primary and 11 metastatic). In primary lung cancers, 
tumor size (≧ 21 mm, p = 0.02), moderate to poor differentiation 
(p < 0.01), vascular invasion or lymphatic permeation (p < 0.01), 
and visceral pleural invasion (p < 0.01) were significant predictors 
of a positive result. In contrast, there were no significant predictors 
in pulmonary metastatic tumors. The cut-ends of the 19 lesions 
among the 22 positive cytology margin lesions were additionally 
resected, but those of the remaining 3 lesions were not because of 
impaired respiratory function. With the median follow-up period 
of 42 months, surgical cut-end recurrence occurred in 2 of the 19 
lesions for which additional resection had been performed (11%, 
1 primary and 1 metastatic). Of the 3 lesions for which additional 
resection was impossible, cut-end recurrence developed in 2 (67%, 
1 primary and 1 metastatic). Among the 297 lesions showing nega-
tive cytology result, cut-end recurrence occurred in 5 (2%, 4 prima-
ry and 1 metastatic).
Conclusion: Intraoperative autostapling cartridge lavage cytology 
in sublobar resection for primary or metastatic lung tumor may be 
useful in preventing surgical cut-end recurrence.
Keywords: pulmonary malignant tumors, limited resection, cart-
ridge lavage cytology, cut-end recurrence
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O09.06 PROGNOSTIC FACTORS FOR LONG-TERM SUR-
VIVAL IN NON-SMALL CELL LUNG CANCER PATIENTS 
WITH INTERSTITIAL LUNG DISEASE
Jaehyun Jeon, Young Tae Kim, Yoohwa Hwang, Hye Sun Kim, In 
Kyu Park, Chang Hyun Kang
Thoracic And Cardiovascular Surgery, Seoul National University Hospi-
tal/Korea
Background: There is little information about prognosis after 
pulmonary resections for non-small cell lung cancer (NSCLC) in 
patients with interstitial lung disease (ILD). In this study, we exami-
ned the long-term outcome and the factors that affect long-term 
survival after resection for NSCLC in patients with ILD.
Methods: Between September 1996 and May 2011, 71 NSCLC 
patients were diagnosed as having ILD based on the CT and pa-
thological findings. The extent of ILD on CT was scored visually 
at the level of 3 cm above the diaphragm as follows: minimal, <2 
cm from the subpleura at the base of the lungs; moderate, >2 cm 
from the subpleura, but less than one-third of the lung area at the 
base of the lungs; severe, more than one-third of the lung area at 
the base of the lungs. Various clinical values such as gender, age, 
preoperative chemotherapy, severity of ILD on CT, preoperative 
pulmonary function test results, arterial blood gas studies, operati-
ve procedure, pathologic stage, cell type, and adjuvant treatment 
were evaluated using univariate and multivariate analysis.
Results: The mean age was 65.9 years, and the majority of patients 
were male(65:91.5%). In-Hospital mortality was 9.9% (7/71). The 
causes of early mortality included pneumonia (n=4), acute respira-
tory distress syndrome (n=2), and acute exacerbation of ILD (n=1). 
similar cohort of patients resected in 2011-2012, only 28% had ≥10 
lymph nodes removed at the time of resection but this did not in-
clude nodes assessed by IMS. However, for 20% of patients lymph 
node resection data was not available or could not be determined. 
Positive resection margins were reported in 7% of patients, howe-
ver in a further 7% of patients margins could not be assessed. 30 
day mortality for lobectomy was 1.9%, reoperation rate was 2.8% 
(2.0% for same day as resection).
Conclusion: Initial results of 7 quality indicators in thoracic sur-
gery identified some quality gaps in processes of care as well as 
limitations in databases. Evaluation of process indicators allowed 
feedback to thoracic surgeons and pathologists who identified 
quality improvement opportunities. Rate of surgical consultation 
and resection for stage I and II disease was lower than expected 
as were rates of invasive mediastinal staging especially for patients 
with stage III disease for whom cytologic or histologic confirma-
tion is recommended. To address variable intraoperative lymph 
node assessment, systematic lymph node sampling or complete 
mediastinal lymphadenectomy was recommended to standardize 
intraoperative lymph node assessment. Quality improvement op-
portunities for pathologists also included dissection of intralobar 
lymph nodes, standardization of pathological processing and mar-
gin assessment. Feedback of quality indicator data was important 
in stimulating quality improvement initiatives by thoracic surgeons 
and pathologists.
Keywords: non-small cell lung cancer, quality indicators, Thoracic 
surgery, lymph node assessment
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O09.05 INTRAOPERATIVE AUTOSTAPLING CARTRIDGE 
LAVAGE CYTOLOGY IN SURGICAL RESECTION OF PUL-
MONARY MALIGNANT TUMORS - POSSIBLE ROLE IN 
PREVENTING LOCAL FAILURE
Tomohiro Miyoshi1, Keiju Aokage1, Genichiro Ishii2, Yuki Matsu-
mura1, Tomohiro Haruki1, Tomoyuki Hishida1, Junji Yoshida1, 
Kanji Nagai1
1Division Of Thoracic Surgery, National Cancer Center Hospital East/
Japan, 2Pathology Division, Research Center For Innovative Oncology, 
National Cancer Center Hospital East/Japan
Background: Limited resection of primary lung cancer or sublo-
bar resection of pulmonary metastatic tumor can result in cut-end 
recurrence. It is important to confirm the absence of tumor cells 
at the cut-end. Since 2004, all autostapling cartridges used for 
wedge or segmental resection of pulmonary malignancies are 
washed with 50 ml saline. Washing saline is centrifuged and the 
sediment is stained using Papanicolaou’s method and examined 
for cancer cells during surgery to confirm negative margin. The aim 
of this study is to evaluate the efficacy of the intraoperative auto-
stapling cartridge lavage cytology in preventing surgical cut-end 
recurrence.
Methods: The intraoperative cytology analysis was performed in 
271 patients undergoing wedge or segmental resection for 319 
lesions including primary lung cancers and pulmonary metastatic 
tumors between April 2004 and April 2010. We retrospectively 
reviewed the clinicopathologic features of patients with positive 
cytology results and those who developed recurrence at the surgi-
cal margins.
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The 5-year overall survival rate was 43.1% (stage I: 59.4%, stage II: 
41.3%, stage III: 35.0%, respectively). In univariate analysis, the risk 
factors for long-term mortality were lower preoperative FEV1, FVC, 
severe ILD on CT, presence of pathologic pulmonary fibrosis, and 
non-squamous cell type. In multivariate analysis, severity of ILD 
on CT and non-squamous cell type remained as poor prognostic 
factors.
Conclusion: Although patients with ILD undergoing pulmonary 
resection for NSCLC has resulted in a high in-Hospital mortality, 
long-term survival can be expected in highly selected patients. 
NSCLC patients with severe ILD on CT findings and those with 
non-squamous cell type should be carefully selected for major 
pulmonary resection.
Keywords: non-small cell lung cancer, interstitial lung disease, 
idiopathic pulmonary fibrosis, surgery
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on acute or chronic post-thoracotomy pain or analgesic require-
ments as compared to a standard posterolateral approach.
Keywords: Thoracotomy, postoperative pain
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O09.07 PHASE II DOUBLE-BLIND RANDOMIZED TRIAL 
COMPARING POSTEROLATERAL THORACOTOMY VER-
SUS NERVE SPARING THORACOTOMY FOR LUNG SUR-
GERY (POTNEST) - IMPACT OF PRESERVATION OF THE 
NEUROVASCULAR BUNDLE DURING THORACOTOMY 
ON POST-OPERATIVE PAIN
C S. Pramesh1, Sabita Jiwnani1, Priya Ranganathan2, Vijaya Patil2, 
George Karimundackal1, Vandana Agarwal2
1Thoracic Surgery, Surgical Oncology, Tata Memorial Centre/India, 
2Tata Memorial Centre/India
Background: Posterolateral thoracotomy has been extensively 
used for non-cardiac thoracic surgery. Although this procedure 
provides excellent access for cancer surgery, it is responsible for 
considerable postoperative pain and contributes to postoperative 
pulmonary insufficiency. Post-thoracotomy pain has been reported 
to occur in 10 to 70% of patients. Intercostal nerve injury has been 
implicated as a major factor in the etiology of post-thoracotomy 
pain. We performed a study to compare post-thoracotomy pain in 
patients undergoing posterolateral thoracotomy with and without 
the preservation of the intercostal neurovascular bundle.
Methods: This randomized double-blind phase II trial was carried 
out in a tertiary-referral cancer centre. We included adult patients 
undergoing posterolateral thoracotomy for pulmonary resection. 
Patients were randomized into two groups – standard posterola-
teral thoracotomy (PoT) where no attempt was made to preserve 
the intercostals neurovascular bundle or modified nerve-sparing 
thoracotomy (NeST) which involved preservation of the inter-
costal neurovascular bundle while opening the intercostal space 
and closure by drilling holes in the lower rib, thereby avoiding 
pericostal sutures. All surgeries were performed under general 
anaesthesia with fentanyl, morphine, diclofenac and paracetamol 
for intra-operative analgesia. Post-operatively, all patients received 
round-the-clock paracetamol and diclofenac with an intravenous 
morphine patient-controlled analgesia pump for additional an-
algesia. Worst and average pain scores (on a Numerical Rating 
Scale) and morphine requirements on the first three post-operative 
days were assessed. Patients and assessors were blinded to study 
group. Chronic pain was assessed 6 months after surgery using a 
standard questionnaire. The primary outcome was the mean worst 
pain score over the first three post-operative days. Secondary 
outcomes were mean average pain score over the first three post-
operative days, morphine consumption and incidence of post-
thoracotomy pain at 6 months.
Results: We recruited 90 patients between May 2010 and July 
2012. Groups were comparable in terms of age, gender, weight 
and type of surgery. There was no significant difference between 
the PoT and the NeST group in mean worst pain scores over the 
first three post-operative days (3.83 versus 3.71, difference 0.12, 
99% CI -0.7 to 0.9). Mean average pain scores were also similar 
between the groups (1.85versus 1.77, difference 0.08, 99% CI -0.4 
to 0.6) as was the mean morphine consumption in milligram per 
kilogram body weight (1.40 versus 1.45, difference of -0.05, 99% 
CI -0.4 to 0.3). Chronic pain was present in 18 of 39 assessable 
patients (46.1%) in the PoT group and 17 of 41 assessable patients 
(41.2%) in the NeST group (difference 4.7%, 99% CI -22.8% to 
30.7%).
Conclusion: Preservation of the neurovascular bundle during tho-
racotomy using a modified nerve-sparing approach has no impact 
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O10.02 RADIATION THERAPY ONCOLOGY GROUP 
(RTOG) PROTOCOL 0915: A RANDOMIZED PHASE II 
STUDY COMPARING 2 STEREOTACTIC BODY RADIATI-
ON THERAPY (SBRT) SCHEDULES FOR MEDICALLY IN-
OPERABLE PATIENTS (PTS) WITH STAGE I PERIPHERAL 
NON-SMALL CELL LUNG CANCER.
Gregory Videtic1, Chen Hu2, Anurag Singh3, Joe Chang4, William 
Parker5, Kenneth Olivier6, Steve Schild6, Ritsuko Komaki4, James 
Urbanic7, Hak Choy8
1Radiation Oncology, Cleveland Clinic/United States Of America, 2Rtog/
United States Of America, 3Roswell Park Insitute/United States Of 
America, 4MD Anderson Cancer Center/United States Of America, 
5McGill University/Canada, 6Mayo Clinic/United States Of America, 
7Wake Forest School Of Medicine/United States Of America, 8University 
Of Texas Southwestern Medical Center/United States Of America
Background: To select the most favorable treatment regimen 
based on the rate of grade 3 or higher protocol-specified adverse 
events (psAEs) at 1 year.
Methods: Pts with documented baseline medical conditions pre-
cluding lobectomy and biopsy-proven peripheral (greater than 2 
cm from the central bronchial tree) T1/T2, N0 (clinically node ne-
gative by PET), M0 tumors were eligible. Patients (pts) were rando-
mized to receive either 34 Gy in one fraction (arm 1) or 48 Gy in 4 
consecutive once-daily fractions (arm 2). Rigorous central accredi-
tation and quality assurance assessments were used to assure pts 
were treated according to protocol guidelines. The study was desi-
gned to detect whether psAEs rate>17% at a 10% significance level 
(1-sided) and 90% power. Secondary endpoints included primary 
tumor control (PC) rate, 1-year overall survival (OS), progression-
free survival (PFS). The regimen selection criteria were based on 
pre-specified rules of psAEs and PC for each arm. Formal compari-
sons were not performed.
Results: The study opened in September 2009 and closed in 
March 2011 after accruing a total of 94 pts. Median follow up was 
20.6 months. Of 86 evaluable pts, 41 were in arm 1 and 45 in arm 
2. Baseline pt and tumor characteristics were balanced between 
both arms. 4 (9.8%) pts on arm 1 (95% CI: 2.7-23.1%; p=0.151) and 
6 (13.3%) pts on arm 2 (95% CI: 5.1-26.8%; p=0.337) experienced 
psAEs. 39 (95.1%) pts on arm 1 and 45 (100%) pts on arm 2 recei-
ved planned SBRT treatment. Contouring compliance indicated 
100% and 95.6% of targets and 89.5% and 82.2% of normal tissue 
structures were outlined per protocol/minor deviations, for arms 
1 and 2, respectively. OS at 1 year was 85.4% (95% CI: 70.3-93.1%) 
for arm 1 pts and 91.1% (95% CI: 78.0-96.6%) for arm 2. PFS at 1 
year was 78.0% (95% CI: 62.1-87.9%) for arm 1 and 84.4% (95% CI: 
70.1-92.3%) for arm 2. The PC rates at 1 year were 97.1% (95% CI: 
85.1-99.9%) for arm 1 and 97.6% (95% CI: 87.1-99.9%) for arm 2.
Conclusion: At one year, 34 Gy in one fraction met pre-specified 
criteria with respect to adverse events and primary control, and 
therefore is selected as the experimental arm for a planned pha-
se III trial. Supported by RTOG U10 CA21661 and CCOP U10 
CA37422 grants from NCI.
Keyword: early stage lung cancer, medically inoperable, stereot-
actic body radiotherapy, randomized phase II
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O10.01 EXPLORING THE OPTIMAL BIOLOGICALLY EF-
FECTIVE DOSE OF STEREOTACTIC BODY RADIATION 
THERAPY FOR STAGE I NON-SMALL-CELL LUNG CAN-
CER - AN UPDATE
Juan Wang, Baosheng Li, Jian Zhang
Radiation Oncology, Shandong Tumor Hospital/China
Background: To investigate the relationship between the different 
levels of biologically effective dose (BED) and the outcome of ste-
reotactic body radiation therapy (SBRT) for Stage I non–small-cell 
lung cancer (NSCLC).
Methods: Eligible studies were identified on Medline, Embase and 
the Cochrane Library from January 2001 to March 2013. According 
to the quartile of included studies, BED was divided into four dose 
groups: low (<100Gy), medium (100–112.3Gy), medium to high 
(112.3–135Gy), high (>135Gy). To obtain pooled estimates of overall 
survival (OS), local control rate (LCR), cancer-specific survival(CSS), 
regional failure rate(RFR), distant failure rate (DFR),data were com-
bined in a random effect model. The difference in pooled estimate 
among BED groups was assessed with the Pearson chi-squared 
test. The meta-regression model was used to explore the relation-
ship between the characteristics of the studies and the prognostic 
index.
Results: Fifty-nine observational studies with a total of 5,562 
patients were included in the meta-analysis. Pooled estimates of 
2-year and 3-year OS in the medium BED (79%, 71%) group were 
higher than in the low (64%, 57%) or medium to high BED (69%, 
57%) or high groups (66%, 56%), respectively (p<0.001, p<0.001, 
p<0.001,respectively). Pooled estimates of 2-year LCR in the medi-
um BED (89%) group was lower than in medium to high BED (94%)
or high groups (94%), respectively (p=0.003,0.009 respectively). 
While no significant differences were observed between each two 
of four different levels of BED and the 3-year RFR.
Conclusion: Based on the meta-analysis, a statistically significant 
OS benefit at 2 and 3 years can be demonstrated in the treatment 
of Stage I NSCLC with the delivery of medium BED compared with 
low, medium to high BED or high BED. The medium BED (range, 
100–112.3Gy) for SBRT may currently be more beneficial and reaso-
nable in Stage I NSCLC.
Keywords: BED, meta analysis, non-small cell lung cancer, SBRT
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O10.05 BLINDED ASSESSMENT OF RADIOLOGICAL 
CHANGES AFTER STEREOTACTIC ABLATIVE RADIOTHE-
RAPY FOR EARLY-STAGE LUNG CANCER: LOCAL RECUR-
RENCES VERSUS FIBROSIS.
Sashendra Senthi1, Kitty Huang2, David Palma2, Andrew Warner3, 
Ben Slotman1, Suresh Senan1
1Department Of Radiation Oncology, VU University Medical Center/
Netherlands, 2Department Of Radiation Oncology, London Regional 
Cancer Program/Canada, 3Department Of Epidemiology And Biostatis-
tics, London Regional Cancer Program/Canada
Background: Stereotactic ablative radiotherapy (SABR) is now a 
guideline-recommended treatment for early-stage lung cancer 
(ES-NSCLC), achieving 5-year local control rates of approximately 
10%. The timely detection of local recurrence (LR) and early sal-
vage following SABR is impaired by fibrotic changes, which occur 
commonly. Seven high-risk CT features (HRFs) that suggest LR 
include; enlarging opacity, cranio-caudal growth, sequential enlar-
ging opacity, enlarging opacity after 12 months, bulging margin, 
loss of linear margin and loss of air bronchograms. We validated 
these, performing blinded clinician assessment in patients with 
and without LR.
Methods: ES-NSCLC patients treated with SABR, who developed 
pathology-proven LR (n=12), were matched 1:2 to patients without 
clinical LR (n=24), based on tumor location, SABR fractionation, 
PTV size and follow-up duration. Three radiation oncologists as-
sessed serial follow-up CT images for HRFs, while blinded to out-
comes. The sensitivity and specificity of HRFs and combinations of 
these were determined.
Results: The median follow-up was 24 months (range 6-67) and 
both cohorts were well matched. All HRFs were significantly 
associated with LR (p≤0.002), Table 1. The best individual pre-
dictor of LR was opacity enlargement after 12 months (100% 
sensitivity, 83% specificity), however this was detected slo-
west, at a median 22 months. The earliest HRF detected was 
cranio-caudal growth detected at a median 13 months. The 
HRFs enlarging opacity and cranio-caudal growth were each 
detected at least 3 months prior to the actual diagnosis of LR 
42% of the time. The odds of LR increased 4-fold for each ad-
ditional HRF detected (p<0.001). The sensitivity and specificity 
of detecting multiple HRFs is shown in Table 2, with ≥3 HRFs 
being the best predictor of LR (sensitivity 92%, specificity 92%). 
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O10.03 SAFETY OF ENDOBRONCHIAL IMPLANTATION 
OF ELECTROMAGNETIC FIDUCIALS FOR REAL-TIME 
TRACKING OF LUNG TUMORS DURING RADIOTHERAPY
Daniel A. Nader
Cancer Treatment Centers Of America/United States Of America
Background: Lung tumor control has improved with advances in 
radiotherapy delivery (RT). Respiratory motion inders improve-
ments. An Anchored Beacon® transponder (Varian Medical Sys-
tems, Palo Alto, CA) can track lung tumors in real time during RT. 
This study evaluates the safety of these bronchoscopically implan-
ted transponders in 50 lung tumor patients undergoing RT
Methods: Each patient underwent implantation of 3 anchored 
transponders in the lung. A delivery catheter was inserted into 
the bronchoscope and using fluoroscopic guidance +/- radial en-
dobronchial ultrsound (EBUS) and/or electromagnetic guidance 
(superDimension): the catheter was positioned in a 2-2.5 mm 
diameter airway, within 3 cm of the tumor. The transponder was 
deployed by depressing a plunger within the delivery catheter. 
The catheter was then withdrawn. CT‘s were acquired before RT 
and every 1-2 weeks during treatment. Transponder positions were 
measured.
Results: 50 patients (28 female/ 22 male) with median age 64 had 
transponders inplanted. Follow-up ranged from 0- 15.5 months 
(median 9.2). Positional stability of the Anchored transponders 
over the course of RT was confirmed. Inter-transponder distance 
from serial CT scans have been evaluated in 47 of 49 patients who 
underwent RT. Inter-transponder distances were stable over the 
course of radiation therapy for 140/141 (99%) of Anchored trans-
ponders. 2 Anchored transponders migrated, one after comple-
tion of RT. Safety: 2 patients (4%) sustained pneumothorax with 
insertion. Each resolved within one day with chest tube placement 
and withdrwal. One patient sustained a cardiac arrest prior to 
bronchoscopy for implantation. 2/147 (1%) sustained migration. 
Patient A coughed one transponder. which was placed in too large 
and proximal airway. Patient B was found the have the transponder 
migrating to the pleural space associated with a suppurative lung 
infection 3 months post-treatment.
Conclusion: Bronchoscopic implantation of Anchored transpon-
ders can be performed with few complications. Anchored trans-
ponders are positonally stable in the lung with a 99% retention 
rate. There are multiple advantages to real-time localization and 
tracking of lung tumors. The Anchored transponder demonstrated 
a high safety profile and significantly low migration.
Keyword: Endobronchial electromagnetic fiducial
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A  
(Modfied-
Conventi-
onal) 
B  
(Mass-like 
Fibrosis) 
C  
(Scar-like 
Fibrosis) 
D  
(No Evi-
dence of 
Increased 
Density) 
6 
months 
43% 9% 6% 42% 
12 
months 
50% 16% 11% 23% 
18 
months 
46% 18% 16% 20% 
24 
months 
46% 22% 17% 15% 
36 
months 
40% 24% 21% 15% 
48 
months 
29% 24% 31% 16% 
 
Category A was the most common at all time points except 48 
months when category C was the most common. KA was 0.28, 
0.27, 0.18 and 0.27 at 12, 24, 36 and 48 months respectively. The 
range of KA in the leave-one-out analysis was 0.25-0.31, 0.24-0.27, 
0.15-0.22 and 0.24-0.31 at 12, 24, 36 and 48 months respectively. 
The KA of the first 20 patients vs the last 20 patients was 0.34 vs 
0.47 at 12 months.
Conclusion: The predominant pattern of post SBRT radiographic 
changes evolves over time. In this study categorization of late post-
SBRT radiographic changes has moderate inter-rater agreement. 
There is a suggestion of a training effect with more experience. 
However, categorization of late radiographic changes following 
SBRT is challenging and may require specific training.
Keywords: SBRT, fibrosis, Local failure
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O10.07 DOSE-RESPONSE ANALYSIS OF RADIATION IN-
DUCED RIB FRACTURES AFTER SBRT FOR NSCLC
Barbara Stam, Alize Scheenstra, Jose Belderbos, Haike Peulen, 
Jasper Nijkamp, Jan Jakob Sonke
Radiotherapy, The Netherlands Cancer Institute/Netherlands
Background: Symptomatic rib fractures occur in approximately 5% 
of patients treated with SBRT for early stage NSCLC. Only in small 
patient cohorts has the dose-effect relation of radiation induced 
rib fractures been determined. Recent developments in automatic 
rib segmentation allow determining the dose-effect relation in a 
large patient cohort, which is the aim of this study.
Methods: From 2006-2012 453 patients with early stage NSCLC 
were treated with SBRT (3x18 Gy). Follow-up (FU) consisted of a 
physical examination and a CT scan 4 months after treatment and 
every 6 months up to two years and yearly thereafter. For the first 
101 patients with FU>6 months, all ribs were automatically seg-
mented using 15 atlases of manually delineated ribcages. A non-
rigid registration followed by a multi-level label fusion produced 
for each patient a set of ribs. The physical dose distributions were 
NTD (Normalized Total Dose) corrected with α/β=3 Gy. Cox pro-
Conclusion: LR following SABR can be accurately predicted by 
the presence of HRFs on surveillance CT scans. This approach may 
reduce unnecessary confirmatory procedures, and facilitate earlier 
salvage treatment.
Keywords: stereotatic, Recurrence, fibrosis, Toxicity
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O10.06 INTER-RATER RELIABILITY OF THE CATEGORIZA-
TION OF LATE RADIOGRAPHIC CHANGES AFTER LUNG 
STEREOTACTIC BODY RADIATION THERAPY (SBRT)
Salman Faruqi1, Meredith Giuliani1, Hamid Raziee1, Mei Ling Yap1, 
Heidi Roberts2, Lisa Le3, Anthony Brade1, Byoung Chun J. Cho1, 
Alexander Sun1, Andrea Bezjak1, Andrew Hope1
1Radiation Oncology, Princess Margaret Cancer Centre/Canada, 2Medi-
cal Imaging, Toronto General Hospital/Canada, 3Department Of Biosta-
tistics, Princess Margaret Cancer Centre/Canada
Background: Radiographic changes following lung SBRT have 
been previously categorized into 4 groups: modified conventional 
pattern (A), mass-like fibrosis (B), scar-like fibrosis (C) and no evi-
dence of increased density (D) (Dahele et al.).The purpose of this 
study was to assess the inter-rater reliability of this categorization 
in patients with early stage non-small cell lung cancer.
Methods: 79 patients treated with SBRT for early stage NSCLC 
at a single institution who had a minimum follow-up of 6 months 
were included in this study. Serial post-treatment CT images were 
presented to expert clinicians (up to 6) familiar with post-SBRT 
radiographic changes and were scored by each individual in a blin-
ded fashion according to the published categorization of A, B, C or 
D. The proportion of patients categorized as A, B, C or D at each 
interval was determined. Krippendorff‘s alpha (KA) was used to 
establish inter-rater reliability at each time point. A leave-one-out 
analysis was performed at each time point on each rater to deter-
mine the sensitivity of the KA score to an individual rater. To explo-
re if a training effect existed the KA of the first and last 20 patients 
scored by the raters was determined.
Results: There were 351 ratings on 67 patients at 12mo, 250 ra-
tings on 49 patients at 24mo, 169ratings on 31 patients at 36mo 
and 80 ratings on 14 patients at 48mo. The proportion of patients 
scored in each category of A,B,C &D is reported in Table 1. Table 
1: Scale Category by Time-Point  
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O11.01 WIKI-BASED TREATMENT GUIDELINES FOR 
LUNG CANCER
Ian N. Olver, Jutta Von Dincklage, Laura Holliday, Christine Vule-
tich
Cancer Council Australia/Australia
Background: The updating of written clincial practice guidelines 
regularly is difficult and expensive. New evidence in cancer treat-
ment is published frequently. Guideline booklets are difficult to 
disseminate widely and stakeholder feedback is mainly pre-pub-
lication. To enable lung cancer guidelines to be rapidly updated 
and widely disseminated and therefore more likely to be utilised, 
Cancer Council Australia developed a web-based wiki platform for 
guidelines and is evaluating its impact.
Methods: The initial methodology paralled the steps in published 
written guideline development but these were integrated with 
the wiki capability. An expert group, whose competing interests 
were documented, were identified, the key clinical questions and 
search strategies were developed for each question and literature 
searches recorded on the wiki. An online literature screening and 
critical appraisal process was developed. This provides data on 
which papers were used to form the guidelines and why papers 
were either selected or rejected depending on their quality. Evi-
dence-based recommendations were formulated and evidence ta-
bles automatically generated. The wiki was closed in that only the 
invited experts could write or change a guideline but any stakehol-
der could comment on the guidelines at any time and the writing 
group would review and respond to comments. The initial vesion 
of the guidelines were distributed for targetted review by expert 
groups. We used web analytics to monitor usage. The writers re-
main engaged to appraise new papers and update the guideline 
rapidly as necessary. All previous versions could be accessed.
Results: Evaluation of the lung caner treatment guidelines develo-
ped on the wiki, showed that 22 authors had identified 67 clinical 
questions covering treatment of all stages of lung cancer. The 
literature search and screening process resulted in 2035 potentially 
relevant articles being forwarded for detailed methodological eva-
luation with another 571 added through snowballing and other me-
thods. To fine-tune the initial draft content, the working party used 
the wiki to exchange 156 internal comments in 9 weeks. When the 
guidelines were released for the initial 30-day public consultation 
period, 1055 users visited lung cancer content pages. The majority 
of users (487) accessed the guidelines directly as a result of tar-
geted emails, while 387 found the site by Google searches. Most 
respondents were from Australia (799) and New Zealand (60) with 
the United States (47) having the largest user group of respondents 
from the other countries who visited the site. A survey of the usa-
bility of the site indicated widespread acceptance. The average 
time on a content page was 1:27minutes. The landing page was 
the most popular content page with 3426 page views and an exit 
rate of 18.85%, which indicates that the landing page served as an 
important tool for visitors to navigate the guidelines. To date there 
were 38 external comments which occasioned 31 edits by the wor-
king party.
Conclusion: Adopting a platform built on MediaWiki, and mo-
portional hazard regression analysis, which takes into account the 
time to event with patient as random intercept, was used to find 
the optimal dose parameter. Evaluated were the dose received 
by x% of the rib Dx (x ranged 1-30%) and equivalent uniform dose 
(EUD) (volume effect 1/n ranged 0.1-60). The Lyman-Kutcher-Bur-
man (LKB) model based on this optimal dose parameter was used 
to model the dose-effect relationship. Using maximum-likelihood 
estimation, parameters were median toxic dose (TD50), steepness 
parameter m and 1/n were optimized.
Results: In 354 patients with FU>6 months (median 22 months), 38 
patients(11%) were diagnosed with a total of 49 rib fractures, sym-
ptomatic (grade 2) for 9 patients(2.5%). Included in the dosimetric 
analysis were 2410 ribs (14 ribs outside field-of-view). 26 ribs in 15 
patients(15%) were fractured, symptomatic for 4 patients(4%). In 
the univariate analysis, all dose parameters significantly correlate 
with rib fracture (p-values<0.001). Hazard ratios (95%CI) for the 
parameters with highest log likelihood: D1=1.022 (1.017-1.027) and 
EUD0.033=1.021 (1.016-1.026). Multivariate analysis identified EUD as 
the predictor with the highest log-likelihood and was used in the 
LKB model. The optimal LKB parameters to predict rib fracture in 
this dataset were (95% CI): TD50=395.5 Gy (244.3-555.1), m=0.348 
(0.311-0.384) and 1/n=32.3 (4.82-inf). The risk of rib fracture was 
<5% in case the NTD-corrected EUD<170 Gy.
Conclusion: In this subgroup of NSCLC patients treated with 
3x18Gy, the risk of rib fracture was significantly correlated to the 
dose, and was <5% in case the biological dose is kept under 170 
Gy.
Keywords: Dose-effect relation, rib fracture, LKB modeling
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Table showing association between cough predictors and 
cough severity (VAS) and cough specific QoL (MCLCS) 
scores on univariate analysis*
Cough Se-
verity (VAS) 
Cough 
Speci-
fic QoL 
(MCLCS) 
Comment
Age 
(≤70yrs vs 
>70yrs) 
p=0.365# p=0.834#
Gender p=0.048# p=0.171#
women worse 
cough severity
Smoking 
Status (cur-
rent, ex, 
never) 
p=0.191## p=0.356##
Perfor-
mance Sta-
tus (WHO 
PS 0-3) 
p<0.0001## p<0.0001##
poorer PS worse 
cough severity 
poorer PS worse 
cough related QoL 
Histology 
(NSCLC vs 
SCLC) 
p=0.348# p=0.274#
Stage (ear-
ly vs ad-
vanced) 
p=0.358# p=0.301#
Tumour 
Location 
(central vs 
peripheral) 
p=0.486# p=0.040#
central tumours 
poorer cough rela-
ted QoL
COPD 
(Chronic 
Obstruc-
tive Pul-
monary 
Disease) 
(self-repor-
ted) 
p=0.578# p=0.128#
LRTI (Lo-
wer Res-
piratory 
Tract Infec-
tion) (self-
reported) 
p=0.022# p=0.044#
LRTI worse cough 
severity LRTI worse 
cough related QoL 
Asthma 
(self-repor-
ted) 
p=0.021# p=0.054#
asthma worse 
cough severity
GORD (BRI 
question-
naire) 
p<0.0001# p<0.0001#
GORD worse 
cough severity 
GORD worse 
cough related QoL 
Nausea 
(EORTC 
QLQ C30) 
p=0.004## p=0.017##
Increased nausea 
worse cough seve-
rity. Increased nau-
sea worse cough 
related QoL 
Oral Stero-
ids 
p=0.434# p=0.017#
On steroids worse 
cough related QoL
ving to electronic guidelines has allowed rapid updates as new 
evidence becomes available and wider dissemination than print 
formats. The next strategy to boost uptake is to write Qstream 
education modules to accompany the guidelines.
Keyword: lung cancer, treatment guidelines, wiki,
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O11.02 THE "CLIC“ COUGH IN LUNG CANCER STUDY: 
THE CHARACTERISATION OF COUGH IN LUNG CANCER
Amelie S.M. Harle1, Alexander Molassiotis2, Jaclyn Smith3, Fiona 
Blackhall1
1Medical Oncology, The Christie NHS Foundation Trust/United King-
dom, 2School Of Nursing, Midwifery And Social Work, University Of 
Manchester/United Kingdom, 3Centre For Respiratory And Allergy Re-
search, University Of Manchester/United Kingdom
Background: The “CLiC” Study seeks to characterise cough and 
identify its predictors using subjective and objective cough assess-
ment tools, including the recently validated Manchester Cough in 
Lung Cancer Scale (MCLCS). Results will enable the identification 
of robust endpoints and therapeutic targets for novel antitussive 
interventional trials.
Methods: Patients with lung cancer (LC) and complaining of cough 
were recruited irrespective of stage and treatment, from two can-
cer centres. Demographic and clinical data were collected. Pati-
ents completed the MCLCS, Cough Severity Diary (CSD), cough 
severity Visual Analogue Scale (VAS) and the Brief Reflux Inventory 
(BRI, a validated 5-item questionnaire assessing gastro-oeso-
phageal reflux disease (GORD)). The oncology specific European 
Organization for Research and Treatment of Cancer Quality of Life 
(QoL) Questionnaire (EORTC QLQ) C30 with the module (LC13), 
(including item 31: "In the past week, how often did you cough?“) 
was also completed. Cough was graded according to Common 
Toxicity Criteria for Adverse Events (CTCAEv4.0). A sample size of 
178 patients was required for analysis of 160 (based on Peduzzi J 
Clin Epidem 1996) for 10 participants per correlate per outcome in 
binary logistic regression, assuming a 10% attrition rate, the preva-
lence of severe cough to be 50% and 8 cough predictors.
Results: We recruited 179 patients (Oct‘11-Nov‘12). The median 
age was 65 yrs (range 25-83 years), with 53% patients male. The 
majority (79%) had non small cell lung cancer (NSCLC) and advan-
ced stage disease (>IIIA 60%). In total, 36% were receiving cancer 
therapy at entry. Overall, 60% felt their cough warranted treat-
ment. Having ensured validity of the cough assessment tools, the 
mean cough severity score (VAS) (n=171) was 43.4mm (SD 29.6). 
The mean cough-specific QoL score (MCLCS) was 25.3 (SD 8.8, 
with a range 1-50, high scores representing worse QoL). 
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Results: We recruited 179 patients (Oct‘11-Nov‘12): median age 
65yrs (range 25-83 years), 53% male. Majority (79%) had non small 
cell lung cancer, 60% advanced stage (>IIIA), 36% were on cancer 
therapy.  
Table showing correlations between subjective cough 
assessment tools
EORTC 
QLQ C30 
cough 
item 31 
CTCAE 
Cough 
Grading 
MCLCS 
Manches-
ter Cough 
LC Scale 
CSD 
Cough 
Severity 
Diary 
VAS 
Cough 
Severity 
0.54**§ 
n=171 
0.50**§ 
n=170 
0.67**§ 
n=163 
0.70**¥ 
n=84 
EORTC 
QLQC-30 
cough 
item Q31 
0.45**§ 
n=173 
0.57**§ 
n=165 
0.52**§ 
n=85) 
CTCAE 
Cough 
Grading 
0.56**§ 
n=164 
0.59**§ 
n=85 
MCLCS 
Manches-
ter Cough 
LC Scale 
0.76**¥ 
n=82 
** p<0.0001 ¥high correlation §moderate correlation 
 
Table showing correlations between objective ACM and 
subjective cough tools
VAS 
Cough 
Severity 
MCLCS 
Man-
chester 
Cough 
LC Scale 
Log 
Cough/
hr As-
leep 
Log 
Cough/
hr Awa-
ke 
Log 
Cough/
hr 24-
hour 
VAS 
Cough 
Seve-
rity 
0.73** 
n=37 
0.33* 
n=37 
0.61** 
n=37 
0.57** 
n=37 
MCLCS 
Man-
chester 
Cough 
LC  
Scale 
0.24 
n=35 
0.51* 
n=35 
0.44* 
n=35 
Log 
Cough/
hr  
Asleep 
0.52** 
n=35 
0.62** 
n=35 
Log 
Cough/
hr  
Awake 
0.97** 
n=37 
** p<0.0001 * p<0.05 
 
Intra-class correlations demonstrated good repeatability over 
time between Days 0&60 for cough frequency (24hour: r=0.77, 
p<0.0001, awake: r=0.79, p<0.0001, sleep: r=0.66, p=0.004) and 
MCLCS: r=067,p<0.001 .The median cough scores/hour were 
Over the 
Counter 
Antitussi-
ves 
p=0.011# p=0.067#
On antitussives 
worse cough se-
verity
Opiates p=0.497# p=0.018#
On opiates worse 
cough related QoL
*Not all analysed cough predictors shown # Mann-Whitney-U 
Test ## Kruskal-Wallis Test
 
Conclusion: This is the largest single study to use validated cough-
specific assessment tools in LC to characterise and assess potential 
influences on cough. LC patients have a severe cough, with com-
parable VAS scores to those of patients presenting to specialist 
chronic cough clinics. New antitussive therapies are needed. Key 
predictors of cough severity and reduced cough-specific QoL are 
performance status (PS), nausea and GORD. Preclinical research 
suggests that the neurokinin-1 pathway may mediate the vagal 
cough reflex pathway. Our results further support this hypothesis 
and imply that the neurokinin-1 pathway may be a relevant thera-
peutic target. The association with GORD may be explained by the 
shared vagal innervation of the airway and upper gastrointestinal 
tract.
Keywords: characterisation, predictors, cough, Lung cancer
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O11.03 THE "CLIC“ COUGH IN LUNG CANCER STUDY: 
THE VALIDATION OF OBJECTIVE AND SUBJECTIVE 
COUGH ASSESSMENT TOOLS IN LUNG CANCER PATI-
ENTS
Amelie S.M. Harle1, Alexander Molassiotis2, Jaclyn Smith3, Fiona 
Blackhall1
1Medical Oncology, The Christie NHS Foundation Trust/United King-
dom, 2School Of Nursing, Midwifery And Social Work, University Of 
Manchester/United Kingdom, 3Centre For Respiratory And Allergy Re-
search, University Of Manchester/United Kingdom
Background: Cough is a common lung cancer (LC) symptom, yet 
effective therapies are lacking. The development and testing of 
novel therapies relies upon appropriate tools for the assessment of 
cough. CLiC is the first study to evaluate two new tools 1) objecti-
ve ambulatory cough monitoring (ACM) from acoustic recordings 
(VitaloJAK™) and 2) the Manchester Cough in Lung Cancer Scale 
(MCLCS) quality of life (QoL) questionnaire. These provide comple-
mentary assessments of cough frequency and its impact upon the 
patient.
Methods: Patients with LC and complaining of cough were recrui-
ted, irrespective of stage or treatment, from two cancer centres. 
Demographic and clinical data were collected. All patients com-
pleted the MCLCS, Cough Severity Diary (CSD) and cough severity 
Visual Analogue Scale (VAS). The European Organization for Re-
search and Treatment of Cancer QoL Questionnaire (EORTC QLQ) 
C30 with the module (LC13), (including item 31: "In the past week, 
how often did you cough?“) was also completed. The Common To-
xicity Criteria for Adverse Events (CTCAEv4.0) was used to grade 
cough. A subgroup underwent ACM and MCLCS on Days 0&60.
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Conclusion: The results provide a relatively comprehensive picture 
about the overall QOL and the sub-patterns of QOL for those new-
ly diagnosed advanced lung cancer patients. The results further 
support the giving timing and tailoring interventions are needed 
to better improve lung cancer patients’ QOL. (Acknowledgement: 
National Health Research Institute,NHRI,Taiwan).
Keyword: quality of life, longitudinal pattern, symptom, advanced 
lung cancer
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O11.06 THE EFFECTS OF INSPIRATORY MUSCLE TRAI-
NING IN THE MANAGEMENT OF BREATHLESSNESS IN 
PATIENTS WITH LUNG CANCER: A PILOT FEASIBILITY 
RANDOMIZED TRIAL
Alex Molassiotis1, Andreas Charalambous2, Paul Taylor3,  
Zoe Stamataki4, Yvonne J. Summers3
1School Of Nursing, The Hong Kong Polytechnic University/Hong Kong, 
2Department Of Nursing, Cyprus University Of Technology/Cyprus, 
3University Hospital South Manchester/United Kingdom, 4Christie NHS 
Foundation Trust/United Kingdom
Background: Breathlessness in patients with lung cancer is com-
mon symptom affecting 50-70% of patients, rising to 90% for those 
with advanced lung cancer. Managing breathlessness is complex, 
treatment options are limited and treatments are sometimes 
unsuccessful. Inspiratory muscle training (IMT) is a non-pharma-
cological method that has shown positive results in Chronic Obs-
tructive Pulmonary Disease and mixed results in other respiratory 
illnesses. As this treatment method has never been tested in pa-
tients with lung cancer, the aim of the current study was to assess 
how feasible this treatment is in the lung cancer population and 
explore changes in outcome variables, before launching a larger 
randomized trial.
Methods: Pilot feasibility randomized trial in patients with lung 
cancer having stable disease. The experimental group received 
training using a pressure threshold device (commercially available 
from Phillips Respironics). Patients were instructed to do 5 sessions 
weekly for 12 weeks for a total of 30mins per day, divided over 
2 sessions. Patients in the control group received standard care 
and received the treatment at the end of their trial participation. 
Outcome measures were completed at baseline and monthly for 3 
months, and included: physiological parameters (FEV1,FVC); per-
ceived severity of breathlessness in six 10-point VAS assessing ave-
rage breathlessness over past 24 hours, worst breathlessness over 
past 24hrs, breathlessness now, distress from breathlessness, abili-
ty to cope with breathlessness and satisfaction with breathlessness 
management; modified Borg scale; quality of life using the short 
form-Chronic Respiratory Disease Questionnaire (with subscales 
on dyspnea, fatigue; emotional function and mastery of breathless-
ness); Hospital Anxiety & Depression Scale, and safety.
Results: 46 patients (M=37, F=9) at a mean age of 69.5 years old 
and a mean of 16 months post-diagnosis who were not currently 
receiving chemotherapy/radiotherapy were recruited from 3 cen-
tres in the UK and Cyprus. Seventy-percent had NSCLC and advan-
ced disease. There were no changes in FEV1 and FVC levels bet-
ween groups. There were time by intervention interaction effects 
in average breathlessness and worst breathlessness in past 24hrs 
(p<0.01) with the intervention arm showing stable breathless-
14.1(24hour: range 0.7-156), 18.5 (awake: range 1-233) and 6.0  
(asleep: range 0-110).
Conclusion: We have demonstrated moderate to strong correla-
tions between established measures of cough and two novel as-
sessment tools, suggesting the validity of MCLCS and ACM. Their 
good repeatability suggests they have excellent potential for the 
assessment of novel treatments in future intervention studies for 
LC-related cough. In contrast, standard oncology tools are blunt 
and poorly discriminate cough.
Keywords: cough, Lung cancer, Validation, Assessment Tools
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O11.04 PATTERNS OF QUALITY OF LIFE, THEIR  
CHARACTERISTICS AND RELATIONSHIP TO SYMPTOMS 
-- 12 MONTHS FOLLOW-UP IN NEWLY DIAGNOSED AD-
VANCED LUNG CANCER PATIENTS
Yeur-Hur Lai1, Yu-Chien Liao2, Yun-Hsiang Lee1, Wei-Yu Liao1, 
Chong-Jen Yu1, Pan-Chyr Yang1
1College Of Medicine, National Taiwan University/Taiwan, 2School Of 
Nursing, Yuanpei University/Taiwan
Background: Patients with newly diagnosed advanced lung cancer 
may experience severe impacts on their quality of life (QOL). How-
ever, relatively few studies have examined the longitudinal patterns 
of QOL and their relationship to patients’ symptoms during the 
first 12 months of cancer diagnosis. Thus, the purposes of this stu-
dy were to (1) examine the overall pattern and the potential sub-
patterns (if any) of QOL in these patients during the first 12 months 
of cancer diagnosis; and (2) identify those important characteristics 
of each QOL sub-pattern and their relationship to patients’ symp-
toms.
Methods: This is a 12-month prospective longitudinal study. Newly 
diagnosed advanced lung cancer patients (Stage IIIB & IV) were eli-
gible to be recruited and followed for 12 months on 5 time points 
(Pre-treatment, 1, 3, 6 and 12 months since treatments). The overall 
QOL was measured by the overall QOL item in the EORTC QLQ-
C30 (0-100 scoring, higher is better). The QOL patterns and factors 
related to the patterns were analyzed by Latent Class Growth 
Analysis (LCGA). Potential factors (independent variables) used to 
predict the overall QOL change and each QOL sub-pattern (de-
pendent variables) included: physical function, selected symptoms, 
emotion distress, self-efficacy (on coping with cancer) and impor-
tant demographic and treatment related variables.
Results: A total of 200 subjects completed the 5 follow-up assess-
ments. Generally, patients had moderate level of QOL across the 
12 months. There were three QOL sub-patterns were identified. In 
the pattern I (around 50% of subjects), patients reported moderate 
to relatively good levels of QOL (scoring around 70-80) across the 
12 months. In the pattern II (around 45% of subjects), patients re-
ported moderate levels of QOL (scoring around 50-70 QOL). In the 
pattern III (<10% subjects), patients reported poor level of QOL 
(scoring around 40 or less). Overall, symptoms including fatigue, 
pain, lack of appetite and dyspnea were significantly related to the 
changes of QOL. Other factors also included psychological dist-
ress, uncertainty and self-efficacy (level of confidence) in coping 
well with lung cancer.
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Conclusion: Central airway obstruction secondary to primary 
lung cancer can cause disabling dyspnoea and impending suf-
focation. Interventional bronchoscopic techniques, in particular 
airway stenting, can provide immediate relief of these symptoms. 
The survival data here reflects the advanced stage of disease 
in this patient group and, although unlikely to improve survival, 
airway stenting can offer the opportunity for further adjuvant 
treatment in some cases. More importantly perhaps, 91% of pa-
tients were discharged home following the procedure allowing 
an improved in quality of life. In our experience, tracheobronchial 
stent insertion can be used effectively to achieve these outco-
mes with minimal complications and a short hospital admission. 
Keywords: Bronchial neoplasms, Stent
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O11.08 A COMPARISON OF TRACHEOBRONCHIAL 
STENT INSERTION WITH AND WITHOUT RADIOLOGI-
CAL GUIDANCE IN PATIENTS WITH ADVANCED PRIMA-
RY LUNG CARCINOMA
Henrietta Wilson, Emma Beddow
Thoracic Surgery, Royal Brompton And Harefield NHS Trust/United 
Kingdom
Background: Tracheobronchial stent insertion is safe and effec-
tive in managing central airway obstruction in advanced lung 
carcinoma. Airway stenting offers both immediate relief of severe 
dyspnoea and time for adjuvant therapy. It is commonly used in 
specialist thoracic centres with a variety of stent models emplo-
yed. A large number of centres still use fluoroscopic guidance for 
stent positioning, leading to increased radiation exposure for both 
patients and staff. The aim of this study was to compare outcomes 
in patients undergoing stent insertion with or without radiological 
guidance.
Methods: 70 patients were identified who underwent a total of 79 
stent procedures. The cohort was divided into two groups based 
on whether stents were inserted under radiological guidance or 
ness and the control group deteriorating, but no between-group 
differences. Statistical and clinically important differences were 
seen with regards to ability to cope with breathlessness (p=0.02), 
satisfaction with breathlessness management (p=0.024), fatigue 
(p=0.007), emotional function (p=0.006), breathlessness mastery 
(p=0.031), anxiety (p=0.027) and depression (p=0.048). The m-
Borg difference between the 2 groups at 3 months was 0.80, which 
is borderline clinically significant but not statistically significant. 
Changes were more evident in the 3-month assessment. IMT was 
safe with only a small number of patients complaining of muscle 
fatigue and dizziness.
Conclusion: This trial shows the IMT is feasible and safe in patients 
with lung cancer with significant benefits particularly in their ability 
to cope with breathlessness and emotional distress. The details of 
this trial allow us to refine the treatment protocol and findings gu-
arantee a fully-powered larger trial (N should be around 196 with 
m-Borg as primary outcome).
Keyword: inpiratory muscle training; breathlessness
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O11.07 TRACHEOBRONCHIAL STENT INSERTION IN  
THE MANAGEMENT OF PRIMARY LUNG CANCER:  
5 YEAR EXPERIENCE
Henrietta Wilson, Emma Beddow
Thoracic Surgery, Harefield Hospital/United Kingdom
Background: Central airway obstruction is seen in around 30% of 
patients with primary lung cancer. This is often a life-threatening 
presentation of the disease due to imminent airway loss and there-
fore requires urgent intervention. Direct bronchoscopic techniques 
including airway stenting can offer an immediate improvement 
in symptoms and quality of life, in addition to providing time for 
further treatment modalities. Here we report outcomes from a large 
single centre five year experience of tracheobronchial stent insertion 
for palliation of advanced primary lung cancer.
Methods: A retrospective review of all patients undergoing tra-
cheobronchial stent insertion between January 2007 and January 
2012 was performed. Patients undergoing stent insertion for benign 
or secondary malignant disease were excluded. A total of 70 pati-
ents underwent 80 stenting procedures with an average age of 66 
years. Patient notes were used to collect patient demographic, di-
sease and stenting data. Outcomes included post-procedure length 
of stay, complications, need for further intervention and overall 
survival.
Results: Disease was identified within the trachea in 18 cases, bila-
terally within the bronchi in 10 cases and in the left or right bronchus 
in 23 and 28 cases respectively. Expandable, nitinol stents were 
used for all patients with either a proximal or distal release system. 
Uncovered stents (57), covered stents (20) or a mixture of the two (3) 
were placed. The average length of stay was 2.5 days (range 0-17); 
however, 69% of patients were discharged on the same day or on 
day one following the procedure. There were no cases of stent mig-
ration identified. The most common complication was retained se-
cretions requiring repeat bronchoscopy which occurred in 5 cases. 
One patient required telescopic insertion of a second stent due to 
malposition of the first. Median survival was 2.6 months with a 20% 
one-year survival. There were 4 in hospital deaths.
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logistics of planning these urgent cases.
Keywords: Lung malignancy, Tracheobronchial stenting, Airways 
disease
SYMPTOM MANAGEMENT  
MONDAY, OCTOBER 28, 2013 - 16:15-17:45
O11.09 IBANDRONIC ACID VS. ZOLEDRONIC ACID IN 
LUNG CANCER PATIENTS WITH SKELETAL METASTASES. 
HOW DO THEY COMPARE?
Ioannis A. Dimitroulis, Agisilaos Dervas, Sofia Vasileiou, Michalis 
Toumbis
"sotiria“ Hospital For Thoracic Diseases/Greece
Background: Amino-biphosphonates are third-generation bis-
phosphonates which act by inhibition of osteoclasts. We have 
presented at two previous ATS conferences (Dimitroulis I.A. et al 
2009, 2011), the role of each amino-biphosphonate separately. We 
set out to investigate the superiority or inferiority of Ibandronic 
acid (Ibandronate) over Zoledronic acid (Zoledronate), in terms of 
efficacy in reducing bone pain, and complications in patients with 
skeletal metastases due to Lung Cancer.
Methods: Ninety six patients with Skeletal Metastases due to 
Lung Cancer were enrolled, and were randomized on a 1:1 basis 
to receive infusions of Ibandronate (50 pts) or Zoledronate (46 pts) 
intravenously, every 21 days. Infusion time for Zoledronate (4mg) 
was 15 minutes, and for Ibandronate (6mg) one hour. Patients (pts) 
were analysed for pain relief, skeletal-related events (SREs) and 
adverse events. All pts underwent dental and cardiac examination 
before enrollment, and completed blood tests every 21 days. Bone 
scan was performed every 6 months. Blood tests (including close 
monitoring of calcium levels and renal function) were performed 
before each amino-biphosphonate administration.
Results: Patients in both arms were well matched for their diagno-
sis, stage of disease, burden of skeletal disease, and performance 
status. Median follow-up was 24 months. At 24 months, mean in-
creases in British Pain Inventory pain scores were lower with Zoled-
ronate compared to Ibandronate (0.43 vs 0.89 [p=0.03]). Analgesic 
effect as defined by the 4 point analgesic scale was less with Zo-
ledronate as compared to Ibandronate. Incidence of SREs was not 
significantly different between two arms (35% for Zoledronate vs 
38% for Ibandronate [p=0.2]). Median time to the first SRE was not 
reached in either arm. At 18 months of median follow up, percen-
tages of patients with skeletal-related events were 41% in the Zole-
dronate arm vs 45% in the Ibandronate arm (p=0.05). Zoledronate 
caused fever in six (12%) patients and hypocalcemia in one patient. 
Ibandronate caused hypocalcemia in one patient (2.2%). No cases 
of jaw osteonecrosis, atrial fibrillation or renal failure (all of them 
possible side-effects of amino-biphosphonates) were observed.
Conclusion: Zoledronate is the preferred amino-bisphosphonate 
for its shorter infusion time, availability and relative benefits. It is 
slightly better than Ibandronate in reducing bone pain and preven-
ting skeletal-related events. The only possible drawback is that, 
locally, Zoledronate is 1.3 times more expensive than Ibandronate 
(according to the mean European Economic Community price).
Keywords: Ibandronic Acid, Zoledronic Acid, Amino-biphospho-
nates, Skeletal Metastases
direct vision at bronchoscopy. Retrospective analysis of notes was 
performed to collect data with regards to stenting strategy and 
post-operative course. The primary outcomes were length of stay, 
complications, repeat procedure and survival.
Results: Of the 79 stent procedures, 41 were with radiologi-
cal guidance (group 1) and 38 were under direct vision only 
(group 2). There was an equal distribution with regards to the 
position of the stents (Table 1). Both techniques were well to-
lerated with minimal complications and no stent migration. 
Post-procedure length of stay was 2.73 days in group 1 and 
2.26 days in group 2, with no significant statistical difference 
seen (p=0.93). There was also no difference in need for further 
stent intervention. A comparison of survival is shown in Figure 1. 
Conclusion: Airway stenting is a vital technique in the manage-
ment of impending central airways obstruction. Although tra-
ditionally carried out under radiological guidance, we found no 
differences in complications, need for repeat procedure or survival 
when using direct vision. This not only saves radiation exposure 
to patients and staff, but also improves the cost-effectiveness and 
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O12.02 PATHWAY ANALYSIS OF GENE EXPRESSION 
PROFILES THAT DISTINGUISH PERSISTENT FROM RE-
GRESSIVE BRONCHIAL DYSPLASIA INDICATE SYNER-
GISTIC ROLE FOR POLO-LIKE KINASE 1 (PLK1) AND 
EPOXIDE HYDROLASE 3 (EPHX3) IN MALIGNANT PRO-
GRESSION.
Daniel T. Merrick1, Michael G. Edwards2, Wilbur Franklin2, Michio 
Sugita2, York Miller3, Micah Friedman3, Lori Dwyer-Nield2, Mere-
dith Tennis2, Kevin Choo3, Greg Hickey2, Tim Kennedy4, Adrie Van 
Bokhoven2, Lynn Heasley2, Fred R. Hirsch2, Paul A. Bunn2, Mark 
Geraci2, Robert L. Keith3, Raphael Nemenoff2
1Pathology, Denver VAMC/United States Of America, 2University Of 
Colorado Anschutz Medical Campus/United States Of America, 3Denver 
VAMC/United States Of America, 4Presbyterian-st. Lukes Hospital/
United States Of America
Background: 160,000 Americans die from lung cancer annually 
and the prognosis for invasive lung cancer is poor. Prevention of 
cancer represents an approach with high potential for significant 
reduction in mortality. Bronchial dysplasia (BD) is a precursor le-
sion of squamous cell carcinoma (SCC) of the lung, and persistent 
BDs represent a high risk subset of these lesions. Genomic insta-
bility is an important process underlying malignant progression. 
Gene expression microarray analyses were used to identify poten-
tial mediators of genomic instability in persistent BD and study 
their activity in these high risk lesions. Two genes, PLK1, which ab-
rogates G2-M checkpoint DNA damage repair, and EPHX3, which 
converts tobacco smoke derived pro-carcinogens to mutagens, 
were selected for further analysis.
Methods: Sixty-three frozen baseline biopsies were classified into 
persistent/progressive BD, regressive BD , progressive non-dyspla-
sia and stable non-dysplasia groups according to the presence or 
absence of BD on follow-up biopsies. H&E staining was performed 
on frozen sections to confirm histology, and RNA was harvested 
for global gene expression microarray analysis. Intergroup compa-
risons employed ANOVA statistical analysis with a false discovery 
rate of 10% to identify differentially expressed genes associated 
with persistence and gene expression alterations related to base-
line histology used Spearman correlation coefficient cutoff of r= 
+/- 0.5. A pathway analysis (Ingenuity) using the persistence rela-
ted genelist was performed to identify active pathways associated 
with persistence of BD. Validational studies were performed by 
quantitative RT-PCR in cell lines established from persistent and 
regressive bronchial sites. Inhibitors of persistence associated 
enzymes were used in tissue culture based assays of cellular proli-
feration.
Results: Gene expression analyses support the unique biolo-
gical nature of persistent BD. Intergroup comparisons showed 
significant numbers of differentially expressed genes only in the 
comparisons of persistent BD with regressive BD (318 genes) or 
stable non-dysplasia (6254 genes). 831 genes showed differential 
expression associated with increasing baseline dysplastic grade 
regardless of outcome. While approximately half of these genes 
also differentiated persistent from regressive BD, the presence of 
numerous persistence related genes that are independent of histo-
logy further substantiates the unique high risk nature of persistent 
BD. A pathway analysis revealed “mitotic roles of PLKs” as having 
the most significant association with persistence. Quantitative RT-
PCR using cultures of 8 persistent BD and 6 regressive BD valida-
ted increased expression in persistent BD of PLK1 (2.77X, p=0.002) 
Session O12: Lung Cancer Biology II 
Tuesday, October 29, 2013
LUNG CANCER BIOLOGY II  
TUESDAY, OCTOBER 29, 2013 - 10:30-12:00
O12.01 PROSPECTIVE ISOLATION OF HUMAN LUNG 
STEM/PROGENITOR CELLS AND THEIR ROLE IN THE 
INITIATION OF LUNG CANCER
Clare E. Weeden1, Kati Viitaniemi1, Georg Ramm2, John Ciciulla3, 
Ivan Bertoncello4, Marie-Liesse Asselin-Labat1
1Acrf Stem Cells And Cancer Division, The Walter And Eliza Hall In-
stitute For Medical Research/Australia, 2Department Of Biochemistry 
And Molecular Biology, Monash University/Australia, 3Department Of 
Anatomical Pathology, The Alfred Hospital/Australia, 4Department Of 
Pharmacology And Therapeutics, The University Of Melbourne/Aust-
ralia
Background: Cells of origin of cancers acquire the first genetic 
aberration(s) that lead to tumourigenesis. An understanding of the 
cell of origin in different subtypes of lung cancer could allow ear-
lier detection of malignancies and more effective treatment. Stem 
or progenitor cells are likely tumour initiating cells due to both 
their longevity, allowing for accumulation of genetic lesions, and 
their capacity for renewal. This study aims to isolate human lung 
progenitor subpopulations based on their differential expression 
of cell surface markers to evaluate their role as the cell of origin of 
the different subtypes of lung cancer.
Methods: Single cell suspensions were generated from adjacent 
normal tissue of patients undergoing lung cancer resection. Epi-
thelial cells were immediately separated based on their expressi-
on of cell surface markers by fluorescence activated cell sorting 
(FACS). The progenitor cell capacity of epithelial cell subsets was 
then assessed using an in vitro colony forming assay. Subsets with 
progenitor activity were analysed for their expression of differenti-
ated lung cell markers both before and after colony formation.
Results: We have identified a sort strategy that allows for enrich-
ment of basal cells, Clara cells, type I and II pneumocytes from 
fresh human lung tissue as shown by qPCR and electron microsco-
py data. The basal cell and type II pneumocyte subpopulations 
consistently formed colonies in vitro - cell types that have previous-
ly shown progenitor activity in the mouse lung. The Clara cell and 
type I cell compartment did not consistently form colonies. Basal 
and type II cells formed phenotypically distinct colonies when 
cultured in a three-dimension matrix that expressed different lung 
specific markers (p63, SP-C…) as shown by RT-PCR analysis and 
immunofluorescence staining.
Conclusion: This study has demonstrated the prospective isolati-
on of four epithelial cell subsets from fresh human lung tissue for 
the first time and confirmed the progenitor activity of basal cells 
and type II cells in the human lung. We are currently comparing 
the genetic profile of these human lung progenitor cells with the 
genetic profile of molecular subtypes of non-small cell lung cancer 
(NSCLC) and small cell lung cancer (SCLC) using next generation 
sequencing. Future studies aim to transform lung progenitor cells 
with genetic alterations common in NSCLC and SCLC to further 
establish their role as cells of origin of these cancers.
Keyword: "cell of origin“ "human progenitor cells“ "RNAseq“
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pseudogene loci (gain>2.3 copies, loss<1.7 copies). Candidate 
pseudogenes (1) have a parent gene that has been previously re-
ported to play a role in cancer biology, (2) are expressed in human 
tissue, and (3) share at least one conserved miRNA binding site 
with its parent gene.
Results: Several pseudogenes for OCT4 (octamer-binding 
transcription factor 4), an early embryonic transcription factor, 
were found to be frequently gained (46.9-34.9%), and could pro-
tect OCT4 from miRNA-mediated translational inhibition. Additio-
nally, pseudogenes for E2F3 (E2F Transcription Factor 3), a potent 
cell cycle regulator, as well as those for the well known lung cancer 
oncogene BRAF, were found to have high frequencies of CN alte-
ration (36.1%, and 19.2%, respectively). These high frequencies of 
alteration suggest that these pseudogenes play an important role 
in NSCLC.
Conclusion: These results suggest that pseudogenes are clonally 
selected for at the DNA level, and pseudogene-mediated protec-
tion of oncogenic transcripts from miRNA-mediated translational 
inhibition may represent a novel mechanism of oncogenicity in 
NSCLC. Analyses of pseudogene expression and corresponding 
parent gene protein level in cell models will yield insight into how 
this class of ncRNA affects tumourigenesis, potentially leading to 
improvements in early detection, diagnosis, and treatment.
Keywords: non-coding RNA, non-small cell lung cancer
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O12.05 DEFINING THE ROLE OF ZEB1 IN THE PATHO-
GENESIS OF NON-SMALL CELL LUNG CANCER (NSCLC) 
USING IMMORTALIZED HUMAN BRONCHIAL EPITHELI-
AL CELLS (HBECS)
Jill E. Larsen1, Jihan K. Osborne2, Alexander Augustyn1, James P. 
Sullivan1, Mitsuo Sato3, Luc Girard1, Adi F. Gazdar1, John D. Minna1
1Hamon Center For Therapeutic Oncology Research, University Of Te-
xas Southwestern Medical Center At Dallas/United States Of America, 
2Pharmacology, University Of Texas Southwestern Medical Center At 
Dallas/United States Of America, 3Respiratory Medicine, Nagoya Uni-
versity Graduate School Of Medicine/Japan
Background: To study the role of common lung cancer mutations 
in transforming lung epithelial cells in an appropriate cellular 
context we used cdk4/hTERT-immortalized normal HBECs. We 
developed an isogenic series of HBECs by introducing genetic 
manipulations representing common lung cancer mutations (such 
as p53, KRASV12, cMYC, and LKB1). This defined in vitro system 
allows characterization of specific tumorigenic contributions as well 
as identification of acquired changes, likely representing tumor 
acquired vulnerabilities and novel therapeutic targets (Mol Cancer 
Res 2013). One acquired change observed with oncogenic trans-
formation of HBECs is a spontaneous epithelial-to-mesenchymal 
transition (EMT), an important biologic process in cancer. This stu-
dy sought to characterize the role of EMT in driving tumorigenesis 
in HBECs and, in turn, lung cancer to identify novel therapeutic 
targets.
Methods: Genetic manipulations were introduced into cell lines 
using siRNA/shRNA or over-expression constructs. Tumorigenicity 
was measured using in vitro (anchorage-dependent and -inde-
pendent colony formation, proliferation, migration and transwell 
and EPHX3 (2.36X, p=0.081). Using a classification of dysplastic 
specimens as high or low expressers of PLK1 and/or EPHX3 (high 
> mean), we found a significant direct relationship with increased 
level of outcome diagnosis score: low expression of both genes 
(2.58); high expression of only one gene (3.60); and high expres-
sion of both (5.06). The baseline diagnosis did not differ between 
groups. Culture of the SCC cell line H2009 with EPHX inhibitor 
revealed a non-significant trend toward decreased proliferation 
(80.4% vs untreated).
Conclusion: Gene expression data confirms the biologically di-
stinct nature of persistent BD. PLK1 and EPHX3 overexpression 
demonstrate a cooperative effect in respect to increased outcome 
histology suggesting a potential role for these enzymes in persis-
tence/progression of BD via promotion of genomic instability.
Keywords: bronchial dysplasia, Malignant progression, Epoxide 
hydrolase 3, Polo-like kinase 1
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O12.03 PSEUDOGENES AS MIRNA SPONGES IN NON-
SMALL CELL LUNG CANCER
Greg L. Stewart1, Katey S. Enfield2, Stephen Lam2, Wan L. Lam2
1Integrative Oncology, British Columbia Cancer Research Centre/Cana-
da, 2Integrative Oncology, BC Cancer Research Centre/Canada
Background: Lung cancer is the most common cause of cancer 
death worldwide, with a five-year survival of less than 15%. This 
poor therapeutic outcome is largely due to complex molecular 
backgrounds as well as typically late stage at diagnosis, with most 
patients presenting with unresectable local tumours or metastatic 
disease. While mutations of driver genes is a well known mecha-
nism of tumorigenesis, approximately half of all non-small cell lung 
cancer (NSCLC) tumours harbour no known actionable oncogenic 
drivers, emphasizing the need to explore alternative mechanisms. 
New sequencing technologies have allowed investigation of pre-
viously unexplored areas of the genome and revealed that several 
classes of non coding RNAs (ncRNAs), those with no protein pro-
duct, are involved in tumourigenesis, emphasizing the need for 
further exploration and study. 
MicroRNAs (miRNAs) have emerged as major players in lung carci-
nogenesis, displaying both oncogenic and tumor suppressive func-
tions through translational inhibition of genes containing miRNA 
target sequences. Pseudogenes are non-coding relatives of prote-
in-coding genes that contain a high degree of sequence similarity 
with their parent genes, thus sharing many of the same miRNA 
target sequences. As a result, when overexpressed, a pseudogene 
can function as a miRNA "decoy“ protecting its parent gene from 
miRNA-mediated translational inhibition. DNA copy number (CN) 
alterations (gain of oncogenes/loss of tumour suppressors), is a 
major molecular mechanism driving cancer. Like protein coding 
genes, CN alterations can influence ncRNA expression levels, and 
several pseudogenes have been reported to be deregulated at the 
CN level in other cancer types. We hypothesize that pseudogenes 
of lung cancer-related genes are deregulated at the CN level in 
NSCLC.
Methods: Global CN profiles for 83 lung adenocarcinomas, and 
12 squamous cell carcinomas, as well as paired adjacent non-
malignant tissues were generated on the Affymetrix SNP 6.0 array. 
Frequencies of DNA CN alterations were assessed at candidate 
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cancers, including NSCLC. We hypothesize that the Hh/Gli signa-
ling pathway may regulate EMT in NSCLC, and inhibition of Hh/Gli 
pathway may provide a novel strategy to treat NSCLC and prevent 
metastasis.
Methods: Tumor tissues of 324 NSCLC patients were analyzed 
by immunohistochemistry for Gli and E-cadherin expression. Me-
chanistic studies were carried out in four NSCLC cell lines, A549, 
H1666, H2170 and H1703. Our lab has developed a novel small 
molecule Gli inhibitor (Gli-I )that effectively suppresses lung cancer 
in vitro and in vivo. Gli-I and a Smoothened inhibitor vismodegib 
were applied to suppress Hh/Gli signaling, while Hh protein was 
utilized to stimulate the pathway. Upon different treatments, EMT 
phenotypes were evaluated by wound healing assays and 3D cell 
invasion assays. Expression of EMT markers was measured by im-
munofluorescent staining and western blot at protein levels, as well 
as quantitative RT-PCR at mRNA levels.
Results: Our results demonstrated elevated Gli expression in 78% 
of NSCLC patient tissues. Gli expression was reversely correlated 
with E-Cadherin in patient tissues and culture cell lines. Inhibition 
of Hh signaling reduced cell migration and invasion, while stimula-
tion of Hh signaling promoted EMT phenotypes. Specifically, Gli-I 
significantly suppressed cell proliferation, migration and invasion 
more effectively than vismodegib. Furthermore, mechanistic stu-
died showed Hh/Gli signaling may regulate EMT through suppres-
sing E-Cadherin.
Conclusion: Our results suggested that SHh/Gli signaling promo-
tes cell proliferation and EMT, leading to NSCLC cell invasion and 
metastasis. Inhibition of Hh/Gli signaling by a novel Gli inhibitor 
Gli-I suppresses cell proliferation and invasion. Our novel Gli in-
hibitor holds the promise to provide an effective therapeutics to 
treat NSCLC and prevent metastasis.
Keywords: Hedgehog, Gli, EMT
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O12.07 PULMONARY FIBROBLASTS INCREASE EMT SIG-
NALING AND DECREASE SENSITIVITY TO CHEMOTHE-
RAPY IN NON-SMALL CELL LUNG CANCER CELLS VIA 
TGF-BETA AND IL-6 SIGNALING
Yasushi Shintani1, Abulimiti Abulaiti1, Toru Kimura1, Soichiro 
Funaki1, Tomoyuki Nakagiri1, Masayoshi Inoue1, Noriyoshi Sawa-
bata1, Masato Minami1, Eiichi Morii2, Meinoshin Okumura1
1Department Of General Thoracic Surgery, Osaka University Graduate 
School Of Medicine/Japan, 2Department Of Pathology, Osaka University 
Graduate School Of Medicine/Japan
Background: The tumor microenvironment is a key factor in tumor 
progression. A specific subset of stromal cells, termed cancer asso-
ciated fibroblasts (CAFs), modulate the behavior of adjacent cancer 
cells by secreting various growth factors and cytokines. The pur-
pose of this study was to clarify the roles of transforming growth 
factor (TGF)-β and interleukin (IL)-6 in the communication between 
CAFs and non-small-cell lung cancer (NSCLC) cells.
Methods: Fibroblasts obtained during surgical exploration were 
co-cultured with human lung adenocarcinoma cell lines. We de-
fined fibroblasts obtained from tumors as CAFs and those from 
normal lung tissue as lung normal fibroblasts (LNFs). Immunohisto-
Matrigel invasion assays) and in vivo (subcutaneous or intravenous 
injection into NOD/SCID mice) methods. Genome-wide mRNA ex-
pression data from five independent datasets was obtained either 
in-house using Illumina HumanHT-12v4 BeadChips or from publicly 
available databases.
Results: Analysis of EMT-promoting transcription factors in our 
isogenic series of oncogenically-manipulated HBECs found ZEB1 
expression highly correlated with mesenchymal-like HBECs. Func-
tional studies confirmed ZEB1 was a significant driver of tumorige-
nic phenotypes in both oncogenic HBECs and human lung cancer 
cell lines where loss of ZEB1 resulted in decreased colony formati-
on, migration and invasion in vitro and subcutaneous tumor growth 
and intravenous colonization in vivo. A set of ZEB1-associated 
genes was identified from analyzing five independent mRNA mic-
roarray datasets comprising both cell lines and lung adenocarcino-
mas. From this gene set we found ZEB1 directly represses ESRP1 
by binding to its promoter, which leads to increased mesenchymal 
splicing of the ESRP1 target CD44. The mesenchymal isoform of 
CD44, CD44s, conferred a CD44hi flow cytometry profile which, in 
turn, could be used to select for a highly tumorigenic subpopula-
tion in partially transformed HBECs. To identify candidate ZEB1-
activated targets we screened ZEB1-upregulated genes in a siRNA 
invasion assay. Several genes including PMP22 and CD70 could 
phenocopy ZEB1 where siRNA-mediated loss of expression led to 
decreased invasiveness in multiple NSCLC cell lines. CD70 (also 
called TNFSF7, tumor necrosis factor ligand superfamily member 
7) may represent a prime therapeutic target for anti-metastatic 
growth in lung cancer. The ligand for CD27, it is involved in immu-
ne regulation, upregulated in some cancers and is being studied as 
a potential target for antibody therapeutics. Importantly, an anti-
CD70 monoclonal antibody inhibited invasion of NSCLC cell lines 
comparably to siCD70 and siZEB1.
Conclusion: We demonstrate in vitro models of defined onco-
genic HBEC transformation provide an invaluable tool to study 
lung cancer progression where EMT is an important mediator. 
ZEB1 is spontaneously expressed with malignant transformation 
of HBECs and is a significant driver of oncogenic progression in 
both HBECs and NSCLC cells. Identification of CD70 and PMP22 
as downstream targets of ZEB1 may represent novel therapeutic 
targets for lung cancer.
Keywords: ZEB1, HBEC, EMT
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O12.06 HEDGEHOG/GLI PROMOTES EPITHELIAL-MES-
ENCHYMAL TRANSITION IN NON-SMALL CELL LUNG 
CANCER
Hui Li1, Dongsheng Yue1, Tsin Hui Tseng1, David M. Jablons1, Tiffa-
ny Cheng1, Biao He1, Michael J. Mann2
1Surgery, University Of California, San Francisco/United States Of 
America, 2Division Of Cardiothoracic Surgery, University Of California, 
San Francisco/United States Of America
Background: A majority of non-small cell lung cancer (NSCLC) 
patients are diagnosed with metastatic phenotypes. Epithelial-
to-Mesenchymal Transition (EMT), characterized by loss of epi-
thelial markers, such as E-cadherin, is suggested to be involved 
in the metastatic process. In addition, aberrant activation of the 
Hedgehog-Gli(Hh/Gli) signaling pathway is implicated in various 
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O13.01 LIMITED RESECTION TRIAL FOR PULMONARY 
GROUND-GLASS OPACITY NODULES: CASE SELECTION 
BASED ON HIGH RESOLUTION COMPUTED TOMOGRA-
PHY: INTERIM RESULTS
Junji Yoshida1, Genichiro Ishii2, Kanji Nagai1, Tomoyuki Hishida1, 
Keiju Aokage1, Hiroyuki Ito3, Tomoyuki Yokose4, Haruhiko Naka-
yama3, Kouzo Yamada5
1Department Of Thoracic Oncology, National Cancer Center Hospital 
East/Japan, 2Pathology Division, Research Center For Innovative Onco-
logy, National Cancer Center Hospital East/Japan, 3Thoracic Surgery, 
Kanagawa Cancer Center/Japan, 4Pathology, Kanagawa Cancer Center/
Japan, 5Thoracic Oncology, Kanagawa Cancer Center/Japan
Background: Japanese researchers have reported good correlati-
on between radiologic and pathologic findings in early lung ade-
nocarcinomas. For negative margin confirmation, we found a tech-
nique using lavage and cytological examination. The objective of 
this study is to confirm limited resection efficacy as radical surgery 
in patients with high-resolution (HR) computed tomography (CT) 
indicated minimally invasive lung cancer, and to confirm intraope-
rative cytology as a negative margin indicator and reliable margin 
non-recurrence predictor.
Methods: Enrollment required patients with a tumor ≤ 2 cm in 
diameter, diagnosed or suspected as a clinical T1N0M0 carcino-
ma in the lung periphery based on a CT scan. They had to have 
a HRCT scan indicating a sub-solid nodule with tumor disappea-
rance ratio; TDR ≥ 0.5. (TDR = 1- DM/DL; DM: maximum tumor 
diameter on mediastinal settings, DL: maximum tumor diameter 
on lung settings). Patients with a malignancy history within the past 
5 years or those unfit for lobectomy and systematic lymph node 
dissection were excluded. We performed a wedge or segmental 
resection. The used stapling cartridges were washed with 50 ml 
saline. Washing saline was centrifuged and sediment stained using 
Papanicolaou’s method and examined for cancer cells. If cytology 
was cancer positive, additional margin was resected, and cytologic 
examination repeated. If the second exam was positive, a routine 
lobectomy and systematic lymph node dissection was performed. 
Patients are followed up every 6 months by chest CT for the first 3 
years, and annually thereafter for at least 5 years. The initial end-
point was 5-year local recurrence free survival rate, but we are now 
looking at 10-year rate.
Results: This prospective study started in November 2003, and 
101 patients were enrolled as of November 2009. This was 4.5% 
of all resected lung cancer patients during this period, and 99 of 
them were eligible for analysis. There were 39 men and 60 wo-
men, aged 30-75, with an average 62 years. Tumor sizes ranged 
from 7 to 20 mm on high-resolution CT, averaging 15 mm. There 
were 11 Noguchi type A tumors, 54 type B tumors, 26 type C tu-
mors, one type D tumor, one malignant lymphoma, one atypical 
adenomatous hyperplasia, one atypical cuboidal cell hyperplasia, 
one alveolar hyperplasia, and 3 inflammatory fibroses. All cancers 
showed no vessel invasion. Although no positive cytology results 
were obtained, pathologically positive margin was reported af-
ter surgery in one type C patient. He later underwent a routine 
lobectomy and systematic lymph node dissection. There was no 
chemistry was used to examine the fibroblast distribution, as well 
as TGF-β and IL-6 expression in 60 tumor specimens obtained from 
patients with NSCLC after undergoing induction chemotherapy or 
chemoradiotherapy (ITx).
Results: The expression levels of myofibroblast markers were high-
er in CAFs than LNFs after 5 passages in the absence of continuing 
interaction with carcinoma cells, and we used at least 2 pairs of 
those CAFs and LNFs in the following experiments. Conditioned 
medium (CM) from both types of fibroblasts induced epithelial me-
senchymal transition (EMT) and acquisition of cancer stemness in 
lung cancer cells (A549 and NCI-H358), indicating it to be biologi-
cally active. Phenotypic changes of cancer cells by CM from CAFs 
were greater than those induced by CM from LNFs. These CAF-
induced changes were inhibited by addition of the TGF-β inhibitor 
SB431542 or IL-6 receptor neutralizing antibody (IL6-R-Ab). The 
concentrations of TGF-β1 and IL-6 were higher in CM from CAFs 
as compared to that from LNFs. Subcutaneous co-injection of lung 
cancer cells and CAFs in mice enhanced tumor growth when com-
pared with cancer cells alone, which was attenuated by administra-
tion of SB431542 or IL-6R-Ab. These findings suggested that CAFs 
may be more activated in our experimental system as compared 
to LNFs, and stimulate tumor progression via TGF-β and IL-6 sig-
naling. In addition, decreased expression of epithelial markers and 
upregulation of mesenchymal markers were detected in surgically 
resected specimens after ITx as compared with biopsy specimens 
obtained before treatment. The disease-free survival rate of pati-
ents with EMT marker-positive tumors was significantly lower than 
that of those with EMT marker-negative tumors, indicating that 
EMT changes are associated with insensitivity to ITx. Furthermore, 
an increased diffuse distribution pattern of SMA-positive activated 
fibroblasts was significantly correlated with the expression of EMT 
markers. Also, though SMA-stained fibroblasts expressed IL-6 in 
the surgical specimens, TGF-β was expressed in cancer cells as 
well as CAFs after ITx. Together, our results suggest that tumor 
stromatic tissues including CAFs increase in response to ITx, while 
CAFs secrete TGF-β and IL-6, inducing EMT in cancer cells.
Conclusion: The TGF-β and IL-6 axis induces EMT and stimulates 
tumor progression, while TGF-β and IL-6 may play roles to contri-
bute to communication between CAFs and NSCLC cells for tumor 
progression. Targeting CAFs as a therapeutic strategy against can-
cer is an intriguing concept that would benefit from further study.
Keywords: cancer associated fibroblasts, non-small-cell lung can-
cer, tumor environment, epithelial mesenchymal transition
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univariate and multivariate analysis (p<0.05, respectively). Part-so-
lid tumors with the size of solid component ≤ 17mm and CTR ≤ 0.7, 
which were obtained as cutoff values of predicting pathological 
lymph node metastasis based on the result of Receiver operating 
characteristics curves, 1(1.4%) in 73 patients with these criteria had 
pathological lymph node positive status even in the c-T1b and c-
T2a part-solid tumors on thin-section CT scan.
Conclusion: Among part-solid tumors with cN0 status, even cT1b 
and cT2a tumors with small size of solid component on thin-section 
CT scan have less frequency of nodal involvement and less invasive 
nature on pathological examination. These tumors could be can-
didates for limited surgical resection such as segmentectomy with 
nodal dissection only when enough surgical margin is warranted.
Keywords: part-solid tumors, Thin-section CT scan, segmentecto-
my
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O13.03 SURVIVAL OF 1963 LOBECTOMY-TOLERABLE 
PATIENTS WHO UNDERWENT LIMITED RESECTION FOR 
CSTAGE I NON-SMALL CELL LUNG CANCER
Motoki Yano1, Junji Yoshida2, Terumoto Koike3, Kotaro Kamey-
ama4, Akira Shimamoto5, Wataru Nishio6, Kentaro Yoshimoto7, 
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clear correlation between tumor size, TDR, and Noguchi subtype. 
No mortality occurred, but one patient developed postoperative 
pneumothorax and pneumonia, and another hemorrhagic gastric 
ulcer. With a median follow-up period of 69 months, there have 
been no recurrences.
Conclusion: So far, HRCT scans appear to predict non- or mini-
mally invasive GGO lung cancers with high reliability, warranting 
limited resection as curative surgery in this cohort. Intraoperative 
cytology reliably indicated negative margins and seems to predict 
freedom from local recurrence.
Keywords: Lung cancer, Ground-glass opacity nodule, High reso-
lution computed tomography, limited resection
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O13.02 IS THE LIMITED SURGICAL RESECTION APPRO-
PRIATE FOR NON-SMALL CELL LUNG CANCERS MORE 
THAN 2 CM IN A DIAMETER? - PROPOSED SURGICAL 
INDICATION BY THE PRESENCE OF GROUND-GLASS 
OPACITY OF THE TUMOR ON THIN-SECTION CT SCAN
Tatsuo Maeyashiki1, Takeshi Matsunaga2, Yukio Tsushima2, Kazu-
ya Takamochi2, Shiaki Oh2, Kenji Suzuki2
1Juntendo University School Of Medicine, Department Of General Tho-
racic Surgery/Japan, 2Thoracic Surgery, Juntendo University School Of 
Medicine/Japan
Background: The size of solid component is much more important 
for predicting survival than maximum tumor dimension on thin-
section CT scan in lung cancer. Moreover, the presence of ground-
glass nodule (GGN) is the other significant predictor of pathologic 
lymph node-positive status. Our previous study showed that 
tumors with the absence of GGN, i.e. pure-solid, have more patho-
logically invasive nature than tumors with the presence of GGN, 
i.e. part-solid, even if both tumors have the same size of solid com-
ponent on thin section CT. Therefore, it could be estimated that 
part-solid tumors with the small size of solid component have less 
frequency of nodal involvement, regardless of the maximum tumor 
dimension for resectable lung cancer patients.
Methods: Between February 2008 and April 2013, 306 consecuti-
ve patients with part-solid tumors that measured less than 30 mm 
in diameter of solid component and had clinically negative nodal 
involvement (cN0) on thin-section CT underwent surgical resection 
at our hospital. The findings of preoperative thin-section CT scan 
were reviewed for all 306 patients and part-solid tumors were de-
fined as a tumor containing both solid and GGN component. Con-
solidation tumor ration (CTR) of those tumors showed 0 < CTR <1.0 
and both pure GGN and pure solid tumors were excluded from 
this study. Univariate and multivariate analyses were performed 
by the logistic regression procedure to determine the relationship 
between pathological lymph node positive status and clinical or 
radiological findings.
Results: Of the 306 patients, 14 (4.6%) had pathological lymph 
node metastasis. Nodal involvement was observed in 3(1.9%) 
out of 156 patients with the maximum tumor dimension less than 
20mm, i.e. cT1a tumors, 5 (4.4%) out of 113 cT1b tumors and 6 
(16.2%) out of 37 cT2a tumors. The size of solid component on 
thin-section CT scan and consolidation tumor ratio (CTR) were 
significant predictors of pathological nodal involvement in both 
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Methods: The total 80 patients with IPF from 1995 to 2012 at Asan 
Medical Center had received pulmonary resection for NSCLC. Pre-
dictors of overall survival and disease-free survival were evaluated. 
Statistical analyses included Kaplan-Meier estimates of survival, 
log-rank tests of survival differences and multivariate Cox proporti-
onal hazards models.
Results: Lobectomy or more resection (lobectomy group) was per-
formed in 65 patients and sublobar resection (sublobar group) in 
15 patients. The median age was 66 years (range, 42 to 86 years), 
The median follow-up was 17 months (range, 0.4 to 96.5 months). 
The postoperative early mortality rate was higher at lobectomy 
group than sublobar group (15.4% versus 6.7%, p<0.3), but there 
was no difference in postoperative late mortality between sub-
lobar group and lobectomy group. (60.0% versus 56.9%, P<0.8) 
Lung cancer related death rate was higher at sublobar group than 
lobectomy group. (50.0% versus 23.4%, p=0.089), but the respi-
ratory problem related death rate was higher at lobectomy group 
than sublobar group. (76.6% versus 50.0%, p=0.089) There was no 
difference in local recurrence between two groups (20.0% versus 
7.7% P=0.15) Distant metastasis was higher at sublobar group than 
lobectomy group. (46.7% versus 10.9%, p<0.001) There was no 
difference in overall survival between two groups with a hazard 
ratio of 0.51 (95% confidence interval, 0.21 to 1.2). A disease-free 
survival of sublobar group was significantly lower than lobectomy 
group, with an increased hazard ratio of 4.7 (95% confidence inter-
val, 1.1 to 20.2, p=0.03).
Conclusion: Although sublobar group was associated with incre-
ased incidence of distant metastasis compared with lobectomy 
group but there is no difference in overall survival. Therefore, sub-
lobar resection might be considered as one of the strategy for lung 
cancer with IPF.
Keyword: NSCLC, IPF, Sublobar resection,Lobectomy
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O13.06 VIO-SOFT-COAGULATION FOR REPAIR OF AIR 
LEAK FROM DISSECTED INTERSEGMENTAL PLANE DU-
RING THORACOSCOPIC SEGMENTECTOMY
Atsushi Watanabe, Taijiro Mishina, Masahiro Miyajima, Junji 
Nakazawa
Department Of Thoracic Surgery, Sapporo Medical University/Japan
Background: The VIO soft-coagulation system is a new device 
for tissue coagulation. This system regulates the temperature 
rise below boiling point without generating sparks, which is high 
enough to denature protein. The purposes of this study are to 
evaluate the effect of intersegmental air leak repair by the use of 
Vio-soft coagulation mode (ERBE Elektromedizin GmbH, Germany) 
during thoracoscopic segmentectomy and to show how to use the 
device.
Methods: Between 2007 and 2013, we have performed 162 tho-
racoscopic segmentectomies for early stage primary lung cancer 
(In this period, 805 thoracoscopic lobectomies have been per-
formed.). Among these patients, 36 underwent anatomical inter-
segmental plane dissection only using electrocautery without any 
staplers. Inclusion criteria for thoracoscopic segmentectomy are 
as follows: 1) c-stage IA peripheral non-small cell carcinoma, 2) No 
prior chemotherapy or radiation therapy, and 3) Confirmation of 
partment Of Chest Surgery, Fukui Red Cross Hospital/Japan, 26Division 
Of Thoracic Surgery, Shizuoka City Shizuoka Hospital/Japan, 27Oncolo-
gy, Immunology And Surgery, Nagoya City University Graduate School 
Of Medical Sciences/Japan
Background: Although the standard operation for lung cancer is 
lobectomy, precise preoperative diagnosis of the “very early” lung 
carcinomas may identify patients that can be treated by limited 
resection. Previous reports on limited resection included patients 
who were not candidates for lobectomy. The survival of non-small 
cell lung cancer (NSCLC) patients who were fit for lobectomy 
and underwent limited resection has not been studied in a large 
enough scale.
Methods: A nationwide multi-Institutional project collected clinical 
data of patients who underwent limited resection (segmentectomy 
or partial resection) for clinical T1-2N0M0 non-small cell lung car-
cinoma, who were 75 years old or younger at the time of operation 
and were considered fit for lobectomy by the physician. Overall 
and disease free survival, freedom from recurrence were analyzed 
and factors affecting survival or recurrence were identified.
Results: The median age of 1963 patients was 63 years. The mean 
maximal diameter of the tumor was 1.4 ± 0.6 cm. The overall and 
recurrence free survival after limited lung resection was 93.7 % 
and 90.4 % at 5 years, respectively. The recurrence free proportion 
and local recurrence free proportion were 93.3 % and 98.4 % at 5 
years, respectively. Prognostic factors in overall survival were pa-
thologically proven lymph node metastasis, interstitial pneumonia, 
male gender, older age, complications (cardiac disease, diabetes 
etc.), radiological invasive cancer, and multiple lesions. The con-
solidation/tumor ratio on CT of ≤ 0.25 predicted good outcome 
especially in cT1aN0M0 disease. Prognosis and recurrence was 
not affected by the method of limited resection (segmentectomy 
(n=1225) or partial resection (n=738)).
Conclusion: If the patient was 75 years old or younger and was 
judged fit for lobectomy, the result of limited resection for cStage 
I NSCLC was excellent and was not inferior to the reported result 
of lobectomy for small sized NSCLC. The radiological noninvasive 
carcinomas rarely recur and are especially good candidates for 
limited resection.
Keyword: lung cancer, limited resection
LIMITED RESECTIONS  
TUESDAY, OCTOBER 29, 2013 - 10:30-12:00
O13.05 OUTCOMES OF SUBLOBAR RESECTION VERSUS 
LOBECTOMY FOR NON SMALL CELL LUNG CANCER 
(NSCLC) WITH IPF
Hee Je Sim1, Dong Kwan Kim2, Geun Dong Lee3, Se Hoon Choi3, 
Hyeong Ryul Kim2, Yong-Hee Kim2, Seung-Il Park3
1Cardiothoracic Office, Asan Medical Center East Building 13rd Floor/
Korea, 2Department Of Thoracic And Cardiovascular Surgery, Seoul 
Asan Medical Center/Korea, 3Department Of Thoracic And Cardiovas-
cular Surgery, Asan Medical Center/Korea
Background: The patients for NSCLC with IPF are having at a high 
risk of pulmonary resection. The objective of this study was to 
compare the survival rate after sublobar resection and lobectomy 
or more resection for NSCLC among patients with IPF.
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receive no preoperative chemotherapy or radiotherapy. The cor-
relation between clinicopathological factors and the nodal status 
was analyzed by logistic regression model.
Results: The prevalence of lymph node metastasis is 69/384 
(18.0%) . Univariate analysis identified tumour size, elevated CEA 
level and Standar uptake value(SUV)≥2.5 affect nodal status. 
Shown in Table1. In multivariate analysis, only tumour size (≤1cm vs 
>1-≤2cm vs >2-≤3cm,P=0.000) was found to be independent pre-
dictors of nodal metastasis. Shown in Table 2.
Conclusion: Tumour size is the only predictive factor of nodal 
metastasis for patients with cT1 lung cancer. Futher invastigation 
is recommend in omission of mediastinal lymphadenctomy in cT1 
patients with tumour size of <2cm and SUVmax<2.5.
Keywords: nodeal metastasis, Lung cancer, lymphadenctomy
N0 status by intraoperative frozen examination. Furthermore, indi-
cation criteria for anatomical intersegmental plane dissection using 
electrocautery followed by any sealing to repair air leak from diss-
ected intersegmental plane include the above-mentioned criteria 
and as follows: 1) Non-emphysematous lung, and 2) No pleural 
adhesion. In this series, we divided the intersegmental plane along 
the intersegmental vein and inflation-deflation demarcation line 
with an electrocautery (monopolar coagulation mode, 80W) and 
vessel sealing system. Soft coagulation was set at Effect 5 and 
80W for divided intersegmental sealing. The massive air leak from 
the divided intersegmental plane was repaired with suture pneu-
morrhaphy or bronchiororraphy before the coagulation. These 
patients were assigned into two groups: group A consisted of 19 
patients with air leak repair using Vio-soft coagulation system and 
group B consisted of 21 patients not subjected to the system.
Results: There was no case of conversion to thoracotomy. The 
mean operative time was 229 + 73 vs 238 + 48 min (group A vs 
group B; P=0.69), and accordingly, the mean intraoperative blood 
loss was 104 + 112 vs 115 + 115 ml (P=0.77). Total number of en-
dostapler cartridges was 1.3 vs 1.4 (P=0.99). Of course, the cart-
ridge number used for intersegmental division was zero in both 
groups. Most importantly, the fibrin sealant was used in 5 patients 
(26.3%) vs13 patients (61.9%) to repair air leak from intersegmental 
division (P=0.031). There were no major postoperative complica-
tions in both groups. There were one cases of prolonged air leak in 
group A and one (requiring redo surgery) in group B (P>0.99). The 
median chest tube duration and postoperative stay were 2.0 + 1.7 
(range 1-8 days) vs 2.4 + 0.8 days (range 2-5 days) (P=0.41) and 7.9 
+ 1.9 vs 7.9 + 2.3 days (P>0.99), respectively.
Conclusion: The VIO soft-coagulation system is safe and feasible 
for repair of dissected intersegmental plane in patients during 
thoracoscopic segmentectomy. It enables reduction in the use of 
fibrin sealant and number of endostapler cartridges in this proce-
dure without any postoperative increased air leak problem.
Keywords: Vio -Soft coaglation system, Thoracoscopic segmen-
tectomy, Lung cancer, Intersegmenteal division
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O13.07 PREOPERATIVE PREDICTIVE FACTORS OF  
NODAL METASTASIS IN PATIENTS WITH CT1 LUNG 
CANCER
Lu-Wen Ren1, Xin-Yue Wang1, Jun-Xiong Liao1, Xiang-Chan Hong1, 
Xue-Ning Yang2
1Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong 
General Hospital & Guandong Academy Of Medical Sciences/China, 
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Background: Lung cancer with small nodules(≤3cm) have less ten-
dency of local regional lymph node metastasis. We investigate the 
value of preoperative clinicopathological characteristics in predict 
regional lymph node metastasis of cT1 lung cancer patients.
Methods: A retrospective review of database identified 384 pati-
ents with cT1N0M0 lung cancer, diagnosed by CT/PET-CT/MRI and 
pathologically confirmed as primary lung cancer. All the patients 
underwent surgery (include sublobar resection, lobectomy and 
pnemonectomy) and systemic mediastinal lymphadenctomy, and 
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trials. In terms of patients with NSCLC, 21 patients were analyzable 
at 4 months, with a mean relative change in HVLT-DR from baseline 
to 4 months of +10.0% (95%CI: -9.5% to +27.1%). At 6 months, 14 
patients with NSCLC were analyzable, with a mean relative change 
in HVLT-DR from baseline to 6 months of 0.0% (95%CI: -18.5% to 
+18.5%).
Conclusion: Conformal avoidance of the hippocampus during 
WBRT is associated with memory preservation at 4 and 6 months 
follow-up in NSCLC patients, who comprised the majority of ac-
crued and analyzable patients on this trial. These promising phase 
II results warrant further validation in a phase III trial, currently un-
der development in the RTOG.
Keywords: Whole-brain radiotherapy, Hippocampal avoidance, 
cognitive function, brain metastasis
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O14.02 VERTEBRAL FRACTURES IN NSCLC PATIENTS 
TREATED WITH IMRT AND CONCURRENT CHEMOTHE-
RAPY
Wilma Uyterlinde1, Chun Chen2
1Thoracic Oncology, NKI-avl/Netherlands, 2Radiation Oncology, NKI-
avl/Netherlands
Background: Purpose To report on the incidence of vertebral 
fractures in locally advanced NSCLC patients treated with intensity 
modulated radiation therapy (IMRT) and concurrent chemotherapy. 
The RT dose to the vertebra was analyzed for its association with 
fractures.
Methods: A total of 524 patients were treated between 2007 and 
2011, with hypofractionated IMRT (66Gy/24fx) and concurrent 
daily low dose cisplatin. Planning and follow-up CT or MRI scans 
were retrospectively utilized to identify vertebral collapse by an 
experienced radiologist and a technician. Clinical and dosimetric 
parameters were retrospectively collected. Patients were exclu-
ded if they had no follow-up CT/MRI scan; had prior irradiation for 
thoracic or head and neck cancer; showed a vertebral fracture in 
the planning CT; or had vertebral collapse due to other causes. 
First, we reported the incidence of vertebral fractures. Afterwards, 
we analyzed the RT dose effect relationship using the maximum 
(Dmax) and mean (Dmean) dose to each vertebra. Dose-response 
was modeled using Cox model with patient as random effect. Data 
were analyzed using R, package “coxme”.
Results: Three hundred and thirty six patients were eligible for 
analysis. The median follow-up was 24 months The median age 
was 64 years (range 32-87); 40% of the patients female and 94% 
had a performance score (PS) 0-1. Twenty-eight (8%) patients de-
veloped ≥ 1 vertebral fracture; 22 had 1 vertebral fracture, 5 had 2 
and 1 patient had 3 vertebral fractures. All fractures were located 
from the 6th-8th thoracic vertebra.The median onset time for the 
fracture was 7 months (range 2-26). The median age for the 28 
fractured patients was 70 years (range 42-82); 61% were female, 
89% had a PS of 0-1. The median Dmax was 40Gy (range 0-83) 
and 72Gy (range 42-83) for non-collapsed and fractured vertebrae, 
respectively. The median Dmean was 12Gy (range 0-65) and 51Gy 
(range 18-71) for non-collapsed and collapsed vertebras, respec-
tively. Both Dmax and Dmean were significantly (p<0.001) associa-
ted with vertebral fractures.
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O14.01 MEMORY PRESERVATION WITH CONFORMAL 
AVOIDANCE OF THE HIPPOCAMPUS DURING WHOLE-
BRAIN RADIOTHERAPY FOR PATIENTS WITH BRAIN ME-
TASTASES: PRELIMINARY RESULTS OF RTOG 0933
Vinai Gondi1, Minesh P. Mehta2, Stephanie Pugh3, Wolfgang A. 
Tome4, Benjamin Corn5, Chip Caine6, Andrew Kanner5, Howard 
Rowley7, Vijayananda Kundapur8, Jeffrey N. Greenspoon9, Andre 
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Background: Preclinical and clinical evidence suggests that hippo-
campal dose during whole-brain radiotherapy (WBRT) plays a role 
in cognitive decline. This may be preventable by conformally avoi-
ding the hippocampus during WBRT (HA-WBRT). RTOG 0933 was 
a single-arm phase II study of HA-WBRT for brain metastases with 
cognitive function assessments and pre-specified comparison to a 
historical control of WBRT without hippocampal avoidance.
Methods: Eligible adult patients with brain metastases received 
HA-WBRT to 30 Gy in 10 fractions. Standardized cognitive func-
tion assessments were performed at baseline, 2, 4, and 6 months. 
The primary endpoint was change in the Hopkins Verbal Learning 
Test-Revised Delayed Recall (HVLT-DR) at 4 months. The histo-
rical control consisted of brain metastases patients treated with 
WBRT on the PCI-P-120-9801 phase III trial, which demonstrated 
a 30% mean relative loss in HVLT-DR from baseline to 4 months. 
To detect a minimum relative 50% improvement in this end-point, 
leading to an absolute 15% or less mean relative loss in HVLT-DR 
following HA-WBRT, 51 analyzable patients were required to ensu-
re 80% statistical power with a one-sided alpha=0.05.
Results: 113 patients were accrued from April 2011-November 
2012; 56 out of 100 eligible patients had non-small cell lung 
cancer (NSCLC). One grade 3 toxicity of cerebral edema and no 
grade 4 or higher toxicities were reported. Median survival was 
6.9 months (95% confidence interval (95% CI) 4.8-15.2 months). 
41 patients were analyzable at 4 months. Mean relative change 
in HVLT-DR from baseline to 4 months was +3.3% (95%CI: -8.0% 
to +14.6%), which was significant in comparison to the historical 
control (p<0.0001) and substantially exceeded the hypothesized 
-15% value. 28 patients were analyzable at 6 months with a mean 
relative change in HVLT-DR from baseline to 6 months of +4.6% 
(95%CI: -8.6% to +17.8%), a finding in dramatic contrast to expec-
ted continued deterioration in HVLT-DR scores from other WBRT 
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Brachial plexopathy was significantly associated with BP BED Dmax 
(p=0.002), and D05 (p=0.015), but not with physical dose. Using 
LR, the strongest correlation of gEUD with brachial plexopathy 
occurred for log10a= 1.0 using BED (p=0.002), which is represen-
tative of the BED Dmax. LR models of BED Dmax versus brachial 
plexopathy for various α/β values showed that any α/β<25 was a 
significantly better predictor than physical dose.
Conclusion: Brachial plexopathy is significantly associated with 
BED Dmax ≥117.5 Gy (equivalent to a physical dose of 17 Gy x1, 9.3 
Gy x3 or 7 Gy x5 fractions) and D05 ≥89.3 Gy. BED Dmax was the 
most important predictor of this rare but serious toxicity.
Keywords: SBRT, Brachial Plexopathy
RADIOTHERAPY - TOXICITY AND CLINICAL TRIALS  
TUESDAY, OCTOBER 29, 2013 - 10:30-12:00
O14.05 EFFECT OF POSTOPERATIVE 3D-CONFORMAL 
RADIOTHERAPY (3DCRT) FOR PATIENTS WITH PIIIA-N2 
NON-SMALL-CELL LUNG CANCER (NSCLC) AFTER COM-
PLETE RESECTION AND ADJUVANT CHEMOTHERAPY: 
INTERIM ANALYSIS OF A PROSPECTIVE PHASE III STUDY
Zhouguang Hui, Jun Liang, Jima Lv, Xiaozhen Wang, Zongmei 
Zhou, Qinfu Feng, Zefen Xiao, Dongfu Chen, Hongxing Zhang, 
Weibo Yin, Luhua Wang
Cancer Hospital & Institute, Chinese Academy Of Medical Sciences/
China
Background: For patients with completely resected pIIIA-N2 
NSCLC, the role of postoperative radiotherapy (PORT) is not well 
defined. 3D-conformal radiotherapy (3DCRT) can deliver high dose 
to the target volume while decreasing the toxicity of normal tissu-
es, which may improve the treatment outcomes. This interim ana-
lysis of our phase III randomized clinical trial (NCT00880971) is to 
evaluate the effect of postoperative 3DCRT on the overall survival 
(OS) and failure pattern in pIIIA-N2 NSCLC patients after complete 
resection and adjuvant chemotherapy.
Methods: Between Jan. 2009 and May 2012, 128 consecutive 
patients with pIIIA-N2 NSCLC, after complete resection and four 
courses of platinum based chemotherapy, were randomized into 
PORT group or control group. Only patients who had finished 
the first follow-up 3 months after treatment were included in this 
interim analysis. PORT, using 3D conformal techniques, was 60 Gy 
by 30 fractions to the subcarinal nodes, ipsilateral mediastinum 
and ipsilateral hilum. The effect of PORT on survival was evaluated 
with Kaplan-Meier method and log-rank test. The treatment failure 
pattern was also analyzed. Pearson chi-Square test was used to 
compare the constituent ratios in different groups.
Results: Totally 96 patients were analyzed, including 49 in the 
PORT group and 47 in the control group. The clinical features were 
comparable between the two groups. For all the patients, the 3-y 
OS, disease free survival (DFS), loco-regional recurrence free survi-
val (LRFS) and distant metastasis free survival (DMFS) were 68.4%, 
54.6%, 68.6% and 63.0%, respectively. The survival rates of pati-
ents in the PORT and control groups are listed in the table. PORT 
markedly increased the 3-y OS, DFS, LRFS and DMFS by 21.6%, 
18.7%, 16.4% and 20.4%, respectively. But the difference was not 
statistically significant due to the limited samples. There were 33 
patients (34.3%) with treatment failure, including 7 (7.3%) with loco-
regional recurrence only, 13 (13.5%) with distant metastasis only, 
Conclusion: Vertebral fractures were retrospectively identified in 
8% of NSCLC patients treated with IMRT and concurrent chemo-
therapy. The median onset time was 7 months. Both Dmax and 
Dmean of the vertebra were significantly associated with collapse 
in the collapsed population. A case-control study is in progress to 
analyze the dose-response relationship in the entire population 
and incorporate clinical variables, such as age, performance status 
and menopause status.
Keywords: IMRT, vertebral fractures, NSCLC
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O14.03 USING GENERALIZED EQUIVALENT UNIFORM 
DOSE (GEUD) TO MODEL VOLUME EFFECTS FOR BRA-
CHIAL PLEXOPATHY AFTER HIGH-DOSE STEREOTACTIC 
BODY RADIATION THERAPY (SBRT)
Shaun U. Din1, Eric L. Williams2, Yoshiya Yamada1, Ellen Yorke2, 
Amanda Foster1, Emily Poppens1, Abraham J. Wu1, Andrew Jack-
son2, Andreas Rimner1
1Radiation Oncology, Memorial Sloan-Kettering Cancer Center/United 
States Of America, 2Medical Physics, Memorial Sloan-Kettering Cancer 
Center/United States Of America
Background: Brachial plexopathy is a rare but important toxicity 
of radiation therapy because of its significant impact on quality of 
life. For standard fractionated raiation therapy, good models of 
brachial plexus (BP) tolerance exist. However, the tolerance of the 
BP to SBRT is not well understood. We combined data from SBRT 
for apical lung and metastatic lesions near the BP spanning a wide 
range of doses and hypofractionation schemes. We determined 
the clinical incidence of brachial plexopathy and modeled the cor-
relation with generalized equivalent uniform dose (gEUD) for both 
physical and biologically effective doses (BED) using a range of 
fractionation-sensitivity parameters (α/β) and volume effect para-
meters (a).
Methods: Between 2004 and 2012, 180 lesions (76 lung lesions 
and 104 metastatic lesions) located above the aortic arch and 
below the level of C3 were treated with SBRT. Patients with prior 
radiation therapy to this region were excluded. Metastases were 
treated to 14-30 Gy in 1-5 fractions and lung tumors to 22-60 Gy 
in 1-5 fractions. The BP was contoured per RTOG atlas definitions. 
For 54 centrally located spine metastases, both left and right BP 
were contoured and analyzed separately for a total of 234 BPs in 
180 patients. Brachial plexopathy of ≥grade 1 (CTCAE v4.0) was 
the primary endpoint. Maximum dose to the BP (Dmax), minimum 
dose to the hottest 5% of the BP (D05), and their respective BEDs 
were calculated using α/β= 3 Gy. The gEUD was also calculated 
with the volume effect parameter (a) ranging from log10a= -1.0 to 
+1.0 in log10a steps of 0.1. A logistic regression model (LR) was fit 
to the data as a function of a. Clinical dose recommendations were 
derived with logrank tests using median splits.
Results: With median follow-up of 15.1 months, brachial plexo-
pathy due to SBRT occurred in 9/234 BPs. Severity of brachial 
plexopathy was grade 1 in two, grade 2 in five and grade 3 in two 
patients. Median time to onset of brachial plexopathy was 6.2 
months and the 1-/2-year actuarial rates were 3.3%/5.6%. For all 
patients the median BED for BP Dmax was 117.5 Gy and for D05 
was 89.3 Gy. Median BED Dmax for patients with and without bra-
chial plexopathy was 234 Gy and 115.2 Gy respectively (p=0.002). 
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Results: Of the 116 patients consented, 70 (85 paired responses) 
completed all 3 questionnaires for at least one time point exclu-
ding baseline. Median age was 71.5 years (39-89 years), 54.3% of 
the patients were male and 85.7% had a diagnosis of non-small 
cell lung cancer. Agreement between patients’ and clinicians’ re-
ported toxicity ranged from poor to substantial (Figure 1). Perfect 
agreement was ≥50% for all assessed items with the exception of 
PS for both the end of radiotherapy and FU. The majority of discre-
pancies (≥74%) differed by 1 grade of toxicity. At the end of radio-
therapy patients reported greater severity than clinicians for all 
items but not for PS; however this was less pronounced at FU. QoL 
scores were generally more strongly correlated with the patients’ 
compared to clinicians’ matching toxicity grades at the exception 
of dyspnoea. The correlation of HADS scores with patients’ CTCAE 
anxiety and depression grades ranged from moderate-to-low to 
moderate. There was no correlation with clinicians’ grading for de-
pression and no-to-moderate correlation for anxiety. The adapted 
Radiogenomics Biorepository and Databank lung questionnaire 
demonstrated a high Cronbach’s α value (0.848) indicating good 
reliability. 
and 13 (13.5%) with the both. PORT markedly decreased the loco-
regional recurrence from 27.7% to 14.3% (P=0.107), but not the 
distant metastasis (from 29.8% to 24.5%, P=0.559). Eight deaths 
were observed up to the last follow-up, which were all caused by 
cancer progression. No death caused by radiation toxicities was 
observed. 
All  
Patients 
(n=96) 
PORT 
Group 
(n=49) 
Control 
Group  
(n=47) 
P Value* 
OS 68.4% 80.8% 59.2% 0.432 
DFS 54.6% 64.2% 45.5% 0.256 
LRFS 68.6% 76.4% 60.0% 0.105 
DMFS 63.0% 67.1% 46.7% 0.542 
 
*Between PORT and control groups.
Conclusion: For pIIIA-N2 NSCLC patients after complete resection 
and adjuvant chemotherapy, postoperative 3DCRT can markedly 
improve the survival and loco-regional control. Further accumulati-
on of patients in our prospective randomized study is warranted.
Keywords: survival, Non–Small-Cell Lung Cancer, postoperative 
radiotherapy, IIIA-N2
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O14.06 INVESTIGATION OF A PATIENT REPORTED OUT-
COME (PRO) TOOL TO ASSESS RADIOTHERAPY-RELA-
TED TOXICITY IN PATIENTS WITH LUNG CANCER
Marianna Christodoulou1, Paula Mccloskey1, Nicola Stones1, Neil 
Bayman2, Paul Burt2, Abbas Chittalia2, Margaret Harris2, Lip W. 
Lee2, Laura Pemberton2, Hamid Sheikh2, Ric Swindell2, Corinne 
Faivre-Finn1
1Radiotherapy Related Research, The Christie NHS Foundation Trust/
United Kingdom, 2The Christie NHS Foundation Trust/United Kingdom
Background: Discrepancies between clinician and patient repor-
ted symptoms validate the investigation of a PRO tool in clinical 
trials and routine practice. There is a paucity of data regarding the 
feasibility and relevance of PRO tools to assess radiotherapy toxici-
ty in patients with lung cancer.
Methods: From January to June 2013, lung cancer patients under-
going thoracic radiotherapy or chemo-radiotherapy completed 
a PRO toxicity tool (adapted Radiogenomics Biorepository and 
Databank lung questionnaire) consisting of 9 patient-adapted 
Common Terminology Criteria for Adverse Events (CTCAE) items 
and World Health Organisation (WHO) performance status (PS) at 
baseline, at the end of radiotherapy and at 4-10 weeks follow-up 
(FU). At the same time points, patients completed the European 
Organisation for Research and Treatment of Cancer Quality of Life 
(QoL) Questionnaire along with its lung cancer specific module 
(EORTC QLQ-C30/LC13) and the Hospital Anxiety and Depression 
Scale (HADS). Clinicians completed the same CTCAE items for 
each time point. Agreement between patients’ and clinicians’ toxi-
city reports was assessed using weighted kappa coefficients. The 
patients’ QoL and HADS scores were correlated with the patients’ 
and clinicians’ reported toxicity using Spearman rank correlation 
coefficients.
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Conclusion: The use of a PRO tool in radiotherapy for lung cancer 
is feasible, reliable and acceptable to patients and complements 
the clinicians’ assessment. Further research is required to evaluate 
its validity.
Keywords: Toxicity, radiotherapy, patient-reported outcome, Lung 
cancer
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prescription dose limit was only rarely associated with an oesopha-
geal dose higher than 71Gy). Median follow up was 11 months (ran-
ge 2,24); median age 66 years (range 43-84); 74% male; 39%/60% 
WHO 0/1; 30% adenocarcinoma, 54% squamous. Mean GTV 121cc 
(range 14-602cc). Mean prescribed dose for patients completing 
RT (n=80) 67.6Gy (range 63-73Gy) in Arm 1 and 70.1 Gy (63-73) in 
Arm 2. Mean 1cc-oesophageal-dose in Arm 1 55.5Gy (range 14.2-
68.0Gy). In Arm 1 grade 3+ oesophagitis was 6% (3/49). In Arm 2, 
Grade 3+ oesophagitis was 17% (2/12) at 68Gy; no Grade 3+ oe-
sophagitis in 65Gy (0/12) and 71Gy (0/10) cohorts. Grade 3+ RTPN 
2% (1/49) in Arm 1 and 6% (2/35) in Arm 2. 1 year OS and PFS rates 
were 92% and 74% respectively.
Conclusion: Isotoxic RT dose escalation was safe and feasible. The 
MTD for oesophagus was not reached. Acceleration of the IDEAL-
CRT schedule to five weeks is under investigation in a second stu-
dy, currently recruiting.
Keywords: radiotherapy, Isotoxic, dose-escalation, Oesophagitis
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O14.07 IDEAL CRT: ISOTOXIC DOSE ESCALATION AND 
ACCELERATION IN LUNG CANCER CHEMORADIOTHE-
RAPY - A PHASE I/II TRIAL OF CONCURRENT CHEMO-
RADIATION WITH DOSE-ESCALATED RADIOTHERAPY 
IN PATIENTS WITH STAGE II OR STAGE III NON-SMALL 
CELL LUNG CANCER.
David B. Landau1, Iftekhar Khan2, Yenting Ngai2, Laura L. Hughes2, 
Elizabeth Miles3, Dean Wilkinson3, Emma Parsons3, Philip Mayles4, 
Helen Mayles4, Andrew T. Bates5, Nazia Mohammed6, Jonathan 
Hicks6, Susan Harden7, Marianne Illsley8, Angel Garcia9, Zafar Ma-
lik4, Simon Hughes1, James Spicer10, Angela Baker4, Paula Wells11, 
Virginia Laurence12, John Fenwick13
1Dept. Of Oncology / Radiotherapy, Guy‘s Hospital/United Kingdom, 
2Cancer Research Uk & Ucl Cancer Trials Centre, Ucl/United Kingdom, 
3National Trials Qa Team, Mount Vernon Hospital/United Kingdom, 
4Medical Physics, Clatterbridge Cancer Centre/United Kingdom, 5Radio-
therapy Department, Southampton General Hospital/United Kingdom, 
6Radiotherapy Department, Beatson West Of Scotland Cancer Centre/
United Kingdom, 7Addenbrooke‘s Hospital/United Kingdom, 8St Luke‘s 
Cancer Center - Radiotherapy, Royal Surrey County Hospital/United 
Kingdom, 9North Wales Cancer Center - Radiotherapy, Glan Clwyd 
Hospital/United Kingdom, 10Medical Oncology, King‘s College/United 
Kingdom, 11Radiotherapy Department, St Bart‘s Hospital/United King-
dom, 12Dorset Cancer Centre - Radiotherapy Department, Poole Hospi-
tal/United Kingdom, 13Department Of Oncology, University Of Oxford/
United Kingdom
Background: The IDEAL-CRT trial uses an individual patient ap-
proach to radiotherapy (RT) dose escalation, escalating the dose 
within a fixed overall treatment time, 6 weeks, by increasing dose 
per fraction. Isotoxic RT is based on the calculated risk of RT-pneu-
monitis (RTPN), RT dose being escalated so that all patients are 
exposed to the same RTPN risk. We investigated the feasibility and 
safety of individualised, isotoxic dose escalation for once daily RT 
delivered in 30 once-daily fractions with concurrent chemotherapy.
Methods: Eligibility; NSCLC stage II/III, PS 0/1, FEV1 (≥40% pre-
dicted or ≥1L), DCLO (≥40% predicted). A radiobiological model 
was used to individualize RT dose-prescription – selecting a dose 
which, in 30# once daily for 6 weeks, is associated with a 10% 
risk of grade 3+ RTPN, but limiting prescribed doses to between 
63Gy - 73Gy (2Gy dose equivalent α:β=10, 63.5Gy-86Gy). Dose 
constraints were fixed for spinal cord, heart, brachial plexus. In 
Arm 1, initially the maximum dose to 1cc oesophageal did not 
exceed 63Gy. Arm 2 comprised patients in whom oesophageal 
dose rather than lung dose limited the prescription dose: the oe-
sophageal dose was raised from 65Gy to 68Gy, 71Gy and 73Gy 
in consecutive cohorts, the prescribed dose lying between 63Gy 
and 73Gy and being the highest consistent with the oesophageal 
limit. Dose escalation was determined using a 6+6 design. Dose 
limiting toxicity (DLT) was defined as Grade 3+ oesophagitis. MTD 
was determined if grade 3+ oesophagitis >42% (>5/12). Two cycles 
of Cisplatin-Vinorelbine chemotherapy given concurrently during 
RT. All contouring and dosimetry on planning CT scans was cen-
trally reviewed. IMRT was introduced in November 2012. Primary 
endpoints: oesophagitis and RTPN. Serial pulmonary function tests 
and ECGs performed. Efficacy endpoints: overall survival (OS), 
progression free survival (PFS), and tumour response.
Results: Between October 2010 and February 2013, 84 patients 
recruited (9 UK centres), 49 patients Arm 1, 35 patients Arm 2 (13 
at 65Gy, 12 at 68Gy, 10 at 71Gy; none at 73Gy as the 73Gy upper 
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Conclusion: Our study demonstrates that a “watch and wait” strat-
egy is potentially detrimental to patients because a significant pro-
portion never receives chemotherapy. A decline in ECOG status 
accounts for 50% of the “missed” chemotherapy. Frequent follow 
up should be employed for patients who are on a WW approach to 
ensure the window of opportunity for chemotherapy is not lost.
Keywords: advanced non-small cell lung cancer, Population-based 
analysis, Watch and wait
NSCLC - CHEMOTHERAPY II  
TUESDAY, OCTOBER 29, 2013 - 10:30-12:00
O15.02 THE SPANISH LUNG CANCER GROUP (SLCG) 
BRCA1-RAP80 EXPRESSION CUSTOMIZATION (BREC) 
RANDOMIZED PHASE III TRIAL OF CUSTOMIZED 
CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL 
LUNG CANCER (NSCLC) PATIENTS WITH WILD-TYPE 
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) 
(NCT00617656/GECP-BREC)
Rafael Rosell1, Teresa Moran1, Manuel A. Cobo Dols2, Manuel Do-
mine3, Maria Sanchez-Ronco4, Isabel Bover5, Mariano Provencio6, 
Bartomeu Massuti7, Alain Vergnenegre8, Guillermo Lopez-Vivan-
co9, Gilles Robinet10, Amelia Insa11, Margarita Majem12, Ramon De 
Las Peñas13, Maria Angeles Sala14, Dolores Isla15, Nathalie Baize16, 
Javier Garde17, Imane Chaib1, Carlos Camps18
1Catalan Institute Of Oncology/Spain, 2Medical Oncology, Hru Carlos 
Haya/Spain, 3Oncology, Fundacion Jiménez-díaz/Spain, 4Statistics, Uni-
versity Of Alcala De Henares/Spain, 5Oncology, Hospital Son Llatzer/
Spain, 6Oncology, Hospital Puerta De Hierro/Spain, 7Oncology, Hospital 
General De Alicante/Spain, 8Service De Pneumologie, Centre Hospita-
lier Universitaire De Limoges/France, 9Oncology, Hospital De Cruces 
De Barakaldo/Spain, 10Oncology-pneumology, Hôpital Morvan/France, 
11Oncology, Hospital Clínico Universitario/Spain, 12Servei D’Oncologia, 
Hospital De Sant Pau/Spain, 13Oncology, Hospital De Castellon/Spain, 
14Oncologia, Hospital De Basurto/Spain, 15Oncology, Hospital Lozano 
Blesa/Spain, 16Oncology, Hôpital De L‘archet/France, 17Oncology, Hospi-
tal Arnau De Vilanova/Spain, 18Oncology, Hospital Clínico Universitario 
De Valencia/Spain
Background: RAP80, a component of the BRCA1 complex, influ-
enced outcome both in p with low BRCA1 expression treated with 
cisplatin (cis)/gemcitabine (gem) and in p with intermediate/high 
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O15.01 EVALUATION OF A "WATCH AND WAIT“ AP-
PROACH FOR PATIENTS WITH NEWLY DIAGNOSED AD-
VANCED NON-SMALL CELL LUNG CANCER IN A DIVER-
SE COMMUNITY POPULATION
Krista Noonan, Janessa Laskin, King Mong Tong, Nevin Murray, 
Barbara Melosky, Sophie Sun, Cheryl Ho
Medical Oncology, BC Cancer Agency/Canada
Background: The current treatment paradigm for metastatic non-
small cell lung cancer (NSCLC) includes systemic therapy, radio-
therapy or both. A “watch and wait” approach (WW) is commonly 
used in clinical practice. Whether this approach would have any 
effect on survival outcomes has not previously been evaluated.
Methods: The British Columbia Cancer Agency (BCCA) provides 
comprehensive cancer care to a population of 4.5 million across 
944735 sq kms. A retrospective review was conducted of all refer-
red patients diagnosed with stage IIIb/IV NSCLC from January to 
December 2009 in BC who saw a medical oncologist (MO). Patient 
characteristics, treatment recommendations, and outcomes were 
abstracted. WW-treated is defined as initial observation with che-
motherapy > 8 weeks from MO consult. WW-missed are patients 
who were on a WW strategy that did not receive chemo. Kaplan-
Meier survival analysis was compared using log rank test. Cox 
proportional hazards modeling was used to evaluate prognostic 
factors and control for potential confounders.
Results: 710 patients were seen by a MO. Median age 66 years 
(29-90), ECOG 0-1 51%, male 52%, non squamous/squamous/NOS 
40%/19%/41%, rural/urban 19%/81%. 327 received upfront chemo, 
171 WW and 209 deemed chemo ineligible due to poor ECOG, 
and comorbidities. Of the 171 patients on a WW approach 44% 
missed an opportunity for chemotherapy (Figure 1). Reasons for 
WW-missed included poor ECOG (50%), death (47%), asymptoma-
tic (1%), and illness (1%). Median OS was highest in the WW-treated 
16.5 months (CI 12.7-20.3), followed by 13.9 months (CI 12.0-15.8) 
in the upfront chemo and lowest in the WW-missed 5.9 months (CI 
4.4-7.4), p<0.0001. On multivariate analysis, factors predicting a 
poorer OS included ECOG >2, squamous histology, and a shorter 
the time from diagnosis to referral and referral to MO consult. 
When controlled for confounding factors (age, sex, ECOG) OS was 
similar between the upfront chemo and WW-treated (HR 1.16, CI 
0.849-1.58, p=0.353), while those who were in the WW-missed had 
a significantly lower OS (HR 5.54, CI 3.00-10.24, P<0.0001). 
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Lamy14, Bartomeu Massuti15, Cecile Dujon16, Ghislaine Fraboulet17, 
Johanna Minguet18, Carine Plassot18, Herve Lena19
1Pneumology, Chu Pontchaillou/France, 2Service De Pneumologie, Cen-
tre Hospitalier Intercommunal De Creteil/France, 3Multidisciplinary 
Oncology And Therapeutic Innovations, Assistance Publique-hôpitaux 
De Marseille, Aix Marseille University/France, 4Centre Hospitalier De 
Draguignan/France, 5Department Of Pneumology, Chits Toulon/France, 
6Service De Pneumologie, Centre Hospitalier Universitaire D‘ Angers/
France, 7Pneumologie, Hôpital D‘instruction Des Armées Sainte-anne/
France, 8Pneumology, Centre Hospitalier De Villefranche Sur Saône/
France, 9Oncology, Centre Oscar Lambret/France, 10Service De Pneu-
mologie, Centre Hospitalier Universitaire De Limoges/France, 11Pneu-
mology, Ch Departemental/France, 12Pneumologie, Centre Hospitalier 
D‘annecy/France, 13Clinique Pneumologique, Hôpital Charles Nicolle/
France, 14Morbihan, Service D‘oncologie Hôpital De Bretagne Sud/
France, 15Medical Oncology, Alicante University Hospital/Spain, 16Pneu-
mology, Hôpital A. Mignot/France, 17Service D‘onco-hématologie, Ch 
René Dubos-pontoise/France, 18Unité De Biostatistique, Institut Univer-
sitaire De Recherche Clinique/France, 19Service De Pneumologie, Hôpital 
Pontchaillou/France
Background: Incidence of advanced NSCLC in the elderly is incre-
asing. The use of a CGA is recommended to detect the patient’s 
vulnerability but its integration in treatment decision making has 
never been prospectively evaluated. The main objective of this 
study was to show that, compared to a standard strategy based 
on PS and age, the use of a CGA can improve the management of 
NSCLC in first line.
Methods: Randomized, multicentric, prospective phase III study 
in patients ≥70 y, PS 0-2 with stage IV NSCLC. We compared in 
arm A a standard algorithm of chemotherapy allocation based 
on PS and age: carboplatin based doublet in PS≤1 and age ≤75y, 
mono-therapy in PS =2 or age >75y with in arm B an experimental 
strategy of treatment allocation based on CGA: carboplatin based 
doublet for fit patients, mono-therapy for vulnerable patients and 
BSC for frail patients. Carboplatin (AUC5,d1), was associated to pe-
metrexed (500 mg/m2,d1) in non-squamous tumors and to gemci-
tabine (1000 mg/m2, d1-8) in squamous tumors, monotherapy was 
docetaxel 38 mg/m2 (d1-8). Four cycles of chemotherapy were to 
be given every three weeks. The main endpoint was time to failure 
treatment (TTF=duration between the date of randomization and 
the date the patient was withdrawn from treatment for any reason 
(progression, toxicity, death), secondary endpoints were Overall 
Response Rate (ORR), overall survival (OS), toxicity and quality of 
life (QoL), survival adjusted on QoL .
Results: 493 patients were randomized from 01/2010 to 01/2013 by 
45 centers. Patients characteristics were: male: 74%, median age: 
77 (70-91) years, non-squamous histology: 71.8%, PS 0-1: 81.4%, 
ADL<6:13.9%, IADL<4:27.5%, Charlson’s index ≥2: 23%, score GDS 
5≥3:2.5%. The 2 arms were well-balanced for patients characteris-
tics except for ADL<6 (17.4% in arm A vs 10.3% in arm B). Respec-
tively in arms A and B, 34.4% and 47% patients received a carbo-
platin based doublet, 65.6% and 31.5% received docetaxel and in 
arm B 21.5% received BSC. There was no significant difference in 
terms of TTF, respectively for arm A and arm B: median TTF was 99 
days (d), 95%CI:[89; 126] vs. 98 d, 95%CI:[81;135], p=0.7149 and in 
terms of mOS: 196 d in arm A, 95%CI [171;231] vs. 185 d in arm B 
,95%CI [148;235], p=0.7784. All grades toxicities were significantly 
less frequent in arm B than in arm A (93% vs.86.2%, p=0.016), but 
there was no difference in terms of grade 3-4 toxicities. All the 
secondary endpoints data will be updated at time of the meeting.
Conclusion: this large phase III study failed to show a superiority 
of a CGA based strategy of treatment allocation in terms of TTF. In 
BRCA1 levels treated with cis/docetaxel (doc) or with doc alone in 
the SLCG phase II customized chemotherapy trial (NCT00883480). 
Based on these findings, the SLCG and the French Lung Cancer 
Group performed a prospective, randomized phase III trial in me-
tastatic NSCLC patients to compare non-customized cis/doc with 
customized therapy customized according to BRCA1 and RAP80 
mRNA expression levels.
Methods: From 2008 to 2013, patients with wild-type EGFR were 
randomized 1:1 to the control or experimental arm. Planned accru-
al was 391 patients. Treatment in the control arm was cis/doc, while 
patients in the experimental arm received treatment according to 
their BRCA1 and RAP80 levels: 1) those with low RAP80, regardless 
of BRCA1 levels, received cis/gem; 2) those with intermediate/high 
RAP80 and low/intermediate BRCA1 received cis/doc; and 3) those 
with intermediate/high RAP80 and high BRCA1 received doc alo-
ne. The primary endpoint was progression-free survival (PFS).
Results: At 15 October 2012, 279 patients had been included and 
the planned interim analysis was performed. PFS was 5.49 months 
(m) in the control and 4.38 m in the experimental arm (P=0.07). 
Overall survival (OS) was 12.66 m in the control and 8.52 m in the 
experimental arm (P=0.006). Response rate (RR) was 37.3% in the 
control and 27% in the experimental arm (P=0.07). In the multivari-
ate analysis including PS, treatment arm, BRCA1, RAP80, histology, 
smoking status and metastatic site, only extrathoracic metastases 
were associated with an increased risk of progression (HR, 1.78; 
P=0.02). In a post hoc analysis restricted to patients with ECOG 
PS 0, PFS was 3.91 m in the control and 7.47 m in the experimental 
arm (P=0.01) for those with low RAP80 levels (experimental group 
1). PFS for patients in experimental groups 1, 2 and 3 was 7.47, 7.01 
and 3.22 m, respectively (P=0.02). OS for patients in experimen-
tal groups 1, 2 and 3 was 28.88, 15.86 and 11.81 m, respectively 
(P=0.04).
Conclusion: Based on the negative results for PFS at the interim 
analysis, accrual was closed on this study. The negative results may 
be due to the poor predictive capacity of RAP80 and/or to the 
inclusion of doc alone as a treatment in the experimental arm. In 
addition, doc/cis may not have been the ideal combination for the 
control arm. Customized chemotherapy could be further encoura-
ged in oncogene-driven pan-negative patients with PS 0.
Keywords: BRCA1, RAP80, Phase III trial, NSCLC
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O15.03 PHASE III, RANDOMIZED, MULTICENTER STUDY 
COMPARING IN ELDERLY PATIENTS (≥70 YEARS) WITH 
STAGE IV NON SMALL-CELL LUNG CANCER (NSCLC) A 
STANDARD STRATEGY OF TREATMENT ALLOCATION 
(CARBOPLATIN BASED BI-THERAPY OR MONOTHERA-
PY WITH DOCETAXEL) BASED ON PERFORMANCE STA-
TUS (PS) AND AGE WITH AN EXPERIMENTAL STRATEGY 
ALLOCATING THE SAME CHEMOTHERAPIES OR BEST 
SUPPORTIVE CARE (BSC) ACCORDING TO A COMPRE-
HENSIVE GERIATRIC ASSESSMENT (CGA) - STUDY ESO-
GIA-GFPC-GECP 08-02.
Romain Corre1, Christos Chouaid2, Laurent Greillier3, Herve Le 
Caer4, Clarisse Audigier-Valette5, Nathalie Baize6, Henry Berard7, 
Lionel Falchero8, Isabelle Monnet2, Eric Dansin9, Alain Vergneneg-
re10, Marie Marcq11, Chantal Decroistte12, Suzanna Bota13, Regine 
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Results: From April 2007 through December 2008, 608 patients 
were randomly assigned to SP (n=303) or DP (n=305) at 66 sites 
in Japan. Patient demographics were well balanced between the 
two groups. Non-Sq and Sq patients in SP/DP arm was 251/247 
and 50/48 respectively. Two interim analyses were preplanned. At 
the final analysis, a total of 480 deaths had occurred. The primary 
endpoint was met. OS in the SP arm was non-inferior to that in 
the DP arm (median survival, 16.1 vs. 17.1 months, respectively; 
HR=1.013; 96.4% confidence interval, 0.837-1.227). PFS was 4.9 
months in the SP arm and 5.2 months in the DP arm. The rates of 
febrile neutropenia (7.4% vs. 1.0%), grade 3/4 neutropenia (73.4% 
vs. 22.9%), grade 3/4 infection (14.5% vs. 5.3%), and grade 1/2 
alopecia (59.3% vs. 12.3%) were significantly lower in the SP arm 
than in the DP arm. In terms of physical functioning and global 
functioning on the EORTC QLQ-C30 and lung cancer module (LC-
13), QOL was better in the SP arm (repeated measures ANOVA: 
p<0.01). Subgroup analysis by histology revealed that the median 
OS of non-Sq and Sq patients in SP/DP group was 17.4/19.1 months 
and 12.3/11.7 months respectively, of which hazard ratio was 0.973 
(95% CI, 0.797-1.187) and 1.239 (95% CI, 0.819-1.874). Interaction P 
value was 0.3004.
Conclusion: S-1 plus cisplatin is a standard first-line chemothera-
peutic regimen for advanced NSCLC both non-Sq and Sq histolo-
gy. Favorable toxicity profile of the SP regimen and encouraging 
outcome in patients with non-Sq prompted us to conduct a pros-
pective study of SP plus BEV and maintenance S-1 BEV for non-SQ 
currently underway.
Keywords: S-1, docetaxel, phase III, cisplatin
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O15.06 RANDOMIZED PHASE III TRIAL OF GEMCITABI-
NE (G)/CARBOPLATIN (C) WITH OR WITHOUT INIPARIB 
(I) IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED 
STAGE IV SQUAMOUS LUNG CANCER
David Spigel1, Edward S. Kim2, Thomas Lynch3, Michael Mccleod4, 
David Waterhouse5, Luis Paz-Ares6, Peter Harper7, John Hains-
worth1, Filippo De Marinis8, Fairooz Kabbinavar9, Rafael Rosell10, 
Mark A. Socinski11, Alain Vergnenegre12, Ignacio Garcia-Ribas13, 
Howard Burris1, Frances A. Shepherd14
1Sarah Cannon Research Institute/United States Of America, 2Levine 
Cancer Institute/United States Of America, 3Yale Cancer Center And 
Smilow Cancer Hospital/United States Of America, 4Florida Cancer 
Specialists/United States Of America, 5Ohc, Oncology Hematology 
Care Inc./United States Of America, 6Hospital Virgen Del Rocío/Spain, 
7Leaders In Oncology Care/United Kingdom, 8San Camillo Forlanini 
Hospital/Italy, 9David Geffen School Of Medicine, University Of Cali-
fornia Los Angeles/United States Of America, 10Catalan Institute Of 
Oncology/Spain, 11University Of Pittsburgh/United States Of America, 
12Cluzeau Hospital/France, 13Sanofi Oncology/United States Of Ameri-
ca, 14Princess Margaret Cancer Centre/Canada
Background: Iniparib is an agent originally thought to function 
as an inhibitor of the DNA repair enzyme PARP-1, which is over-
expressed in squamous lung cancers. Promising phase II activity 
and safety were reported with iniparib in combination with GC in 
pts with metastatic triple-negative breast cancer (O’Shaughnessy, 
NEJM 2011); however, subsequent phase III data were negative. 
Further study of iniparib’s mechanism of action suggests that this 
agent induces DNA damage, cell cycle arrest in the G2/M phase, 
experimental arm, 21.5% of frail patients according to Balducci’s 
criteria were enrolled and received an exclusive BSC management. 
Carboplatin-based doublets with pemetrexed and gemcitabine 
according to histology are feasible with a good profile of toleran-
ce in selected elderly patients. This study will help to precise the 
most relevant geriatric tools and their cut-off in order to improve 
the management of the elderly with advanced NSCLC.
Keywords: non-small cell lung cancer, aged, Treatment, geriatric 
assessment
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O15.05 RANDOMIZED PHASE III TRIAL OF S-1 PLUS CI-
SPLATIN VERSUS DOCETAXEL PLUS CISPLATIN FOR AD-
VANCED NON-SMALL-CELL LUNG CANCER (TCOG0701): 
SUBGROUP ANALYSIS.
Osamu Ishimoto1, Akihiko Gemma2, Hiroshi Sakai3, Nobuyuki 
Katakami4, Kaoru Kubota5, Makoto Nishio6, Akira Inoue7, Hiroaki 
Okamoto8, Hiroshi Isobe9, Hideo Kunitoh10, Yuichi Takiguchi11, 
Kunihiko Kobayashi12, Yoichi Nakamura13, Hironobu Ohmatsu14, 
Kouichi Minato15, Masaaki Fukuda16, Akira Yokoyama17, Masahiro 
Takeuchi18, Hirofumi Michimae18, Shoji Kudoh19
1Respiratory Medicine, Sendai Kousei Hospital/Japan, 2Department 
Of Pulmonary Medicine And Oncology, Nippon Medical School/Japan, 
3Thoracic Oncology, Saitama Cancer Center/Japan, 4Division Of Inte-
grated Oncology, Institute Of Biomedical Research And Innovation/
Japan, 5Medical Oncology Division, Nippon Medical School/Japan, 6The 
Cancer Institute Hospital Of JFCR/Japan, 7Tohoku University Hospital/
Japan, 8Yokohama Municipal Citizen‘s Hospital/Japan, 9Department 
Of Medical Oncology, Kkr Sapporo Medical Center/Japan, 10Respiratory 
Medicine, Mitsui Memorial Hospital/Japan, 11Graduate School Of Medi-
cine, Chiba University/Japan, 12Saitama University International Mrdi-
cal Center/Japan, 13Second Department Of Internal Medicine, Nagasaki 
University Hospital/Japan, 14Division Of Thoracic Oncology, National 
Cancer Center Hospital East/Japan, 15Pulmonary Medicine, Gunma 
Prefectural Cancer Center/Japan, 16National Hospital Organization 
Nagasaki Medical Center/Japan, 17Department Of Internal Medicine, 
Niigata Cancer Center Hospital/Japan, 18Kitasato University, School Of 
Pharmacy/Japan, 19Fukujuji Hospital Japan Anti-tuberculosis Associa-
tion/Japan
Background: Docetaxel plus cisplatin (DP) is the only third-genera-
tion regimen that has demonstrated statistically significant impro-
vements in overall survival and QOL by head-to-head comparison 
with a second-generation regimen (vindesine plus cisplatin) in pa-
tients with advanced non-small cell lung cancer (NSCLC). S-1 plus 
cisplatin (SP) has shown activity and good tolerability in phase II 
settings. Molecularly targeted agents including bevacizumab (BEV) 
have shown activity and safety in non-squamous (non-Sq) NSCLC.
Methods: Patients with previously untreated stage IIIB or IV NS-
CLC, an ECOG PS of 0-1 and adequate organ functions were ran-
domly assigned to receive either oral S-1 80 mg/m2/day (40 mg/
m2 b.i.d.) on days 1 to 21 plus cisplatin 60 mg/m2 on day 8 every 5 
weeks or docetaxel 60 mg/m2 on day 1 plus cisplatin 80 mg/m2 on 
day 1 every 3 weeks, both up to 6 cycles. The primary endpoint 
was overall survival (OS). A non-inferiority study design was em-
ployed; the upper confidence interval (CI) limit of the hazard ratio 
(HR) was <1.322. Secondary endpoints included progression-free 
survival (PFS), response, safety, and QOL. Subgroup analysis by 
histology (non-Sq vs Sq) was conducted.
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O15.07 FINAL RESULTS OF CTONG 0806: A PHASE II 
TRIAL COMPARING PEMETREXED WITH GEFITINIB AS 
SECOND-LINE TREATMENT OF ADVANCED NON-SQUA-
MOUS NSCLC PATIENTS WITH WILD-TYPE EGFR
Qing Zhou1, Ying Cheng2, Ming-Fang Zhao3, Jin-Ji Yang1, Hong-
Hong Yan1, Li Zhang4, Yong Song5, Jian-Hua Chen6, Wei-Neng 
Feng7, Chong-Rui Xu1, Yi-Long Wu1, Chinese Thoracic Oncology 
Group (Ctong)8
1Guangdong Lung Cancer Institute, Guangdong General Hospital And 
Guangdong Academy Of Medical Sciences/China, 2Jilin Provincial 
Cancer Hospital/China, 3Department Of Medical Oncology, The First 
Hospital Of China Medical University/China, 4Perking Union Medical 
Hospital/China, 5Department Of Respiratory Medicine, Jinling Hospital, 
Nanjing University Of Medicine/China, 6Hunan Cancer Hospital/China, 
7The First People‘s Hospital Of Foshan/China, 8All Sites Participating In 
This Clinical Trial Are Members Of Chinese Thoracic Oncology Group 
(ctong)./China
Background: Both Pemetrexed and gefitinib are standard second-
line treatments for advanced non-squamous NSCLC in East Asia. 
The CTONG 0806, a multi-center, randomized, controlled, open-
label phase II trial was designed to explore the efficacy of pemet-
rexed versus gefitinib as second-line treatment in advanced non-
squamous NSCLC with wild-type EGFR.
Methods: Patients with locally advanced or metastatic non-
squamous NSCLC previously treated with platinum-based chemo-
therapy and with wild-type EGFR detected by direct sequencing 
were randomized to receive gefitinib orally 250 mg/day (G arm) 
or pemetrexed 500 mg/m2 iv day 1 every 21 days (P arm) until 
disease progression or unacceptable toxicity. Primary endpoint 
was progression-free survival (PFS). Secondary endpoints included 
4-month and 6-month PFS rate, overall survival (OS), objective 
response rate (ORR), disease control rate (DCR), quality of life and 
safety. Independent Review Committee (IRC) evaluated all pictorial 
data.
Results: From Feb. 2009 to Aug. 2012, 161 patients were enrolled 
and 157 were evaluable (81 in G arm and 76 in P arm). Baseline 
characteristics were balanced between arms. The primary end-
point of median PFS was met with 4.8 months in P arm versus 1.6 
months in G arm (HR 0.54, 95% CI 0.40~0.75, P<0.001), which was 
confirmed by IRC evaluation (5.6 vs. 1.7 months, HR 0.53, 95% CI 
0.38~0.75, P<0.001). Significant difference between two arms was 
also seen in terms of 4-month PFS rate, 6-month PFS rate and DCR 
(Table 1). Median OS showed the trend of superiority in P arm (12.4 
vs. 9.6 months, HR 0.72, 95% CI 0.49 ~ 1.04, P=0.077). In 108 pati-
ents having enough tumor tissue, EGFR mutation status was tested 
again by Scorpion amplification refractory mutation system (ARMS) 
and 32 were found to be positive. In 76 patients with wild-type 
EGFR confirmed by ARMS (35 in P arm and 41 in G arm), median 
PFS was 4.0 vs. 1.3 months (HR 0.42, 95% CI 0.26~0.67, P<0.001). 
More skin rash and diarrhea were seen in G arm while more fatigue 
and ALT increase were in P arm. CTCAE grade 3 or 4 adverse 
events was 12.3% in G arm and 32.9% in P arm (P=0.002). The de-
tailed survival analysis and biomarkers analysis will be presented 
on the ground.
and potentiates DNA-damaging chemotherapies not through 
PARP inhibition. Herein we report the final results from an interna-
tional Phase III trial (NCT01082549) of first-line chemotherapy and 
iniparib in pts with advanced squamous lung cancer.
Methods: Pts were randomized 1:1 to GC or GCI. All pts received 
G 1000 mg/m2 IV days (D) 1 and 8, and C AUC=5 IV D1 of each 
21-D cycle. Iniparib was dosed 5.6 mg/kg IV D 1, 4, 8, and 11. All 
pts were assessed for response per RECIST 1.1 every 6 weeks. 
Pts without evidence of progressive disease (PD) or other reason 
for discontinuation could remain on treatment beyond 6 cycles. 
Accrual of 780 pts provides 89% power to detect an improvement 
in survival from 8 months (mos) anticipated with GC to 10.7 mos 
with GCI (HR of 0.75). Eligibility: Pts with newly diagnosed stage 
IV (M1a and M1b) squamous lung cancer, ECOG PS 0-1. Exclusion 
criteria included: history of recent cardiac disease, untreated brain 
metastases, and treatment for early-stage lung cancer within 12 
months of study entry. The primary endpoint was overall survival 
(OS). Interim analyses for safety and futility were performed by an 
independent data safety monitoring board.
Results: 780 pts were enrolled and randomized (GC, 390), (GCI, 
390) from March 2010 to May 2012. Baseline characteristics were 
well balanced between groups (GC/GCI): median age 66 years (21-
86); 74%/73% male; 30%/33% ECOG 0; 28%/33% current smokers; 
66%/62% past smokers. The median number of cycles for GC/GCI 
were 4 (1-26)/5 (1-32). Dose reductions, dose intensity, and discon-
tinuations due to tumor progression or adverse events were similar 
in both arms. The median OS for GC/GCI was 8.9 v. 8.9 months, 
HR 1.08 (0.92-1.28), p=.348. 1-year OS was 41 v. 40%. The median 
progression-free survival (PFS) for GC vs GCI was 4.9 v. 4.8 months, 
HR 0.99 (0.83-1.19), p=.92. The objective response rate (ORR) for 
GC v GCI was 34 v. 32%, p=.648. The safety profile was similar in 
both arms; anemia (28/26%), neutropenia (31/35%), thrombocyto-
penia (27/28%), and fatigue (6/9%).
Conclusion: The addition of iniparib did not improve the efficacy 
of GC in the treatment of pts with advanced squamous lung can-
cer. Further development of iniparib in squamous lung cancer is 
not recommended.
Keywords: Iniparib, Squamous lung cancer
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Table1. Efficacy of pemetrexed and gefitinib evaluated by investigators and IRC 
Evaluated by Investigators Evaluated by IRC 
Pemetrexed arm Gefitinib arm P Pemetrexed Gefitinib arm P 
PFS 
4.8months 1.6months <0.001 5.6months 1.7months <0.001 
HR 0.54,95% CI 0.40 ~ 0.75 HR 0.53, 95% CI 0.38 ~ 0.75 
4-month 
PFS rate 
59.0% 33.0% <0.001 62.0% 37.0% <0.001 
6-month 
PFS rate 
43.0% 23.0% <0.001 48.0% 27.0% <0.001 
ORR 13.2% 13.6% 0.938 14.5% 12.3% 0.695 
DCR 60.5% 29.6% <0.001 61.9% 30.8% <0.001 
OS 
12.4months 9.6months 0.077 
HR 0.72,95% CI 0.49 ~ 1.04 
Conclusion: CTONG0806 is the first trial to show significant impro-
vement in PFS, DCR and a trend of improving OS with pemetrexed 
compared with gefitinib in second-line setting for EGFR wild-type 
advanced non-squamous NSCLC.
Keywords: non-small cell lung cancer, wild-type EGFR, pemetrex-
ed, gefitinib
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≥3: 7.8 vs 0.9%). Incidence of CTCAE Gr ≥3 AEs was 71.3 vs 64.3%. 
Withdrawals due to AEs (22.7 vs 21.7%) were similar in both arms, 
as were Gr ≥3 hypertension, bleeding or thrombosis.
Conclusion: Nintedanib + docetaxel significantly reduced the 
risk of progression in NSCLC patients independent of histology. 
Adjustment for tumor burden, as represented by the SLD, led to a 
significant reduction in the risk of death. AEs were generally mana-
geable with dose reductions and symptomatic treatment.
Keywords: nintedanib, NSCLC, phase III, tumour burden
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O16.02 EFFICACY OF STANDARD CARE FOR SECOND-
LINE ADVANCED NON-SMALL CELL LUNG CANCER (NS-
CLC) BY KRAS MUTATION STATUS: OBSERVATIONS ON 
MEK INHIBITOR ENHANCEMENT OF CHEMOTHERAPY
Pasi A. Jänne1, Delyth Clemett2, Helen Mann2, Ian Smith2
1Dana-Farber Cancer Institute/United States Of America, 2Astra-
zeneca/United Kingdom
Background: KRAS mutations that activate the MEK/ERK pathway 
are found in 20–30% of NSCLC. Response to second-line therapies 
for advanced NSCLC may be different in the presence or absence 
of a KRAS mutation. MEK inhibitors are being developed in combi-
nation with cytotoxic chemotherapy for NSCLC, based on preclini-
cal findings that MEK inhibition increases pro-apoptotic BIM levels, 
enhancing cytotoxic therapy, and that MEK inhibition reduces 
KRAS mutation-induced oncogenic drive. We reviewed available 
information from KRAS mutation-positive (KRAS+) and KRAS wild-
type subsets in AstraZeneca clinical studies in second-line NSCLC 
and published data on MEK inhibitors. Our objective was to deter-
mine whether differential therapeutic activity is present in KRAS+ 
and KRAS wild-type populations and whether preclinical findings 
translate into enhanced tumour response.
Methods: We reviewed data on objective clinical response in 
second-line NSCLC according to KRAS status in five randomised 
double-blind Phase II or III studies of gefitinib, vandetanib or selu-
metinib and three published studies of trametinib. Ninety-five per-
cent confidence intervals (CI) around point estimates of objective 
response were calculated using exact (Clopper-Pearson) methods 
for a single proportion.
Results: The studies involved 4466 patients receiving second- or 
later line treatment for advanced NSCLC. In total, 1286 patients re-
ceived singlet chemotherapy (docetaxel or pemetrexed), including 
429 with known tumour KRAS mutation status: 138 had KRAS+ and 
291 had KRAS wild-type NSCLC. Additionally, 132 patients with 
known KRAS status received singlet chemotherapy plus a MEK 
inhibitor (selumetinib or trametinib): 91 with KRAS+ and 41 with 
KRAS wild-type NSCLC. 
Session O16: NSCLC - Targeted The-
rapies III 
Tuesday, October 29, 2013
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O16.01 IMPACT OF TUMOR BURDEN ON THE OVERALL 
SURVIVAL ANALYSIS OF THE LUME-LUNG 1 STUDY: A 
RANDOMIZED, DOUBLE-BLIND PHASE 3 TRIAL OF NIN-
TEDANIB (BIBF 1120) + DOCETAXEL IN NSCLC PATIENTS 
PROGRESSING AFTER FIRST-LINE CHEMOTHERAPY
Martin Reck1, Silvia Novello2, Anders Mellemgaard3, Sergei Orlov4, 
Rolf Kaiser5, José Barrueco6, Birgit Gaschler-Markefski5, Jean-Yves 
Douillard7
1Department Of Thoracic Oncology, Lung Clinic Grosshansdorf/Germa-
ny, 2Department Of Oncology, University Of Turin/Italy, 3Department 
Of Oncology, Herlev University Hospital/Denmark, 4Department Of 
Thoracic Oncology, St. Petersburg State Medical University/Russian 
Federation, 5Boehringer Ingelheim Pharma GmbH & Co/Germany, 
6Boehringer Ingelheim Pharmaceuticals Inc./United States Of America, 
7Department Of Medical Oncology, Centre René Gauducheau/France
Background: Nintedanib is an orally available potent anti-angio-
genic agent inhibiting the isoforms of VEGFR, PDGFR and FGFR. 
LUME-Lung 1 is a placebo-controlled phase 3 trial of nintedanib + 
docetaxel in second-line NSCLC patients.
Methods: Patients with stage IIIB/IV or recurrent NSCLC after fai-
lure of first-line chemotherapy were stratified by histology, ECOG 
PS, prior bevacizumab and brain metastases, and were randomised 
to nintedanib 200 mg bid + docetaxel 75 mg/m2 q21d (n=655), or 
placebo + docetaxel (n=659). The primary endpoint was centrally 
reviewed PFS after 714 events. The key secondary endpoint was 
OS after 1,121 events. Predefined sensitivity analyses used baseline 
sum of longest diameters of target lesions (SLD) and stratification 
factors, as covariates in the Cox model.
Results: The study met its primary endpoint demonstrating a 
statistically significant improvement in PFS that translated into a 
21% reduction in the risk of progression in patients treated with 
the combination of nintedanib + docetaxel vs placebo + doceta-
xel (HR 0.79; CI: 0.68, 0.92; p=0.0019; median 3.4 vs 2.7 months), 
regardless of histology (adenocarcinoma HR 0.77, CI: 0.62, 0.96; 
p=0.0193; squamous HR 0.77, CI: 0.62, 0.96; p=0.0200). OS was 
significantly prolonged in adenocarcinoma patients treated with 
the combination of nintedanib + docetaxel vs placebo + docetaxel 
(HR 0.83; CI: 0.70, 0.99; p=0.0359; median 12.6 vs 10.3 months) 
but not in squamous cell carcinoma patients (HR 1.01; CI: 0.85, 
1.21; p=0.8908; median 8.6 vs 8.7 months). The intent-to-treat (ITT) 
analysis of OS in all study patients showed a 1-month improvement 
that did not reach statistical significance (HR 0.94; CI 0.83, 1.05; 
p=0.272; median 10.1 vs 9.1 months). When adjusted for SLD, how-
ever, a significant OS benefit was seen for the ITT population (HR 
0.88; CI: 0.78, 0.99; p=0.0365). Further analyses showed that the 
impact of SLD was reflected in the squamous cell carcinoma popu-
lation (HR 0.92; CI: 0.77, 1.10; p=0.3649), with the greatest impact 
observed for squamous cell carcinoma patients with a large SLD. 
An impact of SLD was also seen in adenocarcinoma patients but 
to a lesser extent (HR 0.81; CI:0.69, 0.97; p=0.0186), as compared 
with the squamous cell carcinoma population. The most common 
AEs reported for the ITT population were diarrhea (any: 42.3 vs 
21.8%; Gr ≥3: 6.6 vs 2.6%) and ALT elevations (any: 28.5 vs 8.4%; Gr 
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O16.03 COST-UTILITY ANALYSIS OF FIRST-LINE TREAT-
MENT WITH ERLOTINIB VERSUS CHEMOTHERAPY IN 
EGFR-MUTANT ADVANCED NON-SMALL-CELL LUNG 
CANCER (NSCLC): ECONOMIC ANALYSIS OF EURTAC 
TRIAL
Alain Vergnenegre1, Rafael Rosell2, Bartomeu Massuti3, Pascal Do4, 
Romain Corre5, Enriqueta Felip6, Ramon Palmero2, Ramon Garcia-
Gomez7, Filippo De Marinis8, Mariacarmela Santarpia9, Elaine 
Wright10, Christos Chouaid11
1Service De Pneumologie, Centre Hospitalier Universitaire De Limoges/
France, 2Catalan Institute Of Oncology/Spain, 3Medical Oncology, Hospital 
General De Alicante/Spain, 414000, Centre De Lutte Contre Le Cancer/
France, 5Pneumology, Chu Pontchaillou/France, 6Hospital Valle Hebron/
Spain, 7Hospital Gregorio Maranon/Spain, 8Azienda Ospedaliera San Ca-
millo-forlanini/Italy, 9Department Of Medical Oncology, Univerity Of Messi-
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Background: The impact of tyrosine kinase inhibitors (TKIs) in EGFR-
mutant advanced NSCLC is poorly documented. Two studies (Jacob 
et al, ISPOR2010, Brown et al, Health Technol Assess, 2010) are based 
on modelisation and indirect comparisons. The present study reports 
a cost-utility analysis of a phase III randomized trial (EURTAC).
Conclusion: Our retrospective comparison suggests that second-
line singlet chemotherapy response rates may be greater in KRAS 
wild-type than in KRAS+ NSCLC, and that MEK inhibition may en-
hance second-line chemotherapy activity in both KRAS+ and KRAS 
wild-type NSCLC. These observations support prospective valida-
tion of these results and further evaluation of MEK inhibitors plus 
chemotherapy in second-line KRAS unselected NSCLC.
Keywords: NSCLC, KRAS, MEK
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O16.05 EFFICACY, SAFETY, AND PATIENT-REPORTED 
OUTCOMES (PROS) WITH CRIZOTINIB VERSUS CHEMO-
THERAPY IN ASIAN PATIENTS IN A PHASE III STUDY OF 
PREVIOUSLY TREATED ADVANCED ALK-POSITIVE NON-
SMALL CELL LUNG CANCER (NSCLC)
Makoto Nishio1, Vera Hirsh2, Dong-Wan Kim3, Keith D. Wilner4, 
Anna Polli5, Arlene Reisman6, Shrividya Iyer4, Fiona Blackhall7
1Japanese Foundation For Cancer Research Hospital/Japan, 2McGill Uni-
versity Health Centre/Canada, 3Department Of Internal Medicine, Seoul 
National University Hospital/Korea, 4Pfizer Oncology/United States Of 
America, 5Pfizer Oncology/Italy, 6Pfizer Specialty Care/United States Of 
America, 7The Christie NHS Foundation Trust/United Kingdom
Background: Crizotinib is a potent selective ATP-competitive ALK 
inhibitor demonstrating a high ORR in patients with advanced 
ALK-positive NSCLC. The main objective of the present post hoc 
analyses was to compare the impact of crizotinib on efficacy, safe-
ty, and PROs with that of standard second-line chemotherapy in a 
subgroup of patients of Asian ethnicity from the ongoing phase III 
study PROFILE 1007.
Methods: Patients with stage IIIB/IV ALK-positive NSCLC who had 
received one prior platinum-based regimen were randomized to 
open-label crizotinib (250 mg PO BID) or chemotherapy (peme-
trexed 500 mg/m2 or docetaxel 75 mg/m2, IV q3w). In these sub-
group analyses, PFS and ORR based on independent radiologic 
review, OS, safety, and PROs were evaluated. PROs were assessed 
at baseline, on day 1 of each cycle, and at end of treatment using 
the validated cancer-specific questionnaire EORTC QLQ-C30 
and its LC module QLQ-LC13. Time to deterioration (TTD) was 
defined as the time from randomization to the earliest time with a 
≥10-point increase from baseline (worsening) in pain in chest, dys-
pnea, or cough. Repeated measures mixed-effects analyses were 
performed to compare change from baseline scores between the 
treatment arms.
Results: Of 347 patients randomized, 45% were of Asian ethnicity 
(crizotinib, n=79; chemotherapy, n=78 [pemetrexed, 50; docetaxel, 
27; no treatment, 1]). At data cutoff (March 2012), 52 Asian patients 
(crizotinib, 41; chemotherapy, 11) were continuing on treatment. 
PFS was significantly longer with crizotinib than with chemotherapy 
(median 8.1 vs. 2.8 months; HR, 0.53; P=0003). The ORR on crizo-
tinib (75%) was significantly higher than on chemotherapy (22%; 
P<0.0001). In an interim analysis, median OS had not yet been 
reached in the crizotinib arm and was 22.8 months in the chemo-
therapy arm (HR, 0.89; P=0.347, noting that in the overall study 
population, only 40% of planned events had occurred and 64% of 
patients in the chemotherapy arm subsequently received crizotinib 
in another study). The most common all-causality AEs with crizo-
tinib were diarrhea (70%), vision disorder (68%), and nausea (66%) 
and with chemotherapy were decreased appetite (40%), nausea 
(39%), and fatigue (35%). Crizotinib treatment was associated with 
a significantly longer TTD in LC symptoms compared with chemo-
therapy (median 4.2 vs. 1.6 months; HR, 0.66; 95% CI, 0.44−0.98; 
P=0.037). A significantly greater improvement from baseline was 
observed with crizotinib for global QOL (P<0.05), cough (P<0.001), 
dyspnea (P<0.001), pain in arm or shoulder (P<0.001), pain in chest 
(P<0.001), pain in other parts (P<0.05), fatigue (P<0.05), insomnia 
(P<0.05), and pain (P<0.001). A significantly greater improvement 
was observed with crizotinib compared with chemotherapy for 
emotional functioning (P<0.05), physical functioning (P<0.05), hair 
loss (P<0.001), and sore mouth (P<0.05). A significantly greater 
Methods: A three state Markov model (first line PFS, second line 
PD and death) was built. Clinical data and resource assessment 
(drugs, drug administration, adverse events, second-line treat-
ment) were collected from the trial. Utility values were derived 
from Nafees et al, as previously published (Vergnenegre et al. JTO 
2011). Incremental cost-utility ratios (ICUR) were calculated for the 
first-line treatment and the overall strategy until death from the 
perspective of different countries (2013 actualized euros). Sensitivi-
ty analyses researched the main cost drivers.
Results: The quality-adjusted life-years gained was 0.124 with erlo-
tinib, which showed an improvement in the quality of life for these 
patients. Despite the extra treatment costs of second-line erlotinib 
in the chemotherapy arm, there was a cost benefit for erlotinib 
first, resulting in fewer patients receiving second-line pemetrexed 
along with other therapy. Cost gain in favor of first-line erlotinib 
was 8,918 Euros. The main results are depicted in Table1. 
First-line erlotinib First-line chemotherapy 
Average 
cost of first-
line (euros 
2013) 
Drugs 21,679 1030 
Administra-
tion 
329 4,455 
Adverse 
events 
546 2,686 
Cost of 
post-first 
progression 
care 
40,467 67,281 
ICUR (erlo-
tinib versus 
chemothe-
rapy) 
ICUR France negative 
ICUR Spain negative 
ICUR Italy negative 
 
Sensitivity analyses will be presented at the meeting.
Conclusion: ICUR favored first-line erlotinib in EGFR-mutant pa-
tients with advanced NSCLC, which is the widely accepted treat-
ment compared to chemotherapy. The cost-utility of the overall 
strategy remained beneficial in three different European countries. 
On behalf GFCP,GEPC and AIOT groups
Keywords: cost utility analysis, tyrosine kinase inhibitors, clinical 
trial, Non small cell lung cancer
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response around 10 months. CH5424802 is a more potent and 
specific ALK inhibitor that is being studied as a treatment for NS-
CLC patients with ALK gene rearrangement.
Methods: A phase 1 dose escalation study of CH5424802 was 
performed using 3+3 study design in NSCLC patients who failed 
crizotinib. The primary endpoint was dose limiting toxicity, and the 
secondary endpoints were efficacy, safety and pharmacokinetic 
(PK) analyses. Key eligibility criteria include prior progression on 
crizotinib, ECOG 0-2, adequate organ functions, confirmed ALK-
rearrangement by an FDA approved test. Patients with sympto-
matic CNS metastases required treatment before participating. 
CH5424802 was administered orally at doses of 300, 460, 600, 760 
and 900 mg BID until lack of clinical benefits. Intensive PK samp-
ling was performed. Efficacy was assessed by RECIST criteria v1.1. 
Toxicities were evaluated by CTCAE v4.0.
Results: 37 NSCLC patients who have failed crizotinib and chemo-
therapy were enrolled in the study from 6 US sites from May 2012 
to May 2013. No DLTs were observed up to the highest dose tes-
ted (900 mg BID). Only 1 patient required dose modification due 
to grade 2 fatigue. The most common AEs were fatigue, CPK in-
crease, myalgia, cough, ALT increased, peripheral edema and rash. 
Grade 3/4 AEs include GGT increase (n=3), neutrophil decrease 
(n=2), hypophosphatemia, hyperglycemia, syncope, renal failure 
and pericardial effusion (n=1 each), but no grade 3 nausea, vomit, 
diarrhea, edema were reported. Preliminary efficacy was observed 
with PR 48% and SD 34% by investigator assessment amongst the 
30 evaluable patients (See Figure of Waterfall plot). Median pro-
gression-free survival has not been reached with 27 patients (73%) 
remaining on study as of June 10, 2013 (median duration 85 days, 
range 39-347+ days). CNS activity was observed and described in 
the companion abstract by Ou et al. CH5424802 single dose half-
life was approximately 22 hr, AUC was dose-dependent from 300 
to 600 mg BID following multiple doses with a potential plateau at 
doses higher than 600 mg BID based on available data.
Conclusion: CH5424802 is a well-tolerated ALK inhibitor with no 
DLTs observed up to the highest dose tested in this study. Promi-
sing anti-tumor activity was observed in patients who have failed 
crizotinib. 
Keywords: ALK-inhibitor, Crizotinib-failure, Phase I, CH5424802
deterioration was observed in the crizotinib arm for constipation 
(P<0.05) and diarrhea (P<0.001) compared with chemotherapy.
Conclusion: Consistent with previously reported results in the 
overall study population, crizotinib treatment showed significantly 
greater improvement in PFS, ORR, patient-reported LC symptoms, 
and global QOL compared with chemotherapy in a subgroup of 
patients of Asian ethnicity with previously treated advanced ALK-
positive NSCLC, confirming the utility of crizotinib in this patient 
population.
Keywords: Efficacy, patient-reported outcomes, Crizotinib, Asian 
patients
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O16.06 A PHASE 1 DOSE ESCALATION STUDY OF A 
NEW ALK INHIBITOR, CH5424802/RO5424802, IN ALK+ 
NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS 
WHO HAVE FAILED CRIZOTINIB (AF-002JG/NP28761, 
NCT01588028).
Shirish Gadgeel1, Sai-Hong Ou2, Alberto A. Chiappori3, Gregory 
Riely4, Ruey-Min Lee5, Linta Garcia6, Jotaro Sato7, Shumpei Yokoya-
ma7, Tomohiro Tanaka7, Leena Gandhi8
1Oncology, Karmonos Cancer Institute/United States Of America, 2Chao 
Family Comprehensive Cancer Center, University Of California, Irvine/
United States Of America, 3Thoracic Oncology, Moffitt Cancer Center/
United States Of America, 4Memorial Sloan Kettering Cancer Center/
United States Of America, 5Hoffmann-la Roche Inc./United States Of 
America, 6Chugai Pharmaceutical Ltd./United States Of America, 7Chu-
gai Pharmaceutical Company/Japan, 8Dana Farber Cancer Institute/
United States Of America
Background: Anaplastic lymphoma kinase (ALK) is a tyrosine kina-
se constitutively activated following chromosomal translocation in 
3-7% of non-small cell lung cancer (NSCLC). These patients usually 
respond to the ALK inhibitor crizotinib with a median duration of 
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Results: As of June 6, 2013, 37 patients were enrolled in the phase 
I study, and 31 of them were evaluable for efficacy. Preliminary 
overall response rate (ORR) is ~48% (15/31) in evaluable patients. 
16 had brain metastases at baseline, and 2 had no prior brain 
irradiation but all had documented CNS progression prior to stu-
dy treatment. These 16 patients received CH5424802 at 300mg 
(n=2), 460mg (n=2), 600mg (n=5), 760mg (n=3), and 900mg (n=4) 
BID. The median duration of follow-up of these 16 patients was 
130+ days, with the longest being 347+ days. Activity against 
CNS lesions was observed as early as the first scan (3rd week). The 
preliminary CNS response is highly promising as shown in the 
representative scans below. Enrollment is still ongoing and CNS 
progression-free survival (PFS) will be presented. Currently 2 pati-
ents had simultaneous CSF and plasma levels of CH5424802, and 
the CSF/plasma ratios will be reported to evaluate any correlation 
between CSF/plasma ratios and the observed clinical activity of 
CH5424802 in brain metastasis.
Conclusion: CH5424802 demonstrates consistent and rapid clini-
cal activity in brain metastases in ALK+ NSCLC patients who pro-
gressed on crizitinib. Within 3-6 weeks of treatment, CH5424802 
dramatically shrinks brain lesions that progressed on crizotinib. 
CH5424802 could potentially replace or delay the need of brain 
radiation in ALK-positive NSCLC patients.
Keywords: ALK-inhibitor, CH5424802/RO5424802, CNS metasta-
sis, Efficacy
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O16.07 CONSISTENT THERAPEUTIC EFFICACY OF 
CH5424802/RO5424802 IN BRAIN METASTASES 
AMONG CRIZOTINIB-REFRACTORY ALK-POSITIVE 
NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN 
AN ONGOING PHASE I/II STUDY (AF-002JG/NP28761, 
NCT01588028).
Sai-Hong I. Ou1, Shirish Gadgeel2, Alberto A. Chiappori3, Leena 
Gandhi4, Michele Azada1, Linta Garcia5, Itsumi Takaya6, Shumpei 
Yokoyama6, Tomonori Kamei6, Tomohiro Tanaka6, Ruey-Min Lee7, 
Gregory Riely8
1Medicine-Hematology/Oncology, Chao Family Comprehensive Cancer 
Center, University Of California Irvine/United States Of America, 2Kar-
manos Cancer Institute/Wayne State University/United States Of Ame-
rica, 3Thoracic Oncology, Moffitt Cancer Center/United States Of Ame-
rica, 4Dana Farber Cancer Institute/United States Of America, 5Chugai 
Pharmaceutical Ltd./United States Of America, 6Chugai Pharmaceutical 
Company/Japan, 7Hoffmann-la Roche Inc./United States Of America, 
8Memorial Sloan Kettering Cancer Center/United States Of America
Background: Disease progression in brain occurs in ~50% ALK-
rearranged NSCLC patients treated with crizotinib. This is likely 
due in part to low penetration of crizotinib into CNS. CH5424802 
is a new ALK inhibitor that is effective in patients who have ALK 
re-arrangement. Preclinical studies in CNS implantation models 
suggest a promising anti-tumor activity of CH5424802 against CNS 
lesions. This report describes CNS activity observed in an ongoing 
phase I/II clinical trial.
Methods: A phase I dose escalation study of CH5424802 was per-
formed in ALK-rearranged NSCLC who have failed crizotinib. Pati-
ents received oral CH5424802 doses ranging from 300 to 900 mg 
BID. All patients had head CT/MRI and body CT scans at baseline, 
and every 6 weeks after initiation of treatment if baseline scans are 
positive for brain metastasis. Brain lesions without prior radiation 
were used to assess CNS response based on modified RECIST 
criteria. Simultaneous collection of cerebrospinal fluid (CSF) and 
plasma PK samples in selective patients is ongoing to evaluate 
CSF/plasma CH5424802 ratios to correlate with clinical activity in 
brain metastasis.
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between the survival curves of 5 subtypes whatever the endpoint. 
No prognostic value of 3 histological subtypes was observed for 
OS (p=0.21 in the control arm) contrary to DFS (p=0.04) and SDFS 
(p=0.03). These last 2 results were explained by the difference 
between PAP+ACN and MPP+SOL with hazard ratio (HR)ACN+PAP vs. 
MPP+SOL=0.66 95% confidence interval (CI)=[0.47-0.91] and HRACN+PAP 
vs. MPP+SOL=0.67 [0.44-0.89] for DFS and SDFS, respectively. Due 
to the small number of patients with LEP predominant pattern, 
the predictive value was assessed after excluding this subtype. 
MPP+SOL patients reported significant DFS benefit from adju-
vant chemotherapy (HR=0.58 [0.43-0.80], p<0.001) compared to 
ACN+PAP patients (HR=1.12 [0.79-1.59], p=0.53; p interaction < 
0.01). A similar result was observed for SDFS with HR=0.58 [0.42-
0.80], p<0.005 in MPP+SOL compared to HR=1.13 [0.78-1.63], 
p=0.52 in ACN+PAP (p interaction <0.01) while no predictive effect 
for OS.
Conclusion: Resectable lung adenocarcinoma patients with micro-
papillary and solid predominant patterns showed a trend for poo-
rer DFS and SDFS compared to patients with the other subtypes, 
and they show a significantly higher benefit from adjuvant chemo-
therapy on these outcomes. Histological subtypes according to 
the IASLC/ATS/ERS classification may be proposed as a stratifica-
tion factor in design of future adjuvant chemotherapy trials.
Keywords: Predictive value, Pathology, randomized clinical trials, 
Adenocarcinoma
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O17.02 CLINICOPATHOLOGIC, RADIOLOGIC, AND MO-
LECULAR CHARACTERISTICS OF COMPLETELY RESEC-
TED MUCINOUS ADENOCARCINOMAS IN THE LUNG: 
IMPLICATIONS FOR PROGNOSIS
Hee Young Lee1, Ho Yun Lee1, Joungho Han2, Kyung Soo Lee1, O 
Jung Kwon3, Byung-Tae Kim4
1Radiology, Samsung Medical Center, Sungkyunkwan University School 
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Samsung Medical Center, Sungkyunkwan University Of School Of Me-
dicine/Korea, 4Nuclear Medicine, Samsung Medical Center/Korea
Background: The real prognosis of mucinous adenocarcinomas 
(MAs) diagnosed according to the current IASLC/ATS/ERS lung 
adenocarcinoma classification is controversial, and in particular, 
the prognostic value of MA and the relationship among pathologic 
features, clinicoradiologic presentation, and response to surgical 
treatment are still unclear. Therefore, the aim of this single-Institu-
tion retrospective study is to analyze the prognostic role of clinico-
pathologic and radiologic features in surgically resected MA in a 
homogenous population of Asian patients.
Methods: Analyzed variables are clinicoradiologic presentations, 
operation type, histologic subtypes, and stage. Univariate and 
multivariate analyses of survival were performed.
Results: From 1994 through 2011, 161 resected lung carcinomas 
were diagnosed as MA in 158 patients, according to the IASLC/
ATS/ERS classification. 158 patients included 114 in 1 stage 
(72%), 29 in 2 (18%), and 15 in 3 (10%). 117 tumors (73%) were 
nodular-type and 44 (27%) were consolidation-type. Among 
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VANT CHEMOTHERAPY TRIALS: A LACE-BIO STUDY
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Minnesota/United States Of America, 6Suny Upstate Medical Univer-
sity/United States Of America, 7Institute Of Pathology, University Me-
dical School Of Graz/Austria, 8Medical Oncology, Catalan Institute Of 
Oncology/Spain, 9Medical Oncology, Ico R Gauducheau/France,  
10Department Of Medical Oncology, Gustave Roussy/France, 11Depart-
ment Of Pathology, University Health Network, University Of Toronto/
Canada
Background: A new IASLC/ATS/ERS classification for lung ade-
nocarcinoma has been proposed to classify invasive lung ade-
nocarcinoma patients according to the predominant growth 
pattern present in the tumor: lepidic (LEP), papillary (PAP), acinar 
(ACN), micropapillary (MPP) and solid (SOL). Several studies have 
reported consistently that early stage resectable lung adenocar-
cinoma patients with LEP predominant pattern have a better 
prognosis, while MPP and SOL predominant patterns have a sig-
nificantly poorer prognosis. However, the prognostic significance 
of these histological patterns has not been tested in clinical trials. 
Furthermore, the clinical utility of this new classification for predic-
ting benefit from adjuvant chemotherapy is unknown.
Methods: The representative single H&E slide of 1766 non-small 
cell lung cancer patients from IALT, JBR.10, CALGB 9633 and ANI-
TA adjuvant chemotherapy trials who participated in the LACE-Bio 
study were reviewed to confirm the histological diagnosis. These 
cases were independently assessed by two pathologists involved 
in the development of this new IASLC/ATS/ERS classification for 
subtyping. Discordant cases were resolved by consensus. Clinical 
outcomes were overall survival (OS, main outcome), disease-free 
survival (DFS) and specific disease-free survival (SDFS) (DFS with 
censoring deaths not related to cancer). Multivariable Cox models 
stratified by trial were used for prognostic analyses and the inter-
action between treatment (chemotherapy / control) and histology 
subtypes added for predictive analyses. The five histology subty-
pes were first analysed separately and 3 groups (LEP, PAP+ACN 
and MPP+SOL) were considered.
Results: 573 patients were classified as 23 (4%) as LEP, 148 (26%) 
as ACN, 99 (17%) as PAP, 39 (7%) as MPP and 264 (46%) as SOL. 
The distribution of histology subtypes was different across trials 
(p=0.02) but not related with standard prognostic variables. The 
number of deaths, events and cancer-related events were 269, 
320 and 292 respectively. No significant difference was observed 
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Conclusion: Consolidation-type on CT, cribriform pattern, higher 
stage, and higher SUVmax would be predictive for lower overall 
survival. Also, SUVmax would be predictive for higher recurrence 
and may necessitate more aggressive adjuvant treatment.
Keywords: mucinous adenocarcinomas of the lung, Clinicopatho-
logic, radiologic, and molecular characteristics, Prognosis
117 nodular MAs, 6 were pure GGO nodules.7 tumors presen-
ted as multiple lesions. 4 were AIS (lepidic pattern), 1 was MIA 
(acinar), and 156 (97%) were invasive adenocarcinoma (147 with 
acinar and 9 with cribriform pattern). The 5-year recurrence 
rate was 22%, and the 5-year survival rate was 88%. Five-year 
OS for patients with nodular type compared with those with 
consolidation-type was 89 versus 57 % (P < 0.001). Based on the 
multivariate Cox-proportional analysis, consolidation-type on CT 
(HR 1.42), cribriform pattern (HR 10.35), higher stage (HR 1.51), 
and higher SUVmax (HR 1.27) were significant poor prognostic 
predictor for DFS. As for recurrence, SUV max was the only sig-
nificant predictor in both multivariate Cox-proportional analysis 
(HR 1.16, P = 0.016) and the log-rank test (cut-off 4.4, P = 0.045). 
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O17.05 ACCURACY AND INTEROBSERVER AGREEMENT 
IN IDENTIFYING HISTOLOGIC SUBTYPES IN STAGE I 
LUNG ADENOCARCINOMAS ≤3 CM USING FROZEN 
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Background: The new IASLC/ATS/ERS classification of lung ade-
nocarcinoma (ADC) histologic subtypes is now recommended for 
prognostic stratification. The ability to determine histologic subty-
pe accurately by frozen section (FS) may help surgeons to choose 
limited resection versus anatomic resection in the management of 
lung ADC. The aim of this study is to investigate the accuracy and 
interobserver agreement of FS for predicting histologic subtype.
Methods: FS and permanent section slides from 361 surgically 
resected stage I lung ADCs ≤3 cm were reviewed for predominant 
histologic subtype and presence or absence of lepidic, acinar, 
papillary, micropapillary, and solid patterns. To determine inter-
observer agreement, 50 cases were additionally reviewed by 3 
pathologists. To test the accuracy of FS in determining degree 
of invasion in cases with predominantly lepidic growth pattern, 5 
pathologists reviewed FS slides from 35 patients and attempted to 
discriminate between adenocarcinoma in situ (AIS), minimally inva-
sive adenocarcinoma (MIA), and lepidic predominant adenocarci-
noma (LPA).
Results: 
Parameter Accuracy, % (95% CI)
Sensitivity, 
% (95% CI)
Specificity, 
% (95% CI)
κ
Predominant 
histologic 
subtype
Overall 68 (63–73)
Not appli-
cable
Not appli-
cable
0.565
Lepidic 90 (86–92) 75 (64–84) 93 (90–96) 0.681
Acinar 76 (71-80) 70 (61–77) 79 (73–84) 0.481
Papillary 85 (81-88) 62 (50–72) 91 (87–94) 0.527
Micropapil-
lary
94 (91-96) 21 (9–40) 99 (97–100) 0.277
Solid 91 (88-94) 79 (67–87) 94 (90–96) 0.700
Presence or 
absence of 
each histolo-
gic pattern
Lepidic 80 (76–84) 75 (69–80) 91 (84–96) 0.588
Acinar 89 (85–92) 90 (86–93) 67 (35–90) 0.252
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O17.03 MORPHOLOGICAL AND MUCIN PROFILE OF 
LUNG ADENOCARCINOMA HARBORING DRIVER MUTA-
TION
Noriko Motoi, Yuichi Saito, Eisaku Miyauchi, Seijiro Sato, Hironori 
Ninomiya, Yuichi Ishikawa
Division Of Pathology, Cancer Institute, Japanese Foundation For Can-
cer Research/Japan
Background: Recent advantages of molecular study reveal several 
subsets of lung adenocarcinoma (AdCa) with specific genetic alte-
rations of receptor tyrosine kinase (RTK), including EGFR, ALK, RET 
and ROS, which are dramatically responding to targeted inhibitors 
for activating RTK. The goal of this study is to evaluate the correla-
tion between genetic alteration and histologic phenotype of lung 
AdCa, including cell type characteristics and mucin phenotype.
Methods: 319 surgically resected lung Ad CA was examined ge-
netic alterations of EGFR by Cycleave or direct sequencing, ALK 
by FISH and immunohistochemistry and KRAS by PCR-RFLP and 
direct sequencing methods. Resected materials were reviewed de-
tail histologic findings, using HE-stained slides of whole tumor. A 
histologic predominant subtype of AdCa, based on a new IASLC/
ATS/ERS classification, and nuclear grading were evaluated. The 
mucin phenotype of AdCa was evaluated by Immunohistochemical 
staining, including muc1, muc2, muc5ac and muc6. The correlation 
between genetic alteration and histologic phenotypes was exami-
ned.
Results: Genetic alterations of this study were 150 EGFR, 44 
ALK, 9 KRAS and 116 wild-type. EGFR mutated AdCa had 55.4% 
lepidic- (lep), 40% papillary- (pap), 2.6% of acinar- (aci) and 2% of 
solid- (sol) predominant subtypes. ALK AdCa had 20.5% of lep, 
36.4% pap, 18.2% aci, 22.7% sol and 2.3% micropapillary predomi-
nant subtypes. Kras mutated AdCa were 44.4% pap, 33.3% aci and 
22.2% sol. All wild type AdCa were 35.3% of lep, 53.4% pap, 5.2% 
aci- and 6% sol. Presence of mucin producing cells was observed in 
4.7, 90.9, 66.7, and 26.7% of EGFR, ALK, KRAS and wild type AdCa, 
respectively. EGFR and ALK showed lower nuclear grade compa-
red to KRAS. IHC examination revealed ALK AdCa was positive for 
muc1, but negative for muc2, 5ac and 6, in contrast to wild type /
EGFR AdCa which were positive for muc1, sometimes for muc2, 
muc 5ac and/or muc6.
Conclusion: In summary, the most common histologic phenotype 
of EGFR AdCa was lepidic-predominant, non-mucin producing 
with low nuclear grade; ALK AdCa was papillary, mucin producing 
with low nuclear grade, and KRAS was papillary, mucin producing 
with high nuclear grade. The predominant subtype-based classi-
fication of AdCa showed an incomplete correlation to a genetic 
abnormality. Cell type characteristics, including mucin phenotype, 
would be useful to predict the genetic alteration of lung AdCa, in 
addition to the predominant subtype which is architecture-based 
assessment.
Keywords: Adenocarcinoma, Morphology, Genotype, Mucin phe-
notype
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10 HPFs. Nuclear diameter was evaluated, at ≥3 HPFs in the largest 
nuclei, using nearby small lymphocytes as reference and was clas-
sified as either large (>4 small lymphocytes) or small (≤4). Overall 
survival (OS) was estimated using the Kaplan-Meier method, and 
multivariate analyses were performed using the Cox proportional 
hazards model.
Results: Basaloid subtype correlated with better OS than nonba-
saloid subtype (p=0.046). Tumor budding (p<0.001), single tumor-
cell invasion (p<0.001), and large nuclei (p=0.005) correlated with 
worse OS (Table). However, tumor differentiation and presence 
of keratinization did not correlate with prognosis. The prognostic 
significance of tumor budding was confirmed in a subgroup analy-
sis limited to stage I (p=0.028) and stage II/III (p=0.008) patients. 
In addition, basaloid subtype correlated with favorable prognosis 
(p=0.042), and both single tumor-cell invasion (p=0.014) and large 
nuclei (p=0.021) were associated with poor prognosis in a sub-
group analysis limited to stage I patients. In multivariate analysis, 
tumor budding (HR=1.04; p=0.024) and large nuclei (HR=1.09; 
p=0.035) were independent prognostic factors for survival. 
Table. Overall survival by histologic findings
Histologic 
finding 5-year OS
p
Subtype Basaloid 69% (n=33) 0.046
Nonbasaloid 58% (n=452)
Tumor bud-
ding
+ 39% (n=76) <0.001
- 62% (n=409)
Single cell 
invasion
+ 47% (n=197) <0.001
- 67% (n=288)
Nuclei Large 50% (n=153) 0.005
Small 63% (n=332)
 
Conclusion: Tumor budding and large nuclei, but not histologic 
subtype, were significant prognostic factors, independent of TNM 
stage, for lung SCC. These findings may help to make therapeutic 
decisions and stratify patients for additional therapy.
Keywords: lung, squamous cell carcinoma, histology, survival
Parameter Accuracy, % (95% CI)
Sensitivity, 
% (95% CI)
Specificity, 
% (95% CI)
κ
Papillary 72 (67–77) 70 (64–75) 79 (69–87) 0.397
Micropapil-
lary
67 (62–72) 37 (30–45) 94 (89–97) 0.321
Solid 84 (80–88) 69 (61–76) 96 (92–98) 0.670
 
The accuracy of FS for predicting histologic subtype is shown in 
the Table. There was moderate agreement on the predominant 
histologic subtype between FS diagnosis and final diagnosis 
(κ=0.565). FS had high specificity for micropapillary and solid pat-
terns (94% and 96%, respectively), but sensitivity was low (37% and 
69%, respectively). The interobserver agreement was satisfactory 
(κ > 0.6, except for acinar pattern). All cases of AIS were correctly 
diagnosed using FS. For MIA, only 41.3% of FS diagnoses were 
correct, and 52% were overdiagnosed as LPA; for cases of LPA, 
79% of FS diagnoses were correct.
Conclusion: FS can provide information on the presence of ag-
gressive histologic patterns—micropapillary and solid—with high 
specificity but low sensitivity. FS is not suitable for determining 
the predominant pattern or degree of invasion. Although FS can 
be helpful in diagnosing AIS, it has poor accuracy in distinguishing 
MIA from LPA.
Keywords: Micropapillary, Interobserver agreement, Adenocarci-
noma, Frozen sections
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O17.06 TUMOR BUDDING AND NUCLEAR GRADE, BUT 
NOT HISTOLOGIC SUBTYPE, ARE SIGNIFICANT PROG-
NOSTIC FACTORS, INDEPENDENT OF TNM STAGE, IN 
PATIENTS WITH LUNG SQUAMOUS CELL CARCINOMA
Kyuichi Kadota, Junichi Nitadori, David J. Finley, Valerie W. Rusch, 
Prasad S. Adusumilli, William D. Travis
Memorial Sloan-Kettering Cancer Center/United States Of America
Background: The new IASLC/ATS/ERS lung adenocarcinoma clas-
sification, proposed in 2011, has significant prognostic value. For 
lung squamous cell carcinoma (SCC), however, no pathologic fin-
dings have been widely accepted to predict patient outcomes with 
the exception of TNM stage. Tumor budding has been recognized 
as a factor of poor prognosis in colorectal cancer, and nuclear gra-
ding has been widely accepted as a prognostic indicator in breast 
cancer. In this study, we determine whether histologic findings can 
independently predict prognosis in lung SCC.
Methods: All available tumor slides from patients with therapy-
naive, surgically resected solitary lung SCC (1999-2009) were 
reviewed (n=485; stage I/II/III, 281/136/68). Tumors were graded 
by means of tumor differentiation. Tumors were classified as kera-
tinizing, nonkeratinizing, and basaloid subtypes by presence (≥5%) 
or absence of keratinization and by predominant (≥50%) basaloid 
pattern. Tumor budding (tumor nests composed of <5 cells) and 
presence of single tumor-cell invasion were assessed using 10 
high-power fields (HPFs) (x200 magnification) in the areas with 
the smallest tumor nests. Tumor budding was considered positive 
when the maximum number of budding was ≥10/HPF. Single tu-
mor-cell invasion was considered positive when it was identified at 
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Conclusion: FGFR1 amplification with FISH was identified in 21.3% 
of pure SqCC or carcinomas with a morphologic component or im-
munoprofile of SqCC, but only 1.4% of completely non-squamous 
tumors. All adenocarcinomas and neuroendocrine tumors were 
negative. FGFR1 SISH showed 1:1 correlation to FGFR1 FISH.
Keyword: FGFR1 amplification; lung cancer; FISH; SISH
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O17.07 PREVALENCE, MORPHOLOGY AND NATURAL 
HISTORY OF FGFR1-AMPLIFIED LUNG CANCER DETEC-
TED BY FISH AND SISH
Prudence A. Russell1, Yong Yu1, Richard J. Young2, Matthew Con-
ron3, Zoe Wainer2, Naveed Alam4, Ben Solomon5, Gavin Wright4
1Department Of Anatomical Pathology, St. Vincent‘s Hospital/Australia, 
2Peter MacCallum Cancer Centre/Australia, 3Department Of Respirato-
ry And Sleep Medicine, St. Vincent‘s Hospital/Australia, 4Department 
Of Thoracic Surgery, St Vincent‘s Hospital/Australia, 5Department Of 
Medical Oncology, Peter MacCallum Cancer Centre/Australia
Background: Fibroblast growth factor receptor 1 (FGFR1), which 
codes for a receptor tyrosine kinase, was recently reported to 
be amplified in 20% of lung squamous cell carcinoma (SqCC). In 
vitro and preclinical tests suggest that FGFR1 amplification is a 
therapeutic target. Our aims were to investigate the prevalence 
of FGFR1 amplification by fluorescence in situ hybridization (FISH) 
and determine correlation with outcome in an Australian cohort 
of resected lung cancer. We also correlated results of FGFR1 FISH 
with silver in situ hybridization (SISH).
Methods: A clinically-annotated tissue microarray was constructed 
from resected lung cancer tissue collected from 1996-2012. FGFR1 
FISH and SISH were performed according to manufacturer’s pro-
tocols, with SISH performed on Ventana benchmark XT platform. 
FGFR1 FISH and SISH were scored by one pathologist, with high 
level amplification defined as ratio of FGFR1/centromere 8 ≥ 2, or 
tumor cell percentage with ≥ 15 signals ≥ 10%, or average number 
of FGFR1 signals/tumor cell nucleus ≥ 6, and low level amplifica-
tion as tumor cell percentage with ≥ 5 signals ≥ 50%. Results of 
FGFR1 FISH and SISH were compared. Patient outcome related to 
FGFR1-amplified tumors was assessed and compared to patients 
with SqCC, or with a morphologic component of, or immunoprofile 
of SqCC, but normal FGFR1 copy number.
Results: Of 406 tumors tested, there were 191 pure SqCC, 28 
carcinomas with a SqCC component, 24 large cell carcinomas 
with an immunoprofile of SqCC, 115 adenocarcinomas, 22 pulmo-
nary neuroendocrine tumors, and 28 other carcinomas without a 
morphologic component or immunoprofile of SqCC. FGFR1 am-
plification was assessable in 368 tumors. FGFR1 amplification was 
identified with FISH in 50 tumors, 48 (48/225; 21.3%) of which were 
either pure SqCC or a carcinoma with morphologic component or 
immunoprofile of SqCC. Only two cases were completely of non-
squamous origin (2/143; 1.4%, p<0.00001). FGFR1 SISH was per-
formed in 385 tumors, with 347 tumors assessable. Of 46 FGFR1 
FISH-amplified tumors assessed with FGFR1 SISH, all showed 
FGFR1 amplification with SISH, whilst all other tumors tested were 
negative. Survival from radically treated FGFR1-amplified tumors 
was similar to all others with a squamous component (73% versus 
60% 5-yr survival, HR 0.68, p=0.25; Figure 1).
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and expression profiling of a LUSC from a never-smoker patient 
chronically exposed to arsenic, we identified a distinct mutational 
spectrum and methylation pattern in the As-LUSC. Our results 
support the concept that arsenic induces lung cancers through 
mechanisms different from tobacco smoke and other carcinogens. 
Further study of the mutational profiles of additional arsenic-
related cancers is warranted and may yield valuable insight into 
arsenic associated tumourigenesis, leading to the development of 
novel diagnostic and therapeutic targets for environmental moni-
toring and treatment.
Keywords: mutational spectrum, methylation, Lung cancer, arsenic
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O18.02 IMPACTS OF ENVIRONMENTAL TOBACCO 
SMOKE ON EGFR MUTATIONS AND ALK REARRANGE-
MENTS IN NEVER SMOKERS WITH NON-SMALL CELL 
LUNG CANCER: ANALYSES ON A PROSPECTIVE MULTI-
NATIONAL ETS REGISTRY
Akihito Kubo1, Masahiko Ando2, Ross Soo3, Tomoya Kawaguchi4, 
Sai-Hong I. Ou5, Myung-Ju Ahn6
1Aichi Medical University School Of Medicine/Japan, 2Nagoya Univer-
sity Hospital/Japan, 3National University Of Singapore/Singapore, 
4Internal Medicine, Kinki-chuo Chest Medical Center/Japan, 5Medicine-
Hematology/Oncology, Chao Family Comprehensive Cancer Center, 
University Of California Irvine/United States Of America, 6Division Of 
Hematology-Oncology, Samsung Medical Center, Sungkyunkwan Uni-
versity School Of Medicine/Korea
Background: EGFR and ALK are important driver mutations in 
never smokers. While we reported the significant association of in-
creased environmental tobacco smoke (ETS) with EGFR mutations 
in Japanese cohort (Kawaguchi, Clin Cancer Res, 2011), it has not 
been fully understood in other ethnicities and also the correlation 
of ETS with ALK has not been reported yet. In this study, we evalu-
ated the association of ETS with the prevalence of EGFR mutations 
and ALK translocations in various ethnicities including East-Asia 
(Japan, Korea, China, and Singapore) and the USA.
Methods: ETS exposure on never smokers with non-small cell lung 
cancer (NSCLC) was evaluated using the standardized question-
naire including exposure period, place, and duration. Cumulative 
dose of ETS (CETS) was defined as a sum of the number of the 
exposure years in childhood/ adulthood and at home/ workplace, 
and was treated as a continuous variable or quintile. EGFR muta-
tions and ALK rearrangements were tested by PCR-based detec-
tion and fluorescence in situ hybridization, respectively. Multivari-
ate analyses were done using the generalized linear mixed model 
(GLIMMIX procedure, SAS v9.3).
Results: From March 2008 to December 2012, 498 never smokers 
with NSCLC were registered with the following patient characteris-
tics: ethnicity (nationality) of Asian/ Caucasian/ others, 425 (Japa-
nese 250, Korean 102, Chinese 46, others 2)/ 48/ 25; male/ female, 
114/ 384; age <65/ >=65, 286/ 212; histology of adenocarcinoma/ 
BAC/ squamous cell carcinoma/ adenosquamous cell carcinoma/ 
other NSCLC, 459/ 12/ 13/ 5/ 9; frequency (%) of CETS < median 
CETS (40 years) in Japanese/ Korean/ Chinese/ Caucasian, 32.8/ 
44.1/ 71.7/ 83.3. EGFR status was wild type 43.6%, exon 19 deleti-
on 25.3%, L858R 21.5% and other mutations 9.6%. ALK status was 
wild type 52.0%, rearranged 10.6% and unknown 37.3%. Average 
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O18.01 MULTI-‘OMIC ANALYSIS OF AN ARSENIC-ASSO-
CIATED LUNG SQUAMOUS CELL CARCINOMA REVEALS 
SPECIFIC DNA LEVEL SIGNATURES
Victor D. Martinez Zamora1, Kelsie L. Thu1, Emily A. Vucic1, Roland 
Hubaux1, Marta I. Adonis2, Lionel Gil2, Calum E. Macaulay1,  
Stephen Lam1, Wan L. Lam1
1Integrative Oncology, BC Cancer Agency/Canada, 2Faculty Of Medici-
ne, University Of Chile/Chile
Background: Chronic low-level exposure to arsenic is an emerging 
cancer risk factor in many parts of the world, including North Ame-
rica. The lung is one anatomical site prominently affected by the 
carcinogenic effects of arsenic, evident by the striking incidence 
of lung cancer in never smokers with chronic exposure. Histologi-
cally, arsenic related lung tumors are indistinguishable from those 
induced by other lung carcinogens, and molecularly, arsenic spe-
cific DNA copy-number, methylation and expression changes have 
been identified. Arsenic mediated carcinogenesis occurs through 
a combination of molecular mechanisms; however, high resolution, 
multi-‘omic analyses of arsenic related tumors have been difficult 
due to the lack of fresh frozen samples required to obtain high 
quality DNA and RNA. In this study, we sought to characterize 
global changes in DNA sequence and methylation levels and their 
impacts on gene expression in a lung tumor from a patient with 
chronic arsenic exposure (As-LUSC).
Methods: Tumor and non-malignant lung tissues were obtained 
from a never smoker with lung squamous cell carcinoma (LUSC) 
who had no family history of lung cancer and 50 years of chronic 
exposure to high levels of arsenic-contaminated driNKIng water. 
Whole genome sequencing was performed and the tumor‘s mu-
tational signature was compared to those observed in 194 previ-
ously characterized NSCLC tumors from the cancer genome atlas 
(TCGA). DNA methylation was measured using high density me-
thylation arrays and gene expression by RNA sequencing.
Results: The As-LUSC exhibited alterations typical of LUSC, 
such as copy number gains at 3q26 (SOX2 locus) and expression 
of squamous markers including up-regulation of KRT6B, DSG3, 
MMP12, KRT5, and down-regulation of PDK4, which are consistent 
with LUSC histology. However, the As-LUSC harbored a low num-
ber of point mutations (only 49 non-synonymous mutations affec-
ting coding DNA sequences) and had a remarkably high fraction 
of T>G/A>C and low fraction of C>A/G>T transversions, which are 
features uncharacteristic of LUSCs that suggest arsenic is associa-
ted with a distinct mutational spectrum. Furthermore, at the gene 
level, we identified a G>C mutation in TP53 which is rare in lung 
tumors (<0.2%) but has been observed in other arsenic-related 
malignancies. Clustering analysis using ~450,000 methylation pro-
bes revealed that the As-LUSC methylation profile was completely 
distinct from never smoker LUSCs from the TCGA. Of interest, the 
As-LUSC exhibited lower levels of methylation at CpG islands sores 
that are not associated with genes, although have been described 
to exhibit cell type specific methylation patterns.
Conclusion: By applying whole genome sequencing, methylation 
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der 55 years-old. None reported alternative smoking (pipe, cigar, 
water-pipe, gum, or cannabis). Most of them originated from Wes-
tern and Southern Europe (90.5%). Overall, 219 (65.6%) reported 
a passive smoking exposure in a domestic setting (n=198; 59.3%), 
and/or at workplace (n=60; 18.0%). Patients had a personal his-
tory of pneumonia in 6.2%, tuberculosis in 8.3%, COPD in 13.0%, 
and a cancer at another site in 16.6%. Eighty patients reported at 
least two relatives with lung cancer (24.0%). Definite occupational 
exposure was observed in 12.0% (n=44) for diesel, 7,1% (n=26) 
for asbestos, 3.3% (n=12) for poly-aromatic hydrocarbons, 2.4% 
(n=9) for silica, 0.8% (n=3) for chrome, and 0.5% (n=2) for painting. 
Exposure to cooking oil was noted in 123 patients (36.8%) with a 
mean of 49.4 ± 356.7 cooking-dish year. Moreover, 79.7% (n=259) 
patients were ever exposed to solid fuel fumes for cooking or 
heating (21.2% during more than 50% of their lifetime). Among 
women, 91.7% already reached menopause (mean age 49.3 ± 5.6 
years-old), 115 (41.7%) were ever-exposed to oral contraceptive 
(mostly oestrogen-containing drugs), and 25.5% to post-meno-
pause hormone replacement therapy (oral or transdermal). Most 
of lung cancers were adenocarcinoma (n=327, 85.2%) followed by 
squamous cell carcinoma (n=29, 7.6%) and large cell carcinoma 
(n=17; 4.4%). Among adenocarcinoma, 71% were invasive, 4% in-
situ, 2% minimally-invasive, 2% variant of invasive, and 20.0% were 
NOS. Cancer stage was I in 9.2%, II in 5.8%, III in 11.8% and IV in 
73.2%. At least one biomarker was tested in 359 patients (93.5%). 
We found 148 patients with EGFR mutations (43.5% out of the 
EGFR-tested patients), 20 with KRAS mutations (6.8%), 24 with ALK 
translocation (12.5%), 10 with BRAF mutation (4.5%), 8 with HER2 
mutation (4.0%) and 4 with PIK3CA (2.1%). Overall, 27.0% samples 
remain wild type, 2.1% with multiple mutations, 71.0% with a single 
mutation, and 20.6% with missing data.
Conclusion: We provide here the largest cohort of LCINS in a 
European setting with reliable data on tobacco intoxication, occu-
pational exposure, and hormonal treatments, since collected by 
a trained staff through phone interview. In this perfectly clinically 
characterized cohort, molecular analyses showed that 72% of tu-
mors exhibited oncogenic targetable mutations.
Keywords: carcinogens, Epidemiology, never-smoker, non-small 
cell lung cancer
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O18.04 IMPACT OF PASSIVE SMOKING ON MOLECULAR 
PATTERN IN NEVER SMOKERS WITH NON-SMALL CELL 
LUNG CANCER: FINDINGS FROM THE BIOCAST / IFCT-
1002 STUDY
Sebastien Couraud1, Patrick Dumont2, Lionel Moreau3, Didier Debi-
euvre3, Jacques Margery4, Elisabeth Quoix5, Bernard Duvert3, Lau-
rent Cellerin6, Nathalie Baize6, Bruno Taviot7, Marie Coudurier3, 
Jacques Cadranel8, Pascale Missy9, Gerard Zalcman10, Pierre-Jean 
Souquet1
1Pneumologie - Hcl/France, 2Pneumologie, Ch/France, 3Centre Hospita-
lier/France, 4Respiratory Medicine Department, Percy Military Hospital/
France, 5Service De Pneumologie, Nhc/France, 6Pneumologie, Chu/
France, 7Centre Médical Nicolas De Pontoux/France, 8Hôpital Tenon, As-
sistance Publique-hôpitaux De Paris/France, 9Ifct/France, 10Respiratory 
Diseases And Thoracic Oncology, Caen University Hospital/France
Background: EGFR and HER2 mutations are usually associated 
with never-smokers while KRAS and BRAF mutations are thought 
CETS (years) of NS with EGFR (+), ALK (+) and wild type tumors 
were 45.4, 26.9 and 37.7, respectively. In multivariate generalized 
linear mixed model, incidence of activating EGFR mutations, not 
ALK rearrangements, was significantly associated with the incre-
ment of CETS in female, not in male gender. Odds ratios (OR) for 
EGFR mutations in female (n=384) were 1.084 (95% CI, 1.003-1.171; 
p=0.0422) for each increment of 10 years in CETS while OR in 
male (n=114) were not significant (OR 0.890; 95% CI, 0.725-1.093; 
p=0.2627). OR for ALK rearrangements in female (n=238) and tho-
se in male gender (n=74) were 0.930 (0.791-1.094; p=0.3814) and 
0.854 (0.620-1.178; p=0.3319).
Conclusion: Increased ETS exposure was closely associated with 
EGFR mutations in never smokers with female gender and NSCLC 
in the expanded multinational cohort. However, the association of 
ETS and ALK rearrangements in never smokers with NSCLC was 
not significant.
Keywords: non-small cell lung cancer, EGFR, ALK, environmental 
tobacco smoke
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O18.03 THE BIOCAST / IFCT-1002 STUDY: A COMPRE-
HENSIVE OVERVIEW OF DEMOGRAPHIC, RISK EXPO-
SURE AND SOMATIC MUTATIONS OF NON-SMALL CELL 
LUNG CANCER OCCURRING AMONG FRENCH NEVER 
SMOKERS
Sebastien Couraud1, Pierre-Jean Souquet1, Christophe Paris2, Radj 
Gervais3, Hélène Doubre4, Eric Pichon5, Adrien Dixmier6, Isabelle 
Monnet7, Bénédicte Etienne-Mastroianni8, Michel Vincent9, Jean 
Tredaniel10, Marielle Perrichon11, Pascal Foucher12, Bruno Cou-
dert13, Denis Moro-Sibilot14, Eric Dansin15, Stéphanie Labonne1, 
Pascale Missy16, Gerard Zalcman17
1Pneumologie - Hcl/France, 2Inserm U420 - Faculté De Médecine/
France, 3Centre François Baclesse/France, 4Hôpital Foch/France, 5Centre 
Hospitalier Universitaire/France, 6Chu/France, 7Service De Pneumolo-
gie, Centre Hospitalier Intercommunal De Creteil/France, 8Pneumologie 
- Hcl Pradel/France, 9Hôpital Saint Joseph - Saint Luc/France, 10Pneu-
mology, Hôpital Saint Joseph/France, 11Pneumologie, Ch/France, 12Pneu-
mologie, Chu/France, 13Clcc/France, 14Unité D’oncologie Thoracique–
pneumologie/France, 15Oncology, Centre Oscar Lambret/France, 16Ifct/
France, 17Respiratory Diseases And Thoracic Oncology, Caen University 
Hospital/France
Background: Lung cancer occurring in never-smoker (LCINS) is 
a particular entity. Although the definition is strict (less than 100 
cigarette in lifetime) never-smokers are frequently misclassified and 
no study gives a comprehensive analysis of this group, particularly 
in a European setting.
Methods: All consecutive never-smoker patients diagnosed with 
a non-small cell lung cancer in one of the 75 participating centers 
throughout France, between November 2011 and January 2013, 
were included in this prospective survey. All patients underwent a 
detailed questionnaire supported by a trained staff during a phone 
interview. Somatic mutations and cancer clinical and histological 
data were also recorded from medical charts.
Results: Overall, 384 never-smokers were included and 336 inter-
views were completed. Most of them were women (n=319, 83.1%). 
The mean age at diagnosis was 69.8 ± 12.02 and 10.9% were un-
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Conclusion: Although we report the largest and more comprehen-
sive study focusing on this topic, we found no significant difference 
in the biomarker mutation profile of NSCLC occurring in French 
never-smokers regarding their exposure to passive smoking as 
compared with the pattern of mutations described never-smoker 
patients with any passive smoking.
Keywords: never smokers, passive smoking, Biomarkers, non-small 
cell lung cancer
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O18.06 VIETNAMESE NON-SMALL CELL LUNG CANCER 
PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND 
CLINICAL CHARACTERISTICS
Kim-Son H. Nguyen1, Millie Das1, Kavitha Ramchandran1, Joseph 
Shrager2, Robert E. Merritt2, Chuong Hoang2, Bryan Burt2, Alison 
Tisch3, Judy Pagtama3, James Zehnder4, Gerald Berry4, Heather A. 
Wakelee1, Anh-Hoa Nguyen5, Joel W. Neal1
1Division Of Oncology, Department Of Medicine, Stanford University 
School Of Medicine/United States Of America, 2Division Of Thoracic 
Surgery, Department Of Cardiothoracic Surgery, Stanford University 
School Of Medicine/United States Of America, 3Stanford Cancer Ins-
titute/United States Of America, 4Department Of Pathology, Stanford 
University School Of Medicine/United States Of America, 5Ak Research 
Group/United States Of America
Background: Lung cancer is the leading cause of cancer-related 
deaths worldwide with 1.3 million deaths per year. Discoveries of 
oncogenic mutations in non-small cell lung cancer (NSCLC) over 
the past decade have led to targeted therapies against epidermal 
growth factor receptor (EGFR) activating mutations, anaplastic 
lymphoma kinase (ALK) gene rearrangement, and repressor of 
silencing 1 (ROS1) gene rearrangement. The frequencies of these 
mutations and gene rearrangements have been elucidated in the 
Western and East Asian populations. However, the frequencies of 
these oncogenic alterations remain unknown in Vietnam, where 
lung cancer is one of the leading causes of cancer mortalities but 
molecular testing is not routinely performed due to limited resour-
ces. In this project, we aimed to analyze the Vietnamese patients 
treated at Stanford, California, with a future plan to compare with 
another cohort inside Vietnam.
Methods: We collected molecular and clinical variables of NSCLC 
patients of Vietnamese origin, based on patients‘ self-reported 
ethnicity, language, or country of origin, treated at Stanford from 
2009 to 2012. Comparison of the molecular and clinical charac-
teristics of never smokers versus smokers was performed with 
Pearson‘s chi-squared test for nominal variables and Student‘s t 
test for continuous variables. Survival analyses were done using 
the Kaplan-Meier method and Cox proportional hazards modeling.
Results: Forty-six patients of Vietnamese origin were seen at the 
Stanford thoracic oncology clinic from 2009 to 2012, including 22 
men and 24 women with a mean age of 58 years. Twenty-seven 
(58.7%) were never-smokers. Forty-two (91.3%) of the tumors were 
adenocarcinoma. Ten patients (21.7%) presented at stage I, none 
at stage II, 8 patients (17.4%) at stage III, 28 patients (60.9%) at 
stage IV. Fifteen patients out of 28 tested for EGFR (53.6%) had an 
activating mutation; 14 of these 15 patients were never-smokers. 
Five patients out of 16 tested for ALK (31.3%) had ALK gene re-
arrangement. No ROS1 gene rearrangement out of 3 patients 
to be link with smoking behavior in Non-Small Cell Lung Cancer 
(NSCLC). Passive smoking exposure is a well-known risk factor for 
lung cancer. Only EGFR and KRAS mutations were investigated in 
association with passive smoking and showed conflicting results. 
We aimed to investigate mutation rate of EGFR, HER2, KRAS, 
BRAF and ALK in a cohort of never smokers regarding their passive 
smoke exposure.
Methods: The BioCAST / IFCT-1002 study is a prospective cohort 
of NSCLC patients diagnosed in French never-smokers patients 
(less than 100 cigarettes in lifetime) between November 2011 and 
January 2013, Passive smoking exposure was evaluated through 
standardized questionnaire. We obtained biomarkers mutation re-
sults through routine testing. We used Fisher, Chi-square, median 
test and Mann-Whitney U test for comparisons as appropriate. We 
used logistic regression to calculate adjusted odds ratio for risk of 
each mutations.
Results: Out of the 384 patients included in the BioCAST databa-
se, 334 (87.0%) had available data on passive smoking exposure. 
Among them, 219 patients (65.6%) were ever exposed to passive 
smoking in their lifetime. 198 (59.3%) reported a domestic expo-
sure (122 during childhood at least) and 60 (18.0%) a workplace 
exposure. Result of at least one biomarker mutation was available 
in 313 patients (93.7%). including 128 EGFR mutations in 297 pati-
ents, 8/174 HER2 mutations, 18/256 KRAS mutations, 10/196 BRAF 
mutations, and 20/171 ALK gene rearrangements. We found no 
difference in mutation rate according to passive smoke exposure 
(cf. Table 1). There was no difference when comparing cumulative 
year of exposure, smoker-year or passive-pack year (as continuous 
variable) to the mutation rate, for any biomarker. When considered 
as categorical variable – after division in quartiles – we found also 
no difference. Results were similar when focusing on domestic 
(childhood versus adulthood included) and workplace exposure 
only. Finally, we found no significant increased risk for mutation for 
any biomarker in logistic regression adjusted for most of other lung 
cancer risk factors. 
EGFR 
Mt 
(n=297)
HER2 
Mt 
(n=171)
KRAS 
Mt 
(n=256)
BRAF 
Mt 
(n=196)
ALK 
Fusion 
(n=171)
% % % % %
Overall 
exposure
Never 46.5 3.5 6.7 5.9 13.0
Ever 41.3 5.1 7.2 4.7 11.1
Domestic 
exposure
Never 45.8 2.9 7.7 6.4 11.1
Ever 41.3 5.7 6.6 4.2 12.0
Exposure 
at work-
place
Never 43.3 5.5 7.0 5.4 12.2
Ever 42.3 0 7.0 3.6 8.3
Total 43.1 4.6 7.0 5.1 11.7
Exposure 
in child-
hood
Ever 40.5 3.0 6.5 2.7 14.7
Only 
in 
adult-
hood
42.6 10.3 6.8 6.7 7.5
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pulmonale among workers involved in nickel mining or smelt in 
China.
Keyword: Nickel, Mortality, Lung cancer, Silicosis
tested was found. Only one patient, a former smoker, out of 23 
tested (4.4%) was found to have a KRAS mutation. Eighteen out of 
27 never-smokers (66.7%) and 3 out of 19 smokers (15.8%) had a 
targetable driver mutation (EGFR, ALK, or ROS1). For all stages, the 
median overall survival (OS) for never-smokers was 22.3 months 
(95% confidence interval (CI); 11.9 months, 24.3 months) compared 
to 12.9 months (95% CI; 5.8 months, 20.0 months) for smokers. For 
only stage IV, the median OS for never-smokers was 21.2 months 
(95% CI; 13.0 months, 24.3 months) compared to 11.6 months (95% 
CI; 1.4 months, 30.9 months) for smokers.
Conclusion: Approximately two-thirds of never-smoker patients of 
Vietnamese origin had NSCLC with a targetable driver mutation. 
OS differ markedly by smoking status. The high percentage of 
Vietnamese patients in California with driver mutations warrants 
further studies to evaluate the frequencies of NSCLC driver muta-
tions inside Vietnam, strongly suggesting that nationwide imple-
mentation of routine molecular testing will have a positive impact 
on clinical management of Vietnamese patients with NSCLC.
Keyword: lung cancer, epidemiology, vietnam, molecular profiles
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O18.07 A RETROSPECTIVE COHORT MORTALITY STUDY 
IN JINGCHUAN OF CHINA - THE LARGEST NICKEL PO-
PULATION IN WORLD
Ning Cheng1, Li Ma1, Tongzhang Zheng2, Jie He3, Min Dai3, Yawei 
Zhang2, Yana Bai1
1Center For Cancer Prevent And Treatment, Lanzhou University/China, 
2Public Hearth School, Yale University/United States Of America, 3Can-
cer Institute And Hospital, Chinese Academy Of Medical Sciences/China
Background: Nickel is an essential trace metal used in the occup-
ational setting and is naturally found in the general environment, 
resulting in both occupational and nonoccupational exposures 
to individuals at varying levels. Exposure to nickel has been as-
sociated with several toxicites and the International Agency for 
Research on Cancer has concluded that there is sufficient evidence 
in humans associating exposure to nickel or nickel compounds 
with risk of lung cancer. We evaluated overall and cause-specific 
mortality among Chinese workers involved in nickel production or 
utilization in order to examine the long-term health effects of occu-
pational exposure to nickel compounds.
Methods: The study design was a retrospective cohort mortality 
study including 432,526 workers who were involved with nickel mi-
ning or smelt between 2001 and 2010. We calculated standardized 
mortality ratios (SMR) using the death rates of Gansu Province in 
China, and estimated by the exact probabilities of the Poisson 
distribution.
Results: Overall, the all-cause mortality was decreased in all 
workers compared to the general population of Gansu province 
(SMR= 0.53, 95%CI: 0.51-0.55). Analyses examining cause-specific 
mortality revealed an increase in the mortality from bronchogenic 
carcinoma and lung cancer (SMR = 2.05, 95% CI = 1.84-2.29), cor 
pulmonale (SMR =4.08, 95% CI = 3.25-5.01), and silicosis (SMR = 
13.59, 95%CI =11.90-15.52) in the workers exposed to nickel.
Conclusion: This study confirmed a significant excess of mortality 
from diseases of the lung including silicosis , lung cancer, and cor 
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measures or treatments commonplace in fully developed coun-
tries. Inexpensive collaborative technologic tools as demonstrated 
in this pilot can serve as a bridge between developed and deve-
loping countries in combination with the will to improve health 
among the planet‘s poorest communities
Keyword: Global Health, Oncology, Informatics, Networking
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O19.02 DEVELOPING GUIDANCE FOR THE SUPPORTIVE 
AND PALLIATIVE CARE OF LUNG CANCER AND MESO-
THELIOMA PATIENTS AND THEIR CARERS
Angela D.M. Richardson1, Jeanette Draffan2, John White3
1Glenfield Hospital, University Hospitals Of Leicester/United Kingdom, 
2University Hospitals Of North Tees/United Kingdom, 3Leeds Teaching 
Hospitals NHS Trust/United Kingdom
Background: Lung cancer remains the United Kingdom‘s commo-
nest cause of cancer death and accounts for 1 in 14 of UK deaths 
from cancers. Approximately 41,428 new cases of lung cancer and 
2500 new cases of mesothelioma are diagnosed in the UK (CRUK 
: Cancer Research UK 2009.) Evidence shows eighty per cent of 
people will present with advanced disease and the majority of the-
se will die within a year of diagnosis (CRUK 2009.) There is a large 
amount of evidence in existence to support end of life care but 
this is very generic in nature. Consensus opinion from the National 
Lung Cancer Forum for Nurses recognised the need for specialist 
guidance for lung cancer and mesothelioma patients to enhance 
their end of life experience and to inform health care professionals 
who are caring for this group of patients. The focus of the project 
was to develop guidance driven by evidence from patients and 
carers, to focus on issues highlighted by them that were important. 
Previous guidance produced had not had this direct focus.
Methods: This guidance has been developed over an eighteen 
month period by a dedicated working party with expertise in ca-
ring for lung cancer and mesothelioma patients and carers and 
incorporating current evidence and guidance which was reviewed 
extensively. The document provides detailed supportive and pal-
liative care specialist interventions to assist any health care pro-
fessional who is caring for a patient with advanced lung cancer or 
mesothelioma. The guidance is focused around nine key elements 
that were identified in work carried out by the Health Experience 
Research Group at the University of Oxford. Cancer patients iden-
tified nine key areas of their care that were important to them or 
that they found to be lacking. Holistic approach to care. Getting 
the bad news. Care co ordination. Responsiveness and ease of 
access to benefits and support. Pain control and symptom ma-
nagement. Staff attitudes and empathy. End of life choice and the 
actual experience. Carer focus. Each of these nine key elements 
are addressed within the guidance. Recommendations are made 
based on evidence and specialist experience. Good practice ex-
amples are included collected from a wide range of lung cancer 
services across the United Kingdom to assist users to develop their 
own practice.
Results: The guidance was completed and published in Novmber 
2012. The guidance provides a usable document with evidence 
and practice examples to assist health care professonals to impro-
ve supportive and palliative care within their area. The document 
is being diseminated locally by specialist lung cancer nurses and 
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O19.01 HEALTH INFORMATICS AND ONCOLOGY IN 
GLOBAL HEALTH: A PILOT PROGRAM IN AFFORDABLE 
NETWORK TECHNOLOGIES IN HAITI
Pierre R. Theodore1, Aenor Sawyer1, John Donovan2, Ruth 
D‘Amuse3, Christopher Yeh4
1Surgery, University Of California San Francisco Medical Center/Uni-
ted States Of America, 2Anesthesia Critical Care, UCSF/United States 
Of America, 3Oncology, Partners In Health Bon Saveur Clinique/Haiti, 
4Pbworks Corporation/United States Of America
Background: A projected 75% increase in cancer deaths are 
expected in Low and Middle Income Countries (LMIC) by 2020. 
As successful battles against infectious disease and malnutrition 
deaths are waged, the demands on poor healthcare systems to 
create affordable oncology infrastructure will become ever more 
acute. Effective and efficient collaborative technologies that per-
mit presentation of cases from resource limited environments to 
healthcare professionals in the developed world can aid in decisi-
on making, treatment planning and education. In this trial a novel 
clinical platform was launched in Haiti and we present a case of a 
chest wall malignancy demonstrating the platform‘s capacity for 
collaboration and clinical management between a resource limited 
community hospital in Haiti and Academic Medical Centers in the 
United States.
Methods: An Extensible Markup Language (XML) based system 
was built according to specifications of clinicians in the Thoracic 
Oncology Service of University of California San Francisco Medical 
Center. In a community hospital in Saint Marc, Haiti 30 cases invol-
ving a variety of clinical conditions across adult and pediatric onco-
logy and traumatic disease were presented to Academic Medical 
Center volunteer physicians in the United States on a web-based 
asynchronous clinical collaboration system. The infrastructure re-
quired transfer over a wireless network in Haiti followed by secure 
transmission via internet to the dedicated servers in the United 
States.
Results: Case 1: A 32 year old Haitian Male presented to the Ho-
pital Saint Nicholas in Saint Marc, Haiti with posterior chest and 
shoulder pain and a chest wall mass extending to the scapula. 
X-rays revealed a destructive lesion of the chest wall without frank 
mass within the pulmonary parenchyma. An open biopsy was per-
formed and the specimen transferred for pathologic evaluation at 
The University of California San Francisco. Clinicians from 3 medi-
cal centers in the US came to a consensus opinion regarding diag-
nosis (unicentric plasmacytoma of chest wall) and treatment strate-
gy within 3 days. Digital images of Immunohistochemical staining, 
X-rays uploaded to the collaboration platform via a smartphone 
photo app and literature reviews of the case were transmitted to 
Haitian physicians including a treatment plan recommendations 
. 29 additional patients have been offered evaluation in a web 
based environment and will be discussed.
Conclusion: Oncology cases in the developing world are increasin-
gly prominent in light of advances in combating infectious disease 
and poverty related malnutrition. However resource limited envi-
ronments may not have access to clinical decision tools, diagnostic 
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referral were for physical symptoms. The majority reported that 
Palliative Care is either very important or important for patients 
with psycho-social issues or foreseeable future psycho-social issu-
es, yet only half of respondents agreed that psycho-social issues 
would trigger a referral to Palliative Care. When asked for the main 
reasons for not referring to Palliative Care, 60% agreed they do 
not refer when the patient has no symptoms and 60% also agreed 
they do not refer if they can manage the patients’ symptoms them-
selves. However, only 38% of clinicians reported they were well 
trained to take care of the symptoms of advanced cancer patients. 
Issues related to patients not understanding or accepting their 
prognosis were cited as barriers to referral by more than a third of 
clinicians.
Conclusion: Clinicians involved in the care of patients with in-
curable lung cancer have positive perceptions and attitudes to 
Palliative Care but this may not translate into routine referral of all 
patients with incurable lung cancer. In order to make referral rou-
tine, we need education around the perception that only patients 
with unmanageable symptoms benefit from referral to Palliative 
Care. Furthermore, additional training of oncologists about symp-
tom management appears desirable since a significant proportion 
reported a deficiency in this area.
Keyword: palliative care, lung cancer, attitudes
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O19.05 GUIDANCE FOR THE ASSESSMENT OF PATIENTS 
FOLLOWING PALLIATIVE RADIOTHERAPY FOR LUNG 
CANCER
John White, Diana Borthwick
United Kingdom National Lung Cancer Forum For Nurses/United King-
dom
Background: Palliative radiotherapy to the thorax is very effective 
at managing symptoms and improving quality of life but can also 
have significant toxicity. Dosing decisions are a balance between 
potential benefit and toxicity in patients whose prognosis and 
performance status is poor and who are likely to have multiple 
co-morbidities and complex causation of symptoms. Observa-
tions made by the members of the Uinted Kingdom National 
Lung Cancer Forum for Nurses (NLCFN) raised concerns that this 
group of patients may not be receiving optimal intervention and 
support following palliative radiotherapy. The NLCFN has there-
fore produced Guidance for the Assessment of Patients following 
Palliative Radiotherapy for Lung Cancer to aid Lung Cancer Nurse 
Specialists (LCNS) in the assessment and intervention of patients 
undergoing low dose palliative radiotherapy for symptoms related 
to lung cancer and side effects from treatment.
Methods: A NLCFN working group was created to analyse the ob-
servation of sub-optimal care following palliative radiotherapy. A 
literature review was undertaken to identify current best evidence 
and practice. A survey was undertaken to question LCNS, Clinical 
Oncologists, as well as Radiographers who could provide whether 
there was a need for such a guideline. 53 responses were received. 
Following analysis of the survey and discussion within the working 
group the Guidance for the Assessment of Patients following Pal-
liative Radiotherapy for Lung Cancer was produced. The guidance 
aims to aid LCNS in the assessment and intervention of patients 
undergoing low dose palliative radiotherapy for symptoms related 
nationally via the National Lung Cancer Forum for Nurses.
Conclusion: Although recently published and to date has not been 
formally evaluated, this guidance has been well received by health 
care professionals and organisations associated with the care of 
lung cancer and mesothelioma patients. References 1. Cancer 
Research UK (2009) : Incidences of Lung Cancer (online) Cancer 
Research UK. Available from 2. Health Experience Research Group 
(HERG) University of Oxford, GC Associates, Unpublished.
Keyword: Guidance, Supportive, Palliative Care
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O19.03 PERCEPTIONS AND ATTITUDES TO EARLY IN-
TEGRATION OF PALLIATIVE CARE FOR PATIENTS WITH 
INCURABLE LUNG CANCER
Linda Mileshkin1, Jennifer Philip2, Odette Spruyt1, Katie Doan3, 
Matthew Conron4, Dishan Gunawardana5, Shirley Carvosso6, Di 
Saward6, Brian Le3
1Division Of Cancer Medicine, Peter MacCallum Cancer Centre/Aus-
tralia, 2Centre For Palliative Care, St Vincent‘s Hospital/Australia, 
3Department Of Palliative Care, Royal Melbourne Hospital/Australia, 
4Department Of Respiratory Medicine, St. Vincent‘s Hospital/Austra-
lia, 5Department Of Medical Oncology, The Royal Melbourne Hospital/
Australia, 6Western And Central Melbourne Inegrated Cancer Services/
Australia
Background: Lung cancer is the leading cause of death from can-
cer in Australia with the majority of patients diagnosed with late 
stage incurable disease. Although there is evidence of patient 
benefit from early involvement with specialist palliative care, this 
may not translate into clinical practice. The aim of this study was 
to explore clinicians’ perceptions and attitudes to Palliative Care 
referral.
Methods: A modified validated self-report palliative care referral 
questionnaire (Johnson, 2008) was given to doctors and nur-
ses working in the multi-disciplinary lung cancer teams at three 
teaching hospitals in metropolitan Melbourne. Participants were 
asked whether listed items had contributed to referral (9 triggers) 
or non referral (15 barriers) of their patients. Level of agreement 
with 22 attitudinal and perception items explored clinicians’ views 
about palliative care.
Results: 55 questionnaires were distributed and 42 completed 
(76% response rate). Respondents had a median of 6 years (in-
terquartile range 3-12) of experience practicing in their specialty. 
One-third (14/42) were doctors working in Medical Oncology, 26% 
(11/42) in Respiratory Medicine, 19% (8/42) in Radiation Oncology, 
and 12%, (5/42) in Surgical Oncology, plus two oncology nurses 
and one physician trainee.93% of respondents agreed that early 
referral to Palliative Care is beneficial to patients and 95% agreed 
that Palliative Care can benefit patients receiving active treatment. 
The majority (69%) of clinicians believe that their relationship with 
the patient continues when she/he elects to have specialist pal-
liative care. 71% indicated that it is not difficult to refer a patient 
they have cared for a long time and have a close relationship with. 
Almost two-thirds (64%) disagreed that when they first bring up 
palliative care patients give up hope. However, only 60% of re-
spondents agreed that all advanced cancer patients should be 
referred to Palliative Care. The most frequently cited reasons for 
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Results: Following the literature review, although there was signi-
ficant evidence of toxicity profiles and effects of treatment, there 
were no examples of how to address the support needs of patients 
following palliative radiotherapy to the thorax. Of the 53 respon-
ses, 75% said that there was a need for the service, 54% were not 
aware of current practice in radiotherapy follow up support, with 
55 % stating that a review should take place between 1 and 2 
weeks after treatment. The working group produced the guideline 
following discussion in relation to these outcomes.
Conclusion: The Guidance for the Assessment of Patients fol-
lowing Palliative Radiotherapy for Lung Cancer aims to guide LCNS 
and the treating teams in the assessment and intervention of pa-
tients undergoing low dose palliative radiotherapy for symptoms 
related to lung cancer. The guideline contains flow charts with 
recommended interventions together with documentation profor-
ma and Common Toxicity Criteria. In the UK patients are treated in 
Cancer Centres and often repatriated to secondary care for review 
and follow-up. The formal assessments provided in the Guidance 
can be implemented either in the clinic, telephone or home visit. 
The guideline could be adapted for use in other health care sys-
tems other than the UK and can be found at http://www.nlcfn.org.
uk/NLCFN-guidelines.htm
Keywords: Lung cancer, palliative radiotherapy, lung cancer nurse 
specialist, supportive care
to lung cancer and side effects from treatment. 
Table 1 
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O19.07 RESOURCE UTILIZATION IN THE LAST THREE 
MONTHS OF LIFE BY LUNG CANCER PATIENTS IN THE 
HAMILTON-NIAGARA-HALDIMAND-BRANT LOCAL 
HEALTH INTEGRATION NETWORK (LHIN)
Peter M. Ellis1, Susan Schiff2, Adrianne Van Dam2, Claire Mcmil-
lan3, Marissa Slaven1, Sally Hapke1, Lorraine Martelli-Reid4, Phillip 
Hughes5, John R. Goffin1, Jonathan Sussman1
1Juravinski Cancer Centre/Canada, 2Supportive Cancer Care Research 
Unit, Mcmaster University/Canada, 3Wayne Medical School, University 
Of Queensland/Australia, 4St Josephs Hospital/Canada, 5Walker Family 
Cancer Centre/Canada
Background: Data from the Ontario Cancer System Quality Index 
demonstrate a high use of Emergency Department (ED) services by 
lung cancer patients in the last three months of life. There is a need 
to better understand the resource utilization of lung cancer patients 
during this time period.
Methods: A retrospective cohort study was undertaken to evaluate 
resource utilization in the last three months of life for new patients 
with lung cancer seen at the Juravinski and Walker Family Cancer 
Centres between January and June 2011and deceased prior to July 
2012. Data abstracted from patient records included demographics, 
staging, treatment, referral to palliative care, use of community ser-
vices, visits to the cancer centre and family doctor, visits to the emer-
gency department and hospitalizations in the last three months of life. 
The primary outcome was the proportion of patients using the ED in 
the last three months of life. Secondary outcomes include the propor-
tion of patients hospitalized, place of death, and the use of communi-
ty and palliative care services.
Results: There were 323 new patients seen during the six month peri-
od and 162 were deceased at the time of data cut-off. There were 86 
men (53%) and 76 women (47%), with a median age at diagnosis was 
68.9 years (range 38-90). The majority were married (66%), but 20% 
were living alone. Twenty percent of patients had SCLC, 73% NSCLC 
and 7% did not have tissue diagnosis. Most patients (n=141, 87%) 
were treated with palliative intent from the outset. Chemotherapy was 
administered to 63 patients (39%) with 11 (7%) receiving chemothe-
rapy within the last 2 weeks of life. A greater proportion of patients 
received radiation therapy (n=111, 69% [10% radical, 90% palliative]). 
The median overall survival was 4.1 months (95%CI 3.4-4.8m). The ma-
jority of patients (n=132, 82%) were referred to community care servi-
ces (CCAC) and most of these received community palliative services 
(n=113, 70%). The median time from CCAC referral to death was 2.5 
months (0.3 – 31 months). There was documentation about a change 
in goal from active treatment to supportive care in 38% of patients 
and documentation of end of life discussion in 66% of patients. Place 
of death was: hospital (51%), home (21%), hospice/palliative care ins-
titution (20%), unknown (8%). During the last three months of life 93% 
visited the cancer centre (median visits 2, range 0-10) and 67% made 
calls to the cancer centre (median 1, range 0-19). Visits to the ED were 
made by 118 patients (73%, median visits 1, range 1-9) and 36 pati-
ents were hospitalized (22%, median 1, range 1-5). Patients referred to 
CCAC were less likely to visit the ED (72% v 83%, p=0.2).
Conclusion: Lung cancer patients use considerable range of services 
during the last three months of life. Use of acute care services such as 
the ED and hospitalizations are common. CCAC referral has a small 
impact on the use of acute care services.
Keywords: Lung cancer, end of life care, resource utilization
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O19.06 A RETROSPECTIVE STUDY INTO THE IMPACT 
PALLIATIVE CARE INTERVENTION HAD ON PLACE OF 
DEATH FOR PATIENTS DIAGNOSED WITH NON-SMALL 
CELL LUNG CANCER BETWEEN 2006 AND 2011 IN THE 
ILLAWARRA SHOALHAVEN LOCAL HEALTH DISTRICT
June A. Rose
Cancer Care Centre, Wollongong Hospital/Australia
Background: Between 01/01/2006 and 31/12/2011, 1070 cases of 
non-small cell lung cancer (NSCLC) were registered in the Illawarra 
Shoalhaven Local Health District (ISLHD) Clinical Cancer Registry 
(ClinCR); having been diagnosed and/or received a cancer directed 
treatment (including end-of-life palliative care) in an ISLHD public 
facility. A retrospective study was undertaken to determine the 
impact palliative care involvement had on the place of death for 
patients in this cohort who were known to be deceased.
Methods: A retrospective study was undertaken using data recor-
ded in ClinCR. Data items include date of death, name of public 
facility where death occurred, palliative care status and date of 
referral to palliative care. Patients who did not die in public hospi-
tal had the place of death recorded in a free text box in ClinCR if 
it was documented in one of ISLHD’s electronic medical records: 
PowerChart, iPM, CHIME or MOSAIQ.
Results: Of the 1070 cases, 936 (87.5%) patients were known to 
be deceased, with 93% (872n) of those patients dying locally: pal-
liative care facility 52% (454n); hospital 27.5% (240n); home 14.5% 
(127) and RACF 6% (51n). The remaining 7% died out of the Area 
(12n) or had “unknown” recorded for place of death (52n). 87% of 
those known to be deceased were referred to palliative care. Of 
the deceased patients not referred to palliative care, 45% died in 
an acute hospital, compared to 14% of those who were referred to 
palliative care. Home was the second most frequent place of death 
(15% 121n) for patients referred to palliative care.
Conclusion: This study shows the impact palliative care involve-
ment had on the place of death for non-small cell lung cancer 
patients in ISLHD. Although more than 50% died in a dedicated 
palliative care ward/facility, the data shows that patients with palli-
ative care intervention are more likely to die in their home, and less 
likely to die in an Acute Hospital. Patients with respiratory cancers 
may require hospital admissions due to local complications which 
may not occur in other cancers; making a comparison between this 
and another tumour stream a worthwhile exercise.
Keywords: place of death, palliative care
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Table 2: Patient numbers according to nodal status.
Path + Path - PET + PET -
TEMLA + 9 0 4 5
TEMLA - 3 53 9 47
PET + 6 7
PET - 6 46
 
Conclusion: TEMLA is superior to PET/CT for restaging of the 
mediastinum after induction therapy. Since TEMLA showed little 
added morbidity despite central tumor and treatment effects, con-
sideration should be given for its widespread adoption for medias-
tinal re-staging of NSCLC after neoadjuvant therapy.
Keywords: NSCLC, Post neo-adjuvant staging, TEMLA, PET-CT
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O20.01 TRANSCERVICAL EXTENDED MEDIASTINAL 
LYMPHADENECTOMY (TEMLA) IS SUPERIOR TO PET/
CT FOR RESTAGING OF THE MEDIASTINUM AFTER 
NEOADJUVANT THERAPY FOR NON-SMALL CELL LUNG 
CANCER (NSCLC)
Sai Yendamuri, Athar Battoo, Isidore Dinga-Madou, Chukwumere 
Nwogu, Elisabeth Dexter, Mark Hennon, Anthony Picone, Todd 
Demmy
Department Of Thoracic Surgery, Roswell Park Cancer Institute/United 
States Of America
Background: Accurate staging of the mediastinum is critical in 
therapeutic decision making in NSCLC. PET/CT has emerged as 
an important modality for staging of treatment-naïve NSCLC, but 
like endobronchial ultrasound and conventional mediastinoscopy 
typically is inaccurate following neoadjuvant therapy. We sought to 
determine the accuracy of TEMLA in staging NSCLC after induc-
tion therapy.
Methods: A retrospective chart review looking at clinical stage 
assessed by PET -CT and TEMLA, pathologic stage, lymph node 
yield and clinical characteristics was performed. Accuracy of sta-
ging by TEMLA and PET-CT was compared.
Results: 71 of 100 consecutive patients that underwent TEMLA 
had it for restaging after neoadjuvant therapy; 65 of these patients 
were also restaged by PET-CT. Clinical characteristics of these 65 
patients are presented (Table 1). TEMLA was completed success-
fully on 63 (96.9%) patients and was associated with permanent 
recurrent laryngeal nerve injury in 2 (3%) patients. On average, 
17 lymph nodes were obtained per TEMLA. Concomitant anato-
mic resections were completed in 58 (89.2%) of patients. 12 and 
3 (18.5% and 4.6%) patients were classified as having N2 and N3 
disease on final pathology. Compared to PET-CT, TEMLA more 
accurately classified these patients (95.4% vs. 80.0%; P<0.05). The 
sensitivity, specificity, positive predictive value and negative pre-
dictive value of PET/CT and TEMLA for detection of N2 disease are 
50.0%, 86.8%, 46.1%, 88.5% and 75%, 100%, 100%, 94.6% respec-
tively (Table 2). Of the 3 patients inaccurately classified by TEMLA, 
only 1 patient had N2 disease in TEMLA-accessible nodes.
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Results: Compared with the current system [hazard ratio (HR), 1.4; 
p = 0.29], the tumor site-based classification (HR, 2.8; p = 3.0E-4), 
the classification based on the number of metastatic lymph nodes 
(HR, 2.8; p = 1.7E-4), and the classification based on the number 
of metastatic mediastinal lymph nodes (HR, 2.3; p = 3.3E-3) were 
considered to be stronger predictors of overall survival. Similar 
results were obtained in terms of disease-free survival (current 
system: HR, 1.6; p = 0.047; tumor site-based classification: HR, 2.7; 
p = 2.3E-5; number of metastatic lymph nodes, HR, 2.3; p = 4.0E-
4; number of metastatic mediastinal lymph nodes: HR, 2.4; p = 
1.4E-4). A combination of the tumor site-based classification with 
the classification based on the number of metastatic lymph nodes 
(p = 9.0E-4) or the classification based on the number of metastatic 
mediastinal lymph nodes (p = 9.5E-4) further increased predictive 
efficiency.
Conclusion: The tumor site-based classification as well as the 
classifications based on the number of metastatic lymph nodes 
and the number of metastatic mediastinal lymph nodes was more 
predictive of surgical outcomes compared with the current nodal 
system. The results need to be further validated in a new set of 
patients. 
Keywords: tumor site-based classification, the classification based 
on the number of metastatic lymph nodes, non-small cell lung 
cancer, nodal classification
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O20.02 A NOVEL NODAL CLASSIFICATION FOR RESEC-
TED NON-SMALL CELL LUNG CANCER: COMPARISON 
BETWEEN LOCATION-BASED AND NUMBER-BASED 
SYSTEMS
Junji Ichinose, Tomohiro Murakawa, Haruaki Hino, Chihiro Ko-
noeda, Yuta Inoue, Kentaro Kitano, Kazuhiro Nagayama, Junichi 
Nitadori, Masaki Anraku, Jun Nakajima
Department Of Thoracic Surgery, University Of Tokyo/Japan
Background: The current UICC/WHO nodal classification system 
is based on the location of metastatic lymph nodes, while some 
studies have revealed that the number or ratio of metastatic lymph 
nodes may work as more effective prognostic indicators. The 
Japan Lung Cancer Society proposed a new tumor site-based 
classification for mediastinal nodal metastases according to the 
tumor-bearing lobe. This study aimed to compare the prognostic 
power of location-based and number-based classification systems 
and elucidate the optimal classification.
Methods: Of 511 patients with non-small cell lung cancer (NSCLC) 
who underwent lung lobectomy and complete hilar and mediasti-
nal lymph node dissection with curative intent at our institute bet-
ween 1998 and 2009, 119 with confirmed lymph node metastases 
were retrospectively analyzed. Ten classifications were compared 
using a log-rank test. Four classifications were location-based: 
the current system, the tumor site-based classification, the clas-
sification based on presence or absence of clinical N2 disease, 
and the classification based on presence or absence of non-skip 
N2 disease. The other 6 classifications were number-based: the 
classifications based on the number or ratio of metastatic lymph 
nodes, the classifications based on that of metastatic stations, and 
the classifications based on that of metastatic mediastinal lymph 
nodes.
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Conclusion: With rigid consideration, lobe-specific lymphadenec-
tomy is feasible in practice. This protocol could be established 
when the lobe-specific key nodes show negative under intraopera-
tive frozen section, especially for those NSCLCs presented as SPN 
smaller than 2 cm preoperatively. Table. Protocols for lobe-specific 
mediastinal lymphadenectomy for SPN  
Tumor locations
RUL LUL RLL LLL RML
Superior me-
diastinum^4
  b  
Inferior me-
diastinum
a b   
Note: : Complete regional lymphadenectomy is warranted; : 
Lymph nodes dissection could be omitted considerably. a: when 
#2 shows negative in intraoperative frozen section; b: when #10, 
11 shows negative in intraoperative frozen section; ^4: #1-4 in 
RUL, #4-7 in LUL 
Keywords: Lung cancer surgery, solitary pulmonary nodules, 
Lobe-specific lymphadenectomy
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O20.03 LOBE-SPECIFIC LYMPHADENECTOMY PROTO-
COL FOR NON-SMALL CELL LUNG CANCER PRESEN-
TING AS A SOLITARY PULMONARY NODULE
Xue-Ning Yang1, Ze-Rui Zhao2
1Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong 
General Hospital& Guangdong Academy Of Medical Sciences/China, 
2Guangdong Lung Cancer Institute, Guangdong General Hospital& 
Guangdong Academy Of Medical Sciences/China
Background: We sought to establish an acceptable lobe-specific 
mediastinal lymphadenectomy protocol for non-small cell lung 
cancer (NSCLC) presenting as solitary pulmonary nodules (SPN) .
Methods: We retrospectively analyzed 415 patients pathologi-
cally diagnosed as NSCLC undergone lobectomy, bilobectomy or 
pneumonectomy with systematic lymphadenectomy from March 
2004 to June 2011 in our hospital. All of the patients enrolled were 
considered SPN preoperatively. Information about primary tumor 
location, lymph node metastasis, and other baseline data were 
collected. Stepwise logistic regressions using N1 and lobe-specific 
regional mediastinal lymph nodes’ conditions as covariates were 
used to figure out the key lymph node station that indicated non-
regional mediastinal lymph nodes metastases (NRM).
Results: As for the location of the primary tumor, 121 cases were 
in right upper lung (RUL), 42 in right middle lung (RML), 77 in right 
lower lung (RLL), 107 in left upper lung (LUL), and 68 in left lower 
lung (LLL). Stepwise regression showed that #2(OR (odds ratio) = 
28.250, 95%CI (confidence interval): 1.756-454.422, P=0.018), N1 
(OR=24.000, 95%CI: 3.346-172.121, P=0.002) and N1 (OR=21.667, 
95%CI: 3.266-143.736, P=0.001) was the key lymph node station for 
RUL, LUL and RLL, respectively. None of the covariates show statis-
tical significant for LLL.Patients with tumors >2 cm rarely had NRM 
without primary regional mediastinal involvement. Figure. Malig-
nant cells’ residue when the key station shows negative metastasis
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O20.06 SURGICAL TECHNIQUES AND RESULTS OF  
RECONSTRUCTION OF THE PULMONARY ARTERY  
FOR PATIENTS WITH CENTRAL NON-SMALL CELL  
LUNG CANCER
Qianli Ma1, Deruo Liu1, Yongqing Guo1, Bin Shi1, Zhiyi Song1, Yan-
chu Tian1, Bingsheng Ge1, Xiaofei Wang2, Thomas A. D‘Amico3
1General Thoracic Surgery, China-japan Friendship Hospital/China, 
2Duke University Medical Center/United States Of America, 3General 
Thoracic Surgery, Duke University Medical Center/United States Of 
America
Background: It is difficult to achieve a margin-negative resection 
(R0) for non-small cell lung cancer (NSCLC) patients with infiltration 
of the pulmonary artery. We report our experience with reconst-
ruction of the pulmonary artery with regard to long-term survival.
Methods: Clinical records of 118 patients with NSCLC who under-
went partial or circumferential pulmonary artery resection during a 
21-year period were reviewed retrospectively. Technical outcomes 
and survival were analyzed.
Results: We performed 22 pulmonary artery sleeve resections, 
51 reconstructions by autologous pericardial patch, 36 tangential 
resections, 3 left main pulmonary artery (PA) angioplasties during 
pneumonectomy without cardiopulmonary bypass, and 6 by only 
preserving the 1st branch of pulmonary arterial trunk. In 41 pati-
ents, bronchial sleeve resection was associated; in 7 cases, superi-
or vena cava reconstruction was also required. Thirty-one patients 
received induction therapy. Thirteen patients had stage IB disease, 
41 stage II, 53 IIIA, and 11 IIIB. Ninety-three patients had squa-
mous cell carcinoma, 22 adenocarcinoma, 2 mixed and 1 large cell 
carcinoma. Negative bronchial and vascular margins were achieved 
in all. 5 positive bronchial margins were due to limited lung func-
tion. The analysis of 118 cases yielded follow-up data in 94 cases. 
The mean follow-up was 70 months (range 1-156 months). There 
was no in hospital death, and the overall 5-year survival was 50.2%. 
Five-year survival for stages Iand II, versus IIIwere 63.9% versus 
37.0% (p=0.0059). Multivariate analysis yielded non-squamous cell 
carcinoma, stage IIIand patch pulmonary arterioplasty as negative 
prognosis factors. PA reconstruction associated with bronchial 
sleeve resection was the positive prognostic factor.´
Conclusion: Pulmonary artery resection and reconstruction is 
feasible and safe, with favorable long-term survival. Our results 
support this technique as an effective alternative to selected pa-
tients with infiltration of the pulmonary artery, such as stage Iand 
IIand those who proved down-staged from stage III. Accurate pre-
operative evaluation, precise and suitable surgical techniques are 
crucial to achieve good results. Only preserving the anterior and 
apical pulmonary arteries reconstruction of the main pulmonary 
artery by using the artery conduit technique without cardiopulmo-
nary bypass in association with left pneumonectomy can be per-
formed successfully. Postoperative anticoagulation is unnecessary.
Keywords: Lung cancer, Plmonary artery, reconstruction, surgery
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O20.05 PROGNOSIS AND OUTCOME AFTER SURGICAL 
RESECTION OF SOLITARY BRAIN METASTASIS IN 82 
NSCLC PATIENTS: A SINGLE INSTITUTION EXPERIENCE
Oleg Pikin1, Kolbanov Konstantin1, Vladimir Glushko1, Anton Zayt-
zev2, Ali Amiraliev1, Dmitriy Vursol1, Artem Kartoveshenko1
1Thoracic Surgery, P.a.hertzen Research Institute Of Oncology/Russian 
Federation, 2Neurosurgery, P.a. Hertzen Research Institute Of Oncolo-
gy/Russian Federation
Background: The brain is one of the most frequent sites of distant 
metastasis in patients with lung cancer. Surgical resection of iso-
lated brain metastases in NSCLC patients is not widely accepted 
and still a matter of debate. The study was aimed to evaluate the 
long-term results and prognosis after surgical resection of primary 
tumor and solitary brain metastasis in NSCLC patients.
Methods: In this retrospective study, the data of 82 patients who 
underwent lung resection for primary NSCLC and brain metas-
tasectomy for solitary metastasis between 1991 and 2011 in our 
clinic were analyzed. There were 68 (82,9%) males and 14 (17,1%) 
females, median age – 59,6 years. The most common histologic 
type of lung cancer was adenocarcinoma (70,7%). Synchronous 
brain metastasis was detected in 21 (25,6%), metachronous – in 61 
(74,4%) patients. The primary lung cancer was completely resected 
in all cases. Surgery included pneumonectomy – in 7 (8,5%), lobec-
tomy – in 69 (85,4%) and wedge resection – in 5 (6,1%) patients. In 
all cases of synchronous brain metastasis, except one, we perfor-
med brain metastasectomy first followed by lung surgery in 4-6 
weeks interval. Simultaneous lung resection and brain metastasec-
tomy was performed only in one patient. Surgery in patients with 
metachronous brain metastasis depended on the time of detection 
and varied from 4 to 38 months.
Results: Postoperative complications were registered in 10 (12,2%) 
patients, mortality rate was 3,7% (3 patients). Overall 1, 3 and 
5-year survival after brain metastasectomy was 52,0%, 29,0% and 
25,6% respectively with median survival 18,6 months. The most 
important prognostic factors were N-status of primary lung cancer 
and synchronous or metachronous diagnosis of brain metastasis. 
Three and 5-year survival after brain metastasectomy in patients 
with N0 status was significantly better than in N+ patients: 56,8% 
and 34,8% versus 21,4% and 6,5% respectively (p<0,01). Median 
survival was 19,8 months in N0 group and only 12,4 months in 
patients with positive lymph nodes. Five-year survival in patients 
with metachronous brain metastases was 19,8% versus 10,0% in 
synchronous group (p<0,05). Eight patients are alive free of recur-
rence, 10 patients – with recurrence in the brain and 64 (78,0%) 
patients died of disease progression in the brain or other distant 
sites.
Conclusion: Surgery in NSCLC patients with operable solitary 
brain metastasis is justified especially in N0 cases and metachro-
nous disease. Surgical resection improves long-term results and 
quality of life in patients with operable brain lung cancer metasta-
sis.
Keyword: lung cancer, solitary brain metastasis, surgery,  
prognosis
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associated with prolonged survival. Local therapy were mainly 
applied for limited metastases, and associated with higher survival 
rates. The number of patients and the 5-year survival rates accor-
ding to the metastatic organ in patients with solitary metastasis 
are shown in Table 2. Other metastatic organ included soft tissue 
in 3 patients, kidney in 3, and trachea, intestine, and abdominal 
lymph node in 1.Finally, 6 patients survived more than 5 years with 
disease-free status; these included 2 brains, 2 lungs, 1 bone, and 1 
subcutaneous metastasis.  
Table 1
Multiple 
organ
Single 
organ
Multiple Single
Treat-
ment
Num-
ber of 
pts
5y 
OS 
(%)
Num-
ber of 
pts
5y 
OS 
(%)
Num-
ber of 
pts
5y 
OS 
(%)
Num-
ber of 
pts
5y 
OS 
(%)
BSC 8 0 48 6.4 43 7.1 5 0
Che-
mo 
Tx
3 0 32 16.3 30 17.7 2 0
Radio 
Tx
19 5.7 101 11.8 43 0 58 21.4
Sur-
gery
0 - 34 38.0 6 66.7 28 33.4
Total 30 3.5 215 15.2 122 8.9 93 23.3
 
Table 2
Organ Number of pts 5y OS (%)
Brain 36 19.2
Bone 24 16.7
Lung 18 32.4
Adrenal 
gland
6 0
Other 9 55.6
 
Conclusion: Prolonged survival can be achieved using local thera-
py in patients with limited distant metastasis irrespective of meta-
static organ.
Keywords: distant metastasis, non-small cell lung cancer, oligome-
tastases, metachronous metastasis
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O20.07 LOCAL THERAPY FOR LIMITED DISTANT  
METASTASIS IN PATIENTS WITH COMPLETELY  
RESECTED NSCLC
Haruhisa Matsuguma1, Rie Nakahara1, Haruko Suzuki1, Tomohi-
de Sugiyama2, Koichi Inoue3, Takashi Kasai2, Yukari Kamiyama2, 
Susumu Katano3, Kiyoshi Mori2, Kohei Yokoi4
1Division Of Thoracic Surgery, Tochigi Cancer Center/Japan, 2Division 
Of Thoracic Diseases, Tochigi Cancer Center/Japan, 3Division Of Radi-
ation Therapy, Tochigi Cancer Center/Japan, 4Department Of Thoracic 
Surgery, Nagoya University Graduate School Of Medicine/Japan
Background: In general, distant metastasis is regarded as an incu-
rable systemic disease. Therefore, local therapies including meta-
stasectomy or radiotherapy are rarely applied, and the treatment 
goals are disease control using chemotherapy or palliation. There 
are, however, several reports in which local therapy can contribute 
to long-term survival in patients with metastatic disease, especially 
for brain metastasis or adrenal metastasis in patients with NSCLC.
Methods: Between 1986 and 2009, among 1548 patients who 
underwent surgical resection for NSCLC in our institution, we iden-
tified 405 patients who experienced recurrence after R0 resection, 
without history of other malignancy, and detailed recurrence infor-
mation available. We investigated the recurrent mode, number of 
metastatic focus and organ, treatment for metastasis, and progno-
sis.
Results: Among 405 patients, 245 patients had distant metastasis 
without local recurrence, 115 had local recurrence, and 45 had 
both local and distant metastasis. We focused on the 245 patients 
with distant metastasis without local recurrence, including 215 
patients who had only single organ metastasis and 93 patients 
who had only solitary metastasis. The treatments for distant meta-
stasis and the 5-year survival rates were shown in the Table 1. The 
number of organ involved and metastatic focus were significantly 
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Conclusion: This trial will report on whether pravastatin 40 mg OD 
added to standard therapy alters the outcome for SCLC patients.
Keywords: SCLC, pravastatin, phase III trial, placebo controlled
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O21.02 PHASE III TRIAL COMPARING IRINOTECAN PLUS 
CISPLATIN (IP) WITH ETOPOSIDE PLUS CISPLATIN (EP) 
IN KOREAN PATIENTS WITH EXTENSIVE DISEASE (ED) 
SMALL CELL LUNG CANCER (SCLC)
Dong-Wan Kim1, Hoon-Gu Kim2, Joo-Hang Kim3, Keunchil Park4, 
Hoon Kyo Kim5, Joung Soon Jang6, Bong-Seog Kim7, Jin-Hyoung 
Kang8, Kyung Hee Lee9, Sang-We Kim10, Hun Mo Ryoo11, Jin-Soo 
Kim12, Ki Hyeong Lee13, Jung Hye Kwon14, Jin-Hyuk Choi15, Dae Sik 
Hong16, Sang Won Shin17, Seokyung Hahn18, Dae Seog Heo1
1Seoul National University Hospital/Korea, 2Gyeongsang National 
University Hospital/Korea, 3Yonsei Cancer Center, Yonsei Universi-
ty College Of Medicine/Korea, 4Samsung Medical Center/Korea, 5St. 
Vincent‘s Hospital/Korea, 6Chung-ang University College Of Medicine/
Korea, 7Vhs Medical Center/Korea, 8Seoul St. Mary‘s Hospital/Korea, 
9Yeungnam University Medical Center/Korea, 10Asan Medical Center/
Korea, 11Daegu Catholic University Hospital/Korea, 12Smg-snu Boramae 
Medical Center/Korea, 13Chungbuk National University Hospital/Korea, 
14Hallym University Kangdong Sacred Heart Hospital/Korea, 15Ajou 
University Hospital/Korea, 16Soon Chun Hyang University Bucheon 
Hospital/Korea, 17Korea University Anam Hospital/Korea, 18Medical 
Research Collaborating Center, Seoul National University College Of 
Medicine/Korea
Background: IP showed superior survival outcomes compared 
with EP in Japanese patients. However, IP failed to show the supe-
riority in subsequent studies in Western population. We conducted 
a multi-center randomized controlled trial to determine whether IP 
regimen is superior to EP regimen in Korean patients (ClinicalTrials.
gov Identifier: NCT00349492)
Methods: Patients were randomly assigned (simple randomization, 
stratified by ECOG performance status and center) to IP (irinote-
can 65 mg/m2 IV on D1&8 plus cisplatin 70 mg/m2 IV on D1, every 
3 weeks) or EP (etoposide 100 mg/m2 IV on D1-3 plus cisplatin 
70 mg/m2 IV on D1, every 3 weeks) for maximum 6 cycles, until 
disease progression, or until unacceptable toxicity occurred. The 
primary objective was to compare overall survival (OS).
Results: A total of 362 patients were randomized to IP (N=173) 
and EP (N=189) arms. Median OS was 10.9 and 10.3 months (m) 
for IP and EP, respectively (hazard ratio for death in the IP group, 
0.879; 95% one-sided confidence interval, 0 to 1.054; P=0.1207). 
Objective response rate was higher with IP than with EP (62.4%, 
48.2%, P=0.0064), however, there was no significant difference 
in median progression free survival between IP and EP (6.5 and 
5.8 m, P=0.1158). In the pre-planned subgroup analyses, IP was 
associated with longer OS than with EP in male (11.3 vs 10.1 m, 
P=0.0361), <65 years old (12.7 vs 11.3 m, P=0.0240), ECOG perfor-
mance status 0/1 (12.4 vs 10.9 m, P=0.0407) patients group. Grade 
3/4 anemia, nausea and diarrhea were more frequent in patients 
treated with IP. There was no difference in the frequency of grade 
3/4 neutropenia, thrombocytopenia, neutropenic fever, infection 
between both arms.
Conclusion: IP failed to show superiority in overall survival compa-
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O21.01 A MULTICENTER PHASE III RANDOMIZED DOUB-
LE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTA-
TIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY 
IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)
Michael J. Seckl1, Christian Ottensmeier2, Michael Cullen3, Peter 
Schmid4, Lindsay James5, Christina Wadsworth5, Hannah Far-
rant5, Dakshinamoorthy Muthukumar6, Joyce Thompson7, Susan 
Harden8, Gary Middleton9, Kate Fife10, Barbara Crosse11, Paul Tay-
lor12, Ifty Khan5
1Imperial College London/United Kingdom, 2Southampton University/
United Kingdom, 3Queen Elizabeth Hospital/United Kingdom, 4Brighton 
And Sussex Medical School/United Kingdom, 5Cancer Research Uk And 
University College London Ctc/United Kingdom, 6Colchester University 
Hospital NHS Foundation Trust/United Kingdom, 7Heart Of England 
NHS Trust/United Kingdom, 8Cambridge University Hospitals NHS 
Foundation Trust/United Kingdom, 9Royal Surrey County Hospital/Uni-
ted Kingdom, 10Peterborough And Stamford Hospitals NHS Foundation 
Trust/United Kingdom, 11Calderdale And Huddersfield NHS Foundation 
Trust/United Kingdom, 12University Hospital South Manchester/United 
Kingdom
Background: Most SCLC patients initially respond to chemo-
therapy but then relapse and die so new therapies are urgently 
required. Pre-clinical data shows statins induce growth arrest and 
apoptosis in SCLC and several other tumour cell types and are 
additive with chemotherapy. This may in part be due to impaired 
Ras superfamily function as statins deplete mevalonate, reducing 
geranylgeranylation and farnesylation of these proteins. We there-
fore undertook this large pragmatic phase III trial in SCLC patients 
to determine if overall survival (OS) was affected by the addition of 
pravastatin to standard treatment.
Methods: Patients with limited (LD) or extensive (ED) stage SCLC 
were randomised to pravastatin 40mg OD or placebo for up to 2 
years and given standard chemotherapy according to local practi-
ce but recommended as either cisplatin 60mg/m2 iv or carboplatin 
AUC 5 or 6 and etoposide 120 mg/m2iv d1 to 3 or 100 mg BD po 
d2 & 3; max 6 cycles plus radiotherapy as usually given. Patients 
were excluded if they had used statins within 12 months prior to 
randomisation. Stratification was: LD vs ED and ECOG 0,1 vs 2,3. 
Endpoints were: primary - OS; secondary - progression free survi-
val (PFS), local PFS (local control), response rates (RR) and toxicity.
Results: This abstract is currently under embargo.
Results: Between 2007 and 2012, 846 patients were randomised, 
422 (49.9.%) received pravastatin and 424 (50.1%) placebo in 93 
participating sites in the UK. The median age was 64 years (range 
54-69); ECOG performance status: 0: 23%; 1: 54%; 2: 17% and 3: 
6%; weight 72.6 kg; LD, 357 (42.2%); ED, 479 (56.6%); 211 (24.9%) 
had ipsilateral effusion and 201 (23.8%) had ipsilateral SCF lymph 
nodes; Relative Dose intensity of cisplatin/carboplatin and etopo-
side was 91.6% (range 80.8 to 99.7), and 94.7% (range 85.7 to 100); 
83.4% vs 86.3% completed >4 cycles of chemotherapy on the pra-
vastatin and placebo arms respectively. Most patients completed 6 
cycles of chemotherapy: 263 (62.3%) vs 265 (62.5%) in the pravas-
tatin vs. placebo groups. Unblinded results showing the effect of 
pravastatin on OS, PFS, local PFS and toxicity will be presented.
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O21.05 A MULTICENTER, DOUBLE-BLIND, PLACEBO-
CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GA-
NITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED 
CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EX-
TENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC)
Bonnie Glisson1, Andrzej Kazarnowicz2, Kristiaan Nackaerts3, 
Sergey Orlov4, Rodryg Ramlau5, Benjamin Besse6, Manuel Cobo 
Dols7, Hari Menon8, Luis Paz-Ares Rodriguez9, Yilong Zhang10, Min 
Zhu10, Yizhou Jiang10, Elwyn Loh10, Jennifer Gansert10, Sarita Du-
bey10
1University Of Texas, MD Anderson Cancer Center/United States Of 
America, 2Samodzielny Publiczny Zespol Gruzlicy I Chorob Pluc W Olsz-
tynie/Poland, 3University Hospitals Leuven, Campus Gasthuisberg/
Belgium, 4St. Petersburg State Medical University Named After Acad. I.p. 
Pavlov Roszdrava/Russian Federation, 5Poznan University Of Medical 
Sciences,wielkopolskie Centrum Pulmonologiii Torakochirurgii/Poland, 
6Institut Gustave Roussy/France, 7Carlos Haya University Hospital/Spain, 
8Tata Memorial Hospital/India, 9Virgen Del Rocío University Hospital/
Spain, 10Amgen Inc./United States Of America
Background: The type 1 insulin-like growth factor receptor (IGF1R) 
and MET, the receptor for hepatocyte growth factor (HGF)/scatter 
factor, appear to play key roles in SCLC. Ganitumab and rilotumumab 
are investigational, fully human monoclonal antibodies targeting IG-
F1R and HGF, respectively. A phase 1b/2 study evaluated ganitumab 
or rilotumumab combined with etoposide plus carboplatin (CE) or 
cisplatin (PE) in extensive-stage SCLC. The phase 1b results were 
previously reported (Lorigan et al. Ann Oncol 2010;21[supplement 8]: 
abstract 444P). Here, the phase 2 results are reported.
Methods: Key eligibility criteria: ≥18 years, confirmed SCLC, ECOG 
performance status ≤1, no prior chemotherapy. Patients were ran-
domized 1:1:1 to receive blinded investigational product (IP) either 
ganitumab (18 mg/kg IV, day 1) or rilotumumab (15 mg/kg IV, day 
1) or placebo, with etoposide (100 mg/m2 IV, days 1-3) plus, at 
investigator’s discretion, either carboplatin (AUC=5 mg/mL*minute 
IV, day 1) or cisplatin (75 mg/m2 IV, day 1) every three weeks for 4-6 
cycles followed by IP monotherapy. Patients were stratified by gen-
der and chemotherapy (CE; PE). Primary endpoint: overall survival 
(OS). Key secondary endpoints included progression-free survival 
(PFS), objective response rate (ORR), adverse events (AEs), pharma-
cokinetics.
Results: 185 patients (ganitumab/rilotumumab/placebo: 62/62/61) 
were enrolled between 2 February 2010 and 12 January 2011. 
Male: 77%/76%/77%. Median age: 60/61/61 years. More patients 
received carboplatin (41/40/40) than cisplatin (21/22/21). Most 
common reason for discontinuation of IP was disease progression 
(69%/61%/74%). Among 179 patients (59/61/59) who received IP, the 
most frequent any grade AEs (occurring in ≥30% of patients in any 
arm) were neutropenia (69%/59%/71%), anemia (39%/34%/36%), 
nausea (41%/30%/22%), alopecia (41%/23%/27%), thrombocytopenia 
(22%/30%/12%), and vomiting (19%/10%/31%). Grade ≥3 AEs and 
serious AEs were reported in 69%/72%/80% and 39%/38%/36% 
of patients, respectively. There were three IP-related grade 5 AEs: 
cardiac arrest (rilotumumab, n=1), febrile neutropenia (rilotumumab, 
n=1), gastric ulcer hemorrhage (placebo, n=1). No neutralizing anti-
bodies were observed for either ganitumab or rilotumumab. Efficacy 
is shown in the table. Ganitumab and rilotumumab combined with 
chemotherapy showed comparable exposures as those under mono-
therapy and did not affect the pharmacokinetics of chemotherapy.  
red to EP in Korean patients with ED SCLC. However, prolongation 
of OS was observed with IP in pre-defined subgroup of patients 
with male gender, young age, or good performance status.
Keywords: small cell lung cancer, etoposide, irinotecan, cisplatin
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O21.03 N-0923, A RANDOMIZED DOUBLE-BLIND PHASE 
II STUDY OF THE SENECA VALLEY VIRUS (NTX-010) VS 
PLACEBO FOR PATIENTS WITH EXTENSIVE STAGE SCLC 
(ES-SCLC) WHO WERE STABLE OR RESPONDING AFTER 
AT LEAST 4 CYCLES OF PLATINUM-BASED CHEMOTHE-
RAPY: ALLIANCE (NCCTG) STUDY
Julian Molina
Oncology, Mayo Clinic/United States Of America
Background: NTX-010 is a naturally occurring replication-compe-
tent picornavirus with potent and selective tropism for SCLC tumor 
cells expressing neuroendocrine markers. A phase I study of NTX-
010 showed evidence of antitumor activity in patients with SCLC.
Methods: ES-SCLC patients (pts) with SD, PR or CR after at least 
4 cycles of platinum-based chemotherapy were pre-registered 
to confirm diagnosis of SCLC with > 1 neuroendocrine marker by 
a central pathology review. Eligible pts were.randomized 1:1 to 
placebo (B) or NTX-010 (A). NTX-010 or placebo was administered 
intravenously as a 1-hour infusion in 100 mL normal saline as a 
single dose of 1 x1011vp/kg. Viral studies to determine distribution, 
clearance of the virus and the presence of neutralizing antibodies 
were done. The primary goal of this trial was to compare the pro-
gression-free survival (PFS) of arm A to B based on a sample size of 
45 patients per arm to detect an improvement in median PFS from 
3 to 5 months (m). A pre-planned interim futility analysis was done 
after 40 PFS events, and reported here.
Results: The trial is permanently closed to accrual. One-hundred 
and twenty pts were pre-registered, of whom 58 were randomized. 
Baseline age, gender, ECOG performance status, and histology 
were balanced between arms. Median age was 63 (range: 44 - 82). 
31% of pts had a PS of 0 and 69% of 1. Grade 4 adverse events 
were seen in 3 (12.5%) patients in arm A and none in arm B. Based 
on the interim futility analysis, PFS was 1.7 m (95% CI: 1.3-3.1) for 
arm A and 1.7 m (95% CI: 1.4-4.3) for arm B. Pts with viral RNA at 7 
(7 pts) and 14 (6 pts) days had worse PFS compared to those with 
no detectable levels within arm A (1.0 vs 1.6 m, p=0.02; 0.9 vs. 1.2 
m, p=0.06). Median follow-up in pts is 6.1 m. The 3-month OS esti-
mates are 83% (95% CI: 69%-100%) and 85% (70%-100%) for arms 
A and B respectively.
Conclusion: This phase II study showed no benefit in PFS for ES-
SCLC patients receiving NTX-010. Pts with detectable virus at 7 
and 14 days had worse PFS
Keywords: small cell lung cancer, Extensive stage, Virotherapy
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O21.06 MLN8237 (ALISERTIB), A SELECTIVE AURORA 
A KINASE (AAK) INHIBITOR, IN PATIENTS WITH RE-
LAPSED/REFRACTORY SMALL CELL LUNG CANCER 
(SCLC): PHASE 2 RESULTS
Libor Havel1, Claire Dees2, Craig Lockhart3, Jaafar Bennouna4, Piotr 
Serwatowski5, Stephen Liu6, Huifeng Niu7, Sunita Badola7, Claudia 
Schusterbauer7, Claudio Dansky Ullmann7, Bin Zhang7, Ely Be-
naim7
1Department Of Pneumology, Hospital Bulovka/Czech Republic, 2Unc 
Lineberger Comprehensive Cancer Center/United States Of America, 
3Washington University School Of Medicine/United States Of America, 
4Institut De Cancérologie De L’ouest/France, 5Specjalistyczny Szpital 
Im., Oddzial Chemioterapii/Poland, 6Usc Norris Cancer Hospital/United 
States Of America, 7Millennium: The Takeda Oncology Company/United 
States Of America
Background: AAK, a key mitotic regulator, plays an important role 
in carcinogenesis. AAK is frequently overexpressed/amplified in a 
variety of human cancers. Inhibition of AAK has been associated 
with tumor inhibition in SCLC patients; thus, AAK is an attractive 
target in SCLC treatment. The investigational, oral, selective AAK 
inhibitor MLN8237 is under evaluation in patients with advanced 
hematologic and non-hematologic malignancies. A phase 1/2 
study (NCT01045421) evaluated MLN8237 in patients with solid 
tumors; phase 2 data for the SCLC cohort are presented.
Methods: Patients aged ≥18 years with relapsed/refractory SCLC, 
ECOG PS 0–1, and ≤2 prior cytotoxic chemotherapy regimens 
were eligible (symptomatic and untreated brain metastases were 
excluded); sensitive and resistant/refractory was defined as recur-
rence > or ≤90 days of frontline therapy respectively. MLN8237 50 
mg was administered twice-daily for 7 days (21-day cycles). Using 
a Simon’s optimal 2-stage design, ≥2 objective responses were 
required in the first 20 response-evaluable patients to proceed 
to the expansion stage. Primary objective: overall response rate 
(ORR) by RECIST v1.1. Secondary objectives: safety, duration of 
response (DOR), and progression-free survival (PFS). Exploratory 
studies included whole-exome sequencing in banked tumor spe-
cimens to identify genetic markers/mutated pathways associated 
with differential response.
Results: As of April 2013, 60 patients were enrolled; median age, 
62 years (range 43–76); median number of cycles 2 (range 1–15). 48 
patients (80%) were response-evaluable (chemo-sensitive, n=36; 
chemo-refractory, n=12). Prior lines of therapy and efficacy data 
are shown in the table. ORR was 21%, median PFS 2.11 months. 
Most common grade ≥3 drug-related AE included neutropenia 
(53%) and febrile neutropenia (8%); all AEs were reversible.14 pati-
ents discontinued due to AEs (treatment-related in 3 patients: hyp-
onatremia, thrombocytopenia, acute generalised exanthematous 
pustulosis; each, n=1). 13 on-study deaths were reported; none 
were considered drug-related (most frequent cause was disease 
progression [n=6]). Whole-exome sequencing of selected tumor 
samples was completed. Preliminary results will be presented.
Conclusion: MLN8237 has a generally manageable toxicity profile; 
data from this study suggests it has single agent antitumor activi-
ty in SCLC patients with sensitive or resistant-refractory relapse, 
supporting further evaluation of MLN8237 in different combination 
strategies in this tumor type.  
Ganitumab 
(n=62) 
Rilotumumab 
(n=62) 
Placebo 
(n=61) 
OS
Median (95% 
CI) months
10.7 (8.1–14.1) 12.2 (8.8–14.6) 10.8 (9.4–11.9)
Adjusted HRa 
(95% CI)
1.01 (0.67–
1.52)
0.91 (0.60–
1.39)
PFS
Median (95% 
CI) months
5.5 (4.4–5.7) 5.4 (4.4–5.7) 5.4 (4.6–5.8)
Adjusted HRa 
(95% CI)
1.03 (0.70–
1.52)
1.03 (0.69–
1.52)
Objective 
Response
Complete 
response,  
n (%)
0 (0) 2 (3) 1 (2)
Partial res-
ponse, n (%)
39 (63) 40 (65) 35 (57)
Stable  
disease, n (%)
13 (21) 12 (19) 16 (26)
 
aAdjusted for baseline lactate dehydrogenase levels and stratifica-
tion factors. CI=confidence interval; HR=hazard ratio.
Conclusion: In this study of chemonaïve patients with extensive-
stage SCLC, the combination of ganitumab or rilotumumab with 
CE or PE was tolerable; no unexpected toxicities were observed. 
There were no meaningful improvements in OS, PFS, or ORR with 
either combination. Survival analyses in biomarker and pharmaco-
kinetic subgroups are ongoing.
Keywords: rilotumumab, Small-cell lung cancer, phase 2, gani-
tumab
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2nd/3rd line SCLC pts, plat-sensitivity status was found to no longer 
be a significant independent variable for survival (Lara, ASCO 
2013). We subsequently developed a new SCLC prognostic model 
for overall survival (OS) for potential clinical trial and bedside ap-
plication.
Methods: Updated data from recent SWOG trials in 2nd and/or 
3rd line ES-SCLC (S0802: topotecan + aflibercept: S0435: sorafe-
nib; and S0327: PS-341) were pooled. Accrual goals were specified 
for sensitive and refractory in each trial. Hazard ratios (HRs) for OS 
were calculated using Cox Proportional Hazard (PH) models [unad-
justed and adjusted]. To investigate a predictive model for OS, re-
cursive partitioning was performed using the likelihood tree model 
of LeBlanc and Crowley. The minimum node size was set at 20.
Results: Of 329 pts, 151 were classified as sensitive, 178 refrac-
tory; median age = 63 years; males = 52%; Performance Status 
(PS) 1 = 67%; weight loss >5% = 28%; > 2 prior chemo = 16%; 
and elevated LDH = 43%. HRs from unadjusted Cox models for 
OS for refractory vs. sensitive were 1.0 (95% CI 0.81-1.25, p=0.98) 
and 1.24 (95% CI 0.99, 1.57; p=0.06). Cox PH models adjusted for 
baseline prognostic factors showed that plat-sensitivity status was 
not significantly associated with OS. Elevated LDH was significantly 
associated with PFS while LDH, PS, weight loss, and male sex were 
independently associated with OS. Clinically relevant prognostic 
risk groups (High, Intermediate, and Low) were identified by recur-
sive partitioning analysis, as shown below (MST= median survival 
time). High Risk (MST = 2 months: Elevated LDH And > 5% Weight 
Loss Or PS >0) Intermediate Risk (MST = 5 months: Elevated LDH 
but not High Risk Or Male) Low Risk (MST=8 months: Normal LDH 
And Female)
Conclusion: In this large database analysis, clinically relevant pro-
gnostic risk groups were identified, categorized as low, interme-
diate, and high risk, with differential survival outcomes observed 
for each group. Validation of these risk groups in an independent 
SCLC dataset is warranted. If validated, these risk groups will have 
important implications for individualized patient counseling in cli-
nic and stratification of patients in prospective trials in the second 
and third line setting.
Keywords: Platinum sensitivity, small cell lung cancer, Prognostic 
model
All Chemo- sensitive
Chemo- 
refractory
Prior lines of 
therapy
First line, n 
(%) N=48 n=36 n=12 
Platinum/eto-
poside
45 (94) 33 (92) 12 (100) 
Other 3 (6) 3 (8) –
Second line, 
n (%) N=23 n=19 n=4
Rechallenge 13 (57) 12 (63) 1 (25) 
Topotecan 3 (13) 2 (11) 1 (25) 
Other 7 (30) 5 (26) 2 (50)
Efficacy data
N=48 n=36 n=12
Median cyc-
les (range)
2.5 (1–15) 3.5 (1–15) 2 (2–6)
Best respon-
se, n (%)
ORR (PR) 10 (21) 7 (19) 3 (25)
SD 16 (33) 13 (36) 3 (25)
PD 22 (46) 16 (44) 6 (50)
Median DOR 
(months)
4.1* –** –**
Median PFS 
(months)
2.11 2.58 1.74
 
* Numbers of events: 7; **Not enough events to give meaningful 
estimates.
Keywords: Aurora A kinase inhibitor, MLN8237, SCLC, antitumor 
activity
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O21.07 A NEW PROGNOSTIC MODEL FOR RELAPSED/
REFRACTORY EXTENSIVE STAGE SMALL CELL LUNG 
CANCER (ES-SCLC) DERIVED FROM PROSPECTIVE 
SWOG TRIALS: IMPLICATIONS FOR STUDY DESIGN
Primo Lara1, James Moon2, Mary Redman2, Karen Kelly1, Jeffrey 
Allen3, Barbara Gitlitz4, Philip Mack1, David Gandara1
1Division Of Hematology And Oncology, UC Davis Comprehensive 
Cancer Center/United States Of America, 2Swog Statistical Center/
United States Of America, 3Humboldt Medical Specialties/United States 
Of America, 4University Of Southern California/United States Of 
America
Background: ES-SCLC patients (pts) with progressive disease (PD) 
following plat-based chemo have traditionally been categorized 
as plat-sensitive (PD >/= 90 days from last plat dose) or refractory 
(PD < 90 days). Plat-sensitivity status has previously been strongly 
associated with response and survival in the 2nd/3rd line treatment 
setting. However, in a recent pooled analysis of SWOG trials in 
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progression-disease (p=0.003). Among the other SNPs reported 
in at least 15 pts there are rs3729674(PIK3CA), rs1800863(RET), 
rs3822214(KIT), rs10006115(KDR), rs75580865(FLT3) and 
rs5030613(SMARCB1).
Conclusion: These extremely preliminary data indicate that NGS 
technology is feasible in FFPE MPM tissues and some of the de-
tected genetic mutations are novel observations of potential prog-
nostic and therapeutic interest.
Keywords: malignant pleural mesothelioma, next-generation se-
quencing
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O22.02 CD8 T-CELL INFILTRATION AND TUMOR IL-7R 
EXPRESSION ARE INDEPENDENT PROGNOSTIC FAC-
TORS IN EPITHELIOID MALIGNANT PLEURAL  
MESOTHELIOMA
Hideki Ujiie, Daniel Buitrago, Junichi Nitadori, Kyuichi Kadota, 
Lee M. Krug, William D. Travis, Valerie W. Rusch, Michel Sadelain, 
Prasad S. Adusumilli
Memorial Sloan-Kettering Cancer Center/United States Of America
Background: Following our publication (Cancer Immunol Immu-
nother 2011) demonstrating the prognostic importance of chronic 
inflammatory cell infiltration in epithelioid malignant pleural me-
sothelioma (MPM), we investigated the prognostic significance of 
the immune microenvironment in the tumor nest and the tumor-
associated stroma in epithelioid MPM.
Methods: A tissue microarray (TMA) was constructed from 170 
epithelioid MPM cases, with 6 representative tumor cores and 3 
representative stromal areas. Immunohistochemical analyses for 
immune cell infiltration (CD3, CD4, CD8, CD20, FoxP3) and inter-
leukin receptors (IL-7R and IL-12Rβ2) were performed. TMA slides 
were analyzed for immune cell infiltration of tumor and stroma (low 
vs high, divided by use of the median), as well as for immune mar-
ker expression (sum of intensity and distribution). Overall survival 
(OS) was estimated using Kaplan-Meier analysis, and log-rank tests 
and Cox proportional hazards models were used to analyze the 
association between each marker and OS.
Results: Analysis of single immune cell infiltration for all patients 
revealed that high tumor CD8+ T-cell infiltration, high CD20+ 
B-cell infiltration, and low tumor IL-7R expression correlated 
with higher OS (Figure). Combined tumor CD8+ and CD4+ cell 
infiltration significantly correlated with better OS (5-year OS, 
36% [n=61] vs. 20% [n=96]; p=0.008). In a multivariate analysis in-
cluding age, stage, lymph node metastases, lymphatic invasion, 
and vascular invasion, high CD8+ T-cell infiltration and low tumor 
IL-7R expression were independent predictors of OS (Table). 
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O22.01 NEXT GENERATION SEQUENCING IN MALIG-
NANT PLEURAL MESOTHELIOMA: PRELIMINARY DATA 
FROM A RETROSPECTIVE COHORT OF 123 PATIENTS
Marco Lo Iacono1, Silvia Novello1, Federica Grosso2, Simona Vat-
rano1, Luisella Righi1, Mauro Papotti1, Paolo Bironzo1, Valentina 
Monica1, Giorgio V. Scagliotti1
1Department Of Oncology, University Of Turin/Italy, 2Aon Ss. Antonio E 
Biagio E Cesare Arrigo/Italy
Background: The median survival of patients with advanced stage 
malignant pleural mesothelioma (MPM) ranges between 9 and 
12 months after diagnosis, regardless of the recent achievements 
with systemic therapies combining cisplatin and antifolates such 
as pemetrexed or raltitrexed. Since MPM is a relatively rare malig-
nancy and early pre-neoplastic lesions are clinically difficult to be 
identified, the understanding of molecular pathogenesis including 
sequential accumulation of genetic/epigenetic alterations for MPM 
development has lagged behind other common malignancies. 
According to the COSMIC database the most frequently mutated 
genes in MPM include CDKN2A, NF2 and BAP1, followed by other 
12 genes having been found mutated in a fraction of MPM cases 
(c-MET, VHL,WT1 among others). Clearly, a better and more sys-
tematic understanding of the role of genomic alterations in MPM 
is needed. In this retrospective study, a consecutive series of 123 
formalin-fixed, paraffin embedded (FFPE) MPM tissue samples with 
clinical annotates, collected at two institutions, was retrospectively 
analyzed through Next-Generation Sequencing (NGS) technology 
to enhance knowledge about tumor-specific genomic profiling.
Methods: Genomic DNA was extracted by tumour microdissec-
ted FFPE samples for all 123 patients. Amplicons NGS libraries 
for 50 Oncogene included in Ion AmpliSeq™ Cancer Hotspot 
Panel (CHP) v.2 were generated as indicated by manufacturer, 
and sequenced in Personal Genome Machine IonTorrent. Variant 
Caller included in Torrent Suite Software was utilised to identify 
mutations in the samples, annotation was performed with Annovar 
software. Genomic analysis for BAP1 and NF2 (not included in the 
CHP) is separately ongoing.
Results: Of 123 advanced stage MPM patients, all treated with pe-
metrexed-based chemotherapy, 70% were males, current smokers 
50%, median age 66.5 (range 36-82) years and histological subty-
pes were 96/22/5 epithelioid/biphasic/sarcomatous. With a cut off 
for allele frequency(AF)>=10% a total of 966 non-synonymous, 8 
del-ins, 62 nonsense, 637 intronic, 204 regulatory and 1140 syno-
nymous somatic sequence variations were detected in 107 patients 
already screened. Excluding synonymous mutations and irres-
pective of AF, the five most frequently altered genes were CSF1R 
(mut:154, pts:80), KDR (mut:148, pts:73), FLT3 (mut:132, pts:99), PIK-
3CA (mut:126, pts:60), TP53 (mut:111, pts:66). Evaluating mutations 
identified at least once, a correlation between HRAS and PIK3CA 
mutations and patient status (dead or alive) was observed (p=0.017 
and p=0.039, respectively). Specifically, HRAS silent mutation 
p.H27H (rs12628) was responsible for the association (p=0.021) 
and occurred in 54% of 107 MPM compared to 30% of reported 
AF in available databases. PIK3CA p.I391M missense mutation 
(rs2230461; AF 24% in this series) was significantly associated to 
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Conclusion: Tumor CD8+ T-cell infiltration and tumor IL-7R 
expression are independently associated with survival, which 
highlights the biologic and prognostic significance of the immune 
microenvironment for patients with epithelioid MPM.
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Pt 
Overall 
Tumor 
Res-
ponse† 
Delayed 
Tumor 
Respon-
se§ 
Post 
Study 
Chemo.
Response 
to Post-
SS1P Che-
mo.
Overall 
Survival 
(months)
1
PR 
(-44%)
Yes 
(7 m+)
- - 18.2+
2
PR 
(-74%)
- - - 17.1+
3 SD - Yes PR (-55%)* 15+
4
PR 
(-70%)
- - - 14.5+
5 SD - - - 8.8
6 PD - - - 6.2
7 PD - - - 5.7
8 PD
Yes 
(4 m+)**
Yes
85% decre-
ase in tumor 
18F-FDG 
uptake¶
10.6+
9 PD - - - 4.2
10 SD - Yes No 7.3
PR, partial response; SD, stable disease; PD, progressive disease; 
18F-FDG, Fluorodeoxyglucose; †In patients with tumor response 
the maximum percent decrease in tumor dimensions is shown; 
§Months from study initiation when response first observed; * PR 
to post-SS1P treatment with previously ineffective chemothera-
py; **Patient 8 had initial PD, but at 4 months had 25% reduction 
in size of one of the target lesions and marked decrease of meta-
bolic activity by PET; ¶Patient 8 had 85% reduction in metabolic 
activity compared to baseline and SD by CT scan on post- SS1P 
chemotherapy.
 
Conclusion: SS1P and immune depletion with P-C results in signifi-
cant and durable anti-tumor activity in heavily pre-treated chemo-
therapy refractory patients with mesothelioma.
Keywords: mesothelioma, Immunotoxin, Major tumor regressions, 
Neutralizing antibody
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O22.03 DURABLE CANCER REGRESSIONS IN CHEMO-
THERAPY REFRACTORY MESOTHELIOMA PATIENTS 
WITH THE ANTI-MESOTHELIN IMMUNOTOXIN SS1P 
AND HOST IMMUNE DEPLETION WITH PENTOSTATIN 
(P) AND CYCLOPHOSPHAMIDE (C)
Raffit Hassan, Andrew Miller, Elad Sharon, Anish Thomas, James 
C. Reynolds, Alexander Ling, Robert J. Kreitman, Seth Steinberg, 
Daniel H. Fowler, Ira Pastan
National Cancer Institute/United States Of America
Background: SS1P is a recombinant immunotoxin targeting the 
tumor differentiation antigen mesothelin, which is highly expressed 
in mesothelioma. Anti-tumor activity of SS1P was limited in phase I 
clinical trials due to development of neutralizing antibodies (NAbs) 
that limited treatment to one cycle. In immunocompetent mice P 
and C (P-C) can abrogate development of anti-SS1P NAbs. This 
pilot study was performed to determine the impact of P-C-based 
immune depletion on anti-SS1P NAb formation and to assess safe-
ty of P-C-SS1P.
Methods: Patients with progressive pleural or peritoneal meso-
thelioma who previously received platinum-based therapy were 
eligible. Up to 6 cycles of P 4 mg/m2 IV (cycle 1: days 1, 5, 9; cycle 
2-6: day 1); C 200 mg PO (cycle 1: days 1-12; cycle 2-6: days 1-4) 
and SS1P IV (35 µg/kg, cycle 1: days 10, 12, 14; cycle 2-6: days 2, 4, 
6) were administered (cycle 1 was 30 days and cycles 2-6 were 21 
days) with restaging every 2 cycles in the absence of progressive 
disease and anti-SS1P NAbs.
Results: Eleven patients were enrolled. The median age was 52 
years (range 43-68); male 7, female 4; pleural 9, peritoneal 2; me-
dian number of prior treatments was 3 (range 2-6). Three out of 10 
evaluable patients had partial response with tumor regressions of 
74%, 70% and 44% with complete resolution of metabolic activity 
in two patients and >70% reduction in the third (Table). The overall 
survival of these patients is 17+, 15+ and 18+ months. In addition, 
one patient with stable disease and one patient with progressive 
disease had dramatic response to post-SS1P chemotherapy using 
drugs to which they had not responded previously. All five patients 
who responded are alive with overall survival ranging from 11 to 
18 months. The regimen of P-C delayed development of NAbs to 
SS1P, thereby allowing multiple cycles of therapy with SS1P. Only 
2 of 10 (20%) patients developed anti-SS1P NAbs after one cycle 
compared to 88% of patients who received single agent SS1P in 
a previous study (p=0.0001), thus meeting the primary endpoint. 
The regimen of P-C-SS1P was safe and well tolerated and no pati-
ent developed opportunistic infections. Grade ≥ 3 adverse events 
were P-C related lymphopenia (100%), transaminitis (18%) and SS1P 
related back pain (9%), non-cardiac chest pain (18%) and fever (9%). 
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O22.06 QUALITY OF LIFE MEASUREMENT PARALLEL 
CHANGES IN PULMONARY FUNCTION IN PATIENTS UN-
DERGOING PLEURECTOMY AND DECORTICATION FOR 
MALIGNANT PLEURAL MESOTHELIOMA
David Burkholder1, Duraid Hadi2, Hedy Kindler2, Kristy Todd1, 
Amy Durkin1, Wickii T. Vigneswaran1
1Univesity Of Chicago Medicine/United States Of America, 2University 
Of Chicago Medicine/United States Of America
Background: The role of maximal cyto-reductive surgery in malig-
nant pleural mesothelioma (MPM) remains controversial. Although 
selected patients achieve long-term disease control following 
extended pleurectomy and decortication (PD), not all patients 
benefit. In addition surgical complications and side effects may 
adversely affect quality of life (QoL). We previously observed sig-
nificant improvement in the quality of life following PD in patients 
who were symptomatic at baseline (Mollberg et al, Ann Thorac 
Surg 2012). In this study, we further examined the effects of PD on 
pulmonary function and correlated changes in pulmonary function 
with QOL.
Methods: Consecutive patients with MPM undergoing PD were 
prospectively enrolled at a single center. The primary endpoint 
was to determine the effects of PD on QoL. Health related QoL 
was assessed using the European Organization for Research 
and Treatment of Cancer Core Quality of Life Questionaire-C30 
(EORTC QLQ-C30) before operation and at one,4-5, 7-8 , 10-11 
and 12-13monthsmonths postoperatively. Pulmonary function tes-
ting was performed (PFTs) were measured immediately before the 
operation and at 6-7 months postoperatively. Patients were grou-
ped according to the World Health Organization baseline perfor-
mance status (PS) and compared.
Results: Twenty-seven patients with a median age of 71 years old 
(range 59 to 91 years), 19 males and 8 females, were enrolled in the 
study from March 2010 to October 2012. At the time of the opera-
tion, 17 patients were WHO PS 0, 10 were PS 1. At baseline, the PS 
1 patients had a significantly worse global QoL (p<.0001), functio-
nal (p<0.0001) and symptoms scores (p<0.0001). PS 0 patients had 
not significant change in global QoL or functional) and symptoms 
scores (except for emotional function and insomnia p<0.01) fol-
lowing the operation. In addition they demonstrated a significant 
decrease in FVC (p<0.003), FEV1 (p<0.005), TLC (<0.001) and 
DLCO (<0.009) following PD. PS 1 patients showed significant 
improvements in Global Health (p=0.05) functional measures (p< 
0.01) and symptoms scores (p <0.03) at 4-5 months and this was 
maintained at 6-7 months following PD. Improvement also was 
noted in the FVC (p=0.09), FEV1(p=0.04) and DLCO (p=0.09) in 
these patients.
Conclusion: At intermediate follow-up, extended PD for MPM had 
a negative impact on pulmonary function in minimally symptomatic 
patients without any significant improvement in QoL. In contrast, 
patients who were symptomatic at baseline significantly improved 
in QoL and showed a modest improvement in pulmonary function 
after PD. The change in pulmonary function may be partially res-
ponsible for the observed QoL in symptomatic patients undergo-
ing PD.
Keyword: Maligant Pleural Mesothelioma, Pleurectomy and decor-
tication, Quality of Life, Pulmonary function
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O22.05 EXPOSURE-RESPONSE RELATIONSHIP OF AMA-
TUXIMAB (AMA) IN COMBINATION WITH PEMETREXED 
AND CISPLATIN (P/C) IN PATIENTS WITH UNRESECTAB-
LE PLEURAL MESOTHELIOMA
Julia D. Maltzman1, Bruce A. Wallin1, Anubha Gupta2, Jason Wust-
ner1, Raffit Hassan3
1Clinical Development, Morphotek, Inc./United States Of America, 2Ei-
sai/United Kingdom, 3National Cancer Institute, Nih/United States Of 
America
Background: AMA is chimeric monoclonal antibody that binds to 
mesothelin, which is highly expressed in malignant mesothelioma 
and largely absent from normal tissue. In vitro studies indicate that 
AMA potentially has anti-tumor activity via antibody-dependent 
cellular cytotoxicity. AMA was studied in a Phase 2 mesothelioma 
trial.
Methods: This was a global, single arm, open label Phase 2 trial in 
89 patients with previously untreated epithelial or mixed histology 
unresectable malignant pleural mesothelioma. Subjects received 
P/C every three weeks for 4 to 6 cycles combined with AMA 5mg/
kg on days 1 and 8 of each 21 day cycle. All patients were fully 
supplemented with folate and B12 as per pemetrexed label re-
quirements. Single agent AMA was then continued in the same 
schedule until disease progression. The primary endpoint was 
progression-free survival (PFS) at 6 months with a secondary end 
point of overall survival (OS).
Results: Median PFS was 6.1 months while median OS was 14.8 
months. An evaluation of serum drug concentration relationship 
with clinical response noted that those subjects who achieved a 
median trough serum concentration of 32.9 µg/mL had an impro-
ved median PFS over those whose trough serum concentration 
was below the median (238 days vs 115 days, p<0.001). Similarly 
those subjects with a serum trough concentration of AMA above 
a median of 38.2 µg /mL had a median OS of 583 days while those 
with a median serum concentration of AMA below 38.2 µg /mL had 
a median OS of 375 days, p=0.0202. The most commonly reported 
adverse event was that of hypersensitivity to the chimeric antibody 
at first dose second cycle.
Conclusion: The safety profile of AMA in combination with P/C was 
consistent with that seen previously for the PC regimen. Although 
PFS is not significantly different from historical results of P/C alone, 
the median OS was 14.8 months (as compared to 13.3 months for 
P/C1). PK/PD analysis demonstrated that AMA trough concentra-
tions were a significant predictor of both PFS and OS where higher 
concentrations were associated with longer OS and PFS. 1Refe-
rence: Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III 
Study of Pemetrexed in Combination With Cisplatin Versus Cispla-
tin Alone in Patients With Malignant Pleural Mesothelioma. J Clin 
Oncol, 2003; 21:2636-2644.
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Figure1. Kaplan-Meier survival curves according to the treatment 
(non surgical treatment vs EPP vs P/D) considering only patients 
with independent good prognostic factors After a median follow-
up of 6.7 years (range 1.1-14.8), 230 (16.8%) patients were alive; me-
dian survival for patients who received palliative treatment or che-
motherapy alone, P/D and EPP groups were 11.7 (95%CI: 10.5-12.5) 
months, 20.5 (95%CI: 18.2-23.1) months, and 18.8 (95%CI: 17.2-
20.9) months, respectively. Testing the hypothesis of equal survival 
distributions the statistical significance was reached for the P/D 
and EPP groups versus non surgical treatment group (p <0.001) 
but not for the EPP versus P/D groups (p=0.885). The 30 day mor-
tality was 2.6% after P/D and 4.1% after EPP (p=0.401). According 
to multivariate analysis (n=1227) age < 70, epithelial histology and 
chemotherapy were independent favourable prognostic factors. 
In the subset of 312 (25.4%) patients with all favourable prognostic 
factors median survival was 15.5 months after medical therapy 
alone, 19.4 months after P/D, and 18.7 months after EPP (Figure 1). 
A risk reduction of 31% (95%CI: 14-45%) for the P/D group and of 
23% (95%CI: 7-36%) for the EPP group was observed compared to 
the medical treatment group.
Conclusion: Our data suggest that patients with good prognostic 
factors had a similar survival whether they received medical the-
rapy only, P/D or EPP. The modest benefit observed after surgery 
over medical treatment requires further investigation, and a large 
multicenter randomized trial, testing P/D after induction chemo-
therapy versus chemotherapy alone in MPM patients with good 
prognostic factors, is needed.
Keywords: malignant pleural mesothelioma, Extrapleural pneu-
monectomy, Pleurectomy/decortication, chemotherapy
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O22.07 DOES SURGERY IMPROVE SURVIVAL OF PATI-
ENTS WITH MALIGNANT PLEURAL MESOTHELIOMA? 
A MULTICENTER RETROSPECTIVE ANALYSIS OF 1365 
CONSECUTIVE PATIENTS.
Andrea Bille1, Francesco Ardissone2, Pietro G. Bovolato3, Caterina 
Casadio4, Giuseppe Garofalo1, Giovanni Battista Ratto5, Luigi San-
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Background: Medical management of malignant pleural mesothe-
lioma (MPM) has obtained a moderate survival improvement over 
the years, while surgery with pleurectomy / decortication (P/D) or 
extrapleural pneumonectomy (EPP) can be an option for selected 
patients with resectable disease. The aim of this study was to in-
vestigate the impact of surgical treatment on the outcome of pati-
ents with MPM.
Methods: We retrospectively reviewed data from 1365 consecu-
tive patients with histologically proven MPM, treated from 1982 
to 2012 in six Institutions.Patients received either chemotherapy 
alone (n=172) or best supportive care (n=690) or surgical treatment 
(n=503), by either P/D (n=202) or EPP (n=301) with or without che-
motherapy. All patients were followed up until death or for a mini-
mum period of one year. The cox proportional hazards regression 
model was used to estimate relative improvements and to test the 
statistical hypothesis; a p-value less than 0.05 was considerd stati-
stical significant.
Results: 
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O23.02 POSITRON EMISSION TOMOGRAPHY (PET) IN 
LUNG CANCER SCREENING - FINAL RESULTS AFTER A 5 
YEAR SCREENING PROGRAME.
Haseem Ashraf1, Zaigham Saghir2, Asger Dirksen1, Jesper H. Pe-
dersen2, Jann Mortensen3
1Department Of Respiratory Medicine, Gentofte University Hospital/
Denmark, 2Department Of Thoracic Surgery Rt, Rigshospitalet, Uni-
versity Of Copenhagen/Denmark, 3Department Of Clinical Physiology, 
Nuclear Medicine And Pet, Rigshospitalet, University Of Copenhagen,/
Denmark
Background: PET is a useful tool in the diagnostic workup of lung 
cancer. However, its role in lung cancer screening with low dose 
Computed Tomography (CT), in which small sized nodules are de-
tected, is still to be determined. We present final PET results from 
the 5 year (2005-2010) randomized Danish Lung Cancer Screening 
Trial (DLCST).
Methods: DLCST participants with indeterminate nodules mostly 
between 5 and 15 mm were referred for a 3-month rescan. Bet-
ween the initial scan and the 3-month rescan, participants were 
also referred for a PET scan. Uptake on PET was categorized as 
most likely benign or malignant on a scale from I to IV). Receiver 
operating characteristic (ROC) analyses were used to determine 
the sensitivity and specificity of PET. Resected nodules and indo-
lent nodules (i.e. stable for at least 2 years) were included, and the 
latter was categorized as benign. Nodules were only included once 
in the study, thus repeat PET scans were excluded.
Results: A total of 90 nodules were included, 50% men, mean age 
67 years (58-79), prevalence of lung cancer was 38% (35/90). Mean 
follow-up time for benign non-resected nodules was approx. 2.8 
years in screening. Clinical follow-up in central digital medical 
logs was done for all participants in 2013. The sensitivity and spe-
cificity of PET was 66% and 91%, respectively, with cut-off points 
for malignancy at PET>II (i.e. categorized as possibly or probably 
malignant at PET). The positive predictive value was 82% (23/28) 
and negative predictive value was 81% (50/62). 12 PET results were 
false negative, and of these 75% (9/12) were either ground glass 
nodules or partly solid nodules. 
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O23.01 VOLUME DOUBLING TIME MEASUREMENT OF 
PULMONARY NODULES: COMPARISON BETWEEN 2D- 
AND 3D-METHODS
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uki Takahashi1, Hodaka Numasaki1, Yasuhiko Tomita2, Masahiko 
Higashiyama2
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Background: Measurement of volume doubling time (VDT) of 
small pulmonary nodules is clinically useful for discrimination bet-
ween benign and malignant etiology, because this discrimination 
capability based only on the initial CT is limited. Recent advance-
ment of CT technology enabled direct 3D measurement of volume 
of pulmonary nodules using commercially available software and 
enabled VDT measurement with these data. However, there are 
only a few reports in which accuracy of the 3D method was as-
sessed with comparing the 3D method with the traditional 2D me-
thod. Here, we compared intra- and inter-observer variability (OV) 
to assess the accuracy of these two methods and compared VDT 
of pulmonary nodules in 2D-method with those in 3D-method. We 
also discussed the clinical relevance of our results.
Methods: Forty-two pulmonary nodules of 3 cm or smaller (CT 
type, 11 of ground-glass opacity, 15 of mixed type, and 16 of solid 
type) of peripheral lung cancer (37 of adenocarcinoma, 4 squa-
mous cell carcinoma, and one small cell carcinoma) in 41 patients 
(mean age±SD, 67±10 years; 25 men and 16 women) who under-
went 16-slice MDCT with 1-mm collimation twice (mean interval, 
369 days, range 60-1119 days) before surgical resection during 
June 2006 and December 2008 were included in this study. Five 
examiners independently calculated VDT by 2D (nodule diameter 
measurement) and 3D methods (nodule volume measurement 
using in-house programmed software) with the use of Schwaltz 
equation and repeated the measurements one month after. Thus, 
intra- and inter-OV in VDT for the two methods was compared 
using 95% confidence intervals (CI) in Blant-Altman plots, and VDT 
calculated with the two methods was compared in each examiner. 
In evaluating inter-OV, averaged values of the two measurements 
in each examiner were used for analysis. A p of less than .05 was 
considered to be significant.
Results: As for inter-OV (n=10), 95% CI (mean±SD in days, 
398±123) for 3D method was significantly greater than that 
(231±87) for 2D method (p=0.005). Regarding intra-OV (n=5), 
95% CI (291±199) for 3D method tended to be greater than that 
(195±36) for 2D method (p=0.388). VDT calculated with 3D method 
was significantly greater than that calculated with 2D method in all 
of the 5 examiners (all p of <0.05).
Conclusion: Inter-OV in VDT measurement was significantly grea-
ter in 3D method than in 2D method and VDT calculated with 3D 
method was greater than that calculated with 2D method. There-
fore, in calculating VDT of pulmonary nodules, the same examiner 
should evaluate with the same method.
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assessed by Cox proportional hazards regression model. Statis-
tically significant clinical variables and imaging biomarkers in the 
multivariable analysis were used to construct a prognostic model 
for predicting survival. The predictive accuracy of the prognostic 
model was evaluated by Harrell‘s concordance index (C-index).
Results: Median follow-up for surviving patients was 7.5 years with 
a range of 5.2 to 9.9. At the time of analysis, 52 (26.3%) patients 
had died. Age (HR = 1.05 for 1-year increase, P = 0.007), histolo-
gic cell type (HR = 0.54 for adenocarcinoma, P = 0.027), SUVmax 
(HR = 1.08 for 1-unit increase, P = 0.002), and TLG (HR = 1.23 for 
a doubling of TLG, P = 0.021) were significantly associated with 
OS by univariable analysis, whereas only age (HR = 1.07 for 1-year 
increase, P = 0.005) and SUVmax (HR = 1.04 for 1-unit increase, P = 
0.012) were significantly associated with OS by multivariable ana-
lysis. The final prognostic model included age as a clinical variable 
and SUVmax as a metabolic imaging biomarker to predict OS. The 
predictive performance of the prognostic model for OS was not 
improved by addition of TLG or COV. The C-index was 0.694 for 
the final model with age and SUVmax. Kaplan-Meier survival cur-
ves stratified by risk score showed high-risk group of patients (n = 
58, SUVmax > 12 and age > 60) and low-risk group of patients (n = 
48, SUVmax ≤ 12 and age ≤ 60). 
Conclusion: A new prognostic model based on pretreatment me-
tabolic imaging may have potential clinical utility for risk stratifica-
tion of stage I NSCLC patients.
Keywords: non–small cell lung cancer, FDG PET/CT, Prognosis, 
standardized uptake value
Conclusion: PET is a valuable tool in lung cancer screening; our 
results show fair sensitivity and high specificity in a trial with long 
time follow-up of benign nodules. False negative PET results were 
found in non-solid nodules. We recommend PET as an integrated 
part of future lung cancer screening programs.
Keywords: screening, Lung cancer, PET
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O23.03 METABOLIC IMAGING BASED PROGNOSTIC 
MODEL FOR PREDICTING SURVIVAL OF PATIENTS WITH 
STAGE I NON-SMALL CELL LUNG CANCER
Seung Hyup Hyun1, Joon Young Choi1, Jhingook Kim2, Young Mog 
Shim2, Kyung-Han Lee1, Byung-Tae Kim1
1Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University 
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Background: The objective of this study was to develop a pret-
reatment prognostic model based on metabolic imaging biomar-
kers that could be used to predict overall survival (OS) in patients 
with stage I non–small cell lung cancer (NSCLC).
Methods: We evaluated 198 patients with pathologic stage I 
NSCLC who underwent pretreatment FDG PET/CT. Metabolic 
imaging biomarkers included maximum standardized uptake value 
(SUVmax), total lesion glycolysis (TLG), and coefficient of variation 
(COV) for primary tumors. SUV is a semiquantitative index of meta-
bolic activity. TLG is a volumetric measurement of tumor glycolytic 
activity. COV is an index of tumor uptake heterogeneity. The pro-
gnostic significance of clinical variables and imaging biomarkers 
(age, sex, histologic cell type, tumor size, SUVmax, TLG, COV) was 
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O23.06 DIFFUSION-WEIGHTED MAGNETIC RESONANCE 
IMAGING AT 3.0-T VERSUS FLUORINE 18 FLUORO-
DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/
COMPUTED TOMOGRAPHY FOR DETECTION OF PUL-
MONARY MALIGNANT TUMORS
Jian Zhang1, Longbiao Cui1, Xing Tang2, Yan Zhang1, Hainan Yang1, 
Lizhan Chen1, Xinling Ren1, Jieran Shi1, Hong Yin2
1Department Of Respiratory Medicine, Xijing Hospital/China, 2Depart-
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Background: Emerging evidences suggests that diffusion-weigh-
ted magnetic resonance imaging (DW MRI) at 1.5-T could be useful 
for tumor detection, together with N and M staging in patients 
with lung cancer, especially non-small cell lung cancer (NSCLC), 
with accuracy as good as, or even better than, that of FDG PET/CT 
most recently. This investigation prospectively examined whether 
DW MRI at 3.0-T might be as useful as FDG PET/CT for detection 
of pulmonary malignant tumors.
Methods: This study was approved by the institutional review 
board, and written informed consent was obtained from all pati-
ents. DW MRI and FDG PET/CT were performed before therapy 
in 113 patients with pulmonary nodules, including lung cancer, 
lung metastases, and benign lesions, diagnosed by pathological 
examination. Apparent diffusion coefficient (ADC), maximal stan-
dardized uptake value (SUVmax), and five-point visual scoring were 
assessed. Immunohistochemical staining for Ki-67 was performed 
in 36 patients with lung cancer, and Ki-67 score was evaluated. 
Receiver operating characteristic (ROC) curve analysis was used 
to determine feasible threshold values. Diagnostic capabilities for 
detection of pulmonary malignant tumors were compared with 
the McNemar test on a per-patient basis, and correlation between 
malignant degree of lung cancer and ADC or SUVmax was analyzed 
by Spearman rank test.
Results: As for diagnostic capability, area under ROC curve (Az) 
for ADC (0.91) were significantly higher than that for SUVmax (0.78, P 
< 0.05), and Az value for DW MRI (0.94) were not significantly dif-
ferent from that for FDG PET/CT (0.92, P > 0.05). For quantitative 
assessment, specificity and accuracy of ADC (91.7%, 92.9%) proved 
to be significantly higher than those of SUVmax (66.7%, 77.9%, P 
< 0.05), although sensitivity of ADC (93.5%) was not significant-
ly different from that of SUVmax (83.1%, P > 0.05). When feasible 
threshold values were used to assess qualitatively, sensitivity, spe-
cificity, and accuracy of DW MRI (96.1%, 83.3%, 92.0%) were also 
not significantly different from that of FDG PET/CT (88.3%, 83.3%, 
86.7%, P > 0.05). Significant correlation was found between Ki-67 
score and ADC (Spearman coefficient r = -0.66, P < 0.05), as well 
as ADC and SUVmax (r = -0.37, P < 0.05). On the contrary, Spearman 
coefficient was -0.11 between Ki-67 score and SUVmax (P > 0.05).
Conclusion: In conclusion, quantitative and qualitative assess-
ments for detection of pulmonary malignant tumors obtained with 
DW MRI at 3.0-T are as useful as, even superior to, those obtained 
with FDG PET/CT. Furthermore, another significant outcome of 
this study was that ADC in DW MRI at 3.0-T can also play a role in 
prediction for malignant degree of lung cancer in particular, but 
SUVmax did not in FDG PET/CT.
Keywords: FDG PET/CT, DW MRI, Lung cancer, assessment
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O23.04 IMPROVED INTEROBSERVER AGREEMENT WITH 
PERCIST 1.0, COMPARED TO A QUALITATIVE METHOD 
FOR EARLY RESPONSE EVALUATION USING FDG-PET/
CT IN NSCLC
Joan Fledelius1, Azza A. Khalil2, Jorgen Frokiaer3
1Nuclear Medicine, Herning Regional Hospital/Denmark, 2Oncology, 
Arhus University Hospital/Denmark, 3Nuclear Medicine, Arhus Univer-
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Background: During the past decade many studies have used FDG-
PET/CT for response evaluation to therapy, both in NSCLC and seve-
ral other cancer forms. A preferential method for evaluation has not 
been established as of yet. Two main approaches tend to single out: 
A visually based model as described by Mc Manus et al in 2003 and 
semi-quantitative approaches, like the recently proposed PERCIST 1.0 
2009, by R. Wahl et al. Few studies have evaluated the interobserver 
variability when using sequential PET/CT scans for response evaluati-
on, and comparison of qualitative- and semi quantitative approaches 
are also scarce. The aim of this study is to determine which method 
will provide the more robust evaluation of response when using FDG-
PET/CT, the qualitative approach or the SUV based semi quantitative 
approach prior to the introduction of routine early response evaluati-
on in NSCLC.
Methods: FDG-PET/CT scans at baseline and after 2 cycles of chemo-
therapy from 35 patients with locally advanced NSCLC were analysed 
by 8 different readers using two different methods: PERCIST 1.0 and 
the qualitative McManus approach. Both methods result in allocating 
patients into one of four response categories. Observers were given 
short written presentations outlying the criteria for evaluation by the 
two methods. The observers represent a wide range in experience 
with PET evaluation, only half had experience in response evaluation 
in NSCLC, but most were experienced in similar evaluation in lympho-
ma patients.
Results: When using PERCIST 1.0, the agreement between obser-
vers in determining the percentage change in SULpeak was “almost 
perfect” with ICC=0.959 similar ICC values were found looking at SUL 
peak at baseline and follow up scans. There was strong agreement 
amongst readers allocating patients to the different response catego-
ries with Fleiss kappa of 0.761 (0.714-0.808). In 22 of the 35 patients 
there was complete agreement. When using the qualitative method 
(A.M. McManus), agreement was lower, down to moderate agree-
ment, with Fleiss kappa of 0.596 (0.554-0.639). And complete agree-
ment was observed in only 10 of the 25 patients. Using chi squared 
the difference is statistically significant (p < 0.005). No difference was 
found between experienced and non-experienced observers.
Conclusion: In spite of a wide range of experience among 8 readers 
receiving minimal introduction to the two methods they were to use, 
we found rather high kappa values, for both methods compared to 
its nearest competitor: Size change in CT images, known to be very 
observer dependent. The more objective, semi-quantitative method 
showed substantially higher agreement than the more subjective me-
thod. We suspect that a more detailed introduction into the methods 
would have improved the kappa values even further, but believe that 
our method is more likely to provide an introduction similar to the one 
you receive when introduced as a new physician at the department. 
Perhaps then the agreement reflects the long-term agreement.
Keywords: response evaluation, FDG-PET/CT, Interobserver agree-
ment, PERCIST 1.0
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Conclusion: DWI has a higher specificity for N2 staging of NSCLC 
compared with PET and has the potential to be a reliable alterna-
tive imaging method with an advantage of radiation-free imaging 
for the preoperative staging of mediastinal lymph nodes in pati-
ents with NSCLC.
Keywords: N-staging, non–small cell lung cancer, diffusion MR 
imaging, F-18 FDG PET
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O23.07 COMPARISON OF DIFFUSION-WEIGHTED MA-
GNETIC RESONANCE IMAGING VERSUS F-18 FLUORO-
DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY 
IN THE ASSESSMENT OF N2 LYMPH NODE METASTASIS 
DUE TO NON-SMALL CELL LUNG CANCER
Erkan Yilmaz1, Atilla Akkoclu2, Askin Gulsen3, Fidan Sever3, 
Berhan Genc4, Sena Kalaycioglu4, Inanc Karapolat5, Ahmet Onen6
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Background: To compare the diagnostic efficacies of diffusion-
weighted magnetic resonance imaging (DWI) and F-18 fluoro-
deoxyglucose positron emission tomography (PET) findings for the 
preoperative prediction of mediastinal nodal metastasis in stage 
N2 disease of non–small cell lung cancer (NSCLC).
Methods: The study included 68 patients (42 men and 26 women; 
mean age, 62 years) with a supicious stage N2 due to NSCLC. In all 
patients, DWI (using a sigle-shot echo-planar sequence with diffu-
sion factor of 0-600 s/mm² at 1.5 Tesla) and PET were performed 
before surgery. In DWI, a patient was regarded to have stage N2 
disease when an ipsilateral mediastinal lymph node showed ap-
parent diffusion coefficent (ADC) value of ≤0.98 s/mm², regardless 
of nodal size. A node was considered as positive for malignancy, if 
it showed standardized uptake value (SUV) of 3 or higher by PET. 
Both DWI and PET images were prospectively evaluated for ma-
lignancy on a per-node basis by two observers. Histopathologic 
results served as the reference standard. N2 disease was decided 
by using the American Joint Committee on Cancer staging system. 
The results were compared between the two modalities and statis-
tically significant differences in nodal metastasis between DWI and 
PET were determined with p<.05 obtained by using the McNemar 
test or with a generalized estimating equation.
Results: Nodes were positive for malignancy in 36 (32%) of 114 
nodal stations and 22 (32%) of 68 patients. The N2 staging was 
correctly diagnosed in 56 (82%) and 52 (76%) patients by DWI and 
PET (p=.09), respectively. For the depiction of malignant nodes, 
DWI and PET showed sensitivities of 78% (31 of 40 nodal groups) 
and 78% (28 of 36), specificities of 93% (69 of 74) and 90% (70 of 
78), positive predictive values of 86% (31 of 36) and 78% (28 of 36), 
negative predictive values of 88% (69 of 78) and 90% (70 of 78) and 
accuracies of 88% (100 of 104) and 86% (91 of 104), respectively 
(p=.23, p<.05, p<.01, p=.08, and p=.12). There were nine false-
positive interpretations by DWI, compared with eight by PET. Eight 
false-negative assessments were present on PET images, but only 
five false-negative results were found in DWI. .
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Conclusion: Occupational risk factors for lung cancer in South Africa 
are gender-specific, having more impact in women than in men. 
Further studies are needed to assess possible specific exposures in 
the mining and transport industries for men, and food industry and 
private homes for women.
Keyword: lung cancer, attributable risk, occupation, case control
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O24.02 LUNG CANCER IN SOUTH EAST SCOTLAND, 
ARE WE STILL MAKING PROGRESS?
Sara C. Erridge1, Gill Kerr1, Christine Dodds2, Sorcha Campbell1, Ja-
net Ironside1, Felicity Little1, Melanie Mackean1, Allan Price1, Jane 
Gysin3, Lesley Bhatti4, Colin Selby2
1Edinburgh Cancer Centre/United Kingdom, 2South East Scotland 
Cancer Network/United Kingdom, 3Dumfries And Galloway Royal In-
firmary/United Kingdom, 4Information Services Division, Nhs National 
Services Scotland/United Kingdom
Background: South-East Scotland Cancer Network (SCAN) serves 
1.4 million people using unified protocols collecting prospective 
data. We published population-based data from 1995 and 2002 
(J Thorac Oncol. 2008;3(5):491-8) demonstrating increased cancer 
treatment and improved overall survival. This review investigates 
whether this has been sustained.
Methods: Patients were identified from Scottish Cancer Registry 
(SCR), SCAN audit and Edinburgh Cancer Centre databases to ext-
ract tumour characteristics, initial management (usually ≤6 months 
of diagnosis) and overall survival (OS). Missing data was sought from 
patients’ health records. Multivariate analysis (MVA) examined sex, 
age(<60,60-69,70-79,80+), deprivation, Healthboard of residence, 
performance status (PS), pathology and stage (localised, regional, 
metastatic) affecting use of any treatment, potentially curative 
treatment (PCT) defined as surgery (S) or potentially curative ra-
diotherapy (PC-RT - ≥50Gy for NSCLC or ≥40Gy+chemo for SCLC) 
using Cox’s proportional hazards model to obtain factors affecting 
survival.
Results: 1117 patients were identified in the audit. 51.5% were men, 
median age 72 (range 31-98) years. 47.3% were from the two most 
deprived quintiles. 49.5% had WHO PS 0-1, 23.5% WHO2, 24.2% 
WHO3-4. 58.5% NSCLC (23.5% Stage I-II, 25.7% III, 48.8% IV), 13% 
SCLC (37.9% stage I-III, 61.4 stage IV) and 28.5% radiology-only 
diagnosis (24.5% Stage I-II, 19.5% III, 52.8% IV). 59.9% received 
some form of treatment; 28.4% with PCT ((126 S+/-chemo(C) = 19% 
of NSCLC), 190 PC-RT +/- C), and 31.5% palliatively. 467 (41.8%) 
received any RT, 268 (24%) any C. MVA showed age >70, PS≥2, me-
tastatic disease, ‘not-SCLC’, but not sex, deprivation or Healthboard, 
were associated (all p<0.01) with lower treatment delivery, and only 
age > 80, PS≥2, radiology-only diagnosis and non-localised disease 
(all p<0.01) with reduced PCT. Median survival was 5.03 months 
(95%CI 4.3-5.8) with 46.8% alive at 6 months, 32.0% 12 and 17.7% 
24 months following diagnosis. Male sex, PS≥2 and non-localised 
disease were associated with increased HR for death (all p<0.01). 
Comparison with the 2002 cohort (n= 971, Dumfries excluded from 
both cohorts) showed similar age and pathology profile, but incre-
ased women, residents from most deprived quintile and metastatic 
disease. Uni-variate analysis showed a similar proportion received 
treatment (62.3% 2002 v. 59.9% 2010 p=0.14) but more received PCT 
(23.6% v. 28.2% p=0.02) principally through increased use of PC-RT 
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O24.01 LUNG CANCER RISK ATTRIBUTABLE TO OCCU-
PATION: IN A CASE CONTROL STUDY IN BLACK SOUTH 
AFRICANS 2001-2008
Cornelius Nattey
Epidemiology And Surveillance, National Institute For Ocupational 
Health/ National Cancer Registry/South Africa
Background: Worldwide, lung cancer is the leading cause of death 
by cancer and most common cancer among occupational related 
cancers. Approximately 90% of men and 60% of women. developing 
lung cancer are smokers. Cancer Morbidity and the increase in can-
cer mortality in South Africa is well documented and has been attri-
buted to different factors, including tobacco consumption, occupa-
tional exposures, infections, changing lifestyles, ageing population 
and environmental pollution The International Agency for Research 
on Cancer (IARC) has estimated that almost 40 000 deaths from can-
cer (58 000 cases) occur annually in South Africa. In men the leading 
causes of deaths were lung cancer (comprising 16% of all cancer 
deaths). Environmental and occupational risk factors contribute to 
the burden of lung cancer, but the extent of this contribution is still 
unclear in most settings especially in Africa, confirmed in a review by 
McCormack and Schuz Estimating the attributable fraction for spe-
cific risk factors helps to assess the potential impact the preventive 
interventions could have on the population. The proposed study will 
estimate lung cancer risk attributable to the different occupations 
and types of workplaces in black South African population repre-
sented in the data base while controlling for smoking and domestic 
fuel use. Identification of the role of occupation on the risk of lung 
cancer may enhance the ability to prevent the disease by permitting 
better focused occupational health and other preventive strategies 
in the fight against non-communicable diseases in black South Af-
ricans. There is very limited research on cancers and occupations in 
Africa; hence findings will contribute to the knowledge of lung can-
cer in relation to occupations in South Africa.
Methods: Data from the on-going Johannesburg Cancer Case-
Control Study (JCCCS) of black African adult cancer patients (2001-
2008) was used. Information from 579 lung cancer cases and 1120 
frequency matched controls was analysed. Controls were randomly 
selected from cancers not known to be associated with the effects 
of tobacco, matched by sex and age (±5years). Usual occupation 
and/or workplace stated at interview were used as an indicator of 
occupational exposure. Odds ratios (OR) and 95% confidence inter-
vals (CI) were estimated using unconditional logistic regression and 
attributable fraction (AF) by Miettinen’s formula, adjusted for smo-
king pack years, HIV status and domestic fuel type use.
Results: The mean age of cases and controls was 56.0 and 57.1 
respectively. Among men the adjusted OR for lung cancer was 3.0 
(95% CI 1.4-6.4) in miners and 1.7 (95% CI 1.3-3.2) in those working 
in transport occupations. In women working as domestic worker 
(maids, child minders etc) the adjusted OR was 7.3 (95% CI 1.7-11.3) 
whereas working in the food & beverage industry, the adjusted OR 
was 4.9 (95% CI 1.4-26.8). Occupation / workplace resulted in an AF 
of 14% in men and 26% in women.
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Methods: For the first time, annual population estimates for Asian-
American ethnic populations were developed for the regions in the 
Surveillance, Epidemiology, and End Results program, comprising 
half of the total U.S. Asian-American population. From 1990-2010, 
incidence rates and average annual percentage change (APC) were 
computed for each racial/ethnic group for lung cancer overall and by 
gender and histology.
Results: Among Asian-American males, trends were either stable or 
declining in all groups (Figure 1). The declines were statistically sig-
nificant among Koreans (APC = -3.0), Hawaiians (APC = -2.3), Vietna-
mese (APC = -1.4), Filipino (APC = -1.9 from 1996-2010), and Chinese 
(APC = -1.5). Among Asian-American females, declining trends were 
seen among Hawaiians (APC = -5.9 from 2002-2010) and Vietnamese 
(APC = -1.5). In contrast, increasing trends were seen among Japa-
nese (APC = 1.7) and Filipinas (APC = 1.5). Among Asian-American 
males, all histologies exhibited stable or declining trends with the 
exception adenocarcinoma, which increased among Chinese males 
from 1997-2010, appearing independent of the decrease in NOS, 
which occurred much later in this group. Among Asian-American 
females, declining or stable trends were seen for most histologies, 
with the exception of adenocarcinoma among Filipina and Korean 
females (APC = 2.5 and 3.0, respectively), and squamous cell carci-
noma among Japanese females (APC = 2.4). 
Conclusion: To the extent that Asian-Americans have distinct pri-
mary and second-hand smoking profiles, unique environmental 
exposures , and population-specific genetic predisposition, analysis 
of incidence trends by histology suggests that, among Asian-Ame-
rican females, additional risk factors beyond primary and perhaps 
secondary smoking may be important for lung cancer etiology. The 
continued increase of lung cancer incidence among Filipina, Korean, 
and Japanese American females, especially in adenocarcinomas and 
squamous cell carcinomas, warrants further attention.
Keyword: lung cancer, incidence trends, Asian-Americans
(13.1% v. 17.1% p=0.01). On MVA (without PS) the use of any treat-
ment reduced (OR 0.73 (0.59-0.92) however, use of PCT increased 
(OR 1.84 (1.37-2.47) due to more PC-RT (1.57 (1.18-2.08)), but not sur-
gery. Median (5.16 v. 4.90 months p=0.65), 1 year (29.0% (31.9-26.1) 
v. 31.4% (34.3-28.5) and 2 year (14.9% (17.3-12.5) v. 17.4% (19.8-15.0) 
survival were unchanged.
Conclusion: In the last 8 years in SCAN, there has been an increase 
in the number of women with lung cancer along with a worsening 
deprivation profile and increased identification of stage IV disease, 
possibly through improved staging. There has been an increase in 
potentially curative, but reduction in all therapy delivered without 
any apparent impact on survival. This analysis demonstrates the 
challenges of improving population-based outcomes in a disease 
where most present with advanced disease and are often unfit for 
treatment .
Keywords: survival, population-based, Treatment, Outcome
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O24.03 LUNG CANCER INCIDENCE TRENDS AMONG 
ASIAN-AMERICAN ETHNIC POPULATIONS IN THE  
UNITED STATES, 1990-2010
Scarlett Lin Gomez1, Iona Cheng1, Kathleen Gali1, Manali I. Patel2, 
Robert Haile2, Anne-Michelle Noone3, Heather Wakelee2
1Cancer Prevention Institute Of California/United States Of America, 
2Stanford University/United States Of America, 3National Cancer Insti-
tute/United States Of America
Background: In the United States (US), anti-smoking policies have 
resulted in a population-wide decline in lung cancer rates over the 
past decade. However, little is known about how lung cancer inci-
dence trends vary among Asian-American ethnic populations, the 
largest growing population in the US.
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O24.05 THE IMPACT OF BODY MASS INDEX ON SURVI-
VAL IN STAGE 3 AND 4 LUNG CANCER
Kit Man Wong1, Sinead Cuffe2, Linda Coate3, Osvaldo Espin-Gar-
cia4, Kevin Boyd5, Ronald Feld2, Natasha Leighl2, Frances A. She-
pherd2, Wei Xu4, Geoffrey Liu2
1Medical Oncology, University Of Toronto/Canada, 2Medical Oncology, 
Princess Margaret Cancer Centre/Canada, 3Medical Oncology, Midwes-
tern Regional Hospital/Ireland, 4Biostatistics, Princess Margaret Cancer 
Centre/Canada, 5Princess Margaret Cancer Centre/Canada
Background: Obesity has been shown to be an adverse prog-
nostic factor in several cancers, including breast, colorectal, en-
dometrial, ovarian, pancreatic and prostate. However, studies of 
body mass index (BMI) and outcomes in lung cancer are lacking. 
Understanding the clinical impact of body weight on cancer outco-
mes is important given the high prevalence of obesity globally. We 
retrospectively evaluated the distribution of BMI at diagnosis and 
its effects on survival in stage 3 and 4 lung cancer patients.
Methods: 1,121 patients with stage 3 or 4 lung cancer from a sing-
le institution were analyzed. Clinicopathologic data were collected 
retrospectively. Adjusted hazard ratios (aHR) for overall survival 
(OS) and progression-free survival (PFS) were generated by Cox 
regression for each BMI (kg/m2) category (underweight: <18.5, nor-
mal: 18.5-24.9, overweight: 25.0-29.9, obese: ≥30), after adjusting 
for age, gender, Charlson Comorbidity Index, performance status 
(PS), clinical stage and treatment regimen.
Results: In this cohort (n=1,121), the frequencies of stage 3A, 3B 
and 4 lung cancers were 35%, 32% and 33%, respectively. There 
were 633 (57%) adenocarcinomas, 238 (21%) squamous cell carci-
nomas, 38 (3%) small cell lung cancers, and 210 (19%) other histo-
logies. Patients had variable BMI: 82 (7%) underweight, 550 (49%) 
normal weight, 333 (30%) overweight, 156 (14%) obese. Being 
overweight/obese was associated with older age (p=0.002) and 
stage 3A disease (p=0.001); underweight patients were more likely 
current smokers (p<0.001). OS was significantly decreased with 
age ≥65, males, PS 2-3, stage 4, and lack of systemic treatment 
(p<0.001). Median OS in underweight, normal weight, overweight 
and obese patients were 14, 23, 24 and 26 months, respectively. 
Compared with BMI ≥18.5, being underweight was associated with 
significantly poorer OS (aHR 1.33, 95% CI 1.01-1.77, p=0.045), but 
not PFS (aHR 1.12, 95% CI 0.86-1.46, p=0.414). The magnitude of 
this association was greatest among those aged less than 65 years 
(aHR 1.57, 95% CI 1.11-2.22, p=0.011).
Conclusion: In stage 3 and 4 lung cancer, being underweight at 
diagnosis is associated with significantly poorer OS, especially in 
patients younger than 65 years of age. Lower BMI is mostly obser-
ved in current smokers, while above normal BMI is seen in older 
patients and stage 3A disease. Unlike other malignancies, obesity 
does not increase mortality in this population. The BMI-survival 
relationship in lung cancer requires further study.
Keywords: Body mass index, Lung cancer
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O24.04 RISK OF SECOND PRIMARY LUNG CANCER 
(SPLC) IN PATIENTS (PTS) WITH PREVIOUSLY TREATED 
LUNG CANCER: ANALYSIS OF THE SURVEILLANCE, EPI-
DEMIOLOGY AND END RESULTS (SEER) DATA
Antoinette J. Wozniak, Ann Schwartz, Fawn D. Vigneau, Ronald D. 
Shore, Md K. Islam, Shirish Gadgeel
Oncology, Karmanos Cancer Institute/Wayne State University/United 
States Of America
Background: Second primary lung cancer (SPLC) in patients who 
have been treated for a prior lung cancer is a recognized pheno-
menon. There has been an improvement in the staging and treat-
ment of lung cancer in the last several decades resulting in longer 
survival for pts and affording an opportunity for the development 
of SPLCs. The objective of this study was to establish the frequen-
cy of SPLCs and to characterize the demographics, histology and 
stage at presentation, time interval between diagnoses, and cumu-
lative risks of developing a SPLC in this pt population.
Methods: The pts were identified from population-based SEER-9 
Registries Data Base. All pts with a primary lung cancer between 
1973 and 2004 were included with follow-up to 2009. The his-
tology and stage of the SPLCs were evaluated in comparison to 
the initial primary lung cancer (IPLC). The incidence of SPLCs was 
compared to the expected incidence by calculating multiple pri-
mary-standardized incidence ratios (MP-SIRs) using the SEER Stat 
program. Selected cohorts were stratified by sex, race, age at dia-
gnosis, and date of diagnosis. Sex-specific cumulative risks of de-
veloping SPLCs were calculated using the Kaplan-Meier method.
Results: 208,486 pts had an IPLC diagnosed from 1973-2004. No 
smoking history was available. Patient Characteristics at time of 
IPLC: 60.4% male; 84.3% white; 8.5% (20-49 yr), 55.9% (50-69 yr), 
35.6% (≥ 70 yr); 84% non-small cell lung cancer (NSCLC); 33.8% 
distant disease, 23.5% regional, 29.9% local. 5,302 pts developed 
SPLC. The majority were male (56.6%), white (84.9%), and in the 50-
69 yr age group (68%). Females had the highest SIR values across 
all ethnicities and age groups particularly in the youngest cohort 
(20-49 yr) where the SIR was 8.58. The SIR values were ≥ 2 for all 
cohorts expect for males ≥ 70 yr (SIR=1.65). The predominant his-
tologic types for IPLCs were adenocarcinoma (ADC) and squamous 
cell cancer and the associated SPLCs were usually of the same his-
tology. IPLC ADC and BAC pts were most likely to develop a SPLC. 
Most SPLCs (50%) presented with regional or distant disease, while 
only 37% were localized at diagnosis. The median time to develop-
ment of SPLCs was 68 mo for males and 74 mo for females. The risk 
of developing a SPLC continually increased as a function of time 
for both sexes.
Conclusion: Patients with a history of IPLC are at high risk for deve-
loping SPLC and this risk increases over time. This is especially true 
of females who are diagnosed at an early age with their initial lung 
cancer. The majority of SPLCs present late and at a more advanced 
stage. These findings could have major implications with regard to 
the length and type of surveillance in pts who survive their initial 
lung cancer diagnosis.
Keyword: second lung cancer
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ted with higher LCS.
Keywords: stigma, surgery, postoperative
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O25.02 THE SOCIAL STIGMA OF LUNG CANCER:  
DEATH ANXIETY AND HEALTH BELIEFS AS ANTECE-
DENT VARIABLES
Tabitha Frew, Vikki Knott
Psychology, University Of Canberra/Australia
Background: Lung cancer patients in Australia report a profound 
experience of stigma. Therapeutic nihilism, differences in chemo-
therapy treatment options compared to other cancers, and the 
onset controllability of the disease are some of the contributing 
factors to the stigma and its effects on the patient, such as poor 
psychosocial and quality of life outcomes. This is the first known 
study to investigate the constructs underlying the community’s 
views on lung cancer through the lens of a prominent social stigma 
model. This model explores three domains of stigma; enforce-
ment of social norms, avoidance of disease and exploitation of 
the stigmatised group. Health Locus of Control Theory and Terror 
Management Theory explore the role of health beliefs and death 
anxiety as antecedent variables to the social stigma of lung cancer.
Methods: A total of 211 university students (males = 56, females = 
155) (64% undertaking a health degree) completed an online sur-
vey containing the Cataldo Lung Cancer Stigma Scale (CLCSS), the 
Death Anxiety Inventory (DAI) and the Internal and Chance subsca-
les of the Multidimensional Health Locus of Control scale (MHLC). 
Approximately 65% of participants were 18-25 years of age and 
“never smokers”. Approximately 40% had current or previous con-
tact with a person suffering lung cancer.
Results: The underlying structure of the CLCSS was investigated 
using principal axis factoring with varimax rotation. Four factors 
accounted for 61% of variance in lung cancer stigma. To test the 
hypothesis that the fear of death and health beliefs respectively 
account for a portion of variance in lung cancer stigma, a hierar-
chical multiple regression analysis (MRA) was employed. On step 
1, demographic variables, smoking status, family smoking history 
and contact with lung cancer accounted for a significant 10% of the 
variance in lung cancer stigma, R2 =.10, F(7, 201) = 3.03, p =.005. 
Entering death anxiety and health beliefs respectively at step two 
explained an additional 4% variance in lung cancer stigma, ∆R2 
=.14, ∆F(3, 198) = 3.16, p =.001. A combined effect of this magni-
tude can be considered “medium” (f 2 = .16). Smoking status (sr2 = 
.03) and fear of death (sr2 = .03) were significant predictors of lung 
cancer stigma. Health beliefs were non-significant predictors.
Conclusion: A lung cancer patient is likely to evoke emotions asso-
ciated with a fear of death for community members who are high 
on death anxiety. This result aligns with the social stigma model; 
empathy for the patient is replaced with avoidance of the diseased 
person. This has implications for media and research representa-
tions which focus on the high mortality rate and the “ugly” nature 
of the disease. The 60% variance in social stigma explained by the 
CLCSS conceptually aligns with domains of lung cancer stigma 
identified in the theoretical model. However, for the remaining 
variance, health beliefs were non-significant predictors of stigma-
tising norms against lung cancer patients. This suggests the moral 
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O25.01 RELIABILITY OF AND CORRELATES WITH A 
MEASURE OF LUNG CANCER STIGMA IN NORWEGIAN 
PATIENTS WHO UNDERWENT LUNG CANCER SURGERY
Trine Oksholm1, Tone Rustoen1, Christine Miaskowski2, Steven 
Paul2, Janine Cataldo2, Johny Kongerud1
1Oslo University Hospital/Norway, 2School Of Nursing, University Of 
California/United States Of America
Background: In HIV, cancer, and other diseases, stigma is known 
to have a negative impact on patient outcomes. Regardless of 
smoking status, lung cancer patients feel stigmatized because their 
disease is strongly associated with smoking. In addition, higher le-
vels of lung cancer stigma (LCS) are associated with higher levels of 
depression and poorer quality of life (QOL). Previous studies have 
measured LCS in heterogeneous samples of patients at various 
stages of their disease and treatment. The purpose of this study 
was to evaluate LCS levels in a homogenous sample of patients 5 
months after lung cancer surgery and to identify correlates of LCS.
Methods: Patients were recruited from three university hospitals 
in Norway. They completed a number of self-report questionnaires 
and the Cataldo Lung Cancer Stigma Scale (CLCSS). The CLCSS is 
a 31-item scale with each item rated on a 4-point Likert scale (i.e., 
strongly disagree to strongly agree). Descriptive statistics were 
used to present demographic and clinical characteristics. Reliabi-
lity of the CLCSS was assessed using Cronbach’s alpha. Multiple 
regression analysis was done to identify characteristics associated 
with higher levels of LCS.
Results: Findings from this study provide data on the first time 
use of the CLCSS in a Norwegian sample of patients with lung 
cancer. Cronbach‘s alpha for the total CLCSS score was 0.95. 
The sample consisted of 121 (57.1%) men and 91 (42.9%) women 
who had a mean age of 66.1 years (SD=8.3, range 30 to 87). The 
mean stigma score was 44.0 (SD=13.8) with a range of 31 to 109 
(a higher score, indicates higher level of stigma). Bivariate analysis 
of demographic and clinical characteristics revealed that patients 
with a higher level of stigma were younger (r = -.18, p =.01), more 
likely to live in a small town compared to rural areas (p=.04), had 
smoked until the time of surgery (p=.008), and had higher levels 
of depression (r = .24, p<.001). Marital status was included in 
the multivariate analysis, because it approached significance in 
the bivariate analysis (p=.07). In the multivariate analysis, marital 
status (p=.002) and depression (p=.006) remained significant. The 
final multivariate model explained 13.5% of the variance in stigma 
scores. Marital status and depression symptom scores uniquely 
explained 3.6% and 4.6% of the variance of stigma, respectively. 
Patients who were married and patients who reported higher 
depression scores reported higher stigma scores.
Conclusion: The CLCSS is a valid measure of stigma in Norwegian 
patients with lung cancer. The majority of the patients (97%) repor-
ted stigma scores below 75.7, the mean score obtained in a United 
States sample. However, 3% of the sample had a stigma score of 
>75.7. In a Norwegian sample of lung cancer patients, being mar-
ried and having a higher mean score on the Center for Epidemio-
logical Studies-Depression Scale (i.e., 27.3 (SD=13.4)) were associa-
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tigation explored this experience of LCS and validated previous 
findings liNKIng QOL and LCS. LCS provides unique explanatory 
contribution to the understanding of QOL for lung cancer patients. 
Therefore, providers should consider not only typical psychoso-
cial aspects of the diagnosis, but also patient experience of LCS. 
Related, LCS literature suggests a gap in the psychosocial care of 
lung cancer patients; no stigma reduction intervention is currently 
available. Providers might encourage their patients to engage in 
potential stigma reduction behaviors that may positively impact 
QOL: 1) self-educate about their diagnosis, 2) critically evaluate 
their treatment plans, 3) attend support groups, and 4) advocate 
against stigma.
Keyword: lung cancer, stigma, quality of life, multiple regression
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O25.04 LUNG CANCER STIGMA, ANXIETY, DEPRESSION 
AND SYMPTOM SEVERITY
Janine K. Cataldo
Physiological Nursing, University Of California, San Francisco/United 
States Of America
Background: Lung cancer survivors experience more physical and 
psychosocial problems for a longer period of time than survivors 
of other cancers. Whether they have ever smoked or not, lung 
cancer patients feel stigmatized because their disease is strongly 
associated with smoking. In our previous work, lung cancer stig-
ma (LCS) was a significant predictor of increased depression and 
decreased quality of life (QOL). With an increased number of lung 
cancer survivors and a dearth of information on all perspectives of 
their health and QOL, additional research is needed to understand 
not only the associations among LCS and psychosocial factors, but 
also associations among LCS and physical symptom burden. This 
study was designed to investigate the relationship between LCS, 
anxiety, depression and physical symptom severity.
Methods: This study employed a cross-sectional, correlational 
design with recruitment of patients from online lung cancer web-
sites. LCS, anxiety, depression and physical symptoms were mea-
sured by patient self-report using validated scales via the Internet. 
Hierarchical multiple regression was performed to investigate the 
individual contributions of LCS, anxiety, and depression to symp-
tom severity.
Results: One hundred and forty-four participants ranged in age 
from 23 to 79 years (mean age=56.7 years); 93% were Caucasian, 
79% were current or former smokers, and 74% were female. The-
re were strong positive relationships between LCS and anxiety 
(r=0.413, p<.001); depression (r=0.559, p<.001); and total lung 
cancer symptom severity (r= 0.483, p<.001). Although small, LCS 
provided a unique and significant explanation of the variance in 
symptom severity beyond that of age, anxiety, and depression, by 
1.3% (p<.05).
Conclusion: Because LCS is associated with both psychosocial and 
physical patient outcomes, research is needed to develop inter-
ventions to assist patients to manage LCS Some evidence suggests 
that LCS is a hindrance to help-seeking behavior and prevents ear-
ly detection and treatment and may keep patients from reporting 
distressing symptoms. A significant number of smokers report 
feeling unworthy of treatment. Patients are frequently reluctant to 
dimensions underpinning the social stigma of lung cancer may 
warrant further investigation, particularly in relation to smoking 
behaviours.
Keyword: lung cancer, social stigma
STIGMA AND NIHILISM  
TUESDAY, OCTOBER 29, 2013 - 16:15-17:45
O25.03 THE UNIQUE CONTRIBUTION OF LUNG CAN-
CER STIGMA TO PATIENT QUALITY OF LIFE
Cati G. Brown-Johnson1, Jennifer Brodsky2, Janine K. Cataldo2
1Center For Tobacco Control Research And Education, University Of 
California, San Francisco/United States Of America, 2Physiological Nur-
sing, University Of California, San Francisco/United States Of America
Background: Lung cancer is associated with greater levels of psy-
chological distress than any other cancer. Anxiety and depression 
are associated with diminished QOL for lung cancer patients, 
but do not explain the total variance in QOL. Lung cancer stigma 
(LCS) may explain some of the additional variance in QOL. LCS 
is a perceived stigma resulting from negative perceptions about 
the relationship between smoking and lung cancer. This study’s 
theoretical framework is the Lung Cancer Stigma Model (LCSM), a 
patient-centered model that includes precursors, perception and 
responses to LCS. LCS, according to LCSM, is characterized by dia-
gnosis and connections to tobacco exposure and smoking stigma; 
experiences of discrimination, isolation or shame; and responses 
ranging from increased symptom burden to Stigma Resistance 
(SR), defined as “opposition to the imposition of … stereotypes by 
others” (Thoits, 2011)and shown to positively correlate with self-
esteem, empowerment and QOL. Study aims and hypotheses were 
to: 1) Investigate the relationship of LCS with anxiety, depression 
and QOL; 2) Explore whether LCS has a unique contribution to the 
explanation of QOL after controlling for significant covariates (i.e., 
sex, age); and 3) Compare whether study variables vary by smo-
king status.
Methods: This was a descriptive, cross-sectional study (N=149). An 
online survey of lung cancer patients recruited from cancer infor-
mation and support websites included demographic questions, 
the Cataldo Lung Cancer Stigma Scale, the Spielberger State Anxi-
ety Questionnaire, the CES-D, and the Quality of Life Inventory.
Results: Data from primarily Caucasian female participants with 
a history of smoking demonstrated strong negative associations 
among anxiety, depression, LCS and QOL, regardless of smoking 
status; this confirmed previous findings that LCS is positively cor-
related with anxiety and depression and negatively correlated 
with QOL. A final hierarchical multiple regression with revealed 
an overall model explaining 71.5% of the total variance of QOL 
(F5,143=71.61, p<.001). After controlling for significant covariates, 
anxiety, and depression, LCS provided a small but significant 
unique contribution to the explanation of variance in QOL (1.2%; 
p=.015). Furthermore, results substantiate previous findings of no 
difference in these relationships by smoking status. Both ever and 
never smokers’ experiences are similar with respect to anxiety, 
depression, LCS and QOL.
Conclusion: Because lung cancer is widely viewed as a smoker’s 
disease, patients who have never smoked often experience the 
same stigmatization as smokers, characterized by a feeling impar-
ted from others that one’s disease was self-inflicted. This inves-
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perspectives: Health-related stigma and the need for positive 
messaging about lung cancer and smoking cessation were prio-
rities. Geographical barriers to access and a lack of rural/regional 
services were described. Barriers for Aboriginal and Torres Strait 
Islander people included fear of dying away from community and 
poor cancer knowledge. Patient and carer perspectives: Qualita-
tive data were consistently indicative of stigma amongst patients 
due to perceived personal responsibility in the smoking-lung 
cancer relationship and perceived links between lung cancer and 
negative outcomes. Quantitative data revealed high levels of psy-
chological distress but low help seeking; health-related stigma was 
significantly related to poorer psychological and QOL outcomes.
Conclusion: Health-related stigma has negative impacts on peop-
le affected by lung cancer in Australia and may contribute to poo-
rer psychological health and QOL outcomes. The research helps 
to build the evidence about factors influencing lung outcomes in 
Australia. It provides an important foundation for further research 
and the development of strategies to ameliorate the effects of 
stigma on patients and carers.
Keywords: Cancer outcomes, Health promotion messages, Re-
search into stigma and nihilism, Impact of stigma and nihilism
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O25.06 ELECTROMAGNETIC NAVIGATION BRONCHO-
SCOPY DIRECTED PLEURAL TATTOO TO AID SURGICAL 
RESECTION OF PERIPHERAL PULMONARY LESION
Jun Hoe Tay1, Marco Larobina2, Prudence Russell3, Louis Irving1, 
Daniel Steinfort1
1Respiratory Medicine, Royal Melbourne Hospital/Australia, 2Cardi-
othoracic Surgery, Royal Melbourne Hospital/Australia, 3Pathology, St 
Vincent‘s Hospital/Australia
Background: Limited (wedge) resection of pulmonary lesions 
is frequently performed as a diagnostic/therapeutic procedure. 
Some lesions may be difficult to locate thoracoscopically and con-
version to open thoracotomy or incomplete resection are potential 
limitations to this approach. Multiple methods have been descri-
bed to aid Video-assisted thoracoscopic surgical (VATS) wedge 
resection of pulmonary nodules including hookwire localization, 
percutaneous tattoo or intra-operative ultrasound. We report on 
our experience using Electromagnetic Navigational (EMN) bron-
choscopic dye marking of small subpleural lesions to assist wedge 
resection.
Methods: Six patients planned for VATS resection of a peripheral 
pulmonary lesion underwent pre-operative bronchoscopy. Electro-
magnetic navigation was utilized to accurately guide a 25-gauge 
needle to within/adjacent to the lesion for resection and 1mL of 
methylene blue or indigo carmine was injected under fluoroscopic 
vision.
Results: Six patients underwent bronchoscopic marking of peri-
pheral pulmonary lesions. Navigation to lesions was successful in 
all six patients. Surgery was performed within 24 hours of broncho-
scopic marking. Pleural staining by dye was visible thoracoscopi-
cally in all six lesions either adjacent to or overlying the lesion. All 
lesions were fully excised with wedge resection. Pathologic exa-
mination confirmed accuracy of dye staining and established the 
diagnosis of malignancy.
report respiratory symptoms when they are smokers, a behavior 
clearly related to the feelings of shame and guilt. This reluctance is 
a consequence of general supposition that lung cancer is a self-in-
flicted disease. Because lung cancer is widely viewed as a smoker’s 
disease, those who have never smoked often experience the same 
stigmatization: a feeling that their disease was self-inflicted. Alt-
hough the prognostic outlook for lung cancer patients is changing, 
clinicians know that lung cancer has one of the poorer prognoses 
of all human malignancies and that might unintentionally limit com-
munication, treatment options, and symptom management. Future 
research is needed to elucidate the mechanisms that underlie lung 
cancer stigma; longitudinal investigations of LCS and patient out-
comes are needed to understand causal relationships; and deve-
lopment of effective interventions to decrease both perceived and 
projected stigma are essential.
Keywords: stigma, symptom burden, supportive care
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O25.05 STIGMA AND NIHILISM IN LUNG CANCER: THE 
PERSPECTIVE OF AUSTRALIAN HEALTH PROFESSIO-
NALS AND CONSUMERS
Sue Sinclair1, Suzanne Chambers2, Dianne O‘Connell3, Pip Youl4, 
Stefano Occhipinti2, Peter Baade4, Joanne Aitken4, Gail Garvey5, 
Patricia Valery5, Helen Zorbas1, Jeff Dunn4, Elizabeth King1
1Cancer Australia/Australia, 2Griffith University/Australia, 3Cancer 
Council New South Wales/Australia, 4Cancer Council Queensland/Aus-
tralia, 5Menzies School Of Health Research/Australia
Background: It has been proposed that stigma and nihilism sur-
rounding lung cancer may influence lung cancer outcomes. A clear 
understanding of the impact of lung cancer related stigma and 
nihilism from the perspectives of health professionals and consu-
mers will assist in informing best practice lung cancer care and 
health promotion messages in Australia. As part of a national lung 
cancer program, Cancer Australia commissioned Cancer Council 
Queensland, in partnership with Griffith University, to undertake 
a three-phase research project on stigma and nihilism about lung 
cancer in the Australian context.
Methods: Phase 1: A systematic literature review examined the 
evidence on the influence of stigma and nihilism on lung cancer 
patterns of care; patients‘ psychosocial and quality of life (QOL) 
outcomes; and how this may link to public health programs. Phase 
2: The perspectives of health professionals on the impact of stig-
ma and nihilism on diagnosis and disease management were inves-
tigated. Semi-structured interviews and a Delphi process with 31 
key informants developed a consensus view, which was then tested 
with 323 health professionals in a national online survey. Phase 3: 
The perspectives of lung cancer patients and carers on the effects 
of stigma and nihilism on their cancer experience were investiga-
ted. Qualitative interviews were undertaken with 17 patients and 
11 carers followed by a cross-sectional survey with 147 lung cancer 
patients in QLD and NSW.
Results: Systematic review: Stigma relating to lung cancer was re-
ported by both patients and health professionals and was related 
to poorer QOL and higher psychological distress in patients. Empi-
rical explorations of nihilism were not evident. Qualitative evidence 
from patients’ perspectives suggested that public health programs 
contribute to stigma about lung cancer. Health professionals’ 
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O26.01 THE IMPACT OF THE LUNG CANCER CLINICAL 
NURSE SPECIALIST ON ACCESS TO ANTI-CANCER 
TREATMENT
Angela M. Tod1, Ann Mcdonnell1, Judy Redman1, John White2, Dia-
na Borthwick3
1Centre For Health And Social Care Research, Sheffield Hallam Univer-
sity/United Kingdom, 2St James`s Institute Of Oncology, Leeds Teaching 
Hospitals NHS Trust/United Kingdom, 3Western General Hospital, 
Edinburgh Cancer Centre/United Kingdom
Background: The National Lung Cancer Audit (NLCA) (NHS In-
formation Centre, 2011) reports annually on services provided to 
38,000 lung cancer patients in the nited Kingdom (UK). The 2010 
NLCA reported that only 58% of lung cancer patients in England 
and Wales received active treatment (chemotherapy, surgery and 
radiotherapy), with only 14% of patients receiving surgery. Lung 
Cancer Nurse Specialists (LCNS) make an important contribution 
to patient care and patient experience and their input is captured 
in the audit. The 2010 NLCA revealed a possible association bet-
ween access to a LCNS and access to treatment: 64% of patients 
seen by a LCNS received anti-cancer treatment compared to 30% 
of those who did not (Ford, 2011, The Lancet 2011). The reason for 
this observation cannot be ascertained from the NCLA data. Thus 
investigation outside of the audit is required. This study begins 
that process using case study methodology. The study is funded 
by a grant from the General Nursing Council Trust. The aims of this 
study are to explore the role of the LCNS within the lung cancer 
multi-disciplinary team (MDT), identify ways the LCNS can increase 
treatment access for people with lung cancer and generaterecom-
mendations for MDTs and for future research.
Methods: A collective case study, comprising four individual LCNS 
in four different lung cancer MDTs (McDonnell, 2012, Stake 1995). 
LCNS cases were selected on the basis of variation in access to 
treatment rates and access to a LCNS according to the NLCA data. 
The four LCNSs also had different models of working within the 
MDT and patient pathway. Methods included in-depth individual 
interviews with the LCNS and clinical lead plus four other MDT 
members, giving a total interview sample of 24. Observation of 
practice and documentary analysis were also used. Findings will be 
tested further in group interviews over the summer. 
Results: These findings provide insight into how the LCNS works 
across the patient pathway to influence access to treatment, while 
maintaining patient preference as central to practice. The findings 
are presented here in four themes: practice approaches, people, 
places and facilitators, with illustrations of how factors combined 
to increase or decrease access to treatment. Approaches to LCNS 
practice identified in the study included negotiating, brokering and 
co-ordinating in order to maximise treatment access and maintain 
patient focus. The range of people and places the LCNS works with 
across different disciplines, services and health sectors means they 
become the lynchpin to clinical treatment decisions. The study 
indicates how workload, relationships, job security and organisa-
tional structures operate as key facilitators to effective treatment 
decision making 
Conclusion: EMN bronchoscopic dye marking of peripheral lesions 
is feasible, and is not compromised by complications associated 
with percutaneous marking procedures. Further experience is re-
quired but early findings suggest this method may have utility in 
aiding minimally invasive resection of small subpleural lesions.
Keywords: Peripheral Pulmonary Lesion, Video-assisted thoraco-
scopic surgery (VATS), pleural tattoo dye marking, Electromagnetic 
Navigational Bronchoscopy
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Recommendations from the report
1
LCNS should be involved in the pre-diagnostic phase of 
care of suspected patients with lung cancer
2
All national clinical guidelines on lung cancer treatment 
should reflect the important role played by LCNS
3
NHS Commissioners / providers should ensure that there 
are sufficient numbers of LCNS
4
All patients should have equitable access to a LCNS at the 
time of diagnosis
5
LCNS posts should be protected to ensure that patients 
and their families are offered adequate support
6
LCNS should be provided with necessary resources to aid 
smoking cessation
7
More research should be undertaken to understand the 
reasons for the correlation between LCNS input and re-
ceipt of active treatment
8
LCNS follow up after treatment should be offered to all 
patients
9 LCNS should be encouraged to offer nurse led clinics
10
LCNS should be recognised as the patient`s advocate at 
multidisciplinary team meetings to deliver patient cente-
red care
11
Patients with lung cancer should have access to a LCNS at 
all stages of their pathway including end-of-life care
Conclusion: The report examines the information made available 
and the role of the LCNS with the aim of helping to understand 
that vital contribution they make to the delivery of high quality 
care and to improved outcomes for patients with lung cancer. 
The report can be found at http://www.roycastle.org/Resources/
Roy%20Castle/Documents/PDF/UnderstandTheValueOfLungCan-
cerNurseSpecialists_V03.pdf
Keywords: Lung cancer, lung cancer nurse specialist, improved 
outcomes
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O26.03 IS EARLY INTEGRATION OF PALLIATIVE CARE 
FOR PATIENTS WITH INCURABLE LUNG CANCER AC-
CEPTABLE TO AUSTRALIAN HEALTHCARE PROFESSIO-
NALS?
Linda Mileshkin1, Brian Le2, Katie Doan2, Odette Spruyt1, Matthew 
Conron3, Dishan Gunawardana4, Shirley Carvosso5, Di Saward5, 
Jennifer Philip6
1Division Of Cancer Medicine, Peter MacCallum Cancer Centre/Austra-
lia, 2Department Of Palliative Care, Royal Melbourne Hospital/Austra-
lia, 3Department Of Respiratory Medicine, St. Vincent‘s Hospital/Aust-
ralia, 4Department Of Medical Oncology, The Royal Melbourne Hospital/
Australia, 5Western And Central Melbourne Inegrated Cancer Services/
Australia, 6Centre For Palliative Care, St Vincent‘s Hospital/Australia
Background: In a recent landmark US study, metastatic NSCLC pa-
tients who received palliative care from the time of diagnosis con-
currently with standard oncology management reported improve-
ments in quality-of-life, symptom control, reduction in “aggressive 
therapies” at end-of-life, and a survival advantage compared to 
Conclusion: This in-depth qualitative study provides valuable in-
sights into the complex landscape that MDTs operate within and 
helps to explain why the observed association between seeing 
a LCNS and access to treatment may occur. The study illustrates 
the value of qualitative research in understanding quantitative 
data such as that generated by national registries and audits. Re-
commendations for MDTs and data capture in the NLCA audit are 
considered. 
Keyword: lung cancer, treatment access, clinical nurse specialist, 
patient preference
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O26.02 UNDERSTANDING THE VALUE OF LUNG CAN-
CER NURSE SPECIALISTS
John White
On Behalf Of The Uk National Lung Cancer Forum For Nurses And The 
Roy Castle Lung Cancer Foundation/United Kingdom
Background: The UK National Lung Cancer Forum for Nurses 
together with the Roy Castle Lung Cancer Foundation have produ-
ced a report which aims to showcase the difference Lung Cancer 
Nurse Specialists (LCNS) make to the lives of patients with lung 
cancer and their families. Eleven recommendations were made 
after an examination of peoples experiences of care delivered 
by LCNSs in addition to LCNSs own accounts of how they help 
to improve patient outcomes. The recommendations, combined 
with existing evidence of the positive impact of LCNSs on patient 
experience from the Cancer Patient Experience Survey and outco-
mes shown in the National Lung Cancer Audit, builds a compelling 
picture of the positive value of LCNSs. The report is called Under-
standing the Value of Lung Cancer Nurse Specialists.
Methods: The National Lung Cancer Audit data was used to 
gather information about whether patients had been seen by a 
LCNS and at what point in their pathway. A survey was conducted 
of patients with lung cancer and their carers with the aim of un-
covering people`s experiences of the care delivered by LCNS. A 
survey of LCNS own accounts of how they help to improve patient 
outcomes was also undertaken. Information was taken from the 
Cancer Patient Experience Survey in England to assess the influ-
ence that Clinical Nurse Specialists had on the patient`s experience 
of care. Evidence was analysed from a number of different sources 
to highlight the potential efficiency savings that LCNS could make 
due to their role.
Results: from the Cancer Patient Experience Survey showed that 
one of the most important findings being that those patients with 
access to a CNS gave more positive scores of experience than tho-
se without. When considering efficiency savings, one study found 
that service improvments along the lung cancer pathway led by 
LCNS could release about 10% of cancer expenditure in the area. 
The National Lung Cancer Audit revealed that around two thirds of 
patients seen by a LCNS went on to receive active treatment com-
pared to less than a third who did not see a LCNS who were given 
active treatment.  
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1Department Of Radiation Oncology & Cancer Imaging, Peter MacCal-
lum Cancer Centre/Australia, 2Department Of Pain & Palliative Care, 
Peter MacCallum Cancer Centre/Australia, 3Department Of Radiothera-
py, Peter MacCallum Cancer Centre/Australia, 4Department Of Cancer 
Allied Health, Nursing & Support, Peter MacCallum Cancer Centre/
Australia, 5Western & Central Melbourne Integrated Cancer Service/
Australia
Background: Radiotherapy (RT) is a clinically and cost effective 
modality of treatment for symptom palliation. It plays a significant 
role in advanced lung cancer, by providing relief from symptoms 
such as haemoptysis and bone pain, as well as preserving neuro-
logical function in patients with brain metastases or spinal cord 
compression. The standard clinical approach for RT may require 
multiple attendances for consultation and planning, followed by 
a waiting period for treatment. However, patients with advanced 
lung cancer presenting for palliative radiotherapy are often of poor 
performance status with limited life expectancy. Prompt and stre-
amlined RT is required to improve the experience of care for these 
patients. The Palliative Radiotherapy Rapid Assessment Clinic 
(PRRAC) was developed as an innovative and sustainable clinic to 
align consultation, planning and treatment within a single visit to 
facilitate efficient access to palliative radiotherapy for patients with 
advanced lung cancer. The PRRAC aims to i) increase accessibility 
of palliative RT for symptomatic patients with lung cancer, ii) redu-
ce waiting times and iii) improve patient and referrer satisfaction.
Methods: A retrospective audit of symptomatic patients with lung 
cancer who received low dose palliative RT from June – November 
2012 at Peter Mac, East Melbourne was performed. Patient demo-
graphics, dates of initial clinic, planning and RT commencement, 
and RT dose fractionation schedules were collected. A service 
model (PRRAC) was developed based on the adaptation of similar 
clinics in operation in Canada and Brisbane, Australia. The propo-
sed PRRAC will be piloted for 6 months. Eligibility criteria include 
those patients with symptomatic locally advanced or metastatic 
lung cancer who require low dose simple RT techniques. Service 
utilisation and average waiting times will be compared to previous 
patterns of care. Patient outcomes and surveys of referring phy-
sicians will be evaluated prospectively. Overall utilisation of the 
service will help assess clinical need & sustainability.
Results: The retrospective audit has demonstrated 79 patients 
with lung cancer who were prescribed low dose palliative RT. The 
mean age was 70 years and 17% of patients were ECOG status >3. 
The mean waiting time from initial clinic assessment to planning 
was 3.6 days (SD 3.7), and from planning to RT commencement 
was 5.4 days (SD 5.1). 48% of patients were prescribed a single 
dose of RT. The early results and challenges in developing the 
prospective PRRAC as a new model of care for patients with lung 
cancer will be presented.
Conclusion: The PRRAC is expected to improve access of patients 
to palliative radiotherapy, and shorten waiting time from clinic to 
RT commencement date with less visits and potentially shorter 
dose fractionation schedules. It is anticipated that PRRAC will also 
improve patient and referrer satisfaction. Following successful 
completion of the project, the PRRAC will be embedded into clini-
cal practice, and extended to other tumour streams.
Keywords: waiting lists & access, Patient reported outcomes, new 
model of care, palliative radiotherapy
those receiving standard oncology management alone. The aim 
of this qualitative sub-study was to explore Australian health care 
professionals’ perceptions of early integration of palliative care for 
patients with incurable lung cancer.
Methods: Members of the lung cancer multi-disciplinary teams 
of three large metropolitan teaching hospitals in Melbourne were 
invited to attend a focus group discussion. Data from focus groups 
were supplemented with interviews from a purposive sample of 
individual health care providers who were unable to attend the 
groups. Participants were asked to describe barriers and facilita-
tors to implementation of a model of early integration of palliative 
care.
Results: Three focus groups and six individual interviews were 
conducted with 28 health care professionals. Key facilitators and 
barriers to referral (see table) were grouped into 4 themes: 1. Trust; 
2. Care Coordination; 3. Ease of Referral; and 4. Perceived patient/
family reaction.  
Key themes Issues discussed as facilitators /  or barriers
Trust
1. Confidence in the quality of the palliative 
care service 2. Palliative care poses a threat 
to the referrer 3. Past experience with com-
munity palliative care 
Care Coordina-
tion
1. Integration of concurrent palliative care 
and “active treatment” 2. Concern about 
adding to fragmented care and lack of co-
ordination 3. Effective Communication bet-
ween care providers 
Ease of Referral
1. The value of a physical presence of the 
palliative care provider in the clinic 2. Per-
ception of limited resources 
Perceived patient/
family reaction
1. Cultural perceptions about what referral 
to palliative care means 2. Concern about 
patient and/or family reaction to referral 
leading to distress and loss of hope 
 
Conclusion: Early involvement of palliative care in patients with 
incurable lung cancer is acceptable to the majority of treating clini-
cians. Palliative care services must be embedded into the system, 
sufficiently resourced and of high quality. For early referral to occur 
the model ideally involves a physical presence of a palliative care 
clinician in clinic who is easily accessible for referrals and conside-
red a core team member.
Keyword: palliative care, incurable, lung cancer, integration
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O26.05 PATTERNS OF CARE IN PALLIATIVE RADIOTHE-
RAPY DELIVERY IN ADVANCED LUNG CANCER:  HOW 
HAS THIS INFLUENCED THE DEVELOPMENT OF A PAL-
LIATIVE RADIOTHERAPY RAPID ASSESSMENT CLINIC 
(PRRAC)?
Kathy Pope1, Chen Liu1, Natasha Michael2, Claire Fitzpatrick3, 
Adam Rutyna4, Wendy Poon4, Jennifer Vassie3, Jung Hock Foo5
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tric interventions in an attempt to decrease chemotherapy related 
toxicity and improve quality of care. Further evaluation of GA and 
geriatric interventions in larger pt groups as well as their imple-
mentation in clinical practice is warranted.
Keyword: geriatric assessment, treatment decision, lung cancer
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O26.07 TOWARDS CANCER REHABILITATION AT HOME 
DESIGN OF A TELEREHABILITATION SERVICE FOR LUNG 
CANCER PATIENTS
Josien G. Timmerman1, Thijs M. Tönis2, Michel W.J.M. Wouters3, 
Marit G.H. Dekker-Van Weering1, Hermie J. Hermens2, Miriam M.R. 
Vollenbroek-Hutten1
1Telemedicine Research Group, Roessingh Research And Development/
Netherlands, 2Faculty Of Electrical Engineering, Biomedical Signals And 
Systems, Telemedicine Group, University Twente/Netherlands, 3Nether-
lands Cancer Institute - Antoni Van Leeuwenhoek/Netherlands
Background: Although lung resection still provides the best long-
term outcome for lung cancer, it is also associated with a consi-
derable decay in physical and psychosocial health status1,2. If not 
controlled, these symptoms can hamper postsurgical recovery, 
and lead to unscheduled healthcare use3. This study aimed to de-
termine the clinical relevance of and functional requirements for a 
telerehabilitation (TR) service to support recovery following lung 
resection.
Methods: A sociotechnical scenario-based design approach was 
used, characterized by early and systematically involvement of pa-
tients and healthcare providers during an iterative design process 
(figure 1). First, end users’ requirements for the TR service were 
explored by means of semi-structured interviews. Subsequently a 
small focus group with healthcare providers from the Netherlands 
Cancer Institute – Antoni van Leeuwenhoek hospital (NKI-AVL) in 
Amsterdam was organised to establish requirements for the TR 
service in more detail. The findings from the interviews and focus 
group were summarized in a scenario and validated by healthcare 
professionals from the NKI-AVL. 
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O26.06 IMPACT OF GERIATRIC ASSESSMENT ON TREAT-
MENT DECISIONS IN OLDER LUNG CANCER PATIENTS.
Leen Vanacker1, Cindy Kenis2, Katrien Van Puyvelde3, Johan 
Flamaing4, Dennis Schallier1, Johan Vansteenkiste5, Godelieve 
Conings6, Kristiaan Nackaerts7, Jean Pierre Lobelle8, Koen Milisen9, 
Jacques De Grève1, Hans Wildiers10, Lore Decoster1
1Medical Oncology, Oncologisch Centrum, Uz Brussel/Belgium, 2General 
Medical Oncology And Geriatric Medicine, University Hospitals Leuven/
Belgium, 3Geriatric Medicine, Uz Brussel/Belgium, 4Geriatric Medicine, 
University Hospitals Leuven/Belgium, 5Pneumology, Respiratory Onco-
logy Unit, University Hospitals Leuven/Belgium, 6University Hospital 
Brussels/Belgium, 7Pneumology, University Hospitals Leuven/Belgium, 
8//Belgium, 9Centre For Health Services And Nursing Research KU Leu-
ven/Belgium, 10Medical Oncology, University Hospitals Leuven/Belgium
Background: This study aims to investigate the influence of a ger-
iatric assessment (GA) on cancer treatment decisions in older lung 
cancer patients (pts). We also studied the changes in functionality 
during treatment and the occurrence of severe chemotherapy-
related toxicity.
Methods: For this analysis, we selected the lung cancer cohort 
that was part of a larger study on GA in older cancer pts in 6 tumor 
types in two Belgian university hospitals1. Between July 2009 and 
September 2011, pts aged 70 years or older with a newly diag-
nosed or progressive lung cancer were evaluated at baseline using 
a uniform GA including geriatric screening with G8 and the Flemish 
Triage Risk Screening Tool (fTRST), pain, social data, Activities of 
Daily Living (ADL), Instrumental Activities of Daily Living (IADL), fall 
history, Mobility-Tiredness Test (MOB-T), Mini Mental State Exa-
mination (MMSE), Geriatric Depression Scale (GDS-15), Mini Nutri-
tional Assessment (MNA), ECOG-Performance Status (ECOG-PS), 
Charlson Comorbidity Index (CCI) and poly-pharmacy assessment. 
GA results were communicated to the treating physician and, after 
the treatment decision, the physician was interviewed using a pre-
defined questionnaire focusing on unknown geriatric problems re-
vealed by GA and impact on cancer treatment decisions. Between 
two and three months of follow-up, functionality was reassessed 
and severe toxicity in pts receiving chemotherapy was recorded.
Results: Seventy three lung cancer pts were included with a 
median age of 76 years; 82.2% were non-small cell lung cancer 
(NSCLC) and 74% were stage IV. Treatment was modified from 
standard according to standard clinical assessment (including age) 
in 56.1%. GA revealed unknown geriatric problems in 25.8% of 
cases, leading to a geriatric intervention in 10.6%. 30% of physici-
ans consulted the GA before final treatment decision and in three 
pts (4%) only this led to a modification of the proposed treatment: 
dose reduction, no chemotherapy or no radiotherapy. At follow up 
(n=50), functional decline was observed in 24% and 54% of pts for 
ADL and IADL, respectively. Grade III-IV toxicity occurred in 14/42 
pts treated with chemotherapy (33%), mainly non-haematological 
(64%).
Conclusion: This analysis indicates that the treatment of older lung 
cancer pts is often influenced (deviated from standard) by standard 
clinical assessment and age. Although GA revealed previously 
unknown information in 25.8% of pts, only a minority of physicians 
consulted these results before the final cancer treatment decision. 
There was little impact on geriatric intervention and even less on 
cancer treatment decision. This discrepancy reveals the need to 
get physicians treating lung cancer acquainted with GA and geria-
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O27.01 THROMBOEMBOLISM IN LUNG CANCER - AN 
AREA OF URGENT UNMET NEED
Marliese Alexander1, Suzanne W. Kirsa1, Rory Wolfe2, Michael 
Macmanus1, David Ball1, Ben Solomon1, Kate Burbury1
1Peter MacCallum Cancer Centre/Australia, 2Department Of Epidemio-
logy And Preventive Medicine, Monash University/Australia
Background: Current management of lung cancer (LC) (chemo-
therapy - CHT, radiotherapy – RT, and biological therapies) occurs 
predominantly in the ambulatory care (AC) setting. Post-surgery 
hospital admission is becoming progressively shorter due to ad-
vances in technique and greater reliance on home recovery.1,2As 
such, LC management occurs outside the scope of current throm-
boprophylaxis (TP) guidelines.2-8 Recommendations for TP strate-
gies in these high thromboembolism (TE) risk patients are lacking.9 
The aim of this study was to profile TE incidence in LC patients 
receiving anti-cancer therapy, exploring patient-, disease- and 
treatment-related risk factors associated with higher thrombotic 
rates. This could identify high-risk populations, disease features 
and/or treatment periods that warrant strong recommendations for 
targeted preventative strategies to reduce LC-associated TE, and 
in particular consideration of pharmacological-TP (P-TP).
Methods: Retrospective review of LC patients referred to Peter 
MacCallum Cancer Centre, a tertiary dedicated cancer centre, bet-
ween 01/07/11 - 30/06/12 for anti-cancer therapy. Data were coll-
ected from medical, pharmacy, pathology and diagnostic imaging 
electronic records. Follow up was defined as time from study entry 
(referral date) to first occurring event; TE, death, loss to follow-up 
or study end. Hazard ratios were calculated using Cox proportional 
hazards model.
Results: 222 patients were followed for a median 10 months from 
time of first hospital registration. The cohort was predominantly 
newly diagnosed (77%), with advanced disease (71%), NSCLC 
(92%). Among NSCLC adenocarcinoma was the predominant his-
tological subtype (77%). 30% of patients received multiple lines 
of therapy within the study period; 49% received CHT (alone or 
combination chemoradiotherapy, CRT), 73% RT (alone or CRT), 
19% biologic therapy and 19% surgical intervention. 10.8% of pa-
tients had radiologically confirmed TE, giving an incidence rate of 
131 events per 1000 person-years (95%CI 87-195). 83% (20/24) of 
events occurred in the AC setting; 71% symptomatic, 29% asym-
ptomatic. 16 events were pulmonary embolism (PE) (5 fatal), 4 
deep vein thrombosis (DVT), 1 combination DVT/PE, 1 atrial and 
2 arterial thrombosis. TE occurred frequently in both NSCLC and 
SCLC (10.8% and 10.5% respectively), and more frequently among 
patients with adenocarcinoma compared to squamous cell histo-
logy (14.7% and 5.3% respectively). Presence of more advanced 
or metastatic disease, prior history of TE and comorbidity score>2 
were associated with higher rates of TE. More than a third (38%) of 
TE events occurred during the CHT period, 13% post-surgery, 8% 
during RT and biologic therapy respectively. CHT demonstrated 
more than five-fold increased TE risk compared to no CHT (HR 5.7 
95% CI 2.2-14.8) with a similar finding for RT (HR 5.2 95%CI 2.0-
13.2). Importantly, P-TP was not routinely or systematically prescri-
Results: Survivors and professionals expected a TR service to 
be beneficial for improving quality of current care, and identified 
three modules that should be included in the TR service: ambulant 
monitoring of recovery and symptoms, home exercise programs 
and patient-provider contact. The functional requirements for 
these three modules and general requirements as reported by the 
patients and professionals are presented in table 1. The results 
also indicated that successful implementation of the service will be 
promoted by structurally embedding the service in existing health-
care processes, and record clearly the specific roles and responsi-
bilities of all involved healthcare professionals. 
Conclusion: End-users showed positive intention to use a TR ser-
vice for home-based symptom monitoring and rehabilitation. At 
this moment, a prototype of the TR service is designed, which will 
be evaluated this summer in patients and healthcare providers to 
improve end-users’ acceptance.
Keywords: lung resection, ambulant monitoring, telerehabilitation, 
web-based exercise
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men; the median age was 65 years; 82% had NSCLC (5% Stages I 
and II, 38% Stage III, 57% Stage IV) and 18% SCLC (63% Extensive 
Disease); 85% had WHO PS 0 or 1; 95% received chemotherapy 
as first treatment. 56% of those in the dalteparin arm received at 
least 90 of the 168 planned injections. By 1/8/2013 there had been 
1891 deaths recorded and, on advice from the Independent Data 
Monitoring Committee, the primary results have been released. 
There was no significant difference in overall survival (HR 0.97; 95% 
CI 0.89-1.06) nor in metastasis-free survival. Exploratory subgroup 
analyses do not suggest a significant survival advantage in any 
subgroup. Dalteparin use was not associated with a significant 
increase in major bleeding complications. There were 78 (7.1%) 
confirmed VTEs in the control group and 47 (4.1%) in the treatment 
group.
Conclusion: This large RCT which recruited mainly good PS lung 
cancer patients having chemotherapy, has confirmed that prophy-
lactic dalteparin reduces the risk of VTE events without a signifi-
cant increase in major bleeding. The baseline VTE risk of 7% and 
relative risk reduction of 40% are consistent with previous studies. 
There was no significant difference in overall survival. These results 
do not support a policy of routine prophylactic anticoagulation of 
all lung cancer patients undergoing chemotherapy.
Keywords: thromboprophylaxis, dalteparin, survival, lung cancer,
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O27.03 META-ANALYSIS OF PROGRESSION-FREE SURVI-
VAL AND OBJECTIVE RESPONSE RATE AS PREDICTORS 
OF OVERALL SURVIVAL IN LOCALLY ADVANCED OR 
METASTATIC NON-SMALL-CELL LUNG CANCER
Evadne J. Turner1, Philip Mccloud2, Peter Germanos1, Francis Deh-
le3, Sarah Norris3, Jonathon Tan3, Paul L. Mitchell4
1Mapor, Boehringer Ingelheim (Australia) Pty Ltd/Australia, 2Mccloud 
Consulting Group/Australia, 3Optum/Australia, 4Ludwig Medical On-
cology Unit, Olivia Newton-john Cancer And Wellness Centre, Austin 
Health/Australia
Background: Improving overall survival (OS) in locally advanced 
or metastatic non-small-cell lung cancer (NSCLC) remains a goal 
for clinicians. OS is often the primary endpoint in Phase III clinical 
trials, however with the increased use of multiple lines of treatment 
and crossover/rescue therapy in NSCLC trials, overall survival dif-
ferences are frequently confounded. Other clinically meaningful 
endpoints such as progression-free survival (PFS) are becoming 
increasingly important. A systematic review and meta-analysis was 
undertaken to investigate whether the treatment effect on PFS, 
or objective response rate (ORR), was predictive of the treatment 
effect on OS in locally advanced or metastatic NSCLC.
Methods: Embase, MEDLINE and the Cochrane Library data-
bases were searched to identify relevant published randomised 
controlled trials (RCTs). Included RCTs compared pharmacological 
treatments in two or more groups in patients with locally advanced 
or metastatic (Stage IIIb or IV) NSCLC. The reported outcomes had 
to include median PFS and median OS. Data were analyzed with 
locally weighted least squares regression (LOWESS) to validate 
the linear relationship. Unweighted linear regression and weighted 
linear regression were used to estimate the relationship between 
OS treatment difference and PFS treatment difference. A similar 
analysis was also done to compare ORR difference and OS dif-
bed for ambulant LC patients during any treatment phase, at this 
institution.
Conclusion: LC patients are at high risk of preventable and poten-
tially life-threatening thrombotic events. TE events occur frequent-
ly in the AC setting and consideration of P-TP is warranted, but not 
used routinely due to a lack of high quality data. There is a de-
mand for appropriate risk-stratification and directed preventative 
strategies. Prospective data and the development of dynamic risk 
profiles which can direct clinical practice are needed.
Keywords: thromboprophylaxis, anticancer treatments, thrombo-
embolism
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O27.02 PRELIMINARY RESULTS FROM THE FRAGMATIC 
TRIAL: A RANDOMISED PHASE III CLINICAL TRIAL IN-
VESTIGATING THE EFFECT OF FRAGMIN® ADDED TO 
STANDARD THERAPY IN PATIENTS WITH LUNG CAN-
CER.
Fergus Macbeth1, Simon Noble2, Gareth Griffiths1, Ruhena Chowd-
hury1, Catherine Rolfe1, Kerenza Hood3, Seamus Linnane4, Barbara 
Moore5, David Cohen6, Robert Cowles1, Mirella Longo6, Dana Kno-
yle7
1Cardiff University, School Of Medicine, Wales Cancer Trials Unit/
United Kingdom, 2Marie Curie Palliative Care Research Group, Cardiff 
University/United Kingdom, 3South East West Trials Unit, Cardiff Uni-
versity/United Kingdom, 4Blackrock Clinic/Ireland, 5Nischr Crc/United 
Kingdom, 6Health Economics And Policy Research Unit, University 
Of South Wales/United Kingdom, 7Prince Charles Hospital, Cwm Taf 
Health Board/United Kingdom
Background: Venous thromboembolism (VTE) is common in lung 
cancer patients and the incidence is increased by treatments inclu-
ding radiotherapy, surgery and chemotherapy. Research suggests 
a survival benefit in cancer patients receiving long term low moe-
cular weight heparin (LMWH). LMWH may also have antimetastatic 
effects through the inhibition of P-selectin. This trial was develo-
ped to investigate whether or not adding LMWH to standard treat-
ment increases overall survival. The study is funded by a research 
grant from Cancer Research UK (C13275/A5323) and free drug and 
an educational grant from Pfizer. The trial is sponsored by Velindre 
NHS Trust, and coordinated by the Wales Cancer Trials Unit, Car-
diff, UK.
Methods: An open label, multi-centre, Phase III randomised 
controlled trial in patients with lung cancer comparing anticancer 
treatment according to local practice plus dalteparin (Fragmin®), 
with anticancer treatment alone. Eligible patients had a histopa-
thological or cytological diagnosis of primary bronchial carcinoma 
(SCLC or NSCLC) within the previous 7 weeks, performance status 
0, 1, 2 or 3 and were willing and able to inject daily subcutaneous 
injection. The dalteparin was given as a daily 5,000 IU subcutane-
ous injection for 24 weeks. The primary outcome measure is overall 
survival and the secondary outcome measures include toxicity, 
VTE-free survival, metastasis-free survival, quality of life, and cost 
utility. To detect an advantage of 5% in overall survival at 1 year (to 
30%) a total of 2200 patients were required (1100 in each arm).
Results: 2202 patients were enrolled and randomised in 4 years. 
The two groups were well balanced for key variables. 60% were 
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Medical University/Japan, 12Radiation Oncology, University Hospital 
Maastricht/Netherlands, 13Radiation Oncology, The Netherlands Cancer 
Institute/Netherlands, 14Pulmonary And Thoracic Oncology, Chru De 
Lille/France, 15Nuclear Medicine, Chru De Lille/France, 16Nuclear Medici-
ne, Institut Jules Bordet/Belgium, 17Thoracic Surgery, Hospital Universi-
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Background: 18F-fluoro-2-deoxy-D-glucose positron emission 
tomography complements conventional imaging for staging lung 
cancer although its ability to predict outcome is less well estab-
lished. Two literature-based meta-analyses suggest a prognostic 
value in univariate analysis. To assess FDG-PET value in predicting 
survival adjusted for some known prognostic factors, we carried 
out a meta-analysis based on individual patients data from multip-
le independent studies.
Methods: Following literature search, and after writing of a pro-
tocol for the meta-analysis, we contacted the authors of identified 
studies and requested individual patients data; we also tried to 
collect some unpublished data. Data analysis used Cox regression 
models stratified for the study with overall survival as primary out-
come. SUV max was used as a binary covariate (median value for 
each study).
Results: Data were collected for 1526 patients (57% of the iden-
tified patients) from 11 publications and 1 unpublished series 
(median age : 64 years, 60% male patients, squamous cell in 34%, 
adenocarcinoma in 47%, stages I-II in 58%). Combined univariate 
hazard ratio (HR) was 1.43 (95% CI : 1.22-1.66); no statistically signi-
ficant interaction between SUV and one of six additional freatures 
(age, gender, histology,stage, tumors size –in stages I-III patients- 
and surgical treatment), was found except for stage (p=0.05) with 
a decreased prognostic value of SUV for stage IV patients. Without 
considering SUV, multivariate analysis identified, in stage I-III pati-
ents, age, stage, tumor size and surgical treatment as independent 
prognostic factors. The addition of SUV improved that model : HR 
estimate for SUV effect was 1.58, statistically significant (95% CI 
: 1.27-1.96), p<0.0001. No interaction was found with SUV. When 
tumor size was not included in the tested covariates, we found SUV 
of additional value (adjustment for age, stage, surgical treatment) 
with a HR of 1.35 (95% CI : 1.15-158). Interaction between SUV and 
stage was detected, restricting the significant impact of SUV on 
survival to stage I-III patients.
Conclusion: s : Although suffering from selection bias and lack of 
homogeneous SUV assessment, these data suggest that SUV at 
the time of diagnosis is an independent prognostic marker for pati-
ents with stage I-III NSCLC. The utility of SUV in predicting survival 
in stage IV patients requires further studies.
Keywords: prognostic factor, non-small cell lung cancer, IPD meta-
analysis, FDG-PET
ference. The analysis also considered whether potential baseline 
prognostic factors could also change OS difference. Univariate 
weighted linear regression was used to assess the relationship of 
each prognostic factor with OS difference, followed by multivariate 
weighted linear regression.
Results: A total of 124 RCTs (N=40,568 patients) were included 
in the analysis. Of the 124 trials, 98 (79%) were published since 
2005. The age of patients ranged from middle aged cohorts to 
the elderly. There were 87 studies (70%) with first-line therapy and 
therapy type was predominantly chemotherapy (71 studies, 57%). 
The LOWESS of OS difference versus PFS difference was a rela-
tively straight line, therefore a linear relationship appeared to be 
justified. Weighted linear regression showed a highly significant 
relationship between OS treatment difference and PFS treatment 
difference [slope 1.317 months (95%CI 1.000, 1.634) p<0.001 R2 
= 36.6%]. Diagnostic plots revealed several statistical outliers. A 
weighted linear regression of OS difference versus PFS difference 
with six outlier studies removed also showed a highly significant li-
near relationship [slope 0.994 months (95%CI 0.749, 1.240) p<0.001 
R2 = 36.7%]. The relationship between ORR difference and OS 
difference was also significant [slope 12.503 (95%CI 7.042, 17.963) 
p<0.001 R2 = 16.0%]. Univariate weighted linear regressions show-
ed that the only baseline prognostic factor with a significant linear 
relationship with OS difference was the proportion of patients with 
non-squamous histology. Multivariate weighted linear regression 
showed none of the baseline prognostic factors was significant 
when PFS difference or ORR difference was included in the model.
Conclusion: The treatment effect on PFS was predictive of the 
treatment effect on OS. For a 1 month increase in PFS treatment 
difference, OS treatment difference increases by approximately 
1.3 months. A 10% increase in ORR treatment difference was also 
associated with an increase in OS of 1.25 months. PFS is an impor-
tant outcome for healthcare decision-making.
Keywords: Overall Survival, progression-free survival, objective 
response rate, Meta-analysis
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O27.05 IS PRIMARY TUMOR STANDARDIZED UPTAKE 
VALUE (SUV) AN INDEPENDENT PROGNOSTIC FACTOR 
FOR NON-SMALL CELL LUNG CANCER (NSCLC)? A ME-
TA-ANALYSIS BASED ON INDIVIDUAL PATIENTS DATA.
Marianne Paesmans1, C Oliver Wong2, Edward Patz3, Ritsuko 
Komaki4, Susanne Eschmann5, Ramaswamy Govindan6, Johan 
Vansteenkiste7, Anne-Pascale Meert8, Wouter K. De Jong9, 
Nasser K. Altorki10, Kotaro Higashi11, Angela Van Baardwijk12, 
Gerben Borst13, Lieveke Ameye1, Jean-Jacques Lafitte14, Thierry 
Berghmans8, Claude Hossein-Foucher15, Arnaud Scherpereel14, 
Camilo Garcia16, Patrick Flamen16, Ramon Rami-Porta17, Jean-Paul 
Sculier8
1Data Centre, Institut Jules Bordet/Belgium, 2Nuclear Medicine, Oakland 
University William Beaumont School Of Medicine Hospital/United Sta-
tes Of America, 3Radiology, Duke University Medical Center/United Sta-
tes Of America, 4MD Anderson Cancer Center/United States Of Ameri-
ca, 5Nuclear Medicine, University Of Tubingen/Germany, 6Division Of 
Medical Oncology, Washington University School Of Medicine/United 
States Of America, 7Pneumology, Respiratory Oncology Unit, Universi-
ty Hospitals Leuven/Belgium, 8Intensive Care And Thoracic Oncology, 
Institut Jules Bordet/Belgium, 9Pneumology, University Medical Center 
S245Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
radically treated lung cancer and mesothelioma patients. Suppor-
ted by research grant 070708 of the Belgian Government Agency 
of Innovation by Science and Technology for applied Biomedical 
Research (NCT: 00752700)
Keywords: chemoradiotherapy, rehabilitation, 6 minutes walking 
distance, surgery
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O27.07 MOLECULAR MULTIDISCIPLINARY TUMOR 
BOARD (MMTB) FOR LUNG CANCER PATIENTS: 2-YEAR 
EXPERIENCE REPORT
Benjamin Besse1, Ludovic Lacroix2, Laura Faivre3, Virginie Kahn-
Charpy1, Maud Ngo Camus1, Nathalie Auger2, Valérie Koubi-Pick2, 
Julien Adam2, Vincent Thomas De Montpreville4, Peter Dorfmul-
ler4, Cecile Le Pechoux5, Marianna Macerelli1, Thierry Le Cheva-
lier1, Jean-Charles Soria1, Benjamin Lacas3, Jean-Pierre Pignon3, 
Arslane Rahal1, Valentina Polo1, David Planchard1
1Cancer Medicine, Gustave Roussy/France, 2Molecular Pathology, Gu-
tave Roussy/France, 3Biostatistics, Gustave Roussy/France, 4Centre 
Chirurgical Marie Lannelongue/France, 5Radiotherapy Dept, Institut 
Gustave Roussy/France
Background: Molecular analysis (MoA) of non-small cell lung can-
cer has led to definition of many subgroups that require dedicated 
treatments, strategy and trials. We created a monthly MMTB dedi-
cated to lung cancer patients (pts) with potential driving molecular 
abnormalitie(s). MMTB includes physicians from the lung tumor 
board and the phase I unit, pathologists and biologists. A medical 
report summarizes the findings and treatment recommendations. 
We report 2 years of activity of MMTB.
Methods: All consecutive files discussed in MMTB in Gustave 
Roussy were reviewed. Tumor and pts characteristics were coll-
ected as well as treatment. Pts outcome was calculated from the 
MMTB.
Results: 245 pt files were discussed between February 2010 and 
March 2012. 53% were male, 27% never-smokers, 89% had PS 0 or 
1, median age was 59. Clinical initial stage was III-IV in 17 pts (7%) 
and 78%/11%/11% were adenocarcinoma/squamous cell carcino-
mas/others NSCLC. Time from diagnosis to MMTB was 7 months 
(m) (1-222), 102 (42%) of pts received more than 1 line of treatment 
before MMTB. Biopsy for MoA mostly came from CT guided biop-
sies (61%), surgery (22%) or endoscopy (15%). Biopsy was repeated 
in 20% of pts to get enough material for MoA. The MoA results 
were ALK rearrangement in 10%, exon 18/19/21 EGFR mutation 
(mut) in 2/14/8%, KRAS mut in 30%, PI3KCA mut in 0.4%, BRAF 
mut in 3%, HER2 mut in 1%, FGFR1 amplification in 3%, other rare 
mutations in 14%. MMTB recommendations were: a clinical trial 
in 75 pts (31%), receive an EMA-approved drug in 49 pts (20%), 
an off-label commercial drug in 18 pts (7%), an expanded access 
program in 18 pts (7%), none in 85 pts (35%). Out of the 160 MMTB 
pts with treatment recommendations, 63 (42%) received the pro-
posed targeted therapy and 16 (11%) might receive it at the time of 
disease progression. After MMTB, 84 pts (34%) received 1 line, 66 
pts (27%) 2 lines or more, 56 pts (23%) no treatment (unknown in 39 
pts). Median follow-up is 20.6 m. Progression-free (in 224 pts) and 
overall survivals (OS, in 221 pts) from MMTB are 3.5 and 13.4 m. In 
univariate analysis for OS, the pts who received the recommended 
treatment from the MMTB had a better prognosis (hazard ratio 
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O27.06 RESISTANCE TRAINING IN PATIENTS WITH RA-
DICALLY TREATED RESPIRATORY CANCER: MATURE 
RESULTS OF A MULTI-CENTRE RANDOMISED PHASE 3 
TRIAL (REINFORCE)
Jan P. Van Meerbeeck1, Bihyiga Salhi2, Christel Haenebalcke3, Syl-
via Perez-Bogerd4, May D. Nguyen5, Thomas L.A. Malfait2, Karim 
Y. Vermaelen2, Veerle F. Surmont2, Georges Van Maele6, Roos Col-
man6, Eric Derom2
1Thoracic Oncology / Moca, Antwerp University Hospital/Belgium, 
2Respiratory Medicine, Ghent University Hospital/Belgium, 3Respiratory 
Medicine, Az St Jan/Belgium, 4Respiratory Medicine, Chu Sart Tilman,/
Belgium, 5Respiratory Medicine, Chu St Pierre/Belgium, 6Biostatistical 
Unit, Faculty Of Medicine, Ghent University/Belgium
Background: There is a lack of data on the effect of conventional 
resistance training (CRT) on exercise capacity, muscle strenght 
and quality of life (QoL) in patients with lung cancer. Whole body 
vibration (WBV) is proposed as an alternative to CRT. We investi-
gated the effect of a radical treatment and of two post-treatment 
resistance training programmes on the 6-minutes walking distance 
(6MWD).
Methods: Selected patients with clinical stage I-IIIB (non-) small 
cell lung cancer or I-II mesothelioma were evaluated before (M1) 
and at completion (M2) of their radical treatment, and thereafter 
randomised to either control (CON), CRT or WBV. 6MWD was mea-
sured at M1, M2 and at least 12 weeks (w) after randomisation (M3) 
considering a minimal clinically important difference (MCID) of 54 
m. Assuming that this MCID would occur in 10% of the CON-group 
and aiming for an increase to at least 50% in the combined inter-
vention groups (CRT and WBV), a sample size of 25 participants in 
each arm was required for a power of 90%. Secondary endpoints 
were estimated by appropriate MCID‘s for maximal exercise ca-
pacity (Wmax), muscle strenght (Quadriceps Force (QF)) and QoL 
(physical functioning (PF), fatigue (F), pain (P) and dyspnea D)). 
Multiple imputation was used to correct for patients not finishing 
the intervention.
Results: Of the 86 patients completing radical treatment, 70 were 
randomised: 24 to CON, 24 to CRT and 22 to WBV. Characteristics 
at M1 were well balanced. Radical treatment significantly decrea-
sed 6MWD, Wmax, QF, PF and increased P, F and D at M2. At M3, 
20 of 37 (54%) patients in the combined CRT-WBV-group reached 
the MCID for 6MWD vs. 5 of 21 CON (24%) patients (p=0·031). 
6MWD increased with 95 m (58–132) in CRT (p<0·0001), 37 m 
(-1–76) in WBV (p=0·06) and 1 m (-33–36) in CON (CRT vs. CON 
p=0·0006 and WBV vs. CON p=0·16). CRT and WBV patients 
recovered and exceeded their M16MWD, albeit not significantly. 
A significant mean increase in Wmax occurred in both CRT and 
WBV but not in CON, while QF increased only significantly in CRT. 
The mean score for PF at M3 improved in CON and WBV but only 
significantly with WBV. The mean score for P and F at M3 did not 
change significantly, however the MCID for F was reached in 37% 
of CRT, 44% of WBV and 30% of CON-patients. The mean score for 
D at M3 decreased significantly after WBV only. Multivariate analy-
sis showed that there was no significant interaction between reha-
bilitation and surgery with regard to the MCID in 6MWD (p=0.96).
Conclusion: Radical treatment significantly impairs exercise ca-
pacity, muscle strength and QoL. CRT significantly improves and 
restores functional exercise capacity, whilst WBV does not fully 
substitute for CRT. Resistance training by CRT should be offered to 
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O28.01 EBUS-CENTERED VS. EUS-CENTERED MEDIAS-
TINAL STAGING IN LUNG CANCER: A RANDOMIZED 
CONTROLLED TRIAL.
Hyo Jae Kang1, Geon Kook Lee2, Byung-Ho Nam3, Moon Soo Kim1, 
Jong Mog Lee1, Hee Seok Lee1, Ji-Youn Han1, Bin Hwangbo1
1Center For Lung Cancer, National Cancer Center/Korea, 2Department 
Of Pathology, Research Institute And Hospital, National Cancer Center/
Korea, 3Cancer Biostatistics Branch, Research Institute For National 
Cancer Control And Evaluation, National Cancer Center/Korea
Background: The impact of primary procedure and procedure 
sequence has not been studied in combined application of en-
dobronchial ultrasound-guided transbronchial needle aspiration 
(EBUS-TBNA) and endoscopic ultrasound-guided fine needle aspi-
ration (EUS-FNA) in lung cancer staging.
Methods: In a randomized controlled trial, 160 patients with 
histologically confirmed or strongly suspected potentially ope-
rable non-small cell lung cancer were enrolled (Group A, n=80, 
EBUS-centered; Group B, n=80, EUS-centered). In Groups A and 
B, EBUS-TBNA and EUS-FNA with ultrasound bronchoscope were 
used as the first procedure, respectively, and secondary procedu-
res were added.
Results: Diagnostic values were evaluated in 148 patients (74 in 
each group). In Groups A and B, the diagnostic accuracy (93.2% 
vs. 97.3%, respectively, p=0.2454) and sensitivity (85.3% vs.92.0%, 
respectively, p=0.4312) in detecting mediastinal metastasis were 
not statistically different. In Group A, adding EUS-FNA to EBUS-
TBNA did not significantly increase the accuracy (91.9% to 93.2%; 
p=0.7540) and sensitivity (82.4% to 85.3%; p=0.7419). In group B, 
adding EBUS-TBNA to EUS-FNA increased the accuracy (86.5% 
to 97.3%; p=0.0160) and sensitivity (60.0% to 92.0%; p=0.0081). 
There were no inter-group differences in procedure time, cardio-
respiratory parameters during procedures, complications, or pati-
ent satisfaction.
Conclusion: In combination of EBUS-TBNA and EUS-FNA in me-
diastinal staging, diagnostic values and patient satisfaction were 
not different between EBUS-centered and EUS-centered group. 
However, the necessity of EBUS-TBNA following EUS suggests 
EBUS-TBNA is a better primary procedure in endoscopic mediasti-
nal staging.
Keywords: endobronchial ultrasound, endoscopic ultrasound, 
Lung cancer, mediastinal staging
[HR]: 0.56, p=0.002), confirmed in multivariate analysis (HR=0.61 
[95% confidence interval: 0.42-0.88], p=0.009) after taking into 
account histology, previous platinum-based treatment and the 
number of previous treatment lines.
Conclusion: MMTB leads to treatment recommendations in a 
majority of the pts, fosters inclusion in clinical trials or expanded 
access programs, and limits the use of off labelled drugs. Updated 
data will be presented
Keywords: Non small cell lung cancer, Multidisciplinary molecular 
tumor board, molecular analysis
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Results: Eighty-five peripheral lung lesions were in the prediction 
set (47 malignant and 38 benign). Benign lesions had larger diffe-
rences between maximum and minimum pixel values, larger stan-
dard deviations of the mean pixel values and a higher entropy than 
malignant lesions (p<0.0001 for all values). Eighty two peripheral 
lesions were in the validation set; 63/82 (76.8%) were correctly clas-
sified. Of these 45/49(91.8%) malignant lesions and 18/33 (54.5%) 
benign lesions were correctly classified. The negative predictive 
value for malignancy was 82% and the positive predictive value 
was 75%. 
Conclusion: Greyscale texture analysis of EBUS-MP images could 
assist in differentiating between benign and malignant peripheral 
lung lesions but tissue diagnosis is still important.
Keywords: bronchoscopy, endobronchial ultrasound, image  
analysis
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O28.02 GREY SCALE TEXTURE ANALYSIS OF EN-
DOBRONCHIAL ULTRASOUND MINI PROBE GUIDE 
SHEATH IMAGES FOR PREDICTION OF BENIGN OR MA-
LIGNANT AETIOLOGY.
Phan Nguyen1, Farzad Bashirzadeh2, Justin Hundloe2, Olivier Sal-
vado3, Nicholas Dowson3, Robert Ware4, Ian Brent Masters5, David 
Fielding2
1Thoracic Medicine, The Royal Adelaide Hospital/Australia, 2Royal Bris-
bane And Women‘s Hospital/Australia, 3Csiro/Australia, 4Queensland 
Children‘s Medical Research Institute/Australia, 5Respiratory Medicine, 
The Royal Children‘s Hospital/Australia
Background: Expert analysis of endobronchial ultrasound (EBUS) 
images obtained with the mini probe (MP) has established certain 
subjective criteria for predicting benign or malignant disease. Mi-
nimal data is available for objective analysis of these images. The 
aim of this study was to determine if greyscale texture analysis of 
EBUS-MP images could differentiate between benign and malig-
nant peripheral lung lesions.
Methods: Digital EBUS-MP images with contrast set at 4 and 
gain set at 10 were included in this study. A region of interest 
(ROI) was mapped for each image and analysed in a predic-
tion set. The ROIs were analysed for the following greyscale 
texture features in MATLAB (v7.8.0.347 (R2009a)); mean pi-
xel value, difference between maximum and minimum pixel 
value, standard deviation of the mean pixel value, entropy, 
correlation, energy and homogeneity. Significant greys-
cale texture features were used to assess a validation set. 
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O28.05 AN ANALYSIS OF A PROSPECTIVE STUDY FROM 
THE EUROPEAN LUNG CANCER WORKING PARTY (ELC-
WP) LOOKING AT PREDICTIVE FACTORS FOR RESPON-
SE TO CHEMOTHERAPY (CT): LIMITATIONS IN TRANSLA-
TIONAL COOPERATIVE RESEARCH.
Ingrid Cstoth1, Thierry Berghmans1, Jean-Jacques Lafitte2, Anne-
Pascale Meert1, Marianne Paesmans3, Arnaud Scherpereel2, Nat-
halie Leclercq1, Jean-Paul Sculier1
1Intensive Care And Thoracic Oncology, Institut Jules Bordet/Belgium, 
2Pneumology, Chu Lille/France, 3Data Centre, Institut Jules Bordet/Belgium
Background: Adequate tumour samplings for biological analyses 
are currently of major importance in treating oncological patients. 
Obtaining histological samplings from the primary lung cancer can 
be a challenge due to tumour accessibility, small biopsies or toleran-
ce to bronchoscopy such as bleeding or dyspnoea in case of limited 
airflow capacity. The ELCWP developed a multicentre prospective 
study searching for predictive factors for response to chemothera-
py based on genomic analyses. We aim to analyse the capability in 
obtaining adequate tumour samplings from the primary non small 
cell lung cancer (NSCLC) for studying the transcriptome (miRNA and 
mRNAs) with high throughput techniques.
Methods: All patients presenting with a suspected lung cancer were 
proposed participating to the study. To be evaluable for the primary 
endpoint of the study, patients needed to have a confirmed diagno-
sis of NSCLC treated with chemotherapy and assessable for respon-
se. During the diagnostic bronchoscopy, 3 biopsies were collected 
from the primary tumour, with a control sample from normally appea-
ring bronchial mucosa. One was formalin fixed and paraffin embed-
ded for pathological diagnosis. A second was used for transcriptome 
analysis and the third one was frozen and stored in a tissue bank. We 
are presenting the flow chart of the patients screened for entry in the 
ELCWP study and the limitations for obtaining tumour samplings in 
assessable patients.
Results: From 1/04/2009 to 12/06/2013, 307 patients suspected 
to have NSCLC were prospectively registered. Eleven are under 
evaluation for pending histological confirmation leaving 296 pati-
ents evaluable for the present analysis. In 25 cases, no lung cancer 
confirmation was obtained (other tumour n = 12, no pathological 
confirmation at all n = 6, benign lesion n = 6, other reason n = 1) and 
6 further patients withdrew their initial consent. Among 265 patho-
logically confirmed lung cancer (samples obtained during broncho-
scopy or by another technique), 38 small cell lung cancers (SCLC) and 
227 NSCLC were diagnosed. In addition to the diagnostic biopsy, 
further samplings for genomic analyses could be obtained during the 
same bronchoscopy in 30/38 SCLC (79%) and 116/227 NSCLC (51%). 
Among 227 NSCLC, 107 were presenting with an advanced disease 
treated with a cisplatin-based chemotherapy and were assessable for 
response to chemotherapy (primary study endpoint). Among these 
107 patients, 59 adequate tumour samplings could be obtained for 
transcriptome analysis (20% from the initial cohort and 55% among 
assessable patients).
Conclusion: This analysis of a prospective multicentre study is show-
ing the difficulties and limitations in obtaining adequate tumour 
samplings for biological analyses when conducting translational co-
operative research in non-small cell lung cancer.
Keywords: bronchoscopy, Translational research, histology, 
Transcriptome
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O28.03 CLINICAL IMPLICATION OF EX VIVO RAMAN 
SPECTROSCOPY AND IN VIVO NIR SPECTROSCOPY FOR 
DIAGNOSIS OF PERIPHERAL LUNG CANCER.
Jirí Votruba1, Tomas Bruha2
1Bronchology, 1 St Pulmonary Clinic/Czech Republic, 2Bronchology, 1 St 
Pulmonary Clinic Of General Faculty Hospital/Czech Republic
Background: Due to a widespread use of a CT there is recently 
increased incidence of smaller peripheral lung lesions. Because of 
an obvious need for a morphological verification new bronchoscopy 
methods for biopsy of such small peripheral lesions are needed. We 
have utilized two methods of spectroscopic detection in peripheral 
lung cancer. In vivo method- NIR spectroscopy of penetrating light 
and ex vivo method-Raman spectroscopy of biopsy specimens. 
Correlation of these two methods gives us the insight into molecular 
biology of in vivo spectroscopic measurement. In vivo NIR spec-
troscopy together with transbronchial biopsy under fluoroscopic 
guidance appears to be useful and reliable method for peripheral 
lung cancer diagnosis.
Methods: We have designed a simple instrument for measurement 
of a penetrated NIR light through the lung tissue. It consists of two 
fibres of 1 mm in diameter contained in one bundle covered with 
insulation sleeving. One of the fibres is a detector; the other is a 
source fibre. The indicator fibre is 1,5 cm longer than the source 
fibre and it is separately covered with insulation till its ending. The 
ending is cut in the angle of 60 degrees and titan coated in order to 
facilitate NIR light transmission toward detector fibre. The detector 
fibre is connected to NIR spectroscope and the source fibre to NIR 
source. The instrument for ex vivo Raman spectroscopy measure-
ment has been derived from above described system. The endings 
of fibres have been grinded down perpendicularly in order to allow 
systematic Raman measurement.
Results: In vivo measurement: Measurements of a normal lung tis-
sue at various areas of a lung tissue show characteristic peak at 735 
nm which is not present during cancer tissue spectroscopy. In can-
cer tissue in addition all detected spectra have got fixed ratio (with 
minimal dispersion) of two standardized transmittance values at two 
chosen wavelengths (773 and 823 nm)- mirroring the source values 
with its mild modification by tissue auto fluorescence. By help of 
those findings we utilized endobronchial measurement of NIR trans-
mittance spectra in attempt to improve sensitivity of trans bronchial 
biopsy under fluoroscopic guidance. Ex vivo measurement: Biopsy 
specimens has been immediately transferred to Raman spectro-
scope laboratory (within 10 minutes) on temperature 8-10°C. For 
tissue Raman studies we used excitation at 785 nm. Raman spec-
tra in the 700-1,800 cm(-1) range from lung tissue biopsies were 
obtained within 10 sec. Raman Spectroscopy results from biopsy 
specimens taken from the in vivo spectroscopy pathological areas 
showed higher signals for nucleic acid, tryptophan and lower signals 
for phospholipids and proline, compared to normal tissue.
Conclusion: In vivo NIR spectroscopy together with transbronchial 
biopsy under fluoroscopic guidance appears to be useful and reli-
able method for peripheral lung cancer diagnosis. Ex vivo Raman 
spectroscopy confirmed diagnostics value of in vivo measurements. 
Such device or its modifications could be easily included for examp-
le into the examination by electromagnetic navigation.
Keywords: Nir spectroscopy, Raman spectroscopy, bronchoscopy, 
peripheral lung cancer
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O28.07 INTRA-OPERATIVE SCANNING CONFOCAL  
ENDOMICROSCOPY OF PLEURAL DISEASE: IN VIVO  
DIAGNOSIS OF MALIGNANCY
Paul L. Mitchell1, Simon Knight2, Peter Crowley3, Faye Putt4, Julian 
Gooi5, Siven Seevanayagam5, Stephen Barnett2, Christine Mcdo-
nald6, Peter Delaney7
1Ludwig Medical Oncology Unit, Olivia Newton-john Cancer And 
Wellness Centre, Austin Health/Australia, 2Thoracic Surgery, Aus-
tin Health/Australia, 3Department Of Anatomical Pathology, Austin 
Health/Australia, 4Olivia Newton-john Cancer And Wellness Centre, 
Austin Health/Australia, 5Department Of Thoracic Surgery, Austin 
Health/Australia, 6Department Of Respiratory Medicine, Austin Health/
Australia, 7Optiscan/Australia
Background: The intra-operative diagnosis of pleural malignan-
cy may facilitate surgical decision-making including the need for 
pleurodesis. A scanning laser confocal endomicroscopy device has 
been developed which allows histological-detail optical imaging 
of subsurface tissues in vivo. Confocal laser microscopy illuminates 
and detects light from a fixed point of a specimen which is scan-
ned across a tissue plane and adjustable depths, providing a 3D 
structural view in a living body. Applied to screening of mucosal 
lesions in patients undergoing GI endoscopy, endomicroscopy ob-
viates the need for many tissue biopsies and operators can rapidly 
learn to identify malignant tissues.
Methods: We performed the first intra-operative examination 
of pleural tissues using this equipment which is a thoracoscope-
mounted endomicroscope device in patients administered iv fluo-
rescein prior to imaging. Intra-operative endomicroscopic images 
were correlated with biopsies of pleural tissues.
Results: Sixteen patients were imaged: including mesothelioma 5 
(2 biphasic) and pleural metastases from malignancies of lung 2, 
ovary 2 and one case each of breast, adenoidcystic (see figure), 
thyroid, colorectal, carcinoid and non-Hodgkin’s lymphoma, and 
also one benign case. We were able to image and identify normal 
mesothelium, sub-mesothelium, connective tissues and blood 
vessels (including RBC). Malignant cells and clusters of cells had a 
characteristic appearance including poor uptake of fluorescein and 
cellular pleomorphism. Appearances of mesothelioma correlated 
closely with histology. Glandular and papillary structures were 
identified in metastatic pleural tumour. In ovarian cancer calcifica-
tion was readily identified as were psammoma bodies, while the 
typical cystic spaces surrounded by small dark cells mirrored close-
ly the histological appearances of adenoidcystic carcinoma.
Conclusion: Images obtained on scanning confocal endomicro-
scopy of pleural malignancy generally correlated well with the 
histological appearance on biopsies. We plan now to extend our 
experience of malignancy and also the ability to discriminate bet-
ween benign disease and malignancy of the pleura. Supported by 
a Tumour Stream Grant from the Victorian Cancer Agency. Figure: 
Endomicroscopy image of pleural metastases from adenoidcystic 
carcinoma of the parotid.  
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O28.06 COMPREHENSIVE MANAGEMENT OF CENTRAL 
TYPE EARLY LUNG CANCER
Norihiko Ikeda1, Tatsuo Ohira1, Naohiro Kajiwara1, Masatoshi 
Kakihana1, Jitsuo Usuda2, Hidetoshi Honda1, Sachio Maehara1, 
Yoshihisa Shimada1
1Surgery, Tokyo Medical University/Japan, 2Nihon Medical School/Japan
Background: Tumor localization and the precise evaluation of 
tumor invasion are most important for the management of central 
type early stage lung cancer (CELC) and Photodynamic therapy 
(PDT) has come to be considered as the first choice of treatment 
for CELC. The present guidelines of PDT for CELC were establis-
hed based mainly on the data obtained from studies since 1980’s. 
CELCs less than 1 cm in diameter showed a favorable cure rate by 
PDT, thus this was a good standard to decide the indications of 
PDT. To obtain complete response (CR) by PDT, evaluation of each 
lesion is extremely important, including the extent of the tumor 
on the bronchial surface and the depth of invasion in the bronchial 
wall. We postulate that the combination of comprehensive diag-
nosis and the new generation of photosensitizers may increase the 
CR rate and expand the indications of PDT for larger tumors.
Methods: Autofluorescence bronchoscopy (AFB) has been used in 
the objective evaluation of the margin of the tumor before endo-
scopic treatment and Endobronchial ultrasonography (EBUS) has 
been employed to determine the depth of tumor invasion. Oopti-
cal coherence tomography (OCT) has been investigated for clinical 
use as well. Also, the relatively newer photosensitizer NPe6, which 
has a stronger antitumor effect than Photofrin has been extensively 
used for PDT. We routinely used these diagnostic methodologies 
and NPe6 since 2004.
Results: A total of 122 consecutive CELCs were treated by PDT 
using NPe6 in Tokyo Medical University and CR was obtained in 
115 lesions (CR rate 94.3%). Of the 122 lesions examined in this 
study, 78 had a diameter of ≦1.0 cm and the rest of the 44 cancer 
lesions were >1.0 cm in size. The CR rate of CELC ≦1.0 cm in dia-
meter was 93.6% (73/78) and for those >1.0 cm in diameter, 95.5% 
(42/44), respectively. There was no significant difference between 
tumor size and clinical response. The CR rate to NPe6-PDT is hig-
her than that of Photofrin-PDT in our previous studies. This early 
result suggests that PDT with NPe6 has a stronger antitumor effect 
than Photofrin therefore similar treatment outcome even for larger 
tumors >1.0 cm in diameter should be possible.
Conclusion: Objective evaluation by a comprehensive approach 
using AFB and EBUS enables to select the optimal therapeutic 
strategy for CELC. These results suggest that PDT with NPe6 may 
have a similar treatment outcome regardless of tumor size, as long 
sufficient laser illumination of the entire tumor is possible.
Keywords: PDT, Autofluorescence bronchoscopy, Early lung can-
cer, brochoscopy
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O29.01 AWARENESS ABOUT THE SIGNS AND SYMP-
TOMS OF LUNG CANCER IN AUSTRALIA, A MIXED  
METHODS STUDY
Melanie Crane1, Sanchia Aranda1, Ingrid Stacey1, Mayanne Lafon-
taine1, Nicola Scott2, Blythe O‘Hara3, David Currow1
1Cancer Institute New South Wales/Australia, 2Minstry Of Health/Aus-
tralia, 3School Of Public Health, University Of Sydney/Australia
Background: The risk of developing lung cancer increases with 
age and is highly associated with exposure to tobacco smoking. 
This study aimed to understand public awareness about the risk of 
developing lung cancer in New South Wales (NSW), Australia and 
to investigate attitudes and beliefs about lung cancer which could 
potentially impact health seeking behaviours regarding symptoms 
of lung cancer. The risk of developing lung cancer increases with 
age and is highly associated with exposure to tobacco smoking. 
This study aimed to understand public awareness about the risk of 
developing lung cancer in New South Wales (NSW), Australia and 
to investigate attitudes and beliefs about lung cancer which could 
potentially impact health seeking behaviours regarding symptoms 
of lung cancer.
Methods: A mixed methods triangulation approach was used, with 
a sequential-parallel design which incorporated 16 qualitative fo-
cus groups (n=125) to explore themes. Participants were aged 45+ 
from metropolitan and regional centres and grouped according 
to smoking status (current, former and never smokers). Data were 
analysed by content and thematically. A cross sectional quantitati-
ve telephone survey (n=1,000) followed to determine overall awa-
reness and generalisability of findings amongst adults >45 years 
across NSW.
Results: The qualitative research highlighted that symptoms of 
haemoptysis, dyspnoea and an unusual or persistent cough were 
well recognised symptoms of lung cancer however participants 
were more likely to assume these symptoms were related to other 
health problems. Haemoptysis was the only symptom which crea-
ted a sense of urgency to seek immediate medical attention. A 
‘wait and see’ attitude towards any concerning symptom was pre-
valent across groups, only severe/ long term persistent symptoms 
would induce action. Smokers and former heavy smokers were 
more likely to say they would delay seeing their doctor because 
of perceived stigma associated with smoking. Older participants 
were more likely to rely on previous experiences of symptoms to 
govern their health seeking behaviour. Perceived susceptibility and 
understanding of causes of lung cancer differed by smoking status; 
smokers more likely to down-play the risk of smoking or attempt 
to offset their risk through lifestyle choices. Former smokers were 
more likely to perceive their risk comparative with a never smoker. 
The quantitative research findings suggested that unprompted 
awareness of lung cancer related symptoms was high with 88.5% 
able to correctly identify ≥1 symptoms however symptoms were 
more typical of late stage cancer. Age(<65 years), sex(female) and 
high socio-economic status were associated with higher recogniti-
on of symptoms (p<0.05). The majority of the survey respondents 
identified smoking as a cause of lung cancer (90.6%, 95%Confi-
Keywords: Thoracoscopy, pleural malignancy, mesothelioma, 
Confocal endomicroscopy
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Lung Cancer Awareness Campaign, the largest lung cancer unit in 
England recorded a 14% increase in patients referred from General 
Practice with suspected lung cancer. There was a 17% increase in 
diagnosed lung cancers, and the percentage of patients undergo-
ing potentially curative surgery for stage I and II disease increased 
from 18% to 29%. Compared to the same time period in 2010, an 
additional 6 patients underwent surgery for stage I and II disease 
in 2012, an increase of 6% in the surgical resection rate. We have 
observed a beneficial effect from the National Lung Cancer Awa-
reness Campaign, with significant increases in our lung cancer 
diagnosis rates and the number of patients undergoing curative 
surgery.
Keywords: surgery, awareness, campaign
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O29.04 A NEW MEDICAL DEVICE FOR IN VIVO ISOLA-
TION OF CIRCULATING TUMOR CELLS IN NON-SMALL 
CELL LUNG CANCER (NSCLC) PATIENTS AND IMMU-
NOFLUORESCENCE IDENTIFICATION OF ALK
Lukasz Gasiorowski1, Kathrin Haubold2, Stefanie Herold2, Björn 
Nowack2, Klaus Pantel3, Thomas Krahn4, Grzegorz Dworacki5, 
Klaus Lücke2, Wojciech Dyszkiewicz6
1Department Of Thoracic Surgery, Poznan University Of Medical Sci-
ence/Poland, 2Gilupi GmbH/Germany, 3Department Of Tumor Biology, 
University Medical Center Hamburg-eppendorf/Germany, 4Global Bio-
marker Research, Bayer Pharma Ag/Germany, 5Clinical Immunology 
Medical University, Poznan University Of Medical Science/Poland, 6Tho-
racic Surgery, Medical University/Poland
Background: Circulating tumor cells (CTCs) in the bloodstream of 
lung cancer patients provide a source for early detection, progno-
sis, and therapy monitoring. CTCs are currently mostly isolated in 
vitro from small volumes of patient blood samples. In order to in-
crease the sensitivity of the CTC detection in the peripheral blood 
GILUPI has developed a novel in vivo method, the CellCollector, 
which enables the capture of CTCs from the patient´s blood stream 
with a higher sensitivity and efficacy than existing methods. Enu-
meration and characterization of those CTCs will serve to improve 
and monitor clinical cancer early detection and treatment. The aim 
of this study was to assess the Detektor CANCER01 (DC01) for in 
vivo isolation of CTCs directly from the blood of NSCLC patients, 
and to compare it to the CellSearch® method.
Methods: The device was inserted in a cubital vein through a 
standard cannula for thirty minutes. The interaction of target CTCs 
with the DC01 was mediated by an antibody directed against the 
epithelial cell adhesion molecule (EpCAM). To confirm the CTCs 
binding to the wire, the immunohistochemical staining against 
EpCAM and/ or Cytokeratins as well as CD45 for negative cell 
selection and nuclei counterstaining was performed. There were 
enumeration data available for 34 stage I-IIIB NSCLC patients and 
8 non cancer patients. For 34 patients, samples were also tested 
with the CellSearch® method.
Results: In this study, we successfully isolated EpCAM-positive tu-
mor cells in the peripheral blood originating from NSCLC patients. 
We obtained in vivo CTC detection rate of 94% in 32 of 34 NSCLC 
patients with a median (range) of 13 (0-300) CTCs. In 2 of 34 sam-
ples (5.8 %), CTCs were detected by the CellSearch® method. In 
all matched pairs, the DC01detected the same number or more 
dence Interval (CI) 88.4-92.8) however fewer recognised the risk 
from second-hand smoke (25.6%,95%CI22.3-28.9). Ever-smokers 
were less likely to recognise the risk of smoking (odds ratio 0.7 
95%CI0.5-0.9).
Conclusion: These findings provide evidence that while aware-
ness of lung cancer symptoms and causative factors is reasonably 
understood in the community, perceived susceptibility is low (par-
ticularly among current and former smokers). A lack of urgency in 
seeking medical attention for symptoms considered not severe, 
together with other smoking-related barriers, may lead to further 
delays in diagnosis and missed opportunity for surgical treatment.
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O29.02 IMPACT OF A NATIONAL LUNG CANCER AWA-
RENESS CAMPAIGN IN MERSEYSIDE
Joe Maguire1, Veronica Kelly1, Andrea Mciver1, Colin Smyth1, Mar-
tin Ledson1, Martin Walshaw1, John Littler2
1Liverpool Lung Cancer Unit, Liverpool Heart And Chest Hospital/
United Kingdom, 2Radiotherapy, Clatterbridge Cancer Centre/United 
Kingdom
Background: In May 2012 the United Kingdom Department of 
Health initiated a centrally funded National Lung Cancer Aware-
ness Campaign. This campaign was influenced by encouraging 
results from local pilot studies, and featured news items and public 
health awareness adverts in national and local media, including na-
tionwide television and radio exposure, accompanied by celebrity 
involvement and endorsements. The cost of this initiative has not 
been disclosed. Liverpool has the highest lung cancer incidence 
and mortality in England, and our Lung Cancer Unit, providing a 
service for patients in South Liverpool, is the largest in the Cancer 
Network and the largest in the country
Methods: To assess the impact of the national campaign we have 
reviewed referrals to our Rapid Access Lung Cancer Service from 
General Practice via the two week suspected cancer pathway, 
during the months of April to December 2012; we have also revie-
wed referrals during the same months in 2011 and 2010. For these 
time periods we have compared the total number of referrals, the 
number and proportion of referrals judged as unsuitable for imme-
diate investigation with CT scan and bronchoscopy, the number 
and stage distribution of cancers diagnosed and the proportion of 
patients undergoing potentially curative surgery.
Results: In the period May to December 2012 a total of 323 pati-
ents were referred to our Rapid Access Service; of these, 140 (43%) 
did not have any features suggestive of a possible lung cancer 
- these patients were reviewed in a routine chest clinic. A total of 
103 patients (32% of referrals in this time period) were diagnosed 
as having lung cancer. Of these 34 (33%) had stage I or II disease 
on CT staging and 30 patients (29%) underwent potentially curati-
ve surgery. The corresponding figures for 2011 are: total referrals 
283, 93 (33%) sent to routine chest clinic, 88 (31%) diagnosed lung 
cancers, 17 (20%) stage I and II and 16 (18%) potentially curative 
operations. In May to December 2010 we received 274 referrals. 75 
(27%) were referred on to routine chest review. 106 patients (39%) 
were diagnosed as having lung cancer. 23 (21%) were stage I or II 
and 24 (23%) underwent potentially curative surgery.
Conclusion: In the 8 months following the initiation of a National 
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Conclusion: The use of clinically modified T descriptors of the 
tumor size measured eliminating the GGO component on HRCT 
may more clearly classify the prognoses of patients with early lung 
cancer.
Keywords: Tumor size, staging, Ground glass opacity, TNM classi-
fication
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O29.06 PROGNOSTIC VALUE OF FDG-PET/CT VOLUME-
TRIC PROGNOSTIC STAGING SYSTEM IN NON-SMALL 
CELL LUNG CANER
Yonglin Pu1, Hao Zhang2, Bill Penney1, Ming Chi Shih1, Yulei Jiang1, 
Chin-Tu Chen1, Daniel; Appelbaum1, Chien-Min Kao1, George Ca-
rey3, Ravi Salgia3
1Radiology, The University Of Chicago/United States Of America, 2Ra-
diology, First Hospital Of Lanzhou University/China, 3Chest Oncology, 
The University Of Chicago/United States Of America
Background: Whole-body metabolic tumor volume (MTVWB) is 
a prognostic index independent of TNM staging, age, gender, 
performance status and treatment in non-small cell lung cancer 
(NSCLC). The current TNM staging system is also a prognostic 
index. However, it lacks advanced quantitative volumetric measu-
rement in the 7th edition NSCLC TNM staging system. Integrating 
quantitative MTVWB measurement into the current NSCLC staging 
system may make the staging system more quantitative and proba-
bly more prognostic. This study’s aim was to determine the utility 
of a FDG-PET volumetric prognostic (PVP) staging system based 
on univariate Cox regression models as a new prognostic index in 
NSCLC.
Methods: 328 consecutive patients (156 males,172 females) with 
histologically proven NSCLC and median age of 68.3 years were 
identified for this retrospective analysis. The PET metabolic tu-
mor volume in the whole body (MTVWB) was measured using a 
semi-automated 3D contouring program on baseline FDG PET/
CT scans. The prognostic power for survival status of the PVP 
staging system was evaluated using the Kaplan–Meier method, 
Cox regression models, and compared with those of TNM staging 
system and ln(MTVWB) using C-statistic index (Gönen and Heller’s K 
concordance statistic).
Results: There were 46 cases with stage IA, 43 stage IB, 19 sta-
ge IIA, 18 stage IIB, 52 stage IIIA, 39 stage IIIB and 111 stage IV 
NSCLC. At the end of this investigation, 249 patients had died 
(88.4%). Median follow-up of 79 lost follow-up and known surviving 
patients was 58 months. On univariate survival analysis the HR of 
ln(MTVWB) was 1.56, and the HRs of TNM stages 2.25, 1.96, 2.89, 
4.24, 4.93 and 7.63 for TNM stages IB, IIA, IIB, IIIA, IIIB and IV in 
reference to stage IA, respectively. These HRs were used for com-
puting the PVP stage of each patient using following equation; PVP 
stage = [Hazard ratio of ln(MTVWB) × ln(MTVWB)] × [Hazard ratios 
of TNM stage]. There was a statistically significant association of 
better overall survival with lower PVP stage on both univariate 
[HR of 1.033 (95%CI =1.027 to1.039)] and multivariate [HR of 1.03 
(95%CI =1.02 to1.04)] survival analyses. The range of the PVP stage 
were 0.06 to 87.57. For comparison with 7th edition of TNM stage 
and ln(MTVWB), the PVP stage and ln(MTVWB) were divided into 7 
groups with similar numbers of patients. The C-statistic value of 
PVP staging system (mean±SE = 0.70±0.014) was statistically sig-
CTCs compared to the CellSearch® method. The sensitivity was 
similar for early and late stage NSCLC patients. In the non-cancer 
patients, no CTCs were detected (100 % specificity). ALK gene 
rearrangements in NSCLC patients are an indication for targeted 
therapy with crizotinib. Therefore the staining for CTCs on the 
CellCollector was enhanced to identify the anaplastic lymphoma 
kinase (ALK). It could be identified by capturing cells and immuno-
histochemical staining.
Conclusion: Due to a detection rate of over 90% this new device 
might overcome present limitations in the enrichment of CTCs. 
This proof of concept study may have important clinical implica-
tions, as the implementation of the device into clinical practice 
may improve early detection, prognosis and therapy monitoring of 
NSCLC patients. The performed IHC for ALK expression on samp-
les using a novel combination of a new ALK antibody with the high 
detection rate of the CellCollector offers an alternative to FISH or 
IHC on tumor tissue. This new technology also allows, as the cap-
tured tumor cells are ready using immunofluorescence approaches 
or qPCR, the possibility of establishing more personalized treat-
ment regiments.
Keywords: CellCollector, NSCLC, Circulating TUmor Cells, ALK
CANCER CONTROL & EPIDEMIOLOGY IV  
WEDNESDAY, OCTOBER 30, 2013 - 10:30-12:00
O29.05 PROGNOSTIC IMPACT OF THE TUMOR SIZE 
ELIMINATING THE GROUND GLASS OPACITY COMPO-
NENT: MODIFIED CLINICAL T DESCRIPTORS OF THE 
TNM CLASSIFICATION OF LUNG CANCER
Shota Nakamura1, Takayuki Fukui1, Tetsuo Taniguchi1, Noriyasu 
Usami1, Koji Kawaguchi1, Futoshi Ishiguro1, Akihiro Hirakawa2, 
Kohei Yokoi1
1Thoracic Surgery, Nagoya University/Japan, 2Center For Advanced 
Medicine And Clinical Research, Nagoya University/Japan
Background: The presence of ground glass opacity (GGO) on 
high-resolution computed tomography (HRCT) is well known to 
be pathologically closely associated with adenocarcinoma in situ. 
Recently, measuring the tumor diameter including areas of GGO 
on HRCT has been reported to possibly overestimate the T status. 
The purpose of this study was to evaluate the significance of the 
tumor size measured eliminating the area of GGO on HRCT as 
a prognostic factor and to propose a refined TNM classification 
based on modified T descriptors.
Methods: Four hundred and seventy-five patients with clinical 
T1a-T2bN0M0 non-small cell lung cancer underwent surgical re-
section. All tumors were reclassified based on the diameter measu-
red eliminating the GGO area on HRCT according to the 7th TNM 
classification of lung cancer. We defined this new classification as 
modified T descriptors categorized into four groups: mTis+T1a, 
mT1b, mT2a and mT2b. The overall survival rates of the patients in 
the current and modified staging groups were evaluated.
Results: The 5-year survival rates were 88% and 82% in the pa-
tients with T1a and T1b tumors and 90% and 75% in the patients 
with mTis+T1a and mT1b tumors, respectively. The differences in 
the survival of the patients classified using mTis+T1a and the other 
modified T descriptors were more clearly separated statistically 
than those of the patients classified using the current T1a and 
other T descriptors.
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Conclusion: Interlobar fissure status clearly affected survival of 
the patients with ALI. ALI should be examined by elastic stains and 
only ALI-A should be classified as true ALI. We propose that ALI-A 
tumors ≤ 5 cm should be assigned to T2b but ALI-D tumors do not 
require adjustment of T descriptor.
Keywords: non-small cell lung cancer, interlobar pleural invasion, 
interlobar fissure, Adjacent lobe invasion
nificantly higher than those of TNM stage (0.67 ±0.015, p=0.002) 
and ln(MTVWB) (0.67±0.015, p=0.02) on univariate survival analysis. 
In multivariate Cox regression models adjusted by patient’s age, 
gender, treatment types, tumor histology and tumor SUVmax, the 
C-statistic value of PVP staging system (mean±SE=0.73±0.013) was 
also statistically significantly higher than that of TNM stage (0.71 
±0.015, p=0.036).
Conclusion: The PVP staging system from FDG-PET/CT has better 
prognostic ability and may prove to be a useful prognostic index 
in NSCLC. It can be treated as a complement to the TNM staging 
system.
Keyword: 18F-FDG-PET; TNM staging, non-small cell lung cancer; 
metabolic tumor burden
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O29.07 THE CLINICAL OUTCOME OF NON-SMALL CELL 
LUNG CANCER PATIENTS WITH ADJACENT LOBE INVA-
SION: PROPOSAL FOR OPTIMAL CLASSIFICATION AC-
CORDING TO THE STATUS OF INTERLOBAR PLEURA IN 
INVASION POINT
Tomoyuki Hishida1, Yoichi Ohtaki2, Junji Yoshida1, Genichiro 
Ishii3, Keiju Aokage1, Kimihiro Shimizu2, Izumi Takeyoshi2, Kanji 
Nagai1
1Department Of Thoracic Oncology, National Cancer Center Hospital 
East/Japan, 2Division Of Thoracic And Visceral Organ Surgery, Gunma 
Graduate School Of Medicine/Japan, 3Division Of Pathology, Research 
Center For Innovative Oncology, National Cancer Center, Hospital East, 
6-5-1 Kashiwanoha/Japan
Background: In the 7th TNM classification, non-small cell lung can-
cer (NSCLC) with adjacent lobe invasion (ALI) is classified as T2a 
regardless of whether across the complete or incomplete fissure. 
However, no validation analysis has been conducted on this classi-
fication. The aim of this study was to analyze the survival of NSCLC 
patients with ALI with emphasis on the interlobar fissure status at 
invasion point.
Methods: We retrospectively evaluated 2097 consecutive patients 
with surgically resected NSCLC from 1993 through 2006. Of these, 
90 (4.3%) patients had tumors with ALI. Interlobar fissure status of 
tumors with ALI was examined by using elastic stain. We classified 
ALI into 2 types: direct ALI beyond incomplete interlobar fissure 
(no visceral pleurae separating two lobes; ALI-D) and ALI across 
complete fissure (two lobes separated by 2 visceral pleurae; ALI-
A), and compared the clinicopathological features and survival 
between the groups.
Results: The patients with ALI without any other criteria higher 
than T2b category (n = 60) demonstrated intermediate survival 
between T2a and T2b tumors (5-year overall survival [OS]: T2a, 
61.0%; ALI, 59.6%; T2b, 49.2%). Distinct survival difference was 
observed between the patients with ALI-A (n = 46) and ALI-D (n = 
14) (5-year OS: ALI-D, 85.7%; ALI-A, 52.0%; p = 0.01). The survival 
of patients with ALI-A was not statistically different from that of 
patients with T2b tumors, regardless of tumor size (p = 0.85). Con-
versely, the survival of the patients with ALI-D did not statistically 
differ from those with T1a or T1b tumors (p = 0.77 and 0.42, res-
pectively).
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the average number of variants in CTC, primary tumour and me-
tastases samples was 283 (range: 110-470), 433 (70-1002), and 242 
(81-166) respectively. The concordance in variants between CTC 
and primary tumour samples was 22% (15-29%) and between CTC 
and metastases samples was 29% (20-38%). Genes frequently mu-
tated in matched CTCs and primary tumours/metastases included 
NOTCH2, AKT1, and RET. Pathway analysis of genes with DNA 
variants revealed an enrichment of genes involved in mTOR signal-
ling in both CTC/primary and CTC/metastases samples. In CTC/
metastases samples, pathways including the JAK-STAT and B-cell 
receptor pathways were additionally enriched.
Conclusion: Our results have highlighted a high level of genetic 
variability between CTCs and their matched tumours, reflective of 
high tumour heterogeneity. Preliminary analysis has identified ge-
nes and pathways with alterations in CTCs that could be potential 
targets for systemic treatment.
Keywords: next generation sequencing, diagnostics, metastasis, 
circulating tumour cells
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MO01.03 TRANSITIONING TO NEXT GEN TESTING OF 
LUNG CARCINOMA
Wilbur A. Franklin1, Jerry Haney1, Daniel T. Merrick2, Kenneth L. 
Jones1, Katherine Gowan1, Adrie Van Bokoven1, Paul Bunn3, York 
Miller2, Dara Aisner1
1Pathology, University Of Colorado Anschutz Medical Campus/United 
States Of America, 2Denver Veterans Affairs Medical Center, University 
Of Colorado/United States Of America, 3Medical Oncology, University 
Of Colorado Denver-AMS/United States Of America
Background: The feasibility of multigene testing in a clinical set-
ting has been demonstrated by the Lung Cancer Mutation Consor-
tium (LCMC) which has evaluated over 1000 cases from multiple 
institutions in a CLIA environment. The initial platforms used by the 
LCMC were SNaPshot and Ion Torrent, allele specific tests. More 
recently the sequencing by synthesis method (Illumina) used for 
whole genome sequencing has been scaled for sequencing of a 
limited number of targeted genes. In this study we compare the 
performance characteristics of Next Generation testing on the 
MiSeq platform with the older allele specific SNaPshot platform 
and evaluate the applicability of Miseq-based testing to a clinical, 
CLIA regulated setting.
Methods: Two Illumina kits, the TruSeq and TruSight evaluating 
221 hotspots in 48 gene and 175 exons in 26 genes, respectively, 
were compared. To assess analytical sensitivity, cell lines with 
known mutations and SNPs were titered into liver DNA known to 
be wild-type for the selected mutations, at tumor cell concentra-
tions ranging from 3% to 50%. In addition, 24 formalin-fixed paraf-
fin-embedded lung tumors that had previously been evaluated by 
SNaPshot or direct sequencing were tested to compare sensitivi-
ties and specificities of methods. Paraffin embedded human tumor 
tissue samples were enriched for tumor cells by coring of paraffin 
block or macrodissection using a pneumatic cell collector. DNA 
was extracted by proteinase K digestion and column chromatogra-
phy, end repaired and phosphorylated. Libraries were prepared 
from each sample by ligating index adapters that allow for mixing 
of samples and binding adapters that link DNA fragments to flow 
cell. Combined libraries were added to flow cells at an appropriate 
MINI ORAL SESSIONS 
Session MO01: Lung Cancer Biology 
- Techniques and Platforms 
Monday, October 28, 2013
LUNG CANCER BIOLOGY - TECHNIQUES AND PLATFORMS  
MONDAY, OCTOBER 28, 2013 - 10:30-12:00
MO01.01 NEXT GENERATION SEQUENCING OF CIR-
CULATING TUMOUR CELLS CAPTURED BY ANTIBODY-
INDEPENDENT ENRICHMENT AND MATCHED PRIMARY 
TUMOURS/METASTASES IN PATIENTS WITH NON-
SMALL CELL LUNG CANCER
Yvonne Teng1, Jia Yang Chua1, Marie Loh2, Samuel Ow3, Alvin 
Wong3, Thirugnanam Agasthian4, John K C Tam4, Brendan Pang5, 
Richie Soong1, Ross Soo3
1Cancer Science Institute Of Singapore, National University Of Singapo-
re/Singapore, 2Department Of Epidemiology And Biostatistics, Imperial 
College London/United Kingdom, 3National University Cancer Institute 
Singapore, National University Health System/Singapore, 4Department 
Of Cardiac, Thoracic & Vascular Surgery, National University Health 
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Background: Circulating tumour cells (CTCs) are considered the 
seeds of metastasis, and characterization of CTCs promises novel 
insights into metastasis, new targets for intervention, and less-
invasive samples for assessing tumour status. CTCs however are 
rare in circulation and thus highly sensitive tools are required for 
their reliable capture and analysis. Antibody-based platforms using 
candidate gene-based approaches have begun to provide insights 
into CTCs. However tumour heterogeneity and the dependence 
of these methods on antigen expression has made antibody-inde-
pendent methods of interest. The Clearbridge ClearCell System is 
a microfluidic-based platform that enables antibody-independent 
capture and retrieval of CTCs based on differences in the biome-
chanical characteristics of blood cells and CTCs. Next Generation 
Sequencing (NGS) has emerged as a tool to perform massive pa-
rallel sequencing of genomic regions with high efficiency and ac-
curacy. The aim of this study was to perform NGS analysis of CTCs 
captured by antibody-independent methods, and their matched 
primary tumour or metastases samples, in patients with NSCLC.
Methods: Three matched CTC and primary tumour samples and 
three matched CTC and metastases samples were obtained from 
patients with NSCLC. Whole blood samples were also obtained 
from the patients for germline DNA. Five patients had adenocar-
cinoma and none of the patients had received targeted therapy 
prior to biospy of the metastatic lesions. CTCs were captured and 
retrieved from 2ml whole blood using the Clearbridge ClearCell 
System near the time of tumour sampling. DNA was extracted from 
CTCs, tumour tissue, and whole blood using the Qiagen QiaAMP 
DNA Micro Kit, DNAeasy Blood and Tissue kit , and Biorobot EZ1 
workstation respectively. NGS was performed on the Ion Torrent 
PGM Sequencer using the AmpliSeq Comprehensive Cancer Panel 
targeted to 409 genes prominent in cancer. DNA variants were 
identified using Ion Torrent Software Suite v3.4, and pathway ana-
lysis was performed using the Database for Annotation, Visualizati-
on and Integrated Discovery (DAVID).
Results: After subtraction of DNA variants found in whole blood, 
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HiSeq 2000 sequencing system (1x 50 bp reads), with multiplexed 
sequencing libraries prepared using 1 ug of RNA with the Illumina 
Truseq Small RNA Preparation Kit (version 2.0). Microarray data 
were processed using the AgiMicroRna Bioconductor package in 
R. Sequencing data were demultiplexed using CASAVA software 
and were mapped against mature human microRNAs in the miR-
Base database (version 16) using STAR aligner software. Absolute 
microRNA count values were then normalized among samples by 
use of the edgeR Bioconductor package.
Results: of RiboGreen fluorometric analysis suggested that an 
average of 16 ug (range, 6-35 ug; SD, 8 ug) of RNA was obtained 
from the FFPE specimens. Significant degradation of RNA was 
observed, as expected, with Bioanalyzer RNA integrity number 
values between 1.9 and 2.5. An average of 1.3 million sequencing 
reads (range, 9.1-16.9 million; SD, 3.5 million) were obtained, but 
only 1.4% (range, 0.4%-2.1%; SD, 1.4%) of them mapped to known 
microRNAs. Of the 1205 human microRNAs detectable with the 
microarray platform, 302 were identified as expressed in the 
8-sample set, and 593 were identified as expressed in the sequen-
cing platform. For the 177 microRNAs detected by both microarray 
and sequencing methods, the interplatform Spearman correlation 
coefficient was >0.5 for only 51 of them. Reverse-transcription PCR 
assays are being performed to identify the platform that yields the 
most accurate microRNA profile.
Conclusion: MicroRNA profiling by RNA sequencing and microar-
ray techniques produced different results. The RNA sequencing 
method described here does not appear to be suitable for profi-
ling microRNAs in RNA from FFPE samples. It is possible that de-
pletion of ribosomal RNA fragments from FFPE RNA samples may 
improve the quality of data obtained from RNA sequencing.
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MO01.06 SCREENING FOR DRUGS THAT OVERCOME 
GEFITNIB RESISTANCE IN EGFR MUTATION-POSITIVE 
NON-SMALL CELL LUNG CANCER CELLS.
Yibo Xue, Chao Wang, Zhi Zheng
Dept. Of Biochemistry And Molecular Biology, Institute Of Basic Medi-
cal Sciences, Chinese Academy Of Medical Sciences And Peking Union 
Medical College/China
Background: EGFR mutation-positive Non-Small Cell Lung Can-
cer (NSCLC) patients who show an initial dramatic response to 
EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy almost always 
acquire resistance due to secondary resistance mutations on 
EGFR or other mechanisms. Strategies to overcome such acquired 
resistance have therefore become critical to improve TKI-based 
targeted therapy. One strategy is the development of therapeutic 
agents to be used in combination with EGFR-TKI to treat EGFR 
mutation-positive relapsed patients. Although several candidate 
drugs targeting putative resistance pathways in NSCLC cells have 
been attempted in combination with EGFR-TKI, a systematic scree-
ning has not been reported. We seek to screen a small molecule 
library for compounds that would specifically enhance the cytoto-
xic effect of TKIs on EGFR mutation-positive tumor cells bearing 
acquired resistance mutations.
Methods: We have used MTS assay to screen a library containing 
about 1000 FDA approved drugs, 600 bioactive compounds, and 
400 natural products, to identify compounds that when used in 
concentration, clusters generated, and sequencing reaction com-
menced. Results were evaluated by software developed by Illumi-
na or locally at the University of Colorado.
Results: Spiking studies indicated that analytic sensitivity for Mi-
seq at loading quantities of 100 to 300 ng (TruSeq) was ~5% for 
known KRAS and TP53 mutations and several synonymous poly-
morphisms in other covered genes, comparable to SNaPshot. For 
clinical samples, average depth of coverage was 5700 (+/- 2267). 
Unfiltered results using Illumina software supplied with the Miseq 
instrument showed an average of 88 heterozygous SNPs, 12 inser-
tions and 17 deletions (uncurated for relevance). All of the muta-
tions that were previously found by SNaPshot were also detected 
by Miseq TruSeq and TruSight protocols (100% concordance). 
Variants representing known polymorphisms, synonymous changes 
and variants identified in the context of low coverage were exclu-
ded. Data analysis using locally developed software indicated the 
presence of 1-9 SNPs in each sample that were not predicted by 
SNaPshot testing, attributable to the wider coverage of the Miseq 
platforms. None of the additional mutations represented treatable 
targets with currently available drugs.
Conclusion: Next-generation testing is feasible in a CLIA environ-
ment using the Miseq platform. However, rigorous software vali-
dation is necessary before this platform can be adopted by a busy 
clinical laboratory. Software limitations currently being addressed 
include long turnaround time, inadequate vetting of new and re-
current SNPs for clinical significance and limited software develop-
ment resources.
Keywords: Sequencing, Next Generation, mutations, predictive
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MO01.04 COMPARISON OF MICROARRAY AND RNA 
SEQUENCING PLATFORMS FOR PROFILING MICROR-
NAS IN FORMALIN-FIXED, PARAFFIN-EMBEDDED NON-
SMALL CELL LUNG CANCER SPECIMENS
Daniel Buitrago1, Kyuichi Kadota1, Valerie W. Rusch1, Santosh K. 
Patnaik2, Prasad S. Adusumilli1
1Memorial Sloan-Kettering Cancer Center/United States Of America, 
2Roswell Park Cancer Institute/United States Of America
Background: MicroRNAs are useful biomarkers for various disease 
states, and their preservation in formalin-fixed, paraffin-embedded 
(FFPE) tissue makes them particularly useful for clinicogenetic 
studies. Although global microRNA expression in FFPE samples is 
routinely measured with microarrays, the utility of RNA sequencing 
for such profiling has yet to be established. In this study, to apprai-
se the suitability of RNA sequencing, microRNAs in RNA from lung 
cancer FFPE samples were quantified by both a microarray and a 
sequencing platform.
Methods: The affinity spin column–based Roche High Pure FFPE 
RNA kit was used to extract total RNA from 8 resected stage I 
lung adenocarcinoma FFPE tumor specimens (~3 mm3) with ≥50% 
tumor content. RNA was quantified by RiboGreen fluorometric 
and absorbance spectrometric analysis at 260 nm, and its quality 
was examined by electrophoresis on an RNA Pico chip in an Agi-
lent Bioanalyzer 2100. MicroRNAs in 120 ng of RNA were profiled 
using the 8x60K Agilent Human miRNA Microarray (release 16.0) 
platform. MicroRNAs were also quantified by use of the Illumina 
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Methods: A series of experimental approaches including cell cul-
ture models, in vitro assays, and a study of patient tumor samples 
prior to and at the time of acquired resistance to ALK TKI therapy 
were employed to test the hypothesis that IGF-1R can be targeted 
therapeutically to enhance anti-tumor responses in ALK+ NSCLC.
Results: Across multiple different ALK+ lung cancer cell lines, 
including a novel ALK+ cell line developed from a patient prior 
to ALK TKI therapy, IGF-1R inhibitors (TKIs and MAbs) sensitized 
ALK+ lung cancer cells to the effects of ALK blockade as assessed 
by standard cell viability assays. Similar to IGF-1R, ALK fusions co-
immunoprecipitated with the adaptor protein, IRS-1, and treatment 
with ALK inhibitors decreased IRS-1 protein levels. Furthermore, 
siRNA mediated knock-down of IRS-1 impaired the proliferation of 
ALK+ lung cancer cells and enhanced the anti-tumor effects of ALK 
inhibitors. The IGF-1R pathway was activated in cell culture models 
of ALK TKI resistance, and combined ALK/IGF-1R inhibition in the 
resistant cells blocked reactivation of downstream signaling and 
markedly improved therapeutic efficacy in vitro. Finally, IGF-1R and 
IRS-1 levels were increased in biopsy samples from a patient with 
advanced ALK+ lung cancer post crizotinib therapy.
Conclusion: Collectively, these data support a role for the IGF-1R/
IRS-1 signaling pathway in both the ALK TKI sensitive and ALK TKI 
resistant states and suggest that this rationally selected combina-
tion of inhibitors may be an effective strategy to attempt to delay 
or overcome acquired resistance to therapeutic ALK inhibition. 
Intriguingly, the ‘second generation’ ALK TKI, LDK-378, which has 
demonstrated an overall response rate of 70% in patients with 
both crizotinib naïve and crizotinib resistant ALK+ lung cancer, can 
inhibit both ALK and IGF-1R in vitro. We speculate, based on these 
data, that this surprising response rate may be due to LDK-378’s 
ability to simultaneously inhibit both targets.
Keyword: ALK, IGF-1R, acquired resistance, tyrosine kinase  
inhibitor
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MO01.08 IDENTIFYING STRATEGIES FOR THE TREAT-
MENT OF ACQUIRED EGFR TYROSINE KINASE INHIBI-
TOR RESISTANCE
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ke2, Nick Pavlakis3, Viive Howell1
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Background: The management of non-small cell lung cancer (NS-
CLC) is becoming increasingly personalised with the identification 
of oncogenic drivers of cancer cell growth which are able to be 
targeted therapeutically. The paradigm of advanced non-squa-
mous NSCLC treatment now incorporates assessment of epidermal 
growth factor (EGFR) mutations and treatment with EGFR tyrosine 
kinase inhibitors (TKIs) in cases where sensitising mutations are 
found, which results in significant prolongation of progression-
free survival compared to empirical chemotherapy. However, the 
emergence of acquired resistance to EGFR TKIs is almost universal 
and the two most common mechanisms of resistance include the 
acquisition of a second mutation in EGFR, the T790M mutation, 
combination with 1µM Gefitnib, can result in significantly more 
toxicity to Gefitnib-resistant NSCLC cell line H1975 than either Ge-
fitnib or the compound alone. The EGFR on H1975 contains both a 
TKI-sensitive mutation L858R and a resistant mutation T790M.
Results: The screening identified one candidate compound 
18G06, an experimental natural product that belongs to a family 
of drugs currently used for heart disease. The compound has an 
IC50 of 270nM on H1975, and acts synergistically with Gifitnib to 
affect cell apoptosis, suggesting that the drug can overcome Ge-
fitnib resistance in H1975. Test of 4 other known drugs in this family 
showed that they all have sub-microM IC50 values against H1975, 
but only Drug D had synergistic effect with Gefitnib, while other 
three drugs showed only additive effects. In addition, 18G06 or 
Drug D can overcome Gefitnib resistance of H1650 cells, a resis-
tant NSCLC cell line with TKI-sensitive exon19 microdeletion and a 
TKI-resistant PTEN deletion. However, these two drugs, when used 
alone or with Gefitnib, had little effect on A549 cells, a resistant 
NSCLC line with wildtype EGFR. Biochemical evidence suggested 
that the improved Gefitnib sensitivities of H1975 and H1960 were 
correlated with specific synergistic inhibition of the ERK signa-
ling pathway during combination treatment. Finally, combination 
therapy with Drug D and Gefitnib inhibited the growth of tumors 
formed by inoculated H1975 cells in nude mice to a greater extent 
than did treatment with either drug alone.
Conclusion: We identified two specific members of a family of 
therapeutics for heart disease that, when each combined with 
Gefitinib, have synthetic lethality effect on H1975 and H1960. The 
FDA-approved Drug D can be readily tested in clinical trials with 
Gefitnib to potentially reverse TKI-resistance of EGFR mutation-
positive patients in targeted therapy.
Keywords: drug resistance, ERK, screening, EGFR-TKI
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MO01.07 INHIBITION OF THE IGF-1R SIGNALING PA-
THWAY POTENTIATES RESPONSES TO ALK INHIBITORS 
IN BOTH ALK TKI NAIVE AND ALK TKI RESISTANT LUNG 
CANCER
Christine M. Lovly1, Nerina T. Mcdonald1, Ya-Lun H. Chen2, Hailing 
Jin1, Diana Lim3, Yoshiyuki Suehara3, Lu Wang3, David H. Johnson4, 
Leora Horn1, Marc Ladanyi3, William Pao1
1Dept. Of Medicine/division Of Hematology-Oncology, Vanderbilt 
University/United States Of America, 2Department Of Biostatistics, 
Vanderbilt University/United States Of America, 3Pathology, Memorial 
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Background: Oncogenic fusions involving the gene encoding the 
anaplastic lymphoma kinase (ALK) define a new clinically relevant 
molecular subset of lung cancer. The majority of patients with ALK+ 
lung cancer are highly responsive to ALK tyrosine kinase inhibitor 
(TKI) therapy, however, the efficacy of these ALK inhibitors is limited 
by the development of acquired resistance. Additional strategies 
using rationally selected therapeutic agents/combinations of agents 
are needed to both delay and overcome acquired resistance to ALK 
inhibition. Based upon an intriguing clinical observation from a pati-
ent with ALK+ lung cancer who had an ‘exceptional response’ to an 
IGF-1R monoclonal antibody (MAb), we report a novel therapeutic 
synergism between ALK inhibitors and IGF-1R inhibitors.
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MO01.09 A NOVEL MURINE XENOGRAFT MODEL 
USING SAMPLES OBTAINED BY EBUS-TBNA
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Nhu-An Pham2, Takashi Anayama3, Hironobu Wada3, Kentaro Hi-
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Background: Endobronchial ultrasound-guided transbronchial 
needle aspiration (EBUS-TBNA) is a minimally invasive approach for 
lymph node staging in patients with lung cancer. Although EBUS-
TBNA has been utilized for various molecular testing, intrinsic cha-
racteristics of different lesions produce variability in the amount of 
cellular material that can be obtained. In some samples, the quan-
tity of tumor recovered may be limited for subsequent testing. To 
overcome this problem, we evaluated the feasibility of establishing 
a murine tumor xenograft model using EBUS-TBNA samples for 
advanced translational research.
Methods: After confirmation of adequate sampling for cytopatho-
logical diagnosis during EBUS-TBNA, one additional pass was per-
formed for this study (NCT01487603). The aspirate was stored in 
cell preservative solution (RPMI1640 with 10% FBS) for inoculation 
of the tumor for the xenograft model. The sample was transported 
to the laboratory on ice, then mixed with Matrigel and centrifuged. 
The pellet which contained tumor fragments was implanted to 
the subcutaneous pocket on the right flank of a NSG (NOD scid 
gamma) mouse. Once we confirmed the engraftment of the tumor, 
we passed the tumor to another mouse until 3 passages were 
completed. The success rate of tumor xenograft establishment was 
examined along with histopathology and the cellularity and cyto-
pathologial diagnosis of the primary EBUS-TBNA samples.
Results: From December 2011 to June 2012, 19 patients were 
enrolled in this study. The cytopathological diagnoses were as 
follows; 12 adenocarcinoma, 3 squamous cell carcinoma, 1 large 
cell carcinoma NOS, and 3 small cell carcinomas. 8 out of 19 cases 
(42.1%) showed tumor formation. The mean duration between 
inoculation and tumor formation was 62.38 days (13-144 days). 
All engrafted tumors could be passed to the second mouse. The 
histological types of the engrafted tumors were 3 adenocarcino-
ma (3/12: 25%), 2 squamous cell carcinoma (2/3: 67%), 1 large cell 
carcinoma (1/1: 100%), and 2 small cell carcinomas (2/3: 67%). The 
tumor cellularity of primary EBUS-TBNA samples was sufficient for 
diagnosis and there was no correlation between engraftment and 
the degree of blood/lymphocyte contamination or percentage of 
necrosis.
Conclusion: EBUS-TBNA samples can be used for establishment 
of tumor xenograft model in immunodeficient mice. EBUS-TBNA 
allows minimally invasive sampling of metastatic lymph nodes in 
patients with advanced lung cancer which opens up possibilities 
for translational research. We need to continuously seek better 
ways to improve and standardize procurement and processing of 
samples obtained by minimally invasive techniques in order to op-
timize diagnosis and molecular analysis for improved patient care. 
and c-MET amplification. Approximately one-quarter of cases of 
resistance are yet to be defined mechanistically and furthermore, 
optimal subsequent treatment remains unknown. Further research 
is required to understand the molecular origins of the develop-
ment of acquired resistance in order to develop rational treatment 
strategies that incorporate both targeted and cytotoxic therapies. 
This study is evaluating, using in vitro models, pathways involved 
in the development of acquired resistance to EGFR TKI and che-
motherapy and evaluating critical differences according to EGFR 
mutation status.
Methods: A panel of human NSCLC cell lines with varying clinically 
relevant molecular characteristics is being assessed and used to 
develop resistance to various cytotoxic agents and EGFR TKIs, 
through chronic low dose exposure, as outlined in the table below: 
Cell 
Line Mutation Status
EGFR 
TKI Sen-
sitivity
Resistant Cell Line 
Generated
HCC827
EGFR Exon 19 
deletion
Sensitive
Erlotinib; Cisplatin; 
Paclitaxel; Pemet-
rexed
H1975
EGFR Exon 21 
Point Mutation 
(L858R) and 
T790M mutation
Resistant
Cisplatin; Paclitaxel; 
Pemetrexed
H1299 EGFR Wild-Type Resistant
Cisplatin; Paclitaxel; 
Pemetrexed
A549
EGFR Wild-Type 
and KRAS Muta-
tion
Resistant
Cisplatin; Paclitaxel; 
Pemetrexed, HDAC-
inhibitor
 
Assessments of proliferation, cytotoxicity and key signalling pa-
thways are being conducted to evaluate mechanisms of chemothe-
rapeutic and targeted therapy resistance.
Results: Chronic low dose exposure has been successful in gene-
rating resistant cell lines to both chemotherapeutic agents and the 
EGFR TKI erlotinib. Cross-resistance to taxol in cisplatin-resistant 
cell lines has been observed, along with evidence of epithelial-
to-mesenchymal transition in the development of EGFR TKI resis-
tance. Antibody arrays of key signalling pathways are being con-
ducted to confirm critical pathways of interest.
Conclusion: The panel of human NSCLC cell lines with parental 
lines harbouring various EGFR sensitising and resistance mutations 
and generated lines resistant to cytotoxic agents and EGFR TKI 
are a useful in vitro model to understand key pathways involved in 
the emergence of therapeutic resistance and to understand how 
both sensitising and resistant EGFR mutations influence response 
to cytotoxic agents. This will guide treatment strategies selected 
for evaluation in vivo that may influence future treatment selection 
for patients.
Keywords: EGFR mutations, acquired resistance, EGFR tyrosine 
kinase inhibitors, non-small cell lung cancer
S258 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Keywords: EBUS-TBNA, Lung cancer, xenograft
S259Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
classification and clinical treatments of lung cancers, a multipa-
rametric approach is needed; this should depict a complete and 
integrated cancer network in each cancer patient. Nonetheless, 
reliable preclinical models are required to define the best treat-
ment choices and to overcome the boundaries between basic 
knowledge and the clinical requirements.
Keyword: patient-derived tumorgraft, biorepository, next-genera-
tion sequencing, integrated approach
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MO01.10 INTEGRATED MOLECULAR CHARACTERIZATI-
ON OF PATIENT-DERIVED TUMORGRAFTS AS INNOVA-
TIVE MODEL FOR CLINICAL MANAGEMENT OF NON-
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Background: Lung cancer is the leading cause of death for cancer. 
Although impressive diagnosis and therapeutic achievements have 
been recently obtained, critical issues remain open. It is now belie-
ved that the generation of reliable preclinical models will provide 
the basis for new discoveries and to validate the clinical efficacy of 
known and novel compounds.
Methods: From 2010 to 2013, we have generated a biorepository 
of 190 frozen tumor samples and matched normal lung tissues, 
peripheral blood mononucleate cell collections, serum and plasma 
samples from patients who had undergone surgery with curative 
intentions (stage Ia, Ib, IIa mainly). This data set has been enriched 
with 480 additional archival tumors. The entire library, encompas-
sing all major histotypes [adenocarcinomas (ADC), squamous cell 
carcinoma (SCC) and large cell carcinoma (LCC)], covers the hete-
rogeneous landscape of NSCLC. All tumors were characterized by 
immunohistochemistry (IHC) (TTF1, SPA, MUC5AC, CK5, CDX2, 
VILLIN, p53, p63, p16, ABCA3 and SOX2) and molecular analyses 
(EGFR, KRAS, BRAF and PI3K mutations). Considering that the 
pathogenetic role of many lesions is only in part elucidated, and 
that many lung cancers lack targetable mutations, we generated 
patient-derived tumorgrafts (PDTs), engrafting fresh and/or frozen 
tumor fragments in highly immunocompromised mice (NSG). Suc-
cessfully grown tumors were propagated up to the third generati-
on (T3). Primary versus PDT features were studied by histology, IHC 
and molecular profiling [Single Nucletoide Polimorphism (SNP), 
WES, RNA sequencing (RNAseq)] and HTP proteomic analyses.
Results: A known distribution of mutations within the first 300 
ADCs samples (17% EGFR; 35% KRAS; 2% PI3K; 1% BRAF) was 
observed. 26 PDT lines (9 adenocarcinoma, 14 squamous, 2 sar-
comatoid, 1 mixed) have been propagated, showing that the time 
growth average required from engraftment was significantly longer 
for the ADC-lines than SCC-lines (ADC-lines 20 weeks vs SCC-lines 
11 weeks). We demonstrated the strong correspondence of prima-
ry cancers and PDT tumors, highlighting primary tumor’s specific 
features or biomarkers. The SNP analysis has revealed the occur-
rence of stress engrafment events (i.e. loss of heterozigosity LOH) 
at the first PDT passage; these alterations, once acquired remain 
relatively stable along later passages. Preliminary data from prote-
omic profiling are demonstrating stable Phospho-Tyrosine-Kinase 
profiles in primary tumors compared to PDTs, reinforcing the idea 
that this PDT tumors aren’t drifted so far from primary cancer ar-
chitecture.
Conclusion: To improve bio-molecular stratification, pathological 
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MO02.02 SIZE DECREASE OF GROUND-GLASS NODU-
LES SHOULD NOT BE END OF FOLLOW-UP, BUT MAY BE 
OPTIMAL TIMING OF CURATIVE SURGERY
Hiroyuki Kaneda, Takahito Nakano, Yohei Taniguchi, Tomohito 
Saito, Toshifumi Konobu, Yukihito Saito
Thoracic Cardiovascular Surgery, Kansai Medical University/Japan
Background: As observed in colon carcinogenesis, recent reports 
support an atypical adenomatous hyperplasia (AAH)–adenocar-
cinoma sequence in lung carcinogenesis. Recent accumulating 
experiences based on pathologic–radiologic correlation show 
that most cases of AAH, adenocarcinoma in situ (AIS), minimally 
invasive adenocarcinoma (MIA) and lepidic predominant adenocar-
cinoma can be detected by ground-glass nodules (GGNs)—the 
radiographic appearance of hazy lung opacity not associated with 
obscuration of underlying vessels. In this study, we retrospectively 
reviewed radiological and pathological characteristics of resected 
GGNs that were radiologically observed for at least 12 months 
before surgery, and discuss optimal timing of curative surgery.
Methods: We retrospectively reviewed clinical charts and chest 
computed tomography (CT) of patients on whom pulmonary re-
section was performed between January 2006 and March 2013 at 
the Kansai Medical University Hirakata Hospital. The definitions 
of pure GGNs and part-solid nodules were based on the tumor 
shadow disappearance rate. The histologic classification of ade-
nocarcinoma followed the International Association for the Study 
of Lung Cancer/American Thoracic Society/European Respiratory 
Society classification of lung adenocarcinoma. We evaluated the 
radiologic findings, such as size change of whole tumor and appea-
rance of solid component, and pathological findings. All statistical 
tests were performed with JMP software.
Results: A total of 568 patients underwent pulmonary resection 
during the study periods and 404 cases were adenocarcinoma 
(ADA), including 207 tumors with lepidic growth pattern. Total 32 
GGNs of 31 patients were observed in chest CT before surgery for 
at least 12 months. Mean GGN size before surgery was 18.6 mm 
and mean follow-up period was 25.8 months. Pathological findings 
of 32 tumors were 6 AISs, 4 MIAs, 8 lepidic predominant ADA, 13 
papillary predominant ADA, 1 acinar predominant ADA. On last 
CT before surgery, 15 lesions showed pure GGNs and 17 showed 
part-solid nodules. Thirteen of the 17 tumors showed slight size 
reduction of GGNs during the follow-up, mostly just before or just 
after appearance of solid component inside GGNs.
Conclusion: Some GGNs showed size reduction during the follow-
up with chest CT. Even when mild collapse of the GGNs are ob-
served, you should neither diagnose non-malignant tumors, such 
as inflammatory nodules, nor decide cessation of follow-up. And 
instead, we recommend rather careful follow-up in order to iden-
tify solid component inside the GGNs. If you confirm appearance 
of the solid component, the finding would be a sign of progression 
from AAH/AIS to invasive adenocarcinoma and may be optimal 
timing of pulmonary resection as curative treatment.
Keywords: minimally invasive adenocarcinoma, lepidic predomi-
nant adenocarcinoma, ground-glass nodules, adenocarcinoma in 
situ
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MO02.01 IS LOWER ZONE LYMPH NODE DISSECTION 
ALWAYS MANDATORY IN PATIENTS WITH LOWER LOBE 
LUNG CANCER?
Hiroyasu Ueno, Kenji Suzuki, Aritoshi Hattori, Takeshi Matsuna-
ga, Yukio Tsushima, Kazuya Takamochi, Shiaki Oh
Division Of General Thoracic Surgery, Juntendo University School Of 
Medicine/Japan
Background: The recent UICC-IASLC classification defines lower 
zone lymph node metastasis, i.e., paraesophageal and pulmonary 
ligament lymph nodes metastasis, as p-N2 disease. Due to the 
relatively rare incidence of lower zone nodal involvement, however, 
controversies still surround regarding the clinical characteristics 
and the possible pathway for lower zone lymph node in patients 
with lower lobe lung cancer.
Methods: From 2009 to 2013, 257 consecutive patients underwent 
lobectomy with mediastinal lymph node dissection for lower lobe 
lung cancer. For all patients, thin-section CT scan was reviewed to 
investigate maximum tumor size, location and consolidation status. 
In a current study, radiologically “solid” tumor was defined as a 
tumor which constructed only by consolidation without ground 
glass opacity (GGO) lesions on thin-section CT scan. Several clini-
cal factors were evaluated to identify significant predictive factors 
of lower zone lymph node metastasis using a multivariate analysis.
Results: Twenty (7.8%) patients revealed lower zone lymph node 
metastasis. Twelve were men and 8 were women. Patients ranged 
in age from 33 to 81 y, with an average of 63 y. Among them, tu-
mors distributed especially in Segment (S) 10 (50%). All patients 
showed solid appearance on thin-section CT scan. A univariate 
analysis revealed that tumor location (S 10 or not) and solid tumors 
with more than 30mm in diameter were the significant predictors 
for lower zone lymph node metastasis (p=0.011, 0.033). Based on 
a multivariate analysis, these two factors were also shown to be 
independent predictors for lower zone nodal metastasis in patients 
with lower lobe lung cancer. (p=0.014, 0.034). Furthermore, the 
frequency of lower zone lymph node metastasis was approximately 
24% for patients with solid tumors more than 30mm located in S10. 
On the other hand, lower zone lymph node metastasis was never 
seen in patients with c-T1a-b lower lobe lung cancer with GGO 
component.
Conclusion: Although lower zone lymph node metastasis is in-
cluded in N2 disease, these incidences are extremely rare even in 
patients with lower lobe lung cancer except for those with radiolo-
gically large-sized solid tumor located in S10 field. Thus, selective 
dissection for lower zone lymph node could be an appropriate 
operative strategy in patients with small-sized lower lobe lung 
cancer especially with GGO predominance.
Keywords: lower lobe lung cancer, lower zone lymph node, selec-
tive dissection
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MO02.04 SAFETY AND LONG TERM OUTCOME OF RE-
PEATED LUNG RESECTION FOR IPSILATERAL SECOND 
PRIMARY LUNG CANCER
Masanori Tsuchida1, Ken-Ichi Togashi2, Takehiro Watanabe3, Ta-
kehisa Hashimoto1, Terumoto Koike1, Seijiro Sato1, Toru Shirato1
1Thoracic And Cardiovascular Surgery, Niigata University Graduate 
School Of Medical And Dental Sciences/Japan, 2Thoracic Surgery, Na-
gaoka Red Cross Hospital/Japan, 3Chest Surgery, Nishi-niigata Chuo 
National Hospital/Japan
Background: Repeated lung resection for second primary lung 
cancer is indicated as an effective treatment in properly selected 
patients. Among repeated lung resections, surgery for ipsilateral 
lesion is a challenging modality for thoracic surgeons. We report 
our experience of repeated lung resection, especially focused on 
ipsilateral reoperation after anatomical major lung resection.
Methods: We retrospectively reviewed patients who had under-
gone a second lung resection for ipsilateral second primary lung 
cancer at the 3 institutions between 2000 and 2012. The diagnosis 
of the second primary lung cancer was based on the criteria from 
Martini. Variables analysis included clinical and pathologic data 
including age, sex, c-stage, surgical procedure, p-stage, histolo-
gy, time interval between the two operations, operative findings, 
operative morbidity and mortality, as well as long term outcomes. 
Overall survival was calculated using the Kaplan-Meier method.
Results: There were 52 reoperations in 50 patients. Of the 50 pa-
tients, 35 were male and 15 were female. The median age at the 
time of a second operation was 69.9 years (range 51 to 85). The 
first lung resection was lobectomy in 48 patients and segmentec-
tomy in 2 patients. According to the current TNM classification, p-
stage of the first lung cancer was IA in 20, IB in 24, IIA in 3, IIB in 1, 
IIIA in 1, and IV in 1. The mean value of %vital capacity and forced 
expiratory capacity in one second /forced vital capacity obtained 
before the second surgery was 94.7% and 72.3% respectively. The 
second operation was wedge resection in 28, segmentectomy in 
9, right middle lobectomy in 4, right upper lobectomy after lower 
lobectomy in one, and completion pneumonectomy in 7. The 
mean interval time between the two operations was 64 months 
(range, 15-156 months). During second surgery, vascular injury was 
occurred in 2 patients. Mean volume of blood loss during surgery 
was 354ml (range, 0 to 3440 ml), and blood transfusion was neces-
sary in 6 patients. Intrapericaridial exposure of the main pulmonary 
artery was employed in 9 patients due to dense vascular adhesi-
ons. There was no operative death. (Complications occurred in 9 
patients (prolonged air leakage in 5, empyema in 2, heart failure 
in 1, and delirium in 1). One patient died of pneumonia 5 months 
after the second operation. Therefore morbidity and hospital mor-
tality was 18% and 2%, respectively. Pathological diagnosis of the 
second primary lung cancer was adenocarcinoma in 41, squamous 
cell carcinoma in 9, and sarcoma in 1. P-stage of the second lung 
cancer was IA in 37, IB in 8, IIA in 1, IIB in 2, IIIA in 1, and IV in 1. 
The 5-year overall survival after the second operation was 67 %, 
and more favorable 5-year survival of 77% was observed in p-stage 
IA.
Conclusion: Most second primary lung cancer in this retrospective 
study was treated in p-stage I. Reoperations for a second primary 
lung cancer on the same side of the first surgery shows an accepta-
ble morbidity and mortality rate, and provides favorable survival in 
selected patients with adequate physiologic pulmonary reserve.
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MO02.03 SURGICAL INTERVENTION STRATEGY FOR 
POSTOPERATIVE CHYLOTHORAX AFTER LUNG RESEC-
TION - CLINICAL ANALYSIS OF FIFTY PATIENTS WHO 
DEVELOPED POSTOPERATIVE CHYLOTHORAX
Shinsuke Uchida, Kenji Suzuki, Yoshikazu Miyasaka, Yukio Tsu-
shima, Kazuya Takamochi, Shiaki Oh
General Thoracic Surgery, Juntendo University School Of Medicine/
Japan
Background: Chylothorax is a rare but well-known complication 
of general thoracic surgery. This study evaluated our treatment 
strategy for postoperative chylothorax and identified associated 
predictors.
Methods: We retrospectively reviewed 1235 patients who un-
derwent lung resection and systematic mediastinal lymph node 
dissection for primary lung cancer at our department from Janu-
ary 2008 to September 2012. Postoperative chylothorax patients 
were analyzed. Chylothorax was diagnosed by the milky aspect 
of drainage fluid and confirmed by an elevated triglyceride level 
(>110 mg/dL) in the drainage fluid. We initially treated chylothorax 
patients conservatively with low fat diet (fat intake < 20 g/day). If 
this treatment was judged to be ineffective, we tried to do com-
plete oral intake cessation or surgical intervention. Comparisons 
between conservative and surgical intervention groups were ana-
lyzed using Fisher’s exact test. Univariate and multivariate analysis 
of predictors for surgical intervention was performed using logistic 
regression analysis. Value of p<0.05 were considered statistically 
significant.
Results: Fifty patients (4.0%) developed postoperative chylotho-
rax. There were 35 men and 15 women with a median age of 
63 years (range 33 to 81 years). The operative procedures were 
pneumonectomy in 2 cases, bilobectomy in 5 cases, lobectomy in 
32 cases, segmentectomy in 1 case, and sleeve lobectomy in 10 
cases. Forty-one patients (82%) cured with conservative treatment. 
These patients continued a low fat diet for one month. The remai-
ning 9 patients (8%) underwent surgical intervention at a median 
of 5.5 days after diagnosis (range 3 to 12 days). Postoperative 
chest tube drainage (ml/h) until first oral intake was significantly 
greater in the surgical intervention group than conservative group 
(37.4±15.7 ml/h vs. 24.7±9.7 ml/h; p=0.003). In multivariate analysis, 
postoperative chest tube drainage (ml/h) until first oral intake was 
significant predictor for the chylothorax patient required surgical 
intervention (p=0.012, Hazard Ratio 1.110, 95% Confidence Interval 
1.024-1.205). Four patients (8%) had chest tube drainage excee-
ding 45 ml/h until first oral intake. Among them 3 patients (75%) 
required surgical intervention.
Conclusion: Postoperative chest tube drainage (ml/h) was inde-
pendent predictor for surgical intervention in postoperative chy-
lothorax patients. If postoperative chest tube drainage exceed 45 
ml/h until first oral intake, we should suspect postoperative chy-
lothorax and consider early surgical intervention.
Keywords: Postoperative chest tube drainage (ml/h), postoperati-
ve chylothorax, surgical intervention
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MO02.07 EFFECT OF OBESITY ON PERI-OPERATIVE 
OUTCOMES AFTER ROBOTIC-ASSISTED PULMONARY 
LOBECTOMY: RETROSPECITVE ANALYSIS OF 227 CON-
SECUTIVE PATIENTS
Matthew R. Thau1, Kathryn L. Rodriguez1, Tawee Tanvetyanon2, 
Frank O. Velez-Cubian1, Wei Wei Zhang1, Jacques-Pierre Fontaine2, 
Joseph R. Garrett2, Carla C. Moodie2, Lary A. Robinson2, Eric M. 
Toloza2
1University Of South Florida College Of Medicine/United States Of 
America, 2Thoracic Oncology, Moffitt Cancer Center/United States Of 
America
Background: Attention has increased over the safety and efficacy 
of robotic-assisted surgeries in recent years. With rates of obesity 
on the rise, the impact of excessive body weight on surgical outco-
mes comprises an important concern for administering care. Our 
purpose was to determine the relationship between preoperative 
body mass index (BMI) on perioperative complications following 
robotic-assisted pulmonary lobectomy for at a high-volume tertia-
ry-care referral cancer center.
Methods: We retrospectively studied 227 consecutive patients 
who underwent robotic-assisted pulmonary lobectomy for known 
or suspected lung cancer. BMI was calculated as being equal to 
weight in kilograms divided by height in meters squared. We stra-
tified BMI into 4 groups as defined by the World Health Organiza-
tion (WHO): Underweight (BMI <18 kg/m2), Normal Weight (BMI 
18-25 kg/m2), Overweight (BMI 25.01-30 kg/m2), and Obese (BMI 
>30 kg/m2). Perioperative complications from surgery to discharge 
from the hospital were assessed and included respiratory failure, 
hemothorax, pleural effusion, prolonged air leak, subcutaneous 
emphysema, aspiration, pneumonia, and hypoxia. Hospital length 
of stay and in-Hospital operative mortality were also assessed. 
Of 227 total patients studied, there were 6 Underweight patients, 
87 Normal Weight patients, 71 Overweight patients, and 63 Obe-
se patients. Initially, with the Underweight group omitted due to 
small sample size, comparison of the remaining three BMI groups 
revealed that there were no significant increases in peri-operative 
complication rates, hospital length of stay, or in-Hospital operative 
mortality among the 3 groups, although there were clear trends 
toward increased morbidity and mortality when patients had hig-
her BMI. Therefore, we compared the peri-operative complication 
rates, hospital length of stay, and in-Hospital operative mortality 
between Obese and Non-Obese patients.
Results: The results are shown in the following table: 
Keywords: reoperation, repeated lung resection, ipsilateral se-
cond primary lung cancer
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MO02.06 PREOPERATIVE ORAL REHYDRATION IN PATI-
ENTS UNDERGOING THORACOSCOPIC SURGERY FOR 
LUNG CANCERS
Kunihiko Terauchi1, Junichi Shimada2
1Department Of Chest Surgery, Nara City Hospital/Japan, 2Division Of 
Chest Surgery, Department Of Surgery, Kyoto Prefectural University Of 
Medicine/Japan
Background: Preoperative dehydration often leads to unstable cir-
culation such as perioperative and/or postoperative hypotension. 
Moreover, too much intravenous infusion sometimes causes postope-
rative pulmonary edema in lung resection. In gastrointestinal surgery, 
postoperative management is becoming well established with ‚Enhan-
ced Recovery After Surgery (ERAS)‘ protocols starting 24 hours prior 
to surgery with carbohydrate loading and early oral or enteral feeding 
given to patients the first day following surgery. In this study, we ap-
plied this preoperative oral carbohydrate-loaded rehydration to VATS 
for lung cancers.
Methods: Thirty patients scheduled for afternoon elective surgery 
against lung cancer were enrolled in this study. As an oral rehydration, 
they drank up to 1,000ml of carbohydrate water (Isocal® Arginaid Wa-
ter®; ArgW (Nestle Health Science Company, Japan)): 500ml between 
the night before surgery and the time they woke up the next morning, 
and additional 500ml during the morning until 3 hours before surgery. 
After oral rehydration, we performed lung resection (lobectomy, seg-
mentectomy or wedge resection) with VATS via general anesthesia. 
The patients started oral intake (water or ArgW) 3 hours after surgery. 
We measured perioperative blood pressure (BP) and evaluated their 
hemodynamics.
Results: Of 30 patients enrolled, 9 were received lobectomy, 5 were 
segmentectomy, and others were wedge resection. 
Mean ArgW intake was 479.1ml the night before the surgery and 
462.5ml on the morning of surgery. There was no claim such as thirst 
and hunger before surgery. Duration of surgery was 122.8 ± 43.7 min 
(54 to 192 min in a range) with 21 g of intraoperative blood loss in ave-
rage. Duration of anesthesia was 197.3 ± 42.9 min and it required for 
965.0 ± 323.0 ml of intravenous fluid. The intraoperative volume balan-
ce was +829.5ml in average. The patients’ mean blood pressure (mBP: 
1/3 × systolic BP + 2/3 × diastolic BP) before and after surgery were 
104.9 ± 11.3 mmHg and 99.0 ± 14.0 mmHg, respectively. Perioperative 
hemodynamics was preserved with over 60 mmHg of mBP in most pa-
tients. Peri- and post-operative cardiopulmonary functions were good 
without blood transfusion nor catecholamine support. Postoperative 
cardiac complication was observed in only one case which caused 
atrial fibrillation at postoperative day3. There were no significant diffe-
rences when categorized operating procedures.
Conclusion: Oral rehydration with ArgW before surgery is safe and 
feasible in VATS for lung cancers. With oral rehydration, less than 
1,000ml of intravenous infusion could be suitable for VATS. A shorter 
operation and the fewer amounts of bleeding contribute these results. 
We insist that preoperative oral rehydration for VATS lung resection 
may improve patients’ hemodynamics and reduce their mental stress.
Keywords: ERAS, Lung cancer, VATS
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thoracotomy was needed in two patients (3.3%). In 54 cases, which 
were completed by single-incision VATS, lobectomies were done 
in 50 patients, segmentectomy in 3, and sleeve lobectomy in 1. 
The resected lobes or segments were right upper in 15 patients, 
right middle in 3, right lower in 15, left upper in 10, and left lower 
in 11. In 50 cases, which were completed by a single-incision VATS 
lobectomy for primary lung cancer, the mean duration of the ope-
ration was 148.2 ± 45.29 minutes, and a total number of dissected 
lymph nodes per patient were 21.3 ± 10.08 (range, 5~55). The 
chest tube was removed on postoperative day 4.7 ± 1.8, and there 
was no occurrence of major perioperative morbidity and mortality.
Conclusion: Single-incision VATS lobectomy is applicable in the 
selected cases, and may obtain similar results with the conventio-
nal VATS lobectomy, through a certain period of learning curve.
Keywords: Lung cancer, video-assisted thoracoscopic surgery, 
Single incision
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MO02.09 NEEDLE SCOPIC SURGERY FOR PRIMARY 
LUNG CANCER: REDUCED PORT SURGERY IN THORA-
CIC SURGERY USING FINE SCOPE AND FORCEPS
Michihiko Tajiri, Takahiro Omori, Yoshihiro Ishikawa
General Thoracic Surgery, Kanagawa Cardiovascular And Respiratory 
Center/Japan
Background: If a surgical approach is less invasive than a conven-
tional method and can maintain a sufficient technical level equal to 
a conventional one, it will bring more benefits to patients. We have 
performed thoracoscopic anatomical segmentectomy and lobec-
tomy for primary lung cancer for more than fifteen years. First we 
use and slide a 5mm-diameter scope through three or four ports. 
Then we start the needle scopic surgery (1 port+ 3 punctures 
method) using a 3mm-diameter scope, which we have used since 
September 2012. Now we would like to explain this operative pro-
cedure and effectiveness.
Methods: Patients Forty one patients underwent the needle 
scopic anatomical segmentectomy and lobectomy of the lung 
between September 2012 to May 2013. They had clinical stage IA 
or IB lung cancer. We compared the operation time, blood loss 
volume, post-operative creatinine phosphokinase (CK) and other 
peri-operative parameters of this method with those of the con-
ventional method using a 5mm-diameter scope which were perfor-
med on 73 patients from January 2012 to August 2012. Operative 
procedure 1. We make a 2.5 to 3 cm length skin incision on the 4th 
or 6th intercostal space of the chest trunk and set the polyuretha-
ne-made retractor. We use it as the main port. 2. We puncture the 
skin with three 3mm-diameter trocars. Then we insert and slide a 
3mm-diameter scope and fine forceps through them. We observe 
thoracic lumen and perform various manipulations using them. 3. 
Endostaplers, energy devices and electric cautery of which dia-
meters are larger than 3mm go into the thoracic lumen through 
the main port. 4. Finally we set the chest tube within the main port 
incision at the end of surgery.
Results: We performed 8 segmentectomies and 33 lobectomies of 
the lung using this method in forty-one cases for the lung cancer. 
We dissected mediastinal nodes in all cases. We had no cases that 
were converted to the conventional method. However we elonga-
Surgical Complication 
Non-Obese 
BMI ≤30 
Obese 
BMI >30 
P-value 
N=162, n 
(%) 
N=65, n 
(%) 
Hypoxia or Respiratory 
failure 
6 (3.7) 7 (10.8) 0.04* 
Hemothorax 3 (1.9) 2 (3.1) 0.57 
Effusion or Empyema 2 (1.2) 2 (3.1) 0.34 
Prolonged air leak 30 (18.5) 5 (7.7) 0.04* 
Subcutaneous emphy-
sema 
6 (3.7) 2 (3.1) 0.82 
Aspiration 4 (2.5) 2 (3.1) 0.79 
Pneumonia 17 (10.5) 8 (12.3) 0.69 
In-Hospital Operative 
Mortality 
2 (1.2) 2 (3.1) 0.34 
Median Length of Stay 
(days+SEM) 
5 + 0.3 4 + 0.6 0.54 
 
*statistically significant, p<0.05
Conclusion: Our study shows that obesity increases the risk of 
peri-operative hypoxia or respiratory failure but results in a lower 
risk of prolonged air leak after robotic-assisted pulmonary lobecto-
my. However, we found no significant difference in hospital length 
of stay or in-Hospital mortality between obese and non-obese 
patients. Thus, our study suggests that robotic-assisted pulmonary 
lobectomy is feasible and safe in obese patients.
Keywords: obesity, Robotic, lobectomy, Body mass index (BMI)
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MO02.08 THE FEASIBILITY OF SINGLE-INCISION VIDEO-
ASSISTED THORACOSCOPIC SURGERY IN MAJOR PUL-
MONARY RESECTION
Hyun Koo Kim1, Kyung H. Kang2, Young H. Choi1
1Thoracic And Cardiovascular Surgery, College Of Medicine, Korea 
University Guro Hospital/Korea, 2Division Of Pulmonary, Allergy And 
Critical Care Medicine, Department Of Internal Medicine, Korea Univer-
sity Guro Hospital/Korea
Background: We performed video-assisted thoracoscopic (VATS) 
lobectomy with one incision for the treatment of malignant or be-
nign lung diseases, and have evaluated the feasibility and safety of 
this procedure.
Methods: Consecutive patients who underwent major pulmonary 
resection through VATS, using one incision from March 2012 to 
May 2013 were included in this study. The incision was placed at 
the 5th intercostal space in the mid-axillary line, approximately 3~5 
cm long.
Results: A total of 60 patients (male 39, female 21; mean age 60.2 
± 12.53 years old, range 21~83) were included in this study. The 
preoperative diagnosis was malignant lung disease in 56 patients 
(93.3%) and benign lung disease in 4 patients (6.7%). Four patients 
(6.7%) needed a second port during surgery and conversion to 
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adenocarcinoma in 2 patients, pulmonary metastases in 11 pati-
ents, an atypical adenomatous hyperplasia in 1 patient, a hamarto-
ma in 1 patient and a nontuberculous mycobacteriosis in 1 patient. 
One case of a bronchiolo-alveolar adenocarcinoma with an exten-
sive two segments was performed a curative segmentectomy.
Conclusion: In this study, CT-guided transbronchial metallic coil 
marking with an ultrathin bronchoscope with a coin on a patient’s 
chest wall after CT-assisted stimulation was found to be feasible 
and safe. In our previous report, CT had been needed at least 
three times, but this method needed only twice CT scan. It might 
be a useful method not only for making a diagnosis but also for 
therapeutic resection in selected early lung cancers.
Keywords: VATS, coil marking, CT assisted, coin
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MO02.11 VIDEO-ASSISTED THORACIC SURGERY, HYB-
RID, VERSUS OPEN THORACOTOMY FOR STAGE I NON-
SMALL CELL LUNG CANCER - A PROPENSITY SCORE 
ANALYSIS BASED ON A MULTI-INSTITUTIONAL  
REGISTRY
Jianxing He1, Christopher Cao2, Tristan D. Yan3, Qun Wang4, Ge-
ning Jiang5, Wenlong Shao1, Lunxu Liu6, Deruo Liu7, Zheng Wang8, 
Zhi-Hua Zhu9, Qian Zhao1, Daoyuan Wang1
1The First Affiliated Hospital Of Guangzhou Medical College/China, 
2Cardiothoracic Surgery, St. George Hospital/Australia, 3Systematic 
Reviews Unit, Collaborative Research Group/Australia, 4Zhongshan 
Hospital Fudan University/China, 5Department Of Thoracic Surgery, 
Shanghai Pulmonary Hospital/China, 6Department Of Thoracic Surge-
ry, West China Hospital, Sichuan University/China, 7General Thoracic 
Surgery, China-japan Friendship Hospital/China, 8Shenzhen People‘s 
Hospital/China, 9Cancer Center Of Sun Yat-Sen University/China
Background: We conducted a multi-Institutional study comparing 
VATS lobectomy to Hybrid, and conventional open lobectomy for 
unmatched and propensity score-matched patients with stage I 
NSCLC in an attempt to stratify any potential differences in peri-
operative outcomes and long-term survival outcomes among the 
three procedures in patients with stage I NSCLC on a homogene-
ous well-balanced large population from multi-Institutions.
Methods: Between January 2001 and December 2008 in eight 
institutions from the People’s Republic of China, a total of 2485 
patients with stage I NSCLC who underwent lobectomy via c-VATS, 
Hybrid, or open thoracotomy were entered into the current multi-
Institutional registry. One thousand and fifty-six patients (42.5%) 
underwent c-VATS lobectomy, 273 patients (11.0%) underwent 
Hybrid lobectomy, and 1156 patients (46.5%) underwent open 
lobectomy. Of the patients who attempted to undergo c-VATS 
lobectomy, 65 were converted to assisted-VATS and 49 patients 
were converted to open lobectomy.
Results: After propensity-matching, c-VATS, Hybrid, and open 
lobectomy patients were similar in regards to age, gender, his-
tological type and pathological TNM staging. Median operative 
time was 156.16±17.08 min in open lobectomy group, higher than 
in c-VATS lobectomy group (145.39±13.1 min) and Hybrid lobec-
tomy group (148.86±11.62) before matching (P<0.001), after mat-
ching, it was 154.5±16.89 min, 145.41±12.17 min, and 148.81±11.63 
min in open, c-VATS, and Hybrid lobectomy group, respectively 
ted the incision of one puncture from 3 mm to 10mm in three ca-
ses in order to insert endostaplers for dissecting pulmonary veins 
and arteries. Mean operation time was 219±49 minutes. Mean 
blood loss volume was 20.5±28.4 ml. They were not significantly 
different from those of the conventional method. Post-operative 
peak titers of CK of this method were significantly lower than that 
of the conventional method. We had no severe intraoperative acci-
dents or postoperative complications. All patients were smoothly 
discharged.
Conclusion: We were able to successfully perform the needle sco-
pic surgery for lung cancer as well as conventional thoracoscopic 
surgery. Though some surgeons have tried the single port method 
for thoracic surgery as another less invasive surgery, we think 
the needle scopic method is more suitable for thoracic surgery. 
Because thoracic surgery needs observations and manipulations 
which are in the wider range of the inner space than that of the 
abdomen. This method would be the optimal and optional method 
if we appropriately select cases.
Keywords: needle scope, VATS, Lung cancer, minimum invasive 
surgery
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MO02.10 FLUOROSCOPY-ASSISTED THORACOSCOPIC 
RESECTION OF PULMONARY NODULES AFTER COMPU-
TED TOMOGRAPHY-ASSISTED BRONCHOSCOPIC ME-
TALLIC COIL MARKING
Takanori Miyoshi, Mariko Aoyama, Seiya Inoue, Naoki Hino, 
Masaru Tsuyuguchi
Department Of Surgery, Tokushima Municipal Hospital/Japan
Background: With advances in computed tomography (CT), small 
pulmonary lesions previously unseen on chest radiographs are 
being increasingly detected. Among lesions less than 10 mm in 
size, a considerable number of malignancies have been reported. 
To localize small and deeply situated pulmonary nodules during 
thoracoscopy with roentgenographic fluoroscopy, we developed a 
marking procedure that uses a metallic coil and a coin.
Methods: Thirty-two patients underwent video-assisted thoraco-
scopic surgery for removal of 33 pulmonary lesions. Fluoroscopy-
assisted thoracoscopic surgery after CT-assisted bronchoscopic 
metallic coil marking was performed using an ultrathin broncho-
scope under fluoroscopy viewing a coin on a patient’s chest wall. 
The coin was simulated a pulmonary lesion by the CT findings, and 
it was put on the patient‘s chest wall. During thoracoscopy, a C-
arm-shaped roentgenographic fluoroscope was used to detect the 
radiopaque nodules. The nodule with coil markings was grasped 
with forceps and resected in partial resection or segmentectomy 
under fluoroscopic and thoracoscopic guidance.
Results: The marking procedure took 10 to 49 minutes from inser-
tion to removal of the bronchoscope. There were no complications 
from the marking, and all 33 nodules were easily localized by me-
ans of thoracoscopy. The metallic coil showed the nodules on the 
fluoroscopic monitor, which aided in nodule manipulation. Nodules 
were completely resected under thoracoscopic guidance, in partial 
resection in 19 cases, in segmentectomy in 9 cases and lobectomy 
after partial resection in 4 cases. The pathologic diagnosis was pri-
mary adenocarcinoma in 16 patients, primary lung cancer except 
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Background: Thymic epithelial tumor, consisting of thymoma, 
thymic carcinoma and thymic neuroendocrine carcinoma, is a rela-
tively rare neoplasm, and there is not a satisfying consensus in the 
treatment strategy. Because of lack of TNM staging system and 
global consensus on pathological classification, global research 
in these research has been difficult. To participate in movement 
of establishing the global database, Japanese Association for re-
search of the Thymus (JART) conducted the project of Japanese 
nation-wide database in 2012.
Methods: Patients undergoing surgical treatment during 20 years 
between 1991 and 2010 in Japan were collected from 32 institutes. 
3182 patients were first enrolled, but after exclusion of cases with 
insufficient information, 3033 cases remained for analysis finally.
Results: 1435 patients (44%) were male, and 1595 were female (not 
identified in 3 patients). The age at operation was 13 to 88 years 
(mean 57 years old).
 
Pathological diagnosis was thymoma in 2505 patients (Type A: 
203, Type AB: 710, Type B1: 599, Type B2: 669, Type B3: 329), 
thymic carcinoma in 381 patients (Squamous cell carcinoma: 223, 
neuroendocrine carcinomas 66), and unclassified or unknown in 
147 patients.
 
According to Masaoka staging system, 1063 patients were in stage 
I, 1084 were in stage II, 477 in stage III, 197 in stage IVA, 57 in sta-
ge IVB (undetermined in 155 patients).
 
Complete resection was achieved in 2753 patients (92%), subtotal 
resection (mass reduction of more than 80%) in 157 patients (5%), 
partial resection including biopsy in 86 patients (unknown in 37 
patients).
 
(P<0.001). Transfusion occurred in 4 (12.9%) patients in c-VATS 
group and 6 (19.4%) patients in Hybrid group, both of them lower 
than in open lobectomy group of 21 (67.7%) patients (P=0.003). 
However, after matching, there was no statistical difference among 
three groups, 5 (41.7%) patients, 1 (8.3%) patients, and 6 (50.0%) 
patients in open, c-VATS, and Hybrid group, respectively (P=0.112). 
After selecting the propensity-matched patients, the 5-year survi-
val of 78%, 74% and 76% in patients who underwent c-VATS, Hyb-
rid, and open lobectomy, respectively. The perioperative mortality 
rate was 1.1% for the open group, 1.0% for the Hybrid group, and 
0.8% for the VATS group. Two prognostic factors were indepen-
dently associated with improved survival outcome in multivariate 
analysis: age < 60 (p = 0.01) and smoking history (p = 0.012). When 
comparing the three propensity-matched populations, patients 
who underwent c-VATS lobectomy had similar long-term survival 
outcomes to patients who underwent Hybrid or conventional tho-
racotomy (p = 0.770).
Conclusion: The present multi-Institutional study represents the 
largest dataset evaluating surgical outcomes of patients who un-
derwent c-VATS or Hybrid for NSCLC. VATS lobectomy for NSCLC 
was not associated with inferior long-term survival compared to 
Hybrid or conventional thoracotomy.
Keywords: Thoracotomy, Lung cancer, VATS, hybrid VATS
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Background: Stage III thymoma has a variety characteristics in 
terms of involved organs, complex surgery and multimodal strate-
gy, and a careful consideration is required in choices of treatments. 
Recently the Japanese Association for Research on the Thymus 
(JART) conducted a nationwide large cohort analysis for thymic 
epithelial tumors. The aim of this study is to clarify clinical charac-
teristics and therapeutic outcome of patients who underwent sur-
gical resection for stage III thymoma using this database.
Methods: Clinical data of 3,033 thymic epithelial tumor patients of 
1991 to 2010 were collected rom 32 Japanese institutes. Medical 
information registered included patients’ characteristics, types of 
surgery, pathological diagnosis, perioperative therapy, and clinical 
outcomes were registered. In this study, stage III thymoma patients 
who underwent surgery were extracted from the database, and 
retrospectively analyzed for clinical characteristics and surgical 
outcome.
Results: A total of 340 records of patients were analyzed in 
this study, which comprised 186 males (54.7%) and 153 females 
(45.0%), 83 (24.4%) with myasthenia gravis, 42 (12.4%) with induc-
tion chemotherapy, 18 (5.3%) with preoperative radiotherapy, and 
29 (8.5%) with adjuvant chemotherapies. WHO histologic types 
comprised 16 A (4.7%), 40 AB (11.8%), 47 B1 (13.8%), 118 B2 (34.7%) 
and 97 B3 (28.5%). Involved organs were lung in 209 (61.4%), pe-
ricardium in 167 (49.1%), chest wall in 7 (2.1%), phrenic nerve in 88 
(25.9%) and great vessels in 134 (39.4%). Completeness of resec-
tion was R0 in 268 (78.8%), R1 in 35 (10.3%) and R2 in 20 (5.9%). 
Complications were observed in 85 (25.0%) including arterial 
fibrillation, phrenic nerve palsy, bleeding and crisis of myasthenia 
gravis, and 30-day mortality rate was 1.8% (6 cases). Tumor recur-
rence was experienced in 96 (28.2%), and 39 (11.5%) died during 
the observation. Overall and disease-free 10-year survival rates 
were 81.0% and 56.7%, respectively. Involved organs except for 
chest wall, completeness of resection or myasthenia gravis did not 
affect the survivals. Number of involved organs (1 vs. >2) and tu-
mor length (<7cm vs. >7cm) affected disease-free survival but not 
overall survival. Among factors suggested to affect overall survival 
by univariate analyses such as male, surgical complication, WHO 
histologic type B1-3, chest wall invasion, induction treatments, 
and recurrence, independent adverse predictors were revealed by 
a multivariate analysis to be male (p=0.031, HR=2.47), induction 
chemotherapy (p=0.034, HR=2.39), postoperative complication 
(p=0.018, HR=2.41) and recurrence of disease (p=0.041, HR=2.15). 
Of 96 patients with recurrence, 47 patients who underwent salvage 
resection showed better prognosis than 49 patients who did not 
(p=0.009).
Conclusion: This nationwide registry study exhibited favorable sur-
gical outcome in Japanese patients with stage III thymoma. Effec-
tiveness of multimodal treatments need to be further investigated 
in prospective controlled trials.
Keywords: Nationwide database, Masaoka stage III thymoma, 
surgery, Prognosis
249 patients were alive with tumor. 316 patients were dead during 
the observation period, and 161 patients died from tumor. Among 
2557 patients who underwent complete resection (R0), 269 pati-
ents (10.5%) had tumor recurrence.
 
In the patients who underwent complete or subtotal resection, 10-
year overall survival rate was 89% in thymoma, 56% in squamous 
cell carcinoma, 30% in non-squamous thymic carcinoma, 72% in 
well-differentiated neuroendocrine carcinoma and 29% in poorly-
differentiated neuroendocrine carcinoma. According to Masaoka 
stage, 10-year overall survival rate was 94% in stage I, 93% in stage 
II, 74% in stage III, 59% in stage IVA and 44% in stage IVB.
 
In thymoma patients who underwent complete resection, recur-
rence-free survival rate at 10 years was 96% in type A, 99% in 
type AB, 92% in type B1, 80% in type B2, 72% in type B3. By Cox’ 
proportional hazard model, involvement of the mediastinal pleura 
(p=0.01), involvement of the lung (p=0.01), pleural dissemination 
(p=0.0009), distant metastasis (p=0.01) and WHO histological sub-
type (p<0.0001) were found to be independent factors for tumor 
recurrence after complete resection, while nodal metastasis, intra-
pericardial dissemination, involvement of pericardium, pulmonary 
artery, SVC, brachiocephalic vein, aorta, or brachiocephalic artery 
were not. 
Conclusion: Japanese nation-wide database revealed the onco-
logical difference among thymoma, thymic carcinoma and thymic 
neuroendocrine carcinoma. In thymoma, involvement of pleura and 
lung, pleural dissemination, distant metastasis and WHO histologi-
cal classification were significant factors of tumor recurrence. The-
se results are supposed to contribute to clinical practice for tumor 
treatment as well as establishment of global TNM classification.
Keywords: thymic carcinoid, thymic neuroendocrine carcinoma, 
thymoma, Thymic carcinoma
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Background: Thymic epithelial tumors sometimes metastasize to 
lymph nodes (LNs). The frequency of lymph node metastasis, the 
pattern of node metastasis and the relationship between progno-
sis and node metastasis are still unclear.
Methods: We registered patients with thymic epithelial tumors 
who had undergone resection between 1991 and 2010 from 29 in-
stitutes in Japan by the Japanese Association for Research on the 
Thymus (JART). We investigated the collected data according to 
the site of lymphatic metastasis. Yamakawa-Masaoka‘s paper (Can-
cer 1991;68:1984–7.) tentatively classified the N factor to 3 groups: 
metastasis to anterior mediastinal lymph nodes around the thymus 
were defined as N1, metastasis to intrathoracic lymph nodes other 
than anterior mediastinal lymph nodes as N2, and metastasis to 
extrathoracic lymph nodes as N3.
Results: The rate of lymphatic metastasis in thymoma was 1.75% 
(44 cases of 2508). Most of metastatic nodes were located in an-
terior mediastinal lymph nodes (N1, 78%). There is a significant 
difference of overall survival between thymomas with LN metas-
tasis and those without LN metastasis (p<0.0001, 10-year survival: 
89.8% vs 63.6%). Thymomas with N1 metastasis showed a good 
prognosis than those with other node metastasis, although there 
is no significant relationship (5-year survival: 64.4% vs 52.5%). The 
rate of lymphatic metastasis in thymic carcinoma including thymic 
carcinoid was 22% (84 cases of 380). Most of metastatic nodes 
were located in anterior mediastinal lymph nodes (N1, 69%). The-
re is a significant difference of overall survival between thymic 
carcinomas with LN metastasis and those without LN metastasis 
(p<0.0001, 10-year survival: 59.5% vs 18.4%). Thymic carcimomas 
with N1 metastasis showed good prognosis than those with other 
node metastases, although there was no significant relationship 
(5-year survival: 55.5% vs 27.5%).
Conclusion: The rate of lymphatic metastasis in thymoma and 
thymic carcinoma was 1.75% and 22%, respectively. Both tumors 
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Background: RYTHMIC (Réseau tumeurs THYMiques et Cancer) is 
a nationwide network for thymic malignancies, which was appoin-
ted in 2012 by the French National Cancer Institute, as part of its 
rare cancer program. The objectives of the network include a ter-
ritorial coverage by regional expert centers, the dissemination of 
highest standards for the diagnostic and therapeutic management 
of patients, and the promotion of collaborative research. Registra-
tion in RYTHMIC of all patients diagnosed with thymic malignancy 
is recommended as part of good clinical practice for oncologists.
Methods: Starting January 2012, the management of all patients 
diagnosed with thymic malignancy in France has been discussed 
on a real-time basis at a reference national multidisciplinary tumor 
board (MTB), which is organized twice a month using a web-based 
conferencing system. Decision-making is based on consensual 
recommendations, that were originally established using availa-
ble evidence, and are updated and approved each year by all 
members of the network. A prospective database of all patients is 
hosted by the French Thoracic Cancer Intergroup. We report the 
characteristics and treatment modalities of patients included du-
ring the first year.
Results: From January to December 2012, 257 patients were 
enrolled in RYTHMIC. There were 126 (49%) men and 131 (51%) 
women; mean age at diagnosis was 54.5 years. Among 214 ca-
ses, histology was thymoma for 146 (56%) patients (11 (5%) type 
A, 28 (13%) type AB, 22 (10%) type B1, 35 (16%) type B2, 24 (11%) 
type B3, 26 (12%) mixed type), and thymic carcinoma for 33 (15%) 
patients, 8 of which were neuroendocrine carcinomas; other his-
tologies were diagnosed for 35 (16%) patients. Among 144 cases, 
Masaoka-Koga stage was I, IIA, IIB, III, IVA, and IVB in 34 (24%), 19 
(13%), 20 (14%), 22 (15%), 35 (24%), and 14 (10%) patients, respec-
tively. 44 (17%) patients presented with autoimmune disorder, con-
sisting of myasthenia gravis in 28 cases. Surgery was performed for 
166 patients, mostly using a median sternotomy approach (52% of 
cases). Postoperative radiotherapy was delivered to 42 patients; 
71 patients received perioperative chemotherapy. Exclusive che-
motherapy/radiotherapy was administered to 20 and 4 patients, 
respectively. Mature data will be presented at the meeting.
Conclusion: This first analysis of the RYTHMIC prospective cohort 
demonstrates the feasibility of a national MTB for thymic malignan-
cies, that, besides ensuring all patients an equal access to highly 
specialized treatment, provides with a comprehensive tool to mo-
nitor dedicated actions to improve the management of patients 
in the future, increase the quality-of-care, and screen patients for 
future translational research and clinical trials. Supported by Insti-
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rs10873142T/C, ERCC1 rs11615A (p<0.05).
Conclusion: To the best of our knowledge this is the largest mono-
centric study analyzing the angiogenetic variants in thymic tumors 
representing a further asset in the definition of high-risk patients 
after curative resection. The selection tool deriving from this analy-
sis may allow an optimal use of innovative treatment strategies in-
cluding targeted agents such as sunitinib, sorafenib or pazopanib.
Keywords: thymic malignancies, Polymorphisms, VEGFR
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Background: There are no standard treatments for patients with 
advanced thymic epithelial tumors (TET) in whom chemotherapy 
has failed. A subset of TETs over-express and harbor activating 
mutations of KIT. Moreover, expression of angiogenic markers 
correlate with invasiveness of TETs. This two-center phase II study 
was conducted to evaluate efficacy of sunitinib, a multi-targeted 
tyrosine kinase inhibitor that blocks angiogenic and other growth 
factors in TETs.
Methods: Patients with TET who had progressive disease fol-
lowing at least one platinum-based chemotherapy were enrolled. 
Sunitinib was administered orally at 50 mg once daily in 6 week 
cycles for 4 weeks followed by 2 weeks off until disease progressi-
on. Tumor response was assessed by computed tomography scans 
every 6 weeks. KIT mutations were assessed in archival tissue. 
Primary end-point was objective response rate in parallel cohorts 
(thymoma, thymic carcinoma).
Results: Between May 2012 and June 2013, 22 patients with thy-
mic carcinoma [median age 58 (40-81); males 59%] and 16 with 
thymoma [median age 54 (31-74); males 44%] enrolled. Median of 4 
(range, 1-7) and 3 (range, 1-8) cycles were administered in patients 
with thymic carcinoma and thymoma respectively. Among 19 eva-
luable patients with thymic carcinoma, there were three partial res-
ponses (16%) and 10 minor responses (50%) (Figure). Thirteen pati-
ents had stable disease (68%) and three progressive disease (16%). 
After median follow up of 7.8 months, the median progression-free 
survival was 6.2 months and 6-month survival probability 85%. In 
contrast, only one out of 16 patients with thymoma had a partial 
response (6%). Twelve patients had stable disease (75%) and three 
progressive disease (19%). After median follow up of 6.4 months, 
median progression-free survival was 5.5 months and 6-month 
survival probability 90.9%. Grade 3 or 4 sunitinib-related adverse 
events which occurred in >10% of patients included neutropenia 
(18%), thrombocytopenia (23%), leucopenia (18%), lymphopenia 
(45%), fatigue (36%), mucositis (32%) and hypertension (18%). Three 
patients (14%) has symptomatic decline in left ventricular ejection 
fraction which improved with medical management and discon-
frequently metastasized to the anterior mediastinal nodes. There 
was a significant difference of overall survival between tumors with 
LN metastasis and without LN metastasis in both tumors. And both 
tumors with N1 metastasis showed good prognoses than those 
with other node metastases, although there was no significant 
relationship. We think that it may be reasonable to consider the 
anterior mediastinal lymph node group (N1) to be a primary lymph 
node of thymic epithelial tumor.
Keywords: N factor, Thymus, Thymic epithelial tumors, LN  
metastasis
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Background: Thymomas are uncommon tumors of thymic epi-
thelial cells. Thymomas display significant heterogeneity from 
morphologic point of view, clinical behaviour, expression of immu-
nohistochemical markers and molecular profiling. Improving our 
understanding of the molecular biology of thymic malignancies 
represents a key challenge in the treatment of these rare tumors.
Methods: The genomic DNA of 57 consecutive patients (31 fe-
males and 26 males; 43 thymomas and 14 thymic carcinomas) 
submitted to total thymectomy at our Institution was extracted 
from paraffin-embedded tissue. We selected polymorphisms in 
the following genes: Hypoxia Inducible Factor-1 alpha (HIF1a: 
rs2057482T>C, rs1951795A>C, rs2301113C>A, rs10873142C>T, 
rs11158358G>C, rs12434438G>A, rs11549465C>T, rs11549467G>A), 
Vascular Endothelial Growth Factor-A (VEGF-A: rs2010963G>C, 
rs699947A>C), VEGF Receptor 2 (VEGFR-2: rs2305948C>T, 
rs1870377T>A), VEGFR-3 (rs307826T>C, rs307821C>A), Platelet-
Derived Growth Factor-A (PDGFR-A: rs35597368C>T) and Excision 
Repair Cross-Complementing 1 (ERCC1: rs11615A>G). Gene po-
lymorphisms were determined by Real-Time PCR using TaqMan 
assays.
Results: The allele frequency of PDGFR-A rs35597368 T (95.24%) 
was significantly higher than general population (86%, p=0.012), 
while the frequency of alleles HIF1-A rs2057482C (76.98%), 
rs1951795C (68.25%), rs2301113A (68.55%), rs10873142T (68.85%), 
rs11158358C (74.6%), rs12434438A (65.87%), rs11549465C (83.33%) 
were significantly lower than those of the control group (90%, 
87%, 82%, 87%, 86%, 84%, 92%, respectively, p<0.01). VEGFR-3 
rs307821C was significantly higher in thymomas vs. thymic car-
cinomas (79.5% vs 72%, p=0.0371). The following factors were 
significantly correlated with a better overall survival: VEGFR-3 
rs307826C, VEGFR-2 rs1870377A, PDGFR-A rs35597368T/C, HI-
F1a rs2301113C, rs2057482C/T, rs1951795C, rs11158358G/C and 
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scored as negative (0), focal positive (1+), or strong positive (2+) by 
a Stanford pathologist, who was blinded to the clinical data. Gal-1 
expression was averaged for each patient sample. Statistical ana-
lysis was performed using SAS Enterprise Guide v5.0 (Cary, NC). 
Non-parametric statistical analyses were used to compare average 
patient gal-1 expression between thymic tumors and benign thy-
mic controls. Stable gal-1 knockdown was achieved in IU-TAB1, a 
human thymoma WHO type AB cell line, using the pLKo.1 vector 
with gal-1 shRNA (Open Biosystems). Lentivirus was produced 
using the Trans-Lentiviral Packaging System (Thermo Scientific). In 
vitro proliferation cell counts were performed by hemocytometer. 
After hypoxia exposure (0.5% O2), apoptotic cells were labeled 
using the APO-Direct kit and quantified by flow cytometry (BD 
Biosciences).
Results: Demographics for 68 patients: M:F (53%/47%), Mean age 
at diagnosis: 55 years, WHO Histology: A (10%), B (57%), AB (24%), 
C (4%), unclassified (4%), Pathologic Maseoka Stage: I (46%), IIa 
(18%), IIb (4%), III (18%), IVa (9%) IVb (6%). Gal-1 expression was 
increased among thymic tumor tissue compared to unpaired con-
trols (mean avg gal-1 expression 1.5 vs. 0.125, p=0.0012, Kruskal-
Wallis test). Logistic regression of tumor vs. control thymus by gal-
1 generated a C-statistic of 0.845. A significant increase in gal-1 
expression was noted across all WHO thymoma subtypes except 
thymic carcinoma (type C) (p < 0.05, non-parametric ANOVA with 
post-hoc ranked Dunnett’s t-test). Among 11 thymic tumors analy-
zed with paired adjacent resected benign thymus tissue from the 
same patient, a significant increase was noted in gal-1 expression 
among tumor compared with adjacent resected normal benign 
thymus (mean avg gal-1 1.82 vs. 0.35, p=0.004, sign-rank test). In 
vitro, gal-1 knockdown did not affect IU-TAB1 proliferation. Preli-
minary results showed gal-1 knockdown increased apoptosis under 
hypoxia compared to scramble control.
Conclusion: Gal1 expression was increased among thymoma com-
pared with benign thymus controls and paired adjacent resected 
benign thymus. A robust C-statistic of 0.845 indicates that gal-1 
expression may discriminate tumor from benign thymus. Increased 
gal-1 expression was conserved across WHO histologic subtype 
except for thymic carcinoma—whose analysis was limited due 
to small sample size. Gal-1 knockdown might increase apoptosis 
under hypoxia. We are continuing to investigate the biologic and 
clinical significance of increased gal-1 expression in thymoma.
Keywords: thymoma, immune marker, knockdown, tissue  
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tinuation of sunitinib. KIT mutations were absent in tumors of 20 
patients who underwent mutational analysis.
Conclusion: In this phase II trial, sunitinib demonstrated anti-tumor 
activity unprecedented for a targeted agent in previously treated 
patients with thymic carcinoma. Activity was modest in thymoma. 
These results are intriguing as response rates of thymic carcinomas 
are usually lower than that for thymomas. KIT mutations did not 
predict responses. Ongoing exploratory analyses are evaluating 
biologic determinants of activity and mechanisms of resistance.
Keywords: thymoma, Thymic carcinoma, Sunitinib, anti-angioge-
nesis
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MO03.08 INCREASED GALECTIN-1 EXPRESSION IN 
A THYMIC EPITHELIAL TUMOR TISSUE MICROARRAY 
(TMA) AND GALECTIN-1 KNOCKDOWN STUDIES IN A 
THYMOMA CELL LINE
Jonathan W. Riess1, Peiwen Kuo2, Christina Kong3, Heather A. Wa-
kelee1, Robert West3, Quynh Le2
1Medicine, Division Of Oncology, Stanford University School Of Medi-
cine/United States Of America, 2Radiation Oncology, Stanford Cancer 
Institute/United States Of America, 3Pathology, Stanford University 
School Of Medicine/United States Of America
Background: Thymoma is a rare malignancy with a paucity of 
data on biology. Thymic epithelial tumors are often admixed with 
developing T-lymphocytes in the microenvironment. Galectin-1 
(gal-1) is a beta-galactosidase binding protein involved in T-cell 
development via thymic stromal and thymocyte interaction as well 
as thymocyte development through negative selection. Gal-1 also 
induces apoptosis of effector T-lymphocytes, promotes angioge-
nesis, and is a poor prognostic indicator when overexpressed in 
several tumor types. To our knowledge expression of gal-1 has not 
been examined in thymic epithelial tumors.
Methods: A TMA was constructed from 68 patients with thymic 
malignancies and 8 benign thymic controls at Stanford University 
School of Medicine (Stanford, CA). Immunohistochemical stains for 
galectin-1 (1:200 dilution; citrate pre-treatment; mouse monoclo-
nal; Novocastra) were performed on 4 µM-thick TMA sections. Ga-
lectin-1 cytoplasmic staining of the epithelial cell component was 
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MO03.10 A MULTICENTER PROSPECTIVE STUDY OF 
CARBOPLATIN AND PACLITAXEL FOR ADVANCED THY-
MIC CARCINOMA: WEST JAPAN ONCOLOGY GROUP 
4207L
Junichi Shimizu1, Fumihiko Hirai2, Takeharu Yamanaka3, Keni-
chi Taguchi2, Haruko Daga4, Yoshihito Kogure5, Tatsuo Kimura6, 
Kaoru Tanaka7, Yasuo Iwamoto8, Akira Ono9, Hidefumi Sasaki10, 
Junya Fukuoka11, Kenichi Nishiyama12, Koji Takeda4, Takashi 
Seto2, Yukito Ichinose2, Kazuhiko Nakagawa7, Yoichi Nakanishi13
1Aichi Cancer Center Central Hospital/Japan, 2National Kyushu Cancer 
Center/Japan, 3National Cancer Center Hospital East/Japan, 4Osaka City 
General Hospital/Japan, 5Department Of Respiratory Medicine, Nagoya 
Medical Center/Japan, 6Osaka City University, Graduate School Of Medici-
ne/Japan, 7Department Of Medical Oncology, Kinki University Faculty Of 
Medicine/Japan, 8Hiroshima City Hospital/Japan, 9Shizuoka Cancer Cen-
ter/Japan, 10Oncology, Immunology And Surgery, Nagoya City University 
Graduate School Of Medical Sciences/Japan, 11Nagasaki University Gra-
duate School Of Biomedical Sciences/Japan, 12Japanese Red Cross Fukuoka 
Hospital/Japan, 13Department Of Clinical Medicine, Research Institute For 
Diseases Of The Chest, Faculty Of Medical Sciences, Kyushu University/
Japan
Background: Thymic carcinoma (TC) is a rare malignant tumor 
originated within the thymus gland and is associated with a poor 
prognosis, differing from thymoma which is the most common type 
of thymic malignant neoplasm. No results of clinical trials focusing 
on TC have been reported. This single-arm study evaluated carbo-
platin and paclitaxel (CbP) in previously untreated patients (pts) with 
advanced TC.
Methods: Pts with Masaoka’s stage III to IVb TC, ECOG PS 0 to 
1, and more than 20 years old were eligible. The study treatment 
consisted of carboplatin (AUC 6) and paclitaxel (200 mg/m2) every 3 
weeks for a maximum of 6 cycles. The primary endpoint was objec-
tive response rate (ORR) by extramural assessment. Secondary end-
points included overall survival (OS), progression-free survival (PFS), 
and safety. All pts were followed-up until 24 months (mo) after last 
enrollment. Based on the SWOG 2-stage design, the planned samp-
le size of 40 pts was determined to reject the ORR of 20% under the 
expectation of 40% with a power of 0.85 and a type I error of 0.05.
Results: From May 2008 to November 2010, 40 pts were enrolled 
from 21 centers. Of 39 evaluable for analysis, the median age was 62 
years (range, 36–84); 23/16 males/females; 3/10/26 with Masaoka’s 
stage III/IVa/IVb; 9/11/19 with squamous cell carcinoma/poorly diffe-
rentiated neuroendocrine carcinoma/other types. The median num-
ber of cycles was 6. There was 1/13 complete/partial responses with 
an ORR of 36% (95% confidence interval [CI], 21-53%; P = 0.031). 
The median PFS was 7.5 mo (6.2-12.3 mo) while OS did not reach the 
median value. The 1-year and 2-year survival rates were 85% (95% 
CI, 69-93%) and 71% (95% CI, 54-83%), respectively. Major adverse 
event was grade 3-4 neutropenia in 34 pts (87%). Two cases (5%) of 
grade 3 febrile neutropenia, neuropathy, and arthralgia were obser-
ved, respectively. There was no treatment-related death.
Conclusion: CbP showed high efficacy in advanced TC. Our results 
established that CbP, one of the standard treatments for non-small 
cell lung cancer, also serves as a key chemotherapy regimen for TC.
Keywords: paclitaxel, chemotherapy, Carboplatin, Thymic  
carcinoma
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MO03.09 DETECTION OF HUMAN POLYOMAVIRUS 7 IN 
THYMOMAS
Marlies Keijzers1, Anne-Marie Dingemans2, Dorit Rennspies3, S 
Pujari3, M A Abdul Hamid3, Monique Hochstenbag2, Ernst-Jan M. 
Speel3, A Haugg2, C Buck3, Marc De Baets4, Axel Zur Hausen3
1Cardiothoracic Surgery, Maastricht University Medical Center/Nether-
lands, 2Pulmonary Diseases, Maastricht University Medical Center+/
Netherlands, 3Pathology, Maastricht University Medical Center+/
Netherlands, 4Neuroscience, Maastricht University Medical Center/
Netherlands
Background: Thymomic pathologies are associated with the au-
toimmune disease myasthenia gravis (MG). The thymomagenesis 
have been studied extensively but the etiology of human thymoma 
remains poorly understood. Based on the consistent finding that 
murine polyomavirus induces thymomas in mice we tested the 
presence of Human Polyomavirus 7 (HPyV7) in human thymic epi-
thelial tumors.
Methods: We applied HPyV7 DNA Fluorescence in situ hybridizati-
on (FISH), DNA PCR and immunohistochemistry (IHC) in 37 thymo-
mas (19 female, 18 male; mean age 58.3 years; range 34 – 82 ye-
ars). Of these, 26 were previously diagnosed with MG. In addition, 
2 thymic carcinomas, 20 follicular hyperplasia and 20 fetal thymus 
tissues were tested for HPyV7.
Results: HPyV7 FISH revealed specific nuclear hybridization signals 
within the thymoma cells of 23 thymomas (62.2%). Fifteen thymo-
mas revealed strong to very strong hybridization signals, whereas 8 
revealed only weak positivity. With one exception the HPyV7 FISH 
data highly correlated with the HPyV7 DNA-PCR data. IHC showed 
the presence of HPyV7 on the translational level and immunohisto-
chemical double stainings confirmed the presence of HPyV7 in the 
epithelial thymoma cellular compartment. One thymus carcinoma 
was HPyV7 positive the other negative. All fetal thymus tissues 
were tested HPyV7 negative. The follicular hyperplasia results are 
pending.
Conclusion: We conclude that HPyV7 is frequently present in hu-
man thymic epithelial tumors and absent in fetal thymic tissues. No 
convincing association on HPyV7 and MG could be found. In as 
much HPyV7 is of relevance to human thymomagenesis remains to 
be established.
Keywords: thymoma, Human Polyomavirus 7
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regulating the transcription of several candidate genes responsible 
for proliferation and apoptosis. Both anti-p-BQ antibody and vit-
amin C (a strong reductant of p-BQ) prevented CS/p-BQ-induced 
proliferation of lung cells.
Conclusion: Despite major advances in the treatment and ma-
nagement of lung cancer, most patients eventually die. Conse-
quently, newer approaches such as chemoprevention(s) are ne-
cessary. We consider that prevention of CS-induced proliferation 
of lung cells by vitamin C and/or anti-p-BQ antibody may provide 
a novel intervention for preventing initiation of CS-induced lung 
cancer.
Keywords: anti-p-BQ antibody, Lung cancer, Cigarette smoke, 
p-benzoquinone
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MO04.02 PACLITAXEL RESISTANCE IS ASSOCIATED 
WITH DRUG ACCUMULATION IN INTRACELLULAR COM-
PARTMENTS AND PACLITAXEL-BINDING PROTEINS IN 
HUMAN LUNG CANCER CELL LINES
Masanori Shimomura1, Takeshi Yaoi2, Daishiro Kato1, Junichi 
Shimada1, Shinji Fushiki2
1Division Of Chest Surgery, Department Of Surgery, Kyoto Prefectural 
University Of Medicine/Japan, 2Department Of Pathology And Applied 
Neurobiology, Kyoto Prefectural University Of Medicine/Japan
Background: Several mechanisms have been suggested for pac-
litaxel resistance in cancer cells, including overexpression of the 
multidrug transporter gene, ATP-binding cassette, sub-family B, 
member 1 (ABCB1), and the presence of a point mutation in the 
β-tubulin gene at the paclitaxel-binding site. However, the mecha-
nisms underlying resistance to this agent have not yet been com-
pletely elucidated.
Methods: Three human lung cancer cell lines, II18, A549, and 
RERF-LC-KJ, were analyzed; their 50% inhibitory concentrations 
of paclitaxel were -8.33, -7.69, and -4.51 logM, respectively. The 
cell lines did not have any β-tubulin mutation. We evaluated the 
expression levels of ABCB1, intracellular accumulation of paclitaxel, 
paclitaxel-induced stabilization of microtubules, and intracellular 
localization of Oregon Green® 488-conjugated paclitaxel in these 
cell lines. Moreover, we prepared paclitaxel conjugated ferritegly-
cidyl metacrylate (FG) beads to purify paclitaxel-binding proteins 
from whole cell lysates of these cells.
Results: The ABCB1 expression level was strongly correlated to 
intracellular [3H]-paclitaxel accumulation (r2 = -0.804) but was not 
related with paclitaxel resistance. The changes in the quantities 
of polymerized tubulin and acetylated tubulin after paclitaxel 
exposure were not related to paclitaxel resistance. Differences 
were observed between the intracellular localization of paclitaxel 
in RERF-LC-KJ, the most resistant cell line, and in the other 2 cell 
lines. The use of Oregon Green® 488-conjugated paclitaxel ena-
bled visualization of not only the normal microtubule formation in 
the partial cells but also the aggregated vesicle formation in RERF-
LC-KJ cells; aggregated vesicle formation was not remarkable in 
the other cell lines. Affinity purification by paclitaxel immobilized 
beads revealed several specific bands in RERF-LC-KJ; these bands 
were not revealed in the other cell lines.
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MO04.01 MOLECULAR MECHANISMS OF CIGARETTE 
SMOKE INDUCED HYPER-PROLIFERATION OF HUMAN 
LUNG CELLS AND ITS PREVENTION.
Neekkan Dey, Dhrubajyoti Chattopadhyay, Indu B. Chatterjee
Department Of Biotechnology And Dr. B. C. Guha Centre For Genetic 
Engineering And Biotechnology, University Of Calcutta/India
Background: Lung cancer is the leading cause of cancer-deaths 
throughout the World. Cigarette smoke (CS) is the strongest risk 
factor of lung cancer. Cigarette smoking and exposure to environ-
mental tobacco smoke account for 90% of lung cancer cases, and 
smokers have a 20-fold increased risk of death from lung cancer 
compared to non-smokers. Unregulated cell proliferation together 
with suppressed apoptosis is a contributory factor for lung-car-
cinogenesis. However, the carcinogenic mechanism of cigarette 
smoking is not well understood. This is particularly because CS is 
a complex mixture of about 4000 compounds. We consider that 
identifying the risk factor(s) in CS and its prevention might be a 
novel way to prevent lung cancer.
Methods: Cytotoxicity was evaluated by the MTT assay. Cell cycle 
analysis was performed by propidium iodide (PI) staining follo-
wed by flow-cytometry. Apoptosis was assessed by AnnexinV- PI 
staining followed by flow-cytometry, phosphorylation of p53 and 
activation (cleavage) of caspase 3. Reactive Oxygen Species (ROS) 
production was detected by 2’, 7’-dichlorodihydrofluorescein 
diacetate (H2DCFDA) using confocal microscope. Cell proliferation 
was assessed using “In Situ Cell Proliferation Kit, FLUOS” (Roche 
Applied Science, Germany). DNA double-strand break was detec-
ted using “OxiSelect DNA Double Strand Break (DSB) Staining Kit” 
(CELL BIOLABS, INC.).
Results: We have identified p-benzoquinone (p-BQ) as a major risk 
factor that is derived from CS. p-BQ has a biphasic-nature as evi-
denced by MTT assay, AnnexinV-PI staining, cell cycle analysis and 
BrdU-incorporation assay. Low concentrations of p-BQ mimicked 
CS-induced proliferation of cultured lung adenocarcinoma cells 
(A549) as well as normal human primary small airway cells (ATCC® 
PCS-301-010™). On the contrary, high concentrations of CS/p-BQ 
resulted in cell death caused by oxidative stress and apoptosis. No 
such cell death was observed with low concentrations of CS/p-BQ. 
Coimmunoprecipitation and immunoblot experiments indicated 
that p-BQ-induced proliferation was mediated via aberrant phos-
phorylation of EGFR that lacked c-Cbl mediated ubiquitination 
and degradation. This resulted in prolonged EGFR signaling lea-
ding to persistent activation of Ras (a potent oncoprotein), the 
downstream survival and proliferative signaling molecules Akt and 
ERK1/2, as well as the transcription factors c-Myc and c-Fos. It is 
known that patients with lung cancer generally have a smoking 
history of more than 30-40 years. We therefore exposed A549 
cells repeatedly to CS/p-BQ for 2 months. Repeated exposure of 
AECS/p-BQ generated high levels of DNA double-strand breaks 
in A549 cells that might lead to genomic instability as well as mu-
tation of different proto-oncogenes and tumor suppressor genes 
– the hallmark events in cancer. In addition, CS/p-BQ altered the 
acetylation pattern of different histone epigenetic marks, thereby 
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cell lines, relative to corresponding PT cells. The most frequently 
occurring of these chromosomal imbalances included gains, losses 
and homozygous deletions on chromosome 3 (MOR, A549, H1299), 
deletions and amplifications on chromosome 7 (H460, A549, 
H1299) and deletions and gains on chromosome 15 (MOR, A549, 
H1299) and chromosome X (MOR, H460, SKMES-1). Deletions on 
chromosomes 4, 6, 11, 12, 14, and amplification of chromosome 5, 
were also identified among the different CisR cell lines. The collati-
on and analysis of data arising from mutation analysis of CisR cells 
using the Sequenom® platform are currently being completed.
Conclusion: High-resolution mapping of chromosomal imbalan-
ces may offer potential in the identification of genes, including 
oncogenes and tumour suppressor genes, affected by these im-
balances. These findings may further contribute to the delineation 
of the genomic profile of cisplatin resistant lung cancer, and offer 
perspectives for the identification of genes contributing to this 
disease phenotype and in assessing the response to new molecu-
lar treatments.
Keywords: Chromosome, mutations, cisplatin resistance, NSCLC
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MO04.04 AEROSOL AZACITIDINE REDUCES METHYLA-
TION LEVELS OF TUMOR SUPPRESSOR GENES AND 
PROLONGS SURVIVAL IN THE ORTHOTOPIC LUNG CAN-
CER MODELS IN MICE.
Xuan Qiu, Yuanxin Liang, Bilal Piperdi, Roman Perez-Soler, Yiyu 
Zou
Albert Einstein College Of Medicine/United States Of America
Background: Promoter hypermethylation plays an important role 
in lung cancer carcinogenesis by silencing key tumor suppressor 
genes (TSG). Reversing the hypermethylation of TSG by direct ae-
rosolized administration of a demethylating agent may have a po-
tential to inhibit lung cancer growth and development. This study 
examines the therapeutic potential of aerosolized azacytidine (Aza) 
in the orthotopic mice model of human NSCLC.
Methods: Vidaza® (the clinical grade Aza formulation for IV admi-
nistration) was dissolved into sterile water for injection and aeroso-
lized in a clinical standard aerosol system. The aerodynamic size, 
the lung deposition, and the Aza level in the lung and circulation of 
mice were measured by previously described methods. The deme-
thylation and gene reactivation functions of aerosolized Aza were 
detected by qPCR methylation array and western blotting assay in 
the human non-small cell lung cancer (NSCLC) tumor tissues from 
the orthotopic intratracheally inoculated xenograft models in nude 
mice. The therapeutic efficacy and toxicity of the aerosolized Aza 
were also evaluated in mice. Mice treated with an intravenously 
administered Aza with clinically equivalent dose and schedules 
were used as a comparison.
Results: The aerosolized Aza is an appropriate pharmaceutical 
inhalation formulation with size distribution of about 80% of dro-
plets from 0.1 to 5 micron. This dynamic size range ensures the 
aerosol droplets depositing in the lower airway as indicated by the 
recovery of approximately 80% Aza from the lung tissue 20 min 
after the aerosol administration. In efficacy and toxicity studies, 
aerosol administration of Aza significantly prolonged the survival 
of nude mice with intratracheally inoculated human NSCLC tumors. 
Conclusion: We propose that paclitaxel resistance is associated 
with intracellular compartments in which paclitaxel accumulates 
and paclitaxel-binding proteins expressed specifically in resistant 
cell line.
Keywords: Lung cancer, paclitaxel resistance, proteome analysis
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MO04.03 CHROMOSOMAL AND MUTATIONAL ANALY-
SIS OF THE CISPLATIN RESISTANT PHENOTYPE IN NS-
CLC CELLS
Martin P. Barr1, Leah C. Alcock2, Raymond L. Stallings2, Sinead 
Toomey3, Aoife Carr3, Bryan T. Hennessy3, Derek Richard4, Ken-
neth O‘Byrne5
1Clinical Medicine, St James‘s Hospital & Trinity College Dublin/Ireland, 
2Cancer Genetics, Royal College Of Surgeons In Ireland/Ireland, 3Medi-
cal Oncology, Royal College Of Surgeons In Ireland/Ireland, 4Translatio-
nal Research Institute, Queensland University Of Technology/Australia, 
5Queensland University Of Technology, Cancer & Ageing Research Pro-
gram/Australia
Background: Primary and acquired resistance to platinum agents 
such as cisplatin have become a major obstacle in the manage-
ment of lung cancer patients, in particular non-small cell lung can-
cer (NSCLC). The availability of comprehensive genomic data on 
DNA copy number changes in cisplatin resistant NSCLC is limited, 
and little is known about the genes driving this chemoresistant 
phenotype. Detailed molecular portraits through high density 
genomic DNA arrays and genome wide mutation profiles will aid in 
understanding the molecular basis of individual responses to new 
molecular therapies.
Methods: A panel of cisplatin resistant (CisR) NSCLC cell lines 
were recently generated and characterised in our laboratory. In 
this study, high resolution array-based comparative genome hy-
bridization (aCGH) was performed on a panel of five CisR NSCLC 
cell lines to examine DNA copy number gains, losses and amplifi-
cations. Cellular DNA (500ng) and control DNA was differentially 
labelled with Cy3 and Cy5, respectively. Labelled test (4µg) and 
reference DNA were hybridised to a 12-plex 135,000 probe array 
(Roche NimbleGen) for 18 hours in a MAUI hybridisation station 
(BioMicro Systems) at 42°C. Fluorescent intensities were extracted 
and log 2 ratios calculated and normalized using NimbleScan Soft-
ware (version 2.4). Chromosomal aberrations were identified using 
the CGH-segMNT algorithm (NimbleScan 2.4). A significance log 
2 ratio threshold of <−0.25 for loss and >0.25 for gain was used to 
identify DNA copy number imbalances. For mutational analysis, 
Sequenom®, a mass-spectrometry-based SNP genotyping tech-
nology, was used to identify mutations in our panel of resistant cell 
lines. Using a literature search and the Catalogue of Somatic Mu-
tations in Cancer (COSMIC) database, a mutation panel was iden-
tified for the detection of 547 frequently occurring and potentially 
clinically relevant mutations in 49 cancer-related genes. Some of 
these include KRAS, NRAS, BRAF, PIK3CA, MET, CTNNB1, STK11, 
AKT, and EGFR. Matrix chips were analysed on a Sequenom® 
MassArray MALDI-TOF system. Visual inspection and Sequenom® 
typer software were used to perform genotyping based on mass 
spectra.
Results: Using aCGH arrays, a number of gains, losses and amplifi-
cations of various chromosomes were found across a panel of CisR 
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epithelium was not seen until 25 weeks. Morphometric analysis of 
immunostained tracheal tissue showed a time-dependent increase 
in the numbers of K5+ cells and a concomitant loss of cells expres-
sing Clara cell secretory protein (CCSP) and ciliated cells. We have 
shown previously that injury to the trachea upregulates expression 
of keratin 14 (K14) in basal cells. Consistent with this phenomenon, 
NTCU exposure showed a time-dependent increase in the number 
of K5/K14 dual-positive basal cells. To understand the mechanism 
by which NTCU treatment mediates ectopic expression of basal 
cells in the lung, we used flow-cytometry to analyze cell-surface 
markers expressed by tracheal basal cells. These studies revealed 
a time-dependent decrease in the level of integrin a6b4 (CD49f). 
CD49f is a hemidesmosomal protein that facilitates attachment of 
basal cells to the basement membrane. These findings suggested 
that NTCU treatment might promote migration of tracheal basal 
cells by destabilizing their adherence to the basement membrane.
Conclusion: Collectively, our results showed an early involvement 
of tracheal basal cells in the generation of dysplastic lung lesions 
in a murine model of SCC. By moving the focus proximal, we have 
discovered a realm of biological developments in the trachea that 
had not been previously examined. Further research of these pro-
cesses will aid in the elucidation of dysplastic development in SCC.
Keyword: Basal cells, NTCU, squamous cell carcinoma and keratins
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MO04.07 CHRONIC LUNG INJURY BY CONSTITUTIVE 
EXPRESSION OF AID LEADS TO FOCAL ALVEOLAR RE-
GENERATION AND CANCER
Jiro Kitamura1, Kazuo Kinoshita2, Munehiro Uemura2, Makoto 
Sonobe3, Hiroshi Hiai4, Hiroshi Date3
1Thoracic Surgery, Nagahama City Hospital/Japan, 2Evolutionary Medi-
cine, Shiga Medical Center Research Institute/Japan, 3Thoracic Surgery, 
Graduate School Of Medicine, Kyoto University/Japan, 4Laboratory For 
Malignancy Control Research, Graduate School Of Medicine, Kyoto Uni-
versity/Japan
Background: Activation-induced cytidine deaminase, AID, is an 
enzyme required for somatic hypermutation and class-switch re-
combination which diversify immunoglobulin genes and causes 
DNA mutations and strand breaks. Uncontrolled expression of AID 
is cytotoxic. AID transgenic mice invariably develop lung lesions 
morphologically similar to human atypical adenomatous hyperpla-
sia (AAH), which can be a precursor of bronchioloalveolar carcino-
ma. About 10 % of these mice develop visible lung tumor including 
adenocarcinoma. However, the relationship between this mouse 
AAH-like lesion (MALL) and lung cancer is unclear. In the present 
study, we examined MALLs to elucidate their characteristics and 
involvement in lung cancer.
Methods: p53, KRAS, and EGFR mutation status in each laser-
microdissected MALL were analyzed. The expression of airway 
epithelial cell markers and lung alveolar regeneration markers in 
MALLs were investigated by immunohistochemistry. Apoptosis 
assay were performed in murine lungs. For cell proliferation assay, 
AID Tg mice were received a daily intraperitoneal injection of 1 mg 
5-ethynyl-2’-deoxyuridine (EdU) for 7 days. Then, mice were stu-
died 1 day (day 1) or 3 weeks (day 20) after the last injection.
Results: We found mutations of p53 in 10.5% of MALLs (4/38), but 
The %-increased in life span was 5- to 10-fold higher than that of a 
systemic treatment of Aza at a clinically equivalent dose. The ae-
rosolized Aza, at a potentially therapeutic dose, did not cause any 
detectable lung toxicity or systemic toxicity (myelosuppression). 
After the aerosolized Aza treatment, the lung tumors were resec-
ted and the methylation levels of the 24 promoters driving the lung 
cancer related tumor suppressor genes (TSGs) in the lung tumors 
were examined by qPCR methylation array. The aerosolized Aza 
significantly reduced the methylation level in 9 of the 24 promo-
ters examined. This demethylating effect also resulted in the gene 
reactivation at the protein level in several tested genes.
Conclusion: In our orthotopic NSCLC model, aerosolized Aza was 
well tolerated with good drug delivery to bronchial epithelium 
at non-cytotoxic doses. The pharmacodynamic effect of the TSG 
demethylation and reactivation was observed. Interesting thera-
peutic efficacy of prolonging survival was observed in our model 
from aerosolized 5-Aza over intravenous administration in mice. 
The phase I clinical trial of aerosolized Aza with pharmacodynamic 
endpoints will be conducted. Acknowledgement: Supported by a 
NIH (NCI) grant 5R01CA154755-02
Keyword: Lung Cancer, aerosol, azacitidine, methylation
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MO04.05 TRACHEAL BASAL CELLS IN THE LUNG SQUA-
MOUS DYSPLASIA: MOVING PROXIMAL.
Moumita Ghosh1, Lori D. Nield2, Jennifer Kwon1, Robert L. Keith3, 
Daniel T. Merrick3
1Pediatrics, National Jewish Health/United States Of America, 2Phar-
macy, University Of Colorado/United States Of America, 3Veteran Af-
fairs Medical Center/United States Of America
Background: Squamous cell carcinoma (SCC) is the second most 
common form of lung cancer, a disease primarily observed in 
smokers. Studies have shown that preneoplastic dysplasias are the 
precursors for SCC. However, only a subset of these lesions pro-
gress to invasive carcinoma and predicting the fate of individual 
lesions is difficult. Understanding the processes associated with 
the development of dysplasia would therefore have significant 
impact on preventative therapy for high-risk lesions. To this goal 
we have studied N-nitroso-tris chloroethyl urea (NTCU) model of 
premalignant murine squamous dysplasia. Bi-weekly topical appli-
cation of NTCU for 32-weeks caused endobronchial dysplasias that 
were pathologically similar to dysplasias encountered in human 
smokers. In the current study we used NTCU model to identify the 
events that precede dysplastic changes in murine airways.
Methods: Immunofluorescence analysis of NTCU treated airways 
showed abundant expression of keratin 5 positive (K5+) basal cells. 
In normal mouse respiratory epithelium K5+ cells are confined only 
in the trachea and are absent in the bronchial epithelium. Ectopic 
expressions of K5+ cells in the mouse bronchial epithelium there-
fore suggested a role for tracheal basal cells in the pathogenesis 
of NTCU-induced dysplasia. To explore this possibility we analyzed 
tracheal and bronchial histology after vehicle and 20mM NTCU 
treatment at 4, 8, 12, 16, 25 and 32 weeks.
Results: Low-grade dysplasia of the tracheal epithelium was ob-
served as early as 4 weeks of NTCU exposure. On the contrary, 
squamous metaplasia or low-grade dysplasia of the bronchial 
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MO04.08 ACTIVATION OF LIVER X RECEPTOR INDUCES 
INTERFERON-GAMMA PRODUCTION AND INHIBITS 
TUMOR GROWTH
Qixue Wang, Xingzhe Ma, Yajun Duan
Nankai University/China
Background: Interferon-γ (IFN-γ) has been well documented to 
have multiple functions including anti-tumorigenesis. Liver X re-
ceptors α and β (LXR) are members of ligand-activated nuclear 
receptor superfamily. LXR can be activated by natural ligands of 
some oxysterols and by numerous synthetic ligands (e.g. T317).The 
LXR-induced ABCA1 expression promotes free cholesterol efflux 
from macrophages thereby inhibiting the development of atheros-
clerosis. LXR has also been demonstrated the important functions 
in immune system . Here we tested the hypothesis that IFN-γ is a 
target for LXR activation, and the induction of IFN-γ expression by 
LXR can lead to inhibition of tumor growth.
Methods: C57 wild type or IFN-γ-/- mice (same background) in 
two groups were s.c. injected with2×10 5 LLC1 cells (ATCC) in the 
right flank to establish a carcinoma tumor model. For carcinogen-
induced tumor: at the first week, C57 mice were i.p. injected with 
MCA (15 mg/kg body); from the second week, the mice were i.p. 
weekly injected with BHT for 6 weeks. The doses of BHT were: 1st 
injection, 150 mg/kg body weight; 2nd to 6th injections, 200 mg/
kg.
Results: In this study, we observed that LXR ligand (T317) induced 
IFN-γ protein expression which was associated with increased 
mRNA and secreted protein levels in culture medium. In vivo,T317 
increased wild type mouse serum IFN-γ levels and IFN-γexpression 
in tissues. T317 inhibited the inoculated LLC1 tumor growth in wild 
type mice but not in IFN-γ knockout (IFN-γ-/-) mice. In addition, 
T317 displayed inhibitory and therapeutic effects on 3-methyl-
cholanthrene/butylated hydroxytoluene (MCA/BHT)-induced 
pulmonary carcinomas. T317 inhibits the growth of inoculated 
LLC1 tumor in wild type mice but not in IFN-γ-/- mice Wild type or 
IFN-γ-/- mice. 
no mutations of KRAS and EGFR. In immunohistochemistry, MALLs 
were partially positive for SP-C (lung alveolar type II cell-specific 
marker), but negative for CC-10 (clara cell-specific marker) and 
podoplanin (lung alveolar type I cell-specific marker). Frequency 
of apoptotic cells among lung alveolar wall cells was significantly 
higher in AID transgenic mice than in wild type mice. Moreover, 
frequency of Edu-positive MALL decreased significantly at day 20 
compared to that at day 1. The expressions of p63, cytokeratin 
5/14, and E-cadherin/Lgr6, the recently described markers of lung 
alveolar regeneration, were observed in MALLs.
Conclusion: Based on these observations, we speculate that MALL 
is a regenerating tissue compensating for alveolar epithelial cell 
loss caused by AID-induced genotoxic stress. AID expression in 
such regenerating tissue should predispose cells to malignant 
transformation by its mutagenic activity. AID transgenic mice could 
be a mouse model that may provide the link between lung regene-
ration after injury and the development of lung cancer.
Keywords: mouse model, AID, lung carcinogenesis, lung regene-
ration
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T1317 inhibits MCA/BHT-induced pulmonary tumors 
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Conclusion: Our study demonstrates IFN-γ is a target gene of  
LXR activation. LXR-induced IFN-γ expression can be attributed,  
at least in part, to the anti-tumorigenic properties of LXR.
Keywords: Liver X Receptor, Interferon-gamma, MCA/BHT-indu-
ced pulmonary tumors
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Methods: Luciferase-tagged A549 lung adenocarcinoma cells 
were injected through the tail vein of nude male mice. Mice under-
went weekly bioluminescent imaging until lung tumors were clearly 
identified. After lung tumors were identified, mice were rando-
mized to daily wheel-running versus no wheel-running. Mice were 
imaged weekly. After 4 weeks, all mice were euthanized and lung 
tumors were harvested. Western blots and immunohistochemistry 
(IHC) studies were undertaken on tumor tissue to identify potential 
differences in protein expression levels in exercise versus sedenta-
ry mice.
Results: Exercising mice tumors grew significantly more slowly 
relative to sedentary mice (figure 1). There was no change in de-
velopment of metastatic lesions between the two groups. Protein 
analysis by Western blot or IHC demonstrated increased p53 pro-
tein levels in exercising mice relative to sedentary mice, as well as 
increased mediators of apoptosis including Bax, Bak and active 
caspase 3 in tumor tissues (figure 2 and data not shown). No nor-
mal tissue toxicity in other organs was observed in the two groups 
of mice. Figure 1. 
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MO04.09 EXERCISE INDUCED LUNG CANCER TUMOR 
GROWTH SUPPRESSION VIA ACTIVATION OF P53: ME-
CHANISTIC FINDINGS FROM A MOUSE MODEL
Kristin A. Higgins, Dongkyoo Park, Walter J. Curran, Xingming 
Deng
Radiation Oncology, Emory University/United States Of America
Background: Regular exercise has been shown to improve the 
quality of life in patients undergoing treatment for lung cancer and 
has been associated with reductions in cancer-specific mortality in 
patients with colon and breast cancer. The direct effects of cardi-
ovascular exercise on lung cancer tumor biology, however, remain 
unknown. This study evaluated cardiovascular exercise in a mouse 
model of lung adenocarcinoma, including clinically relevant end-
points such as lung tumor growth and distant metastasis. Further-
more, biologic mechanisms of action underlying clinical findings 
were also explored.
Conclusion: Daily cardiovascular exercise appears 
to mitigate growth of lung adenocarcinoma tumors 
by activation of p53 tumor suppressor function and 
increased apoptosis.
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significance of evaluating the biological properties of intralym-
phatic tumors for tumor metastasis and suggested the possibility 
of usefulness as a new molecular target, especially as an adjuvant 
therapy.
Keywords: lung adenocarcinoma, lymphogenic metastasis, intra-
lymphatic microenvironment, cancer-initiating cell related molecule
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MO04.11 THE TUMOR MICROENVIRONMENT EXPRESSI-
ON OF THE INHIBITOR OF DIFFERENTIATION-1 (ID1) IS 
DETERMINANT OF THE DEVELOPMENT OF LIVER ME-
TASTASIS FROM LUNG CANCER THROUGH GENE REGU-
LATION OF TUMOR CELLS
Ignacio Gil-Bazo1, Eduardo Castañón1, Inés López1, Mariano Ponz-
Sarvisé1, José M. López-Picazo1, María Collantes2, Margarita Ecay2, 
Isabel Gil-Aldea3, Alfonso Calvo1
1Division Of Oncology, Center For Applied Medical Research Of The Uni-
versity Of Navarra/Spain, 2Micropet. Nuclear Medicine, Clínica Univer-
sidad De Navarra/Spain, 3Tissue Biobank, Navarrabiomed/Spain
Background: Liver metastases appear in about 30% of non-small 
cell lung cancer (NSCLC) patients during the disease course with a 
dramatic impact on clinical outcome and quality of life. TME gene 
expression might be crucial for allowing tumor cells to migrate and 
spread to the liver. However, no candidate genes have ever been 
proposed as responsible for this process. Id1, a member of the 
gene signature that facilitates breast cancer cells to disseminate to 
the lungs, might be determinant for NSCLC LM development.
Methods: For the first time, a mouse model of LM from lung can-
cer was developed. Two cohorts of mice were compared; C57BL/6 
females vs. Id1-knockout (KO) females (gently provided by Dr. 
Benezra, MSKCC, New York). Lewis lung carcinoma cells (500,000) 
were selected for intrasplenic injection. Five minutes after tumor 
cells injection all mice were splenectomized to avoid bulky flank 
tumor formation. Mice were closely followed after tumor cells ino-
culation. Weekly FDG-micro-positron emission tomography (PET) 
scans were performed to study liver metastasis formation in both 
groups of mice. Animals were sacrificed at the time of LM develop-
ment. Liver metastatic lesions were obtained for RNA extraction 
(Qiagen kit). A microarray gene expression analysis (Affymetrix) 
with the support of Ingenuity Pathways Analysis (IPA) was per-
formed to evaluate the potential impact of Id1 genotype on the 
regulation of genes mediating proliferation, invasion, migration, 
angiogenesis and metastasis in LM.
Results: The first week after tumor cells intrasplenic injection, 
FDG-PET scans showed no liver metabolic uptake in any of the 
mice. By week 2 however, 70% of C57BL/6 mice and 10% of Id1-KO 
mice showed clear LM by FDG-PET (p=0.02). Three weeks after in-
trasplenic tumor cells injection, 100% of C57BL/6 animals showed 
LM compared to 30% of Id1-KO mice (p=0.03). In addition, 50% of 
Id1-KO mice remained LM-free 4 weeks after tumor cells injection. 
No other metastatic sites were indentified at the time of necropsy. 
In the mircroarray gene expression analysis, only a set of 50 out of 
nearly 900 genes appeared upregulated in the LM of Id1-KO mice 
compared to C57BL/6 animals whereas the rest of the genes were 
downregulated. Interestingly, amphiregulin, caveolin-1, aurora 
kinase B, MMP3, Hsp90aa1, Cdk1, Hif1a, Cyclin D2 were among the 
significantly downregulated genes in the Id1-KO LM.
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MO04.10 IDENTIFICATION OF BIOLOGICAL PROPERTIES 
OF INTRALYMPHATIC TUMOR RELATED TO THE DEVE-
LOPMENT OF LYMPH NODE METASTASIS IN LUNG ADE-
NOCARCINOMA
Keisuke Kirita1, Genichiro Ishii2, Rie Matsuwaki3, Yuki Matsumu-
ra3, Shigeki Umemura1, Shingo Matsumoto1, Kiyotaka Yoh1, Seiji 
Niho1, Koichi Goto1, Hironobu Ohmatsu1, Yuichiro Ohe1, Kanji Na-
gai3, Atsushi Ochiai2
1Division Of Thoracic Oncology, National Cancer Center Hospital East/
Japan, 2Pathology Division, Research Center For Innovative Oncology, 
National Cancer Center Hospital East/Japan, 3Division Of Thoracic 
Surgery, National Cancer Center Hospital East/Japan
Background: Intralymphatic tumors in the extratumoral area are 
considered to represent the preceding phase of lymph node (LN) 
metastasis. The aim of this study was to clarify the biological pro-
perties of intralymphatic tumors susceptible to the development of 
LN metastasis, with special reference to the expression of cancer 
initiating/stem cell (CIC/CSC) markers in cancer cells and the num-
ber of infiltrating stromal cells.
Methods: A total of 2087 consecutive adenocarcinoma patients 
underwent complete resections and systematic LN dissections 
between May 1998 and December 2012 were identified. Among 
these cases, we selected those that had been diagnosed as having 
lymphatic permeation in the extratumoral area (n = 107). We exa-
mined the expression levels of CIC/CSC related markers including 
ALDH1, OCT4, NANOG, SOX2 and Caveolin-1 in the intralympha-
tic and primary tumor cells to evaluate their relationship to LN me-
tastasis. The number of infiltrating stromal cells expressing CD34, 
α-smooth muscle actin, and CD204 were also evaluated. Moreover, 
we measured E-cadherin expression to identify a correlation bet-
ween CIC/CSC related molecules and epithelial - mesenchymal 
transition (EMT) process.
Results: Intrathoracic LN metastases were detected in specimens 
from 86 patients (80%). Among the intralymphatic tissues, low 
ALDH1 expression in cancer cells, high SOX2 expression in cancer 
cells, and a high number of CD204(+) macrophages were indepen-
dent predictive factors for LN metastasis (odds ratio [95%CI] = 3.25 
[1.11 – 9.82], P = 0.031 for ALDH1; 4.09 [1.38 – 13.4], P = 0.011 for 
SOX2; and 3.45 [1.16 – 11.4], P = 0.026 for CD204(+) macrophages). 
However, in the primary tumors, only a high SOX2 expression level 
in the cancer cells within the primary tumor was significantly corre-
lated with LN metastasis (p=0.008); ALDH1 expression in the can-
cer cells and the number of CD204(+) macrophages were not cor-
related with LN metastasis (P = 0.230 and P = 0.088, respectively). 
Among these factors, only low ALDH1 expression in intralymphatic 
cancer cells was significantly correlated with the farther spreading 
of LN metastasis (mediastinal LN, pN2) (P = 0.046) and higher me-
tastatic LN ratio (metastatic/resected) (P = 0.028). Intralymphatic 
cancer cells expressing low ALDH1 levels exhibited lower E-cad-
herin expression levels than cancer cells with high levels of ALDH1 
expression (P = 0.015). The expressions of other CIC/CSC related 
markers, including OCT4, NANOG, SOX2, and Caveolin-1, were 
not correlated with the E-cadherin expression.
Conclusion: Intralymphatic cancer cells expressing low levels of 
ALDH1 and infiltrating macrophages expressing CD204 have a 
critical impact on LN metastasis. Especially, intralymphatic cancer 
cells expressing low levels of ALDH1 might acquire a metastatic 
aggressiveness by the EMT process. Our study highlighted the 
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MO05.01 VALIDATION OF GENE EXPRESSION BIOMAR-
KER PANELS IN NON-SMALL CELL LUNG CANCER
Jie Dong1, Marianne Huebner1, Ijeoma Azodo1, Sandra C. Tomas-
zek1, Zhifu Sun1, Farhad Kosari1, Lifeng Wang1, Jin Jen1, Marie 
Christine Aubry2, Ping Yang3, George Vasmatzis1, Dennis A. Wigle4
1Mayo Clinic/United States Of America, 2Anatomic Pathology, Mayo 
Clinic/United States Of America, 3Health Sciences Research, Mayo Cli-
nic/United States Of America, 4Thoracic Surgery, Mayo Clinic/United 
States Of America
Background: Many studies in the literature have suggested that gene 
expression biomarkers may guide patient classification and clinical 
management in NSCLC. Despite minimal external validation and no 
clinical trial evidence, gene expression biomarker panels have been 
proposed as tools for making treatment decisions. Recent controversy 
surrounding the validity of such data and its potential applicability to 
clinical practice led us to perform an external validation study of publis-
hed gene expression biomarker panels.
Methods: We performed gene expression profiling for a total of 209 
patients with both Affymetrix whole transcriptome U133Plus2 arrays 
in addition to a NSCLC-specific array constructed by our group for 
assessment of mRNA expression in frozen tumor specimens of NSCLC. 
Clinical outcome data were collected and analyzed for correlations of 
gene expression with disease-free and overall survival. Cox proporti-
onal hazard models were used to test significance of individual genes 
and for gene sets defined by each panel. Panels tested included those 
previously published from Michigan, Mayo Clinic, Taiwan, Toronto, and 
UCSF.
Results: Expression profiling data were generated for a total of 209 
patients with NSCLC. This included U133Plus2 arrays of 242 tumor sam-
ples and 105 matched surrounding normal lung tissue, as well as 111 
tumor profiles using the NSCLC-specific array. There were 98 women 
and 111 men in the study cohort, with 120 patients having Stage I NS-
CLC (57.4%), 38 with Stage II (18.2%), 50 with Stage III (23.9%), and one 
patient with Stage IV disease (0.5%). Mean follow-up time after surgical 
resection was 62.4 ± 48 months. Seventy-four patients (35.1%) develo-
ped post-resection recurrence after a mean of 53.3 ± 49.3 months, of 
which 62 patients died (83.8%). Known clinical predictors such as TNM 
stage, histology, and tumor grade were predictive of survival. Although 
many genes within the published biomarker panels were significantly 
correlated with disease-free and overall survival, none provided additi-
ve prognostic value beyond standard clinical predictors.
Conclusion: Although a number of individual gene expression bio-
markers have prognostic significance in univariate models, published 
biomarker panels perform poorly in external validation studies such 
as this. The additive prognostic value beyond standard, known clinical 
predictors in the TNM staging system casts doubt as to whether such 
information will be useful in clinical practice. Despite the success of 
gene expression biomarkers for molecular subtyping in other cancers, 
our data suggests that this information has a low likelihood of clinical 
translation in NSCLC for unselected patients.
Keywords: biomarker, Gene expression, NSCLC
Conclusion: A novel mouse model for liver metastasis from lung 
cancer has been developed allowing the study of this complex and 
unexplored process. Id1 gene expression seems to be a key medi-
ator of the development of liver metastasis from lung cancer in this 
in vivo model. The absence of Id1 expression in the tumor micro-
environment of Id1-KO mice was sufficient to significantly delay 
and impair the metastatic process of lung cancer tumor cells to the 
liver. Id1 might be able to modulate LM through a direct down-
regulation of genes involved in proliferation, invasion, migration, 
angiogenesis and metastasis. This study has been partially funded 
by "UTE project CIMA“ and an ISCIII-FIS grant 2011.
Keywords: Tumor microenvironment, liver metastasis, Id1, Lung 
cancer
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with our previous cell line data that showed elevated PE and ME 
in non-amplified cells and suggests that GCN may not identify all 
the potential patients who could benefit from FGF/FGFR pathway 
inhibitors.
Keywords: prognostic biomarker, FGFR1 expression, predictive 
biomarker, companion diagnostic
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MO05.03 A GENE EXPRESSION PLATFORM TO PREDICT 
BENEFIT FROM ADJUVANT EXTERNAL BEAM RADIATI-
ON IN RESECTED NON-SMALL CELL LUNG CANCER.
Ben C. Creelan1, Alberto A. Chiappori1, Steven A. Eschrich2, Wil-
liam Fulp2, Javier F. Torres-Roca3
1Thoracic Oncology, H. Lee Moffitt Cancer Center And Research Insti-
tute/United States Of America, 2Bioinformatics, H. Lee Moffitt Cancer 
Center And Research Institute/United States Of America, 3Radiation 
Oncology, H. Lee Moffitt Cancer Center And Research Institute/United 
States Of America
Background: To date, no personalized decision-making tool exists 
for adjuvant radiation after resection of non-small cell lung cancer 
(NSCLC). Our objective was to retrospectively determine if our pre-
viously developed 10-gene expression signature, called radiosen-
sitivity index (RSI), would classify patients into radioresistant (RSI-
poor) or radiosensitive (RSI-good) using disease-free survival (DFS).
Methods: Inclusion criteria: pathologic AJCC v6 stage III NS-
CLC at time of resection, negative margins, at a single institution 
between 2000 and 2012. Neo or adjuvant chemotherapy was 
required. For radiation group (RT), at least 45 Gy of conformal or 
intensity-modulated radiation was required. An identical stage 
group (control) did not receive radiation. Gene expression profiling 
was conducted on primary lung tumor mRNA. DFS was defined as 
time-to-recurrence or death from any cause. Predefined cut-point 
was lowest quartile of calculated RSI. Two-sided log-rank and Cox 
regression were used.
Results: Of 144 screened, 95 were eligible (53 RT and 42 control). 
Demographics: median age 67 yrs, 54% female, 96% white, and 
91% current / former smokers. Operations consisted of 56% lo-
bectomy, 26% pneumonectomy, and 18% segmentectomy/wedge. 
Adjuvant doublet consisted of 48% taxane, 32% gemcitabine, or 
20% other. Mean RT dose 54.8 Gy, median follow-up 3.5 yrs. His-
tology: 64% adenoca, 25% squamous, 10% large-cell. Mean tumor 
volume 58 cm3, 77% were pN2, 58% had angiolymphatic invasion 
and 51% were poorly-differentiated. Mean preoperative PET SU-
Vmax was 9.5. No imbalance in clinical factors were observed bet-
ween RSI-good vs. RSI-poor. On univariate analysis, for RT group, 
median DFS for RSI-good vs RSI-poor was 5.8 yrs vs. 1.4 yrs, HR 4.2 
(95% CI 1.9 – 9.5), p = 0.017. 5-year DFS was 63% vs 22%, p = 0.01. 
No significant difference was observed for the chemo-only control 
group, with median DFS for RSI-good vs. RSI-poor: 2.3 vs 2.7 yrs, 
HR 0.7 (95% CI 0.3 – 1.6), p = 0.98. A test for interaction confirmed 
that the effect was restricted to the RT group and not the control, 
with p = 0.04. On multivariate analysis, for the RT group, the RSI 
was more strongly associated with DFS than any other variable 
(age, gender, tumor volume, nodal status, baseline SUVmax, histo-
logy, grade, LVI, and operation). After inclusion of covariates, it 
remained an independent predictive variable with HR 3.8 (95% CI 
1.6 – 9.2) p = 0.003. 
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MO05.02 OVEREXPRESSION OF FGFR1 MRNA AND 
PROTEIN ARE MORE FREQUENT THAN FGFR1 GENE 
AMPLIFICATION IN NON-SMALL CELL LUNG CANCER 
(NSCLC) PATIENTS
Murry W. Wynes1, Theresa Boyle1, Szymon Wojtylak2, Aleksandra 
Sejda2, Lynn E. Heasley3, Leigh A. Henricksen4, Shalini Singh4, Da-
vid Ross Camidge1, Paul A. Bunn1, Rafal Dziadziuszko5, Wojciech 
Biernat2, Fred R. Hirsch1
1Division Of Medical Oncology / Department Of Medicine, University Of 
Colorado Anschutz Medical Campus/United States Of America, 2Medi-
cal University Of Gdansk/Poland, 3Craniofacial Biology, University Of 
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tana Medical Systems, Inc/United States Of America, 5Department Of 
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Background: Somatic mutations and gene fusions have been 
identified as oncogenic drivers in lung cancer, however, a number 
of lung cancers have no apparent molecular aberration driving 
oncogenesis. It appears that gene/protein overexpression may 
sustain these “pan-negative” cancers. Fibroblast growth factors 
(FGFs) and their receptors (FGFRs) regulate cell proliferation, 
differentiation, migration and survival and dysregulation of this 
signaling pathway is observed in a proportion of lung cancers. A 
number of compounds targeting FGF/FGFR are in clinical deve-
lopment but clinically applicable biomarker assays and companion 
diagnostics that accurately identify patients with tumors sensitive 
to these agents are needed. We previously presented cell line data 
demonstrating that FGFR1 mRNA (ME) or protein expression (PE) 
better identified FGFR1 inhibitor sensitive tumors compared to 
gene copy number (GCN). The goal of this study was to examine 
FGFR1 ME, PE and GCN in a surgically treated NSCLC clinical co-
hort and explore possible associations with clinical features and 
prognosis.
Methods: Immunohistochemistry, brightfield in situ hybridization, 
and silver in situ hybridization were used to investigate ME, PE and 
GCN, respectively, in a cohort of 189 NSCLC surgically-treated 
patients. PE was scored by the H-score method (0-300) and ME on 
a semiquantative integer scale (0-4+), both evaluating the entire 
tumor specimen. GCN was scored on continuous scale by counting 
the individual signals in 50 cells and determining the average GCN 
per tumor cell.
Results: Amplification (GCN >=4) was present in 8% of the entire 
cohort and in 11% of the squamous cell carcinoma (SCC) or mixed 
histology subgroup. No amplifications were found in the adenocar-
cinomas (ADC) or tumors from never smokers. In contrast, 29% of 
SCC and ADC patients had high ME (= 4+). Elevated PE (>= 100) 
was observed in 20% of the cohort, with the highest expression 
observed in SCC/mixed histology, but 6% of ADCs also showed 
elevated PE. There was no elevated FGFR1 PE in the never smo-
kers. There was significant correlation but incomplete overlap bet-
ween biomarkers. There were no prognostic associations, either 
with overall or disease-free survival, for FGFR1 GCN, ME, or PE. 
There was excellent inter-observer agreement among the readers 
of all 3 biomarker assays.
Conclusion: Overexpression of FGFR1 mRNA and protein are 
more frequent than FGFR1 gene amplification in NSCLC patients. 
Although GCN amplification was restricted to SCC, elevated ME 
and PE were found in both ADC and SCC. There was no prognostic 
association with FGFR1 GCN, ME, or PE. These data are consistent 
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MO05.04 A PROSPECTIVE STUDY OF INNOVATIVE 
NON-INVASIVE TOOLS TO ASSESS THE RESPONSE TO 
ANTI-ANGIOGENIC THERAPIES IN NON SMALL CELL 
LUNG CANCER PATIENTS
Frederic Wallyn1, Antoine Claret2, Nunzia Tacelli3, Eric Wasie-
lewski1, Jean-Jacques Lafitte1, Jacques Remy3, Henri Porte2, Julia 
Salleron4, Marie-Capucine Willemin1, Alexis Cortot1, Genevieve 
Marchandise5, Martine Remy-Jardin3, Philippe Lassalle6, Arnaud 
Scherpereel1
1Pulmonary And Thoracic Oncology, Chru De Lille/France, 2Thoracic 
Surgery, Chru De Lille/France, 3Radiology, Chru De Lille/France, 4Statis-
tics, Chru De Lille/France, 5Inserm U1019 Ciil, Institut Pasteur De Lille/
France, 6Lunginnov, Institut Pasteur De Lille/France
Background: Therapies targeting tumor angiogenesis, such as 
anti-VEGF antibodies (bevacizumab), are a major step in the treat-
ment of non small cell lung cancer (NSCLC) but are costly drugs 
and may be responsible for significant toxicities. The goal of our 
study was to assess the value of non-invasive tools evaluating early 
the response to bevacizumab in NSCLC.
Methods: 56 consecutive patients with stage IIIB-IV non-squa-
mous NSCLC were prospectively recruited. According to multidis-
ciplinary committee advice, one group of patients (bevacizumab 
group, n =24) had a chemotherapy combined with bevacizumab, 
the second one (control group, n = 32) had a similar chemotherapy 
but without bevacizumab. Quantitative tumor perfusion was se-
quentially evaluated with CT-scan before (T0) and after 1 cycle (T1) 
and 3 cycles (T2) of chemotherapy. CT-scan parameters included: 
(a) tumor height and diameter; (b) tumoral blood volume (BV) and 
capillary permeability (CP). Blood biomarkers (Endocan, VEGF, An-
giopoïetin-2, VEGFR-2, VE-cadherin) were measured at the same 
time points.
Conclusion: RSI appears to be predictive for benefit from adjuvant 
radiation. Additional independent prospective validation is requi-
red.
Keywords: gene expression profile, radiation oncology, resected 
lung cancer, adjuvant radiation
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Results: From the user’s perspective, usage is as easy as logging 
in and clicking a button to perform any of our current analysis func-
tions: · Survival Analysis: Test the association between the gene 
expression level and patients’ overall survival time in one study. 
· Meta-Survival Analysis: Summarize the association between the 
gene expression level and patients’ overall survival time across 
multiple studies. · Comparative Analysis: Test the association 
between the gene expression level and patients’ characteristics, 
such as gender, age, histology types, disease stages, etc. · Tumor 
vs. Normal: Test whether the gene expression levels different 
significantly between tumor samples and normal samples. · Co-
expression analysis: Calculate the correlations among a list of 
user-specified genes based on the gene expression levels. The 
web application is now online and available for usage: http://qbrc.
swmed.edu/lce/ . I will talk about the data curation, quality control, 
database development and the usage of this resource.
Conclusion: The Lung Cancer Explorer is a highly interactive open 
resource for lung cancer research and it can greatly facilitate the 
translational lung cancer research.
Keywords: gene expression signatures, database, bioinformatics, 
data integration
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MO05.07 NOMOGRAM COMBINING CLINICOPATHO-
LOGIC FACTORS AND MOLECULAR MARKERS FOR PRE-
DICTING SURVIVAL IN PATIENTS WITH RESECTED NON-
SMALL CELL LUNG CANCER
Wenhua Liang, Jianxing He, Daoyuan Wang, Qiuhua Deng, Hui 
Pan, Xiaoshun Shi, Chucheng Zhong, Lili Mo, Jiaxuan Wang
The First Affiliated Hospital Of Guangzhou Medical College/China
Background: Nomogram is a recognized method for individually 
predicting prognosis of cancer patients through combining various 
significant prognostic factors. Although the prognostic value of 
molecular biomarkers has been well studied, previous published 
nomograms are basically built based on only clinical factors. We 
sought to combine the clinicopathologic variables with the mole-
cular markers to develop a more precise nomogram for predicting 
survival for early stage NSCLC patient who underwent surgery.
Methods: Based on data from the China Clinical Trials Consortium 
(CCTC) that included 1038 patients with resected NSCLC for whom 
the 14-gene molecular assay (BAG1, BRCA1, CDC6, CDK2AP1, 
ERBB3, FUT3, iL11, LCK, RND3, SH3BGR, WNT3A with ESD, TBP 
and YAP as internal reference) was tested, we conducted multivari-
ate stepwise Cox regression analyses to identify significant factors 
which were then integrated to establish the nomogram. Nomo-
gram based on clinicopathologic variables only (c-nomogram) or 
both clinical and molecular factors (cm-nomogram) were establis-
hed respectively. Eighty percents of randomly sampled data were 
used to build the nomogram while the remaining data were used 
to validate it. The predictive accuracy and discriminative ability of 
the nomogram was determined by concordance index (C-index). 
Risk group stratification within a certain stage was proposed for 
the nomograms.
Results: We identified 15 independent prognostic factors, in-
cluding 7 clinicopathologic variables (age, sex, histology, diffe-
rentiation, tumor location, T and N stage) and 8 genes (with only 
Results: We observed an early and quite specific decrease of BV, 
CP and blood levels of VEGF, Angiopoïetin-2 and VE-cadherin 
in the bevacizumab group compared to control group. In the 
bevacizumab group, the decrease of BV between T0 and T1 
was more important in patients responding to treatment than 
in subjects with progression on clinical (ΔBVT0-1 =-2.72ml vs 
0.32ml, p=0.004) or RECIST criteria (ΔBVT0-1 =-3.35ml vs 0.04ml, 
p=0.011). An initial high Endocan level appeared as a marker of 
bad prognosis (overall survival) (HR=1.469 [1.120-1.925]; p=0.005) 
using a cut-off value of 0.72ng/ml (HR=2.276 [1.074-4.82]; p=0.032). 
Moreover, in the bevacizumab group, a significant decrease of 
Endocan level between T0 and T1 was a marker of good prognosis 
(HR=0.141 [0.022-0.889]; p=0.037).
Conclusion: Whole tumor perfusion analysis by CT-scan exhibited 
a promising predictive value for patients treated by chemotherapy 
combined with anti-angiogenic drug, whereas blood Endocan ap-
peared as the most interesting blood marker, having a significant 
prognostic value in the same patients. These two exciting non-
invasive tools deserve further and larger studies to confirm their 
value in monitoring NSCLC patients with therapies targeting tumor 
angiogenesis.
Keywords: CT-scan, NSCLC, Anti-angiogenic drugs, Endocan 
biomarker
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MO05.05 LUNG CANCER EXPLORER (LCE): AN OPEN 
WEB PORTAL TO EXPLORE GENE EXPRESSION AND 
CLINICAL ASSOCIATIONS IN LUNG CANCER
Jeffrey D. Allen1, Guanghua Xiao1, Hao Tang1, Jichen Yang1, Beibei 
Chen1, Jonathan Yoder1, John D. Minna2, Yang Xie1
1Clinical Sciences, Univ. Of Texas Southwestern Medical Center/United 
States Of America, 2Hamon Center For Therapeutic Oncology Research, 
The University Of Texas Southwestern Medical Center/United States Of 
America
Background: Lung cancer is the leading cause of death from can-
cer for both men and women in the United States with a 5-year 
survival rate of approximately 15%. Many gene expression microar-
ray datasets have been collected through different studies, while 
a single genomics study usually contains no more than 500 mic-
roarrays due to the high cost. We collected and manually curated 
mRNA expression microarrays together with clinical information 
for 5,218 lung cancer patients from 40 studies. The wealth of these 
large-scale datasets provides us great opportunities to generate 
significant scientific findings, while also posing great challenges for 
data integration.
Methods: To facilitate clinicians and researchers to access and use 
the resource, we developed an open web portal, The Lung Cancer 
Explorer, to explore gene expression and clinical associations in 
lung cancer. This database aggregates over 40 public clinically-
annotated lung cancer gene expression studies, along with some 
private data from the University of Texas Southwestern Medical 
Center, and presents a user-friendly, web-based interface to explo-
re and analyze this data. The database stores various information 
about patients including demographics, histology, stage classifica-
tions, clinical outcomes, and also stores the probe-level genome-
wide mRNA expression information, allowing users to perform very 
rich analysis on the data.
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CDK2AP1, FUT3, iL11, BAG1, CDC6, and RND3 were selected), 
then incorporated them to build the nomogram (Figure 1). The 
calibration curves for probability of 1, 3, 5-year overall survival (OS) 
showed good concordance between prediction by nomograms 
and actual observation in the validation set. The C-index of the 
cm-nomogram was statistically higher than that of the 7th edition 
TNM stage for predicting survival (0.72 vs 0.66, P=0.02) whereas 
the c-nomgram did not show superior performance than TNM 
stage system (0.69 vs 0.66, P=0.463). The stratification into three 
risk groups according to cm-nomogram allows significant distinc-
tion between Kaplan-Meier curves in each TNM stage respectively 
(P<0.01 for all stages, Figure 2).
Conclusion: We developed a novel and validated nomogram that 
combines clinicopathologic factors and molecular markers, which 
provided more accurate predictions for OS of resected NSCLC 
patients compared with the TNM staging system and nomogram 
considering only clinical variables. This prognostic model lent sup-
port to clinicians and patients in decision making. In addition, it 
indicated that it is feasible and essential to incorporate molecular 
markers when building a nomogram to obtain more accurate pre-
diction.
Keywords: predictor factor, 14-gene molecular assay, Lung cancer, 
Nomogram
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LANSCLC based on personalized molecular staging and typing.
Keyword: LANSCLC Individual surgical treatment Individual mole-
cular staging
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MO05.09 ACTIVATION OF THE CLASSICAL COMPLE-
MENT PATHWAY: A NOVEL BIOMARKER FOR THE EARLY 
DIAGNOSIS AND PROGNOSIS OF LUNG CANCER
Daniel Ajona1, Maria J. Pajares1, Leticia Corrales1, Jose L. Perez-
Gracia2, Jackeline Agorreta1, Maria D. Lozano2, Wenceslao Torre2, 
Pierre Massion3, Juan P. De-Torres2, Eloisa Jantus-Lewintre4, Carlos 
Camps4, Javier Zulueta2, Luis Montuenga1, Ruben Pio1
1Oncology Division, Cima-university Of Navarra/Spain, 2Clinical Uni-
versidad De Navarra/Spain, 3Vanderbilt University Medical Center/
United States Of America, 4Hospital General Universitario De Valencia/
Spain
Background: Numerous diagnostic and prognostic molecular 
markers have been proposed for lung cancer. However, genetic 
heterogeneity has limited the success of these initiatives. This li-
mitation may be overcome by the use of biomarkers related to the 
host response to cancer. In this study we tested the capacity of 
lung cancer cells to activate the complement system and evaluated 
the diagnostic performance of complement-activation fragments. 
We demonstrate for the first time that lung cancer cells efficiently 
activate the classical complement pathway and that fragments of 
complement activation are of value for detection and prognosis of 
lung cancer at a very early stage.
Methods: We first assessed complement activation in bronchial 
epithelial and lung cancer cell lines. C4d, a degradation product of 
complement activation, was determined in 90 primary lung tumors; 
in bronchoalveolar lavage supernatants from 50 patients with lung 
cancer and 22 non-malignant respiratory diseases; and in plasma 
samples from different cohorts, including: advanced (n=133) and 
early (n=84) non-small cell lung cancer patients, subjects with in-
flammatory lung diseases (n=133) and asymptomatic individuals 
enrolled in a lung cancer CT-screening program (n=190; 32 of them 
with lung cancer).
Results: Lung cancer cells treated with normal human serum 
activated complement and deposited C3 more efficiently than 
non-malignant bronchial epithelial cells. Incubation of cells with 
different buffer conditions, complement depleted sera and com-
plement inhibitors showed that lung cancer cells bind C1q and 
activate complement through the classical complement pathway. 
In a set of lung cancer cell lines, a significant correlation was found 
between C1q binding and C4 or C3 deposition. The presence of 
phosphatidylserine inhibited C1q binding and diminished comple-
ment activation. Based on these results, C4d, a classical pathway-
derived split product, was evaluated as a possible diagnostic or 
prognostic biomarker in lung cancer. Many lung primary tumors 
(adenocarcinomas and squamous cell carcinomas) deposited 
C4d. More importantly, survival was decreased in patients with 
high C4d deposition in their tumors (HR=3.06; 95% CI=1.18-7.91). 
Moreover, C4d levels were increased in bronchoalveolar lavage 
fluid from lung cancer patients as compared to patients with non-
malignant respiratory diseases (0.61 ± 0.87 vs. 0.16 ± 0.11 µg/ml, 
respectively; P<0.001). C4d levels in plasma samples from lung 
cancer patients at both advanced (III and IV) and early (I and II) 
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MO05.08 INDIVIDUALIZED SURGICAL TREATMENT FOR 
LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER 
BASED ON MOLECULAR BIOMARKERS.
Qinghua Zhou
Tianjin Thoracic Cancer Center, Tianjin Lung Cancer Institute/China
Background: Approximately 35%-40% of NSCLC have locally ad-
vanced disease. The average survival time of these patients only 
have 6-8 months with chemotherapy and radiotherapy. The aim 
of this study is to explore and summarize the probability of mo-
lecular biomarker detection in cancer tissues, mediastinal lymph 
nodes and peripheral blood for molecular stages and types of lung 
cancer, and for individual surgical treatment and postoperative 
adjuvant therapy and for prediction of postoperative recurrence of 
lung cancer in stage III disease; to summarize the long-time survi-
val result of personalized surgical treatment of 1036 patients with 
LANSCLC based on molecular biomarker detection.
Methods: CK19 and Muc-1 mRNA expression of peripheral blood 
was detected in 1036 patients by RT-PCR before and after ope-
ration for individual molecular staging and personalized surgical 
treatment and postoperative adjuvant therapy. micro-RNA and 
gene chips were used to detect the differential micro-RNAs and 
gene profiles between the primary cancer tissues and metastatic 
mediastianl lymph nodes for individual postoperative adjuvant 
therapy and prediction of prognosis of the patients with LANSCLC. 
The long-term survival of personalized surgical treatment was 
retrospectively analyzed in the 1036 patients based on molecular 
staging and typing.
Results: There were 678 squamous cell carcinoma and 358 ade-
nocarcinoma. 212 patients had IIIA disease and 824 had IIIB 
disease according to P-TNM staging. 126 patients had M-IIIA 
disease, 603 had M-IIIB disease and 307 had M-IV disease accor-
ding to molecular staging. Of the 1036 patients, bronchoplastic 
procedures and pulmonary artery reconstruction was carried out 
in 356 cases; double sleeve lobectomy combined with resection 
and reconstruction of partial left atrium, superior vena cava, carina, 
aorta and postcava was performed in 680 cases in this series. Thir-
teen patients died of operative complications and the operative 
mortality was 1.16%. CK19 and Muc-1 mRNA positive expression in 
peripheral blood was found in 265(25.6%) patients. The differential 
micro-RNAs and gene profiles between the primary cancer and 
metastatic mediastinal lymph nodes divide the 1036 patients into 
high and low recurrence risk groups. The median survival time was 
51.74 months. The 1, 3, 5 and 10 year survival rates of the 1036 
cases was 81.1%, 49.3%, 30.8% and 21.4%, respectively.The post-
operative survival rate was remarkably correlated with individual 
molecular staging and typing, micrometastasis, histological clas-
sification and size of primary cancer and LN metastasis (P<0.05). 
Multivariable Cox model analysis showed that “personalized mo-
lecular staging”, micrometastasis, the differential micro-RNAs and 
gene profiles and mediastinal lymph node metastasis were the 
most significant factors for predicting prognosis in the patients 
with LANSCLC.
Conclusion: Detection of micrometastasis in peripheral blood will 
be helpful for individual surgical treatment and postoperative ad-
juvant therapy in LANSCLC patients. The differential micro-RNAs 
and gene profiles can predict the recurrence and prognosis of the 
cancer. Individualized surgical treatment can significantly improve 
prognosis and increase curative rate and long-term survival rate of 
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Results: Of 760 patient treatment courses analyzed, 16 distinct pa-
tients with stage III NSCLC were identified that received metformin 
for diabetes while undergoing definitive chemoradiation. Patients 
were predominantly female (63%) and had stage IIIA disease (69%). 
They were treated to a median of 66.6/1.8 Gy with concurrent 
(81%) or sequential (19%) chemotherapy.A dramatic improvement 
in LLR in patients receiving metformin was seen compared to his-
torical controls. With a median follow-up time of 10.4 months, only 
2 local recurrences (9.6 and 14.9 months post-radiotherapy) have 
occurred. The median disease-free survival and OS have not been 
reached. From our in vivo murine data, early data supports the use 
of metformin as a radiosensitizing agent in the treatment of locally 
advanced NSCLC.
Conclusion: Our clinical experience demonstrates patients recei-
ving definitive chemoradiation for stage III NSCLC who took met-
formin for diabetes had improved local control and OS compared 
with our patients not taking metformin and compared with histori-
cal controls. Additional evidence is needed to supporting radiation 
potentiation effects of metformin in the setting of definitive che-
moradiation for locally advanced NSCLC patients. Such findings, 
along with our clinical retrospective data, will lead to institutional 
prospective clinical trials, for the first-time, using metformin as a 
radiosensitizing agent in combination with radiation therapy and 
chemotherapy in the treatment of lung and potentially other can-
cers.
Keywords: Metformin, non-small cell lung cancer, radiosensitizati-
on, animal model
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MO05.11 THE EFFECT OF TWO BRM PROMOTER POLY-
MORPHISMS ON THE RISK OF ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC) AND SMALL CELL LUNG 
CANCER (SCLC) IN SMOKERS
Sinead Cuffe1, Xin Qiu1, Devalben Patel1, Abul K. Azad1, Dangxiao 
Cheng1, Zhuo Chen1, Kevin Boyd1, Natasha Leighl1, Wei Xu1, Fran-
ces A. Shepherd1, Ming S. Tsao1, David N. Reisman2, Geoffrey Liu1
1Princess Margaret Cancer Centre/university Of Toronto/Canada, 2Uni-
versity Of Florida/United States Of America
Background: BRM, an ATPase subunit of the SWI/SNF chromatin 
remodeling complex, is a putative tumor susceptibility gene in 
lung cancer. Loss of BRM expression occurs in 15% of lung cancers. 
Two BRM promoter insertion polymorphisms (BRM-741 and BRM-
1321) lead to epigenetic silencing of BRM and highly correlate 
with loss of BRM expression and function in lung tumors. Pharma-
cologic reversal of the epigenetic changes of BRM is feasible. We 
previously demonstrated a strong risk association between these 
two polymorphisms and susceptibility to early stage NSCLC. Here, 
we evaluate the association between the two BRM polymorphisms 
and risk of developing: 1) advanced NSCLC, and 2) SCLC among 
smokers.
Methods: Genotyping for BRM promoter polymorphisms was 
performed using TaqMan. The cohorts analyzed were: 1) 417 stage 
III-IV NSCLC cases and 2) 111 SCLC cases treated at the Princess 
Margaret Cancer Centre (PMCC), Toronto; and 3) 43 SCLC cases 
from the University of Florida (U of F), all with a smoking history 
of ≥1 pack-year. Cases were matched to healthy controls by fre-
quency distribution (1:2 for PMCC cases; 1:1 for U of F cases) based 
stages were also increased compared with control subjects (4.13 ± 
2.02 vs. 1.86 ± 0.95 µg/ml, P<0.001; and 3.18 ± 3.20 vs. 1.13 ± 0.69 
µg/ml, P<0.001, respectively). In addition, C4d plasma levels were 
associated with shorter survival in patients at advanced (HR=1.59; 
95% CI=0.97-2.60) and early stages (HR=5.57; 95% CI=1.60-19.39). 
Plasma C4d levels were dramatically reduced after surgical remo-
val of lung tumors. Finally, plasma C4d levels were associated with 
increased lung cancer risk in asymptomatic individuals: OR=4.38; 
95% CI=1.61-11.93.
Conclusion: Lung tumors activate the classical complement pa-
thway and generate C4d, a stable complement split product. 
Moreover, C4d is increased in biological samples from lung cancer 
patients, is associated with poor prognosis, and may be of clinical 
value for the early detection of lung cancer.
Keywords: Complement activation, Early diagnosis and prognosis, 
Molecular marker, Lung cancer
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MO05.10 METFORMIN AS A RADIOSENSITIZER FOR 
LUNG CANCER
Ildiko Csiki1, Charles B. Simone2, Marina Heskel2, Peter Gabriel2, 
Hyun Kim2, Michael N. Corradetti3, Souvik Dey2, Costas Koume-
nis2
1Radiation Oncology, Bldg 421, Trc 8-133, University Of Pennsylvania/
United States Of America, 2Radiation Oncology, University Of Pennsyl-
vania/United States Of America, 3Radiation Oncology, Harvard Univer-
sity/United States Of America
Background: In vitro data and early clinical results suggest that 
metformin, an agent commonly used in diabetes therapy, has 
direct cancer growth inhibition potential via mammalian target of 
rapamycin (mTOR) pathway suppression. Furthermore, a number of 
observational studies have associated lower cancer incidence and 
a lower risk of nonspecific cancer-related mortality with metformin 
use. Our first objective is to determine whether the use of metfor-
min is associated with improved local recurrence (LRR) and overall 
survival (OS) rates in diabetic patients with non-small cell lung can-
cer (NSCLC) treated with definitive chemoradiation. Based on en-
couraging retrospective clinical results, we moved on to establish 
an in-vivo murine model of lung cancer and to evaluate the tumor 
growth delay from using metformin as a radiosensitizing agent.
Methods: Data from 760 consecutive patient treatment courses 
from our institution for patients with NSCLC and small cell lung 
cancer treated with radiation therapy between 6/2008 and 6/2013 
were analyzed. All patients with diabetes and stage IIIA and IIIB 
NSCLC who received metformin during definitive radiotherapy 
were analyzed to determine clinical outcomes. For the in-vivo 
murine study, H1299 adenocarcinoma cells were injected in the 
flanks of nude mice for the subcutaneous tumor model. On day 2, 
mice began receiving daily intraperitoneal injection of metformin 
or vehicle for 5 days, after which they underwent irradiation to the 
flanks of 3Gy X 3 fractions. Tumor measurements were taken every 
other day and tumor growth delay was plotted. In order to assess 
the effect of metformin in the lungs as well as in-situ tumor effects, 
an orthotopic mouse model using bioluminiscence imaging (BLI) 
will be developed to allow serial lung tumor measurements as well 
as assessment of metformin effects on the normal lung when com-
bined with irradiation.
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MO06.01 CLINICAL FEATURES OF PATIENTS WITH NON 
SMALL CELL LUNG CANCER WHO HARBOR EGFR MUTA-
TION AND PRESENT WITH MILIARY INTRAPULMONARY 
OR DISSEMINATED CARCINOMATOSIS
Hee Joung Kim, Seong Hui Kang, Sun Jong Kim, Gwang Ha Yoo, 
Kye Young Lee
Department Of Internal Medicine, Konkuk University Hospital/Korea
Background: It is reported that epidermal growth factor receptor 
(EGFR) mutation is frequent in non-small cell lung cancer (NSCLC) 
patients who are presenting with miliary intrapulmonary carcino-
matosis. We often encountered disseminated carcinomatosis as 
well as intrapulmonary carcinomatosis. This study aims to investi-
gate the clinical characteristics of patients with miliary intrapulmo-
nary or disseminated carcinomatosis.
Methods: Patients with advanced NSCLC who harbor EGFR mu-
tation and presented with miliary intrapulmonary or disseminated 
carcinomatosis were enrolled respectively, from September 2005 
to January 2011. EGFR mutations in exons 18-21 were confirmed 
by pyroseqeuncing method after genomic DNA was extracted 
from paraffin-embedded tissue specimens. Clinical characteristics, 
responses to treatment and outcome were collected from medical 
records.
Results: Histology of sixty-four patients with NSCLC who have 
EGFR mutation revealed adenocarcinoma. The most frequent 
mutation was in-frame deletions in exon 19 (n=44, 68.7%). An argi-
nine-for-leucine substitution at amino acid 858 (L858R) and point 
mutation in exon 18 (G719A) were detected in 19 (29.7%) and 1 
(1.7%) patient, respectively. Patients with miliary intrapulmonary or 
disseminated carcinomatosis were more common in female (80.0% 
vs. 55.1%, p=0.084), non smoker (80.0% vs. 53.1%, p=0.063), and 
in-frame deletions at exon 19 (86.7% vs. 63.3%, p=0.087), however 
there were no significant difference statistically. They showed rela-
tively shorter progression free survival (PFS) to EGFR tyrosine kina-
se inhibitors (median PFS 9.7 vs, 12.8 months, p=0.003) and poorer 
overall survival (median OS 15.9 vs. 29.0 months, p=0.077) compa-
red to patients without miliary metastasis. In multivariate analysis, 
higher metabolic tumor volume (MTV) in PET-CT was confirmed 
to be an independent predictor of shorter overall survival, when 
considered together with tumor stage, gender and smoking status 
(hazard ratio for MTV: 1.001; p = 0.027).
Conclusion: The data indicate that NSCLC presenting miliary int-
rapulmonary or disseminated carcinomatosis were more common 
in female, adenocarcinoma, non smoker and in-frame deletions in 
exon 19 was comparatively frequently detected in those patients, 
however there were no statistically significant difference. PFS to 
EGFR tyrosine kinase inhibitors was less in patients with miliary 
intrapulmonary or disseminated carcinomatosis and overall survival 
was poorer compared to patients without miliary metastasis. Poor 
clinical course of these patients might be associated with high 
tumor burden represented by metabolic tumor volume or total 
lesion glycolysis.
on age, gender, pack-year smoking history, and either current 
smoking status (PMCC) or ethnicity (U of F). Adjusted odds ratios 
(aORs) with their 95% confidence intervals (CI) of the association 
between polymorphisms and lung cancer risk were estimated by 
multiple logistic regression models.
Results: Of the 417 NSCLC cases, 59% were male; 41%, current 
smokers; 63%, adenocarcinoma; 51%, stage IV; median age, 63 
years. The frequency of homozygosity was BRM-741, 21%; BRM-
1321, 20%; both, 11%. The homozygous variants of BRM-741 and 
BRM-1321 were associated with an increased risk of advanced 
NSCLC compared to the wild types, with aOR’s of 1.6 (95% CI: 1.1-
2.2; p=0.008) and 1.4 (95% CI: 1.0-2.0; p=0.04), respectively. Being 
homozygous for both BRM promoter variants carried an even gre-
ater risk (aOR 2.4 [95% CI: 1.4-4.0; p=0.0009]), with the strongest 
effect observed among current smokers (aOR 3.4; p=0.0005), and 
those with a histological diagnosis other than adenocarcinoma 
(aOR 3.2; p=0.0005). Among the 111 PMCC SCLC cases, 62% were 
male; 56%, current smokers; median age 65 years; of the 43 U of F 
SCLC cases, 35% were male; median age, 63 years. The presence 
of double homozygous variants of BRM-741 and BRM-1321 had no 
effect on the risk of developing SCLC in either of the two cohorts 
analyzed, with aOR’s of 1.1 (95% CI: 0.3-3.5; p=0.94) and 0.3 [95% 
CI: 0.04-2.41; p=0.27), respectively.
Conclusion: The presence of double homozygous variants of the 
BRM promoter polymorphisms, BRM-741 and BRM-1321, signifi-
cantly increases the risk of advanced NSCLC among individuals 
with a smoking history greater than one year, with the strongest 
effect observed among current smokers. In contrast, the same two 
polymorphisms had no effect on the risk of developing SCLC in 
either of the two cohorts analyzed. Thus, this study offers further 
insight into potential mechanisms underlying the genetic suscepti-
bility to developing advanced NSCLC among smokers. Validation 
in larger populations is warranted.
Keyword: lung cancer, polymorphisms, BRM, risk
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sease. 43% (38/90) of the patients were treated with EGFR-TKI as 
the first-line therapy, and the rest of them were previously treated 
including 17% of the patients experienced with EGFR-TKI. T790M 
was detected in 23% (21/90) among the entire patients. Forty pati-
ents showed PD two years after beginning of this trial, and T790M 
was detected in 13 patients among the patients who acquired 
resistance to EGFR-TKI; the frquency of T790M positive among the 
patients with PD was 32.5% (13/40). Although T790M was tempora-
rily detected during treatment of EGFR-TKI in 8 patients who were 
still responded to EGFR-TKI, is disappeared after that.
Conclusion: T790M was detected in plasma DNA isolated from 
lung cancer patients whose diseases were progressed. Continuous 
detection of T790M in plasma DNA seemed to be related with 
occurrence of PD.
Keywords: EGFR-TKI, EGFR T790M, MBP-QP, plasma DNA
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MO06.03 BEVACIZUMAB AND ERLOTINIB OR BEVACI-
ZUMAB, CISPLATIN AND PEMETREXED IN PATIENTS 
WITH METASTATIC NON-SMALL CELL LUNG CAN-
CER: EGFR MUTATION BASED TREATMENT ALLOCA-
TION AND REPEAT BIOPSY AT PROGRESSION IN THE 
SAKK19/09 (BIOPRO) TRIAL
Oliver Gautschi1, Nicholas Mach2, Lukas Bubendorf3, Qiyu Li4, 
Alfred Zippelius3, Rolf Stahel5, Richard Cathomas6, Martin Fruh7, 
Daniel Betticher8, Solange Peters9, Daniel Rauch10, Martin Brut-
sche7, Spasenija Savic3, Rolf Jaggi11, Sacha Rothschild3, Elisabeth 
Oppliger Leibundgut11, Christiane Pilop4, Lukas Stalder4, Miklos 
Pless12, Adrian Ochsenbein11
1Medical Oncology, Cantonal Hospital Lucerne/Switzerland, 2University 
Hospital Geneva/Switzerland, 3University Hospital Basel/Switzerland, 
4Sakk/Switzerland, 5University Hospital Zurich/Switzerland, 6Cantonal 
Hospital Chur/Switzerland, 7Cantonal Hospital St. Gallen/Switzerland, 
8Cantonal Hospital Fribourg/Switzerland, 9University Hospital Lau-
sanne/Switzerland, 10Spital Thun/Switzerland, 11University Hospital 
Bern/Switzerland, 12Kantonsspital Winterthur/Switzerland
Background: Treatment allocation by EGFR mutation and mainte-
nance therapy are two new standards for patients (pts) with meta-
static non-small cell lung cancer (NSCLC). This multicenter phase II 
trial (NCT01116219) for the first time prospectively tested pemet-
rexed and bevacizumab maintenance therapy in pts with EGFR wild 
type NSCLC, and included repeat biopsy at progression to study 
molecular mechanisms of drug resistance. Pts with EGFR mutation 
were treated with erlotinib and bevacizumab, based on the results 
of the previous SAKK19/05 trial.
Methods: 100 pts were enrolled with metastatic nonsquamous 
NSCLC, sufficient material for mutation analysis and translational 
research, and consent to repeat biopsy at progression. Pts with 
EGFR wild type received 4 cycles of bevacizumab 7.5mg/kg, ci-
splatin 75mg/m2 (or carboplatin AUC5) and pemetrexed 500mg/
m2 every 3 weeks, followed by maintenance therapy with bevaci-
zumab and pemetrexed until progression. Pts with EGFR mutation 
received bevacizumab 7.5 mg/kg every 3 weeks and erlotinib 150 
mg daily until progression. Pts were followed by CT-scan every 6 
weeks and repeat biopsy was performed at progression. The pri-
mary endpoint was progression free survival (PFS) at 6 months. For 
an unpromising PFS at 6 months rate of ≤20% and a promising rate 
Keywords: Epidermal growth factor receptor mutation, non-small 
cell lung cancer, miliary disseminated carcinomatosis
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MO06.02 MONITORING EGFR T790M WITH PLASMA 
DNA IN LUNG CANCER PATIENTS TREATED WITH EGFR 
TYROSINE KINASE INHIBITOR IN PROSPECTIVE OBSER-
VATIONAL STUDY
Keisuke Aoe1, Naoko Sueoka-Aragane2, Nobuyuki Katakami3, Miy-
ako Satouchi4, Soichiro Yokota5, Kentaro Iwanaga6, Shinya Kimu-
ra2, Shunichi Negoro7
1Department Of Medical Oncology And Clinical Research, National 
Hospital Organization Yamaguchi-ube Medical Center/Japan, 2Division 
Of Hematology, Respiratory Medicine And Oncology, Department Of 
Internal Medicine, Faculty Of Medicine, Saga University/Japan, 3Di-
vision Of Integrated Oncology, Institute Of Biomedical Research And 
Innovation/Japan, 4Hyogo Cancer Center/Japan, 5Department Of Res-
piratory Medicine, National Hospital Organization Toneyama National 
Hospital/Japan, 6Division Of Respiratory Medicine, Saga-ken Medical 
Center Koseikan/Japan, 7Department Of Medical Oncology, Hyogo Can-
cer Center/Japan
Background: Detection of mutations with plasma DNA isolated 
from peripheral blood is an alternative method of biopsy. The 
gatekeeper T790M mutation of EGFR has been observed in half of 
patients who acquired resistance to EGFR tyrosine kinase inhibitor 
(EGFR-TKI). Considering that majority of lung cancer recurrence 
occurs as distant metastases, determination of T790M using a 
non-invasive mutation detection system with plasma DNA would 
be useful. We recently developed a novel non-invasive, fully-
automated monitoring system, MBP-QP (mutation-biased PCR and 
quenching probe) method, to detect T790M using plasma DNA. 
The detection limit was two copies of control plasmid and 0.2 ng 
of genomic DNA, the T790M mutation was 
detected in plasma DNA from 53% of lung adenocarcinoma pati-
ents who acquired resistance in the previous retrospective study. 
Compared with the other methods such as PNA-LNA PCR clamp, 
the cycleave PCR technique, and digital PCR, the MBP-QP method 
is simple, sensitive, and reflective of clinical course. To determine 
the usefulness of the MBP-QP method for monitoring T790M du-
ring treatment of EGFR-TKI, a prospective clinical study has been 
performed.
Methods: This is a prospective, multicenter observational study 
involving lung adenocarcinoma patients carrying EGFR activating 
mutations such as L858R and exon 19 deletions treated with EGFR-
TKI. Primary objective was to determine whether T790M was de-
tected with plasma DNA at the time point of progressive disease 
(PD), and the secondary objective was correspondence of T790M 
with plasma and cancer specimens. The association between de-
tection of T790M and effect of EGFR-TKI were also investigated 
as the exploratory objective. Plasma DNA was isolated from the 
patients before treatment of EGFR-TKI, every four months during 
treatment, at the time of occurrence of PD, and after two courses 
of post-chemotherapy.
Results: Ninety lung adenocarcinoma patients treated with EGFR-
TKI were enrolled, in whom 51% of L858R and 49% of exon 19 
deletions were determined in tumor specimens before treatment. 
Most of the patients, 92.1%, had adenocarcinoma. 62% (55/90) 
was stage IV, and 29% (26/90) had postoperative recurrent di-
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ents with wild-type (WT) tumors had inferior outcomes. Pemetrex-
ed, in combination with cisplatin, (PC) has demonstrated improved 
efficacy in first-line treatment of nSqNSCLC and is a preferred 
chemotherapy choice. The primary objective was to compare PC 
induction therapy followed by G as maintenance therapy to G 
monotherapy, in terms of PFS, as first-line treatment in a similar 
“IPASS” patient population.
Methods: Patients with unknown EGFR mutation status (N=236) 
were randomized 1:1 to PCG treatment for 6 cycles or G. Patients 
on Arm A without progressive disease after 6 cycles received G 
maintenance therapy. Stage IIIB/IV nSQ NSCLC, light ex-smokers 
or never-smokers, and ECOG PS 0-1 patients with no prior syste-
mic therapy were eligible. Primary endpoint analysis was conduc-
ted using a Wilcoxon test after 169 PFS events. This assessment 
provided 80% power if the true hazard ratio (HR) was 0.65. Tissue 
samples from consenting patients were analyzed for EGFR mutati-
on status.
Results: Baseline characteristics were balanced across treatment 
arms. One-hundred-forty-one patients provided tissue for EGFR 
mutation analysis (59.7%). Mutation status was determined for 74 
samples (52.5%);50/74 samples (67.6%) had mutations (mutation 
type: EX19_DEL, n=25; L858R, n=23; other, n=2). The primary ana-
lysis of PFS showed no significant difference between treatment 
arms (Wilcoxon p=0.217). The unadjusted HR was 0.85 (95% CI: 
0.63, 1.13). During most of the study period, the KM curve for PC 
remained above the G curve. In a prespecified subgroup ana-
lysis, EGFR-by-treatment interaction was statistically significant 
(p=0.008), showing treatment effect significantly differed by EGFR 
mutation status. The HR for PFS favored PC in both EGFR-mutated 
and EGFR-WT patients, but the magnitude of benefit was grea-
ter in EGFR-WT patients [EGFR-mutated patients HR=0.83 ([95% 
CI: 0.42, 1.62], p=0.585); EGFR-WT HR 0.18 ([95% CI: 0.06, 0.51], 
p=0.001)]. HRs for ITT and EGFR-mutated patients should be in-
terpreted with caution as they were not constant. Arm A had more 
patients with ≥1 possibly drug-related CTCAE grade 3/4 TEAEs 
but similar rates of all-grade TEAEs during induction. Selected 
grade 3/4 or all-grade TEAEs which occurred significantly more 
included anemia, neutropenia, emesis, and neuropathy in Arm A 
and AST/ALT elevations, diarrhea, pruritus, and skin rash in Arm B. 
The toxicity profile was similar in both arms during the G mainte-
nance period.
Conclusion: In the ITT population, the PFS difference was not sta-
tistically significant. In the biomarker assessable population, results 
are consistent with the existing consensus that patients with WT 
EGFR do not benefit with front-line EGFR TKI treatment. Overall, 
the results show that identification of the EGFR mutational status is 
key in the management of advanced NSCLC. Even in the presence 
of clinically favorable predictors of EGFR mutation positivity (>60% 
in our population), “empirical” choice of EGFR TKIs as front-line 
therapy may be detrimental to NSCLC patients without EGFR mu-
tations.
Keywords: EGFR, East-Asian patients, non-small cell lung cancer, 
pemetrexed
of ≥35%, 77 patients with EGFR wild type were needed to reach a 
power of 90% and an alpha level of 5%. Secondary endpoints were 
median PFS, overall survival (OS), best response rate of CR+PR 
(RECIST), and further biomarkers including KRAS, thymidylate syn-
thase (TS), and multigene expression.
Results: Seventy-seven pts with EGFR wild type and 20 pts with 
EGFR mutation were evaluable, 3 pts were not evaluable. Pts on 
bevacizumab and chemotherapy received on average 9 cycles 
(range 1-25). No unexpected toxicities were observed. PFS at 6 
months was 45.5% (CI: 34.1%, 57.2%), median PFS was 6.9 (CI: 4.6, 
8.3) months, OS was 12.1 (CI: 8.7, 14.7) months, and best response 
rate of CR+PR was 62%. Sixteen pts remain on treatment. Repeat 
biopsy at progression was successful in 31 of 39 (79%) of patients 
on trial treatment, and except for one transient pneumothorax, no 
relevant complications occurred. KRAS mutation was associated 
with poor overall survival (HR 2.0, CI: 1.05, 3.88; P=0.03), but not 
with PFS or best response. Pts on bevacizumab and erlotinib recei-
ved on average 16 cycles (range 6-37). PFS at 6 months was 70.0% 
(CI: 45.7%, 88.1%), median PFS was 14.0 (CI: 8.8, NA) months, me-
dian OS is not yet reached, best response rate of CR+PR was 70%, 
11 pts remain on treatment. Further analysis of serial serum and 
tumor samples is ongoing.
Conclusion: Compared with the previous POINTBREAK trial of 
pemetrexed and bevacizumab maintenance in genetically unse-
lected pts, this trial demonstrates almost identical survival rates in 
pts with EGFR wild type. KRAS mutation was prognostic, repeat 
biopsy at progression was feasible, and laboratory analysis is on-
going to validate TS and to develop a predictive gene signature. 
Firstline therapy with erlotinib and bevacizumab is promising in pts 
with EGFR mutation, and this combination is further tested in the 
ongoing ETOP 2-11 BELIEF trial.
Keywords: NSCLC, maintenance therapy, EGFR, biomarker
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Background: The IPASS study reported that in a clinically selected 
lung cancer patient population (East Asian, light ex-/nonsmokers 
with adenocarcinoma) gefitinib (G) provided superior progression-
free survival (PFS) than chemotherapy with carboplatin/paclitaxel; 
however, the benefit was restricted to patients with epidermal 
growth factor receptor gene (EGFR)-mutant tumors whereas pati-
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agent, with an acceptable safety with both agents. These results 
are sufficiently compelling to consider whether a phase III rando-
mised non inferiority study with oral vinorelbine maintenance after 
induction vinorelbine/cddp could be as effective as pemetrexed 
maintenance. An oral maintenance may be a definite advantage 
over intravenous maintenance.
Keyword: NSCLC, Non squamous, chemotherapy, oral vinorelbine, 
advanced disease
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Background: Metronomic regimens, in which small, frequent do-
ses of chemotherapy are administered, have been suggested to 
lower treatment-associated toxicities while maintaining, or even 
improving, efficacy. The high frequency of administration aims to 
expose tumour cells continuously to the drug, preventing reco-
very between cycles and possibly improving tumour control. We 
present the clinical and pharmacokinetic data of a phase I dose 
finding study in which the maximum tolerated dose (MTD) of daily 
oral vinorelbine was determined in pretreated patients with advan-
ced NSCLC.
Methods: Patients (pts) were treated daily with oral vinorelbine 
(Navelbine® Oral) at fixed doses of 20 mg/d, 30 mg/d, 40 mg/d or 
50 mg/d for 21 days of each four-week cycle. Blood sampling for 
pharmacokinetic assessment was carried out in the first cycle just 
before drug intake (trough concentrations) on days 1, 8, 15 and 21 
and additionally at 1 h, 3 h and 24 h after drug intake on days 1 
and 21.
Results: Daily administration of oral vinorelbine was well tolerated 
up to 30 mg/d without any dose limiting toxicities (DLT). At 40 mg 
one of three patients experienced DLT in cycle 1 and another pati-
ent in cycle 2. The MTD was reached at 50 mg/d when three out of 
six pts experienced DLT in cycle one. The reported DLTs included 
febrile and non-febrile neutropenia (6 DLTs) as well as fatigue (1 
DLT). One patient had an exceptionally good clinical response with 
a long-lasting tumour remission. Twenty-one pts were evaluable 
for pharmacokinetic analysis. Blood concentrations of vinorelbine 
increased with escalating dose levels. Pts were continuously expo-
sed to the drug over the 21-day treatment period as indicated by 
measurable trough concentrations on days 8, 15 and 21. A slight 
accumulation of vinorelbine was observed until day 8 based on 
residual concentrations (ratio c24h ranged 1.96-2.03 between day 
1 and either day 8, 15 or 21). The accumulation had no impact on 
global exposure at repeated dosing, as only minor differences in 
blood concentrations were detected between day 1 and day 21 
(ratio d21/d1 median AUC0h-24h: 0.81, 0.92, 1.07, 0.56 at 20 mg/d, 30 
mg/d, 40 mg/d and 50 mg/d, respectively). Data on four pts ex-
periencing DLT were available (1 pt at 40 mg/d, 3 pts at 50 mg/d). 
Only one DLT correlated with an evidently high 24 h blood exposu-
re to vinorelbine.
NSCLC - CHEMOTHERAPY I  
MONDAY, OCTOBER 28, 2013 - 16:15-17:45
MO06.06 ORAL VINORELBINE (NVBO) AND CISPLATIN 
(P) OR PEMETREXED (PEM) AND P AS FIRST-LINE CHE-
MOTHERAPY FOR NON SQUAMOUS (NS) METASTATIC 
OR LOCALLY ADVANCED NON SMALL CELL LUNG CAN-
CER (M OR LA NSCLC): FINAL RESULTS OF A PROSPEC-
TIVE RANDOMISED PHASE II TRIAL (NAVOTRIAL 1)
Eng-Huat Tan1, Maciej Krzakowski2, Jens Kollmeier3, Radj Ger-
vais4, Eric Dansin4, Monika Serke5, Adolfo Favaretto6, Libor Havel7, 
Manuel Cobo8, Aleksandra Szczesna9, Libero Ciuffreda10, Jacek 
Jassem11, Mario Nicolini12, Rodryg Ramlau13, Domenico Amoroso14, 
Barbara Melotti15, Maria Teresa Almodovar16, Nathalie Vaissière17, 
Marcello Riggi17, Jaafar Bennouna18
1National Cancer Centre/Singapore, 2Centrum Onkologii – Instytut Im. 
Marii Skłodowskiej-Curie/Poland, 3Klinik Für Pneumologie - Helios 
Klinikum Emil Von Behring/Germany, 4Oncology, Centre Oscar Lamb-
ret/France, 5Thoracic Oncology, Hemer Lung Clinic/Germany, 6Second 
Medical Oncology, Istituto Oncologico Veneto/Italy, 7Fakultni Nemocnice 
Na Bulovce/Czech Republic, 8Medical Oncology, Hru Carlos Haya/Spain, 
9Mazowieckie Centrum Leczenia Chorób Płuc I Gruźlicy/Poland, 10On-
cologia Medica, Ospedale Molinette/Italy, 11Department Of Oncology 
And Radiotherapy, Medical University Of Gdańsk/Poland, 12Ospedale 
Cervesi/Italy, 13Z Pododdziałem Dziennej Chemioterapii, Wielkopolskie 
Centrum Pulmonologii I Torakochirurgii/Poland, 14Azienda Usl 12 Di 
Viareggio/Italy, 15Policlinico S. Orsola Malpighi, Azienda Ospedaliero-
universitaria Di Bologna/Italy, 16Pneumologia, Instituto Português De 
Oncologia De Lisboa Francisco Gentil/Portugal, 17Institut De Recherche 
Pierre Fabre/France, 18Dpt Medical Oncology, Centre François Baclesse/
France
Background: NVBo and P are an established regimen in advanced 
NSCLC. The approval of Pem and P in NS NSCLC recognises his-
tology as treatment driver even if the higher chemosensitivity of 
NS NSCLC is recognised and reported with other chemotherapies 
(Ardizzoni. JNCI 2007). NVBo + P also showed better survival in NS 
NSCLC than in Squamous NSCLC (Tan. Ann.Oncol. 2009). The cur-
rent randomised (2:1) phase II trial assessed disease control (DCR) 
(SD + PR + CR) of NVBo/CDDP or PEM/CDDP in NS NSCLC.
Methods: Stage IIIB/IV untreated/relapsed NS NSCLC pts were 
randomised to receive q3w NVBo 80 mg/m² D1D8 (60 at Cycle 1) + 
P 80 mg/m² D1 (Arm A) or Pem 500 mg/m² + P 75 mg/m² D1 (Arm 
B). After 4 cycles of combination, non PD pts received single agent 
NVBo (Arm A) or PEM (Arm B) as maintenance until progression or 
toxicity. Pts were randomised on a 2/1 basis and stratified accor-
ding to Stage (IIIB - IV - relapse), non SCC confirmed by histology 
or cytology, gender, smoking status and centre.
Results: From 11/09 to 02/11, 153 patients were enrolled in 31 
centers and randomised to Arm A (102 pts) or Arm B (51 pts). DCR 
after combination and maintenance was 75.0% (95% CI, 65.3 to 
83.1) in Arm A and 76.5% (95% CI, 62.5 to 87.2) in Arm B. Median 
PFS was 4.2 (95% CI, 3.6 to 4.7) and 4.3 months (95% CI, 3.8 to 5.6) 
in Arm A and Arm B, respectively. Median OS was 10.2 months 
(95% CI, 7.8 to 11.9) and 10.8 months (95% CI, 7.0 to16.4) in Arm A 
and Arm B, respectively. During the combination period Grade 3/4 
neutropenia was 44.0% in Arm A and 18.3% in Arm B but febrile 
neutropenia was 2% in both arms; grade 3/4 thrombopenia was 
0% and 6% in Arm A and Arm B, respectively.
Conclusion: Both doublets reported good efficacy and acceptable 
tolerability. The maintenance allowed continuation of effective 
treatment with either oral vinorelbine or pemetrexed as single 
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CI, 0.56, 1.22; p=0.43). Grade ≥ 3 adverse events (AEs) occurring 
in >10% of patients on RAM containing arm were: anemia, neutro-
penia, thrombocytopenia, nausea, fatigue, back pain, and hyper-
tension.
Conclusion: While the primary endpoint of significant prolon-
gation of PFS was not met, RAM has evidence of clinical activity 
in combination with PEM + Cb/Cis in patients with NSQ NSCLC. 
Addition of RAM to PEM + Cb/Cis did not result in excessive or 
unexpected toxicity.
Keyword: Clinical Research, NSCLC, Advanced Stage, Novel The-
rapies
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Background: Bevacizumab has been shown to amplify efficacy 
against n-Sq NSCLC in combination with platinum doublet, espe-
cially taxane including regimens. Docetaxel is one of best taxane 
composition combined with cisplatin for first line treatment for 
NSCLC, and known to have anti-angiogenic effect and may act 
synergistically with VEGF inhibiting agent. The object of this study 
was to assess the efficacy and safety of bevacizumab, cisplatin and 
docetaxel combination treatment in patients with chemonaive n-Sq 
NSCLC patients. (Trial Registry: UMIN 000004368)
Methods: Eligible patients had advanced or recurrent n-Sq NSCLC 
with no prior chemotherapy. Patients having brain metastasis or 
history of hemoptysis were ineligible. Patients received 4 cycles of 
docetaxel (60mg/m2), cisplatin (80mg/m2) and bevacizumab (15mg/
kg) on day1 every 3 weeks followed by Bev alone as maintenance 
every 3 weeks until disease progression or unacceptable toxicity. 
The primary endpoint was response rate (RR) and planned sam-
ple size of this phase II study was 47 patients (Simon‘s two-stage 
minimax design). We measured circulating endothelial cells (CEC) 
count day1 and 8 of first cycle for exploratory analysis of efficacy 
and safety prediction.
Results: From Oct 2010 to Apr 2012, 47 patients (28 males/ 19 fe-
Conclusion: The recommended dose for daily administration of 
oral vinorelbine is 30 mg in cycle 1 followed by 40 mg in subse-
quent cycles in the absence of DLT. Further studies are necessary 
to determine the clinical impact, and possible anti-angiogenic 
profile of the daily administration schedule of vinorelbine.
Keywords: non-small cell lung cancer, chemotherapy, Metronomic 
Chemotherapy, vinorelbin oral daily
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Background: Vascular endothelial growth factor (VEGF)-mediated 
angiogenesis plays an important role in NSCLC pathogenesis. 
RAM is a human IgG1 monoclonal receptor targeted antibody that 
inhibits VEGF receptor-2 (VEGFR-2) binding and signaling. This 
study investigates RAM in combination with first-line platinum-
pemetrexed chemotherapy in advanced NSCLC.
Methods: Eligible patients had Stage IIIb/IV NSCLC, ECOG PS ≤ 2, 
and no prior chemotherapy or VEGF/VEGFR therapy for metastatic 
disease. Non-squamous (NSQ) pts with advanced NSCLC were 
randomized 1:1 to either Arm A: pemetrexed + carboplatin/cispla-
tin (PEM + Cb/Cis) followed by PEM maintenance or Arm B: Ramu-
cirumab 10 mg/kg + pemetrexed + carboplatin or cisplatin (RAM + 
PEM + Cb/Cis), followed by RAM + PEM maintenance once every 
3 weeks. Patients received the first-line therapy from 4 to 6 cycles 
(21-day cycle); patients without evidence of disease progression 
entered a maintenance phase. The primary endpoint was progres-
sion-free survival (PFS). Secondary endpoints included objective 
response rate (ORR), disease control rate (DCR), overall survival 
(OS), change in tumor size, duration of response, and safety.
Results: From Oct 2010 to 2012, 140 pts were randomized (PEM 
+ Cb/Cis: 71; RAM + PEM + Cb/Cis: 69). Overall, baseline patient 
characteristics were balanced between arms. The median PFS was 
5.6 m PEM + Cb/Cis and 7.2 m for RAM + PEM + Cb/Cis; HR 0.75 
(90% CI, 0.55, 1.03; p =0.132). ORR (CR + PR) was 38% for PEM + 
Cb/Cis and 49.3% including one complete response in the RAM + 
PEM + Cb/Cis arm (p=0.18). Disease control rate (CR + PR + SD) 
was 70% PEM + Cb/Cis and 86% for RAM + PEM + Cb/Cis ( p = 
0.031). Median OS at the time of final PFS analysis was 10.4 m for 
PEM + Cb/Cis and 13.9 m for RAM + PEM + Cb/Cis; HR 0.83 (90% 
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(days 1 and 15). Patients with response or stable disease continued 
pemetrexed and bevacizumab every 14 days until progression or 
unacceptable toxicity. Patients were evaluated on days 1, 8 and 15 
of each 28-day cycle. To assess response, CT scans were perfor-
med after cycles 1 and 2, and every 2 cycles thereafter. ORR was 
the primary endpoint.
Results: Forty-four patients were enrolled: 50% women, median 
age of 59 years (range, 31 to 77), 89% with Karnofsky performance 
status ≥80%. Mutation status was known in 38 patients (KRAS, 
n=16; ALK, n=3; BRAF V600E, n =2; Her2 insertion/PIK3CA, n=1; 
EGFR Exon 20 insertion, n=1; none, n=15). The ORR was 52% (95% 
CI, 37-68), with 23 partial responses and no complete responses. 
The median overall survival and progression-free survival were 17 
months (95% CI, 12-33) and 8 months (95% CI, 6-12), respectively. 
Grade 3/4 toxicities included fatigue (33%); elevated liver function 
tests (15%); leukopenia (9%); hoarseness (7%); nausea (7%); and 
anemia (7%). Two patients died on study of respiratory failure, pos-
sibly related to therapy. No bleeding events were noted.
Conclusion: The “non-platinum” containing regimen of paclitaxel, 
pemetrexed and bevacizumab is an effective first-line treatment for 
patients with advanced NSCLCs, regardless of mutational status. 
Long survival was observed, with acceptable toxicities. This regi-
men warrants further study.
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Background: A post hoc analysis of NSCLC patients (pts) aged ≥70 
y in the pivotal E4599 trial found increased adverse events (AEs) 
and numerically decreased overall survival (OS) benefit associated 
with bevacizumab (BEV) compared with pts <70 y. We evaluated 
the efficacy and safety of BEV by age in pts in a pooled dataset 
from the E4599 and PointBreak (PB) trials.
Methods: Pts randomized to the PC (paclitaxel and carboplatin 
) + BEV arms of E4599 and PB received P 200 mg/m2, C AUC 6, 
and BEV 15 mg/kg q3w for 6 (E4599) or 4 (PB) cycles; Eligible pts 
received maintenance BEV alone q3w until disease progression or 
unacceptable toxicity. OS, progression-free survival (PFS), overall 
response rate (ORR), disease control rate (DCR), and safety were 
assessed in pts grouped according to age (<65 y, 65–74 y, 70–74 y, 
males, median age, 61 years, 39-73) were enrolled. Stage IIIB/IV/re-
current: 5/39/3, ECOG PS 0/1: 31/16. All patients were adenocarci-
noma, EGFR status: mutated/wild/unknown: 13/31/3. Bevacizumab 
maintenance were administered in 87% (41/47) of the patients and 
9 was median number of delivered course, 4 course of induction 
and 5 course of maintenance. Dose reduction was required in 28% 
(13/47) of the patients. Thirty-five partial responses and 11 stable 
diseases were observed among 47 patients, yielding a RR of 74.5% 
(95% confidence interval: 59.7-86.1%) and disease control rate of 
97.9% (88.7-99.9%), respectively. The median progression free sur-
vival duration in the patients was 9.0 (7.0-11.3) months. Grade 3/4 
leukopenia, neutropenia, hypertension, nausea and febrile neu-
tropenia were observed in 60, 96, 47, 13 and 9% of the patients, 
respectively. Alveolar hemorrhage (Grade 5) after 4 cycle occurred 
in one patient.
Conclusion: Bevacizumab, cisplatin and docetaxel combination 
followed by bevacizumab maintenance treatment was highly effec-
tive in patients with n-Sq NSCLC, with acceptable toxicity. Explora-
tory analysis of CEC is ongoing and will be presented.
Keyword: Lung cancer cisplatin docetaxel bevacizumab
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MO06.11 A PHASE II TRIAL OF PACLITAXEL, PEMETREX-
ED AND BEVACIZUMAB IN PATIENTS WITH UNTREATED, 
ADVANCED LUNG CANCERS
Maria C. Pietanza1, Matthew D. Hellmann1, Naiyer Rizvi1, Chris-
topher G. Azzoli1, Stephanie Smith-Marrone1, John Fiore1, Leslie 
B. Tyson1, Dyana K. Sumner1, Alison B. Hergianto1, Samantha L. 
Kass1, Claire P. Miller1, Camelia S. Sima2, Binsheng Zhao3, Michelle 
S. Ginsberg3, Lawrence H. Schwartz3, Mark G. Kris1
1Department Of Medicine/thoracic Oncology Service, Memorial Sloan-
Kettering Cancer Center/United States Of America, 2Department Of 
Biostatistics, Memorial Sloan-Kettering Cancer Center/United States Of 
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States Of America
Background: Standard front-line treatment for patients with un-
resectable or metastatic non-small cell lung cancer (NSCLC) is a 
platinum-based doublet with bevacizumab regimen, which achie-
ves objective response rates (ORR) of 35% and median survival of 
12 months. However, many patients with lung cancer are not eligi-
ble for cisplatin because of baseline neuropathy, hearing loss, renal 
insufficiency, or comorbid medical conditions. Although carbopla-
tin is often substituted for cisplatin, it also is associated with similar 
toxicities, albeit with a smaller risk. This phase II trial of paclitaxel, 
pemetrexed, and bevacizumab was designed to avert the toxicities 
of platinum-based chemotherapeutic regimens and determine the 
efficacy of such a "non-platinum“ containing doublet with bevaci-
zumab.
Methods: Patients with untreated, advanced NSCLCs were en-
rolled if they had measurable disease (RECIST 1.0) and adequate 
organ and marrow function. Patients were excluded if they had 
squamous cell carcinoma; hemoptysis; symptomatic or hemorrha-
gic brain metastases; history of abdominal fistula, gastrointestinal 
perforation or intra-abdominal abscess; and myocardial infarction 
or stroke within 6 months prior to enrollment. For six 28-day cyc-
les, patients received: paclitaxel 90 mg/m2 (days 1, 8, and 15), pe-
metrexed 500 mg/m2 (days 1 and 15), and bevacizumab 10 mg/kg 
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<75 y, and ≥75 y). Pt-level data from the PC + BEV arms of E4599 
and PB were pooled and compared with data from pts in the PC-
alone arm of E4599.
Results: PB and E4599 randomized 467 pts and 434 pts to PC + 
BEV, respectively, while 444 were randomized to receive PC alone 
on E4599. Baseline characteristics were balanced between age 
groups. OS and PFS hazard ratios (HRs) and increases in grade ≥3 
AEs for the pooled pt cohort relative to E4599 PC-alone arm are 
shown (Table). Outcomes were similar in pts <70 y and ≥70 y, and 
data from the pooled population were similar to those seen in 
each individual trial (data not shown). ORR for pts <75 y was 39% 
with PC + BEV vs 26% with PC (P<.01). For pts ≥75 y, ORR was 33% 
vs 30% (P=.71). DCR in pts <75 y was 70% with PC + BEV vs 53% 
with PC (P<.01). For pts ≥75 y, DCR was 60% vs 67% (P=.37).
Conclusion: In a pooled exploratory analysis of pt data from E4599 
and PB, the statistically significant benefit associated with the addi-
tion of BEV to PC appeared consistent across all age groups <75y, 
while pts ≥75 y receiving PC + BEV had no statistically significant 
survival benefit. Pts receiving PC + BEV had an increase in grade 
≥3 AEs compared with pts receiving PC-alone in all age groups.  
PB + E4599 <65 y n=735 65–74 y n=453 70–74 y n=203 <75 y n=1188 ≥75 y n=157
HR for OS 95% CI P 0.75 0.62–0.89 <.01 0.80 0.64–1.00 .05 0.68 0.48–0.96 .03 0.78 0.68–0.89 <.01 1.05 0.70–1.57 .83
HR for PFS 95% 
CI P
0.71 0.60–0.85 <.01 0.62 0.49–0.78 <.01 0.68 0.48–0.96 .03 0.69 0.60–0.79 <.01 0.95 0.62–1.44 .80
E4599 n=499 n=277 n=129 n=776 n=102
Δ Grade ≥3 AEs,a 
% P
13 <.01 21 <.01 23 <.01 15 <.01 25 <.01
 
aRelative to PC-alone arm.
Keywords: NSCLC, Bevacizumab, elderly, pooled analysis
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previous studies of Bv+CP in NSCLC; no new safety signals were 
observed. Treatment discontinuation due to adverse events was 
18.4% (Bv+CP) and 15.0% (Pl+CP). Treatment-related deaths were 
low in both arms (Bv+CP: 2.2%; Pl+CP: 0.0%). Detailed safety data 
and biomarker analyses will be reported.
Conclusion: This study confirms that the addition of bevacizumab 
to first-line platinum-based chemotherapy appears to provide simi-
lar PFS benefits in Chinese patients with advanced non-squamous 
NSCLC compared with global populations. No new safety con-
cerns were reported.
Keywords: NSCLC, Bevacizumab, Chinese patients, first line
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MO06.13 BEYOND: A RANDOMIZED, DOUBLE-BLIND, 
PLACEBO-CONTROLLED, MULTICENTRE, PHASE III STU-
DY OF FIRST-LINE CARBOPLATIN/PACLITAXEL (CP) PLUS 
BEVACIZUMAB (BV) OR PLACEBO (PL) IN CHINESE PA-
TIENTS WITH ADVANCED OR RECURRENT NON-SQUA-
MOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Caicun Zhou1, Gongyan Chen2, Xiaoqing Liu3, Yunzhong Zhu4, 
Shun Lu5, Jifeng Feng6, Jianxing He7, Baohui Han5, Jie Wang8, Guoli-
ang Jiang9, Chunhong Hu10, Hao Zhang11, Gang Cheng12, Xiangqun 
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Shanghai Cancer Center/China, 10The Second Xiangya Hospital Of Cen-
tral South University/China, 11Cancer Hospital Of Shantou University 
Medical College/China, 12Beijing Hospital Of The Ministry Of Health/
China, 13Affiliated Cancer Hospital Of Guangxi Medical University/Chi-
na, 14Cancer Center, West China Hospital, Sichuan University/China, 
15Sir Run Run Shaw Hospital Affiliated To Zhejiang University School Of 
Medicine/China, 16Roche Pharmaceuticals Ltd/China, 17Guangdong Lung 
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Background: Bevacizumab, a monoclonal antibody that inhibits 
angiogenesis via the vascular endothelial growth factor (VEGF) pa-
thway, has proven efficacy in extending overall survival (OS) (Sand-
ler et al, 2006) and progression-free survival (PFS) (Sandler et al, 
2006; Reck et al, 2009) when added to platinum-doublet chemo-
therapy as first-line treatment for advanced non-squamous NSCLC. 
These pivotal studies included mainly Caucasian patients, however 
subgroup analyses in Asian patients also reported efficacy of the 
first-line Bv+CP regimen (Reck et al, 2009). The BEYOND study was 
initiated to confirm efficacy in a Chinese population.
Methods: Patients aged ≥18 years with histologically or cytologi-
cally confirmed, locally advanced, metastatic or recurrent advan-
ced non-squamous NSCLC and an ECOG performance status of 
0–1 were randomised 1:1 to receive CP (paclitaxel 175mg/m2 i.v. 
and carboplatin AUC6 i.v. on day 1 of each 3-week cycle for up to 
6 cycles), plus either Pl or Bv 15mg/kg i.v. on day 1 of each cycle, 
until progression, unacceptable toxicity, withdrawal of patient 
consent or death. Patients had no prior treatment for advanced 
NSCLC. Patients were stratified by gender, smoking status and 
age. The primary endpoint was PFS in the intent-to-treat (ITT) po-
pulation; secondary endpoints included objective response rate 
(ORR), OS, exploratory biomarkers and safety. Collection of blood 
samples for biomarker analyses was mandatory (at baseline, every 
two cycles during treatment, at progression, and 4–6 weeks post-
progression); tissue samples were optional.
Results: 276 patients were randomised into the study, 138 to 
each arm. Baseline characteristics were similar in both treatment 
groups. PFS was prolonged with Bv+CP versus Pl+CP: hazard ratio 
0.40 (95% CI 0.29–0.54); median 9.2 versus 6.5 months; p<0.0001 
(ITT population). ORR was also improved with the addition of Bv to 
CP: 54.4% versus 26.3% with Pl+CP. Disease control rate was 94.4% 
versus 88.7% with Bv+CP and Pl+CP, respectively. Median duration 
of response was 8.0 months with Bv+CP versus 5.3 months with 
Pl+CP. OS data are not yet mature. Safety data were similar to 
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Conclusion: Continuing ALK inhibition after PD may provide sur-
vival benefit to a majority of patients with advanced ALK-positive 
NSCLC. Prolonged PFS on initial crizotinib, good performance 
status at PD, and progression in brain and/or bone are characte-
ristics that were commonly found in patients who benefited from 
continued ALK inhibition.
Keywords: treatment beyond disease progression, Crizotinib, TKI, 
oncogene addiction
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MO07.02 CLINICAL EXPERIENCE WITH CRIZOTINIB IN 
PATIENTS WITH ADVANCED ALK-REARRANGED NON-
SMALL CELL LUNG CANCER AND BRAIN METASTASES 
IN PROFILE 1005 AND PROFILE 1007
Daniel B. Costa1, Alice T. Shaw2, Sai-Hong I. Ou3, Benjamin J. So-
lomon4, Gregory J. Riely5, Myung-Ju Ahn6, Caicun Zhou7, S Martin 
Shreeve8, Robin Wiltshire9, Paulina Selaru8, Anna Polli10, Patrick 
Schnell8, D Ross Camidge11, Lucio Crinò12
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States Of America, 2Massachusetts General Hospital, Harvard Medical 
School/United States Of America, 3University Of California At Irvine/
United States Of America, 4Peter MacCallum Cancer Centre/Australia, 
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6Sungkyunkwan University School Of Medicine, Samsung Medical 
Center/Korea, 7Shanghai Pulmonary Hospital/China, 8Pfizer Oncology/
United States Of America, 9Pfizer Oncology/United Kingdom, 10Pfizer 
Oncology/Italy, 11University Of Colorado/United States Of America, 
12University Hospital Of Perugia/Italy
Background: Crizotinib is an oral tyrosine kinase inhibitor tar-
geting ALK and is approved multinationally for the treatment of 
advanced ALK-rearranged non-small cell lung cancer (NSCLC) due 
to its efficacy in controlling systemic tumor burden. The clinical 
effects of crizotinib in patients with brain metastases have not 
been previously studied in detail. To evaluate the clinical outco-
mes of patients with brain metastases on crizotinib, we conduc-
ted a retrospective analysis of pooled data from PROFILE 1005 
(NCT00932451; a large ongoing global open-label, single-arm 
phase II study of crizotinib in patients with ALK-rearranged NSCLC 
who have received one or more treatment regimen for advanced/
metastatic disease) and PROFILE 1007 (NCT00932893; an ongoing 
global randomized phase III study that compared crizotinib with 
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MO07.01 CLINICAL BENEFIT OF CONTINUING CRIZO-
TINIB BEYOND INITIAL DISEASE PROGRESSION IN PA-
TIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL-
CELL LUNG CANCER
Sai-Hong I. Ou1, Gregory J. Riely2, Yiyun Tang3, Dong-Wan Kim4, 
Gregory A. Otterson5, Lucio Crinò6, Cynthia H. Bartlett3, Darrel P. 
Cohen3, Jeffrey W. Clark7, Pasi A. Jänne8
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Background: Crizotinib is approved multinationally to treat advan-
ced ALK-positive non-small-cell lung cancer (NSCLC). Most pati-
ents with crizotinib-treated ALK-positive NSCLC ultimately develop 
progressive disease (PD). We investigated whether continuing ALK 
inhibition beyond PD is clinically beneficial and the clinicopatholo-
gic characteristics associated with patients who experience clinical 
benefit.
Methods: Patients with advanced ALK-positive NSCLC enrolled 
in two ongoing multicenter, single-arm trials (the molecularly enri-
ched expansion cohort of the phase I trial PROFILE 1001 and the 
phase II trial PROFILE 1005) who developed RECIST-defined PD 
were allowed to continue crizotinib if, in the investigator‘s opinion, 
they were deriving ongoing clinical benefit. In the present retros-
pective analyses, continuation of crizotinib beyond PD (CBPD) was 
defined as >3 weeks of crizotinib treatment after PD documenta-
tion. Baseline and post-progression characteristics, sites of PD, 
progression-free survival (PFS), and overall survival (OS) were com-
pared in patients who continued CBPD versus those who did not. 
The impact of continuing CBPD on OS after adjusting for potential 
confounding factors was assessed.
Results: Among 194 crizotinib-treated patients with RECIST-defi-
ned PD, 120 (62%) continued CBPD. A higher proportion of pati-
ents who continued CBPD responded to initial crizotinib treatment 
(74% vs. 55%), had an ECOG performance status of 0/1 at PD (96% 
vs. 82%), and had brain (56% vs. 28%) and/or bone (20% vs. 9%) as 
sites of PD compared with patients who did not continue CBPD. 
CBPD patients also had numerically longer median PFS from initial 
crizotinib treatment (7.3 months vs. 5.7 months) and significant-
ly longer OS from the time of PD (median 16.4 months vs. 3.9 
months; HR, 0.27; 95% CI: 0.17−0.42; P<0.0001; Figure 1). Multiple-
covariate Cox regression analysis revealed that CBPD remained 
significantly associated with improved OS post-PD after adjusting 
for relevant factors. Figure 1. OS of patients who continued CBPD 
versus those who did not, from the time of PD. Shaded areas are 
95% Hall-Wellner confidence bands.
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Background: Rearrangements of the ROS1 receptor tyrosine kina-
se gene identify a subset of NSCLC sensitive to the small-molecule 
ALK and MET inhibitor crizotinib, approved multinationally for the 
treatment of advanced ALK-positive NSCLC. Here we present up-
dated efficacy and safety data for crizotinib in an expanded cohort 
of patients with advanced ROS1-rearranged NSCLC.
Methods: ROS1 status was determined by break-apart FISH as-
says, and patients were enrolled into an expansion cohort of an 
ongoing phase I crizotinib study (PROFILE 1001; NCT00585195, 
Pfizer). Where available, samples were also tested for concurrent 
ALK rearrangement and MET amplification. Patients received crizo-
tinib 250 mg BID, and responses were assessed using RECIST v1.0.
Results: At the data cut-off, 35 of 40 patients with ROS1-positive 
NSCLC were evaluable for response. Median age was 51 years (ran-
ge 31–77), 80% of patients were never-smokers, and 98% had ade-
nocarcinoma histology; 40% had received one prior regimen, and 
45% had received 2–6 regimens for advanced/metastatic disease. 
25 samples tested for concurrent ALK rearrangement (24 by FISH 
and 1 by PCR) and 12 samples tested for concurrent MET amplifi-
cation (11 by FISH and 1 method not recorded) were all negative. 
The objective response rate (ORR) was 60% (95% CI: 42–76), with 
2 complete responses, 19 partial responses, and 10 cases of sta-
ble disease. Median progression-free survival (PFS) had not been 
reached, with 25 patients (63%) still in follow-up for PFS; six pati-
ents (15%) experienced disease progression, and two (5%) died be-
fore progression occurred; 6-month PFS probability was 76% (95% 
CI: 55–88). The disease-control rate was 80% at 8 weeks and 66% 
at 16 weeks. The most common treatment-related adverse events 
(AEs) were visual impairment (80%), diarrhea (35%), and nausea 
(30%), with most patients (68%) reporting only AEs of grade 1 or 2 
severity. Peripheral edema (28%) and elevated transaminases (18% 
AST, 15% ALT) were also reported, similar to previous experience 
with crizotinib. There were no treatment-related serious AEs and 
one patient discontinued treatment due to treatment-related nau-
sea. Accrual of patients with ROS1-positive NSCLC is ongoing.
Conclusion: Similar to results obtained in ALK-positive NSCLC, 
crizotinib had marked antitumor activity with a high ORR (60%) in 
patients with ROS1-positive NSCLC, with a generally tolerable and 
manageable AE profile. These data suggest that crizotinib is an 
effective therapy for patients with advanced ROS1-positive NSCLC.
Keywords: Crizotinib, ROS1, NSCLC, ALK
standard second-line chemotherapy [docetaxel or pemetrexed] for 
advanced ALK-rearranged NSCLC; Shaw et al, N Engl J Med 2013). 
Subgroup analysis in PROFILE1007 showed that progression-free 
survival was longer with crizotinib than with chemotherapy for both 
patients with brain metastases (HR 0.67) and patients without brain 
metastases (HR 0.43) at baseline.
Methods: Patients with previously treated (but ALK-inhibitor-naïve) 
advanced ALK-rearranged NSCLC enrolled in either PROFILE 1005 
or PROFILE 1007 (and randomized to crizotinib) were included in 
this analysis. Patients with asymptomatic brain metastases were eli-
gible for both studies. The starting dose of crizotinib was 250 mg 
twice daily. Tumor assessments were evaluated by investigators 
based on RECIST. Baseline brain imaging (with either computed 
tomography or magnetic resonance imaging) was required in both 
studies, and if brain metastases were detected, subsequent brain 
imaging was required at 6-week intervals. Otherwise, imaging to 
assess brain metastases on treatment was performed as clinically 
indicated. Brain metastases were monitored as non-target or tar-
get lesions.
Results: A total of 275 patients, 31% of 888 patients included in 
this retrospective analysis, had asymptomatic brain metastases at 
baseline. Of the 888 patients included, 109 patients (12%) had no 
prior radiotherapy and 166 patients (19%) had prior radiotherapy 
for their brain metastases. Among the 109 patients with previously 
untreated asymptomatic brain metastases, the systemic disease 
control rate (DCR; % complete responses + partial responses + 
stable disease) at 12 weeks was 63%, with a systemic objective res-
ponse rate (ORR) of 53%, and the intracranial DCR at 12 weeks was 
56%, with an intracranial ORR of 7%. Among the 166 patients with 
previously treated brain metastases, the systemic DCR at 12 weeks 
was 65%, with a systemic ORR of 46%, and the intracranial DCR at 
12 weeks was 62% weeks, with an intracranial ORR of 7%. Additio-
nal data, including outcomes for patients without brain metastases 
at baseline, will be presented.
Conclusion: In this large retrospective analysis, crizotinib was as-
sociated with an initial intracranial DCR of approximately 60% at 12 
weeks in patients who were ALK-inhibitor-naïve and had untreated 
or previously treated brain metastases identified prior to initiation 
of therapy. Prospective studies may help to determine if crizotinib 
can delay the natural occurrence or progression of brain metasta-
ses in advanced ALK-positive NSCLC.
Keywords: intracranial disease control rate, systemic response, 
Crizotinib, brain metastases
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tinib disposition. No starting dose adjustments of crizotinib 250 
mg BID are recommended based on age, gender, body weight, or 
race.
Keywords: Crizotinib, Population Pharmacokinetics, non-small cell 
lung cancer
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Background: AP26113 is a novel tyrosine kinase inhibitor (TKI) that 
exhibits pan-ALK inhibitory activity against all 9 clinically-identified 
crizotinib-resistant mutants, including the L1196M gatekeeper, in 
preclinical experiments. AP26113 also inhibits ROS1 and selectively 
inhibits mutant EGFR (EGFRm) in preclinical experiments, including 
the T790M resistance mutation, without affecting the native recep-
tor.
Methods: We report data from the dose finding component (3+3 
design) of a phase 1/2 open-label, multicenter study in patients 
with advanced malignancies (except leukemia) refractory to availa-
ble therapies or for whom no standard treatment exists. Dosing 
was once daily (QD) or twice daily.
Results: As of 17 April 2013, 55 patients were enrolled: 30mg 
(daily dose) n=3, 60mg n=3, 90mg n=8, 120 mg n=15, 180mg 
n=15, 240mg n=9, 300mg n=2; 62% female, median age 58 yrs; 
diagnoses: non-small cell lung cancer (NSCLC, n=47), other (n=8). 
33 patients discontinued: 22 disease progression, 6 adverse event 
(AE), 4 deaths (2 possibly related: sudden death, hypoxia), 1 with-
drawal by subject. The most common AEs included fatigue (40%), 
nausea (36%), and diarrhea (33%), which were generally grade 1/2 
in severity. The most common grade 3/4 AE was pneumonia (5%). 
Two patients experienced dose limiting toxicities: grade 3 ALT 
increase in 1 patient (240mg QD); grade 4 dyspnea and grade 3 
hypoxia in 1 patient (300mg QD). Twenty-eight patients had ALK+ 
history (24 NSCLC, 4 other). Among 24 evaluable ALK+ patients, 
15 responded. Responses were observed in 2/4 (50%) ALK+ TKI-
naïve patients and 13/17 (76%) ALK+ patients with prior crizotinib 
therapy and no other ALK inhibitor exposure. Among ALK+ NSCLC 
patients with prior crizotinib only, 12/16 (75%) responded. The 
longest response is 40+ weeks (ongoing). 4 of 5 ALK+ patients 
with untreated or progressing CNS lesions at baseline and with 
follow-up scans had evidence of radiographic improvement in 
CNS, including 1 patient resistant to crizotinib and LDK378 (overall 
response = stable disease). CNS lesion improvements in all 4 pati-
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Background: XALKORIÒ (crizotinib) is a selective small-molecule 
inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine 
kinase (RTK) and its oncogenic variants (ie, ALK fusion events and 
selected ALK mutations). Crizotinib is also an inhibitor of the he-
patocyte growth factor receptor (HGFR, c-Met), c-ros oncogene 1 
(ROS1), and Recepteur d’Origine Nantais (RON) RTKs. Clinical stu-
dies were conducted globally to determine the maximum tolerated 
dose, pharmacokinetics, antitumor efficacy and safety of crizotinib 
in patients with ALK-positive NSCLC and other tumors sensitive to 
crizotinib. The major objectives of this analysis were (1) to develop 
a population PK model that describes crizotinib plasma PK using 
pooled PK data across studies in cancer patients;.and (2) to iden-
tify potential covariates which may account for the inter-individual 
variability in crizotinib PK.
Methods: Population pharmacokinetic models were developed 
from a dataset comprised of 8,973 pharmacokinetic samples from 
1,214 cancer patients receiving crizotinib at a starting dose of 250 
mg BID in Phase I, II, and III trials. The effects of pre-defined co-
variates pertaining to demographic characteristics, baseline renal 
(creatinine clearance) and hepatic function (AST, albumin, and total 
bilirubin) on the pharmacokinetics of crizotinib were tested in the 
models.
Results: The study population consisted of 533 males (44%) and 
681 females (56%). The patients were characterized by a wide ran-
ge of body weights (33 to 160 kg) and ages (19 to 83 years). There 
were 189 (15.6%) elderly patients (over 65 years). The majority of 
patients in the analysis were White (52.8%) and Asian (43.1%), fol-
lowed by Black (1.8%), Hispanic (1.2%), and Other (1%). Crizotinib 
PK was characterized by a two-compartment model with first-order 
absorption and a time-dependent decrease in apparent (oral) clea-
rance (CL/F) from baseline following multiple 250 mg BID dosing. 
The interindividual variability was moderate, with 40% for CL/F 
and 52% for the apparent central volume of distribution (V2/F), 
respectively. The typical PK parameters for a 65 kg non-Asian male 
cancer patient with baseline creatinine clearance 91.6 mL/min and 
total bilirubin 0.41 mg/dL were 136 L/hr, 76 L/hr, 3,520 L, and 0.73 
hr-1 for the CL/F after the first dose, CL/F at steady state, V2/F, 
and absorption rate constant (Ka), respectively. Age, AST, albumin, 
smoking, or ECOG performance status were not significant covari-
ates for crizotinib CL/F (P>0.001). Asian race, gender, body weight, 
creatinine clearance, and total bilirubin described a portion of the 
variability in CL/F, and Asian race and gender also explained some 
of variability in V2/F. Asian race had the greatest effect on crizoti-
nib exposure, with a 97% probability that a typical area under the 
plasma drug concentration-time curve at steady state (AUCss) in 
an Asian patient would be >25% higher than a typical AUCss value 
in a Non-Asian patient. None of the other covariates investigated 
were found to markedly affect the systemic exposure of crizotinib.
Conclusion: There was moderate inter-patient variability in crizo-
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the expansion phase had a mandatory tumor biopsy for biomarker 
analysis at study entry. Endpoints included safety, best overall 
objective response rate (ORR), progression-free survival, and bio-
markers in tumor and blood that are potentially predictive of anti-
tumor activity.
Results: 33 patients were enrolled in the dose-escalation phase of 
the study. Dose-limiting toxicities (DLTs) were the following grade 
3 events: diarrhea (n=1), elevated ALT (n=1), and mucositis (n=1). 
The dacomitinib 30 mg qd plus crizotinib 200 mg bid combination 
showed no DLTs in 10 evaluable patients and was taken forward 
into the expansion phase. At the time of data cut-off on 31 Decem-
ber 2012, 27 patients had enrolled in the expansion phase (23 in 
cohort A and 4 in cohort B). Patient characteristics were as follows: 
M/F, 11/16; median age, 60 years (range 42–82); ECOG PS 0/1/2, 
4/19/4; Caucasian/Asian, 22/5; never-smokers/ex-smokers/smo-
kers, 18/7/2; number of prior systemic therapies 1/2/3/>3, 9/8/3/6. 
Nine patients (33%) in the expansion phase had started ≥4 cycles 
(approximately 12 weeks) of the combination. There were 20 evalu-
able patients in expansion cohort A, with an ORR of 5%. A further 
8 patients (40%) experienced SD, and 1 of these patients had an 
unconfirmed PR. Tumor samples were available for biomarker 
analyses from 18 patients in expansion cohort A. Analyses to date 
revealed 1/17 patient samples had MET amplification (MET:CEP7 
ratio >2); 1/5 had EGFR amplification; 7/12 harbored the EGFR 
T790M mutation; 1/11 displayed a KRAS mutation; 18/18 were ne-
gative for ALK rearrangement by FISH.
Conclusion: The dacomitinib 30 mg qd plus crizotinib 200 mg bid 
combination was administered with a manageable tolerability pro-
file and was associated with clinical activity in patients with EGFR 
TKI-resistant advanced NSCLC. Analysis of predictive tumor bio-
markers is underway in all patients in the expansion phase.
Keywords: dacomitinib, NSCLC, resistance, Crizotinib
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MO07.08 THE FREQUENCY AND IMPACT OF ROS1-RE-
ARRANGEMENT ON CLINICAL OUTCOMES IN NEVER-
SMOKERS WITH LUNG ADENOCARCINOMA
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Hang Kim1, Byoung Chul Cho1
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Hematology/Oncology, Chao Family Comprehensive Cancer Center, 
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ling Technology/United States Of America, 6Je Uk Institute For Cancer 
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Background: To determine the frequency and predictive impact 
of ROS1-rearrangements on treatment outcomes in never-smoker 
patients with lung adenocarcinoma.
Methods: We concurrently analyzed ROS1- and ALK- rearrange-
ments and mutations in the epidermal growth factor receptor 
(EGFR), and KRAS in 208 never-smokers with lung adenocarcino-
ma. ROS1- and ALK- rearrangements were identified by fluorescent 
ents are ongoing, with durations ranging from 15+ to 28+ weeks. 
Twenty patients had EGFRm history (19 NSCLC, 1 SCLC); 18 had ≥1 
prior EGFR TKI. Of 18 evaluable EGFRm patients, 1 patient (prior 
erlotinib) responded at 120mg QD (duration 26+ weeks, ongoing), 
7 patients had stable disease, including 4 with T790M by history (1 
ongoing at 240mg QD, duration 16+ weeks). The maximum tolera-
ted dose has not been defined; however, based on safety, efficacy, 
and pharmacokinetics, the recommended phase 2 dose (RP2D) is 
180mg QD. Updated data will be presented.
Conclusion: AP26113 has promising anti-tumor activity in patients 
with ALK+ NSCLC and other ALK+ tumors, with initial evidence of 
activity in EGFRm patients, and is generally well tolerated. Five 
phase 2 cohorts are enrolling at the RP2D (180mg QD): 1) ALK 
inhibitor-naïve ALK+ NSCLC, 2) crizotinib-resistant ALK+ NSCLC, 
3) single EGFR TKI-resistant NSCLC with documented T790M, 4) 
other tumors with AP26113 targets, 5) crizotinib-naïve or –resistant 
ALK+ NSCLC with active CNS metastases. Further phase 1 tes-
ting at 240mg QD will occur in EGFRm patients with documented 
T790M. NCT01449461
Keyword: NSCLC, ALK, EGFR, AP26113
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MO07.07 COMBINED PAN-ERBB AND ALK/ROS1/MET 
INHIBITION WITH DACOMITINIB AND CRIZOTINIB IN 
ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): 
UPDATE OF A PHASE I TRIAL
Giuseppe Giaccone1, David Ross Camidge2, Pasi A. Jänne3, Ben 
Solomon4, Leonard P. James5, Yiyun Tang5, Jean-François Martini5, 
Zelanna Goldberg5, S Martin Shreeve5, Alice T. Shaw6
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Colorado/United States Of America, 3Lowe Center For Thoracic Onco-
logy, Dana-Farber Cancer Institute/United States Of America, 4Peter 
MacCallum Cancer Centre/Australia, 5Pfizer Oncology/United States Of 
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Background: EGFR T790M mutation and MET amplification have 
been implicated as mechanisms of acquired resistance to first-
generation EGFR tyrosine kinase inhibitors (TKIs) in advanced 
NSCLC. We evaluated the feasibility of combining dacomitinib and 
crizotinib to overcome acquired resistance in patients with NSCLC 
whose last prior treatment was either single-agent erlotinib or 
gefitinib. Dacomitinib is an orally bioavailable, irreversible, small-
molecule inhibitor of all kinase-active HER-family tyrosine kinases 
(EGFR/HER1, HER2, and HER4) with in vitro activity against T790M-
mutated EGFR. Crizotinib is an ALK, ROS1, and MET TKI with 
demonstrated efficacy in the treatment of advanced ALK-positive 
and ROS1-positive NSCLC and several MET-amplified tumor types. 
Here we update previous data reported for PROFILE 1006 (Jänne 
et al, ESMO 2012; Pfizer, NCT01121575).
Methods: The study comprised a 3+3 design dose-escalation 
phase followed by an expansion phase of two concurrent cohorts: 
A) combined dacomitinib plus crizotinib and B) single-agent daco-
mitinib until progression, followed by combined dacomitinib plus 
crizotinib. The study enrolled patients with advanced NSCLC who 
had progressed after ≥1 line of chemotherapy/targeted therapy. 
The expansion phase was restricted to patients with acquired re-
sistance to single-agent erlotinib or gefitinib, which was defined 
as PD following either a response or SD for 6 months. Patients in 
S298 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Methods: Patient’s main inclusion criteria was advanced NSCLC 
with an indication of repeat biopsy by the referent clinician. The 
primary outcome was the percentage of successful procedures; 
secondary outcomes were localization of the new biopsy, type of 
procedure, new biological status (comparison to initial status, new 
biomarkers, resistance biomarkers) and tolerance of the procedure.
Results: From May 2012 to May 2013, 18 centers included 102 pa-
tients. The characteristics of the 67 first patients were: male: 40%; 
age: 64.8 ± 10.9 years; PS 0/1: 87%; adenocarcinoma: 85%; EGFR 
mutated: 46.2%; no biological available assessment: 16.4%; con-
trolled disease as best response to first line: 70%. Repeat biopsy 
was possible in 80.6%. The main failure reasons were: inaccessible 
lesion: 4.5%, medical contraindications: 14.9%. Main procedures 
were: bronchial endoscopy: 48.1%, trans thoracic needle biopsy: 
24.1%. The procedure permits to find, in EGFR wild type popula-
tion, 3 patients with a driver oncogene (1 HER2, 1 Ros1, 1 EML4 
ALK); in EGFR mutated patients, 2 T790M mutations and to obtain 
in 3 patients with no biological data’s at the diagnosis, a biological 
profile. Complications were very low: 2 cases of moderate blee-
ding and 1 case of pneumothorax.
Conclusion: Repeat biopsy is a feasible procedure with accepta-
ble adverse events. Recommendations should be realized on the 
indications of re-biopsy, the timing and the recommended site 
(primary versus metastasis, progressive target versus no progressi-
ve). Analysis of the complete population (n=102) will be presented 
at the meeting. Supported by an academic grant from Boehringer 
Ingelheim Company and Hoffmann-La Roche Company.
Keywords: Non small cell lung cancer, observational study, re-
biopsy, EGFR mutation
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MO07.11 A RANDOMISED PLACEBO-CONTROLLED 
MULTICENTRE PHASE II TRIAL OF ERLOTINIB PLUS 
WHOLE BRAIN RADIOTHERAPY FOR PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG CANCER WITH 
MULTIPLE BRAIN METASTASES (TACTIC)
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Background: Median survival of non-small cell lung cancer (NS-
CLC) patients with brain metastases is poor. We examined concur-
rent erlotinib and whole brain radiotherapy (WBRT) followed by 
maintenance erlotinib in patients with untreated brain metastases, 
given the potential radiosensitising properties of erlotinib and its 
direct effect on brain metastases and systemic activity.
Methods: Eighty NSCLC patients with KPS≥70 and multiple 
brain metastasis were randomised to placebo (n=40) or erlotinib 
(100mg, n=40) given concurrently with WBRT (20 Gy in 5 fractions). 
Following WBRT, patients continued with placebo or erlotinib 
(150mg) until disease progression. The primary end-point was 
in situ hybridization.
Results: Of 208 tumors screened, seven (3.4%) were ROS1-rearran-
ged, and 15 (7.2%) were ALK-rearranged. CD74-ROS1 fusions were 
identified in two patients using reverse transcriptase polymerase 
chain reaction. The frequency of ROS1-rearrangement was 5.7% 
(6/105) among EGFR/KRAS/ALK-negative patients. Patients with 
ROS1-rearrangement had a higher objective response rate (ORR; 
60.0 vs. 8.5%; P=0.01) and a longer median progression-free survi-
val (PFS; not reached vs. 3.3 months; P=0.008) to pemetrexed than 
those without ROS1/ALK-rearrangement. The PFS to EGFR-TKIs in 
patients harboring ROS1-rearrangement was shorter than those 
without ROS1/ALK rearrangement (2.5 vs. 7.8 months; P=0.01).
Conclusion: The frequency of ROS1-rearrangements in clinically 
selected patients is higher than that reported for unselected pati-
ents, suggesting that ROS1-rearrangement is a druggable target 
in East-Asian never-smokers with lung adenocarcinoma. Given the 
different treatment outcomes to conventional therapies and availa-
bility of ROS1 inhibitors, identification of ROS1-rearrangement can 
lead to successful treatment in ROS1-rearranged lung adenocarci-
nomas.
Keywords: lung adenocarcinoma, never smoker, Outcome, ROS1
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MO07.09 FEASIBILITY AND CLINICAL IMPACT OF RE-BI-
OPSY IN ADVANCED NON-SMALL CELL LUNG CANCER: 
A PROSPECTIVE MULTICENTRIC STUDY IN REAL WORLD 
SETTING (GFPC STUDY 12-01)
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Background: In case of progression under initial treatment, repeat 
biopsy is a new option procedure in advanced non-small cell lung 
cancer (NSCLC). Its justification is based on the assessment of 
biological markers (comparison to the initial status, emergence of 
resistance to chemotherapy or new biomarkers). The aim of this 
pragmatic prospective multicenter study was to assess feasibility 
and clinical utility of re-biopsy in real world setting in advanced 
NSCLC.
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. The CNS response rates were 25% complete response (n=5), 
55% partial response (n= 11), 15% stable disease (n=3), and 5% 
progressive disease (n =1). The overall response rate was 80% (n = 
16). The most common adverse events were rash (40.0%), diarrhea 
(15.0%),nausea(45.0%), vomiting(20.0%), headache(35.0%), fatigue 
(45.0%). And no patient experienced grade ≥ 3 toxicity. The mean 
plasma and CSF concentrations of icotinib were 936.47 ± 503.80 
and 8.93 ± 8.01ng/ml, respectively, and the mean ratio of CSF-
plasma concentration was 1.04% ± 0.95.
Conclusion: Icotinib was well tolerated and showed promising ac-
tivity in combination with WBRT in patients with BM from NSCLC. 
The concentrations of icotinib in CSF were much lower than that of 
plasma. Further randomized trials are warranted.
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MO07.13 EFFICACY OF AFATINIB VS. CHEMOTHERAPY 
IN TREATMENT-NAÏVE PATIENTS WITH NON-SMALL 
CELL LUNG CANCER (NSCLC) HARBOURING ACTI-
VATING EGFR MUTATIONS WITH OR WITHOUT METAS-
TATIC BRAIN DISEASE
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Background: Afatinib, an irreversible ErbB Family Blocker, was 
superior to pemetrexed/cisplatin in previously untreated patients 
with epidermal growth factor receptor (EGFR) mutation-positive 
non-small cell lung cancer (NSCLC) in a global Phase III trial, LUX-
Lung 3. In patients with the two most common EGFR mutations 
(Del19, L858R) median progression-free survival (PFS) was 13.6 vs. 
6.9 months (HR=0.47, 95% CI: 0.34–0.65; p<0.0001). Here we pre-
sent the results for subgroups of patients with or without brain me-
tastases (BM) with NSCLC harbouring common EGFR mutations.
Methods: In LUX-Lung 3 EGFR mutation-positive patients were 
randomized 2:1 to afatinib 40 mg daily or up to 6 cycles of peme-
trexed/cisplatin at standard doses. Patients with stable BM (asym-
ptomatic, stable >4 weeks with no treatment required) were allo-
wed. Presence of BM was documented by the investigator during 
screening. Tumour assessments were performed every 6 weeks 
until 48 weeks and every 12 weeks thereafter until progression, 
and reviewed independently and by the investigator.
Results: 308 patients with common EGFR mutations were ran-
domized (afatinib: 204, pemetrexed/cisplatin: 104), including 35 
with baseline BM (afatinib: 20, pemetrexed/cisplatin: 15). Of these, 
Del19 mutation was detected in 11 (afatinib) and 8 (pemetrexed/
cisplatin) patients and L858R in 9 (afatinib) and 7 (pemetrexed/
cisplatin) patients. The baseline characteristics of patients with or 
without BM were comparable (females: 74% vs. 66%, median age: 
61 vs. 62 years, ECOG 0: 31% vs. 41%, median time since diagno-
sis: 1.2 vs. 1.1 months, respectively). Within the BM group, baseline 
characteristics were balanced between treatment arms with the 
exception of ECOG 1; 80% of afatinib-treated patients had ECOG 
neurological progression-free survival (nPFS).
Results: Fifteen patients (37.5%) from each arm were alive and 
without neurological progression 2 months after WBRT. Median 
nPFS was 1.6 months in both arms; nPFS HR 0.95 (95% CI, 0.59-
1.54; p=0.84). Median overall survival (OS) was 2.9 and 3.4 months 
in the placebo and erlotinib arms; HR 0.95 (95% CI, 0.58-1.55; p 
=0.83). The frequency of EGFR mutations was low with only 1 out 
of 35 (3%) patients with available samples had activating EGFR-
mutations. Grade 3/4 adverse event rates were similar between the 
two groups (70% in each arm), except for rash 20% (erlotinib) vs. 
5% (placebo), and fatigue 17% vs. 35%. No significant QoL diffe-
rences were found.
Conclusion: Our study showed no advantage in nPFS or OS for 
concurrent erlotinib and WBRT followed by maintenance erlotinib 
in patients with predominantly EGFR wild-type NSCLC and mul-
tiple brain metastases. Future studies should focus on the role of 
erlotinib with or without WBRT in patients with EGFR mutations.
Keyword: Erlotinib, WBRT, Brain Metastases, Randomised
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MO07.12 PHASE II STUDY OF ICOTINIB AND WHOLE 
BRAIN RADIOTHERAPY (WBRT) IN PATIENTS WITH 
BRAIN METASTASES FROM NON-SMALL-CELL LUNG 
CANCER (NSCLC).
Fan Yun1, Huang Z. Yu1, Gong Lei2, Miao L. Lu2, Yu H. Feng2
1Chemotherapy Department, Zhejiang Cancer Hospital/China, 2Zheji-
ang Cancer Hospital/China
Background: Epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs), such as gefitinib and erlotinib, have shown 
efficacy in advanced NSCLC with brain metastases (BM). Icotinib is 
a new EGFR-TKI. A randomized, double blind phase III trial proved 
that icotinib was non-inferior to gefitinib in terms of median pro-
gression free survival (PFS) in advanced NSCLC. We have conduc-
ted a phase II study to evaluate the efficacy and safety of icotinib 
in combination with WBRT in Chinese NSCLC patients with BM, 
and investigated the cerebrospinal fluid (CSF) concentrations of 
icotinib. .
Methods: From January 2012 to January 2013, 20 patients aged 
18-75 years with Eastern Cooperative Oncology Group perfor-
mance status 0-2 and BM from NSCLC,were recruited regardless 
of EGFR status. The treatment comprised icotinib 125mg, TID 
concurrently with WBRT (30Gy/10f/2w). CSF and plasma samples 
were collected at the same time from 10 patients at least 5 days 
after icotinib treatment. The concentrations of icotinib in the CSF 
and plasma were measured by high performance liquid chromato-
graphy coupled with tandem mass spectrometry. The primary end 
point was progression-free survival (PFS) determined by RECIST. 
Additional end points were response rate, safety and CSF concen-
trations of icotinib. EGFR mutation status was tested by Amplifica-
tion Refractory Mutation System( ARMS)
Results: The median PFS was 7.3 months [95% confidence interval 
(CI) 4. 2-9.8]. Patients with EGFR mutation-positive disease had 
significantly longer median PFS versus EGFR wild-type disease 
[NR versus 4.2 months (95% CI 2.9-5.1); P = 0.000]. The most pre-
valent site of first failure was extracranial in seven patients (70.0%) 
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MO08.01 FIRST ANALYSIS OF TOXICITY AND TREA-
MENT COMPLIANCE IN CUSTOMIZED POSTOPERATIVE 
CHEMOTHERAPY BASED ON BRCA1 LEVELS AFTER 
NSCLC RESECTION: SCAT (SPANISH CUSTOMIZED AD-
JUVANT THERAPY) TRIAL. SPANISH LUNG CANCER 
GROUP/GECP
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Background: Customization is feasible in adjuvant setting (tis-
sue availability). SCAT trial has completed planned recruitment 
with 500 p. For resected NSCLC with nodal involvement adjuvant 
platinum-based CT improves outcomes but survival remains sub-
optimal. Compliance may be a key issue for efficacy in adjuvant 
setting. mRNA BRCA1 levels are prognostic in early NSCLC and 
could be a predictive marker for CT activity. In advanced disease 
patients with low BRCA1 benefit from cisplatin doublets meanwhile 
p with high levels attained longer survival with taxanes.
Methods: Phase III trial testing 4 cycles non-selected vs custo-
mized adjuvant CT. Entry criteria: NSCLC, R0 resection, pN1 or 
pN2, KI > 70, recovered from surgery, adequate hematologic, 
renal and liver functions, no prior CT or RT, age > 18 y, informed 
consent. Stratification: N1 vs N2, histology (squamous vs non-
squamous), resection (lobectomy vs pneumonectomy). Central lab 
mRNA BRCA1 levels and quartile distribution. Primary end-point: 
OS. Secondary end-points: DFS, toxicity, recurrence pattern. De-
sign: R: 1:3. Control treatment: Cis-Docetaxel (CD). Experimental 
1 compared with 53% of those treated with pemetrexed/cisplatin. 
Median PFS by independent review was 13.7 (afatinib) vs. 8.1 (pe-
metrexed/cisplatin) months in patients without BM (HR=0.47, 95% 
CI: 0.33–0.68; p<0.0001), and 11.1 (afatinib) vs. 5.4 (pemetrexed/
cisplatin) months in patients with BM (HR=0.52, 95% CI: 0.22–1.23; 
p=0.13). Objective response in patients without BM was 59% (afa-
tinib) vs. 23% (pemetrexed/cisplatin), odds ratio=4.8, p<0.0001, 
and 70% (afatinib) vs. 20% (pemetrexed/cisplatin), odds ratio=11.0, 
p=0.007, in patients with BM. Investigator review showed a medi-
an PFS of 13.6 (afatinib) vs. 6.9 (pemetrexed/cisplatin) months in 
patients without BM (HR=0.38, 95% CI: 0.27–0.53; p<0.0001), and 
6.7 (afatinib) vs. 5.4 (pemetrexed/cisplatin) months in those with 
BM (HR=0.67, 95% CI: 0.29–1.57; p=0.36). By investigator review, 
progressive disease in the brain was observed for 4.2% (7/167) and 
3.7% (3/82) of patients without BM at baseline for afatinib and pe-
metrexed/cisplatin, respectively. All but one of these patients (on 
afatinib) had intracranial progression only. The median (range) time 
to progression in the brain in this small group was 11.6 (1.3, 20.2) 
months (afatinib) and 5.5 (2.6, 8.2) months (pemetrexed/cisplatin).
Conclusion: In patients with previously untreated NSCLC harbou-
ring common EGFR mutations afatinib remains efficacious regard-
less of the presence or absence of BM. Control of synchronous 
asymptomatic BM with afatinib compares favourably with existing 
data for cranial radiation therapy.
Keywords: afatinib, brain metastases, EGFR
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guidelines do not recommend any adjuvant treatment in resected 
Stage I NSCLC. Pazopanib (P) is a potent, orally active multi-target 
receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, platelet deri-
ved growth factor (PDGFR) type-α and –β, approved in metastatic 
renal cell carcinoma and sarcoma. Neoadjuvant P demonstrated 
single-agent activity in patients with early stage NSCLC. We report 
the feasibility and tolerance of adjuvant P in stage I NSCLC.
Methods: In this double-blind randomized multicenter phase II/
III trial, completely resected patients (pts) with stage I NSCLC (7th 
TNM edition) were randomized to receive either placebo or P 800 
mg/d during 6 months. The Fleming’s two stage phase II primary 
endpoint was compliance (i.e. % of pts able to receive at least 3 
months of P, whatever the dose). After 64 pts included (interim 
analysis), IDMC recommended to start with P 400 mg/d because of 
initial insufficient compliance. A one-step Fleming design was used 
with the new dose. Phase II design was not comparative.
Results: 143 pts were randomized in 29 centers between March 
2009 and August 2012, 71 and 72 in the placebo and P arms re-
spectively. Most pts were male (61%) and smokers (91%), median 
age was 60. Pathological stage was IA in 111 pts (78%) and 16% 
were squamous cell carcinomas. Compliance for P800 was adequa-
te in 38% (95% confidence interval [21-56]) vs. 87% [71-96] in pla-
cebo; for P400 in 69% [50-84] (p=0.01, compared to P800) vs. 93% 
[77-99] in placebo. Dose modifications were seen in 44% and 34% 
of P800 and P400 groups. The proportion of patient with at least 
one grade 3/4 toxicity was 53% [35-71] in P800 (13% [4-29] for pla-
cebo) and 38% [21-56] in P400 (27% [12-46] for placebo). No toxic 
deaths were observed. Only 2 pts has grade 4 toxicities in P800 
(fatigue in P arm, GGT in the placebo arm). Most common toxici-
ties G3 in P800 were diarrhea (9%), hypertension (9%), and incre-
ased transaminases (16% vs. 0% in P400); in P400 gastro-intestinal 
disorders (16%, 6% diarrhea) and hypertension (6%).
Conclusion: IFCT-0703 is the first feasibility study demonstrating 
that full dose of P is safe but not feasible in the adjuvant setting in 
NSCLC. Compliance and tolerance with reduced dose appeared 
acceptable for adjuvant settings.
Keywords: adjuvant, Non small cell lung cancer, angiogenic inhibi-
tor, randomized phase II
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MO08.03 ADJUVANT CHEMOTHERAPY FOR NON-
SMALL CELL LUNG CANCER AFTER THORACOSCOPIC 
VERSUS OPEN LOBECTOMY.
Tine Schytte1, Erik Jakobsen2, Peter Licht3
1Department Of Oncology, Odense University Hospital/Denmark, 2Da-
nish Lung Cancer Registry, Odense University Hospital/Denmark, 3Car-
diothoracic Surgery, Odense University Hospital/Denmark
Background: In general thoracoscopic lobectomy (VATS) is con-
sidered being associated with advantages compared to conventi-
onal thoracotomy when it comes to postoperative outcomes such 
as pain, duration of hospitalization and overall complications. It 
is also believed that a reduction in these complications leads to 
better patient compliance with adjuvant chemotherapy. However, 
this assumption is based on single-Institution case-control studies 
and selection bias is possible. This is a study on the differences in 
patient compliance with adjuvant chemotherapy following lobec-
arm: Q1: Cis-Gemcitabine (CG); Q2-3: Cis-Docetaxel; Q4: Doceta-
xel (D). PORT in pN2 patients. Compliance treatment and toxicity 
profile analyzed by arm and correlation with potential prognostic 
factors explored
Results: 500 included p; 108 control arm, 392 experimental arm. 
Median follow-up 18.6 m (2-59 m). Median mRNA BRCA1 levesl 
15.78 (0.73-132) Q1 212 (42.4%), Q2-3 150 (30%), Q4 138 (27.6%). 
Mean BRCA1: Adenocarcinoma: 8.45 vs Squamous 19.6 (p< 0.001). 
Overall low levels BRCA1: 43.8%. EGFR mut 5.6% 297 p evaluated 
for compliance planned adjuvant treatment: M/F ratio: 82.5/17.5%. 
Median age: 62 (range 36-80). PS 0/1/2: 55.9/43,1/1%. Histology: 
Adenocarcinoma 47.5%, Squamous 44.1%. Stages: IIA/IIB/IIIA: 
11.1/38.4/50.2%. Surgical procedure: Lobectomy 72.1%; Pneu-
monectomy 27.9%.. Toxicity. G3-4 AE: Neutropenic fever: CD 10% 
vs D 4.4% vs CG 0%. (p=0.0056); Nausea/vomits: CG 11.1% vs CD 
10.4% vs D 0%. (p=0.0198); Hypersensitivity: D 5.97% (NS). Dose-
reduction: 34.24% control vs 18.30% experimental (p=0.0044). Full 
4 cycles CT compliance: CD control 80.83%, CG 91.2%, CD expe-
rimental 79.2%, D 88.1% (p=0.052). No differences in dose-reduc-
tions. CT compliance lobectomy 86.4% vs 85.5% pneumonectomy 
(NS). CT compliante < 70 y 91.1% vs 66.6% > 70 y (p<0.01)PORT 
compliance 55.31% of planned cases.
Conclusion: Planned trial recruitment achieved with median f-u 
18.6 m. Majority of resected NSCLC showed low levels expression 
BRCA1. Adenocarcinoma lower levels than Squamous. Safety profi-
les differences observed between treatment schedules: neutrope-
nic fever (CD), nausea/vomits (CG). Customized treatment requires 
less dose-reductions. Trend to poor compliance with Cis-Doc. No 
relation between extensión of surgery and adjuvant Tx compliance 
. Compliance CT significantly lower for age > 70 y. Low compliance 
for PORT.
Keywords: early stages N+, BRCA1 mRNA levels, treatment com-
pliance, adjuvant customized chemotherpay
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MO08.02 ADJUVANT PAZOPANIB OR PLACEBO IN RE-
SECTED STAGE I NSCLC PATIENTS: RESULTS OF THE 
NSCLC ADJUVANT RANDOMIZED PHASE II TRIAL (IFCT-
0703) FROM THE FRENCH COLLABORATIVE INTER-
GROUP
Benjamin Besse1, Julien Mazieres2, L Ribassin-Majed3, Fabrice 
Barlesi4, Jaafar Bennouna5, Radj Gervais6, Lionel Moreau7, Henri 
Berard8, Didier Debieuvre7, Olivier Molinier9, Denis Moro-Sibilot10, 
Pierre-Jean Souquet11, Jean-Pierre Pignon3, Elodie Amour12, A Ce-
lebic3, Franck Morin12, Bernard Milleron12, Gerard Zalcman13, Jean-
Charles Soria1
1Institut Gustave Roussy/France, 2Respiratory Medicine Service, Hôpital 
Larrey, Chu De Toulouse, Université De Toulouse Iii (paul Sabatier)/
France, 3Biostatistics, Gustave Roussy/France, 4Aix Marseille Univer-
sity – Assistance Publique Hôpitaux De Marseille/France, 5Institut 
De Cancérologie De L’ouest/France, 6Centre François Baclesse/France, 
7Centre Hospitalier/France, 8Service De Pathologie Respiratoire, Hôpi-
tal D‘instruction Des Armées Sainte-anne/France, 9Le Mans Regional 
Hospital/France, 10Unité D’oncologie Thoracique–pneumologie/France, 
11Pneumologie - Hcl/France, 12Ifct/France, 13Respiratory Diseases And 
Thoracic Oncology, Caen University Hospital/France
Background: Although UFT is approved in eastern countries, most 
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compare the outcomes of patients to matched controls.
Methods: Patients with Stage I-III KRAS-mutant lung cancers 
who completed curative therapy were enrolled. Each patient was 
routinely administered the genotype-matched vaccine from the 
GI4000 series subcutaneously starting 1-4 months after standard 
treatment completion: weekly x 3, monthly x 6 and every 3 months 
for a total of 3 years (19 doses). KRAS-antigen T-cell response was 
assessed by interferon-γ ELISpot assay in peripheral blood mono-
nuclear cells. The study was powered to detect an immune respon-
se rate of ≥25% (N=24 patients). A comparison group matched for 
age, sex, KRAS genotype and stage was used to compare recur-
rence and survival using the Kaplan-Meier method with a hazard 
ratio for survival adjusted for age, sex and stage.
Results: In 28 months, 33 patients were screened and 24 patients 
enrolled. The study met its primary endpoint with 63% of evalu-
able patients (50% of all patients) developing an antigen-specific 
immune response. 19 patients had evaluable baseline samples, 
9/13 with a negative response at baseline developed a treatment 
emergent response and 3/6 with a pre-existing baseline response 
had an increased response over baseline that met pre-specified 
immunologic criteria. There were no treatment-related Grade 3/4 
or severe AEs. The median number of vaccinations received was 15 
(range 1-19). 1 patient withdrew consent due to local injection site 
reaction and 2 died of recurrent disease during study. The baseline 
characteristics and clinical outcomes of the trial patients and a 
group of matched controls is presented in the Table below.  
GI4000 vs. 
Matched 
controls 
GI4000 N=24 N(%) Matched controls N=64 N(%) 
Stage I II III _____ 12 (50) 5 (21) 7 (29) 
_____ 42 (66) 2 (3) 20 
(31) 
Age at 
diagnosis 
(median) 
63 66 
Sex Male 
Female 
_____ 7 (29) 17 (71) _____ 21 (33) 43 (67) 
Recurrence 
free sur-
vival per 
year 1 2 3 
_____ 86% 68% 60% _____ 85% 71% 69% 
Overall 
survival 
per year 1 
2 3 
_____ 100% 100% 92% _____ 93% 88% 83% 
Hazard 
ratio for 
survival (p-
value) 
0.58 (0.29) 
Conclusion: The GI4000 vaccine is safe, feasible and immunogenic 
after completion of curative-intent therapy in patients with KRAS-
mutant lung cancers. Recurrence rates are equivalent but overall 
survival trends favorably when compared to matched controls. 
Exploratory analysis of survival in the immune responders versus 
matched controls is underway. A randomized study with prospecti-
ve biomarker analyses is warranted.
Keywords: early stage, KRAS-mutant NSCLC, vaccine
tomy by VATS or thoracotomy. Data are obtained from a complete 
national registry on lung cancer patients.
Methods: To investigate if the surgical approach alone had an 
impact on patient compliance to adjuvant chemotherapy we in-
vestigated patients who underwent lobectomy for clinical stage 
I non-small cell lung cancer. The patient population in this study 
had; however, unsuspected nodal involvement and adjuvant 
chemotherapy was indicated. Patients were analyzed for type of 
adjuvant chemotherapy as well as failure to begin or complete full 
treatment. A clinical oncologist who was blinded for surgery ap-
proach reviewed all patient files in order to investigate the data on 
chemotherapy.
Results: From 2007-2011 lobectomy for clinical stage 1 disease 
was performed in a total of 1513 patients by VATS (N=718/ 47.5%) 
or thoracotomy (N=795/ 52.5%). Unsuspected nodal disease was 
diagnosed in 278 (18.4%) patients, 11 patients were excluded. They 
had either distant metastasis or radiotherapy due to nonradical 
resection. This left 267 patients for further analyses, adjuvant che-
motherapy was delivered to 155 (58.1%) and 98 (36.7%) completed 
4 cycles as planned. There was no significant difference in patient 
compliance with chemotherapy and surgical approach (p=0.35). 
Survival was significantly influenced by comorbidity, histology and 
compliance with chemotherapy (p<0.001) in a Cox proportional 
hazard analysis; Survival was not influenced by sex, age or surgical 
approach.
Conclusion: In this study with complete national data we did not 
confirm the assumption that patient compliance with adjuvant che-
motherapy was better after thoracoscopic lobectomy compared 
to conventional lobectomy. Survival was significantly influenced by 
compliance with chemotherapy but not surgical approach.
Keywords: Surgical Procedure, adjuvant chemotherapy, NSCLC, 
Patient compliance
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MO08.04 PHASE 2 STUDY OF THE GI-4000 KRAS VACCI-
NE FOLLOWING CURATIVE THERAPY IN PATIENTS WITH 
STAGE I-III LUNG ADENOCARCINOMA HARBORING A 
KRAS G12C, G12D, G12V OR G12R MUTATION
Jamie E. Chaft1, Maria Arcila2, Payal Patel1, David M. Apelian3, 
Alicia Mattson3, Claire Coeshott3, Mark G. Kris1, Christopher G. 
Azzoli4
1Medical Oncology, Memorial Sloan-Kettering Cancer Center/United 
States Of America, 2Diagnostic Molecular Pathology, Memorial Sloan-
Kettering Cancer Center/United States Of America, 3Globeimmune/
United States Of America, 4Medical Oncology, Massachusetts General 
Hospital/United States Of America
Background: Most patients with early-stage lung cancer will die 
of recurrent disease despite multimodality therapy with curative 
intent. KRAS is the most commonly mutated oncogene in lung 
adenocarcinomas, and patients with resected disease are a unique 
population amenable to a personalized clinical trial approach. 
GI4000 is a vaccine created from whole, heat killed recombinant 
Saccharomyces cerevisiae yeast, overexpressing KRAS Q61L plus 
Q61(R or H) and either a G12C, G12D, G12V, or G12R mutation. This 
study aimed to assess the feasibility and immunogenicity of the 
GI4000 vaccine in patients with KRAS-mutant lung cancers and to 
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MO08.07 RANDOMIZED CONTROLLED PHASE III TRIAL 
OF ADJUVANT CHEMO-IMMUNOTHERAPY WITH ACTI-
VATED KILLER T CELLS AND DENDRITIC CELLS IN PATI-
ENTS WITH RESECTED PRIMARY LUNG CANCER.
Hideki Kimura1, Yukiko Matui2, Aki Ishikawa3, Takahiro Nakaji-
ma3, Mitsuru Yoshino3, Yuuichi Sakairi3
1Thoracic Surgery, Saiseikai Narashino Hospital/Japan, 2Thioracic Sur-
gery, Chiba Cancer Center/Japan, 3Department Of General Thoracic 
Surgery, Chiba University Graduate School Of Medicine/Japan
Background: We conducted a phase III randomized controlled 
study to investigate the efficacy of post-surgical adjuvant chemo-
immunotherapy using activated killer T cells and dendritic cells 
(AKT-DC) obtained from regional lymph nodes of lung cancer pati-
ents. The target of immunotherapy is the residual micrometastases 
after surgery and the resistant clones to chemotherapy.
Methods: Between April 2007 and July 2012, 103 patients with 
post-surgical non-small cell lung cancer were randomly assigned 
to receive either chemo-immunotherapy (group A) or chemothe-
rapy (group B). Immunotherapy was consisted of adoptive transfer 
of autologous activated killer T cells and dendritic cells (AKT-DC) 
obtained from regional lymph nodes of lung cancer patients. The 
primary end point of this study was overall survival. Secondary end 
points were recurrence free survival, toxicity, and adverse effects 
of immunotherapy.
Results: Two and five years over all survival were 93.4% and 81.4% 
in group A and 66.0% and,48.3% in group B respectively. The dif-
ference was statistically significant (log-rank test p=0.0005, gene-
ralized Wilcoxon test p=0.0005) in favor of chemo-immunotherapy 
group A. Hazard ratio was 0.229 (95% CI 0.093 to 0.564).Two year 
recurrence free survival was 68.5%(53.2 to 79.7%: group A) and 
41.4% (27.5 to 54.7: group B). The difference was statistically signi-
ficant (log-rank test p=0.0020 and HR 0.423(95% CI 0.241 to 0.743) 
in favor of group A. [Adverse effects of immunotherapy.] Chill and 
shiver: Out of total 762 courses, 52 courses (6.8%) were accompa-
nied with chill and shiver and 47 courses (6.2%) fever (>38) there-
after. Out of 50 cases treated by immunotherapy, 28 cases had no 
side effect and 22 cases had at least more than one side effect of 
chill, shiver and/or fever.
Conclusion: Immunotherapy using this modality is effective in re-
currence control of post-surgical lung cancer patients by inhibiting 
the growth of disseminated micrometastases.
Keywords: phase III study, NSCLC, adjuvant therapy, immunothe-
rapy
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MO08.05 RESEARCH AND PROGRESS OF VASCULAR 
TARGETED THERAPY IN THE POSTOPERATIVE ADJU-
VANT CHEMOTHERAPY FOR LUNG CANCER
Meilin Liao1, Zhiwei Chen1, Zhen Zhou1, Shun Lu1, Qingquan Luo2
1Lung Tumor Center, Shanghai Chest Hospital/China, 2Clinical Medical 
Center Of Lung Tumor, Shanghai Chest Hospital/China
Background: Postoperative adjuvant chemotherapy is extensively 
received due to its extension of the time to recurrence and enhance-
ment of survival rate in non-small cell lung cancer (NSCLC). However, 
it has reached the plateau at current, the beneficial cases are few, 
and drug-resistance and over-treatment phenomena are present in 
most of patients, hence it is necessary to seek a new postoperative 
adjuvant chemotherapy to improve the survival rate. Angiogenesis 
is one premise of malignant tumors to occur, develop and metas-
tasize, but vascular endothelial growth factor (VEGF) is one of the 
most important tumors in the process of neovascularization. Under 
normal conditions, VEGF is hardly expressed in a lot of normal tissu-
es in vivo, while highly expressed in the tumors like osteosarcoma, 
bladder cancer, breast cancer and colorectal cancer. Recombinant 
human endostatin (endostar) can significantly intervene the angio-
genesis-promoting effect to block the nutritional supply of tumors 
and inhibit tumor proliferation or metastasis. We compare the cu-
rative effect of endostar plus adjuvant chemotherapy and adjuvant 
chemotherapy alone in the treatment of patients with completely 
resected NSCLC at stage IB-IIIA.
Methods: This is an open, multicenter, randomized (1:1) study, strati-
fied by gender, stage and histology. Completely resected pts (stage 
IB to IIIA) were randomized to receive adjuvant NP plus Endostar 
(Vinorelbine 25mg/m2 on d1 and d8 plus Cisplatin 75 mg/m2 on d1, 
and iv plus Endostar 7.5mg/m2 per day iv for consecutive 14 days. 
Every 21 days as one cycle for 4 cycles) or NP regimen alone. The 
primary endpoint was disease-free survival (DFS). Secondary end-
points included tumor response rate, overall survival and safety.
Results: 250 pts (1:1) were included between 07/2007 and 06/2009. 
Two arms were well-balanced with regard to age, gender, histolo-
gy, staging, and resection type. The follow-up time is 42 months. 
The two groups had no significant difference in the incidence of 
toxicity reaction. Endostatin plus NP can prolong the DFS of pati-
ents with complete resectable NSCLC at stage IIIA (19.33±3.73m vs 
17.10±9.68m) with high security, but no statistical difference. Cases 
with high expression of VEGF showed a better DFS than cases 
with low expression in Endostatin plus NP group (48.45±3.52m vs 
40.18±4.54m, P < 0.05). The level of peripheral circulating endothe-
lial progenitor cells (EPCs) in NSCLC patients is significantly higher 
than that in healthy volunteers. EPCs level was associated with NS-
CLC stage. The EPCs levels after treatment significantly decreased 
than that before treatment (P=0.014) in beneficiaries of NP or NP 
plus with endostar. The time to progression (TTP) was longer in 
patients with lower levels of EPCs (<0.35%) before chemotherapy or 
endostatin treatment (P<0.001).
Conclusion: This preliminary result showed vascular targeted the-
rapy in postoperative adjuvant therapy of lung cancer has a good 
application prospect. VEGF and EPCs play important roles in the 
development of lung cancer. Deep studies should be taken for the 
other related molecular targets in the future.
Keyword: adjuvant chemotherapy; non-small cell lung cancer; vas-
cular targeted therapy; VEGF
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Conclusion: This exploratory analysis suggests that use of the 15-
gene expression signature to guide decisions for ACT in resected 
stage IB/II NSCLC patients could be highly cost-effective. Further 
validation of the signature’s impact on ACT outcomes is needed.
Keywords: Early stage non-small cell lung cancer, economic analy-
sis, Gene expression signature, adjuvant chemotherapy
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MO08.09 PET-CT SCANNING DERIVED ARTIFICIAL NEU-
RAL NETWORK CAN 
PREDICT MEDIASTINAL LYMPH NODES METASTASES IN 
NSCLC 
PATIENTS. PRELIMINARY REPORT.
Pawel Wnuk1, Mariusz Kowalewski2, Bogdan Małkowski3, Mariusz 
Bella1, Maciej Dancewicz1, Tomasz Szczęsny1, Przemysław Bławat1, 
Janusz Kowalewski1
1Department Of Thoracic Surgery And Tumours, Franciszek Lukaszczyk 
Oncology Centre, Bydgoszcz, Poland/Poland, 2Department Of Thoracic 
Surgery And Tumours, Collegium Medicum In Bydgoszcz, Nicolaus 
Copernicus University In Toruń, Poland/Poland, 3Department Of Nu-
clear Medicine, Franciszek Lukaszczyk Oncology Centre, Bydgoszcz, 
Poland/Poland
Background: Mediastinal lymph nodes staging in NSCLC is of 
paramount importance. Although relatively precise, diagnostic mo-
dalities still employ certain level of invasiveness. Artificial Neural 
Network (ANN) is a well established predictor tool which, due to 
underlying distribution and relationship among the given variables, 
allow for construction of multidimensional models trained in prog-
nosis of given outcome. Their performance in mediastinal staging 
based on radiological data only, currently remains unknown.
Methods: Samples from 467 lymph nodes were obtained from 
160 patients with primary NSCLC by means of endobronchial ul-
trasound guided-transbronchial needle aspiration (EBUS-TBNA), 
mediastinoscopy or lymphadenectomy during thoracotomy and 
microscopically analyzed. ANN models were created and prospec-
tively validated on unmatched cohort of 50 consecutive patients 
(158 groups of lymph nodes). To identify factors correlated with 
nodal involvement single factor tests and logistic regression analy-
sis were performed. 
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MO08.08 A COST-EFFECTIVENESS ANALYSIS OF THE 
15-GENE EXPRESSION SIGNATURE IN GUIDING ADJU-
VANT CHEMOTHERAPY IN EARLY STAGE NON-SMALL 
CELL LUNG CANCER BASED ON THE JBR.10 TRIAL
Kit Man Wong1, Suzanne Li2, Keyue Ding2, Penelope Bradbury2, 
Ming-Sound Tsao1, Frances A. Shepherd1, Carmen Chung1, Ray-
mon Ng2, Lesley Seymour2, Natasha B. Leighl1
1Princess Margaret Cancer Centre/Canada, 2National Cancer Institute 
Of Canada Clinical Trials Group/Canada
Background: The NCIC CTG JBR.10 trial demonstrated that adju-
vant chemotherapy (ACT) improves survival in resected stage IB/
II non-small cell lung cancer (NSCLC) compared to observation. A 
15-gene expression signature was developed from the trial popu-
lation and subsequently validated to stratify patients with resected 
NSCLC into low and high risk prognostic groups. The signature 
may also be predictive for greater benefit from ACT in high risk 
patients (Zhu et al. JCO 2010), but this has not yet been validated. 
This gene expression signature may offer a risk stratification strate-
gy to identify patients most likely to benefit from ACT. We conduc-
ted an exploratory economic analysis to assess the impact of the 
use of this gene signature compared to current clinical staging to 
guide ACT decisions in resected early stage NSCLC.
Methods: We developed a decision analytic model populated by 
the NCIC CTG JBR.10 trial cost and outcome data, including di-
rect medical costs and overall survival (OS). Utility for each health 
state was estimated from quality of life data to generate quality-
adjusted survival. The analysis was performed over a lifetime 
horizon from the perspective of the Canadian public health care 
system, expressed in 2013 Canadian dollars. Survival and costs 
were discounted at 5% per year. We determined the incremental 
cost-effectiveness ratio (ICER) and incremental cost-utility ratio 
(ICUR) of ACT versus observation in resected stage IB/II NSCLC in 
the following two scenarios: (1) gene signature-directed ACT, whe-
re patients classified as having high risk of recurrence receive ACT 
and those at low risk are observed; and (2) clinical stage-directed 
ACT, where gene signature profiling is not performed – those with 
stage IB tumours >4cm or stage II NSCLC receive ACT, and those 
with stage IB tumours <4cm are observed. Nonparametric boot-
strapping to estimate 95% confidence intervals (CI) and multi-way 
sensitivity analyses were performed.
Results: The analysis included 52 patients in the gene signature-
based strategy and 125 patients in the stage-based strategy with 
available direct medical costs and gene signature data. The mean 
survival gain of ACT versus observation was 2.28 years using gene 
signature-directed selection, and 1.59 years using stage-directed 
selection. The discounted ICER of ACT versus observation was 
$8,327/life-year gained (LYG; 95% CI, $395 to $19,590) using the 
gene signature-directed approach, and $5,623/LYG (95% CI, 
-$2,161 to $14,354) for the clinical approach. There was no signifi-
cant difference in the ICER between the two strategies (p=0.52). 
The discounted ICUR was $11,315/quality-adjusted life-year (QALY; 
95% CI, $211 to $27,314) using the gene signature-directed ap-
proach, and $7,728/QALY (95% CI, -$3,080 to $19,825) for the clini-
cal approach. Sensitivity analyses showed that the ICER was most 
sensitive to changes in the survival hazard ratio (i.e. treatment be-
nefit) and utility, but less sensitive to the cost of the gene signature 
(range $0 to $10,000 per case, with corresponding ICER $15,794 to 
$28,194/LYG, respectively).
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Figure 1. The multilayer perceptron (MLP). Artificial Neural Net-
work (ANN) structure for predicting metastatic involvement of 
mediastinal lymph nodes in NSCLC patients.
Results: Size and standard uptake value (SUV) of the node along 
with primary tumour T characteristics were identified as the most 
sensitive variables regardless of the analysis conducted. Two ANN 
models predicted metastatic involvement with 89% and 92% ac-
curacy. Single factor tests maintained high accuracy only for 2 out 
of 4 most sensitive variables (SUV >2.8 and length >15mm) in pros-
pective validation. Additionally, logistic regression analysis allowed 
for construction of scoring model with certain parameters corres-
ponding to risk thresholds of metastatic disease.
Figure 2. Artificial Neural Network (ANN) characteristics. ROC cur-
ves for 2 manually designed ANNs (A); Sensitivity analyses of coef-
ficients (B) and overall characteristics of ANNs performance (C).
Conclusion: ANN is a repeatable and accurate diagnostic tool in 
mediastinal staging in NSCLC patients. Before its role in clinical 
practice will be established in large multi-centre study, findings of 
this preliminary report should be considered as exploratory only.
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Conclusion: Adjuvant chemotherapy was considered to be effec-
tive for PLC positive lung adenocarcinoma patients. Even in stage 
I cases, our results implicated that adjuvant chemotherapy was 
beneficial.
Keyword: pleural lavage cytology, adenocarcinoma,  
chemotherapy,
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MO08.11 THE ROLE OF AGGRESSIVE LOCAL THERAPY 
AND PROGNOSTIC FACTORS IN POSTOPERATIVE RE-
CURRENT NON-SMALL CELL LUNG CANCER: IS OLIGO-
RECURRENCE STATE POTENTIAL CURABLE DISEASE?
Yoshihisa Shimada, Masatoshi Kakihana, Kouichi Yoshida, Ya-
sufumi Kato, Masaru Hagiwara, Naohiro Kajiwara, Tatsuo Ohira, 
Norihiko Ikeda
Surgery I, Tokyo Medical University/Japan
Background: Non-small cell lung cancer (NSCLC) with postope-
rative recurrence (POR) is generally believed to have an incurable 
disease. However, several studies have indicated that only a limited 
number of distant recurrences (oligorecurrence) may benefit from 
local therapy to the distant site of disease. We investigated factors 
associated with postrecurrence survival (PRS) in recurrent NSCLC, 
and particularly the role of local therapy to the metastatic site.
Methods: From 2000 through 2009, a total of 1542 patients with 
NSCLC underwent complete surgical resection. Of those, we revie-
wed the records of 356 patients with POR.
Results: Type of POR included locoregional only in 114 (32%), 
distant in 242 (68%). Of the 242, there were 65 oligorecurrences. 
Initial recurrence therapy found local treatment for 68 (surgery 5, 
radiation 12, surgery with chemotherapy and/or radiation 12, che-
moradiotherapy 39). Multivariate analysis demonstrated that older 
age (HR1.522), advanced stage (HR1.371), shorter disease-free 
interval (DFI; HR1.733), non-adenocarcinoma (HR1.442), systemic 
treatment (-) (HR1.481), EGFR-TKIs (-) (HR1.563), local treatment (-) 
(HR1.705) and bone metastases (HR2.140) had a significant associ-
ation with poor PRS, and oligorecurrences state appeared as an in-
dependent PRS factor in patient with distant recurrence (HR1.836). 
Median PRS times were 36.3 months for 37 patients with DFI > 16 
months and receiving local treatment, and 16.0 months for other 
(p<0.001) in all patients (Fig.1), and 36.5 months for 29 patients 
with DFI > 16 months and oligorecurrence, and 14.6 months for 
other (p<0.001) in patient with distant recurrence (Fig.2). There was 
no significant difference in survival for the patients with oligorecur-
rence according to whether or not receiving local treatment. 
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MO08.10 EFFICACY OF ADJUVANT CHEMOTHERAPY 
FOR LUNG ADENOCARCINOMA PATIENTS WITH PLEU-
RAL LAVAGE CYTOLOGY POSITIVE FINDINGS.
Hiryuki Ogawa, Kazuya Uchino, Nahoko Shimizu, Kenta Tane, 
Wataru Nishio, Masahiro Yoshimura
Hyogo Cancer Center, Hyogo Cancer Center/Japan
Background: Pleural lavage cytology (PLC) is considered to be a 
prognostic factor for non-small cell lung cancer (NSCLC) patients. 
There has been no report describing the relationship between 
adjuvant chemotherapy and the presence of PLC.Backgroud: Pleu-
ral lavage cytology (PLC) is considered to be a prognostic factor 
for non-small cell lung cancer (NSCLC) patients. There has been no 
report describing the relationship between adjuvant chemothera-
py and the presence of PLC.
Methods: From January 2000 to December 2009, we retrospec-
tively reviewed the medical record of lung adenocarcinoma pa-
tients who underwent tumor resection and were positive for PLC 
immediately after thoracotomy.
Results: There were 53 patients (4.8%) out of 1114 lung adenocar-
cinoma patients had PLC positive findings, including 31 male and 
22 female patients, with a mean age of 66.6 years. Median follow 
up period was 33.6 months. Adjuvant chemotherapy was adminis-
tered intravenously to 24 patients and they were classified as adju-
vant chemotherapy group. The rest of 29 patients were classified 
as surgery alone group. Pathological stage of I / II / III was 12 (41%) 
/ 8 (28%) / 9 (31%) in surgery alone group and 7 (36%) / 8 (30%) / 9 
(38%) in adjuvant chemotherapy group. The regimen of chemothe-
rapy was as follows; 8 patients received cisplatin plus gemcitabine, 
7 patients received carboplatin plus paclitaxel, 7 patients received 
gemcitabine, and 2 patients received others. 5-year survival rate 
was 50.3% and 29.7% (p=0.09) and 5-year recurrence free survi-
val rate was 34.6% and 15.7% (p<0.01) in adjuvant chemotherapy 
group and surgery alone group. Even in stage I cases, there was 
a tendency that adjuvant chemotherapy group had better 5-year 
recurrence free survival than surgery alone group (60.1% and 29% 
p=0.11). In the COX proportional hazard multivariate analysis for 
recurrence free survival revealed that adjuvant chemotherapy (ha-
zard ratio (HR) 0.45, p=0.03), tumor size >30mm (HR 2.23, p=0.02), 
and lymph node metastasis (HR 2.67, p<0.01) were significant inde-
pendent prognostic factors.
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MO09.01 EVALUATION OF TOLERABILITY AND ANTI-
TUMOR ACTIVITY OF GDC-0980, AN ORAL PI3K/MTOR 
INHIBITOR, ADMINISTERED TO PATIENTS WITH ADVAN-
CED MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Saoirse O. Dolly1, Lee M. Krug2, Andrew J. Wagner3, Lawrence H. 
Schwartz4, Johanna C. Bendell5, Jennifer O. Lauchle6, Tanguy Y. 
Seiwert7, Karim Rihawi1, Nina Tunariu1, Marjorie G. Zauderer2, 
Lukas Delasos2, David Kwiatkowski3, J P Marcoux3, Michael S. 
Rabin3, Doris Apt6, Jill Fredrickson6, Mark Lackner8, Hartmut Ko-
eppen8, Joseph A. Ware9, Howard A. Burris5, Johann S. De Bono1, 
Hedy Kindler7
1Drug Development Unit & Cancer Therapeutics, Royal Marsden Hospi-
tal And Institute Of Cancer Research/United Kingdom, 2Department Of 
Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer 
Center/United States Of America, 3Medical Oncology, Dana-Farber 
Cancer Institute/United States Of America, 4Department Of Radiology, 
Columbia University Medical Center/United States Of America, 5Medi-
cal Oncology, Sarah Cannon Research Institute/United States Of Ame-
rica, 6Exploratory Clinical Development, Genentech Inc/United States 
Of America, 7Department Of Medicine, University Of Chicago/United 
States Of America, 8Oncology Biomarker Development, Genentech Inc/
United States Of America, 9Small Molecule Clinical Pharmacology, 
Genentech Inc/United States Of America
Background: The PI3K-AKT-mTOR signaling pathway is dysregu-
lated in a wide variety of cancers. Pathway activation in mesothe-
lioma may occur through diverse cellular mechanisms, including 
activation of receptor tyrosine kinases that signal through Ras 
and PI3K/Akt/mTOR, and loss of PTEN expression. GDC-0980 is a 
potent and selective oral dual inhibitor of class I PI3K and mTOR 
kinases that has demonstrated broad activity in various xenograft 
cancer models.
Methods: A phase I dose-escalation study was conducted in 2 
Stages: Stage 1 evaluated oral, daily (QD) doses of 2-70 mg GDC-
0980 given 21/28 or 28/28 days in a 3+3 dose escalation design. 
Stage 2 evaluated disease specific cohorts at the recommended 
phase 2 dose (RP2D), including a MPM cohort at 30 mg GDC-0980 
QD 28/28 days. Safety and tolerability of GDC-0980 was assessed 
as well as pharmacokinetics (PK) and pharmacodynamics (PD) 
assessment of PI3K pathway inhibition by FDG-PET. Anti-tumor 
activity was assessed by modified RECIST; CT scans were centrally 
reviewed retrospectively by a radiologist with MPM expertise. 
Archival tumor tissue was evaluated for PIK3CA mutation by allele 
specific PCR or Sanger sequencing and PTEN expression was as-
sessed by immunohistochemistry.
Results: 33 MPM patients were enrolled: 6 in Stage 1 at 8-70 mg 
and 27 in Stage 2 at 30mg GDC-0980. Safety and tolerability of 
GDC-0980 in Stage 1 was similar in MPM compared to other so-
lid tumor patients, with the exception of a Grade 5 pneumonitis 
that occurred in a MPM patient at 40 mg GDC-0980 QD. Based 
on Stage 1 tolerability data, a RP2D of 30 mg QD was evaluated 
in Stage 2 for MPM patients. The most frequent Grade ≥3 drug-
related adverse events (AEs) at 30 mg GDC-0980 were rash (19%), 
with one patient (4%) having to discontinue GDC-0980. Other AEs 
were fatigue (15%), and hyperglycemia, diarrhea, and colitis (7% 
Conclusion: This study showed that local therapy improved PRS 
in patients with POR. Optimization of personalized systemic treat-
ment depends on patient selection, and therapeutic strategy for 
adding an aggressive local treatment options based on a careful 
follow-up is important.
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RECIST, and secondary endpoints include overall survival, tumor 
response rate, and toxicity. Translational endpoints included mea-
surement of plasma arginine, citrulline and ADI-PEG20 antibody 
levels, assessment of metabolic response by [18F]Fluorodeoxyglu-
cose Positron Emission Tomography (FDG-PET) and ASS1 methyla-
tion status using Illumina’s 450K DNA methylation array. The target 
sample size was estimated to detect a PFS hazard ratio of 0.60. 
[Trial funded by Cancer Research UK].
Results: ASS1 deficiency was detected in 98 of 214 patients (46%) 
of which 68 were randomized on the trial (44 ADI-PEG20+BSC 
and 24 BSC alone). 66 patients have progressed so far (42 ADI-
PEG20+BSC vs. 24 BSC alone), and 32 patients were alive (23 ADI-
PEG20+BSC vs. 9 BSC alone). The hazard ratio for PFS was 0.53 
(95%, CI 0.31 to 0.90, p=0.02) with a median PFS of 98 days for 
patients randomized to ADI-PEG20+BSC compared with 59 days 
for patients receiving BSC alone. ADI-PEG20 toxicity in patients 
with MPM has been consistent with previous trials of ADI-PEG20 
in melanoma and liver cancer: commonly skin injection site reac-
tions (grade 1-2), infrequent episodes of neutropenia (range: grade 
1-4), anaphylactoid reactions (2 patients with grade 3 episodes) 
and serum sickness (1 patient). The best response by modified 
RECIST was stable disease. Metabolic responses (in 39 evaluable 
ADI-treated patients) were as follows: 46% with partial response 
(18/39), 31% with stable disease (12/39), 15% progressive metabolic 
disease (6/39) and 8% mixed metabolic response (3/39) by FDG-
PET assessment. There was a significant difference between IHC 
assessed ASS1-negative and ASS1-positive patients and the me-
thylation status of the ASS1 gene (p=0.025).
Conclusion: ADI-PEG20 is generally well tolerated and shows 
evidence of clinically significant activity in patients selected for 
arginine-dependent MPM demonstrating differential methylation 
of ASS1. Arginine deprivation may have a role in the future ma-
nagement of MPM either alone or in combination with selected 
therapies.
Keywords: mesothelioma, ASS1, ADI-PEG20, RP2
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MO09.03 A PILOT AND FEASIBILITY TRIAL EVALUA-
TING TWO DIFFERENT CHEMOTHERAPY REGIMENS IN 
COMBINATION WITH INTRAPLEURAL ADENOVIRAL-
MEDIATED INTERFERON-ALPHA (SCH 721015, AD.HIFN-
ALPHA2B) GENE TRANSFER FOR MALIGNANT PLEURAL 
MESOTHELIOMA
Daniel Sterman1, Evan Alley2, Adri Recio1, James P. Stevenson3, Su-
san Metzger1, Edmund K. Moon4, Andrew R. Haas1, Anil Vachani4, 
Sharyn Katz5, Guanjun Cheng6, Jing Sun6, Nate Chertack6, Nahara 
Saballos6, Daniel Heitjan7, Leslie Litzky8, Keith A. Cengel9, Charles 
Simone9, Joseph Friedberg10, Melissa Culligan10, Karen Mudrick10, 
Steven M. Albelda1
1Medicine, Division Of Pulmonology, University Of Pennsylvania/Uni-
ted States Of America, 2Medicine, Division Of Oncology, University Of 
Pennsylvania/United States Of America, 3Medicine, Division Of Onco-
logy, Cleveland Clinic/United States Of America, 4Pulmonary, Allergy, 
And Critical Care, University Of Pennsylvania/United States Of Ameri-
ca, 5Radiology, University Of Pennsylvania/United States Of America, 
6Thoracic Oncology Research Group, University Of Pennsylvania/United 
States Of America, 7Center For Clinical Epidemiology And Biostatistics, 
University Of Pennsylvania/United States Of America, 8Pathology, 
each). Reversible Grade 2 pneumonitis was reported for 2 patients 
(7%). Population PK analysis was used to assess the behavior of 
GDC0980 in MPM patients. Additionally, PK/PD relationships will 
be discussed for efficacy and safety, including exposureresponse, 
where appropriate. Archival tissue was analyzed for 29 MPM pati-
ents. Two samples had PIK3CA mutations (R88Q and E545G) and 
one sample showed loss of PTEN expression. PI3K pathway inhibi-
tion by FDG-PET responses was observed in 8 of 24 MPM patients 
with available scans. Anti-tumor activity was observed in both sta-
ges. Two patients achieved a partial response (PR) in Stage 1, one 
patient at 50 mg and one patient with the PIK3CA mutation R88Q 
at 8 mg GDC-0980. Two PRs were observed at the RP2D of 30 mg 
in Stage 2. Eleven (41%) MPM patients at the RP2D remained on 
study for >6 months, and 2 (7%) patients remained on study >12 
months.
Conclusion: GDC-0980 was generally well tolerated in MPM pati-
ents at the RP2D. Anti-tumor activity, evidenced by tumor regres-
sion and prolonged disease control, has been observed. PIK3CA 
mutations and PTEN loss were uncommon.
Keywords: PI3K, GDC-0980, MPM, mTOR
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MO09.02 A RANDOMISED PHASE II TRIAL OF PEGYLA-
TED ARGININE DEIMINASE IN PATIENTS WITH MALIG-
NANT PLEURAL MESOTHELIOMA
Peter W. Szlosarek1, Jeremy Steele1, Michael Sheaff2, Teresa Szys-
zko3, Stephen Ellis3, Luke Nolan4, Paul Taylor5, David Gilligan6, 
James Spicer7, Michael Lind8, Phuong Luong9, Lee Butcher10, Ste-
phan Beck10, Norbert Avril3, John Bomalaski11, Nick Lemoine12, 
Robin Rudd1, Dean Fennell13, Allan Hackshaw14
1Medical Oncology, St Bartholomew‘s Hospital/United Kingdom, 2His-
topathology, St Bartholomew‘s Hospital/United Kingdom, 3Radiology, 
St Bartholomew‘s Hospital/United Kingdom, 4Medical Oncology, Sou-
thampton General Hospital/United Kingdom, 5Medical Oncology, Wy-
thenshawe Hospital/United Kingdom, 6Clinical Oncology, Addenbrooke‘s 
Hospital/United Kingdom, 7Medical Oncology, King‘s College/United 
Kingdom, 8Medical Oncology, Hull York Medical School/United Kingdom, 
9Molecular Oncology, Barts Cancer Institute/United Kingdom, 10Medical 
Genomics, University College/United Kingdom, 11Medical Affairs, Pola-
ris Group/United States Of America, 12Centre For Experimental Medi-
cine, Barts Cancer Institute/United Kingdom, 13University Of Leicester/
United Kingdom, 14Cruk Cancer Trials Centre, University College/United 
Kingdom
Background: Preclinically, arginine deprivation has shown activity 
as a novel antimetabolite strategy for MPM patients who are defi-
cient for the rate-limiting enzyme in arginine biosynthesis argini-
nosuccinate synthetase (ASS1). Here, we examine the efficacy and 
safety of the arginine-lowering agent ADI-PEG20 (Polaris Group, 
San Diego, US) among patients with MPM.
Methods: We performed a multicentre randomised phase II cli-
nical trial, based on patients with good performance status (0 or 
1), non-resectable disease, ASS1-deficient MPM, and measurable 
disease. Patients were randomized 1:2 to receive best supportive 
care (BSC) or BSC+ADI-PEG20, stratified by: gender, histology (sar-
comatoid versus non-sarcomatoid), prior treatment (chemonaive or 
previous platinum combination therapy), and centre. The primary 
endpoint, progression-free survival (PFS), is assessed by modified 
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Pem/Platin (N=25) Gemcitabine (N=13)
Male % 64% (16/25) 84.6% (11/13)
Median 
Age 67 (51-86) 65 (43-81)
Histologic 
Subtype %
Epithelioid - 17 (68%) 
Biphasic - 4 (17%) Sar-
comatoid - 4 (17%) 
Epithelioid - 11 (84.6%) 
Biphasic - 2 (15.4%) Sar-
comatoid - 0 
Stage I - 2 (8%) II - 6 (24%) III - 13 (52%) IV - 4 (16%) III - 4 (30%) IV - 9 (70%) 
Prior 
Treatment
Chemotherapy - 4 
(16%) RP/PDT - 4 (16%) 
XRT - 5 (20%) 
Chemotherapy - 13 
(100%) RP/PDT - 7 (53%) 
XRT - 2 (15%) 
Platin 
Agent
Cisplatin - 12 Carbo-
platin - 10 Cis-Carbo 
- 1 None - 2 
Cisplatin - 0 Carboplatin 
- 2 None - 8 
Median 
Cycles of 
Chemo
6 (1-6) 3 (0-6)
 
TABLE 1
Conclusion: The combination of intrapleural Ad.IFN-α2b vector, 
Celecoxib, and systemic chemotherapy proved safe. Disease con-
trol rates observed in this study compare favorably with historical 
data andthe especially encouraging OS in the second-line chemo-
therapy group argue strongly for proceeding with a multi-center 
randomized clinical trial of chemo-immunogene therapy versus 
chemotherapy alone.
Keywords: combination therapy, mesothelioma, gene therapy
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MO09.04 DEFINING BAP1 SYNDROME: PRELIMINARY 
RESULTS FROM AN EPIDEMIOLOGIC ASCERTAINMENT 
STUDY
Marjorie G. Zauderer1, Robert Mcmillan2, Camelia S. Sima3, Mark 
Robson1, Valerie W. Rusch4, Lee M. Krug5, Marc Ladanyi6
1Medicine, Memorial Sloan-Kettering Cancer Center/United States Of 
America, 2Surgery, Memorial Sloan-Kettering Cancer Center/United 
States Of America, 3Biostatistics, Memorial Sloan-Kettering Cancer 
Center/United States Of America, 4Thoracic Surgery, Memorial Sloan-
Kettering Cancer Center/United States Of America, 5Department Of 
Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer 
Center/United States Of America, 6Pathology, Memorial Sloan Kettering 
Cancer Institute/United States Of America
Background: Identifying tumorigenic mutations in malignant pleu-
ral mesothelioma (MPM) is essential to advance therapy. Somatic 
mutations in the BRCA-1 associated protein-1 (BAP1) gene occur in 
about 20% of MPM tumors (Bott et al., Nature Genetics, 2011). In 
a retrospective analysis evaluating demographics, exposures, and 
survival, a history of smoking was the only clinical feature associa-
ted with the presence of BAP1 mutations (Zauderer et al., in press, 
J Thorac Oncol, 2013). Germline BAP1 mutations have also been 
identified in families predisposed to MPM (Testa et al., Nature Ge-
netics, 2011). BAP1 germline mutations have also been associated 
with other tumors including atypical Spitz nevi, uveal melanoma, 
University Of Pennsylvania/United States Of America, 9Radiation Onco-
logy, University Of Pennsylvania/United States Of America, 10Thoracic 
Surgery, University Of Pennsylvania/United States Of America
Background: Malignant pleural mesothelioma is an incurable tho-
racic neoplasm for which combination chemotherapy offers limited 
improvement in survival. Novel agents that offer synergy with stan-
dard systemic cytotoxic therapy are under investigation. Among 
these agents are a variety of immunotherapeutics which can be 
administered either locally or in a systemic fashion.
Methods: We conducted a Phase I/II “in situ vaccination” clinical 
trial commencing in March2011 involving repeated intrapleural 
administration of a replication-defective recombinant adenoviral 
vector containing the human interferon-alpha (hIFN-α2b) gene at 
a dose of 3x1011 viral particles concomitant with a 14-day course of 
high-dose cyclo-oxygenase-2 (COX-2) inhibitor (Celecoxib). This 
was followed by standard first-line or second-line chemotherapy 
agents. Primary outcome measures were safety, overall best res-
ponse rate, and survival.
Results: We completed accrual (n=25) in the first-line chemothe-
rapy arm, in which all patients received pemetrexed-based che-
motherapy regimens. This group included patients who previously 
received pemetrexed chemotherapy but did not subsequently 
receive this agent for >6 months. In the second-line chemotherapy 
arm, 13of a planned 15 subjects have enrolled (with 12 evaluable), 
all of whom received gemcitabine-based chemotherapy (Table 1). 
In both arms, the combination of intrapleural Ad.IFN-α2b vector, 
high-dose celecoxib, and systemic chemotherapy proved safe. 
Adverse events during the chemotherapy portion of the study 
were comparable to historical controls.Most patients experienced 
expected mild toxicities from vector (cytokine release syndrome, 
interferon production), including nausea, fatigue, anemia, lympho-
penia (grade 3-4) and hypoalbuminemia. Serious adverse events 
included: pleural catheter infection (n=2); hypoxia (n=2); supra-
ventricular tachycardia (n=1); and esophagitis (n=1), none directly 
attributable to the vector or vector administration. Serial chest 
CT and PET/CT scans demonstrated an overall response rate of 
31% by Modified RECIST criteria and disease control rate (DCR) of 
78% (partial and complete responses plus stable disease) at initial 
follow-up scan after the first two cycles of chemotherapy. Partial 
responses were seen in 9/25 evaluable patients with pemetrexed-
based chemotherapy and 1/12 with gemcitabine. Patients who 
received first-line pemetrexed-based chemotherapy (n=14) had a 
median survival of 10.5 months, 95% ci=(5.5,inf), whereas second-
line patients (n=21; 12 gemcitabine)had a median survival of 15.0 
months, 95% ci=(9.0,inf).  
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and renal cell carcinoma. These discoveries suggest that BAP1 mu-
tations in mesothelioma represent part of a new hereditary cancer 
syndrome but the exact clinical phenotype remains unclear. To es-
tablish the frequency of germline BAP1 mutations in MPM patients 
and to accurately assess exposure history and family histories in 
these patients, we have undertaken a clinical trial to prospectively 
collect this information from patients with MPM.
Methods: All consenting patients provide a saliva or blood spe-
cimen from which germline DNA is extracted. Existing tumor 
samples are collected and analyzed for BAP1 mutation. Everyone 
completes a questionnaire regarding asbestos exposure, perso-
nal cancer history, and family history of malignancy. First, we will 
perform a de-identified assessment of the prevalence of germline 
BAP1 mutation. Patients whose tumors harbor BAP1 mutation 
and/or meet prespecified high risk criteria will be approached for 
identified germline testing after appropriate pre-test counseling. 
Mutations identified through research testing with be confirmed 
with clinical testing and additional genetic counseling will be un-
dertaken. Testing will be offered to family members of patients 
with identified BAP1 germline mutations. Please see Figure 1 for 
study flow. 
Results: During the first 3 months that this protocol was open, we 
accrued 26 patients with mesothelioma, 15 of whom qualify for 
identified research testing. We will present results from ongoing 
testing at the meeting.
Conclusion: Recruiting patients to perform both de-identified and 
identified germline testing is feasible. Given the paucity of infor-
mation regarding penetrance and appropriate screening interven-
tions, BAP1 germline testing should continue only in the context 
of research programs. Additional preclinical work is ongoing to 
exploit this potential therapeutic target. Supported, in part, by a 
grant from the Mesothelioma Applied Research Foundation.
Keywords: asbestos exposure, mesothelioma, BAP1
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treatment 140 days. Survival was highest in patients having “sur-
gery” and chemotherapy (491 days). Use of chemotherapy varied 
across 28 regional cancer networks from 14% to 41% of patients, 
but overall increased over the audit period from 13% to 34%.
Conclusion: Mesothelioma is predominantly a cancer of elderly 
males, with a striking tendency for right-sided disease. Only 11% 
have no histological confirmation, but where this is obtained, the 
epithelioid subtype has best prognosis. Low rates of anti-cancer 
treatment may reflect therapeutic nihilism as well as patient fitness, 
but there is an encouraging trend towards wider use of chemothe-
rapy which was associated with a greater than doubling in survival 
compared with no treatment.
Keywords: mesothelioma, Epidemiology, Treatment, survival
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MO09.07 DISEASE AND PATIENT CHARACTERISTICS RE-
LATED TO SURVIVAL IN A LARGE POPULATION-BASED 
COHORT OF PATIENTS WITH MALIGNANT PLEURAL ME-
SOTHELIOMA (MPM)
Anthony Linton1, Nick Pavlakis2, Steven Kao1, Stephen Clarke2, 
Janette Vardy3, Nico Van Zandwijk1
1Asbestos Diseases Research Institute/Australia, 2Department Of Me-
dical Oncology, Royal North Shore Hospital/Australia, 3Department Of 
Medical Oncology, Concord Cancer Centre/Australia
Background: Despite advances in therapy, the prognosis of MPM 
remains poor (median overall survival (OS) of 9-12 months). Ne-
vertheless, as described in surgical series, a small proportion of 
patients survive far longer. Previously identified prognostic factors 
in patients undergoing extra-pleural pneumonectomy (EPP) inclu-
de histological subtype, gender and neutrophil-lymphocyte ratio 
(NLR). Similar factors including stage and performance status have 
also been shown to be prognostic in chemotherapy studies. We 
aim to assess in the general MPM patient population, what factors 
predict for better prognosis independent of the treatment path 
chosen.
Methods: We reviewed records of patients registered (2002 -2009) 
with the NSW Dust Diseases Board; a government compensation 
body for NSW workers with occupational asbestos exposure. We 
evaluated a priori prognostic factors including age, gender, his-
tological subtype, staging on CT imaging and NLR using Kaplan 
Meier and Cox regression analysis, and by treatment interventions, 
smoking and asbestos exposure history. Exploratory subgroup 
analyses compared these factors in long-term (>20 months) survi-
vors versus the remainder of the study population.
Results: We identified 913 patients: 90% male; median age 71.9 
years; histological subtype (epithelioid 54%; biphasic 11%; sar-
comatoid 16.3%; unknown 19%); stage on CT imaging (Tx-I-II 
49%; III-IV 51%). 51% of patients received chemotherapy and 6% 
underwent EPP (of which 67% received chemotherapy. Median 
age of first occupational asbestos exposure was 18 years, cumu-
lative duration of exposure, 24 years and latency from exposure 
to diagnosis, 50 years. Median OS was 10.0 months, 15.0 months 
(range(1-120) in patients receiving chemotherapy and/or EPP and 
5.8 months (range 0-125) in patients receiving neither. On univari-
ate analysis, younger age (<70 vs. >70yrs at diagnosis; 13.1 vs. 8.5 
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MO09.06 MALIGNANT PLEURAL MESOTHELIOMA IN 
THE UK NATIONAL LUNG CANCER AUDIT: AN ANALYSIS 
OF 8503 CASES
Michael D. Peake1, Paul Beckett1, Ian Woolhouse1, Roz Stanley2, 
Dean Fennell3, John Edwards4, Richard Hubbard5
1Royal College Of Physicians/United Kingdom, 2Health And Social Care 
Information Centre/United Kingdom, 3University Of Leicester/United 
Kingdom, 4Dept. Of Cardiothoracic Surgery, Northern General Hospital/
United Kingdom, 5University Of Nottingham/United Kingdom
Background: The National Lung Cancer Audit is run jointly by the 
Royal College of Physicians and The Information Centre for health 
and social care with the aim of recording outcomes in lung cancer 
(and mesothelioma) on a population scale, explaining the wide 
variations seen within the UK and between the UK and other coun-
tries and ultimately improving outcomes. This abstract presents 
results for England only, focusing on mesothelioma.
Methods: All patients with mesothelioma seen in in secondary 
care 2006-2011 were analysed. A hierarchy of diagnosis from sur-
gical histology to non-surgical histology to clinical diagnosis was 
used to exclude patients with potentially conflicting diagnoses. 
These records were further analysed to extract data on age/sex 
distribution, referral source, histological subtype, treatment regime 
and survival rates.
Results: There were 8,503 patients with mean age 72yrs (83% 
male), representing around 65% of expected incident cases (a 
substantial number diagnosed at autopsy and not included in the 
audit). 45% have right-sided disease, 28% were left-sided, and 1% 
were bilateral (data missing in 26%). The majority of patients (47%) 
were referred by their primary care physician, but at least 20% 
present to secondary care as emergencies. Overall, 89% of cases 
were histo-cytologically confirmed with that figure appearing to 
rise slowly over the audit period from 81% (2006) to 92% (2011). 
Survival data is shown below.  
n (%)
Median 
survival 
(days)
1 year survival 
(%)
All patients
8,503 
(100%)
278 41
Survival was slightly better in females (median 304 days vs 274 
days HR 0.91, p=0.002)
Subtype n (%)
Median 
survival 
(days)
1 year survival 
(%)
Unspecified 3,798 276 39.5
Epithelioid 2,300 388 53.2
Sarcomatoid 439 123 16.4
Biphasic 268 274 36.0
 
37% of patients received no anti-cancer treatment, but 28%, 26% 
and 30% of patients received “surgery”, chemotherapy or radio-
therapy at any time. Most surgical operations (60%) were pleuro-
desis. Median survival varied by first treatment modality: surgery 
378 days, chemotherapy 399 days, radiotherapy 308 days, no anti-
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ables and survival. NF-kB expression was examined in both a panel 
of MPM cell lines and isogenic parent/cisplatin resistant cell lines 
by Western blot analysis. The effect of NF-kB inhibition on cellular 
proliferation was measured by BrdU assay, in a panel of MPM and 
isogenic parent/cisplatin resistant cell lines, using the novel NF-kB 
inhibitor Dehydroxymethylepoxyquinomicin (DHMEQ). In addition, 
the effect of DHMEQ on nuclear translocation of NF-kB was exami-
ned by high content screening (HCS).
Results: Cytoplasmic or membranous immunostaining was seen in 
the majority of tumour samples (96.5%), but nuclear localisation of 
NF-kB was seen in only 11% cases. Kaplan-Meier survival analysis 
showed that nuclear NF-kB expression correlated with reduced 
survival (p=0.05). There was no significant correlation between 
the level of expression of NF-kB and standard clinicopathological 
parameters. NF-kB was expressed in all MPM cell lines tested to 
a varying extent (n=20), with no associations to histology. NF-kB 
levels were shown to be elevated in cisplatin resistant cell lines 
when compared to the isogenic parent from which they were deri-
ved. DHMEQ was shown to reduce nuclear translocation of NF-kB, 
inhibiting cell proliferation in all cell lines but to a lesser extent in 
NCI 2596 cells which have low NFkB expression.
Conclusion: Nuclear NFkB expression is a poor prognostic factor 
in MPM. DHMEQ, which inhibits nuclear translocation of NF-kB, 
inhibits cell proliferation in MPM cell lines. Furthermore, increased 
NF-kB expression in resistant cells suggests this pathway may play 
a role in development of cisplatin resistance in MPM. Inhibition of 
NF-kB may therefore prove to be of potential therapeutic benefit 
in MPM treatment and re-sensitisation of resistant MPM to cispla-
tin.
Keyword: MPM, cisplatin resistance, NF-kB
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MO09.10 VOLUMETRIC RESPONSE CLASSIFICATION CRI-
TERIA IN MESOTHELIOMA
Samuel G. Armato Iii1, Andrew H. Belcher1, Zacariah E. Labby2, 
Anna K. Nowak3, Hedy Kindler4
1Department Of Radiology, The University Of Chicago/United States Of 
America, 2Department Of Radiation Oncology, University Of Michigan/
United States Of America, 3School Of Medicine And Pharmacology, 
University Of Western Australia/Australia, 4Department Of Medicine, 
The University Of Chicago/United States Of America
Background: Tumor response criteria provide a framework for 
therapeutic decisions and clinical trials management in oncology. 
The standard response classification categories (partial response 
(PR), stable disease (SD), and progressive disease (PD)) were defi-
ned by the Response Evaluation Criteria in Solid Tumors (RECIST) 
guidelines based on relative changes in linear measurements of 
tumor diameter on computed tomography (CT) scans. An increase 
in linear dimension of at least 20% is categorized as PD, a decre-
ase in linear dimension of at least 30% is categorized as PR, and 
a change in linear dimension not great enough to exceed either 
of these thresholds is categorized as SD. With improvements in 
imaging technology and enhancements in computer algorithms, 
the extraction of tumor volume from CT scans has become more 
practical. The possibility that tumor volume may eventually be-
come the preferred tumor measurement metric rather than linear 
dimension necessitates the development of volumetric response 
months; p<0.001); female gender (12.0 vs. 9.8months; p<0.001); 
epithelioid subtype (11.8 vs. 7.2 months ;p>0.001); and NLR <5 
(12.9 vs. 7.5months; p<0.001) were associated with prolonged 
OS. Patients who underwent chemotherapy (13.6 vs. 7.2 months; 
p<0.001) and EPP (17.9 vs. 9.6 months; p<0.001) also had an impro-
ved survival. Smoking history (current/ex vs. never) and cumulative 
asbestos exposure did not affect survival. A trend to improved 
survival was noted with early stage disease (11.2 vs. 9.1 months; 
p=0.284) and younger age at first exposure (<18 vs. >18 years 
of age; 10.9 vs. 9.4 months; p=0.091). On multivariate analysis, 
age, gender, histological subtype, NLR, EPP and chemotherapy 
administration remained significant. 24% of patients demonstra-
ted survival over 20 months. Of those, 14% underwent EPP, and 
63% received chemotherapy. On multivariate analysis, epithelioid 
histology (p<0.001), chemotherapy use(p=0.002), undergoing 
EPP(p=0.01) and NLR<5(p=0.007) were independently associated 
with survival over 20 months.
Conclusion: In this large, population based cohort of MPM pati-
ents, we have validated age, gender, histological subtype and NLR 
as significant prognostic factors. Patients undergoing interventions 
such as EPP or chemotherapy demonstrated more favourable 
survival, however it is important to note that 86% of long survivors 
did not receive radical surgery, and 37% did not receive chemo-
therapy. As such, we hypothesise that apart from active treatment 
and inherent selection criteria, there are additional factors, such as 
favourable tumour biology, that seem to positively influence survi-
val of MPM patients.
Keywords: mesothelioma, Prognosis
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MO09.08 NF-KB IN CISPLATIN RESISTANCE AND AS A 
PROGNOSTIC MARKER IN MALIGNANT PLEURAL ME-
SOTHELIOMA
Kathy Gately1, Eliza Jennions2, Peter Godwin1, Martin Barr1, Susan 
Heavey1, Kazuo Umezawa3, J Edwards2, Steven Gray1, Kenneth 
O‘Byrne4
1Thoracic Oncology Research Group, St. James‘s Hospital/Trinity College 
Dublin/Ireland, 2Department Of Oncology, University Of Leicester/Uni-
ted Kingdom, 3Applied Chemistry, Keio University/Japan, 4Queensland 
University Of Technology, Translational Research Institute/Australia
Background: Malignant pleural mesothelioma (MPM) is an aggres-
sive inflammatory cancer associated with exposure to asbestos. 
Currently rates of MPM are rising and estimates indicate that the 
incidence of MPM will peak in western world within the next 10-15 
years. Untreated, MPM has a median survival time of 6 months, 
with poor survival rates for most patients after 24 months of di-
agnosis. Nuclear Factor kappa B (NF-kB) is a pro-inflammatory 
transcription factor which is activated in many cancer types, inclu-
ding MPM. The NF-kB pathway regulates important cellular pro-
cesses including survival and proliferation signals, which are often 
found to be dysregulated in cancer. Furthermore, we and others 
have shown that increased NF-kB activation is linked to develop-
ment of cisplatin resistance. We aim to outline the potential role of 
NF-kB as a mediator of cisplatin resistance in MPM and determine 
its value as a potential candidate for therapeutic intervention.
Methods: NF-kB expression was examined in a cohort of MPM pa-
tients (n=200) by IHC, and correlated with clinicopathological vari-
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among measurable interlobar septae was measured on CT and 
binned into 2 categories (≤5mm, >5mm). Kaplan-Meier estimates 
of overall survival were computed for each combination of volu-
me and septum thickness categories. Combinations with similar 
estimated survival functions were combined to create criteria for 
T classification levels. Cox regression was used to evaluate the 
relative hazard for death and disease recurrence associated with 
classification levels.
Results: 406 patients met inclusion criteria (278 EPP, 128 PDC; 317 
male; 297 epithelial histology on biopsy; median age 64). Align-
ment of survival functions yielded combinations of volume and 
septum thickness categories defining T1 through T4. These classi-
fications were associated with progressively increasing hazard for 
death and recurrence (Table).  
Overall Survival Time to Recurrence
T 
sta-
tus
N Median (mths) HR
95% 
C.I.
Median 
(mths) HR
95% 
C.I.
T1 85 37 1.0 - 16 1.0 --
T2 118 21 1.5
1.0 - 
2.1
11 1.6
1.1-
2.1
T3 105 14 2.5
1.7 - 
3.5
8 2.3
1.7 
-3.2
T4 98 10 4.2
3.0 - 
6.1
5 4.1
3.0 - 
5.8
 
Conclusion: Tumor volume and septum thickness are readily 
measured on standard CT imaging and provide robust prognostic 
information not accounted for by current clinical T classification 
criteria. As quantitative measurements, they should be minimally 
affected by inter-observer variability. The feasibility and value of 
these simple and cost effective adaptations to clinical staging 
should be evaluated as the TNM staging system is revised.
Keywords: T status, mesothelioma, tumor volume, EPP
criteria. Although extrapolation of the RECIST response criteria to 
volume is straightforward for spherical nodules, tumors as non-
spherical as mesothelioma likely will require unique volumetric 
response criteria.
Methods: A semi-automated computerized method was used to 
determine the mesothelioma tumor volume from CT scans (base-
line and all available follow-up scans) retrospectively collected 
from 70 patients undergoing standard-of-care chemotherapy. Re-
lative changes in tumor volume from baseline were categorized as 
PR, SD, or PD based on different combinations of percent change 
thresholds. Overall patient survival was correlated with best res-
ponse using Harrell’s C statistic. The response criteria for PD and 
PR were each varied in 1% increments to obtain optimized classifi-
cation criteria.
Results: The process that systematically evaluated various combi-
nations of response criteria identified an increase in tumor volume 
of at least 58% and a decrease in tumor volume of at least 17% for 
PD and PR, respectively, as the criteria that were best correlated 
with patient survival. These criteria yielded a C statistic of 0.76, 
where a C statistic value of 1.0 would indicate perfect separation 
of response groups with respect to subsequent survival times. This 
result may be compared with the C statistic value of 0.61 obtained 
when volumetric response criteria extrapolated directly from the 
RECIST criteria (+73% for PD and -66% for PR) were applied to this 
cohort.
Conclusion: The evolution toward volumetric assessment of tumor 
burden and response to therapy necessitates the derivation and 
validation of volume-specific tumor response criteria to distinguish 
among PR, SD, and PD. The present study motivates such response 
criteria for mesothelioma and indicates that mesothelioma volume-
tric response criteria differ substantively from a simplistic extensi-
on of the RECIST criteria to three dimensions. Future prospective 
studies will be required to validate these criteria.
Keyword: mesothelioma, tumor volume, response assessment, 
imaging
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MO09.11 QUANTITATIVE CLINICAL T CLASSIFICATION 
CRITERIA FOR MALIGNANT PLEURAL MESOTHELIOMA.
Ritu R. Gill1, William Richards2, Beow Y Yeap3, Raphael Bueno2, 
David J. Sugarbaker2
1Radiology, Brigham And Women‘s Hospital/United States Of America, 
2Surgery, Brigham And Women‘s Hospital/United States Of America, 
3Massachusetts General Hospital/United States Of America
Background: Clinical T classification of Malignant Pleural Mesothe-
lioma involves qualitative estimation of tumor involvement of the 
thorax and does not accurately predict prognosis (JTO 7(11):1631-9, 
2012). We explored whether novel quantitative assessment of stan-
dard CT images might improve the prognostic accuracy of clinical 
T classification.
Methods: All patients who underwent primary extrapleural pneu-
monectomy (EPP) or pleurectomy (PDC) between 2001-2012 with 
available preoperative CT for retrospective review were included. 
Tumor volume was derived using Vitrea software (Vital) and binned 
into 3 categories (≤75cc, >75≤500cc, >500cc). Maximal thickness 
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Conclusion: Bearing in mind the limitations of this retrospective 
study with short-term follow-up, these results suggest that the pos-
terior intercostal lymph nodes may have independent prognostic 
significance. This data has served as a trigger for us to now routi-
nely include the posterior intercostal lymph nodes in our thoracic 
lymphadenectomies in patients undergoing surgery for malignant 
pleural mesothelioma. Further investigation of this nodal station is 
indicated and it is likely that these nodes should be included in any 
future staging system for malignant pleural mesothelioma.
Keywords: mesothelioma, lymph nodes, staging
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MO09.13 COMPARISON OF THREE RADIOGRAPHIC TU-
MOR VOLUME ESTIMATION TECHNIQUES FOR MALIG-
NANT PLEURAL MESOTHELIOMA: THEIR CORRELATION 
WITH EACH OTHER, ACTUAL MEASURED INTRAOPERA-
TIVE TUMOR VOLUMES, AND SURVIVAL
Joseph Friedberg1, Melissa Culligan1, Sharyn Katz2, Drew A. Tori-
gian2, Jay Udupa2, Maya Galperin-Aizenberg2, Mary Putt3, Jiaqi Li3, 
Michael Shin4, Kenneth Mckay4, Eli Glatstein4, Stephen M. Hahn4, 
Keith A. Cengel4, Charles B. Simone4
1Department Of Surgery, Division Of Thoracic Surgery, University Of 
Pennsylvania/United States Of America, 2Department Of Radiology, 
University Of Pennsylvania/United States Of America, 3Department Of 
Biostatistics & Epidemiology, University Of Pennsylvania/United States 
Of America, 4Department Of Radiation Oncology, University Of Penn-
sylvania/United States Of America
Background: Studies have assessed correlation between radiogra-
phically estimated tumor volume (TV) and outcomes for malignant 
pleural mesothelioma, no standard radiographic model exists 
for estimating TV. Although radical pleurectomy yields a surgical 
specimen essentially all cancer, thereby allowing accurate deter-
mination of TV, empirically-derived intraoperative TVs have never 
been reported. We compare multiple radiographic estimates of TV 
with TVs determined at resection to determine which radiographic 
approach most accurately predicts intraoperative TV, and we cor-
relate TV with survival.
Methods: Actual TVs were measured for 41 consecutive radical 
pleurectomy specimens by volume displacement. Radiographic TV 
estimates were performed by radiologists/radiation oncologists 
blinded to intraoperative TVs. Radiographic estimates were obtai-
ned with: Live Wire algorithm (automated tumor delineation after 
manual algorithm training), radiology TeraRecon (tumor automati-
cally circumscribed with subsequent manual tracing corrections), 
and radiation oncology Eclipse (non-automated tumor delineation).
Results: Median age was 63yrs, with 80% male and 83% having 
epithelial histology. Stage distribution was: 3-Stage I (7%), 4-Stage 
II (10%), 29-Stage III (71%), and 5-Stage IV (12%). Median (interquar-
tile range) intraoperative TV was 600(400,800)cm3. Median TV of 
800(575,1100)cm3 among nonepithelial compared to 500(350,838)
cm3 for epithelial was not significantly difference (p=0.099). TVs 
were largest for stage III (p=0.01). Median TVs for Live Wire, Terra-
Recon, and Eclipse were 260(147-452), 293(161-465), and 447(247-
559)cm3, respectively. Pearson correlation coefficients were 0.60, 
0.75, and 0.78, with all models underestimating intraoperative TVs 
(Figure 1A). Among 34 epithelial patients (mean/median follow-up 
9.8/8.0mo), median survival was not reached (only 9 recurrences). 
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MO09.12 POSTERIOR INTERCOSTAL LYMPH NODES - 
FIRST REPORT OF A NEW INDEPENDENT PROGNOSTIC 
FACTOR FOR MALIGNANT PLEURAL MESOTHELIOMA
Joseph Friedberg, Melissa Culligan, Mary Putt, Stephen M. Hahn, 
Evan Alley, Charles Simone, Daniel Sterman, Keith A. Cengel
University Of Pennsylvania/United States Of America
Background: Little is known about the significance of metasta-
ses to the posterior intercostal lymph nodes, located within the 
intercostal spaces at the level of the rib heads, in patients with 
malignant pleural mesothelioma. These nodes are not part of any 
staging system. This report is an initial attempt to determine the 
significance of these lymph nodes.
Methods: We sampled posterior intercostal lymph nodes from 
48 patients undergoing radical pleurectomy for malignant pleural 
mesothelioma. Statistical analyses were then performed correla-
ting metastases to these lymph nodes with progression free and 
overall survival.
Results: 26/48 (54%) patients had positive posterior intercostal 
lymph nodes. Standard staging revealed: 6/48 (13%) N0, 3/48 (6%) 
N1, 39/48 (81%) N2, 9/49 (19%) stage III and 39/48 (81%) stage IV. 
Presence of positive posterior intercostal lymph nodes was not 
associated with stage (Fisher exact P=0.48), but was associated 
with N status. N1 and N2 were associated with higher rates of po-
sitive posterior intercostal lymph nodes (Fisher exact P=0.011). At a 
median follow-up of 9.6 months, progression-free survival was 0.83 
years, 95% CI: (0.74, 1.30) years; median overall survival was 1.89 
years, 95% CI: (1.29, ND) years. Patients with negative posterior 
intercostal lymph nodes had a median progression-free survival 
of 1.25 years, 95% CI: (0.95, 1.95) years, while that for patients 
with positive posterior intercostal lymph nodes was 0.73 years, 
95% CI: (0.61, 1.40) years (p=.017 by log-rank test). Patients with 
negative posterior intercostal lymph nodes had a median overall 
survival of 3.43 years, 95% CI: (1.89, ND) years, while that for pati-
ents with positive ICLNs was 1.01 years, 95% CI: (0.61, 1.40) years 
(p=.007 by log-rank). In a Cox regression model that adjusted for 
stage, positive posterior intercostal lymph nodes were associa-
ted with an increased risk of failure (HR=2.71, 95% CI=1.15.6.39, 
P=.048) and death, (HR=3.3, 95% CI: 1.3, 8.1, P=0.0098. 
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Epithelial patients with large (>500cm3) intraoperative TVs had 
numerically worse progression-free (p=0.148) and overall (p=0.161) 
survival than patients with TVs ≤500cm3(Figure 1B), but limited 
events precluded statistical significance. Larger radiologic TVs 
similarly correlated with shorter survivals. 
Conclusion: This is the first study to compare radiographic estima-
tes of TV to actual TV determined by volume displacement of ra-
dical pleurectomy specimens, arguably the TV measurement gold 
standard. This study is also the first to compare estimated TVs 
using multiple established and previously reported radiographic 
techniques. Our results demonstrate a clear trend toward greater 
overall and progression-free survival for actual TVs <500cm3. All 
radiographic techniques underestimated actual TV, with estimates 
progressively closer to the actual volume with each technique as 
they became less automated and more manual. Further analysis is 
ongoing to determine if any radiographic method can serve as an 
accurate surrogate for actual TV and if models correlate as closely 
with outcomes as actual TVs.
Keywords: radiographic tumor volume estimate, mesothelioma, 
tumor volume, radical pleurectomy
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MO10.02 UPDATE GENOTYPING NON-SMALL CELL 
LUNG CANCER (NSCLC) IN LATIN AMERICA: LATIN-
AMERICAN CONSORTIUM FOR THE INVESTIGATION OF 
LUNG CANCER (CLICAP)
Guillermo Bramuglia1, Claudio Martin2, Andres F. Cardona3, Oscar 
Arrieta4, Alma D. Campos Parra4, Hernán Carranza5, Carlos Var-
gas3, Jorge M. Otero3, Yanina Powazniak1, Mariana Trigo1, Susana 
Sena1, Luis Más6, George A. Oblitas7, Zulay Pastrán8, Laura Bernal3, 
Roberto Sánchez-Reyes4, Carlos Zúñiga-Orlich9, Rafael Rosell10
1Fundación Investigar/Argentina, 2Oncology, Alexander Fleming/Ar-
gentina, 3Clinical And Traslational Oncology Group, Fundación Santa 
Fe De Bogotá/Colombia, 4Thoracic Oncology Clinic And Laboratory Of 
Experimental Oncology, Instituto Nacional De Cancerología (INCAN)/
Mexico, 5Clinical And Translational Oncology Group Institute Of On-
cology, Fundación Santa Fé/Colombia, 6Clinical Oncology, Instituto De 
Enfermedades Neoplásicas/Peru, 7Medical Oncology/ Thoracic Onco-
logy, Unidad Oncologica De Caracas/Venezuela, 8Clinical Oncology, 
Policlínica Metropolitana/Venezuela, 9Medical Oncology, Hospital San 
Juan De Dios-ccss/Costa Rica, 10Medical Oncology, Catalan Institute Of 
Oncology/Spain
Background: Previously we reported that the frequency of muta-
tions in EGFR and KRAS in non-small cell lung cancer (NSCLC) is 
Latinoamerica,finding the frequency of EGFR mutations in Latin-
America between Asian (40%) and European (15%) populations. 
We report the update frequency of mutations in Latin America.
Methods: 3606 biopsies of NSCLC patients from Latin-America 
(Argentina, Colombia, México and Peru) were used by extracted 
genomic DNA which was used to perform direct sequencing of 
EGFR gene (exons 18 and 21) and KRAS gene in 2385 samples.
Results: Of all patients the median age was 62.2 ±12.3, 52.6% 
were women, and 51% had smoking history. Frequency of EGFR 
mutations in NSCLC was 24.4% [CI 95% 22.7-24.1] (Argentina 
14.4%, Colombia 24.9%, Mexico 34.4%, Peru 67.0%). The frequency 
of KRAS mutations was 7.1%. EGFR mutations were independent-
ly associated with gender (29.8% vs 16.3%; p< 0.001), older age 
(<60 vs >60; p= 0.001), non-smokers 25.9% vs 15.7%; p= 0.001), 
ethnicity (Hispanic 37.7%, Caucasic 13%, Afro-American 0%, non-
determinate 22.9%; p< 0.001), histology (adenocarcinoma 23.8%, 
squamous 4.4%, large cells 33.3% and non differenced 22.2%) 
and absence of KRAS mutation. Overall response rate to tyrosine 
kinase inhibitors (EGFR-TKIs) in EGFR mutated patients (n=56) was 
62.5% [95% CI 50-75] with a median overall survival of 16.5 months 
[95% CI 12.4-20.6].
Conclusion: Our findings confirm the high frequency of EGFR 
Mutation in Latino-america and low frequency of K-RAS mutation, 
particularly in patients of Hispanic ethnicity. Differences in risk 
factors associated with lung cancer in our population and ethnic 
variability could explain these findings.
Keyword: EGFR, KRAS, mutation, genotipying, lung cancer
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MO10.01 INTEGRATIVE AND COMPARATIVE GENOMIC 
ANALYSIS OF EAST-ASIAN LUNG SQUAMOUS CELL 
CARCINOMAS
Youngwook Kim1, Peter S Hammerman2, Jaegil Kim2, Ji-Ae Yoon1, 
Yoomi Lee1, Jong-Mu Sun3, Matthew Wilkerson4, Chandra Sekhar 
Pedamallu2, Kristian Cibulskis2, Yeong Kyung Yoo1, Michael Law-
rence2, Petar Stojanov2, Scott L. Carter2, Aaron Mckenna2, Chip 
Stewart2, Andrey Y. Sivachenko2, In-Jae Oh5, Hong Kwan Kim6, 
Yong Soo Choi6, Kwhanmien Kim6, Young Mog Shim6, Kyu-Sik 
Kim5, Sang-Yun Song5, Kook-Ju Na5, Yoon-La Choi7, Neil Hayes4, 
Jhingook Kim6, Sukki Cho6, Young-Chul Kim5, Jin Seok Ahn3, My-
ung-Ju Ahn3, Gad Getz2, Matthew Meyerson2, Keunchil Park1
1Samsung Biomedical Research Institute/Korea, 2Broad Institute Of 
Harvard And Mit, 7 Cambridge Center/United States Of America, 3Di-
vision Of Hematology-Oncology, Samsung Medical Center, Sungkyunk-
wan University School Of Medicine/Korea, 4Lineberger Comprehensive 
Cancer Center/United States Of America, 5Lung And Esophageal Cancer 
Clinic, Chonnam National University Hwasun Hospital/Korea, 6Depart-
ment Of Thoracic And Cardiovascular Surgery, Seoul National Universi-
ty Bundang Hospital/Korea, 7Department Of Pathology, Samsung Medi-
cal Center, Sungkyunkwan University School Of Medicine/Korea
Background: Lung squamous cell carcinoma (SqCC) is the second 
most prevalent type of lung cancer. Currently, no targeted-thera-
peutics are approved for treatment of this cancer, largely due to a 
lack of systematic understanding of the molecular pathogenesis of 
the disease. To identify therapeutic targets and perform compara-
tive analyses of lung SqCC, we probed somatic genome alterations 
of lung SqCC cases from Korean patients.
Methods: We performed whole-exome sequencing of DNA from 
104 lung SqCC samples from Korean patients and matched normal 
DNA. In addition, copy number analysis and transcriptome analysis 
were conducted for a subset of these samples. Clinical association 
with cancer-specific somatic alterations was investigated.
Results: This cancer cohort is characterized by a very high mu-
tational burden with an average of 261 somatic exonic mutations 
per tumor and a mutational spectrum showing a signature of 
cigarette-smoke exposure. Seven genes demonstrated statistical 
enrichment for mutation (TP53, RB1, PTEN, NFE2L2, KEAP1, MLL2 
and PIK3CA). Comparative analysis between Korean and North 
American lung SqCC demonstrated similar spectrum of alterations 
in these two populations, in contrast to the differences seen in 
lung adenocarcinoma. We also uncovered recurrent occurrence of 
therapeutically actionable FGFR3-TACC3 fusion in lung SqCC.
Conclusion: These findings provide new steps towards the identifi-
cation of genomic target candidates for precision medicine in lung 
SqCC, a disease with a significant unmet medical need.
Keyword: lung squamous cell carcinoma, genome, sequencing, 
mutation
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HER2 and PI3K mutation prevalences were more than doubled in 
African population compared to European population (Fisher‘s 
Exact Test, respectively p = 0.10; p = 0.17).
Conclusion: Our data show different EGFR, KRAS, and HER2 mu-
tation rates according to the geographical birth location of pati-
ents. Interestingly, we noted a significant decreased Kras and hig-
her HER2 and PI3K mutations prevalence in African birth location 
mutation rates compared to the other populations studied. The 
incidence of these mutations had not been extensively studied in 
the population of African birth location. That could suggest, espe-
cially in this population, the importance of systematic HER2 and 
PI3K screening to investigate specific targeted therapy.
Keywords: mutation prevalence, African population, lung ade-
nocarcinoma
MOLECULAR PATHOLOGY II  
MONDAY, OCTOBER 28, 2013 - 16:15-17:45
MO10.04 HIGH THROUGHPUT PARALLEL AMPLICON 
SEQUENCING OF COMMON DRIVER MUTATIONS FROM 
FFPE LUNG CANCER SAMPLES IN MOLECULAR PATHO-
LOGICAL ROUTINE DIAGNOSTICS FOR A REGIONAL 
HEALTH CARE PROVIDER NETWORK
Katharina König1, Martin Peifer2, Marc Bos3, Lucia Nogová3, Tho-
mas Zander3, Sabine Merkelbach-Bruse1, Kartin Stamm4, Matthias 
Scheffler5, Masyar Gardizi5, Thomas Henkel4, Monika Serke6, Ste-
fan Krüger7, Winfried J Randerath8, Britta Kaminski8, Tim H Brüm-
mendorf9, Jens Panse9, Wolfgang Schulte10, Ulrich Gerigk11, Jürgen 
Wolf12, Reinhard Büttner1, Lukas C. Heukamp1
1Institute Of Pathology, Universtity Hospital Cologne/Germany, 2Net-
work Genomic Medicine Lung Cancer, University Hospital Cologne, 
Center For Integrated Oncology Köln Bonn/Germany, 3Department I 
Of Internal Medicine, University Hospital Cologne, Center For Integra-
ted Oncology Köln Bonn, 50924 Cologne, Germany/Germany, 4Targos 
GmbH/Germany, 5Lung Cancer Group Cologne, Department I Of Inter-
nal Medicine And Center For Integrated Oncology Köln-Bonn, University 
Hospital Cologne/Germany, 6Thoracic Oncology, Hemer Lung Clinic/
Germany, 7Klinik Für Pneumologie, Allergologie, Schlaf- Und Beat-
mungsmedizin, Florence Nightingale-krankenhaus/Germany, 8Klinik 
Für Pneumologie Und Allerologie, Bethanienkrankenhaus Solingen/
Germany, 9Medizinische Klinik Iv, Uniklinikum Aachen/Germany, 
10Malteser Lungenzentrum, Malteser Krankenhaus, Bonn/Germany, 
11Klinik Für Thoraxchirurgie, Malteser Krankenhaus/Germany, 12Depar-
tement For Internal Medicine I, University Hospital Cologne, Germany/
Germany
Background: Treatment paradigms for non–small-cell lung cancer 
(NSCLC) have shifted from one based only on histology to one that 
incorporates molecular subtypes involving particular genetic alte-
rations such as activating mutations in EGFR or translocations of 
ALK. The list of therapeutically targetable lesions is rapidly increa-
sing including mutations in genes such as EGFR, HER2, KRAS, ALK, 
BRAF, PIK3CA, AKT1, ROS1, NRAS, FGFR1 and MAP2K1. Analysis 
of these potential targets is becoming a challenge in terms of work 
load, tissue availability as well as cost. Within the Network Geno-
mic Medicine Lung Cancer (NGM), a regional molecular screening 
network of the Center for Integrated Oncology Köln Bonn, we 
aimed to improve on the sequential analysis of a set of 9 target 
amplicons by Sanger sequencing using bench top ultra-deep par-
allel sequencing platforms. We aimed to reduce 1) the time requi-
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MO10.03 DECREASED KRAS AND INCREASED HER2 OR 
PI3K MUTATIONS PREVALENCE IN THE FRENCH EMI-
GRANT POPULATION FROM AFRICAN CONTINENT IN 
LUNG ADENOCARCINOMA METASTATIC CANCER
Mohamed Bouchahda1, Raphaël Saffroy2, Nelly Bosselut2, Jocelyne 
Hamelin2, Emmanuel Lecorche2, Jean-Francois Morere1, Philippe 
Slaouti3, Catherine Guettier2, Mathieu Robain4, Antoinette Lemoi-
ne2
1Oncology, Hôpital Paul Brousse/France, 2Oncogenetics, Hôpital Paul 
Brousse/France, 3Centre National Mgen Alfred Leune/France, 4Clinical 
Research, Curie/France
Background: Approximately 1.2 million people are diagnosed with 
lung cancer every year. The identification of genomic alteration 
can impact therapeutics. EGFR mutation status predicts how pati-
ents can respond to EGFR tyrosine kinase drugs (EGFR-TKI). EGFR 
positive patients have an improved response rate to erlotinib or 
gefitinib; KRAS mutated tumors are not sensitive to EGFR-TKI. Re-
cently, it has been published that patients with mutations inHER2 
have a high response rate to trastuzumab. The prevalence of EGFR 
and KRAS mutations are well known to be associated with sex, 
histological type of tumor, smoking status and also ethnic origin. 
HER2, BRAF and PI3K are relevant gene candidates to emerging 
therapies. Mutation prevalence of the latter genes has not yet 
been investigated in large populations.
Methods: We have analyzed 1375 consecutive patients with meta-
static lung adenocarcinomas having the screening of EGFR, KRAS, 
BRAF, PI3K and HER2 gene mutational status in the Paul Brousse 
platform between November 2011 and April 2013. The DNA mu-
tation screening was performed using the HRM technology and 
their identification were analyzed by allelic discrimination and/or 
sequencing. Our database included all mutations results as well as 
anonymous diagnosis and socio-demographic data. The birth loca-
tion has been self-reported.
Results: Of the 1375 tumors, the frequencies of EGFR, KRAS, 
BRAF or HER2 mutations were those usually reported in Caucasian 
population. Mean age was 65.2 years (SD = 11.2), 821 were male 
and 519 female. Among our population, 140 patients reported of 
African birth location, 1220 of European birth location and 15 of 
Asian birth location.  
TABLE 1. Mutation prévalance and birth location 
European 
birth 
location 
African 
birth 
location 
Asia 
birth 
location 
Total 
EGFR (n/%) 129 (10.6) 13 (9.3) 5 (33.3) 147/1375 (10.7) 
KRAS (n/%) 318 (26.3) 21 (15.0) * 340/1366 (24.9) 
BRAF (n/%) 23 (1,9) 1 (0,75) * 24/1345 (1.8) 
HER2 (n/%) 13 (1.1) 4 (2.9) * 19/1327 (1.7) 
PIK3CA (n/%) 20 (2.0) 5 (4,2) * 25/1159 (2.2) 
*Low effective 
 
The percentage of EGFR mutations was higher in Asiatic patients, 
as previously reported. Interestingly the KRAS mutation rate was 
significantly lower in the African patients (15.0%, CI: 10.0 – 21.9) 
than in the European patients (26.3%; I: 23.9 – 28.8; p = 0.004). 
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served, with 138 tumours (60%) with at least one mutation – 97 
tumours (42.2%) with a single mutation in a single gene, 36 tu-
mours (15.7%) with two mutations (either in the same gene or two 
different genes), four tumours (2.2%) with three mutations and 
one with four mutations. The most frequent mutations were EGFR 
(38.5% EA;10.1% WE), KRAS (10.9% EA;31.6% WE), P53 (8.8% 
EA;15.1% WE), MET (14.3% EA;2.2% WE), STK11 (9.9% EA;2.8% 
WE) and PIK3CA (2.2% EA;4.3% WE). Co-occurring mutations were 
found in up to 30% of tumors, although the likelihood differed for 
each gene: KRAS (16/54, 31%), EGFR (18/49, 37%), MET (6/16, 38%), 
P53 (13/29, 45%), STK11 (8/13, 62%) and PIK3CA (5/8; 62%). Among 
the eight tumors harbouring PIK3CA mutations, five cases had a 
co-mutation (four cases with EGFR, one case with KRAS). In EGFR 
mutant cancers, co-occuring mutations include p53 (10%), PIK3CA 
(8%), STK11 (6%) and MET (4%). Significant relationships were also 
detected between EGFR mutation and CNAs on chromosomes 
1p, 7p, and 13q. There were also significant relationships between 
KRAS mutation and CNAs on chromosomes 1q and 3q. For stage 
I, we found a worse prognosis for patients with at least one mu-
tation. PIK3CA was significantly correlated with poor prognosis. 
Consistent with recent pooled analysis, KRAS alone is not prog-
nostic but when CNAs and mutation status are combined, patients 
having both KRAS mutation and the highest related CNA (3q22.3 
copy loss) showed a significant poorer prognosis.
Conclusion: This study highlights the wide diversity of mutation 
profiles within molecularly-defined NSCLCs, revealing co-muta-
tions and associations with numerical chromosomal abnormalities 
that are clinically relevant. This diversity should be taken into 
account when designing stratified treatment approaches and un-
derscores the need for customized assays that broadly screen for 
“actionable” mutations and copy-number alterations.
Keywords: Lung cancer genomics (Non-squamous), Stratified Me-
dicine, mutation profiling
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MO10.07 ALK IMMUNOHISTOCHEMISTRY AND FLUORE-
SCENCE IN-SITU HYBRIDIZATION IN LUNG ADENOCAR-
CINOMAS FROM THE ETOP LUNGSCAPE TUMOUR CO-
HORT
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De Jong14, Ernst-Jan M. Speel15, Eloisa Jantus-Lewintre16, Ying J. 
Zhang17, Rolf Stahel18, Solange Peters19
1Department Of Pathology, Aberdeen University Medical School/United 
Kingdom, 2Pathology, VU University Medical Center/Netherlands, 
3The Christie NHS Foundation Trust/United Kingdom, 4Frontier 
Science Foundation-hellas & University Of Athens/Greece, 5Institute 
Of Pathology,  universitätsspital Basel/Switzerland, 6Patologisk 
Institut, Århus Universitetshospital/Denmark, 7Institute Of Pathology, 
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rement for comprehensive molecular diagnostics, 2) the minimal 
amount of formalin fixed paraffin embedded (FFPE) derived input 
DNA, 3) while at the same time increasing the number of target 
regions analysed.
Methods: We established a multiplex PCR to amplify up to 640 
lung cancer relevant target regions from at least 20ng of FFPE de-
rived tumor DNA. The amplicon libraries were ligated to adapters 
encompassing medical identifier sequences that allowed multiple-
xing of up to 48 patients. The resulting libraries were sequenced 
on a benchtop Illumina platform (MiSeq). Mutations identified by 
parallel sequencing were confirmed by Sanger sequencing.
Results: 330 patients were analyzed both by traditional single 
PCR based Sanger sequencing of 9 amplicons and the newly es-
tablished parallel sequencing protocol. We found that the NGS 
approach worked reliably, was less prone to sequencing analysis 
errors and that the time needed to complete the mutation scree-
ning was significantly reduced to 7 working days from previously 
21 days. A total of at least 300ng of DNA was needed to complete 
the analysis of 9 amplicons by Sanger sequencing compared to 
20 to 100ng of DNA needed for up to 640 amplicons analyzed by 
parallel sequencing.
Conclusion: Newly multiplex PCR based parallel sequencing al-
lows rapid comprehensive mutation testing in routine molecular 
pathological diagnostics even on small FFPE embedded trans-
bronchial biopsies.
Keywords: molecular pathology, Lung cancer, next generation 
sequencing, screening network
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MO10.06 INTERTUMOUR HETEROGENEITY REVEALED 
BY INTEGRATIVE ANALYSIS OF TARGETED SOMATIC 
MUTATION PROFILING AND WHOLE GENOME COPY-
NUMBER ALTERATIONS IN NON-SQUAMOUS NON-
SMALL CELL LUNG CARCINOMAS
Daniel Shao-Weng Tan1, Sophie Camilleri-Broet2, Eng-Huat Tan1, 
Marco Alifano2, Wan-Teck Lim1, Antonio Bobbio2, Shenli Zhang3, 
Jean-François Régnard2, Patrick B. Tan3, Philippe Broet4
1Department Of Medical Oncology, National Cancer Centre Singapore/
Singapore, 2Faculté De Médecine Paris Descartes, Université Paris De-
scartes/France, 3Duke-nus Graduate Medical School/Singapore, 4Faculté 
De Médecine Paris-sud, Université Paris-sud/France
Background: Molecular subtypes of NSCLC are delineated 
through single driver alterations, although this likely underestima-
tes the extent of inter-tumor heterogeneity. The goal of this study 
was to evaluate the potential impact of co-occuring mutations and 
copy number alterations in a series of tumours from both East-
Asian (EA) and Western-Europe (WE) origins.
Methods: 230 non-squamous non-small cell lung carcinomas 
(NSCLC) were analysed using the MassARRAY LungCarta™ panel 
(Sequenom) which examines 214 mutations in 26 oncogenes and 
tumour suppressor genes. Results were integrated with copy num-
ber alterations evaluated using Affymetrix Genome-Wide Human 
SNP 6.0 arrays and clinical variables.
Results: Out of the 230 tumours tested, 185 mutations were ob-
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• IHC 3+ staining (prevalence 1.8%) showed 87% probability of 
ALK FISH positivity
• ALK IHC positivity was higher in never smokers and related to 
better clinical outcome
• ALK testing can be reliably implemented across multiple labora-
tories
{1} Ruschoff et al. Virchows Arch. 2010;457(299-307).
Keywords: ALK, Immunohistochemistry, FISH, Adenocarcinoma
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MO10.08 GENOMIC ALTERATIONS IN PULMONARY 
CARCINOID TUMORS
Michael Asiedu1, Charles Thomas2, Sandra C. Tomaszek2, Jie 
Dong2, Zhifu Sun2, Farhad Kosari2, Jin Jen2, Julian Molina2, George 
Vasmatzis2, Marie Christine Aubry2, Ping Yang3, Dennis A. Wigle1
1Thoracic Surgery, Mayo Clinic/United States Of America, 2Mayo Clinic/
United States Of America, 3Health Sciences Research, Mayo Clinic/Uni-
ted States Of America
Background: Pulmonary carcinoid tumors account for up to 5% of 
all lung malignancies in adults and comprise 30% of all carcinoid 
malignancies. They are defined histologically as typical carcinoid 
(TC) and atypical carcinoid (AC) tumors, and are characterized by 
neuroendocrine differentiation and the potential to metastasize. 
Relatively little is known about bronchopulmonary carcinoid tumo-
rigenesis, and understanding of these tumors has yet to benefit 
from the insight of genomic studies. This unfortunately has transla-
ted into relatively limited treatment options for these patients and 
no recent advances in therapy. We aimed to characterize genomic 
alterations in pulmonary carcinoid tumors under the hypothesis 
that a better molecular understanding may lead to improved thera-
peutic approaches and patient outcomes.
Methods: We characterized genomic alterations in pulmonary 
carcinoid tumors using whole genome, exome, and RNA sequen-
cing, in addition to mRNA expression and SNP genotyping from 
specimens of normal lung, typical and atypical carcinoid, and 
SCLC. Fresh-frozen specimens from 54 patients with primary lung 
neuroendocrine tumors were obtained from our lung specimen 
registry and clinical data collected. This included a total of 31 typi-
cal and 11 atypical carcinoid tumors with associated normal tissue, 
and 12 SCLC. Whole transcriptome mRNA expression profiling and 
SNP genotyping for evaluating copy number variation was perfor-
med using Illumina array platforms. For a subset of tumors, whole 
genome sequencing was performed through Complete Genomics, 
and exome and RNA sequencing performed through BGI and the 
Mayo Clinic Genomics Facility. These data were correlated with 
the histologic subtype, stage and survival data available from this 
cohort of patients.
Results: Gene expression clearly identified distinct profiles dif-
ferentiating carcinoid tumors from SCLC, though not between 
typical and atypical carcinoids. Copy number variations (CNV) 
were widely prevalent in SCLC, less frequent in AC, while TC had 
the lowest frequency of CNV. Validated sequencing data from 
exome and WGS platforms revealed a number of novel mutations 
for pulmonary carcinoid tumors, including ADNP, BRIP1, cyclin 
Medical Center+/Netherlands, 16Hospital General Universitario De 
Valencia/Spain, 17Department Of Radiation Oncology, Shandong 
Cancer Hospital & Institute/China, 18Clinic And Policlinic Of Oncology, 
University Hospital Zurich/Switzerland, 19University Hospital 
Lausanne/Switzerland
Background: The European Thoracic Oncology Platform LungS-
cape database contains 2614 cases of primary resected lung car-
cinoma from 16 centres with patient demographics, pathological 
tumour data and detailed clinical follow-up. A total of 1281 cases 
of adenocarcinoma with >2 years clinical follow-up were selected 
for analysis of ALK status by immunohistochemistry (IHC) and 
fluorescence in situ hybridization (FISH). Test positive cases were 
matched, in order of importance at ratio 1:2, by stage, gender, 
smoking status, study centre, year of surgery and age with test 
negative cases -both for IHC and for FISH testing.
Methods: Testing was performed in all centres using the same 
protocol (IHC: Novocastra 5A4 clone antibody at 1:10 dilution, 
Novolink detection system. FISH: Abbott Vysis ALK break-apart 
probe). Each centre passed an external QA test using unknown 
cases in a tissue microarray before conducting the LungScape 
tumour testing. IHC was scored according to three intensity scores 
(1+, 2+, 3+) using ‘objective’ methodology previously described [1]. 
Maximum staining intensity was recorded. Any IHC staining was 
defined as IHC positive result. FISH preparations were assessed ac-
cording to the Vysis protocol on all 82 IHCpositive cases plus their 
164 IHCnegative matches.
Results:  
IHC cases, 
n=1281 
FISH positive 
(264 tested) 
IHC  
negative 
1199 (93.6%) 
0 (0.0% of 
164 controls) 
FISH specificity: 
100% 
IHC 1+ 43 (3.35%) 
2 (4.6% of 
IHC 1+) 
IHC 2+ 16 (1.25%) 
6 (37.5% of 
IHC 2+) 
IHC 3+ 23 (1.8%) 
20 (87% of 
IHC 3+) 
IHC any 
positive 
82 (6.4%) 
28 (34.1% of 
IHC+) 
FISH sensitivity: 
34.1% 
 
FISH sensitivity was 87% for IHC 3+. IHCpositive/FISHnegative ca-
ses (n=54) were mostly IHC 1+ (75.9%), sometimes IHC 2+ (18.5%) 
and rarely IHC 3+ (5.5%). The frequency of never smokers was 
higher in the ALK IHCpositive group (29.3%) versus IHCnegative 
group (18.3%) {p=0.011}. Age, gender and tumour stage did not 
differ between IHC groups. The hazard of an event for IHCpositive 
cases decreases by 32% in relapse-free survival {RFS; p=0.03} and 
by 38% in either time-to-relapse {TTR; p=0.02} or overall survi-
val {OS; p=0.016}. Multivariate models -adjusted for patient and 
tumour characteristics- indicated that IHC-ALK was a significant 
predictor for all three time-to-event outcomes (RFS, TTR, OS). In 
stratified Cox analysis, significantly higher OS was retained in the 
IHCpositive (HR=0.59, p=0.04) and FISHpositive (HR=0.34, p=0.03) 
cases in the matched cohorts, while conditional logistic regression 
yielded non-significant associations with 3-year survival status.
Conclusion: In this large cohort of surgically resected primary lung 
adenocarcinoma: 
• ALK IHC positivity was 6.4%.
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fully detected KIF5B:RET rearrangements and identified patterns 
suggestive of RET rearrangements with non-KIF5B partners in 
small subset of unselected NSCLC. Interestingly, only a minority 
of RET + patients were never smokers and 1/3 of them had non-
adenocarcinoma histology. Despite the benefits of using enrich-
ment strategies based on clinicopathologic variables for molecular 
testing of NSCLC in search for personalized therapy, these findings 
argue against using variables such as smoking status and histology 
for screening selection when the aim is to detect all potential RET+ 
patients.
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MO10.11 GENETIC POLYMORPHISMS OF TERT AND 
TP63 GENES ARE ASSOCIATED WITH EXON 18 AND 
EXON 21 MUTATIONS OF EGFR IN ADENOCARCINOMA 
OF THE LUNG.
Yoo Jin Jung, Sae Bom Lee, Samina Park, Hyun Joo Lee, Yoohwa 
Hwang, In Kyu Park, Chang Hyun Kang, Young Tae Kim
Thoracic And Cardiovascular Surgery, Cancer Research Institute, Seoul 
National University Hospital/Korea
Background: The presence of mutations of epidermal growth fac-
tor receptor (EGFR) is related to phenotypical characteristics such 
as ethnicity, gender and smoking status. Such observations led us 
to explore associations between genetic polymorphisms and EGFR 
mutational status.
Methods: We set up a set of samples from 677 primary pulmo-
nary adenocarcinoma. We tested two genetic polymorphisms 
(rs2736100 and rs10937405), which were discovered previously as 
to be associated with the risk of lung adenocarcinoma. The associ-
ation between EGFR mutational status and genetic polymorphisms 
were evaluated using logistic regression analysis.
Results: In 673 patients, four exons (18, 19, 20, 21) of EGFR were 
completely evaluated. Presence of EGFR mutations were found in 
382 (56.8%) patients. In logistic regression analysis, female gender 
(aOR, 1.7 with 95% CI, 1.0-2.9) and smoking status (ex-smoker, 
aOR, 0.6 with 95% CI, 0.4-1.1; current smoker aOR, 0.4 with 95% CI, 
0.2-0.8) were associated with presence of EGFR mutations. None 
of two single nucleotide polymorphism (SNP) sites showed signi-
ficant association. In the analysis of individual type of EGFR muta-
tions, however, we found a significant association between EGFR 
exon 18 mutations and a SNP rs27366100T/G located in TERT. 
The G/G genotype showed a 2.8-fold increase in the occurrence 
of the EGFR exon 18 mutations compared to T/T+G/T genotypes 
(aOR, 2.8 with 95% CI, 1.2-8.7). Additionally, C/T+T/T genotypes of 
rs10937405C/T SNP in TP63 showed frequnt occurrences of EGFR 
exon 21 mutations compared to CC genotype (aOR, 1.5 with 95% 
CI, 1.0-2.3).
Conclusion: Our findings suggest that the somatic mutations of 
EGFR may be closely associated with genetic polymorphisms. 
Further investigation of this field may enable us to identify patients 
who may get a benefit from EGFR inhibitors.
Keywords: EGFR mutation, Lung cancer, Polymorphism, Ade-
nocarcinoma
B3, CREBL2, GLI3, HERC1, IRAK3, NEDD4L, PRRX2, and ZDBF2, 
among others. RNA sequencing data did not reveal any novel fusi-
ons from analysis to date. Despite a low overall mutation frequency 
versus other forms of lung cancer, each carcinoid tumor had at 
least one potential driver mutation, suggesting possible targeted 
therapy opportunities for a disease where currently none exist.
Conclusion: Despite a low overall mutation frequency and an 
absence of frequently recurring mutations from the tumors 
sequenced to date, targeted therapy opportunities may exist 
through mutation profiling in broncopulmonary carcinoid tumors.
Keywords: mutations, carcinoid, DNA sequencing
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MO10.10 DETECTION OF RET FUSIONS BY FISH IN UN-
SELECTED NSCLC
Liang-Guo Xu1, Sakshi Mahale1, Luca Toschi2, Anh Le1, Dara 
Aisner1, Marco Alloisio2, Armando Santoro2, Massimo Roncalli2, 
Robert C. Doebele1, Marileila Varella-Garcia1
1University Of Colorado, Anschutz Medical Campus/United States Of 
America, 2Thoracic Surgery, Istituto Clinico Humanitas/Italy
Background: Activation of the RET gene by fusion has been de-
scribed in 1-2% of unselected population of non-small-cell lung 
cancer (NSCLC) and there is early evidence suggesting that pa-
tients with RET activated tumors obtain clinical benefit from RET 
inhibitors. The major fusion partner is KIF5B, but CCDC6, NCOA4 
and TRIM33 have also been reported. The prevalence of RET fu-
sions in different lung cancer subtypes and clinicopathologic cha-
racteristics of remain unclear. In this study, we sought to identify 
RET rearrangements in NSCLC using FISH and to investigate the 
association with histology and clinical features.
Methods: A 3-target, 3-color FISH probe set [3’RET in red, 5’RET 
in green, 5’KIF5B in yellow] was developed to simultaneously de-
tect (a) disruption between 3’ and 5’ RET and (b) specific fusion 
between 5’KIF5B-3’RET. This probe set was used to interrogate a 
cohort of Caucasian NSCLC patients using tumor microarray. In-
clusion of specimens on the tissue microarray was independent of 
gender, age, smoking history, histology and any known molecular 
profile and was only based on patient informed consent and tissue 
availability.
Results: Among 348 evaluable NSCLC patients, 6 (1.7%) were 
found to be positive for RET rearrangement (RET+): 2 showed typi-
cal KIF5B:RET pattern, 2 showed patterns consistent with CCDC6: 
RET fusion; and 2 had split 3’-5’ without suggestion of the fusion 
partner identity. The histology was adenocarcinoma in 4, large cell 
carcinoma in 1 and squamous cell carcinoma in 1. All RET+ tumors 
were wild type for EGFR and negative for ALK and ROS1 rearran-
gements. The mean age of RET+ patients at the time of diagnosis 
was 62 years (49-74) and they were predominantly male (5) and 
former (4) or current smokers (1). The 10p11-q11 region displayed 
high level of genomic instability, with RET doublets, KIF5B and RET 
doublets, unbalanced KIF5B copy number gain, fusion KIF5B with 
5’ and 3’RET, and abnormal separation between KIF5B and RET in 
8.5%, 5.1%, 9.6%, 2.3%, and 2% of specimens, respectively. These 
atypical patterns will be further investigated by RT-PCR.
Conclusion: The customized 3-target, 3-color probe set success-
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in the rearranged cells and lack of evidence of intra-tumoral he-
terogeneity suggests ROS1 rearrangements occur early in tumo-
rigenesis, consistent with their known oncogenic driver role. Data 
from this sample also show that, in FISH negative cases, ROS1 copy 
number was lower than native ALK. This suggests ROS1 may exist 
in a relatively more stable portion of the genome, potentially exp-
laining why ROS1 rearrangements exist at a lower frequency than 
ALK rearrangements in NSCLC.
Keywords: FISH, ALK, NSCLC, ROS1
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Background: Chromosomal rearrangements which generate con-
stitutively activated ROS1 receptor tyrosine kinase (6q22.1) have 
been found in several tumor types, including non-small cell lung 
cancers (NSCLC). In clinical trials, the oral kinase inhibitor crizotinib 
has shown promise in treating tumors with ROS1 rearrangements. 
Currently, fluorescence in situ hybridization (FISH) using dual-color, 
break-apart (BA) probes is used to detect ROS1 rearrangements 
in clinical samples; however, further optimization of this method is 
necessary to ensure patients are accurately diagnosed. This study 
explores BA FISH assay characteristics in NSCLC samples.
Methods: Tumor sections from 464 NSCLC patients were screened 
for ROS1 rearrangement using ROS1 BA FISH. Of these samples, 
206 were co-screened for ALK rearrangement. The copy number of 
fused and isolated 3’/5’ signals, as well as the incidence of atypical 
patterns (doublet and clustered multiple fusions) was investigated. 
Cells were considered ROS1 positive (ROS1+) when ≥ 15% of nu-
clei displayed split 5’/3’ signals or single 3’ signals. Specific fusion 
transcripts in ROS1+ cases were identified by RT-PCR or inverse 
PCR.
Results: ROS1 rearrangements (ROS1+) were found in 21 pati-
ents (5%). The copy number of native ROS1 differed significantly 
between positive and negative tumors (mean of 1.5 versus 2.5, 
p<0.0001). The percent of cells with FISH patterns compatible with 
ROS1 rearrangement ranged from 30% to 100%, with a mean of 
81%, in ROS1+ patients. The distribution of positive cells between 
scored regions within ROS1+ tumors was investigated for 13 cases 
and found to follow a normal distribution, ruling out intra-tumoral 
heterogeneity. Among ROS1+ specimens, 71% had a split signal 
pattern, 19% displayed a single 3’ pattern, and 10% had both a 
split and single 3’ pattern of positivity. For positive tumors, ROS1 
fusion partners were identified as SDC4 (S2;R32 and S2;R34), EZR 
(E10;R34) and CD74 (C6;R32 and C6;R34). Atypical negative pat-
terns such as fused doublets, clusters, 3’ doublets, 5’ doublets, 
and single 5’ signals were observed in 4%, 1%, 1%, <1%, and <1% 
of negative patients. ALK and ROS1 were scored simultaneously in 
the same cells in 206 patients, including 5 ROS1+ and 10 ALK+; no 
double positive cases were found. In ROS1 negative specimens, 
mean native ALK copy numbers were significantly higher than nati-
ve ROS1 in ALK negative samples (3.2 versus 2.3, p<0.0001).
Conclusion: ROS1+ tumors were detected in 5% of patients in this 
large NSCLC cohort. Since these patients were subject to various 
selection strategies, this frequency cannot be transferred to an 
unselected NSCLC population. The low native ROS1 copy number 
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MO11.02 VALIDATION OF ELECTRONIC NOSE EXHALED 
BREATH VOC PROFILE IN DISCRIMINATING BETWEEN 
SUBJECTS WITH EARLY STAGE LUNG CANCER AND 
HEALTHY NEVER SMOKERS.
Annette G. Dent1, Rayleen Bowman2, Paul Zimmerman2, Ian A. 
Yang1, Kwun M. Fong2
1School Of Medicine, The University Of Queensland/Australia, 2Thoracic 
Medicine, The Prince Charles Hospital/Australia
Background: Early diagnosis of lung cancer is associated with a 
better survival. The measurement of volatile organic compounds 
(VOCs) in exhaled breath using an electronic nose may prove to be 
a novel, effective and simple technique for screening and diagno-
sing lung cancer. The aim was to test the validity of the VOC profile 
in discriminating subjects with early stage lung cancer (I and II) 
(ESLC) from healthy ever smokers (HS).
Methods: 243 subjects: 54 ESLC and 189 HS provided a breath 
sample after tidally breathing through an inspiratory port filter for 
5 minutes. It was analysed using a 32 sensor Cyranose 320 (Smiths 
Detection). Subjects were divided into training (n=159) and inde-
pendent test set (n=84) groups. Canonical discrimination analyses 
were performed to determine significance of difference between 
subject groups and calculate cross validated accuracy (CVV) of the 
groups using leave one out classification method. Area under the 
curve (AUC) of Receiver Operating Characteristic Curves were also 
determined (SPSS V17.0).
Results: Validation of the training VOC profile model using an 
independent test group showed 79% accuracy (p=0.001) in dis-
tinguishing ESLC (n=20) from HS (n=64). (AUC 0.933). There was 
no significant difference in age, lung function and smoking history 
between the training and test groups.
Conclusion: Exhaled breath VOC profile model to discriminate 
between ESLC subjects and HS was validated in an independent 
group with a high accuracy. A clinically high sensitivity of the 
VOC profile model to discriminate between ESLC and HS can be 
achieved by selecting an appropriate cut point. The cyranose has 
potential to be a clinically useful diagnostic and screening tool for 
early stage lung cancer.
Keywords: Electronic nose, Exhaled breath, Validation, VOC  
profile
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MO11.03 THE NATURAL HISTORY AND SCREEN- 
DETECTABILITY OF LUNG CANCER: ESTIMATES FROM 
NLST AND THE PLCO
Kevin Ten Haaf1, Harry J. De Koning1, Joost Van Rosmalen2
1Public Heatlh, Erasmus Medical Center/Netherlands, 2Biostatistics, 
Erasmus Mc/Netherlands
Background: Implementing effective lung cancer screening pro-
grams requires extensive knowledge on the natural history of 
lung cancer and the sensitivity of the proposed screening moda-
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MO11.01 POSITRON EMISSION TOMOGRAPHY IN LUNG 
CANCER SCREENING: SIX-YEAR RESULTS
Giulia Veronesi1, Laura Travaini2, Cristiano Rampinelli3, Raffaella 
Bertolotti4, Lorenzo Spaggiari5, Massimo Bellomi5, Alessandro 
Pardolesi1, Giovanni Paganelli2
1Thoracic Surgery, European Institute Of Oncology/Italy, 2Nuclear 
Medicine, European Institute Of Oncology/Italy, 3Radiology, European 
Institute Of Oncology/Italy, 4European Insitute Of Oncology/Italy, 5Uni-
versità Statale Di Milano/Italy
Background: Lung cancer computed tomography (CT) screening 
is a controversial topic. Results from the National Lung Screening 
Trial showed that low dose CT (LD-CT) can reduce lung cancer 
mortality by at least 20%. However a critical issue is the high rate 
of indeterminate lung nodules and false positive cases. The aim of 
the study was to evaluate the diagnostic accuracy of CT/PET for 
lung cancer diagnosis in the context of lung cancer screening.
Methods: Between 2004 and 2005, 5203 asymptomatic high-
risk individuals (≥20 pack-years, age ≥50 years) were enrolled 
to undergo annual LD-CT for 10 years. Nodules ≤5 mm were 
scheduled for repeat LD-CT a year later. Nodules >5.0≤8.0mm 
received LD-CT 3-6 months later. Nodules >8.0mm or growing 
nodules underwent CT-PET. Results from all PET scans performed 
during the screening workup of COSMOS participants were 
reviewed. Those performed for suspected collateral disease 
(pleura, mediastinum, other cancers) were excluded. Outcome was 
based on the pathological findings for patients who underwent 
surgery or on findings at follow-up. Outcome was considered 
negative for those with negative CT findings for at least two years. 
PET results were visually evaluated by expert radiologists.
Results: 383 nodules in 351 patients were studied by CT/PET. In 
5 occasions, PET evaluation was dubious. 197 nodules turned out 
to be malignant. Overall sensitivity, specificity and accuracy of CT/
PET to distinguish between benign and malignant nodules was 
64%, 89% and 76% while it was 82%, 92%, 88% when considering 
only PET scans performed during baseline screening work-up. 
Diagnostic performance was high (sensitivity 87%, specificity 
73%) for nodules larger than 15 mm in their maximum diameter, 
reaching 98% sensitivity for solid nodules larger than 15 mm. The 
diagnostic performance of the test was significantly lower for 
nodules investigated at annual repeat CT compared to baseline 
CT (p<0.0001, sensitivity ranging from 30 to 71%) and for non-solid 
compared to solid nodules (p=0.0001; sensitivity 22% for non-solid 
versus 79% for solid nodules). 
Conclusion: CT/PET is a highly sensitive test for the differential 
diagnosis of screening-detected cancer, in particular at baseline 
CT, for solid nodules and those with a diameter larger than 15mm. 
Sensitivity of CT/PET for sub-solid nodules is very low suggesting 
that other diagnostic tests, such as volume doubling time, should 
be used.
Keywords: Lung cancer, Indeterminate lung nodule, Fluorodexy-
glucose PET/CT, Lung cancer screening
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Conclusion: This study provides detailed insights in the natural 
history of lung cancer and the differences in the effectiveness of 
screening between the NLST and PLCO trials. This knowledge may 
help to determine effective lung cancer screening programs.
Keywords: Preclincal sojourn time, CT sensitivity
lity. Data from the National Lung Cancer Screening Trial (NLST), 
the Prostate, Lung, Colon and Ovarian Cancer Study (PLCO) and 
Surveillance Epidemiology and End Result (SEER) data from 2004-
2008 are used to investigate the screening sensitivity (by stage 
and histological type) of Computed Tomography (CT) and chest 
radiography (CXR) and the mean preclinical sojourn time (MPST) of 
lung cancer (by gender, stage and histological type).
Methods: The MISCAN-Lung model was used to reproduce the 
lung cancer incidence by method of detection (clinical or screen-
detected), gender, histology and stage in both trials, by calibrating 
screening sensitivity and natural history parameters.
Results: Major differences in sensitivity between CT and CXR are 
estimated for the less advanced stages, for example the sensitivity 
for stage IA adenocarcinoma is estimated to be 56.63% for CT 
compared to 16.91% for CXR. The model suggests that the MPST 
varies by histological type and gender. The largest difference bet-
ween genders was estimated for adenocarcinoma for which the 
MPST in pre-clinical stages IA to IV was estimated to be 4.48 years 
for men compared to 6.01 years for women.
Strata PETs VN FN FP VP Sensitivity Specificity Accuracy p-value accuraccy 
Overall 378 164 70 21 123 64% 89% 76% 
Diam <10mm 145 75 40 4 26 39% 95% 70% 
Diam 10-15mm 104 51 19 4 30 61% 93% 78% 
Diam >15mm 117 30 10 11 66 87% 73% 82% 0.06 
Solid 263 123 26 16 98 79% 88% 84% 
Non solid 48 15 25 1 7 22% 94% 46% 
Partially solid 65 25 19 3 18 49% 89% 66% 
Non/Part solid 114 41 44 4 25 36% 91% 58% <0.0001 
Age <60 147 64 31 14 38 55% 82% 69% 
Age >60 231 100 39 7 85 69% 93% 80% 0.02 
Inferior lobe 139 69 29 8 33 53% 90% 73% 
Superior lobe 208 85 33 9 81 71% 90% 80% 
Other location 30 10 8 3 9 53% 77% 63% 0.09 
Left lobe 148 64 27 8 49 64% 89% 76% 
Right lobe 206 90 35 10 71 67% 90% 78% 0.70 
Baseline 148 81 11 7 49 82% 92% 88% 
2nd year 57 17 11 3 26 70% 85% 75% 
3rd year 62 19 28 3 12 30% 86% 50% 
4th year 44 10 10 4 20 67% 71% 68% 
5th year 47 31 6 4 6 50% 89% 79% 
6th year 20 6 4 0 10 71% 100% 80% <0.0001 
Male 264 113 44 12 95 68% 90% 79% 
Female 114 51 26 9 28 52% 85% 69% 0.05 
Non/part solid <15mm 72 27 34 2 9 21% 93% 50% 
Non/part solid >15mm 37 10 9 2 16 64% 83% 70% 
Solid <15mm 177 99 25 6 47 65% 94% 82% 
Solid >15mm 80 20 1 9 50 98% 69% 88% <0.0001 
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Conclusion: These data from the NLST suggest the risk of LC is 
strongly mediated by variables underlying risk of COPD (age, pack 
years and BMI). #Prostate, Lung, Colorectal and Ovarian Cancer 
Screening Trial (PLCO)
Keyword: Lung cancer, screening, COPD, risk models
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MO11.06 MINORITY STATUS AS A STRONG PREDICTOR 
OF HEALTH DISPARITIES: A GLOBAL PERSPECTIVE
Dan C. Li1, Solange E. Cox1, Alicia Hulbert2, James Harris1, Ning 
Wang3, Anjum Memon4, Anthony J. Alberg5, Malcolm V. Brock1
1Department Of Surgery, Johns Hopkins University School Of Medicine/
United States Of America, 2Department Of Oncology, Johns Hopkins 
University School Of Medicine/United States Of America, 3Key Labo-
ratory Of Carcinogenesis And Translational Reesearch, Beijing Cancer 
Registry, Peking University Cancer Hospital/China, 4Division Of Pri-
mary Care And Public Health, University Of Brighton/United Kingdom, 
5Department Of Epidemiology, Johns Hopkins University Bloomberg 
School Of Public Health/United States Of America
Background: The existence of healthcare disparities by race and 
ethnicity is well documented, often attributed to a lack of eco-
nomic and educational parity among groups, and manifested by 
unequal healthcare access and delivery. Inexplicably however, in 
many countries the wealthiest and most educated populations 
have the worst health outcomes. We hypothesize that minority 
status within a country rather than race, ethnicity, socioeconomics 
or educational level is more closely associated with poor health 
outcomes globally and functions independently of other variables.
Methods: Minority and majority populations in 34 countries/ter-
ritories were evaluated for smoking prevalence and age-adjusted 
lung cancer incidence rates. A global, systematic review of over 
1000 sources of epidemiological data was performed using rigo-
rous screening criteria including only national data in original form 
(national cancer registry, census, or health surveys), from an official 
government agency, or from peer-reviewed publications. Rela-
tive risks (RR) of smoking and lung cancer were computed for all 
minority groups with the majority population as the referent null. 
Relative wealth based on median per capita income and relative 
schooling based on educational attainment were also calculated. 
Minority groups were only included if so defined by both the Mino-
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MO11.04 LUNG CANCER RISK MEDIATED THROUGH SU-
SCEPTIBILITY TO COPD: PRELIMINARY RESULTS FROM 
A SUB-ANALYSIS OF THE NLST
Raewyn J. Hopkins1, Robert P. Young1, Fenghai Duan2, Xuan Deng2, 
Caroline Chiles3, Greg D. Gamble1, Denise Aberle4
1University Of Auckland/New Zealand, 2Brown University/United Sta-
tes Of America, 3Wake Forest University Baptist Medical Centre/United 
States Of America, 4Radiological Sciences, David Geffen School Of Me-
dicine At Ucla/United States Of America
Background: Introduction: Based on a 20% reduction in lung 
cancer deaths in the CT screening arm of the National Lung Scree-
ning Trial (NLST), yearly CT screening for lung cancer is now widely 
recommended. Recently, a multivariate risk model for lung cancer 
(LC), be used to identify smokers at greatest risk, has been pro-
posed to better select smokers for CT (#Tammemagi et al. JNCI 
2011;103:1058).This risk model includes age smoking history, his-
tory of COPD, BMI, recent CXR and educational level. This model 
has been validated in the NLST where recent CXR and educational 
level was omitted due to the unavailability of this data. In this sub-
study of the NLST, we examine the role of the known clinical risk 
factors for lung cancer and whether they mediate risk for lung can-
cer via risk for COPD. To test this we compared risk factors bet-
ween LC cases and controls after stratifying cancer-free screening 
participants (controls) by spirometry-defined COPD.
Methods: Using a sub-group of the NLST (drawn for validation 
of a gene-based risk stratification tool), we compared known risk 
factors for LC (recently validated in the PLCO# study) in 345 screen-
detected lung cancer cases and 1482 randomly selected cancer 
free screening controls stratified by COPD (pre-bronchodilator 
GOLD 1-4). These variables included age, pack years, family histo-
ry of LC (FHx), self-reported COPD and BMI.
Results: When the LC risk variables were compared between LC 
cases (N=345) and the cancer-free screening controls, stratified 
from baseline data into controls with COPD (N=489) and without 
COPD (n=993) (see Table1), we found the following; 
• a ge and pack years but not FHx were significantly higher in tho-
se with COPD and LC compared to cancer-free controls with no 
COPD,
• s elf reported COPD was 2 fold higher in COPD controls and LC 
cases compared to controls without COPD, and
• BMI was significantly lower in the LC cases and those with COPD 
compared to cancer-free controls with no COPD.
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hazard ratios (AHR) and 95% confidence intervals (95% CI) were 
reported based on the results of a multivariate Cox regression 
model for overall survival (OS) with adjustment for gender, age at 
diagnosis, race, stage and health insurance.
Results: A total of 1940 pts (86%) had the diagnosis of NSCLC, 
the rest were SCLC. There were 1170 (52%) females. Non-Hispanic 
whites (NHW) were 1,791 pts (79%), Hispanics (H) 266 (12%) and 
African-American (AA) 149 (7%). Fifty eight percent of patients had 
stage III/IV at diagnosis. 2054 of the pts were insured (91%). There 
was a significant difference in age at diagnosis among H (66.5 y), 
AA (64.4y) and WNH (69.5y). The probability of being diagnosed 
at a late stage (IIIB/IV) was two times higher among AA compared 
to NHW (OR= 1.77, p<0.05) or H (OR) = 1.67, p <0.05). There was 
no survival difference between NSCLC and SCLC (19m vs. 16m). 
Females with NSCLC lived significantly longer than males (Adjus-
ted Hazard ratio (AHR= 1.14 p<0.01). The same was true for SCLC 
(AHR = 1.43 p < 0.01). Significant predictors for worse survival for 
patients with NSCLC were: older age at diagnosis (AHR = 1.01, 
p<0.001), male gender (AHR=1.12, p<0.05) and late stage at diag-
nosis (AHR=2.27, p<0.001). Insurance and ethnicity were not signifi-
cant predictors of survival.
Conclusion: There are significant disparities in presentation and 
outcomes among minority patients (AA and H) with lung cancer. 
We will further evaluate if other social or genetic factors can exp-
lain these disparities.
Keywords: Disparities, Minorities, non-small cell lung cancer, small 
cell lung cancer
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MO11.08 THE IMPORTANCE OF A REGIMEN OF SCREE-
NING TO MAXIMIZE EARLY DIAGNOSIS AND TREAT-
MENT OF LUNG CANCER
Claudia I. Henschke1, Rowena Yip2, David F. Yankelevitz2
1Radiology, Icahn School Of Medicine At Mount Sinai/United States Of 
America, 2Radiology, Icahn School Of Medicine At Mount Sinai/United 
States Of America
Background: Writing on behalf of the I-ELCAP Investigators. The 
goal of CT screening is to maximize lung cancer cure rates by early 
diagnosis and treatment of lung cancer. To achieve this, a regimen 
of screening is important, particularly for small nodules. To better 
understand the importance of a regimen, we compared two large 
databases of screen-diagnosed lung cancers, the International 
Early Lung Cancer Action Program (I-ELCAP) and the National 
Lung Screening Trial (NLST) CT arm as the former had a specified 
diagnostic workup algorithm while the latter did not mandate any 
specific approach.
Methods: We compared all lung cancers including small-cell and 
carcinoids, that were diagnosed under screening, that is, either 
screen-diagnosed because of a positive result of the CT screening 
or symptom-prompted after a negative CT screening. We compa-
red the stage and size distribution of the screen-diagnosed can-
cers in the International Early Lung Cancer Action Program (I-EL-
CAP) from 1993 to 2011 and those in the NLST-CT arm from 2002 
to 2006. In I-ELCAP, the screenings were performed according to a 
common protocol in which the diagnostic workup for a participant 
was defined by a specified protocol which has been continually 
rity Rights Group International and the CIA World Fact Book.
Results: Data were collected from approximately 60% of the 
global population including all six WHO world regions and every 
populated continent. The RR of smoking for at least one minori-
ty group was greater than that of the referent majority in every 
country or territory analyzed. The RR of lung cancer for at least 
one minority group was greater than that of the referent majority 
in all but three countries/territories. These results were remarkab-
ly consistent and durable with RR ≥ 1.0 for smoking prevalence 
and lung cancer incidence in nearly all countries despite minority 
status being defined differently in many nations whether by race, 
ethnicity, religion, language, indigenous affiliation, or immigrant 
status. These results were further corroborated by age-specific 
lung cancer incidence for selected countries/territories. Racial 
and socioeconomic status differentials were insufficient explana-
tions for these observations. In the U.S., for example, blacks are 
generally less wealthy and educated than whites and have higher 
smoking prevalence and lung cancer incidence rates. However, in 
neighboring Bermuda and distant South Africa where blacks are 
the majority, whites have both higher smoking prevalence and lung 
cancer incidence rates despite being far wealthier and educated. 
This relationship of increased smoking and lung cancer rates in 
wealthier, more educated minorities is replicated in nine of the 34 
countries in this study.
Conclusion: Our results show an empirical relationship between 
minority status and both increased smoking prevalence and lung 
cancer incidence rates in minority populations globally. This 
suggests that minority status may be a potent, behavioral driver 
leading to elevated health risks in minority populations around 
the world. Moreover, minority status seems to be independent of 
traditional socioeconomic variables, and alone may be a powerful 
predictor of disparate health outcomes in many diverse nations, 
distinctive societies, and unique cultures on a global scale.
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MO11.07 EXPLORING DISPARITIES IN HEALTH CARE 
OUTCOMES IN MINORITY POPULATIONS WITH SMALL 
(SCLC) AND NON-SMALL CELL LUNG CANCERS (NSCLC).
Luis E. Raez1, Candice Sareli2, Raja Mudad2, Francisco Tarrazzi2, 
Evelio Velis2, Srinath Sundararaman2, Mark Block1
1Memorial Cancer Institute/florida International University/United Sta-
tes Of America, 2Memorial Cancer Institute/United States Of America
Background: There are population-specific differences in the 
presence of lung cancer, these are related with: health outcomes, 
quality of health care and access to health care services that exist 
across racial and ethnic groups. Disparities represent a lack of 
efficiency within the health care system and therefore account for 
unnecessary costs. Few publications are available about disparities 
in African-American (AA) populations with lung cancer and very 
few about Hispanic (H) populations with this disease.
Methods: We reviewed registry data on 2,255 pts with non-small 
cell lung cancer (NSCLC) and small cell lung cancer (SCLC) treated 
during last 10 years (2002-2011) at Memorial Health Care System. 
The main objective of the study was to evaluate differences in 
lung cancer survival according to ethnicity. Chi-square was used 
to compare distribution of tumor stage. Survival curves were com-
pared using log-rank test for each of the tumor stages. Adjusted 
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Results: The frequency of positive results in the baseline round, 
using the definition of positive result (any parenchymal, so-
lid or part-solid, noncalcified nodule > 5.0 mm), was 15.9% 
(4,104/25,814). Using alternative threshold values of 6.0, 7.0, 8.0 
and 9.0 mm, the frequencies (95% CI) of positive results were 
10.5% (10.2, 10.9), 7.2% (6.9, 7.5), 5.3% (5.0, 5.6) , and 4.2% (3.9, 
4.4), respectively. Use of these alternative definitions would have 
reduced the workup by 33.8%, 54.7%, 66.6%, and 73.8%, respec-
tively. Concomitantly, proportion of lung cancer diagnoses made 
within first 12 months would be delayed for 0.9%, 2.6%, 6.1%, and 
10.0% of the patients, respectively. These results are similar to 
those found in I-ELCAP.
Conclusion: These results are similar to those found in I-ELCAP 
and suggest that even in the higher-risk participants enrolled in the 
NLST, higher threshold values can be used. This reduction in the 
positive result rate compared to the 28% positive result rate repor-
ted in the NLST, which used a 4mm threshold, is considerable.
Keywords: frequency of cancer diagnosis, CT screening, positive 
result
SCREENING AND EPIDEMIOLOGY  
MONDAY, OCTOBER 28, 2013 - 16:15-17:45
MO11.11 IL-11 AND CCL-1: NOVEL PROTEIN DIAG-
NOSTIC BIOMARKERS OF LUNG ADENOCARCINOMA 
IN BRONCHOALVEOLAR LAVAGE (BAL)
Marilo Pastor1, Ana Nogal1, Sonia Molina-Pinelo1, Alvaro Quinta-
nal1, Beatriz Romero1, Maria Jose De Miguel1, Ricardo Melendez1, 
Jose L. Lopez-Campos1, Jesus Corral2, Rocio Garcia Carbonero1, 
Amancio Carnero1, Luis Paz-Ares3
1Ibis/Spain, 2Medical Oncology, University Hospital Virgen Del Rocio/
Spain, 3Medical Oncology, Ibis/Spain
Background: Lung cancer (LC) and chronic obstructive pulmonary 
disease (COPD) are smoking related diseases and the presence of 
COPD increases itself the risk of developing lung cancer, probably 
due to underlying inflammation. LC is typically detected at late 
stages of the disease and carries a dismal prognosis. There is an 
unmet need for useful early detection methods of lung cancer in 
high risk subjects, such as smokers.
Methods: The expression of inflammatory proteins was studied in 
bronchoalveolar lavage samples (BAL) by antibody arrays in a pros-
pective discovery cohort of 60 patients with the following inclusion 
criteria: age > 40 years, diagnostic broncoscopy due to hemop-
tysis or pulmonary nodule, smokers or ex-smokers pack of more 
than 30 pack-years, divided into four groups (control, LC, COPD, 
LC & COPD). Relevant biomarkers were validated by western blot. 
Additional validation was carried out by ELISA in two independent 
controlled cohorts of 139 (control, LC, COPD, LC & COPD) and 160 
patients (control, all LC histological subtypes).
Results: CCL-1 and IL-11 were selectively expressed in samples 
of adenocarcinoma patients, with or without COPD (p<0•001) in 
the discovery cohort. These proteins exhibited a remarkable dia-
gnostic performance for lung adenocarcinoma in an independent 
cohort of 139 patients. ROC curves showed that the optimum dia-
gnostic cutoff value for IL-11 was 42 pg/mL (area under curve [AUC] 
0•93 [95% CI 0•896-0•975], sensitivity 90%, specificity 86%), and 
for CCL-1 was 39•5 pg/ml (0•83 [95% CI 0•749-0•902], sensitivity 
83%, specificity 74%). Further validation of the ELISA biomarkers 
updated whereas in the NLST, “… no specific diagnostic evaluation 
approach was mandated.” 
Results: In I-ELCAP, a total of 799 patients were diagnosed under 
screening of which 11 (1.4%) were interim-diagnoses; 8 prior to the 
first annual repeat screening and 3 between annual rounds, leaving 
788 screen-diagnosed patients. 
In the NLST CT arm, 1060 patients were diagnosed with lung 
cancer, but only 692 were diagnosed under screening. There 
were 18 interim-diagnosed cases before the first annual repeat 
screening and 26 between the 2 annual repeat screenings, a total 
of 44 (6.4%) interim-diagnosed cases for this cohort. This left 649 
screen-diagnosed patients. 
The frequency of clinical Stage I was 82% (95% CI: 79%-84%) 
vs. 69% (95% CI: 65%-72%) in I-ELCAP and NLST, respectively. 
Average tumor size (95% confidence interval) was 17.3 mm (16.6-
18.1) vs. 23.1 mm (21.7 -24.4), respectively. Surgical resection was 
performed in 86% (676/788) and 77% (497/649) of the screen-diag-
nosed patients, respectively. The frequency of pathologic Stage I 
(clinical, if not resected) was 73% (95% CI: 70%-76%) vs. 63% (95% 
CI: 59%-67%). 
Conclusion: Stage I disease, both clinical and pathologic, was 
significantly higher in I-ELCAP than NLST. The tumor size was si-
gnificantly lower in I-ELCAP than NLST, all strongly suggestive of 
the importance of a specified regimen of screening. This is further 
substantiated by the reported 71% for pathologic Stage I (clinical, 
if not resected) by the NELSON study which is close to that repor-
ted by I-ELCAP as the NELSON also followed a well-defined regi-
men of screening. 
Keywords: stage distribution, CT screening, Lung cancer, regimen 
of screening
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MO11.09 CT SCREENING FOR LUNG CANCER: DEFI-
NITION OF POSITIVE TEST RESULT IN THE NATIONAL 
LUNG SCREENING TRIAL CT COHORT COMPARED WITH 
I-ELCAP
Rowena Yip1, David F. Yankelevitz2, Claudia I. Henschke1
1Radiololgy, Icahn School Of Medicine At Mount Sinai/United States Of 
America, 2Radiology, Icahn School Of Medicine At Mount Sinai/United 
States Of America
Background: Low-dose CT screening for lung cancer can reduce 
mortality among high-risk people but to reduce unnecessary eva-
luations with attendant risks, alternative thresholds for defining 
positive result and cancer diagnoses needs to be further under-
stood. The purpose of the study is to assess the frequency of posi-
tive results and potential delays in diagnosis in the baseline round 
of screening using more restrictive thresholds.
Methods: Among the participants who were randomly assigned to 
the CT arm of the National Lung Screening Trial (NLST) cohort, we 
identified the frequency of solid and part-solid pulmonary nodules 
and the rate of lung cancer diagnoses using a 5.0, 6.0, 7.0. 8.0 and 
9.0 mm threshold for the largest noncalcified nodule identified in 
the baseline CT scan. we compared these results with those previ-
ously published for the I-ELCAP cohort.
S327Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
at the mentioned cutoffs was performed in an additional cohort of 
160 patients (20 controls, 66 LC, 74 LC & COPD). There was a signi-
ficant correlation between BAL levels of IL-11 and CCL-1 (r2= 0•76, 
p<0•001), and the use of both biomarkers increased the diagnostic 
accuracy to 96,1% in the two validation cohorts. Appropriate di-
agnostic performance was observed for all subgroups regardless 
of stage at diagnosis, involvement of bronchial tract, pack-years 
smoked, and number of cells in BAL.  
Diagnostic performance of IL-11 and 
CCL-1 in the first validation cohort 
(N=139) 
Adenocarcinoma vs all patients AUC (95%IC) 
Sensivity 
(95%IC) 
Specificity 
(95%IC) 
PPV 
(95%IC) 
NPV 
(95%IC) 
Positive 
LR 
Negative 
LR 
IL-11 
0.93 
(0.896-
0.975) 
90.2% 
(79%-
95.7%) 
88.7% 
(80.6%-
93.5%) 
80.7% 
(68.7%-
88.9%) 
94.5% 
(87.8%-
97.6%) 
7.95 
(4.53-
13.98) 
0.11 (0.05-
0.26) 
CCL-1 
0.83 
(0.749-
0.902) 
80% 
(66.4%-
87.7%) 
74.1% 
(63.9%-
82.2%) 
72.1% 
(59.2%-
73.4%) 
86.3% 
(76.6%-
92.4%) 
3.02 
(2.05-
4.47) 
0.29 (0.17-
0.52) 
IL11 and CCL-1 
71.2% 
(57.7%-
81.7%) 
94.4% 
(88.4%-
97.4%) 
86% 
(72.7%-
93.4%) 
87.2% 
(79.9%-
92.1%) 
12.8 
(5.77-
28.41) 
0.31 (0.20-
0.47) 
IL-11 and/or CCL-1 
94.3% 
(84.6%-
98.1%) 
74.1% 
(65.1%-
81.4%) 
64.1% 
(53%-
73.9%) 
96.4% 
(89.9%-
98.8%) 
3.64 
(2.63-
5.04) 
0.08 (0.03-
0.23) 
Diagnostic performance of IL-11 and 
CCL-1 in the second validation cohort 
(N=160) 
Adenocarcinoma vs all patients AUC (95%IC) 
Sensivity 
(95%IC) 
Specificity 
(95%IC) 
PPV 
(95%IC) 
NPV 
(95%IC) 
Positive 
LR 
Negative 
LR 
IL-11 
0.95 (0.92-
0.98) 
90.6% 
(79.7%-
95.9%9 
83% (86.8%-
87.7%) 
60.8% 
(49.7%-
70.8%) 
96.8% 
(92.7%-
98.6%) 
5.32 
(3.81-
7.41) 
0.11 (0.05-
0.26) 
CCL-1 
0.91 (0.87-
0.96) 
91.7% 
(80.4%-
96.7%) 
77.5% 
(71.0%-
82.9%) 
51.2% 
(40.8%-
61.4%) 
97.3% 
(93.3%-
99%) 
4.08 
(3.09-
5.04) 
0.11 (0.04-
0.28) 
IL11 and CCL-1 
71.2% 
(57.7%-
81.7%) 
96.3% 
(92.5%-
98.2%) 
84.1% 
(70.6%-
92.1%) 
92.3% 
(87.7%-
95.3%) 
19.1 (9-
41.13) 
0.3 (0.19-
0.46) 
IL-11 and/or CCL-1 
92.3% 
82.6%-
98.1%) 
84% (78%-
88.5%) 
62.5% 
(51.5%-
72.3%) 
98.1% 
(94.6%-
99.4%) 
5.88 
(4.21-
8.22) 
0.07 (0.02-
0.20) 
 
Conclusion: IL-11 and CCL-1 are highly specific biomarkers with 
great accuracy for the diagnosis of lung adenocarcinoma in BAL 
specimens. Further study of these proteins as markers for early 
diagnosis and screening in plasma and other biological materials is 
warranted.
Keywords: biomarker, Proteomic, Adenocarcinoma, screening
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MO12.01 NOVEL MECHANISMS OF SENSITIVITY AND 
ACQUIRED RESISTANCE TO HSP90 INHIBITION BY GA-
NETESPIB
Sara Busacca1, Howard Pringle1, Edward Law1, Laura O’Regan2, 
Andrew M. Fry2, Kyle Matchett3, Vienna Reichert4, Iman El-Hariry4, 
Mohamed El-Tanani3, Dean A. Fennell1
1Department Of Cancer Studies And Molecular Medicine, University Of 
Leicester/United Kingdom, 2Department Of Biochemistry, University Of 
Leicester/United Kingdom, 3Centre For Cancer Research And Cell Biolo-
gy, Queen‘s University Of Belfast/United Kingdom, 4Synta Pharmaceu-
ticals/United States Of America
Background: HSP90 is a promising anti-cancer target. Inhibition 
by the Hsp90 inhibitor ganetespib has shown promising activity 
with improved survival in patients with metastatic lung adenocar-
cinoma, and it is now being evaluated in malignant pleural meso-
thelioma. However, the mechanisms underlying resistance are cur-
rently unknown. The aims of this study were to establish the role 
for mitochondrial apoptosis in mediating the anti-cancer activity of 
ganetespib, and to also identify mechanisms of acquired resistance 
to support personalised therapy.
Methods: We conducted a functional genetic screen to determi-
ne the role of the proapoptotic BAX/BAK proteins using double 
knockout mouse embryonic fibroblasts (MEFs) shRNA and siRNA. 
Focused RNAi targeting BH3-only proteins, Caspase 8 and MCL1 
was conducted in MSTO-211H, H460 and H23 cell lines. Apoptosis 
was measured by a Caspase3 activity assay and data were valida-
ted by western blot and SubG1 population analysis. Prosurvival 
Bcl2 family regulation was evaluated by western blot, and MCL1 
transcriptional suppression monitored by real-time quantitative 
PCR and luciferase reporter assay. MCL1 amplification was quan-
tified by genomic real-time PCR. Ganetespib resistant cells were 
generated by increasing drug exposure. Hsp90 ATP-binding site 
and Caspase8 were sequenced in both parental and resistant cell 
lines.
Results: Ganetespib required a functional mitochondrial pathway 
for induction of apoptosis. Interrogation of pro-apoptotic BH3-only 
proteins revealed a co-operation between BID, BIK and PUMA. 
Caspase8 activates BID and, when silenced, protected cells from 
ganetespib. MCL1 was transcriptionally suppressed by ganetespib, 
and when Mcl-1 downregulation was achieved by siRNA, it was 
sufficient to induce BID/BIK-dependent apoptosis in MCL1-depen-
dent cells. We observed that MCL1 addicted cells were also more 
sensitive to ganetespib than non-addicted. In addition, amplifica-
tion of MCL1 was detected only in ganetespib sensitive cell lines. 
Ectopic MCL1 was not sufficient to rescue from ganetespib-indu-
ced apoptosis. To better understand mechanisms of resistance, we 
established ganetespib-resistant cell lines. Resistant cells did not 
select for HSP90 mutations, and these cells conserved on-target 
suppression of PI3K/AKT, MAPK signalling, upregulation of HSP70, 
and MCL1 downregulation. However addiction to MCL1 was lost as 
was block of Caspase8 activation with consequent cross-resistance 
to TRAIL. PCR of Caspase8 cDNA revealed an acquired structural 
alteration in the 3’-untranslated region.
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MO11.13 LOW SELENIUM SERUM LEVEL IS A GOOD 
PRESELECTION FACTOR FOR PATIENTS INVITED FOR 
LOW DOSE CHEST CT LUNG CANCER SCREENING
Tomasz Grodzki1, Janusz Wójcik1, Anna Jakubowska2, Norbert 
Wójcik1, Magdalena Muszynska2, Bartosz Kubisa1, Katarzyna 
Jaworska-Bieniek2, Jarosław Pieróg1, Satish Gupta2, Jacek Alchimo-
wicz1, Tomasz Gromowski2, Henryk Janowski1, Grzegorz Sukienni-
cki2, Michał Bielewicz1, Jan Lubinski2
1Thoracic Surgery, Pomeranian Medical University/Poland, 2Internatio-
nal Hereditary Cancer Center, Pomeranian Medical University/Poland
Background: Selenium is known as a chemoprotective anti-cancer 
agent. The impact of low selenium serum level on the frequency of 
early lung cancer (LC) detection rate in patients participating in a 
low dose chest CT (LDCT) screening program is assessed.
Methods: A program of early LC detection was conducted in a 
single city of 400000 inhabitants from 2008 till 2011 (Protocol I). 
Enrollment criteria included both sexes aged 55-65 years with a 
history of 20 pack-years of tobacco smoking. All detected lesions 
were followed up in accordance with IELCAP protocols. A new pilot 
study (Protocol II) launched in 2012 was based on preselection of 
the participants by measure of their selenium serum level. Only 
individuals with a low selenium level (< 75 microgramms/ml) were 
invited for CT scans. Other enrollment criteria were the same as 
in Protocol I. All cases requiring surgery were referred to a single 
local thoracic surgery department. The following data were analy-
zed: number of all detected lesions as well as LC detected in both 
protocols.
Results: Protocol I: 15020 patients were screened by LDCT. 6240 
pulmonary lesions were detected with the majority (59%) smaller 
than 5mm. 182 patients (2.9% of all detected lesions) were re-
ferred for thoracic surgery. 119 primary LC were diagnosed and 
treated. Protocol II: 2440 patients have had selenium serum level 
measured. 720 of them were screened by LDCT. 210 lesions were 
detected with 49% smaller than 5mm. 14 patients (6.8%) were 
referred for thoracic surgery. 9 primary LC were diagnosed and 
treated surgically. Protocol II was more specific because number 
of all detected lesions was significantly smaller than in Protocol I 
(p < 0.0001, OR: 0.55; CI: 0.46 – 0.64) but the LC detection rate in 
Protocol II was more than twice as high as in Protocol I (p = 0.0226, 
OR: 2.38; CI: 1.19 – 4.76).
Conclusion: The detection rate of LC in the program of early de-
tection based on LDCT is higher if the protocol is supported by 
preselection of high risk tobacco - smoking patients based on a 
low level of selenium in serum.
Keyword: lung cancer, screening, selenium
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(expression of 1,030 genes summarized from 60,000 transcripts). 
Cox proportional-hazard models were applied to explore the 
association between each gene and PFS/OS, mRNA gene 
expression was used both as continuous and binary (cutpoint: 
median) variable. Unadjusted p-values (significance level =0.01) 
and false discovery rates (FDR) were calculated. Genes significantly 
correlated with PFS/OS were further correlated with TS-protein 
expression (Spearman rank test). Finally, unsupervised clustering 
was applied to all samples with mRNA expression (n=51) for all 
1,030 selected array genes and an overlapping 870-gene subset 
associated with adenocarcinoma (ADC, n=47) previously described 
[2].
Results: 51/70 (72.9%) biopsies were evaluable; 9 of 1,030 genes 
were significantly associated with PFS/OS (unadjusted p<0.01). 8/9 
genes were negatively correlated with nuclear TS expression; the 
test was statistically significant for 5/8 genes (unadjusted p<0.01, 
Table 1). None of these genes has a known relationship to folate 
metabolism. Cluster analysis of all 51 samples based on 1,030 ge-
nes revealed no clear trend regarding PFS/OS. Cluster-analysis of 
47 ADC samples identified 3 groups (n=21, 11 and 15 patients, re-
spectively) with median (95%CI) PFS and OS of 8.1 (6.9, not estima-
ble [NE]) and 20.3 (17.5, N.E) months; 2.4 (1.2, NE) and 4.3 (1.4, NE) 
months; and 4.4 (1.2, NE) and 8.3 (3.9, NE) months, respectively. 
Conclusion: This exploratory analysis provides insights on key ge-
nes potentially linked to low TS expression. Nine genes were signi-
ficantly associated with PFS/OS; however such association cannot 
be differentiated as prognostic or predictive since this study is 
single arm. Further research would be needed to understand the 
relationship of these markers with clinical outcomes. [1] Nicolson 
et al, J Thorac Oncol 2013, May 29 [Epub]. [2] Wilkerson et al, PLoS 
One 2012;7(5):e36530.
Keywords: pemetrexed, non-squamous NSCLC, Gene expression 
profiling, Phase II study.
Conclusion: Here we show that HSP90 inhibition requires engage-
ment of the mitochondrial apoptosis pathway, and involves coope-
ration of multiple BH3-only proteins with parallel suppression of 
MCL1. Interestingly, ganetespib may exploit tumour dependence 
on MCL1; this may be clinically relevant given that MCL1 (1q21.2) 
amplification correlates with dependence and its gene copy num-
ber alteration is one of the most frequent across cancers. Acquired 
resistance involves selection for loss of dependence on MCL1, and 
a block in Caspase8 signalling which lies upstream of BID. Failure 
of ectopic MCL1 overexpression to rescue is indicative of redun-
dant death signalling by ganetespib. Clinical significance of core 
apoptosis gene expression will be explored and presented in a 
correlative analysis of the 9090-06 ganetespib monotherapy clini-
cal trial in NSCLC.
Keywords: HSP90, Apoptosis, resistance, clinical trial
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MO12.02 ASSOCIATION BETWEEN GENE EXPRESSION 
PROFILES AND CLINICAL OUTCOME OF PEMETREXED-
BASED TREATMENT IN PATIENTS WITH ADVANCED 
NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: 
EXPLORATORY RESULTS FROM A PHASE II STUDY
Dean Fennell1, Scott Myrand2, Tuan Nguyen2, David Ferry3, Keith 
M. Kerr4, Perry Maxwell5, Stephen Moore6, Carla Visseren-Grul7, 
Mayukh Das8, Marianne Nicolson9
1University Of Leicester/United Kingdom, 2Eli Lilly And Company/
United States Of America, 3New Cross Hospital/United Kingdom, 
4Department Of Pathology, Aberdeen University Medical School/United 
Kingdom, 5Queens University/United Kingdom, 6Almac Diagnostics/
United Kingdom, 7Medical Oncology, 
Eli Lilly And Company/Netherlands, 
8Eli Lilly And Company/United 
Kingdom, 9Aberdeen Royal Infirmary, 
University Of Aberdeen/United 
Kingdom
Background: We report 
exploratory gene expression 
profiling data from a prospective 
single-arm Phase-II-study in 
patients with non-squamous non-
small cell lung cancer (nsNSCLC) 
treated with pemetrexed. Main 
results indicated a significant 
association of low thymidylate-
synthase (TS) expression with 
longer PFS and OS [1].
Methods: Treatment-naive 
nsNSCLC patients (Stage IIIB/
IV) received 4 cycles of first-line 
pemetrexed/cisplatin; non-
progressing patients continued 
on pemetrexed maintenance [1]. 
Diagnostic tissue samples were 
used to assess TS expression 
(nucleus/cytoplasm) by 
immunohistochemistry (IHC, H 
scores), and to extract total mRNA 
for expression-array profiling 
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wild-type patients(6.0m vs 5.7m,p=0.85), however, the patients of 
EGFR wild-type had better PFS in the PC group compared with GC 
group (5.7m vs 3.5m, p=0.03). There are no significant difference 
between groups in EGFR mutated patients(5.6m vs 6.1m, p=0.59). 
The patients with ALK fusion seem to have better PFS compared 
with fusion negative patients (7.7m vs 5.7m), but the difference is 
not significant(p=0.48). The mRNA expression level was available 
in 225 patients(94.1%) and we determined the median expression 
as the cutoff value. The TS expression is significantly correlated 
with ERCC-1(r=0.67,p<0.001) and negatively correlated with FR-1 
expression(r=-0.21,p=0.002). EGFR mutation correlated with lower 
TS expression(p=0.034) and ALK fusion correlated with higher FR-1 
expression(p=0.017). The differences of PFS between the high and 
low expression of ERCC-1, TS, RRM-1and FR-1 was not significant, 
in both PC group and GC group.
Conclusion: The expression level of ERCC-1, TS, RRM-1and FR-1 
could not effectively predict the progression free survival of NS-
CLC patients receiving platinum-based doublet regimen. The pe-
metrexed plus cisplatin regimen should be the priority choice for 
EGFR wild type patients compared with gemcitabine plus cisplatin 
regimen.
Keywords: Lung cancer, chemotherapy, biomarker
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MO12.04 BIOMARKER ANALYSIS OF NCIC CLINICAL 
TRIALS GROUP IND.196, A PHASE I STUDY OF ERLOTI-
NIB PLUS FORETINIB IN ADVANCED PRETREATED NON-
SMALL CELL LUNG CANCER PATIENTS
Natasha Leighl1, Ming S. Tsao1, Shingo Sakashita2, Dongsheng Tu1, 
Cheryl Ho1, Frances A. Shepherd3, Nevin Murray4, Garth Nicholas5, 
John R. Goffin6, Lucia Kim2, Suzanne Kamel-Reid2, James Ho2, Tong 
Zhang2, Mahadeo Sukhai2, Lesley Seymour1, Glenwood Goss1, 
Penelope Bradbury1
1Ncic Clinical Trials Group/Canada, 2Ontario Cancer Institute, Universi-
ty Health Network/Canada, 3Medical Oncology, Princess Margaret Can-
cer Centre/Canada, 4British Columbia Cancer Agency/Canada, 5Ottawa 
Hospital Centre/Canada, 6Juravinski Cancer Centre/Canada
Background: Upregulation of MET and more recently AXL have 
been described as potential mechanisms of resistance to EGFR ty-
rosine kinase inhibitors in NSCLC. We explored the impact of base-
line MET and AXL tumour expression and circulating hepatocyte 
growth factor levels, (HGF), in advanced NSCLC patients receiving 
erlotinib plus foretinib, an oral multi-targeted kinase inhibitor of 
MET, RON, AXL, TIE-2 and VEGFR.
Methods: Advanced NSCLC patients that previously received one 
or two lines of chemotherapy were treated in IND.196, a phase I 
dose-finding trial with an initial two-week run-in of single agent 
erlotinib (100-150 mg daily). If erlotinib was well tolerated, foretinib 
was then added (30-45 mg daily). Submission of tumour samples 
(archival or fresh) was mandatory, and circulating HGF levels were 
determined at baseline and on treatment. Tumour samples were 
genotyped using Sequenom MassARRAY analysis. MET and AXL 
expression were determined by immunohistochemistry. For AXL, 
the human Axl affinity purified polyclonal goat IgG antibody (R&D 
systems, AF154, Minneapolis MN) was scored manually. For MET, 
the anti-total MET (SP-44) rabbit monoclonal antibody (Ventana 
Medical Systems, Tucson AZ) was scored using the Benchmark XT 
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MO12.03 BIOMARKER ANALYSIS OF A RANDOMIZED, 
CONTROLLED, MULTICENTER CLINICAL TRIAL COM-
PARING PEMETREXED/CISPLATIN AND GMCITABINE/
CISPLATIN AS FIRST-LINE TREATMENT FOR ADVANCED 
NONSQUAMOUS NON-SMALL CELL LUNG CANCER
Li Zhang1, Yan Huang1, Zhihuang Hu1, Yun-Peng Liu2, Jianying 
Zhou3, Nong Xu4, Baolan Li5, Gang Wu6, Xiaoqing Liu7, Jian Fang8, 
Kai Li9, Liu Wei10, You Lu11, Meng-Zhao Wang12, Wenzhao Liu13, 
Houjie Liang14, Yiping Zhang15, Cheng Huang16, Shunjin Wang17, 
Yajie Wang18, Shiying Yu19, Jianhua Chang20, Zhehai Wang21
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pital Of Medical School Of Zhejiang University/China, 4Department Of 
Chemotherapy, The First Affiliated Hospital Of Medical School Of Zheji-
ang University/China, 5Department Of General Medicine, Beijing Chest 
Hospital, Capital Medical Hospital/China, 6Tumor Center, Union Hospi-
tal, Tongji Medical College, Huazhong University Of Science And Tech-
nology/China, 7Department Of Thoracic Medical Oncology, Affiliated 
Hospital Of Academy Of Military Medical Sciences/China, 8Department 
Of Thoracic Medical Oncology, Beijing Cancer Hospital And Institute/
China, 9Department Of Thoracic Medical Oncology, Tianjin Medical Uni-
versity Cancer Institute And Hospital/China, 10Medical Oncology, Hebei 
Medical University Fourth Hospital/China, 11Department Of Thoracic 
Oncology, West China Hospital, West China School Of Medicine Sichuan 
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15Department Of Medical Oncology, Zhejiang Cancer Hospital/China, 
16Department Of Thoracic Oncology, Fujian Provincial Cancer Hospital/
China, 17Department Of Oncology, Second Affiliated Hospital Of Nan-
chang University/China, 18Department Of Oncology, Changhai Hospital 
Of Shanghai second Military Medical University/China, 19Caner Center, 
Tongji Hospital, Tongji Medical College, Huazhong University Of Sci-
ence And Technology/China, 20Department Of Medical Oncology, Fudan 
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Oncology, Shandong Cancer Hospital/China
Background: The platinum-based doublet regimen was standard 
of care in advanced non-small cell lung cancer (NSCLC), but the 
biomarkers to predict the efficacy of first-line chemotherapy is still 
controversial.
Methods: We collected 239 tumor samples (83.0%) from a a 
randomized, controlled, multicenter clinical trial, which enrolled 
288 treatment naïve nonsquamous NSCLC patients who were 
randomly assigned (1:1) to experimental group to receive cisplatin 
plus pemetrexed (PC) or the control group to receive gemcitabine 
plus cisplatin (GC) every 3 weeks for up to 6 cycles. We evalu-
ated the EGFR mutation by Amplification Refractory Mutation 
System(ARMS) method and EML4-ALK fusion by real-time PCR. 
Meanwhile, the mRNA expression of excision repair cross comple-
mentation 1 (ERCC-1), thymidylate synthase (TS), ribonucleotide 
reductase M1(RRM-1), and folatereceptor 1(FR-1) was tested by 
real-time PCR. All of the EGFR mutation, ALK fusion and mRNA 
expression were analyzed for the correlation with progression free 
survival, the primary endpoint in the tiral.
Results: The EGFR mutation rate was 46.6%(110/236) in the ove-
rall population and the ALK fusion rate was 12.0%(29/233). The 
median PFS was similar between the EGFR mutated patients and 
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samples have been reported to verify above standpoint. The 
aim of the present multicenter clinical study was to evaluate the 
expression level of Hsp90α in lung cancer patients and whether 
Hsp90α was monitor and predictor for response to therapy in lung 
cancer.
Methods: A total of 2284 lung cancer patients were enrolled in 
this study which was randomly assigned into two groups as static 
and dynamic groups. The static group (2036 samples) consisted of 
healthy subjects (592 samples), lung cancer (1046 samples), non-
cancerous lesions of the lung patients(361 samples ) and other 
cancer patients(37 samples). Samples of peripheral blood from all 
subjects were collected in sterile EDTA-K2-coated vials. Whereas 
the dynamic group included lung cancer patients who received 
surgical treatment and underwent chemotherapy, with number of 
above mentioned parts 79 and 169, respectively. For surgical pa-
tients, plasma samples were collected at following time points: 3 
days before surgery, 3-7 days after surgery and 3 days after clinical 
efficacy evaluation. Similarly, plasma samples of chemotherapy 
patients were also collected before treatment, after each chemo-
therapy cycle until the forth cycle. The concentrations of Hsp90α in 
plasma were measured by enzyme-linked immunosorbent assay.
Results: The concentration of Hsp90α in lung cancer patients was 
significantly higher than in other control groups (P <0.05). The cut-
off value was 56.33 ng/mL for diagnosis, with high sensitivity and 
specificity (72.18% and 78.70%, respectively). Advanced lung can-
cer (stage III-IV) patients were with higher Hsp90α levels than the 
early patients(stage I-II) (251.38 ng/ml vs 111.50ng/ml, P<0.001), 
no significant relationship was found between non-small cell lung 
cancer (NSCLC,910 samples) patients and small cell lung cancer  
(SLCL, 136 samples) patients, and patients with adenocarcino-
ma(537 samples) and squamouscarcinoma (218 samples). Further-
more, a statistically significant association was observed between 
pre-operative and post-operative patients in surgical patients 
group (P<0.01). In chemotherapy patients group, Hsp90α level was 
correlated significantly with the effect of treatment [concentration 
of Hsp90α was higher in progressive disease(PD)group than in 
partial response(PR)/stable disease(SD) group].
Conclusion: This study firstly developed large clinical samples 
and elucidated the role of Hsp90α in the lung cancer patients. The 
cut-off value of 56.33 ng/mL was recommended to assess the ex-
pression level of Hsp90α in lung cancer patients. Hsp90α may be 
a potential biomarker for therapeutic monitor and prediction for 
lung cancer.
Keyword: Hsp-90α, lung cancer, Plasma , biomarker
autostainer. Staining intensity (0-3+) and percent cells stained were 
used to calculate the H-score; H-scores >100 were deemed positi-
ve for AXL, and >200 positive for MET.
Results: Of 31 patients enrolled, 28 were evaluable for response to 
combination therapy, with a recommended phase II dose of erloti-
nib 150 mg daily for a 2-week run-in and then foretinib 30 mg daily 
added. The overall response rate in the intent to treat population 
(RECIST 1.1) was 16.1% (95% CI 5.5-33.7%), with partial responses 
(PR) seen in 5/31 patients and a median response duration of 17.9 
months (range 3.6-17.9). Stable disease was seen in 42% (13/31), 
with a median duration of 4.8 months (95% CI 2.4-15.4). Tumour 
samples were submitted for 25 patients; 15 had sufficient tissue for 
genotyping, 17 for assessment of MET, and 16 for AXL expression. 
2/5 responding patients had confirmed EGFR mutations, (1 wild-
type, 2 unknown). Another 5 had KRAS mutations, one with >20% 
reduction in tumour size but SD by RECIST. Of 17 patients with 
MET IHC results, 71% (12/17) were positive. PR was seen in 3/12 
patients with MET-positive tumours, (2 with EGFR mutations, 1 
wildtype). No response was seen in those with MET-negative tu-
mours. Of 16 samples with AXL IHC results, 9 were positive (56%). 
PR was seen in 2/9 with AXL-positive tumours and 2/6 with AXL-
negative tumours. AXL expression was not seen in samples with 
EGFR mutations, but 3/5 KRAS mutant samples were AXL positive. 
Assessment of circulating HGF levels will be presented at the 2013 
WCLC meeting.
Conclusion: Baseline MET expression, uncontrolled for EGFR 
status, may be associated with response to combination erlotinib/
foretinib. No correlation between baseline AXL expression and 
response was seen although the sample size is small. Further study 
is needed to control for the impact of EGFR mutation status on 
response, and to assess whether combination erlotinib/foretinib 
can overcome resistance to EGFR TKI therapy mediated by MET 
and AXL.
Keywords: foretinib, Axl inhibitor, MET inhibitor,  
Phase I correlative
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MO12.05 A NEW BIOMARKER HEAT SHOCK PROTEIN 90 
ALPHA AS THERAPEUTIC MONITOR AND PREDICTOR 
FOR LUNG CANCER PATIENTS
Yuankai Shi1, Xiaoqing Liu2, Jiatao Lou3, Xiaohong Han1, Lijian 
Zhang4, Qingtao Wang5, Baolan Li6, Mei Dong7, Yinghong Zhang8
1Medical Oncology beijing Key Laboratory Of Clinical Study On Anti-
cancer Molecular Targeted Drugs, Department Of Medical Oncology 
Laboratory Cancer Institute/ Hospital Chinese Academy Of Medical 
Sciences(CAMS) & Peking Union Medical College(PUMC)/China, 2De-
partment Of Lung Cancer, Affiliated Hospital Of Academy Of Military 
Medical Sciences/China, 3Shanghai Chest Hospital/China, 4Beijing Can-
cer Hospital/China, 5Beijing Chao-yang Hospital/China, 6Beijing Chest 
Hospital/China, 7The 309th Hospital Of Chinese People’s Liberation 
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Background: Heat shock proteins are a group of proteins termed 
stress proteins. The family of Hsp90 includes Hsp90α and Hsp90β, 
but only Hsp90α has been described to be extracellular, and the 
presence of Hsp90α on cell surface has been shown to correlate 
with malignancy in cancer patients, especially with the tumor me-
tastasis. However, to the best of our knowledge, no large clinical 
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Screened 
(n=1605) 
Enrolled 
(n=443) 
Age (years) 
n 1482 442 
Median 63.0 62.5 
Range 24–89 24–84 
Race 
n 1482 443 
White 1187 (80.1%) 316 (71.3%) 
Asian 185 (12.5%) 72 (16.3%) 
Black or African 
American 
44 (3.0%) 11 (2.5%) 
Sex 
n 1483 443 
Male 937 (63.2%) 244 (55.1%) 
Histology 
n 1451 440 
Non-squamous 1096 (75.5%) 374 (85.0%) 
MET IHC score 
n 1474 443 
3+ 162 (11.0%) 97 (21.9%) 
2+ 575 (39.0%) 346 (78.1%) 
1+ 619 (42.0%) 0 (0.0%) 
0 118 (8.0%) 0 (0.0%) 
EGFR activating 
mutation 
n 1422 443 
Yes 114 (8.0%) 46 (10.4%) 
No 1308 (92.0%) 397 (89.6%) 
Conclusion: In this large population, the prevalence of MET IHC 
2+/3+ was 50% in screened samples, consistent with prior IHC 
results for MET prevalence. The prevalence of MET IHC 2+/3+ was 
higher in non-squamous vs squamous tissue samples, but equally 
distributed across ethnicity and EGFR mutation status. The ongo-
ing OAM4971g study will prospectively confirm whether blocking 
MET signaling in patients with MET IHC 2+/3+ over-expressing 
NSCLC provides clinically meaningful benefit in all enrolled pati-
ents and in important clinical subpopulations.
Keywords: Immunohistochemistry, MET expression, NSCLC
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MO12.07 THE PREVALENCE OF MET EXPRESSION BY 
IMMUNOHISTOCHEMISTRY (IHC) IN THE METLUNG 
(OAM4971G) TRIAL: A RANDOMIZED, PLACEBO-CON-
TROLLED, PHASE III STUDY WITH ERLOTINIB + ONAR-
TUZUMAB (METMAB) VS ERLOTINIB + PLACEBO IN PA-
TIENTS WITH PREVIOUSLY TREATED NON-SMALL CELL 
LUNG CANCER (NSCLC)
Martin Edelman1, David Spigel2, Kenneth O‘Byrne3, Tony Mok4, 
Simonetta Mocci5, Wei Yu5, Virginia Paton5, Luis Paz-Ares Rod-
riguez6
1University Of New Mexico Cancer Center, University Of New Mexico 
Health Sciences Center/United States Of America, 2Sarah Cannon Re-
search Institute And Tennessee Oncology Pllc/United States Of Ame-
rica, 3Princess Alexandra Hospital/Australia, 4The Chinese University 
Of Hong Kong/Hong Kong, 5Genentech, Inc./United States Of America, 
6Instituto De Biomedicina De Sevilla (huvr, Us And Csic) And Hospital 
Universitario Virgen Del Rocio/Spain
Background: MET signaling is correlated with a poor prognosis in 
multiple tumor types, including NSCLC. A randomized, controlled, 
phase II clinical trial demonstrated a PFS and OS benefit of inhibi-
ting MET signaling with erlotinib + onartuzumab, a humanized mo-
novalent antibody to the MET receptor, in patients whose NSCLC 
over-expressed MET by IHC (in press). A phase III trial (OAM4971g) 
is ongoing to confirm the benefit of onartuzumab when combined 
with erlotinib in patients with previously treated NSCLC whose tu-
mors over-express MET by IHC (2+/3+ only). Here, we present the 
prevalence rates of MET expression and EGFR mutation status for 
patients whose tumor tissues were screened and for those enrolled 
in the phase III study.
Methods: Archival or fresh biopsy tumor specimens were submit-
ted to a central laboratory for both MET IHC and EGFR mutation 
assessment. MET IHC status was determined using the CONFIRM 
SP44 anti-MET monoclonal antibody (Ventana Medical Systems, 
Inc., Tucson, AZ). Patients were selected based on expression of 
MET by IHC, as defined by moderate or strong staining in at least 
50% of tumor cells (clinical score 2+/3+). The cobas®EGFR mutation 
test was used to stratify enrollment.
Results: Between November 2011 and June 2013, 1605 tumor 
tissue samples were submitted for MET IHC and EGFR activating 
mutation analysis, from 188 clinical study centers. The majority of 
screened and enrolled patients were over 60 years of age, Cauca-
sian, male, and had non-squamous NSCLC histology (see table). 
MET IHC results are available for 1474 (92%) of all submitted sam-
ples: IHC 0 (n=118, 8%), IHC 1+ (n=619, 42%), IHC 2+ (n=575, 39%), 
IHC 3+ (n=162, 11%). The incidence of MET IHC 2+/3+ in screened 
patient subgroups is as follows: non-squamous 52.5%; squamous 
29.2%; non-Asian 45.9%; Asian 48%; EGFR wild type 50.3%; EGFR 
mutant 57.5%. Table: Patient characteristics for screened and en-
rolled patients in the OAM4971g study  
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Patients’ characteristics
N (%)
Median age 65.6 (46-86)
Gender Male 48 (81.4)
Female 11 (18.6)
Smoking sta-
tus
Current 40 (67.8)
Former 18 (30.5)
Never 1 (1.7)
Performance 
status
0-1 44 (74.6)
2-3 15 (25.4)
Stage I-III 16 (27.1)
IV 43 (72.9)
 
Conclusion: HGF serum levels at diagnosis and changes during 
treatment are predictors of survival in patients with SCLC treated 
with standard first-line chemotherapy.
Keywords: serum levels, small cell lung cancer, Hepatocyte 
growth factor, Met
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MO12.09 BIM DELETION POLYMORPHISM IN ASIAN 
AND TREATMENT OUTCOME TO CHEMOTHERAPY IN 
ADVANCED NON-SMALL CELL LUNG CANCER
Jih-Hsiang Lee1, Yu-Lin Lin2, Wei-Hsun Hsu2, Hsuan-Yu Chen3, 
Yeun-Chung Chang2, Chong-Jen Yu2, Jin-Yuan Shih2, Pan-Chyr 
Yang2, Kuan-Yu Chen2, James C. Yang1
1Department Of Oncology, National Taiwan University Hospital/Tai-
wan, 2National Taiwan University Hospital/Taiwan, 3Academia Sinica/
Taiwan
Background: BIM deletion polymorphism was reported to be as-
sociated with poor outcome to epidermal growth factor receptor 
(EGFR) inhibitor in advanced non-small cell lung cancer (NSCLC) 
harboring mutant EGFR gene. Little is known whether BIM deletion 
polymorphism influences treatment outcome to chemotherapy in 
NSCLC.
Methods: We prospectively collect blood samples and clinical 
data from two independent cohorts of advanced NSCLC patients. 
The first cohort is composed of 52 patients who received first-line 
chemotherapies, and the second cohort is composed of 69 pa-
tients who received chemotherapy after front-line gefitinib. BIM 
deletion polymorphism was determined from blood using polyme-
rase chain reaction. EGFR gene was studied in 94 tumors and were 
classified as wild type, common EGFR mutation (deletion 19 or 
L858R), or other mutations.
Results: The median progression-free survival (PFS) to the first 
cohort and second cohort were 4.6 and 5.7 months, respectively 
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MO12.08 HEPATOCYTE GROWTH FACTOR (HGF) SERUM 
LEVELS PREDICT FOR OUTCOME IN PATIENTS WITH 
SMALL CELL LUNG CARCINOMA (SCLC)
Iria González1, Israel Cañadas2, Alvaro Taus1, David Casadevall1, 
Ana Isabel Luque1, Xavier Villanueva1, Ana Rovira2, Joan Albanell1, 
Edurne Arriola1
1Medical Oncology, Hospital Del Mar/Spain, 2Cancer Research Program, 
Imim/Spain
Background: Small cell lung cancer (SCLC) accounts for approxi-
mately 15% of lung cancers. Treatment for SCLC has not changed 
in recent years and no targeted therapy has shown an increase in 
survival. We have previouly shown that Met phosphorylation is an 
adverse prognostic factor in this disease, suggesting a potential 
interest of Met targeted therapies in the treatment of SCLC pati-
ents. The aims of our study were to evaluate serum levels of the 
Met ligand, the hepatocyte growth factor (HGF) in patients with 
SCLC and to assess the correlations with other clinical variables 
and survival.
Methods: This is a prospective study conducted between 2009 
and 2012. Serum samples were obtained from patients with SCLC 
at diagnosis, at first evaluation of response to standard chemothe-
rapy by computerized tomography (CT) and at progression/relapse 
(first event). HGF levels were assessed by ELISA using the Quanti-
kine commercial kit (R&D Systems, Minneapolis, MN). We evalua-
ted the association between HGF levels and clinical-pathological 
variables by the Mann-Whitney tests and with survival in univariate 
(log-rank test) and multivariate analysis (Cox regression), assuming 
a statistical significance of p <0.05.
Results: Fifty-nine patients were included in this study. Median 
follow-up was 11 months. Patients’ characteristics are summa-
rized in Table 1. The median serum HGF (range) at diagnosis, 
response and progression were 1750 pg/ml (651-9853), 1573 pg/
ml (593-8518) and 1461 pg/ml (553-12956), respectively. In 72.5% 
of cases HGF levels decreased after 3 cycles of chemotherapy 
(platinum+etoposide). From the response time point to progres-
sion, 50% patients showed an increase in the HGF levels. The 
median overall survival (OS) for the entire population was 11,8 
months(95% CI 6.4-14.8). The median OS for patients with high 
basal HGF (above 1750pg/ml) was 7,9 months vs 16,7 months for 
patients with basal HGF below the median. Patients whose HGF le-
vels increased at progression presented a decreased survival (9,23 
months) vs. those with a decrease (15,11 months) (p=0.032). In the 
multivariate analysis, PS> 1 (HR: 5.57, 95% CI 2.63-11.77 p < 0.001), 
stage IV (HR: 4.28, 95% CI 1.76-10.44 p = 0.001) and elevated HGF 
basal levels were independently associated with worse OS (HR: 
3.32, 95% CI 1.57-7.03, p =0.002).  
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MO12.10 ANALYSIS OF BIM DELETION POLYMORPHISM 
IN CHINESE PATIENTS WITH NSCLC
Jia Zhong, Jie Wang, Zhenxiang Li, Xiaodan Yang, Hua Bai, Jian-
chun Duan
Peking University Cancer Hospital/China
Background: Drug resistance significantly weakens the effect of 
treatment. BIM deletion polymorphism has emerged as a poten-
tial drug resistant biomarker. This study aimed at assessing the 
correlation of BIM deletion with the outcome of Epidermal growth 
factor receptor tyrosine kinase inhibitors(EGFR-TKIs ) and chemo-
therapy in Chinese NSCLC patients
Methods: 290 patients with advanced NSCLC who received EGFR-
TKIs and chemotherapy were included in this retrospective study. 
BIM deletion polymorphism and EGFR mutations were detected 
by Polymerase Chain Reaction (PCR) and denaturing high-perfor-
mance liquid chromatography (DHPLC) respectively.
Results: BIM deletion polymorphism occurs commonly in Chinese 
NSCLC patients (15.5%, 45/290). No associations were observed 
between BIM deletion polymorphism with clinicopathology cha-
racteristics including sex, smoking and EGFR mutation status. BIM 
deletion polymorphism predicts shorter PFS in Chinese patients 
with EGFR-mutant NSCLC received EGFR-TKIs (6.69 vs 8.47months, 
P=0.023). Meanwhile, we found that BIM deletion polymorphism 
is an effective predictor of short PFS in individuals with EGFR-
mutant NSCLC treated with pemetrexed contained chemotherapy 
(3.32vs5.30, P=0.012) or with second-/beyond-line Taxanes contai-
ned chemotherapy (1.53 vs 2.61months, P=0.025) However, In the 
EGFR-wild type group, the difference is not significant for the for-
mer two groups. patients with this deletion are prone to suffering 
serious adverse event (SAE) (4.5% vs. 15.6%, P=0.018). BIM dele-
tion lacks for correlation with OS. (21.87vs21.90months, P=0.627), 
even in the EGFR-mutant group.
Conclusion: BIM deletion polymorphism occurs in 15.5% Chinese 
NSCLC patients. BIM deletion polymorphism is a drug resistance 
biomarker for TKIs and chemotherapy in NSCLC. BIM deletion 
possibly affects OS, but not a decisive factor.
Keyword: NSCLC, BIM, deletion polymorphism, chemotherapy
(p=0.94). The PFS for tumors carrying wild-type, common mutant, 
and other mutant EGFR genes were 5.8, 4.4, and 7.2 months, res-
pectively (p=0.31). The BIM deletion polymorphism was detected 
in 19 samples (15.7%). The PFS of patients with normal BIM (solid 
line of the figure) and BIM deletion polymorphism (dashed line 
of the figure) were 5.6 and 3.5 months (p=0.03). BIM deletion 
was related to shorter PFS in tumors carrying mutant EGFR gene 
(p=0.006) but not those carrying wild-type or other mutant EGFR 
genes. A multivariate analysis suggested BIM deletion was an 
independent predictor for shorter PFS to chemotherapy (harzard 
ratio=2.71, p=0.003).  
variate hazard ratio p-value
BIM deletion 2.71 0.003
Male gender 1.57 0.04
stage IV disease 1.93 0.18
EGFR mutation 1.0 0.96
Old age 1.01 0.21
 
Conclusion: BIM deletion polymorphism is associated with shorter 
PFS to chemotherapy in advanced NSCLC.
Keywords: chemotherapy, non-small cell lung cancer, BIM deleti-
on, Prognosis
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MO13.01 DISEASE CONTROL RATE AT 8 WEEKS PRE-
DICTS SUBSEQUENT SURVIVAL IN PLATINUM-TREATED 
EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-
SCLC): A PATIENT LEVEL ANALYSIS OF SWOG TRIALS
Primo Lara1, James Moon2, Mary Redman2, Karen Kelly1, Jeffrey 
Allen3, Barbara Gitlitz4, Philip Mack1, David Gandara1
1Division Of Hematology And Oncology, UC Davis Comprehensive 
Cancer Center/United States Of America, 2Swog Statistical Center/
United States Of America, 3Humboldt Medical Specialties/United States 
Of America, 4University Of Southern California/United States Of 
America
Background: Disease control rate (DCR) – the sum of partial (PR) 
and complete response (CR) plus stable disease (SD) – is a signi-
ficant predictor of subsequent survival following platinum-based 
chemotherapy in patients with advanced non-small cell lung can-
cer (Lara, et al. JCO 2008). We evaluated whether this observation 
is also relevant in patients with platinum-treated ES-SCLC on inves-
tigational systemic therapy.
Methods: Updated patient-level data from recent SWOG trials in 
2nd and/or 3rd line ES-SCLC (S0802: topotecan + aflibercept; S0435: 
sorafenib; and S0327: PS-341) were pooled. Landmark analysis was 
performed among patients still alive at 8 weeks for overall survival 
(OS) measured from the 8-week landmark. Association of clinical 
prognostic factors (including age, sex, platinum sensitivity status, 
number of prior chemo, weight loss, and LDH, among others) with 
DCR was assessed using logistic regression. A Cox proportional 
hazards model was used to assess the associations between DCR 
at the landmark time and subsequent OS, adjusted for prognostic 
factors.
Results: 319 patients were included: median age = 63 years; male 
sex = 51%; PS 1 = 68%; weight loss > 5% = 29%; > 2 prior chemo = 
16%; and elevated LDH = 43%. Only 8 patients had PR by RECIST 
for an overall response rate of 2.5%. Disease control at 8 weeks 
was observed in 74 patients (8 PR + 64 SD), for a DCR of 23.2%. 
Bivariate analysis of OS from the 8-week landmark revealed that 
only DCR (Hazard Ratio [HR] 0.53, p<0.0001) and elevated LDH (HR 
1.69, p=0.001) were significantly associated with OS. Multivariable 
analysis showed that only DCR remained as an independent pre-
dictor of subsequent survival from the 8-week landmark (HR=0.58, 
p=0.002).
Conclusion: In this large 2nd- and 3rd-line ES-SCLC database, DCR 
at 8 weeks was found to be the strongest predictor of subsequent 
survival in patients receiving investigational therapy. Thus, DCR at 
8 weeks should be considered for use as a surrogate clinical trial 
endpoint to screen for drug activity against ES-SCLC. These results 
have critical implications in the design of future prospective trials 
in ES-SCLC.
Keywords: small cell lung cancer, disease control rate, prognostic 
factor
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MO12.11 THE PREDICTIVE ROLE OF COMMON BIM DE-
LETION POLYMORPHISM AND BIM EXPRESSION ON 
THE EGFR-TKI THERAPY IN NEVER-SMOKING LUNG 
ADENOCARCINOMA
Ji-Youn Han, Geon Kook Lee, Sung J. Yoon, Sae Rom Goo, Jin Soo 
Lee
Lung Cancer Branch Research Institute And Hospital, National Cancer 
Center/Korea
Background: The BCL-2 homology domain 3 (BH3)-only protein, 
B-cell lymphoma 2 interacting mediator of cell death (BIM) is a po-
tent pro-apoptotic protein. Recent data suggest that pretreatment 
BIM level may predict responsiveness to EGFR-TKI in EGFR-mutant 
non-small cell lung cancer (NSCLC). In addition, a common BIM de-
letion polymorphism contributes to the heterogeneity of response 
to EGFR-TKI in EGFR-mutant NSCLC. We investigated whether BIM 
expression and BIM deletion polymorphism (BIM-DEL) are predic-
tive for response rate (RR) and progression-free survival (PFS) to 
EGFR-TKI therapy in never-smoking lung adenocarcinoma (NSLA).
Methods: We analyzed EGFR mutation status by Sanger sequen-
cing, BIM-DEL genotyping by polymerase-chain reaction and BIM 
expression by immunohistochemistry using archival tissues or 
blood from 203 patients who participated in the FIRST-SIGNAL 
trial (1st line gefitinib vs. Gemcitabine/cisplatin in advanced NSLA).
Results: EGFR mutation test, BIM-DEL genotyping and BIM-IHC 
analysis were available in 82, 126 and 60 patients, respectively. 
Forty-five (55%) patients had EGFR mutations, 22 (18%) showed 
BIM-DEL and 22 (37%) showed negative BIM expression. BIM ex-
pression was significantly associated with EGFR mutation status; 
more patients with EGFR-mutant NSCLC showed negative BIM 
expression (48% vs. 21%, P=0.030). BIM-DEL was not associated 
with EGFR mutation status or BIM expression. Among 181 patients 
who received EGFR-TKI as 1st or 2nd-line therapy, EGFR mutation, 
BIM-DEL and BIM expression data were available in 74, 11, 56 pa-
tients, respectively. EGFR mutation was predictive for higher RR 
(66% vs. 15%, P<.001) and longer PFS (4.5 vs. 1.9 months, P=.061) 
to EGFR-TKI therapy. Negative BIM expression also showed a 
trend toward higher RR (68% vs. 42%, P=.061) and longer PFS (6.9 
vs. 2.3 months, P=.233) with EGFR-TKI. However, BIM-DEL was not 
predictive for RR (41% vs. 47%, P=.645) or PFS (3.5 vs. 3.7 months, 
P=.892) to EGFR-TKI.
Conclusion: Both BIM-DEL and BIM expression were not predic-
tive for responsiveness to EGFR-TKI in NSLA. The trend between 
negative BIM expression and favorable response to EGFR-TKI may 
be resulted from higher frequency of EGFR mutation in these pa-
tients.
Keywords: EGFR, NSCLC, BIM
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Further analysis is ongoing.
Keywords: small cell lung cancer, age, prognostic factors, elderly
SCLC I  
TUESDAY, OCTOBER 29, 2013 - 10:30-12:00
MO13.03 DURATION OF THORACIC RADIOTHERAPY 
WITH CONCURRENT CHEMOTHERAPY IS IMPORTANT 
FOR OUTCOME OF PATIENTS WITH LIMITED-STAGE 
SMALL CELL LUNG CANCER (L-SCLC)
Ritsuko Komaki1, Pamela Allen1, Xiong Wei1, Daniel R. Daniel1, 
John V. Heymach2, James W. Welsh1, Michael S. O‘Reilly1, Osamu 
Takahashi1, Steven H. Lin1, James D. Cox1
1Radiation Oncology, The University Of Texas MD Anderson Cancer 
Center/United States Of America, 2Thoracic/head & Neck Medical On-
cology, The University Of Texas MD Anderson Cancer Center/United 
States Of America
Background: A previous Intergroup study of L-SCLC showed that 
accelerated hyperfractionated thoracic radiotherapy (TRT) given 
over 3 weeks with concurrent etoposide and cisplatin (EP) led to 
improved 5-year survival rates compared with daily TRT given over 
5 weeks, albeit with higher rates of grade 3 acute esophagitis. 
We retrospectively compared the efficacy and toxicity of TRT with 
concurrent EP for L-SCLC given in <6 weeks (Group A) versus >6 
weeks (Group B).
Methods: A total of 577 patients with cytotogically or histologi-
cally biopsy proven L-SCLC (staged by chest/upper abdominal 
CT and brain MRI) received TRT+EP at a single institution in 
1985‒2009. Group A received 45 Gy in 30 fractions over 3 weeks 
(BED=52) or 28 fractions over 5 weeks (BED=43) or 61.2 Gy in 34 
fractions over 5 weeks (BED=72). Group B received a median 60 Gy 
in 6 weeks (BED=72). Cone-down fields were used routinely. Com-
plete responders received prophylactic cranial irradiation (PCI). 
Kaplan-Meier analysis was used to estimate survival, with log-rank 
tests used to compare survival curves; p values ≤0.05 were taken 
to indicate signifiance. Cox regression analysis was used for univa-
riate and multivariate analyses and toxicity was graded according 
to CTCAE v2.0.
Results: The median follow-up time for patients alive at the time 
of analysis was 32 months (range 1.2‒222 months); median age 
was 62 years (range 27–95); and 87% had Karnofsky Performance 
Status (KPS) scores of ≥80. Group A contained 503 patients and 
group B had 74. The groups did not differ in KPS, age, smoking 
history, or receipt of PCI. Group A was more likely to have received 
concurrent chemoTRT than sequential chemoTRT (p<0.001). At 5 
years, the overall survival (OS) rates were 26.1% for group A vs. 
14.1% for group B (p=0.077); disease free-survival (DFS) rates were 
31.6% (group A) vs. 13.5% (group B) (p=0.008); local-regional con-
trol (LRC) rates were 55.1% (A) vs. 36.2% (B) (p=0.077); and distant 
metastasis-free survival (DMFS) rates were 40.8% (A) vs. 20.0% (B) 
(p=0.008). No differences were found in rates of grade ≥3 acute 
esophagitis (17% group A vs.18% group B) or pneumonitis (4% 
group A vs. 3% group B). Group B had a higher rate of grade ≥3 
lung fibrosis (10% group A vs. 22% group B, p=0.01). Multivariate 
analysis showed that factors influencing worse DFS were recei-
ving TRT in more than 6 weeks (HR=1.46, p=0.008) and receipt of 
sequential rather than concurrent chemoTRT (HR=1.51, p=0.001); 
age <62 years (HR=0.99, p< 0.039) and receipt of PCI (HR=0.77, 
p=0.015) were associated with better DFS.
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MO13.02 AGE AS A PROGNOSTIC FACTOR IN SMALL 
CELL LUNG CANCER. A POOLED ANALYSIS OF RAN-
DOMIZED CLINICAL TRIALS FROM THE MANCHESTER 
LUNG CANCER GROUP (MLCG) AND THE UK MEDICAL 
RESEARCH COUNCIL CLINICAL TRIALS UNIT (MRC CTU).
Paul Wheatley-Price1, Elham Sabri2, Linda Ashcroft3, Shane 
White4, Paul Lorigan3, Nicholas Thatcher3, Fiona Blackhall3
1Medicine, University Of Ottawa / Ottawa Hospital Research Institute/
Canada, 2Clinical Epidemiology Program, Ottawa Hospital Research In-
stitute/Canada, 3The Christie NHS Foundation Trust/United Kingdom, 
4Joint Austin-ludwig Oncology Unit, Austin Health/Australia
Background: About 40% of all cases of small cell lung cancer 
(SCLC) occur in the over 70 year age group (70+), and 10% in pa-
tients aged over 80 years. A SEER database reports decreasing 
SCLC 5-year survival with age (7.1%, 3.9% and 2.2% in the <70, 70-
79 and 80+ age groups, respectively). However age has been in-
consistently reported as a prognostic factor in SCLC trials. Recently 
a series of randomized trials of chemotherapy (CT) in SCLC were 
pooled to analyze the prognostic impact of patient sex (Wheatley-
Price et al, Annals of Oncology 2009). We used the same dataset 
to investigate the impact of age.
Methods: Five randomized phase II and III CT trials, performed by 
the MLCG and MRC CTU between 1993 and 2005, were pooled 
for analysis (one study from the previous analysis was excluded 
as it did not contain elderly patients). One trial investigated a 
dose-dense approach and 4 trials compared CT regimens. The 
primary endpoints were overall survival (OS) in limited stage (LS) 
and extensive stage (ES) and the rates of haematological and non-
haematological toxicity.
Results: In total 1439 patients were included, of whom 45% were 
female and 36% had ES disease. The median age was 63 years 
(range 30-88), and 343 (24%) were 70+, and only 33 (2%) were 80+. 
Anthracycline-based CT was given in 61%, versus platinum-based 
CT in 38% of patients. More patients in the younger group had 
a good performance status (ECOG 0-1, Karnofsky 80-100); 65% 
versus 39% (p=0.0007). Baseline hyponatremia was present in 35% 
and did not differ by age group. Overall, median OS was signifi-
cantly longer in younger patients in univariate analysis (9.3 months 
versus 7.4 months; HR 0.79, 95% CI 0.66-0.95, p=0.01). By disease 
stage, median OS in LS patients was significantly longer in younger 
patients (HR 0.88, 95% CI 0.79-0.99, p=0.04), and a similar effect 
was observed in ES (HR 0.75, 95% CI 0.55-1.01, p=0.06). However 
in multivariate analysis (age, stage, sex, hyponatremia, anemia), 
factors significantly associated with longer survival were LS, female 
sex, good PS and absence of hyponatremia, but younger age was 
no longer prognostic (HR 0.96, 95% CI 0.86-1.08, p=0.52). The el-
derly were more likely to experience grade 3 or 4 leucopenia (52% 
versus 40%, p=0.0035), neutropenia (36% versus 31%, p=0.045) 
and thrombocytopenia (34% versus 22%, p=0.0003), but less likely 
to experience grade 3 or 4 emesis (8% versus 14%, p=0.022) or 
mucositis (5% versus 11%, p=0.021). There were no differences 
in infection rates or blood transfusion rates, although the elderly 
required more platelet transfusions (p<0.0001). The dose intensity 
(total number of CT cycles delivered divided by the planned num-
ber of cycles) was higher in the younger group (p<0.0001).
Conclusion: In a large pooled analysis of CT trials in SCLC, age 
was not a prognostic factor for survival. However the elderly ex-
perienced higher rates of grade 3 and 4 hematological toxicity. 
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and hypertension in 2. No deaths related to the study drug were 
observed.
Conclusion: These preliminary results show that pazopanib is an 
active and well tolerated drug in patients with sensitive SCLC. 
Recruitment in both cohorts is ongoing. A biomarker analysis is 
planned.
Keyword: Phase II, second line, Pazopanib, SCLC
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MO13.06 PROPHYLACTIC CRANIAL IRRADIATION FOR 
PATIENTS WITH SMALL CELL LUNG CANCER WITH 30 
GY IN 10 FRACTIONS - ANALYSIS OF EFFICACY AND 
SUBSET ANALYSIS OF NEUROCOGNITIVE IMPAIRMENT.
Subrata Saha1, Aloke G. Dastidar2, Subrata Chattopadhyay3, Pra-
senjit Chattopadhyay4
1Radiotherapy, Medical College Hospital And Apollo Cancer Hospital/
India, 2Radiotherapy, Institute Of Post Graduate Medical Education And 
Research/India, 3Radiotherapy, Medical College Hospital/India, 4Apollo 
Gleneagles Cancer Hospital/India
Background: Prophylactic cranial irradiation (PCI) plays crucial 
role to prevent brain metastasis for small cell lung cancer (SCLC) 
patients – both limited stage (LS) or extensive (ES) – who respond 
to initial therapy. For better quality-adjusted life expectancy and to 
avoid neurointellectual impairment (NIP), optimum dose and frac-
tionation for PCI needs to be explored, with due consideration to 
coexisting medical comorbidities that might enhance the adverse 
events, specially neurocognitive functions. Aim of the study was 
to find the safety and efficacy of PCI with the dose of 30 Gy/ 10 
fractions and to analyze its impact on NIP with special focus on any 
possible influence of these medical comorbidities.
Methods: This is an on-going single arm multicentric trial initiated 
in November 2010 where both LS- as well as ES-SCLC patients 
who responded to initial therapy and were not having any visceral 
metastasis are offered PCI for a dose of 30 Gy in 10 fractions with 
CT-based planning. All patients received Platinum + Etoposide for 
6 cycles. LS-SCLC patients received, in addition, concomitant tho-
racic radiation after 2 cycles of chemotherapy. To minimize neuro-
psychological impairment, at least 2 weeks gap is given before 
PCI and after completion of all chemotherapy to avoid entry of 
more chemotherapeutic agent into brain parenchyma by way of 
radiation induced permeability alterations. All relevant medical 
comorbidities (Diabetes, Hyperlipidimia, previous history of 
CVA) are recorded. Neuropsychological screening measure of 
immediate and delayed verbal memory by using Hopkins Ver-
bal Learning Test - Revised (HVLT - R), assessment of cognitive 
function using Mini-Mental Status Examination (MMSE) and 
Instrumental Activities of Daily Living (IADL) questionnaires are 
applied before initiation of PCI and on follow up .
Results: Result of first 38 patients receiving PCI (LS- SCLC = 28, 
ES-SCLC = 10) with minimum duration of follow up of 18 months 
is being presented. Brain metastasis, in spite of PCI was faced by 
0/28 of LS and 1/10 of ES-SCLC. Median duration of survival was 
8.5 months for ES and 14 months for LS-SCLC. 1/10 ES-SCLC and 
16/28 LS-SCLC lived one year. Corresponding data for 18 months 
is 0/10 and 4/28 respectively. MMSE deterioration was noted in 
12/38 patients. Subset analysis of these 12 patients revealed 8/12 
Conclusion: TRT given with concurrent EP over periods longer 
than 6 weeks led to lower rates of DFS, worse local and distant 
disease control, and higher rates of severe lung fibrosis. Factors as-
sociated with better DFS were younger age, concurrent chemoTRT, 
and use of PCI. Rates of acute grade ≥3 esophagitis and pneumo-
nitis were low in both groups. Final recommendations await the 
results of an ongoing prospective randomized trial.
Keyword: Thoracic Radiotherapy, Concurrent Chemotherapy, 
Limited-stage, Small Cell Lung Cancer
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MO13.04 A PHASE II TRIAL OF SECOND LINE PAZOPA-
NIB IN SMALL CELL LUNG CANCER (SCLC) PATIENTS: 
PRELIMINARY RESULTS IN PATIENTS WITH SENSITIVE 
DISEASE
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62nd Department Of Medical Oncology, Metaxa Hospital, Piraeus/
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Background: Pazopanib, a small molecule competitive inhibitor of 
the tyrosine kinase of VEGFR1, VEGFR2, VEGFR3, PDGF, and ckit 
has been approved for the treatment of renal cell carcinoma and 
soft tissue sarcoma. Microvessel density and VEGF expression in 
SCLC tumor samples correlate with development of metastases 
and poor prognosis. A phase II trial of pazopanib in SCLC patients 
who have relapsed after, or have refractory disease to front-line 
chemotherapy was conducted.
Methods: This is a two-cohort, non-randomized, two-stage phase 
II study. Patients with sensitive (cohort A) and resistant/refractory 
(cohort B) histologically confirmed SCLC are enrolled onto the 
study. An interim analysis has been planned after enrolment of 19 
patients in each cohort. Eligible patients have to have measurable 
disease (RESIST) and ECOG performance status (PS) 0-2. Up to 1 
prior regimen (cisplatin/etoposide) for extended disease is allo-
wed. Treatment consists of daily pazopanib 800 mg given p.o.q28 
days, until disease progression. The primary endpoint is progressi-
on-free rate with a planned sample size of 39 eligible patients per 
cohort.
Results: We present the first interim analysis in cohort A. 19 eli-
gible patients have been enrolled with a median age of 67 years 
(range 46-77); male 16; PS 0, 10 pts; PS 1, 9 pts. Four patients had 
only local relapse. Four (21%) partial responses and 8 (42%) stable 
disease were documented which is translated in a disease control 
rate (DCR) of 63% (95% CI: 41.5- 85%). The median PFS was 4.3 
months and the estimated 1-year survival 58%. Grade 4 neutrope-
nia and diarrhea occurted in 1 patient each; other grade 3 adverse 
events were fatigue (n=2), nausea (n=1); grade 2 hypertransamina-
semia occurred in 2 patients, grade 1 hemorrhage (epistaxis) in 3 
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likely known before resection than for the subgroup of 267 “inci-
dental” cases, where the SCLC diagnosis was likely to have been 
made after resection.
Conclusion: These data serve as a natural experiment testing the 
survival after surgical management of SCLC according to NSCLC 
principles. SCLC patients treated surgically for early stage disease 
may have survival outcomes that approach those of NSCLC, sup-
porting the emerging clinical practice of offering surgical resection 
to selected SCLC patients.
Keyword: small cell lung cancer, surgery, epidemiology
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MO13.08 A PILOT STUDY OF ADJUVANT CHEMOTHERA-
PY WITH IRINOTECAN AND CISPLATIN FOR COMPLETE-
LY RESECTED HIGH GRADE PULMONARY NEUROENDO-
CRINE CARCINONA (LARGE CELL NEUROENDOCRINE 
CARCINOMA AND SMALL CELL LUNG CANCER)
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Background: Large cell neuroendocrine carcinoma (LCNEC) and 
small cell lung cancer (SCLC) are recognized as high grade neuro-
endocrine carcinoma (HGNEC) of the lung. In patients with com-
pletely resected HGNEC, platinum-based adjuvant chemotherapy 
may be considered. However, the optimum chemotherapy regimen 
has not been determined. We conducted a multicenter single-arm 
phase II trial to evaluate irinotecan and cisplatin in postoperative 
adjuvant chemotherapy for HGNEC patients.
Methods: Patients with completely resected stage I- IIIA HGNEC 
received 4 cycles of irinotecan (60 mg/m2, day 1, 8, 15) plus cispla-
tin (60 mg/m2, day 1). This regimen was repeated every 4 weeks. 
Other eligibility criteria included ECOG PS 0–1, age 20, and <75 
years old, adequate organ function, and no prior chemotherapy 
or radiotherapy. Patients with UGT1A1 polymorphisms (homozy-
gous for *6 or *28, or simultaneously heterozygous *6 and *28), 
associated with irinotecan-related severe toxicity, were excluded. 
The primary endpoint was the rate of completion of chemotherapy 
(defined as underwent 3 or 4 cycles), and secondary endpoints 
were 3-year relapse free survival (RFS), rate of 3-year survival and 
toxicities.
Results: Forty patients were enrolled between September 2007 
and April 2010. Patients’ characteristics were as follows: median 
age (range) 65 (45-73) years; male 85%; ECOG-PS 1 60%; LCNEC 
57% and SCLC 43%; stage IA/IB/IIB/IIIA 32/35/8/5%; 95% received 
are having long standing diabetes and another 2/12 had both dia-
betes and hyperlipidimia. HVLT decline in immediate recall (13/38) 
was in 10/12 patients having MMSE deterioration and 9 out of the-
se 12 had delayed recall deterioration also. So NIP (as evidenced 
by HVLT) was found in 10/14 diabetic patients receiving PCI, 
contrary to 3/24 non-diabetics (P = 0.0004).
Conclusion: 30Gy/ 10 fractions is an effective PCI protocol for 
both LS and ES – SCLC. But patients with medical comorbidities, 
specially long standing Diabetes (and may be hyperlipidaemia) are 
more prone to develop impairment of neurocognitive functions 
(possibly due to presence of cerebral microinfarcts and lacunar in-
farcts) and deserve special attention and should be treated possib-
ly with lower dose / fraction size less than 3 Gy. Further study with 
more patient accrual is required to arrive at a definite conclusion.
Keywords: PCI, Neurocognitive function, SCLC
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Background: Chemotherapy or chemoradiotherapy is the re-
commended treatment for small cell lung cancer (SCLC) except in 
stage I disease where clinical guidelines state there may be a role 
for surgery based on favourable outcomes in case series. Evidence 
supporting adjuvant chemotherapy in resected small cell lung 
cancer is limited but this is widely offered.
Methods: Data on 359,873 patients who were diagnosed with a 
first primary lung cancer in England between 1998 and 2009 were 
grouped according to histology (SCLC; non-SCLC [NSCLC]) and 
whether they underwent a surgical resection. We explored their 
survival using Kaplan-Meier analysis and Cox regression, adjusting 
for age, sex, comorbidity and socio-economic status.
Results: The survival of 465 resected SCLC patients was lower than 
resected NSCLC patients (five-year survival 31% and 45%, respec-
tively), but much higher than patients of either group who were not 
resected (3%). The difference between resected SCLC and NSCLC 
diminished with time after surgery. Survival was superior for the 
subgroup of 198 “elective” SCLC where the diagnosis was most 
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had 2 lines, 11% had 3 lines of therapy and 4% had 4 lines or more. 
The agents most commonly used in each line of therapy are below: 
Table 1: Chemotherapy agents by line of therapy in SCOT (% 
within the treatments of the line)  
AGENT/LINE FIRST SECOND THIRD > 3 
Platinum/Etoposide 90.7 26.8 14.5 10.5 
Topotecan 0.2 25.7 20.2 2.3 
Taxanes 2.1 9.3 21.7 26.3 
Cyclophosphamide 3.9 10.9 11.6 15.8 
Cyclo/Vincristine 3.9 12.0 11.6 15.8 
Vinorelbine 0.2 1.1 2.9 2.3 
Gemcitabine 0.0 2.2 0.0 6.8 
 
67 % of patients with LD received chemo + thoracic radiotherapy. 
PCI in the first 6 months was given in 26% of patients (LD 34% ED 
22%). Best overall response at 6 months in patients with combined 
chemoradiotherapy was PR=51%, CR=22%, SD=16%, PD=11%. 
Median overall survival (OS) was 10.6 months [95%CI 9.6, 12.1] with 
17.8mo for limited disease and 8.7mo for extended disease. Wes-
tern Europe and Korea showed OS of 11.5mo and 11.3mo respec-
tively whereas in Eastern European median OS was 9.1 months.
Conclusion: This observational study captured real world data of 
the current treatment paradigm of SCLC. Patients are commonly 
treated with etoposide/platinum or chemoradiotherapy as first line. 
The combination of platinum and etoposide remains by far the first 
choice of chemotherapy in 1st line and often at relapse, followed 
by topotecan starting from second line and beyond. Details on 
patterns of disease, treatment and efficacy by region and smoking 
status plus medical resource utilisation will be available at the mee-
ting.
Keyword: Small cell lung cancer, Platinum/Etoposide, chemora-
diotherapy
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OF SMALL CELL LUNG CANCER (SCLC) UTILIZING THE 
COMPREHENSIVE MUTATION ANALYSIS PROGRAM 
AT MEMORIAL SLOAN-KETTERING CANCER CENTER 
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Background: Oncogenic events in adenocarcinoma and squamous 
cell cancers of the lung are well described. In contrast, the reper-
toire of possible molecular targets in SCLC still is unclear. Recent 
studies using next generation sequencing on rare resected SCLC 
specimens have provided insights into the molecular heterogenei-
ty of this disease. Comprehensive, prospective molecular profiling 
lobectomy. The rate of completion of chemotherapy was 83% (90% 
C.I.; 71-90%). The rate of overall survival at 3 years was estimated 
at 81%, and of RFS at 3 years was 74%. The rates of overall survival 
and RFS at 3 years were 86% and 74% among 23 LCNEC patients, 
and 74%, 76% among 17 SCLC patients, respectively. Nineteen 
patients (48%) experienced grade 3 or 4 neutrophils, but only five 
patients (13%) developed febrile neutropenia. Two patients (5%) 
developed grade 3 diarrhea, and 4 patients (10%) had grade 3 
nausea. No treatment related deaths were observed in this study. 
All 40 specimens were also diagnosed as HGNEC at pathological 
central review among 7 pathologists. There were two specimens 
that showed the difference in between institutional diagnosis and 
central pathological diagnosis.
Conclusion: The combination of irinotecan and cisplatin as post-
operative adjuvant chemotherapy was feasible and possibly effi-
cacious for resected HGNEC.In Japan, a randomized phase III trial 
is ongoing to evaluate adjuvant chemotherapy of irinotecan and 
cisplatin, compared with etoposide and cisplatin, for completely 
resected HGNEC.
Keywords: high grade pulmonary neuroendocrine carcinona, ad-
juvant chemotherapy, small cell lung cancer, large cell neuroendo-
crine carcinoma
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Background: The SCOT registry is an international, multicenter, 
observational registry of newly diagnosed patients with SCLC. 
The treatment plan remained the responsibility of the patient’s 
physician and data collected in this registry reflect a "real world“ 
approach for the diagnosis and treatment of patients with SCLC.
Methods: 56 centers included 507 evaluable patients between 10th 
of November 2009 to 18th of August 2010. Participating countries 
are from Western Europe, Eastern Europe and Korea. Data has 
been entered into an electronic CRF via the internet.
Results: Mean age was 65.4 years, 73% of the patients were male, 
mean BMI was 25.5 Kg/m2. Smoking status showed 50% were 
current and 46% former smokers. The most common symptoms at 
presentation (>25%) were cough, dyspnea, weight loss and fatigue. 
Patients presented with an ECOG status of 0 (24%; 33% for limited 
disease (LD) and 19% for extensive disease (ED)), ECOG 1 (52%), 
ECOG 2 (19%) and ECOG 3 (5%). Histology was small cell carcino-
ma in 98% of patients and 66% presented with extensive disease. 
Chemotherapy alone was given to 59% of patients in the first 6 
months of treatment. 58% of patients had one line of therapy, 26% 
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Background: Radical pleurectomy is our standard approach for 
achieving a macroscopic complete resection in patients with mali-
gnant pleural mesothelioma undergoing surgery-based treatment. 
This procedure, not pneumonectomy, is performed even in the 
setting of advanced stage disease, bulky tumors and/or extensi-
ve involvement of the pulmonary fissures. Although the majority 
of patients subjectively rate their breathing as “good” after this 
operation we recently started measuring postoperative pulmonary 
function, reported herein.
Methods: We examined pre and postoperative FEV1 levels among 
27 patients undergoing radical pleurectomy: 2 stage I, 3 stage II, 
17 stage III, 5 stage IV.
Results: The figure shows pre/postoperative FEV-1. Median 
preoperative levels did not differ significantly between stages 
(P=0.25): 2.47 (Stage I/II) 2.19 (Stage III) and 1.68 (Stage IV) liters/
second. Post-operative median values were 2.16 (Stage I/II), 1.97 
(Stage III) and 1.05 (Stage IV) liters/second. The median (interquar-
tile range) decrease in FEV-1 was 0.28 (0.12, 0.51) liters/second, 
which corresponds to a median (interquartile range) decrease in 
percent predicted FEV-1 of 7% (4.5%, 16.0%), neither change being 
statistically significant between stages. 
of patients with SCLC using the biopsy specimens available in clini-
cal practice has not been performed.
Methods: Utilizing an IRB-approved protocol to prospectively test 
SCLC tumors (Small Cell Lung Cancer Mutation Analysis Program, 
“SCLC-MAP”), these biopsies are evaluated by: FISH for FGFR1 
and MET amplification; immunohistochemistry (IHC) for MGMT 
and PTEN loss; point mutation genotyping with Sequenom for PIK-
3CA (and others); and next-generation sequencing with our MSK-
IMPACT assay (Integrated Mutation Profiling of Actionable Cancer 
Targets). MSK-IMPACT uses exon capture followed by massively 
parallel sequencing to profile all protein-coding exons and select 
introns of 279 cancer-associated genes, enabling the identification 
of mutations, indels, and copy number alterations of these genes. 
First, we tested the feasibility of this approach in a series of SCLC 
patients that were identified retrospectively as they had banked 
matched tumor and normal pairs. We performed next generation 
sequencing with MSK-IMPACT, with findings confirmed by FISH 
on these samples. We are prospectively collecting and evaluating 
SCLC tumors of our patients in active treatment, as detailed above.
Results: For our feasibility cohort, we identified 21 patients with 
SCLC with FFPE samples available from both matched normal tis-
sue and small tumor biopsies. After histologic review and DNA ex-
traction, 10 patients had adequate tissue for MSK-IMPACT (3 core 
biopsies, 7 fine needle aspirates). The following were noted: recur-
rent mutations in Rb1 (N=7) and p53 (N=8), FGFR1 amplification 
(N=2), and MET amplification (N=1), using as little as 15 nanograms 
of DNA. FGFR1 and MET amplification were confirmed by FISH 
testing. We have initiated this prospective SCLC-MAP program 
for our SCLC patients undergoing active treatment. Since 2/2013, 
25 patients have provided consent and tumor tissue for analysis 
(8 surgical resections, 12 core biopsies, 3 lymph node dissections, 
2 fine needle aspirates). Preliminary data are available for 16 pati-
ents: AKT1 E17 mutation by Sequenom (N=1), MGMT loss by IHC 
(N=1); and PTEN loss by IHC (N=2).
Conclusion: As adequate biopsy specimens are necessary to 
match lung cancer patients and treatments, increased number of 
patients with SCLC are presenting with more tissue. Comprehen-
sive molecular evaluation of SCLC is feasible on clinically available 
specimens, as seen in our feasibility cohort. Prospective collection 
of SCLC tumor samples and mutational analyses are ongoing. Such 
analyses will allow us to characterize the molecular diversity of this 
disease and identify patients who will be candidates for targeted 
therapies. Funded, in part, by the Lung Cancer Research Found-
ation.
Keywords: SCLC, mutation analysis, Sequencing
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dings on CT and/or PET. 150 patients underwent laparoscopy (two 
5mm ports) with both peritoneal biopsy and lavage for cytology. 
130/150 laparoscopies were performed in virgin abdomens with 
the remainder being reoperative procedures. 18 patients also un-
derwent contralateral VATS, based upon any suspicious radiogra-
phic findings by either the interpreting radiologist or as reviewed 
by a multidisciplinary panel of treating physicians. All VATS were 
performed through a single 1 cm incision. Laparoscopies were per-
formed as outpatient procedures. Patients undergoing combinati-
on VATS/laparoscopy were scheduled as same day admissions.
Results: There were no operative complications for either proce-
dure. 5/132 (4%) laparoscopy patients scheduled as outpatients 
required overnight hospitalization – the most common reason 
being urinary retention. Laparoscopy revealed inaccuracies in ra-
diographic staging in 13/150 (9%) patients- 6 false positive studies 
(1 interpretation of diaphragm transgression that was not through 
the diaphragm and 5 metastases that were not present) and 7 false 
negative studies (3 detected by lavage and 4 by biopsy). All of the 
false positive and all of the false negative studies occurred in pati-
ents who had PET scans. 2/18 (11%) patients who underwent VATS 
were positive for mesothelioma in the contralateral pleura, only 
one of whom had a positive PET scan finding.
Conclusion: Routine laparoscopy was performed safely and re-
vealed inaccuracy in radiographic staging in 9% of the patients, all 
of whom had both CT and PET scans. Selective contralateral VATS 
was performed safely and revealed cancer in 11% of patients with 
suspicious findings, as determined by the interpreting radiologists 
and/or the treating clinicians and with PET only being accurate in 
one of the two positive findings. We conclude that prior to offering 
patients surgery-based treatment for MPM routine laparoscopy 
and VATS, based upon any suspicion, are indicated.
Keywords: mesothelioma, laparoscopy, staging
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Background: Malignant pleural mesothelioma (MPM) is an ag-
gressive disease of the pleural lining with a dismal prognosis of 
6 – 12 months from the time of diagnosis. Surgical treatment of 
MPM includes extrapleural pneumonectomy and pleurectomy/
decortication (P/D). Recently, IASLC has reclassified P/D according 
to therapeutic intent and surgical technique into partial P/D, P/D, 
and radical P/D. The present meta-analysis aimed to compare the 
perioperative and long-term outcomes of EPP and radical P/D for 
patients with resectable MPM.
Methods: A systematic review of the literature was performed on 
five electronic databases to identify all relevant data on compara-
tive outcomes of radical P/D and EPP. Endpoints included periope-
rative mortality and overall morbidity, as well as long-term overall 
survival.
Conclusion: These operations were conducted in an advanced 
stage cohort of patients, 81% stage III or IV. The nominal decrease 
in FEV1 corresponds with the subjective impression of the patients 
regarding their pulmonary function. While lung parenchyma is 
preserved with radical pleurectomy, we conjecture the decrease 
in FEV1 is likely related to compromise in breathing mechanics. 
Further studies are ongoing to better quantify and characterize the 
decrease in pulmonary function observed with this operation and 
to more rigorously integrate this information with formal quality of 
life assessments.
Keywords: radical pleurectomy, mesothelioma, pulmonary func-
tion
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Background: Surgery for malignant pleural mesothelioma (MPM) 
is typically restricted to patients without intraperitoneal or contra-
lateral pleural spread. Imaging studies are accompanied by both 
false positive and false negative errors for both types of spread. To 
avoid these errors our group has routinely performed laparoscopy 
and selective contralateral video-assisted thoracoscopy (VATS) 
since 1997.
Methods: 168 patients with MPM were evaluated for surgery as 
part of a multimodal treatment protocol. Radiographic staging stu-
dies included CT Chest with contrast for all 168 patients, PET Scan 
(112 patients) and MRI Abdomen (17 patients) for concerning fin-
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by two independent reviewers according to predefined selection 
criteria.
Results: Thirty-four studies involving 1916 patients who un-
derwent pleurectomy were included for quantitative analysis. 
These included 12 studies on ‘extended P/D’, 8 studies on 
‘P/D’ and 14 studies on ‘partial P/D’. Perioperative mortali-
ty ranged from 0% - 11% and perioperative morbidity ranged 
from 13% - 43%. Median overall survival ranged from 7.1 – 31.7 
months and disease-free survival ranged from 6 – 16 months. 
One study reported on quality-of-life outcomes using a stan-
dardized questionnaire suggesting superior outcomes for 
‘extended P/D’ compared to extrapleural pneumonectomy. 
Conclusion: Results of the present systematic review suggested 
similar perioperative mortality outcomes between different P/D 
techniques but a trend towards higher morbidity and length of 
hospitalization for patients who underwent ‘extended P/D’. Howe-
ver, overall and disease-free survival appeared to favour ‘extended 
P/D’ compared to less aggressive techniques. Future studies on 
P/D should adhere to recent definitions to enable accurate ana-
Results: Six relevant studies with comparative data of EPP (n= 
601) versus radical P/D (n=493) were identified from the current 
literature. Comparison of these two groups demonstrated sig-
nificantly lower perioperative mortality (3.0% vs 6.5%, p=0.04) 
and overall morbidity (30.4% vs 64.3%, p<0.0001) for patients 
who underwent radical P/D compared to EPP. Median overall 
survival ranged between 13 – 29 months for radical P/D and 12 
– 22 months for EPP, with a strong trend favouring radical P/D. 
Conclusion: Although it must be emphasized that patient selec-
tion and treatment strategies differ between EPP and radical P/D, 
a number of comparative studies have recently been conducted to 
compare these two surgical techniques for patients with resecta-
ble MPM. The present study indicated that appropriately selected 
patients who underwent radical P/D had lower perioperative mor-
bidity and mortality with similar, if not superior, long-term survival 
compared to EPP.
Keywords: Extrapleural pneumonectomy, radical pleurectomy, 
malignant pleural mesothelioma, Meta-analysis
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MO14.04 CURRENT EVIDENCE OF PLEURECTOMY 
 IN THE TREATMENT OF MALIGNANT PLEURAL  
MESOTHELIOMA
Christopher Cao, David Tian, Kristopher Pataky, Tristan D. Yan
Systematic Reviews Unit, Collaborative Research Group/Australia
Background: Pleurectomy/decortication (P/D) in the treatment  
of malignant pleural mesothelioma includes a number of procedu-
res with different clinical indications and therapeutic intents.  
To unify the nomenclature, IMIG and IASLC recently defined P/D-
related procedures according to surgical technique, including ‘ 
extended P/D’, ‘P/D’ and ‘partial pleurectomy’. The present  
systematic review aimed to assess the safety and efficacy of  
these techniques.
Methods: A systematic review of relevant studies was performed 
by electronic search of five online databases from 1985 to 2012 
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Diagnosis / symptoms CTC AE  grading
Number 
of  
patients
Related 
to  
Cisplatin
Fatigue Grade II 2 possible
Anemia Grade III 2 unlikely
Nausea / vomiting Grade I 1 possible
Increased kreatinin & urea 
levels
Grade II 1 possible
Increased CK levels Grade IV 1 unlikely
Increased level of transami-
nases
Grade III 1 unlikely
Urinary retention Grade II 1 unlikely
Hypotension Grade II 1 unlikely
Pneumothorax Grade II 1 unlikely
 
Conclusion: Our preliminary results show, that cisplatin-fibrin ap-
plication to the chest wall and the lung surface after P/D is safe on 
a dose level of 11mg/m2 BSA. As no treatment related mortality 
and no drug related toxicity was observed we escalate the dosage 
to 22 mg/m2 BSA, further results including chest wall concentra-
tions of cisplatin will be available in October.
Keywords: P/D, surgery, mesothelioma, intracavitary  
chemotherapy
lysis of similar procedures. Direct comparisons of pleurectomy to 
extrapleural pneumonectomy remain challenging, and should be 
restricted to ‘extended P/D’ procedures only.
Keywords: systematic review, IASLC, pleurectomy, mesothelioma
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MO14.05 INTRACAVITARY CISPLATIN-FIBRIN CHEMO-
THERAPY AFTER RESECTION FOR MALIGNANT PLEU-
RAL MESOTHELIOMA PATIENTS (INFLUENCE-MESO) 
- PRELIMINARY RESULTS
Isabelle Opitz1, Olivia Lauk1, Mayura Meerang1, Martina Friess1, 
Cordelia Bommeli1, Alexander Jetter2, Detlef Günther3, Rolf Sta-
hel4, Walter Weder1
1Division Of Thoracic Surgery, University Hospital Zurich/Switzerland, 
2Department Of Clinical Pharmacology And Toxicology, University 
Hospital Zurich/Switzerland, 3Department Of Chemistray And Ap-
plied Biosciences And Laboratory Of Inorganic Chemistry, Eth Zurich/
Switzerland, 4Laboratory Of Molecular Oncology, University Of Zurich/
Switzerland
Background: Local mesothelioma recurrence remains a challenge 
even after multimodal therapy. Intracavitary chemotherapy is a 
promising approach to improve local tumor control. In preclinical 
studies we observed improved pharmacokinetic characteristics 
when cisplatin was loaded to a fibrin carrier and applied to the 
chest wall after surgery while effectiveness remained the same 
compared to cisplatin applied as a solution. We will present the 
first results of a phase I –dose-escalation-clinical study.
Methods: Since 11/2012 3 patients were included in the study. 
Cisplatin-fibrin was applied after pleurectomy/decortication (P/D) 
to the chest wall in a concentration of 11 mg/m2 BSA. Blood samp-
les were taken at several time points after the application (2, 6, 10, 
24, 48 and 120 hours) to assess serum cisplatin levels and to test 
toxicity in the early phase until 14 days postoperatively. The con-
centration of total platinum was quantified by means of inductively 
coupled plasma sector field mass spectrometric detection. Adver-
se events were graded according to the CTCAE.
Results: Between November 2012 and March 2013 three patients 
(2x epithelioid, 1x biphasic) in stage II, III and stage IV were inclu-
ded and received P/D plus Cisplatin-Fibrin in a concentration of 11 
mg/m2. The maximum concentration of cisplatin in the serum was 
below 0.3 µg/g at 2 h after application and continued to decrease 
over a period of 5 days (see image 1). No severe adverse events 
were observed. The adverse events documented were not related 
to cisplatin (table 1):  
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a potential new prognostic factor for patients undergoing EPP. 
Further validation is needed, but this marker has the potential to 
assist in better selection of patients considered for radical surgery 
of MPM.
Keywords: microRNA, Prognosis, malignant mesothelioma, Extra-
pleural pneumonectomy
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MO14.08 VALIDATION OF A STAGE-INDEPENDENT 
PRE-OPERATIVE RISK ASSESSMENT ALGORITHM FOR 
PATIENTS CONSIDERING SURGERY FOR MALIGNANT 
PLEURAL MESOTHELIOMA.
William Richards1, Ritu R. Gill2, Beow Y Yeap3, Raphael Bueno1, 
David J. Sugarbaker1
1Surgery, Brigham And Women‘s Hospital/United States Of America, 
2Radiology, Brigham And Women‘s Hospital/United States Of America, 
3Massachusetts General Hospital/United States Of America
Background: We previously introduced a 3-level risk assessment 
algorithm based on tumor volume, gender and hemoglobin level 
(JTO 6:S486-7). Its applicability was limited to patients with epi-
thelial disease undergoing surgery. We now report an expanded 
4-level risk algorithm incorporating histologic subtype determined 
by pleural biopsy and interlobar septum thickness as additional 
predictors. We test its ability to stratify outcome among patients 
treated on a prospective phase I trial (protocol 07-091) of primary 
surgery and hyperthermic intraoperative intracavitary cisplatin plus 
dose-escalated gemcitabine.
Methods: All patients who underwent primary extrapleural pneu-
monectomy (EPP) or pleurectomy (PDC) between 2001-2012 with 
preoperative CT scan available for retrospective review were in-
cluded. Patients enrolled on 07-091 were reserved for validation; 
the remaining patients were used to train the model. Maximal 
thickness among measurable interlobar septae was measured on 
CT and binned into 2 categories (≤5mm, >5mm). Kaplan-Meier 
estimates of overall survival functions were used to define risk 
strata. Cox regression was used to assess algorithm stratification of 
overall survival and time to recurrence.
Results: The model cohort comprised 308 patients (221 EPP, 87 
PDC; 241 male; 244 epithelial histology on biopsy; median age 63). 
The validation cohort comprised 90 patients (53 EPP, 37 PDC; 70 
male; 53 epithelial histology on biopsy; median age 66). Alignment 
of survival functions after stratification of 3-level risk by septum 
thickness and biopsy histology in the model cohort suggested 4 
risk strata (A-D). The expanded algorithm stratified both model 
and validation cohorts into balanced groups with distinct overall 
survival and time to recurrence (Table).  
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MO14.07 ELEVATED TUMOUR EXPRESSION OF MIR-210 
IS ASSOCIATED WITH SHORT SURVIVAL IN MALIGNANT 
PLEURAL MESOTHELIOMA PATIENTS UNDERGOING 
EXTRAPLEURAL PNEUMONECTOMY
Michaela B. Kirschner1, Yuen Yee Cheng1, Steven Kao1, Brian Mc-
caughan2, Nico Van Zandwijk1, Glen Reid1
1Asbestos Diseases Research Institute/Australia, 2Cardiothoracic, Royal 
Prince Alfred Hospital/Australia
Background: Malignant pleural mesothelioma (MPM) is an aggres-
sive cancer with a median survival of around one year and a 5 year 
survival rate of less than 10%. A selected group of patients with a 
potentially resectable tumour mass and good performance status 
may be considered for extrapleural pneumonectomy (EPP). Howe-
ver the results of this form of treatment are variable. Several prog-
nostic markers have been explored to assist with patient selection 
including histological subtype, neutrophil-to-lymphocyte ratio 
(NLR), calretinin and microRNA miR-29c* expression in tumour 
tissue. In the present study we used microarray profiling to identify 
other microRNAs which might have the potential to serve as a pro-
gnostic biomarker.
Methods: The study used 60 formalin-fixed paraffin embedded 
(FFPE) tumour tissues from MPM patients who underwent EPP 
and had sufficient tumour for RNA extraction, a series which had 
been previously used to assess the prognostic value of the NLR. 
MicroRNA microarray profiling was performed on RNA from the 8 
patients with longest (median: 53.7 months) and the 8 patients with 
shortest (median: 6.4 months) survival. Candidate microRNAs were 
selected on a basis of biological (>2-fold difference) and statistical 
(p<0.05) significance, and selected candidates were independently 
validated in the initial profiling samples using TaqMan assay-based 
microRNA-specific RT-qPCR. Levels of validated candidates were 
then assessed by RT-qPCR in 44 additional tumour samples. Over-
all survival (OS) was calculated from date of EPP and date of death 
or last follow-up, with patients still alive at last follow-up censored. 
The median relative expression level of each candidate was used 
as cut-off to determine high and low expression for examination 
using the Kaplan-Meier method. Individually significant (p<0.05) 
variables were entered into a multivariate model together with the 
established risk factors age, gender, histological subtype, NLR.
Results: Microarray profiling identified 12 microRNAs with lower 
expression in long-term survivors and 4 microRNAs with higher 
expression in long-term survivors. None of the microRNAs with 
higher expression in long-term survivors could be validated using 
RT-qPCR. Of the microRNAs with lower expression in long-term 
survivors, miRs-30e, -93, -106b, -210, and -222 were validated by 
RT-qPCR in the same samples used for the profiling and found to 
be significantly different between long-term and short-term sur-
vivors. The expression levels of miR-30e and miR-210 showed a 
significant association with survival. MiR-30e: median OS of 24.2 
months for low expression vs 13.3 months for high expression 
(p=0.03); miR-210: median OS of 24.2 months for low expression vs 
13.7 months for high expression (p=0.008). In addition, both gen-
der and histological subtype were significant prognostic factors 
using a univariate model. Multivariate analysis with age, gender, 
histological subtype, NLR and microRNA expression included as 
variables revealed that miR-210 was the only factor remaining sig-
nificant (p= 0.006; hazard ratio: 0.41; 95% CI: 0.2-0.85).
Conclusion: This study has identified expression of miR-210 as 
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MO14.09 5-YEAR EXPERIENCE WITH ACCELERATED 
INDUCTION HYPOFRACTIONATED HEMITHORACIC 
INTENSITY MODULATED RADIATION THERAPY (IMRT) 
FOLLOWED BY EXTRAPLEURAL PNEUMONECTOMY 
(EPP) FOR MALIGNANT PLEURAL MESOTHELIOMA 
(MPM)
Marc De Perrot, Olaf Mercier, Ronald Feld, Natasha Leighl, Thomas 
Waddell, Andrew Hope, Kazuhiro Yasufuku, Shaf Keshavjee, By-
oung Chun J. Cho
Toronto General Hospital And Princess Margaret Cancer Centre/Canada
Background: Our experience in tri-modality therapy for MPM with 
induction chemotherapy followed by EPP and high dose hemitho-
racic radiation demonstrated that completion of EPP and radiation 
provided the best results. We therefore developed a new protocol 
of accelerated induction hypofractionated hemithoracic IMRT 
followed by EPP to deliver optimal radiation to the whole tumor 
bed in a short period of time. EPP is performed approximately one 
week after completion of radiation to limit the risk of pneumonitis. 
The results of Surgery for Mesothelioma After Radiation Therapy 
(SMART) was reviewed and compared to our previous cohort of 
patients undergoing induction chemotherapy followed by EPP and 
adjuvant hemithoracic radiation.
Methods: All patients undergoing EPP in our institution between 
01/2001 and 06/2013 were reviewed. The SMART protocol (25 Gy 
in 5 daily fractions over 1 week delivered to the entire ipsilateral 
hemithorax by IMRT with concomitant boost of 5 Gy to volumes at 
high risk based on CT and PET scan findings) was started in 2008. 
EPP was performed 6±2 days after radiation therapy. The results 
of the SMART protocol were compared to the group of patients 
undergoing induction chemotherapy followed by EPP as part of a 
trimodality approach.
Results: A total of 111 patients underwent EPP between 01/2001 
and 06/2013 with a hospital mortality of 4.5% (n=5). A total of 64 
patients (81% men, 59±9 years old, 81% with epithelial histologic 
subtype) underwent induction chemotherapy, while 39 (82% men, 
62±9 years old, 69% with epithelial histologic subtype) underwent 
SMART. Seven patients had no induction therapy and one had pre-
operative chemo- and radiation therapy. Since 2008, the number 
of surgical patients undergoing SMART progressively increased 
Overall Survival Time to recurrence
N median HR 95% C.I. median HR 95% C.I. 
Model 
risk A 82 40 mo 1.0 23 mo 1.0 
risk B 90 19 mo 2.1 (1.5-3.1) 9 mo 2.3 (1.6-3.2) 
risk C 87 12 mo 3.5 (2.4-5.1) 7 mo 3.3 (2.4-4.7) 
risk D 49 6 mo 8.7 (5.7-13.3) 3 mo 9.3 (6.1-14.1) 
Validation 
risk A 21 NR 1.0 21 mo 1.0 
risk B 26 30 mo 2.3 (0.9-6.0) 13 mo 1.4 (0.7-2.9) 
risk C 29 15 mo 5.2 (2.1-12.8) 10 mo 4.0 (1.9-8.1) 
risk D 14 9 mo 19.6 (6.8-55.6) 4 mo 9.0 (3.9-20.8) 
Conclusion: This expanded risk stratification algorithm is based 
on information available preoperatively for the majority of patients 
with pleural mesothelioma being considered for surgical resection. 
It provides important prognostic information that is not reflected in 
conventional clinical stage regarding the risks and potential bene-
fits of aggressive management for individual patients.
Keywords: mesothelioma, Prognosis, surgery
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Methods: Twenty-nine patients with locally advanced MPM have 
been enrolled to date. All patients received up to four cycles of 
pemetrexed/platinum chemotherapy. P/D was performed for all 
resectable patients. Sequential hemithoracic pleural IMRT was 
then administered with the intent of achieving a total planned dose 
of 50.4Gy in 28 fractions, as previously described (Rosenzweig et 
al., IJROBP 2012). All patients were simulated with a 4D-CT scan. A 
PET scan for image fusion and radiation planning was available for 
all patients. A Simon two-stage design was applied. A safety ana-
lysis after the first 9 patients led to the identification of only one 
case with ≥grade 3 RP in the first 3 months. The cohort was there-
fore expanded to 28 evaluable patients, defined as having initiated 
RT. The primary endpoint is the incidence of ≥grade 3 RP defined 
per Common Terminology Criteria for Adverse Events, v4.0. Stero-
ids are typically initiated for ≥grade 2 RP.
Results: To date, 21 out of 29 patients total are evaluable. The 
median follow-up is 10 months. The median age at diagnosis is 66 
years (range 38-79). Median KPS was 90% (range 70-90%). Three 
patients had sarcomatoid, 3 had biphasic and 23 had epithelioid 
MPM. All patients received chemotherapy. Eight patients (28%) 
had a partial response, nine patients (38%) progressed, and all 
others had stable disease. Twenty-four patients (83%) underwent 
surgical exploration. Five patients underwent an extended P/D or 
P/D, 11 had a partial P/D, and 8 were found to be unresectable. 
Eight patients were removed from the study prior to receiving 
IMRT (7 due to disease progression and 1 due to grade 4 pulmo-
nary embolism after one cycle of chemotherapy). To date, nineteen 
patients have completed IMRT [median dose 4680cGy (range 4500 
to 5040cGy)]; one patient had distant disease progression after 16 
fractions; one patient is currently on treatment. Five patients expe-
rienced grade 2 RP that was successfully controlled with steroids. 
One patient experienced grade 3 RP requiring supplemental oxy-
gen, but quickly improved after steroid initiation. Other commonly 
observed ≥grade 2 radiation-related toxicities included fatigue 
(37%), dyspnea (47%), nausea (42%), esophagitis (26%), and cough 
(11%). No grade 4 or 5 radiation-related toxicities were observed.
Conclusion: Hemithoracic pleural IMRT appears to have an accep-
table toxicity profile in this ongoing phase II study. Early interven-
tion with steroids is effective in controlling RP. This novel radiation 
technique has great promise as a component of lung-sparing 
multi-modality therapy in locally advanced MPM.
Keyword: Mesothelioma, pleural IMRT, lung-sparing,  
multimodality
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MO14.12 NEOADJUVANT HEMITHORACIC INTENSI-
TY MODULATED RADIOTHERAPY: THE "SMART“ AP-
PROACH FOR MANAGING MALIGNANT PLEURAL ME-
SOTHELIOMA
John Cho1, Andrew Hope1, Andrea Bezjak1, Anthony Brade1, Mere-
dith Giuliani1, Alexander Sun1, Elantholi Parameswaran Saibish-
kumar1, Marc De Perrot2
1Radiation Oncology, Princess Margaret Cancer Centre/Canada, 2Divisi-
on Of Thoracic Surgery, Toronto General Hospital/Canada
Background: Management of malignant pleural mesothelioma 
(MPM) remains controversial. After extra-pleural pneumonectomy 
(EPP) and adjuvant radiotherapy, many fail distantly (peritoneal 
from 14% in 2008 to 100% in 2013. None of the patients undergo-
ing SMART died in hospital or within 30 days of surgery, while 4 of 
the 64 patients (6.4%) undergoing induction chemotherapy died in 
hospital after EPP (p=0.1). Patients undergoing SMART tended to 
have a greater proportion of ypN2 disease on final pathology than 
patients completing induction chemotherapy before EPP (58% vs 
41%, respectively; p=0.09). After a median follow-up of 16 months 
after the start of therapy, the 3-year survival was significantly bet-
ter in patients with epithelial disease undergoing SMART (n=27) 
compared to patients with epithelial disease undergoing induction 
chemotherapy and EPP (n=52) (79% 3-year survival vs 30% 3-year 
survival, respectively; p=0.04). In contrast, the 3-year survival of 
patients with biphasic disease was similar between patients under-
going SMART (n=12) or induction chemotherapy and EPP (n=12) 
(20% vs 8%, respectively; p=0.8). Multivariate survival analysis 
using Cox regression model demonstrated that epithelial histolo-
gic subtype (p=0.0003), the absence of ypN2 disease (p=0.007) 
and SMART (p=0.03) were predictors of better survival.
Conclusion: Over the past 5 years, accelerated hemithoracic IMRT 
followed by EPP has become our preferred approach for surgically 
resectable MPM. Surgery for mesothelioma after radiation therapy 
was feasible with no operative mortality in 39 patients. Although 
comparison with our historical cohort of patients has limitations, 
our current protocol provides very encouraging results in patients 
with epithelial disease with a 3 year survival of 79%.
Keywords: mesothelioma, surgery, radiation, pneumonectomy
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MO14.11 SAFETY OF HEMITHORACIC PLEURAL INTEN-
SITY-MODULATED RADIATION THERAPY (IMRT) FOR 
MALIGNANT PLEURAL MESOTHELIOMA (MPM) IN THE 
MULTIMODALITY SETTING: INTERIM ANALYSIS OF A 
PHASE II STUDY.
Abraham J. Wu1, Marjorie G. Zauderer2, Daniel Gomez3, Kenneth 
E. Rosenzweig4, Amanda Foster1, Ellen Yorke5, David Rice6, Anne 
Tsao7, Valerie W. Rusch8, Lee M. Krug2, Andreas Rimner1
1Department Of Radiation Oncology, Memorial Sloan-Kettering Cancer 
Center/United States Of America, 2Department Of Medicine, Thoracic 
Oncology Service, Memorial Sloan-Kettering Cancer Center/United Sta-
tes Of America, 3Radiation Oncology, The University Of Texas MD An-
derson Cancer Center/United States Of America, 4Radiation Oncology, 
Mount Sinai Medical Center/United States Of America, 5Department Of 
Medical Physics, Memorial Sloan-Kettering Cancer Center/United States 
Of America, 6Thoracic & Cardiovascular Surgery, University Of Texas 
MD Anderson Cancer Center/United States Of America, 7Thoracic/
head & Neck Med Onc, The University Of Texas MD Anderson Cancer 
Center/United States Of America, 8Thoracic Surgery, Memorial Sloan-
Kettering Cancer Center/United States Of America
Background: Pleurectomy/decortication (P/D) is increasingly used 
for the surgical management of MPM. The presence of the remai-
ning ipsilateral lung poses a challenge when delivering adjuvant 
radiation therapy, as the risk for radiation pneumonitis (RP) is high. 
We developed an IMRT technique targeting the entire pleura of 
the involved hemithorax, with promising early results. Here, we 
present the interim results of a prospective phase II study to deter-
mine the safety and toxicity profile of pleural IMRT following induc-
tion chemotherapy and P/D.
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MO15.01 PATHWAY ACTIVATION MAPPING OF KRAS 
WILD TYPE AND MUTATED ADENOCARCINOMAS OF 
THE LUNG: NEW IMPLICATIONS FOR PATIENT STRATIFI-
CATION FOR MAP KINASE PATHWAY INHIBITION
Elisa Baldelli1, Eric B. Haura2, Lucio Crino3, W Douglas Cress2, Vi-
enna Ludovini3, Matthew B. Schabath4, Guido Bellezza5, Jacopo 
Vannucci6, Valentina Tassi6, Lorenza Pistola3, Francesca R. Tofa-
netti3, Antonella Flacco3, Annamaria Siggillino3, Lance A. Liotta1, 
Emanuel F. Petricoin1, Mariaelena Pierobon1
1Center For Applied Proteomics And Molecular Medicine, George Ma-
son University/United States Of America, 2Thoracic Oncology, H. Lee 
Moffitt Cancer Center And Research Institute/United States Of Ame-
rica, 3Medical Oncology, Santa Maria Della Misericordia Hospital/
Italy, 4Cancer Epidemiology, H. Lee Moffitt Cancer Center And Research 
Institute/United States Of America, 5Institute Of Pathological Anatomy 
And Histology, University Of Perugia/Italy, 6Department Of Thoracic 
Surgery, University Of Perugia/Italy
Background: KRAS proto-oncogene is one of the most frequent 
mutated genes in Non-Small Cell Lung Cancer (NSCLC) with grea-
ter incidence among adenocarcinomas (AD). While the clinical im-
portance of KRAS mutation as a negative predictor for anti-EGFR 
therapy is not clearly understood in NSCLCs, selection of targeted 
therapies for KRAS mutated (MUT) patients has often focused on 
the inhibition of its direct downstream effectors. The aim of this 
study was to explore the impact of the KRAS status on the cellular 
signaling network of ADs of the lung harboring different KRAS 
mutations with a focus on ERK signaling architecture.
Methods: A total of 58 AD samples were collected from chemo-
naïve patients at the H. Lee Moffitt Cancer Center & Research In-
stitute (Tampa, FL) and at S. Maria della Misericordia Hospital (Pe-
rugia, Italy). Twenty-four tumors were KRAS wild type (WT) and 34 
were KRAS MUT (G12C n=18, G12V n=9, G13D n=3 and G12D n=4, 
respectively). All samples were subjected to laser capture micro-
dissection and reverse phase protein microarray to quantitatively 
evaluate the activation status of the MAP Kinase signaling network.
Results: Statistical analysis of signaling protein activation based 
on KRAS status revealed an overall increase in activation level of 
the MAPK signaling network in the KRAS MUT tumors compa-
red to tumors expressing KRAS WT: ERK 1/2 (T202/Y204), Elk-1 
(S383), p90RSK (S380), Smad2 (S245/250/255) and p70S6K (p<0.01; 
p<0.01; p<0.01, p=0.04 and p<0.01 respectively). Nevertheless, 6 
KRAS WT patients (25%) showed activation of ERK greater than the 
median of the entire population and an overall MAPK signaling ac-
tivation comparable to tumors harboring KRAS MUT. Eleven of the 
KRAS MUT tumors (32%) had ERK activation lower than the median 
of the population as a whole. Interestingly a high activation level 
of Estrogen Receptor alpha (ERα) (S118) was detected in the KRAS 
MUT tumors compared to the KRAS WT one (p=0.02). Moreover 
the nonparametric test performed to establish the correlation of 
activated ERK 1/2, Raf, B-Raf, C-Raf and Mek 1/2 with the expres-
sion/activation levels of the 152 endpoints analyzed in this study, 
revealed the activation of distinct pathways in the KRAS MUT tu-
mors when compared to KRAS WT tumors. Significant correlations 
cavity, contralateral lung), possibly due to inadvertent tumour 
spillage at time of EPP. We hypothesize that neoadjuvant radiation 
followed by planned imminent EPP can limit the proliferation of 
clonogens spilt intraoperatively. The radiotherapy technique de-
veloped for the Surgery for Mesothelioma After Radiation Therapy 
(SMART) study is described.
Methods: We conducted a phase II prospective REB approved 
single cohort clinical feasibility study on surgically resectable stage 
T1-3N0M0 MPM. The pre-operative clinical target volume (CTV) 
was defined as the ipsilateral hemithorax, , including biopsy and 
drainage tract sites. The gross tumour volume (GTV) was defined 
as any tumour seen on imaging. The dose prescription to the CTV 
was 25 Gy in 5 daily fractions over approximately 1 week with a 
concomitant boost of 5 Gy to the GTV and tract sites. All patients 
underwent EPP within 1 week of completing the neoadjuvant RT. If 
ypN2 found, patients were offered adjuvant chemotherapy. Treat-
ment related toxicity was defined by the CTCAE v3.
Results: The accrual goal of 25 patients was completed between 
Nov 2008 and Oct 2012. All completed their intended RT and 
EPP. IMRT was well tolerated with only grade 1-2 toxicities noted 
(fatigue, nausea, and esophagitis). EPP was performed 6±2 days 
after completion of IMRT. Dosimetric values are shown in the table 
below. 
Dosimetric Parameter 
dose max (cGy) 3290.5 
CTV>2750 cGy (%) 95.5 
CTV>2300 cGy (%) 97.8 
PTV>2750 cGy (%) 93.3 
PTV>2300 cGy (%) 91.7 
LUNG>700 cGy 4.9 
LUNG mean (cGy) 315.0 
LIVER>1400 cGy (%) 45.3 
LIVER mean (cGy) 1371.8 
HEART>1400 cGy (%) 50.3 
HEART mean (cGy) 1473.7 
contra KIDNEY>750 cGy (%) 19.6 
contra KIDNEY mean (cGy) 318.1 
ipsi KIDNEY>750 cGy (%) 49.5 
ipsi KIDNEY mean (cGy) 561.6 
ESOPHAGUS 2880.1 
CANAL max (cGy) 2026.1 
prv3mmCANAL max (cGy) 2125.4 
 
Conclusion: Short neoadjuvant hemithoracic radiotherapy (30 
Gy in 5 daily fractions over 1 week) using the SMART protocol 
constraints are well tolerated. The SMART protocol is technically 
demanding, requiring very close and careful coordination and 
planning between the multiple disciplines.
Keyword: mesothelioma, neoadjuvant radiotherapy, extra-pleural 
pneumonectomy
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correlated with the KRAS mutation. On the other hand, mutations 
in STK11 were significantly more frequent in the KRAS-mutant 
cohort (p=0.004), as were mutations in ATM (p=0.023) and MTOR 
(p=0.045). The most significant positive association involved muta-
tions in ARHGEF11, a gene that encodes a Rho guanine nucleotide 
exchange factor (p=0.0004). Mutations in STK11 (29.4%) and TP53 
(29.4%), the two most highly prevalent genetic events within the 
KRAS-mutant cohort were mutually exclusive. Unsupervised hie-
rarchical clustering of transcriptomic and quantitative (phospho)
proteomic profiles revealed separation of STK11-mutant tumors at 
the first branch of the cluster dendrogram, indicating activation 
of distinct signaling pathways downstream of this key tumor sup-
pressor gene. Several less frequent genetic events had prominent 
and consistent effects on signaling output. We focused our atten-
tion on signaling via the MAPK pathway which may impact clinical 
sensitivity to MEK inhibitors, one of the most promising classes of 
targeted agents currently in clinical development for KRAS-mutant 
tumors. Preliminary analysis suggests that mutations in 3 individual 
genes can identify a subgroup of tumors (19% of the cohort) with 
profoundly suppressed MAPK signaling flux.
Conclusion: Analysis of recurrent secondary genetic events may 
define distinct and clinically relevant subsets of KRAS-mutant lung 
adenocarcinoma. Efforts to refine the sub-classification further 
and assess the impact of co-mutations on sensitivity to molecularly 
targeted agents are underway and updated results will be presen-
ted at the meeting.
Keywords: co-occurring mutations, lung adenocarcinoma, KRAS, 
STK11
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MO15.03 DECIPHERING THE RASSF1A SIGNALING PA-
THWAY IN LUNG CANCER CELLS REVEALS A METAS-
TASIS-SUPPRESSOR ROLE THROUGH YAP-DEPENDENT 
EPITHELIAL-MESENCHYMAL TRANSITION (EMT)
Gerard Zalcman1, Fatéméh Dubois2, Maureen Keller3, Emmanuel 
Bergot2, Alexander Hergovich4, Jacques Camonis5, Guénaëlle Le-
vallet2
1Respiratory Diseases And Thoracic Oncology, Caen University Hospi-
tal/France, 2“cancers Et Préventons“, Umr Inserm 1086/France, 3“can-
cers Et Préventions“, Umr 1086 Inserm/France, 4Ucl Cancer Institute, 
University College Of London/United Kingdom, 5U830 Inserm, Curie 
Institute/France
Background: RASSF1A gene promoter hypermethylation was 
previously shown to predict poor overall survival in the IFCT-0002 
randomized phase 3 trial of neo-adjuvant platinum-based chemo-
therapy, in early stage (I & II) NSCLC. We investigated the molecu-
lar and cellular basis for such a dramatic influence.
Methods: We studied isogenic immortalized bronchial, non-
tumorogenic, HBEC3 cell lines only differing by their K-Ras status 
(wild-type or mutant K-Ras Val12 allele), and a panel of lung cancer 
cell lines recapitulating the main molecular alterations encountered 
in lung cancer. RASSF1A protein was depleted by 80% using 2 
specific siRNAs, followed by the evaluation of EMT markers and 
cell motility regualors using qRT-PCR, Western blot or Immunofluo-
rescence. Migration of transfected cells was assayed by 2D wound-
healing migration assays or 3D migration assays using transwell 
devices with or without a matrigel coating mimicking basement 
were detected with Akt, KRAS, their downstream substrates and 
with several receptor tyrosine kinases (p<0.0003).
Conclusion: Our results suggest that MAPK signaling activation 
was clearly observed in KRAS MUT tumors. However, the hete-
rogeneity in the activation level of MAPK downstream substrates 
within KRAS MUT and WT tumors suggests that selection of pati-
ents for MAPK targeting might benefit from the evaluation not only 
of the mutation itself, but also from a direct analysis of the MAPK 
protein network architecture. In particular the role played by ERα 
in KRAS MUT tumors deserves further investigations as a possible 
novel therapeutic target in KRAS MUT adenocarcinomas of the 
lung.
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MO15.02 IMPACT OF CO-OCCURRING GENETIC EVENTS 
ON THE SIGNALING LANDSCAPE OF KRAS-MUTANT 
LUNG ADENOCARCINOMA.
Ferdinandos Skoulidis1, Lixia Diao2, Youhong Fan3, John D. Minna4, 
John N. Weinstein5, John V. Heymach1, Jing Wang5, Lauren A. By-
ers1
1Thoracic/head And Neck Medical Oncology, MD Anderson Cancer Cen-
ter/United States Of America, 2Bioinformatics & Computational Biology, 
The University Of Texas MD Anderson Cancer Center,/United States Of 
America, 3Thoracic/head & Neck Medical Oncology, The University Of 
Texas MD Anderson Cancer Center/United States Of America, 4Hamon 
Center For Therapeutic Oncology Research, The University Of Texas 
Southwestern Medical Center/United States Of America, 5Bioinforma-
tics & Comp Biology, The University Of Texas MD Anderson Cancer 
Center/United States Of America
Background: Personalized medicine frameworks centered on 
identification and therapeutic targeting of dominant oncoge-
nic driver mutations are rapidly becoming a standard of care in 
the clinical management of patients with lung adenocarcinoma. 
However, little is currently known about the nature and impact of 
co-occurring genetic events on signaling output downstream of 
initiating oncogenes. This lacuna in our understanding is parti-
cularly pertinent for the subgroup of KRAS-driven tumors, where 
mounting data point towards considerable heterogeneity in 
pathway activation and clinical response to targeted therapies. 
Here, we report a comprehensive analysis of genetic events that 
co-occur with or are mutually exclusive of mutant KRAS in a cohort 
of 230 lung adenocarcinomas and assess the impact of individual 
co-mutations on signaling streams using data derived from state of 
the art transcriptomic and (phospho)proteomic profiling of primary 
tumors.
Methods: An integrated analysis of 230 lung adenocarcinomas 
from The Cancer Genome Atlas (TCGA) consortium was perfor-
med using mutation (whole exome sequencing), transcriptomic 
(RNASeq), and proteomic (reverse phase protein array) datasets. 
Fischer’s exact test was applied to identify secondary mutations 
that occurred more frequently in either KRAS-mutant (n=68) or 
KRAS-wild-type (n=162) tumors and (phospho)protein markers that 
associated with each co-mutation. Genes with a mutation rate of 
≥3% in the overall cohort were included in the analysis.
Results: Mutations in 18 genes were associated with KRAS mu-
tational status in patient tumors (p≤0.01). Mutations in EGFR 
(p=0.0001), NF1 (p=0.001), and TP53 (p=0.001) were negatively 
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pression is associated with reduced patient survival, suggesting re-
duced Hic1 expression is associated with malignant progression of 
NSCLC. However, whether Hic1 silencing is causal in lung cancer is 
not known. Hic1 is a transcriptional repressor that can regulate p53 
function by repressing the expression of SIRT1, a class III histone 
deacetylase. We therefore hypothesized that loss of Hic1 function 
could cooperate with an oncogenic mutation in KRas (KRasG12D) 
to promote lung cancer initiation and/or progression in a similar 
fashion to genetic deletion of p53.
Methods: To address this question, we used a conditional genetic 
mouse model of lung adenocarcinoma in which administration of 
recombinant adenovirus expressing Cre can trigger recombination 
at loxP sites. When virus is administered to mice heterozygous for 
a conditional KRasG12D allele, mice develop multiple lung adeno-
mas that progress to adenocarcinomas over 8-12 weeks. To test 
the function of Hic1 as a tumour suppressor, we created a condi-
tional knockout mouse allele (Hic1lox), in which loxP sites flank the 
single coding exon.
Results: Following administration of Cre adenovirus, mice carrying 
the KRasG12D allele and homozygous for the Hic1lox allele, deve-
loped aggressive lung adenocarcinomas at a markedly accelera-
ted rate and had a significantly shortened survival compared to 
KRasG12D animals. Remarkably, these tumours exhibited a highly 
malignant phenotype with highly proliferative micropapillary and 
pleomorphic features.
Conclusion: These data show that loss of Hic1 function can subs-
titute for p53 mutation as a cooperating event in lung adenocar-
cinoma progression. Since the highly aggressive phenotype of 
KRasG12D/Hic1lox/lox lung tumours has not been reported in the 
KRasG12D/p53lox/lox lung cancer model, we speculate that Hic1 may 
function as a tumour suppressor beyond the regulation of p53 
through Sirt1.
Keywords: lung adenocarcinoma, Hic1, mouse models, tumour 
suppressor gene
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MO15.05 ONCOGENIC ARAF MUTATION IN LUNG ADE-
NOCARCINOMA
Marcin Imielinski1, Heidi Greulich1, Bethany Kaplan1, Luiz Araujo2, 
Joseph Amann2, Leora Horn3, Miguel Villalona-Calero2, Matthew 
Meyerson1, David P. Carbone2
1Dana Farber Cancer Institute/United States Of America, 2James Tho-
racic Center, The Ohio State Wexner Medical Center/United States Of 
America, 3Dept. Of Medicine/division Of Hematology-Oncology, Vander-
bilt University/United States Of America
Background: Targeted cancer therapies often induce “outlier” 
responses in molecularly defined patient subsets.
Methods: One patient with advanced-stage lung adenocarcinoma, 
who was treated with oral sorafenib, demonstrated a complete 
clinical and radiographic remission for five years. Whole genome 
sequencing (WGS) and RNA sequencing (RNA-seq) on primary 
tumor and normal samples from this patient was performed.
Results: We identified a somatic mutation, ARAF S214C, present 
in the cancer genome and expressed at high levels. Additional 
membrane (invasion assay), or an endothelial cell monolayer (trans-
endothelial cell invasion). Phenotypic rescue was studied by using 
plasmids encoding full-length RASSF1A or RASSF1C isoform, and a 
construct encoding a SARAH-deleted RASSF1A protein, unable to 
interact with the Hippo/MST kinase. We also tested co-transfection 
of RASSF1A siRNAs together with siRNAs directed against Hippo 
pathway members LATS1/2, WW45, YAP. Depletion of RASSF1A 
was finally combined with expression of wild-type, activated or 
dominant negative RhoA, RhoB, Rac1 or CDC42 constructs.
Results: In each bronchial/lung cancer cell line tested, RASSF1A 
silencing led to EMT resulting in E-cadherin, Syndecan1, Zo-1, 
miR200 decrease and concurrent N-cadherin, vimentin, Twist1, 
miR-21 increase. RASSF1A silencing-induced EMT was associated 
with cytoplasmic to nucleus translocation of YAP transcription fac-
tor, the terminal effector of the Hippo signaling pathway. RASSF1A 
silencing reduced cell adhesion and increased 2D cell motility 
with collective migration features. RASSF1A knock-down increa-
sed 3D migration, invasion as trans-endothelial migration. These 
effects correlated with the up-regulation of RhoA, RhoC, CDC42, 
MMP2/14 mRNAs and down-regulation of RhoB, DIA1 and MMP9 
mRNAs. We also observed an increase of adhesion/invasion sig-
naling proteins, i.e. CD44v6, cofilin, ERM and NF2, cofilin being 
activated by inhibition of LIMK-induced phosphorylation. Finally 
we report that immortalized non-tumorogenic cell lines, unable to 
grow without adhesion, acquired the capacity to grow in soft agar 
when RASSFIA was knocked-down. Those effects were rescued 
by co-transfection of RASSF1A siRNAs with full-length RASSF1A 
cDNA, showing the specificity of the motile phenotype induced 
by RASSF1A silencing, but not by RASSF1C nor SARAH-deficient 
RASSF1A plasmids. SiRASSF1A-induced cell migration was in-
hibited by LATS1/LATS2/WW45 or YAP siRNAs, showing the in-
volvement of the Lats/YAP signaling cascade. We finally show that 
RASSF1A knockdown-promoted migration was inhibited by using 
RhoB-Val14 constitutively active cDNA but not RhoBN19 dominant 
negative construct, and by specific RhoB GEFs or RhoB effectors 
(DIA1) constructs.
Conclusion: In lung cells, the RASSF1A protein acts as a migration-
suppressor protein by regulating the LIMK/cofilin pathway through 
RhoB signaling. RASSF1A prevents YAP induced EMT by inhibiting 
its nuclear accumulation through LATS1/2 signaling, whereas Hip-
po/MST kinase seemed dispensable. We thus provide evidence, 
for the first time in human lung cancer cells, for a direct connection 
between RASSF1A signaling and the LATS/YAP pathway.
Keywords: RASSF1A, NSCLC, metastasis-suppressor, RNA inter-
ference
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MO15.04 LOSS OF TUMOR SUPPRESSOR HIC1 ACCELE-
RATES THE PROGRESSION OF LUNG ADENOCARCINO-
MA INDUCED BY ONCOGENIC KRAS
Anette Szczepny, Samantha Jayasekara, Amali Mudiyanselage, 
David Neil Watkins
Centre For Cancer Research, Monash Institute Of Medical Research/
Australia
Background: Hypermethylated in Cancer-1 (Hic1) is a novel tumour 
suppressor gene that is frequently epigenetically silenced in adult 
tumours. In non-small cell lung cancer (NSCLC), loss of Hic1 ex-
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centimeter ground-glass nodules. The fourth proband has no fa-
mily history of lung cancer, suggesting variable penetrance or a de 
novo germline event. All cancers in germline T790M carriers have 
also harbored secondary EGFR kinase domain mutations.
Conclusion: Using a novel trial design, including remote accrual, 
genetic counseling by phone, and germline testing by mail, we 
have begun collecting a sizeable cohort of families affected by 
germline EGFR mutations. By leveraging referrals from commercial 
laboratories and contributing academic centers, we aim to study 
100 patients over a three year period in order to better understand 
the natural history and risk associated with this unique familial 
cancer syndrome. Supported by grants from the Conquer Cancer 
Foundation of ASCO, the Bonnie J. Addario Lung Cancer Founda-
tion, and the National Cancer Institute.
Keywords: EGFR, T790M mutation, germline genetics, familial 
lung cancer
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MO15.08 KDR (VEGFR-2) COPY NUMBER GAINS AND 
MUTATIONS ARE TARGETABLE ALTERATIONS IN NON-
SMALL CELL LUNG CANCER
Monique B. Nilsson1, Tina Cascone1, Uma Giri1, Jayanthi Gudikote1, 
Lixia Diao2, Andrew Koo1, Hengyu Lu3, Turgut Dogruluk3, Erick 
Riquelme4, Ximing Tang4, Hai T. Tran1, Kenneth Scott3, Ignacio I. 
Wistuba4, David Carbone5, Mark A. Socinski6, John V. Heymach1
1Thoracic/head And Neck Medical Oncology, The University Of Texas 
MD Anderson Cancer Center/United States Of America, 2Bioinformatics 
& Computational Biology, The University Of Texas MD Anderson Can-
cer Center,/United States Of America, 3Molecular And Human Genetics, 
Baylor College Of Medicine/United States Of America, 4Translational 
Molecular Pathology, The University Of Texas MD Anderson Cancer 
Center/United States Of America, 5College Of Medicine, The Ohio State 
University/United States Of America, 6Hematology/Oncology, Universi-
ty Of Pittsburgh/United States Of America
Background: Therapeutic regimens targeting the vascular endo-
thelial growth factor (VEGF) pathway have been extensively tested 
in the treatment of malignancies including non-small cell lung 
cancer (NSCLC). VEGF pathway inhibitors including bevacizumab 
or VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) have 
been shown to prolong progression-free survival (PFS) and/or 
overall survival (OS). These benefits, however, have been modest, 
occurring only in subsets of patients. Therefore, predictive markers 
to identify patients likely to derive benefit are critically needed. 
Although expression of VEGFR-2, also known as KDR, was initially 
thought to localize primarily on endothelial cells, VEGFR-2 has 
been detected on malignant cells. We recently observed that KDR 
copy number gains (CNGs) were detectable by FISH in ~30% of 
both adenocarcinoma and squamous cell carcinoma and were as-
sociated with poor clinical outcome in early stage NSCLC patients 
treated with adjuvant chemotherapy. In addition to CNGs, muta-
tions and polymorphisms within the KDR gene were also observed. 
The impact of these alterations is unknown. Here, we investigated 
KDR CNGs, polymorphisms, and mutations in NSCLC and their ef-
fects on sensitivity to VEGFR targeting agents in preclinical models 
and in NSCLC patients.
Methods: Cell migration was evaluated by Boyden chamber assay. 
NSCLC cell lines were treated with VEGF pathway inhibitors for 
mutations affecting this residue of ARAF and a nearby residue in 
the related kinase RAF1 were demonstrated across 1% of an inde-
pendent cohort of lung adenocarcinoma cases. The ARAF mutants 
were shown to transform immortalized human airway epithelial 
cells and were associated with in vitro sorafenib sensitivity.
Conclusion: These results suggest that mutant ARAF may be a 
novel oncogenic driver in lung adenocarcinoma and an indicator of 
sorafenib response.
Keywords: Sorafenib, Sequencing, Raf, lung adenocarcinoma
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MO15.06 A PROSPECTIVE INTERNET-BASED STUDY OF 
PATIENTS WITH LUNG CANCER HARBORING BASELINE 
EGFR T790M TO IDENTIFY GERMLINE CARRIERS AND 
CHARACTERIZE FAMILIAL RISK
Geoffrey R. Oxnard1, Jennifer C. Heng1, Irene R. Rainville1, Alicia L. 
Sable-Hunt2, Elizabeth J. Root1, Georgia L. Wiesner3, David P. Car-
bone4, Pasi A. Jänne1, Judy E. Garber1
1Dana-Farber Cancer Institute/United States Of America, 2Addario 
Lung Cancer Medical Institute/United States Of America, 3Vanderbilt-
ingram Cancer Center/United States Of America, 4The Ohio State Wex-
ner Medical Center/United States Of America
Background: The EGFR T790M mutation, commonly seen with ac-
quired resistance to EGFR kinase inhibitors, has also been descri-
bed rarely as a germline mutation in association with familial lung 
cancer. In a prior study (Oxnard et al, JTO, 2012), the presence of 
EGFR T790M at diagnosis was associated with a 50% chance of 
carrying an underlying germline T790M mutation. This suggests 
that by studying patients whose cancer was shown to carry T790M 
at diagnosis, it is possible to efficiently screen for a germline allele 
that otherwise is rare among patients with non-small cell lung can-
cer. We therefore initiated a prospective trial to identify patients 
and families carrying germline EGFR mutations in order to charac-
terize phenotype and cancer risk.
Methods: Subjects are eligible if they (1) have a cancer harboring 
EGFR T790M (excluding acquired T790M), (2) are a relative of a 
known germline carrier, or (3) are already known to carry a germ-
line EGFR mutation on prior testing. Subjects may present at a 
participating cancer center or may enroll remotely using a study 
website (www.Dana-Farber.org/T790Mstudy/). Eligible subjects 
receive genetic counseling in person or over the phone, and then 
submit a saliva and/or blood specimen for central testing in a CLIA 
lab. Results are disclosed to the subject if they wish but do not 
enter the medical record. Those subjects carrying germline EGFR 
mutations are given the option of inviting relatives to participate. 
Chest CT scans are collected from germline carriers and analyzed 
centrally to study nodule prevalence and characteristics. Available 
tumor specimens are collected for central pathology review and 
advanced genomic analysis.
Results: The trial was registered to clinicaltrials.gov 
(NCT01754025) and began accrual in December 2012. To date, 7 
subjects have been enrolled and 5 are actively being screened, 
including 4 kindreds. More than half of the subjects have parti-
cipated remotely via the study website. Of 4 probands with lung 
cancer and germline T790M, 3 have a family history of lung cancer, 
2 of whom have children with CT scans showing multiple sub-
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and more specifically, the putative transcription factor YEATS4 
(YEATS domain containing 4) as frequently amplified and overex-
pressed in NSCLC. Amplification of YEATS4 has been reported in 
dedifferentiated liposarcomas and in the earliest stages of glioma 
and astrocytoma.
Methods: Copy number profiles were generated for 261 NSCLC 
tumors (169 adenocarcinomas (AC) and 92 squamous cell carcino-
mas (SqCC)) and expression profiles for a subset of tumors with 
matched non-malignant tissue. Recurrent DNA amplifications were 
identified using the GISTIC algorithm. Copy number data were 
integrated with gene expression data to identify genes frequently 
amplified and overexpressed (defined as a 2-fold difference in 
expression between tumor and matched non-malignant tissue). 
The functional significance of YEATS4 was assessed by lentiviral 
knockdown in lung cancer cell lines with and without YEATS4 amp-
lification and ectopic expression in human bronchial epithelial cells 
(HBECs). In vitro and in vivo assays measuring proliferation, ancho-
rage independent growth, senescence, apoptosis, drug sensitivity 
and tumor growth were used to assess the phenotypic effect of 
YEATS4 gene expression manipulation.
Results: YEATS4 is gained or amplified and concomitantly overex-
pressed in over 20% of NSCLC tumors, with similar frequencies of 
amplification in both AC and SqCC. Although frequently co-amp-
lified with MDM2, amplification of YEATS4 was observed to occur 
in the absence of MDM2 amplification, suggesting it is not merely 
a passenger event. Overexpression of YEATS4 in HBECs abroga-
ted senescence, whereas knockdown reduced cell proliferation, 
impaired colony formation and induced cellular senescence in cell 
lines with YEATS4 amplification. Western blotting revealed incre-
ased p21, cleaved PARP and p53 in knockdown lines compared to 
empty vector controls, implicating YEATS4 as a negative regulator 
of the p21-p53 pathway. Moreover, YEAST4 expression was found 
to correlate with cisplatin sensitivity, as overexpression increased 
resistance and knockdown conferred sensitivity. Consistent with 
our in vitro findings, tumor size and growth were significantly re-
duced in mice injected with YEATS4 knockdown cells relative to 
control mice. Furthermore, survival analysis revealed that patients 
expressing high levels of YEATS display poorer outcomes.
Conclusion: Our findings reveal YEATS4 as a novel candidate on-
cogene frequently amplified and overexpressed in NSCLC. Gene 
expression manipulation resulted in distinct phenotypic changes 
consistent with oncogenic function, and suggesting YEATS4 amp-
lification is a novel mechanism contributing to NSCLC tumorigene-
sis.
Keywords: p53 pathway, Integrative analysis, oncogene, YEATS4
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MO15.10 ELF3 IS A NOVEL ONCOGENE FREQUENTLY 
ACTIVATED BY GENETIC AND EPIGENETIC MECHA-
NISMS IN LUNG ADENOCARCINOMA
Katey S. Enfield1, David A. Rowbotham1, Daiana D. Becker-Santos1, 
Raj Chari2, Megan Fuller1, May Zhang1, Miwa Suzuki1, Calum E. 
Macaulay1, Aly Karsan1, Stephen Lam1, Wan L. Lam1
1Integrative Oncology, BC Cancer Research Centre/Canada, 2Depart-
ment Of Genetics, Harvard Medical School/United States Of America
Background: Lung cancer remains the cause of the most cancer-
24 hours, and protein lysates where collected. HIF-1α levels were 
evaluated by ELISA assay. VEGFR, p38, and p70s6K were evaluated 
by Western blotting. Tumor DNA and peripheral blood DNA, were 
analyzed in duplicate using Affymetrix Genome-Wide SNP Array 
6.0. Transformation of Ba/F3 cells was evaluated by an IL-3-inde-
pendent growth assay.
Results: In tumor cells with KDR CNG, VEGF stimulation induced 
activation of p38 and p70S6K, and VEGFR TKIs including sorafe-
nib and vandetanib effectively inhibited VEGF-mediated signal 
transduction. In tumor cell lines with KDR CNG, exogenous VEGF 
ligand increased cell motility and this was inhibited by VEGFR blo-
ckade with TKIs including sunitinib, sorafenib, and axitinib. Various 
receptor tyrosine kinases have been shown to drive HIF-1α levels, 
and NSCLC cells with KDR CNG express elevated levels of HIF-1α 
in normoxia compared to NSCLC cell lines without KDR CNG. In 
NSCLC cell lines with KDR CNG, VEGFR TKIs decreased protein 
levels of HIF-1α and HIF-1α regulated proteins. Furthermore, we 
report a clinical case in which a NSCLC patient with KDR CNG had 
a partial response to the VEGFR inhibitor, sorafenib. In addition 
to gene amplification, mutations and polymorphisms within the 
KDR gene were also observed. KDR mutation 1586A>T and poly-
morphism 1416A>T effectively transformed Ba/F3 cells. Finally, we 
report two clinical cases in which NSCLC patients with the 1416A>T 
polymorphism had a partial response the VEGF pathway inhibitor, 
bevacizumab.
Conclusion: Collectively, our data indicate that KDR amplification 
promotes downstream signaling events including activation of the 
p38, mTOR, and HIF pathways and are targetable by VEGF pa-
thway inhibitors. KDR gene alterations may be predictive markers 
for VEGF pathway inhibitors.
Keyword: NSCLC; VEGFR; HIF; KDR
NOVEL GENES AND PATHWAYS  
TUESDAY, OCTOBER 29, 2013 - 16:15-17:45
MO15.09 AMPLIFICATION OF YEATS4, A NOVEL ON-
COGENE IN NSCLC, INHIBITS THE P53 PATHWAY AND 
INCREASES RESISTANCE TO CISPLATIN
Larissa Pikor1, William W. Lockwood2, Kelsie L. Thu1, Emily A. 
Vucic1, Raj Chari3, Adi F. Gazdar4, Stephen Lam1, Wan L. Lam1
1Integrative Oncology, BC Cancer Research Centre/Canada, 2National 
Human Genome Research Unit, National Institutes Of Health/United 
States Of America, 3Department Of Genetics, Harvard Medical School/
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Research, University Of Texas Southwestern Medical Center At Dallas/
United States Of America
Background: Characterization of lung cancer genomes has re-
vealed a number of genes critical to tumorigenesis (e.g. EGFR, 
KRAS, EML4-ALK), resulting in significant changes to the treatment 
of lung cancer and an increase in survival for a subset of patients. 
These successes have prompted the search for additional driver 
alterations, leading to the discovery of a number of recurrently 
mutated or amplified genes and gene fusions with promising cli-
nical utility. Distinguishing the key mechanisms and causal events 
driving tumorigenesis will lead not only to a better understanding 
of lung cancer phenotypes and biology, but also to new molecular 
markers and therapeutic targets. Using an integrative analysis of 
gene expression and copy number data to identify novel candida-
te oncogenes, we identified the chromosomal region at 12q13-15, 
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MO15.11 USING SYNTHETIC LETHAL SCREENING TO 
IDENTIFY THERAPEUTIC TARGETS FOR INNATELY PLATI-
NUM RESISTANT LUNG CANCER
Kieren Marini1, Fernando Rossello1, Luciano Martelotto2, Neil Wat-
kins1
1Centre For Cancer Research, Monash Instituate Of Medical Research/
Australia, 2Human Oncology & Pathogenesis Program, Memorial Sloan-
Kettering Cancer Center/United States Of America
Background: Although platinum-based chemotherapy is the stan-
dard of care for most cases of advanced lung adenocarcinoma, its 
effectiveness is limited by the frequent incidence of innate che-
moresistance. As a result, response rates rarely exceed 20%, even 
though cis-platinum and carboplatin are highly effective in other 
settings such as small cell lung, ovarian and testicular cancers. We 
hypothesized that innate chemoresistance in lung adenocarcinoma 
is mediated by one or more signalling pathways dependent on the 
expression of a single gene, and that these pathways could ulti-
mately be targeted therapeutically.
Methods: To address this question, we developed a synthetic-
lethal high throughput siRNA screen using the innately resistant 
A549 lung adenocarcinoma cell line. Optimisation of the screen 
was performed using a siRNA death control (PLK1), which induced 
cell death in the absence of platinum, and a sensitization control 
(MTOR), which enhanced cell death only in combination with a su-
blethal concentration of carboplatin. These independent controls 
revealed that the screening protocol performed within acceptable 
limits of variability, quality and reproducibility as determined by Z’ 
factor analysis. Screening was then performed using a pool of four 
siRNAs targeting a single gene in conjunction with vehicle treat-
ment, or with carboplatin.
Results: After screening siRNAs targeting the 720 kinases, 256 
phosphatases and 4794 “druggable” targets of the human geno-
me, we identified 50 candidate targets based on fold change dif-
ference between platinum and vehicle treatments, and statistical 
significance determined by multiple t-test corrected for false disco-
very rate. Preliminary pathway analysis revealed a highly significant 
enrichment for genes in previously identified pathways as well as 
novel pathways.
Conclusion: These data demonstrate that a synthetic-lethal ap-
proach can be used to identify therapeutic targets that could 
potentially sensitize lung adenocarcinoma to platinum-based che-
motherapy.
Keywords: Adenocarcinoma, Platinum, resistance
related deaths each year, with a 5 year survival rate of less than 
15%. The predominant type of lung cancer is non-small cell lung 
cancer, and the majority of these cases consist of the adenocarci-
noma (AC) histology. Oncogenes such as EGFR and KRAS are well 
defined drivers of AC, but in approximately 50% of cases the driver 
alterations are unknown. Furthermore, not all defined drivers are 
drugable. Additional oncogenes are clearly involved in driving this 
subtype, and must be elucidated to better understand AC biology 
and improve treatment. ELF3 is an member of the E-Twenty Six 
(ETS) transcription factor family, which includes several well known 
oncogenes such as ETS1. Expression of ELF3 is uniquely epithelial-
specific, with high expression in fetal but not adult lung tissue. 
ELF3 overexpression has been reported in a handful of clinical 
AC cases and cell lines, however a comprehensive analysis of the 
extent and impact of this overexpression is lacking. Therefore we 
conducted a multi-‘omic, functional analysis of ELF3, and hypothe-
size ELF3 represents a novel oncogene in lung AC.
Methods: ELF3 was interrogated in a multidimensional integ-
rative manner by assessing copy number (SNP 6.0), methylation 
(Illumina HM27), and expression (Illumina) data from a panel of 
83 AC tumors and matched adjacent non-malignant tissues. ELF3 
expression was also assessed in The Cancer Genome Atlas (TCGA) 
public database. Stable ELF3 mRNA knock-down models were 
established in AC cell lines with high ELF3 expression, and these 
models were used to assess the role of ELF3 in cell viability and 
proliferation via MTT and BrdU incorporation assay, respectively. 
Knock-down models were also used to assess the impact of ELF3 
overexpression on tumor growth in vitro and in vivo by soft agar 
colony formation assay and flank injections of NOD-SCID mice. 
Subcellular localization of ELF3 was determined by western blot 
and confirmed with immunofluorescence. In addition, an ELF3 
overexpression model was established in immortalized Human 
Bronchial Epithelial Cells (HBECs) to assess proliferation and soft 
agar colony formation in a non-malignant model system.
Results: ELF3 was found to be frequently overexpressed in our co-
hort (72%) and the TCGA cohort (80%). This upregulation correla-
ted significantly with high frequencies of sequence gain (49%) and 
hypomethylation (71%), often seen within the same tumor. In fact, 
82% of tumors with ELF3 overexpression had concurrent gain and/
or hypomethylation of the ELF3 locus. Knock-down of ELF3 in cell 
models led to significantly reduced cell viability and proliferation. 
Western blot and IF revealed ELF3 to be predominantly located in 
the nucleus, indicating ELF3 likely behaves through its transcripti-
on factor activity. A similar hyperproliferative phenotype was seen 
in the HBEC ELF3 overexpression models.
Conclusion: The high frequency of ELF3 overexpression (>70%) 
observed in lung AC is accompanied by frequent DNA-level selec-
tion events. The affect of ELF3 on cell proliferation suggests that 
ELF3 is a novel oncogene in lung AC. Further studies are warran-
ted to determine the mechanism by which ELF3 drives hyperproli-
feration and potentially other oncogenic functions to define novel 
drugable targets for this disease.
Keyword: lung, adenocarcinoma, oncogene, genomics
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MO16.02 TUMOR AND STROMA TREG MARKERS IN RE-
SECTABLE NSCLC
Marta Usó1, Juan José Pérez Marcos1, Eloisa Jantus Lewintre1, Rafa-
el Sirera2, Rut Lucas3, Cristina Hernando4, Carlos Camps5
1Molecular Oncology Laboratory, Fundación Para La Investigación Del 
Hospital General Universitario De Valencia/Spain, 2Department Of Bio-
technology, Polytechnic University Of Valencia/Spain, 3Departamento 
De Historia De La Ciencia Y Documentación, Universitat De Valencia/
Spain, 4Medical Oncology Department, General University Hospital Of 
Valencia/Spain, 5Htal. Gral. Univ. Valencia- Universitat De Valencia/
Spain
Background: Immunosuppressive regulatory T lymphocytes 
(Tregs) have been proved to play a critical role in immune toleran-
ce to tumor. In this study we have analyzed several markers related 
to Tregs, in both tumor and stroma areas in patients with resecta-
ble NSCLC.
Methods: Tumor FFPE samples from 135 early-stage NSCLC pati-
ents were used in this retrospective study. The most representative 
areas of tumor cells and tumor stroma of each sample were care-
fully micro-dissected. RTqPCR using hydrolysis probes was perfor-
med to determine the expression of Treg markers such as: CD127, 
CD25, FOXP3, CTLA-4, IL-10, TGFB-1, LAG-3, GITR and TNF-a 
as well as CD4 and CD8. Relative gene expression was assessed 
using GAPDH and CDKN1B as endogenous controls and results 
were normalized against a human cDNA as a reference. FOXP3 
protein expression was assessed by immunohistochemistry, in 80 
of the 135 patients included in this study. The absolute number of 
FOXP3-positive lymphocytes was determined in both tumor and 
stroma areas by averaging the cell counts in 10 fields (400X). All 
statistical analyses were considered significant at p< 0.05.
Results: Gene expression analyses revealed an over-expression 
of CD25 (5.40X and 7.95X, respectively) and down-expression of 
CD127 (0.28X and 0.37X, respectively) in both, tumor and stro-
ma. There was a tendency toward higher expression of FOXP3 
(1.67X and 2.01X, respectively) and CTLA-4 (1.92X and 1.76X, re-
spectively) as well. Paired Wilcoxon test showed significant gene 
expression differences between tumor and stroma in FOXP3 
(p=0.006), CD25 (p<0.0001), CD4 (p<0.0001), CD8 (p=0.028), IL-10 
(p<0.0001) and TGFB-1 (p<0.0001). Survival analyses revealed that 
patients with a “Treg profile” (↑CD25/↓CD127) had a reduced over-
all survival (OS), whilst those patients with higher levels of the ratio 
FOXP3 stroma/tumor had worse time to progression (TTP) (Table 
1). Spearman test revealed a significant association between stro-
mal FOXP3 expression levels and the number of FOXP3-positive 
lymphocytes (by IHC) in stroma, p=0.006. Moreover, chi-square 
test showed that patients with squamous cell carcinoma histology 
presented a higher number of FOXP3-positive lymphocytes than 
those patients with adenocarcinoma, p= 0.035. Table 1: OS for 
“Treg profile” and TTP for Ratio FOXP3 Stroma/Tumor  
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MO16.01 DIFFERENT MICRO-RNA EXPRESSION IN 
LUNG ADENOCARCINOMA WITH MOLECULAR DRIVER 
EVENTS
Lorenza Landi1, Pierluigi Gasparini2, Carmelo Tibaldi1, Stefania 
Carasi2, Luciano Cascione2, Greta Alì3, Armida D‘Incecco1, Gabriele 
Minuti1, Jessica Salvini1, Antonio Chella3, Gabriella Fontanini3, 
Carlo M. Croce2, Federico Cappuzzo1
1Dipartimento Di Oncologia, Istituto Toscanotumori/Italy, 2The Ohio 
State University, Comprehensive Cancer Center, Department Of Mo-
lecular Viroloy, Immunology And Medical Genetics/United States Of 
America, 3Azienda Ospedaliera Universitaria Pisana/Italy
Background: Oncogenic driver alterations identify several types 
of lung adenocarcinoma with different prognosis and sensitivity 
to targeted agents. MicroRNAs (miRNAs) are a new class of non-
coding RNAs involved in gene expression regulation. How miRNAs 
are dysregulated in lung cancer with ALK translocation, EGFR 
or KRAS mutation is largely unknown. In the present analysis we 
aimed to investigate miRNAs expression according to a specific 
molecular driver and to correlate miRNAs deregulation with pati-
ent outcome.
Methods: The study was conducted in a cohort of 67 lung 
adenocarcinoma patients (pts) including 17 ALK+ tumors, 11 ALK-/
EGFR mutation+, 15 ALK-/KRAS mutation+, 24 ALK-/EGFR and 
KRAS wild-type and defined as triple negative cases. Matched 
normal lung tissues from 18 cases representative of the entire 
cohort were also included onto the analysis. RNA was isolated 
from formalin-fixed paraffin-embedded tissue (FFPE), using the 
Recover ALL kit (Ambion). NanoString nCounter system platform 
was used to generate the miRNA profile. We used Limma to test 
for differential expression analysis of data. Among the miRNAs 
evaluated, the miR-515 family expression between tissues was 
validated by RT-qPCRs, analyzed using the parametric t-test 
(unpaired, 2-tailed for validation).
Results: miRNA expression profile clusters distinctly ALK+ pts 
from ALK- and normal lung tissue. Within the ALK- group we found 
specific miRNAs subsets able to sub-stratify KRAS versus EGFR 
careers clustering sharply triple negative versus EGFR mutation+ 
and triple negative versus KRAS mutation+. miRNAs belonging to 
the miR-515 family seems to be the most deregulated in the ALK+ 
versus ALK-. Although their expression is stably high in normal 
tissues and ALK+ class, they are highly downregulated in KRAS 
mutated versus EGFR mutated and versus triple negative (p-value 
<0.001 for all comparisons).
Conclusion: miRNAs profile significantly differs in lung cancer 
pts with ALK translocation, EGFR mutations and KRAS mutations. 
Putative targets of deregulated miRNAs are under investigation to 
better define differences in driver-dependent pathway activation.
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to be far more effective than either treatment alone in PC-9 cells. 
Furthermore, 2 patients harboring both EGFR mutation and cyto-
ERβ expression underwent PD of EGFR-TKIs, and re-obtained di-
sease control after receiving combined EGFR-TKIs with fulvestrant.
Conclusion: Cyto-ERβ expression may predict relatively poor 
efficacy to EGFR-TKI compared with non- cyto-ERβ expression in 
NSCLC patients harboring EGFR mutation.
Keyword: estrogen receptor, lung carcinoma, EGFR-TKI, non-
genomic
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MO16.04 ANALYSIS OF HER2 AMPLIFICATION IN NON-
SMALL CELL LUNG CANCERS (NSCLCS) WITH ACQUI-
RED RESISTANCE (AR) TO EPIDERMAL GROWTH FAC-
TOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS 
(TKIS)
Katerina Politi1, Anna Wurtz1, Zenta Walther2, Guoping Cai2, Va-
lentina Pirazzoli1, Mary Ann Melnick1, Laura Reynolds1, Julie Bo-
yer3, Anne Chiang3, Daniel Morgensztern3, Sarah Goldberg3, Roy 
Herbst3, Thomas Lynch3, Scott N. Gettinger3
1Pathology And Medicine (medical Oncology), Yale Cancer Center/ Yale 
University School Of Medicine/United States Of America, 2Pathology, 
Yale Cancer Center/ Yale University School Of Medicine/United States 
Of America, 3Medical Oncology, Yale Cancer Center/ Yale University 
School Of Medicine/United States Of America
Background: Recent studies have demonstrated the feasibility of 
rebiopsy in patients (pts) with EGFR mutant NSCLC at the time of 
AR to the EGFR tyrosine kinase inhibitors (TKIs) erlotinib or gefi-
tinib, and provide estimates of the prevalence of well described 
mechanisms of AR including the EGFR T790M mutation, MET am-
plification and small cell lung cancer (SCLC) transformation. HER2 
amplification has also been described in cases of AR to EGFR TKIs, 
however, its exact frequency is still unclear. Moreover, comprehen-
sive analysis of paired pre- and post-treatment samples to estab-
lish whether HER2 amplification is acquired during treatment with 
TKIs have not been performed. This prompted us to further investi-
gate HER2 amplification in EGFR mutant NSCLC cases.
Methods: Pts with metastatic or recurrent NSCLC who developed 
AR while on a molecularly targeted agent were enrolled on an IRB 
approved repeat biopsy protocol. Tumor biopsies were obtained 
at the time of AR, and histopathological and molecular analyses 
of the tumors were performed. Known mechanisms of AR to EGFR 
TKIs were analyzed (T790M mutation, MET amplification and SCLC 
transformation) as well as amplification of HER2. The presence of 
T790M was assessed either by Taqman or pyro-sequencing (unless 
T790M status was available from an outside institution). HER2 and 
MET amplification were determined using fluorescence in situ hyb-
ridization (FISH).
Results: 41 pts with AR to EGFR TKIs (erlotinib or gefitinib) were 
enrolled at YCC between Jan 2012 and May 2013. Histological 
analysis of all specimens revealed transformation of adenocarcino-
ma to SCLC in 3 cases (7%). Depending on the availability of tissue, 
samples were prioritized for T790M analysis followed by MET and 
HER2 amplification. T790M was identified in 36% of pts; MET and 
HER2 amplification were found in 11% and 10% of samples res-
pectively. In the two cases with HER2 amplification, analysis of the 
OS
Median 
(months)
95% CI p
Others 74.33
65.96 - 
82.69
0.003
“Treg profile” 29.90
4.91 - 
6.54
TTP
Median 
(months)
95% CI p
↓ Ratio FOXP3 Stroma/Tumor NR -- 0.040
↑ Ratio FOXP3 Stroma/Tumor 32.50 16.25- 
48.74
Conclusion: Gene expression of Treg markers in tumor microenvi-
ronment seem to play an important prognostic role in early-stage 
NSCLC patients. Furthermore, preliminary IHC analysis indica-
ted a correlation between mRNA and protein levels for FOXP3 
in NSCLC patients. Supported in part, by grants PS09/01149, 
RD06/0020/1024 and RD12/0036/0025 from Red Temática de Inves-
tigación Cooperativa en Cáncer, Instituto de Salud Carlos III (ISCIII).
Keywords: Treg, resectable NSCLC, microenvironmet, FOXP3
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MO16.03 CYTOPLASMIC ERΒEXPRESSION PREDICTS 
POORLY EFFICACY AND SURVIVAL OF EGFR-TKI IN 
EGFR MUTANT NSCLC
Zhijie Wang, Zhenxiang Li, Hua Bai, Jie Wang, Jun Zhao, Meina Wu
Peking University Cancer Hospital/China
Background: Estrogen receptor pathway has been reported to 
be interacted with epidermal growth factor receptor (EGFR) signal 
pathway. This study focused on the impact of intracellular ERβ 
localization (cytoplasmic or nuclear) on the efficacy of EGFR-TKI.
Methods: Tumor tissue specimens from 149 stage IV NSCLC pati-
ents treated with EGFR-TKI were analyzed using immunohistoche-
mistry (IHC) for ER expression (ERαorβ) and their associations with 
clinicopathological variables and clinical outcomes. Significance of 
cyto-ERβ expression was further examined in NSCLC cell lines.
Results: The expression of ERα and ERβ was detected in 15% 
and 28.9% of the patients, respectively. Cyto-ERβ positive cases 
showed shortened progression free survival (PFS) compared with 
cyto- ERβ negative ones (3.1 months vs. 7.3 months, p=0.061). In 
the subgroup with concurrent EGFR mutation, the differences of 
PFS were enlarged with significant statistics (4.7 months vs. 10.9 
months, p=0.042). COX’s proportional hazard model showed 
that female, EGFR mutation and c- ERβ negative expression were 
independent predictive factors for PFS. PC-9 cells present ERβ in 
cytoplasma as well as nucleus. Estrodial (E2) induced PC-9 cells 
moderately resistant to erlotinib with a 3-fold increase of IC50, and 
the resistance can be reversed by ER blocker (fulvestrant) or siRNA 
directed to ESR2. The function of E2 was accomplished by nonge-
nomic activation (MAPK phosphorylation) caused by E2 via cyto- 
ERβ. Combination therapy with erlotinib and fulvestrant turned out 
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insertion hypersensitive to EGFR TKIs using enzyme kinetic and 
cell line models. In patients with EGFR exon 20 mutated NSCLCs, 
the response rates to gefitinib or erlotinib were significantly higher 
for A763_Y764insFQEA (2/3; 66.6%) when compared to all other 
mutations within or following the C-helix (0/17, 0%; p=0.0158). The 
unorthodox homology model of A763_Y764insFQEA suggests 
a mechanism of activation (by shifting the register of the C-helix 
N-terminal) related to TKI-sensitive mutations (such as L858R or 
L861Q).
Conclusion: Our findings not only explain the intricate interplay 
between different EGFR mutations and their response to EGFR 
TKIs, but also have clinical implications for the treatment of EGFR 
exon 20 insertion mutated NSCLCs. Therefore, based on our data 
and previously published reports the aforementioned mutations 
affecting amino acids V765 to V774 should be classified as non-
sensitizing to the reversible EGFR TKIs gefitinib and erlotinib. Our 
models may usher the development of EGFR TKIs specific for EGFR 
exon 20 insertion mutations.
Keywords: EGFR, exon 20 insertions, non-small-cell lung cancer, 
gefitinib/erlotinib
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MO16.07 HIGHER FREQUENCY OF GENETIC ABERRA-
TIONS IN KRAS- THAN IN EGFR-MUTATED NSCLCS. A 
NEXT-GENERATION SEQUENCING STUDY ON 96 SAM-
PLES.
Odd Terje Brustugun1, Åslaug Helland2, Ann Rita Halvorsen3, Ma-
rius Lund-Iversen4, Ola Myklebost5, Eivind Hovig5, Leonardo Meza-
Zepeda5
1Dept. Of Oncology, The Norwegian Radium Hospital/Norway, 2Dept 
Of Oncol, The Norwegian Radium Hospital/Norway, 3Dept Of Genetics, 
The Norwegian Radium Hospital/Norway, 4Dept Of Pathology, The 
Norwegian Radium Hospital/Norway, 5Dept Of Tumor Biology, The 
Norwegian Radium Hospital/Norway
Background: Genetic subtyping is increasingly being clinically re-
levant in NSCLC, and the search for novel targetable driver muta-
tions is warranted. We intended to study the frequency and types 
of a vast number of potential druggable genetic aberrations in a 
large cohort of non-small cell lung cancers of all major histological 
subtypes. Herein we report the first findings.
Methods: Blood samples and tumor tissue was obtained from 96 
operated early stage lung cancer patients admitted to Oslo Uni-
versity Hospital-Rikshospitalet in the period 2006-2011. Tissue was 
taken from the excised tumours, snap frozen in liquid nitrogen in 
the operation room, and stored at -80oC until DNA isolation. The 
tumor cell content in the specimens was found to be more than 
70% in most samples. DNA was isolated from both tumor and 
corresponding blood sample according to standard procedures. 
High-throughput sequencing was performed using the SureSelect 
Human Kinome kit (Agilent Technologies), with capture probes 
that target 3.2 Mb of the human genome and include exons for 
all known kinases, select cancer-specific genes and their associ-
ated UTRs, in total 612 genes. The derived sequence reads were 
analyzed based on a pipeline including calling variations, somatic 
mutations, DNA copy number changes, indels and genomic rear-
rangements, as well as functional annotations.
pre-treatment specimen revealed that amplification of this recep-
tor tyrosine kinase preceded treatment with EGFR-TKIs, however, 
the amplification level was lower pre-treatment in both cases. Spe-
cifically the ratio of HER2 to CEP17 probes was 2.8 pre-treatment 
in both cases and increased to 4.3 and 8 following TKI treatment. 
HER2 amplification was mutually exclusive with the other tested 
mechanisms of resistance.
Conclusion: T790M was the most commonly identified mechanism 
of AR to EGFR TKIs in the YCC cohort consistent with other stu-
dies. MET amplification, HER2 amplification and SCLC transforma-
tion were also observed. The observation that HER2 was amplified 
pre-treatment warrants further investigation of HER2 amplification 
in AR and pre-treatment specimens. Whole exome sequencing of 
specimens without known resistance mechanisms is ongoing.
Keywords: acquired resistance, EGFR mutations, HER2 amplifica-
tion
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MO16.06 CLINICAL, STRUCTURAL AND BIOCHEMICAL 
CHARACTERIZATION OF EGFR EXON 20 INSERTION 
MUTATIONS IN LUNG CANCER
Daniel B. Costa1, Hiroyuki Yasuda1, Eunyoung Park2, Cai-Hong 
Yun2, Mark S. Huberman1, Geoffrey R. Oxnard2, Lecia V. Sequist3, 
Gregory Riely4, Ross Soo5, Michael J. Eck2, Susumu S. Kobayashi1
1Hematology/Oncology, Beth Israel Deaconess Medical Center/United 
States Of America, 2Dana-Farber Cancer Institute/United States Of 
America, 3Massachusetts General Hospital/United States Of America, 
4Memorial Sloan Kettering Cancer Center/United States Of America, 
5National University Of Singapore/Singapore
Background: Epidermal growth factor receptor (EGFR) exon 20 
insertion mutations account for ~10% of EGFR-mutated non-small-
cell lung cancer (NSCLC), for the most part occur at the N-lobe of 
EGFR after its C-helix (after amino-acid M766) and have unsolved 
patterns of response to ATP-mimetic EGFR tyrosine kinase inhibi-
tors (TKIs).
Methods: To understand the patterns of resistance or response 
to EGFR TKIs of EGFR exon 20 insertion mutations, we decided to 
study representative mutations using in vitro systems, structural 
models and also NSCLCs with these specific EGFR mutations.
Results: We selected three mutations located within the C-helix 
(A763_Y764insFQEA [identical to D761_E762insEAFQ], Y764_
V765insHH and M766_A767insAI) and four mutations following the 
C-helix (A767_V769dupASV [identical to V769_D770insASV], D770_
N771insNPG, D770_N771insSVD [identical to S768_D770dupSVD] 
and H773_V774insH [identical to P772_H773insH]) mutations. Our 
data indicates almost all EGFR exon 20 insertions are resistant to 
submicromolar concentrations of gefitinib or erlotinib; data that 
mirrors the lack of clinical response of NSCLCs with these muta-
tions. The crystal structural and enzyme kinetic studies of a proto-
typical post C-helix EGFR TKI-resistant insertion, between residues 
D770_N771 (D770_N771insNPG), highlight that these mutations fa-
vor the active conformation (i.e., are activating), don’t alter EGFR’s 
ATP-binding pocket and are less sensitive than TKI-sensitive muta-
tions. D770_N771insNPG is predicted to be 7.66 fold less sensitive 
than the TKI-sensitive EGFR-L858R. Unexpectedly, we identified 
the atypical EGFR-A763_Y764insFQEA as the only EGFR exon 20 
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slide. After that, tumor cells were(8-150) captured by laser micro-
dissection. DNA sequencing for EGFR exons 18, 19, 20, 21, KRAS 
codons 12 and 13 was performed at Molecular Biology Laboratory( 
ICO-Badalona) and ALK translocation were analyzed at Pathology 
Department by FISH
Results: EGFR mutations were tested in 227 samples.The overall 
output was 86.3% (not evaluable in 15 , insufficient tissue in 8, no 
tumor cells in 4, not done in 4). EGFR mutation was detected in 
8.81% (20/227). KRAS mutation were tested in 41 samples with 
results in 33, 80.5% (2 not evaluable, insufficient tumor cells 3, no 
tumor 1 and not done 2 samples). KRAS mutation was positive 6 
(14.6%). ALk translocation were tested in 9 p with results in 6 p ( 
1 not evaluable and 2 insufficient tumor cells) Both cell-block and 
fresh specimen over an apropiate slide were used to perform mo-
lecular testing. The output for cell-block was 83.3%(124/148) and 
testing was not possible in 23(11 not evaluable, 6 insufficient tumor 
cells, 4 not tumor and 3 not done). The output for membrane was 
91.1% (72/79) and was not possible in 7(4 were not evaluable, 2 
insufficient tumor cells and not done in 1). 54.7% of samples were 
obtained from endobronquial ultrasound guided transbronquial 
needle aspiration of mediastinal adenopathies, 11.3% lung mass 
needle aspiration and 11.7% from pleural effusion.
Conclusion: Our results support the potential use of cytology sam-
ples for molecular testing in NSCLC when biopsy specimens are 
not available. Both membrane preparations and cytology blocks 
have been used and are equally suitable for molecular testing.
Keywords: Cytology, molecular test
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MO16.09 PATTERNS OF METASTASIS AND SURVIVAL 
IN PATIENTS WITH PI3K-ABERRANT AND FGFR1 AM-
PLIFIED STAGE IV SQUAMOUS CELL LUNG CANCERS 
(SQCLCS)
Paul K. Paik1, Andre L. Moreira2, Lu Wang3, Natasha Rekhtman2, 
Camelia S. Sima4, Helen Won2, Marc Ladanyi3, Michael F. Berger2, 
Mark G. Kris1
1Thoracic Oncology, Memorial Sloan-Kettering Cancer Center/United 
States Of America, 2Pathology, Memorial Sloan-Kettering Cancer Center/
United States Of America, 3Pathology, Memorial Sloan Kettering Cancer 
Institute/United States Of America, 4Biostatistics, Memorial Sloan-Kette-
ring Cancer Center/United States Of America
Background: The majority of actionable drivers in SQCLCs occur in 
the PI3K (30%) and FGFR1 (20%) pathways. The biologic behaviors 
and natural histories of these subtypes are not well characterized. 
Characterization of these data may help to elucidate the biologic 
relevance of these putative oncogenic events.
Methods: As of October 2011, all patients with SQCLCs at MSK 
have undergone prospective, multiplex testing of their FFPE tumors 
for FGFR1 amplification (FISH, FGFR1:CEP8 ≥ 2.2), PIK3CA mutations 
(Sequenom and exon sequencing), PTEN loss (IHC, Cell Signaling), 
and PTEN mutations (exon sequencing), among others. The PI3K ab-
berant group was defined as PIK3CA mutant, PTEN complete loss, 
or PTEN mutant. Patient characteristics, outcomes, and metastatic 
sites were identified. Survival probabilities were estimated using the 
Kaplan-Meier method. Group comparisons were performed with 
log-rank tests and Cox proportional hazards methods.
Results: Tissues from 48 females and 48 males were analyzed; 73 
adenocarcinomas, 21 squamous cell carcinomas and 2 large cell 
carcinomas. 55 patients were in stage I, 27 in II and 14 in stage III. 
13 patients were never-smokers. 25 samples harbored a KRAS-
mutation and 10 an EGFR mutation. The number of mutated genes 
per sample varied from 1 to 81. The median number of mutated 
genes was 14 in the overall cohort, 15 in the EGFR wildtype/KRAS 
wildtype tumors, 17 in KRAS- mutated patients, 5 in the EGFR-
mutated group and 6 in the never-smoking patients (of whom 4 
patients were EGFR-mutated).
Conclusion: KRAS-mutated tumors contain the same amount of 
genetic aberrations as in wild-type tumors, whereas EGFR-mutated 
tumors show a much lower number of mutations per tumor. Never-
smokers harbor a low number of mutations independent of EGFR-
mutation status. Novel driver mutations are probably found in 
samples with low numbers of mutations.
Keywords: KRAS, never-smokers, next generation sequencing, 
EGFR
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MO16.08 CYTOLOGY SAMPLES (S) FOR EGFR, KRAS 
AND ALK TESTING IN NON-SMALL-CELL LUNG CANCER 
(NSCLC)
Enric Carcereny1, Teresa Moran1, Anna Estival1, Felipe Andreo2, 
Mariona Lletjos3, Erika Mijangos1, Jose Sanz2, Eva Castellà3, Laia 
Capdevila4, Maria De Los Llanos Gil1, Laura Rodriguez2, Max Har-
dy-Werbin1, Itziar De Aguirre1, Rafael Rosell1
1Catalan Institute Of Oncology/Spain, 2Pneumology, Hospital Germans 
Trias I Pujol/Spain, 3Pathology, Hospital Germans Trias I Pujol/Spain, 
4Medical Oncology, Hospital De Sant Pau I Santa Tecla/Spain
Background: Recent advances in targeted therapy in NSCLC have 
achieved impressive results in advanced disease. For molecular 
testing,cytology samples are not commonly used since is less likely 
to be adequate. At ICO Badalona- Germans Trias i Pujol Hospital 
we have used cytology specimens when biopsy was not available. 
We describe the general results when using cytology specimens in 
NSCLC to detect EGFR mutation, KRAS mutations and ALK trans-
locations.
Methods: From February 2007 to May 2012, 227 cytology samp-
les from patients with NSCLC were collected at the Department 
of Pathology as cell block or fresh specimen over an apropiate 
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MO17.01 RESPONSE ASSESSMENT OF STEREOTACTIC 
ABLATIVE BODY RADIOTHERAPY (SABR) FOR PULMO-
NARY METASTASES: UTILITY OF 4D-FDG-PET AND CT 
PERFUSION
Shankar Siva1, Rod Hicks2, Brooke Sawyer3, Emma Pun3, Brent 
Chesson4, Michael Samuel3, Gavin Wright5, Phillip Antippa6, Jason 
Callahan2, Tomas Kron7, Michael Macmanus1, David Ball1
1Radiation Oncology, Peter MacCallum Cancer Centre/Australia, 2Nuc-
lear Medicine, Peter MacCallum Cancer Centre/Australia, 3Cancer Ima-
ging, Peter MacCallum Cancer Centre/Australia, 4Radiation Therapy 
Services, Peter MacCallum Cancer Centre/Australia, 5Department Of 
Surgery, St. Vincent Hospital, University Of Melbourne/Australia, 6Car-
diothoracic Surgery, The Royal Melbourne Hospital/Australia, 7Physical 
Sciences, Peter MacCallum Cancer Centre/Australia
Background: Response assessment using conventional RECIST 
criteria after SABR of lung targets can be confounded by fibrotic 
response. The purpose of this study was to evaluate the utility of 
4D-FDG-PET/CT and CT perfusion scans in the response assess-
ment of single fraction SABR for inoperable pulmonary oligometa-
stases.
Methods: This is a prospective ethics approved clinical study of 
patients undergoing single fraction SABR with 26Gy for pulmonary 
metastases. Eligible patients had 1-2 metastases with no extratho-
racic disease on staging FDG-PET. Serial 3D / 4D-FDG-PET and 
CT perfusion studies were performed at baseline, 14 days and 70 
days after therapy. Two radiologists independently reported CT 
perfusion scans.
Results: At a median follow-up of 16 months (range 3-27), 10 pati-
ents with 13 metastases received SABR. A further 7 patients (41%) 
were screened from the study due to interval progression of di-
sease between the time of the original FDG-PET and trial 4D-FDG-
PET / perfusion CT. The mean time between the original FDG-PET 
and trial scans was 62 days. No patient progressed locally, 7/10 
patients progressed distantly of which 2/7 received subsequent 
SABR. At the end of study period, 5/10 patients are alive without 
disease. The median progression free survival was 14 months. The 
change in SUVmax from baseline was higher on 3D than 4D-PET 
by a mean of 20.6% (range 0.2%-47.2%) at 14 days and 14.8% (ran-
ge 0-37.8%) at 70 days. Overall, the SUVmax increased at 14 days 
(mean 104.9%, p<0.01) and decreased at 70 days (mean=55.5%, 
p<0.01), despite persistent morphological lesions on the concur-
rent late timepoint CT. There was strong level of inter-observer 
agreement of CT perfusion interpretation with a median intraclass 
correlation coefficient of 89% (range 57%-98%). Perfusion para-
meters of Time to Peak Blood Flow and Blood Volume showed a 
median increase of 18.8% and 23.0% at 2 weeks post-therapy and 
decreased below baseline by a median 7.0% and 14.0% at 70 days 
(non-significant).
Conclusion: High rates of interval progression between staging 
scans indicates a need to expedite management of oligometas-
Results: 77 stage IV SQCLC patients were analyzed. Genotypes 
were: FGFR1 amplified (23%); PTEN loss (22%), PIK3CA mutant 
(8%), PTEN mutant (7%). Events were non-overlapping save for 2 
cases with PTEN nonsense mutations and PTEN loss. The sole sig-
nificant clinical difference (KPS, age, sex, lines of tx, smoking sta-
tus) was sex (women in PI3K group 52% vs. in others 23%, p=0.02). 
Metastatic patterns for PI3K and FGFR1 vs. all others were: 
Site PI3K p FGFR1 p Other Total 
Brain 
6 
(22%) 0.002 0 (0%) 0.6 0 (0%) 6 (7%) 
Pleura 
5 
(19%) 
0.4 5 (28%) 0.7 
9 
(28%) 
19 (25%) 
Liver 
5 
(19%) 
0.4 1 (6%) 1 1 (3%) 7 (9%) 
Bone 
8 
(30%) 
0.8 3 (17%) 0.7 
10 
(31%) 
21 (27%) 
Lung 
12 
(44%) 
0.8 
10 
(56%) 
0.2 
12 
(38%) 
34 (44%) 
Adrenal 
3 
(11%) 
1 3 (17%) 1 
4 
(13%) 
10 (13%) 
Pericardium 
1 
(4%) 
1 1 (6%) 0.3 0 2 (3%) 
 
Median OS for PI3K vs. all others: 9mo (95%CI:8-NR) vs. 16mo 
(95%CI:11-NR), p=0.004. Median OS for FGFR1 vs. all others: 20mo 
(95%CI:11-NR) vs. 10mo (95%CI:9-16), p=0.06. Multivariate analy-
sis for risk of death: PI3K HR=3.3 (95%CI:1.5-7, p=0.003); FGFR1 
HR=0.5 (95%CI:0.2-1.1, p=0.06); Age ≥65, HR=1.3 (95%CI:0.6-2.8, 
p=0.5); KPS≤70, HR=3.2 (95%CI:1.6-.6.4, p<0.001); Lines of the-
rapy ≥ 2, HR=2.3 (95%CI=0.8-5.7, p=0.08), male gender, HR=0.7 
(95%CI:0.3-1.4, p=0.3).
Conclusion: Patients with stage IV PI3K-aberrant SQCLCs have 
poorer survival compared to other patients with SQCLCs while pa-
tients with FGFR1 amplified SQCLCs have a trend towards better 
survival. Brain metastases in SQCLC are rare, and occurred exclu-
sively in patients with PI3K-aberrant tumors. These data suggest 
that PI3K pathway activation confers a distinct biology, and that 
targeting this in SQCLC patients with brain metastases may be an 
effective therapeutic strategy. Whole exome and RNA-sequencing 
data from 8 resected SQCLC brain metastases (4 paired with lung 
primaries) will be presented.
Keyword: squamous, PIK3CA, FGFR1, PTEN
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guidelines specified standard care, if given with chemotherapy, 
of conventional fraction size 2Gy: Ontario, ESMO and Australian 
guidance was a minimum of 60Gy in 30 fractions. NCCN offered a 
range of 60-74Gy at 2Gy/fraction. NICE alone proposed alternative 
standard of 55Gy in 20 fractions, a common UK schedule, or the 
option of 64-66Gy at 2Gy/fraction
Conclusion: International guidelines lag behind the emerging 
evidence for lack of benefit from dose escalation at 2Gy/fraction 
and apparent benefit from shorter treatment courses . We propose 
that accelerating treatment with hypofractionation and shorter 
overall treatment times should be the priority for radiotherapy 
development. We discuss current and pending trials examining this 
approach.
1. Mauguen A, Le Pechoux C, Saunders M et al: Hyperfractionated 
or accelerated radiotherapy in lung cancer: an individual patient 
data meta-analysis. J Clin Oncol 30:2788-2797, 2012 2. Timmerman 
R, Paulus R, Gavin J et al: Stereotactic body radiation therapy for 
inoperable early stage lung cancer. JAMA 303:1070-1076, 2010
Keyword: Radiotherapy, Guidelines, acceleration, fractionation
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MO17.03 INCIDENTAL PROPHYLACTIC NODAL IRRADI-
ATION AND PATTERNS OF NODAL RELAPSE IN INOPE-
RABLE EARLY STAGE NSCLC PATIENTS TREATED WITH 
SBRT: A CASE-MATCHED ANALYSIS
Louis Lao1, Andrew Hope2, Anthony Brade2, Andrea Bezjak2, Elan-
tholi Parameswaran Saibishkumar2, Meredith Giuliani2, Alexan-
der Sun2, Byoung Chun J. Cho2
1Radiation Oncology, Auckland City Hospital/New Zealand, 2Depart-
ment Of Radiation Oncology, University Of Toronto, Princess Margaret 
Cancer Centre/Canada
Background: Reported non-small cell lung cancer (NSCLC) nodal 
failure rates following stereotactic body radiotherapy (SBRT) are 
lower than those reported in the surgical series when matched for 
stage. We hypothesize that this effect is due to incidental prophyl-
actic nodal irradiation.
Methods: A prospectively collected group of medically inoperable 
early stage NSCLC patients (n=179) from 2004 to 2010 was used to 
identify a patient cohort with nodal relapses (n=19). These cases 
were matched, 1:2, to controls, controlling for tumour volume (i.e. 
same or greater) and tumour location (i.e. same lobe). Reference 
(normalized total) point doses at the ipsilateral hilum and carina, 
demographic data, and clinical outcomes were extracted from the 
medical record. Multivariate logistical regression analyses determi-
ned variables of interest.
Results: The case and control cohorts were well matched with res-
pect to age, sex, method of nodal staging, SUVmax, histology sub-
type, dose and length of follow up.. The controls, as expected, had 
larger gross tumour volumes (p=0.02). The mean hilar doses were 
9.6 and 22.4 Gy for cases and controls, respectively (p=0.014). 
Similarly, the mean carinal doses were 7.0 and 9.2 Gy, respectively 
(p=0.13). The mean ipsilateral hilar doses were 19.8 and 3.6 Gy for 
ipsilateral non-hilar and hilar nodal relapses, respectively (p=0.01). 
The conditional density plot appears to demonstrate an inverse 
dose-effect relationship between ipsilateral hilar normalized total 
tases in a timely fashion. Increased tumour perfusion and FDG-
PET intensity at 2 weeks post-RT is likely due to an inflammatory 
response to large single dose SABR. Late PET response was as-
sociated with tumour control despite CT apparent morphological 
lesions. Conventional 3D PET may overestimate change in PET 
intensity post SABR as compared to 4D PET. These findings, in 
particular CT perfusion findings, require a larger patient cohort for 
validation.
Keywords: Stereotactic, response assessment, positron emission 
tomography, lung metastases
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MO17.02 RADICAL RADIOTHERAPY FOR NON-SMALL 
CELL LUNG CANCER - IS IT THE END FOR 2 GRAY PER 
FRACTION?
Noelle O‘Rourke
Beatson Cancer Centre, Cochrane Collaboration Lung Cancer Group/
United Kingdom
Background: The standard of care worldwide for radiation dose 
scheduling in NSCLC has historically been 2Gy per fraction trea-
ting once daily over six weeks. The CHART regimen of accelerated 
hyperfractionated treatment first demonstrated significant survival 
benefit from a two week radical course, attributed to reduced re-
population and improved local control. A recent individual patient 
data meta-analysis confirms significant survival benefit from acce-
lerated radiotherapy1. Meantime the evolving data on stereotactic 
radiotherapy treating early stage lung cancer over two weeks or 
less suggests marked improvement in local control rates compared 
with historical populations treated with conventional fractionati-
on2. The latest challenge to 2Gy per fraction comes from the early 
stop to the dose escalation arm of RTOG 0617 with 74Gy actually 
appearing inferior to the 60Gy arm. We postulate that overall treat-
ment time is a key factor in lung cancer radiotherapy outcomes 
and that standards of care need to be reviewed. This paper exa-
mines the current international guidelines on radical radiotherapy 
schedules, evaluates the supporting evidence and proposes new 
priorities for research.
Methods: Five international guidelines on the management of 
lung cancer were reviewed. All were published 2010-2013: ESMO 
Clinical Practice Guideline on early stage and locally advanced 
lung cancer 2010, NICE guideline (England and Wales) 2011, Aus-
tralian Government Clinical Practice Guideline for treatment of 
lung cancer 2012, Cancer Care Ontario evidence based series lung 
cancer guideline 2013, National Comprehensive Cancer Network 
(NCCN) Lung Cancer guideline v2.2013. Recommendations on ra-
dical radiotherapy dose and fractionation for NSCLC were collated 
from each guideline together with the references cited in support 
of these recommendations to assess levels of evidence.
Results: Two guidelines specifically recommended hypofractio-
nated SBRT for early stage inoperable disease -NICE and NCCN. 
The Australian guideline stated uncertainty over relative benefit 
SBRT versus conventional fractionation in stage I disease. England, 
Ontario and Australia all included CHART regimen as treatment of 
choice for stage II/III radical patients not receiving chemotherapy. 
Cancer Care Ontario undertook specific review of altered fractio-
nation schedules identifying lack of evidence for hyperfractionati-
on but suggesting possible benefit for hypofractionation. All five 
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was used to preplan ideal insertion site and fiducial location in 
relation to tumor mass. Bronchoscopy was performed, using the 
SuperDimension planning and navigation, 1 to 3 Cobra® fiducial 
markers were placed in proximity to 22 different tumors.
Results: There were no instances of pneumothorax, with patient 
followup to one week. There no instances of fiducial migration gre-
ater than 3 mm from insertion site. There were 7 episodes of post 
procedure events, which included cough, dyspnea and hypoxemia. 
All events resolved prior to patient discharge from the outpatient 
treatment area. Imaging included chest radiograph, post procedu-
re, on same day and CT chest within 1 week of procedure.
Conclusion: In this limited series, the Cobra® fiducial marker, 
using bronchoscopy and SuperDimension planning and navigation 
resulted in no instances of pneumothorax and no significant fidu-
cial migration. This contrasts many reports of percutaneous fiducial 
placements regarding complications and migration.
Keyword: endobronchial fiducial marker
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MO17.05 RECURRENCE, SURVIVAL, AND TOXICITY AF-
TER STEREOTACTIC LUNG RADIOTHERAPY (SBRT) FOR 
CENTRAL VERSUS PERIPHERAL STAGE I NON-SMALL 
CELL LUNG CANCER (NSCLC): RESULTS FROM AN IN-
TERNATIONAL COLLABORATIVE RESEARCH GROUP
Inga S. Grills1, Victor S. Mangona1, Andrew Hope2, Jose Belderbos3, 
Maria Werner-Wasik4, Jan Jakob Sonke3, Jean-Pierre Bissonette2, 
Dan Ionascu1, Ying Xiao4, André Toussaint5, Matthias Guckenber-
ger5
1Radiation Oncology, William Beaumont Hospital/United States Of 
America, 2Department Of Radiation Oncology, Princess Margaret 
Hospital/Canada, 3Radiation Oncology, Netherlands Cancer Institute/
Netherlands, 4Thomas Jefferson University/United States Of America, 
5Radiation Oncology, University Of Wuerzburg/Germany
Background: SBRT is an accepted safe and effective treatment 
modality for peripheral (P) stage I NSCLC tumors. Concern of 
excessive toxicity, however, limits its use for central (C) tumors. 
This study evaluates outcomes and toxicities after cone-beam CT 
(CBCT) image-guided SBRT for central vs. peripheral NSCLC.
Methods: 959 lung tumors were treated with lung SBRT from 
1998-2012 at five international centers participating in the Elekta 
Collaborative Lung Research Group; 98% underwent online CBCT 
IGRT. 100 cases were classified as Central (C) and 869 Peripheral 
(P), defined as ≤2cm vs. >2cm from the proximal bronchial tree, 
respectively. Staging included chest CT and routine chemistry 
for all; 93% had PET staging (mean time PET to SBRT 6.4 weeks); 
6% had mediastinal sampling (mediastinoscopy or endobronchial 
ultrasound). 61% had tumor biopsy (84% C vs. 59% P, p<0.001). 
89% were medically inoperable with mean baseline FEV1 of 1.6L 
(63% of predicted) and mean baseline DLCO of 12.1 ml/min/mmHg 
(56% of predicted). Mean age was 74y (42-93) with a large range in 
ECOG performance status (27%; 47%; 23%; 26% for 0-3, respec-
tively). Clinical stage was T1aN0 44%, T1bN0 30%, T2aN0 23%, 
T2bN0 32%. Mean tumor maximum dimension was 2.5cm (range 
0.5-8.5cm); C tumors were larger (mean 3.lcm vs. 2.4 cm, p<0.001). 
Mean SBRT prescription dose was 51.5±6.4 Gy, with mean dose 
per fraction of 14.5±4.0 Gy in 3.9±1.5 fractions. Mean biological 
dose and risk of ipsilateral hilar relapse (Figure 1).
Conclusion: Incidental hilar dose greater than 20 Gy (normalized 
to 2Gy/fraction) appears to be correlated with lack of hilar relapses 
in inoperable early stage NSCLC patients treated with SBRT.
Keywords: Non small cell lung cancer, nodal relapse, prophylactic 
irradiation, stereotactic body radiotherapy
RADIOTHERAPY I: STEREOTACTIC ABLATIVE BODY RADIOTHERAPY  
TUESDAY, OCTOBER 29, 2013 - 16:15-17:45
MO17.04 ENDOBRONCHIAL FIDUCIAL MARKER SAFETY 
AND STABILITY
Daniel A. Nader
Cancer Treatment Centers Of America/United States Of America
Background: Fiducial markers enable lesion tracking and 
localization with radiosurgery. Complications with percutaneous 
insertion are very common with pneumothorax rate reported as 
high as 67%, chest tube insertion 22% and migration of marker 
19%. The purpose of this study was to assess complications 
associated with the bronchoscopic placement of a new commercial 
fiducial marker, designed for bronchoscopic insertion and to 
reduce migration. Twenty-one consecutive patients are reviewed in 
which 60 Cobra® (SuperDimension) fiducial markers were placed 
using electromagnetic navigational bronchoscopy. Accuracy of 
placement, utility of each marker, complications and migration are 
reported.
Methods: The use of these markers was approved by a advisory 
committee at our institution. Records of 21 consecutive patients 
(12 men, 9 women; mean age 61) referred to the Interventional 
Pulmonary Division for fiducial marker placement before initiation 
of cyber knife radiosurgery (Accuray, Sunnyvale CA) between 
December 15, 2012 and June 15, 2013. Indications for radiosurgery 
included non-surgical patients with nonsmall cell lung cancer and 
metatatic disease to the lungs from colorectal carcinoma and renal 
cell carcinoma. Our institution‘s radiation oncologist requested 
between one and three fiducials placed within or adjacent to 
each lesion. A total of 60 Cobra® fiducial markers were placed. In 
each insertion procedure, a computerized tomogram of the chest 
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Cost inputs were defined as personnel costs (number of full-time 
equivalents (FTE) devoted to the actual radiotherapy process 
times reference wages according to the guidelines of the Belgian 
Health Care Knowledge Centre (KCE)), equipment costs (including 
maintenance and upgrade) and specific material costs. Following 
KCE guidelines, overhead was accounted at 56% of global costs 
excluding physician wages. The activities in scope comprised all 
activities performed during the radiotherapy process from the 
first consultation, over treatment preparation, delivery and quality 
assurance until completion of the treatment. Products included all 
radiotherapy treatments delivered in each specific department and 
combined indication with treatment site and technical complexity. 
In view of the comparative analysis, products were aggregated into 
larger categories.
Results: The average cost of all SBRT treatments was calculated 
at 6,221€ (range 3,104€ - 12,649€) and compared favorably to 
the average cost of standard fractionated 3D-CRT (5,919€, range 
4,557€ - 6,564€) and IMRT (7,379€, range 5,054€ - 8,733€). The 
average cost of hypofractionated 3D-CRT and IMRT was lower 
(3,993€ res. 4,730€). Apart from differences in investment costs, 
the relatively larger variability in fraction number and in time requi-
rements for individual personnel types performing the radiothe-
rapy activities explain the larger spread in treatment cost of SBRT 
compared to more standardized radiotherapy treatments. The 
figure demonstrates these differences for various technical SBRT 
solutions and for different 3D-CRT and IMRT fractionation sche-
dules. The overall averages are shown by the bars, minimum and 
maximum center averages by the error bars. The number of cen-
ters is mentioned between brackets. Activity times shown combine 
time per personnel with number of FTE. 
Conclusion: Cost calculation of radiotherapy treatments at the 
multi-Institutional level using Activity-Based Costing is feasible. 
SBRT shows larger variation in cost than more standardized radio-
therapy approaches in line with the larger variability in technical 
solutions, time requirements and resource consumption. Its ave-
rage cost however does not exceed the average cost of standard 
curative radiotherapy. Careful interpretation of these variables 
within the applicable economic context is required when using 
such cost data for determining financing levels.
Keyword: early-stage lung cancer, stereotactic body radiotherapy, 
cost-calculation
equivalent dose (BED) was 126.6±26.6 Gy, higher for P vs. C tu-
mors (129.2 vs. 104.0 Gy, p<0.001. Chemotherapy was adminis-
tered more for C (9%) than P tumors (2%), p<0.001. Groups were 
compared with t-test & chi-square. Competing risks analyses were 
used, accounting for the competing risk of death.
Results: Mean follow-up for all cases was 1.8y (0.1-7.7y; mean po-
tential follow-up 3.4y), similar for C&P. C tumors had higher Local 
Failure (LF) (3y-LF 16.2%C vs. 5.9%P; 5y-LF 20.4%C vs. 8.3%P, 
p<0.001), similar regional nodal recurrences (RR) (3y-RR 12%C 
vs.12%P, p=0.69) and distant metastases (DM) (3y-DM 19%C vs 
20%P, p=0.75), lower cause-specific survival (CSS) (3yr-CSS 75%C 
vs. 88%P, p<0.001), but similar overall survival (OS) (3y-OS 50%C 
vs. 51%P, p=0.70). Grade > 2 pneumonitis was higher for C tumors 
(8%C vs. 1%P, p<0.001). Incidence of grade 3 pneumonitis, chest 
wall pain/myositis, rib fracture, and skin dermatitis were rare (0.8%, 
0.5%, 0.4%, 0.6% respectively for all) with no differences between 
C&P. No grade 4 toxicities were noted, though 2 cases (1C & 1P) of 
fatal pneumonitis were potentially attributable to SBRT. On multi-
variate analysis, BED (HR:0.975, p<0.001) predicted CSS, and both 
BED (HR:0.978, p=0.002) and baseline SUVmax (HR:1.04, p=0.001) 
predicted LF. Weeks from PET-staging until SBRT (HR:1.25, 
p=0.004) and the percent of lungs receiving >20 Gy (HR:1.063, 
p=0.001) were the strongest independent predictors of OS.
Conclusion: In this large data set, pneumonitis was higher for 
central tumors, but both central & peripheral SBRT were safe with 
similar overall and cause-specific survival. LF was higher for central 
tumors, which were larger, had higher baseline SUVmax, and recei-
ved lower dose. Results of the ongoing RTOG 0813 dose-finding 
study for central tumors are awaited.
Keywords: Central, Toxicity, SBRT, radiotherapy
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MO17.07 THE COST OF STEREOTACTIC BODY RADIO-
THERAPY IN EARLY-STAGE LUNG CANCER: A MULTI-
CENTER COST-CALCULATION.
Yolande Lievens1, Caroline Obyn2, Anne-Sophie Mertens3, Dries 
Van Halewyck3, Hilde Engels4, Frank 
Hulstaert2
1Radiation Oncology Department, University 
Hospital Ghent/Belgium, 2Belgian Health Care 
Knowledge Centre - Kce/Belgium, 3Möbius 
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Background: In the framework of a coverage 
with evidence development program on 
innovative radiotherapy techniques in 
Belgium, the cost of stereotactic body 
radiotherapy (SBRT) was calculated and 
compared to the cost of more standardized 
3D-conformal (3D-CRT) and intensity-
modulated (IMRT) radiotherapy treatments.
Methods: Activity-Based Costing 
methodology was used to calculate resource 
costs of radiotherapy treatments delivered 
in ten operational Belgian departments. 
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Conclusion: A dose-volume-effect relation in SBRT for early stage 
NSCLC for local control was derived in a large cohort of pati-
ents. This dose-effect relation requires validation in independent 
datasets and prospective trials. 1.van Baardwijk,Rad.Onc.,2012. 
2.Web&Nahum,PMB,1993.
Keyword: TCP, SBRT, NSCLC
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MO17.09 DOSIMETRIC PREDICTORS OF ESOPHAGEAL 
TOXICITY AFTER STEREOTACTIC BODY RADIOTHERAPY 
FOR CENTRAL LUNG TUMORS
ANKIt Modh1, Eric Williams2, Andreas Rimner1, Amanda Foster1, 
Ellen Yorke2, Andrew Jackson2, Abraham J. Wu1
1Radiation Oncology, Memorial Sloan-Kettering Cancer Center/United 
States Of America, 2Medical Physics, Memorial Sloan-Kettering Cancer 
Center/United States Of America
Background: Stereotactic body radiotherapy (SBRT) is an effective 
treatment for early-stage non-small cell lung cancer (NSCLC) and lung 
metastases. However, increased toxicity has been observed for SBRT 
to lesions near the proximal airways or mediastinal structures. Repor-
ted toxicities have primarily pertained to pulmonary complications, 
but little is known about the risk for esophageal toxicity. Therefore, 
we sought to evaluate dosimetric predictors of esophageal toxicity in 
this patient cohort at our institution.
Methods: We identified 125 patients who received SBRT for single 
lung tumors within 2 cm of the proximal bronchial tree (n=81) or who-
se planning target volume (PTV) intersected mediastinal structures 
(n=44). Ninety-one patients had primary NSCLC, 12 had recurrent 
NSCLC, and 22 had metastatic tumors involving the lung. Patients 
with prior thoracic radiotherapy were excluded. Toxicity was scored 
using the Common Terminology Criteria for Adverse Events v.4.0. 
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MO17.08 TCP MODELING IN STEREOTACTIC BODY 
RADIOTHERAPY FOR EARLY STAGE NON SMALL CELL 
LUNG CANCER: IS A DOSE-VOLUME EFFECT PRESENT?
Heike Peulen1, Jose Belderbos1, Inga Grills2, Andrew Hope3, Matthi-
as Guckenberger4, Maria Werner-Wasik5, Victor S. Mangona2, Ying 
Xiao5, André Toussaint4, Dan Ionascu2, Jean-Pierre Bissonnette3, 
Jan Jakob Sonke6
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ation Oncology, University Of Wuerzburg/Germany, 5Thomas Jefferson 
University/United States Of America, 6Radiation Oncology, The Nether-
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Background: In early stage non-small cell lung cancer (NSCLC) 
stereotactic body radiotherapy (SBRT) has become standard of 
care for inoperable patients. Tumor size >3cm was reported to 
be a predictor of local recurrence (LR), suggesting a dose-volume 
effect. Recently, the dose effect relation was questioned1. We used 
a Tumor-Control-Probability (TCP) model on a large pooled multi-
center cohort to test this.
Methods: 850 patients were analyzed from our five institutes. 
Patients received a 4D CT-scan and plans were inversely opti-
mized using advanced dose calculation algorithms. Treatment was 
delivered using online cone-beam CT guidance. Immobilization, 
margins, dose prescription and treatment planning was performed 
according to institute specific protocols. Median tumor diameter 
was 2.2 cm (range:0.7-8.0), median prescribed dose was 54 Gy 
(range:18-64) and median number of fractions were 3 (range:1-10). 
LRs were either biopsy proven or defined as a FDG-PET positive 
growing mass on CT-scan. The Web-Nahum TCP-model2 was 
fitted to LR-data using maximum-likelihood estimation by op-
timizing its parameters: α representing the population-average 
radio-sensitivity, σα representing the population-variation in α and 
ρ the clonogen density. Input variables were the patient specific 
Gross Tumor Volume (estimated from the tumor diameter), for the 
dosimetric parameter PTV-Dmin, Dmax, Dmean, D1, D99 were evaluated 
after conversion to Biological-Effective-Dose (BED) using the LQ-
model with α/β=10Gy. We tested the optimized TCP model against 
a random model in which TCP was fixed independent of dose and 
volume. The optimal model was selected based on the Akaike-
Information-Criterion (AIC).
Results: After a median follow up (FU) of 17 months (range:0-93), 
43 LRs (5%) were diagnosed at 14 months FU (range:2-56), of which 
25 tumors were biopsy proven and 18 recurrences diagnosed 
on PET-CT. The PTV-BEDmean based TCP model showed the best 
fit with parameters α=0.43Gy-1 (CI:0.33–0.75) and σα=0.17 Gy
-1 
(CI:0.11–0.37). The model-fit was insensitive to ρ and set to litera-
ture values: 107/cm3. The AIC of the optimal model was 12 units 
higher than the random model indicating a clear dose-volume-ef-
fect. At high PTVmean-BEDs, however, the volume effect is modest. 
Additionally, the AIC of the BED corrected model was 9.4 units 
higher than the BED uncorrected model. 
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ground glass opacity’, or ‘diffuse consolidation’. The late (after 6 
months) morphology was characterized between ‘scar-like’, ‘mass-
like’ and ‘modified conventional’. Additionally the severity of radio-
logic change was scored as ‘pronounced’ (more than expected), 
‘expected’, ‘mild’ (less than expected) and none. These outcomes 
were compared to 54 patients treated with SABR by fixed-beam 
delivery, who we previously assessed using the same scoring sys-
tem.
Results: Baseline characteristics of the arc and fixed-beam cohorts 
were well matched and respective median follow-ups were no 
different, 31.7 vs. 28.4 months (p=0.20). Patients treated by arc 
delivery trended towards being more likely to have any radiologic 
change (p=0.06). This was strongly time-dependent (p<0.001) 
and more pronounced early, as by two years radiologic changes 
were almost universally present irrespective of delivery technique. 
Figure 1 shows the morphology of these changes with time. Acu-
te changes were not technique dependent (p=0.23). After six 
months, arc delivery resulted in a modified-conventional morpho-
logy throughout follow-up, while fixed-beam delivery resulted in 
an increasing probability of scar-like or mass-like morphologies. 
The predicted probabilities of a modified-conventional pattern 
following SABR by arc and fixed-beam delivery were 96.3% vs. 
68.9% (p<0.001) respectively. Following arc delivery, radiologic 
changes were more likely to be scored as pronounced or expected 
(p=0.009) than mild or none, a finding that became more evident 
with longer follow-up (p=0.014). The predicted probability of 
pronounced or expected changes two years following arc or fixed-
beam delivery was 83.1% and 26.2%, respectively. 
Conclusion: Patterns of radiologic change more than six months 
post-SABR are influenced by delivery technique. Diagnostic algo-
rithms used to differentiate suspected local recurrence and benign 
change should therefore consider the delivery technique used.
Keywords: stereotatic, Recurrence, fibrosis, Toxicity
Biological equivalent doses (BED) were calculated using the linear 
quadratic formula with either α/β=3 or 10 Gy. Dose-volume histogram 
variables for the esophagus (Dv, minimum dose to the hottest volume 
v and Vd, volume receiving doses greater than d) were then examined 
for all patients and correlation with toxicity was assessed using logistic 
regression. Log rank tests were performed using median splits for 
variables that were significant in logistic regression.
Results: With a median follow-up of 14.3 months, the overall rate of 
grade ≥2 esophageal toxicity was 12.8% (n=16), including two grade 
3 events. The median prescription dose was 45Gy. The most common 
fractionation schemes were 45Gy in 5 fractions (n=56), 48Gy in 4 frac-
tions (n=21), or 50Gy in 5 fractions (n=14). Highly significant logistic 
models were generated on the basis of D3.5cc, D5cc, and Dmax (p<0.001). 
For a complication rate < 20%, D3.5cc ≤ 29.4 Gy10, D5cc ≤ 25.4 Gy10, and 
Dmax ≤ 50.1 Gy10 was observed based on these models (BED10). Log 
rank tests showed that at 2 years, the probability of complication of 
those with a BED10 D3.5cc > 16.6 Gy was 25% (p<0.001), D5cc > 15.1 Gy 
was 26% (p<0.001), and a Dmax > 29.6 Gy was 21% (p=0.032). The pro-
bability of complication for those with a D3.5cc, D5cc, and Dmax (BED10) 
less than or equal to the above limits were 2%, 2% and 7%, respec-
tively. The analysis was insensitive to α/β, and the same Dv variables 
were found to be significant using α/β =3.
Conclusion: This is a novel quantitative analysis providing dose gui-
delines for significant esophagitis in the setting of SBRT. Dose to the 
hottest 3.5cc, 5cc and Dmax were the best parameters for prediction 
of esophageal toxicity. Converting the BED10 limits to physical doses, 
D3.5cc to the esophagus should be kept less than 18.3, 19.7 and 20.8 
Gy for 3, 4, and 5 fractions, respectively, to keep the esophagitis rate 
< 20%. However, these guidelines must be weighed against clinical 
considerations and potential compromise of target coverage. This 
information will be valuable for treatment planning and identifying 
patients at risk for esophageal complications from SBRT.
Keywords: SBRT, esophagitis, radiosurgery, NSCLC
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MO17.10 LATE RADIOLOGIC CHANGE AFTER STEREO-
TACTIC ABLATIVE RADIOTHERAPY FOR EARLY STAGE 
LUNG CANCER: A COMPARISON BETWEEN FIXED-
BEAM VERSUS ARC DELIVERY TECHNIQUES
Sashendra Senthi1, Max Dahele1, Peter M. Van De Ven2, Ben J. Slot-
man1, Suresh Senan1
1Department Of Radiation Oncology, VU University Medical Center/
Netherlands, 2Department Of Epidemiology And Biostatistics, VU Uni-
versity Medical Center/Netherlands
Background: Treatment-related radiologic change occurs com-
monly following stereotactic ablative radiotherapy (SABR) and 
often confound the interpretation of follow-up CT scans. SABR is 
frequently delivered using both fixed-beams and rotational-arcs, 
resulting in different dose distributions and it is unclear how this in-
fluences radiological change. We studied the morphology, timing 
and severity of radiologic change after both delivery techniques.
Methods: Twenty-nine patients with early stage non-small cell 
lung cancer receiving SABR by arc delivery, without clinical evi-
dence of local recurrence, and a follow-up of more than two years, 
were assessed using a published scoring system [Dahele M, JTO 
2011]. Here, the morphology of acute (within six months) radiologic 
change was characterized between ‘patchy (less than 5 cm) ground 
glass opacity’, ‘patchy consolidation’, ‘diffuse (more than 5 cm) 
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traints) and SABR regimens and volumetric image-guided delivery 
are all crucial to avoid overdosing critical structures. Typically, a 
minimum 5-10 mm distance between critical structures and gross 
tumor is required to meet dose-volume constraints.
Keyword: SABR, lung cancer, central lession, isolated parenchymal 
recurrences
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MO17.11 STEREOTACTIC ABLATIVE RADIOTHERAPY 
(SABR) FOR CENTRALLY LOCATED EARLY-STAGE OR 
ISOLATED PARENCHYMAL RECURRENCES OF NON-
SMALL CELL LUNG CANCER (NSCLC): HOW TO FLY IN  
A "NO FLY ZONE“
Joe Y. Chang1, Qing-Yong Xu1, Qiao-Qiao Li1, Neal Rebueno1, Peter 
Balter1, Daniel Gomez1, Ritsuko Komaki1, Reza Mehran2, Stephen 
G. Swisher2, Jack Roth2
1Radiation Oncology, The University Of Texas MD Anderson Cancer 
Center/United States Of America, 2Thoracic & Cardiovascular Surgery, 
University Of Texas MD Anderson Cancer Center/United States Of 
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Background: SABR has become a standard treatment option for 
medically inoperable, peripherally located early-stage NSCLC. 
However, using SABR for centrally located lesions remains chal-
lenging because of the potential for severe side effects. Here we 
sought to validate our previous experience with SABR (50 Gy in 
4 fractions) for central lesions, including the dose-volume con-
straints, and explore a new regimen of 70 Gy in 10 fractions for 
cases in which dose-volume constraints cannot be met with the 
previous regimen.
Methods: We used 4D-based, volumetric image-guided SABR 
to treat 101 patients with biopsy-proven and PET/CT-staged cen-
trally located (within 2 cm of bronchial tree, trachea, major vessels, 
esophagus, heart, pericardium, brachial plexus or vertebral body) 
T1-2N0M0 tumors (n=82) or isolated lung-parenchyma recurrent 
lesions (n=19). The treatment period spanned February 2005 
through May 2011; follow-up visits (every 3 months for 2 years and 
every 6 months for the next 3 years) included chest CT or PET/CT. 
Endpoints were toxicity (CTCAE v3.0), survival, local control, regio-
nal control, and distant metastasis.
Results: At a median follow-up time of 30.3 months for all patients 
(40.5 months for those alive), median overall survival time was 56.5 
months and 5-year overall survival rate was 49.0%. Three-year ac-
tuarial local, regional, and distant control rates were 96.5%, 87.2% 
and 77.3%. The most common toxicities were chest-wall pain (18% 
grade 1 and 13% grade 2) and radiation pneumonitis (10.9% grade 
2 and 1.9% grade 3). No patient experienced grade 4 toxicity and 
one patient with tumor invading bronchial tree who received 70 Gy 
in 10 fractions died from hemoptysis 13 months after SABR. The 
distance between tumor and chest was associated with chest wall 
pain (≤1 cm 45% vs >1 cm 17%, p=0.002). Univariate and multiva-
riate analyses showed that for the 82 patients receiving 50 Gy in 4 
fractions, mean total lung dose (MLD) >5 Gy or ipsilateral lung V20 
(iV20) >16% were independent predictors of radiation pneumonitis; 
3 of 9 patients in that group with Dmax to brachial plexus >35 Gy 
experienced brachial neuropathy versus none of the 73 patients 
with brachial Dmax ≤ 35 Gy (p=0.001).
Conclusion: SABR for centrally located lesions produces clinical 
outcomes similar to those for peripheral lesions when normal tis-
sue constraints are respected. For 50 Gy in 4 fractions, we recom-
mend MLD ≤5 Gy, lung iV20 ≤16%; bronchial tree Dmax ≤ 38 Gy, V35 
≤1 cm3; major vessel Dmax≤ 56 Gy, V40≤1 cm3; esophageal Dmax ≤35 
Gy, V30≤1 cm3 ; brachial plexus Dmax ≤35 Gy, V30≤0.2 cm3 and spinal 
cord Dmax <25 Gy. Giving 70 Gy in 10 fractions is another option 
for challenging cases but can produce severe toxicity if significant 
amounts of critical structures are exposed to ≥70 Gy. Proper se-
lection of cases (based on tumor location and normal tissue cons-
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at data cutoff. The 24-week PFS was 46%. ORR by patient charac-
teristics was also examined. The ORR for patients with ≤2 prior 
therapies was 23% (4/17) and 23% (5/22) for patients with >2 prior 
therapies. Additionally, the response for former/current smokers 
was 23% (8/35) versus 17% (1/6) for never smokers. Between 
EGFR-mutation positive and EGFR WT patients, the ORRs also 
did not differ (25% [1/4] and 19% [5/26], respectively). In contrast, 
PD-L1 status was associated with ORR response as patients with 
PD-L1–positive tumors had an ORR of 80% (4/5) and patients with 
PD-L1–negative tumors had an ORR of 14% (4/28). Updated data, 
including responses by KRAS status, will be presented.
Conclusion: Treatment with MPDL3280A was generally well to-
lerated, with no cases of Gr3-5 pneumonitis. Rapid and durable 
responses were observed, including in an EGFR-mutation positive 
patient. Responses to MPDL3280A did not appear influenced by 
the number of prior treatment regimens but did appear to be as-
sociated with PD-L1 tumor status. Additional studies have been 
initiated in NSCLC.
Keywords: PD-L1, metastatic, PD-1, immunotherapy
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MO18.02 PRELIMINARY CLINICAL SAFETY AND ACTIVI-
TY OF MK-3475 MONOTHERAPY FOR THE TREATMENT 
OF PREVIOUSLY TREATED PATIENTS WITH NON-SMALL 
CELL LUNG CANCER (NSCLC)
Edward B. Garon1, Ani Balmanoukian2, Omid Hamid2, Rina Hui3, 
Leena Gandhi4, Natasha Leighl5, Matthew A. Gubens6, Jonathan 
Goldman7, Gregory M. Lubiniecki8, Jared Lunceford9, Kevin Ger-
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Background: Currently approved cytotoxic chemotherapies for 
previously treated patients with NSCLC demonstrate few objective 
responses, which are generally of short duration, with limited im-
pact on progression-free survival and overall survival. Programmed 
death-1 (PD-1) is an inhibitory T-cell co-receptor whose activation 
by interaction with its ligands, PD-L1 or PD-L2, can lead to sup-
pression of antitumor immunity. Preclinical and clinical data indi-
cate that this pathway is important in NSCLC.MK-3475 is a huma-
nized monoclonal IgG4 antibody against PD-1.
Methods: MK-3475 was administered at 10 mg/kg every three 
weeks to patients with NSCLC previously treated with two systemic 
regimens. At least one measurable tumor lesion, ECOG perfor-
mance status of zero or one, and adequate laboratory function 
were required for eligibility. A new tumor biopsy no earlier than 60 
days before the first dose of MK-3475 was required for study entry. 
Imaging assessments per investigators were performed every nine 
weeks until confirmed disease progression utilizing the immune-
related response criteria (irRC). Independent central review of 
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MO18.01 AN ANALYSIS OF THE RELATIONSHIP OF 
CLINICAL ACTIVITY TO BASELINE EGFR STATUS, PD-
L1 EXPRESSION AND PRIOR TREATMENT HISTORY IN 
PATIENTS WITH NON-SMALL CELL LUNG CANCER (NS-
CLC) FOLLOWING PD-L1 BLOCKADE WITH MPDL3280A 
(ANTI-PDL1)
Leora Horn1, Roy S. Herbst2, David Spigel3, Scott N. Gettinger2, Mi-
chael S. Gordon4, Antoine Hollebecque5, Leena Gandhi6, Enriqueta 
Felip7, Rebecca Heist8, Ahmad Mokatrin9, Marcin Kowanetz9, Dani-
el Waterkamp9, Gregg Fine9, Jean-Charles Soria5
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tave Roussy/France, 6Dana-Farber Cancer Institute, Harvard Medical 
School/United States Of America, 7Vall D‘hebron University Hospital/
Spain, 8Massachusetts General Hospital/United States Of America, 
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Background: NSCLC may utilize PD-L1 overexpression to escape 
immune surveillance. This mechanism has been suggested by re-
cent clinical studies showing that NSCLC can respond to PD-L1/
PD-1 blockade. MPDL3280A, a human monoclonal antibody con-
taining an engineered Fc-domain designed to optimize efficacy 
and safety, aims to restore tumor-specific T-cell immunity by blo-
cking PD-L1 from binding to its receptors, PD-1 and B7.1.
Methods: Patients received MPDL3280A IV q3w for up to 1 year 
in a Phase I dose escalation/expansion study. Objective response 
rate (ORR) was assessed by RECIST v1.1 and included unconfirmed/
confirmed responses. EGFR and KRAS status was initially assessed 
locally by investigators. Archival tissue was analyzed centrally for 
PD-L1 expression by IHC.
Results: As of Feb 1, 2013, 52 NSCLC patients were evaluable for 
safety and treated at doses of 0.03-20 mg/kg. The median age 
of patients was 61 years (range, 24-83). 17 (33%) of patients were 
ECOG PS 0 and 35 (67%) of patients were ECOG PS 1. Prior treat-
ments included surgery (89%), radiotherapy (54%) and systemic 
therapy (98%). 15% of patients received 1 prior regimen, 21% re-
ceived 2 and 62% received ≥3. Additionally, 14%, 62% and 25% of 
patients were EGFR-mutation positive, EGFR WT and EGFR status 
unknown/undetermined, respectively, and 12%, 40% and 48% of 
patients were KRAS-mutation positive, KRAS WT and KRAS status 
unknown/undetermined, respectively. Patients received treatment 
with MPDL3280A for a median duration of 106 days (range 1-450). 
Treatment-related Gr3/4 AEs occurred in 12% of patients, inclu-
ding fatigue (4%) and hypoxia (4%). 1 patient experienced a Gr3/4 
immune-related AE (Gr3 hyperglycemia). No Gr3-5 pneumonitis 
or diarrhea was reported. 41 NSCLC patients first dosed at 1-20 
mg/kg prior to Aug 1, 2012, were evaluable for efficacy. An ORR 
of 22% (9/41) was observed in patients (squamous [n=9]/nonsqua-
mous [n=31]) with a duration of response range of 1+ to 214+ days. 
Additional patients had nonconventional responses after apparent 
radiographic progression but were considered to have progressive 
disease in this analysis. All responses were ongoing or improving 
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efficacy outcomes from a phase 1 study of nivolumab, a fully hu-
man IgG4 PD-1 receptor blocking monoclonal antibody, in patients 
with advanced NSCLC.
Methods: NSCLC patients enrolled between 2008–2012 received 
nivolumab 1, 3, and 10 mg/kg IV Q2W on either dose escalation or 
subsequent expansion cohorts. Tumors were assessed (RECIST 1.0) 
after each 4-dose cycle. Protocol was amended (Jan. 23, 2012) to 
explore nivolumab’s potential to deliver prolonged overall survival 
(OS) for the initial and expansion cohorts and the overall populati-
on.
Results: 129 pretreated NSCLC patients (non-squamous [n=74], 
squamous [n=54], unknown histology [n=1]) were treated as of 
March 2013. Responses (CR/PR) occurred in 22 patients (17%) and 
were durable (estimated median response duration, 74.0 weeks 
[6.1+, 133.9+]), and ongoing in 55% (12/22) of patients. The highest 
objective response rate (ORR) was at 3 mg/kg (24%) across NSCLC 
histologies. Responses were rapid; 50% of patients (11/22) de-
monstrated response at first tumor assessment (8 weeks). Among 
12 responders who discontinued therapy for reasons other than 
disease progression, 3 responded for ≥24 weeks post therapy 
discontinuation, and all 3 had not progressed at the time of this 
analysis. An additional 6 of the 122 patients (5%) demonstrated 
unconventional “immune-related” responses (based on target 
lesions), but were not included among responders. Survival benefit 
was demonstrated by 1-year and 2-year landmark OS rates (42% 
and 14%; Table). Median OS was 9.6 months across doses and 14.9 
months at 3 mg/kg across histologies. Median OS across doses 
was similar for squamous/non-squamous patients. Any grade drug-
related select adverse events (AEs) occurred in 41% (53/129) of 
patients (grade 3/4 select AEs, 5% [6/129]); most common being 
skin (16%), gastrointestinal (12%), and pulmonary (7%). Any grade 
drug-related pneumonitis occurred in 6% (8/129) of patients (grade 
3/4 pneumonitis, 2% [3/129]), resulting in 2 deaths early in the trial, 
leading to increased emphasis on management algorithms. Cha-
racteristics and management of nivolumab-related pneumonitis 
will be summarized. 
images was assessed with RECIST v1.1. PD-L1 expression on the 
pretreatment tumor sample was determined by immunohistoche-
mistry. A cut-point associated with the Youden Index of the recei-
ver-operating characteristic curve for PD-L1 staining was identified.
Results: Between April 2012 and September 2012, thirty-eight pa-
tients were enrolled. Median age was 63 years (range, 34-85 years), 
with 42% men and 42% with an ECOG performance status of zero. 
Previously treated, stable brain metastases were allowed and were 
present in 10%. Seven patients had an EGFR mutation, eight pati-
ents had a KRAS mutation, and one patient had an ALK gene re-
arrangement in their tumor. Fifty percent of patients experienced 
drug-related adverse events; the most common were fatigue, rash, 
and pruritus (16% each). The incidence of diarrhea was 13% (only 
grade 1 or 2 reported). One case of a drug-related grade 3-4 ad-
verse event (grade 3 pulmonary edema: 3%) was seen. There were 
no drug-related fatalities. Using investigator-assessed irRC, the 
objective response rate (ORR; confirmed and unconfirmed) was 
24%, including squamous and nonsquamous subtypes. Similar re-
sults were obtained using RECIST v1.1, yielding an ORR (confirmed 
and unconfirmed) of 21%. Most responses by irRC were observed 
by the time of first planned assessment at Week 9. The median 
duration of response by irRC has not been reached, with a median 
duration of follow-up of 9 months (minimum, 6 months). As of June 
2013, seven of the nine responding patients by irRC continue on 
therapy. Pretreatment tumor PD-L1 expression was a statistically 
significant predictor of response. In patients with evaluable tumor 
PD-L1 expression, all confirmed responses by RECIST v1.1 (and 
irRC) occurred in patients with tumors strongly positive for PD-L1.
Conclusion: MK-3475 is generally well tolerated in previously trea-
ted patients with advanced NSCLC and provides durable objective 
responses. An additional cohort of patients whose tumors express 
PD-L1 is enrolling; preliminary safety and efficacy data, including 
PFS and OS, will be reported further at the World Conference on 
Lung Cancer 2013.
Keywords: lambrolizumab, PD-1, PD-L1
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4538) IN PATIENTS WITH NON-SMALL CELL LUNG CAN-
CER (NSCLC): OVERALL SURVIVAL AND LONG-TERM 
SAFETY IN A PHASE 1 TRIAL
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Background: Blockade of programmed death-1 (PD-1), a co-inhibi-
tory receptor expressed by activated T cells, can overcome immu-
ne resistance and mediate tumor regression (Topalian S, et al. New 
Engl J Med. 2012;366:2443-54). We present long-term safety and 
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Cohort Dose, mg/kg
ORRa 
no. of patients/total 
no. of patients (%) 
[95% CI] 
Estimated median 
response duration, 
wk (range) 
Median OS,b 
mo 
(95% CI) 
OS rate, % 
(95% CI); patients 
at risk, n 
1 y 2 y
NSCLC 
(n=129)c
All 
doses 
22/129 (17.1) 
[11.0, 24.7] 
74.0 
(6.1+, 133.9+) 
9.6 
(7.8, 12.4) 
42 
(33, 51); 
43 
14 
(4, 24); 
5 
1 
1/33 (3.0) 
[0.1, 15.8] 
63.9 
(63.9, 63.9) 
9.2 
(5.6, 11.1) 
3 
9/37 (24.3) 
[11.8, 41.2] 
NR 
(16.1+, 133.9+) 
14.9 
(9.5, NE) 
10
12/59 (20.3) 
[11.0, 32.8] 
83.1 
(6.1+, 117.1+) 
9.2 
(5.2, 12.4) 
Initial cohort 
(n=19)
All 
doses 
9.6 
(4.5, 19.8) 
42 
(20, 64); 
8 
26 
(7, 46); 
5 
Expansion 
cohort 
(n=110)
All 
doses 
9.9 
(7.8, 12.5) 
42 
(32, 51); 
35 
Squamous 
(n=54)
All 
doses 
9/54 (16.7) 
[7.9, 29.3] 
NR 
(16.1, 133.9+) 
9.2 
(7.3, 12.5) 
39 
(25, 53); 
16 
1 0/15 0
8.0 
(2.6, 13.3) 
3
4/18 (22.2) 
[6.4, 47.6] 
NR 
(16.1, 133.9+) 
9.5 
(6.7, NE) 
10
5/21 (23.8) 
[8.2, 47.2] 
83.1 
(16.1, 117+) 
10.5 
(7.8, 12.5) 
Non-squa-
mous 
(n=74)
All 
doses
13/74 (17.6) 
[9.7, 28.2] 
63.9 
(6.1+, 74.0+) 
10.1 
(7.2, 13.7) 
43 
(31, 54); 
26 
1
1/18 (5.6) 
[0.1, 27.3] 
63.9 
(63.9, 63.9) 
9.9 
(5.6, 22.7) 
3
5/19 (26.3) 
[9.1, 51.2] 
74.0 
(24.3, 74.0+) 
18.2 
(10.3, 18.2) 
10
7/37 (18.9) 
[8.0, 35.2] 
NR 
(6.1+, 65.7+) 
7.4 
(4.6, 12.4) 
aORR = ([CR + PR] ÷ n) × 100. 
bOS estimates after 1 year reflect censoring and shorter follow-up for patients enrolling later in the study. 
cNon-squamous (n=74), squamous (n=54), and unknown histology (n=1) 
NE = not estimable; NR = not reached. 
 
Conclusion: In advanced NSCLC patients, nivolumab produced 
durable responses and survival benefit (1-year OS rate, 42%), with 
a long-term safety profile acceptable for the outpatient setting, 
supporting ongoing development in phase 3 trials with survival 
endpoints. Additional follow-up on patient survival will be presen-
ted at the time of the meeting.
Keyword: programmed death-1 receptor, nivolumab, NSCLC, 
survival
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Background: Effective therapeutic strategies for mutant KRAS and 
other biomarkers of resistance in refractory NSCLC remain an un-
met medical need, while a personalized medicine approach is in-
creasingly adopted in NSCLC guided by tumor molecular profiling. 
The BATTLE-2 clinical study is using EGFR, PI3K/AKT and MEK 
inhibitors and is designed to identify biomarkers for optimal pati-
ent selection for these therapies (ClinicalTrials.gov NCT01248247).
Methods: This is a four-arm, open-label, multi-center, biopsy-
driven, adaptive randomization, phase II clinical trial in NSCLC pts 
that failed at least 1 prior line of therapy. Patients are adaptively 
randomized to 4 arms: erlotinib, erlotinib plus the AKT inhibitor 
MK-2206, MK-2206 plus the MEK inhibitor selumetinib, and sora-
fenib. The primary objective is 8-week disease control rate (DCR). 
The trial is conducted in 2 stages. In Stage 1, 200 evaluable pts 
are adaptively randomized (AR) based on observed 8-week DCR 
and KRAS mutation status while predictive biomarkers are being 
developed by means of gene expression profiling, targeted next 
generation sequencing and protein expression. EGFR sensitizing 
mutations and EML4/ALK translocation in pts that are erlotinib and 
crizotinib naïve are exclusion criteria, while erlotinib resistant pati-
ents are excluded from erlotinib monotherapy. In Stage 2, the AR 
model is refined to include the most predictive biomarkers tested 
in Stage 1, with subsequent Stage 2 AR based on the new algo-
rithm, to a total of 400 evaluable pts. Selection of Stage 2 single 
and/or composite markers follows a rigorous, internally and ex-
ternally reviewed statistical analysis that follows a training, testing 
methodology with validation in stage 2 of the trial. All Stage 1 and 
2 randomization biomarker assays are CLIA-certified.
Results: 286 pts have been enrolled, 236 biopsies performed,172 
pts randomized, and 167 pts treated. 144 pts are evaluable for the 
8-week DCR endpoint. Within the randomized pts group KRAS mu-
tation rate is 22.8%, and EGFR mutation rate 14.8%, while 36.3% 
patients have been previously treated with erlotinib. Treatment is 
well tolerated with no unanticipated toxicity.
Conclusion: Accrual updates, demographics, and further de-
tails will be presented at the meeting. (Supported by NCI 
R01CA155196-01A1)
Keyword: KRAS, biomarkers, MEK, AKT
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MO18.04 MUC1-TARGETED DENDRITIC CELL-BASED 
VACCINES IN PATIENTS WITH STANDARD TREATMENTS-
REFRACTORY NON-SMALL-CELL LUNG CANCER
Koji Teramoto1, Jun Hanaoka2, Noriaki Tezuka2, Yataro Daigo1
1Department Of Medical Oncology, Shiga University Of Medical Sci-
ence/Japan, 2Department Of Surgery, Shiga University Of Medical Sci-
ence/Japan
Background: MUC1, a tumor antigen, has been considered to be 
a promising target antigen for cancer immunotherapy because it 
possesses a potent immunogenicity. It is processed and presented 
by antigen-presenting cells in a MHC-unrestricted pattern. Dend-
ritic cell-based vaccine immunotherapy can elicit antigen-specific 
cytotoxic T lymphocytes in tumor-bearing hosts, and activated 
cytotoxic T lymphocytes are expected to attack cancer cells. In 
this study, we evaluated the efficacy of MUC1-targeted dendritic 
cell-based vaccine immunotherapy in patients with standard treat-
ments-refractory advanced non-small-cell lung cancer (NSCLC).
Methods: The eligibility criteria of this immunotherapy were as 
follows: histologic or cytologic evidence of NSCLC that express 
MUC1 protein abundantly; an Eastern Cooperative Oncology 
Group performance status of 0-2; advanced stage of diseases 
refractory to any standard cancer treatments. The dendritic cells 
were prepared from peripheral blood mononuclear cells with cy-
tokines interleukin-4 and granulocyte macrophage colony stimula-
ting factor, pulsed with MUC1 peptides, and subsequently admi-
nistered to patients by subcutaneous injection. The vaccinations 
were repeated bi-weekly, and assessable patients were received 
at least 6 vaccinations. Tumor response was assessed according to 
the Response Evaluation Criteria in Solid Tumors. Adverse events 
were graded according to National Cancer Institute Common Toxi-
city Criteria.
Results: From June 2005 to December 2012, 36 patients were 
treated with dendritic cell-based vaccines, and 25 patients (69.4%) 
with median age of 61 years (range, 49-84 years) were assessable 
for tumor responses. The cohort consisted of 14 males and 11 
females, and 22 patients had adenocarcinomas; 2 patients with 
squamous cell carcinomas and 1 patient with pleomorphic carcino-
ma. Among these patients, neither complete response nor partial 
response was obtained. Fourteen patients had progressive disease 
as the best response, and 10 patients had stable disease, yielding 
overall disease control rate of 40.0% (95%CI=20.8-59.2). Median 
survival time after the vaccines was 10.0 months, and 1-year sur-
vival rate was 32.3%. Adverse events related to the vaccines were 
less frequent. Immunological responses could be monitored in five 
patients, showing that MUC1-specific cytotoxic responses of ef-
fector immune cells were achieved in all of those patients, and the 
population of regulatory T lymphocytes in peripheral blood cells 
was decreased after the vaccines.
Conclusion: MUC1-targeted dendritic cell-based vaccine immu-
notherapy is feasible, and has a potential to control the diseases in 
patients with refractory NSCLC.
Keywords: MUC1 tumor antigen, NSCLC, immunotherapy, dendri-
tic cell-based vaccine
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saw 18 KRAS/PIK3CA, 5 EGFR/PIK3CA, 5 BRAF/PIK3CA double 
mutant samples and 3 samples where a FGFR amplification was co-
occurring with a DDR2 mutation. Overall 40% of NSCLC patients 
harboured a potentially targetable molecular alteration. In addition 
we could allocate more than 40 patients to early personalized cli-
nical trials via the close collaboration of the partners within NGM 
and LCGC. *The frequencies of RET and ROS1 are biased, because 
of a preselection of pan negative patients.
Conclusion: NGM is one of the largest prospective molecular 
screening efforts for NSCLC worldwide, with currently more than 
3000 samples analysed per year. Our experiences so far under-
line that central comprehensive high-quality real time molecular 
diagnostics is feasible in a large health care provider network and 
allows implementation of personalized medicine in routine clinical 
care of lung cancer patients.
Keywords: Targeted therapy, NSCLC, Personalized Medicine, Mo-
lecular Screening Network
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MO18.08 PHASE II/III BIOMARKER-DRIVEN MASTER 
PROTOCOL FOR SECOND LINE THERAPY OF SQUA-
MOUS CELL LUNG CANCER (SCCA).
Vassiliki Papadimitrakopoulou1, David Gandara2, Fred Hirsch3, 
Ellen Sigal4, Mary Redman5, Jeff Allen4, Philip Mack6, Ignacio Wis-
tuba7, Roy Herbst8
1Thoracic/head And Neck Medical Oncology, Ut/MD Anderson Cancer 
Center/United States Of America, 2Division Of Hematology/Oncology, 
UC Davis Cancer Center/United States Of America, 3University Of 
Colorado Cancer Center/United States Of America, 4Friends Of Cancer 
Research/United States Of America, 5Swog Statistical Center/United 
States Of America, 6UC Davis Comprehensive Cancer Center/United 
States Of America, 7Ut/MD Anderson Cancer Center/United States Of 
America, 8Yale University/United States Of America
Background: There are few new effective therapeutic options for 
patients with advanced, lung SCCA; overall survival for metasta-
tic disease being less than one year. The Cancer Genome Atlas 
(TCGA) project and similar studies have detected a significant 
number of somatic gene mutations/amplifications in patients 
with this disease, some of which are targetable by investigational 
agents. However, the frequency of these changes is low (5-20%) in 
these patients, making recruitment and treatment very challenging 
in the traditional single-agent trial setting. Our approach is to use 
a common platform (Next Generation DNA Sequencing) to enable 
a single “umbrella screening protocol” to efficiently find patients 
with varied, uncommon molecular changes.
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MO18.07 THE NETWORK GENOMIC MEDICINE: A PRO-
SPECTIVE COMPREHENSIVE MOLECULAR SCREENING 
NETWORK FOR NSCLC
Marc Bos1, Masyar Gardizi1, Lukas C. Heukamp2, Sabine Merkel-
bach-Bruse2, Hans-Ulrich Schildhaus2, Matthias Scheffler1, Lucia 
Nogová1, Christian Mattonet1, Monika Serke3, Winfried J Rande-
rath4, Stefan Krüger5, Tim H Brümmendorf6, Ulrich Gerigk7, Jens 
Panse6, Yon D Ko8, Britta Kaminski4, Marcel Reiser9
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Background: The potential of personalized medicine for improve-
ment of lung cancer patient outcome has been paradigmatically 
shown by the treatment of advanced EGFR mutation- and ALK 
translocation positive NSCLC patients with the respective tyrosine 
kinase inhibitors. Furthermore numerous targeted drugs for mo-
lecular defined subgroups of NSCLC (e.g. ROS1- rearrangements) 
are in clinical development with the potential to improve outcome. 
Therefore one of the major challenges today is the implementation 
of comprehensive high-quality real time molecular diagnostics and 
personalized therapy for all NSCLC patients regardless of where 
they are treated.
Methods: To increase the availability of molecular testing and 
subsequently personalized treatment options for NSCLC patients 
in the catchment area of our cancer center, we established the 
Network Genomic Medicine (NGM) in January 2010. NGM is a col-
laborative network currently encompassing more than 40 different 
health care providers representing the full spectrum of lung cancer 
care in Germany including university hospitals, large non-university 
lung clinics and office based oncologists. NGM is based at the 
Center for Integrated Oncology (CIO), i.e. the joint comprehensive 
cancer center of the University Hospitals of Cologne and Bonn. At 
the NGM - headquarter genetic and clinical data are analysed and 
patients without approved targeted treatment options are scree-
ned for recruitment into NGM-linked personalized trials offered 
by the Lung Cancer Group Cologne (LCGC). Before the introduc-
tion of routine Next Generation Sequencing (NGS) within NGM 
in 06/2013 we screened lung adenocarcinomas (AD) via single 
gene assays for mutations in EGFR, KRAS, BRAF and PIK3CA, for 
amplifications in HER2 and translocations in ALK, ROS1 and RET. 
Squamous cell lung cancer (SCC) patients were screened for ampli-
fications in FGFR1 and mutations in DDR2.
Results: We screened 5,145 lung cancer patients from January 
2010 till April 2013. Genomic testing was feasible in 3,863 tumor 
samples (75%). 63% of the patients were male and 65% of sam-
ples were AD. In AD the following frequencies of genetic lesions 
were detected: EGFR 13.8% (288/2078); ALK 3.3% (54/1618); KRAS 
33.8% (831/2457); BRAF 3.5% (76/2123); PIK3CA 3.1% (70/2190); 
HER2 amplified 3.6% (62/1717); RET 4.7% (4/85) and ROS1 5.1% 
(7/135). In SCC we found a frequency of 21% (279/1333) for FGFR1 
amplification and 2.1% (11/505) for DDR2 mutations. Further we 
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MO18.10 ORAL MEK1/MEK2 INHIBITOR TRAMETINIB 
(GSK1120212) IN COMBINATION WITH PEMETREXED IN 
A PHASE 1/1B TRIAL INVOLVING KRAS-MUTANT AND 
WILD-TYPE (WT) ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC): EFFICACY AND BIOMARKER RESULTS
Julien Mazieres1, David R. Gandara2, Natasha B. Leighl3, Jennifer 
J. Wheler4, Fabrice Barlesi5, Gérard Zalcman6, Karen Kelly2, Karen 
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Background: KRAS is the most frequently mutated oncogene in 
NSCLC and represents an unmet need for targeted therapy. Tra-
metinib plus pemetrexed enhances growth inhibition and apopto-
sis of NSCLC cell lines with and without RAS/RAF mutations in vitro 
when compared with either agent alone.
Methods: This 2-part, multi-arm, open-label phase 1/1B study 
evaluated the safety and efficacy of trametinib plus chemotherapy 
(NCT01192165). Part 1 determined the recommended phase 2 
dose (RP2D) for trametinib (1.5 mg daily) and pemetrexed (500 mg/
m2 every 3 weeks) in patients with advanced solid tumors. In part 
2, patients with NSCLC were stratified as KRAS WT or KRAS-mu-
tant and treated at the RP2D. Primary study objectives were safety 
and tolerability; secondary objectives were efficacy and pharma-
cokinetics (PK). Next-generation sequencing was used to perform 
exploratory mutational profiling on available archival tissue from 21 
patients (50%). Plasma from 38 patients (90%) was analyzed both 
for tumor-derived mutations in cell-free DNA (eg, KRAS, EGFR) 
using BEAMing technology as well as cytokine and angiogenic 
factors using a Searchlight multiplex assay.
Results: A total of 42 patients with NSCLC (19 KRAS WT [79% ≥ 
2 prior therapies; 74% prior pemetrexed; 16% squamous] and 23 
KRAS-mutant [57% ≥ 2 prior therapies; 43% prior pemetrexed; 4% 
squamous]) were enrolled and treated at the RP2D until disease pro-
gression or unacceptable toxicity. Safety and PK data were previously 
reported (ASCO 2013). Response rate was 17% and disease control 
rate was 69% for the whole population of NSCLC. Of note, we obser-
ved disease control in 75% of patients previously treated with peme-
trexed (including 4 partial responses [PRs]) and in 2 patients out of 4 
with squamous histology (including one PR). Progression-free survival 
(PFS) was 5.1 months for all patients with NSCLC. Detailed efficacy 
results according to mutation status are shown in Table 1. Among 
KRAS WT, activity was seen in cancers with EGFR mutations or ALK 
rearrangement. Final biomarker analyses, including assessment of 
their potential correlation with therapeutic response or resistance,  
are ongoing and will be reported upon completion. 
Methods: This is a prospective, multi-substudy randomized Phase 
II/III Master Registration Protocol in which patients with advanced 
stage Lung SCCA (2nd line therapy)are randomized to biomarker-
driven targeted therapy (TT) or standard of care (SOC) as shown 
in the schema after undergoing genomic screening. Genomic 
screening of a large patient resource provided by sites participa-
ting in the NCI North American Intergroup will identify molecular 
targets/biomarkers with an analytically validated diagnostic assay 
and a new drug match, leading to appropriate drug treatment-arm 
assignment. Archival FFPE tumor and/or core needle biopsies will 
be screened by a broad analytically validated next generation se-
quencing (NGS) platform centrally to establish eligibility within 10-
14 days. This platform will be supplemented by individual immune-
histochemical (IHC) protein assays performed in a CLIA setting as 
necessitated by the specific experimental agent used. Patients will 
be screened with homogeneous eligibility criteria. The overall trial 
objective is to establish a mechanism to genomically screen large 
but homogeneous cancer populations and subsequently assign 
and accrue simultaneously to multiple substudies comparing new 
TT to SOC therapy based on the identified therapeutic biomarker-
drug combination. Each sub-study will function autonomously and 
will open and close independently of the other sub-studies. Drug 
combinations in the experimental arm will be allowed in appropri-
ate settings and where appropriate the control arm may consist of 
FDA approved targeted therapy such as erlotinib. Each sub-study 
is independently powered for OS with an interim analysis for PFS 
to determine the “go-no go” decision to proceed from Phase II 
into Phase III. Each agent, along with the paired biomarker, that 
is successful at the interim analysis based on PFS will advance to 
a Phase III randomized registration trial (on behalf of the Master 
Protocol Steering Committee).
Results: NA
Conclusion: NA
Keyword: squamous, genomic profiling, targets
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MO18.11 ORAL MEK1/MEK2 INHIBITOR TRAMETINIB 
(GSK1120212) IN COMBINATION WITH DOCETAXEL IN 
A PHASE 1/1B TRIAL INVOLVING KRAS-MUTANT AND 
WILD-TYPE (WT) ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC): EFFICACY AND BIOMARKER RESULTS
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Background: KRAS is the most frequently mutated oncogene 
in NSCLC and represents an unmet need for targeted therapy. 
Trametinib enhances docetaxel-induced growth inhibition and 
apoptosis of NSCLC cell lines. Cell lines with the KRAS G12C point 
mutation, the most common KRAS mutation subtype (≈50% of 
KRAS-mutant NSCLC or ≈10% of all NSCLC), are more responsive 
to apoptosis induced by this combination.
Methods: This 2-part, multi-arm, open-label phase 1/1B study 
Conclusion: MEK inhibition with trametinib + pemetrexed de-
monstrated activity in both KRAS-mutant and WT NSCLC; efficacy 
data are encouraging and warrant further study. There was no 
significant difference in activity or efficacy across KRAS mutation 
subtypes. Interestingly, activity with this combination was broad 
and was seen in patients with squamous histology, patients with 
prior pemetrexed treatment, and those with EGFR mutation or ALK 
translocation.
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evaluated the safety and efficacy of trametinib plus chemotherapy 
(NCT01192165). Part 1 determined the recommended phase 2 
dose (RP2D) for trametinib (2.0 mg daily) and docetaxel (75 mg/m2 
every 3 weeks) in the presence of growth factors in patients with 
advanced solid tumors. In part 2, patients with NSCLC were strati-
fied as KRAS WT or KRAS-mutant and treated at the RP2D. Primary 
study objectives were safety and tolerability; secondary objec-
tives were efficacy and pharmacokinetics (PK). Next-generation 
sequencing was used to perform exploratory mutational profiling 
on available archival tissue from 17 patients (36%). Plasma from 42 
patients (89%) was analyzed both for tumor-derived mutations in 
cell-free DNA (eg, KRAS, EGFR) using BEAMing technology as well 
as cytokine and angiogenic factors using a Searchlight multiplex 
assay.
Results: A total of 47 patients with NSCLC (22 KRAS WT [64% ≥2 
prior therapies; 27% squamous] and 25 KRAS-mutant [40% ≥2 prior 
therapies; 0% squamous]) were enrolled and treated at the RP2D 
until disease progression or unacceptable toxicity. Safety and 
PK data were previously reported (ASCO 2013). Progression-free 
survival (PFS) was 4.2 months for all patients; efficacy results accor-
ding to mutation status are shown in Table 1. Among KRAS-mutant 
patients, activity and efficacy were better in G12C compared with 
non-G12C subtypes. Among KRAS WT, activity was seen in cancers 
with EGFR mutations; clinical benefit was noted in 2 patients with 
ALK translocation (disease control 25 weeks and 60+ weeks). Final 
biomarker analyses, including assessment of their potential corre-
lation with therapeutic response or resistance, are ongoing and will 
be reported upon completion. 
Conclusion: MEK inhibition with trametinib + docetaxel (+ growth 
factors) demonstrated activity in both KRAS-mutant and WT NS-
CLC; efficacy data are encouraging and warrant further study. 
Cancers carrying the KRAS G12C point mutation may have impro-
ved activity and efficacy compared with non-G12C subtypes, con-
sistent with preclinical observations. Additionally, clinical benefit 
with this combination was broad and was seen in patients with 
squamous histology and those with EGFR mutation or ALK translo-
cation.
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Subgroup
Selumetinib 
+ docetaxel, 
n (number of 
PFS events)
Doce-
taxel, n 
(number 
of PFS 
events)
Selumetinib + 
docetaxel vs  
docetaxel, PFS 
HR (80% CI)
G12C or 
G12V
24 (18) 23 (21) 0.48 (0.31–0.74)
Other 19 (17) 17 (15) 0.72 (0.44–1.16)
Overall 43 (35) 40 (36) 0.58 (0.42–0.79)
 
Conclusion: Any impacts of codon sub-type on the treatment 
effect in this trial were not sufficiently significant to be detected in 
this small Phase II trial of 87 patients, but the trends observed in 
this retrospective subgroup analysis warrant monitoring of the im-
pact of specific codons or groups of codons in future clinical trials.
Keywords: selumetinib, NSCLC, metastatic, KRAS
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MO18.12 IMPACT OF KRAS CODON SUB-TYPES IN A 
PHASE II SECOND-LINE TRIAL IN KRAS-MUTANT AD-
VANCED NON-SMALL CELL LUNG CANCER (NSCLC) OF 
SELUMETINIB PLUS DOCETAXEL VERSUS DOCETAXEL 
ALONE
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Background: Phase II data from patients with KRAS mutation-
positive NSCLC, selumetinib (AZD6244, ARRY-142886) plus doce-
taxel showed promising efficacy versus placebo plus docetaxel 
alone (Jänne et al. Lancet Oncol 2013;14:38–47). Median OS was 
9.4 months (95% CI 6.8–13.6) in the selumetinib group and 5.2 
months (95% CI 3.8–non-calculable) in the placebo group (HR for 
death 0·80, 80% CI 0.56–1.14; one-sided p=0.21). Median PFS 
was 5.3 months (95% CI 4.6–6.4) and 2.1 months (95% CI 1.4–3.7), 
respectively (HR for progression 0·58, 80% CI 0.42–0.79; one-
sided p=0.014). 37% of patients in the selumetinib group and 
0% in the placebo group had an objective response (two-sided 
p<0.0001). The KRAS mutation codon subtype might impact on 
prognosis and/or response to therapy. The BATTLE trial suggested 
that G12V or C KRAS mutations confer relatively poorer outcome 
within the KRAS mutant NSCLC sub-type (Ihle et al. J Natl Cancer 
Inst 2012;104:228–39). In cell lines carrying these codons, Akt 
phosphorylation but not ERK phosphorylation was low compared 
with other codons, suggesting these codons might confer greater 
dependence upon MEK/ERK signaling. We sought to understand 
if any codons or combinations of codons selected for striking 
treatment effects either between or within treatment groups in the 
Phase II study.
Methods: Post-hoc analysis explored the hypotheses that patients 
whose tumours carried G12C or G12V KRAS mutations would have 
a worse prognosis and that these patients would have a better 
outcome with the addition of selumetinib. Clinical benefit was 
measured by PFS, OS and ORR.
Results: G12V or G12C mutations were present in 57% of patients 
and whilst not reaching statistical significance, trends for PFS, OS 
and ORR support the hypothesis (see table, PFS). Patients with 
G12V mutations responded better to selumetinib plus docetaxel 
than other patients as measured by change in tumour size at week 
6 (G12V=-62%, G12C=-8%, G12D=+3%, reduction across all co-
dons=-18%; two sided p=0.007). It is therefore possible that trends 
supporting the primary hypothesis were driven by effects in the 
small number of G12V codons (n=9). Table. Summary of analysis of 
progression-free survival (PFS): MITT by mutation subgroup  
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MO19.02 THE TUMOR IMMUNE MICROENVIRONMENT 
IN OCTOGENARIANS WITH STAGE I NON-SMALL CELL 
LUNG CANCER: IMPLICATIONS FOR IMMUNOTHERAPY
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William D. Travis2, Valerie W. Rusch2, Michel Sadelain2, Prasad S. 
Adusumilli2
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Background: The elderly have less-robust immune responses to 
infections, immunizations, and tumors, compared with younger 
people. Furthermore, preclinical studies have indicated that im-
munotherapeutic interventions are less effective in older animals. 
Considering the effects of age-associated changes in immune 
function, most clinical trials of cancer-related immunotherapy have 
been conducted in relatively young patients. With the increasing 
focus on immunotherapy for non-small cell lung cancer (NSCLC), 
we investigated the relationship between patient age and tumor 
immune parameters in stage I NSCLC.
Methods: Tissue microarrays from patients with stage I NSCLC 
(n=1371; 1995-2009; median follow-up, 3.5 years) were construc-
ted, and immunohistochemical analyses for immune cell infiltration 
(CD3, CD4, CD8, CD20, FoxP3) were performed. Patients were 
categorized into 3 groups: (1) ≤65 years old, (2) 66-79 years old, 
and (3) ≥80 years old. Stains were analyzed for immune cell infil-
tration (low vs high) in the tumor nest. The Chi-Square test was 
used to analyze the association between immune parameters and 
age group. The Kaplan-Meier method was used to estimate recur-
rence-free survival (RFS).
Results: In total, 1116 patients with stage I lung adenocarcinoma 
and 255 patients with stage I squamous cell carcinoma were en-
rolled. Patients aged ≥80 years did not have a significantly poorer 
prognosis (n=155; 5-year RFS, 76.0%) than the patients in the two 
younger groups (p=0.65; Figure 1A). There were no statistically 
significant differences in numbers of tumor-infiltrating lymphocy-
tes in the tumor nest between the three groups (Figure 1B), nor 
was there a statistically significant difference between the elderly 
group and the younger patients when effector regulatory immune 
response ratios were compared (FoxP3/CD3 ratio; high vs low, 
p=0.85). 
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MO19.01 EPIGENETIC TARGETING OF CD1D INCREASES 
ANTI-TUMOUR INKT ACTIVITY IN NON-SMALL CELL 
LUNG CANCER
Éilis F. Dockry
Thoracic Oncology Research Group, St. James›s Hospital/Trinity College 
Dublin/Ireland
Background: Immunotherapy is now accepted as the fourth 
most important modality for malignant tumours, and is currently 
being applied in the treatment of non-small cell lung cancer (NS-
CLC). CD1d, a MHC class-like molecule, presents glycolipids to 
natural killer T (NKT) cells. In doing so, CD1D contributes to their 
anti-tumour activity. CD1d is expressed in certain tumour types, 
and there is increasing evidence that CD1d acts as a target for 
NKT-mediated cell killing, however most human and mouse solid 
tumours are CD1d-negative. Recently evidence has indicated that 
CD1d expression is epigenetically regulated through HDAC1/2 and 
Spl.
Methods: CD1d levels were examined at the mRNA level by RT-
PCR. To determine whether CD1d expression is subject to epi-
genetic regulation, non-small cell lung cancer (NSCLC) cell lines 
were treated with various epigenetic modifying agents. The A549 
(adenocarcinoma) and SK-MES-1 (Squamous cell carcinoma) cell 
lines were treated with HDACi, (a) SAHA at a dose of 5 µM for 24 h. 
Treatments with other epigenetic modifyng agents such as tricho-
statin A (TSA) and DNA methyltransferase inhibitors are currenly 
ongoing. iNKT cells were co-cultured wiht NSCLC cells to examine 
their antitumourigenic activity using a CD107a externalised assay.
Results: Using RT-PCR it was possible to confirm that SAHA signifi-
cantly induced CD1d expression in both A549 and SKMES cell lines 
(p ≤ <0.005). RT-PCR was also performed on A549 and SKMES 
cell lines that had been allowed to recover, following treatment 
with SAHA. A549 cells showed a statistically significant induction 
in recovered SAHA-treated cells (p < 0.05). Using flow cytometry 
the cytotoxic T-lymphocytes (CTL) activity of iNKTs was measured. 
While there was a slight induction of CD107a-bearing iNKT cells, it 
is believed that treatment with HDACi will increase the anti-tumour 
activity of these cells. This work is ongoing at present.
Conclusion: CD1d expression is significantly induced using the 
HDACi, SAHA. This induction is present in A549 cells treated with 
SAHA and allowed to recover; indicating that SAHA may possibly 
be used to increase the anti-tumourigenic activity of iNKT cells. 
These results may have important consequences for treating pati-
ents with combined epigenetic targeting agents and immunothe-
rapy.
Keyword: iNKT CD1D NSCLC epigenetic
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T-regulatory cells (Tregs), enumeration of dendritic cells and B-
cells, as well as the inhibitory pathway programmed death-1 (PD-1) 
receptor and its ligands PD-L1 and PD-L2 on T cells and antigen-
presenting cells. Changes in immune parameters will be correlated 
with overall survival (OS) and radiological response (RECIST 1.1 
criteria) at 8 weeks post-treatment.
Results: 33 eligible patients were prospectively enrolled. Histo-
pathology was adenocarcinoma (n=23), squamous cell carcinoma 
(n=7) and NSCLC not otherwise specified (NOS, n=3)). 12 patients 
had an activating EGFR mutation, 11 were EGFR wild type, and 
mutation-status was unknown in 10. 6 patients received the TKI 
gefitinib and 4 received erlotinib as first-line treatment for EGFR-
mutation positive disease. 22 patients received erlotinib and 1 
patient received afatinib as second or subsequent line therapy. 
At time of this report, 22/33 patients were deceased. Median OS 
from study entry was: all patients (7.7 months); mutation-positive 
(11.1 months); and mutation negative (4.4 months). Samples for 13 
patients (2 were mutation-positive) have been analysed for effector 
T cell and Treg panels and no significant changes were seen bet-
ween baseline and subsequent time points. Data will be presented 
for all samples.
Conclusion: This is the first study to explore to the immune effects 
of EGFR-TKIs. Initial results have not revealed a significant effect 
on peripheral T-cells, and analysis of remaining patient samples 
and other panels is in progress. An understanding of the immune 
effects of targeted therapies will be crucial in the rational develop-
ment of strategies for incorporating immunotherapy into the anti-
EGFR treatment paradigm, in an era of promising immunotherapy 
and checkpoint blockade approaches.
Keyword: immunotherapy, targeted therapies, EGFR inhibitors
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MO19.05 EGFR SIGNALING EFFECTS ON NK CELL-MEDI-
ATED CYTOTOXICITY VIA NKG2D LIGANDS-NKG2D IN-
TERACTION IN NON-SMALL CELL LUNG CANCER CELLS
Riki Okita1, Yuji Nojima1, Koichiro Yasuda1, Ai Maeda1, Takuro 
Yukawa1, Shinsuke Saisho1, Yuji Hirami2, Katsuhiko Shimizu1, 
Masao Nakata1
1General Thoracic Surgery, Kawasaki Medical School/Japan, 2General 
Thoracic Surgery, National Hospital Organization Fukuyama Medical 
Center/Japan
Background: EGFR-tyrosine kinase inhibitor Gefitinib interrupts 
signaling through the EGFR in non-small-cell lung cancer (NSCLC) 
cells with EGFR driver mutation and has shown impressive activity 
in terms of clinical benefit for patients with NSCLC, however, al-
most all patients develop resistance to this drug. Although much 
research is focusing on the mechanisms of drug resistance in tumor 
cell, the role of EGFR signaling in tumor escape from the host im-
mune system is poorly understood. NK cell activity is promoted 
via NK group 2, member D (NKG2D) on NK cells. The engagement 
between NKG2D and its ligands enhances cell-mediated cytotoxi-
city and cytokine production against transformed cells. Both MHC 
class I-related chain A and B (MICA/B) and UL16 binding protein 
(ULBP)s are expressed by intestinal epithelial and at low levels also 
by other non-malignant cell types. Primary tumor cells and tumor 
cell lines frequently express NKG2D ligands, but the mechanisms 
responsible for the induction of NKG2D ligands during oncoge-
Conclusion: In this large cohort of stage I NSCLC patients selected 
for surgical resection, the tumor microenvironment among elderly 
patients resembles other age groups. Our study provides impor-
tant information while considering immunotherapy in elderly pati-
ents with lung cancer.
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MO19.03 THE EFFECTS OF EPIDERMAL GROWTH FAC-
TOR (EGFR) RECEPTOR INHIBITORS ON THE IMMUNE 
SYSTEM IN PATIENTS WITH ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC)
Tarek Meniawy1, Richard Lake2, Anna K. Nowak1
1School Of Medicine And Pharmacology, University Of Western Austra-
lia/Australia, 2The University Of Western Australia - National Centre 
For Asbestos-related Diseases/Australia
Background: EGFR tyrosine kinase inhibitors (TKIs) have an impor-
tant role in the treatment of NSCLC, particularly in the context of 
activating mutations, but resistance invariably develops. Recently, 
the immune checkpoint blockers anti-PD1 and anti-PDL1 were the 
first immunotherapies to demonstrate activity in advanced lung 
cancer. As immunotherapies such as anti-CTLA4, anti-PD1 and 
anti-PD-L1 antibodies enter clinical practice, there is potential to 
combine immunotherapies with TKIs to improve patient outcomes. 
The immune effects of EGFR-TKIs have not been elucidated, and 
the aim of this study is to examine the effect of TKIs on the immu-
ne response in patients with NSCLC, to provide a rationale and 
pilot data to underpin future clinical development of combinations 
of TKIs and immunotherapy.
Methods: Patients with advanced NSCLC who were commencing 
an EGFR-TKI were included in this prospective study. Eligible pa-
tients had a confirmed diagnosis of NSCLC, were treated with a 
single-agent EGFR-TKI , had no concurrent autoimmune disease 
and received no chemotherapy within 21 days, or corticosteroid 
therapy within 3 days of study entry. Peripheral blood samples 
were collected before commencing a TKI and 7 days, 21 days and 
8 weeks after start of treatment. Peripheral blood mononuclear 
cells (PBMCs) were isolated and immediately frozen for subsequent 
analysis by 8-colour flow cytometry for relevant surface and intra-
cellular marker expression. 4 panels were developed to examine 
the activation and proliferation status of effector CD8+ T and CD4+ 
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Methods: To study the ‘necessity’ of FGF-9 in MPM development 
in vivo we transfected the mouse MM cell line, AB1, with shRNA 
directed against murine FGF-9 (or control vector expressing a 
scrambled sequence). For the heterotopic model murine AB1-
FGF-9 knock-down cells (or controls) were injected (5x105 cells) 
subcutaneously into the flank of Balb/c mice. Tumour dimensions 
were measured thrice weekly and animals sacrificed when tumours 
reached 100mm2 and tumour tissues harvested. FGF-9 expression 
in tumour tissue was determined by immunohistochemistry. For 
orthotopic experiments, Balb/c mice received a single intraperito-
neal injection of 5x105 AB1-FGF-9 knock-down cells (or controls). At 
day 13, animals were sacrificed and the number of peritoneal tu-
mour nodules enumerated by blinded investigators. To determine 
whether the immune system plays a role in the regulation of AB1 
MM tumour growth, 5x105 AB1-FGF-9 knock-down cells (or cont-
rols) were injected subcutaneously into nude mice. To elucidate 
the immune cells involved in AB1 MM tumour growth regulation, 
T cells were depleted in Balb/c tumour bearing mice using specific 
antibodies to CD4 and CD8 and tumour growth monitored. T cell 
depletion was confirmed using flow cytometry.
Results: Heterotopic tumour growth was significantly retarded in 
mice inoculated with AB1-FGF-9 knockdown cells compared to 
the scrambled vector and parent MM cells (p<0.001). A significant 
reduction in the number, and hence tumour burden, of tumour 
nodules was also observed for AB1-FGF-9 knockdown tumours in 
the orthotopic peritoneal model compared to controls (p<0.001). 
When grown in nude mice, which lack a functional T cell repertoire, 
AB1-FGF-9 knockdown tumours grew at a similar rate to that of the 
parent and vector controls which was suggestive of a role of the 
immune response in the regulation of MM tumours lacking FGF-9. 
AB1-FGF-9 knockdown tumours demonstrated significantly greater 
tumour burden in mice depleted of CD4+ and CD8+ T cells, either 
alone or in combination, when compared to saline controls which 
is highly suggestive of a T cell-mediated immune response to 
these tumours. These results also suggest that FGF-9 inhibits the 
tumour-specific immune response in MM.
Conclusion: In combination with our previous in vitro data which 
clearly demonstrated the proliferative and invasive properties of 
FGF-9, we suggest that FGF-9 has an important role in the pat-
hobiological characteristics of MM in vivo and represents a novel 
therapeutic target.
Keyword: Mesothelioma, animal model, FGF-9, therapy
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MO19.07 LUNG CANCER-INITIATING CELLS AVOID  
IMMUNE RECOGNITION
Jason C. Steel, Brian J. Morrison, John C. Morris
Hematology-Oncology, University Of Cincinnati/United States Of  
America
Background: Increasing evidence supports the concept of a 
unique population of cells within a tumor with stem cell-like cha-
racteristics. These cancer-initiating cells (CICs) are thought to be 
responsible for tumor organization, maintenance, progression and 
recurrence, as well as contributing to radiation and chemotherapy 
resistance. In this study we outline a new characteristic of CICs, 
one in which the CIC can subvert the host immune response. We 
pose that this characteristic is essential for the establishment of a 
nesis are also poorly understood. Here we demonstrate Gefitinib 
downregulates NK group 2 member D (NKG2D) ligand MICA/B 
and ULBPs, resulting in attenuation of NK cell-mediated cytotoxici-
ty in NSCLC cells.
Methods: Possible influences of Gefitinib on expressions of MHC 
class I, MICA/B and ULBP1-3 in 5 NSCLC cell lines (A549, PC-9, 
RERF-LC-KJ, RERF-LC-AI, and LC2/ad) were investigated by flow 
cytometry. We also assessed whether genetic silencing of EGFR 
using siRNA of EGFR affected on the expression of NKG2D ligan-
ds. To ask the main downstream pathway of EGFR regulating the 
expression of NKG2D ligands, the cells were treated with PI3K-AKT 
inhibitor LY294002 or MEK inhibitor PD98059 then the expression 
of NKG2D ligands was analyzed. NK cell-mediated cytotoxicity 
against cancer cells was assessed by 51Cr release assay or flow 
cytometry based CD107a degranulation assay.
Results: Gefitinib downregulated NKG2D ligands in NSCLC cell 
lines. In line with these results, siRNA-mediated silencing of EGFR 
downregulated the expression of NKG2D ligand. Among the major 
downstream pathways activated by EGFR signaling, the expression 
of NKG2D ligands was mainly regulated by the PI3K-AKT pathway. 
Treatment with EGF promoted MICA/B expression in 2 of 5 cell li-
nes, while EGF decreased MICA/B in 1 of 5 cell lines. These obser-
vations further emphasize that EGFR signaling is one of the major 
pathways regulating the expression of NKG2D ligands in NSCLC 
cells. As expected, inhibition of EGFR signaling-downregulated 
NKG2D ligands attenuated NK cell-mediated cytotoxicity.
Conclusion: We conclude that EGFR signaling directly regulates 
the expression of NKG2D ligands and that this may influence the 
recognition of tumor cells by the innate immune system.
Keywords: non-small-cell lung cancer, NK cell, EGFR, NKG2D 
ligand
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MO19.06 THE ROLE OF FIBROBLAST GROWTH FAC-
TOR-9 IN THE REGULATION OF THE TUMOUR-SPECIFIC 
IMMUNE RESPONSE IN MALIGNANT MESOTHELIOMA
Sally Lansley1, Ai Ling Tan1, Julius Varano1, Sophia Karabela2, 
George Stathopoulos2, Jenette Creaney3, Yc Gary Lee4
1Lung Institute Of Wa/Australia, 2University Of Patras/Greece, 3Natio-
nal Centre For Asbestos Related Disease/Australia, 4Respiratory Medi-
cine, Sir Charles Gairdner Hospital, University Of Western Australia/
Australia
Background: Identifying key molecules in the pathobiology of 
malignant mesothelioma is needed to develop new therapies and 
biomarkers. Fibroblast growth factor-9 (FGF-9) is an exciting and 
novel target uncovered from our global gene profiling of human 
MPM samples. Recently FGF-9 has been implicated in cancer de-
velopment and neoplastic transformation of embryonic fibroblasts. 
We have verified over-expression of FGF-9 in MPM over other can-
cers and benign pleuritis in five separate cohorts of human pleural 
tissues and effusions. Our preliminary in vitro work demonstrated 
that FGF-9 induces mesothelioma cell proliferation and matrix 
invasion. We therefore hypothesised that antagonising FGF-9 may 
reduce tumour aggressiveness, growth and induce tumour regres-
sion in vivo.
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MO19.09 MOLECULAR CORRELATES OF PD-L1 STATUS 
AND PREDICTIVE BIOMARKERS IN PATIENTS WITH 
NON-SMALL CELL LUNG CANCER (NSCLC) TREATED 
WITH THE ANTI-PDL1 ANTIBODY MPDL3280A
Scott N. Gettinger1, Marcin Kowanetz2, Jean-Charles Soria3, Leena 
Gandhi4, Leora Horn5, Michael S. Gordon6, David Spigel7, Cristina 
Cruz8, Paul Conkling9, Scott Antonia10, Hartmut Koeppen2, Yuany-
uan Xiao2, Ahmad Mokatrin2, Xiaodong Shen2, Gregg Fine2, Roy S. 
Herbst1
1Yale School Of Medicine/United States Of America, 2Genentech Inc./
United States Of America, 3Institut Gustave Roussy/France, 4Dana-
Farber Cancer Institute, Harvard Medical School/United States Of 
America, 5Vanderbilt University Medical Center/United States Of Ame-
rica, 6Pinnacle Oncology Hematology/United States Of America, 7Sarah 
Cannon Research Institute; Tennessee Oncology, Pllc/United States Of 
America, 8Vall D‘hebron University Hospital/Spain, 9Virginia Oncology 
Associates, Usoncology/United States Of America, 10Moffitt Cancer 
Center/United States Of America
Background: In NSCLC, antitumor immune response may be inhi-
bited by PD-L1 expression. MPDL3280A, a human monoclonal an-
tibody containing an engineered Fc-domain designed to optimize 
efficacy and safety, aims to restore tumor-specific T-cell immunity 
by blocking PD-L1 binding to its receptors, PD-1 and B7.1.
Methods: Patients with squamous or nonsquamous NSCLC re-
ceived MPDL3280A IV q3w up to 1 year as part of a phase I dose 
escalation/expansion study. Objective response rate (ORR) was 
assessed by RECIST v1.1 and included unconfirmed/confirmed 
responses. EGFR and KRAS status was initially assessed locally 
by investigators. Archival tumor tissues were evaluated centrally 
by IHC for PD-L1 and CD8. A qPCR-based gene expression panel 
measuring ≈90 immune-related genes was used to characterize 
the tumor immune microenvironment at baseline and during MPD-
L3280A treatment.
Results: 41 NSCLC patients first dosed at 1-20 mg/kg prior to Aug 
1, 2012, were evaluable for efficacy with an ORR of 22%. Baseline 
tumor samples were available for IHC (n=33) and for gene expres-
sion analysis (n=29). Of patients with available tissue, 5 were PD-L1 
tumor status positive and 28 were PD-L1 tumor status negative. 
Relationship between PD-L1 status and EGFR/KRAS status is de-
scribed below (table). Elevated baseline PD-L1 expression was as-
sociated with response to MPDL3280A (80% ORR vs 14% ORR for 
PD-L1negative patients), and PD-L1 expression coordinated with 
CD8+ T cells. A Th1-type T-cell gene signature (including CD8, 
Granzyme-B and EOMES) was associated with treatment response. 
Non-responders exhibited at least a 2-fold higher ratio over CD8 
of genes associated with immunosuppression, including RORC, 
FOXP3, TGFb1 and IL10 compared with responders. On treatment, 
responding tumors across indications showed increasing PD-L1 ex-
pression and a Th1-dominant immune infiltrate, providing evidence 
for adaptive PD-L1 up-regulation.
Conclusion: PD-L1 expression and a Th1 driven T-cell gene sig-
nature correlated with response to MPDL3280A in NSCLC, and 
MPDL3280A therapy led to T-cell reactivation and restored anti-
tumor immunity. Additionally, expression of immune suppressive 
factors in NSCLC tumors is associated with a lack of benefit from 
MPDL3280A. These data provide mechanistic insights into immu-
notherapy and patient selection for MPDL3280A monotherapy. 
Preliminary observations suggest clinical activity and molecular 
tumor in an immunocompetent host and may represent a mecha-
nism in which lung tumors may gain resistance to immune based 
therapies.
Methods: We examined whether lung CICs could be enriched 
from murine and human cell lines through the use of tumorsphere 
culture assays. We vaccinated mice against the HPV E7 antigen 
and challenged mice with HPV E6/7 expressing murine lung can-
cer cells (TC-1) enriched for CICs. We also examined ex-vivo the 
capacity of CD8 and NK cells derived from vaccinated mice to lyse 
CICs. We examined by flow cytometry the expression of MHC-I 
and NK activating ligands. We examined the effect of interferon 
gamma (IFN-γ) on MHC-I expression by CICs and determined whe-
ther increased MHC-I by CICs would inhibit tumor formation in an 
immunocompetent animal.
Results: We showed that both murine and human lung cancer cells 
can be grown and maintained in tumorsphere culture conditions. 
The resulting cells were enriched for CICs as evidenced by increa-
sed OCT4, NANOG, and/or SOX2 expression. Additionally, tumor-
sphere cultures of murine tumor lines had increased tumor take 
in immunocompetent animals, however this was significantly less 
than that seen in immunodeficient mice; indicating that true CICs 
must be able to thwart the immune response to establish tumors. 
In order to further examine this, we vaccinated mice with HPV E7 
peptides and challenged with TC-1 non-CICs or CICs. We showed 
that mice challenged with CICs had no survival advantage compa-
red to non-vaccinated animals; whereas those animals challenged 
with non-CICs exhibited a vaccine induced survival advantage. 
Further we showed ex-vivo that CICs were resistant to lysis from 
CD8+ T-cells compared to the non-CICs. Next, we showed that 
both murine and human lung CICs have down-regulated expres-
sion of MHC-I as well as a number of ligands for NK cell activating 
receptors, essentially making them “opaque” to the immune sys-
tem and therefore less susceptible to CTL or NK cell lysis. Further, 
we demonstrate that IFN-γ increases MHC-I expression on CICs 
and restores sensitivity to CTL killing. Finally, we demonstrate that 
decreased MHC-I expression is a critical component of the ability 
of CICs to establish tumor in immunocompetent hosts.
Conclusion: Increasing evidence indicates that CICs are critical 
players in the development and establishment of cancers. In this 
study we demonstrated that these cells also subvert tumor im-
mune surveillance and play a key role in the resistance of tumors 
to cancer vaccines through their ability to escape host immune 
responses. Our results demonstrated that modulation of MHC-I on 
CICs can alter their susceptibility to T-cell mediated lysis thus ope-
ning a new target for cancer vaccine strategies.
Keywords: MHC-I, immunotherapy, cancer initiating cells, cancer 
stem cells
S377Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
ment in the NSCLC tumor samples. Disease associated biomarkers, 
including the mutation status of EGFR and KRAS, as well as expres-
sion of MET (by IHC) were also evaluated.
Results: Prevalence of PD-L1 was comparable between adenocar-
cinoma and squamous cell carcinoma (≈30% in tumor cells; ≈45% 
and ≈50%, respectively, in immune cells). PD-L1 prevalence varied 
depending on the pathological stage, and was higher in Stages 
I-IIIA than in Stages IIIB-IV. Similarly, the prognostic value of PD-L1 
varied by both stage and histology. In adenocarcinoma, tumors 
with PD-L1–positive tumor cells had a higher frequency of KRAS 
mutation and high Met expression, and a lower frequency of EGFR 
mutation compared with PD-L1–negative tumors. In contrast, tu-
mors with PD-L1–positive and PD-L1–negative immune cells had a 
comparable frequency of high Met expression. Expression of PD-
L1 was frequently co-localized with CD8+ T-cell infiltrates. Gene 
expression profiling revealed differences in the tumor immune 
environment, including genes associated with cytotoxic T-cells, 
between adenocarcinomas and squamous cell carcinomas. PD-L1 
protein and immune gene expression associations with patient 
characteristics will be described in further detail.
Conclusion: These data provide a comprehensive description of 
PD-L1 expression in the context of disease biology utilizing large 
independent cohorts of well-characterized lung cancer tissues. The 
results highlight the complexity of the tumor immune environment 
in NSCLC with particular emphasis on the association with factors 
such as pathological stage, histology and oncogenic mutational 
status. These analyses may help guide future development of im-
munotherapy trials in NSCLC.
Keywords: Lung cancer, PD-L1, immunotherapy, predictive bio-
marker
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MO19.11 CLINICOPATHOLOGICAL AND PROGNOSIS 
FEATURES OF PD-L1 IN NSCLC PATIENTS IN CHINESE 
POPULATION.
Shuai Li, Fei Zhou
Medical Oncology, Shanghai Pulmonary Hospital/China
Background: Programmed Death Ligand-1 is a ligand for Program-
med cell death protein 1 which is a key receptor regarding one 
of the immune checkpoints. PD-L1 expression in tumor is known 
to correlate with post-operative survival in different set of cancer 
patients. In the present study, we investigated PD-L1 expression of 
tumor cells in specimens acquired from non-small cell lung cancer 
patients and analyzed the correlation between the PD-L1 expressi-
on and clinicopathological characteristics and postoperative prog-
nosis of 208 Non-Small Cell Lung Cancer patients.
Methods: PD-L1 expression in 208 specimens of NSCLC was as-
sessed through an immunohistochemical process and inspected 
double-blinded.
Results: PD-L1 expression is associated with clinicopathological 
features (histology, P=0.047 and differentiation, P=0.023). No sig-
nificant association observed between PD-L1 expression and post-
operative prognosis. However, subgroup analysis of squamous 
carcinoma patients with positive PD-L1 protein expression showed 
a tendency of poor overall survival and disease-free survival com-
characteristics may be associated with PD-L1 tumor expression. 
Updated data will be presented. Table: Relationship between PD-
L1 status and EGFR/KRAS mutational status 
PD-L1-
Positive 
(n = 5) 
PD-L1-
Negative 
(n = 28) 
PD-L1 
Unknown 
(n = 7) 
Overall  
(n = 40)* 
EGFRm, n 1 2 1 4 
EGFR WT, n 2 20 4 26 
EGFR Unknown, 
n 
2 6 2 10 
KRASm, n 1 4 1 6 
KRAS WT, n 2 8 3 13 
KRAS Unknown, 
n 
2 16 3 21 
* 1 patient had 
missing data. 
Keywords: PD-1, immunotherapy, predictive biomarker, PD-L1
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MO19.10 PREVALENCE AND PROGNOSTIC ASSOCIATI-
ON OF PD-L1 PROTEIN AND IMMUNE GENE EXPRESSI-
ON IN NSCLC
Marcin Kowanetz1, David S. Shames1, Hartmut Koeppen1, Yua-
nyuan Xiao1, Carmen Behrens2, Rupal Desai1, Ling Fu1, Colombe 
Chappey1, Ahmad Mokatrin1, Edward E. Kadel1, An Do1, Odd Terje 
Brustugun3, Manolo D’Arcangelo4, Theresa Boyle4, Daniel S. Chen1, 
Garret Hampton1, Lukas C. Amler1, Fred R. Hirsch4, Priti S. Hegde1, 
Ignacio I. Wistuba2
1Genentech Inc./United States Of America, 2MD Anderson/United Sta-
tes Of America, 3The Norwegian Radium Hospital/Norway, 4Uc Denver/
United States Of America
Background: Programmed Death Ligand 1 (PD-L1, CD274, B7-H1) 
is an immune checkpoint molecule that binds to the receptors 
PD-1 and B7.1 on activated T cells. Binding negatively regulates 
T-cell function in both physiological and pathological conditions. 
Recent clinical studies have suggested that numerous cancers, in-
cluding NSCLC, may utilize PD-L1 expression to escape T-cell me-
diated cytotoxic activity. Inhibition of PD-L1 can restore anti-tumor 
immunity, leading to clinical responses. A better understanding 
of PD-L1 expression patterns, co-expression with other immune 
markers and actionable disease associated biomarkers may provi-
de insight into the future design of cancer immunotherapy trials in 
NSCLC.
Methods: Expression of PD-L1 was measured by immunohistoche-
mistry (IHC) in archival tumors and, in some cases, in paired metas-
tases in 2 FFPE NSCLC tumor tissue collections. Set 1 (N=561) was 
collected from patients who were eligible for surgery with curative 
intent from 2003 to 2005 at MD Anderson Cancer Center. The 
samples from Set 2 (N=300) contained surgically resected NSCLC 
tissue collected between 2006 and 2011 (UCCC and Norwegian 
Radium Hospital). PD-L1 expression was analyzed in both malig-
nant and non-malignant cells (e.g., infiltrating immune cells). In ad-
dition, a multiplex qPCR assay that measures ≈90 immune-related 
genes was used to characterize the tumor immune microenviron-
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analysis, high CD4+/high FoxP3+ ratios (HR=1.58; p=0.001) and 
high CD10+/low CD20+ counts (HR=1.71; p<0.001) remained signi-
ficantly associated with poorer survival (Table). 
Table. Multivariate analysis for overall survival
Variable HR 95% CI p
High CD4+/high 
FoxP3+ ratios
1.58 1.21–2.06 0.001
High CD10+/low 
CD20+ counts
1.71 1.28–2.27 <0.001
Age (>65 years old) 1.51 1.09–2.09 0.014
Sex (male vs. female) 1.31 1.01–1.69 0.043
Smoking pack years 
(>90)
1.01 1.00–1.01 0.003
Stage (II and III vs. I) 1.53 1.16–2.02 0.002
Lymphovascular inva-
sion
1.38 1.02–1.88 0.040
Conclusion: High CD4+/high FoxP3+ ratios and high CD10+/low 
CD20+ counts are significant factors of prognosis for lung SCC, in-
dependent of TNM staging. Targeting regulatory T cells or enhan-
cing tumor-specific B-cell responses may thus have applicability for 
the treatment of lung SCC.
Keywords: lung, squamous cell carcinoma, Immune Cell, survival
pared with those with negative PD-L1 protein expression.
Conclusion: we have shown for the first time that PD-L1 expression 
is associated with clinicopathological features (histology and diffe-
rentiation). In the subgroup analysis of squamous carcinoma pati-
ents, patients with positive PD-L1 expression showed a tendency 
to be associated with poorer survival compared with those with 
negative PD-L1 expression, which suggested that patients with 
squamous carcinoma might be the most benefit population in the 
anti-PD-1 immunotherapy.
Keywords: Immune Checkpoint, Programmed Death Ligand-1, 
non-small cell lung cancer, Immunohistochemistry
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MO19.12 PROGNOSTIC IMPACT OF TUMOR-INFILTRA-
TING IMMUNE CELLS IN LUNG SQUAMOUS CELL CAR-
CINOMA
Adam Bograd1, Kyuichi Kadota2, Junichi Nitadori2, Leonid Cher-
kassky2, Valerie W. Rusch2, William D. Travis2, Michel Sadelain2, 
Prasad S. Adusumilli2
1Department Of Surgery, New York University/United States Of Ameri-
ca, 2Memorial Sloan-Kettering Cancer Center/United States Of America
Background: The prognostic significance of the tumor immune mi-
croenvironment in lung adenocarcinoma has been established by 
us (CCR 2011, JCO 2013, Oncoimmunology 2013) and others. Here, 
we investigate whether tumor-infiltrating immune cells correlate 
with prognosis, independent from TNM staging, in lung squamous 
cell carcinoma (SCC).
Methods: All available tumor slides from therapy-naive, surgically 
resected solitary lung SCCs (n=485; 1999-2009) were reviewed. 
Tissue microarrays were constructed using 451 cases (stage I, 255; 
II, 131; III, 65) from 3 representative tumor areas. Immunostaining 
for CD3 (pan T cell marker), CD45RO (memory T cell), CD8 (cyto-
toxic T cell), CD4 (helper T cell), FoxP3 (regulatory T cell), CD20 (B 
cell), CD68 (macrophage), and CD10 (neutrophil) was performed. 
For each case, the average number of cells positive for T cell mar-
kers was recorded as the ratio to CD3+ lymphocytes, and classified 
as low or high by use of the median. CD20, CD68, and CD10 were 
classified as low or high by the number of positive cells (≥20, ≥50, 
and ≥10, respectively) as our recent publication (JCO 2013). Ove-
rall survival (OS) was estimated using the Kaplan-Meier method; 
multivariate analyses were performed using the Cox proportional 
hazards model.
Results: Five-year OS was 59% for the entire cohort and 68% for 
stage I patients. Analysis of single immune cell infiltration revealed 
that high CD10+ neutrophil count was correlated with lower OS 
(5-year OS, 53%; n=160) than low CD10+ count (5-year OS, 61%; 
n=286; p=0.006). Analysis of biologically relevant immune cell 
combinations identified 2 significant factors of prognosis: (1) pa-
tients with high CD4+ and high FoxP3+ T cell ratios had worse 
prognosis (5-year OS, 52%; n=140) than the other groups (5-year 
OS, 62%; n=304; p=0.008), and (2) patients with high CD10+ neu-
trophil and low CD20+ B lymphocyte counts had worse prognosis 
(5-year OS, 43%; n=102) than the other groups (5-year OS, 63%; 
n=340; p<0.001). These results were confirmed in a subgroup ana-
lysis limited to stage I patients (p=0.020 for high CD4/high FoxP3+ 
ratios; p=0.007 for high CD10+/low CD20+ counts). In multivariate 
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in LSCC TICs and that PKCι signaling is important for maintaining 
the TIC phenotype. We showed that the selective PKCι inhibitor 
ANF potently inhibits LSCC TIC behavior. Taken together, our data 
support the targeting of LSCC TICs through selective inhibition 
of PKCι for treatment of patients with LSCC. Based on these and 
earlier results showing synergistic tumor inhibition with combined 
PKCι and mTOR inhibition, a phase I clinical trial of auranofin with 
the mTOR inhibitor sirolimus has been instituted as maintenance 
therapy for LSCC patients who have completed initial chemothe-
rapy.
Keyword: PKCiota, Tumor initiating cells, mTOR, auranofin
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MO20.02 PROTEOMIC ANALYSIS IDENTIFIES BASELINE 
PI3K/AKT PATHWAY ACTIVATION AND TREATMENT-
INDUCED SUPPPRESSION OF MTOR SIGNALING AS DE-
TERMINANTS OF RESPONSE TO MEK INHIBITION
Kathryn A. Gold1, Lauren A. Byers1, Dianren Xia1, Youhong Fan1, 
Lixia Diao2, Philip Groth3, Julianne Paul3, Jing Wang2, Uma Giri1, Ja-
yanthi Gudikote1, Hai T. Tran1, John D. Minna4, Kevin R. Coombes2, 
Ningshu Liu3, John V. Heymach1
1Thoracic/head And Neck Medical Oncology, University Of Texas MD 
Anderson Cancer Center/United States Of America, 2Bioinformatics & 
Computational Biology, The University Of Texas MD Anderson Cancer 
Center,/United States Of America, 3Bayer Pharmaceuticals/Germany, 
4Southwestern Medical Center/United States Of America
Background: Inhibition of MEK is a promising treatment strategy for 
non-small cell lung cancer (NSCLC). MEK inhibitors are being inves-
tigated for KRAS mutant disease, but KRAS alone is not predictive 
of efficacy, and other predictors of response and resistance are not 
known. The downstream effects of MEK inhibition have not been 
fully described. Here, we report broad proteomic analysis of NSCLC 
cell lines before and after treatment with MEK inhibitor BAY86-9766.
Methods: We treated 109 NSCLC cell lines with BAY86-9766. Drug 
sensitivity was determined by CellTiter-Glo assay and cell lines were 
classified as sensitive or resistant based on whether their IC50 values 
were in the highest or lowest 1/3rd of those tested. Proteomic analysis 
for regular and phospho-proteins was performed by reverse phase 
protein array. Using paired t-tests, we compared pre- versus post-
treatment protein levels in the overall group and between the sensiti-
ve vs. resistant cell lines.
Results: Increased activation of the PI3 kinase pathway at baseline 
correlated with resistance to MEK inhibition, with resistant cell lines 
showing higher baseline levels of pAkt (S437), pAkt (T308), pPDK1, 
and p4E-BP1 (S65), and lower baseline levels of PTEN (all p<0.05). 
Cell lines with increased MEK phosphorylation at baseline were 
more sensitive to MEK inhibition (p=0.048). BAY86-9766 was very 
effective at reducing pERK (p=1.65x10-35) but this modulation was 
not significantly different between sensitive and resistant cell lines 
(p=0.64). Increased phosphorylation of MEK was seen with treatment 
(1.66x10-16). mTOR signaling was suppressed by MEK inhibition, with 
decreased phospho-p70S6K, pS6 (S235/236), and pS6 (S240/S244) 
and increased eIF4E following treatment (all p<0.02). These effects 
were significantly more pronounced in sensitive vs resistant cell lines 
(all p<0.01). Higher levels of LKB1 total protein, pAMPK, and pTSC2 
were also seen following treatment (all p<0.02).
Session MO20: Preclinical  
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MO20.01 PROTEIN KINASE C IOTA IS REQUIRED FOR 
MAINTENANCE OF A TUMOR INITIATING CELL PHENO-
TYPE IN LUNG SQUAMOUS CELL CARCINOMA
Helen J. Ross1, Verline Justilien2, Kristen Hill2, Michael Walsh2, 
Alan P. Fields2
1Medicine - Hematology & Medical Oncology, Mayo Clinic/United States 
Of America, 2Cancer Cell Biology, Mayo Clinic/United States Of America
Background: We discovered that PKCι is an oncogene in non-
small cell lung cancer (NSCLC), elucidated a major oncogenic PKCι 
signaling mechanism, and identified therapeutic agents that target 
oncogenic PKCι signaling. We have shown that PKCι signaling is 
genetically activated in approximately 70% of lung squamous cell 
carcinomas (LSCCs) through tumor-specific amplification of the 
PKCι gene, PRKCI. More recently, we have investigated the role of 
PKCι in bronchio-alveolar stem cells (BASCs), which are putative 
lung tumor-initiating cells (TICs). We demonstrated that PKCι is 
required for Kras-mediated transformation of BASCs in a mouse 
model of Kras-mediated lung adenocarcinoma. We hypothesize 
that PKCι plays a critical role in the development and maintenance 
of the TIC phenotype in LSCC by activating cell autonomous proli-
ferative signaling mechanisms.
Methods: We isolated “oncospheres” from four human LSCC cell 
lines (H1703, H1299, Calu-1, and ChagoK1) grown in non-adherent 
culture in defined stem cell medium using established protocols. 
Lentiviral shRNA techniques were used to genetically knock down 
expression of PKCι to assess the effect of PKCι depletion on 
the TIC phenotype. Non-target (NT) and PKCι RNAi TICs were 
assessed for the ability to grow as non-adherent oncospheres, 
to clonally expand, express stem marker genes, form colonies in 
soft agar, and initiate tumors in immune deficient mice. The effect 
of the selective and potent PKCι signaling inhibitor auranofin on 
TIC behavior and PKCι signaling activity was assessed as was the 
mTOR inhibitor, rapamycin.
Results: LSCC oncospheres exhibited characteristics of cancer 
stem or tumor-initiating cells including the ability to redifferentiate 
into bulk tumor cells when returned to adherent culture. Oncos-
phere cells express elevated levels of stem genes, clonally expand, 
exhibit enhanced transformed growth, and efficiently initiate and 
maintain lung orthotopic tumors and metastases. Biochemical 
studies indicate that the oncogenic PKCι-Rac1-Ect2-MMP10 sig-
naling axis is activated in LSCC TICs. To assess the role of PKCι in 
TIC growth, we knocked down PKCι in TIC cultures derived from 
the four LSCC cell lines described above. Whereas TICs expressing 
NT RNAi grew efficiently as anchorage-independent colonies in 
soft agar and clonally expanded, PKCι RNAi TICs were severely 
impaired in soft agar growth, clonal expansion, and tumorigenicity 
in vivo. Treatment of TICs with the potent and selective PKCι inhi-
bitor auranofin (ANF) likewise led to inhibition of PKCι signaling, 
TIC growth, clonal expansion, and tumorigenicity. Combined inhi-
bition of PKCι and mTOR with ANF plus rapamycin was synergistic 
against TIC proliferation in vitro.
Conclusion: Our data demonstrate that PKCι signaling is activated 
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the other 3 cell lines. Results from mutational analysis and investi-
gation of the gene and protein expression of each of the 4 pairs of 
parent and resistant cell lines will be presented.
Conclusion: While the panel of four NSCLC cell lines all responded 
well to GDC-0980 treatment initially, resistance to the drug deve-
loped rapidly. As such, understanding the mechanisms involved in 
the development of resistance to this drug will be crucial so that 
we may design optimal treatment strategies. Specific conclusions 
regarding the mechanisms of resistance in this panel of cell lines 
will be drawn based on identified genes and proteins of interest.
Keywords: GDC-0980, PI3K, resistance, NSCLC
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MO20.04 DIVERGENT ACTIVITY OF AFATINIB (AFAT) 
AND CETUXIMAB (CET) IN PATIENT-DERIVED XENO-
GRAFT (PDX) MODELS OF ACQUIRED ERLOTINIB RESIS-
TANCE.
Philip Mack1, Neal Goodwin2, William Holland1, Karen Kelly1, Ti-
anhong Li1, Primo Lara1, David Gandara1
1Division Of Hematology And Oncology, UC Davis Comprehensive 
Cancer Center/United States Of America, 2The Jackson Laboratories 
(jax)/United States Of America
Background: The combination of AFAT and CET has demonstra-
ted remarkable clinical activity in patients with acquired resistance 
to erlotinib. Preclinical modeling in genetically engineered mice 
and cell lines predicted activity in cases where erlotinib resistance 
was mediated by the EGFR T790M gatekeeper mutation. Howe-
ver, in the clinic, patients lacking T790M-positive tumors showed 
equivalent benefit from this combination, suggesting alternative 
mechanisms of synergy. We explored the individual and combined 
molecular and growth inhibitory activity of these agents in PDX 
models derived from NSCLC patient tumors with distinct mecha-
nisms of acquired resistance to erlotinib. These models were deve-
loped by the UC Davis - Jackson Laboratories Consortium, which 
has xenotransplanted over 170 NSCLC models using the nod/scid/
IL2Rgamma chain-null (NSG) mouse.
Methods: EGFR-mutant PDX models LG0703 (T790M-negative) 
and LG1049 (T790M-positive) were established from tumor biop-
sies from patients who progressed following durable responses to 
erlotinib. Both patients were subsequently treated with AFAT+CET, 
with the LG0703 donor patient exhibiting a prolonged response 
and the LG1049 donor patient exhibiting a transient response fol-
lowed by rapid progression. Excised tumors from passage 1 PDXs 
were fragmented and implanted into treatment cohorts. When tu-
mors reached 300mm3, mice were randomized to erlotinib (50 mg/
kg qd po), AFAT (20 mg/kg qd po), CET (10 mg/kg twice weekly iv), 
AFAT-CET, or vehicle control (n per arm = 12) for 3 weeks followed 
by a 75-day monitoring period. In a parallel cohort, tumor phar-
macodynamic changes in signal transduction mediators and RTKs 
were assessed after 6 and 24h treatment exposures using kinase 
arrays (R&D systems) and immunoblotting.
Results: In LG0703, AFAT, CET and AFAT-CET resulted in complete 
tumor response (CR) during the 21-day treatment period. After 
cessation of treatment, mice treated with CET or AFAT-CET remai-
ned in complete remission; whereas AFAT-treated mice progressed 
within 2 weeks. Clinical activity in this model was associated with 
Conclusion: We have performed broad proteomic analysis of NSCLC 
cell lines treated with MEK inhibitor BAY86-9766. Baseline activation 
of the PI3K/Akt pathway predicts for resistance to MEK inhibition. 
Sensitive cell lines, but not resistant cell lines, show suppression of 
mTOR activity with treatment with BAY86-9766. The effects of MEK 
inhibition of mTOR may be modulated by p90RSK through an LKB1 
dependent pathway. This suggests a basis for combining targeted 
agents to overcome resistance, such as combinations of MEK inhibi-
tors with PI3K inhibitors or mTOR inhibitors.
Keywords: MEK inhibitors, Targeted therapeutics, Preclinical models
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MO20.03 DEVELOPMENT AND CHARACTERIZATION OF 
A PANEL OF GDC-0980 RESISTANT NSCLC CELL LINES
Susan Heavey1, Martin Barr1, Kenneth O‘Byrne2, Kathy Gately1
1Clinical Medicine, Trinity College Dublin/Ireland, 2Princess Alexandra 
Hospital/Australia
Background: The PI3K-Akt- mTOR pathway regulates cell growth 
and proliferation and is often dysregulated in cancer due to mu-
tation, amplification, deletion, methylation and post-translational 
modifications. PI3K pathway activation in NSCLC has been shown 
by us and others to lead to a more aggressive disease correlating 
to poor prognosis for patients. Multiple novel agents, targeting 
different regulators within the pathway are currently under deve-
lopment. GDC-0980 is a selective dual inhibitor of PI3K and mTOR, 
which demonstrated excellent downstream inhibition of the PI3K 
pathway in vitro, with the strongest effects being observed in lung, 
breast and prostate cancer cell lines. There are 12 clinical trials on-
going for this drug, with Phase I studies in solid tumours and Phase 
II studies in endometrial carcinoma, renal cell carcinoma, prostate 
cancer and breast cancer. As with all targeted therapies, acquired 
resistance to GDC-0980 is anticipated to be a major hurdle in the 
success of this drug. Multiple mechanisms of resistance to GDC-
0980 may develop while a patient is being treated with this drug. 
The aim of this project is to develop four cell line models of resis-
tance to GDC-0980, each representing a different molecular sub-
type of NSCLC, in order to predict which mechanisms of resistance 
may occur in patients. This will allow us to identify biomarkers of 
response/resistance to the drug that may dictate beneficial treat-
ment strategies.
Methods: H460, A549, H1975 and SKMES-1 cells were treated with 
a dose response curve of GDC-0980 and BrdU proliferation assays 
determined IC50 values for each cell line. Each cell line was then 
cultured in GDC-0980 at IC50 concentrations over a period of se-
veral months, along with matched ‘parent’ cell lines. Each month, 
BrdU proliferation assay were carried out in order to track the 
development of resistance to the drug. When a log fold difference 
between the parent and resistant IC50s was observed, the cells 
were deemed to be resistant. Matched parent and resistant cells 
were then screened for a panel of mutations. Cells lines were also 
screened for gene alterations using a human cancer drug resis-
tance PCR array. Identified genes of interest were validated at the 
RNA and protein level by PCR and Western blot, respectively.
Results: All four cell lines exhibited a dose-dependent decrease 
in proliferation when treated with GDC-0980. H1975 cells (ade-
nocarcinoma; PIK3CA mutant) were most sensitive to GDC-0980, 
however they developed resistance to the drug more rapidly than 
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Results: In NSCLC cell lines and L-CSC, the HDACi ITF2357 dose-
dependently inhibited cell growth (IC50: <1-20 mM), induced histo-
ne H3 acetylation, and downregulated TS expression at the mRNA 
and protein levels. Combined HDAC inhibition and PEM exposure 
was then tested using three different administration schedules: 
simultaneous exposure to both drugs, ITF2357 followed by PEM, 
and the reverse sequence. Simultaneous PEM/ITF2357 treatment 
resulted in antagonistic growth inhibitory interactions (combination 
index – CI >1) in all cell lines tested, while ITF2357 followed by PEM 
had additive effects in A549 cells and slightly synergistic effects 
in H1299 and Calu-1 cells; conversely, PEM followed by ITF2357 
had strikingly synergistic effects (CI <<1) in all NSCLC cell lines, as 
well as in the L-CSC143. Most notably, only the ITF2357 followed 
by PEM sequence synergistically induced apoptosis, resulting in 
approximately 50% Annexin V-positive cells; apoptosis was only 
partially rescued by caspase inhibition by z-VAD-fmk, which led us 
to investigate autophagy as an alternative mechanism of combi-
nation-induced cell death. Indeed, ITF2357, and to a significantly 
greater extent PEM followed by ITF2357, induced autophagy as 
evidenced by AVO formation, LC3BII processing, p62 downregula-
tion, and Beclin1 induction. Most importantly, autophagy induction 
was instrumental to the cytotoxic interaction between PEM and 
ITF2357, as Beclin1 silencing by shRNA completely reversed their 
growth inhibitory synergism and prevented both autophagy and 
apoptosis induction. The synergistic cytotoxic interaction between 
PEM and ITF2357 was at least partly due to ITF2357 ability to 
prevent PEM-induced TS upregulation, as TS silencing by siRNA 
further enhanced apoptosis induction by single and combined 
PEM/ITF2357 exposure. Finally, both H1650 and H1299 xenografts 
had a robust response to sequential PEM/ITF2357 administration 
in vivo, resulting in an approximately doubled mice survival in the 
H1650 model.
Conclusion: Overall, our data indicate that HDAC inhibition by 
ITF2357 downregulates TS expression and synergistically potenti-
ates apoptosis and autophagy induction following PEM exposure, 
supporting the clinical investigation of sequential PEM/ITF2357 
schedules for the treatment of advanced NSCLC.
Keywords: HDAC inhibitors, pemetrexed, thymidylate synthase, 
combination therapy
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MO20.07 IDENTIFICATION OF NEW CHEMOTHERAPEU-
TIC STRATEGIES IN MESOTHELIOMA AND NON-SMALL 
CELL LUNG CANCER USING A DRUG-INDUCED APOP-
TOSIS ASSAY (MICK ASSAY)
Dennis A. Wigle1, Julian Molina2, Allan Hallquist3, Cary Presant3
1Thoracic Surgery, Mayo Clinic/United States Of America, 2Oncology, 
Mayo Clinic/United States Of America, 3Diatech Oncology/United Sta-
tes Of America
Background: Given limited progress in developing novel che-
motherapies for mesothelioma and multi-negative NSCLC, new 
technology is needed to identify promising drug strategies. A 
drug-induced apoptosis assay has been developed that has been 
applied in acute myelocytic leukemia, ovarian cancer, and a variety 
of solid tumors including breast cancer (Cancer Research 2012; 
72:3901). We explored the use of the MiCK assay in mesothelioma 
and NSCLC tumor specimens.
complete blockade of EGFR and Her2 phosphorylation. Substanti-
al down-regulation of AKT1, AKT2, ERK1, p38a, RSK1 and p70S6K 
phosphorylation was evident within 6h of treatment. In contrast, 
the T790M-postive LG1049 model demonstrated only modest 
clinical benefit from AFAT, with no single-agent CET activity, and 
no CET-mediated synergy with AFAT. No treatments were able to 
ablate EGFR phosphorylation or downstream signal transduction, 
and compensatory induction of EGFR, HER2, ERK1 and p38 were 
noted after 24h of drug exposure.
Conclusion: In these PDX models derived from patients with 
EGFR-activating mutant cancer with acquired resistance to erloti-
nib, treatment with AFAT+CET recapitulated the clinical experience 
of the donor patients receiving this combination. In the LG0703 
model, both the AFAT-CET combination as well as single-agent 
CET resulted in complete tumor regression associated with total 
ablation of EGFR phosphorylation and subsequent blockade of 
multiple signal transduction pathways. In the LG1049 model, AFAT 
prompted limited but statistically significant tumor delay, with no 
additional benefit from CET. These experiments demonstrate the 
considerable potential of this PDX resource to assess therapeutic 
strategies in models representing individual patients. Supported 
by BJALCF.
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MO20.06 HISTONE DEACETYLASE INHIBITION DOWN-
REGULATES THYMIDYLATE SYNTHASE (TS) EXPRESSION 
AND ENHANCES PEMETREXED-INDUCED CYTOTOXICI-
TY IN NSCLC MODELS
Daniela Trisciuoglio1, Marianna Desideri1, Marta Di Martile1, Chia-
ra Gabellini1, Teresa De Luca1, Sabrina Vari2, Francesco Cognetti2, 
Adriana Eramo3, Ruggero De Maria4, Michele Milella2, Donatella 
Del Bufalo1
1Experimental Chemotherapy Lab, Regina Elena National Cancer Ins-
titute/Italy, 2Division Of Medical Oncology A, Regina Elena National 
Cancer Institute/Italy, 3Hematology, Oncology, And Molecular Medicine, 
Istituto Superiore Di Sanità/Italy, 4Scientific Direction, Regina Elena 
National Cancer Institute/Italy
Background: Non-small cell lung cancer (NSCLC) is the leading 
cause of cancer-related death worldwide. Pemetrexed (PEM), a 
multi-target folate antagonist, has demonstrated targeted efficacy in 
NSCLC histological subtypes characterized by low thymidylate syn-
thase (TS, one of PEM’s molecular targets) expression. Recently, TS 
expression has been found to be regulated by histone acetylation 
status, thus raising the interesting hypothesis that histone deacetyla-
se inhibitors (HDACi) may sensitize NSCLC cells to PEM cytotoxicity.
Methods: Molecular and functional effects of single and combined 
HDAC inhibition and PEM exposure were assessed in NSCLC cell 
lines (A549, H1299, H1650, Calu-1) and patient-derived lung cancer 
stem cells (L-CSC). Pharmacologic interactions were assessed by 
conservative isobologram analysis using the Chou-Talalay method 
and the Calcusyn software. TS expression was studied by WB ana-
lysis and real-time PCR. Apoposis induction was assessed by flow 
cytometry and WB. Autophagy was assessed by analysis of autopha-
gosome formation in EGFP-LC3B expressing cells, detection of aci-
dic vesicle organelles (AVO) formation and WB. In vivo experiments 
were conducted in xenograft models established by i.m. injection of 
NSCLC cells into 6-8 week-old male athymic mice (nu/nu).
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MO20.08 ACTIVATION OF CD1D-RESTRICTED NKT 
CELLS MAY INHIBIT CANCER CELL REPOPULATION 
BETWEEN CYCLES OF CHEMOTHERAPY THROUGH MO-
DULATING IMMUNE RESPONSES IN MURINE MESOTHE-
LIOMA
Licun Wu, Zhihong Yun, Luis De La Maza, Julie Yu, Yidan Zhao, 
Marc De Perrot
Division Of Thoracic Surgery, Latner Thoracic Surgery Research Labo-
ratories, Toronto General Hospital/Canada
Background: Considerable evidence has shown that cancer cell 
repopulation during the intervals of chemotherapy is a neglected 
factor of treatment failure. The efficacy of cancer treatment may 
be improved if this process could be effectively controlled. It has 
been demonstrated that the number of invariant natural killer T 
cells (iNKT) increased during the development of murine meso-
thelioma models. NKT cells specifically recognize the glycolipid 
α-galactosylceramide (KRN7000, KRN) through CD1d molecule 
resulting in their activation and expansion. Our goal is to study the 
impact of NKT cell activation by KRN on cancer cell repopulation 
between cycles of chemotherapy in murine mesothelioma model.
Methods: Tumor-bearing mice were treated with chemotherapy 
once weekly, and KRN was followed after each cycle of chemothe-
rapy. Both WT and CD1dKO mice were used to evaluate the effect 
on tumor growth. Cancer cell proliferation and apoptosis was 
evaluated by Ki67 and TUNEL immunohistochemistry, respectively. 
The proportion of CD4+ and CD8+ T cells and their activation in 
the tumor, spleen, draining lymph node and peripheral blood from 
tumor-bearing mice were determined by using flow cytometry, and 
gene expression of activated T cell-related cytokines and cytolytic 
enzymes were quantified by RT-PCR. NKT were recognized specifi-
cally by CD1d-tetramer staining.
Results: In WT mice, tumor growth delay was achieved by chemo-
therapy alone, and this effect was improved when combined with 
KRN. Cancer cell repopulation between cycles of chemotherapy 
was significantly inhibited by KRN, whereas apoptosis changed 
inversely. KRN following chemotherapy resulted in an increase of 
IFN-γ production in the draining lymph node, blood and spleen. 
Strikingly, the percentage of ICOS+CD4 T cells, Th17 and Tc17 cells 
increased in splenocytes. NKT expansion was observed in both 
peripheral blood and lymphoid organs. Gene expression of immu-
ne-associated cytokines was somewhat upregulated after NKT cell 
activation during the intervals of chemotherapy. In KO mice, howe-
ver, Cis alone or Cis+KRN was less effective than in WT mice. KRN 
alone had little effect in both animals.
Conclusion: NKT activation between cycles of chemotherapy can 
improve the efficacy of treatment through modulating anti-tumor 
immunity against cancer cell repopulation. KRN may be a promi-
sing agent for mesothelioma immunotherapy.
Keyword: Mesothelioma, NKT cell, chemotherapy,  
immunotherapy
Methods: Fresh tumor specimens from resected tissue or malig-
nant effusions were processed in a central laboratory. Cell separa-
tion techniques were used to prepare >95% tumor cell suspensions 
for the MiCK assay (as described in Cancer 2012; 118: 4877). Over 
48 hours in short term culture, optical techniques based on Mie 
light scattering measured apoptosis in control wells and test wells 
containing different chemotherapy drugs or combinations. Sig-
nificant apoptosis gave results over 1.0 kinetic units (KU). Drugs 
or combinations producing the highest KU +/- 1 SD compared to 
other drugs were defined as best regimens. Differences of over 
0.57 KU correlated with clinically significant better responses.
Results: 15 specimens have been submitted with 9 successfully 
assayed to date. Mean numbers of drugs or combinations 
assayed successfully were 32 in mesothelioma and 20 in 
NSCLC. New treatment strategies in individual patients with 
mesothelioma were: epirubicin 5.0 and 9 KU, idarubicin 4.0 
KU, pemetrexed+doxorubicin 4.9 and 4.6 KU, ifosfamide 3.4 
and 2.2 KU, bendamustine 4.0 KU, dactinomycin 4.7 and 3.4 
KU, vinorelbine 4.7 KU, asacytidine 3.8 KU, bortezomib 3.0 
KU, doxorubicin 3.9 KU, cyclophosphamide+doxorubicin+vinc
ristine 3.0 KU and cisplatin+irinotecan 3.1 KU. New treatment 
strategies in individual patients with NSCLC were: doxorubicin 
2.0, 1.7 and 1.7 KU, epirubicin 1.6 KU, 5-fluorouracil+leucovorin 
1.3 KU, and cyclophosphamide+doxorubicin+vincristine 2.3 KU. 
In class differences in drug activity were apparent in individual 
patients: cisplatin>carboplatin, epirubicin>doxorubicin, and 
docetaxel>paclitaxel. In one mesothelioma patient with paired 
specimens from malignant effusion and solid tumor the most 
active (pemetrexed+doxorubicin) and least active regimens 
(cisplatin+paclitaxel) were concordant. In mesothelioma, the 
most active chemotherapy regimens in individual patients were 
epirubicin, idarubicin, pemetrexed+doxorubicin, vinorelbine, 
cisplatin+etoposide, cisplatin+irinotecan, cyclophosphamide+dox
orubicin+vincristine, and dactinomycin. In NSCLC, the most active 
regimens were doxorubicin, cisplatin, docetaxel, irinotecan, and cy
clophosphamide+doxorubicin+vincristine.
Conclusion: Use of the MiCK assay in mesothelioma and NSCLC 
can identify unexpected new leads for innovative therapeutic stra-
tegies for individual patients, and for candidate enrollment in pha-
se II and III studies. The MiCK assay may play a role in designing 
precision therapeutics for patients with mesothelioma and NSCLC. 
Marked differences between patients in individual drug activities, 
and discordant in-class drug effectiveness indicate the need for 
individualized patient tumor testing of drug-induced apoptosis. 
Since use of the MiCK assay has correlated with improved clinical 
outcomes in prior studies, clinical trials of drugs with unexpected 
activity may be warranted in mesothelioma and NSCLC patients.
Keywords: mesothelioma, personalized therapy, NSCLC
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Background: 2nd-line therapy for advanced NSCLC patients (pts) 
after progression on platinum-based regimens typically employs 
CT or E. A test for optimizing choice of treatment in these pts is 
of clinical value. VeriStrat (VS) is a serum protein test that assigns 
"good“ (VSG) or "poor“ (VSP) classification and has demonstrated 
prognostic and predictive utility. PROSE is a multicenter prospecti-
ve randomized biomarker validation trial, designed to evaluate the 
ability of VS to predict survival in 2nd- line NSCLC pts treated with 
E or CT. As reported at 2013 ASCO1, PROSE met its primary end-
point of demonstrating significant treatment*VS interaction with a 
p value of 0.031, with VSG pts deriving similar overall survival (OS) 
benefit from both treatments (hazard ratio (HR) for E=1.06; p=0.71) 
and VSP pts benefitting more from CT than E (HR for E=1.72; 
p=0.02). Previous studies in EGFR-TKI-treated pts have shown that 
at progression around 30% of pre-treatment VSG pts have chan-
ged classification to VSP2. The present report discusses the explo-
ratory analysis of longitudinal VS classifications generated during 
the PROSE study.
Methods: Of the 263 pts in the PROSE primary analysis popu-
lation, 89 provided serum samples during treatment and 108 at 
progression, with 47 pts providing both. VS testing was performed 
on these longitudinal samples blinded to all clinical and treatment 
outcomes and pts and physicians remained blinded to VS results.
Results: VSG or VSP classifications were obtained for 89 pts from 
treatment samples (67 VSG / 22 VSP) and 107 pts (one sample was 
classified as indeterminate) from progression samples (59 VSG / 48 
VSP). In pts with matched baseline and progression samples, the 
percentage of VSG classifications was lower at progression (55%) 
than at baseline (77%) (p < 0.001 ). Twenty eight pts (34%) classi-
fied at baseline as VSG changed to VSP at progression, in line with 
previous studies2, and this did not show any significant depen-
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MO20.09 SYSTEMIC BLOCKADE OF CTLA-4 SIGNALING 
CAN IMPROVE THE ABSCOPAL EFFECT INDUCED BY 
LOCAL RADIOTHERAPY IN A MURINE MESOTHELIOMA 
MODEL
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Yidan Zhao, Marc De Perrot
Division Of Thoracic Surgery, Latner Thoracic Surgery Research Labo-
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Background: Radiotherapy can induce direct cancer cell death 
and systemic anti-tumor immunity known as abscopal effect. For 
malignant pleural mesothelioma (MPM), postoperative hemitho-
racic radiation is important to control recurrence and metastasis 
for the resectable patients. We hypothesized that the abscopal 
effect also exists in malignant mesothelioma, and removal of the 
immunosuppressive checkpoints was able to enhance this effect 
induced by local radiotherapy.
Methods: Murine malignant mesothelioma AB12 cells were injec-
ted subcutaneously into the right leg and flank of Balb/c mice eit-
her sequentially (primary/secondary tumors) or concurrently (local/
distant tumors). Treatment was initiated on day 5 when primary 
(local) tumors were developed, and the immune-deficient NOD/
SCID mice were used as controls. Local radiotherapy (LRT) with 
Gammacell-40 Irradiator was delivered to the tumor-bearing leg, 
whereas the rest of the body was protected with a lead chamber. 
CTLA-4 blockade with mAb was given 1 day after LRT. Tumor size 
was measured twice weekly to evaluate the anti-tumor effect. The 
immune responses, especially T cell activation in tumor, spleen 
and lymph node was determined by flow Cytometry. The expressi-
on of immune-related genes was quantified by RT-PCR, and tumor-
infiltrating T cells were determined by immunofluorescent staining.
Results: The growth of primary tumors was significantly inhibited 
by LRT alone, and addition of anti-CTLA-4 mAb enhanced the 
antitumor effect. Interestingly, the secondary or distant tumors 
grew more slowly in mice whose primary tumor was treated with 
LRT than those untreated mice. Some secondary tumors were 
completely rejected when combined with anti-CTLA4 mAb. There 
was no such effect on the distant tumors in the immune deficient 
mice. Results demonstrated that LRT resulted in more T cell infilt-
ration into both primary and secondary tumors. Tumor-infiltrating 
T cells had higher levels of ICOS and IFN-γ, and proliferated more 
rapidly after injection of irradiated AB12 cells. More activated CD4 
and CD8 T cells were observed in the the draining lymph node 
(dLn) and spleen, and more dendritic cells trafficked to the dLn. 
The gene expression of cytolytic enzymes and cytokines was upre-
gulated as well.
Conclusion: LRT on primary tumors has abscopal effect on the se-
condary or distant tumor, and this effect can be enhanced by sys-
temic blockade of CTLA-4 in murine mesothelioma. This approach 
might be translated into clinical trials for MPM patients.
Keywords: mesothelioma, Local radiotherapy, abscopal effect, 
immunotherapy
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(82.3%) without the T790M mutation (by PSS) were successfully 
analyzed for the T790M mutation using LNA-PSS. The T790M 
mutation was detected in 17 (40.5%) pts, with a higher incidence 
in never smokers (47.7%), adenocarcinoma (76.2%) and females 
(71.4%).
A treatment response evaluation was available in 39 pts, 18 of 
whom (46.1%) harbored the T790M mutation. Pts with T790M had 
a lower RR (22.2%) to TKIs than wild-type pts (35.3%); however, 
mutated pts had better PFS and OS (median PFS 9.2 vs 7 months, 
respectively; median OS 15.2 vs 11.1 months, respectively). Pts 
treated with afatinib and positive for T790M obtained longer 
PFS compared to pts negative for T790M (median PFS 4.7 vs 3.2 
months, respectively), but their OS was shorter (median OS, 16.3 vs 
18.2 months, respectively). Notably, pts with the T790M mutation 
had a greater response to chemotherapy (44.4%) compared to pts 
without the mutation (18.2%) and had a longer PFS (median PFS 
8.2 vs 6.1 months, respectively) and OS (median OS 21.8 vs 12.4 
months, respectively).
Conclusion: In this study, the high proportion of pretreatment 
tumor samples positive for the EGFR-T790M mutation indicates 
that its identification at diagnosis is more common than expected 
using a highly sensitive method. Consequently, in NSCLC pts with 
EGFR-activating mutations, detection of the T790M mutation at 
diagnosis can help customize therapy and identify a subset of pati-
ents with a relatively more favorable prognosis.
Keywords: EGFR mutation, Sanger sequencing, afatinib, T790M
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Background: Erlotinib is a standard treatment for NSCLC pati-
ents harboring EGFR mutations. Many tumors acquire resistance 
mutations during erlotinib treatment; consequently, confirmation 
of EGFR mutation status is important to select appropriate sub-
sequent therapy after progression. Obtaining tumor samples is 
not easy, therefore, serum samples are more applicable for this 
purpose. This analysis measured serum EGFR mutations before 
and after administration of erlotinib in a phase II study in Japanese 
chemotherapy-naïve patients with advanced NSCLC harboring 
EGFR mutations (JO22903).
dence on treatment. When treated with E, pts whose classification 
changed from VSG at baseline to VSP during treatment (n=6) had 
inferior PFS to the 25 pts who remained VSG (p=0.001, median 
PFS: 3.6 and 7.7 months (mos), respectively). Patients whose clas-
sification changed from VSG at baseline to VSP at progression on 
E (n=18) had numerically inferior OS (median 10.0 mos) compared 
with the 31 pts who remained VSG at progression (median 14.6 
mos) and significantly superior OS (median 5.0 mos) compared 
with the 10 pts who were VSP at both time points (p<0.001).
Conclusion: The observed changes in VS classification at progres-
sion demonstrate the importance of obtaining a VS result prior to 
each line of therapy for which erlotinib is considered as a therapeu-
tic option. The proportion of patients who are good candidates for 
erlotinib therapy (VSG) decreases from 2nd to 3rd line and the possi-
ble impact of this on treatment sequencing and monitoring for 2nd 
and higher line advanced NSCLC pts merits further studies.
Keywords: treatment monitoring, EGFR-TKIs, mass spectrometry
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Background: Preclinical data have shown that the EGFR-T790M 
mutation confers resistance to reversible EGFR-TKIs (gefitinib, erlo-
tinib) but not to irreversible EGFR-TKIs (afatinib). This study evalu-
ated advanced NSCLC patients (pts) harboring an activated EGFR 
mutation (exon 18-21) to investigate the incidence of the T790M 
mutation in pretreatment tumor samples and the correlation bet-
ween the T790M mutation and the clinical outcome, comparing 
patients positive for the T790M mutation treated with reversible 
TKIs, an irreversible TKI or chemotherapy to patients negative for 
the T790M mutation treated with the same agents.
Methods: We screened 317 advanced NSCLC pts for EGFR mu-
tations using the PCR/Sanger sequencing (PSS) method. Tumor 
tissues from EGFR-mutated pts were analyzed for the EGFR-T790M 
mutation using a highly sensitive locked nucleic acid-PSS method 
(LNA-PSS) capable of detecting EGFR-T790M-mutated alleles at 
extremely low frequencies. The response rate (RR), progression-
free survival (PFS) and overall survival (OS) were evaluated retros-
pectively in these pts.
Results: Using PSS, 17.3% (55/317) of pts had an activating muta-
tion in the EGFR-TK domain; 56.3% (31/55) of pts had an in-frame 
deletion in exon 19, 32.7% (18/55) of pts had point mutation L858R 
in exon 21, 3.6% (2/55) of pts had an insertion in exon 20, and 7.2% 
(4/55) of pts had both the T790M mutation and either an exon 
19 or 21 mutation. Forty-two pts with EGFR-activating mutations 
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Background: A significantly greater proportion of females and 
adenocarcinoma patients is found in never-smoking NSCLC groups 
than in smoking NSCLC groups. Recent studies have demonstrated 
that estrogens may contribute to the carcinogenesis and develop-
ment of lung carcinoma. In the present study, we investigate the 
correlation between the expression of aromatase (CYP19-1) and 
clinicopathologic factors and assess the prognostic significance of 
the aromatase expression in patients with primary lung adenocar-
cinoma.
Methods: The aromatase mRNA expression levels in the primary 
tumors and corresponding nonneoplastic lung specimens of 110 
Japanese patients who underwent complete resection for primary 
lung adenocarcinoma were evaluated using quantitative RT-PCR. 
The relationships between the aromatase expression and clinico-
pathologic factors or survival were analyzed. To test the growth 
inhibitory effects of the aromatase inhibitor exemestane alone and 
in combination with the EGFR-TKI erlotinib in vitro, the cell prolife-
ration of the lung adenocarcinoma cell lines HCC4006 and 11-18 
was measured according to the WST-8 method.
Results: The mRNA expression level of aromatase in the carcinoma 
tissues was significantly higher than that in the corresponding nor-
mal lung tissues (P = 0.013). The aromatase expression in the lung 
adenocarcinoma tissues was not correlated with the clinicopatho-
logic factors, including patient gender, age, smoking status, EGFR 
mutation status or pathologic stage. A high aromatase expression 
was associated with a poor prognosis in terms of both the recur-
rence-free survival (RFS) (P = 0.004) and overall survival (OS) (P = 
0.003). A multivariate analysis showed that the aromatase expressi-
on was a significant prognostic factor, with a relative risk of 2.35 (P 
= 0.043) for RFS and 5.19 (P = 0.004) for OS. We further stratified 
the population according to gender, smoking status and EGFR mu-
tation status. A high aromatase expression was related to a poor 
prognosis in femles (RFS; P = 0.008, OS; P < 0.001), never-smokers 
(RFS; P = 0.009, OS; P < 0.001) and patients with EGFR mutations 
(RFS; P = 0.005, OS; P = 0.003). A multivariate analysis showed 
that the aromatase expression was a significant prognostic factor, 
with a relative risk of 5.22 (P = 0.013) for RFS in the patients with 
EGFR mutations. HCC4006, harboring an EGFR mutation with a 
low aromatase mRNA expression, was not sensitive to exemestane 
alone or combination with erlotinib. In contrast, 11-18, harboring 
an EGFR mutation with a high aromatase mRNA expression, was 
sensitive to exemestane alone. In addition, cell growth was signifi-
cantly inhibited by the combination of exemestane and erlotinib.
Conclusion: A high expression of aromatase is correlated with a 
poor outcome in patients with lung adenocarcinoma, especially 
those harboring EGFR mutations. Aromatase may be a therapeutic 
target in lung adenocarcinoma with a high aromatase expression 
and with an EGFR mutation.
Keywords: never-smoker, female hormone, aromatase, EGFR
Methods: We analysed serum samples from patients in the 
JO22903 study by Scorpion-ARMS to confirm the presence of 
EGFR mutations before and after erlotinib administration (190 days 
post treatment initiation and at disease progression). The mutation 
results were evaluated in relation to clinical characteristics and 
effects of erlotinib.
Results: Of the 103 patients registered in JO22903, 95 consented 
to the examination of EGFR mutations in serum samples prior to 
and following administration of erlotinib. Of these 95 patients, 
26 were positive for EGFR mutations (16 were exon 19 deletions, 
nine were exon 21 L858R mutations, one was an exon 20 S768I 
mutation). In the 26 patients classed as EGFR mutation-positive 
in serum samples, the concordance rate between tumor samples 
and serum samples was 96.2% (matching 25 cases except the 
S768I mutation case). The EGFR mutation detection rate in serum 
samples prior to erlotinib administration was 35.6% for exon 19 
deletions (16/45) and 18.0% for L858R mutations (9/50). In six cases 
where exon 20 T790M or minor mutations were detected along-
side major mutations in tumor samples, the major mutations were 
detected in corresponding serum samples of four patients but the 
T790M mutations or minor mutations were not detected in any 
serum samples. In the 65 cases in which serum samples were taken 
190 days after erlotinib administration, five were positive for EGFR 
mutations (exon 19 deletions in four, and L858R in one). Four of 
these cases were consistent with the mutation type of the tumor 
samples taken before erlotinib administration; one case changed 
from L858R to exon 19 deletion. Serum samples at disease pro-
gression were taken for 72 patients. Of these, 16 were positive for 
EGFR mutations (three were exon 19 deletions, five were exon 19 
deletions + T790M, six were L858R and two were L858R + T790M). 
EGFR mutation type had changed after administration of erlotinib 
in three cases; these cases also had multiple metastases. Characte-
ristics of EGFR mutation-positive cases in the pre-treatment serum 
samples were large tumor size, and metastases to other organs 
(bone, brain, liver). Patients with baseline serum EGFR mutations 
had median PFS of 9.7 months and those without baseline serum 
EGFR mutations had median PFS of 15.2 months. Further efficacy 
results will be presented.
Conclusion: The sensitivity of these analyses was not enough to 
draw firm conclusions; however, results show the possibility that 
serum EGFR mutations correlate with disease activity and emer-
gence of resistance mutations. Further study is recommended to 
measure serum EGFR mutations throughout the treatment course, 
to ascertain whether this can predict the risk of disease progressi-
on.
Keywords: NSCLC, EGFR mutations, Japanese patients, erlotinib
PROGNOSTIC AND PREDICTIVE BIOMARKERS V - EGFR  
WEDNESDAY, OCTOBER 30, 2013 - 10:30-12:00
MO21.04 PROGNOSTIC AND THERAPEUTIC IMPLICA-
TIONS OF THE AROMATASE EXPRESSION IN LUNG 
ADENOCARCINOMA HARBORING EGFR MUTATION
Mikihiro Kohno1, Tatsuro Okamoto1, Kenichi Suda2, Yuzo Suzuki1, 
Takatoshi Fujishita1, Shinichiro Shimamatsu1, Hirokazu Kitahara1, 
Tsukihisa Yoshida1, Yosuke Morodomi1, Daigo Kawano1, Tokujiro 
Yano3, Yoshihiko Maehara1
1Department Of Surgery And Science, Graduate School Of Medical Sci-
ences, Kyushu University/Japan, 2Division Of Thoracic Surgery, Depart-
ment Of Surgery, Kinki University Faculty Of Medicine/Japan, 3Clinical 
S386 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Conclusion: We conducted the first ever comprehensive integra-
ted genomic analysis of EGFR TKI resistant NSCLC patients, and 
identified both known and potentially novel drivers of EGFR TKI 
resistance. This study demonstrated the feasibility and utility of 
comprehensive genomic analysis in the clinical management of 
NSCLC receiving targeted therapy. Together, our data provide 
unprecedented insight into the molecular pathogenesis of escape 
from EGFR oncogene inhibition in NSCLC. We are now conducting 
a prospective observational study in additional NSCLC patients on 
targeted therapy.
Keyword: Erlotinib, EGFR, acquired resistance, integrated  
genomics
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Background: EGFR TKI sensitizing mutations in plasma DNA isola-
ted prior to treatment were shown to be a potent predictor for sur-
vival outcome of advanced NSCLC (T. Mok, ASCO 2013). Levels of 
EGFR mutations (pEGFRmut) in plasma during treatment, including 
sensitizing and resistance mutations, may offer an opportunity to 
monitor patient’s response to therapy and disease progression. In 
this study, we measured the levels of pEGFRmut at every 4 weeks 
during erlotinib treatment and investigated the emergence of the 
T790M mutation in relationship to disease progression.
Methods: Retrospective EGFR mutation testing of plasma samples 
from an unselected cohort of 227 patients with adenocarcinoma 
with an allele-specific PCR assay, cobas® EGFR_blood test (in de-
velopment at Roche Molecular Systems, Inc.). The test is designed 
to detect 42 mutations in exon 18-21 of the EGFR gene including 
TKI sensitizing mutations (Exon 19 deletions, L858R, G719X and 
L861Q), resistance mutation (T790M) and atypical mutations (S768I 
and Exon 20 Insertions). 2 ml plasma of each patient was used for 
EGFR_blood PCR test. The genomic equivalent copy number of 
plasma DNA was determined by comparing to a standard curve of 
genomic DNA.
Results: 25 (11%) of 227 unselected patients with adenocarcino-
ma had a sensitizing EGFR mutation in their plasma prior to the 
erlotinib treatment. Sequential plasma samples were retrieved for 
23 of the 25 pEGFRmut+ patients. 22 (96%) of the 23 pEGFRmut+ 
patients had lower TKI sensitizing mutations after the first cycle 
(4 weeks) of erlotinib treatment. The mutated DNA was reduced 
below the limit of detection for 13 (57%) of the 23 pEGFRmut+ 
patients during the course of erlotinib treatment. At the time of 
progression, 6/23 had the same EGFR sensitizing mutations, 9/23 
developed T790M mutation with the original mutation and 6/23 
patients had no detectable mutation.
T790M mutation was not detected in 227 plasma samples taken 
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Background: NSCLC patients with EGFR mutations initially respond 
to EGFR tyrosine kinase inhibitors (TKIs) but ultimately relapse. Sub-
genomic molecular studies indicate that the EGFR T790M mutation 
and the activation of MET, PI3K, AXL, HER2 and MAPK can lead 
to acquired resistance to EGFR TKIs. To date, no integrated com-
prehensive genomic investigation of EGFR TKI resistance has been 
reported.
Methods: FFPE biopsies of erlotinib-sensitive and erlotinib-resistant 
tumors were obtained from 13 EGFR mutant NSCLC patients. The 
samples were analyzed by whole exome sequencing and whole 
transcriptome sequencing utilizing the Illumina HiSeq2500 platform. 
In addition, targeted gene sequencing was performed with the Illu-
mina TruSeq Amplicon-Cancer Panel and run on the MiSeq system.
Results: Erlotinib resistant NSCLC specimens harbored known re-
sistance drivers, including EGFR T790M mutations (9/13; 69%), MET 
amplification (3/13; 23%), HER2 amplification (3/13; 23%), and AXL 
upregulation (3/13; 23%). Differential expression analysis between 
resistant and pre-treatment states revealed enrichment in the pre-
treatment tumors of immune signaling pathways, and in the resistant 
tumors upregulation of ERBB2, mTOR, PI3 kinase and ribosomal 
signaling pathways. PI3K/AKT pathway upregulation also occurred 
through somatic mutations in AKT and LKB1 in the resistant tumors. 
Copy number analysis demonstrated both large scale and focal 
amplifications and deletions in the resistant tumors, including the 
focal loss of EGFR and gain of c-Myc and NKX2-1. There was strong 
correlation between the copy number changes observed and the 
expression mRNA levels of the involved cancer-associated genes. Of 
note, each resistant tumor exhibited greater copy number similarity 
to the corresponding matched pre-treatment sample compared to 
other tumors within the resistance cohort.
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Methods: Plasma DNA and tumor DNA were tested with two 
allele-specific PCR assays, cobas® EGFR_ FFPET tissue test and 
cobas® EGFR_blood test (in development at Roche Molecular 
Systems, Inc.). Both allele-specific PCR assays detect 41 mutations 
in exon 18-21 of the EGFR gene including TKI sensitizing muta-
tions (Exon 19 deletions, L858R and G719X), resistance mutation 
(T790M) and atypical mutations (S768I and Exon 20 Insertions). 
cobas® EGFR_blood test also detects L861Q. Plasma samples of 
all 199 adenocarcinoma were collected immediately (less than 2 
days) prior to the patient’s erlotinib treatment and stored at -80°C. 
From 197 (99%) of 199 of the patients tumor DNA was extracted 
from the diagnostic biopsy.
Results: Among 199 advanced adenocarcinoma patients, 24/199 
(12%) were EGFR mutation positive in plasma. 28/196 (14%) were 
EGFR mutation positive in tumor DNA. The comparison of EGFR 
mutation in plasma and tumor DNA is shown in the table 1. The 
overall concordance of EGFR mutation status in plasma and tu-
mor biopsy was 91% (179/196). 17/196 (9%) patients had the same 
EGFR mutations in plasma as in their original diagnosis biopsy and 
162/196 (82%) patients were mutation negative in both samples. In 
this study, different EGFR mutation status in plasma and original 
biopsy was observed in 17 of 196 (9%) patients. 6 of 17 were EGFR 
mutation positive in plasma only and 11 of 17 were EGFR positive 
in tumor DNA only. These differences could reflect alterations in 
the tumor cells between sampling of biopsy and blood (average of 
10.5 months) where the patients are treated with chemotherapy. 
Another possibility is limitations of assay technology with circula-
ting cell-free DNA in plasma or heterogeneity of tumor.
Conclusion: Tumor mutations in the patient’s original diagnostic 
biopsy can be detected in their plasma when they progress on 
chemotherapy which may provide another opportunity for mutati-
on testing. 
Table 1. Comparison of EGFR mutations detected in plasma and 
diagnostic biopsy. MND=Mutation-Not-Detected.
Keyword: EGFR, plasma DNA, blood, mutation
prior to erlotinib treatment. The figure shows the time course of 
two representative patients where a T790M resistance mutation 
emerges. In the 9 patients with T790M mutation, it can be detec-
ted in the blood between 15 and 344 days (mean of 98 days) befo-
re progression is clinically evident. 
Conclusion: The amounts of EGFR TKI sensitizing mutant DNA in 
plasma change during the erlotinib treatment. T790M mutation 
was not detected prior to erlotinib treatment and is detected bet-
ween 15 and 344 days before disease progression is evident.
Keyword: EGFR, treatment response, blood, mutation
PROGNOSTIC AND PREDICTIVE BIOMARKERS V - EGFR  
WEDNESDAY, OCTOBER 30, 2013 - 10:30-12:00
MO21.08 DETECTION OF EGFR MUTATIONS IN PLASMA 
AND DIAGNOSIS BIOPSIES FROM NON-SMALL CELL 
LUNG CANCER PATIENTS USING ALLELE-SPECIFIC PCR 
ASSAYS.
Britta Weber1, Peter Meldgaard1, Henrik Hager2, Lin Wu3, Julie 
Tsai3, Wei Wen3, Azza A. Khalil1, Ebba Nexo4, Boe Sorensen4
1Department Of Oncology, Aarhus University Hospital/Denmark, 2Ins-
titute Of Pathology, Aarhus University Hospital/Denmark, 3Genomics 
And Onoclogy Department Research, Roche Molecular Systems, Inc./
United States Of America, 4Department Of Clinical Biochemistry, Aar-
hus University Hospital/Denmark
Background: EGFR TKI sensitizing mutations from plasma prior 
to treatment were shown to be a potent predictor for survival 
outcome of advanced NSCLC (T. Mok, ASCO 2013). In this study, 
we tested EGFR mutations in the archived plasma from 199 advan-
ced adenocarcinoma. The plasma samples were taken when they 
progressed on their chemotherapy and before their 2nd erlotinib 
treatment a mean of 10.5 months after the diagnostic biopsy was 
obtained. EGFR mutations detected in plasma after chemotherapy 
and in the tumor DNA from their original diagnostic biopsies were 
also compared.
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MO21.10 SERIAL MONITORING OF PLASMA EGFR 
T790M LEVELS AND EVALUATION OF EGFR MUTATIO-
NAL STATUS IN MATCHED TISSUE AND PLASMA FROM 
NSCLC PATIENTS TREATED WITH CO-1686
Heather A. Wakelee1, Chris A. Karlovich2, Wei Wen3, Jong-Mu 
Sun4, Sean Chien3, Elaina Mann5, Patrick O‘Donnell3, Philipp An-
genendt6, Rafal Dziadziusko7, Leora Horn8, David Spigel9, Lecia V. 
Sequist10, Benjamin Solomon11, Jean-Charles Soria12, D Ross Ca-
midge13, Jonathan Goldman14, Shirish Gadgeel15, Mitch Raponi2, Lin 
Wu3, Keunchil Park4
1Division Of Oncology, Stanford University/United States Of America, 
2Molecular Diagnostics, Clovis Oncology/United States Of America, 
3Roche Molecular Systems/United States Of America, 4Division Of 
Hematology-Oncology, Samsung Medical Center, Sungkyunkwan Uni-
versity School Of Medicine/Korea, 5Clovis Oncology/United States Of 
America, 6Inostics/Germany, 7Medical University Of Gdansk/Poland, 
8Vanderbilt-ingram Cancer Center/United States Of America, 9Sarah 
Cannon Research Institute/United States Of America, 10Hematology/
Oncology, Massachusetts General Hospital/United States Of America, 
11Peter MacCallum Cancer Centre/Australia, 12Institut Gustave Roussy/
France, 13University Of Colorado/United States Of America, 14Ucla/Uni-
ted States Of America, 15Oncology, Karmonos Cancer Institute/United 
States Of America
Background: We explored the minimally-invasive detection of 
EGFR mutations in circulating free DNA from plasma and studied 
the concordance of EGFR mutation status between matched plas-
ma and tumor tissue in a cohort of newly diagnosed or relapsed 
patients with advanced NSCLC. CO-1686 is an oral, potent, small-
molecule irreversible tyrosine kinase inhibitor that selectively 
targets mutant forms of EGFR, including T790M and the common 
initial activating mutations, while sparing wild-type EGFR. Promi-
sing clinical activity has recently been reported from an on-going 
Phase I/II trial.
Methods: Matched tumor tissue and blood from 80 Stage IIIB/
IV NSCLC patients, 41 treated with CO-1686, were tested using 
two allele-specific PCR assays, the cobas® EGFR FFPET and co-
bas® EGFR blood tests. Each test detects 41 mutations in EGFR, 
including the T790M resistance mutation, exon 19 deletions and 
L858R. We also used BEAMing, a highly quantitative and sensitive 
technology based on digital PCR, to assess a subset of 18 patients 
treated with CO-1686. BEAMing was compared to cobas analysis 
at baseline, and also used to serially monitor plasma EGFR mutati-
on levels in response to CO-1686.
Results: Using tissue as reference, the positive percent agreement 
between tissue and plasma was 76% (44/58) for activating muta-
tions and 63% (17/27) for T790M. The cobas® EGFR blood test 
identified two patients with T790M mutations in plasma that were 
not detected in the corresponding tumor biopsy—likely because 
of tumor heterogeneity. The M1a/M1b status was known for 63 
EGFR mutation-positive patients. Of the 44 with extrathoracic 
metastatic disease (M1b), 38 were found to have an activating mu-
tation in plasma (86%). Conversely, only 53% (10/19) of EGFR mu-
tation-positive patients with intrathoracic metastatic disease (M1a) 
had detectable activating mutations in plasma (p = 0.0081). For the 
18 patients profiled by BEAMing, the overall percent agreement 
between BEAMing and the cobas® EGFR blood test was 94% 
(17/18) for T790M and 83% (15/18) for activating mutations. Nine of 
the 18 patients had detectable baseline plasma T790M levels, and 
several patients treated with CO-1686 had an initial decrease in 
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MO21.09 DYNAMIC, QUANTITATIVE, AND NON-INVASI-
VE ANALYSIS OFT790M MUTATION IN MATCHED PLAS-
MA DNA FROM PRE-AND POST-EGFR-TKI TREATMENT 
FOR ADVANCED NON-SMALL CELL LUNG CANCER
Rui Chen, Hua Bai, Shuhang Wang, Yuyan Wang, Jianchun Duan, 
Jie Wang, Tongtong An, Minglei Zhuo, Meina Wu
Peking University Cancer Hospital/China
Background: Resistance to epidermal growth factor receptor tyro-
sine kinase inhibitors (EGFR-TKIs) in advanced non-small cell lung 
cancer patients (NSCLC) is attributed to the T790M mutation of 
EGFR. Here, we evaluated T790M mutation using dynamic, quan-
titative and non-invasive method and explored its role predicting 
outcomes of EGFR-TKI treatment.
Methods: We enrolled 135 EGFR-TKI-resistant NSCLC patients in 
the study. Pre- and post-EGFR-TKI treatment (pre-TKI and post-TKI, 
respectively) plasma samples were obtained for analysis. T790M 
mutation was measured qualitatively and quantitatively by the 
amplification refractory mutation system (ARMS) and digital poly-
merase chain reaction (D-PCR).
Results: D-PCR was more sensitive than ARMS in detecting the 
T790M mutation (pre-TKI: 29.4% (32/109) vs 5.5% (6/109), P<0.001; 
post-TKI: 43.0% (58/135) vs 25.2% (34/135), P=0.001). Patients with 
a pre-TKI T790M mutation (N=32) showed shorter progression 
free survival (PFS) and overall survival (OS) than patients without a 
T790M mutation (N=77) (9.2 vs 12.7 months, P=0.004; and 19.3 vs 
31.9 months, P=0.001, respectively). No differences were obser-
ved in post-TKIPFS or OS (12.5 vs 12.2 months, P=0.744; and 27.0 
vs 29.7 months, P=0.636, respectively). Post-treatment patients 
were divided into high-frequency (>4.375%) and low-frequency 
(≤4.375%) groups, according to the mutant T790M-to-wild-type 
gene ratio calculated from D-PCR results. Patients in the high-
frequency group showed a significantly shorter OS than the low-
frequency group (20.67 vs 29.13 months, P=0.009).
Conclusion: D-PCR is more sensitive than ARMS in detecting the 
T790M mutation. The presence of a pre-TKI T790M mutation and a 
high frequency of post-TKI T790M mutation predicted poor outco-
mes of EGFR-TKI treatment.
Keyword: NSCLC, EGFR-TKI, T790M mutation, acquired resis-
tance, plasma DNA, dynamic and quantitative detection
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Methods: AZD9291 is an oral, irreversible, third generation inhi-
bitor of both EGFR activating (EGFRm+) and resistance mutations 
(T790M). The mechanistic and functional activity of AZD9291 was 
characterised in vitro across a number of cell lines harbouring 
various EGFR-mutations or wild type EGFR. Efficacy of AZD9291 
was further evaluated across a number of different EGFR-mutant 
xenograft and transgenic models in vivo. One open label, dose 
escalation phase I study of AZD9291 (NCT01802632) is ongoing to 
determine the safety and tolerability [primary measure], pharma-
cokinetics and preliminary efficacy profiles of AZD9291, in patients 
with advanced NSCLC who have progressed following EGFR TKI. 
Sequential cohorts of 3-6 patients with advanced NSCLC who 
have had at least one prior regimen containing an EGFR TKI agent 
(with confirmed EGFRm+ status or Jackman criteria), were treated 
with AZD9291 once daily. Other key inclusion criteria were PS 0-1, 
measurable disease, and no prior history of ILD. RECIST assess-
ments were scheduled 6 weekly. Dose escalation can occur after ≥ 
3 patients complete both single dose and the first 21-day cycle of 
AZD9291 multiple dosing with no DLT.
Results: AZD9291 potently inhibits EGFR phosphorylation in EG-
FRm+ (PC9; 14nM) and EGFRm+/T790M (H1975; 13nM) cell lines 
in vitro, whilst demonstrating much less activity against wild-type 
EGFR lines (LoVo; 400nM). Consistently, AZD9291 showed signifi-
cantly more potent inhibition of proliferation in mutant EGFR cell 
lines compared to wild-type in vitro. In addition, AZD9291 treat-
ment caused profound growth regression across multiple EGFRm+ 
(PC9; 250% growth inhibition) and EGFRm+/T790M (H1975; 132% 
growth inhibition) tumour models in vivo, at doses as low as 5mg/
kg after 14 days. Tumour growth inhibition was associated with 
profound inhibition of EGFR activity and key downstream signaling 
pathways. Chronic long-term treatment of in vivo PC9 and H1975 
xenograft tumours with AZD9291 led to a complete and sustained 
macroscopic response. In the phase I study, clinical activity with 
RECIST responses have already been observed at the starting 
dose level of 20mg once daily, with good tolerability, no reported 
events of EGFR wild-type rash, and only grade 1 diarrhoea (based 
on preliminary data, unvalidated and subject to change).
Conclusion: Preclinical data demonstrates that AZD9291 is a po-
tent and effective inhibitor of both EGFR activating (EGFRm+) and 
resistance mutations (T790M) whilst sparing wild-type EGFR and, 
early clinical data have been promising. Taken together, these data 
support the further clinical investigation of AZD9291 in advanced 
EGFR mutant NSCLC.
Keywords: AZD9291, Phase I, EGFR mutations, T790M mutation
plasma T790M by BEAMing.
Conclusion: Using the cobas® EGFR blood test, a high propor-
tion of EGFR mutations identified in tissue were also detected in 
plasma. Mutations were more readily detectable in the plasma of 
patients with M1b rather than M1a disease. These findings suggest 
that the cobas® EGFR blood test and BEAMing can be useful tools 
for the non-invasive assessment and monitoring of EGFR mutations 
in NSCLC patients.  
EGFR  
mutation 
Evaluable 
patients 
Patients 
with tis-
sue mu-
tations* 
Patients 
with 
plasma 
muta-
tions** 
Patients 
with 
same 
mutation 
detected 
in tissue 
and  
plasma 
Positive 
Percent 
Agree-
ment*** 
L858R, 
del19, 
S768I, 
G719X, 
or 
ex20ins 
80 58 44 44 76% 
T790M 80 27 19 17 63% 
* identified by the cobas® EGFR tissue test 
** identified by the cobas® EGFR blood test 
***agreement of blood and tissue mutation-positive results with 
tissue as reference; although tissue is reference, some mutations 
may be missed due to tumor heterogeneity 
Keyword: EGFR plasma concordance cobas
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MO21.12 AZD9291: AN IRREVERSIBLE, POTENT AND 
SELECTIVE TYROSINE KINASE INHIBITOR (TKI) OF AC-
TIVATING (EGFRM+) AND RESISTANCE (T790M) MUTA-
TIONS IN ADVANCED NSCLC
Malcolm Ranson1, William Pao2, Dong-Wan Kim3, Sang-We Kim4, 
Yuichiro Ohe5, Enriqueta Felip6, David Planchard7, Serban Ghior-
ghiu8, Mireille Cantarini8, Darren Cross8, Pasi A. Jänne9
1Christie Hospital NHS Trust/United Kingdom, 2Dept. Of Medicine/divi-
sion Of Hematology-Oncology, Vanderbilt University/United States Of 
America, 3Department Of Internal Medicine, Seoul National University 
Hospital/Korea, 4Department Of Oncology, Asan Medical Center/Korea, 
5Division Of Thoracic Oncology, National Cancer Center Hospital East/
Japan, 6Hospital Universitario De La Vall D‘hebron/Spain, 7Institut 
Gustave Roussy/France, 8Astrazeneca/United Kingdom, 9Dana Farber 
Cancer Institute/United States Of America
Background: The first generation EGFR TKIs gefitinib and erloti-
nib provide significant clinical benefit in patients with advanced 
EGFR mutant NSCLC but many patients ultimately develop disease 
progression due to acquired resistance. The EGFR T790M muta-
tion is the most common mechanism of acquired drug resistance, 
detected in more than 50% of gefitinib/erlotinib resistant patients. 
Current therapeutic strategies are limited for NSCLC patients with 
EGFR T790M.
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MO22.02 RESECTION RATE, AS A MEASURE OF THE 
EFFECTIVENESS OF SURGICAL TREATMENT OF LUNG 
CANCER
Tadeusz M. Orlowski, Piotr Rudzinski
Thoracic Surgery, Institute Of Chest Diseases/Poland
Background: Surgery is the most effective way to treat lung can-
cer. There are significant differences between countries in the 
effectiveness of surgical treatment. The resection rate differe from 
10 to over 20% in Europe
Methods: The National Registry of lung cancer in Poland com-
prises over 95% of patients with NSCLC treated with surgery. 
Resection rate (RR) is monitored for 20 years in Poland. Each year 
RR is calculated by the following formula: R R = (number of resec-
ted patients with NSCLC/ number of new cases) x 100 This ratio is 
calculated for each and even the smallest administrative area (16 
provinces and 380 districts). To achieve such a result- the patient‘s 
place of residence is taken into account rather than a place where 
he had his surgery. This allows to determine how many of the pa-
tients in particular area have been diagnosed in certain stage of 
acceptance (mainly I and II) In year 2012, 3591 patients had surgery 
in Poland. The incidence of NSCLC this year was 22 348 new cases.
Results: The RR in Poland in 2012 was 16.1%. The difference in 
many provinces ranged from 10.2% - 22%. In few districts the RR 
was reported from 0% - 46%. 79% of patients were in stage I and 
II, 11.2% in IIIa, 2.7% in IIIb and and 1.9% in stage IV. Comparing to 
2011, resection rate increased by 5%, and within five years - 16.8%. 
Since 2010 in the areas with the lowest RR a screening program 
with low-dose computed tomography was implemented. The RR 
increased from 1,2 to 22% in majority of districts (14/16)
Conclusion: 1 Implementation of the resection rate allows to mo-
nitor the effectiveness of early diagnosis of lung cancer in different 
areas 2 Monitoring of the resection rate allows to improve the 
efficiency of diagnosis of lung cancer in areas where detection was 
low. 3. Regular evaluation of the RR supports the efforts to impro-
ve the results of surgical tratment of NSCLC
Keyword: resection rate lung cancer
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MO22.03 POSTOPERATIVE REHABILITATION AND FOL-
LOW-UP - A RANDOMIZED STUDY.
Erik Jakobsen, Ole Dan Joergensen, Lars Ladegaard, Susanne Pe-
tersen, Inge Aagaard, Pernille Mikkelsen, Peter Licht
Thoracic Surgery, Odense University Hospital/Denmark
Background: The importance of postoperative follow-up and re-
habilitation after lung cancer surgery remains a controversial topic. 
Previous studies have showed that follow-up programs did not 
influence survival but at that time there was little focus on the ef-
fects of rehabilitation. Introduction of new diagnostic procedures, 
improvements in treatment modalities and increasing awareness 
on quality of life after treatment has changed guidelines and re-
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MO22.01 HIGH PROCEDURE VOLUME IS STRONGLY 
ASSOCIATED WITH IMPROVED SURVIVAL AFTER LUNG 
CANCER SURGERY
Margreet Luchtenborg1, Sharma P. Riaz1, Victoria H. Coupland1, 
Eric Lim2, Erik Jakobsen3, Mark Krasnik4, Richard Page5, Michael 
Lind6, Michael D. Peake7, Henrik Moller8
1Knowledge & Intelligence Team (london), Public Health England/United 
Kingdom, 2Royal Brompton Hospital/United Kingdom, 3Danish Lung 
Cancer Registry, Odense University Hospital/Denmark, 4Rigshospitalet/
Denmark, 5Department Of Thoracic Surgery, Liverpool Heart And Chest 
Hospital/United Kingdom, 6Medical Oncology, Hull York Medical School/
United Kingdom, 7Department Of Respiratory Medicine, Glenfield Hos-
pital/United Kingdom, 8Cancer Epidemiology And Population Health, 
King‘s College London/United Kingdom
Background: Surgical resection is the first line treatment offered 
to patients with early stage non-small cell lung cancer (NSCLC) 
who are considered medically fit. Many studies have shown that 
patients undergoing surgery for lung cancer benefit from receiving 
treatment in hospitals where high numbers of lung cancer resec-
tions are carried out. This study explores the association between 
hospital volume and survival among all NSCLC patients diagnosed 
in England who underwent surgical resection and takes into ac-
count the differences in case selection and propensity to resect.
Methods: We analysed data on 134,293 patients with NSCLC dia-
gnosed in England between 2004 and 2008 of whom 12,862 (9·6%) 
underwent surgical resection. Hospital volume was defined according 
to the number of patients with resected lung cancer in each hospital 
in each year of diagnosis. Cox proportional hazard regression analy-
ses were used to assess the association between hospital volume and 
survival among resected patients. We calculated multivariable hazard 
ratios according to hospital volume, with adjustment for potential 
confounders (sex, age, socioeconomic deprivation, comorbidity and 
resection quintile). In addition, to account for the risk of death poten-
tially varying between groups of patients treated within a given hos-
pital, a shared frailty Cox model was used, with hospital as a random 
effect. The follow-up period was divided into three pre-defined peri-
ods: 0-30 days, 31-365 days and >365 days post-surgery.
Results: There was increased survival in hospitals performing more 
than 150 surgical resections compared with those carrying out less 
than 70 [HR 0·78 (95% CI 0·67-0·90), ptrend <0·01]. The association bet-
ween hospital volume and survival was present in all three periods of 
follow-up, but the magnitude of the association was greatest in the 
period 0-30 days (HR for the 150+ hospital volume group compared 
with less than 70: 0·58, 95% CI 0·38-0·89) and smallest in the period 
after 365 days (HR 0·84, 95% CI 0·71-0·99).
Conclusion: High volume hospitals have higher resection rates, 
operate on patients who are older, have lower socioeconomic status, 
more comorbidities and despite that they achieve better survival, 
most notably in the early post-operative period.
Keyword: non-small cell lung cancer, surgery, hospital volume, epide-
miology
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MO22.04 STANDARDISING THE MANAGEMENT OF  
PATIENTS FOLLOWING LUNG RESECTION: DOES IT 
IMPROVE OUTCOME?
Jonathan Coad1, Annabel J. Sharkey1, Richard Owen-Smith2, Alex 
Cale1, Mubarak Chaudhry1, Steve Griffin1, Mahmoud Loubani1, 
Michael Cowen1
1Department Of Cardiothoracic Surgery, Castle Hill Hospital/United 
Kingdom, 2Department Of Anaesthesia, Castle Hill Hospital/United 
Kingdom
Background: There is marked variation in the management of 
Thoracic surgical patients post-operatively, both between individu-
al surgeons and surgical centres. This lack of standardisation can 
lead to staff and patient dissatisfaction, and differing outcomes for 
patients. In 2012 we introduced a more standardised approach to 
the management of patients undergoing Thoracic surgery under 
the care of one consultant (Consultant A). This was based on the 
‘fast-track’ protocol published in 2001 by Cerfolio et al. We aimed 
to determine whether this approach to patient management has 
affected patient outcome.
Methods: Data for all patients undergoing lung resection at a 
single centre from April 2012 to March 2013 were collected. The 
patients were split into two groups, those under the care of Con-
sultant A (group A), and those under the care of the remaining 4 
consultants (group B). Group A were managed according to the 
new standardised pathway which included; stopping the routine 
use of suction unless clinically required, chest drain removal with 
cessation of an air leak and drainage below 400mls in 24 hours, 
and epidural catheter removal on post-operative day 2. Those in 
group B were managed according to the instructions of the opera-
ting Consultant, or the surgical registrars covering the ward. Pre-
operative, operative and post-operative data were collected and 
analysed. Patients were then propensity matched using operation 
and age.
Results: Two hundred and thirty one patients were identified. Ove-
rall mean length of stay for all patients in group A was 5.65 days 
(SD±4.68), and in group B; 9.97 days (SD±12.06), p<0.001. Of these 
patients 94 were suitable for propensity matching. There were no 
significant differences found in the proportion of patients with 
benign versus malignant pathology, the number with primary lung 
cancer, or in the stage of the resected primary lung cancer. In-
Hospital mortality for both groups was one patient (2.13%). There 
was a lower number of drains inserted peri-operatively in group A 
patients (p<0.001). Mean time to drain removal (all drains) was 3.42 
days (SD±6.35) for group A and 4.24 days (SD±3.08) for group B, 
p=0.026. Mean length of stay for group A was 6.00 days (SD± 4.86) 
and for group B 10.33 days (SD±19.29), p=0.042.
Conclusion: Standardising care following surgery has been shown 
to improve patient safety, and both patient and staff satisfaction. 
We have found that reducing variation, and following a validated 
management pathway, significantly reduces the time to chest drain 
removal and in-Hospital length of stay for patients undergoing 
lung resection for any pathology. We are currently analysing the 
various elements of the pathway to determine which specific fac-
tors impact patient outcome. Further work is required to determi-
ne the effect these differences have on patient reported outcome 
measures, including overall satisfaction.
Keywords: Standardisation of care, lung resection
commendations for follow-up programs. There is little evidence for 
these recommendations which prompted us to conduct a rando-
mized study to evaluate the effect of an intense follow-up program 
on survival and quality of life for patients undergoing surgery for 
lung cancer (NSCLC).
Methods: Between January 2003 and April 2008 a total 197 NS-
CLC patients were included in the study after undergoing surgical 
resection (wedge, lobectomy or pneumonectomy) through a pos-
terolateral thoracotomy. Adjuvant chemotherapy was offered to 
stage Ib - IIIa. Postoperatively patients were randomized to either 
active rehabilitation and follow-up (POREFU, N=103) or passive 
follow-up (Standard, N=94). Patients in the POREFU group had in-
tensive follow-up in the form of annual clinical evaluation, chest X-
ray, chest CT, bronchoscopy and EBUS (Endobronchial Ultrasound) 
for 5 years. In the POREFU group patients were also evaluated by a 
nurse and a physiotherapist after 6 weeks, 6 months and at annual 
controls. When indicated, interventions were established to cor-
rect patient symptoms. Patients in the standard treatment group 
were offered a chest X-ray one year after surgery and a clinical 
examination by their family doctors upon request. Quality of life in 
both groups was assessed after 6 weeks, 6 months, 12 months and 
2, 3, 4 and 5 years evaluating EORTC QLQ-C30/LC13. All survivors 
were followed for 5 years.
Results: 
There was no significant difference in survival between the two 
groups (Kaplan Meier plot). There was a significant difference 
between the two groups in favour of active follow-up regarding 
Global health status as well as “Physical”, “Role” and “Emotional” 
functioning and POREFU patients had significant less pain and 
fatigue. There was no statistical significant improvement of other 
symptoms or functional issues.
Conclusion: This randomized trial shows that a follow-up program 
with an additional focus on rehabilitation and intervention towards 
reported symptoms in patients operated for NSCLC significantly 
improves quality of life but has no effect on overall survival.
Keywords: rehabilitation, Lung cancer, follow up, survival
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RECURRENCE AFTER SURGERY FOR NON-SMALL CELL 
LUNG CANCER.
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kihiro Kohno2, Yoshihiko Maehara2
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Background: We previously reported a retrospective study indi-
cating the prognostic impact of local treatment of postoperative 
oligometastases in patients with non-small cell lung cancer (NS-
CLC) (Yano T et al. J Surg Oncol 2010;102:852-855). However, pre-
vious studies have not been sufficient to determine the therapeutic 
significance of local treatment for postoperative oligometastases 
since the conclusions were based on retrospectively collected 
data and the assessment of overall survival. In the present study, 
we prospectively observed postoperative oligometastatic patients 
and investigated the effects of local treatment on progression-free 
survival (PFS).
Methods: Using a prospectively maintained database of patients 
with completely resected NSCLC treated between October 2007 
and December 2011, we identified 52 consecutive patients with 
postoperative recurrence. Of these patients, 31 suffering from 
distant metastases alone without primary site recurrence were 
included in this study. In order to exclude cases of second primary 
carcinoma of the lungs, the criteria of Martini and Melamed, mo-
dified by Antakli et al., were used to differentiate between second 
primary lung cancer and pulmonary metastasis. According to the 
definition of ‘oligometastases’ as limited recurrence potentially 
controlled with local treatment, 17 patients had oligometastatic 
disease. The number of metastases was less than four.
Results: The oligometastatic sites included the lungs in five pati-
ents, the brain in four patients, bone in four patients, the lungs and 
brain in two patients, the adrenal glands in one patient and soft 
tissue in one patient. Fifteen of the 17 patients first received local 
treatment. Three patients (lung, adrenal gland, soft tissue) under-
went surgical resection, and the remaining 12 patients received ra-
diotherapy. The median PFS was 33 months in the oligometastatic 
patients who received local treatment. There were seven patients 
with a PFS of longer than two years. The metastatic sites in these 
patients varied, and the number of lesions in three patients was 
two or three. On the other hand, the two remaining patients first 
received a systemic chemotherapy of their own selection. The PFS 
of these two patients was five and 15 months, respectively.
Conclusion: Both our previous retrospective study and the present 
study favor a choice of local treatment in patients with postopera-
tive oligometastatic NSCLC.
Keywords: local therapy, non-small cell lung cancer, postoperative 
recurrence, oligometastases
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MO22.05 SURGERY IN OCTOGENARIANS WITH EARLY 
STAGE NON-SMALL CELL LUNG CANCER: A SEER DATA-
BASE ANALYSIS
Apar Kishor Ganti1, Valerie Shostrom2, Alissa Marr2, K Monirul 
Islam2, Rudy P. Lackner2, Karin Trujillo2, Anne Kessinger2
1Internal Medicine, Va Nebraska Western Iowa Health Care System/
United States Of America, 2University Of Nebraska Medical Center/
United States Of America
Background: Surgical resection is the standard of care for patients 
with early stage non-small cell lung cancer (NSCLC). However out-
comes in older patients, especially octogenarians, following resec-
tion have not been studied in detail. This analysis was undertaken 
to evaluate the variations in patterns of care over time and outco-
mes following resection in octogenarians with early stage NSCLC.
Methods: Patients 80 years of age and older diagnosed with clini-
cal stages I and II NSCLC, between 1988 and 2007, were identified 
from the SEER database. Data abstracted included age at diagno-
sis, stage, gender, race, histology, year of diagnosis and cause of 
death. The type of surgical resection was not available for a majo-
rity of patients and hence was not considered. Overall survival was 
estimated as the time from the date of diagnosis to death, or date 
of last contact (if censored). Factors associated with survival were 
assessed using regression analysis based on the Cox proportional 
hazards model. Temporal trends in survival were compared using 
log-rank test. Lung cancer specific survival (LCSS) was also estima-
ted in these patients and temporal trends were compared using 
log-rank tests.
Results: Six hundred and forty-nine patients ≥80 years of age, who 
underwent surgical resection for stages I and II NSCLC, were iden-
tified. The majority of these patients had stage I disease (n=549), 
were white (n=586) and had an adenocarcinoma (n=325). Females 
comprised 50.6% of stage I, but only 37% of stage II patients. Fac-
tors associated with worse overall survival on multivariate analysis 
in this cohort were: increasing age [Hazard ratio (HR) - 1.08; 95% 
CI - 1.03, 1.12], male gender (HR - 1.33; 95% CI - 1.07, 1.65), stage II 
(HR - 2.21; 95% CI - 1.71, 2.87) and squamous histology (HR - 1.36; 
95% CI - 1.07, 1.74). The percentage of patients undergoing sur-
gery increased over time. Of the patients who underwent surgery 
8.6% were diagnosed between 1988-1992, 16% between 1993-
1997, 24.2% between 1998-2002 and 51.2% between 2002-2007. 
Despite this the median survival was not significantly different over 
these time periods. Median survivals for the four different time pe-
riods were as follows: 1988-1992 – 3.9 years; 1993-1997 – 3.2 years; 
1998-2002 – 3.8 years; 2002-2007 – 3.3 years (p = 0.09). These are 
comparable to those reported previously in younger patients (ages 
65-75 years) (5.92 years - stage I, 2.6 years - stage II). Similarly lung 
cancer specific survival was not significantly different between the 
different time points. Median LCSS for the four time periods were 
9.2 years, 6.8 years, 7.9 years, and not reached, respectively (p = 
0.51).
Conclusion: Among octogenarians who had surgical resection for 
lung cancer, increasing age, male gender, higher stage and squa-
mous histology were associated with worse survival. Despite an 
increased incidence of surgical resection for octogenarians, out-
comes remained unchanged between 1988 and 2007. Octogenari-
ans, when carefully selected, are capable of experiencing a similar 
advantage provided by surgical resection of early stage non small 
cell lung cancer as younger patients.
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MO22.09 THORACOSCOPIC HALF CARINA RESECTION 
AND BRONCHIAL SLEEVE RESECTION FOR CENTRAL 
LUNG CANCER
Xin Xu, Hanzhang Chen, Weiqiang Yin, Wenlong Shao, Xinguo 
Xiong, Jun Huang, Jianxing He
The First Affiliated Hospital Of Guangzhou Medical College/China
Background: The objectives of this study were to report the sur-
gical techniques and clinical outcome of thoracoscopic half carina 
resection and thoracoscopic bronchial sleeve resection for central 
lung cancer.
Methods: Between January 2011 and November 2012, 675 pati-
ents with lung cancer underwent radical surgery by thoracoscopy, 
49 (7.3%) underwent bronchial sleeve resection. Among 49 pati-
ents, 20 (41%) received thoracoscopic bronchial sleeve lobectomy. 
Perioperative variables and postoperative outcomes of these cases 
were analyzed to evaluate the technical feasibility and safety of this 
operation.
Results: In one patient, right upper lung sleeve resection was 
combined with half-carinal resection and reconstruction. In ano-
ther, right medial lung sleeve resection was combined with lower 
right dorsal segment resection. The average time of surgery was 
239 min (range, 142-330 min, 239±51 min), and the average time 
of airway reconstruction was 44 min (range, 22-75 min, 44±17 min). 
The intraoperative blood loss averaged 207 ml (range, 80-550 ml, 
207±96 min). The median postoperative hospital stay was 10 days 
(interquartile range, 8-12 days). Postoperatively, extubation was 
achieved in the recovery room without further need for mechani-
cal ventilation. None of the patients developed anastomotic leak. 
Perioperative mortality was not observed.
Conclusion: Thoracoscopic bronchial sleeve resection can be 
considered a feasible and safe operation for selected patients with 
central lung cancer. The complicated anastomosis technique of 
half carina resection was feasible.
Keywords: VATS, sleeve lobectomy, Thoracoscopic bronchial slee-
ve resection, Lung cancer
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MO22.10 SURGERY AFTER CONCURRENT CHEMO-
RADIATION WITH 55 GY IN 20 FRACTIONS OVER FOUR 
WEEKS WITH FULL DOSE PLATINUM AND VINORELBINE
Joe Maguire1, John Littler2, Veronica Kelly1
1Liverpool Lung Cancer Unit, Liverpool Heart And Chest Hospital/
United Kingdom, 2Radiotherapy, Clatterbridge Cancer Centre/United 
Kingdom
Background: Concurrent chemo-radiation is the standard of 
care for patients with inoperable stage III NSCLC and good per-
formance status. Following concurrent chemo-radiation some 
patients may have operable disease, and surgery may be consi-
dered to improve the prospects of cure for patients with negative 
mediastinal nodes and evidence of residual activity in the primary 
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MO22.08 SURGICAL RESECTION OF STAGE IIIA-N2 
NON-SMALL CELL LUNG CANCER: SHOULD WE STILL 
TALK ABOUT THE FUTILE THORACOTOMY?
Olaf Mercier1, Elie Fadel1, Marc De Perrot1, Thibault Pierard1, Sacha 
Mussot1, Dominique Fabre1, Francois Leroy Ladurie1, Benjamin 
Besse2, Cecile Le Pechoux3, Thierry Le Chevalier1, Philippe Darte-
velle1
1Centre Chirurgical Marie Lannelongue/France, 2Department Of Medical 
Oncology, Institut-gustave-roussy/France, 3Radiotherapy Dept, Institut 
Gustave Roussy/France
Background: Stage IIIA-N2 non-small cell lung cancer (NSCLC) 
is currently mainly managed with chemotherapy and radiation 
therapy with limited outcome. Whether surgical resection should 
be offered to patients with resectable IIIA-N2 NSCLC as part of a 
multi-modality approach with adjuvant or neoadjuvant treatment 
remains unclear. We sought to determine the long-term result of 
resected IIIA-N2 NSCLC in a single institution.
Methods: We reviewed the charts from a consecutive series of 263 
patients with a mean age of 62 years (range, 37-68) undergoing 
lung resection and complete en bloc lymph node dissection for 
IIIA-N2 NSCLC from 01/2000 to 12/2011. Clinical N2 (cN2) patients 
were diagnosed preoperatively on chest CT scan and/or PET scan 
and were histologically proven by mediastinoscopy or EBUS. Pati-
ents with cN2 with a single site of mediastinal disease were occa-
sionally treated with surgery upfront followed by adjuvant chemo-
therapy with or without radiation (cN2 adj, n=70). The remaining 
patients with cN2 disease were treated with neoadjuvant therapy 
followed by surgery (cN2 neoadj, n=55). Minimal N2 patients were 
diagnosed postoperatively on final pathology report and received 
adjuvant therapy (mN2, n=138).
Results: Lung resection was a pneumonectomy in 75 patients and 
a lobectomy in 188 patients with a post-operative mortality of 
1.3% and 3.1%, respectively. Adjuvant chemo- or chemoradiation 
therapy was administered in 181 patients. The overall 5-year sur-
vival was 43.6%, with no significant difference between the type 
of lung resection (pneumonectomy: 38.9% vs. lobectomy: 45.5%, 
p=0.18) or the number of mediastinal lymph node site involvement 
(1 site 44.8% vs. 37,7% for multiple sites, p=0.9). Long-term survival 
tended to be better for mN2 compared to cN2 (5-year survival of 
50.4% vs. 35.9%, respectively; p=0.08). However, survival for cN2 
was similar between neoadjuvant and adjuvant therapy (5-year 
survival of 30.3% vs. 40.2%, respectively; p=0.53). The number of 
mediastinal lymph node site involvement did not impact survival in 
patients with cN2 disease (1 site 37.6% vs 27.6% for multiple sites, 
p=0.59).
Conclusion: Surgery for Stage IIIA-N2 NSCLC achieved good 
long-term survival when combined with chemotherapy or chemo-
radiation therapy in well selected patients. Long-term survival was 
similar in patients with clinical N2 disease whether they received 
adjuvant or neoadjuvant therapy. Surgery should be considered 
as part of a multimodality treatment for patients with stage III-N2 
NSCLC.
Keywords: Stage IIIA-N2, Multimodality treatment
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with definitive surgery and PDT (porfimer sodium, 24hr drug-light 
interval, 630nm, 30-60J/cm2) from 1997-2012 on either of two IRB-
approved prospective clinical trials were assessed. Progression-
free survival (PFS) and OS were defined as the time from surgery 
to recurrence and death, respectively, or to last contact. Pleural 
control was defined as absence of ipsilateral pleural disease after 
surgery, whereas locoregional control was defined as absence of 
lung parenchymal or intrathoracic nodal disease.
Results: 34 consecutive patients were assessed, all with ECOG 
performance status 0-1. The cohort was 50% male, predominantly 
Caucasian (85%), and a median of 55yrs at the time of surgery (ran-
ge, 35-73yrs). Most had adenocarcinoma (79%), clinical N2 nodal 
metastasis (64%), and received neoadjuvant chemotherapy (94%) 
and/or radiotherapy (12%). Over half (56%) underwent pneumonec-
tomy, whereas 38% received a lesser anatomic resection. Two 
patients were found intraoperatively to have unresectable disease 
due to pericardial effusion (n=1) or trans-diaphragmatic extension 
(n=1). Pathologic staging was pT4N0 (24%) or pT4N2 (76%). Four 
patients (3/19 pneumonectomy, 1/13 lung-sparing) suffered peri-
operative mortality (day 11-98), with one death attributable to PDT 
(ARDS, day 11). Following surgery/PDT, 59% of patients received 
mediastinal radiotherapy (median 50.4Gy/1.8Gy) and 50% received 
chemotherapy. Pleural recurrence rates and OS were similar for 
patients undergoing pneumonectomy or other procedures (p>0.05 
for both). Cohort median OS was 21.4 months (0.4-161.1 months), 
and survival rates were 59% at 1yr and 41% at 2yrs. Median overall 
PFS was 7.5 months, with numerous patients achieving durable 
disease-free intervals (mean PFS 18.4 months). Median pleural PFS 
was 13.6 months, with pleural recurrences occurring in only 32%. 
Overall, 79% experienced recurrence or unresectable disease pro-
gression, and distant failure was most commonly observed (53%).
Conclusion: This study demonstrates that surgery and intraopera-
tive PDT can achieve durable local control and prolonged survival 
for NSCLC patients with pleural dissemination. Compared with 
current standard treatment, which offers a median survival of 6-9 
months from pleural metastasis diagnosis, our cohort lived a me-
dian of 24.7 months from pleural diagnosis and 21.4 months from 
surgery/PDT. This study also demonstrates that surgery/PDT can 
be performed with acceptable morbidity. Distant recurrence was 
the most common failure, indicating need for improved adjuvant 
systemic therapy. These results are sufficiently encouraging to 
warrant further study and suggest that stage IVA NSCLC patients 
with pleural dissemination, good performance statuses, disease 
limited to one hemithorax, and of the mind to be aggressive about 
their disease could be considered for this investigational treatment 
approach.
Keywords: surgery, photodynamic therapy, non-small cell lung 
cancer, pleural metastasis
tumour. Surgery is usually not considered for patients who have 
received radiation doses higher than 45 Gy in 2 Gy daily fractions 
because of the perceived risk of post operative complications.
Methods: Our standard concurrent chemo-radiotherapy regimen 
comprises 55 Gy in 20 fractions of 2.75 Gy per day, given over four 
weeks with cisplatinum 20 mg/m2 given with radiotherapy fractions 
1-4 and 16-19, and vinorelbine 15 mg/m2 IV (40 mg/m2 orally for pa-
tients without dysphagia) with fractions 1, 6, 15 and 20. Twenty-two 
patients at the Liverpool Heart and Chest Hospital have undergo-
ne thoracotomy with a view to resection of residual tumour after 
completion of this concurrent chemo-radiotherapy schedule.
Results: Resection of residual disease was achieved in 21 out of 
22 cases. In one patient, resection was not possible due to dense 
fibrosis and adhesions at the tumour site. Five patients underwent 
pneumonectomy, 15 lobectomy and one underwent wedge resec-
tion. There was one death in the 30 days following surgery and one 
patient developed a fistula at 4 months. Histological examination 
of resection specimens confirmed complete histological response 
in 14 out of 21 cases (66%). Median survival for was 93.8 months, 
with 5 year survival of 58.8% and 27.6% of patients surviving 10 
years from start of treatment.
Conclusion: Surgical resection is feasible after concurrent chemo-
radiation to a dose of 55 Gy in 20 fractions over 4 weeks. The 
remarkably high complete histological response rate in this series 
confirms the effectiveness of a strategy to minimise accelerated 
repopulation by using hypofractionated radiotherapy with cisplati-
num and vinorelbine over four weeks.
Keywords: hypofractionated, surgery, chemoradiation
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MO22.11 PROSPECTIVE STUDY OF SURGERY WITH CU-
RATIVE INTENT AND INTRAOPERATIVE PHOTODYNA-
MIC THERAPY TO ACHIEVE LONG-TERM PLEURAL CON-
TROL AND IMPROVE OVERALL SURVIVAL FOR PATIENTS 
WITH NON-SMALL CELL LUNG CANCER WITH PLEURAL 
DISSEMINATION
Charles B. Simone1, Kenneth M. Mckay1, Melissa J. Culligan2, Da-
niel Sterman3, Evan Alley4, Theresa M. Busch1, Eli Glatstein1, Ste-
phen M. Hahn1, Keith A. Cengel1, Joseph Friedberg2
1Radiation Oncology, University Of Pennsylvania/United States Of 
America, 2Surgery, University Of Pennsylvania/United States Of Ame-
rica, 3Medicine, Division Of Pulmonology, University Of Pennsylvania/
United States Of America, 4Medicine, Division Of Oncology, University 
Of Pennsylvania/United States Of America
Background: Non-small cell lung cancer (NSCLC) with pleural 
spread carries a dismal prognosis of 6-9 months median survival. 
Standard treatment is palliative chemotherapy. Surgery typically 
has no role, with studies showing no overall survival (OS) benefit 
and high rates of local recurrence of up to 90% due to microscopic 
residual disease following resection. This study investigated the 
use of surgery with the intent of achieving a gross total resection 
and intraoperative photodynamic therapy (PDT) to target micro-
scopic residual disease for patients with NSCLC with pleural meta-
stasis to improve local control and OS.
Methods: All patients with NSCLC with pleural metastasis treated 
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based on conventional anatomical lung volumes. Subsequently, 
a single nuclear medicine physician in conjunction with a single 
radiation oncologist contoured the functional ‘perfused’ lung 
using a visually adapted threshold. Functional lung was defined as 
lung parenchyma with Ga-MAA uptake. A second volume labeled 
as ‘high-perfused’ lung was created based on a visually adapted 
30% max SUV threshold (figure 1). A single RT planner optimised 
the 3D conformal radiotherapy plan to spare the functionally ‘per-
fused’ and ‘high-perfused’ lung volumes respectively. Dose volu-
metrics were compared using mean lung dose (MLD), V5, V10, V20, 
V30, V40, V50 and V60 parameters. figure 1 - RT Plans optimised 
to each of the conventional, ‘perfused’ and ‘high perfused’ 
lung volumes.
Results: 14 consecutive patients had RT plans adapted to functio-
nal lung volumes based on perfusion PET/CT. This patient cohort 
consisted of ex-smokers with pre-existing airways disease, with a 
mean FEV1 of 1.87L (0.83L-2.82L) and DLCO of 54% (27%-87%). 
The average MLD of the original treatment plans was 11.44Gy 
using conventional anatomical lung measurements. When consi-
dering the functional ‘perfused’ lung and ‘high perfused’ lung, the 
original plan produced an average MLD of 11.12Gy and 12.41Gy 
respectively. Plans optimized for ‘perfused’ lung only showed sig-
nificant improvement of the V60 dose parameter (median 1.00Gy, 
p=0.04). However, plans optimized for ‘high perfused’ lung im-
proved MLD, V30, V40, V50 and V60 (all p-values <0.05). The MLD 
was improved by a median of 0.86Gy, p<0.01. The largest impro-
vement was found in the V30 parameter, with a median difference 
of 1.76Gy.
Conclusion: This is the first study of 68Ga perfusion PET/CT for 
planning the treatment of lung cancer patients. RT plans adapted 
to ‘high perfused’ but not ‘perfused’ functional lung volumes al-
lows for significant technical improvement of conventional RT for 
NSCLC patients. The clinical impact of this improvement in plan-
ning technique should be validated in the context of a prospective 
study measuring patient toxicity outcomes.
Keywords: adaptive radiation therapy, Non small cell lung cancer, 
perfusion, positron emission tomography
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MO23.01 FOUR-DIMENSIONAL GALLIUM-68 PERFUSION 
PET/CT SCANS CAN IMPROVE RADIOTHERAPY PLAN-
NING THROUGH FUNCTIONAL AVOIDANCE OF LUNG
Shankar Siva1, Michael Hofman2, Thomas Devereux3, Jason Cal-
lahan2, Peter Eu2, Daniel Pham3, Tomas Kron4, Nicholas Hardcast-
le4, Daniel Steinfort5, Mathias Bressel6, Michael Macmanus1, Rod 
Hicks2, David Ball7
1Radiation Oncology, Peter MacCallum Cancer Centre/Australia, 2Nu-
clear Medicine, Peter MacCallum Cancer Centre/Australia, 3Radiation 
Therapy Services, Peter MacCallum Cancer Centre/Australia, 4Physi-
cal Sciences, Peter MacCallum Cancer Centre/Australia, 5Respiratory 
Medicine, Royal Melbourne Hospital/Australia, 6Biostatistics Centre 
For Biostatistics And Clinical Trials, Peter MacCallum Cancer Centre/
Australia, 7Dept. Radiation Oncology, Peter MacCallum Cancer Centre/
Australia
Background: 68Ga-macroaggregated-albumin (68Ga-MAA) perfusi-
on PET/CT is a novel molecular imaging technique for the assess-
ment of functional lung volumes. This prospective study aims to 
investigate the utility of four-dimensional (4D) 68Ga-perfusion PET/
CT for functional adaptation of radiation therapy (RT) planning in 
patients with non-small cell lung cancer (NSCLC).
Methods: An interim analysis was performed of a prospective 
clinical study of patients with NSCLC who underwent 4D-perfusion 
PET/CT scanning prior to curative intent RT. All patients were pl-
anned to 60Gy in 30fx with or without concurrent chemotherapy 
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Conclusion: HU changes identify objectively the whole range of 
individual radiosensitivity on a continuous, quantitative scale. CT 
density changes may allow more robust and accurate radiogeno-
mics studies.
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MO23.03 DUTCH RADIOTHERAPY LUNG AUDIT: RE-
SULTS OF A NATIONAL PILOT
Jose Belderbos1, Daan Henneman2, Cornelia Verhoef3, Marleen 
Ploegmakers4, Johan Bussink3, Caroline Tissing-Tan5, Ernest 
Vonk6, Antoinet Van Der Wel7, Marcel Verheij1, André Dekker8
1Radiation Oncology, The Netherlands Cancer Institute/Netherlands, 
2Dutch Institute For Clinical Auditing/Netherlands, 3Radiation Oncolo-
gy, Radboud University Nijmegen Medical Centre/Netherlands, 4Dutch 
Association Of Medical Specialists/Netherlands, 5Radiation Oncology, 
Radiotherapeutic Institute Arti/Netherlands, 6Radiation Oncology, 
Radiotherapeutic Institute Riso/Netherlands, 7Radiation Oncology, Ra-
diotherapeutic Institute Friesland/Netherlands, 8Radiation Oncology, 
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Background: The Dutch Society for Radiotherapy and Oncology 
(NVRO) aims to ensure transparency regarding clinical outcome, 
quality and safety of lung cancer treatments in radiotherapy de-
partments throughout The Netherlands. Auditing is considered the 
best instrument to achieve this. The quality of the radiotherapy will 
become transparent by using objective and reliable data from ac-
curate registration of clinical outcome linked to patient and treat-
ment characteristics The results of the audit are communicated 
to the health professionals that supplied the data. This outcome 
registration will provide the local health professionals with a robust 
instrument to compare and improve their lung cancer treatments. 
The decision was made to seek collaboration with the thoracic sur-
geons as their group were already committed to the DICA (Dutch 
Institute for Clinical Auditing) .
Methods: The Quality Assurance Committee of the NVRO, in 
collaboration with a platform of Dutch radiation oncologists dedi-
cated to lung cancer treatment, received a grant to set-up a quality 
assurance program for lung cancer treatment. Quality indicators to 
be collected were defined within the platform of Dutch radiation 
oncologists and a database was setup in October 2012. All pati-
ents receiving primary thoracic radiation treatment with curative 
intent for (primary or recurrent) stage I-IIIB lung cancer will be 
included in the registry. Information will be collected on patient, 
tumor and treatment characteristics, the incidence and severity of 
acute toxicity, mortality within three months of radical radiothera-
py and the time interval between diagnostic work-up and start of 
radiotherapy The adherence to the NVRO and Dutch guidelines 
will be registered and analyzed, as well as the use of new treat-
ment techniques like stereotactic radiotherapy and image-guided 
radiotherapy. A pilot phase was initiated to test the feasibility of 
enrolling patients from six participating centers.
Results: The pilot-database was tested in 6 Dutch centers: NKI-
AVL (Amsterdam), MAASTRO clinic (Maastricht), RIF (Leeuwarden), 
RISO (Deventer), UMC Radboud (Nijmegen) and ARTI (Arnhem). 
A total of 196 patients were entered from January to June 2013. 
Analysis of the patients entered is ongoing. We expect to have a 
national roll-out in October 2013. The patient records were very 
complete with a few exceptions: lung function tests, the Mean 
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MO23.02 QUANTIFICATION OF RADIATION-INDUCED 
LUNG DAMAGE WITH CT SCANS: THE POSSIBLE BENE-
FIT FOR RADIOGENOMICS
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Kerns3, Kim De Ruyck4, Stephanie Peeters1, Johan Vansteenkiste5, 
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1Radiation Oncology, University Hospitals Leuven/ KU Leuven/Belgium, 
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5University Hospitals Leuven/ KU Leuven/Belgium, 6University Of Wis-
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Background: Radiation-induced lung damage (RILD) is an impor-
tant problem. Although physical parameters such as the mean lung 
dose are used in clinical practice, they are not suited for individu-
alised radiotherapy. As radiosensitivity varies between patients, 
genetic correlations have been investigated, which appear to be 
difficult to repeat in validation studies. This may be due, in part, to 
differences in methods for measuring RILD across studies. Objec-
tive, quantitative measurements of RILD on a continuous instead 
of on an ordinal, semi-quantitative, semi-subjective scale, are nee-
ded.
Methods: Hounsfield Unit (HU) changes before vs. 3 months post-
radiotherapy were correlated per voxel with the radiotherapy 
dose. Deformable registration was used to register pre and post 
CT scans and the density increase was quantified for various dose 
bins. The dose-response curve for increased HU was quantified 
using the slope of a linear regression (HU/Gy). The end-point for 
the toxicity analysis was dyspnoea ≥ grade 2.
Results: 95 lung cancer patients were studied. Radiation dose was 
linearly correlated with the change in HU (mean R2=0.74 ± 0.28). 
No differences in HU/Gy between groups treated with stereotactic 
radiotherapy, conventional radiotherapy alone, sequential or con-
current chemo-radiotherapy were observed. In the whole patient 
group, 33/95 (34.7 %) had dyspnoea ≥ G2. Of the 48 patients with 
a HU/Gy below the median, 16 (33.3 %) developed dyspnoea ≥ G2, 
while in the 47 patients with a HU/Gy above the median, 17 (36.1 
%) had dyspnoea ≥ G2 (not significant). Individual patients showed 
a nearly 21-fold difference in radiosensitivity, with HU/Gy ranging 
from 0 to 10 HU/Gy. 
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expansions for the PQE and OQE. Table 1 shows a comparison of 
adherence to protocol regarding OAR outlining between the PQE 
and OQE. Table 1  
Oesopha-
gus outline 
Spinal 
canal 
outline 
Heart 
outline 
Lung-PTV 
outline 
PQE-
OAR 
outline 
as per 
protocol 
(n=29) 
19 (65.5%) 
14 
(48.3%) 
4 (13.8%) 20 (68.9%) 
OQE-
OAR 
outline 
as per 
protocol 
(n=29) 
21 (72.4%) 
18 
(62.1%) 
8 (27.6%) 20 (68.9%) 
 
Organ at risk doses were found to be within the tolerances speci-
fied in the trial protocol for both PQE and OQE.
Conclusion: A PQE improves clinicians’ compliance to trial proto-
col, and has been found in the OQE to reduce deviations across 
the participating centres that may confound the results of the stu-
dy. Despite the fact that consistency of OAR outlining remained an 
issue in both the PQE and the OQE an overall improvement was 
seen following the PQE.
Keywords: small cell lung cancer, radiotherapy, quality assurance, 
clinical trial
Lung Dose / Lung V20, gross tumor volume (23% missing) and 
the non-mandatory follow-up items. The mean age was 68 years 
(range 41-90) with 57% males. Charlson comorbidity index ≥ 2 
was scored in 39% of patients. Most patients (66%) were cN+ with 
14% T4 tumours. Most patients received IMRT or VMAT irradiation. 
Ninety-five percent of patients completed treatment. All registe-
red patients had position verification during irradiation, mostly 3D 
(70%). Acute 3-month toxicity (grade≥ III) was registered in 18% of 
patients and 3-month mortality was 4.4%.
Conclusion: This national audit on outcome after radiotherapy is 
directed towards an improvement of care for lung cancer patients 
and will help to direct evidence into clinical practice. It is expected 
to have an important impact on quality assurance ,safety and pos-
sibly patient mortality.
Keywords: radiotherapy, Audit, quality assurance, Lung cancer
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MO23.04 IS PRE-TRIAL QUALITY ASSURANCE (QA) EF-
FECTIVE? A COMPARISON OF PRE-TRIAL QA VERSUS 
ONGOING QA FOR THE CONVERT TRIAL.
Nicki Groom1, Elena Wilson2, Ethan Lyn3, Allan Price4, Michael 
Snee5, Rhona Mcmenemin6, Nazia Mohammed7, Corinne Faivre-
Finn8
1Mount Vernon Cancer Centre/United Kingdom, 2Royal Free Hospital/
United Kingdom, 3Cancer Care Manitoba/Canada, 4Edinburgh Can-
cer Centre/United Kingdom, 5St James‘s Hospital/United Kingdom, 
6Northern Centre For Cancer Care, Freeman Hospital/United Kingdom, 
7Beatson Cancer Centre/United Kingdom, 8The Christie NHS Foundation 
Trust/United Kingdom
Background: CONVERT is an international randomised phase III 
trial comparing 45Gy in 30 fractions twice-daily and 66Gy in 33 
fractions once-daily (given concurrently with cisplatin/etoposide) 
for good performance status patients with limited stage small cell 
lung cancer. A QA programme was set-up to standardise radiothe-
rapy (RT) delivery across all centres.
Methods: The pre-trial QA exercise (PQE) involved completion 
of a questionnaire and treatment planning exercise. Each partici-
pating clinician was asked to select a previously treated patient, 
who fitted the entry criteria for the trial, and provide disease and 
organs at risk (OAR) outlines and a treatment plan for both arms of 
the trial. QA guidelines, including an atlas for OAR outlining, were 
distributed to participating centres. Additionally, at least one RT 
plan per centre was randomly collected during the trial (ongoing 
QA exercise-OQE). A comparison was made between the PQE and 
OQE for each centre, including a review of eligibility criteria, OAR 
and gross tumour volume (GTV) outlining, expansion to clinical 
target volume (CTV) and planning target volume (PTV).
Results: Twenty nine clinicians from 28 centres who had comple-
ted both the pre-trial QA and the ongoing QA were included in 
the analysis. From the pre-trial questionnaire it was reported that 
3 centres were using beam energies of 10MV or more which was 
not permitted as per protocol. Subsequently the PQE showed that 
these all used acceptable beam energies. Four clinicians submitted 
ineligible patients for the PQE and none for the OQE. Twenty five 
clinicians (86.2%) used the correct GTV to CTV and CTV to PTV 
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MO23.07 IMPACT OF A GRADIENT-BASED FDG-PET 
AUTO-CONTOURING METHOD ON NON-SMALL CELL 
LUNG CANCER DELINEATION
Jasper Jochem1, Wouter Vogel1, Jeroen Van De Kamer1, Matthijs 
Kruis1, Judi Van Diessen1, Joost Knegjens1, Margriet Kwint1, Katri-
en De Jaeger2, Stephanie Peeters3, Angela Van Baardwijk4, Cornelis 
Slump5, Jose Belderbos1
1Radiation Oncology, The Netherlands Cancer Institute/Netherlands, 
2Radiation Oncology, Catharina Hospital/Netherlands, 3Radiation On-
cology, University Hospitals Leuven/ KU Leuven/Belgium, 4Radiation 
Oncology (Maastro Clinic), Grow - School For Oncology And Develop-
mental Biology, Maastricht University Medical Centre/Netherlands, 
5Mira Institute For Biomedical Technology And Technical Medicine, Uni-
versity Of Twente/Netherlands
Background: Manual target volume delineation using CT/FDG-
PET is the standard method used for radiotherapy treatment 
planning of non-small cell lung cancer (NSCLC) patients. Since 
manual delineation is prone to inter-observer variability and is time 
consuming, many FDG-PET auto-contouring methods were pro-
posed in literature. The purpose of this study was to investigate to 
what extent a gradient-based FDG-PET auto-contouring method 
reduces observer variation, reduces delineation time and influen-
ces delineation behavior in radiotherapy treatment planning for 
NSCLC patients.
Methods: Seven radiation oncologists (observers) dedicated to 
lung cancer treatment delineated the primary tumor (PT) and in-
volved lymph nodes (LN) for 10 patients with stage IIA-IIIB NSCLC 
on a co-registered CT/FDG-PET scan. The study was separated in 
two phases. In the first phase, the observers manually delineated 
the PT and LN for all patients. For the second phase (four months 
later), auto-contours were generated for both the PT and LN using 
a gradient-based FDG-PET segmentation method. Bone and air 
tissue were removed from these auto-contours using CT threshol-
ding. These auto-contours were provided as initial delineation 
and were adapted by the observers. Delineation times, delineated 
contours and agreement with the auto-contour were analyzed. De-
lineated contours were analyzed based on volume, the ratio bet-
ween the common volume and the encompassing volume (C/E), 
Dice Index (DI), local standard deviation (SD) and the local distance 
between median surface and delineated surface. Regions were 
identified where the observers did or did not change the provided 
auto-contours.
Results: The observers agreed with the provided auto-contour for 
37.3% of the PT and for 42.6% of the LN. Notable regions of ag-
reement were the tumor/bone and tumor/air interfaces. The mean 
delineation time was reduced by 23.9% from 25.5 minutes in phase 
1 to 19.4 minutes for phase 2 (p=0.000). The mean delineated 
volume was smaller in phase 2 compared to phase 1: 8.9% for the 
PT (155.8 to 142.0 cm3, p=0.000) and by 9.1% for the LN (13.2 to 
12.0 cm3, p=0.001), respectively. The C/E ratio and DI both did not 
change significantly and were 0.79 and 0.88 for the PT and 0.54 
and 0.67 for the LN in both phases. The mean local SD for the PT 
was 1.7 mm and 1.5 mm and for the LN was 1.5 mm and 1.4 mm 
and both did not change significantly, for both phases respectively. 
The mean distance between the median surface and PT delinea-
tions was slightly reduced from 2.1 to 1.8 mm for phase 2, and was 
2.0 mm for the LN in both phases.
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MO23.05 CHANGES IN LUNG RADIOTHERAPY TECH-
NIQUES DURING THE CONVERT TRIAL. A SURVEY OF 
PARTICIPATING CENTRES.
Nicki Groom1, Elena Wilson2, Ethan Lyn3, Allan Price4, Michael 
Snee5, Rhona Mcmenemin6, Nazia Mohammed7, Corinne Faivre-
Finn8
1Mount Vernon Cancer Centre/United Kingdom, 2Royal Free Hospital/
United Kingdom, 3Cancer Care Manitoba/Canada, 4Edinburgh Can-
cer Centre/United Kingdom, 5St James‘s Hospital/United Kingdom, 
6Northern Centre For Cancer Care, Freeman Hospital/United Kingdom, 
7Beatson Cancer Centre/United Kingdom, 8The Christie NHS Foundation 
Trust/United Kingdom
Background: CONVERT is an international randomised phase III 
trial, comparing 45Gy in 30 fractions twice-daily or 66Gy in 33 
fractions once-daily (given concurrently with cisplatin/etoposide) 
for good performance status patients with limited stage small cell 
lung cancer. A survey was sent out to 69 clinicians who had rando-
mised patients into the trial with the aim of establishing how radio-
therapy techniques for lung cancer have changed over the 5 years 
since the trial opened.
Methods: As part of the pre-trial quality assurance process each 
centre was asked to complete a facility questionnaire giving de-
tails of treatment planning, delivery and verification techniques. 
Recruitment to the trial began in April 2008 and in January 2013, 
a further facility questionnaire was sent to centres. The survey was 
completed using an on-line survey tool.
Results: This analysis includes answers from the 34 clini-
cians who responded to the questionnaire. Changes in 
treatment planning techniques and verification since the 
beginning of the trial are summarised in table 1. Table 1 
*Note that some centres reported using more than one beam 
arrangement, beam energy, planning algorithm or treatment verifi-
cation technique. Out of the 34 clinicians who answered the ques-
tionnaire, 14 (41.1%) are currently using 4DCT, 3 (8.8%) are using 
breathold techniques and 16 (47.1%) are not using any technique to 
account for respiratory motion for simulation and treatment plan-
ning of lung patients. Data on management of respiratory motion 
were not available in 2008.
Conclusion: During the 5 years the CONVERT Trial has been open 
there have been significant advances in radiotherapy treatment 
technology. Major changes include the use of Type B treatment 
planning algorithms and PET CT for planning, IMRT for treatment 
and CBCT for treatment verification of patients with small cell lung 
cancer.
Keywords: radiotherapy, clinical trial, technology questionnaire, 
small cell lung cancer
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and RD was 0.40cm, compared with 0.42cm and 0.51cm between 
the RT’s and the RO and RD respectively. The mean CI between 
the RD and RO was 0.56 (0.44,0.69), which was smaller than the 
lower bound of the 95 % confidence intervals (95%) of the RT’s 
compared to the RD (0.5, 0.56) and RO (0.52,0.59). The mean log 
COV difference was -0.82cm between the RD and RO and -0.54 
and -0.65cm between the RT’s and RO and RD respectively. The 
volume results showed that only 6 of thirty comparisons were 
equivalent. The mean volume difference between the RD and RO 
was 0.44cm3 and 4.73 cm3 and 5.7cm3 between the RT’s and RO 
and RD respectively.
Conclusion: The variation between the RTs and the RO and RD 
was greater than the variation between the RO and RD. Advanced 
training is necessary to educate the RTs on soft-tissue matching on 
CBCT for lung cancer radiotherapy.
Keyword: radiotherapy, radiation therapists, cone beam CT
RADIOTHERAPY II: LUNG TOXICITY, TARGET DEFINITION AND  
QUALITY ASSURANCE  
WEDNESDAY, OCTOBER 30, 2013 - 10:30-12:00
MO23.09 INTRA THORACIC ANATOMICAL CHAN-
GES (ITAC) IN LUNG CANCER PATIENTS DURING THE 
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Background: Cone beam-CT (CBCT) guidance is routinely used 
for setup verification of lung cancer patients treated with radiothe-
rapy. CBCT’s frequently show intra-thoracic anatomical changes 
(ITAC) during treatment. We developed a protocol as a decision 
support system to guide the radiation technologist in prioritizing 
these changes. The purpose of this study was to quantify these 
ITAC during the radiotherapy course and evaluate the current de-
cision protocol.
Methods: The CBCT-scans (made the first 3 fractions and weekly 
thereafter) of all lung cancer patients treated in 2010 in our insti-
tute with radical radiotherapy were evaluated. Each CBCT-scan 
was visually compared with the planning-CT and all visible ITAC 
were scored. Additionally, our decision protocol called “traffic-
light protocol” was retrospectively applied to all CBCT-scans. The 
traffic-light protocol has three urgency levels: 1) red: ITAC that 
likely have a considerable impact on the delivered dose to the 
primary tumor and/or involved lymph-nodes such as tumor shifts 
outside the high dose region, large in- or decrease of atelectasis; 
2) orange: ITAC with likely moderate impact on the dose distributi-
on such as tumor progression, minor in- or decrease of atelectasis, 
pleural effusion and post obstructive pneumonia; 3) green: ITAC 
with likely negligible impact on the dose distribution such as tumor 
regression without considerable centre of mass displacement or 
other anatomical changes. For level red changes, the radiation on-
cologist needs to be consulted immediately before the treatment 
fraction is delivered. For level orange, the radiation oncologist will 
be informed by email and a response is required before the next 
fraction. For level green, the radiation oncologist is informed but 
no response is required.
Results: In total 1500 CBCT-scans of 177 patients were evaluated. 
All patients received radical radiotherapy (≥50 Gy); 97 patients 
Conclusion: The gradient-based FDG-PET auto-contouring me-
thod reduced delineation time by 24%, but was sufficient in only 
37.3% of the primary tumors and 42.6% of the involved lymph 
nodes; most notably at the tumor/bone and tumor/air interfaces 
segmented using the CT scan. The results suggest the FDG-PET 
auto-contour is currently primarily used for localization, and not so 
much for delineation. Multi-modal auto-contouring has the poten-
tial to reduce inter-observer variation when further developed in 
close collaboration with radiation oncologists.
Keywords: NSCLC, Auto-contouring, CT/FDG-PET, Interobserver 
variability
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MO23.08 INTER-OBSERVER VARIABILITY IN GROSS 
TUMOUR VOLUME DELINEATION ON KILO-VOLTAGE 
CONE BEAM COMPUTED TOMOGRAPHY (CBCT) SCANS 
FOR LUNG CANCER RADIOTHERAPY TREATMENT VERI-
FICATION
Sandie Watt1, Shalini K. Vinod1, Marion Dimigen2, Joseph Descal-
lar3, Branimir Zogovic4, John Atyeo5, Sian Wallis6, Lois Holloway1
1Radiation Oncology, Liverpool And Macarthur Cancer Therapy Cen-
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tute For Applied Medical Research, Liverpool Hospital/Australia, 4Uni-
versity Of Western Sydney/Australia, 5Radiation Sciences, University 
Of Sydney/Australia, 6Radiation Oncology, Prince Of Wales Hospital/
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Background: The use of CBCT is essential for precise treatment 
delivery of radiotherapy for lung cancer. The current work practice 
at many centres is to use bony landmarks to match on-treatment 
CBCT to the radiotherapy planning CT to verify treatment. To take 
full advantage of this imaging modality for lung cancer, soft-tissue 
matching is preferred as it ensures that the actual lung cancer is 
within the radiotherapy fields regardless of bony anatomy. Howe-
ver Radiation Therapists (RTs) are trained in bony matching and not 
soft tissue matching. The purpose of this study was to determine 
the level of inter-observer variability in lung cancer gross tumour 
volume (GTV) delineation on CBCT and alignment of the CBCT 
with a planning GTV between Radiation Therapists (RTs), a Radiati-
on Oncologist (RO) and a Radiologist (RD)
Methods: Ten RTs, one RO and one RD independently delineated 
the lung cancer GTV for fifteen lung cancer patients on Elekta 
Synergy CBCT image datasets taken on the first treatment fraction. 
The window and level settings used by each observer were recor-
ded. Each observer then performed an alignment of the CBCT 
GVT to the radiotherapy planning GTV and translational errors 
were recorded. The difference in the isocentre corrections for the 
alignment shifts and Centre of Volume, Volume and Concordance 
Index (CI) for the contoured volumes were calculated to determine 
the level of agreement between the RT’s and the RD and between 
the RTs and the RO, in comparison to the variation between the 
RD and RO. In an ideal setting the difference between the RTs and 
the RO and the RTs and the RD would be at least equivalent to the 
difference between the RD and RO.
Results: The difference between the RT’s and RO and RD was 
found to be not statistically equivalent to the difference between 
the RD and RO. The mean isocentre difference between the RO 
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our patients. Results are expressed as mean +/- SD and range.
Results: Twenty-five consecutive patients with a full EBUS-
TBNA mapping before RT were included: 11 women, 14 men; 
17 adenocarcinoma, 8 squamous cell carcinoma; 14 right-sided 
and 11 left-sided tumors. Mean age: 62.5 +/- 9.7 years. All 
patients had stage III-disease based on PET-CT. LN stations 
1,2R,2L,3,4R,4L,5,6,7,8,9,10-11L,10-11R were analyzed on CT- and 
PET-scan (=325 LN). Sixty-seven were enlarged (≥10mm), of which 
63 were PET-positive. Twelve normal-sized LNs were PET-positive. 
Fifty LNs were investigated with EBUS-TBNA (mean: 2/patient +/-
0.96;1-5): 28 were malignant, 22 normal. EBUS-TBNA detected 1 
cancer-containing normal-sized LN without FDG-uptake, thus 1/25 
geographical miss (4%). The cancer prevalence, taking into account 
the FN rate of EBUS of 20%, was calculated (Fig.1). With addition 
of EBUS, in PET-negative patients FN decreases with 10% for en-
larged LN, and with 5% for normal-sized LN. An algorithm when 
to include a LN in the GTV is proposed (Fig.1). According to this 
algorithm, in our population 3/79 (4%) enlarged or PET-positive LN 
would be excluded from the GTV. At patient level, this was a GTV 
decrease in 3 (12%) patients.
Conclusion: When incidental nodal irradiation is low such as in 
IMRT or VMAT, EBUS-TBNA should be added to FDG-PET/CT for 
mediastinal staging. This avoids geographical miss in 4% of pa-
tients, and decreases the radiation volume in 12% of patients. A 
practical algorithm is proposed.
Keywords: radiotherapy, EBUS-TBNA, EBUS-mapping
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MO23.11 DART - BID (DOSE-DIFFERENTIATED ACCELE-
RATED RADIATION THERAPY, 1.8 GY TWICE DAILY): A 
NOVEL THERAPEUTIC APPROACH FOR LOCOREGIO-
NALLY ADVANCED, NONRESECTED NON-SMALL CELL 
LUNG CANCER
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Background: A modern treatment approach for non-resected 
NSCLC comprises radiation dose intensification and short overall 
treatment times. We report on patients treated within a prospecti-
ve trial, correlating doses to tumor volume, combined with chemo-
therapy sequentially.
Methods: Radiation doses to primary tumors were aligned along 
increasing tumor size within 4 groups (<2.5 cm/ 2.5-4.5 cm/ 4.5-
6.0 cm/ >6.0 cm; mean number of three perpendicular diameters). 
ICRU-doses of 73.8 Gy/ 79.2 Gy/ 84.6 Gy/ 90.0 Gy, respectively, 
were applied. Macroscopically involved nodes were treated with a 
median dose of 59.4 Gy, nodal sites about 6 cm cranial to involved 
nodes electively with 45 Gy. Fractional doses were 1.8 Gy twice 
daily (bid). 2 cycles chemotherapy were given before radiotherapy; 
the interval between chemotherapy and radiotherapy was prefe-
with concurrent chemoradiation, 23 with sequential chemoradiati-
on and 57 with radiotherapy only. In 128 patients (72%) ITAC were 
observed with maximum level red, orange and green in 12%, 36% 
and 24% respectively. Fourteen patients (10%) required a new CT 
and treatment plan to account for the changed anatomy. Most 
ITAC occurred in the first week (55%). Of all patients with ITAC 
during treatment, 45%, 36% and 17% had 1, 2, and ≥3 ITAC res-
pectively. Types of observed ITAC were evident regression (36%), 
considerable tumor baseline shift (28%), changes in atelectasis 
(15%), tumor progression (11%), pleural effusion (7%) and pneumo-
nia (3%). Progression seen on the CBCT had a significant correlati-
on with changes in week 1 (p<1e3), and level red changes (p=0.01).
Conclusion: ITAC have been observed in 72% of all lung cancer 
patients during radical radiotherapy. In 12% of the patients the 
radiation oncologist needed to respond immediately and in 10% 
of the patients a new planning-CT was made to mitigate the risk 
of tumor under dosing. Volumetric image guided radiotherapy in 
combination with a decision protocol is recommended for lung 
cancer patients treated with radical radiotherapy. In our institute 
we implemented daily CBCT guidance for accurate patient align-
ment and simultaneously capture ITAC as soon as possible.
Keywords: radiotherapy, cone beam CT, intra thoracic anatomical 
changes, Lung cancer
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ASTINUM TO PET/CT BASED SELECTIVE NODAL IRRA-
DIATION IN NSCLC DECREASES GEOGRAPHICAL MISS 
AND NODAL GTV VOLUME
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Surgery, Universitary Hospitals KU Leuven/Belgium, 4Radiology, 
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Background: FDG-PET/CT based selective lymph node (LN) irra-
diation is the standard when using 3D-conformal techniques (3D-
CRT) for locally advanced NSCLC. With 3D-CRT, adjacent LN not 
included in the target volume still receive a substantial radiation 
dose. With current new techniques (IMRT/VMAT), the radiation 
dose to non-involved LN decreases, which raises the question 
whether selective nodal irradiation based on PET/CT is still safe. 
We therefore evaluated the impact of adding EBUS-TBNA (en-
dobronchial ultrasound guided transbronchial needle aspiration)-
mapping of the mediastinal LN to PET/CT in avoiding geographical 
miss, and on the size of nodal GTV (gross tumor volume).
Methods: Consecutive NSCLC-patients referred for radiotherapy 
(RT) in 2012 who underwent EBUS-TBNA were included. False ne-
gative (FN) LN for different constellations of PET, CT and EBUS-TB-
NA based on literature data were calculated, to evaluate the safety 
of excluding LNs based on CT, PET and EBUS findings. A practical 
algorithm when to include LN in the GTV was made, and tested on 
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Background: Sixty percent of all neoplasms and two-thirds of all 
deaths due to cancer occur in persons older than 65 years. More 
than 50% of patients with lung cancer are older than 65 years and 
30% older than 70 years. With more persons surviving to older age 
treatment of the elderly with lung cancer has become an important 
issue.
Methods: All patients 70 years or older with non small cell lung 
cancer (NSCLC) seen at the Department of Respiratory Medicine 
and Allergy, Karolinska Hospital from 2003 to 2006 were retros-
pective reviewed. In all 659 patients were analyzed.
Results: The mean age was 78 years, 55.5 (%) were men. 93,2% 
of the males and 82.1% of the females were smokers or former 
smokers. There was a significant differences between smoking 
habbits among the genderas (P<0.0001). 77.2 (%) had PS 0-2. 
38.4% adenocarcinoma, 9.8% with small cell lung cancer, 20.6% 
squamous cell carcinoma, 15.6% had clinical lung cancer and the 
others broncheoalveolar cell carcinoma or low differentiated carci-
noma were 15.3%. 10.7% underwent radical surgery, 24% received 
chemotherapy only, 17.8% radiotherapy against the tumour (there 
of stereotactic 4.4%), and 3.7% concomitant chemo-radiotherapy. 
7.4% received radiotherapy against metastases, and 32.1% had no 
therapy. Only 10% were given second-line chemotherapy. Median 
survival for patients 70-75, 76-80 and >80 years was 231, 250 resp 
213. Median survival for patients with PS=0 was 810 days, those 
with PS=3 only 109 days. Median survival was 610 days for patients 
given second line chemotherapy. Survival among those who recei-
ved only first line chemotherapy was 285 days.
Conclusion: Significant survival among patients given second line 
chemotherapy (p<0.003). Significant survival among patients bet-
ween 70-80 versus > 80 years old (P<0.001). Treatment of elderly 
patients with lung cancer is feasible if they have a good PS and 
seems to result in prolonged survival.
Keyword: lung cancer, elderly, survival, treatment
rentially shorter than 8 days. With a median follow up time of 56.1 
months (range 43.2 – 97.1 ) for patients alive, mature results for 
locoregional tumor control, survival and toxicity are presented.
Results: Between 2004 and 2009,123 continuously referred, unse-
lected patients with 127 histologically/ cytologically proven NSCLC 
were enrolled; Stage II: 6 pts.; IIIA: 70 pts.; IIIB: 47 pts. Weight loss 
>5%/ 3 months: 26%; Karnofsky Index ≤ 70%: 46% of the patients. 
The local tumor control rate at 2-/ 5 years is 73%/ 70%, respec-
tively; the regional tumor control rate 91%/ 89%, respectively. The 
median overall survival time is 24.6 months, the 2- and 5-year ove-
rall survival rates are 52% and 19%, respectively. 2 treatment-re-
lated deaths (progressive pulmonary fibrosis) occurred in patients 
with pre-existing pulmonary fibrosis. Further toxicity was mild or 
moderate: Pneumonitis grade 2/ 3 (n=10/ 6); esophagitis grade 2/ 
3 (n=16/ 7). Lung late grade 2 (n=13), esophagus late grade 3 (n=1).
Conclusion: Locoregional tumor control is high; as are survival 
times for this unselected patient cohort. In all outcome parameters 
DART-bid seems to compare favourably with simultaneous chemo-
radiotherapies, at present considered ‘state of the art’; simultane-
ous treatments however are applicable only to a minority of refer-
red patients, patients in good general condition.
Keyword: NSCLC, combined modality, DART-bid, radiotherapy
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Background: Sixty percent of all neoplasms and two-thirds of all 
deaths due to cancer occur in persons older than 65 years. More 
than 50% of patients with lung cancer are older than 65 years and 
30% older than 70 years. With more persons surviving to older age 
treatment of the elderly with lung cancer has become an important 
issue.
Methods: All patients 70 years or older with non small cell lung 
cancer (NSCLC) given chemotherapy at the Department of Respira-
tory Medicine and Allergy, Karolinska Hospital from 2003 to 2006 
were retrospective reviewed. In all 149 patients were analyzed.
Results: The mean age was 75,5 years and median 74 years. 54.4 
% were male. 96,3% of the males and 88.2% of the females were 
smokers or former smokers. There was a significant differences 
between smoking habitts among the genderas (P<0.05). 16.1% , 
50.3% and 27.5% had PS 0 resp 1 resp 2. 57.7% and 30.9% with 
stage IV resp III . 32.9% adenocarcinoma, 24.8% squamous cell 
carcinoma, and the others broncheoalveolar cell carcinoma or low 
differentiated carcinoma were 24.2%. 18.1% of the patients had no 
histopathological diagnosis – clinical diagnosis. Almost all the pati-
ents were given carboplatin/gemcitabin as first line chemotherapy 
regardless of histology. Four cycles was given to almost all the pa-
tients. Only 27.5% were given second-line chemotherapy. Median 
overall survival was 285 days. Longer overall survival among 70-80 
vs > 80 years old patients.
Conclusion: Significant survival among patients between 70-80 
versus > 80 years old.. Treatment of elderly patients with lung can-
cer is feasible if they have a good PS and seems to result in prolon-
ged survival.
Keyword: lung cancer, non small cell lung cancer, elderly, survival.
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Background: In 2004, the Italian Association of Medical Oncology 
(AIOM) created the RIGHT (Research for the identification of the 
most effective and highly accepted clinical guidelines for cancer 
treatment) program. The third step of the program, RIGHT3, aimed 
to evaluate the concordance between AIOM lung cancer guideli-
nes and clinical practice in Italy. Description of treatment decisions 
for elderly patients with advanced non-small-cell lung cancer (NS-
CLC) was among the indicators. According to 2009 AIOM guideli-
nes, single-agent chemotherapy with a third-generation agent was 
a reasonable choice for elderly patients with advanced NSCLC, 
whilst evidence about use of platinum-based treatment in the el-
derly population was judged potentially affected by selection bias 
and not conclusive.
Methods: RIGHT3 was a retrospective observational study con-
ducted in a sample of 53 Italian lung cancer centers, representative 
of 230 AIOM centers. Patients with NSCLC diagnosis who had their 
first visit at the oncology center during 2010 and followed-up for at 
least 6 months were included. Proportion of elderly patients with 
stage IV disease receiving chemotherapy was among the 14 indica-
tors evaluated.
Results: Overall, 306 pts with stage IV NSLSC were enrolled, and 
299 were evaluable. Of these, 91 (30.4%) were older than 70. In the 
elderly subgroup, 81 pts (89%) were treated with first-line chemo-
therapy. In detail, a single-agent treatment was administered in 28 
(34.6%) of cases, and a combination chemotherapy in the other 53 
cases (65.4%). Among pts receiving platinum-containing doublets, 
carboplatin was more frequently used than cisplatin: carbo-gem-
citabine (16 pts), carbo-pemetrexed (12 pts), cisplatin-pemetrexed 
(8 pts), cisplatin-gemcitabine (7 pts), carbo-vinorelbine (4 pts) were 
the 5 most frequently used regimens.Thirty pts (33%) received a 
second-line chemotherapy: single-agent in 23 cases, combination 
chemotherapy in 7 cases.
Conclusion: First-line platinum-based combination chemotherapy 
was commonly used in elderly patients with advanced NSCLC in 
2010 by the Italian Lung cancer centers involved. First-line single-
agent treatment, recommended by AIOM 2009 guidelines as the 
treatment choice with highest level of evidence, was used only in a 
minority of patients.
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Background: PARAMOUNT study confirmed the improvement 
of overall survival with continuation maintenance chemotherapy 
with pemetrexed (PEM) compared with placebo after 4 cycles of 
cisplatin plus PEM induction chemotherapy recently. JMEN study 
also showed the usefulness of switch maintenance with PEM after 4 
cycles of platinum doublet without PEM. In this study, we conduc-
ted the randomized phase II study comparing switch or continua-
tion maintenance chemotherapy with PEM after standard doublet 
regimen.
Methods: Histologically/cytologically confirmed stage IIIb or IV 
non-squamous NSCLC patients with mesurable disease, ECOG PS 
0-1, age over 20 years and adequate organ function were eligible 
for the study. Randomization was stratified by gender and stage 
of disease. Patients received 3 cycles of PEM 500mg/m2 plus CB 
AUC6 (Arm 1) or PAC 200mg/m2 plus CB AUC6 (Arm 2). All pati-
ents with non-PD after induction chemotherapy continued PEM 
500mg/m2 until PD. Primary endopoint is progression free survival 
(PFS).
Results: 140 pts were enrolled and assigned to Arm1 or Arm2 
randomly. The clinical data of 132 pts were used as full analysis set 
(median age 64.5 yrs (42-83), 85 male, 120 stage IV, 58 PS0, 127 
adenocarcinoma, 46 never smoker). 42 pts had prior treatment 
including 9 sugery, 1 adjuvant chemotherapy, 24 radiotherapy and 
8 others. In both arms, 50% of pts entered into the maintenance 
treatment with PEM after completion of 3 cycles induction che-
motherapy. The median PFS was 113 days in Arm 1 and 143 days 
in Arm 2, respectively. Cox-proportinal Hazard ratio was1.047, and 
95% HR confidential interval was 0.707-1.549. Stratified Log-Rank 
test showed no significant difference in both arms.
Conclusion: There was no significant difference for PFS in Arm 
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Background: The number of seniors in Canada is expected to 
double by 2036 and 40% of new cancers are diagnosed in those 
≥70 years. New data over the last decade suggests an increasing 
role for systemic treatment options for elderly lung cancer pati-
ents. However, age-related changes in organ function, co-morbid 
health problems, and a greater risk of death from other causes may 
impact on toxicity and expected survival gains. Historically, many 
oncologists excluded older patients from receiving chemotherapy. 
This study investigated trends in the treatment of NSCLC patients 
over the last decade contrasting patients ≥70 years to those <70 
years old.
Methods: We conducted a retrospective cohort study of NSCLC 
patients (ICD-9 codes 162.2-162.9) residing in Ontario and diag-
nosed between January 1, 2000-December 31, 2010. Data inclu-
ding demographic, staging, treatment and outcome information 
were extracted by the Institute for Clinical Evaluative Sciences and 
de-identified before release. The primary outcomes were the pro-
portion of elderly v non-elderly patients referred to an oncologist 
and receipt of chemotherapy. Standard statistical methods were 
used.
Results: Of 61,646 patients, 32,131 (52.1%) were ≥70 years. There 
was an increase in the number and proportion of cases diagnosed 
in the elderly over the time period. Fewer adenocarcinomas were 
diagnosed in the elderly (29.8 v 44%) and more elderly patients 
lacked microscopic confirmation of malignancy (20.1 v 6.2%). Charl-
son co-morbidity scores and the need for homecare services prior 
to diagnosis (12.6 v 4.7%) were higher in the elderly. Staging infor-
mation was inconsistent prior to 2007. In 53.6% of patients, stage 
was unknown. Stage distribution in remaining patients was: I (18%), 
II (6%), III (28%), IV (48%). Referral to any lung cancer specialist 
(defined as medical oncologist, radiation oncologist, or thoracic 
surgeon) was significantly lower in the elderly population (80.6 vs 
93.9%). This was true for each sub-specialty. Only 59.5% of elderly 
lung cancer patients were referred to a medical oncologist, com-
pared to 78.5% of younger patients. The elderly were less likely to 
receive chemotherapy (18.3 v 46.7%), even after referral to medical 
oncology. Elderly patients had a shorter overall (5.8 v 9.6 months) 
and lung cancer specific survival (9.5 v 13.9 months). Among pati-
ents receiving chemotherapy, there was less difference in overall 
(13.6 v 14.9 months) and lung cancer specific survival (18.6 v 19.9 
months). Receipt of chemotherapy increased only marginally 
among elderly patients between 2000 and 2010. P-values for all 
comparisons (p<0.001).
Conclusion: There is evidence of disparity in treatment of elderly 
lung cancer patients. Fewer patients ≥70 years old are referred to a 
lung cancer specialist and receive treatment. This trend is particu-
larly evident for referral to medical oncology and receipt of chemo-
therapy. In those elderly patients who receive chemotherapy, their 
survival approximates that seen in younger patients. Published 
evidence supporting the use of chemotherapy in the elderly does 
not appear to have been implemented into practice.
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Background: FRAME was a European non-interventional prospec-
tive observational study of patients with advanced or metastatic 
non-small cell lung cancer (NSCLC) initiating platinum-based thera-
pies as first-line treatment (FLT).
Methods: Patients were enrolled between April 2009 and Febru-
ary 2011. Consenting adult NSCLC (Stage III/IV) patients initiating 
FLT with a platinum-based doublet chemotherapy, with or without 
an additional targeted agent, were eligible for the study. The 
choice of FLT was left to physician discretion, as per routine clinical 
practice. The primary objective of FRAME was to evaluate overall 
survival (OS) among different platinum-based treatment cohorts in 
patients with and without additional targeted therapy. Secondary 
objectives included the evaluation of OS in patients with different 
histological subtypes of NSCLC. Survival outcomes were assessed 
using Kaplan-Meier analysis, and unadjusted estimates are presen-
ted.
Results: A total of 1564 eligible patients from 11 EU countries were 
observed. Patient cohorts were: pemetrexed + platinum, gemcita-
bine + platinum, vinorelbine + platinum, taxanes + platinum and 
other therapy + platinum. Table 1 shows a subset of baseline pati-
ent characteristics, which varied across several parameters in the 
treatment cohorts, including age, performance status (PS), stage 
and histology. The median OS across the 4 main treatment cohorts 
was 10.3 months (95% CI: 9.5-11.2). A subset of overall survival esti-
mates in the different treatment cohorts is shown in Table 1.  
1(PEM plus CB followed by PEM) and Arm 2 (PAC plus CB followed 
by PEM).
Keywords: Continuation Maintenance, phase II, pemetrexed, 
switch maintenance
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Background: Continuous maintenance is defined as continuation 
of ≥ 1 first-line agents after 4-6 cycles of induction therapy in pts 
who have not progressed. In a pivotal phase 3 trial, first-line treat-
ment to progression with nab-paclitaxel (nab-P, 130-nm albumin-
bound paclitaxel particles) + carboplatin (C) vs solvent-based pa-
clitaxel (sb-P) + C resulted in a 68% improvement in response rate 
(41% vs 24%; P < .001) and a trend toward improved survival (medi-
an, 10.7 vs 9.5 months; P = .808) in the subset of pts with SCC. This 
unplanned exploratory analysis examined outcomes in pts with 
SCC receiving > 4 cycles of nab-P/C to assess the feasibility of the 
nab-P/C regimen in the maintenance setting in SCC.
Methods: Pts with untreated stage IIIB/IV NSCLC were rando-
mized 1:1 to nab-P 100 mg/m2 on days 1, 8, 15 or sb-P 200 mg/
m2 on day 1 every 21 days; both arms received C AUC 6 on day 1. 
Overall response rate and progression-free survival (PFS) were de-
termined by blinded centralized review. To allow comparison of the 
results of this analysis with maintenance studies, PFS is expressed 
from day 1 of cycle 5 (C5D1).
Results: 229 pts with SCC received nab-P/C and 221 received 
sb-P/C in this study. In the nab-P/C arm, 60% (n = 138) of pts with 
SCC were progression-free at the end of cycle 4 and entered cyc-
le 5 (the study population). In these pts, the median PFS was 3.4 
months (range 2.8 – 4.2) from C5D1. The median OS from randomi-
zation in these pts was 13.8 months (range 12.4 – 16.8). Survival at 
1year was 59% (51% – 67%). The median number of treatment cyc-
les was 7 (range 5 – 31). A total of 125 (91%), 64 (46%) and 35 (25%) 
pts were treated for up to 6, 8 and 10 cycles, respectively, with a 
median weekly dose of 75 mg/m2 for nab-paclitaxel in each group, 
and carboplatin AUC of 6, 4.75, and 4.5, respectively. Preliminary 
safety findings in this population revealed that the most common 
grade 3/4 treatment-related adverse events were neutropenia 
(49%), anemia (31%), and thrombocytopenia (27%). The overall rate 
of grade 3 peripheral neuropathy in the nab-P/C arm was 4% (with 
no grade 4); 1%, 3%, and 0% of pts had grade 3 peripheral neuro-
pathy at cycle 6, 8, and 10, respectively.
Conclusion: Continued treatment with nab-P/C to progression was 
feasible, well tolerated, and effective in pts with advanced SCC 
who had not progressed after 4 cycles of first-line therapy. Future 
randomized, prospective studies are warranted to further evaluate 
the activity of nab-P/C as maintenance therapy in SCC pts.
Keywords: nab-Paclitaxel, non-small cell lung cancer, Phase III trial
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Background: Despite the introduction of antiemetic treatments 
including corticosteroids, serotonin (5-HT3) receptor antagonists 
and neurokinin-1 receptor antagonist, chemotherapy-induced 
nausea and vomiting (CINV) remains major adverse toxicity of 
cancer chemotherapy deteriorating patient’s quality of life. It is 
recommended that these antiemetic treatments should be adop-
ted according to the emetic risk classification of clinical practice 
guideline, however, the treatments are not so effective in delayed 
CINV comparing to acute CINV. The mechanism of delayed CINV 
is not clear so that effective antiemetic drug have not been develo-
ped yet. Iron poisoning in cases of blood transfusion or oversupply 
of iron supplement have various symptoms such as nausea, vo-
miting, gastroenteritis and liver injury caused by free radical iron, 
so-called Fenton reaction. We hypothesized that these symptoms 
are very similar to the adverse effects of cancer chemotherapy and 
that CINV may be related to the iron level of the patients receiving 
chemotherapy.
Methods: The patients with lung cancer received cytotoxic che-
motherapy were included to this study if the serum level of iron, 
unsaturated iron binding capacity (UIBC ) and ferritin before the 
chemotherapy, on day 2, and day 8 were available. All chemothera-
peutic regimens were administered as standard practice indicated 
by Japan governmental insurance. The treatment regimens were 
classified to highly emetogenic chemotherapy (HEC), moderately 
emetogenic chemotherapy (MEC) and low emetogenic chemothe-
rapy (LEC) according to the clinical practice guideline of the Ame-
Table 1. Select baseline patient characteristics and overall survival
Baseline Patient Characteristics Overall Survival Estimates (unadjusted)
Treatment Cohorta
Age 
≥70 
Years 
(%)
ECOG 
PS of 
2/3 (%)
Stage 
IV (%)
Non-squa-
mous Histo-
logy (%)
All patients 
Median OS 
in Months 
(95% CI) 
Non-squa-
mous Median 
OS in Months 
(95% CI) 
Non-squa-
mous Cispla-
tinb Median 
OS in Months 
(95% CI) 
Pemetrexed + Platinumb (n=569) 23 18 86 97
10.7 
(9.4-12.3) 
[n=569] 
10.6 
(9.4-12.0) 
[n=553]
11.6 
(9.9-13.8) 
[n=374]
Gemcitabine + Platinumb (n=360) 35 11 74 56
10.0 
(8.4-11.8) 
[n=360] 
8.4 
(7.0-10.6) 
[n=201]
8.4 
(6.7-10.8) 
[n=107]
Taxanes + Platinumb (n=295) 36 23 75 64
9.1 
(8.0-11.3) 
[n=295] 
8.1 
(7.4-10.1) 
[n=189]
9.6 
(7.1-14.1) 
[n=44]
Vinorelbine + Platinumb (n=300) 28 15 67 53
10.7 
(8.9-12.8) 
[n=300] 
10.1 
(8.0-13.1) 
[n=160]
9.9 
(7.2-13.4) 
[n=91]
 
aA fifth cohort, the ‘other’ + platinum cohort contained a small 
number of subjects (n=40) and it was not included in the analyses 
presented here bCisplatin is the platinum agent in the EMA appro-
ved prescription drug label
Conclusion: This observational study of first-line treatment for 
advanced NSCLC provides data describing patients and their sur-
vival outcomes in a real-world European practice setting between 
2009 and 2012.
Keywords: observational study, pemetrexed, Overall Survival, 
NSCLC
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Results: Patient background was as follows; median age 65, 318 male 
and 111 female patients, 190 patients treated with HEC and 239 with 
MEC. In acute phase, nausea and vomiting were observed in 5.6% 
(HEC 6.8%, MEC 4.6%) and 1.2 % (HEC 0.5%, MEC 1.7%) of all pati-
ents, respectively. In late phase, nausea and vomiting were observed 
in 40.1% (HEC 46.3%, MEC 35.2%) and 9.6 % (HEC 7.9%, MEC 10.9%) 
of all patients, respectively. The frequency of nausea in late phase is 
significantly higher in HEC than that in MEC. The predictive factors for 
nausea were a younger age in female patients, and younger age, no 
driNKIng history, decreased hemoglobin in male patients. The predic-
tion of CINV by physician was relatively poor in late phase vomiting.
Conclusion: In this study, the current status of CINV and antiemetic 
therapy in lung cancer patients in Japan were elucidated. CINV was 
frequently observed in late phase and the appropriate management 
for late emesis is needed according to the guideline.
Keywords: emesis, chemotherapy, CINV, Lung cancer
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Background: POLI is one of the Y-family polymerases, which are 
considered as error-prone replicases with low fidelity and involved in 
translesion synthesis (TLS) pathway. Polymorphisms on POLI genes may 
affect efficiency of DNA damage tolerant repair, therefore affect the 
platinum-based chemotherapy tolerance in tumor tissue and maintain 
routine function of normal organs. Our study aimed to investigate the 
association of five SNPs of POLI at codon 731, 5’-upstream and 3’UTR 
with prognosis and severe toxicity in advanced NSCLC patients in eas-
tern developed regions in China.
Methods: 663 stage III-IV aNSCLC patients treated with first-line plati-
num-based chemotherapy were genotyped with MassARRY platform 
on the five polymorphisms.
Results: p.731Ala (G of rs8305) indicated protective tendency from 
severe grade III-IV gastrointestinal toxicity in a dominant genetic model 
(adjusted odds ratio for Ala/Ala+Ala/Thr: 0.51, 95% confidence internal, 
0.28-0.93;  P for trend = 0.028). Stratified analysis revealed that the 
protective effect was rather for cisplatin- than carbonplatin-based regi-
ments (adjusted OR for Ala/Ala+Ala/Thr: 0.38, 95% CI, 0.18-0.81;  P for 
trend = 0.012). As linked loci of rs8305, rs3730668 on 5’-upstream and 
rs513543 on 3’-UTR of POLI performed similar protective tendency to 
gastrointestinal toxicity. No significant association was discovered for 
these five SNPs with other hematological toxicity, progress-free survival 
and overall survival. Both haplotype and diplotype analysis revealed 
consistent result as single polymorphism analysis. Haplotype “AAA” (in 
the order of rs3730668-rs8305-rs513543) indicated a significant suscep-
tibility to gastrointestinal toxicity (adjusted OR: 1.92; 95% CI, 1.19-3.10; 
P = 0.007).
Conclusion: For the first time, our study indicated error-prone replicase 
POLI was associated with gastrointestinal toxicity in aNSCLC patients 
accepting first-line platinum-base chemotherapy, especially for cispla-
rican Society of Clinical Oncology to investigate the relationship 
between the change of serum iron level and CINV.
Results: A total of 37 patients (male26/femal11) were included. 
The number of patients of each classification were 18 in HEC 
(cisplatin+etoposide), 14 in MEC(caboplatin+gemcitabine, 
calboplatin+paclitaxel, calboplatin+etoposide, carboplatin+pem
etrexed,irinotecan and amrubicin), 5 in LEC(pemetrexed). Serum 
iron level (µg/dl) of patients received HEC were 64.6±42.0 before 
treatment, 233.5±50.0 on day 2, and 235.5±41.3 on day 8. Those 
of MEC were 62.8±17.0 before treatment, 224.3±33.0 on day 2, 
and 175.7±87.6 on day 8. Those of LEC were 54.6±17.3 before 
treatment, 116.4±36.6 on day 2, and 40.7±33.5 on day 8. The 
serum iron levels of all patients markedly increased on day 2 and 
there were significant difference between LEC and the other two 
groups (p=0.01). The iron levels of LEC decreased to normal, on the 
contrary, those of other two groups remained abnormally high on 
day 8. With the increase of iron, the significant decrease of UIBC 
was observed implying that free radical iron appeared after the 
chemotherapy
Conclusion: Serum iron levels were closely correlated to CINV. This 
phenomenon may be a clue to new approach for antiemetic treat-
ments.
Keywords: CINV, iron, emesis
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Background: Chemotherapy-induced nausea and vomiting (CINV) is 
one of the major causes to deteriorate patient’s quality of life. There-
fore, it is important to assess the current status of CINV nationwide for 
the appropriate treatment method to manage CINV. For this purpose, 
prospective multi-center observational study was performed in Ja-
pan.
Methods: Between 2011/Apr and 2012/Dec, 458 lung cancer patients 
who underwent systemic chemotherapy with high (HEC) or moderate 
emetogenic agents (MEC) were registered and the data in 429 pati-
ents were analyzed. CINV status was assessed in acute phase (within 
24 hours from chemotherapy start) and late phase (after 24 hours) 
separately. Multivariate analysis was performed to clear the predictive 
factors in patient background for CINV.
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of tumor size and volume based on the whole tumor volume, on 
baseline contrast-enhanced CT scans and on follow-up CT scans 
of every two treatment cycle. A quantify for tumor response was 
evaluated with growth tumor kinetics, followed by determining 
correlation with early tumor parameters including change of size, 
volume, and response rate. Cox-proportional hazard model and 
Log-rank test were also applied to predict the overall survival. 
Results: Percent of volume change after two cycles of TKI 
treatment had a strong correlation with progression rate based on 
growth tumor kinetics (P < 0.001). Responders based on percent 
of volume change after two cycles of TKI treatment had a higher 
overall survival rate than non-responders (P = 0.001). The velocity 
of progression was also a good potential parameter to predict 
overall survival (P < 0.001). 
Conclusion: Early radiologic 
parameters of the tumor helped 
predict treatment response and 
overall survival in EGFR mutant lung 
adenocarcinoma patients treated 
with TKIs. Longitudinal tumor data 
also showed potential as a predictive 
factor.
Keywords: EGFR TKI, growth tumor 
kinetics, Prognosis, tumor volume
tin-based regiments.
Keywords: POLI, translesion synthesis, aNSCLC, platinum-based che-
motherapy
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MO24.13 VOLUME BASED GROWTH TUMOR KINETICS 
AS A PREDICTIVE BIOMARKER IN PATIENTS WITH EGFR-
MUTANT LUNG ADENOCARCINOMA RECEIVING EGFR 
TYROSINE KINASE INHIBITOR
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Background: To determine whether volumetric assessment has 
potential as a predictive biomarker and to assess relationship 
between longitudinal tumor data during treatment and prognosis 
in lung adenocarcinoma patients with sensitizing EGFR mutations 
treated with EGFR tyrosine kinase inhibitor (TKIs).
Methods: We retrospectively assessed patients with EGFR-mutant 
stage IV lung adenocarcinoma, who underwent EGFR TKIs as 
second-line therapy and this treatment was repeated every three 
weeks until disease progression. All 106 patients with at least one 
measurable lung lesions were quantitatively analyzed in terms 
S408 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
RECIST 1.1, and secondary endpoints were overall response rate, 
overall survival, and safety profile. To guarantee an overall type-1 
α error (one side) no greater than 0.05 and a type II (β) error 0.1 for 
the primary endpoint of PFS, a sample size of 134 pts allocated in a 
1:1 ratio is planned.
Results: Since August 2011 77 pts have been recruited. 46 pts 
have been included in the interim analysis, 23 pts have been ran-
domly allocated to each treatment arm. Patient’s characteristics 
were: Male 91.3%; median age 64 (range 44-75); PS1 56.5%; smo-
kers 46.8%; adenocarcinoma 40.4% / squamous 55.3%; stage IIIA 
46.8% / IIIB 53.2%. Median of months between initial diagnosis 
and study start was 1 (range 0.3-15.7). Safety: 118 cycles (cy) were 
analysed, 79 in arm OV-P and 39 in arm E-P. Hematological toxici-
ties arms OV-P/E-P (% cy): grade (g) 3/4 neutropenia 8.9%/13.1%; 
g3 thrombocytopenia 0%/5.3%; g3 anemia 0%/2.6%; febrile neu-
tropenia 3 cases on OV-P arm (all during induction CT on cy 1) and 
1 case on E-P arm (during concurrent chemoradiation). Non-hema-
tological toxicities arms OV-P/E-P (% cy): g3 esophagitis/mucositis 
1.3%/15.5%; g3 infection without neutropenia 1.3%/5.1%. No 
treatment-related deaths were reported. There was no remarkable 
difference in other toxicities between both arms. 39 pts completed 
the treatment as per protocol, 19 in arm OV-P and 20 in arm E-P. 
Overall response rates were 73.7% and 50% for the OV-P and the 
E-P arm, respectively.
Conclusion: This interim analysis shows that OV-P and E-P when 
administered concurrently with RT have a manageable safety 
profile with efficacy. Safety data is consistent with other studies 
reported for both chemoradiation regimens. Based on these posi-
tive results for safety, accrual is ongoing. Clinical trial information 
EudraCT 2010-022927-31.
Keywords: cisplatin, vinorelbine, etoposide, radiotherapy
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CED (LA) STAGE III NON-SMALL CELL LUNG CANCER 
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Background: Chemoradiation is the standard of care for the treat-
ment of unresectable LA-NSCLC. Cisplatin plus either etoposide 
or vinorelbine are two of the chemotherapy (CT) regimens widely 
used for the disease concurrently with radiotherapy. Oral vinorel-
bine is a formulation which has achieved comparable results to the 
IV vinorelbine. The purpose of the study is to evaluate the efficacy 
and safety of cisplatin when combined with etoposide or oral vi-
norelbine with radical radiation for the management of stage III 
NSCLC.
Methods: Patients (pts) between 18 and 75 years, with histologi-
cally proven untreated and unresectable LA stage IIIA/IIIB NSCLC, 
adequate bone marrow, hepatic and renal function, ECOG PS 0-1, 
were randomized to: Arm OV-P: OV 60 mg/m2 D1, D8 cycle 1 and 
80 mg/m2 cycle 2 (if no grade 3-4 toxicity) plus P 80 mg/m2 D1 eve-
ry 3 weeks for 2 cycles as induction; patients without progression 
received OV 40 mg/m2 D1, D8, and P 80 mg/m2 D1 every 3 weeks 
for 2 more cycles (4 cycles in total). Arm E-P: E 50 mg/m2 intrave-
nously D1 to D5 plus P 50 mg/m2 D1, D8 every 4 weeks for 2 cyc-
les. Both regimens administered with concurrent RT 66 Gy in 6.5 
weeks. The primary endpoint was progression free survival using 
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Background: This single-arm multicenter Phase II study investiga-
ted the efficacy and safety of PEM+CIS induction chemotherapy 
(CT) followed by full-dose PEM+CIS with concurrent radiotherapy 
(RT) in patients with LA NS-NSCLC. The 1-year progression-free 
survival (PFS) rate (primary endpoint) was 51.3% (ESMO 2013). 
Here, we report the safety data for induction CT and concurrent 
CT+RT.
Methods: Patients with unresectable Stage IIIA/IIIB NS-NSCLC 
(AJCC Version 6), ECOG-PS 0-1 and forced expiratory volume 
(FEV) >50% of predicted normal FEV received 2 cycles of PEM 
500mg/m2 + CIS 75mg/m2 on Day 1, every 21 days. Patients who 
did not progress, with no residual neurological toxicity >Grade 
(G)2, ECOG-PS 0-1 and lung V20<35% were candidates to receive 
2 cycles of the same full-dose PEM+CIS regimen with concurrent 
thoracic RT of 2Gy/fraction, 5d/week for 7wks (66Gy total). All pa-
tients received vitamin supplementation/dexamethasone prophy-
laxis as per PEM-label.
Results: 90 patients were enrolled in 4 European countries, 75 
(83.3%) completed induction CT and started concurrent CT+RT. 
Characteristics of 90/75 patients starting induction/concurrent the-
rapy: median age 61/62yrs, male 57%/53%, ECOG-PS 0 66%/65%, 
mean(SD) FEV 2.3(0.62)/2.3(0.59)L, adenocarcinoma 90%/92%, 
Stage IIIA 36%/37%. 63 of 75 patients starting concurrent CT+RT 
(84.0%) received all 4 CT cycles and full dose RT. Median PEM+CIS 
dose intensities were 90-92% during induction and >97% during 
concurrent CT+RT, median RT dose was 66Gy (only 6 patients 
<60Gy). One patient died from study-drug-related toxicity (ente-
ritis) during Cycle 4. Four patients discontinued due to non-fatal 
drug- or radiation-related adverse events (AEs), 1 on induction CT 
(renal failure), 3 on concurrent CT+RT (hypoacusis, 2 patients with 
radiation esophagitis). During induction/concurrent therapy, 8 of 
90 patients (8.9%)/12 of 75 patients (16.0%) had ≥1 CT dose delay 
due to AEs, mainly neutropenia (n=5/6). 2/6 patients (2.2%/8.0%) 
required CT dose reductions. 13 of 75 patients (17.3%) experi-
enced AEs requiring interruption of radiation, mainly radiation 
esophagitis (9.3%). Common G1-4 toxicities are presented in the 
table. 41.3% of patients reported ≥1 G3/4 toxicity during concur-
rent CT+RT, mainly esophagitis (12.0%), neutropenia (10.7%) and 
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Background: The Japan Clinical Oncology Group (JCOG) under-
took 2 randomized phase III trials (JCOG9812 and JCOG0301) to 
assess whether daily low-dose carboplatin plus radiotherapy could 
improve survival in elderly patients with stage III non-small cell 
lung cancer (NSCLC) when compared to radiotherapy alone. Alt-
hough JCOG9812 was prematurely terminated because of a high 
incidence of treatment-related deaths (TRDs) and instances of pro-
tocol violation, especially with regard to radiotherapy planning, the 
trial regimen was assumed promising. Therefore, JCOG0301 was 
conducted for the same subjects using the same protocol regimen 
with modified inclusion criteria regarding pulmonary function and 
radiotherapy quality control (RTQC) measures. We then carried out 
a preplanned pooled analysis of these 2 studies.
Methods: The eligibility criteria for both trials were age of ≥71 
years and unresectable stage III NSCLC. Patients were randomized 
to receive radiotherapy alone (60 Gy, RT arm) or chemoradiothe-
rapy (radiotherapy, 60 Gy plus concurrent carboplatin, 30 mg/m2 
per fraction up to the first 20 fractions, CRT arm). The primary end-
point for both studies was overall survival (OS). The pooled analy-
sis included OS, progression-free survival (PFS), response rate, and 
toxicities.
Results: In JCOG9812, 46 patients (RT arm, n=23; CRT arm, n=23) 
were enrolled from November 1999 to August 2001. In JCOG0301, 
200 patients (RT arm, n=100; CRT arm, n=100) were enrolled from 
September 2003 to May 2010, and in total, 246 patients were 
included in the pooled analysis. Patient characteristics for the RT 
(n=123) and CRT (n=123) arms were as follows: median age, 77 ye-
ars (range, 71–93) and 77 years (range, 71–89); stage IIIA/IIIB, 65/58 
patients and 63/60 patients; performance status (PS) 0/1/2, 44/74/5 
patients and 50/69/4 patients; men/women, 103/20 patients and 
96/27 patients, respectively. The median OS for the RT (n=121) 
and CRT (n=122) arms were 16.3 months (95% CI, 13.4–18.6) and 
20.7 months (95% CI, 16.3–26.9), respectively (HR, 0.672; 95%CI, 
0.502–0.898, stratified log-rank test one-sided p=0.0034). The 
pooled HR for PFS was 0.671 (95%CI, 0.514–0.875, stratified log-
rank test one-sided p=0.0015). Response rates for the RT and CRT 
arms were 46.3% and 53.3%, respectively. The number of patients 
with grade 3/4 hematological toxicities was higher in the CRT arm 
than in the RT arm: leucopenia (62.2% vs 1.7%), neutropenia (54.6% 
vs none), and thrombocytopenia (30.3% vs 3.3%). The incidence of 
grade 3/4 pneumonitis decreased from 4.4% (JCOG9812; RT, 4.5% 
and CRT, 4.3%) to 2.1% (JCOG0301; RT, 3.1% and CRT, 1.0%), and 
that of late lung toxicity, from 14.0% (JCOG9812; RT, 10.0% and 
CRT, 17.4%) to 5.9% (JCOG0301; RT, 5.3% and CRT, 6.5%). The inci-
dence of TRD also decreased from 8.9% (JCOG9812; RT, 1 patient 
and CRT, 3 patients) to 3.6% (JCOG0301; RT, 4 patients and CRT, 3 
patients). As per subgroup analyses, ≤75 years, stage IIIA, male, PS 
0, and smoking history were associated with statistically significant 
improvement in OS in the CRT arm.
Conclusion: This combination chemoradiotherapy for elderly pa-
tients with locally advanced NSCLC provides clinically significant 
benefits and RTQC measures are imperative to improve treatment 
outcome.
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Results: 156 patients were registered. Eventually, 149 were assi-
gned to PE arm (73) and PC (76). The median follow-up time was 
38 months. The median survival time (MST) was 20 months. The 
2-year overall survival (OS) and 3-year OS were 39.8% and 32.9%. 
The 2-year progress free survival (PFS) and 3-year PFS were 24.8% 
and 22.4%. The MST of PE arm and PC arm were 22 months and 20 
months, and the median progress free time were 13 months and 
11months, respectively. The 2-year OS of PE arm and PC arm were 
44.9% and 35%, the 3-year OS were 40% and 26.2% (p=0.323), 
respectively. The 2-year PFS of PE arm and PC arm were 27.7% and 
22.1%, 3-year PFS were 24.5% and 20.5% (p=0.449), respectively. 
The incidence of Great 3/4 bone marrow depression of PE arm and 
PC arm were 34.2% and 23.7% (p=0.29). The incidence of Great 2 
or greater radiation pneumonitis of PE arm and PC arm were 19.2% 
and 26.3% (p=0.059).
Conclusion: For stage III NSCLC, concurrent TRT with PE regimen 
has improved PFS and OS comparing with PC regimen without si-
gnificant difference. Concurrent PE regimen has a lower incidence 
of Great 2 or greater radiation pneumonitis.
Keywords: non-small cell lung cancer, Concurrent chemoradiothe-
rapy, Local advanced
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Background: Endostatin has been proved to be a potent endo-
genous angiogenic inhibitor. Recombinant human endostatin (En-
dostar) was reported to be efficient in blocking angiogenesis and 
suppressing tumor growth. Preclinical studies demonstrated that 
Endostar could normalize tumor vasculature, alleviate hypoxia and 
sensitize the function of radiation. This study was conducted to 
evaluate the efficacy and safety of Endostar combined with con-
current chemo-radiotherapy (CCRT) in patients with stage IIInon-
small-cell lung cancer (NSCLC).
Methods: Patients with unresectable stage IIINSCLC were eligible. 
Patients received Endostar (7.5 mg/m2/d) through 7 days at weeks 
1, 3, 5, and 7, and two cycles of docetaxel (65 mg/m2) and cisplatin 
(65 mg/m2) on days 8 and 36, with concurrent thoracic radiation at 
60~66 Gy. Primary end points included the short-term efficacy and 
treatment-related toxicity of Endostar combined with CCRT.
Results: In all, 50 patients were enrolled onto the study, and 48 
were assessable. Median follow-up was 32.1 months. Response 
leukopenia (9.3%). G3 mucositis, G3 dysphagia and G3 acute pneu-
monitis were each reported by 1 patient (1.3%); 6 patients (8.0%) 
required blood-cell transfusions. 
Conclusion: PEM+CIS induction CT followed by full-dose 
PEM+CIS with concurrent thoracic RT was well tolerated in this stu-
dy. Incidences of both G3/4 and low-grade toxicities were low, not 
only during PEM+CIS induction CT, but also during the subsequent 
2 cycles of full-dose PEM+CIS CT with concurrent thoracic RT.
Keywords: concomitant CT+RT, Phase II study, locally advcanced 
NSCLC, pemetrexed
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RAPY IN PATIENTS WITH LOCALLY ADVANCED NON-
SMALL CELL LUNG CANCER
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Background: To evaluate the effect and safety of concurrent tho-
racic radiotherapy (TRT) with Cisplatin/Etoposide (PE) compared 
with weekly Paclitaxol/Carboplatin (PC) regimens in patients with 
stage III non-small cell lung cancer (NSCLC).
Methods: Patients with stage III NSCLC were randomly assigned 
to receive PE regimen (PE arm) cisplatin 50mg/m2 d1, 8, 29 and 36, 
etoposide 50mg/m2 d1-5 and 29-33 concurrent with TRT 60Gy, or 
PC regimen (PC arm) carboplatin (AUC=2) and paclitaxol 45mg/m2 
concurrent with TRT 60Gy.
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Conclusion: The combination of Endostar with CCRT is feasible 
and shows promising activity. This regimen should be studied 
further in patients with locally advanced NSCLC.
Keywords: endostatin, Lung cancer, radiotherapy, chemotherapy
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Background: Increased treatment-associated esophagitis could be 
responsible for concurrent chemo-radiotherapy (CT-RT)-induced 
weight loss in patients with non-small cell lung cancer (NSCLC). 
However, based on clinical observations, we hypothesized that 
weight loss already starts early after initiation of concurrent CT-RT 
and might therefore be not solely dependent on decreased intake 
due to esophagitis symptoms.
Methods: In a retrospective cohort, the onset and frequency of 
weight changes and their association with esophagitis grade ≥2 
were assessed in patients with NSCLC treated with concurrent 
(n=102) or sequential (n=92) CT-RT. The findings in the retrospec-
tive cohort were validated in a prospective study in which weight 
loss and esophagitis grade ≥2 was assessed over a longer time 
period and additional data on nutritional intake, muscle strength 
and quality of life was obtained of patients treated with concurrent 
CT-RT (n=9).
Results: In the retrospective cohort, both the number of patients 
with weight loss and the magnitude of weight loss was significantly 
higher in concurrent than sequential treated patients in week 2, 
3 and 4 of (CT-)RT (p<0.05). Longitudinal data analysis showed 
no significant associations between weight loss and grade eso-
phagitis ≥2 in patients treated with concurrent CT-RT (p=0.10). 
In the prospective cohort, a similar pattern of ‘early’ weight loss 
was observed in the first weeks of concurrent CT-RT (p<0.05). This 
early weight loss was not accompanied by significant decreases in 
nutritional intake but muscle strength did already decline in this 
early stage (p<0.05). In the following weeks of concurrent CT-RT, 
the weight further decreased and reached its minimum at the end 
of treatment (p<0.05), while the number of patients with grade 
esophagitis ≥2 increased during this time period. During the later 
part of concurrent CT-RT, dietary intake was significantly lower and 
patients became more reliant on supplemental nutrition (p<0.05). 
Although the weight increased again in the weeks after concurrent 
CT-RT, it had still not reached the baseline level after 4 weeks post 
rate was 77%. The estimated median progression-free survival 
(PFS) was 10.2 months and the estimated median overall survival 
(OS) was 22.6 months. The 1-year and 2-year PFS rates were 48% 
and 25%, respectively. The 1-year and 2-year OS rates were 81% 
and 47%, respectively (Figure 1).Nine patients (19%) experienced 
grade 3 or higher treatment-related nonhematologic adverse 
events (AEs). Predominant nonhematologic toxicities were grade 
3 esophagitis (n = 4; 8%), and grade 3 to 5 pneumonitis (n = 6; 
13%). The rates of observed grade 3 and 4 hematologic AEs were 
77% (n = 37). The predominant hematologic toxicity was grade 
3 to 4 lymphopenia (n = 32; 67%) and neutropenia (n = 23; 48%). 
Overall, the entire treatment regimen was well tolerated. Figure 1 
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pretreatment WBCC (4.000-11.000 vs >11.000; p<0.001) were the 
significant prognostic factors. These factors also retained their sig-
nificance on multivariate analyses as well (p<0.05 for each). Table. 
Pretreatment patients characteristics 
Characteristics 
Whole Group 
(n=718) 
Group 
1 
(n=555) 
Group 2 
(n=163) 
P value 
Median age 
(Years) Range 
54.0 31-69 
53 33-
64 
54 31-69 0.28 
Sex [N,(%)] Fe-
male Male 
246 (34.3) 472 
(65.7) 
51 (7.1) 
112 
(15.6) 
195 
(27.2) 
360 
(50.1) 
0.39 
Performance 
Status [N,(%)] 
ECOG 0 ECOG 
1 
314 (43.7) 404 
(56.3) 
73 
(10.2) 
90 
(12.5) 
241 
(36.6) 
314 
(43.7) 
0.78 
Histology [N,(%)] 
Squamous cell 
Adenocancer 
388 (54.0) 330 
(46.0) 
92 
(12.8) 
71 (9.9) 
296 
(41.2) 
259 
(36.1) 
0.53 
TN stage T1N3 
T2N3 T3N3 
T4N2 T4N3 
73 (10.2) 115 
(16.0) 292 
(40.7) 123 
(17.1) 115 
(16.0) 
17 (2.4) 
26 (3.6) 
51 (7.1) 
28 (3.9) 
41 (5.7) 
56 (7.8) 
89 (12.4) 
241 
(33.6) 95 
(13.2) 74 
(10.3) 
0.11 
Conclusion: Worse survival outcomes observed in patients with 
pretreatment WBCC above the reference limits suggest that pret-
reatment WBCC may be a potentially cheap and relevant indepen-
dent prognostic factor that can be used besides other well-known 
factors to predict treatment outcomes in LA-NSCLC patients trea-
ted with definitive CRT.
Keywords: locally advanced non-small cell lung cancer, Concur-
rent chemoradiotherapy, pretreatment white blood cell count
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MO25.09 A PHASE II STUDY OF 18F-FDG PET GUIDED 
OPTIMIZATION OF NEOADJUVANT CHEMOTHERAPY 
FOR RESECTABLE NON-SMALL CELL LUNG CANCER
Jamie E. Chaft1, Matthew D. Hellmann1, Mark Dunphy2, Whitney 
Jappe1, Camelia S. Sima3, Robert J. Downey4, William D. Travis5, 
Christopher G. Azzoli6, Mark G. Kris1
1Medical Oncology, Memorial Sloan-Kettering Cancer Center/United 
States Of America, 2Nuclear Medicine, Memorial Sloan-Kettering Can-
cer Center/United States Of America, 3Biostatistics, Memorial Sloan-
Kettering Cancer Center/United States Of America, 4Thoracic Surgery, 
Memorial Sloan-Kettering Cancer Center/United States Of America, 
5Pathology, Memorial Sloan-Kettering Cancer Center/United States Of 
America, 6Massachusetts General Hospital/United States Of America
Background: Perioperative chemotherapy improves overall survi-
val in patients with resectable non-small cell lung cancers. In con-
trast to adjuvant chemotherapy, neoadjuvant chemotherapy ena-
bles radiographic assessment of chemotherapy effect and hence, 
the option to switch non-responding patients to a potentially more 
treatment (p<0.05).
Conclusion: Weight loss is a common complication of concurrent 
CT-RT for locally advanced NSCLC, starts early after initiation 
of CT-RT and is not dependent of esophagitis. It is presumably 
caused by active catabolism as this ‘early’ weight loss is accompa-
nied by decreased muscle strength, despite stable dietary intake. 
In the later weeks of treatment, concurrent CT-RT is characterized 
by a further decline in body weight, decreased dietary intake and 
higher reliance on nutritional support. In this phase the occurrence 
of radiation-induced esophagitis grade ≥2 increases. In the weeks 
following concurrent CT-RT, partial recovery of body weight takes 
place but this is still not complete after 4 weeks post CT-RT. The 
sustained weight loss during and following concurrent CT-RT 
might have major negative consequences as weight loss in pati-
ents with underlying malignant disease might has been associated 
with higher mortality, lower treatment responses and decreases in 
quality of life. Though the origin of weight loss during concurrent 
CT-RT seems to be different in the subsequent phases, more ag-
gressive supportive nutritional support throughout the treatment 
course seems conceivable to prevent negative energy balances 
and optimize concurrent CT-RT management.
Keywords: weight loss, concurrent CT-RT, esophagitis, nutritional 
support
NSCLC - COMBINED MODALITY THERAPY II  
WEDNESDAY, OCTOBER 30, 2013 - 10:30-12:00
MO25.08 IMPACT OF PRETRETMENT LEUKOCYTOSIS 
ON PROGNOSIS IN LOCALLY ADVANCED NON-SMALL 
CELL LUNG CANCER PATIENTS TREATED WITH CON-
CURRENT CHEMORADIOTHERAPY
Erkan Topkan1, Cem Parlak1, Ozan C. Guler1, Berrin Pehlivan2, 
Ugur Selek3
1Department Of Radiation Oncology, Baskent University Medical Facul-
ty/Turkey, 2Department Of Radiation Oncology, Medstar Antalya Hos-
pital/Turkey, 3Department Of Radiation Oncology, American Hospital, 
University Of Texas MD Anderson Radiation Oncology Center/Turkey
Background: In this study, impact of high pretreatment white 
blood cell count (WBCC) on survival outcomes in locally advanced 
non-small cell lung cancer (LA-NSCLC) patients treated with con-
current chemoradiotherapy (CRT) was investigated.
Methods: Medical records of LA-NSCLC patients treated with 
definitive CRT at our department between dates January 2007 and 
December 2011 were retrospectively evaluated. All patients re-
ceived 60-66 Gy thoracic radiotherapy concurrently with 1-3 cycle 
cisplatin-vinorelbine/taxane (q21) regimen chemotherapy. Patients 
were divided into two groups according to pretreatment basal 
WBCC: Group1: normal (4.000-11.000) and Group 2: high (>11.000). 
These two groups are compared in terms of overall survival (OS), 
and progression-free survival (PFS).
Results: Pretreatment characteristics of 718 patients were given 
in Table 1. At a median follow-up of 23.2 months (range 8.8-44.6), 
median OS and PFS for whole group were 20.6 (%95 CI: 19.3-21.9) 
and 9.9 months (%95 CI: 9.4-10.1), respectively. On comparative 
survival analyses, patients with high pretreatment WBCC had infe-
rior OS (22.8 vs.14.7 months; p<0.001) and PFS (10.4 vs. 7.0 months; 
p<0.001) than those with normal WBCC. On univariate analyses, 
T-stage (T1-2 vs. 3-4; p=0.035), N-stage (N2 vs. N3; p=0.002), and 
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1Department Of Radiation Oncology, University Of Michigan And 
Veteran Administration Hospital, Currently At Gru Cancer Center, 
Georgia Regent University/United States Of America, 2Department Of 
Radiation Oncology, University Of Michigan/United States Of America, 
3Department Of Biostatistics, University Of Michigan/United States Of 
America, 4Department Of Surgery, Section Of Thoracic Surgery, And 
Department Of Internal Medicine, University Of Michigan/United Sta-
tes Of America
Background: We hypothesized that individualized radiation treat-
ment targeting to the FDG-avid tumor identified mid-treatment 
would improve local tumor control.
Methods: This is a phase II trial for patients with inoperable/un-
resectable NSCLC. Conformal radiotherapy (RT) was given in 30 
daily fractions. RT dose was individualized to a fixed rate of grade 
>2 lung toxicity and adaptively escalated to the residual tumor on 
mid-tx FDG-PET upto a total dose of 86 Gy. Patients were given 
concurrent weekly followed by consolidation carboplatin/paclita-
xel. The primary endpoint was local-regional tumor control (LRTC) 
and local-regional progression free survival (LRPFS) at 2 years.
Results: 42 patients were enrolled: median age 63 years (range 
45-83); 28 (67%) male; 39 (93%) smokers; 38 (92%) stage III; and 
45% squamous cell. Median physical dose reached was 83 Gy 
(range 63-86 Gy), equivalent to 90 Gy in 2 Gy fractions (biological 
effective dose 107 Gy). Minimum and median follow-up were 9 and 
27 months, respectively. The 2-year rates of in-field LRTC, overall 
LRTC, and LR-PFS were 84% (62-94%), 61% (39-77%), and 37% 
(22-52%), respectively. 15 patients progressed: 2 (13%) at primary 
tumor alone; 4 (27%) first at distant sites alone; 2 (13%) at nodal re-
gions alone; 5 (33%) at both distant sites and nodal regions; 1 (7%) 
at both distant site and primary tumor; 1 (7%) at both nodal region 
and primary tumor. Median overall survival was 22 months (10-33 
months) and 2-year overall survival rate was 49% (32-63%). These 
results compared favorably to stage-matched patients treated with 
standard-dose RT in our center 2-year overall survival 23% (8-41%) 
during the same time period.
Conclusion: Adapting RT by targeting high dose radiation to the 
FDG avid region detected mid-treatment provides outstanding 
2-year local-regional tumor control. RTOG 1106 is currently testing 
this regimen in a randomized fashion.
Keyword: Non-small cell lung cancer; adaptive radiation therapy; 
mid-treatment FDG-PET
effective regimen. Responses to neoadjuvant chemotherapy as-
sessed by PET imaging correlate better with clinical outcomes than 
does CT imaging. We have initiated a Phase II trial of PET response 
guided chemotherapy, where chemotherapy administration deci-
sions are based on comparisons of baseline PET imaging, imaging 
after 2 cycles of platinum-based chemotherapy, and imaging after 
‘switch’ chemotherapy in patients with an initial suboptimal res-
ponse.
Methods: This Phase II trial (NCT01443078) is enrolling patients 
with clinical Stage IB-IIIA non-small cell lung cancers deemed ope-
rable by a thoracic surgeon. To be eligible, the primary lung mass 
must be >2 cm with a SUV ≥4.5. Patients with diabetes requiring 
insulin are excluded. Patients are initially treated with cisplatin (or 
carboplatin if cisplatin ineligible) + gemcitabine (squamous cell) 
or pemetrexed (non-squamous). After 2 cycles, if repeat PET ima-
ging shows less than a 35% decrease in SUV of the primary tumor, 
patients are switched to vinorelbine + docetaxel every 2 weeks 
with pegylated filgrastim support (2 doses = 1 cycle). The primary 
endpoint of this study is partial metabolic response after 2 cycles 
of switch vinorelbine + docetaxel as assessed by PERCIST (SUV de-
crease of ≥30% using the pre-switch scan as the new baseline). We 
considered a >20% partial metabolic response rate in those who 
received vinorelbine + docetaxel worthy of further study. Therefo-
re this study was powered to see at least 6 of 25 partial metabolic 
responses to vinorelbine + docetaxel, estimating a total patient 
accrual of 100 patients.
Results: 27 patients have been enrolled. 5 are undergoing pla-
tinum-based chemotherapy and have not yet been reassessed. 
22 patients have been reimaged after 2 cycles of platinum-based 
chemotherapy, 13 (59%) have had a > 35% decrease in SUV and 
continued on platinum-based chemotherapy. 9 (41%) patients have 
had a <35% decrease in SUV after platinum-based therapy and 
were assigned to switch chemotherapy. 7 received vinorelbine + 
docetaxel, and 5 (71%, 95% CI 29-96%) have had a PERCIST partial 
metabolic response after 2 cycles, 1 progressive disease and 1 is 
pending reassessment. 17 patients have been surgically explored 
with 13 (76%) R0 resections.
Conclusion: Preliminary results from this ongoing trial suggest that 
patients with resectable non-small cell lung cancers who have a 
suboptimal PET-assessed response to standard histology-selected, 
platinum-doublet neoadjuvant chemotherapy can be effectively 
treated with vinorelbine and docetaxel followed by surgery. This 
study is on-going. Assessment of pathologic response in resected 
patients and clinical follow-up in all patients will be available by the 
time of presentation.
Keywords: neoadjuvant chemotherapy, PET scan, non-small cell 
lung cancer
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MO25.10 A PHASE II TRIAL OF MID-TREATMENT FDG-
PET ADAPTIVE, INDIVIDUALIZED RADIATION THERAPY 
PLUS CONCURRENT CHEMOTHERAPY IN PATIENTS 
WITH INOPERABLE NON-SMALL CELL LUNG CANCER 
(NSCLC)
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MO26.02 PREDOMINANT HISTOLOGIC SUBTYPE BY 
IASLC/ATS/ERS CLASSIFICATION IS CORRELATED WITH 
PROGNOSIS AND EGFR MUTATION IN SURGICALLY RE-
SECTED LUNG ADENOCARCINOMA
Naoki Yanagawa1, Satoshi Shiono2, Masami Abiko2, Shin-Ya Oga-
ta1, Toru Sato2, Gen Tamura1
1Pathology And Laboratory Medicine, Yamagata Prefectural Central 
Hospital/Japan, 2Thoracic Surgery, Yamagata Prefectural Central Hos-
pital/Japan
Background: The purpose of this study is to validate the prog-
nostic impact and the frequency of EGFR mutation in lung ade-
nocarcinoma of Japanese patients based on new lung adenocarci-
noma classification proposed by the International Association for 
the Study of Lung Cancer, American Thoracic Society, and Euro-
pean Respiratory Society (IASLC/ATS/ERS).
Methods: We reclassified 486 adenocarcinomas according to the 
new classification. The percentage of each histopathological sub-
type and the predominant pattern were determined. EGFR muta-
tion also was investigated 241 of 486 adenocarcinomas. The relati-
onship between these results and clinicopathological backgrounds 
was investigated statistically.
Results: The histopathological assessment according to the IASLC/
ATS/ERS classification showed that 8.4% (n = 41) of the cases 
were adenocarcinoma in situ (AIS) ; 9.2% (n = 45) were minimally 
invasive adenocarcinoma (MIA) ; 18.3% (n = 89) were lepidic 
predominant ; 20.4% (n = 99) were acinar predominant ; 28.0% 
(n = 136) were papillary predominant ; 10.5% (n = 51) were solid 
predominant ; 2.3% (n=11) were micropapillary (MP) predominant, 
and 2.9% (n=14) were invasive mucinous adenocarcinoma (IMA). 
In univariate analysis, the patients with AIS and MIA subtypes had 
neither recurrence nor death within the follow-up periods. This was 
followed by the patients with lepidic predominant. The patients 
with papillary predominant, those with acinar predominant and 
those with IMA showed almost similar disease-free survival. The 
patients with solid predominant and MP predominant showed 
worse disease-free survival (Figure). Multivariate analysis showed 
that the new classification was an independent predictor of 
disease-free survival (Hazards ratio: 2.59; 95% confidence interval: 
1.69-3.96; p<0.001). EGFR mutation was detected in 131 of 241 
adenocarcinomas (54.4%). The each prevalence of EGFR mutation 
of AIS/MIA/Lepidic/Papillary/Acinar/Solid/MP/IMA was 62.1%/60%/
77.1%/50%/49%/27.8%/42.9%/0%.
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MO26.01 COMPARISON OF OUTCOMES FOR PATIENTS 
WITH “BRONCHIOLOALVEOLAR CARCINOMA (BAC)” 
DEFINED BY THE IASLC CLASSIFICATION VERSUS THE 
AJCC STAGING SYSTEM
Candice L. Wilshire1, Brian E. Louie1, Matthew P. Horton2, Shaun 
Deen1, Jennifer L. Kramer2, Ralph W. Aye1, Alexander S. Farivar1, 
Howard L. West3, Jed A. Gorden2, Eric Vallieres1
1Thoracic Surgery, Swedish Medical Center/United States Of America, 
2Swedish Medical Center/United States Of America, 3Swedish Cancer 
Institute/United States Of America
Background: Integration of the proposed IASLC classification of 
adenocarcinomas (ACA) into TNM staging has been challenging 
for pathologists. Until recently, at Swedish, we staged patients per 
the AJCC staging and separately described lesions with a BAC 
component placing them into 3 groups based on the percent of 
ACA invasion. But, we found this was not a good predictor of survi-
val. We aimed to more clearly define this population by comparing 
patients reclassified according to the proposed IASLC classification 
and the AJCC 7th edition staging to determine if they could be 
integrated as a single staging system.
Methods: We retrospectively reviewed patients with BAC from 
2000-2012 and classified them according to the IASLC classifica-
tion as ACA in situ (AIS), minimally invasive ACA (MIA) or lepidic 
predominant ACA (LPA) and according to the AJCC 7th edition 
staging (stage I, II or III). We then reclassified these patients sepa-
rating AIS and MIA as stage 0 in the AJCC 7th edition staging.
Results: We evaluated 145 consecutive patients with a median 
follow-up of 30 months. Using IASLC [AIS (N=23), MIA (N=18), LPA 
(N=104)]; local recurrence rates were: AIS (4%), MIA (11%) and LPA 
(2%). Regional (8%) and distant (10%) recurrences were only with 
LPA. Disease-free survival in patients with AIS (96%) and MIA (89%) 
was higher versus patients with LPA (80%). Five year cancer-specific 
survival was 100% for patients with AIS and MIA while it was 84% 
for LPA patients. Using AJCC 7th edition [I (N=125), II (N=12), III 
(N=8)]; recurrence rates were local: stage I (3%), stage III (13%). 
Regional: stage I (5%), stage II (8%), stage III (13%); and distant: 
stage I (6%), stage II (17%), stage III (13%). Stage I disease-free 
survival was 86%, stage II 75% and stage III 61%. Five year cancer-
specific survival was stage I 90%, stage II 81% and stage III 60%. 
Separating AIS and MIA as stage 0 [0 (N=42), I (N=84), II (N=11), III 
(N=8)]; local recurrence rates were: stage 0 (7%), stage I (1%), stage 
III (13%). Regional: stage I (7%), stage II (9%), stage III (13%); and 
distant: stage I (10%), stage II (18%), stage III (13%). Disease-free 
survival was higher in stage 0 (93%) compared to stage I (82%), 
stage II (73%) and stage III (61%). Five year cancer-specific survival 
was 100% for stage 0, while it was lower for stage I 84%, stage II 
80%, and stage III 60%, p<0.05.
Conclusion: The IASLC/ATS/ESR classification system appears to 
better discriminate patients with BAC compared to current AJCC 
staging. The results also suggest that patients with AIS and MIA 
may be classified as stage 0 in the AJCC staging system based on 
favorable outcomes and survival.
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IL-7R, and IL-12Rβ2 was performed. Lymphocytes positive for CD3 
and FoxP3 were scored in tumor and stroma, and tumors were 
classified using our recently reported FoxP3/CD3 risk index (JCO 
2013). Tumoral expression of IL-7R and IL-12Rβ2 was dichotomized 
by the sum of intensity (0-3) and distribution (1, 1%-50%; 2, >50%) 
scores: negative (total score <1) and positive (≥1). Recurrence-free 
probability (RFP) was estimated using the Kaplan-Meier method; 
multivariate analyses were performed using the Cox proportional 
hazards model.
Results: RFP was lowest for patients with budding grade 3 (n=180; 
5-year RFP, 69%; p<0.001), followed by grade 2 (n=139; 75%), 1 
(n=189; 81%), and 0 (n=530; 89%). Budding grade was dichoto-
mized into negative (grades 0-1) or positive (grades 2-3) using 
colorectal cancer criteria. The RFP for patients with positive bud-
ding (n=319; 5-year RFP, 72%) was significantly lower than that for 
patients with negative budding (n=719; 87%; p<0.001), which was 
confirmed in a subgroup analysis limited to stage IA (p=0.004) and 
IB (p<0.001) patients. Tumor budding further stratified RFP in pati-
ents with acinar (p<0.001), papillary (p=0.027), and solid (p=0.015) 
tumors. Budding was more frequently observed in tumors with 
high-grade histology (solid and micropapillary; p<0.001), lympho-
vascular invasion (p<0.001), and high mitotic count (p<0.001). Tu-
mor budding was positively correlated with stromal CD3+ lympho-
cytes (p<0.001), stromal FoxP3+ (p<0.001), FoxP3/CD3 risk index 
(high FoxP3, low CD3) in stroma (p<0.001), and tumoral IL-7R ex-
pression (p<0.001). In multivariate analysis, tumor budding was an 
independent prognostic factor for recurrence (HR=1.13; p=0.002).
Conclusion: Tumor budding was a significant prognostic factor in 
stage I lung ADC, independent of IASLC/ATS/ERS classification, 
and it correlated with a protumor immune microenvironment (high 
FoxP3+ lymphocyte infiltration and high IL-7R expression). These 
findings may inform therapeutic decisions and stratify patients for 
additional therapy, including immunotherapy.
Keywords: lung, Adenocarcinoma, tumor budding, Recurrence
ANATOMICAL PATHOLOGY II  
WEDNESDAY, OCTOBER 30, 2013 - 10:30-12:00
MO26.04 RECLASSIFICATION OF RESECTED NON-
SMALL CELL LUNG CARCINOMAS ORIGINALLY DIA-
GNOSED AS SQUAMOUS CELL CARCINOMA, AFTER 
REEVALUATION USING IMMUNOHISTOCHEMICAL 
ANALYSIS (P40, P63, TTF-1, AND NAPSIN A): MEMORIAL 
SLOAN-KETTERING CANCER CENTER EXPERIENCE
Kyuichi Kadota, Junichi Nitadori, Valerie W. Rusch, Natasha 
Rekhtman, Inderpal S. Sarkaria, Prasad S. Adusumilli, William D. 
Travis
Memorial Sloan-Kettering Cancer Center/United States Of America
Background: Currently, non-small cell lung carcinomas (NSCLCs) 
are mainly classified by histologic analysis and mucin staining: (1) 
squamous cell carcinoma (SCC) shows keratinization and intercel-
lular bridges; (2) adenocarcinoma shows lepidic, acinar, papillary, 
micropapillary, or solid pattern, with mucin production; and (3) 
large cell carcinoma lacks these findings. However, recent studies 
have shown promising improvements in the classification of NS-
CLC with immunostain-based markers, including p40 and thyroid 
transcription factor–1 (TTF-1). In this study, we investigate the use 
of immunohistochemical analysis in reclassifying NSCLCs originally 
diagnosed as SCCs.
Conclusion: The new IASLC/ATS/ERS adenocarcinoma classifica-
tion is very useful predictive marker to plan and determine a thera-
peutic strategy for lung adenocarcinoma.
Keywords: predominant, adenocarcinoma, prognosis, EGFR
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MO26.03 IN PATIENTS WITH STAGE I LUNG ADENOCAR-
CINOMA, TUMOR BUDDING IS A SIGNIFICANT PRO-
GNOSTIC FACTOR FOR RECURRENCE, INDEPENDENT 
OF THE IASLC/ATS/ERS CLASSIFICATION, AND CORRE-
LATES WITH A PROTUMOR IMMUNE MICROENVIRON-
MENT
Kyuichi Kadota, Yi-Chen Yeh, Nabil P. Rizk, Valerie W. Rusch, 
Prasad S. Adusumilli, William D. Travis
Memorial Sloan-Kettering Cancer Center/United States Of America
Background: In 2011, the IASLC/ATS/ERS proposed a new clas-
sification for lung adenocarcinoma (ADC) that has powerful pro-
gnostic value. However, tumors in each subtype may still include 
heterogeneous prognostic subgroups - especially in the acinar, 
papillary, and solid subtypes, in which the majority of tumors are 
classified. Recently, immune markers such as CD markers and cyto-
kines have been identified as prognostic factors in lung cancer. In 
this study, we investigate whether tumor budding further stratifies 
prognosis for stage I lung ADC, independent of the IASLC/ATS/
ERS classification, and whether it correlates with prognostic immu-
ne markers.
Methods: All available tumor slides from patients with therapy-
naive, surgically resected solitary stage I lung ADC (1995-2009) 
were reviewed (n=1038). Tumors were classified according to the 
IASLC/ATS/ERS classification. Mitoses were counted at 10 high-
power fields (HPFs) (x400 magnification). Tumor budding (tumor 
nest composed of <5 cells) was assessed, at 10 HPFs (x200 mag-
nification), in areas with the smallest tumor nests and was graded 
by the maximum number of budding : 0, 0/HPF; 1, 1-4/HPF; 2, 5-9/
HPF, and 3, ≥10/HPF. Tissue microarrays were constructed from 
tumoral and stromal cores, and immunostaining for CD3, FoxP3, 
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EBUS-TBNA to improve the yield of this procedure. However, many 
centres do not have the resources to meet this demand. Due to 
new therapeutic options in lung cancer, it is not sufficient to me-
rely distinguish between non-small cell lung carcinoma (NSCLC) 
and small cell lung carcinoma (SCLC). Immunohistochemistry (IHC) 
distinction where possible is now standard practice, as well additi-
onal molecular testing where clinically indicated. We investigated 
the diagnostic yield of smears vs. cell block and the provision of 
cellular material for ancillary testing.
Methods: A retrospective audit of all EBUS-TBNA procedures 
performed until the end of July 2012 was undertaken. Diagnostic 
yield on smears versus cell block was recorded. Cell blocks were 
reviewed by an experienced pathologist to determine diagnostic 
accuracy and whether IHC and molecular testing were possible.
Results: 208 procedures were recorded with 101(48.5%) malignant 
cases, 81(38.9%) benign cases and 26(12.5%) with insufficient sam-
pling. The average number of passes was 4.5. For malignancies, 
smear diagnosis was possible in 95% of cases and cell block dia-
gnosis in 93.5% (87/93) of cases. There was sufficient material for 
IHC in 97.7% (85/87) of malignant cases where required. In 79.3% 
(69/87) of NSCLCs molecular testing was theoretically possible 
based on the tumour load of samples obtained.
Conclusion: Cell blocks are not inferior to smears for diagnostic 
accuracy and provide sufficient samples for ancillary testing. How-
ever, ROSE assists the physician on how best to manage samples 
for ancillary testing.
Keywords: endobronchial ultrasound, Immunohistochemistry, 
EGFR, Rapid onsite examination
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MO26.07 USEFULNESS OF CYTOLOGICAL SAMPLES 
FOR THE ASSESSMENT OF ALK REARRANGEMENTS IN 
NSCLC PATIENTS.
Tania Labiano1, Mi Zudaire2, Myriam Montañana1, Ji Echeveste1, M 
Aguirre1, A Gúrpide3, Jl Pérez Gracia3, S Martín - Algarra3, Jp Fus-
co3, Maria D. Lozano1
1Pathology, Clínica Universidad De Navarra/Spain, 2Oncology, Centre 
For Applied Medical Research/Spain, 3Medical Oncology, Clínica Univer-
sidad De Navarra/Spain
Background: ALK gene rearrangement defines a new molecular 
subtype of NSCLC with response to Crizotinib, (Xalkori®) a dual 
MET and ALK inhibitor. To date, determination of ALK gene rear-
rangements has been performed in biopsies and/or surgical speci-
mens. However, advanced lung cancer is often diagnosed by FNA 
cytology obtained through minimally invasive procedures, and 
frequently cytological specimens are the only samples available. 
We assessed the feasibility of determining ALK gene rearrange-
ments in cytological samples.
Methods: We studied prospectively 53 cytological samples from 
53 NSCLC patients (30 M/23 F) for ALK gene rearrangements by 
FISH (Abbot dual colour break apart probe). Tumour samples were 
obtained by bronchoscopy -FNA in 26 cases (49.1%), EBUS-FNA 
in 7 (13.2%), EUS-FNA in 3 cases (5.7%), CT-FNA in 3 (5.7%), and 
direct FNA in 6 cases (11.3%). Two cavity fluids (3.8%), 4 imprints 
from surgical specimens (7.5%), and 2 cellblocks received for con-
Methods: All available tumor slides from patients with therapy-
naive, surgically resected solitary NSCLCs originally diagnosed 
as SCC (1999-2009) were reviewed. Tissue microarrays were con-
structed with 3 cores (n=480), and immunostaining for p40, p63, 
TTF-1 (clone 8G7G3/1), TTF-1 (SPT24), napsin A, chromogranin A, 
synaptophysin, and CD56 was performed. Immunoreactivity was 
scored semiquantitatively by staining intensity (weak, moderate, or 
strong) and percentage of positive tumor cells (diffuse, ≥50%; fo-
cal, <50%). Tumors were first grouped by p40 and TTF-1 (8G7G3/1) 
status: (1) group A (favor SCC): p40 (+) and TTF-1 (8G7G3/1) (-); (2) 
group B (favor adenocarcinoma): p40 (- or +) and TTF-1 (8G7G3/1) 
(+); and (3) group C (favor large cell carcinoma): p40 (-) and TTF-1 
(8G7G3/1) (-). Immunostain-based tumor classification was then 
confirmed with histologic findings and other markers.
Results: In group A (n=448), 1 tumor was reclassified as adenos-
quamous carcinoma by histologic findings and focal immunoreac-
tivity for p40, p63, and TTF-1 (SPT24). In group B (n=15), 2 tumors 
were reclassified as large cell neuroendocrine carcinoma (LCNEC) 
by neuroendocrine morphologic findings and differentiation (1 
as pure LCNEC and the other as combined LCNEC with SCC). In 
group C (n=17), 6 tumors were confirmed as large cell carcinoma 
because they lacked adenocarcinoma morphology and TTF-1 
[SPT24] expression (2 of these showed focal p63 reactivity without 
keratinization); 4 were reclassified as large cell carcinoma (favor 
adenocarcinoma) because they were focally positive for TTF-1 
(SPT24) but negative for TTF-1 (8G7G3/1) and napsin A; 2 were 
reclassified as adenocarcinoma because they were diffusely and 
strongly positive for TTF-1 (SPT24) but focally (<10%) positive for 
p63, without keratinization; 3 were reclassified as LCNEC by neu-
roendocrine morphologic findings and differentiation; and 2 were 
reclassified as small cell carcinoma by morphologic findings. All 
tumors finally diagnosed as SCC (n=447) using histologic findings 
and immunohistochemical analysis were positive for p40 and p63. 
Among them, 27 tumors were positive for TTF-1 (SPT24) (19 focally 
and 8 diffusely) but negative for TTF-1 (8G7G3/1), with all showing 
clear squamous morphologic pattern, thus verifying the greater 
specificity of the TTF-1 8G7G3/1 clone in SCC.
Conclusion: After immunohistochemical reevaluation of 480 NS-
CLCs originally diagnosed as SCC by classical morphologic analy-
sis, 33 (7%) were reclassified as other histologic types. Immunohis-
tochemical analysis may provide additional valuable information to 
achieve an accurate diagnosis, particularly in poorly differentiated 
NSCLCs and in tumors for which the diagnosis of nonkeratinizing 
SCC is considered.
Keywords: lung, squamous cell carcinoma, p40, TTF-1
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MO26.06 CELL BLOCK SAMPLES FROM ENDOBRONCHI-
AL ULTRASOUND TRANSBRONCHIAL NEEDLE ASPIRATI-
ON (EBUS-TBNA) PROVIDE SUFFICIENT MATERIAL FOR 
ANCILLARY TESTING IN LUNG CANCER.
Phan Nguyen1, Emily Viiret1, Peter Robinson1, Hubertus Jersmann1, 
Brendan Dougherty1, Irfan Birader1, Ian Parkinson2, Kate Francis2, 
David Moffat2
1Thoracic Medicine, The Royal Adelaide Hospital/Australia, 2Surgical 
Pathology, Sa Pathology/Australia
Background: Rapid on site examination (ROSE) is encouraged at 
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chemotherapy with cisplatin or carboplatin plus docetaxel or gem-
citabine. Tumor specimens were available from 95 of these pati-
ents for the analysis of EML4-ALK. EML4-ALK variants 1 and 3 (v1, 
v3) were analyzed by an independent single round of PCR followed 
by sequencing, using cDNA as a sample.
Results: EML4-ALK was detected in 15 samples (15.79%). Nine 
tumors contained v1 (E13;A20) and six v3 (E6;A20). No significant 
differences were found in baseline characteristics between pati-
ents with and without EML4-ALK. Progression-free survival was 
10.4 months (m) for patients harboring the EML4-ALK fusion gene 
compared to 7.1 m for those without EML4-ALK. Overall survival 
(OS) was not reached in patients with EML4-ALK, compared to 22.9 
m in those without. Complete data on outcome according to treat-
ment arm will be presented.
Conclusion: Our findings indicate that the EML4-ALK rearrange-
ment is concomitant with EGFR mutations in a considerable num-
ber of NSCLC patients and may affect outcome.
Keywords: NSCLC, erlotinib, EML4-ALK, EGFR
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MO26.09 PROGNOSTIC IMPACT OF CD204-POSITIVE 
MACROPHAGES IN LUNG SQUAMOUS CELL  
CARCINOMA
ShuNKI Hirayama1, Genichiro Ishii2, Rie Matsuwaki1, Yuki Matsu-
mura1, Keiju Aokage1, Tomoyuki Hishida1, Junji Yoshida1, Kanji 
Nagai1
1Division Of Thoracic Surgery, National Cancer Center Hospital East/
Japan, 2Pathology Division, Research Center For Innovative Oncology, 
National Cancer Center Hospital East/Japan
Background: Stromal cells, including macrophages, lymphocytes 
and fibroblasts, are known to interact with cancer cells and to 
produce a specific microenvironment capable of influencing tumor 
progression. Tumor-associated macrophages (TAMs) are recruited 
into cancer-induced stroma and produce a specific microenviron-
ment for cancer progression. CD204 positive TAMs are reportedly 
related to tumor progression and clinical outcome in some tumors. 
The aim of this study was to clarify the correlation between CD204 
positive TAMs and the clinicopathological features of lung squa-
mous cell carcinoma.
Methods: We investigated the relationships between the numbers 
of CD204 positive TAMs and clinicopathological factors, microves-
sel density (MVD), and the numbers of Foxp3 positive lymphocytes 
in 208 consecutively resected cases. We also examined the rela-
tionships between the numbers of CD204 positive TAMs and the 
expression levels of cytokines involved in the migration and diffe-
rentiation of CD204 positive TAMs.
Results: A high number of CD204 positive TAMs in the stroma 
was significantly correlated with an advanced p-stage, T factor, N 
factor, and the presence of vascular and pleural invasion. A high 
number of CD204 positive TAMs in the stroma was also a signifi-
cant prognostic factor for all p-stages and p-stage I. Moreover, the 
numbers of CD204 positive TAMs were correlated with the MVD 
and the numbers of Foxp3 positive lymphocytes. A high number 
of CD204 positive TAMs was strongly correlated with the tissue 
expression level of MCP-1. CD204 positive TAMs were shown to be 
sultation (3.8%) were also studied. FISH was performed on Papa-
nicolau stained smears in 15 cases (28.3%), non-stained ThinPrep 
in 28 cases (52.8%), cell block in 9 cases (17%), and 1 stained Thin-
Prep. All cases were tested for EGFR and KRAS mutations.
Results: Thirty-seven samples (69.8%) were adequate for FISH ana-
lysis. Three cases (8.1%) had ALK gene rearrangements: positive 
cases were non-smoker women with adenocarcinoma, two of them 
with signet ring cells. One case had a concurrent EGFR mutation in 
exon 21. FISH study was unsuccessful in 16 cases (30.2%): 10 from 
Papanicolau stained smears (62.5%), 5 from unstained ThinPrep 
(31.3%), and 1 from a cell block. Nineteen ThinPrep slides were 
adequate for FISH analysis (86.4%) as well as 8 out of 9 cell blocks. 
Correlation cytological / paraffin embedded samples was perfor-
med in 4 cases with a concordance rate of 100%.
Conclusion: Determination of ALK gene rearrangements in cyto-
logical specimens is feasible. It is mandatory an exquisite manage-
ment and care of the samples to preserve quality. ThinPrep and 
cell blocks are the most suitable samples for FISH analysis, while 
Papanicolau stained smears provide poor results. Coexistence of 
ALK gene rearrangements and EGFR mutations was observed in 
one case, indicating that such alterations are not necessarily mutu-
ally exclusive.
Keywords: ALK, Pathology, NSCLC
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MO26.08 THE CONCOMITANT PRESENCE OF ECHINO-
DERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 
- ANAPLASTIC LYMPHOMA KINASE (EML4-ALK) EML4-
ALK FUSION GENE IN EGFR-MUTANT NON-SMALL-CELL 
LUNG CANCER (NSCLC) PATIENTS TREATED WITH ER-
LOTINIB OR CHEMOTHERAPY IN THE EURTAC TRIAL
Niki Karachaliou1, Carlota Costa1, Ana Gimenez-Capitan1, Ana 
Drozdowskyj2, Radj Gervais3, Alain Vergnenegre4, Filippo De Mari-
nis5, Margarita Majem6, Enriqueta Felip7, Rosario Garcia-Campelo8, 
Teresa Moran9, Santiago Viteri1, Amaya Gasco1, Bartomeu Massu-
ti10, Rafael Rosell9
1Quiron-dexeus University Hospital, Pangaea Biotech, Molecular On-
cology Research (MORE) Foundation/Spain, 2Pivotal/Spain, 3Medical 
Oncology, Centre François Baclesse/France, 4Service De Pneumologie, 
Centre Hospitalier Universitaire De Limoges/France, 5Azienda Ospedali-
era San Camillo-forlanini/Italy, 6Medical Oncology, Hospital De La San-
ta Creu I Sant Pau/Spain, 7Medical Oncology, Hospital Valle Hebron/
Spain, 8Medical Oncology, Complejo Hospitalario A Coruña/Spain, 9Ca-
talan Institute Of Oncology/Spain, 10Medical Oncology, Hospital General 
De Alicante/Spain
Background: Activating mutations in the epidermal growth fac-
tor receptor (EGFR) confer sensitivity to gefitinib and erlotinib in 
patients with NSCLC. However, response is often short-lived, and 
patients ultimately relapse, indicating that other concomitant ac-
tionable mutations could influence outcome in these patients. The 
EML4-ALK fusion gene has recently been identified in a subset of 
NSCLCs, but its specific role remains unclear. We have evaluated 
the frequency and impact of the concomitant presence of EML4-
ALK in patients included in the randomized phase III EURTAC trial.
Methods: The EURTAC study enrolled 173 EGFR-mutant NSCLC 
patients who were randomized to receive erlotinib or standard 
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MO26.12 PROGNOSTIC IMPACT OF MICROSCOPIC VES-
SEL INVASION AND VISCERAL PLEURAL INVASION IN 
NON-SMALL CELL LUNG CANCER
Shinya Neri1, Junji Yoshida1, Genichiro Ishii2, Yuki Matsumura1, 
Keiju Aokage1, Tomoyuki Hishida1, Kanji Nagai1
1Division Of Thoracic Surgery, National Cancer Center Hospital East/
Japan, 2Pathology Division, Research Center For Innovative Oncology, 
National Cancer Center Hospital East/Japan
Background: In non-small cell lung cancer (NSCLC), visceral pleu-
ral invasion (VPI) is incorporated as a staging factor in the current 
TNM classification. Microscopic vessel invasion (MVI: defined coll-
ectively as histological blood vessel invasion and lymphatic per-
meation) has been reported to be a strong independent predictor 
of poor prognosis, but it has not been incorporated in the TNM 
classification. We assessed the prognostic significance of MVI as 
well as VPI.
Methods: Between August 1992 to December 2009, 2657 conse-
cutive patients with pathological T1-4N0-2M0 NSCLC underwent 
complete resection at our institution. We analyzed the prognostic 
significance of MVI for recurrence in addition to the conventional 
prognostic factors. The recurrence-free proportion was estimated 
using the Kaplan-Meier method and differences were analyzed by 
the log-rank test. Cox regression analyses were used to identify 
independent risk factors for recurrence.
Results: The 5-year recurrence-free proportion for patients with 
or without MVI was 52.6% and 87.5%, respectively (p < 0.001). 
On multivariate analysis, MVI, similarly to VPI, was found to be 
an independently significant predictor of recurrence (HR 2.78). In 
1601 patients with pathological stage I disease without adjuvant 
chemotherapy, MVI and VPI were the two strongest independent 
predictors of recurrence on multivariate analysis (HR 2.74 and 1.84, 
respectively). Evident and significant separation of the recurrence-
free proportion curves among the following 3 groups according 
to the number of the two risk factors (VPI and MVI) was observed; 
both VPI and MVI absent (0), either VPI or MVI present (1), and both 
VPI and MVI present (2). We compared the recurrence-free pro-
portion of patients stratified by tumor size and the number of the 
risk factors (0/1/2) (Table 1). The groups of small tumor size without 
PL and MVI showed the best recurrence-free proportions (T1a_0, 
T1b_0, and T2a_0). The T1a_1, T1b_1, and T2a_1 subgroups show-
ed poorer outcomes which were comparable with the T2b_0 sub-
group. The groups with both PL and MVI, even in small tumor size 
groups, resulted in poor outcomes equivalent to that of T3_0/1 
groups. The T3_2 group showed the poorest outcome equivalent 
to the T4 group.
Conclusion: This study demonstrated that MVI was a significantly 
independent risk factor for recurrence in resected T1-4N0-2M0 
NSCLC patients. We propose the T-classification of tumors with 
either MVI or VPI (1) should be upgraded to the next T level and 
that with both MVI and VPI (2) to the second T level (Table 1).  
significant independent prognostic factors in a multivariate analy-
sis.
Conclusion: CD204 positive TAMs were an independent prog-
nostic factor in lung squamous cell carcinoma. CD204 positive 
TAMs, along with other tumor-promoting stromal cells such as re-
gulatory T cells and endothelial cells, may create tumor-promoting 
microenvironments. 
Keywords: CD204, squamous cell carcinoma, Pathology, macro-
phage
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MO26.11 PROPOSAL ON INCORPORATING BLOOD 
VESSEL INVASION INTO THE T CLASSIFICATION PARTS 
AS A PRACTICAL STAGING SYSTEM FOR STAGE I NON-
SMALL CELL LUNG CANCER
Yujin Kudo1, Hisashi Saji1, Yoshihisa Shimada1, Jun Matsubayashi2, 
Masatoshi Kakihana1, Naohiro Kajiwara1, Tatsuo Ohira1, Norihiko 
Ikeda1
1Division Of Thoracic Surgery, Department Of Surgery, Tokyo Medical 
University/Japan, 2Anatomic Pathology, Tokyo Medical University/
Japan
Background: We investigated blood vessel invasion (BVI) as a pos-
sible negative prognostic factor in patients with stage I non-small 
cell lung cancer (NSCLC) according to the 7th Edition of the TNM 
classification.
Methods: Between 1999 and 2007, a total of 694 consecutive 
patients with pathological stage I NSCLC underwent complete 
resection with systematic lymph node dissection at Tokyo Medical 
University Hospital. All sections of the specimens were stained by 
Elastica van Gieson to visualize elastic fibers and were examined to 
determine the prognostic symptoms of BVI. We statistically analy-
zed the association between BVI and clinicopathologic factors, as 
well as clinical outcomes.
Results: BVI was detected in 201 patients with stage I NSCLC 
(29.0%). The 5-year overall survival (OS) rates of the non-BVI and 
BVI patients were 90.5% and 66.0%, respectively (p < 0.0001). BVI 
was found to be a significant independent prognostic factor by 
multivariate survival analysis in stage IA and stage IB NSCLC (HR 
2.591, p < 0.001; HR 2.347, p = 0.009, respectively). The 5-year 
OS rate of patients with BVI was significantly worse than that of 
patients without BVI in the T1a (94.5% vs 87.5%, p < 0.0001), T1b 
(82.7% vs 65.9%, p = 0.034), and T2a (90.9% vs 61.8%, p < 0.0001) 
subgroups.
Conclusion: We identified the presence of BVI as an independent 
poor prognostic factor in patients with stage I NSCLC. In the future 
revision of the TNM staging system, the routine use of elastic fiber 
stains in pathological evaluations of lung cancer for BVI determi-
nation might be recommended, and tumors with BVI should be 
upstaged to the higher current T staging.
Keywords: Elastica van Gieson stain, non-small cell lung cancer, 
Blood vessel invasion, TNM classification
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Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) to 
differentiate multiple lung primary non-small cell carcinomas from 
metastases, the limitations of CHA have been addressed. Lung 
adenocarcinoma in situ is characterized by noninvasive lepidic 
growth. Whether this histological characteristic could be served 
for assessing primary lung cancer has not been well determined. In 
this study we evaluated the application value of CHA and lepidic 
growth component (LGC) in distinguishing multiple primary lung 
cancers from intrapulmonary metastases.
Methods: We retrospectively analyzed a cohort of 23 patients 
with 50 multiple lung tumors. All of the patients have follow up 
data. The histological evaluation was performed according to 
2011 IASLC/ATS/ERS Classification of Lung Adenocarcinoma. The 
percentage of each tumor subtype in each case was recorded. The 
intrapulmonary metastases and multiple primary tumors were dif-
ferentiated based on CHA and LGC (if applicable).
Results: According to CHA alone, there were 11 and 12 cases diag-
nosed as multiple primary tumors and intrapulmonary metastases, 
respectively. Disease-free interval (DFI) of the 11 patients with mul-
tiple primary tumors was ranged from 11 to 110 months and DFI of 
the 12 patients with intrapulmonary metastases was ranged from 
1 to 93 months. There was no statistically significant difference 
between these two types of patients (P=0.362). According to CHA 
with inclusion of LGC, 15 and 8 cases were diagnosed as multiple 
primary tumors and intrapulmonary metastases, respectively. DFI 
of the 15 and 8 cases were ranged from 11 to 110 months and from 
1 to 34 months, respectively. Statistical significance was detected 
(P=0.034). These results suggested that CHA combining with LGC 
might have assessment advantage to distinguish multiple primary 
tumors from intrapulmonary metastases compared to use CHA 
alone. 
Table 1. Incorporation of PL and MVI into T classification
Current 
(7th) T 
Classifi-
cation
Tumor 
Size 
(cm)
No. of 
VPI and 
MVI Risk 
Factors
Recurrence-
free Proporti-
on at 5 Years 
(%)
OurPropo-
salT
T1a ≤ 2 0 92.2 T1
≤ 2 1 72.2 T2
≤ 2 2 58.2 T3
T1b
> 2, 
≤ 3 0 89.6 T1
> 2, 
≤ 3 1 64.8 T2
> 2, 
≤ 3 2 50.9 T3
T2a
> 3, 
≤ 5 0 87.8 T1
> 3, 
≤ 5 1 61.9 T2
> 3, 
≤ 5 2 44.8 T3
T2b
> 5, 
≤ 7 0 75.9 T2
> 5, 
≤ 7 1 49.4 T3
> 5, 
≤ 7 2 47.5 T3
T3 > 7 0 58.2 T3
> 7 1 50.6 T3
> 7 2 38.8 T4
Keywords: non-small cell lung cancer, microscopic vessel invasion, 
visceral pleural invasion, prognostic factor
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MO26.13 SIGNIFICANCE OF LEPIDIC GROWTH COMPO-
NENT IN THE DISCRIMINATION OF MULTIPLE PRIMARY 
LUNG CANCERS FROM INTRAPULMONARY METASTA-
SES
Dongmei Lin1, Wei Sun1, Yu Liu2, Xiangyang Liu3, Ling Shan1, Xin 
Yang1, Fang Lian1
1Department Of Pathology, Cancer Institute And Hospital Of The Chine-
se Academy Of Medical Sciences, Peking Union Medical College/China, 
2Department Of Etiology And Carcinogenesis, Cancer Institute And 
Hospital Of The Chinese Academy Of Medical Sciences, Peking Union 
Medical College/China, 3Department Of Thoracic Surgery, Cancer Insti-
tute And Hospital Of The Chinese Academy Of Medical Sciences, Peking 
Union Medical College/China
Background: The distinction of intrapulmonary metastases from 
multiple primary tumors is of great clinical importance as it influen-
ces staging, prognosis and therapeutic strategy. Although Com-
prehensive Histologic Assessment (CHA) was recommended by 
International Association for the Study of Lung Cancer/American 
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MO26.14 HISTOLOGICAL PROGNOSTIC MARKERS IN 
SQUAMOUS CELL CARCINOMA OF THE LUNG
Alexander Drilon1, Camelia S. Sima2, Paul K. Paik3, Andre L. Mo-
reira4
1Medicine, Memorial Sloan-Kettering Cancer Center/United States Of 
America, 2Biostatistics, Memorial Sloan-Kettering Cancer Center/Uni-
ted States Of America, 3Thoracic Oncology, Memorial Sloan-Kettering 
Cancer Center/United States Of America, 4Pathology, Memorial Sloan-
Kettering Cancer Center/United States Of America
Background: The current IASLC/ERS/ATS classification of pulmo-
nary adenocarcinoma indicates that different patterns of growth 
in adenocarcinoma are associated with prognostic value. There is 
however, very little information concerning histological prognostic 
markers in squamous cell carcinomas of the lung. In contrast to 
adenocarcinoma, squamous cell carcinoma is more homogeneous 
histologically. However, the World Health Organization classifi-
cation of lung tumors recognizes different patterns of growth in 
squamous cell carcinomas. In this study we evaluated several histo-
logical parameters including growth patterns and nuclear features 
and their association with prognosis in a population of stage 1 
squamous cell carcinomas.
Methods: A cohort of 165 stage I squamous cell carcinomas of 
the lung were evaluated. The presence of different histological 
growth patterns such as papillary, infiltrative, pushing borders, 
intraalveolar, pseudo-glandular, basaloid, small nest and presence 
of infiltrating single cells, as well as the cell type (clear cell, transi-
tional, syncytial, and glassy) were evaluated in a semi- quantitative 
manner by recording the percent of each histological pattern or 
cell type with 10% increments totaling 100% for tumor. In addition, 
the presence of peripheral palisading, nuclear features (nuclei size, 
chromatin patterns, nuclear contour, presence of nucleoli, and 
Conclusion: The appearance of adenocarcinoma with LGC might 
indicate lung primaries. Combining with CHA, LGC could potenti-
ally improve diagnosis to differentiate multiple primary tumors and 
intrapulmonary metastases.
Keywords: Lepidic growth, multifocal lung adenocarcinoma, om-
prehensive Histologic Assessment
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MO27.01 OPERABLE LUNG CANCER PATIENTS EXPERI-
ENCES OF REHABILITATION AND SUPPORTIVE NEEDS 
AT DIAGNOSIS. A QUALITATIVE STUDY
Malene Missel1, Jesper H. Pedersen2, Carsten Hendriksen3, Lis 
Adamsen4
1Dept. Of Thoracic Surgery, University Hospital Of Copenhagen/Den-
mark, 2Department Of Thoracic Surgery Rt, Rigshospitalet, University 
Of Copenhagen/Denmark, 3Faculty Of Health And Medical Sciences, 
University Of Copenhagen/Denmark, 4University Centre For Nursing 
And Care Research, Copenhagen University/Denmark
Background: Lung cancer patients have complex problems and 
are considered as disadvantaged when compared with other 
cancer patients. The needs of lung cancer patients during the 
treatment trajectory still remain to be identified systematically. 
The present study is part of a Ph.D. study investigating ’Four criti-
cal moments’ in daily life during disease and treatment trajectory 
in operable lung cancer patients. The Ph.D. study is part of the 
Centre for Integrated Rehabilitation of Cancer Patients – CIRE. The 
present study aims to explore lived experiences at diagnosis of 
operable lung cancer patients in order to identify needs of suppor-
tive and rehabilitative care.
Methods: A sample of nineteen patients is included in the study. 
Inclusion criteria are a diagnosis of non small cell lung cancer refer-
red for surgery at department of Thoracic surgery, Rigshospitalet 
and age above 18. Individual in-depths interviews with a pheno-
menological approach were conducted approximately seven days 
following diagnosis. The phenomenological approach is based on 
the French philosopher Paul Ricoeur. Focus in the interviews is the 
present and deals with themes of patients’ experiences with the 
diagnosis and daily life, bodily experiences, smoking and physical 
activity. Follow-up interviews are performed 14 weeks post surgery 
focusing on the patients return to daily life.
Results: Through the analysis of the narrative interviews, patients‘ 
lived experiences are described in themes such as onset of illness 
with no symptoms; resilience expressed as managing on their own, 
used to be strong and not complaining; psychological response 
expressed as feelings of unreality, trying to push it away and ex-
periences of lack of concentration, lack of energy and excessive 
thoughts; existential thoughts, expressed as a confrontation with 
death, anxiety, loneliness, afraid of the unknown and an emotional 
rollercoaster ride; the continued daily life focusing on continuing 
with usual activities and patterns; disruptions in the social relations 
expressed as withdrawal from social situations or experiences of 
family and friends’ withdrawal from the ill person. Will not be a 
burden or receive compassion from family and friends and will not 
express their vulnerability to family and friends; physical activity as 
a daily activity but not used to exercise; smoking as stress reduc-
tion; supportive needs from a patient perspective such as conver-
sations with healthcare professionals about the whole situation, 
early information about surgery and no need of further written 
information; confidence in the meeting with the health care system; 
uncertain but hopeful about the future.
Conclusion: It is important that health care professionals provide 
mitotic figures), and keratinization were also evaluated. The asso-
ciation of predominant pattern of growth, cell type, and nuclear 
features with recurrence free survival (RFS), characterized by time 
to recurrence or death of disease and overall survival (OS) were 
evaluated.
Results: There were 66 women and 97 men in this population with 
a mean age of 75±9 year old. All patients were smokers. The mean 
follow-up was of 47.8 months (4 years). Among histological growth 
patterns, tumors with predominant papillary and pushing bor-
ders appear to have a slightly better outcome compared to other 
predominant patterns of growth (RFS p=0.05 and OS 0.025). It is 
interesting to note that squamous cell carcinomas with a predomi-
nant basaloid growth pattern, which is considered to be a pattern 
of poor differentiation, did not have worse prognosis copared 
to other features. There was no association of cell type, nuclear 
features, presence of palisading or keratinization with prognosis. 
There was no difference of nuclear features among tumors with 
different growth patterns and cell types.
Conclusion: Squamous cell carcinomas appear to be more homo-
geneous than adenocarcinomas of the lung despite some histolo-
gical variances. Evaluation of several histological parameters like 
growth pattern, cell type, and nuclear features failed to indicate a 
strong association of any of these parameters with prognosis, with 
exception of papillary and pushing border growth patterns that 
when present as predominant patterns of growth were associated 
with a better prognosis. This suggests that contrary to adenocarci-
noma, a histological based grading system may not be easily esta-
blished for squamous cell carcinomas of the lung.
Keywords: squamous cell carcinoma, tumor grade, histologic fea-
tures, Prognosis
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cant difference between treatment groups. However, individuals 
treated with chest tube + pleurodesis had a decrease in treatment 
satisfaction, while individuals who were treated with VATS + Tenck-
hoff (p=0.03) or Tenckhoff alone (p=0.04) reported improvement in 
their treatment satisfaction. LOS was longer for individuals treated 
with chest tube + pleurodesis (median 10 days) and VATS pleuro-
scopy (median 6 days) when compared to VATS + Tenckhoff (medi-
an 3 days) & Tenckhoff catheter alone (median 2 days).
Conclusion: In the management of MPE, patient centered out-
comes are most important. All treatment strategies evaluated in 
this study provided similar improvements in dyspnea, ability to 
perform activities of daily living and QOL. However, Tenchkoff 
catheter treatment strategies offer shorter LOS as well as impro-
ved treatment satisfaction which is important given the limited life 
expectancy of patients with MPE.
Keyword: MPE, QOL, Tenckhoff, Satisfaction with treatment
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MO27.03 RAPPORT BETWEEN CANCER PATIENTS AND 
PHYSICIANS IS A CRITICAL ISSUE FOR PATIENTS‘ SATIS-
FACTION WITH TREATMENT DECISION.
Junko Umihara1, Kaoru Kubota2, Mariko Nishikitani3
1Academic Quality And Development Office, Nippon Medical School/Ja-
pan, 2Pulmonary Medicine And Oncology, Graduate School Of Medicine, 
Nippon Medical School/Japan, 3Environmental Sciences, International 
College Of Arts And Sciences, Fukuoka Womens‘ University/Japan
Background: Cancer patients‘ satisfaction with their treatment 
decision has been proven to be associated with improved health 
outcome, but few studies have been conducted in Japan. Doctor-
centered medicine has been prevailing in the area of cancer treat-
ment in Japan. It has been common among Japanese physicians to 
withhold "bad news“ from patients. Several studies have reported 
that cancer patients were dissatisfied with this situation and desi-
red to participate in the decision -making on their cancer treat-
ments. Such trends led to the enactment of Cancer Control Act in 
2006.The purpose of this law was to establish an environment in 
which cancer patients were informed about their diagnosis ,and 
allowed to participate in making decision on their treatment. In this 
study we hypothesized that cancer patients‘ satisfaction with their 
treatment can enhance their psychological outcomes. Furthermo-
re, we hypothesized that cancer patients‘ satisfaction with their 
treatment was associated with a rapport established by patient-
centered communication with their caregivers. We conducted a 
cross-sectional survey among 576 Japanese cancer patients.
Methods: We conducted cross-sectional questionnaire surveys 
among patients who had received cancer treatment. One source 
was inpatients of a Cancer Center Hospital, and the other a web-
site of Japan‘s biggest newspaper. The questionnaire included 
demographics, and general self-rated life status such as peace of 
mind, quality of life, daily activities, family relationships, rapport 
with attending physician, assessment of physician‘s explanations 
and feeling of happiness during the previous week.
Results: Of 576 participants who responded, 383 subjects were 
satisfied and 193 dissatisfied. The dissatisfied group included 
more females and fewer mandatory retired subjects than did the 
satisfied group. The patients in the more satisfied group had a 
patients with opportunities to talk about their fears, concerns and 
experiences. Through listening to and understanding operable 
lung cancer patients, nurses can identify appropriate resources 
and help patients to access them. Results are expected to contri-
bute to the development and initiation of further interventions for 
lung cancer patients early in the treatment trajectory.
Keyword: Lived experiences, Nursing, rehabilitation, Supportive 
needs
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MO27.02 PATIENT CENTERED OUTCOMES IN THE MA-
NAGEMENT OF MALIGNANT PLEURAL EFFUSION
Susan J. Walker1, Marijana Zubrinic2, Christine Massey1, Yaron 
Shargall1, Eric Bédard3, Gail E. Darling4
1University Health Network/Canada, 2Thoracic Surgery, Toronto Gene-
ral Hospital/Canada, 3Royal Alexandra Hospital/Canada, 4Division Of 
Thoracic Surgery, Toronto General Hospital, University Health Network, 
University Of Toronto/Canada
Background: Malignant pleural effusion (MPE) is common in in-
dividuals with advanced cancers and has an adverse impact on 
respiratory function and quality of life (QOL). Research evaluating 
treatment methods for MPE have focused on medical endpoints 
such as chest x-ray and there are no studies that have evaluated 
patient centered outcomes. Taking into consideration the short life 
expectancy in this patient population at the time of diagnosis, this 
study aims to determine the effect of any of the currently accepted 
treatment methods on QOL and hospital length of stay (LOS).
Methods: A prospective study of patients with a radiologically 
confirmed pleural effusion and an underlying malignancy evalua-
ted patient centered outcomes using the London Chest Activity 
of Daily Living Scale (LCADL), Functional Assessment of Chronic 
Illness Therapy –Palliative (FACIT-PAL) and Functional Assessment 
of Chronic Illness Therapy Treatment Satisfaction (FACIT-TS-G). 
Cytological confirmation of MPE was obtained in the majority of 
patients. Treatment of MPE was determined by the attending phy-
sician. The study was approved by the institutional REB. Patients 
who were unable to read or speak English were excluded from the 
study. After providing informed consent, patients completed the 
questionnaires (LCADL, FACIT-PAL and FACIT-TS-G) prior to treat-
ment, immediately post treatment and 2 and 6 weeks post treat-
ment. Spearman correlation coefficients were calculated with 95% 
confidence intervals and p-values were utilized to assess linear re-
lationships between QOL measurements. Mixed model regression 
analysis was used to estimate linear trends in LCADLS, FACIT-PAL, 
FACIT-TS Recommendation and FACIT-TS Satisfaction scores in the 
entire cohort and between treatment groups. Mean QOL scores 
at measurement time points were plotted in order to assess trends 
over time for both the entire cohort and for treatment groups.
Results: There were 105 study participants from 4 hospitals with a 
median age of 61 years (range 26-89 years). Lung cancer was the 
most common underlying malignancy, followed by breast and gas-
trointestinal cancers. MPE was treated by chest tube + pleurodesis 
(n=39), Tenckhoff catheter alone (n=27), VATS + Tenchkoff (n=20) 
and VATS + pleurodesis (n=17). In analyzing the entire cohort, the-
re was an overall improvement in shortness of breath (p<0.0001), 
ability to perform activities of daily living (p=0.03) and quality of 
life (p<0.0001) for all treatments. There was no statistically signifi-
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MO27.06 FEASIBILITY OF MEASUREMENT OF FUNC-
TION IN ADVANCED CANCER: COMPARISON OF THE 
6-MINUTE WALK TEST, 2-MINUTE WALK TEST, ISOMET-
RIC ARM EXERCISES AND READING NUMBERS ALOUD.
Meera Agar1, Kahren White2, David Currow3
1Department Of Palliative Care, Braeside Hospital/Australia, 2Private 
Consultant Occupational Therapist/Australia, 3Department Of Palliati-
ve And Supportive Services, Flinders University/Australia
Background: The pattern in which functional decline in people 
living with advanced cancer occurs has been described as an initial 
period of reasonably stable function, followed by more rapid func-
tional deterioration with a defined terminal phase. However little 
is known about the more subtle changes in function in the more 
advanced stages of cancer, and the role that breathlessness plays 
in functional changes. The aim of this pilot study is to compare 
the feasibility of conducting a range of standardised assessments 
at different levels of performance status in people with advanced 
cancer.
Methods: A consecutive cohort was recruited to a cross sectional 
study from three large palliative care units in metropolitan Sydney. 
Participants completed four breathlessness-inducing assessments: 
Six-minute Walk Test, Two-minute Walk Test, Isometric Upper limb 
Exercises and Reading Numbers Aloud. Performance status was 
assessed using the Australian Modified Karnofsky Performance 
Scale, Eastern Cooperative Oncology Group Performance Scale 
and Life-Space Assessment. Comorbidity was identified using 
the Charlson Comorbidity Index. Four scales were used to assess 
breathlessness in each participant: Medical Research Council Dys-
pnoea Scale, Intensity and Unpleasantness of Breathlessness Visual 
Analogue Scales and Numerical Rating Scale for Breathlessness.
Results: The results of the pilot study have allowed a compari-
son of the four methods of breathlessness-inducing assessments 
by functional status in 37 people with advanced cancer. Median 
scores for performing breathlessness-inducing assessments by 
level of function where ≥80% of people could complete the as-
sessments will also be presented.
Conclusion: This oral presentation will highlight the pilot study re-
sults and the feasibility of using these assessments in research and 
clinical practice, to improve the assessment of functional capacity 
and breathlessness in people living with advanced cancer. There 
is currently limited evidence into how function can be assessed in 
advanced cancer when breathlessness is present. This study adds 
to the evidence and knowledge base around the assessment of 
function in people living with advanced cancer.
Keyword: Performance status, breathlessness, function, assess-
ment
more favorable subjective opinion on their recent life. Assessment 
of physician‘s role showed significant differences between the two 
groups; the patients in the satisfied group felt more than those in 
the dissatisfied group that the doctor‘s explanations of treatment 
were sufficient and were satisfied with the rapport with their doc-
tors. Multiple logistic regression analysis revealed that rapport 
with their doctors showed a significant odds ratio (3.79, 95% CI, 
2.25-6.39).
Conclusion: Cancer patients‘ well-being is associated with treat-
ment satisfaction. Rapport between physicians and patients is the 
most important key factor for patients‘ satisfaction with their treat-
ment decision.
Keywords: Cancer patients‘ well-being, Treatment decision, Rap-
port
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MO27.04 DELIVERING BETTER SUPPORTIVE CARE TO 
PEOPLE WITH LUNG CANCER: AN EXPLORATION OF 
THE USE OF A PATIENT-REPORTED OUTCOME MEASU-
RE IN CLINICAL NURSING PRACTICE
John Mcphelim1, Roma Maguire2, Constantina Papadopoulou2, 
Grigorios Kotronoulas2, Mhairi Simpson1, Lynn Irvine1
1Cancer Division, Hairmyres Hospital/United Kingdom, 2Cancer Care 
Research Team, University Of Dundee/United Kingdom
Background: Supportive care needs (SCNs) of people with lung 
cancer (LC) are highly prevalent; yet, are often unrecognised and 
unmet. Patient Reported Outcome Measures (PROMs) are a way of 
identifying the SCNs of people with lung cancer in clinical practice. 
Objectives: To explore the use of PROM‘s by lung cancer nurse 
specialists (LCNS) in the delivery of supportive care to people with 
LC.
Methods: A mixed-methods study design was used. Patients 
(N=20) were recruited from 3 sites in Scotland and took part in 
the study over 3 time-points: baseline (T1), one month (T2), two 
months (T3). At each time point, patients completed the Sheffield 
Profile for Assessment and Referral to Care (SPARC) and used the 
PROM to direct consultations with their LCNS (N=3). End of study 
interviews explored patients’/clinicians’ experiences of using the 
SPARC in the delivery of supportive care.
Results: SCNs were highly prevalent at baseline. A significant re-
duction in overall psychological and spiritual needs from T1-T2, 
and family/social and treatment concerns from T1- T3 was recor-
ded. The use of the SPARC resulted in patients disclosing needs 
that they would not have previously raised and promoted them to 
ask questions about their condition/care. LCNSs perceived that 
using the SPARC to guide consultations resulted in patients dis-
cussing a wider array of SCNs particularly sensitive issues such as 
death/dying, concerns regarding family/carers, and sexuality.
Conclusion: Our findings demonstrate the feasibility and accep-
tability of the use of PROMs in the delivery of supportive care to 
people with LC in clinical practice.
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MO27.08 NEEDS ASSESSMENT OF ADVANCED LUNG 
CANCER PATIENTS - EVOLUTION OVER A DECADE?
Dianne Zawisza1, Valari Ali1, Sarvar Djalalov1, Milan Patel2,  
Stephanie Lin1, Roxana Tudor1, Lisa Le1, Natasha Leighl1
1Medical Oncology, Princess Margaret Cancer Centre/Canada, 2Trillium 
Health Centre/Canada
Background: Lung cancer patients continue to experience high-
er symptom distress than others with different cancer types. We 
assessed changes in the needs and symptoms of advanced lung 
cancer patients over a 10 year period.
Methods: Consecutive outpatients with advanced lung cancer 
attending thoracic oncology clinics at a major Canadian cancer 
centre were invited to complete a 25-item self-administered ques-
tionnaire assessing physical and psychosocial symptoms, functio-
nal impairment, cancer knowledge and information preferences. 
Patients were surveyed over 6 months in 2002, and a second co-
hort surveyed over 3 months in 2012. Summary data and relevant 
changes over time are presented here.
Results: 108 advanced lung cancer patients were surveyed in 
2002, and 100 in 2012. Fatigue, cough, and shortness of breath are 
the most common physical symptoms, affecting over one-third of 
patients on a frequent or constant basis. Significant anxiety was 
reported by 27% in 2002, 20% in 2012, and 15% reported depres-
sion, unchanged over time. Lung cancer or treatment-related sym-
ptoms impair daily activities in approximately two-thirds of pati-
ents. More than a third experience significant financial hardship, 
and 62% believe their lung cancer imposed significant hardship 
on their family. More patients in 2012 reported receiving advice 
on symptom management, information on the goals and benefits 
of cancer therapy, and an understanding of clinical trials. However 
a quarter of patients still perceived that they received little to no 
advice on symptom management, and 19% felt uninformed about 
treatment goals for their advanced lung cancer. Despite advances 
in palliative care, less than 20% discussed their end-of-life care 
wishes with their healthcare team, even though ~40% had speci-
fic wishes or plans, with no change over 10 years. In 2002, most 
advanced lung cancer patients preferred to receive information in 
print media. In 2012, while most would still be interested in print 
media, significantly more were interested in a telephone helpline 
(~60%). Half of patients indicated they would not use internet-
based resources even if readily available in 2002, but this number 
did not change over time (46% in 2012).
Conclusion: Advanced lung cancer patients continue to experi-
ence a significant burden of physical and psychosocial symptoms, 
with no decrease in this burden over time despite perceived 
advances in treatment and support. Patients are more informed 
about symptom management and treatment goals than a decade 
ago, although a significant number still require more informati-
on. Patients with advanced lung cancer also need greater em-
powerment and support from their oncology team in advanced 
care planning. Printed information continues to be preferable to 
internet-based resources for the majority of advanced lung cancer 
patients, and a growing number are interested in telephone help-
line support.
Keywords: patient education, Advanced lung cancer, needs as-
sessment, symptom burden
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MO27.07 HOLISTIC NEEDS ASSESSMENT - WHAT THE 
PATIENT DOESN‘T TELL US
Josie Roberts1, John White2
1Rotherham District Hospital/United Kingdom, 2The National Lung 
Cancer Forum For Nurses/United Kingdom
Background: All cancer survivors should have a personalised 
assessment and care plan, and support to self manage their con-
dition (UK DoH 2010) The SPARC (Sheffield Profile for Assessment 
and Referral to Care) is a tool designed to be completed by the 
patient, with support from carers if needed, and forms the starting 
point for the holistic needs assessment process. SPARC is a scree-
ning questionnaire that explores a variety of issues and may help 
the patient/carers to reflect on their needs. The SPARC assessment 
tool was evaluated for its application utilising lung cancer patients 
who attended the Lung Cancer Clinic in Rotherham from 2011-
2012.
Methods: 100 patients responses utilising the SPARC assessment 
tool were analysed at various time points of their pathway inclu-
ding diagnosis, post treatment, disease recurrence and 5 years 
post discharge.
Results: The results analysed were in the domains of physical sym-
ptoms, communication and information issues, treatment issues, 
psychological symptoms and distress thermometer outcomes. Key 
results showed that: - all patients suffered with common symp-
toms from lung cancer; - were mostly concerned about the effect 
that their illnes was having on their family or other people; - many 
required input to help with their personal affairs; - psychological 
symptoms were evident in a significant proportion of patients; - 
the distress thermometer was an appropriate tool in this clinic. The 
results will be shown in detail in the poster.
Conclusion: The SPARC assessment tool is an efficient and valida-
ted audit tool for assessing patient concerns and to provide feed-
back to the patients healthcare team. In Rotherhamm the tool will 
continue to be utilised and evaluated and is offered to all patients 
at the first post treatment phase and when no further active treat-
ment is planned. The tool is an appropriate audit tool for assessing 
patient concerns and to provide feedback to clinicians and com-
munity health care teams.
Keywords: Lung cancer, assessment tool, lung cancer nurse  
specialist
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the UK and could be adapted for use in other countries.
Keywords: Lung cancer, Thoracic surgery, follow up, guideline
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MO27.09 GUIDELINE FOR TELEPHONE FOLLOW UP FOR 
PATIENTS UNDERGOING 
THORACIC SURGERY
John White1, Angela Longe1, Vanessa Beattie2
1United Kingdom National Lung Cancer Forum For Nurses/United 
Kingdom, 2Aintree Chest Centre, University Hospital Aintree/United 
Kingdom
Background: Lung cancer affects nearly 41, 500 people per year in 
the United Kingdom (UK) of which 5000 (12%) will undergo major 
lung resection for primary lung cancer with approximately 15% of 
all patients having complications post operatively. Once the pati-
ent develops a post surgical pulmonary complication mortality in-
creases from 0.5% to 12%, ITU admission rate increases from 1.5% 
to 26% and the length of stay increases from 5 to 14 days. The UK 
National Lung Cancer Forum for Nurses have produced a Guideli-
ne for Telephone Follow Up for Patients Undergoing Thoracic Sur-
gery . The aim of the Guideline is to help to provide a telephone 
follow up service to patients to reduce rates of re-admission and  
to improve patients satisfaction of their care. The guideline was 
produced following an audit of patients who had undergone  
thoracic surgery and a consensus of expert opinion within the  
thoracic surgical speciality.
Methods: In 2012 a retrospective audit of patients who had lung 
surgery was undertaken by UK National Lung Cancer Forum for 
Nurses Thoracic Surgical Group (TSG) in 2012 to assess the timing 
of intervention after discharge and what assessments would be im-
portant to patients. Following a literature review, opinions gathe-
red from Thoracic Surgeons (who worked with the TSG members) 
and other Lung Cancer Nurse Specialists an assessment was made 
on how best to support patients after lung surgery. The guideline 
was developed through regular meetings of the TSG and was de-
veloped following the audit, literature review and consideration of 
the expert views provided.
Results: The audit data was collected from 147 patients from 
across four Thoracic Surgical Centres in the UK and received 439 
comments and focused specifically on post-operative care. The 
data showed that the consensus opinion from patients was that a 
preferred interval for post-operative assessment by telephone was 
between two and seven days after discharge and provided infor-
mation on the aspects of care that were important to them. The 
aspects of care that were important to patients included wound 
management, pain, breathlessness, activity, anxiety, constipation, 
fatigue and sleep. Following the literature review and expert opini-
on gathered from Thoracic Surgeons and Clinical Nurse Specialists 
the decision was made to produce the Guideline for Telephone 
Follow Up for Patients Undergoing Thoracic Surgery for which can 
be used by any health professional. The guideline includes assess-
ment tools and interventions utilising best available evidence to 
assist in the identification of concerns or problems that a patient 
may face after thoracic surgery. The full guideline can be found at 
www.nlcfn.org.uk
Conclusion: This guideline aims to help support health professio-
nals in the provision of a follow up service to patients after thoracic 
surgery. The audit of patients who had undergone lung surgery 
helped to focus on the problems that patients had identified as 
being important to them and, together, with best available evi-
dence and expert consensus opinion allowed the development of 
this guideline. The guideline is being utilised in thoracic centres in 
S426 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
in NP1 stable transfectants upon the addition of VEGF, while neu-
tralising antibodies to VEGF inhibited this effect. Expression levels 
of pAkt protein was significantly increased following treatment of 
cells with VEGF, with little or no effect on the pErk1/2 pathway. 
Tumour growth was significantly increased in mice injected with 
NP1-overexpressing cells (p=0.0052). HDAC inhibitors increased 
VEGFR1 and VEGFR2 and downregulated NP1 and NP2 expressi-
on. Significant inhibition in proliferation of NP1-positive lung can-
cer cells was associated with a decrease in the NP1 receptor at the 
mRNA and protein levels.
Conclusion: We demonstrate that VEGF is an autocrine survival 
factor for NSCLC cells, mediating its effects through the Neuro-
pilin-1 receptor. Combining anti-VEGF therapies with HDAC inhi-
bitors may offer potential as a promising avenue for future clinical 
research in the treatment of NSCLC.
Keywords: Targeted therapy, VEGF, Neuropilin, Cell survival
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P1.01-002 CLINICOPATHOLOGICAL AND BIOLOGICAL 
SIGNIFICANCE OF EPIREGULIN EXPRESSION IN NON-
SMALL CELL LUNG CANCER
Noriaki Sunaga1, Yoshio Tomizawa2, Kimihiro Shimizu3, Hisao 
Imai1, Gen Takahashi2, Seiichi Kakegawa4, Yoichi Ohtaki3, Tos-
hiteru Nagashima3, Osamu Kawashima4, David S. Shames5, Luc 
Girard6, Junichi Soh7, Mitsuo Sato8, Kyoichi Kaira1, Takeshi Hisa-
da1, Adi F. Gazdar6, John Minna6, Masanobu Yamada1
1Medicine And Molecular Science, Gunma University School Of Medicine/
Japan, 2Respiratory Medicine, Nishigunma National Hospital/Japan, 3Tho-
racic And Visceral Organ Surgery, Gunma University School Of Medicine/
Japan, 4Thoracic Surgery, Nishigunma National Hospital/Japan, 5Onco-
logy Biomarker Development, Genentech Inc/United States Of America, 
6Hamon Center For Therapeutic Oncology Research, University Of Texas 
Southwestern Medical Center At Dallas/United States Of America, 7Tho-
racic Surgery, Okayama University Hospital/Japan, 8Respiratory Medicine, 
Nagoya University Graduate School Of Medicine/Japan
Background: KRAS mutations are one of the most common driver 
mutations in non-small cell lung cancer (NSCLC) and efficient thera-
peutic stratergies for oncogenic KRAS-driven NSCLC are urgently 
needed. We recently identified epiregulin (EREG) as one of several 
putative transcriptional targets of oncogenic KRAS signaling in 
KRAS-mutant NSCLC cells and immortalized bronchial epithelial 
cells expressing ectopic mutant KRAS. In the present study, we 
assessed clinicopathological and biological significance of EREG 
expression in NSCLC.
Methods: Seventy-eight lung cancer cell lines (23 small cell lung 
cancers [SCLCs] and 35 NSCLCs), five noncancerous bronchial epi-
thelial cell lines and 174 surgical specimens from NSCLC patients 
(136 adenocarcinomas and 38 squamous cell carcinomas) were used 
for EREG expression analysis by real-time RT-PCR methods. In vitro 
cell growth was evaluated by MTT assay, colony-formation assay in 
liquid culture and soft agar assay. Apoptosis was evaluated by the 
DNA fragment detection method and the annexin-V-fluorescein 
staining method. The Kaplan-Meier method was used for analysis of 
disease-free survival (DFS) and overall survival (OS) and log-rank test 
was used for survival differences. Cox proportional hazards model 
was used to identify independent prognostic factors for PFS  
and OS.
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P1.01-001 VEGF IS AN AUTOCRINE SURVIVAL FACTOR 
IN NON-SMALL CELL LUNG CANCER, MEDIATING ITS 
EFFECTS VIA THE NEUROPILIN-1 RECEPTOR.
Martin P. Barr1, Steven G. Gray1, Kathy A. Gately1, Kenneth 
O‘Byrne2
1Clinical Medicine, St James‘s Hospital & Trinity College Dublin/Ireland, 
2Queensland University Of Technology, Cancer & Ageing Research Pro-
gram/Australia
Background: The VEGF pathway has become an important thera-
peutic target in lung cancer. In Phase III trials, blocking VEGF using 
Bevacizumab (Avastin®) has yielded improved progression-free 
and overall survival in NSCLC patients when combined with stan-
dard chemotherapy, demonstrating the use of VEGF as a target 
for therapy. In this study, we examined the mechanisms of VEGF-
mediated survival in NSCLC.
Methods: NSCLC cells (H460, H647, A549 and SKMES-1) were 
screened for expression of VEGF and its receptors at the mRNA 
and protein levels. The effect of recombinant VEGF (100ng/ml) and 
its blockade using neutralising antibodies (1µg/ml) on lung tu-
mour cell proliferation (BrdU) and cell cycle (FACS) was examined. 
Phosphorylation of Akt and Erk1/2 proteins was examined by High 
Content Analysis (HCA) and confocal microscopy. The effects of 
silencing VEGF (100nM siVEGF)) on cell proliferation and survival 
signalling were assessed using BrdU and Western blot analysis, 
respectively. The role of NP1 in cell proliferation (BrdU), apoptosis 
(HCA) and cell survival signalling was also examined. A NP1 sta-
ble transfected H460 cell line (NP1-negative) was generated and 
NP1 overexpression verified at the mRNA (RT-PCR) and protein 
(Western Blot) levels relative to empty vector controls (EVC). Cell 
proliferation, pAkt and pErk1/2 levels were assessed in response to 
recombinant VEGF and VEGF antibodies. Tumour growth studies 
were carried out in female Balb/c nude mice following subcutane-
ous injection of NP1-overexpressing cells (n=8) and EVC control 
cells (n=8). The role of epigenetic modifications in the regulation 
of VEGF and its receptors was also examined using the histone 
deacetylase (HDAC) inhibitors, Trichostatin-A (TSA) and Virinostat 
(SAHA).
Results: VEGF increased proliferation of NP1-expressing NSCLC 
cells (H647, A549 and SKMES-1). Blocking VEGF inhibited VEGF-
mediated proliferation and induced growth arrest in the G0/
G1 phase of the cell cycle. Phosphorylation of Akt and Erk1/2 
proteins was significantly upregulated in response to VEGF, while 
antibodies to VEGF inhibited this effect. VEGF siRNA significantly 
inhibited lung tumour cell proliferation and decreased phospho-
rylation of pAkt and pErk1/2. NP1 blockade significantly inhibited 
proliferation and apoptosis of NP1-expressing NSCLC cells, with 
no effect on the NP1-negative cell line, H460. Cell proliferation 
was significantly decreased in response to NP1 siRNA. Stable 
transfection of H460 cells with NP1 pcDNA significantly increased 
proliferation relative to EVC cells. This effect was further increased 
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(NSCLC). This analysis also identified Axl, a receptor tyrosine 
kinase, as a novel target for mesenchymal lung cancers. Here, we 
conducted an integrated molecular analysis of EMT in resected, 
treatment-naïve tumors from three clinical cohorts, including the 
Cancer Genome Atlas (TCGA) lung adenocarcinomas (LUAD) and 
squamous cell carcinomas (LUSC), with particular focus on Axl as a 
potential target in mesenchymal NSCLC.
Methods: Using our 76-gene EMT signature, TCGA patient tumors 
(230 LUAD, 178 LUSC) and a large MDACC cohort of resected tu-
mors (n=279) were assigned an “EMT score.” Expression of >160 
total and phosphoproteins were measured in the tumors by rever-
se phase protein array (RPPA). Proteomic profiles and other mole-
cular markers (including mutation status, miRNA expression, and 
copy number) were correlated with EMT scores and Axl expression 
levels.
Results: The EMT score, derived from our EMT signature, identi-
fied NSCLC tumors with mesenchymal gene expression signatures 
(average 23% of tumors across all cohorts, range 14-34%). In both 
LUAD and LUSC, EMT scores were highly correlated with (1) ex-
pression levels of the miR200 family, a group of miRNAs previously 
known to regulate EMT (p-values <0.001 by Pearson correlation) 
and (2) levels of proteins central to EMT (e.g., E-cadherin, alpha-
catenin, beta-catenin, claudin-7, fibronectin; p<0.001 for all). 
Mesenchymal tumors also had lower expression of TTF1 in LUAD 
(p=0.0002) and lower p63 in LUSC (p=0.003). Although pEGFR le-
vels were higher in epithelial LUAD tumors (p=0.01), the frequency 
of EGFR mutations was not significantly higher in this group. EMT 
score was not associated with smoking status. Consistent with our 
previous findings in cell lines and patients with advanced NSCLC 
(BATTLE trial), protein expression of the receptor tyrosine kinase 
Axl was significantly higher in tumors with mesenchymal signatu-
res (high EMT scores) and with low E-cadherin protein expression 
(p<0.005 for both). The inverse correlation between tumor E-cad-
herin and Axl expression was confirmed in an independent group 
of NSCLC cases by immunohistochemistry. Although a small num-
ber of Axl mutations were observed (<3% of tumors), few occurred 
in the kinase domain and their biological significance is unknown. 
Other potential therapeutic targets expressed at higher levels in 
mesenchymal lung cancers included PKC-alpha, NFKB, and FGFR1.
Conclusion: The EMT gene expression signature performed well 
in the TCGA LUAD, TCGA LUSC, and MDACC cohorts, correlating 
strongly with established markers of EMT on other data platforms 
(miRNA and protein). We observed strong protein expression of 
the receptor tyrosine kinase Axl (as well as other targets) among 
mesenchymal tumors, supporting further investigation of AXL as a 
potential EMT target and into the mechanism of its overexpression 
in NSCLC.
Keywords: NSCLC, Epithelial-Mesenchymal Transition, Axl, TCGA
Results: EREG is predominantly expressed in NSCLC lines har-
boring KRAS, BRAF or EGFR mutations whereas most SCLC lines 
lack EREG expression. Small interfering RNAs (siRNAs) targeting 
against these mutations resulted in down-regulation of EREG 
expression in NSCLC cells. EREG expression was significantly 
reduced by treatments with the inhibitors of MEK or ERK in EREG-
overexpressing NSCLC cell lines, irrespective of mutation status of 
KRAS, BRAF and EGFR. EREG expression significantly correlated 
with KRAS copy number in KRAS-mutant NSCLC cell lines whereas 
EREG expression significantly correlated with EGFR copy num-
ber in NSCLC cell lines with wild-type KRAS/BRAF/EGFR. In the 
analysis of surgical specimens from NSCLC patients, EREG was 
predominantly expressed in lung adenocarcinomas. In a subgroup 
of adenocarcinomas, EREG expression was significantly higher in 
the tumors from elderly patients (≥70-year-old), males and smokers 
and was higher in the tumors with pleural involvement-, lymphatic 
permeation- or vascular invasion-positive. EREG was highly ex-
pressed in lung adenocarcinomas with KRAS mutation compared 
to those with EGFR mutation or wild-type EGFR/KRAS. Lung ade-
nocarcinoma patients with high EREG expression had significantly 
shorter DFS and OS compared to those with low EREG expression. 
When the patients were divided into four groups according to 
EREG expression levels and KRAS mutation status, DFS and OS 
were significantly shorter in the patients with KRAS-mutant/EREG-
high than those with wild-type KRAS/EREG-low. Cox regression 
analysis demonstrated that elevated EREG expression was an 
unfavorable prognostic factor. siRNA-mediated EREG silencing 
inhibited anchorage-dependent and -independent growth and 
induced apoptosis in KRAS-mutant and EREG-overexpressed lung 
adenocarcinoma cells.
Conclusion: Our findings suggest that oncogenic KRAS-induced 
EREG overexpression contributes to an aggressive phenotype and 
unfavorable prognosis in lung adenocarcinoma patients, and EREG 
could be a promising therapeutic target in oncogenic KRAS-driven 
NSCLC.
Keyword: Epiregulin, KRAS, EGFR, NSCLC
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P1.01-003 TARGETING EMT IN LUNG CANCER: AN IN-
TEGRATED ANALYSIS OF AXL AND OTHER MESENCHY-
MAL TARGETS IN THE CANCER GENOME ATLAS (TCGA)
Lauren A. Byers1, Lixia Diao2, Jing Wang2, Don L. Gibbons1, Gordon 
Robertson3, Robert Cardnell1, Fatemeh Masrorpour1, Youhong 
Fan1, Jaime Rodriguez4, Ximing Tang4, John N. Weinstein2, John D. 
Minna5, Ignacio I. Wistuba4, Gordon B. Mills6, John V. Heymach1
1Thoracic/head & Neck Medical Oncology, The University Of Texas MD 
Anderson Cancer Center/United States Of America, 2Bioinformatics & 
Comp Biology, The University Of Texas MD Anderson Cancer Center/
United States Of America, 3Echelon Building, Canada‘s Michael Smith 
Genome Sciences Centre/Canada, 4Translational Molecular Pathology, 
The University Of Texas MD Anderson Cancer Center/United States Of 
America, 5Hamon Center For Therapeutic Oncology Research, The Uni-
versity Of Texas Southwestern Medical Center/United States Of Ame-
rica, 6Systems Biology, The University Of Texas MD Anderson Cancer 
Center/United States Of America
Background: We previously developed a 76-gene signature of 
epithelial-to-mesenchymal transition (EMT) that predicted resis-
tance to EGFR and PI3K inhibition in non-small cell lung cancer 
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P1.01-005 EGFR AND KRAS MUTATIONS IN PATIENTS 
HAVING LUNG ADENOCARCINOMA ASSOCIATED WITH 
HUMAN PAPILLOMA VIRUS INFECTION
Andres F. Cardona1, Rafael Rosell2, Carlos Vargas1, Hernán Carran-
za1, Pilar Archila3, Jorge M. Otero1, July Katherine Rodriguez3, Os-
car Arrieta4, Claudio Martin5, Luis Más6, Luis Corrales-Rodriguez7, 
Guillermo Bramuglia8, Mauricio Cuello9, Zulay Pastrán10, Elizabeth 
Curcio11, Leonardo Rojas4, Laura Bernal1, Petros Giannikopoulos12
1Clinical And Traslational Oncology Group, Fundación Santa Fe De 
Bogotá/Colombia, 2Medical Oncology, Catalan Institute Of Oncology/
Spain, 3Fundation For Clinical And Applied Cancer Research – Ficmac/
Colombia, 4Thoracic Oncology Clinic And Laboratory Of Experimental 
Oncology, Instituto Nacional De Cancerología (INCAN)/Mexico, 5On-
cology, Alexander Fleming/Argentina, 6Clinical Oncology, Instituto De 
Enfermedades Neoplásicas/Peru, 7Medical Oncology, Hospital San Juan 
De Dios-ccss/Costa Rica, 8Fundación Investigar/Argentina, 9Clinical 
Oncology, Hospital De Clínicas, Udelar/Uruguay, 10Clinical Oncology, 
Policlínica Metropolitana/Venezuela, 11Grupo De Trabajo De Oncologia 
Médica/Venezuela, 12Cancer Therapeutics Innovation Group/United 
States Of America
Background: Many studies have reported the presence of human 
papilloma virus (HPV) primary oncoproteins in lung cancer pati-
ents. Their detection depends on histological and geographical 
patterns and seems to be associated with the response obtained 
to EGFR inhibitors.
Methods: Information regarding 84 patients suffering lung ade-
nocarcinomas and EGFR mutations and another 48 patients lacking 
them (including 7 KRAS carriers) was explored for the presence of 
HPV16 in paraffin-embedded tumour tissue using INNO-LiPA PCR-
based assays. The results were correlated with clinical characteris-
tics and multiple outcomes, including response rate, progression-
free survival (PFS) and overall survival (OS).
Results: Mean age was 59.9 years (+/- 12.2) and HPV16 infection 
positivity was 39% (N=52). HPV was predominant in females 
(N=42; p=0.032), no differences being found regarding histologi-
cal pattern (p=0.72) or having a background of smoking (p=0.54). 
62% of the patients had EGFR exon 19 deletions and 22.6% the 
L858R mutation. Changes in exon 19 were positively related to 
the presence of HPV16 (p=0.043), differently to the exon 21 mu-
tation (p=0.3). Overall response rate to tyrosine -kinase inhibitors 
in EGFR mutation carriers’ was 65%, stable disease was 31% and 
clinical benefit 86.5%. Positive differences were found for respon-
se according to HPV virus status (p=0.03). PFS rate was greater in 
patients who were EGFR+/HPV+ compared to the EGFR+/HPV- po-
pulation (p=0.014). Likewise, OS was longer for the EGFR+/HPV+ 
population compared to the EGFR+/HPV- population (34 months 
versus 24 months; p=0.0001). OS was also longer for HPV+ pati-
ents in the absence of EGFR mutations (p=0.001). The presence of 
HPV also discriminated OS in the small cohort of KRAS+ patients.
Conclusion: The present study has documented a high HPV posi-
tivity rate in Hispanic patients suffering lung adenocarcinoma. The 
presence of viral DNA can thus be presumed to be a positive pro-
gnostic factor for EGFR and KRAS mutated patients, thereby lea-
ding to considering infection as a dominant part of carcinogenesis 
amongst non-smokers in Latin America.
Keyword: HPV, carcinogenesis, lung cancer, EGFR mutations
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P1.01-004 ROLE OF THE EXTRACELLULAR MATRIX IN 
VARIATIONS OF INVASIVE PATHWAYS IN LUNG CAN-
CERS
Vanessa K. De Sa1, Lina Carvalho2, Ana Alarcão2, Patricia Coucei-
ro2, Ana Gomes2, Vera L. Capelozzi1
1Pathology, Faculdade De Medicina Da Universidade De SÃo Paulo/Bra-
zil, 2Patholohy, Universidade De Coimbra/Portugal
Background: Among the most common features of highly invasive 
tumors, such as lung adenocarcinomas (AD) and squamous cell 
carcinomas(SqCC), is the massive degradation of the extracellular 
matrix (ECM); and the remarkable qualitative and quantitative mo-
difications of hyaluronidases (HAases), hyaluronan sinthases (HAS), 
E-cadherin adhesion molecules, and the transformer growth factor 
β (TGF-β) may favor invasion, cellular motility, and proliferation.
Methods: We examined HAases proteins (Hyal), HAS, E-cadherin, 
and TGF-β profiles in lung AD subtypes and SqCC obtained from 
smokers and nonsmokers.Fifty-six patients, mean age 64 years, 
who underwent lobectomy for AD (n = 31) and SqCC (n = 25) were 
included in the study.
Results: HAS1, 2 and 3, and Hyal 1 and 3 were significantly more 
expressed by tumor cells than normal and stroma cells (P<0.01) . 
E-cadherin and TGF-β immunostaining indices were significantly 
increased in the tumour cells compared to stroma cells (p<0.01). 
When stratified according to histologic types, HAS3 and Hyal 1 
immunoreactivity was significantly increased in tumour cells of AD 
(p = 0.01) and stroma of SqCC (p = 0.002), respectively. Tobacco 
history in patients with AD was significantly associated with in-
creased HAS 3 immunoreactivity in tumour cells (p<0.01). Stroma 
cells of SqCC from non smokers patients presented a significant 
association with HAS3 (p<0.01). A positive association was found 
between TGF-β in tumor cells and HAS2 in stroma cells (R = 0.40, 
p= 0.03), Hyal 3 and HAS1 in stroma cells (R = 0.58 p = 0.02), Hyal 
1 in tumor cells and HAS1 in stroma cells (R: 0.44, p = 0.01), Hyal 3 
and HAS1 in tumor cells (R: 0.35, p = 0.01). A negative association 
was found between TGF-β and HAS3 (R = -0.54, p = 0.004), and 
TGF- β and Hyal 1 (R = -0.40, p = 0.03). A Cox model analysis show 
low risk of death associated with female patients (R=0.11) age < 
69 yrs (R=0.02), I and II stage (R=0.18 and 0.00, respectively), and 
high risk of death associated to HAS2 < 14.6% (R=8.69) and HAS3 
> 7.4%.
Conclusion: HAase,HAS, E-cadherin, and TGF-β modulate a dif-
ferent tumor-induced invasive pathway in lung AD subgroups and 
SqCC. An inverse relationship between epithelial and stroma bio-
marker expression provides a different spectrum of aggressiven-
ess. While an overexpression of HAS1 and HAS3 indicates aggres-
sive subtypes of SqCC and AD, an overexpression of TGF-β and 
E-cadherin, indicates a protective role of the ECM in avoiding in-
vasion by tumor cells in both histological types. HAasesin resected 
AD and SqCC were strongly related to the prognosis,Therefore, 
our findings suggest that strategies aimed at preventing high 
HAS3 and Hyal1 synthesis, or local responses to low TGF-β and 
E-cadherin, may have a greater impact in lung cancer prognosis. 
Proof of this idea will require further study in a randomized, pros-
pective clinical trial.
Keywords: Lung cancer, Prognosis, Hyaluronidases, Extracelular 
matrix
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P1.01-007 ANTIMETASTATIC ACTIVITY OF GANETESPIB: 
PRECLINICAL STUDIES AND ASSESSMENT OF NEW LE-
SION GROWTH IN THE GALAXY-1 NSCLC TRIAL
David A. Proia, Masa Nagai, John-Paul Jimenez, Chaohua Zhang, 
Jim Sang, Wei Guo, Manuel Sequeira, Donald L. Smith, Safi R. Bah-
call, Vojislav M. Vukovic
Cancer Biology, Synta Pharmaceuticals/United States Of America
Background: Heat shock protein 90 (Hsp90) maintains the stabi-
lity and activity of numerous signaling proteins involved in cancer 
metastasis. Interim results of the GALAXY-1 trial (NCT01348126) 
showed an improvement in overall survival in patients with non-
small cell lung cancer (NSCLC) treated with an Hsp90 inhibitor, 
ganetespib (G), plus docetaxel (D) compared to D alone. We evalu-
ated the antimetastatic activity of ganetespib in preclinical models, 
and compared time to appearance of new lesions in patients with 
radiologic progression in the two arms of the GALAXY-1 trial.
Methods: Preclinical effects of ganetespib were investigated on 
the: (1) migration and invasion of cancer cells via scratch and Boy-
den chamber assays, (2) expression of metastatic factors using pro-
tein array and gene profiling, (3) architecture of NSCLC xenografts 
by IHC, and (4) metastasis to the lung in tail vein and orthotopic 
breast cancer mouse models assessed by bioluminescence and 
histology. GALAXY-1 is a Synta sponsored randomized, internatio-
nal open-label study of D with or without G in patients with advan-
ced lung adenocarcinoma, one prior systemic therapy, and ECOG 
PS 0/1. D was given at 75 mg/m2 on Day 1 of a three-week cycle in 
both arms. In the combination arm, G was given at 150 mg/m2 on 
days 1 and 15. Time to appearance of new lesions (TTNL) was mea-
sured using serial computed tomography scans, starting from ran-
domization and until a new metastatic lesion was reported. Patient 
enrollment completed in November 2012.
Results: Ganetespib blocked the directional migration of NSCLC 
cells in a monolayer of cancer cells, significantly reduced their 
invasion into type I collagen and induced the degradation of me-
tastasis drivers including HIF-1α, activated FAK and MET. In mouse 
models, ganetespib significantly reduced tumor angiogenesis 
and proliferation in NSCLC xenografts; significantly blocked (>8X, 
p<0.005) the development of lung cancer metastases in a tail vein 
model; and significantly reduced multi-organ metastasis in an 
orthotopic model and blocked extramedullary hematopoiesis in-
duced by the primary tumor. In GALAXY-1 trial patients, the popu-
lation that exhibited the strongest survival improvement (diagnosis 
of advanced disease >6 months, N=175), median TTNL increased 
from 6.9 months (D) to 11.3 months (G+D), with hazard ratio 0.5 
(p=0.0053) at time of abstract submission.
Conclusion: Ganetespib induces the degradation of key drivers of 
metastasis, resulting in the reduction of cancer cell migration and 
invasion in vitro and tumor angiogenesis and new lesion formation 
in vivo. Preliminary data from the GALAXY-1 study suggests that 
ganetespib treatment may reduce the risk of emergence of new 
metastatic lesions by 50% in advanced NSCLC patients.
Keywords: Ganetespib, HSP90, metastasis, NSCLC
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P1.01-006 INTRA-TUMOR PRESSURE OF LUNG CANCER 
MAY CORRELATE TUMOR AGGRESSIVENESS
Takeshi Mori, Eri Matsubara, Kosuke Fujino, Hidekatsu Shibata, 
Kentarou Yoshimoto, Koei Ikeda, Kenji Shiraishi, Makoto Suzuki
Thoracic Surgery, Kumamoto University Hospital/Japan
Background: Intra-tumor pressure (ITP) was reported to be one 
of prognostic factors for head and neck cancer and hepatocellular 
carcinoma. It was reported that ITP of rectal cancer fell after Beva-
cizumab treatment. We measured ITP of lung cancer and investi-
gated relationship between ITP and clinicopathological factors of 
lung cancer.
Methods: After institutional review board approval, we measured 
ITP in the center of the tumor after resection of lung cancer using 
Ultra-Miniature Mikro-Tip Pressure Transducer Catheters (SPR1000, 
Millar). Lung cancer showing pure ground glass opacity (GGO) ap-
pearance in CT was excluded from this study. Between September 
2009 and January 2013, 219 lung cancer patients, 142 male and 77 
female, entered the study. Mean age of patients was 70 ± 10 year 
old (range: 39 to 87). The histologic types of lung cancer were ade-
nocarcinoma (AD) in 148 patients, squamous cell carcinoma (SqCC) 
in 52 patients, adenosquamous carcinoma (AdSq) in 10 patients, 
and others. The clinical (c) T stages were T1a in 69 patients, T1b in 
64 patients, T2a in 60 patients, T2b in 11 patients, T3 in 14 pati-
ents, and T4 in one patient. The cN stages were N0 in 187 patients, 
N1 in 22 patients, N2 in 8 patients, and N3 in 2 patients. The cSta-
ges were IA in 122 patients, IB-IIIB in 97 patients. The pathological 
(p) T stages were T1a in 84 patients, T1b in 45 patients, T2a in 67 
patients, T2b in 9 patients, T3 in 9 patients, and T4 in 4 patients. 
The pN stages were N0 in 183 patients, N1 in 21 patients, N2 in 14 
patients. The pStages were IA in 117 patients, IB in 53 patients, IIA 
in 19 patients, IIB in 6 patients, IIIA in 21 patients, and IIIB in 2 pa-
tients. Mean maximal diameter of the tumors on CT was 2.7±1.4cm 
(range: 0.8 to 7.9). Of these tumors, 59 showed part-solid and 147 
showed solid appearance on CT.
Results: Mean ITP was 8.7 ± 6.5 mmHg (range: 0 to 37.2) . Mean 
ITPs according to histological type were as follows: 8mmHg in AD, 
10mmHg in SqCC, 7mmHg in AdSq. Mean maximal standardized 
uptake value (SUVmax) in fluoro-deoxy glucose-positron emission 
tomography was 4.6±3.5 (range: 0.3 to 15.1). ITP correlated to ma-
ximal diameter of tumor on CT (r=0.312) and pT factor (r=0.336). 
The ITP in pN0 (8mmHg) was significantly lower than that in pN(+) 
(12mmHg) (p=0.005). The ITP in pStage IA patients (6mmHg) was 
significantly lower than that in other stages patients (11mmHg) 
(p=0.001). The ITP of tumors showing solid appearance (10mmHg) 
was significantly higher than that of tumors showing part-solid 
(5mmHg). While ITP correlated to SUVmax (r=0.402), lymphatic 
vessel invasion (r=0.269), blood vessel invasion (r=0.293), pleural 
invasion (r=0.287), tumor grade (r=0.238), MIB-1 index (r=0.292), 
did not correlate to microvessel density (CD34) .
Conclusion: ITP showed correlation to tumor aggressiveness fac-
tors of lung cancer.
Keywords: intra-tumor pressure, Lung cancer, tumor  
aggressiveness
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Methods: A 16 amino acid peptide mimicking the central se-
quence of OPN exon 4 and a scrambled sham were constructed. 
Competitive binding assays had previously determined that the 
OPN exon 4 peptide binds the NSCLC cell surface and inhibits 
OPN binding. Two NSCLC cell lines with wt p53, A549 (modera-
te endogenous OPN) and H460 (high endogenous OPN), were 
placed in serum-free media with OPN exon 4 peptide or scram-
bled peptide for 48 hours. Cells were then evaluated by TUNEL 
assay or harvested, lysed and protein expression measured using 
Human Apoptosis Array (R&D, Minneapolis, MN).
Results: Exon 4 peptide treatment resulted in significant increases 
in apoptosis in both cell lines (Fig). A similar pattern of change in 
apoptotic protein expression was seen in both cell lines, with sig-
nificant increases in Bax, cleaved Caspase-3, CytC, Hsp32, Pon2, 
Cdnk1, and p53-pS15, p53-pS46, and p53-pS392, while Survivin 
and Claspin expression were significantly decreased (Fig). Notably 
no significant change was seen in Bclx, Bcl2, and pro-Caspase 3 
expression. Scrambled peptide had no effect on apoptosis or pro-
tein expression. 
Conclusion: Inhibition of binding between OPN exon 4 and NS-
CLC cells significantly increased the rate of apoptosis and expressi-
on of proteins which modulate apoptosis associated with oxidative 
stress, including several key phosphorylated p53 variants. These 
data implicate OPN exon 4 interactions in NSCLC progression and 
resistance mechanisms and may explain the importance of OPN’s 
A and B isoforms as opposed to isoform C in NSCLC pathogenesis.
Keywords: non-small cell lung cancer, Apoptosis, osteopontin, 
p53
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P1.01-008 INHIBITION OF BINDING AT EXON 4 OF OS-
TEOPONTIN INCREASES APOPTOSIS AND APOPTOTIC 
PROTEIN EXPRESSION IN NON-SMALL CELL LUNG CAN-
CER
Chandra Goparaju, Nathalie Hirsch, Harvey Pass, Jessica Doning-
ton
New York University School Of Medicine/United States Of America
Background: Osteopontin (OPN) is a ubiquitous extracellular 
protein associated with a wide range of normal and pathologic 
functions. It is a central regulator of the malignant phenotype in 
non-small cell lung cancer (NSCLC) through binding of cell surface 
receptors, but underlying mechanisms are poorly understood. 
Among OPN’s critical roles in NSCLC progression, is preventing 
apoptosis related to oxidative stress by activating alternative survi-
val pathways. While OPN’s central RGD domain is considered im-
portant to this function, we hypothesize that exon 4, in the amino 
terminus, which is present in OPN’s A and B isoforms, but not in 
the C isoform, is essential to this process. We sought to determi-
ne the impact of inibition of binding between NSCLC cells and 
OPN exon 4 on apoptosis and apoptotic protein expression in 
NSCLC.
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P1.01-010 HETEROGENEITY OF BIOMARKERS BETWEEN 
THE PRIMARY TUMOR AND THE METASTATIC LYMPH 
NODES IN NON-SMALL CELL LUNG CANCER
Katsuhiko Shimizu, Masao Nakata, Riki Okita, Shinsuke Saisho, 
Ai Maeda, Takuro Yukawa, Koichiro Yasuda, Yuji Nojima
General Thoracic Surgery, Kawasaki Medical School/Japan
Background: Recently, the personalized treatments for non-small 
cell lung cancer (NSCLC) have progressed with the understan-
ding of the biology and the molecular mechanisms of the tumor. 
Treatment strategy is determined based on the biomarker profiles 
examined with the primary tumor tissue or the metastatic lymph 
nodes. However, because tumor cells acquire the metastatic phe-
notype through the process of clonal evolution occurring during 
the tumor progression, there could be the heterogeneity of the 
biomarker profiles between the primary tumor and the metastatic 
lesions. The aim of this study was to investigate the heterogeneity 
of the biomarkers between the primary tumor and the metastatic 
lymph nodes, and to evaluate the clinical significance of its dis-
cordancy.
Methods: Seventy-two patients of NSCLC with lymph node meta-
stases who underwent complete resection with systematic lymph 
node dissection between 2004 and 2010 were studied. The study 
was conducted with the approval of the institutional ethics com-
mittee. Immunohistochemical analysis of ERCC1 and VEGF and the 
mutation analysis of EGFR were performed with the paraffin-em-
bedded tissue of both the primary tumor (PT) and the metastatic 
lymph nodes (LN).
Results: There were 47 male and 25 female, with the median age 
of 69.4 years. Thirty-eight patients had adenocarcinoma, 23 had 
squamous cell carcinoma, and 11 had other histologic types of 
NSCLC. Twenty-nine patients had N1 disease, and 43 had N2. 
Median observation period was 35.7 months. The 5-year overall 
survival rate of 72 patients was 38.0%, with 53.2% in N1 cases and 
28.8% in N2 cases. ERCC1 was positive in 41.7% of PT and 58.3% 
of LN. There were 34 cases (47.2%) with the discordant expression 
of ERCC1. VEGF was positive in 66.7% of both PT and LN, whereas 
32 cases (44.4%) were discordant. EGFR mutation was detected 
in 31.9% of PT and 18.1% of LN. There were 10 cases (13.9%) with 
discordant mutation status. All 10 cases had mutant EGFR in PT, 
whereas EGFR mutation was not found in LN. Of the 49 patients 
with EGFR mutation-negative in PT, none showed mutations in 
LN. There were no differences in relapse-free survival and overall 
survival among the biomarker profile groups. Among patients who 
had negative ERCC1 in PT or LN, overall survival was significantly 
better in patients who received platinum-based chemotherapy pe-
rioperatively compared with that in patients who did not. However, 
there were no differences in patients with positive ERCC1 in PT or 
LN. Seventeen patients who had mutant EGFR in PT were treated 
with gefitinib. The responses were CR in 4, PR in 7, SD in 2, and PD 
in 4, with the response rate of 64.7% and the disease control rate 
of 76.5%. All the nine patients who had mutant EGFR in both PT 
and LN showed disease control, whereas 4 out of 8 patients who 
had mutant-negative EGFR in LN showed PD.
Conclusion: It should be noted that discordancy of biomarker pro-
files between PT and LN was not a few. Understanding the hetero-
geneity of biomarkers would be essential for the establishing the 
personalized treatments for NSCLC.
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P1.01-009 THE ROLE OF AUTOPHAGY INDUCED BY TY-
ROSINE KINASE INHIBITORS IN NON-SMALL CELL LUNG 
CARCINOMA
Yuan Yuan Li, Sze Kwan Lam, Chun Yan Zheng, James Chung Man 
Ho
Department Of Medicine, The University Of Hong Kong/Hong Kong
Background: Non-small cell lung cancer (NSCLC) is one of the 
leading causes of cancer deaths. Erlotinib (tyrosine kinase inhibi-
tor, TKI) is widely used as a specific treatment targeting epidermal 
growth factor receptor (EGFR), while crizotinib serves as a c-MET 
and anaplastic lymphoma kinase (ALK) inhibitor. Autophagy is a 
regulated cellular catabolic process in response to stress. This stu-
dy aimed to investigate whether autophagy could confer acquired 
resistance to TKI in NSCLC.
Methods: Two NSCLC cell lines (HCC827 and HCC4006) with 
EGFR mutations (exon 19 deletions) and two NSCLC cell lines 
(H1993 and H2228) with c-MET amplification or ALK rearrangement 
were selected. Cell proliferation (MTT) and annexin-V binding 
assays were performed to determine cell proliferation and apop-
totic cell death upon TKI treatment respectively. Autophagy was 
determined by conversion of LC3I to LC3II and p62 degradation 
using Western blot. Acidic vesicular organelle (AVO) formation was 
shown by acridine orange staining. Autophagy inhibitor (chloro-
quine) was used to study the functional significance of TKI-induced 
autophagy.
Results: MTT assay confirmed that all cell lines were sensitive to 
corresponding TKI after 72 hours incubation (IC50 <0.5 µM). Er-
lotinib or crizotinib increased LC3II expression, p62 degradation 
and formation of AVO, compatible with induction of autophagy. 
Combination of 10 µM chloroquine (autophagy inhibitor) with 0.2 
µM erlotinib or crizotinib for 48 hours increased apoptotic events 
compared to single treatment (Table 1)  
Table 1. Apoptotic events in NSCLC cell lines after different 
treatments.
Cell line
Chloroquine 
+ Erlotinib
Erlotinib Chloroquine p-value
HCC827 52.3 ± 2.8%
21.2 ± 
4.2%
13.0 ± 2.5% <0.01
HCC4006 49.3 ± 4.8% 9.4 ± 2.4% 9.0 ± 1.8% <0.01
Chloroquine 
+ Crizotinib
Crizotinib Chloroquine
H1993 42.6 ± 12.0% 17.3 ± 5.1% 10.5 ± 5.4% <0.01
H2228 34.9 ± 10.1%
12.2 ± 
2.6%
7.6 ± 1.2% <0.01
Conclusion: TKI induced both apoptosis and autophagy in EGFR-
mutated, c-MET-amplified and ALK-rearranged NSCLC cell lines. 
Inhibition of autophagy with chloroquine enhanced TKI-induced 
cell death. Autophagy may serve as a protective mechanism in 
NSCLC upon treatment with TKI.
Keywords: Autophagy, tyrosine kinase inhibitors, Non-small cell 
lung carcinoma
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P1.01-012 THE KDM6 LYSINE DEMETHYLASES ARE CAN-
DIDATE THERAPEUTIC TARGETS IN MALIGNANT PLEU-
RAL MESOTHELIOMA
Sian Cregan1, Maeve Breslin1, Gerard Roche1, Sigrid Wennstedt1, 
Cinaria Albadri1, Yun Gao2, Kenneth O‘Byrne3, Steven G. Gray4
1Clinical Medicine, Trinity College Dublin/Ireland, 2Department Of 
Oncology, Aerospace Central Clinical Medical College Of Peking Univer-
sity/China, 3Queensland University Of Technology, Cancer & Ageing 
Research Program/Australia, 4Clinical Medicine, Trinity College Dublin/
st Jame‘s Hospital/Ireland
Background: Malignant pleural mesothelioma (MPM) is a rare can-
cer affecting the pleura and is commonly caused by prior exposure 
to asbestos. Treatment of MPM is difficult with limited options. 
The current standard of care for MPM patients is a combination of 
cisplatin and pemetrexed (or alternatively cisplatin and raltitrexed), 
yet most patients die within 24 months of diagnosis. There is ther-
fore an unmet need to identify new therapeutic approaches for the 
treatment of MPM. Lysine Demethylases (KDMs) represent novel 
targets for the treatment of cancer. Overexpression of many KDMs 
occurs in many cancers, and these proteins play important roles 
in tumorigenesis. One such family, the KDM6/JMJD3 family, was 
investigated for changes in expression in MPM and to determine if 
this family could represent a novel candidate target(s) for interven-
tion in MPM.
Methods: A panel of MPM cell lines inluding the normal pleural 
cells LP9 & Met5A were screened for expression of KDM6 family 
members (KDM6A/UTX and KDM6B/JMJD3) by RT-PCR. mRNA 
levels were subsequently examined by RT-PCR in a cohort of snap-
frozen patient samples isolated at surgery comprising benign, 
epithelial, biphasic, and sarcomatoid histologies. The effects of 
a small molecule inhibitor of KDM6B/JMJD3, (GSK-J4) on cellular 
proliferation and gene expression were examined.
Results: We show that the expression of the KDM6 family is de-
tectable in all cell lines across our panel of cell lines. In primary 
tumours however, the expression of KDM6A/UTX was very signi-
ficantly (p<0.001) and KDM6B/JMJD3 was significantly elevated 
(p<0.05) in malignant MPM compared to benign pleura. When se-
parated across histological subtype KDM6A/UTX was most signi-
ficantly elevated in the Sarcomatoid subtype (p<0.001), while only 
KDM6B/JMJD3 was significantly elevated (p<0.05) in the Biphasic 
subset. Treatment of REN/ NCI-H226 cells with the KDM6B/JMJD3 
inhibitor GSK-J4 caused significant inhibition of cellular proliferati-
on, with the REN cell line being more sensitive than NCI-H226. The 
effects of GSK-J4 on gene expression were examined on a panel 
of genes associated with Tumor-Invasion/Metastasis and on pro-
inflammatory cytokines.
Conclusion: The KDM6 family of lysine demethylases are signifi-
cantly altered in MPM. A small molecule inhibitor of this protein 
shows significant anti-proliferative effects in MPM cell lines. We 
continue to assess the effects of this compound on gene expres-
sion and cellular health by other methodologies to confirm its po-
tential utility in the treatment of MPM.
Keywords: Lysine Demethylase, epigenetics, mesothelioma,  
GSK-J4
Keywords: EGFR mutation, biomarker, non-small cell lung cancer, 
ERCC1
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P1.01-011 TARGETING THE UROKINASE PLASMINOGEN 
ACTIVATOR (UPA) SYSTEM TO OVERCOME CISPLATIN 
RESISTANCE IN NSCLC
Peter Godwin1, Anne-Marie Baird1, Kim Lüdtke1, Susan Heavey1, 
Martin Barr1, Andrew Mazar2, Kenneth O‘Byrne3, Kathy Gately1
1Thoracic Oncology Research Group, St. James‘s Hospital/Trinity College 
Dublin/Ireland, 2Chemistry Of Life Processes Institute, Robert H. Lurie 
Cancer Center Northwestern University/United States Of America, 
3Queensland University Of Technology, Cancer & Ageing Research Pro-
gram/Australia
Background: The urokinase plasminogen activator (uPA) system 
(uPAS) has been shown to play a significant multifunctional role in 
tumour progression including angiogenesis, adhesion and migrati-
on. Increased levels of urokinase plasminogen activator (uPA) and 
its receptor uPAR (CD87) strongly correlate with poor prognosis 
and a poor clinical outcome. It has been shown previously that a 
subpopulation of uPAR-positive cells in Small Cell Lung Cancer 
(SCLC) cell lines demonstrate significant drug resistance to tradi-
tional chemotherapeutic agents such as cisplatin, 5-fluorouracil 
(5-FU) and etoposide. The uPAS is regulated by NF-κB which has 
been shown to be constitutively activated in several cancer types 
including non-small cell lung cancer (NSCLC). Furthermore, we 
have shown NF-κB to be involved in the development of resistance 
to cisplatin in NSCLC. This project focuses on determining the role 
of the uPA system in the invasive phenotype of cisplatin resistant 
NSCLC cells.
Methods: Expression of NF-κB (p65) in parent and resistant NS-
CLC cell lines was quantified by qPCR, western blot and high con-
tent screening (HCS). The expression profiles of NFκB target genes 
were quantified using a Roche custom NFκB RTPCR array. Gene 
“hits” with a fold change >2 between parent and cisplatin resistant 
cells were validated by qPCR analysis. The upregulation of the 
urokinase-type plasminogen activator (uPA) in cisplatin resistant 
cells was determined by western blot. The effect of uPA inhibition 
on cell migration and invasion, using the monoclonal anti-uPAR an-
tibody ATN-658, is being determined using the novel impedance-
based xCELLigence Real-Time Cell Analysis detection platform.
Results: Gene expression data, from the NFκB target gene array 
identified a panel of genes including; PLAU (gene for uPA), RIPK 
and NLRP12 amongst others that were over-expressed in H460 ci-
splatin resistant cell lines compared to the isogenic parent cell line. 
uPA overexpression at the protein level was confirmed in a panel of 
cisplatin resistant cells compared to parent cell lines. The effect of 
ATN-658 on the inhibition of cell migration and invasion in cisplatin 
sensitive and resistant cell lines will be presented.
Conclusion: Overexpression of uPA across a panel of cisplatin 
resistant NSCLC cell lines highlights its significance as a marker of 
resistance. Targeting the uPA system may be exploited in cisplatin 
resistant NSCLC to inhibit cell migration and invasion.
Keywords: uPA, NF-kB, cisplatin resistance, NSCLC
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network was established to identify the core genes in regulating 
cancer cell cisplatin resistance.
Results: A number of genes were differentially expressed in 7 
groups of cancer cell lines. They mainly participated in 85 GO 
terms and 11 pathways in common. All differential gene interac-
tions in the Signal-Net were analyzed. CTNNB1, PLCG2 and SRC 
were the most significantly altered.
Conclusion: Bioinformatics may help excavate and analyze large 
amounts of data in microarrays by means of rigorous experimental 
planning, scientific statistical analysis and collection of complete 
data about cancer cell cisplatin resistance. In the present study, 
a novel differential gene expression pattern was constructed and 
advanced study will provide new targets for diagnosis and mecha-
nism of cancer cisplatin resistance.
Keywords: cisplatin, pathway, RNA, drug resistance
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P1.01-013 DIFFERENCES IN GENE EXPRESSION PROFI-
LES AND CARCINOGENESIS PATHWAYS IN CISPLATIN 
RESISTANCE OF FOUR CANCERS
Yong Yang1, Hui Li1, Jun Wang2
1Department Of Thoracic Surgery, Beijing Chao-yang Hospital, Capital 
Medical University/China, 2Department Of Physiology, Capital Medical 
University/China
Background: Cisplatin-based chemotherapy is the standard thera-
py used to many cancers. However, its efficacy is largely limited by 
the acquired drug resistance. So far, little is known about the RNA 
expression changes in the cisplatin resistant cancers. Identification 
the RNAs related to the cisplatin resistance may provide precise 
clues for cancer therapy.
Methods: Expression profiling of 7 cancer cell lines that perfor-
med using oligonucleotide microarray analysis got from GEO 
database. Bioinformatic analyses such as the Gene Oncology and 
KEGG pathway were used to identify genes and pathways speci-
fically associated with cisplatin resistance. Signaling transduction 
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P1.01-015 OVERABUNDANCE OF ACTIVATED STROMAL 
FIBROBLASTS (TAFS) IN NSCLC ON RESPONSE TO EXT-
RACELLULAR MATRIX (ECM) RIGIDITY
Noemi Reguart1, Marta Puig2, Jose Ramirez3, Roberto Lugo2, Abel 
Gomez-Caro4, Alicia Gimenez2, Pere Gascon1, Jordi Alcaraz2
1Medical Oncology, Hospital Clinic/Spain, 2Biophysics, University Of 
Barcelona/Spain, 3Anathomopatology, Hospital Clinic/Spain, 4Thoracic 
Surgery, Hospital Clinic/Spain
Background: Breathing demands our lungs to be soft and elastic. 
In contrast, lung tumors exhibit an abnormal tissue hardening con-
comitantly with an altered lung architecture and function, which 
brings the mechanical microenvironment of the tumor closer to 
that of muscle or bone. Carcinoma-associated fibroblasts (TAFs) 
within the tumor stroma are known to be conspirators of tumor 
progression. It remains unknown whether tissue hardening is suf-
ficient to drive abnormal abundance of activated fibroblasts in the 
stroma of the different NSCLC subtypes. We aimed to determine 
the role of abnormal tumor tissue hardening in the overabundance 
of TAFs in different NSCLC subtypes
Methods: To address this question, we cultured the human lung 
fibroblast cell line CCD-19Lu or primary human lung fibroblasts on 
collagen-coated polyacrylamide gels exhibiting normal (soft) or 
tumour (stiff)-like substrates in the absence (0%) or presence (0.1%) 
of serum for 5 days. Primary cells were isolated from both tumor-
free regions (referred to as control fibroblasts) or tumors of NSCLC 
patients diagnosed with either Adenocarcinoma (ADC, n=5) or 
Squamous Cell Carcinoma (SCC, n=5) histological subtypes.
Results: We observed a significantly higher density of CCD-19Lu 
fibroblasts in tumor-like gels compared to normal-like gels regard-
less the presence of serum. Similar results were obtained in both 
primary control fibroblasts and SCC-TAFs. In contrast, tumor-like 
gels induced a weaker density increase in primary ADC-TAFs. The 
increased fibroblast density in the tumor-like gels was associated 
with increased survival rather than proliferation, as revealed by 
a downregulation of caspase-3 and a rise in FAK and AKT phos-
phorylation. To further understand the apoptotic effect on stiffer 
substrates, we examined the expression of the mechanoreceptor 
integrin beta-1, responsible of sensing stiffness signals from the 
ECM. We found a significantly higher expression of integrin beta-1 
in SCC compared to control and ADC primary fibroblasts .
Conclusion: Our results indicate that tumor extracellular hardening 
alone is sufficient to induce an increased density in activated lung 
fibroblasts, a well known conspirators of tumor progression, by ac-
tivating pro-survival FAK-AKT pathways. Collectively these findings 
underline the major role of tissue hardening in the abnormal ab-
undance of TAFs in NSCLC, particularly in the SCC subtype. These 
data warrants the development of novel targeted therapies against 
the pro-survival effects of tissue hardening.
Keyword: NSCLC, fibroblast, stiffness, squamous
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P1.01-014 EFFECTS OF COMBINED EPIGENETIC THE-
RAPY WITH THE HISTONE METHYLTRANSFERASE EZH2 
INHIBITOR AND THE HISTONE DEACETYLASE INHIBI-
TOR ON NSCLC CELLS.
Taichi Takashina1, Ichiro Kinoshita2, Junko Kikuchi1, Eiki Kikuchi1, 
Yasushi Shimizu2, Jyunn Sakakibara-Konishi1, Satoshi Oizumi1, 
Masaharu Nishimura1, Hirotoshi D. Akita2
1First Department Of Medicine, Hokkaido University/Japan, 2Depart-
ment Of Medical Oncology, Hokkaido University Graduate School Of 
Medicine/Japan
Background: EZH2, a polycomb group protein, has histone me-
thyltransferase activity, and is involved in malignant transformation 
of several cancers. We have previously shown that an EZH2 inhibi-
tor, DZNep, inhibits growth of non-small cell lung cancer (NSCLC) 
cell lines via G1 arrest and apoptosis. Recent studies have shown 
that EZH2-mediated gene silencing requires a recruitment of the 
histone deacetylase (HDAC) activity. Co-treatment with DZNep 
and an HDAC inhibitor has been shown to induce apoptosis syner-
gistically in AML, ovarian cancers and renal cancers. However, the 
effect of combined therapy with DZNep and an HDAC inhibitor on 
NSCLC cells has not been reported.
Methods: We evaluated the effect of combined therapy with 
DZNep and an HDAC inhibitor, SAHA, on four human NSCLC cell 
lines, H1299, H1975, A549 and PC-3. Cell proliferation of untreated 
or drug-treated cells was measured by MTT assay. Percentage of 
apoptotic cells was measured using FITC-conjugated annexin V 
with a flow cytometer. Western blot analysis was performed on 
total cell lysates.
Results: Co-treatment with DZNep and SAHA inhibited cell proli-
feration synergistically, and reduced EZH2 expression and histone 
H3 lysine 27 trimethylation more effectively compared with each 
agent alone. The co-treatment greatly induced accumulation of 
p27 Kip1 and decrease in cyclin A expression. Flow cytometry ana-
lysis demonstrated that the apoptotic fraction was increased in an 
additive or synergistic manner by the combination therapy. These 
effects were more evident in H1975 and PC-3 cells with EGFR mu-
tation, in which expression of EGFR and phosphorylation of EGFR, 
AKT and ERK1/2 were markedly decreased by the co-treatment.
Conclusion: Combined epigenetic therapy with an EZH2 inhibitor 
and an HDAC inhibitor may represent an effective strategy for 
NSCLCs.
Keywords: EZH2, DZNep, HDAC inhibitor, SAHA
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P1.01-017 THE RETAIN OF EXTRAPULMONARY ADMI-
NISTERED COLLOIDAL CARBON IN THE MEDIASTINAL 
LYMPHNODES OF WISTAR RAT
Martin Sobotka1, Ladislav Mitas2, Ilona Kocakova3, Jana Petraso-
va4, Jana Hlozkova4, Drahomir Horky5, Teodor Horvath6
1Early Diagnosis, Cbc Vznik/Czech Republic, 2Department Of Surge-
ry, Faculty Hospital Brno/Czech Republic, 3Department Of Complete 
Oncological Care, Masaryk Memorial Cancer Institute/Czech Republic, 
4Department Of Physiology, Veterinary And Pharmaceutical University/
Czech Republic, 5Department Of Histology, International Clinical Re-
search Center/Czech Republic, 6Medical Faculty, Masaryk University/
Czech Republic
Background: Model of metastatic spreading of extrapulmonary 
malignancy into mediastinal lymhnodes.
Methods: Subcutaneous administration of 0,4 ml of the ink (com-
pound from black carbon dispersed on colloid casein solution i.e. 
colloidal carbon / KOH-I-NOOR Hardtmuth Ltd., Praha, CZ) diluted 
with sterile saline solution 1:3 was performed under i.m. general 
anesthesia (diazepam, xylazine, ketamine) in 42 outbred Wistar rats 
(An-Lab Praha, CZ) divided into 7 groups according the application 
sites: retroperitoneum, testis / ovary, hind leg, front leg, thoracic 
wall, pleural cavity. On seventh day after the administration all rats 
were euthanatized, the thoracic wall was opend and mediastinal 
lymphnodes were detected macroscopically, taken out, and pre-
served in 18% formalin. Paraplast fixation and the hematoxyline-
and-eosine staining were used for histological examination by 
40-times and 100-times magnification. The samples with mono-
cyte- macrophage system cells containing colloidal carbon (CC) 
in the mediastinal lymphnodes (MLNs) were considered positive. 
Two statistical methods were used to determine the probability of 
model cell transport and retention. First is based on random error 
theory and consists of mean values, standard deviations and con-
fidence intervals. Second analysis calculated the confidence inter-
vals of probabilities using F-distribution. Programs Matlab 2012 
(MathWorks) and Microsoft Office 2010 Excel (Microsoft Corp.) 
were used for the statistical analysis. FIG 1 The sites of ink admi-
nistration 1 2 3 4 5 6 7 1 - thoracic wall, 2 - front leg, 3 - pleural 
cavity, 4 - retroperitoneum, 5 – testis, 6 - hind leg, 7- ovary
Results: Macrophages containing carbon particles were found in 
MLNs of all groups of animals, at least in one animal of each tested 
group. Positive lymphnodes were found in 4/6 (66.7%) of animals 
after paraovarial, paratesticular and pleural cavity application and 
in 2/6 (33.3%) with retroperitoneal and distal part of hind leg appli-
cation. In animals injected in distal part of front leg and in thoracic 
wall it was 1/6 (16.7%) with positive nodes. Statistical analysis show-
ed significant retain of CC administered into different parts of the 
periphery of the body on the 5% significance level.
Conclusion: The transport of CC with the monocyte macrophage 
system cells from very different parts of the body to the medias-
tinal lymph nodes of Wistar rats and their persistence there after 
seven days has been proved on the 5% significance level. That 
indicates the relation between mediastinal lymphnodes and alien 
loading of the body.
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P1.01-016 TARGETING NF-ΚB REGULATED PATHWAYS 
TO OVERCOME CISPLATIN RESISTANCE IN NON SMALL 
CELL LUNG CANCER
Anne-Marie Baird1, Peter Godwin1, Susan Heavey1, Kazuo Um-
ezawa2, Martin Barr1, Derek Richard3, Kenneth O‘Byrne4, Kathy 
Gately1
1Thoracic Oncology Research Group, St. James‘s Hospital/Trinity College 
Dublin/Ireland, 2Molecular Target Medicine Screening, Aichi Universi-
ty/Japan, 3Translational Research Institute, Queensland University Of 
Technology/Australia, 4Queensland University Of Technology, Cancer & 
Ageing Research Program/Australia
Background: Cisplatin based doublet chemotherapy is the main-
stay of non small cell lung cancer (NSCLC) treatment with an ini-
tial objective response rate of approximately 40-50%. However, 
intrinsic and acquired resistance to cisplatin constitutes a major 
clinical obstacle in lung cancer management and has yet to be fully 
understood. Inflammatory mediators may play an important role 
in the development of cisplatin resistance, such as those regulated 
by NF-κB. We have previously demonstrated that levels of NF-κB 
are increased in cisplatin resistant cells compared with sensitive 
Parent cells. We are currently assessing a number of NF-κB regu-
lated targets in cisplatin resistant cell line models, using DHMEQ, 
a specific NF-κB inhibitor. DHMEQ treatment results in greater cell 
death in the cisplatin resistant cells compared with Parent. This 
study will elucidate the efficacy of DHMEQ to overcome cisplatin 
resistance and identify novel targets within the NF-κB pathway that 
may improve therapeutic strategies for NSCLC patients.
Methods: NF-κB downstream targets and signalling mediators 
were examined using NF-κB signalling and target pathway qPCR 
arrays (168 genes) in the H460 CisR and Parent cell line model. 
Targets identified are currently undergoing validation using qPCR 
and western blot. Biological and functional relevance of these 
targets in the development of cisplatin resistance will be examined 
further using DHMEQ and siRNA knockdown strategies. In additi-
on, a xenograft murine model will be utilised to assess the effect of 
DHMEQ alone and in combination with cisplatin on tumour growth 
in vivo.
Results: Data from qPCR arrays have demonstrated that a number 
of genes are differentially regulated between the CisR and Parent 
cell lines. These include genes which activate the NF-κB signalling 
cascade (TLR3, TLR4), regulators of the pathway (BIRC3, CASP1), 
transcription factors (Myc) and NF-κB responsive genes (TNF, 
CXCL8). A number of these genes will be modulated to determine 
their involvement in cisplatin resistance. In addition, DHMEQ is 
being used in combination studies to determine, whether it can 
re-sensitise cells to cisplatin therapy. At present a dosing study is 
ongoing to establish the effect of DHMEQ on xenograft tumours 
derived from Parent and CisR cells. The results of which will be 
presented.
Conclusion: Preliminary data indicates that NF-κB and a number of 
its downstream targets are deregulated in cisplatin resistant cells. 
This project aims to validate the role of these NF-κB regulated 
genes in cisplatin resistant NSCLC. It will also determine whether 
DHMEQ may be a novel targeted agent for the treatment of NS-
CLC. The data obtained in this study will ultimately benefit patients 
by providing insights into novel druggable targets and new clinical 
strategies to re-sensitise patients to cisplatin therapy.
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P1.01-019 STUDY OF ABERRANT COPY NUMBER OF 
GENES IN ADENOCARCINOMA OF LUNG IN NEVER-
SMOKERS WITH RESPECT TO EGFR MUTATIONS BY 
MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICA-
TION (MLPA®)
Joseph Siu-Kie Au1, Peter P F So2, C K Kwan2, Stephen Yau2
1Clinical Oncology, Queen Elizabeth Hospital/Hong Kong, 2Queen Eliz-
abeth Hospital/Hong Kong
Background: MLPA® is a robust method that detects aberrant 
copy numbers in one simple PCR reaction by using one primer-
pair. The SALSA® MLPA® kits P171, P172-B1 and P173 (MRC-Hol-
land, Amsterdam, Netherlands) containing 42, 42 and 43 probes 
respectively for genes that often have an increased copy number 
in one or more types of tumours were used.
Methods: Tumor samples from 42 lung adenocarcinoma of never-
smokers were studied (17 with EGFR L858R mutation, 9 with EGFR 
exon 19 deletions, and 16 with wild type EGFR). Normal lung pa-
renchyma from the same individual was used as internal control. 
The normalization with reference controls and data analysis was 
done according to the MLPA® protocol and Coffalyser developed 
at MRC-Holland.
Results: Significant copy number gains in > 15% cases (incidence 
rates indicated in brackets) were reported here. For tumours with 
EGFR L858R mutation, significant gains were detected in EGFR 
(60%), RNF139 (50%), TERT (28%), NFKBIE (22%), UCKL1 (23%), MYC 
(18%), NTRK1 (17%), RUNX1 (17%) and SERPINB9 (17%). For tumours 
with EGFR exon 19 mutations, significant gains were detected in 
PSMB4 (50%), EGFR (45%), UCKL1 (23%), MYC (23%), MET (23%), 
CENPF (23%), CYP27B1 (23%), CDK4 (23%) and ERBB4 (23%). For 
tumours with wild-type EGFR, significant gains were detected in 
STK6 (25%), IRS2 (20%) and MYC (20%). Therefore, gains in MYC 
copy numbers were common in all 3 groups. Gains in EGFR and 
UCKL1 were common in the 2 groups with EGFR mutations. Gains 
in STK6 were common to L858R mutation and wild-type EGFR 
groups.
Conclusion: The 3 groups of adenocarcinoma in never-smokers 
with respect to the absence, presence and types of EGFR mutation 
showed quite different patterns of aberrant copy numbers in other 
cancer-associated genes. This in turn reflected the distinctively 
different patterns of genetic instability.
Keywords: aberrant gene copy numbers, multiplex ligation-de-
pendent probe amplification, EGFR mutations, never smoker
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P1.01-020 EXPRESSION PROFILE OF SEROTONIN 2B RE-
CEPTOR (HTR2B) IN NON-SMALL-CELL LUNG CANCER
Hiroshi Yokouchi1, Takashi Ishida2, Kenya Kanazawa1, Yoshinori 
Tanino1, Xintao Wang1, Jun Osugi3, Hiroyuki Suzuki3, Chitose Ko-
bayashi4, Satoshi Waguri4, Shinya Watanabe4, Mitsuru Munakata1
1Department Of Pulmonary Medicine, Fukushima Medical University/
Japan, 2Department Of Pulmonary Medicine, Clinical Oncology Center, 
Keywords: extrapulmonary injection, mediastinal lymphnodes, 
colloidal carbon, animal model of metastatic spreading
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P1.01-018 EPIDERMAL GROWTH FACTOR UP-REGULA-
TES CD151 PROTEIN EXPRESSION TO PROMOTE NON-
SMALL CELL LUNG CANCER PROLIFERATION
Chin Yein Chin1, Sheryl S L Tan1, Thai Tran1, John K C Tam2
1Department Of Physiology, Yong Loo Lin School Of Medicine, National 
University Of Singapore/Singapore, 2Department Of Surgery, Yong Loo 
Lin School Of Medicine, National University Of Singapore/Singapore
Background: CD151 is a member of the tetraspanin superfamily. It 
is expressed on the surface of a variety of cell types and is involved 
in cellular processes such as cell motility, adhesion, proliferation, 
differentiation and signal transduction. CD151 is a positive regu-
lator of tumor progression; metastasis, tumor cell growth and sur-
vival. It is over-expressed in various cancers, including non-small 
cell lung cancers (NSCLCs). The 5-year survival rate for NSCLC 
patients with CD151 gene-positive tumors has been shown to be 
lower than that of those with CD151 gene-negative tumors. Most 
CD151 studies to date have compared the cellular functions in the 
presence or absence of CD151 via over-expression and knockdown 
techniques respectively. However, the endogenous mechanisms 
by which CD151 protein is up-regulated in cancer cells remain 
unknown. The epidermal growth factor (EGF) is a distinct ligand 
for EGF receptors (EGFRs). Over-expression of EGFRs has been 
observed in more than 60% of NSCLCs. EGF is secreted by NS-
CLCs, causing the hyperactivity of EGFRs and the activation of its 
downstream signaling pathways to promote cell proliferation. In 
this study, we investigated the impact of EGF stimulation on CD151 
protein expression in NSCLC cell proliferation.
Methods: A549 cells (a NSCLC cell line) were stimulated with incre-
asing concentrations of EGF for 48hr and the CD151 protein abun-
dance was measured via immunoblotting. To examine whether the 
effect of EGF on CD151 expression was a class-effect of growth 
factors, we also stimulated A549 cells with various stimulants (IL-1b, 
TNF-a, TGF-b1 and VEGF). To determine whether the effect of EGF 
on CD151 protein expression in NSCLC cells was cell-type selecti-
ve, we examined the effects of EGF stimulation on CD151 protein 
abundance in other NSCLCs (H358, H1975), colon cancer (SW620) 
and breast cancer (MDA-MB-231) cell lines. Subsequently, silenci-
ng of CD151 via siRNA was carried out to investigate the effect of 
CD151 on EGF-stimulated A549 cell proliferation. Cell number was 
measured via trypan blue exclusion after 72hr of EGF stimulation, 
and phospho-ERK1/2 levels were examined via immunoblotting 
after 6hr of EGF stimulation.
Results: In A549 cells, EGF induced significant up-regulation of 
CD151 protein expression and this effect was not a class effect of 
growth factors. The up-regulation of CD151 protein by EGF was 
observed in more than one type of NSCLCs and in other cancer 
cell types. Silencing of CD151 down-regulated EGF-stimulated 
increase in A549 cell number and this effect was dependent on 
ERK1/2 phosphorylation.
Conclusion: This is the first study to show that EGF up-regulates 
CD151 protein expression to promote NSCLC cell proliferation, 
possibly via the MAPK (ERK1/2) pathway.
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(ED50) in the histoculture drug response assay (HDRA). The HDRA 
was perfomed for paclitaxel at several concentrations (minimum 0 
µg/ml ,maximal 256µg/ml), in order to analyze the dose-response 
curves for individual patients. The value that was obtained from 
HDRA were directly applied for non-linear least square analysis 
using a formula of simplified dose-response curve. Subsequent-
ly, 41 surgically resected NSCLC specimens were applied to the 
HDRA and inhibition ratio at the concentration of 25µg/ml paclita-
xel (IR25) was measured. H-scores were calculated by immunohis-
tochemical staining. The patients comprised 26 male patients and 
15 female patients. Mean age was 72±6.8. The specimens exami-
ned were 24 adenocarcinomas 17 squamous cell carcinomas.
Results: The mean (±SD) slope factor, ED50 and maximal response 
was 11.7±6.5, 24.6±7.73 µg/ml and 87.4±6.15% respectively. And 
the mean H-score was 50; (20-140). Among 12 specimens whose 
dose-response curve was obtained, the ED50 was higher than 
25µg/ml in 5 (Resistant group) and lower in 7 (Sensitive group). 
The median H-score was significantly (p=0.0076) higher in Resis-
tant group (240) than in Sensitive group (10). The mean IR25 was 
53.8±26.6%. The median H-score in the specimens with IR25 abo-
ve 50% (60, n=15) was significantly (p=0.0337) higher than that in 
specimens with IR25 under 50% (35, n=26).
Conclusion: Tumors with high TUBB3 levels exhibited chemore-
sistance to paclitaxel than tumors with low TUBB3 levels. HDRA 
revealed that TUBB3 expression is a true predictive factor for the 
response of paclitaxel in NSCLC.
Keywords: Class III beta-tubulin, histoculture drug response assay, 
Lung cancer, predictive marker
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P1.01-022 CALBINDIN-D28K EXPRESSION IS CORRELA-
TED WITH THE ORGANOTROPISM OF LUNG CANCER 
ADRENAL METASTASIS.
Tatsuya Yoshimasu, Shoji Oura, Yozo Kokawa, Mitsumasa Ka-
wago, Yoshimitsu Hirai, Takuya Ohashi, Rie Nakamura, Haruka 
Nishiguchi, Masako Matsutani, Mariko Honda, Yoshitaka Okamu-
ra
Department Of Thoracic And Cardiovascular Surgery, Wakayama Me-
dical University/Japan
Background: Lung cancer easily metastasizes to multiple organs, 
such as bone, lung, brain, liver, and adrenal gland. The frequency 
of the distant metastasis usually appears to be dependent on the 
volume of each target organ. However, metastasis to the adrenal 
gland is frequently observed in spite of its small volume. We hypo-
thesized that some organotropic mechanisms exist in lung cancer 
adrenal metastasis. We applied microarray analysis to find the 
gene expression influencing organotropism of lung cancer adrenal 
metastasis.
Methods: Human lung adenocarcinoma cell lines PC-14, A549, and 
VMRC-LCD were used. Cell were cultured for 7 days on the fresh 
tissue slice of athymic mouse (Balb/c-nu/nu) adrenal gland. After 
that, proliferated cancer cells were collected from the surface of 
adrenal gland and cultured in the flask again. This process was re-
peated up to 5 times. This procedure was also applied to the other 
organs, which were lung, kidney, bone, and muscle, at the same 
time. Then the conditioned cells from each organ were obtained. 
Fukushima Medical University Hospital/Japan, 3Department Of Thora-
cic Surgery, Fukushima Medical University/Japan, 4Translational Re-
search Center, Fukushima Medical University/Japan
Background: Recently developed molecular targeting drugs are 
highly effective against various cancers, however the duration of 
response is limited. To overcome this problem, researchers have 
sought to find the resistance mechanism and identify novel tar-
gets. The majority of the drugs are related to receptors tyrosine 
kinase (RTKs), and recently, G-protein coupled receptor (GPCR) has 
also been reported to play a critical role in cancer biology. We thus 
attempted to identify the target GPCR for the treatment of lung 
cancer cells.
Methods: We analyzed 124 patients with non-small-cell-lung can-
cer who had undergone surgery from January 2008 through No-
vember 2011. Expression levels of GPCR mRNA in the tumor tissu-
es and the adjacent normal tissues were examined by comparative 
genomic analysis. We then sought to find the relationship between 
clinical features and the GPCRs that showed differential expression 
levels between the two types of tissues. In addition, we examined 
the protein levels of the GPCRs by immunohistochemistry.
Results: We identified 3 GPCRs and 1 related molecule. Of the 4 
molecules, serotonin receptor 2B (HTR2B) was expressed higher 
in tumor tissues than in normal tissues. HTR2B was expressed sta-
tistically higher in the tumor tissues of female, adenocarcinoma, 
and non-smokers (p=0.012. 0.001, 0.045, respectively), and tended 
to be expressed higher in patients who harbored EGFR mutation 
(p=0.086). No statistically significant differences were observed in 
relapse-free survival. Immunohistochemistry demonstrated that 
HTR2B was expressed especially in the invasive front of the tumor.
Conclusion: Differential expression of HTR2B between cancer cells 
and normal tissues and its invasive potential suggest that further 
investigation into this molecule is needed.
Keywords: mRNA, immunihistochemistry, GPCR, HTR2B
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P1.01-021 CLASS III BETA-TUBULIN EXPRESSION IN 
NON-SMALL CELL LUNG CANCER AS A PREDICTIVE 
MARKER FOR PACLITAXEL.
Takuya Ohashi, Tatsuya Yoshimasu, Shoji Oura, Yozo Kokawa, 
Rie Nakamura, Mitsumasa Kawago, Yoshimitsu Hirai, Haruka 
Nishiguchi, Masako Matsutani, Mariko Honda, Yoshitaka Okamu-
ra
Department Of Thoracic And Cardiovascular Surgery, Wakayama Me-
dical University/Japan
Background: Paclitaxel is one of the key drugs used in chemothe-
rapy for the non-small cell lung cancer (NSCLC). Anti-microtubule 
agents, such as paclitaxel, stabilizes the microtubule polymer and 
prevents their breakdown. Data from the metastatic study suggest 
high tumor class III beta-tubulin (TUBB3) expression is a determi-
nant of insensitivity to paclitaxel. To clarify whether TUBB3 is a true 
predictive marker for chemotherapy with paclitaxel, chemosensiti-
vity was examined using an in vitro drug sensitivity assay.
Methods: Initially, 12 specimens were obtained to analyze the 
dose-response curve and to measure the median effective dose 50 
S438 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
differentiated cancer. We generated five antibodies against ATBF1 
(MB34-2, MB39-1, D1-120, MB44-2, MB47-2) at distinct part of the 
protein from N-terminal to C-terminal. We also analyzed the ex-
pression of p53, p21, ATM, psATM, estrogen receptors (ER), pro-
gesterone receptor (PR) , thyroid transcription factor 1 (TTF-1) and 
CEA by immunohistochemical analysis. The intensity of each factor 
was graded (score: 0-3) from weak expression (score: 0) to strong 
expression (score: 3). The intensity was scored in comparison with 
the intensity of ATB1 for other factors.
Results: Positive rates of ATBF1 with each antibody (MB34-2, 
MB39-1, D1-120, MB44-2, MB47-2) were 88%, 100%, 100%, 76% 
and 71%. Positive rates of p53, p21, ATM, psATM, ER, PR, TTF-1 
and CEA were 53%, 41%, 47%, 41%, 65%, 42%, 29% and 76%, re-
spectively. There was no significant difference in the expression 
pattern of each factor between adenocarcinoma and squamous 
cell carcinoma but TTF-1. We divided lung cancer cells into two 
groups by expression pattern of ATBF1. Wide range expression 
(W) group is characterized by the positive expression with all anti-
body whereas the limited expression (L) group that is characterized 
by limited number of positive with these antibodies. The expressi-
on rate of ER was significantly low in W group (45%, 5/11) in cont-
rast to L group (100%, 6/6) (p=0.025).
Conclusion: The higher expression of ER, the lower and limited 
expression of ATBF1. The observation may be relevant to the brea-
king down mechanism of ATBF1 through estrogen-ER signaling 
discovered in breast cancer. The protein stability of ATBF1 should 
be an important factor for the prognosis of lung cancer distinguis-
hed by the sex.
Keywords: Sex difference, Lung cancer, ATBF1, estrogen receptor
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P1.01-024 EVALUATION OF VASCULAR NORMALIZATI-
ON IN HUMAN LUNG ADENOCARCINOMA INDUCED BY 
EGCG AND THE EFFICACY OF COMBINE CHEMOTHE-
RAPY IN ITS NORMALIZATION TIME WINDOW
Peng Bo Deng, Cheng Ping Hu, Hua Ping Yang, Zeng Xiong, Yuan 
Yuan Li
Department Of Respiratory Medicine, Xiangya Hospital, The Central 
South University/China
Background: Microvasculature and microenvironment play impor-
tant roles in proliferation, metastasis and prognosis in human lung 
adenocarcinoma, which might be altered by many anti-angiogenic 
drugs and cause “vessel normalization”. Epigallocatechin-3-gallate 
(EGCG), a natural anti-angiogenesis agent refined from green tea, 
was defined to have multiple effects on angiogenesis factors. So 
we hypothesizing that EGCG might cause “vessel normalization”, 
and in addition combined chemotherapy exert a synergistic effect 
in the tumor vessel normalization window caused by EGCG.
Methods: Build nude mice xenograft tumor model(A549 cell line). 
Randomly divided them into three groups (treated with saline, 
EGCG, bevacizumab). Test following indexes at day of 0, 2, 4, 6, 9, 
12: Vessel structure: MVD, MPI; vessel GBM; Transmission-elect-
ron-microscope of microvessles; Vessel functional: perfusion func-
tion, vessel permeability; Microenvironment effect: IFP, PO2. Test 
cisplatin concentration in tumor tissues with different combination 
of EGCG and cisplatin. Treated mice with saline, cisplatin, EGCG, 
Microarray analysis was applied to these cells including original 
cells in order to detect specific gene alteration in each organ. Ex-
pressions of 28869 genes were evaluated in each cell using mic-
roarray analysis. Gene expressions of conditioned cells obtained 
from each organ were compared with original cells. The genes with 
expression altered 1.5 fold or more were regarded as significant. 
Adrenal gland specific alterations were checked using unpaired 
t-test. The values P<0.05 were regarded as significant.
Results: Adrenal gland metastasis specific alteration was obser-
ved in 76 genes. There were 59 genes with increased expressions 
and 17 genes with decreased expressions. The same statistical 
analysis was applied to lung, liver, kidney, bone, and muscle, too. 
We detected 22 genes as lung metastasis specific alterations, 212 
with liver, 25 with kidney, 141 with bone, and 27 with muscle. The 
most change in adrenal grand was increased expression of calbin-
din-D28k. Calbindin-D28k has anti-apoptotic properties. These 
properties may suppress steroid induced apoptosis and promote 
adrenal metastasis in lung cancer. In vitro evaluation revealed 
that proliferation of original PC-14 cells was inhibited by 1,4, 16, 
64 µg/ml of dexamethasone in the dose-dependent manner. On 
the other hand, proliferation of PC-14 cells obtained from adrenal 
grand was not inhibited by dexamethasone in all concentrations.
Conclusion: Microarray analysis was applied to find the gene ex-
pression influencing organotropism of lung cancer adrenal metas-
tasis. Our study results detected 76 genes as the candidates. Cal-
bindin-D28k seemed to regulate lung cancer adrenal metastasis.
Keywords: organotropism, adrenal metastasis, steroid induced 
apoptosis, microarray analysis
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P1.01-023 THE EXPRESSION OF ATBF1 IS INVERSELY 
PROPORTION TO THE EXPRESSION OF ESTROGEN RE-
CEPTOR IN LUNG CANCER CELLS
Masaaki Inoue1, Makoto Kawaguchi2, Junya Fukuoka3, Yutaka 
Miura4
1Chest Surgery, Shimonoseki City Hospital/Japan, 2Pathology, Niigata 
Rosai Hospital/Japan, 3Pathology, Nagasaki University, Graduate School 
Of Biomedical Sciences/Japan, 4Bioregulation & Molecular Neurobiology, 
Nagoya City University, Graduate School Of Medical Sciences/Japan
Background: Sex difference is an important factor to differentiate 
the clinical characteristics of lung cancers. Sex hormones derived 
signaling should be involved in the etiology of lung cancers. The 
most important factor may be estrogen that is suspected car-
cinogen, since strong epidemiological evidence associates the 
hormone to breast, endometrial, and uterine cancers. We have 
been studied the involvement of ATBF1 that is a large transcription 
factor playing an important role as a tumor suppressor in various 
cancers. Intriguing fact is that estrogen at lower levels increases 
the expression of ATBF1, but at higher levels decreases ATBF1. The 
response of ATBF1 is explained by the negative feedback through 
the estrogen-responsive proteasome system. This is the first study 
to reveal the expression of ATBF1 in lung cancers and explain the 
clinical characteristic of lung cancer differentiated by sex.
Methods: We prepared a cell line array from 17 lung cancer cell 
lines, which was consisted of twelve adenocarcinomas, three 
squamous cell carcinomas, one large cell carcinoma and one un-
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membrane potentials and to activate caspase-9 followed by the 
effector caspase-3, via A3 adenosine receptor.
Keywords: A549 lung cancer cell, Apoptosis, Transcription, Bcl-2 
family
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P1.01-026 PRO-TUMORIGENIC ALTERATION OF SIGNAL-
LING PATHWAYS IN NORMAL MESOTHELIUM: CONTRI-
BUTION OF NON-MESOTHELIAL CELLS IN MALIGNANT 
MESOTHELIOMA CARCINOGENESIS
Tatyana Chernova1, Pavithra Kumar1, Fiona Murphy1, Xiao Ming 
Sun1, Stefano Grosso1, Jonathan Bennett2, Apostolos Nakas2, Mari-
on Macfarlane1, Martin Bushell1, Anne E. Willis1
1Toxicology Unit, Mrc/United Kingdom, 2Glenfield Hospital, University 
Hospitals Of Leicester, NHS Trust/United Kingdom
Background: Malignant mesothelioma (MM) is an aggressive, 
fatal tumour of the pleura or peritoneum and strongly related to 
asbestos exposure. Malignant pleural mesothelioma (MPM) is the 
most common and occurs with a latency of up to 40 years. The 
mechanism of MM carcinogenesis is not well understood and the 
heterogeneity of the tumour is considered to be a major barrier to 
successful therapy. Several studies have identified changes in the 
expression and activities of defined cell signalling pathways in me-
sothelial and stromal cells, but the relationship between different 
cell types in the process of tumorigenesis has not been studied.
Methods: To examine the pro-oncogenic role(s) of different cell 
populations, the effect of primary fibroblasts from human meso-
theliomas and activated macrophages on cellular signalling in nor-
mal untransformed mesothelial cells was monitored using imaging 
and immunoblotting techniques.
Results: Although the subcellular location of damage-associated 
molecular pattern (DAMP) protein HMGB1 remained nuclear in 
normal mesothelial cells co-cultured or treated with conditioned 
medium, the activation levels of growth modulating signalling pa-
thways were altered in these cells. The proliferation and migration 
rates of normal mesothelial cells were also affected by paracrine 
signalling from activated fibroblasts and macrophages.
Conclusion: Thus, non-mesothelial cells instigate alterations in 
cellular signalling in mesothelial cells. Further integral examination 
of the aberrant signalling pathways, especially at early stages of 
neoplasia, will provide new insights into the mechanisms underly-
ing malignant mesothelioma carcinogenesis.
Keyword: mesothelioma, carcinogenesis, proliferation, migration,
EGCG+cisplatin on day0 and EGCG+cisplatin on day5 and record 
growth delay.
Results: EGCG treated group undergoing a persisting decrease 
of MVD, a gradual decrease of MPI, a transient elevation of vessel 
perfusion function, permeability and PO2, transient decrease of 
IFP in tumor tissue. Full-dose cisplatin at day5 had a concentration 
significantly higher than Full-dose at day0 and half-dose at d5. 
Statistical analysis shows EGCG and cisplatin had synergistic effect 
as a combined anti-tumor chemotherapy. Combined treatment 
groups had significantly lower xenograft tumor growth rates than 
other three groups, and tumor growth rate in combining cisplatin 
on day5 was significantly lower than on day0.
Conclusion: EGCG causes vessel normalization in human lung ade-
nocarcinoma tumor, the window is between Day 4 to Day 9. Com-
bined therapy in this window period can escalate drug concentrati-
on in local tumor tissue, and leads to anti-tumor synergistic effect, 
providing a new strategy for EGCG applying as a complementary 
chemotherapy drug.
Keywords: complementary chemotherapy, EGCG, human lung 
adenocarcinoma, tumor vessel normalization
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P1.01-025 APOPTOSIS-RELATED GENE TRANSCRIPTION 
IN HUMAN A549 LUNG CANCER CELLS VIA A3 ADENO-
SINE RECEPTOR
Hitomi Kamiya1, Takeshi Kanno2, Eriko Fujimoto1, Yoshiki Negi1, 
Yuichi Koda1, Daisuke Horio1, Shingo Kanemura1, Eisuke Shibata1, 
Miki Honda1, Hisaya Okuwa1, Eriko Masachika1, Risa Maeda1, Yos-
hitaka Nogi1, Koji Mikami1, Taiichiro Otsuki1, Takayuki Terada1, 
Kunihiro Tamura1, Chiharu Tabata1, Tomoyuki Nishizaki2, Taka-
shi Nakano1
1Division Of Respiratory Medicine, Hyogo College Of Medicine/Japan, 
2Division Of Bioinformation, Hyogo College Of Medicine/Japan
Background: Extracellular adenosine induces apoptosis in a varie-
ty of cancer cells via diverse signaling pathways. The present study 
investigated the mechanism underlying adenosine-induced apop-
tosis in A549 human lung cancer cells.
Methods: MTT assay, TUNEL staining, flow cytometry using pro-
pidium iodide and annexin V-FITC, real-time RTPCR, Western blot-
ting, monitoring of mitochondrial membrane potentials, and assay 
of caspase-3, -8, and -9 activities were carried out in A549 cells, 
and the siRNA to silence the A3 adenosine receptortargeted gene 
was constructed.
Results: Extracellular adenosine induces A549 cell apoptosis in 
a concentration(0.01-10 mM)-dependent manner, and the effect 
was inhibited by the A3 adenosine receptor inhibitor MRS1191 or 
knocking-down A3 adenosine receptor. Like adenosine, the A3 ade-
nosine receptor agonist 2-Cl-IB-MECA also induced A549 cell apo-
ptosis. Adenosine increased expression of mRNAs for Puma, Bax, 
and Bad, disrupted mitochondrial membrane potentials, and acti-
vated caspase-3 and -9 in A549 cells, and those adenosine effects 
were also suppressed by knocking-down A3 adenosine receptor.
Conclusion: Adenosine induces A549 cell apoptosis by upregula-
ting expression of Bax, Bad, and Puma, to disrupt mitochondrial 
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P1.02-001 A COMMON POLYMORPHISM IN PRE-MI-
CRORNA-146A IS ASSOCIATED WITH LUNG CANCER 
RISK IN A KOREAN POPULATION
Hyo-Sung Jeon1, Shin Yup Lee2, Mi Young Kim3, Keum Ju Choi3, Ji 
Yun Jeong4, Mi Jung Hong1, Ji-Ae Jang1, Jin Eun Choi1, Seung Soo 
Yoo2, Jaehee Lee3, Eung Bae Lee2, Seung Ick Cha3, Chang Ho Kim3, 
Jae Yong Park2
1Department Of Biochemistry, Kyungpook National University, School 
Of Medicine/Korea, 2Lung Cancer Center, Kyungpook National Universi-
ty Medical Center/Korea, 3Department Of Internal Medicine, Kyungpook 
National University Hospital/Korea, 4Department Of Pathology, Kyung-
pook National University Medical Center/Korea
Background: MicroRNAs (miRs) play important roles in the deve-
lopment and progression of human cancers. MiR-146a down-regu-
lates epidermal growth factor receptor and the nuclear factor-κB 
regulatory kinase interleukin-1 receptor-associated kinase 1 genes 
that play important roles in lung carcinogenesis. This study was 
conducted to evaluate the association between rs2910164C>G, a 
functional polymorphism in the pre-miR-146a, and lung cancer risk.
Methods: The rs2910164C>G genotypes were determined in 
1,094 patients with lung cancer and 1,100 healthy controls who 
were frequency matched for age and gender.
Results: The rs2910164 CG or GG genotype was associated with a 
significantly decreased risk for lung cancer compared to that of the 
CC genotype (adjusted odds ratio = 0.80, 95% confidence interval 
= 0.66-0.96, P = 0.02). When subjects were stratified according to 
smoking exposure (never, light and heavy smokers), the effect of 
the rs2910164C>G genotype on lung cancer risk was significant 
only in never smokers (adjusted odds ratio = 0.66, 95% confidence 
interval = 0.45-0.96, P = 0.03, under a dominant model for the C 
allele) and decreased as smoking exposure level increased (Ptrend < 
0.001).
Conclusion: These findings suggest that the rs2910164C>G in pre-
miR-146a may contribute to genetic susceptibility to lung cancer, 
and that miR-146a might be involved in lung cancer development.
Keyword: Lung cancer, Risk factor, miR-146a, MicroRNA
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P1.01-027 LONG NON-CODING RNAS: A NEW FRON-
TIER IN THE STUDY OF HUMAN DISEASES
Yong Song
Department Of Respiratory Medicine, Nanjing Jinling Hospital/China
Background: With the development of whole genome and 
transcriptome sequencing technologies, long noncoding RNAs (ln-
cRNAs) have received increased attention. Multiple studies indica-
te that lncRNAs act not only as the intermediary between DNA and 
protein but also as important protagonists of cellular functions. 
LncRNAs can regulate gene expression in many ways, including 
chromosome remodeling, transcription and post-transcriptional 
processing. Moreover, the dysregulation of lncRNAs has increa-
singly been linked to many human diseases, especially in cancers. 
Here, we reviewed the rapidly advancing field of lncRNAs and 
described the relationship between the dysregulation of lncRNAs 
and human diseases, highlighting the specific roles of lncRNAs in 
human diseases.
Methods: not applicable
Results: not applicable
Conclusion: Continuing advances in transcriptomics indicate that 
lncRNAs fulfill important functions in the regulation of gene ex-
pression. With this updated view of molecular biology, the central 
dogma may be re-written. In this review, we have described some 
examples of lncRNAs involved in disease-associated processes 
(such as cancer initiation and progression), as well as highlighted 
the diverse mechanisms of lncRNAs. As with the dysregulation of 
miRNAs, dysregulation of lncRNAs is becoming recognized as a 
hallmark feature of many types of diseases. Importantly, cancer-
associated lncRNAs may serve as diagnostic or predictive biomar-
kers of cancer and also provide a new therapeutic strategy of se-
lectively silencing cancer-associated lncRNAs. However, compared 
with coding RNA and miRNA, there are still significant gaps in our 
current understanding of lncRNA function. Further studies are nee-
ded to elucidate the networks of proteins, miRNAs and lncRNAs.
Keywords: human diseases, mechanism, long non-coding RNAs
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P1.02-003 SYNERGETIC STUDY OF CHEMOTHERAPEU-
TIC DRUGS ACCORDING TO ATM STATUS IN NSCLC 
CELL LINES
Rachel A. Yee, Lars F. Petersen, Anifat A. Elegbede, D G. Bebb
Oncology, Tom Baker Cancer Centre, University Of Calgary/Canada
Background: The ataxia telangiectasia mutated (ATM) gene pro-
duces a protein essential in mechanisms responsible for regulating 
the controlled growth and proliferation of cells, as well as the DNA 
damage response. The lack of ATM expression can lead to a pre-
disposition to cancer due to the inability for the protein to actively 
respond to DNA damage. Previous work in the Bebb lab has shown 
that the lack of ATM gene expression in non-small cell lung cancer 
(NSCLC) cells increases sensitivity to ionizing radiation, however 
little is known about whether ATM status can influence sensitivity 
to commonly used chemotherapeutic agents. In this study we will 
explore the chemosensitivity of NSCLC cells in relation to their 
ATM status, as well as the synergistic effects of combining multiple 
agents to help develop new treatment strategies for patients with 
low or absent ATM expression.
Methods: Several NSCLC cell lines were screened to identify the 
ATM and p53 status. Of the cell lines screened, four NSCLC cell 
lines: NCI-H460, NCI-H226, NCI-H23, and NCI-H1395 were chosen 
to treat with various chemotherapeutic agents. Optimization of 
cell proliferation for each cell line was conducted to determine the 
appropriate concentration of cells that allows for continued proli-
feration after a 72 hour period. Each of the agents used for cyto-
toxicity assays target a different mechanism of the cell, including 
topoisomerase I inhibitors, DNA damaging and alkylating agents, 
and mitotic and cell cycle inhibitors. The Chou-Talalay method for 
drug combinations was utilized as the combination index theorem 
provides a quantitative definition for examining additive, synergi-
stic and antagonistic effects with our primary focus of observing 
synergy.
Results: Several NSCLC cell lines were characterized for their ATM 
status, and four were selected for cytotoxicity assays: H460 and 
H226 (ATM normal), and H23 and H1395 (ATM deficient). We ob-
served a noticeable difference in growth rate between cell lines 
in addition to the differences in ATM and p53 status. Similarly, the 
cytotoxic response to the chemotherapeutic agents varied greatly, 
and the relationship of drug sensitivity to ATM status in the cells, 
as well as the synergistic response to combinational therapy will be 
presented and discussed.
Conclusion: The results of this study have several important im-
plications. Our previous work has shown that resected, early sta-
ge NSCLC patients with low ATM expression have worse overall 
survival, however our demonstration that ATM deficient cell lines 
are more sensitive to cancer therapy could indicate that these 
same patients would respond better to certain lines of treatment. 
Similarly, increased sensitivity to combinational therapy will help 
mitigate detrimental side effects, leading to better quality of life 
during treatment periods.
Keywords: ATM, chemosensitivity, NSCLC, combination therapy
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P1.02-002 ATM DEFICIENCY INCREASES RADIATION 
SENSITIVITY IN NSCLC CELL LINES IN VITRO AND CON-
FERS A POOR OUTCOME IN EARLY RESECTED NSCLC.
Gwyn Bebb
Medicine, University Of Calgary/tom Baker Cancer Centre/Canada
Background: ATM is a nuclear protein that plays a central role in 
the cellular response to DNA double stand breaks (DSBs), the DNA 
damage response (DDR). In mammalian cells, the DDR consists of 
co-ordinated multi-facet cellular processes, including DSB repair, 
cell cycle checkpoints and apoptosis which together act as barriers 
to tumor-genesis. Germ-line mutations in ATM result in the cancer-
predisposing human disorder A-T (Ataxia telangiectasia). Inactivati-
on of ATM due to gene mutations, epigenetic silencing and altered 
protein expression is found in many cancers including NSCLC. The 
role of ATM loss in NSCLC is incompletely defined. Early loss of 
ATM would be expected to cause an increased predisposition to 
mutation accumulation and the generation of neo-antigens that 
increase a tumour’s immunogenicity and lead to an increased sen-
sitivity to PARP inhibition and radiation. We set out to determine 
the prevalence and significance of ATM loss in NSCLC cell lines 
and in resected NSCLC samples.
Methods: A panel of 7 NSCLC cell lines was screened for ATM 
protein expression levels using western blot. ATM signaling was 
investigated using specific antibodies to determine p-S1981 ATM, 
p-S824 KAP1 and p-S15 p53 following treatment of the cells with 
IR. ATM functionality was assessed by clonogenic survival assay 
to assess cellular viability after IR treatment. Clinical data was 
collected retrospectively through chart review of NSCLC patients 
diagnosed at the Tom Baker Cancer Centre from 2003 to 2006 
and entered into the Glans-Look Lung Cancer Database. Archived 
formalin-fixed paraffin-embedded (FFPE) resected NSCLC tumour 
samples were retrieved and tissue microarrays constructed. Au-
tomated image acquisition was performed using a HistoRx PM-
2000™. The ATM expression index was defined as the minimum 
ratio of the malignant cell specific AQUA score as compared with 
the non-malignant tumour-associated stromal cell specific AQUA 
score. Differences in the survival were compared using the log-
rank test for low versus high ATM expression index groups and 
ATM expression groups as well as the stage subgroups. Cox pro-
portional hazards regression was used to assess the prognostic 
effect of both ATM expression index.
Results: ATM deficiency was found in two NSCLC cell lines. The 
ATM deficient cell line, H23 demonstrates increased sensitivity to 
IR, disrupted ATM signaling and has the least surviving fraction of 
cells after treatment with single agent PARP inhibitor and topo-
tecan. Our methodology identified an ATM-EI cutpoint of 0.716, 
defining 36/165 (21.8%) of patients as being ATM-deficient, many 
with stage I disease. After adjusting for histology, gender, age, and 
adjuvant treatment, the ATM-EI had no impact on stage I disease, 
but was a significant adverse prognostic factor for disease free sur-
vival (HR: 4.75, 95% CI: 2.02 to 11.17, p<0.001) and overall survival 
(HR: 5.09, 95% CI: 2.07 to 12.52, p<0.001) among those with stage 
II/III disease.
Conclusion: This study confirms ATM loss occurs in NSCLC cell 
lines and has therapeutic implications. It also demonstrates that 
ATM loss is seen in early stage NSCLC and is the first to show the 
prognostic consequences of this molecular deficiency. ATM status 
should be considered in designing new NSCLC clinical trials.
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ne response, and inflammatory pathways. Anandamine degradati-
on and ephrin receptor signaling were preferential to NS.
Conclusion: Our novel, multi-omics tumour system based ap-
proach revealed genes prominently disrupted in CS and NS lung 
AC which were associated with several cellular pathways commonly 
or differentially disrupted in these two groups. Pathways affected 
by genes disrupted at both the DNA and RNA level may contribute 
to the distinct clinical characteristics associated with CS and NS 
lung cancer and may serve as targets for intervention.
Keyword: adenocarcinoma, smokers, never-smokers, genomics
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P1.02-005 PROGNOSTIC ROLE OF EXPRESSION LEVELS 
OF FABP3, H19, TFPI2, AKR1B10 CYP3A5, SCGB3A2 GE-
NES IN ADENOCARCINOMA STAGE I PATIENTS
Vienna Ludovini1, Annamaria Siggillino1, Fortunato Bianconi2, 
Lorenza Pistola1, Francesca R. Tofanetti1, Rita Chiari1, Giulio Met-
ro1, Antonella Flacco1, Elisa Baldelli1, Mark Ragusa3, Lucio Cagini3, 
Stefano Treggiari4, Guido Bellezza5, Giuseppe Servillo6, Angelo 
Sidoni5, Francesco Puma3, Lucio Crino1
1Medical Oncology Department, S. Maria Della Misericordia Hospital/
Italy, 2Department Of Electronic And Information Engineering/Italy, 
3Department Of Thoracic Surgery, S. Maria Della Misericordia Hospital/
Italy, 4Department Of Thoracic Surgery, S. Camillo Forlanini Hospital/
Italy, 5Institute Of Pathological Anatomy And Histology, University Of 
Perugia/Italy, 6Department Of Clinical And Experimental Medicine, 
University Of Perugia/Italy
Background: In resected lung cancer, no reliable clinical or mo-
lecular predictors are currently available for identifying patients 
with high risk for developing recurrent disease. In a previous study, 
we compared gene expression profiling from adenocarcinoma 
specimens and normal lung tissue with non relapse (NR) and early 
relapse (ER), using Affimetrix human microarray HG-U133Plus 2.0. 
We selected 5 genes up-regulated and 4 genes down-regulated 
were predictive for clustering patients in ER and NR (Siggillino et 
al. ECCO 2011). Here, we validate our results using an independent 
cohort of patients with lung adenocarcinoma stage I to identify 
novel genes involved in the risk of ER compared to NR disease.
Methods: From tissue baNKIng of 180 consecutive resected NS-
CLC stage I patients at two Italian institutions, we selected 58 fro-
zen specimens of lung adenocarcinoma tissue with corresponding 
normal lung. Total RNA was isolated from tumor and normal lung 
specimens using RNA Universal Tissue Kit and automatically puri-
fied by Biorobot-EZ1 instrument (Qiagen). Quantification of mRNA 
expression levels of 9 genes (5 up-regulated: CLCA2, FABP3, 
H19, TFPI2, AKR1B10 and 4 down-regulated: CYP3A5, ALDH3A1, 
SCGB3A2, SCGB1A1, were analyzed by real-time one-step RT-PCR 
using QuantiFast technology by RotorGeneQ instrument (Qiagen), 
and the results were compared considering β-actin as the internal 
reference gene and as calibrator the pool of normal tissues of 
analyzed patients. The gene expression of all evaluated genes and 
their association with relapse disease measures were assessed by 
t-test and logistic regression model was used for multivariate ana-
lysis.
Results: Fifteen-eight adenocarcinoma stage I patients were 
evaluable, 17% of which had an ER. Patients characteristics were 
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P1.02-004 DIFFERENTIAL PATHWAY DISRUPTION IN 
LUNG ADENOCARCINOMAS FROM CURRENT AND NE-
VER SMOKERS - A MULTI-OMICS DATA INTEGRATION 
ANALYSIS
Kelsie L. Thu1, Mitra Mosslemi1, Emily A. Vucic1, Larissa A. Pikor1, 
Wei Zhang2, Suhaida Selamat3, Ite Laird-Offringa3, Adi F. Gazdar2, 
Raymond Ng4, John C. English5, Stephen Lam1, Calum E. Macau-
lay1, Wan L. Lam1
1Integrative Oncology, BC Cancer Research Centre/Canada, 2Utsw Ha-
mon Center For Therapeutic Oncology Research/United States Of Ame-
rica, 3Usc, Norris Cancer Center/United States Of America, 4University 
Of British Columbia Computing Science And Proof Centre Of The Heart 
And Lung Institute/Canada, 5Department Of Pathology, Vancouver 
General Hospital/Canada
Background: Lung cancers in smokers and never smokers (NS) are 
distinct clinical diseases. Specific molecular differences identified 
in these two groups include: EGFR and KRAS mutation, DNA me-
thylation levels at specific loci, and most recently, global mutation 
spectra. However, much remains to be understood about the 
biology driving lung tumourigenesis in smokers and NS in order to 
improve treatment outcome. To date, no multi-dimensional integ-
rative genomics (i.e. multi-omics) analysis designed to specifically 
compare current (CS) and NS lung tumours has been performed. 
We hypothesize that a multi-omics analysis which considers each 
tumour as its own unique perturbed system (as opposed to a grou-
ped approach) will reveal molecular mechanisms of lung adenocar-
cinoma (AC) biology that are common or different in CS and NS.
Methods: Copy number, DNA methylation, and gene expression 
profiles were generated for lung AC and matched non-malignant 
lung tissues from 34 CS and 30 NS. PCR was performed to deter-
mine EGFR and KRAS mutation status. Copy number, methylation 
and expression alterations were integrated for 14,000 genes on an 
individual tumour basis. Disrupted genes were ranked according 
to the magnitude of alterations they exhibited using a novel algo-
rithm we developed denoted MITRA. Of the genes scored by MIT-
RA, those raNKIng in the 99th and 1st (top) percentiles for up- and 
downregulation, respectively, were subjected to Ingenuity Pathway 
Analysis (IPA). IPA was performed separately on all 64 lung tu-
mours and pathway results for CS and NS were compared.
Results: We identified 361 genes that ranked in the top percen-
tiles for up- or downregulation in at least 20% of the lung ACs we 
assessed. Identification of recurrent RASSF1A downregulation, and 
EGFR upregulation predominantly in NS demonstrates the ability 
of our raNKIng algorithm to prioritize genes known to be involved 
in lung tumour biology using multi-dimensional genomics data. To 
determine cellular pathways and functions likely deregulated as a 
consequence of gene disruption, we performed IPA on each tu-
mour and determined the frequency of individual pathway disrup-
tion across tumours. This analysis revealed 88 annotated pathways 
with a minimum disruption frequency of 15% in either or both CS 
and NS. Commonly affected pathways involved: adhesion and 
extravasation implicating tumour invasion and migration; various 
catabolic and anabolic processes implicating cell metabolism; and 
several specific signaling pathways including atherosclerosis and 
Wnt/β-catenin signaling implicating inflammation and cell proli-
feration. Comparison of the pathways identified in CS and NS re-
vealed 13 differentially disrupted pathways (Fisher‘s Exact test p < 
0.05 and disruption frequency difference > 15%). Eleven pathways 
were preferentially disrupted in CS and affected metabolic, immu-
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ary 2013. 20 specimens were included in a tissue microarray (TMA) 
analysis, whereas 8 were screened in separate subset, due to the 
scarce samples. FISH test was performed using a combination of 
commercial reagents and custom designed probes. Median overall 
survival (OS) of mutated pts compared to the pan-negative ones, 
was evaluated by Cox multivariate analysis.
Results: Clinicopathological characteristics: among the 28 pa-
tients, 27 were never smokers and 1 former light smoker, with a 
good performance status; 20 (72%) presented with a metastatic di-
sease at diagnosis, 8 (28%) were locally advanced; median age was 
56 years-old, with a predominance of female sex (18/28, 64%). All 
cases were invasive adenocarcinomas and classified into 18 (64%) 
solid predominant type, 1 (3.5%) mixed acinar/lepidic pattern, 
1 (3.5%) papillary, no predominant subtype for 8 (28%) patients, 
because of unsufficient histological material available. Of the 28 
never smoker cases, we identified 7 gene fusions (25%), including 
2 pts ALK+ (7.1%), 3 pts ROS1+ (10.7%) and 2 RET+ cases (7.1%), 
one compatible with KIF5B:RET and other with CCDC6:RET fusion. 
Median OS for the entire cohort was 24.5 months (mo), 61.2 mo for 
mutated pts (any rearrangement) vs 24.1 mo for not-mutated, res-
pectively (P = .292).
Conclusion: Molecularly selected never smoker lung adenorcino-
mas associates with a high incidence of driver genes mutations and 
further investigations to confirm our frequencies in larger cohorts 
are needed. In line with literature data, our findings suggest a dif-
ferent survival outcome among genotypes, and identification of 
specific subsets in this special population can lead to successful 
treatment with target therapies.
Keywords: never smoker, lung adenocarcinoma, Driver mutation
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P1.02-007 VALIDATION AND FUNCTION OF A NOVEL 
MIRNA SIGNATURE IN CISPLATIN RESISTANT NON-
SMALL CELL LUNG CANCER CELLS
Lauren A. Mac Donagh1, Kenneth O‘Byrne2, Martin Barr1
1Institute Of Molecular Medicine, Trinity Centre For Health Sciences, 
Thoracic Oncology Research Group, School Of Clinical Medicine/Ireland, 
2Queensland University Of Technology, Cancer & Ageing Research Pro-
gram/Australia
Background: Lung cancer is the leading cause of cancer-related 
deaths worldwide, where non-small cell lung cancer (NSCLC) ac-
counts for 85% of cases. While cisplatin-based chemotherapy re-
mains the gold standard treatment for lung cancer, response rates 
are low due to increasing development of resistance to cisplatin. 
Circumventing cisplatin resistance, therefore, remains a critical 
goal for anti-cancer therapy. The aim of this study is to examine 
the role of miRNA’s in the regulation of cisplatin resistance in NS-
CLC using a panel of isogenic cisplatin resistant NSCLC cell lines 
developed in our laboratory, and to examine the putative cancer 
stem cell markers within this chemoresistant phenotype.
Methods: MicroRNA profiling of a panel of isogenic cisplatin re-
sistant (CisR) NSCLC cell lines, and age-matched parent cells (PT) 
was carried out using a 749 miRNA in-situ hybridisation array plat-
form (Nanostring Technologies). The miRNA signature obtained 
was validated by qPCR using miRCURY LNATM Universal RT miRNA 
PCR technology (Exiqon). In order to determine the role of these 
as follows: median age was 65.8 years (38.7-81.5), 67.2% were 
male, 91.3% were PS 0, 70.7% were ever-smokers. The expression 
median values of 9 genes: CLCA2, FABP3, H19, TFPI2, AKR1B10, 
CYP3A5, ALDH3A1, SCGB3A2, SCGB1A1 were 0.30, 0.71, 0.34, 
1.10, 0.26, 0.24, 0.42, 0.53, 0.09, respectively. Among all genes 
evaluated, the NR vs ER mean expression levels of two genes 
down-regulated (CYP3A5, 1.09 vs 0.30; SCGB3A2, 2.28 vs 0.98) 
and two genes up-regulated (AKR1B10, 4.53 vs 34.20; FABP3 1.25 
vs 1.55) were superimposable respect to the results of previous 
microarray analysis. The median disease free survival (DFS) and 
overall survival (OS) were 21 and 23 months, respectively. In the 
logistic multivariate analysis the mean expression levels of all ge-
nes showed a tendency to predict the ER in the overall population 
(p=0.07). Nevertheless considering only the expression levels of 
genes (FABP3, H19, TFPI2, AKR1B10, CYP3A5, SCGB3A2) identified 
as significant with t-test, the covariates in multivariate analysis in-
creased their capacity of ER prediction (p= 0.028).
Conclusion: Our results indicate that it is possible to define, 
through gene expression, a characteristic gene profiling of early 
relapse tumor patients with an increased risk of relapse disease. 
The contemporary expression levels of 6 genes (FABP3, H19, 
TFPI2, AKR1B10, CYP3A5, SCGB3A2) predicted a worse DFS. Such 
features may have important implications for future targeted the-
rapies. We thank Italian Association for Cancer Research (AIRC) for 
supporting the study.
Keywords: Gene expression, relapse of disease, stage I, lung ade-
nocarcinoma
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P1.02-006 IDENTIFICATION OF TARGETABLE DRIVER 
MUTATIONS IN MOLECULARLY SELECTED NEVER SMO-
KER LUNG ADENOCARCINOMAS
Chiara Bennati1, Dara Aisner2, Rita Chiari1, Marileila Varella-
Garcia3, Severine Kako3, Giulio Metro1, Guido Bellezza4, Vincenzo 
Minotti1, Vienna Ludovini1, Verena De Angelis1, Luca Marcomigni1, 
Lucio Crino1
1Medical Oncology, Santa Maria Della Misericordia Hospital/Italy, 2De-
partment Of Pathology, University Of Colorado Anschutz Medical Cam-
pus/United States Of America, 3Division Of Medical Oncology, Depart-
ment Of Medicine, University Of Colorado Anschutz Medical Campus/
United States Of America, 4Pathology, Santa Maria Della Misericordia 
Hospital/Italy
Background: Approximately 25% of lung cancers occur in lifelong 
never smokers. Although no dominant risk factor has been iden-
tified yet, the discover of molecular drivers potentially targetable 
with biological agents, makes lung cancer in never smokers a 
unique disease, candidate for a personalized therapy. Through 
the FISH test, we performed a screening for ALK, ROS1, and RET 
rearrangements, in a highly selected population of lung adenocar-
cinoma never smoker patients, previously demonstrated to be 
wild-type for EGFR and K-RAS mutations.
Methods: We collected archived histological material of 28 EGFR 
and K-RAS wild-type patients (pts), from a 200 never-smoker ad-
vanced lung adenocarcinomas database, to be analyzed for the 
presence of rearrangements in ALK, ROS1 and RET genes. All pts 
were treated at the Division of Medical Oncology of the S Maria 
della Misericordia Hospital in Perugia from October 2003 to Febru-
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mutations which are common in cancer. Therefore, understanding 
the molecular basis for genomic instability is key to the develop-
ment of future therapeutics with clinical relevance.
Methods: To determine if hSSB1 expression is associated with 
lung cancer progression, a tissue microarray (TMA) with cores from 
550 patients was stained with an anti-hSSB1 antibody. Kaplan-
Meier survival curves were generated with the clinical data and 
patient prognosis was correlated with hSSB1 expression levels. 
To determine an in vitro association with lung cancer, A549 lung 
cancer cells were treated with hSSB1 specific siRNA. Cell survival 
was determined by microscopy and MTT assay. To examine the 
role of hSSB1 in repair of oxidised DNA, U2OS cells were treated 
with 500 µM H2O2. Cells treated with H2O2 were fixed, stained with 
antibodies for hSSB1 and 8-oxoG and examined by deconvolution 
microscopy. Lysates were collected from H2O2 treated U2OS cells 
and subjected to immunoprecipitation and Western blot analysis. 
Genomic DNA isolated from scrambled or hSSB1 siRNA U2OS cells 
treated with H2O2 were immobilised on nylon membrane and stai-
ned with antibodies for 8-oxoG.
Results: Significantly, TMA staining of lung cancer tissues indica-
ted universal overexpression of hSSB1. Survival curves generated 
from the patient data indicated a poorer prognosis for patients 
with increased hSSB1 expression versus lower expressing tumours. 
Interestingly, in vitro inhibition of hSSB1 using siRNA significantly 
reduced cell survival. These data highlight the potential prognostic 
value of hSSB1 expression. As oxidative stress is prevalent in lung 
cancers, we also tested whether hSSB1 is capable of repairing 
8-oxoG DNA lesions. Following oxidative DNA damage, hSSB1 
localises rapidly to chromatin. hSSB1 also directly interacts with 
OGG1 to facilitate OGG1 recruitment to chromatin and repair of 
DNA damage. Importantly, cells lacking hSSB1 display ineffective 
repair of 8-oxoGs.
Conclusion: Our data highlight a potential role for hSSB1 in lung 
cancer progression and a novel role in maintenance of genome 
integrity. As tumours have increased genomic instability, elevated 
hSSB1 expression in lung cancer may enable tumours to cope with 
genomic instability. Taken together, these data present hSSB1 
both as a prognostic marker and a novel therapeutic target.
Keyword: Oxidative stress, genome instability
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P1.02-009 KCTD11 METHYLATION IN NON-ADENOCAR-
CINOMA LUNG CANCER
Jian Ni1, Jianfang Xu1, Ying Xu1, Zhidong Xu2, Liang You2, David M. 
Jablons2
1Department Of Oncology, Shanghai Pulmonary Hospital/China, 2Jab-
lons Lab,UCSF/United States Of America
Background: Lung cancer is the leading cause of cancer-related 
death worldwide. Nowdays, the histological subtypes of lung can-
cer and corresponding genetic polymorphisms play an important 
role in deciding the treatment options. KCTD11, a novel tumor sup-
pressor, acts on antagonizing Hedgehog (Hh) signaling pathway 
. The deregulation of KCTD11 might activate glioma-associated 
oncogene homolog 1(Gli) transcription factors and lead to tumo-
rigenesis. The present study was designed to analyze expression 
of the KCTD11 in different pathological lung cancer cell lines and 
miRNA’s in conferring cisplatin resistance, transfection of cell lines 
using miR-specific antagomirs and pre-miR’s will be carried out 
to examine this effect on sensitising lung cancer cells to cisplatin 
using clonogenic survival assays, apoptosis (APC), proliferation 
(BrdU) and DNA damage repair (γH2AX) assays. Furthermore, the 
characterisation and potential role of exosomes and exosomal-
derived miRNA in modulating the cellular response to cisplatin 
chemotherapy will also be examined in this model of resistance. 
Putative stem cell markers (Oct-4, Sox-2, Nanog, SSEA4, Klf-4 and 
c-Myc) will be assessed in holoclones derived from resistant subli-
nes. An in vivo model will be used to The tumourigenic potential of 
putative cancer stem-like cells within the cisplatin resistant popula-
tion will be investigated in vivo using NOD/SCID mice. In parallel, 
asymmetric division assays will also be used.
Results: MicroRNA profiling of MOR, H460, A549, SKMES-1 and 
H1299 cisplatin resistant cell lines deduced a 3-miR signature ac-
ross all five chemoresistant cell lines. Validation of this miR signa-
ture by qPCR showed differential expression of only one miRNA, 
miR30-c. miR-30c was significantly up-regulated (15-40 fold) in 
MOR, H460, SKMES-1 and H1299 CisR NSCLC cell lines and sig-
nificantly down-regulated (5-fold) in A549 CisR cells relative to PT 
cells. The effects of miR-30c antagomirs and pre-miR’s in reversing 
the cisplatin resistant phenotype of NSCLC cells are currently 
being examined.
Conclusion: Differential expression of 3 specific miRNA’s was de-
monstrated in CisR lung cancer cells, relative to their parent coun-
terparts, using an in-situ miRNA profiling hybridisation platform. 
While validation of this panel of miRNA’s identified only one dif-
ferentially regulated miRNA species, miR30-c, further studies are 
warranted to explore the role of miR-30c in the cisplatin resistance 
phenotype of NSCLC. Exosome and cancer stem cell studies are 
currently under investigation.
Keyword: Cisplatin Resistance, MicroRNA
POSTER SESSION 1 - NOVEL CANCER GENES AND PATHWAYS  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.02-008 HSSB1: AN ESSENTIAL REGULATOR OF GE-
NOMIC INTEGRITY IN LUNG CANCER
Mark N. Adams1, Vincent Leong1, Nicolas Paquet1, Emma Bolder-
son1, Dean A. Fennell2, Kenneth O‘Byrne1, Derek Richard1
1Queensland University Of Technology, Translational Research Institu-
te/Australia, 2Department Of Cancer Studies And Molecular Medicine, 
University Of Leicester/United Kingdom
Background: Lung cancer remains a leading cause for cancer mor-
tality worldwide. A key feature of lung cancer development is ge-
nomic instability resulting from an accumulation of DNA lesions. In 
normal settings, these DNA lesions, such as double strand breaks 
and oxidised DNA, are rapidly repaired to prevent cytotoxicity and 
loss of genetic information. However, the molecular basis for the 
loss of genome integrity during cancer development remains to be 
determined. Herein, we have examined the involvement of hSSB1 
in maintenance of genome stability and its potential role in lung 
cancer progression. hSSB1 is a critical component of the repair 
of DNA double strand breaks. As part of this study, we examined 
if hSSB1 is also involved in the repair of oxidative stress-induced 
DNA modifications. The most common nucleotide modification, 
8-oxo-7,8-dihydro-guanine (8-oxoG), is repaired by the enzyme 
OGG1. Failure to repair these modifications results in mismatch 
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P1.02-010 EVALUATION OF THE ONCOGENIC ABILITY 
OF EML4-ALK TO TRANSFORM HUMAN BRONCHIAL 
EPITHELIAL CELLS (HBECS)
Shigehisa Kajikawa1, Mitsuo Sato1, Tetsunari Hase1, Tomohiko Ka-
kumu1, Eiichi Maruyama1, Ryo Yamashita1, Masashi Kondo1, John 
D. Minna2, Yoshinori Hasegawa1
1Department Of Respiratory Medicine, Nagoya University Graduate 
School Of Medicine/Japan, 2Hamon Center For Therapeutic Oncology 
Research And The Simmons Comprehensive Cancer Center, University 
Of Texas Southwestern Medical Center At Dallas/United States Of 
America
Background: Lung cancer is a highly lethal disease, and is belie-
ved to develop through a multistep carcinogenic process, which 
involves numerous genetic and epigenetic alterations. Among 
these alterations, mutations in “driver genes” such as KRAS and 
EGFR are found in non-small cell lung cancer (NSCLC) and they are 
demonstrated to contribute to a phenomenon, oncogene addic-
tion. Recently, the EML4-ALK (echinoderm microtubule-associated 
protein–like 4 anaplastic lymphoma kinase) fusion gene has been 
discovered as a novel driver gene in a subset of NSCLC. We evalu-
ated the oncogenic transformation ability of EML4-ALK by using an 
hTERT/CDK4-immortalized normal human bronchial epithelial cell 
(HBEC) model.
Methods: We used two HBEC lines, HBEC3 and HBEC4. Mutant 
KRASV12-expressing HBEC was used as a positive control for on-
cogenic transformation. A lentiviral vector system was used to 
generate HBECs stably expressing EML4-ALK. EML4-ALK protein 
expression was confirmed by westernblotting, and downstream 
pathways were analyzed by westernblotting with phospho-specific 
antibodies. Malignant phenotypes of EML4-ALK-expressing HBECs 
were examined by WST-1 proliferation assay and liquid and soft 
agar colony formation assays.
Results: Westernblotting analysis showed that EML4-ALK was ex-
pressed in HBECs. Analysis of downstream pathways did not show 
significant differences between EML4-ALK-expressing and control 
HBECs. Introduction of EML4-ALK in HBECs increased the number 
of soft agar colonies but its effect was not as strong as KRASV12.
lung cancer tissues, also the mechanism of KCTD11 inactivation 
and the possible affected downstream signal pathway.
Methods: Lung cancer cell lines and tissues were used to detect 
the expression of KCTD11. The clinical significance was analysed.
Methylation detection was completed. KCTD11 vectors were trans-
fected to squamous cell lung cancer cell lines to detect the Gli1 
expression.
Results: The expression of KCTD11 was detected in Small airway 
epithelial cell (SAEC) and 14 lung cancer cell lines. RT-PCR showed 
reduced expression in lung cancer cell lines, especially in small 
cell lung cancer cell (SCLC) lines and squamous cell lung cancer 
cell (SCC) lines compared with SAEC. In all 14 tested cell lines (5 
adenocarcinoma, 2 large cell, 3 SCC and 4 SCLC), we found these 
CpG islands were densely methylated in 3 of 4 SCLC cell lines, 2 of 
3 SCC cell lines and 1 of 2 large cell lung cancer (LCC) cell linesbut 
none of the 5 adenomacarcinoma cell lines and SAEC. TMA stai-
ning showed significantly lower expression of KCTD11 in SCC lung 
cancer tissues than in normal tissues (24.2% vs 87.5%, p=0.000) 
.Also 5 of 10 SCC tissues compared with 1 of 12 adenocarcino-
ma showed methylation status. IHC analysis showed that there 
was 44.1% (55/118) positive Gli1 expression in group of negative 
KCTD11 expression. Correlation analysis showed they might exist 
marginally negative correlation (r=-0.165, p=0.052). H2170 cell lines 
with KCTD11 plasmid transfection showed significantly reduced 
Gli-1 expression compared with control plasmid transfection. (pic-
ture 1) 
Conclusion: In summary, we found the reduced KCTD11 expressi-
on in lung cancer. Hypermethylation was the important mechanism 
of KCTD11 epigenetic change in non-adenocarcinoma lung cancer 
cell lines and tissues. KCTD11 silencing resulted in the high ex-
pression of Gli1, a downstream mediator of Hh signaling pathway, 
and might affected the tumorigenesis and development in lung 
cancer. Targeting the KCTD11 treatment and thus controlling the 
Hh pathway might a new treatment target in non-adenocarcinoma 
lung cancer.
Keyword: KCTD11, methylation,non-adenocarcinoma lung cancer, 
Gli1
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Recent clinical studies in patients with advanced cancer, inclu-
ding lung cancer, showed that RANKL inhibition with denosumab 
reduced the risk of skeletal-related events. Denosumab also im-
proved overall survival compared with zoledronic acid in patients 
with lung cancer. In addition to the well-defined expression in the 
bone compartment, RANK and RANKL expression has also been 
demonstrated in human lung cancer cell lines and the functional 
expression of RANK has been confirmed through the demonstra-
tion of RANKL-dependent responses. The current study assessed 
the expression of human RANK and RANKL in human primary lung 
cancer samples in order to gain a potential mechanistic understan-
ding of these clinical observations.
Methods: RANK and RANKL expression was analyzed in a panel 
of human primary lung cancer samples. Specific, monoclonal anti-
bodies against human RANK (N-1H8, N-2B10; Amgen) and human 
RANKL (M366, AMG161; Amgen) were validated and optimized 
for immunohistochemistry (IHC) and used for expression analysis. 
mRNA was quantified using RT-PCR. Expression of RANK and 
RANKL was determined by IHC in the carcinoma element, tumor 
adjacent normal lung, and infiltrating cells. Incidence was scored 
as a positive IHC signal (any intensity). The specificity of the anti-
bodies was substantiated by concordant signals observed using 
multiple independent analyses, including IHC, flow cytometry, and 
Western blots of positive and negative control cells and xenograft 
samples.
Results: Analysis of primary human lung cancer using IHC de-
monstrated RANK staining in the tumor epithelium of 9/16 (56%) 
non-small cell lung cancer (NSCLC) adenocarcinomas, 9/26 (34%) 
squamous cell carcinomas (SCC), and 5/10 (50%) small cell carcino-
mas (SCLC). RANKL staining was observed in the tumor epithelium 
of 12/16 (75%) adenocarcinomas, 5/26 (19%) SCC, and 3/10 (30%) 
SCLC. RANK and RANKL were also observed in infiltrating mac-
rophages and lymphocytes, respectively, within the majority of 
tumors examined. In addition, RANKL expression was frequently 
observed in type II pneumocytes of the alveoli, Clara cells of the 
terminal bronchioles, and in lymphocytes within the bronchus-
associated lymphoid tissue (BALT); RANK expression was observed 
in alveolar macrophages proximal to the tumor and in M-cells of 
BALT. Analysis of mRNA levels indicated significantly greater levels 
of both RANK and RANKL in primary human NSCLC as compared 
with normal lung.
Conclusion: RANK and RANKL expression was observed in the 
epithelial carcinoma element in human primary lung cancer. Whe-
ther the expression of RANK and/or RANKL on lung cancer will 
directly contribute to tumor progression and/or metastatic activity 
and whether RANKL inhibition has a potential direct anti-tumor 
effect in lung cancer beyond the well established bone-targeted 
mechanism remains an objective of ongoing research.
Keywords: denosumab, RANK, RANKL, NSCLC
 
A. Soft agar colony formation assay showing that EML4-ALK incre-
ased the number of colonies compared to control cells to a lesser 
extent than did KRASV12. B. Cell proliferation assay (MTS-1) showing 
no significant difference between EML4-ALK-expressing and con-
trol HBECs.
Conclusion: EML4-ALK alone did not induce dramatic oncogenic 
changes in HBECs. To acquire more malignant phenotype, addi-
tional genomic alterations may be required and this is now under 
investigation.
Keywords: EML4-ALK, malignant transformation, human bronchial 
epithelial cells, KRAS
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P1.02-011 RANK AND RANK LIGAND (RANKL) EXPRES-
SION IN PRIMARY HUMAN LUNG CANCER
Daniel Branstetter, Li-Ya Huang, William C. Dougal
Dept. Of Pathology, And Therapeutic Innovation Unit, Amgen, Inc./Uni-
ted States Of America
Background: RANKL is an essential mediator of osteoclast diffe-
rentiation, function, and survival. Tumor cells can induce RANKL 
expression in the bone stroma, causing activation of osteoclasts, 
leading to bone breakdown and subsequent tumor growth. In 
mouse models of lung cancer bone metastasis, RANKL inhibition 
by OPG-Fc can prevent tumor-induced osteolysis, decrease skel-
etal tumor burden, and increase survival. The effects on disease 
progression and survival may be explained by direct effects on the 
tumor in addition to indirect effects via osteoclast suppression. 
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P1.02-013 SDHB IS OVEREXPRESSED AND MAY BE A 
CANDIDATE TARGET FOR THERAPEUTIC INTERVENTI-
ON IN MALIGNANT PLEURAL MESOTHELIOMA
Cormac J. Jennings1, Arcangela G. Manente2, Stefan J. Marciniak3, 
Giulia Pinton2, Doris M. Rassl4, Luciano Mutti5, Warren Thomas1, 
Robert C. Rintoul3, Laura Moro2, Kenneth O‘Byrne6, Steven G. Gray7
1Molecular Biology, Royal College Of Surgeons In Ireland/Ireland, 2Dept. 
Of Pharmacological Sciences, University Of Piemonte Orientale/Italy, 
3Cambridge Institute For Medical Research (CIMR), University Of Cam-
bridge, Welcome Trust/MRC Building/United Kingdom, 4Histopathology, 
Papworth Hospital NHS Foundation Trust/United Kingdom, 5Medicine, 
Vercelli Hospital/Italy, 6Queensland University Of Technology, Cancer & 
Ageing Research Program/Australia, 7Clinical Medicine, Trinity College 
Dublin/st Jame‘s Hospital/Ireland
Background: Malignant pleural mesothelioma (MPM) is a rare 
aggressive cancer of the pleura. Asbestos exposure (through in-
halation) is the most well established risk factor for mesothelioma. 
The current standard of care for patients suffering from MPM is a 
combination of cisplatin and pemetrexed (or alternatively cisplatin 
and raltitrexed). Most patients however, die within 24 months of 
diagnosis. New therapies are therefore urgently required for this 
disease. The Succinate Dehydrogenase Complex, Subunit B, Iron-
Sulfur Protein (SDHB), is a subunit of the Succinate dehydrogenase 
or succinate-coenzyme Q reductase (SQR) or respiratory Complex 
II, and has recently been identified by us as an important element 
in MPM.
Methods: A panel of MPM cell lines inluding the normal pleural 
cells LP9 & Met5A were screened for expression of SDHB by RT-
PCR. Levels were subsequently examined in a cohort of snap-
frozen patient samples isolated at surgery comprising benign, 
epithelial, biphasic, and sarcomatoid histologies by RT-PCR and 
western blot. Finally the expression of SDHB in a large cohort of 
MPM specimens with clinical data was asessed by IHC.
Results: Expression of SDHB occurs in all cell lines. Significantly 
higher expression of SDHB is observed in the malignant tumour 
material versus benign pleura. There was a trend towards better 
survival for patients expressing higher levels of SDHB, but this was 
not statistically significant.
Conclusion: SDHB, a key member of oxidative energy metabolism 
is significantly altered in MPM. This may have important future 
implications for the management of MPM.
Keywords: SDHB, mesothelioma, mitochondria
POSTER SESSION 1 - NOVEL CANCER GENES AND PATHWAYS  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.02-012 PARACRINE RECEPTOR ACTIVATION BY MI-
CROENVIRONMENT AS A MECHANISM OF RET INHIBI-
TOR RESISTANCE IN CCDC6-RET LUNG CANCER CELLS
Hyun Chang1, Ji Hea Sung2, Sung Ung Moon2, Hye Jun Youn2, Jong 
Seok Lee1
1Internal Medicine, Seoul National University Bundang Hospital, Seoul 
National University College Of Medicine/Korea, 2Seoul National Univer-
sity Bundang Hospital/Korea
Background: Rearrangement of the proto-oncogene RET is a 
newly identified potential driver mutation in lung adenocarcinoma. 
Clinically available tyrosine kinase inhibitors (TKIs) such as suniti-
nib, sorafenib, and vandetanib target RET kinase activity, sugges-
ting that the patients with RET fusion genes may be treatable with 
a kinase inhibitor. However, the mechanisms of resistance to these 
agents remain largely unknown. Cancer cell microenvironments 
can critically affect cancer cell behaviors, including drug sensitivity. 
We determine whether microenvironmental factors trigger RET 
inhibitor resistance in LC-2/ad cell with CCDC6-RET fusion gene.
Methods: We investigated the effects of epidermal growth factor 
(EGF) and hepatocyte growth factor (HGF) on the susceptibility of 
CCDC6-RET lung cancer cell line to RET inhibitors (sunitinib, sora-
fenib, vandetanib and E7080)
Results: CCDC6-RET lung cancer cell was highly sensitive to RET 
inhibitors. EGF receptor (EGFR) ligand, EGF, activated EGFR and 
triggered resistance to sunitinib, E7080, sorafenib and vandetanib 
by transducing bypass survival signaling through Erk1/2 and Akt. 
The resistance to RET inhibitors was not induced by EGF in EGFR 
siRNA-treated cells. EGFR-TKI (gefitinib) resensitized cancer cells 
to RET inhibitors even in the presence of EGF. Endothelial cells, 
which were known to produce EGF, decreased the sensitivity of 
CCDC6-RET lung cancer cell to RET inhibitors, an effect inhibited 
by anti-EGFR antibody (cetuximab). HGF, MET receptor ligand, 
affected a drug response of sunitinib, not sorafenib, vandetanib 
and E7080.
Conclusion: Paracrine receptor activation by ligand from the mic-
roenvironment may trigger resistance to RET inhibition in CCDC6-
RET lung cancer cells, suggesting that receptor ligands from micro-
environment may be additional targets during treatment with RET 
inhibitors. LC-2/ad cell line was sensitive to E7080, which inhibited 
RET and its downstream targets. E7080 and other RET inhibitors 
may provide therapeutic benefits in the treatment of RET-positive 
lung cancer patients.
Keywords: E7080, RET gene, microenvironment, resistance
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Conclusion: Our results demonstrate that gene expression profiles 
are different in advanced lung adenocarcinoma patients with brain 
metastasis with or without WSE. These results could be used for 
predictive models related with BM in advanced lung cancer. The 
best genomic statistical value was obtained with Affymetrix conso-
le and “R” software language in this work. These results must be 
confirmed by increasing the experimental samples and validating 
in an independent cohort by PCR.
Keywords: Lung cancer, wood smoke, genomic profiles, tobacco
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P1.02-015 DIVERSE EFFECTS OF PAI-1 PROTEINS ON 
LUNG AND PROSTATE CANCER CELL INVASION.
Joanna Chorostowska-Wynimko1, Adriana Rozy1, Marta Kedzior1, 
Paulina Jagus1, Ewa Skrzypczak-Jankun2, Jerzy Jankun2
1Laboratory Of Molecular Diagnostics And Immunology, National In-
stitute Of Tuberculosis And Lung Diseases/Poland, 2Urology Research 
Center, Health Science Campus, University Of Toledo/United States Of 
America
Background: Acquisition of ability to uncontrolled migration is one 
of the fundamental properties of cancer cells, enabling them to 
infiltrate tissues and metastasize. PAI-1 is the major physiological 
inhibitor of urokinase (uPA), which plays a key role in migration and 
invasion of tumor cells.
Methods: The aim of present study was to analyze the impact of 
increasing concentrations of PAI-1 mutated forms: VLHL PAI-1 with 
very long half-life time, Vn neg PAI-1 - devoid of affinity towards 
vitronectin and wPAI -1 on lung (A549, NCI-H1299) and prostate 
(LNCaP, DU145) cancer cells invasive activity. Selected cell lines are 
characterized by different (normal and high) urokinase production.
Results: No effect of PAI-1 proteins on invasiveness of lung cancer 
cells was observed, while dose-dependent significant inhibition 
was demonstrated in both prostate cancer lines (DU145 and LN-
CaP) cultured with VLHL PAI-1 (respectively p<0,05 and p<0,01) 
and Vn PAI-1 neg (p<0,05). Not surprisingly wPAI-1 significantly 
stimulated prostate cancer cells invasiveness in all concentrations.
Conclusion: PAI-1 inhibitory effect on prostate cancer invasive 
activity is associated with anti-proteinase activity. Lung cancer cells 
invasiveness regulation seems not to be PAI-1-urokinase regulated.
Keywords: prostate cancer, PAI-1, Plasminogen activator inhibitor 
type 1, Lung cancer
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P1.02-014 THE GENE-EXPRESSION PROFILES IN ADVAN-
CED LUNG ADENOCARCINOMA ASSOCIATED WITH 
WOOD SMOKE OR TOBBACCO EXPOSURE ARE DIFFE-
RENT IN BRAIN METASTASIS
Alette O. Gomez1, Omar Macedo2, Gabriela M. Celis3, Claudia R. 
Escareño4, Oscar Arrieta5
1Internal Medicine, Instituto Nacional De Cancerologia/Mexico, 2Thora-
cic Oncology Clinic And Laboratory Of Experimental Oncology, Instituto 
Nacional De Cancerología (INCAN)/Mexico, 3Genomics, Instituto Naci-
onal De Medicina Genómica/Mexico, 4Biomatematics, Instituto Nacional 
De Medicina Genomica/Mexico, 5Clínica De Oncología Torácica Y Labo-
ratorio De Oncología Experimental, Instituto Nacional De Cancerología 
(INCAN)/Mexico
Background: Environmental factors contributed toward lung carci-
nogenesis. Tobacco-smoking is the major etiological factor related 
with lung cancer in 90% in the world compared with Mexico with 
66% of cases. In previous works we have demonstrated that other 
factors such as chronic exposure to wood smoke (WSE) are related 
to non-small-cell lung cancer (NSCLC) and it´s clinically and patho-
logically different from lung cancer arisen from tobacco-exposure, 
regarding on tumor histology, mutation profiles, brain metastasis 
incidence, response rate and overall survival. This work is aimed 
to estimate expression profiles related WSE on adenocarcinoma 
histology associated to pathological mechanisms that differ from 
other carcinogenic factors, such as tobacco exposure.
Methods: This study used clinical, longitudinal, prospective and 
observational. From January 2008 to June 2011, patients were 
admitted in Cancerology Institute with lung adenocarcinoma in 
stage IV, eligible for the inclusion. Clinical variables, WSE, gender 
and age. WSE was defined to being exposed to fumes by burning 
wood in fireplaces and wood stoves for five years for at least 4 
hours per day. The WSE index was calculated multiplying the num-
ber of daily hours exposed by years of exposure. Collaboration 
agreements with the Institute of Medical Genomics and approved 
within the Health Research Sectorial Fund, CONACyT-México (SA-
LUD-2009-01-115552). Primary biopsies were taken by guided tru-
cut needle by tomography. Samples were analyzed by the Patholo-
gy for histological/quantification of neoplasic celularity, and stored 
at -80°C. RNA was extracted from tumor biopsies. RNA integrity 
(RIN>6) was analyzed using the Agilent 6000. We used an Affy-
metrix Human GeneChip® 1.0 ST. Two-Cycle Target Labeling was 
followed for microarrays. Analysis was done by Affymetrix console 
and “R” software language. Matrices employ 29 microarrays with 
experimental contrasts. Differential expressed genes were analy-
zed by linear model that analyze contrasts between experimental 
contrasts. The Partek Genomic Software 4 and SAM (Significant 
Analysis) was used for microarray comparisons and integration of 
genomic data.
Results: Using computational genomics using fold changes and 
confiability data we found differences in genomic expression. In 
brain metastasis (BM) patients the Fold Change values >1 shows 6 
upregulated and 11 downregulated genes compared with or wit-
hout WSE. Patients without BM the Fold Change values >1 shows 
90 downregulated and 7 upregulated genes with or without WSE. 
Prior both analysis were confirmed with B statistics data (significant 
value ≥0). No difference were found using computational Geno-
mics SAMS (False discovery rate), neither PARTEK (p-value, fold 
change), on gene expression evaluation.
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information which is a key issue for the targeted treatment options.
Keywords: EGFR mutation, Cytology, non-small cell lung cancer
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P1.02-017 NLBP (NOVEL-LZAP BINDING PROTEIN) PRO-
MOTES THE PROLIFERATION OF LUNG ADENOCAR-
CINOMA CELLS THROUGH THE REGULATION OF P120 
CATENIN
Hae-Seong Nam1, Chang Hee Kim2, Eun Hee Lee2, Seung Hun Han2, 
Hee Jin Chung2, Hyun Jung Cho2, Nam Soo Lee2, Suk Jin Choi3, Ho-
joong Kim4, Jeong Seon Ryu1, Junhye Kwon5, Hongtae Kim2
1Pulmonology, Inha University Hospital/Korea, 2Sungkyunkwan Uni-
versity/Korea, 3Pathology, Inha University Hospital/Korea, 4Pulmonary 
And Critical Care Medicine, Samsung Medical Center/Korea, 5Biological 
Sciences, Sookmyung Women’s University/Korea
Background: NLBP (novel-LZAP binding protein, also known as 
KIAA0776 or Maxer) was originally indentified as a reciprocal binding 
partner of LZAP. LZAP possesses dual functionality as a tumor sup-
pressor and an oncogene in human cancers. Despite its strong associ-
ation with LZAP, the biological roles and underlying molecular mecha-
nisms of NLBP remain unknown. Recent studies indicating a possible 
link between p120 catenin (p120ctn) and NLBP in tumorigenesis.
Methods: We examined NLBP expression in 29 non-small cell lung 
cancers using immunohistochemical staining and immunoblotting, as 
well as an in vitro analysis of NLBP activity during cell proliferation in 
lung cancer cell lines. We next examined whether p120ctn plays a role 
in the molecular mechanism underlying NLBP activity
Results: In this study, we found that NLBP expression was increased 
in human lung adenocarcinomas, particularly early-stage adenocar-
cinomas, compared to squamous cell carcinomas. Furthermore, the 
overexpression of NLBP in H1299 cells resulted in an increase in cell 
proliferation. We next identified p120ctn as a novel NLBP-binding 
protein, and identified the reciprocal binding regions of these prote-
ins in lung cancer cell lines. We also demonstrated that NLBP promo-
tes cell proliferation by regulating the stability of p120ctn. This effect 
is mediated through the inhibition of ubiquitination, which occurs as 
a result of NLBP binding to p120ctn, leading to an increase in protein 
stability. 
Conclusion: In conclusion, the data presented here show that NLBP 
may act as a novel oncogene in the early stages of lung adenocarci-
noma, and may promote cell proliferation in lung adenocarcinoma 
through interactions with p120ctn. The interaction between NLBP and 
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P1.02-016 NON-SMALL CELL LUNG CANCER AND EGFR 
MUTATION IN POLAND - PRELIMINARY RESULTS FROM 
SINGLE INSTITUTION STUDY
Anna Szumera-Cieckiewicz1, Wlodzimierz Olszewski2, Andrzej 
Tysarowski2, Dariusz M. Kowalski2, Maciej Glogowski2, Janusz 
Siedlecki2, Michał Wągrodzki2, Monika Prochorec-Sobieszek1
1Department Of Diagnostic Hematology, Institute Of Hematology And 
Transfusion Medicine/Poland, 2Maria Skłodowska Curie Memorial Can-
cer Center And Institute Of Oncology/Poland
Background: Lung cancer is the first cause of death among all can-
cers in the world and every year more than 1.6 million patients die 
from lung cancer. In Polish population morbidity and mortality from 
lung cancer persist in the first location and amount respectively 21.4% 
and 31.2% of all cancers. Over the last 30 years the development of 
targeted therapy significantly influenced the routine practice in pa-
thology. The treatment based on identification of the type of tumor is 
still crucial information however the importance of predictive or prog-
nostic molecular markers has become significant step in the choice of 
treatment. Identification of mutations in the EGFR gene in non-small 
cell lung cancer (NSCLC) fully illustrates the impact of molecular biolo-
gy in treatment decisions. The use of one of the small molecule tyro-
sine kinase inhibitors, gefitinib or erlotinib depends on confirmation 
presence of activating somatic EGFR mutation.
Methods: The aim of the study was to evaluate the EGFR mutations 
in two types of material cytological and histological. 189 histological, 
paraffin-embedded materials as well as 12 fresh and 72 fixed cytology 
specimens obtained by trans-thoracic, computed tomography sup-
ported biopsy or during bronchofiberoscopy were included. Material 
and methods. 273 patients with confirmed NSCLC were entered into 
the study. Each specimen contained at least 50% of tumor cells. The 
macrodissecion was performed on histological specimens to maximi-
ze tumor cells content. DNA was extracted from both types of mate-
rial and the EGFR mutation was analyzed in exons 18, 19 20 and 21 
using the direct sequencing method
Results: The mean age of patients was 61.5 years (range 25 – 84 
years) with males predominance (151 males vs. 122 females). The his-
tological types included: adenocarcinoma 186 (69%), squamous cell 
carcinoma 44 (16%), NSCLC, not-otherwise specified 30 (11%), large 
cell carcinoma 9 (3%) and adenosquamous carcinoma 4 (1%). Both 
types of material were equally sufficient to evaluate EGFR mutations. 
The ratio of molecularly non-diagnostic material due to DNA degra-
dation or too scant DNA probe was respectively for cytological and 
histological material 1.2% vs. 4.75% (p<0.01). The percentage of EGFR 
somatic mutations were 10.62%. Females suffered more frequently 
from adenocarcinoma (females 70.49% vs. males 66.23%, p <0.01) 
and had significantly higher rate of EGFR mutations (females 17.21% 
vs. males 3.97%, p<0.01). Mutations in exons 21 and 19 together ac-
counted for 87% of all types of mutations of the EGFR gene. Apart 
from these, two patients had co-existence of activating/inhibiting 
mutations: L858R (exon 21) with T790M (exon 20) and G719C (exon 
18) with S768I (exon 20).
Conclusion: This study allows for the first time to estimate an EGFR 
mutation frequency in Polish population. Moreover the results have 
strengthened the importance of reusing cytological material in mo-
lecular evaluation. Cytological material recovered from fixed prepa-
rations and stained with hematoxylin and eosin showed comparable 
DNA quality to fresh tumor cells. The cytology especially fine needle 
aspirates as well as small biopsy material provide molecular biological 
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P1.02-019 C-MET EXPRESSION IN UNRESECTABLE OR 
STAGE IV CHEMONAIVE ADENOCARCINOMA OF THE 
LUNG AND ITS CO-EXISTENCE WITH OTHER DRIVEN 
MUTATIONS OR GENETIC ABNORMALITIES.
Edgardo S. Santos, Harold Richter, Stephen Grabelsky, Hilary Go-
molin, Howard Adler, Warren Brenner, Albert Begas
Medical Oncology, Lynn Cancer Institute/United States Of America
Background: EGFR mutation and EML4/ALK rearrangement have 
become standard genetic tests for patients with advanced ade-
nocarcinoma of the lung. Other driven mutations and genetic ab-
normalities are still investigational including c-Met expression. c-Met 
overexpression has shown to confer resistance to EGFR TKI. By 
targeting c-Met, studies suggest that lung cancer cells may respond 
again to EGFR TKI therapy. The incidence of c-Met in NSCLC is not 
clear yet as well as how it does interact with other biomarkers.
Methods: A retrospective study of 32 consecutive biomarker profile 
tests from patients with either unresectable or stage IV chemonaive 
adenocarcinoma of the lung were analyzed. We adopted a compre-
hensive biomarker panel as part of a common decision made from a 
lung cancer consortium. All patients’ samples were sent to Response 
Genetics Inc with an order to perform a panel of 9 biomarkers. We 
report the incidence of c-Met expression and its co-existence with 
other biomarkers.
Results: The tumor sample of 32 patients with unresectable or sta-
ge IV chemonaive adenocarcinoma of the lung were analyzed. All 
patients were Caucasian; gender: 18 females/14 males; median age: 
76 (range, 58-89); distribution of staging was: stage I: n=3, stage II: 
n=1, stage III: n=7 and stage IV: n= 21 patients. c-Met was ordered 
in 26 patients: 9 patients had c-Met overexpressed (34%), 5 had low-
expression (19%); 12 had no enough tissue for the test. None of the 
c-Met high expression patients had EGFR mutation; in this cohort, 
4/27 patients had EML4/ALK (15%) rearrangement; 2 of them had 
high c-Met expression; the other 2 did not have enough tissue. The 
presence of K-ras (25 tumor samples tested), PI3K (25 tumor sample 
tested), and ROS-1 (n=26 tumor samples tested) mutations were 
12/25 (48%), 1/25 (4%), and 0/26, respectively.
Conclusion: Our cohort is small, and this may explain the high 
EML4/ALK and low EGFR incidence (sample size and patient selec-
tion). However, it is crucial to increase our knowledge on how these 
biomarkers interact themselves and what kind of role do they play in 
lung carcinogenesis. Some novel trials propose a double target ap-
proach in patients who have two pathways overexpressed. Hence, it 
is imperative that we develop a molecular phenotype data to under-
stand these co-existence genetic phenomenon. Our cohort confir-
med the high incidence of K-ras mutations in adenocarcinoma of the 
lung and also showed that c-Met high expression may be common 
in chemonaive patients without prior exposure to EGFR TKI. Interes-
tingly, our 2 EML4/ALK patients also had c-Met highly expressed. 
PI3K and ROS-1 mutations seem to be rare genetic abnormalities.
Keywords: unresectable lung cancer, c-Met, EGFR, EML-4/ALK, 
ROS-1, adenocarcinoma of the lung, chemonaive
p120ctn provides new implications for interplay between signaling 
pathways and protein networks in tumor development
Keywords: p120 catenin, NLBP (novel-LZAP binding protein), cell 
proliferation, lung adenocarcinoma
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P1.02-018 THE WNT SIGNALING PATHWAY IN LUNG 
CARCINOID
Rosario Garcia Campelo1, Guadalupe Aparicio Gallego1, Guillermo 
Alonso1, Teresa Hermida1, Mar Haz Conde1, Moises Blanco Calvo1, 
Angel Concha1, Manuel Valladares1, Luis Miguel Anton Aparicio2
1Chu A Coruña/Spain, 2Medical Oncology, Chu A Coruña/Spain
Background: Among many molecular markers associated with tumor 
progression, the Wnt family has been shown to encode the multifunc-
tional signaling glycoproteins that are involved in the regulation of a 
wide variety of normal and pathological processes in lung epithelium. 
Defects in Wnt signaling are associated with several tumor types, in-
cluding lung cancer. Numerous reports have demonstrated aberrant 
Wnt (wnt-1, 2, 5a, and 7) activation in lung cancer. The Wnt signaling 
pathway has been extensively investigated in NSCLC, but not in lung 
carcinoid tumors.
Methods: Sixty formalin-fixed paraffin embedded typical (TC) and 
atypical (AC) human lung carcinoid tumor samples were analyzed by 
qRT-PCR for Wnt-1, 5a, 7a, 10b, 13 and Fz2 and Fz5 gene expression 
as potential tumor-associated markers, using SYBR Green-based qRT-
PCR.
Results: The heatmap (Figure) shows low expression of Wnt genes 
(Wnt-1, 5a, 7a, 10b and 13) in almost all samples analyzed. Otherwise, 
Wnt-ligands are frequently positive, strongly positive for Fz2 and with 
lower levels for Fz5 in both carcinoid types (AC and TC). Wnt-1 and 
13 expression was found negative in all TC and AC samples; Wnt-7a 
was expressed in 0% AC and 4.55% TC; Wnt -10b was expressed in 
0% AC and 11.36% TC; and Wnt-5a was expressed in 18.18% AC and 
20.45% TC. Regarding Wnt receptors, Fz2 was positive in 90.9% AC 
and 95.45% TC, and Fz5 was positive in 45.45% AC and 20.45% TC. 
Conclusion: In the current study, we assessed the clinical-patho-
logical implications of changes in Wnt expression across a serie of 
lung carcinoids. Our data indicate that Wnt gene family is scarcely 
expressed both in TC and AT lung carcinoids. Conversely, ligands 
(Fz2, Fz5) are positively expressed in both types of lung carcinoids. 
Whereas the Wnt pathway has been shown to have a role in NSCLC, 
there are limits on the contribution of this signaling mechanism in 
lung carcinoids (TC and AC).
Keywords: wnt signaling pathway, lung carcinoid, typical and atypical 
carcinoid, frizzled
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Mostly, lung adenocarcinoma cannot be clearly differentiated from 
malignant pleural mesothelioma (MPM). Because of The limitations 
in the immunohistochemical methods there has been a growing in-
terest in the use of gene expression profiling for diagnosis in many 
cancers. So we aimed to evaluate the gene expression profiles in 
tumor cells by using RT-PCR array, between two separate groups 
of lung adenocarcinoma and MPM patients.
Methods: Ten newly diagnosed patients with adenocarcinoma and 
paraffin-embedded tissues of 12 patients with MPM were included 
in this study without considering gender differences. Eight healthy 
individual were recruited as a control group. After processing the 
fresh samples of lung adenocarcinoma stored at -80°C for RNA 
isolation, cDNA synthesis and the expression of 84 genes were 
associated with DNA repair were analyzed with RT-PCR Array. 
Paraffin tissues of patients with MPM were deparaffinized and the 
same procedure was applied. Fold change values of gene expres-
sions in each group are calculated in “SA Bioscience” data analysis 
expression page.
Results: ACBT, B2N, GADPH AND RPLPO genes were identified as 
housekeeping genes. Table 1 and 2 shows the comparisons of fold 
change values  of the gene expression differences between lung 
adenocarcinoma, MPM and control groups.  
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P1.02-020 EVALUATION OF GENE EXPRESSION PRO-
FILES FOR THE DIFFERENTIAL DIAGNOSIS OF LUNG 
ADENOCARCINOMA AND MALIGNANT PLEURAL ME-
SOTHELIOMA
Gokcen Omeroglu Simsek1, Ismail Ağababaoğlu2, Duygu Dursun1, 
Selver Özekinci3, Pınar Erçetin1, Safiye Aktaş1, Hülya Ellidokuz1, 
Duygu Gurel4, Ilhan Oztop5, Atila Akkoclu6
1Department Of Basic Oncology, Dokuz Eylül University Institute Of 
Oncology/Turkey, 2Department Of Thoracic Surgery, Dokuz Eylül Uni-
versity Medicine School/Turkey, 3Pathology, Dicle University Medicine 
School/Turkey, 4Pathology, Dokuz Eylül University Medicine School/
Turkey, 5Department Of Medical Oncology, Dokuz Eylül University 
Medicine School/Turkey, 6Department Of Chest Diseases, Dokuz Eylül 
University Medicine School/Turkey
Background: Squamous cell carcinoma is the most commonly 
diagnosed lung cancer type in Turkey; however lung adenocarci-
noma diagnosis has risen among women and nonsmokers. MPM is 
common in Turkey because of the high asbestos exposition rates. 
Table 1: Fold changes  
of the gene expressions 
of lung adenocarcinoma 
and MPM tumor cells 
comparing to control 
group 
Gene Adenocarcinoma/control fold change 
MPM/control 
fold change 
p value (comparing to control group) (ade-
nocarcinoma/MPM) 
APEX2 1,6763 6,1243 >0.05 / >0.05 
BRCA1 9,5919 20,2646 >0.05 / 0,01558 
BRCA2 4,3804 10,8169 >0.05 / 0,012071 
CCNH 2,3922 4,4773 >0.05 / 0,032102 
CDK7 3,909 15,4192 >0.05 / 0,019161 
LIG4 2,2608 13,7822 0,044834 / >0.05 
MLH1 2,5581 7,5515 >0.05 / 0,013792 
MLH3 5,9579 15,4275 >0.05 / >0.05 
MSH3 2,2494 10,2785 >0.05 / >0.05 
MSH4 6,5356 12,0767 >0.05 / >0.05 
NEIL3 14,3334 80,5092 0,015299 / >0.05 
PARP1 0,9019 2,0543 >0.05 / >0.05 
PARP2 4,7127 7,4604 0,043874 /0,009579 
PARP3 2,3613 8,2119 >0.05 / 0,049911 
PMS1 1,8236 7,3582 >0.05 / 0,039034 
RAD50 2,6223 10,2765 >0.05 / 0,03758 
RAD51 2,6223 10,2765 >0.05 / >0.05 
RAD51B 4,3683 16,7622 >0.05 / >0.05 
RAD51D 3,2769 7,0688 >0.05 / >0.05 
RAD52 2,0126 5,1099 >0.05 / >0.05 
RPA3 2,8581 7,9353 >0.05 / >0.05 
PRKDC 0,5309 2,9778 >0.05 / >0.05 
SMUG1 6,7053 18,0914 >0.05 / >0.05 
TREX1 0,5115 4,1669 >0.05 / >0.05 
UNG 7,422 26,6752 0,027669 / 0,009662 
XPA 2,0485 8,8342 >0.05 / >0.05 
XRCC2 5,6758 17,6367 >0.05 / >0.05 
XRCC4 5,9765 17,0836 >0.05 / >0.05 
S452 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
more, we demonstrated overexpression of αB-Crystallin enhanced 
the invasion ability of lung cancer cells by resulting in lung cancer 
cells epithelial-mesenchymal transition (EMT) through ERK1/2/slug 
pathway. Clinically, we showed that αB-Crystallin overexpression 
is associated with lymph node metastasis and poor prognosis of 
NSCLC. Together, our findings indicate that αB-Crystallin may 
represent a potential therapeutic target and a novel prognostic 
marker of NSCLC.
Conclusion: Our findings indicate that αB-Crystallin may represent 
a potential therapeutic target and a novel prognostic marker of 
NSCLC.
Keywords: NSCLC, αB-Crystallin, EMT
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P1.02-022 DOWNREGULATION OF PAX6 BY SIRNA INHI-
BITS PROLIFERATION AND CELL CYCLE PROGRESSION 
OF HUMAN NON-SMALL CELL LUNG CANCER CELL 
LINES
Xiaoting Zhao, Wentao Yue, Lina Zhang, Li Ma, Wenyun Jia, Zhe 
Qian, Chunyan Zhang, Yue Wang
Capital Medical University, Beijing Chest Hospital/China
Background: The transcription factor PAX6 is primarily expressed 
in embryos. PAX6 is also expressed in several tumors and plays an 
oncogenic role. However, little is known about the role of PAX6 in 
lung cancer.
Methods: In this study, the function of PAX6 in lung cancer cells 
was evaluated by small interfering RNA-mediated depletion of 
the protein followed by analyses of cell proliferation, anchorage-
independent growth, and cell cycle arrest. The PAX6 mRNA level 
in 53 pairs of tumors and corresponding matched adjacent normal 
tissues from non-small cell lung cancer patients and lung cancer 
cell lines was detected by real-time PCR.
Results: Suppression of PAX6 expression inhibited cell growth and 
colony formation by A549 and H1299 cells. The percentage of cells 
in G1-phase increased when PAX6 expression was suppressed. The 
cyclin D1 protein level, as well as the pRB phosphorylation level, 
decreased as a result of PAX6 down-regulation. PAX6 mRNA was 
highly expressed in lung cancer tissue and lung cancer cell lines.
Conclusion: Our data support the hypothesis that PAX6 accelera-
tes cell cycle progression by potentiating G1-S progression.
Keyword: lung cancer, PAX6, cell growth, cyclin D1
Table 2: The genes 
that fold change va-
lues  were statistically 
significant (p <0.05) in 
MPM and adenocarci-
noma tumor cells rela-
tive to each other 
Gene MPM / Adenocarcinoma fold change 
P 
CDK7 4.39 <0.05 
MLH1 5.32 <0.05 
TREX1 9.29 <0.05 
PRKDC 7.64 <0.05 
XPA 5.54 <0.05 
PMS1 5.19 <0.05 
UNG 4.93 <0.05 
RPA3 2.97 <0.05 
Conclusion: We showed that adenocarcinoma and MPM tumor 
cells have different expression profiles of DNA repair genes. Our 
study suggests that TREX1, PRKDC, PMS1 genes can be significant 
in support of differential diagnosis between MPM and lung ade-
nocarcinoma.
Keyword: DNA repair genes, gene expression, lung adenocarcino-
ma, malignant pleural mesothelioma
POSTER SESSION 1 - NOVEL CANCER GENES AND PATHWAYS  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.02-021 OVEREXPRESSION OF ΑB-CRYSTALLIN PRE-
DICTS POOR PROGNOSIS IN NON-SMALL-CELL LUNG 
CANCER
Jie Gu, Di Ge
Department Of Thoracic Surgery, The Affiliated Zhongshan Hospital Of 
Fudan University/China
Background: αB-Crystallin has been shown to correlate with the 
invasion of several tumors. In this study we investigate the role and 
mechanism of αB-Crystallin in non-small cell lung cancer (NSCLC).
Methods: Twelve cases of NSCLC and matched nontumorous 
samples were used to analyze αB-Crystallin expression at the level 
of protein. Then, we up- and down-regulated the expression of 
αB-Crystallin in NSCLC cells with specific vshRNA and αB-Crystallin 
cDNA , and assessed the role of αB-Crystallin in the proliferation, 
invasion of NSCLC cell line, Furthermore, The molecular mecha-
nism of αB-Crystallin in NSCLC cells were determined by genetic 
and functional screens. Finally, expression of αB-Crystallin was 
further examined by Immunohistochemistry (IHC) in tissue microar-
ray (TMA) consisting of 208 cases of NSCLC, and the prognostic 
role of αB-Crystallin in NSCLC was evaluated by Kaplan-Meier and 
Cox regression analysis.
Results: The expression of αB-Crystallin in NSCLC tissues was 
much higher than those in nontumorous samples, and forced loss 
of αB-Crystallin expression suppressed the invasive potential of 
lung cancer cell lines, whereas up-regulated αB-Crystallin expres-
sion enhanced the cells invasion both in vitro and in vivo. Further-
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SCC. Among the several previously reported prognostic markers 
evaluated in this study, only CA9 expression was associated with 
overall patient survival with a hazard ratio of 1.47, p-value 0.0005 
(N=278). Again, analysis of serial section produced a similar result 
confirming the robustness of the platform.
Conclusion: The study demonstrates the capabilities of multi-
plexing technology (MultiOmyxTM) for assessment of limited lung 
samples, encompassing topographic expression features and the 
ability to observe relationships between markers through in situ 
pathway profiling. Additionally, by evaluating markers on exactly 
the same sample set (same section), a direct comparison of their 
relative significance in predicting course of disease is now feasible.
Keyword: Subtype, biomarker profile, multiplex, limited sample
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P1.03-002 MULTIPLEXED ANALYSIS OF LUNG CANCER 
FOR DISTINGUISHING ADENOCARCINOMA FROM 
SQUAMOUS CELL CARCINOMA
Lakshmi S. Kaanumalle1, Vidya Kamath1, Yousef Al-Kofahi1, Ka-
thleen Bove2, Rod Beck2, Denise Hollman2, Fiona Ginty1, Edward 
Kim3, Brion D. Sarachan1, Mike Lazare2, Christina Lowes1, Brian 
Ring2, Teng J. Ong4, Qing Li1, Alberto Santamaria-Pang1
1Ge Global Research/United States Of America, 2Ge Healthcare/United 
States Of America, 3Levine Cancer Institute/United States Of America, 
4Ge Healthcare Medical Diagnostics/United States Of America
Background: Lung cancer is a leading cause of cancer related 
deaths, 80% of which are classified as non-small cell carcinomas 
(NSCLC). Differentiating the two main sub-types of NSCLC, ade-
nocarcinoma (AD) from squamous cell carcinoma (SCC) is crucial 
for therapeutic decision-making. Current methods for characteri-
zing subtypes may involve DAB stains on up to 7 tissue sections, 
depending on complexity of diagnosis. This process may deplete 
precious tissue required for molecular studies sequencing and 
other predictive markers. The goal of the current study was to 
measure 11 proteins on a single section using a novel multiplexed 
immunofluorescence (IF) technology (MultiOmyxTM) and evaluate 
performance of analytical workflows in automatic biomarker sco-
ring and in AD, SCC discrimination, with reference to the Pulmoty-
pe® test of 5markers
Methods: The protein markers included in the study were com-
prised of the five antibodies from the Pulmotype® test - Muc1, 
CK5/6, TRIM29, CEACAM5 and SLC7A5. Six additional markers 
TTF1, p40, CK7, CK20, p63, NapsinA were selected based on 
literature reports. These markers were applied to two separate 
cohorts of NSCLC cases. The entire set of 11 markers was multi-
plexed on a 378 core tissue microarray (TMA) containing 213 cases 
of AD or SCC diagnosis (cohort 1). A second 74 core TMA with 50 
cases of AD or SCC was stained with the Pulmotype® markers. 
Manual scores were generated for the immunofluorescence pro-
tein images and DAB stained serial tissue sections were used to 
generate manual ground truth protein expression scores. The first 
cohort was used to model diagnosis of AD or SCC using an imple-
mentation of Breiman and Cutler’s Random Forest and compared 
to the performance of a previously published lung classifier using 
manual DAB scores. Image and data analysis algorithms were de-
veloped to aid automated biomarker scoring. These algorithms 
segment the immunofluorescence images into tumor and stromal 
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P1.03-001 MULTIPLEXING TECHNOLOGY FOR IN SITU 
BIOMARKER PROFILING OF NON-SMALL CELL LUNG 
CANCER (NSCLC)
Anup Sood1, Alexander Bordwell2, Kathleen Bove3, Elizabeth Mc-
donough1, Iza Ferreira4, Fiona Ginty1, Vidya Kamath1, Sireesha 
Kaanumalle1, Edward S. Kim5, Qing Li1, Colin Mcculloch1, Teng J. 
Ong2, Zhengyu Pang1, Luis Paz-Ares6, Alberto Santamaria-Pang1, 
Yunxia Sui1, Lawrence Weiss2, Jin Xia1, Jingyu Zhang1
1Ge Global Research/United States Of America, 2Ge Healthcare Medical 
Diagnostics/United States Of America, 3Ge Healthcare/United States Of 
America, 4Ge Heathcare Healthcare Systems/United States Of America, 
5Levine Cancer Institute/United States Of America, 6Instituto De Inves-
tigaciones Biomédicas De Sevilla/Spain
Background: NSCLC is a heterogeneous neoplasm comprising se-
veral histologic types, etiology, genetics, survival and response to 
therapy. Accurate analysis of these subtypes has increased sample 
requirements, which is challenging in the era of minimally invasive 
procedures. A recent survey of 90 US pathologists presented at 
ASCO 2013 meeting, concluded insufficient sample availability in 
6% of all NSCLC samples recently handled by these pathologists. 
Moreover, subcellular localization of marker expression linked to 
tumor pathobiology necessitates methodological advancement. 
With the development of a new platform that allows in situ, multi-
plexed sub-cellular analysis of over 60 proteins, this project aims 
to demonstrate the feasibility of detailed in situ molecular profiling 
and perform comparative analysis of known cancer pathways and 
prognostic markers on the same serial section.
Methods: Multiplex immunofluorescence staining and imaging of 
over 30 biomarkers, including several RTKs, cell adhesion mole-
cules, select members of PI3K, MAPK/ERK, JAK/STAT pathways, 
angiogenesis, hypoxia, proliferation and chemotherapy resistance 
markers were performed on replicate FFPE tissue microarrays 
(TMA) from 382 samples. Cell-level and subcellular-level marker 
expressions were quantified using image analysis algorithms and 
compared between serial sections. Associations between marker 
expressions and histological subtypes and survival were investi-
gated in European male smokers. Multivariate analysis was perfor-
med using logistic regression and Cox proportional hazard models 
on over 300 quantitated features of marker expression. All models 
controlled for age. Serial sections were modeled separately and 
combined to improve confidence in associations. EGFR and cMET 
positivity was evaluated using whole cohort median expression 
values to define positive cells and the summary statistics are re-
ported using 10% positive cells as cutoff for characterizing positive 
samples.
Results: In concordance with previous reports, differential expres-
sion of RRM1, CK5 and CK7 was observed in SCC vs AD in the high 
grade, early stage male smokers (N=86). With a 10% cell positivity 
threshold, 72.7% (76.3%, serial section (SS)) of all male smokers 
(N=183 (190, SS)) were positive for EGFR. EGFR positivity was 
higher in SCC, 83.9% (86.0%, SS) compared to AD 54.9% (61.8%, 
SS). Opposite was observed for cMET with 81.7% (78.9%, SS) of 
AD characterized as positive compared to only 58.0% (57.0%, SS) 
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Epidermal growth factor receptor (EGFR) mutation status is the 
primary issue on the appropriate therapy of EGFR-tyrosine kinase 
inhibitor (EGFR-TKI) in non-small lung cancer. The point mutation 
of EGFR T790M (C→T) is known to be an acquired and the most 
common resistance against EGFR-TKI. Highly sensitive mutation 
detection system has been desired considering the difficulty in 
(obtaining tissue specimens during disease progression. Eprobe 
is new fluorescence labeled probe with high affinity toward target 
ssDNA and works as competitive probe (Figure 1). Here we descri-
be a novel method to identify T790M mutation using Eprobe on 
real-time monitoring of PCR and melting curve analysis.
Methods: 
Eprobe was designed to bind wild type allele including T790M 
region with competing primer, which enriches mutant allele amp-
lification (Figure 2). The T790M mutation was detected by melting 
curve analysis following real-time monitoring of PCR. We verified 
detection ability by genomic DNA containing wild type and mu-
tated EGFR T790M (cell lines H1975) gene. For clinical evaluation, 
338 tumor tissues from the patients with lung adenocarcinoma, 
of which EGFR gene mutation status had been revealed by the 
nucleic acid-locked nucleic acid PCR clamp (PNA-LNA PCR clamp), 
were assayed by Eprobe method. We compared the two methods 
on T790M mutation assay.
Results: The T790M mutant genome could be detected when it 
accounted for as little as 0.5% of a mixture of wild type genome by 
enrichment of mutation amplicon. The activating EGFR mutation 
(exon19 deletion, L858R, and L861Q) had been detected in 143 out 
of 338 samples (42.3%) but no T790M mutation was identified by 
PNA-LNA PCR clamp. Among 143 samples harboring activating 
EGFR mutation, T790M mutation was identified in 2 samples (1.4%) 
by Eprobe method.
Conclusion: The Eprobe method is sensitive for detecting EGFR 
T790M. Since Eprobe works in simple manner, current method is 
expected to apply to other gene detections.
Keywords: T790M, Eprobe, competitive probe, PCR and melting 
curve anaysis
areas and compute a large number of biomarker-related metrics. 
Linear regression modeling was used on a down-selected set of 
metrics to generate automated protein expression scores per bio-
marker for the second cohort.
Results: Manual scoring of all 11 targets demonstrated excellent 
concordance between fluorescence and DAB. Concordance was 
also demonstrated between manual DAB scores and automated IF 
metrics for the five Pulmotype® markers with an overall sensitivity 
and specificity of 95% and 87%, respectively. Statistical modeling 
indicated that 9 (of the 11) multiplexed markers provided 97% 
specificity and 90% sensitivity in classifying AD versus SCC. The 
observed 7% indeterminate rate measures well against the existing 
published indeterminate rates for the Pulmotype® test (11%) and 
the classic IHC marker combination TTF-1/p63 (29%).
Conclusion: Multiplexed analysis of a single tissue section allows 
maximum use of limited sample and enhanced protein profiling 
in context of tissue histology. We have shown that differential 
diagnosis of AD and SCC may be achieved using a multiplexed 
panel of markers in a single tissue section, when compared to the 
Pulmotype® test panel. Concordance between fluorescence and 
DAB shows transferability of the two detection methods. Further-
more, we demonstrated that image and data analysis tools can be 
applied for consistent automatic biomarker scoring.
Keywords: MultiOmyx technology, Non small cell lung cancer, 
Adeno and Squamous, Pulmotype
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P1.03-003 NOVEL DETECTION METHOD FOR EGFR 
T790M MUTATION BY EPROBE MEDIATED PCR AND 
MELTING CURVE ANALYSIS
Jun Atsumi1, Kimihiro Shimizu1, Takeshi Hanami2, Yasumasa 
Mitani3, Yasumasa Kimura3, Yasuaki Enokida1, Izumi Takeyoshi1
1Division Of Thoracic And Visceral Organ Surgery, Gunma Graduate 
School Of Medicine/Japan, 2Omics Application Technology Group, Riken 
Center For Life Science Technologies/Japan, 3Division For Molecular 
Diagnostics, Kabusiki Kaisha Dnaform/Japan
Background: 
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and FFPE tissue. Although microarrays and qRT-PCR have been 
used more extensively for expression profiling and are highly re-
producible, they are limited to the detection of only known targets 
identified at the time of assay development and manufacturing. 
With the rapid increase in miRNAs being discovered and deposi-
ted in public databases, sequencing will offer a more comprehen-
sive view of the miRNA transcriptome.
Keyword: microRNA, expression profiling, next-generation se-
quencing, microarrays
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P1.03-005 HIGH THROUGHPUT ARRAY AND SENSITI-
VE MASS SPECTROMETRY TECHNOLOGY APPLIED TO 
TRANSBRONCHIAL NEEDLE ASPIRATION ALLOW THE 
(DETECTION OF HUNDREDS MOLECULAR TARGETS) TU-
MOR PROFILING FOR ROUTINE CARE PERSONALIZED 
MEDICINE
Armine Izadifar1, Raphaël Saffroy2, Antoinette Lemoine2, Michel 
Febvre1, Christos Chouaid1
1Saint Antoine, Chu/France, 2Hôpital Paul Brousse/France
Background: The personalized therapies against specific genetic 
targets in tumoral cells like EGFR mutations or EML-ALK trans-
location, or the development of minimized invasive procedures 
for diagnosis and cancer staging have dramatically improved the 
outcome of patients with lung cancer. The combination of the wide 
use of Endobronchial Ultrasound-Guided Transbronchial Needle 
Aspiration (EBUS-TBNA) and genetic testing to individually tailor 
chemotherapy should become the standard of care. However, the 
rapid evolution of personalized medicine is toward the routine tes-
ting of high number of biomarkers per patient. Therefore, we have 
tested whether the recently developed DNA arrays and multiplex 
technologies could increase the suitability of very small size biop-
sies performed by EBUS-TBNA for the high-throughput molecular 
diagnosis
Methods: Fourty consecutive EBUS TBNAs with histologically dia-
gnosed lung adenocarcinoma were tested using the high through-
put array and sensitive mass spectrometry technology (Massarray, 
Sequenom) for the detection of 216 mutations in 26 cancer genes 
(Lungcarta).Each of the 40 DNAs extracted from only one 19- to 
22-gauge needle aspiration spread on a glass slide per patient has 
been successfully amplified and analyzed within one-day experi-
ment for all of the 238 mutations
Results: Five patients (12.5 %) exhibited EGFR mutations and re-
ceived either gefitinib or erlotinib, 1 of them exhibiting the T790M 
resistance mutation. One patient had the BRAFV600E mutation 
confirmed 1-y later on a skin metastasis and thus entered a phase 
II trial to receive anti-BRAF therapy. There were EBUS-TBNA ex-
hibiting mutations in KRAS (n=7), PI3K (n=1) and cMET (n=1), and 
insertion in HER2 (n=2).
Conclusion: In conclusion, only one 19-22 gauge needle aspiration 
is suitable in routine care for the detection of at least 238 muta-
tions, to guide treatment decisions and offer patients to benefit 
from current and future individually targeted drugs
Keyword: Transbronchial Needle Aspiration, molecular targets 
tumor
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P1.03-004 ROBUST GLOBAL MICRORNA EXPRESSION 
PROFILING USING NEXT-GENERATION SEQUENCING 
TECHNOLOGIES
Shirley Tam1, Richard De Borja2, John D. Mcpherson3, Ming-Sound 
Tsao1
1Princess Margaret Cancer Centre/Canada, 2Informatics And Bio-
computing, Ontario Institute For Cancer Research/Canada, 3Genome 
Technologies, Ontario Institute For Cancer Research/Canada
Background: MicroRNAs (miRNA) are endogenous, small re-
gulatory nucleotides that negatively regulate gene expression 
post-transcriptionally. They are involved in a wide range of cellular 
functions, including growth, development, and apoptosis. Given 
their widespread roles in biological processes, changes in their 
expression are likely to be associated with the development and 
progression of diseases. Understanding their patterns of expressi-
on could provide new insights into complex biological processes 
and the possible clinical implications of miRNA dysfunction. As 
such, global miRNA expression profiling of human malignancies is 
increasingly performed, but to date, the majority of such analyses 
have used microarrays and quantitative real-time PCR (qRT-PCR). 
With the introduction of digital count technologies, such as next-
generation sequencing (NGS) and the NanoString nCounter Sys-
tem, we have at our disposal, many more options.
Methods: To compare the attributes of different profiling metho-
dologies, five pairs of non-small cell lung cancer cell lines and their 
corresponding xenograft models were analysed using a microarray 
platform (Illumina Human microRNA Expression Profiling v2), NGS 
(Applied Biosystems SOLiD™ 3 Plus and 4 Systems and Illumina 
HiSeq2500), and the NanoString nCounter System (Human miRNA 
Expression Assay v1). The platforms were evaluated according 
to the following criteria: (i) inter-platform concordance, (ii) con-
cordance with an independent validation method, qRT-PCR, and 
(iii) detection of differentially expressed miRNAs in a biologically 
relevant setting.
Results: Inter-platform correlations ranged from 0.62 – 0.80, while 
correlations with qRT-PCR, the current gold standard for validating 
expression profiling studies, was highly statistically significant for 
all platforms, with Spearman’s ρ ranging from 0.79 – 0.86. The 
accuracy in detecting differential expression was the highest for 
NGS (88%). Overall, sequencing technologies had the greatest 
detection sensitivity, along with the largest dynamic range of 
detection, and highest concordance with qRT-PCR. To assess the 
technical reproducibility of NGS, the same set of samples was 
profiled in duplicates. Using unsupervised hierarchical clustering, 
technical replicates for each biological sample clustered together, 
with Spearman’s ρ > 0.93 in all cases. miRNA analysis of formalin-
fixed paraffin-embedded tissue (FFPE) was also evaluated. FFPE 
samples represent a rich source of archived specimen for retros-
pective studies of human disease. The feasibility of miRNA analysis 
with FFPE tissues would offer many opportunities to evaluate such 
large banks of archival materials. Three pairs of matched frozen 
and FFPE xenografts tumors were profiled using the Illumina 
HiSeq2000 platform. Hierarchical clustering showed similarity 
between expression profiles of paired frozen and FFPE samples 
(Spearman’s ρ > 0.88); whereas, samples of different biological 
origin were less correlated (Spearman’s ρ < 0.81).
Conclusion: These results show the superior sensitivity, accuracy 
and robustness of NGS for global miRNA profiling in both frozen 
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Conclusion: The result of our study indicates that the DNA ext-
racted from CTCs can be used to screen for primary tumour mu-
tations with reasonable concordance. Differences in the mutation 
results from the CTC and primary tumours needs to be explored in 
more detail and may be due to issues related to processing and / 
or tumour versus CTC heterogeneity.
Keywords: circulating tumour cells, predictive testing, mutation 
detection, Lung cancer
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P1.03-006 THE EFFICIENCY OF DETECTION OF KRAS, 
EGFR AND BRAF MUTATIONS IN PRIMARY LUNG CAN-
CER VIA PERIPHERAL BLOOD CIRCULATING TUMOUR 
CELLS
Maxim B. Freidin1, Debbie Mair2, Andee Tay3, Dasha V. Freydina1, 
Dimple Chudasama4, Sanjay Popat5, Andrew G. Nicholson1, Alex-
andra Rice4, Angeles Montero-Fernandez1, Vladimir Anikin4, Da-
vid Gonzalez De Castro2, Eric Lim1
1Royal Brompton Hospital/United Kingdom, 2Institute Of Cancer Re-
search/United Kingdom, 3Imperial College London/United Kingdom, 
4Harefield Hospital/United Kingdom, 5Royal Marsden Hospital/United 
Kingdom
Background: Circulating tumour cells (CTCs) are present in the 
blood of a proportion of patients with lung cancer. However, it is 
currently unclear how suitable CTCs are for use in the detection of 
predictive genetic mutations. We sought to determine the utility 
of DNA extracted from CTCs to screen for the underlying primary 
tumour mutation.
Methods: Using ScreenCell™ MB devices, from 20/01/12 to 
25/01/2013, CTCs were captured in peripheral blood of 100 
patients who underwent surgery for lung cancer at The Royal 
Brompton Hospital. DNA was extracted using QIAamp DNA Micro 
kit (QIAGEN) followed by whole-genome amplification using Ge-
nomePlex® SingleCell WGA kit (Sigma). DNA from matched pri-
mary tumours was used as reference. Mutation detection in EGFR 
and KRAS genes was undertaken using cobas®4800 (Roche) and 
single-strand conformation analysis for BRAF gene. Sensitivity and 
specificity analyses were undertaken to measure predictive perfor-
mance of mutation testing in CTCs.
Results: The DNA extracted from CTCs, were of sufficient quality 
to allow mutation analyses to be successfully performed in 100%, 
99%, and 98% of samples for EGFR, KRAS, and BRAF genes, res-
pectively. In CTC DNA, the KRAS mutation rate (codons 12/13 and 
61) was 9.1% and concordance with the primary tumour was 78.8%. 
Six mutations were detected in CTCs, but not in primary tumours, 
and 13 mutations in primary tumours were not detected in corres-
ponding CTC samples. Three mutations were detected in matched 
CTC and primary tumour specimens. One mutation in EGFR was 
detected in CTC DNA and 3 mutations were detected in primary 
tumours. In all cases, the mutations were detected in discordant 
specimens. The concordance between mutations detection in 
CTCs and primary tumours was 95.8%. BRAF V600E mutation was 
not detected in any sample. In general, the results suggested low 
sensitivity but high specificity (Table). Due to low number of EGFR 
mutations detected, test performance results require further vali-
dation.  
The performance of mutation testing in circulating tumour cells
Statistic KRAS EGFR
Sensitivity (95% CI), % 18.8 (4.05-45.6) 0.0 (0.0-70.8) 
Specificity (95% CI), % 91.8 (83.0-96.9) 98.9 (94.1-100) 
Positive predictive 
value (95% CI), % 
33.3 (7.49-70.1) 0.0 (0.0-97.5) 
Negative predictive 
value (95% CI), % 
83.8 (73.8-91.1) 96.8 (91.0-99.3) 
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Conclusion: Anti-tumour P/B vaccination induced tumourspecific 
immunity resulting in delayed tumour growth when combined with 
debulking surgery. Depletion of CD4 T cells during neoadjuvant 
P/B vaccination enhanced P/B vaccine efficacy leading to cures in 
60% of treated mice. Transient depletion of CD4+ FoxP3+ Treg 
suggesting that vaccine induced antitumour immunity is “restrai-
ned”, possibly by regulatory T cells. Based on these findings we 
are investigating whether combining novel immunotherapies with 
conventional treatments in the absence of “immunological restrai-
ners” may generate effective therapy for MM. Financial disclosure: 
This research was funded by a research grant from the Workers’ 
Compensation Dust Diseases Board, an agency of the New South 
Wales Government.
Keywords: immunotherapy, Cancer Vaccine, Regulatory T cells, 
surgery
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P1.04-001 COMBINING PRIME-BOOST ANTI-TUMOUR 
VACCINATION WITH DEBULKING SURGERY FOR THE 
TREATMENT OF MALIGNANT MESOTHELIOMA
Scott Fisher1, Amanda Cleaver1, Andrea Khong1, Theresa Connor1, 
Ben Wylie1, Daphne Lakhiani1, Bruce Robinson1, Richard Lake2
1Medicine And Pharmacolgoy (m503), The University Of Western Aust-
ralia/Australia, 2The University Of Western Australia - National Centre 
For Asbestos-related Diseases/Australia
Background: Malignant mesothelioma (MM) is a highly aggressive 
cancer with a very poor prognosis. Debulking surgery is often used 
as the principal therapy but is seldom curative. Adjuvant chemo-
therapy or radiotherapy can be used as to target residual disease, 
but these too are largely ineffective, while some early post-surgery 
immunotherapy strategies had limited clinical success. However, 
there is renewed interest in the use of immunotherapy to treat MM 
as new modalities have been developed. Recent work form our 
laboratory and others, has demonstrated that specific immuno-
therapies can alert the immune system to the presence of tumour. 
These therapies are particularly useful when used in conjunction 
with standard treatment protocols such as surgery or chemothera-
py. Here we describe the development of a Prime Boost (P/B) anti-
tumour vaccination protocol that when combined with debulking 
surgery and removal of CD4 T cells improved survival outcome of 
AB1-HA tumour bearing mice.
Methods: Using our established mouse model of mesothelio-
ma, AB1-HA tumour bearing BALB/c mice received influenza A 
PR/8/34/H1N1 (PR8; Prime) and HA expressing recombinant mo-
dified Vaccinia Ankara (rMVAHA; Boost) antitumour vaccinations 
before (neoadjuvant) or after (adjuvant) 75% debulking surgery. 
Diphtheria toxin (DTX) was administered to tumour bearing BALB/c 
FoxP3.dtr mice to specifically deplete CD4+ FoxP3+ regulatory 
T cells (Treg). In both models, tumour growth and overall survival 
was monitored and immunological parameters assessed by multi-
colour FACS.
Results: Neoadjuvant P/B vaccination alone or in combination with 
75% debulking surgery induced a significant increase in splenic 
tumourspecific CD8 T cells as well as significant increases in the 
proportion, activation and proliferation status of peripheral CD8 
T cells relative to other treatment groups. However, a significant 
delay in tumour growth was only observed when neoadjuvant P/B 
vaccination was combined with debulking surgery. Specific deple-
tion of CD8 T cells demonstrated that they were essential for the 
delay in tumour growth, although their presence was not sufficient 
to eliminate the tumour outright. Depletion of CD4 T cells during 
P/B vaccination enhanced the survival outcome of the surgery + 
vaccination group with 60% of these mice remaining tumour free 
for > 60 days post-surgery. Data from preliminary experiments in 
which Treg in tumour bearing FoxP3.dtr mice resulted in complete 
tumour regression in 20% of DTX treated mice. Tumour specific im-
munological memory was confirmed as all surviving mice remained 
tumour free for at least 60 days post rechallenge with the parental 
AB1 tumour.
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P1.05-002 REVERSAL OF RESISTANCE TO EGFR TYROSI-
NE KINASE INHIBITOR BY EGFR T790M SPECIFIC SIRNA 
IN NON-SMALL CELL LUNG CANCER
Choon-Taek Lee, Mi-Young Park, Eun Young Eo, Jong Sun Park, 
Young Jae Cho, Ho-Il Yoon, Jae Ho Lee
Internal Medicine, Seoul National University Bundang Hospital/Korea
Background: Analysis for EGFR mutation became new standard in 
management of lung adenocarcinoma. Mutations in EGFR tyrosine 
kinase domain such as L858R or small deletions in exon 19 result in 
sustained phosphorylation of EGFR and become driver oncogenic 
mutation. EGFR TKI, such as gefitinib, induces dramatic response 
in lung adenocarcinoma with sensitive mutations. Unfortunately, 
this dramatic response can not last long and resistance to EGFR 
TKI emerges and induces treatment failure. More than 50% of 
resistant mutations are EGFR T790M mutation. In this study, we 
investigated the role of siRNA specific to EGFR T790M and its 
clinical significance.
Methods: We designed three sequences (siRNA1, 2, 3) specific to 
EGFR T790M according to siRNA design guideline. Lung cancer 
cells were used: A549, NCI H460 (EGFR; wild type), NCI H1975 
(EGFR L858R + T790M), PC9 (EGFR small deletion in exon 19), 
PC9-G (EGFR small deletion in exon 19 + T790M). We investigated 
the effect of three siRNAs on suppression of EGFR T790M and 
reversal of resistance to gefitinib.
Results: Transfection of siRNA 1 and 3 showed marked suppressi-
on of EGFR expression in NCI H1975 and PC9-G, however, siRNA 
2 failed to suppress. All siRNA don‘t affect EGFR expression in 
A549, NCI H460 and PC-9. This finding suggested that suppressi-
ons of EGFR by siRNA 1 and 3 were specific to EGFR T790M. EGFR 
T790M siRNA 1 and 3 not 2, markedly suppressed the growth of 
NCI H1975 and PC9-G via increased apoptotic cell death and also 
suppressed in vitro tumorigenicity. No significant effect was found 
in other cell lines. This finding strongly supports that EGFR T790M 
is another oncogenic driver mutation. Cotreatment of EGFR siRNA 
1 and 3 with gefitinib induced marked increase in sensitivity of NCI 
H1975 and PC-9 to gefitinib (synergistic interaction), however, no 
effects were found in A549 and NCI H460.
Conclusion: Application of EGFR T790M specific siRNA can rever-
se the resistance of lung adenocarcinoma and shows its potential 
to be a breakthrough in EGFR TKI. Further study will focus on prec-
linical application with efficient delivery system, such as, nanotech-
nology or viral vectors. (This study was supported by a grant from 
the National Research Foundation of Korea, 2011-0002169).
Keywords: Lung cancer, EGFR TKI, resistance, siRNA
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P1.05-001 EGFR-TKI RESISTANCE DUE TO BIM POLY-
MORPHISM CAN BE CIRCUMVENTED IN COMBINATION 
WITH HDAC INHIBITION
Shinji Takeuchi, Takayuki Nakagawa, Tadaaki Yamada, Seiji Yano
Division Of Medical Oncology, Cancer Research Institute, Kanazawa 
University/Japan
Background: BIM (BCL2L11) is a BH3-only pro-apoptotic member 
of the Bcl-2 protein family. BIM upregulation is required for apo-
ptosis induction by EGFR tyrosine kinase inhibitors (EGFR-TKIs) in 
EGFR-mutant forms of non-small cell lung cancer (NSCLC). Notab-
ly, a BIM deletion polymorphism occurs naturally in 12.9% of East 
Asian individuals, impairing the generation of the pro-apoptotic 
isoform required for the EGFR-TKIs gefitinib and erlotinib and 
therefore conferring an inherent drug resistant phenotype. Indeed, 
NSCLC patients who harbored this host BIM polymorphism exhi-
bited significantly inferior responses to EGFR-TKI treatment than 
individuals lacking this polymorphism. In attempt to correct this 
response defect in the resistant group, we investigated whether 
the histone deacetylase (HDAC) inhibitor vorinostat could circum-
vent EGFR-TKI resistance in EGFR mutant NSCLC cell lines that 
also harbored the BIM polymorphism.
Methods: not applicable
Results: We found that such cells with BIM polymorphism were 
much less sensitive to gefitinib-induced apoptosis than EGFR mu-
tant cells which did not harbor the polymorphism. Notably, vori-
nostat increased expression in a dose-dependent manner of the 
pro-apoptotic BH3 domain-containing isoform of BIM, which was 
sufficient to restore gefitinib death sensitivity in the EGFR mutant, 
EGFR-TKI resistant cells. In xenograft models, while gefitinib in-
duced marked regression, via apoptosis, of tumors without the 
BIM polymorphism, its combination with vorinostat was needed to 
induce marked regression of tumors with the BIM polymorphism in 
the same manner.
Conclusion: Our results show how HDAC inhibition can epige-
netically restore BIM function and death sensitivity of EGFR-TKI, 
in cases of EGFR mutant NSCLC where resistance to EGFR-TKI is 
associated with a common BIM polymorphism.
Keywords: BIM polymorphism, EGFR mutation, EGFR-TKI resis-
tance
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Conclusion: Our findings suggest that a combination of the pro-
apoptotic FUS1-nanoparticle with novel PDGFR or Src inhibitors 
targeting the PDGFR-Src-PI3K-Akt signaling pathway that is si-
gnificantly mutated and predominantly activated in lung cancer 
cells could sensitize their response to PDGFR and Src inhibitors 
by more efficiently inhibiting tumor cell proliferation and survival, 
facilitating apoptosis, and overcoming drug resistance. (This ab-
stract is supported by NIH/NCI Grants SPORE P50CA70907 and 
RO1CA116322).
Keywords: Lung cancer, PDGFR-Src signaling pathway, TUSC2 
(FUS1)-nanoparticle, PDGFR and Src kinase inhibitors
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P1.05-004 MOLECULAR MECHANISM OF RESISTANCE 
TO AFATINIB IN EGFR-MUTATED NON-SMALL CELL 
LUNG CANCER (NSCLC) CELL LINES AND POTENTIAL 
THERAPEUTIC IMPLICATIONS
Francesco Grossi1, Anna Truini1, Angela Alama1, Maria Giovanna 
Dal Bello1, Giulia Barletta1, Carlo Genova1, Erika Rijavec1, Claudio 
Sini1, Anna Garuti2, Simona Coco1
1Lung Cancer Unit, National Institute For Cancer Research/Italy, 2Cli-
nical And Experimental Oncology And Hematology Cellular Therapies 
Laboratory, University Of Genova/Italy
Background: Somatic activating mutations in the tyrosine kinase 
(TK) domain of EGFR are harbored by 10-20% of Caucasian NSCLC 
patients (pts). Reversible TK inhibitors (TKIs), including erlotinib or 
gefitinib, have demonstrated significantly longer progression-free 
survival compared to chemotherapy alone in EGFR-mutated pts. 
Nevertheless, the majority of these tumors develop drug resis-
tance due to an acquired mutation (T790M) in EGFR that determi-
nes disease progression. Recent clinical trials have demonstrated 
interesting activity of the irreversible EGFR-TKI afatinib (BIBW-
2992) in advanced NSCLC carrying EGFR mutations and in unse-
lected pts failing previous treatments with reversible TKIs. The aim 
of this study was to clarify the mechanisms of acquired resistance 
to afatinib using in vitro models of resistant cell lines.
Methods: A dose-escalation study was performed to establish 
afatinib-resistant (R) clones in NSCLC cell lines harboring different 
EGFR mutations: H-1650 (exon 19 delE746-A750) and H-1975 (exon 
21 L858R/exon 20 T790M). The entire genomes of parental (P) 
and R cells were screened by array comparative genomic hybridi-
zation (aCGH) using a 105 k oligonucleotide microarray. All EGFR 
and KRAS exons and 10 known hot spots (5 in genes involved in 
the EGFR signaling cascade and 5 in genes frequently altered in 
NSCLC) were deep sequenced using an Ion PGM™ Sequencer in 
P and R cells. The relative expression of 92 genes belonging to 
the EGF pathway was studied by quantitative polymerase chain 
reaction (qPCR). The expression of proteins related to the EGF 
pathway, including EGFR, AKT and ERK (total and activated forms), 
was investigated by Western blot.
Results: Genomic analysis indicated that both R cell lines had ge-
nomic profiles similar to the P cells. However, H-1975-R showed 3p 
and 12p loss and gains at 4q and 10q compared to the P cell line. 
Sequence analyses identified a novel frame-shift mutation within 
exon 14 of MET and confirmed EGFR mutation status in 100% of 
H1975-R cells. In contrast, H-1650-R cells showed a single-base 
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P1.05-003 THE PDGFR/SRC SIGNALING PATHWAY-TAR-
GETED THERAPY WITH NOVEL TUSC2-NANOPARTICLES 
AND TYROSINE KINASE INHIBITORS FOR HUMAN LUNG 
CANCER
Quanglin Wu1, Qing Liu1, Ryo Sakai1, David Hangauer2, Jack Roth1, 
Lin Ji1
1Thoracic & Cardiovascular Surgery, University Of Texas MD Anderson 
Cancer Center/United States Of America, 2Chemistry, The State Univer-
sity Of New York At Buffalo/United States Of America
Background: The PDGFR is among the significantly mutated 
pathways and the PDGFR and downstream Src family protein ki-
nases are often aberrantly activated and play important roles in 
mediating oncogenic signaling and modulating sensitivity to the 
molecularly-targeted therapy in lung cancer. We have previously 
shown that the novel tumor suppressor TUSC2 (FUS1) functions 
as a key mediator in the apoptosis signaling pathway and down-
regulates activities of multiple oncogenic protein kinases such as 
EGFR, PDGFR, Src, and c-Abl in lung cancer cells. A systemic treat-
ment with FUS1-DOTAP:Cholesterol nanoparticles demonstrated a 
potent antitumor efficacy in preclinical lung cancer animal models 
and showed promising clinical benefits in advanced lung cancer 
patients. 
Methods: In this study, we evaluated a rationalized therapeutic 
strategy using a combined systemic treatment with the multifunc-
tional FUS1-nanoparticles and the PDGFR kinase inhibitor imatinib 
(gleevec) or the Src inhibitor Dasatinib or KX2-391 to simultaneous-
ly target the dysregulated PDGFR-Src-PI3K-Akt signaling pathways 
and suppress tumor cell growth by facilitating apoptosis in human 
lung cancer cells in vitro and in vivo.
Results: We have compared the effectiveness of the orally-availa-
ble Src inhibitor dasatinib (a ATP competitive inhibitor) or KX2-391 
(a novel non-competitive inhibitor that interrupts binding of the 
Src kinase to its substrates) as an single agent or in combination 
with FUS1-nanopaticles for potentiating their anticancer efficacy 
in NSCL and SCLC cells. We found that the dasatinib treatment 
alone showed a moderate level of tumor cell growth arrest and 
cell viability reduction but a low degree of apoptosis induction in 
selected NSCLC cells and exhibited a very low degree of tumor 
cell killing in SCLC cells. In comparison, the KX2 demonstrated a 
10-100 fold higher tumor cell killing and apoptosis induction than 
Dasatinib in more than 20 NSCLC and SCLC cells tested. The ec-
topic expression by FUS1- nanoparticle-mediated gene transfer 
in these lung cancer cells markedly enhanced the dasatinib- or 
KX2-mediated tumor cell killing. The combination treatment with 
FUS1-nanoparticles and Src inhibitors dramatically reduced their 
IC50s in NSCLC cells and suppressed NSCLC cells growth through 
a mechanism of action by a significant induction of apoptosis 
and the down-regulation of activated EGFR, PI3K, Akt, and Src 
kinases. Furthermore, the ectopic expression of wt-FUS1 in the 
PDGFRß-expressing SCLC H128, N417. and NSCLC H358 cell lines 
inactivated PDGFR oncogenic signaling, as evidenced by a signi-
ficant reduction in levels of phospho-PDGFRß and downstream 
phospho-PI3-K and phospho-AKT protein expression, relative to 
untransfected or lacZ-transfected controls. A combined treatment 
with FUS1-nanoparticles and the PTK inhibitor imatinib synergisti-
cally inhibited growth and induced apoptosis in SCLC and NSCLC 
cell lines and in preclinical mouse models with N417 SCLC orthoto-
pic lung tumor xenografts.
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differences in body weight between groups. In both models, cedi-
ranib or radiation therapy alone inhibited tumor growth and lymph 
node metastasis with efficacy superior to paclitaxel. Cediranib 
markedly enhanced the antitumor and antimetastatic effects of 
radiation with 99.3% and 92.1% reductions in primary lung tumor 
volume in the PC14PE6 and NCI-H441 models, respectively, while 
paclitaxel only modestly improved the effects of radiation therapy. 
Trimodality therapy resulted in a near-complete suppression of 
tumor growth and metastasis, with 99.8% and 98.3% reductions in 
tumor volume compared to control in the PC14PE6 and NCI-H441 
models, respectively, without evidence of lymph node metasta-
sis. Immunohistochemical analyses of lung tumors revealed that 
cediranib inhibited angiogenesis and tumor cell proliferation and 
increased tumor and endothelial cell apoptosis. The antiangioge-
nic and apoptotic effects of cediranib were substantially enhanced 
when combined with radiation and paclitaxel. Cediranib alone or 
in combination with radiation and/or paclitaxel increased VEGFR2 
expression, but VEGF expression was not significantly impacted by 
treatment. VEGFR2/3 activation was blocked by cediranib alone or 
in combination therapy.  
PC14PE6 NCI-H441
Treatment
Left 
Lung 
Weight 
(mg)
Left 
Lung 
Tumor 
Vo-
lume 
(mm3)
Medi-
astinal 
Lymph 
Node 
Metas-
tasis
Left 
Lung 
Weight 
(mg)
Left 
Lung 
Tumor 
Vo-
lume 
(mm3)
Medi-
astinal 
Lymph 
Node 
Meta-
stasis
Vehicle
710 
(490-
1210)
753 
(254-
1089)
7/8
935 
(800-
1230)
1146 
(860-
1601)
8/8
Paclitaxel 
200ug/ 
week 
545 
(150-
860)
506 
(37-
817) 
6/8
785 
(485-
820)
820 
(576-
1208)
7/8
Radiation 
20Gy/ 
5fractions 
220** 
(50-
360)
154* 
(34-
270)
4/8
485** 
(330-
820)
501* 
(333-
879)
6/8
Cediranib 
3mg/kg/
day 
215* 
(70-
540)
137* 
(13-
316)
4/8
395** 
(230-
570)
414** 
(261-
698)
5/8
Radiation  
+Paclitaxel 
185** 
(60-
260)
87** 
(21-
268)
2/8
360** 
(260-
650)
327** 
(236-
651)
5/8
Cediranib 
+ Paclitaxel 
125** 
(60-
260)
41** (0-
150) 
1/8†
225** 
(160-
630)
241** 
(79-
651) 
4/8†
Radiation + 
Cediranib 
50* 
(40-60)
0** 
(0-28) 
0/8†
120** 
(70-
190)
88** 
(1-182) 
2/8†
Radiation + 
Cediranib 
+ Paclitaxel
40** 
(40-60)
0** 
(0-1) 
0/8†
100** 
(60-
120)
9** 
(1-64) 
0/8†
Data are presented as medians and ranges or as incidence. †p<0.05 
versus vehicle (lymph nodes), *p<0.01, **p<0.001 versus vehicle 
(others)
Conclusion: Trimodality therapy with cediranib, paclitaxel, and 
radiation resulted in the near complete suppression of lung tumor 
growth and metastasis with markedly enhanced antiangiogenic 
and apoptotic effects. The radiosensitizing effects of cediranib 
upon lung tumors and their vasculature was superior to those of 
deletion 12 bp upstream of exon 8 of PIK3CA within a sequence 
of nine repeated Ts. Furthermore, a novel missense variant (exon 
8 K368E) was found in FGFR2 in both R cell lines compared to the 
P cell line. Gene expression profiles identified an increase in the 
FGFR2 and PIK3 regulatory subunits and EGFR ligand silencing in 
H-1975-R. Notably, H-1975-R cells maintained in afatinib-free medi-
um for over 6 months showed higher EGFR and AKT phosphoryla-
tion compared to the P cell lines. 
Conclusion: The lack of novel EGFR mutations suggests the in-
volvement of other mechanisms implicated in afatinib resistance. 
In particular, the identification of mutations involving MET and 
FGFR2 in H-1975 and PI3KCA in H-1650 suggests their contribution 
to resistance against irreversible TKIs, sparing EGFR activation. 
Furthermore, the different mutation status of the two cell lines 
indicates that the T790M mutation may be partially responsible 
for the mechanism of resistance. Validation studies are ongoing to 
confirm the genomic results. In conclusion, these preliminary data 
may help identify novel therapeutic strategies to delay or reverse 
resistance to irreversible TKIs in EGFR-mutated NSCLC patients.
Keywords: NSCLC, afatinib resistance, T790M, EGFR mutation
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P1.05-005 VEGF SIGNALING INHIBITION BY CEDIRANIB 
ENHANCES THE ANTITUMOR AND ANTI-METASTATIC 
EFFECTS OF RADIATION THERAPY MORE SUBSTANTI-
ALLY THAN CHEMOTHERAPY IN ORTHOTOPIC LUNG 
CANCER MODELS
Osamu Takahashi1, Ritsuko Komaki1, Julian M. Jürgensmeier2, 
Paul D. Smith2, B N. Bekele3, Ignacio I. Wistuba4, Ramesh C. Tailor1, 
Jörg J. Jacoby5, Maria V. Korshunova1, Anna Biernacka1, Baruch 
Erez1, Roy S. Herbst5, Michael S. O‘Reilly1
1Radiation Oncology, University Of Texas, MD Anderson Cancer Cen-
ter/United States Of America, 2Astrazeneca/United Kingdom, 3Biosta-
tistics, The University Of Texas MD Anderson Cancer Center/United 
States Of America, 4Translational Molecular Pathology, The University 
Of Texas MD Anderson Cancer Center/United States Of America, 5Tho-
racic/head And Neck Medical Oncology, The University Of Texas MD 
Anderson Cancer Center/United States Of America
Background: The outcome for lung cancer patients remains poor 
and new therapeutic approaches are urgently needed. Cediranib 
is an orally available inhibitor of all 3 VEGFR tyrosine kinases. We 
evaluated the therapeutic efficacy and radiosensitizing effects of 
cediranib and paclitaxel, alone or in combination, in orthotopic 
models of human lung adenocarcinoma that mimic clinical patterns 
of malignant progression.
Methods: PC14PE6 or NCI-H441 human lung adenocarcinoma 
cells (1 x 106) were injected into the left lungs of nude mice. Mice 
were randomized (8/group) to treatment with vehicle control, ce-
diranib (3 mg/kg/day po), paclitaxel (200 µg/week ip), radiation to 
the left lung and mediastinum (20 Gy in 5 fractions over 2 weeks), 
or radiation with cediranib and/or paclitaxel. When controls beca-
me moribund, all mice were sacrificed and assessed for lung tumor 
burden and mediastinal nodal metastasis. Lung tumors and adja-
cent tissues were analyzed immunohistochemically.
Results: All treatments were well tolerated without significant 
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P1.05-007 LARGE SCALE ESTABLISHMENT OF GENE-
TICALLY DIVERSE PATIENT-DERIVED PRIMARY TUMOR 
XENOGRAFTS FROM RESECTED EARLY STAGE NON-
SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Lucia Kim1, Nhu-An Pham2, Jenna Sykes2, Shingo Sakashita2, 
Ghassan Allo3, Bizhan Bandarchi2, Ming Li2, Ni Liu2, Chrinstine 
To2, Kevin Boyd4, Thomas John5, Melania Pintilie4, Geoffrey Liu6, 
Frances A. Shepherd6, Ming-Sound Tsao3
1Department Of Pathology, Inha University Hospital/Korea, 2Ontario 
Cancer Institute, University Health Network/Canada, 3Department Of 
Laboratory Medicine And Pathobiology, University Of Toronto/Cana-
da, 4Princess Margaret Cancer Centre/university Of Toronto/Canada, 
5Ludwig Institute For Cancer Research/Australia, 6Medical Oncology, 
Princess Margaret Cancer Centre/Canada
Background: The fidelity of established NSCLC cell line models to 
reflect patient tumors has been challenged. Patient-derived pri-
mary tumor xenografts (PTXGs) established directly from patient 
tumors in immunodeficient mice reproduce closely the histology of 
the primary tumors, thus are potentially better preclinical models 
to investigate novel therapies. We previously reported that early 
stage NSCLC patients whose tumors form PTXGs have significantly 
greater risk of relapse after surgery (Clin Cancer Res 2011; 17: 134-
141). We report here a more extended analysis of clinical-molecu-
lar-pathological features of early stage NSCLC that are associated 
with engraftment and its impact on patient outcome.
Methods: Resected NSCLC tumors were harvested within 30 mi-
nutes after surgery and were implanted into severely immunodefi-
cient mice to establish PTXGs. Tumors that grew were propagated 
for up to 3 passages. The mutational profiles of the primary tumors 
were assessed by the MassARRAY platform that included 133 mu-
tations with ‘putative’ driver function, which have been reported 
in COSMIC database as recurrent in NSCLC. All identified muta-
tions were verified by direct sequencing in both the primary and 
PTXG tumors. Engraftment rate among clinical factors were tested 
using the Fisher’s exact or Mann-Whitney tests. The Kaplan-Meier 
method was used to estimate 3-year overall (OS) and disease-free 
survival (DFS) probabilities. The effect of engraftment on OS and 
DFS adjusting for clinical variables was assessed using a Cox pro-
portional hazards model.
Results: From April 2005 to December 2010, 261 rigorously ve-
rified resected primary non-carcinoid NSCLCs were engrafted; 
38 xenografts that were lymphoma were excluded from further 
analysis. For the remaining 223 primaries, 101 (45.3%) successfully 
engrafted and formed PTXG lines. Engraftment rates were 33.8% 
(48/142) for adenocarcinoma (AdC), 67.7% (42/62) for squamous 
cell carcinoma (SqCC), 66.7% (4/6) for large cell neuroendocrine 
carcinoma, and 53.8% (7/13) for others. The tumors forming PTXGs 
were more likely to be poorly differentiated (p=0.00012) and of 
larger tumor size and higher pT stage (p<0.0001), but were not 
correlated with the pN stage. Among 95/101 (94.1%) PTXG cases 
profiled for mutations, 6 had mutations in the EGFR tyrosine kinase 
domain, 18 in KRAS/HRAS, 5 in PIK3CA, 2 in paxillin and 1 in STK11/
LKB gene; 56 (62.2%) were negative for mutations. The median 
follow-up time was 2.7 years (range 0.04 – 7.5 years). Patients who-
se tumors engrafted had decreased DFS (HR 2.68, 95% CI 1.16-
4.60, Wald p<0.0001) and OS (HR 3.14, 95% CI 1.56-6.33, Wald 
p=0.0014). Significantly poorer survival was maintained in AdC. 
Among 33 patients with EGFR mutation, only 6 (18.2%) engrafted. 
paclitaxel with markedly enhanced apoptosis. The combination of 
cediranib with radiotherapy or chemoradiotherapy is a potentially 
promising therapy for cancer and our data provides a strong basis 
for the design of clinical trials in lung adenocarcinoma patients.
Keywords: Cediranib, selumetinib, Orthotopic lung cancer model, 
radiation therapy
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P1.05-006 TARGETED DELIVERY OF RRM1-SPECIFIC SIR-
NA LEADS TO TUMOUR GROWTH INHIBITION IN MALI-
GNANT PLEURAL MESOTHELIOMA
Glen Reid1, Marissa Williams1, Michaela B. Kirschner1, Yuen Yee 
Cheng1, Nancy Mugridge2, Jocelyn Weiss2, Sonja Klebe3, Himanshu 
Brahmbhatt2, Jennifer Macdiarmid2, Nico Van Zandwijk1
1Asbestos Diseases Research Institute/Australia, 2Cancer Therapeutics, 
Engeneic Ltd/Australia, 3Department Of Anatomical Pathology, Flinders 
University And Sa Pathology/Australia
Background: Malignant pleural mesothelioma (MPM) is an as-
bestos-related malignancy with poor prognosis. MPM is typically 
recalcitrant to treatment and new therapies are urgently needed. 
Multiple genes involved in proliferation and metabolic activity are 
upregulated in MPM and these represent attractive targets for an 
siRNA-based therapeutic intervention.
Methods: We carried out an RNAi-based screen of 40 target ge-
nes previously shown to be upregulated in MPM to identify candi-
date genes with roles in cell growth and survival in MPM cell lines. 
Effects of target gene silencing were measured using standard in 
vitro proliferation assays. Lead candidates were further assessed 
with siRNA dose response experiments. The specificity of siRNA-
mediated growth inhibition was confirmed by assessing gene 
knockdown by real-time qPCR and Western blotting. The effects 
of the most potent siRNAs on xenograft tumour growth were as-
sessed in vivo by delivery using EGFR-targeted, siRNA-loaded, 
minicells.
Results: All 40 genes were effectively silenced, and for 6 genes 
(PLK1, CDK1, NDC80, RRM1, RRM2 and BIRC5) knockdown with 2 
independent siRNAs resulted in significant growth inhibition over 
time in multiple cell lines. Dose response experiments revealed 
that siRNAs specific for RRM1 and RRM2 were the most effective 
at inhibiting growth with IC50 values in the low nanomolar range. 
Intravenous administration of RRM1 siRNA packaged in minicells 
targeted with EGFR-specific antibodies (2x109 minicells per dose, 4 
times per week for 3 weeks) led to consistent and dose-dependent 
inhibition of MPM tumor growth compared with treatment with an 
inactive siRNA. Reducing the dose and number of administrations 
did not reduce growth inhibition; as little as 1x109 minicells admi-
nistered once a week were sufficient to completely inhibit MPM 
tumour growth.
Conclusion: RRM1 is an attractive target for siRNA-based inhibiti-
on, and siRNA delivery with EGFR-targeted minicells represents a 
novel therapeutic approach for MPM.
Keywords: malignant mesothelioma, RNAi, RRM1
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P1.05-009 DEVELOPMENT OF SMALL CELL LUNG CAN-
CER PRIMARY XENOGRAFTS USING SPECIMENS OBTAI-
NED BY ENDOBRONCHIAL-ULTRASOUND TRANSBRON-
CHIAL NEEDLE ASPIRATION: A NOVEL PRE-CLINICAL 
MODEL
Tracy Leong1, Daniel Steinfort2, Aneta Strezlecki1, Samantha Ja-
yasekara1, Beena Kumar3, Prudence A. Russell4, Michael Farmer3, 
Louis Irving2, David Neil Watkins1, Anette Szczepny1
1Monash Institute Of Medical Research/Australia, 2Royal Melbourne 
Hospital/Australia, 3Monash Health/Australia, 4St Vincent‘s Hospital/
Australia
Background: Lung cancer has the highest cancer incidence and 
mortality worldwide. Small cell lung cancer (SCLC) accounts for 
15% of all cases. Platinum-based chemotherapy induces responses 
in up to 70%. However, treatment-resistant recurrence is near uni-
versal, and 5-year survival remains poor at 1-2%. Therefore, there 
is urgent need for pre-clinical models that accurately recapitulate 
the parent tumour and allow testing for predictive biomarkers of 
response and resistance to drugs, and also screening of novel anti-
cancer agents. Furthermore, as the vast majority of SCLC are in-
operable, it is crucial that the mode of tumour tissue acquisition be 
minimally invasive and repeatable in cases of recurrence. Here we 
describe a novel pre-clinical model using samples obtained by the 
minimally invasive technique of endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA) to develop primary 
xenografts of SCLC.
Methods: Cell suspensions from samples of SCLC obtained by 
EBUS-TBNA were implanted directly into the flanks of NSG (Non-
Obese Diabetic, Severe Combined Immune Deficient, IL2Rγ 
knockout) mice to generate primary xenografts. The mice were 
monitored for tumour growth, and if engraftment was successful, 
pre-graft and post-graft tumours were compared in terms of mor-
phology, immunohistochemistry and molecular characteristics.
Results: Thus far, 14 SCLC specimens have been implanted, with 
7 cases completing 6 months of tumour monitoring. Of these, 6 
have undergone successful engraftment (86%). Samples typically 
contained over 1 million tumour cells with minimal stromal con-
tamination. Mean engraftment lag time was 96 days. In all cases 
of engraftment, histological and molecular fidelity to the original 
tumour was demonstrated.
Conclusion: This is the first report of the generation of a primary 
xenograft model of lung cancer using a new method of tissue ac-
quisition by EBUS-TBNA. Furthermore, it is the largest reported 
group of primary xenografts of SCLC. The primary xenograft lines 
from these specimens may provide the much-needed basis for 
more accurate pre-clinical modeling of SCLC, and hold great trans-
lational promise for novel therapeutic agents.
Keywords: small cell lung cancer, primary xenograft, endobronchi-
al ultrasound, pre-clinical model
Engraftment was associated with significantly poorer DFS (HR 4.76; 
1.43-15.86, log-rank p=0.005) and OS (HR 8.55, 95% CI 0.77-94.3, 
log-rank p=0.035) in this population.
Conclusion: The ability to form PTXGs of early stage NSCLC is 
confirmed as a very strong poor prognostic marker. Although 
EGFR mutant tumors usually do not engraft, engraftment of EGFR 
mutant tumors is associated with poor patient survival. PTXGs 
appear to represent biologically aggressive NSCLC.
Keywords: non-small cell lung cancer, xenograft, Epidermal 
growth factor receptor
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P1.05-008 THE HSP 90 INHIBITORS SUPPRESS CELL 
GROWTH BY SUPPRESSION OF ALK AND TGF-BETA1 
SIGNALING IN CRIZOTINIB-RESITANT H2228 CELLS BY 
EPITHELIAL TO MESENCHYMAL TRANSITION
Hyeong Ryul Kim1, Jin Kyung Rho2, Woo Sung Kim3, Yun Jung 
Choi2, Chang Min Choi2, Jae Cheol Lee2
1Department Of Thoracic And Cardiovascular Surgery, Seoul Asan 
Medical Center/Korea, 2Oncology, Seoul Asan Mediacal Center/Korea, 
3Pulmonary And Critical Care Medicine, Asan Medical Center/Korea
Background: Epithelial to mesenchymal transition (EMT) is related 
with reduced sensitivity to many chemotherapeutic drugs inclu-
ding EGFR tyrosine kinase inhibitors. We investigated whether 
EMT also could contribute to the resistance to crizotinib and there 
are other therapeutic options overcoming EMT-mediated resis-
tance.
Methods: We established a crizotinib-resistant subline (H2228/CR), 
which was derived from the parental H2228 cell line by long-term 
exposure to increasing concentration of crizotinib. Characteristics 
related with EMT including morphology, EMT marker proteins and 
cellular mobility were analyzed. We examined whether the induc-
tion of EMT affect sensitivity to Hsp90 inhibitors.
Results: Compared with the H2228 cell, the growth of H2228/
CR cells was independent on EML4-ALK, and they showed cross-
resistance to TAE-684 (a 2nd-generation ALK inhibitor). Phenotypic 
change of a spindle-cell shape was found in H2228/CR, which was 
accompanied by a decrease of E-cadherin and an increase of vi-
mentin and AXL. In addition, they showed the increased secretion 
and expression of TGF-β1. The capability of invasion and migration 
was dramatically increased in H2228/CR cells. TGF-b1 treatment 
for 72 h in parental H2228 cells induced reversible EMT leading to 
crizotinib-resistance while this was reversed through the removal of 
TGF-β1. Suppression of vimentin by siRNA treatment in H2228/CR 
cells restored the sensitivity to crizotinib. Furthermore, these resis-
tant cells remained highly sensitive to the Hsp90 inhibitors similar 
to parental cells, H2228. HSP90 inhibition resulted in downregulati-
on of TGF-β receptor II in addition to ALK.
Conclusion: EMT should be considered as one of possible acqui-
red resistant mechanisms to crizotinib and HSP90 inhibitors can be 
a promising therapeutic option for EMT-mediated resistance.
Keywords: epithelial to mesenchymal transition, HSP 90, ALK, 
resistance
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P1.05-011 ANTITUMOR AGENT KNG-I-484C CAUSES 
CELL DEATH THROUGH INDUCING CELL CYCLE ARREST
Ting-Fang Che1, Ching-Wen Lin1, Kyoko Nakagawa-Goto2, Hiroyuki 
Tsurimoto2, Tse-Ming Hong3, Kuo-Hsiung Lee4, Pan-Chyr Yang1
1Institute Of Molecular Medicine, National Taiwan University/Taiwan, 
2Institute Of Medical, Pharmaceutical And Health Sciences, Kanazawa 
University/Japan, 3Graduate Institute Of Clinical Medicine, Ational 
Cheng Kung University/Taiwan, 4Eshelman School Of Pharmacy, Uni-
versity Of North Carolina/United States Of America
Background: Lung cancer is the leading cause of cancer deaths 
in the world, and is classified into two major groups, non-small 
cell lung cancer (NSCLC, ~85%) and small-cell lung cancer (SCLC, 
~15%). EGFR mutation is a validated predictive marker for response 
and progression-free survival with EGFR tyrosine kinase inhibitors 
in advanced lung adenocarcinoma. However, secondary EGFR mu-
tation may cause drug resistant and cancer relapse. Further investi-
gation and drug development is necessary for lung cancer therapy. 
KNG-I-484C is an analog of Desmosdumotin B compound, iso-
lated and modified from the roots of Desmos dumosus. Previous 
studies showed that KNG-I-484C can inhibit cell proliferation of 
multidrug resistant (MDR) cancer cell line, KB-V, as well as multiple 
non-MDR cancer cell lines. Therefore, KNG-I-484C may act as a 
potential antitumor agent to inhibit drug-resistant cancer cells.
Methods: KNG-I-484C anti-tumorigenesis activity is estimated in 
non-small cell lung cancer cell lines by SRB assay and by the soft 
agar colony formation assay. Flow cytometry is used for cell cycle 
progression and cell apoptosis evaluation. The centrosomes ob-
servation is by the IF staining. The gene expression affected by the 
compound is by DNA microarray. Nude mice are subcutaneously 
injected with non-small cell lung cancer cell lines. When the tumor 
volume reaches about 2 mm3, KNG-I-484C is administered by int-
ra-peritoneal injection. The body weight of mice will be monitored. 
Before tumor volume reaches 1 cm3, the mice will be sacrificed for 
the measurement of the tumor volume and blood.
Results: KNG-I-484C can inhibit cell proliferation and colonies 
formation in the soft agar in NSCLC cell lines. The compound indu-
ces G2/M arrest by flow cytometry and the G2/M markers, cyclin 
B1 and phospho-histone H3, are upregulated at the early stage. 
And it then causes cell apoptosis by annexin-V staining assay, and 
the apoptotic markers, caspase 3 and cleaved PARP increases by 
the treatment. KNG-I-484C treatment causes abnormal formation 
of centrosomes in NSCLC cell lines. The microarray results showed 
that EGR1 (early growth response protein 1) may be one of the 
target candidate. In the animal model, KNG-I-484C tends to inhibit 
the tumor growth.
Conclusion: KNG-I-484C can inhibit cell proliferation and induce 
cell apoptosis in lung cancer cell lines by directly inhibiting tubulin 
polymerization. Additional mechanisms of action may go through 
the centrosome abnormality. Therefore, KNG-I-484C may serve as 
a new and potential antitumor agent against NSCLC.
Keywords: Cancer therapy, EGR1, non-small cell lung cancer
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P1.05-010 PRE-CLINICAL VALIDATION OF ELECTRO-
CHEMOTHERAPY (ECT) IN THE TREATMENT OF LUNG 
TUMOURS
Saleem Jahangeer1, Patrick Forde2, Declan Soden2, John Hinchion1
1Cardiothoracic Surgery, Cork University Hospital/Ireland, 2University 
College Cork, Cork Cancer Research Centre/Ireland
Background: Lung cancer remains the most common cancer diag-
nosed and has one of the lowest survival rates of all cancers, with 
less than a third of all patients undergoing a curative resection. 
Electrochemotherapy (ECT) has emerged as a novel treatment in 
treating various kinds of malignancies. ECT is the local potentiati-
on, by means of permeabilising electric pulses, of the anti-tumour 
activity of a non-permeant anticancer drug possessing a high 
intrinsic cytotoxicity. We have devised a study to demonstrate the 
safety of using a needle based electrode device (ThoraVe) in deli-
vering electrochemotherapy to lung tissues. A comparison of ECT 
with other modalities such as radiofrequency ablation (RFA) and 
Irreversible Electroporation (IRE) was carried out to explore the sa-
fety of electrochemotherapy as a novel treatment in lung tumours.
Methods: Healthy female pigs were randomised into the following 
treatment groups: ECT, Electroporation only (EP), RFA, IRE and 
No procedure (Sham). Each animal underwent a pre-treatment 
CT scan as a baseline. The scans were repeated at Days 1, 3, 7, 
10 and 21 following treatment. The area of trauma/opacification 
seen radiologically was calculated using volume-analysis software. 
Histological samples were taken from each group at the same time 
points. Secondary outcomes analysed included airleak and draina-
ge volume following each procedure
Results: A total of 65 pigs were used, 3 in each treatment group 
and 2 for each histological time point. Following each treatment, 
the area of trauma to the lung represented by an area of opaci-
fication on the CT scan, was identified and calculated. The ECT 
and EP groups were similar in terms of volume of opacification 
over the 3-week period, and demonstrated less radiological chan-
ges than RFA and IRE. The volume of opacification was minimal 
at the end of the 3-week period compared to the RFA and IRE 
groups. H&E staining demonstrated evidence of alveolar edema 
and hyperaemia in all groups but more marked in the RFA and IRE 
groups at day 1 and 3. Area of necrosis was evident in the RFA 
and IRE groups, which persisted until Day 21. ECT and EP groups 
did not show any evidence of persisting necrosis with normal lung 
parenchyma seen on Day 10 and 21. There was minimal to no air 
leak measured for the Sham, EP and ECT groups at the end of the 
surgical procedure with no air leak observed by day 1 postopera-
tively for the 3 groups. RFA and IRE groups showed significant air 
leakage immediately following treatment. The drainage volume 
was minimal and comparable in the Sham, EP and ECT groups. 
Both RFA and IRE groups had significantly higher drainage volume 
on Day 1. Drainage persisted until Day 3 in the IRE group.
Conclusion: We have successfully demonstrated the feasibility and 
safety of using ECT as compared to other established and experi-
mental treatment modalities. Our data show radiological and his-
tological evidence of preservation of lung parenchyma post ECT 
treatment, which was well tolerated, with minimal complications 
such as air leaks or bleeding.
Keywords: Radiofrequency Ablation, Irreversible Electrochemo-
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were depleted for up to 72 hours in xenograft tumors treated with 
a single dose of 70 mg/kg AT13387, whilst a reduction in phospho-
ERK and phospho-S6 again demonstrated an inhibition of signalling.
Conclusion: AT13387 was shown to be effective in erlotinib-
sensitive and -resistant NSCLC models, depleting levels of EGFR 
regardless of its mutation status. These data suggest that AT13387 
treatment may also be a potential approach for combating EGFR 
inhibitor resistance in the clinic.
Keywords: HSP90, AT13387, EGFR, resistance
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P1.05-013 APOPTOSIS-TARGETED DRUG AND T-CELL 
DELIVERY TO LUNG CANCER
Keon Uk Park1, Jin Young Kim1, Hong Suk Song1, Ilseon Hwang2, 
Hun Mo Ryoo3, Young Joo Min4, Byung-Heon Lee5
1Department Of Hematology/Oncology, Keimyung University Dongsan 
Hospital/Korea, 2Department Of Pathology, Keimyung University Dongsan 
Hospital/Korea, 3Department Of Hematology/Oncology, Daegu Catholic 
University/Korea, 4Department Of Hematology/Oncology, Ulsan University 
Hospital, University Of Ulsan College Of Medicine/Korea, 5Department Of 
Biochemistry And Cell Biology, School Of Medicine, Kyungpook National 
University/Korea
Background: When tumor cells undergo apoptosis in response to 
chemotherapy, the levels of apoptotic biomarkers such as phosphati-
dylserine and histone H1 are increased at the cell surface. Here we hy-
pothesized that the chemotherapy-induced apoptosis would amplify 
in situ apoptotic biomarkers (homing signals) for apoptosis-targeted 
drug carriers and enhance drug delivery to lung cancer.
Methods: To examine this possibility, we employed a phage display-
identified CQRPPR peptide (ApoPep-1) as a targeting moiety, which 
was able to recognize apoptotic cells by binding to histone H1 on the 
surface of apoptotic cells.
Results: When injected into lung cancer-bearing mice, ApoPep-1-la-
beled, fluorescent liposomes containing doxorubicin inhibited tumor 
growth more efficiently than untargeted or folate-labeled liposomes. 
Moreover, in vivo fluorescence imaging could enable monitoring of 
tumor response during the chemotherapy. The imaging signals at tu-
mor were increased by the homing of apoptosis-targeted liposomes, 
which was correlated with the increase of apoptosis and the amount 
of doxorubicin (payloads) at the tumor and, conversely, with the 
decrease of tumor volume. Next, we harnessed the chemotherapy-
induced apoptosis of tumor cells as a homing signal for the delivery 
of apoptosis-targeted T cells to lung cancer. When labeled with Apo-
Pep-1 using an oleyl acid-derived membrane anchor, targeted T cells 
preferentially bound to apoptotic tumor cells over living cells. In vivo 
imaging showed higher levels of tumor homing of targeted, fluore-
scent T cells in mice treated with chemotherapy more than those of 
untargeted T cells.
Conclusion: These results demonstrate that the apoptosis-targeted 
delivery can efficiently enhance the delivery of cells or drugs to lung 
cancer and, when combined with imaging of apoptosis, provides a 
real-time monitoring of tumor response for lung cancer theragnosis.
Keywords: biomarker, Apoptosis, T cell delivery
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P1.05-012 THE HSP90 INHIBITOR, AT13387, DISPLAYS 
SINGLE AGENT ACTIVITY IN ERLOTINIB-SENSITIVE AND 
-RESISTANT MODELS OF EGFR-ACTIVATED NSCLC
Keisha Hearn1, Tomoko Smyth1, Jon Lewis1, Vanessa Martins1, Neil 
Thompson1, Mohammad Azab2, John Lyons1, Nicola G. Wallis1
1Astex Pharmaceuticals/United Kingdom, 2Astex Pharmaceuticals/Uni-
ted States Of America
Background: Epidermal growth factor receptor (EGFR) is activated 
in subsets of non-small cell lung cancer (NSCLC) by mutations such 
as L858R and exon19 deletions. EGFR-tyrosine kinase inhibitors 
such as gefitinib and erlotinib have been successfully used to treat 
tumors with these mutations, but responses tend to be limited by 
the development of resistance, often through further mutations 
in EGFR such as T790M. EGFR and its mutated forms are clients 
of HSP90 and so dependent on this chaperone for their stability. 
HSP90 inhibition is therefore an alternative mechanism for tar-
geting EGFR-driven disease, which should be effective on EGFR 
inhibitor-sensitive or -resistant disease alike. AT13387 is a novel, 
potent, fragment-derived HSP90 inhibitor and is the subject of a 
number of Phase II clinical trials, including one in NSCLC.
Methods: The activity of AT13387 was investigated in vitro and in 
vivo in erlotinib-sensitive and -resistant EGFR-activated NSCLC cell 
lines and mouse xenograft models (see Table). The HCC827R cell 
line was generated by prolonged incubation of HCC827 cells with 
erlotinib. Cell proliferation was measured by Alamar blue assay. 
Protein levels were determined by western blotting.
Results: AT13387 was tested in a panel of EGFR-driven NSCLC cell 
lines and potently inhibited proliferation of both erlotinib-sensitive 
and -resistant cells including a cell line with acquired erlotinib re-
sistance (HCC827R) (see Table).  
Inhibition of proliferation of EGFR-dependent NSCLC cell lines
Cell line EGFR mutation status
Erlotinib in-
hibition of 
proliferation 
IC50 (nM) 
AT13387 
inhibition 
of proli-
feration 
IC50 (nM) 
HCC827 Exon19 Del 57 33
NCI-H1650 Exon19 Del > 10 000 54
NCI-H1975 L858R/T790M > 10 000 30
H820 Exon19 Del/T790M > 10 000 70
HCC827R N/D > 10 000 26
 
Treatment of both erlotinib-sensitive and -resistant cell lines with 
AT13387 resulted in depletion of EGFR and its phospho-form, 
irrespective of its mutation status (L858R, T790M, Exon19 deleti-
on). Other clients such as AKT were also depleted. A decrease in 
the levels of phospho-ERK and phospho-S6 indicated that EGFR 
signalling was also being inhibited in both erlotinib-sensitive and 
-resistant cells. In vivo, AT13387 significantly inhibited tumor growth 
in EGFR-driven tumor xenograft models (HCC827, NCI-H1975) when 
administered at 70 mg/kg ip once weekly. As expected, erlotinib 
dosed at 12.5 mg/kg once daily caused regression in HCC827 xeno-
grafts, whilst 75 mg/kg once daily had no effect on tumor growth in 
the resistant NCI-H1975 model. Levels of EGFR and phospho-EGFR 
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P1.05-015 ASSESSMENT OF THE ACTIVITY OF PEME-
TREXED AND DASATINIB AS SINGLE AGENTS AND IN 
COMBINATION IN THREE MALIGNANT PLEURAL MESO-
THELIOMA CELL LINES
Valentina Monica, Marco Lo Iacono, Enrico Bracco, Luisella Righi, 
Silvia Novello, Giorgio V. Scagliotti, Mauro Papotti
Department Of Oncology, University Of Turin/Italy
Background: Malignant pleural mesothelioma (MPM), an asbestos 
exposure related disease, is a highly aggressive tumor. Pemetrexed 
is a third-generation multitargeted antifolate approved as single 
agent or in combination with cisplatin as standard of care in first/
second line treatment of unresectable MPM. Thymidylate synthase 
(TS), a key enzyme in the de novo synthesis of thymidine, is the 
main target of Pemetrexed and its overexpression has been related 
to Pemetrexed-resistance. Experimental data suggest that c-SRC 
tyrosine kinase hyperactivation has a key role in MPM. The effect 
of c-SRC pharmacological inhibition in correlation with TS expres-
sion levels and Pemetrexed resistance, has been investigated in 
three MPM cell lines.
Methods: Cell growth inhibitory effects of both Pemetrexed and 
Dasatinib (10nM-100µM) were evaluated by MTS proliferation 
assay in epithelial (MPP89, REN) and biphasic (MSTO-211) MPM 
cell lines. Apoptosis was detected by AnnexinV-propidium iodide 
method using a FACScan, while drug-mediated changes in invasive 
ability were tested using “wound healing” scratch assay. Real-Time 
PCR and Western blot were assessed to identify drugs-associated 
genes and/or proteins modulation.
Results: The cell lines assayed displayed different sensitivity to 
both Pemetrexed and Dasatinib treatments. Among the three 
cell lines, MSTO-211 was the most sensitive to Pemetrexed (IC50 
0.5 µM); on the contrary REN was the most resistant (IC50 5 µM). 
A similar trend was observed upon Dasatinib treatment with IC50 
values ranging from 1 to 5 µM. The synergistic effect of Dasatinib 
and Pemetrexed was also evaluated, being significantly relevant 
in MPP89 and REN after 72h treatment while, in MSTO-211, was 
already detectable after 48h. Early and late apoptosis assessment 
confirmed, for both drugs, the ability to induce apoptosis, being 
MPP89 the most Dasatinib-sensitive and MSTO-211 the most Pe-
metrexed-sensitive cell line. In MPP89 and REN cells co-administra-
tion of Pemetrexed/Dasatinib significantly increased the apoptotic 
rate of 16 folds and this behaviour was enhanced in MSTO-211 (up 
to 27 folds). Both TS, gene and protein levels were higher in REN 
compared to MPP89 and MSTO-211 cells. Pemetrexed administ-
ration increased TS levels over time, in those cells most sensitive 
to the drug. Interestingly, in REN cells Pemetrexed treatment did 
not affect the high baseline TS levels but Dasatinib administration 
suppressed TS protein and, to a lesser extent, mRNA expression, 
thus increasing sensitivity to Pemetrexed. In addition, in REN cells 
the pretreatment with Dasatinib (5 µM) enhanced Pemetrexed sen-
sitivity leading to a strong cell viability reduction. In all 3 cell lines, 
SRC was expressed (mRNA and protein), decreasing its levels from 
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P1.05-014 CANCER STEM CELL-LIKE POPULATION 
FROM NON-SMALL CELL LUNG CANCER IS PREFEREN-
TIALLY SUPPRESSED BY EGFR-TKIS
Qinghua Zhou
Tianjin Thoracic Cancer Center, Tianjin Lung Cancer Institute/China
Background: Lung cancer is the leading cause of death worldwide 
with a high metastasis and recurrence rate. Non-small cell lung 
cancer (NSCLC) accounts for 75-85% of lung cancers. Growing 
evidences show that some, if not all, tumors derive from a minor 
subpopulation of cancer cells, also known as cancer stem-like cells 
(CSCs), either retain or acquire the capacity for self-renewal and 
drug resistance. By the virtue of altered cell signaling pathways 
related to cell survival and/or apoptosis, CSCs are able to survive 
radiation or chemotherapeutic insults. Thus, the targeting of key 
signaling pathway(s) that is active in CSCs is very attractive thera-
peutic strategy to treating cancers. However, research has been 
hampered due to the lack of distinct molecular makers on CSCs. 
We take advantage of a rare subset of cells that can efflux the DNA 
binding dye out of the cell. These cells, called side population (SP) 
cells, are proved to be enriched with CSCs and have stem cell cha-
racteristics.
Methods: The SPs in PC-9 cells ware detected by staining them 
with Hoechst 33342. CSC population in PC-9 cells, the phospho-
rylation of EGFR at Tyr1068, AKT at Ser473 and ERK at Thr202/
Tyr204 were investigated by FCM after treatment with EGFR/PI3K/
AKT signaling inhibitors including Gefitinib, LY294002, U0126 
and Erlotinib. significantly reduced the stem-like cancer cells. The 
effects of over-expression and silencing of β-catenin on the CSC 
population in PC-9 cells were detected by FCM. The PC-9 trans-
planted tumor model was used to detect the effects of Gefitinib 
and Cisplantin on CSC population in PC-9 cells. The Boyden cham-
ber was used to determine the effects of Gefitinib and Cisplntin on 
the vitro invasion of PC-9 cells.
Results: EGFR-TKIs (Gefitinib or Erlotinib) regulate CSC, constituti-
ve activation of EGFR increased the subpopulation almost 4.5-fold 
to 4.0%. EGFR-TKI almost completely ablated it resulting in only 
0.2% or 0.3% of the total cells. EGF promote CSC population, the 
phosphorylation of EGFR at Tyr1068, AKT at Ser473 and ERK at 
Thr202/Tyr204 were investigated and they are all positive. EGFR/
PI3K/AKT signaling inhibitors including Gefitinib, LY294002, U0126 
and Erlotinib, significantly reduced the stem-like cancer cells. A si-
gnificant decrease in cancer stem-like cells was observed following 
β-catenin suppression. The treatment with Gefitinib dramatically 
reduced the tumor numbers and size in vivo xenograft model with 
PC9 cells. Although there were few SP cells (1.3% as detected) in 
Gefitinib-treated mice in the primary tumors, more discernible 
numbers of SP cells were detected in Cisplatin-treated (13.6%) or 
control-treated tumors (8.3%). Tthe reduction of SP cells by Gefi-
tinib treatment significantly reduced the migration capability of 
PC-9 cells. As a comparison, those primary culture cells derived 
from Cisplatin-treated tumors had an increased migration rate.
Conclusion: EGFR-TKI can dramatically decrease the CSC popula-
tion and invasion ability in PC-9 cells in vitro and in vivo. The mole-
cular mechanisms of EGFR-TKI decrease CSCs of lung cancer might 
be related to that EGFR-TKIs can suppress the Wnt/β-cateninsignal 
pathway.
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P1.05-017 ASCORBIC ACID AND AHCC SUPPRESS LUNG 
FIBROSIS AND CANCER CAUSED BY IRRADIATION
Tadashi Hongyo, Hiroo Nakajima
Radiation Biology, Osaka University Graduate School Of Medicine/
Japan
Background: Lung fibrosis can be caused by irradiation in radio-
therapy or bone marrow transplantation, and many reports have 
documented an association between diffuse pulmonary fibrosis 
and lung cancer. Although a large number of compounds showed 
good radioprotection in in vitro studies, most of them failed in 
vivo due to acute toxicity and side effects. We tried to induce lung 
fibrosis in mice by irradiation, and at the same time, examined 
some compounds which are clinically used and thought to work as 
radioprotectors.
Methods: C57BL/6J mice,4-6weeks old were exposed to X-ray ra-
diation, dose rate 0.88Gy/min, in the following conditions; (1) local 
fractionate irradiation (limited to the thorax); 2Gy/day x 10 or 20 
days. (2) local single doze irradiation; 10, 15, 20 Gy. (3) total body 
single doze irradiation; 4Gy. At the same time, we administrated to 
each mouse by subcutaneous or intraperitoneal injection prior to 
irradiation sterile saline or 11 compounds which are clinically used 
and consist of antioxidants, sulfhydryl compounds, immunomo-
dulators and so on. We examined the lung tissue of each mouse 
5-8 months after irradiation, by checking microscopic change with 
Masson trichrome staining, and measured the Sircol assay level of 
the lung.
Results: By Masson trichrome staining, lung fibrosis were seen in 
the tissues irradiated with 40Gy in 20 equal fraction and 15 and 
20Gy single dose more than 7 months after irradiation. The Sircol 
assay level of the lung rose as the radiation dose increased except 
for 4Gy total body irradiation, suggesting lung fibrotic change. 
Among the 11 compounds, administration of ascorbic acid and 
AHCC (Active Hexose Correlated Compound) showed no fibrotic 
change by Masson trichrome staining and they suppressed all the 
Sircol level of the lung.
Conclusion: Lung fibrosis after irradiation was suppressed by as-
corbic acid and AHCC. We might be able to prevent lung tissue 
impairment after irradiation by using ascorbic acid and/or AHCC, 
and find other compounds which can be safe radioprotectors by 
this method.
Keywords: lung fibrosis, radioprotector, ascorbic acid, radiothera-
py
MSTO and MPP89 to REN, and activated. Dasatinib impaired also 
cell migration, as observed by wound-healing assay.
Conclusion: In vitro data suggest that inhibition of both TS and 
SRC might represent a potential therapeutic strategy in MPM. The 
evidence indicates that Dasatinib plays a role by inhibiting cell 
motility and, more surprisingly, by down-regulating TS. Dasatinib-
mediated TS expression impairment suggests a cross-talk between 
SRC and TS pathways thus leading to hypothesize a therapeutic 
use of Dasatinib to sensitize those Pemetrexed-resistant MPM pa-
tients’ cohort.
Keywords: c-SRC tyrosine kinase, malignant pleural mesothelioma, 
thymidylate synthase
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P1.05-016 EPHB4 RECEPTOR KINASE, A NOVEL THERA-
PEUTIC TARGET FOR LUNG CANCER
Barbara Gitlitz, Parkash Gill, R Liu, Grace Li, Stephen Liu, Ram 
Subramanyan, Anthony El-Khoueiry
University Of Southern California Keck School Of Medicine/United Sta-
tes Of America
Background: EphB4, a receptor tyrosine kinase and its ligand 
EphrinB2 are both cell membrane bound proteins that regulate 
cell migration, boundary formation, venous or arterial specifica-
tion, vessel formation and maturation. EphB4-EphrinB2 interaction 
leads to bidirectional forward and reverse signaling. EphB4 is indu-
ced in certain cancers where it regulates cell survival, growth and 
metastasis.
Methods: We have studied the expression of EphB4 in lung can-
cer. 89 cases of matched normal and lung tumor samples were 
analyzed by IHC using EphB4 specific monoclonal antibody. Bio-
logical function of EphB4 was studied specifically in Kras mutant 
lung adeno Ca due to induction of EphB4. In addition, an in vivo 
efficacy study was conducted with soluble EphB4 receptor fused in 
frame at the C-terminus with Albumin (sEphB4HSA).
Results: EphB4 is significantly over-expressed compared to paired 
normal tissues in adenocarcinoma (n=41; 4.3-fold mean difference), 
large cell carcinoma (n=15; 2.9-fold mean difference), small cell 
carcinoma (n=13; 2.4-fold mean difference), and squamous cell 
carcinoma (n=10; 2.7-fold mean difference) subtypes. Overall, lung 
tumors were found to express EphB4 3.2-fold more strongly than 
paired normal tissues. EphB4 gene amplification (>3 fold) was also 
seen in 23% of squamous cell carcinoma tissues. Knock down of 
EphB4 led to near 70% loss of cell viability indicating that EphB4 
is downstream of Kras and plays essential role in Kras mutant lung 
adenoCa. sEphB4 blocks bidirectional signaling and albumin fusi-
on provides long circulation time in vivo. Kras mutant human tumor 
xenografts showed tumor regression and combination with taxol 
resulted in complete regression in lung adenoca.
Conclusion: sEphB4HSA cGMP material toxico-kinetic studies in 
non-human primates were performed and found to be safe up to a 
dose of 30mg/kg IV weekly. A first in human, phase I clinical trial of 
sEphB4HSA is approaching completion.
Keyword: EphB4, KRAS, Phase I, sEphB4HSA
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P1.05-019 JNJ-42756493 IS A POTENT AND SELECTIVE 
FGFR1-4 KINASE INHIBITOR WITH PROMISE FOR CLINI-
CAL USE IN PATIENTS WITH FGFR DRIVEN TUMORS
Timothy P.S. Perera1, Eli Jovcheva1, Jorge Vialard1, Tinne Verhulst2, 
Norbert Esser2, Peter King3, Berthold Wroblowski3, Suso Platero4, 
Olivier Querolle5, Laurence Mevellec5, Eddy Freyne6, Ron Gilissen7, 
Christopher Murray8, Lynsey Fazal8, Gordon Saxty8, Herbie Ne-
well9, George Ward8, Patrick Angibaud5
1Lung Disease Area Stronghold, Janssen Research And Development/
Belgium, 2In Vivo Pharmacology, Janssen Research And Development, 
Beerse/Belgium, 3Janssen Pharmaceutical Companies Of Johnson And 
Johnson/Belgium, 4Biomarkers, Janssen Pharmaceutical Companies Of 
Johnson And Johnson/United States Of America, 5Medicinal Chemistry, 
Janssen Pharmaceutical Companies Of Johnson And Johnson/France, 
6Medicinal Chemistry, Janssen Pharmaceutical Companies Of Johnson 
And Johnson/Belgium, 7Adme, Janssen Pharmaceutical Companies Of 
Johnson And Johnson/Belgium, 8Astex Pharmaceuticals/United King-
dom, 9Cancer Centre, Newcastle University/United Kingdom
Background: The fibroblast growth factor (FGF) signaling axis is 
increasingly implicated in tumorigenesis and chemoresistance. Fo-
cal amplification of FGF receptor 1 (FGFR1) has been identified in 
a subset of squamous and small cell lung cancers and is associated 
with tumor growth and survival, suggesting that FGFR inhibitors 
may be a viable therapeutic option in these cohorts of patients. 
A number of small-molecule FGFR targeted agents, with diverse 
kinase inhibitory and pharmacological profiles, are currently in 
clinical development.
Methods: Fragment-based drug discovery coupled to structure-
based design was used to identify JNJ-42756493. Fragments were 
optimized into potent FGFR inhibitors with selectivity against VEG-
FR2, which shares 57% sequence identity with the kinase domains 
of FGFR1 and FGFR3, and 54% with that of FGFR4.
Results: JNJ-42756493 has a pharmacological profile that is diffe-
rentiated from other agents in this class currently under investigati-
on. JNJ-42756493 displays potent pan FGFR (1, 2, 3 and 4) tyrosine 
kinase inhibitory activity and is highly selective outside the FGFR 
family. JNJ-42756493 inhibited recombinant FGFR kinase activi-
ty in vitro and suppressed FGFR signaling and growth in tumor 
cell lines dependent upon deregulated FGFR expression. JNJ-
42756493 demonstrated highly specific tumor inhibitory effects in 
FGFR1-4 dependent cell lines in vitro and xenografts in vivo, with 
no discernible activity in models that were not dependent on FGFR 
signaling. JNJ-42756493 showed favorable drug like properties 
and displayed a high distribution to lung tissue. JNJ-42756493 was 
well tolerated at efficacious doses and resulted in potent dose-
dependent antitumor activity accompanied by pharmacodynamic 
modulation of tumor FGFR and downstream pathway components.
Conclusion: Data presented here highlights JNJ-42756493 as a 
novel, highly potent and selective small-molecule pan FGFR kinase 
inhibitor with potent antitumor activity against FGFR-deregulated 
tumors in preclinical models. These data, together with our ongo-
ing Phase 1 clinical trial, position JNJ-42756493 as a differentiated 
selective pan-FGFR family inhibitor and support its continued clini-
cal development in lung cancer and other malignancies associated 
with aberrant FGFR signaling.
Keyword: FGFR kinase inhibitor JNJ-42756493
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P1.05-018 INHIBITION OF NON-SMALL-CELL LUNG 
CANCER GROWTH BY PH CONTROL RELEASE NANO-
PARTICLE CARRYING MIR-135B ANTAGOMIR
Ching-Wen Lin1, S-Ja Tseng2, Ting-Fang Che1, Tse-Ming Hong3, 
Pan-Chyr Yang1
1Institute Of Biomedical Science, Academia Sinica/Taiwan, 2Institute Of 
Physics, Academia Sinica/Taiwan, 3Graduate Institute Of Clinical Medi-
cine, National Cheng Kung University/Taiwan
Background: We identified an intronic miRNA, miR-135b, up-regu-
lated in aggressive non-small-cell lung cancer(NSCLC). Ectopically 
delivering mir-135b enhanced cell invasive and migratory ability 
in vitro and in vivo; whereas specific inhibition of miR-135b by 
miR-135b-specific molecular sponge and antagomirs suppressed 
cancer cell invasion, orthotopic lung tumor growth and metastasis 
in mouse model. We showed that miR-135b could directly repress 
the expression of Hippo pathway components. In this study, we 
design a tunable pH-responsive hydrogels to enhance the bioacti-
vity of chemically modified antisense RNA oligonucleotide and SPI-
ON in tumor microenvironment for acidosis-related tumor therapy.
Methods: pH-responsive matrix of PEG-imidazole hydrogel re-
leases chemically modified oligonucleotides (antagomir) and 
positively charged superparamagnetic iron oxide nanoparticles 
(SPION) were prepared. NOD-SCID mice were subcutaneously 
injected with CL1-5 cells and control antagomiR or antagomir-135b 
was intra-tumoural injected for 3 weeks. Body weight was determi-
ned. Blood was collected before euthanasia. Total tumor volume, 
metastatic nodules, and miR-135b expression are measured.
Results: By using pH-responsive release of SPION from hydrogels 
to release antagomiR, we found the hydrogel administered to 
natural physiology had a rate of slower release at pH6.7 than at 
pH7.4, which is sufficient to restrain cellular uptake of antagomir 
and the rate of release in acidic environments can be manipulated 
via the imidazole content. .In addition, systematic administrated 
antagomiR-135b through I.V. injection inhibited the orthotopic lung 
tumor growth and decreased the volume of lung metastases. Both 
results trigger us to examine the possibility of in vivo placing the 
antagomiR-containing hydrogels by the side of tumor, to evaluate 
the effect of localized releasing antagomiR on tumor growth.
Conclusion: Our results support that inhibition of miR-135b by pH 
control release nanoparticle may be promising to develop a new 
therapeutic strategy for NSCLC.
Keyword: NSCLC; miR-135b; antagomiR
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P1.05-021 DUAL CHECKPOINT BLOCKADE USING ANTI-
PD-1 AND ANTI-CTLA4 COMBINED WITH CISPLATIN 
CHEMOTHERAPY IS EFFECTIVE IN A MURINE MESO-
THELIOMA MODEL
Andrea Khong, Esdy Rozali, Catherine Boylen, Joanne Salmons, 
Bruce Robinson, Joost Lesterhuis, Richard Lake
School Of Medicine And Pharmacology, The University Of Western Aus-
tralia/Australia
Background: Chemotherapy (cisplatin, pemetrexed) remains is 
the standard of care for mesothelioma (MM) in Australia, however 
novel immunotherapies are now emerging in clinical trial. Anti-
PD-1 (MDX-1106) and anti-CTLA4 (tremelimumab) block different 
aspects of negative T cell regulation to prolong the activation 
and survival of anti-tumour cytotoxic T lymphocytes (CTL). While 
anti-CTLA4 is being tested in Phase II clinical trial, the efficacy of 
anti-PD-1 in MM patients is yet to be determined. The notion of 
combining chemo-immunotherapy has gained ground in recent 
years with the discovery that chemotherapy-induced tumour cell 
death can be immunogenic, and thus exploited with the right im-
munotherapy drug.
Methods: The murine mesothelioma line generated in our lab, 
AB1-HA, was inoculated subcutaneously into the flanks of Balb/c 
mice. Tumour growth and survival following treatment with anti-
PD-1 and/or anti-CTLA4, plus chemotherapy (gemcitabine, cispla-
tin) was monitored. Tissues (spleen, lymph nodes) were harvested 
at various time-points for flow cytometric analaysis to investigate 
immune correlates of response.
Results: Dual checkpoint blockade (anti-CTLA4 + anti-PD-1) was 
effective at delaying tumour outgrowth and improving survival, 
over either treatment alone (anti-PD-1 had negligible effect on 
AB1-HA growth). Combining this with cisplatin chemotherapy 
achieved an even greater effect, however this was not the case 
with gemcitabine.
Conclusion: The effect of dual checkpoint blockade mirrors that 
which has recently been discovered in mouse models of melanoma 
[1]and colon cancer [2]. The ability to combine this with chemo-
therapy to our knowledge has not been previously identified. Fur-
thermore, it is interesting that the triple combination was only suc-
cessful with cisplatin rather than gemcitabine, which in our hands 
has been shown to be immunogenic and works synergistically 
with other immunotherapies, such as anti-CD40. Not only can this 
finding be directly translated to the clinic, it also prompts future 
investigation into how best to combine different therapies to tack-
le malignancies that may be refractory to standard monotherapy 
treatments. 1. Curran, M.A., et al., PD-1 and CTLA-4 combination 
blockade expands infiltrating T cells and reduces regulatory T and 
myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S 
A, 2010. 107(9): p. 4275-80. 2. Duraiswamy, J., et al., Dual Blockade 
of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Res-
tores T-Cell Rejection Function in Tumors. Cancer Res, 2013. 73(12): 
p. 3591-603.
Keywords: anti-PD-1, anti-CTLA4, chemotherapy, mesothelioma
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P1.05-020 IDENTIFYING THERAPEUTIC TARGETS FOR 
MESOTHELIOMA USING SIRNA
Elliot Sollis, Samantha Woo, Ian Dick, Jenette Creaney, Richard 
Lake, Cleo Robinson
Uwa School Of Medicine And Pharmacology, National Centre For As-
bestos Related Diseases/Australia
Background: Mesothelioma is essentially incurable and new drugs 
to effectively treat it are urgently needed. Our strategy to achieve 
this aim was to identify candidate mouse and human genes that 
may have a role in mesothelioma growth and to inhibit their ex-
pression in fully transformed mesothelioma cell lines using siRNA.
Methods: The initial selection of candidate genes was made on 
the basis of their differential expression in transcriptome or CGH 
analyses when comparing malignant to normal mesothelial cells. 
This was combined with known functional information relevant to 
tumorigenesis. We also selected a small number of candidates 
from other published studies. A second set of candidates was 
chosen from expressed kinases with the idea that these genes are 
more likely to represent druggable targets given the broad range 
of kinase inhibitors that are widely available. Where possible, we 
identified mouse and human homologues of the 40 candidates 
and then generated both mouse and human siRNA libraries. We 
tested the effect of gene knockdown on the growth of mouse and 
human mesothelioma cell lines in vitro.
Results: We found knockdown was efficient and inhibition of a 
subset of the selected genes slowed cell growth significantly ac-
ross a range of cell lines in both mouse and human systems. There 
was not complete concordance between the mouse and human: 
Incenp, Plk1 and Tpx2 were important pathways for murine cellular 
proliferation; whereas, AURKA, TPX2 and BIRC5 were relevant for 
human cellular proliferation only. KIF11 was identified in both stu-
dies.
Conclusion: These genes all have a function in chromosome po-
sitioning, centrosome separation and spindle assembly during 
cell mitosis. Our data show that targeting these gene products in 
mesothelioma cell line causes growth inhibition both in vitro and in 
vivo. These studies could provide new leads for drug development.
Keyword: mesothelioma, siRNA library, therapeutic drugs
S469Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 1 - PRECLINICAL MODELS OF THERAPEUTICS/
IMAGING  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.05-023 THE KDM4/JMJD2 LYSINE DEMETHYLASES 
ARE CANDIDATE THERAPEUTIC TARGETS IN MALIG-
NANT PLEURAL MESOTHELIOMA
Maeve Breslin1, Sigrid Wennstedt1, Gerard Roche1, Cinaria Albad-
ri1, Sian Cregan1, Yun Gao2, Kenneth O‘Byrne3, Steven G. Gray4
1Clinical Medicine, Trinity College Dublin/Ireland, 2Department Of 
Oncology, Aerospace Central Clinical Medical College Of Peking Univer-
sity/China, 3Queensland University Of Technology, Cancer & Ageing 
Research Program/Australia, 4Clinical Medicine, Trinity College Dublin/
st Jame‘s Hospital/Ireland
Background: Malignant pleural mesothelioma (MPM) is a rare 
aggressive cancer of the pleura associated with exposure to as-
bestos. Treatment options are limited, and the current standard 
of care for MPM patients is a combination of cisplatin and pemet-
rexed (or alternatively cisplatin and raltitrexed). Despite this treat-
ment option, almost all patients die within 24 months of diagnosis. 
Therefore, new therapeutic options are urgently required for the 
treatment of MPM. Lysine Demethylases (KDMs) represent novel 
targets for the treatment of cancer. Overexpression of KDMs are 
common in many cancers, and play important roles in tumorigene-
sis. The jumonji (JMJ) family of lysine demethylases are Fe2+- and 
α-ketoglutarate-dependent oxygenases that are essential compo-
nents of regulatory transcriptional chromatin complexes. One such 
family, the KDM4/JMJD2 family, may therefore be altered in MPM 
and could represent a novel candidate target for intervention
Methods: A panel of MPM cell lines inluding the normal pleural 
cells LP9 & Met5A were screened for expression of KDM4 family 
members by RT-PCR. mRNA levels were subsequently examined 
by RT-PCR in a cohort of snap-frozen patient samples isolated at 
surgery comprising benign, epithelial, biphasic, and sarcomatoid 
histologies. The effects of a small molecule inhibitor of KDM4A/
JMJD2A, 3,4-dihydroxybenzaldehyde (protocatechuic aldehyde or 
PA) on cellular proliferation and gene expression were examined.
Results: We show that the expression of the KDM4 family is 
ubiquitously expressed across our panel of cell lines. In primary 
tumours however, the expression of KDM4 members KDM4A, 
KDM4B and KDM4C were significantly elevated in malignant MPM 
compared to benign pleura. Treatment of REN/ NCI-H226 cells 
with the small molecule PA caused significant inhibition of cellular 
proliferation (p<0.0001). We continue to asess the effects of this 
compound on gene expression and cellular health by other metho-
dologies to confirm its potential utility in the treatment of MPM.
Conclusion: The KDM4/JMJD2 family of lysine demethylases are 
significantly altered in MPM. A small molecule inhibitor of this pro-
tein shows significant anti-proliferative effects in MPM cell lines. 
Targeting this protein may have important future implications for 
the management of MPM.
Keywords: Lysine Demethylase, mesothelioma, inhibitor, epigene-
tics
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P1.05-022 BET BROMODOMAINS: ARE THEY A POTEN-
TIAL THERAPEUTIC TARGETS IN MALIGNANT PLEURAL 
MESOTHELIOMA?
Cinaria Albadri1, Maeve Breslin1, Sigrid Wennstedt1, Gerard Ro-
che1, Kenneth O‘Byrne2, Steven G. Gray3
1Clinical Medicine, Trinity College Dublin/Ireland, 2Queensland Uni-
versity Of Technology, Cancer & Ageing Research Program/Australia, 
3Clinical Medicine, Trinity College Dublin/st Jame‘s Hospital/Ireland
Background: Malignant pleural mesothelioma (MPM) is an aggressive 
cancer affecting the pleura. Treatment options are limited and most 
patients die within 24 months of diagnosis. The recommended first 
line chemotherapy for MPM is a combination of cisplatin/pemetrexed 
(or alternatively Raltitrexed), and there is no recommeneded second-
line therapy. As such new therapeutic approaches are required for 
the management of MPM. Bromodomain and extra terminal domain 
(BET) proteins function as epigenetic signaling factors that associate 
with acetylated histones to facilitate the transcription of target genes. 
Various inhibitors targeting the activity of BET proteins have been 
developed and have shown potent antiproliferative effects in hema-
tological cancers, and more recently been studied for in vitro efficacy 
in lung adenocarcinoma cell lines (1). We examined the expression of 
various members of the BET in MPM and assessed the effects of one 
of these inhibitors (JQ-1) to determine if this family could represent a 
novel candidate target(s) for therapeutic intervention in MPM.
Methods: A panel of MPM cell lines inluding the normal pleural cells 
LP9 & Met5A were screened for expression of BRD2 and BRD4 by 
RT-PCR. mRNA levels were subsequently examined by RT-PCR in a 
cohort of snap-frozen patient samples isolated at surgery comprising 
benign, epithelial, biphasic, and sarcomatoid histologies. The expres-
sion of a known target of the BET inhibitor JQ1, oncogenic transcrip-
tion factor FOSL1 was also examined. The effects of a small molecule 
inhibitor of BET proteins (JQ-1) on cellular proliferation was examined 
(BrdU ELISA).
Results: We show that the expression of the BRD2 and BRD4 variants 
are detectable in all cell lines across our panel of cell lines. In prima-
ry tumours however, the expression of BRD2 was very significantly 
downregulated (p=0.0006). BRD4 comprises 2 transcript variants, 
a long variant (BRD4L – Refseq NM_058243.2), and a short variant 
(BRD4S – Refseq NM_014299.2). BRD4L was not significantly affected 
in malignant MPM compared to benign pleura, whereas BRD4S was 
significantly elevated in the tumours compared to the benign pleura 
(p<0.05). When separated across histological subtype BRD2 was 
significantly decreased across all histological subtypes (p=0.0009). 
FOSL1 a candidate target of JQ1 (1) was found to be significantly ele-
vated in malignant MPM compared to benign pleura (p<0.05). Treat-
ment of REN/ NCI-H226 cells with JQ1 caused significant inhibition of 
cellular proliferation, with NCI-H226 being more sensitive than REN to 
this compound.
Conclusion: The BET domain proteins are altered in MPM, and a 
small molecule inhibitor of this protein shows significant anti-prolife-
rative effects in MPM cell lines. We continue to asess the effects of 
this compound on gene expression and cellular health by other me-
thodologies to confirm its potential utility in the treatment of MPM. 
Reference: 1. Lockwood WW et al., (2012). Proc Natl Acad Sci U S A. 
109(47):19408-13.
Keywords: JQ-1, FOSL1, mesothelioma, BET domain protein
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cells with the PARP inhibitor, PJ34, sensitises lung cancer cells 
to the cytotoxic effects of the platinum drug, cisplatin. Further 
studies are warranted to investigate the role of PARP inhibitors in 
cisplatin resistant NSCLC cells.
Keywords: NSCLC, PARP, cisplatin, PJ34
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P1.05-025 EGFR BLOCKADE INCREASES LUNG CANCER 
STEM CELL-LIKE CELLS BY UPREGULATION OF NOTCH3 
SIGNALING.
Rajeswara R. Arasada1, Joseph Amann1, Stacey Huppert2, David P. 
Carbone1
1James Thoracic Center, The Ohio State Wexner Medical Center/United 
States Of America, 2Developmental Biology, Cincinnati Childrens Hospi-
tal/United States Of America
Background: Blockade of genetic driver alterations in cell signa-
ling pathways such as the epidermal growth factor receptor (EGFR) 
have led to dramatic tumor responses in the metastatic setting. 
However, these agents have unexpectedly failed to improve out-
comes in clinical trails of early stage (BR.19) and locally advanced 
(S0023) NSCLC. In fact, survival was significantly worse among pa-
tients receiving gefitinib in the S0023 trial, and trended to be wor-
se in BR.19. While it is clear that EGFR TKIs can reduce the tumor 
bulk and improve symptoms in the metastatic setting, these results 
raise the possibility that EGFR inhibition might somehow stimulate 
tumor growth either directly or indirectly.
Methods: We studied the fractions and numbers of ALDH+ cells 
and activation of stemcell signaling pathways in two EGFR mutated 
cell lines treated with erlotinib.
Results: Here, we report that treatment of EGFR-mutated lung 
cancer cell lines with erlotinib, while showing robust cell death, 
essentially increases the fraction and absolute number of ALDH+ 
clonogenic stem cell-like cells. This phenomenon can be abolished 
by inhibition of Notch3, while Notch1 inhibition has little effect or 
slightly increases ALDH+ cells. We demonstrate EGFR kinase acti-
vity-dependent coprecipitation of Notch and EGFR receptors and 
EGFR kinase dependent tyrosine phosphorylation of the Notch3 
receptor. We further found that inhibition of EGFR activity leads to 
increased nuclear accumulation of gamma-secretase dependent 
Notch3 that correlates with the increase in ALDH+ cells.
Conclusion: These data suggest that while EGFR TKIs are very 
effective at debulking tumors in the metastatic setting, inhibition 
of EGFR paradoxically causes Notch activation and an increase in 
clonogenic stem cell-like cells. Therefore, curative-intent therapy 
may be best accomplished by dual targeting of EGFR and Notch3.
Keywords: stem cell, EGFR, Notch
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P1.05-024 PARP INHIBITION INCREASES SENSITIVITY OF 
NSCLC CELLS TO CISPLATIN
Raya Rausch1, Martin P. Barr1, Juergen Thomale2, Derek Richard3, 
Kenneth O‘Byrne4
1Clinical Medicine, St James‘s Hospital/Ireland, 2Cell Biology (cancer Re-
search), University Duisberg-essen/Germany, 3Translational Research 
Institute, Queensland University Of Technology/Australia, 4Queensland 
University Of Technology, Cancer & Ageing Research Program/Austra-
lia
Background: Primary and acquired resistance to platinum agents 
is a serious clinical problem in lung cancer. Its mechanisms are pro-
bably multifactorial and remain poorly understood. Enhanced DNA 
repair can lead to increased cell viability in the face of DNA dama-
ge and has been proposed to be important in mediating platinum 
resistance. PARPs (poly(ADP-ribose) polymerases) are a family of 
nuclear enzymes that regulate the repair of DNA single-strand 
breaks (SSBs). Cisplatin sensitivity and DNA repair mechanisms 
following treatment with the PARP inhibitor, PJ34, was investigated 
in this study.
Methods: A panel of isogenic cisplatin resistant (CisR) NSCLC cells 
lines (MOR, SKMES-1, H1299) previously generated in our labo-
ratory were used. The cisplatin resistant phenotype was initially 
assessed by treating CisR and parental (PT) cells with increasing 
doses of cisplatin (0-80uM) for 72h, after which time, cell prolifera-
tion was measured (BrdU). The effects of PJ34 on cell survival were 
also examined in a similar dose-response study. IC25 concentra-
tions were calculated for each cell line using GraphPad statistical 
software. Cells were treated with PJ34 (IC25) alone, or in combi-
nation with cisplatin and cell survival/proliferation measured after 
72h. Under similar experimental conditions, RNA was isolated from 
cells from which cDNA was reverse transcribed. All cell lines were 
screened for PARP1, PARP2, BRCA1, BRCA2 and ERCC1 mRNA at 
basal levels, and in response to treatment (RT-PCR). To investigate 
DNA double strand break (DSB) repair capacity in our panel of cell 
lines in response to PARP inhibition and cisplatin, phosphorylated 
γH2AX foci was examined by High Content Analysis (HCA) fol-
lowing treatment of cell lines for 24h. Cisplatin-DNA adduct for-
mation (Pt-GpG) was studied following treatment of cells for 24h. 
Cells (1x106/ml) were spotted on Superfrost® Gold glass slides. 
Immunofluorescence staining of specific DNA platination products, 
and quantification of adducts, was performed using an antibody 
that specifically recognises cisplatin-GpG DNA adducts.
Results: MOR and H1299 CisR cells were significantly more resis-
tant to cisplatin (10µM and 20µM) compared to PT cells. SKMES-1 
CisR cells were also significantly more resistant at 10µM, 20µM and 
40µM cisplatin. While PJ34 had no effect on NSCLC cells when tre-
ated as a single agent, cell proliferation was significantly inhibited 
in MOR and H1299 cells when used in combination with cisplatin. 
No effect however was observed in our panel of CisR cell lines. 
While baseline expression levels of PARP1/2, BRCA1/2 and ERCC1 
mRNA levels were similar in PT and CisR cell lines, BRAC1/2 mRNA 
expression was increased in cells treated with cisplatin alone, 
and in combination with PJ34 in PT cells but not in CisR cells. The 
formation of γH2AX foci and measurement of cisplatin-GpG DNA 
adducts in response to PARP inhibition and cisplatin are currently 
being investigated.
Conclusion: Data from this study show that inhibition of NSCLC 
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P1.06-002 INTRATUMOR VARIATION OF BIOMARKER 
EXPRESSION BY IMMUNOHISTOCHEMISTRY IN RESEC-
TABLE NON-SMALL CELL LUNG CANCER
Jan N. Jakobsen1, Eric Santoni-Rugiu2, Jens B. Sorensen1
1Oncology, National University Hospital/Denmark, 2Pathology, National 
University Hospital/Denmark
Background: Prognostic and predictive biomarkers are increa-
singly used to customize treatment of patients with solid tumors. 
Intra- and inter-tumor heterogeneous distribution of biomarker ex-
pression are potential confounders for use of biomarkers, as small 
biopsies may not necessarily truly reflect the pattern of biomarker 
expression. It may also be an important factor in chemoresistance, 
as tumors with heterogeneous biomarker expression may potenti-
ally harbor chemoresistant tumor clones.
Methods: Immunohistochemical evaluation of expression of ex-
cision repair cross complementation group 1 (ERCC1), epidermal 
growth factor receptor (EGFR), class III-β-tubulin (TUBB-3), Thy-
midylate synthase (TS), Ki-67 and ribonucleotide reductase M1 
(RRM1) was performed in 15 separate areas in each of 6 small mi-
croscopically completely resected adenocarcinomas of the lung in 
order to elucidate any heterogeneous distribution.
Results: Clinically relevant biomarker heterogeneity with respect 
to expression of EGFR, ERCC1, RRM1, TUBB-3, and Ki-67 was ob-
served in 4 (66%), 4 (66%), 2 (33%), 3 (50%) and 5 (83%) out of 6 
tumors, respectively. Thus, heterogeneity could potentially alloca-
te these tumors erroneously into high or low expressers by chance 
alone, according to previously reported cut-off values. In contrast, 
TS was almost completely homogenously distributed.
Conclusion: Most biomarkers examined, except for TS, showed 
clinically significant intratumor heterogeneity in 33% to 87% of 
tumors examined. This heterogeneity may influence results in stu-
dies investigating the therapeutic impact of predictive biomarkers 
in NSCLC.
Keyword: NSCLC, biomarker, heterogeneity
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P1.06-003 COMPARATIVE EFFECTIVENESS OF DDPCR 
FOR THE DETECTION OF EGFR MUTATIONS.
Marissa Daniels1, Krishna Sriram1, Edwina Duhig2, Belinda Clar-
ke2, Andrew Dettrick2, David Godbolt2, Kayla Tran2, Morgan Wind-
sor3, Rishendran Naidoo3, Kevin Matar3, Robert Tam3, Rayleen 
Bowman1, Ian Yang1, Kwun Fong1
1University Of Queensland/the Prince Charles Hospital Thoracic Re-
search Centre/Australia, 2Department Of Pathology, The Prince Charles 
Hospital/Australia, 3Cardiothoracic Surgery, The Prince Charles Hospi-
tal/Australia
Background: Selection of EGFR TKIs for lung cancer requires ac-
curate detection of activating mutations. Traditional techniques 
are limited by small biopsy sizes. We compared droplet digital PCR 
(ddPCR, Bio-Rad) to Sanger sequencing, mutant-enriched PCR 
Session P1.06: Poster Session 1 -  
Prognostic and Predictive  
Biomarkers 
Monday, October 28, 2013
POSTER SESSION 1 - PROGNOSTIC AND PREDICTIVE BIOMARKERS  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.06-001 HDL-CHOLESTEROL IS REDUCED IN ADVAN-
CED STAGE LUNG CANCER PATIENTS WITH WEIGHT 
LOSS
Bulent Karagoz1, Levent Emirzeoglu1, Oguz Bilgi1, Rauf Gorur2, 
Alpaslan Ozgun1, Tolga Tuncel1, Turgut Isitmangil2
1Medical Oncology, Gata Haydarpasa Training Hospital/Turkey, 2Thora-
cic Surgery, Gata Haydarpasa Training Hospital/Turkey
Background: Lipids play roles in several biological functions such 
as cell growth, division, and membrane stabilization in normal and 
cancer cells. There has been also interest in the relation of serum 
lipid levels and cancer in various studies. Epidemiological studies 
have demonstrated that high total cholesterol level is associated 
decreased cancer incidence. On time of diagnosis, HDL-choleste-
rol levels are reduced in lung cancer patients. We investigated the 
relation between lipid profile and weight loss in advanced stage 
lung cancer patients.
Methods: Forty-eight advanced stage lung cancer patients and 
20 healthy subjects were included in the study. SCLC patients had 
extensive stage disease and NSCLC patients were stage IIIB and 
IV. All of study patients and control subjects were smoker and non-
obese. Serum lipid profile, total protein, albumin, erythrocyte sedi-
mentation rate (ESR) and clinical data were recorded.
Results: Lower HDL-cholesterol levels detected in advanced stage 
lung cancer patients. Serum total cholesterol, total protein, and 
albumin levels were also lower in cancer patients than controls. 
Serum LDL-cholesterol measurements were not different between 
patients and healthy subjects. However, ESR is higher in patients 
than controls. Twenty-four patients had weight loss. Total choleste-
rol, HDL-cholesterol, and LDL-cholesterol levels were lower in the 
patients with than without weight loss. However, total cholesterol, 
HDL-cholesterol, and LDL-cholesterol levels were not different 
between lung cancer patients without weight loss and control 
subjects. In lung cancer patients, serum HDL-cholesterol level was 
correlated with inversely ESR; directly with serum albumin level.
Conclusion: Although the weak association between HDL-choles-
terol and cancer has been reported and the effect of HDL-choles-
terol in carcinogenesis has been discussed, we not found diffe-
rence in lipid profiles of lung cancer patients without weight loss. 
We consider that the reduction of lipid levels may be related to 
cancer cachexia. Moreover, serum albumin level and ESR, indirect-
ly markers of inflammation, were correlated with HDL-cholesterol. 
It is known that inflammation reduce HDL-cholesterol. The cause 
of coincidence between reducing HDL-cholesterol and cancer may 
be inflammatory process. Further studies that investigate the cli-
nical signification of reduced HDL-cholesterol and other lipids are 
necessary.
Keywords: HDL, cachexia, weight loss
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P1.06-004 ROS1 IMMUNOHISTOCHEMISTRY AMONG 
MAJOR GENOTYPES OF NON-SMALL CELL LUNG  
CARCINOMA
Theresa Boyle1, Kim Ellison1, Murry W. Wynes1, Katuyasu Masago2, 
Yasushi Yatabe2, Fred Hirsch3
1Medical Oncology, University Of Colorado/United States Of America, 
2Dept. Of Pathology And Molecular Diagnostics, Aichi Cancer Center/
Japan, 3University Of Colorado Cancer Center/United States Of America
Background: ROS1 (c-ros oncogene 1) is a receptor tyrosine kinase 
that can become constitutively active and drive cellular prolifera-
tion in a variety of cancers. Approximately 1-2% of patients with 
non-small cell lung cancer (NSCLC) harbor activating ROS1 gene 
fusions and these patients may benefit from ROS1-targeted inhibi-
tor therapy.
Methods: Immunohistochemistry for ROS1 expression was perfor-
med on 33 NSCLC specimens previously characterized for the pre-
sence of genetic abnormalities. These specimens were selected for 
ROS1 gene rearrangements (6 specimens) detected by RT-PCR and 
FISH, ALK gene rearrangements (5 specimens), EGFR mutations 
(5 specimens), KRAS mutations (5 specimens), HER2 mutations (3 
specimens), RET gene rearrangements (3 specimens), and pan-
negative (6 specimens). Immunohistochemistry was performed in 
a CLIA-certified laboratory with manual application of the ROS1 
DFD6 antibody (Cell Signaling Technology, Inc) for 1 hour. ROS1 
protein expression was evaluated by a pathologist with a hybrid 
(H)-score scale of 0 (no expression in any tumor cells) to 300 (inten-
se expression in all tumor cells). ROS1 over-expression was defined 
as an H-score greater than 100.
Results: ROS1 protein over-expression was detected by immuno-
histochemistry in all 6 of the NSCLC specimens with ROS1 gene 
fusions detected by RT-PCR (example in figure below). None of 
the remaining 27 lung cancer specimens with ALK gene rearran-
gements, EGFR mutations, KRAS mutations, HER2 mutations, RET 
gene rearrangements, or pan-negative exhibited ROS1 protein 
over-expression. 
(ME-PCR) and high resolution melt (HRM) PCR.
Methods: A comparative effectiveness study was performed on 
317 resected NSCLCs with salt extracted gDNA. EGFR exons 19 & 
21 Sanger sequencing and (Shigematsu et al., 2005) and HRM/ME-
PCR mutation detection (Sriram et al., 2011) was previously repor-
ted. ddPCR (Bio-Rad) was performed with competitive allele spe-
cific Taqman PCR (CastPCR; Life Technologies); EGFR L858R assay 
for exon 21 c.2573T>G and c.2572_2572CT>AG; exon 19 deletion 
assay for 20 common deletions (EGFR_ex19dels_mu, EGFR_6224_
mu). 8ng gDNA was tested in 20uL reactions partitioned into 
20000 droplets; valid reads contained ≥ 10000 droplets. Controls 
were 8ng gDNA from mutation positive cell lines (AJCC: H1975, 
H1650), human female DNA (Promega) and no template controls. 
QuantaLife (Bio-Rad) calculated Poisson statistics determined alle-
le copy/uL; samples with minimum estimated mutant copy number 
≥ 0.15/uL (3 copies/8ng) were “called” positive.
Results: Serial dilution of control assay demonstrated de-
tection of template to 40pg input gDNA. 209 (66%) men 
and 108 (34%) women of mean age 63 years (range 36 to 
83) were included. 295 (93%) had smoked and 18 (6%) were 
never smokers; 4 (1%) were unknown. 1 subject (0.3%) was 
Asian. pTNM stages were I (47%), II (31%) and III (22%) res-
pectively (6th Ed). 171 (54%) were adenocarcinomas, 109 (34%) 
squamous cell carcinomas, and 37 (12%) other histologies. 
Exon 19 and 21 ddPCR assays yielded valid results for 300 and 301 
samples respectively. ddPCR detected all mutations previously 
demonstrated by Sanger sequencing (13) and HRM (13) but not 
ME-PCR (13/15). Mean droplet counts were lower in ddPCR only 
called (30 droplets/ng) than those samples also called by other 
methods (3600 droplets/ng; p=0.039). Median percentage tumour 
and necrosis content of mutation positive samples only by ddPCR 
were 30% and 0% respectively, identical to those called by other 
methods.
Conclusion: ddPCR identifies mutations detected by Sanger se-
quencing and HRM. Limitations include nanodrop quantitation 
of input DNA and data replication is required. This technique 
demonstrates high sensitivity but limited specificity and requires 
further validation to examine the significance of low droplet num-
ber positive calls. The authors acknowledge the assistance of R 
Harrison and A Beckhouse, Bio-Rad. Financial support gratefully 
received from: NHMRC (MD PhD Scholarship), CCQ (MD PhD 
Scholarship), Cancer Australia, TPCH Foundation, Queensland 
Health.
Keywords: molecular diagnosis, Lung cancer genetics, Genetic 
testing, EGFR mutations
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TRACP 5b and ICTP may serve as a useful supplement for SPECT 
in lung cancer BM screening. If the 3 markers can be properly used 
together with SPECT, BM screening would turn to be more timely 
and accurate.
Keywords: Bone Metastasis, Lung cancer, Markers, diagnosis
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P1.06-006 PROGNOSTIC VALUE OF SERIAL PERIPHERAL 
CIRCULATING TUMOUR CELLS (CTC) EVALUATION IN 
PATIENTS WITH ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC) DURING FIRST LINE TREATMENT.
Teresa Alonso Gordoa1, Jose Luis Gonzalez Larriba1, María Luisa 
Maestro De Las Casas2, Carlos Aguado De La Rosa1, Miguel Jhona-
tan Sotelo Lezama1, Silvia Veganzones De Castro2, Virginia De La 
Orden2, Eduardo Díaz-Rubio1, Javier Puente Vázquez1
1Medical Oncology, Hospital Clínico San Carlos/Spain, 2Medical Analy-
sis, Hospital Clínico San Carlos/Spain
Background: Treatment strategy in lung cancer is lack of surro-
gate markers that may improve the clinical management in such 
an aggressive and deadliest tumour. Recently, CTC detection and 
characterization has been suggested as a promising and valuable 
outcome biomarker that is beginning to be elucidated in this con-
text. The study investigates whether CTC reduction along treat-
ment has a prognostic significance in previously untreated patients 
with advanced NSCLC receiving chemotherapy.
Methods: Patients with histologically confirmed stage III or IV NS-
CLC and suitable for chemotherapy treatment were selected for 
the study irrespective of other baseline characteristics. From each 
patient, two peripheral blood samples for CTC analysis were coll-
ected at baseline and concomitantly with first radiological evalua-
tion, after three cycles of chemotherapy. CTC expressing EpCAM 
were detected in the semiautomated platform; the CellSearch® 
system.
Results: In this single institution prospective study, 25 consecutive 
patients were included between April 2011 and January 2013. The 
patients had a median age of 67 years (range 41-80), most were 
former or current smokers (60% and 32%, respectively), had ECOG 
1 (80%), adenocarcinoma subtype (80%) and stage IV tumour at 
diagnosis (84%). First line platinum-containing chemotherapy was 
combined with antiangiogenics in 64% and with antifolates in 
36% of patients. After 34 months of follow up, the median overall 
survival for the whole population was 10.9 months (95% IC 6.9-15 
months). A non-significant survival benefit was identified in the 
group of patients for whom a reduction in CTC enumeration was 
achieved (N=12), in comparison to those with equal or greater 
number of CTC detected (N=13) between the first and second 
blood samples collected [11.2 months (95%IC 9.07 – 13.4) vs 7.2 
months (95% IC 4.9 – 9.5); p=0.44] (figure 1). However, progression 
free survival was similar in both groups of patients (5.9 months vs 
5.6 months, respectively). 
Conclusion: Detection of ROS1 over-expression by immunohisto-
chemistry exhibited 100% concordance with results of ROS1 gene 
rearrangement for 33 NSCLC specimens and did not overlap with 
any of the other genetic alterations. Six specimens were positive 
for ROS1 gene rearrangement by both RT-PCR and immunohisto-
chemistry. Tumors positive for genetic alterations associated with 
the ALK, EGFR, KRAS, HER2, and RET genes were all negative 
for ROS1 gene rearrangement and ROS1 immunohistochemistry. 
ROS1 immunohistochemistry is a sensitive, specific and cost-
effective method for identification of a subset of patients with lung 
cancer that may benefit from ROS-1 targeted-therapy.
Keyword: immunohistochemistry, ROS1, NSCLC
POSTER SESSION 1 - PROGNOSTIC AND PREDICTIVE BIOMARKERS  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.06-005 THE CLINICAL SIGNIFICANCE OF SERUM BAP, 
TRACP 5B AND ICTP AS BONE METABOLIC MARKERS 
FOR BONE METASTASIS SCREENING IN LUNG CANCER 
PATIENTS
Chuanhao Tang1, Yi Liu2, Haifeng Qin1, Xiaoyan Li1, Xiaoqing Liu1
1Department Of Lung Cancer, Affiliated Hospital Of Academy Of Milita-
ry Medical Sciences/China, 2Translational Medicine Center, Laboratory 
Of Oncology, Affiliated Hospital Of Academy Of Military Medical Scien-
ces/China
Background: The early diagnosis of bone metastasis (BM) may 
bring improvements of life quality and treatment to cancer pati-
ents. Although single-photon emission computed tomography 
(SPECT) is the most frequently used method for BM screening, it 
still has some shortages. This study was initiated to investigate the 
clinical significance of serum BAP, TRACP 5b and ICTP as bone 
metabolic markers for BM screening in lung cancer patients.
Methods: Newly diagnosed advance lung cancer patients with 
(N=130) and without (N=135) BM were enrolled in present study. 
In addition, newly diagnosed primary lung cancer patients (N=38) 
were enrolled as control. Serum BAP, TRACP 5b and ICTP were 
measured using enzyme-linked immunosorbent assay (ELISA) be-
fore the initiation of treatment. The differences in concentration 
of BAP, TRACP 5b and ICTP were analyzed by one-way analysis of 
variance (ANOVA) (or Kruskal-Wallis tests when appropriate). The 
screening effectiveness of BAP, TRACP 5b, ICTP and the combi-
nation of TRACP 5b and ICTP was assessed by receiver operating 
characteristic (ROC) curves analysis in patients with and without 
BM.
Results: For concentrations of BAP, TRACP 5b and ICTP, significant 
differences was found between patients with and without BM (all 
P<0.0001), as well as patients with solitary and multiple BM (BAP: 
P<0.0001, TRACP 5b: P=0.0008, ICTP: P=0.0474). ROC curves 
analysis reveals the area under curve (AUC) of BAP, TRACP 5b and 
ICTP was 0.760, 0.753 and 0.835 (all P=0.0001), respectively. The 
optimal cut-off value for BAP, TRACP 5b and ICTP was 21.8 µg/L 
(sensitivity=63.1%, specificity=77.0%), 7.8 U/L (sensitivity=58.5%, 
specificity=80.7%) and 8.8µg/L (sensitivity=63.1%, specifici-
ty=90.4%), respectively. When TRACP 5b and ICTP was combined 
for BM screening , AUC was elevated to 0.895 (P=0.0001), and the 
optimal cut-off value was TRACP 5b > 7.6 U/L and ICTP >8.4µg/L 
(sensitivity=71.5%, specificity=93.3%).
Conclusion: Our research has demonstrated that serum BAP, 
S474 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
the molar ratio 1:0.4:1. We then evaluated the relation between 
the EGFR mutation status, each of the 5FU related enzymes and 
various clinicopathological factors. In vitro, DPD mRNA and protein 
expression was investigated in various cell lines.
Results: Among the 49 cases (thirty adenocarcinoma (ADC), 
sixteen squamous cell carcinoma (SQCC), two adenosquamous 
carcinoma, and one carcinoid), EGFR mutation was observed only 
in ADC (12 patients; 24.5%). In immunohistochemical examination, 
10 patients were DPD immune-positive (20.4%), 31 patients were 
OPRT immune-positive (63.3%), and 16 patients were TS immune-
positive (32.7%). Three year disease free survival rate of single S-1 
adjuvant therapy was 77.6%, and three year overall survival rate 
was 89.7%. DPD immune-positive cases were significantly correla-
ted with EGFR mutation status (p = 0.003). In vitro, EGFR mutated 
cell lines showed high DPD mRNA and protein expression.
Conclusion: High DPD expression was shown to be correlated with 
EGFR mutation in adenocarcinoma cells and tissues. This result in-
dicates that 5FU might be effective for EGFR wild type tumors than 
mutant type tumor, and EGFR mutation status might be a potential 
poor predictive marker for treatment with 5FU drugs.
Keywords: EGFR mutation, NSCLC, 5FU, DPD
Figure 1. Kaplan-Meier curves for overall survival (OS) of patients 
with a reduction in the number of CTC (R-CTC) versus patients with 
equal or greater number of CTC (NR-CTC) detected in peripheral 
blood samples during chemotherapy treatment.
Conclusion: CTC serial isolation along treatment is a non-invasive 
tool that shows an encouraging prognostic value in advanced non-
small cell lung cancer. Those findings strengthen the introduction 
of outcome markers in treatment decisions in this setting, but war-
rants further investigation for its validation in larger studies.
Keywords: circulating tumour cells, Lung cancer, Prognosis
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P1.06-007 RELATIONSHIP BETWEEN 5FU RELATED EN-
ZYMES AND EGFR MUTATION STATUS IN NON-SMALL 
CELL LUNG CANCER TREATED WITH S-1 ADJUVANT 
THERAPY
Koji Mochinaga, Tomoshi Tsuchiya, Toshiya Nagasaki, Junichi 
Arai, Tetsuro Tominaga, Naoya Yamasaki, Keitaro Matsumoto, 
Takuro Miyazaki, Takeshi Nagayasu
Division Of Surgical Oncology, Nagasaki University/Japan
Background: Anti-cancer effect of 5-fluorouracil (5FU) is affected 
by the expressions of 5FU related enzymes, such as dihydropy-
rimidine dehydrogenase (DPD) and thymidine synthase (TS) and 
orotate phosphoribosyltransferase (OPRT), in each tumor. On the 
other hand, anti-cancer effect of epidermal growth factor receptor 
tyrosine kinase (EGFR-TKI) is affected by EGFR mutation status in 
each tumor. In 2007, Suehisa and colleagues reported that adju-
vant chemotherapy with uracil-tegafur, a fluorouracil prodrug, sig-
nificantly prolonged survival rates among patients with EGFR wild-
type adenocarcinoma but not among patients with EGFR mutant 
tumors. In this study, the correlation between 5FU related enzymes 
and EGFR mutation status was analyzed.
Methods: We analyzed 49 patients with primary NSCLC who were 
postoperatively treated with S-1, an oral fluorouracil anticancer 
prodrug composed of tegafur, CDHP, and potassium oxonate in 
S475Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 1 - PROGNOSTIC AND PREDICTIVE BIOMARKERS  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.06-009 EXPRESSION OF BMP-7 IN NON-SMALL CELL 
LUNG CANCER AND ITS CLINICAL SIGNIFICANCE
Masaya Aoki1, Masakazu Yanagi2, Tsunayuki Otsuka1, Naoya Yo-
komakura1, Tadashi Umehara1, Soichi Suzuki1, Aya Harada1, Go 
Kamimura1, Kazuhiro Wakida1, Yui Watanabe1, Toshiyuki Nagata1, 
Kota Kariatsumari1, Koichi Sakasegawa1, Yoshihiro Nakamura1, 
Masami Sato1
1General Thoracic Surgery, School Of Medical And Dental Sciences, 
Kagoshima University/Japan, 2Kagoshima Kouseiren Hospital/Japan
Background: Bone morphogenetic protein-7 (BMP-7) is signaling 
molecule belonging to the transforming growth factor (TGF) - beta 
superfamily. Expression of BMP-7 is highest in the kidney and it is 
thought to be related to kidney and eye development and skeletal 
patterning. Recent studies demonstrated that BMP-7 was expressed 
in various human cancers. However, there have been few reports 
detailing this in non-small cell lung cancer (NSCLC). Then, the pur-
pose of the present study was to investigate expression of BMP-7 in 
clinical samples of NSCLC to determine its clinicopathological and 
prognostic impact.
Methods: 160 NSCLC patients who received complete resection at 
Kagoshima University Hospital from 2001 to 2007 were enrolled in 
the study. Two patients underwent pneumonectomy, 4 bilobectomy, 
154 lobectomy. A total of 160 patients were classified, including 102 
male and 58 female patients (range, 26- 84 years; average, 69 years). 
The final pathological examination disclosed that cases of stage IA, 
IB, IIA, IIB, IIIA NSCLC numbered 50, 52, 16, 15 and 27, respectively. 
The patients were histopathologically classified as 112 adenocar-
cinoma, 40 squamous cell carcinoma or 8 others (adenosquamous 
carcinoma, large cell carcinoma, mucoepidermoid carcinoma, pleo-
morphic carcinoma) according to the 7th Edition of General Rule for 
Clinical and Pathological Record of Lung Cancer (The Japan Lung 
Cancer Society, 2010). Expression of BMP-7 in cancer (tissue was 
evaluated by immunohistochemistry. Correlations between expres-
sion of BMP-7 and clinicopathological factors and prognosis were 
analyzed retrospectively. The study was approved by the Institutio-
nal Review Board of Kagoshima University and performed according 
to the Helsinki Declaration. A statistical analysis of group differences 
was performed using Χ2 test. The Kaplan-Meier method was used 
for survival analysis and evaluated by the log-rank test. The Cox 
proportional hazard model was used in multivariate analysis. p<0.05 
was considered statistically significant.
Results: Immunohistochemically, in NCSLC, BMP-7 expression was 
identified in cell membranes but also in the cytoplasm of cancer 
cells. The patients were classified into two groups (BMP-7-positive 
group, 68 cases; BMP-7-negative group, 92 cases). Expression of 
BMP-7 correlated with T factor (p=0.047), N factor (p=0.013) and pa-
thological stage (p=0.046). BMP-7 expression was significantly cor-
related with overall survival after the operation (p=0.003). Moreover, 
multivariate analysis revealed BMP-7-positivity as an independent 
prognostic factor (p=0.022).
Conclusion: We can use BMP-7 expression as a predictor of lymph 
node metastasis and postoperative outcome in NSCLC. The signals 
activated by BMP-7 are complicated and involve intracellular and 
extracellular factors, so further analysis seems to be necessary to 
determine the mechanism involved.
Keywords: non-small cell lung cancer, Lymph node metastasis, 
postoperative outcome, Bone morphogenetic protein-7
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P1.06-008 EXPRESSION OF PTRF/CAVIN-1 IS ASSOCIA-
TED WITH POOR PROGNOSIS OF LUNG ADENOCARCI-
NOMA
Hidetoshi Inoue1, Noritoshi Nishiyama1, Nobuhiro Izumi1, Shinjiro 
Mizuguchi1, Kyukwang Chung1, Shoji Hanada1, Hiroaki Komatsu1, 
Hiroko Oka1, Satoshi Okada1, Kantaro Hara1, Hideki Wanibuchi2, 
Min Wei2, Shotaro Yamano2
1Thoracic Surgery, Osaka City University Hospital/Japan, 2Pathology, 
Osaka City University/Japan
Background: Polymerase I and transcript release factor (PTRF)/
Cavin-1 was initially identified as a regulator of rRNA transcription 
in the nucleus. It then was demonstrated to be essential to the 
formation of mature caveolae at the plasma membrane. Recently, 
downregulation of PTRF/Cavin-1 was reported in several types of 
cancers including non-small cell lung cancer compared to normal 
tissue. However, its precise expression pattern and clinical signifi-
cance in lung adenocarcinoma remains unclear.
Methods: Proteomic analysis of 12 lung adenocarcinomas and 
the paired non-cancer lung tissue were preformed using iTRAQ 
coupled LC-MS/MS. To determine the expression pattern of PTRF/
Cavin-1, we then performed immunohistochemical staining of 
PTRF/Cavin-1 on 186 adenocarcinoma tissues completely resected 
at Osaka City University Hospital from January 2005 to December 
2008. To evaluate the clinical significance of PTRF/Cavin-1, the rela-
tionship between PTRF/Cavin-1 expression and clinicopathological 
parameters was analyzed.
Results: Proteomic analysis shows that expression level of PTRF/
Cavin-1 is significantly lower in the cancer compared to the paired 
non-cancer lung tissue. This result suggests that PTRF/Cavin-1 may 
be involved in the development of lung adenocarcinoma. Immu-
nohistochemistry analysis reveals that 30 cases (16%) were strongly 
positive for PTRF/Cavin-1 as observed in the non-cancer lung tis-
sues, while 158 cases (84%) were negative. Furthermore, we found 
that overall survival rate of PTRF/Cavin-1-positve cases was signifi-
cantly lower than that of negative cases (Log-rank test, p=0.0010). 
These findings imply that PTRF/Cavin-1 in cancer cells may facilita-
te the progression of lung adenocarcinoma progression.
Conclusion: These findings indicate that expression of PTRF/
Cavin-1 in adenocarcinoma is associated with poor prognosis and 
might be a useful prognostic marker for lung adenocarcinomas.
Keywords: Adenocarcinoma, PTRF/Cavin-1, biomarker, Prognosis
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P1.06-011 NEXT GENERATION SEQUENCING IN LUNG 
CANCERS - FOCUSING ON THE KINOME
Åslaug Helland1, Odd Terje Brustugun2, Ann Rita Halvorsen1, Jin-
chang Sun3, Susanne Lorenz4, Daniel Vodak3, Sigve Nakken4, Ola 
Myklebost5, Eivind Hovig5, Leonardo Meza-Zepeda5
1Genetics, Institute For Cancer Reserach/Norway, 2Dept. Of Oncology, The 
Norwegian Radium Hospital/Norway, 3Tumour Biology, Dept Of Tumour 
Biology/Norway, 4Tumour Biology, Ins For Cancer Reserach/Norway, 
5Dept Of Tumor Biology, The Norwegian Radium Hospital/Norway
Background: The majority of newly diagnosed patients with lung 
cancer are at an advanced stage, implying small chances of cure. 
However, lung cancer treatment has in the last years taken advan-
tage of newly developed targeted therapies. EGFR-mutations and 
ALK-translocations are druggable alterations used in treatment deci-
sions. There are several additional druggable mutations in cancers, 
specially among kinases, but their frequency in lung cancer is not 
fully elucidated.
Methods: Blood samples and tumour tissue were obtained from 
96 operated early stage lung cancer patients admitted to Oslo 
University Hospital-Rikshospitalet in the period 2006-2011. 48 were 
women, 21 squamous cell carcinomas, 73 adenocarcinomas and two 
large cell carcinomas. Tissue was taken from the excised tumours, 
snap frozen in liquid nitrogen in the operation room, and stored at 
-80oC until DNA isolation. The tumour cell content in the specimens 
was found to be more than 70% in most samples. DNA was isola-
ted from both tumour and corresponding blood sample according 
to standard procedures. Targeted resequencing was performed 
using the SureSelect Human Kinome kit (Agilent Technologies), with 
capture probes targeting 3.2 Mb of the human genome, including 
exons for all known kinases, and selected cancer related genes and 
their associated UTRs, in total 612 genes. Targeted regions were 
sequenced at 50-60x coverage, allowing the detection of subpopu-
lations down to 20%. The derived sequence was analysed based on 
a pipeline including calling variations, somatic mutations, DNA copy 
number changes, indels and genomic rearrangements, as well as 
functional annotations.
Results: There were significant differences in the number of somatic 
mutations detected within each tumour, ranging from 1 to 81, with 
a median of 14 mutations. Each mutation was supported by at least 
20% mutant reads in the tumour, and the great majority correspon-
ded to missense mutations. Over 1000 mutations were identified 
among all the samples analysed, but recurrent mutations were iden-
tified in specific pathways like the PI3K- and CHEK2-pathways. The 
TP53-gene was the most frequent mutated gene, in almost 50% of 
the samples, and these mutations have been validated by Sanger 
sequencing. Of the samples with more than 30 mutations, 55% re-
vealed a mutation in the ATM-gene, whereas the frequency among 
the other samples was 14%, indicating a deregulation in DNA repair. 
Using the exon data from tumour and normal samples, we estimated 
DNA copy number changes, detecting gains and amplifications in 
cancer relevant genes i.e. KIT, ERK, EGFR.
Conclusion: In this pilot study, we have analysed 96 lung carcinomas 
by next generation sequencing, focusing on the kinome. We have 
identified several interesting mutational events, and analyses on 
different clinical subgroups are ongoing.
Keywords: mutations, kinome, Lung cancer
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P1.06-010 EXPRESSION OF Α1,6-FUCOSYLTRANSFERASE 
IS ASSOCIATED WITH PROGNOSIS AND HISTOLOGY IN 
NON-SMALL CELL LUNG CANCERS
Rio Honma1, Ichiro Kinoshita1, Eiji Miyoshi2, Utano Tomaru3, Yos-
hihiro Matsuno4, Yasushi Shimizu1, Satoshi Takeuchi1, Kichizo 
Kaga5, Naoyuki Taniguchi6, Hirotoshi Dosaka-Akita1
1Department Of Medical Oncology, Hokkaido University Graduate 
School Of Medicine/Japan, 2Department Of Molecular Biochemistry And 
Clinical Investigation, Osaka University Graduate School Of Medicine/
Japan, 3Department Of Pathology, Hokkaido University Graduate School 
Of Medicine/Japan, 4Department Of Surgical Pathology, Hokkaido Uni-
versity Hospital/Japan, 5Department Of Cardiovascular And Thoracic 
Surgery, Hokkaido University Graduate School Of Medicine/Japan, 
6Disease Glycomics Team, Systems Glycobiology Reserch Group, Riken 
Advanced Science Institute/Japan
Background: Lung cancer is one of the leading causes of cancer 
death throughout the world. A more sophisticated understanding 
of the pathogenesis and biology of NSCLCs could provide use-
ful information for predicting clinical outcome and personalized 
treatment. α1,6-FT is the only one enzyme responsible for the core 
α1,6-fucosylation of N-glycans of glycoproteins, including EGF 
receptor, TGF-β1 receptor, and integrin α3β1.
Methods: α1,6-FT expression was studied by 
immunohistochemistry in a cohort of 129 surgically resected 
NSCLCs, classified categorically based on the proportion of 
positively stained cancer cells (high, > 20%; or low, < 20%), and 
analyzed statistically in relation to various characteristics, including 
histology, survival and prognosis.
Results: High and low expression of α1,6-FT was found in 67 and 
62 of 129 NSCLCs, respectively. Multivariate logistic regression 
analysis revealed a significant association between high α1,6-FT 
expression and non-squamous cell carcinoma (mostly adenocar-
cinoma), as compared with squamous cell carcinomas (odds ratio, 
3.51; p = 0.008). Patients with tumors having high α1,6-FT expressi-
on had significantly shorter survival time than patients with tumors 
having low expression in potentially curatively resected NSCLCs 
(p = 0.03) and adenocarcinomas (p = 0.009), as well as in pStage 
I NSCLCs (p = 0.03) by the log-rank test. Surprisingly, in pStage 
I adenocarcinomas, none of 15 patients with tumors having low 
expression died of lung cancer, although 12 of 23 patients with 
tumors having high α1,6-FT expression died of lung cancer. High 
α1,6-FT expression was a significant and independent unfavorable 
prognostic factor in potentially curatively resected NSCLCs (hazard 
ratio, 1.81; p = 0.047) and in pStage I NSCLCs (hazard ratio 2.55; p 
= 0.03) by Cox’s proportional hazards model analysis.
Conclusion: These results suggest that α1,6-FT may play a pivotal 
role for the biological characteristics of NSCLCs. α1,6-FT expressi-
on is associated with histology of NSCLCs, and may be a new pro-
gnostic marker for overall NSCLCs and adenocarcinomas.
Keywords: GMD, PhoSL, NSCLC, α1,6-FT
S477Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
stasis and pTNM stage; highly expressed ADAM9 predicts worse 
prognosis, suggesting that ADAM9 is a useful novel prognostic 
biomarker. Importantly, ADAM9 could become a novel useful pre-
dictive biomarker helping decide if postoperative chemo-radiation 
therapy should be selected or not; adjuvant chemo-radiation 
therapy might benefit ADAM9+ NSCLC much more, instead of 
ADAM9- NSCLC. (This study was partly supported by grant from 
the Nature Science Foundation of Liaoning Province, China, 
No.20102285; and the Fund for Scientific Research of The First 
Hospital of China Medical University, No.FSFH1210).
Keywords: prognostic biomarker, ADAM9, Lung cancer invasion 
and metastasis, chemo-radiation predictive biomarkers
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P1.06-013 DETECTION OF CIRCULATING TUMOUR 
CELLS IN ADVANCED NON-SMALL CELL LUNG CANCER
Michael Fanning1, Margot Lehman2, Tao Mai2, Keith Horwood3, 
Michelle Murphy1, Elizabeth Mccafferey3, Lidija Jovanovic4, John 
Upham1
1Respiratory And Sleep Medicine, Princess Alexandra Hospital/Austra-
lia, 2Radiation Oncology, Princess Alexandra Hospital/Australia, 3Me-
dical Oncology, Princess Alexandra Hospital/Australia, 4Translational 
Research Institute/Australia
Background: The aim of the study was to determine whether cir-
culating tumour cells (CTCs) can be detected and whether they 
provide predictive or prognostic information in a cohort of patients 
with locally advanced and metastatic non-small cell lung cancer 
(NSCLC).
Methods: Participants with locally advanced or metastatic NSCLC 
had blood samples collected and analysed for circulating tumour 
cells with the CellSearch® platform at baseline, prior to their third 
cycle of chemotherapy and two weeks following treatment.
Results: Of thirty-four participants, circulating tumour cells were 
detected in 15 (44%). Ten out of 19 adenocarcinomas had detecta-
ble CTCs. Three of nine squamous cell carcinomas had detectable 
CTCs. Two of six NSCLC “not otherwise specified” had detectable 
CTCs. Of the 15 detected CTC cases, 10 were stage IV NSCLC. 
No significant associations have been seen to date with histology 
type, stage, performance status, age at diagnosis, gender, history 
of weight loss at presentation, time to progression or overall sur-
vival.
Conclusion: Circulating tumour cells can be detected in advanced 
non-small cell lung cancer. These results are intriguing and require 
further investigation - plans are underway to extend the study to 
a larger sample size to determine if there is any prognostic or pre-
dictive value to circulating tumour cell detection.
Keywords: NSCLC, CTC, biomarker
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P1.06-012 A DISINTEGRIN AND METALLOPROTEINASE-9 
IS HIGHLY EXPRESSED, CORRELATED WITH LYMPH NO-
DES METASTASIS, PREDICTS WORSE PROGNOSIS AND 
MAY HELP IMPROVING PERSONALIZED POSTOPERATI-
VE TREATMENT IN RESECTED NON-SMALL CELL LUNG 
CANCER
Jun Zhang1, Juan Qi2, Ning Chen3, Baosen Zhou1, Anguang He1
1China Medical University Lung Cancer Center, The First Hospital Of 
China Medical University/China, 2Department Of Molecular Targeted 
Therapeutics, The First Hospital Of China Medical University/China, 
3Department Of Logistic Management, College Of Economics And Ma-
nagement, Liaoning University Of Traditional Chinese Medicine/China
Background: Recently we found a disintegrin and metalloproteina-
se-9 (ADAM9) was highly expressed in resected stage I non-small 
cell lung cancer (NSCLC), correlated with shorterned survival time. 
Here, we investigate the abnormal expression of ADAM9 in surgi-
cally resected advanced NSCLC, to elucidate the relationship bet-
ween ADAM9 expression and lymph node metastasis, to further 
evaluate the significance of ADAM9 as a novel biomarker in pre-
dicting the prognosis, and predicting the necessity of personalized 
postoperative chemo-radiation for the resected NSCLC.
Methods: One hundred and twenty eight cases of completely 
resected stage I, II and III NSCLC with mediastinal N2 lymph no-
des dissected were immunohistochemically analyzed for ADAM9 
protein expression. Survival analysis were conducted to asses the 
significance of ADAM9 expression and the relationship with other 
clinicopathological characteristics.
Results: Of the 128 NSCLC, 64 were stage I, 19 stage II and 45 
stage III; 66.4% (85/128) was found with ADAM9 protein highly 
expressed (ADAM9+), significantly higher when compared with 
normal control lung tissues (P=0.000). The ADAM9+ rate in ade-
nocarcinoma was higher than in squamous cell carcinoma (75.5% 
vs 41.2%) (P=0.000). ADAM9+ rates in stage II and III NSCLC were 
84.2% and 77.8%, respectively, significantly higher than 53.1% in 
stage I (P=0.006). Stratified, ADAM9+ rates in N1 and N2 cases 
were 76.2% and 80.6%, respectively, significantly higher than 
56.3%, the ADAM9+ rate in N0 NSCLC (P=0.025). There was 
no difference found between ADAM9+ rates in T factor groups 
(P>0.05). The overall 5-year survival rate was 54.6% for this group 
of 128 completely resected NSCLC. The 5-year survival rate in 
ADAM9 low expression (ADAM9-) group (43 cases) was 68.8%, 
however, the 5-year survival rate was sharply decreased to 47.7% 
in ADAM9+ group (85 cases), the difference was statistically sig-
nificant (P=0.039). Linear correlation analysis discovered that the 
ADAM9 expression showed a significantly negative correlation with 
the survival time of the 128 cases of resected NSCLC (R=-0.217, 
P=0.014). Patients who received postoperative chemo-radiation 
therapy (41 cases) had a higher 5-year survival rate of 69.5% when 
compared with those who received surgery only but without adju-
vant chemo-radiation (87 cases) whose 5-year survival was 47.9% 
(P=0.017). When stratified, in the 85 ADAM9+ cases, the 5-year 
survival rate for those who received postoperative chemo-radiati-
on therapy was 63.7%, higher than 40.4% who did not receive ad-
juvant chemo-radiation (P=0.037); however, in the ADAM9- cases, 
postoperative chemo-radiation did not improve the 5-year survival 
rate with a statistic significance (P=0.198).
Conclusion: ADAM9 is highly expressed in human resected non-
small cell lung cancer tissues, correlated with lymph nodes meta-
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The multivariable model with Ki-67 index showed a c-index of 0.79 
which was identical to a multivariable model with pathological 
diagnosis (c-index 0.79). The nomogram showing the probability of 
5-year RFS estimates is shown in Figure 1.  
Variables
Adjusted by Ki-67 and 
Clinical Variables HR; 
95% CI (P) 
Adjusted by Patholo-
gical Diagnosis and 
Clinical Variables HR; 
95% CI (P) 
Ki-67 1.25; 1.11-1.41 (0.0016) --
AC vs. TC -- 2.01; 1.05-3.88 (0.0436)
Age 1.05; 1.03-1.08 (<0.0001)
1.06; 1.03-1.09 
(<0.0001)
Smoking 
Never 
Former 
Current 
(<0.0001) -- 3.11; 1.68-
5.74 4.34; 1.94-9.74
(0.0003) -- 2.86; 1.56-
5.24 3.74; 1.67-8.40
Size of 
Tumor
1.42; 1.20-1.67 (0.0002) 1.33; 1.13-1.56 (0.0012)
Metas-
tatic LN 
Negative 
Positive 
(0.0007) -- 3.05; 1.66-
5.59
(0.0068) -- 2.51; 1.33-
4.76
Conclusion: Ki-67 index is a valuable prognostic biomarker for 
pulmonary carcinoids based on this large cohort. The nomogram 
based on Ki-67 index, age, smoking history, LN involvement, and 
tumor size is a useful clinical tool for predicting the 5-year RFS rate. 
Updating this nomogram with additional clinical follow-up, as well 
as external validation of this nomogram is critical before routine 
clinical use.
Keyword: Pulmonary carcinoids, Ki-67, Neuroendocrine tumor of 
the lung, Prognostic factor of lung carcinoids
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P1.06-014 A NOMOGRAM FOR PREDICTING 5-YEAR RFS 
IN PATIENTS WITH PULMONARY CARCINOID TUMORS 
INCORPORATING KI-67 AND CLINICAL VARIABLES
Thanyanan Reungwetwattana1, Nathan Foster2, Lindsay Renfro2, 
Trynda Kroneman2, Marie Christine Aubry2, Joanne Yi2, Sarah 
Kerr2, Jesse Voss2, Benjamin Kipp2, Sumithra Mandrekar2, Julian 
Molina2
1Internal Medicine, Division Of Medical Oncology, Ramathibodi Hospi-
tal/Thailand, 2Mayo Clinic/United States Of America
Background: Evaluation of prognostic factors in carcinoid tumors 
of the lung is limited due to the rarity of disease. This study as-
sessed Ki-67 expression and other clinical variables as prognostic 
factors in cohort of 262 patients seen at Mayo Clinic, and subse-
quently developed a nomogram for predicting recurrence-free 
survival (RFS).
Methods: A systematic search of Mayo Clinic lung cancer epide-
miology and tumor registry databases from 1997 to 2009 iden-
tified 448 consecutive patients, with 262 having available tissue 
blocks [40 atypical carcinoids (AC) and 222 typical carcinoids (TC)]. 
Clinical data were collected by chart review. Tissue blocks were 
reviewed by 1 of 3 pathologists using WHO criteria. Tumors were 
tested for the Ki-67 index using digital image analysis (tumor tra-
cing) by two operators. The associations of the factors with RFS 
were explored using multivariable Cox proportional Hazards mo-
dels, including concordance (c) index. A nomogram was developed 
using the variables from the final multivariate model.
Results: Age, smoking history, lymph node (LN) involvement, tu-
mor size, and Ki-67 index were significant prognostic factors for 
RFS from a multivariate model (Table 1). Median follow-up on alive-
patients was 5.6 years (0.008-16.2). Median percentage of Ki-67 in-
dex of AC and TC were 1.61% and 0.56% (P<0.0001), respectively. 
S479Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
ded. Data regarding age, gender, histology, performance score, 
treatment, MBD and BM diagnosis, SRE and subsequent survival 
were collected.
Results: 222 patients were included: 73 EGFR+, 76 KRAS+ and 
73 WT (table 1). Respectively 56.2%, 51.3% and 50.7% had MBD 
(p=0.768) of which respectively 41.5%, 25.6% and 40.5% were 
diagnosed during follow up (p=0.262). Time to MBD was (mean, 
[SD]) respectively 13.4 [±10.6], 20.7 [±17.8], 16.8 [±9.6] months 
(p=0.360). Post MBD survival was (median, [95% confidence in-
terval (CI)]) 15.0 [11.0-19.0], 7.1 [1.3-12.8], 3.2 [0.0-8.3] months res-
pectively (p=0.008). Time to 1st SRE was not significantly different 
(p=0.164). Respectively 28.8%, 39.5% and 34.2% had BM (p=0.444) 
of which 76.2%, 60.0% and 48.0% were diagnosed during follow 
up (p=0.148). Mean time to BM was 20.3 [±11.7], 10.8 [±9.3], 14.3 
[±10.8] months respectively (EGFR+-KRAS+ p=0.013, EGFR+-WT 
p=0.176). Post BM survival was 11.0 [2.2-19.8], 6.9 [0-14.1], 12.5 
[5.6-19.5] months respectively (p=0.969). Results did not change 
significantly when patients with only best supportive care were 
excluded nor when in the EGFR+ group only exon 19/21 patients 
were included.  
Conclusion: Incidence of MBD or BM was not different between 
EGFR+, KRAS+ and WT patients. Time from diagnosis of mNSCLC 
to MBD, 1st SRE or post-BM survival did not differ. However, sur-
vival after MBD was significantly longer in EGFR+ patients. This 
stresses the impact of bone management in these patients and 
probably warrant more intense screening for MBD. In EGFR+ pa-
tients BM remain a serious event with short survival. This should 
stimulate investigators to search for BM specific treatments in or-
der to prolong survival post BM in EGFR+ patients.
Keywords: NSCLC, EGFR, KRAS, metastasis
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P1.06-015 EGFR MUTATED PATIENTS: DIFFERENT PAT-
TERN AND OUTCOME OF METASTATIC BONE DISEASE 
AND BRAIN METASTASES?
Lizza Hendriks1, Egbert Smit2, Bettine A.H. Vosse1, Wouter W. 
Mellema2, Daniëlle A M Heideman3, Gerben P. Bootsma4, Marcel 
Westenend5, Cordula Pitz6, Michiel J. De Vries7, Ruud Houben8, Erik 
Thunnissen3, Matyas Bendek9, Ernst-Jan M. Speel9, Anne-Marie 
Dingemans1
1Pulmonary Diseases, Maastricht University Medical Center+/
Netherlands, 2Pulmonary Diseases, VU University Medical Center/
Netherlands, 3Pathology, VU University Medical Center/Netherlands, 
4Pulmonary Diseases, Atrium Medical Centre/Netherlands, 5Pulmonary 
Diseases, Viecuri/Netherlands, 6Pulmonary Diseases, Laurentius Hos-
pital/Netherlands, 7Pulmonary Diseases, Orbis Medical Center/Nether-
lands, 8Radiation Oncology (Maastro), Grow-school For Oncology And 
Developmental Biology, Maastricht University Medical Center+/Nether-
lands, 9Pathology, Maastricht University Medical Center+/Netherlands
Background: Bone and brain are frequent and problematic sites 
of metastasis in metastatic non-small cell lung cancer (mNSCLC). 
Conflicting studies exist whether patients with EGFR mutations 
develop brain metastases (BM) more often or have a longer sur-
vival after diagnosis of mNSCLC than EGFR/KRAS wild type (WT) 
or KRAS+ patients. For metastatic bone disease (MBD) this is not 
known. In this retrospective matched control study we compared 
in EGFR+, KRAS+ and WT patients time from mNSCLC to develop-
ment of MBD/BM, skeletal related events (SREs) and subsequent 
survival.
Methods: In this retrospective case-control study all EGFR+ pa-
tients diagnosed at two molecular pathology departments were 
selected (VUMC 01-11-2004 to 01-01-2012, MUMC 01-10-2008 to 
01-08-2012). For every EGFR+ patient a consecutive KRAS+ and 
WT mNSCLC patient was selected. Patients with another malignan-
cy within 2 years of mNSCLC diagnosis or no follow up were exclu-
table: patient characteristics and results bone and brain metastasis
Characteristics EGFR+ N = 73 KRAS+ N = 76 Wildtype N = 73 p-value
Female N (%) 51 (72.6) 44 (57.9) 29 (39.7) 0.001
Mean age, years (range) 59.6 (29.3-90.7) 
60.6 (35.1-83.3) 
62.5 (39.6– 81.8) 0.228
Never smoker N (%) 29 (45.3) 2 (2.7) 10 (15.2) <0.001
WHO PS 0-2 N (%) 63 (98.4) 72 (97.3) 60 (92.3) 0.270
Adenoca N (%) 67 (91.8) 63 (84.0) 55 (76.4) 0.209
1st line no treatment 1st line 
chemo 1st line EGFR-TKI 
3 ( 4.1) 23 (31.5) 47 
(64.4)
10 (13.2) 64 (84.2) 
2 ( 2.6)
14 (19.2) 54 (74.0) 5 
( 6.8)
0.069 
<0.001 
<0.001
MBD N (%) Yes - at diagnosis 
- during follow up No 
41 (56.2) -24 (58.5) 
-17 (41.5) 32 (43.8)
39 (51.3) -29 (74.4) 
-10 (25.6) 37 (48.7)
37 (50.7) - 22 (59.5) - 
15 (40.5) 36 (49.3)
0.768 0.262 
SRE+ N (%) 22 (53.7) 23 (59.0) 21 (55.3) 0.887
BM N (%) Yes -at diagnosis 
-during follow up No 
21 (28.8) - 5 (23.8) 
-16 (76.2) 52 (72.2)
30 (39.5) -12 (40.0) 
-18 (60.0) 46 (60.5)
25 (34.2) - 13 (52.0) - 
12 (48.0) 48 (65.8)
0.444 0.148 
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N (%) 
Median age 
(range) 
62.46 (32-91) 
Gender Male 330 (70.1) 
Female 141 (29.9) 
Smoking status Never 121 (25.7) 
Current/Former 350 (74.3) 
Sample origen Lung 425 (90.2) 
Pleura 15 (3.2) 
Lymph node 15 (3.2) 
Other 16 (3.3) 
Type of sample Citology 66 (14) 
Biopsy 405 (86) 
Stage I 104 (22) 
II 40 (8.5) 
III 87 (18.5) 
IV 240 (51) 
Histology Adenocarcinoma 363 (77.1) 
Squamous cell carcinoma 44 (9.3) 
Large cell carcinoma 11 (2.3) 
Other 43 (11.3) 
Conclusion: ALK translocation is present in about 3% in Spanish 
NSCLC patients and is associated with adenocarcinoma histology 
and non-smoking status. The performance of ALK FISH in biopsy 
specimens is significantly better than in citologies.
Keywords: ALK, NSCLC, Translocation
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P1.06-017 TARGETED PROTEOMICS AND HT-IHC FOR 
LUNG CANCER BIOMARKER STUDIES.
Yeoun Jin Kim1, Guy Berchem2, Katriina Sertamo1, Julie Hinsinger3, 
Melanie Beland3, Louis Gaboury3, Fernand Ries2, Bruno Domon1
1Laboratory Of Clinical Proteomics, Crp-santé/Luxembourg, 2Hemato-
oncology, Centre Hospitalier De Luxembourg/Luxembourg, 3Pathologie, 
Institut De Recherche En Immunologie Et En Cancérologie/Canada
Background: Lung cancer is the leading cause of cancer-related 
death in Luxembourg with high metastatic potential and mortality 
rate. Despite tremendous efforts made in biomarker studies for 
this disease, none of the blood-based tests available in the clinic 
are able to detect the presence of lung cancer early enough or 
to predict outcome in patients subjected to targeted treatments. 
Analytical difficulties of plasma proteome due to the high comple-
xity and large dynamic range, and the lack of accessibility to the 
high-quality clinical samples are major obstacles, requiring a stra-
tegic and efficient experiment design to develop potent diagnostic 
and predictive/prognostic biomarkers.
Methods: In this study, liquid chromatography-mass spectro-
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P1.06-016 ANAPLASTIC LYMPHOMA KINASE (ALK)  
ALTERATIONS BY FISH IN A COHORT OF SPANISH  
NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS 
ANALYSED IN A CERTIFIED CENTRE OF REFERENCE
Joana Vidal1, Iria González1, Silvia De Muga2, Marta Salido2, Lara 
Pijuan2, Ana Isabel Luque1, Jordi Remon3, Noemí Reguart4, Nuria 
Viñolas4, Regina Gironés5, Laia Bernet5, Lourdes Calera6, Margarita 
Magem7, Inmaculada Maestu8, Lioba Ferrera9, Alfredo Paredes10, 
Luis Bernadó11, Alvaro Taus1, Joan Albanell1, Blanca Espinet2, Edur-
ne Arriola1
1Medical Oncology, Hospital Del Mar/Spain, 2Pathology, Hospital Del 
Mar/Spain, 3Medical Oncology, Hospital De Mataró/Spain, 4Medical 
Oncology, Hospital Clinic/Spain, 5Medical Oncology, Hospital Lluís Al-
canyís/Spain, 6Medical Oncology, Hospital Universitario Miguel Servet/
Spain, 7Medical Oncology, Hospital De La Santa Creu I Sant Pau/Spain, 
8Medical Oncology, Hospital Universitario Dr. Peset/Spain, 9Hospital 
Nuestra Señora Candelaria/Spain, 10Medical Oncology, Hospital Donos-
tia/Spain, 11Medical Oncology, Hospital Josep Trueta/Spain
Background: Patients with NSCLC harbouring an ALK transloca-
tion exquisitely respond to ALK inhibitors. It is therefore important 
to know ALK status for newly diagnosed NSCLC patients. Our insti-
tution has become centre of reference in Spain for ALK determina-
tion by FISH for other hospitals. The aim of this work was to report 
the clinical and pathological characteristics of the samples with 
ALK results evaluated in our institution.
Methods: We entered clinical-pathological characteristics of ex-
ternal and in-house samples into a database. ALK was evaluated 
by FISH with the FDA approved test (Abbot Molecular Inc, Des 
Plaines, IL). Whole sections were analysed evaluating a minimum of 
50 nuclei per case. The case was considered typically rearranged 
when separated green and orange/red signals (at least by three 
times the signal diameter) were identified and atypically rearran-
ged when a single orange signal was observed. Gain (including 
both low or high genomic gain) was defined as a mean copy num-
ber of 3 to 5 fusion signals in >=10% of cells and amplification as 
the presence of >=6 copies of ALK per cell in >=10% of analysed 
cells (Salido et al, JTO 2010). To analyse correlations between ALK 
status and clinical-pathologic variables, we used the Chi-square 
test or Fisher’s exact test with a significance at p<0.05.
Results: A total of 471 cases were included in the database. 
Patients’ clinical characteristics are summarized in Table 1. ALK 
translocation was found in 15 of 471 patients (3.2%). Within the 
ALK translocated cases 8 were female, 11 were adenocarcinomas, 
2 squamous cell histology, 1 large cell neuroendocrine carcinoma, 
and 1 not otherwise specified. There was a significant association 
between smoking status and ALK translocation (6.6% of translo-
cations among non-smokers and 2% among smokers, p=0.042). 
Fourteen patients (3%) showed ALK amplification, 366 (77.7%) 
gain in ALK copy number, 50 (10.6%) were disomic and 5 (1%) mo-
nosomic for ALK and 20 cases were not evaluable (4.2%). EGFR 
mutation was found in 23 of 252 patients (9.1%) and non of these 
was observed in cases with ALK translocation. We observed an as-
sociation between the type of sample and the ability to obtain an 
evaluable result for ALK with 97.5% assessable biopsies vs 84.4% 
citologies, (p<0.0001). 
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to progression were recorded. Histology was classified as solid or 
mixed with noninvasive features. Pre-operative plasma OPN was 
measured blinded and in duplicate by ELISA (R&D, Minneapolis, 
MN) and is reported in ng/ml. Cut points to predict recurrence 
were determined by X-tile (Yale University, CT) plots.
Results: There were 141 patients (50M/91F), 103 were stage IA. 
Median follow-up was 43.9 months and was complete in all to 3 
years. Thirty-nine patients (27.8%) recurred by 3 years. The medi-
an pre-operative OPN was 54.9 (range, 2.3 – 150.6). OPN levels 
correlated with tumor size (r=0.25, p=0.003), but not with age, 
pack years, t-stage, extent of resection, or invasive histologic 
component. Median OPN was higher in males than females (62.9 
vs. 50.5, p=0.009), and in current smokers compared to former/
never smokers (68.5 vs. 53.3, p=0.04). In Cox regression analysis, 
an increased risk for recurrence was associated with preoperative 
plasma OPN >49.6 (HR=3.8, CI:1.7-7.8, p=0.001), solid histology 
(HR=2.5, CI:1.3-4.9, p=0.008) and male gender (HR=2.5, CI:1.3-
4.6, p=0.005), but not with size, stage, age, pack years, and ex-
tent of resection. A model incorporating preoperative OPN and 
invasive histologic component stratified recurrence risk for both 
genders, but was highly significant in females (p=0.006) (Fig). 
Receiver operator curve (ROC) incorporating sex, OPN and inva-
sive histologic component had AUC=0.76 (CI: 0.6-0.8, p=0.03). 
Conclusion: Circulating OPN provides a view of the tumor micro-
environment and can serve as an important indicator of the course 
of the disease in resected NSCLC. When combined with sex and 
measures of histologic invasive component, plasma OPN >49.6 
form a highly predictive cumulative model to predict early recur-
rence in resected stage I adenocarcinomas and should be valida-
ted to assess its value in selecting patients for adjuvant and tumor 
prevention protocols.
Keywords: Recurrence, resected NSCLC, Adenocarcinoma, bio-
marker
metry (LC-MS) based targeted proteomics and high-throughput 
immunohistochemistry (HT-IHC) screening were applied to plasma 
and tissue samples derived from the matching patients in order 
to identify lung cancer biomarkers detectable in plasma. A total 
of 95 biomarker candidates potentially secreted or shed to blood 
were selected from the previously performed discovery studies. 
Two proteotypic peptides per target were selected as surrogate 
peptides and selected reaction monitoring (SRM) based LC-MS 
assays for 190 peptides were developed. The evaluated assays 
were multiplexed in two LC-MS methods and analyzed in depleted 
plasma samples of lung cancer patients. For HT-IHC, tissue micro 
arrays (TMAs) of matching patients were prepared from formalin 
fixed and paraffin embedded (FFPE) blocks acquired during the 
surgery of the patients whose plasma samples were used for pro-
teomic analyses. Both tumor and adjacent non tumor area of the 
FFPE blocks were included in the TMAs and screened against 50 
potential biomarkers.
Results: The complementary results of LC-MS based assays and 
HT-IHC were analyzed to find the correlation of the expression pro-
files of targets found in tumor tissues and plasma samples. Several 
targets in the IHC experiment exhibited significant scores in tumor 
compared adjacent normal. 17 plasma proteins were analyzed in 
the corresponding patients’ plasma samples to identify a panel of 
biomarkers. This panel of biomarkers were further used to monitor 
the responsiveness of tumors upon therapeutic and surgical inter-
ventions.
Conclusion: Targeted proteomics was successfully applied to lung 
cancer biomarker study in plasma samples. Expression profiles of 
cellular protein markers measured by HT-IHC were critical to group 
the patient samples to be analyzed. A panel of biomarkers is cur-
rently being tested as diagnostic, predictive, or prognostic markers 
in lung cancer, and preliminary results will be shown.
Keywords: NSCLC, Biomarkers, proteomics
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P1.06-018 CUMALATIVE BIOMARKER MODEL PREDICTS 
3-YEAR RECURRENCE IN RESECTED STAGE I ADE-
NOCARCINOMA OF THE LUNG
Jessica Donington, Nathalie Hirsch, Joseph Levine, Ryan Harring-
ton, Bernard Crawford, Micheal Zervos, Costas Bizekis, Harvey 
Pass
New York University School Of Medicine/United States Of America
Background: Stage I adenocarcinoma is the most curable form 
of non-small cell lung cancer (NSCLC), yet recurrence following 
complete resection is >30%. To improve this, it is important to 
identify indicators of tumor biology, which can predict a more ag-
gressive disease course so adjuvant therapies can be considered. 
Osteopontin (OPN) is a regulator of malignant function in NSCLC. 
In more advanced NSCLC patients, plasma OPN levels correlate 
with prognosis. We hypothesize that pre-operative plasma OPN 
in combination with clinical factors can predict recurrence fol-
lowing resection in stage I adenocarcinoma.
Methods: A cohort of completely resected stage I adenocarcino-
ma patients without adjuvant or neoadjuvant therapy was prospec-
tively collected and followed through 3 years. Pretreatment demo-
graphics, operative variables, pathologic characteristics, and time 
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P1.06-020 IDENTIFICATION OF PROGNOSTIC IMMUNO-
PHENOTYPIC FEATURES IN CANCER STROMAL CELLS 
OF HIGH-GRADE NEUROENDOCRINE CARCINOMAS  
OF THE LUNG
Akiko Takahashi
National Cancer Center Hospital East/Japan
Background: Purpose: The immunophenotypes of cancer-stromal 
cells have been recognized as prognostic factors of cancer. Previ-
ous reports have indicated the prognostic value of stromal cells in 
adenocarcinoma or non-small cell lung cancer. However, the pro-
gnostic value of stromal cells in completely resected high-grade 
neuroendocrine carcinomas of the lung (HGNEC; both small cell 
carcinoma and large cell neuroendocrine carcinoma) has not been 
reported. The purpose of this study was to analyze the prognostic 
markers of HGNEC by examining the immunophenotypes of can-
cer-stromal cells, including tumor-associated macrophages (TAMs), 
regulatory T cells (Tregs), and cancer-associated fibroblasts (CAFs).
Methods: Materials and Methods: One hundred and fifteen pati-
ents who underwent a complete resection of HGNEC were inclu-
ded in this study. There were 98 men (85%), and their median age 
at the time of surgery was 68 years (range, 22-86 years); 71 patients 
had p-stage I diseases. The histologic type was SCLC in 52 pati-
ents and LCNEC in 63. We examined the presence of CD204-posi-
tive TAMs, Foxp3-positive Tregs, and podoplanin-positive CAFs to 
evaluate the prognostic values of these markers.
Results: The number of CD204-positive TAMs and Foxp3-positive 
Tregs did not influence the overall survival (OS) or the relapse-free 
survival (RFS) of the patients. However, patients with podoplanin-
positive CAFs had a significantly better prognosis than those with 
podoplanin-negative CAFs (OS: p=0.002, RFS: p=0.002, 5-year 
overall survival (5 YR): 74% vs. 45%). According to subgroup ana-
lyses, patients with podoplanin-positive CAFs displayed a better 
prognosis for both small cell carcinoma (OS: p=0.046, 5 YR: 74% 
vs. 46%) and large cell neuroendocrine carcinoma (OS: p=0.020, 5 
YR: 74% vs. 45%). A univariate analysis identified 4 significant risk 
factors for OS: sex (female), pN(+), lymphatic permeation (+), and 
podoplanin-negative CAFs. In a multivariate analysis using the Cox 
regression model, sex, the presence of lymphatic permeation (ly), 
and podoplanin-negative CAFs were shown to be statistically sig-
nificant independent predictors for recurrence.
Conclusion: The current study reported that podoplanin-positive 
CAFs had prognostic value in both SCLC and LCNEC. Our results 
imply that podoplanin expression reflects a tumor-inhibitory phe-
notype of CAFs in HGNEC. Although the exact mechanisms res-
ponsible for this phenomenon are not fully understood, our results 
provide novel insights into the pathogenesis of a unique microen-
vironment of HGNEC as well as basic data for new treatment stra-
tegies for HGNEC.
Keywords: small cell carcinoma, large cell neuroendocrine carci-
noma, cancer-associated fibroblasts
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P1.06-019 COMMON AND UNCOMMON EGFR MUTA-
TIONS AND THEIR IMPACT ON RESPONSE TO EGFR 
TYROSINE-KINASE INHIBITORS AND PLATINUM-BASED 
CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER 
(NSCLC): LATIN-AMERICAN CONSORTIUM FOR THE IN-
VESTIGATION OF LUNG CANCER (CLICAP)
Oscar Arrieta1, Andrés Cardona2, Alma D. Campos Parra1, Luis 
Corrales-Rodriguez3, Roberto Sánchez-Reyes1, July Katherine Rod-
riguez4, Hernán Carranza2, Carlos Vargas4, Carlos Zúñiga-Orlich3, 
Melissa Juárez-Villegas3, Rafael Rosell5
1Thoracic Oncology Clinic And Laboratory Of Experimental Oncology, 
Instituto Nacional De Cancerología (INCAN)/Mexico, 2Clinical And 
Translational Oncology Group Institute Of Oncology, Fundación Santa 
Fé/Colombia, 3Medical Oncology, Hospital San Juan De Dios-ccss/Costa 
Rica, 4Fundation For Clinical And Applied Cancer Research – Ficmac/
Colombia, 5Medical Oncology, Catalan Institute Of Oncology/Spain
Background: An association has been well-established between 
common EGFR mutations and response to reversible and irrever-
sible direct EGFR tyrosine-kinase inhibitors (EGFR-TKIs); however, 
there is a significant lack of information about the impact of un-
common mutations on outcomes such as overall response (OR), 
progression-free survival (PFS) and overall survival (OS) rates after 
being exposed to EGFR-TKIs or platinum-based chemotherapy 
(CT).
Methods: Information regarding 186 NSCLC patients from three 
Latin-American countries was analysed. Tests were made for EGFR 
and KRAS mutations; the clinical and pathological characteristics 
and the presence of common and uncommon EGFR mutations 
were considered according to OR, PFS and OS rates concerning 
EGFR-TKIs and CT.
Results: 79.5% of the patients had common EGFR mutations and 
20.5% uncommon mutations, including complex alterations. Lepi-
dic and acinar histological subtypes were associated with higher 
common EGFR mutation frequency (p= 0.010). Patients having 
an OR to EGFR-TKIs treatment also had an OR to CT (p< 0.001). 
Patients harbouring common EGFR mutations had greater sensiti-
vity to EGFR-TKIs than those having uncommon mutations (63.8% 
[IC 95% 51.1-76.5] vs 32.4% [20.0-44.7] p< 0.0001). Median PFS 
regarding EGFR-TKIs (16.4 [12-21.1] vs 4.1 months [1.9-5.9]) and CT 
(16 [10.9-21] vs 4.3 months [0.9-12.9]) was better in patients having 
common EGFR mutations compared to patients carrying uncom-
mon mutations. The median OS of patients treated with EGFR-TKIs 
that harbored common EGFR mutations (37.3 months [33.2-41]) 
was longer compared to those patients who harbored uncommon 
mutations (17.4 months [12.9-21.8]).
Conclusion: Our findings suggest that patients with EGFR uncom-
mon mutations, could receive platinum-based chemotherapy as 
first line of treatment and EGFR-TKIs can be reserved as second or 
third line treatment options.
Keyword: EGFR mutations, EGFR-TKIs, NSCLC, Chemotheraphy
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lung cancer diagnosis in symptomatic patients. A panel of biomar-
kers RASSF1A, 3OST2 and PRDM14 showed high sensitivity, but 
relatively low specificity.
Keywords: sputum, diagnosis, Biomarkers, DNA hypermethylation
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P1.06-022 INVESTIGATING THE UTILITY OF PLASMA DE-
RIVED CIRCULATING FREE DNA FOR THE DETECTION 
OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) 
MUTATIONS IN EUROPEAN AND JAPANESE PATIENTS 
WITH ADVANCED NON-SMALL-CELL LUNG CANCER 
(NSCLC): ASSESS STUDY DESIGN
Martin Reck1, Koichi Hagiwara2, Sergei Tjulandin3, Baohui Han4, 
Gael Mcwalter5, Rose Mccormack5, Nicola Normanno6
1Onkologischer Schwerpunkt, Krankenhaus Großhansdorf, Zentrum Für 
Pneumologie Und Thoraxchirurgie/Germany, 2Department Of Respira-
tory Internal Medicine, Saitama Medical University/Japan, 3Department 
Of Clinical Pharmacology And Chemotherapy, Russian Cancer Research 
Center/Russian Federation, 4Department Of Respiratory Medicine, 
Shanghai Chest Hospital , Shanghai Jiao Tong University/China, 5Perso-
nalized Healthcare And Biomarkers, Astrazeneca/United Kingdom, 6Cell 
Biology And Biotherapy Unit, Int-fondazione Pascale/Italy
Background: In patients with NSCLC, accurate and accessible 
EGFR mutation testing is important for guiding treatment decisi-
ons. Current procedures involve the testing of biopsy or cytology 
samples, which are not always available from all patients. However, 
plasma of patients with advanced NSCLC contains circulating-free 
tumor-derived DNA (cfDNA) that is suitable for mutational analy-
sis. The large, multi-center, non-interventional, non-comparative 
ASSESS diagnostic study (NCT01785888) will evaluate the utility 
of plasma-based testing compared with tissue or cytology-based 
testing as a less invasive methodology by which to assess EGFR 
mutation status in patients with NSCLC.
Methods: A total of 1300 patients (age ≥18 years in Europe; ≥20 
years in Japan) with newly diagnosed locally advanced/metastatic 
(Stage IIIA/B/IV) chemotherapy-naïve NSCLC who are not eligible 
for curative treatment, or patients with recurrent disease after sur-
gical resection with/without adjuvant chemotherapy, will be scree-
ned for EGFR mutation status in tumor and plasma across Japan 
and 7 European countries over 18 months. To allow determination 
of sensitivity between tumor and plasma-based EGFR screening 
(95% confidence interval [CI] 40-60%, assuming 50% sensitivity), 
100 patients each with mutation-positive NSCLC in Europe (EGFR 
mutation frequency: ~10%) and Japan (EGFR mutation frequency: 
~30%) will be required; 1000 and 300 patients will therefore be 
enrolled from Europe and Japan, respectively. Provision of tumor 
(biopsy/cytology/other tumor cell sample) and plasma samples for 
EGFR mutation testing will be mandatory. Precise clinical phenoty-
ping will be performed, and clinical information about first line (all 
patients) and second line (patients with mutation-positive NSCLC) 
therapy decisions will be recorded. EGFR testing will be performed 
according to local practices, with Exon 19 deletions and L858R 
point mutations assessed as a minimum. The primary objective is 
determination of concordance between EGFR mutation status ob-
tained via tissue/cytology and plasma-based testing (concordance 
rate, sensitivity, specificity, positive and negative predictive values, 
and exact 2-sided 95% CIs). Secondary objectives: determination 
of EGFR mutation frequency (including mutation subtypes) in pati-
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P1.06-021 VALIDATION OF DNA HYPERMETHYLATION 
ANALYSIS IN SPUTUM FOR THE DIAGNOSIS OF LUNG 
CANCER
A Jasmijn Hubers1, Daniëlle A M Heideman1, Sjaak Burgers2, Gerar-
da J. Herder3, Peter Sterk4, Robert J. Rhodius4, Henk J. Smit5, Frans 
Krouwels6, Alle Welling7, Emile F. Comans8, Birgit I. Witte9, Sylvia 
Duin1, Renske D. Steenbergen1, Pieter E Postmus10, Gerrit A Meijer1, 
Peter J F Snijders1, Egbert F Smit10, Erik Thunnissen1
1Pathology, VU University Medical Center/Netherlands, 2Thoracic Onco-
logy, NKI - Antoni Van Leeuwenhoek Hospital/Netherlands, 3Pulmona-
ry Diseases, Sint Antonius Hospital/Netherlands, 4Pulmonary Diseases, 
Academic Medical Center/Netherlands, 5Sint Lucas Andreas Hospital/
Netherlands, 6Spaarne Hospital/Netherlands, 7Medisch Centrum Alk-
maar/Netherlands, 8Nuclear Medicine, VU University Medical Center/
Netherlands, 9Epidemiology And Biostatistics, VU University Medical 
Center/Netherlands, 10Pulmonary Diseases, VU University Medical 
Center/Netherlands
Background: Lung cancer has the highest mortality of all cancers 
worldwide with a 5 year survival rate of <15%. The prognosis 
improves dramatically when the disease is detected at an early 
stage, and when curative treatment is possible. Current (low dose 
CT) screening and diagnostic procedures are suboptimal with low 
specificity. Thus, novel detection methods for lung cancer as stand 
alone or in combination with other methods are needed. DNA hy-
permethylation of biomarkers in sputum have shown to distinguish 
lung cancer cases from cancer-free controls. The aim of the pre-
sent study was to validate the usage of DNA hypermethylation of 
biomarkers in sputum samples of lung cancer patients and controls 
for lung cancer diagnosis, in comparison with sputum cytology.
Methods: We prospectively collected sputum of lung cancer 
patients and controls during 3-9 days in the Amsterdam and Nieu-
wegein area, The Netherlands. From this sputum bank, a learning 
set (n=80 lung cancer patients, n=91 controls) and validation set 
(n=173 lung cancer patients, n=164 controls) were randomly com-
posed. DNA promoter hypermethylation of the following biomar-
kers was assessed by means of quantitative methylation specific 
PCR: RASSF1A, APC, cytoglobin, 3OST2, PRDM14, FAM19A4 and 
PHACTR3. Cut-off values for positive hypermethylation were calcu-
lated using Youden’s index. Sputum cytology analysis was perfor-
med for all sputum samples. McNemar’s test was used to compare 
the difference between sensitivity of hypermethylation and sputum 
cytology for lung cancer diagnosis. A two-sided p-value <0.05 was 
considered significant.
Results: RASSF1A was best able to distinguish cases from controls, 
with sensitivity of 37-41% and specificity of 91-97% in both learning 
and validation sets. In multivariate analysis, a panel of RASSF1A, 
3OST2 and PRDM14 showed highest sensitivity of 82% [95% confi-
dence interval (CI): 76 – 88%] with a specificity of 68% [95% CI: 61 
– 74%] in the learning set, with consistent results in the validation 
set. Molecular analysis was superior (P<0.001) over sputum cyto-
logy (sensitivity of 15%). The sensitivity of the biomarker panel did 
not improve when it was combined with sputum cytology. There 
was no association observed between DNA hypermethylation and 
clinical parameters such as age, smoking status, tumor stage, and 
histology.
Conclusion: This study validates hypermethylation analysis in spu-
tum for the diagnosis of lung cancer. RASSF1A hypermethylation 
showed high specificity and thereby can have an important role in 
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daily routine practice.
Methods: Material and methods: To test the reliability of ALK-
IHC-diagnosis in a multi-centre environment (17 European insti-
tutes from Belgium, Denmark, France, Germany, Scotland, Spain, 
Sweden and Switzerland) two tissue microarrays (TMA) consisting 
of 15 NSCLC cases (all adenocarcinomas; 3 cores for each case) 
were independently tested for ALK-expression by each laboratory 
using Ventana Medical System’s ALK (D5F3) primary antibody com-
bined with OptiView DAB IHC detection and OptiView Amplifica-
tion kits. Cases included in the study were unequivocal ALK-break 
positive or negative (by FISH), as well as so called “ALK-borderline” 
cases (low percentage of ALK-break positive cells by FISH, around 
the cut-off of 15%, therefore challenging in diagnosis, but PCR-
confirmed as harbouring EML-4-ALK-fusion variants and thus 
eligible for therapy). Prior to the TMA-based case testing, each 
participating instrument was qualified using the VENTANA ALK 2 
in 1 Control Slides. To provide a uniform baseline interpretation, 
a webinar-based training was given to all observers. This training 
included an overview of the ALK Interpretation Guide, a guided 
review of 50 patient cases using digital whole slide images, and a 
proficiency exam certifying each observer.
Results: Detailed data analysis was only partly accomplished at 
the time of abstract submission and will be presented in detail at 
the “World Conference on LUNG Cancer” in Sydney. Besides the 
binary evaluation of the cases (ALK-negative vs. ALK-positive) ob-
servers were asked to estimate the staining intensity (0-3) within 
positive cases in correlation to the number of tumor cells and to 
generate the H-score.
Conclusion: Referring to the EMA-approval text our multi-centre 
study may contribute to validation and accuracy of IHC-based 
ALK-testing. Such a validated and reliable IHC-assay could be 
used: (a) as a good pre-screening method reducing time consu-
ming and costly FISH analysis (shorten turn-around time for test 
results) and (b) as a final predictive approach in cases with reduced 
interpretability of FISH results (e.g. minimal tumor cell content 
in small biopsies, decalcified or artificial altered tissue, FISH in 
doubt/”borderline”).
Keywords: Anaplastic Lymphoma Kinase (ALK)-detection, non-
small cell lung cancer, European IHC-based (D5F3-Optiview) panel 
test
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P1.06-024 FAM83B, A NOVEL MOLECULAR TARGET FOR 
LUNG SQUAMOUS CELL CARCINOMA.
Naoyuki Okabe1, Hiroyuki Suzuki1, Mitsunori Higuchi1, Jun Osu-
gi1, Takeo Hasegawa1, Hiroshi Yaginuma1, Satoshi Muto1, Takumi 
Yamaura1, Yuzuru Watanabe1, Yuki Owada1, Shinya Watanabe2, 
Satoshi Waguri2, Jyunji Ezaki2
1Department Of Thoracic Surgery, Fukushima Medical University/
Japan, 2Translational Research Center, Fukushima Medical University/
Japan
Background: Recently, personalize therapy for non-small cell lung 
cancer (NSCLC) has been improving and significantly to extract 
various molecular target. However, development of molecular tar-
geted drugs is proceeding only in lung adenocarcinoma to date, 
while there are few drugs for lung squamous cell carcinoma (SCC). 
ents with adenocarcinoma/non-adenocarcinoma NSCLC; descrip-
tion of first-line (all patients) and second-line (all available patients) 
therapy following mutation testing; characterization of current 
EGFR testing practices; correlation between EGFR mutation status 
identified in tumor/plasma samples and demographic/disease sta-
tus data. Pre-planned exploratory objective: investigation of explo-
ratory biomarkers which may help to define molecular features of 
NSCLC (prevalence, co-occurrence, correlation with demographic 
data) using optional, additional tumor (biopsy/cytology/other) sam-
ples. The secondary analyses from the study will help define the 
current status of EGFR mutation testing procedures across Japan 
and Europe, and provide further information regarding mutation 
frequency across patient subgroups, and the relationship between 
EGFR mutation status and therapy decisions.
Results: Not applicable.
Conclusion: Not applicable.
Keyword: EGFR mutation testing; cfDNA; NSCLC
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P1.06-023 ANAPLASTIC LYMPHOMA KINASE (ALK)-DE-
TECTION IN NON-SMALL CELL LUNG CANCER: RESULTS 
OF THE FIRST EUROPEAN IHC-BASED (D5F3-OPTIVIEW) 
PANEL TEST WITHIN 16 INSTITUTES
Maximilian Von Laffert1, Arne Warth2, Roland Penzel2, Peter 
Schirmacher2, Keith M. Kerr3, Göran Elmberger4, Hans-Ulrich 
Schildhaus5, Reinhard Büttner5, Fernando Lopez-Rios6, Simone 
Reu7, Thomas Kirchner7, Patrick Pauwels8, Katja Specht9, Enken 
Drecoll9, Heinz Höfler9, Daniela Aust10, Gustavo Baretton10, Lukas 
Bubendorf11, Annette Fisseler-Eckhoff12, Alex Soltermann13, Verena 
Tischler13, Holger Moch13, Sonja Stallmann12, Frederique Penault-
Llorca14, Hendrik Hager15, Frank Schäper16, Dido Lenze1, Michael 
Hummel1, Manfred Dietel1
1Institute Of Pathology, Charité Berlin/Germany, 2Institute Of Patho-
logy, University Of Heidelberg/Germany, 3Department Of Pathology, 
Aberdeen University Medical School/United Kingdom, 4Dept Of Pa-
thology & Cytology, Karolinska University Hospital, Solna/Sweden, 
5Department Of Pathology, University Hospital Cologne, Germany/
Germany, 6Laboratorio De Dianas Terapeuticas, Hospital Universita-
rio Sanchinarro/Spain, 7Institute Of Pathology, Klinikum Großhadern 
Ludwig-maximilians-universität/Germany, 8Institute Of Pathology, Uz 
Antwerpen/Belgium, 9Institute Of Pathology, Klinikum Rechts Der Isar, 
Tu/Germany, 10Institute Of Pathology, University Hospital Carl Gustav 
Carus/Germany, 11Institute Of Pathology,  universitätsspital Basel/Ger-
many, 12Institute Of Pathology, Hsk Dr.-horst-schmidt-kliniken GmbH I/
Germany, 13Institute Of Pathology, Universitäts Spital Zürich/Switzer-
land, 14Institute Of Pathology, Centre Jean Perrin/France, 15Patologisk 
Institut, Århus Universitetshospital/Denmark, 16Pathology-berlin, Biopt. 
Institut Gem.praxis F. Pathologie/Germany
Background: The study was supported by Ventana Medical Sys-
tems, Inc., a Member of the Roche Group Background: The reli-
able identification of NSCLC patients with anaplastic lymphoma 
kinase (ALK) gene rearrangement is crucial for the prescription 
of ALK tyrosine kinase inhibitors (e.g. crizotinib). Whereas the US 
FDA-approval (2011) is based upon FISH-testing, the European 
EMA-approval (2012) refers to the definition of “ALK-positive” 
NSCLCs without mandating a particular test. Therefore a reliable 
ALK-immunohistochemistry (IHC) could be a promising option in 
S485Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 1 - PROGNOSTIC AND PREDICTIVE BIOMARKERS  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.06-025 DETERMINATION OF THE ACTIVITY OF LYSO-
SOMAL ENZYMES AND PROTEASE INHIBITORS IS USE-
FUL IN THE DIAGNOSTICS OF LUNG CANCER.
Przemysław Bławat1, Gerard Drewa2, Tomasz Szczęsny1, Maciej 
Dancewicz1, Mariusz Bella1, Pawel Wnuk1, Mariusz Kowalewski3, 
Janusz Kowalewski1
1Department Of Thoracic Surgery And Tumours, Franciszek Lukaszczyk 
Oncology Centre, Bydgoszcz, Poland/Poland, 2Department Of Medical 
Biology, Collegium Medicum In Bydgoszcz, Nicolaus Copernicus Uni-
versity In Toruń, Poland/Poland, 3Department Of Thoracic Surgery And 
Tumours, Collegium Medicum, In Bydgoszcz, Nicolaus Copernicus Uni-
versity In Toruń, Poland/Poland
Background: Lysosomal proteolytic enzymes play an important 
role in carcinogenesis and metastasizing processes. Activation of 
lysosomes may result in an increased exfoliation of cancer cells, 
which in vivo may promote metastatic progression. It was also ob-
served that increased activity of lysosomal enzymes is connected 
with an increased permeability of cellular membranes and vascular 
endothelium, in turn associated with promoting metastasizing, also 
in lung cancer.
Methods: We evaluated the activity of selected lysosomal enzy-
mes and one of protease inhibitors in serum, lung parenchyma and 
lung tumour, in 41 patients operated on with radical intent due to 
non-small cell lung cancer (NSCLC). Control group consisted of 44 
healthy individuals. Cathepsin D, acid phosphatase, arylsulfatase 
and alpha-1-antitrypsin serum concentration was measured in pa-
tients before surgery, and on day 7, and 30 after operation. The 
concentration of these enzymes was also measured in the tumor 
and in healthy lung parenchyma. Obtained results were compared 
with control group, where concentration of enzymes was measured 
only in serum.
Results: In NSCLC patients an elevated serum concentration of ca-
thepsin D (p<0.001), acid phosphatase (p<0.001) and arylsulfatase 
(p<0.001) was observed, compared with the control group. Serum 
concentration of acid phosphatase (p=0.033) and arylsulfatase 
(p=0.004) was elevated in patients with metastases to regional 
lymph nodes. Concentration of acid phosphatase (p<0.001), aryl-
sulfatase (p<0.001) and alpha-1-antitrypsin (p<0.001) was higher in 
pulmonary tumor than in the healthy lung parenchyma. Concent-
ration of acid phosphatase (p=0.002) and arylsulfatase (p<0.001) 
in pulmonary tumor was also elevated in patients with metastases 
to regional lymph nodes. In lung cancer patients, postoperative 
concentration of acid phosphatase and arylsulfatase decreased 
significantly, as comperative values. 
Therefore, we tried to extract molecular targets for SCC by com-
prehensive gene expression analysis of clinical specimen.
Methods: The subjects of this study consisted of 215 patients with 
NSCLC who underwent complete resection since 2005 to 2011 in 
our hospital. They included 102 adenocarcinomas and 113 SCC. 
First, we tried to extract molecules specific to SCC by tissue array 
analysis of clinical specimen. We selected FAM83B as a candidate 
marker for SCC by using comprehensive gene expression analysis. 
Then, we examined the protein expression of FAM83B in NSCLC 
tissues by immunoblot and immunohistochemical analysis (IHC). 
The relationship between the FAM83B expression and clinic-pa-
thological factors was statistically analyzed.
Results: FAM83B expression at mRNA level was significantly hig-
her in SCC than in normal lung or adenocarcinoma (P<0.0001). 
Immunoblot analysis also confirmed this tendency. In IHC, FAM83B 
was diffusely localized in the cytoplasm and/or plasma membrane. 
When more than 10% positive area for FAM83B were judged as 
“positive”, 94.3% (107/113) of SCC and 14.7% (15/102), of adenocar-
cinoma were positive. If the patients were divided into two sub-
groups by IHC (54 high-expression patients and 53 low-expression 
patients), high-expression group was associated with a better 
disease free survival rate (P=0.042, log-rank test). 
Conclusion: Our results indicated that FAM83B could be a reliable 
diagnostic and prognostic biomarker for SCC. Biological function 
of FAM83B in lung cancer is not well known. Further analyses 
should be required to identify its clinical significance and biologi-
cal function.
Keywords: FAM83B, SCC, lung squamous cell carcinoma
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P1.06-026 VALIDATION OF A PROLIFERATION-BASED 
EXPRESSION SIGNATURE AS PROGNOSTIC MARKER IN 
EARLY STAGE LUNG ADENOCARCINOMA
Raphael Bueno1, Yifan Zheng1, Michael Archer1, Corinne Gustaf-
son1, Joshua T. Jones2, Susanne Wagner3, Elisha Hughes3, Kristen 
Rushton2, Anne-Renee Hartman2
1Brigham And Women‘s Hospital/United States Of America, 2Myriad 
Genetic Laboratories, Inc./United States Of America, 3Myriad Genetics, 
Inc./United States Of America
Background: Use of adjuvant chemotherapy in non-small cell lung 
carcinoma (NSCLC) is based upon pathological stage and is not 
generally recommended for patients with Stage I disease despite 
a five-year overall mortality of 30% in Stage IA and 50% in Stage 
IB. Molecular biomarkers have the potential to guide treatment 
by identifying patients at highest risk for recurrent cancer. An 
evaluation of prognostic breast RNA profiles revealed a common 
component of cell cycle regulated mRNAs which contains the ma-
jor prognostic power of each expression profile. The expression 
levels of cell cycle progression (CCP) genes measure tumor growth 
irrespective of the underlying genetic aberrations. CCP has been 
shown to be a highly significant predictor of cancer specific mor-
tality at five years in three individual datasets. From these data a 
prognostic model was generated incorporating the CCP expressi-
on signature with pathological stage. The study herein will assess 
the validity of this combined clinical and gene expression score 
to predict five-year risk of lung cancer death in patients with early 
stage lung adenocarcinoma. A high combined prognostic score 
will identify patients with an increased risk for relapse whom may 
benefit significantly from adjuvant chemotherapy.
Methods: A cohort of patients with NSCLC adenocarcinoma was 
assembled with the following clinical covariates: age at diagnosis, 
gender, smoking status, tumor size and grade, pleural invasion, 
TNM Stage, adjuvant treatment status, and EGFR mutation status 
(if known). Outcome variables include cause of death and time to 
recurrence and death. An event is defined as death due to lung 
cancer within five years of surgery. If cause of death is unknown, 
death following recurrence will be used as a surrogate. A cohort 
with 150 events will have 99% statistical power at the 5% signifi-
cance level to demonstrate an association between CCP and death 
from lung cancer outcome. A CCP score will be calculated from 
the mRNA expression levels of 31 proliferation genes in this cohort 
and combined with stage in a final prognostic score.
Results: To date, 631 Stage I and Stage II adenocarcinomas have 
been assembled. Two hundred and fifty-five deaths have occurred 
in the cohort with more than 100 deaths caused by lung cancer. 
Also, there have been over 150 instances of lung cancer recurrence 
documented. Two hundred and thirty-four samples have been 
processed with CCP scores ranging from -3.20 to 2.20. The distri-
bution of CCP scores is consistent with those observed in previous 
cohorts of early stage lung adenocarcinoma. Complete analysis 
will be presented.
Conclusion: This validation cohort will provide adequate events to 
significantly demonstrate whether the prospectively defined pro-
gnostic score can define a high–risk group of early stage NSCLC 
patients with a high risk of death from lung cancer. This informati-
on may help guide adjuvant treatment decisions.
Keywords: prognostic marker, NSCLC
Figure 1. Chosen biomarkers activity comparison. (A) Comparison 
of cathepsin D (Cat D) activity in NSCLC patients with (N1+N2) and 
without (N0) lymph node metastases at baseline, POD 7 and POD 
30. (B) Comparison of arylsulfatase (AS) activity in NSCLC patients 
with (N1+N2) and without (N0) lymph node metastases at baseline, 
POD 7 and POD 30. P values for each comparisons were obtained 
with Mann-Whitney U tests; POD, post-operative day.
Conclusion: Serum concentration of cathepsin D, acid phosphata-
se, arylsulfatase and alpha-1-antitrypsin is useful in the diagnostics 
of NSCLC. Moreover, serum acid phosphatase and arylsulphatase 
concentrations are useful in postoperative monitoring of these 
patients.
Keyword: Non-small cell lung cancer, lung cancer diagnostics, 
lysosomal enzymes, protease inhibitors
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P1.06-028 DROPLET DIGITAL PCR: A NOVEL DETEC-
TION METHOD OF ACTIVATING EPIDERMAL GROWTH 
FACTOR RECEPTOR (EGFR) MUTATIONS IN PLASMA OF 
PATIENTS WITH ADVANCED STAGE NON-SMALL CELL 
LUNG CANCER (NSCLC)
Carmen K.M. Lee1, Allen K.C. Chan1, K Park2, Linda Leung3, K C 
Lam3, S W Yeung4, Dennis Y.M. Lo4, Tony S.K. Mok3
1Chemical Pathology, The Chinese University Of Hong Kong, Li Ka 
Shing Institute Of Health Sciences, State Key Laboratory Of Oncology 
In South China, Sir Y.k. Pao Centre For Cancer/Hong Kong, 2Division Of 
Hematology/Oncology, Innovative Cancer Medicine Institute, Samsung 
Medical Center, Sungkyunkwan University School Of Medicine/Korea, 
3Department Of Clinical Oncology, The Chinese University Of Hong 
Kong, Prince Of Wales Hospital/Hong Kong, 4Chemical Pathology, The 
Chinese University Of Hong Kong, Li Ka Shing Institute Of Health Sci-
ences, State Key Laboratory In Oncology In South China, Sir Y.k. Pao 
Centre For Cancer/Hong Kong
Background: In-frame deletion at exon 19 and point mutation at 
exon 21 are the two most common activating mutations in EGFR 
tyrosine kinase accounting for >85% of all clinical relevant EGFR 
mutations. In this study, we aim to develop a highly sensitive 
method to detect and quantify these two mutations in plasma of 
patients with advanced non-small cell lung cancer (NSCLC) using 
droplet digital PCR (ddPCR).
Methods: We analyzed 208 plasma samples from patients with 
advanced NSCLC from the ASPIRATION study using the QX100 
ddPCR system (BioRad). ASPIRATION study is a single arm study 
on the use of first line erlotinib in patients with EGFR mutation 
(confirmed from tissue samples) and test the concept of treatment 
beyond RECIST progression. 36 archived plasma samples with 
known EGFR wild type were used as control. ddPCR simultaneous-
ly performs PCR reactions in 20,000 DNA containing droplets, and 
for each plasma sample we measured the absolute quantities of 
circulating EGFR mutant and wild-type sequences partitioning in 
discrete droplets.
Results: Specific ddPCR assays were developed for detecting 
EGFR exon 19 deletion and L858R mutation independently. 126 
(61%) of 208 plasma samples were positive for EGFR mutation (63 
cases for Exon 19 deletion, 63 cases for L858R). Table 1 summari-
zes the concordance of the tissue and plasma analysis. Sensitivity 
is 61%, specificity is 94% and positive predictive value is 98%. The 
mean absolute concentration for detectable exon 19 deletion and 
L858R in plasma is 1,060 and 1,510 copies/ml plasma respectively. 
Mean fractional concentration is 11%. Further correlation between 
plasma EGFR mutation results and clinical data will be performed.  
Table 1
EGFR mutation
Tumor tissue 
+ive
Tumor tissue 
-ive
Plasma ddPCR 
+ive
126 2 128
Plasma ddPCR 
-ive
82 34 116
208 36 244
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P1.06-027 POLYMORPHISMS IN DNA REPAIR AND APO-
PTOSIS-RELATED GENES AND CLINICAL OUTCOMES 
OF PATIENTS WITH NON-SMALL CELL LUNG CANCER 
TREATED WITH FIRST-LINE PACLITAXEL-CISPLATIN CHE-
MOTHERAPY
Shin Yup Lee1, Mi Young Kim2, Ji Yun Jeong3, Hyo-Gyoung Kang1, 
Yi Young Choi1, Kyung Min Shin4, Seung Soo Yoo1, Jaehee Lee2, 
In-Jae Oh5, Kyu-Sik Kim5, Seung Ick Cha2, Chang Ho Kim2, Young-
Chul Kim5, Jae Yong Park1
1Lung Cancer Center, Kyungpook National University Medical Center/
Korea, 2Department Of Internal Medicine, Kyungpook National Univer-
sity Hospital/Korea, 3Department Of Pathology, Kyungpook National 
University Medical Center/Korea, 4Department Of Radiology, Kyung-
pook National University Medical Center/Korea, 5Lung Cancer Clinic, 
Chonnam National University Hwasun Hospital/Korea
Background: This study was conducted to analyze a comprehen-
sive panel of single nucleotide polymorphisms (SNPs) in genes in 
DNA repair and apoptosis pathways and determine the relation-
ship between polymorphisms and treatment outcomes of patients 
with non-small cell lung cancer (NSCLC) treated with first-line 
paclitaxel-cisplatin chemotherapy.
Methods: Three hundred eighty two patients with NSCLC were 
enrolled. Seventy-four SNPs in 48 genes (42 SNPs in 27 DNA repair 
pathway genes and 32 SNPs in 21 apoptotic pathway genes) were 
genotyped and their associations with chemotherapy response 
and overall survival (OS) were analyzed.
Results: Among SNPs in DNA repair genes, BRCA1 rs799917 was 
significantly associated with both chemotherapy response and 
OS. XRCC1 rs25487 exhibited a significant association with che-
motherapy response and ERCC2 rs1052555 with OS. Four SNPs 
in apoptotic genes (TNFRSF1B rs1061624, BCL2 rs2279115, BIRC5 
rs9904341, and CASP8 rs3769818) were significantly associated 
with OS, but not with response to chemotherapy. When the six 
SNPs which were associated with OS in individual analysis were 
combined, OS decreased as the number of bad genotypes incre-
ased (Ptrend = 2x10
-6). Patients with 3, and 4-6 bad genotypes had 
significantly worse OS compared with those carrying 0-2 bad ge-
notypes (adjusted hazard ratio [aHR] = 1.54, 95% CI = 1.14-2.08, P 
= 0.005; aHR = 2.10, 95% CI = 1.55-2.85, P = 2x10-6, respectively).
Conclusion: In conclusion, these findings suggest that the SNPs 
identified could be used as biomarkers predicting chemotherapy 
response and survival of NSCLC patients treated with first-line 
paclitaxel-cisplatin chemotherapy.
Keyword: Lung cancer, DNA repair and apoptosis genes, Chemo-
therapy, Response, Survival
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Conclusion: Droplet digital PCR analysis is a novel sensitive detec-
tion method for EGFR mutation in plasma of patients with advan-
ced NSCLC. Quantification of low level of circulating EGFR mutant 
DNA is feasible. Future investigation aims to correlate the quanti-
fied plasma EGFR mutation DNA with clinical outcomes.
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P1.06-029 SERUM NITRIC OXIDE COULD BE A PREDIC-
TOR FOR THE RESPONSE OF BEVACIZUMAB IN PATI-
ENTS WITH NON-SMALL CELL LUNG CANCER
Satoshi Muto, Hiroyuki Suzuki, Mitsunori Higuchi, Jun Osugi, 
Takeo Hasegawa, Hiroshi Yaginuma, Naoyuki Okabe, Takumi 
Yamaura, Yuzuru Watanabe, Yuki Owada
Department Of Thoracic Surgery, Fukushima Medical University/Japan
Background: Bevacizumab (BEV), an inhibitory monoclonal anti-
body to VEGF, is widely used to treat patients with non-small cell 
lung cancer (NSCLC), but biomarkers that predict BEV response 
are controversial. Reportedly, hypertension is linked to response 
to BEV therapy, possibly because BEV might suppress vascular 
nitric oxide (NO) production. However, the usefulness of serum NO 
(NOs) as a predictive biomarker for BEV therapy has not previously 
been shown. Here, we studied the predictive value of NOs in BEV-
treated patients with NSCLC.
Methods: Fifteen patients with advanced or recurrent NSCLC 
treated with BEV-based regimens were evaluated retrospectively. 
Blood samples were taken before treatment (Pre), and after the 1st 
and 2nd chemotherapy courses (Post1 and Post2, respectively). NOs 
(NO2
–/NO3
–) was assayed by the Griess method. Relationships bet-
ween clinical parameters (e.g., clinical responses, adverse events) 
were analyzed against NOs. This study was approved by the ethics 
committee of Fukushima Medical University.
Results: Median Pre NOs was 62.7 ±42.9 µmol/L (range: 1.9–138.8 
µmol/L). NOs tended to decrease at Post1 (46.6 ± 30.8 µmol/L; P 
= 0.246) and Post2 (37.6 ± 29.4 µmol/L; P = 0.072) compared to 
Pre values. Post/Pre NO ratios correlated with hypertension onset 
(Post1/Pre: P = 0.316; Post2/Pre: P = 0.148) and clinical response 
(Post1/Pre: P = 0.389; Post2/Pre: P = 0.163). Decrease at Post2 might 
correlate with progression-free survival (P = 0.127). NOs level of 
patients with treatment responder increased at Post PD (P = 0.101).
Conclusion: NOs, could be a predictive biomarker for response to 
BEV in patients with NSCLC. Prospective confirmation is needed; 
we are conducting a prospective translational study of NOs in BEV 
therapy. 
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P1.06-031 IS THERE ANY ROLE FOR MONITORING 
CIRCULATING TUMOR CELLS (CTC) IN STAGE III NON-
SMALL-CELL LUNG CANCER (NSCLC) PATIENTS?
Pilar Garrido1, Eugenia Olmedo1, Amparo Benito2, Almudena 
Santón3, Julie Earl3, Carme Guerrero3, Gemma Muñoz4, Carmen 
Vallejo5, Luis Gorospe6, Javier Zamora7
1Medical Oncology, Hospital University Ramon Y Cajal. Irycis/Spain, 
2Pathologist, Hospital University Ramon Y Cajal. Irycis/Spain, 3Molecu-
lar Biologist, Hospital University Ramon Y Cajal. Irycis/Spain, 4Thoracic 
Surgeon, Hospital University Ramon Y Cajal. Irycis/Spain, 5Radiothe-
rapist, Hospital University Ramon Y Cajal. Irycis/Spain, 6Radiologist, 
Hospital University Ramon Y Cajal. Irycis/Spain, 7Biostatistics, Hospi-
tal University Ramon Y Cajal. Irycis/Spain
Background: The value of CTC has not been fully examined in 
patients (p) with NSCLC, in particular in those with locally advan-
ced disease
Methods: A prospective study to evaluate CTC in NSCLC p is 
been conducting. Peripheral blood samples have been collected 
for CTC analysis basally in all stages and after finishing chemothe-
rapy and radiotherapy in stage III. CTC analysis is performed using 
CellSearch (Veridex).
Results: One hundred and twenty nine patients were enrolled 
between January 2009 and May 2013. CTC was positive (CTC ≥1) 
in 21% (27/129 p). The number of CTC varied between 1 and 136 
(7 p had only 1 basal CTC, 4 p had 2, 4 p 3 , 2 p 4, 2 p 5 , 2 p 6 and 
1 p 7, 8 11,14, 37 and 136 CTC respectively). Basal positive CTC 
according to the stage were: 4% stage I and II p (1/26), 13% stage 
III p (6/45) and 35% stage IV p (20/58). In p with positive basal CTC, 
no differences were found in terms of histology (adenocarcinoma 
22% p (18/81), squamous 20% p (7/34), others 14% p (2/14)), smo-
king status (current smoker 16% (10/61 p), non-smoker 21% (3/14 
p), former smoker 26% (14/54 p)), EGFR status (EGFR + 17% (2/12 
p), EGFR wt 25% (25/117 p), but a statistically significant difference 
was found in terms of ECOG (17% ECOG 0-1 (16/97 p) versus 34% 
ECOG 2 (11/32 p); p: 0.044). In 58 p with stage IV no differences 
were found related to location of metastasis (mts): M1a 32% (5/16 
p), M1b 33% (8/24 p) although none of p with brain mts showed 
basal CTC. With a median follow-up using inverse Kaplan-Meier of 
315 days, no differences were found in terms of survival based on 
basaline CTC status. Data of dynamic changes are still pending
Conclusion: Although this study is still ongoing, the role of basal 
CTC in stage III NSCLC is still unclear with only 13% of p positive at 
diagnosis. The value as predictive factor will depend on the data 
of dynamic changes that will be presented at the meeting
Keyword: NSCLC, stage III, circulating tumor cell, predictive factor
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P1.06-030 KRAS MUTATIONS IN RESECTABLE NSCLC 
PATIENTS. PROGNOSTIC IMPLICATIONS.
Sandra Gallach1, Eloisa Jantus Lewintre1, Ana Blasco2, Eva Escori-
huela1, Santiago Figueroa3, Cristina Hernando2, Rut Lucas4, Rafael 
Sirera5, Ricardo Guijarro6, Carlos Camps7
1Molecular Oncology Laboratory, General University Hospital Research 
Foundation/Spain, 2Department Of Medical Oncology, General Universi-
ty Hospital Of Valencia/Spain, 3Thoracic Surgery Department, General 
University Hospital Of Valencia/Spain, 4Departamento De Historia De 
La Ciencia Y Documentación, Universitat De Valencia/Spain, 5Depart-
ment Of Biotechnology, Polytechnic University Of Valencia/Spain, 6De-
partamento De Cirugía, Universitat De Valencia/Spain, 7Departamento 
De Medicina, Universitat De Valencia/Spain
Background: Development of Non-Small Cell Lung Cancer (NS-
CLC) requires multiple genetic and epigenetic alterations, with 
some differences according to etiology and histology. The most 
frequently mutated genes in these tumors are EGFR and KRAS 
(present mostly in adenocarcinomas), however, the prognostic 
value of KRAS mutations in NSCLC is still controversial.
Methods: Fresh tumor tissue samples (n=150) were obtained from 
resectable NSCLC patients. DNA was extracted by standard me-
thods based in TriZol® and analyzed for KRAS mutational status 
by RTqPCR with ARMS technology and Scorpions probes. Non-
parametric methods were used fos statistical analysis. Progression 
free survival (PFS) and overall survival (OS) were evaluated by Kap-
lan-Meier method (log-rank test). A p value ≤ 0.05 was considered 
statistically significant.
Results: Baseline characteristics of the patients were: median 
age, 64 years [26-82]; 86.0% male; 71.3% ECOG-PS 0; 40% ade-
nocarcinomas (ADC). KRAS mutations were detected in 10.7% of 
the tumors (n= 150). Table 1 summarizes the mutations found in 
our cohort. In the subgroup of ADC + ADC-SCC samples, mutant 
KRAS represents 20% of the tumors. Considering only the never-
smoker group of patients, 31.6% of the samples were mutated for 
KRAS. Our results showed that patients with KRAS mutated tumors 
had significantly shorter PFS than patients with wild type KRAS 
(11.633 vs 45.833 months, respectively, p= 0.043) and a trend to a 
shorter OS (23.067 vs 66.967 months, respectively, p= 0.074). Table 
1: Distribution of KRAS mutations in our cohort  
n %
Wild Type 134 89.3
12SER 1 0.7
12CYS 5 3.3
12ASP 7 4.7
12VAL 3 2.0
TOTAL 150 100.0
Conclusion: KRAS gene mutation is a poor prognostic factor for 
PFS in our cohort of resectable NSCLC; therefore, the determina-
tion of the mutational status of KRAS gene might be implemented 
routinely in clinical practice. This work was supported in part, by a 
grant [RD06/0020/1024 and RD12/0036/0025] from Red Temática 
de Investigación Cooperativa en Cáncer, RTICC, and Instituto de 
Salud Carlos III (ISCIII).
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chemotherapy regimens. The patients with EFGR-negative / PTEN-
negative had poorer clinical outcomes than those with positive 
EGFR or positive PTEN expression: with shorter median PFS (2.1 vs. 
4 months, HR = 1.713, p = 0.036). PI3KCA gene amplification was 
not related to clinical outcomes.
Conclusion: EGFR and PTEN protein expression could be used to 
identify which patients with SqCLC are likely to gain a benefit from 
EGFR-TKIs. The potential clinical application of specific EGFR-ID 
antibody for prediction of clinical outcomes in SqCLC needs vali-
dations.
Keywords: EGFR and PTEN protein expression, EGFR-TKI, Predic-
tive factors, Squamous cell lung cancer
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P1.06-033 THE IMPACT OF PLASMA LEVELS OF VAS-
CULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 
2(VEGF R2) AND HEPATOCYTE GROWTH FACTOR (HGF) 
ON SURVIVAL IN LONG-TERM SURVIVORS WITH AD-
VANCED LUNG CANCER (ALCP)
Zhasmina Mihaylova1, Rositza Vladimirova2, Mila Petrova1, Dobro-
mira Petkova1
1Medical Oncology, Military Medical Academy/Bulgaria, 2Clinical Labo-
ratory, Military Medical Academy/Bulgaria
Background: HGF, a ligand of the c-met proto-oncogene, ex-
hibits activating effects on human lung cancer both in vitro and 
in vivo (Hosoda H, 2012). The major mediator of angiogenic and 
permeability-enhancing effects of VEGF-A is the tyrosine kinase 
receptor VEGFR2.(Ferrara N. 2001, Takahashi H 2005). Some data 
indicate negative impact on survival of HGF and VEGF/VEGFR2 in 
lung cancer patients (Yang F, 2011;Kumara 2009, Han Y,2011 Ikeda 
N, 2010). EGFR-mutated lung cancer patients have longer survival 
under treatment with anti-EGFR TKI than non-mutated tumors. The 
biological reasons for long-surviving advanced lung cancer pati-
ents (ALCP) with not EGFR mutated tumors are not described.
Methods: The plasma samples of ALCP without EGFR-mutation 
who survived more than 20 months (mo) are taken for analyses 
from serum/plasma bank storage at -80C. The measurement of 
HGF and VEGFR2 are done according to the manufacturing inst-
ructions of eBioscience Instant ELISA test and Platinum ELISA eBi-
oscience test. Statistical analysis is made by SPSS.9.0.
Results: 30 plasma samples from 13 ALCP taken before treatment 
and at response evaluation thereafter are analyzed in duplicate. 
ALCP, mean age 60.4(range 44-75) years, 10/3 man/woman, 7/6 
smokers/nonsmokers, 3/7/3 squamous/adeno/small cell, 10/3- 
ECOG PS 0/1, 6/7 died/censored, have mean PFS (measured from 
diagnosis till first progression) of 24.07 months (SD 5.2) and mean 
OS of 37.5 mo (SD 4.7). ALCP have disease confined to the thorax 
(pulmonary mets, pl. effusion) with 5 pts with bone and 2 with 
suprarenal mets. IHC confirmation of diagnosis is done in 60% of 
pts. The first line chemotherapy is platinum based with addition 
of VP-16 for small cell, Gemcitabine for squamous and Pemetrex-
ed for adeno-histotype. Ten pts receive maintenance treatment 
and 9 had more than three lines of treatment. None of pts receive 
anti-angiogenesis therapy. The mean baseline values (13 samp-
les) of VEGFR2 and HGF are 520,4 pg/ml(SD262,2) and 104,4 pg/
ml(SD91,5), while at second (10 samples) and third (7samples) mea-
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P1.06-032 THE HIGH PROTEIN EXPRESSION OF EGFR 
USING A SPECIFIC INTERNAL DOMAIN ANTIBODY AND 
LOSS OF PTEN CAN BE USED AS PREDICTIVE FACTORS 
FOR EGFR TKIS IN PATIENTS WITH ADVANCED SQUA-
MOUS CELL LUNG CANCER
Jisu Oh1, Hyun Chang2, Xianglan Zhang3, Jae Ho Lee2, Choon-Taek 
Lee2, Yu Jung Kim2, Dae-Won Lee4, Jin-Haeng Chung5, Jong-Seok 
Lee2
1Internal Medicine, Cha Bundang Medical Center/Korea, 2Internal Me-
dicine, Seoul National University College Of Medicine, Seoul National 
University Bundang Hospital/Korea, 3Oral Cancer Research Institute, 
Yonsei University College Of Dentistry/Korea, 4Internal Medicine, Seoul 
National University College Of Medicine, Seoul National University 
Hospital/Korea, 5Pathology, Seoul National University College Of Medi-
cine, Seoul National University Bundang Hospital/Korea
Background: Over the last decade encouraging new targeting 
agents have afforded benefits to patients with adenocarcinoma (ie. 
bevacizumab, erlotinib, gefitinib, crizotinib) but, very few advances 
were made in the treatment of squamous-cell lung cancer (SqCLC). 
However, many genomic abnormalities (PTEN, PI3KCA and FGFR1 
etc.) are present in SqCLC and there is growing evidence of their 
cell survival, proliferation, and growth. These expressions have also 
been related to the resistance of epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor (TKI) in preclinical models. The 
objective of this study is to investigate the molecular and clinical 
factors that predict EGFR-TKI efficacy as a second-line or higher 
therapy in previously treated patients with SqCLC. We especially 
focused on the protein expression of EGFR, PTEN and PI3KCA 
gene amplification.
Methods: This retrospective study included 67 SqCLC Korean 
patients with available tumor tissue and data on EGFR-TKI treat-
ment response and survival. EGFR protein expression in tumor 
tissue was evaluated by immunohistochemistry (IHC) with a specific 
antibody that detects the intracellular domain (ID) of EGFR. In ad-
dition PTEN expression in tumor tissue was assessed by IHC. PI3K-
CA gene amplification by quantitative real-time polymerase chain 
reaction (PCR) and mutational analyses of EGFR exon 19 and 21 by 
a PCR-based assay were performed.
Results: The median age was 70 years. The proportions of males 
and ever smokers were 85% and 82%. Patients had received a 
median of 2 prior chemotherapy regimens for advanced disease 
before treatment with EGFR-TKI. Eighty-four percent (n=56) of the 
patients received erlotinib treatment and the other (n=11) recei-
ved gefitinib. Of the 54 patients available for response evaluation 
at 12 weeks, disease control rate was 35% (2 patients in partial 
response; 17 patients in stable response). The median progressi-
on free survival (PFS) and overall survival (OS) were 1.8 and 4.63 
months, respectively. Positive EGFR protein expression in tumor 
tissue was present in 56 patients (85%), loss of PTEN expression 
(PTEN-negative) in 26 (39%) and PI3KCA gene amplification in 12 
(21%). No cases exhibited EGFR activating mutation. But positi-
ve EGFR expression correlated with improved PFS (1.87 vs. 0.9 
months, p=0.049). Negative PTEN expression was associated with 
a significantly higher risk of death (3.7 vs. 5.7 months median OS, 
p=0.028). Multivariable model confirmed that positive EGFR ex-
pression correlated with improved PFS (HR = 0.435, 95% CI = 0.21-
0.89, p = 0.024) and positive PTEN expression was associated with 
an increased OS (HR = 0.437, 95% CI = 1.17-4.45, p = 0.015) after 
adjusting sex, age, performance status and number of previous 
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Median H-scores were significantly higher in adenocarcinoma com-
pared to squamous cell carcinoma (140 vs 91.5, p<0.0001). Increa-
sed MET expression (H-score>100) was seen in 227 (45%) patients. 
High quality DNA was isolated in 443/508 (87%) of samples. The 
commonest mutations were in KRAS (21%), TP53 (10%), EGFR (5%), 
PIK3CA (4%) MET (3%) and NRF2 (3%). No mutation was found in 
44% of samples. EGFR and KRAS mutations were associated with 
significantly higher MET expression, whereas TP53 was associated 
with significantly lower expression (Chi square p=0.0005). These 
differences may reflect the higher rates of adenocarcinoma in both 
EGFR and KRAS mutated tumours. Increased MET copy number by 
SISH was only observed in 6 samples. MET expression was not as-
sociated with cancer specific survival across all stages. In tumours 
harbouring mutations and in wild type tumours, there were no 
significant differences in survival according to MET expression.
Conclusion: Although increased MET expression was associa-
ted with both KRAS and EGFR mutations, it was not prognostic 
in this large cohort of resected NSCLC. MET expression may be 
both predictive and prognostic in advanced NSCLC, but its role 
in early stage NSCLC is unclear. References: 1. Dziadziuszko R, et 
al. Correlation between MET Gene Copy Number by Silver In Situ 
Hybridization and Protein Expression by Immunohistochemistry in 
Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2012 
Feb;7(2):340–7. 2. Cappuzzo F, et al. Increased MET gene copy 
number negatively affects survival of surgically resected non-
small-cell lung cancer patients. Journal of Clinical Oncology. 2009 
Apr 1;27(10):1667–74.
Keywords: Prognosis, SISH, MET expression, Oncogenic muta-
tions
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P1.06-035 VEGF-A 165 FAMILY OF ISOFORMS AS PRE-
DICTIVE BIOMARKERS IN PATIENTS WITH NON-SQUA-
MOUS NON-SMALL CELL LUNG CANCER (NSCLC) TREA-
TED WITH BEVACIZUMAB.
Manuel Domine, Federico Rojo, Tatiana Hernández, Sandra Zazo, 
Gloria Serrano, Cristina Chamizo, Cristina Caramés, Nerea Carva-
jal, Irene Moreno, Nuria Pérez González, Ana León, Carmen Laura 
Auz, Jose Ignacio Martín Valades, Juan Madoz, Francisco Lobo, 
Victoria Casado, Gustavo Rubio, Yann Izarzugaza, Juan Luis Ar-
ranz, Jesús García Foncillas
Translational Oncology Division, ISS-Hospital Universitario Fundación 
Jiménez Díaz/Spain
Background: Bevacizumab is a recombinant monoclonal huma-
nized antibody targeted against vascular endothelial growth factor 
(VEGF) that improves Time to Progression (TTP) in patients with 
advanced non-squamous NSCLC in combination with a doub-
let of platins, but currently no proven predictive markers exist. 
The VEGF-A 165 splice variant has been described as the most 
abundant and active isoform in cancer. Exon 8 distal splice site 
modifications of VEGF 165 generates the VEGF-A 165a family of 
isoforms, which has a pro-angiogenic effect, and the VEGF-A 165b 
family, with an anti-angiogenic activity in in vivo models. This study 
is aimed to explore the role of VEGF165a and VEGF165b isoform 
expression in tumors as predictive biomarkers of efficacy in pati-
ents with non-squamous NSCLC treated with a doublet of platin 
plus bevacizumab.
surements mean values are 544,9 pg/ml (SD 95,5) / 49,2 pg/ml (SD 
20,4) and 563,65 pg/ml (SD 152,1)/ 147,13 pg/ml(SD53,6). Strong 
negative Pearson correlation between plVEGFR2 and Hb levels is 
found (p=0.007). No correlation between albumin, LDH, WBC , PLT 
and cytokine baseline levels are found. According to the median 
baseline value of VEGFR2, ALCP with values bellow 422.7 pg/ml 
have significantly longer PFS (34,6mo) and OS (47,1mo) than those 
with VEGFR2 values above 422,7 – PFS -11,8 mo and OS-26,2 mo. 
(p=0.023 and p=0.020, ANOVA test). Median baseline HGF va-
lues of 88.3 bellow/above separate ALCP with longer/shorter OS 
46/32,1 mo but without reaching statistical significance (p=0.17)
Conclusion: Classical clinical prognostic factors cannot identify 
ALCP with long survival –PS and numbers of therapeutic lines have 
positive effect on prognosis. Circulating baseline angiogenesis-
related cytokines particularly VEGFR2 and HGF might be used 
for biological determinates of long survivors identification among 
patients with advanced lung cancer. However further studies with 
enlarged patients number with long survival are needed.
Keyword: long-term lung cancer survivors, plasma HGF, plasma 
VEGFR2
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P1.06-034 MET EXPRESSION, COPY NUMBER AND ON-
COGENIC MUTATIONS IN EARLY STAGE NSCLC
Thomas John1, Carmel Murone1, Khashayar Asadi2, Marzena Wal-
kiewicz3, Adrienne Morey4, Simon Knight5, Paul Mitchell1
1Joint Austin-ludwig Oncology Unit, Austin Health/Australia, 2Patho-
logy, Austin Health/Australia, 3Ludwig Institute For Cancer Research/
Australia, 4Pathology Department, St Vincents Hospital/Australia, 
5Thoracic Surgery, Austin Health/Australia
Background: The MET receptor tyrosine kinase and its ligand are 
associated with the malignant phenotype. In non-small cell lung 
cancer (NSCLC) MET expression increases with disease stage and 
is involved in de novo and acquired resistance to tyrosine kinase 
inhibitors. Despite this, in early stage NSCLC, conflicting data 
series have reported MET expression and copy number to be pro-
gnostic in some studies but not others1,2. We investigated a large 
cohort of patients who underwent curative surgical resection at 
our institution to determine whether MET receptor or gene amplifi-
cation was prognostic.
Methods: Tissue Microarrays (TMAs) were constructed using 1mm 
cores of FFPE primary NSCLC tissues in triplicate. TMAs were 
stained with the MET SP44 clone and a H-score calculated based 
on % cells stained and intensity; (%cellsx1)+(%cellsx2)+(%cellsx3) 
with a minimum of 0 and maximum of 300. The mean of triplicate 
values was calculated. MET gene amplification was detected using 
Ventana’s MET DNP probe with ultraView SISH DNP silver detec-
tion, performed on Ventana’s XT autostainer. DNA was isolated 
and subjected to mutational profiling using Sequenom’s LungCar-
ta panel.
Results: Data for 508 patients, 352 (69%) male, were available for 
analysis including 329 pathological node negative (pN0), 67 pN1, 
104 pN2 and 8 patients with resected primaries and solitary brain 
metastases (M1). Most patients were smokers with only 33 (6%) 
non-smokers. The median MET H-score was 100 and consistent ac-
ross N0, N1 and N2 patients, although was higher in M1 patients. 
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level of 136meq/l or lower was used as a cut-off between high and 
low sodium groups. Data was analyzed using Chi Square statistical 
analysis and the Fishers Exact Test. Inferences were tested to be 
significant at P value of 0.05 or less.
Results: There were 234 (59.7%) males out of 389 patients. The 
mean age was 67.3 ± 11.4 years. The distribution of race was 227 
(58%) white patients, 91 (23%) black patients, and 71 (20%) other 
races. Patients in low stage constituted 218 (55%) of the patients. 
Low Na levels were significantly more common in patients with 
high stage NSCLC [Odds ratio 1.85, CI 95% (1.19, 2.87), P<0.006]. 
On further sub-group analysis, low sodium levels were found to 
be significantly associated with higher stage in patients with Ade-
nocarcinoma (n=183, 47%), [Odds ratio 2.07, CI 95% (1.12, 3.84), 
P<0.021]. No statistical association was seen between Na levels 
and other tumor variables.
Conclusion: We demonstrated higher stages of NSCLC and Ade-
nocarcinoma Lung were associated with lower sodium levels. Pos-
sible mechanisms explaining this phenomenon includes Syndrome 
of Inappropriate Anti Diuretic Hormone secretion, increased levels 
of Atrial Natriuretic Peptides, release of Neuropeptide Y stimu-
lating the posterior pituitary & metastases to adrenal or brain. 
Previous studies have demonstrated that lower sodium levels are 
associated with poor prognosis in LC. Serum sodium is an inexpen-
sive and a routinely ordered test. Further prospective and larger 
studies are needed to substantiate the role of serum sodium levels 
as an easily assessable biomarker for advanced disease. It might 
also be useful to explore its potential as a marker of the disease 
progression.
Keywords: Adenocarcinoma, Hyponatremia, Non small cell lung 
cancer
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P1.06-037 ANGIOPOIETIN-2 SERUM AND MRNA LEVELS 
AS PROGNOSTIC FACTORS IN NON SMALL CELL LUNG 
CANCER
Ana Coelho1, Antonio Araujo2, Monica Gomes1, Raquel Catarino1, 
Rui Medeiros1, Agostinho Marques3
1Portuguese Institute Of Oncology/Portugal, 2Centro Hospitalar De Ent-
re O Douro E Vouga Epe/Portugal, 3Faculty Of Medicine Of University 
Of Porto/Portugal
Background: Tumor vasculature is a very important target for the 
management of NSCLC, with antiangiogenic therapy becoming 
part of standard antitumor treatment. Angiopoietin-2 (ANG-2) is 
a functional ligand of the Tie2 tyrosine kinase receptor expressed 
on endothelial cells. The dominant biologic role of ANG-2 as a 
destabilizing agent of established blood vessels as a prerequisite 
to sprouting angiogenesis includes it among the most intensely 
explored target molecules for the development of second-gene-
ration antiangiogenic drugs. The aim of this study was to evaluate 
peripheral blood leukocytes’ ANG-2 mRNA expression levels and 
serum circulating levels of ANG-2 as prognostic factors for NSCLC 
patients.
Methods: The study included 150 Caucasian NSCLC patients from 
the North region of Portugal, with a mean age of 64.0 years. The 
samples were collected at the time of diagnosis, before treatment, 
and included 52 epidermoid, 76 adenocarcinomas, 20 undifferen-
Methods: 22 patients were included (20 adenocarcinomas and 2 
large cell carcinomas): 5 received carboplatin-taxol-bevacizumab, 
14 carboplatin-taxotere-bevacizumab and 3 cisplatin-gemcitabine-
bevacizumab. Total RNA was isolated from clinical samples by 
RNeasy FFPE procedure (Qiagen). VEGF165a and VEGF165b expres-
sion was analyzed by RT-qPCR using appropriate specific primers 
and probes in LightCycler 480II platform at 45 cycles. Individual 
VEGF165a and VEGF165b family of isoforms expression was calib-
rated to normal tissue and the ratio between both isoforms was 
calculated.
Results: From studied cases, VEGF165a overexpression was detec-
ted in 14 (63.6%) cases and VEGF165b overexpression in 15 (68.2%) 
tumors. Individual overexpression for each family of isoforms was 
not predictive of benefit to bevacizumab therapy (p=0.933 and 
0.166). However, the ratio between VEGF165a and VEGF165b was 
associated with TTP, correlating a predominant expression of the 
pro-angiogenic VEGF165a in tumor with a significant benefit compa-
red with cases with predominant VEGF165b expression (median TTP, 
15 vs. 8 months respectively, p=0.005). The expression of both 
family isoforms did not impact on overall survival (p=0.477).
Conclusion: The overexpression of VEGF165a family of isoforms as-
sociated with a low expression of VEGF165b correlated with benefit 
to anti-angiogenic therapy in this small cohort of advanced NSCLC 
patients, supporting a potential use as predictive biomarkers for 
bevacizumab treatment in stage IV non-squamous NSCLC.
Keywords: metastatic, Biomarkers, Bevacizumab, NSCLC
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P1.06-036 RELATIONSHIP BETWEEN SERUM SODIUM 
LEVELS AND TUMOR CHARACTERISTICS IN NON-
SMALL CELL LUNG CANCER.
Abhishek Kumar1, Elie B. Geara2, Anurag Sharma3, Michael Ma-
roules1
1Hematology Oncology, St. Joseph Regional Medical Center/United Sta-
tes Of America, 2School Of Medicine, St George’s University/United Sta-
tes Of America, 3Internal Medicine, St. Joseph Regional Medical Center/
United States Of America
Background: Lung cancer (LC) is the second most common cancer 
diagnosed in men and women. The age-adjusted incidence rates 
are 62.6 per 100,000 populations per year. LC is also the most 
common cause of cancer mortality in the United States with 56% of 
the cases being metastatic at the time of diagnosis. Hyponatremia 
has classically been associated with Small Cell LC. Studies have 
shown Non Small Cell LC (NSCLC) to be associated with Hyponat-
remia. Hyponatremia is a predictor of mortality and worse progno-
sis in NSCLC. We studied the association of sodium (Na) levels with 
histological type, level of differentiation and staging in NSCLC.
Methods: We retrospectively enrolled 490 patients with NSCLC 
from the tumor registry data of our hospital from 2001 to 2011. 
One hundred one patients were excluded based on the following 
criteria: 1) patients without biopsy proven NSCLC, 2) medical re-
cords unavailable, and/or 3) age < 18 years at time of diagnosis. 
The following variables were collected: TNM staging (Stage 1, 
2,3 as low stage and 4 as high stage),histological type, level of 
differentiation (well differentiated, moderately differentiated, or 
poorly differentiated) and Na levels at the time of diagnosis. Na 
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lification with Multiple Annealing and Looping-Based Amplification 
Cycles (MALBAC). The individual CTCs’ copy number variations 
(CNVs) were determined by whole-genome sequencing, and their 
single nucleotide variations (SNVs) and insertions/deletions (IN-
DELs) were detected by exome sequencing.
Results: We sequenced 24 CTCs from four patients with advan-
ced lung adenocarcinoma and compared them with the matched 
primary/metastatic tumors. Patient 1 with EGFR mutation experi-
enced a phenotypic transition from lung adenocarcinoma to small 
cell lung cancer in liver, and resistance to EGFR-TKIs. Individual 
CTCs from each patient exhibited reproducible copy number va-
riation (CNV) patterns, which resembled those of the metastatic 
tumors. CTCs from different patients showed similar CNV patterns 
on certain chromosomes. Some rare single nucleotide variations 
(SNVs) and insertions/deletions (INDELs) in primary tumor, inclu-
ding those that may relate to drug resistance and phenotypic tran-
sition, were enriched in CTCs.
Conclusion: CTCs exhibit highly reproducible CNV patternswhich 
offer a potential biomarker for cancer diagnosis and classification. 
The SNVs/INDELS in individual CTCs can be detected and provide 
molecular targets for personalized treatment.
Keyword: CTC,single cell sequencing,CNV
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P1.06-039 IMPACT OF KI-67 LABELING INDEX AS A PRE-
DICTIVE MARKER FOR CHEMOTHERAPY IN NON-SMALL 
CELL LUNG CANCER
Yoshimitsu Hirai, Tatsuya Yoshimasu, Shoji Oura, Yozo Koka-
wa, Rie Nakamura, Mitsumasa Kawago, Takuya Ohashi, Masako 
Matsutani, Mariko Honda, Yoshitaka Okamura
Department Of Thoracic And Cardiovascular Surgery, Wakayama Me-
dical University/Japan
Background: Ki-67 is a nuclear proliferation marker that reflects 
growth of tumor. Recently, the predictive implication of ki-67 labe-
ling index (LI) for response to chemotherapy has been evaluated. 
Since St. Gallen International Expert Consensus in 2009, the ki-67 
LI have been used one of factors that should help decide whether 
chemotherapy is given in breast cancer. In the present study, we 
examined the predictive value of ki-67 LI for chemotherapy for 
non-small cell lung cancer (NSCLC) patients using the histoculture 
drug response assay (HDRA).
Methods: Surgically resected fresh tumor specimens were obtai-
ned from 92 NSCLC patients at our institution from January 2007 
to June 2011. The patients comprised 56 male patients and 36 
female patients who ranged in age from 39 to 84 years (median= 
73 years). The specimens examined were 57 adenocarcinomas, 
26 squamous cell carcinomas, 4 adenosquamous carcinomas, 3 
pleomorphic carcinomas and 2 other histological types. HDRA 
were used as an in vitro drug sensitivity test. HDRA technique was 
the same as we previously reported (JTCVS 133: 303-8, 2007). The 
inhibition rate of cisplatin and docetaxel were measured. Immu-
nohistochemical staining for ki-67 was done and measured ki-67 
LI. Relationships between ki-67 LI and the inhibition rate were 
examined using Spearman’s correlation coefficient test by rank 
test and chi-square test. Values of p<0.05 were considered to be 
significant.
tiated NSCLC, 2 large cells and 2 mixed carcinomas, of which 76% 
were male and 73,5% smokers or former smokers, divided in 77 
non-metastatic and 73 metastatic cases. ANG-2 circulating levels 
were evaluated in subject samples with R&D Quantikine ELISA Kit, 
and mRNA expression levels (92 patients) with High Capacity RNA-
to_cDNA™ kit and Taqman®Gene Expression Assay, by real-timeP-
CR, both from Applied Biosystems, according to manufacturer’s 
instructions.
Results: Our results demonstrate that patients with high ANG-2 
circulating levels present a worst overall survival (OS) than patients 
with lower circulating levels (21.0 months vs 42.6 months, respec-
tively; Log Rank Test, p=0.001). Equally, patients with high mRNA 
expression levels have diminished overall survival when compared 
to those with low mRNA expression (20.3 months vs 34.3 months, 
respectively; Log Rank Test, p=0.016). Moreover, Cox Regression 
analysis adjusted to tumor stage, smoking status and histological 
type indicates that both high ANG-2 circulating levels and high 
mRNA expression levels are independent prognostic factors in NS-
CLC (HR=1.83, CI95%=1.19-2.80, p=0.006; HR=1.82, CI95%=1.02-
3.23, p=0.043, respectively).
Conclusion: ANG-2 is considered as a major player of the angio-
genic switch in the course of tumor progression, and it is found 
to be particularly increased in highly vascularized tumors. In fact, 
in some tumor models, the mRNA induction of ANG-2 in tumor 
endothelium has made it a very attractive circulating biomarker of 
angiogenesis activation. Several studies are currently investigating 
the promising role of ANG-2 as a target of antiangiogenic inhi-
bitors in several cancers, as an alternative to acquired resistance 
to currently used anti-VEGF molecules. Our results indicate that 
higher levels of ANG-2 mRNA in peripheral blood leukocytes and 
circulating ANG-2 are associated with worst survival in NSCLC 
patients. Assuming that blockage of ANG-2 is achieved in tumor 
stroma in a near future, this might represent a new breakthrough 
in cancer treatment and its circulating levels and mRNA expression 
levels may be helpful as predictive factors of treatment response, 
surpassing the need to obtain tumor tissue samples to assess its 
levels of expression.
Keyword: Angiopoietin-2; NSCLC; prognostic factor; overall sur-
vival
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P1.06-038 SINGLE CELL GENOMIC ANALYSES OF CIR-
CULATING TUMOR CELLS FROM LUNG CANCER PATI-
ENTS
Xiaohui Ni1, Minglei Zhuo2, Zhe Su1, Jianchun Duan2, Yan Gao1, 
Zhijie Wang2, Hua Bai2, Jie Wang2, Fan Bai1, Youyong Lu2, Xiaoliang 
Xie1
1Peking University/China, 2Peking University Cancer Hospital/China
Background: Circulating tumor cells (CTCs),which can be detected 
from peripheral blood, offer the potential for the assessment of 
clinical outcome. Whole genome sequencing of CTCs may provide 
comprehensive information related to tumor invasion and metasta-
ses, but has been hampered by their low abundance
Methods: From 7.5 ml peripheral blood, we captured with the 
CellSearch platform a small numberof CTCs, which, after further 
isolation with 95% specificity, were subject to whole genome amp-
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lymorphism had inferior response to TKI therapy despite EGFR 
mutation status. And Bim polymorphism could serve as an inferior 
prognostic factor in NSCLC TKI therapy.
Keywords: BIM, TKI, Polymorphism, NSCLC
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P1.06-041 PROGNOSTIC IMPACT OF CYTOSKELETON 
REGULATORY PROTEIN HUMAN MENA (HMENA) ISO-
FORMS IN RESECTED, NODE-NEGATIVE, NON-SMALL-
CELL LUNG CANCER: VALIDATION OF A CLINIC-MOLE-
CULAR PROGNOSTIC MODEL.
Emilio Bria1, Marcella Mottolese2, Francesca Di Modugno2, Gabri-
ele Alessandrini2, Vienna Ludovini3, Barbara Antoniani2, Pierluigi 
Iapicca2, Anna Ceribelli2, Angelo Sidoni4, Lucio Crino3, Francesco 
Cognetti2, Francesco Facciolo2, Paolo Visca2, Sara Pilotto1, Giam-
paolo Tortora1, Isabella Sperduti2, Michele Milella5, Paola Nisticò2
1Medical Oncology, Az. Osp. Univ. Integr. (a.o.u.i.), University Of Vero-
na/Italy, 2Regina Elena National Cancer Institute/Italy, 3Medical Onco-
logy, Santa Maria Della Misericordia Hospital/Italy, 4Pathology, Santa 
Maria Della Misericordia Hospital/Italy, 5Medical Oncology, Regina 
Elena National Cancer Institute/Italy
Background: Human Mena and the isoform hMena+11a are cytoske-
leton regulatory proteins involved in adhesion, motility, regulated 
in the epithelio-mesenchimal transition. Here, we investigated their 
potential prognostic value in node-negative non-small-cell lung 
cancer (NSCLC) patients.
Methods: Pan-hMena, hMena+11a, E-cadherin, vimentin, ER-beta, 
EGFR, HER-2, pAKT, detected immunohystochemically on dupli-
cate TMA and clinical factors (sex, age, histology, grading, T-size, 
number of resected nodes, RN) were correlated to 3-yr disease-
free (DFS), cancer-specific (CSS), and overall survival (OS) using 
a Cox model. ROC analysis provided optimal cut-off values and 
model validation. A logistic equation including regression analysis 
coefficients was constructed to estimate individual patients’ pro-
bability (IPP) of relapse. Internal cross-validation (100 simulations 
with 80% of the dataset) and external validation was accomplished.
Results: In a training set of 248 patients (median follow-up: 36 
months, range 1-96), Pan-hMmena and hMena+11a were the 
only biological variables displaying significant correlation with 
outcome(s), confirmed by the cross-validation (replication rate: 
78%, 83%), with a prognostic model accuracy of 61% (standard er-
ror 0.04, p=0.0001). Patients with high pan-hMENA expression had 
a non-significant trend towards a worse outcome, while patients 
with high hMena+11a expression had a significant and borderline 
significant advantage in DFS (p=0.03) and OS (p=0.056), respec-
tively, and a non-significant trend towards a better CSS. Univariate 
and multivariate 3-yr median individual patient probabilities of 
recurrence were 70.9 (range 40.3-94.4) and 41.2 (range 13.6-86.5), 
respectively (data not shown). The subgroup of patients with High 
Pan-hMena/Low hMena11a relative expression fared significantly 
better than any of the other 3 groups (p≤0.002 for all outcomes). 
On the basis of the combination between this molecular hybrid 
variable and T-size and RN, a 3-class risk stratification model 
was generated; the derived 3-risk class survival model strikingly 
discriminated between patients at different risk of relapse, cancer-
related death, and death for any cause, with a prognostic accuracy 
of 61% (standard error 0.03, p=0.01), according to ROC analysis. 
Results: Immunohistochemical staining of ki-67 and the HDRA 
for cisplatin and docetaxel were successful in all specimens. Ki-67 
LI was significantly correlated with the inhibition rate of cisplatin 
(rs=0.24, p=0.025) and docetaxel (rs=0.29, p=0.005) evaluated by 
HDRA. Ratio that have positive sensitivity for cisplatin in higher 
ki-67LI (ki-67 LI≧70) patients (52.6%) was significantly higher than 
that in lower ki-67LI (ki-67 LI≦30) patients (21.2%) (p=0.04). Ratio 
that have positive sensitivity for docetaxel in higher ki-67LI (ki-67 
LI≧70) patients (40.0%) was significantly higher than that in lower 
ki-67LI (ki-67LI≦30) patients (10.8%) (p=0.025).
Conclusion: Our result revealed the ki-67 LI was the predictive 
marker for chemosensitivity in NSCLC. The high expression of ki-67 
indicates positive sensitivity to cisplatin and docetaxel in patients 
with NSCLC.
Keywords: Lung cancer, ki-67, chemotherapy, histoculture drug 
response assay
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P1.06-040 THE BIM DELETION POLYMORPHISM PROFI-
LE AND ITS RELATIONSHIP WITH TKIS RESISTANCE IN 
CHINESE NSCLC POPULATION
Yishi Zhang1, Caicun Zhou1, Jiayu Li2, Mingchuan Zhao1
1Department Of Medical Oncology, Shanghai Pulmonary Hospital Affi-
liated To Tongji University/China, 2Medical Oncology, Tongji University 
Medical School Cancer Institute/China
Background: Tyrosine kinase inhibitors (TKIs) are widely used in 
advanced non-small cell lung cancer (NSCLC) patients with EGFR 
mutations. A research recently found that some patients, including 
NSCLC patients failed their TKI therapy due to a Bim deletion 
polymorphism. We here try to distinguish the prevalence and clini-
copathologic characteristics of the Bim deletion polymorphism in 
Chinese NSCLC patients.
Methods: 300 patients were included in the study for Bim poly-
morphism analysis. PCR and direct sequencing were applied to 
determine the polymorphism status of tissue or blood sample ext-
racted from these patients. 187 patients who received TKI therapy 
were further analyzed for relationship between clinicopathologic 
characteristics, therapeutic effects of TKI and Bim polymorphism 
status.
Results: 40 of 300 (13.3%) patients were detected of Bim deletion 
polymorphism. Further analysis among the 187 patients indicated 
that this polymorphism distributed randomly in clinical characte-
ristics including age, gender, smoking history, histological type 
and disease stage. However, patients harboring the Bim polymor-
phism had significantly shortened progression free survival (PFS) 
than those without the polymorphism (3.0±1.4 m vs. 7.5±0.9 m, 
p=0.012). Objective response rate (ORR) in Bim polymorphism 
carrying patients and wild typed patients also showed significant 
difference (21.7% vs. 50.6%, p=0.009). In further stratified analysis 
by EGFR mutation status, the PFS and ORR differences in Bim po-
lymorphism and wild type patients remained significant. Disease 
control rate (DCR) of the polymorphism carriers also showed a 
tendency of inferiority (39% vs. 75%, p=0.061), though without a 
significant difference.
Conclusion: Chinese NSCLC patients carrying Bim deletion po-
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Conclusion: Klotho expression revealed by immunohistochemistry 
in lung adenocarcinoma patients having EGFR mutations facilitated 
stratifying prognosis.
Keyword: Klotho, iflammation, mutation, epidermal growth factor 
receptor
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P1.06-043 PHARMACOGENETIC STUDY IN ADVANCED 
NON-SMALL CELL LUNG CANCER PATIENTS TREATED 
WITH PLATINUM BASED CHEMOTHERAPY.
Ivana G. Sullivan1, Juliana Salazar2, Margarita Majem1, Cinta Palla-
rés1, Elisabeth Del Río2, Antoni Berenguer3, David Páez1, Agustí 
Barnadas1, Montserrat Baiget2
1Medical Oncology, Hospital De La Santa Creu I Sant Pau/Spain, 2Ge-
netics, Hospital De La Santa Creu I Sant Pau/Spain, 3Idibell, Institut 
Catala D’Oncologia/Spain
Background: Platinum-based doublet chemotherapy (CT) is the 
standard treatment in non-small cell lung cancer (NSCLC) patients, 
but less than 30% respond to CT, and survival remains between 
10-12% at five years. The most important prognostic factor in sur-
vival is the stage, although there is significant variability in survival 
among patients with similar disease. It is postulated that different 
single nucleotide polymorphisms (SNPs) in DNA repair genes may 
play a role in the effectiveness of the platinum-based chemothera-
py. The purpose of this study was to evaluate the association of 17 
SNPs in 8 genes involved in DNA repair mechanisms, with the res-
ponse to treatment with platinum-based chemotherapy in NSCLC 
patients.
Methods: The genomic DNA was automatically extracted from 
blood samples using the salting out procedure (Autopure, Qiagen) 
and was quantified using the BioSpec-nano spectrophotometer. 
We analyzed 17 polymorphisms belonging to 8 genes, using 48.48 
dynamic array on the Biomark™ system (Fluidigm): six genes be-
long to the Nucleotide Excision Repair pathway (ERCC1, ERCC2/
XPD, ERCC3/XPB, ERCC4/XPF, ERCC5/XPG and XPA), and two ge-
nes belong to the Base Excision Repair pathway (XRCC1, XRCC2).
Results: We included 161 patients with stage IIIA-IV. The median 
age was 63.7 years; 77.6% were men, and 54% had stage IV di-
sease. All patients received a platinum agent (cisplatin: 95, carbo-
platin: 66) in combination with a third-generation drug. Patients 
with stage IIIA and IIIB also received concomitant or sequential 
radiotherapy. In patients with stage IIIA and IIIB (n=74), the multi-
variate analyses showed a significant association between the fol-
lowing SNPs and response: rs11615 (ERCC1) (p=0.0448 in a reces-
sive model), rs3738948 (ERCC3) (p=0,0049 in an additive model). 
In patients with stage IV (n=87), the multivariate analyses showed 
a significant association between the following SNPs and respon-
se: rs1799793 (ERCC2) (p=0.013 in a recessive model), rs179801 
(ERCC4) (p=0.033 in a dominant model) and rs25487 (XRCC1) 
(p=0.002 in a recessive model).
Conclusion: These results confirm the association between poly-
morphisms in genes ERCC1, ERCC2 and XRCC1 and response to 
treatment with platinum compounds as previously described. In 
our cohort, response to treatment was also associated with genes 
ERCC3, ERCC4, also involved in DNA repair processes. Prospective 
studies are needed in order to validate the role of polymorphisms 
The 3-risk class survival model was externally validated in an inde-
pendent dataset of 133 patients, and significantly discriminated 
between patients at Intermediate- and High-Risk of relapse and 
cancer-related death.
Conclusion: The expression of the hMena and its isoform may 
represent a powerful prognostic factor in early NSCLC and usefully 
complements clinical parameters to accurately predict individual 
patient risk.
Keyword: lung cancer; prognosis; epithelio-mesenchimal transiti-
on.
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P1.06-042 KLOTHO EXPRESSION IN PATIENTS HAVING 
EGFR MUTATIONS (CLICAP STUDY)
Carlos Vargas1, Andres F. Cardona1, Hernán Carranza1, Pilar Archi-
la2, July Katherine Rodriguez2, Laura Bernal1, Oscar Arrieta3, Alma 
D. Campos Parra3, Mauricio Cuello4, Rafael Rosell5
1Clinical And Traslational Oncology Group, Fundación Santa Fe De Bo-
gotá/Colombia, 2Fundation For Clinical And Applied Cancer Research 
– Ficmac/Colombia, 3Thoracic Oncology Clinic And Laboratory Of Expe-
rimental Oncology, Instituto Nacional De Cancerología (INCAN)/Mexi-
co, 4Clinical Oncology, Hospital De Clínicas, Udelar/Uruguay, 5Medical 
Oncology, Catalan Institute Of Oncology/Spain
Background: Klotho is a type I transmembrane protein which is 
encoded by the KL gene; it is associated with many metabolic pro-
cesses in differing neoplasias, including lung adenocarcinoma. Its 
abnormal expression conditions irregular endothelial growth and 
hyperactivation of proliferation via the PI3K/Akt signalling pathway.
Methods: Information concerning 84 patients with epidermal 
growth factor receptor (EGFR) mutations was taken to explore 
Klotho’s cytoplasmic positivity using an anti-Klotho antibody (Cal-
biochem, BD Biosciences, San Jose, CA, USA; 1:100 dilution). The 
results were correlated with multiple outcomes, including differing 
clinical characteristics, response rate, progression-free survival 
(PFS) and overall survival (OS).
Results: Mean age was 60.7 years (SD±13.1) and Klotho expres-
sion in the population of patients having EGFR mutations was 
considered positive in 35.7% of them (n=30), negative in 31.0% 
(n=26) and unknown in the remaining 33.3% (n=28). Positive Klotho 
expression was not influenced by gender (p=0.51), histological 
pattern (p=0.063), base functional state (p=0.49) or a history of 
smoking (p=0.19); nevertheless, Klotho overexpression was greater 
amongst exon 19 deletion carriers (p=0.030) and in patients having 
the L858R mutation (p=0.009) compared to the group of subjects 
having infrequent mutations. EGFR mutation patients’ overall re-
sponse was greater in those having increased Klotho expression 
compared to the population of subjects lacking reactivity or in 
those where evolution following the administration of any type of 
reversible tyrosine-kinase inhibitor remained unknown (p=0.011). 
Overall population PFS was 16.7 months (12-21 95%CI) after direc-
ted therapy was started; PFS lasted longer in the Klotho positive 
group (positive expression 21.1 months vs. negative 13.7 months; 
p=0.032). Median OS was 28.5 months (25.8-31.2 95%CI), longer 
for patients having increased Klotho expression (31.9 versus 22.0 
months; p=0.039).
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<50% (p=0.004). Reevaluation with direct sequencing proved posi-
tive only in 24 out of 36 (67%) mutation positive samples [Table 2].  
[Table 2. ]Comparison of PNA-LNA PCR clamp vs direct sequen-
cing EGFR mutation detection sensitivity in 36 EGFR mutation 
positive materials with different %TCC.
PNA-LNA PCR clamp direct sequencing
≥50% 25/25 (100%) 22/25 (88%)
20<50% 6/6 (100%) 2/6 (33%)
≤20% 5/5 (100%) 0/5 (0%)
total 36/36 (100%) 24/36 (67%)
Conclusion: PNA-LNA PCR clamp method is characterized by high 
sensitivity of EGFR exon 19 and 21 mutations detection in tissue 
and biopsy material, particularly in samples with TCC lower than 
50%. Fixation procedures did not affect PNA-LNA PCR clamp me-
thod mutation detection effectiveness.
Keywords: Direct sequencing, EGFR mutations, NSCLC, PNA-LNA 
PCR clamp
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P1.06-045 SERUM MICRORNA AS A PREDICTIVE MAR-
KER FOR RADIATION PNEUMONITIS IN PATIENTS WITH 
INOPERABLE/UNRESECTABLENON-SMALL CELL LUNG 
CANCER (NSCLC)
Nan Bi1, Paul Stanton1, Weili Wang1, Martha Matuszak1, Randall T. 
Haken1, Feng-Ming (Spring) Kong2
1University Of Michigan/United States Of America, 2Department Of Ra-
diation Oncology, University Of Michigan And Veteran Administration 
Hospital, Currently At Gru Cancer Center, Georgia Regent University/
United States Of America
Background: Radiation pneumonitis (RP) is a major dose-limiting 
toxicity after thoracic radiotherapy (RT), with no good models 
available to accurately predict the individual risk.MicroRNAs (miR-
NAs) are found to be stable in serum and other body fluids,with 
exciting potential as novel non-invasive biomarkers. This study is to 
investigate serum microRNAs associated with RP grade ≥ 2 in in-
operable/unresectable NSCLC patients treated with definitive RT.
Methods: 134 patients with inoperable/unresectable NSCLC trea-
ted with definitive RT (18-month minimum follow-up) were eligible. 
Serum samples were collected prospectively before treatment. 
100 patients who had enough serum and reliable miRNA profile 
quality were included in this study. MiRNA profiling was performed 
using real-time PCR-based array, containing a panel of 84 miRNAs 
detectable in human bodily fluids. Spiked-in cel-miR-39 was used 
for normalization. The primary endpoint was symptomatic RP (gra-
de 2 and higher). 2-sample mean comparisons were used between 
the RP and non-RP subgroups.Stepwise Logistic regression model 
building was used to build a miRNA signature. Receiver operator 
characteristic (ROC) analysis was used to assess the predictive 
ability of single-marker and signature of RP.
Results: Of 100 patients enrolled, 17 (17.0%) patients developed 
symptomatic RP. Patients received a median of 70 Gy (34-85.6Gy) 
as predictors of response to chemotherapy in NSCLC patients.
Keyword: Non-small cell lung cancer, platinum, single nucleotide 
polymorphisms
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P1.06-044 DIAGNOSTIC VALIDATION OF PNA-LNA PCR 
CLAMP ASSAY FOR DETECTION OF EGFR EXON 19 AND 
21 MUTATIONS IN NON-SMALL CELL LUNG CANCER 
SPECIMENS.
Michal Skronski1, Paulina Jagus1, Renata Langfort2, Krystyna 
Maszkowska-Kopij3, Adam Szpechcinski1, Jacek Grudny4, Tadeusz 
Orlowski5, Kazimierz Roszkowski-Sliz4, Joanna Chorostowska-
Wynimko1
1Laboratory Of Molecular Diagnostics And Immunology, National Re-
search Institute Of Tuberculosis And Lung Diseases/Poland, 2Dept. 
Of Pathology, National Research Institute Of Tuberculosis And Lung 
Diseases/Poland, 3Outpatient Clinic, National Research Institute Of 
Tuberculosis And Lung Diseases/Poland, 4Iiii Department Of Lung Di-
sease, National Research Institute Of Tuberculosis And Lung Diseases/
Poland, 5Department Of Thoracic Surgery, National Research Institute 
Of Tuberculosis And Lung Diseases/Poland
Background: PNA-LNA PCR clamp is highly sensitive, real-time 
PCR-based laboratory technique developed to enable reliable 
detection of EGFR gene mutations in wide spectrum of tissue/
biopsy samples from NSCLC patients. The aim of the study was to 
assess diagnostic reliability of PNA-LNA PCR clamp assay in EGFR 
mutations detection in different NSCLC samples.
Methods: Evaluation was performed: (i) in reference NSCLC tis-
sue FFPE samples (n=10), (ii) in comparison to direct sequencing 
in resected NSCLC tissue (n=199) and biopsy material specimens 
(n=179) characterized by different tumor cells content (TCC) and 
fixation [Table 1].  
[Table 1.] NSCLC samples
Resected tissue Biopsy material
fresh 
-frozen
FFPE FFPE 
Cytology 
smear
84 115 115 64
 
Results: (i) PNA-LNA PCR clamp correctly detected all exon 19 
deletions and L858R mutations in the reference FFPE materials, 
including those with meager TCC (5% and 10%). (ii) In total of 
378 samples analyzed with PNA-LNA PCR clamp method EGFR 
mutations were detected in 36 (9.5%). No significant differences 
in detection efficiency were observed in reference to material (re-
sected tissue vs biopsy, p=0,3972; OR=0,7405; CI=0,3694-1,4844) 
and fixation procedure (FFPE vs fresh-frozen tissue, p=0,5459; 
OR=0,7304; CI=0,2635-2,0248; biopsy material FFPE vs cytology 
smear, p=0,4366, OR=0,6908; CI=0,272-2,7544). (iii) PNA-LNA PCR 
clamp method and direct sequencing presented high conformity 
(overall percent agreement, OPA=99%; Cohen’s Kappa score of 
0.94 (95% CI=0.9, 0.99) in n=100 samples with >50% TCC. (iv) PNA-
LNA PCR clamp presented higher sensitivity in samples with TCC 
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P1.06-047 TUMOR EXPRESSION OF TTF1 IS ASSOCIA-
TED WITH A DOUBLING OF OVERALL SURVIVAL IN PATI-
ENTS WITH ADVANCED LUNG ADENOCARCINOMAS
Matthew D. Hellmann1, Patrick D. Hilden2, Camelia S. Sima2, Mark 
G. Kris1, Natasha Rekhtman3, Jamie E. Chaft1
1Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center/
United States Of America, 2Department Of Biostatistics, Memorial 
Sloan-Kettering Cancer Center/United States Of America, 3Department 
Of Pathology, Memorial Sloan-Kettering Cancer Center/United States 
Of America
Background: Expression of thyroid transcription factor 1 (TTF1) 
is commonly assessed to diagnose lung adenocarcinomas. TTF1 
may also be an oncogenic driver. The prognostic impact of TTF1 
expression in lung cancers has been evaluated. However, small 
sample sizes, population heterogeneity, and lack of control for 
genotype or targeted therapies have limited the interpretation and 
use of TTF1 as a prognostic variable.
Methods: We examined 638 consecutive patients with newly 
diagnosed (i.e. not recurrent disease) stage IV lung adenocar-
cinomas between 01/2009 and 09/2011. TTF1 was assessed by 
immunohistochemistry (8G7G3/1, DAKO, dilution 1:100); binary 
results were recorded (positive = any nuclear reactivity; negative 
= no reactivity). The association between TTF1 status and clinical 
variables (Chi-squared and t-tests), median survival (Kaplan-Meier 
methods, compared using logrank test), and outcomes with speci-
fic chemotherapies (Cox proportional hazard) and were assessed. 
Multivariate analysis of overall survival (Cox proportional hazard) 
was performed.
Results: TTF1 was assessed in 484 (76%) patients; 80% were 
TTF1+. TTF1 positivity associated with improved survival in 
all cohorts examined, although the EGFR cohort is limited by 
the small number of TTF1 negative tumors. TTF1+ was more 
common in EGFR (93%) than KRAS (76%) mutants (p<0.01). 
of RT with a mean lung dose (MLD) of 16.9 Gy (2.1-25.5 Gy). Serum 
miRNA profiling identified pre-treatment expressions of 9miRNAs 
were significantly associated with risk of RP (p<0.05). Significant 
correlations were not found for any clinical or dosimetric parame-
ters including age, gender, stage, MLD (p>0.05). Stepwise regres-
sion modeling identified only has-miR-191 as significant predictors 
of symptomatic RP (HR=4.94, 95%CI:1.46-16.66, p=0.01). Using 
ROC curves, we found has-miR-191 was independent predictors of 
symptomatic RP (p=0.01). A model of combining has-miR-191 and 
MLD had AUC of 0.72 (p=0.004) comparing to 0.64 of MLD alone 
(p=0.08).
Conclusion: In our preliminary analysis, baseline serum has-
miR-191 may help predictingsymptomaticRP. However, analysis 
on larger and independent datasets will be required to verify our 
findings.
Keywords: NSCLC, Radiation-induced pneumonitis, MicroRNAs/
blood, Gene expression profiling
POSTER SESSION 1 - PROGNOSTIC AND PREDICTIVE BIOMARKERS  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.06-046 PROGNOSTIC RELEVANCE OF THE QUANTI-
FICATION OF CIRCULATING TUMOR CELLS BY MEAN 
EPITHELIAL MARKERS IN ADVANCED NON-SMALL CELL 
LUNG CANCER PATIENTS.
Sae Muniz-Hernandez1, Oscar Arrieta2, Benjamin Pineda3, Graciela 
Ordoñez3, Jose R. Borbolla-Escoboza4
1Subdireccion De Investigacion Basica, Instituto Nacional De Cancerolo-
gia/Mexico, 2Thoracic Oncology Clinic And Laboratory Of Experimental 
Oncology, Instituto Nacional De Cancerología (INCAN)/Mexico, 3Neu-
roimmunology Unit, National Institute Of Neurology And Neurosur-
gery Of Mexico/Mexico, 4México, Central America & The Caribbean, 
Boehringer-ingelheim Oncology/Mexico
Background: Measurement of CTCs is being increasingly recog-
nized as a promising tool in oncology. Several studies have evalua-
ted CTC in early and locally advance disease; however, few studies 
have evaluated the prognostic impact of the quantification of CTCs 
in advanced disease. The aim of this work was to quantify CTCs in 
peripheral blood through the simultaneous use of three epithelial 
markers in patients with stages IIIB (pleural effusion) and IV in NS-
CLC.
Methods: Seventy advanced NSCLC patients were included in the 
study. All patients received platinum-based chemotherapy in first 
line treatment. Peripheral blood was obtained of each participant, 
circulating tumor cells were quantified by RT-PCR using three mar-
kers: CK-18, CK-19 and CEA. The expression levels of CEA, CK-18 
and CK-19 mRNA were quantified from a standard curve using the 
cDNA obtained from A549 cells. The protocol was registered in 
ClinicalTrials.gov (NCT01052818).
Results: We found a significant statistical correlation between 
levels of CK-18, CK-19 and CEA mRNA. CTC was lower in patients 
with oligometastatic disease; higher CTCs determinate by CEA 
mRNA levels was associated a worse progression-free survival to 
platinum-based chemotherapy and overall survival.
Conclusion: Detection of high CTC numbers by RT-PCR using CEA 
as a biomarker is useful as a prognostic marker in patients with 
advanced NSCLC.
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of cancer do not affect survival. In average 8 ± 5,5 (range 3-28) 
lymphnodes were resected in 3 ± 1,3 stations (range 2-7): neither 
numbers of lymphnodes resected nor number of stations exami-
ned affect survival. All MicroRNAs considered were compared to 
the pathological and clinical variables.
Conclusion: T1N0 non small cell lung cancer have a good survival 
with a low recurrence rate. In our experience histology, grading 
and the kind of resection (wedge resection and segmentectomy vs 
lobectomy) do not seem to influence recurrence rate and the pro-
gnosis. MicroRNAs tools have a good potential role as prognostic 
and predictive factors in lung cancer.
Keyword: early stage, non small cell lung cancer, microRNA, sur-
vival
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P1.06-049 ANALYSIS OF TN ANTIGEN AND ITS RELATI-
ONSHIP WITH CLINIC, HISTOLOGIC AND BIOMARKERS 
PROFILE IN PATIENTS WITH NON-SMALL-CELL LUNG 
CANCER (NSCLC).
Diego Touya1, Nora Berois2, Carmen Behrens3, Luisa M. Solis3, 
Rafael Alonso4, Mario Varangot1, Ignacio Wistuba3, Eduardo Osi-
naga2
1Departament Of Oncology, School Of Medicine, University Of The Re-
public/Uruguay, 2Laboratory Of Glycobiology And Tumor Inmunology, 
Institut Pasteur/Uruguay, 3The University Of Texas MD Anderson 
Cancer Center/United States Of America, 4Departament Of Quantitati-
ve Methods, School Of Medicine, University Of The Republic/Uruguay
Background: The Tn antigen (GalNAc alpha-O-Ser/Thr), a product 
of incomplete O-glycosylation, is expressed in about 90% of hu-
man carcinomas, but not in normal human tissues, being associa-
ted with poor prognosis in breast cancer. There is no information 
about the relationship between Tn antigen expression and clinical 
outcome of patients with lung cancer. Aim: To study the frequency 
of expression of the Tn antigen in a large set of surgically resected 
NSCLC tumor tissues, and its association with clinical, pathological 
and molecular characteristics including patient’s recurrence-free 
survival (RFS) and overall survival (OS).
Methods: We used tumor tissue microarrays containing 426 NS-
CLCs, including 281 adenocarcinomas (ADC) and 145 squamous 
cell carcinomas (SCC). We performed immunohistochemistry using 
the murine monoclonal antibody 83D4. The expression of the Tn 
antigen was quantified using a four-value intensity score (0, 1+, 2+, 
and 3+) and the percentage (0-100%) of tumor stained cells. The fi-
nal score obtained was in the range 0-300. The patients were divi-
ded into 2 groups: those who received neoadjuvant chemotherapy 
(WNA) (n=67), and those without this treatment (WONA) (n=359).
Results: We found frequent Tn antigen expression in NSCLC. 
ADCs expressed high levels of the Tn antigen in 72.7% of cases 
while in SCCs Tn antigen was found in 27.3% of cases (p<0,004). In 
relation to smoking, patients with positive smoking history (smo-
kers and former smokers) presented statistically higher expression 
of Tn than nonsmokers, (p = 0.001). We observed a trend of the 
Tn antigen expression in favor of male, Caucasian, under 70 years, 
adjuvant treatment and stage higher than I, not statistically signifi-
cant. In patients with ADC but without neoadyuvant treatment, we 
found a statistically significant correlation of Tn antigen expression 
To reduce confounding from the effect of targeted therapy on 
survival, subsequent analyses excluded those with EGFR (n=129) 
mutations or ALK (n=12) rearrangements: In multivariate analysis, 
the HR for survival in TTF1+ patients was 0.42 (p<0.001), excee-
ding the prognostic impact of good performance status (KPS≥80, 
HR=0.54, p<0.001). There was no association between TTF1 and 
age (p=0.96), sex (p=0.41), smoking status (p=0.68), or perfor-
mance status (p=0.07). TTF1 status did not predict improved out-
comes with specific chemotherapies.
Conclusion: TTF1+ robustly and independently associates with im-
proved survival in advanced lung adenocarcinomas. TTF1 exceeds 
the prognostic impact of clinical features (e.g. KPS) more common-
ly used to stratify patients. TTF1 should be assessed in all lung 
adenocarcinomas and should be used to stratify patients enrolled 
in clinical trials. Randomized trials are needed to conclusively as-
sess if TTF1 predicts differential sensitivity to chemotherapies.
Keyword: TTF1, adenocarcinoma, prognosis, chemotherapy
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P1.06-048 AN EXTENSIVE ANALYSIS ON T1AN0 NON-
SMALL CELL LUNG CANCER: FROM SURGERY TO PA-
THOLOGY.
Pietro Bertoglio1, Marco Lucchi1, Laura Boldrini2, Gabriella Fonta-
nini2, Alfredo Mussi1
1Cardiac And Thoracic Department - Division Of Thoracic Surgery, Azi-
enda Ospedaliero-universitaria Pisana/Italy, 2Division Of Pathological 
Anatomy, Azienda Ospedaliero-universitaria Pisana/Italy
Background: Unfortunately, non-small cell lung cancers are often 
diagnosed at an advanced stage. Early stage, and particularly 
T1aN0 NSCLCs, still represent a small percentage of all lung can-
cers at the moment of diagnosis. Research on early stage lung 
cancer may lead to discover new molecular insights which, hope-
fully, will reflect on new treatment opportunities: in particular, 
MicroRNAs (miRNAs) play a key role in cancer pathogenesis. We 
retrospectively reviewed our recent experience on surgically resec-
ted T1aN0 non small cell lung cancers, focusing on their surgical, 
histological, and molecular characteristic.
Methods: From 2000 to 2010 we operated 114 T1aN0 non small 
cell lung cancers (81 male and 33 female). Most of them (90; 
78,94%) underwent a lobectomy, 11 (9,65%) a segmental resection 
and in 13 cases (11,40%) a wedge resection; systematic lymph-
adenectomy was always performed. Operation was performed in 
104 (91,23%) cases by thoracotomy (either posterolateral or lateral), 
3 (2,63%) by VATS surgery and in 7 (6,14%) cases by robot assisted 
technique. All specimens were reviewed by two pathologists: 48 
(42,10%) were invasive adenocarcinoma, 14 (12,28%) in situ/mini-
mally invasive adenocarcinoma, 51 (44,74%) squamous cell carcino-
ma and 1 (0,88%) anaplastic carcinoma. Furthermore we evaluated 
Let-7g, miR-21 and miR-205 expression and their prognostic and 
predictive value.
Results: With a mean follow-up of 67 months, the 5-year overall 
survival is 75,00%. Recurrence occurred in 25 cases (21,93%), with 
a average disease-free interval of 26 months: 7 cases had a local 
recurrence, while 18 patients had distant metastasis. No correlati-
on between survival, the kind of intervention performed, histology 
and cancer grading was found. Furthermore, maximum diameter 
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with cisplatin+vinorelbine, monitoring, post-recurrence care, and 
chemotherapy adverse events. We calculated the incremental 
cost-effectiveness ratio (ICER), and evaluated uncertainty using 
one-way and probabilistic sensitivity analyses. We also evaluated 
non-predictive and strong predictive (based on Zhu et al.’s JBR.10 
reanalysis) chemotherapy benefit scenarios. Our analyses used a 
lifetime horizon, a payer perspective, and a 3% discount rate. 
Results: The PervenioTM and standard care strategies resulted in 
55% and 33% of patients receiving chemotherapy, respectively. 
Life year, QALY, and cost outcomes are displayed in Table 1. The 
corresponding base case PervenioTM strategy ICER was $22,270/
QALY (Stage I: $29,210/QALY; Stage II: $12,190/QALY). One-way 
sensitivity analyses demonstrated that the proportion of high-risk 
patients receiving chemotherapy and the high-risk recurrence ha-
zard ratio were the most influential inputs. Probabilistic sensitivity 
analyses demonstrated that the PervenioTM strategy was cost-
effective at a willingness to pay threshold of $50,000/QALY in 68% 
of simulations.
Conclusion: The results of our analysis suggest that in the U.S., 
the PervenioTM Lung RS assay may be a cost-effective alternative 
to a standard care strategy in early-stage NSCLC. Future studies 
should evaluate the presence and magnitude of a differential che-
motherapy benefit by risk group and post-testing chemotherapy 
preferences,as these were key determinants of model results.
Keyword: Pervenio, Early-Stage, NSCLC, Cost-Effectiveness
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P1.06-051 DEVELOPMENT OF A SERUM BIOMARKER 
PANEL PREDICTING CLINICAL OUTCOME OF CHEMO-
THERAPY WITH PEMETREXED IN PATIENTS WITH NSCLC
Jeffrey A. Borgia1, Marta Batus2, Mary Jo Fidler3, Shruthi Melina-
mani4, Ravi Pithadia5, Sanjib Basu6, Cristina Fhied5, Brett Mahon5, 
Philip Bonomi2
1Pathology And Biochemistry, Rush University Medical Center/United 
States Of America, 2Department Of Medical Oncology, Rush University 
Medical Center/United States Of America, 3Medical Oncology, Rush 
University Medical Center/United States Of America, 4Rush University 
Medical Center/United States Of America, 5Pathology, Rush University 
Medical Center/United States Of America, 6Department Of Preventive 
Medicine, Rush University Medical Center/United States Of America
Background: Pemetrexed disodium is a novel folate antimetaboli-
te approved for first-line treatment in combination with a platinum 
doublet, for second-line treatment as a single agent and, more 
recently, as maintenance treatment after first-line chemotherapy in 
patients with non-squamous non-small cell lung cancer (NSCLC). 
Circulating factors associated with folate metabolism and/or phe-
with positive smoking history too (p = 0.001) and its expression is 
different according the histology pattern, showing higher value in 
solid histology pattern and lower in lepidic, papilar and acinar his-
tology pattern. Using Spearman Correlation test, Tn antigen cor-
related significantly with EpCAM-N (n = 393, r = 0.20, p = 0.001), 
EpCAM-C (n = 391, r = 0.12, p = 0.01), TTF-1 (n = 250, r = -0.29 p 
= 0.001), mutated EGFR status (p = 0.001) and KRAS (p = 0.01) and 
not with EML4-ALK fusion gene (p = NS). Interestingly, in the ADC-
WONA subset, the high level of Tn antigen, are significantly asso-
ciated with poor prognosis in RFS (p <0.04, HR = 1.45) and strong 
tendency in OS (p = 0.06, HR = 1.47). In the group ADC-WNA, high 
level of Tn antigen was significantly associated with poor prognosis 
in OS (p <0.02, HR = 2.84) and no difference in RFS. Patients with 
SCC in both groups, with or without neoadjuvant, showed no diffe-
rence in prognosis regarding Tn antigen expression.
Conclusion: Tn antigen is frequently expressed in NSCLC and 
associates with worse prognosis in patients with ADC. Our data 
showed a significant correlation between the Tn antigen expres-
sion and other useful molecular markers in lung cancer (EPCAM, 
TTF-1, EGFR and KRAS), opening a new possible candidate for 
targeted therapy.
Keyword: Tn Antigene, NSCLC, adenocarcinoma, worse prog-
nostic
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P1.06-050 COST-EFFECTIVENESS OF THE PERVENIO™ 
RISK-SCORE (RS) ASSAY IN EARLY-STAGE NON-SMALL 
CELL LUNG CANCER
Joshua A. Roth1, Paul Billings2, Scott D. Ramsey1, Robert Duma-
nois2, Josh J. Carlson3
1Public Health Sciences, Fred Hutchinson Cancer Research Center/Uni-
ted States Of America, 2Life Technologies/United States Of America, 
3Pharmacy, University Of Washington/United States Of America
Background: Life Technologies Clinical Services Laboratory has 
developed a 14-gene molecular assay (PervenioTM Lung RS) that 
provides mortality risk stratification in resected early-stage non-
squamous non-small cell lung cancer (NSCLC). The test classifies 
patients as low, intermediate, or high-risk (for death), informing 
decisions about use of adjuvant chemotherapy. Accordingly, a 
high-risk sub-group can be identified to receive chemotherapy, 
and a low-risk sub-group can avoid chemotherapy-associated 
morbidity and costs. The objective of this study was to evaluate 
the cost-effectiveness of the PervenioTM assay in Stage I/II NSCLC 
relative to standard care.
Methods: We developed a Markov model to estimate life expec-
tancy, quality-adjusted life-years (QALYs), and costs for PervenioTM 
testing versus standard care. Risk-group classification was based 
on PervenioTM validation studies, and chemotherapy uptake was 
based on a study of pre/post testing recommendations from 58 
surgeons and oncologists. We derived overall chemotherapy 
benefit from Lung Adjuvant Cisplatin Evaluation (LACE) databa-
se disease-free survival hazard ratios. In the PervenioTM strategy, 
we differentially distributed chemotherapy benefit across risk 
groups, with high-risk patients deriving the greatest benefit, 
intermediate-risk patients deriving moderate benefit, and low-
risk patients experiencing the least benefit (Table 1). Included 
costs were those related to the PervenioTM test, chemotherapy 
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P1.06-052 BIOMARKERS OF PHENOTYPIC PLASTICITY 
ASSOCIATED WITH CLINICAL OUTCOMES IN PATIENTS 
WITH LOCALLY-ADVANCED NSCLC TREATED WITH CHE-
MORADIATION WITH AND WITHOUT SURGERY.
Marta Batus1, Mary Jo Fidler1, James Clark1, Ellis Ziel1, Mark Pool1, 
Sanjib Basu2, David Sher2, Lela Buckingham2, Micheal Liptay2, 
Gary Chmielewski2, William Warren2, Kelly Kaiser-Walters2, Shru-
thi Melinamani2, Brett Mahon2, Jeff Borgia2, Philip Bonomi2
1Medical Oncology, Rush University Medical Center/United States Of 
America, 2Rush University Medical Center/United States Of America
Background: Thoracic chemoradiotherapy (CRT) with or without 
surgery (S) is the standard-of-care in management of stage III 
NSCLC. However, it appears that plateau has been reached. New 
treatment strategies are needed. The objective of this retros-
pective study was to evaluate the relationships between patient 
outcomes and expression of biomarkers associated with either 
the epithelial-to-mesenchymal transition, or EMT ( E-cadherin and 
vimentin), or a lung cancer “stem-cell” phenotype (CD133), DNA 
repair enzyme (ERCC1), and cell survival/apoptosis (BCL-2, survi-
ving and PTEN) in attempt to identify new therapeutic strategies.
Methods: Stage III NSCLC pts who were treated with chest radiati-
on (40-65Gy) and concurrently with platinum doublet and who had 
sufficient pretreatment tissue were included in this study. Surgical 
pts received 40-45 Gy of radiation preoperatively and non-surgical 
patients received 60-65 Gy. Immunohistochemistry was used to 
detect nuclear and cytoplasmic expression of ERCC1, bcl-2, sur-
vivin, PTEN, vimentin, E-cadherin, and CD133. Scores were calcu-
lated using the Allred scoring system. The log-rank tests used to 
evaluate progression free survival (PFS) and overall survival (OS) 
with Kaplan-Meier plots used to plot group characteristics.
Results: A total of 119 patients receiving chemoradiotherapy with 
adequate tumor specimens for analysis were enrolled in this study; 
61 had definitive chemoradiation whereas 58 had pulmonary resec-
tion after chemoradiation. Patients (n=79) with low nuclear survivin 
immunostaining (score ≤6) had significantly improved PFS as com-
pared to those patients (n=34) with higher expression levels (14.1 
vs. 10.5 months, p=0.042). Patients (n=72) with a cytoplasmic vi-
mentin score ≤ 5 had superior PFS than the with higher expression 
levels (n=33) (13.17 vs. 9.99 months, p=0.045). High nuclear ERCC1 
values (n=72) were associated with a worse OS than those patients 
(n=44) with low immunostaining (22.7 vs. 59.1 months; p=0.023). 
Patients with low cytoplasmic E-cadherin (n=25) had a significantly 
better OS than those patients (n=85) with immunostaining scores 
(62.6 vs. 24.6 months, p=0.036). The cytoplasmic vimentin/ E-
cadherin ratio provided the most impressive separation of cohort 
performance with high V/E ratios being associated with a poor PFS 
(12.6 vs. 3.1 months; score ratio 10 cutoff; p=0.00073). No signi-
ficant associations with cytoplasmic CD133 were observed in this 
cohort for either PFS or OS.
Conclusion: The association of inferior overall survival in locally-
advanced NSCLC patients whose tumors express high ERCC1, high 
cytoplasmic E-cadherin (which is associated with mesenchymal 
phenotype and lower adherence of cells which are able to metas-
tasize easier), and lower progression free survival with high survivin 
and high vimentin/ E-cadherin ratio suggests that combining inhi-
bitors of survivin, DNA repair, EMT pathways might improve outco-
mes in molecularly defined subset of stage III NSCLC patients.
notypic plasticity (e.g. the epithelial-to-mesenchymal transition 
(EMT)) may have predictive value in selecting advanced NSCLC for 
first-line pemetrexed. The objective of this study was to identify 
serum biomarkers capable of predicting improved outcomes for 
pemetrexed added to first-line platinum based chemotherapy 
relative to standard platinum doublet.
Methods: Pretreatment serum from a total of 72 patients with 
non-squamous stage IV NSCLC was evaluated with 76 biomarkers 
using Luminex immunobead assays. Patients were treated either 
with platinum combined with pemetrexed (P: n= 26) or with other 
agents (O; n=51) at the discretion of the treating physician. Pati-
ents were evaluated for disease progression using RECIST criteria. 
Biomarker data was processed using Ingenuity Pathway Analysis 
(IPA) Suite to identify interactions with folate metabolism. Cox 
Proportional Hazard (PH) regression model was used to assess the 
association between H-scores and progression-free/overall survival 
(PFS/OS) distribution estimated by the Kaplan-Meier method. PH 
interaction model was used to capture the differential effects of 
the biomarkers on the O vs. P treatment groups.
Results: Univariate PH regression analysis identified 10 biomarkers 
that were negatively associated (p<0.05) with progression-free 
survival (PFS) in either the O (sTNF-RI, sTNF-RII, Tenascin C, sIL-
2Rα, spg130, sIL-6R, CA-125, and CA 19-9) or the P subgroups 
(total PSA, amphiregulin). Four other biomarkers (MMP-1, MMP-2, 
sVEGFR2, and PDGF-B) were all significantly (p<0.05) positively as-
sociated with PFS in the P group. Similarly, seven biomarkers were 
strongly negatively associated (p<0.01) with overall survival (OS) 
in the O group, including osteopontin, sTNF-RI, sTNF-RII, CA 15-
3, sIL-2Rα, CYFRA 21.1, and IL-6; whereas the P group possessed 
both negative (osteopontin and amphiregulin) and positive (sVEG-
FR2, MMP-1, MMP-2, and sRAGE) associations (P<0.05) with OS. In 
our assessment of differential association with PFS, we found two 
serum biomarkers (PSA (total) and amphiregulin) with significant 
positive interaction terms, thus indicating differentially increa-
sed hazard of progression in the P group with higher level of the 
biomarker. MMP-1, HGF, and Tenascin C, sVEGFR2 were similarly 
noted to have significant negative interaction terms for PFS. Evalu-
ations of the differential associations with respect to OS, demons-
trated five biomarkers with significant (MMP-1, MMP-2, sVEGFR2, 
sTNF-RI, and Tenascin C; p≤0.05) and three strongly associated 
(osteopontin, HGF, s-IL-6R; p≤0.01) negative interaction terms, 
demonstrating a decreased hazard of progression in the P group.
Conclusion: Serum biomarkers with potential predictive (PFS, OS) 
value for selecting patients most likely to benefit from pemetrexed 
have been identified. Pathway analysis demonstrates interactions 
of biomarker candidates identified with folate metabolism. This 
study is currently being expanded with additional front-line pati-
ents (P=90; n=56) from our institutional archives to further evaluate 
their potential predictive value.
Keywords: pemetrexed, biomarker, serum, therapy selection
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creases in Ang1 and VEGFA were observed. The median survival 
overall was 16.8 months at a median follow up of 12 months. In 
univariate analysis there were non-significant trends to worse sur-
vival for older patients, weight loss >5%, higher TNM stage, higher 
co-morbidity scores and current smokers. Better survival was ob-
served for patients with higher baseline levels of IL1b (p = 0.005) 
and TNFa (p = 0.022).
Conclusion: Preliminary analysis demonstrates appreciable chan-
ges of various circulating biomarkers during RT and identifies in-
terleukin-1 beta and tumor necrosis factor alpha as potential prog-
nostic factors. Multivariate analyses and correlation of biomarkers 
with response and toxicity are ongoing and will be presented.
Keywords: Prognostic, inflammatory cytokines, radiotherapy, cir-
culating biomarker
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P1.06-054 TARGETING MCL1 AMPLIFICATION IN NSCLC 
THROUGH ANTHRACYCLINE-MEDIATED TRANSCRIPTI-
ONAL SUPPRESSION
Sara Busacca1, Edward Law1, Kathy Gately2, Kenneth J. O’Byrne2, 
Egbert F Smit3, Harry J.M. Groen4, Jillian Harrison5, Athanasios 
Pallis5, Baktiar Hasan5, Howard Pringle1, Dean A. Fennell1
1Department Of Cancer Studies And Molecular Medicine, University Of 
Leicester/United Kingdom, 2Research Institute Of Molecular Medicine, 
St. James Hospital/Ireland, 3Pulmonary Diseases, VU University Medi-
cal Center/Netherlands, 4Pulmonary Diseases, UMC Groningen/Nether-
lands, 5European Organisation For Research And Treatment Of Cancer 
(EORTC)/Belgium
Background: Targeting oncogene dependency for effective the-
rapy has been one of the most successful strategies for managing 
metastatic non-small cell lung cancer (NSCLC). Although validating 
therapeutically tractable oncogenic driver mutations are a major 
focus, non-driver mutations may also confer dependencies that 
may also be exploitable. The prosurvival BCL2 protein, MCL1 pre-
vents mitochondrial apoptosis by blocking interaction of proapo-
ptotic BH3 only proteins with their multidomain proapototic coun-
terparts, BAX and BAK. MCL1 is often mutated in cancers, and 
ranks as one of the most frequently amplified loci at 1q21.2. MCL1 
amplified tumours exhibit addiction to this oncogene. Anthracyc-
lines have been shown to transcriptionally suppress MCL1. Phase 
IIA studies in NSCLC have shown that epirubicin has useful single 
agent activity in unselected patients, with a significantly greater 
response rate than that achieved with standard chemotherapy. We 
therefore set out to evaluate MCL1 addiction in NSCLC, its corre-
lation with anthracyline induced apoptosis and the prevalence of 
1q21.2amplification to support a planned 1q21.2 stratified phase II 
trial in NSCLC, (EORTC-1303-LCG).
Methods: RNAi targeting MCL1was conducted in NCI-H460, 
NCI-H1299, NCI-H28 and NCI-H23 cell lines. Doxorubicin activity 
was measured by viability assay and apoptosis was assessed by 
western blot. gDNA from cell lines was obtained by Phenol-Chlo-
roform extraction. The QIAamp DNA FFPE Tissue Kit was used to 
extract gDNA from FFPE tissues. MCL1 amplification was quan-
tified by real-time PCR with a set of two primers and one probe 
(minor groove-binding (MGB) hydrolysis probe assay) for the gene 
of interest MCL1 and the two reference genes CCT3 and H6PD. 
Tonsil samples were used as a control diploid population.
Keywords: vimentin, E-cadherin, Biomarkers, locally advanced 
NSCLC
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P1.06-053 CLINICAL UTILITY OF CIRCULATING SERUM 
AND PLASMA BIOMARKERS FOR PERSONALISED RA-
DIOTHERAPY TREATMENT OF NON-SMALL CELL LUNG 
CANCER (NSCLC)
Corinne Faivre-Finn1, Fiona Blackhall2, Alison Backen3, Clare 
Hodgson3, Pek Koh4, Emma Dean4, Lynsey Priest5, Caroline Dive5, 
Andrew Renehan5
1Radiotherapy Related Research, The Christie NHS Foundation Trust/
United Kingdom, 2Manchester University And The Christie NHS Foun-
dation Trust/United Kingdom, 3The Paterson Institute/United Kingdom, 
4The Christie NHS Foundation Trust/United Kingdom, 5Paterson Insti-
tute For Cancer Research, University Of Manchester/United Kingdom
Background: Personalised strategies that tailor radiotherapy (RT) 
dose and schedule according to clinical and molecular factors, 
novel drug-RT combinations and/or advanced RT techniques are 
needed to optimise outcomes from RT for NSCLC. Development of 
such approaches would benefit from objective measures to inform 
on survival, chance of response and/or toxicity. We evaluated 26 
circulating proteins and cytokines implicated in angiogenesis, me-
tastasis, apoptosis, hypoxia and inflammation for prognostic (sur-
vival), predictive (RT response/toxicity) and/or pharmacodynamic 
significance in the context of RT for stage I-III NSCLC.
Methods: NSCLC patients donated blood prior to, serially and on 
completion of RT treatment. Samples were analysed for cell death 
(M30, M65, CYFRA), hypoxia (osteopontin, CA-IX), angiogenesis 
(Ang2, FGFb, HGF, VEGFA, VEGFC, PDGF, IL8, PlGF, KGF, VEGFR1, 
VEGFR2, Ang1, Tie2), metastatic (EGF, E-Selectin, VCAM1) and 
inflammatory (IL1b, IL10, IL12, TNFa, IL6) cytokines using single- 
or multi-plex ELISAs (SearchLight multiplex Aushon BioSystems, 
Peviva, R&D Systems). Clinical data were collected for age, gen-
der, performance and smoking status, ace27 co-morbidity score, 
weight loss, TNM stage, haemoglobin, treatment received, various 
lung function and RT treatment parameters, histology, treatment 
received, toxicity, response and survival. Standard statistical me-
thods were used to explore for associations and prognostic signifi-
cance (Stata version 10).
Results: Seventy-eight patients were enrolled from March 2010 to 
August 2011: 61% male; majority (44%) squamous histology; 82% 
PS 0 or 1; 72% ex-smoker; 9% stage I/II, 44% stage IIIA, 47% IIIB; 
median age 66 years (range 31-86), 42% age > 70; 20% weight 
loss of 5-10%, 11% weight loss >10%; 62% prior chemotherapy/se-
quential RT, 20% concurrent chemoradiotherapy, 18% radiotherapy 
alone. RT treatment doses administered ranged from 50-55Gy in 
20 fractions to 60-66 Gy in 33 fractions. Significant associations 
(p<0.05) were observed for EGF levels with gender and age, for 
FGFb with co-morbidity score and for IL8, IL1B and KGF with 
smoking status. Positive correlations of biomarkers at baseline 
(p<0.001) were observed for TNFa with FGFb, IL1b, IL8, IL12; FGFb 
with IL1b, IL8, IL12 KGF; IL1b with IL8, IL12; IL8 with KGF, IL12; KGF 
with IL12. In the overall population, at day 8 during RT significant 
decreases were observed for Ang2, EGF, E Selectin, FGFb, HGF, 
VCAM1, VEGFC & VEGFR2. Post completion of RT Ang2, EGF, E 
Selectin, FGFb, HGF & VEGFC levels remained significantly lower 
than at baseline prior to RT, and in addition significant global de-
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the expression of MSP and RON at the mRNA (RT-PCR) and protein 
(Western blot) level. The effect of MSP, IMC-RON8 (a humanised 
IgG1 monoclonal antibody), LCRF004 (a small molecule inhibitor) 
and NRWHE (a small peptide) was examined in the H226 cell line 
using proliferation (BrdU ELISA), apoptosis (Multi-parameter apop-
tosis assay) and migration assays (xCELLigence). A phospho-kinase 
proteome profiler array was utilised to detect the downstream 
signalling pathways activated upon MSP stimulation. The expressi-
on of MSP and the macrophage marker, CD-68, was examined by 
IHC using MPM TMAs. Studies are ongoing to determine the effect 
of the LCRF004 compound in vivo using a xenograft murine model 
with the H226 cells.
Results: The mRNA and protein levels of RON and MSP were 
differentially expressed in a panel of MPM cell lines. Treatment 
with LCRF004 resulted in significantly decreased proliferation and 
increased apoptosis in the H226 cells. MSP was unable to rescue 
the cells from the effects of LCRF004. NRWHE and RON8 had little 
effect on either proliferation or apoptosis. All of the compounds 
examined inhibited the migration capacity of the H226 cells. The 
combination of LCRF004 and MSP produced a synergistic effect, 
showing greater inhibition of migration than either compound 
alone. However, MSP treatment resulted in the up-regulation of a 
number of phosphor-kinases including Akt, ERK and the Src family. 
Currently, a number of proteins identified in the array studies are 
undergoing validation. Results of an in vivo H226 murine model 
using the LCRF004 compound will be presented at the meeting.
Conclusion: From previous work performed in this laboratory, we 
have determined that high expression of RON in MPM is an inde-
pendent predictor of favourable prognosis. IHC was performed on 
a TMA of MPM patient samples and high expression levels of MSP 
correlated with better survival. There was no association between 
CD68 staining and MSP, nor correlation of CD68 expression with 
survival. Targeting the RTK domain of the RON receptor with a 
small molecule inhibitor is an effective interventional strategy in 
MPM. The seemingly counter intuitive results obtained from the 
MPM TMA studies and the in vitro experimental data, may be RON 
isoform dependant. Additional studies are ongoing to further deli-
neate the RON-MSP axis in MPM.
Keywords: mesothelioma, RON (MST1R), MSP
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P1.06-056 ISOLATION & ENUMERATION OF CIRCULA-
TING TUMOR CELLS IN NON-SMALL CELL LUNG CAN-
CER, USING SCREENCELL & VITAASSAY TECHNIQUES.
John O‘Flaherty1, Steven Gray1, Martin Barr1, Kathy Gately1, Ken-
neth O‘Byrne2
1Thoracic Oncology Research Group, Institute Of Molecular Medicine, St. 
James‘s Hospital/Trinity College Dublin/Ireland, 2Queensland Universi-
ty Of Technology, Cancer & Ageing Research Program/Australia
Background: Circulating Tumour Cells (CTCs) have been the sub-
ject of much interest as a potential biomarker however methods 
for isolating CTCs are still in their infancy. A promising method of 
CTC detection is ScreenCell. This technique uses polycarbonate 
filtration membranes containing multiple tiny pores. When blood is 
made to flow across the membrane, tumour cells are captured due 
to their greater size. Another such method is the use of the modi-
fied invasion assay, VitaAssay. This technique uses CAM (Collagen 
Results: MCL1 silencing efficiently induced apoptosis in a subset 
of NSCLC cells, however we identified two cell lines that were 
resistant to MCL1 knockdown (NCI-H1299 and NCI-H28). Doxoru-
bicin efficiently induced apoptosis in MCL1 addicted cells but ex-
hibited significantly less activity in cells that were not addicted. We 
developed a genomic DNA based quantitative real time PCR assay 
to evaluate copy number variation (CNV) at the 1q21.2 locus. A 
clear correlation r2 >0.91 was observed for 1q21.2 CNV compared 
with reference Conan Copy Number Analysis Tool (Cancer genome 
project, Sanger). Increased 1q21.2 copy number was consistently 
associated with MCL1addiction; however addiction also occurred 
in cells lacking 1q21.2 CNV, suggesting that MCL1 amplification 
represents a subset of MCL1 dependence. The concentration of 
doxorubicin was titrated against MCL1 protein downregulation 
into therapeutically sub-micromolar concentration range and we 
observed that MCL1 downregulation occurred coincidently with 
cleavage of poly-ADP ribose polymerase. We then screened DNA 
isolated from 19 adenocarcinomas, and identified 1q21.2 CNVs in 
36.8%, with high level amplification (CNV >5) in 1q21.2 in 10.5%.
Conclusion: Targeting MCL1 addiction in 1q21.2 amplified NSCLC 
induces apoptosis and this dependence can be exploited by an-
thracyclines at therapeutically relevant concentrations. Given its 
significant prevalence in NSCLC, our data suggests that 1q21.2 
amplification could be a novel non-driver mutation predictive for 
anthracycline response.
Keywords: Mcl-1, doxorubicin, 1q21.2 amplification
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P1.06-055 THE RON (MST1R)/MSP PATHWAY IS A PO-
TENTIAL THERAPEUTIC TARGET IN MALIGNANT PLU-
RAL MESOTHELIOMA
Anne-Marie Baird1, Kenneth O‘Byrne2, David Easty1, Liam Shiels3, 
Annette Byrne3, Alex Soltermann4, Daisuke Nonaka5, Dean Fen-
nell6, Luciano Mutti7, Harvey Pass8, Isabelle Opitz9, Steven Gray1
1Thoracic Oncology Research Group, St. James‘s Hospital/Trinity Col-
lege Dublin/Ireland, 2Queensland University Of Technology, Cancer & 
Ageing Research Program/Australia, 3Royal College Of Surgeons In 
Ireland/Ireland, 4Institute Of Pathology, Universitäts Spital Zürich/
Switzerland, 5The Christie NHS Foundation Trust/United Kingdom, 
6University Of Leicester/United Kingdom, 7Medicine, Vercelli Hospital/
Italy, 8Nyu Langone Medical Center/United States Of America, 9Division 
Of Thoracic Surgery, University Hospital Zurich/Switzerland
Background: Malignant pleural mesothelioma (MPM) is an ag-
gressive inflammatory cancer. Treatment options are limited and 
drug resistance is common. Thus, there is a need to identify novel 
therapeutic targets in this disease in order to improve treatment 
options and survival times. Macrophage stimulating protein (MSP) 
is the only ligand recognised to bind to the RON receptor (MST1R). 
RON is a member of the MET proto-oncogene family. The MSP-
RON signalling pathway has been implicated in a variety of cellular 
functions such as macrophage morphogenesis and phagocytosis. 
De-regulation of this pathway has been linked to tumour progres-
sion and metastasis in a number of cancers. We have previously 
identified RON as frequently activated in MPM and high positivity 
for RON by IHC was an independent predictor of favourable pro-
gnosis.
Methods: A panel of mesothelioma cell lines were screened for 
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P1.06-057 INCIDENCE AND SIGNIFICANCE OF TUMOR 
EGFR AND KRAS MUTATIONS IN GREEK METASTATIC 
NON-SMALL CELL LUNG CANCER PATIENTS TREATED 
WITH 1ST LINE CHEMOTHERAPY.
Helena Linardou, Dimitrios Pectasides, Sophia Agelaki, Vassiliki 
Kotoula, Vasilios Karavasilis, Anastasia G. Eleftheraki, Epami-
nondas Samantas, Athanasios Kotsakis, Evangelia Razis, George 
Fountzilas
Hellenic Cooperative Oncology Group/Greece
Background: KRAS mutations are reported in 20-25% of non-small 
cell lung cancer (NSCLC). Little is known about the prognostic/
predictive role of KRAS in advanced NSCLC, with conflicting re-
sults among small studies, while recent evidence showed that they 
could predict for worse outcome in patients treated with platinum-
based adjuvant chemotherapy. Evidence is also inconclusive on the 
prognostic role of EGFR mutations. Given that ethnicity may play 
a role on the mutational profiling of NSCLC, we report here on the 
first large scale mapping of NSCLC in Greek patients.
Methods: KRAS and EGFR genotypes were evaluated in 634 NS-
CLC patients with available clinical data, diagnosed from March 
2000 to December 2012 (tissue blocks from the HeCOG tumor 
repositories). KRAS and EGFR mutations were associated with clini-
copathological parameters (mutated vs. wild-type). Outcome com-
parisons were performed in 469 metastatic patients with available 
treatment data, following 1st line chemotherapy without tyrosine 
kinase inhibitors.
Results: The majority of the patients were male (78%), current 
smokers (47%), with adenocarcinoma (AC) histology (68%). EGFR 
mutations were found in 14% and KRAS mutations in 15% of all 
histological types, while in AC they were 17% and 22%, respec-
tively. Most EGFR mutations were classical (79%), while the most 
common KRAS mutations were p.G12C (35%), p.G12D (25%) and 
p.G12V (11%). Five tumors had concurrent EGFR and KRAS muta-
tions. EGFR mutations were significantly associated with female 
gender, AC histology and non-smoking status, as previously de-
scribed. KRAS mutations were associated with AC histology and 
younger age (<60). At a median follow-up of 39 months, EGFR 
status was prognostic for improved PFS (HR=0.52, 95% CI 0.35-
0.78, p=0.001), in patients treated with 1st line chemotherapy and 
no TKIs, and OS (HR=0.64, 95% CI 0.43-0.95, p=0.028). KRAS mu-
tations did not show any significant associations with OS or PFS, 
although a trend for worse outcome in KRAS mutated patients 
was observed. Furthermore, there was a significant difference 
in response to 1st line treatment according to KRAS status, with 
KRAS mutations associated with worse outcome (Clinical benefit, 
CR+PR+SD: 64.4% in wildtype vs 48.8 in mutant, and PD 23.4% in 
wildtypet vs 39.5% in mutant). No significant interaction between 
KRAS/EGFR status (EGFRmut vs. KRASmut vs. any wt) and plati-
num-based treatment was observed (p=0.975 for PFS and p=0.892 
for OS).
Conclusion: EGFR and KRAS genotype incidences are presented 
for the first time in Greek metastatic NSCLC patients. In this set-
ting, the presence of EGFR mutations shows prognostic signifi-
cance in patients treated with 1st line chemotherapy, without TKIs, 
while the presence of KRAS mutations seems to adversely affect 
the response to 1st line chemotherapy.
Keyword: KRAS, EGFR, mutations, NSCLC
Adhesion Matrix) coated plates to capture CTCs with an invasive 
phenotype.
Methods: Peripheral blood samples were obtained from patients 
with advanced NSCLC using both Screencell & VitaAssay. In ad-
dition healthy blood samples spiked with NSCLC cells were also 
analysed. ScreenCell: Peripheral blood is diluted with specified 
buffer and drawn across the Screencell filter using a vacuum tube. 
The filters with captured fixed cells are then stained with H&E and/
or immunocytochemistry. VitaAssay: Peripheral blood mononuc-
lear cells (PBMCs) were obtained by Ficoll density centrifugation. 
PBMCs were seeded onto VitaAssay plates and cultured for 12-18 
hrs. The supernatant is removed and the remaining captured cells 
are enriched for CTCs due to their invasive phenotype. Captured 
cells are fixed and stained using immunocytochemistry.
Results: Using the ScreenCell technique CTCs were identified by 
size & morphology using H&E staining. CTCs were detected in 
70% of patient samples with. (n=10) Numbers of CTCs detected 
ranged from 6-82 per ml of blood. In addition, clumps of tumour 
cells or Circulating Tumour Microemboli (CTM) were detected 
in 50% of patient samples. (An example of CTM is illustrated in 
Fig. 1) Cells captured from NSCLC patients using VitaAssay were 
stained for EpCAM/pan-Cytokeratin and CD45. EpCAM/Pan-CK 
positive, CD45 negative cells were classed as CTCs. In healthy 
blood samples spiked with A549 & H2228 cells, approximate-
ly 20% (range 9%-26.4%) of spiked cells were recovered using 
VitaAssay. In NSCLC patients an average of 30.67 CTCs per ml of 
blood were identified. (range 14-52, n = 6) (An example of CTCs 
detected by immunocytochemistry is illustrated in Figs. 2 & 3) 
Conclusion: ScreenCell & VitaAssay techniques both appear to 
be viable methods of isolating & enumerating CTCs, in both mo-
del cell-spiking experiments and in NSCLC patient samples, as 
determined by morphology and antigen expression detected with 
immunocytochemistry. Of particular interest many of the CTCs 
isolated using Screencell, were detected as clusters or microem-
boli. Additional samples are being taken to compare CTC & CTM 
numbers with clinical outcomes.
Keyword: CTC, circulating tumor cells, microemboli
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Methods: Not applicable
Results: Not applicable
Conclusion: Not applicable
Keyword: Lung cancer, Predictive biomarkers, Pharmacogenomic
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P1.06-059 COMPARISON OF THE CHARACTERISTICS 
AND CLINICAL COURSE OF PATIENTS WITH METASTA-
TIC KRAS MUTANT LUNG CANCERS
Gregory Riely1, Helena A. Yu1, Camelia S. Sima2, Ronglai Shen2, 
Samantha L. Kass1, Mark G. Kris1, Marc Ladanyi3
1Memorial Sloan-Kettering Cancer Center/United States Of America, 
2Biostatistics, Memorial Sloan-Kettering Cancer Center/United States 
Of America, 3Pathology, Memorial Sloan Kettering Cancer Institute/
United States Of America
Background: Patients (pts) with KRAS mutant lung cancers have 
a shorter survival compared to pts withKRAS/EGFR wild type 
tumors(Johnson et al, Cancer 2013). Whether outcomes for pati-
ents with KRASmutant metastatic lung cancers differ by smoking 
status or specific amino acid substitution is unknown. In order to 
understand the impact of KRAS mutation subtype in the metasta-
tic setting, we analyzed a large cohort of patients with KRAS mu-
tant metastatic lung cancer.
Methods: We identified all pts with KRAS mutant metastatic or 
recurrent lung cancers from Feb 2005 to Aug 2011. KRAS mutation 
type, clinical characteristics, and outcomes from diagnosis were 
obtained from the medical record. A multivariate cox proportion 
hazard model was used to identify factors associated with overall 
survival.
Results: KRAS mutations were identified in 677 pts (53 at codon 
13, 624 at codon 12). Median age: 66 (range 31-89), women: 62%, 
never smokers: 7%. Pts with transition mutations (n=157) were 
more likely to be never-smokers (p<0.0001). There was no diffe-
rence in outcome for pts with KRAS transition versus transversion 
mutations (p=1) or when comparing current/former smokers to 
never smokers (p=0.33). There was no difference in overall survival 
(OS) when comparing specific amino acid substitutions (G12C=366, 
G12V=141, G12D=114, G12A=68, G13C=27, G13D=23, G12S=19, 
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P1.06-058 THE PHALCIS TRIAL (PHARMACOGENOMIC 
ALIMTA CISPLATIN): A CLINICAL TRIAL IN PROGRESS BY 
THE SPANISH LUNG CANCER GROUP
Jose-Miguel Sanchez-Torres1, Delvis Rodriguez2, Juana Oramas3, 
Pilar Lopez Criado4, Jose Antonio Macias5, Joaquim Bosch6, Nati-
vidad Martinez-Banaclocha7, Pilar Diz8, Lara Iglesias9, Christian 
Rolfo10, Gaspar Esquerdo11, Oscar Juan12, Javier Garde13, M Esteller14, 
Rafael Rosell15
1Medical Oncology, Hospital La Princesa/Spain, 2Oncology, Hospital 
Universitario Insular De Gran Canaria/Spain, 3Hospital Universitario 
De Canarias/Spain, 4Medical Oncology, MD Anderson Cancer Center/
Spain, 5Medical Oncology, Hospital Morales Messeguer/Spain, 6Medical 
Oncology, Ico-girona/Spain, 7Medical Oncology, Hospital General Uni-
versitario De Elche/Spain, 8Medical Oncology, Hospital De Leon/Spain, 
9Medical Oncology, Hospital 12 De Octubre/Spain, 10Clínica Rotger/
Spain, 11Hospital Clínica Benidorm/Spain, 12Hospital La Fe/Spain, 13On-
cology, Hospital Arnau De Vilanova/Spain, 14Medical Oncology, Hospi-
tal De Tarragona/Spain, 15Medical Oncology, Hospital Germans Trias I 
Pujol/Spain
Background: The inherent molecular heterogeneity prevents the 
efforts to improve outcomes for patients with non-small cell lung 
cancer (NSCLC). Platinum doublets are the standard option for the 
treatment of advanced NSCLC, but none of the platinum-based 
combinations used offer a significant advantage over the others. 
Pemetrexed is an antifolate antimetabolite that inhibits several 
key folate-dependent enzymes, mainly thymidylate synthase (TS). 
A phase III trial conducted in the first-line setting of advanced 
NSCLC demonstrated that survival was statistically superior for 
cisplatin plus pemetrexed in patients with adenocarcinoma (12.6 
versus 10.9 months; HR 0.84, P = 0.03), and large-cell carcinoma 
(10.4 versus 6.7 months; HR 0.67; P = 0.0 3 compared with cisplatin 
plus gemcitabine (1). Preclinical data have indicated that overex-
pression of TS correlates with reduced sensitivity to pemetrexed 
(2). Baseline expression of the TS gene is superior in squamous cell 
carcinoma compared with adenocarcinoma (P < 0.0001) (3). BRCA1 
is a component of multiple DNA repair pathways and functions 
as a molecular determinant of response to a range of cytotoxic 
chemotherapeutics agents. The analysis of BRCA expression levels 
in patients who had received neoadjuvant gemcitabine/cisplatin 
chemotherapy found that patients with low levels of BRCA1 had 
longer survival (P = 0.01) compared to those with high expression 
levels (4). RAP80 is an interacting protein that form complexes with 
BRCA1 and could modulate the effect of BRCA1. In patients with 
non-squamous lung carcinoma, survival was influenced by RAP80 
expression (5). Taking into account this background, the Spanish 
Lung Cancer Group has started a phase IIA study of pemetrexed 
plus cisplatin as first line treatment for advanced/metastatic non-
squamous lung carcinoma. The availability of tissue samples for 
analysis of expression of BRCA1, RAP80 and thymidylate synthase 
is mandatory. The primary objective is response rate adjusted for 
different expression levels of BRCA1, RAP80 and TS. Secondary 
objectives are OS, TTP and toxicity profile of the combination and 
its relationship with the biomarkers. The expected total number of 
patients accrued will be 90. Forty-nine patients have been inclu-
ded up to now. References 
• Scagliotti GV, Parikh P, Pawel J, et al. Phase III study compa-
ring cisplatin plus gemcitabine with cisplatin plus pemetrexed in 
chemotherapy-naïve patients with advanced-stage non–small-cell 
lung cancer. J Clin Oncol 2008.
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P1.07-001 THE IMPACT OF COMBINED PULMONARY 
FIBROSIS AND CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE ON LONG-TERM SURVIVAL AFTER LUNG CAN-
CER SURGERY
Yasuo Sekine1, Yuichi Sakairi2, Hidemi Suzuki3, Mitsuru Yoshino4, 
Eitetsu Koh4, Ichiro Yoshino5
1Tokyo Women‘s Medical University Yachiyo Medical Center/Japan, 
2Thoracic Surgery, Graduate School Of Medicine Chiba University/
Japan, 3Graduate School Of Medicine Chiba University/Japan, 4Thoracic 
Surgery, Tokyo Women’s Medical University Yachiyo Medical Center/
Japan, 5Department Of General Thoracic Surgery, Chiba University 
Graduate School Of Medicine/Japan
Background: The purpose of this study was to determine the im-
pact of pulmonary fibrosis on postoperative complications and on 
long-term survival after surgical resection in lung cancer patients 
with chronic obstructive pulmonary disease.
Methods: A retrospective chart review was conducted of 380 pa-
tients with chronic obstructive pulmonary disease who had under-
gone pulmonary resection for lung cancer at Chiba University Hos-
pital between 1990 and 2005. The definition of chronic obstructive 
pulmonary disease was a preoperative forced expiratory volume 
in one second /forced vital capacity ratio of less than 70%; pulmo-
nary fibrosis was defined as obvious bilateral fibrous change in the 
lower lung fields, confirmed by computed tomography. Statistical 
comparisons were carried out between the groups, and multiple 
logistic regression analysis was used to evaluate for independent 
risk factors for decreased survival.
Results: Pulmonary fibrosis was present in 41 patients (10.8%) with 
chronic obstructive pulmonary disease; the remaining 339 patients 
(89.2%) did not have pulmonary fibrosis. The preoperative forced 
vital capacity and forced expiratory volume in one second were 
significantly lower in patients in the group with pulmonary fibrosis 
than in the group without (p < 0.05). Acute lung injury and home 
oxygen therapy were significantly more common in the pulmonary 
fibrosis group; however, the 30-day mortality was similar between 
the groups. The cumulative survival at 3 and 5 years was 53.6% 
and 36.9% in the pulmonary fibrosis group and 71.4% and 66.1% in 
the non-pulmonary fibrosis group (p = 0.0009). The group without 
pulmonary fibrosis had significantly better survival, due to a lower 
rate of cancer recurrence. Increased age, decreased body mass 
index, advanced pathologic stage and the existence of pulmonary 
fibrosis were identified as independent risk factors for decreased 
survival.
Conclusion: Pulmonary fibrosis is a risk factor for decreased sur-
vival after surgical treatment in lung cancer patients with chronic 
obstructive pulmonary disease.
Keywords: CPFE, Lung cancer, chronic obstructive pulmonary 
disease, pulmonary fibrosis
G12F=11)(p=0.20). Pts with KRAS codon 13 mutant tumors had 
inferior OS compared to pts with codon 12 mutant tumors, median 
13 months (mo) (95% CI 13-17 mo) and 16 mo (95% CI 9-16 mo), res-
pectively (p=0.009). There was no difference in frequency of recei-
ving platinum-based chemotherapy or chemotherapy of any kind 
between pts with codon 12 and 13 mutant tumors. In a multivariate 
Cox model which included age, gender and smoking status, KRAS 
codon 13 mutation was associated with worse overall survival than 
KRAS codon 12 mutation (HR 1.52 95% CI 1.11-2.08 p=0.008).
Conclusion: Among pts with KRAS mutant metastatic lung can-
cers, smoking history, and specific amino acid substitution do not 
affect outcome. Among patients with KRAS mutant metastatic 
lung cancers, those with codon 13 mutations have shorter survival 
compared to pts with KRAS codon 12 mutations.
Keywords: molecular diagnostics, prognostics, KRAS
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P1.07-003 SURGICAL INDICATION FOR ELDERLY LUNG 
CANCER PATIENTS ACCORDING DEPENDING ON THE 
MORTALITY RATE BY DUE TO OTHER DISEASE
Masafumi Kataoka1, Haruyuki Kawai2, Kazuhiko Watanabe2, Mts-
uru Muguruma2, Toshinori Ohara1
1Surgery, Okayama Saiseikai General Hospital/Japan, 2Internal Medici-
ne, Okayama Saiseikai General Hospital/Japan
Background: As society ages, the incidence of lung cancer is in-
creasing. Elderly patients with lung cancer are also more suscepti-
ble to other diseases than are younger patients.
Methods: In this study, 357 patients with non-small cell carcinoma, 
who underwent pulmonary resection at our hospital, were retros-
pectively reviewed. These patients were classified into 3 groups: 
Group A, 121 patients aged <64 years; Group B, 149 patients aged 
65–74 years; Group C, 87 patients aged >75 years. The causes of 
death were investigated with a special focus on other diseases.
Results: The follow-up rate of all cases was 95.8%. One patient 
died of pulmonary embolism, and the operative mortality rate was 
0.26%. Out of the 357 cancers, 71.1% had stageI, 8.1% stageII, and 
20.1% stageIII. In Group A, 9.1% of the cases underwent wedge 
resection, 18.9% in Group B, and 47.7% in Group C. The propor-
tion of wedge resection cases increased with age. In Group A, 
cancer-related survivals were 59.5%, 61.1% in Group B, and 66.7% 
in Group B, and there was no statistical significance between 
the groups. The overall survivals were 57.9％ in Group A, 55% in 
Group B, and 51.7% in Group C. There were significant differences 
between cases in Group C and those in other groups (p = 0.019, 
log rank test). Within 5 years of the operation, the mortality rates 
due to other disease were 1.6% in Group A, 6% in Group B, and 
14.9% in Group C. Chi-squared test showed significant differences 
between cases in Group C and those in other groups. Twenty-four 
patients died due to other diseases: 5 from cardiovascular disease, 
5 from respiratory disease, 5 from other malignant diseases, 3 from 
gastrointestinal disease, 1 from cerebrovascular disease, and 5 
from other causes.
Conclusion: Since after lung-cancer surgery, the mortality due to 
other diseases increases in elderly patients, a postoperative survey 
or therapy for other diseases are important especially in elderly 
patients. Therefore, in order to prevent death due to other disea-
ses or to enhance the quality of life until their death, a less-invasive 
surgery or limited resection to preserve respiratory function are 
more important in elderly patients than in younger patients
Keywords: Lung cancer, Elderly Patient, operation, mortality of 
other cause
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P1.07-002 EFFECT OF SYNCHRONOUS SOLITARY BONE 
METASTASECTOMY ON RESECTABLE NON-SMALL CELL 
LUNG CANCER PATIENTS
Tiancheng Zhao, Yi Yang
Cardiothoracic Surgery Department, Shanghai Sixth People’s Hospital/
China
Background: Lung cancer is the most common cause of cancer 
related death among both men and women all over the world. 
Skeleton is one of the most common metastatic sites. Most of the 
patients with bone metastasis should be treated with systemic the-
rapy or symptom-based palliative approach without surgery. We 
try to improve the therapeutic effect by synchronous surgeries in 
resectable non-small cell lung cancer(NSCLC) patients with solitary 
bone metastasis.
Methods: Five patients have undergone synchronous lung cancer 
resections and solitary bone metastasectomies between 2009 to 
2011 in our hospital. All of them have received 18FDG-PET-CT or 
Bone Scintigraphy (BS) to demonstrate solitary bone metastasis 
and exclude other site metastases. They received standard lung 
cancer resections and mediastinal lymph node resections. Mean-
while, bone leasions were assessed by orthopedists and operated 
with standard procedures synchronously. After operations they all 
had standard chemotherapies. Perioperative indicators including 
time of thoracic drainage, hospital stays, incidence of postoperati-
ve complications and progress free survival (PFS) were observed.
Results: The average time of postoperative drainage is 4.6±1.1 
days, postoperative hospitalization is 8.8±2.2 days. All of the 
procedures were carried out safely with no serious complications. 
The PFS of these patients is 13.2±7.7 months. Two patients with 
spine metastasis died about one year after operation, and the 
other three patients with limb bone metastases have survived 
more than 16 months in average after operation and still alive.
Conclusion: Synchronous metastasectomy and lung tumor resec-
tion is safe to patients. The PFS time and survival results show that 
in the rare situation in which a patient has a solitary bone metasta-
sis, aggressive surgical treatment may be an available choice.
Keywords: synchronous operation, metastasectomy, solitary bone 
metastasis, non-small cell lung cancer
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P1.07-005 LENGTH OF DISEASE FREE SURVIVAL INTER-
VAL IS AN INDEPENDENT PREDICTIVE PROGNOSTIC 
FACTOR FOR POSTRECURRENT SURVIVAL IN NSCLC
Masato Kato
Surgery, Hamanomchi General Hospital/Japan
Background: Lung cancer is still one of the deadly types of cancer. 
Once the disease has relapsed, long survival cannot be anticipa-
ted. However, prognostic factors after postoperative recurrence in 
non-small cell lung cancer (NSCLC) have not been well elucidated. 
In the present study, to improve the prognosis for NSCLC, we fo-
cused disease free survival (DFS) interval length and newly exami-
ned predictive survival factors after recurrence for NSCLC for over 
10 years.
Methods: Consecutive 419 patients with NSCLC were performed 
curative surgical operation between January 2001 and March 2012 
at the Department of Thoracic Surgery, Hamanomachi Hospital, 
Fukuoka, Japan. Out of 419 patients, 116 cases had been recurrent. 
Predictive prognostic factors for 116 recurrent NSCLC cases were 
retrospectively examined.
Results: DFS time which is longer than 18 months as well as female 
gender and adenocarcinoma histology were independent better 
prognostic factors for 116 recurrent patients. For 74 patients with 
adenocarcinoma, DFS time which is longer than 20 months as well 
as female gender, younger age and EGFR mutation status were 
independent better prognostic factors in multivariate analysis.
Conclusion: In the present study,we for the first time demonst-
rated that DFS time is an independent prognostic factor for re-
current NSCLC.We have also shown that female gender, younger 
age and adenocarcinoma histology were independent predictive 
prognostic factors for all cases. Among several prognostic factors, 
in this study, however, we emphasis DFS interval time as an inde-
pendent prognostic factor for postrecurrent survival. The recurrent 
patients whose DFS time is shorter than 20 months should be ta-
ken care intensively.
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P1.07-006 LUNG CANCER RESECTION IN PATIENTS 
WITH CHRONIC RENAL FAILURE ON HEMODIALYSIS
Yasufumi Kato, Kimitoshi Nawa, Hideyuki Furumoto, Kouichi 
Yoshida, Masaru Hagiwara, Masatoshi Kakihana, Naohiro Kajiwa-
ra, Tatsuo Ohira, Norihiko Ikeda
Thoracic Surgery, Tokyo Medical University Hospital/Japan
Background: The number of patients with malignant tumors re-
ceiving long-term hemodialysis (HD) has been increasing. Patients 
on HD who undergo surgery represent a high-risk group requiring 
careful perioperative management to avoid electrolyte imbalance 
and hemodynamic instability. This retrospective study analyzed the 
postoperative outcome in terms of complications and survival of a 
group of patients on HD who underwent pulmonary resection for 
non-small cell lung cancer.
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P1.07-004 MULTIMODALITY MANAGEMENT AND SUR-
GICAL OUTCOMES FOLLOWING POST NEO-ADJUVANT 
CHEMOTHERAPY, RADICAL CHEST WALL RESECTION 
AND RECONSTRUCTION FOR PNET CHEST WALL
Svs Deo1, Nk Shukla1, Palaniappan Ramanathan1, S Bakhshi2, Dn 
Sharma3
1Surgical Oncology, All India Institute Of Medical Sciences/India, 2Me-
dical Oncology, All India Institute Of Medical Sciences And Research/
India, 3Radiation Oncology, All India Institute Of Medical Sciences/India
Background: Primitive neuroectodermal tumor (PNET) is a rare 
undifferentiated and highly aggressive tumor , most commonly ari-
sing in chest wall in teen age patients. Treatment of these patients 
is challenging and multimodality treatment had a major impact on 
their outcome. We present our experience of post neo-adjuvant 
chemotherapy , radical chest wall resection and reconstruction and 
surgical outcomes.
Methods: A retrospective review of a prospectively maintained 
computerized database of patients was performed and patients 
with histologically proven chest wall PNET undergoing surgery 
were identified and analyzed for clinical profile , surgical details 
and peri-operative outcomes.
Results: A total of 71 patients had surgery for chest wall tumor 
between 2000 to 2009. Fifteen out of 71 were diagnosed as ha-
ving PNET chest wall. The mean age of presentation was 21 years 
(15 - 30 years) and there was a slight male preponderance (1.16 : 
1). Most common presenting symptom was chest wall swelling and 
pain. Mean pre chemotherapy tumor size was 20cm. As per our 
institutional protocol , all patients received neoadjuvant chemothe-
rapy comprising VAC + IE regime followed by surgery. The number 
of resected ribs ranged from 2 to 5 and the mean chest wall defect 
was 15cm. Majority required resection of adjoin pleura and in 5 pa-
tients segment of adherent lung was resected. A composite chest 
wall reconstruction was performed using bi-layered synthetic mesh 
and latissimus dorsi (10) , pectoralis major (3) and serratus (2) mu-
scle flaps. All patients had an uneventful post operative recovery 
and the peri-operative mortality was nil. Six patients had complete 
pathological response to chemotherapy and 9 patients had residu-
al tumor and were given post operative radiotherapy. At a median 
follow up of 36 months , 8 patients are alive and disease free.
Conclusion: Multimodality management and advances in surgical 
techniques had revolutionized the approach to chest wall PNET in 
the recent past. Our experience has shown that radical chest wall 
resection and composite reconstruction can be accomplished with 
excellent outcomes even in patients with advanced PNET and post 
intensive chemotherapy sessions.
Keywords: Chest wall reconstruction, PNET, Chest wall tumors, 
Chest wall resection
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patients (8 men, 9 women) received intraoperative intrapleural 
administration of a combination of cisplatin and fibrin glue 
(treatment group; mean age, 68.6±7.9 years; range, 55-85 years). 
The control group received no intraoperative treatment of the 
pleural space. Intrapleural administration treatment involved 
spraying the entire thorax with cisplatin (25 mg) and fibrin glue 
before closure of the open thorax. Histopathological tumor 
types included adenocarcinoma in 16 cases and squamous cell 
carcinoma in 1 case. According to the TNM classification, 2 cases 
were stage IA and 15 cases were stage IB.
Results: No complications were seen with intrapleural ad-
ministration. In the treatment group, median time to follow-
up was 42 months and the 5-year survival rate was 75.0%, 
respectively. Two of these 17 patients showed distant recurrence 
(brain metastasis, n=1; axillary lymph node metastasis, n=1), and 
none had locoregional recurrence. In the control group, median 
time to follow-up was 33.8 months and the 5-year survival rate 
was 45.1%. Recurrence developed in 16 patients (locoregional 
recurrence, n=7; distant recurrence, n=4; unknown lesion, n=5). No 
significant difference was observed between groups (p=0.0565), 
but 5-year survival rates for patients with treatment tended to be 
better than in the control group.
Conclusion: Intraoperative intrapleural administration with a com-
bination of cisplatin and fibrin glue for patients with positive results 
from pleural lavage cytology was found to effectively suppress the 
appearance of locoregional recurrence without severe complica-
tions.
Keywords: Intrapleural administration, pleural lavage cytology-
positive, non-small cell lung cancer, cisplatin and fibrin glue
Methods: Between January 1995 and March 2013, 10 patients (7 
men, 3 women; median age, 71.5 years) with non-small cell lung 
cancer who were also receiving HD underwent radical pulmonary 
resection by open thoracotomy or video-assisted thoracic surgery 
at Tokyo Medical University Hospital. We retrospectively evaluated 
their postoperative clinical outcomes and survival results. Most 
patients had comorbidities, including cardiovascular disease (5), 
diabetes (3), and brain infarction (1). The distribution of clinical 
staging was IA in 2 cases, IB in 5, IIB in 1, and IIIA in 2. Procedures 
included 8 lobectomies and 2 segmentectomies. We performed 
4 systematic lymph node dissections and 6 selective lymph node 
dissections.
Results: The median intraoperative time was 215.5 minutes (range, 
101-308). The median blood loss was 55 mL (range, 0-478 mL). 
Blood transfusion was not necessary. There was no intraoperative 
mortality. There were major perioperative complications in 4 pati-
ents, including atrial fibrillation (3), cardiac failure (1), shunt failure 
(1), and pneumonia (1). The median length of hospital stay was 21 
days (range, 11-47). Thoracic drainage removal was at 4.5 postope-
rative days (range, 3-9). Pathological staging was IA in 3 cases, IB 
in 2, IIA in 2, IIB in 1, and IIIA in 2. Two cases were upstaged from 
the preoperative period to the final period. Seven of the 10 pati-
ents are currently alive and recurrence-free. Two patients had me-
diastinal lymph node and lung recurrence. One patient died from 
mediastinal lymph node recurrence at 8 months after surgery, and 
the other patient died at 26 months after surgery from malignant 
lymphoma.
Conclusion: Patients with chronic renal failure on HD who undergo 
lung resection have a high rate of postoperative complications 
(40%). Surgical treatment remains one of the effective treatments 
for patients on HD with lung cancer.
Keywords: Lung cancer, surgery, hemodialysis, Complication
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P1.07-007 INTRAPLEURAL ADMINISTRATION OF A 
COMBINATION OF CISPLATIN AND FIBRIN GLUE FOR 
PLEURAL LAVAGE CYTOLOGY-POSITIVE PATIENTS WITH 
NON-SMALL CELL LUNG CANCER
Hirohiko Shinohara1, Takahisa Koizumi1, Tadashi Aoki1, Katsuo 
Yoshiya1, Teruaki Koike1, Masanori Tsuchida2
1Thoracic Surgery, Niigata Cancer Center Hospital/Japan, 2Thoracic And 
Cardiovascular Surgery, Niigata University Graduate School Of Medical 
And Dental Sciences/Japan
Background: Several reports have described intraoperative 
intrapleural hypotonic cisplatin treatment as effective for 
suppressing the appearance of pleuritis carcinomatosa in resected 
patients who demonstrated positive findings from pleural lavage 
cytology. Furthermore, fibrin glue may allow the efficacy of 
cisplatin to be prolonged. We investigated the effectiveness and 
safety of intrapleurally administering a combination of cisplatin and 
fibrin glue.
Methods: This study retrospectively analyzed 6923 patients who 
underwent resection of primary lung cancer in Niigata Prefecture 
between January 2001 and December 2010. Sixty-four patients 
with positive pleural lavage cytology underwent complete 
resection and showed p-stage I. Of these, 17 consecutive 
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various types of anterior and middle mediastinal tumors in clinical 
practice. We evaluated the feasibility, safety and appropriate set-
tings of this system for the surgical treatment of these tumors. One 
review reports about the importance of the appropriate settings 
according to tumor location in robot-assisted thoracic surgery 
(RATS), because no target always exists in the same location within 
the thoracic cavity. In this report, we evaluated the efficacy of a 
high-speed three-dimensional (3D) image analysis system (SYNAP-
SE VINCENT; Fuji Photo Film Co., Ltd.) for preoperative simulation 
and navigation during a RATS procedure.
Methods: In this study, a high-speed 3D-image analysis system 
was used to decide the best positioning of robotic-arms and in-
struments preoperatively. Moreover, this system has capable of 
detecting the tumor location and extracting surrounding tissues 
quickly, accurately and safely. Accurate and speedy set-up of the 
da Vinci S® Surgical System was possible for this operation. Syn-
apse Vincent facilitated determining the best positioning of robot 
arms and instruments, and was an excellent device for navigation 
in real time. All patients who underwent RATS in our institution 
provided written informed consent to receive robotic surgery using 
the dVS, and the institutional review committees of each institution 
gave their permission. In this report, a representative mediastinal 
tumor which was located in the upper thoracic cavity was selected 
to establish the merits of this procedure.
Results: The patient, a 38-year-old woman, had a posterior medi-
astinal tumor located at the upper level of Th 1 to 3. Accurate and 
speedy set-up of the dVS was capable on this operation. It was 
feasible to decide the best positioning of robot-arms and instru-
ments, and excellent device for the navigation on real time. The 
total operation time was 270 minutes, the time of the dVS setting 
was 21 minutes, and the console time (the dVS working time) was 
132 minutes. The amount of bleeding was 167 mL and the drainage 
time was 2 days after the operation and this patient had no compli-
cations. The pathological report revealed a schwannoma (85 × 42 
× 20 mm) with no malignancy.
Conclusion: For the optimal performance of RATS, the positioning 
of all units and the locations of instrument ports need suitable 
directional setting. Preoperative simulation and navigation during 
of operation using SYNAPSE VINCENT for the RATS has efficacy 
for planning the setting, especially in deciding the points of instru-
ment ports and the angle of robot arms, and very useful as a de-
vice of the navigation software and education use operating on it.
Keywords: high-speed 3D-image analysis system, Synapse Vin-
cent, Robotic surgery, da Vinci S® Surgical System
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P1.07-010 PREOPERATIVE FLOURODEOXYGLUCOSE-PO-
SITRON EMISSION TOMOGRAPHY SCAN WITH POSITI-
VE N1 DISEASE DOES NOT PREDICT WORSE SURVIVAL 
IN PATHOLOGIC STAGE II PATIENTS
Min P. Kim1, Arlene M. Correa2, Shanda H. Blackmon1, Jeremy 
Erasmus3, Wayne Hofstetter2, Homer Macapinlac4, Reza Mehran2, 
David Rice2, Jack Roth2, Ara A. Vaporciyan2, Garrett L. Walsh2, 
Stephen G. Swisher2
1Surgery, The Methodist Hospital/United States Of America, 2Thoracic 
& Cardiovascular Surgery, University Of Texas MD Anderson Cancer 
Center/United States Of America, 3Diagnostic Radiology, University Of 
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P1.07-008 THE APPLICATION OF SOFT COAG IN COM-
BINATION WITH TRIANGLE-TENSIONING FOR VATS LO-
BECTOMY AND SEGMENTECTOMY
Tohru Sakuragi, Sumio Okuda, Yoshihiro Nakayama
Ohsumi-kanoya Hospital/Japan
Background: This article describes the application of SOFT COAG 
electrosurgical output mode of VIO (ERBE Elektromedizin GmbH, 
Tubingen, Germany) in combination with triangle-tensioning 
(HIMEJI method, Yamamoto et al, 2010, Annals of Thoracic Sur-
gery). The method is to expand the operative field in 3 directions, 
centering the targeted area. With the combination 2 advantages 
are considered; operative ease by the method and additional safe-
ty by SOFT COAG that generates no electric sparks for unintended 
tissue damage.
Methods: By the method each apex is tensioned in radial fashion 
towards 3 directions, making effective operative field. For re-
section of pulmonary artery A2 in upper lobectomy, the artery is 
pulled to its original direction with the lung fully stretched. The 
principal surgeon and his assistant oppositely stretch the tissue 
around the artery in parallel directions to the longitudinal axis of 
the artery. Connected with SOFT COAG, the endoscopic scissors 
are applied slightly open, to capture, coagulate, and dissect the 
capsule. Including the bronchial artery, the method can be used to 
treat other arteries in VATS lobectomy. One of the fine applications 
is to treat thin pulmonary arteries with ERBE’s BiClamp® forceps 
which enables ligation and clip-less procedure.
Results: In consecutive anatomical resections of 58 cases: 49 
lobectomies (right upper: 18, right middle: 4, right lower: 12, left 
upper: 6, left lower: 9) including 20 mediastinum lymph nodes 
dissection: 9 segmentectomies are included. Blood-loss and mean 
operation time are: 257 minutes and 130ml with mediastinum 
lymph nodes dissection and 223 minutes and 86ml without. All 
cases went safe with no severe complications.
Conclusion: The triangle-tensioning method in VATS resection 
is rational and practical. In addition, the combination with SOFT 
COAG enables safe and simple dissection.
Keywords: SOFT COAG, BiClamp(R), VATS, Triangle-tensioning
POSTER SESSION 1 - SURGERY  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.07-009 PREOPERATIVE SIMULATION AND NAVIGA-
TION USING THE COMBINATION OF HIGH-SPEED 3D-
IMAGE ANALYSIS SYSTEM AND ROBOTIC SURGERY IN-
CREASE THE EFFICACY AND ACCURACY IN THORACIC 
SURGERY
Naohiro Kajiwara, Yoshinori Sakata, Kimitoshi Nawa, Yoshihisa 
Shimada, Takefumi Oikawa, Keishi Ohtani, Masatoshi Kakihana, 
Tatsuo Ohira, Norihiko Ikeda
Surgery, Tokyo Medical University/Japan
Background: Previously, we reported the utility of the da Vinci® 
Surgical System (dVS: Intuitive Surgical, Inc., Sunnyvale, CA) for 
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P1.07-011 EXAMINATION OF THE RELEVANCE OF PRO-
LONGED PULMONARY FISTULA AFTER PULMONARY 
RESECTION FOR LUNG CANCER AND FACTORS ABOUT 
DELAYED WOUND HEALING
Koshi Nagano1, Kiyotoshi Inoue1, Aya Yamamoto1, Nobuhiro Izu-
mi2, Shinjiro Mizuguchi2, Hidetoshi Inoue2, Noritoshi Nishiyama2
1Thoracic Surgery, Bell-land General Hospital/Japan, 2Thoracic Surgery, 
Osaka City University Hopspital/Japan
Background: Prolonged pulmonary fistula is a common compli-
cation in pulmonary resection, which happens in 8% to 26% in 
patients undergoing routine pulmonary resection. And its manage-
ment is difficult in many cases. Air leakages are associated with 
prolonged hospital stays, infectious, cardiopulmonary complica-
tions, and reoperation occasionally despite of the progress of the 
recent conservative cure. Blood coagulation factor XIII (BCF XIII) 
is known to play a role in wound healing. However little is known 
about the role of BCF XIII in the field of thoracic surgery. BCF XIII 
is known to fasciculate closure of fistula in gastro-intestine surgery. 
This time, we examine the relationship for prolonged air leakage 
and BCF XIII diabetes, chronic obstructive pulmonary disease 
(COPD), and total protein amount of postoperative.
Methods: In 32 patients who underwent pulmonary resection for 
lung cancer at Bell-land general hospital or Osaka city university 
hospital and experienced air leakage for at least 2 days after ope-
ration. Pre-operative HbA1c and BCF XIII and pulmonary function 
measured within 2 weeks pre-operatively .Post-operative total 
protein (TP) and BCF XIII measured at 5 days post-operatively. We 
evaluated the relationship between BCF XIII or HbA1c or TP or 
COPD and duration of chest drain placement respectively.For sta-
tistical analysis, t-test was used
Results: Six patients experienced a decrease in factor XIII to 70% 
or under normal range that was indication for administration of 
BCF XIII. The mean duration of chest drain placement was 5.2± 2.8 
days in patients with post-operative BCF XIII level of ≥71% compa-
red to 8.3 ± 2.8 days in those with post-operative BCF XIII level of 
≤70%. Patients with post-operative BCF XIII level of ≤70% required 
drain placement for a significantly longer period (p<0.05). In this 
analysis, we did not recognize significant difference in other fac-
tors (HbA1c≦6.5% group and HbA1c≧6.6% group, Post operative 
TP ≧6.6 g/dl group and TP ≦6.5 g/dl , forced expiratory volume 
1.0%(FEV1.0%)≧70% group and FEV1.0%<70% group).
Conclusion: Factor XIII promotes crosslink of fibrin in the early 
stages of wound healing. Thus, factor XIII is considered to be con-
sumed for lesion repair. In this study, we were considered the pos-
sibility BCF XIII is related to lung healing fistula. In diabetic pati-
ents, the occurrence of delayed wound healing has been reported 
frequently. No significant difference was noted between diabetic 
and non-diabetic patients in this study. We continue to increase 
the study case in the future, we want to evaluate the relationship 
between BCF XIII, diabetes or nutrition and the drainage period.
Keyword: Blood coagulation factor XIII, Pulmonary fistula,  
Diabetes
Texas MD Anderson Cancer Center/United States Of America, 4Nuclear 
Medicine, University Of Texas MD Anderson Cancer Center/United 
States Of America
Background: The rate of fluorodeoxyglucose uptake measured 
as standardized uptake value (SUV) on positron emission tomo-
graphy (PET) of the primary tumor has been correlated with tumor 
aggressiveness and poor survival in patients with lung cancer. A 
retrospective review of patients with lung cancer who were treated 
with surgical resection at MD Anderson Cancer Center (MDACC) 
was performed to determine if the pre-operative SUV uptake of N1 
disease has any prognostic significance in patients with pathologic 
stage II lung cancer.
Methods: We reviewed all patients who underwent surgical resec-
tion for lung cancer at MDACC from 1998 to 2011. We evaluated 
non-small cell lung cancer patients who had at least a lobectomy 
at MDACC as first mode of surgical therapy who had pathologic 
stage T1-2 and N1 disease and pre-operative PET-CT scan. We 
determined the clinicopathologic characteristics of patients who 
had PET-positive N1 disease and compared them to patients who 
had PET-negative N1 disease. We also performed Kaplan Meier 
analysis to determine the survival between the two groups.
Results: Among patients who underwent surgical resection for 
lung cancer at MDACC during this time period, 120 patients met 
the inclusion criteria for the study. There were 100 stage IIA or 
T1aN1, T1bN1 or T2aN1 and 20 stage IIB or T2bN1 patients in 
the study. There were 62 patients (50% of the patients) who had a 
primary tumor in the periphery of the lung and 58 patients (50% 
of the patients) who had a primary tumor in the central portion of 
the lung. Within this group of 120 patients, only 29 patients (24% 
of the patients) had PET-positive N1 disease. Only 16 out of 58 
patients (28%) in the central group and only 13 out of 62 patients 
(21%) in the peripheral group had PET-positive N1 disease. There 
was no clinical or pathological difference between the patients 
who had PET-positive N1 disease and PET-negative N1 disease. 
The average maxSUV of the primary tumor was 13 ± 10.7 and ave-
rage maxSUV of the PET-positive N1 disease was 6.3 ± 4.1. Kaplan 
Meier analysis showed that there was no significant difference in 
survival between the patients who had PET-positive N1 disease 
and PET-negative N1 disease.
Conclusion: Among patients with pathologic stage II non-small 
cell lung cancer, preoperative PET scan was very poor at predic-
ting positive pathologic N1 disease. Since it is difficult to predict 
pN1 disease, operative patients with clinical stage I non-small cell 
lung cancer should have surgical resection oppose to ablative the-
rapy. Moreover, SUV uptake of N1 disease in patients with patholo-
gic stage II lung cancer did not predict worse survival in pathologic 
stage II patients. Thus, patients with cN1 disease should undergo 
surgical resection after appropriate mediastinal staging.
Keywords: PET-CT, Stage II, N1 disease, survival
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a multimodal postoperative pain management plan avoiding the 
use of epidural analgesia and opioids is feasible and provides and 
optimal pain management.
Keywords: Paravertebral analgesia, Postoperative management, 
Thoracic surgery, Multimodal pain management
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P1.07-013 
"
MINIMALLY INVASIVE SMALL INCISION,  
MUSCLE- AND RIB-SPARING THORACOTOMY,  
MINIMALLY INVASIVE LUNG CANCER RADICAL  
SURGERY“, CURES 
"
AGING, CARDIOPULMONARY  
DYSFUNCTION PATIENTS WITH LUNG CANCER“
Jun Zhang, Houwen Li
China Medical University Lung Cancer Center, Department Of Molecu-
lar Targeted Therapeutics, The First Hospital Of China Medical Univer-
sity/China
Background: Developing "minimally invasive small incision, musc-
le- and rib-sparing thoracotomy (miMRST), minimally invasive lung 
cancer radical surgery“, to cure aging, cardiopulmonary dysfunc-
tion patients with lung cancer, who could not tolerate traditional 
large-incision posterolateral thoracotomy. Typical cases will be 
discussed here.
Methods: Man, aged 64, left lower lobe lesions 1.0cm, localized in 
central, deep part, not suitable for needle-biopsy, nor for wedge 
resection; smoking for 44 years, with serious chronic bronchitis 15 
years, asthma episodes per year; coronary heart disease 13 years, 
coronary stenting 10 years; anticoagulation 10 years; serious gast-
ric ulcers, colorectal polyps 2 years. Consulted in hospitals in She-
nyang and Beijing for months, advised for follow-up considering 
his current cardiopulmonary condition and no malignant evidence. 
Then referral to China Medical University Lung Cancer Center in 
Dec 26, 2012. Surgical resection was advised at once. Preoperative 
examination: pulmonary function test revealed airway dysfunction, 
low blood oxygen. Anti-inflammatory, antispasmodic strategy and 
preoperative pulmonary function exercise did not improve lung 
function as expected. The patient was discussed not suitable for 
regular thoracotomy, unable to tolerate the damage from traditio-
nal large-incision posterolateral thoracotomy. “miMRST, minimally 
invasive lung cancer radical surgery” was scheduled.
Results: About 10cm lateral chest incision was enough for most 
lung cancer resection and mediastinal lymph nodes dissection. 
Latissimus dorsi and serratus anterior muscles were protected, 
chest cavity entered through intercostals space, no rib cut. 
Widespread intrathoracic adhesions, localized severe adhesions, 
and undifferentiated lung fissures were confirmed. The lesion was 
found in left lower lobe, adjacent to pulmonary vessels not suitable 
for wedge resection; swollen lymph nodes adhered around 
pulmonary vessels were confirmed. Left lower lobe resection, and 
No.3A,4,5,6,7,8,9,10,11,12,12u,13,14 group regional and mediastinal 
lymph nodes and surrounding adipose tissue were dissected. 
When awake after surgery, operative lateral upper limb recovered 
freedom of movement; the patient got out of bed in the 2nd 
postoperative day with catheter unplugged in the same day; the 
chest tube pull out in the 3rd postoperative day; no complications 
happened. Pathological examination reported lung squamous cell 
carcinoma, no lymph nodes metastasis. The patient recovered 
much better and quickly than other patients who received 
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P1.07-012 COLLABORATIVE MULTIMODAL PAIN  
MANAGEMENT STRATEGY FOR PATIENTS WITH  
NON-SMALL CELL LUNG CANCER SUBMITTED TO  
THORACOTOMY
Juan J. Fibla1, Laureano Molins2, Jorge Hernandez1, José M. Mier1, 
Ana Sierra3, Xon Bataller4
1Thoracic Surgery, Sagrat Cor University Hospital/Spain, 2Thoracic 
Surgery, Sagrat Cor University Hospital And Hospital Clinic/Spain, 
3Anaesthesiology, Sagrat Cor University Hospital/Spain, 4Physiothera-
py, Sagrat Cor University Hospital/Spain
Background: Relieving the intense pain associated with a tho-
racotomy incision improves patient well-being and pulmonary 
function, resulting in a more comfortable and ambulatory patient. 
Epidural analgesia and opioids have been classically employed 
to treat post-thoracotomy pain (“Gold Standard”), however these 
techniques have important secondary effects and drawbacks. Pain 
management strategies have evolved within the last years and 
significant advances have been achieved with the appearance of 
multimodal pain treatment. This new concept might be safe and 
efficacious in controlling post-thoracotomy pain and reducing the 
amount of systemic opioids consumed.
Methods: From 2007 to present date we have incorporated into 
our general thoracic surgery protocol a collaborative multimodal 
post-thoracotomy pain management strategy involving Thora-
cic Surgery, Anaesthesiology and Physiotherapy Departments. 
Patients eligible for this protocol were those scheduled for a tho-
racotomy for non-small cell lung cancer resection. Two sorts of 
thoracotomies were employed depending on the tumour location: 
Anterior Thoracotomy (AT) for tumours in the upper or middle 
lobe, and Postero-lateral thoracotomy (PT) for tumours in the lo-
wer lobe. At the end of surgery a paravertebral catheter (PC) was 
inserted under direct vision in the thoracic paravertebral space at 
the level of incision. Postoperatively patients received 300 mg/day 
of local anaesthetic (ropivacaine) through the PC combined with an 
intravenous non-steroidal anti-inflammatory drug (NSAID) (metami-
zole 2gr) every 6 hours and daily Transcutaneous Electrical Nerve 
Stimulation (TENS) sessions. A subcutaneous opioid (meperidine) 
was employed as rescue drug. Drugs dosages were controlled by 
the Anaesthesiology Department. The level of pain was measured 
with the visual analogic scale (VAS) at 1, 6, 24, 48 and 72 h after 
surgery. The need of meperidine as rescue drug and secondary 
effects were also recorded.
Results: A total of 270 patients entered the protocol. We did not 
register secondary effects in relation to the PC, NSAID or TENS. 
Thirty-five patients (13%) needed meperidine as rescue drug. 
Mean VAS values were the following: all the cases (n=270): 4.9+/-
2.0, AT (n=150): 4.3+/-2.1, PT (n=120): 5.8+/-1.8. VAS 1 hour: AT 2.9, 
PT 4.3; VAS 6 hours: AT 6.7, PT 7.5; VAS 24 hours: AT 6.0, PT: 6.8; 
VAS 48 hours: AT 4.0, PT 6.0, VAS 72 hours: AT 3.0, PT: 4.7. Patients 
submitted to AT experienced less pain than those with PT in mean 
and at any time (p< 0.01).
Conclusion: Paravertebral block is an effective alternative to epi-
dural analgesia in the management of post-thoracotomy pain. The 
analgesic scheme combining paravertebral block (PVB) through a 
PC placed by the thoracic surgeon, NSAID and TENS performed 
by the physiotherapist has proven to be effective for postoperative 
pain control after thoracotomy. Inasmuch as surgical extirpation of 
lung cancers remains the best hope of survival for many patients, 
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Group A had 31 patients with advanced age >77yrs (range 77-86yr; 
16 men, 15 women); Group B had 149 patients (range of 29-76yr; 
74 men, 75 women). Overall intraoperative complication rate was 
17/180 (9%), overall postoperative complication rate was 87/180 
(48%), and overall in-Hospital mortality was 5/180 (3%). Group A 
had 7/31 (6%) intra-operative complications, compared to 10/149 
(3%) for Group B (p=0.006). The most common intraoperative com-
plication in both groups was bleeding from the pulmonary artery, 
with 3/31 (10%) in Group A and 3/149 (2%) in Group B. The overall 
rate of conversion to open lobectomy was 7/31(23%) in Group 
A versus 13/149 (2%) in Group B (p=0.026); although the rate of 
emergent conversion to open lobectomy was 3/31 (10%) in Group 
A compared to 3/149 (2%) in Group B. There were 19/31 (61%) 
patients in Group A with minor and/or major post-operative com-
plications, compared to 68/149(46%) in Group B (p=0.11). The most 
common post-operative complications experienced by Group A 
were prolonged air leak 8/31 (26%), atrial fibrillation 6/31 (19%), 
pneumonia 4/31 (13%) and mucus plugs requiring intervention 
4/31 (9%; p=0.24), while those for Group B were prolonged air leak 
26/149 (17%; p=0.28), pneumonia 19/149 (13%; p=0.98), atrial fib-
rillation 16/149 (11%; p=0.23) and anemia 9/149 (6%). Group A had 
medians of 5+2.8 (S.E.M.) chest tube days and 7+1.3 (S.E.M.) hos-
pital days, compared to 4+0.3 chest tube days and 5+0.4 hospital 
days for Group B (p=0.09 and p=0.004, respectively). Interestingly, 
Group A had 0/31 (0%) in-Hospital mortality, compared to an in-
Hospital mortality rate of 5/149 (3%) for Group B (p=0.30).
Conclusion: Patients with advanced age >77 yr and who undergo 
robotic-assisted lobectomy have a higher risk of perioperative 
complications and conversion to open lobectomy. In addition, 
advanced age also resulted in longer hospital LOS. However, ad-
vanced age was not associated with increased in-Hospital mortali-
ty and was actually associated with decreased mortality. Thus, our 
study suggests that robotic pulmonary lobectomy is feasible and 
safe in patients with advanced age.
Keywords: age, outcomes, Robotic, lobectomy
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P1.07-015 DYSPHAGIA PALLIATION IN LOCALLY ADVAN-
CED CARCINOMA ESOPHAGUS: ROLE OF INTRALUMI-
NAL BRACHYTHERAPY.
Manoj K. Behera1, Samrat Dutta2, Pallani Appan3
1Clinical Oncology, All India Institute Of Medical Sciences (aiims)/India, 
2Radiotherapy, North Bengal Medical College/India, 3Surgical Oncology, 
All India Institute Of Medical Sciences (aiims)/India
Background: About 60-70 % patients present with advanced 
disease in carcinoma oesophagus with limited curative option. 
There are high local recurrence rate of 32%-45% when treated 
with surgery alone and 77% when radiation therapy only. So, the 
results of the treatment of ca oesophagus have been poor inspite 
of advances in various treatment modalities. A high tumour dose is 
needed to achieve adequate local control, which is possible by an 
intraluminal boost following teletherapy. The advantage of intralu-
minal brachytherapy as a means of dose escalation following EBRT 
based on inverse square law and quick dose fall off which results 
in relative sparing of surrounding normal tissues, and potentially 
improving the therapeutic ratio. Dysphagia is a potential problem. 
Brachytherapy is effective in palliation of dysphagia by delivering 
high tumoricidal dose may achieve excellent local control rate and 
lung cancer resection via traditional standard posterolateral 
thoracotomy.
Conclusion: "miMRST“, "minimally invasive small incision, musc-
le- and rib-sparing thoracotomy, minimally invasive lung cancer 
radical surgery“, shows advantage of small incision, less pain; less 
damage; quick recovery, better recovery; operative side upper 
extremity activities early, pulling out catheter early, get out of bed 
early, being out of ICU early, chest tube pulled out early; stopping 
antibiotics early, discharge early; no need using expensive rib nails 
because of no-rib-cut; no need using expensive thoracoscopic ves-
sel staples; almost no complications; significantly less cost. “miM-
RST”, is minimally invasive thoracic surgery, very suitable for aging, 
cardiopulmonary dysfunction patients with lung cancer, who could 
not tolerate traditional large-incision posterolateral thoracotomy. 
“miMRST”, is also economical, no need using expensive thora-
coscopic devices, to some degree, very suitable for lung cancer 
surgery in developing countries. (This study was partly supported 
by the Fund for Scientific Research of The First Hospital of China 
Medical University, No.FSFH1210).
Keywords: muscle-sparing rib-sparing thoracotomy, minimally 
invasive lung cancer radical surgery, lung cancer lymph nodes 
dissection, minimally invasive small incision
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P1.07-014 EFFECT OF ADVANCED AGE ON PERI-OPERA-
TIVE OUTCOMES AFTER ROBOTIC-ASSISTED PULMO-
NARY LOBECTOMY: RETROSPECTIVE ANALYSIS OF 180 
CONSECUTIVE CASES
Wei Wei Zhang1, Frank O. Velez-Cubian1, Tawee Tanvetyanon2, 
Kathryn L. Rodriguez1, Matthew R. Thau1, Jacques-Pierre Fontai-
ne2, Joseph R. Garrett2, Carla C. Moodie2, Lary A. Robinson2, Eric M. 
Toloza2
1University Of South Florida College Of Medicine/United States Of 
America, 2Thoracic Oncology, Moffitt Cancer Center/United States Of 
America
Background: Technological advances and increased life expec-
tancies have resulted in increasingly complex procedures being 
performed more frequently on patients with advanced age. As 
surgeons gain competency in robotic-assisted surgery, surgeons 
are extending the benefits of these minimally-invasive procedures 
to geriatric patients. Thus, we investigated the complication rates 
after robotic-assisted pulmonary lobectomy in patients with ad-
vanced age.
Methods: We retrospectively analyzed 180 consecutive patients 
who underwent robotic-assisted lobectomy by one surgeon bet-
ween September 2010 and February 2013. Patients were grouped 
by age >77 at the time of operation (Group A) versus age <77 
(Group B). Clinically significant perioperative complications were 
noted, including minor complications, such as wound infection and 
anemia requiring transfusion, and more serious major complica-
tions, such as empyema and deep venous thrombosis/pulmonary 
embolus (DVT/PE). Rates of perioperative complications, conver-
sion to open lobectomy, chest tube days, hospital length of stays 
(LOS), and in-Hospital mortality were compared between the two 
groups, with p-value <0.05.
Results: A total of 180 patients were included (mean age 67yr). 
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had undergone a lobectomy / segmentectomy for lung cancer 
between April 2009 and April 2013 at Ayabe City Hospital. Video 
assisted thoracic surgery (VATS) was performed in all 41 patients. 
They were classified into 2 groups: the stapler group underwent 
the routine surgical procedure (ST group), and the other group did 
not have staplers applied; other devices were used (OD group). 
Postoperative respiratory function after pulmonary resection was 
analyzed mainly. We also analyzed other things between the ST 
group and the OD group (for example; gender, laterality, smoking, 
synechia, excision site, and the number of staplers). Postoperative 
respiratory function was analyzed by means of the ratio between 
predicted postoperative FEV1.0 (Forced Expiratory Volume in first 
second) and postoperative FEV1.0. The predicted postoperative 
FEV1.0 was calculated utilizing the methodology of Juhl B. et al 
(Acta Anaesthesiol Scand, 1975).
Results: There were 25 men and 16 women with a mean age of 
69.6 years old (51-83 years old). Forty-one patients underwent 39 
lobectomies and 2 segmentectomy. All patients recovered and 
were discharged home. There was no operative mortality, and no 
hospital deaths. No significant difference of Postoperative respi-
ratory function was observed between the ST group and the OD 
group (106.6±15.4 vs 105.1±20.7 %; p=0.833). However, Postopera-
tive respiratory function of laterality was significantly lower for the 
right side than the left side (101.8±16.3 vs 114.9±12.1 %; p=0.012). 
Moreover, the operative time was significantly longer in the ST 
group compared with the OD group (275±74.8 vs 206±31.6 min; 
p=0.02). There was no statistically significant difference between 
the two groups regarding the postoperative hospitalization length 
(5.6±2.8 for ST vs 5.1±1.4 days for OD; P=0.639) and the duration 
of the chest tube placement (3.5±2.9 for ST vs 3±1.8 days for OD; 
P=0.67).
Conclusion: Persistent air leaks require prolonged chest tube drai-
nage time, which increases the risk of pleuropulmonary infections, 
associated pain, and consequently longer hospital stays. Several 
tools and techniques have been used to prevent postoperative air 
leaks, but in this study, the utilization of staplers for the interlobar 
fissures dissection did not affect postoperative respiratory func-
tion when patients underwent lung resections.
Keywords: Video assisted thoracic surgery, postoperative FEV1.0, 
Lung cancer, interlobar fissures dissection
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P1.07-017 PROGNOSTIC IMPACT OF CYTOREDUCTIVE 
SURGERY FOR NON-SMALL CELL LUNG CANCER WITH 
MALIGNANT PLEURAL EFFUSION DETECTED AT  
SURGERY
Yohei Taniguchi, Hiroyuki Kaneda, Takahito Nakano, Tomohito 
Saito, Toshifumi Konobu, Yukihito Saito
Thoracic Surgery, Kansai Medical University Hirakata Hospital/Japan
Background: Malignant cells in the pleural effusion are classified 
as stage IV in the 7th edition of the TNM-staging of lung cancer. 
The prognosis of non-small cell lung cancer patients with malig-
nant pleural effusion is reported to be poor as the patients with 
malignant pleural effusion are generally not subjected to surgery. 
However, clinically relevant question whether or not the primary tu-
mor should be resected when malignant pleural effusion is first de-
tected at thoracotomy, is controversial. Our purpose is to address 
disease free survival with acceptable toxicities.
Methods: Total of 40 atients with histologically proven carcinoma, 
tumour ≤ 5 cm in length, KPS > 50 with no prior malignancy or N0 
status and unfit for surgery were taken in to the study. Intraluminal 
high dose rate (HDR) brachytherapy treatment was performed with 
the remote after loading HDR microselecton unit which contained 
a single cylindrical high-activity 192Ir source. Dose fractionation 
used 15 Gy in 3 # at 1 week interval. The prescription point was 0.5 
cm from mucosal surface from the mid source. The improvement 
in dysphagia free scores, patterns of failure and treatment related 
toxicities were assessed. After treatment all patients were followed 
up with UGIE, barium swallow and chest X-ray at 2 months.
Results: Out of 40 cases analyzed, the lesion was present in mid 
1/3rd in 18 patients, upper 1/3rd in 12 and involving GE junction in 
10 cases. The median length of treatment was 5 cm. Gr II dyspa-
hagia was in 34% and Gr III in 66% patients were seen. After treat-
ment 40% of patients had improvement in dyspahgia. Stricture was 
found in 4 patients, ulceration in 7 and bleeding in 3 and 2 patient 
had trachea-esophageal fistula. Eight patients lost to follow up. 
Patients who had Gr II dysphagia initially had no progression in the 
complain. The median overall survival is 12.1 months and the me-
dian PFS was 18 months. who had initially Gr II dysphagia had no 
progression of dysphagia.
Conclusion: With dose fractionation of 5 Gy / # for 3 # and CT 
based planning enabled good optimisation along with decreased 
risk of high dose to mucosa by using 6 Fr tube, this schedule has 
shown effective palliation in dysphagia and few complication rates 
and comparable survival benefits. However a larger number of 
cases and a longer follow up is required.
Keywords: Intraluminal brachytherapy, Dysphagia palliation,  
Esophageal cancer
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P1.07-016 DOES THE UTILIZATION OF STAPLERS FOR 
THE INTERLOBAR FISSURES DISSECTION REALLY AF-
FECT POSTOPERATIVE RESPIRATORY FUNCTION?
Masashi Yanada1, Junichi Shimada2, Masanori Shimomura2, Hiro-
aki Tsunezuka3
1Thoracic Surgery, Ayabe City Hospital/Japan, 2Division Of Chest Sur-
gery, Department Of Surgery, Kyoto Prefectural University Of Medici-
ne/Japan, 3Chest Surgery, Division Of Chest Surgery, Kyoto Prefectural 
University Of Medicine,/Japan
Background: We need to separate the interlobar fissures during 
pulmonary lobectomy / segmentectomy. Accordingly, we can 
select from among several different devices to separate the in-
terlobar fissures. But it is difficult to determine which devices are 
most beneficial. On one hand, there is an opinion that it is not 
recommended to use staplers for the interlobar fissures dissection 
because of a reduction of pulmonary compliance. On the other 
hand, some surgeons feel that staples do not affect postoperative 
pulmonary function. The purpose here is to elucidate on whether 
the use of staplers for the interlobar fissures dissection affects 
postoperative respiratory function.
Methods: The study consisted of 41 patients who were exami-
ned for pulmonary function test before and after surgery. They 
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chest roentgenograms, bronchoscopy, computed tomography 
of the thorax, abdomen, MRI of brain, and radionuclide bone 
scanning. Indications for surgery included clinical stage I,II, or IIIA 
(except bulky N2 ) disease. The surgical procedure was lobectomy 
in 19 patients, sleeve lobectomy in 2 patients, segmentectomy in 1 
patient, and wedge resection in 7 patients. Curative operation ratio 
was 75.9%. The median intraoperative blood loss and operative 
time were 96 ml and 165 min. There was no blood transfusion case 
in this series. Postoperative pathological stage was stage IA in 11 
patients, IB in 8 patients, IIA in 1 patient, IIB in 5 patients, IIIA in 
2 patients, IIIB in 1 patient. 25 patients (86%) were what is called 
limited disease. Histological diagnosis was adenocarcinoma in 14 
(48.3%) patients, squamous cell carcinoma in 11(37.9%) patients, 
large cell neuroendocrine carcinoma (LCNEC) in 2 (6.9%) patients, 
large cell carcinoma in 1 (3.45%) patient, undifferentiated carcinoma 
in 1 (3.45%) patient. Patients presented postoperative complications 
in high rate. The complications recorded were delirium in 9 (31.0%) 
patients, respiratory failure 3 (10.3%) patients, acute renal failure in 
2 (6.9%) patients, angina attack in 2 (6.9%) patients, atrial fibrillation 
in 1(3.5%) patient, cerebral infarction in 1 (3.5%) patient. Although 
surgical morbidity rate was 62.1%, surgical mortality rate was 0%. 
14 patients died until now, 7 of them were recurrent death. Overall 
patient 1, 3, and 5 years survival rate were 100%, 68.5% and 38.6%, 
respectively. Postoperative hospital days were 19.5±7.51.
Conclusion: Although surgical morbidity rate is high and 
postoperative hospital days is long, surgical results in this study are 
acceptable and support the value of surgical treatment in super-
elderly patients with lung cancer.
Keywords: Super-elderly Patients, Surgical Treatment, Lung cancer
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P1.07-019 IS VATS LOBECTOMY TOO EXPENSIVE? A 
COST ANALYZE OF INTRODUCING VATS LOBECTOMY 
TO A TERTIARY CARE HOSPITAL
Daniel G. French, Gordon Buduhan
Department Of Thoracic Surgery, Dalhousie University/Canada
Background: Video-assisted thoracoscopic (VATS) lobectomy is 
being performed more frequently in thoracic centers, but cost is a 
concern. Earlier studies have shown increased intraoperative but 
lower postoperative costs over open thoracotomy, but to date 
there has not been a published cost analyses in North America. The 
objective of this study is to compare the cost of introducing VATS 
lobectomy and traditional open lobectomy in a Canadian tertiary 
care hospital.
Methods: A retrospective cost analysis was done comparing 78 
VATS to 149 open lobectomies performed over 32 month period. 
Intraoperative (disposables, operating time) and postoperative 
costs (days in intensive care, intermediate care and ward units, days 
requiring acute pain service (APS), readmission) were compared, as 
well as hospital stay. A secondary analysis was performed to look at 
the effect on hospital costs of a learning curve for VATS lobectomy.
Results: The mean intraoperative, postoperative and total costs for 
VATS and open lobectomy were $4,770 and $2,166 (p-value = 0.01), 
$3929 and $5,604 (p < 0.0001), and $8,499 and $7,771 (p= 0.3), 
respectively. Median hospital stay for VATS and open lobectomy 
were 4 and 5 days (p< 0.0001), respectively. A significant difference 
the role of surgical resection for main tumor in such patients.
Methods: A retrospective review was conducted with clinical 
charts of 155 patients with non-small cell lung cancer who had 
pleural effusion detected at radical surgery between January 2006 
and December 2012 at Kansai Medical University Hirakata Hospi-
tal. We compared prognosis of the patients with or without surgi-
cal tumor resection.
Results: Of the 155 patients with pleural effusion, 30 patients had 
malignant cells and 125 did not. Of the 30 patients, 18 were men 
and 12 were women. Twenty-five tumors were adenocarcinoma, 
3 were large-cell neuroendocrine carcinoma, 1 was small cell car-
cinoma and 1 was squamous cell carcinoma. Seven patients were 
treated with lobectomy, 12 were treated with wedge resection and 
11 were with exploratory thoracotomy. Five-year survival rate was 
35.0% in patients with primary tumor resection, whereas none of 
the patients without surgical resection of tumors survived 5 years. 
Two-year survival rate was 22.7% in patients with exploratory tho-
racotomy.
Conclusion: The prognosis of patients with malignant pleural ef-
fusion detected at surgery was not such poor compared to that 
of generally reported stage IV patients. Patients with surgical re-
section of main tumor showed better survival compared to those 
without surgical resection, suggesting that cytoreductive surgery 
contributed to multimodality treatment in patients with malignant 
pleural effusion. Based on our series of patients, status of N0 may 
be candidates for primary tumor resection even in patients with 
malignant pleural effusion.
Keywords: malignant pleural effusion, non-small cell lung cancer, 
surgical resection
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P1.07-018 SURGICAL TREATMENT FOR SUPER-ELDERLY 
PATIENTS ( OVER 85 YEARS OLD ) WITH LUNG CANCER
Osamu Kawashima1, Seiichi Kakegawa1, Kimihiro Shimizu2, Izumi 
Takeyoshi2, Yoshio Tomizawa3, Akihiro Yoshii3, Reiko Yoshino3, 
Ryusei Saito3
1Thoracic Surgery, National Hospital Organization Nishigunma Hospital/
Japan, 2Division Of Thoracic And Visceral Organ Surgery, Gunma 
University Graduate School Of Medicine/Japan, 3Respiratory Medicine, 
National Hospital Organization Nishigunma Hospital/Japan
Background: It is by now widespread that surgical resection is 
standard curative treatment for lung cancer, however in super-
elderly cancer patients (over 85 years old) there is no clear evidence 
of safety and efficacy of surgical approach. This study attempts to 
clarify the benefit of surgical treatment for them.
Methods: Between January 2002 and December 2012, among 
1229 consecutively treated patients with primary lung cancer who 
underwent surgical resection, 29 patients (2.4%) were over 85 
years old. Clinicopathological information on these patients was 
retrospectively reviewed and the surgical outcome was investigated.
Results: There were 21 men and 8 women, with a mean age of 
86.5 years old (range, 85-91 years old). All patients were selected 
as operable candidates based on the results of routine staging 
procedures consisting of physical examination, blood chemistry, 
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scoring, Thoracic surgery
POSTER SESSION 1 - SURGERY  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.07-021 THE RISK FACTOR OF LATE RECURRENCE IN 
PATIENTS WITH COMPLETELY RESECTED NON-SMALL 
CELL LUNG CANCER
Yoshihisa Kobayashi1, Yasushi Yatabe2, Osamu Takahashi3, Tetsu-
ya Mizuno1, Hiroaki Kuroda1, Noriaki Sakakura1, Yukinori Sakao1
1Department Of Thoracic Surgery, Aichi Cancer Center Hospital/Japan, 
2Dept. Of Pathology And Molecular Diagnostics, Aichi Cancer Center/
Japan, 3St. Luke’s Life Science Institute, St. Luke’s International Hospi-
tal/Japan
Background: Recurrences in patients with completely resected 
non-small cell lung cancer (NSCLC) rarely occur more than 5 years 
after operation. Various follow-up programs for postoperative pati-
ents are recommended in each guideline. The purpose of this stu-
dy is to clarify the risk factor of late recurrence and to determine 
which patients might benefit from routine computed tomography 
(CT) follow-up more than 5 years after operation.
Methods: Between January 1995 and December 2006, 1,437 con-
secutive patients with NSCLC underwent pulmonary resections at 
our institution. Of these, 617 patients remained recurrence-free for 
5 years after resection. We retrospectively analyzed the clinicopa-
thological features of these patients. Disease free survival (DFS) 
was defined as endpoint and was analyzed using Cox proportional 
hazards model. Variables for univariate analysis were as follows: 
age, gender, smoking history, carcinoembryonic antigen, operative 
procedure, pathological type, pathological stage, and pleural lava-
ge cytology (PLC).
Results: At the median follow-up time of 7.5 years, 20 patients 
(3.2%) developed late recurrence more than 5 years after resec-
tion. Distant metastasis occurred in 15 patients and locoregional 
recurrence occurred in 5 patients (Table 1). There were 3 patients 
(15%) with positive PLC in late recurrence group and 7 patients 
(1.2%) in recurrence free group. In univariate analysis, only PLC was 
significant. In a multivariate analysis, PLC was a significant pre-
dictor of late recurrence. The Hazard ratio (HR) for positive PLC in 
comparison to negative PLC was 5.75 (95% CI 1.16–19.26; p=0.04)
.
in the intraoperative cost of VATS lobectomy was realized after the 
first 20 cases, with the mean intraoperative cost decreasing from 
$5095 to $4510 (p = 0.03).
Conclusion: The total costs of VATS and open lobectomy are 
equivalent. Increased disposables cost and longer operating time 
account for higher intraoperative cost of VATS; shorter hospital 
stay and less requirement for APS reduce the VATS postoperative 
costs. There is a learning curve present when introducing VATS 
lobectomies to an institution. After 20 cases intraoperative costs 
reduce significantly with more efficient use of disposables and 
operating time.
Keywords: VATS lobectomy, Lung cancer, cost analyze
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P1.07-020 THORACOSCORE AND EUROPEAN SOCIETY 
OBJECTIVE SCORE DO NOT PREDICT MORTALITY IN 
THE UK POPULATION - IS IT TIME FOR A NEW RISK MO-
DEL?
Annabel J. Sharkey1, Priyadharshanan Ariyaratnam1, Elizabeth 
Belcher2, Simon Kendall3, Eric Lim4, Babu Naidu5, Wyn Parry6, 
Mahmoud Loubani1
1Department Of Cardiothoracic Surgery, Castle Hill Hospital/United 
Kingdom, 2John Radcliffe Hospital/United Kingdom, 3The James Cook 
University Hospital/United Kingdom, 4Royal Brompton Hospital/United 
Kingdom, 5Department Of Thoracic Surgery, Heart Of England NHS 
Foundation Trust/United Kingdom, 6Norfolk And Norwich University 
Hospital/United Kingdom
Background: Thoracoscore and the European Society Objective 
Score (ESOS.01) are two risk scoring systems used to estimate risk 
of death as part of informed consent, and to allow risk adjusted 
outcomes to be evaluated. We aimed to evaluate if these are valid 
tools for use in the United Kingdom (UK) population.
Methods: A multi-centre, prospective study was carried out on 
patients undergoing lung resection at 6 UK centres. Data were 
submitted electronically using our online data collection tool. 
Univariate and multivariate analyses were carried out to determine 
the factors affecting mortality. A Receiver Operating Characteristic 
(ROC) analysis was performed in order to determine the ability of 
the Thoracoscore and ESOS.01 to predict in-Hospital mortality.
Results: Data were submitted for 2570 patients. 345 patients were 
excluded due to incomplete data fields. Of the remaining 2245 
patients, the observed in-Hospital mortality was 31 patients (1.38%). 
Mean Thoracoscore was 2.66(SD±3.21). Logistic regression analysis 
identified gender (p=0.004, hazard ratio 4.786) and co-morbidity 
score (p=0.005, hazard ratio 3.289) as risk factors for mortality. A 
sub-analysis was performed using data from 1912 patients. In this 
group, mean Thoracoscore was 2.55(SD±2.94), mean ESOS.01 was 
2.11(SD±1.41), and these were statistically significantly different 
(p<0.0001). The observed in-Hospital mortality was 28 patients 
(1.46%). The c-index for Thoracoscore was 0.705, and for ESOS.01, 
0.739. Furthermore, there was poor correlation between the two 
scoring systems (r=0.362).
Conclusion: Both Thoracoscore and ESOS.01 overestimated 
mortality in the UK population. There is a continued need to 
develop an appropriate risk prediction system for the UK.
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P1.07-023 DIRECT PROJECTION OF THREE DIMENSIO-
NAL VOLUME ANALYZED CT IMAGES TO THE SURGICAL 
FIELD BY THE PORTABLE DIGITAL LIGHT PROCESSING 
PROJECTOR FOR ASSISTING MINIMALLY INVASIVE 
THORACIC SURGERY
Takashi Anayama, Ryohei Miyazaki, Nobutaka Kawamoto, Ken-
taro Hirohashi, Hironobu Okada, Motohiko Kume, Kazumasa 
Orihashi
Department Of Surgery Ii, Kochi Medical School, Kochi University/
Japan
Background: Video-assisted thoracoscopic surgery (VATS) has 
been applied widely to thoracic surgery such as VATS lobectomy, 
resection of chest wall/ mediastinal tumors. The appropriate place-
ment of trocar is the keys for these procedures. Many surgeons 
places the first -port to look inside of the thoracic cavity by thora-
coscope, and determine the position of the other ports. However, 
there are differences in deformation and the thickness of the tho-
rax of individual patients. In this study, we analyzed the adequate 
surgical approach by analyzing the three dimensional Computed 
tomography (3D-CT), and develop the prototype system to project 
the 3D-CT image to the patient body directly to mark the points of 
surgical approach.
Methods: 3D-CT based minimally invasive surgery was designed 
using 3D-CT volume analyzer Synapse Vincent (Fuji film, Japan). 
Skin window, skeletal structure, intra-thoracic anatomical images 
were reconstructed respectively. The designed points of trocar 
were marked in 3D-CT image of skin window and projected on 
the patinet’s body by a liquid projector. Positional / magnification 
power correction was made using the land marks such as sternal 
notch, bilateral nipples, costal arch, and acromion. The error of the 
system was evaluated using artificial thorax model. Two chest wall 
tumor patients and 2 mediastinal tumor patients were enrolled for 
the clinical study. Each surgical incision was planned based on the 
system. The system validity was evaluated by 3 surgeons.
Results: The error of liquid projector guided skin marking was 
within 9.3 ± 2.5mm in the distance of 15 cm the center of pro-
jection point using artificial thorax model. 3D-CT based surgical 
approach were prospectively planned and the position of skin 
incisions were marked on the patients’ body by the liquid projector 
which projecting the position of the trocars determined by 3D-CT 
simulations. In the clinical study, Each skin incision made on the 
point indicated by the liquid projector were placed in the adequa-
te position.
Conclusion: Direct projection of three dimensional volume analy-
zed CT images to the surgical field by the portable liquid projector 
indicated the adequate approaching point on the surgical field for 
the minimally invasive surgery. This method may present the ap-
propriate surgical approach to thoracic surgeons.
Keywords: image-guided surgery, Three dimensional computed 
tomography, volume rendering, pure VATS lobectomy
Conclusion: PLC is a strong independent factor for late recurrence. 
Patients with positive PLC might be good candidates for routine 
chest CT more than 5 years after resection.
Keywords: pleural lavage cytology, late recurrence, non-small cell 
lung cancer, postoperative recurrence
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P1.07-022 RESULTS OF STUDY EVALUATING INFLAMM-
ATORY BIOCHEMICAL PARAMETERS AND OXIDATIVE 
STRESS IN PATIENTS UNDERGOING VATS AND OPEN 
LOBECTOMY FOR EARLY STAGE NSCLC.
Ints Silins1, Alvils Krams2, Maris Apsvalks1, Arta Sirgeda1, Alise 
Silova3, Aigars Petersons3
1Department Of Thoracic Surgery, Riga Eastern Clinical University 
Hospital, Centre Of Tb And Lung Diseases/Latvia, 2Department Of Pul-
monology, Riga Eastern Clinical University Hospital, Centre Of Tb And 
Lung Diseases/Latvia, 3Riga Stradins University/Latvia
Background: Surgery results in a wide range of unfavorable altera-
tions in body homeostasis which are referred to as surgical stress. 
Low total antioxidant capacity could be indicative of oxidative 
damage associated with increased morbidity and mortality. When 
surgical stress generates oxygen radicals, they are quickly detoxi-
fied by antioxidant network, leading to a decrease in the potential 
of antioxidants which can be measured. Video-assisted thoraco-
scopic (VATS) and open lobectomy approaches were evaluated to 
determine if there is any difference in acute phase response and 
oxidative stress associated with surgery for early stage non-small 
cell lung cancer (NSCLC).
Methods: Our prospective study included 30 patients who un-
derwent lobectomy for early stage NSCLC: by conventional open 
thoracotomy approach (n=15) and VATS approach (n=15). We mea-
sured changes in plasma total antioxidant capacity (TAC), lactate 
dehydrogenase (LDH) and C-reactive protein (CRP), fibrinogen, 
total protein (TP) concentrations and WBC count preoperatively, 
24h and 72h postoperatively, on the day of drain removal, and 1 
and 9 days after the drain removal. Concentrations of TAC, LDH 
and TP in pleural fluid were observed 24h, 72h postoperatively and 
on the day of drain removal.
Results: Changes in TAC, LDH, CRP, fibrinogen, TP and WBC count 
in plasma for both groups followed similar kinetics. The response 
of CRP and LDH (p<0.05), as well as WBC count and fibrinogen 
(0.05<p<0.1) all were lower in VATS lobectomy (VATS-L) group 
compared with open lobectomy (OL) group. TAC level in plasma 
started to decline quicker and recovered later during postoperati-
ve course in OL group in comparison with VATS-L group. TAC valu-
es in pleural fluid were diminishing postoperatively until the day of 
drain removal in both groups.The most dynamic parameters were 
LDH and TP levels in pleural fluid – both were highest 24h post-
operatively and made fast recovery until the day of drain removal, 
and both also showed tendency to be lower in VATS-L patients 
compared with OL patients.
Conclusion: Our results suggest that the VATS approach compa-
red to open thoracotomy approach could be associated with less 
tissue trauma and surgical stress. We can expect that decreasing 
intraoperative oxidative stress could dynamically contribute to the 
improvement of postoperative recovery.
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with cN2/pN2 stage who underwent surgery with neoadjuvant or 
adjuvant treatment from 2003 to 2011. Overall survival (OS) and 
disease-free survival (DFS) were estimated using Kaplan-Meier me-
thods. A multivariate analysis for prognostic factors was performed 
by the Cox proportional hazards regression model.
Results: The median follow-up time was 24.5 months (range, 1 to 
110 months) for 72 NSCLC patients. Neoadjuvant treatment was 
administered to 32 patients (44.4%), and adjuvant therapy was 
given to 40 patients (55.6%). Pneumonectomies were performed 
more frequently in patients who were treated with neoadjuvant 
therapy (25% vs. 15%). Complete resection was achieved more 
commonly in patients who underwent surgery followed adjuvant 
treatment (95% vs. 75%). Five year OS was 40.5% and 3-year DFS 
was 34.3%. In a multivariate analysis, incomplete resection was 
prognostic for a worse OS (hazard ratio: 3.07, 95% CI: 1.20 to 7.86). 
The more advanced pathological T stage was prognostic factor for 
a worse DFS (hazard ratio: 3.21, 95% CI: 1.42-7.24). Number of me-
tastatic lymph node is important prognostic factor for OS and DFS.
Conclusion: Favorable survival can be achieved in cN2/pN2 NS-
CLC patients after resection with neoadjuvant therapy or adjuvant 
therapy. Survival is more favorable for complete resection than 
incomplete resection.
Keywords: surgery, Lung cancer, Mediastinal node metastasis, 
survival
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P1.07-026 VATS REDUCES SURGICAL RISK OF LOBECTO-
MY FOR HIGH RISK PATIENTS WITH EARLY NON-SMALL 
CELL LUNG CANCER
Moira De Valence, Wael C. Hanna, Eshetu G. Atenafu, Thomas 
Waddell, Marcelo Cypel, Andrew Pierre, Marc De Perrot, Kazuhiro 
Yasufuku, Shaf Keshavjee, Gail E. Darling
Division Of Thoracic Surgery, Toronto General Hospital, University 
Health Network, University Of Toronto/Canada
Background: Patients considered to be at increased risk from 
surgery may be offered nonsurgical therapies for early stage non-
small cell lung cancer (NSCLC). However, video assisted thoracic 
surgery (VATS) is associated with lower morbidity and thus may 
permit anatomic resection for patients considered increased risk.
Methods: Our institutional database was queried to find all pa-
tients who received lobectomy for early stage NSCLC between 
2002-2010. Patients were grouped into cohorts of standard (SR, 
n=536) or increased risk (IR, n=72) using the ACOSOG Z4099/
RTOG 1021 eligibility criteria. Morbidity and mortality were com-
pared based on risk group and surgical method.
Results: Median age was 72 and 67 years for IR and SR respec-
tively. Most patients were stage I (IR: 83.3%; SR: 84.5%). Although 
IR patients had increased overall and pulmonary complications 
compared to SR (overall: p=0.0004; pulmonary: p<0.0001), there 
were no differences between the subset of IR patients who had 
VATS resections and SR patients resected by either open or VATS 
techniques (overall: p=0.7697; pulmonary: p=0.3219) [Table 1]. 
Survival at 5 years was significantly lower for IR patients resected 
by open techniques (46.2%; p=0.0028) but those resected by VATS 
(61.2%) had similar survival to SR patients resected by either VATS 
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P1.07-024 SURGICAL OUTCOME OF ELDERLY PATIENTS 
WITH NON-SMALL CELL LUNG CARCINOMA
Tomas Gudbjartsson1, Kristjan Baldvinsson1, Andri W. Orrason1, 
Hunbogi Thorsteinsson1, Martin I. Sigurdsson1, Steinn Jonsson2
1Cardiothoracic Surgery, Landspitali University Hospital/Iceland, 2Pul-
monlogy, Landspitali University Hospital/Iceland
Background: Elderly patients are increasingly diagnosed and tre-
ated for non-small cell lung carcinoma (NSCLC). We studied short- 
and long-term outcomes following pulmonary resection in elderly 
(≥75 yrs) patients and compared them to younger patients.
Methods: This was a nation-wide study of all patients in Iceland 
that underwent pulmonary resection for NSCLC between 1991 and 
2010. Clinical features, complications and survival were compared 
between patients older (n=108, 21%) and younger (n=404, 79%) 
than 75 years.
Results: Preoperative lung function and histology were compa-
rable in both groups, however, coronary artery disease was more 
common in the elderly group, as were sublobar resections (24% 
vs. 8%, p<0.001). In the elderly group 91% of patients were diag-
nosed in TNM-stages I+II compared to 75% in younger patients 
(p<0.001). Mortality within 30 days was similar in both groups (<1%) 
as was the rate of minor and major complications. Overall survival 
at 5 years was comparable for both groups (39% vs. 42%, p=0.28) 
as was cancer specific survival (55 vs. 47%, p=0,64). In multivariate 
analysis age over 75 years did not significantly influence survival 
(HR 1.20, CI: 0.87-1.66, p=0.26).
Conclusion: Early and late outcomes of pulmonary resections in 
elderly NSCLC-patients were comparable to younger patients. 
However, selection of patients could have biased the outcome in 
favour of the elderly patients with lower stages, and more sublobar 
resections. Surgery seems to be a valid treatment option for NS-
CLC in the elderly.
Keyword: NSCLC, elderly, surgery, outcome
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P1.07-025 LONG-TERM SURVIVAL OF PATIENTS WITH 
CN2/PN2 NON-SMALL-CELL LUNG CANCER
Sanghoon Jheon, Eunjue Yi, Kwhanmien Kim, Sukki Cho, Hee 
Chul Yang, Yangki Seok, Dongsub Noh
Department Of Thoracic And Cardiovascular Surgery, Seoul National 
University Bundang Hospital/Korea
Background: Optimal management of stage IIIA-N2 non-small cell 
lung cancer (NSCLC) is controversial. However, surgery is used in-
creasingly for stage IIIA NSCLC. We believe that surgical outcome 
of NSCLC patients with clinical N2 and pathological N2 (cN2/pN2) 
is worst among the NSCLC patients with cN2 disease. Analysis 
aimed at evaluating survival rates of patients with cN2/pN2 stage, 
and at studying prognostic factors for long-term survival.
Methods: This is a retrospective study of 72 NSCLC patients 
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Results: The preoperative FEV1/FVC was <70% and FEV1% <50% 
in all 61 patients in this study, with a mean preoperative FEV1 of 
0.99 L (0.54-1.58 L) and mean FEV1% of 38.4% (22-49.82%). All of 
the 61 patients underwent the VATS lobectomy or sleeve resection 
plus systemic lymph node dissection. The mean operative time 
was 218 minutes (120-355 minutes), with a mean intraoperative 
blood loss of 342 ml (50-1600 ml). None of the patients converted 
to thoracotomy. Multivariate statistical analysis revealed that age 
and TNM staging after tumor resection were independent predic-
tive factors for the 5-year survival in those patients (p=0.014 and 
0.013).
Conclusion: With preoperative imaging studies, pulmonary func-
tion assessment and target positioning, VATS leboectomy can be 
safely and effectively performed for patients with NSCLC and se-
vere COPD to achieve a satisfying long-term survival outcome.
Keywords: lobectomy, VATS, COPD, Lung cancer
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P1.07-028 THORACOSCOPIC MINIMALLY INVASIVE 
SURGERY FOR NON-SMALL CELL LUNG CANCER IN 
PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE
Fei Cui, Jun Liu, Jianxing He
The First Affiliated Hospital Of Guangzhou Medical College/China
Background: To determine the incidence of peri-operative complica-
tions in non-small cell lung cancer (NSCLC) patients with co-existent 
chronic obstructive pulmonary disease (COPD) who undergo lung 
resection via traditional and minimally invasive techniques.
Methods: A retrospective analysis was conducted of 152 NSCLC pati-
ents with COPD who underwent thoracoscopic minimally invasive sur-
gery. Particular attention is given to the relationship between disease 
severity or surgical approach and the incidence of complications.
Results: The prevalence of respiratory and cardiac complications was 
significantly higher in patients with severe/extremely severe COPD 
than those with mild to moderate COPD (respiratory compications: 
37.3% vs. 20.4%, P=0.022; cardiac complictions: 16.9% vs. 6.5%, 
P=0.040). Patients who underwent complete-video assisted thora-
coscopic surgery (c-VATS) had a significantly lower overall morbidity 
of adverse reactions than those who had undergone VATS major 
resection surgery (26.3% vs. 42.1%, P=0.044). Among patients with 
severe/extremely severe COPD, there was no significant difference 
in the incidence of any complication between the lobectomy group 
and wedge resection group (38.8% vs. 70.0%, P=0.072). Overall, the 
occurrence of adverse reactions was significantly lower in patients 
who underwent c-VATS than in those who had undergone VATS major 
resection surgery (34.2% vs. 61.9%, P=0.038).
Conclusion: VATS techniques are suitable for COPD patients and are 
demonstrated here to lower the incidence of post-operative compli-
cations when compared with more invasive approaches. Minimally 
invasive approaches should be considered in patients with COPD who 
are deemed high risk for curative surgery by traditional techniques.
Keywords: surgery, VATS, COPD, Lung cancer
(65.1%) or open techniques (64.3%; p=0.83) [Figure 1]. There was 
no significant difference in operative mortality between the IR and 
SR groups (IR: 1.4%; SR: 0.4%; p=0.2832).  
Table 1: Post-operative complications stratified by risk subgroup 
and surgical method
Increased 
risk (%) 
Standard 
Risk (%) 
Increased Risk with 
VATS resection (%) 
Overall 
Complica-
tions
33.3 16.2 18.2
Pulmonary 
Complica-
tions
30.6 11.8 18.2
Figure 1: Overall survival following lobectomy for NSCLC, stratified 
by risk group and surgical method
Conclusion: Surgical morbidity and mortality are reduced in pa-
tients at increased risk from lobectomy when resected by VATS 
offering them equivalent outcomes to standard risk patients.
Keywords: Video-assisted thoracic surgery, non-small cell lung 
cancer, lobectomy, Surgical risk assessment
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P1.07-027 VATS LOBECTOMY FOR NON-SMALL CELL 
LUNG CANCER IN PATIENTS WITH SEVERE COPD
Wei Wang, Zhiqiang Xu, Xinguo Xiong, Weiqiang Yin, Wenlong 
Shao, Xin Xu, Hanzhang Chen, Jianxing He
The First Affiliated Hospital Of Guangzhou Medical College/China
Background: To assess the feasibility, safety and long-term outco-
mes of video-assisted thoracic surgery (VATS) lobectomy for the 
treatment of non-small cell lung cancer (NSCLC) in patients with 
severe COPD.
Methods: The clinical data of patients with NSCLC and severe 
COPD (preoperative FEV1% <50%) who underwent VATS lobec-
tomy from January 2000 to January 2011 were retrospectively 
analyzed to identify their demographic parameters, postoperative 
complications and outcomes.
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factors, which were then integrated to build the nomogram. Se-
venty-five percents of randomly sampled data were used to build 
the nomogram while the remaining data were used to validate the 
model. The predictive accuracy and discriminative ability of the 
nomogram was determined by concordance index (C-index). Risk 
group stratification within a certain stage was proposed for the 
nomograms.
Results: Among 26 clinical variables, 13 independent prognostic 
factors finally entered the nomogram (Figure 1), including 
age, sex, histology, tumor location, operation type, assess to 
complete video-assisted thoracoscopic surgery (VATS), primary 
tumor (T) stage, lymph nodes (N) stage, TN stage, number of 
dissected lymph nodes, blood loss volume, and complications. 
The calibration curves for probability of 1, 3, 5, 10-year overall 
survival (OS) represented good agreement between prediction 
by nomogram and actual observation in the validation set. The 
C-index of the nomogram was statistically higher than that of the 
7th edition TNM stage for predicting survival (0.71 vs 0.66, P=0.01). 
The stratification into different risk groups allows significant 
distinction between Kaplan-Meier curves for survival outcomes in 
each TNM stage respectively (P<0.01 for all stages, Figure 2).
 
Conclusion: We developed a novel 
and validated clinical nomogram 
that could provide individual and 
more accurate predictions for OS of 
resected NSCLC patients compared 
with the TNM staging system. This 
prognostic model may support 
clinicians and patients in decision 
making, such as to identify those with 
higher risk for poor prognosis.
Keywords: Lung cancer, surgery, 
Nomogram, predictor factor
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P1.07-029 NOMOGRAM FOR PREDICTING SURVIVAL 
IN PATIENTS WITH RESECTED NON-SMALL CELL LUNG 
CANCER
Wenhua Liang, Daoyuan Wang, Qiuhua Deng, Hui Pan, Xiaoshun 
Shi, Chucheng Zhong, Lili Mo, Jiaxuan Wang, Jianxing He
The First Affiliated Hospital Of Guangzhou Medical College/China
Background: Nomogram is a widely used tool for cancer progno-
sis due to its improved individual prediction of survival through 
combining various significant prognostic factors. The objective of 
this study was to develop a clinical nomogram for predicting survi-
val for patient with resected non-small cell lung cancer (NSCLC).
Methods: Based on data from a multi-Institutional registry for 6111 
patients with resected NSCLC at China between January 2001 
and December 2008, we performed univariate and multivariate 
stepwise Cox regression analyses to identify survival prognostic 
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T1-4N0-2M0 NSCLC in the middle lobe, were analyzed retrospec-
tively. 27 patients had lymph node metastases (N1:13, N2:14).
Results: The distribution of lymph node metastasis is shown 
in Figure 1a and 1b. Lobectomy was performed in 82 patients, 
lobectomy plus additional lung resection was performed in 8, 
bilobectomy was performed in 22, and pneumonectomy was per-
formed in two. Six patients underwent bronchial sleeve resection. 
The overall 5-year survival rate was 80.2% in patients without 
lymph node metastasis, 11.3% in N1, and 0% in N2 (p<0.0001). 
Four patients had metastasis to station 11s, and in all of these 
patients the tumors were located in the lateral segment (S4), were 
larger than 3 cm in diameter, and showed adenocarcinoma his-
tologically. Three of these four patients underwent bilobectomy. 
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P1.07-030 PROGNOSTIC FACTORS FOR PATIENTS IN 
BRAIN METASTASIS WITH NO EXTRACRANIAL METAS-
TASIS AFTER RESECTION OF NON-SMALL CELL LUNG 
CANCER
Mi Kyung Bae, Seong Yong Park, Chang Young Lee, Jin Gu Lee, Dae 
Joon Kim, Hyo Chae Paik, Kyung Young Chung
Thoracic And Cardiovascular Surgery, Yonsei University College Of 
Medicine/Korea
Background: We investigated the prognostic factors in patients 
with only brain metastasis as the postoperative initial recurrence 
after resection of NSCLC
Methods: We conducted a retrospective study of patients who 
had undergone resection for NSCLC between 1992 and 2012 and 
found 113 had experienced postoperative brain metastasis as initi-
al metastasis. We reviewed these patients retrospectively.
Results: The 1-year survival and 3-year survival rate after the di-
agnosis of brain metastasis was 39.8% and 19.0 %. On univariate 
analysis, the significant prognostic factors included gender (3-year 
survival rate, female versus male; 26.3% versus 15.6%, p = 0.027), 
pneumonectomy (3-year survival rate, pneumonectomy versus 
non-pneumonectomy; 5.6% versus 27.4%, p = 0.009), adenocarci-
noma (3-year survival rate, adenocarcinoma versus non-adenocar-
cinoma; 10.7% versus 25.3%, p = 0.016) and interval to brain meta-
stasis after surgery (3-year survival rate, < 1 year versus 1 ~2 year 
versus >2 year; 14.2% versus 25.3% versus 38.9%, p = 0.049).
Conclusion: In patients with brain metastasis after lung resection 
for NSLCL, female, non-pneumonectomy, non-adenocarcinoma 
and longer interval to metastasis after surgery showed favorable 
positive prognosis.
Keywords: brain metastasis, Prognosis, NSCLC
POSTER SESSION 1 - SURGERY  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.07-031 IS LYMPH NODE DISSECTION AT STATION 11S 
NECESSARY IN PRIMARY LUNG CANCER LOCATED IN 
THE MIDDLE LOBE?
Riken Kawachi, Keisei Tachibana, Shin Karita, Yoko Nakazato, 
Yasushi Nagashima, Hidefumi Takei, Haruhiko Kondo, Tomoyuki 
Goya
Thoracic Surgery, Kyorin University Hospital/Japan
Background: Incomplete fissure between right upper and lower 
lobe must be divided when lymph nodes at station 11s are dissec-
ted, and an additional maneuver is required to divide the fissure 
for middle lobectomy. The purpose of this study was to determine 
whether or not dissection of station 11s lymph nodes is necessary 
in the case of lung cancers located in the middle lobe.
Methods: Between 2000 and 2012, 1657 patients underwent sur-
gical resection for non-small cell lung cancer (NSCLC). Of these, 
112 patients who underwent pulmonary resection greater than 
lobectomy and systemic lymph node dissection, and who had 
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consider that a complete longitudinal sternotomy is better in cases 
of invasion of tumor to the mediastinal great vessels or in suspicion 
on presence of aberrant thymic tissue in the mediastinal and neck 
cellular spaces.
Keyword: myasthenia,thymoma,endoscopic thymectomy, Sterno-
tomy
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P1.07-033 VIDEO-ASSISTED THORACOSCOPIC SURGERY 
(VATS) LOBECTOMY: A CONSENSUS STATEMENT
Tristan D. Yan1, Christopher Cao1, Thomas D‘Amico2, Jianxing He3, 
Henrik Hensen4, Scott Swanson5, William Walker6
1Systematic Reviews Unit, Collaborative Research Group/Australia, 
2Cardiothoracic Surgery, Duke University Medical Centre/United Sta-
tes Of America, 3The First Affiliated Hospital Of Guangzhou Medical 
College/China, 4Cardiothoracic Surgery, Rigshospitalet, Copenhagen 
University Hospital/Denmark, 5Cardiothoracic Surgery, Brigham And 
Women‘s Hospital/United States Of America, 6Cardiothoracic Surgery, 
Royal Infirmary Of Edinburgh/United Kingdom
Background: Video-assisted thoracoscopic surgery (VATS) lobec-
tomy has been gradually accepted as an alternative surgical ap-
proach to open thoracotomy for selected patients with non-small 
cell lung cancer (NSCLC) over the past 20 years. The aim of this 
project was to standardize the perioperative management of VATS 
lobectomy patients through expert consensus and to provide in-
sightful guidance to clinical practice.
Methods: A panel of 55 experts on VATS lobectomy was identi-
fied by the Scientific Secretariat and the International Scientific 
Committee of the ‘20th Anniversary of VATS Lobectomy Conference 
– The Consensus Meeting’. The Delphi methodology consisting of 
two rounds of voting was implemented to facilitate the develop-
ment of consensus. Results from the second-round voting formed 
the basis of the current Consensus Statement. Consensus was 
defined a priori as more than 50% agreement amongst the panel 
of experts. Clinical practice was deemed ‘recommended’ if 50-74% 
of experts reached agreement and ‘highly recommended’ if 75% 
or more of experts reached agreement.
Results: Fifty VATS lobectomy experts (91%) from 16 countries 
completed both rounds of standardized questionnaires. No stati-
stically significant differences in the responses between the two 
rounds of questioning were identified. Consensus was reached on 
21 controversial points, outlining the current accepted definition of 
VATS lobectomy, its indications and contraindications, periopera-
tive clinical management, as well as recommendations for training 
and future research directions. 
Conclusion: Lymph node metastasis is a significant prognostic 
factor for primary lung cancer in the middle lobe. Among patients 
who had lymph node metastasis in middle-lobe NSCLC, 15% had 
metastasis to station 11s. Therefore, lymph node dissection of sta-
tion 11s is required for patients with primary lung cancer located in 
the middle lobe to ensure accurate staging.
Keywords: Lung cancer, Lymph node dissection
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P1.07-032 EXPERIENCE OF SURGICAL TREATMENT OF 
MYASTHENIA
Anatoliy Kasatov1, Iuliia Trefilova1, Irina Schetkina2
1Hospital Surgery, Perm State Medical Academy/Russian Federation, 
2Thoracic Surgery, Perm Regional Clinical Hospital/Russian Federation
Background: . Thymomas are the most common tumors of the 
anterior mediastinum. Clinical manifestations of thymomas depend 
on their endocrine activity, growth pattern and size. Non-invasive 
thymomas are mostly asymptomatic. According to different au-
thors, more than 75% of thymomas are combined with myasthenia 
gravis. Myasthenia gravis affects people of working age, is cha-
racterized by a progressive course and often leads to disability. In 
the last decade, as a result of the active introduction of minimally 
invasive surgical techniques to the practice, the question of the 
choice of surgical approach between open access and endoscopic 
surgery remains to be open.
Methods: In the period 2002-2012 45 patients with tumor and hy-
perplasia of thymus were treated in Perm regional clinical hospital. 
Mean age was 43.9 years. Women of working age prevailed among 
the patients - 31 (68.8%). During examination hyperplasia of thy-
mus was revealed in 15 patients, thymoma in 30 patients besides 
5 of them had invasive malignant tumor growth. Among patients 
with hyperplasia of thymus (15 patients) the clinic of myasthenia 
was revealed in 9 cases (60%), 5 of them had generalized form and 
4 – local form of myasthenia. In the group of patients with tumor 
of thymus (30 patients) myasthenia gravis was diagnosed in 26 of 
them, which amounted to 86.6%. Thus generalized form of my-
asthenia gravis was observed in 24 patients (92,3%), and its local 
forms were revealed only in 2 cases.
Results: Surgical treatment was performed in 42 patients, that is 
93.3%. In 3 patients surgical treatment wasn’t carried out due to 
the presence of severe comorbidity. Sternotomy and extended 
thymectomy was performed in 25 patients, thymectomy through 
thoracotomy was performed in 4 cases. Since 2008 endoscopy 
(VATS) started to be used for thymectomy (pic. 2A, pic.2B). It was 
carried out in 13 patients, but in 3 cases complementary (extra) 
minithoracotomy was required because of the intraoperatively 
diagnosed invasion of large vessels. Pic. 2 A Pic. 2 B General post-
operative mortality was 4.5%. Two patients after VATS died. They 
had invasion of the tumor to the mediastinal great vessels and the 
endoscopic operation required a conversion to thoracotomy be-
cause of the massive intraoperational blood loss. The regression 
of neurological symptoms and the decrease of necessity of the 
anticholinesterase drugs were revealed in all the patients that were 
operated.
Conclusion: In spite of the technical capability for extended thy-
mectomy and less traumatic rate of the endoscopic method we 
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Conclusion: The present Consensus Statement represents a coll-
ective agreement amongst 50 international experts to establish a 
standardized practice of VATS lobectomy for the thoracic surgical 
community after 20 years of clinical experience.
Keywords: NSCLC, surgery, VATS, Consensus Statement
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P1.07-035 UNCERTAIN RESECTION DUE TO INCOMPLE-
TE INTRAOPERATIVE NODAL ASSESSMENT
Taketsugu Yamamoto1, Takamitsu Maehara1, Kenji Inafuku1, Ko 
Takahashi2, Hiroyuki Adachi2, Kohei Ando2, Yoshihiro Ishikawa2, 
Teppei Nishii2, Kazuki Yamanaka2, Katsuya Watanabe2, Yutaka 
Kumakiri2, Takuya Nagashima2, Masahiro Tsuboi2, Keita Fujii2, 
Munetaka Masuda3
1Yokohama Rosai Hospital/Japan, 2Yokohama Consortium Of Thoracic 
Surgeons/Japan, 3Department Of Surgery, Yokohama City University 
School Of Medicine/Japan
Background: The standard surgical approach for non-small-cell 
lung cancer is lobectomy with systematic hilar and mediastinal 
lymph node dissection. The purpose of lymph node dissection 
is considered to be improvement of prognosis and intraoperati-
ve staging. Although improvement of prognosis is controversial, 
it is clear that intraoperative nodal assessment is important for 
identifying N2 disease and making postoperative therapeutic 
decisions. For complete resection (CR), at least three mediastinal 
nodes including subcarinal nodes and three hilar/ intrapulmonary 
nodes had to be retrieved. Otherwise It is defined as uncertain 
resection(UR). The objective of this study is to clarify the difference 
of prognosis between CR and UR.
Methods: The medical records and the follow-up data of the pa-
tients operated for NSCLC(c-stage I to III) between January 2005 
and December 2006 in Yokohama City University Hospital and 8 
associate hospitals were analyzed retrospectively. Four hundred-
eighty-four patients with NSCLC who underwent lung resections 
(lobectomy or pneumonectomy) with negative surgical margins 
were included in this study. Complete resection (CR) was perfor-
med in 198 patients. And in 286 patients, uncertain resection was 
done. We compared these 2 groups.
Results: There were no statistically difference between the 
both groups for age, gender, pathological stage( IA:CR n=69/
UR n=153,IB 59/71,IIA 4/12,IIB 27/21,IIIA 36/24,IIIB 3/5), and 
histology (adenocarcinoma: CR n=122/UR n=185,squamous 
carcinoma:51/68,large cell carcinoma:15/14,others:14/20 respec-
tively). Five-year disease-free-survival rate in the CR group was 
58.1% compared with 63.3% in the UR group. Among patients with 
p-stage I, the 5-year disease-free-survival rate was significantly 
lower in UR group (78.1%) than in CR group (88.0%, p=0.027).
Conclusion: Uncertain resection might not be enough for accurate 
intraoprerative staging to determine pN0 status. However whether 
the accurate intraoperative staging leads to good prognosis was 
unclear.
Keywords: non-small cell lung cancer, intraoperative staging, 
uncertain resection
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P1.07-034 NUMBER OF METASTATIC LYMPH NODES 
AND METASTATIC LYMPH NODE RATIO PREDICT PATI-
ENT SURVIVAL IN RESECTED NON-SMALL CELL LUNG 
CANCER
Seijiro Sato, Toru Shirato, Terumoto Koike, Takehisa Hashimoto, 
Masanori Tsuchida
Thoracic And Cardiovascular Surgery, Niigata University Graduate 
School Of Medical And Dental Sciences/Japan
Background: The non-small cell lung cancer TNM classification 
system uses the anatomic extent of lymph node (LN) metastases to 
define the N category. However, the TNM classification system for 
breast, gastric, and colorectal cancer has been updated to include 
number of metastatic lymph nodes (MLNs) in the N staging. In 
these cancers, the number of MLNs has been shown to be a more 
effective prognostic factor than the anatomic location of MLNs. 
Moreover, it has been suggested the ratio of MLNs to total number 
of LNs examined (lymph node ratio [LNR]) in breast, bladder, gas-
tric, and colorectal cancer is a better prognostic factor. Here, we 
evaluated the effect of these factors on the disease-free-survival 
(DFS) of non-small cell lung cancer.
Methods: We retrospectively reviewed 428 patients who under-
went with pathological examination of resected LNs from 2001 
through 2010. The prognostic value of number of MLNs, LNR, or 
current pN classification was assessed using a multivariate Cox 
proportional hazards model for DFS, with sex, age, smoking histo-
ry, tumor size, histology, histological grade. The number of MLNs 
and LNR were analyzed as a categorical variable, and the patients 
were divided into 4 groups by the number of MLNs (n0: no MLNs, 
n1-3: 1-3 MLNs, n4-6: 4-6 MLNs, and n≧7: 7 or more MLNs), or by the 
LNR (nnone: 0%, nlow: 1%-9%, nmoderate: 10-24%, and nhigh: 25% or hig-
her).
Results: At least one nodal metastasis was found in 100 patients 
(23%), represented by n0 in 328 cases, n1-3 in 77 cases, n4-6 in 15 
cases, and n≧7 in 8 cases. By the LNR, 328, 55, 25, and 20 cases 
were assigned to nnone, nlow, nmoderate, and nhigh groups, respectively. 
The 5-year DFS rate of n0, n1-3, n4-6, and n≧7 groups were 83%, 48%, 
24%, and 0%, respectively, and the 5-year DFS rate of nnone, nlow, 
nmoderate, and nhigh groups were 83%, 51%, 38%, and 9%, respec-
tively. Multivariate analysis showed the number of MLNs and LNR 
were significant independent prognostic factor, equal to the cur-
rent pN classification. Hazard ratios for pN1 and pN2 with respect 
to pN0 were 2.07 and 5.04. In contrast, hazard ratios were 2.70, 
4.03, and 14.7 for n1-3, n4-6, and n≧7 with respect to n0; and 2.16, 
3.62, and 9.95 for, nlow, nmoderate, and nhigh with respect to nnone.
Conclusion: The number of MLN and LNR are strong independent 
prognostic factor in non-small cell lung cancer. They may add new 
information to the pN categories of the current TNM classification.
Keywords: number of metastatic lymph nodes, metastatic lymph 
node ratio, non-small cell lung cancer
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P1.07-037 CLINICAL CHARACTERISTICS OF COMPLETE-
LY RESECTED LUNG CANCER WITH COMBINED PULMO-
NARY FIBROSIS AND EMPHYSEMA
Junichiro Osawa1, Yoshihisa Shimada1, Soichi Akata2, Kouichi Yos-
hida1, Yasufumi Kato1, Masaru Hagiwara1, Masatoshi Kakihana1, 
Naohiro Kajiwara1, Tatsuo Ohira1, Norihiko Ikeda1
1Surgery I, Tokyo Medical University/Japan, 2Radiology, Tokyo Medical 
University/Japan
Background: The occurrence of both emphysema and pulmonary 
fibrosis in the same patient has received increased attention as 
the syndrome of combined pulmonary fibrosis and emphysema 
(CPFE). Patients with CPFE show severely impaired DLCO, hypoxe-
mia at exercise, characteristic computed tomography (CT) imaging 
feature, and high probability of lung cancer. However, the clinical 
characteristics of lung cancer patients with CPFE are not well 
known. The aim of this study is to identify clinical characteristics of 
completely resected lung cancer with CPFE.
Methods: A total of 559 consecutive patients who underwent 
complete surgical resection for lung cancer from January 2008 
through December 2010 were reviewed. Based on preoperative 
chest HRCT findings, patients were categorized into three groups: 
those with normal lung (N) (except for lung cancer), emphysema 
without pulmonary fibrosis (E), and CPFE. The HRCT inclusion cri-
teria of CPFE is as follows; 1) Presence of emphysema, defined as 
well-demarcated areas of decreased attenuation in comparison 
with contiguous normal lung and marginated by a very thin or no 
wall, and/or multiple bullae with upper zone predominance. 2) 
Presence of a diffuse parenchymal lung disease with significant 
pulmonary fibrosis, defined as reticular opacities with peripheral 
and basal predominance, honeycombing, architectural distortion 
and/or traction bronchiectasis or bronchiolectasis. Chest HRCT 
scans were reviewed separately by two thoracic surgeons and one 
radiologist. The clinical characteristics of patients with CPFE were 
compared with those of the other groups.
Results: This study cohort included 328 (58.7%) patients in N 
group, 136 (24.8%) patients in E group, and 95 (17.0%) patient in 
CPFE group, with median age of 67 years. The 3-year survival ra-
tes were 68.4% in CPFE group, 80.2% in E group, and 89.7% in N 
group (p < 0.001). CPFE group found a positive correlation with 
each of the following factors compared to N and E groups; > 67 
years (p = 0.004), lymph node metastases (p = 0.033), male gen-
der (p < 0.001), tumor size > 3cm (p < 0.001), vascular invasion (p 
< 0.001), non-adenocarcinoma (p < 0.001), pleural invasion (p < 
0.001), elevated preoperative serum CEA level (p < 0.001). The fre-
quency of patients presenting grade 2 or more severe postopera-
tive complication under CTCAE or Clavien-Dindo classification was 
28.4% for CPFE group, 24.3% for E group, and 14.9% for N group 
(p = 0.004), and respiratory complication was higher for CPFE 
group (22.1%) than N group (5.8%) and E group (11.8%) (p < 0.001).
Conclusion: Resected lung cancer patients with CPFE had some 
different clinical characteristics in comparison with those with em-
physema. Intensive postoperative management and a strict follow-
up are required because of higher rate of postoperative complica-
tions and aggressive malignant behavior in CPFE patients.
Keywords: CPFE, NSCLC
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P1.07-036 IS RADIOTHERAPY UNAVOIDABLE FOR N2 
DISEASE IN NSCLC
George Karimundackal, Parveen Yadav, Marzi Mehta, Sabita Jiw-
nani, C S Pramesh
Surgical Oncology, Tata Memorial Hospital/India
Background: The ideal treatment for N2 disease in NSCLC is a 
subject of controversy. The treatment policy followed by individual 
institutes is generally a reflection of physician preference and phy-
sical characteristics of the patient population. In view of stronger 
evidence supporting neoadjuvant chemotherapy and the desire 
to reserve one modality of treatment it has been the policy in our 
institution to administer neoadjuvant chemotherapy followed by 
surgery in all pathologically proven cases of N2 disease. We con-
ducted a retrospective analysis to asses the pathological response 
of mediastinal lymph nodes to neoadjuvant chemotherapy and the 
need for adjuvant radiotherapy in this patient population.
Methods: Data from a prospectively maintained database from 
August 2009 to March 2013 was analyzed. Information regarding 
number of patients detected to be N2 on mediastinoscopy, pati-
ents advised neoadjuvant chemotherapy, number of lymph node 
stations affected, curative resections, pathological response in me-
diastinal nodes and adjuvant treatment advised was retrieved. The 
rate of complete response after neoadjuvant therapy and patients 
advised postop radiotherapy were calculated as percentages
Results: 231 patients underwent mediastinoscopy for operable 
NSCLC. 36 patients were detected to have N2 lymph nodes of 
which 29 patients were advised neoadjuvant chemotherapy. The 
remaining patients were advised definitive chemoradiation in view 
of significant nodal disease precluding R0 resection. 13/17 patients 
with single station lymphadenopathy underwent curative resection 
with 8 (61%)patients achieving complete pathological response in 
the mediastinal nodes. 8/9 patients with multiple station lymph-
adenopathy also underwent resection with only 2(25%) patients 
achieving complete pathological response. 11/21(52%) patients 
who underwent R0 resection after neoadjuvant therapy were 
advised post operative radiotherapy in view of residual disease 
in mediastinal nodes while 6/8 (75%) patients with multistation 
lymphadenopathy required postoperative radiotherapy
Conclusion: Patients with resectable multistation mediastinal 
lymphadenopathy on preoperative invasive mediastinal staging 
have a very high likelyhood of having residual viable disease in the 
mediastinal nodes even after neoadjuvant chemotherapy. In this 
subset of patientss radiotherapy should be incorporated in to the 
treatment strategy at the outset, to achieve mediastinal steriilizati-
on. The ideal timing of radiotherapy neoadjuvant or post operative 
needs more study. In patients with single station lymphadenopathy 
neoadjuvant chemotherapy with surgery may be an adequate stra-
tegy with radiation reserved for those with residual disease.
Keywords: Residual N2 disease, neoadjuvant chemotherapy, post-
operative radiotherapy
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P1.07-039 PREDICTORS OF ONE YEAR SURVIVAL AFTER 
LUNG CANCER SURGERY
Shoni Colquist1, Tracey Guan2, Dannie Zarate1, Kevin Matar3, Mor-
gan Windsor4
1Queensland Cancer Control Analysis Team (QCCAT), Queensland 
Health/Australia, 2Queensland Cancer Control Analysis Team, Queens-
land Health/Australia, 3Thoracic Medicine, Prince Charles Hospital/
Australia, 4Cardiothroacic Surgery, Prince Charles Hospital/Australia
Background: There have been few reports regarding short term 
survival after lung cancer surgery in Australia. In this study, we 
analysed the predictors of survival at one year following lung 
cancer resection in Queensland, the third most populous state in 
Australia.
Methods: Data on all Queensland residents who were diagnosed 
with non-small lung cancer (NSCLC) between 2000 and 2010 and 
who subsequently underwent surgery for lung cancer was obtai-
ned from the Queensland Oncology Repository. One year survival 
following surgery was modelled using multivariate Cox proporti-
onal hazards regression controlling for gender, age, comorbidity, 
anaesthetic score, remoteness of residence, and socioeconomic 
status.
Results: A total of 2,799 NSCLC patients who underwent resection 
for lung cancer in 17 hospitals across the state were included in the 
analysis; the median age was 67 years and 61% were males. Overall 
one year survival was 88%. In multivariate modelling, independent 
predictors of death within one year of surgery included male gen-
der (hazard ratio [HR] 1.4, 95% confidence interval [CI] 1.0-2.0, p 
= 0.04), age (per 10 year increment, HR 1.2, CI 1.1-1.3, p < 0.001), 
presence of one or more major comorbidities (HR 1.4, CI 1.1-1.8, 
p = 0.004), and anaesthetic scores of severe disease or worse (HR 
1.40, CI 1.1-1.8, p = 0.01). Remoteness of residence and socioeco-
nomic status were insignificant factors in the model.
Conclusion: Demographic and clinical patient characteristics are 
significant prognostic factors for short term survival following lung 
cancer surgery. This study further suggests that remoteness and 
socioeconomic status do not influence the quality of surgical care 
for lung cancer in Queensland.
Keywords: surgery, survival, Treatment, predictors
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P1.07-038 SURGICAL TREATMENT FOR T4 NON-SMALL 
CELL LUNG CANCER INVADING MEDIASTINAL STRUC-
TURES
Hae-Won Lee, Moon-Chul Kang, Hee-Jong Baek, Jong-Ho Park
Thoracic Surgery, Korea Cancer Center Hospital/Korea
Background: Non-small cell lung cancer (NSCLC) with invasion of 
mediastinal structures is now classified as stage IIIA or IIIB accor-
ding to N stages, and has been considered surgically unfavorable. 
However, in a selected group of these patients, better results have 
been reported after surgical resection compared to non-surgical 
group. The aim of this study is to evaluate the role of surgical re-
section in treatment of mediastinal T4 NSCLC and risk factors that 
should be considerated.
Methods: Among 2215 patients who underwent surgical interven-
tion for non-small cell lung cancer from Aug 1987 to Dec 2011 in 
Korea cancer center hospital, 119 patients had an invasion of T4 
mediastinal structures. Their medical records in Data Base were 
reviewed, and they were followed up completely until Apr 2013. 
Surgical results and prognostic factors of NSCLC invading medias-
tinal structures were evaluated retrospectively.
Results: Lung cancer was resected completely in 83 patients 
(69.7%, 83/119). Lobectomy was performed in 25 patients and 
pneumonectomy in 58. The mediastinal structures invaded by 
primary tumor were great vessels (44.6%), heart (15.7%), vagus 
nerve (12.1%), carina (8.4%), esophagus (9.6%), and vertebral body 
(9.6%). Nodal status was N0 in 16, N1 in 28, and N2 in 39. Neoad-
juvant therapy was executed in 11 (13.25%) and adjuvant therapy 
was added in 53 (63.9%) out of complete resection group (n=83). 
Complication rate was 30.1% and operative mortality was 8.4% 
in complete resection group. Median and 5 year overall survival 
including operative mortality was 20.1 months and 22.7% in com-
plete resection group (n=83), and 6.1months and 0% in exploration 
only group (n=36, p=.001). Overall 5year survival rates of N2(-) and 
N2(+) group were 32.8% and 9.3% respectively (p=.002). There was 
no survival difference between T4 N2(-) group and other IIIA stage 
group. Mediastinal structure invaded, old age, gender, neoadju-
vant and adjuvant chemotherapy showed no significant prognostic 
difference.
Conclusion: The operative risk of NSCLC invading mediastinal 
structures was high because of high rate of pneumonectomy and 
wider range of resection, however it can be acceptable. Long-
term result of complete resection was favorable in selected group. 
Aggressive surgical approach is recommended in well selected 
patients with good performance and N2(-) in mediastinal T4 group. 
Stage grouping of T4N2(-) patients in AJCC 7th edition is thought 
to be adequate when complete resection was likely.
Keywords: NSCLC, Mediastinal invasion, surgery, T4
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P1.07-041 CHARACTERISTICS OF A NORTH AMERI-
CAN PATIENT POPULATION WITH THE DIAGNOSIS OF 
"BRONCHIOLOALVEOLAR CARCINOMA (BAC)“
Brian E. Louie1, Candice L. Wilshire1, Matthew P. Horton2, Shaun 
Deen1, Jennifer L. Kramer2, Ralph W. Aye1, Alexander S. Farivar1, 
Howard L. West3, Jed A. Gorden2, Eric Vallieres1
1Thoracic Surgery, Swedish Medical Center/United States Of America, 
2Swedish Medical Center/United States Of America, 3Swedish Cancer 
Institute/United States Of America
Background: A body of literature exists describing the evolution 
of BAC from a subtype of adenocarcinoma of the lung to the cur-
rently proposed classification where it is further categorized as 
adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma 
(MIA) or lepidic predominant adenocarcinoma (LPA) based on the 
size of the invasive component of the lesion. The majority of these 
studies, however, were conducted with Asian populations and very 
few non-Asian studies on BAC have been published. Our aim was 
to describe the characteristics of North American patients with 
BAC, review the management and determine the influence of the 
epidemiologic difference.
Methods: We retrospectively reviewed all patients with a diag-
nosis of BAC or adenocarcinoma with BAC features on pathology 
from February 2000 to June 2012. Patients were categorized ac-
cording to the IASLC/ATS/ESR classification into those with AIS, 
MIA or LPA based on the dominant lesion resected. Patients with 
mucinous BAC were excluded (n=7).
Results: One hundred and forty four patients were evaluated: AIS 
(23), MIA (18) and LPA (103). Patient demographics were similar 
between the groups with over 75% being of non-Asian ethnicity. 
More patients with AIS and MIA were clinical stage IA (table). Lo-
bectomy was performed at comparable frequencies for AIS (48%) 
and MIA (53%), though it was the predominant resection approach 
for LPA (70%). The median size of the resected lesion in patients 
with AIS (1.5cm) and MIA (1.3cm) was significantly smaller than 
those with LPA (2.5cm), p<0.001. Patients with AIS and MIA had no 
clinical or pathological nodal involvement, whereas 12% of patients 
with LPA were found to have positive nodes (pN1: 6%, pN2: 6%). 
At a median follow-up of 30 months, recurrence rates were – lo-
cal: AIS 4%, MIA 11% and LPA 2%; regional: LPA 8%; and distant: 
LPA 10%. Disease-free survival was significantly higher in the AIS 
(96%) and MIA (89%) groups versus the LPA group (80%). Five year 
cancer-specific survival was 100% for patients with AIS and MIA 
dropping to 84% for patients with LPA.  
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P1.07-040 OUTCOMES OF SURGICAL TREATMENT FOR 
ISOLATED ADRENAL METASTASIS IN NON-SMALL CELL 
LUNG CANCER: A SYSTEMATIC REVIEW AND POOLED 
ANALYSIS
Xinliang Gao1, Wei Liu1, Kewei Zhang1, Yang Li1, Jing Wang2, Kejian 
Zhang1, Teng Jia1
1Thoracic Surgery, The First Hospital Of Jilin University/China, 2Radio-
logy, The First Hospital Of Jilin University/China
Background: Several small studies have reported that some non-
small cell lung cancer (NSCLC) patients with isolated adrenal me-
tastasis can achieve long-term survival through an adrenalectomy 
followed by a surgical resection for primary lung cancer. However, 
most studies treated such patients as IV stage and suggested that 
the survival outcome was poor. The choice of treatment approach 
for such patients is still controversial.
Methods: A search for publications on surgical treatment for pri-
mary lung cancer and isolated adrenal metastasis from NSCLC was 
performed via the MEDLINE and Siencedirect datebase. Studies 
reporting on survival outcomes were included. When we analyze 
data to determine which clinical characteristics predict long-term 
survival, studies not allowing separation of outcomes between 
groups were excluded. Synchronous metastasis was defined as an 
adrenal metastasis which occurred before or within 6 months after 
the primary lung cancer.
Results: There were 11 publications contributing 87 patients (age 
from 35 to 78 years, 82.1% men and 17.9% women). Median overall 
survival was 16 months. The 1-year survival, 2-year survival and 
5-year survival was 64.0%, 37.7% and 29.2% respectively. Median 
overall survival (OS) for patients with synchronous metastasis was 
shorter than those with metachronous metastasis (12 months vs 31 
months, P = .017). However, the difference of media overall survi-
val between patients whose pathology of primary lung cancer was 
adenocarcinoma and squamous carcinoma was not significant (20 
months vs 13 months, p = .068). Whether there was mediastinal 
lymph node metastasis or not was not a prognostic factor because 
there was no striking difference in media overall survival (p = .496). 
The patients with ipsilateral adrenal metastasis had the same me-
dian overall survival as those with contralateral tumors.
Conclusion: For an isolated adrenal metastasis from NSCLC, part 
of the patients undergoing surgical treatment for both primary 
lung cancer and isolated adrenal metastasis have a long survival. 
Patients with metachronous metastasis predict a better survival.
Keywords: Lung cancer, surgery, adrenal metastasis, survival
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Results: The overall survival time for all 358 patients was 
33.26±0.90 months. The overall survival time for 117 cases in the 
VATS lobectomy group was 36.02±1.44 months. The overall survi-
val time for 241 cases in the open thoracotomy lobectomy group 
was 31.92±1.14 months. The survival rates for patients in the VATS 
lobec-tomy group were 92.31%, 36.75%, 5.13% at one, three, and 
five years, respectively. The survival rates for patients in the open 
thoracotomy lobectomy group were 92.12%, 21.58%, 2.49% at one, 
three, and five years, respectively. A significant differ-ence was 
found between the two groups regarding this factor (X2 =3.88 ,P = 
0.049).
Conclusion: VATS lobectomy is feasible and safe to perform on 
patients with minimal N2 non-small cell lung cancer. Even if lymph 
node metastasis is unexpect-edly detected during surgery, with 
rigor ous preoperative evaluation and systematic lymph node diss-
ection, there is no need to convert to open thoracotomy lobecto-
my.
Keywords: lobectomy, non-small cell lung cancer, outcomes
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P1.07-043 SURGICAL MANAGEMENT OF LEFT NON-
SMALL-CELL LUNG CANCER WITH IPSILATERAL AND 
CONTRALATERAL MEDIASTINAL NODE METASTASIS 
(N2 AND N3Α DISEASE) BY SYSTEMIC EXTENDED BILA-
TERAL MEDIASTINAL DISSECTION (HATA‘S METHOD)
Toshiya Yokota, Shin Ikeda
Surgery Respiratory Center, Mitsui Memorial Hospital/Japan
Background: The role of surgery in the treatment of non-small-cell 
lung cancer (NSCLC) with clinically manifested mediastinal lymph 
node metastasis is controversial. But, the removal of the whole 
regional lymphatic system together with primary tumor is one 
of the fundamental rules in oncological surgery. Systemic nodal 
dissection (SND)  has been accepted by the IASLC to be an impor-
tant component of intrathoracic staging. Studies addressing the 
survival benefit of mediastinal lymph node dissection have been 
inconclusive. According to the study of regional lymphatic draina-
ge, we considered reasonable lymphadenectomy contributes the 
post-operative survival of the patient with NSCLC. And we had de-
vised Systemic extended bilateral mediastinal dissectionand lung 
resection through a median sternotomy (ND3 operation (Hata’s 
method)), and reported that ND3 operation can allow for complete 
dissection of all stations of mediastinal lymph nodes.
Methods: This is a retrospective study of 28１ patients [198 male 
and 83 female, mean ages 59.5 years (range, 38-75)], underwent 
ND3 operation due to Left NSCLC, from January 1990 till Decem-
ber 2012. The patients with Lt. NSCLC who are estimated to be 
able to conventional radical operation and aged 75 year-old or less 
becomes the adaptation of our ND3 operation. All patients had 
assessed pathologically stageI-IIIB, underwent R0 operation. The 
operation were performed through the median sternotomy. As 
N3αoperation, bilateral mediastinal nodal dissection including bi-
lateral thoracic inlet and lung resection is performed. Lymph node 
station #1,#2R,#4R,#2L,#4L,#3a,#5,#6,#7,(#8,#9:Left lower NSCLC) 
were removed.
Results: Postoperative survival rates calculated with Kaplan-Meier 
method. The clinicopathological data of patients and surgeical 
Comparative characteristics between AIS, MIA and LPA
AIS 
(N=23) MIA (N=18) LPA (N=103)
Age (median) 68 68 69
Female 19 (83%) 15 (83%) 77 (75%)
Non-Asian 19 (83%) 14 (78%) 92 (89%)
Smoker 16 (70%) 13 (72%) 81 (79%)
# Comorbidities 
(median)
1 1 1
FEV1% (median) 91 89 86
DLCO/VA% 
(median)
94 a 104 a 82
Clinical Stage
IA 19 (83%) 16 (89%) 70 (68%)
IB 4 (17%) 2 (11%) 29 (28%)
IIA 0 0 3 (3%)
IIB 0 0 1 (1%)
Pathologic 
Stage
IA 23 (100%) 18 (100%) 53 (51%)
IB 0 0 31 (30%)
IIA 0 0 7 (7%)
IIB 0 0 4 (4%)
IIIA 0 0 8 (8%)
 
ap < 0.05 vs. LPA
Conclusion: Patients with AIS and MIA have favorable outcomes 
reflected by the absence of nodal metastases and a 100% 5 year 
cancer-specific survival compared to patients with LPA. The results 
of this North American population are consistent with those of 
published reports based on Asian populations.
Keywords: MIA, LPA, BAC, AIS
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P1.07-042 VIDEO-ASSISTED THORACIC SURGERY LO-
BECTOMY FOR UNEXPECTED PATHOLOGIC N2 NON-
SMALL CELL LUNG CANCER
Wen Yong Zhou
Department Of Cardiovascular And Thoracic Surgery, East Hospital, 
Tongji University/China
Background: This study was performed to assess early and late 
outcomes of patho-logic N2 disease unexpectedly detected in 
patients with non-small cell lung cancer undergoing video-assisted 
thoracic surgery (VATS) lobectomy for clinical stage I.
Methods: We retrospectively reviewed the clinical features of 
patients with unex-pected N2 non-small cell lung cancer and their 
early and late outcomes in the VATS lobectomy group versus the 
open thoracotomy lobectomy group.
S528 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Although improvement during rehabilitation, 4 patients were dis-
qualified from lobectomy due to unsatisfactory performance sta-
tus. Another 3 patients experienced complications during periope-
rative period. Analysis of pulmonary rehabilitation efficacy showed 
that 8 patients with favourite outcome, without surgical and car-
diovascular complications after thoracic surgery in comparing to 
others, were characterised by significantly higher improvement in: 
1). FEV1 (L): 0,37 vs 0,08 (p=0,02) 2). distance in 6MWT (m): 85 vs 
25 (p=0,01)
Conclusion: The increases of FEV1 and 6MWT have important po-
sitive predictive value for favourite outcome after thoracic surgery
Keywords: pulmonary rehabilitation, lung surgery, Postoperative 
complications
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P1.07-045 PROGNOSTIC IMPLICATIONS OF BLOOD 
TESTS PERFORMED ROUTINELY PRIOR TO SURGICAL 
RESECTION OF NON-SMALL CELL LUNG CANCER
Matthew O. Smith1, Robert George1, Richard Hubbard2, Annabel J. 
Sharkey1, Jagan N. Rao1, John Edwards1
1Department Of Cardiothoracic Surgery, Northern General Hospital/
United Kingdom, 2University Of Nottingham/United Kingdom
Background: Routinely performed blood tests may yield impor-
tant information regarding the risks of post-operative morbidity 
and survival. Whilst the association between systemic pre-opera-
tive inflammatory response and survival in NSCLC chemotherapy 
patients is recognized, the clinico-pathological correlates in NS-
CLC surgical patients are less clear.
Methods: NSCLC patients undergoing surgery between 29/8/2007 
and 30/3/11 were included. Preoperative blood tests were retrie-
ved from laboratory databases and correlated with prospectively 
collected data held in our surgical database including clinico-
pathological factors, pathological TNM stage and survival. Survival 
analysis was performed on 17/06/13.
Results: 722 patients underwent surgery for suspected NSCLC. In 
563 (78.0%) patients (54.2% males, median age 68.5 (range 37.8 
- 90.8) years), complete data for all factors enabled subsequent 
multivariate analysis. At the time of analysis, 377 (60%) were alive 
and were censored in survival analyses. In univariate analysis, the 
following factors were identified as poor prognostic factors; serum 
fibrinogen >4g/dL (p=0.011), haemoglobin <13.1g/dL (p=0.003), 
platelet count >370x109 or<140x109 (p=0.006), ALT >63 IU/L or <17 
IU/L (p=0.039), total protein >80g/L or <60g/L (p<0.001), albumin 
>48g/L or <35g/L (p=0.005), globulin >36g/L or <18g/L (p=0.001), 
cholesterol <5mmol/L (p=0.011). Other factors identified as poor 
prognostic factors were, age (p<0.001), male gender (p=0.033), 
nodal stage (p=0.001), tumour size (p=0.001), completeness of 
resection p=0.025), and histological grade (p=0.008). In multiva-
riate analysis of the factors identified from the blood tests, total 
protein (HR 2.263 95% CI 1.357-3.775, p=0.002), globulin (HR 1.507 
95% CI 1.015-2.238 p=0.042), and haemoglobin (HR 1.462 95% CI 
1.091-1.958 p=0.011) Including stage, age and gender in the mo-
del, stage (HR 1.286 95% CI 1.164-1.442 p<0.001), age (HR 1.028 
95% CI 1.011-1.046 p=0.001), gender (HR 1.419 95% CI 1.048-1.920 
p=0.024), total protein (HR 2.503 95% CI 1.465-4.274 p=0.001) and 
haemoglobin (HR 1.500 95% CI 1.110-2.026 p=0.008) remained 
outcomes were evaluated. The overall 5-year survival rate in the 
281 patients of left lung primary was 64.1%. Operative mortality in 
281 patients was 3.2%(2001-2012: 1.3%). Lymph node metastasis 
to the mediastinum was confirmed in 89 (31.6%) patients. (pN2 
was 50 patients,pN3α was 26 patients, pN3β was 2 patients, pN3γ 
was 11 patients) Five-year survival rate was 54.5% in cN2(n=47) 
caces, 49.1% in pN2 cases(n=50), 44.1% in cN3α(n=18), 40.2% in 
pN3α(n=26), and 53.3% in p-stageIIIA5pN2 (n=46). In these stag-
eIIIA5pN2 caces, no significant difference in survival were found 
regarding age, sex, tumor location, histologic type, tumor size, 
clinical N stage (accidental N2 or not), the number of metastatic 
nodal station (single-station N2 or multi-station N2). There was 
significant difference in survival regarding recurrence after surge-
ry. ( Five-year survival rate was 42.2% in recurrence cases (n=28), 
68.6% in no recurrence cases(n=18)) The patients with N2 disease 
who have no distant micrometasis can obtain oncological benefit 
from our ND3 operation.
Conclusion: N2 and N3α Lt.NSCLC. And better local tumor control 
than conventional lung operation after complete resection for N2 
and N3α disease without leading to increase morbidity. It is impor-
tant to perform curative operation with complete dissection of all 
station of mediastinal lymph nodes.
Keywords: Lymphadenectomy, NSCLC, surgery, Hata‘s method
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P1.07-044 EFFECTS OF PREOPERATIVE REHABILITATION 
ON OUTCOME OF PATIENTS WITH THORACIC TUMORS 
AND BORDERLINE ABNORMAL SPIROMETRY RESULTS
Oliwia Glogowska1, Sebastian Szmit2, Maciej Glogowski3
1Department Of Rehabilitation, The Maria Sklodowska-Curie Memorial 
Cancer Centre & Institute Of Oncology/Poland, 2Department Of Pulmo-
nary Circulation And Thromboembolic Diseases, The Medical Centre 
Of Postgraduate Education, European Health Centre/Poland, 3Lung & 
Thoracic Tumors Department, The Maria Sklodowska-Curie Memorial 
Cancer Centre & Institute Of Oncology/Poland
Background: The aim of the study was efficacy of preoperative 
pulmonary rehabilitation in patients with thoracic tumors and bor-
derline abnormal spirometry results
Methods: Clinical inclusion criteria were: diagnosis of thoracic 
tumors and reduced values of FEV1 and FVC predicting postope-
rative complications. We observed 15 patients (8 women, 7 men) in 
mean age of 63 (range 46-82) years. Spirometry, six minute walking 
test distance (6MWT) and maximum metabolic equivalent during 
exercise on treadmill (MET) were chosen for evaluation of lung 
function and physical performance during rehabilitation. The tests 
were performed twice during screening phase to eliminate the 
factors of learning, and were repeated after first and second week 
of rehabilitation. Pulmonary rehabilitation included two weeks of 
training on the treadmill with individually selected speed, physio-
therapy exercises and breathing training with using of Triflo
Results: The significant differences were observed during pul-
monary rehabilitation: 1). FEV 1 (L): 1,35 ± 0,24 vs 1,58 ± 0,29 
(p=0,002) 2). FEV1 (%N): 54,5 ± 13,6 vs 65,5 ± 14,3 (p=0,001) 3). 
FVC (L): 2,33 ± 0,44 vs 2,76 ± 0,62 (p=0,02) 4). FVC (%N): 75,2 ± 
15,5 vs 90,6 ± 12,0 (p=0,006) 5). 6MWT Distance (m): 302 ± 127 vs 
359 ± 121 (p=0,0005) 6). MET: 3,20 ± 1,91 vs 3,85 ± 2,27 (p=0,002) 
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derstanding of their clinico-pathological profiles. Although inci-
dence of newly diagnosed patients with carcinoid tumors of the 
lung is low, the long survival for those with low and intermediate 
differentiation grade, and the deeper knowledge we now have on 
molecular processes that governs tumors growth make these tu-
mors a challenging field in Oncology.
Keywords: lung carcinoid, Pathological profile, clinical profile, 
typical and atypical carcinoid
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P1.07-047 COULD VIDEO-ASSISTED THORACOSCOPIC 
LOBECTOMY PLUS MEDIASTINAL LYMPH NODE DISS-
ECTION BE PERFORMED FOR NON-SMALL CELL LUNG 
CANCER IN A LOW-VOLUME HOSPITAL?
Yanguang Ding1, Hao Wang2, Wei Jin1, Xiangzhi Xiao1, Shengchao 
Zhang1, Jun Yuan1, Ruheng Zheng2
1Thoracic Surgery, Qingpu District Center Hospital Of Shanghai/China, 
2Thoracic Surgery, Zhongshan Hospital, Fudan University/China
Background: Video-assisted thoracoscopic lobectomy plus me-
diastinal lymph node dissection has been regularly performed for 
the treatment of patients with non-small cell lung cancer (NSCLC) 
in high-volume hospitals, owing to its advantage of less trauma 
and faster recovery. However, it is questioned whether it could be 
popularized more widely with worry about the technically difficulty 
and perioperative management. Up to date, no study has discussed 
the technical and clinical differences based on the number of this 
minimally invasive surgery performed per year. This study aimed 
to compare the clinical outcomes of video-assisted thoracoscopic 
lobectomy plus mediastinal lymph node dissection between a low-
volume center (LVC) and a high-volume center (HVC).
Methods: This prospective study was conducted from January 2012 
to December 2012 in a LVC and a HVC in the same city. Clinical fea-
tures and operation characteristics of all patients were collected and 
compared to determine the differences between the 2 groups.
Results: A total of 511 cases with NSCLC were enrolled in this stu-
dy. And 469 cases (91.8%) were performed in HVC, while 42 cases 
(8.2%) in LVC. There was no significant difference found between 
the two groups in age, gender, body mass index, ASA score, tumor 
location, histological type and clinical stage. LVC group has longer 
operation time (131.7±32.4min vs 89.2±39.4min, p=0.000) and more 
blood loss (125.7±97.1ml vs 82.7±52.6ml, p=0.000), compared with 
HVC group. However, the other clinical outcomes between LVC 
and HVC were similar, including the rate of conversion to thoraco-
tomy (4.8% vs 1.9%, p=0.226), number of lymph nodes harvested 
(12.9±3.7vs 14.1±6.3, p=0.484), postoperative hospital stay (7.6±3.9d 
vs 6.8±2.7d, p=0.224), total complications (16.7% vs 12.8% , p=0.476) 
and 30-day mortality (0.0% vs 0.2% , p=1.000).
Conclusion: The study shows that video-assisted thoracoscopic 
lobectomy plus mediastinal lymph node dissection could also be 
performed feasibly and safely in LVC with similar clinical outcome, 
though the long term survival are still necessary to be confirmed 
with follow up.
Keywords: video-assisted thoracoscopic lobectomy, non-small cell 
lung cancer, Mediastinal lymph node dissection, low-volume hospital
independent prognostic factors.
Conclusion: Although survival data are not yet fully mature, pre-
operative anaemia and an abnormal serum total protein level are 
adverse prognostic factors for survival following lung cancer surge-
ry, being independent of other variables including stage, age and 
gender. Further work is required to determine the clinical implica-
tions of these findings.
Keywords: Prognostic indicators, surgical resection
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P1.07-046 CLINICAL AND PATHOLOGICAL PROFILE OF 
LUNG CARCINOID
Teresa Hermida, Rosario Garcia Campelo, Guillermo Alonso, Mar 
Haz Conde, Guadalupe Aparicio Gallego, Moises Blanco Calvo, 
Natalia Fernandez, Aurea Molina, Jorge Mosquera, Jose Ramon 
Navarro, Angelica Figueroa, Manuel Valladares, Angel Concha, 
Luis Miguel Anton Aparicio
Chu A Coruña/Spain
Background: Carcinoid tumours have been reported in a wide ran-
ge of organs, but they most commonly involve lungs and gastro-
intestinal tract. Pulmonary or bronchial carcinoid tumours account 
for over 25% of all carcinoid tumours and for 2% of all pulmonary 
neoplasms. Approximately 10-20% of pulmonary carcinoids are 
atypical, the remaining 80-90% are typical. It was generally accep-
ted that carcinoid tumours were very slow-growing and benign 
neoplasm with no potential for invasiveness and no tendency to 
develop metastases.
Methods: This study includes 60 consecutive carcinoid patients 
referred to the Department of Thoracic Surgery, for surgical treat-
ment, between 1989 to 2011. The study includes all patients trea-
ted at the unit during the study period. The inclusion criteria was 
a histopathologically verified carcinoid tumor. Tumor specimens 
were obteined at operation.
Results: According to the histological findings, 47 patients (22 
male and 25 female patients) had a typical carcinoid tumor, and 13 
patients (8 male and 5 female patients) had an atypical carcinoid 
tumor. All patients were treated with curative surgery: 50 patients 
had not progressed, 4 had recurrence and in 6 the follow-up was 
lost. Among patients with typical carcinoid tumor, 37.2% smoked 
>10 pack-years at the time of diagnosis, while in atypical tumors 
69.2% were heavy smokers. The majority of patients in our series 
presented evidence of bronchial presentation (87.5%), obstructive 
pneumonitis (78.8%), pleuritic pain (70.7%), pulmonary atelec-
tasis (75.0%), and dyspnea (56.1%). This was followed by cough 
(75.9%), hemoptysis (41.8%), and a variety of other symptoms/
signs, including weakness, nausea, weight loss, night sweats, and 
neuralgia. The lesions ranged in size from 0.4 to 7 cm, with 35% of 
the neoplasm having a maximum dimension >3.0 cm. Histological 
examination of samples showed oncocytic (4 cases), papillary (4 
cases) and mixed trabecular/insular/organoid (52 cases) patterns. 
The growth pattern of carcinoid samples was polypoid (23 cases), 
nodular (16 cases), hourglass (11cases), stenotic (3 cases), and lobu-
lar (1 case).
Conclusion: The goal of this work is not so much to recapitulate 
lung carcinoids tumors classification but rather to provide an un-
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P1.08-001 CORRELATION OF INTRA-FRACTION DIS-
PLACEMENT OF THE MEDIASTINAL METASTATIC LYMPH 
NODES WITH PRIMARY TUMOR, LUNG AND HEART 
BASED ON 4DCT IN NON-SMALL CELL LUNG CANCER
Su Z. Wang1, Huai X. Xing2, Jian B. Li1, Ying J. Zhang1, Ting Y. Fan1, 
Min Xu1, Shao Qian1, Feng X. Li1
1Department Of Radiation Oncology, Shandong Cancer Hospital & Insti-
tute/China, 2Department Of Anesthesiology, Shandong Cancer Hospital 
And Institute/China
Background: To investigate the correlation of intra-fraction dis-
placement of the mediastinal metastatic lymph nodes with dis-
placement of primary tumor and rates of volume change of lung 
and heart based on four-dimensional computed tomography 
(4DCT) for non-small cell lung cancer (NSCLC).
Methods: Twenty-six patients diagnosed as NSCLC with fifty-one 
mediastinal metastatic lymph nodes were scanned by 4DCT simu-
lation during free breathing. The left group (1L, 2L, 4L, 5 region) 
and right group (1R, 2R, 4R region) and under group (7, 9 region) 
mediastinal metastatic lymph nodes and primary tumor, heart, 
bilateral lungs were contoured on CT images of 10 phases separa-
tely. Then the displacement of the lymph nodes and primary tumor 
at left-right(LR), anterior-posterior(AP) and superior-inferior(SI) 
direction were measured. And the rates of volume change of lung 
and heart were acquired on the whole respiratory cycle. Compa-
rison and correlation analysis were performed between displace-
ment of the lymph nodes and the primary tumor as well as the 
correlation of the displacement with the rates of volume change of 
lung and heart.
Results: In LR and AP direction, the correlation was significant bet-
ween the displacement of the left group of lymph nodes and the 
ipsolateral primary tumor (r=0.965, 0.897; P=0.008, 0.015). It was 
significant correlation of displacement of the left group of lymph 
nodes in LR and the right group in AP with rates of volume change 
of ipsolateral lung (r=0.609, 0.645; P=0.035, 0.024). There were 
significant correlations between displacement of the left group 
lymph nodes and rates of volume change of heart in LR, AP and SI 
directions (r=0.614, 0.897, 0.607; P=0.044, 0.015, 0.037).
Conclusion: There was no difference between the displacements 
of primary lung tumor and the lymph nodes in three directions 
during free breathing. The displacement of left primary lung tumor 
was able to predict displacement of left mediastinal lymph nodes 
of trachea in the LR and AP directions. Meanwhile, it was reasonab-
le to predict three-dimensional lymph node motion by monitoring 
the rates of volume change of ipsolateral lung and heart for the 
mediastinal lymph nodes located in 1L, 2L, 4Land 5 regions.
Keywords: displacement measurement, heart-beat, four dimensio-
nal CT, mediastinal metastatic lymph nodes
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P1.07-048 LEARNING CURVE FOR VIDEO-ASSISTED 
THORACOSCOPIC SURGERY LOBECTOMY PLUS MEDI-
ASTINAL LYMPH NODE DISSECTION FOR NON-SMALL 
CELL LUNG CANCER: HOW MANY CASES ARE NEEDED 
TO REACH COMPETENCE WITH GUIDANCE OF CON-
SULTANT SURGEON?
Hao Wang1, Wei Jin2, Yanguang Ding2, Xiangzhi Xiao2, Shengchao 
Zhang2, Jun Yuan2, Ruheng Zheng1
1Thoracic Surgery, Zhongshan Hospital, Fudan University/China, 2Tho-
racic Surgery, Qingpu District Center Hospital Of Shanghai/China
Background: Video-assisted thoracoscopic surgery (VATS) lobec-
tomy plus mediastinal lymph node dissection is an innovative tech-
nique shown to be minimally invasive and oncologically adequate 
for the treatment of non-small cell lung cancer (NSCLC), though it 
is technically difficulty. This study aimed to describe the learning 
curve for this minimally invasive surgery with guidance by consul-
tant surgeon.
Methods: From September 2011 to March 2013, a total of 46 pa-
tients with NSCLC underwent VATS lobectomy plus mediastinal 
lymph node dissection in our low-volume center. The procedures 
were guided by experienced consultant surgeons. The patients 
were divided into three groups. Group A included the first 15 ca-
ses. Group B comprised cases No. 16 to 30, and group C included 
the final 16 cases. The demographic characteristics and the intra- 
and postoperative variables were collected retrospectively and 
analyzed.
Results: There was no significant difference found among the 
three groups in age, gender, body mass index, ASA score, tumor 
location, histological type and clinical stage. No postoperative 
death occurred. Two patients required conversion (1 in Group A, 
1 in Group B). Compared with group A, a significant decrease in 
intrathoracic operative time (132±30 vs 185±29 min; P = 0.000), 
blood loss (128±64 vs 209±117ml; P =0.003), but more retrieved 
nodes (12.2±3.1 vs 9.3±2.5; P =0.014) was observed in group 
B, while the postoperative hospital stay was similar (9.9±3.3 vs 
11.8±7.0 days; P =0.572). And compared with group B, the last 16 
patients (group C) involved significantly less intrathoracic operative 
time (119±20 vs 132±30 min; P =0.091), less blood loss (92±43 vs 
128±6ml; P =0.021), more retrieved nodes (14.3±3.4 vs 12.2±3.1; 
p=0.040) as well as a shorter postoperative hospital stay (6.8±2.5 
vs 9.9±3.3 days; P =0.003). A decline in the overall morbidity from 
group A to group C (46.7%, 33.3%, 12.5, P = 0.098) was also obser-
ved.
Conclusion: This study suggests that at least 30 cases were nee-
ded to reach the plateau of VATS lobectomy plus mediastinal 
lymph node dissection for NSCLC. The guidance of experiened 
consultant surgeons might be meaningful to reduce the learning 
curve.
Keywords: learning curve, video-assisted thoracoscopic surgery, 
lobectomy, non-small cell lung cancer
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P1.08-003 I LOVE A SUNBURNT COUNTRY ... TRIPARTITE 
COLLABORATIVE APPROACHES TO BRINGING STEREO-
TACTIC ABLATIVE BODY RADIOTHERAPY (SABR) LUNG 
TO THE PEOPLE OF REGIONAL AUSTRALIA
Fiona Hegi-Johnson1, Eric Hau2, Kylie Unicomb1, Jeffrey Barber1, 
Melissa Rains1, Dan Lu2, Michael Bailey3, Jianje Luo1, Matthew 
Foote4, Roland Yeghiaian-Alvandi1
1Radiation Oncology, Nepean Cancer Care Centre/Australia, 2Radiation 
Oncology, St George Hospital/Australia, 3Radiation Oncology, Illawarra 
Cancer Care Centre/Australia, 4Radiation Oncology, Princess Alexand-
ria Hospital/Australia
Background: Australia is one of the most urbanized countries in 
the world. Patients with cancer in regional Australia have poorer 
access to oncology services, resulting in lower survival rates for 
lung cancer1. Implementation of SABR lung is focused in metro-
politan centres, limiting access for regional patients. The develop-
ment of new regional radiotherapy centres could improve this, but 
these centres require support to implement this complex techno-
logy. A tripartite collaboration consisting of radiation oncologists, 
physicists and radiation therapists was formed to enable imple-
mentation of SABR.
Methods: The collaboration includes the following 11 radiation 
oncology departments: 
• Regional hospitals: North Coast Cancer Institute ( Lismore, Port 
Macquarie and Coff’s Harbour), Newcastle Calvary Mater Hospital, 
Central Coast Cancer Care Centre ( Gosford)
• Sydney Metropolitan Hospitals: Westmead and Nepean Hospi-
tals, St George Hospital, Royal North Shore Hospital, Royal Prince 
Alfred Hospital, Prince of Wales Hospital.
The goal was to support centres starting an SABR programme, 
and facilitate ongoing assessment of outcomes. Multidisciplinary 
working groups consisting of radiation oncologists, radiation the-
rapists and physicists were formed to cover: 
• Clinical protocol development: existing protocols, including the 
Dutch (ROSEL), Leeds, RTOG and TROG Chisel protocols were 
reviewed. Ethically approved SABR protocols for Stage I NSCLC, 
pulmonary and vertebral metastases were developed with assis-
tance from international and local experts.
• Planning protocols: development of prescription pages and IMRT 
checklists for treatment.
• Physics quality assurance: specification documents for equip-
ment, quality assurance and image verification procedures are 
being developed.
• Data collection: a database to archive clinical data and all radio-
therapy planning and diagnostic imaging was developed.
Ongoing support for regional centres includes: email servers for 
rapid response to questions, video-conferenced clinical and tech-
nical audits of SABR cases. Data collection will facilitate quality 
assurance and future research.
Results: The tripartite approach has led to the uniform adoption 
of clinical and technical protocols, and facilitated large-scale data 
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P1.08-002 RELATION OF TUMOR RESPONSE TO RADI-
ATION DOSE DISTRIBUTION IN LOCALLY ADVANCED 
NON-SMALL CELL LUNG CANCER UNDERGOING CON-
CURRENT CHEMORADIOTHERAPY
Won Sup Yoon1, Young Je Park2, Jung Ae Lee3, Suk Lee2, Dae Sik 
Yang3, Chul Yong Kim2, Je Hyong Kim4
1Radiation Oncology, Ansan Hospital, Korea University Medical Center/
Korea, 2Radiation Oncology, Anam Hospital, Korea University Medical 
Center/Korea, 3Radiation Oncology, Guro Hospital, Korea University 
Medical Center/Korea, 4Internal Medicine, Ansan Hospital, Korea Uni-
versity Medical Center/Korea
Background: To determine whether the quality of radiation dose 
distribution is associated with the tumor response of advanced 
non-small cell lung cancer (NSCLC) undergoing concurrent chemo-
radiotherapy (CCRT).
Methods: Thirty one patients with stage IIIA/IIIB NSCLC under-
went CCRT with a median dose of 63 Gy (range 40-66 Gy). The 
chemotherapy combined taxene and alkylating agents. On our 
actual plans, we drew the planning target volume (PTV) including 
the electric nodes and tried to make a plan to cover the PTV with 
at least 95% of prescribed dose. The following CT simulation was 
done when a cumulative dose was about 36 Gy and the cone-
down was undergone at about 40 Gy only including the primary 
tumor and the bulky nodes. For this retrospective study, each PTV 
of primary tumor (n=30) and lymph nodes (n=36) was separately 
re-defined with even margins from gross target volume (GTV) to 
reduce the variation of target delineation, and the actual plan 
overlaid the re-defined PTV. For the measurement of tumor res-
ponse rate during CCRT (RR(mid)) and after CCRT (RR(end)), the 
GTV on initial simulation was compared with the GTV on following 
CT simulation and following CT scan after 2 months from end of 
CCRT, respectively. The relations between the RR(mid), RR(end), 
dose distribution parameters (D95, V95, mean tumor dose (MTD) 
and homogeneity index (HI)), total dose and tumor volume were 
evaluated by bivariate correlation analysis.
Results: Median overall survival was 15.5 months and 2-year sur-
vival 42.3%. For primary tumors and lymph nodes, the dose distri-
bution parameters were favorable (Table). For primary tumors, the 
relation between dose distribution parameters and tumor respon-
se was not significant. The RR(end) was correlated with the GTV 
on following CT simulation (γ=0.627, p<0.001) and the RR(mid) 
(γ=0.541, p=0.003). For lymph nodes, the RR(mid) was correlated 
with the mean tumor dose (γ=0.356, p=0.033).  
Mean/SD 
(%) 
D95 V95 MTD HI
Tumor Node 
97.4/2.5 
96.6/6.7 
99.7/5.4 
100.0/23.5 
100.3/1.0 
98.6/3.1 
2.9/1.4 
2.2/1.7 
Conclusion: The quality of radiation dose distribution minimally 
affected the tumor response. Based on the marked association 
between the RR(mid) and RR(end), further studies of tumor intrinsic 
factors related to radiation sensitivity will be rewarding.
Keywords: non-small cell lung cancer, chemoradiotherapy, tumor 
response, dose-volume histogram
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highest for 3D-CRT plans (29.4 Gy and 28.7 Gy for CP and NCP). 
V20 was between 4.4 and 6.1% for all plans. VMAT plans were 
three times as fast to deliver as NCP IMRT (6min and 6s vs. 19 min 
34s) and twice as fast as NCP 3D-CRT plans (12min 35s) . TROG 
CHISEL criteria: one CP-3D-CRT plan had a major violation on spinal 
cord. There were no other violations. RTOG 0915 criteria: no major 
violations were recorded for VMAT plans. CP IMRT plans had 2 
major violations and NCP IMRT had 1 major violation. All violations 
were in the D2cm and 50% CI constraints. Seven CP 3D-CRT had 
major violations in 50% CI, D2cm and high dose spill, and 4 NCP-
3DCRT plans had major violations in high dose spill and 100% CI.
Conclusion: VMAT plans are similar in quality to NCP IMRT, but 
are faster to deliver due to reduced gantry and couch movements. 
3D-CRT plans were unable to deliver equivalent dose conformality, 
and a larger region of normal tissue was exposed to a high dose 
when equivalent PTV coverage was achieved. CP 3D-CRT plans do 
not meet RTOG criteria due to the inability to meet low dose wash 
constraints, and more complex planning is beneficial in these cases.
Keywords: Volumetric Modulated Arc Therapy, non-small cell lung 
cancer, Stereotactic, radiotherapy
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P1.08-005 ACTIVE BREATHING COORDINATION TO 
MEASURE TUMOUR MOTION IN LUNG CANCER PATI-
ENTS: A FEASIBILITY STUDY
Shivani S. Kumar, Lois C. Holloway, Eng-Siew Koh, Penny D.T. 
Phan, Callie H. Choong, Shalini Vinod
Liverpool Hospital, Cancer Therapy/Australia
Background: Lung tumour motion poses a significant challenge in 
accurate delivery of radiotherapy. To prevent geographical miss, 
a generic margin is often added to the CTV to create an internal 
target volume (ITV). Studies have shown the effectiveness of Active 
Breathing Coordinator (ABC) (Elekta, Crawley, UK) in reducing this 
internal margin. For the purpose of this study we wanted to evaluate 
the feasibility of utilising ABC for our patient population and of 
defining ITV margin based on breath-hold scans.
Methods: 13 patients receiving radical radiotherapy were 
prospectively recruited. Each patient received a 1 hour training 
session prior to CT simulation to determine eligibility for the study 
and provide training for the breath hold procedure. A minimum 
of fourteen seconds breath-hold was required for patients to be 
eligible. If eligible, patients were positioned on the CT simulator 
as per department protocol with the addition of ABC. Standard 
departmental CT protocol for lung treatment was first performed 
with contrast. This scan was used to identify the tumour region. A 
breath-hold scan at normal inspiration and expiration was done in 
the region of visible tumour volume with the aid of ABC. A radiation 
oncologist defined ITV based on current departmental protocol and 
using the ABC scans. To verify accuracy of ABC volume, a 4D Cone 
Beam CT (4D CBCT) scan was done during week 1 of treatment. 
To verify the reproducibility of ITV and breath-hold position, a 
second ABC scan and 4DCBCT were performed mid-way through 
treatment. The planning ITV and ABC ITV were compared. Variation 
in tumour position and volume were quantified and compared.
Results: From the 13 patients recruited, only 5 patients were able to 
tolerate ABC. On average, eligible patients were able to maintain a 
pooling of SABR patient information across NSW. Key drivers of 
success were: the recognition of the need to data pool, identifica-
tion of key team members to lead the process who had expertise 
in trial coordination, database development and implementation 
of radiotherapy technology, and administrative support from invol-
ved departments.
Conclusion: By increasing collaboration between metropolitan 
and regional radiotherapy centres we have successfully facilitated 
the safe implementation of SABR lung, increasing accessibility for 
patients in regional Australia. This model could be used as the 
basis for a national collaboration, and the development of accredi-
tation and credentialing procedures for Australian departments. 1. 
Vinod, S. K. et al. . Cancer 116, 686–694 (2010).
Keywords: Lung cancer, Stereotactic, radiotherapy
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P1.08-004 AUSTRALIAN IMPLEMENTATION OF VMAT 
FOR STEREOTACTIC BODY RADIOTHERAPY IN EARLY 
LUNG CANCER LUNG: COMPARING VMAT WITH CO-
PLANAR AND NON-COPLANAR INTENSITY MODULA-
TED RADIOTHERAPY AND 3D-CONFORMAL RADIOTHE-
RAPY.
Fiona Hegi-Johnson1, Kylie Unicomb1, Katherine Small1, Sean 
White1, Jeffrey Barber1, Kevin Van Tilburg1, Roland Yeghiaian-
Alvandi2
1Radiation Oncology, Nepean Cancer Care Centre/Australia, 2Radiation 
Oncology, Crown Princess Mary Cancer Care Centre/Australia
Background: Stereotactic ablative body radiotherapy is being 
implemented in Australia on a wider scale. Significant differences 
exist between protocols, particularly in the constraint of dose 
wash. To achieve a high level of dose conformality large numbers 
of beams, and non-coplanar techniques may be used, resulting in 
long treatment times. We report on a study comparing volumetric 
modulated arc therapy (VMAT) to coplanar (CP) and non-coplanar 
(NCP) conformal radiotherapy (3D-CRT) and intensity modulated 
radiation therapy (IMRT), and assess whether plans meet RTOG 0915 
and TROG CHISEL criteria.
Methods: Eight Pinnacle VMAT, and CP and NCP 3D-CRT and 
IMRT plans for delivery on Elekta Linacs were assessed for: target 
coverage (coverage with the prescribed dose), dose conformality 
(100% and 50% conformity indices, D2cm and high dose outside 
the PTV) and V20 (volume of lung receiving 20 Gy). Plans aimed to 
deliver the prescription dose to at least 98% of the volume, with 
a V20 ≤ 8% . All VMAT plans were single arc with 4° spacing, and 
all IMRT and 3D-CRT plans used identical beam angles with 10-12 
beams. Treatment time was measured by delivering the plans to a 
phantom. All patients had peripheral tumours and received 48 Gy in 
4 fractions.
Results: VMAT achieved equivalent radiotherapy target coverage 
to 3D-CRT and IMRT (>98.2%). However, 3D-CRT plans had a large 
volume of surrounding normal tissue receiving a high dose (24.0% 
and 21.3% of the PTV volume for CP and NCP ) when compared 
to VMAT and IMRT plans (3.9% and 4-5% of PTV volume). 100% 
conformity indices were lowest for VMAT and NCP IMRT (1.1 for 
both) and highest for 3D-CRT (1.5 and 1.4 for CP and NCP). D2cm 
was also lowest for VMAT and NCP IMRT (26.1 Gy and 25.3 Gy) and 
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Keyword: Lung Cancer, MRI, Gross Tumour Volume, Interobserver 
Variability
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P1.08-007 OUTCOMES AND PROGNOSTIC FACTORS OF 
STAGE I NON-SMALL CELL LUNG CANCER PATIENTS 
TREATED WITH STEREOTACTIC BODY RADIOTHERAPY 
OR 3-DIMENTIONAL CONFORMAL RADIOTHERAPY.
Itaru Soda1, Kazushige Hayakawa1, Hiromichi Ishiyama1, Masato 
Katagiri2, Shoko Komori1, Akane Sekiguchi1, Yuzuru Niibe1, Shogo 
Kawakami1, Kouji Takenaka1, Noriyuki Masuda2
1Department Of Radiology And Radiation Oncology, Kitasato University 
School Of Medicine/Japan, 2Department Of Respiratory Medicine, Kita-
sato University School Of Medicine/Japan
Background: Although stereotactic body radiotherapy (SBRT) 
has become a one of the preferred treatment options for patients 
with stage I non-small cell lung cancer, the patients are not always 
suitable for SBRT. The purpose of this study was to present the 
treatment outcomes and prognostic factors for stage I NSCLC 
treated with SBRT or 3-dimentional conformal radiotherapy 
(3DCRT).
Methods: The medical records of 77 patients with stage I NSCLC 
treated in our hospital were retrospectively reviewed. Forty-four 
patients were treated with SBRT which was delivered a total dose of 
48Gy in 4 fractions for one week. Thirty-three patients were treated 
with 3DCRT which was delivered a total dose of 60-66Gy in 20-30 
fractions. SBRT was done with the real-time tumor-tracking system 
(RTRT) using 3 to 4 fiducial gold markers. 3DCRT was adapted to 
the patients who had difficulty of bronchoscopic implantation of 
fiducial markers, centrally located tumors or low performance status. 
In dose calculation for the majority of patients, inhomogeneity was 
corrected by the superposition method. Univariate and multivariate 
analysis were performed for predictive factors.
Results: Median follow-up time was 30 months (range, 1 to 94 
months). The 3-year local control (LC), disease-free survival (DFS), 
and overall survival rate (OS) of all patients were 69.2%, 57.1%, and 
68.6%, respectively. There was no significant difference between 
the two groups in 3-year LC (SBRT, 78.6%; 3DCRT, 58.5%; p=0.146) 
and 3-year OS (SBRT, 66.4%; 3DCRT, 71.1%; p=0.83), but in 3-year 
DFS SBRT was superior to 3DCRT (SBRT, 66.2%; 3DCRT, 46.3%; 
p=0.039). Multivariate analysis detected pathological type and 
patient’s age as significant predictive factors for LC and DFS, 
respectively. Especially the histologic type of squamous cell 
carcinoma was detected as an adverse predictive factor for local 
control. The type of radiotherapy was not detected as a prognostic 
factor on multivariate analysis. No serious radiation morbidity was 
observed with either RT method.
Conclusion: Our results suggested that 3DCRT may be a good 
alternative treatment for patients who are not suitable for SBRT. 
Well-designed prospective studies investigating the optimal 
schedule of dose fractionation in early-stage lung cancer are 
warranted.
Keywords: non-small cell lung cancer, stereotactic body 
radiotherapy, 3-dimentional conformal radiotherapy
20 second breath-hold. The generic ITV margin was larger than the 
patient specific ABC ITV margin in all cases. A change in centre of 
volume was noted between simulation ABC GTV and mid treatment 
ABC GTV. There was an average overall difference of 0.8cm for 
the 3 dimensional vectors for two eligible patients. There was no 
correlation between breath hold ability and the patient’s pulmonary 
function.
Conclusion: ABC was not feasible for the cohort of patients 
recruited for this study. For the patients who could tolerate ABC 
scans, the ITV could be individualized and reduced from that based 
on generic population data.
Keywords: Feasibility Study, Active Breathing Co-ordinator, Lung 
tumour motion, Internal target volume
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P1.08-006 INTER-OBSERVER VARIABILITY OF GTV DELI-
NEATION BASED ON LUNG MRI: IMPACT OF RADIOLO-
GIST LED WORKSHOP
Shivani Kumar1, Lois C. Holloway2, Daniel Moses1, Shalini Vinod2
1University Of New South Wales/Australia, 2Liverpool Hospital, Cancer 
Therapy/Australia
Background: Magnetic Resonance Imaging (MRI) with its superior 
soft tissue contrast resolution has the potential to improve Gross 
Tumour Volume (GTV) delineation of lung cancer. The aim of this 
study was to assess the inter-observer variability between observers 
for MRI based GTV delineation for Lung cancer and evaluate 
whether this factor changed following a GTV delineation workshop 
with a thoracic radiologist.
Methods: Five radiation oncologists from three different institutions 
were asked to delineate GTV on 3 patient datasets. Each observer 
was given a planning CT, PET, T1 and T2 weighted 1.5 T MRI 
datasets along with patient history and relevant diagnostic test 
results. Each observer was instructed to delineate a primary GTV 
and nodal GTV as required on the T1 and T2 weighted MRI datasets 
(pre workshop contours). A workshop was then conducted. The aim 
of the workshop was to discuss each case with a thoracic radiologist 
and for the radiologist to educate each of the observers in how to 
review thoracic MRI for both T1 and T2 weighted images. Following 
the workshop each observer delineated a post workshop GTV. 
Conformity index (CI) was used to evaluate improvement in inter-
observer variability between pre and post workshop contours.
Results: of two observers are presented here. For patients 1 and 3 
slight improvement in CI was noted between pre and post primary 
and nodal GTV for T1 and T2 weighted datasets. Similarly for patient 
3 slight improvements were noted in inter-observer variability for 
primary GTV for both T1 and T2 weighted images. However there 
was significant improvement in both T1 and T2 weighted nodal 
GTV. CI improved from 0.2 to 0.6 and 0-0.6 for T1 and T2 weighted 
images respectively.
Conclusion: Preliminary results from this study indicate that a 
radiologist led workshop assisted in improving inter-observer 
variability for MRI based GTV delineation. Further analysis of all 
observers is required to assess the significance of the impact of a 
radiologist led contouring workshop in improving inter-observer 
variability on MRI delineation of lung cancer.
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Conclusion: RPA class I or II (KPS>70), adenocarcinoma and no 
previous chemotherapy were associated with longer survival. These 
factors should be taken into account for decision-making in an 
attempt to find optimal treatment for patients with brain metastasis.
Keywords: radiotherapy, whole brain radiotherapy, brain metasta-
sis, Prognosis
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P1.08-008 PROGNOSTIC FACTORS IN PATIENTS WITH 
BRAIN METASTASIS FROM NON-SMALL CELL LUNG 
CANCER TREATED WITH WHOLE-BRAIN RADIOTHERA-
PY
Hideyuki Harada1, Koichi Mitsuya2, Keita Mori3, Hirofumi Asaku-
ra1, Hirofumi Ogawa1, Tsuyoshi Onoe1, Nakamasa Hayashi2, Tos-
hiaki Takahashi4, Yoko Nakasu2, Tetsuo Nishimura1
1Radiation Oncology, Shizuoka Cancer Center/Japan, 2Neurosurgery, 
Shizuoka Cancer Center/Japan, 3Clinical Trial Coordination Office Bio-
statistics, Shizuoka Cancer Center/Japan, 4Division Of Thoracic Oncolo-
gy, Shizuoka Cancer Center/Japan
Background: To evaluate the prognostic factors associated with 
overall survival in patients with brain metastasis from non-small 
cell lung cancer(NSCLC) who received whole-brain radiotherapy 
(WBRT).
Methods: From September 2002 to December 2010, 257 patients 
with brain metastasis from NSCLC who received WBRT. Those who 
had undergone craniotomy or stereotactic radiotherapy before 
WBRT and those with leptomeningeal metastasis were excluded. 
The prognostic factors evaluated for overall survival were; gender, 
neurological deficit, histology, epidermal growth factor receptor 
(EGFR) mutation status, previous cytotoxic chemotherapy, previous 
EGFR tyrosine kinase inhibitor (TKI) treatment, RTOG-recursive 
partitioning analysis (RPA) (age,Karnofsy Performance Scale [KPS], 
primary tumor control), and diagnosis-specific graded prognostic 
assessment (DS-GPA)(age, KPS, extra cranial control, number of 
lesions). All factors with a Pvalue < 0.05 at univariate analysis were 
entered into a multivariate analysis using Cox regression with con-
fidential interval of 99%.
Results: At the time of analysis, 225 patients (88%) died, 14 
patients (5%) were alive, and 18 patients (7%) were lost to follow-
up. The median follow-up time was 16.2 months. The median 
survival time (MST) was 5.6 months and 1-year survival rate 
was 28.6%. The MST according to gender, neurological deficit, 
histology, EGFR mutation status, previous chemotherapy, previous 
EGFR-TKI treatment, RPA class, and DS-GPA were shown in Table 
1. In univariate analysis, the significant prognostic factors were; 
gender (P=0.0002), neurological deficits (P<0.0001), histology 
(P<0.0001), previous chemotherapy (P=0.0463), EGFR mutation 
(P=0.0236), RPA class (P<0.0001) and DS-GPA (P=0.0003). In 
multivariate analysis, RPA class (I and II vs III,KPS>70 vs <70), 
histology (adenocarcinoma vs non-adenocarcinoma) and previous 
chemotherapy (none vs present) were found to be significant 
prognostic factors (Table 2).
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P1.08-010 NSCLC AND RADIATION PNEUMONITIS POST 
RADIOTHERAPY
Saxby Brown, Louise M. Nott, Marianne Hercus, Katharine See, 
Raef Awad
Royal Hobart Hospital/Australia
Background: Lung cancer is the main cause of cancer deaths in 
the developed world and non-small cell lung cancer (NSCLC) ac-
counts for 80-85% of all lung cancers [1]. Of these with NSCLC, 
30-40% have locally advanced or inoperable disease, for which 
the mainstay of treatment remains thoracic irradiation. Radiation 
pneumonitis (RP) is one of the major dose limiting toxicities. The 
aim of this study is to retrospectively analyse the incidence and 
risk factors for RP in NSCLC patients treated with radiotherapy at 
Royal Hobart Hospital and to determine suitable dose restriction 
parameters.
Methods: 273 patients with NSCLC who had radiotherapy treat-
ment between 2006 and 2012 were retrospectively reviewed. For 
each patient, all records were examined for documented evidence 
of RP using the Common Terminology Criteria for Adverse Events 
(CTCEA 4.0 [2]) grading criteria at least six months post treatment. 
In addition, radiation dose, dose per fraction, planning target volu-
me (PTV), total lung volume, mean lung dose, v5, v10, v20 and v30 
values were obtained and a comparable biological effective dose 
(BED) for each treatment was calculated. Previous chemotherapy 
treatments, smoking status, performance status, use of ACE inhibi-
tors, existing cardiovascular disease, established chronic obstruc-
tive pulmonary disease (COPD) and pulmonary function tests were 
also obtained.
Results: Out of the 273 NSCLC patients treated with radiotherapy 
at Royal Hobart Hospital, 25 (9%) had stage 1, 15 (5%) had stage 
2, 75 (27%) had stage 3 and 129 (47%) had stage 4 NSCLC. 29 
(11%) patients had no staging documented. 41 patients (15%) had 
documented evidence of RP. Of these 41 patients, 24 patients had 
level 1 RP, 14 patients had level 2, 1 patient had level 3, 1 patient 
had level 4 and 1 patient had level 5 (death). The mean BED (nor-
malised to 2 Gy per fraction) was 64.9 +/- 21.0 Gy and the mean 
lung dose was 10.3 +/- 10.50 Gy. Twenty out of the 41 patients had 
been treated with radical intent and 21 with palliative intent.
Conclusion: In this study, RP has been documented in 15% of pati-
ents. More than half of these patients received palliative radiation 
dose. This could be explained by their advanced disease, poor 
lung function, and poor performance status. References: 1. Jemal 
A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 
2008. CA Cancer J Clin 2008;58:71–96. 2. Common Terminology 
Criteria for Adverse Events (CTCEA 4.0), http://ctep.cancer.gov/
protocolDevelopment/electronic_applications/ctc.htm
Keywords: NSCLC, radiation, pneumonitis, radiotherapy
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P1.08-009 DYNAMIC TUMOR TRACKING RADIOTHERA-
PY WITH REAL-TIME MONITORING USING VERO4DRT
Yukinori Matsuo1, Nami Ueki1, Kenji Takayama2, Mitsuhiro Na-
kamura1, Yuki Miyabe1, Hiroaki Tanabe2, Shuji Kaneko1, Takashi 
Mizowaki1, Hajime Monzen1, Akira Sawada3, Masaki Kokubo4, 
Masahiro Hiraoka1
1Radiation Oncology And Image-applied Therapy, Kyoto University/
Japan, 2Radiation Oncology, Institute Of Biomedical Research And In-
novation/Japan, 3Kyoto College Of Medical Science/Japan, 4Radiation 
Oncology, Kobe City Medical Center General Hospital/Japan
Background: The Vero4DRT is a newly-developed innovative ra-
diotherapy system with two special features. One is a pair of kV 
x-ray imagers which can monitor a 3-dimensional position of tumor 
in real time. The other is a gimbaled x-ray head which enables 
tumor tracking. This study is to evaluate the initial clinical experien-
ces of dynamic tumor tracking irradiation with real-time monitoring 
for the lung using the Vero4DRT system.
Methods: Eligibility criteria for this study were (1) lung tumor 
with a diameter of 50 mm or less, (2) respiratory motion of 10 mm 
or more, (3) performance status of 0–2, and (4) written informed 
consent. Prior to treatment planning, spherical gold markers were 
placed around the tumor using a bronchoscope. Gross tumor 
volume (GTV) for tracking was delineated on a breath-hold CT at 
end-exhale. Margins for planning target volume (PTV) were de-
termined for each patient considering errors due to the tracking 
irradiation. Prescription dose was 56 Gy in 4 fractions for T2a 
lung cancer and metastatic tumor, and 48 Gy in 4 fractions for the 
others. Dose-volume metrics were compared between the tumor 
tracking and conventional static irradiation using an in-house deve-
loped software. A 6-MV photon beam was delivered to the tumor 
with the gimbaled x-ray head toward predicted position based on 
the abdominal wall. During the irradiation, the tumor and the gold 
markers were monitored with kV imagers and EPID.
Results: The dynamic tumor tracking radiotherapy was successfully 
performed for 12 patients (10 males and 2 females). A median age 
was 83 years (range, 60-87 years). Histology was adenocarcinoma 
in 4 patients, squamous cell carcinoma in 3, non-small cell lung 
cancer in 1, metastatic tumor in 3, and unconfirmed in 2, respec-
tively. Tumor diameter ranged from 12 to 36 mm (median, 21 mm). 
Median amplitude of respiratory motion was 16.8 mm (range, 11.3 
to 33.5 mm). A mean PTV volume was 42.9 cc for the dynamic 
tracking, while that was 62.5 cc for the conventional irradiation. 
The tracking irradiation could reduce normal lung doses by 21.3% 
in mean. Dose covering 95% volume of GTV was not different 
between the two irradiation techniques with a mean difference of 
0.66%. A mean treatment time per fraction was 37 minutes. The 
gold markers were well recognized with kV x-ray imagers through 
the whole treatment fractions. With a median follow-up period of 
7.7 months (range, 2.1 – 19.2 months), local tumor was controlled in 
all patients. One patient experienced grade 2 radiation pneumo-
nitis. No severe toxicity has been observed in any of the patients 
so far.
Conclusion: Dynamic tumor tracking irradiation with real-time 
monitoring using the Vero4DRT could reduce normal lung doses 
without any excess time. Preliminary outcomes were promising.
Keywords: stereotactic body radiotherapy, dynamic tracking irra-
diation
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is first report to show the α/β ratio for esophageal toxicity may be 
lower than 10. Confirmations of these data are needed in an inde-
pendent data set.
Keyword: Radiotherapy, Chemotherapy, Toxicity Predictors
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P1.08-012 SIGNIFICANT ASSOCIATION BETWEEN RADI-
ATION INDUCED OESOPHAGITIS, NEUTROPENIA AND 
V20 IN PATIENTS WITH NON-SMALL CELL LUNG CAN-
CER
Sarah Everitt1, Mary Duffy2, Mathias Bressel3, Belinda Mcinnes1, 
Christine Russell3, David Ball4
1Radiation Therapy, Peter MacCallum Cancer Centre/Australia, 2Ambu-
latory Care, Peter Mac Callum Cancer Centre/Australia, 3Biostatistics 
And Clinical Trials, Peter MacCallum Cancer Centre/Australia, 4Radia-
tion Oncology, Peter MacCallum Cancer Centre/Australia
Background: Radiation induced oesophagitis (RIO) is frequently 
associated with high dose thoracic radiation therapy (RT). Alt-
hough RIO is uncommonly life threatening, it is a distressing toxici-
ty associated with pain, decreased oral intake and can significantly 
impact on patient’s quality of life. The aim of this retrospective 
analysis was to assess the rates of acute and late RIO and investi-
gate the association of RIO with radiation dosimetrics and neutro-
penia.
Methods: Criteria for inclusion of patient data included a patholo-
gical confirmation of non-small cell lung cancer (NSCLC), treatment 
with concurrent chemotherapy and radical or high dose palliative 
RT at our centre between 03/04 and 08/07. Exclusion criteria in-
cluded previous thoracic RT, RT alone, treatment breaks of > five 
days, inconsistent radiation dose per fraction and hyper-fractiona-
ted RT. Acute and late RIO and neutropenia were scored using the 
Common Toxicity Criteria for Adverse Events (CTCAE v3.0) criteria. 
Using Focal (Computerized Medical Systems CMS, St Louis, MO, 
USA), the outer muscular border of the oesophagus was delinea-
ted from the cricoid (superior border) to the gastro-oesophageal 
junction (inferior border) on CT derived images, using pre-defined 
soft-tissue window/level settings. Dosimetric data was derived 
from Xio (CMS) plans (three-dimensional conformal RT (3DCRT) 
with 6MV photons), including the oesophageal length and volume, 
maximum and mean doses, percentage of oesophagus receiving 
20 to 60 Gy (in 5 Gy increments) and percentage length of oeso-
phagus (whole and partial circumference) receiving 20 to 60 Gy (10 
Gy increments). Assessment of potential prognostic factors with 
respect to acute oesophagitis was done using Wilcoxon rank sum 
test and Spearman’s correlation. Acute oesophagitis and acute 
neutropenia reaction were dichotomised as grade 0+1 vs. grade 
2+3+4. The association of acute oesophagitis with acute neutrope-
nia was examined using Barnard’s test.
Results: The data of 54 patients were eligible for inclusion in this 
trial. 48 (89%) patients had acute RIO of at least grade 1 (95% CI 
[78% to 95%]) and five patients (9%) had late RIO of at least grade 
1 (95% CI [4% to 20%]). There was a statistically significant correla-
tion between the grade of acute RIO, oesophagus V20 (r=0.303, 
p=0.026) and length oesophagus receiving 20Gy (whole circum-
ference) (r=0.319, p=0.019). The mean (SD) maximum dose to the 
oesophagus was 50.2 Gy (18) (r=0.143, p=0.302) and the mean (SD) 
mean oesophageal dose was 20.8 Gy (10.8) (r=0.269, p=0.049). The 
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P1.08-011 DOSIMETRIC PREDICTORS OF ESOPHAGEAL 
TOXICITY IN PATIENTS WITH NON-SMALL CELL LUNG 
CANCER RECEIVING CHEMOTHERAPY AND RADIOTHE-
RAPY
Andre A. Konski1, Michael Snyder1, Antoinette J. Wozniak2, Erin 
Mcspadden1, Ladonna Hartsing1, Rachel Powell1, Laura Mantha2, 
Ammar Sukari2, Steven Miller1, Michael Joiner1, Shirish Gadgeel2
1Radiation Oncology, Wayne State University/ Karmanos Cancer Cen-
ter/United States Of America, 2Karmanos Cancer Institute/Wayne 
State University/United States Of America
Background: Esophageal toxicity can be a dose-limiting event in 
patients with non-small cell lung cancer receiving chemotherapy 
and radiotherapy necessitating treatment breaks with potential 
to cause adverse treatment related factors. The objective of this 
study was to investigate those factors, both clinical and dosimetric, 
which predict for esophageal toxicity.
Methods: Patients (pts) with non-small cell lung cancer prospec-
tively enrolled into an IRB approved database were retrospectively 
reviewed. Pts with biopsy-proven non-small cell lung cancer tre-
ated with radiotherapy alone, sequential or concurrent chemora-
diotherapy had maximal esophageal toxicity scored per CTCAE 
4.0 criteria. V5, V10, V20, V30, V40, V50, V60, V70, esophageal 
hot spot, and dose per fraction were the dosimetric variables and 
age, sex, race, chemotherapy, and stage were the clinical variab-
les investigated. Data were analyzed using SAS (SAS INC, Cary, 
NC) Version 9.2 software package. Ordinal maximum reported 
esophageal toxicity was evaluated using logistic regression. A 
multivariable regression model was fit using important univariate 
predictors along with a backwards elimination stepwise regression. 
Probability of esophageal toxicity as a function of absorbed dose 
in a partial volume was modeled by the method of Lyman, by con-
verting the dose volume histograms into an equivalent fractional 
volume receiving the maximum dose in the DVH, using the effecti-
ve volume method of Kutcher and Burman. The parameters in this 
model (D50, slope m and volume exponent n) were determined by 
maximum likelihood estimation.
Results: A total of 100 pts were enrolled between 7/10 and 12/12 
into a prospective database and eligible for analysis. Pts were ex-
cluded without a complete dose volume histogram data or were 
stage I disease leaving 71 eligible for analysis, 43 females and 28 
males with a median age of 61 (range: 39-85). 14 pts were treated 
with radiotherapy alone while 23 received sequential treatment 
and 34 concurrent treatment. The median delivered dose was 
66.6 Gy (range: 27.5-66.6) in a median of 1.8 Gy (range: 1.8-3.0) 
per fraction. Maximal esophageal toxicity was rated as 0: 12pts, 1: 
21 pts, 2: 33 pts, and 3: 5pts. Univariate predictors of > grade 2 
esophageal toxicity included, V5-V60 and use of concurrent che-
motherapy. The maximum likelihood fit of the Lyman model pa-
rameters to patients with ≥ 2 esophageal symptoms were n=0.26 
m=0.32, TD50=39.1 Gy when the α/β ratio was assumed to be 10 
Gy. The maximal likelihood fit of the Lyman model parameters to 
patients when the α/β ratio was not set were n=0.26, m=0.32 and 
TD50 39.3 with the α/β calculated at 7.6 Gy. Patients not having 
chemotherapy had a higher TD50, 46.4 Gy as compared to pati-
ents having chemotherapy, TD50=37.1 Gy, p=0.09.
Conclusion: We have shown the TD50 for > grade 2 esophageal 
toxicity is lower for patients receiving chemotherapy and radio-
therapy compared to patients receiving radiotherapy alone. This 
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Fig. 2. Dose distribution, tumoricidal 60Gy isodose (orange), signi-
ficant lung tissue sparing - 7Gy isodose (dark blue)
Conclusion: CyberKnife´s SABR of NSCLC is feasible and our 
image-guidance protocol allows to use high number of online tu-
mor tracking to spare as much lung tissue as possible. This results 
in excellent overall survival and minimal toxicity in patients that 
were not candidates for surgery. Longer follow-up is necessary for 
mature data.
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P1.08-014 PET-BASED RADIOTHERAPY PLANNING IS 
HIGHLY COST-EFFECTIVE COMPARED TO CT-BASED 
PLANNING: A MODEL-BASED EVALUATION.
Mathilda L. Bongers1, Veerle M.H. Coupe1, Dirk De Ruysscher2, 
Cary Oberije3, Philippe Lambin3, Carin A. Uyl-De Groot4
1Epidemiology And Biostatistics, VU University Medical Center/Nether-
lands, 2Radiation Oncology, Universitary Hospitals KU Leuven/Belgium, 
3Department Of Radiation Oncology (Maastro), Maastricht University 
Medical Center/Netherlands, 4Institute For Medical Technology Assess-
ment/Netherlands
Background: The new developments in PET technology are ex-
pensive. With the need to impose budget constraints, hospitals 
may be conservative to implement new developments. Although 
the use of PET-imaging in radiotherapy treatment planning for 
non-small cell lung cancer is proven effective, the cost-effective-
ness was never evaluated. Evaluations of the cost-effectiveness of 
new developments can support decision makers to better invest 
the available health care budget. In this study, we evaluated the 
cost-effectiveness of PET-CT-based radiotherapy treatment plan-
ning compared to CT-based radiotherapy treatment planning.
Methods: The cost-effectiveness analysis was performed using a 
previously developed decision model that simulates the disease 
progression of individual lung cancer patients until they are de-
ceased or have reached a pre-specified time-horizon of 3 years. 
Simulated patients move from the start of radiotherapy treatment 
to the absorbing state of death, potentially visiting the interme-
diate health states ‘local recurrence’ and ‘metastasis’. Transition 
rates in the model were estimated by multi-state statistical mo-
delling and include the impact of patient and tumour features on 
disease progression. Data for model quantification was available 
for 200 NSCLC patients with inoperable stage I-IIIB, provided 
by the Maastro Clinic. Resource use estimates, costs and utilities 
were obtained from the data of the Maastro Clinic, the literature 
and Dutch guidelines. Primary outcomes were the difference in 
life years, quality adjusted life years and costs and the incremental 
cost-effectiveness and cost-utility ratio (ICER and ICUR) of PET-CT 
maximum grade of acute oesophagitis was significantly associated 
with acute neutropenia (p=0.035).
Conclusion: Acute neutropenia, mean oesophageal dose and the 
volume and length of oesophagus receiving low radiation doses 
were significantly associated with acute RIO in our patient cohort. 
No association was demonstrated between RIO and maximum 
radiation dose.
Keywords: Oesophagitis, Neutropenia, radiation therapy, Toxicity
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P1.08-013 STEREOTACTIC ABLATIVE RADIOTHERAPY 
OF EARLY STAGE NON-SMALL CELL LUNG CANCER
Jakub Cvek, David Feltl, Lukas Knybel, Bretislav Otahal, Eva 
Skacelikova, Andrea Binarova
Oncology, Fn Ostrava/Czech Republic
Background: To evaluate the feasibility of stereotactic ablative 
radiotherapy (SABR) for Non-Small Cell Lung Cancer (NSCLC), 
especially when tumor tracking system is used.
Methods: From August 2010 to March 2013, 66 patients (44 male, 
22 female, mean age 70, range 55-86 years) with node-negative 
NSCLC were treated. CyberKnife ver. 8.5 and Multiplan ver. 3.2 
were used. Mostly, 60 Gy in 3-5 fraction was applied for GTV (CT 
lung window –W2000 L700) + 3 mm margin, in case of tumor di-
mension smaller than 1 cm, 30-33 Gy in one fraction was delivered. 
XSight Lung (XLT) for real-time tumor tracking or Xsight Spine 
(XST) for internal target volume (ITV) were used. Volume of GTV, 
treatment time, toxicity, 1-year year local control (LC), free survival 
(PFS) and 2-year overal survival (OS) were analyzed.
Results: Of the 66 patients, XLT and XST were used in 83% 
and 17%, respectively. Median tumor volume was 18 ml (ran-
ge 2-137 ml). Mean treatment time of one fraction was 56 
minutes (range 20-90 minutes). Acute toxicity was mild with 
no need for therapeutic intervention. We have noticed only 
radiological signs of late pneumonitis and/or fibrosis with 
no clinical manifestation. One year LC, PFS and OS were 
95%, 85% and 92%, respectively. Two years OS was 75%. 
Fig. 1. Overall survival 
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starting 1~2 cycle of EP. Once-daily group (33 patients) irradiated 
total 50~56 Gy in 28~32 fractions, and twice-daily group (18 pati-
ents) irradiated 45 Gy in 30 fractions. Subsquently, additional 1~2 
cycles of EP was given. After CRT, 38 patients who get remission in 
thorax, received prophylactic cranial irradiation(PCI). PCI consisted 
of total 24~30 Gy over a 2-weeks period.
Results: Median follow-up duration is 47.5 months. 2-year overall 
survival(OS) rate of all patient was 61.2 % (median 27.4 months). 
2-year OS rate was higher (83.9%) in once-daily group, compared 
with twice-daily group (53.1%), but there were no statistically si-
gnificant difference (p=0.071). After CRT, 47 patients (93%) had 
partial to complete remission, but 30 patients were eventually 
progressed or recurred. Main failure pattern was distant failure 
(46.7%). The trend of higher loco-regional failure (50%) was detec-
ted in twice-daily group compared with once-daily group (30%), 
but there was no statistically difference between two groups 
(p=0.055). 7 brain metastasis were detected in once-daily group 
and 2 in twice-daily group, but there was no statistically difference 
between two groups (p=0.184). In subgroup analysis of 38 PCI 
patients, brain metastasis rate were not statistically differ from two 
groups (once-daily; p=0.171, twice-daily; p=0.146). There were also 
no significant differences of 2-year progression free survival(PFS), 
loco-regional disease free survival(LRDFS) and distant metasta-
sis free survival(DMFS) between groups(PFS; p=0.541, LRDFS; 
p=0.238, DMFS; p=0.792), and no statistically differences in acute 
toxicities(non-hematologic p=0.128, hematologic p=0.277).
Conclusion: Our results showed no statistically significant diffe-
rences between two groups, although showing relatively higher 
OS rate and lower brain metastasis in twice-daily group favoring 
twice-daily radiation scheme and the trend of higher loco-regional 
failure in twice-daily group. It could be clues for considering thora-
cic radiation dose escalation above 45 Gy in twice-daily scheme to 
lower loco-regional failure. Small patients number and short follow 
up duration of twice-daily group could be the factor and limitation 
of the results causing these low statistical power. Further long term 
evaluation and analysis of comparing two groups could be impor-
tant in that points.
Keywords: LD-SCLC, EP CCRT
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P1.08-016 DOES LUNG STEREOTACTIC BODY RADIATI-
ON THERAPY AFFECT LUNG MEMBRANE DIFFUSION?
Selma Mehiri1, Badr Elmorabit1, Naoual Oulmoudne1, Meryem Ha-
time1, Ronan Tanguy1, Olivia Diaz1, Ciprian Enachescu1, Sevastien 
Couraud1, Francoise Mornex2
1Département De Radiothérapie Oncologie, Hospices Civils De Lyon/
France, 2Département De Radiothérapie Oncologie, Hospices Civils De 
Lyon, Chu, Et Emr 3738, Université Claude Bernard/France
Background: Stereotactic body radiation therapy (SBRT) is beco-
ming a standard of care in medically inoperable early stage non-
small cell lung cancer (NSCLC), and is increasingly used in some 
solitary lung metastases. Lung toxicity remains however the main 
concern of this technique. This study aims to evaluate pulmonary 
function and lung membrane diffusion modifications after lung 
SBRT.
Methods: Retrospective analysis of pulmonary function tests 
versus CT based radiotherapy planning. Model outcomes were ob-
tained from averaging the outcome for 50 000 simulated patients. 
A probabilistic sensitivity analysis was done as well as a number of 
scenario analyses.
Results: The incremental costs of PET-CT based planning were 
€581 (95% CI: €-4474 – €6064) for 0,42 incremental life years (95% 
CI: 0,20 – 0,62) and 0,33 quality adjusted life years gained (95% CI: 
0,16 – 0,54) (figure 1). The base-case scenario resulted in an ICER 
of €1370 per life year gained and an ICUR of €1761 per quality ad-
justed life year gained. The probabilistic analysis gave a 35% pro-
bability that PET-CT based planning improves health outcomes at 
reduced costs and a 65% probability that PET-CT based planning 
is more effective at slightly higher costs. 
 
Figure 1. Results of probabilistic sensitivity analyses showing in-
cremental costs and incremental life years for PET-CT-based radio-
therapy treatment planning compared to CT-based radiotherapy 
treatment planning.
Conclusion: PET-based radiotherapy planning for non-small cell 
lung cancer is highly cost-effective compared to CT-based plan-
ning.
Keywords: radiotherapy, PET-based treatment planning, persona-
lized treatment, cost-effectiveness
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P1.08-015 COMPARISION OF ONCE-DAILY VS TWICE-
DAILY THORACIC RADIOTHERAPY OUTCOMES IN LI-
MITED DISEASE SMALL CELL LUNG CANCER TREATED 
CONCURRENTLY WITH CISPLATIN AND ETOPOSIDE: A 
SINGLE INSTITUTION RETROSPECTIVE ANALYSIS
Songmi Jeong, Young-Gyun Won, Sei-Chul Yoon, Hong Seok Jang, 
Byung Ock Choi, Yong Nam Kang, Yeon Sil Kim
Radiation Oncology, Seoul St. Mary‘s Hospital, College Of Medicine, The 
Catholic University Of Korea/Korea
Background: To evaluate and compare outcomes of two fractio-
nation scheme of thoracic radiotherapy(once-daily vs twice daily), 
concurrently with cisplatin and etoposide(EP) in limited disease 
small cell lung cancer(LD-SCLC).
Methods: LD-SCLC patients treated with definitive chemora-
diotherapy at Seoul St. Mary’s Hospital were reviewed. Total 51 
patients received radiotherapy concurrently with EP, after initially 
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and initial treatment. In patients who did not receive PCI, we revie-
wed clinical notes from both medical and radiation oncologists to 
determine the reason. Overall survival (OS) and brain metastasis-
free survival (BMFS) were estimated using the Kaplan-Meier tech-
nique. Pearson’s chi-squared test was used to evaluate factors 
associated with PCI use.
Results: We identified 229 patients treated with thoracic radio-
therapy (TRT) for LS-SCLC at our institution. Median followup was 
15.1 months. Of these, 119 (52.0%) did not receive PCI. Thirty-three 
patients (27.7%) had progressive disease or concern for progressi-
on after initial therapy and therefore did not receive PCI. The next 
most common causes for no PCI were patient refusal (n=25, 21%) 
or deemed medically unfit by an oncologist (n=25, 21%). In 20 pa-
tients (16.8%), the reason for lack of PCI could not be ascertained. 
Other infrequent causes were patient death or lack of followup 
(n=8), age (n=3), and prior radiotherapy to the head (n=2). Patients 
who did not get PCI were significantly older (p<0.001) and had 
worse performance status at initial presentation (p<0.001). Patients 
who received sequential rather than concurrent chemoradiation, or 
who received once-daily rather than twice-daily TRT, were also si-
gnificantly less likely to receive PCI (p<0.001). Patients who did not 
receive PCI had significantly worse OS (median 17 vs. 30 months, 
p=0.01) and BMFS (71% vs. 91% at 1 year, p=0.02) than those who 
did.
Conclusion: Even at a major academic center, fewer than half of 
patients with LS-SCLC ultimately receive PCI. Patients receiving 
PCI had better intracranial control. They also had better OS, but 
this is likely also attributable to other clinical and treatment cha-
racteristics. Younger and fitter patients, as well as those receiving 
optimal TRT, are significantly more likely to undergo PCI. The most 
common reason for lack of PCI is progression of disease after ini-
tial therapy, which is clinically appropriate. However, a significant 
number of patients are appropriate for PCI yet refuse therapy, 
generally due to concerns about toxicity. PCI is withheld from an 
equivalent number of patients due to oncologist concerns about 
ability to tolerate therapy. This indicates that efforts to reduce 
neurotoxicity of PCI, such as hippocampal-sparing radiation, may 
impact a significant number of patients with LS-SCLC and expand 
the application of this survival-enhancing intervention.
Keywords: patterns of care, prophylactic cranial irradiation, small 
cell lung cancer, PCI
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P1.08-018 POSTOPERATIVE RADIOTHERAPY IN T3N0 
NON-SMALL-CELL LUNG CANCER: PROGNOSTIC VALUE 
OF TUMOR SIZE AND COSTAL PLEURAL INVASION
Yunseon Choi1, Won Hoon Choi2, Ik Jae Lee2
1Radiation Oncology, Samsung Medical Center/Korea, 2Yonsei Cancer 
Center/Korea
Background: This study was conducted to identify prognostic fac-
tors in resected NSCLC T3N0, and to determine what factors were 
related to postoperative radiotherapy (RT) outcome.
Methods: Non-small-cell lung cancer (NSCLC) T3N0 patients 
(n=102) who underwent resection between January 1990 to Octo-
ber 2009 at four hospitals were enrolled. The median tumor size 
was 5 cm (range 1-15). Postoperative chemotherapy (CT) and radio-
(PFTs) in 40 patients undergoing SBRT for NSCLC (N=30) or lung 
solitary metastases (N=10), between 2009 and 2010. SBRT doses 
ranged between 48-60 Gy in 5-13 fractions. Normal lung volume 
receiving ≥ 30 Gy (V30), ≥ 20 Gy (V20), ≥ 5 Gy (V5) and mean 
lung dose (MLD) were calculated. Forced Expiratory Volume in 1 
Second (FEV1), the ratio FEV 1 and Forced Vital Capacity (FEV1/
FVC), and diffusing capacity of the lung for carbon monoxide 
(DLCO) were measured 1 month before SBRT, 6 weeks, then 4 and 
6 months after SBRT. Respiratory symptoms were assessed accor-
ding to CTCAE v4.0. Pre-and post-treatment values were compa-
red using t Student test
Results: Median follow-up was 7 months (3-32 months), and medi-
an age was 70.6 years (51-86 years). Grade II-III chronic obstructive 
pulmonary disease was observed in 7 patients. Mean tumours dia-
meter was 19.2 mm (7-53 mm), and 72% of lesions were peripheral. 
Mean planned target volume (PTV) and normal lung volume were 
44 cc (3-162 cc), and 36149 cc (993-5146 cc) respectively. The mean 
values of MLD, V30, V20, and V5 were 4.7 Gy, 3.5%, 6.5%, 17.8% 
respectively. The mean decrease was 6.8% for FEV1, and 11.3% for 
FEV1/FVC. Mean DLCO remained unchanged with values of 48% 
predicted, and no significant respiratory symptoms were observed. 
The complete response rate was 90%, and 2 years progression free 
survival and overall survival were 72 and 76% respectively.
Conclusion: SBRT did not impair DLCO, and the changes of forced 
expiratory volumes were not significant, without significant clinical 
repercussion, even in COPD patients. These data are similar to tho-
se observed in several studies, and confirm the safety of the dose 
fractionation delivered to the current patients. Further studies are 
needed to evaluate the impact of SBRT on membrane diffusion. 
We are presently evaluating, the diffusing capacity for nitric oxide, 
a potentially more sensitive surrogate that could unmask subtle dif-
fusion troubles and allow more accurate lung function monitoring.
Keyword: Lung cancer; SBRT; Pulmonary function
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P1.08-017 FACTORS INFLUENCING UTILIZATION OF 
PROPHYLACTIC CRANIAL IRRADIATION IN LIMITED-
STAGE SMALL CELL LUNG CANCER
Abraham J. Wu1, Amanda Foster1, Carmen A. Perez1, Leonard T. 
Ong2, Maria C. Pietanza3, Lee M. Krug3, Andreas Rimner1
1Radiation Oncology, Memorial Sloan-Kettering Cancer Center/United 
States Of America, 2Nuclear Medicine, Memorial Sloan-Kettering Can-
cer Center/United States Of America, 3Medical Oncology, Memorial 
Sloan-Kettering Cancer Center/United States Of America
Background: Prophylactic cranial irradiation (PCI) improves survi-
val in limited-stage small cell lung cancer (LS-SCLC). However, PCI 
is not always delivered to these patients, possibly due to concerns 
about neurocognitive effects. Efforts to reduce neurotoxicity of 
PCI, such as hippocampal-sparing radiation, may mitigate these 
concerns. Little is known about the utilization rate of PCI and the 
reasons it is not delivered. Therefore, we reviewed the experience 
with LS-SCLC at a large academic institution to determine the rate 
of PCI use and factors associated with the lack of use.
Methods: We retrospectively reviewed all patients with LS-SCLC 
treated at our institution between 2000 and 2012. Receipt of PCI 
was recorded, as well as information about clinical presentation 
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used to assess inter-rater reliability. The association between RS 
score and known local failure was compared using Fisher’s Exact 
Test. The association between ‘growing tumor’ on the SRS and 
known local failure was compared using Fisher’s Exact Test.
Results: 79 patients were scored; 7 of them had documented local 
failures. Experts did 11243 scorings in total, ranging from 2351 at 
6 months to 480 at 48 months. For the RS, the KA was 0.27, 0.36, 
0.23 and 0.45 at 12, 24, 36 and 48 months respectively. For the 
SRS, KA was 0.22, 0.14 and 0.11 for the treated tumor at 12, 24 and 
48 months and 0.33, 0.36 and 0.22 for consolidation at 12, 24 and 
36 months. The tumor was scored as obscured in 40% of patients 
by 24 months. Of patients with local failure, 71% were at least once 
scored as ‘suspicious for recurrence’ by at least one rater, compa-
red to 28% in patients without failure (p = 0.03). 86% of patients 
with failure were scored at least once as increased opacity in tumor 
site by at least one of raters, compared to 35% in patients without 
failure (p = 0.01).
Conclusion: The RS has a significant relationship with local failure, 
and there is fair inter-agreement among experts on the suspicion 
of recurrence following SBRT. The SRS has low inter-rater reliability. 
Among its categories, only an increase in the opacity of treated 
tumor site is significantly related to failure. With future refinement 
of SRS categories, it can be a useful tool to standardize post-SBRT 
radiology reporting.
Keywords: SBRT, local recurrence, fibrosis
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P1.08-020 STEREOTACTIC ABLATIVE RADIOTHERAPY 
FOR PULMONARY OLIGOMETASTASIS FROM HEPATO-
CELLULAR CARCINOMA
Si Yeol Song1, Hyoung Uk Je2, Wonsik Choi3, Eun Jin Jwa1, Jong 
Hoon Kim1, Sang Min Yoon1, Su Ssan Kim1, Eun Kyung Choi1
1Asan Medical Center, University Of Ulsan College Of Medicine/Korea, 
2Ulsan University Hospital, University Of Ulsan College Of Medicine/
Korea, 3Gangneung Asan Hospital, University Of Ulsan College Of Me-
dicine/Korea
Background: Stereotactic ablative Radiotherapy (SABR) is a safe 
and effective treatment modality for primary or metastatic lung 
cancer. Despite its no great difference in response by pathology 
according to known publications, there is few report for pulmonary 
oligometastasis (PM) from hepatocellular carcinoma (HCC). We 
conducted this study to evaluate treatment outcomes of the SABR 
for PM from HCC under primary control.
Methods: We reviewed the records of patients with PM from HCC 
who received SABR for metastatic lesion from January 2006 to De-
cember 2011. Thirty-seven patients were included for analysis and 
total number of metastatic lesions was 52. SABR dose was 45, 48 
or 60Gy in 3 or 4 fractions. Patients were evaluated by chest and 
liver dynamic CT scan at 1 and 3 months after completion of SBRT 
and followed up regularly thereafter.
Results: Median follow-up time was 19.9 months (range 6.1-33.6). 
The complete response (CR) rate was 38.0%. The local progressi-
on free survival (LPFS) rate was 92.1% and 88.7% at 1 and 3 years, 
and mean LPFS time was 69.9±3.6 months. Survival rates at 1 and 
3 years were 52.1% and 33.5% in DFS, 67.6% and 35.5% in OS, 
therapy (RT) were given in 51.0% and 55.9% of cases, respectively. 
The median follow-up was 43.7 months.
Results: Forty two patients (41.2%) experienced recurrence. Large 
tumor size (> 7 cm) and costal pleural invasion were associated 
with a higher relapse rate (p=0.015 and p=0.077, respectively). 
The 5-year overall survival (OS) was 46.6%. Tumor size and pleural 
invasion were significant prognostic factors for overall survival 
(p=0.003 and p=0.044, respectively). Patients with costal pleural 
invasion tended to have worse survival than others (5-year OS: 
42.8% vs. 48.9%, p=0.117). CT and RT did not affect OS (p=0.122 
and p=0.584). The patients that had moderate to large tumors (≥ 3 
cm) combined with costal pleural invasion had decreased OS after 
postoperative RT (p=0.046) compared with others.
Conclusion: In postoperative T3N0M0 patients, tumor size is an 
independent prognostic factor and predicts survival. The primary 
tumor site also tends to be related to treatment outcomes. Pleural 
invasion was associated with lower survival. PORT should be avo-
ided in moderate to large size (≥3 cm) tumors with costal parietal 
pleura invasion.
Keywords: non-small cell lung cancer, postoperative radiotherapy, 
prognostic factor, Pleural invasion
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P1.08-019 LATE RADIOGRAPHIC CHANGES AFTER 
LUNG STEREOTACTIC BODY RADIOTHERAPY: PILOTING 
A RECURRENCE SCALE AND A SYNOPTIC REPORTING 
SCALE
Hamid Raziee1, Meredith Giuliani1, Salman Faruqi1, Mei Ling Yap1, 
Heidi Roberts2, Lisa Le3, Anthony Brade1, Byoung Chun J. Cho1, 
Andrea Bezjak1, Alexander Sun1, Andrew Hope1
1Radiation Oncology, Princess Margaret Cancer Centre/Canada, 2Medi-
cal Imaging, Toronto General Hospital/Canada, 3Department Of Biosta-
tistics, Princess Margaret Cancer Centre/Canada
Background: Radiographic lung changes after Stereotactic Body 
Radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) are 
difficult to interpret. The reliability of previous scoring systems and 
their relationship to local failure has not been assessed. The pur-
pose of this study was to design a synoptic radiographic scale for 
characterizing late radiographic changes after SBRT and to deter-
mine the inter-rater reliability of the scale.
Methods: A Recurrence Scale (RS) was developed among lung ra-
diation oncology/SBRT experts at a single institution, and a Synop-
tic Radiographic Scale (SRS) was designed in collaboration with an 
expert thoracic radiologist. For the RS, the suspicion for local re-
currence on CT images was scored on a 5 point scale: 1) complete 
response, no recurrence; 2) fibrosis, not suspicious for recurrence; 
3) fibrosis/mass, indeterminate for recurrence; 4) fibrosis/mass, 
suspicious for recurrence and 5) biopsy proven recurrence. On the 
SRS, CT changes were scored as ‘increasing’, ‘stable’, ‘decreasing’, 
‘no change’ or ‘obscured’, along five dimensions: changes in the 
primary tumor site, involved lobe, consolidation, ground-glass 
opacity, and volume loss. Early stage NSCLC patients treated with 
SBRT at the institution with a minimum follow-up of 6 months were 
included. Serial post-treatment CT images at 12, 18, 24, 36, and 48 
months were presented to the expert group (up to 6) who scored 
both scales in a blinded fashion. Krippendorff‘s alpha (KA) was 
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Toxicity Two patients developed grade 2 pneumonitis. Grade 1 
chest, dyspnoea or cough were seen in 7 patients. No other toxici-
ty was seen.
Conclusion: Our data support the increasing use of SABR lung 
as an effective and non-toxic treatment. However, there were a 
number of local recurrences in NSCLC patients occurring after 15 
months, supporting the need for long-term follow-up. In patients 
with pulmonary metastases the median time to further disease 
progression was 7 months- more rigorous patient selection may 
help to identify patients in whom SABR lung will be most benefi-
cial.
Keywords: Stereotactic, radiotherapy, non-small cell lung cancer, 
Pulmonary Metastases
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P1.08-022 NUMBER OF PATHOLOGIC NODES IN REGI-
ONS CLOSEST TO THE OESOPHAGUS IS THE STRON-
GEST PREDICTOR FOR ESOPHAGITIS IN SMALL CELL 
LUNG CANCER PATIENTS TREATED WITH CONCURRENT 
CHEMO-RADIATION: AN ANALYSIS OF 170 PATIENTS.
Bart Reymen1, Cary Oberije1, Judith Van Loon1, Angela Van Baard-
wijk1, Rinus Wanders1, Esther Troost1, Frank Hoebers1, Anne-
Marie Dingemans2, Gerben P. Bootsma3, Ragnar Lunde4, Wiel Ge-
raedts5, Dirk De Ruysscher6, Philippe Lambin1
1Maastro Clinic/Netherlands, 2Pulmonary Diseases, Maastricht Univer-
sity Medical Center+/Netherlands, 3Pulmonary Diseases, Atrium Me-
dical Centre/Netherlands, 4Pulmonary Diseases, Laurentius Hospital/
Netherlands, 5Pulmonary Diseases, Orbis Medical Center/Netherlands, 
6Radiation Oncology, Universitary Hospitals KU Leuven/Belgium
Background: Radiation esophagitis grade III caused by chemo-
radiation for small-cell lung cancer is a burden for patients and 
thus of concern to radiation oncologists. Neutropenia and radiati-
on dose to the esophagus are known treatment factors influencing 
the rate of esophagitis during treatment, but currently the only 
respectively. Median survival time was 13.6 months (95% CI; 3.9-
23.4) in DFS and 19.9 months (95% CI; 6.1-33.6) in OS. Only the 
initial treatment modality of primary HCC was significant factor in 
OS from univariate and multivariate analysis, and hazard ratio was 
2.70 (95% CI: 1.04-6.96, p=0.040). There was no significant SABR-
related acute or chronic complication.
Conclusion: SABR for pulmonary oligometastasis from HCC show-
ed good local tumor control equal to the result in primary lung 
cancer. Patient with pulmonary oligometastasis from HCC can be 
treated without complication by SABR and assured good quality 
of life
Keywords: oligometastasis, SABR, SBRT, HCC
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P1.08-021 OUTCOMES OF STEREOTACTIC BODY RADI-
ATION THERAPY FOR STAGE I NON-SMALL CELL LUNG 
CANCER AND PULMONARY METASTASES.
Fiona Hegi-Johnson1, Johnson Lam2, Val Gebski3, Thomas Eade4
1Radiation Oncology, Nepean Cancer Care Centre/Australia, 2Radiation 
Oncology, Central Coast Cancer Care Centre/Australia, 3Nhmrc Clinical 
Trial Centre/Australia, 4Radiation Oncology, Northern Sydney Cancer 
Care Centre/Australia
Background: Stereotactic ablative body radiotherapy (SABR) can 
achieve high local control rates in patients with Stage I non-small 
cell lung cancer (NSCLC) and pulmonary metastases. We report 
the outcomes of patients treated at Royal North Shore Hospital 
between January 2010 and January 2012.
Methods: Patients were discussed in a multi-disciplinary meeting 
and were medically inoperable, or refused surgery. Lesions were 
divided into central or peripheral zone lesions. Peripheral lesions 
received 48 Gy in 4 fractions, and central lesions 50 Gy in 5 frac-
tions. Minimum coverage was 98% of the target to receive the 
prescribed dose. Treatment was delivered on a Varian Clinac with 
7-10 field IMRT. Toxicity was graded according to CTC-AE version 
4.0.
Results: Patient Characteristics Thirty-four lesions were treated 
in 27 patients. Eleven patients (41%) had Stage I NSCLC, 15 (56%) 
pulmonary metastases, and 1 patient presented with synchronous 
primary NSCLC and brain metastases. The commonest primary 
site for pulmonary metastases was colorectal cancer (n=6). The 
median age was 72 years. Sixty-seven percent (n=18) of patients 
were medically inoperable with the other patients refusing surgery. 
Radiotherapy Dosimetry Eighteen tumours received 48 Gy in 4 
fractions, and 12 tumours received 50 Gy in 5 fractions. Three pati-
ents with multiple lesions received 18 Gy in 1 fraction to their third 
lesion. One patient, with a tumour adjacent to the brachial plexus, 
received 49 Gy in 7 fractions. Survival With a median follow-up 
period of 24 months, 4 patients with pulmonary metastases and 3 
patients with primary NSCLC have died. In patients with pumonary 
metastases the first site of failure was distant in 5 patients and pul-
monary in 5 patients, with 1 in-field recurrence. In NSCLC patients 
there were 4 pulmonary recurrences, 3 of these were in-field. Two 
patients have developed metastatic disease. The median time to 
first event was 18 months in NSCLC patients and 7 months in pati-
ents with pulmonary metastases. 
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are required to account for the variability and unpredictability of 
lung tumor motion. The spatial and temporal information on tumor 
motion can be derived with respiration-correlated 4DCT scans. In 
this study, we investigated how these uncertainties may be indivi-
dually minimized for SBRT of NSCLC.
Methods: Twelve patients with early stage NSCLC who were un-
dergoing SBRT were imaged with free-breathing 3-dimensional 
computed tomography (3DCT) and 10-phase 4-dimensional CT 
(4DCT) for delineating gross tumor volume (GTV)3D and ITV10Pha-
se (ITV2). The maximum intensity projection (MIP) CT was also cal-
culated from 10-phase 4DCT for contouring ITVMIP (ITV1). Then, 
ITVCOMB (ITV3), and ITV10Phase+GTV3D (ITV4), were generated 
by combining ITVMIP, ITV0% phase and ITV50% phase, ITV10pha-
se and GTV3D, respectively. All 5 volumes (GTV3D and ITV1 to 
ITV4) were delineated in the same lung window by the same radia-
tion oncologist.
Results: The mean (range) tumor motion (RSI, RAP, RML, and R3D 
) were 6 mm (2-11 mm), 3 mm (1-4 mm), 4 mm (0-6 mm), and 7 
mm (3-12 mm), respectively. The trend of volume variation was 
GTV3D < ITV1 < ITV2 < ITV3 ≈ ITV4 . The means ± SDs of these 
volumes were 10 ± 7 cc, 10 ±8 cc, 12 ± 7 cc, 11 ± 8 cc, and 12 ± 
8 cc, respectively. All comparisons between the target volumes 
showed statistical significance ( P<0.05), except for ITV3 and ITV4 
(P= 0.732). The volume of the combining ITVMIP, ITV0% phase and 
ITV50% phase was closed to ITV10phase plus GTV3D.
Conclusion: Uncertainties in individualized ITVs for SBRT of early 
stage NSCLC could effectively be minimized by combining infor-
mation from free-breathing 3DCT and 10-phase 4DCT. If these 
images cannot be efficiently contoured, a combination of ITVMIP, 
ITV0% phase and ITV50% phase could be an effective alternative.
Keyword: 4DCT scans, Internal target volume, lung cancer, SBRT
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P1.08-024 FUNCTIONAL IMAGING FOR NORMAL LUNG 
AVOIDANCE WITH PROTON RADIOTHERAPY
Matthew Nyflot1, Stephen Bowen1, Juergen Meyer1, Kristi Hen-
drickson1, Paul Kinahan2, George Sandison1, Hubert Vesselle2, 
Ramesh Rengan1, Shilpen Patel1, Jing Zeng1
1Department Of Radiation Oncology, University Of Washington/United 
States Of America, 2Department Of Radiology, University Of Washing-
ton/United States Of America
Background: Preservation of lung function is critical for patients 
undergoing radiotherapy for thoracic malignancies, especially in 
patients with compromised lung function at diagnosis. Physical 
properties of proton radiotherapy may permit selection of beam 
pathways that avoid functional lung while providing adequate tu-
mor coverage. We demonstrate the potential for proton radiothe-
rapy avoidance of functional lung volumes defined on SPECT/CT 
perfusion and ventilation imaging.
Methods: SPECT/CT imaging was performed with 99mTc-MAA for 
lung perfusion and 99mTc-DTPA for lung ventilation assessment. 
SPECT/CT images were co-registered to treatment planning CT 
images and avoidance structures representing perfused or ventila-
ted lung regions were defined using a gradient search algorithm in 
MIM 6.0. Photon and proton radiotherapy plans were calculated to 
factors that can be discussed with the patient at diagnosis are the 
choice of concurrent versus sequential chemo-radiation and the 
radiation dose fractionation schedule. In order to build predictive 
models to more accurately tailor treatment and advise patients on 
treatment options, more prognostic factors known at the moment 
of diagnosis are needed.
Methods: Analysis of all patients in our prospective database 
with stage I-III SCLC referred for concurrent chemo-radiotherapy 
between 5-2004 and 1-2012. All patients were PET-staged and 
received 45 Gy in 1.5 Gy fractions twice daily to the tumour and 
PET-or pathologically proven positive lymph nodes. Chemotherapy 
consisted of carboplatin-etoposide given concurrently with radio-
therapy. All pathological lymph node regions were noted for each 
patient. Based on the Mountain Dressler atlas, the lymph node 
regions closest to the oesophagus were designated ``high risk`` 
regions for esophagitis, namely: 1R, 1L, 3P, 4L, 7, 8 and 9. Toxicity 
was scored according to CTC AE 3.0. Univariate analysis was done 
using the Chi-square test, reporting for p-value the Fischer exact 
Test for small numbers of events. Multivariate analysis was done 
using logistic regression. .
Results: 170 patients were included in the present analysis. Thirty-
seven (20%) patients developed grade III esophagitis. In univariate 
analysis the number of nodal regions (0, 1-4, ≥5) (p=0.02) and the 
number of high risk nodal regions (0, 1-2, ≥3) (p=0.001) had a sig-
nificant effect on the risk of grade III esophagitis whereas the loca-
tion of the primary tumour or having a T4 tumour did not. In multi-
variate analysis including age, gender and T4 tumour, the number 
of pathological nodal stations lost significance. In the multivariate 
analysis using age, gender, T4 tumour and the ``high risk`` count (0, 
1-2, ≥3 areas) having nodes in ≥3 high risk areas was the only sig-
nificant factor (p=0.002), with a hazard ratio (HR) of 7.4 for develo-
ping oesophagitis grade III (95% CI for HR: 2.2-25.2). The absolute 
rates of esophagitis grade III were: 5/51 (10%), 19/91 (21%), 12/28 
(43%) for patients with respectively 0, 1-2 and ≥3 pathological high 
risk nodal areas.
Conclusion: In this series of stage I-III small cell lung cancer tre-
ated with radical chemo-radiation, the strongest predictor for 
esophagitis grade III known at diagnosis is the presence of nodal 
disease in ``high-risk regions`` 1R, 1L, 3P, 4L, 7, 8 and 9. Analysis 
of the correlation of this finding with the dose to the esophagus 
(Dmax/ Dmean) is ongoing and will also be presented at the con-
ference.
Keyword: SCLC, esophagitis, risk factors
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P1.08-023 HOW TO MINIMIZE THE UNCERTAINTIES OF 
INTERNAL TARGET VOLUME IN 4DCT SCANS FOR STE-
REOTACTIC BODY RADIATION THERAPY OF EARLY STA-
GE NON-SMALL CELL LUNG CANCER
Xiaojiang Sun, Xue Bai, Yuanda Zheng, Weijun Chen, Yaping Xu, 
Xiaoyun Di, Weimin Mao
Zhejiang Cancer Hospital/China
Background: Precise definition of the target volume is one of cru-
cial factors in the management of early stage non-small cell lung 
cancer (NSCLC) with stereotactic body radiation therapy (SBRT). 
Recent studies have shown that individualized planning margins 
S543Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Background: Internal margin was a margin to compensate for ex-
pected physiologic movements and variations in size, shape, posi-
tion of the target during therapy. The purpose of our study was to 
identify the particular tumor characteristics to determine suitable 
internal margin.
Methods: 43 patients with 44 lung tumors who underwent 4DCT 
based radiotherapy were included. GTVs on 10 respiratory pha-
ses were contoured by single radiation oncologist. Internal gross 
tumor volume (IGTV) was obtained by combining the GTVs at ten 
phases of the respiratory cycle. No separate margins were used to 
account for microscopic tumor extension. Additional isotropic se-
tup margin of 3mm to derived the PTV-4D from the IGTV. In order 
to encompass PTV-4D, there were four expansion approaches 
to derive PTVs by adding uniform expansion in step of 1mm in 
each three direction: (1)PTV(lowest), derived from a margin to the 
GTV whose phase corresponding to the movement of lowest; (2) 
PTV(highest), derived from GTV at peak positon of the breathing 
cycle with an appropriate margin; (3) PTV(20%), derived from GTV 
on phase 20% with a suitable margin; (4) PTV(20%80%), derived 
from the composite GTV on phase 20% and 80% with a fit margin. 
The GTV centroid motions were collected. The association bet-
ween margin expansion and tumor motion was analyzed. Using 
multivariate logistic regression, image-based risk factors for the 
presence of narrow margin (≤8mm) in four expansion approach 
were identified, and a prediction model was developed based on 
these factor.
Results: For the cases of GTV centroid motion less than 3mm, an 
isotropic margin of 10mm from any GTV can fully covered PTV-4D 
(IGTV+3mm). For the cases of GTV centroid motion exceeding 
5mm, the dominant directions for GTV and margin expansion were 
not always in accordance. The former was almost all in SI, while the 
latter may be affected by tumor shape heavily. Even an irregular 
tumor in very small mobility, probably needed a large margin ex-
pansion. A model of three steps to screen the tumors with margin 
less than 8mm: As an initial step, tumors with fSI >0.5 and fAP >0.6 
were filter out. In a second step, the small tumors (<45 cm3) with fSI 
0.4-0.5 and fAP 0.5-0.6 were kicked out. In a third step, the irregu-
lar tumors were eliminated. (fSI or fAP was the relative fractional 
location in the lung in AP or SI direction. fSI equaled to 0 when tu-
mor located in the apex of the lung ,and equaled to 1 when tumor 
in the lowest of the lung. fAP was the same, equaling to 0 meant 
front edge of the lung and equaling to 1 meant at the back.)
Conclusion: In selected patient group, fewer internal margins 
could be applied. Individual internal margin is necessary for high-
mobility tumors. More cases were needed to confirm our model.
Keyword: 4DCT; lung cancer; internal margin; radiotherapy
spare lung avoidance structures in Pinnacle 9.0 and XiO 4.8, res-
pectively, and dose-volume parameters in total lung and functional 
lung avoidance structures were compared.
Results: A representative thoracic cancer patient with com-
promised and spatially heterogeneous lung function is re-
ported on (Fig. 1). Relative to the photon plan, the proton 
plan provided superior total lung dose sparing (V5=9% vs. 
25%, mean dose = 1.6 Gy vs 4.5 Gy; Fig. 2) while achieving 
similar tumor coverage. Additionally, superior sparing of 
functional lung was achieved by protons in perfused regions 
(V5<1% vs. 22%, mean dose = 0.1 Gy vs 3.1 Gy) and ventila-
ted regions (V5=1% vs. 33%, mean dose = 0.1 Gy vs 4.5 Gy). 
Conclusion: Functional avoidance treatment planning for thora-
cic patients receiving radiotherapy has been demonstrated with 
SPECT/CT imaging. In particular, proton radiotherapy may provide 
strong advantages in this paradigm. Future investigation will focus 
on regional dose-response modeling and radiotherapy targeting 
strategies for functional avoidance.
Keywords: spect/ct, proton radiotherapy, functional avoidance
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P1.08-025 HOW TO DETERMINE INTERNAL MARGIN 
FOR CLINICAL PRACTICE? - A STUDY OF 44 LUNG CAN-
CER CASES WITH 4D-CT IMAGING.
Ming Chen1, Yan Wang2, Yong Bao3, Xiao Hu1, Xiaowu Deng4, Wei 
Fan5
1Department Of Radiation Oncology, Zhejiang Cancer Hospital/China, 
2Department Of Oncology,and Tomotherapy Cancer Center, General 
Hospital Of Guangzhou Military Command Of Pla/China, 3Department 
Of Radiotherapy Oncology, Sun Yat-Sen University Cancer Center/Chi-
na, 4Department Of Radiation Physics, Sun Yat-Sen University Cancer 
Center/China, 5Department Of Nuclear Physics, Sun Yat-Sen University 
Cancer Center/China
S544 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
V5-V60 by using during-RT V and Q SPECT was higher in patients 
with RILT than without RILT, but not statistically significant.
Conclusion: Functional DVH metrics of V and Q SPECT and du-
ring-RT CT based DVH may be more significant in their association 
with RILT than pre-CT. However, these results need to be valida-
ted.
Keywords: Radiation-induced lung injury, non-small cell lung 
cancer, Single photon emission computed tomography, radiation 
therapy
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P1.08-027 IS THERE A BENEFIT OF LUNG STEREOT-
ACTIC ABLATIVE RADIOTHERAPY (SABR) IN OUR PA-
TIENTS WITH MULTIPLE CO-MORBIDITIES?: AGE-AD-
JUSTED CHARLSON COMORBIDITY INDEX (ACCI) AS A 
PREDICTOR OF SURVIVAL IN MEDICALLY INOPERABLE 
EARLY STAGE NON SMALL CELL LUNG CANCER PATI-
ENTS TREATED WITH DEFINITIVE RADIOTHERAPY
Jason R. Pantarotto, Oliver Holmes, Vimoj J. Nair, Robert Macrae, 
Peter Cross
Division Of Radiation Oncology, University Of Ottawa/Canada
Background: The Age-adjusted Charlson Comorbidity Index 
(ACCI) was originally developed as a tool to predict survival for a 
wide range of patients based on their co-morbidities. As a growing 
proportion of Stage I non-small cell lung cancer (NSCLC) patients 
are treated with radiotherapy alone, in part due to extensive co-
morbidities, we hypothesize that a) ACCI is a useful prognostic tool 
for this understudied group of patients and b) the advent of ste-
reotactic ablative radiotherapy (SABR) has lead to a redistribution 
of patients such that more patients of the poorest class are now 
treated, with similar or better survival.
Methods: A single institution, ethics-approved database with out-
come data for 406 Stage I NSCLC patients treated with curative 
radiotherapy alone from 2001 to 2011 was queried. 283 patients 
were treated with conventional radiotherapy and 123 with SABR. 
Conventional doses ranged from 50-60Gy over 15-30 fractions, 
SABR 48-60Gy over 3-8 fractions. For each patient the ACCI score 
was retrospectively calculated and then arbitrarily stratified into 3 
groups based on score ( ≤3, 4-5, ≥6) (higher score indicates higher 
number of comorbidities). Log rank test and Kaplan-Meier survival 
analyses was performed and the relationship between ACCI and 
survival was assessed using proportional hazards analysis.
Results: Median follow up was 26.4 months (22.8 months in the 
SABR group). The median patient age at treatment was 75 (range 
41 to 92) for the entire cohort and for the SABR subset 74 (range 
54-89). Percentage of patients by ACCI grouping was 22% (≤3), 
48% (4-5) and 30% (≥6) for the entire cohort and for the SABR 
subset was 21% (≤3), 59% (4-5) and 20% (≥6) (p> 0.05). The me-
dian overall survival (OS) from time of diagnosis was 39.6 months 
(95% CI 34.8-44.4) and by ACCI groupings (≤3, 4-5, ≥6) was 51.6, 
39.6 and 30 months (log rank test p=0.023) with hazard ratios for 
survival of 1.00, 1.45 (p = 0.049) and 1.73 (p = 0.0067) respectively. 
In the subset of patients treated with SABR, median OS was 46.8 
months however there is lack of power to demonstrate any OS 
difference between ACCI groups.
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P1.08-026 FUNCTIONAL DOSIMETRIC METRICS BASED 
ON THE VENTILATION AND PERFUSION SPECT-CT DU-
RING THE COURSE OF RADIOTHERAPY AND ASSOCI-
ATION WITH RADIATION-INDUCED LUNG TOXICITY IN 
PATIENTS WITH NON-SMALL-CELL LUNG CANCER
Fang Peng1, Stanton Paul2, Martha Matuszak3, Kirk Frey4, Piert 
Morand4, Nan Bi3, Ling Li2, Randall T. Haken3, Feng-Ming (Spring) 
Kong2
1Department Of Radiation Oncology, University Of Michigan, Currently 
At Sun Yat-Sen University Cancer Center And State Key Laboratory Of 
Oncology In South China, Guangzhou, China/United States Of America, 
2Department Of Radiation Oncology, University Of Michigan And Vete-
ran Administration Hospital, Currently At Gru Cancer Center, Georgia 
Regent University/United States Of America, 3Department Of Radiation 
Oncology, University Of Michigan/United States Of America, 4Nuclear 
Medicine, University Of Michigan/United States Of America
Background: To investigate volume changes in single photon 
emission computed tomography (SPECT) ventilation (V) and per-
fusion (Q) - weighted functional lung (FL), and dose-volume his-
togram of functional lung (FDVH) from V or Q SPECT and factors 
associated with radiation-induced lung toxicity (RILT) during the 
course of radiotherapy (RT) in patients with non-small-cell lung 
cancer (NSCLC).
Methods: Seventy NSCLC patients treated with definitive RT were 
enrolled prospectively. V and Q SPECT-computed tomography 
(CT) were performed prior to and during RT at approximately 45 
Gy. FL was created from the whole lung (WL) in V and Q SPECT 
using a threshold of 30% of the maximum uptake of normal lung. 
Patients had dose calculated on CT scan to provide a standard 
dose-volume histogram (DVH). V and Q SPECT scans provided 
FDVH and functional dosimetric parameters. From the FDVH; the 
percent of FL receiving from 5 to 60 Gy and the mean doses of 
functional lungs (FMLD) were computed. Differences of volume 
and volume change of WL and FL between pre-RT and during-RT 
were compared. Differences of functional and standard dosimetric 
parameters between the patients with and without RILT were com-
pared. Clinical fibrosis and pneumonitis were graded according 
to Common Terminology Criteria for Adverse Events version 3.0, 
grade 2 and above were considered to be clinically significant.
Results: The accumulative incidence of ≥ grade 2 clinical fibrosis 
and pneumonitis were 23.4%. The volume of lung measured by 
using CT or V and Q SPECT did not change significantly during 
radiotherapy (All p>0.05). The difference of lung volume between 
standard CT or V and Q SPECT was not significant in patients with 
RILT and without RILT (All p>0.05). However, the volume of V and 
Q both functional lung changed -12.4% (95% CI, -29.6% to 4.9%) 
in patients with RILT and 13.3% (95% CI, 2.7% to 23.9%) in patients 
without RILT during RT (p=0.02). The difference of mean lung dose 
(MLD) measured by using CT or V and Q SPECT was not significant 
in patients with RILT and without RILT (All p>0.05). However, the 
MLD was significantly higher in patients with RILT in during-RT than 
pre-RT CT (17.1 Gy and 15.4 Gy, p=0.01); the FMLD was significant-
ly higher in patients with RILT in during-RT than pre-RT V and Q 
SPECT (16.7 Gy and 13.0 Gy, p=0.03). The V20-V55 by using du-
ring-RT CT were higher in the patients with RILT than without RILT 
(V20:29.0% and 22.0%, p=0.06; V25: 26.4 % and 19.0 % p=0.04; 
V30: 23.7 % and 16.6 %, p=0.03; V35: 21.1 % and 14.6 %, p=0.03; 
V40: 18.9 % and 12.6 %, p=0.02; V45: 16.4 % and 10.9 %, p=0.03; 
V50: 14.3 % and 9.1 % p=0.03; V55: 11.6 % and 7.5 %, p=0.04). The 
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P1.09-001 INDUCTION THERAPY FOR PATIENTS WITH 
POTENTIALLY UNRESECTABLE NSCLC (ADENOCARCI-
NOMA). PRELIMINARY RESULT.
Igor Polyakov, Vladimir Porhanov
Thoracic Oncology, Regional Clinical Hospital 1/Russian Federation
Background: Induction therapy for non-small cell lung cancer has 
given promising results in a select group of patients, but no pro-
gnosis of these patients makes the future uncertain. Using a tech-
nique revild EGFR mutations and expression of ALK translocation 
with follow targeting induction chemotherapy increased the possi-
bility of this technique, even in previously unresectable patients
Methods: From 2008 to 2013, 78 patients with potentially unre-
sectable NSCLC was held from 2 to 4 courses of standard (pla-
tinabased) induction chemotherapy and 5 patients of targeted 
chemotherapy with the identification of mutations in EGFR or ALC 
traslocation. Subsequently assessed resectability of the tumor and 
in the case of regression of tumors - lung resection
Results: In the first group (standard) was 29 patients with ade-
nocarcinoma. Tumor regression was achieved in 3 (10%), partial 
response in 5 (17%), the rest had stable or progress desease. 
Toxicity grade 3-4 was observed in 45% of patients. Resectability 
was achieved in 5 patients (17%). In the second group (target), 
complete response was achieved in 60% of cases, partial in 1 (20%) 
and stabilization in 1 patient (20%). Toxicity of chemotherapy is 
not more than grade 3. Resectability rate was 80%. In operated 
patients - time to progression was 9 months in the (standard) and 1 
year 4 months in the second group (target). Median survival was 11 
months versus 18 months.
Conclusion: Using the induction of targeted therapy in patients 
with previously unresectable NSCLC is promising, since the best 
results were found tolerability, objective response rate and better 
survival rates of patients.
Keyword: target induction chemotherapy
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P1.09-002 PREOPERATIVE CHEMOTHERAPY REGIMENS 
FOR LOCALLY ADVANCED STAGE III NON-SMALL CELL 
LUNG CARCINOMA: DOWNSTAGING DEPENDING ON 
HISTOLOGY, AGE, CHEMOTHERAPY PROTOCOL
Marroan Bachoor
Medical Oncology, Albayrouni University Hospital/Syria
Background: newly diagnosed patients with Non-small cell lung 
carcinoma (NSCLC) presented with advanced stages IIIA and IIIB 
were randomized to receive 3 protocols of neoadjuvant chemo-
Conclusion: The ACCI is predictive of overall survival in medically 
inoperable Stage I NSCLC patients irradiated with curative intent. 
The benefit of radiation is evident in even the poorest of patients 
(CMI ≥6) with a median survival of 30 months exceeding what one 
would expect without any treatment at all. Further follow up will be 
required to comment on any increased benefit with SABR.
Keywords: outcomes, Stereotactic, comorbidity, radiotherapy
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P1.09-003 PROGNOSTIC IMPACT OF SECONDARY PA-
THOLOGIC FINDINGS ON THE OUTCOME OF PATIENTS 
WITH RESECTED LOCALLY ADVANCED NON-SMALL 
CELL LUNG CANCER PREVIOUSLY TREATED WITH IN-
DUCTIVE CHEMOTHERAPY OR CHEMORADIATION
Diego Marquez-Medina1, Ariadna Gasol-Cudos1, Antonio Martin-
Marco1, Teresa Taberner-Bonastre1, Virginia Garcia-Reglero2, An-
geles Montero-Fernandez3
1Medical Oncology, University Hospital Arnau De Vilanova/Spain, 2Ra-
diation Oncology, University Hospital Arnau De Vilanova/Spain, 3Pa-
thology, Royal Brompton And Harefield Trust/United Kingdom
Background: Half of non-small cell lung cancers are diagnosed in 
locally-advanced stages (LA-NSCLC), and warrant multidisciplina-
ry treatments. Inductive and adjuvant therapies obtain the same 
survival benefit after surgery, but the first ones also provide prog-
nostic information. Mediastinal downstaging and pathologic com-
plete response preclude a better outcome. However, the value of 
minor pathologic features has been scarcely analyzed. We report 
the impact of lymphovascular invasion (LVI) and tumor necrosis 
(TN) on the prognosis of resected LA-NSCLC after inductive che-
motherapy (iCT) or chemoradiation (iCRT).
Methods: We retrospectively reviewed 50 resected LA-NSCLC 
treated with iCT or iCRT in our center from October-2004 to June-
2012. Three patients died due to early surgery complications and 
were not analyzed. The impact of ILV, TN, pneumonitis, extracap-
sular (EI) and pleural invasion (PI) on disease free (DFS) and overall 
survival (OS) was analyzed in the remaining patients
Results: Our series included 42 men and 5 women aged between 
47-82 years. Non-specified NSCLC was diagnosed in nine, ade-
nocarcinoma in two, and squamous carcinoma in 36. Thirty-seven 
received cisplatin-based and 10 carboplatin-based chemotherapy. 
Concurrent radiation was administered in 21. Pneumonectomy was 
performed in 15, lobectomy in 26, and segmentectomy in 6. The 
presence of pneumonitis, EI, or PI in the resected specimens did 
not impact on the outcome of the patients. However, DFS and OS 
clearly worsened when LVI (34.1 vs. 14.1 months, p= 0.01; and 43 
vs. 29, p= 0.005; respectively), and absence of TN (31.6 vs. 24.3, 
p= 0.045; and 42 vs. 33, p= 0.041, respectively) were found. Radi-
ation, cis- or carboplatin administration, and treatment length did 
not modify LVI and TN incidence
Conclusion: Minor pathologic features as LVI and TN significantly 
impact on the prognosis of resected LA-NSCLC after iCT or iCRT. 
Implications of that should be further analyzed. Figure 1. DFS and 
OS Kaplan-Meier curves according to the presence of LVI. 
therapy aiming at determining of both (pathologic response, and 
local-regional control) before undergoing surgery according to the 
response.
Methods: 85 enrolled Patients treated from Jan 2009 till Dec 2011 
with neoadjuvant chemotherapy. 75 pts males and 10 pts fema-
les.48 patientsts (56,5% ) had less than 60 years. 58 patientsts 
(68,2%) had Squamous cell carcinoma subtype (SCC) , while the 
other 28 patients (31,8%) had (Non SCC). All patients underwent 
pretreatment evaluation at AL BAYROUNI University cancer center. 
Some patients (32%) had complete mediastinoscopy staging, and 
all were believed to be poor candidates for up-front surgery be-
cause of the bulky disease. Different chemotherapeutic protocols 
were employed (Gemcitabine/cisplatin)(Docetaxel/cisplatine) and( 
vinorelbine/cisplatine). Study end points included resectability, 
pathologic response, local-regional control,and the best chemo-
therapy regimen . An exploratory comparison between pathologic 
response and both histology and age was performed. On the 
other hand,An exploratory comparison between the three diffe-
rent regimens of chemotherapy was also done.
Results: Of the 85 patients, 26 (30,5%) were deemed surgical 
candidates after induction therapy however 7 patients of which 
(8,2%) refused surgery, were 27/85 males and 2/10 females had 
good downstaging P value (0.0001) and (0.0003) respectively with 
T downstaging 20/85 (23.5%), and N downstaging 18/85 (21.2%) 
but T+N downstaging was seen in only 9 patients (10.6%)P value 
(0,0001).The response to induction chemotherapy was 30/85 pati-
ents (35.2%) with one patient only (1.2%)` in a complete response 
. furthermore, 26/85 patients were in objective response (30.5%) 
and while 3 patients (3,5%) had a stable disease.Regarding respon-
ders‘ age, there were 18/48 patients (37%) aged 60 years and less, 
and only 8/37 patients (21.6%) were over 60 years.Depending on 
response to histology, 21/58 patients (34.5%) of SCC had got a res-
ponse to preoperative chemotherapy, P value (0,0015), while 10/27 
patients (37%) had no SCC,P value ( 0,0295).50/85 patients (58.8%) 
treated by (Gemcitabine / Cisplatin) protocol with 15 responders( 
30%) P value (0,0197 ),24/85 patients (28.2%) treated with (Vinorlbi-
ne / Cisplatin) protocol with 11 responders (45.8%) P value(0.0125) 
. And finally,11/85 of pts (12,9%) treated by (docetaxel / cisplatin) 
protocol showed four responders (36.4%) P value ( 0,0332 )
Conclusion: The preoperative chemotherapy gives a good res-
ponse for a possible surgery in patients with stages IIIA and IIIB 
NSCLC. this response was better in patients under 60 years , P 
value ( 0,0055 ). With response was better seen in Vinorelbine and 
Cisplatin arm . However , regarding histology based response, 
there was no preference.the former results lead us to use neoadju-
vant chemotherapy in locally advanced NSCLC,but we still need a 
larger trials to reach the best protocol.
Keywords: preoperative chemotherapy, non-small cell lung can-
cer, downstaging, locally advanced
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Keywords: Lymphovascular invasion, Outcome, non-small cell lung 
cancer, inductive treatment
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Keywords: non-small cell lung cancer, inductive treatment, dama-
ged respiratory fuction, feasibility
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P1.09-004 FEASIBILITY AND EFFICACY OF INDUCTIVE 
CHEMO OR CHEMORADIATION FOR PATIENTS WITH 
LOCALLY ADVANCED NON-SMALL CELL LUNG CAN-
CERS AND REDUCED RESPIRATORY FUNCTION
Diego Marquez-Medina1, Ariadna Gasol-Cudos1, Antonio Martin-
Marco1, Virginia Garcia-Reglero2, Noemi Tuset Der-Abrain1, Anto-
nieta Salud-Salvia2
1Medical Oncology, University Hospital Arnau De Vilanova/Spain, 2Ra-
diation Oncology, University Hospital Arnau De Vilanova/Spain
Background: Half of non-small cell lung cancers are diagnosed a 
locally advanced stage (LA-NSCLC) and are treated by combining 
chemotherapy, radiation, and surgery (S). However, many patients 
are not able to receive complete multidisciplinary therapies due 
to previous respiratory dysfunctions. We report the feasibility and 
efficacy of inductive chemotherapy (iCT) or chemoradiation (iCRT) 
followed by S or consolidative radiation (RT) in LA-NSCLC patients 
with normal (NRF) and reduced respiratory function (RRF)
Methods: We retrospectively reviewed 100 LA-NSCLC ECOG-0-2 
patients treated with iCT or iCRT followed by S or RT in our center 
between October-2004 and June-2012. No patient was excluded 
to receive treatment due to RRF, but all those without initial de-
termination of basal forced expiratory volume in the first second 
(FEV1) were not analyzed. Patients were classified into two groups 
according to initial FEV1: 1) NRF FEV1≥ 60%, and 2) RRF FEV1< 
60%. A comparison of toxicity, compliance, treatment modality, 
and outcome between these groups was performed
Results: Seventy-two patients initially presented NRF, and 28 RRF. 
Seventy (97.2%) patients with NRF completed curative treatments 
(20 iCRT+S; 20 iCRT+RT; 19 iCT+S; and 11 iCT+RT). Twenty-six pati-
ents (92.8%) with RRF completed curative treatments (3 iCRT+S; 14 
iCRT+RT; 3 iCT+S; and 6 iCT+RT). The rest of them progressed du-
ring inductive treatment and did not receive curative approaches. 
Any patient interrupted the treatment due to toxicity. Resection 
rate was lower among patients with RRF (55.7% vs. 23%, p= 0.004), 
but tolerance to S was similar to those with NRF (p= 0.72). RT was 
applied in 44.2% and 76.9% of patients with NRF and RRF, respec-
tively. Incidence of grade 3-4 toxicities was similar in both groups 
of patients (13.9% vs. 11%; p= 0.72). There were no significant dif-
ferences in disease free survival (16 vs. 21.8 months, p= 0.689), but 
overall survival paradoxically trended to be better in patients with 
RRF (27.4 vs. 37.3 months, p= 0.066)
Conclusion: RRF does not necessarily contraindicate a multidiscip-
linary curative approach for LA-NSCLC. In our series, iCT and iCRT 
were followed by S in 23% of patients with RRF, and by RT in 77%. 
Outcome of patients with RRF receiving an intentionally curative 
treatment was at least as good as that of patients with NRF. Figure 
1. Kaplan-Meier DFS and OS curves according to initial FEV1. 
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P1.09-006 CHEMO-RADIOTHERAPY FOR LOCALLY AD-
VANCED NSCLC IN RESOURCE LIMITED POPULATION: 
IS IT ISOEFFECTIVE?
Jai Prakash Agarwal1, C Hotwani1, A Mathew1, A Munshi1, N Kalya-
ni1, K Prabhash2, A Joshi2, V Norohna2, S Ghosh Laskar1, S Misra1,  
S Tandon3, N Purandare4, George K5, S Jiwnani5, Cs Pramesh5
1Radiation Oncology, Tata Memorial Hospital/India, 2Medical Oncology, 
Tata Memorial Hospital/India, 3Pulmonary Medicine, Tata Memorial 
Hospital/India, 4Bio Imaging, Tata Memorial Hospital/India, 5Surgical 
Oncology, Tata Memorial Hospital/India
Background: Annually 63,000 approximately new patients of lung 
cancer are diagnosed in India, with two-third of them in advanced 
stage at presentation.. Radiotherapy with concurrent chemothe-
rapy has shown survival benefit and is the standard of care for this 
group of patients in western literature.
Methods: One hundred seventy four consecutive patients Of Non 
Small cell Lung cancer (NSCLC) were treated with radical (chemo)-
radiotherapy at Tata Memorial hospital from January 2008 to 
December 2012, . Detailed study of patient, tumour and treatment 
related factors were performed. Outcomes in the form of pro-
gression free survival (PFS) and overall survival (OS) at two years 
were calculated. Follow-up and analysis of data was performed in 
February 2013. Univariate and multivariate analysis was performed 
to see the impact of patient related factors like age, smoking, KPS, 
presence of comorbidity, tumour related factors including T stage, 
N stage and stage group and treatment related factors chemothe-
rapy timing , total dose, duration of radiotherapy and response to 
treatment on PFS and OS.
Results: Of 174 patients, Males were 154(88.5%) with median age 
of 58 years (range 30-84 years) and 121(69.5%) were smokers. 
Median KPS was 80 (range 60-100) and 59 patients had significant 
comorbidity. Cough was the commonest presenting symptom 
(28%) followed by chest pain (27%) and haemoptysis (24.7%). Most 
common histology was squamous carcinoma 47.1% followed by 
adenocarcinoma in 41.4%. Stage III (A+B) constituted 90.2% of 
the patients. All patients received thoracic radiotherapy using 3D 
Conformal technique using 6/15 MV photons to a median dose 
of 60Gy (range 4-66Gy) over a median duration of 44 days(2-85 
days) .Of 174 patients 166 patients (95.4%) completed the planned 
treatment. Median GTV and PTV volumes were 132 cc (16.7-741cc) 
and 538 cc(56-5680 cc) respectively. The median lung-PTV volu-
me was 2599cc and V20 Gy was 23.79 %. Out of 174 patients 76% 
patients received concurrent chemotherapy, while 11.5% received 
sequential chemotherapy also. Response assessment using WHO 
criteria was done at 2 months post treatment, 63 (36.1%) had com-
plete response whereas 64patients (36.8%) had partial response 
or stable disease and 7 patients(3.4%) had progressive disease . 
At last follow-up of with mean follow up 9.3 months (range 0-37 
months), 32 patients had loco-regional recurrence and 33 patients 
had distant metastases. Acute pneumonitis grade I and II was ob-
served in 87(50%) and 13(7.4%), acute oesophagitis grade II and III 
was seen in 56(32.1%) and 7(4%) patients respectively as per RTOG 
grading. Median PFS and OS were 20 months and 23 months with 
the estimated 2 year PFS & OS was 35% & 47.4%respectvely.On 
Univariate analysis, complete response to treatment (p=0.000) had 
favourable impact on PFS whereas smoking (p=0.009), advanced 
T stage (p=0.002) and less than complete response (p=0.000) had 
negative impact on OS.
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P1.09-005 THE OPTIMAL TIMING OF SRS ADD TO EGFR-
TKI TREATMENT FOR BRAIN METASTASIS FROM ACTI-
VATING EGFR MUTANT NSCLC
Hyun Jung Kim1, Woo Sung Kim1, Chang Min Choi1, Sang-We Kim2, 
Dae Ho Lee2, Jeong Hoon Kim3, Do Hoon Kwon3, Young Hyun Cho3
1Pulmonary And Critical Care Medicine, Asan Medical Center/Korea, 
2Oncology, Asan Medical Center/Korea, 3Neurological Surgery, Asan 
Medical Center/Korea
Background: Lung cancer is the most frequent cause of cancer-
related death worldwide. Brain metastasis is an important issue 
because its incidence of 20-40% in non small cell lung cancer (NS-
CLC) patients and association of significant mortality and morbidi-
ty. There are several therapeutic modalities for CNS lesions such 
as whole brain radiotherapy (WBRT), stereotactic radiosurgery 
(SRS) and metastasectomy. It is well known that conventional che-
motherapy is not effective for brain metastasis because of blood 
brain barrier (BBB). On the other hand, tyrosine kinase inhibitors 
(TKI) have showed efficacy in patients with brain metastasis from 
activating epithelial growth factor receptor (EGFR) mutant NSCLC. 
We assumed that SRS for brain metastasis could be delayed for 
the patients with activating EGFR mutation on taking gefitinib or 
erlotinib.
Methods: We retrospectively identified patients with brain meta-
stasis from NSCLC harboring a sensitizing mutation of EGFR who 
were treated with SRS for the brain metastasis combined with TKI. 
EGFR mutations in exons 18, 19, 20 and 21 were analyzed by direct 
sequencing. SRS treatment was indicated for brain metastasis less 
than 6 lesions and not exceeding 4cm each of them. The patients 
in SRS first group were treated by SRS for brain metastasis, and 
then TKI was administrated. The other patients were treated with 
TKI before SRS and they were assigned to TKI first group. Progres-
sion free survival time was compared with each group.
Results: Forty-three patients were eligible (SRS first: 29, TKI first 
14). Twenty-nine patients of them (67.4%) were women, median age 
was 56 (range 36-78). Most of them were adenocarinoma, except 
1 squamous cell carcinoma and 1 NSCLC NOS. All patients have 
activating EGFR mutations, 2 patients had also T790M mutation 
known as TKI resistant mutation. TKI was used as 2nd line treatment 
for twenty five patients (58.1%). WBRT and brain metastasectomy 
were additionally employed for 9 and 6 patients. Although eight 
patients complained headache after SRS, it was self-limited. The 
median duration of TKI treatment were not different from each 
group (13.4 months in SRS first group, 14.7 months in TKI first 
group, p=0.986) As a result, the median progression free survival 
time was prolonged in SRS first group than in the TKI first group 
(12.6 months versus 2.3 months, p<0.001). And there was no signi-
ficant adverse effect related with SRS in both groups.
Conclusion: It is better to consider SRS for brain metastasis as 
soon as possible, even if TKI is effective for patients with brain me-
tastasis from activating EGFR mutant NSCLC. Also, the combined 
treatment of TKI with SRS was well tolerated by all patients in this 
study.
Keywords: stereotactic radiosurgery, brain metastasis, Non small 
cell lung cancer, EGFR-TKI
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Conclusion: Our results revealed that CV protocol was a relatively 
well-tolerated chemotherapy regimen given concurrently with TRT 
in stage IIIB NSCLC cases, and number of chemotherapy cycles 
than could be given during TRT course was an important prog-
nostic indicator in such patients. Although results of randomized 
trials are needed, findings of superior survival in cases receiving 2 
or 3 cycles of chemotherapy during TRT and similar survival results 
between 2 and 3 cycles suggest that 2 cycles of chemotherapy 
may potentially reduce toxicity rates, which results in increased 
treatment tolerability and quality of life, without compromising 
efficacy of treatment.
Keywords: Prognosis, number of chemotherapy cycle, non-small 
cell lung cancer, chemoradiotherapy
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P1.09-008 OUTCOMES IN A SINGLE INSTITUTION SE-
RIES OF PATIENTS WITH STAGE III NON-SMALL CELL 
LUNG CARCINOMA TREATED WITH CURATIVE-INTENT 
RADIOTHERAPY AND CONCURRENT CARBOPLATIN 
AND PACLITAXEL CHEMOTHERAPY.
Hon Trinh, Mark Pinkham, Margot Lehman, Dannie Zarate, Mar-
garet Dauth, Margaret Mcgrath, G Tao Mai, Elizabeth Mccaffrey, 
Keith Horwood
Cancer Care Services, Princess Alexandra Hospital/Australia
Background: The standard of care for patients with a good perfor-
mance status and inoperable stage III non-small cell lung cancer 
(NSCLC) is concurrent chemoradiotherapy (1–3). Carboplatin and 
paclitaxel is an alternative to the cisplatin-based doublets that 
have been used traditionally (4). Early-phase studies with small 
numbers have been reported (5–7) but a randomised phase 3 
comparison has not been performed. The objective of this study 
was to assess outcomes in a large cohort of patients treated with 
curative-intent radiotherapy and concurrent carboplatin and pacli-
taxel chemotherapy.
Methods: Consecutive patients between March 2004 and 
May 2012 with stage III NSCLC undergoing curative-intent 3D-
conformal radiotherapy to 60-66 Gy in 30-33 daily fractions with 
concurrent weekly carboplatin (45mg/m2) and paclitaxel (AUC=2) 
were identified from a prospective database. Consolidation che-
motherapy was not given. Individual medical charts, radiology and 
laboratory investigations were reviewed retrospectively. Baseline 
clinico-pathologic, treatment, outcome and toxicity details were 
recorded. A minimum follow-up of three months after completion 
of treatment was required unless death occurred sooner. Median 
follow-up and survival times were calculated from date of first con-
tact using the Kaplan-Meier method.
Results: One hundred and sixteen patients were identified and 
baseline characteristics are provided in Table 1. Nine patients were 
excluded as the chemotherapy regimen changed after at least one 
cycle and the remaining 107 patients were analysed. Median fol-
low-up was 43.5 months. Imaging at three months post-treatment 
demonstrated a complete response in 4 (4%) patients and a partial 
response in 68 (64%) patients. Nine (8%) patients had already died. 
Median progression free survival and median survival were 15 and 
22 months, respectively. Locoregional control was 53%. Failure 
at any site occurred in 75 (70%) patients. Isolated distant failure 
occurred in 24 (22%) patients with 9 in the brain. Adjustments to 
Conclusion: Even under resource limited conditions patients who 
were treated with an intensive (chemo) radiation with supportive 
care had an acceptable treatment compliance and comparable 
treatment outcomes. , Patients with advanced stage and smokers 
did worse. Patients treated with concurrent chemoradiation and 
complete responders had better OS.
Keywords: Combined modality, Concurrent chemoradiotherapy, 
ADVANCED NSCLC
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P1.09-007 PROGNOSTIC VALUE OF NUMBER OF CHE-
MOTHERAPY CYCLE IN STAGE IIIB NON-SMALL CELL 
LUNG CANCER PATIENTS TREATED WITH THORACIC 
RADIOTHERAPY AND CONCURRENT CISPLATIN-VINO-
RELBINE
Erkan Topkan1, Cem Parlak1, Ozan C. Guler1, Ugur Selek2, Ozgur 
Ozyilkan3
1Department Of Radiation Oncology, Baskent University Medical Fa-
culty/Turkey, 2Department Of Radiation Oncology, American Hospital, 
University Of Texas MD Anderson Radiation Oncology Center/Turkey, 
3Department Of Medical Oncology, Baskent University Medical Faculty/
Turkey
Background: The study was aimed to evaluate association bet-
ween number of chemotherapy (CT) cycles and prognosis in stage 
IIIB non-small cell lung cancer (NSCLC) patients treated with thora-
cic radiotherapy (TRT) and concurrent CV CT protocol given in 1-3 
cycles according to the toxicity or patient preference.
Methods: A total of 475 18-70 years old stage IIIB NSCLC patients, 
who received 60-66 Gy TRT concurrently with at least 1 cycle CV 
(q21) regimen between January 2007 and December 2011 were 
retrospectively evaluated. Primary end point was overall survival 
(OS), and secondary end points were progression-free survival 
(PFS) and locoreginal PFS (LRPFS).
Results: Median follow-up time was 21.7 months (range 17-24.1). 
Histolopathologic subtype was squamous cell in 51.8%, and ade-
nocarcinoma in 48.2% of cases. Treatment-related mortality was 
reported in 6 (1.3%) patients. There was no grade-4 non-hemato-
logical toxicity but grade-4 hematological toxicity was observed 
in 59 (12.4%) patients. Respective grade-3 non-hematological 
and hematological toxicity rates were 14.5% (n=69) and 24.6% 
(n=117), with leukopenia (9.3%) and esophagitis (17.3%) being the 
most common toxicities. Median OS, PFS and LRPFS for whole 
group were 20.7 (%95 CI: 19.4-22.0), 9.9 (%95 CI: 9.9-10.4) and 13.4 
months (%95 CI: 12.6-14.2), respectively. Comparative median OS, 
PFS and LRPFS results for groups receiving 1 (n=44), 2 (n=68) and 3 
(n=363) cycles of chemotherapy were 13.2 vs. 19.3 vs. 21.9 months 
( p≤0.001), 6.1 vs. 9.7 vs. 10.5 months (p≤0.001), 6.6 vs. 12.8 vs.14.2 
months ( p≤0.001), respectively. For all survival parameters, there 
were significant difference between patients receiving 1 cycle and 
2 or 3 cycles of chemotherapy (p<0.05 for each) but there was no 
difference between those receiving 2 and 3 cycles of chemothe-
rapy (p≥0.05 for each). T-satge (T1-2 vs T3-4) and N-stage (N2 vs 
N3) were the other factors influencing OS (p<0.05 for each) on 
univariate analyses. However, only T-stage (p=0.004) and Number 
of chemotherapy cycles (p≤0.001) retained prognostic significance 
on multivariate analyses.
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Squamous cell carcinoma 45 (39)
Carcinoma NOS 22 (19)
Other 3 (3)
Unknown 3 (3)
Conclusion: This review of a large, single institution series of pati-
ents with inoperable Stage III NSCLC treated with curative intent 
demonstrates that the concurrent administration of carboplatin 
and paclitaxel with radiotherapy is feasible. Survival and toxicity 
outcomes compare favourably to those reported with concurrent 
cisplatin and etoposide (4).
Keywords: Stage III non-small cell lung cancer, chemoradiation, 
Carboplatin, paclitaxel
POSTER SESSION 1 - COMBINED MODALITY  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.09-009 PRELIMINARY SAFETY AND TREATMENT 
DELIVERY DATA DURING CONCURRENT PHASE OF CHE-
MORADIATION THERAPY OF THE PROCLAIM TRIAL: A 
PHASE 3 TRIAL OF PEMETREXED, CISPLATIN, AND RA-
DIOTHERAPY FOLLOWED BY CONSOLIDATION PEME-
TREXED VERSUS ETOPOSIDE, CISPLATIN, AND RADIO-
THERAPY FOLLOWED BY CONSOLIDATION CYTOTOXIC 
CHEMOTHERAPY OF CHOICE IN PATIENTS WITH STAGE 
III NONSQUAMOUS CELL LUNG CANCER.
Everett Vokes1, Luhua Wang2, Johan Vansteenkiste3, Shaker 
Dakhil4, Bonne Biesma5, Maite Martinez Aguillo6, Joachim 
Aerts7, Ramaswamy Govindan8, Belen Rubio-Viqueira9, Conrad 
Lewanski10, Anthony Brade11, Neill Iscoe12, Anwar M. Hossain13, 
Joseph A. Treat13, Nadia Chouaki14, Suresh Senan15
1Department Of Medicine, University Of Chicago/United States Of Ame-
rica, 2Dept Of Radiation Oncology, Cancer Hospital (institute),chinese 
Academy Of Medical Sciences & Peking Union Medical College/China, 
3University Hospital KU Leuven/Belgium, 4Cancer Center Of Kansas/
United States Of America, 5Dept Of Pulmonology, Jeroen Bosch Hospi-
tal/Netherlands, 6Medical Oncology Dept, Hospital Of Navarre/Spain, 
7Dept Of Pulmonology, Erasmus Mc, Amphia Hospital/Netherlands, 
8Dept Of Internal Medicine, Washington University School Of Medicine/
United States Of America, 9Hospital Of Madrid/Spain, 10Charing Cross 
Hospital/United Kingdom, 11Princess Margaret Hospital, University Of 
Toronto/Canada, 12Eli Lilly Canada Inc/Canada, 13Eli Lilly And Com-
pany/United States Of America, 14Eli Lilly And Company/France, 15VU 
University Medical Center/Netherlands
Background: Pemetrexed platinum regimens, unlike other regi-
mens, can be given at full systemic doses with thoracic radiation 
therapy (TRT) in locally advanced stage III nonsquamous non–small 
cell lung cancer (NSCLC). Study JMIG was initiated to determine if 
this finding would translate into a survival advantage versus con-
temporary standard of care.
Methods: Study JMIG randomized patients with stage III unresec-
table nonsquamous NSCLC to experimental Pem+Cis (pemetrexed 
plus cisplatin and concurrent TRT for three 21-day cycles, followed 
by consolidation pemetrexed) or to control Etop+Cis (etoposide 
plus cisplatin and concurrent TRT for two 28-day cycles, followed 
by consolidation chemotherapy regimen of choice [excluding pe-
metrexed]). The primary objective was overall survival of Pem+Cis 
chemotherapy dose or number of planned cycles were required in 
29 (27%) patients. Fifty two (49%) patients were admitted during 
treatment. Seven patients experienced an acute hypersensitivity 
reaction to paclitaxel. Grade 3/4 neutropenia, thrombocytopenia, 
nephrotoxicity, oesophagitis and pneumonitis were observed in 
15%, 1%, 3%, 11% and 9% of patients, respectively. There was 1 
episode of fatal radiation pneumonitis.  
Table 1. Patient characteristics. ECOG= Eastern Co-operati-
ve Group; FEV-1= forced expiratory volume in one second; PET= 
positron emission tomography; NOS = not otherwise specified.
Total number of patients 
(%)
116 (100)
Age, years
Median 65
Range 32-80
Sex: number (%)
Male 78 (67)
Female 38 (33)
Performance status: num-
ber (%)
ECOG 0 45 (39)
ECOG 1 62 (53)
ECOG 2 7 (6)
Unknown 2 (2)
Smoker: number (%)
Never 3 (3)
Current or ex-smoker (≥10 
pack-years)
111 (96)
Unknown 2 (2)
Smoking history, pack-
years
Mean 53.4
Range 0-250
FEV-1, litres
Mean 2.05
Range 0.62-4.25
Loss of weight: number 
(%)
None 98 (84)
≥10% 18 (16)
Stage: number (%)
IIIA 75 (65)
IIIB 41 (35)
PET-staged before treat-
ment: number (%)
Yes 113 (97)
No 3 (3)
Histology: number (%)
Adenocarcioma 43 (37)
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Table 1. Summary of Common Terminology Criteria for 
Adverse Events Grade 3 Plus 4 Occurring in ≥2% of Pati-
ents Randomized and Treated 
CTCAE (Grades 
3 and 4) 
Pem+Cis 
N=283 n (%) 
Etop+Cis 
N=272 n (%) p-value 
Patients with ≥1 
CTCAE* 
170 (60.1) 186 (68.4) 0.042 
Neutrophils/gra-
nulocytes* 
52 (18.4) 78 (28.7) 0.005 
Leukocytes* 44 (15.5) 65 (23.9) 0.014 
Esophagitis 42 (14.8) 47 (17.3) 0.488 
Lymphopenia 48 (17.0) 37 (13.6) 0.290 
Hemoglobin 14 (4.9) 20 (7.4) 0.289 
Febrile neutro-
penia 
9 (3.2) 18 (6.6) 0.075 
Dysphagia 18 (6.4) 16 (5.9) 0.861 
Platelets 15 (5.3) 16 (5.9) 0.854 
Vomiting 12 (4.2) 13 (4.8) 0.839 
Hypokalemia 6 (2.1) 12 (4.4) 0.153 
Infection—lung 
(pneumonia)*a 
1 (0.4) 9 (3.3) 0.010 
Dehydration 11 (3.9) 8 (2.9) 0.643 
Nausea 13 (4.6) 8 (2.9) 0.376 
Anorexia 10 (3.5) 7 (2.6) 0.625 
Fatigue 9 (3.2) 6 (2.2) 0.603 
Hyponatremia 5 (1.8) 6 (2.2) 0.768 
Thrombosis/
thrombus/embo-
lism 
7 (2.5) 5 (1.8) 0.772 
Abbreviations: Cis = cisplatin; CTCAE = Common Terminology 
Criteria for Adverse Events, Version 3.0; Etop = etoposide; N = 
number of patients dosed; n = number of patients with at least 
one CTCAE; Pem = pemetrexed.
* Statistically significant; p<.05 based on Fisher’s exact test. 
a CTCAE was defined as Infection (clinical/microbio)—Gr3/4 neu-
trophils—Pulmonary/upper respiratory—Lung (pneumonia). 
Conclusion: During the concurrent treatment phase, patients with 
stage III locally advanced nonsquamous NSCLC in either treatment 
arm received comparable systemic therapy; however Pem+Cis had 
significantly lower incidences of some toxicities. Further toxicity 
differences may emerge with longer follow-up.
Keyword: pemetrexed, NSCLC, safety, PROCLAIM
compared with Etop+Cis with safety as a secondary objective 
using Common Terminology Criteria for Adverse Events (CTCAE). 
Adverse event incidences were analyzed using Fisher’s exact test 
(2-sided α=0.05).
Results: Of 598 randomized patients, 555 received treatment: 283 
Pem+Cis and 272 Etop+Cis. Baseline characteristics were similar 
(Pem+Cis/Etop+Cis); age (mean±SD) 59.2±9.5/58.7±9.3 years; 
women, n=114 (40.3%) / n=105 (38.6%); stage IIIB, n=153 (54.1%)/
n=138 (50.7%); Eastern Cooperative Oncology Group performance 
standard of 1, n=138 (48.8%)/n=137 (50.4%); and planned target 
volume (mean±SD) 628.9 ±463.3/581.2±417.0 ml. Pem+Cis mean 
weekly dose intensities were 95.9% for both pemetrexed and ci-
splatin; Etop+Cis dose intensities were 96.4% and 94.1% for etopo-
side and cisplatin. TRT therapies were similar (Pem+Cis/Etop+Cis); 
TRT median (range) of 66.0 (2.0–66.3) gray (Gy)/66.0 (2.0–66.0) Gy, 
mean (SD) number of fractions 31.4 (4.3)/31.1 (5.2), V20 of 27.5% 
(6.5%)/26.7% (7.3%). Table 1 summarizes AEs during the concurrent 
phase by treatment. Few patients (n≤4) had grade 3 or 4 CTCAE 
of mucositis/stomatitis or rash. Pem+Cis had fewer SAEs of febrile 
neutropenia and pneumonia but increased vomiting compared 
with Etop+Cis. Nine patients died during the concurrent phase 
(not included in this safety analysis by treatment to preserve the 
integrity of final efficacy analysis). 
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P1.09-011 PHASE I CLINICAL TRIAL ASSESSING THE 
MEK INHIBITOR SELUMETINIB (AZD6244; ARRY-142886) 
WITH CONCOMITANT THORACIC RADIOTHERAPY (RT) 
IN PATIENTS WITH STAGE III-IV NON SMALL CELL LUNG 
CANCER (NSCLC)
Alberto Fusi1, Fiona Blackhall1, Pek Koh1, Caroline Dive2, Ian Strat-
ford3, Kaye Williams3, Neil Bayman1, Linda Ashcroft1, Tracy Coy-
ne1, Sally Falk1, Corinne Faivre-Finn1
1The Christie NHS Foundation Trust/United Kingdom, 2Paterson Insti-
tute For Cancer Research, University Of Manchester/United Kingdom, 
3School Of Pharmacy, University Of Manchester/United Kingdom
Background: The RAS/RAF/MEK/ERK signalling cascade has a 
central role in cancer proliferation and in modulating response 
to treatment. RAS mutations can confer a radiation-refractory 
phenotype and MAPK signaling can be stimulated by treatment 
with ionizing radiation in non-small cell lung cancer (NSCLC). Selu-
metinib (AZD6244; ARRY-142886) is an orally available inhibitor of 
MEK1/2 which was shown to enhance the effect of radiotherapy in 
preclinical studies. This effect was due to the ability of selumetinib 
to directly sensitize tumor cells to the cytotoxic effect of radiation 
and to modulate tumor vessel functionality by reducing VEGF-A 
expression. In a Phase II study, selumetinib given in combination 
with docetaxel showed promising activity in NSCLC patients with 
KRAS activating mutations. Aim To determine the recommended 
Phase II dose (RP2D) of selumetinib in combination with standard 
dose thoracic radiotherapy (RT) in NSCLC.
Methods: Selumetinib (Hyd-Sulfate capsule) was administered 
orally twice daily as a single agent for one week and then in com-
bination with thoracic RT for 6 to 6.5 weeks (60 to 66 Gy in 30 to 
33 fractions) in a single institution, open label Phase I trial using a 
modified Fibonacci sequence. Prior standard chemotherapy was 
permitted with a minimum interval between day8 of the last cycle 
of chemotherapy and day1 of administration of selumetinib of ≥ 
2weeks. Other eligibility included: histologic or cytologic diagnosis 
of NSCLC, stage III not suitable for concurrent chemo-radiotherapy 
or stage IV with dominant thoracic symptoms, disease encompas-
sable within a radical RT treatment volume, ECOG PS 0-1., no prior 
RT or investigational agents.
Results: A total of six consecutive patients with inoperable stage 
III (n=3) or stage IV (n=3) NSCLC were given selumetinib 50 mg 
twice daily (dose level 1) with concomitant thoracic RT (59.8-66 Gy 
in 30-33 fractions). All patients completed the combined treat-
ment. Selumetinib delivery was > 80%. Four out of the six patients 
had dose interruptions of 2-3 days due to expected adverse events 
(AEs). Skin rash (6/6), diarrhoea (5/6) and fatigue (4/6) were the 
most common toxicities. Grade 3/4 AEs included hypertension 
(2/6), diarrhoea (2/6), skin rash (1/6), pulmonary embolism (1/6), 
fatigue (1/6) and pericardial effusion (1/6). Pulmonary embolism 
(grade 3) was considered not related to the study treatment. One 
patient experienced dose limiting toxicity (DLT) consisting of a 
combination of diarrhoea (grade 3) and fatigue (grade 3). Respon-
se to treatment was assessed 4 weeks post RT. Distant recurrence 
was seen in 1 patient; 3 patients had SD, 1 patient experienced a 
PR and 1 a CR. Median duration of response was 2 months (range 
1-4 months).
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P1.09-010 IMPACT OF THE PRESENCE OF EGFR MUTA-
TION ON THE DEFINITIVE CHEMORADIOTHERAPY IN 
PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL 
LUNG CANCER: PATTERN OF RELAPSES AND SURVIVAL 
ANALYSES IN 198 PATIENTS
Hidehito Horinouchi1, Shigehiro Yagishita1, Tomoko Katsui Tani-
yama1, Shinji Nakamichi1, Satoru Kitazono1, Hidenori Mizugaki1, 
Shintaro Kanda1, Yutaka Fujiwara1, Hiroshi Nokihara1, Noboru 
Yamamoto1, Minako Sumi2, Kouya Shiraishi3, Takashi Kohno3, 
Koh Furuta4, Koji Tsuta5, Tomohide Tamura1
1Department Of Thoracic Oncology, National Cancer Center Hospital/
Japan, 2Division Of Radiation Oncology, National Cancer Center Hos-
pital/Japan, 3Division Of Genome Biology, National Cancer Center 
Research Institute/Japan, 4Division Of Clinical Laboratories, National 
Cancer Center Hospital/Japan, 5Division Of Pathology, National Cancer 
Center Hospital/Japan
Background: The epidermal growth factor receptor (EGFR) muta-
tional status is an important biomarker in patients with advanced 
non-small cell lung cancer (NSCLC). However, little is known about 
the frequency and clinical significance of EGFR mutation in pati-
ents with potentially curable locally advanced NSCLC (LA-NSCLC) 
who are eligible for definitive chemoradiotherapy (CRT).
Methods: Between Jan 2001 and Dec 2010, we conducted analy-
sis for the presence of EGFR mutations, in consecutive non-squa-
mous NSCLC (mainly in adenocarcinoma) patients who were eligi-
ble for CRT. The response rate (RR), progression-free survival (PFS), 
2-year progression-free rate, first recurrent sites, and overall survi-
val were investigated according to the EGFR mutational status.
Results: A total of 528 patients received CRT at the National Can-
cer Center Hospital during the study period, of which 274 were 
diagnosed as having non-squamous NSCLC (mainly adenocar-
cinoma). Sufficient specimens for mutational analyses could be 
obtained from 198 patients, and EGFR mutations were found at a 
frequency of 17% in these patients. In addition to the well-known 
characteristics of NSCLC patients carrying EGFR mutations (fe-
male, adenocarcinoma, and never/light smoker), the proportion 
of cases with smaller (T1/2) primary lesions was also higher in the 
patients carrying mutated EGFR than in those carrying wild-type 
EGFR. Patients carrying mutated EGFR showed similar RR (79% vs. 
76%), median PFS (11.8 m vs. 10.6 m) and 2-year progression-free 
survival rate (22% vs. 30%) as compared to those carrying wild-ty-
pe EGFR. Local recurrence as first relapse occurred less frequently 
in patients carrying mutated EGFR than in those carrying wild-type 
EGFR (4% vs. 21%). A majority of the patients with mutated EGFR 
showing disease progression received EGFR-TKIs (55%), and these 
patients showed a longer post-progression survival and a higher 
5 year survival rate (50% vs. 34%) than the patients with wild-type 
EGFR.
Conclusion: Among the LA-NSCLC patients eligible for definitive 
CRT who were included in this analysis, 17% harbored EGFR-
activating mutations in the carcinoma specimens. Although de-
finitive CRT was similarly effective in both patients with mutated 
EGFR and wild-type EGFR, substantially lower frequency of local 
relapse was noted in the patients carrying mutated EGFR. Among 
the LA-NSCLC patients harboring EGFR mutations who developed 
disease progression, those treated with EGFR-TKIs showed a lon-
ger post-progression survival and overall survival as compared to 
those who did not receive EGFR-TKIs.
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From January 2009 to July 2012, 43 patients were included, 21 of 
which were stage IIIB diseases (19 with stage N3- IIIB). In the 22 pa-
tients with stage IV disease, 17 had oligometastases (≤5) and 5 had 
polymetastases. The median chemotherapy cycles was 4.27 pati-
ents (62.8%) received ≥ 4 cycles of chemotherapy and 16 patients 
(37.2%) received <4 cycles. 36 patients (83.7%) received radical 
dose radiotherapy (≥60 Gy) and 7 patients (16.3%) received pallia-
tive dose to primary tumor. The median radiation dose was 60Gy. 
The median follow-up time of survival patients was 17.0months 
(range, 5.8 to 45.2 months). The median progression free survival 
(PFS) was 12 months. 12-, 18- and 24-months PFS rate were 50.4% 
(95%CI, 35.3-65.5%), 25.1% (95%CI, 21-39.2%) and 21.5% (95%CI, 
7.8-35.2%), respectively. 12-, 18- and 24-months overall survival 
(OS) rate were 90.1% (95%CI, 75.8-96.2%), 72.2% (95%CI, 54.2-
84.1%) and 65.7% (95%CI, 44.3-80.5%), respectively. The median 
OS was not reached. Toxicities were better tolerated except one 
death of radiation-induced pneumonitis.
Conclusion: Pemetrexed plus platinum as first-line treatment in 
combination with early radiotherapy had encouraging short 
term efficacy with acceptable toxicity in selected patients with 
advanced NSCLC. Although the long-term efficacy needs further 
observation, the result showed potential advantage of early radio-
therapy in Asian patients with advanced non-squamous NSCLC, 
especially stage IV.
Keywords: early radiotherapy, advanced non-squamous non-small 
cell lung cancer, pemetrexed
Conclusion: Selumetinib given at 50 mg twice daily with concomi-
tant radical thoracic RT was tolerated with no unexpected toxicities 
or enhancement of expected RT toxicities. Although the protocol-
defined criteria to further escalate the selumetinib dose were met, 
because of the heterogeneous and small patient cohort and AEs 
encountered further evaluation of the 50 mg twice daily was pre-
ferred in order to obtained additional safety data. An expanded 
cohort of 15 patients having additional FLT-PET scans.
Keywords: MEK inhibitor, thoracic radiotherapy, Phase I trial, Non 
small cell lung cancer
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P1.09-012 PEMETREXED AS FIRST-LINE TREATMENT IN 
COMBINATION WITH EARLY RADIOTHERAPY IN AD-
VANCED NON-SQUAMOUS NON-SMALL CELL LUNG 
CANCER: A RETROSPECTIVE ANALYSIS
Xuwei Cai, Qin Zhang, Wen Yu, Qi Liu, Min Fan, Wen Feng, Weixin 
Zhao, Xiaolong Fu
Radiation Oncology, Fudan University Shanghai Cancer Center, Shang-
hai, China/China
Background: Pemetrexed plus platinum recommended as first-line 
treatment for patients with advanced non-squamous non-small cell 
lung cancer (NSCLC) were more effective in East Asian patients. 
Few studies have evaluated the role of radiotherapy in combina-
tion with pemetrexed in advanced NSCLC. We hypothesized that 
pemetrexed plus platinum at full dose in combination with early 
radiotherapy can improve the clinical efficacy in advanced NSCLC, 
especially for selected patients.
Methods: Patients of stage IIIB or IV non-squamous NSCLC with 
unknown epidermal growth factor receptor (EGFR) mutation status 
were treated with pemetrexed plus platinum at full dose as first-
line chemotherapy. All patients underwent concomitant chemo-
radiotherapy for primary cancer with or without radiotherapy for 
metastases. No patients had maintenance therapy with TKI after 
chemotherapy.
Results: 
S555Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 1 - COMBINED MODALITY  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.09-014 PROGNOSTIC VALUE OF AGE IN PATIENTS 
RECEIVING CONCURRENT CHEMORADIOTHERAPY 
WITH DIAGNOSIS OF STAGE IIIB NON-SMALL CELL 
LUNG CANCER
Erkan Topkan1, Cem Parlak1, Ozan C. Guler1, Ugur Selek2
1Department Of Radiation Oncology, Baskent University Medical Fa-
culty/Turkey, 2Department Of Radiation Oncology, American Hospital, 
University Of Texas MD Anderson Radiation Oncology Center/Turkey
Background: In this study, prognostic role of age in stage IIIB non-
small cell lung cancer (NSCLC) patients treated with definitive con-
current chemoradiotherapy (CRT) was investigated.
Methods: Medical records of 942 18-70years old stage-IIIB NSCLC 
patients treated between January 2007 and December 2011 were 
retrospectively evaluated. Patients received 60-66 Gy radiotherapy 
concurrently with 1-3 cycle cisplatin-based (q21) chemotherapy. 
Patients were divided into groups [Group 1= ≤45 years(N=145), 
Group 2= 45-70(N=680) and Group 3=70-80(N=117)] according 
to the cut-off ages defined in the literature. Moreover, a further 
age cut-off point that might potentially influence survival was 
researched from ROC analysis, and comparatively analyzed with 
other factors. Primary end point was the evaluation of association 
between treatment duration and overall survival (OS), and secon-
dary end points were progression-free survival (PFS) and locoregi-
onal PFS (LRPFS).
Results: Median follow-up for alive patients was 30.8 months 
(range 17.4-38.2), there was no statistically significant difference 
between groups in terms od demographic characteristics (p>0.05). 
Overall treatment was well-tolerated, and treatment-related mor-
tality was reported in only 7 (0.7%) cases, which was not different 
between groups (%1.4 vs. %0.6 vs. 0.9; p=0.87). The most com-
mon grad 3-4 hematological and non-hematological toxicities 
were leukopenia (%37.3; %35.9 (n=52) vs. %36.2 (n=243) vs. %45.3 
(n=53); p=0.26), and eosophagitis (%20.6 (n=194); %17.2 (n=25) 
vs. %20.7 (n=141) vs.%23.9 (n=28); p=0.36), respectively. Median 
OS for whole group was 23.6 months (%95 CI: 22.8-24.3). Results 
of comparative survival analyses between 3 groups were given in 
Table, and there was no statistically significant survival difference 
between groups in all survival measures. Moreover, no significant 
age cut-off that might be used to evaluate age as prognostic factor 
could be determined from ROC analyses. 
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P1.09-013 THORACIC MULTIDISCIPLINARY CLINIC 
(TMDC) AND THE TREATMENT OF STAGE III NON-
SMALL CELL LUNG CANCER
Eliot L. Friedman1, Michael F. Szwerc2, Robert Kruklitis3, Michael 
Weiss4
1Hematology - Medical Oncology, Lehigh Valley Health Network/United 
States Of America, 2Cardiothoracic Surgery, Lehigh Valley Health Net-
work/United States Of America, 3Pulmonary Medicine, Lehigh Valley 
Health Network/United States Of America, 4Network Of Research Inno-
vation, Lehigh Valley Health Network/United States Of America
Background: Treatment of stage III NSCLC involves surgery, radia-
tion therapy and chemotherapy. This treatment varies, depending 
on the size and location of the primary tumor and lymph nodes 
as well as the clinical status of the patient. Evaluation of these 
patients should take place in a multidisciplinary clinic, where all 
treating physicians and pulmonary medicine provide a unified 
treatment plan.
Methods: We performed a retrospective analysis of all patients 
with Stage III NSCLC seen at the Lehigh Valley Health Network 
(LVHN) between March of 2010 and March of 2012. We compared 
the initial treatment of patients seen in our TMDC with those pati-
ents whose treatment was arranged outside the TMDC.
Results: Thirty-five patients were seen in the TMDC (34 treated 
at LVHN) and forty-four patients were seen outside the MDC (34 
treated at LVHN). The 11 patients not treated at LVHN either were 
not treatable or were treated elsewhere. Of patients with stage III 
NSCLC, 37.5% were seen in the TMDC year 1 (March 2010 – March 
2011) as compared year 2 (March 2011 – March 2012) during which 
over 61% of patients seen in the TMDC (p = 0.05). Patients were 
seen by physicians from at least two specialties 100% of the time 
when seen in the TMDC, but only 64.7% of the time when seen 
outside the TMDC (p < 0.001). Mediastinal staging by either endo-
scopic bronchoscopic ultrasound (EBUS) or mediastinoscopy was 
performed more frequently in patients seen in the TMDC; 58.9% 
compared to 23.5% outside the TMDC (p = 0.009). The LVHN cli-
nical pathway for stage III NSCLC recommends initial therapy with 
concomitant weekly chemotherapy and radiation either in the neo-
adjuvant setting or as definitive treatment. Eighty-eight percent of 
patients seen in the TMDC followed our clinical pathway while 46% 
of patients seen outside the TMDC conformed to the clinical pa-
thway (p < 0.001). The time from first contact with a treating phy-
sician to initiation of treatment was reduced by almost 30% (29.03 
days outside the TMDC; 20.62 days at the TMDC).
Conclusion: All patients with stage III NSCLC should be seen in a 
multidisciplinary setting. At LVHN we saw an increase in these pa-
tients being referred to our TMDC over time. These patients were 
more likely to have mediastinal staging and enjoyed quicker initi-
ation of their therapy. They were more likely to have at least two 
physicians involved in their initial treatment plan and were more 
likely to conform to our clinical pathways.
Keywords: Stage III NSCLC, Multidisciplinary Clinic, Clinical Pa-
thways
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taxane (q21) doublet chemotherapy. For all analyses, patients 
were divided into two groups according to their pretreatment TC: 
Group-1: normal (130.000-400.000; n=639) and Group-2: high 
(>400.000; n=153). Primary and secondary end points were overall 
survival (OS), and progression-free survival (PFS), respectively.
Results: At a median follow-up of 23.1 months (range 18.8-24.6), 
Median PFS and OS for whole group were 10.1 (%95 CI: 9.7-10.5) 
and 20.9 months (%95 CI: 20.9-22.9), respectively. On comparative 
survival analyses, patients with high pretreatment TC had inferior 
OS (23.2 vs. 15.6 months; p≤0.001) and PFS (10.6 vs. 7.8 months; 
p<0.001) than those with normal TC. Similarly, 3-years OS was 
significantly lower in Group-2 patients (8.9 vs. 33%, p<0.001). TC 
cut-off value determined from ROC curve analysis was 278.000, 
and median OS (18.7 vs. 24.5 months; p<0.001 and PFS (9.1 vs. 
11.3 months, p<0.001) was significantly lower in patients with TC 
above this cut-off point. On univariate analyses, T-stage (T1-2 vs. 
3-4), N-stage (N2 vs. N3), pretreatment TC (130.000-400.000 vs. 
>400.000), and ROC TC cut-off (<278.000 vs. ≥278.000) were the 
significant prognostic factors (p<0.05 for each), which retained 
their significance on multivariate analyses as well (p<0.001, 0.022, 
<0.00, 0.01, respectively).
Conclusion: Results of this study has shown that pretreatment TC 
may be a relevant and independent prognostic factor that can po-
tentially be used besides other well-known factors to predict treat-
ment outcomes in LA-NSCLC patients treated with definitive CRT.
Keywords: Concurrent chemoradiotherapy, locally advanced non-
small cell lung cancer, pretreatment thrombocyte count
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P1.09-016 A SINGLE ARM, MULTI-CENTER, PHASE II 
STUDY OF INTERCALATED ERLOTINIB WITH GEMCI-
TABINE/CISPLATIN AS NEOADJUVANT TREATMENT IN 
STAGE IIIA NON-SMALL CELL LUNG CANCER (CTONG 
1101, NCT01297101): PRELIMINARY RESULT
Shun Lu1, Gening Jiang2, Zhiwei Chen1, Xin Wang3, Qingquan Luo1
1Shanghai Lung Cancer Center, Shanghai Chest Hospital Affiliated To 
Jiaotong University/China, 2Department Of Thoracic Surgery, Shanghai 
Pulmonary Hospital/China, 33. Department Of Oncology Surgery, Sun 
Yat-Sen University Cancer Centre (sysucc), Guangzhou, China/China
Background: The optimal treatment for stage IIIA non-small cell 
lung cancer (NSCLC) disease is not well established with only 15% 
of 5-year survival rate, probably due toalready micro-metastatic le-
sion at the diagnosis. Thus, neoadjuvant therapy might be a good 
choice for IIIA NSCLC patients. The treatment modality of EGFR 
(TKI) intercalated with chemotherapy has been demonstrated to 
significantly improve objective response rate (ORR), progression 
free survival(PFS) and overall survival (OS) in advanced NSCLC 
patients with or without activating EGFR mutations. The objective 
of this study is to assess the efficacy and safety profile of intercala-
ted erlotinib with gemcitabine/cisplatin as neoadjuvant treatment 
in stage IIIA NSCLC.
Methods: This is a single arm, multi-center, clinical phase II trial. 
Patients with untreated stage IIIA bulky N2 NSCLC and ECOG PS 
0/1 were enrolled to received up to 2 cycles of gemcitabine 1,000 
mg/m2 on days 1 and 8 and cisplatin 75 mg/m2 on day 1 or carbo-
platin AUC=5 d1, followed by oral erlotinib (150 mg, once a day) on 
Table: Comparative survival analyses  
Survival 
Group 1 
≤45 years 
(N=145) 
Group 
2 45-70 
(N=680) 
Group 
3= 70-80 
(N=117) 
P 
Overall Sur-
vival Median 
(%95 CI) 2 
years 3 years 
4 years 5 
years 
24.8 (22.3-
27.3) 51.9 38.0 
24.2 24.2 
23.4 (22.5-
24.3) 46.8 
30.2 23.2 
19.2 
21.2 (17.3-
25.1) 47.5 
27.6 14.3 
14.3 
0.32 
Locoregional 
Progression-
free Survival 
Median (%95 
CI) 2 years 3 
years 4 years 
5 years 
15,7 (12,2-19,2) 
33.3 25.5 12.2 
12.2 
14,7 (14,2-
15.2) 22.1 
18.5 15.6 
12.6 
14.7 (13,9-
15.5) 27.4 
26.4 9.2 
9.2 
0.13 
Progression-
free Survival 
Median (%95 
CI) 2 years 3 
years 4 years 
5 years 
12.0 (9.9-14.1) 
24.3 18.2 11.2 
11.2 
10.6 (10.1-
11.1) 17.5 
15.1 13.4 
12.5 
10.6 
(10.0-11.1) 
20.3 18.2 
7.3 7.3 
0.18 
Conclusion: Results of this study has demonstrated that age was 
not a prognostic parameter that could be used alone to predict 
outcomes in stage IIIB NSCLC treated with CRT. The observation 
that patients >70 years old could also tolerate aggressive CRT pro-
tocols, treatment of elderly patients with good performance status 
and no comorbidity with protocols similar to younger counterparts 
is recommended
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P1.09-015 IMPACT OF PRETRETMENT LEUKOCYTOSIS 
ON PROGNOSIS IN LOCALLY ADVANCED NON-SMALL 
CELL LUNG CANCER PATIENTS TREATED WITH CON-
CURRENT CHEMORADIOTHERAPY
Erkan Topkan1, Cem Parlak1, Berrin Pehlivan2, Ozgur Ozyilkan3, 
Ugur Selek4
1Department Of Radiation Oncology, Baskent University Medical Fa-
culty/Turkey, 2Department Of Radiation Oncology, Medstar Antalya 
Hospital/Turkey, 3Department Of Medical Oncology, Baskent University 
Medical Faculty/Turkey, 4Department Of Radiation Oncology, American 
Hospital, University Of Texas MD Anderson Radiation Oncology Cen-
ter/Turkey
Background: Purpose of this study was to evaluate the association 
between pretreatment thrombocyte count (TC) and prognosis in 
locally advanced non-small cell lung cancer (LA-NSCLC) patients 
treated with concurrent chemoradiotherapy (CRT).
Methods: Medical records of 792 LA-NSCLC patients, who had 
been treated with definitive CRT at our department between dates 
January 2007 and December 2011, and whose pretreatment TC 
values are available, were retrospectively evaluated. All patients 
received 60-66 Gy thoracic 3-dimentional conformal radiothera-
py concurrently with 1-3 cycle cisplatin/carboplatin-vinorelbine/
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received Temozolamide were continued either till progression or 
unacceptable toxicity.
Results: 41 patients - 24 men and 16 women with proven advan-
ced Non Small Cell Lung Cancer (NSCLC) who were on treatment 
and developed brain metastasis, which was not operable or ami-
cable to stereotactic radiotherapy.  
Radiotherapy 
(n=20) 
Radiotherapy & Low 
Dose Temozolamide 
(n=21) 
Median Karnofsky 
Score 
> 60 > 60 
Response Rate 7 (35%) 12 (57%) 
Complete Response 1 (5%) 5 (24%) 
Partial Response 4 (20%) 7 (33%) 
Stable Disease 3 (15%) 3 (14%) 
1 year survival rate 6 (30%) 14 (67%) 
Median Overall 
Survival 
9.2months 17.6months 
Thrombocytopenia 
Grade III/IV 
3 (15%) 5 (24%) 
Neutropenia Grade 
III/IV 
1 (5%) 2 (10%) 
Anemia Grade III/IV 3 (15%) 6 (29%) 
 
Conclusion: Metronomic dosing of temozolamide with concurrent 
whole brain radiation is an effective option in treatment of brain 
metastasis from Non Small Cell Lung Cancer (NSCLC). The median 
survival time is almost doubled. Side-effects are manageable.
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P1.09-018 PEMETREXED AND CARBOPLATIN CONCO-
MITANT WITH THORACIC RADIOTHERAPY IN TREAT-
MENT OF ELDERLY PATIENTS WITH NON- SQUAMOUS 
NON SMALL CELL LUNG CANCER (NSCLC): INSTITUTIO-
NAL EXPERIENCE
Sherif Abdelwahab1, Dina Salim1, Zeinab Abdelhafiez1, Iman Fou-
ad1, Amr Mahmoud2, Hussein Shalabi3
1Clinical Oncology, Ain Shams University/Egypt, 2Radiodiagnosis, Ain 
Shams University/Egypt, 3Chest Diseases, Ministry Of Health, Abbas-
sia Chest Hospital/Egypt
Background: Concomitant chemoradiotherapy is the standard 
treatment of unresectable stage IIIA/IIIB non- small cell lung can-
cer (NSCLC). However, the optimal chemotherapy regimen is still 
controversial. Therefore; we conducted this prospective clinical tri-
al to evaluate the efficacy and safety of pemetrexed and carbopla-
tin when given concomitantly with thoracic radiotherapy followed 
by consolidation therapy of pemetrexed and carboplatin in elderly 
patients with locally advanced non-squamous NSCLC
Methods: Thirty seven patients with previously untreated, unre-
sectable stage IIIA or IIIB non-squamous NSCLC with ECOG PS 
days 15 to 28 as neoadjuvant therapy. A repeat computed tomo-
graphy (CT) scan evaluated the response after induction therapy 
and eligible patients would undergo surgical resection. The pri-
mary endpoint was ORR, and secondary endpoints included pCR, 
resection rate, DFS (disease free survival) and OS , safety, QoL and 
biomarker analyses. Subgroup analysis of ORR by EGFR mutation 
status was also performed
Results: Between March 2011 and December 2012, a total of 39 
patients were enrolled in the study, in which 36 patients (92.3% ITT 
population) have completed 2-cycle neoadjuvant treatment. Accor-
ding to Response Evaluation Criteria in Solid Tumors (RECIST) cri-
teria, 18 patients achieved partial response (PR) (ORR=46.2%) and 
18 patients achieved stable disease (SD) (DCR=92.3%); 22(56.4%) 
patients underwent resection with 18 R0 (46.2%), 2 R1(5.1%),1 
R2(2.6%),1 NE(2.6%). Fifteen patients have had EGFR mutation test, 
with 7 EGFR mutation and 8 EGFR wild type. ORR in patients with 
EGFR mutations and wild type was 85.7%(6/7) vs. 50%(4/8), res-
pectively. Common toxicities included myelosuppression (38.5%), 
rash (28.2%), neutropenia (5.1%), alanine transaminase (ALT) eleva-
tion(5.1%), diarrhea(5.1%) , fatigue(2.6%) and alopecia(2.7%) . Five 
(12.8%) patients suffered from CTCAE ≥3. No CTCAE ≥4 complica-
tions were recorded perioperatively.
Conclusion: Two cycles of intercalated administered gemcitabine/
cisplatin with erlotinib as an induction treatment is a feasible and 
efficacious approach for stage IIIA NSCLC, which provides evi-
dence for the further investigation.
POSTER SESSION 1 - COMBINED MODALITY  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.09-017 CONTINUOUS LOW DOSE TEMOZOLAMIDE 
IN BRAIN METASTASIS FROM LUNG CANCER
Tanweer Shahid1, Gouri Shankar Bhattacharyya2, Hemant Malho-
tra3, Kanaka Govindbabu4, Purvish M. Parikh5, A A B Ranade6, G 
Biswas7, Shailesh Bondarde8, Saumen Basu9
1Radiation Oncology, Apollo Hospital/India, 2Medical Oncology, H.O.D. 
Medical Oncology, Fortis Hospital Anandapur, Amri Hospital And Or-
chid Nursing Home,/India, 3Medical Oncology, Sms Medical College & 
Hospital/India, 4Medical Oncology, Kidwai Memorial/India, 5Icon-aro,/
India, 6Medical Oncology, Deenanath Mangeshkar Hospital,/India, 
7Medical Oncology, Sparsh Hospital/India, 8Medical Oncology, Shatabdi 
Super Specialty Hospital/India, 9Radiation Oncology, Amri, Dhakuria/
India
Background: Metastasis of Lung cancer to Brain is associated with 
poor prognosis despite aggressive treatment. Available treatment 
options are limited beside radiotherapy as most drugs do not 
penetrate the blood brain barrier. Temozolamide has a good sa-
fety profile and crosses the blood brain barrier. One of the novel 
methods of delivering temozolamide is to use metronomic dosing 
which also has anti angiogenic properties, other than cytotoxic 
properties.
Methods: Eligible patients had to have confirmed Non Small Cell 
Lung Cancer (NSCLC) with no prior radiotherapy or radio-surgery 
for brain metastasis; with multiple brain metastasis. All patients 
were treated with Temozolamide 20mg in empty stomach twice a 
day continuously. Radiation was given to these patients as stan-
dard procedures. This was compared only to standard whole brain 
radiation. All patients continued on standard planned chemothe-
rapy which was paclitaxel + carboplatinum and patients who had 
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patient and was administered with curative intent, with or without 
chemotherapy, to the rest of patients of stage IIIA. All the patients 
in stage IIIB disease (177 patients) received curative radiotherapy 
with or without chemotherapy. Conventional daily 3-D radiothera-
py at standard fractionation was used and median dose of radio-
therapy was 50 Gy in adjuvancy and 66 Gy (range 2-70) in curative 
intention. EGFR gene mutation determination was performed in 99 
patients.
Results: Five-year overall survival for all patients is 22.8%, with a 
median survival of 22 months. By stage, 5-year overall survival is 
29% for stage IIIA (median survival of 26 months) and 16.2% for 
stage IIIB (median survival of 20 months). Five-year overall survival 
for non-surgical stage IIIA disease is 17.1%, being the median survi-
val 18 months and showing no difference with patients with stage 
IIIB disease. For the 99 patients analyzed for the EGFR gene status, 
the mutation was present in 9 patients while 90 patients were wild 
type. The overall 5-year survival for the patients whom the EGFR 
mutation was determined is 24% (median of 30 months) and there 
is no difference with the survival found for all patients. The EGFR 
gene status mutation does not imply a difference in survival.
Conclusion: The survival for stage III non-small cell lung cancer 
remains about 15% at 5 years and there is no difference for inope-
rable stages IIIA and IIIB. Median survival has achieved 20 months, 
which is better than the previous observed in the last decade of 
twentieth century. Given the small size of the sample with EGFR 
gene mutation (9 cases) we cannot conclude whether or not this 
factor has a prognostic value.
Keywords: locally advanced non-small cell lung cancer, EGFR 
gene status mutation, Combined treatment
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P1.09-020 CLINICAL GUIDELINE ADHERENCE IN  
LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER: 
A SOUTH WESTERN SYDNEY PERSPECTIVE
Kirsten J. Duggan1, Shalini K. Vinod2, Joseph Descallar2
1Sws&slhd Clinical Cancer Registry, Liverpool Hospital/Australia, 
2Ingham Institute For Applied Medical Research, Liverpool Hospital/
Australia
Background: Stage III non-small cell lung cancer (NSCLC) typically 
represents up to one third of all new NSCLC diagnoses, and can be 
a technically difficult and controversial group of patients to defini-
tively manage. In 2004, the National Health and Medical Research 
Council published a set of evidence based clinical guidelines for 
the management of lung cancer in Australia. This study aims to 
investigate adherence to these national guidelines in the treatment 
of Stage III cancers and identify factors associated with the receipt 
of guideline recommended therapy (GRT) and patient survival.
Methods: A retrospective cohort of newly diagnosed, Stage III 
NSCLC was identified from the South Western Sydney (SWS) Local 
Health District Clinical Cancer Registry. Cases were diagnosed 
between 2006 and 2011 and resided within SWS local postcode 
boundaries. Pre-2010 diagnosed “wet” stage IIIB cases with mali-
gnant pleural effusion were excluded from analysis. GRT was assi-
gned to each case based on stage group and performance status 
(ECOG) at diagnosis. Significant factors associated with adherence 
to GRT and the effect these factors had on patient survival was 
of ≤2, ≥65years old, and had adequate organs functions were 
enrolled into the study between August 2010 and April 2013. Pati-
ents received pemetrexed 500 mg/m2 and carboplatin area under 
the curve (AUC) 5 on day 1 repeated every 3 weeks concomitant 
with thoracic radiotherapy 60-66 Gy over 6-6.5 weeks, followed by 
pemetrexed and carboplatin for 3 cycles as consolidation therapy. 
Treatment response, toxicity, progression free survival and overall 
survival were evaluated.
Results: The median age was 71 (range 65-79). Twenty seven pati-
ents (73%) were men. Twenty four patients (65%) had Stage IIIB and 
13 patients (35%) had stage IIIA. Performance status was measured 
by ECOG and it was 0 in 23 patients (62%), 1-2 in 14 patients (38%). 
Eight (22%) patients had a complete response, 22 (59%) patients 
had partial response, while 5 (14%) patients had a stable disease 
and 2 (5%) patients had a progressive disease. The overall respon-
se rate (81%, 95% confidence interval (CI): 68-96%).The median PFS 
was 11 months (95% CI: 9.8-12.9 months).Grade 3/4 toxicity were 
reported as neutropenia in 12 (32%) patients; thrombocytopenia 
in 9 (24%) patients; anemia in 7 (19%) patients; vomiting in 3 (8%) 
patients; dysphagia in 2 (5%) patients, radiation pneumonitis in 2 
(5%) patients and fatigue in 3 (8%) patients. No treatment related 
deaths (neither due to sepsis nor bleeding) were reported in the 
study.
Conclusion: Concomitant chemoradiotherapy using full doses of 
pemetrexed and carboplatin for treatment of elderly patients with 
locally advanced non-squamous NSCLC is a safe and effective re-
gimen and it needs enrolling more patients to confirm the current 
results.
Keywords: NSCLC, Carboplatin, elderly, pemetrexed
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P1.09-019 SURVIVAL ANALYSIS AND EGFR GENE  
MUTATION STUDY FOR LOCALLY ADVANCED NON-
SMALL CELL LUNG CANCER IN PATIENTS TREATED 
WITH CURATIVE INTENTION.
Josep Jove1, Antonio Arellano1, Erika Mijangos2, Mónica Caro1, 
Victòria Tuset1, Anabel Mañes1, Rosa Ballester1, Isabel Planas1, 
Ana Álvarez1, Salvador Villà1, Sílvia Comas1, Ernest Luguera1, Álex 
Melero1, Jaume Molero1, Geovanna Pérez1
1Radiation Oncology, Ico Hospital Germans Trias I Pujol/Spain, 2Medical 
Oncology, Ico Hospital Germans Trias I Pujol/Spain
Background: On 2005 began the EGFR gene mutations determi-
nation in our Centre. We want to know the survival of patients with 
locally advanced non-small cell lung cancer treated with radical 
intention and to determine if there is a dependency for the EGFR 
gene mutation status.
Methods: We have treated 399 patients with locally advanced 
non-small cell lung cancer from 2005 until now. Mean age is 63,38 
years (range 26-86). By gender, 346 patients were males (87%) and 
53 were females (13%). All the patients were treated in our Depart-
ment of Radiation Oncology. Squamous cell carcinoma was found 
in 188 patients (47%), adenocarcinoma in 169 patients (42%) and 
42 patients (11%) had large cell or undifferentiated carcinomas. 
The majority of cases of radical treatment received concomitant 
radiotherapy and chemotherapy. Radiotherapy in stage IIIA (222 
patients) was adjuvant to surgery in 53 cases, preoperatory in 1 
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who had PET/CT was 30 months (p:0.098). Thirtythree patients re-
lapsed on follow-up; of these 28 presented with symptoms, 17 was 
detected with CT, 5 with MRI of brain and 12 with PET/CT.
Conclusion: Response evaluation with PET/CT after CRT in stage 
III NSCLC might prolong survival in this selected group of patients. 
But during the follow-up period PET/CT might not be as beneficial 
as expected, because most of the patients present with symptoms 
on relapse. Further clinical well designed studies should be done 
in this field, because usage of PET/CT for follow-up is increasing in 
the entire world. PET/CT might be unnecessary in the follow-up of 
stage III NSCLC patients after initial response evaluation.
Keywords: Combined Modality Therapy, Positron-Emission To-
mography and Computed Tomography, carcinoma, non-small-cell 
lung
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P1.09-022 A MULTICENTER, RANDOMIZED, OPEN-
LABEL, PHASE II TRIAL OF ERLOTINIBVERSUS ETOPOSI-
DEPLUS CISPLATINWITH CONCURRENT RADIOTHERAPY 
IN UNRESECTABLESTAGE III NON-SMALLCELL LUNG 
CANCER (NSCLC) WITH ACTIVATING MUTATION OF EPI-
DERMAL GROWTH FACTOR RECEPTOR (EGFR) IN EXON 
19 OR 21(RECEL, ML28545, NCT01714908)
Ligang Xing1, Minglei Zhuo2, Lvhua Wang3, Ming Chen4, Shenglin 
Ma5, Tingyi Xia6, Xiaolong Fu7, Jinming Yu1, You Lu8
1Department Of Radiation Oncology, Shandong Cancer Hospital And In-
stitute/China, 2Beijing Cancer Hospital/China, 3Cancer Institute, Chine-
se Academy Of Medical Sciences/China, 4Department Of Radiotherapy 
Oncology, Zhejiang Cancer Hospital/China, 5Department Of Radiation 
Oncology, The First People‘s Hospital Of Hangzhou/China, 6Department 
Of Radiation Oncology, Air Force General Hospital/China, 7Radiation 
Oncology, Fudan University Shanghai Cancer Center, Shanghai, China/
China, 8Department Of Radiation Oncology, West China School Ofmedi-
cine, Sichuan University/China
Background: The standard treatment for unresectable stage IIIA/
IIIB NSCLC patients with good PS is concurrent chemo-radiothe-
rapy. However, local tumor control remains suboptimal and distant 
metastases remain the major failure. Moreover, the treatment re-
lated toxicities limit application. EGFR-targeting agents including 
tyrosine kinase inhibitor (TKI)such as erlotinibwere demonstrated 
to sensitize tumor cells to radiation by a variety of mechanisms in 
preclinical studies. Subsequently, Phase I/II studies forcombination 
of TKI with radiotherapy in different cancer types have been con-
ducted. Based on those findings, the RECEL study is comparing 
efficacy and tolerability of erlotinib versus etoposide plus cisplatin 
with concurrent radiotherapy in unresectablestage III NSCLC with 
activating mutation of epidermal growth factor receptor (EGFR) in 
exon 19 or 21.
Methods: The study was designed as a prospective, open-labeled, 
randomized, multicenter phase II clinical trial.Patients aged bet-
ween 18 and 75 with ECOG PS 0–1IIIA/IIIB NSCLCconfirmed by 
histopathology or cytology and clinically unresectablewith acti-
vating mutation ofEGFR in exon 19 (loss) or 21 (L858R point muta-
tion)will be enrolled (n=100). The enrolled patientswould be ran-
domly assigned (1:1) into two arms: erlotinibarm(erlotinib 150mg/
day taken orally for up to 2 years which begin on day 1 of radiation) 
or EP chemotherapy arm(etoposide50mg/m2I.V. on days 1-5 and 
determined using univariate analysis and Cox proportional hazards 
regression model.
Results: Of 316 eligible cases identified, 19 patients (6%) had no 
ECOG documentation found, and were excluded from the analysis. 
Median age of the remaining cohort was 69 years, and 64% were 
male. Disease stage distribution was 58% for IIIA cases and 42% 
for IIIB. 85% of patients were identified as having Good ECOG (0-
2) at diagnosis. Overall 55% of the total; 63% of IIIA and 46% of IIIB 
patients received GRT. 24% of IIIA patients received surgery alone 
in combination with chemotherapy and/or radiotherapy. 31% of IIIB 
patients received either concurrent or combination chemo-radiati-
on. On univariate analysis, the receipt of GRT was associated with 
patient age (p <0.001), disease stage (p 0.003), and performance 
status (p <0.001). Morphological subtype was trending (p 0.056). 
Overall median survival was 11.4 months. Patient survival was not 
significantly improved with the receipt of GRT.
Conclusion: Adherence to GRT was associated with tumour stage, 
patient age and performance status. In this cohort of patients, the 
receipt of GRT did not have a significant impact on survival.
Keywords: NSCLC, guideline treatment, Advanced, survival
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P1.09-021 IS PET/CT A BETTER TOOL THAN CT IN RE-
SPONSE EVALUATION AND FOLLOW-UP OF STAGE III 
NON-SMALL CELL LUNG CANCER AFTER CHEMORA-
DIOTHERAPY?
Perran F. Yumuk1, Mehmet Besiroglu1, Faysal Dane1, Metin 
Kanıtez1, Bilge Aktas1, Hale Caglar2, Bedrettin Yıldızeli3, Fuat 
Dede4, Besrte Atasoy2, Nazim S. Turhal1
1Medical Oncology, Marmara University Medical School/Turkey, 2Radi-
ation Oncology, Marmara University Medical School/Turkey, 3Thoracic 
Surgery, Marmara University Medical School/Turkey, 4Nuclear Medici-
ne, Marmara University Medical School/Turkey
Background: Although pretreatment evaluations are well defined 
for the diagnosis of stage III NSCLC, we have very little data about 
the follow-up of these patients after completion of therapy. No do-
cumented standards for surveillance were set in the NCCN, ACCP 
or ESMO guidelines. To determine if there is a survival difference 
in stage III NSCLC patients who were followed by PET/CT or CT 
after chemoradiotherapy.
Methods: Data from 50 patients who were treated with CRT in 
Marmara University Medical Oncology clinics between 2003-2012 
were retrospectively reviewed. All patients were followed-up by 
CT or PET/CT. Median age was 57 (range 29-73 years), 90% were 
male, and PS was 0 in 74%. Adenocarcinoma was seen in 28% and 
squamous cell carcinoma in 48%. PET/CT was done in 86% of pati-
ents during metastatic workup. Median follow-up was 17 months. 
Median overall survival for all patients was 26 months (range 
3-70 months) and progression free survival was 10 months (3-63 
months).
Results: PET/CT was used in 58% of the patients to evaluate re-
sponse and was done a median of 6 months after the first treat-
ment. Eight patients had complete, 23 had partial response and 4 
had progressive disease. Median survival was 18 months in patient 
who were followed by CT scans, whilst the survival in the group 
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P1.10-001 PHASE II STUDY OF BEVACIZUMAB AND 
ERLOTINIB IN PATIENTS WITH NON-SQUAMOUS NON-
SMALL LUNG CANCER THAT IS REFRACTORY OR RE-
LAPSED AFTER 1-2 PREVIOUS TREATMENT (BEST STU-
DY)
Kazuhiro Yanagihara1, Shiro Tanaka2, Miyuki N. Niimi2, Katsuhiro 
Masago3, Yosuke Togashi3, Hiroki Nagai3, Young Hak Kim3, Junichi 
Nikaidou4, Masataka Hirabayashi4
1Translational Clinical Oncology, Kyoto University/Japan, 2Clinical Trial 
Design And Management, Translational Research Center, Kyoto Univer-
sity/Japan, 3Respiratory Medicine, Kyoto University/Japan, 4Respiratory 
Medicine, Hyogo Prefectural Amagasaki Hospital/Japan
Background: We report the interim-analysis result of the BEST tri-
al, which examines efficacy and safety of second- or third-line che-
motherapy with erlotinib (E) and bevacizumab (B) for the Japanese 
patients (pts) with non-squamous, non-small cell lung cancer.
Methods: E was administered initially at 150 mg/day orally and B 
was administered at a dose of 15 mg/kg on the first day of each 
3-week cycle. The primary endpoint was objective response rate 
(RR). The secondary endpoints included overall survival (OS), 
progression-free survival (PFS), disease control rate (DCR) and in-
cidence of adverse events. This trial was planned to accrue 80 pts 
based on a two-stage design employing a binomial distribution 
with an alternative hypothesis response rate of 35% and a null hy-
pothesis threshold response rate of 20%. A subset analysis accor-
ding to EGFR mutation status was planned (Trials. 2011; 12: 120).
Results: Total of 28 pts enrolled in 2 years from November, 2010. 
One patient was excluded due to thrombosis in lower limb and 27 
pts (15 men and 12 women) with a median age of 67 (43-82) were 
analyzed; 18 pts had a PS of 0; all had adenocarcinoma; 11 pts had 
EGFR mutation; 1 patient had stage IIIB, 23 pts had stage IV and 
3 pts had recurrences after surgery; 21 pts received as second-
line and 6 pts received as third-line chemotherapy. RR was 18.5% 
(p=1.00; one-sided); DCR was 77.8%. Median PFS was 5.6 months 
(m); OS data were not yet mature (median follow-up time was 11.9 
m). Grade 3/4 non-hematologic toxicities were mainly acne (11.1%) 
and hypertension (11.1%). The subset analysis according to EGFR 
showed significantly higher RR (p=0.02) and better PFS (p=0.03) 
in mutant group than in wild group. RR in mutant group was 
compared with 20% null hypothesis using the same binomial test 
(p=0.056).
Conclusion: Combination therapy of B and E had mild adverse 
effects but did not increase anti-cancer effect.
Keywords: erlotinib, Bevacizumab, phase II, 2-3 treatment
days29-33,cisplatin50mg/m2I.V. after etoposideon days 1,8,29,36. 
28-day schedule for 2 cycleswhich begin on day 1 of radiation).
Concurrent radiotherapy in both arms is prescribed at 200cGy/
day, 5 days/week for a total of 30-33 fractions, total dose of 6000-
6600cGy. Duration of the recruitment will be 36 months. Patients 
will receive long-term follow-up including chest and upper-abdo-
minal CT scan every 3months, brain MRI every 6 months and bone 
scan every 12 months. Primary endpoint is progress free survival 
(PFS). Secondary endpoints areobjective response rate(ORR), local 
control rate (LCR), overall survival (OS), quality of life (QoL) and 
safety.Biomarker profile will be the exploratory research.
Results: Till June 2013, 24 patients were screened for EGFR muta-
tion, and 4patient has been enrolled.
Conclusion: Concurrent erlotinib with radiation therapy might be a 
promising treatment strategy.
Keywords: EGFR mutation, randomized, erlotinib concurrent ra-
diotherapy, unresectable stage III NSCLC
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P1.10-003 ALTERATION OF THE E-CADHERIN/Β-
CATENIN COMPLEX PREDICTS POOR RESPONSE TO 
EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE 
KINASE INHIBITOR (EGFR-TKI) TREATMENT
Seol Bong Yoo1, Yu Jung Kim2, Hyojin Kim3, Yan Jin3, Ping-Li Sun3, 
Sanghoon Jheon4, Jong Seok Lee2, Jin-Haeng Chung3
1Pathology, Presbyterian Medical Center/Korea, 2Internal Medicine, 
Seoul National University Bundang Hospital, Seoul National Univer-
sity College Of Medicine/Korea, 3Pathology, Seoul National University 
Bundang Hospital, Seoul National University College Of Medicine/Ko-
rea, 4Thoracic And Cardiovascular Surgery, Seoul National University 
Bundang Hospital, Seoul National University College Of Medicine/Korea
Background: Epidermal growth factor receptor (EGFR) mutation 
alone may be insufficient to predict clinical outcomes in the res-
ponse to EGFR-tyrosine kinase inhibitor (TKI) therapy. The secon-
dary mutation T790M and MET amplification are mechanisms of 
acquired resistance to EGFR-TKI in approximately 50% of patients, 
but the remaining mechanisms are unknown.
Methods: Eight metastatic lesions and specimens from 41 non-
small cell lung carcinoma (NSCLC) patients harbouring activating 
EGFR mutations who underwent surgical resection and EGFR-TKI 
therapy were available. Immunohistochemistry was used to eva-
luate E-cadherin, β-catenin, and PTEN. Chromogenic in situ hyb-
ridisation and silver-enhanced in situ hybridisation were used to 
evaluate EGFR and MET amplification.
Results: Patients with E-cadherin/β-catenin alteration showed a 
poor objective response rate (ORR) (p=0.005) and shorter overall 
survival (p=0.059). Additionally, β-catenin alteration was associa-
ted with a poor ORR (p=0.012). In the metastatic tumours, 3 cases 
(37.5%) showed the acquisition of altered E-cadherin/β-catenin and 
PTEN loss, and 2 cases (25.0%) demonstrated MET/EGFR amplifi-
cation.
Conclusion: Altered E-cadherin/β-catenin expression in NSCLC 
harbouring EGFR mutations was associated with a poor res-
ponse to EGFR-TKI. During metastatic progression, changes in 
E-cadherin/β-catenin were found. These results may suggest that 
E-cadherin/β-catenin alteration is related to poor TKI response and 
resistance.
Keywords: Non-small cell lung carcinoma, Resistance., Epidermal 
growth factor receptor, E-cadherin, β-catenin, Tyrosine kinase in-
hibitor
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P1.10-002 COMPARISON OF THE TOXICITY AND EFFI-
CACY BETWEEN TOPOTECAN- AND BELOTECAN-, A 
NEW CAMPTOTHECIN ANALOG, MONOTHERAPY FOR 
SMALL CELL LUNG CANCER: A SINGLE INSTITUTIONAL 
EXPERIENCE
Bo Mi Park, Jeong Eun Lee, Sang Ock Jung, Jae Wook Jung, Dong Il 
Park, Hee Sun Park, Sung Soo Jung, Ju Ock Kim, Sun Young Kim, 
Jae Young Moon
Department Of Internal Medicine, Chungnam National University, 
School Of Medicine/Korea
Background: There has been no randomized controlled study for 
comparing tumor response, toxicity and survival between belote-
can- and topotecan- monotherapy in patients with SCLC. To aim of 
this study is to assess and compare tumor response, toxicity and 
survival between belotecan- and topotecan- monotherapy in pati-
ents with SCLC.Therefore, we try to help physicians to select drugs 
through a comparison of the efficacy and toxicity for both drugs in 
this study.
Methods: The clinical data of 94 patients treated with belotecan- 
(n=59, total 188cycles) or topotecan- (n=35, total 65cycles) mono-
therapy were reviewed retrospectively from September 2003 to 
December 2011. Hematologic and Nonhematologic toxicities were 
evaluated according to the Common Terminology Criteria for Ad-
verse Events (CTCAE) version 4.0. Statistical significance of Time to 
progressive disease (TTPD), chemotherapy-specific survival (CSS) 
and overall survival (OS) between the 2 chemotherapies were eva-
luated by the Kaplan-Meier analysis.
Results: There were no significant differences in baseline charac-
teristics between belotecan- and topotecan- monotherapy except 
the line of chemotherapy. The overall response rate was 12.7% 
in patients treated with belotecan monotherapy and 5% in topo-
tecan monotherapy. Thrombocytopenia was developed in 42% 
and 61.5% of cycles in belotecan- and topotecan- monotherapy, 
respectively (P = 0.007). In nonhematological toxicities, grade 4 
or 5 in lung infection, headache, grade 4 or 5 in elevation of liver 
enzyme developed in 3.2% and 10.8% (P=0.003), 3.2% and 10.8% 
(p=0.017), 0.5% and 4.6% (p=0.023) of cycles in belotecan- and 
topotecan- monotherapy, respectively. The median TTPD, CSS and 
OS were 14 months and 11.6 months (P=0.646), 10 month and 7 
month (P=0.179), 34.5 months and 21.4 months (P=0.914) in belote-
can- and topotecan- monotherapy, respectively.
Conclusion: In our experience, belotecan monotherapy seemed 
to be efficient compared with topotecan monotherapy in small cell 
lung cancer, with acceptable toxicity, especially in thrombocytope-
nia, severe lung infection and elevation of liver enzyme.
Keywords: belotecan, topotecan, small cell lung cancer
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sites at 16.5 months versus 11.4 months, p=0.1906 (HR=0.6605; 
95% CI: 0.355 – 1.229). Median PFS was also higher at academic 
sites at 6.9 months versus 4.6 months, p=0.9149 (HR =0.9690; 95% 
CI: 0.544 – 1.726). Drug-related grade 3/4 AEs in the Pem arm 
showed higher percentages for Caucasians with the exception of 
neutropenia, as follows: anemia (7.3%/15.9%), thrombocytopenia 
(9.8%/25.5%), fatigue (4.9%/11.5%), neutropenia (31.7%/25.3%), 
febrile neutropenia (0%/1.6%). Among AAs in the Pem/Pac Arm 
respectively, drug-related grade 3/4 AEs were: anemia (7.3%/0%), 
thrombocytopenia (9.8%/4.0%), fatigue (4.9%/4.0%), neutropenia 
(31.7%/44.0%), and febrile neutropenia (0%/4.0%).
Conclusion: There were no significant differences between AAs 
and Caucasians for OS, PFS, and ORR. Among AAs, median OS 
was not superior for either arm. PFS and OS were similar for aca-
demic and community settings among AAs. Caucasians had a 
significantly higher incidence of Grade 3/4 thrombocytopenia 
(p=0.0217), but this should be interpreted with caution due to the 
sample size for the AAs.
Keywords: paclitaxel, PointBreak, African Americans, pemetrexed
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P1.10-005 BEVACIZUMAB (BV) CAN BE SAFELY ADMI-
NISTERED IN PTS AGED > 80 YEARS OLD
Konstantinos N. Syrigos, Dimitrios Vassos, Meropi Panagiotarak-
ou, Georgios Tsoukalas, Georgios Athanasiadis, Evangelos Sepsas, 
Ioannis Gkiozos
Oncology Unit Gpp, Sotiria General Hospital/Greece
Background: Bv is a novel anti-angiogenic agent used in many ad-
vanced solid tumours, including non-squamous NSCLC. In contrast 
to clinical studies where enrolled pts are fit, many elderly NSCLC pts 
suffer from co-morbidities and often have history of a CVD
Methods: Medical records of 2672 pts diagnosed with NSCLC bet-
ween 2001-2012 were screened. We identified and examined pts 
≥75 yrs old treated with bev, for their demographics, clinical data 
and treatment (Tx) details. We focused on those elderly pts with 
stable pre-existing cardiovascular disease.
Results: 356/2672 NSCLC pts received Bv at any Tx line. 33/382 
(8,6%) were ≥75 yrs old. Of those, 29 had various co-morbidities 
including 19 pts with stable CVD on medical Tx. In the 19 pts with 
CVD the male:female ratio was 17:2 and mean age 77 yrs (range 
75-86). 8/19 pts had impaired renal function. All pts were of Per-
formance Status ECOG 0/1. Median number of Bv cycles was 5 
(range 2-11). 17/19 pts experienced ≥1 side effects (11 epistaxis and 
haemoptysis, 5 proteinuria, 4 hypertension) which led to treatment 
discontinuation in 5 pts. No major/fatal adverse events were noted. 
8/19 pts (42%) showed radiological partial response and 5 (19%) 
stable disease (total disease control rate 61%). Median survival from 
initiation of Bv till death/last follow up was 7 months (range 2-28, 
95% CI 5.14-12.55).
Conclusion: Treatment with Bevacizumab seems to be safe and 
effective in elderly NSCLC patients with controlled pre-existing car-
diovascular disease and good PS. These patients might benefit from 
participation in clinical trials similarly to younger NSCLC patients.
Keywords: NSCLC, elderly, comorbidities, chemotherapy
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P1.10-004 EXPLORATORY SUBSET ANALYSIS IN  
AFRICAN AMERICANS FROM THE POINTBREAK STUDY 
(RANDOMIZED PHASE 3 PEMETREXED + CARBOPLA-
TIN + BEVACIZUMAB FOLLOWED BY MAINTENANCE 
PEMETREXED + BEVACIZUMAB VERSUS PACLITAXEL + 
CARBOPLATIN + BEVACIZUMAB FOLLOWED BY MAIN-
TENANCE BEVACIZUMAB IN PATIENTS WITH STAGE IIIB/ 
IV   NONSQUAMOUS NON-SMALL CELL LUNG CANCER)
Craig Reynolds1, Jyoti D. Patel2, Edward Garon3, Mark R. Olsen4, 
Philip Bonomi5, Ramaswamy Govindan6, Coleman Obasaju7, Edu-
ardo J. Pennella7, Jingyi Liu7, Susan C. Guba7, David Spigel8, Robert 
C. Hermann9, Mark A. Socinski10
1Us Oncology Research/United States Of America, 2Feinberg School Of 
Medicine, Northwestern University/United States Of America, 3Trans-
lational Oncology, David Geffen School Of Medicine, University Of 
California/United States Of America, 4Cancer Care Associates/United 
States Of America, 5Rush University Medical Center/United States Of 
America, 6Washington University School Of Medicine/United States Of 
America, 7Eli Lillyand Company/United States Of America, 8Sarah Can-
non Research Institute/United States Of America, 9Northwest Georgia 
Oncology Centers, P.c./United States Of America, 10Hematology/Oncolo-
gy, University Of Pittsburgh/United States Of America
Background: African Americans (AA) have a higher rate of lung 
cancer than Caucasians per 100,000 population (74.7 versus 64.4) 
but are underrepresented in randomized clinical trials. In the Point-
Break study, AAs were enrolled at the same rate as the US inci-
dence of non-small cell lung cancer (NSCLC) for AAs in 2011 (13%; 
now 15% in 2013). Post-hoc analyses of the AA subgroup were 
conducted from this study to evaluate efficacy and safety, as well 
as these outcomes by treatment center.
Methods: All patients (N=939) were chemonaive with an ECOG 
performance status (PS) of 0/1. AAs were analyzed against Cau-
casians for efficacy/safety in the pemetrexed (Pem) arm only. Sub-
group analyses of AAs alone were conducted for efficacy/safety 
(between arm comparisons) as well as academic versus community 
settings (pooled two treatment arms). Hazard ratios and p-values 
were derived from a multivariate Cox-PH model, adjusting for di-
sease stage, gender, PS and measurable/nonmeasurable disease. 
Response rates and adverse events (AEs) were compared using the 
exact test.
Results: Patients had stage IIIb (with pleural effusion)/IV nonsqua-
mous NSCLC, according to AJCC edition 6. There were 94 AAs 
(42 = Pem arm; 52 = Paclitaxel [Pac] arm) and 805 Caucasians in 
the treated population. Demographics were statistically compa-
rable between AAs and Caucasians in the Pem Arm, respectively: 
62%/53% male, 71%/53% ≤65 years, 98%/89% ever smokers, 
81%/90% Stage IV disease, with ECOG PS of 0/1, 33%/67%, versus 
44%/56%. Median OS was similar between AAs and Caucasians in 
the Pem arm at 12.4 versus 12.3 months. Median PFS for AAs and 
Caucasians was 4.6 months versus 6.0 months (HR 1.229 (0.864 – 
1.749; p=0.251). Overall response rate (ORR) for AAs was higher, 
though not statistically, at 38.1% versus 33.3% (p=0.607). Efficacy 
among AAs was fairly similar with median OS for Pem arm at 12.4 
versus 13.7 months for Pac arm (p=0.1208). Median PFS by arm 
was 4.6 versus 5.1 months (p=0.6699). ORR among AAs was 38% 
in both arms. AAs showed a heavy trend (80%) for enrollment in 
community centers (n=74) versus academic center (n=20). Efficacy 
among AAs by setting showed a higher median OS at academic 
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P1.10-007 BIWEEKLY CISPLATIN AND GEMCITABINE AS 
FIRST-LINE TREATMENT IN ADVANCED NON-SMALL 
CELL LUNG CANCER
Mustafa Benekli1, Yusuf Gunaydin1, Mevlude Inanc2, Metin 
Ozkan2, Ayse Demirci3, Umut Demirci1, Ali Suner4, Halit Karaca2, 
Onder Tonyali5, Veli Berk2, Suleyman Buyukberber1
1Gazi University/Turkey, 2Erciyes University/Turkey, 3Ankara Oncology 
Hospital/Turkey, 4Gaziantep University/Turkey, 5Antakya State Hospi-
tal/Turkey
Background: Non-small cell lung cancer (NSCLC) is the most com-
mon cancer worldwide. Majority of the patients present with ad-
vanced disease. For patients with good performance status, pallia-
tive chemotherapy consisting of a platinum-containing doublet has 
become Standard of care. Cisplatin plus gemcitabine is a viable 
option in the treatment of metastatic NSCLC. Biweekly use of this 
regimen has been found to be effective and tolerable in various 
cancers. Moreover, this schedule offers a more convenient way of 
administration. We retrospectively evaluated the efficacy and tole-
rability of this regimen in advanced NSCLC patients.
Methods: Medical records of advanced NSCLC patients who were 
treated with first-line biweekly cisplatin + gemcitabine chemo-
therapy were analyzed retrospectively. Cisplatin 50 mg/m2 and 
gemcitabine 1000 mg/m2 were given on day 1 of every 14 days of 
the cycle. Response rates, survival outcomes and toxicities were 
recorded.
Results: A total of 109 patients were evaluated in six centers of 
Anatolian Society of Medical Oncology. Of those, 94 patients 
were men (86%) and 15 were women (14%). The median age was 
58 years (range, 25-82). Most of the patients had adenocarcinoma 
(n=62, 57%). All of them had ≤2 ECOG PS. Median 7 cycles therapy 
were given (range, 2-12). Patients were evaluated for response usu-
ally after every 4 cycles. There was no complete response. Forty-
five patients (41%) achieved partial response (PR). Stable disease 
was observed in 27% of the patients leading to an overall clinical 
benefit rate of 68%. Median progression-free survival (PFS) was 5.9 
months. Median overall survival (OS) was 12.6 months. Eight pati-
ents died due to progression during therapy. The most common 
non-hematologic toxicities were nausea and vomiting. Grade 3/4 
toxicity was detected in eight (7%) patients. They were four ane-
mias, two neutropenias, one vomiting and one nephropathy. In all 
grades, the most common hematologic toxicity was anemia (48%). 
Neutropenia was seen in 21% of the cases, but only one patient 
had febrile neutropenia. One patient had to discontinue therapy 
due to grade 2 nephropathy.
Conclusion: Biweekly cisplatin and gemcitabine is an effective and 
tolerable regimen in the first-line treatment of NSCLC.
Keywords: NSCLC, biweekly cisplatin and gemcitabine, advanced 
stage
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P1.10-006 EXAMINATION OF RECURRENCE PREDIC-
TORS IN CASES RECEIVING UFT AS POSTOPERATIVE 
ADJUVANT CHEMOTHERAPY FOR LUNG CANCER
Kimitoshi Nawa, Seisuke Nagase, Kouichi Yoshida, Yasufumi 
Kato, Masaru Hagiwara, Masatoshi Kakihana, Naohiro Kajiwara, 
Tatsuo Ohira, Norihiko Ikeda
Thoracic Surgery, Tokyo Medical University Hospital/Japan
Background: Although the 2012 version of the clinical practice 
guidelines for lung cancer published by the Japan Lung Cancer 
Society recommends performing a tegafur-uracil (UFT) compound 
drug therapy on cases of non-small cell lung cancer for stage 1A 
and 1B tumors measuring > 2 cm in diameter after surgery, we 
often encounter cases of recurrence. Therefore, we obtained data 
on T2a tumors (> 3 cm but < 5 cm in diameter) treated with UFT as 
postoperative adjuvant chemotherapy at our hospital and exami-
ned their recurrence predictors.
Methods: Among 2,724 cases of total surgical removal of non-
small cell lung cancer performed between January 1997 and De-
cember 2007, we examined 168 cases with stage 1B T2a tumors 
treated with UFT to clarify the recurrence predictors in these 
cases. We examined age, sex, tumor diameter, vascular invasion, 
lymphatic involvement, pleural invasion, histologic degree of diffe-
rentiation, tissue, and CEA.
Results: The age range was 38 to 85 years (median 66 years), and 
there were 108 men and 60 women. The 5-year recurrence-free 
survival rate was 72.7%. In cases of recurrence, the median time to 
recurrence was 662 days in 48 of the 168 cases (28.6%). On univari-
ate analysis, vascular invasion (p < 0.001), male sex (p = 0.045), and 
non-differentiation (p < 0.002) were identified as significant recur-
rence predictors. On multivariate analysis, vascular invasion (p = 
0.009) was found to be a significant recurrence predictors. Please 
confirm this part as the changes were made based on the original 
Japanese text.
Conclusion: It was inferred that vascular invasion is a primary 
recurrence predictor in cases receiving UFT as postoperative adju-
vant chemotherapy. We need to consider a more careful follow-up 
during UFT administration as postoperative adjuvant chemothera-
py in stage 1B T2a tumors.
Keywords: UFT, Postoperative adjuvant chemotherapy, Stage1B, 
Lung cancer
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P1.10-009 COMPARISON OF CHEMOTHERAPY EFFECT 
BETWEEN CISPLATIN-ETOPOSIDE AND CISPLATIN-
DOCETAXEL IN 2-YEAR SURVIVAL RATE AND PROGRES-
SION FREE SURVIVAL RATE OF ADVANCED NON-SMALL 
CELL LUNG CANCER PATIENTS
Noorwati Sutandyo1, Salman P. Harahap2, Eddy Suratman3
1Internal Medicine-medical Oncology, Dharmais Cancer Hospital/Indo-
nesia, 2Internal Medicine, Cipto Mangunkusumo Hospital/Indonesia, 
3Pulmonology, Dharmais Cancer Hospital/Indonesia
Background: One of the therapies for the advanced Non-Small 
Cell Lung Cancer (NSCLC) is chemotherapy. The success therapy 
is measured by 1-year survival, 2-year survival and progression free 
survival (PFS). The success is influenced by many factors such as 
resistant to the cytostatic, dosage, administer intensity, chemo-
therapy regiment, type of histology, stage, performance status, 
comorbidity and socioeconomics. In Indonesia, chemotherapy 
expense is one of the problem for the treatment which docetaxel is 
much expensive than etoposide. Purposes this study are to deter-
mine the survival and PFS difference between the NSCLC patients 
that were treated with Cisplatin-Etoposide (EC) against Cisplatin-
Docetaxel (DC).
Methods: The study was using the retrospective cohort study 
with survival analysis. The patients that included to this study were 
the advanced NSC Lung Cancer (at least stadium IIIa) who came 
to Dharmais Cancer Hospital and Cipto Mangukusumo Hospital 
during January 2006 until December 2010 for their first chemothe-
rapy until finished the cycle (6 times) and had 2-year monitoring. 
Data was analyzed by SPSS 16.0 by cox regression analysis, and 
featured on the Kaplan Meier Curve.
Results: Fifty five patients were using EC and the other 55 patients 
were using DC. There were significant difference in survival: 1-year 
survival of EC group was 30.9% and DC group was 47.3% (p 0.030); 
2- year survival of EC group was 0% and DC group was 5.5% (p 
0.003); median time survival of EC group was 27 weeks and DC 
group was 38 weeks (p < 0.016). Compared to DC group, chemo-
therapy in EC group increased the death risk (HR 1.684; CI 95% 
1.010-2.810). Moreover, twenty four weeks PFS in EC group (54.5%) 
was better than DC group (32.7%) with p < 0.022.
Conclusion: The survival and PFS with cisplatin-docexatel is better 
compare to cisplatin-etoposid. But we can still give cisplatin eto-
poside if patients have financial problem.
Keywords: Survival, PFS, NSCLC cisplatin etoposide and cisplatin 
docetaxel., survival
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P1.10-008 CLINICAL SIGNIFICANCE OF HYPERPIGMEN-
TATION DUE TO PEMETREXED TREATMENT IN ADVAN-
CED NON-SQUAMOUS NON-SMALL CELL LUNG CAN-
CER IN CHINA
Qiong Hu1, Aiwu Li2, Shengxiang Ren3, Xiaoxia Chen1, Guanghui 
Gao1, Caicun Zhou4
1Department Of Medical Oncology, Tongji University Affiliated Shang-
hai Pulmonary Hospital/China, 2Outpatient Department, Tongji Uni-
versity Affiliated Shanghai Pulmonary Hospital/China, 3Department Of 
Lung Cancer And Immunology, Tongji University Medical School Cancer 
Institute/China, 4Department Of Medical Oncology, Tongji University 
Medical School Cancer Institute/China
Background: Previous publications have demonstrated the effica-
cy of pemetrexed (PEM) as first-line, second-line and maintenance 
therapy in advanced non-small cell lung cancer (NSCLC). A recent 
study found skin toxicities compromised continuation of PEM treat-
ment. The purpose of this study is to investigate the clinical signifi-
cance of hyperpigmentation (HP) in advanced non-squamous (NS) 
NSCLC receiving PEM-based therapy in China.
Methods: Medical records of patients with advanced NS NSCLC 
who received PEM-based treatment in our hospital were retros-
pectively studied. Chi-square test, Pearson’s test as well as Kaplan-
Meier method and Cox Proportional Hazards model were perfor-
med for statistical analysis.
Results: A total of 101 patients were collected with a median 
age of 58 years old. Among them, 53 (52.5%) were female and 65 
(64.4%) were nonsmokers. 52 (51.5%) patients received first-line 
treatment. Presence of HP was associated with better ORR (22% 
vs 7.1%, p=0.043), higher DCR (84.7% vs 54.8%, p=0.001), and 
had longer PFS (186 days versus 96 days, p<0.0001). There were 
no significant differences according to grade of HP in ORR, DCR 
and PFS. There was a higher incidence of hyperpigmentation 
in patients who received first-line treatment (73.1%% vs 42.9%, 
p=0.023) and doublet chemotherapy (43.1% vs 74.0%, p=0.002). 
However,multivariate analysis demonstrated HP was not an inde-
pendent factor for better clinical outcomes (vs absence, Hazard Ra-
tio [HR] 0.417, 95% Confidential Interval [CI] 0.255-0.690, p=0.493).
Conclusion: HP due to PEM is frequent in advanced NS NSCLC 
receiving PEM. It might be a predictive factor for better clinical 
outcomes in Pemetrexed-treated advanced NS NSCLC in China.
Keywords: skin toxicity, pemetrexed, NSCLC, hyperpigmentation
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P1.10-011 CLINICOPATHOLOGICAL ANALYSIS OF LONG-
TERM (MORE THAN 2 YEARS) PROGRESSION-FREE SUR-
VIVORS TREATED WITH EPIDERMAL GROWTH FACTOR 
RECEPTOR - TYROSINE KINASE INHIBITORS (EGFR-TKIS) 
IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-
SMALL CELL LUNG CANCER
Masahiro Morise, Koichi Goto, Shigeki Umemura, Shingo Matsu-
moto, Kiyotaka Yoh, Seiji Niho, Hironobu Ohmatsu, Kanji Nagai, 
Yuichiro Ohe
Division Of Thoracic Oncology, National Cancer Center Hospital East/
Japan
Background: Presence of activating EGFR mutations is known to 
be predictive of a favorable response to treatment with EGFR-TKIs 
in non-small cell lung cancer (NSCLC) patients. Indeed, in clinical 
practice, EGFR-TKI treatment in patient with NSCLC harboring 
EGFR mutations sometimes yields a progression-free survival (PFS) 
of more than 2 years. The aim of this study was to evaluate the 
clinicopathological features of patients showing long-term (in the 
context of this study, more than 2 years) PFS.
Methods: Data of 194 consecutive patients with EGFR mutation-
positive NSCLC treated with EGFR-TKIs between May 2003 and 
May 2011 were reviewed. PFS was measured from the date of start 
of EGFR-TKI treatment to the date of documentation of disease 
progression, death or the last follow-up.
Results: The characteristics of the 194 patients were as follows, 
male/female: 70/124; median age: 65 years (range 36-88); PS 
0-1/2-3: 170/24; adenocarcinoma/non-adenocarcinoma: 189/5; 
advanced/recurrent: 104/90; EGFR-TKI 1st line/2nd or 3rd line: 
120/74; gefitinib/erlotinib: 170/24; Exon 19 deletion/L858R/other 
mutations: 98/86/10. The median progression-free survival was 
9.7 months. Of the 194 patients, 32 (16%) showed long-term pro-
gression-free survival. The results of univariate analyses revealed 
significant associations between the PFS and the PS and site of 
EGFR mutation. The EGFR-TKI treatment line (1st line/2nd or 3rd 
line) and specific EGFR TKI used (gefitinib/erlotinib) exerted no 
significant influence on the PFS. Multivariate analysis with a Cox 
proportional hazards model identified PS0-1 and Exon 19 deletion 
as independent favorable prognostic factors for PFS. The median 
PFS in patients with PS 0-1 and Exon 19 deletion (n=88) was 13.2 
months, and 20 of the 88 patients (23%) showed long-term pro-
gression-free survival.
Conclusion: Patients with good PS and Exon 19 deletion appear 
to have a higher likelihood of showing long-term progression-free 
survival. Therefore, the site of EGFR mutation, in addition to the 
PS, may be useful as a stratification factor in future clinical trials.
Keywords: non-small cell lung cancer, progression-free survival, 
EGFR-TKI, EGFR mutation
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P1.10-010 SURVIVAL OUTCOME ASSESSED BY RESPON-
SE AND TUMOR SHRINKAGE PATTERN IN NON-SMALL 
CELL LUNG CANCER PATIENTS WITH ACTIVATING MU-
TATIONS OF THE EPIDERMAL GROWTH FACTOR RECEP-
TOR
Masayuki Takeda1, Isamu Okamoto2, Kazuhiko Nakagawa1
1Medical Oncology, Kinki University Faculty Of Medicine/Japan, 2Center 
For Clinical And Translational Research, Kyushu University Hospital/
Japan
Background: Somatic mutations in the epidermal growth factor 
receptor (EGFR) gene are associated with the dramatic therapeutic 
response to EGFR-tyrosine kinase inhibitors (TKIs) in patients with 
advanced non–small cell lung cancer (NSCLC); however, there are 
no studies investigating clinical indicators that affect the likelihood 
of survival benefit from EGFR-TKI in selected patients with EGFR 
mutations. We evaluated the progression-free survival (PFS) and 
overall survival (OS) according to response and tumor shrinkage 
pattern among EGFR-mutated NSCLC.
Methods: Among 145 EGFR-mutation positive patients treated 
with EGFR-TKI, 68 patients were selected for the present analysis.
Results: Of those 68 patients, six patients achieved complete res-
ponse (CR), 42 patients partial response (PR), and 14 patients sta-
ble disease (SD). The PFS and OS of CR/PR group was significantly 
longer than that of the SD group. A multivariate analysis demons-
trated that response (CR/PR) to EGFR-TKI significantly correlated 
with both PFS and OS. Among CR/PR group, the median maximum 
tumor change from baseline was -56%, and the median time to 
response (TTR) was 4.2 weeks. No trend toward more favorable 
PFS and OS benefit was seen in the subset of patients who had 
experienced rapid tumor regression (TTR < 4.2 weeks) as well as 
high degree of tumor shrinkage (< -56%) compared with those who 
showed slow tumor regression (TTR > 4.2 weeks), or low degree of 
tumor shrinkage (> -56%) among CR/PR patients.
Conclusion: Response (CR/PR) may represent the optimal surroga-
te for efficacy among EGFR mutation-positive patients treated with 
EGFR-TKI patients.
Keywords: Epidermal growth factor receptor, non–small cell lung 
cancer, tyrosine kinase inhibitor, best tumor shrinkage
S566 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 1 - CHEMOTHERAPY  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.10-013 NAB-PACLITAXEL (ABRAXANE) BASED CHE-
MOTHERAPY FOR PRETREATED ELDERLY ADVANCED 
NSCLC PATIENTS: AN OPEN-LABEL, SINGLE CENTER, 
RANDOMIZED PHASE II TRIAL
Lizhu Lin, Hanrui Chen, Xuewu Huang, Shutang Wang, Xinting 
Zheng, Jietao Lin, Peng Li
Guangzhou Tcm University 1st Affiliated Hospital/China
Background: To evaluate the efficacy and safety of nab-paclitaxel 
single agent and in combination with nedaplatin in elderly patients 
who have had prior treatment in the recurrent or metastatic NSCLC 
setting.
Methods: Elderly (age ≥ 65) advanced NSCLC patients with ECOG 
PS 0-1 were recruited and 1:1 randomized to Abraxane single agent 
arm (arm A) or Abraxane plus nedaplatin arm (arm AP). In arm A 
Abraxane was 130 mg/m2, d1, 8, q3w and in arm AP nedaplatin was 
added by 20 mg/m2, d1-d3, q3w. The primary endpoint was ORR 
and secondary endpoints were DCR, PFS, OS and safety.
Results: From October 2009 to January 2013, 48 patients were 
enrolled, 24 patients in each arm. In arm AP, 1 patient was lost to 
follow up and 1 patient withdrew from study. The median treatment 
cycle number was 4 and more than 80% of patients finished 4 cyc-
les. The overall ORR of all patients was 21.3% and DCR was 55.3%, 
median PFS was 4.5 months, and median OS was 12.6 months. The-
re was no significant ORR difference between arm A and AP (16.7% 
vs 26.1%, P=0.665) as well as DCR (54.2% vs 56.5%, P=0.871). The 
median PFS was 3.3 months (95% CI: 1.74-4.86) in arm A and 5.5 
months (95% CI: 1.59-9.41) in arm AP, with no significant difference 
(P=0.738). Median OS was 12.6 months in arm A (95% CI: 3.70-
21.50) and 15.1 months in arm AP (95% CI: 6.71-23.49), with no sig-
nificant difference (P=0.770). There was no significant difference of 
ORR between squamous cell carcinoma and adenocarcinoma sub-
groups within arm A or AP (P>0.05). There was no ORR difference 
between subgroups pretreated with or without solvent-based pacli-
taxel within arm A or AP (P>0.05). Most adverse events were grade 
1-2. Grade 3-4 toxicities included neutropenia, thrombocytopenia, 
neuropathy, fatigue, nausea and vomiting. The incidence of ≥ grade 
3 neutropenia were 62.5% in arm AP and 29.1% in arm A (P=0.020). 
There was no treatment related death. Table 1 Patients demogra-
phics and baseline characteristics (n=48) 
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P1.10-012 ACTIVITY OF S-1 FOR NON-SMALL CELL 
LUNG CANCER PRETREATED WITH OR WITHOUT PEME-
TREXED.
Yusuke Takagi, Yoshiro Nakahara, Makiko Yomota, Yusuke Oku-
ma, Shinichiro Mikura, Yukio Hosomi, Masahiko Shibuya, Tatsu-
ru Okamura
Department Of Thoracic Oncology And Respiratory Medicine, Tokyo 
Metropolitan Cancer And Infectious Diseases Center Komagome Hospi-
tal/Japan
Background: S-1, a 5-fluorouracil derivative, and pemetrexed 
(PEM) are antimetabolites that both mainly target thymidylate 
synthase. S-1 received approval as a therapeutic drug for treating 
non-small cell lung cancer (NSCLC) in Japan in December 2004, 
and has been primarily used as a single agent for salvage chemo-
therapy. To our knowledge, there has been no clinical evidence 
whether the activity of S-1 is influenced by PEM resistance.
Methods: Patients with pretreated NSCLC who underwent S-1 
monotherapy were identified from an institutional database. This 
study was approved by the institutional review board. Eligible pati-
ents were classified into three groups; patients with non-squamous 
NSCLC pretreated with PEM (PEM+) or not (PEM−), or those with 
squamous cell lung cancer (SQ). Progression-free survival (PFS) 
and overall survival (OS) from S-1 administration were estimated 
using the Kaplan-Meier method and the log-rank test was used for 
inter-group comparisons. Impacts of prior PEM therapy on PFS and 
OS were examined using Cox proportional hazards modeling with 
variables including number of prior chemotherapy regimens, histo-
logical subtype of NSCLC, sex and age (<70 vs. ≥70 years).
Results: We identified 125 patients who underwent S-1 mono-
therapy for pretreated NSCLC. Median age was 69 years (range, 
39-86 years), with 31% female. Histological subtype was 82 (66%) 
adenocarcinoma, 33 (26%) squamous cell carcinoma and 10 (8%) 
NSCLC not otherwise specified. Number of prior chemotherapy re-
gimens was one in 32 (26%), two in 54 (43%), three in 26 (21%) and 
four or more in 13 (10%) patients. Among 108 patients with measu-
rable disease, response rate was 12% and disease control rate was 
45%. Response rates for S-1 monotherapy as second-, third- and 
fourth-line chemotherapy were 19% (5/27), 13% (6/45) and 9% 
(2/23), respectively. Forty-eight patients had received PEM-based 
chemotherapy prior to S-1 administration. Median PFS were 2.0 
months for the PEM− group (reference), 2.1 months for the PEM+ 
group (crude hazard ratio (HR) 1.11, 95%CI 0.73-1.69, p = 0.6), and 
2.2 months for SQ group (crude HR 0.72, 95%CI 0.44-1.15, p = 0.2). 
Median OS were 4.5 months for the PEM− group (reference), 5.9 
months for the PEM+ group (crude HR 0.65, 95%CI 0.41-1.03, p = 
0.07), and 8.4 months for SQ group (crude HR 0.76, 95%CI 0.47-
1.23, p = 0.3). Multivariate analyses revealed that only female sex 
was associated with longer PFS (HR 0.59, 95%CI 0.38-0.91, p = 
0.02) and OS (HR 0.58, 95%CI 0.36-0.91, p = 0.01), with history of 
PEM therapy or histological subtype exerting no influence.
Conclusion: Activity of S-1 is unaffected by prior PEM therapy. 
These results are compatible with recent preclinical findings. 
Further study is warranted.
Keywords: S-1, pemetrexed, non-small cell lung cancer, drug re-
sistance
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P1.10-014 BIA-6: A NOVEL AKT INHIBITOR WITH PO-
TENT ACTIVITY IN LUNG CANCER
Saketh S. Dinavahi1, Reshma Alokam1, Srikant Viswanadha2, Sri-
ram Dharmarajan1, Yogeeswari Perumal1
1Birla Institue Of Technology And Science/India, 2Incozen Therapeutics 
Pvt Ltd/India
Background: Akt, a serine- threonine kinase and a downstream 
mediator of the phosphoinositide-3-kinase (PI3K) pathway, is a sig-
nal transduction protein that plays a key role in tumorigenesis and 
metastases. Anomalies of Akt regulation including overexpression 
in lung cancer, impart resistance to conventional chemotherapy 
and radiation, thereby implicating this kinase as a therapeutic in-
tervention point for this dreadful disease.
Methods: A novel scaffold of Akt inhibitors were assessed through 
virtual screening of chemical databases available at BITS-Pilani, 
Hyderabad using GLIDE (Maestro, Version 8.5, Schrodinger). BIA-
6, a benzothienopyrimidine derivative was identified as a lead mo-
lecule. The compound was tested for in vitro Akt inhibition using 
a fluorescence resonance energy transfer assay kit (Z-lyte, Invitro-
gen). Anti-proliferative activity of BIA-6 was studied in NCI-H460, 
a lung adenocarcinoma cell line, routinely used as a surrogate for 
lung cancer. Effect of the compound on downstream biomarkers 
such as pAkt (S473) and p-P70S6K in NCI-H460 cells were determi-
ned by western blotting. Bands were quantified using ImageJ (Ver: 
1.46, NIH) and normalized to actin.
Results: BIA-6 inhibited Akt1 enzyme activity with an IC50 of 0.26 
µM with no apparent change in potency upon increasing the ATP 
concentration 10 fold, indicating allosteric interaction with the 
kinase. The compound caused a dose dependent reduction in 
growth of NCI-H460 cells with a GI50 of 0.7 µM. Cell cycle analysis 
indicated that BIA-6 arrested NCI-H460 cells in the G1 phase at 
<100 nM but led to apoptosis at higher doses. BIA-6 did not af-
fect the viability of normal human tracheal epithelial cells and lung 
fibroblasts at concentrations upto 40 µM suggesting a high thera-
peutic window in vitro. Downstream effectors, pAkt and p-p70S6K, 
were suppressed in a dose dependent manner.
Conclusion: BIA-6 is a novel, allosteric Akt1 inhibitor with potent 
anti-proliferative activity in lung cancer cell lines and effectively 
blocks the PI3K/Akt pathway with a high safety margin. Further 
preclinical profiling of the compound is in progress.
Keyword: Akt, Inhibitor, Lung
Characteristics All patients (n=48)
Arm A 
(n=24)
Arm AP 
(n=24)
Age, years 
Mean (range) 70.8 (65-80) 71.0 (65-80) 70.5 (66-79)
Gender, n (%)
Male 31 (64.6) 16 (66.7) 15 (62.5) 
ECOG PS, n (%)
0 17 (35.4) 10 (41.7) 7 (29.2) 
1 31 (64.6) 14 (58.3) 17 (70.8)
TNM stage, n (%)
IIIb 13 (27.1) 8 (33.3) 5 (20.8)
IV 35 (72.9) 16 (66.7) 19 (79.2)
Histology, n (%)
Adenocarcinoma 32 (66.7) 17 (70.8) 15 (62.5) 
Squamous 16 (33.3) 7 (29.2) 9 (37.5)
Smoking status, 
n (%)
Yes 27 (56.2) 15 (62.5) 12 (50.0) 
No 21 (43.8) 9 (37.5) 12 (50.0)
EGFR mutation, 
n (%)
EGFR (-) 38 (79.2) 18 (75.0) 20 (83.3) 
EGFR (+) 10 (20.8) 6 (25.0) 4 (16.7)
Pretreated with 
solvant-based 
paclitaxel
Yes 13 (27.1) 6 (25.0) 7 (29.2) 
No 35 (72.9) 18 (75.0) 17 (70.8)
Prior treatment
Radiotherapy 7 (14.6) 4 (16.7) 3 (12.5) 
Targeted therapy 18 (37.5) 10 (41.7) 8 (33.3) 
Chemotherapy 42 (87.5) 20 (83.3) 22 (91.7) 
Median treatment 
cycle, n (range)
4 (1-8) 4 (2-8) 4 (1-6)
 
Conclusion: Nab-paclitaxel-based chemotherapy is well tolerated 
in pretreated elderly advanced NSCLC patients and has good ORR 
and OS. Nab-paclitaxel single agent is more adaptable for elderly 
patients’ performance status. Nab-paclitaxel can be used in pati-
ents formerly treated by solvent-based paclitaxel and there is no 
significant difference of clinical benefit between squamous cell 
carcinoma and adenocarcinoma.
Keywords: ADVANCED NSCLC, pretreated, nab-Paclitaxel, elderly
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P1.10-016 TULUNG REGISTRY: ANALYSIS OF DATA FROM 
PS 0-1 PATIENTS WITH ADVANCED/METASTATIC NON-
SQUAMOUS NSCLC (ADENOCARCINOMA, LARGE CELL 
CARCINOMA) TREATED IN SECOND LINE WITH PEMET-
REXED
Jaromir Roubec1, Karel Hejduk2, Zdenek Bortlicek2, Milos Pesek3, 
Jana Skrickova4, Petr Zatloukal5, Vitezslav Kolek3, Frantisek Sala-
jka3, Leona Koubková6, Marcela Tomiskova4, Ivona Grygarkova3, 
Libor Havel5, Michal Hrnciarik3, Milada Zemanova7, Dimka Sixto-
va8, Helena Coupkova9, Katerina Kosatova10
1Pneumology Department, University Hospital/Czech Republic, 2Institut 
Biostatistiky A Analýz, Masaryk University/Czech Republic, 3Pneumo-
logy, University Hospital/Czech Republic, 4Department Of Respiratory 
Diseases And Tb, University Hospital Brno And Masaryk University/
Czech Republic, 5Pneumology, Hospital Na Bulovce/Czech Republic, 
6Pneumology, University Hospital Motol/Czech Republic, 7Oncology, 
General University Hospital/Czech Republic, 8Pneumology, Thomayer 
Hospital/Czech Republic, 9Oncology, Masaryk Memorial Cancer Institu-
te/Czech Republic, 10Pneumology, Hospital Na Homolce/Czech Republic
Background: The TULUNG registry is an independent national 
non-interventional clinical registry, focused on collection and 
analysis of epidemiologic and clinical data of non-small cell lung 
cancer (NSCLC) patients who have been treated with pemetrexed 
(Alimta®), erlotinib (Tarceva®), gefitinib (Iressa®) and/or bevaci-
zumab (Avastin®) in 10 centers of complex thoracic oncology care 
in the Czech Republic. The report is based on data analysis of 476 
advanced/metastatic non-squamous (adenocarcinoma or large cell 
carcinoma) NSCLC patients, who had good performance status (PS 
0-1), were treated with pemetrexed in the second line of treatment, 
and whose data were recorded in TULUNG registry as of March 18, 
2013.
Methods: There were analyzed baseline demographic data, infor-
mation about treatment aministered and efficacy and safety clinical 
outcomes of pemetrexed second line treatment in this selected 
registry patient population, using descriptive statistics.
Results: In analyzed group of 476 patients slightly prevailed men 
(56.9%) over women, median age at start of pemetrexed treatment 
was 62 years (range 27-81 let). Majority of patiens were current 
smokers and ex-smokers (41.0% and 32.8% resp.). 95% of tumours 
had adenocarcinoma histology. Vast majority of analyzed patiens 
(87.4%) had metastatic disease at start of second line pemetrexed 
treatment, the rest had stage IIIb. 83.8% of patiens had ECOG PS 1 
at start of second line pemetrexed treatment and 87.4% of patiens 
received pemetrexed in monotherapy. At the moment of analysis, 
pemetrexed treatment was already terminated in 408 patients out 
of 476 patients (the most frequent reasons for discontinuation of 
treatment were disease progression in 56.9% and planned comple-
tion of treatment in 28.2%), treatment was at moment of analysis 
ongoing in 68 patients. Median duration of treatment with peme-
trexed was 12.3 weeks (corresponds with 4 cycles). When focusing 
on the subset of patients with finished pemetrexed treatment, the 
disease control rate (i.e. CR+PR+SD) was reported in 59.6% of pa-
tients, while progressive disease (PD) was reported in 33.3%. For 
7,1% of patiens there were missing data on treatment response. 
Median overall survival was 11.3 months (95% CI 9.6 – 13.0) and 
median progression-free survival was 3.3 months (95% CI 2.7 – 3.8). 
1-year survival rate from start of pemetrexed treatment was 47,5%. 
Adverse events were reported to registry for 21.8% of pemetrexed 
treated patiens from analysed population. The most frequent (>5% 
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P1.10-015 PHASE II STUDY OF PEMETREXED PLUS 
INTERMITTENT ERLOTINIB COMBINATION THERAPY 
FOR PRETREATED ADVANCED NON-SQUAMOUS NON-
SMALL CELL LUNG CANCER WITH DOCUMENTATION 
OF EPIDERMAL GROWTH FACTOR RECEPTOR MUTATI-
ON STATUS
Yoshiko Takeuchi1, Takashi Kijima1, Seigo Minami2, Kiyoshi Ko-
muta2, Masanari Hamaguchi2, Takeshi Nakatani2, Taro Koba2, Ryo 
Takahashi1, Hiroshi Kida1, Izumi Nagatomo1, Suguru Yamamoto2, 
Isao Tachibana1, Ichiro Kawase3
1Department Of Respiratory Medicine, Allergy And Rheumatic Disea-
ses, Osaka University Graduate School Of Medicine/Japan, 2Department 
Of Respiratory Medicine, Osaka Police Hospital/Japan, 3Osaka Prefectu-
ral Medical Center For Respiratory And Allergic Diseases/Japan
Background: Erlotinib and pemetrexed are recommended for 
the second-line treatment of non-small cell lung cancer (NSCLC). 
With the recommended doses determined by our previous phase 
I study [BMC Cancer 2012;12(1):296], we conducted a phase II stu-
dy to evaluate the efficacy and safety of combination of the two 
agents in patients with pretreated non-squamous NSCLC.Erlotinib 
and pemetrexed are recommended for the second-line treatment 
of non-small cell lung cancer (NSCLC). With the recommended 
doses determined by our previous phase I study [BMC Cancer 
2012;12(1):296], we conducted a phase II study to evaluate the effi-
cacy and safety of combination of the two agents in patients with 
pretreated non-squamous NSCLC.
Methods: Patients with stage III/IV or post-surgically recurrent 
non-squamous NSCLC whose disease had progressed after first-
line chemotherapy were enrolled. Patients received 500 mg/m2 of 
intravenous pemetrexed every 21 days and 150 mg of oral erlotinib 
on days 2–16 until disease progression or unacceptable toxicity. 
The primary objective was the response rate (RR). The secondary 
objectives were the disease control rate (DCR), progression-free 
survival (PFS), overall survival (OS) and safety.
Results: A total of 27 patients, 16 males and 11 females, with the 
median age of 70 (range, 48–80) were enrolled. They included 
21 stage IV diseases and 22 adenocarcinomas. The Epidermal 
growth factor receptor (EGFR) gene mutations were examined in 
all patients and only one patient was positive. The median number 
of treatment courses was 3 (range, 1 to over 19). The RR and DCR 
were 11.1% and 63.0%. The median PFS and OS were 2.8 months 
(95% confidence interval (CI); 1.9 to 7.5) and 15.8 months (95% CI; 
9.3 to not available), respectively. As for safety, dermal, hepatic, 
gastrointestinal and hematological disorders were the frequently 
observed adverse events. Grade 3/4 toxicities observed in more 
than 15% patients were neutropenia (n = 10), anemia (n = 6), febrile 
neutropenia (n = 6), ande anorexia (n = 5). One patient experi-
enced grade 3 drug-induced interstitial lung disease.
Conclusion: We could not demonstrate the add-on effect of inter-
mittent erlotinib on pemetrexed in the second-line treatment of 
non-squamous NSCLC without EGFR mutations.
Keywords: pemetrexed, erlotinib, non-small cell lung cancer, com-
bination therapy
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ess, on an intention-to treat basis the ORR was 23% (95%CI: 8-45). 
Severe myelosuppression, G3/4 neutropenia or thrombocytopenia, 
was observed in 67/42% of pts, respectively. Other toxicities, in ≥ 
10% of pts, were generally mild and comprised anemia, ALT/AST 
or creatinine increases, fatigue, mucositis, nausea/vomiting and 
anorexia. No alopecia was reported. Serious adverse events inclu-
ded febrile neutropenia (FN), pneumonia, sepsis and shock, and 
resulted in two treatment-related deaths, both occurred at dose 
levels over the RD. The RD was established at PM01183 3.0 mg + 
GEM 800 mg/m2 on Days 1 and 8 q3wk.
Conclusion: PM01183 and GEM combination resulted in relevant 
and durable clinical activity in NSCLC pts. Toxicity seems both ma-
nageable and predictable at the RD. The novel mechanism of ac-
tion of PM01183, and particularly its lack of Pt cross-resistance are 
of special interest in this population. A randomized trial is ongoing 
to assess the role of this new CT combination in relapsed NSCLC.
Keywords: chemotherapy, Combinations, NSCLC, New Drugs
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P1.10-018 NAB-PACLITAXEL IN COMBINATION WITH 
CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS 
WITH ADVANCED NON-SMALL CELL LUNG CANCER 
(NSCLC): ANALYSIS OF PERIPHERAL NEUROPATHY
Hiroshi Sakai1, Amy Ko2, Markus F. Renschler2, Mark A. Socinski3
1Thoracic Oncology, Saitama Cancer Center/Japan, 2Celgene Corpora-
tion/United States Of America, 3Hematology/Oncology, University Of 
Pittsburgh/United States Of America
Background: Peripheral neuropathy (PN) is a common side effect 
associated with taxane treatment. In a phase III trial, nab-paclitaxel 
(nab-P, 130 nm albumin-bound paclitaxel particles) + carboplatin 
(C) vs solvent-based paclitaxel (sb-P) + C significantly improved 
ORR (primary endpoint; 33% vs 25%; P = 0.005), with a trend 
toward improved OS and PFS in patients with advanced NSCLC. 
Here, we report on the PN profile of nab-P/C vs sb-P/C.
Methods: Patients with untreated stage IIIB/IV NSCLC were rando-
mized 1:1 to nab-P 100 mg/m2 on d 1, 8, 15 or sb-P 200 mg/m2 q 1 
q21d; both arms received C AUC 6 day 1 q21d. PN was assessed 
by Standardized MedDRA Query (SMQ) for neuropathy (broad 
scope) unless otherwise indicated. Patient-reported taxane-related 
neuropathy symptoms were assessed by the Functional Assess-
ment of Cancer Therapy (FACT)-Taxane Additional Concerns scale.
Results: nab-P/C was associated with significantly less PN vs sb-
P/C (all grade: 46% vs 62%; P < 0.001) and grade 3/4 treatment-
related PN (3% vs 12%; P < 0.001). Grade 4 PN occurred in 2 
patients in the sb-P/C arm vs 0 patients in the nab-P/C arm. PN 
led to taxane dose reductions in 2% vs 7% and delays in 3% vs 8% 
of patients in the nab-P/C vs sb-P/C arm. Physician assessment of 
PN based on NCI CTCAE grade showed fewer instances of wor-
sening with nab-P/C vs sb-P/C. At baseline, ≥ 95% of patients in 
both arms were assessed with grade 0 PN, but at final evaluation, 
significant treatment differences favoring the nab-P/C arm were 
observed, with fewer nab-P/C−treated patients shifting from grade 
0 to grades 1-4 (38%) relative to the sb-P/C arm (58%; P < 0.001). 
Fewer patients receiving ≤ 6 cycles (median number of cycles = 
6) in the nab-P/C vs sb-P/C arms experienced all-grade PN (41% 
vs 60%); 2% vs 10% of these patients experienced grade 3/4 PN 
patients) reported adverse events were neutropenia (9.7%), anemia 
(6.5%), leukocytopenia (6.1%), and fatigue (6.1%). 
Conclusion: Reported efficacy and safety outcomes from registry 
are more favourable than results of published controlled rando-
mized registrational trial. It probably reflects the different metho-
dology of data collection and more prudent approach to patient 
selection for pemetrexed second line treatment in real clinical 
practice in the Czech Republic in participating centers. Based on 
registry data, pemetrexed treatment was in suitable patiens with 
good PS very well tolerated (78.2% of patiens without reported ad-
verse events in registry) and allowed for reaching disease control in 
almost 60% of treated patiens, with median OS approaching one 
year from starting second line therapy.
Keywords: NSCLC, non-squamous, pemetrexed, second line treat-
ment
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P1.10-017 CLINICAL ACTIVITY OF LURBINECTEDIN 
(PM01183) IN COMBINATION WITH GEMCITABINE (GEM) 
IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS 
(PTS): PRELIMINARY SUBGROUP ANALYSIS OF A PHASE 
IB STUDY.
Luis Paz-Ares1, E Calvo2, M Forster3, V Boni2, I Lopez Calderero1, S 
Benafif3, C Kahatt4, S Turnbull3, J Corral1, A Cubillo2, M Flynn3, M 
Luque Ibañez4, A Soto Matos-Pita4, S Szyldergemajn4
1Hospital Virgen Del Rocío/Spain, 2Start Madrid, Centro Integral On-
cológico Clara Campal/Spain, 3University College Of London Hospital/
United Kingdom, 4Pharmamar/Spain
Background: PM01183 is an inhibitor of transactivated transcrip-
tion and also acts on the tumor microenvironment. It lacks cross-
resistance with platinum (Pt) agents. Evidence of synergism with 
GEM has been observed preclinically. PM01183 is undergoing 
intensive clinical evaluation as single agent in phase II studies in 
pancreatic, ovarian, breast and NSCLC pts. Its primary side effects 
are reversible myelosuppression and high emetogenic potential.
Methods: Consenting adults with selected solid tumors (including 
NSCLC), age ≤ 75 years, Eastern Cooperative Oncology Group 
performance status (ECOG PS) 0-1, adequate major organ function 
and up to 2 prior chemotherapy-containing (CT) lines were inclu-
ded in successive cohorts aiming to primarily define the recom-
mended dose (RD) of PM01183 when combined with GEM, both on 
Days 1 and 8 every three weeks (q3wk). Prior GEM was not allowed 
in the metastatic setting. Available results exclusively from the 
NSCLC population are described here.
Results: Recruitment was closed in December 2012. Overall, 22 
of 45 treated pts (49%) had NSCLC. Of these, 73% were males. 
Median age was 65 years (r: 37-73). Patients received 1, 2 or 3 prior 
lines, in 64/27/9% of cases respectively. Non-squamous histology 
was reported in 91% of pts and 18% had known central nervous 
system (CNS) involvement. Five of 14 pts evaluable for efficacy 
by Response Evaluation Criteria In Solid Tumors (RECIST) v.1.1, 
responded to therapy [4 PRs and 1 CR], reaching an overall respon-
se rate (ORR) of 36% [95% confidence interval (CI): 13-65] in the 
RECIST evaluable population. Median response duration was 31 
weeks (r: 7-52+). Eight of 22 pts were not evaluated for efficacy, as 
this was not the primary endpoint of the phase Ib study. Neverthel-
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14.27) (p = 0.0129). Insertion mutations were found in 20 patients 
(18%), and 91 patients (82%) were without insertions. PFS without 
insertions (12.0 months, 95% CI 9.27-15.17) was significantly longer 
than with insertions (10.0 months, 95% CI 3.97-12.67) (p = 0.0173). 
No relationships were found for RR in all patient characteristics. In 
univariate analysis, PS (0-1 vs 2-4, p = 0.0001), clinical stage (IIIB/
IV vs recurrence, p = 0.0408), treatment line (1st line vs after 2nd 
line, p = 0.0122), initial site of deletion, and presence of insertion 
were statistically significant factors for longer PFS. PS (p <0.0001), 
histology (Adeno vs Squamous, p = 0.0134) and treatment line (p = 
0.0052) were statistically significant factors for longer OS. In mul-
tivariate analysis, PS (hazards ratio [HR] 0.580, 95% CI 0.43-0.80, p 
= 0.0009) and initial site of deletion (HR 0.696, 95% CI 0.55-0.89, 
p = 0.0047) remained as significant factors for longer PFS. PS (HR 
0.525, 95% CI 0.35-0.78, p = 0.0016), gender (Female vs Male, HR 
0.701, 95% CI 0.53-0.93, p = 0.0140) and histology (HR 0.479, 95% 
CI 0.30-0.83, p = 0.0120) were selected as significant factors for 
longer OS.
Conclusion: Our data indicated better efficacy of EGFR-TKI in 
⊿E746 group than ⊿L747 group. Deletional locations may affect 
the sensitivity to EGFR-TKI.
Keywords: non-small cell lung cancer, Epidermal growth factor 
mutation, Tyrosine kinase inhibitor treatment, exon19 delation
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P1.10-020 DOSE ADJUSTMENT OF SINGLE AGENT AM-
RUBICIN IN LUNG CANCER PATIENTS WITH IMPAIRED 
HEPATIC FUNCTION
Toshiaki Takahashi1, Nobuyuki Yamamoto1, Koji Takeda2, Shinz-
oh Kudoh3, Kazuhiko Nakagawa4, Toyoaki Hida5, Katsuyuki Kiura6, 
Nagio Takigawa6, Takashi Seto7, Hiroshi Tsukuda8, Noriyuki Ma-
suda9, Masahiro Fukuoka8
1Division Of Thoracic Oncology, Shizuoka Cancer Center/Japan, 2De-
partment Of Clinical Oncology, Osaka City General Hospital/Japan, 
3Department Of Respiratory Medicine, Osaka City University/Japan, 
4Department Of Medical Oncology, Kinki University Faculty Of Medici-
ne/Japan, 5Department Of Thoracic Oncology, Aichi Cancer Center Hos-
pital/Japan, 6Department Of Respiratory Medicine, Okayama University 
Hospital/Japan, 7Thoracic Oncology, National Kyushu Cancer Center/Ja-
pan, 8Medical Oncology, Izumi Municipal Hospital/Japan, 9Department 
Of Respiratory Medicine, Kitasato University School Of Medicine/Japan
Background: The pharmacokinetics (PK) of amrubicin (AMR) in 
lung cancer patients with impaired hepatic function have not been 
reported. The objectives of this study were to evaluate the PK 
of AMR and its major metabolite, amrubicinol (AMR-OH), in lung 
cancer patients with or without impaired hepatic function, and to 
assess the validity of dose adjustment of AMR based on hepatic 
function.
Methods: Eligibility criteria included the presence of histologically 
or cytologically proven lung cancer, an ECOG PS of 0 to 2, age 20 
to 70 years old, and no evidence of hepatitis B virus infection. The 
dose was adjusted from 25 to 45 mg/m2/day (iv, days 1-3, q3w) 
based on the history of prior treatment and baseline values of total 
bilirubin (T-bil), AST and ALT (Table 1). 
(no patients in the nab-P/C arm experienced grade 4 PN). Median 
time to PN onset of any grade was longer with nab-P/C vs sb-P/C, 
49 vs 38 days (P < 0.001); grade 2-4, 105 vs 78 days (P = 0.04) 
and grade 3/4, 121 vs 106 days (P = 0.723). The median time to 
improvement of grade 3/4 PN to grade 1 was 38 vs 104 days (P = 
0.326) with nab-P/C vs sb-P/C. Patient-reported FACT-Taxane PN 
subscore at final evaluation also demonstrated a statistically signi-
ficant treatment effect favoring nab-P/C (P < 0.001). Most patients 
completed the FACT-Taxane questionnaire at baseline (98%) and 
provided follow-up assessments (94%) at each cycle. Deterioration 
in patient-reported PN subscore at or after the development of 
grade 3/4 PN was lower for nab-P/C vs sb-P/C (median change 
from baseline 4.5 vs 10).
Conclusion: In this trial, nab-P/C was associated with lower rates 
PN compared with sb-P/C. PN occurred later during treatment 
with nab-P/C vs sb-P/C, and the majority of patients experienced 
improvement of PN symptoms within approximately 1 month. 
Patients receiving ≤ 6 cycles of therapy with nab-P/C had less PN 
compared with those receiving sb-P/C.
Keywords: nab-Paclitaxel, peripheral neuropathy, non-small cell 
lung cancer
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P1.10-019 DIFFERENTIAL EFFICACY OF EGFR-TKI AC-
CORDING TO VARIANTS OF EXON 19 DELETIONAL MU-
TATION IN NON-SMALL CELL LUNG CANCER
Toshihiko Kaneda1, Akito Hata2, Kosuke Tanaka2, Reiko Kaji2, 
Shiro Fujita2, Hiromi Tomioka1, Keisuke Tomii3, Nobuyuki Kataka-
mi2
1Respiratory Medicine, Kobe City Medical Center West Hospital/Japan, 
2Integrated Oncology, Institute Of Biomedical Research And Innovation/
Japan, 3Respiratory Medicine, Kobe City Medical Center General Hospi-
tal/Japan
Background: Deletional mutations in exon 19 (Del-19) and L858R 
point mutation in exon 21 are the most common mutations in the 
epidermal growth factor receptor (EGFR) gene. In Del-19, several 
variants actually exist, consisting of different amino acid positions 
or different sizes. Little evidence has been described whether the 
variation of Del-19 mutation affects EGFR-tyrosine kinase inhibitor 
(TKI) sensitivity.
Methods: Between December 2005 and March 2013, we scree-
ned 111 patients harboring Del-19 who had received EGFR-TKIs. 
Efficacies of EGFR-TKI such as response rate (RR), progression-free 
survival (PFS), and overall survival (OS) were retrospectively eva-
luated among various patient characteristics (age, gender, ECOG 
performance status [PS], smoking status, clinical stage, histology, 
treatment line, types of TKI, initial site of deletion, and presence 
of insertion). We also performed a multivariate analysis with the 
proportional hazards model to exclude several confounds. A back-
ward stepwise approach was adopted as our variable selection 
method for multivariate analyses.
Results: Among these 111 patients with exon 19 deletion muta-
tions, 83 (75%) patients had a deletion from E746 (⊿E746 group), 
and a deletion from L747 (⊿L747 group) 28 (25%). PFS of ⊿E746 
group (12.0 months, 95% confidence interval [CI] 9.27-15.63) was 
significantly longer than ⊿L747 group (10.0 months, 95% CI 6.43-
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EGFR-mutated NSCLC. However, standard subsequent regimen 
after the failure of those treatments remains unclear. Some reports 
suggested high synergistic effect between S-1 (a novel oral fluo-
rouracil derivative) and irinotecan against TKI-resistant cell lines. 
We therefore conducted this phase II trial of the combination of 
S-1 plus irinotecan to evaluate the efficacy and safety in EGFR-
mutated NSCLC patients resistant to both platinum-based chemo-
therapy and EGFR-TKI.
Methods: Eligible patients were required advanced or recurrent 
NSCLC with an EGFR activating mutation, disease progression 
(PD) during or after second- or third-line EGFR-TKI, and previous 
chemotherapy including platinum doublet prior to EGFR-TKI. All 
patients received S-1 (80 mg/m2, day 1 to 14) orally and irinotecan 
(70 mg/m2, day 1 and 15) intravenously every 3 weeks. The primary 
endpoint was disease control rate (DCR) at 8 weeks after enroll-
ment. The estimated accrual was 23 patients to confirm a DCR of 
60% as a desirable target level and a DCR of 30 % as a lower limit 
of interest with alpha = 0.05 and beta = 0.10.
Results: From February 2009 to April 2012, 25 patients were en-
rolled from 6 institutions. The patients comprised 5 males and 
20 females with a median age of 62 years (range, 53 to 78 years). 
ECOG performance status was PS 0 in 4 patients and PS1 in 21 
patients. The histological subtypes were: adenocarcinoma 23 pa-
tients (92%), squamous cell carcinoma 1 patient, adenosquamous 
carcinoma 1 patient. EGFR activating mutations were, exon 19 
deletion in 17 patients and exon 21 point mutation termed L858R 
in 8 patients. The current line of treatment in this study was the 
3rd in 22 patients and the 4th in 3 patients. The median cycles of 
treatment was 4 (range 1-12). The objective responses were CR 0, 
PR 13, SD 8, and PD 4, giving a DCR at 8 weeks of 84.0% (95% CI, 
63.9-95.5%). The overall response rate was 52.0% (95% CI, 31.3-
72.2%). The median PFS was 5.0 months, whereas the median ove-
rall survival was 17.1 months. There was no significant difference in 
efficacy between the two types of EGFR mutations. Major grade 3 
or worse toxicities included neutropenia (52%), anemia (20%), feb-
rile neutropenia (16%), diarrhea (16%), thrombocytopenia (4%), and 
pulmonary thromboembolism (4%). No treatment-related death 
was observed.
Conclusion: This combination therapy with S-1 and irinotecan in 
EGFR-mutated NSCLC that was resistant to both platinum-based 
chemotherapy and EGFR-TKI showed promising efficacy with 
manageable toxicities. Further evaluation of this regimen in com-
parison with other cytotoxic agents or with irreversible EGFR-TKI is 
warranted.
Keywords: S-1, EGFR mutation, EGFR-TKI resistant, phase II
Results: Five patients with impaired hepatic function (arm I) and 
10 patients with normal hepatic function (arm N) were enrolled. 
Terminal half-life (t1/2) and clearance of AMR in plasma, and t1/2 of 
AMR-OH in blood did not differ between the two arms. Area un-
der the curve (AUC0-24) of AMR in plasma and AUC0-120 of AMR-OH 
in blood in arm I were similar or lower compared to those in arm 
N (Table 2). The dose-adjusted AUCs of AMR and AMR-OH did 
not show a tendency to increase with increases in baseline T-bil, 
AST and ALT. Two deaths occurred in arm I (one due to disease 
progression, and the other due to an unspecified reason), but the 
toxicities in arm I were not severe compared with those in arm N. 
Conclusion: These data show the validity of dose adjustment of 
AMR in patients with impaired hepatic function.
Keywords: amrubicin, pharmacokinetics, Dose adjustment, im-
paired hepatic function
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P1.10-021 PHASE II STUDY OF S-1 PLUS IRINOTECAN 
FOR EGFR-MUTATED NON-SMALL CELL LUNG CANCER 
(NSCLC) RESISTANT TO BOTH PLATINUM-BASED CHE-
MOTHERAPY AND EGFR-TKI: NJLCG0804
Akira Inoue1, Shunichi Sugawara2, Masao Harada3, Makoto 
Maemondo4, Toshiyuki Harada5, Kunihiko Kobayashi6, Osamu 
Ishimoto2, Shinichi Fukumoto3, Nobumichi Matsubara4, Tetsuya 
Okano6, Toshihiro Nukiwa1
1Tohoku University Hospital/Japan, 2Sendai Kousei Hospital/Japan, 
3Department Of Respiratory Medicine, Hokkaido Cancer Center/Japan, 
4Miyagi Cancer Center/Japan, 5Hokkaido Social Insurance Hospital/Ja-
pan, 6Saitama University International Mrdical Center/Japan
Background: From the results of recent trials, both EGFR-TKI and 
platinum doublet are believed to be important for patients with 
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of lung cancer in Central European countries.
Keyword: prevention, diagnosis, therapy, Central Europe
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P1.10-023 FAVORABLE RESPONSE TO EGFR-TKI IS A 
PREDICTIVE MARKER OF TAXANE ACTIVITY, BUT NOT 
OF PEMETREXED IN PATIENTS WITH NON-SQUAMOUS 
NON-SMALL CELL LUNG CANCER
Seung Hun Jang, Joo Hee Kim, Sunghoon Park, Yong Il Hwang, Ki-
Suck Jung
Pulmonary, Allergy And Critical Care Medicine, Hallym University 
Sacred Heart Hospital/Korea
Background: Both taxane and pemetrexed have significant ac-
tivities as salvage chemotherapeutic agents in non-squamous 
non-small cell lung cancer (NSCLC). The purpose of this study was 
to compare the efficacy of taxane and pemetrexed according to 
EGFR activating mutation status in patients with advanced non-
squamous NSCLC.
Methods: This retrospective analysis included patients with stage 
IIIA-IV non-squamous NSCLC given both taxane and pemetrexed 
in their clinical courses regardless of treatment line. Patients were 
dichotomized into favorable or unfavorable EGFR-tyrosine kinase 
inhibitor (TKI) response group. Favorable response group was 
defined as harboring EGFR activating mutation or partial remission 
and progression-free survival (PFS) ≥ 4 months with EGFR-TKI.
Results: 62 patients were eligible for analysis (24 of favorable and 
38 of unfavorable EGFR-TKI response group). Response rate (RR) of 
taxane based regimen was 37.5% vs. 28.9% (p=0.483) and disease 
control rate (DCR) was 79.2% vs. 55.3% (p=0.055) in favorable and 
unfavorable EGFR-TKI response group, respectively. RR of pemet-
rexed based regimen was 12.5% vs. 34.2% (p=0.057) and DCR was 
66.7% vs. 76.8% (p=0.407) in favorable and unfavorable group, 
respectively. PFS with taxane based regimen was 5.5 months (95% 
CI 5.0-6.0) vs. 2.6 months (95% CI 1.4-3.8) in favorable and unfavo-
rable group, respectively (p=0.006). PFS with pemetrexed based 
regimen was 4.1 months (95% CI 2.9-5.3) vs. 4.6 months (95% CI 
1.9-7.2) in favorable and unfavorable group, respectively (p=0.361). 
PFS with taxane vs. pemetrexed based regimen was 5.5 vs. 4.1 
months in favorable EGFR-TKI response group (p=0.027), and 2.6 
vs. 4.6 months in unfavorable EGFR-TKI response group (p=0.112). 
The adjusted HR for disease progression of taxane based regimen 
in favorable EGFR-TKI response group compared with unfavorab-
le group was 0.455 (95% CI 0.252-0.819; p=0.009) in multivariate 
Cox-regression analysis. However, PFS with pemetrexed based 
regimen was not associated with EGFR-TKI responsiveness (HR 
1.014, 95% CI 0.547-0.877; p=0.966). The overall survival of favora-
ble group vs. unfavorable EGFR-TKI response group was 45.4 vs. 
22.8 months (p<0.001).
Conclusion: Favorable response to EGFR-TKI is a predictive 
marker of taxane activity, but not of pemetrexed in patients with 
non-squamous NSCLC. Taxane would be the first consideration for 
patients with disease progression after durable response to EGFR-
TKI.
Keywords: pemetrexed, chemotherapy, EGFR, Taxane
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P1.10-022 CENTRAL EUROPEAN INITIATIVE AGAINST 
LUNG CANCER: RESULTS OF THE INAUGURAL WORK-
SHOP
Robert Pirker1, Gyula Ostoros2, Lubos Petruzelka3, Martin Filipits4, 
Krisztina Bogos5, Rudolf M. Huber6, Christoph Zielinski1, Jean 
Klastersky7
1Department Of Medicine 1, Medical University Of Vienna/Austria, 
2Department 8, National Koranyi Institute Of Pulmonology/Hungary, 
3Department Of Oncology, Charles University Hospital/Czech Republic, 
4Department Of Cancer Research, Medical University Of Vienna/Aust-
ria, 5Department 4, National Koranyi Institute Of Pulmonology/Hunga-
ry, 6Thoracic Oncology Centre Munich, University Of Munich - Campus 
Innnenstadt/Germany, 7Centre Des Tumeurs De L´ universite Libre De 
Bruxelles, Institut Jules Bordet/Czech Republic
Background: Lung cancer is a major health problem in Central 
Europe where some of the countries have the world-wide highest 
incidence rates of this cancer. The CENTRAL EUROPEAN INITIA-
TIVE AGAINST LUNG CANCER aims at decreasing the burden of 
lung cancer in this region. The Inaugural Workshop of this Initiative 
was planned in order develop strategies to achieve this goal.
Methods: Participation at the Workshop was by invitation and 
more than 100 lung cancer experts from several Central European 
Countries and Israel did participate. The participants discussed the 
current status of lung cancer management and suggested strate-
gies for improvement in the various areas of lung cancer manage-
ment.
Results: The Workshop focused on all aspects of lung cancer. The-
re was agreement that lung cancer is a major health problem in all 
Central European countries and that improvement in all aspects of 
lung cancer management must be attempted. Prevention strate-
gies have steadily been improved but remain insufficient in most 
countries. The potential of screening was recognized but routine 
implementation of screening was not considered to be feasible in 
most Central European countries at this time. Access to modern 
radiological imaging such as PET-CT must be improved in many 
centers. A future project will assess the accuracy of radiological 
staging in several hospitals. Molecular diagnosis is increasingly 
implemented in most countries but patient selection for molecular 
analyses varies between countries. A major area of discussion was 
the implementation of standard treatments. Multidisciplinary tu-
mor boards have been established in most centers but participants 
disagreed on whether all or only selected patients should be pre-
sented during tumor board meetings. Concerning stage III NSCLC, 
great heterogeneity with regard to both staging and treatment 
has been recognized. A future project plans to assess current ma-
nagement of patients with stage III NSCLC and to define areas for 
improvement. Access to systemic treatment has improved over the 
years but timely access to novel and expensive drugs remains chal-
lenging in several countries. Strategies to increase the scientific 
co-operation and education have also been discussed and should 
increasingly be implemented in the future.
Conclusion: The Workshop did outline the current status including 
challenges in the management of patients with lung cancer in Cen-
tral Europe. Next projects will assess staging accuracy and de-
tailed treatment of patients with locally advanced NSCLC. Future 
events such as the 14th Central European Lung Cancer Congress 
in 2014 and the 17th World Congress on Lung Cancer in 2016 in 
Vienna should also have a major impact on decreasing the burden 
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P1.10-025 RANDOMIZED PHASE II TRIAL OF SAFETY OF 
BIWEEKLY DOCETAXEL/CISPLATIN VS GEMCITABINE/
CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED 
NON-SMALL CELL LUNG CANCER PATIENTS WHO ARE 
ELDERLY OR POOR PERFORMANCE STATUS
Hoon K. Kim1, Joung-Soon Jang2, Byoung Chul Cho3, Kyung Hee 
Lee4, Hwan Jung Yun5, In Sook Woo6, Chi Hong Kim7
1Medical Oncology, St. Vincent‘s Hospital/Korea, 2Medical Oncology, 
Chung-ang University, College Of Medicine/Korea, 3Department Of 
Internal Medicine, Yonsei University College Of Medicine/Korea, 4Medi-
cal Oncology, Yeungnam University Hospital/Korea, 5Medical Oncology, 
Chungnam Natl University Hospital/Korea, 6Medical Oncology, Yeouido 
St. Mary Hospital, Catholic University Of Korea/Korea, 7Pulmonology, 
St. Vincent‘s Hospital/Korea
Background: Cisplatin with docetaxel (DP) or gemcitabine (GP) 
is one of standard regimen for advanced non-small cell lung 
cancer(NSCLC). DP is regarded more toxic compared with GP. 
There is an increasing interest in a biweekly split administration of 
DP to reduce its toxicity. Hypothesis here was 1st-line biweekly DP 
is as safe as GP in elderly or poor performance status (PS) patients 
(pts).
Methods: Chemotherapy naïve pts with NSCLC (IIIB/IV) who were 
elderly(>65) or poor PS (ECOG 2) were randomized to biweekly DP 
or GP by balancing for ECOG (0-1 vs 2), stage (IIIB vs IV) and age 
(<65 vs >65). DP with docetaxel (35mg/m2)/cisplatin(30mg/m2) iv 
or GP with gemcitabine (1000mg/m2) /cisplatin(30mg/m2) iv was 
given on days 1,8 every 3 weeks . Chemotherapy lasted upto 6 cy-
cles or until progression. Primary endpoint was safety (proportion 
of grade 3/4 toxicities). Planned sample size was 49 pts in each.
Results: From Nov 2009 to Jan 2013, a total of 97 pts were rando-
mized (DP 50/GP 47). Adenoca was 58% in DP and 51% in GP while 
that of squamous cell ca 34% in DP and 40% in GP. Stage IIIB/IV 
was 33%/66% in DP and 42%/59% in GP. In DP a total 228 adverse 
events (AEs) were reported and 27 were grade 3/4 toxicities while 
211 AEs and 21 grade 3/4 toxicities in GP. Neutropenia was the 
most frequent grade 3/4 toxicity in both (DP 8.9%; GP 15.9%). In 
DP grade 3/4 leukopenia (8.9%), hyponatremia(6.7%), anemia(4.4%) 
and anorexia (4.4%) were observed while anemia (9.1%) and hyp-
onatremia (6.8%) in GP. In total AEs, anemia was the most com-
mon in both (DP 66.7% ; GP 63.6%). Then, in the following order, 
hyponatremia (53.3%), anorexia (53.3%) and fatigue(40%) were 
common in DP while anorexia, (56.8%), fatigue(36.4%) and neu-
tropenia(45.5%) were common in GP. Death during treatment was 
occurred in 1 pt in each. Both regimen showed similar grade 3/4 
toxicities with similar profiles. Survivals seemed to be favorable in 
GP compared with DP with no statistical significance. Progression-
free survivals were 3.72 (DP) and 5.56 (GP) months (p=0.341). Over-
all survivals were 14.93 (DP) and 20.82 (GP) months (p=0.209).
Conclusion: This study showed DP is similar with GP in terms of 
toxicity and efficacy in treatment of elderly or poor performance 
patients.
Keywords: chemotherapy, toxicity, elderly, poor performance 
status
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P1.10-024 CLINICAL FEATURES OF EARLY INTERRUPTI-
ON OF EGFR-TKIS IN UNSELECTED NON SMALL CELL 
LUNG CANCER PATIENTS
Taewon Jang, Jungwook Yang, Chulho Oak, Mannhong Jung
Pulmonology, Kosin Medical School/Korea
Background: Epidermal growth factor receptor tyrosine kinase 
inhibitor (EGFR-TKI) is treatment of choice in non-small cell lung 
cancer patients with EGFR mutation, as well as has been recom-
mended in the unselected patients in the 2nd or 3rd line treat-
ment. However, many patients have no response from the EGFR-
TKI treatment and there was often a lot of progress in early time of 
treatment.
Methods: The aim of this study was to analyze clinical features of 
patients who discontinued EGTF-TKI treatment within two months. 
We reviewed clinical characteristics of the patients, retrospectively.
Results: Two hundred and fifty five patients received EGFR-TKIs 
from January 2010 to May 2013. Sixty nine patients (27%) disconti-
nued within 2 months. The mean age was 64.4 years and smoking 
rate was 71%. The stages were IIIB 19 patients, IVa 14 (20.3%), and 
IVb 35 (50.7%), respectively. Forty four (63.8%) patients were ade-
nocarcinoma, 19 (27.5%) squamous cell carcinoma, and 2 large cell 
carcinoma. In EGFR-TKI treatment, six patients (8.7%) in first line, 
43 patients (62.2%) in second line, and 20 patients (30%) in third 
line or more were treated. Early discontinuation rate of gefitinib 
was 15.9% (22/138), elortinib 40.1% (47 / 117). EFGR mutation was 
positive in five patients who all have in exon 19 deletion. The mean 
duration of EGFR-TKIs was the average 25.5day. Tumor response 
was no change 42%, progressive disease 39.1%, and non-evaluable 
18.9 %. After start of EGFR-TKIs, median survival time was only 68 
days. The mean of mass diameter before treatment was 4.7cm, and 
increased to 5.9 cm when stop the drug. Survival time after EGFR-
TKI treatment were significantly different based on ECOG PS (log-
rank, p = 0.002), WBC> 10,000/uL (p = 0.007), albumin <3.0 g/dl (p 
= 0.001), and > LDH 500 IU/L (p = 0.036). Sixty five (94.2%) patients 
were stopped medication before routine response evaluation with 
CT scan. The reasons of drug discontinuation were disease pro-
gression in 24 (34.8%), serious side effect in 17 (24.6%), patient’s 
refusal in 3 (4.3%), doctor‘s decision in 22 (31.9%).
Conclusion: In conclusion, drop-out rate was higher in elortinib 
treated patients. Patients with poor PS, elevated WBC count, low 
albumin level, high LDH level have to be careful in the treatment 
with EGFR-TKI.
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Specimen Cytology 
Direct Pyro PNA 
Cytology 
Direct - - - 
Pyro 0.381* - - 
PNA 0.486* 0.624* - 
FFPE 
Direct Pyro PNA 
FFPE 
Direct - - - 
Pyro 0.509* - - 
PNA 0.745* 0.684* - 
Cytology 
Direct Pyro PNA 
FFPE 
Direct 0.546* 0.504* 0.743* 
Pyro 0.386* 0.735* 0.626* 
PNA 0.491* 0.683* 0.936* 
FFPE, formalin-fixed, paraffin-embeded; Di-
rect, direct sequencing; Pyro, pyrosequenci-
ng; PNA, peptide nucleic acid (PNA) clamping 
method *k coefficient 
Conclusion: Cytology specimens had a diagnostic performance for 
the detection of EGFR mutations that was comparable to that of 
FFPE tissues. The high concordance rate among three techniques 
had good diagnostic performance. Additionally, At least two me-
thods are more likely to improve the detection rate of EGFR muta-
tion than only one.
Keywords: Cytology, Base sequence, EGFR genes, non-small cell 
lung cancer
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P1.10-027 A PHASE II TRIAL OF GENEXOL-PM(A CREMO-
PHOR-FREE, POLYMERIC MICELLE FORMULATION OF 
PACLITAXEL) AND GEMCITABINE IN PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG CANCER.
Eun Kyung Cho1, Shin Myung Kang2, Minkyu Jung1, Hee Kyung 
Ahn1, Inkeun Park1, Young Saing Kim1, Junshik Hong1, Sun Jin 
Sym1, Jinny Park1, Dong Bok Shin1, Jae Hoon Lee1
1Division Of Hematology And Oncology, Gachon University Gil Medical 
Center/Korea, 2Department Of Internal Medicine, Gachon University Gil 
Medical Center/Korea
Background: Genexol-PM is a Cremorphor EL(CrEL)-free poly-
meric micelle formulation of paclitaxel, which renders higher dose 
administration with less hypersensitivity. This study was designed 
to evaluate the efficacy and safety of Genexol-PM and gemcitabi-
ne combination in advanced non-small cell lung cancer patients as 
first line treatment
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P1.10-026 VALIDATION OF EGFR MUTATION TESTING 
USING CYTOLOGY SPECIMENS IN NON-SMALL CELL 
LUNG CARCINOMA: MULTI-INSTITUTIONAL STUDY OF 
128 CASES IN KOREA
Kyueng-Whan Min1, Wan Seop Kim1, Se Jin Jang2, Yoo Duk Choi3, 
Sunhee Chang4, Soo Hee Jung5, Lucia Kim6, Mee-Sook Roh7, 
Choong Sik Lee8, Jung Weon Shim9, Mi Jin Kim10, Geon Kook Lee11
1Department Of Pathology, Konkuk University School Of Medicine/
Korea, 2Asan Medical Center, University Of Ulsan/Korea, 3Chonnam 
National University Medical School/Korea, 4Inje University School Of 
Medicine Ilsan Paik Hospital/Korea, 5Yonsei University Wonju College 
Of Medicine/Korea, 6Inha University School Of Medicine/Korea, 7Dong-a 
University College Of Medicine/Korea, 8Chungnam National University 
College Of Medicine/Korea, 9Hallym University College Of Medicine/
Korea, 10Yeungnam University College Of Medicine/Korea, 11National 
Cancer Center/Korea
Background: EGFR gene mutations are the important factors pre-
dicting a patient’s response to EGFR TK inhibitors (EGFR TKIs). The 
importance of sensitive methods for the EGFR mutant detection is 
emphasized. The aim of study is to examine the comparative and 
concordance analyses among application of direct sequencing, 
pyrosequencing and peptide nucleic acid (PNA) clamping method 
to detect EGFR gene mutation using archived cytology specimens.
Methods: A total of 128 cases, which were diagnosed as ade-
nocarcinoma of the lung at 9 hospitals in Korea between 2006 and 
2012, were collected. Based on the above three methods, the con-
cordance rates of EGFR mutations for in exon 18, 19, 20, 21 were 
analyzed and validated in comparative cytology specimens and 
formalin-fixed, paraffin-embeded (FFPE) tissues.
Results: Comparison of EGFR mutant detection between cytology 
specimens and concurrent FFPE tissues from the same anatomic 
site had a concordance rate of 74.7%. The diagnostic performance 
of pyrosequencing and PNA clamping method in cytology spe-
cimen was higher than that of direct sequencing as well as FFPE 
tissue. In comparison of EGFR mutant detection in cytology speci-
men and FFPE tissue according to three methods, PNA clamping 
method showed high concordance rate (93.6%), than other me-
thods. The concordance rate between PNA clamping method and 
pyrosequencing was high (62.4%) in cytology specimen, whereas 
direct sequencing and PNA clamping method was as high as 74.5% 
in FFPE tissue.  
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Results: A total of 123 patients were enrolled (61 in the erlotinib 
arm and 62 in the pemetrexed arm). Median progression-free 
survival was 4.1 months (95% confidence interval [CI] 1.6-6.6) in 
the erlotinib group versus 3.9 months (95% CI 2.7-5.1) in the pe-
metrexed group, and the 6-month PFS was 45.1% and 38.8%, res-
pectively. The difference in the progression-free survival between 
the erlotinib and pemetrexed group was not significant (hazard 
ratio [HR] 0.92; 95% CI 0.62-1.37; P=0.683). Objective response rate 
appeared to be higher among patients in the erlotinib arm compa-
red with patients in the pemetrexed arm (19.7% vs 8.1%, P=0.062). 
Overall survival were similar between the two arms (P=0.970). Both 
regimens were well tolerated. The three most commonly reported 
adverse events were rash (54.1%) , fatigue (19.7%) and diarrhea 
(16.4%) in the erlotinib group, while they were fatigue (25.8%), nau-
sea (24.2%) and anorexia (14.5%) in the pemetrexed group.
Conclusion: Treatment with erlotinib or pemetrexed demonstrated 
clinically equivalent efficacy and toxicity in the second-line setting 
for advanced EGFR wild-type and EGFR FISH-positive adenocar-
cinoma, although objective response rate appeared to be higher 
among patients in the erlotinib arm. Clinical trial information: 
NCT01565538.
Keywords: non-small cell lung cancer, second-line
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P1.10-029 AN ANALYSIS OF THE DRUG-DRUG INTER-
ACTION BETWEEN DOCETAXEL AND GEFITINIB IN 
PATIENTS WITH ADVANCED NON-SMALL CELL LUNG 
CANCER
Masanori Motonaga1, Yoshinori Makino1, Noboru Yamamoto2, 
Reiko A. Makihara1, Tomohide Tamura2, Yoshikazu Hayashi1
1Department Of Pharmacy, National Cancer Center Hospital/Japan, 
2Department Of Thoracic Oncology, National Cancer Center Hospital/
Japan
Background: Both Docetaxel (DTX) and Gefitinib (Gef) have been 
established as a standard therapy for the treatment of non-small 
cell lung cancer (NSCLC). Since these active two agents have diffe-
rent mechanisms of action as well as toxicity profiles, the combined 
use of DTX and Gef could be highly effective for the advanced 
NSCLC. However, as they are both metabolized by cytchrome P450 
(mainly CYP3A4) enzyme, there are concerns about drug-drug 
interactions. The aim of this study is to assess the influence by the 
combined use of Gef on DTX‘s pharmacokinetics (PKs) and toxicity 
in patients with advanced NSCLC.
Methods: DTX was intravenously administered over 1-hr every 3 
weeks on day 1. Gef (250-mg) was co-administrated orally once 
daily from day 2. The dose of DTX was escalated from 45 mg/m2 
(level 1, n = 6) to 60 mg/m2 (level 2, n = 6). The total of 20-point 
PK samplings were performed on day 1 (DTX alone) and day 22 
(DTX + Gef) to measure plasma concentrations of DTX using high- 
performance liquid chromatography (HPLC). DTX PK profile was 
estimated by non-compartment analysis. Analysis of variance was 
performed on AUC0-24h to estimate adjusted mean differences bet-
ween day 1 and 22. DTX clearance (CL), geometric mean (GM) of 
AUC, adjusted GM ratio (GMR, i.e., the ratio of DTX AUC on day 22 
to that in day 1) and 90% CI of the GMR were also calculated.
Results: Twelve patients with advanced NSCLC were enrolled. 
Methods: This is a prospective single arm, single center Phase 
II study. Patients with advanced NSCLC received Genexol-PM at 
230mg/m2 on day 1 and gemcitabine 1000mg/m2 on day 1 and 
day 8 of a 3-week cycle as first-line chemotherapy. Six cycles of 
chemotherapy were administered unless there is a disease pro-
gression. The primary endpoint was response rate.
Results: Forty-three patients received the study drugs with median 
of 4 cycles per patient (range, 1-6). Among 35 patients who recei-
ved more than one cycle, mean dose intensity of CrEL-free pacli-
taxel and gemcitabine was 209 mg/m2/3-week and 1853mg/m2/3-
week respectively. Overall response rate was 46.5%. The median 
progression free survival was 4.0 months (95% CI 2.0-6.0 months) 
and median overall survival was 14.8 months (95% CI 9.1-20.5 
months). 18 patients (51%) experienced grade 3/4 adverse events, 
including neutropenia or febrile neutropenia (n=7), pneumonia 
(n=3), asthenia (n=3), peripheral neuropathy (n=2), diarrhea (n=1), 
skin rash (n=1), myalgia (n=1), pulmonary thromboembolism (n=1), 
LV dysfunction (n=1), dyspnea with sudden death (n=1). Adverse 
events leading to drug discontinuation were occurred in 9 patients, 
among which 2 patients were died of adverse events (pneumonia, 
dyspnea with sudden death)
Conclusion: CrEL-free paclitaxel in combination with gemcitabine 
demonstrated comparable antitumor activity with less emetogeni-
cities in non-small cell lung cancer patients. Safety issue should be 
evaluated cautiously.
Keywords: non-small cell lung cancer, chemotherapy, CrEL-free 
paclitaxel
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P1.10-028 A PHASE II TRIAL OF ERLOTINIB VERSUS PE-
METREXED AS SECOND-LINE THERAPY IN TREATING 
PATIENTS WITH ADVANCED EGFR WILD-TYPE AND 
EGFR FISH-POSITIVE LUNG ADENOCARCINOMA
Si-Yu Wang, Ning Li, Wei Ou, Liang Zhang, Song-Liang Zhang
Thoracic Surgery, Sun Yat-Sen University Cancer Center/China
Background: Both erlotinib and pemetrexed are second-line 
treatment options for patients with advanced non-small cell lung 
cancer. The value of erlotinib in the second-line setting in lung 
adenocarcinoma with EGFR wild-type and EGFR gene high polyso-
my or gene amplification remains unclear. Therefore, we undertook 
this study to investigate the efficacy and safety of erlotinib versus 
pemetrexed as second-line therapy in treating patients with ad-
vanced EGFR wild-type and EGFR FISH-positive (high polysomy or 
gene amplification) lung adenocarcinoma.
Methods: In this open-label, phase II study, EGFR mutation sta-
tus was assessed by the amplification-refractory mutation system 
(ARMS) method and EGFR copy number was assessed by fluores-
cent in situ hybridization (FISH) method in patients with adenocar-
cinoma who had progressed during the first-line platinum-doublet. 
Only patients with EGFR wild-type and EGFR FISH-positive ade-
nocarcinoma were randomly assigned (1:1) to receive erlotinib 
(250mg, per day, orally) or pemetrexed (500mg/m2, day 1 of 21-day 
cycle, intravenously), until disease progression or death, unaccep-
table toxicity, or a request for discontinuation by the patient. The 
primary end point was progression-free survival.
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between the groups. However, a higher incidence of grade III/
IV hyponatrimia (25%) was observed in our patients which needs 
to be investigated further. Global health status improved signifi-
cantly in both treatment arms at the end of 3 cycles compared to 
baseline. Pooled data of selected Quality of Life indices is shown 
below. Table 1: Mean difference in selected Quality of Life indices 
(3rd Cycle Vs. Baseline)  
QOL scale Mean  difference SEM P value 
Global health status 18.39 3.10 0.001 
Pain -7.77 3.46 0.023 
Dysponea -7.77 3.81 0.05 
Insomnia -4.44 3.06 0.017 
Haemoptysis -3.33 2.10 0.043
Conclusion: Pemgem had similar pharmacokinetic and safety profi-
le as Alimta. Generic substitution would be cost effective and likely 
to yield comparable efficacy.
Keyword: Pemetrexed,Generic formulation,Pharmacokinetic,Non-
Small Cell Lung Cancer
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P1.10-031 PLATINUM-BASED THERAPY WITH GEMCITA-
BINE OR DOCETAXEL IN ADVANCED NON-SMALL CELL 
LUNG CANCER: A RETROSPECTIVE ANALYSIS TO EVA-
LUATE DIFFERENCES IN RESPONSE DUE TO ETHNICITY
Qamruzzaman Chowdhury1, Md Salim Reza2, Arifur Rahman2, 
Latifa Sultana2, Ferdous A. Begum3, Fariah Sharmeen2, Md Nurun-
nabi2, A S M F.K. Chowdhury4, Daud H. Khan4
1Radiation Oncology, National Institute Of Cancer Research And Hos-
pital/Bangladesh, 2Radiotherapy And Oncology, Square Hospitals 
Limited/Bangladesh, 3Medical Oncology, National Institute Of Cancer 
Research And Hospital/Bangladesh, 4Public Health, North South Uni-
versity/Bangladesh
Background: Lung cancer has one of the highest incidences and 
mortalities of cancer worldwide, majority being non-small cell lung 
carcinoma (NSCLC). Platinum-based doublet chemotherapy re-
mains the standard regimen for the treatment of NSCLC, providing 
an overall median survival of 8-10 months. The most common regi-
mens include cisplatin or carboplatin with gemcitabine, paclitaxel 
or docetaxel. A multicenter study noted ethnicity to be a particular 
prognostic factor where significant differences were observed in 
response rates between Asian and Caucasian patients (65% vs 31% 
respectively) who all received docetaxel (75 mg/m2) and carbopla-
tin (AUC 6). To investigate any such differences in therapeutic res-
ponse in Bangladeshi patients from previous trials, a retrospective 
analysis was performed to evaluate survival in Bangladeshi NSCLC 
patients from a single institution.
Methods: 62 patient records, between January 2009 and March 
2013, from Square Hospital, Bangladesh were eligible. For the 
gemcitabine-platinum (GP) arm, 30 patients received either gem-
citabine (D1 and D8-1000mg/m2) and cisplatin (75 mg/m2) or gem-
citabine (1000mg/m2) and carboplatin (AUC 5). For the docetaxel-
platinum (DP) arm, 32 patients received either docetaxel (75mg/
Two out of 12 patients at dose level 1 withheld the second cycle 
of treatment (i.e., on day 22) due to progressive disease, and DTX 
PKs data were available for the rest of 10 patients treated on day 
1 and 22. The toxicity profiles of DTX and Gef in this study were 
generally acceptable, and frequency and severity of hematological 
toxicity possibly related to DTX were similar to those with historical 
data in Japanese NSCLC patients. The ≥ grade 3 neutropenia was 
observed in 66% of patients. GMs of AUC0-24 on day 1 and 22 were 
1128 and 1184 ng•h /ml at dose level 1 (n=4), while those were 
1827 and 1630 ng•h /ml at dose level 2 (n=6). GMs of DTX CL in 
all patients on day 1 and 22 were 60 and 63 L/h and GMRs at dose 
level 1 and 2 were 1.05 (90%CI: 0.96-1.14) and 0.89 (90%CI: 0.82-
0.97), respectively.
Conclusion: The above results demonstrate that DTX PKs is not 
affected by the combined use of Gef in patients with advanced 
NSCLC. These two active agents can be safely co-administered.
Keywords: drug-drug interaction, advanced non-small cell lung 
cancer, docetaxel, gefitinib
POSTER SESSION 1 - CHEMOTHERAPY  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.10-030 COMPARATIVE PHARMACOKINETICS OF 
TWO FORMULATIONS OF PEMETREXED IN INDIAN 
ADULT CHEMO-NAIVE, ADENOCARCINOMA NON-
SMALL CELL LUNG CANCER PATIENTS.
Krunal V. Kavathiya1, Vikram Gota1, Damodaran Se1, Anand G. 
Patil1, Murarilal Gurjer1, K Prabhash2, A Joshi2, V Noronha2
1Clinical Pharmacology,ks-102, Tata Memorial Centre,actrec/India, 
2Medical Oncology, Tata Memorial Hospital/India
Background: Pemetrexed (Alimta, Eli Lilly) with platinum doublet is 
an effective drug for first-line treatment of patients with locally ad-
vanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Inno-
vator products are generally highly priced which limits their utility 
in developing countries. In India, a generic formulation (Pemgem, 
Dr. Reddy’s Laboratories) is marketed at 25% the cost of Alimta. 
Results of a study comparing the pharmacokinetic and safety profi-
le of the two formulations of pemetrexed are discussed here.
Methods: This study was approved by TMC-ACTREC-IRB and 
registered with Clinical Trials Registry- India (CTRI). Patients were 
enrolled from a tertiary care cancer hospital in India as per prede-
fined selection criteria mentioned the protocol. Pemetrexed (500 
mg/m2) was administered as a 10 minute short infusion. All patients 
received standard premedication. Pharmacokinetic blood samples 
were collected at predose and 10 minutes (just before end of in-
fusion), 15 min., 30 min., 50 min., 1 hr., 1 hr. 20 min., 2 hrs.,4 hrs.,6 
hrs., 8 hrs. and 24 hrs after starting the infusion. Plasma pemetrex-
ed levels were determined by a validated HPLC method. Toxicity 
was graded using CTCAE v. 4.03. Quality of life questionnaire was 
taken at baseline and at end of 3rd cycle.
Results: Twenty four patients were enrolled on the study, eight 
in Alimta arm and sixteen in Pemgem arm. Patient demogra-
phics were comparable in the two arms. Mean Area Under the 
Concentration-Time Curve (AUC0-24 hr) was 222.06 vs. 253.7 mg h/L 
and mean Cmax was 106.5 and 130.7 mg/L in Pemgem and Alimta 
arms respectively. Volume of distribution of pemetrexed was 16.59 
and 17.56 L, clearance was 3.83 vs. 4.3 L/hr and half-life was 3.29 
and 2.43 hr in the two arms respectively. Toxicity was comparable 
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Background: Patients affected by lung adenocarcinoma carrying 
a EGFR sensitizing mutation of significantly benefit from TKIs in 
terms of progression free survival (PFS), activity and symptoms 
control. The potential predictive role of clinico-pathological pre-
dictors should be investigated in order to optimize the benefit of 
the currently available drugs.
Methods: A literature-based meta-regression and sensitivity ana-
lyses to investigate the differential effect of TKIs according to de-
mographic and molecular factors, was accomplished, analyzing all 
RCTs exploring TKIs versus chemotherapy for 1st-line treatment of 
patients affected by EGFR mutant NSCLC.
Results: 9 trials (3,741 patients) were identified (EGFR mutant: 
1,797). 9 RCTs were evaluable for PFS (1,790 patients) and response 
(1,733 patients); 7/9 for survival (1,075 patients). With regard to PFS 
and response, a significant interaction according to ethnicity (Asi-
an versus Caucasian versus mixed, p=0.006 [Cochrane-Q 10.275] 
and p=0.047 [6.129], respectively), and trial design (retrospective 
versus prospective EGFR analysis, p=0.024 [5.067] and p<0.0001 
[13.633]), was found. No difference was observed in term of survi-
val. A significant interaction for response was found, with an Odds 
Ratio in favour of afatinib, erlotinib and gefitinib (versus chemothe-
rapy) of 2.70 (95% CI 2.11-3.45), 2.67 (95% CI 1.81-3.93) and 1.81 
(95% CI 1.46-4.78).  
Interaction  
[Cochrane-Q] 
 P value
Interaction  
[Cochrane-Q]  
P value
PFS Response
Overall (ERL vs 
GEF vs AFA)
[4.266] p=0.188 [9.924] p=0.007
ERL vs AFA [3.321] p=0.068 [0.056] p=0.813
ERL vs GEF [9.714] p=0.054 [5.169] p=0.023
AFA vs GEF [0.002] p=0.962 [7.351] p=0.007
Conclusion: Although limited by the retrospective nature and the 
heterogeneity, these data indicate a differential effect of TKIs ac-
cording to the design and the ethnicity, and in response according 
to TKIs. These data may constitute the background to develop a 
clinical predictive model to better estimate the expected benefit 
when using EGFR TKIs in patients with EGFR mutant NSCLC
Keyword: meta-analysis; lung cancer; gefitinib; afatinib; erlotinib; 
ethnicity; trial design
m2) and cisplatin (75mg/m2) or docetaxel (75mg/m2) and carbopla-
tin (AUC 5). Median age for GP arm and DP arm were 61 and 57.5 
years respectively. All the patients have received a minimum of 3 
cycles of the respective regimen. Primary end-point was median 
overall survival (MOS)
Results: Analysis revealed a MOS of 14 months for GP (95% CI; 
8.56-19.43) and 13 months (95% CI; 8.94-17.06) for DP. The 1 year 
survival percentages were 33.3% and 46.9%% for the GP and DP 
arms respectively; 2 year survival was only observed in GP arm 
(6.67%). Adverse neutropenic response was reported in only 4.8% 
(3) of all patients. This includes 2 cases of Grade III neutropenia in 
the DP arm and 1 Grade neutropenia in the GP arm.
Conclusion: Though no statistical significance (p>0.05) was obser-
ved between the two groups, the MOS obtained for both groups 
were significantly longer than previous trials conducted for the res-
pective regimens, thus confirming our hypothesis and highlighting 
the potential impact of ethnicity on therapeutic response. Therefo-
re, ethnicity based trials should be conducted in the future to pro-
perly evaluate response of any particular therapeutic regimen.
Keywords: Gemcitabine and Docetaxel, Non small cell lung can-
cer, Median Overall Survival (MOS), Ethnicity
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P1.10-032 SENSITIVITY AND META-REGRESSION ANA-
LYSIS EXPLORING POTENTIAL OUTCOMES PREDICTORS 
IN RANDOMIZED TRIALS (RCTS) EVALUATING THE 
BENEFIT OF 1ST-LINE TYROSINE KINASE INHIBITORS 
(TKIS) FOR EPIDERMAL GROWTH FACTOR RECEPTOR 
(EGFR) MUTANT LUNG ADENOCARCINOMA.
Sara Pilotto1, Umberto Peretti1, Massimo Di Maio2, Francesco Mas-
sari1, Stefania Kinspergher1, Roberto Ferrara1, Isabella Sperduti3, 
Diana Giannarelli3, Filippo De Marinis4, Giampaolo Tortora1, Emi-
lio Bria1
1Medical Oncology, Az. Osp. Univ. Integr. (a.o.u.i.), University Of Vero-
na/Italy, 2National Cancer Institute/Italy, 3Regina Elena National Can-
cer Institute/Italy, 4Azienda Ospedaliera San Camillo-forlanini/Italy
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Grade 1/2 hemorrhage in pulmonary/upper respiratory (1.8% 
vs. 13.3%; p< 0.001) and Grade 1/2 joint pain (1.8% vs. 13.9%; 
p<0.001) with PCB. Patients on PemC required more red blood 
cell (RBC) transfusions (34.5% vs. 11.4%; p<0.001), but there was 
no difference in platelet transfusions (p=0.621). Erythropoietic 
stimulating agents (ESAs) were used more frequently (19.9% vs. 
7.2%; p<0.001) in PemC, and granulocyte colony-stimulating factor 
(G-CSF) use was significantly higher with PCB (17.0% vs. 30.1%; 
p=0.005). Requirement for antibiotics (p=0.323) and antiemetics 
(p=0.574) did not differ between PemC and PCB. There were no 
differences between PemC and PCB in the number of patients with 
at least one hospitalization (34.5% vs. 31.9%; p=0.645), and the 
mean length of stay between PemC (8.2d +/- 6.79) and PCB (8.8d 
+/- 7.33) did not differ (p=0.682;Wilcoxon rank sum test).
Conclusion: The toxicity profiles of PemC and PCB were consis-
tent with previous reports. Toxicities documented as important to 
patients were split, with mild-to-moderate nausea more common 
for PemC and alopecia, infection and neuropathy more frequent 
for PCB. Resource intense toxicities were also divided. Hospitali-
zations did not differ between treatments. ESAs and RBC transfu-
sions were more common with PemC, and G-CSF use was more 
common with PCB. ClinicalTrials.gov identifier:NCT00948675
Keyword: pemetrexed, NSCLC, resource utilization, carboplatin
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P1.10-034 WEIGHT GAIN AS A PROGNOSTIC FACTOR 
ON PATIENT OUTCOMES IN ADVANCED, NONSQUA-
MOUS, NON-SMALL CELL LUNG CANCER
Jyoti D. Patel1, Jose R. Pereira2, Jian Chen3, Jingyi Liu3, Susan C. 
Guba3, William J. John3, Mauro Orlando3, Giorgio Scagliotti4, Philip 
Bonomi5
1Feinberg School Of Medicine, Northwestern University/United States 
Of America, 2Instituto Brasileiro De Cancerologia Toracica/Brazil, 3Eli 
Lillyand Company/United States Of America, 4University Of Turin/Ita-
ly, 5Rush University Medical Center/United States Of America
Background: Patients with advanced/metastatic non-small cell 
lung cancer (NSCLC) have a poor prognosis and low survival rates. 
One of the first notable symptoms of advanced lung cancer is un-
explained weight loss. We evaluated weight gain (> 5% post base-
line), as an early prognostic factor for clinical outcome, in advanced 
nonsquamous, NSCLC patients.
Methods: This retrospective analysis reports on three randomized 
phase III studies with survival and response data from a total of 
2301 advanced, nonsquamous NSCLC patients who received 
pemetrexed or other chemotherapy plus a platinum or targeted 
agent, as first-line therapy. Body weight was recorded before and 
after treatment by each study’s schedule. Baseline weight was 
defined as the last non-missing weight measure before first treat-
ment. Post baseline weight was defined as the maximum weight 
measured after starting treatment. Patients were analyzed using 
log-rank test and adjusted Cox modeling to assess the relationship 
between weight gain and overall survival (OS) and progression-
free survival (PFS). Logistic regression was used to assess the asso-
ciation between baseline covariates and post-baseline weight gain.
Results: Patients were a mean age of 61 years (range 26 – 86) and 
most were of Caucasian descent (77.0%). A majority of patients 
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P1.10-033 SAFETY AND RESOURCE USE IN PRO-
NOUNCE: A RANDOMIZED, PHASE 3, OPEN-LABEL 
STUDY OF PEMETREXED PLUS CARBOPLATIN WITH 
MAINTENANCE PEMETREXED (PEMC) AND PACLITA-
XEL PLUS CARBOPLATIN PLUS BEVACIZUMAB WITH 
MAINTENANCE BEVACIZUMAB (PCB) IN PATIENTS WITH 
ADVANCED NON-SQUAMOUS (NS) NON-SMALL-CELL 
LUNG CANCER (NSCLC)
Helen J. Ross1, David Spigel2, Robert W. Weaver3, Ramaswamy 
Govindan4, Viran Holden5, Naveed M. Chowhan6, Thaddeus Beck7, 
David Waterhouse8, Manuel R. Modiano9, Vijay P. Rao10, Katherine 
B. Winfree11, Symantha Melemed11, Jingyi Liu11, Andrew G. Kous-
tenis11, Susan C. Guba11, Waldo I. Ortuzar11, Coleman Obasaju11, 
Ralph Zinner12
1Mayo Clinic/United States Of America, 2Sarah Cannon Research Insti-
tute/United States Of America, 3Florida Cancer Specialists/United Sta-
tes Of America, 4Washington University Medical School/United States 
Of America, 5Mercy Clinic Cancer And Hematology/United States Of 
America, 6Floyd Memorial Cancer Center Of Indiana/United States 
Of America, 7Highlands Oncology Group/United States Of America, 
8Ohc, Oncology Hematology Care Inc./United States Of America, 9Acrc/
arizona Clinical Research Center/United States Of America, 10Mid Da-
kota Clinic Hematology And Oncology/United States Of America, 11Eli 
Lillyand Company/United States Of America, 12University Of Texas MD 
Anderson Cancer Center/United States Of America
Background: Two combination chemotherapy regimens were 
compared in a Phase 3, randomized, open-label United States only 
study. The two-drug regimen of pemetrexed/carboplatin followed 
by maintenance pemetrexed (PemC) was compared to the three-
drug regimen of paclitaxel/carboplatin/bevacizumab followed by 
maintenance bevacizumab (PCB). The primary endpoint of impro-
ved progress-free survival (PFS) without Grade 4 toxicity (G4PFS) 
for PemC over PCB was not met in PRONOUNCE, as reported by 
Zinner et al. (ASCO, 2013). No difference in PFS or overall survival 
(OS) for PemC vs. PCB was observed. Both regimens demonstra-
ted tolerability, but toxicity profiles differed.
Methods: Patients 18+ years of age with Stage IV chemonaïve 
non-squamous non-small-cell lung cancer (NS-NSCLC) were rando-
mized to PemC (n=182) or PCB (n=179). Safety data were compared 
for patients who received ≥1 dose of study treatment (PemC:171; 
PCB:166), and resource use including concomitant medications, 
transfusions, and hospitalizations was recorded. Measures were 
compared between arms using Fisher’s exact test, if not otherwise 
specified. Protocol-defined chemotherapy infusion time was 0.7 
hours for PemC and 4-5 hours for PCB. For the primary endpoint of 
G4PFS, the G4 events were reported regardless of drug causality.
Results: Of 152 G4PFS events for PemC, 37 (24.3%) resulted from 
first occurrence of a G4 event. Of 144 G4PFS events for PCB, 64 
(44.4%) resulted from first occurrence of a G4 event. The safety 
profile for the entire study demonstrated that patients on PemC 
experienced significantly more drug-related Grade 3/4 anemia 
(18.7% vs. 5.4%; p<0.001), Grade 3/4 thrombocytopenia (24.0% vs. 
9.6%; p<0.001), and Grade 1/2 nausea (46.8% vs. 28.9%; p<0.001). 
Patients on PCB experienced significantly more drug-related 
Grade 3/4 neutropenia (24.6% vs. 48.8%; p<0.001) and Grade 1/2 
alopecia (8.2% vs. 28.3%; p<0.001). There was a significantly hig-
her rate of drug-related Grade 1/2 sensory neuropathy (8.2% vs. 
30.1%; p<0.001), Grade 1/2 hypertension (0.0% vs. 9.6%; p<0.001), 
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tary Hospital of Mexico retrospective evaluation was conducted on 
the records of patients who were treated for NSCLC adenocarcino-
mas between 2008 and 2011, for those who use the combination 
of Pemetrexed / Carboplatin / Bevacizumab and Pemetrexed / 
carboplatin. The primary objectives of this study are an analysis of 
descriptive and multivartiate statistics on the following variables: 
Overall survival , progression-free interval, response rate , number 
of cycles received, toxicity, , diagnosis and smoking history. The 
results were analyzed using the SPSS program, in which we used 
Kaplan-Meier for the analysis of Overall survival (OS) and Progres-
sion-free-survival and U-MANN-WHITNEY for the correlation bet-
ween PFS and smoking history and PFS and response rate.
Results: Data were obtained from a review of thirty patients with 
lung adenocarcinoma stage IIIb and IV treated between the years 
2008-2011 (fifteen each arm) with the schemes of Pemetrexed / 
Carboplatin / Bevacizumab and Pemetrexed / carboplatin with the 
following results: 
VARIABLE
PEMETREXED/
CARBOPLATIN 
(months) n=15 
PEMETREXED/CARBO-
PLATIN/BEVACIZUMAB 
(months) n=15 
OS (GENE-
RAL)
15.2 12.7 (P=0.77NS)
OS SMOKER 12.1 18.0 (NS)
OS NON 
SMOKER
10.5 13.1 (NS)
PFS (GENE-
RAL)
8.9 8.5 (P=0.69NS)
PFS SMOKER 10.2 8.1 NS
PFS NON 
SMOKER
8.1 9.5 NS
Conclusion: In this case series shows That adding bevacizumab 
to first-line treatment with chemotherapy in NSCLC (Adenocarci-
noma) based on pemetrexed / carboplatin / bevacizumab not In-
creased OS and PFS in overall population (OS 15.2 VS 12.7 m, P = 
0.77NS), (PFS 8.5 vs 8.0 m P = 0.69 (NS). They found a trend toward 
increased overall survival in smokers who used Avastin not reached 
statistical significance.the hematologic and non-haematological 
toxicity was higher in the PCB arm vs. PC.There were no grade IV 
adverse events In this series of cases as well as bleeding events or 
deaths related to treatment
Keyword: bevacizumab,efectiveness,pemetrexed,carboplatin, 
chemotherapy
had adenocarcinoma (73.8%), were male (59.8%) with an ECOG 
performance status (PS) of 0/1/2 (38.5%/60.2%/1.4%). Many pati-
ents were smokers or former smokers (55.7%) with Stage IV disease 
(83.1 %), according to the American Joint Committee on Cancer, 
editions. 5/6 and had an average weight at baseline of 71.4 kg. A 
total of 421 (18.3%) patients had a >5% increase in weight (>5% 
subgroup) after baseline with a statistically significant increase in 
OS and PFS. Median OS was 16.7 months for patients in the >5% 
subgroup versus 10.7 months for patients who gained <5% weight 
(< 5% subgroup; [n=1880]; p<0.001). PFS was 6.9 months for the 
>5% subgroup versus 4.8 months for <5% subgroup; p<0.001). 
Differences in overall response rate (ORR = CR + PR) and disease 
control rate (DCR = CR + PR + SD) were also significant. ORR 
was 50.8% for >5% subgroup versus 25.4% for < 5% subgroup 
(p<0.001). DCR was 91.5% for >5% subgroup and 63.6% for <5% 
subgroup (p<0.001). Cox modeling revealed patients in the >5% 
subgroup had significantly longer survival (HR=0.56, [95% CI 0.49-
0.64]; p<0.001) than patients with <5% subgroup, after adjusting 
for baseline age (<65 versus 65), sex, ECOG PS (0 versus 1/2), 
histology (adenocarcinoma versus others), and study. Similar signi-
ficant results were also found for PFS. Logistic regression indicated 
a significant association between weight gain and age. More pati-
ents aged <65 had a >5% weight gain (p<0.001).
Conclusion: This exploratory analysis showed that substantial 
weight gain (>5%) occurred after initiation of platinum-based che-
motherapy in approximately 20% of advanced/metastatic, nons-
quamous NSCLC patients. There was a positive correlation bet-
ween weight gain and improved, OS, PFS and response in patients 
treated in these phase III studies.
Keywords: prognostic factor, nonsquamous, pemetrexed, weight 
gain
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P1.10-035 EFFECTIVENESS OF BEVACIZUMAB IN PATI-
ENTS WITH LUNG ADENOCARCINOMA TREATED WITH 
PEMETREXED / CARBOPLATIN AS FIRST-LINE CHEMO-
THERAPY
Manuel E. Magallanes1, Angelica Cruz2, Fernando P. Zincer1, Yolan-
da Bautista3, Isabel E. Aceves4, Monica S. Velazco1
1Medical Oncology, Militar Hospital Of Mexico/Mexico, 2Medical Oncolo-
gy, Hospital Angeles Roma/Mexico, 3Medical Oncology, Instituto Mexi-
cano Seguro Social/Mexico, 4Medical Oncology, Issste Leon/Mexico
Background: The combination of pemetrexed /carboplatin / beva-
cizumab based on previous findings it is possible and has been 
tested in phase II studies (Patel, ASCO 2008) which showed an 
increase in progression-free survival to 14.1 months / 7.8m months 
patients using the combination of pemetrexed / carboplatin / 
bevacizumab vs pemetrexed / carboplatin, in patients with lung 
adenocarcinoma. Recent evidence on the combination of peme-
trexed / carboplatin / bevacizumab in first line of treatment for 
NSCLC (Pointbreak study showed no benefit in terms of overall 
survival asurvival (6.0 vs 5.6months (P = 0.012)) In maintenance 
therapy esenario AVAPERL study shows a significant Increase in 
progression-free survival to 10.2 months in patients receiving pe-
metrexed / carboplatin / bevacizumab versus pemetrexed / carbo-
platin / placebo, which is data that is unprecedented.
Methods: In the medical oncology department of the Central Mili-
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vements in supportive care, in the later time period more effective 
second and third line therapy may have contributed to longer OS.
Keyword: overall survival, meta-analysis, second line therapy
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P1.10-037 A RETROSPECTIVE COMPARISON OF AD-
JUVANT CHEMOTHERAPEUTIC REGIMEN FOR NON-
SMALL CELL LUNG CANCER (NSCLC): PACLITAXEL PLUS 
PLATINUM VERSUS VINORELBINE PLUS CISPLATIN
Won Jin Chang, Moon Ki Choi, Jung Yong Hong, Moonjin Kim, Su 
Jin Lee, Silvia Park, Sungmin Kim, Ji Yun Lee, Sung Hee Lim, Jin 
Seok Ahn, Keunchil Park, Myung-Ju Ahn, Jong-Mu Sun
Samsung Medical Center/Korea
Background: Adjuvant vinorelbine/cisplatin (VC) has been de-
monstrated to increase overall survival in patients with AJCC 6th 
stage II/IIIA non-small cell lung cancer (NSCLC). Although adjuvant 
paclitaxel/carboplatin failed to demonstrate its efficacy in a study 
which enrolled only patients with AJCC 6th stage IB NSCLC, the 
exploratory analysis showed that patients with large tumor (≥ 4cm) 
got survival benefits from this regimen. We need to compare the 
clinical outcomes of these two regimens as adjuvant chemotherapy 
for NSCLC, since the previous prospective trials used different eli-
gible stage criteria and AJCC stage system was recently updated.
Methods: We retrospectively analyzed patients with surgically 
completely resected NSCLC between December 2004 and De-
cember 2011. They received adjuvant chemotherapy using either 
paclitaxel/platinum (PP) or VC. Clinicopathological parameters, 
survivals including disease free survival (DFS) and overall survival 
(OS) and toxicity between two groups were compared. All tumor 
stages were updated based on the AJCC 7th edition.
Results: Of the 467 patients with surgically resected NSCLC, 236 
received PP (paclitaxel/cisplatin, n=29; paclitaxel/carboplatin, 
n=206) and 231 patients got VC (n= 231). Two groups were well 
balanced with regard to demographics, histology, stage and type 
of surgery. Efficacy was comparable between two regimens: DFS 
(PP vs. VC: 65 vs. 55 months; p=0.42) and OS (73 vs 58 months; 
P=0.37). Regarding the adverse events, sensory neuropathy (41% 
vs. 11%), alopecia (19% vs. 4%), and myalgia (32% vs. 5%) are more 
frequent in the PP group, while anemia (71% vs. 87%), neutropenia 
(22% vs. 71%), fatigue (11% vs. 18%), anorexia (19% vs. 41%), and 
vomiting (9% vs. 19%) are more frequent in the VC group.
Conclusion: Although the adverse event profiles were different, 
the efficacy data in terms of DFS and OS were comparable bet-
ween the two adjuvant regimens. Therefore, both regimens are 
appropriate as the adjuvant chemotherapy for NSCLC, and the 
selection can be done personally according to the expected profi-
les of adverse events.
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P1.10-036 PROLONGATION OF OVERALL SURVIVAL IN 
NON-SMALL CELL LUNG CANCER BEFORE AND AFTER 
FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL 
OF ACTIVE SECOND LINE AGENTS: A META-ANALYSIS
Mary Jo Fidler, Sanjib Basu, Marta Batus, Philip Bonomi
Rush University Medical Center/United States Of America
Background: Overall survival (OS) may be confounded by subse-
quent treatments in advanced NSCLC. To explore the potential 
effect of newer second-line and subsequent therapies on the re-
sults of clinical trials, a systematic literature review was conducted 
to examine OS and progression free (PFS) data from first line treat-
ment trials published prior to and after the emergence of targeted 
therapies and newer FDA-approved second-line agents.
Methods: The PubMed database was searched for phase III first 
line trials in NSCLC over two 2 time frames: 1998 to 2005 and 2006 
to 2011. Trials were included if platinum-based doublets were eit-
her the investigational or control regimen in previously chemothe-
rapy-naive patients and if published in the English language. Baye-
sian statistical methods were used in random effects meta-analysis 
and meta-regression.
Results: 13 clinical trials were included from the 1998-2005 and 
17 trials from 2006-2011. The median percentage of women and 
adenocarcinoma included in the two time frames were 28 and 33, 
and 44 and 52 percentages, respectively. The difference in median 
survivals for the early and recent time frames (9.35 and 11.03 mo) 
in the treatment group was found to be significantly different (95% 
interval being shifted away from 0, Fig 1). However, the difference 
in the control group (9.74 and 10.59 mo) was not significant. The 
temporal trend in median survival over the time scale was further 
examined using meta regression with time as a covariate. The 
time trends or regression slopes for both the treatment (0.37, 95% 
interval 0.14 to 0.61) and the control (0.25, 0.06 to 0.43) arms were 
found to be significantly positive suggesting increasing trends in 
median survival over time. Only 18 of the 30 trials had PFS data 
with only 5 from the 1998-2005 timeframe. No significant diffe-
rence in PFS was found over the two time periods. 
 
Conclusion: These analyses suggest longer survival in more re-
cently treated NSCLC patients without a significant difference in 
PFS. Although this observation may have been influenced by the 
inclusion of more women and adenocarcinoma patients and impro-
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P1.10-039 CHARACTERISTICS OF RE-BIOPSIED NSCLC 
PATIENTS WITH ACQUIRED RESISTANCE TO EPIDERMAL 
GROWTH FACTOR RECEPTOR TYROSINE KINASE INHI-
BITORS
Daisuke Arai1, Kenzo Soejima1, Hiroyuki Yasuda1, Tetsuo Tani1, 
Aoi Kuroda1, Kota Ishioka1, Keiko Ohgino1, Takashi Sato1, Hideki 
Terai1, Shinnosuke Ikemura1, Junko Hamamoto1, Katsuhiko Nao-
ki1, Yuichiro Hayashi2, Tomoko Betsuyaku1
1Division Of Pulmonary Medicine, Department Of Medicine, Keio Uni-
versity School Of Medicine/Japan, 2Department Of Pathology, Keio 
University School Of Medicine/Japan
Background: Dramatic response of epidermal growth factor re-
ceptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) to non-small 
cell lung cancer (NSCLC) with activating EGFR mutations is known 
to be followed by subsequent resistance. Although various mecha-
nisms of acquired resistance, such as EGFR secondary mutation 
(exon 20 T790M), the amplification of mesenchymal-epithelial 
transition factor, and hepatocyte growth factor overexpression 
have been reported, their frequency is not globally consistent. The 
purpose of this study is to retrospectively analyze the frequency of 
appearance of exon 20 T790M in re-biopsied specimens from NS-
CLC patients exhibiting acquired resistance to EGFR-TKIs.
Methods: We enrolled 16 patients who were treated with EGFR-
TKIs after diagnosis of NSCLC with EGFR activating mutations and 
were re-biopsied after the resistance acquirement from January 
2008 to December 2012 in Keio University hospital. Written infor-
med consents were obtained from all the patients. We detected 
second mutations (exon 20 T790M) by PNA-LNA PCR clamp.
Results: The median (range) age of the patients was 59 (34-86) 
years, including 9 male and 7 female. Pathological diagnosis of 
primary tumors were adenocarcinoma for 14, mixed adenocarci-
noma with small cell carcinoma for 1 and NSCLC-NOS for 1, with 
clinical staging stage IV for 13 and postoperative recurrence for 
3 before starting EGFR-TKIs. Five patients were ex-smokers and 
11 were non-smokers. Mutations of EGFR are exon 19 deletion 
for 7 patients, exon 21 L858R for 6, exon 21 L861Q for 2, and 
unspecified for 1. The median PFS was 306 days (95%CI: 97-514 
days) with EGFR-TKIs (6 patients were treated with erlotinib and 
10 patients were with gefitinib).For 11 patients, re-biopsy was 
performed during the treatment or within 2weeks of withdrawal of 
EGFR-TKIs. The specimens were obtained from primary sites in 6 
patients and from metastatic sites in 5 (1 from cerebrospinal fluid, 
1 from pleural effusion, 2 from lymph nodes and 1 from the skin). 
Pathological diagnosis was consistent to the original tumors for all 
cases, adenocarcinoma, except one with squamous cell carcinoma 
which was initially diagnosed as NSCLC-NOS. While all specimens 
remained original EGFR activating mutations, 3 out of 11 exhibited 
EGFR secondary mutation (exon 20 T790M).On the other hand, 
re-biopsy was performed long after discontinuation of EGFR-TKIs 
for 5 patients (median 6 months). All patients received subsequent 
chemotherapies after EGFR-TKIs. The specimens were taken from 
primary sites for 3 patients and from metastatic sites for 2 (1 from 
cerebrospinal fluid and 1 from lymph node). All specimens were 
adenocarcinoma as was so in initial diagnosis. All specimens kept 
original EGFR activating mutations, while 2 out of 5 exhibited 
EGFR secondary mutation (exon 20 T790M).
Conclusion: The frequency of exon 20 T790M in re-biopsied spe-
cimens was 27 % in NSCLC patients exhibiting acquired resistance 
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P1.10-038 A PHASE II TRIAL OF THE COMBINATION OF 
GEMCITABINE AND CARBOPLATIN AS ADJUVANT CHE-
MOTHERAPY IN PATIENTS WITH COMPLETELY RESEC-
TED NON-SMALL CELL LUNG CANCER. (KENBYO 0601)
Masashi Muraoka1, Shinji Akamine2, Tomoshi Tsuchiya2, Shi-
geyuki Morino2, Ryotaro Kamohara2, Koji Mochinaga1, Koichiro 
Shimoyama2, Hideyori Sengyoku1, Tomohiro Obata,2, Satoshi Mi-
zoguchi2, Yasushi Ikuta2
1Department Of Chest Surgery, Health Insurance Isahaya General Hos-
pital/Japan, 2Chest Surgery, Oita Prefectural Hospital/Japan
Background: Adjuvant chemotherapy for resected non-small cell 
lung cancer (NSCLC) is recommended with survival benefit, howe-
ver low compliance in recent clinical trials. Objectives: We conduc-
ted a phase II trial of gemcitabine(G) and carboplatin(C) regimen 
for patients with completely resected NSCLC and carboplatin is 
administrated on day 8 to reduce hematological toxicity especially 
thrombocytopenia.
Methods: Eligibility criteria included: PS(ECOG) 0-1, age≦75 
years, p-stage IB-IIIA NSCLC is complexly resected (R0), ade-
quate hematological liver renal and cardiac function. Regimen: G 
(1000mg/m2) d1 +8 and C (AUC 5, d8) q.3wks. Primary end point 
of this study is feasibility and secondary end points are toxicity, 
overall and disease-free survival.
Results: 44 patients (20 male, 24 female) were included, median 
age 63 (40-71) years. Adenocarcinoma in 39, squamous cell ca. in 
4, pleomorphic ca. in 1, and pathological stage IB in 25, IIA in 8, 
IIB in 5, and IIIA in 6 patients. Thirty-three patients (75%) comple-
ted the planned 4 cycles of GC therapy and 28 (64%) received the 
planned doses. Thirty-four percent of the patients had grade 3/4 
neutropenia, 2 (6%) had thrombocytopenia, and the other 2 (6%) 
had anemia. Non-hematological adverse effects were infrequent 
and no treatment-related death was noted in this study.
Conclusion: Hematological toxicity, especially thrombocytopenia 
in this study is less than that in the standard administration of CG 
(C day1) regimen. We conclude that this regimen is feasible with 
sufficient compliance as adjuvant chemotherapy for completely 
resected stage IB-IIIA NSCLC patients.
Keywords: adjuvant chemotherapy, Non-small cel lung cancer, 
feasibility
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Conclusion: There is median OS benefit in lung cancer treatment 
outcomes tracked over a decade. This observed benefit is in tan-
dem with the increased use of drugs that have clinical benefit in 
adenocarcinoma. Unmet needs remain for both small cell lung 
cancer and other NSCLC subtypes.
Keyword: Lung cancer; survival outcomes
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P1.10-041 A PHASE II TRIAL OF ERLOTINIB FOR PREVI-
OUSLY TREATED JAPANESE PATIENTS WITH ADVANCED 
NON-SMALL CELL LUNG CANCER HARBORING EGFR 
MUTATIONS: RESULTS OF THE CENTRAL JAPAN LUNG 
STUDY GROUP TRIAL (CJLSG0904).
Tetsunari Hase1, Masahiro Morise1, Hiroyuki Taniguchi2, Joe Shin-
doh3, Eiji Kojima4, Yoshimasa Tanikawa5, Ryujiro Suzuki6, Tomo-
hiko Ogasawara7, Yoshiyuki Yamada8, Masahiko Ando9, Masashi 
Kondo1, Hiroshi Saito10, Yoshinori Hasegawa1
1Department Of Respiratory Medicine, Nagoya University Graduate 
School Of Medicine/Japan, 2Department Of Respiratory Medicine And 
Allergy, Tosei General Hospital/Japan, 3Department Of Respiratory 
Medicine, Ogaki Municipal Hospital/Japan, 4Department Of Respiratory 
Medicine, Komaki Municipal Hospital/Japan, 5Department Of Respira-
tory Medicine And Allergy, Toyota Kosei Hospital/Japan, 6Department 
Of Respiratory Medicine, Toyohashi Municipal Hospital/Japan, 7Depart-
ment Of Respiratory Medicine, Japanese Red Cross Nagoya Daini Hospi-
tal/Japan, 8Department Of Respiratory Medicine, Konan Kosei Hospital/
Japan, 9Center For Advanced Medicine And Clinical Research, Nagoya 
University Hospital/Japan, 10Department Of Respiratory Medicine, Aichi 
Cancer Center Aichi Hospital/Japan
Background: Several prospective studies have demonstrated ac-
tivating mutations in the epidermal growth factor receptor (EGFR) 
gene are a predictor of response to EGFR tyrosine kinase inhibitor 
(TKI). Erlotinib is one of EGFR-TKIs available in Japan. However, 
there are a few prospective reports on the efficacy and safety 
of erlotinib therapy in Japanese patients with previously treated 
advanced EGFR mutation-positive non-small cell lung cancer (NS-
CLC).
Methods: We undertook a multicenter, open-label, single-arm, 
phase II study. Patients with performance statuses of 0 to 2 and 
stage IIIB/IV NSCLC with EGFR-sensitive mutations (exon19 and 
21) were eligible if they were treated with one or two prior chemo-
therapy regimens containing at least one platinum-based doublet. 
They received oral erlotinib at a dose of 150mg daily until disease 
progression or unacceptable toxicity. The primary endpoint was 
objective response rate (ORR), while secondary endpoints inclu-
ded disease control rate (DCR), progression free survival (PFS), 
overall survival (OS) as well as toxicity. This study is registered with 
UMIN (University Hospital Medical Information Network in Japan), 
number 000002716.
Results: Between November 2009 to July 2012, 29 patients (medi-
an age, 68 years; range, 40-77 years) were enrolled. No complete 
response and 17 partial responses were observed, giving the ORR 
was 58.6% (95% confidence interval (CI): 38.9-76.5%). Ten patients 
had stable disease and 2 patients had progressive disease. Thus, 
the DCR was 93.1% (95% CI: 77.2-99.2%). After a median follow-up 
of 14.7 months (range, 5.3-37.0 months), the median PFS was 9.5 
months (95% CI, 5.9-13.2 months). The median OS has not yet been 
to EGFR-TKIs (under or within 2 weeks after discontinuation of 
EGFR-TKIs). The other mechanisms behind the acquired resistance 
to EGFR-TKIs remain to be determined in this population.
Keywords: EGFR mutation, aquired resistance, re-biopsy
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P1.10-040 LUNG CANCER OUTCOMES IN AN ERA OF 
MORE OPTIONS - SURVIVAL ANALYSIS FROM AN ASIAN 
CANCER CENTER
Whee-Sze Ong, Eng-Huat Tan, Quan-Sing Ng, Mei-Kim Ang, Chee-
Keong Toh, Noan-Minh Chau, Ravindran Kanesvaran, Kam-Weng 
Fong, Wan-Teck Lim
National Cancer Center/Singapore
Background: Lung cancer therapy has changed in the last decade 
with the advent of EGFR tyrosine kinase inhibitors (TKI) and newer 
chemotherapeutics such as pemetrexed. Most of these benefits 
have been limited to lung adenocarcinoma and not other histologi-
cal subtypes. In addition, this has translated to improved progres-
sion free survival benefits but no apparent overall survival benefits 
in some of the phase III studies conducted. We hypothesized that 
the benefits seen in these phase III clinical trials would translate to 
improved overall survival in the wider population of patients (pts) 
treated in a cancer center.
Methods: We conducted a survival analysis of all primary stage 
3B/4 lung cancer diagnoses available from a cancer center data-
base between 1 Jan 2000 and 31 Dec 2012. The diagnoses were 
identified based on ICD-9 162 and ICD-10 C34. Recurrent lung 
cancers were excluded. Histological classification for analysis was 
based on the IASLC system. Molecular data from adenocarcinoma 
(AC) was available with routine testing from 2010. Treatment given 
in the form of pemetrexed and EGFR TKI was also tracked from the 
pharmacy system from 2001. Vital status was checked against the 
National Registry of Births and Deaths as at 31 March 2013. The 
primary endpoint was overall survival (OS) which was defined from 
the time of diagnosis till death from any cause or last follow-up and 
estimated using Kaplan-Meier method. Log-rank test was used 
to compare survivals. Jointpoint regression models were used for 
trend analyses.
Results: A total of 5320 cases of stage 3B/4 primary lung cancer 
diagnoses were identified. The cases were predominantly male 
(65%) and Chinese (81%). The median age at diagnosis and gender 
distribution among the diagnoses in each year remained stab-
le over time. Non-small cell lung cancer (NSCLC) made up 92% 
of all diagnoses. NSCLC subtypes were adenocarcinoma (52%), 
squamous (13%), large cell (2%), and Others (25%). EGFR mutation 
rate among 708 tested cases was 55%, and ALK translocation rate 
among 108 tested cases was 9%. The jointpoint regression mo-
del identified 2005 as a significant turning point in improvement 
in median OS. Hence comparing 2001-2005 and 2006-2010, the 
median OS for the entire cohort improved from 8.0 mths (95% CI, 
7.1-8.7) to 9.5 mths (95% CI, 8.9–10.2), p = 0.001. This median OS 
survival benefit was contributed by OS benefits in AC 10.3 mths 
(95% CI, 9.3-11.8) vs 13.3 mths (95% CI, 12.1 -14.5). The turning 
point for improvement for median OS survival coincided with in-
creased usage of EGFR TKI and pemetrexed from 2006 and 2008 
respectively.
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Conclusion: In pts previously treated with adjuvant CT, re-
treatment with platinum doublet CT upon relapse is feasible and 
associated with numerically higher response rates and significantly 
longer survival than those receiving other first-line ST.
Keywords: platinum chemotherapy, Non small cell lung cancer
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P1.10-043 DOUBLET COMBINATION OF PLATINUM 
WITH PEMETREXED FOR ADVANCED NON-SMALL-CELL 
LUNG CANCER: A RETROSPECTIVE ANALYSIS OF A  
SINGLE INSTITUTION
Santiago Ponce Aix, Lara Iglesias, Juan Antonio Núñez, Jon Zuga-
zagoitia, Maria Blázquez, Muñoz Cesar, Lucia Parrilla, Cristina 
Pernaut, Irene Otero, Hernan Cortes-Funes
Medical Oncology, Hospital 12 De Octubre/Spain
Background: There is no single standard doublet combination of 
platinum chemotherapy for non-small cell lung cancer (NSCLC). 
In non-inferiority phase III study, cisplatin/pemetrexed showed a 
significant improvement in survival in patients with non-squamous 
histology compare to cisplatin/gemcitabine. Recently, continu-
ation maintenance with pemetrexed after cisplatin/pemetrexed 
was found to prolong overall survival as well. The objective of this 
retrospective study was to evaluate the efficacy of pemetrexed in 
combination with cisplatin or carboplatin for stage IV NSCLC at our 
institution
Methods: We reviewed the medical records of 103 patients with 
stage IV non squamous NSCLC (between January 2008 and De-
cember 2012) treated with pemetrexed in combination with plati-
num (cisplatin 75 mg/m2 or carboplatin AUC5 on day 1 plus peme-
trexed 500 mg/m2 on day 1 every 3 weeks) at our institution. After 
induction chemotherapy patients received pemetrexed 500 mg/
reached. The most common adverse events were skin rash (96.6%; 
13.8% grade ≥ 3), and hepatic function disorder including incre-
ased ALT (65.5%) and increased AST (48.3%). No interstitial lung 
disease events or cases of toxic death were reported.
Conclusion: These results indicate that erlotinib monotherapy 
could be a potential treatment option with favorable clinical out-
comes for Japanese patients with previously treated advanced 
NSCLC with EGFR mutations.
Keyword: erlotinib, phase II, EGFR
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P1.10-042 CHEMOTHERAPY IN ADVANCED NON-SMALL 
CELL LUNG CANCER PATIENTS PREVIOUSLY TREATED 
WITH ADJUVANT CHEMOTHERAPY
Mario Valdes, Glenwood Goss, Garth Nicholas, Paul Wheatley-
Price
Medicine, University Of Ottawa / Ottawa Hospital Research Institute/
Canada
Background: Adjuvant chemotherapy (CT) improves survival in 
patients (pts) with completely resected early stage NSCLC. Adju-
vant cisplatin/vinorelbine (CV) is considered a standard of care in 
this population. However many pts relapse and require palliative 
CT, which may involve platinum doublet CT again. We investigated 
treatment choices on relapse after prior adjuvant CT, specifically 
in pts receiving palliative platinum doublet CT, and its impact on 
response rate (RR) and overall survival (OS).
Methods: With ethics approval, we performed a retrospective 
chart review of all pts with resected NSCLC who received adjuvant 
CT from January 2002 until December 2008 at our institution. 
Baseline pt demographics and cancer stage were recorded, along 
with treatment decisions upon relapse. The primary outcome was 
the RR to first-line palliative systemic therapy (ST).
Results: We identified 176 pts who received adjuvant platinum 
doublet CT (82% received CV). Patient characteristics were: me-
dian age 63 years (range 25-82); 55% female: median follow up 
4.2 years: the primary surgical procedures were lobectomy (79%) 
or pneumonectomy (16%). The pathologic stage at surgery was 
1A (2%), 1B (30%), 2A (7%), 2B (40%) and 3A (15%). In total 85 pts 
relapsed (48%), with a median time to relapse of 18.5 (95%CI 15-
21.3) months. The variable most strongly associated with a shorter 
time to relapse was nodal stage (p=0.03); increasing T stage also 
demonstrated a trend towards shorter time to relapse (p=0.09). 
Of the 85 relapsed pts, 43 received palliative CT, and 42 received 
best supportive care (BSC) alone. Of the 43 pts treated, 25 (58%) 
were re-challenged with platinum doublet CT, with a RR of 28%, 
versus 17% (p=0.47) in 18 pts receiving other ST (most commonly 
docetaxel [n=7, 39%] or erlotinib [n=4, 22%). There was a trend 
towards increased clinical benefit rate (CR+PR+SD) in patients who 
were treated with a platinum doublet (67% versus 41% p=0.12). For 
all pts the median OS after relapse was 11.6 months. In pts recei-
ving any CT (n=43), median OS was 15.3 months, compared to 7.8 
months in those receiving BSC alone. Pts in the platinum-treated 
group had a longer survival after relapse than those pts treated 
with non-platinum regiments (18.4 versus 9.7 months, p=0.041). 
See Figure 
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advanced NSCLC.
Methods: Patients with untreated stage IIIB/IV NSCLC were rando-
mized 1:1 to nab-P 100 mg/m2 on d 1, 8, 15 or sb-P 200 mg/m2 d 
1 q21d; both arms received C AUC 6 d 1 q21d. ORR and PFS were 
determined by blinded, centralized review. P values for ORR were 
based on chi-square test, and those for OS and PFS were based 
on log-rank test. Multiple sensitivity analyses were performed to 
confirm treatment differences and to rule out confounding effects 
from other baseline covariates.
Results: 31 patients in the nab-P/C and 30 patients in the sb-P/C 
arms were included in this analysis. Similar to the intent-to-treat 
(ITT) population, most diabetic patients were male (75%), white 
(62%), with ECOG PS 1 (79%), and stage IV disease (85%). In these 
patients, ORR for nab-P/C vs sb-P/C was 52% vs 27% (response 
rate ratio 1.935; P = 0.046), median PFS was 10.9 vs 4.9 months 
(HR 0.416; P = 0.016), and median OS was 17.5 vs 11.1 months (HR 
0.553; P = 0.057). Treatment difference in PFS remained significant 
(P ≤ 0.026) after adjusting for baseline characteristics (including 
histology, region, stage, and age). For OS, region, stage, race, and 
age were not observed to be confounding factors on treatment 
effect. Metformin was concomitantly used in 29% and 37% of di-
abetic patients in the nab-P/C vs sb-P/C arms, respectively. The 
percentage of patients experiencing ≥ 1 adverse event (AE) was 
similar between the diabetic and ITT populations. Among diabetic 
patients, the most common grade 3/4 AEs in the nab-P/C vs sb-
P/C arms were neutropenia (53% vs 55%), anemia (23% vs 10%), 
peripheral neuropathy (PN, 7% vs 23%), thrombocytopenia (20% vs 
7%), and fatigue (7% vs 10%); differences were not statistically sig-
nificant. Safety findings were similar to those observed in the ITT 
population; however, the incidence of grade 3/4 PN was slightly 
higher for both arms in the diabetic population compared with the 
ITT population (for nab-P/C vs sb-P/C, 3% vs 12%; P < 0.001).
Conclusion: In this analysis, nab-P/C demonstrated improved ef-
ficacy and was well tolerated in diabetic patients with advanced 
NSCLC. These findings warrant further study in a larger diabetic 
patient population. The relationship between the efficacy of nab-P 
and glucose level/metformin use also merits additional study.
Keywords: nab-pacitaxel, non-small cell lung cancer, diabetes
m2 every 3 weeks or best supportive care until disease progressi-
on or unacceptable toxicity
Results: From 103 patients, 27,2% were female and 72,8% were 
male. The ECOG was 0-1 in 80% of patients, and the median age 
was 63 years old. Smoking status was 39,5% current smokers, 
48,9% former smokers, 10,4% never smokers and 1% unknown. His-
tologic type was 66% adenocarcinoma, 27% large-cell carcinoma 
and 7% non other. EGFR status was 46% wild type, 49% unknown 
and 5% mutated. The median cycles of doublet combination of 
platinum with pemetrexed was four cycles (1-8). 77,7% patients 
received carboplatin and 22,2% cisplatin. Thirty-three patients 
(32%) received maintenance therapy with pemetrexed. The median 
cycles of maintenance pemetrexed was four (1-34). The response 
rate achieved was 52,1% (Complete Response 4,4% + Partial Res-
ponse 47,7%) and 21,1% stable disease, so 73,2% with clinical be-
nefit. Median time to disease progression was 6,6 months (95% CI 
4,8 to 7,6 months) in all patients. The median time to disease pro-
gression was 8,1 months (95% CI 5,9 to 9,9 months) in maintenance 
pemetrexed group and 4,1 months (95% CI 3,1 to 5,1 months) in 
best supportive care group (p<0,001). Median overall survival was 
9,6 months (95% CI 8,1 to 11 months) in all patients. The median 
overall survival was 12,4 months (95% CI 10,4 to 17,1 months) in 
maintenance pemetrexed group and 9,1 months (95% CI 8,2 to 11,1 
months) in best supportive care group (p=0,005)
Conclusion: Doublet combination of platinum with pemetrexed 
and maintenance pemetrexed is effective achieving good respon-
se rates and prolonging overall survival. The schema is feasible in 
patients with non-squamous NSCLC and we reproduced the data 
from clinical trials in our daily clinical practice. However, there are 
some questions remaining as the optimal number of induction 
cycles and most important which biomarkers factors are predicting 
benefit from maintenance chemotherapy
Keywords: Lung cancer, pemetrexed, maintenance
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P1.10-044 NAB-PACLITAXEL IN COMBINATION WITH 
CARBOPLATIN AS FIRST-LINE THERAPY IN DIABETIC 
PATIENTS WITH ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC)
Vera Hirsh1, Scott Owen2, Amy Ko3, Markus F. Renschler3, Mark A. 
Socinski4
1McGill University Health Center/Canada, 2McGill University Health 
Centre/Canada, 3Celgene Corporation/United States Of America, 4He-
matology/Oncology, University Of Pittsburgh/United States Of America
Background: Diabetes and other age-related comorbidities fre-
quently occur together in patients with NSCLC and may affect 
treatment efficacy and tolerability. Several studies demonstrated 
that diabetic patients have worse outcomes than those without 
diabetes. Additionally, studies have suggested that metformin may 
enhance the effects of chemotherapy, leading to improved out-
comes. In a phase III trial, nab-paclitaxel (nab-P, 130 nm albumin-
bound paclitaxel particles) + carboplatin (C) significantly improved 
the primary endpoint of overall response rate (ORR) from 25% to 
33% (P = 0.005), with a trend toward improved overall survival (OS) 
and progression-free survival (PFS) vs solvent-based paclitaxel (sb-
P) + C in patients with advanced NSCLC. This exploratory analysis 
examined efficacy and safety outcomes in diabetic patients with 
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P1.10-046 HEAT SHOCK PROTEIN 70 AS A PREDICTIVE 
MAKER IN PATIENTS WITH PLATINUM-BASED ADJU-
VANT CHEMOTHERAPY IN RESECTED NON-SMALL CELL 
LUNG CANCER
Tai Sun Park1, Hye-Ryoun Kim2, Jae Soo Koh3, Seung Hun Jang4, 
Yong Il Hwang4, Ho-Il Yoon5, Jin-Haeng Chung6, Cheol Hyeon Kim2, 
Chang Min Choi1, Jae Cheol Lee7, Woo Sung Kim1
1Department Of Pulmonary And Critical Care Medicine, Asan Medical 
Center, University Of Ulsan College Of Medicine/Korea, 2Department Of 
Internal Medicine, Korea Cancer Center Hospital/Korea, 3Department 
Of Pathology, Korea Cancer Center Hospital/Korea, 4Division Of Pul-
monary, Allergy And Critical Care Medicine, Hallym University Sacred 
Heart Hospital/Korea, 5Department Of Internal Medicine, Seoul Nati-
onal University Bundang Hospital/Korea, 6Department Of Pathology, 
Seoul National University Bundang Hospital/Korea, 7Department Of 
Oncology, Asan Medical Center, University Of Ulsan College Of Medici-
ne/Korea
Background: Although adjuvant platinum-based chemotherapy 
improves survival in completely resected non-small cell lung can-
cer (NSCLC), its effect is limited. We hypothesized that heat shock 
protein 70 (Hsp70) would be a biomarker for selecting patients 
for adjuvant chemotherapy, and evaluated the prognostic or pre-
dictive significance of Hsp70 in patients with surgically resected 
NSCLC.
Methods: Patients who underwent curative resection for NSCLC 
and diagnosed as stage IIA through IIIA between January 1996 
and December 2010 were included. We conducted immunohisto-
chemical staining for Hsp70 on surgical specimens and compared 
survival rates depending on whether of Hsp70 expression and 
adjuvant platinum-based chemotherapy.
Results: Among 327 patients, Hsp70 expression was positive in 
220 (67.3%). For the patients without adjuvant chemotherapy, 
Hsp70 expression did not significantly affect survival. However, 
for the patients with adjuvant chemotherapy, patients with Hsp70-
positive tumors had longer disease-free survival (DFS; 82.4 vs. 29.7 
months; P = 0.004) as well as longer overall survival (OS; 101.9 vs. 
73.4 months, P = 0.12) than those with Hsp70-negative tumors. 
Multivariate modeling showed that patients with Hsp70-postitive 
tumors had a lower risk of recurrence and death than those with 
Hsp70-negative tumors after adjusting for age, gender, perfor-
mance status, pathologic stage, and histologic types in adjuvant 
chemotherapy group (DFS: adjusted hazard ratio [AHR], 0.54; 95% 
CI, 0.36 to 0.80; P = 0.002; OS: AHR, 0.66; 95% CI, 0.42 to 1.05; P 
= 0.08). 
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P1.10-045 VALIDATION STUDY OF POSTOPERATIVE PLA-
TINUM-BASED ADJUVANT CHEMOTHERAPY FOR JAPA-
NESE PATIENTS WITH COMPLETELY RESECTED PATHO-
LOGICAL STAGEIIIA NON-SMALL CELL LUNG CANCER
Kazu Shiomi1, Noriyuki Takakura2, Shinichiro Ryuge3, Syoko Ha-
yashi1, Dai Ishii1, Hirotsugu Yamazaki1, Masahito Naito1, Yoshio 
Matsui1, Masashi Mikubo1, Fumihiro Ogawa1, Jiichiro Sasaki2, Hi-
royasu Nakashima1, Noriyuki Masuda2, Yukitoshi Satoh1
1Thoracic Surgery, Kitasato University School Of Medicine/Japan, 2Res-
piratory Medicine, Kitasato University School Of Medicine/Japan, 3Res-
piratory Medicine, Kitasato University/Japan
Background: In the Japanese Clinical Practice Guideline for Lung 
Cancer, postoperative platinum-based adjuvant chemotherapy in 
patients with pathological stage IIIA (p-stage IIIA) non-small cell 
lung cancer (NSCLC) is recommended (grade B). However, the 
verification of the effect of adjuvant chemotherapy in Japanese 
patients is not sufficient. In this study, we aimed to validate the ef-
fectiveness of platinum-based adjuvant chemotherapy for p-stage 
IIIA NCSLC.
Methods: Between January 2002 and December 2009, we retro-
spectively reviewed records of patients with completely resected 
p-stage IIIA NSCLC in our institution. Exclusion criteria include the 
patients with oral anticancer drug, tegafur and uracil (UFT), >75 
years old, large cell neuroendocrine carcinoma and pleomorphic 
carcinoma. The primary endpoint of this study was progression-
free survival. Cumulative survival curves were estimated with the 
Kaplan-Meier method and compared with the log-rank test. Multi-
variable analysis was performed with the Cox proportional hazards 
regression model to estimate the independent prognostic effect of 
adjuvant chemotherapy on prognosis by adjusting for confounding 
factors.
Results: Sixty-seven patients (median age, 63 years; 40 men, 27 
women) were eligible. 49 patients had adenocarcinoma and 18 had 
squamous cell carcinoma. 63 patients underwent lobectomy and 
4 patients had pneumonectomy. Of the 33 patients with platinum-
based adjuvant chemotherapy regimens, 16 had cisplatin plus 
gemcitabine, 13had carboplatin plus paclitaxel, and 4 had cispla-
tin plus vinorelbine. Five-year progression-free survival (PFS) and 
5-year overall survival (OS) in the adjuvant chemotherapy group 
versus in surgery alone group were not statistically significant 
(5-year PFS rates were 28% and 31%, respectively; p = 0.69, and 
5-year OS rates were 54% and 40%, respectively; p = 0.10). Multi-
variate analysis showed that platinum-based adjuvant chemothera-
py did not affect patient prognosis significantly (HR, 0.70; 95% CI, 
0.37-1.32; p=0.27).
Conclusion: Our date showed that platinum-based adjuvant che-
motherapy in patients with p-stage IIIA NSCLC did not have such 
impact on our patient’s prognosis as we could understand in daily 
medical practice. Although there were some limitations of this 
study, we feel a strong need for searching more effective chemo-
therapy regimens or individualized treatment strategies.
Keywords: Postoperative adjuvant chemotherapy, Lung cancer, 
adjuvant chemotherapy, pathological stage IIIA
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Conclusion: Hsp70 is a positive predictive factor in completely 
resected NSCLC and Hsp70-positive tumors seem to benefit from 
adjuvant platinum-based chemotherapy.
Keywords: biologic markers, carcinoma, non-small-cell lung, che-
motherapy, adjuvant, heat shock protein 70
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mitropoulos7, Qiong Xiao8, Bin Wen8, Wendong Chen9
1Department Of Respiratory Medicine, Xiangya Hospital, The Central 
South University/China, 2Department Of Medical Oncology, Cancer Ins-
titute (hospital), Chinese Academy Of Medical Sciences And Peking Uni-
on Medical College/China, 3Medical Oncology, Hunan Province Tumor 
Hospital, Central South University/China, 4Education And Research, 
Hunan Province Tumor Hospital, Central South University/China, 5Cli-
nical Pharmacy, Xuanwu Hospital, Capital Medical University/China, 
6Lilly Suzhou Pharmaceutical Co., Ltd/China, 7Global Health Outcomes 
Research, Eli Lilly/United States Of America, 8Normin Health Changsha 
Office/China, 9Leslie Dan Faculty Of Pharmacy, University Of Toronto/
Canada
Background: Real world evidence for clinical effectiveness, toxi-
city, and hospitalization costs associated with second-line chemo-
therapy in patients with advanced non-squamous non-small cell 
lung cancer (NSCLC) is needed to guide clinical practice and reim-
bursement decision making in China.
Methods: This study retrospectively identified advanced non-
squamous NSCLC patients treated with second-line chemothe-
rapy between 2007 and 2012 in four triple-A hospitals. Patients’ 
baseline characteristics, chemotherapy, clinical response, adverse 
events, and hospitalization costs were extracted from medical and 
financial records associated with hospitalizations during second-
line chemotherapy. They were compared by treatment using de-
scriptive statistical methods. Kaplan-Meier (KM) survival analysis 
was conducted to explore the differences in time to progression 
(TTP) between the treatments. Hospitalization costs were strati-
fied into non-drug costs and non-chemotherapy drug costs, and 
chemotherapy drug costs. Propensity score methods were used to 
create matched patients with balanced baseline characteristics to 
confirm the findings in the unadjusted analyses.
Results: 414 patients received pemetrexed singlet (n=57), doceta-
xel singlet (n=64), docetaxel-platinum doublet (n=119), and peme-
trexed-platinum doublet (n=174) as second-line chemotherapy in 
the four hospitals. The identified patients had similar baseline cha-
racteristics except that patients receiving docetaxel-platinum dou-
blet (53.2 years vs. 58.5 years, p = 0.003) or pemetrexed-platinum 
doublet (54.3 years vs. 58.5 years, p = 0.010) were younger than 
those treated by pemetrexed singlet. KM survival analysis indica-
ted a non-significant trend suggesting longer mean TTP for pe-
metrexed singlet than that for docetaxel singlet (95.6 days vs. 53.4 
days; p = 0.139), for docetaxel-platinum doublet (95.6 days vs. 52.4 
days; p = 0.139), and for pemetrexed-platinum doublet (95.6 days 
vs. 76.3 days; p = 0.716). The adverse event comparisons demons-
trated that pemetrexed singlet had lower incidence rates for neu-
tropenia (8.8% vs. 25.0%, p = 0.035 for docetaxel singlet; 21.9%, 
p = 0.055 for docetaxel-platinum doublet; 23.0%, p = 0.031 for 
pemetrexed-platinum doublet) and leukopenia (10.5% vs. 21.9%, p 
= 0.152 for docetaxel singlet; 28.6%, p = 0.013 for docetaxel-plati-
num doublet; 26.4%, p = 0.021 for pemetrexed-platinum doublet) 
and had lower incidence rates for vomiting (35.1% vs. 62.6%, p < 
0.001) and nausea (43.9% vs. 69.0%, p < 0.001) than pemetrexed-
platinum doublet. Pemetrexed singlet was associated with the 
lowest hospitalization costs per treatment cycle (3 weeks) for non-
drug expenses (RMB 3,949 vs. RMB 5,154 for docetaxel singlet, p 
= 0.043; RMB 6,067 for docetaxel-platinum doublet, p = 0.002; 
RMB 5,045 for pemetrexed-platinum doublet, p = 0.029; 1 RMB = 
0.16 US$) and non-chemotherapy drugs (RMB 5,471 vs. RMB 8,421 
for docetaxel singlet, p = 0.006; RMB 7,874 for docetaxel-platinum 
doublet, p = 0.015; RMB 7,665 for pemetrexed-platinum doublet, 
p = 0.009). Similar trends were observed in the comparisons bet-
ween the treatments in propensity score matched patients.
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P1.10-047 CLINICAL FACTORS ASSOCIATED WITH THE 
EFFICACY OF PEMETREXED AS CONTINUATION MAIN-
TENANCE CHEMOTHERAPY IN PATIENTS WITH ADVAN-
CED LUNG ADENOCARCINOMA
Chung-Yu Chen1, Kuan-Yu Chen2, Chong-Jen Yu2, Pan-Chyr Yang2
1National Taiwan University Hospital Yunlin Branch/Taiwan, 2National 
Taiwan University Hospital/Taiwan
Background: Pemetrexed maintenance therapy significantly im-
proved survival in patients with advanced nonsquamous non-small 
cell lung cancer. This study was to investigate the clinical charac-
teristics and to identify the prognostic factors of pemetrexed as 
continuation maintenance chemotherapy for patients with advan-
ced lung adenocarcinoma.
Methods: Patients with advanced lung adenocarcinoma treated 
with pemetrexed for continuation maintenance therapy after pla-
tinum-based doublet frontline treatment without disease progres-
sion were enrolled. The medical records were analyzed for basic 
characteristics, epidermal growth factor receptor (EGFR) mutation 
analysis, treatment responses, progression-free survival (PFS) and 
overall survival (OS).
Results: From September 2009 to September 2012, the medical 
records of 121 patients with advanced lung adenocarcinoma trea-
ted with pemetrexed and platinum as first line chemotherapy were 
reviewed. Sixty-nine patients treated with pemetrexed for continu-
ation maintenance therapy after 6 cycles platinum-based doublet 
frontline treatment were included. Thirty-five patients (50.7%) 
were male. The mean of age was 66 ± 13 years old. Twenty-one 
patients (30.4%) were current or former smoker. The median cycles 
of pemetrexed as maintenance therapy was 6 cycles (range from 
1 to 36 cycles). Elderly patients (age ≥ 70 years old v.s. age < 70 
years old, median PFS: 9.6 months v.s. 4.0 months, p=0.002) and 
patients with lower glomerular filtration rate (GFR) (GFR ≥ 60 ml/
min vs. GFR < 60 ml/min, median PFS: 4.0 months vs. 7.9 months, 
p=0.03) had longer PFS in maintenance phase of pemetrexed 
treatment. Other clinical factors, including EGFR mutation status, 
use of cisplatin or carboplatin, gender, smoking history, and treat-
ment response to first-line chemotherapy, had no eventful effect 
on PFS. However, there was no significant association between OS 
and these clinical factors.
Conclusion: Pemetrexed continuation maintenance therapy may 
be more beneficial for elderly patients and patients who had lower 
renal function.
Keywords: pemetrexed, lung adenocarcinoma, maintenance
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P1.10-048 REAL-WORLD EVIDENCE FOR CLINICAL 
EFFECTIVENESS, TOXICITY, AND HOSPITALIZATION 
COSTS ASSOCIATED WITH SECOND-LINE CHEMOTHE-
RAPY IN CHINESE PATIENTS WITH ADVANCED NON-
SQUAMOUS NON-SMALL CELL LUNG CANCER
Cheng Ping Hu1, Yan Wang2, Jianhua Chen3, Shengqi Wu4, Xiaoling 
Li5, Yuqin Wang5, Yicheng Yang6, Narayan Rajan7, Manny Papadi-
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P1.10-050 PHASE II TRIAL OF BIWEEKLY CHEMOTHE-
RAPY WITH DOCETAXEL AND CISPLATIN IN HIGH RISK 
PATIENTS WITH UNRESECTABLE NON-SMALL CELL 
LUNG CANCER
Gyeong-Won Lee, Se-Il Go
Internal Medicine, Gyeongsang National University School Of Medicine/
Korea
Background: We investigated the efficacy and toxicity of a bi-
weekly schedule of docetaxel and cisplatin in high risk patients 
with unresectable (stages IIIB–IV) non-small cell lung cancer (NS-
CLC).
Methods: In this study, 48 high risk patients with previously unt-
reated locally advanced or metastatic NSCLC were administered 
combination chemotherapy consisting of docetaxel 40 mg/m2 and 
cisplatin 40 mg/m2; both drugs were given biweekly, on days 1 and 
15, every 4 weeks in an outpatient setting.
Results: A complete response, partial response, and stable di-
sease were observed in 1 (2.1%), 30 [62.5%, 95% confidence in-
terval (CI): 47.9–77.1%], and 4 (8.3%) patients. The median overall 
survival was 15.1 months (95% CI: 11.7–18.5) and the median time 
to progression was 7.5 months (95% CI: 6.4–8.6). The major toxicity 
was grade 3 anemia in 7 (14.6%) patients. Grade 3/4 neutropenia 
was observed in 5 (10.4%) patients. Among the non-hematologic 
toxicities, grade 3 infection and grade 3 diarrhea were observed in 
5 (10.4 %) and 4 (8.3%) patients, respectively. No treatment-related 
mortality was found.
Conclusion: As a front-line chemotherapy for high risk patients 
with unresectable NSCLC in an outpatient setting, the biweekly 
schedule of docetaxel and cisplatin showed feasible efficacy with 
manageable grade 3–4 hematologic toxicities, comparable to the 
result of previous studies of triweekly or weekly schedules. Additi-
onal large randomized studies are needed to optimize the schedu-
le and dosage of combination therapy with docetaxel and cisplatin 
in high risk patients with unresectable NSCLC.
Keywords: docetaxel, cisplatin, non-small cell lung cancer, BI-
WEEKLY
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P1.10-051 PEMETREXED MAINTENANCE TREATMENT IN 
ADVANCED NON SQUAMOUS NON-SMALL CELL LUNG 
CANCER (NSCLC)
Ahlem Megaiz, Abdelkader Bousahba, Aicha Rabah, Amel Zem-
mour, Malika Ahed-Messaoud, Soumia Ghazli
Medecine, Institut National Des Etudes Supérieures En Sciences Médi-
cales Oran/Algeria
Background: Patients with advanced non squamous NSCLC bene-
fit from pemetrexed maintenance therapy after induction therapy 
with a platinum-containing, pemetrexed or non-pemetrexed dou-
blet. We evaluated the efficacy and safety of pemetrexed mainte-
nance therapy in advanced non squamous NSCLC.
Conclusion: Advanced non-squamous NSCLC patients treated 
with pemetrexed singlet for second-line therapy had less toxicity 
and lower hospitalization costs for non-drug expenses and non-
chemotherapy drugs in this Chinese cohort. When compared to 
pemetrexed singlet, pemetrexed-platinum doublet as second-line 
chemotherapy was associated with greater occurrence of adverse 
events and higher hospitalization costs without giving any additio-
nal survival benefits.
Keywords: adverse event, Cost, second-line chemotherapy, non-
squamous NSCLC
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P1.10-049 EFFICACY OF BEVACIZUMAB COMBINED 
WITH PACLITAXEL AND CARBOPLATIN: A SECOND LINE 
TREATMENT OF ELDERLY PATIENTS WITH ADVANCED 
NON-SMALL CELL CARCINOMA (NSCLC)
Sherif Abdelwahab1, Dina Salim1, Aly Azmy1, Maha Margerges1, 
Hussein Shalabi2
1Clinical Oncology, Ain Shams University/Egypt, 2Chest Diseases, Mi-
nistry Of Health, Abbassia Chest Hospital/Egypt
Background: The aim of this phase II study was to assess the 
efficacy and safety of paclitaxel combined with carboplatin plus 
bevacizumab as a second line treatment of elderly patients with 
advanced NSCLC.
Methods: Twenty one elderly patients with NSCLC who previously 
received only one line of chemotherapy were enrolled into this 
study between March 2009 and March 2013. All patients recei-
ved paclitaxel 175 mg/m2 followed by carboplatin AUC of 5, and 
followed by bevacizumab 15mg/kg, all agents were given via I.V 
infusion on day 1 and the cycle was repeated every 21 days for 
maximum 6-8 cycles. Patients who attained at least stable disease 
continued to receive single agent bevacizumab every 21 days until 
disease progression or unacceptable toxicity developed.
Results: The median age was 73 years old (range 66-82 years); 17 
(81%) patients were men; ECOC PS was 0 in 4 (19%) patients, 1 in 
9 (43%) patients and 2 in 8 (38%) patients. The objective response 
rate was 30.3%, while disease control rate was 63.7%, respectively, 
and the median progression-free survival time was 4. 2 months. 
Grade 3/4 neutropenia, grade 3/4 thrombocytopenia occurred in 
2(10%) patients, while grade 3/4 peripheral neuropathy occurred in 
3(14%) patients and grade 3/4 fatigue had occurred in 4(19%) pati-
ents. No treatment-related deaths had been reported in this study.
Conclusion: Bevacizumab when given with paclitaxel and carbo-
platin exhibits activity in previously treated elderly patients with 
advanced NSCLC and has acceptable toxicity.
Keywords: NSCLC, Bevacizumab, paclitaxel, Carboplatin
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the patients with deletion mutation in exon 19 was 32 (the ratio of 
E746-A750 del was 78%); while the number of those with mutation 
in exon 21 was 24 (L858R was 96%). EGFR-TKIs were administered 
to 52 (86.7%) patients (erlotinib, gefitinib, and both was given in 
20, 20, and 12 patients, respectively), including 35 patients without 
prior chemotherapy. The median duration of observation was 557 
days. Any relationship between OS and clinical factor (gender, 
smoking history, and EGFR gene mutation subtypes) was not seen. 
In the patients treated with EGFR-TKIs, there was no significant 
difference in median OS regarding the administered drug (300 
days with erlotinib or 285 days with gefitinib). In the patients with 
the exon 21 mutation, erlotinib-treated group had longer survival 
time than that of gefitinib group (200 days vs 150 days in median 
OS, p = 0.079). This observation was not confirmed in the patients 
with the exon 19 mutation.
Conclusion: Our retrospective analysis showed no difference of 
OS under subtype of EGFR gene mutation; however, the efficacy of 
EGFR-TKIs may differ in subtypes of EGFR gene mutation.
Keywords: NSCLC, PFS, OS, EGFR gene mutation subtype
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P1.10-053 SODIUMSELENITE AS A TREATMENT 
AGAINST CANCER. A PHASE I STUDY.
Ola Brodin1, Staffan Eksborg2, Erik Huusfeldt-Larsen3, Mikael 
Björnstedt4
1Oncology, Karolinska University Hospital/Sweden, 2Women‘s And 
Children‘s Health, Karolinska University Hospital/Sweden, 3Division Of 
Food Chemistry, National Food Institute/Denmark, 4Pathology, Karo-
linska University Hospital/Sweden
Background: Selenite is a trace element, necessary in doses of 
40 – 200 microg/day. In these doses it has a reducing, detoxifying 
effect. However, in human cell-lines in much higher doses, it beco-
mes toxic resulting in apoptosis. Most malignant cell-lines are sig-
nificantly more sensitive than benignant ones. This indicates that 
there might be a therapeutic index, so we have started a clinical 
study.
Methods: This phase I study, the SECAR study has the purpose to 
find the maximal tolerable dose (MTD) of sodiumselenite. Patients 
with progressing malignant disease, mainly lung cancer, already 
treated with established drugs, were included. Treatment was 
given iv once daily 10 times during 2 weeks. According to a fixed 
schedule doses were escalated for each new cohort of 3 patients. 
If a serious adverse event (SAE) was observed 3 more patients 
were included. If 3/6 patients had an SAE, this dose level was con-
sidered too high and MTD was defined as the nearest lower dose.
Results: After 34 patients MTD has been defined to 10.2 mg/m2. 
Half life is 10 – 16 hours. The most common toxicity was sickness, 
vomiting and fatigue. However, at higher doses confusion and 
hallucinations were observed, and the most alarming toxicity was 
signs of heart ischemia and dyspnea with chock. One patient had a 
complete remission, but in the rest stable disease and very limited 
tumour shrinkage was observed at best. Tumour reevaluation is 
ongoing.
Conclusion: We now have defined the MTD for sodiumselenite. 
However, we also have got pharmacokinetic data indicating that 
Methods: We used pemetrexed (500 mg/m2 every 21 days) and 
best supportive care in patients with advanced, non squamous 
NSCLC who had not progressed after at least 4 cycles of induction 
chemotherapy. Pemetrexed was administered with folic acid and 
vitamin B12 supplementation until disease progression or the de-
velopment of intolerable toxicity.
Results: Eleven patients were enrolled. Patient characteristics 
were: 9 men, 2 women, median age 60 years (range 44 to 73), 
2/4/5 never, former and current smokers, 9 adenocarcinoma, 2 
large cell, 3 stage IVa, 8 stage IVb, 100% ECOG PS 1. A total of 
87 cyclesof pemetrexed was administered [median 6 (range 2 to 
23)], relative dose intensity 91%. Nine pts were evaluable for tumor 
response 1 PR, 7 SD, 1 PD. Median PFS was 4.14 months (95% CI 
3.3 to 9.5 mo). Toxicity was anemia G 1/2 (3/4 pts), neutropenia G 2 
(1 pt), fatigue G 1/2 (8/3 pts),nausea-vomiting G 1/2 (5/2 pts), mu-
cositis G 1/2 (2/2 pts), oedema (0 pt).
Conclusion: Pemetrexed maintenace therapy is a well tolerated 
and an effective option for patients with advanced non-squamous 
NSCLC. The study is ongoing.
Keyword: pemetrexed, maintenance therapy, advanced non-squa-
mous NSCLC, safety, efficacy
POSTER SESSION 1 - CHEMOTHERAPY  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.10-052 INFLUENCE OF THE EPIDERMAL GROWTH 
FACTOR RECEPTOR GENE MUTATION SUBTYPES TO 
THE PROGNOSIS OF THE PATIENTS WITH NON-SMALL 
CELL LUNG CANCER
Kenichiro Hirai1, Kenya Kanazawa1, Takashi Ishida2, Hiroyuki 
Minemura1, Satoko Sekine1, Kengo Oshima1, Hiroshi Yokouchi1, 
Yoshinori Tanino1, Mitsuru Munakata1
1Department Of Pulmonary Medicine, Fukushima Medical University/
Japan, 2Clinical Oncology Center, Fukushima Medical University Hospi-
tal/Japan
Background: Thirty to forty percent of East Asian patients with 
non-small cell lung cancer (NSCLC) have epidermal growth factor 
receptor (EGFR) gene mutations, which are recognized as pre-
dictive factors of the response to EGFR tyrosine kinase inhibitors 
(EGFR-TKIs). The most common mutations are the in-frame deleti-
on in exon 19 and a substitution of lysine for arginine mutation at 
amino acid position 858 (L858R) in exon 21. It has been reported 
that subtype of EGFR gene mutation affects the efficacy of EGFR-
TKIs in Caucasian patients with NSCLC. The deletion in exon 19 
was reported to be an independent predictive factor of longer 
progression free survival (PFS); however, it was not a predictive fac-
tor of overall survival (OS).
Methods: We reviewed the records of patients with NSCLC refer-
red to our hospital from May 2007 to May 2013, to clarify the influ-
ence of EGFR gene mutation subtype to clinical features.
Results: We found 128 patients with EGFR mutation, involving 124 
cases of adenocarcinoma. According to the UICC-TNM ver.7, num-
ber of the patients with stage I/II disease was 59, while patients 
with stage III/IV was 69. We selected 60 patients with non-resecta-
ble disease (stage IIIB and IV) for the detailed analysis. The median 
age of the 60 patients was 74 year-old (range, 41-83). There were 
39 female patients, and 39 light or never-smokers. The number of 
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P1.10-055 TREATMENT RATIONALE AND STUDY DESIGN 
FOR AN OPEN-LABEL RANDOMIZED PHASE II TRIAL 
OF GEMCITABINE AND CISPLATIN WITH OR WITHOUT 
BEVACIZUMAB IN EGFR WILD-TYPE NON-SQUAMOUS 
NON-SMALL-CELL LUNG CANCER
Juan Li, Ping Yu, Bin Liu, Ye Yang, Xiaoqin Liu, Yan Wen, Xiaohui 
Tan
Department Of Lung Cancer Medical Oncology, Sichuan Cancer Hospi-
tal/China
Background: EGFR wild-type non-squamous non-small-cell lung 
cancer (NSCLC) accounted for the majority of lung cancer patients, 
but the outcome of its first-line treatment was not satisfactory. 
INNOVATION study provided a new therapy perspective for those 
patients. EGFR wild-type subgroup analysis of this study revealed 
gemcitabine/cisplatin first-line chemotherapy plus bevacizumab 
showed significant advantage compare with gemcitabine/cisplatin 
alone (PFS 8.4m vs. 3.4m, OS 18.0 vs. 10.3m), which suggested 
that gemcitabine/cisplatin plus bevacizumab may be the preferred 
first-line therapy for EGFR wild-type non-squamous NSCLC. How-
ever, no other prospective trail has been preceded to confirm this 
conclusion in patients with EGFR wild-type non-squamous NSCLC. 
As a new type of anti-tumor angiogenesis monoclonal antibody, 
bevacizumab precisely targets VEGF to inhibit angiogenesis for 
continuous tumor control. We conduct this randomized phase II 
trial to investigate if gemcitabine/cisplatin first-line chemotherapy 
plus bevacizumab is a better treatment for advanced non-squa-
mous NSCLC patients without EGFR mutations. This study will also 
explore plasma biomarkers of bevacizumab efficacy.
Methods: This is an open-label randomized (1:1) 2-arm phase II 
study. Stage IIIB/IV EGFR wild-type non-squamous NSCLC with 
performance status (PS) 0 or 1 will be included; patients who have 
received prior chemotherapy or radiotherapy will be excluded. 
Patients (N=40) will receive (1:1) gemcitabine/cisplatin orgemci-
tabine/cisplatinplus bevacizumab (chemotherapy up to 6 cycles) 
until disease progression, unacceptable toxicity, patient/physician 
decision to discontinue, or death. Patients in the control arm recei-
ve first-line gemcitabine/cisplatin (gemcitabine 1250mg/m2 IV D1 
and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle). Patients 
in the experimental arm receive gemcitabine/cisplatin plus beva-
cizumab (7.5 mg/kg IV D1, every 21-day cycle). At the time point 
of start of chemotherapy and six weeks after chemotherapy, peri-
pheral blood of patients from both arms will be collected to detect 
plasma VEGF, VEGFR and VEGFR-2 level by ELISA. The primary 
endpoint is progression-free survival (PFS). Secondary endpoints 
include response rate, disease control rate, safety of bevacizumab 
and quality of life. Exploratory objective is biomarker analysis. 
Recruitment began in February 2013; the estimated final data coll-
ection for the primary endpoint is Aug 2014. Further details can be 
found on ClinicalTrials.gov (NCT01623102).
Results: not applicable
Conclusion: not applicable
Keywords: non-small-cell lung cancer, First-line, Bevacizumab, 
Study design
treatment might probably be optimized. Antitumoural effect has 
been observed, so the SECAR study will go on at first with an alte-
red treatment schedule.
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P1.10-054 REDUCTION LEVELS OF CARCINOEMBRYO-
NIC ANTIGEN AS A PREDICTIVE FACTOR OF RESPONSE 
TO CHEMOTHERAPY IN LUNG CANCER PATIENTS WITH 
ADVANCED NON-SMALL-CELL LUNG CANCER.
David O. Cortez1, Oscar Arrieta2
1Thoracic Oncology, National Cancer Institute Of Mexico/Mexico, 2Tho-
racic Oncology Clinic, National Cancer Institute Of Mexico/Mexico
Background: High serum carcinoembryonic antigen (CEA) levels 
are an independent prognostic factor for recurrence and survival in 
patients with non-small cell lung cancer (NSCLC). Its role as a pre-
dictive marker of treatment response with chemotherapy has not 
been widely characterized.
Methods: Two-hundred and fifty patients with advanced NSCLC 
(stage IIIB or Stage IV), who had an elevated CEA serum level (>10 
ng/ml) at baseline and who had no more than one previous chemo-
therapy regimen, were included. CEA levels were measured after 
two treatment cycles of platinum based chemotherapy (75%) or a 
tyrosine kinase inhibitor (25%). We evaluate the change in serum 
CEA levels and the association with response measured by RECIST 
criteria.
Results: After two chemotherapy cycles, the patients who achie-
ved an objective response (OR, 30.2%) had a reduction of CEA 
levels of 97% compared to its basal level. Patients that achieved a 
decrease in CEA levels> =20% presented and overall response in 
72% of cases, stable disease in 26% and progression in 2%. Pati-
ents with stable disease and progression have an increase of CEA 
levels of 12% and 90% from baseline, respectively (p < 0.001).
Conclusion: A reduction of serum CEA level (20%) from baseline 
after 2 cycles of treatment in advanced NSCLC is an accurate mea-
surement of OR. The comparison de CEA levels (Before and after 
chemotherapy) in NSCLC is associated with objective response by 
RECIST and should be part of the routine follow-up of advanced 
NSCLC patients.
Keyword: serum carcinoembryonic antigen (CEA) ,non-small cell 
lung cancer (NSCLC), objective response
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median survival time of 8 months in the control arm we anticipate 
to detect an improvement of 3 months in the median survival time 
in the experimental arm. To have 90% power to detect a three-
month improvement in median survival at a significance level of 5% 
(2-sided) and assuming a 10% failure rate in gene analyses or loss 
to follow up rate, a sample size of 567 patients is planned to be 
enrolled.
Results: Not Applicable
Conclusion: We hypothesize that such tailored approach will im-
prove survival decreasing the exposure to ineffective toxic agents 
in advanced NSCLC elderly pts. To our knowledge this is the first 
pharmacogenomic-driven randomized trial in this population.
Keywords: Predictive markers, NSCLC, Traslational Research, Cus-
tomized Chemotherapy
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P1.10-057 ADDITION OF CUSTIRSEN, A CLUSTERIN 
(CLU) INHIBITOR, TO DOCETAXEL IN STAGE IV NON-
SMALL CELL LUNG CANCER (NSCLC): DESIGN OF THE 
ENSPIRIT PHASE 3 STUDY
Joachim Von Pawel1, Amitkumar Pande2, Ofra Barnett-Griness3, 
Cindy Jacobs4
1Asklepios-fachkliniken München-gauting/Germany, 2Teva Pharmaceu-
tical Industries Ltd./United States Of America, 3Teva Pharmaceutical 
Industries Ltd./Israel, 4Oncogenex Pharmaceuticals, Inc./United States 
Of America
Background: The cytoprotective chaperone clusterin (CLU) is up-
regulated in NSCLC and other cancers in response to anticancer 
therapies, such as docetaxel (DOC). Custirsen inhibits CLU expres-
sion, enhances chemotherapeutic activity, and has been shown in 
vivo to reverse DOC resistance. In a non-randomized, phase 1/2 
study, patients with stage IIIB/IV NSCLC who received first-line 
custirsen with gemcitabine/cisplatin had a median overall survival 
(OS) of 14.1 months. In early phase studies in castration resistant 
prostate cancer, custirsen plus DOC was well tolerated and show-
ed encouraging efficacy results. DOC is recommended as second-
line chemotherapy for advanced NSCLC with a median OS of only 
7-8 months. Treatments that improve OS in advanced NSCLC are 
greatly needed. ENSPIRIT is designed as a Phase 3 study to assess 
the clinical benefit of adding custirsen to second-line DOC therapy 
in advanced or metastatic NSCLC.
Methods: ENSPIRIT was initiated in September 2012. Eligible 
patients in this phase 3, multinational, open-label trial (planned 
enrollment: 1100) have failed 1 prior line of platinum (PT)-based 
therapy and have a life expectancy >12 wks; ECOG score of 0-1; 
and adequate bone marrow, renal, and liver function. Patients 
receive 21-day cycles of DOC (75 mg/m2 IV day 1) or DOC plus 
custirsen (640 mg IV/wk, preceded by 3 doses during a 9-day loa-
ding period) until progressive disease (PD), unacceptable toxicity, 
or withdrawal. Randomization is 1:1 and patients are stratified by 
gender, NSCLC histology (squamous vs non-squamous), best ove-
rall response to the first-line PT therapy (stable disease [SD], com-
plete response [CR], partial response [PR], vs PD), and ECOG score. 
The primary efficacy measure is OS. Secondary efficacy measures 
are progression-free survival, objective response (OR: CR or PR), 
disease control (DC: CR, PR, or SD), and duration of OR and DC. 
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P1.10-056 THE ELDERLY PATIENT INDIVIDUALIZED CHE-
MOTHERAPY TRIAL (EPIC): A RANDOMIZED PHASE III 
MULTICENTER TRIAL OF CUSTOMIZED CHEMOTHERA-
PY VERSUS STANDARD OF CARE FOR 1ST LINE TREAT-
MENT OF ELDERLY PATIENTS WITH ADVANCED NON-
SMALL-CELL LUNG CANCER
Tiziana Vavala‘1, Silvia Novello1, Francesco Grossi2, Domenico Ga-
letta3, Giuseppe Valmadre4, Alessandra Bearz5, Diego Cortinovis6, 
Fabiana Cecere7, Ida Colantonio8, Lorenzo Cordero9, Valter Torri10, 
Valentina Monica1, Mauro Papotti1, Giorgio V. Scagliotti1
1Department Of Oncology, University Of Turin/Italy, 2Medical Oncology 
Unit, National Institute For Cancer Research/Italy, 3Medical Oncology, 
National Cancer Research Centre “Giovanni Paolo Ii“/Italy, 4E. Morelli 
Hospital Aaovv/Italy, 5Department Of Medical Oncology, National Insti-
tute For Cancer Research/Italy, 6Medical Oncology Unit, Aou San Gerar-
do/Italy, 7Medical Oncology Unit, Aou Careggi/Italy, 8Medical Oncology 
Unit, Aou Santa Croce E Carle/Italy, 9Oncopneumology Department, 
Aou Sassari/Italy, 10Department Of Oncology, Mario Negri Institute/
Italy
Background: This is an ongoing phase III multicenter randomized 
trial comparing first line pharmacogenomic-driven chemothera-
py based on Excision-Repair-Cross-Complementing-1 (ERCC1), 
Ribonucleotide Reductase subunit M1 (RRM1) and Thymidylate 
Synthase (TS) gene expression, versus standard first line treatment 
in elderly patients (pts) with advanced non-small-cell lung cancer 
(NSCLC). Chemotherapy selection based on an individual patient’s 
molecular profile is a potentially promising approach to optimize 
efficacy with the already available cytotoxic drugs. In older pts this 
is particularly relevant owing to their rapid deterioration of sym-
ptoms and their increased propensity to suffer therapy-induced 
toxicity.
Methods: Pts aged >70 years, with ECOG Performance Status (PS) 
0 or 1, previously untreated for stage IV NSCLC will be evaluated. 
In a 2:1 fashion, pts will be randomized to experimental arm (A) or 
standard arm (B). They must have measurable disease and EGFR 
negative mutational status. In arm A, treatment with single or dual-
agent chemotherapy will be based on histology, ERCC1 (E), RRM1 
(R) and TS (T) expression at the mRNA level. Expression of E, R and 
T is assessed by qRT-PCR on paraffin-embedded tumor specimens 
in a central laboratory. The cut off for high or low expression have 
been previously defined. Pts with squamous NSCLC who are: E 
low/R high will be treated with single agent carboplatin, E high/R 
low with single agent gemcitabine, E low/R low with carboplatin 
and gemcitabine and E high/R high with docetaxel or vinorelbine. 
In non-squamous NSCLC pts: E low/T high will be treated with 
carboplatin, E high/T low with pemetrexed, E low/T low with car-
boplatin and pemetrexed, E high/T high/R low with gemcitabine 
and E high/T high/R high with docetaxel or vinorelbine. In arm 
B treatment will be standard of care at the discretion of the care 
provider. The primary endpoint is overall survival (OS). The secon-
dary endpoints are progression-free survival (PFS), disease respon-
se according to RECIST 1.1 and tolerability (using CTCAE version 
4.0). Feasibility of treatment selection based on pharmacogenomic 
parameters will also be assessed. Treatment will continue to a ma-
ximum of 6 cycles if tolerated or until disease progression. Switch 
maintenance treatment is not allowed in either arm. Continuation 
maintenance (one or more of the agents used in the initial regimen) 
is allowed at the discretion of the investigator. Treatment upon 
progression is at the discretion of the care provider. Assuming an 
exponential survival distribution for both treatment arms and a 
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P1.11-001 EPIDERMAL GROWTH FACTOR RECEPTOR TY-
ROSINE KINASE INHIBITOR (EGFR-TKI) RELATED INTER-
STITIAL LUNG DISEASE IN TAIWANESE PATIENTS WITH 
NON-SMALL CELL LUNG CANCER
Chi-Lu Chiang, Chun-Ming Tsai, Yu-Chin Lee, Chao-Hua Chiu
Department Of Chest Medicine, Taipei Veterans General Hospital/ 
Taiwan
Background: In the recent years, it has been shown that epidermal 
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), gefi-
tinib or erlotinib, can provide significant benefit to patients with 
advanced non-small cell lung cancer (NSCLC). A major concern 
during EGFR-TKI treatment is the development of interstitial lung 
disease (ILD). The incidence and clinical characteristics of ILD asso-
ciated with EGFR-TKIs in Taiwanese patients are less well defined.
Methods: Patients with advanced NSCLC in the Taipei Veterans 
General Hospital were screened and patients who had received 
EGFR-TKIs were enrolled in this study. The clinical information 
including medical records and chest images were reviewed. The 
diagnosis of EGFR-TKI related ILD was confirmed by two pulmo-
nologists according to previously published criteria. Association 
between ILD development and clinical factors was evaluated.
Results: From February 2008 to July 2012, a total of 1214 patients 
who received EGFR-TKI as single therapy for NSCLC were scree-
ned. Patients who developed severe ILD and needed hospitaliza-
tion (grade 3-5) were included. Consequently, 9 of 1214 patients 
(0.7%) were diagnosed to have severe EGFR-TKI related ILD. The 
median age of the patients with ILD was 61.0 years and 6 were 
male (66.7%). The median time interval from EGFR-TKIs use to 
onest of ILD was 31 days (range: 10-75 days). The most common 
symptom of EGFR-TKIs related ILD was dyspnea (88.9%). The most 
common radiological manifestation was bilateral ground glass 
opacity (GGO), which was noted in 5 patients (55.6%). All patients 
discontinued EGFR-TKIs immediately when ILD was suspected and 
8 patients (88.9%) received systemic steroids. Six of nine patients 
(67%) patients died from ILD.
Conclusion: EGFR-TKIs, both gefitinib and erlotinib may cause 
fatal ILD in Taiwanese NSCLC patients. Physicians should be aware 
of this rare but severe side effect of EGFR-TKI and monitor this 
pulmonary toxicity closely.
Keywords: Epidermal growth factor receptor, tyrosine kinase inhi-
bitor, interstitial lung disease, non-small cell lung cancer
All efficacy analyses are intent to treat. Adverse events and labora-
tory results will be assessed. Two interim analyses are planned for 
stopping the trial early based on inadequate evidence of clinical 
benefit or futility.
Results: Not applicable.
Conclusion: This Phase 3 study will assess the potential survival 
benefit of second-line custirsen and DOC therapy in the treatment 
of advanced or metastatic NSCLC. This study is sponsored by Teva 
Branded Pharmaceutical Products R&D, Inc., in collaboration with 
OncoGenex Pharmaceuticals, Inc.
Keywords: custirsen, second-line therapy, trial in progress,  
clusterin
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P1.11-003 EXON 19 DELETIONS, SMOKING HISTORY 
AND GENDER AS ADDITIONAL PREDICTIVE FACTORS 
FOR TREATMENT BENEFIT WITH EGFR TYROSINE KINA-
SE INHIBITORS IN PATIENTS HARBOURING ACTIVATING 
EGFR MUTATIONS: A META-ANALYSIS OF 1432 PATI-
ENTS IN SIX RANDOMISED TRIALS.
Pei Ni Ding1, Richard Gralla2, Akira Inoue3, Sally Lord1, Nick Pavla-
kis4, Tetsuya Mitsudomi5, Matthew Links6, Val Gebski1, James C. 
Yang7, Chee Khoon Lee1
1Nhmrc Clinical Trial Centre/Australia, 2Albert Einstein College Of Me-
dicine, Jacobi Medical Center/United States Of America, 3Tohoku Uni-
versity Hospital/Japan, 4Department Of Medical Oncology, Royal North 
Shore Hospital/Australia, 5Department Of Surgery, Kinki University, 
Faculty Of Medicine/Japan, 6Medical Oncology Department, St George 
Hospital/Australia, 7Institute Of Oncology And Cancer Research Centre, 
National Taiwan University/Taiwan
Background: Epidermal growth factor receptor tyrosine kinase 
inhibitors (EGFR-TKIs) are now recognised as the standard first-
line therapy for patients with advanced non-small cell lung cancer 
(NSCLC) harbouring activating EGFR mutations. Many studies con-
sistently demonstrated superior tumour response and progression-
free survival (PFS) over chemotherapy. However, there are still 
ongoing questions whether there are any significant differences in 
treatment outcomes between patients of different ethnicity, gen-
der, age, performance status, smoking history, tumour histology 
and different subtypes of EGFR mutation. We performed a meta-
analysis to assess the impact of these factors on the PFS benefit 
of EGFR-TKIs in advanced NSCLC patients harbouring activating 
EGFR mutations.
Methods: An electronic search of all randomised controlled trials 
comparing efficacy of first-line therapy of EGFR-TKI vs chemo-
therapy in advanced NSCLC patients harbouring EGFR mutation 
was performed. We extracted the published hazard ratio (HR) and 
the 95% confidence interval (CI) for PFS, if available, or obtained 
unpublished data, for subgroups defined by each factor. For each 
subgroup, pooled estimates of treatment efficacy of EGFR-TKI vs 
chemotherapy were calculated with the fixed-effects inverse vari-
ance weighted method. The predictive effect of each factor was 
analysed by a test for interaction between the factor and treatment 
effect; P<0.05 was considered statistically significant. All statistical 
tests were two-sided.
Results: We included 6 eligible studies, with two trials for each of 
these different EGFR-TKIs - Gefitinib, Erlotinib, and Afatinib – with 
a total of 1432 patients. As expected, overall the use of EGFR-TKIs 
in this mutated population significantly prolonged PFS as compa-
red with chemotherapy (HR 0.37, 95% CI 0.32 to 0.43, P<0.001). 
While mutations at both Exon 19 (deletions) and at Exon 21 (L858R 
point mutations) were associated with significantly prolonged 
PFS, the benefit with Exon 19 mutations was greater: HR 0.26, 
95% CI 0.21 to 0.31, P<0.001; as contrasted to Exon 21: HR 0.42, 
95% CI 0.34 to 0.52, P<0.001 (treatment-EGFR mutation interac-
tion P=0.001). Smoking status also showed differential benefit in 
this mutated population: never smokers: HR 0.30, 95% CI 0.26 to 
0.36, P<0.001; contrasted to current or ex-smokers: HR 0.48, 95% 
CI 0.37 to 0.61, P<0.001; treatment-smoking history interaction 
P=0.003). There was also a trend for greater benefit for females 
with EGFR-TKI therapy as contrasted to males (HR [females] 0.32, 
95% CI 0.27 to 0.38, P<0.001; HR [males] 0.42, 95% CI 0.33 to 
0.53, P<0.001; treatment-gender interaction P=0.06). Interestingly, 
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P1.11-002 TOXICITY OF EPIDERMAL GROWTH FACTOR 
RECEPTOR TYROSINE KINASE INHIBITORS (EGFR-TKIS) 
IN THE TREATMENT OF ADVANCED NON-SMALL CELL 
LUNG CANCER (NSCLC): A META-ANALYSIS
Pei Ni Ding1, Sally Lord1, Matthew Links2, Victoria Bray3, Val 
Gebski1, James C. Yang4, Chee Khoon Lee1
1Nhmrc Clinical Trial Centre/Australia, 2Medical Oncology Department, 
St George Hospital/Australia, 3Medical Oncology Department, Liverpool 
Hospital/Australia, 4Institute Of Oncology And Cancer Research Centre, 
National Taiwan University/Taiwan
Background: We performed a meta-analysis to evaluate the risk 
of toxic death, treatment discontinuation and grade 3 or 4 (G3/4) 
adverse events (AEs) of epidermal growth factor receptor tyrosine 
kinase inhibitors (EGFR-TKIs) in the treatment of advanced non-
small cell lung cancer (NSCLC).
Methods: Randomized trials comparing EGFR-TKI monotherapy 
or combination EGFR-TKI-chemotherapy with chemotherapy or 
placebo were included. We extracted data on toxicity events, and 
computed pooled relative risks (RR) adjusted for median treat-
ment duration as the ratio of the risks in the EGFR-TKI arm versus 
the control group. Three treatment comparisons were analysed: 
EGFR-TKI versus placebo, EGFR-TKI versus chemotherapy, EGFR-
TKI-chemotherapy versus chemotherapy. All statistical tests were 
two-sided.
Results: Thirty-five trials (16,507 patients) were included. EGFR-
TKI was associated with 1.7% risk of toxic death (95% CI 1.4-2.0). 
Compared with EGFR-TKI, we demonstrated no difference in risk 
of toxic death for placebo (RR 1.15, 95% CI 0.08-1.86, p=0.86) or 
chemotherapy (RR 0.77, 95% CI 0.50–1.16, p=0.22), but higher 
risk for EGFR-TKI-chemotherapy compared to chemotherapy (RR 
4.23, 95% CI 1.12-14.41, p=0.03). The risks of treatment-related 
discontinuation and G3/4 AEs were lower for EGFR-TKI than che-
motherapy (RR 0.41, 95% CI 0.34-0.50, p<0.001; RR 0.35, 95% CI 
0.32-0.38, p<0.001 respectively) but higher for EGFR-TKI than 
placebo (RR 2.43, 95% CI 1.73-3.40, p<0.001; RR 1.18, 95% CI 1.04-
1.33, p=0.008) and for EGFR-TKI-chemotherapy than chemothera-
py (RR 1.99, 95% CI 1.66-2.39, p<0.001; RR 1.50, 95%CI 1.32-1.70, 
p<0.001).
Conclusion: EGFR-TKI therapy in advanced NSCLC has a low in-
cidence of toxic death and similar safety to chemotherapy with 
fewer serious AEs. Likelihood of benefit and careful consideration 
of toxicity profiles should inform treatment selection. Improved 
toxicity reporting in future trials would allow better quantification 
of EGFR-TKI-associated toxicity.
Keyword: Toxicity, Lung cancer, EGFR, Chemotherapy
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rall survival was 19 months. Patients who continued with mainte-
nance BVZ obtained a significant benefit in progression-free survi-
val (10 vs 6 months, p= 0.047) and median survival (20 vs 7 months, 
p= 0.003). The most frequent grade 3-4 adverse events were 
neutropenia in 18%, febrile neutropenia in 12%,nausea/vomiting in 
12%, diarrhea, hemoptysis in 6% of the patients respectively. Two 
toxic deaths were observed.
Conclusion: A regimen consisting of carboplatin, docetaxel, and 
BVZ followed by maintenance BVZ has shown to be feasible and 
very effective as front-line treatment in a non-selected population. 
Maintenance BVZ obtains a significant impact in progression-free 
survival and overall survival.
Keywords: metastatic, Bevacizumab, Maintenance treatment, Non 
squamous NSCLC
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P1.11-005 EVEREST STUDY: EVOLUTION OF DISEASE-
RELATED SYMPTOMS OF PATIENTS (P) WITH ADVAN-
CED NON-SMALL CELL LUNG CANCER (NSCLC) AND 
ITS CORRELATION WITH RESPONSE TO FIRST-LINE (1L) 
TREATMENT.
Manuel Domine1, Bartomeu Massuti2, Javier Puente Vázquez3, 
Antonio Calles4, Emilio Esteban Gonzalez5, Alberto Triguboff6, 
Regina Gironés7, Yashmin S. Afonzo Gobbi8, Francisco Aparisi9, 
Juana Oramas10
1Fundación Jimenez Diaz/Spain, 2Hospital General De Alicante/Spain, 
3Medical Oncology, Hospital Clínico San Carlos/Spain, 4Centro Integral 
Oncológico Clara Campal/Spain, 5Medical Oncology, Hospital Universi-
tario Central De Asturias/Spain, 6Hospital Comarcal De Melilla/Spain, 
7Medical Oncology, Hospital Lluís Alcanyís/Spain, 8Hospital Mateu 
Orfila/Spain, 9Medical Oncology, Hospital Virgen De Los Lirios/Spain, 
10Hospital Universitario De Canarias/Spain
Background: The control of symptoms to maintain the health-
related quality of life continues to be a priority in the treatment of 
advanced NSCLC. The aim of our study was to assess the evolution 
of the disease-related symptoms and, due to the lack of evidence, 
to evaluate its correlation with the response to 1L treatment in p 
with advanced NSCLC.
Methods: EVEREST is an observational prospective study car-
ried out in 33 Spanish institutions. A total of 155 p with advanced 
NSCLC initiating standard platinum-based 1L treatment were 
included. Disease-related symptoms were assessed at baseline 
and after completing 4-6 cycles of 1L treatment (final visit) with the 
Lung Cancer Symptom Scale (LCSS) and an ad-hoc specific ques-
tionnaire evaluating their frequency. Response to treatment was 
assessed according to RECIST criteria.
Results: Baseline characteristics of the 155 p enrolled were: 76.1% 
male, 96.1% Caucasian, 70.3% adenocarcinoma, 16.8% squa-
mous-cell carcinoma; median age was 62 years. ECOG PS 0/1/2: 
26.5%/54.8%/14.8%. 65.3% and 12.9% of p maintained or impro-
ved the ECOG status during the study, respectively. 118 p comple-
ted at least 4 cycles of treatment. Best response to 1L treatment 
was: 1.7% complete response, 68.4% partial response and 26.5% 
stable disease. Most frequent disease-related symptoms were 
asthenia and pain. 1L treatment did not deteriorate disease-related 
symptoms compared to baseline (LCSS score was reduced 1.4 
several parameters were not significant predictors of PFS benefit 
with EGFR-TKI treatment in this mutated population: performance 
status (ECOG 0 and 1 vs 2; interaction P=0.86); age (<65 vs ≥65 
years; interaction P=0.58); ethnicity (Asian vs others; interaction 
P=0.18); and tumour histology (adenocarcinoma vs others; interac-
tion P=0.52).
Conclusion: While EGFR-TKIs significantly prolong PFS in all ad-
vanced NSCLC patients harbouring classic activating EGFR mu-
tations when compared with chemotherapy, other molecular and 
demographic factors have a further influence on benefit. Exon 19 
deletions, never-smoking history, and possibly female gender were 
all associated with longer PFS in these patients when treated with 
EGFR-TKIs as compared with chemotherapy. These findings should 
enhance better trial design in future clinical trials.
Keywords: Predictive factors, EGFR-TKI, treatment benefit, EGFR 
mutation
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P1.11-004 PHASE II STUDY OF CARBOPLATIN-DOCETA-
XEL-BEVACIZUMAB AS FRONT-LINE TREATMENT IN PA-
TIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL-
CELL LUNG CANCER. ANALYSIS OF THE BEVACIZUMAB 
(BVZ) MAINTENANCE POPULATION
Manuel Domine, Francisco Lobo, Ana León, Victoria Casado, Gus-
tavo Rubio, Jose Ignacio Martín Valades, Yann Izarzugaza, Juan 
Luis Arranz, Gloria Serrano, Cristina Caramés, Tatiana Hernán-
dez, Irene Moreno, Jose Antonio López-Vilariño, Raquel Fuentes, 
Natalia Ramirez, Carolina Ortega, Andrea Correa, Victor Zenzola, 
Natalia Ramirez, Brezo Martinez-Amores, Alberto Lendinez, Mau-
ro Oruezabal, Jesús García Foncillas
Oncology, Fundacion Jiménez-díaz/Spain
Background: BVZ combined with carboplatin-paclitaxel as initial 
treatment followed by BVZ maintenance improves overall survival 
in advanced non-squamous non-small-cell lung cancer. We con-
ducted a phase II trial in order to study the efficacy and tolerability 
of a regimen consisting of BVZ-carboplatin-docetaxel in these 
patients. The objectives were to assess the efficacy and safety of 
this combination and to evaluate the impact of BVZ in patients who 
received maintenance BVZ after initial combined treatment compa-
red with patients who did not continue with maintenance BVZ.
Methods: Patients were treated with carboplatin (AUC 5), doceta-
xel (75 mg/m2), and BVZ (7.5 mg/kg) on day 1 every 21 days, up to 
6 cycles. Patients with an objective response or stable disease con-
tinued maintenance BVZ (7.5 mg/kg) every 21 days until disease 
progression or unacceptable toxicity . Performance Status-2, brain 
metastases, tumor cavitation, central tumors and mild hemoptysis 
were not exclusion criteria.
Results: Thirty-seven patients were enrolled into the study. 26 
male, 11 female. Median age was 64 years (39 – 82). ECOG 0/1/2: 
3.5%/70%/27.5%. 34 patients had adenocarcinoma and 3 undiffe-
rentiated large cell carcinoma. The median number of cycles for 
chemotherapy + BVZ was 6 (3-6) and 9 (3 – 22) for maintenance 
BVZ. All patients were evaluable for efficacy and toxicity. Overall 
response rate was 70.3% (complete response 2.7%, partial respon-
se 67.6%). 21.6% remained in stable disease and 8.15% progressed. 
Median progression-free survival was 10 months and median ove-
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we concluded that tyrosine kinase inhibitors should be used as 
first-line treatment in patients with EGFR mutation or during the 
course of their disease.
Keywords: Lung cancer, mutation, EGFR, tyrosine kinase inhibitors
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P1.11-007 PHASE I STUDY OF THE ALK INHIBITOR 
LDK378 IN JAPANESE PATIENTS WITH ADVANCED, ALK-
REARRANGED NSCLC AND OTHER TUMORS HARBO-
RING GENETIC ALK ALTERATIONS
Takashi Seto1, Haruyasu Murakami2, Fumihiko Hirai1, Atsushi 
Horiike3, Toshiaki Takahashi2, Naoko Suenaga4, Takeshi Tajima4, 
Kota Tokushige4, Anthony Boral5, Matthew Robson4, Makoto 
Nishio3
1National Kyushu Cancer Center/Japan, 2Shizuoka Cancer Center/Ja-
pan, 3The Cancer Institute Hospital Of JFCR/Japan, 4Novartis Pharma 
K.k./Japan, 5Novartis Pharmaceuticals Corporation/United States Of 
America
Background: Genetic alterations in anaplastic lymphoma kinase 
(ALK), including ALK rearrangements, occur in 3–7% of NSCLC. 
ALK-rearranged (ALK+) NSCLC is sensitive to the tyrosine kinase 
inhibitor (TKI) crizotinib, but acquired resistance inevitably deve-
lops. LDK378 is a novel, potent ALK TKI, with significant preclinical 
antitumor activity, even in crizotinib-resistant models. An ongoing 
pivotal Phase I study in Western patients established the MTD as 
750 mg/day, with overall response rates (ORRs) of 58% in all pati-
ents (n=114) and 57% in crizotinib-resistant patients (n=79), treated 
at ≥400 mg/day (Shaw, et al. ASCO 2013, Abstr 8010). The primary 
objective of the present study was to estimate the MTD and/or 
recommended dose in Japanese patients with tumors harboring 
ALK alterations; secondary objectives included safety, PK, and 
preliminary antitumor activity.
Methods: In this multicenter, open-label, dose-escalation study, 
patients with ALK alterations were enrolled. Japanese patients 
(ECOG PS 0–2) with locally advanced or metastatic disease that 
had progressed on standard therapy, or for which no standard the-
rapy exists, were eligible. LDK378 was administered orally at doses 
of 300–750 mg once daily (21-day cycles, with a PK run-in period). 
Adaptive dose escalations were guided by a Bayesian logistic re-
gression model with overdose control. Patients were treated until 
disease progression, unacceptable toxicity, or consent withdrawal.
Results: As of April 29, 2013, the dose-escalation part had enrolled 
19 patients (median age 45 years; 11 female), including 18 patients 
with ALK+ NSCLC (by FISH assay) and one patient with inflamm-
atory myofibroblastic tumor (IMT) harboring an ALK alteration. 
Fourteen patients with NSCLC had received prior ALK inhibitors 
(crizotinib, n=9; others [ASP3026 and CH5424802], n=5) and 4 pa-
tients with NSCLC were ALK inhibitor-naïve. Patients were treated 
at 300 mg (n=3), 450 mg (n=6), 600 mg (n=4), and 750 mg (n=6). 
Two DLTs occurred, at 600 mg (Grade 3 lipase increase) and 750 
mg (Grade 3 drug-induced liver injury); the MTD was 750 mg. The 
most common AEs regardless of drug relationship were nausea 
(n=18, 95%), diarrhea (n=14, 74%), vomiting (n=14, 74%), blood 
creatinine increase (n=12, 63%), decreased appetite (n=10, 53%), 
and fatigue (n=7, 37%). The most common Grade 3/4 AEs were 
hepatic enzyme increase (n=3) and drug-induced liver injury/ab-
normal hepatic function (n=2). Among 18 patients with NSCLC (all 
points) and an improvement in cough was observed (p=0.026). The 
frequency of cough (p<0.001), dyspnea (p=0.025), pain (p=0.009) 
and discomfort (p=0.034) were significantly reduced. No signifi-
cant correlation with response to treatment and the evolution of 
symptomology between visits was found.
Conclusion: 1L treatment was associated with a reduction of the 
frequency (cough, dyspnea, pain and discomfort) and intensity 
(cough) of disease-related symptoms in p with advanced NSCLC, 
irrespective of the response achieved.
Keywords: first-line treatment, health-related quality of life, non-
small cell lung cancer, disease-related symptoms
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P1.11-006 TYROSINE KINASE INHIBITORS VERSUS CHE-
MOTHERAPY IN PATIENTS WITH METASTATIC NON-
SMALL CELL LUNG CANCER HARBORING EGFR MUTATI-
ON: VENEZUELAN EXPERIENCE
George A. Oblitas1, Jean G. Bustamante Alvarez1, Maria B. Fuen-
tes1, Juan J. Rodriguez2, Cristina Garcia2, Maria A. Perez2, Karen 
Kubicec3, Patricia Nunes4
1Medical Oncology/ Thoracic Oncology, Unidad Oncologica De Caracas/
Venezuela, 2Medical Oncology, Instituto Oncologico Luis Razetti/Vene-
zuela, 3Medical Oncology, Hospital Militar De Caracas/Venezuela, 4Me-
dical Oncology, Oncologico Padre Machado/Venezuela
Background: Lung cancer is the first cause of death globally. 
Platinum based chemotherapy is the standard of care for NSCLC. 
Maintenance therapy and switch therapy with novel agents have 
shown clinical benefit. The determination of the mutation of EGFR, 
allowed personalized therapy with tyrosine kinase inhibitors, provi-
ding benefit in terms of progression free survival and quality of life 
to those patient harboring the mutation.
Methods: An observational, analytic and descriptive study was 
conducted in Venezuela. 36 patients harboring the EGFR mutation 
were submitted to chemotherapy or tyrosine kinase inhibitors. The 
primary endpoint was the determination of the clinical benefit in 
terms of progression free survival according to the first line thera-
py.
Results: From a total of 296 patients with lung adenocarcinoma, 
the mutation rate was 12.2%. The EGFR mutation was found more 
frequently in patients with adenocarcinoma histology, males, less 
than 65 years old and those who were former smokers or nonsmo-
kers. The most common type of mutation of the EGFR was found in 
the EXON 21, followed by EXON 19. 31 of these patients received 
first-line treatment with chemotherapy and 5 with tyrosine kinase 
inhibitors. The median progression-free survival for patients recei-
ving tyrosine kinase inhibitors was 10 months and for those who 
received chemotherapy was 6 months. These findings were statis-
tically significant (p = 0.03). Regarding the overall survival, no stati-
stical significance was found, probably due to the crossing-over of 
the treatment.
Conclusion: The clinical benefit evidenced in Venezuelan patients 
harboring the EGFR mutation when treated with tyrosine kinase 
inhibitors in first and second line, was superior to the one shown 
by patients who received chemotherapy. These results are similar 
to those evidenced in clinical trials done worldwide. On this basis, 
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algias, nausea, mucositis, and night blindness. Sixty-eight percent 
(17/25) experienced night blindness (grade 1-2 only), and three 
patients came off study due to eye-related toxicity. Grade 3 toxici-
ties included elevated liver function tests, diarrhea, fatigue, consti-
pation and anemia.
Conclusion: AUY922 and E is an active, well-tolerated regimen 
for patients with EGFR-mutant lung cancer. Visual disturbances, 
particularly night blindness, were common, but resolved with drug 
discontinuation. AUY922 and erlotinib demonstrate activity as 
combination therapy for patients with EGFR mutant lung cancers 
and AR to EGFR TKI. Activity is not limited to patients with EGFR 
T790M. Supported by Novartis, Inc.
Keywords: acquired resistance, HSP90, erlotinib, EGFR
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P1.11-009 AN OPEN LABEL, MULTICENTER, PROSPECTI-
VE NON-INTERVENTIONAL (NIS) POST-AUTHORIZATION 
STUDY TO MONITOR THE ROUTINE CLINICAL PRACTICE 
OF BEVACIZUMAB IN ADDITION TO PLATINUM-BASED 
CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL 
LUNG CANCER (NSCLC) IN GERMANY
Christian Schumann1, Walburga Engel-Riedel2, Christian Gess-
ner3, Christoph Losem4, Dirk Buschmann4, Holger Metze5, Ina Dit-
trich6, Hans W. Tessen4
1Department Of Internal Medicine Ii, Pneumology, University Hospital 
Ulm/Germany, 2Merheim Lung Hospital, Cologne Clinics/Germany, 
3Department Of Respiratory Medicine, University Of Leipzig/Germany, 
4Hematology & Oncology Practice/Germany, 5Department Of Internal 
Medicine I, Rhoen Clinic Frankfurt Oder/Germany, 6Department Of 
Thoracic Oncology, Lung Clinic Lostau/Germany
Background: The objective of NIS AVAILABLE was the evaluation 
of safety and efficacy of Bevacizumab plus platinum-based chemo-
therapy for the first-line treatment of metastatic or locally advan-
ced histologically confirmed NSCLC in routine practice to comple-
ment the data that emanates from pre-authorization randomized 
controlled trials. The trial also collected data on Bevacizumab 
dosage, combination partner, duration of treatment and causes for 
modifications or termination.
Methods: The NIS AVAILABLE was conducted in Germany from 
October 2007 until June 2013. Patients were recruited in 200 
centers, which included office based and outpatient clinics spe-
cialized in oncology and pneumology to be widely representative 
of the NSCLC population. The study aimed to enroll 900 patients 
receiving chemotherapy and Bevacizumab according to physician’s 
decision and label instructions. For each patient baseline charac-
teristics, treatment regime and results on efficacy and safety were 
documented. Progression-free survival (PFS) was estimated with 
the Kaplan-Meier-method.
Results: Preliminary results of the first interim analysis including 
745 patients are presented with focus on baseline characteristics, 
treatment regimens, dosages and PFS under the perspective of 
histology and age (≥65/<65 years). The population consisted of 
61.3% males, the median age was 62 years (range 29-84), 40.7% of 
the participants were >65 years of age. At diagnosis 88.6% presen-
ted with adenocarcinoma and 82.1% with stage IV disease. 62.0% 
of the patients had not received any previous treatment (radiation, 
doses), the ORR (confirmed responses) was 50% (95%CI 26.0─74.0; 
partial responses [PRs], n=9). PRs were observed in 7/9 crizotinib-
pretreated patients (2 unconfirmed). In patients pretreated with 
other ALK inhibitors, 3/5 had a PR (including 1 who also received 
crizotinib, and 2/4 who received CH5424802). The patient with IMT 
also achieved a PR. The preliminary PK profile was similar to that 
seen in Western patients.
Conclusion: The MTD was 750 mg once daily in Japanese patients. 
The safety profile was tolerable and comparable to that of Western 
patients; gastrointestinal toxicities were most common, and the 
most frequent Grade ≥3 AEs were liver toxicities. LDK378 exhi-
bited antitumor activity against ALK+ NSCLC, in both crizotinib-
resistant and other ALK inhibitor-resistant patients. An expansion 
part will further evaluate oral LDK378 750 mg. ClinicalTrials.gov 
identifier NCT01634763.
Keywords: LDK378, non-small cell lung cancer, ALK inhibitor
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P1.11-008 A PHASE II STUDY OF HSP90 INHIBITOR 
AUY922 AND ERLOTINIB (E) IN PATIENTS (PTS) WITH 
EGFR-MUTANT LUNG CANCER AND ACQUIRED RESIS-
TANCE (AR) TO EGFR TYROSINE KINASE INHIBITORS 
(EGFR TKIS).
Helena A. Yu1, Melissa L. Johnson2, Alexandra Urman1, Alfred 
Rademaker2, Eric Hart2, Bing Bing Weitner2, Jyoti D. Patel2, Mark 
Kris1, Gregory Riely1
1Memorial Sloan Kettering Cancer Center/United States Of America, 
2Division Of Hematology/Oncology, Northwestern University Feinberg 
School Of Medicine/United States Of America
Background: AUY922 is an HSP90 inhibitor that degrades client 
onco-proteins including mutant EGFR. Preclinical studies utilizing 
cell lines and xenografts harboring EGFR T790M demonstrate that 
HSP90 inhibition is effective in models of AR. This phase II study 
combines AUY922 and E for the treatment of patients with EGFR-
mutant lung cancer and RECIST-progression on EGFR TKIs.
Methods: Eligible patients had EGFR mutations and developed AR 
(per Jackman, JCO 2010) after treatment with EGFR TKIs. Patients 
underwent tumor biopsies after developing AR and prior to study 
entry. Tumor tissue from re-biopsy was analyzed for EGFR T790M 
and other mechanisms of resistance. Patients received AUY922 70 
mg/m2 IV weekly and E 150 mg oral daily in 28-day cycles. Respon-
se assessment was done at 4 weeks (wks), 8 wks, and every 8 wks 
thereafter. The primary objective was overall response rate (ORR, 
CR+PR) at 8 wks. A Simon mini-max design determined sample 
size (stage I: 16 pts (≥2 responses needed to proceed to stage II), 
stage II: 9 pts; α=10%, β=10%, p0=10%, p1=30%).
Results: The trial has completed accrual, and twenty-five patients 
have been treated (18 women, median age 59 (range 42-76)). The 
median time on EGFR TKI prior to the development of AR was 11 
mo (range 3-26 mo). Ten patients (40%) had EGFR T790M identi-
fied by tumor re-biopsy. In the 25 patients evaluable for response, 
ORR was 4/25 (16%, 95% CI 6-35%). Three of four patients with PR 
had EGFR T790M. An additional four patients had stable disease 
for at least 8 weeks. To date, four patients were on study drug for 
≥ 4 cycles, and four patients currently remain on study. Adverse 
events reported in ≥ 20% of patients were diarrhea, fatigue, my-
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(JY Chang, PI) or were part of a randomized trial of PBT vs. inten-
sity modulated radiation therapy (IMRT) (Z Liao, PI). They were 
evaluated before treatment with positron emission tomography 
(PET) and contrast enhanced computed tomography (CT), studies 
that were also used for planning treatment. Consultation with tho-
racic surgeons assured they were not candidates for resection. The 
mediastinal lymph nodes stations were evaluated with mediastino-
scopy and/or fiberoptic bronchoscopy with ultrasound. Treatment 
planning consistently included motion management with 4D CT 
simulation and creation of an internal target volume (ITV). Patients 
were assessed for failure patterns and survival as well as normal 
tissue effects. Kaplan Meier estimates and Cox regression analysis 
were used to calculate survival outcomes.
Results: Of the 178 patients enrolled, the median age at diagnosis 
was 69 yrs (range 37.8 yrs to 94.9 yrs). KPS ranged from 60 to 100, 
median 80. 43% of patients had squamous carcinoma, and 57% 
had non-squamous histology. Stage distribution was 15% stage II, 
65% III, 5% IV, 15% postoperative recurrence. The median tumor 
volume was 59 cc (range 4-753 cc) and the median total tumor 
dose was 74 Gy(RBE). Median follow-up time for living patients was 
34.6 mos. Median survival was 32.7 mos. Three year survival rate 
was 46.5% (49.8% for squamous, 42.1% for non-squamous. Local 
failure at 3 years was 36.4% for squamous and 48.9% for non-
squamous tumors. Distant metastasis-free survival at 3 years was 
44.5% for squamous and 55.8% for non-squamous cell histology. 
Multivariate analysis found age, squamous histology and tumor 
size adversely affected survival.
Conclusion: Prognostic factors with PBT and concurrent chemo-
therapy are similar to those seen in series of patients treated with 
x-irradiation. Favorable median and 3 year survival rates with this 
relatively large data set suggest superior outcomes with PBT and 
quite possibly a new platform for physical targeting upon which to 
build chemical and molecular targeting strategies.
Keyword: Protons, Locally Advanced, NSCLC, Chemotherapy
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P1.11-011 OBSERVATIONAL STUDY OF TREATMENT OF 
EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING 
MUTATION POSITIVE (EGFRM+) ADVANCED OR RECUR-
RENT NON-SMALL-CELL LUNG CANCER (NSCLC), AF-
TER RADIOLOGICAL PROGRESSION TO THE FIRST-LINE 
THERAPY WITH EGFR TYROSINE KINASE INHIBITORS 
(EGFR-TKI).
Hideo Kunitoh1, Chiharu Tanai2, Yukio Hosomi3, Kiyotaka Yoh4, 
Yasushi Goto5, Yasuo Ohashi6
1Respiratory Medicine, Mitsui Memorial Hospital/Japan, 2Division Of 
Respirology, Ntt Medical Center/Japan, 3Department Of Thoracic Onco-
logy And Respiratory Medicine, Tokyo Metropolitan Cancer And Infec-
tious Diseases Center Komagome Hospital/Japan, 4Division Of Thoracic 
Oncology, National Cancer Center Hospital East/Japan, 5Department Of 
Respiratory Medicine, Tokyo University Hospital/Japan, 6Department 
Of Biostatistics, University Of Tokyo/Japan
Background: Although NSCLC with activating EGFR mutation is 
generally sensitive to EGFR-TKI, such as gefitinib or erlotinib, it 
eventually gets acquired resistance. However, the clinical course 
after radiological (RECIST-based) “progressive disease (PD) judg-
ment“ is highly variable. Some patients are reported to do well 
surgery or chemotherapy) for lung cancer. Bevacizumab was most 
frequently administered in addition to platinum-based chemothe-
rapy and a third-generation cytotoxic agent. A selection of the 
most frequently used combination therapies (>6%) and respective 
PFS values are shown (Table).  
Chemotherapy combinations Patients 
receiving 
the 
combinati-
on (%)*
Median 
PFS in 
months 
(95% CI)
Bevaci-
zumab
Carbo-
platin
Gemcitabine 9.0 5.9 (4.7-9.8)
Paclitaxel 35.3 6.7 (5.8-7.4)
Pemetrexed 10.7 6.5 (4.2-8.5)
Cisplatin 
Gemcitabine 12.1 6.0 (4.6-9.9)
Pemetrexed 9.2 6.8 (3.5-8.4)
Vinorelbin 6.8 5.9 (4.2-9.1)
* multiple answers were allowed
Conclusion: In the interim analysis of the NIS AVAILABLE Beva-
cizumab was more frequently combined with carboplatin (64%) 
than cisplatin (32%) backbone chemotherapy highlighting carbo-
platin/paclitaxel plus Bevacizumab as the most prominent regime 
(35.3%). Overall Bevacizumab demonstrated a promising efficacy 
with a median PFS of 6.7 months in routine practice confirming fin-
dings from randomized controlled phase III trials such as E4599 or 
AVAiL. Although the study was not designed to compare PFS, the 
results indicate that there might be a difference across regimens.
Keyword: Bevacizumab, NSCLC, first-line, routine pracitce
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P1.11-010 PHYSICAL TARGETING OF LOCALLY ADVAN-
CED NON-SMALL CELL LUNG CANCER (NSCLC):  
PROTON THERAPY
James D. Cox1, Quynh Nguyen1, Pamela Allen1, Ngoc B. Ly2, Daniel 
Gomez1, Joe Chang1, Zhongxing Liao1, Anne Tsao3, Ritsuko Koma-
ki1, Charles Lu3
1Radiation Oncology, The University Of Texas MD Anderson Cancer 
Center/United States Of America, 2Tulane University School Of Medice/
United States Of America, 3Thoracic/head & Neck Med Onc, The Uni-
versity Of Texas MD Anderson Cancer Center/United States Of Ameri-
ca
Background: Radiation therapy is a critical element in the poten-
tially curative treatment of locally advanced NSCLC. Important 
developments have permitted more precise and effective physical 
targeting with radiations, an important complement to molecular 
targeting with drugs. Proton beam therapy (PBT) represents the 
most advanced physical targeting available thus far. A review of 
our experiences with proton therapy for NSCLC may serve as a 
benchmark for technically advanced radiation therapy.
Methods: Patients were enrolled on a protocol to investigate nor-
mal tissue effects of proton therapy between 2006 and December, 
2010. Patients were excluded if they did not received concurrent 
chemotherapy, were treated on a phase II study of high dose PBT 
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P1.11-012 CLINICAL OBSERVATION FROM THE TREAT-
MENT OF ICOTINIB FOR 196 CASES WITH ADVANCED 
NON-SMALL CELL LUNG CANCER
Qin A. Gu, Hui B. Han, Yan L. Jiang, Min H. Wang, Lei C. Shi, Wen 
L. Xiong, Zhuo Y. Zhao, Qing T. Chu, Jun Pei
Pneumology, Shanghai Chest Hospital Of Jiaotong Uniyersity/China
Background: Icotinib is a selective epidermal growth factor re-
ceptor tyrosine kinase inhibitor (EGFR-TKI) and a large number 
of previous studies have demonstrated that icotinib is a safe and 
efficacious molecule-targeted drug. The treatment of icotinib im-
proves the quality of life and prolongs the survival time for patients 
with advanced non-small cell lung cancer (NSCLC) who suffer the 
failure of platinum-based chemotherapy. The aim of this study is 
to evaluate the efficacy and safety of the treatment of icotinib on 
patients with advanced NSCLC.
Methods: From August 2011 to March 2013, 196 patients with ad-
vanced NSCLC were enrolled for treatment with icotinib including 
104 male and 92 female. The age of the patients ranged from 39 
to 85 years old, with a median age of 65 years old. There were 66 
smokers and 130 never-smokers. By the cytological or histological 
analysis, all cases were validated as NSCLC which included 159 ca-
ses of adenocarcinoma, 22 cases of squamous carcinoma, and 15 
cases of other carcinoma. According to the Union for International 
Cancer Control lung cancer staging system (1997 version), 9 pati-
ents were at stage IIIB and 187 patients were at stage IV. Among 
them, 151 patients had been given one or more chemotherapy 
regimens, and 45 had not been given any chemotherapy because 
they were intolerant of or reluctant about chemotherapy. A total 
of 196 patients received the treatment of icotinib at a dose of 125 
mg, 3 times per day. The treatment of icotinib was carried out un-
til the observation of disease progression or the development of 
unacceptable toxicity.
Results: After the treatment of icotinib for the total of 196 patients 
with advanced NSCLC,two (1.0%) patients achieved complete 
remission (CR), 58 (29.6%) patients achieved partial response (PR), 
78 (39.8%) patients achieved stable disease (SD), and 58 (29.6%) 
patients exhibited progression of disease (PD). the overall respon-
se rate (ORR) and the disease controlled rate (DCR) of icotinib was 
30.6％(60/196) and 70.4％(138/196), respectively. The ORR and DCR 
were significantly improved in patients with adenocarcinoma com-
pared with those with non-adenocarcinoma (P < 0.05).The median 
progression-free survival was 5.0 months. Icotinib had a moderate 
effect for the treatment of brain metastasis of lung cancer. Among 
21 patients with brain metastasis, 8 patients achieved PR and 8 
achieved SD. The main toxicities were showed to be rash (31.6%, 
62/196) and diarrhea of grade I to II (16.3%, 32/196). No bone mar-
row suppression and impaired renal function were observed.
Conclusion: Icotinib showed a definite efficacy with little toxicity 
for patients with advanced NSCLC. The treatment of icotinib ef-
fectively relieved the symptoms and improved the life quality for 
patients. Also, patients were well tolerant of the treatment of icoti-
nib. As an EGFR-targeted agent, icotinib represents a new safe and 
efficacious therapeutic option for patients with tumor relapse or 
metastasis who are intolerant of or reluctant about chemotherapy.
Keywords: ADVANCED NSCLC, EGFR-TKI, Icotinib
with continuation of TKI beyond PD, with or without local therapy. 
But, prior reports are only on small-numbered and selected cases. 
The objective of this study is to investigate the clinical course and 
the actual pattern of care after radiological "progressive disease“ 
to the first-line therapy with EGFR-TKI in such cases.
Methods: Thirty-four institutions in Japan participate in the survey 
of the patterns of care and outcomes of the patients with EGFRm+ 
advanced or recurrent NSCLC, who received first-line gefitinib or 
erlotinib during the period from 2009 to 2011. The primary end-
point is the time from RECIST-based radiological PD to clinical PD 
in patients who were continuously received EGFR-TKI beyond “RE-
CIST PD”. Clinical PD was defined as one or more of the following 
events: 1) symptomatic progression, 2) worsening of performance 
status due to progression, 3) threat to major vital organ(s), 4) multi-
organ unequivocal progression. Durations of TKI administration 
and reasons of discontinuation (RECEIST PD vs. clinical PD vs. 
toxicity), concomitant administration of chemotherapy and/or lo-
cal therapy with TKI, occurrence of “flare” phenomenon after TKI 
stoppage, and overall survival were also recorded.
Results: At the time of the abstract submission, 24 institutions 
reported the number of patients. There were 1,177 patients (395 in 
2009, 397 in 2010 and 385 in 2011) with EGFRm+ advanced or re-
current NSCLC. Among them, 602 (51.1%) received first-line EGFR-
TKI. The median number of EGFRm+ patients per institution was 
32 (range: 9 to 151). The rates of those who received first-line TKI 
varied substantially among institutions, ranging from 30% to 88%, 
and tended to increase over time (41.0% in 2009, 56.9% in 2010 
and 55.6% in 2011). In 2009, there were no institutions which admi-
nistered TKI to every EGFRm+ patient, whereas there were 1 and 3 
such institutions in 2010 and 2011, respectively.
Conclusion: In this large observational study, we will collect data 
on approximately 1,600 patients with EGFRm+ NSCLC, some 800 
of them received first-line EGFR-TKI. Since the median progres-
sion-free survival of those patients with TKI has generally been 
reported to be 1 year or less, we will be able to see the pattern 
of care and outcome after PD in the majority of the cases. Clinical 
significance of continuation of EGFR-TKI “beyond PD” in the real 
world will be clarified. This research was conducted by Compre-
hensive Support Project for Oncology Research (CSPOR) of Public 
Health Research Foundation. The research fund was provided to 
CSPOR with support from an Investigator Sponsored Study Pro-
gramme of AstraZeneca. Trial registry with UMIN#000010538.
Keywords: EGFR, progression, RECIST, beyond PD
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Conclusion: In a group of 74 patients with advanced NSCLC and 
with activated mutations who were treated with gefitinib in first line, 
the therapy was well tolerated, median progression-free survival 
from gefitinib treatment initiation is 8.1 months (95% CI: 6.9; 9.3) and 
median overall survival (OS) was not reached.
Keywords: EGFR mutations, gefitinib, EGFR, NSCLC
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P1.11-014 OUTCOME OF METASTATIC NSCLC PATIENTS 
TREATED AT WINDSOR REGIONAL HOSPITAL CANCER 
PROGRAM OVER 7 YEARS
Swati Kulkarni1, Shaili Dholakia2, Maher El Masri3, Abeer Omar3, 
Pamathy Vivek4, Yasmin Alam1
1Medical Oncology, Windsor Regional Hospital Cancer Program/Canada, 
2University Of Windsor/Canada, 3Nursing, University Of Windsor/Canada, 
4Windsor Regional Hospital Cancer Program/Canada
Background: Lung cancer is second most commonly diagnosed can-
cer in Canada and commonest cause of cancer related mortality in 
men and women. It is estimated that it represents 14% of all new can-
cer diagnoses in 2013. More than half of the patients are diagnosed 
when they have metastaic disesse. We wanted to study the survival of 
metastaic non small cell lung cancer patients treated before and after 
2005.
Methods: The purpose of this study was to explore the outcome 
of metastatic non small cell lung cancer (NSCLC) patients treated at 
Windsor Regional Hospital Cancer pogram over 7 years. We were 
specially interested in exploring the influence that advances in syste-
mic management of NSCLC may have had on outcome, in this patient 
population. A retrospective chart review was conducted on patiets 
treated from 2003-2009 at Windsor Regional Hospital Cancer Pro-
gram.Total 483 patients with lung cancer were identified and details 
of demographics, type of lung cancer, stage, comorbidities and treat-
ment related information was obtained.
Results: Total 213 patients with metastatic NSCLC were identified. 
Mean age at diagnosis was 65.55 ± 10.52 years. 54 % were males. 
While 93.4 % self identified as smokers 76.5 % were heavy smokers. 
Most common sites of metastatic disease include brain (23%), bones 
(21.6%), lung (12.7%) and liver (6.6%). While 31.5 % received first line 
platinum based chemotherapy only 13.6 % received second line te-
ratment. Median survival was 22 weeks. No difference in survival was 
found between the two groups of patients treated before or after 
2005.
Conclusion: Our findings showed that there was no difference in sur-
vival between the two groups of patients who were treated before or 
after 2005. Median survival was noted to be 22 weeks and we specu-
late this might be related to patients presenting late in the course of 
disease and therefore had poor performance status and were unable 
to receieve the second and third line of treatment. Smoking is associ-
ated with poor survival and a large number of patients were smokers 
in this cohort. This was a single institution retrospective study with 
small number of patients and we may need larger number to assess 
the difference in survival. Paradigm in treatment of lung cancer is still 
shifting and may be we need to wait further to observe any meaning-
ful difference in outcome.
Keyword: Metastatic NSCLC, Systemic Treatment, Survival
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P1.11-013 GEFITINIB FOR THE FIRST-LINE TREATMENT 
OF NSCLC PATIENTS WITH EGFR MUTATIONS IN EXONS 
19 OR 21: ANALYSIS OF 74 PATIENTS FROM CZECH RE-
PUBLIC
Jana Skrickova1, Zdenek Bortlicek2, Karel Hejduk3, Milos Pesek4, 
Vitezslav Kolek5, Leona Koubková6, Marcela Tomiskova1, Monika 
Satankova2, Zdenka Povolna1, Helena Coupkova7, Libor Havel8, 
Milada Zemanova9, Dimka Sixtova9, Frantisek Salajka4, Marketa 
Cernovska10, Michal Hrnciarik4
1Department Of Respiratory Diseases And Tb, University Hospital Brno 
And Masaryk University/Czech Republic, 2Institut Biostatistiky A Analýz, 
Masaryk University/Czech Republic, 3Institute Of Biostatistics And Ana-
lyses Masaryk University Brno/Czech Republic, 4Pneumology, University 
Hospital/Czech Republic, 5University Hospital Olomouc/Czech Republic, 
6Pneumology, University Hospital Motol/Czech Republic, 7Oncology, 
Masaryk Memorial Cancer Institute/Czech Republic, 8Pneumology, Hospi-
tal Na Bulovce/Czech Republic, 9Charles University Hospital/Czech Repu-
blic, 10Thomayer University Hospital/Czech Republic
Background: Gefitinib (Iressa®) is a potent oral non-cytotoxic anth-
raquinone. It is the active and selective EGFR-TKI (epidermal growth 
factor receptor tyrosine kinase inhibitor). In the Czech Republic NS-
CLC patients with EGFR activated mutations were treated with ge-
fitinib in first line from 2/2011 in 10 institutions. This study evaluates 
treatment outcomes in 74 NSCLC with EGFR activated mutations in 
exons 19 and/or 21 treated between 2/2011 and 3/2013.
Methods: Patients with advanced NSCLC and with EGFR activated 
mutations in exons 19 and/or 21 were treated with gefitinib in first 
line between 2/2011 and 3/2013. Retrospective analyses were 
carried out to assess the effectiveness of treatment and to evaluate 
the safety of targeted therapy.This study evaluates treatment 
outcomes in 74 patients. The outcomes include following: response, 
median overall survival (mOS) and median progression free survival 
(mPFS). Response was assessed by imaging techniques after 4-6 
weeks of treatment and was confirmed one month later by chest 
X-ray and/or CT scanning. The difference in response relative to 
baseline characteristics was determined using Pearson Chi-square 
test. Differences in OS and PFS relative to baseline characteristics 
were evaluated for significance using Log-rank test.
Results: Out of 74 treated patients, 46 had EGFR mutations in exon 
19 and 28 had EGFR mutations in exon 21. 53 patients (71.6%) were 
woman, 21 patients (28.4%) were man. At the time of treatment 
initiation with gefitinib, the following characteristics were recorded. 
The median age of patients was 67 years. 9 patients (12.1%) were 
smokers, 19 patients (25.7%) were former smokers, 46 patients 
(62.2%) were non-smokers; performance status (PS) was 0 in 16 
patients (21.6%), 1 in 49 patients (66.2%) and 2 in 9 patients (12.2%); 
adenocarcinoma was confirmed in 67 patients (90.5%); most of the 
patients were in stage IV (64 patients, 86.5%). As on the date of data 
analysis (18 March 2013), treatment was terminated in 32 patients 
(43.2%). The median duration of treatment was 19.0 weeks (mean 
24.7). Among patients in which treatment was terminated, complete 
response was not achieved in a single case; partial response was 
achieved in 10 patients (31.3%), stable disease in 10 patients 
(31.3%), progressive disease in 7 patients (21.9%) and treatment 
response was not evaluated in 5 patients (15.6%). Adverse effects 
during treatment with gefitinib were reported in 23 patients (31.1%). 
Median progression-free survival from gefitinib treatment initiation 
is 8.1 months (95% CI: 6.9; 9.3). Median overall survival (OS) was not 
reached.
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P1.11-016 A PROSPECTIVE, MULTI-CENTER PHASE II 
TRIAL ON THE EFFICACY AND SAFETY OF LOW-DOSE 
ERLOTINIB MONOTHERAPY FOR PATIENTS WITH EGFR 
MUTATION-POSITIVE, PREVIOUSLY TREATED NON-
SMALL CELL LUNG CANCER: RESULTS OF THORACIC 
ONCOLOGY RESEARCH GROUP (TORG) TRIAL 0911.
Kazuhiko Yamada1, Hideo Kunitoh2, Yukio Hosomi3, Hiroaki Oka-
moto4, Terufumi Kato5, Yuko Komase6, Masanori Nishikawa7, Sa-
toshi Morita8, Koshiro Watanabe9
1Kurume University School Of Medicine/Japan, 2Respiratory Medicine, 
Mitsui Memorial Hospital/Japan, 3Department Of Thoracic Oncology 
And Respiratory Medicine, Tokyo Metropolitan Cancer And Infectious 
Diseases Center Komagome Hospital/Japan, 4Yokohama Municipal 
Citizen‘s Hospital/Japan, 5Division Of Respiratory Medicine, Kanagawa 
Cardiovascular And Respiratory Center/Japan, 6St. Marianna Univer-
sity School Of Medicine/Japan, 7Department Of Respiratory Medicine, 
Fujisawa City Hospital/Japan, 8Yokohama City University Graduate 
School Of Medicin/Japan, 9Thoracic Oncology Research Group/Japan
Background: Several studies of erlotinib and gefitinib have shown 
similar benefit in terms of response and progression-free survival 
(PFS) for EGFR mutation-positive (EGFRm+) non-small cell lung 
cancer (NSCLC). However, the steady-state plasma trough concen-
tration of erlotinib was approximately 3.5 times higher than that 
of gefitinib when administered at the respective approved dose. 
Hence, low-dose treatment of erlotinib may be as effective as 
gefitinib or erlotinib given at full dose, with reduced toxicity and 
treatment cost.
Methods: Eligible patients were adults (over 20 years), with advan-
ced or recurrent EGFRm+ NSCLC who had received one to three 
prior chemotherapy regimens, ECOG PS of 0-2, measurable lesion, 
and adequate organ function. Erlotinib 50 mg was administered 
daily until disease progression or unacceptable toxicities. Dose 
was escalated to 150 mg/day in case of not achieving CR or PR 
classified by RECIST criteria (i.e., not responded, NR) at the first 4 
weeks. The primary endpoint was objective response rate (ORR); 
SWOG two-stage design with an early stopping rule based on res-
ponse rate was used. Response was initially judged by the investi-
gators and confirmed by the independent review committee (IRC). 
Finally, 26 or more responses among 40 eligible patients were to 
be considered as evidence of sufficient efficacy of this treatment.
Results: Thirty-four patients were enrolled between April 2010 and 
November 2012: males/females 20/14; median age 67 (range 31-
81); PS 0/1/2 16/18/0; Ad/Sq 33/1. EGFR mutation types were: exon 
18 and 19/19/21/other 1/21/11/1. One patient was excluded for 
evaluation because of not having a measurable lesion, therefore, 
efficacy and safety were evaluated among 33 patients. The study 
was closed early according to the protocol definition at the time 
that NR was confirmed in 15 of 33 patients, because it was deter-
mined impossible to meet the primary endpoint even if the study 
was continued. The IRC-judged best responses to the 50 mg/day 
erlotinib were: PR 18 (54.5%), SD 10 (30.3%) and PD 5 (15.2%). ORR 
and disease control rate were 54.5% (95%CI: 36.4-71.9%) and 84.8 
% (95%CI 68.1-94.9%), respectively. In addition, 4 out of the 10 
patients with SD to the initial dose yielded PR after dose escalation 
to 150 mg/day. At data cut-off (April, 2013), median PFS was 8.6 
months (95%CI: 6.7-15.0 months). Toxicities were generally mild, 
with a few grade 3 or more toxicities. The only grade 3 toxicities 
were 2 cases with neutropenia and 1 with AST/ALT elevation. No 
grade 4 toxicity or treatment-related death was observed. There 
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P1.11-015 THE PROGNOSTIC VALUE OF TOTAL NUMBER 
OF HARVESTED LYMPH NODES AND NODAL RATIO IN 
NODE POSITIVE NON-SMALL CELL LUNG CANCER
Jae-Sung Kim1, Wan Jeon2, Sanghoon Jheon3
1Radiation Oncology, Seoul National University Bundang Hospital/
Korea, 2Radiation Oncology, Seoul National University Hospital/Ko-
rea, 3Thoracic And Cardiovascular Surgery, Seoul National University 
Bundang Hospital, Seoul National University College Of Medicine/Korea
Background: The purpose of this study is to evaluate the pro-
gnostic value of nodal ratio (NR) and total number of harvested 
lymph nodes (HLN) in postoperatively node positive Non-small-cell 
lung cancer (NSCLC).
Methods: Between June 2003 and December 2010, 1192 NSCLC 
patients had undergone surgical resection at Seoul National Uni-
versity Bundang Hospital. In this study, we excluded patients who 
had preoperative adjuvant treatments and were revealed to have 
pathologic T4, N3 or M1. Total 240 patients with N1 or N2 disease 
were analyzed in this study. According to the number of HLN and 
NR, we evaluated disease-free survival (DFS), locoregional recur-
rence-free survival (LRRFS), distant metastasis-free survival (DMFS) 
and overall survival (OS).
Results: The median follow-up time was 36 months for the sur-
viving patients and median total number of HLN was 23 (range, 
6-64). On univariate analysis, patients with more than 20 HLN 
showed better 3-year DFS (55.6% vs 46.4% p = 0.045) and OS 
(78.2% vs 61.1%, p = 0.058), respectively. Patients who had NR > 
0.1 showed worse 3-year DFS (39.3% vs 64.4%, p = 0.045), LRRFS 
(72.8% vs 84.0%, p = 0.037), DMFS (45.5% vs 69.6%, p < 0.001) and 
OS (62.9% vs 79.8%, p = 0.067), respectively. On multivariate ana-
lysis, NR > 0.1 showed statistical significance in 3-year LRRFS (p = 
0.009) and marginal statistical significance in DFS (p = 0.083) and 
OS (p = 0.068).
Conclusion: The current nodal classification system does not in-
clude the total number of HLN and NR. The results of this study 
suggest that the total number of HLN and NR could be regarded 
as important prognostic factors and these factors might be used 
as decision criteria to postoperative adjuvant radiotherapy for 
patients with operable NSCLC.
Keyword: Non-small-cell lung cancer, Lymph node ratio, Number 
of metastatic lymph nodes
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Conclusion: The present study reveals that first-line therapy with 
gefitinib is effective and feasible for elderly patients harboring 
EGFR mutation and improves disease-related symptoms, espe-
cially shortness of breath and cough.
Keywords: non-small cell lung cancer, EGFR mutation, gefitinib, 
elderly
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P1.11-018 AN OPEN-LABEL, MULTICENTER, RANDO-
MIZED, PHASE II STUDY OF CISPLATIN AND PEMET-
REXED WITH OR WITHOUT CIXUTUMUMAB (IMC-A12) 
AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED 
NONSQUAMOUS NON-SMALL CELL LUNG CANCER
Giorgio Scagliotti1, Gilberto Castro Jr.2, Murat Kiyik3, Kowalyszyn 
Ruben4, Karl-Matthias Deppermann5, Edurne Arriola6, Lionel Bos-
quee7, Richard G. Willey8, Jan Cosaert8, Martin Reck9
1Ospedale S. Luigi Gonzaga/Italy, 2Instituto Do Cancer Do Estado De 
Sao Paulo/Brazil, 3Yedikule Chest Disease Hospital/Turkey, 4Centros 
De Investigaciones Clinicas, Viedma/Argentina, 5Helios Klinikum/Ger-
many, 6Oncologia Medica, Hospital Del Mar/Spain, 7Centre Hospitalier 
De Bois De L-abbaye/Belgium, 8Imclone Systems Llc, A Wholly-owned 
Subsidiary Of Eli Lilly And Company/United States Of America, 9Lun-
genclinic Grosshansdorf, Member Of The German Center For Lung Re-
search (dzl)/Germany
Background: Pemetrexed combined with cisplatin is an approved 
first-line treatment regimen for patients with advanced/metastatic 
nonsquamous non-small cell lung cancer (NSCLC). New targets 
are needed to further improve first-line therapy outcomes. Cixu-
tumumab, a fully human IgG1 monoclonal antibody, specifically 
blocks the insulin-like growth factor-type 1 receptor, inhibiting its 
activation and signal transduction. Early studies have reported 
clinical efficacy and safety with cixutumumab. However, the clinical 
benefit of adding cixutumumab to conventional chemotherapy is 
yet to be established. This study assessed whether pemetrexed 
and cisplatin combined with cixutumumab was superior to pemet-
rexed and cisplatin as first-line therapy.
Methods: This open-label, multicenter, randomized, phase II study 
(N=172) enrolled patients ≥18 years of age with stage IV nonsqua-
mous NSCLC and ECOG performance status 0–1. Patients were 
randomized (1:1) to receive cixutumumab 20 mg/kg combined with 
pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 (cixutumumab 
arm; n=87) or pemetrexed and cisplatin (control arm; n=85) every 
21 days up to 6 cycles of induction therapy. Patients eligible for 
maintenance therapy received pemetrexed and cixutumumab 
(cixutumumab arm) or pemetrexed (control arm). The primary end-
point was progression-free survival (PFS) based on radiographic 
assessments. To test for superiority (1-sided significance level 
20%; study power 80%), a median PFS of 7.16 months in the cixutu-
mumab arm (HR cixutumumab/control=0.74) was expected. Secon-
dary endpoints included objective response rate (ORR), duration 
of response, and overall survival (OS). Adverse events (AEs) were 
assessed using CTCAE version 4.0. Between-arm comparisons of 
unstratified data are presented.
Results: Baseline patient and disease characteristics were similar 
between arms in the intent-to-treat population. The mean age of 
the population was 59 years (range, 32 to 83). Dose intensity for all 
treatments was ≥90% during both study phases. Median PFS was 
was no treatment-related interstitial lung disease.
Conclusion: Although low-dose erlotinib appeared to have a cer-
tain efficacy in this population, this study could not meet the pri-
mary endpoint. Because of its relatively lower toxicity and cost, it 
may be worth further evaluation for elderly or frail patients.
Keywords: NSCLC, erotinib, low-dose, EGFR mutation
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P1.11-017 FIRST-LINE GEFITINIB THERAPY FOR ELDER-
LY PATIENTS WITH NON-SMALL CELL LUNG CANCER 
HARBORING EGFR MUTATION: CENTRAL JAPAN LUNG 
STUDY GROUP 0901
Kosuke Takahashi1, Hiroshi Saito1, Yoshinori Hasegawa2, Masa-
hiko Ando3, Masashi Yamamoto4, Eiji Kojima5, Yasuteru Sugino6, 
Tomoki Kimura7, Toshihiko Yokoyama8, Tomohiko Ogasawara9, 
Joe Shindoh10, Norio Yoshida11, Ryujiro Suzuki12
1Aichi Cancer Center Aichi Hospital/Japan, 2Nagoya University Gra-
duate School Of Medicine/Japan, 3Center For Advanced Medicine And 
Clinical Research, Nagoya University Hospital/Japan, 4Nagoya Ekisaikai 
Hospital/Japan, 5Komaki Municipal Hospital/Japan, 6Toyota Memorial 
Hospital/Japan, 7Tosei Genaral Hospital/Japan, 8Japanese Red Cross 
Nagoya Daiichi Hospital/Japan, 9Japanese Red Cross Nagoya Daini Hos-
pital/Japan, 10Department Of Respiratory Medicine, Ogaki Municipal 
Hospital/Japan, 11Kariya Toyota General Hospital/Japan, 12Toyohashi 
Municipal Hospital/Japan
Background: Recently, the elderly population of lung cancer pati-
ents is increasing worldwide. Although first-line gefitinib is one of 
the standard treatments for advanced non-small cell lung cancer 
(NSCLC) harboring epidermal growth factor receptor (EGFR) mu-
tation, few data have been reported on elderly patients. Thus, we 
conducted a phase II trial to evaluate the efficacy, safety, and qua-
lity of life of first-line gefitinib therapy for this specific population.
Methods: Chemotherapy-naïve patients aged 70 years or older 
with stage IIIB or IV non-small cell lung cancer harboring EGFR 
activating mutation were enrolled and treated with gefitinib 250 
mg daily until disease progression or unacceptable toxicity occur-
red. Quality of life was assessed by the Lung Cancer Subscale of 
the Functional Assessment of Cancer Therapy-Lung (FACT-LCS) 
questionnaire, before and during treatment (at 4, 8, and 12 weeks). 
The primary endpoint was response rate.
Results: Twenty patients were enrolled between June 2009 and 
March 2011. The median age was 79.5 years (range: 72-90). All the 
patients had adenocarcinoma, 13 patients (65%) were female, 12 
had exon 19 deletion, and 8 had L858R mutation. Overall response 
rate was 70% (95% CI, 46 - 88%), and the disease control rate was 
90% (95% CI, 68 - 99%). The median progression-free survival was 
10.0 months and the 2-year survival rate was 55%. The median 
follow-up time was 26.4 months and median overall survival time 
has not been reached yet. The most common adverse events were 
rash and liver dysfunction, and grade 1 interstitial lung disease de-
veloped in one patient. No treatment-related death was observed. 
The scores of FACT-LCS improved significantly four weeks after the 
initiation of gefitinib and maintained a favorable tendency during 
12 weeks (p = 0.037). Among the seven items of FACT-LCS, espe-
cially shortness of breath and cough improved significantly after 4 
weeks of treatment (p = 0.046, p = 0.008, respectively).
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Results: One hundred and thirty patients were randomized. All 
had adenocarcinoma with one patient having a mixed adeno-
squamous histology. All subjects had some expression of FRA in 
their tumor tissue as assessed by IHC. Median PFS as determined 
by primary investigator was 5.9 (placebo) and 4.7 (FAR) months 
with no statistically significant difference between arms (HR=1.22 
[95% CI: 0.78, 1.89]). PFS as assessed by an independent evaluator 
showed a median PFS of 5.9 (placebo) and 6.7 (FAR) months with 
a HR of 0.91 (95% CI: 0.54, 1.51). The most commonly reported 
adverse events across arms were those known to be associated 
with chemotherapy such as hematologic toxicities occurring during 
combination therapy phase of the study. Preliminary analysis show-
ed that subjects whose serum farletuzumab concentration level 
was in the top quartile did not reach a median PFS compared to 
those on placebo. Further investigation is currently on-going.
Conclusion: The study did not meet its primary PFS endpoint. 
The secondary end point of OS was immature at the time of this 
analysis. The most commonly reported adverse events across arms 
were those known to be associated with the study chemotherapy 
agents. Preliminary pharmacokinetic / pharmacodynamic analysis 
identified patients with a high serum concentration of FAR that 
may have benefited from treatment.
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P1.11-020 ECONOMIC ANALYSIS OF TORCH: ERLOTINIB 
VERSUS CISPLATIN AND GEMCITABINE AS FIRST-LINE 
THERAPY FOR ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC)
Carmen Chung1, Haiyan Jiang2, Wanrudee Isaranuwatchai3, Mas-
simo Di Maio4, Anthea Lau2, Jeffrey Hoch3, Ronald Feld2, Ming-
Sound Tsao5, Cesare Gridelli6, Ciro Gallo7, Fortunato Ciardiello7, 
Charles A. Butts8, Francesco Perrone4, Natasha B. Leighl9
1Postgraduate Medical Education, University Of Toronto/Canada, 2Uni-
versity Health Network/Canada, 3Cancer Care Ontarior Pharmacoeco-
nomics Unit/Canada, 4National Cancer Institute/Italy, 5Princess Marga-
ret Hospital/Canada, 6S.g.moscati Hospital/Italy, 7Second University/
Italy, 8Cross Cancer Institute/Canada, 9Medical Oncology, Princess 
Margaret Cancer Centre/Canada
Background: The TORCH (“Tarceva or Chemotherapy”) rando-
mized phase III trial demonstrated that first-line erlotinib followed 
by second-line cisplatin-gemcitabine (N=380) compared to ci-
splatin/gemcitabine followed by erlotinib (N=380) in unselected 
advanced NSCLC patients yielded inferior survival, without major 
differences in first-line global quality of life. We determined the 
incremental costs and utility between arms, including in the EGFR 
mutation positive subgroup (N=39).
Methods: Direct medical resource utilization data and EQ5D 
scores were collected prospectively during the trial. Mean survival 
and quality-adjusted survival per arm were calculated for the en-
tire study population and the subgroup with documented EGFR 
mutations. The analysis was conducted from the Canadian public 
health perspective, using a lifetime horizon. Costs for medications, 
outpatient visits, investigations and toxicity management including 
hospitalization were determined, and presented in 2012 Canadi-
an dollars (CAD). The primary outcomes of the analysis included 
costs and outcomes per treatment arm, and the incremental cost 
per quality-adjusted life-year (QALY) gained in the EGFR mutation 
positive subgroup.
5.45 months (95% CI, 3.88–6.05) vs. 5.22 months (95% CI, 4.24–
6.74) in the cixutumumab and control arms, respectively (HR 1.15, 
95% CI, 0.81–1.61; P=0.440). ORR did not significantly differ bet-
ween treatments (37.9% cixutumumab vs. 30.6% control; P=0.338); 
however, the median duration of response was numerically greater 
in the cixutumumab arm (4.9 months; 95% CI, 4.17–6.28) than in the 
control arm (3.91 months; 95% CI, 2.92–6.41), although differences 
were not significant (HR 0.74, 95% CI, 0.40–1.38; P=0.340). Median 
OS was 10.68 months (95% CI, 8.74–not evaluable) in cixutumumab 
vs. 10.38 months (95% CI, 7.43–14.39) in control patients (HR 0.85, 
95% CI, 0.56–1.30; P=0.450). Common AEs reported in ≥10% of 
patients were nausea, hyperglycemia, fatigue, vomiting, and an-
emia. A greater proportion of patients in the cixutumumab arm 
(74.1%) had grade 3/4 AEs than patients in the control arm (61.7%). 
Grade 3/4 hyperglycemia occurred at a higher rate in the cixutu-
mumab arm than the control arm (11.8% vs. 1.2%). One possibly 
cixutumumab-related death occurred during the study.
Conclusion: Superior PFS was not achieved in nonsquamous NS-
CLC patients when cixutumumab was added to the pemetrexed 
and cisplatin treatment regimen, and no significant improvement 
for any other endpoint was observed. Pemetrexed combined with 
cisplatin and cixutumumab was tolerable, with no new safety con-
cerns reported.
Keywords: first-line therapy, IMC-A12, NSCLC, cixutumumab
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P1.11-019 PHASE 2 DOUBLE-BLIND, PLACEBO-CONT-
ROLLED STUDY OF THREE-WEEKLY FARLETUZUMAB 
WITH A PLATINUM CONTAINING DOUBLET IN SUB-
JECTS WITH PREVIOUSLY UNTREATED FOLATE RECEP-
TOR ALPHA (FRA) EXPRESSING NON-SMALL-CELL LUNG 
CANCER (NSCLC)
Julia D. Maltzman1, Penny Fatato1, Kimberly Hoffman1, Kathleen 
Dougherty1, Daniel J. O‘Shannessy1, Elizabeth B. Somers1, En-
riqueta Felip2, Mohammad Jahanzeb3
1Clinical Development, Morphotek, Inc./United States Of America, 2Hos-
pital Universitario De La Vall D‘hebron/Spain, 3University Of Miami, 
Sylveter Comprehensive Cancer Center/United States Of America
Background: Farletuzumab (FAR) is a humanized monoclonal anti-
body that binds to folate receptor alpha, which is highly expressed 
in NSCLC, specifically adenocarcinoma. FAR potentially has anti-
tumor activity via antibody-dependent cell-mediated cytotoxicity 
and complement-dependent cytotoxicity, and was studied in a 
Phase 2 NSCLC trial.
Methods: This was a global, double-blind, randomized Phase 2 
trial in 130 patients with previously untreated FRA-expressing NS-
CLC. Patient tumors were screened using a FRA immunohistoche-
mical diagnostic assay at a central pathology lab. Subjects could 
receive carboplatin and paclitaxel, carboplatin and pemetrexed, 
or cisplatin and pemetrexed for 4 to 6 cycles combined with ran-
domized test product (FAR 7.5 mg/kg every three weeks with che-
motherapy, or placebo). Cycle 1 included a loading dose on Day 
1 of Week 2. Single agent test product was then continued every 
three weeks until disease progression. The primary endpoint was 
progression-free survival (PFS) by Response Evaluation Criteria in 
Solid Tumors, 1.1.
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Medical College/China, 10Lung Cancer Department, Beijing Tuberculosis 
And Thoracic Tumor Research Institute/China, 11Nanjing Bayi Hospital/
China, 12Fujian Provincial Tumor Hospital/China, 13Department Of On-
cology, Sir Run Run Shaw Hospital/China, 14Affiliated Xinan Hospital 
Of Third Military Medical University/China, 15First Affiliated Hospital, 
Medical School Xi’an Jiaotong University/China, 16Hospital Tengku 
Ampuan Afzan/Malaysia, 17Cancer Hospital, Fudan University/China, 
18Manila Doctors Hospital/Philippines, 19Roche (china) Holding Ltd/Chi-
na, 20Lung Center Of The Philippines/Philippines
Background: Erlotinib, an epidermal growth factor receptor 
(EGFR) tyrosine-kinase inhibitor, has proven efficacy in second-/
third-line advanced NSCLC, and provides superior first-line effica-
cy to chemotherapy for patients whose tumors harbor activating 
EGFR mutations. The phase 3, randomized, open-label ENSURE 
study evaluated erlotinib vs GP in patients from China, Malaysia 
and the Philippines with EGFR mutation-positive NSCLC.
Methods: Patients ≥18 years with histologically or cytologically 
confirmed stage IIIB/IV EGFR mutation-positive NSCLC and an 
ECOG PS of 0–2 were randomized 1:1 to receive either erlotinib 
(oral; 150mg qd until progression/unacceptable toxicity) or GP (G 
1250mg/m2 iv d1 & 8 q3w; P 75mg/m2 iv d1 q3w for up to 4 cycles). 
Patients were stratified by EGFR mutation type, PS, gender, and 
country). Primary endpoint is progression-free survival (PFS) by in-
vestigator, with Independent Review Committee (IRC) assessment 
for sensitivity analysis; other endpoints include objective response 
rate (ORR), overall survival (OS), and safety. A pre-planned interim 
analysis was conducted after 73% of PFS events (cut-off 20 July 
2012). An additional exploratory updated analysis (cut-off of 19 
November 2012), included all planned PFS events.
Results: In total, 217 patients were randomized: 110 to erlotinib 
and 107 to GP. Baseline characteristics were similar in both groups. 
Efficacy data by treatment arm for the interim and updated ana-
lyses are presented (Table 1). PFS by investigator in EGFR exon 19 
Results: The costs per patient in the chemotherapy were higher 
than in the erlotinib arm, with an incremental mean cost of $4,190 
CAD. This was related to longer duration of chemotherapy treat-
ment, associated with higher drug and outpatient visit costs. High-
er costs from hospitalization and adverse event management were 
seen in the erlotinib arm, likely related to disease progression. 
Mean overall survival in the entire study population was longer in 
the chemotherapy arm , although mean quality-adjusted survival 
was similar (0.82 QALY in chemotherapy arm and 0.87 in erlotinib 
arm). In the EGFR mutation positive subgroup, mean survival was 
slightly higher in the chemotherapy arm, but quality-adjusted sur-
vival was longer in the erlotinib arm (1.19 QALYs versus 1.08 QALYs 
with chemotherapy). The incremental cost-effectiveness ratio for 
first-line erlotinib compared to chemotherapy in the EGFR mutati-
on positive subgroup was $32,916 CAD per QALY.
Conclusion: While first-line platinum doublet chemotherapy re-
mains the standard for unselected advanced NSCLC patients, first-
line erlotinib appears to be cost effective in the EGFR mutation 
positive subgroup. This supports routine EGFR genotyping to se-
lect first-line therapy in advanced NSCLC, and targeted EGFR TKI 
therapy for those with EGFR mutation positive NSCLC.
Keywords: cisplatin and gemcitabine, erlotinib, advanced non-
small cell lung cancer, economic analysis
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P1.11-021 FIRST-LINE ERLOTINIB VERSUS CISPLATIN/
GEMCITABINE (GP) IN PATIENTS WITH ADVANCED EGFR 
MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER 
(NSCLC): INTERIM ANALYSES FROM THE PHASE 3, 
OPEN-LABEL, ENSURE STUDY
Yi-Long Wu1, Chong-Kin Liam2,  
Caicun Zhou3, Gang Wu4, Xiaoqing 
Liu5, Zhaoyang Zhong6, Shun Lu7,  
Ying Cheng8, Baohui Han7, Lei Chen9,  
Yunzhong Zhu10, Shukui Qin11,  
Cheng Huang12, Hongming Pan13, 
Houjie Liang14, Enxiao Li15, Soon Hin 
How16, Guoliang Jiang17, Marie Cherry 
Lynn Fernando18, Meng Chen19,  
Yunxia Zuo19, Guia Ladrera20
1Guangdong Lung Cancer Institute, 
Guangdong General Hospital & 
Guangdong Academy Of Medical 
Sciences/China, 2Department Of 
Medicine, Faculty Of Medicine, University 
Of Malaya/Malaysia, 3Department Of 
Oncology, Affiliated Shanghai Pulmonary 
Hospital Of Tongji University/China, 
4Department Of Cancer, Union Hospital 
Of Tongji Medical College/China, 
5Internal Medicine Tumor Department, 
307 Hospital Of The Academy Of 
Military Medical Sciences/China, 6Cancer 
Centre, Research Institute Of Surgery, 
Daping Hospital, Third Military Medical 
University/China, 7Department Of Lung 
Cancer, Shanghai Chest Hospital/China, 
8Jilin Cancer Hospital/China, 9Medical 
Oncology Department, Cancer Hospital Of Shantou University  
Efficacy Outcome Interim analysis (cut-off 20 July 2012) 
Updated analysis (cut-off 19 
November 2012) 
E GP E GP 
Investigator-assessed PFS Events, n 35 66 61 87 
Median, 
months 
11.0 5.5 11.0 5.5 
HR (95% CI) 0.34 (0.22–0.51) 0.33 (0.23–0.47) 
log-rank p-
value 
<0.0001 <0.0001 
IRC-assessed PFS Events, n 33 47 51 55 
Median, 
months 
11.0 5.6 11.1 5.7 
HR (95% CI) 0.42 (0.27–0.66) 0.43 (0.29–0.64) 
log-rank p-
value 
0.0001 <0.0001 
ORR % 62.7 33.6 68.2 39.3 
p-value 0.0001 <0.0001 
Disease control rate (DCR) % 89.1 76.6 91.8 82.2 
p-value 0.015 0.0354 
EGFR exon 19 deletion sub-
group PFS 
Median, 
months 
11.1 4.2 11.1 4.3 
HR (95% CI) 0.20 (0.11–0.37) 0.20 (0.12–0.33) 
EGFR exon 21 L858R sub-
group PFS 
Median, 
months 
8.3 7.1 8.3 5.8 
HR (95% CI) 0.57 (0.31–1.05) 0.54 (0.32–0.90) 
p-value significance level: alpha=0.05
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Results: A total of 134 patients, 65% (87/134) males, of age 63 ± 
9.7 (mean ± SD) years were included. While 34% (46/134) of pati-
ents were presented with adenocarcinoma, the proportion of lar-
ge-cell carcinoma, squamous cell carcinoma and NSCLC not other-
wise specified were 33% (44/134), 29% (39/134) and 4% (5/134), 
respectively. The clinical stage at the start of first-line SACT were 
28% (37/134) IIIB and 72% (97/134) IV. Aside from the relatively 
small subset of patients (12%, 16/134) harboring oncogenic drivers, 
platinum-based combination chemotherapy regimens were the 
mainstay of treatment. For a median survival of 7.1 months (95% CI 
5.9-8.1), total lifetime costs were averaged to $39,992 ± $20,928 
per patient. The influential cost-drivers across all lines of thera-
py were hospitalizations ($15,521± $16,511) and SACT ($11,628± 
$7,583), mainly platinum-based gemcitabine or docetaxel. Monthly 
costs per patient were amounted to $11,932± $14,571. The degree 
of associations between predictors and outcomes were observed 
for clinical stage of disease at the start of SACT, administration of 
prior treatment and smoking history. Although clinically imperati-
ve, age and gender were not predictors of variability of healthcare 
costs at alpha ≤0.05.
Conclusion: Real-world medical costs, in particular hospital admis-
sions and SACT, are substantial in the management of stage IIIB/
IV NSCLC in the Netherlands. In a molecularly enriched patient 
population, biomarker-driven treatments are expected to result 
in higher likelihood of clinical benefit. Consequently, the average 
hospitalization costs and long-term management of treatment-
related events are likely to reduce. Future research assessing the 
quantification of disease burden based solely on molecularly tar-
geted agents in daily practice is encouraged. These results may 
collectively inform decision-making of registration, reimbursement 
and pricing of interventions in NSCLC.
Keywords: advanced non-small cell lung cancer, real-world, medi-
cal costs, retrospective analysis
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P1.11-023 MOLECULAR SCREENING IN ADVANCED 
NON-SMALL CELL LUNG CANCER: A SYSTEMATIC RE-
VIEW OF COST-EFFECTIVENESS ANALYSES FOR FIRST-
LINE THERAPY
Remziye Zaim1, Erik Thunnissen2, Anne-Marie Dingemans3, Pieter 
E Postmus4, Carin A. Uyl-De Groot1
1Medical Technology Assessment, Health Policy And Management, 
Erasmus University/Netherlands, 2Pathology, VU University Medical 
Center/Netherlands, 3Pulmonary Diseases, Maastricht University Me-
dical Center/Netherlands, 4Pulmonary Diseases, VU University Medical 
Center/Netherlands
Background: Novel molecularly targeted therapies are increasin-
gly licensed in conjunction with companion diagnostics to stratify 
patients with oncogenic aberrations and to help improve patients‘ 
likelihood of clinical benefit. Cost-effectiveness analyses (CEAs) are 
now expected to examine the value of molecular screening as well 
as traditional costs and benefits of therapeutic choices. The aim of 
this study was to assess the impact of first-line predictive biomar-
ker screening on the cost-effectiveness of molecularly targeted 
agents in locally advanced or metastatic non-small cell lung cancer 
(NSCLC).
Methods: A systematic literature review was performed using 
deletion and exon 21 L858R mutation subgroups is also presented 
(Table 1). Erlotinib was better tolerated than GP, with treatment-
related serious adverse events (SAEs) occurring in 2.7% vs 10.6% 
of patients, respectively. The most common grade ≥3 AEs of any 
cause were neutropenia (25.0%), leukopenia (14.4%) and anemia 
(12.5%) in the GP arm, and rash in the erlotinib arm (6.4%). At the 
updated analysis (19 November 2012), erlotinib remained better 
tolerated than GP, with treatment-related SAEs occurring in 3.6% 
vs 11.5% of patients, respectively. Median duration of follow-up 
was 10.3 months and 11.7 months for the GP and erlotinib arms, 
respectively, at latest cut-off. OS data are not yet mature. 
Conclusion: These analyses demonstrate that erlotinib provides 
statistically significant and clinically meaningful improvement in 
both investigator-assessed and IRC-assessed PFS compared with 
GP in Asian patients with EGFR mutation-positive NSCLC. Primary 
efficacy results were also supported by secondary endpoints inclu-
ding ORR and DCR.
Keywords: EGFR mutations, Asian patients, erlotinib, NSCLC
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P1.11-022 RETROSPECTIVE LONGITUDINAL CHART RE-
VIEW OF PATIENTS WITH ADVANCED NON-SMALL CELL 
LUNG CANCER IN THE NETHERLANDS: A QUANTIFICA-
TION OF DISEASE BURDEN
Remziye Zaim1, Ly Tran2, Anne-Marie Dingemans3, Gerarda J. Her-
der4, Ernst Lammers5, Pieter E Postmus6, Carin A. Uyl-De Groot1
1Medical Technology Assessment, Health Policy And Management, 
Erasmus University/Netherlands, 2Boehringer Ingelheim/Netherlands, 
3Pulmonary Diseases, Maastricht University Medical Center/Nether-
lands, 4Pulmonary Diseases, St Antonius Hospital/Netherlands, 5Gelre 
Hospital/Netherlands, 6Pulmonary Diseases, VU University Medical 
Center/Netherlands
Background: The availability of novel therapeutic regimens has led 
to increase in duration of treatment and utilization of healthcare 
in non-small cell lung cancer (NSCLC). Although medical resource 
use and costs were assessed in previous studies, characterization 
of disease burden exclusively for advanced-stage, in real-world 
setting is scarce. The aims of our study were to quantify medical 
costs of stage IIIB/IV NSCLC and identify components of care, that 
are likely to alter in light of new developments, in Dutch clinical 
practice.
Methods: A retrospective longitudinal chart review was performed 
to obtain healthcare utilization of patients, age ≥18 years, with 
stage IIIB/IV NSCLC (based on the sixth edition of tumor-node-
metastasis classification) who received first- and subsequent-line of 
systemic anti-cancer therapy (SACT). As part of the LUng Cancer 
Economics and Outcomes Research (LUCEOR), a multi-country 
retrospective patient chart review, two academic and two non-
academic Dutch hospitals participated in the study. Patients who 
deceased before April 2010 were included. The components of 
care, from the initiation of first-line SACT until death, were quanti-
fied by twelve distinct categories. Total and monthly medical costs 
attributable to each component were calculated and expressed 
in 2012 US dollars. Outcomes were fit with statistical models to 
compare trends. Potential predictors of lifetime NSCLC costs and 
variability were examined.
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P1.11-024 A PHASE I/II RANDOMIZED TRIAL USING GM-
CSF-PRODUCING AND CD40L-EXPRESSING BYSTANDER 
CELL LINE (GM.CD40L) VACCINE PLUS OR MINUS CCL21 
IN STAGE IV LUNG ADENOCARCINOMA: UPDATED RE-
SULTS
Jhanelle E. Gray1, Alberto A. Chiappori1, Charles Williams1, Mary 
Pinder-Schenck1, Eric B. Haura1, Tawee Tanvetyanon1, Germaine 
Gonzalez-Vazquez1, David Noyes1, Jongphil Kim2, Scott Antonia1
1Thoracic Oncology, H. Lee Moffitt Cancer Center And Research Institu-
te/United States Of America, 2Biostatistics, H. Lee Moffitt Cancer Cen-
ter And Research Institute/United States Of America
Background: The GM.CD40L vaccine, an allogeneic tumor cell-
based vaccine generated from a human bystander cell line which 
secretes GM-CSF and expresses CD40L on the surface (GM.
CD40L), was developed by our team. It serves to recruit and ac-
tivate dendritic cells. The mature dendritic cells in turn travel to 
regional lymph nodes and help to activate T cells which result in 
systemic tumor cell killing. CCL21 is a chemokine which serves 
to enhance recruitment of T cells and enrich T cell responses. In 
NSCLC mouse model, the vaccine combination of GM.CD40L plus 
CCL21 demonstrated additive effects.
Methods: We conducted a phase I/II randomized study to evalua-
te the GM.CD40L (Arm A) vs. GM.CD40L.CCL21 (Arm B) vaccine in 
patients with lung adenocarcinoma who had failed first-line thera-
py. Primary endpoints were safety and tolerability of Arm B in pha-
se I and 6 month progression-free survival (PFS) in phase II; secon-
dary endpoints included anti-tumor immune responses and T-cell 
responses by ELISpot assay on PBMC. Immune-related response 
criteria (irRC) determined discontinuation from study treatment 
at the discretion of the PI/treating physician. Intradermal vaccines 
were administered in the bilateral axilla and groin every 14 days 
for 3 doses and then monthly for 3 doses. A two-stage minimax 
design was used. Survival probabilities over time in each treatment 
group were estimated using the method of Kaplan and Meier.
Results: Between 4/2012 and 4/2013, phase 1 enrolled 3 patients 
on GM.GD40L.CCL21, while Arm A enrolled 17 and Arm B enrolled 
14 patients. The baseline characteristics, including those in phase 
I are as follows: median age: 66/68 years, females: 50%/50%, PS1: 
64.7%/76.5%, median prior regimens: 2.5/3 for Arm A vs. Arm B, 
respectively. No DLT’s were observed during phase 1. The most 
common toxicities for Arm A vs. Arm B were injection site reaction 
(70.6%/70.6%), fatigue (29.4%/41.2%), anorexia (23.5%/29.4%), and 
pain in extremity (5.9%/5.9%). Median PFS for Arm A vs. B was 1.9 
vs. 4.4 months (p=0.10). All patients who remained on study per 
MD discretion/irRC, did ultimately demonstrate further progres-
sion on subsequent imaging. Treatment was discontinued in all of 
those patients. In Arm A versus Arm B, stable disease was 4/8 and 
progressive disease was 8/8, respectively. The disease control rate 
(DCR) for Arm B compared with Arm A was 50% versus 33%, res-
pectively. ELISpot assay for immune responses and flow cytometry 
studies on PBMCs are underway.
Conclusion: GM.CD40L plus CCL21 chemokine is well tolerated. 
The phase II trial including further immune response assays collec-
ted pre and post vaccine are underway and updated results will be 
presented.
Keywords: vaccine, immunotherapy, lung adenocarcinoma, 
GM.CD40L.CCL21
MEDLINE, EMBASE and NHS EED. CEAs of epidermal growth 
factor receptor (EGFR)-, Kirsten RAS (KRAS)-, and anaplastic lym-
phoma kinase (ALK)-guided screening prior to first-line treatment 
were appraised according to a priori eligibility criteria. The impact 
of screening guided patient management was quantified by incre-
mental cost-effectiveness ratios (ICERs) and expressed in 2013 US 
dollars. Sensitivity analyses were explored to examine the influ-
ence of extracted parameters on the ICERs. Methodological quali-
ty of the studies was assessed by standardized checklists.
Results: Based on the explicit test-treat combined strategy, eight 
CEAs met the inclusion criteria. Although six EGFR- and two ALK-
guided diagnostic-therapeutic pairings were reviewed, none of the 
retrieved CEAs explored the potential benefits of KRAS mutation 
screening on the molecularly targeted agents in the front-line 
setting. Country-specific decisions regarding utilization of health-
care were conducted from the perspectives of the United States, 
England and Wales, France, Singapore and China. Efficacy data 
including biomarker prevalence (ALK: 1.6-4.4%, EGFR: 16.6-60%), 
sensitivity of the test (ALK: 67-100%, EGFR: 92-100%), specificity of 
the test (ALK: 93-100%, EGFR: 96-100%) and Quality-Adjusted Life 
Years (QALY) gained (ALK: 0.009-0.014, EGFR: 0.04-0.5) were ext-
racted. Base-case costs for ALK- and EGFR-guided screening were 
$98-$1,421 and $105-$516, respectively. The ICERs of EGFR-gui-
ded test-treat strategy ranged from being less costly/more effecti-
ve to unlikely to be cost-effective (ICER range: dominant-$160,123/
QALY gained). The ICERs of ALK-guided strategy ranged from 
likely to be cost-effective to unlikely to be cost-effective (ICER ran-
ge: $59,240-$213,869/QALY gained). Sensitivity analyses revealed 
that ICERs of molecularly enriched patient groups were profoundly 
dependent on the monthly costs of targeted agents (erlotinib, 
gefitinib, crizotinib) and duration of treatment. Conversely, at low 
biomarker frequencies, ICERs were influenced by the cost of the 
screening test. Test specificity, the proportion of advanced NSCLC 
patients correctly identified as not having EGFR/ALK positivity, 
was more influential than the test sensitivity. Although clinically 
imperative, re-biopsy and subsequent therapy were not explored. 
Furthermore, critical assessment of the CEAs revealed that justifi-
cation of preferred methods, transparency of input parameters and 
generalizability of results affected quality.
Conclusion: This study investigates indications of cost-effective 
screening of ‚actionable‘ molecular aberrations and highlights the 
impact of clinical and cost parameters on the ICERs. While advan-
cements in mechanisms of resistance and histological transforma-
tions will shed light on the future of lung cancer care, CEAs of no-
vel diagnostic-therapeutic pairings will continue to help informed 
decision-making of all stakeholders.
Keywords: advanced non-small cell lung cancer, molecular scree-
ning, cost-effective, systematic review
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P1.11-026 FINAL RESULTS OF A PHASE 2 TRIAL OF THE 
ONCOLYTIC VIRUS REOVIRUS SEROTYPE 3-DEARING 
STRAIN (REOLYSIN®) IN METASTATIC NSCLC PATIENTS 
WITH A RAS-ACTIVATED PATHWAY.
Miguel Villalona-Calero1, Elaine Lam1, Weiqiang Zhao2, Gregory 
Otterson1, Deepa Subramaniam3, Bo Chao1, Matthew Timmons4, 
Larry Schaaf5, George M Gill6, Matt Coffey6
1Medical Oncology, The Ohio State University/United States Of Ame-
rica, 2Pathology, The Ohio State University/United States Of America, 
3Lombardi Cancer Center, Georgetown University/United States Of 
America, 4Clinical Trials Office, The Ohio State University/United States 
Of America, 5Cancer Center, The Ohio State University/United States Of 
America, 6Oncolytics Biotech Inc/Canada
Background: Reovirus is a naturally occurring virus which prefe-
rentially infects and causes oncolysis in tumor cells with a Ras-
activated pathway. In preclinical studies, reovirus induces cell cycle 
arrest, acting synergistically with standard cytotoxic agents. We 
have hypothesized that patients with EGFR-mutated, EGFR-am-
plified, BRAF or Kras-mutated NSCLC should all have a common 
downstream activated Ras pathway and should be susceptible to 
treatment with reovirus.
Methods: We conducted a Fleming, single-arm, phase II study 
to evaluate safety and the objective response rate (primary end-
points), as well as 6-month progression-free and 1 year survival 
(secondary end-points) of metastatic NSCLC patients treated with 
reovirus in combination with paclitaxel/carboplatin (P/C). Eligible 
patients had ECOG PS 0-2, adequate organ function, no prior che-
motherapy for metastatic disease, and tumors with the specified 
above genotype, as per CLIA certified laboratory testing. Prior 
adjuvant chemotherapy, or erlotinib/gefitinib for pts with EGFR-
mutant tumors was permitted. Patients received Reovirus (3 x 1010 
TCID50) intravenously daily on days 1-5, in combination with P/C at 
initial doses of P 200 mg/m2 and C AUC 6, on day 1 of each 21-day 
cycle. Due to exacerbation of prior colitis and febrile neutropenia 
(1 each) in the first two pts, doses were subsequently reduced to P 
175 mg/m m2 and C AUC 5.
Results: Overall, 37 patients received 209 cycles (per pt median 
4, range 1 to 18). Grade 3-4 toxicity included febrile neutropenia 
(3 pts), G3 diarrhea (2 pts), G3 anemia (8 pts), fatigue in 6 pts (5 
G3, 1 G4), nausea/vomiting and thrombocytopenia (2 pts each), 
electrolyte abnormalities, and single G3 episodes of arthralgia and 
transaminitis. Molecular tumor demographics included: 20 Kras (2 
G12A, 9 G12C, 1 G12D, 1 G12R, 1 G12S, 3 G12V, 1 G13C, 1 G13R, 
1 G12C/V double mutant), 3 EGFR exon 19, 4 BRAF V600E muta-
tions, and 10 EGFR amplified only. Response evaluation showed 
11 RECIST partial responses (30%) (EGFR amp 5, BRAF 2, Kras 3, 
EGFR mut 1), 21 SD, and 4 PD. PFS (by CT and PET) at 6 months for 
36 patients with enough follow up to date is 36%, with PET results 
influencing switching to second line therapy in several patients 
with SD by CT. Sixteen patients received 6 or more cycles. One 
year survival was 53%.
Conclusion: Reovirus can be administered safely in combination 
with P/C and patient selection by Ras-activated pathway is feasible 
in the clinical setting. Overall clinical efficacy is encouraging. Ran-
domized evaluation is planned.
Keywords: oncolytic reovirus, Kras activated, BRAF, Lung cancer
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P1.11-025 EGFR MUTATION STATUS IN ADENOCARCI-
NOMA LUNG: A SINGLE CENTRE EXPERIENCE FROM 
NORTHERN INDIA
Jyoti Wadhwa1, Sunny Jandyal1, Sandeep Batra1, Neelam Sharma1, 
Devender Sharma1, Atul Gupta1, Rohit Puri1, Bhanu P. Singh1, San-
deep Bali1, Vimarsh Raina2, Ashok K. Vaid1
1Medical Oncology, Medanta The Medicity/India, 2Laboratory Medicine, 
Medanta The Medicity/India
Background: Epidermal Growth Factor Receptor (EGFR) has emer-
ged as an important molecular marker with a therapeutic impli-
cation in many malignancies including lung cancer. The tyrosine 
kinase domain is known to be associated with a number of genetic 
aberrations including deletions, insertions, and single nucleotide 
polymorphism. TKIs targeting EGFR, including gefitinib and erloti-
nib, have become the standard first-line therapies for patients with 
advanced non-small cell lung cancer (NSCLC) who harbour EGFR 
mutations most often in exons 18-21. The objective of the present 
study was to explore the EGFR mutational status of a population of 
lung cancer patients in northern India and evaluate the correlation 
with clinical characteristics.
Methods: Of the 105 consecutive patients of adenocarcinoma of 
lung treated in our department between January 2011 and May 
2013, information regarding mutational status of EGFR was availa-
ble for 80 patients. We present the correlation of various clinical 
parameters with EGFR mutational status for this group of patients. 
EGFR testing was done on the available biopsy material using a 
PCR based method.
Results: EGFR mutation status was known in 80 patients with 
adenocarcinoma lung. Their median age at presentation was 61.5 
years with a range of 27 to 87 years. Thirty six (45%) patients were 
younger than 60 years. The male to female ratio was 2.6:1. The 
most common biopsy sites, in descending order were: lung mass- 
56 (70%), pleura -13 (16%), lymph node – 06 (7.5%), liver- 03 (3.7%) 
and bone- 02 (2.5%),. All but 2 patients had stage IIIB or IV ade-
nocarcinoma lung. The frequent sites of metastases were- bones 
(31%), brain (24%), hepatic (14%), adrenals (11%) and contralateral 
lung (5%). EGFR mutations were detected in twenty two (27.5%) 
patients. Among the mutant positive cases, the deletions in exon 
19 (47%) and exon 21(38%) were most predominant. Out of the en-
tire cohort (N=80), thirty seven (46%) patients had been smokers. 
Nine (41%) of the mutant patients had history of smoking.
Conclusion: Earlier published data from India had reported an 
incidence of 51.8% in a group of 220 patients of NSCLC who had 
been tested for EGFR mutations. At 27.5%, the rate of mutations in 
our group of patients is lower than that reported in the earlier pub-
lication from India. However, this is still higher than the prevalence 
reported in western literature. The proportion of smokers in the 
population with EGFR mutations was higher than that reported in 
other studies (41% in this study vs 22% in a study of Chinese lung 
cancer patients). This may be on account of retrospective analysis 
of a smaller sample size and selection bias in subjecting patients to 
EGFR testing. A prospectively designed trial incorporating a larger 
population of patients correlating clinical, radiological and other 
pathological features shall be required to answer various questions 
linked to EGFR mutational status in lung cancer patients particular-
ly in the Indian sub-continent.
Keywords: EGFR, mutation, Adenocarcinoma, India
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P1.11-028 ANTITUMOR AND IMMUNE-BIOLOGICAL 
ACTIVITY OF A NEW METRONOMIC CHEMOTHERAPY 
WITH FRACTIONED CISPLATIN AND ORAL ETOPOSIDE 
COMBINED WITH BEVACIZUMAB (MPEBEV) FOLLOWED 
BY ERLOTINIB MAINTENANCE IN NON SMALL CELL 
LUNG CANCER (NSCLC) PATIENTS
Pierpaolo Correale1, Ignazio Martellucci2, Pierpaolo Pastina3, Ciri-
no Botta4, Elodia Martino3, Daniela Mazza3, Pierosandro Tagliafer-
ri4, Luigi Pirtoli3, Michele Caraglia5
1Oncology / Siena University Hospital, Translational Immuno-oncology 
Center / Radiotherapy Unit/Italy, 2Oncology, Medical Oncology, Siena 
University Hospital/Italy, 3Oncology, Unit Of Radiotherapy, Siena Uni-
versity/Italy, 4Medical And Experimental Medicine, Medical Oncology 
Unit “magna Graecia” University/Italy, 5Biochemistry, Biophysics And 
General Pathology, Second University Of Naples/Italy
Background: We recently, concluded a phase II trial (mPEBev 
trial) aimed to evaluate in metastatic non-small-cell-lung-cancer 
patients (NSCLC), the toxicity and biological and anti-tumour 
activity of a newest bio-chemotherapy strategy combining metro-
nomic chemotherapy with fractioned cisplatin, oral etoposide with 
bevacizumab, an anti-vasculo-endothelial-growth-factor (VEGF) 
monoclonal antibody. All responsive patients had to continue the 
treatment with a TKI inhibitor (Erlotinib) until disease progression. 
The treatment resulted safe and very active with effective anti-
angiogenic effects (Correale P, 2011 12(2):112). By considering 
that this treatment strategy was designed on preclinical results 
suggesting additive interaction of metronomic chemotherapy with 
VEGF deprivation and EGFR inhibition, in term of anti-tumor/anti-
angiogenic-activity and immune-modulation, we investigated in 
this patients‘ population the ability of our treatment to generate 
immune-biological effects with potential antitumor activity.
Methods: The mPEBev Phase II trial was approved by the Ethical 
committee of Siena University. All the enrolled patients signed and 
informant consent. Thirty-five inoperable NSCLC patients (25 ma-
les and 10 females) with an ECOG < 1, and median age of 68 years 
(range 3-75) were enrolled. Twenty-six had an adeno-carcinoma, 6 
a squamocellular and 3 NAS carcinoma. All patients received ci-
splatin (30mg/sqm days 1-3q21 etoposide 50mg/sqm days 1-15/21 
and bevacizumab 5mg/kg on the day 3q21). After four treatment 
courses, all patients who achieved a partial response (PR) or a 
stable disease (SD) received daily Erlotinib (150 mg/day), starting 
one week after the end of chemotherapy until disease progression 
(PD). A cytokine multiplex analysis and an immune-cytofluorimetric 
analysis was performed on blood samples isolated at the baseline, 
after 4 bio-chemotherapy courses and 3 months after the end of 
bio-chemotherapy. Statistical significance (p <0.05) was searched 
between by comparing the results obtained on the samples taken 
at baseline and treatment timing as described above.
Results: Our biological multiplex analysis revealed a significant 
decrease in serum levels of VEGF (68,9 +/-23 vs. 30+/-12 ng/ml), 
and interleukin (IL)-10 (326 +/-136 vs. 187,6 +/-60 ng/ml) which was 
maintained along TKI treatment. There was no change in angiopoi-
etin, interferon gamma, IL-12, PECAM and follistatin levels. During 
TKI maintenance we additionally, recorded an increase in IL-8 (59,2 
+/-11 vs. 165,15 +/- 38 ng/ml), and leptine (7275+/- 2202 vs. 11078 
+/- 4280 ng/ml) associated with a significant decrease in G-CSF 
levels (94,3 +/-59 vs. 17,61 +/-3 ng/ml) and angiopoietin levels 
(1099,9 +/- 123 vs. 603 +/-162 ng/ml). Our immune-cytofluorimetric 
analysis of patients’ PBMCs showed a significant treatment-related 
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P1.11-027 PHASE I STUDIES OF HM781-36B, AN IRRE-
VERSIBLE PAN-HER TYROSINE KINASE INHIBITOR (TKI) 
IN PATIENTS WITH ADVANCED SOLID TUMOR AND THE 
THERAPEUTIC POTENTIAL IN PATIENTS WITH ADVAN-
CED NON-SMALL CELL LUNG CANCER (NSCLC)
Dong-Wan Kim1, Tae Min Kim1, Jong Seok Lee2, Tae-You Kim1, Se-
Hoon Lee1, Yu Jung Kim2, Kyung Joon Lim3, Jeewoong Son3, Yung-
Jue Bang1
1Department Of Internal Medicine, Seoul National University Hospital/
Korea, 2Department Of Internal Medicine, Seoul National University 
Bundang Hospital, Seoul National University College Of Medicine/Ko-
rea, 3Hanmi Pharmaceutical Co., Ltd./Korea
Background: HM781-36B is an irreversible pan-HER TKI, which 
showed a strong anticancer activity in many cell lines, including 
epidermal growth factor receptor (EGFR) TKI resistant ones in pre-
clinical studies. Two phase I studies were conducted to determine 
the maximum tolerated dose (MTD) in patients with advanced 
solid tumor.
Methods: Patients with advanced malignancies refractory to 
standard therapies were eligible. Standard 3+3 dose escalation 
scheme was used in two phase I studies; a 2-weeks on / 1-week off 
schedule and a continuous dosing schedule.
Results: A total of 75 patients were enrolled; 55 patients in the 
2-weeks on / 1-week off schedule and 20 patients in the conti-
nuous dosing schedule. 27 NSCLC patients were enrolled. Among 
25 evaluable NSCLC patients, 3 patients achieved partial response 
(PR) and 10 patients had stable disease (SD). All 3 patients who 
achieved PR were previously treated with gefitinib, and one of 
them harbored EGFR T790M mutation. In addition, two of them 
had been treated with 4 or more regimens. Among 10 SD patients, 
5 patients showed some degree of tumor shrinkage. Dose -limiting 
toxicity (DLT) was grade 3 diarrhea. The MTD was determined as 
24 mg/day in the 2-weeks on / 1-week off schedule and 18 mg/day 
in the continuous dosing schedule. The recommended phase II 
dose was 16 mg/day (continuous) on the basis of toxicity, pharma-
cokinetic and pharmacodynamic profiles. Two phase II studies of 
HM781-36B are ongoing in NSCLC patients with previously EGFR 
TKI treated and EGFR TKI naive, respectively.
Conclusion: HM781-36B showed good safety profile and antican-
cer activity in NSCLC patients in two phase I studies. Effectiveness 
in the gefitinib refractory and heavily pretreated patients suppor-
ted the potential of HM781-36B as a therapeutic agent for NSCLC.
Keywords: HM781-36B, Pan-HER inhibitor, Phase I clinical trial, 
Advanced non-small cell lung cancer (NSCLC)
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df = 14, P = 0.58; I² = 0% for OS. Chi² = 10.64, df = 13, P = 0.64; 
I² = 0% for PFS). The addition of AATKI to chemotherapy signifi-
cantly increased ORR (OR 1.64, 95% CI 1.34, 2.02; P<0.00001) and 
G≥3CTCAEs (OR 1.78, 95% CI 1.41, 2.25; P<0.00001). Used first 
line (N = 3867), AATKI significantly prolonged PFS (HR 0.86; 95% 
CI 0.79, 0.93; P<0.0001) but not OS (HR 0.96; 95% CI 0.89, 1.05; 
P=0.38). Used second line (N=4037), AATKIs significantly prolon-
ged both OS (HR 0.91; 95% CI 0.84, 0.98; P=0.02) and PFS (HR 
0.80; 95% CI 0.74, 0.87; P<0.00001). Here, the greatest OS benefit 
was seen in patients with adenocarcinoma (HR 0.85; 95% CI 0.75, 
0.96, P=0.01) and patients receiving docetaxel (HR 0.89; 95% CI 
0.81, 0.98; P=0.02). The addition of AATKIs to second line pemet-
rexed did not improve OS (HR 0.95; 95% CI 0.79, 1.13; P=0.54) nor 
in patients with squamous histology (HR 1.01; 95% CI 0.87, 1.16; 
P=0.92).
Conclusion: The addition of AATKIs to chemotherapy in patients 
with advanced NSCLC prolongs OS, PFS and increases ORR, at the 
expense of increased toxicity. Greatest benefit is in second line, 
in adenocarcinomas and in patients receiving docetaxel. Whilst 
the search for predictive biomarkers of the angiogenic phenotype 
continues, an individual patient data meta-analysis may clarify sub-
groups with the most benefit from AATKIs to guide future studies 
in enriched populations.
Keywords: Meta-analysis, randomised controlled trials, anti-angio-
genesis, tyrosine kinase inhibitor
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P1.11-030 TRANSAMINITIS INDUCED BY EPIDERMAL 
GROWTH FACTOR RECEPTOR TYROSINE KINASE INHI-
BITOR PREDICTS FOR FAVOURABLE OUTCOME IN EGFR 
MUTATION POSITIVE NON-SMALL CELL LUNG CANCER
John Kay Hooi Ang1, Amit Jain1, Kian Sing Chan2, Angela Takano3, 
Tony Kiat Hon Lim3, Quan-Sing Ng1, Mei-Kim Ang1, Lynette Lin 
Ean Oon2, Wan-Teck Lim1, Eng-Huat Tan1, Daniel Shao Weng Tan1
1Department Of Medical Oncology, National Cancer Centre Singapore/
Singapore, 2Molecular Laboratory, Singapore General Hospital/Singapo-
re, 3Department Of Pathology, Singapore General Hospital/Singapore
Background: Epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKI) are used as first-line therapy in patients with 
advanced non-small cell lung cancer (NSCLC) harbouring sensi-
tizing mutations. Transaminitis is a known complication, and may 
impede the delivery of optimal doses of TKIs. We describe the 
incidence and severity of TKI induced transaminitis in patients with 
NSCLC treated with first line EGFR TKI and investigate its associati-
on with clinical outcomes. In addition, we review the management 
of patients who developed Grade 2/3 (G2/3) transaminitis or other 
TKI toxicity.
Methods: A retrospective study of 127 patients with EGFR 
mutation positive NSCLC treated at the National Cancer Cen-
tre Singapore with TKIs (gefitinib or erlotinib) over seven years 
(1/1/2006-30/5/2012) was conducted. Transaminitis was graded in 
accordance with CTCAE v4.0 criteria. Endpoints included dose ad-
justments, progression free survival (PFS) and overall survival (OS).
Results: Of 127 patients, 85 (66.9%) developed at least CTCAE 
v4.0 all grade transaminitis (G1/2/3: 75.3/11.8/12.9%) and 39 
(30.7%) developed G1/2 bilirubin levels. No patients developed 
increase in activated (CD3-CD11C+CD14+CD80+CD83+) dendritic 
cells [4.3+/-1.5 vs. 8.5+/-2,1%] and activated (CD3+CD8+CD62L+) 
cytotoxic-T -lymphocytes [2.5 +/-1,2 vs. 5,5 +/-0,259%)].
Conclusion: Our results suggest that this treatment strategy is safe 
and active in NSCLC patients, and is able to affects their systemic 
inflammatory status also inducing immune-modulation with poten-
tial antitumor.
Keywords: Metronomic Chemotherapy, Bevacizumab, immunebio-
logical actvity, erlotinib
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P1.11-029 THE ADDITION OF ANTI-ANGIOGENIC TY-
ROSINE KINASE INHIBITORS TO CHEMOTHERAPY FOR 
ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTE-
MATIC REVIEW AND META-ANALYSIS OF RANDOMISED 
CONTROLLED TRIALS
Bob T. Li1, Csilla Hasovits2, Adrian Lee1, Angela E. Li3, Mustafa 
Khasraw4, Gavin Marx5, Nick Pavlakis6
1Department Of Medical Oncology, Royal North Shore Hospital/Austra-
lia, 2Kolling Institute Of Medical Research, Royal North Shore Hospital, 
University Of Sydney/Australia, 3Royal Prince Alfred Hospital/Austra-
lia, 4Royal Melbourne Hospital, Geelong Hospital, Deakin University/
Australia, 5Sydney Adventist Hospital, University Of Sydney/Australia, 
6Department Of Medical Oncology, Royal North Shore Hospital, Univer-
sity Of Sydney/Australia
Background: Non-small cell lung cancer (NSCLC) remains a major 
cause of death worldwide. Targeting tumour angiogenesis has held 
great promise in NSCLC based on the ubiquitous role of angioge-
nesis in NSCLC biology. The monoclonal antibody bevacizumab 
has shown greatest efficacy when added to first line chemotherapy 
in the adenocarcinoma subgroup. Small molecule, anti-angiogenic 
tyrosine kinase inhibitors (AATKIs) have been evaluated in several 
settings. This review was undertaken to evaluate the benefits and 
harms of AATKIs when added to chemotherapy for advanced NS-
CLC.
Methods: We undertook a systematic review of randomised cont-
rolled trials (RCTs) of AATKIs added to chemotherapy for advanced 
or metastatic NSCLC. We searched the electronic databases (MED-
LINE/PubMed, EMBASE, The Cochrane Library) in addition to con-
ference proceedings from ASCO, ESMO, IASLC WCLC and Clinical 
Trials Registries. Data was independently extracted by two review-
ers. The primary endpoint was overall survival (OS), with secondary 
endpoints progression-free survival (PFS), objective response 
rate (ORR) and ≥ grade 3 common toxicity criteria adverse events 
(G≥3CTCAE). Meta-analysis of the data was performed to obtain 
pooled hazard ratios (HR) for OS and PFS, and pooled odds ratios 
(OR) for ORR and G≥3CTCAE. Statistical analysis was performed 
using Review Manager v5.2 software (Cochrane). Pre-specified 
subgroup analyses were performed according to line of chemothe-
rapy, second-line chemotherapy partner and histology.
Results: Fifteen RCTs involving 7904 patients with advanced NS-
CLC were included in this meta-analysis. In the overall population 
(N = 7904), the addition of AATKI to chemotherapy significantly 
prolonged OS (HR 0.93; 95% confidence interval [CI] 0.88, 0.99; 
P=0.02) and PFS (HR 0.83; 95% CI 0.79, 0.88; P<0.00001). There 
was no significant heterogeneity between the RCTs. (Chi² = 12.31, 
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and 738,441.30 baht, while Erlotinib group were 718,443.50 baht 
and 837,126.30 baht. The cost effectiveness ratio (CER) in term of 
overall survival were 581,883 baht per life year gain in Gefitinib 
group and 688,791.50 baht per life year gain in Erlotinib group.
Conclusion: This long term observational study shows that the 
effectiveness between Erlotinib and Gefitinib in Non Small Lung 
Cancer treatment were comparable. Nevertheless, Gefitinib is 
more cost saving than Erlotinib by payer’s perspective.
Keywords: erlotinib, Non small cell lung cancer, cost effectiveness 
analysis, gefitinib
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P1.11-032 RESULTS WITH DACOMITINIB (PF-00299804), 
AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBI-
TOR, IN A PHASE II COHORT OF PATIENTS WITH HER2-
MUTANT OR AMPLIFIED LUNG CANCERS
Mark G. Kris1, David Ross Camidge2, Giuseppe Giaccone3, Toyoaki 
Hida4, Joseph O‘Connell5, Ian Taylor5, Hui Zhang6, Zelanna Gold-
berg5, Pasi A. Jänne7
1Memorial Sloan-Kettering Cancer Center/United States Of America, 
2University Of Colorado Anschutz Medical Campus/United States Of 
America, 3Georgetown University, Lombardi Comprehensive Cancer 
Center/United States Of America, 4Department Of Thoracic Oncology, 
Aichi Cancer Center Hospital/Japan, 5Pfizer Oncology/United States Of 
America, 6Pfizer (china) Research & Development Co. Ltd/China, 7Lowe 
Center For Thoracic Oncology, Dana Farber Cancer Institute/United 
States Of America
Background: Dacomitinib is an oral, irreversible small molecule in-
hibitor of all active members of the HER (human epidermal growth 
factor receptor) family of tyrosine kinases: EGFR (HER1), HER2 and 
HER4. Dacomitinib has shown superior activity to the reversible 
EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib in pre-
clinical studies of lung cancer cell lines with sensitive and resistant 
EGFR mutations, and superiority to gefitinib in cell-line models 
with a HER2 insertion mutation or amplified HER2. As part of 
dacomitinib’s phase II testing, we studied a cohort of patients with 
HER2-mutant or -amplified lung cancers.
Methods: As a cohort of a larger phase II study, we enrolled pati-
ents who had stage IIIB/IV lung cancers and either HER2 mutations 
or HER2 amplification ([centromere of chromosome 17]; ratio >2), 
any number of prior systemic chemotherapies, but no prior HER2-
targeted treatment. Dacomitinib was administered at 45 mg once 
daily continuously, or 30 mg if the patient had no prior systemic 
therapy, with the option to escalate to 45 mg. Patients were evalu-
ated every 28 days. Endpoints included progression-free survival 
(PFS) rate at 4 months (PFS4m), PFS, objective response rate by 
RECIST, duration of response, overall survival (OS), and toxicity.
Results: 30 patients with HER2-mutant (n=26) or HER2-amplified 
lung cancers (n=4) were enrolled. Characteristics: 15 female; 18 
never smokers (60%); 11 (37%) former smokers. 25 received a 45 
mg starting dose; 5 patients received 30 mg. 10 patients had recei-
ved ≥3 prior systemic therapies. 73% of patients had a PFS event. 
PFS4m overall was 27% (95% CI: 11%–46%; HER2-mutant sub-
group: 21% [95% CI: 6%–43%]). Median overall PFS was 3 months 
(95% CI: 2–4; HER2-mutant subgroup: 3 months [95% CI: 2–4]). Of 
25 patients in the HER2-mutant subgroup evaluable for response, 
Grade 4 transaminitis. None had encephalopathy suggestive of 
fulminant liver failure. Median duration to onset of transaminitis 
was 1.87 months. Of 24 patients who had G2/3 transaminitis (n=21) 
or stopped TKI therapy due to other TKI toxicity (n=3), 8 switched 
to alternative regimen and/or therapies (alternative TKI only, n=3; 
alternative dosing schedule only, n=2; alternative dosing schedule 
followed by alternative TKI, n=2; switch to chemotherapy followed 
by alternative TKI, n=1). There was no change in TKI treatment and/
or regimen for the other 16 patients. Development of transaminitis 
was independent of age, gender, smoking status and presence of 
brain metastases at baseline. Patients who developed transaminitis 
(all grades) had significantly longer PFS than those who did not 
(12.4 vs 8.2 months) (p=0.002). Patients with G1 ALT/AST had sig-
nificantly longer PFS compared to G2/3 (G1/G2/G3: 13.4/3.0/11.9 
months) (p=0.034). OS was not significantly affected by the pre-
sence and severity of transaminitis.
Conclusion: The incidence of EGFR TKI induced transaminitis in 
this cohort of patients appears higher than previously reported. 
Transaminitis, in particular G1, may be predictive of PFS for pati-
ents on TKIs. Patients should be monitored for the development 
of transaminitis, especially during the first two months of TKI treat-
ment. Further studies are recommended to evaluate the role of 
transaminitis as a marker for TKI treatment efficacy.
Keywords: non-small cell lung cancer, tyrosine kinase inhibitors, 
transaminitis
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P1.11-031 COST EFFECTIVENESS ANALYSIS BETWEEN 
GEFITINIB AND ERLOTINIB IN THE TREATMENT OF AD-
VANCED /METASTATIC NON SMALL CELL LUNG CAN-
CER IN THAILAND BY PAYER‘S PERSPECTIVE: SIX YEARS 
DATA FOLLOW UP
Sureerat Jaruhathai1, Savitree Maoleekoonpairoj2, Pawarisa 
Chaichamnan2, Alisara Sangviroon1
1Police General Hospital/Thailand, 2Health System Research Institute/
Thailand
Background: Lung cancer is the second most common cancer in 
Thailand. Oral TKI, Gefitinib and Erlotinib are available for second 
line and third line treatment in advanced non small cell lung cancer 
by registration Central Health Informatics for reimbursement. This 
study aims to compare cost-effectiveness between Erlotinib and 
Gefitinib by Payer’s perspective.
Methods: A retrospective observational study of Thai patients 
who were diagnosed advanced non small cell lung cancer and be 
registered for Oral TKI treatment in either line from 1st Jan 2006-
31st Dec 2011. The demographic and clinical data were collected 
from registered database. The cost analysis data was from reim-
bursement system. It was analyzed in terms of the direct medical 
costs during on oral TKI and total direct medical costs through 
patient’s life time.
Results: Total 1,520 cases database were recruited for analysis. 
There were 572 and 948 patients in Gefitinib and Erlotinib group 
respectively. The mean age was 64.8±11.0 years. Most of patients 
(94.4%) were in ECOG 0-2. The mean overall survival was 15.1 
months [95% CI 14.1-16.0]. The mean of the direct medical costs 
and total direct medical costs of Gefitinib were 623,204.80 baht 
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year. The majority were females (N=63/64.9%), never/former smo-
kers (N=94/96,9%), with good performance status (ECOG PS 0-1; 
N=90/90.2%) and pretreated with > 3 therapy lines (N=68/70.0%). 
EGFR status was assessed in tumor tissue obtained at the time 
of original diagnosis. The majority of pts (N=64, 66%) harbored a 
deletion in exon 19, while T790M mutation was detected in two 
cases including one case with double exon 19 and T790M mutati-
on. Among the 95 pts evaluable for toxicity, 54.7% had any grade 
skin rash, including 11.6% with grade 3, and 50,5% had any grade 
of diarrhea, with grade 3 recorded in 10,5%. Among the 87 pts 
evaluable for efficacy, response rate (RR) was 11.5%, with a median 
progression free-survival and overall survival of 3.9 months and 7.3 
months respectively. In 25 pts a tumor biopsy was repeated imme-
diately before starting Afatinib therapy and 1 patient out of 5 indi-
viduals harboring T790M mutation showed a short extracerebral 
partial response, with following brain progression.
Conclusion: Our findings suggest that afatinib is modestly effec-
tive in EGFR mutant NSCLC with acquired resistance to reversible 
EGFR-TKIs.
Keyword: Afatinib, acquired resistance, EGFR, NSCLC
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P1.11-035 OUTCOMES OF AFATINIB-BASED REGIMENS 
FOR SALVAGE TREATMENT OF ADVANCED STAGE 
NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS 
WHO HAD BEEN HEAVILY PRETREATED
Chun-Ming Tsai1, Chao-Hua Chiu1, Chiang Chi-Lu1, Ya-Chi Huang2, 
Kuo-Ting Chang2
1Division Of Thoracic Oncology, Department Of Chest Medicine, Taipei 
Veterans General Hospital, School Of Medicine, National Yang-Ming 
University/Taiwan, 2Division Of Thoracic Oncology, Department Of 
Chest Medicine, Taipei Veterans General Hospital/Taiwan
Background: The therapeutic development for advanced stage 
NSCLC has improved in the past decade, but the poor treatment 
outcome still poses a major challenge. Investigators have com-
bined conventional platinum-based chemotherapy with epidermal 
growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), in the 
hope of achieving greater therapeutic efficacy. However, current 
data show that the combination strategy has repeatedly failed to 
provide a better survival benefit, irrespective of the mutation sta-
tus of the tumors. However, it might not be true for combination 
of EGFR-TKI with individual agents which exhibit a variety of anti-
cancer actions. Afatinib, a novel irreversible ErbB-family blocker, 
has shown to provide efficacious effects for advanced stage NS-
CLC patients. From the Phase I data, afatinib in combination with 
chemotherapy or anti-EGFR therapy exhibited tumor inhibition 
response. We present retrospective clinical evidences of patients 
from Compassionate Usage Program. These patients are treated 
with continuation of afatinib in combination, alternately, with vari-
ous chemotherapies or anti-EGFR therapy.
Methods: Between August 2012 to February 2013, 37 patients 
were enrolled for the program, 11 of these patients died of di-
sease progression either received afatinib for less than 2 weeks or 
never started afatinib treatment, the remaining 26 patients were 
included in this analysis. Patient characteristics are median age 
was 67 (range 46-84), gender (male/female = 8/18), ECOG status 
(PS 1/2/3: 16/2/4), EGFR mutation status (exon 19 deletion = 10; 
3 (12%; 95% CI: 3%–31%) experienced a partial response, all with 
9 base-pair insertions in HER2 exon 20. The partial response dura-
tions were 3+, 11, and 11+ months. The preliminary estimate of me-
dian OS was 10 months (95% CI: 7–21; HER2-mutant subgroup: 10 
months [95% CI: 7–21]). Among the 4 patients with HER2 amplified 
lung cancers, no partial responses were seen and the PFS ranged 
from 1–5 months. Of 29 patients evaluable for toxicity, the most 
common treatment-related adverse events were diarrhea (90%; 
grade 3/4: 21%/3%), dermatitis (72%; grade 3/4: 3%/0), fatigue 
(52%; grade 3/4: 3%/0), and dry skin (48%; grade 3/4: 0/0). 10% of 
patients discontinued treatment due to adverse events.
Conclusion: Dacomitinib demonstrated an overall 12% objective 
response rate in patients with HER2-mutant lung cancers. All 3 
responding patients had 9 base-pair HER2 exon 20 insertions. No 
responses were seen in the 4 patients with HER2-amplified lung 
cancers. Dacomitinib was well tolerated with manageable toxici-
ties, consistent with the class effects of EGFR TKIs.
Keywords: dacomitinib, tyrosine kinase inhibitor, Lung cancer, 
phase II
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P1.11-033 AFATINIB IN EGFR MUTANT NON-SMALL-CELL 
LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE 
TO REVERSIBLE EGFR-TKIS
Federico Cappuzzo1, Marcello Tiseo2, Rita Chiari3, Lorenza Landi1, 
Serena Ricciardi4, Elisa Rossi1, Domenico Galetta5, Silvia Novello6, 
Michele Milella7, Armida D‘Incecco1, Eva Regina Haspinger8, Diego 
Cortinovis9, Antonio Santo10, Giuseppe Banna11, Francesco Facchi-
netti2, Matteo Giaj Levra6, Sabrina Vari7, Lucio Crino3, Filippo De 
Marinis4
1Dipartimento Di Oncologia, Istituto Toscanotumori/Italy, 2Medical On-
cology Unit, University Hospital Of Parma/Italy, 3Ospedale Santa Maria 
Della Misericordia/Italy, 4High Specialization Hospitals , Oncological 
Pulmonary 1st Unit, San Camillo-forlanini/Italy, 5Medical Oncology, 
National Cancer Research Centre “Giovanni Paolo Ii“/Italy, 6Diparti-
mento Di Oncologia Aou San Luigi-orbassano, Università Di Torino,/
Italy, 7Division Of Medical Oncology A, Regina Elena National Cancer 
Institute/Italy, 8Oncologia Medica 1, Fondazione Ircss Istituto Nazionale 
Dei Tumori/Italy, 9Medical Oncology Unit, Aou San Gerardo/Italy, 10Azi-
enda Ospedaliera Universitaria Integrata Di Verona/Italy, 11Division Of 
Medical Oncology, A.o. Cannizzaro Hospital/Italy
Background: Afatinib, an irreversible EGFR-HER2 dual inhibitor, 
demonstrated superiority versus standard platinum-based chemo-
therapy as front-line therapy in non-small-cell lung cancer patients 
(NSCLC) with activating Epidermal Growth Factor Receptor (EGFR) 
mutations. In pretreated NSCLC afatinib failed to improve survival 
when compared to placebo in patients refractory to gefitinib or er-
lotinib and not selected for EGFR status. Aim of the present study 
was to evaluate clinical efficacy of afatinib in EGFR mutant NSCLC 
patients (pts) with secondary resistance to reversible EGFR-TKIs.
Methods: We retrospectively analyzed a cohort of 97 EGFR mu-
tant lung cancer pts resistant to EGFR-TKI according to criteria 
used in the LUX-Lung 1 trial (Miller VA, Lancet Oncol 2012) and 
treated with Afatinib at the daily dose of 40-50 mg. The drug was 
given as compassionate use.
Results: The study included individuals with a median age of 62,5 
S611Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
the important prognostic risk factors influencing NSCLC survival.
Results: The median PFS of all 30 treated patients was 1.25 
months (95% CI: 0.90-1.9 months), and the median OS was 3.40 
months (95% CI: 3.00-6.80 months). Of the 29 patients eligible for 
efficacy evaluation, none achieved partial response. Cox regressi-
on analysis suggested that Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) is predictive of both PFS (p=0.001) 
and OS (p<0.001). Hand-foot syndrome (53.3%), mucositis (40.0%), 
rash (36.7%) and diarrhea (33.3%) were most commonly reported 
adverse events.
Conclusion: In this study, the sunitinib treatment did not demons-
trate overall clinical benefits to the EGFR-TKI pretreated NSCLC 
Chinese patients. Most side effects were mild to moderate. These 
results need further validation in prospective studies.
Keyword: sunitinib,EGFR-TKI, pretreated ,advanced NSCLC
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P1.11-037 PHASE II ACTIVITY OF THE HSP90 INHIBITOR 
AUY922 IN PATIENTS WITH EGFR-MUTANT ADVANCED 
NON-SMALL CELL LUNG CANCER (NSCLC)
Fabrice Barlesi1, Benjamin Besse2, Quincy Chu3, Leena Gandhi4, 
Frank Griesinger5, Enriqueta Felip6, Jin Hyoung Kang7, Sang-We 
Kim8, Rafael Rosell9, Lecia V. Sequist10, Ross Soo11, John Wall-
mark12, Emin Avsar13, William Ofosu-Appiah13, Scott Pain14, Mik-
hail Akimov14, Edward B. Garon15
1Aix Marseille University – Assistance Publique Hôpitaux De Marseille/
France, 2Institut Gustave Roussy/France, 3Cross Cancer Centre/Cana-
da, 4Dana Farber Cancer Institute/United States Of America, 5Hemato-
logy And Oncology, Pius-Hospital Oldenburg, University Of Oldenburg/
Germany, 6Vall D‘hebron University Hospital/Spain, 7Medical Oncology, 
The Catholic University Of Korea/Korea, 8Oncology, Asan Medical Cen-
ter/Korea, 9Hospital Universitatio Germans/Spain, 10Massachusetts 
General Hospital Cancer Center/United States Of America, 11National 
University Cancer Institute/Singapore, 12Associates In Oncology/hema-
tology/United States Of America, 13Novartis Pharmaceuticals Corpo-
ration/United States Of America, 14Novartis Pharma Ag/Switzerland, 
15David Geffen School Of Medicine At Ucla/United States Of America
Background: AUY922 is a highly potent, non-geldanamycin, 
HSP90 inhibitor. HSP90 is a molecular chaperone of oncogenic cli-
ent proteins relevant in NSCLC pathogenesis, including epidermal 
growth factor receptor (EGFR), which is mutated in 10% of NSCLC 
cases in the Western population, and in 30% of NSCLC cases in 
the Asian population. We report here a subgroup analysis of data 
from the 2 EGFR mutation strata of a Phase II study of AUY922 in 
patients with previously treated, advanced NSCLC stratified by 
molecular status.
Methods: Patients with advanced NSCLC who progressed fol-
lowing ≥1 prior line of therapy, received AUY922 (70 mg/m2) as a 
once-weekly, 1-hour infusion. Patients with EGFR-mutant NSCLC 
were divided into 2 strata: pretreated EGFR-mutant (>2 prior regi-
mens), or less-heavily treated EGFR-mutant (≤2 prior regimens and 
documented response to an EGFR tyrosine kinase inhibitor [TKI]). 
The primary endpoint was confirmed response, stable disease at 
18 weeks, or no clinical benefit. Secondary endpoints included 
overall survival (OS), progression-free survival (PFS), and safety/
tolerability.
L858R mutation = 6; exon 18 mutation = 1; wild type = 5; unknown 
= 5). All of these patients had been previously treated with either 
gefitinib or erlotinib with no disease progression for more than 6 
months. The median TKI-free interval was 125 days (range 0-1,450 
days); 8 patients had no TKI-free interval. All patients but 1 started 
the treatment of afatinib monotherapy (30 mg or 40 mg daily), and 
subsequently, either paclitaxel (60 mg/m2, day 1, 8, and 15, 4-week 
cycle), docetaxel (30 mg, day 1, and 8, 3-week cycle), or cetuximab 
(250mg/m2, every 2 weeks) was added. The combination was al-
ternated or discontinued when patient had disease progression 
according to RECIST criteria version 1.1, intolerability or severe 
toxicity.
Results: Of the whole group of patients, 25 received afatinib 
monotherapy, 11 with 1 afatinib doublet (afatinib/cetuximab = 3; 
afatinib/paclitaxel = 6; afatinib/docetaxel = 2); 2 with 2 afatinib 
doublets (afatinib/cetuximab and afatinib/docetaxel = 1; afatinib/
cetuximab and afatinib/docetaxel = 1) and 1 with 3 afatinib doub-
lets (afatinib/cetuximab, afatinib/paclitaxel and afatinib/docetaxel). 
The median duration from administration of frontline systemic 
treatment to initiation of afatinib was 3 years (range 1 - 10 years). 
These patients had received 2 to 7 (median 5) lines of treatment 
before receiving afatinib-based treatment. The median time to 
treatment failure was 223 days (95% CI: 217, 249) and median ove-
rall survival was 288 days (6 events). The toxicities were mild and 
manageable. There was no correlation between the values of TKI-
free interval and duration of afatinib monotherapy.
Conclusion: Integration of afatinib with various treatment agents 
based on different treatment rationales, the afatinib-based treat-
ment may potentially extend treatment duration and patient survi-
val.
Keywords: non-small cell lung cancer, epidermal growth factor 
receptor-tyrosine kinase inhibitor, afatinib, drug combination
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P1.11-036 THE EFFICACY AND SAFETY OF SUNITINIB IN 
EGFR-TKI PRETREATED ADVANCED NON-SMALL CELL 
LUNG CANCER: A RETROSPECTIVE REVIEW FROM CHI-
NESE PATIENTS AT A SINGLE INSTITUTION
Liyan Jiang1, Wei Zhu2, Jianliang Zhang3, Jiaqi Huang2, Yizhuo 
Zhao1, Wei Zhang1, Baohui Han1, Yao Yihong2
1Shanghai Chest Hospital Affiliated To Shanghai Jiaotong University/
China, 2Translational Sciences, Medimmune Llc/United States Of Ame-
rica, 3Clinical, Medimmune Llc/United States Of America
Background: Sunitinib is an oral, selective multi-targeted tyrosine 
kinase inhibitor (TKI) with antiangiogenic and antitumor activities. 
The result from a previous study suggested that the treatment of 
sunitinib might present favorable survival outcomes for the EGFR-
TKI pretreated NSCLC Chinese patients. This study was therefore 
to evaluate the efficacy and toxicity of this therapeutic strategy.
Methods: This is a retrospective review of 30 stage IV NSCLC pa-
tients who received sunitinib as salvage therapy in Shanghai Chest 
hospital, from January 2009 until August 2011. All of the patients 
had previously been treated with EGFR-TKIs. Kaplan-Meier method 
was employed to estimate the median progression-free survival 
(PFS) and overall survival (OS). Univariate and multivariate Cox pro-
portional hazard regression analyses were carried out to determine 
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underwent ALK screening by FISH, 20 patients with EGFR muta-
tion, 87 patients with wild type status and 2 (3.4%, 2/59) patients 
with concurrent ALK rearrangement and EGFR mutation. Of the 59 
patients with FISH-positive ALK rearrangement, 45 received crizo-
tinib in the phase II clinical trial (PROFILE 1005), 8 were enrolled in 
the phase III clinical trial (PROFILE 1014) and 6 did not participate 
in any clinical trial. ALK-positive patients have distinct clinicopatho-
logical features. ALK FISH-positive and crizotinib-treated patients 
(PROFILE 1005) had a median progression-free survival (PFS) of 7.6 
months and longer overall survival (OS) compared with crizotinib-
naïve (P<0.0001) or wild type cohorts (P=0.0138), but there was 
no significant difference in OS compared with EGFR mutation 
patients(P=0.8959). ALK positive and negative patients divided 
by qRT-PCR in the ALK FISH crizotinib-treated patients had no 
different in clinical outcomes. ALK expression was not associated 
with PFS (P=0.792) and OS (P=0.325). However, when used IHC 
expression as a dichotomous variable, moderate and strong ALK 
expression had a decreased risk of death (P=0.026). The two pati-
ents with concurrent EGFR mutation and ALK rearrangement had 
difference in ALK expression, response to TKIs and crizotinib, and 
overall survival.
Conclusion: In the era of ALK-targeted inhibitors, enriching NSCLC 
patients according to clinicopathologic characteristics could high-
ly improve ALK detection rate for molecular target therapy. IHC 
could be a supplementary method to provide more clues for clini-
cal trial design and therapeutic strategies for NSCLC patients who 
harbor ALK rearrangement including patients with double genetic 
aberration of ALK and EGFR.
Keywords: Alk rearrangement, non-small cell lung cancer, ALK 
expression, Crizotinib
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P1.11-039 A RANDOMIZED PHASE II TRIAL OF CELE-
COXIB COMBINED WITH PLATINUM-BASED CHEMO-
THERAPY AS FIRST-LINE AND WITH ICOTINIB AS SE-
COND-LINE TREATMENT FOR ADVANCED NON-SMALL 
CELL LUNG CANCER
Tianqing Chu, Baohui Han, Liyan Jiang, Hua Zhong, Aiqin Gu
Department Of Pulmonary Medicine, Shanghai Chest Hospital, Shang-
hai Jiaotong University/China
Background: To evaluate the anti-tumor effect and safety of COX-
2 inhibitors through a randomized controlled study by treating 
advanced non-small cell lung caner (NSCLC) with celecoxib + 
platinum-based chemotherapy as first-line treatment and celecoxib 
+ icotinib as second-line treatment; to investigate the mechanism 
of action and efficacy predictors related to COX-2 inhibitors by 
detecting and monitoring serum VEGF, MMP-9 and E-cardrin in the 
course of treatment.
Methods: 81 untreated patients with stage III-IV NSCLC were 
randomized into vinorelbine/cisplatin + celecoxib group and vino-
relbine/cisplatin chemotherapy group. If disease progression was 
found in the followed-up visits in the middle or after the end of the 
4th cycle, the patients would enter second-line icotinib + continued 
celecoxib group, while the mono-chemotherapy group became 
the second-line icotinib monotherapy group until the disease pro-
gressed. The patients’ serum VEGF, MMP-9 and E-cardrin were 
detected by ELISA assay at different time points before initial che-
Results: At the cut-off date of 14 March 2013, 66 patients with 
EGFR-mutant NSCLC had been treated (median age 58 years; 67% 
female; 94% adenocarcinoma; EGFR-initial stratum n=35; less-hea-
vily pretreated EGFR-mutant stratum n=31); all patients had been 
pretreated with an EGFR TKI. Clinical activity of AUY922 was seen, 
with any responses (investigator assessed), in 12/66 (18.2%) pati-
ents. A total of 34/66 (51.5%) patients had a best overall response 
of stable disease or non-confirmed partial response; of these pati-
ents, 11 (32%) had stable disease for ≥18 weeks. The 18-week PFS 
rate was 39% in all patients with ≤2 prior lines of therapy (n=43), 
and 28% in all patients (n=21) who had received >2 lines of thera-
py. The most frequent adverse events (AEs; any grade, regardless 
of study drug relationship) were diarrhea (73%), nausea (47%), 
decreased appetite (38%), fatigue (35%), and headache and night 
blindness (both 29%). Most AEs were Grade 1 or 2; Grade 3 or 4 
AEs included diarrhea (9%), and fatigue, decreased appetite, and 
hyponatremia (all 6%).
Conclusion: AUY922 had an acceptable safety profile. Strong evi-
dence of clinical activity was demonstrated in EGFR TKI-pretreated 
patients with EGFR-mutant NSCLC. Median PFS, OS and biomarker 
data for the EGFR-mutant stratum will be presented.
Keywords: ADVANCED NSCLC, AUY922, EGFR-mutant, HSP90
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P1.11-038 THE SIGNIFICANCE OF ALK REARRANGE-
MENT IN SELECTED ADVANCED NON-SMALL CELL 
LUNG CANCER: ALK EXPRESSION PROVIDES INSIGHTS 
INTO ALK TARGET THERAPY
Ningning Zhang1, Yuankai Shi1, Li Ma1, Xuezhi Hao1, Dongmei Lin2, 
Xiaohong Han1, Yutao Liu1, Lin Wang1, Zheng Yuan2, Sheng Yang1
1Medical Oncology, Beijing Key Laboratory Of Clinical Study On Anti-
cancer Molecular Targeted Drugs, Cancer Institute/Hospital, Chinese 
Academy Of Medical Sciences & Peking Union Medical College/China, 
2Department Of Pathology, Cancer Institute/Hospital, Chinese Academy 
Of Medical Sciences & Peking Union Medical College/China
Background: ALK rearrangements are detected in 3%~7% in un-
selected non-small cell lung cancer (NSCLC) and accurate deter-
mination of ALK rearrangements are the key importance to screen 
appropriate candidates for ALK inhibitor therapy. Previous studies 
showed that IHC could be a promising prescreening method. How-
ever, the correlation between IHC results and clinical outcomes 
had not been confirmed. This study aimed to elucidate clinical sig-
nificance of ALK rearrangement in selected advanced NSCLC pati-
ents and evaluate a possible association between ALK expression 
and clinical outcomes in ALK positive crizotinib-treated patients.
Methods: ALK status was assessed by FISH, immunohistoche-
mistry (IHC) and quantitative RT-PCR(qRT-PCR) in 173 selected 
advanced NSCLC patients who were aiming at undergoing ALK 
screening for crizotinib therapy. Clinicopathologic data, genotype 
status and survival outcomes were analyzed. In addtion, we cor-
related ALK expression with clinical outcomes in crizotinb treated 
patients including two patients with concurrent ALK rearrange-
ment and EGFR mutation.
Results: ALK positive detection rate was 35.5% (59/166), 36.3% 
(61/168), 27.9% (34/122) by FISH, IHC and qRT-PCR, respectively. 
Among the 166 advanced NSCLC patients who were successfully 
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59.4 % received TKI as first line therapy; 87% were initial stage IV. 
mPFS for the rTKI was 9,9 months (mo) and mOS was 32.8 mo for 
the entire population. P were treated with a median of 2 therapeu-
tic strategies after the rTKI failure. 6 therapeutic strategies have 
been identified. As immediate approach, 31p were switched to 
chemotherapy (CT) with a mPPS of 5,6 mo. 10 p were switched to 
an irreversible TKI obtaining a mPPS of 4 mo. rTKI plus other drug 
was maintained in 12 p: rTKI plus CT in 9 p with a mPPS of 5,8 mo 
and rTKI plus other drug different to CT in 3 with a mPPS of 2 mo. 
Despite the progression, rTKI was maintained in 3 p, considered 
slow progressors obtaining a mPPS of 1,4 mo with an OS of 9mo. 
Furthermore, 3p with oligometastatic progressive disease local 
therapy was added to rTKI, obtaining mPPS of 1,4mo, but an OS of 
17 mo. 4 p were treated sequentially with ≥5 strategies. These p 
attained a mOS of 45mo.
Conclusion: The combination of different strategies when treating 
EGFR mut p after rTKI failure may impact the survival especially 
when p are candidates to receive some of this treatments sequen-
tially. These strategies may reflect different subsets of EGFR mut 
disease.
Keywords: EGFR mutation, tyrosine kinase inhibitors, Treatment 
strategies, NSCLC
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P1.11-041 OVERALL SURVIVAL OF ALK TRANSLOCATION 
- AND OF EGFR MUTATION POSITIVE NSCLC PATIENTS 
TREATED WITH AND WITHOUT PERSONALIZED THE-
RAPY. A RETROSPECTIVE ANALYSIS WITHIN THE NET-
WORK GENOMIC MEDICINE
Marc Bos1, Masyar Gardizi1, Lukas C. Heukamp2, Hans-Ulrich 
Schildhaus3, Sabine Merkelbach-Bruse2, Lucia Nogová1, Matthias 
Scheffler1, Monika Serke4, Holger Schulz5, Stefan Krüger6, Tim H 
Brümmendorf7, Jens Panse7, Stefan Schmitz8, Ulrich Gerigk9, Win-
fried J Randerath10, Yon D Ko11, Kato Kambartel12, Ali-Nuri Hünerli-
türkoglu13, Reinhard Büttner14, Jürgen Wolf1
1Lung Cancer Group Cologne, Department I Of Internal Medicine And 
Center For Integrated Oncology Köln-Bonn, University Hospital Colo-
gne/Germany, 2Institute Of Pathology, Universtity Hospital Cologne/
Germany, 3Department Of Pathology, University Hospital Cologne, 
Germany/Germany, 4Thoracic Oncology, Hemer Lung Clinic/Germany, 
5Onkologische Schwerpunktpraxis, Pioh Frechen/Germany, 6Klinik Für 
Pneumologie, Allergologie, Schlaf- Und Beatmungsmedizin, Florence 
Nightingale-krankenhaus/Germany, 7Medizinische Klinik Iv, Uniklini-
kum Aachen/Germany, 8Onkologische Schwerpunktpraxis/Germany, 
9Klinik Für Thoraxchirurgie, Malteser Krankenhaus/Germany, 10Klinik 
Für Pneumologie Und Allerologie, Bethanienkrankenhaus Solingen/Ger-
many, 11Internistische Onkologie, Evangelische Kliniken Bonn/Germany, 
12Lungenklinik, Moers, Bethanienkrankenhaus Moers/Germany, 13Abt. 
Innere Medizin Ii, Lukaskrankenhaus Neuss/Germany, 14Departement 
Of Pathology, University Hospital Cologne, Germany/Germany
Background: Erlotinib, Gefitinib and Crizotinib have been appro-
ved by the European Medicines Agency (EMA) for the treatment of 
molecular defined patient subgroups with advanced EGFR mutati-
on positive (EGFR M+) and ALK translocation positive (ALK +) NS-
CLC, respectively. In randomized clinical trials for ALK + and EGFR 
M+ patients comparing standard chemotherapy to TKI treatment 
so far no significant improvement in overall survival (OS) could be 
shown, based on the high crossover rate of patients initially treated 
motherapy and after chemotherapy.
Results: First-line treatment and second-line celecoxib group 
showed significant differences in disease control rate (73.2% vs. 
65.0%, P=0.036; 56.5% vs. 55.6%, p=0.078). PFS in the second-
line celecoxib group was superior to that in the monotherapy 
group (5.3m vs. 5.0m, p=0.045). One case in the celecoxib group 
during second-line treatment experienced arrhythmia after con-
tinuous use of celecoxib, while the treatment was well tolerated 
in the other patients. After chemotherapy, serum VEGF, MMP-9 
and E-cardrin were decreased, the decline in serum VEGF in the 
experimental group was significantly greater than that in the con-
trol group (p=0.027). Serum VEGF, MMP-9 and E-cardrin in the 
experimental group after chemotherapy were significantly lower 
than before chemotherapy (respectively: p=0.025, 0.035, 0.002). 
The efficacy of chemotherapy in patients with lower baseline 
serum VEGF and E-cardrin levels in the experimental group was 
better (p=0.033, 0.047). After chemotherapy, the efficacy of che-
motherapy in patients with greater decline in VEGF and MMP-9 
levels was better (p=0.038, 0.039). Only baseline serum VEGF was 
found to be related to the efficacy of chemotherapy in the control 
group (p=0.023). Baseline serum VEGF levels and the decline after 
chemotherapy were significantly associated with the patients’ PFS 
(p=0.019, 0.035).
Conclusion: COX-2 inhibitor celecoxib can improve disease con-
trol rate and be well tolerated by patients when combined with 
either chemotherapy for first-line treatment or targeted therapy for 
second-line treatment. Serum VEGF level is a good biomarker to 
predict efficacy and survivals, while serum MMP-9 and E-cardrin 
are potential biomarkers requiring large-sample studies.
Keyword: COX-2, celecoxib, chemotherapy, icotinib, NSCLC
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P1.11-040 TREATMENT STRATEGIES AFTER FAILURE TO 
REVERSIBLE TYROSINE KINASE INHIBITORS (RTKI) IN 
EGFR MUTANT (MUT) NON-SMALL CELL LUNG CANCER 
(NSCLC) PATIENTS (P). A RETROSPECTIVE ANALYSIS OF 
59 SPANISH PATIENTS
Jordi Remon1, Teresa Moran2, Maria Jove3, Laia Capdevila2, Diego 
Alcaraz4, Enric Carcereny2, Maria Plana3, Noemi Reguart4, Rut 
Porta5, Rafael Rosell2
1Medical Oncology, Hospital De Mataró/Spain, 2Catalan Institute Of 
Oncology/Spain, 3Medical Oncology, Institut Català D’Oncologia/Spain, 
4Hospital Clinic/Spain, 5Catalan Institute Oncology/Spain
Background: Different therapeutic approaches have been used 
in the clinical setting in NSCLC p harbouring EGFR mutations pro-
gressing to rTKI, although the standard of care in this situation is 
still not well established.
Methods: A multinstitutional database from five different centers 
in Spain was review to identify EGFR mut p with acquired resis-
tance to rTKI in order to evaluate the therapeutic strategies after 
rTKI failure and the effect on the post-progression survival (PPS) of 
these treatments.
Results: 59 p with acquired resistance to rTKI were identified: 61% 
female; median (m) age 63 ±11 yrs; 96.6% Caucasian; del19 73.7%, 
never or light former smokers 98.3%; 93.2% adenocarcinomas; 
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Germany, 8Klinik Für Pneumologie Und Allerologie, Bethanienkranken-
haus Solingen/Germany, 9Mvz, St. Marien Hospital/Germany, 10Hem-
taology And Oncology Practice/Germany
Background: Inhibition of signaling pathways interfering with cell 
proliferation and angiogenesis may increase anti-tumor efficacy. 
Sorafenib as well as mTOR inhibitors showed preliminary activity in 
KRAS mutated NSCLC.
Methods: In the dose escalation part, patients with relapsed so-
lid tumors were treated with escalating doses of everolimus from 
2.5-10.0 mg daily p.o. in a 14 days run-in phase followed by the 
combination with a fixed dose of sorafenib 400 mg bid p.o. The 
extension phase is currently recruiting patients with KRAS mutated 
NSCLC. The KRAS mutation status is determined by PCR based 
high resolution melting curve analysis (HRM) on DNA extracted 
from FFPE material and validated using Sanger sequencing. HRM 
has now been replaced by multiplex PCR. Pharmacokinetic (PK) 
analyses are performed during run-in and during the combination. 
Treatment outcome is validated with CT scans on day 57.
Results: In the dose escalation part, 19 patients were recruited. 
The dose limiting toxicity (DLT) was not reached. At everolimus 
dose level of 10 mg/day, increased rates of grade 3 thrombocy-
topenia (3 patients), leukocytopenia (2 patients) and anaemia (2 
patients) occurred after the DLT interval of 29 days. Based on 
these observations, the dose level of 7.5 mg/day everolimus in 
combination with 400 mg sorafenib bid was defined as a maximal 
tolerated dose. The AUC and Cmax values of everolimus at all 
dose levels were comparable on days 5 and 14. On day 29, AUC 
and Cmax of everolimus showed a 20 - 40% reduction when co-
administered with sorafenib. The best treatment outcome on day 
57 was stable disease in 11 patients. Median PFS and OS were 3.7 
and 5.5 months, respectively. The extension phase in KRAS muta-
ted NSCLC is currently ongoing. Nine patients have been recruited 
so far. The CT response at day 57 compared to the baseline of four 
evaluable patients is ranging from -22% to +5% in the sum of the 
longest diameter of all targeted lesions.
Conclusion: Treatment of patients with relapsed solid tumors with 
the combination of 7.5 mg everolimus p.o. daily and 400 mg sora-
fenib p.o. bid is safe and feasible. Current results of an extension 
phase in KRAS mutated NSCLC patients show preliminary clinical 
activity in this patient group with an unfavorable prognosis.
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P1.11-043 BARIS: A PHASE I TRIAL TO EVALUATE THE 
SAFETY AND TOLERABILITY OF COMBINED BIBF 1120 
AND RAD001 IN SOLID TUMORS AND TO DETERMINE 
THE MAXIMUM TOLERATED DOSE (MTD) OF THE COM-
BINATION.
Matthias Scheffler1, Masyar Gardizi2, Marc Bos2, Lucia Nogová2, 
Thorsten Persigehl3, Jürgen Wolf2
1Department I Of Internal Medicine - Lung Cancer Group Cologne, Uni-
versity Hospital Of Cologne/Germany, 2Lung Cancer Group Cologne, 
Department I Of Internal Medicine And Center For Integrated Oncology 
Köln-Bonn, University Hospital Cologne/Germany, 3Institute For Radio-
logy, University Hospital Of Cologne/Germany
Background: Simultaneious inhibition of several signalling pa-
thways involved in angiogenesis as well as in tumor cell growth 
in the standard chemotherapy arm into the TKI arms upon pro-
gression. Since prevention of crossover is obsolete due to ethical 
reasons, registry data may gain in importance for investigating the 
impact of new effective targeted drugs on OS in the near future.
Methods: Since January 2010 EGFR sequencing and ALK FISH 
analysis for lung adenocarcinoma was performed within the Net-
work Genomic Medicine (NGM) as part of a broad genetic scree-
ning effort. This included mutation screening for EGFR, KRAS, 
BRAF and PIK3CA as well as HER2 amplification and recently also 
translocations of RET and ROS. Clinical and follow-up data were 
extracted from medical records, directly collected from physicians 
and patients and additionally matched with data of the Epidemio-
logical Cancer registry of North Rhine-Westphalia, Germany.
Results: So far, we included a total of 44 ALK+ and 143 EGFR M+ 
patients into our analysis. The median age of the ALK + and EGFR 
M+patients was 53.5 yrs and 71 yrs, respectively. 39% of the ALK+ 
patients received crizotinib and 54% of the EGFR M+ patients re-
ceived an EGFR TKI during the course of their disease. The median 
OS (mOS) of patients with an initial stage IIIb/IV was 14 months 
(95% CI 6.2 - 21.8) for ALK+ and 29 months (95% CI 16 - 41) for 
EGFR M+ patients. Both groups showed a significant difference in 
mOS when separated by targeted treatment status. ALK+ patients 
who received crizotinib had a mOS of 23 months (95% CI 12.2 - 
33.8) and patients who did not receive crizotinib had a mOS of 8 
months (95% CI 0.0 - 17.4) (p = 0.01). EGFR M+ patients who recei-
ved an EGFR TKI had a mOS of 31 months (95% CI not computa-
ble) and patients who did not receive an EGFR TKI had a mOS of 
9 months (95% CI 4.9 - 13.1) (p < 0.001). There were no significant 
differences with regard to treatment of a platinum-containing che-
motherapy, age or sex between the two groups.
Conclusion: Screening patients for genetic driver mutations iden-
tified patients with EGFR mutations and ALK translocations that 
were not treated with a kinase inhibitor. Comparing these cohorts 
of patients that only received standard chemotherapy to those 
subsequently treated with a personalized approach showed a 
significant improvement in OS. This confirms the predictive value 
of ALK translocations and EGFR mutations for treatment with the 
respective TKIs
Keywords: ALK, EGFR, predictive, TKI
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P1.11-042 SORAVE: SORAFENIB AND EVEROLIMUS FOR 
PATIENTS WITH SOLID TUMORS AND WITH KRAS MU-
TATED NSCLC - RESULTS OF A PHASE I STUDY.
Lucia Nogova1, Marc Bos1, Christian Mattonet1, Masyar Gardizi1, 
Matthias Scheffler1, Claudia Wompner1, Karin Topelt1, Lukas C. 
Heukamp2, Ahmed Suleiman3, Sebastian Frechen3, Fritz Sorgel4, 
Uwe Fuhr3, Roland Schnell5, Ildiko Katay5, Dirk Behringer6, Tho-
mas Geist7, Britta Kaminski8, Martina Eichstaedt9, Dirk Tummes10, 
Reinhard Büttner2, Jürgen Wolf1
1Lung Cancer Group Cologne, Department I Of Internal Medicine And 
Center For Integrated Oncology Köln-Bonn, University Hospital Colo-
gne/Germany, 2Institute Of Pathology, University Hospital Cologne/
Germany, 3Institute Of Pharmacology, Center For Integrated Oncology, 
University Hospital Cologne/Germany, 4Institute For Biomedical And 
Pharmaceutical Research/Germany, 5Pioh - Oncology And Hematology/
Germany, 6Augusta-kranken-anstalt/Germany, 7Pulmology Practice/
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P1.11-044 PROGRESSION-FREE SURVIVAL IS A POOR 
SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN 
THE FIRST LINE EGFR-TKI TREATMENT IN ADVANCED 
NON-SMALL-CELL LUNG CANCER WITH EGFR MUTATI-
ON
Ri-Qiang Liao1, Xue-Ning Yang2, Hong-Hong Yan2, Qing Zhou2, Yi-
Long Wu3, Wen Zhao Zhong3
1Division Of Pulmonary Oncology, Guangdong Lung Cancer Institute, 
Guangdong General Hospital, Guangzhou/China, 2Division Of Pulmo-
nary Oncology, Guangdong General Hospital/China, 3Guangdong Lung 
Cancer Institute, Guangdong General Hospital/China
Background:  (Although epidermal growth factor receptor tyrosi-
ne kinase inhibitor (EGFR-TKIs), gefitinib and erlotinib have shown 
antitumor activity in patients with non-small cell lung cancer (NS-
CLC) , it is unclear if progrssion-free survival (PFS) could be a good 
surrogate endpoint for overall survival(OS) in the clinical trials of 
first-line EGFR-TKIs treatment in patients with advanced NSCLC, 
especially with activating EGFR mutation.) 
Methods: A PubMed search identified 12 randomized trials 
comparing first-line EGFR-TKIs treatment with chemotherapy in 
patients with advanced NSCLC. A total of 1816 patients were en-
rolled and EGFR mutation status was known in 554 patients. Linear 
regression analysis was carried out to estimate the correlation of 
PFS, response rate (RR), and survival post-progression (SPP) with 
OS
Results: PFS, RR and PPS were all strongly associated with OS 
(r=0.942, 0.982 and 0.895, respectively, P< 0.01)  for all trials. But in 
trials enolled patients with EGFR mutation, PFS and RR were poor 
correlate with OS (r =-0.121 and 0.131, respectively, P< 0.01), while 
PPS strongly associated with OS (r =0.849, P<0.01 ) PFS, RR and 
PPS were all strongly associated with OS (r=0.942, 0.982 and 0.895, 
respectively, P< 0.01)  for all trials. But in trials enolled patients 
with EGFR mutation, PFS and RR were poor correlate with OS (r 
=-0.121 and 0.131, respectively, P< 0.01), while PPS strongly associ-
ated with OS (r =0.849, P<0.01 ) 
Conclusion: Our findings indicate that PFS is a poor surrogate 
endpoint for OS in the first line EGFR-TKI treatment in advanced 
EGFR mutation NSCLC. Further studies are needed to search for 
appropriate surrogate endpoint for OS.
Keywords: Surrogate, PFS, EGFR mutation, OS
regulation by kinase inhibitor combination therapy may increase 
therapeutic efficacy. Here we evaluate the combination of the 
mTOR-inhibitor RAD001 (everolimus) and the triple kinase (FGFR, 
VEGFR, PDGFR) inhibitor BIBF 1120 in a phase I trial in advanced 
solid tumors. In addition we use DCE-MRI for early identification of 
patients with benefit from BIBF 1120.
Methods: This is an open-label, monocentric phase I trial with 3 
dosage arms in a classical "3+3“-design: Patients in arm A recei-
ve 5 mg of RAD001 and 2 x 150 mg BIBF 1120, in arm B 10 mg 
RAD001 and 2 x 150 mg BIBF 1120 will be administered, whereas 
in arm C, 10 mg of RAD001 and 2 x 200 mg BIBF 1120 will be gi-
ven. There is no interindividual dose escalation, and the enrollment 
of the patients will be performed sequentially. Eligible are all pati-
ents with relapsed or refractory advanced/metastatic solid tumors 
(UICC stage IV) and an ECOG performance state of 0-1 for whom 
no further standard therapies are available and who have predefi-
ned adequate organ functions. All patients will start with a 2-week 
run-in phase of 2 x 200 mg BIBF 1120. Dynamic contrast-enhanced 
magnetic resonance imaging (DCE-MRI) scans will be performed 
at baseline staging, on day 3 and day 14. On day 14, there will also 
be 12 hours-pharmacokinetic (PK) assessment. Combination the-
rapy within the forementioned dosage arms starts on day 15. After 
two weeks of combination therapy, on day 29, a DCE-MRI scan and 
12-hours PK will be performed. Restaging for the evaluation of the 
efficacy will be performed on day 57. The safety of this combinati-
on will be assessed throughout the complete therapy phase using 
CTC-AE V4.0, with predefined dose-limiting toxicities (DLTs) being 
assessed until day 42. Patients who experience clinical benefit (i. 
e., response or stable disease) on day 57 with adequate tolerability 
of the combination will further receive the medication, as long as 
the benefit lasts.
Results: 10 patients have been enrolled so far. In one patient with 
FGFR-amplified lung cancer, there was a partial response after six 
weeks of therapy. No DLTs were detected within the first dosage 
step. Tolerability of the combination was good, as there were no 
toxicities of CTC-AE grade 3 or greater. In arm B, there has been 
one DLT (elevation of transaminases), which turned out to be rever-
sibel.
Conclusion: So far, the combination of BIBF 1120 and RAD001 
seems tob e very good tolerated, demonstrating activity in a pati-
ent with NSCLC and FGFR1-amplification. Enrollment into the se-
cond dosage stage has already started. We expect the termination 
of the trial by winter 2013/2014.
Keywords: Phase I, Solid tumors, BIBF 1120, everolimus
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P1.11-046 WOMEN WITH LUNG CANCER HARBORING 
EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS: 
PREVALENCE, CLINICAL CHARACTERISTICS AND  
EGFR TYROSINE KINASE (TKI) TREATMENT-RELATED 
OUTCOMES. RESULTS FROM THE SPANISH WORLD07 
DATABASE
Enriqueta Felip1, Pilar Garrido2, Nuria Viñolas3, Dolores Isla4, 
Margarita Majem5, Angel Artal6, Enric Carcereny7, Rosario Garcia-
Campelo8, Pilar Lianes9, Ramon De Las Peñas10, Isabel Bover11, 
Silvia Catot12, Javier D. Castro Carpeño13, Ana Blasco14, Josefa Ter-
rasa15, Jose Luis Gonzalez Larriba16, Mariano Provencio17
1Vall D‘hebron University Hospital/Spain, 2Medical Oncology, 
Irycis,hospital University Ramon Y Cajal/Spain, 3Hospital Clinic/
Spain, 4Medical Oncology, Hospital Clinico Lozano Blesa/Spain, 5Servei 
D’Oncologia, Hospital De Sant Pau/Spain, 6Medical Oncology, Hospital 
Universitario Miguel Servet/Spain, 7Catalan Institute Of Oncology/
Spain, 8Medical Oncology, Complejo Hospitalario A Coruña/Spain, 
9Hospital De Mataró/Spain, 10Medical Oncology, Hospital De Castellon/
Spain, 11Medical Oncology, Hospital Son Llatzer/Spain, 12Hospital Alt-
haia/Spain, 13Hospital Universitario La Paz/Spain, 14Department Of 
Medical Oncology, Hospital General Universitario De Valencia/Spain, 
15Hospital Son Espases/Spain, 16Medical Oncology, Hospital Clínico San 
Carlos/Spain, 17Oncology, Hospital Puerta De Hierro/Spain
Background: EGFR mutations define a distinct molecular subset of 
non-small-cell lung cancer patients (p). Prevalence, baseline clinical 
characteristics and outcomes for women with lung cancer harboring 
EGFR mutations would be of interest.
Methods: We analyzed the clinical characteristics of women with 
lung cancer harboring EGFR mutations included in the WORLD07, 
a Spanish prospective, multicenter, epidemiologic female-specific 
e-database.
Results: A total of 2081 newly-diagnosed women with lung cancer 
from 38 Spanish centers were included in the WORLD07 e-database 
from October/2007 to October/2012. Overall 915 p were evaluated 
for EGFR mutation status, and 342 of them were found to have EGFR 
mutation (16% of all p in the e-database, 37% of p tested). EGFR-
mutated p characteristics: median age 64.6 years; 86% had offspring; 
8.2% had used oral contraceptives; smoking habit: 72% never smo-
kers, 14% current smokers, 13% former smokers; for those never smo-
kers, second-hand smokers 35%; histology: 91% adenocarcinoma, 
1.5% squamous cell carcinoma, 2% large-cell carcinoma, 5% other; 
EGFR mutation type: 60% deletions in exon 19, 32.5% L858R muta-
tions, 8% exon 20 mutations, 1% exon 18 mutations, 14% unknown. 
Sixty-nine percent of p had stage IV disease. A total of 184 EGFR 
mutated p received an oral EGFRTKI as 1st line (ECOG PS: 0 in 24%, 1 
in 53%, 2 in 13%, 4 in 4%, unknown in 5%) achieving a 59% response 
rate (RR), 20% stable disease (SD), 10% progression (PD) and 11% 
not evaluable (NE); with a median follow-up of 12 months, median 
overall survival for these p was 21 months. A total of 72 p received an 
EGFRTKI as 2nd line with 37% RR, 34% SD, 19% PD and 10% NE. Only 
16 p received an EGFRTKI as 3rd line, achieving a 38% RR, 19% SD, 
31% PD and 12.5% NE. For those EGFR mutated women receiving an 
EGFRTKI as 1st line, RR to an EGFRTKI was 70% in those women har-
boring deletion in exon 19, and 45% in those with L858R mutation; 
median overall survival was 24 months in those with deletion in exon 
19, and 17 months in those with L858R mutation. Response rate to an 
EGFRTKI as 1st line treatment was 59% in never-smoker p and 53% in 
current-smoker/former-smoker p with a median overall survival of 23 
months and 21 months, respectively.
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P1.11-045 COST-EFFECTIVENESS OF CARBOPLATIN 
AND PEMETREXED VERSUS SINGLE AGENT PEMETREX-
ED IN PATIENTS WITH ADVANCED NSCLC AND PERFOR-
MANCE STATUS OF 2 (PS2)
Carlos Gil Ferreira1, Rogerio Lilenbaum2, Isabele Small1, Renata 
Knust1, Carlos Barrios3, Mauro Zukin1, Ulises Garay4, Luciene 
Schluckebier1
1Clinical Research Division, Brazilian National Cancer Institute/Brazil, 
2Yale Cancer Center/United States Of America, 3Pontifícia Universidade 
Católica Do Rio Grande Do Sul/Brazil, 4Institute For Clinical Effectiven-
ess And Health Policy/Argentina
Background: Health care expenditures have increased dramati-
cally over the past 20 years. Particularly in oncology new technolo-
gies may be accompanied by higher costs but a mild health gain. 
As part of decision-making process, not only effective, but eco-
nomic value evidence is mandatory in many developed countries. 
We have recently shown that the combination of carboplatin and 
pemetrexed improves survival in a dedicated ECOG PS2 populati-
on when compared to pemetrexed alone (Zukin et al. J Clin Oncol 
2013). Because combination chemotherapy tends to increase toxi-
city and costs, a cost-effective analysis was performed in that PS2 
dedicated trial.
Methods: Clinical data and resource consumptions were obtained 
from the multicenter phase III randomized trial which tested carbo-
platin and pemetrexed vs. pemetrexed alone in 205 patients with 
advanced NSCLC and PS 2. Direct costs were estimated based on 
Brazilian public health care system. Life time was divided into sta-
ble disease stage, progression stage and death. Utilities for each 
stage were taken from the literature. One-way sensitivity analysis 
and non-parametric bootstrapping approach were performed to 
explore the uncertainties regarding the results.
Results: Combination chemotherapy demonstrated a gain in 0.22 
life years (LY) and 0.15 quality-adjusted life year (QALY) compared 
to single therapy at an additional cost of $1,667.28 (in 2012 USD). 
The incremental cost-effectiveness ratio (ICER) was $7,436.79/LY 
and $10,949.88/QALY. Estimates of ICER were more sensitive to 
change by the influence of stable disease utility and pemetrex-
ed cost. The probability of being cost-effective at a threshold of 
$36,000 (3 times Brazilian GDP per capita) per additional QALY 
was > 99%.
Conclusion: Adding carboplatin to pemetrexed therapy for ad-
vanced NSCLC patients with PS2 status is cost-effective when 
compared to pemetrexed alone. To the best of our knowledge this 
is the first report on cost-effectiveness in a dedicated NSCLC PS2 
population. This finding adds up to the efficacy data favoring the 
combination arm and may support health care policies in that sub-
population. This analysis is particularly relevant for countries with 
limited health care resources.
Keywords: non-small cell lung cancer, advanced stage, cost-effec-
tiveness, pemetrexed
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were significant independent favorable prognostic factors. Regar-
ding treatment variables, platin-based doublets with third genera-
tion drugs, use of targeted therapies were both independent favo-
rable prognostic factors with respective RR of 0.66 (CI95%=0.53; 
0.84), and 0.30 (CI95%=0.22; 0.40).
Conclusion: In this population-based study we found the same 
epidemiological trends recently seen in France (increase in women 
proportion and of adenocarcinoma histological subtype). Never-
smokers were a non negligible fraction of the patients. The intro-
duction of modern chemotherapy schemes and targeted therapies 
explain probably the slight improvement in survival observed bet-
ween 1998-1999 and 2004-2005 as in multivariate analysis there 
were significant independent favorable prognostic factors whreas 
peiods were not.
Keywords: chemotherapy, targeted therapies, non-small cell lung 
cancer, Epidemiology
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P1.11-048 A PHASE 2 STUDY OF INTRAVENOUS ADMI-
NISTRATION OF REOLYSIN® (REOVIRUS TYPE 3 DEA-
RING) IN COMBINATION WITH PACLITAXEL (P) AND 
CARBOPLATIN (C) IN PATIENTS WITH SQUAMOUS CELL 
CARCINOMA OF THE LUNG
Alain C. Mita1, Athanassios Argiris2, Matt Coffey3, George M. Gill3, 
Monica Mita1
1Samuel Oschin Comprehensive Cancer Institute, Cedars-sinai Medical 
Center/United States Of America, 2Cancer Therapy & Research Center, 
University Of Texas Health Science Center At San Antonio/United Sta-
tes Of America, 3Oncolytics Biotech Inc./Canada
Background: Squamous Cell Carcinoma of the lung (SCCLung) 
has long been recognized as very difficult to treat, with few agents 
showing effectiveness. Because the combination of P/C and REO-
LYSIN was shown to be active in 2 trials in SCC of the head and 
neck, we elected to test this regimen in this Phase 2 trial in SC-
CLung.
Methods: We conducted a single-arm, open-label phase II stu-
dy to determine (primary) the Objective Response Rate (ORR) 
and(secondary) the 6-month Progression-free Survival (PFS) and 
the Overall Survival (OS) of patients with metastatic or recurrent 
squamous cell carcinoma of the lung, treated with REOLYSIN in 
combination with P/C. The study had a two-stage design, with 19 
patients in the first stage. The trial would be terminated if 3/19 or 
fewer patients obtained an objective response. If the trial continu-
ed to the second stage, a total of up to 36 patients would be stu-
died. The primary endpoint wouldbe met if patients in both stages 
had an ORR of at least 35%. Eligible patients had ECOG PS 0–2, 
adequate organ function, and no prior systemic chemotherapy for 
their metastatic or recurrent disease. Prior adjuvant chemothera-
py or chemo-XRT for treatment of primary disease was allowed, 
provided it had been ≥ 6 months since the last chemotherapy. 
Treatment dosages were: paclitaxel 200 mg/m2 IV over 3 hours; 
carboplatin at a dose of AUC 6 mg/mL minute calculated using 
standard formula(s)and REOLYSIN 3x1010 TCID50IV over 1 hour 
daily for 5 days.
Results: 32 patients entered the study and received at least one 
dose of study drug. The patient population included 20 males and 
Conclusion: According to our prospective e-database of women 
with lung cancer, not selected for clinical trials and including all 
histologies, a high proportion harbor an EGFR mutation (16% of 
non-selected women, 37% of those tested). The vast majority of 
women with lung cancer harboring EGFR mutation are never smo-
kers, have adenocarcinoma histology and outcomes similar to tho-
se previously reported in the literature. Additional epidemiologic 
and treatment data will be presented at the meeting.
Keywords: Lung Cancer in women, NSCLC, EGFR mutation
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P1.11-047 MANAGEMENT AND OUTCOME OF STAGE 
IV NON-SMALL CELL LUNG CANCER IN A FRENCH DE-
PARTMENT BETWEEN 1998 AND 2005 : THE ROLE OF 
MODERN CHEMOTHERAPY SCHEMES AND OF THE AD-
VENT OF TARGETED THERAPIES
Olivier Carpentier1, Lucia Selvaggi2, Ashok Purohit2, Nathalie 
Prim2, Michel Velten1, Elisabeth Quoix2
1Departement D‘epidémiologie, Université De Strasbourg/France, 2Ser-
vice De Pneumologie, Nhc/France
Background: Platin-based doublets with a third generation drug 
are the mainstay of the treatment of fit patients with stage IV 
non-small cell lung cancer (NSCLC). However, the results reached 
a plateau at the beginning of the XXIst century with a median 
survival time of 8-9 months in the randomized trials. Since 2002, 
personnalized treatment was developed with histology-guided 
chemotherapy and targeted therapies with a median survival time 
around 12 months and even 21 months in some patients harboring 
mutations.
Methods: To ascertain the improvement in survival of patients 
with advanced NSCLC since the advent of new chemotherapies 
and targeted therapies, we conducted a retrospective population 
based-study on a sample of 1047 patients diagnosed with stage 
IIIb (wet) and IV primary NSCLC in a French department (Bas-Rhin) 
from 1998 to 2005.
Results: Median age at diagnosis was 65.0 years [26-92]. Patients 
aged > 70 represented 32.4% of the patients. The proportion of 
women increased throughout the period with an initial sex-ratio 
of 3.8/1 in 1998-2001 to 2.5/1 in 2002-2005. Thirteen % of the 
patients were never smokers. The proportion of adenocarcinomas 
increased significantly throughout the period at the expense of 
squamous cell carcinoma subtype. Best supportive care was the 
sole treatment for only 11.75% of the patients. The use of chemo-
therapy increased from 74.2% to 87.1% of the patients (p = 0.0021), 
and type of chemotherapeutic agents have evolved with a signi-
ficant increased use of carboplatin (while there was a decreased 
use of cisplatine) and of drugs of third-generation. Among them, 
vinorelbine was the most frequently used at the beginning of the 
period (38.8 % versus1.75% paclitaxel whereas during the two 
last years, the proportions were respectively 18.9% and 22.7%. 
Use of targeted therapies (gefitinib and erlotinib) began in 2002 
with 15% of the patients receiving these therapies in 2004-2005 
essentially as 2nd, third or 4th line therapy (only 4 patients as 1st 
line). Overall survival was 6.5 months [CI 95% 5.8; 7.2]. There was a 
significant increase from 5.3 months [CI 95% 4.4; 7.2] in 1998-1999 
to 7.3 months [CI 95% 6.1;8.6] in 2004-2005. In multivariate analysis 
of survival, female gender, adenocarcinoma histological subtype 
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pharmacologic properties that predict a low clearance, minimal 
risk for drug interactions, wide distribution and long half life, make 
TSR-011 a promising 2nd generation ALK inhibitor.
Methods: A Phase 1-2a dose escalation and cohort expansion stu-
dy is underway to evaluate safety, tolerability, PK, and preliminary 
efficacy of TSR-011. Phase 1 is evaluating unselected patients with 
advanced solid tumors and lymphomas. The recommended Phase 
2 dose will be evaluated in Phase 2a in patients required to have 
ALK+ tumors (defined by immunohistochemistry or fluorescent in-
situ hybridization) including those with NSCLC progressing on, or 
naïve to, ALK inhibitor therapy.
Results: As of June 2013, patients have been enrolled at oral do-
ses between 30 and 480 mg. Pharmacokinetic parameters have 
been dose responsive and human drug exposures in excess of that 
associated with efficacy in murine xenograft models are maintai-
ned for the entire dosing interval. Two of the first five patients have 
SD. A patient with EML4-ALK+ NSCLC with metastatic pericardial 
thickening and symptomatic disease, who progressed on crizoti-
nib showed clinical improvement in symptoms and thinning of the 
pericardium by 6 weeks of treatment and continues on study.
Conclusion: Based on tight binding to ALK, potency at inhibiting 
enzymatic activity, as well as activity against crizotinib resistant 
mutations and early clinical data, TSR-011 is a promising agent for 
both ALK-dependent and crizotinib resistant NSCLC.
Keywords: resistance, Targeted therapy, ALK, TRK
12 females, median age was 62 years (range: 37 to 80 years) and all 
were Caucasian including one Hispanic patient. Of the 32 entered, 
25 patients received more than one Cycle of therapy and a total of 
125 cycles were administered in that group (per patient mean=5, 
median=6, range 2-12). The 7 non-evaluable patients received 1 
cycle or less. Of the 25 evaluable patients who received more than 
one cycle, 12 (48%) had a PR, 10(40%) had stable disease (SD), and 
3 (12%) had progressive disease (PD) for overall disease control (CR 
+ PR + SD) in 22/25 (88%). Of 21 patients with >6 months follow-
up, 7 (33.3%) have PFS of at least 6 months. The most common 
adverse events (AEs) seen were those expected with P/C---neutro-
penia 17 (9=Gr 3-4) and thrombocytopenia 15 (5=Gr 3-4) and tho-
se expected with REOLYSIN---fever 6 (1=Gr 3) and fatigue 11 (4=Gr 
3). The AE profile of P/C therapy did not appear to be significantly 
altered by the addition of REOLYSIN. The only serious adverse 
event reported as unexpected and related to study therapy was 
reversible Gr 2 elevation of creatinine (and increased BUN) which 
occurred 3 weeks after Cycle 8 in a 65-year-old woman.
Conclusion: Combination therapy with paclitaxel/carboplatin/
REOLYSIN was well-tolerated in patients with recurrent/metastatic 
SCClung and the response results justify further studies.
Keywords: SCCLung, Reovirus
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P1.11-049 TSR-011: A POTENT INHIBITOR OF ALK INCLU-
DING CRIZOTINIB-RESISTANT MUTATIONS IN PHASE 1-2 
DEVELOPMENT FOR ALK+ NSCLC
Glen J. Weiss1, Jasgit C. Sachdev2, Jeffrey R. Infante3, Monica Mita4, 
Keith M. Wilcoxen3, Vikram Kansra3, David G. Brooks3, Robert E. 
Martell3, Stephen P. Anthony5
1Cancer Treatment Centers Of America/United States Of America, 
2Scottsdale Healthcare/United States Of America, 3Translational Medi-
cine, Tesaro/United States Of America, 4Samuel Oschin Comprehensive 
Cancer Institute, Cedars-sinai Medical Center/United States Of Ameri-
ca, 5Evergreen Hematology And Oncology/United States Of America
Background: Significant progress has been made in the identi-
fication of subsets of non-small cell lung cancer (NSCLC) driven 
by tyrosine kinase gene fusions (including gene fusions of ALK, 
RET, ROS1 and NTRK1). Despite approval of crizotinib for ALK+ 
NSCLC there are still significant challenges and high unmet need 
to develop new agents with durable efficacy against these kinase 
gene fusions that initiate NSCLCs. In order to address limitations of 
crizotinib, and to provide treatment option with increased activity 
against crizotinib resistance mutations and amplified EML4-ALK, 
TSR-011, a potent, small molecule, second generation ALK inhibi-
tor is undergoing clinical evaluation. TSR-011 was designed using 
X-ray structure based drug design, and hence has high affinity 
for the ALK kinase domain (Kd = 0.36 nanomolar, [nM]). TSR-011 
inhibits wild type, recombinant ALK kinase activity with an IC50 
value of 0.7 nM and exhibits sustained potent inhibition of EML4-
ALK-dependent tumor growth in mice. ALK amplification and mu-
tations that are important drivers of tumor cell growth or crizotinib 
resistance are inhibited by TSR-011 at low nM (IC50 values of 0.1 
to 2.2 nM) concentrations. TSR-011 is a similarly potent inhibitor of 
recombinant TRK kinases including suppressing proliferation of a 
NTRK1-rearranged colorectal cancer cell line in vitro. Collectively, 
the selective and potent activity of TSR-011 against ALK, and 
clinically observed crizotinib resistance mutations, coupled with 
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in long-term survival in 5 of 6 patients with synchronous brain me-
tastasis from NSCLC. Although only a small number of cases were 
studied, this report may provide promising data with regard to a 
multidisciplinary therapeutic strategy for patients with newly dia-
gnosed thoracic stage I or II NSCLC with brain metastasis. Further 
analysis and clinical studies are necessary to validate our findings.
Keywords: multidisciplinary treatment, gamma knife surgery, non-
small cell lung cancer, brain metastasis
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P1.12-002 THE CLINICOPATHOLOGICAL FEATURES OF 
RESECTED PERIPHERAL SQUAMOUS CELL CARCINO-
MAS OF THE LUNG: PROGNOSTIC IMPACT OF VASCU-
LAR AND PLEURAL INVASION
Tomonari Kinoshita1, Takashi Ohtsuka1, Tai Hato1, Taichiro Goto1, 
Ikuo Kamiyama1, Katsura Emoto2, Yuichiro Hayashi2, Mitsutomo 
Kohno1
1Division Of General Thoracic Surgery, Keio University School Of Medi-
cine/Japan, 2Pathology, Keio University School Of Medicine/Japan
Background: Although the incidence of peripheral squamous cell 
carcinomas (SqCCs) of the lung has increased over recent years, 
clinicopathological factors influencing prognosis of resected peri-
pheral lung SqCCs remain to be elucidated.
Methods: We reviewed the clinical data of 186 patients who un-
derwent complete resection of peripheral lung SqCCs in our ins-
titute and analyzed the clinicopathological features in relation to 
their overall survival (OS) and recurrence free survival (RFS).
Results: The enrolled patients ranged in age 40 to 91 years, with 
a median age of 69 years. Multivariate analysis revealed that nodal 
metastasis (OS; Hazard ratio (HR) = 2.47, P = 0.02), vascular invasi-
on (OS; HR = 1.93, P < 0.05, RFS; HR = 2.07, P = 0.01) and pleural 
invasion (OS; HR = 2.27, P = 0.02, RFS; HR = 2.30, P < 0.01) were 
independent unfavorable prognostic factors. Among patholo-
gically confirmed stage I peripheral SqCCs patients, high serum 
squamous cell carcinoma antigen (SCC) levels (OS; HR = 3.91, P < 
0.01, RFS; HR = 2.30, P < 0.01), vascular invasion (RFS; HR = 2.68, 
P = 0.02) and pleural invasion (OS; HR = 4.44, P = 0.01, RFS; HR = 
4.57, P < 0.01) were strongly correlated with poor prognosis.
Session P1.12: Poster Session 1 - 
NSCLC Early Stage 
Monday, October 28, 2013
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P1.12-001 EFFICACY OF PULMONARY RESECTION AND 
GAMMA KNIFE SURGERY FOR NON-SMALL CELL LUNG 
CANCER WITH SYNCHRONOUS BRAIN METASTASIS
Reiko Mitsueda1, Takashi Yoshimatsu1, Takeaki Miyata1, Atsusi 
Sekimura2, Naohiro Nose3, Tetsuya So4, Kosei Yasumoto4
1General Thoracic Surgery, Fukuoka Wajiro Hospital/Japan, 2General 
Thoracic Surgery, Shintakeo Hospital/Japan, 3General Thoracic Surgery, 
Shinyukuhashi Hospital/Japan, 4General Thoracic Surgery, Shinkomonji 
Hospital/Japan
Background: Several studies suggest that pulmonary resection 
and gamma knife surgery (GKS) protocol prolong survival in pati-
ents with thoracic stage I or II non-small cell lung cancer (NSCLC), 
without extra-cranial or lymph node metastases, and with a limited 
number of small synchronous brain metastases. According to the 
Japanese Lung Cancer Society guidelines published in 2012, ste-
reotactic radiosurgery (SRS) or surgery for a single brain metastatic 
lesion and SRS or stereotactic radiotherapy (SRT) for 2-4 brain me-
tastatic lesions, less than 3 cm in length, are Grade B recommen-
dations. To validate these recommendations, we retrospectively 
examined the prognosis of patients with NSCLC who underwent 
GKS for synchronous brain metastasis and pulmonary resection.
Methods: We retrospectively reviewed the cases of patients with 
NSCLC and synchronous brain metastasis who underwent GKS 
preceding pulmonary resection from January 2006 to December 
2012 at our institution. The eligibility criteria were thoracic stage I 
or II NSCLC, a performance status of 0–1, a predicted post-opera-
tive forced expiratory volume in 1 second of >600 ml/m2, no extra-
cranial metastasis, and brain metastatic lesions of < 3 cm.
Results: In total, 253 patients underwent pulmonary resection for 
NSCLC between January 2006 and December 2012. Six patients 
with NSCLC and synchronous brain metastasis underwent GKS 
preceding pulmonary resection, and received postoperative adju-
vant systemic chemotherapy or molecular targeted therapy. All of 
them were Japanese, 4 were male and 2 were female. The mean 
age was 63 years (range, 47–78 years). Four patients had neuro-
logic symptoms. The mean size of the primary lung lesion was 35 
mm (range, 22–59 mm). The median number of brain metastases 
was 1 or 2 (range, 1–8) and the mean size was 16 mm (range, 
7–28 mm). GKS was performed before pulmonary resection in all 
patients. The median time between GKS and thoracotomy was 
2 weeks (range, 2–8weeks). Combined pulmonary resection was 
performed in 2 patients because of inter-lobar pleural invasion and 
lobectomy was performed in 4. Postoperative complications oc-
curred in 1 patient: (thoracic empyema with bronchopleural fistula). 
Histologically, 4 patients had adenocarcinoma and 2 had large cell 
carcinoma. None of the patients showed evidence of lymph node 
metastasis after pulmonary resection (pN0). All patients received 
either platinum-taxol doublet therapy or molecular targeted thera-
py as postoperative adjuvant chemotherapy. One patient died 28 
months after surgery because of new brain metastasis, and 5 were 
alive at 15, 18, 30, 66, and 88 months after pulmonary resection.
Conclusion: The pulmonary resection and GKS protocol resulted 
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Conclusion: Pleural and vascular invasions were independent poor 
prognostic factors for completely resected peripheral SqCC. Ad-
juvant chemotherapy might be beneficial for patients having SqCC 
with pleural and vascular invasion.
Keywords: peripheral squamous cell carcinoma of the lung, vascu-
lar invasion, Pleural invasion, prognostic factor
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Conclusion: Preoperative neutrophil count and lymphocyte count 
were independent prognostic factors in completely resected NS-
CLC. High neutrophil count was associated with tumor size and 
pleural invasion, and low lymphocyte count was associated with 
tumor size and vascular invasion.
Keywords: prognostic factor, lymphocyte count, neutrophil count
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P1.12-004 ACCURACY OF PET/CT IN THE EVALUATION 
OF N1 AND N2 LYMPH NODE STATIONS IN OPERABLE 
NSCLC
Fatma Kutluhan1, Aylin Ozgen Alpaydin1, Berna Degirmenci Po-
lack2, Ahmet Onen3, Duygu Gurel4, Atilla Akkoclu1, Atila Akkoclu1
1Pulmonary Diseases, Dokuz Eylul University Medical Faculty/Turkey, 
2Nuclear Medicine, Dokuz Eylul University Medical Faculty/Turkey, 
3Thoracic Surgery, Dokuz Eylul University Medical Faculty/Turkey, 
4Pathology, Dokuz Eylul University Medical Faculty/Turkey
Background: Aim: Mediastinal lymph node metastases are fre-
quent in non small cell carcinomas (NSCLC). We aimed to investi-
gate the diagnostic accuracy of PET-CT for different mediastinal 
lymph nodes in operable NSCLC patients by comparing PET-CT 
results with cervical mediastinoscopy and thoracotomy findings.
Methods: Medical records of 124 operable NSCLC patients to 
whom PET-CT was applied for clinical staging between November 
2009 and December 2011 were evaluated retrospectively. PET-
CT was negative in 64 of 124 patients. Thirty-four of the patients 
underwent cervical mediastinoscopy, 4 underwent anterior medi-
astinotomy, 3 underwent thoracotomy and the remaining 83 were 
operated without any prior invasive procedure. PET/CT uptake 
of different stations were explored, sensitivity, specifity, negative 
(NPV) and positive predictive (PPV) values and accuracy rates were 
calculated
Results: Sensitivity, specifity, PPV, NPV and accuracy rates for N1 
and N2 lymph nodes are shown in the table. Accuracy rates were 
low for 4th, 7th and 10th numbered lymph nodes. However any 
significant correlation was not observed between pathology and 
PET-CT for nodal stations 3 and 10.  
% Sensitivity Specifity PPV NPV Accuracy
N1 8 94 21 82 78
N2 57 93 49 95 89
 
Conclusion: The lower rates of PET-CT sensitivity and PPV for N1 
lymph nodes than N2 lymph nodes reflect the poor success rates 
of N1 determination with PET-CT. The lower accuracy rates of 4, 7 
and 10 station lymph nodes with PET-CT as well as the pathology 
and PET-CT uncorrelation for 3 and 10 lymph nodes might be exp-
lained by the close localization of these stations to N1 lymph no-
des and the restriction of the PET-CT in discrimination of N2 lymph 
nodes from N1 in this area.
Keyword: PET/C, NSCLC
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P1.12-003 PREOPERATIVE NEUTROPHIL AND LYMPHO-
CYTE COUNTS ARE INDEPENDENT PROGNOSTIC FAC-
TORS IN COMPLETELY RESECTED NON-SMALL CELL 
LUNG CANCER
Naohiro Kobayashi, Shingo Usui, Jun Yamamoto, Hisashi Suzuki, 
Shinji Kikuchi, Yukinobu Goto, Mitsuaki Sakai, Masataka Onizu-
ka, Yukio Sato
Department Of General Thoracic Surgery, Graduate School Of Compre-
hensive Human Science, University Of Tsukuba/Japan
Background: The pretreatment ratio of neutrophils to lymphocy-
tes has recently been reported as a prognostic factor in non-small 
cell lung cancer (NSCLC). However, the mechanism behind this 
is unclear. Therefore, we separately investigated the influences 
of neutrophil and lymphocyte counts on prognosis in completely 
resected NSCLC.
Methods: We conducted retrospective analyses of patients dia-
gnosed with NSCLC who underwent surgery involving complete 
resection at Tsukuba University Hospital between 2000 and 2009. 
Patients with preoperative treatment, suspicion of granulocyte 
colony-stimulating factor-producing tumor, and unmeasured dif-
ferential leukocyte count were excluded. Univariate analysis was 
performed using the Kaplan-Meier method, and statistical signi-
ficances were assessed by the log-rank test. The cut-off values of 
neutrophil and lymphocyte counts were defined as the maximal 
log-rank statistical values. Then, we divided the patients into two 
groups according to the optimal cut-off values to investigate the 
association with clinicopathological factors. Chi-square test was 
used for categorical variables and t test was used for continuous 
variables. To assess the independent predictive values, Cox pro-
portional hazards model was used. The result was considered to 
be significant when the P value was less than 0.05.
Results: A total of 328 patients were evaluated. There were 217 
men and 111 women. The patients’ age at the time of operation 
ranged from 29 to 89 years (mean, 67.0 years). The mean follow-
up was 41.0 months (range, 1-118 months). Two hundred and ten 
patients were classified as Stage I, 72 patients as Stage II, and 
46 patients as Stage III. The overall 5-year survival rate of all 328 
patients was 71.1%. As for the neutrophil count, the maximum log-
rank statistical value was 11.456 (P < 0.001) when the cut-off value 
was 5200 mm-3. The overall 5-year survival rates were 74.2% for 
the low-neutrophil-count group (neutrophil count ≤ 5200 mm-3), 
and 48.8% for the high-neutrophil-count group (neutrophil count 
> 5200 mm-3). As for the lymphocyte count, the maximum log-rank 
statistical value was 7.275 (P = 0.007) when the cut-off value was 
1700 mm-3. The overall 5-year survival rates were 65.5% for the 
low-lymphocyte-count group (lymphocyte count ≤ 1700 mm-3) and 
75.4% for the high-lymphocyte-count group (lymphocyte count > 
1700 mm-3). High neutrophil count was significantly associated with 
tumor size, pleural invasion, sex, smoking index, lactate dehydro-
genase, and C-reactive protein. On the other hand, low lympho-
cyte count was related to tumor size, vascular invasion, and age. 
Cox proportional hazards model showed that neutrophil count 
and lymphocyte count were independent prognostic factors. The 
hazard ratio of neutrophil count was 1.880 (P = 0.022), and that of 
lymphocyte count was 1.645 (P = 0.036). Other significant factors 
were tumor size (hazard ratio: 2.418, P = 0.001) and lymphatic inva-
sion (hazard ratio: 1.829, P = 0.035). Pleural invasion, nodal status, 
and vascular invasion were not significant.
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P1.12-006 PREDICTIVE RISK FACTORS FOR MEDIASTI-
NAL LYMPH NODE METASTASIS IN PATIENTS WITH CLI-
NICAL STAGE I ADENOCARCINOMA OF THE LUNG
Geun Dong Lee, Yong-Hee Kim, Se Hoon Choi, Hyeong Ryul Kim, 
Dong Kwan Kim, Seung-Il Park
Department Of Thoracic And Cardiovascular Surgery, Asan Medical 
Center/Korea
Background: The standard operation for patients with stage I lung 
adenocarcinoma is considered as a lobectomy. Recently, some 
researchers have reported that patients with tumors tend to show 
less aggressive nature which it could be candidates for thoraco-
scopic limited resection. In regard to mediastinal nodal metastasis, 
however, the precise criteria as an index for planning limited re-
section are obscure. Therefore, we have attempted to determine 
low-risk or high-risk populations for mediastinal nodal metastasis 
in patients with clinical stage I adenocarcinoma of the lung.
Methods: A retrospective analysis was made of 617 patients who 
underwent curative pulmonary resection with mediastinal lymph 
node dissection by video-assisted thoracoscopic surgery (VATS) 
between Jan 2006 and Nov 2012 for clinical stage I adenocarcino-
ma of the lung. Preoperative computed tomography (CT) and po-
sitron emission tomography (PET) were performed in all patients. 
Additionally, endobronchial ultrasound transbronchial needle aspi-
ration (EBUS-TBNA) was performed in 12 patients, mediastinosco-
pic lymph node biopsy in one patient, and endoscopic ultrasound 
(EUS) was performed in one patient. The patients had received 
the treatment with wedge resection or the patients who had other 
malignancies were excluded in this study.
Results: Among 617 patients, mediastinal nodal metastasis was 
found in 47 patients (7.6%), consisted of N1 disease in 24 pati-
ents (3.9%), N2 disease in 23 patients (3.7%), and skipped N2 
disease in 6 patients (0.9%). Five year survival rate of the patients 
with N0 disease, N1 disease, and N2 disease was 90.3%, 55.6%, 
54.8%, respectively (p<0.001). A univariate analysis identified the 
following four variables as significant predictors for mediastinal 
nodal metastasis: tumor size (p=0.003), consolidation/tumor ratio 
(p<0.001), maximal standardized uptake value (SUVmax) of tumor 
(p=0.002), and differentiation of tumor (p < 0.001). The optimal 
cutoff points of continuous variables were determined as: 1.7cm 
for the tumor size, 84.0% for consolidation/tumor ratio, and 3.3 
for SUVmax. A multivariate analysis revealed that following three 
significant predictors for mediastinal nodal metastasis as shown in 
the next statement: the consolidation/tumor ratio of 84% or more 
(OR: 4.097, p=0.001), maximal SUV of 3.3 and more (OR: 3.662, 
p=0.002), moderate or poorly differentiation of histology (OR: 
3.794, p=0.016). The prevalence of nodal metastasis was 0% in 
patients who had none of these three predictors. 2.1% in patients 
with one of the three predictors, 10.8% in patients with two of the 
three predictors, and 21.0% in patients with all of the three predic-
tors (p<0.001).
Conclusion: Among the patients with clinical stage I adenocarci-
noma of the lung, low-risk population for mediastinal nodal metas-
tasis could be predicted by following the three predictors (84% of 
consolidation/tumor ratio, 3.3 of SUVmax, ‘moderate’ and ‘poorly’ 
differentiation of tumor). These predictive parameters may provide 
detailed criteria for thoracoscopic limited resection in regard to 
mediastinal nodal metastasis.
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P1.12-005 SURVIVAL FOLLOWING SURGERY WITH OR 
WITHOUT ADJUVANT CHEMOTHERAPY FOR STAGE I-
IIIA NON-SMALL CELL LUNG CANCER
Zhong-Zhe Lin1, Wen-Yi Shau2, Yu-Yun Shao3, Yen-Yun Yang4, Ray-
mond Nien-Chen Kuo5, James C. Yang1, Mei-Shu Lai6
1Oncology, National Taiwan University Hospital/Taiwan, 2Division Of 
Health Technology Assessment, Center For Drug Evaluation (taiwan)/
Taiwan, 3Oncology, Ntuh/Taiwan, 4Center For Comparative Effective-
ness Research, Clinical Trial Center, Ntuh/Taiwan, 5Taiwan Cancer 
Registry/Taiwan, 6Institute Of Preventive Medicine, College Of Public 
Health, National Taiwan University/Taiwan
Background: Asian ethnicity is associated with distinct molecular 
etiology, treatment response, and survival among patients with 
non-small cell lung cancer (NSCLC). This study examines the sur-
vival impact of platinum-based adjuvant chemotherapy for Asian 
patients with stage I-IIIA NSCLC.
Methods: This study recruited patients ³ 18 years old with histolo-
gically proven stage IA-IIIA NSCLC registered in the Taiwan Cancer 
Registry Database between January 2004 and December 2007. 
Platinum-containing adjuvant chemotherapy should be started 
within 90 days of the primary surgery. Kaplan-Meier survival cur-
ves, log-rank tests, and the Cox proportional hazards regression 
model were used to assess the influence of various risk factors on 
survival time.
Results: This study included 2,231 patients with stage IA to IIIA 
NSCLC who underwent primary surgery with a clear surgical mar-
gin. The percentages of all causes of death were significantly lower 
for the chemotherapy group in stage II and stage IIIA patients. 
Multivariate analysis identified platinum-based adjuvant chemothe-
rapy as an independent prognostic factor for the overall survival 
of stage II (HR 0.61, 95% CI 0.39-0.94, p = 0.024) and IIIA (HR 0.71, 
95% CI 0.52-0.96, p = 0.029) patients. Among these patients, those 
who received adjuvant chemotherapy demonstrated superior ove-
rall survival in both genders and in the subgroups of patients aged 
³ 70 years and those with adenocarcinoma.
Conclusion: Platinum-based adjuvant chemotherapy should be 
considered in the treatment plan for Asian patients with resected 
stage II and stage IIIA NSCLC.
Keywords: adjuvant chemotherapy, Asian ethnicity, comparative 
effectiveness, non-small cell lung cancer
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P1.12-008 THE EFFECTS OF DIFFERENT PREOPERATIVE 
BRAIN SURVEY STRATEGY ON THE PATHOLOGICAL 
STAGE I NON-SMALL CELL LUNG CANCER PATIENTS
Cheng-Che Tu, Chien-Sheng Huang, Po-Kuei Hsu, Jung-Jyh Hung, 
Chih-Cheng Hsieh, Han-Shui Hsu, Yu-Chung Wu, Wen-Hu Hsu
Surgical Department, Taipei Veterans General Hospital/Taiwan
Background: Brain metastasis is rare in pathological stage I non-
small cell lung cancer (NSCLC). Brain magnetic resonance imaging 
(MR) should discover more synchronous asymptomatic brain me-
tastasis than computed tomography (CT), but the efficacy of brain 
MR in pathological stage I NSCLC is not yet determined. This study 
aimed to investigate the effect of different strategies for preope-
rative brain imaging survey of pathological stage I NSCLC under-
went complete resection.
Methods: The clinicopathological characteristics of 870 patients 
underwent complete resection of stage I NSCLC at Taipei Veterans 
General Hospital between Jan. 2002 and Dec. 2011 were retros-
pectively reviewed. The patients were divided into three groups 
according to pre-operative brain survey strategy (no imaging stu-
dy, CT, or MR). Multivariate analysis for survival was done.
Results: In total 870 patients, 446 patients with no brain imaging 
study, 304 had brain CT and 120 had brain MR. Median age was 
65±11.36. Average tumor size was 2.2±1.07, 2.8±1.16 and 2.4±1.01 
centimeters in the three groups, respectively. 238, 103 and 544 
patients were pathological T1a, T1b and T2a, respectively. Ade-
nocarcinoma was identified in 716(82.3%) patients, while 94(10.8%) 
had squamous cell carcinoma. With median follow up time of 42.3 
months, 21 (2.4%) brain metastases in 870 patients after complete 
resection were identified, with 7(1.5%), 10(3.3%) and 4(3.3%) pati-
ents in each group, respectively (p = 0.027). Within the first year 
and the second year follow-up, 2 and 11 brain metastases were 
noted, respectively. In subgroup analysis, 3 patients with brain me-
tastases had pathological T1a, 1 had T1b, and 17 had T2a. The ove-
rall 5-year survivals were 76.9%, 72.0% and 85.4% in non-imaging, 
CT and MR group, respectively (p = 0.014). Disease free survival of 
each group were 84.1%, 84.0% and 83.4% (p = 0.167). Under multi-
variate analysis adjusted with age, gender, T stage, pathohistologi-
cal grading, pleural invasion status and whether patient receiving 
whole body PET/CT, there were 3 factors associated with poorer 
survival: age, male sex and T stage. Brain survey strategy did not 
affect survival in multivariate analysis. 
Keywords: Lung cancer, Lymph node metastasis, Video-assited 
thoracoscopic surgery (VATS), Adenocarcinoma
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P1.12-007 THE PREDICTORS OF EARLY RECURRENCE 
IN PATIENTS WITH COMPLETELY RESECTED P-STAGE I 
NON-SMALL CELL LUNG CANCER
Kazunori Hata1, Junji Yoshida1, Genichiro Ishii2, ShuNKI Hiraya-
ma1, Rie Matsuwaki1, Yuki Matsumura1, Keiju Aokage1, Tomoyuki 
Hishida1, Kanji Nagai1
1Division Of Thoracic Surgery, National Cancer Center Hospital East/
Japan, 2Pathology Division, Research Center For Innovative Oncology, 
National Cancer Center Hospital East/Japan
Background: The objective of this study was to identify the risk 
factors for early (within 2 years after surgery) recurrence in patients 
with completely resected pathological stage I (p-stage I) non-small 
cell lung cancer (NSCLC).
Methods: We reviewed retrospectively 864 consecutive patients 
with p-stage I NSCLC who underwent complete resection between 
1992 and 2012 at our institution. The correlation between clinico-
pathologic factors (sex, age, preoperative CEA level, tumor latera-
lity, primary lobe, smoking history, histological type, histological 
differentiation, p-T status, lymphatic permeation, vascular invasion, 
pleural invasion) and early recurrence was evaluated using chi-
square test and multivariate analysis.
Results: There were 498 men and 366 women, with an average 
age of 67 years. (range: 33-87). The median follow up period was 
78 months. Histologically, 659 patients had adenocarcinomas, 189 
squamous cell carcinomas, and 16 other types. T status was 1a in 
230 patients, 1b in 274, and 2a in 360. Vascular invasion was obser-
ved in 326 patients, and lymphatic permeation in 169. Recurrence 
developed in 208 patients (24.1%), and 64 (7.4%) of them develo-
ped within 2 years after surgery. By multivariate analysis, vascular 
invasion (hazard ratio 3.441, 95% confidence interval 1.892-6.428) 
and moderate to poor differentiation (hazard ratio 3.252, 95% 
confidence interval 1.242-8.512) were shown to be independently 
significant risk factors for early recurrence. In patients with vascu-
lar invasion, distant failure occurred significantly more frequently 
than locoregional recurrence. The early recurrences were distant 
failure in 46 patients (72%). Of the 18 patients with locoregional 
recurrence only, 13 had malignant pleural effusion or pleural disse-
mination.
Conclusion: Moderate to poor differentiation and vascular invasi-
on were the significant predictors of early recurrence within 2 years 
after complete resection of p-stage I NSCLC. More than 90% of 
the early recurrences were disseminated diseases. Therefore, adju-
vant chemotherapy after complete resection may be beneficial for 
p-stage I NSCLC patients with vascular invasion or moderately to 
poorly differentiated tumors.
Keyword: recurrence, surgery, NSCLC
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P1.12-009 ORAL VINORELBINE IN COMBINATION WITH 
CISPLATIN OR CARBOPLATIN IN ADJUVANT CHEMO-
THERAPY OF NON-SMALL CELL LUNG CANCER: A PRO-
SPECTIVE MULTICENTRE STUDY OF TOLERABILITY AND 
SURVIVAL.
Vitezslav Kolek1, Ivona Grygarkova1, Jiri Chalupa2, Leona Koubko-
va3, Jirina Svecova4, Jana Skrickova5, Dimka Sixtova6
1Department Of Respiratory Medicine, University Hospital/Czech 
Republic, 2Oncology, Hospital Liberec/Czech Republic, 3Pneumology, 
Praha Motol/Czech Republic, 4Oncology, Hospital Tábor/Czech Republic, 
5Pneumology, University Hospital/Czech Republic, 6Pneumology, Tho-
mayer Hospital/Czech Republic
Background: Adjuvant cisplatinum-based chemotherapy is recom-
mended for routine use in patients with stages IIA, IIB, and IIIA of 
non small-cell lung cancer (NSCLC) after radical resection. Results 
in stage IB were not conclusive. Vinorelbine is a preferable drug 
in this indication and a randomized study proved the comparable 
effectiveness and tolerability of vinorelbine given both orally or 
intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine 
gives better comfort to patients. Also tolerance of carboplatin 
(CBDCA) in better than tolerance of cisplatin (CDDP). Randomized 
studies in adjuvant chemotherapy (ACT) settings are missing.
Methods: This prospective multicenter study evaluates the tole-
rance and survival parameters of the ACT based on CDDP (75mg/
m2) or CBDCA (AUC 5) with vinorelbine (25 mg/m2 D1 i.v. and 35 
mg/m2 D8 given orally). After radical resection, ACT (4 cycles of 
21 day, out-patient regimen) was applied to patients with stage 
IB, II, and IIIA of NSCLC. Selection of CDDP or CBDCA was based 
on individual center preference. During the follow-up period of 
42.2 months (m) survival was evaluated according to gender, smo-
king, age, tumor histology, stage and grading, surgical procedure, 
CDDP or CBDCA treatment.
Results: ACT was applied to 154 eligible patients (110 men, 44 wo-
men, median of age 63 years). Surgically determined stages were 
IB in 46 pts, II in 46 pts, and IIIA in 52 pts. CBDCA was given to 77 
patients and CDDP to 77 patients,11 of whom switched to CBDCA 
due to toxicity. Mean age was 63.6 years in CBDCA group and 
61.7 years in CDDP group. Altogether 586 cycles were administe-
red, 82.6% of patients finished four cycles of planned ACT. Mean 
number of cycles was 3.79 per patient (3.76 in CDDP and 3.83 in 
CBDCA). The most frequent WHO grade 3/4 of toxicity were neu-
tropenia in 16.8%, leucopenia in 7.9%, anemia in 1.2%, thrombocy-
topenia in 0.5%, alopecia in 2.9%, vomiting in 2.3%, neurotoxicity, 
diarrhoea and mucositis in 0.2% of cycles. Neutropenia, nausea 
and vomiting were more frequent in CDDP group. Relative dose in-
tensity (RDI) was 94 % for vinorelbine i.v. and 88.6 % for vinorelbine 
p.o. In CBDCA RDI was significantly higher than CDDP (94 % vs 90 
%, p 0.009). Three years overall survival (OS) was 68.2%, 5-year OS 
was 55.0% and 79 pts still live, 66 live without progression of the 
disease. OS was significantly longer in stage IB and II than in stage 
IIIA (p 0.007) and in CBDCA than CDDP treatment (p 0.01). Disease 
free survival (DFS) was 41.6 m, it was longer in men (p 0.049), in 
stage IB and II (p 0.041) and in DBDCA treatment (p 0.021).
Conclusion: Both applied regimen were tolerable. Survival was 
influenced by stage of the tumor. Patients treated with CBDCA ex-
perienced less toxicity, obtained higher RDI of planned treatment 
and lived longer than those treated with CDDP. Study showed 
that both CBDCA and CDDP can be used in combination with oral 
Conclusion: Preoperative brain MR survey did not have a less 
frequent rate of brain metastasis comparing with non-imaging 
and brain CT strategy, nor a better survival in pathological stage I 
NSCLC patients. Use brain MR in preoperative staging routinely in 
clinical stage I patients should be reconsidered, especially in NS-
CLC with smaller tumor size.
Keywords: early stage lung cancer, brain metastasis, non-small 
cell lung cancer
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influence discussions and decisions about ACT in NSCLC.
Keywords: clinician preferences, adjuvant chemotherapy, non-
small cell lung cancer
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P1.12-011 PATIENTS‘ PREFERENCES FOR ADJUVANT 
CHEMOTHERAPY (ACT) IN EARLY NON-SMALL CELL 
LUNG CANCER (NSCLC): WHAT MAKES IT WOR-
THWHILE?
Sue-Anne Mclachlan1, Brett Hughes2, Catherine Crombie3, Tim 
Christmas4, Malcolm Hudson5, Chris Brown5, Anne-Sophie Veil-
lard5, Nick Muljadi5, Michael Millward6, Gavin Wright7, Peter 
Flynn8, Morgan Windsor9, Martin Stockler5, Prunella Blinman10
1Oncology, St Vincent‘s Hospital/Australia, 2Oncology, Prince Charles 
Hospital/Australia, 3Oncology, Nepean Hospital/Australia, 4Oncology, 
Auckland Hospital/New Zealand, 5Nhmrc Clinical Trials Centre/Aust-
ralia, 6University Of Western Australia/Australia, 7Cardiothoracic Sur-
gery, St Vincents Hospital/Australia, 8Cardiothoracic Surgery, Nepean 
Hospital/Australia, 9Cardiothroacic Surgery, Prince Charles Hospital/
Australia, 10Oncology, Concord Repatriation General Hospital/Australia
Background: ACT for NSCLC improves overall survival, but the 
benefits are modest and must be weighed against the harms 
and inconvenience of the treatment. The aim of this study was to 
determine the survival benefits judged necessary to make ACT 
worthwhile for patients with resected early NSCLC, and the factors 
associated with their judgments.
Methods: 122 patients considering ACT completed a self-admi-
nistered questionnaire at baseline (before ACT, if they were having 
it) and 6 months later (after ACT, if they had it). The time trade-off 
method was used to determine the minimum survival benefits jud-
ged sufficient to make ACT worthwhile in 4 hypothetical scenarios. 
Baseline survival times were 3 and 5 years and baseline survival ra-
tes (at 5 years) were 50% and 65%. All tests were 2-sided and non-
parametric. Determinants of preferences were assessed by (rank 
test) comparison of preferences in groups defined by each factor.
Results: Most patients were male (57%) with a median age of 63 
years (range, 43-79 years), married (72%) and previous smokers 
(81%). The majority had had a lobectomy (84%), adenocarcinoma 
histology (60%), and half had stage II disease (50%). 106 patients 
decided to have ACT (87%), 16 declined ACT (13%); female sex 
and age over 65 years were associated with declining. ACT was 
most commonly 4 cycles (68%) of cisplatin/ vinorelbine (73%). At 
baseline, the median benefit judged sufficient (by 50% of patients) 
was 9 months (IQR 1-12 months) beyond life expectancies of 3 
years and 5 years, and 5% (IQR 0.1-10%) beyond 5-year survival 
rates of 50% and 65%. Preferences varied across the entire range 
of possible benefits (from 0 days and 0% to an extra 15 years and 
50%). At baseline, deciding to have ACT (p=0.01) was the only 
factor that predicted judging smaller benefits sufficient to make 
ACT worthwhile. At 6 months (n=91), the median benefits judged 
sufficient were the same as at baseline (9 months & 5%), but pre-
ferences varied over a greater range (IQR’s 0-18 months & 0-15%). 
At 6 months, deciding to have ACT (p=0.02) and better physical 
(p=0.02), emotional (p=0.004), and overall well-being (p=0.004) 
during adjuvant chemotherapy were associated with judging smal-
ler benefits sufficient to make ACT worthwhile. Fatigue, nausea, 
sleeplessness and reduced appetite were the side effects of ACT 
vinorelbine in ACT of NSCLC. This study was supported by Grant 
NT-13569 and NS-9959-3 of the Czech Ministry of Health
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P1.12-010 LUNG CANCER CLINICIANS‘ PREFERENCES 
FOR ADJUVANT CHEMOTHERAPY (ACT) IN NON-
SMALL-CELL LUNG CANCER (NSCLC): WHAT MAKES IT 
WORTHWHILE?
Sue-Anne Mclachlan1, Brett Hughes2, Malcolm Hudson3, Chris 
Brown3, Anne-Sophie Veillard3, Nick Muljadi3, Catherine Crombie4, 
Tim Christmas5, Michael Millward6, Gavin Wright7, Peter Flynn8, 
Morgan Windsor9, Martin Stockler3, Prunella Blinman10
1Oncology, St Vincent‘s Hospital/Australia, 2Oncology, Prince Charles 
Hospital/Australia, 3Nhmrc Clinical Trials Centre/Australia, 4Oncology, 
Nepean Hospital/Australia, 5Oncology, Auckland Hospital/New Zeal-
and, 6University Of Western Australia/Australia, 7Cardiothoracic Sur-
gery, St Vincents Hospital/Australia, 8Cardiothoracic Surgery, Nepean 
Hospital/Australia, 9Cardiothroacic Surgery, Prince Charles Hospital/
Australia, 10Oncology, Concord Repatriation General Hospital/Australia
Background: Clinicians play an important role helping patients 
make decisions about ACT, but their views about trade-offs bet-
ween the benefits and harms of ACT may differ from those of their 
patients. We sought to determine the minimum survival benefits 
that lung cancer clinicians judged sufficient to make ACT in NSCLC 
worthwhile, the factors associated with these judgements, and 
comparisons with the preferences of their patients.
Methods: 82 lung cancer clinicians (medical oncologists & thoracic 
surgeons) completed a self-administered questionnaire. The time 
trade-off method was used to determine the minimum survival 
benefits judged sufficient to make ACT worthwhile in 4 hypotheti-
cal scenarios. Baseline survival times were 3 years and 5 years and 
baseline survival rates (at 5 years) were 50% and 65%. Patients’ 
preferences were those of 122 patients considering ACT for NS-
CLC elicited in a related study using similar methods. Differences 
between groups were assessed by 2-sample non-parametric tests. 
Determinants of preferences were assessed by univariable com-
parison after normal score transformation. Variance was assessed 
with the Ansari-Bradley rank test.
Results: Most clinicians were male (75%) with a median age of 
43 years (range 28-65), had 5 or more years of professional ex-
perience (69%), were married (92%), and had dependent children 
(72%). More were medical oncologists (63%) than thoracic surge-
ons (31%). The median benefit judged sufficient (by 50% of clini-
cians) was an extra 9 months (IQR 6-12 months) beyond survival 
times of both 3 years and 5 years, and an extra 5% (IQR 5-10%) 
beyond 5-year survival rates of both 50% and 65%. Medical onco-
logists, compared with thoracic surgeons, judged smaller benefits 
sufficient to make ACT worthwhile (median benefit 8 months v 12 
months, p=0.03). Clinicians’ preferences, compared with patients’ 
preferences, had the same median benefit (9 months survival time, 
5% survival rate) but varied over a smaller range (IQR, 6-12 months 
v 1-12 months, p<0.001; 5%-10% v 0.1-10% p<0.001).
Conclusion: Lung cancer clinicians judged moderate survival be-
nefits sufficient to make ACT in NSCLC worthwhile, but preferen-
ces differed according to specialty. Clinicians’ preferences were 
similar to patients’ preferences, but varied less. Lung cancer clinici-
ans should be mindful of their own preferences and how they may 
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patients with AD and SQ in the large-scale Japanese cohort. 
Especially, patients with stage I SQ showed a significantly worse 
outcome. Newly defined stage grouping applied for SQ patients 
provided comparable outcomes with those of AD patients. There-
fore, stage I disease of SQ may not be there.
Keywords: Adenocarcinoma, squamous cell carcinoma, TNM clas-
sification
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P1.12-013 LIMITED RESECTION FOR SOLID NON SMALL 
CELL LUNG CANCERS PROVIDES WORSE OUTCOME 
DESPITE OF CLINICAL EARLY STAGE.
Sook Whan Sung, Hyun Woo Jeon, Hyung Joo Park, Young Pil 
Wang, Jae Kil Park
Thoracic And Cardiovascular Department, Seoul St. Mary‘s Hospital/
Korea
Background: In recent years, Limited resection for ground glass 
opacity lesions is not inferior to lobectomy. However, the effect of 
limited resection on solid type early lung cancer is controversial. 
The aim of this study was to compare clinical outcomes of patients 
with solid type early stage non small cell lung cancer undergoing 
limited resection or lobectomy.
Methods: This is a retrospective study between March 2000 and 
September 2010. the patients with ground glass opacity lesion 
were excluded. Medical records of 164 patients with clinical stage 
IA were reviewed. 31 patients underwent limited resection and 133 
patients underwent Lobectomy Disease free survival and overall 
survival were estimated by Kaplan Meier methods Prognostic fac-
tors associated with disease free survival and overall survival were 
analyzed by the Cox proportional hazards model.
Results: Limited resection group had medical comobidities si-
gnificantly including old age (p<0.001), cardiovascular disease 
(p=0.001) and lower diffusing capacity of the lung for carbon 
monoide (p<0.001). The lobectomy was associated with longer 
disease free survival and overall survival (p=0.001) By multivariate 
analysis, Sublobar resection (p=0.011), lymphatic vessel invasion 
(p=0.006), and number of positive lymph nodes (p=0.028) were 
predictors for survival. Sublobar resection (p<0.001), visceral pleu-
ral invasion (p=0.002), and lymphatic vessel invasion (p<0.001) 
were predictors for disease-free interval.
Conclusion: Solid-type lung cancers demonstrated aggressive 
behavior and there were numerous significant pathologic prog-
nostic factors in clinical stage IA NSCLC from our study. Lymph 
node metastasis was not rare in clinical stage IA NSCLC with a 
solid component. Lobectomy with lymph node dissection remains 
the standard surgical procedure for patients with solid-type clinical 
stage IA NSCLC.
Keywords: limited resection, Non small cell lung cancer
that patients were most concerned about experiencing (at base-
line) and were rated the most troublesome (at 6 months).
Conclusion: Most patients judged moderate survival benefits suf-
ficient to make ACT worthwhile, but preferences varied widely and 
were not predicted by baseline characteristics. Preferences were 
stable over time. Patients with NSCLC judged larger benefits ne-
cessary for ACT than patients with breast and colon cancer in our 
previous studies. Clinicians should elicit the preferences of indivi-
dual patients when discussing and making decisions about ACT.
Keywords: non-small cell lung cancer, patient preferences, adju-
vant chemotherapy
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P1.12-012 A COMPARISON OF CLINICOPATHOLOGIC 
FEATURES AND SURVIVAL OUTCOMES BETWEEN THE 
LUNG CANCER PATIENTS WITH ADENOCARCINOMA 
AND SQUAMOUS CELL CARCINOMA: STAGE I DISEASE 
OF SQUAMOUS CELL CARCINOMA IS THERE?
Takayuki Fukui1, Yukinori Sakao2, Tetsuo Taniguchi1, Noriyasu 
Usami1, Koji Kawaguchi1, Futoshi Ishiguro1, Shota Nakamura1, 
Kohei Yokoi1
1Thoracic Surgery, Nagoya University/Japan, 2Department Of Thoracic 
Surgery, Aichi Cancer Center Hospital/Japan
Background: Patients with lung cancer should be treated diffe-
rently based on their histologic subtypes because of the disparities 
in tumor aggressiveness and treatment response. In addition to 
epidermal growth factor receptor tyrosine kinase inhibitor, recent 
chemotherapeutic agents such as pemetrexed and bevacizumab 
have dissimilar activities between adenocarcinoma (AD) and squa-
mous cell carcinoma (SQ). Therefore, it would be important to ree-
valuate the clinicopathologic features of the two major subtypes, 
both of which were classified as non-small cell lung cancer.
Methods: Between 1995 through 2012, 2412 patients with primary 
lung cancer underwent pulmonary resection in Nagoya University 
and Aichi Cancer Center Hospital. For the present study, a total of 
2057 patients with AD and SQ who underwent complete resection 
were extracted, and their clinicopathological features and outco-
mes were evaluated.
Results: The cohort consists of 1585 ADs (77%) and 472 SQs (23%). 
Female sex, no history of smoking and smaller size of the tumor 
were distinct characteristics of AD patients, and higher age was 
that of SQ patients (p < 0.0001). Pathological stage I disease was 
found in 70% of AD patients and 41% of SQ patients. Significant 
difference was observed for overall survival with the 5-year survival 
rate of 78% in AD patients and 63% in SQ patients. Limited to sta-
ge I disease, SQ patients also showed significant worse outcomes 
(p < 0.0001). Since no survival difference was observed between 
pN0 and pN1 patients with SQ (p = 0.39), we tried to regard the 
pN0 patients as pN1 and restage them according to the newly 
defined N status. Thirty-seven stage IA and 42 stage IB patients 
were upstaged to stage IIA, 36 stage IB patients to stage IIB, and 
47 stage IIB patients to stage IIIA. As a result, comparable survival 
curves were obtained between AD and SQ patients in stage II and 
IIIA.
Conclusion: We identified some significant differences between 
S627Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 1 - NSCLC EARLY STAGE  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.12-015 PROGNOSTIC IMPACT OF THE AMOUNT OF 
TOBACCO SMOKING IN PATIENTS WITH RESECTED 
NON-SMALL CELL LUNG CANCER
Tatsuro Okamoto, Yuzo Suzuki, Takatoshi Fujishita, Hirokazu 
Kitahara, Shinichiro Shimamatsu, Mikihiro Kohno, Yosuke Moro-
domi, Daigo Kawano, Yoshihiko Maehara
Department Of Surgery And Science, Graduate School Of Medical Scien-
ces, Kyushu University/Japan
Background: The purpose of this study was to investigate the 
relationship between the amounts of tobacco smoking and the 
clinicopathological features of non-small cell lung cancer (NSCLC) 
patients.
Methods: We retrospectively reviewed the clinical records of 1825 
consecutive NSCLC patients who underwent surgery in our depart-
ment. Among them, the data sets of 363 squamous cell carcinoma 
(Sq) patients and 720 adenocarcinoma (Ad) patients who recei-
ved lobectomy or more extensive resection were available. The 
definitions of smokers used in the study were: light smoker had a 
smoking history of 30 pack-years (PY) or less, heavy smokers had 
a history of more than 30 to 60 PY and super-heavy smokers had 
a history of more than 60 PY. The survival curves were estimated 
according to the Kaplan-Meier method and were assessed by the 
log-rank test. A multivariate survival analysis was performed using 
the Cox proportional hazards model. Differences were considered 
to be statistically significant for values of P < 0.05.
Results: There were more male patients, more aggressive ope-
rations (bi-lobectomy or pneumonectomy) and heavier smokers 
in the Sq patients than Ad patients (p< 0.0001, p=0.012 and 
p<0.0001). In Ad patients, the never-smokers (n=309) were more 
likely to be female, to have less advanced stage tumors and had 
a significantly better prognosis than ever-smokers (n= 441) (five-
year OS: never-smokers, 67.9%; smokers, 53.7%, p<0.0001). In Sq 
patients, the never-smokers (n=15) were more likely to be female 
than the ever-smokers (n=348). There was no significant prognostic 
difference between never-smokers and ever-smokers in the Sq 
patients (five-year OS: never-smokers, 28.6%; ever-smokers, 46.7%, 
p=0.36). Among ever-smokers, the light-smokers (n=56) had more 
female patients, more advanced stage tumors and a significantly 
worse prognosis than heavy smokers (n=292) (p = 0.0003). The 
multivariate survival analysis showed that light smoking was related 
to a worse prognosis compared to heavy smoking (HR=2.06, 96%CI 
1.43-2.98, p=0.0001).
Conclusion: The never-smokers had a better prognosis than ever-
smokers in Ad patients, whereas the light-smokers (PY ≤ 30) had a 
significantly worse prognosis than heavier smokers (PY > 30) in Sq 
patients. There might be other factors than tobacco carcinogens 
that influence the development of squamous cell carcinoma in light 
smokers.
Keywords: surgery, Smoking, Prognosis, non-small cell carcinoma
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P1.12-014 LYMPH NODE DISECTION AND MEDIASTINAL 
RECURRENCE IN EARLY STAGE NSCLC
Laura Romero Vielva, Ricardo Zapata Gonzalez, Joan Solé Monts-
errat, María Deu Martín, Javier Pérez Vélez, Iker López Sanz, 
Alberto Jáuregui Abularach, Manuel Wong Jaen, Irene Bello Rod-
riguez, Mercedes Canela Cardona
Thoracic Surgery, Vall D‘hebron University Hospital/Spain
Background: The aim of this paper was to evaluate survival accor-
ding to tumor size, and the extent of mediastinal lymphadenecto-
my. Besides, we analyzed if a more extensive lymphadenectomy, 
based on the number of lymph nodes (LN) obtained, improves 
survival in early stages.
Methods: Retrospective review of 620 consecutive early stage 
NSCLC patients operated between 1995 and 2008. None of the 
patients underwent neoadyuvant treatment. T1 and T2 patients 
were divided in two subgroups, according to the number of LN 
resected (0-5, 6-10, ³11).
Results: We analyzed a total of 8.484 LN resected and an average 
of 13.68 (0-48). The majority of patients were male (86%) with a 
mean age of 65 (33-84). Mean follow-up was 52.6 months. Mean 
time to relapse was 28.6 months. SCC was the commonest histolo-
gy (47.4%). Lobectomy was the commonest resection (81.6%) and 
56.3% of the patients were staged as T2N0. 5-year overall survival 
was 53%. Mean survival according to size was 9.9 and 5.6 years 
(T1 and T2 respectively). In-Hospital mortality was 2.7%. Mean 
survival according to N factor was 6.3 and 4.1 years (N0 and N1 
respectively). 67% of the patients had mediastinal recurrence. The 
number of positive LN increased with the number of LN removed 
(26.4% vs 9.3% and 10.5%;p <0.001). The analysis showed that 
patients with more LN resected tend to have better survival (7.5 
years, 7.8 years and 8 years; p=0.21). Data were similar if when 
analyzing LN resected from N2 stations. Survival was significantly 
worse in the group with positive LN (8.1 vs 2 years). The group with 
more N2 LN resected had significantly less mediastinal recurrence 
(16.3%, 9.2% vs 5.9%; p<0.002).  
MEDIASTINAL RECURRENCE 
RESECTED LYMPH 
NODES 
NO YES 
0-5 (N= 458) 190 (83,7%) 37 (16,3%) 
6-10 (N = 152) 187 (90,8%) 19 (9,2%) 
³11 (N=174) 176 (94,1%) 11 (5,9%) 
 
Conclusion: The probability of finding some positive mediastinal 
lymph node increases with a more extensive lymphadenectomy. A 
complete mediastinal lymphadenectomy provides a better staging 
and decreases mediastinal recurrence. A complete lymphadenec-
tomy should be performed in all lung cancer patients to achieve a 
correct staging and a better survival, even in those with an early 
stage.
Keyword: NSCLC, early stage, lymphadenectomy
S628 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Conclusion: The incidence of ALK positive in completely resected 
NSCLC in northern Thailand is 8.2 % by IHC method. Age less than 
55 years and simultaneous multiple sites of tumor recurrence are 
predictive factors of ALK positive. Other clinicopathologic factors 
are neither predictive factors nor prognostic factors for ALK positi-
ve. Validation of IHC positive cases with fluorescence in situ hybri-
dization (FISH) is being conducted.
Keywords: anaplastic lymphoma kinase (ALK), NSCLC, Immunohis-
tochemistry (IHC)
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P1.12-017 A PHASE IB PREOPERATIVE PHARMACOKINE-
TIC AND PHARMACODYNAMIC STUDY OF EVEROLIMUS 
IN OPERABLE NON SMALL CELL LUNG CANCER
Taofeek K. Owonikoko1, Daniel L. Miller1, Seth Force1, Gabriel Sica1, 
Nabil F. Saba1, Scott A. Kono1, Madhusmita Behera1, Colleen Le-
wis1, Zhengjia Chen1, Alan Pickens1, Jennifer Mendel1, William F. 
Auffermann1, Jaqueline W. Rogerio2, William E. Torres1, R Donald 
Harvey1, Haian Fu1, John A. Hohneker2, Shi-Yong Sun1, Anthony A. 
Gal1, Suresh S. Ramalingam1, Fadlo R. Khuri1
1Emory University/United States Of America, 2Novartis Oncology/Uni-
ted States Of America
Background: We conducted this ‘window- of-opportunity’ study 
to characterize the biologic activity of everolimus, an allosteric 
inhibitor of mTOR pathway, in patients with surgically resectable 
NSCLC.
Methods: Patients with surgically resectable NSCLC (Stage I-III) 
underwent baseline tumor biopsy and FDG PET/CT scan followed 
by treatment with everolimus (5 or 10mg daily for up to 28 days). 
A repeat PET/CT scan was obtained 24 hours prior to surgery. 
Blood samples for pharmacokinetic (PK) assay for drug levels were 
collected at 0.5, 1, 2, 5, 8 and 24 hours post drug ingestion on 
Days 1, 8 and 21. Control patients not treated with everolimus also 
had paired FDG PET/CT scans prior to surgery. Pharmacodynamic 
(PD) effect of everolimus was assessed in vivo by PET and ex vivo 
by immunohistochemical detection of total and phosphorylated 
mTOR, Akt, S6, eIF4e and 4EBP1 in pretreatment and posttreat-
ment tissue samples. Alterations in common driver mutations in 
NSCLC were assessed using SnapShot multiplex minisequencing 
technique. Statistical comparisons by T-Test, ANOVA, Wilcoxon 
signed rank test or Kruskal-Wallis test were performed as approp-
riate using SAS statistical package V9.3. The significance level was 
set at 0.05 for all tests.
Results: We enrolled 33 patients; 23 on everolimus and 10 on 
the control arm. Median age: 64 yrs (range 36-77), gender: (14/19 
-M/F), stage (I - 14; II - 13; IIIA - 6); histology (adenocarcinoma - 22; 
squamous - 7; others - 4). Treatment was tolerated well with mostly 
grade 1/2 anticipated toxicities (hyperglycemia, hypertriglyceride-
mia, stomatitis, anemia and fatigue) and 32 of 33 patients procee-
ded with surgery on schedule. Compared to controls, there was 
significant reduction in SUVmax and median anatomic tumor size 
in a dose-dependent manner in everolimus-treated patients (15.38 
vs. -21.74 vs. -23.23; p=0.012 and 4.39 vs. 0 vs.-13.33; p=0.039 
in the control, 5mg and 10mg cohorts respectively). There was a 
similar trend in reduced metabolic activity in Ras mutant tumors 
treated with 10mg everolimus compared to control (88% vs. -28%). 
Comparison of baseline biopsy samples and resected tumor spe-
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P1.12-016 RETROSPECTIVE STUDY OF ALK EXPRESSION 
AND CLINICAL IMPLICATIONS IN COMPLETELY RESEC-
TED NON-SMALL CELL LUNG CANCER PATIENTS IN 
NORTHERN THAILAND
Apichat Tantraworasin
Surgery, Chiang Mai University Hospital/Thailand
Background: Correlation between clinicopathologic features 
and prognostic implications of anaplastic lymphoma kinase (ALK) 
gene rearrangement in non-small cell lung cancer (NSCLC) has 
been intensively studied. Thailand is one of the high prevalence 
of NSCLC, therefore the Northern Thailand Thoracic Oncology 
Group (NT-TOG) would like to identify the incidence of ALK rear-
rangement which might be different from Western and predictive 
or prognostic factors for ALK positive in resectable NSCLC in nort-
hern Thailand.
Methods: From January 2008 to December 2012, 266 completely 
resected NSCLC patients in Chiang Mai University Hospital were 
enrolled in this study. General characteristics, histo-pathologic re-
sults and clinical outcomes were retrospectively reviewed from the 
computerized medical records. Anatomical resection (lobectomy 
or pneumonectomy) with systematic mediastinal lymphadenecto-
my was performed in all cases. Immunohistochemistry (IHC) me-
thod with mouse monoclonal, clone 5A4, Ventana D5F3 antibody 
using a Ventana automated immunostainer (Ventana Medical Sus-
tems, Tucson, AS) by optiview detection system was used to evalu-
ate ALK rearrangement in all pathological specimens. The positive 
stained cancer cells were collected. Multivariable logistic regressi-
on analysis was used to identify the clinico-pathological correlation 
with positive results of IHC.
Results: Twenty-two (8.2 %) of 267 specimens were ALK IHC-
positive with intense cytoplasmic staining. Age less than 55 years 
(Diagnostic odds ratio (DOR) of 7.3, 95 % confidence interval (CI) of 
2.0-26.4, p-value of 0.002) and simultaneous multiple sites of tu-
mor recurrence (DOR of 5.3, 95 % CI of 2.9-9.8, p-value of < 0.001) 
were identified as predictive factors of ALK positive from IHC. 
Female seem to be predictive factor for ALK positive but there is 
no statistically significant difference. There were no statistically si-
gnificant differences in term of histology, tumor grading, stages of 
disease, tumor recurrence, intratumoral lymphovascular invasion, 
ERCC1 and RRM1 expression, EGFR mutation and overall survival 
between ALK positive and ALK negative. Table1 Multivariable logi-
stic regression analysis of predictive factors of ALK positive  
Covariates 
Diagnostic Odd 
Ratio (DOR) 
95% Confidence 
Interval 
P-value 
Age < 55 years 7.3 2.0-26.4 0.002 
Female 2.0 0.9-5.0 0.123 
Visceral pleural 
invasion 
3.9 0.9-16.2 0.061 
Intratumoral 
lymphatic inva-
sion 
4.0 0.4-37.1 0.222 
Multiple site of 
recurrence 
5.3 2.9-9.8 <0.001 
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Conclusion: Smoking status was not associated with overall survi-
val across the entire cohort. In patients whose tumour harboured a 
mutation, increased smoking was associated with a less favourable 
mutation profile including in KRAS, TP53 and PIK3CA. In patients 
with pN0 disease a significant difference in overall survival was 
observed favouring light smokers. The presence of mutations in 
association with heavy smoking negatively impacts overall survival.
Keyword: Smoking, survival, resectable lung cancer
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P1.12-019 SURVIVAL ANALYSIS OF 106 FEMALE PATI-
ENTS WITH COMPLETELY RESECTED LUNG ADENOCAR-
CINOMA IN SHAANXI PROVINCE
Yun Dai, Yanfei Cao, Wei Li, Wei Tian, Yawei Dou, Xianghui Luo, 
Shudong Li, Hongtao Wang
Department Of Thoracic Surgery, Shaanxi Provincial People’s Hospital/
China
Background: The female patients with Non-small cell lung cancer 
in China have higher mortality than in the most of other countries. 
And the main pathological type is adenocarcinoma. Even though 
after complete resection, these patients still have an unsatisfactory 
prognosis. We retrospectively analyzed prognostic factors of 106 
female patients with completely resected lung adenocarcinoma in 
Shaanxi province to find patients with unfavorable factors for pro-
per management.
Methods: Clinical data of 106 female patients with complete 
resection of lung adenocarcinoma at Shaanxi Provincial People’s 
Hospital between January 2003 and December 2010 were revie-
wed retrospectively and analyzed the effect of factors about age, 
with symptoms or not, operation types, the maximum-diameter 
of tumor, postoperational pathological stage, dissected lymph 
nodes, the adjuvant therapy and the recurrence or metastasis on 
5-year overall survival(OS). Cumulative survival was analyzed by the 
Kaplan-Meier method and compared by log-rank test. Prognosis 
was analyzed by the Cox proportional hazards model.
Results: The overall 5-year survival rates were 57.0%. 38(35.8%) of 
the 106 patients had recurrence or metastasis. A univariate analysis 
demonstrated that age(>54 years), postoperational pathological 
stage, the total number of removed lymph nodes(>12), the total 
number of removed N1 lymph nodes(>7), the total number of 
removed N2 lymph nodes(>7), the number of involved N2 lymph 
nodes(>2), removed N2 stations(>2), the adjuvant therapy and the 
recurrence or metastasis were significant prognostic factors for 
cimens in control and everolimus-treated patients showed reduc-
tion of S6 (-27.38 vs. 0 vs. -78.95; p=0.0536), pS6 (-20 vs. -29.17 vs. 
-57.14 ; p=0.0233) and p4EBP1 (-45.83 vs. 0 vs. -75; p=0.057) with 
greatest reduction observed in patients treated with higher dose 
of everolimus.
Conclusion: Everolimus exerts a measurable, dose-dependent 
biologic activity in NSCLC. ‘Window of opportunity’ studies in ear-
ly stage NSCLC can provide strong mechanistic insights to guide 
optimal development of novel targeted agents.
Keywords: mTOR, everolimus, Phase I, Lung cancer
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P1.12-018 OVERALL SURVIVAL AND SMOKING STATUS 
IN RESECTABLE NON-SMALL CELL LUNG CANCER
Lavinia Spain1, Marzena Walkiewicz2, Simon Knight3, Paul Mit-
chell4, Thomas John4
1Medical Oncology, Austin Health/Australia, 2Ludwig Institute For 
Cancer Research/Australia, 3Thoracic Surgery, Austin Health/Australia, 
4Joint Austin-ludwig Oncology Unit, Austin Health/Australia
Background: Although the carcinogenic effects of cigarette smo-
king are important in the pathogenesis of lung carcinoma, the 
impact of quantitative smoking history on survival in resectable 
tumours has not been well described. Using a comprehensive da-
tabase in which smoking was quantitatively documented, we ana-
lysed the impact of increasing number of pack years of smoking on 
stage, histology, mutation status and overall survival in an Australi-
an population. We focused on patients without nodal involvement 
(N0) as they were less likely to have received neoadjuvant or adju-
vant therapy.
Methods: Data was extracted from a large single institution data-
base containing information on patients who underwent curative 
resection of non-small cell lung cancer from 1992 to 2012. Ciga-
rette smoking history was documented in pack years. DNA was 
isolated and analysed using Sequenom’s LungCarta panel which 
interrogates 214 mutations in 26 genes. Statistical analysis was 
performed using Chi-square tests and the Kaplan Meier method 
for survival.
Results: Information on pack year smoking status was available 
for 470 patients, 70% of whom were male. This included 311 (66%) 
pathological N0 (pN0), 64 (14%) pN1 and 95 (20%) pN2. Smoking 
history ranged between 0 (never smokers N=32, 7%) and 180 pack 
years, with a median of 45 and mean of 48. Patients were divided 
into quartiles based on their smoking history: never- and < 10 pack 
year smokers (N=43; 9%), 11-25 pack years (N=74; 16%), 26-50 pack 
years (N=180; 38%) and >50 pack years (N=173; 37%). Adequate 
DNA was isolated in 425 samples. Frequencies of mutations were 
as follows: KRAS 21%, TP53 10%, EGFR 5%, PIK3CA 4%; other 
mutations occurred at lower frequencies. In 44% no mutation was 
found. Increased pack year history of smoking was not associated 
with overall survival. In the pN0 wild type population, no associ-
ation with smoking and survival was seen. In the pN0 mutation 
group (Figure 1) those with a <25 pack year history had significant-
ly better overall survival than heavier smokers (HR 0.61, 95% CI 
0.40-0.92). Figure 1: Overall Survival by smoking status in pN0 
tumours with a mutation
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in the current clinical setting, to identify potential reasons that may 
inhibit the popularization of the VATS lobectomy technique, and to 
hypothesize potential strategies that can advance this field in the 
future.
Methods: Participants included thoracic surgeons identified 
through an index search from the Web of Science and the car-
diothoracic surgery network. A confidential questionnaire was 
emailed in June, 2012. Non-responders were given two reminder 
emails at monthly intervals.
Results: 838 thoracic surgeons completed the questionnaire within 
a three-month period, including 416 surgeons who only performed 
lobectomy through open thoracotomy and 422 surgeons who per-
formed VATS or robotic-VATS. Two sets of standardized question-
naires were completed by these two groups. Ninety-five percent of 
VATS surgeons agreed with the definition of ‘true’ VATS lobectomy 
according to the CALGB trial. Ninety-two percent of surgeons 
who did not perform VATS lobectomy were prepared to learn 
this technique, but were hindered by limited resources, exposure 
and mentoring. Both groups believed VATS lobectomy should be 
incorporated into thoracic surgical training and for more standar-
dized workshops to be made available. Figure 1. Survey responses 
for surgeons who performed video-assisted thoracoscopic surgery 
lobectomy (n=422) 
Conclusion: The X-SOLA study represents the largest cross-sec-
tional report within the thoracic community to date, demonstrating 
the current status of clinical practice of lobectomy approach for 
NSCLC worldwide and identifying areas in need of further deve-
lopment.
Keywords: VATS, Cross sectional survey, surgery, NSCLC
5-year OS. In the multivariate analysis, the total number of remo-
ved N2 lymph nodes(>7) and the recurrence or metastasis were 
independent prognostic factors for 5-year OS.
Conclusion: For female patients with completely resectable lung 
adenocarcinoma in Shaanxi province, it is very important to give 
systematic mediastinal lymphadenectomy,7 and more N2 lymph 
nodes should be removed during surgical resection. The individual 
adjuvant therapy and the intensive follow-up should be given to 
the patients with the high risk for the recurrence or metastasis. 
Total number of removed N2 lymph nodes >7 was the favorable 
prognostic factor and the recurrence or metastasis was the adver-
se one.
Keywords: surgery, multivariate analysis, lung adenocarcinoma, 
Female
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P1.12-020 CROSS-SECTIONAL SURVEY ON LOBECTOMY 
APPROACH (X-SOLA)
Christopher Cao1, David Tian1, William Walker2, Tristan D. Yan1
1Systematic Reviews Unit, Collaborative Research Group/Australia, 
2Cardiothoracic Surgery, Royal Infirmary Of Edinburgh/United Kingdom
Background: To improve the understanding of current attitudes of 
the thoracic community to video-assisted thoracoscopic surgery 
(VATS) lobectomy, the Collaborative Research Group conducted 
the Cross-sectional Survey On Lobectomy Approach (X-SOLA) 
study. The aim was three-fold: to assess the practice of lobectomy 
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Figure 1. The ROC curves of our model, the VA model and the 
Fudan model for all patients of group B. The AUC of our model 
was 0.786 (95% CI, 0.690-0.881); the VA model was 0.673 (95% CI, 
0.554-0.792); the Fudan model was 0.757 (95% CI, 0.659-0.885).
Conclusion: Our prediction model estimated the pretest probabi-
lity of N2 disease in computed tomography–defined stageINSCLC 
and was more accurate than the existing models. Use of our model 
can be of assistance when making clinical decisions about invasive 
or expensive mediastinal staging procedures.
Keywords: Lung cancer, Prediction model, N2 lymph node  
metastasis
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P1.12-022 PREDICTIVE VALUE OF SUV MAX/INVASIVE 
SIZE RATIO IN THE SUBTYPES OF LUNG ADENOCARCI-
NOMA
Eunjue Yi, Yangki Seok, Jayoung Lee, Hee Chul Yang, Kwhanmien 
Kim, Sanghoon Jheon, Sukki Cho
Department Of Thoracic And Cardiovascular Surgery, Seoul National 
University Bundang Hospital/Korea
Background: In lung adenocarcinoma, prognostic importance of 
maximum standardized uptake (SUV max) value on positron emis-
sion tomography (PET) has been well observed. Different subtypes 
had different 18F-fluorodeoxyglucose (FDG) uptake, and it was 
also related with tumor size. The ratio of SUV max and tumor size 
was supposed to be different depending on the subtypes of lung 
adenocarcinoma.
Methods: Medical records of the lung adenocarcinoma patients 
who underwent surgery in Seoul National University Bundang 
Hospital between 2003 and 2012 were reviewed. Ratio of SUV 
max and invasive tumor sizes was calculated and categorized into 
two groups. Group 1 included patients of ratio < 1.5, and Group 
2 included the rest. The subtypes of lung adenocarcinoma were 
categorized into 4 groups; solid, acinar, lepidic, papillary according 
to their pathologic reports. Overall survival and disease-free sur-
vival rates of Group 1 and 2 were compared in each predominant 
subtype patients.
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P1.12-021 DEVELOPMENT AND VALIDATION OF A CLI-
NICAL PREDICTION MODEL FOR N2 LYMPH NODE ME-
TASTASIS IN STAGE I NON-SMALL CELL LUNG CANCER
Kezhong Chen, Guanchao Jiang, Jianfeng Li, Jun Wang
Peking University People‘s Hospital/China
Background: The true incidence of occult N2 lymph node me-
tastasis in patients with clinical stageInon-small cell lung cancer 
(NSCLC) remains controversial. Estimation of the probability of N2 
lymph node metastasis can assist physicians when making diagno-
sis and treatment decisions.
Methods: We reviewed the medical records of 739 patients with 
computed tomography–defined N0 NSCLC that had an exact 
Tumor-Node-Metastasis stage after surgery. A random subset of 
three fourths of the patients (n=554) were selected to develope 
the prediction model. Logistic regression analysis of the clinical 
characteristics was used to estimate the independent predictors of 
N2 lymph node metastasis. A prediction model was then built and 
internally validated by using cross validation and externally valida-
ted by the remaining one fourth(n=185) patients which made up 
the validation data set. The model was also compared to 2 previ-
ously described models.
Results: We identified 4 independent predictors of N2 disease: a 
younger age, larger tumor size, central tumor location, and ade-
nocarcinoma or adenosquamous carcinoma pathology. The model 
showed good calibration (Hosmer–Lemeshow test: P = .92) with 
an area under the receiver operating characteristic curve (AUC) of 
0.748 (95% confidence interval, 0.687-0.809). The AUC of our mo-
del was better than those of the other two models when validated 
with independent data.  
Table 1 . Multivariate Logistic Regression Analysis
Variable
Regressi-
on Coef-
ficient
P OR 95%CI Lower 
95%CI 
Upper 
Age -0.032 0.007 0.969 0.957 0.981
Tumor 
Size
0.456 <0.001 1.577 1.449 1.705
Central 1.753
<0.001 5.771 
5.453 6.089
Ade-
nocarci-
noma /
mixed
1.787 <0.001 5.970 5.546 6.394
Constant -2.983 0.001 0.051
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analysis. TNM stage (II-III vs. I) (P = 0.005) was still a significant pre-
dictive factor of freedom from recurrence in multivariate analysis. 
Conclusion: The overall survival and freedom from recurrence 
rates were good in lepidic predominant adenocarcinoma. TNM 
stage (II-III vs. I) was a significant predictive factor of freedom from 
recurrence in these patients.
Keywords: Recurrence, lepidic predominant, Adenocarcinoma
Results: Total number of patients was 680. The average ratio of 
SUV max/invasive size was 1.63. The ratio of SUV max/invasive size 
of solid subtype was 2.48 and it was significantly higher than acinar 
and lepidic subtypes. (p<0.000) Overall survival (OS) and disease-
free (DF) survival of lepidic subtype were 39.3 months and 41.4 
months each, and were significantly higher than solid and acinar 
subtypes. OS and DF of Group 1 were 36.4 and 32.8 each. Those 
of Group 2 were 29.8 and 21.6 months. Group 1 had significantly 
longer OS and DF than Group 2. (p<0.000, and p=0.001 each) In 
solid subtype, OS and DF of Group 1 were 32.8 and 27.7 months 
and those of Group 2 were 22.7 and 17.6. But there were no signifi-
cant differences. (p=0.117 and p=0.123 each) In acinar subtype, OS 
and DF of Group 1 were 38.2 and 34.4 months, those of Group 2 
were 32.9 and 24.3 months. The differences were statistically sig-
nificant. (p<0.000, p=0.023, each) Three-year overall survival rates 
and 3-year disease-free survival of Group 1 were 45.2% and 39.1%. 
Those survival rates of Group 2 were 32.2% and 19.2% respec-
tively. Recurrence hazard ratio of Group 2 was 1.68. (p<0.000, 95% 
confidence interval 1.379-2.061) In acinar subtype, recurrence ha-
zard ratio of Group 2 was 1.83 and there was significant difference. 
(95% confidence interval: 1.410-2.381, p< 0.000) In other subtypes, 
recurrence hazard ratio showed no significant differences.
Conclusion: Ratio of SUV max and invasive tumor size had limited 
prognostic value in subtypes of lung adenocarcinoma. It could be 
used as a prognostic factor for recurrence in acinar predominant 
subtype category.
Keywords: lung adenocarcinoma, SUV max, prognostic factor
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P1.12-023 PREDICTIVE FACTORS OF RECURRENCE IN 
LEPIDIC PREDOMINANT LUNG ADENOCARCINOMA
Jung-Jyh Hung, Wen-Hu Hsu, Yu-Chung Wu
Taipei Veterans General Hospital/Taiwan
Background: The new International Association for the Study of 
Lung Cancer, American Thoracic Society and European Respiratory 
Society (IASLC/ATS/ERS) lung adenocarcinoma classification has 
been proposed in 2011. The aim of the study is to demonstrate the 
prognostic factors and pattern of recurrence in lepidic predomi-
nant lung adenocarcinoma.
Methods: We retrospectively reviewed 545 patients undergoing 
surgical resection for lung adenocarcinoma in Taipei Veterans 
General Hospital between 2006 and 2010. Fifty-two patients with 
lepidic predominant lung adenocarcinoma were identified. The 
predictive factors and pattern of recurrence of these patients were 
investigated.
Results: The 5-year overall survival and recurrence-free rates were 
84.0% and 83.0%, respectively. During follow-up, 7 (13.5%) pati-
ents developed recurrence. The median time to recurrence was 
28.7 months (range, 10.6 to 57.8 months). The percentage of T2-4 
(P = 0.003), N1-2 (P < 0.001), TNM stage II-III (P < 0.001), and vis-
ceral pleural invasion (P = 0.049) was significant higher in patients 
with recurrence. N status (N1-2 vs. N0) (P < 0.001), TNM stage (II-III 
vs. I) (P < 0.001) were significant prognostic factors of freedom 
from recurrence in univariate analysis. Visceral pleural invasion (P = 
0.093) and presence of solid pattern (P = 0.089) tended to be sig-
nificant prognostic factors of freedom from recurrence in univariate 
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and colony-stimulating factors (CSFs) are not currently indicated. 
The novel mechanism of action, and particularly the lack of Pt 
cross-resistance, is of interest in this patient population. These 
results warrant further study of the potential role of this regimen in 
relapsed SCLC pts.
Keywords: Second line, SCLC, chemotherapy, New drug
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P1.13-002 PROGNOSTIC VALUE OF 18F-FLUORODEOXY-
GLUCOSE UPTAKE IN SMALL CELL LUNG CANCER PATI-
ENTS TREATED WITH CONCOMITANT CHEMO-RADIO-
THERAPY OR CHEMOTHERAPY ALONE
Krystel H. Tran1, David Binns2, Sze Ting Lee3, Mathias Bressel4, 
Arun Azad5, Ashley Cox6, Andrew Scott3, Rod Hicks2, Benjamin 
Solomon5, Michael Macmanus6, David Ball6
1Radiation Oncology, PeterMacCallum Cancer Centre/Australia, 2Nuc-
lear Medicine, Peter MacCallum Cancer Centre/Australia, 3Centre For 
Pet, Austin Hospital/Australia, 4Biostatistics Centre For Biostatistics 
And Clinical Trials, Peter MacCallum Cancer Centre/Australia, 5Depart-
ment Of Medical Oncology, Peter MacCallum Cancer Centre/Australia, 
6Dept. Radiation Oncology, Peter MacCallum Cancer Centre/Australia
Background: There is some evidence that the standard uptake 
value (SUV) measured using 18F- fluorodeoxyglucose positron 
emission tomography (18FDG-PET) in patients with non-small cell 
lung cancer (NSCLC) may be prognostic for survival. Small cell lung 
cancer (SCLC) clinically differs from NSCLC by its rapid proliferation 
and is staged as either limited disease (LD) defined as disease con-
fined to one hemithorax and the regional lymph nodes or extensive 
disease (ED) which is disease that has spread beyond this. There is 
much less information available on the potential prognostic value of 
the SUV obtained during 18FDG-PET scanning in SCLC. This study 
thus aims to explore whether SUV can be effective in the prog-
nostic stratification of SCLC patients with LD and ED.
Methods: Retrospective study of patients diagnosed with SCLC 
who underwent a pre-treatment 18FDG-PET scan between 1999 
– 2008 at the Peter MacCallum Cancer Centre and 2004 -2011 
at the Austin Hospital. Patients with LD were treated with radical 
concomitant chemo-radiotherapy and those with ED treated with 
chemotherapy alone. Maximum and mean SUVs were retrieved, 
and survival of patients measured. The correlation between SUV 
and other patients’ clinicopathological factors, including age, sex, 
performance status, weight loss and tumour stage (TNM) were also 
explored.
Results: Thirty-six eligible patients were identified, with a medi-
an follow-up of 14 months (range, 3-103 months). There were 23 
males and 13 females. The median age was 69 years (55-84 years). 
Twenty patients had LD and 16 had ED. Thirteen patients had stage 
IV disease and 10 patients each had stage IIIA and IIIB disease (3 
patients were unable to be staged according to TNM classification 
system). Higher TNM stage was associated with higher SUVmax 
(rs=0.37, p=0.036) but not with SUVmean (rs=0.30, p=0.086). There 
was no evidence of a significant association between clinicopatho-
logical factors with SUVmax in patients with LD and ED, except for 
age in patients with ED. Increasing age was associated with higher 
SUVmax (rs=0.72, p=0.002) and higher SUVmean in patients with ED 
(rs=0.81, p<0.001). SUVmax and SUVmean were not significantly as-
sociated with OS in patients with LD or ED or in the whole sample.
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P1.13-001 CLINICAL ACTIVITY OF LURBINECTEDIN 
(PM01183) IN COMBINATION WITH DOXORUBICIN 
(DOX) IN SMALL CELL LUNG CANCER (SCLC) PATIENTS 
(PTS): PRELIMINARY RESULTS OF A PHASE IB STUDY 
SUBPOPULATION ANALYSIS.
M Forster1, E Calvo2, S Szyldergemajn3, V Boni2, S Benafif1, C Fern-
andez3, S Turnbull1, A Cubillo2, M Flynn1, A Velasco Sampayo3, A 
Soto Matos-Pita3
1University College Of London Hospital/United Kingdom, 2Start Madrid, 
Centro Integral Oncológico Clara Campal/Spain, 3Pharmamar/Spain
Background: PM01183 is an inhibitor of transactivated transcrip-
tion and also acts on the tumor microenvironment. It lacks cross-
resistance with platinum (Pt) agents whereas strong synergism 
with DOX has been observed preclinically. Single agent PM01183 
clinical evaluation in non-small cell lung cancer (NSCLC), pancrea-
tic, ovarian and breast cancer patients (pts) is ongoing. Reversible 
myelosuppression and high emetogenic potential are common 
side effects.
Methods: Consenting adults with selected solid tumors, including 
SCLC, and ≤ 75 years, Eastern Cooperative Oncology Group per-
formance status (ECOG PS) 0-1, adequate organ function and up 
to 2 prior chemotherapy-containing (CT) lines were included in 
successive cohorts aiming to primarily define the recommended 
dose (RD) of PM01183 and DOX (50 mg/m2, fixed dose) combina-
tion every three weeks (q3wk). No prior DOX was allowed in the 
metastatic setting. DOX had to be discontinued once a maximal 
cumulative dose of 450 mg/m2 during treatment was reached. 
Available results in the SCLC population are presented here.
Results: Recruitment was closed in December 2012; 13 of 43 en-
rolled/treated pts (30%) had SCLC diagnosis. Of these, 8 (62%) 
were males. Median age was 58 years (r: 48-73). Ten (77%) and 2 
pts (15%) were chemo-refractory or had known central nervous 
system (CNS) involvement, respectively. Five of 12 pts evaluable 
for efficacy [Response Evaluation Criteria In Solid Tumors (RECIST) 
v.1.1] were responders, for an overall response rate (ORR) of 42% 
[95% confidence interval (CI): 15-72]. No responses occurred in pts 
with >1 prior CT lines (n=5). In evaluable pts with 1 prior CT line 
(n=7), the ORR reached 71% (95%CI: 29-96). All chemosensitive 
pts (n=3) responded to treatment. Severe myelosuppression, G3/4 
neutropenia or thrombocytopenia, was observed in 89/22% of pts, 
respectively. Other toxicities, in ≥ 10% of pts, were generally mild 
and included transaminase increases, fatigue, alopecia, mucositis, 
nausea/vomiting, diarrhea, anorexia and constipation. No cardiac 
toxicity was observed. Febrile neutropenia (FN) occurred in 11% 
of pts. Overall, 2 pts discontinued treatment due to toxicity (pneu-
monia; and repetitive myelosuppression despite successive dose 
adjustments, respectively). No treatment-related deaths occurred. 
The RD was defined as PM01183 4.0 mg and DOX 50 mg/m2 q3wk.
Conclusion: PM01183 and DOX resulted in relevant activity in 
SCLC patients with less than 2 prior CT-lines. Toxicity with this 
combination seems both manageable and predictable. Despite 
the high level of myelosuppression, FN was relatively uncommon 
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Conclusion: This study confirms the prognostic significance of 
sLDH. LD patients with an elevated sLDH had a MOS which was 
similar to ED patients with a normal sLDH. Further studies to deter-
mine the biology of this subgroup of poor prognostic patients will 
be important to tailor therapeutic strategies.
Keyword: LDH prognostic survival SCLC
Conclusion: In patients with SCLC there was an association bet-
ween higher SUVmax and higher TNM stage, as observed in pa-
tients with NSCLC. However, in this small patient cohort, we were 
unable to find evidence of an independent prognostic effect of 
SUVmax on overall survival.
Keywords: small cell lung cancer, PET, Prognosis, SUV
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P1.13-003 IMPACT OF PRE-TREATMENT SERUM LACTA-
TE DEHYDROGENASE ON SURVIVAL IN PATIENTS WITH 
SMALL CELL LUNG CANCER.
Harminder S. Takhar1, Shawgi Sukumaran1, Marleesa Ly1, Richard 
Woodman2, Chris Karapetis1, Bogda Koczwara1, Ganessan Ki-
chenadasse1, Amitesh Roy1
1Medical Oncology, Flinders Medical Centre/Australia, 2Flinders Univer-
sity/Australia
Background: Serum lactate dehydrogenase (sLDH) is a prognostic 
factor in small cell lung cancer (SCLC). The aim of this study was 
to evaluate the impact of pre-treatment levels on survival in a con-
temporary patient population with limited disease (LD) and exten-
sive disease (ED).
Methods: SCLC patients were identified by searching the hospital 
cancer registry from 1999 to 2009. Patient characteristics, sLDH, 
management and outcomes were collated by reviewing clinical 
records. A sLDH result < 230 was designated normal and a result 
>230 was designated elevated in line with our institutional refe-
rence range. Survival analysis was performed using stata software 
using cox regression.
Results: 168 patients were diagnosed with SCLC, 103 males and 
65 females. Median patient age was 71 years. Pre-treatment sLDH 
was available for 128 patients. An elevated sLDH was associated 
with worse survival with Hazard Ratio (HR) 2.17 (95% CI 1.46-3.20, 
p-value <0.001). Elevated sLDH remained a significant indepen-
dent poor prognostic factor in a multivariate model when adjusted 
for age, sex, treatment and stage. In LD patients 52.6% had an 
elevated sLDH and median overall survival (MOS) was significantly 
worse in patients with elevated sLDH compared with normal sLDH, 
7.97 months versus 16.50 months (HR 2.1, 95% CI 1.07-4.32, p-value 
= 0.032). In ED patients 69.4% had an elevated sLDH and MOS was 
also significantly worse in patients with elevated sLDH compared 
with normal sLDH, 5.22 months versus 8.23 months (HR 1.8, 95% CI 
1.1-2.9, p-value = 0.019). 
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institution, collaborative studies are warranted.
Keyword: LCNEC, Ki67 score, somatostatin receptors, pulmonary 
NE
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P1.13-005 PACLITAXEL AND IRINOTECAN IN PLATINUM 
REFRACTORY OR RESISTANT SMALL CELL LUNG CAN-
CER: A GALICIAN LUNG CANCER GROUP EXPERIENCE.
F Javier Afonso-Afonso1, Sergio Vazquez-Estevez2, Joaquin Casal 
Rubio3, Xosé Luis Fírvida Pérez4, Martin Lazaro3, Cristina López 
Jato1, B Campos2, G Huidobro3, Mc Areses4, Noelia Garcia Cid3
1Complexo Hospitalario Universitario De Ferrol/Spain, 2Hula/Spain, 
3Oncoloxía Médica, Complexo Hospitalario Universitario De Vigo/Spain, 
4Oncoloxia Médica, Complexo Hospitalario Universitario De Ourense/
Spain
Background: Patients with Small Cell Lung Cancer (SCLC) whose 
disease progresses during or shortly after treatment with platinum, 
have a poor prognosis. Paclitaxel (P) and irinotecan(I) have de-
monstrated activity both as monotherapy as in combination regi-
men for this neoplasm. We present preliminary data from our ex-
perience in patients with SCLC refractory or resistant to platinum.
Methods: We included patients with measurable disease that had 
progressed during or within six months of first-line chemotherapy 
based on platinum, with an Eastern Cooperative Oncology Group 
(ECOG) performance status <2, adequate liver, renal and bone 
marrow function. They were treated with (P): 75 mg/m2 and (I): 
50 mg/m2, both drugs administered on days 1 and 8 of a 21 day 
cycle. Treatment was maintained until disease progression and/or 
unacceptable toxicity.
Results: We included 24 patients with a mean age of 59.5 years 
(43-79) and with metastases in two or more locations in 21 of them 
(87.5%). A median of 4 cycles of treatment was administered and 
eight patients (33.3%) received six or more cycles. The main rea-
son for discontinuation of chemotherapy was disease progression, 
observed in 20 patients (83.3%). Partial response was documented 
in 16 patients (66.6%), stable disease in three (12.5%) and disease 
progression in five (20.8%). The median survival time was 24,9 
weeks and the 1-year survival time was 22%. There have been no 
treatment-related deaths. The clinical and hematologic toxicities 
most frequently observed were grade 1 and 2: nausea (n:7; 29,2%), 
asthenia (n:7; 29,2%), anorexia (n:6; 25%), diarrhea (n:4; 16,6%), ane-
mia (n:16; 66,6%) and neutropenia (n:12; 50%). There was one (4,1%) 
grade 4 and two (8,3%) grade 3 neutropenia. There were no cases 
of grade 4 clinical toxicity and there were eight (33,3%) grade 3 : 
three of diarrhea (12,5%), two hepatic (8,3%) and three of asthenia 
(12,5%).
Conclusion: This (P) and (I) regimen is an effective and well tolera-
ted option for this subgroup of poor prognosis patients with SCLC. 
We still continue including patients in this protocol, which ensures 
future communications of the same.
Keyword: Small Cell Lung Cancer, Platinum Refractory, Platinum 
Resistant, Second-Line Treatment
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P1.13-004 THE HETEROGENEOUS PHENOTYPE OF 
LARGE-CELL NEUROENDOCRINE PULMONARY CAR-
CINOMA (LCNEC): A CLINICO-PATHOLOGICAL SINGLE 
INSTITUTION SERIES.
Haim Biran1, Sayeh Ben Arieh1, Marina Perelman2, Yehudit Rozen-
man3, Simona Ben Haim4, Jair Bar1, Alon Ben-Nun5
1Oncology, Chaim Sheba Medical Center/Israel, 2Pathology, Chaim 
Sheba Medical Center/Israel, 3Radiology, Chaim Sheba Medical Center/
Israel, 4Nuclear Medicine, Chaim Sheba Medical Center/Israel, 5Thoracic 
Surgery, Chaim Sheba Medical Center/Israel
Background: According to 2004 WHO classification there are 
four pulmonary neuroendocrine (NE) histopathologic entities, ran-
ging from low- to high-grade (HG) neoplasms. LCNEC belongs to 
the latter group. There are different opinions regarding whether 
LCNEC and small-cell lung cancer (SCLC), both HG, are essenti-
ally indistinct and thus deserve the same therapy, or not. LCNEC 
consists only about 3% of all lung cancer patients. We aimed to 
examine biologic characteristics of LCNEC patients and their impli-
cations on therapy choice and outcome.
Methods: A retrospective observational study of 21 consecutive 
patients seen at the thoracic oncology unit, division of oncology, 
Sheba Medical Center during the years 2008-2012. Histopathology 
was studied in a dedicated thoracic pathology unit and was based 
on 2004 WHO classification. Ki67 index evaluation was performed. 
Staging followed the 2009 TNM classification. Patients were exami-
ned for tumor somatostain receptors (SSTR): by In-111 Octreoscan 
or by Ga68 DOTANOC/DOTATATE PET/CT scans. We studied cir-
culating proGRP as NE tumor marker.
Results: 21 Patient fulfilled the LCNEC diagnostic criteria, 14 M, 
7 F. 8/21 were diagnosed at an operable stage, 7/8 had received 
post operative adjuvant chemotherapy and 5/7 of this subgroup 
are still alive. At a 17-month median follow-up time, of the entire 
series 7/21 are alive. The Ki67 score ranged 20-100%, median 
72.5%. The score was less than 70% in 7 cases. Two cases were 
defined HG, without Ki67 score. Five Stage IV patients were SSTR-
positive and received octreotide depot therapy, which in 2/5 
was given 1st-line (their Ki67 index was 20-25%). One of the latter 
received also peptide-related radionuclide therapy ( PRRT). An 
additional patient had received octreotide as 2nd-line therapy, and 
achieved durable (> 3-years) stabilization. Of note is metastatic 
brain disease in six patients: synchronous with initial diagnosis in 
two cases and metachronous in the others. Also, six patients have 
had non cerebral, non synchronous 2nd primary tumors. Additional 
histological elements were found in 6 patients: SCLC in 3, basa-
loid- 2 and adenocarcinoma-1. Circulating proGRP in LCNEC was 
elevated less frequently, and showed lower titers, as compared 
with SCLC patients data.
Conclusion: LCNEC is an uncommon entity within the pulmonary 
NE neoplasms spectrum. Despite its similarity to SCLC it is distinct 
in several senses: biologically, an aggressivity profile is not always 
seen, as reflected by the broader Ki67 range. A related feature is 
the higher rate of LCNEC operable patients, compared with excep-
tional primary surgery in SCLC. A substantial fraction of patients 
are SSTR positive and can benefit from corresponding targeted 
therapy. Due to LCNEC heterogeneity it is important to characte-
rize it adequately prior to 1st line therapy so that the therapeutic 
options are delineated on time, thus optimizing patients benefit 
and quality of life. Due to the limited patient number in a given 
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Top-2 as predictors of response are ongoing.
Keyword: Bendamustine irinotecan SCLC chemotherapy
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P1.13-007 THE CLINICAL IMPACT OF SUM OF THE MA-
XIMUM STANDARDIZED UPTAKE VALUE ON PRETREAT-
MENT 18F-FDG-PET/CT IN SMALL CELL LUNG CANCER 
TREATED WITH FRONT-LINE PLATINUM BASED CHEMO-
THERAPY
Gyeong-Won Lee, Se-Il Go
Internal Medicine, Gyeongsang National University School Of Medicine/
Korea
Background: The aim of this study was to investigate the clinical 
significance of sum of the maximum standardized uptake value on 
pretreatment positron emission tomography/computed tomogra-
phy (18F-FDG-PET/CT) in patients with newly diagnosed small cell 
lung cancer (SCLC) treated with front-line platinum-based chemo-
therapy.
Methods: We retrospectively analyzed 93 SCLC patients from 
March 2005 to May 2013 who underwent pretreatment 18F-FDG-
PET/CT. The sum of the maximum standardized uptake value (sum-
SUVmax) was measured in all malignant lesions up to a maximum of 
five lesions and a maximum of two lesions per organ according to 
the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Results: Patients were divided into two groups according to the 
median value of sumSUVmax (46 patients, < 21.8; 47 patients, ≥ 
21.8). Although no significant difference was found between low 
and high sumSUVmax group (low versus high sumSUVmax, 87.9% ver-
sus 76.9%; p = 0.186) in response rate (RR) following front-line plati-
num based chemotherapy, the group with low sumSUVmax showed 
significantly better overall survival (OS) [low versus high sumSUVmax, 
18.9 months (95% CI, 15.3-22.6) versus 10.8 months (95% CI, 7.6-
14.1); p = 0.002] as well as better progression free survival (PFS) 
[low versus high sumSUVmax, 8.3 months (95% CI, 6.9-9.7) versus 
6.2 months (95% CI, 5.8-6.6); p = 0.005], compared with the group 
with high sumSUVmax. Moreover, multuvariate analysis revealed that 
high sumSUVmax alone was an independent poor prognostic factor 
for OS (HR 1.95, 95% CI 1.12-3.39; p = 0.018).
Conclusion: This study showed that the sumSUVmax in pretreatment 
18F-FDG PET/CT was significantly correlated with the OS and PFS in 
patients with SCLC treated with front-line platinum based chemo-
therapy.
Keywords: small cell lung cancer, positron emission tomography, 
Platinum, survival
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P1.13-006 PHASE I/IIA STUDY OF THE NOVEL COMBI-
NATION OF BENDAMUSTINE PLUS IRINOTECAN FOL-
LOWED BY ETOPOSIDE PLUS CARBOPLATIN IN UNTRE-
ATED PATIENTS WITH EXTENSIVE STAGE SMALL CELL 
LUNG CANCER
Stefan C. Grant1, Daniel J. Allendorf1, Rodolfo Bordani2, Mansoor 
Saleh2, Mary Jerome1, Debi Miley1, Alan Cantor1, Vishnu Reddy1, 
Francisco Robert3
1Comprehensive Cancer Center, University Of Alabama At Birming-
ham/United States Of America, 2Georgia Cancer Specialists/United 
States Of America, 3Comprehensive Cancer Center, University Of Ala-
bama Of Birmingham/United States Of America
Background: Standard therapy for extensive stage small cell lung 
cancer (ES-SCLC) with etoposide (VP16) plus cisplatin or carbopla-
tin (Carbo) results in median time to progression (TTP) of 4 months 
with overall survival (OS) of 9 months. Bendamustine (B) induced 
DNA damage is repaired by excision repair and irinotecan (I), a 
topoisomerase-1 inhibitor (Top-1), leads to increases in topoiso-
merase-2 (Top-2), the target of VP16. Therefore, the sequence B+I 
→ VP16+Carbo was hypothesized to increase TTP by exploiting 
mitotic catastrophe, with subjects with low ERCC-1 expression and 
high Top-1 or Top-2 expression having longer TTP and OS compa-
red to those with high ERCC-1 expression
Methods: This is an open label trial enrolling patients (pts) with 
evaluable ES-SCLC. Phase I primary endpoint was to determine 
the maximum tolerated dose (MTD) of B+I; the phase IIa primary 
endpoint was TTP after B+I→E+C. Secondary endpoints were 
objective response rate (ORR) and OS. In the phase I (N=15), pts 
received I (150 mg/m2, d 1) with B at 80, 100, or 120 mg/m2/day (d 
1,2) every 3 weeks for 3 cycles. Phase IIa pts were treated at the 
selected phase II dose of B+I for 3 cycles, followed by E (100 mg/
m2, d 1-3) + Carbo (AUC 6, d 1) for 3 cycles. Restaging was perfor-
med after 3 cycles of each regimen. The phase IIa was powered 
to detect a 30% increase in TTP from 4 to 5.2 m with a of 0.1. The 
Kaplan-Meier method was used to calculate TTP and OS. Toxicities 
were evaluated using the NCI CTCAE.
Results: The MTD of B was not reached and a dose of 100 mg/m2 
was selected as the phase IIa dose, with dose-escalation allowed in 
subsequent cycles of therapy for ≤ grade 2 toxicity. Dose limiting 
toxicities were diarrhea, nausea, and vomiting. Two treatment-
related deaths, from metabolic encephalopathy and from neutro-
penic sepsis, occurred in the Phase IIa portion. The commonest 
grade 3/4 hematologic toxicity was neutropenia. Fatigue, nausea, 
vomiting, and diarrhea were common non-hematologic toxicities. 
Efficacy Parameters (N=28): Median TTP 6.0 m (95% CI 4.8-7.2); 
Median OS 10.0 m (95% CI 8.4-11.6); ORR 83% (4% CR); Median 
tumor reduction after B+I 65%; Median tumor reduction after E+C 
73%. Statistically significant prognostic factors for TTP were sex, 
LDH, Top-1 and Top-2 and for OS were Top-2 and LDH. The pre-
dictive significance of Top-1 for TTP is confounded by insufficient 
samples with no expression of Top-1 and failure to demonstrate 
correlation with ERCC1 levels may have been related to antibody 
selection – reanalysis in in progress.
Conclusion: B+I is an active regimen in ES-SCLC and the treatment 
sequence B+I→E+C seems to improve the TTP and OS in ES-SCLC 
compared to historic results for E+C. Toxicities were increased 
compared to historic results for E+C, but were manageable. Corre-
lative studies with pre-treatment assessment of tumor ERCC-1 and 
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Conclusion: The results indicate that irradiation to the post-
chemotherapy tumor extent and initially involved positive nodal 
regions did not increase local/regional failure. However, the sam-
ple number in this analysis did not meet the design requirements. 
Enrollment of patients is still in progress.
Keywords: small cell lung cancer, limited-stage, radiation therapy, 
radiation target volume
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P1.13-008 OMITTING ELECTIVE NODAL IRRADIATION 
AND IRRADIATING POST-INDUCTION VERSUS PRE-IN-
DUCTION CHEMOTHERAPY TUMOR EXTENT FOR LIMI-
TED-STAGE SMALL CELL LUNG CANCER: AN UPDATE 
OF A PROSPECTIVE RANDOMIZED TRIAL
Ming Chen1, Xiao Hu1, Yong Bao2, Li Zhang3, Yu J. Xu1, Yuan Y. 
Chen1
1Department Of Radiation Oncology, Zhejiang Cancer Hospital/China, 
2Department Of Radiation Oncology, Sun Yat-Sen University Cancer 
Center, And State Key Laboratory Of Oncology In South China/China, 
3Department Of Medical Oncology, Sun Yat-Sen University Cancer Cen-
ter/China
Background: Thoracic radiation target volume for limited-stage 
small cell lung cancer (SCLC) has long been a controversial topic. 
This study prospectively compares the local/regional failure pat-
tern and overall survival (OS) between limited-stage SCLC patients 
who received different target volumes of thoracic radiotherapy 
(TRT) after induction chemotherapy.
Methods: Patients diagnosed as limited-stage (AJCC/UICC T1-
4N0-3M0) SCLC received 2 cycles of etoposide and cisplatin (EP) 
and were randomly assigned to receive TRT to either the post-
induction tumor extent (study arm) or pre-induction chemotherapy 
tumor extent (control arm). Elective nodal irradiation was omitted 
in both arms i.e. clinical target volume-nodal included only initially 
involved nodal regions. TRT dosage of forty-five Gy/30Fx/19d 
was administered concurrently with the third cycle of EP regimen. 
Then, additional 3 cycles of EP consolidation were administered. 
Prophylactic cranial irradiation was administered to patients who 
achieved complete or partial remission.
Results: Seventy-nine and 91 patients were randomly assigned 
to study arm and control arm. Five patients in study arm and 1 
patient in control arm developed distant metastasis before TRT 
and received palliative treatment. One patient in study arm deve-
loped spontaneous pneumothorax and did not receive TRT. These 
patients were not included in the analysis of local/regional failure. 
However, they were included in the analysis of OS. Median follow 
up time for the whole group was 15.6 months (1.1 months- 129.3 
months). The local recurrence rates were 30.1% (22/73) and 33.3% 
(30/90) respectively (P = .73). The isolated nodal failure (INF) rates 
were 2.7% (2/73) and 5.6% (5/90) respectively (P = .46). All INF 
were developed in supraclavicular regions except for one patient 
developed contralateral hilum lymph node recurrence. The esti-
mated 1 and 2-year local/regional progression free survival time 
were 88.6%, 82.1% and 77.3%, 63.5% respectively in study arm and 
control arm (P = .56). The median OS time were 23.5 months (95% 
CI: 15.5-31.4 months) and 25.4 months (95% CI: 19.6-31.1 months) 
respectively in study arm and control arm. One, three and 5-year 
OS rates were 79.4%, 33.6%, 22.5% and 84.0%, 34.3%, 29.1% res-
pectively (P = .74).
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P1.14-002 LACK OF RESPONSE TO CHEMOTHERAPY 
FOR PREVIOUSLY TREATED MALIGNANT PLEURAL ME-
SOTHELIOMA (MPM)
Marjorie G. Zauderer1, Samantha L. Kass1, Camelia S. Sima2, Mi-
chelle S. Ginsberg3, Lee M. Krug4
1Medicine, Memorial Sloan-Kettering Cancer Center/United States Of 
America, 2Biostatistics, Memorial Sloan-Kettering Cancer Center/Uni-
ted States Of America, 3Radiology, Memorial Sloan-Kettering Cancer 
Center/United States Of America, 4Department Of Medicine, Thoracic 
Oncology Service, Memorial Sloan-Kettering Cancer Center/United 
States Of America
Background: After initial therapy with pemetrexed/platinum, 
second-line therapy options are not well established. Gemcitabine 
and vinorelbine are often used based on small trials and first-line 
data. To augment the existing data, we examined our institutional 
experience using vinorelbine and gemcitabine in patients with 
previously treated MPM.
Methods: We reviewed the records of all patients treated with 
vinorelbine and/or gemcitabine as second- or third-line therapy for 
MPM between 2003 and 2010. Vinorelbine was administered at a 
dose of 25 mg/m2 days 1 and 8 in a 3-week cycle and gemcitabine 
was given at 1000 mg/m2 days 1, 8, and 15 in 28 day cycles. CT 
scans were generally performed after every two cycles. Imaging 
studies were reviewed with a radiologist according to the modified 
RECIST criteria.
Results: 60 patients were identified: 33 treated with vinorelbine, 
15 with gemcitabine, and 12 with both. Patient characteristics are 
as follows: 78% men: median age 67 (range 41-85); 63% epithelio-
id, 19% mixed histology, and 18% sarcomatoid; 83% received first-
line pemetrexed-platinum therapy and 10% gemcitabine-platinum 
therapy. One partial radiographic response was identified among 
the 56 patients with follow up imaging available for review (Figure 
1) giving a response rate of 2% (95% CI 0-5%). With gemcitabine, 
10 patients (37%) had radiographic progression, 6 (22%) had clini-
cal progression, 6 (22%) had radiographic stable disease, 4 (15%) 
had clinically stable disease, and 1 (4%) had radiographic partial 
response. With vinorelbine, 20 patients (43%) had radiographic 
progression, 2 (4%) had clinical progression, 19 (42%) had radiogra-
phic stable disease, 4 (8%) had clinically stable disease, and there 
were no responses. 53% experienced at least one episode of gra-
de 3-4 toxicity, most commonly anemia, neutropenia, fatigue, and 
neutropenic fever. 24 patients received more than 2 cycles. Median 
progression free survival was 1.6 months and median overall survi-
val was 5 months. 
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P1.14-001 ESTIMATES OF EXPECTED YEARS OF LIFE 
LOST AND LIFETIME DIRECT MEDICAL COSTS FOR MA-
LIGNANT PLEURAL MESOTHELIOMA PATIENTS: DATA 
FROM TAIWAN AND NEW SOUTH WALES, AUSTRALIA
Matthew J. Soeberg1, Lukas J. Lee2, Steven Kao3, Nico Van Zandwi-
jk3, Yu-Yin Chang2, Jung-Der Wang4
1Cancer Epidemiology And Services Research, The University Of Syd-
ney/Australia, 2National Health Research Institute/Taiwan, 3Asbestos 
Disease Research Institute/Australia, 4National Cheng Kung University 
College Of Medicine/Taiwan
Background: Quantifying the burden of malignant pleural me-
sothelioma (MPM) is an important yet challenging task. Little is 
understood about the societal and economic costs following a 
diagnosis of MPM. We investigated survival, years of life lost, and 
direct medical costs associated with MPM using data from Austra-
lia and Taiwan.
Methods: 159 and 136 MPM patients from New South Wales 
(NSW) Disease Dust Board data and Taiwanese Cancer Registry 
(TCR) data respectively were included in: (i) survival function ana-
lyses and (ii) analyses to estimate the years of life lost associated 
with a MPM diagnosis. Further, data on 428 patients from the 
Taiwanese National Health Insurance Research Database, and the 
NSW data linked to Medicare data, were also used to (iii) estimate 
lifetime healthcare expenditure following a MPM diagnosis.
Results: (i) The mean age at MPM diagnosis in NSW was 71 and 60 
in Taiwan. Median survival in months for NSW MPM patients was 
11.7 (95% CI 9.3, 13.5) and 6.0 (95% CI 5.1, 7.8) for TCR patients. 
Four and eight percent of patients in NSW and Taiwan respectively 
were estimated to survive up to five years following a MPM diag-
nosis. (ii) The lifetime survival difference between the MPM patient 
cohort and a comparable population free of the disease was esti-
mated to be 13.6 (95% CI 13.4, 13.8) years in the NSW cohort and 
18.8 (95% CI 18.5, 19.1) years in the TCR cohort. (iii) Using national 
health insurance data in Taiwan, we estimated that the direct heath 
care costs following a MPM diagnosis to be USD$18,812. In NSW, 
this cost was estimated to be USD$20,573.
Conclusion: We analysed MPM cohort data from Taiwan and Aust-
ralia to estimate survival and expected life years lost, with possible 
differences in the age at diagnosis and median survival. We also 
analysed Taiwan and Australian data to estimate direct medical 
costs following a MPM diagnosis. The impact of selection bias in 
this study cannot be ruled out as there is likely under-ascertain-
ment of MPM cases in the Taiwanese Cancer Registry and the NSW 
data is a subset of all MPM cases diagnosed in NSW. However, the-
se estimates provide useful data to contribute to evidence-based 
clinical and policy decision-making in the area of MPM prevention 
and care services.
Keywords: mesothelioma, Direct medical costs, Taiwan, New Sou-
th Wales, Australia
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regimen. There was no statistically significant difference between 
the patients who received pemetrexed-platinum and gemcitabine-
platinum regimens in terms of the median overall survival (p = 
0.15).
Conclusion: s: Results of our study suggest that chemotherapy 
prolongs overall survival. Survival rates in patients who received 
combining platinum analogues with pemetrexed or gemcitabine as 
front-line chemotherapy were found to be similar.
Keyword: mesothelioma, chemotherapy, overall survival
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P1.14-004 EXTENDED SURVIVAL FOLLOWING RECUR-
RENCE FOR PATIENTS WITH MALIGNANT PLEURAL ME-
SOTHELIOMA TREATED WITH RADICAL PLEURECTOMY, 
PHOTODYNAMIC THERAPY AND CHEMOTHERAPY: THE 
POTENTIAL ROLE OF STAT3.
Joseph Friedberg1, Charles Simone2, Melissa Culligan1, Stephen M. 
Hahn2, Evan Alley3, Daniel Sterman4, Eli Glatstein2, Sally Mcnulty5, 
M Shin2, S Hagan2, Keith A. Cengel2
1Thoracic Surgery, University Of Pennsylvania/United States Of Ame-
rica, 2Radiation Oncology, University Of Pennsylvania/United States Of 
America, 3Medicine, Division Of Oncology, University Of Pennsylvania/
United States Of America, 4Medicine, Division Of Pulmonology, Univer-
sity Of Pennsylvania/United States Of America, 5University Of Pennsyl-
vania/United States Of America
Background: Survival after recurrence following surgical manage-
ment with curative intent for malignant pleural mesothelioma is 
typically measured in months. In this study, we compare survival 
after recurrence in patients progression free less than or greater 
than one year after radical pleurectomy.
Methods: 67 consecutive patients with malignant pleural meso-
thelioma, epithelial subtype, who underwent radical pleurectomy 
and intraoperative photodynamic therapy were assessed in this 
IRB-approved study. Four patients who experienced perioperative 
mortality were excluded from this analysis. Local recurrence was 
defined as recurrent disease in the ipsilateral hemithorax. Early vs. 
late recurrence was defined as recurrence before versus after the 
median recurrence time, respectively. STAT3 expression was quan-
tified in tissue microarrays using computer-based quantification of 
immunohistochemical staining.
Results: Among the 63 evaluable patients, 78% (n=49) were male, 
the median age of patients was 64 years, and the overwhelming 
majority (87.5%) had locally advanced (AJCC stage3/4) disease. 
49 patients (78%) had lymph node metastases (N1/N2). 60 pati-
ents (95%) received neoadjuvant or adjuvant pemetrexed-based 
chemotherapy. With a median follow-up of 31 months, 42 patients 
demonstrated disease recurrence. Of these recurrences, 18 were 
isolated local recurrences and 24 were combined local + distant. 
The median time to recurrence was 11.6 months and patients who 
experienced an early recurrence (<11.6 mo) demonstrated signifi-
cantly decreased survival as compared to patients experiencing a 
late recurrence (p < 0.0001, Figure 1). The median survival after 
recurrence was significantly decreased for patients who experi-
enced an early vs late recurrence (54.7 mo [46.0-63.4 mo 95% CI] 
vs 10.8 mo [8.5-22.7 mo 95 % CI], respectively). We and others 
have previously shown that STAT3 expression can make mesothe-
Conclusion: Response to second-line therapy with gemcitabine or 
vinorelbine is rare. The rate of stable disease suggests some level 
of activity of these agents. Therefore, it remains a reasonable stan-
dard therapeutic option. However, survival was comparable to the 
placebo arm in the phase III vorinostat trial (Krug, ECCO/ESMO, 
2011). This lack of efficacy supports the use of placebo control 
arms in randomized second-line MPM trials. Novel therapies are 
desperately needed for this patient population.
Keywords: gemcitabine, mesothelioma, vinorelbine
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P1.14-003 THE EFFECT OF FRONT-LINE CHEMOTHERA-
PY ON OVERALL SURVIVAL IN PATIENTS WITH MALIG-
NANT PLEURAL MESOTHELIOMA.
Alper Sevinc1, Emin T. Elkiran2, Hakan Harputluoglu2
1Medical Oncology, Gaziantep University/Turkey, 2Inonu University/
Turkey
Background: Malignant pleural mesothelioma (MPM) is a relatively 
rare, but aggressive tumor that causes high mortality. The major 
risk factor involved in the etiology is environmental and occupa-
tional exposure to asbestos. The optimal modality of therapy is 
controversial.
Methods: The present study retrospectively evaluated the 141 
patients from the database.
Results: There were 80 males and 61 females with a mean age of 
56 ± 1.07 years. The median survival in patients who were adminis-
tered front-line chemotherapy was 17 months (95% CI: 13.19-20.81). 
106 patients were administered pemetrexed-platinum combination 
and 35 patients were administered gemcitabine-platinum combi-
nation as front-line chemotherapy. For the patients who received 
pemetrexed-platinum regimen, a median of 6 cycles of chemothe-
rapy was administered and 50 patients (47.2%) were able to receive 
all 6 cycles as planned. For the patients who received gemcitabi-
ne-platinum regimen, a median of 6 cycles of chemotherapy was 
administered and 19 patients (54.3%) were able to receive all 6 
cycles. Median survival was found 16 months in the pemetrexed-
platinum regimen and 26 months in the gemcitabine- platinum 
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preferentially targets MPM tumors cell. In patients with refractory 
ovarian cancer the intraperitonial administration of MV-NIS was 
recently found to be safe and induced an anti-tumor immune res-
ponse.
Methods: Phase I dose escalation study (3+3 design). MV-NIS is 
administered intrapleurally. Starting dose level was 108 TICID 50 
(Level 1) and the current dose level is 3 x 108 TICID 50 (Level 2). In 
the absence of dose limiting toxicity and disease progression pati-
ents continue MV-NIS therapy for up to six 28-day cycles. MV-NIS 
infection and replication is monitored by Iodine123 SPECT/CT and 
RT-PCR and anti-tumor and anti-viral immunity are monitored in 
correlative studies. Patients are followed clinically using modified 
RECIST criteria.
Results: Up to now 4 patients have received MV-NIS therapy. 
Three patients were treated at Level 1 and the fourth patient at 
Level 2. No dose limiting adverse events occurred. The best the-
rapeutic response was stable disease, observed in patient #1 for 6 
months and patient #2 for 2 months. The remaining two patients 
progressed radiologically after one treatment cycle. I123 SPECT-CT 
imaging did not demonstrate changes in iodine uptake compared 
to baseline in any of these patients. However, we detected MV 
RNA by QRT-PCR within the pleural cells 24-48 hours after the 
intrapleural administration of MV-NIS in 3/4 patients. In patient #4, 
treated with 3x108 TCID 50, MV replication was detectable within 
the pleural space by plaque assay 24 hours after MV-NIS adminis-
tration. Following MV-NIS therapy a profound influx of neutrophils 
into the pleural space occurred in 3/4 patients and pleural fluid 
cytokine concentrations changed significantly. In addition, a humo-
ral anti-tumor immune response emerged in patients #2.  
Patient 
# Age 
Disease 
Stage Histology 
Line  
therapy 
1 75 II (T2N0M0) Epitheloid First 
2 53 IV (T4N0M0) Epitheloid Second 
3 84 IV (T4N0M0) Epitheloid First 
4 73 IV (T2N3M0) Mixed First 
 
Conclusion: Thus far the intrapleural administration of MV-NIS 
appears to be safe and well tolerated in MPM. Our study will conti-
nue to enroll patients.
Keywords: malignant pleural mesothelioma, measles virus, onco-
lytic virotherapy, immunotherapy
lioma more resistant to cytotoxic agents such as chemotherapy 
or photodynamic therapy. Preliminary analysis of TMA staining 
indicates that patients who experience an early disease recur-
rence in our series exhibit significantly higher STAT3 expression. 
Conclusion: This study is among the largest to describe the sur-
vival after initial recurrence for malignant pleural mesothelioma 
in patients undergoing definitive surgical management. Patients 
recurring prior to the median of 11.6 months experienced an ag-
gressive tumor recurrence phenotype with a median 10.3 months 
from recurrence to death. Patients recurring after the median of 
11.6 months experienced a relatively indolent disease course with 
a median survival of 37 months after recurrence. Further evaluation 
and additional studies are necessary to confirm if elevated STAT3 
expression could be a poor prognostic factor for patients under-
going radical pleurectomy, photodynamic therapy and chemothe-
rapy.
Keywords: mesothelioma, photodynamic therapy, radical pleurec-
tomy
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P1.14-005 PRELIMINARY RESULTS - "A PHASE I TRIAL OF 
ONCOLYTIC MEASLES VIROTHERAPY IN MESOTHELIO-
MA“ INVESTIGATING THE INTRAPLEURAL ADMINIST-
RATION OF THE MODIFIED VACCINE STRAIN MEASLES 
VIRUS (MV-NIS) TO PATIENTS WITH MALIGNANT PLEU-
RAL MESOTHELIOMA
Tobias Peikert1, Julian Molina1, Ileana Aderca1, Stephen Albelda2, 
Stephanie Carlson1, Val Lowe1, Fabien Maldonado1, Sumithra 
Mandrekar1, Manish Patel3, Anja Roden1, Virginia Van Keulen1, 
Robert Kratzke3, Evanthia Galanis1
1Mayo Clinic/United States Of America, 2University Of Pennsylvania/
United States Of America, 3University Of Minnesota/United States Of 
America
Background: Malignant pleural mesothelioma (MPM) remains an 
almost universally fatal disease. Preclinical models indicate that 
the oncolytic modified vaccine strain measles virus (MV) carrying 
the gene for the human sodium-iodine symporter (NIS) - MV-NIS 
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Background: Indwelling pleural catheters (IPC) are commonly used 
in managing malignant pleural effusions (MPE). Development of 
loculations within the effusion can prohibit effective fluid drainage. 
Intrapleural instillation of fibrinolytics has been used though little 
data exist on this practice. Aim: To describe a single centre expe-
rience in the use of fibrinolytic therapy for symptomatic loculation 
in IPC patients.
Methods: We defined Symptomatic Loculation (SL) as presence of 
(a) residual pleural effusion that failed to be evacuated via a patent 
IPC, b) breathlessness clinically judged to be related to the residu-
al effusion, and c) in the absence of pleural infection. All patients 
(n=108; 77% male) who had IPC (n=111) inserted for MPE (60% 
mesothelioma) were entered prospectively into a database over 
a 50month period. The incidence of SL and the effectiveness and 
safety of fibrinolytic therapy were analyzed.
Results: The incidence of SL was 1 case per 74.2 IPC person-
months, affecting 9% (10/111) of the patients. Most affected were 
males (9/10) with a mean age of 74.2yrs and 7/10 had mesothelio-
ma. Various fibrinolytics had been used: tPA 10mg (n=6), strepto-
kinase 250000U (n=1), urokinase 100000U (n=2) and 1 patient re-
ceived a combination of streptokinase followed by tPA. Outcomes: 
The majority (89%) of patients reported subjective symptomatic 
improvement in breathlessness. Fibrinolysis induced a significant 
increase in fluid output: 1459ml (mean after 24hrs) and 2136ml 
(72 hours after instillation). The mean hospital stay was 4.5 days 
from first treatment dose. Treatment was well tolerated. The most 
common symptom was pain on pleural drainage (8 patients) that 
resolved with cessation of drainage. There were no severe adverse 
events, such as pleural bleeding. However, SL recurred after fibri-
nolytic therapy in 5 (56%) patients after a mean period of 9.6 days 
with two needing further pleural interventions.
Conclusion: Intra-pleural fibrinolytic therapy is an effective and 
safe option for management of SL following IPC insertion for MPE. 
Support: Cancer Council WA; NHMRC Fellowship (YCGL) Conflict 
of interest: Nil.
Keywords: malignant pleural effusion, Symptomatic loculation, 
Fibrinolytic therapy, Indwelling pleural catheter
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P1.14-008 CLINICAL FEATURES AND CURRENT MA-
NAGEMENT OF MALIGNANT PLEURAL MESOTHELIOMA 
IN FRANCE. THEGFPC 0804 STUDY.
Christine Raynaud1, Julien Mazieres2, Laurent Greiller3, Christos 
Chouaid4, Philippe David5, Gilles Robinet6, Gislaine Fraboulet7, 
Henri Berard8, Regine Lamy9, Jacques Letreut10, Herve Lena11, Jean 
Yves Delhoume12, Henri Janicot13, Isabelle Borget14
1Pneumologie, Centre Hospitalier Argenteuil/France, 2Respiratory Me-
dicine Service, Hôpital Larrey, Chu De Toulouse, Université De Toulouse 
Iii (paul Sabatier)/France, 3Hopital Sainte Marguerite/France, 4Service 
De Pneumologie, Centre Hospitalier Intercommunal De Creteil/France, 
5Centre Hospitalier Elbeuf/France, 6Oncology-pneumology, Hôpital Mor-
van/France, 7Oncologie, Centre Hospitalier René Dubos/France, 8Service 
De Pathologie Respiratoire, Hôpital D‘instruction Des Armées Sainte-
anne/France, 9Morbihan, Service D‘oncologie Hôpital De Bretagne Sud/
France, 10Centre Hospitalier Du Pays D Aix/France, 11Service De Pneu-
mologie, Hôpital Pontchailloux/France, 12Centre Hospitier/France, 13Chu 
Hopital Montpied/France, 14Institut Gustave Roussy/France
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P1.14-006 CATHETER TRACT METASTASES ASSOCIATED 
WITH INDWELLING PLEURAL CATHETERS FOR MALIG-
NANT EFFUSIONS
Rajesh Thomas1, Yi Jin Kuok2, Sean Bydder3, Charley Budgeon4, Yc 
Gary Lee5
1Respiratory Medicine, Sir Charles Gairdner Hospital & University Of 
Western Australia/Australia, 2Radiology, Sir Charles Gairdner Hospi-
tal/Australia, 3Radiation Oncology, Sir Charles Gairdner Hospital/Aust-
ralia, 4Dept Of Research, Sir Charles Gairdner Hospital/Australia, 5Res-
piratory Medicine, Sir Charles Gairdner Hospital, University Of Western 
Australia & Lung Institute Of Western Australia/Australia
Background: Indwelling pleural catheter (IPC) is commonly used 
in managing malignant pleural effusion (MPE). Tumor spread along 
the catheter tract remains a clinical concern for which limited data 
exist. We report the largest series of catheter tract metastases 
(CTM).
Methods: All patients who had IPC inserted for MPE in our Pleural 
Service were entered prospectively into a database. A retrospec-
tive review of the cases for CTM over a 50-month period from Jan 
2009 was conducted. CTM was defined as a new chest wall swel-
ling over the IPC insertion site or the tunneled subcutaneous tract. 
Patient demographics and risk factors were recorded. Multivariate 
regression analysis was performed.
Results: 108 patients (77% male; 60% had mesothelioma) under-
went a total of 111 IPC insertions. CTM occurred in 11 (10.2%) 
patients; 7 were males and 9 had mesothelioma. CTM developed 
after a median of 280 days (range 56-692 days) post-IPC insertion. 
7 patients were symptomatic with chest wall pain and 6 received 
palliative radiotherapy for CTM. Radiotherapy was tolerated well 
with no major complications. CTM occurred more commonly, OR 
3.30 (0.68-16.06), in mesothelioma patients than those with me-
tastatic pleural cancers. Patients who had CTM had a significantly 
longer survival (median 369 days) than those who did not, HR 0.24 
(CI 0.08-0.68).
Conclusion: Clinicians and patients should be aware that CTM 
could complicate IPC, especially in mesothelioma patients. The 
longer the patient survived after IPC placement, the higher risk of 
developing CTM. Symptoms associated with CTM were generally 
mild and responded well to palliative radiotherapy.
Keywords: Indwelling pleural catheter, catheter tract metastases, 
malignant pleural effusion, mesothelioma
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P1.14-007 INTRAPLEURAL FIBRINOLYSIS IS EFFECTIVE 
IN TREATING SYMPTOMATIC LOCULATION COMPLICA-
TING INDWELLING PLEURAL CATHETER DRAINAGE
Rajesh Thomas1, Catherine Read2, Edward Fysh1, Yc Gary Lee1
1Respiratory Medicine, Sir Charles Gairdner Hospital & University Of 
Western Australia/Australia, 2Respiratory Medicine, Sir Charles Gaird-
ner Hospital/Australia
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therapy study S0509. S0905 combined cediranib (2 dose cohorts 
30 mg and 20 mg daily) with cisplatin and pemetrexed for 6 cycles 
followed by maintenance cediranib in unresectable chemo-naïve 
MPM patients.
Methods: Baseline tumor tissue specimens from the phase I MPM 
patients will be assessed for immunohistochemical biomarkers 
specific to the VEGF/VEGFR and PDGF/PDGFR pathway and flu-
orescent in situ hybridization for PDGFRbeta gene copy number 
gain (CNG). Standard laboratory methods will be employed and 
the H-score and gene CNG will be correlated to progression-free 
(RECIST 1.1, modified RECIST) and overall survival results. The 
correlation between IHC biomarkers will be assessed using the 
Spearman’s rank correlation. Wilcoxon rank-sum test or Kruskal-
Wallis test is used to detect marker differences between groups. 
The distributions of overall survival (OS) and recurrence free 
survival (RFS) are estimated by the Kaplan-Meier method. Log-
rank test23 is performed to test the difference in survival between 
groups. SAS version 9.1 and S-Plus version 8.0 are used to carry 
out the computations for all analyses.
Results: In S0905 phase I, a total of 20 patients (7 to cohort 1 - 30 
mg, 13 to cohort 2 - 20 mg) were enrolled. For all cycles, 12 pati-
ents reported Grade 3 AEs, the most common being diarrhea (4), 
dehydration (3), fatigue (3) and neutropenia (3). Two episodes of 
grade 4 thrombocytopenia were reported with 1 treatment-related 
death due to encephalopathy of unclear etiology. Based on the to-
xicity profile, the remaining phase I/II trial proceeded with cedira-
nib at 20 mg daily. Two radiographic response measurements were 
utilized. 18/20 patients were evaluable for response by RECIST 1.1 
(7 - 30 mg cohort, 11 - 20 mg cohort). The RECIST 1.1 RR was 22% 
(95% CI: 6% - 48%) and median PFS was 14 months (95% CI: 8 – 17). 
Two patients had inadequate assessments and are classified as 
non-responders. There were 19 patients measurable by modified 
RECIST with RR 53% (95% CI: 29%-76%) and median PFS 10 months 
(7-13). For all patients, the median OS was 16 months (95% CI: 
11-19). One patient in the 30 mg cohort remains on trial after 25 
cycles of therapy; 2 patients at the 20 mg cohort remain on trial on 
cycles 19 and 15 of therapy. Cisplatin-pemetrexed-cediranib shows 
significant clinical activity and acceptable toxicity with cediranib 20 
mg/day. The randomized phase II portion of the trial is ongoing. 
Translational studies from the phase I MPM patients is ongoing.
Conclusion: The biomarker results from the phase I portion of the 
trial will be reported and correlated to clinical outcome results.
Keywords: PDGFR, VEGFR, S0905 biomarkers, mesothelioma
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P1.14-010 ESTIMATION OF AN OPTIMAL CHEMOTHERA-
PY UTILISATION RATE FOR MALIGNANT PLEURAL ME-
SOTHELIOMA: AN EVIDENCE-BASED BENCHMARK FOR 
PATIENT CARE
Annette Tognela1, Steven Kao2, Nico Van Zandwijk2, Stephen Clar-
ke3, Janette Vardy3, Victoria Bray4, Sumit Lumba1, Weng Ng4
1Medical Oncology Department, Liverpool Hospital/Australia, 2Asbes-
tos Diseases Research Institute/Australia, 3The University Of Sydney, 
Faculty Of Medicine/Australia, 4Collaboration For Cancer Outcomes 
Research And Evaluation/Australia
Background: Chemotherapy has been shown to provide a survival 
Background: Malignant pleural mesothelioma (MPM) is a rare and 
aggressive primitive pleural tumour, which is associated with expo-
sure to asbestos. Chemotherapy is the main part of therapy with 
new cytotoxic agents resulting in superior survival time. Recently 
the European Respiratory Society and the European Society of 
Thoracic Surgeons proposed practical and up-to-date guidelines 
on the management of MPM. The objective of this study was to 
assess the current management of MPM in France between Janua-
ry 2005 and December 2008.
Methods: Observational, multicentric, national, study. The medical 
records of patients with MPM diagnosed during the study period 
in the 37 participating centers were retrospectively reviewed. 
Epidemiological data, clinical data, diagnosis procedures and se-
veral components of management were recorded. Mains inclusion 
criteria’s were a new diagnosis of MPM, a histology diagnosis and a 
management in the center.
Results: Four hundred and six patients (males: 76%) were included; 
median age: 68.9± 9.8 years; > 75 years: 27.8%; Asbestos exposure 
was found out in 259(63.8%) patients (251 professional exposure, 
8 environmental exposure). Histological diagnosis was: epithelial 
MPM: 82.9%, sarcomatoid MPM: 10%, biphasic MPM 7.1%. The 
main diagnosis procedure was thoracoscopy (296 (73.1%)). Thirty 
patients underwent surgery (25 radical surgery, 5 pleurectomy). 
Pleurodesis was performed 191 times. Prophylactic drain site ra-
diotherapy was performed in 268. Three hundred and three pati-
ents (74.6%) received first-line combination chemotherapy (mean 
cycles: 4.7 ± 1.7, median 6); 162 (40.2%) received second line che-
motherapy (mean cycles: 3.5 ± 1.9, median 3); 56 ( 13 %) received 
third line chemotherapy (3.1± 2, median 3). One and two year sur-
vival rates will be updated at the congress.
Conclusion: This study provides an assessment of diagnosis mo-
des and therapeutic strategies for the management of MPM in 
France. Further analyses are needed to model the management 
strategies and assess the cost-effectiveness of this disease.
Keywords: mesothelioma, Epidemiology, MANAGEMENT
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P1.14-009 BIOMARKER RESULTS FROM A PHASE I STU-
DY OF CEDIRANIB (NSC #732208) IN COMBINATION 
WITH CISPLATIN AND PEMETREXED IN CHEMONAIVE 
PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA 
(SWOG S0905)
Junya Fujimoto1, Ignacio I. Wistuba1, James Moon2, Gregory Ka-
lemkerian3, Mary Redman2, David J. Stewart4, Percy Ivy5, David 
Gandara6, Anne Tsao7
1Translational Molecular Pathology, The University Of Texas MD 
Anderson Cancer Center/United States Of America, 2Swog Statistical 
Center/United States Of America, 3University Of Michigan/United 
States Of America, 4Medical Oncology, University Of Ottawa/Canada, 
5National Cancer Institute/United States Of America, 6Division Of 
Hematology/Oncology, UC Davis Cancer Center/United States Of 
America, 7Thoracic Head And Neck Medical Oncology, Univ Of Texas 
M.D. Anderson Cancer Center/United States Of America
Background: The VEGF/VEGFR and PDGF/PDGFR pathways are 
potential therapeutic targets in mesothelioma. Cediranib, a VEG-
FR/PDGFR inhibitor, showed anti-tumor activity in a salvage mono-
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cells from each line were passaged in parallel in medium only. Cells 
were in log phase growth and culture medium was free of platinum 
for at least two weeks prior to extraction of RNA using Qiagen 
RNAeasy Mini kits. High quality RNA (assessed by denaturing gel 
electrophoresis) was then DNase treated and reverse transcribed 
using Qiagen RT² Profiler PCR Array reagents. Gene expression in 
control and platinum resistant cells was determined from the Can-
cer Drug Resistance PCR Array of (Catalogue Array PAHS-004Z) 
according to manufacturer’s instructions.
Results: SULT1E1 was overexpressed in one mesothelioma line 
resistant to carboplatin at 8µg/ml, and in two of three resistant 
to 20µg/ml carboplatin, in comparison with parallel passaged 
controls. One of three cell lines resistant to carboplatin at both 
the 8µg/ml and 20µg/ml level overexpressed ERBB3, and another 
resistant at 20µg/ml overexpressed PPARγ. Drug resistance genes 
displayed more aberrant expression in cells resistant to higher 
concentrations of carboplatin.
Conclusion: The increase in expression of these three genes in 
mesothelioma resistant to carboplatin suggests that they may be 
useful targets for circumvention of resistance, but their mechanistic 
role in development of platinum resistance requires demonstrati-
on. In particular, since PPARγ ligands (e.g. roglitazone) have been 
shown to sensitise cancer cells to chemotherapeutic agents, and 
are proposed as anticancer agents, it is possible that the functio-
nal effect of PPARγ upregulation is moderating rather than causal. 
Supported by Cancer Australia.
Keyword: Drug Resistant Genes Mesothelioma
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P1.14-012 ACTIVATION OF MTOR SIGNAL PATHWAY IS 
ASSOCIATED WITH PROLONGED SURVIVAL IN MALIG-
NANT PLEURAL MESOTHELIOMA PATIENTS
Ayumi Kuroda1, Seiji Matsumoto1, Akifumi Nakamura1, Masaki 
Hashimoto1, Teruhisa Takuwa1, Nobuyuki Kondo1, Ikuko Torii2, 
Tohru Tsujimura2, Takashi Nakano3, Seiki Hasegawa1
1Thoracic Surgery, Hyogo College Of Medicine/Japan, 2Pathology, Hyogo 
College Of Medicine/Japan, 3Respiratory Medicine, Hyogo College Of 
Medicine/Japan
Background: Malignant Pleural Mesothelioma (MPM) is a rare di-
sease with poor prognosis. The combination chemotherapy with 
cisplatin and pemetrexed is the first line of MPM. The AKT/mTOR 
(Mammalian Target of Rapamycin) pathways are known to be acti-
vated in some kind of cancer. The purpose of this study is to evalu-
ate the correlation between the activation of these pathways and 
prognosis of MPM patients.
Methods: 46 patients with MPM underwent a multimodality thera-
py including extrapleural pneumonectomy (EPP) at Hyogo College 
of Medicine, Nishinomiya, Japan from April 2004 to October 2012. 
The 46 cases included 35 males (76.0%) and 11 females (23.9%). 
Median Ages is 59.8 (ranged from 37 to 71 years). Histologic sub-
type is 42 epithelial type (91.3%), 2 biphasic type (4.3%), 1 des-
moplastic type (2.1%), 1 small cell type (2.1%). Paraffin embedded 
surgical sample was used for immunohistochemistry to evaluate 
the expression of phospho- mTOR (p-mTOR) and phospho-S6 
Ribosomal Protein (p-S6RP). Overall survival (OS) from the time of 
surgery was determined by Kaplan-Meier method and results were 
benefit in malignant pleural mesothelioma (MPM). There are wide 
ranging chemotherapy utilisation rates internationally (18 – 61%). 
This study aims to determine the optimal proportion of patients 
with MPM that should receive chemotherapy at least once during 
the course of their illness, based on the best available evidence, so 
that it can be determined whether chemotherapy is under-utilised 
in MPM.
Methods: An optimal chemotherapy utilisation tree was con-
structed using indications for chemotherapy identified from 
evidence-based treatment guidelines. Epidemiological data on 
the proportion of patient and tumour-related attributes for which 
chemotherapy was indicated (resectability of the tumour, degree 
of comorbidities and patient performance status) were obtained 
and merged with the treatment indications to calculate an optimal 
chemotherapy utilisation rate, using the decision analysis software 
(TreeAge Pro 2007). Sensitivity analyses were performed to assess 
the impact of major variations in the epidemiological data on the 
overall utilisation rate. This optimal rate was compared with repor-
ted actual rates of chemotherapy utilisation in the literature.
Results: Chemotherapy is recommended at least once in 65% of 
all MPM patients. Sensitivity analyses indicate an optimal utilisation 
rate ranging from 50 to 65% for at least once during the course of 
their illness. The optimal utilisation rate is consistently higher than 
the reported actual chemotherapy utilisation rates in United King-
dom (18%), Netherlands (36%), United States (37%), and Australia 
(54%).
Conclusion: An evidence-based model provided an optimal che-
motherapy utilisation rate for patients with MPM of 65%. It can 
serve as a feasible measure of the quality of cancer care. Chemo-
therapy appears to be under-utilised in the management of MPM 
in a number of high-income countries.
Keywords: mesothelioma, Chemotherapy utilisation
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P1.14-011 CHANGES IN EXPRESSION OF CANCER DRUG 
RESISTANCE GENES IN MESOTHELIOMA CELLS EXPO-
SED TO CARBOPLATIN
Vandana Relan1, Leanne E. Morrison1, Kelly Chee1, Kwun Fong2, 
Ian Yang2, Rayleen Bowman3
1Uqtrc The Prince Charles Hospital/Australia, 2Thoracic Medicine, The 
Prince Charles Hospital/Australia, 3Department Of Thoracic Medicine, 
The Prince Charle Hospital/Australia
Background: A proportion of patients with mesothelioma respond 
to chemotherapy consisting of pemetrexed and platinum, but 
tumour responsiveness most often becomes blunted after several 
cycles. To discover the mechanism of loss of sensitivity to che-
motherapeutic agents, we compared expression of cancer drug 
resistance genes between platinum sensitive and resistant meso-
thelioma cells.
Methods: Mesothelioma cells generated from three chemo-naïve 
patients propagated in cell culture were exposed to increasing 
concentrations of carboplatin until in vitro resistance of at least 
one log10 concentration difference in IC50 was achieved in dose 
response cytotoxicity assays. For each individual, cells resistant 
to carboplatin at 8µg/ml and at 20µg/ml were generated. Control 
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Conclusion: This study confirmed that the activity of platinum 
based gemcitabine is as effective as platinum based pemetrexed 
and safe schema in malignant pleural mesothelioma.
Keywords: mesothelioma, chemotherapy
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P1.14-014 PATIENTS‘ WILLINGNESS TO PARTICIPATE IN 
A RANDOMIZED CONTROLLED TRIAL FOR MALIGNANT 
PLEURAL MESOTHELIOMA: A NEW PARADIGM TO IM-
PROVE ACCRUAL TO THORACIC ONCOLOGY TRIALS
Charles B. Simone1, Anand Shah1, Melissa J. Culligan2, Joseph 
Friedberg2, Daniel Sterman3, Evan Alley4, James P. Stevenson5, 
Keith A. Cengel1, Stephen M. Hahn1
1Radiation Oncology, University Of Pennsylvania/United States Of 
America, 2Surgery, University Of Pennsylvania/United States Of Ame-
rica, 3Medicine, Division Of Pulmonology, University Of Pennsylvania/
United States Of America, 4Medicine, Division Of Oncology, University 
Of Pennsylvania/United States Of America, 5Medicine, Division Of 
Oncology, Cleveland Clinic/United States Of America
Background: Predicting if a trial will accrue is critical, especially 
for thoracic oncology trials that have notoriously low accruals. Our 
group demonstrated unusually good results treating malignant 
pleural mesothelioma (MPM) with radical pleurectomy (RP), int-
raoperative photodynamic therapy (PDT), and chemotherapy. To 
establish if PDT is contributing to our results, a randomized trial 
of RP+/-PDT is needed. To determine if such a trial is feasible, we 
conducted a willingness to participate (WTP) study. We quantified 
differences in WTP before and after physician training designed to 
increase WTP.
Methods: All consecutive MPM patients who were candidates for 
RP+PDT were prospectively enrolled in this IRB-approved study. 
Patients participated in structured interviews, reviewed a writ-
ten description of a hypothetical RCT comparing RP to RP+PDT, 
answered open-ended and focused questions regarding their mo-
tivations for and concerns about enrollment, and completed a writ-
ten questionnaire. WTP was assessed using a 6-point Likert scale 
(1=definitely not, 6=definitely). Interview transcripts were analyzed 
using thematic data analysis and constant comparison techniques. 
Questionnaire and transcript data were used to educate physicians 
and modify their presentation of the RCT to subsequent patients.
Results: 25 participants (median age 66yrs, 72% male, 88% epi-
thelial histology) enrolled. Some had pre-existing knowledge of 
RP (44%) or PDT (40%). Following the first 8 patients enrolled, 
we identified 15 factors impacting WTP focusing on five themes: 
randomization, hope for cure, desire to compare treatments, al-
truism, and physician opinion (Table 1). Based on these findings, 
physicians were trained to more thoroughly explain the WTP and 
proposed RTC and addressed concerns raised by these initial 8 
patients when meeting with subsequent patients. Physician time 
explaining the WTP increased following training (median 9min vs. 
3min, p<0.0001). Overall, 56% “definitely” or “probably” would, 
28% “may,” and 16% would “probably not” or “definitely not” 
participate. More patients would be “definitely” or “probably” 
willing to participate after physician training (71% vs. 25%, p=0.03). 
Furthermore, none of the initial 8 patients were “definitely” willing, 
compared with 8 of the subsequent 17 (p=0.02). Following consul-
tation, 16 underwent surgical-based therapy, with no difference 
compared by log-rank test.
Results: OS was significantly better in phospho-S6RP positive pati-
ents (32/46) in comparative with phosphor-S6RP negative patients 
(14/46) (43.6 months vs. 14.4 months, P=0.03). OS was significantly 
better in phospho-mTOR positive patients (18/46) in comparative 
with phosphor-mTOR negative patients (28/46) (37.1 months vs. 
14.4 months, P=0.08).
Conclusion: In MPM patients, high phospho-S6RP expression is 
predictive of improved OS. The assessment of phospho-S6RP 
expression is worth of prospective validation in future studies on 
a multimodality therapy of MPM. And this study support that the 
AKT/mTOR pathways is a promising candidate of molecular target 
therapy for MPM.
Keyword: malignant pleural mesothelioma
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P1.14-013 THE EFFECTIVENESS AND SAFETY OF PLA-
TINUM BASED PEMETREXED AND PLATINUM BASED 
GEMCITABINE TREATMENT IN THE PATIENTS WITH MA-
LIGNANT PLEURAL MESOTHELIOMA
Guntulu Ak1, Selma Metintas2, Muhittin Akarsu1, Muzaffer Metin-
tas1
1Pulmonary Medicine, Eskisehir Osmangazi University Medical Faculty/
Turkey, 2Public Health, Eskisehir Osmangazi University Medical Facul-
ty/Turkey
Background: Chemotherapy schemas evaluated in terms of ef-
ficiency and safety are limited in malignant pleural mesothelioma 
treatment. In our study we aimed to evaluate efficiency and safety 
of cis/carbo+pemetrexed, which is known as effective in meso-
thelioma and cis/carbo+gemcitabine, which is used in the past 
for mesothelioma but doesn’t have proved information about its 
efficiency, in comparable historical groups of malignant pleural 
mesothelioma.
Methods: One hundred and sixteen patients received cis/
carbo+pemetrexed (group 1) and 30 patients received cis/
carbo+gemcitabine (group 2) between June 1999 and June 2012 
composed study groups.
Results: The mean age of group 1 and 2 were 60.7 and 60.8 years. 
Female ratio of group 1 and 2 were 50% and 53%. Most of pati-
ents (98%) exposed to asbestos in part of their life. 78.1% of the 
patients have epithelial type tumor and 47% of patients have stage 
IV disease. There was no difference between two groups in terms 
of age, sex, asbestos exposure, histological cell type, stage and 
Karnofsky performance status. The median survival time and 95% 
confidence interval were 12±0.95 months (95% CI: 10.15 – 13.85) 
for group 1 and 11.0±1.09 months (95% CI: 8.85 – 13.15) for group 
2. The median survival of two groups was not different (Log-Rank: 
0.142; p=0.706). Stage and Karnofsky performance status were 
found as significant variables on median survival time by univariate 
analysis (p=0.002 and p=0.045 respectively). After adjusting for 
stage and Karnofsky performance status, chemotherapy schema 
was not impressive on median survival (OR: 0.837; 95% CI: 0.548 
– 1.277; p=0.409). The treatment was generally well tolerated and 
side effects were similar in both groups.
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before or after training (50% vs. 71%, p=0.34).  
Table 1. Motivations (m) and concerns (c) reported by patients (N=25) when deciding if they would enroll in the proposed randomized 
clinical trial for malignant pleural mesothelioma
Trial Design Factors N= Therapy-relate Factors N= Humanistic/Ethical Factors N=
Randomization (c) 12 Hope for a cure (m) 10 Altruism towards other patients (m) 9
Deference to physician opinion 
(m)
7
Desire to compare treatments 
(m)
8 Deference to family opinion (m) 4
Concerns with experimentation (c) 2 PDT side effects (c) 6
Altruism towards science/physician/ hospital 
(m)
1
Financial incentives (m) 1 Potential benefit of PDT (m) 3
Reputation of the hospital (m) 1 Prior knowledge of PDT (m) 1
Close follow-up (m) 1
Availability of alternative treat-
ments (c)
1
 
Conclusion: This study demonstrated analyzing and addressing 
patient motivations and concerns about enrollment, physician trai-
ning, and increasing time spent with patients can increase WTP. In 
this study, most patients expressed a WTP in a RCT of RP+/-PDT 
for MPM. Performing WTP studies prior to planned prospective 
thoracic oncology trials should be considered to optimize trial 
design and accrual strategies.
Keywords: malignant pleural mesothelioma, oncology trial accrual, 
randomized control trial, willingness to participate
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whole, adjuvant RT did not significantly improve survival or reduce 
recurrence. This was a retrospective study, and a multicenter ran-
domized trial will be necessary to verify the role of adjuvant 3D-
CRT/IMRT in this disease.
Keywords: thymoma, radiation, surgery, failure pattern
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P1.15-002 RESULTS AND PROGNOSTIC FEATURES OF 
RECURRENT THYMOMA
Cai Xu, Qinfu Feng, Chengcheng Fan, Yirui Zhai, Yidong Chen, 
Hongxing Zhang, Zefen Xiao, Zongmei Zhou, Jun Liang, Zhougu-
ang Hui, Dongfu Chen, Jie He, Lvhua Wang
Radiation Department, Cancer Institute &hospital.chinese Academy Of 
Medical Sciences, Peking Union Medical College/China
Background: This study sought to analyse the results and progno-
sis of recurrent thymoma.
Methods: Between 1991 and 2012, 32 patients who developed 
recurrence after radical resection of thymoma were reviewed.
Results: The initial Masaoka staging was stage I, 3; stage II, 14; 
stage III, 10; stage IVa, 4;and stage IVb, 1. World Health Organiza-
tion tumor type: A and AB, 5; B1, 7; B2, 6; B3, 12; and unknown, 2. 
Among the 32 patients, relapses were found in the following sites: 
pleura (20 cases), tumor bed (10),non-tumor bed in mediastinum 
(one), lung (seven), chest wall (six), lymph node metastasis (four) , 
abdominal node metastasis (one),liver (one), pleural effusion (four), 
and overlapped recurrence (14).The patterns of recurrence: local 
recurrence, 6; regional recurrence, 8; distant recurrence, 5; local 
and regional recurrence, 6; regional and distant recurrence, 4; 
local, regional and distant recurrence, 3. The median recurrence 
interval was 42 months (range, 5–193 months). The median follow-
up time after recurrence was 49.5 months (range, 1-136months). 
Overall 5-year survival after recurrence was 65.5%. 7 patients with 
relapse in the thorax are still alive after re-resection, with a median 
survival time of 26 months (range, 6-95 months). The perioperative 
mortality was 0% and the morbidity was 14%. 4 patients with local 
relapse were given radiotherapy (RT) alone, with a median survival 
of 60 months (range, 51-107months) and one was dead of progres-
sive disease, probably due to lower reirradiation dose (50Gy), com-
pared to others with radical radiation dose (60Gy). In patients with 
regional and/or distant relapse, 6 patients received chemotherapy, 
and had 37.5% of overall 5-year survival. 5 patients without re-
treatment had 50% of overall 1-year survival, with median survival 
3 months (range,1-20months). After re-treatment, 9 patients had 
re-relapse, and the re-relapse free survival rate was 63% at 5 ye-
ars, with a median re-relapse free survival of 53 months (range, 
11-69months). 1 of 15 patients with RT had radiation pneumonitis 
and recovered after management. In univariate analysis, age (<55y, 
≥55y; p=0.009), patterns of relapse (p=0.042), and recurrence-free 
interval (<20months, ≥20months; p=0.038) were prognostic fac-
tors.
Conclusion: Reoperation for resectable thymoma recurrences is 
associated with better outcome and relative safety, and it should 
be recommended. In patients with local recurrence of thymoma, 
RT may get comparable survival to re-operation. RT/CT probably is 
the treatment of choice when re-resection is not feasible. Younger 
age, local and regional recurrence, and longer relapse-free interval 
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P1.15-001 POSTOPERATIVE RADIOTHERAPY FOR COM-
PLETELY RESECTED MASAOKA STAGE III THYMOMA: A 
RETROSPECTIVE STUDY OF 65 CASES FROM A SINGLE 
INSTITUTION
Chengcheng Fan1, Qinfu Feng1, Yidong Chen2, Yirui Zhai1, Zong-
mei Zhou1, Dongfu Chen1, Zefen Xiao1, Zhouguang Hui3
1Radiation Oncology, Chinese Academy Of Medical Scinse, Peking Union 
Medical School,cancer Hospital./China, 2Radiation Oncology, Beijing 
Shijitan Hospital/China, 3Radiation Oncology, Chinese Academy Of Me-
dical Scinse And Peking Union Medical School, Cancer Hospital/China
Background: The role of adjuvant radiotherapy (RT), especially 
three-dimensional conformal RT (3D-CRT)/intensity modulated RT 
(IMRT) for patients with stage III thymoma after complete resection 
was not definite. In this study, we retrospectively evaluated the 
effect of 3D-CRT/IMRT on survival as well as tumor control in this 
subgroup of patients.
Methods: Between September 1965 and December 2010, 68 
patients who underwent complete resection of stage III thymoma 
entered the study. Fifty-six patients had adjuvant RT after surgery 
(S+R) and 12 had surgery only (S alone). Of patients who had adju-
vant RT, 30 had 3D-CRT/IMRT and 26 had conventional RT.
Results: Five- and 10-year overall survival (OS) rates were 89.4% 
and 70.3%, respectively, for S+R and 81.5% and 65.2% for S alone 
(p=0.576). In the subgroup analysis, patients with 3D-CRT/IMRT 
showed a trend of improved 5-year OS compared with conventi-
onal RT (100% vs. 83.5%, p=0.093). Compared with S alone, the 
5-year OS was significantly improved (100% vs. 81.5%, p=0.045). 
Recurrence rates were similar with and without adjuvant RT, but 
there was a significantly lower recurrence rate with 3D-CRT/
IMRT compared with conventional RT (10% vs. 38.5%, p=0.012).
Conclusion: Adjuvant 3D-CRT/IMRT is potentially advantageous in 
improving survival rates and reducing recurrence in patients with 
completely resected stage III thymoma, but for the cohort as a 
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P1.15-004 RELATIONSHIP OF THERAPEUTIC RESULTS 
WITH IMMUNOHISTOCHEMICAL FINDINGS IN THYMIC 
CARCINOMA CASES
Toru Kimura, Yasushi Shintani, Tomohiro Kawamura, Soichiro 
Funaki, Tomoyuki Nakagiri, Masayoshi Inoue, Noriyoshi Sawaba-
ta, Masato Minami, Meinoshin Okumura
Department Of General Thoracic Surgery, Osaka University Graduate 
School Of Medicine/Japan
Background: A thymic carcinoma is a thymic epithelial neoplasm 
that has a large number of malignant features as compared to 
a thymoma. Since a thymic carcinoma is presented with locally 
advanced disease or distant metastasis, unresectable cases are 
frequently encountered at diagnosis, thus systemic chemotherapy 
is a key treatment strategy. Although cisplatin-based chemothe-
rapy is usually administered for such cases, an optimal regimen 
has not been established. To determine a prognostic indicator for 
chemotherapy in patients with thymic cancer we evaluated the ex-
pressions of excision repair cross complementing-1 (ERCC1), class 
III β-Tubulin (TubIII), ribonucleotide reductase M1 (RRM1), and thy-
midylate synthase (TS)/orotate phosphoribosyltransferase (OPRT), 
which have been reported as possible indicators of the anticancer 
activity of cisplatin, taxanes, gemcitabine, and 5-fluorouracil drugs 
such as S-1, respectively.
Methods: Thymic carcinoma tissue samples obtained from 15 
patients who underwent surgery or core-needle biopsy proce-
dures between 1996 and 2007 at Osaka University Hospital were 
used. Immunohistochemical analysis was utilized to determine the 
expressions of ERCC1, TubIII, RRM1, TS, and OPRT in thymic cancer 
specimens, then the relationship between expression levels and 
clinical course were examined in a retrospective manner.
Results: Twelve males and 3 females (median age, 60.3 years) were 
studied. The histological subtype was squamous cell carcinoma in 
10, small cell carcinoma in 2, large-cell neuroendocrine carcinoma 
in 2, and carcinoid in 1, while Masaoka classification was stage III in 
4, IVa in 4, and IVb in 7. Surgical resection was performed as initial 
treatment in 8 patients. Chemotherapy, mainly platinum-based 
combinations, was administered in 12, including 6 who received 
combined radiotherapy. The median number of administered 
regimens and cycles were 2 (range, 1-9) and 7 (range, 2-44), res-
pectively, for each patient. The response rate/disease-control rates 
following first- and second-line treatments were 83%/92% and 
56%/78%, respectively. In 6 patients treated with gemcitabine, 3 
tumors with a low expression of RRM1 showed a good response, 
whereas 2 of 3 tumors with a high expression of RRM1 showed a 
progressive disease response. S-1 was administered to 1 patient, 
which successfully suppressed tumor progression, and the speci-
men from that case demonstrated a low expression of TS and high 
expression of OPRT. We were able to obtain biopsy specimens 
before and resected tumors after treatment from 5 patients, in 
which the expressions of ERCC1, Tub III, and RRM1 were increased 
after treatment in 4, 3, and 4, respectively. Our results suggest that 
sensitivity to chemotherapy is lowered with additional courses in 
thymic carcinoma patients. The median survival was 36 months, 
while the 1-, 3-, and 5-year survival rates were 81.9%, 55.5%, and 
23.1%, respectively.
Conclusion: First-line chemotherapy with platinum compounds 
may be effective treatment for patients with thymic cancer, while 
new drugs such as gemcitabine and S-1 might be useful in some 
are associated with positive prognosis.
Keyword: Recurrent Thymoma, Management, outcomes,  
Prognosis.
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P1.15-003 PHASE II STUDY OF AMRUBICIN (AMR) AND 
CARBOPLATIN (CBDCA) FOR INVASIVE THYMOMA (IT) 
AND THYMIC CARCINOMA (TC) : NORTH JAPAN LUNG 
CANCER GROUP 0803
Shoichi Kuyama1, Akira Inoue2, Masamoto Nakanishi1, Yosuke Ka-
washima3, Masao Harada4, Kunihiko Kobayashi5, Toshiyuki Kozu-
ki6, Tomohiro Sakakibara2, Makoto Maemondo7, Hajime Asahina8, 
Akiko Hisamoto9, Taku Nakagawa10, Toshihiro Nukiwa2
1Respiratory Medicine, Iwakuni Clinical Center/Japan, 2Tohoku Uni-
versity Hospital/Japan, 3Sendai Kosei Hospital/Japan, 4Department Of 
Respiratory Medicine, Hokkaido Cancer Center/Japan, 5Saitama Univer-
sity International Medical Center/Japan, 6Shikoku Cancer Center/Japan, 
7Miyagi Cancer Center/Japan, 8Hokkaido Univercity/Japan, 9Okayama 
Univercity/Japan, 10Senboku Kumiai Hospital/Japan
Background: There has been no standard chemotherapy for ad-
vanced thymic malignancies including invasive thymoma(IT) and 
thymic carcinoma(TC) although anthracycline or platinum agents 
have been commonly used for them. AMR, a new anthracycline 
agent, was approved for lung cancer in Japan and we had previ-
ously conducted some prospective studies of AMR combined with 
CBDCA for patients with small-cell lung cancer, which revealed this 
regimen was active with acceptable toxicity. The objective of this 
study is to evaluate the efficacy and safety of this combination for 
patients with advanced thymic malignancies.
Methods: Patients with histologically confirmed thymic malignan-
cies received AMR (35 mg/m2, day1-3) and CBDCA (AUC 4.0, day1) 
every 3 weeks. Patients who underwent previous chemotherapy 
received reduced dose of AMR (30 mg/m2). The primary endpoint 
was overall response rate (ORR), and secondary endpoints were 
progression-free survival (PFS), overall survival and toxicity profile. 
Assuming that ORR of 75% and 45% would indicate the potential 
usefulness while ORR of 50% and 20% would be the lower limit of 
interest, with alpha = 0.10 and beta = 0.20, for IT patients and TC 
patients, respectively, 18 IT patients and 16 TC patients were at 
least required.
Results: From December 2008 to October 2012, 51 patients (18 IT 
and 33 TC) were enrolled from 20 institutions in Japan. The ORR 
and disease control rate were 17% and 89% in IT, and 30% and 
85% in TC. Median PFS was 7.6 months in both groups. Toxicity 
was generally moderate and no treatment related death was ob-
served.
Conclusion: This is the largest prospective study of chemotherapy 
for advanced thymic malignancies. AMR combined with CBDCA 
was effective for TC patients with acceptable toxicities.
Keywords: Thymic carcinoma, Phase 2 Sudy, chemotherapy,  
thymoma
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P1.15-006 THYMIC MALIGNANCIES. A SINGLE INSTITU-
TION SERIES FROM 2000-2012
Hannah Jonker1, Marcio Gomes2, Farid Shamji3, Paul Wheatley-
Price1
1Medicine, University Of Ottawa / Ottawa Hospital Research Institute/
Canada, 2Pathology And Laboratory Medicine, University Of Ottawa/
Canada, 3Surgery, University Of Ottawa/Canada
Background: Thymoma and thymic carcinoma are rare malignan-
cies, despite being amongst the most common tumours of the 
anterior mediastinum. The incidence of thymoma in the United 
States is approximately 0.15 per 100,000 person years. Thymoma 
research has proved challenging, and as such the International 
Thymic Malignancy Interest Group (ITMIG) has created an interna-
tional database in an effort to promote the advancement of clinical 
and basic science research in thymic malignancies. We performed 
a single institution retrospective chart review to submit to ITMIG, 
collecting additional data regarding systemic therapy regimens.
Methods: With ethics approval, we performed a retrospective 
chart review of all patients seen at our institution between January 
2000 and December 2012 with a diagnosis of thymic neoplasm. 
Data collected included baseline patient demographics, histology 
(WHO), staging (Masaoka), the presence or absence of associated 
paraneoplastic syndromes such as myasthenia gravis (MG), treat-
ment decisions and survival. All lines and indications of systemic 
therapy were recorded.. The primary analysis is descriptive.
Results: In total 76 patients were included; 35 female (46%); me-
dian age at diagnosis 60 years (range 25-89) and 71 (93%) had a 
good performance status (ECOG 0-1). MG was present in 16 (21%). 
The WHO histological classification was: A (11, 15%), AB (23, 30%), 
B1 (12, 16%), B2 (10, 13%), B3 (13, 17%), C (5, 7%), NETT (1, 1%), and 
unclassified (1, 1%). Definitive surgery occurred in 64 cases (84%), 
with an R0 resection in 53 patients. For those who had surgery, 11 
also received chemotherapy either as induction (6), adjuvant (4) or 
both (1); 27 received radiotherapy either as induction (2) or adju-
vant therapy (25). Twelve patients (16%) were not treated surgically, 
and three patients received no therapy at all. In total only 14 pati-
ents (18%) received systemic therapy in any setting. Where evalu-
able, the first-line RECIST response rate was 55%, but no patients 
had progressive disease (Figure). Common first-line regimens were 
platinum/etoposide (8), carboplatin/paclitaxel (3) and CAP (cyclo-
phosphamide, adriamycin, cisplatin, n=2). Only 3 patients received 
further chemotherapy (1 patient received 2 further lines; 2 patients 
received 3 more lines). The median follow up for all patients was 45 
months, and 59 (78%) remain alive. Of the 5 thymic carcinoma pati-
ents, 4 have died (median survival 10 months).
Conclusion: While few patients received systemic therapy for thy-
mic malignancies, it remains a chemosensitive disease, but surgical 
resection is the mainstay of treatment.
cases. Prospective multi-Institutional studies are required to ascer-
tain the effectiveness of immunohistochemical evaluation used as 
a screening test for selecting the optimum chemotherapy regimen 
for thymic cancer patients.
Keywords: Thymic Cancer, chemotherapy, immunohistochemical 
evaluation
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P1.15-005 MULTIMODALITY TREATMENT FOR THYMO-
MA AND THYMIC CARCINOMA: RESULTS OF A SINGLE 
CENTER EXPERIENCE.
Hüseyin Mertsoylu, Fatih Köse, Sadık Muallaoğlu, Ahmet Sezer, 
Ali A. Beşen, Cemile Karadeniz, Ozgur Ozyilkan
Department Of Medical Oncology, Baskent University Medical Faculty/
Turkey
Background: There are no randomized clinical trials that provide 
clear algorithm for the management of patients with thymoma or 
thymic carcinoma due to the rarity of these tumors.We review our 
experience with a multimodal approach in fourteen cases
Methods: Patients with thymoma and thymic carcinoma who 
were treated with multimodality treatment in our center between 
periods of 2006 and 2012 were retrospectively analyzed. Basic 
demographics, clinicalcharacteristics’ of the patients such as status 
of stage of tumor according to Masaoka Staging System, type of 
systemic chemotherapy, presence of paraneoplastic myasthenia 
gravis syndrome and surgical marginswere collected.
Results: Fourteen eligible patients were analyzed retrospectively. 
There were seven (50%) thymic carcinoma and seven (50%) thymo-
ma. Included were 14 patients with a mean age of 50 years. Three 
patients (21.4%) had diagnosis of Myasthenia Gravis initially. There 
were four patients (28.6%), nine patients (64.3), one patient (7.1%) 
at stage II, Stage III, and stage IV, respectively. Nine patients were 
treated with multimodality treatment including surgery, chemora-
diotherapy and adjuvant chemotherapy. Five patients were treated 
with chemoradiotherapy and adjuvant chemotherapy without sur-
gical excision. Eight patients out of nine patients who were treated 
with primary surgery had positive resection margin (R1).Adjuvant 
protocol was consisted of cisplatin based chemotherapy. Median 
overall survival was 55 months (95% CI 11,4-98,5).One, two, and 
three year survival rate for thymoma was 85%, 85%, and 85%. Alt-
hough, statistical analysis failed to show significant difference one, 
two, and three year survival rate for thymic carcinoma was inferior 
and found as 85%, 70%, and 43%, respectively. We were not able 
to show significant effects of patient and tumor baseline characte-
ristics on overall survival.
Conclusion: Overall survival in our analysis seems to relatively 
inferior when compared with literature. We suggest that this result 
may be related with high rate of positive surgical margins and even 
absence of surgical excision in five patients a part of multimodal 
treatment.
Keywords: Multimodality treatment, thymoma and thymic carci-
noma
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type and carcinoid. The most frequent combined thymomas were 
B2B3 (19) and B1B2 (8) types. The most histologic types appeared 
equally in both genders. B2B3 tumors concerned two times more 
frequent male patients and AB, B1 and micronodular were more 
common in women. Median age fell from micronodular type (78,5 
years) followed by A (63 years), AB (58 years), B1 (55 years), B2 
(52,5 years) and B3 (48 years). The tumors were usually in the 2nd 
stage. 18 (12%) patients died, 92 (60%) are still alive. The data 
were not available in 42 (28%) cases. The interval from resection 
to death was 1 month to 10 years. Histological types of thymomas 
diagnosed in patients who died included B1 (5 cases), AB (3), A (2), 
B2 (1) and 3 combined thymomas. The most tumors were in the 
2nd stage. Recurrence occurred in 8 (5%) patients. Recurrent tu-
mors appeared from 2 to 11 years after resection (median interval 
8 years). The tumors were classified as B2 (2 cases), B2B3 (2), B1B2 
(1), AB/B3 (1), AB/micronodular (1). The type was not determined in 
one case. Thymomas were in all stages except the 1st.
Conclusion: The thymomas appear mainly in 6th decade, more 
often in women. The most frequent histological type is AB and the 
tumors are usually microinvasive (the 2nd stage). High percentage 
of tumors has combined morphology. Recurrence can occur in any 
type of thymoma even considered as well-predicting but time to 
the progression often exceeds 5 years, so the tumors require long-
term observations.
Keywords: thymomas, histopathology, classification
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P1.15-008 A MULTIVARIATE ANALYSIS OF FACTORS PRE-
DICTING SURVIVAL IN 70 PATIENTS WITH THYMIC CAR-
CINOMA: IMPLICATIONS FOR TREATMENT STRATEGY
Masahiko Harada1, Yusuke Okuma2, Tsunekazu Hishima3, Satoko 
Murakami1, Hirotoshi Horio1
1Department Of Thoracic Surgery, Tokyo Metropolitan Cancer And 
Infectious Diseases Center Komagome Hospital/Japan, 2Department Of 
Thoracic Oncology And Respiratory Medicine, Tokyo Metropolitan Can-
cer And Infectious Diseases Center Komagome Hospital/Japan, 3Depart-
ment Of Pathology, Tokyo Metropolitan Cancer And Infectious Diseases 
Center Komagome Hospital/Japan
Background: Thymic carcinomas are considered to be more ag-
gressive than thymomas and carry a worse prognosis. Although 
a multimodality treatment is made in many cases as for thymic 
carcinomas, optimal therapeutic strategy still remains controversial 
especially in thymic carcinomas having poor prognostic factors. In 
the present study, we attempted to clarify the prognostic factors 
based on the survival to establish suitable treatment strategy.
Methods: We performed a single-Institution retrospective cohort 
study. Between June 1987 and October 2012, 70 patients were 
eventually given a diagnosis of thymic carcinoma. Data included 
patient demographics, stage, first treatment (e.g. chemotherapy 
(CT), chemoradiotherapy (CRT), and surgery (S)), pathologic fin-
dings, and outcomes. For the univariate analysis, we constructed 
survival curves using the Kaplan-Meier method and compared 
survival between groups using log-rank tests. Multivariate analysis 
was performed by constructing a Cox proportional hazards model 
using the significant factors from the univariate analysis. The ana-
lyses were performed with the Stat view v5.0 statistical software 
program.
Keywords: chemotherapy, case series, thymoma
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P1.15-007 CHARACTERISTICS OF THYMOMAS DIAG-
NOSED IN NATIONAL TUBERCULOSIS AND LUNG DI-
SEASES RESEARCH INSTITUTE IN WARSAW (POLAND)
Malgorzata Szolkowska1, Renata Langfort1, Piotr Rudzinski2, Ewa 
Szczepulska-Wójcik1, Beata Maksymiuk1, Tadeusz Orlowski2
1Pathology Dpt., National Tuberculosis And Lung Diseases Research 
Institute/Poland, 2Thoracic Surgery, National Tuberculosis And Lung 
Diseases Research Institute/Poland
Background: There were 152 thymomas diagnosed in Pathology 
Department of National Tuberculosis and Lung Diseases Research 
Institute from 1999 to the beginning of 2013. We performed a 
clinico-pathologic analyze of this rare group of neoplasms.
Methods: The diagnosis was establish on the investigation of to-
tally resected tumors (126 cases) or small biopsied material (26). 
WHO histological classification of thymic tumors (2004) and Masa-
oka staging system were applied. The informations about patients 
age and gender, symptoms, other neoplasms, death and recur-
rence were collected.
Results: There were 86 (57%) women (median age 59 years) and 66 
(43%) men (median age 54 years) in analyzed group. Myasthenic 
symptoms accompanied 50 (33%) tumors, 1 patient suffered from 
superior vena cava syndrom, the rest (101, 66%) was asymptoma-
tic. In 6 (4%) patient another cancer was discovered: lung (3), renal 
(1), thyroid (1) and laryngeal (1) carcinoma. 147 thymomas were 
radiologically described as "mediastinal tumor”, 4 - "mediastinal 
cyst” and 1 thymoma on CT-scan was treated as mediastinal lymph 
node. Microscopic analysis revealed 9 (6%) type A thymoma, 42 
(28%) AB, 27 (18%) B1, 16 (11%) B2, 4 (3%) B3, 4 (3%) micronodular, 
2 (1%) metaplastic, 2 (1%) sclerosing and 1 (less then 1%) microsco-
pic. 4 tumors were almost totally necrotized and the type could not 
be established, in 3 cases the specimen was to small to recognized 
the type. 38 (25%) tumors showed combined morphology com-
posed of different types of thymomas, 1 tumor consisted of AB 
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Methods: Princess Margaret Cancer Center radiation and surgical 
oncology databases were queried from 1983-2012. Retrospective 
analyses using electronic patient records and Mosaiq radiotherapy 
database were performed to assess demographic data, clinical 
presentation and treatment. Descriptive statistics were used to re-
port demographic data. Time to event analyses and correlation of 
outcomes with demographic and treatment variables are planned.
Results: Details on 104 patients treated with post-operative ra-
diotherapy from 1983-2012 were available. The mean age was 52, 
range 29-73. Of patients assessed, 55/104 were male. Masaoka-
Koga stage was assessed: 6% of patients were stage I, 31% IIA, 
21% IIB, 27% III, 10% IV and 6% unknown. The most common WHO 
grade was B2 (37%) followed by B1 (16%). Complete surgical re-
section (R0) was obtained in 72% patients, R1 in 21%, R2 in 2% and 
5% unknown. Radiotherapy doses ranged from 40 Gy – 66 Gy de-
livered in daily 2 Gy fractions; 57% patients were deemed low risk 
(typically R0 resection and WHO grade B2 or lower) and received 
40Gy while 36% received between 45-66Gy. Neoadjuvant or adju-
vant chemotherapy was delivered to 13% of all patients. The mean 
follow up period was 9.4 years, range 0.5-25.5 years, during which 
22% patients experienced relapse. Of these, 43% experienced 
regional recurrence, defined as an intrathoracic relapse in an area 
not-contiguous with the thymic bed or original tumour; 39% local 
(intrathoracic relapse contiguous with original disease or thymic 
bed), and 17% distant recurrence defined as extrathoracic or int-
raparenchymal pulmonary nodules. For patients that experienced 
relapse, the median time to relapse was 8.7 years (range 1.3-18.3 
years). Of the 59 patients who received 40 Gy/20 fractions, 8 deve-
loped local relapse (13.5%). Overall survival and multivariable ana-
lyses will be reported as will assessment of long term toxicities.
Conclusion: Risk-adapted RT prescription for patients with resec-
ted thymoma appears efficacious, and may result in an improved 
therapeutic ratio for these patients. Long-term, randomized con-
trolled trials are required to further identify patients that are best 
suited to this approach.
Keyword: Thymoma, Radiotherapy, Surgical resection
Results: The overall 2- and 5-year survival rate was 61.9% and 
36.4%, respectively ; mean and median observation time was 30M 
and 24M, respectively. Two-year survival rates in patients treated 
with CT, CRT, and S group were 38.7, 52.4, and 80.5%, and 5-year 
survival rates in patients treated with CT, CRT, and S group were 
17.4, 21.0, and 55% for all patients. S group showed significantly 
better prognosis than the others in overall stage (p=0.0006). Pa-
tients undergoing S, however, had similar survival compared with 
undergoing CT or CRT alone in stage IV a,b subset; CT vs. CRT 
(p=0.6598), CT vs. S (p=0.1159), CRTvs.S (p=0.3030). Univariate 
analysis among patients underwent surgery revealed two signifi-
cant prognostic factors (P <.05): stage by the Masaoka system and 
resection status. Based on the result, 5-year survival rate in each 
factor were compared statistically by Kaplan–Meier’s method; 
Masaoka stage II,III vs. IVa,b =82.5% vs.35.3% (p=0.0182), comple-
te resection vs. incomplete resection=76.4% vs.34.1% (p=0.0173). 
Multivariate analysis revealed no statistically significant indepen-
dent prognostic factor, probably due to confounding. The hazard 
ratio for death for being Masaoka stage II,III was 0.463 [95%CI 
0.082-2.623](p=0.3843), for being complete resection was 0.552 
[95%0.110-2.762](p=0.4701). According to the subset analysis on 
CT group, response to first-line chemotherapy was an independent 
prognostic factor.
Conclusion: Our analyses indicated that stage by the Masaoka 
system and resection status would have the prognostic impact. If 
complete excision is possible at earlier than Masaoka stage III, it 
may be cured completely. The role of debulking surgery at stage 
IV a,b was negative. Patient selection, accurate staging, and choice 
of anticancer drug with a high response rate may be critical to opti-
mizing outcomes.
Keywords: Thymic carcinoma, prognostic factor, surgical interven-
tion
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P1.15-009 OUTCOMES AND PREDICTORS OF RECUR-
RENCE IN PATIENTS TREATED WITH RISK-ADAPTED, 
POST-OPERATIVE RADIOTHERAPY (RT) FOR THYMO-
MA - A SINGLE INSTITUTION, 30 YEAR RETROSPECTIVE 
STUDY
Anthony Brade1, Nafisha Lalani1, Najib Safieddine2, David Hwang3, 
Shaf Keshavjee2, Andrea Bezjak1
1Radiation Medicine Program, Princess Margaret Cancer Centre/Cana-
da, 2Division Of Thoracic Surgery, Toronto General Hospital, University 
Health Network, University Of Toronto/Canada, 3Pathology, University 
Health Network/Canada
Background: Thymoma is a rare epithelial cell tumour of the thy-
mus, with an incidence of 0.15 per 100 000 persons. Thymic carci-
nomas comprise a distinct subset and have a greater propensity 
for capsular invasion and distant metastases when compared to 
thymomas. Resection is the standard of care for localized disease 
but local recurrence is generally incurable, thus post-operative RT 
is often employed for high risk cases. The optimal dose of RT has 
not been established, nor whether lower doses can be utilized in a 
risk-adapted fashion for cases where RT is recommended but the 
aggressiveness of the disease/risk of recurrence is felt to be at the 
lower end of the spectrum. Use of lower dose RT may help reduce 
the chances of late RT toxicity. Our institution employs such a risk 
adapted strategy and we present here our long term results.
S651Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 1 - OTHER THORACIC MALIGNANCIES  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.16-002 HISTOLOGICAL IMPACT OF PRIMARY TUMOR 
ON INDICATION OF REPEATED PULMONARY METAS-
TASECTOMY
Tetsuya Mizuno, Tetsuo Taniguchi, Noriyasu Usami, Koji Kawa-
guchi, Takayuki Fukui, Futoshi Ishiguro, Shota Nakamura, Naoki 
Ozeki, Taketo Kato, Chihiro Yamatani, Kohei Yokoi
Department Of Thoracic Surgery, Nagoya University Graduate School 
Of Medicine/Japan
Background: Lung is one of the most common metastatic sites 
from malignances. Although efficacy of pulmonary metastasecto-
my (PM) has been reported recently, the prevalence has not been 
enough among thoracic surgeons. Moreover, beneficial effects of 
repeated PMs for longer survivals have been poorly evaluated. The 
aims of this study are to examine the efficacy of repeated PMs (Re-
PM) for re-recurred diseases and evaluate the histological impact 
of the primary tumor on the treatment.
Methods: We retrospectively reviewed 263 patients who under-
went PMs for various malignancies from 1996 through 2011. These 
factors below were evaluated; age, gender, origin of primary tu-
mors, disease free interval (DFI) to the first PM, surgical procedure 
of PM, number of resected tumors, frequency of PMs, DFI after the 
first PM, overall survival after the first PM and prognosis.
Results: Among 263 patients, 166 were male, and 98 were female. 
The median age was 60 years old (range: 7-85). Origins of primary 
tumors were following; 91 colorectum, 54 bone and soft tissue, 22 
head and neck, 20 adnexa uteri, 17 urinary tract, 14 testis (germ 
cell tumor), 45 others. Mean number of resected nodules at the 
first PM was one, and the maximum was 19. Wedge resections 
were performed most frequently in 159 patients (60%), lobecto-
mies in 69 (26%), segmentectomies in 32 (12%), and bilobectomies 
in 5 (2%). Re-PMs were indicated in 47 patients (18%). Among 
them, while the prevalence of Re-PM was 20% (18/91) in colorectal 
cancer patients, that is as high as 37% (20/54) in bone and soft 
tissue sarcoma patients. Estimated five-year survival rate of the 
whole patients was 50.6%. And that of patients without recurrence, 
with Re-PM and without Re-PM were 92.9, 58.5 and 14.5%, respec-
tively. In univariate analyses, sublober resection of the first PM, DFI 
and presence of complete resection at the first PM were significant 
favorable factors for overall survival. In the multivariate analysis, 
sublober resection and presence of complete resection at the first 
PM were revealed to be the independent prognostic factors.
Conclusion: The large portion of Re-PM patients had colorectal 
cancer, or bone and soft tissue sarcoma as their primary tumor. Re-
PM may improve the survival of selected patients who experienced 
re-recurrence in lung after PM. Primary tumor of bone and soft 
tissue sarcoma were the most applicable histology for Re-PM.
Keywords: pulmonary metastasectomy, repeated pulmonary me-
tastasectomy
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P1.16-001 OUTCOMES OF SURGICAL RESECTION AND 
RADIOFREQUENCY ABLATION FOR LUNG METASTASIS 
FROM HEPATOCELLULAR CARCINOMA
Teruki Kobayashi1, Masafumi Kataoka1, Tohru Kojima1, Takefumi 
Niguma1, Kotarou Yasui2, Kazuhiko Watanabe3, Haruyuki Kawai3, 
Mtsuru Muguruma3, Tetsushige Mimura1, Toshinori Ohara1
1Surgery, Okayama Saiseikai General Hospital/Japan, 2Radiology, Oka-
yama Saiseikai General Hospital/Japan, 3Internal Medicine, Okayama 
Saiseikai General Hospital/Japan
Background: The lung is the most frequently targeted organ for 
extra-hepatic metastasis from hepatocellular carcinoma (HCC). Pul-
monary metastases account for 33.1% of extra-hepatic metastases 
from HCC. However, in most cases, pulmonary metastatic lesions 
are multiple and the prognosis of patients is poor. No standardized 
treatment for this condition has been established to date. Radio-
frequency ablation (RFA) is commonly used for the local control of 
hepatic tumors. Recently, computed tomography-guided RFA has 
been indicated for lung tumors, and promising results have been 
reported. We analyzed the outcomes of surgical resection and 
RFA, used either alone or consecutively, for pulmonary metastatic 
lesions from HCC.
Methods: Eleven patients with lung metastasis from HCC under-
went surgical resection alone, RFA alone, or surgical resection 
followed by RFA for pulmonary metastases from HCC. The initial 
treatment for pulmonary metastasis was surgical resection in 7 
cases and RFA in 4 cases. Two patients who underwent surgical 
resection as initial treatment also received RFA. Seven patients 
were male, and the average age at initial treatment for the lung 
lesions was 69.8 years (range, 50–78 years). Surgical resection was 
indicated especially for lesions close to the visceral pleura and RFA 
was indicated for relatively medial lesions.
Results: The average number of metastases per patient was 1.8 
(range, 1–4). Tumor size ranged from 5 to 40 mm. No treatment-
related deaths or severe complications were noted. The median 
survival time for all cases was 25 months. Three patients survived 
for more than 3 years after initial treatment. Of these 3 patients, 
2 underwent both metastectomy and RFA and 1 underwent me-
tastectomy alone. At initial presentation, none of these 3 patients 
had extra-pulmonary lesions and all 3 patients had solitary lung 
metastatic lesions.
Conclusion: Local therapy comprising surgical resection, RFA, or 
both might be beneficial for the treatment of lung metastasis from 
HCC in cases with no extra-pulmonary lesions and few lung lesi-
ons. RFA is minimally invasive and can be performed under local 
anesthesia, without the loss of lung volume.
Keywords: hepatocellular carcinoma, operation, radio-frequency 
ablation, lung metastasis
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Conclusion: The ability to excise tissue from the lung is limited, 
and we would like to avoid excision of lesions against which che-
motherapy has already been successful and which do not contain 
residual cells. However, the present results suggest the difficulty of 
specifying regions with viable cells based on CT. For this reason, 
minute lesions should still be excised, and marking has a very im-
portant role to play.
Keywords: non-seminoma, pulmonary metastasis, lipiodol mar-
king, surgery
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P1.16-004 PLEURAL SOLITARY FIBROUS TUMOR: A CASE 
SERIES
Horacio Vidrio-Morgado1, Angel Herrera-Gomez1, Edgardo Jime-
nez-Fuentes2, Oscar Arrieta3, Omar Macedo3, Monika Blake-Cer-
da4, Jose F. Corona-Cruz2
1Surgical Oncology, Instituto Nacional De Cancerologia (INCAN)/Mexi-
co, 2Surgical Oncology And Thoracic Oncology Clinic, Instituto Nacional 
De Cancerologia (INCAN)/Mexico, 3Thoracic Oncology Clinic And La-
boratory Of Experimental Oncology, Instituto Nacional De Cancerología 
(INCAN)/Mexico, 4Radiation Oncology - Thoracic Oncology Clinic, Insti-
tuto Nacional De Cancerologia (INCAN)/Mexico
Background: Solitary fibrous tumors are rare neoplasm arising in 
the visceral pleura. Despite that most of them are known to have a 
benign course, caution is advocated because of their unpredicta-
ble clinical behavior. Surgery is the best treatment approach and 
longer survival is associated with complete resection.
Methods: Retrospective review from January 2005 to december 
2012 for patients with diagnosis of pleural solitary fibrous tumor. 
Demographic and tumor variables were analyzed.
Results: Seven patients were treated at the National Cancer 
Institute in Mexico City with the clinical impression of a rare tho-
racic tumour. There were 5 females and 2 males with a mean age 
of 51.42 years old. After discarding other pleural and pulmonar 
malignancies, surgery was the only treatment modality used in 
the series with a curative intention. Tumorectomy with negative 
macroscopic margin was performed in 4 patients, a thoracoscopic 
wedge resection was performed in 1 patient, ; and 1 patient with 
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P1.16-003 FEATURES OF COMPUTED TOMOGRAPHY 
IMAGES AND TUMOR VIABILITY: 141 LESIONS OF PUL-
MONARY METASTASIS OF NON-SEMINOMA
Daishiro Kato, Junichi Shimada, Masanori Shimomura, Hiroaki 
Tsunezuka, Satoru Okada, Shunta Ishihara, Hirofumi Suzuki, 
Motohiro Nishimura, Kazuhiro Itoh
Division Of Chest Surgery, Department Of Surgery, Kyoto Prefectural 
University Of Medicine/Japan
Background: The standard treatment for advanced non-seminoma 
is to excise all residual masses, including pulmonary metastatic 
lesions, in patients whose tumor markers return to normal after 
chemotherapy. However, too many regions and too great a volume 
of the patient’s lung are often resected. On the other hand, viable 
cells are frequently not present in the resected tissue. This study 
therefore tried to identify distinct features of viable lesions on 
computed tomography (CT).
Methods: 
From January 2008 to December 2011, 17 cases of non-seminoma 
with lung metastasis underwent lung resection after normalization 
of tumor markers (α-fetoprotein and hCG). To excise all very small 
or impalpable lesions, we performed lipiodol marking under com-
puted tomography, for a maximum of 8 sites in one operation. CT 
images of the 141 resected lesions were investigated for size and 
properties, and compared with pathological findings. Statistical 
analysis was performed using the chi-square test.
Results: We confirmed viable cells in 8 of 17 cases and 47 of 141 
lesions. In those cases, viable cells were detected in both lungs. 
However, no significant relationship was found between average 
size and cell viability. The minimum diameter of tumor showing 
positive pathological change was 3 mm. No significant relation was 
observed between pathological findings and CT characteristics 
such as solid, cystic, scar-like or clear boundary.
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P1.17-001 TRANSUMBILICAL VERSUS CONVENTIONAL 
THORACOSCOPIC LUNG WEDGE RESECTION: SAFETY 
AND EFFICACY IN A CANINE SURVIVAL MODEL
Yun-Hen Liu1, Yen Chu1, Yi-Cheng Wu1, Ming-Ju Hsieh1, Hui-Ping 
Liu2
1Chang Gung Memorial Hospital/Taiwan, 2Beijing New Journey Cancer 
Hospital/Taiwan
Background: Transumbilical single-port surgery has been shown 
to be associated with less postoperative pain and offers better 
cosmetic outcomes than conventional 3-port laparoscopic surgery. 
This study compares the safety and efficacy of transumbilical and 
conventional thoracoscopy for lung wedge resection.
Methods: The animals (n = 16) were randomly assigned to the 
transumbilical approach group (n = 8) or conventional thoracosco-
pic approach group (n = 8). Transumbilical lung resection was per-
formed via an umbilical incision combined with a diaphragmatic 
incision. In conventional thoracoscopic group, lung resection was 
completed through a thoracic incision. Surgical outcomes (opera-
ting time, operative complications), physiologic parameters, (res-
piratory rate, body temperature), inflammatory parameters [white 
blood cell (WBC), and pulmonary parameters (arterial blood gases) 
were compared for both procedures. The animals were killed at 
two weeks after surgery for gross and histologic evaluations
Results: The lung wedge resection was successfully performed in 
all animals. There was no significant difference between the mean 
operating times and complication for transumbilical or thoraco-
scopic approach group. Regarding the physiologic impact of the 
surgeries, transumbilical approach was associated with significant 
elevations in body temperature on postoperative days 1, when 
compared with the standard thoracoscopic approach.
Conclusion: This study suggests that both approach were compa-
rable with respect to efficacy and post-operative complication in 
performing lung wedge resection.
Keyword: Transumbilical, lung resection
a voluminous tumor required a pleuro-pneumonectomy to achie-
ve a negative margin. One patient received only best supportive 
care because of the advanced of his disease and low performance 
status.. Resection was made by thoracotomy in 6 patients and only 
one patient was treated with thoracoscopy. The mean size of the 
primary tumour was 10.44 cm.. Median follow up was of 18 months 
(mean 42.4 months, range 3-158 months). Two patients developed 
a thoracic recurrence which could not be controlled with surgical 
resection and received only best supportive care.
Conclusion: Due to the rarity of this tumor there are no many tre-
tament options. Most of this neoplasms have an indolent course 
with diagnosis only after they became larger and symptomatic. 
Complete surgical resection is by far the best chance for cure. 
However, in case of malignant solitary fibrous tumors, there are no 
established systemic therapy alternatives, either preoperatively or 
postoperatively.
Keywords: Thoracoscopy, solitary fibrous tumor, pleural tumor, 
rare pleural tumors
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persistent postoperative pulmonary air leak.
Methods: In a prospective study, the efficacy of endobronchial 
valve treatment in 10 patients with a prolonged persistent pul-
monary air leak after anatomic surgical resection for cancer was 
investigated. The primary study endpoint is the clinical efficacy 
on air leak cessation assessed using a digital thoracic drainage 
system and allowing chest tube removal. Other evaluations inclu-
ded avoidance of Heimlich valve, avoidance of additional surgical 
intervention, safety issues including complications related to en-
dobronchial valve treatment, evaluation of consequences of airway 
closure on pulmonary function, and timing of endobronchial valve 
removal.
Results: Of all included patients, 90% was scheduled for valve 
treatment. We demonstrated air leak cessation at a median of 2 
days after endobronchial valve placement, which resulted in chest 
tube removal at a median of 4 days after valve placement. Three 
patients were discharged with a Heimlich valve despite a signifi-
cant reduction of their air leak after valve implantation. No single 
patient required additional surgical intervention. No deaths or 
implant-related events (such as infection distal to the endobronchi-
al valve, hemoptysis, persistent cough, pneumothorax or expec-
toration of a valve) did occur. A significant decrease in FEV1 was 
found at airway closure by valve implantation, as compared to the 
functional status after valve removal (mean FEV1 53% versus 61% 
of predicted; p=0.0002). A 5-10% decrease in FEV1 was observed 
in patients when a right upper lobe was treated with endobronchi-
al valves, while a 10-15% decrease in FEV1 was observed when a 
lower lobe was treated with endobronchial valves. Elective removal 
of the endobronchial valves was safely performed at a median of 
23 days (range 14-28) after valve implantation.
Conclusion: Endobronchial valve treatment is an effective therapy 
for patients with a prolonged pulmonary air leak after anatomic 
resection for cancer. The aid of a digital thoracic drainage system 
is required as it guides endobronchial valve placement and allows 
a safe fast-tracking chest tube removal.
Keywords: pulmonary air leak, endobronchial valve, surgery
POSTER SESSION 1 - BRONCHOSCOPY, ENDOSCOPY  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.17-004 BRONCHOSCOPY GUIDED BY FINE MAPPING 
BASED ON THIN SECTION CT.
Run Tong1, Lei Zhang1, Jianwei Wang2, Meng Li2, Shun He1, Guiqi 
Wang1, Shujun Cheng3
1Department Of Endoscope, Cancer Hospital And Institute, Chinese 
Academy Of Medical Sciences, Peking Union Medical College/China, 
2Department Of Diagnostic Radiology, Cancer Hospital And Institute, 
Chinese Academy Of Medical Sciences, Peking Union Medical College/
China, 3Department Of Etiology And Carcinogenesis, Cancer Hospital 
And Institute, Chinese Academy Of Medical Sciences, Peking Union 
Medical College/China
Background: Diagnostic bronchoscopy has undergone a ma-
jor shift in the past ten years, as the emerging of new guidance 
technologies, such as electromagnetic navigation bronchoscopy 
(ENB), virtual bronchoscopy (VB), radial endobronchial ultrasound 
(R-EBUS), ultrathin bronchoscope and guide sheath. These tech-
nologies have significantly enhanced the diagnostic capabilities of 
flexible bronchoscopy on peripheral pulmonary lesions (PPLs) com-
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P1.17-002 THE CLINICAL SIGNIFICANCE OF EN-
DOBRONCHIAL ULTRASOUND IN THE DETECTION OF 
PERIPHERAL PULMONARY LESIONS
Ioannis Gkiozos, Ekaterini Syrigou, Ioannis Kokkonouzis, Andria-
ni Charpidou, Sotirios Tsimpoukis, Antonios Vassias, Konstanti-
nos N. Syrigos
Oncology Unit Gpp, Sotiria General Hospital/Greece
Background: Flexible fiberoptic bronchoscopy (FB) is the standard 
of care for the evaluation of pulmonary lesions. The aim of the 
current study is to investigate the effectiveness of EBUS-guided 
bronchoscopy compared to blind FB techniques in the study of 
non-visible pulmonary lesions.
Methods: We conducted a one year, retrospective, study com-
paring two populations: In the first one biopsies were performed 
conventionally (FB-B) with the help of static CT images and in the 
second biopsies were performed after EBUS- guidance (FB-EBUS). 
A 20- MHz radial- type ultrasound probe was used to obtain ima-
ges. Sampling techniques, like bronchial brushing (BR) and trans-
bronchial biopsies (TBB), were conducted in both populations by 
two separate bronchoscopists. If not a diagnosis was achieved a 
surgical biopsy or observation strategy was followed.
Results: Forty patients appeared with non visible lesions and were 
included in this study. Twenty patients were examined with the use 
of EBUS (FB- EBUS) and in twenty cases a conventional FB (FB-B) 
was conducted. Moreover left lower lobe was the most promising 
to obtain a diagnosis using ultrasonographic images.
Conclusion: Our results suggest that in patients with a non visible 
pulmonary lesion or SPNs a diagnostic strategy involving EBUS- 
guided biopsy techniques is a reasonable and effective choice.
Keywords: transbronchial biopsy, Lung cancer, brushing cytology
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P1.17-003 ENDOBRONCHIAL VALVE TREATMENT FOR 
PULMONARY AIR LEAK AFTER ANATOMICAL RESEC-
TION FOR CANCER.
Christophe Dooms1, Herbert Decaluwé1, Jonas Yserbyt1, Paul De 
Leyn1, Dirk Van Raemdonck1, Vincent Ninane2
1University Hospitals Leuven/Belgium, 2Hopital Universitaire St-pierre/
Belgium
Background: Around 50,000 patients undergo each year a surgical 
resection for early stage lung cancer in the United States. Their 
median hospital stay after a lobectomy is 4-7 days. The European 
Society of Thoracic Surgery database shows that the percentage 
of pulmonary air leak present on day 5 is 6.8% for segmentectomy 
and 8.3% for lobectomy. This postoperative pulmonary expira-
tory air leak is usually managed conservatively. However, this is 
independently associated with prolonged hospital length of stay, 
decreased patient satisfaction, increased morbidity or postopera-
tive complications. The use of endobronchial valves is a minimal 
invasive method that may be effective for the treatment of such a 
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P1.17-005 EVALUATION OF THE IMPLEMENTATION 
OF INTERVENTIONAL BRONCHOSCOPY: LOCAL DATA 
FROM THE AUSTIN HOSPITAL, MELBOURNE
Yet H. Khor, Peter Wallbridge, Barton Jennings
Department Of Respiratory And Sleep Medicine, Austin Hospital/Aus-
tralia
Background: Newer interventional bronchoscopy techniques, 
including radial and linear endobronchial ultrasound (EBUS), and 
electromagnetic navigation bronchoscopy (ENB), have recently 
been established at the Austin Hospital, Melbourne. Linear EBUS 
has been recommended as the preferred method for preoperative 
invasive staging of non-small cell lung cancer with comparably high 
sensitivity compared to mediastinoscopy. Radial EBUS and ENB 
improve the sensitivity compared to conventional bronchoscopy 
for investigation of peripheral lung lesions. Radiologically guided 
transthoracic biopsy has superior diagnostic performance, radial 
EBUS and ENB are safer with significantly lower pneumothorax 
rate. We present our results of a newly established interventional 
bronchoscopy service in the evaluation of patients with suspected 
lung cancer.
Methods: A retrospective review was performed of all patients re-
ferred to our department for interventional bronchoscopy between 
April 2012 and June 2013 in whom lung cancer was suspected 
based on clinical presentation, radiographic imaging and/or posit-
ron emission tomography. Using physician-led conscious sedation, 
the procedures were performed or supervised by an experienced 
bronchoscopist. Procedure related complications were also recor-
ded. Non-diagnostic procedures were classified as true negative 
if an alternative tissue diagnosis was found, the lesion resolved on 
follow up or if another diagnostic procedure confirmed the nega-
tive result. Patients with negative results with no follow up data 
available were included as false negative.
Results: Linear EBUS 
Of the total 92 cases, 43 (47%) were performed for investigation 
of suspected malignancy. TBNA was not performed in one of the 
cases as no abnormal lymph nodes were identified on EBUS. Sen-
sitivity was 98%, specificity 100%, positive predictive value 100% 
and negative predictive value 91%.  
Malignanat Lesions Numbers (n)
Primary Lung Cancer 
Small cell carcinoma 
Non-small cell carcinoma - unclassified 
Adenocarcinoma 
Adenosquamous carcinoma 
Squamous 
 
Others 
Metastatic breast cancer 
Lymphoma
 
14 
2 
16 
2 
4 
 
 
1 
2
 
Peripheral lung lesions 
40 cases of radial EBUS and 16 cases of ENB were performed. For 
malignancy, the diagnostic yields for radial EBUS and ENB were 
70% and 40%, respectively. Non-malignant diagnoses were found 
in 10 cases and an infective organism was identified in 8 of these. 
Complications 
There was no significant complication requiring hospital admissi-
pared with traditional methods. However, these procedures have 
not been routinely carried on in developing coutries, largely due to 
the high cost of both time and money. We invented a low cost and 
time-saving method, fine mapping by bronchoscopist based on 
thin-section CT, which could be extensively applied in developing 
countries to advance the diagnostic rate of PPLs.
Methods: This fine mapping method means bronchoscopist pre-
cisely analyzes the information of thin-section CT and targets the 
region of lesion, and draws the route from the segmental bronchial 
to the interested bronchial, including messages about relative 
spatial position and number of bronchial divarication along the 
route. The bronchoscopist inserts the bronchoscope according to 
the map, carefully observes the target, and then takes a brushing. 
The key point of this method is to comfirm the vertical sections of 
every bronchial divarication based on the multiplanner reconstruc-
tion (MPR) of CT scans. A cross-sectional study was conducted on 
1148 PPLs of 1155 cases in terms of cytological diagnosis, lesion 
size, age, gender and histological type which cytological diagnosis 
all confirmed by histopathology, from July 2010 to June 2013 in the 
department of Endoscopy, Cancer Hospital, Chinese Academy of 
Medical Sciences. Between July 2010 and June 2012, traditional 
bronchoscopy and routine brush biopsy were done on 705 cases 
of PPLs. The new method of fine mapping was developed around 
June 2012, and selectivley carried on part of the PPLs from July to 
December 2012. Then we recruited 169 consecutive patients bet-
ween January 2013 and June 2013 with records of possible related 
factors .
Results: The diagnostic rate on PPLs of these three groups was 
increased as 17.3%, 25.8% and 31.5% (P<0.001), while statisti-
cally significant was also revealed in lesion size as the average 
diameter of these each group was decreased as 3.02±1.538cm, 
2.89±1.279cm, 2.72±1.227cm (P=0.04) , and there was no signi-
ficant difference between each groups in terms of age, gender, 
histological type. For PPLs of lesion size >3cm, these three groups’ 
diagnostic rate were 25.9%, 38.6% and 50.9% (P<0.001). For the 
third group that introduced the fine mapping method, according 
to the univariate logistic regression, the diagnostic yield of the 
143 malignant PPLs were statistically significant with the lesion 
size, solid-appearing, relationship between lesion and targeted 
bronchus, distance from lesion to opening of the lobar bronchus 
and the mapping satisfaction degree (P<0.001, P=0.039, P<0.001, 
P=0.031 and P=0.012, respectively).
Conclusion: This convenient and economic method of fine map-
ping greatly advanced the cytology diagnositic rate of PPLs, es-
pecially for PPLs that of bigger size, solid-appearing, cut off sign 
of targeted bronchus, nearer to the lobar bronchial opening and 
clearer mapping to target. It showed that routine bronchoscopy 
introduced this new method might be necessary for selected pati-
ents of PPLs.
Keywords: peripheral pulmonary lesions, bronchoscopy, thin-
section CT, Fine Mapping
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Age cohort (years) 
n patients 
<70 112 >70 47 p-value 
Gender 
- Male 
- Female 
 
93 (83%) 
19 (17%) 
 
39 (83%) 
8 (17%) 
NS 
Mean age years 
(range) 
60(42-70) 74(70-83) 
Indication for close 
surveillance: 
- Previous LC /ENT 
cancer 
- Suspicion occult 
lung cancer 
 
55 (49%) 
57 (51%) 
 
19 (40%) 
28 (60%) 
NS 
Mean pack-years 
smoked (range) 
44(4-120) 49(20-137) NS 
COPD Non-COPD 
Unknown 
72 (64%) 
32 (29%) 8 
(7%) 
29 (62%) 10 (21%) 
8 (17%) 
NS 
Interval to (subse-
quent) primaries 
(months) 
69(0-198) 54(1-184) NS 
Acquiring (subse-
quent) squamous 
ca. 
Recurrences of pre-
vious primaries 
41 (37%) 
4 (4%) 
12 (26%) 
2 (4%) 
NS 
NS 
Death due to lung 
cancer 
Other causes 
25 (22%) 
31 (28%) 
7 (15%) 
17 (36%) 
NS NS 
Survival after cu-
rative treatment 
(months) 
19 (0-110) 36 (0-106) 0,01 
 
Conclusion: In contrast to the undocumented belief about less 
aggressive cancer, the need for less aggressive treatment, poten-
tial toxicities in the co-morbid elderly and their expected shorter 
life span, the outcome shows that early interventional strategy is 
warranted. LC mortality is relatively low despite the highly negati-
ve selection bias, especially in the frail – ageing – subcohort. This 
warrants further studies to increase the cost-effectiveness of NiMiT 
in our ageing population.
Keywords: Lung cancer, AFB, NiMiT, bronchoscopy
ons, blood transfusions or surgical interventions. Minor complica-
tions include bleedings (3), tachycardia or arrhythmia (5), excessive 
cough (3), agitation (1), hypertension (1).
Conclusion: The results of the interventional bronchoscopy service 
at the Austin Hospital is comparable with published data on these 
procedures. This has improved the assessment of patients with 
suspected lung cancer.
Keywords: endobronchial ultrasound, bronchoscopy, electromag-
netic navigation bronchoscopy, Lung cancer
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P1.17-006 EARLY BRONCHOSCOPIC INTERVENTIONAL 
STRATEGY IN HIGHLY AT RISK MORBID AGEING  
COHORT
Illaa Smesseim1, Robert Boerdonk2, Katrien Grünberg3, Johannes 
M A Daniels4, Andrea Maier5, Pieter E Postmus4, Tom Sutedja4
1Free University Amsterdam/Netherlands, 2Pathology, Free University/
Netherlands, 3Pathology, VU University Medical Center/Netherlands, 
4Pulmonary Diseases, VU University Medical Center/Netherlands, 5Free 
University/Netherlands
Background: We retrospectively reviewed our longitudinal data 
(1992 - 2012) with regard to early interventional techniques using 
advancements of non- and minimally invasive techniques (NiMiT) 
as alternatives for early intervention in squamous carcinogenesis in 
highly at risk -including frail elderly individuals. >50% lung cancer 
develops in >70 years age cohort and cancer and ageing are beco-
ming an important health care issue in our society.
Methods: So far, 159 surgically non-resectable candidates with va-
rious comorbidities (Previous LC/ENT primaries, COPD, etc.) have 
been closely monitored using autofluorescence bronchoscopy for 
suspicious endobronchial lesions (e.g. dysplasia, carcinoma in situ 
and microinvasive squamous cancer). End points were the deve-
lopment of squamous cancer and its outcome with the use NiMiT 
(Chest 2001;120:1327; Respiration 2004;71:391
Results: Patient characteristics and outcome are shown in the 
table. Cohort analyses of age ≤70 years versus over, showed a 
significant longer time of survival in the elderly cohort (35.9 vs 18.5 
months; p = 0.01). Lung cancer specific mortality was low ,respec-
tively 15% and 22%. Table: Longitudinal carcinogenesis study in 
cohorts highly at risk to develop (subsequent) squamous cancer 
primaries and its outcome.  
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BT Completi-on Surgery 
Remark 
Number of 
patients 
62 71 
Histology TC 
AC 
56 (90%) 6 
(10%) 
43 (61%) 28 
(39%) 
Follow up 
(median) in 
months 
87.5 (2-
223) 
87 (12-264) 
Completely 
resected 
57 (92%) 64 (90%) 
Residual 
after CT/
recurrences 
Additional 
treatment 
bronchosco-
py Additi-
onal treat-
ment surgery 
3 4 0 0 
Interval in 
months: 10,13,63 
47,104,115,192 
Alive with 
disease 
5 0 
2 unfit for surgery 3 
refused surgery 
Alive with 
metastatic 
disease 
0 1 40 months 
Carcinoid 
related mor-
talities 
0 2 
Pulmonary metas-
tases 
Treatment 
related mor-
talities 
0 1 
Non-carci-
noid related 
mortalities 
8 3 
 
Conclusion: Initial bronchoscopic treatment strategy in patients 
with bronchial carcinoids is justifiable. Local regrowth after suc-
cessful bronchoscopic removal was infrequent (3%) and was timely 
detected by HRCT. HRCT can be performed much less frequent 
and regular bronchoscopy was redundant if IBT attempt was suc-
cessful. The significance of an iceberg phenomenon is questiona-
ble.
Keywords: bronchial carcinoids, Outcome, follow up
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P1.17-007 A PROPOSAL FOR A NEW CLINICAL STRAT-
EGY AND FOLLOW-UP IN PATIENTS WITH BRONCHIAL 
CARCINOIDS INITIALLY TREATED BRONCHOSCOPI-
CALLY.
Hes A.P. Brokx1, Marinus A. Paul2, Koen J. Hartemink3, Johannes M 
A Daniels1, Tom Sutedja1, Pieter E Postmus1
1Pulmonary Diseases, VU University Medical Center/Netherlands, 
2Cardiothoracic Surgery, VU University Medical Center/Netherlands, 
3Surgery, VU University Medical Center/Netherlands
Background: Bronchial carcinoids (BC) belong to the wide spec-
trum of neuroendocrine tumors; ranging from tumorlets, typical 
carcinoid (TC), intermediate-grade atypical carcinoid (AC), to 
highly malignant large cell neuroendocrine and small cell carci-
noma. The Travis classification (Am J SurgPathol 1998; 22:934) 
seems essential for choosing the best treatment strategy based 
on retrospective analyses of surgically resected specimens. We 
implemented an initial bronchoscopic treatment (IBT) strategy and 
its long term outcome have been reported with update of the final 
analysis (J Thorac Cardiovasc Surg. 2007 Apr;133(4):973; Abstract 
IASLC Sydney submitted). The long-term outcome seems to justify 
IBT and the histological differentiation between typical versus 
atypical seems to matter much less, while conservation of normal 
lung parenchyma is optimal. We question how optimal the close 
surveillance strategy of IBT protocol should be, i.e. in performing 
regular high resolution CT (HRCT) and/or bronchoscopy after the 
initial success of bronchoscopic treatment.
Methods: In the IBT protocol, HRCT and bronchoscopy were per-
formed 6-monthly in the first two years and annually until the fifth 
year. Thereafter a yearly check-up was advised to the referring 
pulmonologists. We analyzed retrospectively the value of HRCT 
and/or bronchoscopy in this IBT cohort for early detection of local 
recurrences, that require surgical salvage.
Results: So far, IBT was successful in 57 of the 133 patients (43%). 
Sixty-seven patients (50%) could be immediately identified to be 
surgical candidates without further delay due to obvious extralu-
minal tumor growth. Four patients (3%) developed extraluminal 
tumor recurrence and surgical salvage was performed at 47, 104, 
115, 192 months. In all four cases follow-up HRCT suggested local 
extraluminal tumor growth, which were confirmed by broncho-
scopy. The surgical outcome was radical and did not lead to more 
extensive resections than initially anticipated. Detailed treatment 
results are shown in table 1. Table 1. Initial bronchoscopic treat-
ment strategy in patients with bronchial carcinoids  
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total
Referral 
for ra-
diogra-
phically 
occult 
lesion 
Follow-up 
after  
surgery for 
early-stage 
NSCLC / 
ENT ca 
individuals, n 164 92 72 
Gender 
male 134 72 62 
female 30 20 10 
Age at baseline 
years, mean (range) 64.2 (42-83) 
64.8 (42-
81) 64.0 (43-82) 
Smoking status 
current smoker 75 44 31 
former smoker 74 36 38 
unknown 15 12 3 
Smoking history 
Pack-years, mean (range) 45 (4-137) 45 (4-120) 40 (15-137) 
COPD-status 
COPD 100 56 44 
non-COPD 45 22 23 
unknown 19 14 5 
AF Bronchoscopies 
Number, mean (range) 7 (1-27) 5 (2-27) 6 (1-18) 
CT-scans 
Number, mean (range) 3 (0-20) 2 (0-20) 3 (0-18) 
No. of detected lung cancers 
During surveillance period 61 29 32 
Parenchymal cancer 21 12 9 
Site-specific lesion progression 24 13 11 
Interval cancer 10 4 6 
Recurrences previous primaries 6 0 6 
Patient outcome 
alive 80 56 24 
died of lung cancer 33 13 20 
died of other/unknown cause 51 23 28 
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P1.17-008 RESULTS OF A CLOSE SURVEILLANCE STRAT-
EGY FOR SUBJECTS WITH PRE-INVASIVE ENDOBRON-
CHIAL SQUAMOUS LESIONS
Illaa Smesseim1, Robert A A Van Boerdonk2, Daniëlle A M Heide-
man2, Veerle M.H. Coupe3, Darryl Tio1, Pieter E Postmus1, Egbert 
F Smit1, Peter J F Snijders2, Katrien Grünberg2, Erik Thunnissen2, 
Johannes M A Daniels1, Tom Sutedja1, Hes A.P. Brokx4
1Pulmonary Diseases, VU University Medical Center/Netherlands, 2Pa-
thology, VU University Medical Center/Netherlands, 3Epidemiology & 
Biostatistics, VU University Medical Center/Netherlands, 4Deparment 
Of Pulmonary Diseases, VU University Medical Center/Netherlands
Background: The dismal overall 5-year survival of non-small cell 
lung cancer (NSCLC) patients is mainly due to advanced stage of 
disease at time of initial diagnosis in most and the inability to cure 
metastatic disease in all patients. In contrast, the prognoses of in 
situ mucosal and small parenchymal lesions are excellent. Early de-
tection strategies might result in the identification of early-stage, 
(pre-)invasive lesions that are still eligible for curative treatment. 
The present study was set out to characterize the risk of lung can-
cer development in a cohort of high-risk subjects harboring pre-
invasive endobronchial lesions and to assess the results of surveil-
lance using autofluorescence bronchoscopy (AFB) and computed 
tomography (CT) scan.
Methods: Between November 1995 and December 2012, one 
hundred and sixty-four at risk individuals with pre-invasive en-
dobronchial lesions were monitored by repeated AFB and CT. 
During the course of surveillance, progression of lesions to cancer 
(in situ), recurrences and second primary cancers were treated 
with different modalities (e.g. endobronchial techniques, surgery, 
radiotherapy), depending on tumor stage and location. Log-rank 
tests were performed to examine the relation between baseline 
characteristics and progression-free and overall survival (PFS and 
OS, respectively). Cox regression was used for multivariate survival 
analysis.
Results: Demographical and clinical variables of the cohort are 
shown (Table). At inclusion, 80 individuals were identified with one 
or more high-grade pre-invasive lesions (severe dysplasia or CIS; 
HGD), whereas 84 subjects were identified solely with lower gra-
de pre-invasive lesions (LGD). During close surveillance (median 
follow-up (FU) of 30 months, range 4-152), sixty-one lung cancers 
were detected (26 CT-detected, 35 AFB-detected cancers) in 55 
individuals within a median time to event of 16.5 months. Mean 
PFS was similar between individuals with radiographically occult 
lesions vs. FU after surgery for early-stage NSCLC/ENT ca (122.3 
vs. 126.9 months, p=0.237) and COPD vs. non-COPD (118.8 vs. 
136.8 months, p=0.162). There was a relatively large difference 
in PFS between LGD and HGD groups (142.6 vs. 93.7 months, 
p=0.057). Independent risk determinants for OS were indication 
for surveillance (FU after surgery for early-stage NSCLC/ENT ca vs. 
radiographically occult lesions, p=0.008) and COPD-status (COPD 
vs. non-COPD, p<0.001).  
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77% whereas negative predictive value for EBUS TBNA was 83%.
Conclusion: Our study confirms a negative predictive value (83%) 
of EBUS-TBNA in excluding N2/3 disease in patients diagnosed 
with NSCLC which is higher than PET CT scan (77%). The slightly 
lower negative predictive value of EBUS TBNA may be attributed 
to the fact that not all the surgical candidates were staged with a 
pre operative histological confirmation of the mediastinal lymph 
nodes. However a combination of PET CT scan and EBUS TBNA is 
a reasonable pre operative staging for mediastinal lymph nodes 
with low complication rates.
Keyword: EBUS TBNA,PET CT scan ,Mediastinal lynpmh nodes
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P1.17-010 DIAGNOSTIC MEDICAL THORACOSCOPY 
FOR PLEURAL EFFUSIONS OF UNKNOWN ETIOLOGY: 
INSPECTION DELAY MAY CAUSE NON-DETERMINISTIC 
ENDOSCOPIC DIAGNOSIS
Kenya Kanazawa1, Takashi Ishida2, Ken-Ichiro Hirai1, Hiroyuki 
Minemura1, Satoko Sekine1, Hiroshi Yokouchi1, Atsuro Fukuhara1, 
Suguru Sato1, Yoshinori Tanino1, Mitsuru Munakata1
1Department Of Pulmonary Medicine, Fukushima Medical University/
Japan, 2Clinical Oncology Center & Department Of Pulmonary Medicine, 
Fukushima Medical University/Japan
Background: Thoracoscopy is a useful tool for diagnosis of exudati-
ve pleural effusion of unknown etiology, and the efficacy and safety 
have already been established. The procedure is relatively easy and 
can be performed under local anesthesia with conscious sedation. 
We investigated the factors associated with thoracoscopically undia-
gnosed patients in our hospital.
Methods: Clinical records were reviewed retrospectively. We found 
101 patients who underwent medical thoracoscopy from April 2000 
to May 2013, and then we identified 91 eligible patients for the de-
tailed analysis. All the procedures were performed utilizing a flexible 
bronchoscopy (type-240, Olympus Corporation, Tokyo, Japan) or a 
semi-rigid thoracoscopy (LTF type-240, Olympus Corporation, To-
kyo, Japan) from a single-port under local anesthesia.
Results: The median age of the patients was 69 years old (range, 32-
89), and 79 (86.8%) were male. Affected sides of effusion were right/
left/bilateral = 60/26/5. Definitive diagnoses were obtained in 73 
(80.2%) cases. In 21 (23.1%) patients, the duration from the disease-
onset to the examination was more than 3 months. In 18 (19.8%) 
thoracoscopically undiagnosed patients, the number of patients 
according to the time from disease-onset to the examination was as 
follows; none within 1 month, 7/46 patients (15.2%) in 2 to 3 months, 
and 11/36 patients (30.6%) in more than 4 months. No remarkable 
complications, other than a moderate hemoptysis, were seen.
Conclusion: Medical thoracoscopies were safe, and they contribut-
ed to definitive diagnoses. The delay of thoracoscopic examination 
from the disease-onset tended to lead non-specific findings in pa-
thological diagnosis. Diagnostic medical thoracoscopy should be 
performed as soon as possible when the cause of pleural effusion is 
undetermined with thoracentesis.
Keywords: Medical thoracoscopy, semi-rigid thoracoscopy, pleural 
effusion of unknown etiology
Conclusion: Our findings demonstrate that individuals with pre-
invasive endobronchial lesions are at high risk of developing (se-
cond primary) lung cancers. Combined surveillance using AFB in 
addition to CT screening facilitated early detection and early (en-
dobronchial) intervention in most patients. Future clinical trials are 
warranted to determine whether the current approach improves 
patient outcome.
Keywords: Autofluorescence bronchoscopy, computed tomogra-
phy, Lung cancer screening, early detection
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P1.17-009 WHAT IS THE RATE OF SURGICAL UPSTAGING 
FOLLOWING NEGATIVE EBUS-TBNA OF MEDIASTINAL 
LYMPH NODES FOR NSCLC?
Phillip N. Antippa1, Marzi G. Mehta1, Louis Irving2, Daniel Stein-
fort2, Mun Yoong Cheang1, Alpha Tsui3
1Cardiothoracic Surgery, Royal Melbourne Hospital/Australia, 2Respira-
tory Medicine, Royal Melbourne Hospital/Australia, 3Pathology, Royal 
Melbourne Hospital/Australia
Background: Mediastinal lymph node evaluation is a critical deter-
minant of treatment strategy in NSCLC. Many staging modalities, 
both invasive and non-invasive, have been evaluated over the past 
few decades with varying degrees of accuracy. Despite the fact 
that CT imaging is the preliminary investigation for diagnosis of 
lung cancer, various studies have shown that CT scanning is less 
accurate (sensitivity of 41% to 63%, a specificity of 43% to 57%, 
and an accuracy of 39% to 59%) for the detection of mediastinal 
nodal metastasis. According to a meta analysis looking at nodal 
disease, the sensitivity for PET is 79% to 84% and its specificity 
is 89% to 91%.The ability of PET CT to provide morphologic and 
functional information enhances the diagnostic accuracy of medi-
astinal nodal staging in NSCLC . Most guidelines would however 
need tissue confirmation which can be obtained by EBUS- TBNA. 
This procedure has the advantage that it can be performed under 
sedation , however , the downside to this is the small samples wi-
thout accurate anatomical definition. In our institute we perform 
PET-CT scan followed by EBUS TBNA for pre operative staging of 
the mediastinal lymph node {in selected cases}. However, in cases 
where EBUS-TBNA of mediastinal lymph nodes is negative for mali-
gnancy, there is still a possibility that metastases to these lymph 
nodes are found at surgery. This will result in an upstaging of the 
NSCLC following surgery. We aimed to determine the rate of surgi-
cal upstaging following negative EBUS-TBNA of mediastinal lymph 
nodes for NSCLC.
Methods: This is a retrospective study. From January 2009 till 
May 2013, we identified 304 patients who underwent surgery for 
NSCLC. All the patients who were planned for surgical resection 
underwent a staging CT scan thorax or a PET CT scan. Only those 
patients with suspicious lymph nodes on either of the imaging, 
were subjected to EBUS TBNA. These lymph nodes were then re-
evaluated by histopathology following surgery. Of these 65 pati-
ents who had EBUS-TBNA prior to surgery , fifty-three patients had 
negative EBUS-TBNA and they formed the basis of this report.
Results: Out of the 53 patients with a negative EBUS-TBNA, nine 
of them (17%) demonstrated positive lymph nodes in surgery, gi-
ving a negative predictive value of 83% for EBUS-TBNA in this se-
lected group. The negative predictive value of PET CT was around 
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and the data of survival are being analyzed in all patients and will 
be presented at the conference.
Keywords: ROS1 fusions, RET fusions, clinicopathologic feature, 
EML4-ALK
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P1.18-002 EPIDERMAL GROWTH FACTOR RECEPTOR 
MUTATIONS IN PRIMARY AND METASTATIC ADE-
NOCARCINOMAS FROM A TERTIARY HOSPITAL IN SAO 
PAULO, BRAZIL
Vanessa K. De Sa, Ellen C. Nascimento, Sibele I. Meireles, Vera L. 
Capelozzi
Pathology, Faculdade De Medicina Da Universidade De SÃo Paulo/
Brazil
Background: Recently, the epidermal growth factor receptor 
(EGFR) mutation emerges promise as target for molecular therapy 
in Adenocarcinomas of the lung. However, a number of clinical 
features are associated with EGFR mutations: women, never-smo-
kers than former or current smokers and Asians than other ethnic 
groups. Sao Paulo population is made up of a confluence of peop-
le of several different origins, from the original Native Americans, 
with the influx of Portuguese colonizers, Black African slaves, and 
recent European, Arab and Japanese immigration. Other signifi-
cant groups include Koreans, Chinese, Paraguayans and Bolivians. 
The aim of this study was to evaluate the frequency and distribu-
tion of EGFR mutations in 100 consecutive patients with surgically 
excised primary and metastatic Adenocarcinomas.
Methods: Direct bidirectional sequencing evaluated EGFR gene 
mutations on exons 18 to 21 and was correlated with ethnia (East-
Asian or European), gender, age, tobacco history, primary (N=75) 
or metastatic (N=25) and histologic subtypes.
Results: Twenty-eight tumors (28%) exhibited EGFR mutation. The 
most frequent EGFR mutation detected was a deletion in exon 19 
(50%), followed by multiple mutations in the exon 20 (28%) and 
an L858R amino acid substitution in exon 21 (21,4%). EGFR muta-
tion was significantly associated with men (N=59), older patients 
(>60yrs), smokers, non-East Asian or non-European origins, prima-
ry tumor and acinar predominant histologic subtype.
Conclusion: Our results indicate that if the current clinical features 
were strictly followed as the criteria for selecting patients for EGFR 
testing, a substantial number of patients who might benefit from 
treatment will be excluded.
Keywords: Lung cancer, EGFR mutations, Prognosis, Adenocarci-
nomas
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P1.18-001 THE PREVALENCE AND CLINICOPATHOLOGIC 
FEATURE OF ALK, ROS1 AND RET FUSIONS IN EAST 
ASIAN PATIENTS WITH LUNG ADENOCARCINOMA
Weijing Cai1, Caicun Zhou1, Shengxiang Ren1, Chunxia Su1, Xuefei 
Li2, Wei Li1, Shuai Li1
1Department Of Medical Oncology, Shanghai Pulmonary Hospital, 
Tongji University School Of Medicine, Tongji University Medical School 
Cancer Institute/China, 2Department Of Lung Cancer And Immunology, 
Shanghai Pulmonary Hospital, Tongji University School Of Medicine, 
Tongji University Medical School Cancer Institute/China
Background: ALK, ROS1 and RET fusions have been demonst-
rated as oncogenic drivers in lung cancer. Of these, ALK fusions 
were shown to occur more frequently in patients with mucinous 
adenocarcinoma or solid histology with signet-ring cells. The asso-
ciation of ROS1 and RET fusions with the adenocarcinoma compo-
nent remains unclear. We conducted this study to determine the 
prevalence and clinicopathologic characteristics of ALK, ROS1 and 
RET fusions in East Asian patients with lung adenocarcinoma, and 
investigate the association of the above-mentioned gene fusions 
with histological subtype of adenocarcinoma according to the 
IASLC/ATS/ERS Classification.
Methods: We screened 620 Chinese patients with histologically 
confirmed lung adenocarcinoma for ALK, ROS1 and RET fusions 
using multiplex RT-PCR and validated all fusion-positive patients 
using direct sequencing. The patterns of gene fusions scree-
ned in this study contained EML4-ALK (17 variants), CD74-ROS1, 
SLC34A2-ROS1, SDC4-ROS1, EZR-ROS1, TPM3-ROS1, LRIG3-ROS1, 
GOPC-ROS1, KIF5B-RET, CCDC6-RET and NCOA4-RET. The as-
sociation of ALK, ROS1 and RET fusions with different subtype 
of adenocarcinoma were analyzed in 331 patients. The data for 
remaining 289 patients are being analyzed. All patients enrolled in 
this study were followed up for survival.
Results: Of the 620 patients with adenocarcinoma screened, 472 
(76.1%) patients were never/light smokers (<10 pack-years), and 
148 (23.9%) were smokers (≥10 pack-years), with the median age 
of 59 (range, 27-82) years; 348 patients were female, accounting 
for 56.1%. Patients with stage I, II, III, or IV disease accounted 
for 56.6%, 8.7%, 27.1% and 7.6%, respectively. The prevalence of 
ALK, ROS1 and RET fusions in this study was 8.1% (50/620), 3.5% 
(22/620) and 1.9% (12/620), respectively. Among the 331 patients 
diagnosed by the IASLC/ATS/ERS Classification, 15 patients were 
identified positive for EML4-ALK fusions (including 8 solid, 2 acinar, 
2 colloid, 1 lepidic, 1 papillary and 1 micropapillary predominant), 
7 patients were positive for ROS1 fusions (including 2 acinar, 2 
papillary, 1 lepidic, 1 solid and 1 mucinous predominant), and 4 
patients were positive for RET fusions (including 2 acinar, 1 micro-
papillary and 1 solid predominant).
Conclusion: These fusion-positive patients may have unique pa-
thologic feature compared with fusion-negative patients. EML4-
ALK fusions were shown to occur in solid predominant adenocarci-
noma with a higher frequency in this study. The association of ALK, 
ROS1 and RET fusions with the subtype of lung adenocarcinoma 
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RT- PCR as reference. This method is very sensitive compared to 
conventional Sanger sequencing being able to detect mutations 
present in 1% of the malignant cells. Some studies in NSCLC have 
questioned whether detection of such a small fraction of malignant 
tumor cells has clinical relevance for treatment of the whole tumor. 
The mutation-specific antibodies might be compared to highly 
sensitive methods, including RT-PCR and validated in clinical trials 
in order to detect the clinical impact of both methods.
Keyword: EGFR mutations, NSCLC, IHC, RT-PCR
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P1.18-004 THE RELATIONSHIP BETWEEN EGFR MU-
TATIONS AND THE CLINICOPATHOLOGIC FEATURES 
OF LUNG ADENOCARCINOMAS DIAGNOSED BY THE 
SMALL BIOPSIES
Kyeong-Cheol Shin1, Jin Hong Chung1, Kwan Ho Lee1, Mi Jin Kim2
1Pulmonology And Allergy, Internal Medicine, Yeungnam University 
Medical Center/Korea, 2Pathology, Yeungnam Univerity Medical Center/
Korea
Background: EGFR mutation analysis is necessary and important 
in clinical practice. But sometimes advanced lung cancer is diag-
nosed by cytology or inadequate specimens for DNA extractions. 
To decide the treatment of these patients, it is helpful to investiga-
te the surrogate marker to predict EGFR mutation. There has been 
many reports about the association of EGFR mutation with clini-
copathologic features, but most of them were investigated by the 
resection specimens. This study was aimed to find the relationship 
between EGFR mutations and clinicopathologic features in small 
biopsy specimens.
Methods: The medical records of 359 lung adenocarcinoma pa-
tients who diagnosed from 2008 to 2011 were reviewed. All the 
specimens of these patients were investigated for EGFR mutations 
(Exon 18-21) by direct sequencing method. 134 specimens were 
classified according to IASLC/ATS/ERS classification and studied 
the relationship between EGFR mutation and histologic subtype.
Results: We can ascertain that incidence of EGFR mutations 
is associated with gender and smoking history in small biopsy 
specimens(Table 1). This is already well-known, but almost re-
searches were investigated by resection specimens. EGFR mu-
tations were more frequently observed with acinar and lepidic 
components, conversely infrequently with solid and mucinous 
components. The positive expression of TTF-1 was also related 
with more frequent EGFR mutations than negative expression. 
Pathologic features that even if it is confirmed by small biopsy 
specimens can predict EGFR mutation status. Table 1. Relationship 
between EGFR mutation and clinical features 
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P1.18-003 IMMUNOHISTOCHEMICAL DETECTION OF 
EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS 
IN PATIENTS WITH NON-SMALL CELL LUNG CANCER.
Anna-Louise Bondgaard1, Estrid Hoegdall2, Anders Mellemgaard3, 
Birgit G. Skov1
1Department Of Pathology, Copenhagen University Hospital/team 
Bispebjerg,University Of Copenhagen/Denmark, 2Department Of Patho-
logy, Molecular Unit, Herlev University Hospital, Copenhagen Univer-
sity/Denmark, 3Department Of Oncology, Herlev University Hospital, 
Copenhagen University/Denmark
Background: Determination of Epidermal Growth Factor Receptor 
(EGFR) mutational status has pivotal impact on treatment in non-
small cell lung cancer (NSCLC). A standardized test has not yet 
been approved. DNA sequencing has previously been regarded 
as gold standard method. The rather low sensitivity of this method 
has led to development of more sensitive, but also more complica-
ted methods including real-time PCR (RT-PCR). Immunohistoche-
mistry (IHC) with mutation specific-antibodies may be a promising 
method for detection EGFR mutations in NSCLC.
Methods: This case-control study includes 191 patients (36 pa-
tients with an EGFR mutation and 155 wild type (WT) patients 
(randomly selected)) as detected by RT-PCR (Therascreen EGFR 
PCR kit, Qiagen, UK). This method identifies 29 somatic mutations 
from exons18-21 with a sensitivity of 1%. For EGFR IHC, antibodies 
against mutations in exon19 (clone 6B6) and exon21 (clone 43B2) 
by Cell Signaling Technology (USA) were used. All specimens 
were visualized according to the standardized protocol of EnVision 
FLEX+ system (DAKO, DK).The protein expression for each speci-
men was evaluated and a H-score, including intensity (graded 0-3) 
and percentages (0-100) of stained malignant cells, was calculated. 
A positive tumor was defined by a H-score value>0. The sensitivity 
(true positive/(true positive + false negative) and specificity (true 
negative/(true negative + false positive) were evaluated with the 
results from Therascreen EGFR PCR kit as reference.
Results: The sensitivity and specificity of the mutation-specific 
antibodies are presented in Table1.  
Sensitivity 
(%) 95% CI
Specificity 
(%) 95% CI
Exon19del 
(E746-
A750)
60.0 32.3-83.4 99.3 96.3-100
Exon21 
(L858R)
87.5 47.4-99.7 97.4
93.5-
99.3
 
Table1: Performance of the EGFR mutation-specific antibodies. 
CI = confidence interval, Del = deletion. For mutations in exon19, 
5 specimens were false negative (IHC-, RT-PCR+) and 1 was false 
positive (IHC+, RT- PCR-). For mutations in exon21, 3 samples were 
false negative and 3 were false positive. 1 false positive for exon21 
had maximal H-score (300).
Conclusion: We demonstrated a high specificity for IHC with 
mutation-specific antibodies for detecting EGFR mutations in 
patients with NSCLC. However, the sensitivity was low, especially 
for del19-mutations, and thus these antibodies are not yet ready 
as a screening method for detection of these mutations. We used 
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subtypes of lung adenocarcinma, even if it confirmed by small 
biopsy specimens can be a good predictive marker of EGFR muta-
tions.
Keywords: Small biopsy, Pulmonary adenocarcinoma, EGFR muta-
tion, TTF-1
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P1.18-005 CLINICOPATHOLOGICAL FEATURES AND 
PROGNOSTIC SIGNIFICANCE OF TUMOR INVASION 
INTO THE INTERLOBULAR SEPTAL AREA AND PERIVAS-
CULAR AREA (ISA/PA) IN LUNG ADENOCARCINOMA
Kazunori Kamiya1, Toshinori Fukutomi1, Akira Yoshizu1, Hiroyuki 
Hayashi2
1General Thoracic Surgery, Yokohama Municipal Citizen`s Hospital/
Japan, 2Department Of Pathology, Yokohama Municipal Citizen`s Hos-
pital/Japan
Background: Lung interstitium is composed of the interlobular 
septal area (ISA), perivascular area (PA), and visceral pleural area. 
Tumor invasion into the visceral pleural area is recognized as a 
prognostic factor in lung cancer, whereas invasion into the ISA/PA 
has not been clearly examined. The aim of this study was to evalu-
ate the clinicopathological features and prognostic significance of 
invasion into the ISA/PA in lung adenocarcinoma.
Methods: A total of 132 patients with pathological stage I lung 
adenocarcinoma who were treated with surgical complete resec-
tion from 2000 to 2006 in the Yokohama Municipal Citizen’s Hos-
pital were retrospectively evaluated (mean follow-up period 79.1 
months). Tumor invasion into the ISA/PA was defined as the exis-
tence of tumor cells in that area or septum discontinuity around 
the area due to tumor cells. Hematoxylin-eosin and Victoria-blue 
stained slides for each case were reviewed by two investigators. 
The correlation between a presence of the feature and clinicopa-
thological characteristics or prognosis was analyzed using the chi-
square test, log-rank test, and Cox proportional hazards regression 
model.
Results: In 53 cases, we were unable to identify the ISA/PA area 
adjacent to the tumor or the existence of the septum itself, particu-
larly in those with small sized tumors or poorly differentiated cases; 
therefore, they were excluded from the analysis. We subsequently 
divided the remaining 79 cases into the following two groups: 
invasion in the ISA/PA-positive (n = 36) and ISA/PA-negative group 
(n = 43). Lymphatic and venous invasion was identified signifi-
cantly more frequently in the positive than negative group (p = 
0.012/0.001). No significant difference between the two groups in 
gender, age, smoking habit, tumor size, or visceral pleural invasion 
was observed. Disease-free and overall survival rates for the posi-
tive were significantly worse than those for the negative group (p = 
0.002/0.012). Multivariate analysis demonstrated an independent 
prognostic effect of the feature (p = 0.04). Further, when we limi-
ted the analysis to lymphatic and venous invasion-negative cases 
(n = 42), we found that every relapsed case (n = 4) had the feature 
but no visceral pleural invasion.
Table 2. Relationship between EGFR mu-
tation and histologic subtype by IASLC.
Conclusion: Clinicopathologic features can predict the EGFR mu-
tation status, but cannot replace the mutation analysis. Histologic 
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differentiated adenocarcinoma. Five months later, gastroscopy 
showed a mass with deep ulcer in the fungus of the stomach (Fig 
B). She underwent partial gastrectomy. The HE staining showed 
the same morphorlogy as the primary lung cancer, and the cancer 
tissue invaded the submucosa of esophagus and stomach. (Fig C) 
The diagnosis of gastric metastasis from primary lung cancer was 
confirmed by positive staining for TTF-1 (Fig D) and CK-7 (Fig E). 
In the systematic review, we identified 22 eligible cases from 16 
articles. The average age at presentation was 67.3 years. There 
was a male predominance of 90.9% versus 9.1% female. Epigastric 
pain (45.5%) was the most common chief complaint, following by 
melena (22.7%), nausea/vomiting(13.6%), and hematemesis(9.1%). 
Three patients were asymptomic. Five patients firstly went to see 
doctors for gastrointestinal symptoms. The median time span 
between the diagnosis of lung cancer and gastric metastasis was 
5 months.Endoscopically, gastric lesions are described as nodule 
or volcano-like ulcer. The body of stomach was the most com-
mon site (62.5%) of metastases. Gastric metastasis was reported 
in adenocarcinoma, squamous-cell cancer, small cell cancer and 
pleomorphic carcinoma of lung cancer. Comprehensive treatment 
was the strategy for these patients. The median survival was 4 
months, and 1-year postmetastasis survival rate was 35.3%. Three 
of the five patients who were treated surgically for solitary gastric 
metastasis survived longer 1 year after detection of metastases.
Conclusion: Primary lung cancer metastasizing to the stomach is 
an exceptional event, but doctors should be aware of the possibi-
lity. Comprehensive treatment and personalized treatment should 
be the strategy according to patients’ situation.
Keywords: outcomes, primary lung cancer, gastric metastsis, clini-
copathological features
Conclusion: It is believed that invasion into the ISA/PA is a feature 
predictive of tumor invasiveness and may be a prognostic factor in 
stage I lung adenocarcinoma. This finding may portray the previ-
ous phase of lymphatic or venous invasion. Unfortunately, we were 
unable to evaluate the feature in many cases of this study. Further 
studies are needed to elucidate the clinical significance of this 
finding.
Keywords: prognostic significance, tumor invasion into the interlo-
bular septal area and perivascular area (ISA/PA), lung adenocarci-
noma, clinicopathological feature
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P1.18-006 CLINICOPATHOLOGICAL FEATURES AND 
OUTCOME OF GASTRIC METASTASIS FROM PRIMARY 
LUNG CANCER: A CASE REPORT AND SYSTEMATIC RE-
VIEW
Qingyuan Huang, Xiaodong Su, Jianhua Fu, Kongjia Luo, Shuishen 
Zhang, Tiehua Rong, Amos Ela Bella
Thoracic Oncology, Sun Yat-Sen University Cancer Center/China
Background: Primary lung cancer is one of leading cancer all over 
the world, while gastric metastasis from lung cancer is extremely 
rare. We know little about its clinicopathological features, prog-
nosis and treatment strategy.Primary lung cancer is one of leading 
cancer all over the world, while gastric metastasis from lung cancer 
is extremely rare. Its clinicopathological features, prognosis and 
treatment strategy remain largely unknown.
Methods: We present a case of primary lung cancer metastasizing 
to the stomach. Furthermore, we systematically search the Medline 
database for similar cases from 1966 through 31 December 2012. 
Data concerning clinicopathological features, treatment strategies 
and outcomes were extracted and analyzed to explore the nature 
of gastric metastasis from primary lung cancer.
Results: A 61-year-old and asymptomatic woman was admitted 
for a mass shadow in chest X-ray (Fig A). A right lower lobectomy 
was performed and pathological examination revealed a poorly 
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Conclusion: Our analysis of NSCLCs shows that AAs were more 
likely to have multiple genetic mutations than whites and the muta-
tion profile differs by race.
Keyword: Multiplex, Mutations, African-Americans, STK11
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P1.18-008 CLINICAL IMPACT OF THE TWO TYPES OF 
MUCIN IN THE MUCINOUS ADENOCARCINOMA OF THE 
LUNG - CLINICAL DIFFERENCES BETWEEN THE BRON-
CHOGENIC-TYPE AND THE GASTRIC-TYPE MUCINOUS 
ADENOCARCINOMAS
Ryoichi Kondo1, Keiko Ishii2, Mieko Chino1, Kentaro Miura1, Mako-
to Kurai1
1Thoracic Surgery, National Hospital Organization Matsumoto Medical 
Center/Japan, 2Diagnostic Pathology, Okaya Principal Hospital/Japan
Background: Mucinous adenocarcinoma is one histological-
subtype of the lung cancer. The mucin produced by the tumor cell 
is usually acidic like as the bronchial gland-type mucin. However, 
there is one subtype of pulmonary mucinous adenocarcinoma 
designated as the gastric type, which differentiated into gastric py-
loric mucosa and possessed neutral mucin (i.e. class III mucins). It is 
unclear whether dividing these two mucinous types of the pulmo-
nary mucinous adenocarcinoma has a clinical meaning. This study 
was aimed for clarify the presence of clinical meaning between two 
types of the mucinous adenocarcinoma.
Methods: 69 cases of the mucinous adenocarcinoma of the lung 
were performed curative operation in Matsumoto Medical Center 
between 2001 and 2012. HIK1083, designed as specific monoclo-
nal antibodies against gastric pyloric mucin, and TTF-1 were used 
for judge whether the mucin of the tumor was gastric-type. We 
divided the mucinous adenocarcinoma into B-type which had the 
bronchial gland-type mucin (HIK1083 negative and TTF-1 positive), 
and G-type which had the gastric-type mucin (HIK1083 positive 
and TTF-1 negative). Then, we compared clinical features and pro-
gnoses of these two groups.
Results: In the mucinous adenocarcinoma, 34 cases were B-type 
and 35 cases were G-type. The clinical backgrounds of the two 
groups were similar including gender, age and smoking status. 
The locations of the tumor were different between B-type (24 on 
upper-middle lobes, 10 on lower lobes) and G-type (8 on upper-
middle lobes, 27 on lower lobes). Histological-subtypes in B-type 
were 15 of pure- or mixed-BAC, 12 of papillary, 2 of aciner and 5 of 
solid. Those in G-type were all 35 of pure- or mixed-BAC. Lymph 
invasion has often seen in B-type (16 cases), and rarely seen in G-
type (2 cases). The number of the cases of each pathological-stage 
of IA, IB, IIA, IIB, IIIA, IIIB and IV were 12, 5, 1, 4, 8, 3 and 1 in B-
type, and were 17, 4, 2, 8, 0, 3 and 1 in G-type, respectively. Ana-
lysis of the gene for B-type mucinous adenocarcinoma revealed 
38% of EGFR-mutation-positive, 18 % of EML4-ALK-positive, 9% 
of K-ras-mutation-positive and 35% of the others. On the other 
hand, the gene for G-type showed 3% of EGFR-mutation-positive, 
55% of K-ras-mutation-positive and 42% of the others. About pro-
gnostic analyses, aerogenous metastases have occurred in 8 cases 
on both of B-type and G-type. However, there was no lymph-node 
recurrence in G-type, although 6 cases were seen in B-type. Dis-
tant-metastases were seen in 8 cases of B-type and 3 of G-type. 
Over all 5-year-survival-rates were 67.9% of B-type and 78.6% of 
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P1.18-007 MULTIPLEX TESTING OF DRIVER MUTATIONS 
IN NON-SMALL CELL LUNG CANCER (NSCLCS) OF  
AFRICAN-AMERICAN (AA) PATIENTS
Shirish Gadgeel, Michele Cote, Ann Schwartz, Aliccia Bollig-
Fischer, Susan Land, Angie Wenzlaff, Antoinette J. Wozniak, Am-
mar Sukari, Laura Mantha, Gerold Bepler
Karmanos Cancer Institute/Wayne State University/United States Of 
America
Background: Recently driver genetic alterations have been iden-
tified in NSCLC that can be targeted for therapeutic interventions. 
Previous reports have suggested that rates of certain mutations 
may vary according to ethnic background. We conducted multiplex 
testing of NSCLCs of AA and white patients to assess variability in 
the mutation rates by race.
Methods: We identified tumor tissues of 139 AA and 340 white 
NSCLC patients collected as part of three different institutional 
review board approved studies. Using the Sequenom MassArray 
system and a multiplexed panel, we analyzed tumor DNA for 214 
oncogenic mutations in 26 genes previously identified in NSCLC. 
Estimated risk (Odds Ratios (OR)) of any mutation and specific 
gene mutations among AA patients compared to white patients 
were calculated after adjusting for age, sex, smoking status and 
histology (adenocarcinoma versus non-adenocarcinoma). Informa-
tion on smoking status was unavailable on 45 patients and was not 
included in calculations of ORs for some genes (ORb).
Results: The median age at diagnosis was 60 vs 66 years in AA vs 
white patients; 42% of AA patients and 65% of white patients were 
males; 67% of AA patients and 49% of white patients had ade-
nocarcinoma; 67% of AA patients and 85% of white patients had 
stage I/II NSCLC and 10% of AA patients and 6% of white patients 
were never smokers. 43% of the AA patients and 46% of white 
patients had at least one mutation detected (OR=0.8; 0.5-1.2). 19% 
of AA patients and 8% of white patients had more than 1 mutation 
detected (OR 2.1; 1.1-4.1) (Table 1). AA patients were more likely to 
harbor mutations in STK11 (LKB1) (OR=7.5; 3.1-18.2) and NOTCH1 
(ORb=8.4; 2.2-31.7), and they were less likely to have MET muta-
tions (ORb=0.2; 0.1-1.1) then white patients. While not statistically 
significant, AA had lower prevalence of Kras mutations (ORb=0.5, 
0.2-1.0) and p53 mutations (OR= 0.7; 0.4-1.4). Table 1  
Outcome 
OR for African Ameri-
can Race 
95% CI P 
Any driver mutationa 0.8 0.5-1.2 0.203 
>1 driver mutationa 2.1 1.1-4.1 0.036 
STK11 Mutationa 7.5 3.1-18.2 <.001 
P53 Mutationa 0.7 0.4-1.4 0.359 
Kras Mutationb 0.5 0.2-1.0 0.041 
NOTCH1 Mutationb 8.4 2.2-31.7 0.002 
MET mutationb 0.2 0.1-1.1 0.065 
aAdjusted for age, sex, ever/never smoking and adeno/non-
adeno 
bAdjusted for age, sex, and adeno/non-adeno 
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Histologic invasiveness was associated with advanced disease 
stage (p<0.001), lower TDR (p<0.001), and tumor size (p<0.001), 
but could not predict molecular biomarkers status. Low TDR was 
associated with nodal involvement (p<0.001), advanced disease 
stage (p<0.001), but not with molecular biomarkers status.
Conclusion: ALK rearrangement is not common in lung cancer 
presented as nGGO lesion, and associated with progressive stage 
and larger tumor size, suggestive of aggressive feature in the pro-
gression of lung adenocarcinoma. Role of K-ras mutation in nGGO 
lesion is indefinite. The status of three molecular biomarkers was 
not associated with histologic invasiveness or proportion of GGO 
portion itself.
Keywords: EGFR, Lung cancer, K-ras, ALK
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P1.18-010 RUNNING TO KEEP UP! THE TIMELINE OF 
EVOLVING RESEARCH IN EGFR TESTING AND TARGE-
TED THERAPIES IN NEW ZEALAND
Helen S. Winter1, Claire Hardie1, Maureen Holdaway2, Lesley Bat-
ten2
1Regional Cancer Treatment Service/New Zealand, 2Massey University/
New Zealand
Background: The rapid pace of the development of new know-
ledge that may impact on clinical practice means that the time 
between scientific developments and their implementation in 
clinical practice may be short. This makes research work rewarding 
and exciting, but also much more akin to sprinting than running a 
marathon. We use a Health Research Council-funded study on the 
feasibility of introducing EGFR testing into New Zealand for Maori 
lung cancer patients as an example of the complexity of timelines 
between research and clinical practice
Methods: Aims of this mixed method study included exploring 
clinicians‘ and patients’ views on EGFR testing, which was not rou-
tinely available in New Zealand at that time.
Results: Between the time of the research proposal being written 
and the 12-month study completed and findings published, the 
landscape changed dramatically, with an emerging national focus 
on access to both EGFR testing and tyrosine kinase inhibitors. The 
time line for the project and key findings are presented alongside 
the evolving research, international and national guidelines for mo-
lecular testing and implementation of EGFR testing. We suggest 
how these developments may influence the implementation of 
future molecular testing such as ALK testing, which remains spora-
dic in New Zealand.
Conclusion: The translation of scientific discoveries to research 
findings to clinical practice guidelines is convoluted and complex 
rather than orderly and sequential. This case of EGFR testing provi-
des lessons for the translation of other scientific discoveries, which 
may significantly improve the care of lung cancer patients
Keywords: Nsclc , EGFR, targeted therapies, timeline
G-type (p=0.34). Disease-free-survival-rates for 5-years were 51.2% 
in B-type and 73.0% in G-type (p=0.05). Median-survival-months 
from the post-operative-recurrence were 25.3 in B-type and 6.9 in 
G-type (P=0.016).
Conclusion: The present study showed many differences of the 
clinical characteristics between B-type and G-type mucinous ade-
nocarcinoma in the lung. This study also suggests that there is a 
clinical meaning to classify mucinous adenocarcinoma of the lung 
into the two groups according to the mucin properties.
Keywords: mucinous adenocarcinoma, Lung cancer, mucin, HIK 
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P1.18-009 CLINICOPATHOLOGIC AND RADIOLOGIC 
CHARACTERISTICS OF LUNG CANCER PATIENTS WITH 
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR), K-
RAS MUTATION AND ANAPLASTIC LYMPHOMA KINASE 
(ALK) REARRANGEMENT PRESENTED AS NODULAR 
GROUND-GLASS OPACITY
Jae Ho Lee1, Sung-Jun Ko2, Yeong Joo Lee1, Jong Sun Park1, Young-
Jae Cho1, Ho-Il Yoon1, Jin-Haeng Chung3, Sanghoon Jheon4, Choon-
Taek Lee1
1Internal Medicine, Seoul National University Bundang Hospital/Korea, 
2Internal Medicine, Seoul National University Hospital/Korea, 3Patholo-
gy, Seoul National University Bundang Hospital, Seoul National Univer-
sity College Of Medicine/Korea, 4Thoracic And Cardiovascular Surgery, 
Seoul National University Bundang Hospital, Seoul National University 
College Of Medicine/Korea
Background: Nodular ground-glass opacity (nGGO) lesion at 
computed tomography (CT) is a pattern of lung cancer at early 
stage, and a few studies revealed the characteristics of lung cancer 
presented as nGGO. Recently, several driver mutations of lung 
adenocarcinoma such as epidermal growth factor receptor (EGFR), 
K-ras mutation and anaplastic lymphoma kinase (ALK) rearrange-
ment were found, and EGFR mutation is considered to play a role 
in early tumorigenesis of nGGO lesion, but the role of ALK rearran-
gement and K-ras mutation in nGGO lesion is still unknown.
Methods: We studied 217 nGGO lesions of 215 patients with lung 
cancer presented as nGGO, who had undergone surgical resec-
tion, retrospectively. We measured sizes of nGGO lesions at chest 
CT and calculated tumor disappearance rate (TDR). Pathologic 
analysis and molecular biomarker examination of surgical spe-
cimens were performed. Correlation between clinicopathologic 
and radiologic characteristics and molecular biomarker status was 
investigated.
Results: EGFR mutations were found in 119 among 217 cases 
(54.8%), positive ALK FISH in 6 among 217 cases (2.8%), and K-ras 
mutations in 7 among 154 cases (4.5%). Progressed disease stage 
(p=0.018), larger tumor size (p=0.035-0.037) were observed in 
ALK-positive group. Lower TDR, i.e. more solid portion in nGGO 
were observed in ALK-positive group, but it was not statistically 
significant (TDR 0.533 vs. 0.700, p=0.209). Female (p=0.004) and 
non-smoker or less smoker (p<0.001) were characteristics of EGFR-
positive group, but tumor size and TDR revealed no significant dif-
ference. K-ras-positive group revealed no meaningful clinicopatho-
logic and radiologic difference compared to K-ras-negative group. 
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P1.18-012 THYROID TRANSCRIPTION FACTOR (TTF-1) 
NEGATIVE LUNG ADENOCARCINOMAS WILL BE WILD 
TYPE FOR EPIDERMAL GROWTH FACTOR RECEPTOR 
(EGFR) MUTATIONS.
Mary Jo Fidler1, Neeta Somaiah2, Elizabeth Garrett-Mayer3, Xu Hu-
ang4, Keisuke Chirai5, Carol Sherman5, Amy Wahlquist3, Kathleen 
Danenberg4, Thomas Hensing6, Philip Bonomi1, George R. Simon5
1Rush University Medical Center/United States Of America, 2Depart-
ment Of Sarcoma Oncology, MD Anderson/United States Of America, 
3Biostatistics, Medical University Of South Carolina/United States Of 
America, 4Response Genetics/United States Of America, 5Medical On-
cology, MD Anderson/United States Of America, 6Medical Oncology, 
Evanston Memorial Hospital/United States Of America
Background: TTF-1 is expressed in approximately 70% of ade-
nocarcinomas (ACs) of the lung. EGFR mutations are present in 
13-15% of unselected patients with AC in the United States and 
national guidelines suggest initiating first line EGFR tyrosine kinase 
inhibitors in this population. Both high TTF1 expression and EGFR 
mutations are associated with terminal respiratory unit (TRU) type 
ACs, female sex, never-smoking status and longer survival. We hy-
pothesized that TTF-1 negative AC would have a high probability 
of being negative for EGFR mutations.
Methods: Microdissected formalin-fixed paraffin-embedded tu-
mors from 693 patients with NSCLC were analyzed for EGFR muta-
tions by allele-specific PCR in a pilot data set to test the hypothesis 
(pilot cohort). TTF-1 status was documented as positive, negative 
or not reported. Negative predictive value (NPV) for a range 
of true prevalences of EGFR mutation (1%-50%) was estimated 
using a Bayesian modeling approach. To further corroborate the 
hypothesis, a separate validation cohort of patients treated with 
erlotinib at two academic affiliated institutions with known TTF1 
and EGFR mutation status was studied using the same modeling 
approach (validation cohort).
Results: 301 patients with documented ACs and known TTF-1 
status were included in the pilot cohort. In this population enri-
ched to have EGFR mutations, EGFR mutations were present in 224 
specimens (74%). Only 2 of the 224 specimens that were positive 
for EGFR mutations were negative for TTF-1 expression yielding a 
sensitivity of 99.1% (95% confidence interval (CI) 96.8-99.9%). For 
prevalence rates of EGFR mutations of 13% and 15%, the estima-
ted NPV are 99.5% (95% credible interval (CRI) 98.6%-99.9%) and 
99.4% (98.4%-99.9%), respectively. Data from 211 patients com-
prised the validation cohort. With an 11% rate of EGFR mutations, 
the estimated NPV was 92% (95% CRI - 73%-99%). For true EGFR 
mutation rates of 13% and 15%, using the data from the validation 
cohort, the estimated NPVs were 97% (95% CRI 92%-99%) and 96% 
(95% CRI 91%-99%), respectively. 
Conclusion: An overwhelming majority of Lung ACs that are TTF-1 
negative will be negative for EGFR mutations. These findings may 
be useful in avoiding delay of chemotherapy initiation in TTF-1 
negative patients with newly diagnosed non-small cell lung cancer.
Keyword: TTF1, egfr gene mutation, predictive marker
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P1.18-011 IS VISCERAL PLEURAL INVASION SIGNIFI-
CANT PROGNOSTIC FACTOR IN LUNG CANCER  
PATIENTS WITH GROUND GLASS OPACITY ON  
THIN-SECTION CT SCAN?
Aritoshi Hattori, Kenji Suzuki, Takeshi Matsunaga, Yukio Tsushi-
ma, Kazuya Takamochi, Shiaki Oh
Thoracic Surgery, Juntendo University School Of Medicine/Japan
Background: Due to the recent amendment of lung cancer staging 
by the IASLC committee, pathological visceral pleural invasion 
(VPI) has been considered as a new prognostic factor and even 
pT1a-b lung cancers is included in pT2a, if the tumors have VPI. 
Basically, lung cancers with VPI are often revealed in patients with 
radiologically “pure-solid” appearance on thin-section CT scan. 
On the other hand, controversies still remain with regard to the 
prognostic significance of VPI in patients with radiologically early 
lung cancer with ground glass opacity (GGO) predominance.
Methods: Between 2004 and 2012, among 543 patients with sur-
gically resected pN0 non-small cell lung cancer less than 30mm in 
diameter, 466 patients that revealed radiologically “part-solid” and 
“pure-solid” appearance on thin-section CT scan were retrospec-
tively reviewed. Pure-solid tumors were defined as a tumor con-
structed only by consolidation without GGO, whereas part-solid 
tumors were defined as a focal nodular opacity that contained 
both consolidation and GGO on thin-section CT scan. Several clini-
copathological factors were evaluated to elucidate the prognostic 
factors for each group using a multivariate analysis. Survivals for 
each group were calculated by Kaplan-Meier estimation.
Results: Among 466 eligible lung cancers, 209 (45%) were pure-
solid and 237 (55%) were part-solid nodule on thin-section CT 
scan. In the group with pure-solid nodule, 128 patients were men 
and 81 were women with average age of 67 years. VPI was found in 
79 (38%) patients. Based on a multivariate analysis, VPI, maximum 
tumor diameter and CEA level were significant prognostic factors 
in patients with pure-solid nodule (p=0.0071, 0.0278, 0.0314). The 
5-year survival in patients with VPI (-) (81.3%) was significantly gre-
ater than that in VPI (+) (70.1%) (p=0.0051). While the group with 
part-solid nodule included 97 men and 140 women with average 
age of 66 years. VPI was found in 24 (10%) of the patients with 
part-solid nodule, however, it was not a significant prognostic fac-
tor in these lesions (p=0.4697). Furthermore, the 5-year survival in 
patients with VPI (-) was 94.9%, whereas that with VPI (+) was 85.6% 
(p=0.3798).
Conclusion: It is no doubt regarding the prognostic significance of 
visceral pleural invasion in patients with radiologically pure-solid 
lung cancer. On the other hand, even pleural invasion may not par-
ticipate in the prognosis in patients with part-solid lung cancers. 
Thus, upgrading of TNM staging system and administration of 
postoperative chemotherapy due to pleural factor should be care-
fully considered in lung cancer patients with GGO predominance.
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efforts remain problematic and further optimization is needed.
Keywords: FFPE, RNA, Quality, Analysis
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P1.18-014 AN ANALYSIS OF MRNA AND LONG NON-
CODING RNA (LNCRNA) EXPRESSION DURING THE 
PROGRESSION FROM PRE-INVASIVE LESIONS (PL) TO 
INVASIVE SQUAMOUS CELL CARCINOMA (SQCC) OF 
THE BRONCHUS.
Andre Koper1, Leena Joseph2, John R. Gosney3, Keith M. Kerr4, 
Matthew Evison2, Philip Crosbie1, Mark Lindsay5, Richard Booton1
1Faculty Of Medicine And Human Science, Univeristy Of Manchester/
United Kingdom, 2University Hospital Of South Manchester/United 
Kingdom, 3Dept Of Cellular Pathology, Royal Liverpool University Hos-
pital/United Kingdom, 4Department Of Pathology, Aberdeen University 
Medical School/United Kingdom, 5Pharmacy And Pharmacology, Uni-
versity Of Bath/United Kingdom
Background: Lung cancer is a common disease, with a poor 5-year 
survival rate often attributed to late diagnosis where curative treat-
ment is uncommon. SqCC account for ~40% of non-small cell lung 
cancer (NSCLC) that possess a clinically detectable preinvasive 
phase. Intervention following early diagnosis of NSCLC using low-
dose CT and autofluorescence bronchoscopy can significantly re-
duce mortality. PL are histological changes of bronchial epithelium 
that can be classified into squamous metaplasia (M), mild dysplasia 
(MID), moderate dysplasia (MOD), severe dysplasia (SD), carcinoma 
in-situ (CIS). They are found with varying prevalence, in high-risk 
cohorts such as smokers or individuals exposed to occupational 
carcinogens. MID and MOD are more frequently identified but 
only a minority progress to a SqCC. SD and CIS more commonly 
progress to SqCC but this is not universal.
Methods: The natural history of PL is not sufficiently understood. 
In order to address this, we have used exon arrays to profile mRNA 
and lncRNA levels in total RNA samples derived from formalin 
fixed wax embedded bronchial biopsies subject to laser micro-
dissection. Three thoracic pathologists (KK, JG, LJ) reviewed all 
biopsies and agreed the morphological classification. We will re-
port changes in differential expression of mRNA and lncRNA levels 
when we compare the transcriptome profiles of 5 categories of PL 
(M, miD, moD, sD, CIS) and 2 categories of SqCC (node negative 
and node positive), with those of matched normal bronchial epi-
thelial cells. We believe this analysis provides an unprecedented 
insight into the molecular events that drive progression towards 
invasive malignancy, and may aid the identification of novel tools 
for the management of early squamous cell lung cancer.
Results: not applicable
Conclusion: not applicable
Keywords: preinvasive lesions, squamous cell carcinoma, expressi-
on profiling, laser capture microscopy
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P1.18-013 EXTRACTING HIGH QUALITY RNA FROM FFPE 
SAMPLES FOR GENE EXPRESSION STUDIES
Jonathan Weiss1, Hongdo Do1, Prudence A. Russell2, Gavin Wright3, 
Alexander Dobrovic1
1Pathology, Peter MacCallum Cancer Centre/Australia, 2Anatomical 
Pathology, St Vincent‘s Hospital/Australia, 3Department Of Surgery, St. 
Vincent Hospital, University Of Melbourne/Australia
Background: The use of targeted therapies in the treatment of 
non-small cell lung cancer is still limited to a relatively small frac-
tion of patients. Chemotherapy remains the mainstay of treatment 
for most patients today. So far, the best predictors for chemothe-
rapeutic success are based on the expression of certain nucleotide 
metabolism genes or DNA damage response and repair related 
genes. However, the samples available for study most commonly 
comprise FFPE samples, which are characterised by a high degree 
of RNA fragmentation or degradation.
Methods: To address this problem, we have developed a protocol 
to reliably extract reasonable-quality RNA from FFPE samples. The 
protocol includes pathology review of the FFPE block, removal 
of a 2mm core, followed by RNA extraction. Next, the total RNA 
amount is quantified and a small proportion is accessed for frag-
mentation e.g. by TapeStation technology and/or a multiplex RT-
PCR to determine the amount and size of amplifiable templates. 
We then assessed the extracted total RNA by various RNA based 
methodologies.
Results: To this end, we prepared core punches from 118 diffe-
rent lung adenocarcinomas and successfully extracted sufficient 
amounts of total RNA (> 50ng /ul in a 20ul elution) from 111 of the 
cores (average is 307ng/ul ranging from 53ng to 1.1ug/ul). Frag-
mentation assessment of 26 of these RNAs showed that all samp-
les contained sufficient amounts of fragments with at least >100 nt. 
We first tested single gene expression by RT-qPCR. Of 26 samples 
tested, 24 samples showed robust amplification of a 161 bp frag-
ment of the TBP housekeeping mRNA. We next assessed our RNA 
using gene expression analysis by NanoString®. We interrogated 
150ng total RNA from 10 samples for the expression levels of 45 
genes. Data analysis showed robust expression values and no 
quality control problems in all samples. Finally, we tested whether 
the RNA was of sufficient quality for next-generation RNA sequen-
cing. We used 100 and 50 bp paired end sequencing on un-size-
selected RNA, and 100 bp paired end sequencing after one round 
of size selection. On average, we obtained 23 million reads per 
sample, of which 70% mapped to reference sequences after either 
extensive read clipping or size selection.
Conclusion: In conclusion, our extraction protocol enables us to 
reliably extract total RNA from FFPE samples, which can be used 
for single-gene expression by RT-qPCR and gene expression 
of limited gene sets by NanoString® technology. However, the 
amount of samples and genes tested here were not sufficient to 
allow identification significant differences between samples, but 
shows the possibility to use the RNA extracted following our ext-
raction protocol. RNAseq, however, poses a larger problem. The 
amount of mapped reads is significantly lower compared to high 
quality RNA from e.g. fresh frozen material or cell lines. The reason 
for these problems and possible solutions remain elusive. Overall, 
we present a simple and fast way to accurately extract RNA from 
FFPE material and show that after QC, single or small gene panels 
can successfully be assessed. However, large-scale sequencing 
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logy Platform protocol. All IHC-positive cases (intensity score 1+, 
2+ or 3+) were tested for ALK rearrangement by both fluorescent 
in situ hybridisation (FISH) and reverse transcriptase polymerase 
chain reaction (RT-PCR). FISH analysis using the Abbott Molecular 
LSI ALK Dual Colour Break Apart Probe required a minimum of 
15% of (at least 100) tumour cells with gene rearrangement for a 
positive diagnosis. RT-PCR testing was employed to detect EML4-
ALK fusion transcripts using a series of primers located in EML4 
exons 1 to 22, a reverse primer located in ALK exon 20 (Sanders et 
al., 2011;204:45-52) and sample RNA extracted from a single 40 µM 
section. Amplified products were Sanger sequenced to establish 
the fusion variant present.
Results: Ninety-one specimens were screened by ALK IHC and 
of these, 13 demonstrated positive staining. FISH and RT-PCR re-
sults were concordant (with the exception of one RT-PCR negative 
case which failed FISH testing) and 9 cases were diagnosed with 
ALK-rearrangement (9.9%). The majority of the EML4-ALK fusion 
transcripts were of variant 1 type (77.8%), with just two subtypes 
diagnosed as variant 3 (22.2%). The median time from referral for 
FISH/RT-PCR to the issue of reports was 5 working days.  
Conclusion: In keeping with reported findings ALK-rearranged 
NSCLC was found in 9.9% of selected adenocarcinomas. Although 
FISH/RT-PCR was not carried out on IHC-negative cases in this 
group, the application of IHC as a screening method appears to 
be a cost-effective means of highlighting ALK-rearranged tumours. 
RT-PCR testing of formalin-fixed, paraffin-embedded tissue is 
feasible in the clinical diagnostic setting, and may have an impor-
tant role in the determination of specific variants detected by IHC.
Keyword: ALK immunohistochemistry FISH RT-PCR
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P1.18-015 SCREENING FOR ALK-REARRANGED NSCLC 
IN SELECTED CASES USING IMMUNOHISTOCHEMISTRY 
FOLLOWED BY FISH AND RT-PCR TESTING OF  
TUMOURS WITH INCREASED ALK PROTEIN EXPRESSI-
ON IN A ROUTINE CLINICAL DIAGNOSTIC SETTING
Anne Marie Quinn1, Jade Harris1, Shuwen Huang1, Paul Bishop2, 
Antonio Paiva-Correia3, William Newman1, Fiona Blackhall4, An-
drew Wallace1, Daisuke Nonaka4
1Dept. Of Genetic Medicine, St. Mary‘s Hospital/United Kingdom, 
2Pathology, University Hospital South Manchester/United Kingdom, 
3Pathology, Royal Oldham Hospital/United Kingdom, 4The Christie NHS 
Foundation Trust/United Kingdom
Background: The diagnosis of anaplastic lymphoma kinase (ALK) 
gene rearrangement in non small cell lung cancer (NSCLC) has 
acquired therapeutic significance, subsequent to the established 
response of ALK-rearranged tumours to crizotinib therapy. General 
recommendations on NSCLC ALK testing will be published later 
this year by the National Institute for Health and Care Excellence. 
In advance of this, patients were prospectively screened for ALK-
rearranged NSCLC at the Christie Hospital, Manchester, U.K. from 
May 2012 to May 2013.
Methods: Pulmonary adenocarcinomas were selected for testing 
by ALK immunohistochemistry (IHC) based the presence of any of 
the following clinicopathologic features associated with ALK rear-
rangement; never smoker, light ex-smoker, age less than 50 years, 
signet ring/goblet cell morphology. IHC was performed with the 
5A4 clone (Novocastra) according to the European Thoracic Onco-
Table 1. Summary of clinicopathological features, IHC, FISH and RT-PCR results of cases positive for ALK protein staining on IHC. (ACA 
=adenocarcinoma)
Case Age Sex Sample type Histology
IHC 
H-
score
FISH 
% + RT-PCR
Final ALK 
diagnosis EGFR mutation
1 84 F Node excision ACA, signet ring cells 170 55
E13;A20 
variant 1
+ -
2 59 M Lung resection
ACA, solid with he-
patoid cells
190 77
E13;A20 
variant 1
+ -
3 56 M Pleural effusion ACA, hepatoid cells 240 64
E13;A20 
variant 1
+ -
4 46 M Node biopsy Adenosquamous 300 64
E6;A20 
variant 3
+ -
5 64 M Pleural biopsy
ACA, solid with he-
patoid cells
300 48
E13;A20 
variant 1
+ -
6 60 F Node aspirate
ACA, signet ring and 
hepatoid cells
300 66
E13;A20 
variant 1
+ -
7 41 F Node biopsy ACA, hepatoid cells 300 71
E13;A20 
variant 1
+ -
8 40 M Pleural biopsy
ACA, solid with he-
patoid cells
300 58
E6;A20 
variant 3
+ -
9 65 F Node aspirate
ACA, signet ring and 
hepatoid cells
300 45
E13;A20 
variant 1
+ -
10 54 M Pleural effusion ACA 20 5 Negative - -
11 52 F
Pericardial effu-
sion
ACA 10 Failed Negative - -
12 49 F Pleural fluid ACA 35 0 Negative - +
13 70 F Lung resection
ACA, solid with he-
patoid cells
54 9 Negative - Unknown
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Conclusion: Despite the statistically significant tendency for LN 
with metastasis to be larger than those without metastasis, there 
was broad size distribution overlap. Furthermore, a third of mate-
rials that grossly appeared to be LN were not, though some were 
satellite metastatic nodules. This probably contributes to the rela-
tively low LN yield in routine examinations. LN size is not a reliable 
means of distinguishing between those with and without metasta-
sis. The protocol for gross N1 LN retrieval should be modified to 
facilitate a more thorough routine examination.
Keywords: Pathologic nodal staging, quality of care, non-small cell 
lung cancer, surgical resection
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P1.18-017 THE PREVALENCE OF MICROMETASTASIS 
(MM) IN DISCARDED INTRAPULMONARY LYMPH NO-
DES (LN) IN RESECTED NON-SMALL CELL LUNG CAN-
CER (NSCLC).
Raymond U. Osarogiagbon1, Srishti Sareen1, Christopher G. Wang2, 
Robert Ramirez3, Laura E. Miller4, Jaime Rodriguez5, Rosana Eisen-
berg6, Saul Suster7, Ignacio Ivan Wistuba8
1Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center/
United States Of America, 2Medical Oncology, University Of Alabama/
United States Of America, 3Louisiana State University/United States Of 
America, 4Medical Oncology, Tulane University/United States Of Ame-
rica, 5Thoracic/head & Neck Medical Oncology, The University Of Texas 
MD Anderson Cancer Center/United States Of America, 6Vanderbilt 
University/United States Of America, 7Pathology, Medical College Of 
Wisconsin/United States Of America, 8Translational Molecular Patholo-
gy, The University Of Texas MD Anderson Cancer Center/United States 
Of America
Background: 44% of pN0 NSCLC resection patients die within 
5 years. We recently showed 12% of pN0 NSCLC resection spe-
cimens have discarded LN with metastasis on H&E microscopy. 
ACOSOG Z0040 demonstrated the prognostic impact of immuno-
histochemistry positive (IHC+) LN MM. In this report, we investi-
gated the prevalence of IHC+ LN MM in patients with and without 
H&E + LN metastasis in discarded lung resection specimens.
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P1.18-016 THE ASSOCIATION BETWEEN SIZE AND  
HISTOLOGY IN DISCARDED INTRAPULMONARY LYMPH 
NODES (LN) FROM NON-SMALL CELL LUNG CANCER 
(NSCLC) RESECTION SPECIMENS: CAN WE SELECT  
NODES FOR EXAMINATION BY THEIR SIZE?
Raymond U. Osarogiagbon1, Robert Ramirez2, Christopher G. 
Wang3, Laura E. Miller4, Xinhua Yu5, Matthew Smeltzer5
1Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center/
United States Of America, 2Louisiana State University/United States Of 
America, 3Medical Oncology, University Of Alabama/United States Of 
America, 4Medical Oncology, Tulane University/United States Of Ameri-
ca, 5Epidemiology And Biostatistics, School Of Public Health University 
Of Memphis/United States Of America
Background: Pathologic nodal staging is the most important 
prognostic factor in resected NSCLC, but LN yields are low. A me-
dian of 3 N1 nodes are examined in US lung resection specimens, 
though fastidious examination yields a median of 11 N1 LN. A bias 
towards examination of larger nodes may cause understaging 
when small LN with metastasis are missed. We examined the size 
and histologic characteristics of LN material retrieved during a fas-
tidious redissection of discarded lung cancer resection specimens.
Methods: Prospective study of lobectomy specimens discarded 
after completion of the routine pathology examination. A fasti-
dious redissection protocol was used to retrieve all grossly LN-like 
material for histologic examination, irrespective of size. The Wil-
coxon-Mann-Whitney test was used to compare the materials with 
and without metastasis.
Results: 1094 LN-like materials retrieved from 112 resection speci-
mens: 345 (32%) were not LN on histologic examination (including 
11 satellite metastatic nodules); 749 (68%) were LN, of which 71 
(9%) had metastasis. The distribution of size and histology is shown 
(Figure). The median size (range) of the non-LN, LN without meta-
stasis, and LN with metastasis was: 4.0 (0.9 - 20); 6.0 (1.0 - 27), 12.0 
(1.0 - 27) mm (p<.0001, for all comparisons). Twenty-six patients 
(23%) had LN with metastasis (see histogram). In 4 patients, LN 
with metastasis were smaller than LN without metastasis. 
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Methods: Using a fastidious redissection special pathology exa-
mination (SPE) protocol, we retrieved LN from discarded NSCLC 
resection specimens after the routine pathology examination 
(RPE). All retrieved LN were examined for metastasis by H&E light 
microscopy. We matched 26 patients with 1 or more H&E+ LN 
(irrespective of whether detected on RPE or SPE) with 28 patients 
without detectable nodal metastasis. Fresh sections were cut from 
all retrieved LN tissue blocks of these 54 patients and stained with 
AE1/AE3 immunostain (Dako) at an independent institution. All sli-
des were examined independently by pathologists at two different 
institutions, and discordant reports resolved at a consensus review 
session. The prevalence of IHC positivity was determined from the 
final consensus of pathologists.
Results: 
Conclusion: Micrometastatic disease is evident in a significant 
proportion of the LN retrieved from discarded NSCLC resection 
specimens, further extending the potential clinical implications 
of incomplete LN examination. IHC+ nodes were not found in LN 
from patients with H&E negative disease after fastidious examinati-
on by SPE. The survival implications of these findings will be inves-
tigated in future clinical trials.
Keywords: pathologic staging, Occult metastasis, quality of care
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Conclusion: All procedures had a substantial to almost perfect 
agreement in diagnosis of non-small-cell lung cancer subtype. 
Broncoscopy had 69% sensibility, lower than literature maybe be-
cause only operable tumors were considered, influenced by tumor 
size and an agreement in diagnosis independent of all factors 
considered. Transthoracic procedures had a sensibility lower than 
literature with substantial agreement influenced by tumor size. 
Broncoscopy was better in squamous-cell diagnosis and transtho-
racic procedures in adenocarcinoma maybe due to location in lung
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P1.18-019 MICROPAPILLARY HISTOLOGY IS ASSOCIA-
TED WITH OCCULT LYMPH NODE METASTASIS (PN2) 
IN PATIENTS WITH CLINICALLY N2-NEGATIVE (CN0/N1) 
LUNG ADENOCARCINOMA
Yi-Chen Yeh1, Junichi Nitadori2, Kyuichi Kadota3, Camelia S. 
Sima4, Nabil P. Rizk3, Valerie W. Rusch3, William D. Travis5, Prasad 
S. Adusumilli3
1Department Of Pathology And Laboratory Medicine, Taipei Veterans 
General Hospital/Taiwan, 2Department Of Thoracic Surgery, The 
University Of Tokyo Hospital/Japan, 3Division Of Thoracic Service, 
Department Of Surgery, Memorial Sloan-Kettering Cancer Center/
United States Of America, 4Department Of Biostatistics, Memorial 
Sloan-Kettering Cancer Center/United States Of America, 5Department 
Of Pathology, Memorial Sloan-Kettering Cancer Center/United States 
Of America
Background: Among patients with lung adenocarcinoma staged 
as N2-negative in the mediastinum by PET/CT scan, up to 16% will 
have occult N2 metastasis (pN2) detected on mediastinoscopy or 
surgical resection. We investigated the association between histo-
logic subtyping (according to the newly proposed IASLC/ATS/ERS 
classification) and occult lymph node metastasis in patients with 
unsuspected N2 disease.
Methods: We performed a retrospective review of 297 patients 
with lung adenocarcinoma (≤2 cm, 51%; >2 cm, 49%) who under-
went surgical resection and mediastinal nodal dissection from 
2007 to 2009. Mediastinal lymph node disease was assessed 
preoperatively by FDG-PET/CT scan. Histologic subtyping was 
performed according to the newly proposed IASLC/ATS/ERS clas-
sification.
Results: Ninety-three percent of patients had N0 disease, and 7% 
had N1 disease, as detected by preoperative PET/CT scan. Of the 
297 patients, 32 (10.8%) had occult N2 metastasis identified by 
pathologic examination (9.7% of patients with cN0 disease, 25% 
of patients with cN1 disease). On univariate analysis, SUVmax of 
the primary tumor >4 (p=0.001), predominant histologic subtype 
(p=0.001), presence or absence of lepidic pattern (p<0.001), mi-
cropapillary pattern (p=0.009), and solid pattern (p=0.011) were 
associated with pN2 disease. On multivariate analysis, presence of 
lepidic pattern (odds ratio [OR], 0.33; 95% confidence interval [CI], 
0.14-0.77; p=0.011), presence of micropapillary pattern (OR, 2.58; 
95% CI, 1.13-5.92; p=0.025), and SUVmax of the primary tumor >4 
(OR, 2.44; 95% CI, 1.03-5.79; p=0.042) were significantly associated 
with occult N2 metastasis.
Conclusion: Micropapillary histology and primary tumor SUVmax 
>4 on FDG-PET/CT were independently associated with occult N2 
metastasis.
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P1.18-018 DIAGNOSIS OF LUNG CANCER: PERFOR-
MANCE OF PRE-OPERATIVE PROCEDURES IN CLINICAL 
PRACTICE CORRELATED WITH CHARACTERISTICS OF 
THE TUMOR.
Maria Teresa Almodovar1, Claudia Matos2, Filipa Santos3, Fernan-
do Cunha3, Susana Esteves4, José Duro Da Costa1
1Pulmonology, Instituto Português De Oncologia De Lisboa Francisco 
Gentil/Portugal, 2Pulmonology, Hospital Garcia Orta/Portugal, 3Pa-
thology, Instituto Português De Oncologia De Lisboa Francisco Gentil/
Portugal, 4Clinical Research Unit, Instituto Português De Oncologia De 
Lisboa Francisco Gentil/Portugal
Background: Recent treatments for advanced non-small cell carci-
noma (NSCLC) have increased the demand for accurate diagnosis 
of NSCLC rendered by histology or cytology. However precise 
classification is not always possible
Methods: We investigated the performance characteristics of 
preresection procedures for diagnosis of NSCLC Database was 
searched for resected NSCLCs during 2008-2011 with correspon-
ding preresection cytology and/or biopsy cases. The pre-resection 
diagnoses were correlated with resection diagnosis considering 
the type of bronchoscopic or transthoracic procedure, size, loca-
tion of tumor in bronchoscopy and distance from thoracic wall in 
transthoracic cases. Pathologic data were reviewed by two patho-
logists and TAC by two pulmonologists. Pathology of resection 
was categorized as adenocarcinoma- AD, squamous cell- SQ, 
adenosquamous carcinoma (ADSQ), and large cell carcinoma-
LCC. The bronchoscopy (BF) procedures- bronchial biopsy BB, 
distal biopsy DB, bronchial washing (BW), bronchial brushing (BBr), 
endobronchial/transbronchial biopsy (ETBX), and trans-thoracic 
procedures (TT)—transthoracic fineneedle aspiration(TT-FNA) and 
transthoracic needlecore biopsy(TT-NCB) were identified. Sen-
sitivity of procedures was determined taking surgical pathology 
as reference; 95% confidence intervals were estimated by Wilson 
method. Agreement was evaluated using Cohen’sKappa. Univaria-
te and multivariate logistic regression was used to evaluate factors 
possibly associated with absence of pre-surgery tumor diagnosis 
and lack of agreement in the subset with pre-surgical diagnosis.
Results: A total 189 patients were included, with 538 previous dia-
gnostic procedures. The distribution for diagnosis was 105 AD, 48 
SQ, 9 ADSQ, and 17 LC. Median (Max-Min) size of the tumor was 
27mm (10-25). Median (Max-Min) distance from the thoracic wall 
was 7 mm (0 – 50). Procedures sensibility were: all 69% (63% - 76%), 
, TT 57% (46%-66,5%) , TT-NCB 71%, TT-FNA 33%,BF 54% (47%-
62%)BB 63%, DB 54%, ETBX 32%, BBR 22%, BW 12%. The 131 
patients in the subset with pre-surgery diagnosis agreement bet-
ween pre and post-surgical diagnosis was: all procedures k=0,54, 
TT k=0,69, TT-NCB k=0,69, TT-FNA k=0,34, BF k=0,69, BB 0,59, 
DB k=0,73, ETBX k=0,80, BBR k=0,57, BW k=0,51. Concordance 
by histology was all procedures- AD 82%, SQ 78%; TT - AD85%, 
SQ 67%; NCB- AD 93%,SQ 75%; TT-FNA AD 78%, SQ 50%; BF AD 
81%, SQ 87%; BB AD 82%,SQ 86; DB AD 100%, SQ 90%; ETBX 
88% SQ 100%; BBR AD 79%, SQ 38%; BW AD 67%, SQ 60%. From 
factors possibly associated with diagnosis sensibility only the size 
of the tumor, in TT ODD 5% by additional mm (p=0,001), in BF 
ODD 3% (p=0, 0038) was significantly associated in univariated 
and multivariated analysis. From the factors possibly associated 
with agreement between pre-surgical and surgical diagnosis only 
the size of tumor in PATT was significantly associated in univariated 
and multivariated analysis.
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Breakdown of KRAS and EGFR Mutations
Gene
Codons 
Tested
Mutation 
Codons 
Detected
Number of 
Mutations
% of Detected 
Mutations
KRAS
12, 13, 61, 
146
12 19 95%
61 1 5%
EGFR
709-719, 
exon 19 
deletion, 
768-790, 
exon 20 
insertion, 
833, 858-
861
769 2 13%
796 1 7%
833 1 7%
852 1 7%
858 3 20%
Deletion 7 40%
Insertion 1 7%
Conclusion: This program confirms the feasibility of molecular 
profiling in the community setting to assist medical oncologists in 
treatment decisions for pts with lung cancer, including enrollment 
in clinical trials.
Keywords: molecular profiling, next-generation sequencing, 
KRAS, EGFR
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P1.18-021 RETROSPECTIVE ANALYSIS OF THE PREVA-
LENCE OF NSCLC DRIVER MUTATIONS IN UNSELECTED 
SAMPLES.
Wissam Saliba1, Luis Corrales-Rodriguez2, Roula Albadine1, Denis 
Soulieres1, Xiaoduan Weng1, Isabelle Gorska1, Marie-Lise Audet1, 
Danh Tran-Thanh1, Boli Fan1, Mustapha Tehfe1, Marie Florescu1, 
Normand Blais3
1Centre Hospitalier Universitaire De Montreal - Chum/Canada, 2Grupo 
De Oncología Torácica, Hospital San Juan De Dios-ccss/Costa Rica, 
3Centre Hospitalier De L‘universite De Montreal/Canada
Background: Much of the recent improvement in lung cancer out-
comes owes to the advent of the Lung Cancer Mutation Consor-
tium. We aimed to assess thequality of the pathologic specimens 
and to study the prevalence of each of the most clinically relevant 
driver mutations in a non-referred population with non-squamous, 
non-small cell lung cancer (NS-NSCLC) treated in a tertiary center 
in the province of Quebec characterized by a high prevalence of 
smokers (25% of adult population).
Methods: Consecutive patients with pathologically proven NS-NS-
CLC diagnosed or treated in our institution between January 2006 
and June 2009 inclusively were accrued. Patients whose diagnosis 
is based uniquely on a positive cytology or whose diagnostic ma-
terial was not available were excluded. Specimens were tested for 
ALK translocations (by IHC and FISH), for EGFR mutations in exons 
19 and 21 by PCR (fragment analysis and qPCR) and for mutations 
in KRAS codons 12 and 13 by PCR-RFLP. ALK-FISH and ALK-IHC 
results were analyzed in a blinded manner.
Results: A total of 1017 consecutive patients were screened. We 
excluded 209 patients who had only cytologic material, 55 patients 
who had no residual material and 197 patients who had insufficient 
Keywords: Adenocarcinoma, Micropapillary, Lymph node metas-
tasis, PET/CT
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P1.18-020 MOLECULAR ALTERATIONS IN ADVANCED 
LUNG CANCER: GENOMIC SEQUENCING IN A COMMU-
NITY PROFILING PROGRAM OF THE SARAH CANNON 
RESEARCH INSTITUTE (SCRI)
Shile Liang1, Todd Bauer1, Pranil Chandra2, Zeqiang Ma1, Debbie 
Haynes1, James Prescott2, Dawn Stults1, Suzanne Jones1, John 
Hainsworth1, Jeffrey Infante1, Howard Burris1, David Spigel1
1Sarah Cannon Research Institute/United States Of America, 2Path-
group/United States Of America
Background: In October 2012, SCRI launched a genomic sequen-
cing program at a single community clinical research center in 
middle Tennessee to explore molecular alterations with proven or 
potential therapeutic significance for patients (pts) with advanced 
solid and hematologic tumors. Herein we report the findings from 
the lung cancer cohort tested to date.
Methods: Biospecimens from pts with advanced lung cancer 
(ECOG ≤ 2) who consented to molecular profiling were tested by 
Next-Generation Sequencing (NGS) with 1000X average coverage 
in a CLIA/CAP-certified laboratory. Oncogenic hotspot mutations 
in 35 genes were tested (copy number variation and translocation 
were not tested). Results were reported to the treating physician 
within 12 days of receipt of suitable tissue, and were used to in-
form treatment decisions. Molecular profiling results were stored in 
a database to enable correlation with clinical outcomes.
Results: As of May 31 2013, a total of 594 tumor samples were 
profiled, 143 (24%) of which were from pts with lung cancer. 23% 
(33/143) of the lung samples were inadequate for assay. Of the 110 
lung samples with sufficient tissue, 47 (43%) were found to have 
at least 1 identifiable mutation: 30 (27%) single mutations and 17 
(16%) multiple mutations. The mutation frequency by histology was 
adenocarcinoma 63% (34/54 pts), squamous 19% (4/21 pts), large 
cell 67% (4/6 pts), and small-cell 8% (1/13 pts). The most frequent 
mutations from this 35-gene panel were KRAS and EGFR (18% and 
14%, respectively). Other genetic alterations identified included 
STK11 6%, MET 5%, RUNX1 4%, FGFR3 3%, BRAF 2%, MEK1 2%, 
PIK3CA 2%, WT1 1%, SMO 1%, KIT 1%, GNAS 1% and FGFR4 1%.  
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tissue. Analysis was possible on 556 patients. The median age of 
the analyzed population was 64 years and male gender frequency 
was 45.5%. Compared to our entire cohort, metastatic cases were 
significantly under-represented in the analyzed population 27.3% 
vs. 79.1% for local disease (p<0.0001). The distribution according 
to stage and year of diagnosis along with that related to overall 
eligible population as well as the percentage of each of the 3 dri-
ver mutations status in the specimens analyzed so far are shown in 
the table below:  
Local disease analyzable / 
overall
Loco-regional analyzable 
/ overall
Metastatic analyzable / 
overall
Total analyzable / 
overall
2006 - 2007 188/227 (82.8%) 66/147 (44.9 %) 55/207 (26.6 %) 311/583 (53.3 %)
2008 - Mid 2009 161/214 (75.2%) 50/96 (52.1 %) 36/126 (28.6 %) 247/436 (56.7 %)
Total 349/441 (79.1%) 116/243 (47.7%) 91/333 (27.3 %) 556/1017 (54.7 %)
Mutation re-
sults:
Local disease positive/to-
tal analyzed
Loco-regional positive/
total analyzed
Metastatic positive/total 
analyzed
Total positive/total ana-
lyzed
KRAS codon 12 76/216 (35.2%) 20/55 (36.4%) 17/54 (31.5%) 113/325 (34.8%)
KRAS codon 13 7/216 (3.2%) 2/55 (3.6%) 2/54 (3.7%) 11/325 (3.1%)
KRAS mutated 83/216 (38.4%) 22/55 (40%) 19/54 (35.2%) 124/325 (37.9%)
EGFR exon 19 11/128 (8.6%) 2/42 (4.8%) 4/39 (10.3%) 17/209 (8.1%)
EGFR exon 21 6/128 (4.7%) 3/42 (7.1%) 1/39 (2.6%) 10/209 (4.8%)
EGFR mutated 17/128 (13.3%) 5/42 (11.9%) 5/39 (12.8%) 27/209 (12.9%)
ALK-FISH 2/264 (0.8%) 0/90 (0%) 1/69 (1.4%) 3/423 (0.7%)
ALK – IHC* 1/277 (0.4%) 0/97 (0%) 1/75 (1.3%) 2/453 (0.4%)
 
*One ALK-FISH positive case was IHC negative on repeated tes-
ting.
Conclusion: Our study shows that adequate tumor sampling is 
a challenge when performing retrospective molecular biology 
studies, creating a bias of adequate tissue availability in favor of 
more localized stages of disease. Nonetheless, our study shows a 
lower percentage of EGFR/ALK mutations and a higher percenta-
ge of KRAS mutations than that reported by the LCMC and other 
groups. This may be related to the non-selected, regional distri-
bution and smoking habits of our study population. Prospective 
studies on the molecular diagnosis of NS-NSCLC will refine epide-
miologic features of the different genetic subtypes of this disease.
Keyword: NSCLC
S674 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
invasive cancer and further studies are required to test the role of 
endobronchial intervention to prevent progression and to determi-
ne the most efficacious modality of treatment.
Keyword: natural history, pre-invasive, progression
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P1.18-022 THE NATURAL HISTORY OF BRONCHIAL  
PRE-INVASIVE DISEASE
Jim Brown, Georgia Hardavella, Bernadette Carroll, Mary Falzon, 
Neal Navani, Jeremy George, Sam Janes
University College London Hospital/United Kingdom
Background: Bronchial pre-invasive lesions represent the earliest 
stages of the stepwise progression of squamous carcinogenesis, 
they predominantly affect the large airways and are readily de-
tectable using autofluoresence bronchoscopy (AFB) however very 
little is known about the natural history of these lesions and no 
randomised data exists to determine whether intervention before 
progression to invasion improves outcome.
Methods: A total of 94 patients with bronchial dysplasia were en-
rolled into an on-going surveillance cohort at University College 
London Hospital running prospectively since 1999. Lesions were 
biopsied longitudinally and kept under regular surveillance with 
AFB and low dose annual CT scanning until resolution or progres-
sion to invasive disease occurred. Retrospective analysis of lesional 
destiny was undertaken to determine the proportions of progres-
sive vs. regressive lesions that occur in low grade dysplasia (LGD- 
squamous metaplasia, mild and moderate dysplasia) vs. high grade 
dysplasia (HGD- severe dysplasia (SD) and carcinoma-in-situ). A 
lesion was considered to have progressed/ regressed if it crossed 
between groups (LGD, HGD, invasive cancer).
Results: A total of 117 separate lesions that were biopsied on 
more than one occasion were identified of which 61 were HGD 
and 56 LGD. Of the low grade lesions 54/56 (96%) regressed or 
remained static, 1 (2%) progressed to CIS and 1 (2%) to invasi-
ve carcinoma both of these lesions progressed from moderate 
dysplasia. Of the high grade lesions there were 13 SD and 48 
CIS, overall 35/61 (57%) of HGD progressed to invasive cancer 
9/61 (15%) regressed and 17/61 (28%) remained static. There was 
a trend toward higher progression to cancer (62% vs 56%) and 
lower rates of regression (8% vs. 17%) for SD versus CIS in the 
HGD cohort although the numbers are too small to be statistically 
significant (see fig. 1). In the HGD group median time to invasion 
was 9.5 months (range 3-49), static lesions were documented to 
have remained as such for a median of 17 months (range 4-60). 
Conclusion: In our cohort we see very few lesions following the 
traditional stepwise progression and LGD remains relatively indo-
lent. There is a significant proportion of HGD that progresses to 
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Results: 
First picture represents an optical image lymph node station 7 
after inhaled cisplatin. Second image represents spectral image 
of lymph node station 7 red areas represent the cisplatin diffusion 
within the tissue. Third image spectral library of inhaled cisplatin 
(90minutes after aerosol cisplatin administration, 40mg) The con-
centration 90 minutes after the aerosol cisplatin administration 
(40mg) was 2.09 µg/g Pt. in lymph node station 7 as measured with 
biochemistry techniques in a second patient.
Conclusion: We have efficiently presented data correlating at the 
same time local deposition with diffusion of aerosol cisplatin and 
concentration within lymphnodes. Using an optical technique and 
a biochemistry technique. Aerosol chemotherapy is an efficient 
method of treatment and further investigation is warranted with or 
without additional carriers added to the drug formulation.
Keyword: aerosol cisplatin, lung cancer, cytoviva, hyperspectral 
microscope system.
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P1.19-001 INHALED CISPLATIN DISPLAYED WITH THE 
CYTOVIVA TECHNIQUE IN STAGE II NON-SMALL CELL 
LUNG CANCER PATIENTS
Paul Zarogoulidis1, Dora Sparopoulou2, Kaid Darwiche3, Dionysis 
Spyratos1, Jay F. Turner4, Wolfgang Hohenforst-Schmidt5, Haidong 
Huang6, Qiang Li6, Leslie Krauss7, Robert Browning8, Konstantinos 
Zarogoulidis1
1Pulmonary Department-oncology Unit, g`. Papanikolaou General Hospi-
tal, Aristotle University Of Thessaloniki/Greece, 2Experimental Labora-
tory, theiageneio Anticancer Research Center/Greece, 3Department Of 
Interventional Pneumology, Ruhrlandklinik, West German Lung Center, 
University Hospital, University Duisburg-Essen/Germany, 4Professor 
Of Medicine University Of Nevada School Of Medicine Senior Research 
Fellow, National Supercomputing Center For Energy And The Environ-
ment University Of Nevada Las Vegas/United States Of America, 5Ii 
Medical Department, Coburg Hospital, University Of Wuerzburg/Ger-
many, 6Department Of Respiratory Diseases, Changhai Hospital/First 
Affiliated Hospital Of The Second Military Medical University/China, 
7Product Manager Of Cytoviva®, Inc./United States Of America, 8Di-
rector Of Interventional Pulmonology, Commander, Medical Corps, U.s. 
Navy/United States Of America
Background: Lung cancer therapies during the last decade are 
targeting the genome of cancer cells. However, investigating the 
gene pathways of tumor has the disadvantage so far that muta-
tions are found in a limited number of patients therefore limiting 
the production of targeting therapies. Novel routes for adminis-
tering lung cancer therapies have been investigated for decades. 
Aerosol therapies for several systematic diseases and systemic 
infections have been introduced in the market for a decade. One 
of the main issues of aerosol therapies has been the investigation 
of the deposition of a drug compound throughout the systematic 
circulation and lymph node circulation. Until now none of the pu-
blished studies have efficiently displayed the deposition of a che-
motherapy pharmaceutical within the lymph node tissue.
Methods: The CytoViva® technique can be summarized to the fol-
lowing information. Optical and hyperspectral images along with 
hyperspectral data were captured utilizing a research grade optical 
microscope equipped with the CytoViva® advanced darkfield illu-
mination system, dual mode fluorescence module and integrated 
hyperspectral imaging system. This integrated system builds hy-
perspectral image files via “push broom” method, enabling the 
creation of a high signal to noise spectral image file. Subsequent 
image analysis delineates the reflectance spectral response of the 
sample elements in each nanoscale pixel of the image file.
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P1.19-003 TEST PERFORMANCE OF PET-CT FOR  
MEDIASTINAL LYMPH NODE STAGING OF PULMONARY 
CARCINOID TUMOURS
Holly Pattenden1, Maria Leung1, Emma Beddow1, Michael Dusmet1, 
Andrew G. Nicholson1, Michael Shackcloth2, Saifullah Mohamed3, 
Adnan Darr3, Babu Naidu3, Swetha Iyer4, Adrian Marchbank4, Amy 
Greenwood5, Doug West5, Felice Granato6, Alan Kirk6, Eric Lim On 
Behalf Of The Uk Thoracic Surgery Collaborative1, Priyadhars-
hanan Ariyaratnam7, Mahmoud Loubani7
1Department Of Thoracic Surgery, Royal Brompton & Harefield Trust/
United Kingdom, 2Department Of Thoracic Surgery, Liverpool Heart & 
Chest Hospital NHS Foundation Trust/United Kingdom, 3Department 
Of Thoracic Surgery, Heart Of England NHS Foundation Trust/United 
Kingdom, 4Department Of Cardiothoracic Surgery, Derriford Hospital/
United Kingdom, 5Department Of Cardiothoracic Surgery, Bristol Royal 
Infirmary, University Hospitals Bristol NHS Trust/United Kingdom, 
6Department Of Thoracic Surgery, West Of Scotland Regional Heart 
& Lung Centre, Golden Jubilee National Hospital/United Kingdom, 
7Department Of Cardiothoracic Surgery, Castle Hill Hospital/United 
Kingdom
Background: PET-CT is a standard investigation to stage the me-
diastinum in non-small cell lung cancer when radical management 
is planned. The absence or presence of mediastinal lymph node 
involvement on PET-CT informs surgical selection (with or without 
further nodal sampling). The clinical utility of PET-CT in carcinoid 
tumours is uncertain as its test performance at identifying medi-
astinal lymph node disease in these tumours is as yet undefined 
with such tumours being rare and FDG avidity often considered 
to be variable or low. As such, it is argued whether PET-CT serves 
the same purpose in selecting patients for radical management in 
carcinoid tumours as it does with other non-small cell lung cancers. 
The aim of this study was to determine the test performance of 
PET-CT for mediastinal lymph node staging of pulmonary carcino-
id tumours by collating a multicentre database.
Methods: We collated retrospective data from 7 institutions by 
performing a search on pathological databases for a consecutive 
series of patients who underwent thoracic surgery for a carcinoid 
tumour from Nov 1999 - Jan 2013. Preoperative PET-CT staging re-
ports (prior to surgery with lymph node dissection) were obtained 
from patients’ records and compared against the reference stan-
dard of pathologic results obtained from lymph node dissection, 
and test performance reported using sensitivity and specificity.
Results: From Nov 1999 - Jan 2013, a total of 247 patients from 7 
institutions underwent surgery for a carcinoid tumour with a corre-
sponding preoperative PET-CT scan. The mean age of the patients 
was 61 (SD 15) and 84 were male (34%). The pathologic sub-type 
was typical carcinoid in 217 patients (88%) and atypical carcinoid in 
30 patients (12%). The mean SUV uptake in the primary tumour was 
4.8 (SD 4). Results from lymph node dissection were obtained in 
213 patients. PET-CT reported uptake at mediastinal lymph nodes 
in 19 patients, of which only 3 were positive on subsequent pa-
thology. Pathological results, from lymph node dissection carried 
out in 213 patients at the time of surgery, found 8 patients with 
mediastinal lymph node positive disease, of which only 3 had been 
picked up in preoperative PET-CT staging. The calculated sensiti-
vity and specificity of PET-CT to identify mediastinal lymph node 
disease was 38% (95% CI 8-76%) and 93% (88-96%) respectively.
Conclusion: In non-small cell lung cancer, preoperative PET-CT 
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P1.19-002 AN OPEN-LABEL, SINGLE ARM TRIAL TO EVA-
LUATE THE PREDICTIVE VALUE OF PERFUSION CT AND 
EARLY RADIOLOGIC RESPONSE TO CISPLATIN (C) GEM-
CITABINE (G) AND BEVACIZUMAB (B) IN PATIENTS (PTS) 
WITH ADVANCED OR METASTATIC NON-SQUAMOUS 
NON-SMALL CELL LUNG CANCER (NSNSCLC).
Noemi Reguart1, Pedro Arguis2, Marcelo Sanchez2, Nuria Viñolas1
1Oncology, Hospital Clinic I Provincial De Barcelona/Spain, 2Radiology, 
Hospital Clinic I Provincial De Barcelona/Spain
Background: Classically the evaluation of response in oncology 
has been based in comparing pre and post treatment tumour vo-
lume by means of studying changes in the diameter lesions. The 
introduction of new targeted drugs creates the need of a different 
evaluation of tumours and their response to treatment. Functional 
imaging techniques that are able to study in vivo physiological 
processes of tissues and tumours have lately acquired more impor-
tance. The dynamic techniques may be more appropriate for as-
sessing response to antiangiogenic drug, such as B, whose mecha-
nism of action appears to focus on the normalization of the tumor 
vasculature. Preliminary studies have demonstrated significant and 
very early changes in flow, blood volume and tumor perfusion with 
therapy. These techniques could be useful to select patients those 
that are going to respond to drugs with an early evaluation of res-
ponse by means of functional imaging
Methods: IMPACT is an open-label, single arm phase II study to 
evaluate the predictive value and early radiologic response or 
perfusion CT in pts diagnosed with unresectable advanced, meta-
static or recurrent nsNSCLC treated with C, G and B. Pts receive B 
(7.5 mg/kg IV on d1), C (80 mg/m2 on d1) and G (1250 mg/m2 on 
d1 and 8) up to 6 cycles of 21 d. Pts with no evidence of progres-
sion of disease continue to receive single-agent B 7.5 mg/Kg on 
d1 every 21 d until progression or unacceptable toxicity. Primary 
endpoint is to assess basal results and early tumour response (at 
day +7) in terms of blood flow (BF), blood volume (BV), time to 
enhancement peak (TTEP) and permeability (P) as compared to 
Objective Response Rate (ORR) in terms of RECIST at d42. Secon-
dary objectives include to assess tumour response (at d42) in terms 
of BF, BV, TTEP and P as compared to ORR at d42, to assess basal 
results in terms BF, BV, TTEP and P as compared to PFS and OS, to 
assess tumour response (at d7 and d42) in terms of BF, BV, TTEP 
and P to PFS and OS, to describe the safety profile using NCI-CTC 
AE and efficacy in the subgroup of adenocarcinoma. Planned sam-
ple size is 20 pts.
Results: not applicable
Conclusion: not applicable
Keywords: non-squamous non-small cell lung cancer, Bevaci-
zumab, perfusion CT, early radiologic response
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all response (CR, PR, SD, PD) at all time points. Precisely, 6 and 8 
evaluations were discordant at time point 1 and 2, respectively. . 
Half of discordances (7/14) were explained by a difference in the 
selection of target lesions. There were 3 /14 discordances due to 
a difference in lesion segmentation. The different segmentations 
occurred when the lesions were adjacent to mediastinum or pleu-
ra, where limits of lesions are not very contrasted.
Conclusion: The study shows the feasibility of imaging evaluation 
based on cloud services for clinical studies involving multiple inter-
national sites. Centralization of data made possible the on-going 
monitoring of evaluations through specialized services reducing 
variability among sites. Analysis of discordances between readers 
identified areas of improvement for cloud-based services such as 
a consensus process for target selection at baseline and the de-
velopment of segmentation tools to standardize management of 
measurable lesions.
Keywords: imaging evaluation, cloud-based software solution, 
RECIST
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P1.19-005 COMPUTER-AIDED LUNG NODULE ANALYSIS 
FOCUSED ON GROUND GLASS OPACITY AND  
CONSOLIDATION ON THIN-SECTION COMPUTED  
TOMOGRAPHY.
Eiji Yamada1, Keiju Aokage1, Hironobu Ohmatsu2, Tomohiro Miyo-
shi1, Yuki Matsumura1, Tomoyuki Hishida1, Junji Yoshida1, Kanji 
Nagai1
1Division Of Thoracic Surgery, National Cancer Center Hospital East/
Japan, 2Division Of Thoracic Oncology, National Cancer Center Hospital 
East/Japan
Background: Ground-glass opacity (GGO) component in a nodule 
on thin-section computed tomography (TSCT) often corresponds 
to a lepidic growth pattern of adenocarcinoma. In contrast, solid 
attenuation or consolidation on TSCT corresponds to invasive 
components. Many researchers reported consolidation tumor ratio 
(CTR; defined as the ratio of the size of solid attenuation to the 
maximum tumor dimension) was a reliable parameter in predicting 
tumor invasiveness. However, it has been pointed out that inter-/
intra-observer variability in CTR measurement is a major problem 
in precise and reproducible evaluation of tumor characteristics. 
The aim of this study was to determine the optimal CT settings to 
reproducibly diagnose GGO and consolidation areas on TSCT by 
using an imaging software.
Methods: We reviewed preoperative TSCT images of the patients 
undergoing surgical resection for T1 lung adenocarcinoma in our 
institution between 2005 and 2009. The TSCT images were ob-
tained without contrast enhancement and reconstructed in 1.0 or 
2 mm thickness, using several CT systems. The imaging software 
colored GGO areas with cut-off CT levels of -800, -700 and -600 
HU. Consolidation areas were colored with cut-off CT levels of 
-300, -200 and -100 HU. These GGO/consolidations identified by 
the software were compared with those visually determined by the 
consensus of the 4 authors (EY, KA, YM, HO). The 4 authors scored 
the correspondence between visual evaluation and software iden-
tification according to the cut-off levels. The scores were summa-
rized to determine the optimal cut-off CT levels.
is used for nodal and distant staging to assist in the selection of 
patients for radical treatment. British Thoracic Society guidelines 
for the radical management of patients with lung cancer recom-
mend “radical treatment without further mediastinal lymph node 
sampling if there is no significant uptake in normal sized medias-
tinal lymph nodes on PET-CT scanning”. In carcinoid tumours, our 
results of the largest cohort to date suggest that PET-CT has a 
poor sensitivity but good specificity for the presence of mediasti-
nal lymph node metastases in the staging of pulmonary carcinoid 
tumours. Therefore lymph node metastases cannot accurately be 
ruled out in carcinoid tumours with a negative PET-CT. If treatment 
decisions are based on the N2 status, invasive mediastinal staging 
should be undertaken in carcinoid tumours.
Keywords: PET-CT, Pulmonary Carcinoid, staging
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P1.19-004 EVALUATION OF A CLOUD-BASED SOLUTION 
FOR LOCAL IMAGING EVALUATIONS IN CLINICAL  
TRIALS FOR LUNG CANCER
Naoko Aragane1, Naomi Kobayashi1, Eric Bonnard2, Colette Char-
bonnier3, Junta Yamamichi4, Hideaki Mizobe4, Shinya Kimura1
1Division Of Hematology, Respiratory Medicine And Oncology, Depart-
ment Of Internal Medicine, Saga University/Japan, 2Radiology Depart-
ment, Nice University Hospital/France, 3Median Technologies/France, 
4Global Healthcare It Project, Canon Inc/Japan
Background: Clinical trials for determination of anti-cancer effects 
of chemotherapeutic agents are key for developing new strategies 
for cancer treatment. In most trials, primary endpoints are pro-
vided by imaging evaluations. Regulatory authorities have been 
recommending an Independent Central Review (ICR) with several 
readers to mitigate potential biases resulting from variance bet-
ween investigator sites in clinical trials. Based on recent publica-
tions promoting site -based evaluation as imaging endpoint, they 
currently investigate an alternative to ICR. The goal of this study is 
to evaluate a cloud-based paradigm implementing software solu-
tions and services that standardize the imaging evaluations among 
international investigator sites.
Methods: Ten lung cancer patients, who received epidermal 
growth factor receptor-tyrosine kinase inhibitor and for which 
chest CT scans were available at three time points from baseline 
to progression, were retrospectively selected. CT scans were 
evaluated according to the RECIST 1.1 criteria by two oncologists 
(Saga University) and one radiologist (Nice University Hospital) 
independently, through a cloud-based software solution named 
LMS (Lesion Management Solutions, MEDIAN Technologies), which 
offers reviewing tools and lesion segmentation algorithms. Such 
system was hosted on the data center (Canon IT Solutions, Japan) 
and used by readers and data managers (Canon and MEDIAN 
Technologies) for de-identification, quality control and centrali-
zation of the images and their evaluations. The study compared 
response evaluations between readers and analyzed the reasons 
for discordances.
Results: Readers with different medical training and education, 
working at distant locations were able to reliably perform radio-
logical evaluations using the same cloud-based system. Between 
the oncologists and the radiologist, a discordance rate of 35 % 
(14/40 evaluations) was observed when considering RECIST over-
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Results: 975 nodules in 618 participants were included. 
31 nodules (3%) were diagnosed as lung cancers. 10(33%) 
of the malignant nodules were nonsolid/partsolid. Fig. 1 
shows histograms of growth measurements. Fig. 2 show 
the logistic regression analysis. In both cases FEV1 and 
Mass Doubling Times predicted malignancy significantly.
Conclusion: Growth rates measured by volumetric software and 
FEV1 are powerful predictors for malignancy when a pulmonary 
nodule is present in a low dose chest CT scan.
Keywords: screening, imaging, Lung cancer
Results: We have reviewed 20 patients so far. Figure 1 shows 
a TSCT image and software-yielded image showing good 
correspondence with each other of GGO and consolidati-
on areas. The best score was obtained when the cut-off level 
was -700 HU for GGO and -200 HU for consolidation. Figure1. 
Conclusion: Although based on a small cohort, we found optimal 
cut-off CT levels to identify GGO and consolidation areas using an 
imaging software. We need to analyze more cases, but this image 
analysis method is promising in determining CTR reproducibly.
Keywords: ground-glass opacity, consolidation, image, thin-sec-
tion computed tomography
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P1.19-006 PREDICTORS OF NODULE MALIGNANCY IN 
THE DANISH LUNG CANCER SCREENING TRIAL (DLCST)
Zaigham Saghir1, Asger Dirksen2, Jesper H. Pedersen1
1Department Of Thoracic Surgery Rt, Rigshospitalet, University Of 
Copenhagen/Denmark, 2Department Of Respiratory Medicine, Gentofte 
University Hospital/Denmark
Background: Pulmonary nodules are detected more frequently 
than ever in both clinical and screening settings. Timely and cor-
rect suspicion of malignancy is of great importance in the subse-
quent management of the nodules. We present data on pulmonary 
nodule growth and participants baseline characteristics to deter-
mine predictors of malignancy.
Methods: In DLCST, 4,104 current and former smokers, with a his-
tory of at least 20 pack years and age between 50-70 years, were 
randomized to either five annual multi-slice low-dose CT scree-
nings or no screening. All participants had an annual visit to the 
screening clinic where lung function tests and questionnaires con-
cerning health, lifestyle, smoking habits etc. were performed. The 
scans were read by two chest radiologists who recorded the loca-
tion and size of any nodules. Nodules of diameters between 5-15 
mm were considered indeterminate, and rescanned after three 
months. Participants with nodules larger than 15 mm were referred 
to diagnostic workup, as were those with growing nodules. Lung 
cancer was diagnosed by pathological evaluation. Using volumetric 
software solid and nonsolid/partsolid nodules were segmented 
and followed. Only visually correct segmented nodules that were 
present more than one year were included. Doubling times of 
mass, volume and diameter from the first to the last record of the 
nodule were calculated. We performed logistic regression analysis 
with malignancy as the outcome and baseline characteristics, no-
dule type and growth measurements as explanatory variables.
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Keywords: VATS, Forced expiratory volume in 1 second, Pleural 
adhesion, Prediction
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P1.19-008 CLINICORADIOLOGICAL EVALUATION OF 
SURGICALLY RESECTED PULMONARY PLEOMORPHIC 
CARCINOMA
Akifumi Nishida1, Hajime Abiru2, Hideyuki Hayashi3, Masataka 
Uetani3, Tetsuya Iida1, Tomayoshi Hayashi4, Keitaro Matsumoto5, 
Tomoshi Tsuchiya5, Naoya Yamasaki5, Takeshi Nagayasu5, Kazuto 
Ashizawa1
1Clinical Oncology, Unit Of Translational Medicine, Nagasaki Univer-
sity Graduate School Of Biomedical Science/Japan, 2Radiology, Saga 
National Hospital/Japan, 3Radiological Sciences, Nagasaki University 
Graduate School Of Biomedical Science/Japan, 4Pathology, Nagasaki 
University Graduate School Of Biomedical Science/Japan, 5Division Of 
Surgical Oncology, Department Of Translational Medical Science, Naga-
saki University Graduate School Of Biomedical Science/Japan
Background: Pulmonary pleomorphic carcinoma is rare and ag-
gressive subtype of non-small cell lung cancer, with a dual-cell 
component of spindle and/or giant cells, and of epithelial cells. 
The objective of this retrospective study was to assess the clinico-
radiological characteristics and surgical outcome of this tumor.
Methods: Data were retrospectively examined for 25 patients who 
had undergone surgical resection for pulmonary pleomorphic car-
cinoma. Epithelial components of the pleomorphic carcinoma were 
as follows: 13 adenocarcinoma (52%), 3 squamous cell carcinoma 
(12%) and 2 large cell carcinoma (8%). 7 tumors (28%) were compo-
sed only of spindle and giant cells.
Results: 21 patients (84%) were male. 19 patients (76%) were smo-
kers. Of the 14 symptomatic patients (56%), 7 had cough, 5 had 
hemoptysis, 1 had back pain and 1 had fatigue. The size of the 
tumor ranged from 1.9 to 10.1cm (mean 5.2cm). The tumors were 
located peripherally in 21 patients (84%). Calcification within the 
tumor was visible in only one patient. The margin of the tumors 
was well defined in 24 patients (96%). Notch, spiculation and pleu-
ral indentation of the tumors were observed in 14, 8 and 6 patients 
respectively. The tumors were inhomogeneously enhanced in 20 
patients (80%) on contrast-enhanced CT. Low attenuation areas 
on contrast-enhanced CT were found to correspond to areas of 
necrosis in pathologic specimens. Surrounding area of ground-
glass attenuation was seen in 14 patients (56%). Among them, 
hemorrhagic foci were observed in the pathologic specimens in 5 
patients. Invasion of chest wall, diaphragm, other lobes of the lung 
and SVC was noted in 7, 2, 2, 1 patients, respectively. In addition, 6 
patients had pleural invasion. The median length of the follow-up 
examinations was 46 months (range, 2.3–153.5 months). The 5-year 
overall survival rate was 30%. Patients with tumors invading the 
parietal pleura, chest wall, diaphragm, and other lobes of the lung 
had significantly worse overall survival (P=0.027). The subtype of 
epithelial components did not affect prognosis. 
POSTER SESSION 1 - IMAGING  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.19-007 PREDICTION OF PLEURAL ADHESION DU-
RING VIDEO-ASSISTED THORACOPIC SURGERY IN 
LUNG CANCER PATIENTS
Kwang Nam Jin1, Hyeon-Jong Moon2, Yong Won Sung2, Hyobin Seo3
1Radiology, Smg-snu Boramae Medical Center/Korea, 2Thoracic Surgery, 
Smg-snu Boramae Medical Center/Korea, 3Radiology, Seoul National 
University Hospital Healthcare System Cangnam Center/Korea
Background: Pleural adhesions increase the risk of lung injury and 
lead consequent prolonged air-leak or conversion to open thora-
cotomy. We aimed to find the clinical or image predictor for pleural 
adhesion during video-assisted thoracoscopic surgery (VATS) in 
lung cancer patients.
Methods: Eighty-nine consecutive patients who underwent VATS 
for lung cancer were included. We retrospectively investigated 
operative records and clinical information including age, gender, 
smoking history, body mass index (BMI), forced expiratory volume 
in 1 second (FEV1), and forced vital capacity (FVC). Pleural ad-
hesion was categorized into 5 grades; none, minimal, moderate 
(requiring adhesiolysis during VATS with 30 minute or less), severe 
(requiring adhesiolysis with 30 minute or longer), and very severe 
(near total involvement of the hemithorax). Advanced adhesion 
was defined as the presence of moderate or severe or very severe 
adhesion. Two radiologists blinded to clinical information perfor-
med visual analysis for image characteristics of chest CT in consen-
sus. The presence of parenchymal band or calcified granuloma or 
pleural retraction around the tumor was determined. Severity of 
emphysema or interstitial fibrosis was assessed as 5 grades (none, 
trivial, mild, moderate, and severe). The extent of bronchiectasis or 
pleural thickening or pleural calcification or extrapleural fat thicke-
ning was evaluated as 3 grades (none, localized, and extensive).
Results: Pleural adhesion was found in 51 subjects (57.3 %) inclu-
ding 15 (16.9 %) minimal, 18 (20.2 %) moderate, 16 (18.0 %) severe, 
2 (2.2 %) very severe adhesion. Male gender and current smoker 
was 66 subject (74.2 %) and 60 (67.4 %), respectively. Mean age 
was 64.6 ± 10.4 years-old. Mean value of FEV1 and FVC was 2.4 
± 0.6 ml (range; 0.7-3.9) and 3.4 ± 0.8 ml (range; 1.3-5.0), respec-
tively. Tumor size was 3.1 ± 1.5 cm. Parenchymal band, calcified 
granuloma, pleural retraction was found in 41.6 %, 27 %, and 44.9 
%, respectively. Most subjects had no (49.4 %) or minimal (23.6 %) 
emphysema. Mild, moderate, and severe emphysema was found in 
18.0 %, 7.9 %, and 1.1 %, respectively. Most patients have no bron-
chiectasis (86.5 %) and no interstitial fibrosis (89.9 %). Localized and 
extensive bronchiectasis was found in 12.4 % and 1.1 %, respec-
tively. Trivial and moderate interstitial fibrosis was found in 6.7 % 
and 3.4 %. Localized and extensive pleural thickening was found 
in 10.1 % and 1.1 %, respectively. Localized and extensive pleural 
calcification was found in 4.5 % and 1.1 %, respectively. Both lo-
calized and extensive extrapleural fat thickening was found in 5.6 
%. In univariate analysis, male gender (P = 0.013), age (P = 0.21), 
FEV1 (P < 0.001), tumor size (P = 0.003) were significant predictors 
of advanced adhesion. Among the image characteristics, severity 
of emphysema was a significant predictor of advanced adhesion in 
univarite analysis (coeffient of 1.83, P = 0.007). Multivariate analysis 
revealed that independent predictor for advanced pleural adhesi-
on was only FEV1 (coefficient of 0.13, P < 0.001).
Conclusion: Severity of emphysema and FEV1 might enhance the 
prediction of pleural adhesion during VATS in lung cancer patients.
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Results: Median frequency of positive cells by immunohistoche-
mistry for MIB-1 was 9% (range, 1-42%) and the high proliferation 
group comprised 10 cases (35.7%). This group correlated signi-
ficantly with high-density GGO, defined as showing a difference 
>400 Hounsfield units between the GGO field and adjacent lung 
field (P=0.038), and tended to correlate with tumor diameter >20 
mm (P=0.095).
Conclusion: Density of GGO lesions correlates with proliferation of 
tumor cells. This clinical feature appears likely to allow differentiati-
on of high-risk patients with GGO lesions.
Keywords: ground-glass opacity, bronchioloalveolar carcinoma, 
non-small cell lung cancer, MIB-1
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P1.19-010 PROGNOSTIC VALUE OF FDG-PET-BASED ME-
TABOLIC TUMOR VOLUME IN CONJUNCTION WITH MA-
THEMATICAL CLASSIFIERS IN NON-SMALL CELL LUNG 
CANCERPATIENTS
Yulei Jiang, Jianing Wang, Bill O‘Brien-Penney, Yonglin Pu
Department Of Radiology, The University Of Chicago/United States Of 
America
Background: The TNM staging system for prognostication in non-
small cell lung cancer (NSCLC) is less than satisfactorily accurate. 
Previous research suggests that FDG-PET-based metabolic tumor 
volume (MTV) may be an independent prognostic marker in NS-
CLC when used in Cox-regression models. This study was to deter-
mine the potential prognostic utility of FDG-PET-based MTV used 
in mathematical classifiers for prognostication of NSCLC.
Methods: A consecutive cohort of 328 NSCLC patients (156 ma-
les, 172 females) with histologic confirmation and FDG-PET scans 
was identified for retrospective analysis. MTV measurements were 
made on baseline 18F-FDG PET/CT scans of the primary tumor 
(MTVT), metastatic lymph nodes (MTVN), and metastatic tumors 
(MTVM). Whole-body MTV (MTVWB) was defined as the sum of 
MTVs of primary tumor, metastatic lymph nodes, and metastatic 
tumors (MTVWB = MTVT + MTVN + MTVM). A semi-automated 3D 
contouring program was used for obtaining the MTVs. Patient sur-
vival was determined from cancer registry data, and known survival 
length of living and lost-to-follow-up (i.e., censored) patients was 
recorded. Patient survival was determined at one year (189 survi-
ved, 129 did not) and two years (127 survived, 186 did not) after 
baseline FDG-PET scan, and survival status was known for most 
censored patients except for ten at one year and 15 at two years. 
Linear discriminant analysis classifiers were constructed on data of 
patient age, gender, histology, TNM stage, and MTVs. Cross-vali-
dation was done as follows: to predict a patient‘s survival status, a 
classifier was trained on data of all other patients of known survival 
status and not on the patient in question. Areas under receiver 
operating characteristic (ROC) curve (AUC), analogous to C con-
cordance statistics, were compared statistically.
Results: The median patient age was 68.3 years and patient dis-
tribution by stage was 46 stage IA, 43 stage IB, 19 stage IIA, 18 
stage IIB, 52 stage IIIA, 39 stage IIIB, and 111 stage IV. Median 
follow-up of living and lost-to-follow-up patients was 58 months 
and death confirmation was known in 249 (88.4%) patients. For 
one-year survival, the AUC (± standard error) value of the classifier 
Conclusion: The CT features of pulmonary pleomorphic carcinoma 
were well-defined and lobulated tumor located peripherally with 
inhomogeneous enhancement. Peritumoral areas of ground-glass 
attenuation are associated with tumoral hemorrhage in some ca-
ses. Pleomorphic carcinoma carried a poor prognosis, even when 
completely resected. The lung cancer comprised of at least 10 % 
of spindle and/or giant cells is suggested to have an aggressive 
malignant behavior.
Keywords: pleomorphic carcinoma, CT, surgery, Lung cancer
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P1.19-009 DIFFERENCES IN PROLIFERATION OF TUMOR 
CELLS IN GROUND-GLASS OPACITY LESIONS ON COM-
PUTED TOMOGRAPHY FOR PRIMARY NON-SMALL CELL 
LUNG CANCER
Go Nishii, Kenji Takahashi, Yuji Hirami
General Thoracic Surgery, National Hospital Organization Fukuyama 
Medical Center/Japan
Background: Ground-glass opacities (GGOs) on computed to-
mography (CT) represent a distinctive finding for nodules of bron-
chioloalveolar carcinoma that are generally stable or growing very 
slowly due to a low degree of malignancy. Therefore, small GGOs 
are often followed conservatively. However, some GGO nodules 
undergo clear enlargement during follow-up. The present study 
aimed to define the clinical features of GGO with potentially high 
degree of malignancy.
Methods: Among patients who underwent surgery for non-small 
cell carcinoma between June 2010 and April 2013 in our hospital, 
all 28 patients with GGO or mixed GGO nodules who had been 
prospectively evaluated with high-resolution computed tomogra-
phy (CT) were enrolled in this study. Immunohistochemical studies 
using MIB-1 antibody to evaluate cell proliferation were performed 
using specimens obtained from GGO parts of 6 pure GGO and 22 
mixed GGO nodules. A high-proliferation group was defined as ca-
ses showing >10% positive cells. The following clinical parameters 
were assessed: sex; age; smoking history; tumor size; tumor shape; 
tumor contour; ratio of consolidation area to whole area of tumor; 
and density of GGO. Correlations between high-proliferation 
status and clinical parameters were analyzed using Fisher’s exact 
probability test.
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Adenocarcinoma was the most common histological type, follo-
wed by squamous cell carcinoma and metastasis respectively. The 
mean radiologic tumor sizes on chest radiograph, CT using medi-
astinal and lung window settings were 4.8 cm, 4.8 cm and 5.1 cm in 
maximal diameters, respectively. The mean pathologic tumor size 
was 4.7 cm in maximal diameter. The mean errors of chest radio-
graphic measurement, CT measurement using mediastinal and 
lung window settings were 0.25 cm, 0.04 cm and 0.41 cm, respec-
tively. The error of tumor size measured by using CT in mediastinal 
window setting was statistically significant less than that of using 
lung window setting (p<0.001). There was a statistically significant 
difference between tumor size measured by using CT in mediasti-
nal window setting and pathologic tumor size (p<0.001). Predicted 
tumor size was calculated by using the equation “calculated tumor 
size (cm) = 1+(0.78xtumor size on CT in mediastinal window (cm)).
Conclusion: Although there is a statistically significant difference 
between CT measurement and pathologic tumor size, the tumor 
size measured by using CT in mediastinal window setting is seemly 
more accurate than in lung window setting or chest radiograph.
Keywords: Chest radiograph, Pathologic size, Tumor size, Compu-
ted tomography (CT) chest
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P1.19-012 THE QUALITY OF CONSOLIDATION IN PART 
SOLID NODULE COULD BE A PREDICTOR OF SURVIVAL
Tomohiro Ichikawa, Kenji Suzuki, Takeshi Matsunaga, Yukio Tsu-
shima, Shiaki Oh, Kazuya Takamochi
Thoracic Surgery, Juntendo University/Japan
Background: The size of consolidation on thin-section computed 
tomography (CT) has been one of the most important preoperati-
ve prognostic factors in resected lung cancer. On the other hand, 
few reports mentioned the nature of consolidation as prognostic 
factor.
Methods: A retrospective study was conducted on 617 lung can-
cers of clinical stage IA which were resected between 2009 and 
2012. Thin-section CT scans were available for all cohorts, which 
were reviewed by authors. Moreover authors divided lung cancers 
into three categories: ground glass opacity (GGO), part solid and 
pure solid. 235 cases are part solid nodule. We classified these 235 
part solid lung cancers into two groups: homogeneous or hete-
rogenous. The relationship between these consolidation statuses 
were evaluated using the chi-square test and Fisher’s exact test. 
The medical record of each patient was examined for investigating 
following clinicopathological factors: age, gender, smoking status 
(pack-year smoking), preoperative serum carcinoembryonic an-
tigen (CEA), SUV max of the primary tumor on positron emission 
tomography (PET), pathological pleural, vascular, and lymphatic 
invasion. P-value <0.05 was considered statically significant.
Results: Ninety pts (38.3%) had homogeneous consolidation. The-
re were 32 (35.6%) , and 56 (38.6%) men, 6 (14.6%), and tumor ha-
ving 3 or more SUV max on PET was found in 6 (14.6%), 5 (10.4%), 
respectively. Based on univariate analysis, age, gender, and pack-
year smoking were not statistically significant differences. In homo-
geneous consolidation group, 2 patients have nodal metastasis, 
however nodal metastasis were not observed in scattered conso-
lidation group. (P=0.023) Vascular invasive was frequently found in 
based on age, gender, histology, and stage was 0.77±0.026 and 
that of the classifier based on age, gender, histology, stage, and 
MTVs was 0.82±0.023 (p < 0.01). For two-year survival, the corres-
ponding AUC values were 0.75±0.028 and 0.79±0.026, respectively 
(p < 0.02). The AUC values were similar for classifiers based on age, 
gender, histology and MTVs and for classifiers based on age, gen-
der, histology, and stage (p > 0.5). These results were consistent 
with previous results of statistically significantly better prognostic 
ability of multivariate Cox-regression models of MTVWB compared 
with models not including MTVWB, after adjusting for age, gender, 
histology, treatment options, and whole-body tumor SUVmax.
Conclusion: FDG-PET-based metabolic tumor volume can poten-
tially increase prognostic accuracy for NSCLC patients beyond that 
of the TNM staging system at one and two years, and mathema-
tical linear classifiers can potentially be used as an alternative to 
Cox-regression models for estimating survival probability.
Keywords: Prognosis, non-small cell lung cancer, tumor burden, 
18F-FDG-PET
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P1.19-011 CORRELATION BETWEEN THE TUMOR SIZE 
MEASURED BY USING CHEST RADIOGRAPH AND CT 
CHEST COMPARISON TO THE PATHOLOGIC SIZE
Thatchai Hantrakul1, Juntima -. Euathrongchit1, Yutthaphan Wan-
nasopha1, Nirush Lertprasertsuke2, Somcharoen Saeteng3, Apichat 
Tantraworasin3
1Radiology, Chiangmai University/Thailand, 2Pathology, Chiang Mai 
University/Thailand, 3Surgery, Chiang Mai University Hospital/Thai-
land
Background: The size of the tumor is an important prognostic 
factor in cancer patient. It is ultimately based on the pathologic 
measurement of gross specimen from surgical resection. However, 
the preoperative tumor size could be determined by direct measu-
rement of palpable superficial lesion or radiologic imaging such as 
chest radiograph or computed tomography (CT) in both lung win-
dow setting and mediastinal window setting. To our knowledge, 
there is no definite method to measure tumor’s size on radiogra-
phic imaging, moreover, the correlation between pulmonary tumor 
size measured by using radiographic imaging and pathologic 
size has not been studied in Thailand yet. The Northern Thailand 
Thoracic Group (NT-TOG) would like to determine the correlation 
between tumor size measured by using chest radiograph and CT 
chest comparison to the pathological tumor size.
Methods: After institutional review board approval, the retrospec-
tively analytic cross sectional study from pathological records of all 
patients who underwent surgery in Chiang Mai University Hospital 
were reviewed. All cases that achieved CT imaging in the depart-
ment of radiology were included. Finally 60 pulmonary tumors 
were collected to measure their sizes on chest radiograph and 98 
pulmonary tumors were gather to measure their sizes on mediasti-
nal and lung window sets and compared to the pathological sizes. 
The location of the tumor and histological cell type were recorded. 
Data analysis was performed using STATA software to find out the 
correlation between sizes that had been measured on chest radio-
graph and on CT images comparison to the tissue pathologic size.
Results: The tumor locations were common in the RUL and LUL. 
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P1.19-014 STAGE SURVIVAL FOR LUNG CANCER STAGED 
BY PET/CT, EUS FNA AND/OR EBUS TBNA
Mark Krasnik, Anders Mellemgaard
Thoracic And Cardiovasc. Surgery, Rigshospitalet/Denmark
Background: The seventh edition of the TNM classification of lung 
cancer was based on the 67.725 patients from 19 countries treated 
by all modalities between 1990 and 2000. There was no informa-
tion about how the c TNM and pTNM was determined and there 
were probably differences in the preoperative staging methods. 
At Gentofte University Hospital diagnostic work-up and staging 
procedures included PET / CT, EUS FNA and EBUS TBNA early on 
after the introduction of these technologies. The purpose of the 
project was to evaluate the survival after lung cancer surgery in 
patients who were diagnosed and staged by PET / CT, EUS FNA 
and / or EBUS TBNA and to compare survival with the results from 
the IASLC‘s staging project.
Methods: All patients in the period 1.1.2005 to 12.1.2012 who had 
had PET / CT, EUS FNA and / or EBUS TBNA leading to a diagno-
sis of non small cell lung cancer before surgery were included in 
the project The date of surgery and the date of death if any were 
recorded. Survival was measured from the date of surgery and was 
calculated by the Kaplan-Meier method. cTNM and the methods 
by which the diagnosis and stage was determined was included in 
the analysis.
Results: In this period, 4090 lung cancer patients were diagnosed 
and staged at Gentofte University Hospital.1187 were staged by 
PET CT, EUS FNA and/or EBUS TBNA and of these 791 were ope-
rated. Over all, survival based on cTNM for patients staged at Gen-
tofte University Hospital was on the same level level as found in 
the the IASLC‘s analysis for pTNM. In particular, the survival curves 
for cTNM stage IA, IB and IIIA found in this material appears to be 
identical with those found in the Stage survicalIASLC‘s project for 
the same pTNM stages. For example, the 3-year survival for the cIA 
in our study was 84% where the IASLC‘s pIA was 83% and cIIIA in 
our study was 32% while the IASLC‘s pIIIA was 37% The cTNM IIIB 
in our material shows a better survival than IASLC pTNM IIIB (33% 
vs 14%) There were too few patients in stages IIA and IIB for any 
meaningful conclusion.
Conclusion: As the treatment regime is based on the cTNM, it 
is important that it is as accurate as possible. Thus, concordance 
between cTNM and pTNM should ideally be very high. Using new 
technologies, the concordance at our institution has increased 
to the current level of 95%. It is therefore not surprising that the 
survival of the various cTNM stages in our study are similar to the 
survival curves from IASLCs staging project.
Keywords: Lung cancer, staging with PET/CT EUS FNA EBUS 
TBNA, survival
homogeneous consolidation group. (P=0.04)
Conclusion: This result of our study shows that the quality of con-
solidation in part solid lung cancer could be the prognostic factor.
Keywords: part solid nodule, Thin-section-CT
POSTER SESSION 1 - IMAGING  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.19-013 FDG-PET/CT DIFFER BRONCHIAL NETS FROM 
HAMARTOMAS
Oscar Grundberg
Department Of Pulmonary And Respiratory Medicine, Karolinska Uni-
versity Hospital/Sweden
Background: Bronchial NET:s account for approximately 1% of all 
lung cancers and usually require surgical removal. Hamartoma is a 
benign tumor not necessary to treat. The two conditions may have 
a very similar radiological appearance when studied by chest x-ray 
or CT, especially when the bronchial NET has a peripheral location. 
The objective was to assess if integrated FDG PET-CT examination 
could contribute to the decision-making process.
Methods: The material consists of 119 consecutively operated pa-
tients at our Centre during the Period of October 2005 to February 
2012, where the Diagnosis (pathologically confirmed) either was 
Hamartoma or bronchial NET. Retrospective analysis of the Patient 
Charts and Radiology were performed. Out of these 119 cases, 
58 hamartomas and 38 bronchial NET:s had been subject to FDG-
PET-CT. All examinations were reviewed by one single radiologist/
nuclear medicine physician. SUV-values were measured as well as 
morphological characteristics were assessed.
Results: Of the 38 Bronchial NET:s, 23 were peripheral and 8 
central according to radiological appearance. Mean SUVmax of 
the Bronchial NET:s was 3.5 ( range 0–7.5). 6 Bronchial NET:s did 
not show any FDG-uptake. Mean SUVmax of the hamartomas was 
0.77 (range 0.0–3.7). 31 of the hamartomas (61%) showed no FDG-
uptake.
Conclusion: Although peripheral Bronchial NET:s may be indistin-
guishable to hamartoma at CT, the two conditions differ in FDG-
PET appearance. Thus, it may be possible to avoid unnecessary 
thoracotomy when a peripheral solid lesion shows absence of 
FDG-uptake.
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P1.20-001 EARLY LUNG CANCER DETECTION PRO-
GRAMME - ITS IMPACT ON ACTIVITY OF THE LOCAL 
THORACIC SURGERY DEPARTMENT
Tomasz Grodzki, Jacek Alchimowicz, Janusz Wójcik, Bartosz Kubi-
sa, Jarosław Pieróg, Anna Kozak, Norbert Wójcik
Thoracic Surgery, Pomeranian Medical University/Poland
Background: The impact of massive early lung cancer detection 
program on patients` profile and surgical activity of the local thora-
cic surgery department is analyzed.
Methods: Early lung cancer detection program was conducted in 
a single city of 400000 inhabitants from 2008 till 2011. Enrollment 
criteria included both sexes aged 55-65 years with history of 20 
pack-years of tobacco smoking. All detected lesions were followed 
up in accordance with IELCAP protocols. All cases requiring sur-
gery were referred to a single local thoracic surgery department 
serving for the population of appr. 2 million people. Following data 
were analyzed: number of NSCLC detected and resected, number 
of stage I resected patients, histology, type of surgery.
Results: 15020 patients were screened (39.5% of the population 
of people aged 55-65 in our city). 6240 pulmonary lesions were 
detected, majority (59%) smaller than 5mm. 445 lesions (7.1%) were 
bigger than 15mm. 182 patients (2.9% of all detected lesions) were 
referred to the local thoracic surgery. Overall 925 NSCLC were 
resected at our department in 2008-2011. 232 (25%) of them were 
stage I. Number of pneumonectomies was 166 (18%). Dominant 
histology was squamous cell (52%) 247 metastatic lesions were 
resected in the same period. The early detection group delivered 
77 NSCLC resections (8.3% of all resections). 53/77 (69%) were 
stage I (significant difference versus the entire group). Number of 
pneumonectomies was 2/77 (2.5%, significant difference vs entire 
group). Dominant histology was adenoca (50%). 33 metastatic 
lesions (13.3% of all metastases resections) were treated surgically. 
15 small cell lung cancer were diagnosed and referred for chemo-
therapy. 33 metastatic lesions were resected, too.
Conclusion: The patients with NSCLC detected by the early lung 
cancer detection programme are treated surgically in earlier sta-
ges in comparison to the entire population of patients referred to 
our department. They require pneumonectomy significantly less 
frequently than the entire group.
Keyword: early lung cancer detection, surgical resection
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P1.19-015 CLINICAL APPLICATION OF THIN SECTION 
CHEST CT WITH COMPUTER-AIDED DETECTION SYS-
TEM FOR THE DETECTION OF SMALL METASTATIC NO-
DULES IN PULMONARY METASTASECTOMY.
Hye-Seon Kim1, Chang Hyun Kang1, Jin Mo Goo2, In Kyu Park1, 
Young Tae Kim1
1Department Of Thoracic And Cardiovascular Surgery, Seoul National 
University Hospital/Korea, 2Department Of Radiology, Seoul National 
University Hospital/Korea
Background: It is important to identify possible metastatic nodule 
prior to metastasectomy, in order to perform complete resection. 
Thin section chest CT (TSCT) can detect small metastatic nodules 
more accurately than conventional chest CT. Conventional CT is 
known to miss metastatic nodules that are manually palpable by 
up to 40%. Reported sensitivity of helical CT cannot exceed 90%, 
also. We adopted TSCT and applied computer-aided detection 
(CAD) system for the search of small metastatic nodules to improve 
the detection power of TSCT.
Methods: From March 2009 to February 2013, 333 patients were 
referred to thoracic surgeon for pulmonary metastasectomy. TSCT 
with CAD was performed in every candidate for pulmonary meta-
stasectomy. Every nodule detected by TSCT and CAD was anno-
tated by radiologists and the whole map and annotation numbers 
of nodules were reported before operation. Intraoperatively, bi-
manual palpation in open metastasectomy and finger palpation in 
video assisted thoracoscopic surgery (VATS) were used to detect 
the nodules. Only operations with complete available data were 
included in the study and 251 operations from 239 patients were 
analyzed.
Results: A total of 1021 nodules were identified by TSCT with 
CAD, while 115 nodules (11.3%) were additionally detected by 
CAD. Among the annotated nodules, 742 nodules were palpable 
during operation. Including intraoperatively detected 49 nodules, 
a total of 824 nodules were resected. Of 527 pathologically proven 
malignant nodules, 518 (62.9%) nodules were metastatic lesions. 
Among metastatic lesions, 496 were detected by TSCT (95.8%), 
9 by CAD (1.7%) and 13 by manual palpation (2.5%). Also, 11 me-
tastatic nodules were no palpated during operation but resected 
according to the annotation on CT. The overall sensitivity of thin 
section chest CT with CAD was 97.5%. Though overall specificity of 
TSCT with CAD was very low as 12.1% because that of radiologist’s 
reading was 14.2%, specificity only for CAD was 45.6%.
Conclusion: TSCT could detect small subcentimetre nodules and 
CAD enabled detecting additional small nodules. With help of 
TSCT with CAD, even the metastatic nodules, which were not pal-
pable during operation, could successfully be resected. Further-
more, TSCT with CAD could detect tiny nodules with rather high 
specificity compare to radiologist’s reading only. Although the 
number of true metastatic nodules was small and several metasta-
tic nodules were undetected, the TSCT with CAD system increased 
the detection sensitivity and would be helpful in complete metas-
tasectomy.
Keywords: Pulmonary Metastases, Computer-aided detection, 
metastasectomy
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Screening/Japan, 2Department Of Diagnostic Radiology, National Can-
cer Center Hospital/Japan, 3Department Of Thoracic Surgery, National 
Cancer Center Hospital/Japan, 4Division Of Pathology, National Cancer 
Center Hospital/Japan, 5Department Of Endoscopy, Respiratory Endo-
scopy Division, National Cancer Center Hospital/Japan, 6Department 
Of Thoracic Oncology, National Cancer Center Hospital/Japan, 7Division 
Of Pathology, National Cancer Center, Research Center For Innovative 
Oncology/Japan, 8Division Of Thoracic Surgery, National Cancer Center 
Hospital East/Japan
Background: To evaluate lung cancers detected using low-dose 
CT screening between February 2004 and March 2012.
Methods: The number of screenees analyzed in the observatio-
nal study was 12,116. Screenees were classified into three groups 
based on their smoking index (SI): SI ≥ 600, SI < 600, and never-
smokers. Overall, 147 lung cancers in 132 cases treated at the 
National Cancer Center Hospital and the National Cancer Center 
Hospital East were evaluated according to the smoking index. 
Adenocarcinomas were evaluated based on the following classi-
fication: group A (adenocarcinoma in situ and minimally invasive 
adenocarcinoma), and group B (invasive adenocarcinoma). Statisti-
cal analyses were performed using the chi-square test.
Results: The ages of the patients with lung cancer ranged bet-
ween 42 and 85 years (mean, 61 years). Thirty-two of the 2989 male 
screenees (1.48%) and 2 of the 149 female screenees (1.34%) in the 
SI≥600 group, 22 of the 2989 male screenees (0.74%) and 10 of the 
796 female screenees (1.26%) in the SI<600 group, and 16 of the 
2148 male screenees (0.74%) and 50 of the 3878 female screenees 
(1.29%) in the never-smoker group were diagnosed as having lung 
cancer. Among the 147 lung cancers, 8 lesions (5.4%) did not pre-
sent as nodules and instead appeared as a partial thickening of the 
bulla wall, a funicular-like shadow, a pneumonia-like shadow, etc. 
Among the remaining 139 lung cancers, 35 lesions (25.2%) presen-
ted as pure ground-glass nodules (GGNs), 64 lesions (46%) presen-
ted as part-solid nodules, and 40 lesions (28.8%) presented as solid 
nodules. The histology of the lung cancers was adenocarcinoma 
in 132 cases (89.8%), squamous cell carcinoma in 8 cases (5.4%), 
small cell carcinoma in 3 cases (2%), adenosquamous carcinoma 
in 1 case (0.7%), carcinoid tumor in 2 cases (1.4%), and NSCLC in 1 
case (0.7%). The disease stages were as follows: IA, 127 (86.4%); IB, 
11 (7.5%); IIA, 2 (1.4%); IIB, 1 (0.7%); IIIA, 3 (2.0%); and IIB, 3 (2.0%). 
Among the 147 cancers, the number of incident cases was 8 in the 
SI≥600 group (median follow-up period, 3.1 years), 3 in the SI<600 
group (median follow-up period, 2.9 years), and none in the never-
smoker group (median follow-up period, 3.0 years). Lung cancer 
cases in smokers (including ex-smokers) occurred predominantly in 
men (male, 54; female, 12), while lung cancer cases in never-smo-
kers occurred predominantly in women (female, 50; male, 16) (P < 
0.0001). The number of adenocarcinomas in smokers (including ex-
smokers) was 29 in group A and 24 in group B, while the number 
of adenocarcinomas in never-smokers was 42 in group A and 23 
in group B (P = 0.274). In the never-smoker group, the number of 
adenocarcinomas in men was 7 in group A and 9 in group B, while 
the number of adenocarcinomas in women was 35 in group A and 
14 in group B (P < 0.05).
Conclusion: The number of invasive adenocarcinomas was not 
statistically different between smokers (including ex-smokers) and 
never-smokers. Never-smokers should also be a target population 
of CT lung cancer screening. Adenocarcinoma may be overdiag-
nosed among female never-smokers.
Keyword: lung cancer, CT screening, adenocarcinoma
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P1.20-002 ELEVATED INFLAMMATORY MARKERS 
COULD BE USEFUL IN EARLY DIAGNOSING AND MONI-
TORING LUNG CANCER
Idris Yucel1, Yasemin Kemal1, Bahittin Yılmaz1, Guzin Demirag1, 
Kubilay Ekiz2, Fatih Teker1, Engin Kut1
1Medical Oncology, 19 Mayis University Faculty Of Medicine/Turkey, 
2Internal Medicine, 19 Mayis University Faculty Of Medicine/Turkey
Background: Lung cancer is still the first leading cause of cancer 
death worldwide, and late diagnosis is a major obstacle to impro-
ving lung cancer outcomes. Tumor inflammation and immunology 
are recently identified as enabling cancer characteristics and play 
important roles in tumor progression and metastasis. Recently, ele-
vated preoperative or pretreatment neutrophil to lymphocyte ratio 
(NLR), platelet to lymphocyte ratio(PLR) and mean platelet volume 
(MPV) detected in peripheral blood were identified as indepen-
dent prognostic factors associated with poor survival in various 
cancers, including colon cancer, esophageal cancer, gastric cancer 
and breast cancer. These markers are highly repeatable, inexpen-
sive and widely available. The aim of this study is to examine whe-
ther MPV, NLR and PLR could be useful inflammatory markers for 
differentiating lung cancer from healthy controls; also to determine 
the relation between these markers and other prognostic factors 
and histopathologic subgroups.
Methods: Retrospectively eighty-one lung cancer patients and 
81 age-sexes matched healthy subjects included into the study. 
Patients with hypertension, hematological and renal disease, heart 
failure, chronic infection, hepatic disorder and other cancer were 
excluded from the study. The preoperative or pretreatment blood 
count data was obtained from the recorded computerized databa-
se.
Results: NLR and PLR values were significantly higher in lung 
cancer patients compared to healthy subjects.( NLR: 4.42 vs 2.45 
p=0.001, PLR: 245.1 vs. 148.2 p= 0.002) MPV values were similar in 
two study groups (7.7 vs. 7.8). On the other hand we did not find 
statistically significant relationship between these markers ( MPV, 
NLRand PLR) and histopathologic subgroups, TNM stages, grade, 
OS and PFS (all p>0.05).
Conclusion: Our data suggests that NLR and PLR values may be 
used as easily and available biomarkers for early diagnosis of lung 
cancer, but needs more large prospective studies to predict pati-
ents outcome.
Keywords: Lung cancer, platelet, neutrophil, lymphocyte
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P1.20-003 LUNG CANCERS DETECTED USING LOW-
DOSE CT SCREENING: RESULTS OF AN EIGHT-YEAR OB-
SERVATIONAL STUDY
Ryutaro Kakinuma1, Masahiko Kusumoto2, Hisao Asamura3, Koji 
Tsuta4, Takaaki Tsuchida5, Tomohide Tamura6, Genichiro Ishii7, 
Kanji Nagai8
1National Cancer Center, Research Center For Cancer Prevention And 
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P1.20-005 COMPARISON BETWEEN CHEST RADIOGRA-
PHY, CHEST TOMOSYNTHESIS AND COMPUTED TOMO-
GRAPHY TO DETECT PULMONARY NODULES: A PHAN-
TOM STUDY AND CLINICAL EXPERIENCE.
Juntima -. Euathrongchit1, Thanate Kattipathanapong2, Yuttha-
phan Wannasopha2, Supoj Ua-Apisitwong2, Kiattipong Jirapong1, 
Somcharoen Saeteng3, Apichat Tantraworasin3, Nirush Lertpra-
sertsuke4
1Radiology, Chiang Mai University/Thailand, 2Radiology, Faculty Of 
Medicine, Chiang Mai University/Thailand, 3Surgery, Chiang Mai Uni-
versity Hospital/Thailand, 4Medicine, Chiang Mai University/Thailand
Background: It is true that treatment in the early stage of lung 
cancer provides the best benefit, so many researchers have ac-
tively sought a good screening test for early detection. Although, 
chest radiography (CXR) is commonly used for evaluating patient 
with pulmonary disease. There are some limitations in early detec-
tion small nodule. Computed Tomography (CT) can easily solve 
this problem. However, the disadvantages of the CT are high cost 
and high radiation dose. Recently, there is a new technique called 
digital tomosynthesis, which can reconstruct sectional images at 
arbitrary depths by collecting a number of projection images at 
different angles using a digital detector. The overlapping anatomy 
of the section images is much less than the standard projection 
radiograph. Currently, many articles have presented the benefits of 
DT. The learning curve for interpretation of the technology is also 
important. The purpose of this study is to find the detection 
rate of nodule by using CXR, chest digital tomosynthesis (CDT) 
and CT examination with phantoms and preliminary clinical 
application in Maharaj Nakorn Chiang Mai hospital. 
Methods: After institutional review broad approval, in-house chest 
phantom was made from acrylic, plaster and catheters. The plastic 
beads, diameter size 1-2 mm., 3-4 mm., 5-6 mm., 7-8 mm. and 9-10 
mm. were implanted to represent pulmonary nodules in a phan-
tom. None to 20 nodules were randomly embedded in each model 
and photographed by digital chest radiograph (CXR), chest digital 
tomosynthesis (CDT) and chest computed tomography (CT). Two 
thoracic radiologists were blinded to review and label nodules on 
each image. Percentage of nodular detection in each study was 
calculated and compared between each other. After gain expe-
rience from phantom study, CDT was preliminary applied to the 
surgical cases for preoperative evaluation.
Results: There were 332 nodules in the 34 phantom-models. No-
dule detection rate from each modality was 75.3% of CXR, 91.0% 
of CDT and 98.8% of CT, respectively. CT could detect all nodules, 
which were larger than 3 mm in diameter. There were over 90 % of 
detected nodules from CDT that diameter were larger than 5mm. 
Percentages of nodular detection of CDT and CT were not stati-
stically significant difference in 5-10 mm sized nodules. Poor no-
dular detection areas on CXR were mediastinal and hilar regions, 
while on CDT was costophrenic sulcus. Clinical examinations were 
shown.
Conclusion: CT showed the highest percentage of nodular detec-
tion, followed by CDT and digital CXR, respectively. The percen-
tage of detection in nodules size 5 – 10 mm between CT and CDT 
was not statistically significant difference.
Keywords: Chest radiograph, computed tomography., Digital 
tomosynthesis
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P1.20-004 UK LUNG CANCER SCREENING TRIAL (UKLS): 
BASE LINE DATA
John K. Field1, Anand Devaraj2, David R. Baldwin3, John Hole-
mans4, Nicholas Screaton5, Martin Ledson6, Robert C. Rintoul7, Ar-
jun Nair8, John R. Gosney9, Doris Rassl10, Keith M. Kerr11, Stephen 
Duffy12, David H. Hansell8
1Cancer Research Centre, University Of Liverpool/United Kingdom, 
2Radiology, St George‘s Hospital/United Kingdom, 3Respiratory Medicine 
Unit, Nottingham University Hospitals And University Of Nottingham/
United Kingdom, 4Radiology, Liverpool Heart & Chest Hospital/United 
Kingdom, 5Radiology, Papworth Hospital/United Kingdom, 6Respiratory 
Medicine, Liverpool Heart & Chest Hospital/United Kingdom, 7Thora-
cic Oncology, Papworth Hospital/United Kingdom, 8Radiology, Royal 
Brompton Hospital/United Kingdom, 9Cellular Pathology, Royal Liver-
pool University Hospital/United Kingdom, 10Pathology, Papworth Hos-
pital/United Kingdom, 11Department Of Pathology, Aberdeen University 
Medical School/United Kingdom, 12Wolfson Institute Of Preventive Me-
dicine, Queen Mary University Of London/United Kingdom
Background: Lung Cancer causes over 35,000 UK deaths per year: 
early detection by CT screening has been shown to reduce morta-
lity in the USA by 20%.
Methods: UKLS is a pilot randomised controlled trial, screening 
individuals at a high risk of developing lung cancer (>5% over 5yrs) 
with low-dose CT. UKLS is population-based, approaching people 
of 50-75yrs identified through local primary care records and using 
a validated lung cancer risk prediction model to identify high risk 
individuals from the target group (Raji Annals of Int. Med 2012). 
We report observations made from the initial recruitment to the 
trial. 250,000 individuals were approached in Liverpool and Cam-
bridgeshire, 30% responded positively to the first questionnaire. 
4000 individuals were recruited and randomised to receive either 
a low-dose CT scan or usual care. All CTs were double read accor-
ding to UKLS protocol. Nodules were reported as category 1, 2, 
3 or 4 depending on size and volume (Baldwin et al. Thorax 2011). 
Participants with category 4 nodules (>500mm3) were referred to 
the lung cancer multi-disciplinary team (MDT) for further workup. 
Individuals with a category 3 nodule (50-500 mm3) underwent a re-
peat CT within 3 months, whereas category 2 nodules (15-50mm3) 
were followed up at 12 months. The trial is currently in follow-up 
and some participants are still in the 3 and 12 month phases.
Results: 1991 high risk UKLS participants underwent baseline CT 
by June 2013. 1044/1991(52.4%) individuals had nodules requiring 
further imaging or work-up. 79/1991 (4.0%) had nodules which 
required referral to the MDT clinics at the pilot sites for further 
workup. At this time 31/1991(1.6%) had a prevalent lung cancer. 
27/31 lung cancers (87.1%) were non-small cell lung cancer and 
25/31 lung cancers (80.6%) were Stage I or II (based on pathologi-
cal staging or clinical staging where the pathology staging was not 
available).
Conclusion: UKLS has already demonstrated 1.6% prevalence, uti-
lising the LLP risk prediction model to identify high risk individuals, 
which compares favourably with the NELSON and other European 
trials. The Pilot UKLS is due to provide an interim report in 2014.
Keywords: UK Lung cancer screening trial, Lung Cancer CT scree-
ning, UKLS
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in 11 of the 12 cases. This result is statistically significant and de-
monstrates that the Cell-CT can achieve an abnormal cell detec-
tion rate for lung cancer cells in sputum nearing 92% sensitivity. 
The area under the receiver operator characteristic curve (aROC) 
for abnormal cell detection is 0.99 (see figure). We can estimate 
the specificity for normal specimens by examining the rate of cor-
rect normal cell detection and classification. With the detection of 
9,683 normal cells, seven were falsely classified as abnormal (false 
positives). However, following human evaluation using Surveyor, 
the resulting specimen specificity was essentially 100%.
Conclusion: This first important study of Cell-CT shows there 
are sufficient abnormal cells in adequate, spontaneous sputa to 
achieve high-sensitivity lung cancer detection rates without false 
positives. The power of 3D single-cell morphometry supports the 
future potential impact of a non-invasive, sputum-based lung can-
cer screening test.
Keywords: Cell-CT, sputum, cancer, 3D
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P1.20-007 LOW-DOSE COMPUTED TOMOGRAPHIC 
SCREENING IN HEALTHY ADULTS AT LOW RISK FOR 
LUNG CANCER
Chin A Yi1, Kyung Soo Lee1, Myung-Hee Shin2, Yun Yung Cho2, 
Kyung Eun Shin3, Yoon-Ho Choi4
1Radiology, Samsung Medical Center, Sungkyunkwan University School 
Of Medicine/Korea, 2Social And Preventive Medicine, Samsung Medical 
Center, Sungkyunkwan University School Of Medicine/Korea, 3Radio-
logy, Kyung-hee University Medical Center/Korea, 4Center For Health 
Promotion, Samsung Medical Center, Sungkyunkwan University School 
Of Medicine/Korea
Background: The benefit of low-dose CT screening was proved by 
showing reduced mortality from lung cancer in persons at high risk 
for lung cancer. We evaluated the effect of low-dose CT screening 
in healthy adults at low risk for lung cancer.
Methods: From January 2006 through December 2008, we retros-
pectively enrolled 13,085 symptom-free healthy adults who under-
went three annual screenings with either low-dose CT (6,256 per-
sons) or chest radiography (6,829) for regular check-ups. They were 
divided into groups at high risk (≥30 pack-year smoking and ≥ 55 
years), intermediate risk (≥20 pack-year smoking and ≥ 50 years), or 
low risk (<20 pack-year smoking). Data were collected on numbers 
of screening detected lung cancer and survival from screening 
detected lung cancer that occurred through December 31, 2012.
Results: The rate of positive screening test was 53.2% with low-
dose CT and 13.1% with radiography. A total of 98.2% of the posi-
tive screening results in CT group and 97.9% in radiography group 
were false positive results. CT screening increased the number of 
screening detected lung cancers in the less than high risk populati-
on (multivariable-adjusted odds ratio (OR) 4.75, 95% confidence in-
terval (CI) 2.56 to 8.82, P <.001), but not in high risk population (OR 
1.23, CI 0.38 to 3.93, P =.730). In the less than high risk population 
CT screening detected lung cancers were all adenocarcinomas and 
were more frequently part-solid or non-solid nodules (P=.008). The 
stage of CT screening detected lung cancer more commonly in IA 
disease (76.1% in CT vs. 20% in radiography, P <.001) and the sur-
vival of CT screening detected lung cancer was consistently better 
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P1.20-006 NON-INVASIVE DETECTION OF LUNG CAN-
CER FROM CELLS IN SPUTUM USING CELL-CT™
Alan Nelson1, Michael Meyer1, Thomas Neumann1, Jon Hayenga1, 
Rahul Katdare1, Chris Presley1, Ben Hawthorne1, David Steinhau-
er1, Timothy Bell1, Scarlett Spring1, Anna Tourovskaia1, Florence 
Patten1, Gene Pawlick2, Terrance Colgan3, David Wilbur4, Douglas 
Johnson5, Nir Peled6, Ralph W. Aye7, Paul Zarogoulidis8, Jason Chi-
en9
1Visiongate/United States Of America, 2Kaiser Permanente/United 
States Of America, 3Mt. Sinai Hospital/Canada, 4Massachusetts Gene-
ral Hospital/United States Of America, 5Baptist Cancer Institute/Uni-
ted States Of America, 6Sheba Medical Center/Israel, 7Department Of 
Thoracic And Foregut Surgery, Swedish Medical Center/United States 
Of America, 8Pulmonary Department-oncology Unit, g. Papanikolaou 
General Hospital, Aristotle University Of Thessaloniki/Greece, 9Gilead 
Sciences/United States Of America
Background: Cell-CT is a fully-automated, single-cell analysis 
system that has been developed to enable non-invasive screening 
for lung cancer. We report the results of a pilot clinical study using 
Cell-CT for lung cancer detection from patient sputum, including 
the determination of criteria that define specimen adequacy, the 
detection of abnormal cells in adequate specimens (sensitivity), 
and the detection of normal cells (specificity), performed automati-
cally or further enhanced with human evaluation.
Methods: Twenty-seven patients with biopsy-confirmed lung can-
cer produced spontaneous-cough sputa (three morning-pooled) 
that were fixed, stained with hematoxylin following mucus dis-
solution, then enriched for epithelial cells using the method of 
fluorescence-activated cell sorting. The specimens were analyzed 
using Cell-CT, which computes 3D digital images of single cells 
through tomographic reconstruction with isometric, sub-micron 
resolution (see figure). The 3D cell images were automatically 
interrogated to measure morphometric biosignatures for lung 
cancer. 3D feature measurements were combined to produce 
two probabilistic scores: one that identifies abnormal cell candi-
dates (moderate, marked dysplasia, and cancer) and another that 
identifies normal bronchial epithelial cells to determine speci-
men adequacy. 3D images of the abnormal cell candidates were 
transmitted to a workstation for cytopathologist confirmation and 
final diagnosis, using a custom computer interface (Surveyor™). 
Results: Based on a stringent criterion for determining specimen 
adequacy, 12 of the 27 sputum specimens (or roughly 50%) were 
deemed adequate. In the adequate specimens, abnormal cells 
were automatically detected, correctly classified, and confirmed 
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Results: 
Table 1. Cumulative relative health care costs in the dia-
gnostic groups compared with the control group in the 
DLCST, shown as the multiplicative factor the costs on 
average differ from the costs in the control group. 
Annual costs were significantly higher in the screening group 
compared with the control group (p<0.001), but when cost of CT-
scans was excluded, there was no longer a significant difference 
(p=0.52). Analyses according to diagnostic groups showed that 
annual costs were 10.57 times higher for the true-positive and 1.67 
times higher for the false-positive group compared with the con-
trol group (Table 1).
Conclusion: Lung cancer CT screening increases overall healthcare 
costs compared with no screening, equivalent to the costs of the 
CT-screening scans. Overall healthcare costs were higher for the 
true-positive and false-positive groups than for the control group, 
even when excluding CT-screening scan costs. This increase was 
outweighed by the larger true-negative group who had reduced, 
but not statistically significant, costs compared with the control 
group (Table 1 and Figure 1). .
Keyword: randomized trial, CT screening, health care, costs,
than radiography screening detected lung cancers in the less than 
high risk population (multivariable-adjusted hazard ratio (HR) 0.08, 
CI 0.01 to 0.60, P =.014), in the less than intermediate risk populati-
on (HR 0.07, CI 0.01 to 0.66, P =.021), and in the low risk population 
(HR 0.07, CI 0.01 to 0.69, P =.023).
Conclusion: CT screening in low risk population detected more 
number of stage IA adenocarcinomas which area more frequently 
part-solid or nonsolid nodules, as compared with chest radiogra-
phy or with CT in high risk population. The survival of CT screening 
detected lung cancer was better than that of chest radiography 
detected lung cancers in the lower risk population.
Keywords: Lung cancer screening, low-dose CT, chest radiogra-
phy, risk stratification
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P1.20-008 HEALTH CARE COSTS IN THE RANDOMIZED 
CONTROLLED DANISH LUNG CANCER CT SCREENING 
TRIAL.
Jakob F. Rasmussen1, Volkert Siersma1, Jesper H. Pedersen2, Bruno 
Heleno1, Saigham Zaghir2, John Brodersen1
1The Research Unit For General Practice And Section Of General Practi-
ce, Department Of Public Health, University Of Copenhagen/Denmark, 
2Department Of Thoracic Surgery Rt, Rigshospitalet, University Of 
Copenhagen/Denmark
Background: Low dose computerized tomography (CT) screening 
for lung cancer can reduce mortality but it is currently unclear whe-
ther CT screening is cost effective. Denmark is a small country (5.3 
mio. inhabitants) with a uniform and a public health care system 
covering all inhabitants. The unique civil registration system allows 
a liNKIng of all health care expenses to the individual person. The 
objective of this study is to evaluate the direct healthcare costs 
generated by a randomized lung cancer CT screening trial in Den-
mark.
Methods: A Registry study nested in the Danish lung cancer scree-
ning trial (DLCST), involving 4104 participants, current or former 
heavy smokers, aged 50–70 years. Participants were randomized 
to five annual low dose CT scans or usual care during 2004 – 2010. 
Total healthcare costs and utilization data for the primary and the 
secondary healthcare sector, were retrieved from public registries, 
covering the period from randomization until September 2011
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Conclusion: The results presented suggest a promising role of HA 
in the developing and progression of lung cancer and its concen-
tration in the sputum as a novel diagnostic marker for differentia-
ting normal from lung cancer patients.
Keyword: extracellular matrix, diagnosis, hyaluronan
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P1.20-010 A PROSPECTIVE STUDY OF ANNUAL CT 
SCREENING FOR LUNG CANCER IN HIV SMOKERS
Alicia Hulbert1, Craig Hooker2, Dan C. Li2, Mario D. Teran2, Solange 
Cox2, Travis Brown3, Karen Horton4, John Wrangle1, Elliot Fish-
man1, Kristen Pelowski2, Beverly Lee2, Celis Sam4, Salina Tsai4, 
Elizabeth Welthe4, Beatrice Mudge4, Genevieve Pridham4, Jeanne 
Keruly5, Richard Moore5, James Herman1, Robert Brown6, Malcolm 
V. Brock2
1Department Of Oncology, Johns Hopkins University School Of Medici-
ne/United States Of America, 2Department Of Surgery, Johns Hopkins 
University School Of Medicine/United States Of America, 3Department 
Of Internal Medicine, University Of Maryland School Of Medicine/
United States Of America, 4Department Of Radiology, Johns Hopkins 
Universtiy School Of Medicine/United States Of America, 5Department 
Of Internal Medicine, Johns Hopkins University School Of Medicine/Uni-
ted States Of America, 6Department Of Anesthesiology, Johns Hopkins 
University School Of Medicine/United States Of America
Background: Of all the non-AIDS associated malignancies, lung 
cancer is the most deadly because of its advanced stage of pre-
sentation. Within the HIV population, the incidence of non-small 
cell lung cancer (NSCLC) is estimated to be 2-4 times that of the 
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P1.20-009 NEW POTENTIAL MARKER FOR THE  
DIAGNOSIS OF LUNG CANCER: HYALURONAN.
Maristela P. Rangel1, Vanessa K. De Sa2, Edwin R. Parra2, Vera L. 
Capelozzi2
1Pathology, Faculty Of Medicine - University Of Sao Paulo/Brazil, 2Pa-
thology, Faculdade De Medicina Da Universidade De SÃo Paulo/Brazil
Background: HA concentration is elevated in several cancers, but 
there is no data regarding its concentration in the sputum of lung 
cancer patients. In this study, we examined the HA concentrations 
in tissue and sputum samples and its impact on the screening and 
diagnosis of lung cancer patients.
Methods: Hyaluronic Acid (HA) was examined in lung cancer tissue 
of 14 patients through immunohistochemistry using a HA-probe. 
The analysis was performed using ImageProPlus 7.0. The HA con-
centration in sputum samples of 90 lung cancer patients, 25 COPD 
patients and 15 healthy controls was also analyzed. All the patients 
and healthy controls selected underwent a sputum induction. Spu-
tum samples were incubated with urea 7M at 60oC and afterwards 
incubated with a proteolytic enzyme. The levels of HA were mea-
sured by a noncompetitive ELISA-like fluorometric assay.
Results: It was observed a different expression pattern of HA 
in squamous cell carcinomas vs. adenocarcinomas specimens 
(p<0.05). In sputum, a significant different concentration pattern 
of HA was found among lung cancer, COPD and healthy indivi-
duals (p<0.001; Fig1A). Equally significant was the difference bet-
ween HA in the sputum from lung cancer and healthy volunteers 
(p<0.001), as well as lung cancer and COPD patients (p=0.002). 
ROC curve between lung cancer and healthy volunteers furni-
shed an area of 0.821 (0.727–0.915). Assuming a cut off value of 
31,44ng/mg, the specificity was 100% and the sensitivity was 51% 
(Fig1B). ROC curve to distinguish COPD patients from lung cancer 
patients showed an area of 0.698 (0.600-0.797) and the cut off 
value of 48.3ng/mg presented 100% of specificity and 33% of sen-
sitivity (Fig1C). 
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P1.20-011 RETROSPECTIVE STUDY OF LUNG CANCER 
SCREENING.
Yuki Morishige, Shiaki Oh, Tatsuo Maeyashiki, Shinsuke Uchi-
da, Tomohiro Ichikawa, Ryosuke Tachi, Mariko Fukui, Takeshi 
Matsunaga, Yukio Tsushima, Kazuya Takamochi, Kenji Suzuki
General Thoracic Surgery, Juntendo University/Japan
Background: The lung cancer screening in Japan is only chest 
radiography now. But in 2011, the national lung screening trial 
research team was reported reduced lung-cancer mortality with 
low-dose computed tomographic screening. We studied lung can-
cer patients about a difference of a screening type, for example 
radiography and computed tomography.
Methods: From January 2008 through May 2013, we performed 
the operation of 1344 lung cancer patients. In those patients, 1018 
patients were proved the type of screening.
Results: 
symptom radiography CT
pt 146 340 378
age 64±1 64±0.7 67±0.5
cStage IA 50 199 296
IB 22 66 42
IIA 18 25 6
IIB 15 13 8
IIIA 25 21 12
IIIB 6 4 2
IV 7 3 1
pStage IA 35 155 259
IB 18 57 53
IIA 12 31 13
IIB 16 23 11
IIIA 41 50 30
IIIB 6 4 1
IV 12 7 4
 
The number of patients by symptom, radiography and computed 
tomography are 146 (14%), 340 (33%) and 378 (37%), respectively. 
The rate of clinical stage I (789, 78%) are 72 (7%), 265 (26%), 338 
(33%), respectively. The rate of pathological stage I (672, 66%) are 
53 (5%), 212 (21%), 312 (31%), respectively. On the other hand, the 
rate of clinical III are 31 (3%), 25(2%), 14 (1%), respectively. The 
rate of pathological III are 47 (5%), 54 (5%), 31 (3%), respectively. 
The difference of between clinical stage I and screening type are 
0.000, 0.813, and 0.000, respectively. The difference of between 
pathological stage I and screening are 0.000, 0.081, and 0.000, 
respectively.
general population. Despite this growing burden of NSCLC in 
HIV-infected smokers, no data exist regarding early detection of 
lung cancer in this population since screening trials, such as the 
U.S. National Lung Cancer Screening Trial, excluded HIV-infected 
participants. Preliminary data have highlighted the ineffectiveness 
of chest x-rays in diagnosing lung cancer early, and waiting for 
HIV-positive individuals to develop symptoms is misguided. These 
facts provide a compelling argument for the use of helical CT as a 
screening tool for lung cancer in HIV-infected patients.
Methods: From 2006-2013, a prospective feasibility study was 
conducted to determine the prevalent and incident CT detection 
rates in HIV-infected smokers of lung cancer. The secondary ob-
jective was to determine if CT screening could change the stage 
distribution of HIV lung cancer to that of an early stage disease. 
Annual CT screening was conducted for lung cancer in current or 
former smokers over age 25 years old with ≥20 pack-years histo-
ry and a confirmed HIV diagnosis. To determine markers of lung 
cancer risk, we also analyzed from trial participants, clinical data, 
sera, and CT scans using quantitative, densitometry imaging as an 
estimate of emphysema, and compared these variables to similar 
parameters from 130 HIV patients at our institution with known 
lung cancer.
Results: Of the 224 individuals enrolled, 72% were males, 90% Af-
rican-Americans, 9.5% Caucasian, and 0.5% Hispanic. The median 
age was 48 years and the median number of smoking pack-years 
was 34. No prevalent lung cancers were detected by CT screening 
and only lung cancer was found on incident screening. There were 
no interim diagnoses of lung or extrapulmonary cancers. Eighteen 
deaths occurred but none were cancer-related. Of 29 nodules 
detected at baseline screening, fifteen were further imaged, five 
biopsied, but none progressed to cancer at study end. Emphyse-
ma was commonly observed and its heterogeneity across the en-
tire lung as measured by CT densitometry was significantly higher 
in HIV subjects with lung cancer than in those without (p≤0.01). On 
multivariate regression, increased age, higher smoking pack-years, 
low CD4 nadir, and increased heterogeneity of emphysema on 
quantitative CT imaging were all significantly associated with lung 
cancer in HIV individuals.
Conclusion: This pilot feasibility study is the world’s first reported 
annual lung cancer CT screening trial in HIV-positive smokers. Du-
ring 4 years of CT screening of 224 HIV subjects with a median age 
of 48 years, only one incident lung cancer was found. This sug-
gests that until the median age of the worldwide HIV population 
increases, the ability of annual CT screening to detect lung cancers 
in HIV-infected smokers will be low. Immunologic and radiographic 
differences that exist between HIV patients with and without lung 
cancer may serve as biomarkers of lung cancer risk.
Keywords: HIV, Lung cancer, screening
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P1.21-001 CANCER DIAGNOSIS IN THE ACUTE SETTING 
(CADIAS): A STUDY ON BEHALF OF THE LONDON CAN-
CER ALLIANCE
Tom Newsom-Davis1, Tim Benepal2, Cathy Hughes1, Lindsay For-
bes3
1Oncology, Chelsea And Westminster Hospital/United Kingdom, 2Onco-
logy, St Georges Hospital/United Kingdom, 3Promoting Early Presentati-
on, Kings College London/United Kingdom
Background: The United Kingdom has poorer cancer survival rates 
than other comparable countries (EUROCARE and International 
Cancer Benchmarking Partnership studies). Furthermore, for some 
cancers stage at diagnosis is more advanced; largely explained 
by differences in one-year survival, a marker of later diagnosis. In 
2012, the National Cancer Intelligence Network published a report 
as part of National Awareness and Early Diagnosis Initiative, Routes 
to Diagnosis. The key findings were that 24% of newly diagnosed 
cancer patients in England presented as emergencies. Tumour 
types most likely to present in this way included lung (39%). Emer-
gency new cancer presentations were more likely in older patients 
and those from a more deprived background, and the relative 
one-year survival was significantly lower across nearly all tumour 
types. However, little is known about the reasons why so many 
patients present acutely with a potentially delayed diagnosis. Fac-
tors that lead to delayed diagnosis have been associated with the 
patient, the doctor and the healthcare system. Previous research in 
the area has been restricted by separating primary and secondary 
care, and data on the patient experience is limited. The CADIAS 
study is designed to examine the whole diagnostic pathway and 
consider improvements across all three domains.
Methods: This National Cancer Research Network approved study 
recruits patients who present to hospital as an emergency with a 
new diagnosis of lung or colorectal cancer. Data are collected from 
three sources, the patient, primary care and secondary care. The 
study aims to understand the whole diagnostic pathway; from first 
recognising a symptom to emergency presentation in secondary 
care, including the role of primary care; map the patient, clinical 
and organisational factors that contribute to an emergency new 
cancer diagnosis; and suggest ways to improve outcomes by iden-
tifying gaps in service provision and any opportunities to diagnose 
cancer earlier. Six hospitals within the London Cancer Alliance will 
aim to recruit 250-300 patients into the study (Chelsea and West-
minster, Lewisham, Croydon, Hillingdon, St. Georges and Gyus 
and St. Thomas‘). A small pilot study was conducted to confirm the 
feasibility of the recruitment methods and data collection tools, 
specifically the use of patient interviews across a relatively large 
scale and with a group of potentially unwell participants. This part 
of the study, which included research nurse training, was designed 
by the Promoting Early Cancer Presentation team at Kings College 
London.
Results: Data analysis of 9 patients and of the 1st cohort of nurse 
training demonstrated that the methods used and data collected is 
of the required quality and standard to open the study to full rec-
ruitment. CADIAS is now open across the remaining hospital sites 
Conclusion: In the group of symptom and radiography, there are a 
lot of advanced lung cancer patients, while in the group of compu-
ted tomography, we can detect a lot of early lung cancer patients. 
Computed tomography is better than the other screening about 
the detecting lung cancer. We should use a computed tomography 
in screening of lung cancer.
Keywords: computed tomography, screening, Lung cancer, radio-
graphy
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proportion of NSCLC patients tested for EGFR mutations was 
31.9% (95% CI 31.2-32.6%), with an EGFR mutation positivity 
rate of 40.2% (95% CI 39.1-41.4%) overall, ranging from 28.7% to 
53.4% (Table). Additional data on demographic and histological 
subgroups and current testing practices (methods, sample types, 
sample preparation) will be presented. [*: Wilson score confidence 
interval. **: Note that the sites from Vietnam (one site) and Philip-
pines (one site) did not test ≥ 100 patients. N.D.: No data.] 
Table: Proportion of Patients Tested and EGFR Mutation 
Rates at Participating Sites
Country
Total number 
of newly  
diagnosed 
NSCLC  
patients 
Proportion 
of patients 
tested, % 
(95% CI*)
EGFR mutati-
on positivity, 
% (95% CI*)
Total 18,050
31.9 (31.2-
32.6)
40.2 (39.1-41.4)
Japan 2,379
64.8 (62.9-
66.7)
30.2 (28.0-
32.6)
China 12,086
18.3 (17.6-
19.0)
38.1 (36.3-
39.9)
Taiwan 2,530
52.9 (50.9-
54.8)
53.4 (50.7-
56.0)
Hong Kong 399
31.1 (26.7-
35.8)
49.2 (40.6-
57.9)
Malaysia 357
98.6 (96.8-
99.4)
45.7 (40.6-
51.0)
Thailand 249
57.8 (51.6-
63.8)
45.1 (40.6-
49.8)
Vietnam** 50
100.0 (92.9-
100.0)
36.0 (24.1-49.9)
Philippines** N.D. Not Known
38.9 (29.5-
49.2)
Indonesia N.D. Not Known
28.7 (20.8-
38.2) 
Conclusion: The data collected in this survey indicate that, in 2011, 
testing practices varied widely across the region, despite the well-
known high incidence of the mutation. The data provide an insight 
into these practices and provide a reference platform on which to 
compare and build on for the future of EGFR mutation testing and 
molecular diagnosis of NSCLC in Asia Pacific.
Keyword: molecular testing, survey, EGFR-TKI, NSCLC
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P1.21-003 IMPACT ON STAGE MIGRATION IN LUNG 
CANCER FROM 6TH TO 7TH EDITION OF TNM A STUDY 
CONDUCTED AT TWO HOSPITALS IN NEPAL.
Sandhya C. Acharya1, Rashmey Pun2, Ambuj Karn1, Bibek Acha-
rya1, Bishnu D. Poudel1, Madan K. Piya3
1Radiotherapy And Oncology, National Academy Of Medical Sciences, 
Bir Hospital/Nepal, 2Clinical Oncology, National Hospital And Cancer 
Research Center/Nepal, 3Medical Oncology, National Hospital And Can-
cer Research Center/Nepal
and, at the time of abstract submission, a total of 19 patients had 
been enrolled.
Conclusion: Understanding the factors which contribute to an esti-
mated 39% of lung cancer patients presenting as an emergency is 
key to improving cancer services and outcomes. This study brings 
the patient story together with data from primary care and secon-
dary care to present a rich picture of this type of presentation and 
identifying any opportunities to diagnose cancer earlier.
Keywords: acute oncology, Emergency, diagnosis, presentation
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P1.21-002 A SURVEY OF EGFR MUTATION FREQUENCY 
AND TESTING PRACTICES IN ASIA PACIFIC
Yasushi Yatabe1, Keith M. Kerr2, Ahmad Utomo3, Rajadurai Pa-
thmanathan4, Van Khanh Tran5, Xiang Du6, Teh-Ying Chou7, Ma 
Luisa D. Enriquez8, Geon Kook Lee9, Jabed Iqbal10, Shanop Shu-
angshoti11, Rose Mccormack12, Tony Mok13
1Dept. Of Pathology And Molecular Diagnostics, Aichi Cancer Center/
Japan, 2Department Of Pathology, Aberdeen University Medical School/
United Kingdom, 3Kalgen Laboratory/Indonesia, 4School Of Medicine, 
Monash University Malaysia & Sime Darby Medical Centre/Malaysia, 
5Center For Gene And Protein Research, Hanoi Medical University/Viet-
nam, 6Fudan University Cancer Center/China, 7Department Of Patholo-
gy And Laboratory Medicine, Taipei Veterans General Hospital/Taiwan, 
8Research And Biotechnology Division, St. Luke‘s Medical Center & De 
La Salle University/Philippines, 9National Cancer Center/Korea, 10Sin-
gapore General Hospital/Singapore, 11Chulalongkorn Hospital/Thailand, 
12Personalised Healthcare, Astrazeneca/United Kingdom, 13Department 
Of Clinical Oncology, The Chinese University Of Hong Kong/Hong Kong
Background: The efficacy of EGFR TKIs in EGFR mutation-positive 
NSCLC patients has led to a need for accurate, timely EGFR muta-
tion testing worldwide. Although EGFR mutation testing has been 
adopted by many laboratories in Asia, accurate data are lacking 
on the proportion of NSCLC patients tested in each country, and 
the most commonly used testing methods. The objectives are to 
investigate the practice of EGFR mutation analysis in Asian Pacific 
countries and document the prevalence of routine testing in this 
population.
Methods: This is a retrospective database survey of records from 
NSCLC patients tested for EGFR mutations from 1 January 2011 to 
1 January 2012 at participating sites across the Asia Pacific region. 
The majority of eligible hospitals/laboratories that participated 
had performed ≥ 100 EGFR mutation tests during that period. 
Accessible patient records were used to complete an online ques-
tionnaire, with data being stored in a central database. Primary 
objectives were to determine the number of NSCLC patients tes-
ted for EGFR mutations and the rate of EGFR mutation positivity: 
overall, by histological subtype, and by demography. Other varia-
bles included the number of NSCLC cases diagnosed, EGFR muta-
tion testing methods used, and tumour sample characteristics and 
processing. The proportion of EGFR mutation-positive patients 
and 95% CI were calculated; other variables will be summarized 
descriptively. An interim analysis has been conducted using data 
collected from more than 18,000 newly diagnosed NSCLC patients 
at 29 sites.
Results: The data from surveyed sites indicates that the overall 
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St. James‘s Hospital/Ireland, 3Medical Oncology, The Adelaide And 
Meath Hospital, Incorporating National Children’s Hospital, Tallaght 
Tallaght, Dublin 24, Ireland/Ireland, 4Clinical Medicine, Trinity College 
Dublin/Ireland, 5Histopathology, Beaumont Hospital/Ireland, 6Medical 
Oncology, The Hermitage Clinic/Ireland, 7Princess Alexandra Hospital/
Australia
Background: The presence of an EGFR mutation in NSCLC pro-
vides prognostic and therapeutic information for patients and 
clinicians. This study investigates the clinical behaviour of EGFR 
mutant (MT) versus EGFR wild-type (WT) NSCLC in an Irish cohort 
of patients. Differences in the pattern of presentation, metastasis 
and diagnostic methods between patients with EGFR-MT and WT 
tumours are poorly characterised. In this retrospective study, we 
investigated these parameters, variations in EGFR mutation type 
and resultant impact on overall survival (OS).
Methods: Patients with EGFR-MT NSCLC were identified from 
a National Multi-Institutional database. Patient demographics, 
diagnostic and clinical data were collected by review of medical 
records. From the database, EGFR-WT controls matched for age, 
gender and stage were identified and used as a comparator group. 
Fisher’s exact and Mann-Whitney tests were used to compare vari-
ables between groups. Cox model was used to examine the effect 
of mutation type on OS.
Results: We identified 416 patients with NSCLC. Forty (10%) pati-
ents had EGFR-MT positive tumours, of which data were available 
on 35 (87%) patients. Among patients with EGFR-MT tumours, 
median age was 64 (range 35-89), 29 (83%) were female, 34 (97%) 
patients had adenocarcinoma, and 1 (3%) patient had adenos-
quamous carcinoma. Twelve (34%) patients had resected disease, 
and 23 (66%) had metastatic disease. At median follow up of 12.8 
months, 3 (25%) patients with localised EGFR-MT disease recurred, 
0 (0%) of EGFR-WT recurred. There were no significant differences 
in the pattern of disease between EGFR MT and WT in terms of 
central/peripheral localisation of primary lesion, or sites of meta-
stasis such as the lung, liver, adrenal gland, bone or brain (p=1.0). 
Patients with EGFR-MT disease were more likely to be diagnosed 
via transbronchial biopsy (n=16, 47%) than EGFR-WT (n= 4, 11% 
p<0.01.) Patients with EGFR-WT disease were more likely to be 
diagnosed via endobronchial ultrasound/fine needle aspiration 
(FNA) (n= 21, 58%. p<0.01.) Among those with EGFR-MT disease, 
19 (54%) patients had tumours which harboured Exon 19 deletions, 
and 6 (17%) harboured L858R mutations. The remaining mutations 
comprised L861Q, V689M and deletions in Exons 18, 20 and 21. 
Among patients with stage IV disease at diagnosis, the median 
OS was 20.9 months and 7.3 months for EGFR-MT and EGFR-WT 
disease respectively (p=0.16.) The median OS for patients who 
underwent resection was not reached in either group.
Conclusion: There were no significant differences in patterns of 
presentation and metastasis between patients with EGFR-MT and 
WT tumours in this cohort. Patients with EGFR mutations were 
more likely to be detected by transbronchial biopsy compared to 
patients with WT disease, who were diagnosed more commonly by 
FNA. Possible explanations for this include institutional preferen-
ces or ease of tissue acquisition. In this cohort, the most common 
mutations in EGFR were Exon 19 deletion or L858R. The likelihood 
of mutation detection might be improved with the inclusion of a 
full EGFR mutational analysis.
Keywords: non-small cell lung cancer, clinical pathway, diagnostic 
pathway, EGFR mutant
Background: Lung cancer is the leading cause of cancer related 
morbidity and mortality in both the sexes in Nepal. It accounts for 
15.4 % of total cancer as per hospital based Cancer Registry in Ne-
pal. Patient usually present with stage III (55%) or IV (34%) disease. 
With the revision of Lung cancer staging system by International 
Association of the study of Lung Cancer (IASLC) and adoption of 
this Seventh edition of staging system by American Joint Comitte 
on Cancer (AJCC) in 2010, we tried to make an attempt and to 
recognize how many percentages of patients will upstage and 
downstage with comparison to the sixth edition of staging system.
Methods: This retrospective cross-sectional observational study 
was conducted at Department of Radiotherapy and Oncology, Bir 
Hospital and National Hospital and Cancer Research Centre, Ne-
pal. We reviewed the record of the entire registered, histologically 
diagnosed lung cancer patient in these two centers during the year 
2012. Total of 151 patient’s record were analyzed and restaged 
using both sixth and the seventh edition of staging system. The 
data were recorded and evaluated.
Results: Male preponderance observed with 63% of the cases 
and female of 37%. The mean age group was 63.93 years with the 
youngest being 31 years and the eldest with 83 years of age. The 
total patients in the different stage with seventh edition observed 
are IB 2(1%0, IIA 6(4%), IIB (8%), IIIA 59(39%), IIIB 24(16%), and IV 52 
(34%. Stage migration was seen in 15.23 % of the total cases. Most 
prominent was downstage from IIIB to IIIA which accounts for the 
7% of all the cases. This downstage is due to the Tumor size >7cm 
and a separate tumor nodule in the same lobe which elaborates 
T3 of the seventh edition. Next prominent stage migration noti-
ced was due to categorization of pleural fluid cytology as M1a in 
seventh edition, which cause a total of 4% of cases to be upstaged 
from IIIB to IV, which in fact this may further increase. The entire 
patients presented with pleural effusion have not undergone cyto-
logical evaluation because in most of these cases T4 disease was 
due to invasion and or satellite nodule along with the pleural effu-
sion so effusion was ignored as per 6th edition. Rest patient were 
downstage from T4 to T3 and T3 to T2, which is due to the sub 
categorization of the tumor by size.
Conclusion: In this cohort of patients, there was downstaging 
from IIIB to IIIA and upstaging from IIIB to IV because of revised 
TNM classification. Thus, we feel that a prospective larger study 
is required as it will further allow us to explain the prognosis and 
the survival pattern based on the staging system and we strongly 
recommend to have detailed staging and a routine pleural fluid 
cytology in the patient with pleural effusion before initiation of the 
treatment.
Keyword: IASLC, Lung Cancer, Pleural fluid, TNM staging.
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P1.21-004 PROFILING THE CLINICAL AND DIAGNOSTIC 
PATHWAY OF EPIDERMAL GROWTH FACTOR RECEPTOR 
(EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NS-
CLC) IN IRELAND
Jarushka Naidoo1, Sinead Noonan2, Min Yuen Teo3, Young Soo 
Rho1, Janet Clince1, Kathy Gately4, Cathal O‘Brien4, Tony O‘Grady5, 
Elaine Kaye1, Patrick G. Morris6, Kenneth O‘Byrne7, Oscar S. Brea-
thnach1
1Medical Oncology, Beaumont Hospital/Ireland, 2Medical Oncology, 
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P1.21-006 DIAGNOSTIC VALUE OF CT FLUOROSCOPY-
GUIDED TRANSBRONCHIAL BIOPSY IN ENDOBRONCHI-
ALLY INVISIBLE AND TRANSTHORASICALLY INACCES-
SIBLE NODULE/MASS OF THE LUNG
Erkan Yilmaz1, Atila Akkoclu2, Aylin Alpaydin2, Askin Gulsen3, 
Neslin Sahin1, Fidan Sever3
1Radiology, Sifa University School Of Medicine/Turkey, 2Pulmonary 
Diseases, Dokuz Eylul University Medical Faculty/Turkey, 3Pulmonary 
And Critical Care Medicine, Sifa University Medical School/Turkey
Background: To evaluate the usefulness of transbronchial needle 
biopsy (TBNB) under computed tomography fluoroscopy (CTF) for 
pulmonary nodule/mass that is invisible at bronchoscopy and not 
suitable for biopsy using transthoracic approach.
Methods: The study included 23 patients (14 men, 9 women and 
mean age of 57 years) with pulmonary mass/nodule on computed 
tomography (CT) scans. In all patients, there was no an endolumi-
nal lesion at bronchoscopy previously carried out and transthoracic 
biopsy was considered to be inappropriate owing to location of 
the lesion and/or presence of serious emphysema with abnormal 
pulmonary function test result. The procedure was done in a CT 
room with a monitor faced to the radiologist, while performing the 
broncoscopy by a bronchoscopist. CT fluoroscopic real-time scans 
were used to confirme that the tip of the bronchoscopic needle 
was exactly inside of the pulmonary target lesion. After the biopsy 
performed under CTF guidance, the obtaining samples were exa-
mined histopathologically.
Results: 
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P1.21-005 MULTIPLE PRIMARY MALIGNANCIES IN PATI-
ENTS WITH LUNG CANCER: CLINICAL FEATURES AND 
PROGNOSIS
Seowoo Kim, Seok Jeong Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun 
Chang
Division Of Pulmonary And Critical Care Medicine, Ewha Womans 
University, School Of Medicine, Mokdong Hospital/Korea
Background: The development of multiple synchronous primary 
malignancies in an individual is uncommon and unfortunate, but 
the frequency is increasing. The metachronous cancers will appear 
more commonly as cancer patients live longer lives. The aim of 
this study was to determine clinical features, organ location, and 
prognosis in patients with multiple primary malignancies (MPM) 
including lung cancer.
Methods: Following a retrospective review of clinical data, 101 
patients with MPM including lung cancer confirmed with a histo-
pathological diagnosis between 2002 and 2012 were enrolled in a 
tertiary referral hospital.
Results: The median age was 67 years (interquartile range (IQR), 
61-73 years) at lung cancer diagnosis, and 66 (65%) patients were 
male. The most common histologic type of lung cancer was ade-
nocarcinoma (47%), and 5 patients (5%) were diagnosed with triple 
cancers. In a total 56 metachronous cancer (55%), the median time 
between lung cancer and other cancer was 47.1 months (IQR 23.6-
72.1 months) and 20 had lung cancer diagnosed before the occur-
rence of other primary cancers. The synchronous tumors were in 
45 of 101 (46%). The most frequent cancers accompanying lung 
cancer were urogenital malignancies (30%) followed by gastroin-
testinal tract (28%) and thyroid malignancies (17%). Median survival 
duration calculated from the diagnosis of the first cancer was 33 
months in the lung cancer first patients, 11 months in the other 
cancer first patients and 1.5 months in synchronous patients (p ≤ 
0.001) with median follow up of 12.2 months. The factors of signifi-
cantly associated with the survival of MPM were adenocarcinoma; 
histologic type of lung cancer (p = 0.010), the initial intensive treat-
ments of lung cancer (p ≤ 0.001), non-smoker (p = 0.045) and ope-
rable lung cancer stage (p = 0.049) using Kaplan–Meier method 
with the log-rank test.
Conclusion: The synchronous tumors showed worse outcomes 
compared with those of the metachronous tumors including lung 
cancer. Despite multiple primary malignancies in patients with lung 
cancer, the influence of effective anticancer therapies that improve 
the survival, and the prognostic factors including the histologic 
type, staging, and smoking status were similar to the known fac-
tors of lung cancer.
Keyword: lung cancer, multiple primary malignancies, prognosis, 
clinical features
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them (1.5%) required a chest drain. The significant risk factors for 
pneumothorax were lesion depth >20 mm (p<0.0001), pathology 
type (malignant; p<0.0001), larger needle size (p<0.0001), number 
of passes >2 (p=0.001), lesion size <30 mm (p=0.009). There were 
no haemothoraces or major bleeding complications. However, 
post-interventional local hemorrhages were observed in 9 patients 
(4.4%) and hemoptysis was reported in 2 patients.
Conclusion: Percutaneous transthoracic CT guided biopsies of 
lung lesions were an effective procedure in the diagnosis of mali-
gnant lung lesions. Our study also shows that CT-guided needle 
biopsy is relatively safe, with only 1.5% of pneumothorax requiring 
chest drain and no major bleeding complications observed.
Keywords: malignant pulmonary lesions., Pneumothorax, Comput-
ed tomography guided, percutaneous transthoracic biopsy
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P1.21-008 ACCURACY OF NODAL STAGING IN EARLY 
STAGE NSCLC IN THE MODERN ERA OF PET-CT, EBUS-
TBNA AND MULTIDISCIPLINARY TEAM APPROACH
Tajalli Saghaie1, Katrina Tonga1, Chuong Bui2, Paul Bui2, Lucy Mor-
gan1, Peter Flynn3, Benjamin Ng1
1Thoracic Medicine, Nepean Hospital/Australia, 2Nuclear Medicine, 
Nepean Hospital/Australia, 3Cardiothoracic Surgery, Nepean Hospital/
Australia
Background: Accurate staging of NSCLC remains the most impor-
tant step in predicting outcome. It has been proposed that PET-
CT, as an addition to conventional work up, allows for more accu-
rate pre operative detection of stage IIIa and IIIb disease. On the 
other hand, it appears to have limitations in reliably staging nodal 
involvement in early stage NSCLC. We aimed to compare pre-
operative nodal staging (PET-CT and/or EBUS-TBNA findings) with 
post-operative histopathological results to determine the accuracy 
of PET- CT in a multi-disciplinary team setting.
Methods: This was a prospective, observational study of conse-
cutive patients discussed through Nepean Lung Cancer MDT that 
underwent surgical resection for NSCLC from Jan 2010 until Feb 
2013. PET-CT parameters of all patients, including FDG uptake in 
primary lesion(s) as well as hilar and mediastinal lymph nodes, were 
compared with post operative histopathology of the primary lesi-
ons and resected lymph nodes. Pre-operative nodal staging based 
on PET-CT +/- EBUS-TBNA was compared with post-operative 
histopathological staging. A PET-CT SUV (max) of equal or more 
than 2.5 was considered positive.
Results: 74 patients (mean age 69 years, range 47-86, 45 M ) un-
derwent surgical resection with lymph node dissection for NSCLC 
(65 lobectomies, 5 bi-lobectomies, 2 wedge resections and 2 
pneumonectomies). The most common malignancy in this group 
was Adenocarcinoma (39 [52.7%]) followed by Squamous Cell Car-
cinoma (25 [33.7%]) and undifferentiated large cell carcinoma (10 
[13.5%]). Most patients were post-operatively confirmed to be in 
early stages (32 stage I and 26 stage II) with other patients in stage 
III (12 IIIa and 1 IIIb) and stage IV (3). In 47% of cases, PET-CT nodal 
staging was concordant with final histopathological results. There 
was discordance in 39/74 cases with PET-CT being more likely to 
upstage (30/74) than to downstage (9/74) the mediastinum. Sym-
metrical FDG uptake in hilar lymph nodes was common amongst 
CTF-guided transbronchial biopsy samples were adequate for defi-
nitive diagnosis in 19 (83%) patients and inadequate in 4 (17%) pati-
ents. Inadequate results were caused by inability to reach the le-
sion as seen on CTF scans. 15 nodules/masses were diagnosed as 
malignant, 4 as benign. For malignant lesions, the final diagnoses 
were adenocarcinoma (n=5), small cell lung cancer (NSCLC) (n=4), 
non-NSCLC of undetermined cell type(n=2), epidermoid carcinoma 
(n=2), lymphoma (n=1) and sarcoma (n=1). Among the benign lesi-
ons, specific diagnoses were obtained in 2 (%50) patients. Mild to 
moderate hemoptysis occurred in 4 (17%) patients.
Conclusion: CT fluoroscopy-guided transbronchial biopsy is an 
effective and safe method to obtain the diagnosis of the lung lesi-
on. It seems to be particularly valuable with a real-time guidance 
in pulmonary nodule/mass which is invisible at bronchoscopy and 
inappropriate for transthoracic biopsy.
Keywords: bronchoscopy, Computed tomography/fluoroscopy, 
Lung biopsy, Pulmonary nodule/mass
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P1.21-007 USEFULNESS OF COMPUTED TOMOGRAPHY 
GUIDED PERCUTANEOUS TRANSTHORACIC BIOPSIES 
IN DIAGNOSING THORACIC MALIGNANCIES - EXPERI-
ENCE FROM A STATE HOSPITAL IN MALAYSIA
Choo Khoon Ong, Lalitha Pereirasamy, Kumaresh Raj, Irfhan Ali
Department Of Respiratory Medicine, Hospital Pulau Pinang/Malaysia
Background: Computed tomography (CT) guided percutaneous 
transthoracic biopsy is a minimally invasive procedure that has 
been widely accepted as an effective, safe and feasible alternative 
for diagnosis of thoracic lesions. It guides therapeutic decisions, 
avoiding surgical biopsies in many clinical settings. The diagnosis 
sensitivity rate for malignant lung lesions was high (88-95%). The 
study was conducted to evaluate the diagnostic accuracy and 
complications of CT guided percutaneous transthoracic biopsies 
of suspected malignant pulmonary lesions.
Methods: Retrospective study involving all consecutive patients 
who underwent diagnostic CT guided percutaneous biopsies of 
suspected thoracic malignancies on dual slice CT equipment bet-
ween Jan 2010 and December 2012. Percutaneous core needle 
biopsies were performed using a 16 / 18 / 20G Temno trucut au-
tomatic cutting needle under CT guidance. After the biopsy, a CT 
slice through the area of biopsy was performed to determine the 
presence of significant bleeding or pneumothorax. The samples 
were sent for the histological analysis. Evaluation included clinical 
data, pathologic results and therapeutic consequences. Statistical 
analysis of factors related to patient characteristics, lung lesions 
and biopsy technique was performed to determine possible contri-
bution to the occurrence of pneumothorax.
Results: A total of 204 patients (143 males; 61 females) with mean 
age of 59.5 ± 14.0 years were included in the study. Mean diameter 
of lung lesion was 44.4 ± 14.5 mm. Mean depth of lung lesion was 
14.4 ± 6.9 mm. Biopsies samples were adequate in 198 patients 
(97.1%) and inadequate in 6 patients (2.9%). Percutaneous transt-
horacic biopsy had an overall diagnostic accuracy of 93.6%. For 
malignant lesions, biopsy was positive in 161 patients (sensitivity of 
97.6%) and for benign lesions, in 30 patients (sensitivity of 76.9%). 
Pneumothorax was observed in 30 patients (14.7%) and only 3 of 
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Conclusion: CNB of diagnosis of MA is feasible and accurate. Our 
data support the suitability of small biopsy specimens for the new 
therapeutic paradigms even in mucinous adenocarcinoma.
Keywords: diagnostic accuracy, pulmonary mucinous adenocarci-
noma, transthoracic fine needle aspiration and core needle biopsy
upstaged cases. Anthracosis/silicosis was reported in lymph node 
histopathology of 16/74 (%21.6) patients, with 8 upstaged by PET-
CT. Overall, sensitivity of PET-CT mediastinal staging in our cohort 
was 31.25% with a specificity of 70.5%. This translates into accu-
racy of 70.2%. In 7 cases, EBUS-TBNA was performed to establish 
nodal staging. One case of micro-metastasis, confirmed on post-
operative histopathology, was not detected on EBUS-TBNA.
Conclusion: Nodal staging by PET-CT in early stage NSCLC has 
reasonable specificity but poor sensitivity, tending to upstage 
rather than downstage. Benign inflammatory processes affecting 
intra-thoracic lymph nodes such as anthracosis/silicosis may cause 
false positive PET-CTs. Nodal staging based only on PET-CT is in-
adequate and discussion through a multidisciplinary panel as well 
as minimally invasive investigations such as EBUS-TBNA is recom-
mended. This is consistent with current international guidelines.
Keywords: NSCLC, staging, PET
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P1.21-009 RELIABILITY OF TRANSTHORACIC FINE 
NEEDLE ASPIRATION AND CORE NEEDLE BIOPSY FOR 
THE DIAGNOSIS OF PULMONARY MUCINOUS ADE-
NOCARCINOMA
Hee Young Lee1, Ho Yun Lee1, Joungho Han2, O Jung Kwon3, Kyung 
Soo Lee1
1Radiology, Samsung Medical Center, Sungkyunkwan University School 
Of Medicine/Korea, 2Pathology, Samsung Medical Center, Sungkyunk-
wan University School Of Medicine/Korea, 3Samsung Medical Center/
Korea
Background: In case of mucinous adenocarcinoma (MA), cytologic 
atypia is usually mild to moderate and can be absent in some ca-
ses, creating a diagnostic pitfall in recognizing MA in small tissue 
biopsy and cytology specimens. Specific diagnosis of mucinous 
subtype in small tissue n FNA is important because it is considered 
an invasive neoplasm until proven otherwise, and it carries a worse 
prognosis for its aggressive behavior with frequent multicentricity 
and intrapulmonary metastatic spread. The purpose of this study 
was to evaluate the diagnostic accuracy of transthoracic fine need-
le aspiration (FNA) or core needle biopsy (CNB) of MA of the lung.
Methods: We retrospectively reviewed a consecutive series of 184 
patients who underwent curative operation for MA. Among those 
patients, 105 patients underwent pre-operative percutaneous FNA 
(n= 34) or CNB (n= 79). Eight patients underwent both FNA and 
CNB for the same tumors. Diagnostic accuracies of FNA and CNB 
for MA were evaluated, and the contribution of various clinicopa-
thologic parameters to subtyping accuracy was analyzed.
Results: Diagnostic accuracies of FNA and CNB in determining 
malignancy were 67.6% and 87.3%, respectively. 20.6% and 59.5% 
were successfully diagnosed as MA through FNA and CNB, res-
pectively. Univariate analysis implicated type of procedure and 
prominent growth pattern of mucinous adenocarcinoma as signifi-
cant factors for successful pathologic diagnosis. 
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P1.22-002 NON-SMALL CELL LUNG CANCER IN YOUNG 
PATIENTS: CLINICOPATHOLOGICAL FEATURES
Ugur Coskun1, Yusuf Gunaydin1, Arife Ulas2, Ozan Balakan3, Mev-
lude Inanc4, Ali Inal5, Mahmut Gumus6, Rima Davutoglu3, Necati 
Alkis2, Mustafa Benekli1
1Gazi University/Turkey, 2Ankara Oncology Hospital/Turkey, 3Gazian-
tep University/Turkey, 4Erciyes University/Turkey, 5Dicle University, 
School Of Medicine/Turkey, 6Medical Oncology, Kartal Dr.lutfi Kirdar 
Research And Training Hospital/Turkey
Background: Non-small cell lung cancer (NSCLC) is the most com-
mon cancer worldwide. NSCLC is strongly related to age. Its inci-
dence increases with advancing age and the median age at diag-
nosis is 70 years. Less than 5% of all NSCLC is seen before 40 years 
of age. Furthermore, young patients have different characteristics 
compared with older patients. In this study, the clinical features of 
patients less than 40 years of age were analyzed.
Methods: Medical records of patients diagnosed as having NSCLC 
between March 2000 and March 2013 were retrospectively exa-
mined in 17 institutions of Anatolian Society of Medical Oncology. 
Epidemiological data such as age, gender and smoking history was 
collected. Additionally, histological subtype, ECOG performance 
status, stage, number of organ metastasis, presence of cranial 
metastases were analyzed.
Results: A total of 210 patients were evaluated. Median age was 
35 years (range, 18-40). The majority of the patients were males 
(148 males and 62 females). There were 120 patients with a history 
of smoking. Seventy-eight patients were non-smokers and twelve 
were unknown. Majority of the patients (64%) had stage IV disease 
at presentation. Most of the patients had good performance sta-
tus. Half of these patients had two or more organ metastasis (53%). 
Cranial metastases were detected in 55 patients. Adenocarcinoma 
was the most common histological subtype (57%). Other subtypes 
were squamous cell carcinoma (20%) and unclassified (20%). In 
stage IV disease, adenocarcinoma was more frequent (64%). There 
was no association between histopathologic subtype and smoking 
history. Median overall survival (OS) of the entire cohort was 15.1 
months. Median OS was similar to the literature data (stage II: 
45.8 months, IIIA: 44.4 months, IIIB: 21.1 months and stage IV: 9.9 
months).
Conclusion: Adenocarcinoma was more common in the younger 
patients. These patients had advanced disease and good perfor-
mance status at presentation. However, survival was not better 
than older patients based on historical literature data.
Keyword: non-small cell lung cancer, young age
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P1.22-001 AN NICKEL WORKERS COHORT STUDY IN 
CHINA (JINCHUAN COHORT)-THE LARGEST NICKEL PO-
PULATION IN WORLD
Yana Bai1, Aimin Yang1, Hong Q. Pu2, Jie He3, Tongzhang Zheng4, 
Min Dai3, Wei Y. Zhang4, Qiuying Wang2, Ning Cheng1
1Center For Cancer Prevent And Treatment, College Of Public Health, 
Lanzhou University/China, 2Workers’ Hospital Of Jinchuan Group Co., 
Ltd./China, 3Cancer Institute And Hospital, Chinese Academy Of Me-
dical Sciences/China, 4Public Hearth School, Yale University/United 
States Of America
Background: Nickel is one of the most widely distributed and used 
metals in the world. Exposure to nickel compounds can result in a 
variety of adverse effects on human health. The China Nickel Wor-
kers Cohort Study (Jinchuan cohort) is estimated to include more 
than 50 000 nickel workers.
Methods: Since 2011, all staff and workers have been eligible for 
a medical examination every 2 years, and these workers who par-
ticipated in the medical examination will be in-person interviewed 
with a standardized and structured questionnaire with trained 
interviewers and will be included in the Jinchuan cohort study. The 
medical examination includes a comprehensive physical examinati-
on, biochemical examination, epidemiologic survey and collection 
of biological samples. The Jinchuan cohort has the largest data set 
from a cohort of nickel exposed workers with both questionnaire 
and laboratory-based information and the exposure and disease 
information will be updated every 2 years through the biannual 
survey and medical examination.
Results: The comprehensive epidemiological and biological data 
will permit the evaluation of a number of hypotheses concerning 
the health effects of nickel exposure. The unique repository of 
blood samples including blood cell, plasma, and serum collected 
at the time the epidemiology survey will provide a population-
based platform to examine biological indicators that closely corre-
late with nickel exposure and illness by using molecular epidemio-
logic methods. All of the cryopreserved blood samples are being 
stored in cryogenic tubes for future studies.
Conclusion: 
• We are conducting the first occupational epidemiological 
study of nickel exposure in China among over 50 000 workers 
• Comprehensive physical and biochemical examinations, an 
epidemiologic survey, and collection of biologic samples from 
workers are being used to evaluate the relationship between 
nickel exposure, cancer, and other health outcomes
• The cohort will be followed every two years with a repeat 
medical examination to update exposure and outcome infor-
mation
Keyword: Nickel, Cohort Study,Epidemiologic survey, Blood  
samples
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P1.22-004 PATHOLOGIC SUBGROUP ANALYSIS IN PA-
TIENTS WHO WERE DIAGNOSED AS NON-SMALL CELL 
LUNG CARCINOMA AND ANALYSIS OF ITS EFFECT TO-
GETHER WITH BASIC DEMOGRAPHIC AND CLINICAL 
CHARACTERISTICS OF PATIENTS ON SURVIVAL PARA-
METERS.
Cemile Karadeniz, Fatih Köse, Hüseyin Mertsoylu, Ali A. Beşen, 
Sadık Muallaoğlu, Ahmet Sezer, Ozgur Ozyilkan
Department Of Medical Oncology, Baskent University Medical Faculty/
Turkey
Background: Lung cancer is the most common cause of cancer-
related deaths in the world. In the last decades, the patients with 
adenocarcinoma histology have been increasing, although we 
don’t know the exact reason, and now constitute most common 
histological subgroup of Non-small Lung Carcinoma (NSCLC).Main 
aim of this study is analysis of histological subgroup of NSCLC, 
changing of histological subgroupsover time and its effect on sur-
vival parameters.
Methods: We analyzed 493 NSCLC patients those who were fol-
lowed at our department between January 2006 and December 
2011. Basic demographic and clinical characteristics such as stage 
of disease, initial diagnostic tests including invasive procedures, 
immunohistemochemical methods to clarify the histopathological 
subgroups, treatment protocols together with survival parameters 
were recorded retrospectively.
Results: Included were 493 patients with a median age of 60 years 
(35-102). There were 426 men (86.4%)and 67 women(13.6%)446 
(90.5%) patients had a history of cigarette smoking. The percen-
tage of female patients in whole group had been increased over 
timenonsignificantly(p=0.24). We found that adenocarcinoma was 
most common histopathological diagnosis (44.9%). Better perfor-
mance status, early diagnosis, and adenocarcinoma histology ex-
hibit statistically significant effect on overall survival with p values 
of (p=0.003,p=0.054, p=0.006), respectively. Statistical analysis 
showed that overall survival and TTF-1 positivity were significantly 
increased over time in the study with p values of (p=0.011) and 
(p=0,001) respectively. We also found that TTF-1 positivity was 
higher in female gender (p=0.005). Additionally,we were not able 
to show significant effects of basic demographic and clinical cha-
racteristicsof the patients such as age, TTF-1 positivity and primary 
localization of tumor on overall survival (p>0.05).
Conclusion: Our study showed that adenocarcinoma is the domi-
nant histology of NSCLC in Turkey and the percentage of female 
patients in NSCLC and overall survival in NSCLC had been increa-
sed significantly over time.Patient and tumor characteristics, such 
as histological shifting to adenocarcinoma over time, that we found 
during our study is compatible with literature.
Keyword: Non-small Lung Carcinoma, adenocarcinoma, overall 
survival
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P1.22-003 LUNG CANCER SURVIVAL IN SOUTHERN TAS-
MANIA
Katharine See, Nick Harkness, Cameron Hunter
Respiratory, Royal Hobart Hospital/Australia
Background: Lung cancer incidence and mortality are high in 
Tasmania; Incidence Mortality Australia (AIHW 2007) 43/100 000 
34/100 000 Tasmania (Cancer Registry 2007) 58/100 000 54/100 
000 There is limited published data looking at 5 year survival for 
primary Non-Small Cell Lung Cancer (NSCLC) particularly from 
Australian cohorts.
Methods: Local clinical practice information was collected in a 
prospective database. Cases presented at a multidisciplinary lung 
cancer meeting over a 24 month period (April 2006 -March 2008) 
were analysed. Patients with NSCLC were identified (n=181). Survi-
val data was obtained for all NSCLC cases (n=181/181) via hospital 
and general practitioner records as well as the Registry of Births, 
Deaths and Marriages. Lung cancer stage was based on the 6th 
edition IASLC TNM classification. Mortality data and survival times 
were calculated according to clinical stage.
Results: Five year survival was 10.5% (19/181) for all stages of NS-
CLC. Stratified by stage, 5 year survival was: Stage I 25% (13/52), 
Stage II 25% (3/12), Stage III 6% (3/52), and Stage IV 0% (0/65). 
Overall median survival was 7 months and when stratified by stage 
was: 30 months for Stage I, 5.5 months for Stage II, 9.1 months for 
Stage III and 3 months for stage IV disease. Patients who under-
went surgical resection with curative intent had a 60% 5 year survi-
val (13/22) which is in keeping with other published Australian data.
Conclusion: The five year survival rates for Stage II, III and IV 
NSCLC were comparable with that of internationally published 
cohorts. In contrast, all-cause mortality rates for Stage I NSCLC 
appear higher than expected however rates of surgical cure are in 
keeping with published data.
Keyword: NSCLC 5yr survival
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frequency was 35.3%. 12 patients provided both histology and cy-
tology samples. Among these 11 had concordant EGFR mutations 
status and 1 had mutation results that did not match.
Conclusion: Locations and types of the samples used for EGFR 
mutation testing were various in clinical practice. The overall EGFR 
mutation frequency in clinically unselected Chinese ADC was 
50.2%. Smoking status and pack years had a statistically significant 
association with presence of EGFR mutation.
Keywords: EGFR mutation, lung adenocarcinoma
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P1.22-006 THE IMPACT OF SEX HORMONE-BINDING 
GLOBULIN LEVELS ON THROMBOEMBOLIC EVENTS AT 
CANCER PATIENTS WITH ADENOCARCINOMA
Mustafa Bozkurt
Medical Oncology, Haseki Eğitim Ve Araştırma Hastanesi/Turkey
Background: Thromboembolic events (TE) are common compli-
cation of cancer, may lead to mortality and detoriate quality of 
life. The most common malignancies associated with TE’s are ade-
nocarcinomas and the mechanism needs to be elucidated.Several 
studies suggest that increased risk of TE’s with hormonal contra-
ceptives is mediated through the sex hormone-binding globulin le-
vels (SHBG). The aim of this study is to investigate if the SHBG level 
is associated with TE’s in cancer patients with adenocarcinoma.
Methods: We compared the SHBG levels in 45 patients with TE 
and 23 patients without TE, all of them cancer with adenocarcino-
ma histology. A p value of less than 0.05 was considered statisti-
cally significant.
Results: Sixty eight patients, aged between 37-80, are evaluated. 
Thirty five women. There was no statistical significant relationship 
for age and gender between TE and non-TE groups. AT TE group, 
20 (44%) had distal lower extremity (DLE) deep venous thrombosis 
(DVT), 17 (38%) had PE and the rest includes 4 central/proximal 
DVT (9%), 4 central venous catheter-related DVT (9%). Frequencies 
of histopathology for TE and non-TE group were; colorectal can-
cer 20 (30 %), gastric cancer 13 (20 %), pancreatic cancer 11(16%), 
breast 10 (%14), Lung 6 (9 %), and other (prostatic 3, hepatobiliary 
2, unknown primary 2 and ovarian 1) 8 (%11). There was no diffe-
rence between SHBG levels with TE group (mean±SD; 59±41) and 
non-TE group (60±49)( student’s t test; p=0.98).
Conclusion: SHBG levels do not play any role in the mechanism of 
cancer- related thrombosis in patients with adenocarcinoma.
Keyword: cancer-related thrombosis, sex hormone-binding globu-
lin, adenocarcinoma
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P1.22-005 A PROSPECTIVE, MOLECULAR EPIDEMIOLO-
GICAL STUDY OF EGFR MUTATIONS IN ASIAN PATIENTS 
WITH ADVANCED NON-SMALL-CELL LUNG CANCER 
WITH ADENOCARCINOMA HISTOLOGY (PIONEER STU-
DY) - CHINA SUBSET ANALYSIS
Yuankai Shi1, Jun-Ling Li1, Shu-Cai Zhang2, Meng-Zhao Wang3, 
Shu-Jun Yang4, Ning Li5, Gang Wu6, Wei Liu7, Guo-Qing Liao8, Kai-
Can Cai9, Liang-An Chen10, Mei-Zhen Zheng11, Ping Yu12, Xiu-Wen 
Wang13, Yun-Peng Liu14, Qi-Sen Guo15, Li-Gong Nie16, Ji-Wei Liu17, 
Xiaohong Han1
1Department Of Medical Oncology, Cancer Institute/Hospital, Peking 
Union Medical College & Chinese Academy Of Medical Sciences; Beijing 
Key Laboratory Of Clinical Study On Anticancer Molecular Targeted 
Drugs/China, 2Beijing Chest Hospital, Capital Medical University/
China, 3Peking Union Medical College Hospital/China, 4Henan Cancer 
Hospital/China, 5Medical Oncology, Guangzhou Chest Hospital/China, 
6Department Of Cancer, Union Hospital Of Tongji Medical College/Chi-
na, 7Fourth Hospital, Hebei Medical University/China, 8309 Hospital/
China, 9South Hospital/China, 10301 Hospital/China, 11Liaoning Cancer 
Hospital/China, 12Sichuan Cancer Hospital/China, 13Qilu Hospital, 
Shandong University/China, 14The First Hospital Of China Medical Uni-
verstiy/China, 15Shandong Cancer Hospital/China, 16Peking University 
First Hospital/China, 17The First Affiliated Hospital Of Dalian Medical 
University/China
Background: PIONEER (A molecular ePIdemiOlogy study in Asian 
patients with advanced NSCLC of adEno histology to assess EGFR 
mutation status; NCT01185314) was a multinational prospective 
epidemiological study planned to investigate EGFR mutation fre-
quency in patients from Asia with newly diagnosed advanced lung 
adenocarcinoma (ADC) and the influence of demographic and 
clinical factors on EGFR mutation frequency. Here we report analy-
sis results for the subset of patients from China.
Methods: Patients were aged ≥20 years, with treatment naïve 
stage IIIB/IV lung ADC. The primary objective was assessment of 
overall EGFR mutation frequency. The secondary endpoints inclu-
ded investigation of the correlation between EGFR mutation status 
and demographic and clinical factors and attrition rates of EGFR 
mutation testing. The acquisition, preparation, and processing 
of tumor material was performed in line with the routine clinical 
practice of the participating hospital laboratories. Tumor EGFR 
mutation status was determined in central labs using amplification 
refractory mutation system (ARMS)-based EGFR mutation detec-
tion kit (Scorpion ARMS IVD2, Qiagen, Crawley, UK). 29 mutations 
were detectable by this method across Exons 18, 19, 20, and 21.
Results: 747 patients were registered in 17 investigational sites in 
China (50.4% of the overall study population). 46.9% of the pati-
ents were female, mean age was 58 years (range 17-83), and 56.4% 
were never-smokers. 72.4% (541/747) of the samples used for mu-
tation testing were primary tumor. Sample locations include lung 
(73.5%), local lymph nodes (10.3%), distant lymph nodes (6.3%), 
pleural effusion (2.5%), pleura (2.0%), and others. sample types 
include image-guided core biopsy (29.7%), bronchoscopic biopsy 
(24.1%), incisional biopsy(12.7%), cytology and others. The median 
time interval taken from order to report of mutation test was 16 
days with a range from 3 days to 62 days. EGFR mutation status 
was successfully evaluated in 741 patients: 372 (50.2%) were muta-
tion positive, 369 (49.8%) were mutation negative. Smoking status 
and pack years had a statistically significant association with pre-
sence of EGFR mutation, but even in regular smokers, the mutation 
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P1.22-008 IDENTIFYING EVIDENCE-PRACTICE GAPS IN 
LUNG CANCER AND PRIORITY SETTING WITH CLINICI-
ANS IN NSW, AUSTRALIA.
Nicole M. RaNKIn1, Tim Shaw2, Deborah Mcgregor2, Phyllis Bu-
tow2, Jane Young2, Kate White2, Jane Phillips3, Sallie Pearson2, John 
Simes2, Rachel O‘Connell2, Emily Stone4, David Barnes5
1Sydney Catalyst, The University Of Sydney/Australia, 2The University 
Of Sydney/Australia, 3University Of Notre Dame/Australia, 4Lung Can-
cer Mdt, St Vincent‘s Hospital/Australia, 5Royal Prince Alfred Hospital 
Medical Centre/Australia
Background: Implementation Science has emerged over the past 
20 years to highlight a fundamental problem in health care: that 
knowledge about optimal care is not applied in clinical practice. A 
‘gap analysis’ is an initial research activity undertaken when quan-
tifying the gap between existing knowledge and clinical practice. 
The purpose of this presentation is to describe outcomes of a gap 
analysis conducted in lung cancer and priority setting focus groups 
held with oncology health professionals. This research is being 
conducted by Sydney Catalyst, a Translational Cancer Research 
Centre that brings together teams of clinicians and researchers 
from more than 20 member organisations across NSW, Australia, 
for the purpose of facilitating rapid translation of scientific evi-
dence into clinical practice and policy.
Methods: A systematic approach was used to examine the evi-
dence across the lung cancer patient journey. Data sources inclu-
ded international and national clinical practice guidelines, syste-
matic reviews and meta-analyses, and research from peer reviewed 
publications, including population-based patterns of care studies 
and data linkage studies. We also conducted a descriptive analysis 
of data from clinical cancer registries and administrative databases 
used in the local setting of Sydney and regional NSW, Australia, to 
determine what gaps were locally relevant. All data sources were 
reviewed and synthesised to create the list of evidence-practice 
gaps. The gaps are presently being tested in three focus groups 
in urban and regional cancer services in NSW, Australia. Focus 
group participants include specialists in lung and thoracic onco-
logy, medical, nursing, allied health and supportive care health 
professionals. The purpose of these focus groups is to conduct a 
priority setting exercise, where clinicians can rate the relevance of 
gaps to the local context and agree on which gaps should first be 
addressed in any subsequent research projects.
Results: Seven evidence-practice gaps were identified across the 
patient journey (from initial presentation and diagnosis through 
to palliative care). We analysed 2008 data from one local hospital 
for all lung cancer patients (N=329) and found that local patterns 
of care appear to be consistent with those previously observed in 
a NSW patterns of care study. This assists in demonstrating that 
gaps identified at the population level are also present in local 
health care settings and strengthens a rationale for developing 
collaborative lung cancer specific research projects that engage 
clinicians and researchers. The analysis and outcomes of focus 
groups will be presented, along with a critical appraisal of the gap 
analysis methodology and show how this approach in lung cancer 
is relevant to other tumour groups and health conditions.
Conclusion: A gap analysis enables researchers and clinicians to 
identify where deficiencies exist between published research evi-
dence and optimal patient care. By drawing together and synthesi-
zing data from multiple sources of evidence, identifying gaps and 
POSTER SESSION 1 - EPIDEMIOLOGY, ETIOLOGY  
MONDAY, OCTOBER 28, 2013 - 09:30-16:30
P1.22-007 THE PREVALENCE OF EPIDERMAL GROWTH 
FACTOR RECEPTOR (EGFR) MUTATION IN NON-SMALL 
NON-SQUAMOUS LUNG CANCER IN UAE (A SINGLE 
INSTITUTE EXPERIENCE IN THE MIDDLE EAST)
Hassan Jaafar, Khaled Quasmeh, Mohammed Jaloudi
Oncology, Tawam Hospital/United Arab Emirates
Background: Epidermal growth factor receptor (EGFR) is a trans-
membrane protein it belongs to the ErbB-family, its activity in-
cludes transmitting of growth factor signaling from the surface of 
cells into the cells and activates the enzyme tyrosine kinase, trig-
gering reactions that cause the cells to grow and multiply. EGFR 
has an impact on malignant cells development in various tumors, 
affecting their proliferation, apoptosis, motility and angiogenesis. 
In NSCL cancer EGFR-protein mutations in exons 18–21 results in 
constant hyper-activation of downstream pro-survival signaling 
pathways, independent from any external receptor stimulation. 
Approximately 10% of US patients and 35% in East Asia patients 
show EGFR mutation of which, almost 90% of these mutations 
are exon 19 deletions or exon 21 l858r point mutations. EGFR has 
been identified as an important therapeutic target for the treat-
ment. Purpose: To evaluate the prevalence of EGFR mutations in 
the diagnosed cases of NSCLC in our hospital, which deals with 
approximately 80% of lung cancer cases in UAE and to compare it 
with other geographic and ethnic groups.
Methods: A retrospective analysis of all non-small non-squamous 
lung ca cases that had EGFR testing was performed. LAB 21 in UK 
was used for the EGFR mutation testing. A total of 50 tumor blocks 
were sent to the laboratory. The test could not be performed on 
one case. Out of the remaining 49 patients, 13 (26%) were fema-
le and 36 (74%) were male. Open biopsy by either lymph node 
excision, pleuroscopy, open lung biopsy or craniotomy were the 
tissue source for the EGFR analysis in 23 patients while only 15 
had enough tissue from one procedure (bronchoscopy or guided 
biopsy).
Results: EGFR mutation was identified in 18/49 (37%) patients. 
of the 18 patient, who had EGFR mutation, 10 (56%) patients had 
exon 19 mutation, 6 (33%) patients had exon 21 deletion and 2 
(11%) patient had double mutation. in those two patients with dou-
ble mutation, one had mutation in exons 19 and 21 and the other 
had mutation in exons 18 and 20. No significant difference was 
observed in EGFR-mutations among the gender of patients, 35% 
in men and 38% in women. Analysis of ethnicity and prevalence of 
EGFR-mutation showed a significant difference between Arabs (15 
of 32 / 46%) and non-Arabs (3 of 17 / 18%). in the Arabian cohort 
with EGFR mutations 8 out of 22 patients (36 %) had a smoking 
history and 7 out of 10 (70%) were documented as non (never)-
smoker.
Conclusion: Local prevalence of EGFR mutation was found to be 
37% among all the ethnic groups, which is in line with the inci-
dence in Asian population but the Prevalence of EGFR mutations 
in Arabs was (46%). it is to be stressed here that testing for EGFR 
mutations should be considered for all patients with non-small 
non squamous cell lung cancer at diagnosis, regardless of clinical 
characteristics. This strategy can warrant the prompt use of EGFR 
tyrosine kinase inhibitors to promote the practice of personalized 
medicine.
Keywords: lung ca, EGFR, middle east
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P1.22-010 GODDARD CLASSIFICATION IS ASSOCIATED 
WITH CLINICAL CHARACTERISTICS IN PATIENTS WITH 
COPD AND ADVANCED NSCLC.
Kuniomi Matsuura, Tatsuo Kimura, Toshiyuki Nakai, Norio Yama-
moto, Gakuya Tamagaki, Shigeki Mitsuoka, Yoshihiro Tochino, 
Kazuhisa Asai, Shinzoh Kudoh, Kazuto Hirata
Respiratory Medicine, Osaka City University/Japan
Background: Chronic obstructive pulmonary disease (COPD) is a 
frequent complication seen in 24.9% in patients with lung cancer. In 
practice, a decreased respiratory function due to COPD influences 
to decision of treatment. The airway obstruction is assessed by the 
Global Initiative for obstructive lung disease (GOLD) classification. 
On the other hand, Goddard classification is a method for evaluating 
the emphysema using CT images. The respiratory function of an ad-
vanced lung cancer has various modifications such as tumor airway 
obstruction or atelectasis. The hypothesis is that in patient with COPD 
and advanced lung cancer patients, GOLD classification may not cor-
respond to the Goddard classification. We evaluated the associations 
of clinical characteristics with Goddard classification as well as GOLD 
classification.
Methods: Between May 2007 and April 2012, the pre-treatment 
respiratory function was assessed for patients diagnosed at Osaka 
City University Hospital as non-small cell lung cancer stage IIIB or IV 
without EGFR gene active mutations. FEV/FVC% less than 70% were 
diagnosed for COPD. GOLD and Goddard classification were evalua-
ted. Two doctors independently determined the Goddard classifica-
tion, and the final score was adopted from the average of two scores. 
The association of clinical characteristics with Goddard classification 
as well as GOLD classification was performed by fisher exact test. An 
univariate analysis was performed to evaluate the prognosis by COX 
regression method. In multivariate analysis, histology, stage, number 
of cigarette smoking, and FEV/FVC% were performed to evaluate 
the prognosis by COX regression selected variable method (stepwise 
method).
Results: A total of 67 patients were enrolled with median age of 70 
(49-81). GOLD classification showed normal (n=32), mild (stage I/II, 
n=30), and moderate (stage III, n=5) airflow obstructions. There was no 
severe COPD (stage IV) patient. In GOLD classification, no-significant 
associations of clinical characteristics were observed such as lobe site 
of primary lesion (p=0.84), tumor histology (p=0.21), gender (p=0.17), 
and cigarette smoking (p=0.42). Goddard classification showed non 
(score zero, n=12), mild (score <8, n=32), and moderate-severe (score 
8-20, n=23) emphysema findings. In Goddard classification, there were 
significant associations of clinical characteristics in tumor histology of 
squamous cell carcinoma (p=0.010), male (p=0.031), and number of ci-
garette smoking (p=0.020). Univariate analyses showed neither GOLD 
nor Goddard classification was associated with overall survival. In mul-
tivariate analysis, FEV/FVC% was not associated with overall survival.
Conclusion: As compared with Goddard classification, the distribution 
of GOLD classification shift relatively mild direction. Therefore, there 
is no-significant association of clinical characteristics in GOLD classifi-
cation, and Goddard classification was significant association of squa-
mous cell carcinoma, male, and cigarette smoking. Surprisingly, the 
FEV/FVC% did not become a prognostic factor for NSCLC received 
chemotherapy. The severity of COPD might not influence outcome of 
chemotherapy in advanced NSCLC.
Keywords: COPD, emphysema, NSCLC, Goddard classification
setting priorities with local health professionals, we believe we can 
address the goal of more rapidly translating evidence into practice.
Keywords: Translational research, implementation science, priority 
setting
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P1.22-009 MESOTHELIOMA IN AUSTRALIA 2012: DATA 
FROM THE NEW AUSTRALIAN MESOTHELIOMA REGIS-
TRY
Lisa Huang1, Bruce Armstrong2, Ewan Macfarlane3, Malcolm R. 
Sim3, Fleur De Crespigny4, Anita Anderson4, Nico Van Zandwijk5, 
A William Musk6, Vicki Dalton7, Carly Scott8, Andria Ratchford1, 
Paula Laws1
1Cancer Institute Nsw/Australia, 2The University Of Sydney/Australia, 
3Monash Centre For Occupational And Environmental Health, Monash 
University/Australia, 4Safe Work Australia/Australia, 5Asbestos Disea-
ses Research Institute/Australia, 6Western Australian Mesothelioma 
Registry/Australia, 7Comcare/Australia, 8Cancer Council Queensland 
Cancer Registry/Australia
Background: Australia has the highest incidence rates of malig-
nant mesothelioma in the world. The exact mechanism of meso-
thelioma development is only partly understood, however it has 
been linked to occupational and increasingly, non-occupational 
exposures to asbestos. The Australian Mesothelioma Registry 
(AMR) was established to collect incidence and mortality data on 
all cases of mesothelioma in Australia, including detailed informa-
tion on asbestos exposure. The Australian Mesothelioma Registry 
completed its second full year of data collection on cases from 1 
July 2010.
Methods: The AMR compiles notifications from state/territory 
cancer registries. Clinicians may be requested to advise if their 
patients are suitable for recruitment to the asbestos exposure 
component. Consenting participants are assessed for past asbes-
tos exposure by The Monash Centre for Occupational and Envi-
ronmental Health, after completing a job and residential history 
questionnaire and telephone interview using OccIDEAS, an online 
exposure assessment tool.
Results: More than 600 cases of mesothelioma have been noti-
fied to the Registry for 2011. At 30 June 2013, 619 diagnoses of 
mesothelioma had been reported to the AMR for 2012. Exposure 
assessments collected within the AMR framework will provide in-
formation not previously available. Data will be presented for 2012, 
the second calendar year of data collection, in addition to results 
for the exposure assessment component.
Conclusion: AMR information has the potential to provide an ac-
curate assessment of sources of asbestos exposure currently con-
tributing to causing newly diagnosed mesothelioma in Australia. 
The AMR is a national resource for researchers and may assist in 
preventing mesothelioma in the future.
Keyword: Mesothelioma Asbestos Exposure Registry
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Table 1
Health 
Behavi-
our
N
Missing 
Data in 
EPR
Ag-
ree-
ment 
(k)
95% CI 
(P value) Se Sp
Smoking 
(E/N)
709 0 0.95
(0.79, 
0.89)
0.995 0.94
Smoking 
(Pkyrs)*
606 81(11%) 0.77 P<0.0001
Smoking 
(C/F/N)**
705 4(0.5%) 0.47
(0.41, 
0.51)
Alcohol 
(E/N)
575 150(20.5%) 0.44
(0.36, 
0.52)
0.9 0.5
Comor-
bidity
Emphy-
sema
589 126(17.2%) 0.41
(0.33, 
0.49)
0.41 0.95
Chronic 
Bronchi-
tis
601 94(12.8%) 0.28
(0.19, 
0.37)
0.39 0.88
*Spearman correlation coefficient
**Weighted kappa
Conclusion: In the absence of PRS data, EPR provides a reliable 
surrogate for ever/ never smoking status and moderately reliable 
for lifetime smoking exposure in this lung cancer population. How-
ever current/ former/ never smoking status and ever/ never alcohol 
status cannot be reliably ascertained from medical records. Mis-
sing EPR data related to smoking pack years, alcohol consumption 
and lung co-morbidities is concerning and suggests more systema-
tic or synoptic reporting by physicians would improve opportuni-
ties for research
Keywords: abstracted data from Electronic Patient Record, Smo-
king & Alcohol data patient self report, Comorbidity data, Lung 
cancer population
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P1.22-011 ASSESSMENT OF THE ACCURACY AND RE-
LIABILITY OF HEALTH RELATED BEHAVIOURAL DATA 
OBTAINED FROM PATIENT-REPORTED SURVEYS (PRS) 
COMPARED WITH ELECTRONIC PATIENT RECORDS 
(EPR) IN LUNG CANCER PATIENT POPULATION
Prakruthi R. Palepu1, Catherine Brown2, Osvaldo Espin-Garcia3, 
Gautam Joshi2, Lawson Eng2, Jayalakshmi Ramanna2, Sinead Cuf-
fe4, Shaf Keshavjee5, Thomas Waddell5, Gail E. Darling5, Andrew 
Pierre5, Kazuhiro Yasufuku5, Marc De Perrot5, Marcelo Cypel5, Wei 
Xu3, Geoffrey Liu4
1Thoracic Surgery & Applied Molecular Oncology, University Health 
Network/Canada, 2Applied Molecular Oncology, University Health 
Network/Canada, 3Department Of Biostatistics, Ontario Cancer Insti-
tute, Princess Margaret Hospital/Canada, 4Medical Oncology, Princess 
Margaret Cancer Centre/Canada, 5Division Of Thoracic Surgery, Toron-
to General Hospital, University Health Network, University Of Toronto/
Canada
Background: Cigarette smoking, alcohol consumption and pre-
sence of co morbidities are important factors that affect health 
status and mortality in patients diagnosed with lung cancer. While 
the gold standard for presence or absence of co-morbidities is 
EPR, the gold standard for obtaining accurate data pertaining to 
health-related behaviours is by PRS. The purpose of this study is 
to ascertain, whether in the absence of patient self-reported data, 
health related behavioural data pertaining to cigarette smoking 
and alcohol consumption abstracted from EPR provides an accura-
te and reliable surrogate.
Methods: 731 lung cancer patients completed a PRS pertaining to 
information on their lifetime tobacco use, alcohol consumption and 
whether or not they had been diagnosed with certain co-morbid 
conditions. Relevant smoking, alcohol consumption and co-morbi-
dity data was collected independently from EPR. Kappa coefficient 
analysis was used to assess the agreement.
Results: can be seen in Table 1. Ever/never status for smoking 
showed almost perfect agreement (k=0.95) between PRS and EPR 
and surpassed all other health behavioural measures and all co-
morbidity agreement values. The calculation of pack-years from 
EPR and PRS showed substantial agreement (k=0.77); However, ca-
tegorizing the smoking status into current/ former / never, resulted 
in only moderate agreement (k=0.47). Alcohol ever/ never status 
agreement was moderate (0.44) with high sensitivity (0.90) but low 
specificity (0.50). The lung related co-morbidities like emphysema 
(k=0.41) and chronic bronchitis (k=0.28) showed fair agreement but 
with substantial missing data through EPR.  
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P1.23-001 THE REAL ROLE OF HEALTH CARE PROFES-
SIONALS IN PROVIDING SMOKING CESSATION COUN-
SELLING AMONG LUNG CANCER PATIENTS: PRELIMI-
NARY DATA
Stefania Vallone1, Sara Demichelis2, Simonetta Rapetti2, Benedetta 
Crida2, Elisa Gobbini2, Maria Vittoria Pacchiana2, Silvia Novello2
1Walce/Italy, 2Department Of Oncology, University Of Turin/Italy
Background: According to the World Health Organization, one 
hundred million deaths were caused by tobacco in the 20th cen-
tury and the expectation for 2030 is equal to 10 million deaths. 
Lung cancer is the leading cause of cancer death and in the United 
States cigarette smoking is responsible for an estimated 90% of all 
lung cancers. About 50% of lung cancer patients are current smo-
kers at the time of diagnosis and 11 to 48% of all smokers continue 
to smoke. Parsons et al. in a review of 10 studies suggest that smo-
king cessation after early stage lung cancer diagnosis improves 
prognostic outcomes and, despite evidences that smoking cessa-
tion is related with more effective treatment, reduced chemothe-
rapy and radiotherapy toxicities and a better prognosis, the belief 
prevails that treating tobacco dependence is less important than 
the other therapeutic approaches.
Methods: 122 lung cancer patients referring to the Thoracic 
Oncology Unit of the S. Luigi Hospital in Orbassano – Italy (31% 
of the total number of patients referring to this center in this pe-
riod of time) were prospectively and sequentially evaluated from 
02/01/2013 to 30/05/2013. In order to collect data, a dedicated 
15 question-anonymous survey was developed with the aim to 
understand if smoker or former smoker patients had received in-
formation by health professionals, about smoking cessation before 
or after the diagnosis, which reaction they had and which actions 
were adopted for quitting smoking.
Results: The median age of participants was 65 years or more, 
75% were men, 25% women. 27% were smokers, 73% former smo-
kers. Among active smokers, most patients (87.8%) reduced the 
number of cigarettes after being diagnosed. 45.4% of patients 
report not to have received information on smoking cessation by 
the healthcare professionals and among patients who received it, 
the majority (84.2%) declared a good or very good ability of health 
workers to understand the difficulty of quitting smoking. About 
76% considers positively the action of health care providers and 
a little percentage reports a warning and paternalistic attitude 
of them. 67.7% of patients who attempted to quit smoking, state 
the sudden termination as the most effective measure, more than 
the gradual reduction of cigarettes. Analyzing anti-smoking tech-
niques or therapies adopted, most patients declare not to resort to 
such methods: only 25% started using electronic cigarettes, 5.5% 
has used a nicotine replacement treatment, 4.1% is attending an 
antismoking clinic.
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P1.22-012 CONTINUOUS EXPOSURE TO CHRYSOTILE 
ASBESTOS CAN CAUSE TRANSFORMATION OF HUMAN 
MESOTHELIAL CELLS VIA HMGB1 AND TNF-Α SIGNA-
LING.
Fang Qi1, Gordon Okimoto1, Sandro Jube1, Andrea Napolitano1, 
Harvey Pass2, Rozalia Laczko1, Richard M Demay3, Ghazal Khan3, 
Maarit Tiirikainen1, Caterina Rinaudo4, Alessandro Croce4, Hai-
ning Yang1, Giovanni Gaudino1, Michele Carbone1
1University Of Hawaii Cancer Center/United States Of America, 2Nyu 
Langone Medical Center/United States Of America, 3University Of Chi-
cago Medical Center/United States Of America, 4Università Del Piemon-
te Orientale "amedeo Avogadro“/Italy
Background: Malignant mesothelioma is strongly associated with 
asbestos exposure. Among asbestos fibers, crocidolite is con-
sidered the most and chrysotile the least oncogenic. Chrysotile 
accounts for >90% of asbestos used worldwide but its capacity to 
induce malignant mesothelioma is still controversial.
Methods: Human mesothelial cells were exposed to crocidolite or 
chrysotile for a period of 48hr or 5 weeks, either in the presence of 
TNF–α or human macrophages in a co-culture system mimicking 
the process of recruitment and activation of inflammatory cells 
to sites of fiber deposition, which leads to the carcinogenesis of 
mesothelioma. Functional studies, as well as whole-genome wide 
expression profiling were performed to compare the molecular 
mechanisms and the carcinogenic potential of chrysotile and cro-
cidolite.
Results: We found that chrysotile and crocidolite exposures have 
similar effects on human mesothelial cells. Morphological and mo-
lecular alterations suggestive of epithelial-mesenchymal transition, 
such as E–cadherin down-regulation and β–catenin phosphoryla-
tion followed by nuclear translocation, were induced by chrysotile 
and crocidolite. Gene expression profiling data detected High-
Mobility Group Box-1 protein (HMGB1) as a key regulator of the 
transcriptional alterations induced by both chrysotile and crocidoli-
te. Crocidolite and chrysotile induced differential expression of 57 
out of 28,869 genes interrogated by oligo-nucleotide microarrays 
and 13 were HMGB1 targeted genes. Crocidolite-induced gene 
alterations were sustained, while chrysotile effects returned to 
background levels in five weeks. Similarly, HMGB1 release in vivo 
progressively increased for 10 or more weeks following crocidolite 
exposure, while returned to background levels eight weeks from 
chrysotile exposure.
Conclusion: Our results show that chrysotile has the capacity to 
induce, in HM, molecular changes associated to MM development 
similar to those induced by crocidolite, but these changes are 
short lasting. The data suggest that HMGB1 and TNF–α are key 
mediators of these processes for both crocidolite and chrysotile. 
However a continuous administration of chrysotile was required for 
inducing sustained HMGB1 levels. These data support the hypo-
thesis that the different bio-persistence of the two asbestos fibers 
influences their biological activities.
Keyword: Mesothelioma, HMGB1, asbestos, chrysotile
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Methods: Population: smokers enrolled in a LDCT screening study, 
age 60-74years, with >=30 pack-year smoking history. Smokers 
could enrol at any time during the LDCT study. Intervention: sin-
gle face-to-face counselling session on the day of attendance for 
LDCT screening plus audio cessation advice (on mp3 player) plus 
written quit materials. The individualised counselling session was 
given by a thoracic physician using motivational interview tech-
niques. Control: written quit materials only. Outcome: point pre-
valence self-reported smoking cessation at 1 year, confirmed with 
exhaled CO measurement (ECO) where available; ≥10ppm level 
indicating non-abstinence.
Results: Fifty-four participants were randomized (control group 
n=26, intervention group n=28). There were no statistically signifi-
cant differences between groups in age, sex, pack-years smoking, 
baseline CT scan findings, nicotine dependence score, self-belief 
in ability to quit (on a scale of 1-5, higher score indicating stronger 
belief) or education level although the intervention group reported 
a higher number of cigarettes smoked per day (table 1). Baseline 
LDCT scans were reported as positive if one or more non-calcified 
nodules >=4mm diameter were detected. The mean duration of 
interview was 26 minutes. Overall, ten participants (18.6%) repor-
ted smoking cessation (five had ECO confirmation and five did not 
have ECO testing); two patients (3.7%, one from each group) had 
missing data and were assumed to be continuing smokers; the 
remainder reported continued smoking. There was no difference 
in self-reported cessation between the intervention and control 
groups (17.8% vs 19.2% respectively). 
Conclusion: The 18% quit rate in this study is higher than reported 
background rates however the brief intervention provided did not 
increase quit rates above that of the control group. Smokers in this 
study reported moderate to high levels of nicotine dependence 
with extensive smoking histories, and, although motivated to quit, 
may require more intensive assistance to support smoking cessa-
tion.
Keywords: smoking cessation, randomized controlled trial, Lung 
cancer screening
Conclusion: The analysis of the study results underline that most 
lung cancer patients are interested in smoking cessation programs 
and although many of them receive advice and assistance by 
healthcare workers, the recourse to the use of techniques, drugs 
or access to specific clinic is very low. In Italy there are few centers 
offering counseling for smoking cessation, while in UK, Norway 
and Netherlands innovative interventions are available and onco-
logy nurses are essential in the identification of and intervention 
with patients who struggle with this dependence. This is a pivotal 
experience and other Italian and Spanish centers are already been 
involved in the questionnaire collection to get more complete and 
heterogeneous results
Keyword: lung cancer, counselling, smoking habits, smoking ces-
sation programs
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P1.23-002 A RANDOMIZED CONTROLLED TRIAL OF 
BRIEF COUNSELLING INTERVENTION AND AUDIO MA-
TERIALS FOR SMOKING CESSATION IN A LOW-DOSE CT 
SCREENING STUDY
Henry M. Marshall, Ian A. Yang, Linda Passmore, Elizabeth M. 
Mccaul, Rayleen Bowman, Kwun M. Fong
University Of Queensland Thoracic Research Centre, The Prince Charles 
Hospital/Australia
Background: Smoking cessation is a highly cost-effective health 
intervention. Embedding a smoking cessation program within 
a lung cancer screening program may significantly enhance the 
cost-effectiveness of screening. Smokers enrolling in Low-dose CT 
screening studies are motivated to quit but the best strategy to aid 
smoking cessation is not yet defined.
Table 1
Control Intervention p value
Women 10 10 ns
Men 16 18 ns
Education Up to High School 13 13 ns
Teriary 13 15 ns
Age, years, mean 64 64 ns
Age started smoking, years 16 17 ns
Cigarette consumption per day, n 23 30 0.03
Pack years smoking, mean 61 64 ns
FEV1 % predicted, mean 92 90 ns
Fagerstrom nicotine dependence score, mean 4.9 5.2 ns
Baseline CT Scan 
report
Negative 12 10 ns
Positive 14 18 ns
Self-belief in ability to quit 3.7 3.4 ns
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Stage + 
Anual total 
cost 
Anual total cost 
due to tobacco * 
LC I 45,787.2 30,219.5 
LC II 76,244.7 50,321.5 
LC III 928,261.2 612, 652.4 
LC IV 27,445,699.0 18,114,161.3 
Total 28,495,992.1 18,807,354.8 
Currency: USA dollar, 1 dollar = 13.0659 mexican pesos Ex-
change according to Banco de México(Banxico) information + 
Estructure established by the Lung Cancer experts of the INCan 
and the CIE-10 2009. *Obtained with tobacco attributable frac-
tion of LC, calculated for national IMSS; 0.66. Reynales et al. 
Conclusion: Health care costs for Non Small Cell Lung Cancer 
attributable to smoking represent an important and high cost to 
the INCan and the health sector of Mexico. These costs could be 
avoided if all the provisions of the Agreement-framework of the 
World Health Organization for tobacco control were implemented 
in our country.
Keywords: Non-Small Cell-Lung Cancer (NSCLC), Medical care 
costs, Mexico, Smoking
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P1.23-003 HEALTH CARE COSTS OF PATIENTS WITH 
NON SMALL CELL LUNG CANCER RELATED TO  
SMOKING IN THE NATIONAL CANCER INSTITUTE  
OF MEXICO
Oscar Arrieta1, Roger Quintana2, Francisco Corona3, Elma Correa3, 
Juan Zinser3, Dolores De La Mata3, Alejandro Mohar3, Gabriel Ahu-
mada3, Luz Myriam Reynales4
1Clínica De Oncología Torácica Y Laboratorio De Oncología Experimen-
tal, Instituto Nacional De Cancerología (INCAN)/Mexico, 2Instituto 
Nacional De Enfermedades Respiratorias (iner)/Mexico, 3Instituto Na-
cional De Cancerología (INCAN)/Mexico, 4Instituto Nacional De Salud 
Pública (insp)/Mexico
Background: Smoking is a public health problem in Mexico and 
the world, the economic impact in developing countries have not 
been fully documented. In our country there is a direct relationship 
between smoking and the 10 leading causes of death in adults. 
The purpose of this study was to estimate the direct costs of me-
dical care for lung cancer attributable to the tobacco habit in the 
National Cancer Institute of Mexico (INCAN).
Methods: The study was conducted at the National Cancer Institu-
te of Mexico (INCAN) during 2009. Costs were estimated from the 
perspective of services supplier based on the Cost of Illness me-
thod. An expert panel developed a diagnostic-therapeutic guide 
which integrated infrastructure, human resources, technology and 
health services provided at INCan. Costs were valued in Mexican 
pesos using an exchange rate of 1USD=13.0659 pesos.
Results: 297 incident cases of any type of Non Small Cell Lung 
Cancer during 2009 were analyzed. The annual average cost 
attributable to smoking per patient was 84,189 USD regardless 
of clinical stage. The 96% of the annual cost corresponded to 
stage IV. The annual total cost of Non Small Cell Lung cancer as-
sociated to tobacco habit at the INCan was 18, 807,354.8 USD. 
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P1.24-002 EFFICACY AND SAFETY OF ORAL PALONO-
SETRON COMPARED WITH IV PALONOSETRON ADMI-
NISTERED WITH DEXAMETHASONE FOR THE PREVEN-
TION OF CHEMOTHERAPY-INDUCED NAUSEA AND 
VOMITING (CINV) IN PATIENTS WITH SOLID TUMORS 
RECEIVING CISPLATIN-BASED HIGHLY EMETOGENIC 
CHEMOTHERAPY (HEC)
Meinholf Karthaus1, Csőszi Tibor2, Vito Lorusso3, Rajender Singh-
Arora4, Alexander Filippov5, Giada Rizzi6, Maria Elisa Borroni6, 
Giorgia Rossi6, Steven M. Grunberg7
1Department Of Hematology And Oncology, Klinikum Neuperlach/Ger-
many, 2G. Hetényi Hospital/Hungary, 3Istituto Tumori Giovanni Paolo 
Ii/Italy, 4Sujan Surgical Cancer Hospital And Amravati Cancer Found-
ation/India, 5Mbuz City Clinical Hospital/Russian Federation, 6Helsinn 
Healthcare Sa/Switzerland, 7The University Of Vermont/United States 
Of America
Background: Cisplatin is a cornerstone of lung cancer treatment 
and is associated with CINV, which impacts severely quality of life 
and may cause non-compliance. Palonosetron (PALO) is clinically 
superior and pharmacologically distinct from old-generation 
5-HT3 receptor antagonists. Non-inferiority of 0.50 mg oral PALO 
(O-PALO) in preventing moderately emetogenic CINV when com-
pared with 0.25 mg intravenous PALO (IV-PALO) has been demons-
trated.
Methods: This multicenter, multinational, randomized, double-
blind, parallel group study investigated the efficacy and safety of 
single doses of O-PALO and IV-PALO administered prior to HEC. 
Adult chemotherapy-naive patients with malignant solid tumors 
and adequate hepatic, renal and hematological function scheduled 
to receive cisplatin-based HEC were enrolled. Eligible patients re-
ceived O-PALO (0.50 mg) or IV-PALO (0.25 mg) with oral dexame-
thasone (Dex) 20 mg (day 1) followed by Dex 8 mg bid (days 2–4). 
The primary study objective was to demonstrate the non-inferiority 
of O-PALO vs IV-PALO (O-vs-IV-PALO) as a percentage of patients 
with complete response (CR: no emesis and no rescue medication) 
within the acute phase (0–24 hours after chemotherapy administra-
tion). Secondary objectives included the assessment of safety and 
tolerability of O-vs-IV-PALO and CR in the delayed (25–120 hours) 
and overall (0–120 hours) phases.
Results: Of 743 patients randomized 1:1 to receive O-vs-IV-PALO, 
739 received study medications and 738 were included in the full 
analysis set. The majority of patients were male (59.3%) and white 
(86.7%) with a median age of 59 years; 46.5% of patients had lung/
respiratory tract cancer. The CR rate in the acute phase was high 
for both treatment groups (O-PALO 89.4%; IV-PALO 86.2%). The 
difference in proportions (stratum-adjusted Cochran-Mantel-
Haenszel method) was 3.21% with two-sided 99% Confidence 
Interval (CI) from 2.74% to 9.17%. Non-inferiority of O-vs-IV-PALO 
was demonstrated since the lower limit of the 99% CI for the diffe-
rence in proportions was closer to zero than the pre-defined non-
inferiority margin of 15%. The same conclusion was obtained in 
the Per-Protocol population. Furthermore, results were similar with 
no statistically significant differences between treatment groups 
for delayed CR (O-PALO 76.2% vs. IV-PALO 74.8%, CMH odds 
ratio 1.09, 95% CI: 0.77–1.52, p=0.637) and for overall CR phases 
(O-PALO 73.7% vs. IV-PALO 70.2%, CMH odds ratio 1.20, 95% CI 
0.87–1.67, p=0.269). Treatment-emergent adverse events (TEAEs) 
were reported for approximately half of all patients in each treat-
ment arm. TEAEs related to the study drug were low (3.2% and 
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P1.24-001 VALIDATION OF A NOVEL SUPERIOR VENA 
CAVA SYNDROME IDENTIFICATION, CLASSIFICATION, 
AND MANAGEMENT ALGORITHM
Charles R. Thomas, Jr.1, Dave Hampton2, Christina Gamboa1, John 
Zatarain2, Brian Diggs2, Pierre R. Theodore3
1Radiation Medicine, Oregon Health And Science University/United Sta-
tes Of America, 2Surgery, Oregon Health And Science University/United 
States Of America, 3Surgery, University Of California San Francisco 
Medical Center/United States Of America
Background: Superior vena cava (SVC) syndrome results from 
great vessel extrinsic compression or intraluminal obstruction 
resulting in facial erythema, edema, or venous distension. This 
presentation can escalate into a life threatening condition. The 
Yale SVC classification system and management algorithm was 
proposed for tumor-related causes. We hypothesized its inclusion 
criteria may be limited in scope and not capture common causes 
and symptoms of SVC. The specific aim was to develop a SVC 
identification, classification, and management algorithm.
Methods: Retrospective data from Oregon Health & Science 
University pts diagnosed with ICD-9 code 459.2, compression of 
vein, between 2008-11 were collected. Pt demographics, vital 
signs, physical examination findings, hospitalization records, and 
outcomes were analyzed. ANOVA and Mann-Whitney U tests were 
utilized to assess significant between genders, p ≤ 0.05.
Results: The study population consisted of 207 pts; 157 were re-
moved due to compression of a vessel other than the SVC. SVC 
syndrome was secondary to a malignancy (n=30), fibrotic stricture 
(n=5), or indwelling catheter-related thrombus (n=11). Dyspnea 
(n=31), facial edema (n=24), and cough (n=18) were the most com-
mon physical examination findings. Patients who presented with 
cough or dyspnea secondary to a malignancy, without facial, neck, 
or extremity edema (n=7) or those with a post-procedure fibrotic 
stricture (n=5) or an indwelling catheter-related thrombus (n=11) 
did not meet the Yale classification system inclusion criteria.
Conclusion: A SVC classification system, which accounts for non-
oncologic causes and symptoms due to the mass effect on sur-
rounding tissues (vasculature, trachea, and esophagus) is a more 
comprehensive approach to SVC treatment.
Keywords: SVC Syndrome, cancer emergencies
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Results: Preliminary results show that there are clear differences 
in times to first specialist appointments, diagnosis and definitive 
treatment experienced by patients living in more regional and 
remote areas compared to patients from the metropolitan area. 
Patients from more regional and remote areas on average waited 
longer for their first specialist appointments e.g. Non Metro: N= 
103 60% of patients seen within 30 days of a written referral and 
28% were seen within 7 days. Metro: N= 60 78% patients seen 
within 30 days of a written referral and 50% were seen within 7 
days There was also a pattern of admitting patients from remote 
areas to have all diagnostic workup and commence treatment as 
an inpatient. Admitting patients from remote areas for diagnostic 
workup appears to have decreased time to treatment for this co-
hort of patients although the cost effectivenss to the health service 
is unknown.
Conclusion: Lung cancer is a devastating disease and has a poor 
prognosis. Lung cancer diagnostic and treatment pathways should 
be developed for patients living in more regional and remote are-
as of Queensland to ensure times to diagnosis and treatment are 
optimised. Potentially this will decrease emotional and financial 
strain suffered by patients and their families as well as being cost 
effective to health services.
Keyword: cancer, metropolitan, non metropolitan, patient journey
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P1.24-004 CHARACTERISTICS AND PROGNOSTIC ANA-
LYSIS OF PULMONARY SARCOMATOID CARCINOMA
Ying Liang1, Yongbin Lin2, Han Yang2, Guowei Ma2, Qingqing Cai1, 
Daofeng Wang3, Hao Long2, Jianhua Fu2, Lanjun Zhang2, Peng Lin2, 
Tiehua Rong2, Guangchuan Xu1
1Department Of Medical Oncology, Sun Yat-Sen University Cancer Cen-
ter/China, 2Department Of Thoracic Surgery, Sun Yat-Sen University 
Cancer Center/China, 3Intensive Care Unit, Sun Yat-Sen University 
Cancer Center/China
Background: Pulmonary sarcomatoid carcinoma (PSC) is a group 
of rare tumor .The incidence in previous reports is from 0.1% to 
4.7% of all lung malignancies. The recent 2004 WHO classification 
identified sarcomatoid carcinoma as a group of poorly differenti-
ated non-small cell lung carcinomas that contained a component 
of sarcoma or sarcoma-like(spindle or giant cell or both) differenti-
ation.There are 5 recognized subgroups: carcinosarcoma, spindle 
cell carcinoma, pleomorphic carcinoma, giant cell carcinoma, and 
pulmonary blastoma. Because of its rarity, the actual characte-
ristics and prognosis of PSC is controversial. Some investigations 
reported PSC having a much more aggressive clinical course and 
significantly poorer outcome in comparison with other NSCLC, 
even when disease was diagnosed in early-stage.But others failed 
to show a poor prognosis for PSC.
Methods: We studied a cohort of 69 patients with PSC who recei-
ved treatment in Sun Yat-Sen University Cancer Center from Janua-
ry 1991 to December 2011 retrospectively.We analyzed the clinical 
characteristics, immunohistochemical profiles, epidermal growth 
factor receptor (EGFR) mutation status, K-RAS mutation status, 
treatments, and prognosis.
Results: PSC mainly occurred in young, male patients with a his-
tory of smoking. Eleven patients were stage I, 26 patients were 
6.5% for O-PALO and IV-PALO respectively). Serious TEAEs related 
to the study drug occurred in 2 (0.5%) patients (O-PALO arm only); 
abdominal pain and constipation (one patient) and diarrhea and 
asthenia (one patient). No TEAEs related to study drug leading to 
discontinuation were reported.
Conclusion: Non-inferiority of O-PALO compared with IV-PALO 
was demonstrated. The results of the secondary efficacy endpoints 
supported the demonstration of non-inferiority based on the pri-
mary efficacy endpoint. For both O-PALO and IV-PALO the CR rate 
in the acute phase was >86% in patients undergoing HEC, nearly 
50% of whom had lung/respiratory tract tumors. The safety profile 
of O-PALO and IV-PALO were comparable, with no concerns.
Keywords: Palonosetron, Chemotherapy-induced nausea and 
vomiting, Non-inferiority with oral vs IV, Cisplatin-based chemo-
therapy
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P1.24-003 A COMPARISON OF THE LUNG CANCER 
JOURNEY - METROPOLITAN AND NON-METROPOLITAN
Barbara J. Page1, Alison Hanks2, Henry Marshall3, Ian A. Yang3, 
Rayleen Bowman3, Kwun Fong3
1Central Integrated Regional Cancer Service, Queensland Health/Aus-
tralia, 2School Of Medicine, The University Of Queensland/Australia, 
3Department Of Thoracic Medicine, The Prince Charles Hospital/Aust-
ralia
Background: Referrals and diagnostic pathways for people with 
symptoms of suspected lung cancer vary by where a person lives 
and ease of accessing services. Lung cancer diagnostic specialist 
and treatment services are mostly located in major cities, which 
can make access for people living in regional/rural and remote 
areas more difficult compared to major cities. Studies have shown 
that remoteness of residence is associated with an increase of lung 
cancer incidence and mortality. Hypothesis: The time required for 
the evaluation of suspected lung cancer is longer for people from 
regional/rural and remote areas compared to people living in met-
ropolitan Queensland. The aim of the research study is to describe 
and compare the journey from referral to diagnosis for people 
with suspected lung cancer from regional/rural and remote areas 
referred to The Prince Charles Hospital , a tertiary referral center, 
compared to metropolitan residents.
Methods: A retrospective study of consecutive people with sus-
pected lung cancer referred to The Prince Charles Hospital from 
December 2010 onwards will be reviewed. Data on patient de-
mographics and referral patterns will be collected from medical 
records and relevant Queensland Health patient information sys-
tems. Information systems include Queensland Oncology Online, 
Queensland Oncology Analysis System (OASys), The Viewer, Hos-
pital Based Corporate Information System (HBCIS), Practix, Out-
patient Services Information Management (OSIM), Picture Archive 
and Communication System (PACS) and Auscare. The following 
times will be compared between regional/rural/remote (defined as 
>50km from TPCH) and metropolitan (<50km from TPCH) patients: 
(A) from receipt of referral to first specialist appointment (FSA), (B) 
FSA to first pathological (cytology or histology) diagnosis (FPD), (C) 
FPD to first multidisiciplinary team discussion (MDT) and (D) MDT 
to first definitive treatment (FDT).
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Results: In August 2012 a 43-year-old man was hospitalized for 
a severe impairment in his left eye, onset abruptely the day be-
fore. In his medical history no trauma had occurred in the days 
before hospital admission. He had been reporting cephalea for 
one month, mostly in the left eye area, with metamorphopsias.He 
underwent a fluoroangiography,showing signs of left retinal de-
tachment due to multiple, non-primitive, retinal neoplasias, mostly 
in the left eye, but also in the right retina. CT-scan of the brain 
showed abnormal tissue in the left retina, with important choroi-
dal swelling. A thorax CT-scan revealed a 5-cm nodule in his right 
lung, median lobe, with enlargement of right mediastinal lymph 
nodes. Bone scan showed involvement of several bones, cervical 
and dorsal vertebral bodies, sternum. Biopsy was done through 
mediastinoscopy and adenocarcinoma of the lung was diagnosed. 
Genetic characterizazion was: EGFR and KRAS wild type, EML4-
ALK translocation, diagnosed by FISH. Clinical TNM at the diagno-
sis was T2aN2M1, and distant localizations were at the bone and 
bilateral retinal tissue, mostly on the left.The patient reported pain 
at his head, neck, dorsal back, severe asthenia; his left eye was off, 
he had been spending most of his daily time resting at bed since 
one week. He started to receive Crizotinib 250 mg BID orally at 
the beginning of October 2012. Treatment was well tolerated, with 
few G1 episodes of diarrhoea.In few weeks his symptoms impro-
ved with resolution of pain and asthenia, the patient returned 
progressively to a normal life. CT-scan showed a reduction of the 
main nodule in the right lung and mediastinal lymph nodes, partial 
response according to RECIST criteria. Surprisingly he reported an 
improvement in his left eye vision, he could see the light and some 
objects in the lower left eye field of view. Ophtalmologist reported 
a reduction of the temporal nodule in the right retina, while in the 
left retina there was an impressive reduction of the swelling; for 
that reason at the end of January 2013 the patient underwent sur-
gery to the left eye for the retinal detachment, gaining a complete 
left eye field of view. He is still on Crizotinib and no progression of 
disease has been documented up to now.
Conclusion: Crizotinib has induced an impressive response over 
retinal metastasis from NSCLC; the patient had an eye off at the 
diagnosis of NSCLC and on treatment gained a complete left eye 
field of view. Crizotinib is active over cerebral tissue like retina.
Keyword: Alk translocation, crizotinib, retinal metastasis
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P1.24-006 DISCUSSION AND ANALYSIS OF LUNG CAN-
CER AMONG YOUNG PEOPLE AT OUR HOSPITAL
Keisuke Imasaka1, Yuuki Kamata1, Hiroki Takakura1, Akio Komu-
ro1, Koichi Sunada1, Nobuyuki Hamanaka1, Miki Takahashi1, Kuni-
hiko Shimizu1, Yoshimasa Inoue2, Teruhiro Aoki2
1Department Of Respiratory Medicine, Saiseikai Yokohamashi Tobu 
Hospital/Japan, 2Department Of Thoracic Surgery, Saiseikai Yokohama-
shi Tobu Hospital/Japan
Background: The incidence of lung cancer among young people 
has been increasing in recent years. There are many difficulties 
in the diagnosis and treatment of this disease in young people, 
including the need for social support. Therefore, we attempted to 
clarify the clinical features of lung cancer in young people based 
on an observation of the clinical course.
Methods: A total of about 600 lung cancer patients visited our 
stage II, 23 patients were stage III, and nine patients were stage 
IV at the time of initial diagnosis. The pathology of our patients 
included pleomorphic carcinoma (4 patients), spindle cell carcino-
ma (11 patients), giant cell carcinoma (10 patients), carcinosarcoma 
(34 patients), and pulmonary blastoma (10 patients).Most patients 
received multimodality treatments and the majority had early 
stage disease. Fifty patients achieved a complete resection while 
eleven patients achieved only an incomplete resections for a vari-
ety of reasones.Eight patients had inoperable disease when they 
were diagnosed.Among them, 5 received palliative chemotherapy 
alone.Eleven patients were tested for EGFR mutations, and all were 
wild type. Two patients tested for K-RAS mutations and identified 
1 KRAS mutation.Five patients received EGFR tyrosine kinase 
inhibitor(EGFR-TKI) Gifitinib or Erlotinib as palliative salvage treat-
ment: three patients maintained stable disease for 2,3,5 months 
with gefitinib, respectively; and the other two patients developed 
progressive disease after receiving treatment with erlotinib for 2 ,4 
months , respectively. Median survival time (MST) was not reached, 
and the 5-year survival rate was 17.4%. Neither neo-adjuvant nor 
adjuvant chemotherapy improved patient survival for those with 
early stage disease. The patients without distant metastasis, with 
normal or higher BMI (≥18.5), with normal HGB, with smaller tumor 
size (≤4cm), and those who received complete resection had sig-
nificantly better OS (p<0.05). The patients with pleomorphic carci-
noma had much worse prognosis. In a COX regression model, sex, 
smoking status, BMI, LDH, tumor size, N stage, M stage, pathology 
and having received a complete resection were independent prog-
nostic factors (p<0.05).
Conclusion: PSC is a unique lung malignancy with poor prognosis. 
Patients receiving complete resection had better prognosis, likely 
a reflection of early stage disease. Neither neo-adjuvant nor adju-
vant chemotherapy improved patient survival for those with early 
stage disease. Future multi-center collaborations may be necessa-
ry to determine the optimal treatment.
Keywords: K-ras Mutation, Lung cancer, pulmonary sarcomatoid 
carcinoma, EGFR mutation
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P1.24-005 IMPRESSIVE RETINAL RESPONSE TO CRIZOTI-
NIB IN A PATIENT WITH NSCLC AND ALK TRANSLOCA-
TION
Alessandra Bearz1, Sandra Santarossa1, Valentina Da Ros1, Umber-
to Tirelli1, Antonio Manfre‘2, Ivana Sartor1
1Medical Oncology, Cro-IRCCS/Italy, 2Ophtalmology Dep., Pordenone 
General Hospital/Italy
Background: Adenocarcinoma of the lung EML4-ALK-rearranged 
are about 5-7% of all Non-Small-Cell-Lung Cancer (NSCLC). Treat-
ment for patients affected by metastatic adenocarcinoma of the 
lung harbouring an EML4-ALK translocation is the oral compound 
anti-Met, Crizotinib. Crizotinib is considered to be poorly active 
over cerebral localizations, due to a possible difficult CNS penet-
ration.
Methods: Herein we report a case of a patient with adenocar-
cinoma of the lung and ALK translocation, with bone and retinal 
metastases at diagnosis and impressive response to Crizotinib in 
all those sites.
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P1.24-007 LONG-TERM MAINTENANCE THERAPY WITH 
BEVACIZUMAB FOR CHINESE ADVANCED NON-SMALL 
CELL LUNG CANCER: A CASE REPORT
Zhe Liu, Wei Wu, Junfang Tang, Yuhua Wu, Qiyi Meng
Department Of Oncology, Beijing Chest Hospital, Capital Medical Uni-
versity/China
Background: Phase IV Safety of Avastin in Lung (SAiL) study was 
conducted to determine the safety and efficacy of first-line beva-
cizumab plus standard chemotherapy regimens in a broad patient 
population. Herein, we report a Chinese female patient enrolled in 
SAiL study who received chemotherapy and subsequent bevaci-
zumab maintenance for 39 months.
Methods: not applicable
Results: A 59-year-old female presented with a cough for 6 
months, and was admitted to our hospital on December 2007. 
CT scan showed multiple patchy shadows in both lungs, multiple 
nodular shadows in the right pleura, and mediastinal lymph node 
enlargement. CT-guided biopsy of the lower left lung showed 
adenocarcinoma, and biopsy of the right supraclavicular lymph 
nodes confirmed metastasis. The patient was a non-smoker, and 
was negative for EGFR and KRAS gene mutations, and negative for 
EML4-ALK rearrangement. From January, 2008, this patient was 
enrolled in the SAiL study and received bevacizumab(15 mg/kg) 
plus paclitaxel(175 mg/m2)/carboplatin(AUC=6) for 6 cycles. Re-
examination was performed at cycles 2, 4, and 6, and the results 
showed the target lesion was reduced by 9.4%, 32.9%, and 22.9%, 
respectively. The non-target lesions were stable and no new lesi-
ons were noted. The therapeutic efficacy was defined as PR, and 
re-examination was carried out every 6 weeks. After 6 cycles of 
chemotherapy, maintenance bevacizumab was begun (15 mg/kg) 
every 3 weeks and continued until March, 2011. A total of 42 cycles 
of bevacizumab were administered, for a total dose of 44,730 mg. 
CT in April 2011 showed the target lesion and the non-target lesi-
ons had increased, and new metastatic nodules were also found. 
The therapeutic efficacy was defined as PD. The last follow-up visit 
was in Apr 2012, PFS was 39 months and OS was 52 months. Du-
ring maintenance therapy with bevacizumab, the main side effects 
included proteinuria, secondary hypertension, and pneumothorax. 
Secondary hypertension was observed after 6 months of bevaci-
zumab, and controlled with nifedipine extended-release tablets. 
At 7 months from beginning bevacizumab, urinalysis showed pro-
teinuria (++) and bevacizumab maintenance was continued with 
no dose decrease. According to the protocol, a 24-h urine protein 
level was obtained every 3 weeks. When the urine protein level 
was <2,000 mg/24h, bevacizumab maintenance was continued, 
and if the level was ≥2,000 mg/24h, treatment was discontinued 
and re-examination of the urine protein level was carried out every 
3 weeks. Bevacizumab maintenance was continued when the 24-h 
urine protein decreased to <2,000 mg/24h. After 19 months of 
bevacizumab, the patient‘s urine protein level was >2,000 mg/24h, 
when treatment was discontinued. Between August 2009 and 
March 2011, bevacizumab maintenance therapy was stopped se-
veral times; the longest duration of discontinuation was 3 months. 
The maximal 24-h urine protein level was 3,926 mg/24h (grade 
3), which was noted 33 months after beginning bevacizumab. It is 
noteworthy that 12 months after discontinuation of bevacizumab, 
urinalysis still showed proteinuria (+). Spontaneous pneumothorax 
of her left lung occurred 36 months after initiation of bevacizumab 
and chemotherapy. The patient experienced no symptoms, and 
hospital during the six-year period from April 2007-March 2013. 
Out of these, we extracted patients of lung cancer who were un-
der the age of 40, and carried out a retrospective analysis of the 
data based on the medical records. We summarized the diagnosis, 
treatment and clinical course of the disease in this study populati-
on and then analyzed and discussed the characteristic features.
Results: There were a total of 10 cases of lung cancer among pa-
tients who were under the age of 40, of which 80% were male and 
20% were female, 80% were smokers and 20% were non-smokers. 
The reasons for the first hospital visit was the presence of clinical 
symptoms, e.g., chest pain, bloody sputum, etc., in 70% of the 
patients. On the other hand, the remaining 30% of the patients 
were asymptomatic at the first visit and had been referred to our 
hospital based on the detection of abnormalities on the chest x-ray 
during periodic medical examination. Their performance status at 
the time of diagnosis was as follows: “0” in 6 cases (60%), “1” in 2 
cases (20%), “2” in 1 case (10%), “3” in 1 case (10%), and “4-5”in 0 
case (0%). Histologically, 7 cases (70%) were diagnosed as having 
adenocarcinoma, and 3 cases (30%) as having other subtypes (in-
cluding unknown); classified by the disease stage, 70% patients 
had Stage 3A or more advanced cancer. Therefore, radical surgery 
could be performed in only 30%, of which one case showed pa-
thological stage3B, and developed recurrence. Chemotherapy was 
administered in 9 cases, and 6 cases received 3rd or more advan-
ced-line chemotherapy. Radiation therapy was administered in 7 
cases. The remaining patients received alternative therapy, such as 
immunotherapy and local intra-arterial injection therapy, which was 
performed in 3 cases, at another medical institution. Clinical psy-
chologist intervention was needed in 5 cases, all of which showed 
progression or recurrence.
Conclusion: Among young patients with lung cancer, the majority 
were male and smokers. Most of the patients had some symptoms 
at the first visit, although the performance status was generally 
good. There were many patients with adenocarcinoma and advan-
ced cancer, and many patients received 3rd line or more advanced-
line chemotherapy and radiation therapy. Alternative therapy, 
off-label in respect of insurance coverage, such as immunotherapy 
was also employed in many cases. In addition, there were many 
cases needing clinical psychologist intervention. Thus, there were 
many situations in which the patients required mental care for 
themselves and/or for their families. In conclusion, among young 
people with lung cancer, there were many who required a variety 
of medical and social interventions, including for the diagnosis and 
treatment, including palliative care.
Keywords: lung cancer in young patients, social intervention, clini-
cal psychologist, alternative therapy
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P1.24-009 PRIMARY GIANT AND DESTRUCTIVE HYDA-
TIDE DISEASE MIMICKING MALIGN TUMOR OF THE 
CHEST WALL: CASE REPORT AND LITERATURE REWIEVE
Abdullah Erdogan, Sirin Akdeniz, Gokcen Kenar, Yasin Toker, Abit 
Demircan
Thoracic Surgery, Akdeniz University/Turkey
Background: Hydatid disease, a naturally zoonotic disease, is fre-
quently encountered some region; such as Mediterranean Coun-
tries. It is generally occupied on the liver and lung; nevertheless, 
it can pose on all organs. Primary chest wall origin of the Hydatid 
disease is very rarely observed.
Methods: In this report; a sixty five years old female patient who 
has primary chest wall located, having ribs and soft chest wall 
tissues destruction giant hydatide disease has been presented 
due to its so many rare observations, atypical localization and 
mimicking primary chest wall tumor. She has chest and neck pain 
continuing for about 5 months. In the examination made, a remar-
kable finding was not encountered in the patient’s medical history 
and physical examination. In the computerized thorax tomography, 
it was reported that there were combined but multiple number of 
tumoral masses in the giant soft tissue density having dimensions 
of totally approximately 10*15*10 cm. It was reported that the lesi-
ons observed in the whole body PET/CT appearance tomography 
drawn were not active to the highest degree and their SUX max 
levels were at the level of 3-5 values.
Results: In the exploration, it was observed that the lesions were 
cystic structures having very high density. Additionally, the thorax 
wall muscle and soft tissues and the front lateral areas of 2,3 and 
4 ribs from above were totally necrotic and destructed. All de-
structive and necrotic tissues were removed and resected in the 
operation.
Conclusion: In the postoperative period, no complications de-
veloped and the patient was discharged with full recovery after 
10 days. Hystopathological examination was reported as necrotic 
hydatid disease. The patient is still under control in the postopera-
tive 3rd year and she has not symptoms.
after 1 month CT showed full expansion of the left lung.
Conclusion: not applicable
Keywords: Bevacizumab, chemotherapy, non-small cell lung  
cancer
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P1.24-008 ARE PATIENTS‘ NEEDS BEING MET AFTER-
HOURS? AN EVALUATION OF PHONE CALLS MADE 
AFTER HOURS FOR PATIENTS WITH THORACIC MALIG-
NANCIES.
Manali I. Patel1, Donna Williams2, Carla Wohlforth3, George A. 
Fisher4, Doug Blayney4, Heather A. Wakelee4
1Medicine, Division Of Oncology, Stanford University/United States Of 
America, 2Oncology, Stanford Cancer Institute/United States Of Ame-
rica, 3Ucla/United States Of America, 4Medicine, Division Of Oncology, 
Stanford University School Of Medicine/United States Of America
Background: Understanding phone calls that patients with lung 
cancer make after hours is important as it represents an opportunity 
to provide improved care for patients and their caregivers. Further-
more, better understanding of after- hours phone calls can help to 
influence ways to reduce healthcare spending. Therefore, we sought 
to evaluate the nature of after-hours calls initiated by patients and 
their caregivers to the thoracic oncology clinic from the hours of 
5pm-8am and on weekends.
Methods: The study is a retrospective analysis of 4 months of out-
patient phone calls made to the Stanford Cancer Institute during the 
weekends and hours of 5pm until 8am on weekdays. On-call after-
hours physicians documented who made the call, chief complaint, 
age, gender and the advice given. Phone calls were excluded from 
analysis if there was missing information regarding reason for call or 
advice given. Differences in proportions were analyzed by Fisher‘s 
exact test. A two-sided p value <0.05 was considered significant.
Results: There were a total of 271 phone calls made after hours 
by patients with lung cancer, however after exclusions, there were 
215 phone calls for analysis. The majority of phone calls occurred 
between the hours of 5pm and 11pm (n = 157; 73%) followed by 
daytime calls made during the weekend (n = 37; 17%). A majority 
of the phone calls were made by the patient (50%) with a slightly 
lower proportion made by a family member (46%). The majority of 
the patients who called were in their 50’s (29%) and female (54%). A 
high proportion of patients called for more than one chief complaint 
(30%) although almost all patients complained of more than one 
symptom on review of systems (95%). The main symptoms patients 
called for were cough (28%) followed by shortness of breath (27%). 
Of the phone calls made, 62% (133) were referred to the emergency 
room. Of those patients referred to the emergency department, 
77% (103/133) resulted in a hospital admission.
Conclusion: Most after-hours phone calls from patients with lung 
cancer are related to symptoms. A large proportion of patients who 
were referred to the emergency department subsequently required 
an admission. Future studies should evaluate whether there are ways 
to improve patient triage after hours and improve symptom control 
to prevent hospitalizations for these patient populations.
Keywords: healthcare delivery, symptoms, Lung cancer, after-hours
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P1.24-011 EXERCISE AS A STRATEGY FOR REHABILITATI-
ON / PALLIATION IN ADVANCED STAGE LUNG CANCER 
PATIENTS
Morten Quist
The University Hospitals Centre For Health Science, University Hospital 
Copenhagen/Denmark
Background: Potential beneficial effects of physical exercise for 
cancer patients remains to be demonstrated for lung cancer pa-
tients with advanced disease. Advanced lung cancer is incurable, 
and is the leading cause of cancer deaths world-wide. The aim of 
the treatment is to improve QoL and prolong life for these pati-
ents; therefore interventions with a focus on VO2peak and functio-
nal capacity are much needed as physical exercise has shown to 
have a positive impact on QoL. Kasymjanova et al 2009 has been 
shown that patients with advanced stage lung cancer significantly 
lowered their functional capacity after two series of chemotherapy. 
Moreover, patients with low functional capacity before starting 
chemotherapy had significantly more disease progression and 
significantly shorter lifespan, compared to those with a higher 
functional capacity. Another study from Jones et al 2011 supports 
this and found that functional capacity is a strong independent 
predictor of survival in advanced NSCLC that adds to the predic-
tion of survival beyond traditional risk factors, which may improve 
risk stratification and prognostication in NSCLC. Based on these 
results this study seeks to examine the effect of a 6-week exercise 
intervention for advanced lung cancer patients.
Methods: Patients with inoperable NSCLC (IIIb-IV) and SCLC (ED) 
were screened for eligibility. Aerobic capacity (VO2peak), muscle 
strength (1RM), functional capacity (6MWD), lung capacity (FEV1), 
HRQOL, cancer related symptoms (FACT-L) and anxiety and de-
pression (HADS) were measured at baseline and 6 weeks.
Results: One-hundred-two patients were included and 72 patients 
undergoing concurrent systemic treatment were eligible for ana-
lysis. There was a significant increase in aerobic capacity - VO2peak 
(p=0.014) and functional capacity- 6 MWD (p=0.006). There was 
significant improvement in strength (P<0.001). There was a signifi-
cant change in the parameter for ‘emotional wellbeing’ (p=0.000) 
with a moderate effect size of 0.30 and ‘social well-being’ 
(p=0.000) with a small effect size of 0.23. However, there was no 
significant improvement or decline in general QOL. Theere was a 
significant reduction in anxiety (HADS-A) (p=0.008) a significant 
change in Psychological Morbidity (HADS-T) (p= 0.023). However, 
there was no significant change in Depression (HADS-D) (p=0.124).
Conclusion: The results from this study shows that it is beneficial 
for advanced lung cancer patients to participate in a 6 weeks exer-
cise intervention. The significant reduction in anxiety has not been 
found in other studies with advanced lung cancer patients, further 
research will show the clinical relevance of these findings.
Keywords: Advanced lung cancer, Aerobic capacity, functional 
capacity
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P1.24-010 SUCCESSFUL RECHALENGE OF ERLOTINIB IN 
PATIENT WITH NON-SMALL CELL LUNG CANCER - RE-
GAIN OF TYROSINE KINASE SENSITIVITY. CASE REPORT
Ewa Chmielowska, Maciej Studzinski, Anna Krause, Mariusz Kwi-
atkowski
Clinical Oncology, Oncology Center/Poland
Background: Activating mutation in EGFR gene is a predictive 
marker for treatment response for tyrosine kinase inhibitors (TKI), 
such as gefitinib and erlotinib. These drugs are approved for treat-
ment in any line of advanced stage EGFR-mutated non-small cell 
lung cancer. The TK domain EGFR mutations are more frequently 
found in Asian population than Caucasian, and are more prevalent 
in women than in men. There is scarce data regarding reintroduc-
tion of TKI after developing drug resistance during previous treat-
ment.
Methods: We report on the case of 56-years old Caucasian, non-
smoking woman diagnosed with cancer of the right lung. In 2004 
patient underwent lobectomy of lower right lobe with mediastinal 
lymph nodes sampling – histopathology showed a grade 2 lung 
adenocarcinoma, pathological stage was pT2N1; no distant metas-
tases were found. Adjuvant chemotherapy has been applied – pa-
tient received 4 cycles of PG regimen (Cisplatin with Gemcitabine); 
radiotherapy was not used. In March 2008, three and a half years 
after completion of primary treatment regional recurrence was 
documented by thoracic CT scan – mediastinal lymph nodes and 
parietal pleura were involved. Sequential chemoradiotherapy was 
used – patient received 4 courses of pemetrexed and radiotherapy 
(RTH) 44 Gy in 22 fractions – partial remission was obtained. Six 
month after RTH completion, in April 2009, the CT scan demonst-
rated the progression – large lytic lesion on sternum appeared and 
mediastinal nodes increased in size.
Results: Because primary tumor was positive for mutation in EGFR 
exon 19 by polymerase chain reaction, erlotinib treatment in dose 
150 mg/d was initiated. The dose has been reduced to 100 mg 
after 4 courses due to toxicity – persistent and recurrent genitouri-
nary infection. After dose reduction no adverse events were repor-
ted. Erlotinib treatment was continued for 18 months until disease 
progressed in November 2010 - lytic lesion in sternum increased 
and became symptomatic. Palliative radiotherapy on sternum was 
applied and third line of systemic treatment was introduced – six 
cycles of paclitaxel and carboplatin. Result of treatment was stabili-
zation by RECIST 1.0 criteria and bone pain was gone. For the next 
12 months CT scans were performed every 12 weeks – during that 
period there was no need for anticancer treatment. On February 
2012 progression was confirmed – dissemination to both lungs. 
Because of reports in literature suggesting that EGFR-TKI drug 
resistance may be result of non-mutational, reversible mechanism 
that can be overcome by temporarily withholding TKI usage (so 
called “chemotherapy holidays”), decision was made to restart 
treatment with erlotinib. Treatment with reduced dose of 100 mg/d 
was initiated in March 2012 and is continued 15 months later. Every 
three months CT scans are performed – after initial shrinkage there 
is a tendency to increase tumor size, but progression criteria by 
RECIST are not met. 60 months after disease recurrence patient is 
in good condition, fully active and no adverse events were noticed.
Conclusion: The intermittent therapy of TKI inhibitors may be be-
neficial for some patients with lung cancer, given they have reversi-
ble TKI-resistance.
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P1.24-013 PROPHYLAXIS AGAINST PULMONARY 
THROMBOEMBOLISM WITH UNFRACTIONATED HEPA-
RIN FOR THE PATIENTS UNDERGOING PULMONARY 
RESECTION FOR LUNG CANCER
Toshiki Takemoto, Masaya Nishino, Hiroshi Mizuuchi, Katsuaki 
Sato, Kenichi Suda, Takuya Iwasaki, Kenji Minami, Tetsuya Mit-
sudomi
Department Of Surgery, Division Of Thoracic Surgery, Kinki University, 
Faculty Of Medicine/Japan
Background: Pulmonary thromboembolism (PTE) is a well-reco-
gnized potentially fatal complication after lung cancer surgery. 
In Japan, PTE had been relatively uncommon. However, it has re-
cently been increasing probably due to changes in lifestyle. In our 
institution, deep vein thrombosis (DVT) is intensively screened by 
measuring preoperative D-dimer. Unfractionated heparin (UFH) is 
routinely administered to the patients having lung cancer surgery 
in addition to mechanical prophylaxis using elastic stockings(ES) 
or intermittent pneumatic compression devices(IPC). Here, we 
retrospectively evaluated efficacy and safety of these strategies to 
prevent PTE.
Methods: We retrospectively reviewed charts of 531 patients who 
underwent lung cancer surgery from January 2009 through April 
2013. The patients who were deemed high-risk for DVT (those with 
past history of thrombosis, or those with elevated preoperative D-
dimer (>1.0µg/ml), or those with varicose veins in their lower ext-
remities), in principle, underwent venous ultrasonography of lower 
extremities. Among high-risk patients, those with or without DVT 
were classified as a group A and B, respectively. Those who failed 
to undergo venous ultrasonography were referred to as a group 
C. Those who did not meet above-mentioned criteria for high-risk 
group were classified as a group D. As perioperative prophylactic 
measures against PTE, all the patients in the group A wore ES from 
two days before surgery to one month after surgery. The patients 
also received continuous intravenous UFH (6000 units per day) im-
mediately after surgery to postoperative day (POD) 1, and then re-
ceived subcutaneous UFH (5000 units twice daily) from POD 2 until 
the patients became ambulatory. The patients in groups B, C and 
D wore ES during and after surgery. In addition, IPC was applied 
intraoperatively. The patients also received continuous intravenous 
UFH (6000 units per day) immediately after surgery to POD 1.
Results: Number of patients in each group were 14, 41, 87, and 
389 in the group A, B, C, and D, respectively. In the group A, none 
was diagnosed as having PTE preoperatively. Eleven patients 
received postoperative UFH. However, two patients with intratho-
racic adhesions did not receive UFH to avoid excessive postopera-
tive bleeding. One patient with coronary artery complications un-
derwent perioperative anticoagulation therapy. In this group, one 
patient without postoperative UFH administration due to adhesion 
developed symptomatic PTE. One patient was diagnosed asymp-
tomatic exacerbation of DVT by ultrasonography one week after 
surgery despite UFH administration. In the groups B, C and D, 473 
patients received postoperative UFH. Twenty-one patients with 
intraoperative bleeding or intrathoracic adhesions did not receive 
UFH. Twenty-three patients with coronary artery complications 
underwent perioperative anticoagulation therapy. In these groups, 
none developed symptomatic PTE. In 4 patients of 473 who recei-
ved UFH, UFH was discontinued before POD 1 due to increase in 
sanguineous drainage without further complication.
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P1.24-012 HOW TO BUILD A BETTER LUNG CANCER 
SUPPORT GROUP: BEST PRACTICES FROM AUSTRALIA, 
THE UNITED KINGDOM AND THE UNITED STATES
Maureen Rigney1, Linda Dornan2, Amy Copeland1, Kerrie Callag-
han3, Allison Hatton3, Rosemary Taylor4
1Lung Cancer Alliance/United States Of America, 2The Roy Castle Lung 
Cancer Foundation/United Kingdom, 3Lung Foundation Australia/Aust-
ralia, 4Sydney Adventist Hospital/Australia
Background: Research shows that people diagnosed with lung can-
cer experience high levels of distress and that their unmet physical 
and emotional needs are greater than those diagnosed with other ty-
pes of cancer. One significant unmet need for lung cancer patients is 
social support. An important way for patients to connect and to know 
they are not alone is through face-to-face support groups. The bene-
fits to cancer patients attending such groups go beyond support and 
may include increased feelings of control and confidence and a decre-
ase in depression and distress. For many reasons, the majority of lung 
cancer patients prefer lung cancer-specific support groups rather than 
those for all cancers. However, facilitators report that starting and 
maintaining lung cancer groups is often a challenge. As a result, the 
number of such groups is insufficient to meet the need. Cancer cha-
rities play an important role in fostering lung cancer support groups 
by directly running groups or supporting those who do. Toward the 
goal of increasing the number and viability of these groups, a study 
was conducted to understand the challenges related to starting and 
sustaining lung cancer support groups and the solutions successful 
facilitators have found to overcome those challenges.
Methods: To understand the challenges of lung cancer specific 
support groups and how to overcome them, a literature review of 
research about cancer support groups was conducted. Lung cancer 
support group faclitators in Australia, the United Kingdom and Aus-
tralia were surveyed and in-depth interviews were conducted on a 
sample. Program evaluation data from 37 groups in the UK was also 
included.
Results: An international guide to lung cancer support groups best 
practices was developed. The guide provides solutions suitable for all 
facilitator skill levels and addresses resource constraints that facilita-
tors may face. The solutions presented are designed to assist anyone 
interested in running a successful lung cancer support group anywhe-
re in the world. A second phase of the research will involve formative 
research to determine desirability and feasibility of adopting best 
practices in a sample of control groups in the United States that were 
not involved in the initial survey and interviews. Those results will be 
presented at future conferences.
Conclusion: People with lung cancer can benefit from in-person 
support groups in immeasurable ways but many do not have access 
due to the lack of available groups. While challenges to initiating and 
maintaining successful lung cancer specific support groups exist, 
expert facilitators have found creative ways to advertise their groups, 
keep participants engaged and their groups thriving. With the infor-
mation provided, professionals at charities and treatment facilities 
interested in starting lung cancer support groups will know what to 
consider as they organize their groups and will have at the ready tried 
and true techniques for making their groups successful. Charities not 
able to run their own groups will learn the importance of dissemina-
ting this information to facilitators as well as understand how to best 
support them to reach the goal of increasing the number of lung 
cancer-specific support groups.
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P1.24-015 CHEMORADIOTHERAPY-ASSOCIATED MYE-
LOSUPPRESSION: ANALYSIS OF RISK FACTORS FOR PA-
TIENTS WITH NON-SMALL CELL LUNG CANCER
Ufuk Yilmaz, Burcu Yalcın, Ceyda Anar
Dept Of Chest Disease, Izmir Dr. Suat Seren Chest Disease And Surgery 
Training And Research Hospital/Turkey
Background: Concurrent chemoradiotherapy (CRT) is standard 
treatment for patients with stage III non–small cell lung cancer 
(NSCLC). Myelosuppression can be a significant problem in con-
current CRT, but its risk factors remain largely unkown. The aim of 
the present study was to assess clinical and biological parameters 
obtained before concurrent CRT to define the risk factors for mye-
losuppression in patients with locally advanced NSCLC.
Methods: We retrospectively analyzed 81 patients with NSCLC 
who received concurrent platinum-based chemoradiotherapy 
between January 2008 and December 2012. A total of 78 patients 
(96.2%) received etoposide (50 mg/m2, intravenously (IV) on days 
1-5, 29-33) plus cisplatin (50 mg/m2, IV, on days 1,8,29, and 36) 
and 3 patients (3.8%) treated docetaxel (20 mg/m2/w, IV, on weeks 
1-8) plus cisplatin (20 mg/m2/w, IV, on weeks 1-8) concurrently with 
thoracic radiotherapy to a total dose of 40-66.6 Gy. The risk factors 
were examined for their association with myelosupression (grade 
3 or 4 leukopenia, neutropenia, thrombocytopenia or anemia) by 
logistic regression analysis.
Results: Grade 3 or higher neutropenia, leukopenia, thrombocy-
topenia, or anemia occurred in 51.8, 53.0, 8.6, and 7.4 % of the 
patients, respectively. Multivariate analysis revealed that the risk 
factors for neutropenia were performance status (odds ratio [OR] , 
3,196 ; p=0,032; 95 % confidence interval [CI], 1,104-9,524), white 
blood cell count (OR, 3,250; p=0,023; 95% CI,1,173-9009 ) and 
pretreatment creatinine level (OR, 3,325; p=0,018; 95% CI,1,228 - 
8,999 ). On multivariate analysis, white blood cell count (OR, 3,311; 
p=0,027; 95% CI, 1,148-9545 ) was found as significant risk factor 
for CRT-induced leukopenia. No significant association was found 
between patient’s characteristics and anemia or thrombocytopenia
Conclusion: This information on grade 3-4 neutropenia and leuko-
penia is considered to contribute significantly to its safe and effec-
tive use of concurrent chemoradiotherapy for treatment of locally 
advanced NSCLC.
Keywords: chemoradiotherapy, Lung cancer, risk factors,  
Neutropenia
Conclusion: Only one patient of 531(0.19%) developed sympto-
matic PTE after surgery. This patient had had preoperative DVT. 
Therefore, we regard that our strategies were effective to prevent 
PTE at least for patients without preoperative DVT. However, it 
may be necessary to apply even more intensive prophylactic mea-
sures for patients with evidence of preoperative DVT or PTE.
Keywords: Lung cancer, perioperative management, pulmonary 
thromboembolism
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P1.24-014 METASTATIC ANGIOSARCOMA PRESENTING 
AS HAEMOPTYSIS AND SEVERE PAIN ON THE BACK
Mediha G. Ortakoylu1, Ceyda Aslan2, Ayşe Bahadir1, Figen Alkan1, 
Asuman Kara1, Cem Ar2, Orhun Ç. Taşkın3, Emel Çağlar1
1Yedikule Chest Disease And Thoracic Surgery Training Annd Research 
Hospital/Turkey, 2Istanbul Training And Research Hospital/Turkey, 
3Pathology, Istanbul University/Turkey
Background: Angiosarcoma is a rare malignant neoplasm of the 
vascular or lymphatic endothelium that accounts for 2% of all soft-
tissue sarcomas.Angiosarcoma in the lung is a rare disorder and 
is usually attributable to metastasis from primary site such as skin, 
soft-tissue, heart, breast or liver.We describe a case of pulmonary 
metastatic angiosarcoma who presented with episodic haemopty-
sis and severe pain on the back.
Methods: A 21-year-old male was admitted with history of recur-
rent hemoptysis and pain on the his back for two months.There 
were no other constitutional symtoms.Thoracic and abdominal 
computed tomograhy scan revealed left hilar lymphadenopathy 
and bilateral multiple nodules; the spleen was enlarged and shown 
multipl hypodense lesions.Hilar lymphadenopathy was sampled 
by real time convex prob EBUS TBNA and CT guided transthoracic 
fine needle aspiration was performed.Definitive diagnosis couldnt 
be obtained with both procedures.PET scan revealed the wides-
pread FDG uptake bone marrow, liver and spleen and lung. The 
patients underwent bone marrow biopsy and histopathological ex-
amination of yields reported angiosarcoma.Immunohistochemistry 
(CD 31 positivity) confirmed the diagnosis of angiosarcoma.
Results: The patient showed progressive deterioration and anemia 
and thrombositopenia and hemoperitoneum owing to spontane-
ous liver rupture appeared.He was managed with repeated blood 
transfusions but he died twenty-seventh days after admitted hos-
pital.
Conclusion: We presented a rare angiosarcoma case with aggres-
sive clinical course and a fatal prognosis for the patient.
Keywords: angiosarcoma, haemoptysis, pulmonary metastasis
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P1.24-017 MONITORING OF PATIENTS UNDER TREAT-
MENT WITH SINGLE FRACTION OF SBRT IN LUNG LESI-
ONS.
Dina Najjari1, Arturo Navarro1, Maria Dolores Arnaiz1, Ramon 
Ramos2, Samantha Aso3, E Garcia1, Ferran Guedea1, Manuel Galde-
ano1, Rafael Piñeiro1, Felipe Cardenal4
1Radiation Oncology, Hospital De Belllvitge/Spain, 2Thoracic Surgery, 
Hospital De Bellvitge/Spain, 3Pulmonology, Hospital De Bellvitge/Spain, 
4Medical Oncology, Institut Català D’Oncologia/Spain
Background: Oligometastasic pathology has become a usual pa-
thology present in our clinical routine activity.Although invasive 
treatments are available, SBRT is a non invasive therapy which 
can be a viable treatment of choice.We introduce our preliminary 
study of pulmonary lesions treated using a single fraction of 34Gy 
OBJECTIVES: The main goal of this report is to demonstrate that a 
fraction of 34Gy is a viable and attainable therapy to treat lesions 
in oligometastasic patient’s lungs
Methods: Seven patients with 7 pulmonary lesions were treated 
with single dose of 34Gy. Inclusion criteria were : lesion size smal-
ler than 2 cm , distance from the chest wall and main bronchus tree 
higher than 2 cm , primary tumor under control in PET scan. Mean 
Age 61.57y (r39-82), Gender distribution 3 women and 4 men, 
Histology: 4 cases (57.14% were Metastasic lesions from Colon), 1 
metastasic from Adenoid Cystic, 1 Adenocarcinoma from Lung and 
1 NSCLC. All patients underwent 4DCT for contouring. Inmobili-
zation was done by thermoplastic mask (Lorca Marin) . Dosimetric 
characteristics: Mean volume of GTV 1.46cc (r 0.6-4.1), mean volu-
me of PTV 11.29cc (r7.1-22.2), D Max oesophagus 5.06 (r 2.6-8.4), 
D max Heart 4.05 (r6.86-17.0), D max trachea 5.12 Gy (r 0.3-11.1), 
Dmax skin 10.98(r7.0-14.4). Patients were treated using True Beam 
machine. In 6 cases treatments were delivered without flattering 
filter beams
Results: After 6 months of follow up (r 6-2.19) no toxicity higher 
than grade 2 was detected. Local control rates and survival are 
100%, 100% respectively. To sum up, even this is a preliminary 
study, seems than long term results can show us a new perspective 
in these oligometastasic patients. 
Conclusion: not applicable
Keyword: oligometastasic pathology, single fraction of SBRT, Lung 
cancer, toxicity
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P1.24-016 SINGLE AGENT ORAL ETOPOSIDE FOR EL-
DERLY AND INFIRM ADVANCED NON SMALL CELL 
LUNG CANCER : A REASONABLE THERAPEUTIC OPTI-
ON
Krishnakumar Rathnam, Kirushnakumar Kosanam Subrama-
niam
Medical Oncology, Meenakshi Mission Hospital And Research Centre/
India
Background: The use of chemotherapy has been shown to in-
crease the effectiveness of best supportive care (BSC) in elderly 
patients with non-small cell lung cancer (NSCLC). The use of Intra-
venous chemotherapy ( IV ) has many times been difficult in elderly 
patients or patients with poor performance status owing to fear of 
toxicity.We studied the effectiveness of a non toxic regimen with 
single agent oral chemotherapy with etoposide plus best suppor-
tive care versus best supportive care alone in subjects with advan-
ced non small cell lung cancer unfit for IV chemotherapy
Methods: Eighty five cases of advanced non small cell lung cancer 
and ECOG performance status of 2 to 3 , unfit for IV chemotherapy 
as per treating physician‘s discretion were included in the study. 
Forty three patients received chemotherapy with Tablet Etoposide 
50 mg once daily for 14 days along with best supportive care ( BSC 
)every 21 days for a maximum of 8 cycles in responding patients. 
Regimen was re challenged on progression. The remaining recei-
ved BSC only.
Results: We measured at least 1 of the following outcomes: Ove-
rall survival ( OS ) or treatment-related mortality. Overall, patients 
that received chemotherapy plus BSC had significant longer OS 
than those that received BSC alone (HR 0.75; 95%CI, 0.68–0.82; 
P,0.001). Additionally, chemotherapy plus BSC as compared to BSC 
alone resulted in a 24% RR reduction (95%CI: 10–38; P = 0.001) 
in 6-month mortality, 10% RR reduction (95%CI: 8–15; P,0.001) in 
12-month mortality and 6% RR reduction (95%CI: 2–9; P = 0.02) in 
2-year mortality. Toxicity was not significantly greater in patients 
who received chemotherapy plus BSC.
Conclusion: Chemotherapy with single agent oral etoposide plus 
BSC is a non toxic therapeutic option in infirm and elderly NSCLC 
patients unfit to receive intravenous chemotherapy.
Keywords: NSCLC,infirm,oral etoposide, NSCLC,infirm,Etoposide, 
Elderly,NSCLC,chemotherapy,best supportive care, Elderly infirm 
NSCLC chemotherapy
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P1.24-019 THERAPEUTIC AND PREVENTIVE EFFECTS OF 
APREPITANT FOR CHEMOTHERAPY-INDUCED NAUSEA 
AND VOMITING IN JAPANESE PATIENTS WITH THORA-
CIC MALIGNANCIES
Sumiyo Ito1, Ikuto Tsukiyama1, Masahiko Ando2, Masayo Tanaha-
shi1, Rie Hamanaka3, Kenji Kosaka3, Ayako Matsubara3, Masaki 
Nishimura3, Hiroyuki Tanaka3, Nobuhiro Asai3, Norihito Yokoe3, 
Ayumu Takahashi3, Kenji Baba3, Katsuhiko Matsuura1, Etsuro 
Yamaguchi3, Akihito Kubo3
1Department Of Pharmacy, Aichi Medical University Hospital/Japan, 
2Center For Advanced Medicine And Clinical Research, Nagoya Univer-
sity Hospital/Japan, 3Department Of Respiratory Medicine And Allergo-
logy, Aichi Medical University Hospital/Japan
Background: Neurokinin-1 receptor antagonist (NK1RA) in addi-
tion to 5-hydroxytryptamine receptor antagonists (5HT3RA) and 
dexamethasone (Dex) is recommended for chemotherapy-induced 
nausea and vomiting (CINV) in highly emetogenic chemotherapy 
(HEC). It had been also reported that 40-60% of patients recei-
ving HEC had not experienced significant nausea and/or vomiting 
before NK1RA became available. In 2010 NK1RA aprepitant was 
introduced for CINV prophylaxis in Japan. However, what propor-
tion of patients receiving emetogenic chemotherapy need NK-
1RA, and whether all patients undergoing HEC truly need NK1RA 
remain unknown. Increasing medical costs due to uniform use of 
NK1RA is another concern. The primary objective of this study is 
the prevalence of patients who require aprepitant. Therapeutic 
and preventive effects of aprepitant on CINV induced by HEC or 
moderately emetogenic chemotherapy (MEC), and quality of life 
(QOL) regarding CINV are secondary objectives. We conducted 
this single-Institute study before fully introducing aprepitant into 
clinical practice in our institute.
Methods: From July 2011 to January 2013, 96 consecutive patients 
receiving HEC or MEC, with age ≥ 20, able to use Japanese lan-
guage, and with written informed consent, were enrolled onto the 
study, and 77 patients were analyzed who received ≥ 2 courses in 
the same chemotherapy regimen. 5-HT3RA and Dex were adminis-
tered to prevent CINV. Aprepitant was administered to treat CINV 
in the first course when CINV occurred, or administered to prevent 
CINV in the second course. All patients who experienced CINV in 
the first course received prophylactic aprepitant from the second 
course. QOL regarding CINV was assessed by Functional Living 
Index of Emesis (FLIE). Numerical rating scale (NRS) was used to 
assess the severity of nausea. This study was approved by the Insti-
tutional Review Board of Aichi Medical University.
Results: Patient characteristics were: median age (range), 67 (38-
85); gender (male/female), 64/13; cancer type (lung cancer/thymic 
tumor/other), 72/3/2; chemotherapy regimen (HEC/MEC), 28/49. 
Aprepitant was not administered in 57% and 88% of patient who 
received HEC and MEC, respectively. In patients treated with ap-
repitant (n=18), therapeutic use of aprepitant after CINV occurred 
(n=9) decreased average NRS for nausea and average frequency 
of vomiting per day from 7.44 to 5.44 (p=0.10), and 2.11 to 0.11 
(p=0.03), respectively. Prophylactic use of aprepitant in the se-
cond course (n=18) increased the proportion of patients with no 
significant nausea from 6% (first course) to 50% (second course, 
p=0.007), and those with no vomiting from 33% to 89% (p=0.002). 
In contrast, in patients who did not require aprepitant (n=59), pro-
portion of patients with no significant nausea and those with no 
vomiting did not change during the 2 courses (76% to 76% [p=1.00] 
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P1.24-018 CHARACTERISTICS OF PATIENTS WITH LUNG 
CANCER WITH VENOUS THROMBOEMBOLISM: A POST 
HOC ANALYSIS OF 676 PATIENTS ENROLLED TO THE 
CLOT TRIAL
Kannan Subramaniam1, Wing Lowe1, Seth Woodruff2, Joseph Hal-
wagy3
1Pfizer Australia/Australia, 2Medical Affairs, Pfizer Inc/United States 
Of America, 3-, Pfizer Australia/Australia
Background: Patients with cancer, especially those with lung cancer 
have an elevated risk for venous thromboembolism (VTE). Impor-
tantly, the adjusted risk of VTE is estimated to be 30 % higher among 
lung cancer patients undergoing chemotherapy with the majority of 
VTE events occurring within 6 months of initiation of chemotherapy. 
The presence of a VTE event is significantly associated with an in-
creased risk of mortality1 1Huang et al, J Thromb Thrombolysis. 2012 
Nov;34(4):446-56. This study examines the baseline characteristics of 
patients with lung cancer with VTE, of the participants enrolled to the 
CLOT trial - a six month multi-centre study involving 676 cancer pati-
ents with acute, symptomatic, proximal deep-vein thrombosis (DVT), 
pulmonary embolism (PE), or both who were randomly assigned at 1:1 
ratio to receive dalteparin sodium subcutaneously once daily for five 
to seven days and a coumarin derivative for six months (target interna-
tional normalized ratio, 2.5) or dalteparin sodium alone for six months2 
2Lee et al N Engl J Med 2003;349:146-53.
Methods: Post-hoc analysis aimed at interrogating the descriptive 
fields of the Intention-To-Treat (ITT) CLOT trial population was con-
ducted to determine the quantitative and qualitative base line charac-
teristics of patients with lung cancer at randomisation.
Results: Of the 676 patients with cancer randomised 
into the CLOT trial, 90 patients had cancer of the lung. 
Conclusion: Baseline characteristics of patients with lung cancer with 
VTE as randomised in the CLOT trial indicate they were more likely to 
be males, under 65 years of age, had no previous VTE to the diagno-
sis of their lung cancer, were receiving treatment for their lung cancer, 
with surgical pathology and chronic immobilisation not being a signi-
ficant risk factor for VTE. Review of published literature also suggests 
that in comparison to the non cancer population, patients with lung 
cancer experience significant level of pulmonary embolism3 3Shinaga-
re et al Cancer. 2011 Aug 15;117(16):3860-6
Keywords: CLOT, cancer, thromboembolism, VTE
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P1.24-021 BRONCHOPLASTY AND BRONCHOANGIO-
PLASTY FOR PRIMARY NON-SMALL CELL LUNG CAN-
CER
Naoya Yamasaki, Tomoshi Tsuchiya, Keitaro Matsumoto, Takuro 
Miyazaki, Gou Hatachi, Koichi Tomoshige, Hideyori Sengyoku, 
Hironosuke Watanabe, Ryouichiro Doi, Ryusuke Machino, Takeshi 
Nagayasu
Division Of Surgical Oncology, Nagasaki University/Japan
Background: The objective of this study was to evaluate the ope-
rative mortality, morbidity, and survival of bronchoplasty and bron-
choangioplasty for non-small cell lung cancer. Multivariate analysis 
was done to determine potential prognostic factors for both pro-
cedures based on our 27-year single-center experience.
Methods: Between January 1985 and March 2012, 204 broncho-
plastic procedures were done in 1978 patients who underwent 
lung resections for non-small cell lung cancer at Nagasaki Uni-
versity Hospital. After excluding 18 carino-plasty patients and 13 
wedge angioplasty of pulmonary artery, 173 patients (141 broncho-
plasty and 32 broncho-angioplasty) were included.
Results: In the bronchoplasty group, the postoperative morbidity 
was 29% (41/141) and the 90-day postoperative mortality was 5.7% 
(8/141), while in the broncho-angioplasty group the postoperative 
morbidity was 28% (9/32) and the postoperative mortality was 
15.6% (5/32). Eleven patients (6.4%) experienced bronchopleural 
fistulas. Multivariate analysis demonstrated that induction therapy 
(p=0.047) and combined multiple organ resection (p=0.012) were 
risk factors for postoperative anastomotic complication. The 5-year 
survival rate for all patients was 46.3%. The 5-year survival rate was 
69.5% in patients with pathological stage I disease. In patients with 
stage II disease, the 5-year survival rate was 34.7%. In patients with 
stage III-IV disease, the 5-year survival rate was 33.2%. The survi-
val rate in stage I disease was significantly better compared with 
other stage disease (p<0.0003). Multivariate analysis indicated that 
the type of operation (bronchoplasty versus bronchoangioplasty), 
postoperative complications, histologic type (squamous cell carci-
noma versus non squamous cell carcinoma), and pN status (N0-1 
versus N2-3) were significant factors affecting survival.
Conclusion: Both bronchoplasty and broncho-angioplasty are 
useful for the treatment of patients with non-small cell lung cancer 
and should be performed in stage I. However, careful patient se-
lection is mandatory in patients with advanced tumor stages and 
in those with nonsquamous cell carcinoma, especially if broncho-
angioplasty is being considered.
Keywords: bronchoplasty, bronchoangioplasty, non-small cell lung 
cancer
and 92% to 92% [p=1.00], respectively). In patients who required 
aprepitant, aprepitant use significantly improved FLIE scores in the 
second course while these did not change in patients who did not 
require aprepitant.
Conclusion: More than half of patients receiving HEC and 88% 
of patients receiving MEC did not require aprepitant. Aprepitant 
showed significant therapeutic and preventive effects on CINV in 
patients who truly need it.
Keywords: aprepitant, therapeutic effect, CINV, NK-1 receptor 
antagonist
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P1.24-020 EFFICACY AND SAFETY OF CARBOPLATIN 
AND PEMETREXED FOR THE FIRST LINE TREATMENT 
OF UNFIT PATIENTS TO RECEIVE CISPLATIN WITH 
NONSQUAMOUS NON SMALL CELL LUNG CANCER
Gaspar Esquerdo1, Jose Luis Fírvida2, Javier Garde3, Jose Manuel 
Cervera1, Mc Areses2, Enrique Barrajon1, Macarena Espinoza1, 
Rafael Peiro1, Belen Montiel1, Jose Garcia3
1Hospital Clínica Benidorm/Spain, 2Complejo Hospitalario Ourense/
Spain, 3Arnau De Vilanova/Spain
Background: Pemetrexed activity is synergistic with both carbo-
platin and cisplatin in chemonaive NSCLC patients. Two phase II 
Pem plus carboplatin trials have confirmed the doublet’s activity 
in NSCLC and response rates were 31% and 24% (Scagliotti and al 
2003, Zinner and al 2005). Carboplatin is a good alternative in unfit 
patients suggesting a balanced benefit/risk profile when combined 
with Pem.
Methods: Sixty-four patients unfit to receive cisplatin with measu-
rable stage III-B IV NSCLC, received at least one dose of chemo-
therapy. Pem 500 mg/m2 over 10 min on day 1 with folic acid and 
vitamin B12 supplementation followed by carboplatin AUC 5 on 
the same day were given every 21 days for 4- 6 cycles. Primary 
endpoint was safety and efficacy ( progression free survival)
Results: Sixty four patients received at least one dose of chemo-
therapy. Median age was: 71.3 yrs (86−44,3), 90,6% of patients 
presented comorbilities , mainly cardiopathy (73,4%) . Stages IIIb: 
15,6%, IV: 84,4%. Non squamous cell carcinoma: 100.% (adenocar-
cinoma: 92,2%, large cell carcinoma: 7.8% )Male 76,6%, female 
23,4%. The median number of administered cycles was 4. Median 
progresion free survival and overall survival will be presented at 
the meeting. Grade 3/4 toxicities related to study drugs were: 
asthenia 6.1%, skin 3.1%, dyspnea 3.1% .Hematological grade 3/4 
events were: neutropenia: 6.1%, thrombocytopenia: 1,6%, anemia: 
14.1%. 10,9% of patients need dose reduction
Conclusion: In first line NSCLC, the combination of Pem plus car-
boplatin could be a valuable treatment alternative in unfit patients 
to recive cisplatin. Anemia is the most frequent toxicity in this com-
bination.
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Keywords: stigma, mHealth, symptom management,  
communication
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P1.24-023 ENVOY SERVICE, A FORM OF DIGNITY THE-
RAPY, DESIGNED TO ASSIST COMMUNICATION AND 
PALLIATIVE CARE DECISION FOR PATIENTS WITH AD-
VANCED CANCER: A PRELIMINARY REPORT.
Sang Won Shin1, So Yeon Oh2, Hyun Jung Jun2, Yeul Hong Kim1, 
Seung Tae Kim1, Chul Yong Kim3
1Medical Oncology, Korea University Medical Center/Korea, 2Medial On-
cology & Hematology, Seoul Medical Center/Korea, 3Radiation Oncology, 
Anam Hospital, Korea University Medical Center/Korea
Background: Patients with advanced cancer experience various 
difficulties to communicate and express regarding their wishes, 
personal values and end-of-life care options. These difficulties 
could be serious obstacles to initiate early palliative care decision 
and consequently lead to unwanted and/or futile invasive end-of- 
life care. There is an urgent need to develop innovative approach 
to address suffering and distress and improve communication 
between patients and family members, care givers’ and medical 
providers.
Methods: “Envoy Service” was designed to assist patients‘ own 
words delivered to family members, friends, care givers in pro-
cessed and edited form. The assigned patients were interviewed 
by trained dialogist (2 nurses and 3 clinical psychologists), in indivi-
dualized and narrative style for 30 to 60 minutes per session up to 
3 sessions. During the interview, pre-structured questioned regar-
ding palliative care and end-of-life care options. Additionally, pa-
tients are offered to speak what matters most to them, things they 
would most want remembered. The whole interview process could 
be videotaped, or voice recorded, or writes down by the dialogist, 
or in combination upon the patients’ own choices. Once interview 
sessions completed, the dialogues were reshaped into narrative 
form and carefully edited in the form of video-audio clip recorded 
in CDs, or letters. The final products were returned to patients to 
bequeath to a friend or family member. The responses of patients 
and family members and caregivers’ and medical provider’s opini-
ons were collected and examined.
Results: Twelve patients with advanced cancer (age 40-68, median 
57, 5 female, 7 male, 4 lung cancer, 2 head and neck cancer, 5 GI 
cancer, 1 Gy cancer) received “Envoy service”. It was offered in two 
hospitals; five patients in Korea University Medical Centre (univer-
sity Hospital) and seven patients in Seoul Medical Centre (General 
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P1.24-022 MHEALTH TOOL FOR LUNG CANCER - DEVE-
LOPMENT AND DEMONSTRATION
Janine K. Cataldo
Physiological Nursing, University Of California, San Francisco/United 
States Of America
Background: With the rise of technology in health care, the use 
of electronic or virtual games provides new possibilities for cost 
effective and individually tailored health care interventions. The 
advantages of virtual games are the ability and opportunity to in-
corporate ethnic and cultural diversity and sensitivity, access hard 
to reach populations, provide motivation and positive feedback for 
behavior change, and provide information for personalized cancer 
symptom management. Lung cancer is the leading cause of can-
cer death in both men and women and is associated with greater 
levels of psychological distress than any other cancer. Stigma has 
been found to have a major role in the distress and health outco-
mes of lung cancer patients. Lung cancer stigma (LCS) is based 
on the belief that one caused their own cancer (ie, smoking) and 
negatively impacts patient outcomes. Lung cancer patients report 
inadequate communication with physicians about important topics 
such as: symptom experience, prognosis, treatment preferences, 
practical and financial worries, spiritual concerns, and hospice 
care. Stigma is a factor that contributes to poor patient-clinician 
communication and inappropriate referrals. Although palliative 
care consultation is recommended throughout the trajectory of 
lung cancer, it is underutilized. Understanding factors that influ-
ence communication and referral decisions, such as stigma, can 
improve integration of symptom assessment and support and pal-
liative care into lung cancer management. Currently there are no 
interventions to decrease LCS and improve lung cancer patient-cli-
nician communication. The goal of this project was to develop, the 
mHealth TLC an interactive, immersive 3-dimensional iPad health 
game that allows individuals to experience first person virtual visits 
with their clinicians and to conduct initial usability testing.
Methods: Because of the innovative nature of an immersive 3D 
game for lung cancer patients, iterative development/validation 
was used. Usability was assessed with participation satisfaction 
questionnaires and focus groups. Four areas were explored: be-
lievability and value; technical issues; transparency of goals; and 
game outcomes.
Results: Positive usability results for the mHealth TLC included 
believable game narrative, minimal game experience interference, 
participant generation of game and intervention goals, and indica-
tions that mHealth TLC will be able to influence lung cancer patient 
outcomes.
Conclusion: mHealth TLC can provide engagement and experien-
tial learning by delivering important information about lung cancer 
and symptom management and by providing lung cancer patients 
the opportunity to practice a new communication strategy. 
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honeycombing) was also assessed. We performed the correlation 
between HRCT findings and presence of acute exacerbation. We 
used binary logistic regression analysis and student t-test with 
SPSS 21.0 version as statistics.
Results: Of the 78 lung cancer patients, six patients experienced 
postoperative acute exacerbation (7.7%). Smoking history and PFT 
between two groups were not significantly different except age 
and gender. Inter- and intra-reader correlation coefficient were 
0.496~0.928 and 0.667~0.936/0.657~0.949, respectively, good to 
fair. Honeycombing (p=0.001; OR, 1.243; CI, 1.087~1.422) and fib-
rotic score (p=0.007; OR, 1.188; CI, 1.047~1.347) and abnormal area 
(p=0.042; OR, 1.059; CI, 1.002~1.119) were significantly high in AE 
group.
Conclusion: Physicians should consider the high extent of honey-
combing, as well as high fibrotic score in CT, a potential risk factor 
for acute exacerbation after pulmonary resection for lung cancer.
Keywords: idiopathic interstitial pneumonia, Acute exacerbation, 
surgical biopsy pathology, Lung cancer
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P1.24-025 PALLIATION OF MALIGNANT PLEURAL EFFU-
SION BY PLEURODESIS A COMPARATIVE STUDY
Abdelrahman M. Abdelrahman1, Fatma Aboulkasem2, Rabab 
Gaafar3, Ahmed El Bastawisy2, Maha Yahia2, Hala Aziz2
1Surgery, National Cancer Institute,cairo/Egypt, 2Medical Oncology, 
National Cancer Institute/Egypt, 3Nedical Oncology, National Cancer 
Institute/Egypt
Background: Sever dyspnea secondary to persistent or recurrent 
malignant pleural effusion in terminally ill cancer patients offers 
great challenge to the treating physicians. It has a significant ne-
gative impact on the quality of life which is already poor. The main 
goal of treating physician is symptomatic relief of dyspnea with 
the least possible tools. A variety of agents can be used to induce 
pleurodesis. Multiplicity of those agents indicates that none of 
them is optimal. Whatever the agent used, it should achieve high 
success rate with no or minimal side effects and tolerability by the 
patient. Great care should be taken to properly select patients with 
malignant effusion for pleurodesis to minimize treatment failure. 
Unsuccessful pleurodesis my be more problematic and difficult to 
treat due to conversion of the free effusion into encysted one. The 
aim of this work is to evaluate the success rate of palliative treat-
ment of malignant pleural effusion comparing talc powder ( either 
through poudrage or slurry) versus Mistletoe preparation (Viscum 
Fraxini 2). To evaluate also the tolerability of both preparations, 
coast and the complication rate.
Methods: This is a retrospective non randomized study during 
the period between (Jan. 2008 – Feb 2011). Sixty patients with 
malignant pleural effusion were included. Patients were divided 
into 2 groups (30 patients were included in each group) according 
to the method of pleurodesis used. The first group included pa-
tients in whom talc powder ( either through poudrage or slurry) 
was used for pleurodesis. The second group included patients 
with Mistletoe preparation (Viscum Fraxini 2) used as pleural scle-
rosant. CT scan of the chest was ordered for all patients prior to 
treatment. Criteria for potentially successful pleurodesis: There 
should be no pleural septations or loculation (if present based on 
Hospital) respectively. Interview with dialogist took usually 30-60 
minutes (median 40 min) in each session and 1-3 (median 1) sessi-
ons. All twelve patients expressed their emotional feeling regar-
ding their illness, fear of death and dying, briefly reviewed their 
own lives and personal appreciation to their family members and 
medical providers. Regarding the end-of-life care options, 6 pati-
ents choose non-invasive care and 3 patients wished to be chosen 
by their care giver and physician’s discretion, 3 patients did not 
evidently spoke about. The edited products, 1 CD, 11 letters were 
returned to patients to bequeathed to family members. Seven 
patients reported feeling satisfied. Five patients indicated that the 
service heightened their physical and psychological well-being. 
One dialogist reported that completion of services, patients were 
looked “ready” for dignified end-of-life. Four patients died, 3 wit-
hout any invasive care, but 1 in ICU.
Conclusion: "Envoy service” a form of dignity therapy, is feasible 
and could be a novel approach to address distress and suffering 
of patients with advanced cancer. It might help patients to com-
municate with family members and caregivers and leads to initiate 
early palliative care and avoid unnecessary invasive procedure near 
end-of-life.
Keywords: early palliative care, end-of-life, communication, digni-
ty therapy
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P1.24-024 ACUTE EXACERBATION OF IDIOPATHIC IN-
TERSTITIAL PNEUMONIA AFTER RESECTION OF LUNG 
CANCER: INVESTIGATION OF PRE OPERATIVE CT PRE-
DICTOR
Mi Young Kim1, Sang Young Oh1, Dong Soon Kim2, Chang Min 
Choi3, Sang-We Kim4
1Radiology And Research Institute Of Radiology, Asan Medical Center/
Korea, 2Pulmonary And Critical Care Medicine, Asan Medical Center/
Korea, 3Oncology, University Of Ulsan College Of Medicine, Asan Medi-
cal Center/Korea, 4Oncology, Asan Medical Center/Korea
Background: To investigate the ‘preoperative CT predictor’ of 
postoperative acute exacerbation (AE) of lung cancer with under-
lying idiopathic interstitial pneumonia (IIP) compared to those wit-
hout AE as control.
Methods: The 78 pulmonary resections for lung cancer with 
underlying IIP in a single tertiary center, 72 males (92.3%) and 6 
females (7.7%), aged from 47 to 80 years old, with a median age 
of 66 years were retrospectively included. This study was appro-
ved by the Institutional Review Board and informed consent was 
waived. Underlying IIP was retrospectively assessed histological 
(n=46, 59.0%) and clinico-radiological (n=32, 41.0%) according to 
ATS/ ERS guidelines. We divided them in two groups, one acute 
exacerbation (AE group) and the other without acute exacerbation 
(non AE group) after operation of lung cancer. Records of patients 
who experienced postoperative acute exacerbation were extrac-
ted from the clinical data-base. Two independent expert chest 
radiologists analyzed CT findings in two times (four data sets) for 
one month interval. We analyzed age, gender, smoking history and 
pulmonary function test (PFT) differences between two groups. 
We analyzed HRCT findings as follows; extent of reticulation, ho-
neycombing, ground-glass opacity, and emphysema in overall 
extent with area percentage. Fibrotic score (sum of reticulation and 
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lung cancer webpages (2315), direct referrals to the National 
Smokers Quitline (4), likes/ comments/ shares/views of social 
media posts (9741) and of a live Q&A via Facebook (21,449). 
Conclusion: During the campaign, the National Cancer Helpline 
received more preventative and undiagnosed enquiries about lung 
cancer than any other cancer. The majority of contacts were female 
and aged 50-59yrs; our target audience. A sharp rise in webpage 
views was noted and social media interaction exceeded expecta-
tions considering the young audience. Using traditional as well as 
online advertising mediums, PR and social media platforms also 
worked well to reach a wide audience and campaign evaluations 
show traction with both young and old. DeliNKIng lung cancer 
from tobacco and going with an empowering message meant that 
more people engaged with the campaign and it was deemed a 
success. 
Keyword: Lung Cancer, Awareness, Campaign, Evaluation.
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P1.24-027 INTRAPULMONARY RECURRENCE AFTER 
COMPUTED TOMOGRAPHY-GUIDED PERCUTANEOUS 
NEEDLE BIOPSY OF STAGE I LUNG CANCER
Yeo Kon Kye1, Young-Du Kim2, Hyun Woo Jeon1, Myung-Jun Kim3
1Bucheon St. Mary‘s Hospital, College Of Medicine, The Catholic Univer-
sity Of Korea/Korea, 2Thoracic And Cardiovascular Surgery, Bucheon 
St. Mary‘s Hospital, College Of Medicine, The Catholic University Of 
Korea/Korea, 3Department Of Physiology, College Of Medicine, The 
Catholic University Of Korea/Korea
Background: CT-guided percutaneous needle biopsy is a useful 
diagnostic procedure that is used for the evaluation of pulmonary 
nodules, and is regarded as a relatively safe procedure. Although 
tumor seeding along the biopsy needle tract after CT-guided per-
cutaneous needle biopsy is an extremely rare complication with a 
reported incidence of 0.06% in Japan, it can lead to unnecessary 
procedures or fatal outcomes. Most of the reported cases of im-
plantation metastasis after CT-guided percutaneous needle biopsy 
were about the tumor seeding, which occurred in the chest wall 
or the pleura; however, we present here a case of intrapulmonary 
recurrence after CT-guided percutaneous needle biopsy.
Methods: A 70-year-old woman was admitted to our hospital for 
the evaluation of a growing lung mass. She had undergone a tho-
CT scan should be lysed pre pleurodesis). The lung should not be 
entrapped and fully inflated (the presence of residual space will 
convert the free effusion into encysted one). Response definition 
: Successful pleurodesis is defined as no recurrence of effusion on 
clinical and radiologic follow-up 4 weeks after pleurodesis.
Results: There were 34 males and 26 females , the mean age was 
59 years, right sided effusion was present in 37 patients (61.6%) 
and left sided effusion in 23 patients (38.4%) . All patients presen-
ted with grade I-III dyspnea and 15% also presented with chest 
pain. In Group I: Twenty three patients had successful pleurodesis 
(76.7%), while 7 patients showed treatment failure. Treatment rela-
ted complications developed in 4 patients. In Group II : Pleurode-
sis was successful in 19 patients (63.3%)(After 2, 6, 7, 8 injections), 
treatment failure developed in 11 patients after 6 injections. Four 
patients developed allergic reactions and two patients suffered 
empyema.
Conclusion: Both methods used for pleurodesis were well tolera-
ted by the patients with good success rate with minimal compli-
cations. Talc offers higher success rate, less coasty and also con-
sidered single use therapy while the use of Mistletoe preparation 
needs repeated injections.
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P1.24-026 LUNG CANCER - YOU CAN AVOID IT, GET IT, 
SURVIVE IT; AN EVALUATION OF THE IRISH CANCER 
SOCIETY‘S ANNUAL LUNG CANCER AWARENESS CAM-
PAIGN FROM 2011 - 2013.
Aishling Deegan1, Aoife Mc Namara2
1Communications Department, Irish Cancer Society/Ireland, 2Cancer 
Information Service, Irish Cancer Society/Ireland
Background: Each year almost 2,000 new cases of lung cancer are 
diagnosed in Ireland (1). It is the biggest cancer killer for Irish men 
and women (2) and Irish women rate fifth highest in incidence of 
lung cancer in Europe (3). In 2011 the Irish Cancer Society (the So-
ciety) launched a three year advertising and PR campaign to raise 
awareness of lung cancer in a novel and engaging way. The Society 
wished to move away from the grim, grey, tobacco led and often 
frightening messages and imagery normally associated with lung 
cancer. The campaign directed people to the Society’s National 
Cancer Helpline. 
Methods: The Society undertook market research in 2011 and 
2013 to evaluate the impact of the campaign. The objective of the 
quantitative survey was to evaluate public awareness of lung can-
cer as well as prompted awareness of the campaign. This survey 
was nationally representative and 1,000 interviews were comple-
ted. The helpline database was also used to record the number of 
lung related enquiries during the campaign. 
Results: Just under three million adults recall some media at-
tention on the issue of lung cancer in February (2013). This is up 
considerably on 2011 levels (2.1 million Vs. 2.8 million). Whilst 
just over six in ten are aware of some media attention in Ja-
nuary, this figure rises to seven in ten among smokers. In total 
34,342 enquiries about lung cancer were recorded during the 
two week campaign. This included calls and emails to the Na-
tional Cancer Helpline (167), walk in enquiries to the daffodil 
centres in hospital settings (670), unique views of the Society’s 
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statistical sample size. Of patients who needed pleurodesis for 
malignant pleural effusion, the patients who had full expansion 
of lung within 24 hours after pleural drainage, expected life span 
more than 2 months, and Karnofsky performance scale of more 
than 50 were enrolled. Efficacy was evaluated by the amount of 
pleural effusion in chest x ray taken four weeks after pleurodesis 
(WHO guidelines of response – complete response; few effusion, 
partial response; lesser than 50% of initial pleural effusion, no re-
sponse, or not evaluable), and changes of clinical symptoms and 
karnofsky performance scale. Safety was evaluated by serious 
adverse event (SAE) and changes of kidney and liver function (AST, 
ALT, BUN, or creatinine) after pleurodesis. A follow-up period was 
4 weeks after last pleurodesis.
Results: A total of 68 patients were enrolled which 7 of them 
dropped out. Median age of patients was 60 years old [range, 34-
80]. The number of male and female was 23 and 38, respectively. 
49(80.3%) had complete response, 11(18.0%) had partial response, 
and one patient had no response. Mean response rate of reference 
for other agents in chemical pleurodesis was 64%. The mean kar-
nofsky performance scale before the pleurodesis was 79.5 and the 
mean karnofsky performance scale on fourth week after pleurode-
sis was 81.9. SAE definitely related to ABNOVAviscum® Injection 
was presented in two cases; dyspepsia and generalized muscle 
weakness. Both of these cases were recovered before the end 
of this study. SAE probably related to ABNOVAviscum® Injection 
was seven cases; dyspepsia, fever (3), constipation, vomiting, and 
fatigue. These seven cases were recovered before the end of this 
study as well. No other toxicity related to ABNOVAviscum® Injec-
tion was presented in laboratory findings such as AST, ALT, BUN, 
or creatinine during a follow-up period.
Conclusion: This study suggests that chemical pleurodesis using 
ABNOVAviscum® Injection for malignant pleural effusion might be 
an effective and safe modality.
Keywords: malignant pleural effusion, chemical pleurodesis
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P1.24-029 METASTATECTOMY FOR LUNG CANCER AND 
LUNG RESECTION FOR METASTASES - OUR EXPERI-
ENCE
Swamyvelu Krishnamurthy, Prashanth Shivappa, Vasu Reddy 
Challa
Surgical Oncology, Kidwai Memorial Institute Of Oncology/India
Background: Metastectomy for lung cancer had shown varied 
results some showing survival benefit and in some studies as only 
palliation. But unlike metastatectomy for lung cancer , lung re-
section for metastases had shown definitive role atleast in some 
selected cases like colorectal cancer, renal cell carcinoma, breast 
cancer, etc. Here we would like to share our experience conside-
ring the above mentioned topics.
Methods: Our study was a retrospective analysis of medical re-
cords from January 2006 to March 2012 in a single unit in a teritiary 
care center in India. Clinicopathological features, treatment, prog-
nosis and disease free survival were assessed.
Results: Fourteen patients underwent metastatectomy in lung and 
five patients underwent metastatectomy for lung cancer (Fig.1). 
racoscopic lobectomy of the right upper lobe 17 months ago, after 
CT-guided percutaneous needle biopsy, using a 22-gauge needle, 
which had confirmed the lung mass as an adenocarcinoma. She 
was discharged uneventfully and had been followed-up without 
additional treatment because there was no evidence of metastasis 
to the lymph nodes or to the distant organs. On the follow-up, a 
CT scan of the chest revealed a small lung nodule (0.5 cm in the 
longest diameter), which was located in the superior segment of 
the right lower lobe. Six months later, a repeat CT scan of the chest 
showed that the nodule had grown up to 1.2 cm.
Results: On admission, we performed successful CT-guided per-
cutaneous needle biopsy of the lesion of the right lower lobe, and 
pathologic examination revealed an adenocarcinoma, which took 
the same characteristics as the previous diagnosis from the right 
upper lobe, which suggested a recurrence. We suspected implan-
tation metastasis, and reviewed the previous biopsy procedures. 
Finally, we found that the biopsy needle had passed through the 
superior segment of the right lower lobe to target the right upper 
lobe lesion, and concluded that the new lesion might be an im-
plantation metastasis, as a result of tumor seeding along the bio-
psy needle tract. She underwent segmentectomy of the superior 
segment of the right lower lobe, because there was no evidence of 
distant metastasis. She recovered well and was followed-up wit-
hout additional treatment as before.
Conclusion: We present a case of implantation metastasis that 
occurred in the pulmonary parenchyma, after a CT-guided per-
cutaneous needle biopsy of stage I lung cancer. We also present 
here a lesson from this case that the biopsy needle should not pass 
through different anatomical compartments other than the target 
compartment, and this strategy should be kept in mind, especially, 
when the lesion is located deeply.
Keywords: CT-guided biopsy, Recurrence
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P1.24-028 CHEMICAL PLEURODESIS USING MISTLETOE 
EXTRACTION (ABNOVAVISCUM® INJECTION) FOR MA-
LIGNANT PLEURAL EFFUSION
Jeong Su Cho1, Yeong-Dae Kim1, Hoseok I1, Kook-Ju Na2, Yong Jik 
Lee3
1Department Of Thoracic And Cardiovascular Surgery, Pusan Natio-
nal University Hospital, Pusan National University Hospital/Korea, 
2Chonnam National University Hwasun Hospital/Korea, 3Department 
Of Thoracic And Cardiovascular Surgery, Ulsan University Hospital/
Korea
Background: Malignant pleural effusion is common in patients 
with advanced cancer. Several treatment modalities for malignant 
pleural effusion have known and of those, chemical pleurodesis 
can be considered for malignant effusion that do not respond to 
chemotherapy, radiotherapy, or therapeutic thoracentesis. Howe-
ver, which agent is more effective and safe in chemical pleurodesis 
is not yet clear.
Methods: This study was designed as a single arm, multicenter, 
and open-label phase III clinical trial to evaluate efficacy and safety 
of chemical pleurodesis using ABNOVAviscum® Injection (Abnoba 
GmbH. Germany). Reference of other agents in chemical pleuro-
desis was investigated to compare efficacy and safety, and decide 
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Results were described in Table 1 and 2. Among 14 patients who 
underwent lung resection for metastases, 5 cases were for osteo-
sarcoma of extremity, 5 for soft tissue sarcoma of extremity, one 
for pyriform fossa cancer, one for breast cancer, one for gestational 
trophoblastic neoplasia and one for metastatic gaint cell tumor of 
bone (Table 1&2). Fig: 2: Clinicopathological features of patients: 
Conclusion: Stage IV disease in cancer though considered as incu-
rable in adult solid malignancies, a selective group of patients can 
still be cured. The success of the surgery depends on disease free 
survival from the detection of primary, number of lesions, grade 
and stage of initial primary and site of primary. Metastatectomy for 
lung cancer in our study is done with a palliative intent.
Keyword: Lung metastases, metastatectomy for lung cancer, lung 
cancer, sarcoma
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P1.24-031 CONFIRMATION OF SURGICAL MARGIN OF 
RESECTED PULMONARY ADENOCARCINOMA WITH 
LEPIDIC GROWTH WITH THIN SLICE CT OF THE RESEC-
TED SPECIMEN DURING SURGERY
Yasuhiro Hida, Kichizo Kaga, Kei Hiraoka, Naotake Honma, Reiko 
Nakada-Kubota, Yoshiro Matsui
Cardiovascular And Thoracic Surgery, Hokkaido University/Japan
Background: Limited resections such as wedge resections for 
ground-glass opacity (GGO) adenocarcinomas have been propo-
sed and widely performed. However there have been reports of 
cut-end recurrences after wedge resection of those lesions. One 
of the major obstacles to solve this problem is a lack of method to 
achieve thorough confirmation of surgical margin during surgery. 
Here we report a successful confirmation of cut-end using thin slice 
CT on resected lung specimen.
Methods: A patient with a ground-glass opacity in the right 
upper lobe underwent a wedge resection under thoracosco-
py. The resected specimen was sent for thin slice CT scan, 
which revealed that there were enough surgical margins from 
the cut-end to the GGO lesion in any of 0.5mm thick slices. 
Results: Pathological examination confirmed that the cut-end was 
free from adenocarcinoma as being consistent with CT findings.
Conclusion: It is feasible and effective to confirm surgical margin 
of resected lung tumor with GGO during surgery using CT on the 
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P1.24-030 A RARE CASE OF SYNCHRONOUS AND ME-
TACHRONOUS LUNG CANCERS
Paul Q.L. Bui1, Chuong Bui1, Lucy Morgan2
1Department Of Nuclear Medicine, Nepean Hospital, Nepean Blue 
Mountains Local Health District/Australia, 2Department Of Respiratory 
Medicine And Nepean Lung Cancer Group, Nepean Hospital, Nepean 
Blue Mountains Local Health District/Australia
Background: Multiple primary lung tumours can be either syn-
chronous or metachronous. Clarification between synchronous 
primary tumours and metastatic lesions is vital given the differing 
prognosis and therapeutic options. We present a case of a patient 
with a combination of synchronous and metachronous primary 
lung malignancies, who did well because she had careful multidis-
ciplinary follow-up.
Methods: Not applicable
Results: A 63-year-old female ex-smoker, with history of mode-
rately severe chronic obstructive pulmonary disease but good 
performance status, was found to have pulmonary nodules in the 
left upper and lower lobes that increased slightly in size over 2 
years on serial thoracic CT scans. On FDG-PET, the lesion in the 
left upper lobe demonstrated marked FDG-avidity (SUVmax 7.5) 
while the left lower lobe nodule demonstrated much lower FDG 
uptake (SUVmax 2.5). These were considered synchronous early-
stage lung tumours by consensus of our multidisciplinary lung 
cancer group. Intra-operatively, frozen sections confirmed malig-
nancy in each lesion and the patient successfully underwent wide 
local excision of both nodules. Histopathology revealed infiltrating 
moderately differentiated adenocarcinoma in the left upper lobe 
(T1N0M0) and infiltrating undifferentiated large cell carcinoma in 
the left lower lobe with no hilar or mediastinal nodal involvement 
(T1N0M0). The patient remained disease-free until 6 years later, 
when new right lung opacities were found incidentally on a chest 
radiograph. Chest CT confirmed 2 new pulmonary nodules in the 
right upper lobe, one intensely FDG-avid (SUVmax 11.0) and the 
other poorly avid (SUVmax 1.2). No other FDG-avid foci suspicious 
of metastatic disease were detected elsewhere. Following mul-
tidisciplinary discussion, wedge resections of both lesions were 
performed. Histopathology revealed high-grade neuroendocrine 
carcinoma (small and large cell types) in the intensely FDG-avid 
lesion and adenocarcinoma in situ in the other lesion. The patient 
was subsequently offered adjuvant chemotherapy and prophyl-
actic whole brain irradiation.
Conclusion: This rare case of synchronous and metachronous 
primary lung cancers illustrates the importance of long-term fol-
low up of patients with previously treated non-small cell lung with 
curative intent. These patients may develop new metachronous 
early-stage lung tumours that would benefit from aggressive treat-
ment. New lung opacities may not necessarily represent recurrent 
metastatic disease with poor prognosis.
Keywords: synchronous, metachronous, Lung cancer
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P1.24-033 A RARE CASE: LUNG CANCER AND MULTIPLE 
MYELOMA
Ayse Bahadir1, Mediha G. Ortakoylu1, Figen Alkan1, Emel Çağlar1, 
Cem Ar2, Nurcan Unver3, Sakine Yılmaz1
1Pulmonology, Yedikule Chest Diseases And Thoracic Surgery Education 
And Research Hospital/Turkey, 2Hematology, Istanbul Training And 
Research Hospital/Turkey, 3Pathology, Yedikule Chest Diseases And 
Thoracic Surgery Education And Research Hospital/Turkey
Background: A multiple myeloma (MM) is a malignant disease of 
plasma cells, which manifests as one or more of lytic bone lesions, 
monoclonal protein in the blood and/or urine and disease in the 
bone marrow. The most typical thoracic manifestation of multiple 
myeloma is bony involvement of the thoracic cage. Other manifes-
tations include pneumonia, intra-parenchymal mass lesions, me-
diastinal lymphadenopathy, interstitial pattern like reticulonodular 
shadows and intrapulmonary calcification. The diagnosis of a se-
condary solid neoplasm in patients with MM is uncommon, and it 
is debatable whether the MM itself is a risk factor for the incidence 
of a secondary solid neoplasm.
Methods: 62 year-old men, former heavy smoker ,treated pulmo-
nary tuberculosis(1977), autologous bone marrow transplantation 
(BMT) for MM two years ago.He admitted complaints of fever, 
cough,sputum and nigth sweats for a month. Physical examinati-
on was remarkable moderate pallor. Routıne serum biochemistry 
parameters were within normal limits except hemoglobin (6.6 
gm/dl),ESR was 84 mm in the first hour.Chest xray and computed 
tomography (CT )showed multiple, bilateral,various size, well-cir-
cumscribed pulmonary nodules, containing calcification solid no-
dul 2 cm in diameter and periferal consolidatıon ın the rigth upper 
lob . Previous chest radiographs and CT had revealed the presence 
bilateral multiple nodules and low uptake18Ffluorodeoxyglucose 
(FDG) positron emission tomography/computed tomography (PET/
CT) ( suv max:2.4).
Results: The patient underwent wedge resectıon rigth upper lobe 
for evaluating nodules three years ago.Histological examination 
demonstared weak -granulom formation and nodüles consisting 
dystrophic calcification ,multifocal hyalinisation and ossification It 
was considered sequelae of tuberculosis. Follow –up imaging stu-
dies increased in size,the number of pulmonary nodules and newly 
rigth 8th and left 6th rib hypermetabolik uptake in PET.CT -guided 
transthoracic needle aspiratıon biopsy performed the increasing 
nodul in the rigth upper lobe diagnosed adenocarcinoma.The 
patient is still alive and on follow-up.
Conclusion: Studies have shown that people who have had al-
logeneic transplants have a higher risk of second cancer than 
people who got a different type of stem cell transplant. In this 
case it is difficult to conclude whether TB sequelae caused lung 
cancer or the lung cancer simply associated in a patient with 
previously known pulmonary TB. Initial diagnosis of tuberculosis 
in such patients often misleads the physician to abandon further 
work-up resulting in overlooking or delayed diagnosis of the lung 
neoplasm,thus affecting their outcome
Keywords: Lung cancer, multipl myeloma, tuberculosis
resected specimen.
Keywords: ground-glass opacity, CT, surgical margin, adenocarci-
noma with lepidic growth
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P1.24-032 IS TUBERCULOSIS A CHALLENGE FOR THE 
MANAGEMENT OF LUNG CANCER?
Deniz Koksal, Derya Ozaydin, Ayse N. Ozcan, Ozge Safak, Nilgun 
Kalac, Mine Berkoglu
Chest Diseases, Ataturk Chest Disease And Chest Surgery Education 
And Research Hospital/Turkey
Background: It is well known that old pulmonary tuberculosis (TB) 
is associated with an increased risk of lung cancer and lung cancer 
mortality. Malignancy per se and cytotoxic chemotherapy for its 
treatment both are recognized risk factors for the development of 
active tuberculosis. Coincidence of tuberculosis and lung cancer at 
initial diagnosis or development of tuberculosis during the course 
of lung cancer is a challenge for management of both diseases.
Methods: Herein we analyzed 10 male lung cancer cases (9 NS-
CLC/ 1 SCLC) coincidentally had tuberculosis.
Results: The ages were ranging between 43-71 years. Only one of 
these patients had a pulmonary TB history. The sites of TB were 
lung in 7 patients, mediastinal lymphadenopathy (LAP), cervical 
LAP, and subcutanous nodules in 1 patient each. Four patients 
were diagnosed as tuberculosis and lung cancer simultaneously. 
The diagnosis was confirmed by mediastinoscopic lymph node 
biopsy in 1, transthoracic biopsy in 1 and sputum smear positivity 
in 2 patients. In 4 patients the diagnosis of pulmonary TB were 
confirmed by sputum culture 2-3 months after the diagnosis of 
lung cancer. All these 4 patients were suspicious for pulmonary 
TB at the time of lung cancer diagnosis, but sputum smears were 
negative for acid-fast bacilli. In 2 patients TB were diagnosed later 
in the follow-up period of the patient. One was diagnosed as TB 
lymphadenitis by cervical lymph node biopsy, the other was diag-
nosed as TB by biopsy of subcutaneous nodules on the right leg. 
One patient who was surgically resected for lung cancer tolerated 
antituberculosis therapy well. Another patient who was initially sta-
ged as T3N2MO lung cancer clinically and radiologically (including 
PET/CT evaluation) also tolerated the therapy fairly well. After 6 
months of antituberculosis therapy, he was restaged as T2aN0M0 
and treated with definitive radiotherapy. He died due to venous 
thromboembolism 1 week after the completion of radiotherapy. 
Another patient had progressive lung cancer during antituberculo-
sis therapy. Hepatotoxicity was the leading adverse reaction (in 3 
patients, 30%) due to antituberculosis therapy.
Conclusion: In conclusion; these cases highlighted the importance 
of thiNKIng TB in the course of lung cancer especially in countries 
with high TB prevalence. TB may cause advanced staging of lung 
cancer at initial diagnosis; chemotherapy may worsen TB course or 
cause reactivation TB. Reactivation TB may be considered as pro-
gression of lung cancer without a tissue diagnosis. The tolerability 
of antituberculosis therapy is poor in these patients. Guidelines 
should refer how to manage these patients especially in certain 
areas with high TB prevalence.
Keywords: tuberculosis, Lung cancer, MANAGEMENT
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P1.24-035 TIMES TO PRESENTATION AND TREATMENT : 
A PROSPECTIVE COMPARISION OF RURAL AND URBAN 
LUNG CANCER PATIENTS IN NORTH QUEENSLAND
Abhishek Joshi1, Sabe Sabesan1, Petra Beuttner2, Suresh Varma1, 
Zulfiquer Otty1
1Medical Oncology, Townsville Cancer Centre/Australia, 2Epidemeology 
And Biostatistics, James Cook University/Australia
Background: Disparities in cancer survival among rural and urban 
population is known. Time delay from symptom to presentation for 
medical attention and treatment in rural lung cancer population is 
partly responsible for lower survival rates in this population. Iden-
tification of specific barriers can help form strategies to improve 
survival. There are no prospective studies evaluating referral pa-
thways and identifying barriers in lung cancer presentation in rural 
areas . This study‘s aim was to analyse time delays in management 
pathways of rural lung cancer patients and explore the influence of 
various demographic factors on these times.
Methods: Lung cancer patients presenting to Townsville Cancer 
Centre, Cairns Base Hospital and Mackay Base Hospital were pro-
spectively recruited over a 36 month period from 2009 to 2012. As 
per ASGC (Australian Standard Geographical Classification) guide-
lines of remoteness patients were classified as regional or remote. 
Fisher’s test was used to identify differences between these two 
cohorts. Times along referral pathway were divided into symptoms 
to first presentation, symptoms to diagnosis, symptoms to speci-
alist visit, specialist to treatment and symptoms to treatment. The 
influence of clinical and socio-demographic factors like gender, 
ethnic status, education level, income, remoteness of location and 
stage of disease on these times were analysed using Kruskal-Wallis 
and Mann-Whitney tests for statistical significance.
Results: A total of 252 lung cancer patients were eligible for re-
cruitment. Of these 180 (71.4%) were classified as urban and rest 
remote. In remote compared to urban patients there were more 
males (73.6% vs 60%, p=0.046) and more Caucasians (96.2% vs 
90%,p=0.068). Also level of secondary or higher education was 
significantly more in urban compared to remote cohort (88.5% 
vs62.7%). Tumour demographics like histology and stage were 
balanced between the two cohorts. Median time from symptoms 
to first presentation was significantly affected by ethnicity (indige-
nous vs non indigenous 92 vs 57 days, p=0.05), older age (<51yr 
vs >51yr 14 vs 45 days, p= 0.026) and lower level of education (pri-
mary/secondary vs tertiary/TAFE 61 vs 23 days, p=0.023). Median 
time between symptoms to specialist consultation were signifi-
cantly higher for lower level of education ( primary / secondary vs 
tertiary/TAFE 140 vs 55 days, p=0.05) and remoteness of location 
(remote vs urban 113 vs 89 days, p=0.05). Specialist to treatment 
time was delayed by stage (III vs IV 34 vs 18 days, p=0.021). On 
multivariate analysis time between symptoms to first presentation 
was influenced by level of education (primary/secondary vs terti-
ary/TAFE, p=0.006). For rural compared to urban patients, time 
between first consultation to specialist visit (p=0.022) and time 
between symptoms to first treatment (p=0.015) were significantly 
longer.
Conclusion: The demographic profile of lung cancer patients from 
remote areas is quite smilar to their regional counterparts. In the 
five time zones from presentation to treatment, median time from 
symptoms to first presentation was the most susceptible. In the 
referral pathways, indigenous ethnicity, level of education, remote-
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P1.24-034 CYSTIC AND CAVITARY APPEARANCE:AN 
USUAL FORM OF PULMONARY METASTASIS OF PRIMER 
LUNG ADENOCARCINOMA
Ayse Bahadir1, Mediha G. Ortakoylu1, Figen Alkan1, Asuman As-
lan1, Emel Çağlar1, Nur Ürer2
1Pulmonology, Yedikule Chest Diseases And Thoracic Surgery Education 
And Research Hospital/Turkey, 2Pathology, Yedikule Chest Diseases 
And Thoracic Surgery Education And Research Hospital/Turkey
Background: Cystic and cavitary pulmonary lesions are abnormali-
ties encountered on chest radiography and computed tomography 
(CT).Malignant lesions, including metastases, rarely present as 
cystic and cavitary lesions.Due to rarity such cases ,we report here 
a case of unusual form of pulmonary metastasis of primer lung 
adenocarcinoma
Methods: A 82-year old female patient admitted to hospital with 
complaints of dry cough,progressive dsypnea for a month .Her 
past history was unremarkable. Physical exam was normal.Chest 
X-ray revealed bilateral diffuse multpil cavitary and cystic lesions 
In routine laboratory tests, all were normal excepting Hb:10.7 g/dl, 
CRP:43 The thorax CT showed bilateral diffuse cysticand cavitary 
lesions in 1-3 cm diameter, with no thoracic lymphadenopathy . 
As the multiple lung nodules were suspected to be metastatic, 
18Ffluorodeoxyglucose (FDG) positron emission tomography/
computed tomography (PET/CT) was conducted, which revealed 
that the nodules had mild uptake of 18FFCG ,a metabolic behavi-
our consistent with bening aetiologies diseases according to the 
nuclear medicine report.
Results: Bronchoscopy with bronchial lavage was performed. 
Cytology was negative for malignancy. Repeat CT scan of chest 
showed increase in size of lung lesions and new right-sided pleu-
ral effusion .CT-guide transthoracic needle aspiratıon biopsy was 
performed. The pathological examination revealed a metastasis of 
adenocarcinoma ,however histological differentiation of primary 
pulmonary adenocarcinoma from metastatic adenocarcinoma is 
sometimes difficult because of their phenotypic similarities So im-
munohistochemistry (IHC) was performed, the IHC of lung tumor: 
cytokeratin 20 (CK20)(-), cytokeratin7(CK7)(+), thyroid transcription 
factor(TTF)(-)Because of PET CT was no showed extrathoracic 
uptake,It was considered primary lung adenocarcinoma for final 
diagnosis.
Conclusion: One of the most important differences in the diffe-
rential diagnosis of cystic or cavitary lung lesions is the distinction 
between malignant and benign aetiologies. Primary lung cancer is 
a common disease, cavitation being detected by CT for up to 22% 
of primary lung cancers but for near 11% by plain thoracic radio-
graphy. However pulmonary metastases can rarely cavitate, with 
a reported incidence less than 4% on chest radiographs [2]. Even 
cavitary lung metastases are rare and benign differential diagnosis 
are more common, clinician should be careful in neoplastic context 
and investigation should be done In rarity such cases ,we report 
here a case of unusual form of pulmonary metastasis of primer 
lung adenocarcinoma
Keywords: Lung cancer, elderly, imaging
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remaining progression free. The median progression free survival 
is 9.4 months (mean 12.4), with a median overall survival of 16.6 
months. This study demonstrated a 3-year survival rate of just 
below 20 %.
Conclusion: These outcomes and toxicities are comparable to the 
reported international studies and would support continued use 
of our current protocol. Further studies may be helpful to identify 
the optimum chemotherapy regimen in concurrent therapy for 
inoperable NSCLC. The future role of molecular tailored regimens 
in subgroups of patients undergoing CMT is evolving.
Keyword: chemotherapy, radiotherapy, non-small cell lung cancer, 
combined modality treatment
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P1.24-037 ADDITION OF BEVACIZUMAB TO STANDARD 
PALLIATIVE CHEMOTHERAPY IN ADVANCED NON 
SQUAMOUS CELL LUNG CARCINOMA: TATA MEMORIAL 
HOSPITAL EXPERIENCE.
Amit Joshi, Bharat Chauhan, Vanita Noronha, K Prabhash
Medical Oncology, Tata Memorial Hospital/India
Background: Outcome of advanced NSCLC is poor. Platinum based 
chemotherapy is standard of care. Addition of antiangiogenic agent 
such as bevacizumab improves the results.
Methods: Prospectively collected data of patients received bevaci-
zumab, platin and pemetrexed as initial therapy for 6 cycle followed 
by maintenance pemetrexede and bevacizumab till disease progres-
sion or unacceptable toxicity.
Results: We had 18 patients, 14 were males and 4 were females. The 
age of the patients ranged from 45 to 68 years with a median age 
of 54 years. About one third of the patients were smokers and most 
of the patients were of good performance status (ECOG-0/1-94%). 
The most common symptoms of presentation were, cough in 61% 
of patients followed by dyspnea in 39% of patients. The chest pain 
and neck swelling were present in 11% of patients whereas bony 
pains were present in 39% of patients. Co-morbidities of diabetes 
and hypertension each were present in 17% of patients. Most of the 
patients were stage IV(94%). The patients received chemotherapy 
which comprised of pemetrexed, platin and bevacizumab for 6 cycle 
followed by pemetrexed and bevacizumab maintenance till progres-
sion in responding patients after six cycle. Number of cycle’s recei-
ved ranged from 2 to 21 with a median of 10 cycles. Response rates 
achieved were stable disease in 72%, partial remission in 22% with 
disease stabilization rate of 95%. Grade 3 and 4 toxicities observed 
were neutropenia 11%,proteinuria 11%, anemia and Hyponatremia 
were present in 17%.One patient each developed pulmonary throm-
boembolism and hypertension. Bevacizumab was stopped because 
of toxicitty in one patint who developed pulmonary throboembo-
lism. Median progression free survival was 7 month and median 
overall survival for whole group is not reached.
Conclusion: Addition of bevacizumab to standard platin based the-
rapy in both initial and maintenance phase is feasible with acceptab-
le toxicities. Some patients have long term disease control.
Keyword: bevacizumab , palliative chemotherapy, nonsquamous 
cell NSCLC
ness and stage of disease affected time delays but no impact was 
found for socio-economic status. On multivariate analysis level of 
education and remoteness of location emerged as significant barri-
ers to presentation.
Keyword: rural, remote, time, pathways
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P1.24-036 COMBINED MODALITY TREATMENT FOR 
INOPERABLE NON-SMALL CELL LUNG CANCER - A RE-
TROSPECTIVE STUDY FROM A NEW ZEALAND REGIO-
NAL CANCER CENTRE.
Wen-Hsun Tsai, Claire Hardie, Donald Chan, Garry Forgeson, 
Helen S. Winter, Michael Carr, Nikolay Nedev, Johan Nel, Rix Du 
Plessis, Simon Allan, Richard Isaacs
Regional Cancer Treatment Service/New Zealand
Background: Lung cancer in New Zealand is associated with poor 
survival and regional inequalities. Non-small cell lung cancer (NS-
CLC) accounts for 80%–85% of all newly diagnosed lung cancer 
cases. Forty five percent of these patients present with stage III di-
sease (mediastinal node involvement). The Regional Cancer Treat-
ment Service (RCTS), Palmerston North Hospital is using combined 
modality treatment (CMT) chemotherapy / radiotherapy protocol 
for inoperable Stage II and Stage III NSCLC since 2006. The che-
motherapy regimen employs 3 cycles of Cisplatinum/Vineralbine. 
This audit reviews the outcomes and side effects of treatment.
Methods: This retrospective study comprises patients with a cli-
nical diagnosis of inoperable NSCLC from the RCTS, Palmerston 
North Hospital database. Patients confirmed to have stage IIIB 
and/or inoperable stage II and IIIA NSCLC are included. These 
patients completed treatment based on the RCTS NSCLC CMT 
guideline from 1st July 2005 to 31st May 2012. Information was ob-
tained from Oncology electronic records and paper based clinical 
notes in RCTS. The treatment protocol includes one neoadjuvant 
cycle of chemotherapy, given 3 weeks prior to commencing of 
the radiotherapy. It is followed by further two cycles of Cisplatin/
Vinorelbine, given concurrently with radical radiation therapy on 
day 1 and 22 of the radiotherapy. All patients were treated with 3D 
conformal radiotherapy to total dose is 60Gy in 30 fractions, over 
6 to 7 weeks. Common Terminology Criteria for Adverse Events 
(CTCAE) Version 4.0 were applied. Progression free survival (PFS) 
and median survival were estimated and reviewed.
Results: From 1st of July 2005 to 31st of May 2012, 39 patients com-
pleted CMT. All cases in the study had a history of smoking. Thirty 
two (82%) patients had inoperable stage III NSCLC (IIIA - 15 cases, 
IIIB - 17 cases). The remaining seven patients had stage II disease, 
(IIA - 3 cases, IIB - 4 cases), who were deemed inoperable due to 
significant medical problems. Protocol doses were maintained in 
79% of patients, with dose reduction typically used due to transi-
ent renal impairment, ototoxicity and myelosuppression. Neutro-
penia (ANC <1000/mm3) was documented in 21% of patients. Six 
patients (15%) had neutropenia on day 14-15 and 2 patients (5%) 
on day 22-23. One patient had hospital admission for febrile neu-
tropenia. Five other patients developed neutropenia but remained 
asymptomatic. Grade III anaemia (Hb <80 g/L) was noted in 6 
patients - all of them had 2 units of blood transfusion. There were 
no treatment related deaths. 23 patients developed progression 
of the disease. At the time this study is completed, 16 patients are 
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( aged 84 years or more were referred with a stage IV (11 M1a and 
14 M1b) non-small cell lung cancer to our university hospital. There 
were 11 females and 14 males. There were 11 never-smokers. Me-
dian age was 87 years (range : 84-92). Histological subtypes were 
: 8 squamous cell carcinoma, 14 adenocarcinoma and 3 large cell 
carcinoma. Molecular analyses was performed in 17 cases among 
which 2 were impossible due to inappropriate biopsy specimen. 
EGFR- mutations were found in 4 female patients, 1 with exon 19 
deletion and 3 with exon 21 point mutations. There were 3 K-RAS 
mutations and no ALK translocations. 6 patients received TKIs 
as first line treatment (5 gefitinib and 1 erlotinib). Two patients 
with no molecular analysis were treated with first-line TKI (both of 
them had PS 4, one died after 1.1 month, the other recovered very 
quickly and is still alive after 15.3 months). The other patients were 
treated with doublet carboplatine AUC 6 and weekly paclitaxel (90 
mg/m², D1, 8, 15), with D1 = D29 (12 patients) or single agent the-
rapy (paclitaxel (2), Gemcitabine (1), vinorelbine(1)). Three patients 
received only best supportive care (BSC). Doses of TKIs had to be 
lowered due to toxicity in 1 case. Median overall survival was 8.1 
months with a one-year probability of survival of 46%. Survival of 
the 6 patients treated with first-line TKIs was 1.1, 3.1+, 6.43+, 14, 
15.33+, 15.9+ months.
Conclusion: It must be noted that EGFR-mutations were more 
frequent compared to younger patients (at least 4/25) paralleling 
the high proportion of never-smokers (44%) and of female patients 
(44%). In this unselected consecutive series of older elderly pati-
ents, only 3 received BSC as sole treatment, while 4 were treated 
with single agent chemotherapy, 12 with a carboplatine-based 
doublet and 6 with TKIs as first line therapy, of which only 4 had 
proven EGF-R mutations. Survival was very similar to what is obser-
ved with younger counterparts and thus, nihilism is not appropriate 
in this category of patients.
Keywords: non-small cell lung cancer, metastatic, TKI, elderly
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P1.24-040 MANAGEMENT OF SOLID LUNG MALIGNAN-
CY BY CT-GUIDED PERCUTANEOUS CATHETER ABLATI-
ON --- DOES ADJUVANT CHEMOTHERAPY HELP?
Peter Andrew1, Stephen O‘Connor2, Richard Lee-Ying3, Sandra 
Jerat4
1Internal Medicine, The Ottawa Hospitals/Canada, 2City University/
United Kingdom, 3Tom Baker Cancer Center/Canada, 4Atlas Medical 
Research Inc/Canada
Background: With a burgeoning population of elderly patients 
with lung cancer deemed non-surgical, increasing utilization of 
minimally-invasive techniques such as CT-guided percutaneous 
catheter ablation is occurring for the management of solid tumors. 
However, it is unknown whether a strategy of ablation plus adju-
vant chemotherapy improves locoregional and survival outcomes 
in aged patients with solid lung malignancy. The aim of this study 
was to compare local tumor recurrence and survival outcomes of 
ablation plus adjuvant chemotherapy versus ablation alone for ma-
nagement of primary and metastatic solid lung tumors in patients 
unsuitable for lung resection.
Methods: Searched PubMed, the Cochrane Library, EMBASE, and 
CANCERLIT databases from January 2000 to December 2012. 
Blinded duplicate screening was used to extract data from captu-
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P1.24-038 BARRIERS AND FACILITATORS TO PHYSICAL 
ACTIVITY RECEIVING CHEMOTHERAPY FOR LUNG  
CANCER: AN EXPLORATORY STUDY
Sebastien Mas1, Xavier Quantin2, Gregory Ninot1
1Epsylon Laboratory/France, 2Respiratory Diseases Service, Arnaud De 
Villeneuve Hospital/France
Background: Physical activities (PA) induce a positive effect on 
cardiorespiratory fitness, lung cancer symptoms and quality of life 
of patients suffering from lung cancer. While 92% of patients are 
interested in participating in a PA program, only 1/3 of them do 
sufficient amount of PA to provide important health benefits. The 
aim of our study was to identify barriers and facilitators to PA in 
patients with lung cancer receiving chemotherapy.
Methods: Our study provided data from patients diagnosed with 
primary NSCLC in advanced stages of the disease receiving che-
motherapy. We chose a qualitative approach using a semi-struc-
tured interview. We conducted an exploratory analysis, using the 
thematic analysis technique to process the data.
Results: Seven barriers and facilitators to PA were identified (side 
effects of the disease/cancer-related treatment, other physiologi-
cal limitation, timing/loss of meaning of projects, kinesiophobia, 
support/care, social usefulness/useless feeling, nature of the PA) 
and were grouped into 4 categories: physiological, psychological, 
social and environmental factors. These factors were identified 
to have different effects on the barriers to PA. Psychological and 
social factors mainly have an impact on the willingness and ability 
to practice PA; while physiological and environmental factors have 
an impact on the duration, intensity and regularity of PA.
Conclusion: Our study highlighted some of the effects that the 
barriers to PA have on the practice of PA in patients with NSCLC 
receiving chemotherapy. Our findings may be used by professio-
nals to design an adapted PA program in this population.
Keywords: palliative care, facilitators, Physical Activity, Barriers
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P1.24-039 OUTCOME OF A SERIES OF 25 CONSECUTIVE 
PATIENTS AGED 84 AND MORE WITH STAGE IV NSCLC : 
AN INVITATION TO SYSTEMIC TREATMENT
Justine Gantzer1, Nathalie Prim1, Bertrand Mennecier1, Michèle 
Beau-Faller2, Alain Ducoloné1, Philippe Fraisse1, Cezar A. Matau1, 
Rodolphe Stenger1, Anita Molard1, Ashok Purohit1, Elisabeth  
Quoix1
1Service De Pneumologie, Nhc/France, 2Hôpital De Hautepierre, Service 
De Biologie Moléculaire/France
Background: Elderly patients and even more older elderly with 
stage IV NSCLC are often not optimally treated.
Methods: Not applicable
Results: Between april 1st 2010 and february 28th 2013, 25 patients 
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Conclusion: A strategy of CT-guided percutaneous catheter abla-
tion plus adjuvant chemotherapy delivers the benefit of retarding 
LTP, and expectedly lengthens both OS and DFS. Elderly patients 
with solid lung tumors who are most likely to benefit from this 
strategy would be non-surgical candidates with relatively good 
performance status who could tolerate both catheter ablation and 
chemotherapy.
Keywords: ablation, chemotherapy, lung, tumor
red clinical studies involving patients with non-surgical solid lung 
tumors, both primary and/or metastatic. Population was deemed 
non-surgical, with solid lung tumors, both primary and/or metasta-
tic. Generated aggregate effect estimates from constituent studies 
for three outcomes (e.g., local tumor progression [LTP], overall 
survival [OS], and disease-free survival [DFS]) with comparison of 
pooled fixed effect analyses concerning ablation plus adjuvant 
chemotherapy versus ablation alone. Data were analyzed using 
dedicated meta-analysis statistical software (BioStat Inc., NJ, USA).
Results: Ablation + chemotherapy group: 684 patients and 1,314 
lung tumors. Ablation only group: 1,874 patients and 2,604 lung 
tumors. Histology was NSCLC >> mets from colorectal cancer > 
sarcoma > renal > other. Ablation + chemotherapy versus ablati-
on alone: LTP of 15% over median follow-up of 31 months [range 
12 to 59] versus 19% over median follow-up of 21 months [range 
12 to 29]; odds ratio (OR) 0.73 (95% CI: 0.61-0.86, p<0.05) at 12 
month follow-up. OS was 89% versus 78%, respectively, at 12 
month follow-up; OR 1.52 (95% CI: 1.16-2.00, p=0.003). DFS was 
90% versus 82%, respectively, at 12 month follow-up; OR 3.18 (95% 
CI: 2.04-4.96, p<0.05). Forrest plots for the outcomes of LTP, OS, 
and DFS are shown. Sensitivity analyses were robust, publication 
bias relatively narrow, and Q statistic <21; p>0.13 for all outcomes.
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needs of these patients are well-defined or well-integrated. Mo-
dels which integrate primary care with other lung cancer services 
offer the prospect of improved continuity, access, care co-ordinati-
on and management of co-morbidities.
Keyword: lung cancer, primary care, family medicine, integration
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P1.24-042 VIDEO-ASSISTED THORACIC SURGERY  
LOBECTOMY FOR PATIENT RECEIVING INDUCTION 
CHEMORADIOTHERAPY FOR LOCALLY ADVANCED 
NON-SMALL CELL LUNG CANCER
Kentaro Anami, Takashi Miura, Masao Chujo
Division Of Thoracic Surgery, Shin Beppu Hospital/Japan
Background: Video-assisted thoracic surgery (VATS) lobectomy is 
an accepted oncologic approach for early-stage peripheral typed 
non-small cell lung cancer (NSCLC).Recently the indication of VATS 
lobectomy is becoming widely adapted to more complicated cases 
thanks to development of thoracoscopic instruments and technical 
aspects.
Methods: We here report a case of patient who underwent VATS 
lobectomy after induction chemoradiotherapy for locally advanced 
NSCLC.
Results: A 56-year-old man with a 35 pack-year history of tobacco 
use presented with productive cough. A computed tomography 
(CT) revealed a 6-cm hilar mass with consolidation in the right 
upper lobe and hilar, interlobar,and single mediasitnal lymphnode 
metastases. There was a significant mass uptake of FDG (standar-
dized uptake value: 16.1 to 19.2) on Positron emission tomography 
(PET). Bronchofiberscopy showed an intraluminal extension of the 
tumor centrally to the orifice of the right upper lobe. Bronchofiber-
scopic biopsy demonstrated squamous cell carcinoma. This patient 
have a clinical T2bN2M0 IIIA NSCLC. He received two cycles of 
CDDP+GEM followed by concurrent CDDP+VNR and 40Gy irradi-
ation. Preoperative assessment by CT and PET revealed marked 
regression of the tumor. A VATS lobectomy was then performed. 
One utility incision (4 cm) was made over the 4th intercostal and 
three ports (0.5-1.5 cm each) were placed without rib spreading. By 
using bipolar scissors, the major vascular structures and the bron-
chus were safely dissected from the irradiated surrounding tissue 
similarly to an open procedure. The bronchus could be divided 
using a stapling device. An anatomic lobectomy with sysytematic 
mediasitanal lymphnode dissection was fully and safely performed. 
The chest tube was removed on the postoperative 1st day. He had 
an uneventful 9-day hospital course. This final pathological finding 
revealed microscopically residual tumor only in the bronchial wall 
and lung parenchema andin the single mediastinal lymphnode. 
This patient have an yield pathological T3N2M0 StageIIIA NSCLC.
He received additional 4 cycles of CDDP based chemotherapy 
postoperatively and is alive with disease free 25 months after sur-
gery.
Conclusion: VATS lobectomy is a feasible approach for selected 
patients undergoing resection after induction chemoradiotherapy 
for locally advanced NSCLC.
Keyword: video-assisted thoracic surgery (VATS) lobectomy, in-
duction chemoradiotherapy, locally advanced non-
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P1.24-041 FOLLOW UP OF PATIENTS WITH LUNG  
CANCER: THE ROLE OF PRIMARY CARE
David P. Weller1, Christine Campbell1, Scott Murray1, Richard 
Neal2
1Centre For Population Health Sciences, University Of Edinburgh/Uni-
ted Kingdom, 2North Wales Centre For Primary Care Research, Bangor 
University/United Kingdom
Background: Despite improvements in lung cancer treatments, 
there is little international agreement over the key elements of 
follow-up; frequency of visits and investigations, and choice of 
models of care remain controversial. Worldwide there is an em-
phasis on survivorship in patients who have been treated for lung 
cancer. Further, there is growing interest in the role of primary care 
in cancer survivorship and follow-up; primary care has the potential 
to provide more comprehensive and coordinated care in cancer 
patients. To date there have been few studies investigating the 
role of primary care in lung cancer follow-up and survivorship. As a 
prelude to developing and trialing a primary care-focused package 
of care for UK patients with lung cancer, we undertook a descripti-
ve study, based on analysis of audit, database and qualitative data.
Methods: Case notes of 183 lung cancer patients from 60 practi-
ces in Wales Scotland and England , and data from two Scottish 
primary care databases (3025 patients) were analysed (attendance 
patterns in primary care, co-morbidity, investigations, referrals and 
prescribing). For a subset of database patients, data from con-
trol patients, matched for age and sex, were examined. We also 
interviewed 84 primary and secondary health care professionals 
from across the UK, and undertook four focus groups of patients 
and carers. Transcripts were coded thematically using a grounded 
theory approach; the analysis was conducted inductively, driven by 
the interview data. 
Results: Most (90%) of the patients’ cancers were NSCLC; 57% had 
received treatment with ‚curative intent‘; the remainder received 
essentially palliative treatment. Three-quarters of patients had at 
least one co-morbidity (32% had two or more). Particularly in the 
first year post-diagnosis, lung cancer patients had significantly 
higher primary care consultation rates than matched controls 
- these differences persisted over time. Approximately 80% of 
presentations to primary care were for lung cancer-related prob-
lems; almost 20% of all primary care consultations led to investi-
gations (predominantly blood tests), and 7% led to a referral. Most 
prescriptions were for antibiotics, analgesia and antidepressants. 
There was little evidence of structured approaches to lung cancer 
follow-up and survivorship. Our qualitative data showed some 
support amongst key stakeholder groups for an enhanced role for 
primary care in the follow-up of lung cancer patients. There was, 
however, a strong perception of ‚disaggregation‘ between secon-
dary and primary care services. Care models involving enhanced 
roles for primary care were particularly favoured for long-term lung 
cancer ‘survivors’, with a high burden of psycho-social concerns 
and unmet need; also, the role of specialist lung cancer nurses was 
consistently emphasised.
Conclusion: Much of the care provided to lung cancer patients is 
already based in primary care. Further, specialist nurses provide 
expert knowledge, familiarity with and access to hospital-based 
services and engagement with multi-disciplinary team processes. 
There is, however, limited evidence from our study or the wider 
literature that the services needed to meet the broad and complex 
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Conclusion: The inclusion of a multidisciplinary team in the ma-
nagement of NSCLC lead to an earlier diagnosis and increased 
survival of patients. This approach should be considered in the 
management of NSCLC patients in a developing country.
Keywords: NSCLC, Multidisciplinary Team, Developing country, 
survival
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P1.24-043 RESULTS OF A MULTIDISCIPLINARY TEAM IN 
THE MANAGEMENT OF NON-SMALL CELL LUNG CAN-
CER IN A DEVELOPING COUNTRY
Luis Corrales-Rodriguez, Allan Ramos-Esquivel, Manuel Caballe-
ro, Sofía Antillón, Mónica Araya, Manuel Villalobos, Tatiana Soto, 
Melissa Juárez-Villegas, Ileana González, Zenén Zeledón, René 
Valladares, Carlos Zúñiga-Orlich, Joao Baptista, Tania Rivera, 
Christian Campos-Fallas, Randall Guadamuz, Adriana Murillo, 
Ernesto Jiménez, Marco Herrera, Carlos Arce-Lara
Grupo De Oncología Torácica, Hospital San Juan De Dios-ccss/Costa 
Rica
Background: Lung cancer has the highest cancer-related mortality 
in the World. In developing countries, mortality rates tend to be 
higher due to deficits of diagnostic and professional resources, 
and long time intervals between patient’s symptoms and the initia-
tion of treatment. Multidisciplinary teams improve the care of pa-
tients with NSCLC, but this practice is not common in developing 
countries. In Costa Rica more than 90% of cancer patients are tre-
ated in a public hospital where resources are limited. To improve 
patient care a weekly multidisciplinary thoracic oncology meeting 
was organized in Hospital San Juan de Dios, one of Costa Rica’s 
three adult general hospitals. This hospital is responsible for the 
management of more than 40% of Costa Rica’s cancer patients.
Methods: A multidisciplinary team including Medical Oncology, 
Pneumology, Pathology, Thoracic Surgery, Radiology and Radia-
tion Oncology started to meet in a weekly basis since November 
2011. All patients with a possible lung cancer in the hospital were 
evaluated by the team and recommendations were given. Data 
of patients with NSCLC seen by the multidisciplinary team during 
2012 was compared to a historic data of NSCLC patients diag-
nosed in the same hospital between 2003 and 2008 when there 
was no multidisciplinary team involved in patient care. Exclusion 
criteria included insufficient clinical information. Epidemiologic 
data was analyzed and survival curves were obtained.
Results: In the periods 2003-2008 and 2012, 92 and 39 patients 
respectively with NSCLC were included for analysis. Epidemiologic 
results are summarized in Table 1 and overall survival is plotted in 
Figure 1. 
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tion of BM. These pts may preferably be considered for resection.
Keyword: lung cancer, brain metastasis, resection, survival
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P1.24-045 A CASE WITH LONG TERM SURVIVAL FOL-
LOWING RECEIVED PACLITAXEL AS FOURTH LINE CHE-
MOTHERAPY IN REFRACTORY-RELAPSED SMALL-CELL 
LUNG CARCINOMA. (ON BEHALF OF NT-TOG GROUP)
Busyamas Chewaskulyong
Medicine, Chiang Mai University/Thailand
Background: Small-cell lung cancer constitutes 10-15% of lung 
cancer cases. Although it is sensitive to chemotherapy and radio-
therapy, but usually relapsed and recurred with median survival 
time less than 6 months after second line therapy. Paclitaxel mo-
notherapy had been reported its efficacy with minimal toxicity in 
relapsed small-cell lung cancer treatment. This presenting case 
demonstrated activity of paclitaxel in relapsed-refractory small-cell 
lung cancer in fourth line of treatment.
Methods: This is the case report of paclitaxel monoherapy in 
fourth line of refractory -relapsed small-cell lung cancer treatment.
Results: A 72-year-old woman with a history of ex-smoker and 
hypertension presented in September 2007 with weight loss and 
left- sided chest pain.On physical examination revealed bronchi-
al breathsound at left lung .Computed tomography scan of the 
thorax showed 5.7 * 4.5 cm mass at left hilar region and occlude 
left middle part of bronchus. Bronchoscopic biopsy was done and 
histology showed small-cell lung carcinoma. Staging work up was 
performed and resulted was limited stage disease. The patients 
was admininistered chemotherapy with standard cisplatin and 
etoposide regimen. Concurrent chemoradiotherapy was started on 
3rd cycle of chemotherapy . She received first line chemotheapy 
with total 5 cycles of chemotherapy with good clinical response. 
Chest imaging showed nearly partial response. Before 6th cycle of 
chemotherapy she developed relapsed small-cell lung carcinoma 
and was treated with cisplatin plus irinotecan as second line thera-
py for 2 cycles and third line with cyclophosphamide/adriamycin/
vincristine regimen for 1 cycle with no response and had worse 
lung symptoms . Fourth line chemotherapy was administered with 
paclitaxel 175 mg/m2 every 3 weeks for 4 cycle between April and 
July 2008 . After second cycle of paclitaxel her symptoms and 
chest imaging were improved. After 4 cycle of paclitaxel mono-
therapy she was evaluated as stable disease and had long survival 
since 2008 until now with symptom- free and no relapsed of di-
sease for more than 5 years.She had minimal toxicity from paclita-
xel with only mild neuropathy.
Conclusion: In conclusion this case demonstrated that paclitaxel 
still had benefit with long-term survival and minimal toxicity event-
hough in the fourth line therapy of refractory-relapsed small-cell 
lung cancer.
Keyword: paclitaxel
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P1.24-044 FAVORABLE SURVIVAL OF WOMEN WITH 
NON-SMALL CELL LUNG CANCER (NSCLC) AFTER RE-
SECTION OF BRAIN METASTASES (BM) AND WHOLE 
BRAIN RADIOTHERAPY (WBRT)
Paul Martin Putora1, Cedric Panje1, Thomas Hundsberger2, Karin 
Van Leyen3, Silvia Ess4, Ludwig Plasswilm1, Martin Fruh5
1Department Of Radiation Oncology, Kantonsspital St. Gallen/Swit-
zerland, 2Dept. Of Neurology / Dept. Of Haematology & Oncology, 
Kantonsspital St. Gallen/Switzerland, 3Department Of Neuro-surgery, 
Kantonsspital St. Gallen/Switzerland, 4Cancer Registry St. Gallen/ap-
penzell/Switzerland, 5Department Of Haematology & Oncology, Kan-
tonsspital St. Gallen/Switzerland
Background: In NSCLC, BM are found in 20%-50% overall and 
10-18% at initial presentation. Average survival of these patients 
(pts) is only 3–6 months. The selection of pts who may benefit from 
surgical resection of BM is challenging. Our goal was to distinguish 
which pts might benefit from surgical resection of BM.
Methods: We retrospectively reviewed all pts receiving surgical 
resection of BM from NSCLC at our institution between 2000 and 
2011. Survival after Brain surgery was measured.
Results: A total of 52 pts were identified. Median age was 59 ye-
ars (35-81). ECOG Performance status was 2 or less in 88%.Only 2 
were never smokers, and 94% smoked until < 5 years before diag-
nosis. Nineteen (37%) were women, 29 (56%) had adenocarcinoma 
(AC), 14 (27%) squamous cell carcinoma (SCC) and 9 (17%) not 
otherwise specified NSCLC. In 35 pts (67%) single BM was present, 
2 in 6 (12%), 3 in 5 (9 %) and 4 or more in 3 (6%) pts. The stage of 
the primary lung tumor was T1-3 in 40 (78%) and N0-1 in 25 (48%). 
Synchronous BM were resected within one month of diagnosis in 
29 (56%) pts. Twenty-three (44%) had no other distant metastases 
at the time of diagnosis of the BM. Distribution of distant metasta-
ses was adrenal (21%), liver (19%), bone (15%), lung (13%) and other 
(19%). Median time from lung cancer diagnosis to resection of BM 
was 7.5 months (0-63 months). WBRT was applied to 45 (87%) pts 
post brain surgery and once before surgery. The primary tumor 
was resected in curative intent in 14 (27%) pts at diagnosis. Thirty 
four (65%) received first line platinum chemotherapy doublets. 
Second line systemic therapy was given to 19 (37%) pts. Only 8 
pts received tyrosine kinase inhibitors, but no one was treated for 
longer than 4 months. Eight are still alive. Median survival was 9.1 
months with only one patient (initially pT2 pN0) surviving more 
over 5 years. One year survival was 42%. Median survival for ma-
les was significantly shorter (6.7 vs. 14 months [p<0.005]). AC was 
associated with improved survival compared to SCC (10.6 vs. 6.7 
months [p<0.05]) with no correlation between gender and histolo-
gy. In a multivariate analysis, the use of TKI, age and WBRT were 
not associated with outcome. Thirteen (25%) died within 3 months 
after surgery including 4 (8%) within 1 month. Six (46%) of them 
had other metastatic sites involved. New brain lesions post-surgery 
were documented in 12 (23%) and 4 (8%) had local progression at 
the resection site.
Conclusion: Resection of BM followed by WBRT lead to good 
local control. Despite patient selction with almost one third being 
treated with surgery of the primary tumor "curative intent“ as well, 
only one patient lived > 5 years. The relatively high death rate 
(25%) within 3 months of surgery indicate the need for further re-
search to better select patients suitable for survery. Female gender 
and AC histology were associated with better survival after resec-
S730 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
suggesting sensitivity or resistance of the rare mutation. 2) in par-
allel, a more accurate information on the lack of knowledge on the 
sensitivity or resistance, 3) a website for quick access to this type of 
information and changes along with the knowledge evolution.
Keywords: EGFR rare mutations, metastatic lung adenocarcinoma, 
therapetic management
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P1.24-047 A PULMONARY NEUROGENIC TUMOR: PRI-
MARY PULMONARY CELLULAR SCHWANNOMA
Turgut Isitmangil1, Zafer Kartaloglu2, Rauf Gorur1, Nurettin Yiyit1
1Thoracic Surgery, Gmma Haydarpasa Training Hospital/Turkey, 2Pul-
monary Medicine, Gmma Haydarpasa Training Hospital/Turkey
Background: Although primary neurogenic tumors of the lung are 
very rare, cellular schwannoma is a subtype of the classical sch-
wannoma, which is a tumor of nerve sheath. Despite of pseudosar-
comatous appearance, histopathologically, cellular schwannoma 
is considered as a benign tumor. However, it may carry atypical 
characteristics and risk of malign degeneration. We are presenting 
a case of primary pulmonary cellular schwannoma for discussing its 
clinical presentation and the prognosis.
Methods: A 65 years old male patient applied with the symptoms 
of cough and sputum production and found to have a 3x2.5 cm 
mass in the upper lobe of the right lung. At that time, retrospective 
examination of his available chest radiographs suggested a slowly 
growing lesion during a 4 years period. The mass was removed by 
extirpation and the histopathological diagnosis was cellular sch-
wannoma. After surgical treatment no residuel lesion was detecta-
ble and he was doing well clinically.
Results: He had been followed up yearly for 5 years. Eight years af-
ter the operation a 3x3x4 cm mass was seen at the same site of the 
previous lesion but the patient refused any surgical or diagnostic 
intervention. During follow up the lesion was found to be 6x6x5 cm 
in diameters 12 years after the operation.
Conclusion: In cellular schwannoma the treatment of choice is 
surgical removal of the mass and the relapse of the disease is very 
rare. However, in this case the lesion seems to be the relapse of 
the previous disease. We suggest that in some cases extirpation of 
the mass may not suffice and surrounding tissue of close contact 
should also be removed to avoid relapses.
Keywords: Pulmonary Schwannoma, Pulmonary neoplasm
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P1.24-046 HOW ARE TREATED FRENCH PATIENTS WITH 
METASTATIC LUNG ADENOCARCINOMA WITH "UN-
COMMON“ EGFR MUTATIONS? HOW COULD WE DO 
BETTER?
Raphaël Saffroy1, Nelly Bosselut1, Pierre Validire2, Philippe Slaou-
ti3, Armine Izadifar4, Jean-Francois Morere5, Jean Tredaniel6, An-
toinette Lemoine1
1Oncogenetics, Hôpital Paul Brousse/France, 2Pathology, Institut Mont-
souris/France, 3Centre National Mgen Alfred Leune/France, 4Saint An-
toine, Chu/France, 5Oncology, Hôpital Paul Brousse/France, 6Pneumolo-
gy, Hôpital Saint Joseph/France
Background: The progression-free survival and response rate 
of patients with EGFR-mutant tumors treated with an EGFR TKI 
has been reported to be superior to standard chemotherapeutic 
regimens. These mutations, concentrated in the exons 18 to 21 
encoding the tyrosine kinase domain of the receptor. However, TKI 
sensitivity depends upon the nature and location of the mutations. 
Eighty to 90% of all lung adenocarcinoma-associated EGFR muta-
tions are short, in-frame deletions in exon 19 and the exon 21 point 
mutation L858R; 70% of tumors with the latter mutations respond 
to treatment with the EGFR TKIs. The remaining 10 to 20 % of 
EGFR mutations include several additional point mutations that 
can be considered as "uncommon mutations“. Their identification 
is problematic for therapeutic decision. Indeed, it remains unclear 
whether these mutations have benefit upon progression-free or 
overall survival. Therefore a comprehensive strategy is required to 
prioritize treatment decisions by physicians in the routine clinical 
practice.
Methods: By retrospectively analyzing mutational data of 3,200 
consecutive patients with metastatic lung adenocarcinomas diag-
nosed for EGFR mutational status, we have identified those whose 
tumors had uncommon mutations (mutations that were neither 
base pair deletion in exon 19 nor the L858R in exon 21). We have 
contacted the physicians in charge of these patients and asked 
them the individual therapeutic decision. We have also questioned 
them about the level of their knowledge on the sensitivity of un-
common mutations to TKIs and how to improve this knowledge.
Results: Out of 3,200 metastatic lung adenocarcinomas, 351 tu-
mors (11%) exhibited abnormalities in the exons 18 to 21. Of these 
351 EGFR mutated tumors, 171 (48.7%) were base pair deletions in 
the exon 19: and 129 (36.7%) were the L868R in the exon 21. The 
14.5 % remaining tumors showed "uncommon“ mutations. There 
were G719 to A, C, or S mutations in 18 patients (5%), the L861Q 
mutation in 14 patients (3%) and only 1 Ins 18 pb in the exon 19. 
In exon 20, the T790M mutations were found in 4 tumors and in-
frame insertions of varying lengths that confer resistance to TKI in 
2 patients. Ten additional mutations, most of them being double 
mutations, were observed in 12 patients (3.4%). Of the 51 patients 
with uncommon mutations, 15 (29%) have received gefitinib or 
erlotinib whereas at least 32 patients should have received anti-
EGFR therapies. Reasons for this difference were 1) the lack of 
knowledge of the sensitivity of rare mutations, and mostly double 
mutations, 2) the difficulty of finding the answer, either on the re-
cord or in the scientific literature, 3) the possibility of introducing 
a platinum-based chemotherapy, 4) the lack of experience of the 
theranostic which includes many gene mutations.
Conclusion: Opportunities for improvement could be: 1) better 
information on the medical report when there is scientific evidence 
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P1.24-049 COMPARISON OF INFORMATION PROVIDED 
BY THE LUNG CANCER PTS THROUGH THE SURVEY 
WITH THE PHYSICIAN‘S EVALUATION.
Norma G. Pilnik1, Oscar Mareca2, Julio Di Rienzo3
1Oncology Department., Hospital Transito Caceres.cordoba University/
Argentina, 2Public Health, Cordoba University/Argentina, 3Satisticis, 
Cordoba University/Argentina
Background: Various factors such as age, stage and PS may provi-
de prognostic information in advanced NSCLC; however, a better 
understanding of a patient’s judgement can help the Physician to 
make appropriate decisions.Purpose:1- To study the information 
provided by pts in a questionnaire. 2 To study PS evolution ob-
tained by the doctor (DPS) and by the pts themselves (PPS).3-To 
evaluate the correlation between some different variables with 
survival.
Methods: Patients and Method: 224 pts with stages III and IV 
NSCLC, age range 38 - 74 years, were studied. The study was 
prospective. Pts underwent chemotherapy and/ or radiotherapy. 
They determined their own PS through a questionnaire . Some 
different variables such as age, stage, DPS, PSP, appetite, food 
intake, amount of solid food, evening meals, average meal per 
day, serving size, vomiting frequency, daily work activity , activity 
restrictions, and hours of rest per day were analyzed . DPS and PPS 
were studied at diagnosis and at 3 months. Statistical methods: 
Cox Proportional-Hazards Regression, Chi Square Pearson, Irwin-
Fisher,Mac Nemar Wilcoxon tests and Kaplan Meier Curves were 
used.
Results: According to the univariate logrank test applied to the 
comparison of the Kaplan and Meier survival curves, many factors 
seem to be related to survival. 9 of all variables studied were sta-
tistically significant. There were no complete agreement between 
DPS and PPS neither at initial evaluation nor at 3 months. Pts’ self 
assessment showed higher PS score than PS obtained by doctors.
(Mac Nemar Test p< 0.0001).The correlation among predictor 
variables is not taken into account when using the univariate ap-
proach, so a Cox hazard model for the proportional risk was ad-
justed using all the predictor variables available. To eliminate the 
less prognostic variables a backward regression test was applied 
It was found that only initial WL and DPS at the third month of 
evaluation were positively related to the risk of death. However the 
low correlation between WL as well asDPS provide independent 
information.there was statistically significant association between 
response rate with DPS and PPS. Nutritional parameters revealed 
no significant data.
Conclusion: Although the univariate approach showed that many 
factors are related to the survival of pts, the simultaneous analysis 
of these factors through the Cox model revealed that few of them 
summarize the most relevant prognostic information. These variab-
les are DPS at the third month of evaluation and initial WL.
Keyword: cancer care
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P1.24-048 STAGE 1 RESULTS OF A 2-STAGE PHASE II 
TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS 
WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES
Heather A. Wakelee1, Jonathan W. Riess1, Melanie San Pedro-Sal-
cedo1, Sukhmani K. Padda1, Kavitha Ramchandran1, Matthew A. 
Gubens2, Joel W. Neal1
1Medicine, Division Of Oncology, Stanford University School Of Medici-
ne/United States Of America, 2Division Of Hematology And Oncology, 
UCSF/United States Of America
Background: There are limited treatment options for patient 
with advanced thymic malignancies and the utility of many of the 
available chemotherapies is restricted by cumulative toxicity such 
as neuropathy (taxanes) and cardiomyopathy (anthracyclines). We 
designed this study to look at single agent amrubicin, a third ge-
neration anthracycline and topoisomerase II inhibitor with minimal 
cardiac toxicity, in patients with advanced thymic malignancies.
Methods: Eligible patients have confirmed thymic malignancy 
(thymoma (T) or thymic carcinoma (TC)) with progression or relapse 
after at least 1 prior chemotherapeutic regimen, and adequate 
organ function including left ventricular ejection fraction (LVEF) of 
>50%. The initial treatment plan consisted of amrubicin at 40 mg/
m2 IV days 1-3 repeated in 3-week cycles. The study is a Simon 
2-stage design based on a null hypothesis of a true response rate 
<5%, with 90% power to detect a 20% true response rate and a 
plan to accrue 12 evaluable patients in stage 1, then if at least 1 
response is seen, to add 25 additional evaluable patients in stage 
2 for a total of 39 patients.
Results: Enrollment was initiated in July 2011. Here, we report 
on the first 12 patients, all enrolled at Stanford University over a 
19-month period. Of the first 12 patients enrolled, 11 were dosed. 
All were pre-treated (5 with prior anthracycline). There were 5 
women and 7 men; age range of 30-67 years old; 6 were of Asian 
ethnicity, 5 were non-Hispanic White and 1 was Hispanic. After 
enrollment of the first 8 patients, of whom 3 were hospitalized with 
febrile neutropenia (FN) (38%), the study was amended to a star-
ting dose of 35 mg/m2 days 1-3 repeated in 3-week cycles. Other 
than FN in the 3 patients mentioned above, G4 thrombocytopenia 
in 1 patient, and treatment-related G3 fatigue in 2 patients, other 
toxicities were generally mild and well tolerated. No significant 
changes in LVEF have been noted on serial echocardiograms. Of 
the 11 treated patients, there were 3 partial responses (2 T and 1 
TC), 7 with stable disease for at least 4 cycles, and 1 with progres-
sive disease (PD) after 2 cycles (TC). Of the 11 treated patients, 
only 1 patient, with PD after C2, has stopped before completing 6 
cycles, and 5 to date have tolerated >10 cycles (with others still on 
treatment who may receive >10 cycles), with 15 cycles as the high-
est number to date.
Conclusion: Amrubicin, at 35 mg/m2 IV days 1-3 on a 3-week cycle, 
shows promise as a single agent in pre-treated patients with thy-
moma and thymic carcinoma with a 27% RR in the first 11 treated 
patients. This exceeded the threshold for proceeding to step 2 and 
the study will now continue to a total of 39 patients and has expan-
ded to other sites including Indiana University.
Keywords: chemotherapy, thymoma, Thymic carcinoma, amrubicin
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• Eventual treatment plan
• Outcome of community referral
• Introduce an anonymous patient satisfaction questionnaire.
• Consider using a nutritional screening tool specific to oncology 
patients.
References: Ravasco P. Monteiro-Grillo I. Marques Vidal P. & Cami-
lo ME. (2004) Cancer: disease and nutrition are key determinants 
of patient‘s quality of life. Supportive Care in Cancer. 12: 246-252 
Howell G. (2013) Nutritional reassessment and dietary support of 
thoracic oncology patients is a "MUST“. Lung Cancer. 79 (suppl 1): 
S42
Keyword: Dietetic telephone clinic, MUST score, weight loss, nut-
ritional support.
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P1.24-051 VIDEO-ASSISTED THORACOSCOPIC SURGE-
RY (VATS) FOR DIAGNOSIS AND THERAPY IN PRIMARY 
AND SECONDARY PLEURO-PULMONARY ANGIOSAR-
COMA
Johannes Bodner, Stefanie Kerber, Ibrahim Alkoudmani, Wilhem 
Stertmann, Martin Reichert
Division Of Thoracic Surgery, University Hospital Giessen/Germany
Background: Angiosarcoma is a rare (1-2% of all soft-tissue tumors) 
but highly-malignant tumor deriving from the endothelia of small 
vessels. It primarily affects the skin, mamma, liver and spleen and the 
lung is the predominant organ of metastatic spread. Symptoms as 
well as radiologic characteristics are unspecific and diagnosis is made 
by biopsy and histopathological assessment.
Methods: Single-center case series focusing on the role of VATS in 
diagnosis and (palliative) therapy of primary and secondary pleuro-
pulmonary angiosarcoma.
Results: From 11/2012 to 04/2013 three male patients (77 (74-78) y/o) 
underwent VATS for diagnosis and therapy of primary disseminated 
pleuro-pulmonary angiosarcoma (n=2) or bilateral pulmonary metas-
tases of a cutan angiosarcoma. All patients presented with unspecific 
symptoms like dyspnoea and chest pain. Primary angiosarcoma was 
associated with severe and recurrent hemorrhagic pleural effusion, 
while bilateral pulmonary angiosarcoma metastases led to a bilateral 
pneumothorax under systemic chemotherapy. Two patients suffered 
from recurrent hemoptysis. Indication for VATS was diagnosis (pleural 
biopsies, n=3) and palliative therapy (talcum pleurodesis [n=3] and 
apical wedge resection with pleurectomy [n=1]). Mean operating time 
was 62 (31-117) min. Following VATS (and diagnosis) all patient recei-
ved chemotherapy. One patient died 4 month after primary diagno-
sis, the two others are alive with stable disease.
Conclusion: Multiple unspecific pleural lesions on CT in patients 
presenting with hemoptysis and recurrent hemothorax may indicate a 
primary or secondary pleuro-pulmonary angiosarcoma. VATS is a safe 
minimally invasive single step procedure for both diagnosis and pallia-
tive therapy in this highly malignant soft tissue tumor.
Keyword: VATS
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P1.24-050 PILOT OF A WEEKLY DIETETIC TELEPHONE 
CLINIC FOR THORACIC ONCOLOGY OUTPATIENTS:  
A UK CANCER CENTRE EXPERIENCE.
Georgina Howell1, Lovisa Hilwig2
1Thoracic Oncology, Papworth Hospital NHS Foundation Trust/United 
Kingdom, 2Dietetics, Papworth Hospital NHS Foundation Trust/United 
Kingdom
Background: Nutritional decline and weight loss are common 
features in thoracic oncology patients and are independent prog-
nostic indicators for survival in lung cancer. Malnutrition reduces 
tolerability to treatment and increases both risk of complications 
and unplanned hospitalisation, all of which lead to increased disa-
bility and reduced quality of life (Ravasco et al, 2004). Changes in 
eating habits and weight loss can also cause significant psycholo-
gical distress to both patients and carers. Nutritional assessment 
and support should therefore be an integral component of the 
lung cancer patient’s care. The UK National Institute for Clinical Ex-
cellence recommends that all outpatients are screened for malnu-
trition at their first visit. We previously reported on a three month 
nutritional audit which identified that 37% of patients were at risk 
of malnutrition, confirming the need for dietary intervention (How-
ell, 2013). Subsequently an online referral system and a weekly 
dietetic telephone clinic were established to offer interim support 
to all outpatients. Data is presented here on the first 7 months of 
our year-long pilot project.
Methods: Between November 2012 and May 2013 all patients 
presenting to the Papworth Thoracic Oncology Service (PATHOS) 
with suspected thoracic malignancy were screened for malnutrition 
using the Malnutrition Universal Screening Tool (MUST) as part of 
a Holistic Needs Assessment. Patients at high risk of malnutrition 
(i.e. MUST score ≥2) received written and verbal advice on first line 
nutritional support, were commenced on oral dietary supplements 
and referred to the dietetic telephone clinic.
Results: 26 patients were referred to the dietetic telephone clinic. 
Assessment calls took approximately 30 minutes, whilst follow-up 
calls took 10-15 minutes. All patients received an initial assessment 
call, and the majority of patients received at least one additional 
follow-up call. 13 (50%) patients were subsequently referred to a 
community dietician for further management. The following com-
ments are examples of the feedback received. Patient A “it was 
helpful to have confirmation of what I should be eating and the 
types of foods to focus on”. Patient B “the information I received 
on food consistency and the different products available really 
helped”.
Conclusion: A multi-disciplinary team approach has been establis-
hed to support and educate thoracic oncology outpatients about 
their nutritional requirements. Although the numbers are small, the 
new service has been well received by both patients and staff. The 
online referral system is easy to use and the written information 
leaflet contains details of the referral and when patients will be 
contacted. Developments: 
• Modify the online referral system to include likely diagnosis and 
future plans.
• Maintain continuous audit, also collect data on:
• Diagnosis and stage of disease
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Conclusion: CXR was abnormal in the majority of these patients 
with early tumours. The mean time to presentation with a domi-
nant symptom was short. Almost a quarter of patients were asym-
ptomatic and picked up as an icidental finding.The challenge to 
identify lung cancer patients early, at a curable stage, continues. 
Keyword: symptoms presentation resectable
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P1.24-053 REPEATED PULMONARY RESECTIONS AT 
PULMONARY METASTASES SURGERY
Ivan Capov1, Jan Dolezel2, Vaclav Jedlicka3, Adam Pestal3, Zdenek 
Chovanec3
1I.st Department Of Surgery, Masaryk University/Czech Republic, 21st 
Department Of Surgery, St Anne´s Hospital/Czech Republic, 3First De-
partment Of Surgery, St. Anne´s Hospital, Masaryk University/Czech 
Republic
Background: Repeated pulmonary resections there are predo-
minantly used in sarcomas and colorectal cancers and in young 
age. Bad prognosis is in patients with reccurency of pulmonary 
metastases in period to six months. There are exist four prognostic 
groups according present risk factors (short disease free interval, 
multiple metastases).
Methods: We performed in period I/1997 to XII/2011 165 ope-
rations in 149 patients. 10patients had multiple pulmonary re-
sections. According origin histology were – 6x sarcomas. 2x tu 
Grawitz, 1x Schwannoma malignum, 1x ca laryngis. There are syn-
ovialosarcoma, osteosarcoma, rhabdomyosarcoma, alveolar sarco-
ma and sarcoma uteri in group of sarcomas.
Results: As approach we used VATS 2x, clamshel thoracotomy 2x, 
muscle sparing vertical thoracotomy 7x and posterolateral thora-
cotomy 6x. We performed extraanatomic resection 13x, lobectomy 
4x and completion pneumonectomy 1x. We observed 6x complica-
tions (3x small air leak, 3x wound infection) in postoperative peri-
od. No necessary rethoracotomy for complications, letality 0.
Conclusion: Surgery is part of complex therapy. There are very ne-
cessary strict selection of candidates for surgery and experienced 
team of thoracic surgeons. Surgery is safe and useful procedure at 
pulmonary metastases surgery.
Keywords: pulmonary metastases, repeated surgery, Pulmonary 
Metastases
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P1.24-052 SYMPTOMS AND EARLY DIAGNOSIS OF 
LUNG CANCER.
Marianne C. Nicolson1, Nicola Price1, Keith M. Kerr2, Elizabeth 
Steven1, Diane Stuchbury1
1Oncology, Aberdeen Royal Infirmary/United Kingdom, 2Department Of 
Pathology, Aberdeen University Medical School/United Kingdom
Background: In the UK, the 5-year survival for lung cancer pati-
ents is less than 10%. One of the reasons contributing to this poor 
survival is the late stage at diagnosis, with approximately 80% of 
patients presenting with unresectable disease. CT screening of 
high risk patients may be effective but is expensive and still under 
investigation in clinical trials. Symptom-driven investigations may 
be more likely to detect advanced than early disease. We present 
data of the presenting symptom type and duration in patients 
diagnosed at an early, potentially curable stage.
Methods: Data from available casenotes of patients with resected 
non-small cell lung cancer were extracted by one data manager 
(NP) to study the main presenting symptom, other tumour-related 
symptoms, duration (where documented), smoking history and 
stage of disease. All patients were treated in a single institution 
between 2003 and 2008. 
Results: 105 patients’ details are included. 54 were male; age 
range 40-83 years, mean 67 years. Chest X-ray was abnormal in 
103/105 patients. Smoking status was recorded in 83 (79%) cases. 
Three were never smokers. At time of diagnosis, 32 patients were 
still smoking and 17 had just quit. Of those who had stopped pre-
viously, 7 did so < 5 years before diagnosis, 5 at >5 < 10 years and 
19 > 10 years before diagnosis. Pack year estimates were available 
in 91 patients and ranged from 5 to 180 (mean 40). Tumour stage 
at resection was 1a in 28, 1b in 29, IIa in 19, IIb in 15 and IIIa in 14. 
25 patients had no symptoms (25%). The most common major pre-
senting symptoms are in Table 1. Pre-diagnosis duration of symp-
toms was recorded in 67 patients (84%). 31 (39%) had >1 symptom.  
Dominant 
symptom 
 
No of  
patients 
 
Duration in months (mean) 
 
Cough 
 
25 
 
1-24 (3) 
 
+haemoptysis 
 
10 
 
0.5-6 (1) 
 
Lower respira-
tory infections 
 
10 
 
0.5-36 (3) 
 
Dyspnoea 
 
10 
 
0.25-12 (1) 
 
Chest/arm 
pain 
 
9 
 
2 hours – 4months (1) 
 
Weight loss 
 
4 
 
3-6 
 
Other 
 
12 
 
1-12 (2) 
 
None 
 
25 
 
- 
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P1.25-002 TESTING THE FEASIBILITY OF A LUNG CAN-
CER NURSE COORDINATION MODEL DURING EARLY 
TREATMENT: PHASE II STUDY (CLINICAL TRIAL IN PRO-
GRESS)
Andrea Serena1, Anne-Claude Griesser2, Serge Leyvraz2, Nadia 
Fucina2, Solange Peters2, Kate White3, Manuela Eicher1
1University Of Applied Sciences And Arts Western Switzerland, School 
Of Health Fribourg/Switzerland, 2University Hospital Of Lausanne/
Switzerland, 3University Of Sydney/Australia
Background: To develop adequate self-care strategies, patients 
with lung cancer and their families are in need of emotional, infor-
mational and behavioural supportive care. Supportive care in can-
cer can reduce symptom burden and improve patients and their 
families self-management skills. As lung cancer incidence continu-
es to rise, and increased attention is given to early diagnosis, re-
search on early involvement of lung cancer nurse (LCN) in care, the 
feasibility and impact on patient outcomes is needed. The primary 
aim of this study is to assess the feasibility and acceptability of a 
LCN model of care commenced during first line of chemotherapy, 
and the impact on patient self-reported changes in self-efficacy, 
symptoms and supportive care needs. In addition perceived bar-
riers and facilitators for the application of the LCN model will be 
examined.
Methods: An exact single-stage phase II design will be conduc-
ted. Lung cancer patients with planned chemotherapy with or wit-
hout radiotherapy will be recruited at the thoracic cancer center in 
a Swiss University Hospital. The LCN model of care consists of two 
face-to-face consultations alternating with two telephone consulta-
tions during first line of chemotherapy. LCN consultations will com-
prise focused assessment of physical and psychological symptoms, 
information (printed and oral) about disease and its treatment, 
therapeutic education concerning strategies to manage physical 
and psychosocial symptoms and review of available support re-
sources. Participants will be invited to complete the validated pati-
ent reported Lung Cancer Symptom Scale, Supportive Care Needs 
Screening Tool 9 and Self-Efficacy Scale for Lung Cancer. Study 
data will be collected at baseline (day 1 of 1st chemotherapy cycle), 
time 1 (week 3 of 2nd cycle) and time 2 (week 3 of 3rd cycle). Parti-
cipants will be categorized as compliant if they complete all their 
scheduled LCN consultations and questionnaires. For a 5% proba-
bility of accepting a poor feasibility (alpha) and a 20% probability 
of rejecting an acceptable feasibility (beta) we then need to enroll 
71 patients. Feasibility will be considered as acceptable for further 
studies if at least 36 patients will be compliant. Secondary outco-
mes will be analyzed descriptively for each variable (self-efficacy, 
symptoms and supportive care needs) across each time point. 
At the end of quantitative data collection, a focus group will be 
conducted to explore acceptability of the new role among health 
professionals working with the LCN in order to identify perceived 
barriers and facilitators for collaborative work with the new role.
Results: N.A.
Conclusion: This project is expected to have direct impact on 
enhancing the quality of supportive care for patients with lung 
cancer. Findings will provide evidence for refining the LCN model 
prior to embarking on a full-scale evaluation using a comparative 
experimental design. Furthermore, phase II designs have rarely 
been applied to psycho-social interventions. This method could 
give new insights to the nursing and allied health professionals 
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P1.25-001 THE NATIONAL LUNG CANCER FORUM FOR 
NURSES (NLCFN)
Diana Borthwick1, John White2
1Edinburgh Cancer Centre, Western General Hospital, Nhs Lothian/Uni-
ted Kingdom, 2St James`s Institute Of Oncology, Leeds Teaching Hospi-
tals NHS Trust/United Kingdom
Background: Lung cancer affects nearly 40,000 patients per year in 
the UK and despite recent improvements in treatments, outcomes 
remain poor (NCIN 2012). Therefore the delivery of high quality 
care is vital. Lung Cancer Nurse specialists (LCNS) are well placed to 
provide holistic care, ensuring needs are addressed throughout the 
pathway, and there is an improvement in outcomes and experience 
for patients. The National Lung Cancer Forum for Nurses (NLCFN) 
was established in 1999 and is a national organisation in the United 
Kingdom (UK) developed to support lung cancer nurses through 
education, sharing best practice and peer support through a natio-
nal network. The Forum has grown inexplicably and its success can 
be measured by the links and networks for nurses involved in caring 
for people with lung cancer as well as the strategic groups it is invol-
ved with nationally and internationally. The members are from diver-
se backgrounds of palliative care, respiratory medicine and thoracic 
oncology which results in a wealth of experience and knowledge. 
The NLCFN has approximately 280 members.
Methods: The NLCFN runs a Research Interest Group (RIG) and 
a Thoracic Nurses Subgroup (TNS) and both groups are active in 
improving practice and initiating research projects in lung cancer. 
The NLCFN proactively supports nursing research and offers a small 
grant award scheme each year to support lung or thoracic nurses 
who wish to develop a research project. Collaboration between the 
Forum and Sheffield Hallam University has led to the development 
of funding for a part-time PhD studentship. The RIG has been suc-
cessful in obtaining a research grant to explore in more detail the 
evaluation of the LCNS role in treatment access. The NLCFN also 
hosts a website where patients, carers and clinicians can assess up-
to-date information on lung cancer management, treatments and 
interventions and find out about local and national services for lung 
cancer patients. There is a NLCFN members section which houses 
guidelines and relevant documents
Results: Over the last 10 years the NLCFN has developed into a 
national voice on clinical and strategic issues and as such is repre-
sented on all lung cancer improvement and strategic groups in the 
UK. The NLCFN have produced several documents and guidelines 
which are available to all health care professionals.
Conclusion: The number of Lung Cancer Nurse Specialists has in-
creased since the introduction of the role in 1995. They play a vital 
role in supporting patients and carers throughout their pathway 
from pre-diagnosis to end of life care and ensuring that all their 
needs are addressed. The NLCFN aims to provide the LCNS with a 
good infrastructure for networking and support as well as continu-
ally striving for better care for their patients.
Keyword: Forum, Lung Cancer, Nurses
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(31%). Two thirds were stage IV, and 57% did not have ongoing on-
cological treatment. On 83 occasions (34%), referral was by the ge-
neral practitioner (GP-REF), for 101 (41%) own initiative (SELF-REF), 
and for 63 (26%) specialist advice. The most frequent main presen-
ting symptoms were respiratory (21%), infection (15%), general wea-
kness (15%), and pain (13%). The mean hospitalization duration was 
9.5 days, shorter and with more same-day-return in SELF-REF pati-
ents (Table). Final diagnoses were categorized in nine groups: infec-
tion (22%), respiratory problems (17%), lab abnormalities (13%), pain 
(12%), abdominal problems (11%), cardiovascular problems, neuro-
logical events, general weakness and other (6% each). This differed 
from the problem as recorded in the ER in one third of the events. 
Final grading (CTC AE v3.0) of the main event was 1-2 in 38%, 3 in 
51%, 4 in 8% and 5 in 2%. Causality was decided as therapy-related 
(THER-REL) in 59, cancer-related (CANC-REL) in 117, unrelated in 
48, and unclear in 23. In the THER-REL events, lab abnormalities 
(36%), infection (34%) and abdominal complaints (22%) were most 
common, while this was respiratory problems (23%), pain (18%) and 
infection (16 %) for CANC-REL events. On subgroup analysis (Table), 
length of stay was higher in CANC-REL events. Nearly all THER-REL 
events had medical therapy, while for CANC-REL events this was 
medical 50%, interventional 33% and supportive only 17%. 
Conclusion: UHA in lung cancer are predominantly cancer- rather 
than therapy-related, with a variety of symptoms. More than half of 
the events are not seen by the GP first, and the majority results in 
hospital stay of 9.5 days on average . Our work is a first step in iden-
tifying specific groups of events, where better interaction with GPs 
and education of patients might reduce the incidence of UHAs.
Keywords: attitude to health, outpatients, chemotherapy,  
unplanned admissions
how to investigate the efficacy and feasibility as well as the needed 
intensity of newly developed interventions in order to improving 
supportive care in oncology.
Keywords: Self-management, Lung Cancer Nurse, supportive care
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P1.25-003 CHARACTERISTICS AND OUTCOME OF  
UNPLANNED ADMISSIONS IN PATIENTS WITH LUNG 
CANCER: A LONGITUDINAL TERTIARY CENTER STUDY.
Christel Oyen, Aurélie Derweduwen, Christophe Dooms, 
Kristiaan Nackaerts, Johan Vansteenkiste
Respiratory Oncology Unit (Dept. Pulmonology) And Leuven Lung 
Cancer Group, University Hospital KU Leuven/Belgium
Background: Unplanned hospital admissions (UHAs) are frequent 
in lung cancer patients, but literature on this topic is scarce. The 
aim of this study is to get better insight in the demographics, pat-
terns of referral, presenting symptoms, and outcome of lung can-
cer patients with UHA.
Methods: Data of all consecutive events of UHA between July 1 
and December 31, 2012 were reviewed. Details on the factors lis-
ted above were examined.
Results: There were 247 UHA events during the 6 month study peri-
od. Male/female ratio was 185/62, mean age was 66 years (range 40-
90), PS on admission was 0-1 in 79 (32%), 2 in 92 (37%), and 3-4 in 76 
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the medication adherence affects the outcomes of cancer treatment 
and quality of life of people with cancer.
Methods: Not applicable
Results: Not applicable
Conclusion: In this presentation we will discuss the role of tumor 
biomarkers in designing personalized therapy Identify different oral 
cancer therapies and how they are named Define adherence Discuss 
different factors impacting patient adherence and Implications for 
clinical practice
Keyword: personalised medicine, safety, adherence, education
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P1.25-006 LUNG CANCER AND COMORBIDITIES:  
A REGIONAL POPULATION COMPARED WITH AN  
URBAN POPULATION
Renae Grundy1, Dawn Bedwell2
1Oncology, Royal Hobart Hospital/Australia, 2Royal Brisbane And Wo-
mens Hospital/Australia
Background: Li and Girgis (2006) note patients with lung cancer 
have a higher level of unmet needs than patients with other types 
of cancer. Wilder et al (2008) found cancer patients report signifi-
cantly more comorbid conditions, poorer physical and mental health 
compared to the general population. Lung Cancer Nurses utilise 
a community wide approach to optimise cancer care for patients, 
provide patient centred care and promote multidisciplinary care. 
The implications of lung cancer patients having the presence of 
multiple comorbidities at diagnosis include; an increased need for 
nursing education surrounding the more common comorbidities, 
poly-pharmacy issues, increased clinical needs, increased communi-
ty supports and psychosocial support. Also the financial implications 
of increased care needs both to the patient and the community. 
Data is being collected from two different hospitals, one regional 
and one urban, from two different states within Australia. Although 
geography and resources determine the fine tuning of the Lung 
Cancer Nurse role to individual hospitals, essentially both models of 
care promote improved patient outcomes.
Methods: All new patients presented in the Lung cancer Multidisci-
plinary team meeting for a twelve monthe period from September 
2012 to end of August 2013 will have their comorbidity data collec-
ted. Including associated pharmacy, performance status, main carer 
and smoking status. The same data is being collected at both sites 
in this study.
Results: and their implications will be discussed once data collec-
tion completed at end of August 2013.
Conclusion: Preliminary data is showing that the majority of our 
patients with lung cancer have multiple comorbidities and thus, poly 
pharmacy and increased needs. The data between the urban and 
regional hospitals will be compared and the implications, differen-
ces, simliarties and the impact this has on the Lung Cancer Nurse‘s 
role at each site will be discussed as well as future directions and 
what regional and urban areas can learn from each other.
Keywords: Lung Cancer Nurse, comorbidities
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P1.25-004 DEEP VENOUS THROMBOSIS PREVENTION 
EFFECT OF ELECTRICAL STIMULATION OF ACUPOINT 
COMBINATIONS IN ELDERLY BEDRIDDEN PATIENTS  
AFTER MAJOR SURGERY
Lili Hou
Nursing Department, Nursing Department Of Shanghai Pulmonary 
Hospital/China
Background: not applicable
Methods: During November 2010 to October 2011, 160 elderly 
bedridden patients after major surgery were divided into the con-
ventional care group, “invigorating qi and promoting qi” group, 
“Blood-activating and Dampness-eliminating” group and acupoint-
combination stimulation group. Whole blood viscosity, plasma 
viscosity, D-dimer, lower limb skin temperature, lower limb circumfe-
rence and flow velocities of the external iliac vein, the femoral vein, 
the popliteal vein and the calf deep veins in all patients were docu-
mented and compared as four individual groups.
Results: Whole blood viscosity, plasma viscosity, D-dimer and lower 
limb circumference were significant reduced in “Blood-activating 
and Dampness-eliminating” group compared to conventional care 
group (P<0.05) and almost equal to the results in acupoint-combi-
nation stimulation group (P>0.05). Lower limb venous flow velocities 
were accelerated in“invigorating qi and promoting qi” group com-
pared to groups other than the acupoint-combination stimulation 
group (P<0.05).
Conclusion: Hemorheological indexes in postoperative bedridden 
elderly patients were improved after electrical stimulations of Yin-
lingquan (SP 9) and Sanyinjiao (SP 6) in combination. Electrical stimu-
lations of Zusanli (ST 36) and Taichong (LR 3) in combination, on the 
other hand, accelerated the lower limb venous flow.
Keywords: Nursing care, Thrombosis, Blood flow velocity, Acupoint
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P1.25-005 PATIENT SAFETY FRAMEWORK ROLE OF 
ONCOLOGY NURSES IN THE ERA OF ORAL CANCER 
TREATMENTS IN PATIENTS WITH NSCLC: ARE WE  
READY?
Massey Nematollahi
Stronach Regional Cancer Centre/Canada
Background: With recent progresses and advances in technology, 
the number of oral cancer treatment is on the rise. Treatment for 
NSCLC was once chosen only according to the stage of disease and 
its histologic classification. Though these are important , but disco-
very of tumor markers and identification of biomarkers and genetic 
profiling in lung cancer have led to an added layer of classification. 
This new evolution have improved lung cancer treatment by provi-
ding information that helps oncologist match the right patient with 
the right treatment which will move majority of these patients from 
infusion centres to their homes. The concern will show up about how 
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P2.01-002 TARGETING CHAPERONE ACTIVITY AND 
CHAPERONE EXPRESSION IN HUMAN LUNG CANCER 
CELLS SENSITIZES THEM TO CHEMOTHERAPY AND  
RADIOTHERAPY
Alexander Kabakov, Vladimir Kudryavtsev, Vera Mosina
Medical Radiology Research Center/Russian Federation
Background: Development of new methods for selective che-
mosensitization and radiosensitization of human lung tumors is 
acutely needed. We propose to combine inhibitors of the chape-
rone activity along with inhibitors of chaperone expression to treat 
lung cancer. Our approach is based on such facts: (i) cancer cells 
are addicted to the chaperone activity of heat-shock protein 90 
(Hsp90) because it is required for their survival and proliferation, (ii) 
inhibitors of the Hsp90 chaperone activity (e.g. 17AAG) may have a 
100-fold higher affinity to Hsp90 in malignant cells than in normal 
cells and (iii) these Hsp90 inhibitors cause undesirable induction of 
cytoprotective chaperones Hsp70 and Hsp27 that can impair anti-
tumor effects of the Hsp90 inhibition.
Methods: Cultured cells of human lung cancer cell lines SQ-5, 
H460 and A549, and, for comparison, human normal lung-derived 
alveolar epithelium or fibroblasts were subjected to 17AAG and 
known inhibitors of the Hsp induction (quercetin, triptolide, NZ28) 
and conventional drugs (carboplatin, doxorubicin, paclitaxel) or cli-
nically relevant doses (3-5 Gy) of gamma-photon irradiation. Inhibi-
tion of the intracellular Hsp90 chaperone activity was detected on 
a delay in the Hsp90-dependent reactivation of thermally denatu-
red luciferase in the heat-stressed transfectants. The cell death or 
survival was assessed in annexin V-staining and clonogenic assays. 
The angiogenic potential of lung cancer cells was tested in cell-
proliferation assays with cultured human vascular endothelial cells 
(EC). The cellular levels of cell survival- and angiogenesis-related 
proteins were analyzed by Western blotting.
Results: It was found that 10-100 nM 17AAG significantly retar-
ded proliferation in all the three lung cancer cell lines studied. As 
biomarkers of the Hsp90 activity inhibition, the specific depletion 
of Akt, survivin and HIF-1alpha as well as up-regulation of Hsp70 
and Hsp27 were revealed in those cell samples. In parallel, co-
treatment with 10-30 uM quercetin or 2-4 nM triptolide, or 0.3-1 
uM NZ28 fully prevented the Hsp up-regulation in the 17AAG-
treated lung cancer cells and rendered them much more sensitive 
to carboplatin, doxorubicin and paclitaxel, and to gamma-radiation 
exposure. Importantly, no enhanced cytotoxicity was observed in 
cultures of normal human fibroblasts and epithelial cells co-treated 
by the same way. The enhanced chemo- and radiosensitization 
of lung cancer cells appears to be due to simultaneous blocka-
de of both the Hsp90-dependent antiapoptotic pathways and 
the 17AAG-induced up-regulation of cytoprotective Hsp70 and 
Hsp27. Besides the sensitizing effects on the lung cancer cells, the 
double-inhibitor combination considerably reduced their angio-
genicity that was manifested in down-regulation of the HIF-1alpha 
and VEGF expression levels, and also in the clearly impaired pro-
liferative response of EC stimulated with lung cancer cell culture-
conditioned growth medium.
Conclusion: Combined use of the Hsp90 chaperone activity inhi-
bitors and blockers of the concomitant induction of inducible cha-
perones Hsp70 and Hsp27 enables to selectively sensitize human 
lung cancer cells to chemo- and radiotherapy, and to suppress 
the lung cancer-associated angiogenesis. In perspective, such an 
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P2.01-001 DEREGULATED INTERLEUKIN-6 SIGNALING 
SUPPRESSES LUNG TUMOURIGENESIS IN MICE INDU-
CED BY NICOTINE-DERIVED NITROSAMINE KETONE
Saleela Ruwanpura, Alistair Miller, Louise Mcleod, Brendan JeN-
KIns
Monash Institute Of Medical Research, Monash University/Australia
Background: Serum levels of the potent immune-modulatory cyto-
kine interleukin (IL)-6, which signals via the shared gp130 co-recep-
tor, are elevated in smokers, and are higher still in those with lung 
cancer, the leading cause of cancer death worldwide. However, 
the precise role that IL-6 plays in the pathogenesis of lung cancer 
remains to be elucidated. To utilize in vivo molecular dissection of 
gp130 signaling to identify specific molecular components of the 
IL-6 cytokine family network which facilitate tobacco-related lung 
carcinogenesis.
Methods: Nicotine-derived Nitrosamine Ketone (NNK) is a potent 
tobacco carcinogen and reliably induces lung tumours in mice. 
We therefore examined the effect of deregulated IL-6 signaling on 
NNK-induced lung carcinogenesis by using gp130F/F mice which 
carry a knock-in mutation in the endogenous gene for gp130, the 
critical co-receptor for the IL-6 cytokine family.
Results: The lungs of these mice display IL-6-induced hyperac-
tivation of the latent transcription factor Stat3 via gp130 in the 
absence of gp130-mediated PI3K/Akt and Mapk signaling. The 
gp130F/F and control gp130+/+ (wild-type) mice were injected with 
NNK or PBS and observed over 16 weeks prior to the evaluation of 
lung tumourigenesis at the cellular (immunohistochemistry, histo-
logy) and molecular (qPCR) levels. In response to NNK, the abso-
lute number of lung lesions in gp130F/F mice (3.81 ± 0.84; mean ± 
SEM) was significantly reduced compared to gp130+/+ (6.43 ± 1.72; 
p<0.05) mice. In addition, we also observed a significant reduction 
in the size of lesions in gp130F/F compared to gp130+/+ mice (1.00 ± 
0.05mm vs 0.69 ± 0.05; p<0.0001). Notably, the number and size of 
lesions in the lungs of NNK-treated gp130F/F:Stat3-/+ mice display-
ing genetically-reduced Stat3 hyperactivation were comparable to 
gp130F/F mice.
Conclusion: Collectively, our data suggest that IL-6/gp130-me-
diated activation of the PI3K/Akt and/or Mapk pathways, but not 
Stat3, plays an important role in promoting NNK-induced lung 
carcinogenesis.
Keywords: mouse model, cancer signalling, Lung cancer, interleu-
kin 6
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adducts from DNA, was excluded by our experiments.
Conclusion: Altogether these data reveal the possibility that the 
presence of G12C KRAS mutation stimulates a DNA repair me-
chanism, not yet identified, able to faster remove platinum from 
DNA before the formation of double strand cross-links. Studies are 
ongoing to specifically address this point. Understanding why the 
different KRAS mutations influence the response to cisplatin could 
be useful in the clinical setting to tailor therapies for patients.
Keywords: resistance, KRAS, NSCLC, cisplatin
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P2.01-004 TYPE OF P53 MUTATION INFLUENCES ONCO-
GENIC POTENTIAL AND SPECTRUM OF ASSOCIATED K-
RAS MUTATIONS IN LUNG SPECIFIC TRANSGENIC MICE.
Wenrui Duan1, Li Gao2, Arjun Kalvala2, Christopher Christopher 
Brooks2, Brittany Barnwell2, Xiaokui Mo2, Haiming Ding2, Konstan-
tin Shilo2, Gregory Otterson1, Miguel Villalona-Calero1
1Medical Oncology, The Ohio State University/United States Of Ameri-
ca, 2Cancer Center, The Ohio State University/United States Of America
Background: p53 mutations have been categorized as type I (con-
tact) and type II (conformational) mutations. Differential effects of 
type I vs. type II p53 mutations in spontaneous lung tumor forma-
tion, and their relationship with secondary genetic alterations have 
not been previously reported. .
Methods: We evaluated the potential of two common type I 
(273H) and type II (175H) mutations under the transcriptional con-
trol of the human surfactant protein C (SP-C) promoter to induce 
lung tumors in transgenic mice. Necropsies of 138 non-transgenic, 
207 SP-C-p53-273H and 171 SPC-p53-175H transgenic mice in 
progressive age cohorts were performed.
Results: Ninety-one tumors, all adenocarcinomas, were observed; 
8 (5.8%), 37 (17.9%) and 46 (26.9%) in non-transgenics, p53-273H 
and p53-175H, respectively (non-transgenic vs. 273H, p=0.010; 
non-transgenic vs. 175H, p= 0.0003; logistic regression). Type II 
p53 mutants had an earlier onset of tumors; 23 of 98 p53-175H 
mice developed tumors before the age of 13 months, compared to 
7 of 108 p53-273H mice (p=0.012, logistic regression). K-ras muta-
tions occurred in a substantial proportion (21 of 50, 42%) of murine 
lung tumors sequenced. For both the non-transgenic and the p53-
273H transgenics, tumor K-ras codon 12-13 mutations occurred 
after 13 months with a peak incidence at 16–18 months. However, 
for the p53-175H transgenics K-ras codon 12-13 mutations were 
observed as early as six months, with a peak incidence between 
the ages of 10-12 months. Codons 12-13 were the predominant 
location in p53-175H transgenics (6 of 7), whereas codon 61 (6 of 
10) was more common in p53-273H transgenics.
Conclusion: The observation of accelerated tumor onset, early 
appearance and high frequency of K-ras codon 12-13 mutations in 
type II p53-175H mice confirms the enhanced oncogenic function 
of conformational p53 mutations, and the gains in early genetic 
instability for tumors containing these mutations compared to 
contact mutations. These data would suggest that not only the 
presence, but also the type of p53 mutations in human lung cancer 
should be considered when evaluating prognosis and developing 
treatment strategies for this malignancy. These mice develop a 
approach may be developed into a new, effectual strategy for lung 
cancer treatment.
Keyword: chemosensitization, radiosensitization, heat-shock pro-
teins, targeted therapy
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P2.01-003 MODULATION OF CISPLATIN ACTIVITY IN 
NSCLC BY KRAS MUTANTS: ROLE OF SPECIFIC MUTA-
TIONS AT CODON 12
Elisa Caiola1, Roberta Frapolli1, Massimo Broggini1, Marina C. Ga-
rassino2, Gabriella Farina3, Mirko Marabese1
1IRCCS-Istituto Di Ricerche Farmacologiche "Mario Negri“/Italy, 2Me-
dical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori/Italy, 
3Fatebenefratelli E Oftalmico Hospital/Italy
Background: Non-small-cell lung cancers (NSCLCs) constitute 
about 85% of lung cancers and have been associated with a poor 
prognosis, despite the introduction in clinical practice of targeted 
therapies. The majority of patients are still treated in first-line with 
a cisplatin containing doublet. New molecular predictors should 
be discovered. Our attention has been focused on KRAS. Muta-
tions in the KRAS gene have been found in 17% of NSCLC patients 
mostly at codon 12. It has been observed that a pool of mutations, 
responsible for different aminoacid substitutions, occured at this 
position. In NSCLC these mutations are present at a different 
frequency compared to colon and pancreatic cancer. It has been 
supposed that different aminoacids in the same position of KRAS 
protein could differently impact on tumor progression and drug re-
sistance. To test this hypothesis, KRAS overexpressing clones with 
the three most common mutations found in NSCLC patients (G12C, 
G12D and G12V) have been generated in NCI-H1299 cell line. The 
clones showed a different response in vitro to cisplatin (Garassino 
MC et al, Annals of Oncology, 2011).
Methods: The clones were xenografted in nude mice to determine 
the antitumor activity of cisplatin in vivo. The effect of cisplatin on 
signalling pathways and DNA damage response was determined 
by western blotting, immunofluorescence and Real-Time PCR. 
Platinum adducts on DNA were revealed by DRC-ICP-MS.
Results: The resistance induced by the presence of G12C KRAS 
was still present compared to wild-type KRAS clone when these 
clones were transplanted in nude mice and treated with cisplatin. 
Some of the logic pathways functionally linked to KRAS, such as 
MAPK and PI3K, did not seem to account for the different cisplatin 
sensitivity observed. Factors previously reported to be associated 
to cisplatin resistance, such as the levels of cisplatin transporter 
CTR-1, of GSH and GST enzyme, and the total intracellular plati-
num levels were comparable among the clones. Several concor-
dant results seem to indicate that, with a similar ability to enter 
the cells and to reach the DNA, an increased removal of platinum 
bound to DNA might account for the resistance of G12C clone: i) 
the cell cycle perturbation induced by cisplatin indicated that a 
reduced G2/M cell cycle phase block was observed in the G12C 
clone compared to all the others; ii) H2AX foci and ATM phos-
phorylations following treatment were barely detectable in the 
resistant clone; iii) the levels of platinum bound to DNA were much 
faster declining in G12C cells. The involvement in the resistance 
of G12C clone of Nucleotide Excision Repair and Fanconi Anemia 
repair mechanisms, which have been associated to the removal of 
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cantly lower in homozygous deletion-positive MPM (21/25 cases) 
than homozygous deletion-negative MPM (4/25 cases) (p= 0.01).
Conclusion: 9p21 FISH was useful for differentiating MPM from 
RMH, and p16 homozygous deletion in MPM has the potential to 
be a prognostic factor. Moreover, a combination of p16 FISH, p16 
real-time PCR and MSP is useful for discriminating heterozygous 
deletion from homozygous deletion in MPM. The presence of he-
terozygous deletion suggest the possibility of a p16-independent 
tumorgenesis pathway in MPM.
Keywords: Homozygous deletion, real-time PCR, malignant meso-
thelioma, p16 FISH
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P2.01-006 NOVEL SMALL COMPOUNDS TARGETING 
CANCER STEM CELLS OF NON-SMALL CELL LUNG CAN-
CER
Chia-Ning Yang1, Yu-Peng Liu2, Pei-Jung Lu2
1Institute Of Biotechnology, National University Of Kaohsiung/Taiwan, 
2Institute Of Clinical Medicine, National Cheng Kung University/Taiwan
Background: Platinum-based combination chemotherapy is the 
first-line treatment for advanced non-small cell lung cancer, but 
tumor recurrence occurs in most of patients who have received 
this treatment. Recent evidences suggested existence of CD133+ 
cancer stem cells is the cause of drug resistance and tumor re-
currence. However, there is no efficient way to eliminate CD133+ 
cancer stem cells. Accordingly, the goal of this study is to identify 
novel compounds that targeting CD133+ CSCs of non-small cell 
lung cancer.
Methods: A hCD133 promoter-driven GFP reporter construct was 
used to identify CD133+ cells. CD133+ cells were FACS sorted 
from H460 cell line. The stemness and drug resistance of CD133+ 
cells were characterized according to their sphere formation, dif-
ferentiation, gene expression, and chemo-response. IC50 of each 
novel compound was determined using MTT assay.
Results: CD133+ lung cancer cells identified by a human CD133 
promoter- driven GFP reporter exhibited drug resistance and ex-
pressed stem-cell characteristics. Treatment of lung cancer cells 
with cisplatin was sufficient to result in enrichment of CD133+ cells, 
to induce DNA damage responses, to up-regulate levels of ABCG2 
and ABCB1 which therefore increased resistance to doxorubicin 
and paclitaxel. We further found that cisplatin-induced enrichment 
of CD133+ cells was mediated by activation of notch signaling as 
judge by increased levels of NICD. Pre-treatment of cells with g-
secretase inhibitor, DAPT, remarkably reduced cisplatin-induced 
enrichment of CD133+ cells and increased the sensitivity to do-
xorubicin and paclitaxol. Ectopic expression of NICD reversed the 
function of DAPT on drug sensitivity. The similar effect was also 
observed in tumor-engraft experiments as cisplatin treatment 
significantly increased the number of CD133+ cells in tumor-
engraft in nude mice. In contrast, intra-tumor injection of DAPT 
together cisplatin was able to significant decrease the number 
of CD133+ cells in the tumor-engraft of mice. To identify novel 
compounds that may target CSC and cancer cells, we tested the 
cytotoxic effect 30 synthesized small compounds. Among of these 
compounds, 4 compounds, NCKU-44, NCKU-291, NCKU487 and 
NCKU-570, effectively killed both CD133+ CSCs and parental can-
single-lung tumor that is easy to follow with CT imaging. Thus, the-
se animal models provide a framework for evaluation of the effects 
of these mutations on response to standard and novel anticancer 
treatment interventions.
Keywords: p53 mutation, K-ras Mutation, gain of function, non-
small cell lung cancer
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P2.01-005 DIAGNOSTIC APPLICATION OF 9P21 HOMO-
ZYGOUS AND HETEROZYGOUS DELETION DETECTED 
BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH) AND 
P16 REAL-TIME PCR IN MALIGNANT MESOTHELIOMA
Makoto Hamasaki1, Shinji Matsumoto1, So Miyahara1, Toshiaki 
Kamei2, Kenzo Hiroshima3, Yoshihiro Matsuno4, Kunimitsu Kawa-
hara5, Tohru Tsujimura6, Akinori Iwasaki7, Takayuki Shirakusa8, 
Kazuki Nabeshima1
1Pathology, Fukuoka University/Japan, 2Yamaguchi Grand Medical 
Center/Japan, 3Pathology, Tokyo Women‘s Medical University/Japan, 
4Surgical Pathology, Hokkaido University Hospital/Japan, 5Osaka Pre-
fectural Medical Center For Respiratory And Allergic Disease/Japan, 
6Pathology, Hyogo College Of Medicine/Japan, 7Thoracic, Breast, Endo-
crine, And Pediatric Surgery, Fukuoka University/Japan, 8Fukuseikai 
Hospital/Japan
Background: Detection of homozygous deletion of the 9p21 locus, 
the site of the CDKN2A/p16 gene, is useful in differentiating reacti-
ve mesothelial hyperplasia (RMH) from malignant pleural mesothe-
lioma (MPM) in pleural effusion cytology, biopsy specimens, and 
surgical specimens. However, the cutoff value for 9p21 FISH varies. 
Furthermore, 9p21 FISH reveals not only homozygous deletion, but 
also heterozygous deletion, in MPM tissue samples, and only two 
studies have evaluated heterozygous deletion. The aim of this stu-
dy was to establish a FISH cutoff value for 9p21 homozygous dele-
tion and apply it to a clinical diagnosis. In addition, we investigated 
the significance of 9p21 heterozygous deletion in MPM.
Methods: Design: Ninety-five histopathological (49 MPM + 47 
RMH) and 35 cytological (15 MPM + 20 RMH) cases were studied. 
Cutoff values were evaluated as mean + 3SD based on the results 
of RMH 9p21 FISH. The copy number of the p16 gene was ana-
lyzed in 22 MPM tissue samples and 17 RMH by real-time PCR, 
using RSP6 as a control gene, and samples were divided into three 
groups (1.0: no deletion, 0.5: one allele deletion, and 0: two allele 
deletions). Methylation-specific PCR (MSP) was performed in two 
heterozygous deletion dominant cases. Overall survival was evalu-
ated using Kaplan-Meier survival analysis and log-rank test.
Results: In MPM, 44/49 (90%) cases were homozygous deletion-
positive (>10% cutoff value), and 12/49 (24%) cases were heterozy-
gous deletion-positive (>46.6% cutoff value) by p16 FISH. None of 
RMH cases were deletion-positive in tissue samples. Real-time PCR 
was performed for 22 cases of MPM and 17 cases of RMH. The p16 
copy number in RMH was 0.83-1.28 (average 1.06). In MPM, 16/22 
(73%) revealed a two-allele deletion pattern for p16. Two cases of 
homozygous deletion-negative MPM by FISH also had no deletion 
pattern by real-time PCR. One case of heterozygous deletion-
dominant MPM (over 55%) revealed a two-allele deletion of p16 by 
real-time PCR, and two cases showed a one-allele deletion of p16. 
These cases had no methylation by MSP. In 25 cases of MPM for 
which follow-up was available, the overall survival rate was signifi-
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of SCLC between central type and peripheral type.
Keywords: small cell lung cancer(SCLC), tumor location, microar-
ray analysis
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P2.01-008 SIGNIFICANCE OF CANCER-ASSOCIATED FIB-
ROBLASTS IN THE REGULATION OF GENE EXPRESSION 
IN THE LEADING CELLS OF INVASIVE LUNG CANCER
Jian An
Respirology, Centra South University, Xiangya Hospital/China
Background: Cancer-associated fibroblasts (CAFs) contribute to 
cancer progression through multiple pathways.
Methods: Here we comprehensively compared gene expression 
in lung cancer cells cultured with conditioned medium from lung 
CAFs and normal lung fibroblasts by cDNA microarray analysis.
Results: The expression of many genes was up-regulated in can-
cer cells by CAFs’ conditioned medium, particularly cell adhesion 
molecules integrins and anti-apoptotic protein Bcl-2. Additional 
analysis indicated that the expression of integrins seems to be 
upstream of that of Bcl-2. We identified transforming growth 
factor-β as a candidate factor that induces the expression of those 
genes in cancer cells. Immunohistochemical studies on clinical lung 
cancer tissues revealed that integrins and Bcl-2 are more highly 
expressed in the leading cells, but not the following cells, at the 
invasive front of cancer nests, which are adjacent to or in proximity 
to the stroma. Furthermore, the expression of integrins and Bcl-2 
in the leading cells was correlated with the clinical stages of cancer 
progression including lymph node metastasis.
Conclusion: In conclusion, our results suggest that CAFs promote 
lung cancer progression partly through the direct regulation of 
gene expression in the leading cells of invasive cancer nests.
Keywords: leading cells, Lung cancer, cancer-associated fibro-
blasts, collective invasion
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P2.01-009 ALTERED EXPRESSION OF APKC LAMBDA/
IOTA AND LGL2 CORRELATES WITH INVASION AND 
METASTASIS IN LUNG ADENOCARCINOMA
Naoko Imamura1, Yosuke Horikoshi2, Tomohiko Matsuzaki1, Ryota 
Masuda1, Susumu Takekoshi3, Masayuki Iwazaki1
1Division Of Thoracic Surgery, Department Of Surgery, Tokai University 
School Of Medicine/Japan, 2Division Of Medical Biochemistry, Depart-
ment Of Pathophysiological And Therapeutic Science, Tottori University 
Faculty Of Medicine/Japan, 3Department Of Cell Biology, Division Of 
Host Defense Mechanism, Tokai University School Of Medicine/Japan
Background: Many early-stage NSCLCs in spite of treating with 
surgical resection and adjuvant therapy relapse, occur metastasis 
and become fatal. Therefore there is an urgent need for research 
cer cells. Three compounds, NCKU-46, NCKU-mo and NCKU-ts, 
specifically targeted to CD133+ CSCs.
Conclusion: In our study, we developed a drug-screening platform 
of CD133+ CSC of non-small cell lung cancer. At least 7 novel com-
pounds were identified as potential CSC-targeting agents, which 
could be used in the future pre-clinical trials.
Keywords: CD133, cancer stem cell, non-small cell lung cancer, 
novel compound
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P2.01-007 DISTINCT CHARACTERISTICS OF SMALL CELL 
LUNG CANCER (SCLC) CORRELATE WITH CENTRAL 
OR PERIPHERAL ORIGIN - MICROARRAY ANALYSIS OF 
SNAP FROZEN TISSUE SAMPLES.
Eisaku Miyauchi1, Yuichi Saito1, Hironori Ninomiya1, Noriko Mo-
toi1, Makoto Nishio2, Sakae Okumura2, Yuichi Ishikawa1
1Pathology, Japanese Foundation For Cancer Research/Japan, 2Thoracic 
Center, The Cancer Institute Hospital Of JFCR/Japan
Background: We previously reported that SCLC distinct characte-
ristics by primary tumor location (central type or peripheral type) 
and TTF-1 expression. Peripheral type and/or TTF-1 expression 
were predictive factors of poor prognosis in SCLC. In this study, 
we examined whether or not SCLC distinct characteristics of gene 
expression by primary tumor location, using microarray analysis of 
snap frozen tissue samples.
Methods: Fourteen SCLC, diagnosed from biopsies and/or surgi-
cal materials, for which snap frozen tissue samples were available, 
were collected during 2004-2011 from Japanese patients. We eva-
luated the location of primary tumor (central or peripheral) by CT 
at diagnosis. Total RNAs from the snap frozen fresh tissue sample 
of the surgically resected SCLC (n=14, central type:3, peripheral 
type:11) were used to prepare cDNAs, which were hybridized to 
the Whole genome Human 60K Microarray chips (Agilent Techno-
logies Inc, Tokyo, Japan). Data normalization, log transformation, 
statistical analysis, gene ontology (GO) analysis, and pattern study 
were performed with GeneSpring GX12 (Agilent Technologies Inc, 
Tokyo, Japan) and Ingenuity Pathway Analysis software, with the 
stringency of P < 0.01 and a < 2-fold change by moderated t-test 
corrected with Bonferroni multiple testing.
Results: There were a total of 31551 genes scored as differentially 
expressed between groups. A total of 833 genes were identified 
that differed significantly in expression: 424 genes were upre-
gulated and 409 genes were downregulated in peripheral type 
compared with central type. Interestingly, upregulated gene 
analysis revealed that peripheral type SCLC had increased levels 
of neuroendocrine genes such as NCAM, Synaptophysin (SYN), 
Chromogranin A (CGA), Gastrin-releasing peptide (GRP), ASCL1, 
and TTF-1. Subsequently, GO and network analysis revealed that 
most of upregulated genes in peripheral group were related to 
neuron functions. Hierarchical cluster analysis clearly distinguished 
between central type and peripheral type.
Conclusion: SCLC had a distinct gene expression profile from 
tumor location and had higher expression of genes associated with 
neural function in peripheral SCLC. Defining gene expression pro-
files by tumor location may help elucidate distinct characteristics 
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thermore, inflammation is linked to all of the six hallmarks of cancer 
(evasion of apoptosis, insensitivity to anti-growth signals, unlimited 
replicative potential, angiogenesis, increase in survival factors and 
invasion and metastasis). It is thought that inflammation may play 
a critical role in lung carcinogenesis given that individuals with 
inflammatory lung conditions have an increased risk of lung cancer 
development. This study focuses on inflammation as a contributory 
factor in non small cell lung cancer (NSCLC), concentrating primari-
ly on the pathological involvement of the pro-inflammatory cytoki-
nes, TNF-α, IL-1β, and hypoxia.
Methods: A normal bronchial epithelial cell line (HBEC4) was 
modified to stably and functionally over-express TNF-α and IL-1β 
(alone or in combination) and were continuously cultured for three 
months under normoxic or hypoxic (Invivo2 Hypoxia Workstation 
- 0.5% oxygen) conditions. Subsequently a range of experimental 
assays were carried out to assess functional cell change. These in-
cluded: transformation assay (soft agar), proliferation (BrdU ELISA), 
invasion (Cell Invasion assay), migration (Scratch assay) and angio-
genesis (Endothelial tube formation). Gene expression changes 
were also assessed using qPCR Cancer PathwayFinder arrays.
Results: Although transformation was not evident by soft agar, 
the adhesion potential (ICAM and VCAM levels) of normoxic and 
hypoxic clones has amplified and the growth rate has increased 
over time. Under normoxia the IL-1β and the TNF-α/IL-1β clones 
displayed an increased invasive capacity compared with the em-
pty vector control (p<0.05). Differences were also detected in the 
gene expression profile implicated in the pathways involved in the 
hallmarks of cancer - cell signalling (FOS, JUN), apoptosis (BAD, 
BAX, BCL2), angiogenesis (CXCL8), adhesion (ITGB3), invasion 
(S100A4, TIMP1) and cell cycle regulation (p53, c-myc). A number of 
these targets are currently undergoing validation.
Conclusion: This study provides a valuable isogenic cell line model 
in which to study the effect of prolonged chronic inflammation. 
Although the cells have not developed anchorage independent 
growth as assessed by soft agar, there are distinct indications that 
phenotypic changes occurred within the three month time frame. 
As pro-longed chronic exposure to inflammation is a pre-requisite 
for many disease states, these results warrant extended growth 
studies to further delineate the complex roles of TNF-α, IL-1β and 
hypoxia in the process of carcinogenesis. This will assist in the 
development of novel cancer target therapeutics and chemo-pre-
ventive agents in lung cancer.
Keywords: IL-1, Hypoxia, NSCLC, TNF
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P2.01-011 THE IL-23 FAMILY MAY BE A NOVEL THERA-
PEUTIC TARGET IN NON SMALL CELL LUNG CANCER
Anne-Marie Baird1, Éilis F. Dockry1, Anne Daly1, Emma Stack1, 
Derek Doherty2, Kenneth O‘Byrne3, Steven Gray1
1Thoracic Oncology Research Group, St. James‘s Hospital/Trinity College 
Dublin/Ireland, 2Immunology, Trinity College Dublin/Ireland, 3Queens-
land University Of Technology, Cancer & Ageing Research Program/
Australia
Background: IL-23A is a member of the IL-6 super-family and is 
composed of covalently bound IL-12p40 and IL-23p19 (IL-23A) sub-
units. The functional IL-23R is composed of the IL-23R and IL-12Rβ1 
the key molecular events driving lung cancer invasion and metasta-
sis that could lead to achieve effective prevention, reliable diagno-
sis, preparing useful prognostic indicator and treatment. Atypical 
protein kinase C lambda/iota (aPKCλ/℩), Partitioning defective-3 
(Par3), Partitioning defective-6 (Par6) and Drosophila Lethal giant 
larvae mammalian homologue (Lgl2) are implicated in cell growth 
and apoptosis, and the maintenance of epithelial cell polarity. Loss 
of apical-basal polarity in epithelial cells is one of the hallmarks of 
aggressive and invasive cancer. This study was designed to inves-
tigate the correlation of expression of aPKCλ/℩ and Lgl2 with the 
clinicopathological characteristics and prognosis of lung adenocar-
cinoma, and to analyze the molecular mechanisms of invasion and 
metastasis of the tumor.
Methods: This study included 107 patients who underwent resec-
tion of lung tumor and diagnosed as lung adenocarcinoma at the 
Tokai University Hospital between 2002 and 2005. The expression 
of aPKCλ/℩ and Lgl2 was examined by immunohistochemistry. E-
cadherin-mediated cell-cell adhesion is considered a suppressor of 
cancer cell invasion. Low E-cadherin expression in NSCLC tumors 
has been reported in several studies to be associated with a more 
aggressive behavior of tumor cells and a worse prognosis. In this 
study, the colocalization of aPKCλ/℩ and E-cadherin was observed 
by double-immunohistochemistry. Furthermore, we also analyzed 
the interaction of aPKCλ/℩, Par3 and Lgl2 by immunoprecipitation-
Western blot assays.
Results: Immunohistochemical analysis showed that aPKCλ/℩ and 
Lgl2 were expressed in lung adenocarcinoma and correlated with 
lymphatic invasion and metastasis. Kaplan-Meier regression ana-
lysis showed that patients withincreased aPKCλ/℩ expression had 
significantly shorter overall survival than those with lower aPKCλ/℩ 
expression. Double-immunohistochemistry showed E-cadherin 
decreased in highly expressed aPKCλ/℩ of tumor cells. Furthermo-
re, immunoprecipitation-Western blot assays showed that aPKCλ/℩-
Lgl2-Par6 complex and aPKCλ/℩-Par3-Par6 complex increased in 
lung adenocarcinoma tissue.
Conclusion: These results suggested that aberrant formation of 
both aPKCλ/℩-Lgl2-Par6 complex and aPKCλ/℩-Par3-Par6 complex 
could induce lung cancer progression by loss of cell-cell adhesion 
in lung adenocarcinoma.
Keywords: aPKCλ/℩, Adenocarcinoma, Invasion, Lgl2
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P2.01-010 A MODEL OF CHRONIC INFLAMMATION AF-
FECTS THE INVASIVE CAPACITY AND INDUCES SEVER-
AL HALLMARKS OF CANCER IN A NORMAL BRONCHIAL 
EPITHELIAL CELL LINE
Anne-Marie Baird1, Steven Gray1, Kenneth O‘Byrne2
1Thoracic Oncology Research Group, St. James‘s Hospital/Trinity Col-
lege Dublin/Ireland, 2Queensland University Of Technology, Cancer & 
Ageing Research Program/Australia
Background: Acute inflammation is usually a rapid and self-limiting 
process, however it does not always resolve. This leads to the 
establishment of a chronic inflammatory state and provides the 
perfect environment for the transformation process. It has been 
estimated that approximately 25% of all malignancies are initiated 
or exacerbated by inflammation caused by infectious agents. Fur-
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P2.01-012 PEQUI FRUIT (CARYOCAR BRASILIENSE 
CAMB) PROTECTS AGAINST OXIDATIVE STRESS INDU-
CED BY URETHANE IN A EXPERIMENTAL MODEL OF 
LUNG CANCER.
Natalia Colombo1, Edwin R. Parra1, Daniel P. Gelain2, Carlos E. 
Schnorr2, Eduardo Kolling2, César K. Grisólia3, Marcia Hage4, De-
nise F. Barbeiro5, Vera L. Capelozzi1
1Pathology, Faculdade De Medicina Da Universidade De SÃo Paulo/
Brazil, 2Oxidative Stress, Universidade Federal Do Rio Grande Do Sul/
Brazil, 3Genetic And Morphology, Universidade De Brasilia/Brazil, 4Ex-
perimental Atmospheric Pollution, Faculdade De Medicina Da Universi-
dade De SÃo Paulo/Brazil, 5Clinical Emergency, Faculdade De Medicina 
Da Universidade De SÃo Paulo/Brazil
Background: Pequi (Caryocar brasiliense Camb) is a Brazilian fruit 
that has high concentrations of antioxidants, such as vitamin C 
and E, carotenoids, phenolic compounds and essential oils. Con-
sumption of foods high in antioxidants, particularly carotenoids 
and phenolic compounds have been associated in the prevention 
of oxidative damage caused by reactive species (ROS), including 
DNA damage, and can reduce the risk of cancer, atherosclerosis 
and other degenerative diseases. The aim of this study was to 
estimate the antioxidant enzyme activity of catalase, superoxide 
dismutase and glutathione peroxidase and to evaluate the antioxi-
dant activity of the pequi oil, measuring lipid peroxidation, DNA 
damage and nitric oxid synthases expression.
Methods: The study was performed in 40 male BALB/c mices: 35 
animals were submitted to two doses of 1,5g/kg intraperitoneal 
of urethane (U=5), 10 of these mices received by gavage 15µL 
of pequi pulp oil (U+O), 10 animals received by gavage 15µL of 
ethanolic extract of pequi pulp (U+E=10) and the other 10 animals 
received by gavage 3µg/kg of betacarotene (U+B). 5 mices didn’t 
receive the urethane doses neither the gavage (C=5). After 60 
days, the groups were sacrificed. The enzymatic antioxidant de-
fense was measured by biochemical test. The antioxidant activity 
of pequi oil was evaluated in the lung tissues by the biochemical 
TBARS test (Thiobarbituric acid-reactive substances) and the DNA 
damage by the comet test method. Nitric Synthase expression was 
analyzed by imunohistochemestry.
Results: The lung parenchyma from the Urethane groups that 
received and didn’t receive gavage, showed neoplasic formations 
induced by the chemical carcinogenesis in contrast with control 
group (C). The results of the TBARS test showed a significant de-
creased of the lipid peroxidation in the groups that were treated 
by gavage (U+O)(U+E)(U+B), when compared with Urethane group 
(U) (p<0,05). In the same way, the image analysis of the comet as-
say showed a statistical significant decreased of the DNA damage 
cells in the groups that received treatment by gavage (U+O)(U+E)
(U+B) when compared with urethane group (p<0.001). The nitric 
oxid synthases expression was higher in the urethane group (U), 
but showed a significant decrease in groups that received the ga-
vage (p<0,05). The catalase, glutathione peroxidase and superoxi-
de dismutase test, as well as the ratio between then, didn’t show a 
significant difference.
Conclusion: We conclude that because of its composition, high in 
antioxidants, pequi fruit is efficient to diminish the oxidative stress 
status (DNA damage and lipid peroxidation) and the nitric oxid 
subunits and once activated can promote the STAT3 signalling 
pathway. IL-23A plays a key role in chronic inflammation through 
the promotion of IL-17 production by T helper 17 cells (Th 17). 
Stimulation of IL-23A associated pathways produces pro and anti 
oncogenic effects which are cell type dependant. We have previ-
ously identified IL-23A axis as deregulated in NSCLC and sought to 
examine the family in greater detail.
Methods: The expression of IL-23A/IL-23R was examined in a se-
ries of resected fresh frozen NSCLC tumours and in a panel of nor-
mal (HBEC) and NSCLC cell lines. Epigenetic regulation of IL-23A/
IL-23R was determined in NSCLC cell lines using histone deacety-
lase (HDi) and DNA methyltransferase (DNMTi) inhibitors. A ChIP 
assay was performed to investigate the direct effect of Trichostatin 
A (TSA) on the IL-23A/IL-23R promoter regions. Additionally, the 
effect of Gemcitabine on IL-23A/IL-23R expression was examined. 
Finally, the effect of recombinant IL-23 treatment and Apilimod 
(STA 5326) (a small molecule which blocks the expression of IL-23 
and IL-12) on NSCLC cell line proliferation was examined. IL-23 
expression was also studied in a panel of NSCLC cisplatin sensiti-
ve and resistant cell lines. Furthermore due to its role in immune 
regulation, we are currently studying the effect of IL-23 on innate 
immune cell function.
Results: IL-23A expression was significantly elevated in a cohort 
of NSCLC patient tumour samples (p<0.05). Differential IL-23R 
expression was evident in a panel of NSCLC normal/tumour 
matched pairs (n=20), with no expression in 25%, reduced levels 
in 20% and increased levels in 55% of tumour samples compared 
with matched normal. In addition, IL-23A/IL-23R was found to 
be epigenetically regulated through histone post-translational 
modifications and DNA CpG residue methylation in the A549 
cell line (p<0.05), with associated chromatin remodelling at both 
promoters. Gemcitabine, also induced IL-23A/IL-23R expression 
in this cell line (p<0.05). Furthermore, treatment with recombinant 
IL-23 resulted in increased cellular proliferation in the A549 cell 
line, while Apilimod reduced cellular proliferation. Preliminary 
results indicate that IL-23 can potentially affect the function of 
innate γΔ T cells. In a panel of cisplatin resistant and sensitive cell 
lines, IL-23A was up-regulated in 3/5 resistant cell lines. Work is 
ongoing to assess the IL-23R expression in CisR and Parent cells 
lines and the effect of co-treating cells with HDi and Apilimod and 
to determine whether these compounds can re-sensitise cells to 
cisplatin therapy.
Conclusion: Based on our results the IL-23A/IL-23R axis is dysregu-
lated in NSCLC. The IL-23 family is subject to epigenetic regulation 
through HDAC modifications and CpG island methylation. Gem-
citabine treatment also affected the expression of this family. Re-
combinant IL-23 was pro-proliferative in NSCLC and blocking IL-23 
with Apilimod reduced the proliferative capacity of the cells. Levels 
of IL-23A are differentially expressed between cisplatin sensitive 
and resistant cell lines. Apilimod may be a novel therapeutic drug 
in the treatment of NSCLC.
Keywords: Apilimod, NSCLC, IL-23, epigenetics
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P2.01-014 FUNDAMENTAL EXAMINATION IN THE PLAS-
TICITY OF CANCER STEM-LIKE CELL (CSC) / CANCER-
INITIATING CELL (CIC) IN LUNG CANCER
Saijo Hiroshi1, Hirohashi Yoshihiko2, Yokoo Keiki1, Ikeda Kimiyu-
ki1, Umeda Yasuaki1, Shioya Makoto1, Torigoe Toshihiko2, Yamada 
Gen1, Sato Noriyuki2, Takahashi Hiroki1
1Respiratory Medicine And Allergology, Sapporo Medical University 
School Of Medicine/Japan, 2Department Of Pathology, Sapporo Medical 
University School Of Medicine/Japan
Background: Cancer stem-like cells (CSCs) / Cancer-initiating cells 
(CICs) have been described as a small population that have (i) tu-
mor initiating ability, (ii) differentiation ability and (iii) self-renewal 
ability and regarded as major causes of cancer recurrence, dis-
tant metastasis and treatment resistance. CSCs/CICs have been 
thought to have similar molecular mechanisms to normal stem cells 
and keep undifferentiated state. And we thought that Lung CSCs/
CICs constantly exchange the state of differentiation and dedif-
ferentiation. Previously we showed that SOX2 is overexpressed in 
stem-like cells of human lung adenocarcinoma cell lines. And so, 
we think SOX2 is important for the sustention of CSCs/CICs. In this 
study, we examined the differentiation and dedifferentiation of 
Lung CSCs/CICs in single-cell level and investigated the regulation 
of SOX2 expression in Lung CSCs/CICs.
Methods: Lung adenocarcinoma cell lines LHK2 were stained with 
Hoechst33342 dye and CSCs/CICs were isolated as Side populati-
on (SP) cells and non-CSCs/CICs were isolated as Main population 
(MP) cells using a FACS Aria II cell sorter. Many single cell clones 
(SP clones, MP clones) were established from SP cells and MP cells 
respectively. SOX2 expression was addressed by qPCR. LHK2 were 
treated with HDAC inhibitor Trichostatin A (TSA).
Results: SP cells and MP cells were generated from each SP clones 
and MP clones. The SOX2 expression of SP clones were higher 
than that of MP clones. TSA treatment enhanced the expression of 
SOX2 and increased the rate of SP cells.
Conclusion: It was indicated that the differentiated Lung carci-
noma fractions were dedifferentiated into CSCs/CICs and SOX2 
expression was important for the mechanisms. It was considered 
that the differentiation and dedifferentiation occurred with compa-
rative ease in Lung carcinoma, so we thought that the mechanisms 
related to the epigenetic regulation. In this study, it was indicated 
that SOX2 expression in Lung cancer cells were regulated by his-
tone acetylation. Therefore, Lung CSCs/CICs phenotype might be 
regulated by epigenetic mechanisms.
Keywords: cancer stem cell, differentiation and dedifferentiation, 
epigenetic regulation, Lung cancer
synthases expression in chemical carcinogenesis induced by ure-
thane. Our results also suggest that the antioxidant enzyme defen-
se are not envolved in this process, suggesting that antioxidants 
present in pequi fruit may have a greater impact in lung cancer 
treatment.
Keyword: pequi fruit, caryocar brasiliense camb, lung cancer, oxi-
dative stress, experimental model
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P2.01-013 MICRORNA EXPRESSION OF NON-TERMINAL 
RESPIRATORY UNIT TYPE LUNG ADENOCARCINOMA
Mi-Hyun Kim1, Min Ki Lee2, Dong Hoon Shin2, Chang Hun Lee2
1Internal Medicine, Pusan National University Hospital/Korea, 2Pusan 
National University Hospital/Korea
Background: Lung adenocarcinomas can be classified into two ma-
jor subtypes, terminal respiratory unit (TRU) type and non-TRU type. 
We previously reported that non-TRU type adenocarcinoma has 
unique clinical and morphological features compared with TRU type 
adenocarcinoma. In brief, among 36 cases of non-terminal respira-
tory unit type adenocarcinoma, 24 cases revealed mucous columnar 
cell changes that were continuous with bronchial ciliated columnar 
cells. The mucous columnar cells became dysplastic showing loss 
of cilia, disorientation, and enlarged nuclei. Adenocarcinoma arose 
from these dysplastic mucous columnar cells and, characteristically, 
this type of adenocarcinoma showed acute inflammation, and ho-
neycombing changes in the background. TTF-1 immunostaining was 
consistently negative. In a case study with 14 males and 10 females, 
including 12 smokers or ex-smokers, EGFR and KRAS mutations 
were detected in 3 and 6 patients, respectively. We think that this 
kind of adenocarcinoma arising through mucous columnar cell 
change belongs to non-terminal respiratory unit type adenocarci-
noma, and mucous columnar cell change is a precursor lesion of 
pulmonary adenocarcinoma. We investigated whether microRNA 
(miRNA) expression profiles can differentiate between non-TRU type 
and TRU type lung adenocarcinoma.
Methods: MiRNA expression in lung adenocarcinoma with non-TRU 
and TRU type was analyzed by microarray analysis with 1205 human 
and 144 human viral miRNAs.
Results: Eight pairs of lung adenocarcinomas and corresponding 
noncancerous lung tissues (4 for non-TRU type and 4 for TRU type) 
were analyzed by microarray analysis. Initially, 44 miRNAs showed 
statistical differences in expression between lung cancer tissues and 
corresponding noncancerous tissues. Comparison analyses between 
non-TRU type and TRU type revealed 30 miRNAs with statistically 
different expression. Particularly, hsa-mir-494 and ebv-mir-BART19 
were upregulated with more than 5-fold difference as compared 
with TRU type adenocarcinoma. Similarly, hsa-mir-551b was downre-
gulated at more than 4-fold as compared with TRU type adenocar-
cinoma. Only 2 miRNAs (hsa-mir-1 and hsa-mir-133b) were shared in 
both non-TRU and TRU type of adenocarcinoma.
Conclusion: We demonstrated that non-TRU type adenocarcinoma 
showed different miRNAs expression patterns compared with TRU 
type adenocarcinoma, suggesting different carcinogenic pathways 
for these tumors. Further studies are required for validation the 
results from microarray analysis.
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EGFR mutational status was not associated with MAGE-A3 expres-
sion but was significantly associated with PRAME expression (tab-
le). There was no association between KRAS mutational status and 
MAGE-A3 (P=0.6109) or PRAME (P=0.8983) expression.
Conclusion: In this study, tumor samples expressing PRAME ten-
ded to be associated with wild-type EGFR status. Thus, among pa-
tients with PRAME-positive tumors, only very few would be eligible 
for EGFR-TKI therapy. This indicates a potentially straightforward 
treatment choice for patients and physicians, should EGFR-TKIs 
and PRAME cancer immunotherapeutics become available for simi-
lar indications. Funding: GlaxoSmithKline Biologicals SA.
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P2.01-016 TARGETING THE PI3K-MTOR-NFΚB PATHWAY 
TO OVERCOME CISPLATIN RESISTANCE IN NSCLC.
Susan Heavey1, Anne-Marie Baird1, Peter Godwin1, Martin Barr1, 
Connla Edwards1, Kazuo Umezawa2, Kenneth O‘Byrne3, Kathy 
Gately1
1Clinical Medicine, Trinity College Dublin/Ireland, 2Applied Chemistry, 
Keio University/Japan, 3Princess Alexandra Hospital/Australia
Background: Non-small cell lung cancer (NSCLC) is the leading 
cause of cancer morbidity and mortality in the Western world 
with a poor overall 5 year survival of <15%. The most effective 
systemic chemotherapy for NSCLC is cisplatin-based combinati-
on treatment. However, chemoresistance is a major therapeutic 
problem and understanding the mechanisms involved is critical to 
the development of new therapeutic intervention strategies. The 
PI3K pathway plays an important role in NSCLC and we and others 
have shown increased PI3K signaling to be associated with a more 
aggressive disease with poor prognosis. Several proteins in this 
pathway have been indicated as potential mediators of cisplatin 
resistance in other cancers, and our group has previously identified 
the PI3K-activated transcription factor NFκB as a key player in this 
setting. In this study, targeted inhibition of three strategic points 
of the PI3K pathway was carried out with the aim of overcoming 
acquired resistance to cisplatin in these cell lines.
Methods: A panel of cisplatin resistant cell lines was previously 
generated in our laboratory through prolonged exposure to the 
drug. Expression of PI3K pathway related genes was compared 
between H460 parent (H460PT) and H460 cisplatin resistant 
(H460CR) cells using a PI3K pathway SABiosciences RTPCR array. 
Identified genes of interested were further investigated via PCR 
and Western blot in these cells as well as A549 parent (A549PT) 
and A549 cisplatin resistant (A549CR) cells. Three strategic points 
of the pathway were inhibited using GDC-0980, a dual PI3K-mTOR 
inhibitor currently in Phase II clinical trials in NSCLC, and DHMEQ, 
an inhibitor of NFkB translocation which has been used extensively 
both in vitro and in vivo. Effects of the two inhibitors on the parent 
& cisplatin resistant cell lines both with and without cisplatin were 
assessed by BrdU proliferation assay and multiparameter apopto-
sis assay (High Content Analysis).
Results: One of the most notable targets to emerge from the PI3K 
pathway RTPCR array screen was NFKBIA; the gene which codes 
for NFκB inhibitor IκBα. This gene was shown to be 12 fold overex-
pressed in H460CR compared to H460PT. This finding was valida-
ted at both the RNA and protein level by PCR and Western blot. 
NFκB was also found to be overexpressed in cisplatin resistant 
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P2.01-015 GENE EXPRESSION OF MAGE-A3 AND 
PRAME TUMOR ANTIGENS AND EGFR MUTATIONAL 
STATUS IN LUNG ADENOCARCINOMA IN A GERMAN 
CENTER
Nicolas F. Delahaye, Fernando Ulloa Montoya, Thierry Coche, Oli-
vier Gruselle, Karen Langfeld, An De Creus, Bart Spiessens, Jamila 
Louahed, Frédéric F. Lehmann, Vincent G. Brichard
GlaxoSmithKline Vaccines/Belgium
Background: The MAGE-A3 and PRAME tumor antigens are 
potential targets for cancer immunotherapy. In patients with non-
small cell lung cancer (NSCLC), specific mutations of the epidermal 
growth factor receptor (EGFR) gene are associated with improved 
therapeutic response to EGFR tyrosine kinase inhibitors (EGFR-
TKIs); mutations in the KRAS gene confer resistance to EGFR-TKIs. 
In NSCLC, EGFR and KRAS mutations are predominantly found in 
adenocarcinomas. The relationship between MAGE-A3 or PRAME 
expression and EGFR/KRAS mutational status is unknown. The pre-
sence of specific EGFR mutations determines the selection of pati-
ents for EGFR-TKIs therapy. With cancer immunotherapeutics and 
EGFR-TKIs potentially moving on to the same treatment stages, it 
is important to determine whether patients eligible for EGFR-TKI 
therapies might be also eligible for treatment with MAGE-A3 or 
PRAME cancer immunotherapeutics. We have previously reported 
that MAGE-A3 and PRAME were expressed in 36% and 66% of 
NSCLC tumor samples, and in 27% and 44% of adenocarcinoma 
samples, respectively (Linder et al. ASCO 2012). Here we report 
the MAGE-A3 and PRAME expression rates and mutational status 
of EGFR and KRAS in NSCLC adenocarcinoma.
Methods: This was a single-center, non-interventional, retros-
pective study conducted at the Lungenklinik Hemer (Germany). 
MAGE-A3 and PRAME mRNA expression patterns in patients with 
pathologically proven stage I, II or III NSCLC were determined by 
quantitative real-time PCR on formalin-fixed paraffin-embedded 
(FFPE) tumor samples. EGFR and KRAS mutational status was ana-
lyzed on DNA extracted from FFPE samples using laboratory-de-
veloped PCR-based assays. Samples from patients with adenocar-
cinoma i.e. adenocarcinoma, bronchoalveolar adenocarcinoma, 
adenosquamous carcinoma, for which MAGE-A3 and/or PRAME 
expression results were available were selected for this analysis.
Results: Out of 311 samples, 277 and 287 produced valid 
results for EGFR and KRAS mutational status, respectively. 
EGFR mutations were found in 10.1%, and KRAS mutations in 
33.8% of samples. The association between MAGE-A3 or PRA-
ME expression and EGFR mutational status is shown (table). 
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Conclusion: In this study, mutated EGFR status was observed in 
more than half of MAGE-A3-positive adenocarcinoma samples. 
However, due to a small number of samples analyzed, no statis-
tical association could be concluded. Additional larger studies, 
especially in Asian patients with adenocarcinoma, are needed to 
confirm the findings. This study was funded by GlaxoSmithKline 
Biologicals SA.
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P2.01-018 DEFECTIVE DNA DAMAGE RESPONSE IN 
LUNGS OF ASTHMATICS: A POSSIBLE LINK TO LUNG 
CANCER?
Rakhshinda Rehman, Anurag Agrawal, Balaram Ghosh, 
Ulaganathan Mabalirajan
Council Of Scientific And Industrial Research, Institute Of Genomics 
And Integrated Biology/India
Background: The new lifestyle adaptations in the developing 
countries altered the environment and these contribute in the 
development of various respiratory diseases like asthma, COPD, 
etc. Though it is well known that COPD may lead to development 
of lung cancer, the effect of asthma on lung cancer development 
is not well studied. Lung cancer is a leading cause of mortality 
worldwide as more than a million people die every year. Few re-
cent meta-analytic studies showed a positive correlation between 
asthma and lung cancer. But, there are no reports to demonstrate 
the status of DNA damage in asthma.
Methods: 8-hydroxydeoxyguanosine, DNA damage marker, was 
measured in BAL fluids and sera samples of human asthmatics. To 
see the gene expression related to DNA damage response, we 
performed the quantitative Real Time PCR array in human normal 
and asthmatic lungs. Significantly altered genes were validated at 
mRNA as well as in protein levels by using western blotting and 
immunohistochemistry.
Results: Increased levels of 8-hydroxydeoxyguanosine was obser-
ved in BAL fluids and sera of human asthmatics. Human and muri-
ne asthmatic lungs show an increase in the expression of 8-hydro-
xy-2‘-deoxyguanosine. In comparison to normal, human asthmatics 
showed a decrease in the expression of key DNA damage respon-
se proteins like gamma-H2AX, Atm, chk2, Mre11 and DNA-pkcs.
cells compared to their respective parent cells. Inhibition of NFκB 
by DHMEQ led to significantly improved inhibition of proliferation 
and induction of apoptosis in cisplatin resistant cells compared to 
parent cells. Preliminary data indicates that inhibition of PI3K and 
mTOR by GDC-0980 did not offer as significant a benefit as inhibi-
tion of NFκB in the cisplatin resistance setting, though further data 
from combination studies will be presented.
Conclusion: We conclude that the PI3K pathway plays an impor-
tant role in resistance to cisplatin in NSCLC, particularly when sig-
naling proceeds through the transcription factor NFκB. Targeting 
this pathway may be of benefit in re-sensitizing cisplatin resistant 
tumours to the drug.
Keywords: cisplatin, NFkB, PI3K, resistance
POSTER SESSION 2 - CANCER BIOLOGY  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.01-017 GENE EXPRESSION OF MAGE-A3 TUMOR 
ANTIGEN AND EGFR MUTATIONAL STATUS IN CHINESE 
NSCLC PATIENTS
Yi-Long Wu1, She-Juan An1, Zhi-Hong Chen1, Jian Su1, Xu-Chao 
Zhang1, Nicole Kusuma2, Nicolas F. Delahaye3, Olivier Gruselle3, 
Fernando Ulloa Montoya3, Bart Spiessens3, Jamila Louahed3, Aung 
Myo2, Vincent G. Brichard3
1Guangdong General Hospital (GGH)/China, 2GlaxoSmithKline Vacci-
nes/Singapore, 3GlaxoSmithKline Vaccines/Belgium
Background: The MAGE-A3 tumor antigen is expressed in non-
small cell lung cancer (NSCLC), and is a potential target for cancer 
immunotherapy. NSCLC patients may also have specific epidermal 
growth factor receptor (EGFR) gene mutations, which are respon-
sible for sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs) 
in metastatic NSCLC patients. In Asian populations, a relatively 
low MAGE-A3 expression (Therasse et al. ASCO 2012) and a re-
latively high frequency of EGFR mutations (An et al. 2012) have 
been reported compared to Caucasian populations. Three phase 
III studies, one with MAGE-A3 cancer immunotherapeutic and two 
with EGFR-TKIs, are ongoing in patients with early-stage, resected 
NSCLC. However, to date, a direct association between MAGE-
A3 expression pattern and EGFR mutational status has not been 
investigated. Here, we evaluate a potential link between MAGE-A3 
expression and frequency of EGFR mutations in Chinese NSCLC 
patients.
Methods: This single-center, non-interventional, retrospective stu-
dy was conducted at Guandong Lung Cancer Institute, China. Ade-
nocarcinoma and squamous cell carcinoma (SCC) fresh frozen (FF) 
stage IB, II or IIIA NSCLC tumor samples were collected. MAGE-A3 
transcript levels were determined using quantitative real-time PCR. 
The presence of EGFR mutations was detected using bidirectional 
Sanger sequencing on genomic DNA extracted from the same FF 
tumor samples.
Results: MAGE-A3 was expressed in 15.6% of adenocarcinoma 
(N=96) and 31.6% of SCC (N=95) samples. EGFR mutations were 
found in 43.8% of adenocarcinoma and 5.3% of SCC samples. 
MAGE-A3 expression rates and EGFR mutational status are shown 
(table). 
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in exon21. Secondary T790M mutations were not detected in both 
areas. The result of direct sequencing analysis supported hetero-
geneous distribution of L858R point mutations which was found on 
immunohistchemical staining. Comparing with pathological finding 
of HE staining, it was implied that therapeutic effect of gefitinib 
was limited only to the tissue area having L858R point mutation 
and cells of non-mutated tissue area survived.
Conclusion: This study suggested that there may be intratumoral 
heterogeneity of EGFR mutation and therapeutic effect of EGFR-
TKIs could be limited only to mutant cells. As a result, wild-type 
cells would survive and develop drug resistance against EGFR-
TKIs, even if tumors had no secondary T790M mutations in exon 
20 of EGFR.
Keywords: L858R, Heterogeneity, EGFR, gefitinib
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P2.01-020 DOWN-REGULATION OF SOMATOSTATIN  
RECEPTOR 2 DECREASES CELL PROLIFERATION IN 
LUNG CANCER
Megan Hoeksema, Jennifer Miao, Mohamed Hassanein, Jamshe-
dur Rahman, Pierre P. Massion
Division Of Allergy, Pulmonary, And Critical Care Medicine, Vanderbilt 
University Medical Center/United States Of America
Background: Somatostatin receptors (SSTRs) have been shown to 
be overexpressed in 80-90% of all neuroendocrine tumors, including 
SCLCs. Previous reports have shown that SSTR2 activation modula-
tes cell proliferation by acting through the ERK signaling cascade. 
We hypothesized that down regulation of SSTR2 will inhibit cell pro-
liferation in lung cancer cell lines that overexpresses this receptor.
Methods: SSTR2 expression was assessed by western blot analysis 
in 28 lung cancer cell lines. H520 (SCC) and H727 (Carcinoid) were 
used as an in vitro model for studying the effects of targeted down-
regulation of SSTR2 by shRNA. Several SSTR2 null-colonies of these 
cell lines were generated by antibiotic selection. Cell proliferation 
was measured at four different time points using MTS metabolic 
assay. In addition, we evaluated the effect of SSTR2 down regulation 
in colony formation potential of our lung cancer cell lines.
Results: Western blot analysis of 28 lung cancer cell lines showed 
expression of SSTR2 in 17/18 (94%) of SCLCs including carcinoids, 
3/6 (50%) of NSCLCs, and 0/4 (0%) of non-immortalized human 
bronchial cells. Post transfection analysis by western blot revealed a 
significant decrease in SSTR2 protein expression in multiple SSTR2 
null-colonies. We observed a 37% decrease in cell growth in H520 
and a 38% decrease in H727 by day 6 with p values of 0.007 and 
0.002 respectively. In addition, down regulation of SSTR2 resulted in 
reduction in the number of colonies formed by both cell lines.
Conclusion: These results demonstrate that that knocking down 
SSTR2 in lung cancer cells induces a marked decrease in cell prolife-
ration. Ongoing studies are focused on understanding the effect of 
knocking down SSTR2 on oncogenic traits of lung cancer cells inclu-
ding cell survival, apoptosis, migration and invasion and the cellular 
mechanisms underpinning our original observation.
Keywords: SSTR2, Lung cancer, proliferation
Conclusion: For the first time, we have shown that there may be 
defective DNA damage response in asthmatics which might link 
asthma to lung cancer. As various meta-analysis studies indicate a 
positive correlation between asthma and lung cancer, it is necessa-
ry to delineate the mechanisms underlying this.
Keyword: Asthma, DNA damage, lung cancer
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P2.01-019 HETEROGENEITY OF EGFR MUTATION DE-
TECTED IN A PATIENT TREATED WITH GEFITINIB 
AS NEO-ADJUVANT CHEMOTHERAPY
Kosuke Mizoguchi, Takaya Ikeda, Kohei Motoshima, Shinnosuke 
Takemoto, Seiji Nagashima, Tetsuya Iida, Yoichi Nakamura, Shi-
geru Kohno
Second Department Of Internal Medicine, Nagasaki University Hospi-
tal/Japan
Background: Epithelial growth factor receptor-tyrosine kinase 
inhibitors (EGFR-TKIs) show incredible response rate up to around 
80 % to non-small cell lung cancer patients with EGFR sensitive 
mutations, and also contribute to improve overall survival time 
of such patients. However, it is no doubt that almost all patients 
have recurrences in time. Some genetic aberrant changes such as 
the secondary mutation T790M in exon 20 of EGFR are known to 
have influence on drug resistance, but most mechanisms of drug 
resistance are still unclear. Recently, Some studies suggested that 
heterogeneous distribution of EGFR mutations seemed to have 
correlations with treatment failure of EGFR-TKIs, but others re-
ported that heterogeneity was extremely rare. Heterogeneity of 
EGFR is still remains to be controversial. In this study, we reported 
one rare case that resected lung after chemotherapy with gefitinib 
showed heterogeneous distribution of L858R point mutations and 
it’s correlation with effects of EGFR-TKIs.
Methods: A 68-year-old woman was diagnosed as lung adenocar-
cinoma (T3N1M0 stageIIIa) with the L858R point mutation. Unila-
teral Pulmonary Artery Occlusion test before operation showed a 
high probability that patient’s oxygenation would decrease to near 
the tolerance limit by right peumonectomy. For the purpose of re-
ducing the tumor volume to avoid the pneumonectomy, she recei-
ved gefinitib (250mg/body/day) as neo-adjuvant chemotherapy for 
three months and succeeded. Continuously, she underwent right 
middle and lower lobectomy and lymph node dissection (ND2a). 
Pathological examinations of resected lung specimens were done 
using H&E staining and immunohistochemistry with L858R Mutant 
Specific Rabbit monoclonal antibody for EGF Receptor. Two diffe-
rent tissue parts were respectively macrodissected from Formalin-
Fixed Paraffin-Embedded tissue slides and analyzed genetically by 
direct sequencing analysis.
Results: H&E and immunohistochemical staining specimens show-
ed that this resected identical tumor was divided into two areas. 
One area consisted of necrotizing and degenerating cell popula-
tion and was stained with L858R specific antibody. The other area 
consisted of viable cell population with relatively low nuclear grade 
and was not stained with L858R specific antibody. Additionally, 
direct sequencing analysis of each extracted DNA from these two 
different areas revealed that the former area contained only wild 
type base sequence in exon 21 of EGFR, but the latter contained a 
mixture of point mutation of L858R and wild type base sequence 
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in non-small cell lung cancer (NSCLC), which might be altered by 
many anti-angiogenic drugs. Epigallocatechin-3-gallate (EGCG), 
a natural anti-angiogenesis agent refined from green tea, was 
defined to have multiple effects on angiogenesis factors, such as 
endothelial growth factor (VEGF) and angiopoietins (ANGs). Hypo-
thesizing that EGCG might regulate microvasculature and microen-
vironment in NSCLC, the effects of EGCG on microvessel density 
(MVD), expression of Ang-1 and Ang-2, interstitial fluid pressure 
(IFP), tumor hypoxia, and chemotherapy sensitivity were examined.
Methods: Build nude mice xenograft tumor model(A549 cell line). 
Treat them with EGCG(i.p.), Counting MVD labeled by CD31, ob-
serving Ang-1 and Ang-2 expressions detected by quantum dots 
double-label immunofluorescence assessment. interstitial fluid 
pressure (IFP) was measured by the Wink-in-needle method, while 
hypoxia was assessed by polarographic electrode and pimonida-
zole (PIMO) immunohistochemistry. Assuming that these changes 
would increase response to chemotherapy, tumor growth studies 
were performed in nude mice with xenografts, which were then 
treated with EGCG and the chemotherapeutic agent.
Results: EGCG treatment led to a significant decrease of MVD, 
and of Ang-2 expression, while Ang-1 decreased with no signi-
ficance. Both IFP and hypoxia were decreased. Tumor growth 
studies show that EGCG therapy combined with cisplatin led to 
synergistic inhibition of tumor growth, compared with administra-
tion of each treatment separately (P < 0.001). According to linear 
regression analysis, IFP was positively correlated with PIMO stai-
ning (R2 = 0.618, P = 0.002), Ang-2 was correlated with MVD (R2 = 
0.423, P = 0.022), IFP (R2 = 0.663, P = 0.01) and PIMO staining (R2 
= 0.694, P = 0.01).
Conclusion: IFP and delivery of oxygen might be improved by 
rebalance of Ang-1/Ang-2 under the treatment of EGCG in NSCLC, 
which also acts as a sensitizer of chemotherapy. These studies 
established a new mechanism for using EGCG as an adjuvant che-
motherapy agent through modifying microvasculature and micro-
environment.
Keywords: EGCG, NSCLC, Tumor microenvironment, Angiopoie-
tins
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P2.01-023 ER HOMEOSTASIS AND MOTILITY OF NSCLC 
CELL LINES CAN BE THERAPEUTICALLY TARGETED 
WITH COMBINED HSP90 AND HDAC INHIBITORS.
Victoria Zismanov1, Liat Drucker2, Maya Gottfried3
1Lung Cancer Research Laboratory, Meir Medical Center/Israel, 2Onco-
genetic Laboratory, Meir Medical Center/Israel, 3Oncology, Meir Medical 
Center/Israel
Background: Lung cancer remains the most common cause of 
cancer-related death in the world for which novel systemic treat-
ments are urgently needed. Protein homeostasis that regulates 
protein levels and their fold is critical for cancer cell proliferation 
and survival. A complex network of cellular organelles and signa-
ling cascades is involved in control of protein homeostasis inclu-
ding endoplasmatic reticulum (ER). Thus, proteins in control of ER 
homeostasis are increasingly recognized as potential therapeutic 
targets. Molecular chaperone heat shock protein 90 (Hsp90) and 
histone deacetylase (HDAC) play an important role in ER homeos-
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P2.01-021 AMP CONVERTED FROM INTRACELLULARLY 
TRANSPORTED ADENOSINE UPREGULATES P53 EX-
PRESSION TO INDUCE MALIGNANT PLEURAL MESO-
THELIOMA CELL APOPTOSIS
Yoshitaka Nogi1, Tomoyuki Nishizaki2, Yuichi Koda1, Eriko Fuji-
moto1, Daisuke Horio1, Eisuke Shibata1, Eriko Masachika1, Hisaya 
Okuwa1, Miki Honda1, Hitomi Kamiya1, Koji Mikami1, Risa Maeda1, 
Taiichiro Otsuki1, Takayuki Terada1, Kunihiro Tamura1, Chiharu 
Tabata1, Takashi Nakano1
1Respiratory Medicine, Hyogo College Of Medicine/Japan, 2Division Of 
Bioinformation, Department Of Physiology, Hyogo College Of Medicine/
Japan
Background: The present study investigated adenosine-induced 
apoptosis in human malignant pleural mesothelioma cells.
Methods: MTT assay, TUNEL staining, flow cytometry using propidi-
um iodide and annexin V-FITC, real-time RT-PCR, Western blotting, 
and assay of caspase-3, -8, and -9 activities were carried out using 
malignant pleural mesothelioma cell lines such as NCI-H28, NCI-
H2052, NCI-H2452, and MSTO-211H cells, and P53 or A3 adenosine 
receptor was knocked-down by transfecting each siRNA into cells.
Results: Adenosine induced apoptosis in all the malignant pleural 
mesothelioma cells used here, independently of caspase activation. 
The adenosine effect was prevented by the adenosine transporter 
inhibitor dipyridamole, the adenosine kinase inhibitor ABT-702, or 
the A3 adenosine receptor inhibitor MRS1191. Adenosine upregu-
lated expression of the p53 mRNA and protein, that is abolished by 
ABT-702, but not by knocking-down A3 adenosine receptor. Adeno-
sine-induced apoptosis in NCI-H28 cells was significantly inhibited 
by knocking-down p53 and in part by knocking-down A3 adenosine 
receptor.
Conclusion: The results of the present study show that AMP con-
verted from intracellularly transported adenosine upregulates p53 
expression to induce caspase-independent apoptosis in malignant 
pleural mesothelioma cells and that A3 adenosine receptor also 
participates partially in the apoptosis by the different mechanism.
Keywords: Apoptosis, Malignant pleural mesothelioma cell, AMP, 
p53
POSTER SESSION 2 - CANCER BIOLOGY  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.01-022 TREATMENT WITH EGCG IN NSCLC LEADS 
TO DECREASING INTERSTITIAL FLUID PRESSURE AND 
HYPOXIA TO IMPROVE CHEMOTHERAPY EFFICACY 
THROUGH REBALANCE OF ANG-1 AND ANG-2
Peng Bo Deng1, Cheng Ping Hu2, Hua Ping Yang2, Zeng Xiong2, 
Yuan Yuan Li2
1Department Of Respiratory Medicine, Xiangya Hospital, Central South 
University/China, 2Department Of Respiratory Medicine, Xiangya Hos-
pital, The Central South University/China
Background: Microvasculature and microenvironment play im-
portant roles in proliferation, invasion, metastasis and prognosis 
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(10vs7.4, p = 0.037) and in overall promoter area (10.6vs7. 6, p = 
0.034). The %Mth was higher in women vs men in TT CpG1 island 
(16.2vs24.9, p = 0.042) and TT CpG2 island (15.8vs26.5, p = 0.013). 
The %Mth was higher in squamous histology compared to ade-
nocarcinoma in NT CpG2 island (22.6vs14.1, p = 0.017) and S CpG1 
island (13.7vs8.2, p = 0.047). However, the %Mth was higher in the 
overall promoter area of adenocarcinoma respect to squamous 
histology (19.7vs12.8 TT, p = 0.042). The %Mth was higher in overall 
promoter area of NT respect Stage I vs II vs III (22.3 vs 13 vs 17.5, 
p = 0.03). The %Mth was higher in former smokers compared to 
current smokers and non smokers in NT CpG3 (22.8 vs 13 vs 14.1, p 
= 0.032). The %Mth in NT CpG3 was higher in never smokers and 
former smokers > 5 years, respect to current smokers and former 
smokers <5 years, (23.3 vs 15.8, p = 0.05).
Conclusion: EGFR aberrant hypermethylation was higher in tumor 
tissue respect to sputum, with no correlation with EGFR mutation. 
The %Mth in normal tissue was higher in never smoker and former 
smokers > 5 years patients. * This study was funded by the Carlos 
III Health Institute (PS09/00308), Spain
Keywords: Lung cancer, methylation, EGFR
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P2.01-025 DIFFERENTIAL MIRNA EXPRESSION IN NEU-
ROENDOCRINE TUMOURS OF THE LUNG
Annette Fisseler-Eckhoff, Christoph Aszyk, Holger Bartsch, Mela-
nie Demes
Institute Of Pathology, HSK Dr.-Horst-Schmidt-Kliniken GmbH I/ 
Germany
Background: Four neuroendocrine subtypes are distinguishable 
which differ in the extent of differentiation and grade of biological 
aggressiveness. Therefore the differentiation of atypical from typi-
cal carcinoids or large cell neuroendocrine carcinomas and small 
cell carcinomas is essential for treatment options and prognosis. 
However, for pathologists it is often a challenge to establish a 
faithful differential diagnosis with an accurate prognosis which is 
restricted in terms of limited specificity of immunohistochemical 
markers and possible artifacts. Thus we investigated two types of 
miRNAs as an additional tool for differential diagnosis and possib-
le molecular targets.
Methods: A collective of 38 patients suffering from well to poorly 
differentiated neuroendocrine lung tumours were examined. Two 
different miRNAs (miR-21, miR-34a) were investigated in four dis-
tinct subtypes of pulmonary neuroendocrine tumours by compara-
tive gene expression analysis.
Results: miRNA 21 was upregulated in G3-neuroendocrine tumors 
(Mean rank: 26.8; 28.75) as compared to carcinoids (mean rank: 
12.33; 12.07) with a significance of 0.00033. High-expression level 
of miRNA 34a was associated with atypical carcinoids (p = 0.010).
Conclusion: miRNAs are suitable candidates for differential neuro-
endocrine lung cancer diagnosis. A close association is implicated 
between the elevated miR-21 in high-grade and miR-34a in low 
grade atypical neuroendocrine lung carcinomas which could po-
tentially be exploited as practical supportive markers for differenti-
al lung cancer diagnosis in routine. However, some additional re-
search and validation studies are needed to utilize them as routine 
tasis. Previous studies demonstrate that Hsp90 and HDAC inhibi-
tors are individually functional against lung cancer. In this work we 
suggested that combined Hsp90 and HDAC inhibitors may elevate 
ER stress thereby enhancing the anti non small lung cancer (NS-
CLC) activity.
Methods: NSCLC cell lines (A549, H1299, H460) were treated with 
17-DMAG (Hsp90 inhibitor), PTACH (HDAC inhibitor) and both 
drugs simultaneously for 24 hours. Cells were harvested and ana-
lyzed for ER stress markers (Immunoblot), viability (WST1 assay), 
motility (Scratch assay), and death (Flow cytometer).
Results: Using an in vitro cell line model we demonstrated that 
17-DMAG co-administration with PTACH caused elevated ER stress 
(more than 110%, p<0.05) accompanied by apoptotic cell death 
(Annexin V) (7-21%, p<0.05). Moreover, 17-DMAG/PTACH treated 
cells lost the ability to migrate (57-85% of scratch closure, p<0.05).
Conclusion: Our findings provide proof-of-concept that targeting 
ER homeostasis is therapeutically beneficial in lung cancer cell 
lines. Indeed, the elevated ER stress caused by 17-DMAG/PTACH 
combined treatment leads to increased cell death of NSCLC cell 
lines compared to the application of the drugs separately.
Keywords: ER homeostasis, heat shock protein 90, histone deace-
tylase, ER stress
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P2.01-024 QUANTITATIVE DETERMINATION OF EGFR 
GENE ABERRANT METHYLATION IN NON SMALL CELL 
LUNG CANCER (NSCLC): A COMPARATIVE ANALYSIS IN 
TUMOR TISSUE, NORMAL LUNG TISSUE, PERIPHERAL 
BLOOD, SPUTUM AND BRONCHIAL ASPIRATE. CORRE-
LATION WITH CLINICAL VARIABLES.
Manuel A. Cobo Dols1, F P. Codeso2, Enrique B. Casero3, Rocio L. 
Valenzuela4, Roberto M. Ponce3, Carlos P. Navarrete3, Ricardo A. 
Sanchez3, Jose Luis De La Cruz Rios2, Miguel Angel Gerciano Guer-
rero1, Dolores Bautista5, Manuel Benavides Orgaz1
1Medical Oncology, Hru Carlos Haya/Spain, 2Pneumology Department, 
Hru Carlos Haya, Malaga/Spain, 3Thoracic Surgery Department, Hru 
Carlos Haya/Spain, 4Research Laboratory, Imabis Foundation, Hru Car-
los Haya/Spain, 5Pathology Department, Hru Carlos Haya/Spain
Background: To evaluate and compare quantitatively aberrant 
methylation in the promoter area of EGFR gene in patients (p) with 
in non small cell lung cancer (NSCLC) lung tumor tissue (TT), lung 
normal tissue (NT), blood (B), bronchial aspirate (BA) and sputum 
(S). Correlate these methylation patterns with clinical variables.
Methods: DNA was extracted from samples of B, S and BA from 
patients with NSCLC prior to surgery and resected TT and NT. 
Methylation patterns were analyzed by the bisulfite conversion and 
subsequent pyrosequencing (QIagen PyroMark System). We analy-
zed three CpG islands in the promoter region of EGFR gene.
Results: 43p were included, median age 66 years (range 46-79), 35 
men and 8 women. Histology: 26p adenocarcinoma, 14 squamous 
and 3 others. 2p had EGFR mutation. Smoking status: 4p never 
smokers, 21p former smokers, 18p smokers. Significant differences 
in methylation percentage (%Mth) were observed between TT 
and S in the following islands: CpG2 (11.8vs7.1, p = 0.008), CpG3 
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P2.02-001 MED12, A COMPONENT OF THE TRANSCRIP-
TIONAL MEDIATOR COMPLEX, AND STAT3 INFLUENCE 
OUTCOME TO PLATINUM-BASED CHEMOTHERAPY IN 
PATIENTS (P) WITH ADVANCED NON-SMALL-CELL LUNG 
CANCER (NSCLC)
Daniela Morales-Espinosa1, Carlota Costa2, Niki Karachaliou2, 
Miguel Angel Molina-Vila2, Ana Gimenez-Capitan2, Laura Bonan-
no3, Margarita Majem4, Bartomeu Massuti5, Jose Javier Sanchez6, 
Rafael Rosell7
1Medical Oncology, Cancer Center, Médica Sur/Mexico, 2Quiron-dexeus 
University Hospital, Pangaea Biotech/Spain, 3Second Medical Oncology 
Unit, Istituto Oncologico Veneto,/Italy, 4Servei D’Oncologia, Hospital 
De Sant Pau/Spain, 5Hospital General De Alicante/Spain, 6Autonomous 
University Of Madrid/Spain, 7Medical Oncology, Catalan Institute Of 
Oncology/Spain
Background: MED12 negatively regulates TGF-b receptor signa-
ling. Loss of MED12 induces an EMT-like phenotype associated 
with chemotherapy resistance. IDO and IL6 activate the JAK2/
STAT3 signaling pathway, which – together with NFkB (RelA) signa-
ling – is often altered in lung cancer. BIM could influence response 
to chemotherapy. We have examined these components and KRAS 
mutations in NSCLC tumor samples and correlated results with 
progression-free survival (PFS).
Methods: The mRNA expression of MED12, IDO, JAK2, STAT3, 
RelA and BIM was examined in microdissected tumor samples 
from p with stage IV NSCLC. mRNA levels were assessed by RT-
PCR and categorized by terciles (high vs low/intermediate). KRAS 
mutations were assessed by high resolution melting.
Results: A total of 55 p with performance status (PS) 0-1, treated 
with platinum plus either gemcitabine or pemetrexed: median age, 
62 years; 27.6% females; 84.2% smokers; 66% adenocarcinoma; 
16% with KRAS mutations. There was no correlation between gene 
expression levels and KRAS mutation status. In the multivariate 
analysis, including gene expression levels, histology and PS, only 
MED12 and STAT3 were associated with PFS (low MED12: HR=11.6, 
P=0.005; high STAT3: HR=6.5, P=0.01). HR for low BIM expression 
was 2.4 (P=0.16). None of the markers were associated with overall 
survival.
Conclusion: To the best of our knowledge, this is the first time that 
low expression of MED12 with significantly shorter PFS in NSCLC p 
receiving platinum-based chemotherapy. MED12 could be a new 
biomarker of chemoresistance and inhibition of TGF-bR signaling 
can restore chemotherapy response in patients with low MED12.
Keywords: Biomarkers, TGF-bR signaling, progression-free  
survival
markers or potential molecular targets for personalized medicine.
Keywords: LCNEC, miRNAs, Carcinoids, SCLC
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P2.01-026 "EGFR“ GENE MUTATION IN ADVANCED 
NON SMALL CELL LUNG CANCER-A CASE SERIES
Azhar Rashid, Sadaf Usman, Muhammad Irfan, Tahir Mehmood, 
Muhammad A. Munawar
Radiation Oncology, Shaukat Khanum Memorial Cancer Hospital & 
Research Center/Pakistan
Background: Molecular targeted therapy based on TKIs, directed 
at the Epidural growth factor receptor (EGFR) is one of the recent 
option for the management of advanced Non-Small Cell Lung 
Cancer (NSCLCs). EGFR gene mutations, exon 19 deletions (E19 
del (LREA deletions)) and exon 21(L858R) are most common and 
good predictions of response to EGFR-TKI treatment. EGFR gene 
mutations are found in approx. 10% of Caucasian patients and up 
to 50% of Asian populations(1) .Recent studies have endorsed these 
incidences in European and Asian populations. The frequency of 
EGFR mutation is higher in non-smokers and in women(2,3) .The aim 
of the study was to determine the frequency of EGFR gene muta-
tion in advanced non small cell lung cancer patients presenting to 
SKMCH & RC.
Methods: Between Sep 2011 to Sep 2012, we have sent EGFR Mu-
tation testing for 15 patients with proven histology of TTF-1 positi-
ve adenocarcinoma lung. EGFR gene mutations in exons 18, 19,20 
and 21 were carried out by National University Hospital Singapore 
and Singapore General Hospital. Data was collected and analysed. 
Frequencies were determined.
Results: 10 (66.6 %) patients were male and 5 (33.3 %) were fema-
les. Eight (53.3 %) were smokers and 7 (46.6 %) were non smokers.
Three (20 %) patients were having EGFR mutation +ve . One with 
+ve mutation on exon 19, one with +ve mutation on exon 21 and 
one with +ve EGFR mutation on exon 20. Two of these three( 
66.6%) patients were smoker and one ( 33.3%)out of them was 
non smoker. All three patients were male. One (6.6%) patient has 
insufficient biopsy material to carry out the test. While 8 (53.3 %) 
patients have –ve EGFR mutation on all exons and 3 (20%) pati-
ents have unsatisfactory results on few exons and –ve mutation on 
other exons.
Conclusion: The frequency of EGFR mutation in our institution 
was 20 % and all these patients were male, two third patients were 
smokers. This trend is not in accordance with literature, needs 
more number of patients to find out the real trend.
Keywords: EGFR Gene, Non small cell lung cancer, Tyrosin Kinase 
Inhibitors, EGFR gene mutations
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sion through an increase of cyclin E1 phosphorylation in lung ade-
nocarcinoma. In conclusion, SFN facilitates cell proliferation and 
malignant progression of lung adenocarcinoma, and its mechanism 
of action is thought to be associated with inhibition of SCFFbw7 ubi-
quitination and degradation.
Keywords: adenocarcinoma progression, stratifin, SCF complex
POSTER SESSION 2 - NOVEL CANCER GENES AND PATHWAYS  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.02-003 DNA METHYLATION AND EXPRESSION 
PATTERNS IN ADENOCARCINOMAS OF THE LUNG OF 
NEVER-SMOKERS WITH DISCORDANT METHYLATION 
AND EXPRESSION PATTERNS OF HOMEOBOX RELATED 
GENES
Aaron S. Mansfield1, Liang Wang2, Julie M. Cunningham3, Jin Jen3, 
Chris Kolbert4, Zhifu Sun5, Ping Yang6
1Medical Oncology, Mayo Clinic/United States Of America, 2Cancer 
Center, Department Of Pathology, Medical College Of Wisconsin/United 
States Of America, 3Department Of Laboratory Medicine And Patholo-
gy, Mayo Clinic/United States Of America, 4Medical Genome Facility, 
Mayo Clinic/United States Of America, 5Division Of Biomedical Stati-
stics And Informatics, Mayo Clinic/United States Of America, 6Health 
Sciences Research, Mayo Clinic/United States Of America
Background: Lung cancer occurs in a significant number of never-
smokers. Epigenetic changes in lung cancer potentially represent 
important diagnostic, prognostic and therapeutic targets. Accor-
dingly, we sought to determine if there are differences in DNA 
methylation between lung adenocarcinomas and adjacent non-
malignant lung tissue in never-smokers.
Methods: Using the Illumina Infinium HumanMethylation27 Bead-
Chip we compared the DNA methylation profiles of 28 adenocarci-
nomas of the lung of never-smokers with their paired adjacent non-
malignant lung tissue. The β value represents each methylation 
data point as the ratio of fluorescent signals between the methyla-
ted sites and the sum of methylated and unmethylated sites, which 
ranges continuously from 0 (unmethylated) to 1 (fully methylated). 
We used the Mann Whitney U test to compare β values between 
groups using JMP (SAS Institute Inc. Cary, NC USA). Then, using 
the Illumina Human WG DASL beadchip, we correlated differential 
methylation changes with gene expression changes from the same 
28 samples. We validated our findings with 24 samples of lung 
adenocarcinomas and paired non-malignant tissue from The Can-
cer Genome Atlas (TCGA). Database for Annotation, Visualization, 
and Integrated Discovery was used to determine gene enrichment.
Results: We observed a distinct separation in methylation profiles 
between tumor and adjacent nonmalignant lung tissue using prin-
cipal component analysis. Tumors were generally hypomethylated 
(β=0.15) when compared to adjacent non-malignant tissue (β=0.17; 
p=0.02). There were 1906 differentially methylated (Bonferroni 
corrected p value <0.05) CpG sites between tumor and adjacent 
non-malignant lung tissue. Of these sites, 1198 were within clas-
sically defined CpG islands where tumors (median β=0.38) were 
hypermethylated compared to adjacent non-malignant tissue (me-
dian β=0.22; p<0.0001), and 708 sites were outside of CpG islands 
where tumors (β=0.49) were hypomethylated compared to adja-
cent non-malignant tissue (β=0.56; p<0.0001). When compared to 
a dataset of 24 lung adenocarcinomas and paired non-malignant 
tissue from TCGA, 1841 of these 1906 (96.6%) sites were also dif-
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P2.02-002 STRATIFIN EXPRESSED IN EARLY INVASIVE 
LUNG ADENOCARCINOMA FUNCTIONALLY ENHANCES 
TUMOR PROGRESSION AND DOWN-REGULATES SCFF-
BW7 UBIQUITIN LIGASE ACTIVITY
Aya Shiba1, Yukari Iguchi1, Yukio Morishita2, Toshihiro Shiozawa1, 
Shinji Iyama1, Shun-Ichiro Iemura3, Tohru Natsume3, Junko Kano1, 
Yuko Minami1, Masayuki Noguchi1
1Department Of Diagnostic Pathology, Faculty Of Medicine, University 
Of Tsukuba/Japan, 2Department Of Pathology, Tokyo Medical Univer-
sity Ibaraki Medical Center/Japan, 3Biomedicinal Information Research 
Center, National Institutes Of Advanced Industrial Science And Techno-
logy/Japan
Background: Adenocarcinoma in situ (AIS) of the lung shows 
a very favorable prognosis, with a 5-year survival rate of 100%. 
However, early but invasive adenocarcinoma (eIA) sometimes has 
a fatal outcome. In order to elucidate the key molecule that affects 
the malignant progression of adenocarcinoma at an early stage, 
we previously compared the expression profiles of AIS with those 
of eIA, and found that stratifin (SFN, 14-3-3 sigma) is one of the 
differentially expressed genes related to tumor progression (Aya 
Shiba-Ishii, IJC. 2011). Immunohistochemistry (IHC) with anti-SFN 
antibody revealed that more than 95% of eIAs were SFN-positive, 
in comparison with only 13% of AISs. We also found that promoter 
demethylation triggered aberrant SFN overexpression in eIAs (Aya 
Shiba-Ishii, AJP. 2012). Here, we performed functional analysis of 
SFN and identification of SFN binding protein (SBP) to clarify how 
SFN affects the progression of lung adenocarcinoma.
Methods: For in vitro functional analysis, we performed RNA 
interference and expression vector transfection analyses and sub-
sequent cell proliferation assays or cell cycle phase assay using 
a lung adenocarcinoma cell line (A549). An in vivo animal study 
was also performed using siSFN-transfected A549. Additionally, in 
order to identify SBP, SFN vector-transfected A549 was subjected 
to pull-down assay and subsequent LC-MS analysis. Interaction 
of SFN and SBP was examined using co-IP and western western 
blotting.
Results: Suppression of SFN expression by siSFN significantly 
reduced cell proliferation activity and the S-phase subpopulation. 
Transfection of the SFN expression vector led to a significant incre-
ase in cell proliferation. A549 treated with siSFN showed reduced 
tumor development relative to the controls. Pull-down assay and 
LC-MS analysis revealed that SKP1 is one of the SBPs. SKP1 is a 
component of the SKP1-Cullin1-F-box containing complex (SCF 
complex). We found that Fbw7, one of the substrate recognition 
subunits of SCF complex, also binds to the SFN-SKP1 complex, 
resulting in up-regulation of cyclin E1 phosphorylation by SFN.
Conclusion: Although SFN was originally identified as a negative 
regulator of the cell cycle, especially in response to p53-sensitive 
DNA damage, subsequent reports indicated that it is a positive 
mediator of cell proliferation. In breast cancer, SFN induces G1/S 
progression by increasing the expression of cyclin D1. Here, we 
demonstrated that SFN enhanced the proliferative capacity of lung 
adenocarcinoma cells both in vitro and in vivo. We also revealed 
that SFN down-regulated expression of the SCFFbw7 complex. As 
cyclin E1 is a common target of SCFFbw7 ubiquitination, we predict 
that SCFFbw7 down-regulation by SFN might induce stabilization of 
cyclin E1. Since we also found that the S-phase subpopulation was 
decreased after siSFN treatment, SFN might induce G1/S progres-
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sphorylated ERK1/2 expression of lung tumors know to have NED. 
ERK1/2 positivity was defined by 5% or more tumor cells stained 
positive with phospho-Erk½.
Results: We discovered that NED of NSCLC was associated with 
the activation of Erk1/2-MAPK signal transduction pathway, and 
the inhibition of the Akt signal transduction pathway. Using speci-
fic activator (Pb2+) and inhibitors (siRNA-Erk1/2, and U0126) to the 
Erk1/2 /MAP-kinase pathway, as well as the inhibitor (LY294002) to 
the Akt pathway, we found that Erk1/2/MAP-kinase activation was 
essential for NED of NCI-H157 cells. Staining of Erk1/2/MAP-kinase 
pathway reveals a high rate of positivity in NSCLC tumors with 
NED when compared with other neuroendocrine lung tumors. The 
positive rate of IHC was 0/10 (0%) for typical carcinoid; 2/10 (20%) 
for atypical carcinoid; 4/9 (44.4%) for small cell lung carcinoma; and 
was 7/10 (70%) for large cell neuroendocrine lung carcinoma.The 
ERK1/2 activation was statistically different (**p<0.01 by two tailed 
Fisher exact test) comparing all carcinoid tumors (2/20, typical plus 
atypical) with high-grade neuroendocrine carcinoma (11/19, SCLC 
plus NSCLC) .
Conclusion: Through the in vitro NED induction of NSCLC cell 
line NCI-H157, and in vivo correlative investigations in lung tumors 
with NEC, we discovered that NED of NSCLC was associated with 
the activation of Erk1/2-MAPK signal transduction pathway. To 
our knowledge, our findings are the first to describe the potential 
involvement of Erk/MAPK signal transduction pathway of NSCLC 
in the association with NED. Further investigation of the Erk/MAPK 
signal transduction pathway of NSCLC may yield discoveries in 
identifying specific molecular targets for the treatment of NSCLC 
with NED.
POSTER SESSION 2 - NOVEL CANCER GENES AND PATHWAYS  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.02-005 EXPRESSION OF FIBROBLAST GROWTH FAC-
TOR-9 IS ASSOCIATED WITH POOR PROGNOSIS OF RE-
SECTED NON-SMALL CELL LUNG CANCER PATIENTS
Keiko Ohgino1, Kenzo Soejima1, Hiroyuki Yasuda1, Yuichiro Ha-
yashi2, Tetsuo Tani1, Aoi Kuroda1, Daisuke Arai1, Kota Ishioka1, 
Takashi Sato1, Hideki Terai1, Shinnosuke Ikemura1, Sohei Nakaya-
ma1, Satoshi Yoda1, Junko Hamamoto1, Katsuhiko Naoki1, Tomoko 
Betsuyaku1
1Division Of Pulmonary Medicine, Department Of Medicine, Keio Uni-
versity School Of Medicine/Japan, 2Department Of Pathology, Keio 
University School Of Medicine/Japan
Background: Fibroblast growth factor (FGF) family consists of at 
least 23 polypeptides which have important functions in embryo-
nic development, tissue repair, and tumorigenesis. Recent studies 
have shown that the activation of FGF9 is associated with pathoge-
nesis of several cancers. In the lungs, FGF9 was highly expressed in 
adenocarcinoma by immunohistochemistry, and disturbing FGF9 
function reduced the proliferation of lung adenocarcinoma. Howe-
ver, its clinicopathological and biological significance in non-small 
cell lung cancer (NSCLC) is unclear. The purpose of this study is to 
clarify the characteristics of FGF9-expressing NSCLC.
Methods: Using a cDNA microarray data set for 90 surgically 
resected NSCLC and corresponding non-tumorous lung tissue 
samples, we analyzed the relationship between the expression of 
FGF9 and their clinicopathological characterisitics. Also, we vali-
dated FGF9 expression by quantitative RT-PCR, and immunohisto-
ferentially methylated with the same direction of change between 
tumor and non-tumor lung tissue. We matched 1483 genes with 
the differentially methylated CpG sites and found that these genes 
were enriched with the terms glycoprotein, signal, plasma memb-
rane part, homeobox in addition to a few other terms. There were 
significant differences in expression of 376 genes (Bonferroni cor-
rected p<0.05) of the 1483 (25.4%) differentially methylated CpG 
sites. There was an inverse correlation between methylation and 
gene expression in 80% of these genes. Genes that were not signi-
ficantly differentially expressed and were hypermethylated within 
CpG sites were enriched for homeobox genes (false discovery rate 
= 1.2E-27).
Conclusion: The methylation profiles of lung adenocarcinomas of 
never-smokers and their adjacent non-malignant lung tissue are 
significantly different. Differential methylation of a CpG site was 
associated with altered gene expression in approximately 25% of 
cases. Despite the differential methylation of homeobox genes, no 
significant changes in expression of these genes were detected.
Keywords: methylation, homeobox, epigenetics, Lung cancer
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P2.02-004 ERK/MAP-KINASE SIGNALING PATHWAY 
AND NEUROENDOCRINE DIFFERENTIATION OF NON-
SMALL CELL LUNG CANCER
Yuhchyau Chen1, Irena Nowak1, Peter C. Keng1, Hongliang Sun1, 
Haodong Xu2, Jiaoti Huang3
1Radiation Oncology, University Of Rochester/United States Of Ameri-
ca, 2Pathology & Laboratory Medicine, University Of Rochester/United 
States Of America, 3Pathology & Laboratory Medicine, University Of 
California/United States Of America
Background: Neuroendocrine differentiation (NED) has been ob-
served in approximately 25-33% of all lung tumors. Essentially all 
small cell lung cancer (SCLC) and carcinoid tumors show distinct 
histological morphology and stain positive to neuroendocrine mar-
kers such as neuroamines, neuropeptides, dense core secretory 
granules, chromogranin A, neuroendocrine specific protein (NSP), 
and neuron-specific enolase (NSE). It was later recognized that 
NED was not limited to SCLC and carcinoid, and it could involve 
non-small cell lung cancer (NSCLC) such as large cell neuroendo-
crine carcinoma (LCNEC). Subsequently, it was found that about 
10-20% of NSCLC, including adenocarcinomas and squamous cell 
carcinomas, also exhibit some neuroendocrine properties despite 
being considered non-neuroendocrine types. It has been postu-
lated that NED of NSCLC represents an intermediary transition 
between SCLC and NSCLC, or that NED may be a predictor of the 
response to chemotherapy or radiotherapy, as well as a predictor 
of shorter survival in patients with stage I adenocarcinoma of the 
lung. Irrespective of these observations, the clinical significance of 
NED of NSCLC remains unclear.
Methods: We hypothesize that the investigation of the intracellular 
signal transduction pathway involved with NED of NSCLC cells may 
reveal potential molecular targets for the treatment of NSCLC with 
NED. We explore the potential molecular pathway involved in NED 
of NSCLC and its clinical association, through the induction of NED 
of a NSCLC cell line NCI –H157 in vitro. We further confirmed our 
findings using activators vs. inhibitors to these signal transduction 
pathways in vitro. We conducted immunochemical stains for phop-
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Background: Somatic mutations in the tyrosine kinase domain of 
the epidermal growth factor receptor (EGFR) are response predic-
tive markers for the treatment of lung adenocarcinoma by using 
EGFR tyrosine kinase inhibitors. The stability of EGFR is dependent 
on its interaction with heat shock protein 90 (Hsp90), and Hsp90 
inhibition may induce ubiquitin-mediated degradation of EGFR 
proteins. However, the mechanism of EGFR downregulation by 
HSP90 inhibition remains unclear. Here, we report a novel interac-
tion between EGFR mutants and the E3 ubiquitin ligase C-terminus 
of Hsp70-interacting protein (CHIP), which can ubiquitinate and 
destabilize EGFR mutants
Methods: Cell culture, transfection and drug treatments 
NSCLC (A549, H358, H827, and PC9 cells) and Chinese hamster 
ovarian (CHO) cell lines used in the study were obtained from 
ATCC. Transfections of different DNA constructs were performed 
using Lipofectamine 2000 or PolyJet Western blot and immuno-
precipitation 
Cells were then chilled on ice, washed twice with ice-cold PBS, and 
lysed in a buffer. Protein concentrations were determined using a 
Bradford assay kit. Equal amounts of protein (20 µg) in cell lysates 
were separated by SDS-PAGE, transferred to membranes, immu-
noblotted with specific primary and secondary antibodies, and 
detected by chemiluminescence with the enhanced chemilumine-
scence detection reagents. Cell viability assay 
After trasnfection with or without CHIP, cell metabolic activity was 
determined every 24 hours by using the CCK-8 (Dojindo, Gaithers-
burg, MD) colorimetric assay according to the manufacturer’s inst-
ructions. Cell cycle analysis by FACS 
Cells were seeded in 6-well plate and incubated overnight before 
transfection. After harvest at 48 h following transfection, cells were 
washed twice with pre-chilled PBS and resuspended in PBS (100 
µL) at a concentration of 1 × 106 cells/mL. Cell cycle analysis was 
performed using the Coulter DNA PrepTM Reagents Kit. Xeno-
graft studies A549 and PC9 cells were cultured as monolayers, 
trypsinized and resuspended in an equal volume of PBS at 5 × 107 
per ml, respectively. BALB/c female nu/nu mice (5 weeks of age) 
were given bilateral subcutaneous injections of 5 × 106 (0.1 ml). 
Tumor growth was monitored twice each week by measuring the 
tumor size using calipers
Results: In CHO cells expressing either WT or mutant EGFR, the 
expression of the EGFR mutants L858R, G719S, and L747_E749del 
A750P was inhibited 
following overexpression of CHIP, whereas WT EGFR expression 
was not diminished in CHIP transfected cells. In a pull-down assay, 
CHIP interacted with G719S and del L747_E749del A750P, but not 
L858R, and simultaneously induced the ubiquitination and pro-
teasomal degradation of its proteins. Similarly, the expression of 
mutant EGFR proteins in the non-small cell lung cancer cell line 
PC9 was also diminished by CHIP-mediated ubiquitination and 
degradation relative to WT EGFR. In EGFR mutant cell lines, CHIP 
inhibited cell proliferation as well as the depletion of phosphoryla-
ted Akt. In addition, CHIP inhibited the tumor growth of PC9 cells 
in xenografts of CHIP-overexpressing stable cell lines.
Conclusion: These data suggest that CHIP-induced ubiquitination 
of EGFR mutants may be responsible for EGFR regulation in lung 
adenocarcinoma and provide evidence that CHIP could be a novel 
E3 ligase for EGFR mutants.
Keywords: non-small cell lung cancer (NSCLC), ubiquitination, C-
terminus of Hsc70-interacting(CHIP), EGFR mutants
chemistry at protein level. Associations between FGF9 expression 
and clinicopathological factors were assessed by the Χ2 test and 
Mann-Whitney U-test. Log-rank test was applied for survival analy-
sis, and Kaplan-Meyer curve (Fig.1) was drawn. Multivariate analy-
ses of the influence of variables on overall survival were performed 
with using Cox proportional hazards model.
Results: Nine out of 90 (10%) NSCLC had “high” FGF9 expres-
sion compared with corresponding non-cancerous lung tissues. 
Histologically, 5 out of 9 FGF9-high NSCLC were adenocarcino-
ma, and there was no squamous cell carcinoma. The correlations 
between FGF9 expression and sex, smoking history or clinical 
stage were not observed. On the other hand, postoperative 
recurrence rates and 3-year survival rates were 56% vs. 36% 
(p=0.033) and 44% vs. 88% (p=0.001) for FGF9-high vs. -low NS-
CLC patients, respectively. The overall survival of the patients 
with high-FGF9 expression was significantly worse compared 
that with FGF9-low NSCLC patients (p<0.001). At protein level, 
FGF9 expression (immunohistochemistry) was significantly hig-
her in FGF9-high mRNA group compared with FGF9-low group. 
FGF9 was confirmed to be expressed in cancer cells in these 
resected NSCLC tissues, and localized in cytoplasm of the cells. 
Conclusion: FGF9 is highly expressed in a subset of lung ade-
nocarcinoma, and is associated with poor prognosis.
Keywords: Fibroblast growth factor-9, non-small cell lung cancer, 
Prognosis, Immunohistochemistry
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P2.02-006 THE SELECTIVE REGULATION OF EGFR 
MUTANTS BY C-TERMINUS OF HSC70-INTERACTING-
PROTEIN(CHIP) IN LUNG ADENOCARCINOMA
Chaeuk Chung1, Kang Won Jang2, Hye Rim Cha1, Bum Jin Kwon1, 
Hee Sun Park1, Sung Soo Jung1, Ju Ock Kim1, Sun Young Kim1, Jae 
Cheol Lee3, Jin Hwan Kim4, Seung Pyung Lim5, Jeong Eun Lee1
1Department Of Pulmonology, Chungnam National University Hospi-
tal/Korea, 2Cancer Institute, Chungnam National University Hospital/
Korea, 3Department Of Oncology, Asan Medical Center/Korea, 4Depart-
ment Of Radiology, Chungnam National University/Korea, 5Department 
Of Thoracic And Cardiovascular Surgery, Chungnam National Universi-
ty School Of Medicine/Korea
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and metastasis. High expression of HDGF and ADAM9 correlate 
with shortened survival time, predict lower 5-year survival rates, 
suggesting that HDGF and ADAM9 are novel biomarkers for 
predicting prognosis in resected stage I NSCLC, revealing their 
significance as novel molecular staging biomarkers. HDGF and 
ADAM9 may also become useful predictive biomarkers for the 
selection of adjuvant chemotherapy treatment of NSCLC to impro-
ve personalized postoperative treatment in resected stage I non-
small cell lung cancer. (This study was partly supported by grant 
from the Nature Science Foundation of Liaoning Province, China, 
No.20102285; and the Fund for Scientific Research of The First 
Hospital of China Medical University, No.FSFH1210).
Keywords: ADAM9 pathway, molecular staging biomarkers, prog-
nostic and predictive biomarkers of NSCLC, HDGF pathway
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P2.02-008 ELEVATED MICROSATELLITE ALTERATIONS 
AT SELECTED TETRA-NUCLEOTIDE (EMAST) IN NON-
SMALL CELL LUNG CANCERS - A POTENTIAL DETERMI-
NANT OF SUSCEPTIBILITY TO MULTIPLE MALIGNAN-
CIES
Hiromasa Arai1, Koji Okudela2, Hisashi Oshiro3, Noriko Komitsu2, 
Keita Fujii1, Masahiro Tsuboi4, Munetaka Masuda1
1Surgery, Yokohama City University Graduate School Of Medicine/
Japan, 2Pathology, Yokohama City University Graduate School Of Me-
dicine/Japan, 3Tokyo Medical University/Japan, 4Respiratory Disease 
Center (Surgery), Yokohama City University Medical Center/Japan
Background: Microsatellite instability (MSI) can be analyzed by 
microsatellite markers consisting of mono-, di- and trinucleotide 
repeat sequences. In primary lung cancer, chromosomal instability 
including loss of heterozygosity (LOH) has been thought to play 
an important role in carcinogenesis. Although MSI was thought 
to be unrelated to lung carcinogenesis, recent findings suggest 
the role of tetranucleotide repeat sequence instability in prostate, 
skin, bladder and lung cancers. Unlike Bethesda panel markers 
(D17S250, D2S123, D5S346, BAT25 and BAT26) for Lynch syndro-
me, these tetranucleotide markers are not unified. Moreover, there 
are frequent elevated microsatellite alterations at selected tetranu-
cleotides (EMAST) that are distinct from traditional MSI in several 
tumor types. EMAST in lung cancer has not been reported to date. 
We investigated EMAST in non-small cell lung cancers (NSCLCs) 
using selected tetranucleotide repeat markers (EMAST markers: 
D8S321, D20S82, UT5037, D8S348, D2S443, D21S1436, D9S747, 
D9S303, D9S304 and MYCL1) based on previous reports and ana-
lyzed their correlation to clinicopathological factors.
Methods: Sixty-five NSCLC tissue samples (19 squamous cell carci-
nomas, 39 adenocarcinomas, one adenosquamous cell carcinoma 
and six large cell carcinomas) without lymph node metastasis and 
preoperative chemotherapy or radiation therapy were obtained 
after resection from Yokohama City University Medical Center. 
Tumorous DNA was extracted by laser captured microdissection, 
and paired normal DNA was extracted from non-tumorous tissue 
or normal lymph nodes. Genotyping for EMAST determination was 
carried out using ten tetranucleotide repeat markers and five Be-
thesda panel markers.
Results: Using the ten tetranucleotide repeat markers, MSI was de-
tected in 42 of 65 (64.9%) of the tissue samples. There was a higher 
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P2.02-007 HDGF, ADAM9 INVOLVED IN A NOVEL PA-
THWAY OF CELL GROWTH AND INVASION OF NON-
SMALL CELL LUNG CANCER CELLS, MAY BECOME NO-
VEL MOLECULAR STAGING BIOMARKERS, PROGNOSTIC 
AND PREDICTIVE BIOMARKERS OF NSCLC
Jun Zhang1, Ning Chen2, Juan Qi3
1China Medical University Lung Cancer Center, The First Hospital Of 
China Medical University/China, 2China Medical University Lung Can-
cer Center Of The First Hospital Of China Medical University, Depart-
ment Of Logistic Management, College Of Economics And Management, 
Liaoning University Of Traditional Chinese Medicine/China, 3Depart-
ment Of Molecular Targeted Therapeutics, The First Hospital Of China 
Medical University/China
Background: Our recent studies revealed that hepatoma-derived 
growth factor (HDGF) was highly expressed in non-small cell lung 
cancer (NSCLC) cells, when HDGF targeted-silenced by siRNA 
strategy, anchorage-independent growth of NSCLC cells can be 
significantly inhibited, the ability of NSCLC cells to invade across 
BD Matrigel membrane barrier can also be significantly inhibited, 
clearly suggested HDGF’s important role in cell growth, invasion 
and metastasis of NSCLC. However, the molecular mechanism is 
still undiscovered. Here, we reported that HDGF-ADAM9…may 
be the novel pathway for HDGF promotes growth and invasion of 
NSCLC cells. The expression of HDGF, ADAM9 in human resected 
NSCLC tissues will be detected, and the co-relationship, coordina-
tion of HDGF and ADAM9 will be evaluated to provide evidence, 
to elucidate the logic possibility of the HDGF-ADAM9…pathway.
Methods: siRNAs targeting HDGF were designed, used for specifi-
cally silencing HDGF in NSCLC cells. In vitro and in vivo cell growth 
and invasion assay were conducted. cDNA microarray and Western 
blot were used to explore the novel pathway, the possible molecu-
lar mechanism, by which HDGF promotes growth and invasion of 
NSCLC cells. Immunohistochemical SP method was used to detect 
the expression of HDGF and down-stream modulated genes in 
NSCLC tissues. Multivariate analysis and survival analysis were 
conducted to evaluate the clinical significance, the co-relationship, 
the possible coordination of HDGF and down-stream genes.
Results: Western blot revealed that HDGF protein expression in 
NSCLC cells were down-regulated more than 90% after silenced 
by targeted siRNA; anchorage-independent growth of A549 and 
H226 cells were inhibited significantly (P=0.000, 0.003, respec-
tively); the ability of invading across BD Matrigel membrane barrier 
were inhibited significantly (P=0.004, 0.000, respectively). cDNA 
microarray revealed that a panel of genes, including AXL, GLO1, 
and ADAM9, were significantly down-regulated when HDGF was si-
lenced by siRNA, suggested the possible pathways in which HDGF 
was involved. The expression of HDGF and ADAM9 were Immuno-
histochemically detected in 63 cases of completely resected stage 
I NSCLC, found highly expressed in NSCLC when compared with 
normal control lung tissues (P=0.003, 0.001, respectively); highly 
expressed HDGF and ADAM9 were found correlated with signifi-
cantly declined 5-year survival rates (P=0.009, 0.015, respectively). 
HDGF expression was revealed correlated positively and signifi-
cantly with ADAM9 expression in these resected stage I NSCLC 
(Pearson r=0.547, P=0.000).
Conclusion: These results clearly revealed that HDGF may promo-
te cell growth and invasion of NSCLC cells via ADAM9 pathway, 
HDGF-ADAM9…should be a novel pathway of lung cancer invasion 
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when transfected into SBC5, a SCLC cell lacking CADM1. Inversely, 
suppression of CADM1 expression by shRNA reduced spheroid-
like cell aggregation of NCI-H69, a SCLC cell expressing a high 
amount of CADM1. These findings suggest that CADM1 enhances 
the malignant features of SCLC, as is observed in ATL.
Conclusion: CADM1 could provide a novel molecular target for 
the diagnosis and growth suppression of SCLC cells.
Keywords: CADM1, SCLC, splicing variant
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P2.02-010 FREQUENCY OF ALK GENE REARRANGE-
MENT IN SAUDI LUNG CANCER
Fouad H. Al-Dayel1, Hamad Al Husaini2, Asma Tulbah1, Halah 
Abalkhail1, Prashant Bavi3, Khawla Al Kuraya3
1Pathology And Laboratory Medicine, King Faisal Specialist Hospital 
And Research Centre/Saudi Arabia, 2Oncology Center, King Faisal Spe-
cialist Hospital And Research Centre/Saudi Arabia, 3Research Centre, 
King Faisal Specialist Hospital And Research Centre/Saudi Arabia
Background: Lung carcinoma is the fifth common cancer affecting 
Saudi men. Recently, translocation of the anaplastic lymphoma ki-
nase (ALK) gene is found to play a predictive role in adenocarcino-
ma tumor genesis. ALK gene rearrangement can identify patients 
with adenocarcinoma who are sensitive to ALK inhibitors. However, 
no data are available on the prevalence of ALK rearrangements 
changes in Middle Eastern population. Therefore, we carried out 
this study to evaluate the prevalence of ALK rearrangements in 
lung adenocarcinoma of Saudi patients.
Methods: ALK gene rearrangements were studied using fluores-
cence in situ hybridization (FISH) on 97 adenocarcinoma samples 
utilizing tissue microarray format. ALK gene translocations iden-
tified by BAC clone RP11-328L16 were studied by the break part 
probe from Vysis (Abott Molecular, Il, USA).
Results: Ninety seven (97) lung adenocarcinoma cases were evalu-
ated. There were 3 cases exhibited ALK gene rearrangement (3%). 
All of these 3 cases was moderately differentiated adenocarcino-
ma. None of our cases showed signet cells or abundant intracellu-
lar mucin.
Conclusion: This is the first study that reveals frequency of ALK 
translocation in a ethically unique cohort of Saudi lung cancer 
patients. The findings of this study show that incidence of ALK 
adenocarcinoma is similar to the published western data and these 
patients can benefit from targeted therapy like Crizotinib- a dual 
ALK and MET inhibitor that has shown promising results in clinical 
trials.
Keyword: Lung adenocarcinoma, ALK gene rearrangement
rate of MSI at selected tetranucleotide markers than at Bethesda 
panel markers in the tissue samples (12.3%). The high EMAST 
group (MSI found at two or more markers) was significantly corre-
lated to the presence of multiple malignant neoplasms (p=0.021) 
compared to the low EMAST group (MSI at none or one marker). 
We also examined a representative malignant neoplasm (renal pel-
vic carcinoma) complicated with NSCLC using EMAST markers. The 
tumor showed EMAST in the two markers (D2S443 and D21S1436).
Conclusion: Our results suggest that EMAST could participate in 
carcinogenesis of NSCLCs and lead to other malignant neoplasms.
Keywords: Elevated microsatellite alterations at selected tetra-nu-
cleotide, non-small cell lung cancer, multilpe malignant neoplasms, 
EMAST
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P2.02-009 EXPRESSION OF A SPLICING VARIANT OF 
THE CADM1 SPECIFIC TO SMALL CELL LUNG CANCER
Shinji Kikuchi1, Miwako Iwai2, Mika Sakurai-Yageta2, Yumi Tsub-
oi2, Takeshi Ito2, Tomoko Maruyama2, Hitoshi Tsuda3, Yae Kanai4, 
Yukinobu Goto1, Mitsuaki Sakai1, Masataka Onizuka1, Yukio Sato1, 
Yoshinori Murakami2
1Department Of Thoracic Surgery, Tsukuba University Hospital/Japan, 
2Division Of Molecular Pathology, Institute Of Medical Science, The 
University Of Tokyo/Japan, 3Department Of Diagnostic Pathology, Na-
tional Cancer Research Center Hospital/Japan, 4Division Of Pathology, 
National Cancer Research Center Research Institute/Japan
Background: CADM1, a member of the immunoglobulin super-
family cell adhesion molecules, acts as a tumor suppressor in a 
variety of human cancers. CADM1 expression is frequently lost in 
various cancers and CADM1 inactivation by promoter methylation 
was observed in 44% of non-small cell lung cancer (NSCLC). In 
contrast, CADM1 is ectopically expressed in adult T-cell leukemia 
(ATL), conferring an invasive phenotype characteristic to ATL. 
Therefore, CADM1 plays dual roles in human oncogenesis: as a 
tumor suppressor in epithelial cancers and as an oncoprotein that 
promotes invasion in ATL cells. Here, we investigate the roles of 
CADM1 in small cell lung cancer (SCLC).
Methods: We studied splicing variant of CADM1 in 5 primary NS-
CLC tumors and a primary SCLC tumor, as well as 16 SCLC and 10 
NSCLC cell lines. Expresssion and splicing variant of CADM1 was 
examined by RT-PCR, Western blotting, immunohistochemistry, 
and SSCP, respectively.
Results: Immunohistochemistry demonstrates that 10 of 35 (29%) 
primary SCLC tumors express CADM1 protein. Western blotting 
and RT-PCR analyses have revealed that CADM1 is significantly 
expressed in 11 of 14 SCLC cells growing in suspension cultures 
but in neither of 2 SCLC cells showing attached growth to plastic 
dishes, suggesting that CADM1 is involved in anchorage-indepen-
dent growth in SCLC. Then, we demonstrate that SCLC expresses 
a unique splicing variant of CADM1 (variant 8/9) containing additi-
onal extracellular fragments corresponding to exon 9 in addition to 
variant 8, a common isoform in epithelia. Variant 8/9 of CADM1 is 
almost exclusively observed in SCLC and testis, although this va-
riant protein localizes along the membrane and shows similar cell 
aggregation activity to variant 8. Interestingly, both variant 8/9 and 
variant 8 of CADM1 show enhanced tumorigenicity in nude mice 
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ding RNAs (lncRNAs) which regulate gene expression during initi-
ation and progression of human lung cancers. The present study 
was undertaken to utilize a novel in vitro model system to examine 
long non-coding RNA alterations mediated by cigarette smoke in 
normal respiratory epithelia and lung cancer cells.
Methods: Normal human small airway epithelial cells (SAEC) 
and cdk-4/h-TERT immortalized human bronchial epithelial cells 
(HBEC), as well as Calu-6 and H-841 lung cancer cells were cul-
tured in the presence or absence of cigarette smoke condensate 
(CSC). Array and qRT-PCR techniques were used to assess lncR-
NA and gene expression profiles in CSC-treated or control cells. 
qRT-PCR techniques were used to evaluate expression levels of 
BC070487 and its target gene, ZNFX1 in primary lung cancers rela-
tive to paired normal lung tissues. Chromatin immunoprecipitation 
(ChIP), RNA-crosslink immunoprecipitation (CLIP), and methyl DNA 
immunoprecipitation (MeDIP) techniques were used to evaluate 
chromatin alterations within the ZNFX1 promoter region mediated 
by BC070487. MTS, invasion, and murine xenograft experiments 
were performed to examine proliferation, invasion and tumorige-
nicity of lung cancer cells following manipulation of BC070487 or 
ZNFX1 expression.
Results: Under relevant exposure conditions, CSC mediated a 4-7 
fold up-regulation of BC070487, with a 4-8 fold down-regulation 
of ZNFX1 in normal respiratory epithelia and lung cancer cells. 
BC070487 epression correlated inversely with expression of ZNFX1 
(BC070487: 1.38-10.31 fold up vs ZNFX1: 2.26-26.29 fold down) 
in primary lung cancers relative to adjacent normal lung tissues. 
Over-expression or depletion of BC070487 inhibited or enhanced 
expression, respectively, of ZNFX1 in normal respiratory epithelia 
and lung cancer cells. CSC as well as BC070487-mediated re-
pression of ZNFX1 coincided with increased occupancy of EZH2, 
SUZ12 and BMI1, as well as increased H3K27Me3 and decreased 
H3K4Me3 levels within the ZNFX1 promoter region. CSC or over-
expression of BC070487 enhanced binding of BC070487 with 
EZH2, SUZ12 and BMI1 proteins in SAEC and Calu-6 cells. CSC ex-
posure mediated a significant increase in DNA methylation in one 
of two CpG islands spanning the ZNFX1 regulatory region in SAEC 
and Calu-6 cells; this phenomenon coincided with enhanced bin-
ding of BC070487 with DNMT3a and 3b, and recruitment of these 
de-novo DNA methyltransferases to the ZNFX1 regulatory region 
in these cells. Over-expression of BC070487 increased proliferation 
and invasion potential of lung cancer cells in-vitro, and enhanced 
growth of lung cancer xenografts in nude mice. Consistent with 
these findings, ZNFX1 depletion enhanced, whereas constitutive 
over-expression of ZNFX1 inhibited growth and tumorigenicity of 
lung cancer cells.
Conclusion: Cigarette smoke induces expression of LncRNA 
BC070487, which in turn represses ZNFX1 in normal respiratory 
epithelia and lung cancer cells. These findings provide a novel 
mechanism by which cigarette smoke mediates initiation and pro-
gression of lung cancers, and highlight the potential implications 
of smoking status of lung cancer patients at diagnosis or during 
therapy.
Keywords: Lung cancer, Cigarette smoke, long non-coding RNA, 
epigenetics
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P2.02-011 IMPACT OF FAMILY HISTORY OF CANCER 
ON THE INCIDENCE OF MUTATION IN EPIDERMAL 
GROWTH FACTOR RECEPTOR GENE IN NON-SMALL 
CELL LUNG CANCER PATIENTS
Yayi He, Caicun Zhou, Jiayu Li
Department Of Medical Oncology, Shanghai Pulmonary Hospital, Tongji 
University Medical School Cancer Institute, Tongji University School Of 
Medicine/China
Background: Epidermal growth factor receptor (EGFR) activating 
mutation is an important predictive biomarker of EGFR tyrosine 
kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC), while 
family history of cancer also plays an important role in the neopla-
sia of lung cancer. This study aimed to investigate the association 
between family history of cancer and EGFR mutation status in NS-
CLC population.
Methods: From February 2008 to May 2012, 538 consecutive NS-
CLC patients with known EGFR mutation status were included into 
this study. Amplification refractory mutation system (ARMS) me-
thod was used to detect EGFR mutation. The associations between 
EGFR mutation and family history of cancer were evaluated using 
logistic regression models.
Results: EGFR activating mutation was found in 220 patients and 
117 patients had family cancer histories among first-degree relati-
ves. EGFR mutation was more frequently detected in adenocarci-
noma patients (p<0.001), never-smoker (p<0.001) and with family 
history of cancer (p=0.031), especially who had family history of 
lung cancer (p=0.008). In multivariate analysis, the association of 
EGFR mutation with family history of cancer also existed (p=0.027).
Conclusion: NSCLC Patients with family history of cancer, espe-
cially family history of lung cancer, might have a significantly higher 
incidence of EGFR activating mutation.
Keywords: non-small cell lung cancer, family history of cancer, 
Epidermal growth factor receptor
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P2.02-012 LONG NON-CODING RNA BC070487 REPRES-
SES THE NOVEL TUMOR SUPPRESSOR GENE ZNFX1 
DURING TOBACCO-INDUCED HUMAN PULMONARY 
CARCINOGENESIS
Sichuan Xi1, Jigui Shan2, Hongliang Guo3, Hong Xu4, Zuoxiang 
Xiao5, Tricia F. Kunst1, Leandro Mercedes1, Julie A. Hong1, Mary 
Zhang1, David S. Schrump1
1Thoracic Oncology Section, Surgery Branch, Center For Cancer Re-
search, National Cancer Institute/United States Of America, 2Advanced 
Biomedical Computing Center, National Cancer Institute/United States 
Of America, 3Gastrointestinal Surgery, Shandong Tumor Hospital And 
Institute/China, 4Laboratory Of Cancer Prevention, National Cancer In-
stitute/United States Of America, 5Cancer And Inflammation Center For 
Cancer Research, National Cancer Institute/United States Of America
Background: Limited information exists regarding long non-co-
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P2.02-014 DISCOVERY OF CIRCULATING PROTEIN  
BIOMARKERS OF LUNG DYSPLASIA
Rachel Ostroff1, Michael R. Mehan1, Stephen Williams1, Wilbur 
Franklin2, William Feser2, Anna Baron2, Mark Geraci2, Daniel T. 
Merrick3, Robert Keith3, York Miller3
1Somalogic/United States Of America, 2University Of Colorado Cancer 
Center/United States Of America, 3Denver Veterans Affairs Medical 
Center, University Of Colorado/United States Of America
Background: Endobronchial dysplasia is a premalignant lesion 
commonly found in current and former smokers. Identifying and 
treating these lesions before they progress to lung cancer may 
improve survival. The iloprost chemoprevention trial demonstrated 
that supplementation with the prostacyclin analog, iloprost, redu-
ced histologic dysplasia in former smokers (Keith et al. Cancer Prev 
Res. 2011). However, accurate detection of dysplasia requires inva-
sive bronchoscopy to collect multiple endobronchial biopsy samp-
les. This study is the first step in generating blood-based markers 
of dysplasia to identify individuals at high risk for developing lung 
cancer and who could benefit from chemoprevention treatment.
Methods: Baseline serum samples (n=70) collected from current 
and former smokers enrolled in the iloprost chemoprevention tri-
al were analyzed with the SOMAscan proteomic platform, which 
measures 1129 proteins with a median limit of detection of 40 fM 
and 5% CV. To characterize dysplasia, 6 standardized endobron-
chial sites, as well as any others that appeared suspicious by either 
white light or autofluorescence visualization, were biopsied from 
each study participant and scored by expert pathologists. Samples 
were stratified by worst biopsy score (Max) for proteomic analysis. 
Biomarkers correlating with Max pathology score were identified 
using principal component analysis (PCA), a multivariate technique 
to identify correlated variables, and the univariate, non-parametric 
Kolmogorov-Smirnov test (KS test). Serum proteins correlating with 
pulmonary function were also analyzed.
Results: Six proteins correlated with the progression of Max pa-
thology. The change in serum level of these proteins ranged from 
14-50% when comparing the lowest (n=16) and highest (n=39) 
Max pathology score groups. The proteins function in neoplastic 
progression, cell adhesion, inflammation and metabolic regula-
tion. The protein with the most significant change (FDR correct 
p value = 0.05) regulates plasma clearance of steroid hormones. 
The serum protein most strongly correlated with lung function in 
our study was VEGFR2, which mediates VEGF induced endothelial 
proliferation and is known to be reduced in the lungs of smokers 
and patients with COPD and emphysema.
Conclusion: Our preliminary results of serum biomarkers associa-
ted with preneoplastic dysplasia warrant further study. If validated, 
this serum-based test to identify individuals who may benefit from 
chemopreventive intervention could impact lung cancer survival. 
This work was supported by NCI grants CA 58187 and CA165780.
Keywords: dysplasia, Proteomic analysis, Biomarkers
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P2.02-013 THE IMPORTANCE OF IMMUNOREGULATORY 
GENES IN NON SMALL CELL LUNG CANCER
Eva García1, José B. Sanchis2, Jesus M. Baños1, Isabel M. Maradia-
ga1, Antonio A. Obrer1, Santiago Figueroa1, Enrique P. Martínez1, 
Eloisa Jantus-Lewintre3, Rafael Sirera4, Carlos Camps5, Ricardo 
Guijarro6
1Thoracic Surgery, General University Hospital Valencia/Spain, 2Mútua 
Terrasa Hospital/Spain, 3Molecular Oncology Laboratory, Hospital Ge-
neral Universitario De Valencia/Spain, 4Department Of Biotechnology, 
Polytechnic University Of Valencia/Spain, 5Hospital General Univer-
sitario De Valencia/Spain, 6Departamento De Cirugía, Universitat De 
Valencia/Spain
Background: In non small cell lung cancer (NSCLC) it is of vital 
importance to develop biomarkers that allow us to assign a more 
accurate prognosis for patients in early stages, so we can apply 
the right treatment at the right time, preventing that the cancer 
reaches advanced stages when the cure rate is close to zero.
Methods: In this study we have selected a set of 9 genes related 
to immunoregulation and inflammation processes to analyze their 
relative expression on mRNA by qPCR in lung tissue samples from 
patients with NSCLC and resectable stage. CCL2 and CD1c genes 
showed a significantly lower expression in tumor tissue versus 
healthy tissue. After that, we analyzed the correlation between 
expression levels of these genes and relevant clinicopathological 
variables in the patients. Poorly differentiated tumors showed hig-
her expression levels of CD209, CCL2, LGALS1 and LGALS2, whe-
reas in smokers an increased expression of galectin LGALS1 was 
documented. Finally, survival analysis was performed using the 
Kaplan-Meier method to assess the utility of genes as prognostic 
biomarkers in this disease.
Results: In the subgroup of patients with squamous cell histology, 
those with lower levels of expression of CCL22 showed a signifi-
cant increase in overall survival (OS) and progression-free survival 
(PFS). In our cohort of patients with resectable NSCLC, survival 
analyses showed that elevated levels of galectin LGALS2 and CCL2 
chemokine are associated with a better prognosis in overall survi-
val (OS) and progression-free survival (PFS).
Conclusion: The data obtained in our study provide further evi-
dence about the necessity of tumors to manipulate the microenvi-
ronment around them as a prelude to progress and invade tissues.
Keywords: galectin LGALS2, CCL2 chemokine ,overall survival 
(OS) ,and progression-free survival (PFS)., IMMUNOREGULATORY 
GENES lung cancer
S757Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
and Cancer Center Support Grant (P30CA046934).
Keywords: Tumor markers, Proteomic analysis, Driver mutation, 
Histology markers
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P2.02-016 PRMT5, A NOVEL EPIGENETIC TARGET IN 
LUNG CANCERS
Gregory A. Otterson1, Xin Wu1, Meng Welliver2, Smita Sharma2, 
Konstantin Shilo3
1Internal Medicine, Division Of Medical Oncology, Ohio State Universi-
ty/United States Of America, 2Ohio State University/United States Of 
America, 3Cancer Center, The Ohio State University/United States Of 
America
Background: PRMT5 is an arginine methyltransferase that regula-
tes cellular events by methylation of Arginine residues on histone 
and non-histone proteins. PRMT5 cooperates with chromatin re-
modelers and co-repressors to induce epigenetic silencing, and is 
overexpressed in several human cancers. It also has impact on cell 
growth and transformation pathways by modulation of E2F1, p53, 
EGFR and CRAF. We investigated the role of PRMT5 in lung cancer.
Methods: The expression pattern of PRMT5 using immunohisto-
chemistry from resection specimens obtained with an IRB appro-
ved protocol. Immortalized lung cancer cells (A549, H719, H520 
and H1299) were obtained from ATCC and normal bronchial airway 
cells (HPAEpiC, HBEpiC) were obtained from ScienCell. Western 
immunoblot and cell cycle analysis by flow cytometry was perfor-
med using standard techniques. A novel and specific inhibitor of 
PRMT5 developed by colleagues at OSU was applied to in vitro 
culture systems.
Results: The expression of PRMT5 was analyzed in 9 lung cancer 
resection specimens (3 adenocarcinoma, 3 squamous, 2 small cell 
and 1 large cell neuroendocrine cancer). All 9 showed diffuse cy-
toplasmic and variable nuclear PRMT5 expression. PRMT5 was also 
seen in reactive type 2 pneumocytes and respiratory epithelium 
adjacent to the tumors but not in alveolar parenchyma, fibroblasts 
or endothelial cells. Using Western immunoblot, PRMT5 is highly 
expressed in A549, H719, H1299 and H520 cells compared with 
normal cells such as HPAEpiC and HBEpiC. We knockdowned the 
expression of PRMT5 by lentiviral shRNAs and identified several 
clones with effective PRMT5 inhibition. Inhibition of PRMT5 was 
associated with slow cell growth. The cell proliferation decreased 
58.4% and 62.3% in H1299 and A549 knockdown cells respectively. 
Interestingly, while H4R3 methylation was decreased with PRMT5 
knockdown in A549 it was not in H1299 cells. We further analy-
zed the role of PRMT5 by using a specific inhibitor developed by 
researchers at OSU, CPD5. One of the PRMT5 specific marks of 
histone H4R3 methylation was inhibited and significant cell cycle 
changes were observed in A549 and H1299 cells treated for 24 hr 
and 48 hr. At 24 hours, the percentage of cells in G0/G1 was 57.1% 
(control) compared with 66.4% in CPD5 treated A549 cells, and 
52.5% (control) compared with 70.9% in CPD5 treated H1299 cells. 
The expression of p21 was increased while cyclin E1 was decreased 
in A549 cells treated with CPD5. In contrast, the expression of cell 
cycle related proteins were not found in PRMT5 knock-down cells. 
Immunoprecipitation and other protein interaction techniques are 
in process to identify new PRMT5 targets.
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P2.02-015 PROTEOMIC INSIGHTS WITH LUNG CANCER 
TUMORS BASED ON HISTOPATHOLOGIC SUBTYPES 
AND GENOTYPES
Rachel Ostroff1, Michael R. Mehan1, Stephen Williams1, Alexandru 
Niculescu-Mizil2, Wilbur Franklin3, Daniel T. Merrick4, Adrie Van 
Bokhoven3, Holly Wolf3, William Feser3, Anna Baron3, York Miller4
1Somalogic/United States Of America, 2Nec Laboratories America/Uni-
ted States Of America, 3University Of Colorado Cancer Center/United 
States Of America, 4Denver Veterans Affairs Medical Center, University 
Of Colorado/United States Of America
Background: Proteomic analysis of blood and tissue can reveal es-
sential connections between the biochemical pathways altered in 
malignancy and tools for cancer diagnosis and treatment. The two 
major histologic subtypes of non-small cell lung cancer (NSCLC), 
adenocarcinoma (AD) and squamous cell carcinoma (SQ) differ in 
prognosis and optimal treatment. Targeting molecular pathways 
that drive malignancy has led to a paradigm shift in the develop-
ment of specific treatments for patients based on their tumor mu-
tation profile. We have conducted a comparative proteomic analy-
sis of lung tumor histologic and driver mutation subsets to reveal 
biomarkers that link critical pathways for cell growth and survival to 
specific tumor phenotypes and genotypes.
Methods: We analyzed 68 NSCLC tumor and matched non-tumor 
tissue lysates (2 ug total protein/sample) with the SOMAscan pro-
teomic platform, which measures 1129 proteins with a median limit 
of detection of 40 fM and 5% CV. The study consisted of 49 AD 
and 19 SQ tumors, 88% of which were Stage I or II. Somatic driver 
mutations were identified with multiplex PCR (SnapShot geno-
typing). Pairwise proteomic comparisons of tumor/non-tumor or 
AD/SQ tissue samples were performed using the Mann-Whitney 
test. The non-parametric Kruskal-Wallis test was used to discover 
differences among multiple pairwise driver mutation comparisons. 
Dependency network analysis was used to explore correlations 
enriched in tumor tissue vs non-tumor tissue. The statistical signi-
ficance of the results was adjusted for multiple comparisons using 
false discovery rate (FDR) correction.
Results: Differences between tumor and non-tumor tissue were 
dominated by inflammatory, apoptotic and cell proliferation prote-
ins. A total of 79 proteins were significantly different between AD 
and SQ at a 15% FDR. When compared to non-tumor levels, these 
proteins divided into 3 phenotypes: AD only (9 proteins), SQ only 
(19 proteins) or Both (51 proteins). Both refers to proteins that are 
tumor biomarkers in both AD and SQ and the protein levels are 
different between AD and SQ. The most common pattern was a 
progression in protein levels from non-tumor to AD to SQ, whether 
the pattern was higher or lower in tumor tissue. These proteins 
are members of cell proliferation and inflammatory pathways. This 
observation is consistent with the SQ only proteins, which are en-
riched for angiogenesis, cell proliferation and cell adhesion prote-
ins. Driver mutation analysis revealed 5 inflammatory proteins that 
were higher in KRAS vs EGFR mutations and a TNF-alpha antago-
nist that was suppressed in EGFR mutants.
Conclusion: Unexpected findings that the AD proteome is closer 
to non-tumor lung tissue than SQ were revealed through broad 
proteomic profiling. Alteration in cell proliferation and inflamma-
tion pathways discovered in this study may lead to new insights in 
tumor biology and targeted therapeutics. This work was supported 
by a grant from the LUNGevity Foundation, NCI grant CA 58187 
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ferentiation in pulmonary carcinoid tumors is controlled by multip-
le genetic determinants.
Keywords: lung carcinoid, p53, Rb, PDGF
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P2.02-018 THE NOTCH/HES1/ASCL1 SIGNALING PA-
THWAY IN LUNG CARCINOID
Rosario Garcia Campelo1, Guillermo Alonso1, Guadalupe Aparicio 
Gallego2, Teresa Hermida2, Mar Haz Conde2, Moises Blanco Calvo2, 
Angel Concha2, Luis Miguel Anton Aparicio1
1Medical Oncology, Chu A Coruña/Spain, 2Chu A Coruña/Spain
Background: Neuroendocrine (NE) lung tumors display a broad 
spectrum of morphological types, ranging from typical carcinoids 
(TC), with low malignant potential, to small cell lung carcinoma 
(SCLC) with the most rapid and disseminated growth. Two new 
additional NE forms are recognized: the intermediate grade, aty-
pical carcinoid (AC), and high-grade large cell neuroendocrine 
carcinoma (LCNEC). It is believed that lung carcinoid tumors are 
derived from endocrine cells (PNECs/NEBs), regulated by ASCL-1, 
of the airway tract. Active Notch-1 signaling in the developing en-
doderm inhibits endocrine differentiation via supression of ASCL-1. 
The aim of this study was to evaluate expression of developmental 
transcription factors and Notch signaling components in human 
lung carcinoids samples.
Methods: Sixty formalin-fixed paraffin embedded human lung 
carcinoid tumor (typical and atypical) samples were analyzed by 
IHQ and qRT-PCR. Tissue arrays were used in order to perform the 
IHQ. We assessed the profile of markers involved in lung carcinoid 
tumors using qRT-PCR with SYBR Green.
Results: In the present work we found that Notch pathway com-
ponents have variable levels when we compare typical vs atypical 
histology in a set of human lung carcinoids. The heatmap (Figure) 
shows the presence of a group of genes with low expression by 
IHQ in almost all samples analyzed (NOTCH1, NOTCH4, DLL3 and 
DLL4). The remaining genes (NOTCH2, NOTCH3, JAG1, DLL1 and 
HES5) show clear differences in expression between samples.
Conclusion: In summary, PRMT5 is highly expressed in lung cancer 
cells compared to normal lung. A novel PRMT5 inhibitor and shR-
NAs can inhibit cell proliferation. Although PRMT5 inhibitor could 
induce cell death by cell cycle regulation and apoptosis, different 
pathways may be involved in PRMT5 knock-down cells and speaks 
to the complexity regulating mechanisms in different histological 
lung cancer patients. The differences in H4R3 methylation suggest 
that epigenetic repression may be dominant in some cancers, but 
that non-epigenetic mechanisms may be relevant in others. Further 
exploring of PRMT5 targets are ongoing.
Keywords: PRMT5, epigenetics
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P2.02-017 ANALYSIS OF P53, RB, C-MET, C-KIT AND 
PDGFA/B IN LUNG CARCINOIDS
Guillermo Alonso1, Rosario Garcia Campelo1, Guadalupe Aparicio 
Gallego2, Teresa Hermida2, Mar Haz Conde2, Moises Blanco Cal-
vo2, Angelica Figueroa2, Manuel Valladares1, Angel Concha2, Luis 
Miguel Anton Aparicio1
1Medical Oncology, Chu A Coruña/Spain, 2Chu A Coruña/Spain
Background: Although p53 alterations have been studied in pul-
monary neuroendocrine tumors, these studies have only tested im-
munochemistry. Typical (TC) and atypical (AC) carcinoids manifest 
a heterogeneous Rb-protein pattern. Other markers (c-kit, c-met, 
and PDGFa/b) have unknown functions on pulmonary carcinoids.
Methods: We have evaluated 60 consecutive lung carcinoid sam-
ples, referred between 1989 to 2011 for surgical treatment with 
respect to assessed the profile markers involved in lung carcinoids 
(AC and TC) using qRT-PCR.
Results: All genes studied were positives in both TC and AC sam-
ples. When we compared TC and AC results, we found differences 
as follow: p53 was positive in 72.72% AC and 50% TC; Rb positivity 
was found in 63.64% AC and 70.45% TC; 81.82% AC and 59.1% 
TC were positive for c-met; c-kit was positive in 27.27% AC and 
22.73% TC; 36.36% AC and 25% were positive for PDGFa; PDGFb 
was positive in 72.73% AC and 50% TC.
Conclusion: From these results, it can be hypothetized that a pro-
gressive higher degree of malignancy from TC to AC is paralleled 
by alterations in profile markers of proliferation, apoptosis, and 
angiogenesis. The regarding markers (c-met, c-kit, and PDGFa/b) 
have unknown functions on lung carcinoids. Thus, our results are 
added to the evidence that the expression of neuroendocrine dif-
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P2.02-020 MICRORNA DEREGULATION ASSOCIATED 
WITH NODE POSITIVE LUNG ADENOCARCINOMA
Katey S. Enfield, Varune R. Ramnarine, David A. Rowbotham, 
Stephen Lam, Wan L. Lam
Integrative Oncology, BC Cancer Research Centre/Canada
Background: Lung cancer is the leading cause of cancer-related 
deaths worldwide, with poor survival largely attributed to late 
stage of disease at diagnosis and frequent metastasis. Typically, 
tumor cells colonize the regional lymph nodes before spreading 
to distant sites, significantly dampening prognosis. The presence 
and number of affected nodes can be detected by routine imaging 
procedures, but occasionally, additional affected nodes are not 
detected until time of surgery, which impacts staging. The iden-
tification of biomarkers that stratify node positive (NP) and node 
negative (NN) patients could improve detection of aggressive 
disease, while a deeper understanding of the underlying biology 
of NP lung cancer could lead to the design of novel therapeutic 
interventions. MicroRNAs (miRNAs) are major regulators of gene 
expression that control a wide range of cellular processes, and 
have been shown to be excellent biomarker candidates due to 
their stability in biofluids. The role of miRNA deregulation in NP 
lung cancer is poorly understood; therefore, we sought to compare 
miRNA expression levels of lung adenocarcinoma (AC) cases with 
and without nodal involvement in order to identify miRNAs associ-
ated with tumor aggressiveness. We hypothesize that a subset of 
miRNAs are specifically deregulated in NP AC, representing poten-
tial biomarkers, and that identification of miRNA-mRNA interaction 
networks will shed light on the biological mechanisms of tumor 
spread that may be therapeutically exploited.
Methods: A panel of 45 NN and 28 NP primary AC tumors were 
collected along with paired adjacent non-malignant tissues. All 
samples underwent expression profiling of miRNA (Illumina GAIIx 
small RNA sequencing) and mRNA (Illumina microarray). NN and 
NP groups were analyzed separately as follows: matched tumor 
and normal miRNA normalized read count comparisons were per-
formed (Wilcoxon Signed-Rank test, Bejamini-Hochberg corrected 
p<0.05), and miRNAs that were significantly deregulated in tumors 
were further investigated. miRNA fold changes (FC) were calcula-
ted on a case by case basis, and FC values were then compared 
between groups (Mann Whitney U Test p<0.05). miRNAs that (i) 
displayed a minimum 2-fold frequency of disruption >50% of NP 
cases, (ii) had a median FC>2 in the NP group, (iii) had a Signed-
Rank corrected p<0.05, and (iv) had a MWU p<0.05 were conside-
red to be NP-specific. Target prediction analysis of these miRNAs 
was then performed, and mRNA expression data was utilized to 
ensure predicted target expression was anti-correlated with miR-
NA expression. Candidate targets were input into Ingenuity Pa-
thway Analysis to determine pathways implicated in NP AC.
Results: Fourteen miRNAs were NP-specific according to our 
criteria. These miRNAs included those previously associated with 
biology and metastasis of epithelial cancers, as well as miRNAs 
novel to lung AC. Target analysis implicated several pathways and 
functions previously associated with a metastatic phenotype such 
as the TGFβ pathway.
Conclusion: These results indicate that miRNA expression differs 
between NP and NN lung AC, further demonstrating the involve-
ment of miRNAs in the regulation of the metastatic process. The 
role of these miRNAs as prognostic markers and serum biomar-
Conclusion: The molecular studies on human lung carcinoid samp-
les indicate that the Notch signaling pathway, and the basic Helix-
Loop-Helix (bHLH) transcription factors, including ASCL1, might 
regulate the neuroendocrine phenotype in human lung carcinoids. 
The Notch signaling pathway components and their transcription 
factors may be significant regulators of neuroendocrine indifferen-
tiation in human lung carcinoid tumors.
Keywords: Notch, ascl1, hes1, lung carcinoid
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P2.02-019 ANALYSIS OF P53, RB, C-MET, C-KIT AND 
PDGFΑ/Β IN LUNG CARCINOIDS.
Rosario Garcia Campelo1, Guillermo Alonso1, Teresa Hermida2, Gu-
adalupe Aparicio Gallego2, Mar Haz Conde2, Moises Blanco Calvo2, 
Luis Miguel Anton Aparicio1
1Medical Oncology, Chu A Coruña/Spain, 2Chu A Coruña/Spain
Background: Although p53 alterations have been studied in pul-
monary neuroendocrine tumors, these studies have only tested im-
munochemistry. Typical (TC) and atypical (AC) carcinoids manifest 
a heterogeneous Rb-protein pattern. Other markers (c-kit, c-met, 
and PDGFa/b) have unknown functions on pulmonary carcinoids.
Methods: We have evaluated 60 consecutive lung carcinoid sam-
ples, referred between 1989 to 2011 for surgical treatment with 
respect to assessed the profile markers involved in lung carcinoids 
(AC and TC) using qRT-PCR.
Results: All genes studied were positives in both TC and AC sam-
ples. When we compared TC and AC results, we found differences 
as follow: p53 was positive in 72.72% AC and 50% TC; Rb positivity 
was found in 63.64% AC and 70.45% TC; 81.82% AC and 59.1% 
TC were positive for c-met; c-kit was positive in 27.27% AC and 
22.73% TC; 36.36% AC and 25% were positive for PDGFa; PDGFb 
was positive in 72.73% AC and 50% TC.
Conclusion: From these results, it can be hypothetized that a pro-
gressive higher degree of malignancy from TC to AC is paralleled 
by alterations in profile markers of proliferation, apoptosis, and 
angiogenesis. The regarding markers (c-met, c-kit, and PDGFa/b) 
have unknown functions on lung carcinoids. Thus, our results are 
added to the evidence that the expression of neuroendocrine dif-
ferentiation in pulmonary carcinoid tumors is controlled by multip-
le genetic determinants.
Keywords: p53, PDGF, lung carcinoid, c-Met
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Conclusion: The CXCR4 and ER pathways are active in NSCLC cell 
lines. There appears to be differences in the responsiveness of 
male and female NSCLC cell lines to CXCR4 and ER pathway acti-
vation. ERs and PRs are present in stage IV NSCLC tissue samples, 
and are associated with both CXCR4 expression and overall survi-
val in our patient cohort. The full implication of these observations 
is still being investigated and further analyses will be presented.
Keywords: NSCLC, IHC, CXCR4, ER/PR
kers, as well as the mechanism of action of these miRNAs in AC 
biology must be further explored.
Keyword: adenocarcinoma, microRNA, metastasis
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P2.02-021 IMPLICATIONS OF CXCR4 AND ESTROGEN/
PROGESTERONE RECEPTOR (ER/PR) PATHWAY ACTIVI-
TY IN NON SMALL CELL LUNG CANCER (NSCLC)
Simone Withecomb, Shannon Otsuka, Alexander Klimowicz, 
Brant Pohorelic, Karen Kopciuk, Yukun Zhang, Lars Petersen, Mie 
Konno, Don Morris, Gwyn Bebb
University Of Calgary/Tom Baker Cancer Centre/Canada
Background: CXCR4 is a chemokine receptor that activates signa-
ling pathways responsible for trafficking of cells to sites of inflam-
mation, retention of stem cells in the bone marrow and plays a role 
in migration and metastatic processes in tumour cells. Previous 
work by the Bebb lab demonstrated that female stage IV NSCLC 
patients with high CXCR4 expression have significantly worse 
survival compared to their low CXCR4 expressing counterparts. 
Recently, a positive regulatory loop was discovered liNKIng CXCR4 
and ER signaling pathways leading to increased gene expression 
of SDF-1 and other ER dependent genes. We explored the relati-
onship between CXCR4 and ER/PR signaling in NSCLC cell lines, 
and assessed the expression of ER/PR in stage IV tissue samples to 
determine if ER/PR could be contributing to the observed gender 
dependent difference in clinical outcome seen in CXCR4 high ex-
pressers.
Methods: Two male and two female NSCLC cell lines were charac-
terized for ER and CXCR4 by western blot. Activity of the CXCR4 
and ER pathways in each cell line after stimulation with SDF-1 
and estradiol (E2), respectively, were assessed by western blot 
of downstream signaling targets ERK, AKT, phospho-ER and PR. 
Cross activity of the CXCR4 and ER pathways was examined by 
stimulating cells with E2 and quantifying SDF-1 and PR mRNA by 
rtPCR. Tumor specimens from stage IV NSCLC patients (Glans-
Look Lung Cancer Database) previously assessed for CXCR4 were 
analyzed for ERα and PR expression by quantitative immunohis-
tochemistry (IHC) using the HistoRx AQUA® platform. Correla-
tion between CXCR4 and ER/PR expression was assessed using 
Pearson’s rank correlation, and associations between marker ex-
pression and clinical factors/overall survival were assessed using a 
Cox proportional hazards model.
Results: All cell lines expressed varying levels of CXCR4, ERα and 
ERβ, and were responsive to both SDF-1 and E2 stimulation. Preli-
minary data suggests that activation of AKT and ERK after stimu-
lation with SDF-1 occurs more rapidly in the male cell lines than in 
the female cell lines, and that there were differences in SDF-1 gene 
expression after E2 stimulation between the male and female lines. 
Other experiments are ongoing and full data will be presented. ER 
and PR AQUA scores were obtained for 131 patients (63 females 
and 68 males). There were weak positive correlations between 
both ER/CXCR4 (r = 0.153) and PR/CXCR4 (r = 0.278), however, only 
the correlation between CXCR4 and PR was significant (p = 0.002). 
Similarly, only PR expression was significantly associated with 
overall survival in the model (p = 0.03)(HR = 1.46). More detailed 
sub-group analyses further exploring the association with gender 
is ongoing, and will be presented.
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model show the genes important in tumor cell interaction with 
matrix without difference in genes identify cells with mesenchymal 
features. Thus, there may be fewer cells with invasive properties, 
which may explain the good survival in lung cancer patients. The 
4D ex vivo lung cancer model may be a better mimic of the natural 
progression of tumor growth in lung cancer patients compared to 
3D model.
Keywords: Matrigel, 4D Model, A549, survival
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P2.03-002 CIRCULATING TUMOR CELLS FROM 4D MO-
DEL MIMIC METASTATIC PATTERN IN VIVO AND GENE 
EXPRESSION PROFILE PREDICTS POOR PROGNOSIS IN 
LUNG CANCER PATIENTS
Dhruva K. Mishra1, Chad Creighton2, Michael J. Thrall3, Yiqun 
Zhang2, Don L. Gibbons4, Jonathan M. Kurie4, Min P. Kim1
1Surgery, The Methodist Hospital Research Institute/United States Of 
America, 2Biostatistics, Baylor College Of Medicine/United States Of 
America, 3Pathology And Genomic Medicine, The Methodist Hospital/
United States Of America, 4Thoracic/head And Neck Medical Oncology, 
University Of Texas MD Anderson Cancer Center/United States Of 
America
Background: Circulating tumor cells are tumor cells found in the 
vasculature or lymphatics of cancer patients that are thought to be 
responsible for metastasis. Recently, we developed an ex vivo 4D 
lung cancer model that forms perfusable tumor nodules. We have 
found that there are live tumor cells in the circulation in the model 
(CTCs). In this study, we aim to determine (i) the characteristics of 
these cells in vivo and (ii) whether the gene expression profile sig-
nature of these cells predicts survival in patients with lung cancer.
Methods: We used 393P and 344SQ mouse lung cancer cells for 
the in vivo experiment. The 393P cells that were grown on petri 
dish (2D) did not form metastatic lesions when injected into the 
flank of 129sv mice while 344SQ 2D cells did form metastatic lesi-
ons. Both cells were grown in the 4D model. We measured the size 
of the tumors and the number of CTCs for 14 days. We analyzed 
the mesenchymal characterisitics of 2D vs CTCs. We injected the 
CTCs in the tail vein of the 129sv mice and determined if they for-
med metastasis. We used A549 cells for the gene expression expe-
riment. We placed the A549 2D cells in the 4D model and measu-
red the size of the tumors and the number of CTCs. We compared 
the gene expression profile (Human OneArray v5 chip) of A549 2D 
against the A549 CTCs. We analyzed the differential gene signa-
ture in human lung cancer database for survival.
Results: All of the cell lines formed perfusable lung nodules in 
the 4D model by day 2 and formed circulating tumor cells starting 
day 5. The 344SQ cells grew faster (p = 0.01) and formed more 
circulating tumor cells (p = 0.8) compared to the 393P cells initially 
but by day 14 there was no significant difference in tumor size (p 
= 0.8) and number of circulating tumor cells (p = 0.7). The 393P 
CTCs were less mesenchymal (lower CDH2 (p < 0.0001), ZEB1 (p 
= 0.001) and VIM (p < 0.0001)) compared to 393P 2D while 344SQ 
CTCs were more mesenchymal (higher CDH2 (p < 0.0001), ZEB1 
(p < 0.0001) and VIM (p < 0.0001)) compared to 344SQ 2D. When 
393P CTCs were injected into the tail vein of 129sv mice, they did 
not form metastatic lesions while 344SQ CTCs formed metastatic 
lesions in the lung. Gene expression analysis of A549 2D compared 
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P2.03-001 GENE EXPRESSION PROFILE OF A549 CELLS 
FROM TISSUE OF 4D MODEL PREDICTS POOR PROG-
NOSIS IN LUNG CANCER PATIENTS
Dhruva K. Mishra1, Chad Creighton2, Yiqun Zhang2, Don L. Gib-
bons3, Jonathan M. Kurie3, Min P. Kim1
1Surgery, The Methodist Hospital Research Institute/United States Of 
America, 2Biostatistics, Baylor College Of Medicine/United States Of 
America, 3Thoracic/head And Neck Medical Oncology, University Of 
Texas MD Anderson Cancer Center/United States Of America
Background: Tumor microenvironment plays an important role in 
regulating cell growth and metastasis. Recently, we developed an 
ex vivo lung cancer model (4D) that forms perfusable tumor nodu-
les on tissue that mimics human lung cancer histopathology and 
protease secretion patterns better than tumor cells grown on a pe-
tri dish (2D). In this study, we aim to determine if the gene expres-
sion profile of cells grown in the model (4D) is a better predictor of 
survival in lung cancer patients compared to the gene expression 
profile of cells grown on a matrigel (3D).
Methods: We compared the gene expression profile (Human One-
Array v5 chip) of A549 cells, human lung cancer cell line, grown on 
petri dish (2D) against the same cells grown in the tissue of our ex 
vivo model (4D) and performed gene ontology (GO) analysis. We 
obtained gene expression data of A549 cells grown on petri dish 
(2D) and matrigel (3D) from GEO Accession No. GSE17347 and 
compared the gene expression profiles. We analyzed the differen-
tial gene signature for 4D and 3D in human lung cancer database 
for survival.
Results: Expression array analysis showed that there were 2954 
gene probes differentially expressed between 2D and 4D. The 
analysis showed up-regulation of genes associated with mesen-
chymal cells (CDH2 and VIM). GO analysis showed up-regulation 
of several genes associated with extracellular matrix (MMP1, 
MMP9, MMP10, COL4A1, COL5A1), polarity (DLX2, GLI2, HOXD10, 
HOXD11), and cell fate and development (PPM1A, SALL1, SOX4, 
ZEB2, JAG1, SOX2, TP63). Moreover, expression array analysis 
of the 2D and 3D showed 1006 genes that were differentially 
expressed, with only 36 genes (4%) having the same expression 
pattern as differential expression between 2D and 4D. There was 
no difference in expression of genes associated with mesenchymal 
features (CDH2 and VIM) between 2D and 3D. Finally, the differen-
tial gene expression signature between 2D and 4D correlated with 
poor survival in patients with lung cancer (n = 1492, Log rank p = 
1.5 x 10-7) while the differential gene expression signature between 
2D and 3D correlated with good survival in patients with lung can-
cer (n = 1492, Log rank p = 1.7 x 10-9).
Conclusion: The genes necessary to form a perfusable nodule in 
the 4D model are the genes that are important in cell-matrix inter-
action, polarity and cell fate, which are lacking in a 2D model. The 
gene expression signature in the 4D model correlates with poor 
survival in lung cancer patients, which may be due to presence of 
more cells with mesenchymal features in the 4D model compared 
to 2D culture. On the other hand, the tumor cells grown on 3D 
S762 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
into immunocompromized mice, essentially all tumors derived 
from Group 1 cell lines were enriched with stromal fibroblast, while 
most tumors derived from Group 2 cell lines exhibited medullary 
histology with scanty stromal fibroblast.
Conclusion: Collectively, the data suggest that our two-way clas-
sification based on gene expression pattern has relevance for 
genetic, morphologic, and biologic properties of lung adenocarci-
nomas.
Keywords: epithelial mesenchymal transition, cancer stromal inter-
action, lung adenocarcinoma, stromal fibroblast
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P2.03-004 CLINICAL APPLICATION OF TARGETED DEEP 
SEQUENCING AS A MOLECULAR SCREENING FOR 
EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE 
KINASE INHIBITOR (EGFR-TKI) THERAPY IN NEVER-
SMOKING LUNG ADENOCARCINOMA
Ji-Youn Han1, Yeon S. Lee2, Geon Kook Lee1, Sung J. Yoon1, Jin Soo 
Lee1
1Lung Cancer Branch Research Institute And Hospital, National Cancer 
Center/Korea, 2Functional Genomic Branch Research Institute And Hos-
pital, National Cancer Center/Korea
Background: The molecular screening is a key step to epidermal 
growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) the-
rapy. We investigated the clinical relevance of targeted next ge-
neration sequencing (NGS) as a molecular screening for EGFR-TKI 
therapy in never-smoking lung adenocarcinoma (NSLA).
Methods: We obtained DNA from 48 NSLA received gefitinib 
or erlotinib for their recurrent disease after surgery. The Sanger 
sequencing and peptide nucleic acid clamp polymerase chain re-
action (PCR) were used to analyze EGFR, KRAS, BRAF and PIK3CA 
mutations. We analyzed ALK, RET and ROS1 rearrangements by 
fluorescent in situ hybridization or reverse transcriptase-PCR and 
quantitative real-time PCR. Finally, Ion Torrent NGS was perfor-
med in 31 cases harboring only EGFR exon 19 deletions (19DEL) or 
L858R mutation or none of above mutations.
Results: After excluding mutations other than EGFR 19DEL or 
L858R, samples were divided into 4 groups; 1) responders to EG-
FR-TKIs with only 19DEL or L858R (n=15); 2) primary resistance to 
EGFR-TKI with only 19DEL or L858R (n=4); 3) primary resistance to 
EGFR-TKI without any mutations (n=8); 4) responders to EGFR-TKI 
without any mutations (n=4). All conventionally detected mutations 
were confirmed with NGS. Additionally uncovered predictive mu-
tations include; one PIK3CA E542K and one BRAF in group 2; two 
KRAS (G12V and G12D), one PIK3CA E542K and one concomitant 
PIK3CA and EGFR L858R in group 3; one EGFR 19DEL in group 4. 
Newly detected mutations were validated by Sanger sequencing.
Conclusion: Targeted NGS provided more accurate and clinically 
useful molecular classification of NSLA. It may improve persona-
lized therapy for individual patients.
Keywords: NGS, NSCLC
to A549 CTCs showed that there were 2504 gene probes that were 
differentially expressed. This signature correlated with poor survi-
val in patients with lung cancer (n = 1492, Log rank p = 2.6 x 10-5).
Conclusion: The circulating tumor cells that were isolated from the 
ex vivo 4D lung cancer model mimic the pattern of metastasis in 
vivo. Moreover, the circulating tumor cell signature correlates with 
poor survival in patients with lung cancer. The circulating tumor 
cells that are isolated in the ex vivo 4D lung cancer model may be 
the cells responsible for metastasis.
Keywords: Lung cancer, Circulating TUmor Cells, survival
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P2.03-003 TWO GROUPS OF LUNG ADENOCARCINOMA 
CELL LINES THAT SHOW DISTINCT MORPHOLOGY AND 
CANCER-STROMAL INTERACTION IN 3 DIMENSIONAL 
CULTURE AND MOUSE XENOGRAFT
Toshiro Niki1, Daisuke Matsubara2
1Jichi Medical University/Japan, 2Division Of Molecular Pathology, Insti-
tute Of Medical Science , University Of Tokyo/Japan
Background: We previously reported that lung adenocarcinoma 
cell lines could be classified into two groups according to gene ex-
pression patterns (Matsubara et al. Am J Pathol 2010). Group 1 cell 
lines expressed bronchial epithelial markers (CK7, MUC1, TTF-1) at 
high levels, while Group 2 cell lines showed epithelial-mesenchy-
mal transition (EMT) phenotype (low-E-cadherin and high vimentin) 
and reduced expression of the bronchial epithelial markers. All cell 
lines mutated for EGFR, MET, HER2, and a cell line, LC-2/ad, re-
cently found to harbor CCDC6-RET fusion (Matsubata, et al. J Tho-
rac Oncol 2012), belonged to Group 1, and expressed EGFR, MET, 
HER3 at high levels, while KRAS-mutated cells lines were equally 
distributed in the two groups. Also, these two groups showed dis-
tinct sensitivity for gefitinib and cisplatin, respectively (Matsubara 
et al. J Thorac Oncol 2010, 2012). Here we tested the relevance of 
this classification for morphology and cancer-stromal interaction in 
3 dimensional culture and mouse xenograft.
Methods: The 40 lung carcinoma cell lines consisted of 35 ade-
nocarcinomas, 4 large cell carcinomas, and 1 adenosquamous 
carcinoma. These cells were plated onto Matrigel with or without 
lung-derived fibroblasts. Cell lines were also allowed to form sphe-
roid in suspension culture, and then plated into collagen gel with 
or without lung-derived fibroblasts. To form xenograft tumors, 
cell lines were injected subcutaneously into NOD/SCID mice and 
allowed to form tumors, and resulting tumors were subjected to 
histologic analysis at 4-8 weeks.
Results: We demonstrated that on Matrigel essentially all Group 1 
cell lines formed round spheroid, while Group 2 cell lines formed 
either round, stellate, or grape-like spheroid. Round spheroid 
forming cells remained non-invasive in monoculture, but upon co-
culture with fibroblast, they acquired the ability to invade into Ma-
trigel or collagen gels. In contrast, Groups 2 cell lines that formed 
stellate or grape-like spheroid showed invasive growth in mono-
culture, and co-culture with fibroblast seemed to enhance the inva-
sive growth in some, but not all Groups 2 cell lines. Thus, Group 1 
cell line required stromal fibroblast for invasion, while most Group 
2 cell lines are endowed the ability to invade the stroma on their 
own. Consistent with this notion, when subcutaneously injected 
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P2.03-006 DETERMINING READ ORIGIN OF NEXT-GE-
NERATION SEQUENCING DATASETS FROM LUNG CAN-
CER XENOGRAFTS
Kieren Marini1, Richard Tothill2, Kara Britt3, Jeanette Falzon3, Ja-
son Li2, Samara Bennett3, Erwin Tantoso4, Tracey J. Brown3, Lucia-
no Martelotto5, Neil Watkins6, Fernando Rossello1
1Centre For Cancer Research, Monash Instituate Of Medical Research/
Australia, 2Centre For Cancer Genomics And Predictive Medicine, Peter 
MacCallum Cancer Centre/Australia, 3Monash University/Austra-
lia, 4Partek Sg Pte Ltd/Singapore, 5Human Oncology & Pathogenesis 
Program, Memorial Sloan-Kettering Cancer Center/United States Of 
America, 6Centre For Cancer Research, Monash Institute Of Medical 
Research/Australia
Background: Next-generation sequencing (NGS) studies in cancer 
are often limited by the amount, quality and purity of tissue sam-
ples obtained from patients. In this situation, primary xenografts 
have proven useful in providing preclinical models. Although 
xenograft lines are maintained in immunodeficient mice, we and 
others have shown that they retain important characteristics that 
are irreversibly lost in cell culture. Since the stromal component of 
xenograft tumors is derived from the host, the presence of mouse 
DNA and RNA has the potential to limit the use of these models 
for next-generation sequencing (NGS) analysis.
Methods: We prospectively addressed this question in an estab-
lished primary xenograft model of small cell lung cancer (SCLC), a 
malignancy that is almost always diagnosed using small biopsies or 
needle aspiration cytology. We first developed an in-silico strategy 
that separates human and mouse reads with at least 97% accuracy. 
We then compared NGS data from a series of primary xenograft 
models with clonally derived, stroma-free cell lines, and with pub-
lished datasets derived from the same models.
Results: Starting with the NCI-H209 cell line as a reference sample, 
we show that low coverage whole genome analysis demonstrated 
remarkable concordance between published genome data and 
internal controls, despite the presence of mouse genomic DNA. 
NGS analysis of exon-capture DNA revealed that this enrichment 
procedure was highly species-specific, with less than 4% of reads 
aligning to the mouse genome. Human-specific expression profi-
ling with RNA-Seq replicated array-based gene signatures, whe-
reas mouse- transcript profiles correlated with published datasets 
from human cancer stroma.
Conclusion: Primary xenograft models may therefore be a useful 
NGS platform for cancers where tissue samples are limiting.
Keywords: xenografts, Next-generation sequencing (NGS), Small 
Cell Lung Cancer (SCLC)
POSTER SESSION 2 - TECHNOLOGY AND NOVEL DEVELOPMENT  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.03-005 ROTARY DISSECTOR: FRICTIONAL FORCE 
ACHIEVED BY USING THE POROUS POLYPROPYLENE 
ROTARY DISSECTOR IN CLINICAL SETTINGS
Junichi Shimada, Daishiro Kato, Masanori Shimomura, Hiroaki 
Tsunezuka, Satoru Okada, Shunta Ishihara, Hirofumi Suzuki
General Thoracic Surgery, Kyoto Prefectural University Of Medicine/
Japan
Background: 
During thoracoscopic surgery, rounded cotton-tip dissectors (Blunt 
Cherry Dissectors®) have been used to maintain the position of the 
lungs. However, moistening of cotton tips due to blood or pleural 
effusion often makes it difficult for surgeons to maintain the lung 
position when using this equipment. Therefore, we developed a 
polygonal-shaped tip dissector using porous polypropylene, called 
the Rotary Dissector, in order to achieve a greater amount of fric-
tional force against the lung. In the present study, we assessed the 
difference in the rotational frictional force between the Blunt Cher-
ry Dissector and Rotary Dissector, as well as the usefulness of the 
Rotary Dissector in thoracic surgery.
Methods: The rotational frictional force of the Rotary Dissector 
and the Blunt Cherry Dissector was estimated using a gel. We 
measured the weight and volume of gel that was scooped and pu-
shed out in one direction by each dissector. Furthermore, we used 
the newly developed Rotary Dissectors for video-assisted thoracic 
surgery (VATS), and assessed the usefulness of this equipment.
Results: The weight and volume of gel pushed out was 1.14 g 
and 948.4 mm3 with the Rotary Dissector and 0.34 g and 270.6 
mm3 with the Cherry Dissector, respectively. Moreover, the Rotary 
Dissector had 3 times the frictional force compared to that of the 
Cherry Dissector. During VATS, we used the Rotary Dissector and 
successfully detached the pleural adhesion without causing any 
lung injuries and could maintain the lung position to obtain a clear 
surgical field.
Conclusion: Thus, we noted that Rotary Dissectors can yield a 
greater amount of frictional force as compared to conventional 
dissectors, and can be safely used in VATS.
Keywords: Rotary Dissector, VATS, frictional force, Blunt Cherry 
Dissector
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P2.04-001 MYELOID DERIVED SUPPRESSOR CELLS 
(MDSC) ARE INCREASED IN PATIENTS WITH ADVANCED 
NON-SQUAMOUS LUNG CANCER (ANSQ) COMPARED 
TO HEALTHY CONTROLS AND EARLY STAGE NON-
SQUAMOUS LUNG CANCER (ENSQ) AND ARE RELATED 
TO THE WHO PERFORMANCE STATUS. SUBANALYSIS 
OF THE NVALT12 STUDY
Joachim G. Aerts1, Marlies Heuvers1, Egbert F Smit2, Harry J.M. 
Groen3, Joost P. Hegmans1, Anne-Marie Dingemans4
1Pulmonary Diseases, Erasmus MC/Netherlands, 2Pulmonary Diseases, 
VU University Medical Center/Netherlands, 3Pulmonology, UMC Gro-
ningen/Netherlands, 4Maastro/Netherlands
Background: Recent evidence shows a role for immunotherapy via 
checkpoint antibodies in a subgroup of patients with non-small cell 
lung cancer (NSCLC). We have recently published the complex in-
terplay between tumors and the immune system1. The modulating 
effect of the tumor on the immune system, mainly immunosup-
pressive, is challenging. MDSC are described to play a major role 
in this tumor associated immune suppression by inhibiting cyto-
toxic Tcell function. The aim of the present study is to relate the 
number of MDSC to two well-known prognostic factors in NSCLC: 
stage of the disease and WHO performance status.
Methods: MDSC were determined in peripheral blood mononu-
cleair cell fractions of 195 treatment-naive NSCLC patients (185 
stage IV (aNSQ), 10 stage I-III(eNSQ), and 20 healthy controls (HC)). 
WHO performance status was determined by experienced inves-
tigators prior to the start of treatment. In this abstract the relation 
between clinical data and polynucleair MDSC are presented. Flow-
cytometric analysis was performed within 5 hours after the blood 
was drawn. MDSC were characterized as CD16low,CD11b+,CD14-
,HLA-DR-,CD15+, and CD33+.
Results: A large variation in the number of MDSC was observed 
in patients with NSCLC, also in the same stage of the disease and 
WHO performance status. In a subgroup of patients with eNSQ 
high MDSC levels were found, but also in patients with aNSQ low 
levels of MDSC were found. For the group as a whole, however, an 
increased number of MDSC was found in patients with aNSQ com-
pared to HC and eNSQ (p<.001, in both comparisons). Comparison 
of the limited number of patients with of eNSQ and HC no statisti-
cal difference was found but there is a tendency for an increase in 
the number of MDSC per stage of NSCLC. The number of MDSC 
increased with worse WHO performance status ( p=0.05 between 
0 and 2). Whether the number of MDSC has prognostic or predic-
tive value to response to chemotherapy in all patients is subject 
of current research. Follow up data in all patients with response to 
chemotherapy, progression free survival and overall survival are at 
present collected.
Conclusion: Peripheral blood MDSC levels are increased in pati-
ents with aNSQ compared to eNSQ and HC. MDSC are increased 
in patients with worse WHO performance status. The number of 
MDSC shows large variation between patients with similar stage 
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P2.03-007 CHANGES IN PULMONARY IMMUNE CELL 
RECRUITMENT AND FUNCTION DURING CIGARETTE 
SMOKE-INDUCED LUNG CARCINOGENESIS IN MICE
Robert Keith1, Ajay Wagh2, Micah Friedman3, Daniel T. Merrick4, 
Kevin Choo3, Greg Hickey2, Tyler Hudish3, Micah Johnson1, Mere-
dith Tennis5, Lori Dwyer-Nield6
1Denver VAMC/Univ. Colorado Denver/United States Of America, 
2Denver VAMC/University Of Colorado/United States Of America, 
3Denver VAMC/United States Of America, 4Denver Veterans Affairs 
Medical Center, University Of Colorado/United States Of America, 5Me-
dicine, University Of Colorado Anschutz Medical Campus/United States 
Of America, 6Pharmaceutical Sciences, University Of Colorado Denver/
United States Of America
Background: Smoking-mediated lung cancer will cause at least 
134,000 deaths in the USA this year. Even when detected at the 
earliest stages (stage IA and IB), five year survival is just slightly 
more than 50%. Chronic pulmonary inflammation is an established 
risk factor for lung cancer. Increased lung tumor macrophage infil-
tration is associated with poor prognosis, and murine lung tumor 
models exhibit increased macrophage infiltration. We hypothesize 
that chronic cigarette smoke exposure causes changes in inflamm-
atory cell numbers and phenotypes creating a permissive environ-
ment for tumor formation. Chemopreventive agents such as the 
prostacyclin analog iloprost, may mitigate these changes.
Methods: FVB mice were given control AIN-76A chow or AIN-76A 
with 0.015% pioglitazone two weeks prior to smoke exposure. Mice 
were exposed to 70-90 mg/m3 particulate level cigarette smoke for 
6 hours/day, 5 days/week. Lungs were harvested 1 and 22 weeks 
after smoke exposure and after 22 weeks smoke/20 weeks ambient 
air (standard protocol for tumor induction). Bronchoalveolar cells 
were collected for qRT-PCR analysis of macrophage markers. Tu-
mors were harvested and dissected from uninvolved tissue. Unin-
volved lung tissue was digested and immune cell content analyzed 
by flow cytometry.
Results: Cigarette smoke exposure induced changes in macropha-
ge phenotype after 1 week as indicated by CD11b exression (flow 
cytometry) and phenotypic markers (qRT-PCR). Macrophage infil-
tration increased in 22 week smoke/20 week ambient air exposed 
mice. Neutrophil numbers were increased at one week of smoke 
exposure. CD4 and CD8 positive T cell numbers decreased during 
smoke exposure but returned to control levels after smoking ces-
sation. Smoke exposure differentially affected macrophage pro-
gramming at each time point.
Conclusion: Cigarette smoke exposure affects pulmonary inflamm-
atory cell numbers and function as early as 1 week after smoking 
initiation. Some of these changes are transient (increases in neu-
trophil numbers), while others are consistent but return to normal 
after smoking cessation (decreases in T cell populations). Smoke 
exposure resulted in early functional effects on macrophages and 
alveolar macrophage infiltration was still increased 20 weeks after 
smoking cessation, indicating that the effects of cigarette smoking 
on innate immunity are long lasting.
Keyword: Lung cancer, chemoprevention, inflammation, smoking
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PD1 receptor in the lung of smokers vs. ex-smokers: 599 +/- 278 vs. 
695 +/-216, p=0.46. 
No associations between CTLA4, PD1 and PD-L1 in the tumour 
or the lung and gender, age, COPD and CRP blood levels were 
found.
Conclusion: RNA sequencing is a useful method to dissect rele-
vant molecules in the tumour and the lungs. Our results show more 
PD-L1 expression in adenocarcinoma than in squamous cell cancer, 
more PD-L1 expression in the non-malignant lung of ex-smokers 
than in current smokers and reduced PD-L1 in tumours compared 
to adjacent lung tissue.
Keywords: non-small cell lung cancer, immune marker, PD-L1
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P2.04-003 NOVEL MECHANISM OF IMMUNE-TOLERAN-
CE DUE TO ABERRANT EXPRESSION OF NATURAL KIL-
LER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS (KIRS) 
AND ENHANCED PLATELET INTERACTIONS
Daniel C. Chan1, Zhiyong Zhang1, Di Zheng1, Tiffany T. Chan1, 
Mary Berg1, Kathryn Horwitz1, Natalie Ahn2, Lewis Lanier3, Paul 
Bunn1
1Medical Oncology, University Of Colorado Denver/United States Of 
America, 2Biochemistry, University Of Colorado Boulder/United States 
Of America, 3Immunology, University Of California/United States Of 
America
Background: Cancer metastasis is the main cause of cancer-
related deaths. Metastatic cancer cells spread through blood ves-
sels where they constantly interact with platelets and leukocytes, 
forming tumor microemboli and thereby protected from otherwise 
rapid elimination from host immune defense cells such as NK cells. 
Platelets are known to be prometastatic and pro-angiogenic. They 
release platelet-derived growth factors, chemokines, various ad-
hesion molecules and coagulation factors that effectively promote 
cancer spreading and metastasis. We previously demonstrated 
that many metastatic cancer cells acquire immune-resistance by 
aberrant expression of KIRs on their surface. We showed that 
cancer cells with aberrant expression or with forced ectopic ex-
pression of KIRs are more resistant to NK killing than those with 
null or low KIR expression. Pre-blocking with anti-KIR antibodies 
effectively reverses their sensitivity to NK killing. Here we report 
that KIR-expressing cancer cells interact strongly with platelets 
leading to increase NK tolerance compared to cancer cells with 
null or low KIR expression. These data support a novel mechanism 
of immune-tolerance due to aberrant KIR expression on metastatic 
cancer cells.
Methods: DNA microarrays were performed on metastatic lung 
cancer cells re-derived from orthotopic human metastatic lung 
tumors in athymic nude rats. Aberrant expression of KIR genes 
was detected and verified with immunohistochemistry and flow 
cytometry. For ectopic expression, lung adenocarcinoma paren-
tal cells (H2122-GFP) were transfected with KIR2DL1 (LL454) and/
or KIR3DL1 (LL456) plasmids. Stable transformants were enriched 
by cell sorting. Binding of these cancer cells with differential KIR 
expression with human platelets, pre-labeled with anti-CD41-
APC antibodies, were analyzed by flow cytometry. NK killing of 
GFP-tagged cancer cells with differential KIR expressions in the 
presence and absence of human platelets was accessed with fluo-
of the disease, showing the complex interplay between tumor and 
immune system. 1 Aerts JG, Hegmans JP, Cancer Research 2013
Keywords: NSCLC, myeloid derived suppressor cells (MDSC), 
immunology
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P2.04-002 DIFFERENTIAL EXPRESSION OF PD-L1, PD1 
AND CTLA4 RECEPTOR ACCORDING TO HISTOLOGY 
AND TUMOUR VS. SURROUNDING NON-MALIGNANT 
LUNG TISSUE IN NON-SMALL CELL LUNG CANCER: RNA 
SEQUENCING DATA
Dirk De Ruysscher1, Els Wauters2, Kobe Reynders1, Johan 
Vansteenkiste3, Herbert Decaluwé4, Paul De Leyn4, Kristiaan 
Nackaerts3, Stephanie Peeters1, Christophe Dooms3, Wim 
Janssens5, Diether Lambrechts2
1Radiation Oncology, University Hospitals Leuven/ KU Leuven/Belgium, 
2Laboratory Of Translational Genetics (Vesalius Research Center), KU 
Leuven/Belgium, 3Respiratory Oncology Unit (Dept. Pulmonology) And 
Leuven Lung Cancer Group, University Hospital KU Leuven/Belgium, 
4Thoracic Surgery, Universitary Hospitals KU Leuven/Belgium, 5Pulmo-
nology, University Hospitals Leuven/ KU Leuven/Belgium
Background: Immune modulatory strategies directed against 
CTLA4 (Cytotoxic T-Lymphocyte Antigen 4), PD1(Programmed cell 
Death 1) and PD-L1 (Programmed cell Death 1 Ligand 1) either in 
monotherapy or in combination with chemotherapy and radiothe-
rapy offer great promise as novel treatments against lung cancer. 
Its outcome and therapeutic ratio may depend on the expression 
of the target molecules in tumours and the surrounding non-
malignant lung tissue. We here report the expression of CTLA4, 
PD1 and PD-L1 in primary resected NSCLC and in the surrounding 
non-malignant lung.
Methods: RNA sequencing was performed on tumor tissue and 
normal lung tissue from resection specimens of NSCLC patients. 
The association between CTLA4, PD1 and PD-L1 expression le-
vels and histology, gender, age, smoking status (current smoker 
vs. smoking cessation of at least one year), COPD and CRP blood 
levels was calculated both in the primary tumour and the normal 
lung. Results are expressed as mean +/- SD and range. Means 
were compared using Wilcoxon’s signed rank test for the distri-
butions were non-parametrical. P-values <0.05 were considered 
significant.
Results: Fourteen patients were studied, 11 males and 3 females, 
with a mean age of 64.6 +/- 10.0 years (41-79). All patients had a 
smoking history: 6 were current smokers, 8 former smokers. COPD 
status: 8 no COPD, 1 GOLD class I, 3 GOLD class II, 2 GOLD class 
III. Pre-operative CRP (mg/dL): 15.0 +/- 2.9 (0.20-54.7). Seven pati-
ents had squamous cell cancer, 7 adenocarcinoma. 
PD-L1 expression in the lung was 3833 +/- 787 (372-5072), PD-L1 in 
the tumour 2595 +/- 1657 (788-6689), with a tumour/lung ratio of 
0.67 +/- 0.37 (0.21-1.32). PD-L1 squamous vs. adenocarcinoma was 
1840 +/- 1012 vs. 3350 +/- 1896, p<0.001. PD-L1 in the lung of ex-
smokers vs. current smokers: 4136 +/- 811 vs. 3430 ± 591, p<0.001. 
These associations were not found for CTLA4 and PD1 receptor: 
CTLA4 tumour squamous vs. adenocarcinoma: 100.9 +/- 46.3 vs. 
95.3 +/- 73.6, p=0.86; CTLA4 lung smokers vs. ex-smokers: 78.4 +/- 
41.3 vs. 107.0 +/- 75.1, p=0.75. PD1 receptor tumour squamous vs. 
adenocarcinoma: 591 +/- 244 vs. 689 +/- 263, p=0.31 
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P2.05-001 RECOMBINANT HUMAN APO2L/TRAIL (DU-
LANERMIN) IN COMBINATION WITH CARBOPLATIN/PE-
METREXED IN MALIGNANT PLEURAL MESOTHELIOMA 
(MPM): ANTICANCER EFFECTS IN VITRO AND IN VIVO.
Giulia Pasello1, Loredana Urso1, Micol Silic-Benussi2, Marco Schia-
von3, Vincenzo Ciminale2, Federico Rea3, Adolfo Favaretto1
1Second Medical Oncology, Istituto Oncologico Veneto/Italy, 2Surgical 
Oncologic And Gastroenterological Sciences Department, University Of 
Padua/Italy, 3Thoracic Surgery Unit, University Of Padua/Italy
Background: Malignant pleural mesothelioma (MPM) is an ag-
gressive tumour linked to chronic inhalation of asbestos fibers, 
with poor prognosis and increasing incidence in industrialized 
countries. Currently available chemotherapeutic regimens achieve 
a median progression free and overall survival of 6 and 12 months 
respectively. Tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) is a member of the TNF family, which induces can-
cer cell death through extrinsic apoptotic pathway, while sparing 
normal cells. The aim of this study was to investigate the antitu-
mor activity of recombinant human Apo2L/TRAIL (Dulanermin, 
Amgen;Genentech) in combination with antifolate-based chemo-
therapy in MPM cell lines and in vivo preclinical mouse model.
Methods: In vitro apoptosis assay was performed using Annexin-
V-Fluos staining kit (Roche) according to the manufacturer’s inst-
ructions. Epithelioid (ZL55) and sarcomatoid (ZL34) cell lines were 
treated with carboplatin plus pemetrexed (CP), dulanermin (D) or 
CPD and then Annexin V positive cells were detected by flow cyto-
metry using a FACSCalibur apparatus and CellQuest software (BD 
Biosciences). p53 protein expression level was detected by wes-
tern blot analysis using a specific antibody. TRAIL death receptors 
(DR4 and DR5) and decoy receptors (DcR1 and DcR2) expression 
levels were assessed by flow cytometric analysis. In vivo experi-
ments were performed in 30 SCID male mice, implanted subcu-
taneously in the right flank with 2x106 ZL55 cells suspended in 0.1 
ml volume of RPMI, aged 6 weeks. When tumor volume reached 
50-150 mm3, the mice were randomized in 4 treatment groups: 1) 
not treated (NT); 2) C (75 mg/Kg day 1) plus P(100 mg/Kg day 1); 3) 
D (60 mg/Kg days 1 to 3); 4) CPD. Tumor volumes were recorded 
every second day, and mice suppressed at the 21th day or when 
tumor volume reached 500 mm3.
Results: We observed a significant increase of specific cell death 
in epithelioid and sarcomatoid cell lines treated with CPD compa-
red to those receiving CP or D as single agent (p<0.001). We then 
observed p53 activation in both cell lines after chemotherapy, 
and a subsequent significant increase of DR4/5 expression levels 
(p<0.005) without upregulation of decoy receptors. We finally as-
sessed antitumor activity of CP and/or D in a ZL55 mouse model. 
We observed a statistically significant reduction of tumor volume 
at every time point in the three treatment groups compared to not 
treated; moreover, tumor volume was significantly reduced in mice 
treated with CPD (mean volume 58 mm3) compared to CP (mean 
rescence intensity in a fluorescent plate reader.
Results: Using in vitro cytotoxic assays, we found that KIR expressi-
on or platelet coating on cancers clearly increased their resistance 
to NK cell killing when compared with parental cells. Interestingly, 
we found that platelet coating on those metastatic cancer cells 
with high aberrant KIR expression increased their IC50 values by 6 
to 14 folds respectively when compared with parental cells, while 
platelet coating on those cells with forced KIR expression also in-
creased their IC50 values by 9 to 12 folds respectively. Our obser-
vation shows that NK tolerance correlates positively with platelet 
coating and the levels of KIR expression on the cancer cells (with 
correlation coefficient = 0.9 to 0.98), and that the NK resistance is 
the highest when both KIR aberrant expression and platelet coa-
ting are present on the cancer cells.
Conclusion: We discovered a novel mechanism of immune resis-
tance to NK cells due to aberrant expression of KIRs on cancer 
cells. Aberrant KIR expression on cancer cells enhanced their in-
teraction with platelets leading to further increase in NK tolerance 
than those cells with null or low KIR expression. This observation 
suggests that anti-platelet antagonists and anti-KIR antibodies may 
have clinical potential for the treatment or prevention of metastatic 
and immune resistant cells.
Keyword: NK cells, Platelets, KIRs, immune escape, metastasis
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Conclusion: These results provide significant novel insights into 
the molecular mechanisms for crosstalk between ER stress and 
endogenous apoptotic pathways in SCLC following BH3 mimetics 
treatment.
Keywords: SCLC, ERK1/2, Bcl-2 phosphorylation, BH3 mimetics
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P2.05-003 REGULATION OF SIRT2 FOR HUMAN NON-
SMALL CELL LUNG CANCER THERAPY
Ziming Li, Shun Lu
Shanghai Lung Cancer Center, Shanghai Chest Hospital/China
Background: Seven Sirtuin family members (SIRT1-7), comprising a 
family of NAD+-dependent protein deacetylases and ADP-ribosyl-
transferases, are key proteins that regulate multiple physiological 
processes. SIRT2 was recently reported to play an important role 
in carcinogenesis. However, its role in non-small cell lung cancer 
(NSCLC) has not yet been investigated.
Methods: In this study, we analyzed the expression pattern of 
SIRT2 in NSCLC tissues from clinical patients and in cell lines
Results: We found that SIRT2 was significantly down-regulated at 
both the mRNA and protein levels in tumor than non-tumor tissues 
or cells, which were corroborated by the NSCLC tissue microarray 
results. Overexpression of SIRT2 in A549 and H1299 cells caused 
cell proliferation inhibition, cell apoptosis induction and cell cycle 
arrest. Further analysis showed that SIRT2 overexpression increa-
sed the ROS (reactive oxygen species) production and P27 levels. 
Moreover, up-regulation of SIRT2 by Resveratrol in NSCLC cells 
increased the sensitivity to cisplatin treatment. .
Conclusion: Taken together, our results implied that down-regula-
tion of SIRT2 was associated with NSCLC, and regulation of SIRT2 
might be an important target for NSCLC therapy
Keyword: SIRT2, non-small cell lung cancer, cancer therapy
volume 175 mm3) or D (mean volume 109 mm3) as single agent at 
the 21th day (p= 0.005). Finally, no difference in tumor growth was 
observed between mice treated with D compared to CP.
Conclusion: CP sensitizes MPM cell lines to TRAIL-dependent apo-
ptosis in vitro, probably through p53 activation and subsequent 
upregulation of death receptors. CPD significantly reduces tumor 
volume in epithelioid mesothelioma mouse model compared to 
chemotherapy alone or dulanermin as a single agent; furthermore 
antitumor activity of dulanermin was comparable to that reported 
with chemotherapy. In vivo experiments in a sarcomatoid mouse 
model are currently ongoing.
Keywords: mesothelioma, TRAIL, chemotherapy
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P2.05-002 RESISTANCE TO BH3 MIMETIC S1 IN SCLC 
CELLS THAT UP-REGULATE AND PHOSPHORYLATE BCL-
2 THROUGH ERK1/2
Yubo Liu, Zhichao Zhang
School Of Chemistry, Dalian University Of Technology/China
Background: Lung cancer is the leading cause of cancer-related 
mortality worldwide and there are more than one million new ca-
ses reported worldwide each year. Small cell lung cancer (SCLC) 
makes up 15% to 20% of all lung cancers with a 5-year survival 
rate of 5% to 10%. Bcl-2 is a central regulator of cell survival that 
is overexpressed in the majority of SCLC and contributes to both 
malignant transformation and therapeutic resistance. The emer-
gence of BH3 mimetics that modulate Bcl-2 pathway by occupying 
the BH3 groove represents a rational approach for the treatment of 
this neoplasm. S1 is a BH3 mimetic that depends on Bax/Bak com-
pletely. The purpose of this work was to study the key factors that 
determine the sensitivity of SCLC cells to S1 and the mechanism 
underlying the resistance of BH3 mimetics.
Methods: Western bolt was used to evaluate the contribution of 
Bcl-2 family members to the cellular response of 11 SCLC cell li-
nes to a BH3 mimetic S1. Viable cells were determined using MTS 
assay. To study the potential mechanism of resistance to S1, we 
derived resistant lines from initially sensitive H1688 cells. Quan-
titative PCR was performed to investigate Bcl-2 up-regulation. 
Gene silencing and MEK/ERK inhibitor PD98059 were used to de-
monstrate the involvement of ERK1/2 signaling in S1-induced Bcl-2 
expression.
Results: showed relatively higher levels of Bcl-2 and phosphoryla-
ted Bcl-2 (pBcl-2) characterized naïve SCLC cell lines that were 
de novo resistant to S1. Likewise, a progressive increase in the 
relative levels of Bcl-2 and pBcl-2 characterized the increased ac-
quired resistance of H1688 cells following chronic exposure to S1. 
Furthermore, acute treatment of S1 induced Bcl-2 expression and 
phosphorylation. We showed that BH3 mimetics including S1 and 
ABT-737 induced ER stress and then activated MEK/ERK pathway. 
The dual function of MEK/ERK pathway in defining BH3 mimetics 
was illustrated: ERK1/2 activation leaded to Bcl-2 transcriptionally 
up-regulation and sustain phosphorylation in naïve and acquired 
resistant SCLC cells. pBcl-2 played a key role in creating resistance 
of S1 and ABT-737 not only by sequestrating pro-apoptotic pro-
teins, but also a positive feedback to promote ERK1/2 activation.
S768 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
of NSCLC harboring EGFR activating mutations. The encouraging 
preclinical results warrant further investigation in a clinical setting.
Keywords: erlotinib, combination, xenografts, Bevacizumab
POSTER SESSION 2 - PRECLINICAL MODELS OF THERAPEUTICS/
IMAGING  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.05-005 ANTITUMOR ACTIVITY OF BEVACIZUMAB IN 
COMBINATION WITH DOCETAXEL IN EGFR-TKI RESIS-
TANT NON-SMALL CELL LUNG CANCER XENOGRAFT 
MODELS.
Kaname Yamamoto, Keigo Yorozu, Mitsue Kurasawa, Toshiki 
Iwai, Naoki Harada
Product Research Department, Chugai Pharmaceutical Co., Ltd/Japan
Background: Bevacizumab (BEV), a humanized anti-vascular endo-
thelial cell growth factor monoclonal antibody, is used in combina-
tion with chemotherapy for patients with non-small cell lung cancer 
(NSCLC). The epidermal growth factor receptor tyrosine kinase 
inhibitors (EGFR-TKIs) benefit patients with NSCLC, especially 
when this cancer harbors EGFR mutations (mtEGFR); however, 
those who initially respond eventually develop resistance. To treat 
the patients with EGFR-TKI acquired resistance, a combination of 
BEV and docetaxel (DTX) may be a possible treatment modality 
based on different mechanisms of action. In the present study, we 
investigated the antitumor activity of BEV in combination with DTX 
in EGFR-TKI-resistant NSCLC xenograft models.
Methods: Mice (BALB-nu/nu) were subcutaneously inoculated with 
NSCLC cell lines; NCI-H1993 (MET amplification) and NCI-H1975 
(mtEGFR/T790M). The treatment was started (day 1) after tumor 
growth was confirmed. BEV (5 mg/kg) was administered intraperi-
toneally on days 1, 8, 15 and DTX was administered intravenously 
on day 1 at a dose of 60 or 20 mg/kg as a maximum effective dose 
in NCI-H1993 or NCI-H1975 xenografts, respectively. The antitu-
mor activity was evaluated by tumor volume (TV; mm3) on day 46 
in the NCI-H1993 model and on day 50 (with an interim evaluation 
on day 19) in the NCI-H1975 model. Tumor cells in the proliferation 
phase were immunohistochemically evaluated using Ki-67 as an 
index (count/1000 tumor cells) on day 8 in both tumors. Statistical 
analysis was performed using the Wilcoxon test.
Results: In the NCI-H1993 model, the TV (mean±SD) of control, 
BEV, DTX, BEV+DTX on day 46 was 1630±492, 670±116, 204±85, 
49±34, respectively. The antitumor activity of BEV+DTX was signi-
ficantly better than that of DTX monotherapy (p≤0.05). In the NCI-
H1975 model, TV of control, BEV, DTX, BEV+DTX was 4631±2384, 
1581±572, 18±19, 16±10, respectively, on day 19. The BEV+DTX 
combination and DTX monotherapy showed similar effects on 
tumor regression at this point. However, after that, tumor regrowth 
was observed in the DTX group, and increased beyond the initial 
TV in 5 out of 6 mice, whereas no tumor regrowth was observed in 
BEV+DTX group at day 50. The TV of DTX and BEV+DTX groups 
on day 50 was 2631±2391 and <10 respectively. The number of 
Ki-67 positive cells (mean±SD) in tumor tissue taken from control, 
BEV, DTX, BEV+DTX on day 8 was, respectively, as follows: NCI-
H1993: 672±50, 638±25, 559±38, 459±37; NCI-H1975: 533±28, 
401±57, 381±49, 290±34. The number of Ki-67 positive cells in 
tumors treated with BEV+DTX was significantly lower than in those 
treated with DTX (p≤0.05) in both models, although there were no 
significant differences in TV between the two groups on day 8.
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P2.05-004 SYNERGISTIC ANTITUMOR ACTIVITY OF 
BEVACIZUMAB AND ERLOTINIB IN EGFR-MUTATED 
NON-SMALL CELL LUNG CANCER XENOGRAFT MO-
DELS
Yoichiro Moriya, Kaname Yamamoto, Mieko Yanagisawa, Keigo 
Yorozu, Mitsue Kurasawa, Koh Furugaki, Toshiki Iwai, Nobuyuki 
Ishikura, Naoki Harada
Product Research Department, Chugai Pharmaceutical Co., Ltd./Japan
Background: Erlotinib (ERL), a specific inhibitor of epidermal 
growth factor receptor (EGFR) tyrosine kinase, benefits patients 
with non-small cell lung cancer (NSCLC), especially if the cancer 
harbors EGFR active mutations (mtEGFR). However, those who 
initially respond eventually develop progressive disease through 
acquired resistance. Bevacizumab (BEV), a humanized anti-vascular 
endothelial cell growth factor monoclonal antibody, has been 
demonstrated to be effective in combination with standard che-
motherapies for advanced NSCLC patients. We hypothesized that 
the combination of the two agents may be more effective because 
they work through different modes of action. In the present study, 
we examined the antitumor activity of BEV in combination with ERL 
in human NSCLC xenograft models harboring mtEGFR.
Methods: Mice (BALB-nu/nu) were subcutaneously inoculated with 
NSCLC cell lines harboring mtEGFR (exon19 deletion); HCC827 and 
B901L. BEV (5 mg/kg) was intraperitoneally administered once a 
week for 3 weeks, and ERL was orally given daily for 21 days at do-
ses of 5 and 40 mg/kg for HCC827 and B901L, respectively. Antitu-
mor activity was evaluated by tumor volume (TV; mm3) on day 22. 
In order to examine the prolonged antitumor effect of the combi-
nation of BEV with ERL, the B901L xenograft model was used. BEV 
(5 mg/kg) was intraperitoneally administered once a week for 13 
weeks and ERL (60 mg/kg; maximum effective dose) was orally gi-
ven daily for 91 days. The antitumor activity was evaluated on day 
92, with an interim evaluation on day 22. The microvessel density 
(MVD) of tumor tissues was evaluated by CD31 immunohistoche-
mistry of specimens obtained on day 2 from mice treated with BEV 
(5 mg/kg) and ERL (40 mg/kg). Statistical analysis was performed 
using the Wilcoxon test.
Results: In the HCC827 model, the TV (mean±SD) of control, BEV, 
ERL, and BEV+ERL was 1300±424, 686±84, 615±185, and 194±29, 
respectively. In the B901L model, the TV of control, BEV, ERL, and 
BEV+ERL was 1739±761, 819±293, 294±198, and 57±19, respec-
tively. The antitumor activity of BEV+ERL was significantly better 
than that of BEV or ERL monotherapy (p≤0.05) in both models. In 
the prolonged treatment experiment using B901L, on day 22, BEV 
(1096±298) showed significantly higher (p≤0.05) tumor growth in-
hibition than control (2452±731), but the ERL (61±31) and BEV+ERL 
(53±30) showed even better (p≤0.05) tumor regression effects than 
BEV. However, during further treatment, tumor regrowth was ob-
served in the ERL group, even though ERL was consecutively given, 
and the TV on day 92 (1105±1001) was significantly greater than 
that on day 22 (61±31). Tumor regrowth was also observed in the 
BEV+ERL group; however, it was much slower compared to the ERL 
group and there was no significant difference between TV on day 
92 (79±70) and that on day 22 (53±30). The MVD was significantly 
decreased to the same level in the BEV and BEV+ERL groups.
Conclusion: Compared to ERL monotherapy, the combination of 
BEV and ERL demonstrated promising efficacy in mouse models 
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lower (p < 0.01) in BEV (1.40±0.36) and BEV+PEM (1.24±0.49) groups 
than in control (6.63±1.89) and PEM (4.62±0.71) groups, indicating 
that the decrease in MVD caused by BEV treatment was not affected 
by the combination with PEM. TS expression level, which is inversely 
correlated with the effect of PEM, was lower in BEV+PEM group than 
in PEM group.
Conclusion: Compared to PEM monotherapy, the combination of 
BEV with PEM showed better antitumor effect as a maintenance the-
rapy in a xenograft model. Decreases in MVD and TS expression may 
contribute to the effect of combination therapy.
Keywords: Bevacizumab, thymidylate synthase, pemetrexed, mi-
crovessel density
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P2.05-007 SIGNIFICANCE OF THE RECOMMENDED 
DOSE ERLOTINIB FOR AVOIDING ACQUIRED RESIS-
TANCE IN NSCLC CELLS WITH EXON19 DELETION AND 
L858R MUTATION OF EGFR
Koh Furugaki, Yoichiro Moriya, Naoki Harada
Product Research Department, Chugai Pharmaceutical Co., Ltd./Japan
Background: Erlotinib, an epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitor, shows notable effects against non-small 
cell lung cancers (NSCLCs) harboring EGFR-activating mutations 
such as exon 19 deletion or L858R mutation. However, almost all 
patients eventually acquire resistance to erlotinib. In this study, we 
investigated whether the level of exposure to erlotinib affects inci-
dence of acquired resistance in EGFR-mutated NSCLC cell lines and 
examined their resistant mechanisms.
Methods: Human NSCLC cells B901L and PC-9 harboring exon 
19 deletion and II-18 cells with L858R mutation were continuously 
exposed to 0.5 or 5 µM of erlotinib in 96-well plates for several 
months. The upper dose was chosen because the recommended 
dose of erlotinib (150 mg) has been reported to achieve maximum 
plasma concentration (Cmax) of about 5 µM. Cell growth inhibition 
was determined by a crystal violet assay. EGFR mutation status was 
determined by melting curve analysis. MET copy number was deter-
mined by real-time PCR analysis. Phosphorylations of EGFR, HER2 
and ERK were measured by Western blot analysis.
Results: Resistant B901L, PC-9 and II-18 cells were emerged in 24, 
8 and 7 wells by exposing to 0.5 µM erlotinib, and in 13, 2 and 0 
wells by exposing to 5 µM erlotinib, respectively. No alterations in 
EGFR mutation status including T790M mutation nor acquisition 
of MET amplification were detected in any resistant cells. In parent 
cells, treatment with erlotinib markedly inhibited phosphorylation 
of EGFR, HER2 and ERK. In the parent cells, treatment with erlotinib 
markedly inhibited EGFR phosphorylation but not HER2 and ERK 
phosphorylation, compared with the parent cells.
Conclusion: In present in vitro analysis, it was suggested that expo-
sure to the recommended dose of erlotinib would avoid acquired re-
sistance in NSCLC with exon19 deletion or L858R mutation of EGFR. 
Pathways activated by phosphorylated HER2 may affect acquired 
resistance to erlotinib.
Keywords: EGFR, erlotinib, resistance, mutation
Conclusion: Combining BEV with DTX can decrease the tumor 
cells in a proliferation phase more effectively than DTX alone in the 
early stage of the therapy. This may provoke a stronger antitumor 
effect later on and delay tumor regrowth. These data are encoura-
ging, and the combination of BEV+DTX may be a promising treat-
ment modality for patients with NSCLC after acquiring a resistance 
to EGFR-TKIs.
Keywords: xenograft, Bevacizumab, EGFR-TKI, docetaxel
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P2.05-006 ANTITUMOR ACTIVITY OF BEVACIZUMAB IN 
COMBINATION WITH PEMETREXED AS MAINTENANCE 
THERAPY FOR NON-SMALL CELL LUNG CANCER IN A 
XENOGRAFT MODEL: COMPARISON WITH PEMETREX-
ED MONOTHERAPY AND ANALYSIS OF THE COMBINA-
TION MECHANISM
Nobuyuki Ishikura, Kaname Yamamoto, Toshiki Iwai, Keigo Yoro-
zu, Mitsue Kurasawa, Naoki Harada
Product Research Department, Chugai Pharmaceutical Co., Ltd./Japan
Background: Bevacizumab (BEV) is a humanized monoclonal antibo-
dy against vascular endothelial cell growth factor (VEGF) that inhibits 
VEGF-mediated angiogenesis in many types of tumors. OS and PFS 
were significantly prolonged in patients with advanced non-small cell 
lung cancer (NSCLC) who received BEV maintenance after induction 
with BEV+chemotherapy (ECOG4599 study). The maintenance stu-
dy AVAPERL demonstrated that, after induction with pemetrexed 
(PEM)+BEV+cisplatin therapy, BEV+PEM combination significantly 
prolonged PFS compared to BEV monotherapy. However, the com-
parative efficacy of BEV+PEM to PEM monotherapy is not clear. In the 
present study, we investigated the antitumor effect of the BEV+PEM 
combination compared to BEV or PEM monotherapy as continuation 
maintenance after BEV+PEM treatment in a human NSCLC xenograft 
model.
Methods: SCID mice were subcutaneously inoculated with human 
NSCLC cell line NCI-H2228. As an induction treatment, BEV (5 mg/kg; 
maximum effective dose) and PEM (400 mg/kg; maximum effective 
dose) were administered intraperitoneally on days 1, 8, and 15 after 
randomization by tumor volume (TV). On day 22, the mice treated 
with BEV+PEM were re-randomized and BEV and/or PEM were admi-
nistered intraperitoneally weekly until day 85. The antitumor activity 
was evaluated by TV on day 85. Microvessel density (MVD) and thymi-
dylate synthase (TS) expression in tumor tissues were evaluated using 
specimens taken on day 85. MVD was analyzed by CD31 immuno-
histochemistry and evaluated in terms of the ratio of stained area to 
observed area. TS expression was evaluated by Western blot analysis. 
Statistical analysis was performed using the Wilcoxon test.
Results: TV (mm3; mean±SD) of BEV+PEM group on days 1 and 22 
was 335±72 and 329±59, respectively, whereas TV of control group on 
day 22 was 671±67, indicating that BEV+PEM completely inhibited tu-
mor growth during induction treatment. TV of control, BEV, PEM, and 
BEV+PEM groups on day 85 was 2748±1334, 586±320, 883±271, and 
348±48, respectively. Each treatment group showed a significantly 
higher antitumor activity (p < 0.001) compared to control. Specifically, 
BEV+PEM completely inhibited tumor growth throughout the expe-
riment, and showed a significantly higher antitumor activity than BEV 
(p < 0.05) or PEM (p < 0.001) monotherapy. MVD (%) was significantly 
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those with positive expression (72.8 vs. 50.2 month, P = 0.021) and 
(76.5 vs.47.7 months, P=0.000). Patients with positive expression of 
E-Cadherin survived longer than those with negative markers (67.6 
vs 54.1 months, P=0.035), While N-Cadherin+ patients survived 
shorter than N-Cadherin- patients (55.1 vs. 77.1 months, P=0.025). 
In overall survival between patients with and those without che-
motherapy, there is no significant difference (63.8 vs. 60.6 months, 
P=0.851). But subgroup analysis revealed patients undergoing 
chemotherapy with positive expression of CD133 enjoyed signifi-
cantly longer survival (53.8 vs. 32.3 months). A subgroup analysis 
also showed that patients with negative expression of Nanog with 
chemotherapy survived longer than those without chemotherapy 
(69.3 vs. 76.4 months), while patients with positive Nanog trea-
ted with chemotherapy could survive longer than those without 
chemotherapy (57.0 vs. 38.7 months). In the 74 patients received 
chemotherapy after progression, we found that many patients with 
PR are Nanog- (82.1% vs. 17.9%), while patients with Nanog+ tend 
to have progression diease (61.4% vs. 38.6%). K-M survival analysis 
indicated that patients with Nanog (-) N-Cadherin (-) CD133 (-) 
survived longer than those with Nanog (+) N-Cadherin (+) CD133 
(+), Nanog (+) N-Cadherin (-) CD133 (-), Nanog (+) N-Cadherin (-) 
CD133 (+) and Nanog (-) N-Cadherin (-) CD1 33 (-) patients (101.9 
vs. 60.0, 101.9 vs. 54.6, 101.9 vs. 38.2 months). Multivariate regres-
sion analysis showed that stage of lung cancer, CD133, N-Cadherin 
and Nanog were independent prognostic factors. Downregulation 
of Nanog could partially restore the cell sensitivity to cisplatin in 
cisplatin-resistant cell line under RNA interference. In the EGFR 
primary drug resistance experiment, we found that CD133 and 
ABCG2 were higherly expressed in H23 (EGFR primary resistance 
cell line) than PC-9 (EGFR sensitive cell line). Detection of CD133, 
ABCG2 and Oct4, Nanog expression by RT-PCR and western blot 
in PC-9 and H23 cell lines showed that these markers expressed 
significantly higher in H23; Using immunohistochemical method, 
we analysed EGFR, C-met and CD133, ABCG2 and Oct4,Nanog 
in 104 cases of postoperative samples and analysed the relation-
ship between their expression and prognosis. The results showed 
that C-met expressed in patients in advanced stage (P=0.0860), 
adenocarcinoma(P=0.0355) and non-smoking patients. K-M 
analysis showed that C-met expressed in patients with wild type 
EGFR(P= 0.0436). We further tested stem cell factors in 94 cases of 
advanced stage who received ERFG-TKI and analysed relationship 
between drug efficacy and prognosis. The results suggest that 
Nanog tend to express in smokers (39.4%vs.14.8%, P=0.0071), and 
Oct4 in adenocarcinoma (38% vs.8.3%, p=0.0170). Patients with 
negative Oct4 expression have longer PFS (time to progression of 
disease) (11 vs.7.0 m, P=0.041), patients with negative expression 
of Nanog have significantly longer PFS than patients with higher 
expression (13.5 vs.3.8m, P=0.000). Patients with high E-cadherin 
expression have longer PFS than patients with lower expression 
(13.5m vs 6.8., P=0.015), Patients with lower N-cadherin expression 
have longer PFS than patients with high expression (12.3 vs.7.4m, 
P=0.020). Multiple regression analysis suggested that Nanog, 
ECOG score and RR are independent prognostic factor. RNA inter-
ference results showed that down-regulation of Nanog expression 
can increase sensitivity to EGFR-TKI in H23.
Conclusion: This study will reveal the mechanisms of drug resis-
tance in lung cancer from a new point of view. To provide the evi-
dence of stem cell factor and EMT related pathway as a new target 
for reverse the drug resistance in the future.
Keywords: epithelial mesenchymal transition, chemoresistance, 
Lung cancer, stem cell transcription factors
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P2.05-008 STEM CELL TRANSCRIPTION FACTORS OCT4 
AND NANOG INVOLVED IN CHEMORESISTANCE AND 
EGFR-TKI RESISTANCE OF NSCLC
Chunxia Su1, Xuefei Li2, Caicun Zhou3, Jiayu Li4
1Shanghai Pulmnary Hospital/China, 2Department Of Lung Cancer And 
Immunology, Tongji University Medical School Cancer Institute/China, 
3Department Of Medical Oncology; Lung Cancer And Immunology Labo-
ratory, Shanghai Pulmonary Hospital, Tongji University; Tongji Univer-
sity Medical School Cancer Institute/China, 4Medical Oncology, Tongji 
University Medical School Cancer Institute/China
Background: Despite rapid strategy improvments of advanced 
lung cancer , traditional chemotherapy or targeted therapies, es-
pecially EGFR-TKI (epidermal growth factor receptor) will emerge 
treatment resistant eventually. The main cause for treatment failure 
of advanced lung cancer is drug resistance, and it’s molecule me-
chanism could be key to improve theraputic effect. The transcrip-
tion factors Oct4 and Nanog were reported to be involved in drug 
resistance of many malignant tumors, which are closely related 
with the prognosis of patients. These factors are expected to be 
potential drug targets. The present study is designed to explore 
potential mechanisms about stem cell transcription factors’ regu-
lation of epithelial mesenchymal transition (EMT) invlolved in drug 
resistance of lung cancer.
Methods: MTT,immunohistochemistry, immunofluorescence, Wes-
tern blot, RT-PCR experiments in vitro and in vivo were employed. 
Clinical samples (104 postoperation and 94 advance stage samp-
les) were collected to assess the clinical prognostic value of stem 
transcription factors( Oct4 and Nanog),  (CD133 and ABCG2) and 
epithelial mesenchymal transition (EMT) markers (E-Cadherin and 
N-Cadherin) with clinical features. Down-regulation of Nanog by 
RNA interference were used to find the change of chemosensitivity 
and EGFR-TKI sensitivity. Combined with the specific mechanisms 
in vitro and clinical samples to interpret the regulation of EMT 
involved in drug resistance.
Results: The immunocytochemistry experiments showed that ex-
pression pattern of A549 cell line are CD133 (+), ABCG2 (+ +), Oct4 
(-) and Nanog (-); A549/DDP cell line are CD133 (+ + +), ABCG2 (+ 
+), Oct4 (+ +) and Nanog (+ + +). There are significant differences 
in expression of CD133, Oct4 and Nanog between the two cell 
lines. Cell immunofluorescence experiments showed that stem cell 
transcription factors expressed in cell nucleus of A549 cell line, and 
stem cell surface marker CD133 located on the cell membrane. 
RT-PCR and Western blot were used to the examination of A549 
and A549/DDP cell lines for CD133, ABCG2 and Oct4, Nanog’ 
expression. The results showed that the expression of these mar-
kers in cisplatin resistance cell line. Examination by RT-PCR of the 
samples from 40 paired cases of lung cancer and adjacent tissue, 
showed that Oct4 and Nanog in lung cancer group was higher 
than those in paracancerous tissues, suggesting that Oct4 and 
Nanog might play an important role in lung cancer initiation and 
malignant growth process. The expression of these transcription 
factors in 104 samples from lung cancer patients, analysed by im-
munohistochemical method, showed the expression level of these 
factors were significantly higher in stage III and IV patients than 
in stage I and II patients. It also showed that the higher the Oct4 
and Nanog expressed, the poorer prognosis were (54.3 vs 68.5 
months, P=0.053) and (52.7vs.72.1months, P= 0.022). The patient 
with negative expression of CD133 or ABCG2 survived longer than 
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P2.05-010 SEVERAL RECEPTOR TYROSINE KINASE IS 
ACTIVATED BUT ORCHESTRATED BY EGFR IN EGFR-
TKI ACQUIRED RESISTANT LUNG ADENOCARCINOMA 
CELLS WITH EGFR MUTATION
Kenichi Suda1, Hiroshi Mizuuchi1, Katsuaki Sato1, Toshiki Take-
moto1, Takuya Iwasaki1, Kenji Minami1, Yasushi Yatabe2, Tetsuya 
Mitsudomi1
1Division Of Thoracic Surgery, Department Of Surgery, Kinki University 
Faculty Of Medicine/Japan, 2Dept. Of Pathology And Molecular Diag-
nostics, Aichi Cancer Center/Japan
Background: Lung adenocarcinomas with EGFR mutation initially 
show good responses to EGFR- tyrosine kinase inhibitors (TKIs). 
However, emergence of acquired resistance is almost inevitable. 
To analyze molecular mechanisms underlying acquired resistance, 
we established a cell line from a patient who acquired resistance to 
gefitinib/erlotinib.
Methods: A 64-year-old woman underwent a pulmonary resection 
for lung adenocarcinoma in February 2009 (pT2aN0M0, EGFR 
L858R mutation). In April 2010, pulmonary metastases, mediastinal 
lymph node metastases, and right pleural effusion were identified. 
Gefitinib was started and this led to a complete response. Howe-
ver, despite continuous treatment with gefitinib, pleural effusion 
and serum carcinoembryonic antigen (CEA) levels gradually increa-
sed. In December 2010, gefitinib was switched to erlotinib but the 
serum CEA level continued to increase, and erlotinib was stopped 
on March, 2011. Even though she received no treatment after erlo-
tinib withdrawal, interestingly, the serum CEA level was decreased 
significantly (from 89.5ng/ml on March 2011 to 19.2ng/ml on April 
2011), and erlotinib was re-started on April 2011. The serum CEA 
level increased after re-administration of erlotinib (55.7ng/ml on 
May 2011). Therefore the regimen was switched to cisplatin/peme-
trexed and she responded to this combination chemotherapy (CEA 
9.1ng/ml on July 2011). This clinical experience may be an actual 
case of “drug addiction phenomenon” that we and others have 
observed in preclinical acquired resistance models (Suda K, et al. 
Lung Cancer 2012; Das Thakur M, et al. Nature 2013). We establis-
hed a cell line from her pleural effusion obtained on March 2011 in 
drug-free condition (designated as ACC-GR1 cells). We analyzed 
this cell line to evaluate the efficacy of erlotinib and dacomitinib, 
an irreversible EGFR-TKI. In addition, we examined phosphoryla-
tion status of 42 receptor tyrosine kinase (RTK) of ACC-GR1 cells 
using Human Phospho-RTK Array Kit (R&D Systems) with/without 
erlotinib or dacomitinib. We also examined PC9 lung adenocar-
cinoma cell line for phosphorylation status of RTKs with/without 
erlotinib.
Results: ACC-GR1 cells harbored the T790M mutation, in addition 
to the original L858R mutation in the EGFR gene. ACC-GR1 cells 
do not have amplification of MET proto-oncogene. IC50 values for 
erlotinib and dacomitinib were 2.9 uM and 0.05 uM, respectively. 
Phospho-RTK array analysis revealed marked activation of EGFR 
and MET, in addition, activation of ERBB2, ERBB3, RET, and AXL 
in a culture condition without EGFR-TKI. Treatment with 1 uM of 
erlotinib led to mild inhibition of EGFR and MET phosphorylation 
(71% and 58%, respectively, compared with control), and phospho-
rylation of other RTKs fell below detectable limits. Treatment with 
1 uM of dacomitinib led to further inhibition of EGFR phosphoryla-
tion (35% compared with control). In PC9 cells, phosphorylation 
of EGFR and MET were also observed in drug-free condition, and 
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P2.05-009 PORPHYSOME-ENHANCED BRONCHOSCO-
PIC FLUORESCENCE DETECTION AND PHOTOTHERMAL 
ABLATION OF PERIPHERAL LUNG CANCER: PRELIMINA-
RY IN VIVO STUDIES
Takashi Anayama1, Cheng S. Jin2, Patrick Mcveigh3, Takahiro Na-
kajima1, Kenneth Ng2, Johnathan F. Lovell4, Kentaro Hirohashi1, 
Hironobu Wada1, Brian Wilson3, Kazuhiro Yasufuku1, Gang Zheng2
1Division Of Thoracic Surgery, Department Of Surgery, Toronto General 
Hospital, University Health Network, University Of Toronto, Toronto/
Canada, 2Institute Of Biomaterials And Biomedical Engineering, Univer-
sity Of Toronto/Princess Margaret Cancer Centre/Canada, 3Department 
Of Medical Biophysics, University Of Toronto/Princess Margaret Cancer 
Centre/Canada, 4Department Of Biomedical Engineering, University At 
Buffalo, The State University Of New York/United States Of America
Background: Bronchoscopic ablation of lung cancer has to date been 
limited to carcinoma in-situ located in the central airway or, using high-
power lasers, to palliation in advanced obstructive disease . Broncho-
scopic ablation of peripheral lung cancer is still under development. 
We are developing a new technology platform for localization (by 
fluorescence) and enhanced photothermal therapy (PTT) of peripheral 
lung lesions, based on porphysomes, which are novel, multi-functional, 
all-organic porphyrin-lipid nanoparticles. Even without active targe-
ting, porphysomes accumulate within tumor through the enhanced 
permeability and retention (EPR) effect. In parallel, we have developed 
a prototype fluorescent endoscope system that allows visualization of 
peripheral lesions by the porphyrin fluorescence. Using this combinati-
on of novel instrumentation and nanoparticles, endoscopic PTT of lung 
cancer is demonstrated in preclinical lung cancer animal models in vivo.
Methods: The in vivo porphysome biodistribution was evaluated in 
both orthotopic lung tumors (A549, H460, H520) in mice and in VX2 
tumors implanted directly in rabbit lung. Porphysomes were adminis-
tered intravenously at a dose of 20 mg/kg, and the tumor fluorescence 
was imaged in vivo daily for 3 days (excised lung in the mouse model 
and endoscopically in the rabbit model). Ex vivo VX2 tissue was illumi-
nated using a 670 nm diode laser to determine the optimized treatment 
parameters for PTT. Subsequently, in vivo bronchoscopic visualization 
of VX2 fluorescence and PTT was demonstrated in the rabbit model. 
The extent of ablation was histologically evaluated by NADH metabolic 
activity staining.
Results: The highest tumor-to-normal lung fluorescence ratio was 
achieved at 48 h post-injection of porphysomes(Rabbit VX2: n=4). The 
same trend was confirmed in the 3 kinds of orthotopic lung cancer 
mouse Xenografts (n=8). The ex vivo study revealed that 250 mW and 
10 min of 670 nm laser irradiation raised the tumor tissue temperature 
by more than 20oC, so that this setting was used also in vivo and achie-
ved thermal coagulation zones within the tumor of up to 13 mm diame-
ter. In comparison, laser treatment alone without porphysomes caused 
minimal ablation zones of < 1.5 mm diameter.
Conclusion: Systemically administrated porphysomes accumulated 
in the lung cancer tissue with a high enough concentration to enable 
marked photothermal coagulation. The combination of systemically-
administrated porphysomes with endoscopic near-infrared laser irra-
diation is a promising strategy for minimally-invasive bronchoscopic 
interventional therapy for peripherally-located lung cancer.
Keywords: Porphysomes, nanoparticles, bronchoscopic laser, mini-
mally inasive therapy for lung cancer
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cally indistinct from human mesothelioma with positive labeling for 
WT1, calretinin, HBME-1, cytokeratin and popoplanin and negative 
labeling for two carcinoma related markers TTF-1 and CD15. Ho-
mozygous deletion of p16INK4A/p14ARF, and increased expression of 
several members of the ATP-binding cassette transporter superfa-
mily and Androgen receptor (AR) were demonstrated, consistent 
with findings in human mesothelioma. Corresponding with biomar-
kers studies in human disease, increased levels of osteopontin (p < 
0.01), mesothelin (p < 0.01), vascular endothelial growth factor (p < 
0.001) and neutrophil to lymphocyte ratio were identified relative 
to control bloods. Further, the acquisition of chemo-resistance 
resulted in changes to tumour morphology with tumours ranging 
from essentially epithelioid in the gemcitabine resistant tumours to 
entirely sarcomatoid in the combination (cisplatin and pemetrexed) 
resistant tumours. Overall survival was also affected by the acqui-
sition of resistance with rats with pemetrexed resistant tumours 
having decreased survival.
Conclusion: These models display many features corresponding 
with the human disease, and thus provide powerful and robust 
pre-clinical platforms for in vivo mesothelioma studies.
Keyword: mesothelioma, pre-clinical models, chemo-resistance
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P2.05-012 AN INDUCIBLE TRANSITION CELL MODEL 
REFLECTING EPITHELIOID VERSUS SARCOMATOID DIF-
FERENTIATION OF MALIGNANT PLEURAL MESOTHE-
LIOMA
Karin Schelch1, Christina Wagner1, Mir Alireza Hoda2, Balazs He-
gedus3, Balazs Dome3, Walter Berger1, Walter Klepetko4, Michael 
Grusch1
1Institute Of Cancer Research, Inner Medicine I, Medical University Of 
Vienna/Austria, 2Institute Of Cancer Research And Divison Of Thoracic 
Surgery, Medical University Of Vienna/Austria, 3Translational Thoracic 
Oncology Laboratory, Division Of Thoracic Surgery, Medical University 
Of Vienna/Austria, 4Department Of Surgery, Division Of Thoracic Sur-
gery, Medical University Of Vienna/Austria
Background: Malignant pleural mesothelioma (MPM) is an aggres-
sive asbestos-related malignancy characterized by frequent resis-
tance to chemo- and radiotherapy. Signals induced by Fibroblast 
growth factors (FGF) and their high-affinity receptors (FGFR) have 
been identified as important drivers for malignant growth in sever-
al tumor entities including thoracic malignancies. We have recently 
demonstrated that FGFR signals stimulate growth and migration 
in MPM cell models, whereas inhibition of FGFR1 reduced tumor 
growth and had an antagonistic effect on malignant behavior of 
MPM cells. In several cell models of biphasic MPM, FGF2 induced 
phenotypical changes reminiscent of epithelial-mesenchymal-
transition (EMT). In this study we analyzed these FGF-induced 
morphological and functional alterations and the associated signal 
transduction mechanisms in more detail.
Methods: Cells were stimulated with recombinant FGF2 and ana-
lyzed by microscopy and ImageJ software. The specific inhibitors 
PD166866, UO126, MK2206, LY294002 and SB431542 were used to 
block FGFR1, MEK, AKT, PI3K and TGFbeta receptors, respectively. 
Alterations in gene expression were determined via whole-geno-
me expression arrays and further evaluated by immunofluores-
remarkably inhibited by 1 uM erlotinib treatment (10% and 64%, 
respectively, compared with control).
Conclusion: A cell line model established from pleural effusion 
of a patient who acquired resistance to gefitinib/erlotinib harbo-
red T790M mutation and responded to dacomitinib in vitro. The 
acquired resistant cells showed activation of several RTKs in drug 
free condition, and these are remarkably inhibited by EGFR-TKI 
treatment.
Keywords: EGFR mutation, EGFR tyrosine kinase inhibitors, acqui-
red resistance, molecular target therapy
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P2.05-011 CHARACTERISATION OF CHEMO-RESISTANT 
SYNGENEIC ORTHOTOPIC RAT PRE-CLINICAL MODELS 
OF MESOTHELIOMA.
Amanda Hudson1, Chris Weir1, Elizabeth Moon1, Rozelle Harvie1, 
Sonja Klebe2, Nick Pavlakis1, Stephen Clarke1, Viive Howell1
1Medical Oncology, University Of Sydney, Bill Walsh Translational Can-
cer Research Laboratory, Kolling Institute/Australia, 2Department Of 
Anatomical Pathology, Flinders University And Sa Pathology/Australia
Background: Malignant mesothelioma is an aggressive cancer with 
a low response to current therapies and consequently a poor prog-
nosis. There is an urgent need to identify novel and more effective 
treatments to improve survival and quality of life for patients with 
mesothelioma. While a number of novel therapeutic agents have 
recently been examined in clinical trials, to date none of these has 
resulted in changes to standard management. This is due in part to 
a lack of robustness and relevance of the pre-clinical models used 
to assess new treatments. Therefore validated and biologically re-
levant pre-clinical models that demonstrate the clinical behaviour 
and drug sensitivity of mesothelioma, as well as typical resistance 
mechanisms, are necessary to improve the discovery of new treat-
ments. Here we describe the generation and evaluation of chemo-
therapy resistant pre-clinical models of mesothelioma derived from 
the previously utilized syngeneic II-45 rat mesothelioma model.
Methods: Cell lines resistant to the current standard of care 
agents: cisplatin, pemetrexed gemcitabine, vinorelbine, and cispla-
tin and pemetrexed in combination, were generated by 15 rounds 
of exposure to the respective agent. Normal rat mesothelial cells 
(4/4 RM.4), the parental II-45 and the 5 resulting chemo-resistant 
mesothelioma cell lines were characterised for resistance to these 
and other agents. Tumours arising from syngeneic pleural en-
graftment of these cell lines were assessed by size, morphology, 
immunohistochemical markers of human malignancy, chromosomal 
changes and expression of genes involved in drug resistance and 
metabolism. Engrafted rats were assessed for survival, and circula-
ting haematological, cytokine and biomarker profiles were genera-
ted and compared.
Results: Five different II-45 cell lines with approximately 2-fold 
resistance to the chemotherapeutic agent they were repeatedly 
exposed to, were established (cisplatin, p < 0.05; pemetrexed, 
gemcitabine, vinorelbine, p < 0.001). Cross resistance to other 
classes of anti-cancer agents also developed indicating potential 
multi-drug resistant phenotypes. Tumours derived from both the 
parental and chemo-resistant cell lines were immunohistochemi-
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chemo sensitisation. Mouse tumour growth was monitored using 
non-invasive xenogen imaging. Statistical analysis included Mann–
Whitney test and Log rank (Mantel-Cox).
Results: Transient transfection of NSCLC H460 cells with the βIIITRP 
vector resulted in >40% decrease of TUBB3 gene expression and 
a concomitant decrease in βIII-tubulin protein level compared to 
the ContTRP vector. This led to increased in vitro sensitivity to both 
paclitaxel and cisplatin. Using a clinically relevant orthotopic mo-
del of NSCLC we treated H460 tumour-bearing mice with the βIIITRP 
vector encapsulated in a lipophilic delivery agent and this resul-
ted in a potent decrease (71.6%) in TUBB3 expression in tumours 
compared to ContTRP vector (P=0.03). Median survival increased 
by 6 days in the ContTRP+ cisplatin versus ContTRP groups although this 
increase was not significant. In contrast, median survival increased 
by 21 days in the βIIITRP + cisplatin versus βIIITRP+ vehicle groups (P=0.003). 
Importantly, in vivo suppression of TUBB3 combined with cisplatin 
treatment led to a significant increase in overall survival compared 
to βIIITRP + vehicle control mice (P=0.0174).
Conclusion: This study provides the first evidence that a vector-
based gene suppression approach can potently silence TUBB3 
expression and increase chemosensitivity in vivo, highlighting 
this as a promising treatment strategy for drug refractory NSCLC. 
References 1. Kavallaris M. Microtubules and resistance to tubulin-
binding agents. Nat Rev Cancer. 2010;10:194-204. 2. McCarroll 
JA, Gan PP, Liu M, Kavallaris M. betaIII-tubulin is a multifunctional 
protein involved in drug sensitivity and tumorigenesis in non-small 
cell lung cancer. Cancer Res. 2010;70:4995-5003. 3. Gan PP, Pas-
quier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to 
chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 
2007;67:9356-63.
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P2.05-014 SCHEDULE-DEPENDENT INTERACTIONS BET-
WEEN PEMETREXED AND VINORELBINE IN HUMAN 
LUNG CANCER CELLS
Zhe Wang, Xiaoqing Liu, Fei Tian, Rosemarie Kiefl, Amanda Tuf-
man, Rudolf M. Huber
Thoracic Oncology Centre Munich, University Of Munich - Campus 
Innnenstadt/Germany
Background: Lung cancer is the leading cause of cancer deaths 
worldwide. Despite advances and progresses in surgery, chemo-
therapy, and radiotherapy over the last decades, the death rate 
from lung cancer has remained largely unchanged, which is mainly 
due to metastatic disease and multi drug resistance. Because of 
the overall poor prognosis, new treatment strategies for lung can-
cer patients are urgently needed. The aim of this study was to in-
vestigate the interactions between pemetrexed and vinorelbine for 
human adenocarcinoma via various chemotherapy schedules.
Methods: HCC cells and cisplatin resistant HCC cells (HCC-res) 
were treated with different schedules of combination of cisplatin 
(Cis), vinorelbine (Vin), and pemetrexed (Pem) respectively, more 
specific as Cis, Vin, Pem, Cis+Vin, Cis+Pem, Vin+Pem, Vin→Pem, 
Pem→Vin, Cis+Vin+Pem, Cis→Pem→Vin, and Cis→Vin→Pem. Cell 
cence. Downstream signaling was investigated by immunoblotting.
Results: In M38K and SPC212 cells FGF2 induced morphological 
alterations that were characterized by a more spindle-shaped ap-
pearance and reduced contacts with adjacent cells. This correlated 
with increased cell migration. With respect to signal transduction, 
the effects of FGF2 could be blocked by inhibition of FGFR1 or 
MEK, whereas inhibition of AKT, PI3K or receptors of the TGFbeta/
activin family had no effect. Expression arrays of both cell models 
indicated regulation of several matrix metalloproteinases (MMP1, 
MMP4), the integrin subunit ITGA6 and the two TGFbeta family-
related proteins INHBB and Smad7. Since the phenotypical chan-
ges were similar to EMT, genes previously connected to EMT were 
analyzed. Whereas slug/SNAI2 and ZEB1 were increased, other 
mesenchymal genes such as vimentin or N-cadherin were already 
expressed at high levels in the untreated cells, likely due to the 
mesodermal origin of mesothelial cells. In M38K, E-cadherin was 
decreased whereas in the more “fibroblastoid-type” SPC212 E-
cadherin was generally expressed at very low levels.
Conclusion: Our data suggest that FGF2 induces morphological 
changes that result in a more sarcomatoid cell morphology and 
expression of some markers connected to EMT. These effects 
depend on the MAPK pathway and are connected to more aggres-
sive cell behavior, paralleling the higher aggressiveness and worse 
prognosis of the sarcomatoid and biphasic compared to the epi-
thelioid histological subtype of MPM.
Keywords: fibroblast growth factors, Epithelial-Mesenchymal 
Transition, malignant pleural mesothelioma
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P2.05-013 SILENCING THE TUBB3 GENE IN VIVO SENSI-
TISES NON-SMALL CELL LUNG CANCER TO CISPLATIN
Maria Kavallaris1, Kathleen Kimpton1, Miriam Brandl1, Anja Go-
bel1, Rafael Erlich1, Tanya Dwarte1, Nigel Mccarthy1, Sharon Sag-
nella1, Michael Graham2, Peter French2, Joshua Mccarroll1
1Children‘s Cancer Institute Australia/Australia, 2Benitec Ltd/Australia
Background: Lung cancer is the most common cause of cancer 
death. Despite advances in treatment of other cancers, overall 
5-year survival rates for advanced non-small cell lung cancer (NS-
CLC) are dismal. Expression of βIII-tubulin (encoded by TUBB3 
gene) is associated with resistance to tubulin-binding agents in 
a range of tumor types including NSCLC1. We identified a multi-
factorial role for βIII-tubulin in chemosensitivity by showing that 
it can mediate response not only to tubulin-binding agents, but 
also DNA damaging agents in NSCLC2, 3, validating βIII-tubulin 
as a therapeutic target in NSCLC. We hypothesized that in vivo 
targeting of the TUBB3 gene would sensitise NSCLC tumours to 
chemotherapy.
Methods: DNA-directed RNA interference (ddRNAi) is a potent 
gene silencing approach that can achieve prolonged suppression 
of target genes. We developed a triple cassette shRNA vector con-
taining three unique targets against the TUBB3 gene (βIIITRP) and a 
control vector containing three non-targeting sequences (ContTRP). 
Gene and protein analysis was achieved using RT-qPCR and wes-
tern blotting respectively. An orthotopic mouse xenograft model 
of NSCLC was used to evaluate gene ddRNAi delivery, efficacy and 
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cell lines with EGFR-TKI resistance mutation.
Methods: KPT-185 and KPT-276 are selective inhibitors of nuclear 
export (SINE) that block CRM1. Cell viability, apoptosis and cell 
cycle were evaluated in 6 NSCLC cell lines (H1975, H1650, A549, 
H2228, HCC827, H1650 Gefitinib Resistance (H1650GR)) after tre-
ated with KPT-185; expression level of CRM1 in NSCLC cell lines 
was detected after exposed to KPT-185; TSPs were detected by 
western blot to explore the possible mechanisms of KPT-185 indu-
cing NSCLC cells growth inhibition and apoptosis. NOD-SCID mice 
bearing H1975 (epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitor (TKI) resistant) tumors were treated orally with KPT-
276 (similar structure to KPT-185, but improved animal pharmacoki-
netics) to examine the efficacy and side-effects of KPT-276 in vivo.
Results: In 6 NSCLC cell lines, growth inhibition showed in a 
time- and dose-dependent way after treated with KPT-185. The 
EGFR TKI resistant cell lines H1975 and H150GR were sensitive 
to KPT-185. Cell apoptosis analysis showed that KPT-185 induced 
NSCLC cells apoptosis in a dose-dependent manner. Also, KPT-
185 induced cell cycle arrest at the G1/S checkpoint in NSCLC cell 
lines. CRM1 protein expression of 6 NSCLC cell lines was down 
regulated when treated with KPT-185, which could be completely 
abolished by bortezomib. CRM1 inhibition by KPT-185 up-regula-
ted the expression of proteins involved in apoptosis in NSCLC cell 
lines, and down-regulated the expression of EGFR and survivin. In 
the xenograft H1975 model, tumor growth was significantly inhibi-
ted in KPT-276 oral treatment group compared with vehicle control 
group and EGFR-TKI treatment group (P<0.01), and there was no 
significant loss in body weight or side-effects in KPT-276 treatment 
group.
Conclusion: SINE CRM1 inhibitors showed anti-tumor activity in 
NSCLC both in vitro and in vivo, especially in EGFR-TKI resistance 
cell lines, it could inhibit the growth of NSCLC, arrest cell cycle, 
reduce expression of CRM1 protein, and the anti-tumor activity 
of SINE is mainly through inducing cell apoptosis. SINE is a novel 
CRM1 inhibitor and a promising clinical candidate.
Keywords: CRM1, inhibitor, NSCLC, EGFR
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P2.05-016 THORACOSCOPIC COLOR AND FLUORES-
CENCE IMAGING SYSTEM FOR SENTINEL LYMPH NODE 
MAPPING IN PORCINE LUNG USING INDOCYANINE 
GREEN-NEOMANNOSYL HUMAN SERUM ALBUMIN
Hyun Koo Kim1, Yujin Oh2, Yun-Sang Lee3, Yu Hua Quan1, Yeonho 
Choi2, Jae Min Jeong3, Ji Ho Park4, Beop-Min Kim2
1Thoracic And Cardiovascular Surgery, College Of Medicine, Korea Uni-
versity Guro Hospital/Korea, 2Bio-convergence, Korea University/Korea, 
3Seoul National University Hospital/Korea, 4Korea Advanced Institute 
Of Science And Technology/Korea
Background: This study was performed to validate a newly de-
veloped sentinel lymph node (SLN) targeting tracer, indocyanine 
green–neomannosyl human serum albumin (ICG:MSA), and a 
thoracoscopic version of the intraoperative color and fluorescence 
imaging system (ICFIS) for lung cancer SLN mapping.
Methods: 5 µg/kg ICG concentrations of ICG alone or ICG:MSA 
growth inhibition was determined by cell viability analysis. Cell 
apoptosis was analyzed via annexin V staining and FACS analysis. 
And cytoplasm Ca2+ was measured with Ca2+ indicator dye Fura-2 
AM.
Results: Vin and Pem caused a strong dose-dependent cytoto-
xic effect in both HCC and HCC-res cells. The IC50 values of Vin 
against HCC and HCC-res cells were 10.34 ± 1.12 nM and 9.98 
±2.12 nM, respectively. The IC50 values of Pem against these cells 
were 110.77 ± 17.28 nM and 118.89 ±18.77 nM respectively. The 
application of different therapy schedules induced a significant 
time dependent cell growth inhibition on HCC naïve and cisplatin 
resistant cells. The therapy scheme of Cis→Pem→Vin showed the 
strongest inhibitory effect on both HCC and HCC-res cells. The 
application of different therapy schedules on HCC and HCC-res 
cells increased the percentage of cells undergoing apoptosis, 
except the application of Vin alone. In both HCC and HCC-res 
cells, Cis→Pem→Vin was found the most effective to induce apo-
ptosis. The application of different therapy schedules on HCC and 
HCC-res cells increased [Ca2+]c. Only the application of Vin alone 
failed to increase [Ca2+]c in HCC cells. The most elevated [Ca
2+]c 
was found in the cells treated with Cis→Pem→Vin in both HCC and 
HCC-res cells
Conclusion: We demonstrated that the sequential application of 
Cis, Vin and Pem has a synergistic effect in cell growth inhibition, 
apoptosis induction, and [Ca2+]c elevation in HCC and HCC-res 
cells. The Ca2+ overload could lead to apoptosis, which was related 
to the cell growth inhibitory effect of chemotherapeutics in lung 
cancer cells. It might cast a light to develop chemotherapy sche-
dules for patients, and to overcome cisplatin resistance in lung 
cancer.
Keywords: chemotherapy resistance, cisplatin, vinorelbin, pemet-
rexed
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P2.05-015 A NOVEL CRM1 INHIBITOR TARGETING FOR 
NSCLC WITH EGFR-TKI RESISTANCE MUTATION
Shuai Wang1, Xiaohong Han1, Yuankai Shi1, Michael Wang2, Liang 
Zhang2, Dilara Mccauley3, Michael Kauffman Kauffman3, Sharon 
Shacham Shacham3
1Medical Oncology,Beijing Key Laboratory Of Clinical Study On Anti-
cancer Molecular Targeted Drugs, Department Of Medical Oncology 
Laboratory Cancer Institute/ Hospital Chinese Academy Of Medical 
Sciences(CAMS) & Peking Union Medical College(PUMC)/China, 2De-
partment Of Lymphoma & Myeloma, The University Of Texas M.D. 
Anderson Cancer Center/United States Of America, 3Karyopharm The-
rapeutics Inc./United States Of America
Background: Chromosome Region Maintenance 1 (CRM1) is a nu-
clear exporter which transports certain proteins from the nucleus 
to the cytoplasm, including tumor suppressor proteins (TSPs) and 
other modulators of proliferation. Overexpression of CRM1 corre-
lates with cancer progression in several human cancers, suggesting 
that CRM1 could serve as a novel target for treatment of cancers. 
NSCLC is an aggressive carcinoma which is not yet curable. The 
aim of our study was to explore the therapeutic efficiency of novel 
drug-like CRM1 inhibitors in NSCLC in vitro and in vivo, and to 
investigate the cytotoxic mechanisms of CRM1 inhibitors in NSCLC 
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nM was 60-93% of control growth. Growth inhibition marginally 
correlated with MYC amplification (p=0.044) and was strongly cor-
related with MYC + MYCL1 + MYCN amplification (p=0.011). Apo-
ptosis (20-28%) was induced by 30 nM AZD1152-HQPA at 24-48 
hours in the most sensitive cell lines. Marked increases in DNA plo-
idy (8N) was observed after 24 hour exposure to AZD1152-HQPA 
(30nM) in the most sensitive cell lines and at 48 hours in the 5 in-
termediate lines and in 2 of the resistant lines. In vivo AZD1152 (i.p. 
100 mg/kg/M-F for two weeks) induced tumor regression in nude 
mice implanted with a sensitive cell line. AZD1152 at 50mg/kg/day 
inhibited tumor growth; however these tumors began growing fol-
lowing treatment cessation. A resistant line was also implanted into 
nude mice and AZD1152 at 50 and 100 mg/kg/day caused tumor 
regression. Polyploidy was induced in this cell line at 48 hours post 
30 nM AZD1152-HQPA. Anchorage independent growth in this 
resistant line was also completely inhibited by AZD1152-HQPA 25 
nM. The doses of AZD1152-HQPA used in this study are within the 
range reported to be clinically achievable.
Conclusion: s: AZD1152-HQPA growth inhibition significantly cor-
related with MYC-family amplification in SCLC lines but some SCLC 
lines without MYC-family amplification were also inhibited. Additi-
onal biomarkers are needed to identify SCLC patients most likely 
to respond to AZD1152.
Keyword: SCLC AURKB
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P2.05-018 INTERFERON-Β EFFICIENTLY INHIBITED EN-
DOTHELIAL PROGENITOR CELL-INDUCED TUMOR AN-
GIOGENESIS
Wen Yong Zhou
Department Of Cardiovascular And Thoracic Surgery, East Hospital, 
Tongji University/China
Background: Neovascularization has a critical role in the growth 
and metastatic spread of tumors, and involves recruitment of cir-
culating endothelial progenitor cells (EPCs) from bone marrow. In 
this study, we examined whether EPCs could promote tumor an-
giogenesis, and found that the tumor growth was enhanced by the 
administration of EPCs.
Methods: To test the hypothesis that genetically modified bone 
marrow-derived EPCs can be effective carriers of therapeutic 
agents to tumor sites, we conducted human interferon-beta (Hu-
IFN- b) gene transfection of EPCs with a virus vector in vitro .
Results: When HuIFN-b was applied in the ex vivo culture of EPCs, 
HuIFN- β-transduced EPCs achieved efficient killing of the total po-
pulation of SPC-A1 cells, indicating a bystander effect was elicited 
by HuIFN- b-transduced EPCs in vitro . When SCP-A1 cancer cells 
were coimplanted along with 
ex vivo cultivated EPCs subcutaneous injection in nude mice, the 
tumor growth was increased. However, the anti-tumor effect of 
interferon-beta (IFN- β) offset the tumor-progressive character 
of EPCs and the tumor growth, and the vascular density of tumor 
tissues increased by coimplanted EPCs were decreased upon 
IFN- b treatment. In addition, overall expression levels of vascular 
endothelial growth factor in tumor tissues were decreased upon 
IFN-b treatment.
were injected into rat thigh and the results were compared. The 
fluorescence signal-to-background ratio (SBR) of SLNs were recor-
ded and evaluated over a 2-h period using ICFIS. In addition, a SLN 
biopsy by video-assisted thoracoscopic surgery (VATS) was perfor-
med using ICG:MSA in porcine lung by using thoracoscopic ICFIS.
Results: The newly developed ICG:MSA showed a significantly im-
proved SBR compared to ICG alone throughout the trials. All SLNs 
were identified in both rat (10 SLNs in 10 rat thighs) and pig (10 
SLNs in 10 porcine lungs) under in vivo conditions. All SLNs were 
dissected successfully using VATS with help of thoracoscopic ICFIS.
Conclusion: ICG:MSA is accumulated in the SLN by uptake and re-
tention through the mannose-specific receptors on a macrophage. 
Thoracoscopic ICFIS successfully assisted SLN mapping despite low 
near-infrared (NIR) light transmission in the commercial thoraco-
scope. Based on the results of the thoracoscopic SLN mapping, we 
expect that the ICG:MSA and thoracoscopic ICFIS can be translated 
to clinical trials in the near future.
Keywords: Lung cancer, Sentinel node, Fluorescence, Thoracosco-
py
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P2.05-017 EVALUATION OF THE SELECTIVE AURORA B 
KINASE INHIBITOR AZD1152 IN SCLC LINES WITH AND 
WITHOUT MYC FAMILY AMPLIFICATION.
Barbara Helfrich, Daniel Chan, Zhiyong Zhang, Xian Li, Dexiang 
Gao, Paul A. Bunn
Medical Oncology, University Of Colorado Denver-AMS/United States 
Of America
Background: Small cell lung cancer (SCLC) has an overall 5-year 
survival rate of < 5% despite initial response rates to first line che-
motherapy of 70-90%. MYC family amplification occurs in 30% of 
SCLC and MYC amplified tumors have been shown to be depen-
dent on aurora kinase B for their survival. Aurora B kinase (AURKB) 
is a chromosomal passenger protein that plays a critical role in 
mitosis by regulating chromosome alignment, accurate segrega-
tion, and cytokinesis during the mitotic stages. We evaluated the 
effects of the selective aurora B kinase inhibitor AZD1152-HQPA 
(active drug) in a panel of 15-SCLC lines.
Methods: Nine lines had MYC-family amplification (MYC-5 lines, 
MYCL1-2 lines, MYCN-2 lines) and 6-lines had no MYC-family am-
plification. Growth inhibition by AZD1152-HQPA was assessed by 
tetrazolium based assays. Apoptosis was determined using the 
DNA binding dyes YOPRO and propidium iodine (PI) and analysis 
by flow cytomery. The induction of polyploidy was evaluated by 
flow cytometry following PI staining of the DNA. The effect of 
AZD1152-HQPA on anchorage independent growth was determi-
ned by soft agar colony forming assays. Finally, we evaluated the 
in vivo efficacy of AZD1152 (prodrug) on SCLC xenografts in nude 
mice.
Results: AZD1152-HQPA GI50 values for the 4 most sensitive SCLC 
lines were 11-30 nM and < 25% of untreated control growth was 
observed at 60 nM. Five lines had GI50 values of 30-60 nM but at 
600 nM AZD1152-HQPA cell viability remained at 49-55% of unt-
reated control growth. In the remaining 6-lines cell viability at 600 
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P2.05-020 COMBINED GEMCITABINE AND ANTI-CTLA4 
THERAPY TO TARGET RESIDUAL TUMOUR FOLLOWING 
PARTIAL DEBULKING SURGERY IN A MOUSE MESOTHE-
LIOMA MODEL
Andrea Khong, Joanne Salmons, Richard Lake, Bruce Robinson
School Of Medicine And Pharmacology, The University Of Western Aus-
tralia/Australia
Background: Complete surgical resection of solid malignancies is 
often not achieved due to growth of occult tumour cells, distant 
metastases, or the invasiveness of the tumour mass. Hence there is 
a need for adjuvant therapies that may be administered following 
surgery to target residual tumour. Using a murine mesothelioma 
model we have previously shown that combining gemcitabine 
with anti-CTLA4 is effective at generating an anti-tumour immune 
response, leading to tumour regression and improved survival. We 
sought to use this treatment regimen to improve the post-surgical 
outcome of debulking surgery.
Methods: The murine mesothelioma line generated in our lab, 
AB1-HA, was inoculated subcutaneously into the flanks of Balb/c 
mice. Established tumours (<50mm2) were debulked by surgical 
removal of 75% of the tumour mass. Treatment with gemcitabine 
and anti-CTLA4 were commenced on the day of surgery, and mice 
were monitored for residual tumour outgrowth and survival. Size-
matched controls were treated in parallel.
Results: Dual administration of gemcitabine with anti-CTLA4 was 
effective at causing regression of remaining tumour and improving 
survival following partial debulking surgery, over either therapy 
alone. The outcome of this treatment when administered to de-
bulked tumours was comparable to that achieved against smaller, 
size-matched tumours.
Conclusion: We have shown that larger tumours can be success-
fully partially debulked and the remaining tumour treated using a 
combination of gemcitabine and anti-CLTA4. Thus, combined che-
mo-immunotherapy is a feasible option for post-surgical treatment 
option to remove residual tumours.
Keywords: mesothelioma, debulking surgery, gemcitabine, anti-
CTLA4
Conclusion: Our results suggest that gene-transfected EPCs could 
be useful as a tumor-specific drug delivery system.
Keywords: IFN-β, EPCs, VEGF
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P2.05-019 THERAPEUTIC EFFICACY OF DNA VACCINE 
BY TARGETING THE MUTANT KRAS IN KRASG12D-IN-
DUCED LUNG CANCER MODEL
Meng-Chi Yen, Tzu-Yang Weng, Chun-Tzu Huang, Ming-Derg Lai
Department Of Biochemistry And Molecular Biology, College Of Medici-
ne, National Cheng Kung University/Taiwan
Background: Mutant Kras was observed in more than 20% of non-
small cells lung cancers (NSCLC) and represented one of the most 
dominant oncogene during cancer progression. However, there 
were fewer effective inhibitors which specific targeting of mutant 
Kras in clinical trials. The immunotherapeutic effects of Kras DNA 
vaccine in lung cancer were not well understood.
Methods: In this study, we investigated anti-tumor efficacy of mu-
tant Kras DNA vaccine in spontaneous mouse lung tumor model 
driven by KrasG12D. TetO-KrasG12D and Scgb1a1-rtTA bitransgenic 
mice were treated with doxycycline to induce lung tumor for 5 
months. To evaluate therapeutic effects of Kras DNA vaccine, bit-
ransgenic mice with lung tumor were treated with wild-type Kras or 
mutant KrasG12D plasmids by skin administration.
Results: In this model, we found that skin administration of mutant 
Kras DNA vaccine had better therapeutic effects compared to 
control group. Additionally, dominant negative Kras (N17) DNA 
vaccine significantly decreased tumor nodules on lung in trans-
genic mice expressed mutant Kras. Th-1 immune response was 
dramatically enhanced in vaccine-treated mice compared with in 
control mice.
Conclusion: Overall, our results indicated that Kras DNA vaccine 
produced an effective anti-tumor response. Furthermore, skin 
administration of Kras DNA vaccine is effective as a potential ap-
proach for lung cancer therapy.
Keyword: KRAS, DNA vaccine, immunotherapy
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P2.05-022 THERAPEUTIC POTENTIAL OF THE FGFR TY-
ROSINE KINASE INHIBITOR, AZD4547 IN SQUAMOUS 
NON-SMALL CELL LUNG CANCER
Paul Gavine1, Neil Smith2, Dawn Baker2, Claire Rooney2, Sylvie 
Guichard3, Christopher Denz3, Brian Dougherty3, Jingchuan 
Zhang1, Lin Zhang1, Xinying Su1, Ming Li1, Shuqiong Fan1, Xiaolu 
Yin1, Yanping Xu1, Kunji Liu1, Zhenwei Dong1, Guanshan Zhu1, 
David Ferry4, Paul Stockman2, Nigel Brooks2, Elaine Kilgour2, Paul 
D. Smith2
1Icc, Astrazeneca/China, 2Oncology Imed, Astrazeneca/United King-
dom, 3Oncology Imed, Astrazeneca/United States Of America, 4New 
Cross Hospital/United Kingdom
Background: As a result of the recent deep molecular profiling of 
NSCLC samples, FGF receptor inhibition has emerged as a pro-
mising strategy for targeting a sub-set of squamous NSCLC (Sq 
NSCLC) tumours that carry FGFR gene amplifications, mutations 
and fusions. AZD4547 is a potent, orally available and selective 
inhibitor of FGFR 1, 2 and 3 and is currently in phase II clinical de-
velopment.
Methods: not applicable
Results: In pre-clinical patient derived models of FGFR1 amplified 
Sq NSCLC, AZD4547 is able to induce dose dependent tumour 
growth inhibition and tumour regression and this is correlated to 
FGFR1 protein expression and inhibition of signalling pathways 
downstream of FGFR1. Since the FGFR2 mutations described in Sq 
NSCLC do not present as clear codon hot-spots we also investiga-
ted a sub-set of the FGFR2 mutations using inducible expression 
in non-transformed cells. We found these mutations to be cons-
titutively active and capable of inducing 3D colony formation in 
non-transformed cells. Both FGFR signalling and 3D colony growth 
were inhibited potently by AZD4547 treatment. We have develo-
ped a number of biomarker assays that enable both patient selec-
tion and exploratory analysis of patient samples. We found that 
FGFR1 gene amplified samples are enriched for those expressing 
both FGFR1 mRNA and protein. AZD4547 is currently being tes-
ted as a monotherapy in Sq NSCLC patients whose tumours carry 
FGFR1 amplification and we will describe preliminary observations 
from this trial including a comprehensive molecular profile of the 
tumour from a patient who experienced a durable partial response 
following AZD4547 treatment.
Conclusion: In view of the strong and emerging platform of evi-
dence that implicates dis-regulated FGFR signalling in Sq NSCLC 
and the early evidence of clinical activity, FGFR inhibition warrants 
continued clinical investigation in patients whose tumours carry 
FGFR genetic lesions including amplification, mutation and gene 
fusions.
Keywords: FGFR inhibitor, AZD4547, squamous, NSCLC, FGFR, 
AZD4547, squamous
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P2.05-021 MOLECULAR ANALYSIS OF ASBESTOS-INDU-
CED MESOTHELIOMAS FROM SV40 TAG TRANSGENIC 
MICE SHOWS THAT THEY ARE HIGHLY CONCORDANT 
WITH HUMAN MESOTHELIOMA
Cleo Robinson1, Ian Dick1, Michael Wise2, Bruce Robinson1, Ri-
chard Lake1
1University Of Western Australia, National Centre For Asbestos Related 
Diseases/Australia, 2University Of Western Australia/Australia
Background: Asbestos-induced mesothelioma in MexTAg trans-
genic mice closely resembles the key features of human disease. 
This model is highly suited to testing new chemotherapies and 
cancer prevention strategies. The resultant mesothelioma res-
ponds to cytotoxic chemotherapy with efficacy of the same order 
of responsiveness as human mesothelioma. The transgene, large T 
Antigen is an oncogene encoded by Simian Virus 40, and the role 
of this viral oncogene in tumourigenesis has been widely studied. 
Here we investigate the gene expression differences between TAg 
tumours and wild type tumours and examine overall similarity to 
human mesothelioma at the molecular level.
Methods: not applicable
Results: We found TAg expressing mouse tumours were 90% 
identical to wild type mouse tumours. The key pathway that was 
affected by these gene differences was cell cycle. Gene set enrich-
ment analysis showed that the TAg:wild type tumour differences 
were homolgous to the Rb null genotype in a TAg dose dependent 
manner. To address whether transgenic mouse tumours were a 
good representation of human mesothelioma when compared to 
wild type mouse tumours, we showed that of genes differentially 
expressed between i) TAg or ii) wild type mouse tumours and 
mouse mesothelial cells, there were the same number of gene 
similarities with the set of genes that differentiate between human 
mesothelioma and human mesothelial cells. Human mesothelio-
mas commonly have a deletion of the cdkN2 locus, encoding the 
tumour suppressor genes p16 and p15. We found that while wild 
type mouse tumours contained the p16 deletion, TAg tumours did 
not.
Conclusion: In summary, the asbestos-induced mesotheliomas 
in MexTAg mice are comparable to human mesothelioma at the 
molecular level. We hypothesize that TAg expressing mice deve-
lop tumours in a more uniform way than wild type mice following 
asbestos exposure and are not dependent on deletion of p16 for 
tumourigenesis.
Keyword: mesothelioma, animal model, molecular analysis
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Conclusion: Early in vivo micro-imaging of apoptosis using FCFM 
makes it possible to differentiate sensitive from resistant tumors to 
Erlotinib in a murine xenograft model of human lung adenocarci-
noma.
Keyword: Apoptosis, In-vivo imaging, EGFR-TKI resistance
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P2.05-024 PREDICTION OF DRUG SENSITIVITY IN SE-
COND LINE TREATMENT OF PATIENTS WITH MALIG-
NANT PLEURAL MESOTHELIOMA
Josine M. Quispel-Janssen1, Laurel Schunselaar2, Wieneke Buik-
huisen1, Michel Van Den Heuvel1, Sjaak Burgers1, Jacques Neefjes2, 
Paul Baas1
1Thoracic Oncology, NKI-Antoni Van Leeuwenhoek/Netherlands, 2Cell 
Biology, NKI-AVL/Netherlands
Background: In second line setting there is no standard treatment 
for patients with mesothelioma, since all agents tested in clinical 
trials failed to improve survival. An individual patient however, 
may actually benefit from second line treatment, considering the 
patient population is heterogeneous. Yet, there are no predictive 
markers to identify those patients likely to respond to a certain 
drug. We developed protocols for in vitro drug sensitivity testing 
with several cytotoxic agents using primary tumor cells derived 
from pleural fluid of our patients. Recently, we implemented a 
personalized second line treatment protocol. Here we will report 
the outcome of the pilot study.
Methods: Cells were isolated from pleural fluid, drawn from pa-
tients with mesothelioma for symptom relief. Diagnosis of each 
mesothelioma patient was confirmed by regular pathological 
staining. Cells were plated and incubated with a five point concen-
tration range of 5 single drugs and 2 two-drug combinations for 
72 hours. Cell viability was determined by a metabolic assay. Each 
concentration point was measured in triplo and a biological duplo 
experiment was performed to check reproducibility. The drugs 
used in this screen were all previously tested in clinical mesothe-
lioma trials. Patients with pleural fluid that were fit and progressed 
after standard first line treatment were considered for second line 
chemotherapy. Choice of second line treatment was based on 
screening results.
Results: Thirty-nine mesothelioma patients had pleural fluid drawn 
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P2.05-023 IN VIVO MICRO-IMAGING OF APOPTOSIS 
IN A MURINE XENOGRAFT MODEL OF HUMAN LUNG 
ADENOCARCINOMA
Florian Guisier1, Mathieu Salaun1, Pierre Bohn2, Marie Cornic3, 
Jean-Michel Picquenot3, Pierre Vera2, Luc Thiberville1
1Clinique Pneumologique, Chu De Rouen/France, 2Service De Médecine 
Nucléaire, CLCC Henri Becquerel/France, 3Service D‘Anatomie Et Cyto-
logie Pathologiques, CLCC Henri Becquerle/France
Background: Resistance to apoptosis is a hallmark of cancer that 
can be reversed by several chemotherapy drugs and targeted 
therapies, including cisplatin and erlotinib. In vivo imaging of apo-
ptosis would be of great interest to study molecular mechanisms of 
drug activity and resistance. The aim of this study is to investigate 
whether in vivo micro-imaging of apoptosis could be used for early 
assessment of treatment response in a murine xenograft model of 
human lung cancer.
Methods: A549 (EGFR wild type), H1650 (carrying EGFR exon 19 
deletion that confers sensitivity to Erlotinib) and H1975 (carrying 
EGFR mutations L858R and T790M, resistant to Erlotinib) cell lines 
were used to induce subcutaneous tumors in Nude mice. In vivo 
micro-imaging of apoptosis was performed using fibered confocal 
fluorescence microscopy (FCFM) after intra-venous injection of a 
fluorogenic caspase 3 substrate. Tumors were treated by cisplatin 
(10mg/kg) (5 mice, A549 xenografts), erlotinib (25mg/kg) (6 mice, 
2 A549, 2 H1650, 2 H1975), or vehicle (6 mice, 2 A549, 2 H1650, 2 
H1975).
Results: In A549 xenografts treated by cisplatin, apoptosis was 
detected in vivo at 24h post-treatment. Fluorescence intensity ratio 
(FIR) was significantly higher than in untreated tumors (16.9+/-3.1 
vs 4.8+/-2.1 respectively, p<0.001). 24h after treatment by erloti-
nib, FIR in H1650 erlotinib sensitive tumors was significantly higher 
than in A549 tumors, and than in H1975 erlotinib resistant tumors 
(12.2+/-2.4 vs 6.1+/-1.2 vs 1.9+/-0.7 respectively, p<0.01, Figures 1 
and 2). Results were confirmed ex vivo on harvested tumor xeno-
grafts by TUNEL assay and immunohistochemistry for activated 
caspase 3, and on cell lines in vitro by flow cytometry and fluores-
cence microscopy. 
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NSCLC cells, through receptor-mediated endocytosis. Accumulati-
on of peptide-conjugated liposomal doxorubicin (SP-LD) in tumor 
tissues was 11.2-fold higher than that of free doxorubicin, and the 
area under the concentration-time curve (AUC0-72 hours) was 
increased 159.2-fold. Furthermore, SP-LD enhanced therapeutic 
efficacy and increased the survival rate of tumor-bearing mice in 
syngenic, metastatic and orthotopic animal models.
Conclusion: The current study suggests that tumor-specific pep-
tides may be used to create chemotherapies specifically targeting 
tumor cells in the treatment of NSCLC. The use of lung cancer 
targeting peptide-conjugated liposomes enhances pharmacokine-
tic properties, improves efficacy and safety profiles, and allows for 
controlled biodistribution and drug release.
Keywords: non-small cell lung cancer, phage display, targeting 
liposome, drug delivery
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P2.05-026 A DEVELOPMENT DRUG CANDIDATE TARGE-
TING EGFR KINASE FOR LUNG CANCER: DBPR112
Hsing-Pang Hsieh, Hui-Yi Shiao, Chiung-Tong Chen, Teng-Kuang 
Yeh
National Health Research Institutes, Institute Of Biotechnology And 
Pharmaceutical Research/Taiwan
Background: Lung cancer is the major cause of cancer death in the 
world while non small cell lung cancer (NSCLC) accounts approxi-
mately 85% of all lung cancer diagnosis. EGFR mutations, found in 
10–30% of patients with NSCLC characterize a subpopulation with 
exquisite sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs). 
However, the clinical benefits of first-generation TKIs (like gefitinib 
or erlotinib) can be further improved because of the development 
of drug-acquired resistance within 10–14 months in patients who 
initially respond to the treatment. Therefore, there is a need to dis-
cover next generation medicines as EGFR-TKIs for NSCLC patients.
Methods: Our EGFR program was first started to screen 20,000 
in-house compounds for EGFR (wild type, 32D- EGFRWild-Type) 
activity in EGFR-transfected 32D cells and further performed 
knowledge-based design. More than 300 analogues were synthe-
sized in this series and US and ROC patents were granted in 2013 
and PCT patent application is under examination. We had iden-
tified DBPR112 as a potent EGFR-TKI with oral in vivo activity in a 
mouse model for lung adenocarcinoma.
Results: DBPR112 showed IC50 of 2 nM in HCC827 cells and po-
tent EGFRWild-Type (IC50: 10 nM) and EGFRL858R/T790M (IC50: 
70 nM) kinase inhibition which are better than gefitinib and similar 
to that of BIBW2992 (Afatinib, developed by Boehringer Ingelheim) 
that is currently under phase III clinical trial. DBPR112 was orally (F 
= 49%) administered against the growth of human lung HCC827 
tumors subcutaneously xenografted in nude mice. A dramatic 
reduction of the tumor size was noted in the tumors treated with 
DBPR112 without significant loss of body weights in the nude mice. 
In addition, the pharmacokinetics properties of DBPR112 are supe-
rior to those of Afatinib.
Conclusion: Considering the fact that EGFR kinase plays an impor-
tant role in lung adenocarcinoma with drug-sensitive mutations in 
for culture of primary tumor cells and subsequent drug sensitivity 
screening. Drug screens were successful in 22 patients (56%). Drug 
sensitivity profiles were available within two weeks after isolation 
of tumor cells, which is appropriate for clinical decision making. 
Agents tested for were cisplatin or carboplatin, pemetrexed, gem-
citabine, vinorelbine, oxaliplatin, a combination of cisplatin and 
pemetrexed and of oxaliplatin and gemcitabine. Individual dose-
response curves showed different sensitivity to the various cytoto-
xic agents. Ten patients were chemo-naive at the time of the drug 
sensitivity screen. Five of them received first line chemotherapy 
(cisplatin and pemetrexed). Two of them had progressive disease. 
Both demonstrated evident resistance to cisplatin and pemetrexed 
in their drug sensitivity profile. Four patients received second line 
treatment based on the drug sensitivity profile of their primary 
tumor cells. To date, treatment response is evaluated for two 
patients. Both patients received a combination of oxaliplatin and 
vinorelbine. The first patient had a clinical response. For the se-
cond patient, oxaliplatin/vinorelbine was the best option, although 
her in vitro profile suggested a rather resistant tumor. She was 
progressive and showed an unusual large amount of necrosis on 
repeated CT imaging. Patient three and four are currently treated 
with oxaliplatin and gemcitabine and gemcitabine monotherapy, 
respectively. Their treatment responses have to be awaited.
Conclusion: Personalized drug screening using primary tumor cells 
is feasible within a clinically relevant time period and may yield 
new treatment combinations with better responses.
Keywords: primary tumor cells, mesothelioma, personalized  
treatment
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P2.05-025 PEPTIDE-MEDIATED LIPOSOMAL DOXORU-
BICIN ENHANCES DRUG DELIVERY EFFICIENCY AND 
THERAPEUTIC EFFICACY IN LUNG CANCER ANIMAL 
MODELS
Han-Chung Wu1, De-Kuan Chang1, Pi-Chun Li1, Hsing-Pang Hsieh2
1Institute Of Cellular And Organismic Biology/Taiwan, 2National Health 
Research Institutes, Institute Of Biotechnology And Pharmaceutical 
Research/Taiwan
Background: Lung cancer ranks among the most commonly occur-
ring malignancies, and is the leading cause of cancer-related mor-
tality worldwide. Chemotherapy for lung cancer can be made more 
specific to tumor cells, and less toxic to normal tissues, through the 
use of ligand-mediated drug delivery systems.
Methods: For the screening of targeting peptides, a phage-
displayed peptide library underwent affinity selection with lung 
cancer cells. Targeting phage clones were selected by ELISA, 
immunofluorescence, flow cytometry and an in vivo homing as-
says. Targeting peptides can be used to develop ligand-mediated 
targeted therapy or targeting imaging probe. For preclinical study, 
we evaluated therapeutic efficacy of targeting liposomes using 
xenograft, orthotopic- and metastatic-tumor animal models
Results: In this study, we investigated the targeting mechanism 
of the ligand-mediated drug delivery system using lung cancer 
targeting peptides. Conjugation of lung cancer targeting peptides 
to liposomes enhanced the amount of drug delivered directly into 
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P2.06-001 INTRODUCING A NOVEL RT-PCR ASSAY FOR 
THE DETECTION OF ROS1 FUSION GENES IN NSCLC
Martin K. Maus1, Melinda S. Epstein2, Stephanie H. Astrow2, Jack 
H. Hsiang2, Craig L. Stephens2
1Department Of General, Visceral And Tumor Surgery, University Of 
Cologne/Germany, 2Research And Development, Response Genetics 
Inc./United States Of America
Background: ROS1 is a receptor tyrosine kinase that regulates 
pathway signaling related to cell proliferation, growth and survi-
val. Chromosomal rearrangements involving ROS1 have recently 
been identified as potential driver mutations in non-small-cell 
lung cancers (NSCLC) and preclinical and clinical studies indicate 
a significant response to crizotinib in tumor cells harboring this 
mutation. We developed an RT-PCR assay for all ROS1 fusion gene 
transcripts described in NSCLC to date which is suitable for use 
with FFPE tissue.
Methods: Primers and probes have been specifically designed 
to detect 14 known fusion transcripts from seven different fusion 
partners with the ROS1 gene using six multiplexed reactions. The-
se fusion gene pairs include: CD74-ROS1, SLC34A2-ROS1, GOPC 
(FIG)-ROS1, SDC4-ROS1, EZR-ROS1, TPM3-ROS1, and LRIG3-ROS1. 
The 14 different ROS1 fusion products were represented by speci-
fically designed and manufactured pCR 2.1-TOPO and pZErO 2.1 
plasmids. After screening and identifying ROS1 rearrangements in 
clinical samples, the specific variants were further differentiated by 
gel electrophoresis and sequencing.
Results: All 14 ROS1 fusion genes could be detected using this 
RT-PCR assay. We screened 578 FFPE lung cancer samples that 
were negative for EGFR, KRAS and ALK mutations and detected 
12 ROS1 rearrangements in this cohort (2.08%). All positive tu-
mors were adenocarcinomas of the lung, 75% of the patients were 
female and median age was 53 years. The ROS1 rearrangements 
that were identified are: SLC34A2 (Exon 13)-ROS1 (Exon 32 and 
34), CD74 (Exon 6)-ROS1 (Exon 34), EZR (Exon 10)-ROS1 (Exon 34) 
and SDC4 (Exon 2)-ROS1 (Exon 32). Messenger RNA expression of 
ROS1 was significantly higher in ROS1 positive samples than wild-
type samples (median 5.2 vs.1.0; p<0.001). An inter-assay compa-
rison of 31 samples containing four ROS1 positives using RT-PCR 
and FISH showed 100% concordance.
Conclusion: The clinical relevance of ROS1 testing in NSCLC and 
potentially other solid tumors as a predictive biomarker for sensiti-
vity to crizotinib is rapidly increasing. We developed a multiplexed 
RT-PCR assay that enables the detection of ROS1 fusion genes 
using FFPE tissue and provide a rapid and cost effective screening 
tool.
Keyword: ROS1-rearrangement, Lung Cancer, crizotinib
EGFR, our goal is to develop novel and potent EGFR kinase inhi-
bitors for the treatment of lung cancer, either as a single agent or 
in combination with existing cancer treatment. DBPR112 is a highly 
potent small-molecule against various forms of EGFR kinase. The 
non-clinical profile of DBPR112 showed promising in vivo efficacy. 
We, therefore, propose to design a preclinical program to assess 
the developability of DBPR112 and conduct comprehensive pre-
clinical studies. We hope to make DBPR112 an investigational new 
drug for the treatment of lung cancer in the near future.
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P2.05-027 GENERATION AND BIOLOGICAL CHARACTER 
ANALYSIS OF EGFR-TKI RESISTANT CELL LINE
Yuankai Shi, Xiaohong Han, Ningning Zhang, Li Ma, Dan Tao, 
Yinchen Shen, Jianfei Wang
Medical Oncology, Beijing Key Laboratory Of Clinical Study On Antican-
cer Molecular Targeted Drugs, Cancer Institute/Hospital, Chinese Aca-
demy Of Medical Sciences & Peking Union Medical College/China
Background: Patients with non-small cell lung cancer (NSCLC) who 
have activating epidermal growth factor receptor (EGFR) mutations 
derive remarkable benefit from treatment with EGFR-tyrosine kinase 
inhibitors (EGFR-TKIs). But drug-resistant problem appears sequenti-
ally and novel therapeutic strategies should be explored to overcome 
EGFR-TKI resistance. As the first EGFR-TKI in China and the third in 
world, icotinib shows good efficacy and tolerability in patients with 
advanced NSCLC. This study aims to establish icotinib resistant cell 
line-HCC827/IR and analyze it’s biological character for further study 
of EGFR-TKIs resistance.
Methods: HCC827 is a cell line with a deletion in the exon 19 of EGFR 
gene. HCC827 cells were exposed to increasing concentrations of ico-
tinib (10nM to 20uM). Cells with the ability to grow in 20uM of icotinib 
were obtained 8 months after the initial drug exposure. The cell proli-
feration, viability, distribution of cell cycle, EGFR gene sequence (exon 
18, 19, 20 and 21), EGFR-TKIs cross-resistance and the response to 
a histone deacetylases inhibitor (Chidamide, CS055) were evaluated 
after allowing the cells to grow in drug-free conditions for 2 months.
Results: Population doubling time (PDT) of HCC827/IR was not diffe-
rent from HCC827 (32.3±6.0h vs. 36.3±2.4h, P=0.198). In the cell cycle 
distributions of HCC827/IR, the cell number in G0/G1 phase were de-
creased (P=0.035), but the cell number in S and G2/M phase had no 
significant change compared with parent cells (P=0.388 and P=0.205, 
respectively). The resistance index (RI=HCC827IRIC50/ HCC827IC50) of 
HCC827/IR to icotinib was (1.98±0.15)×103. And HCC827/IR cells also 
showed high resistance to the other two EGFR-TKIs (gefitinib and 
erlotinib), the RI of gefitinib and erlotinib was (2.36±0.082)×103 and 
(1.069±0.004)×103, respectively. But, the sequence of EGFR gene did 
not changed before and after resistance to EGFR-TKIs. In addition, 
HCC827/IR was sensitive to CS055 (IC50=254±32nM).
Conclusion: This study successfully established icotinib resistant 
NSCLC cell line-HCC827/IR. HCC827/IR cells had some different bio-
logical characters compared with parent cells and showed high cross-
resistance to other EGFR-TKIs, but it was sensitive to CS055. The 
results could provide experimental reference for clinical application of 
TKIs and provide cell line model for further study of TKI-resistance.
Keywords: Icotinib, EGFR-TKIs, non-small cell lung cancer, HCC827/IR
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P2.06-003 CLINICAL SIGNIFICANCE OF DETECTION OF 
EGFR AND KRAS MUTATIONS IN PLASMA/PLEURAL EF-
FUSION IN PATIENTS WITH ADVANCED NSCLC
Zhengtang Chen, Jie Sun, Hua Ming, Jianguo Sun, Xinxin Wang, 
Lina Peng
Xinqiao Hospital Of Third Military Medical University, Institute Of 
Cancer/China
Background: In this study, we attempted to detect EGFR and 
KRAS mutations in plasma/pleural effusion of patients with advan-
ced NSCLC by pyrosequencing, to investigate whether plasma and 
pleural effusion DNA could be used as a substitute for tumor tis-
sues for detecting gene mutations, and to explore the correlation 
of EGFR/KRAS mutations with the efficacy of the epithelial growth 
factor receptor-tyrosine kinase inhihitor (EGFR-TKI) as well as their 
correlation with survival in TKI-treated patients.
Methods: Blood, pleural effusion and tumor tissues were obtained 
from 146, 64 and 63 patients with advanced NSCLC, of whom the-
re were 40 matched tissue and plasma samples, 24 matched tissue 
and pleural effusion samples. The exons 19, 20 and 21 of EGFR was 
amplified by mutant-enriched PCR using selective restriction en-
zyme digestion, and exon 2 of KRAS in plasma were amplified by 
nested-PCR. Then mutations were detected by pyrosequencing. 
The association between mutations and the patients’ survival was 
analyzed using Kaplan-Meier.
Results: EGFR mutations were detected in 34.38% tissues (22/64), 
24.24% plasma samples (24/96) and 30.16% pleural effusion samp-
les(19/63). KRAS mutations were detected in 4.69% tissues (3/64), 
6.16% plasma samples (9/146) and 7.93% pleural effusion samples. 
No statistical significance was found in EGFR/KRAS mutations 
between plasma/pleural effusion and tumor tissues (p>0.05). The 
same EGFR genes were observed in plasma and matched tissue 
in 34 patients (consistency: 85%).The sensitivity of detecting EGFR 
mutations is 73.33% and the specificity is 92 %.There was only 1 
KRAS mutation detected in the 40 tissues , but no mutation in the 
matched plasma (consistency: 97.5%). Same EGFR/KRAS genes 
were observed in 21, 23 pleural effusion and matched tissue res-
pectively (consistency: 87.5%, 95,83%). The sensitivity of detection 
of EGFR/KRAS mutations is 77.78% and 66.67%. The specificity is 
93.33 % and 100%. Significant correlation existed between EGFR 
mutations in tumor tissue/pleural effusion from patients with ad-
vanced NSCLC, and a smoking history, and histopathologic type 
(p<0.05). Among the 38 TKI-treated patients, the disease control 
rate (DCR) and objective response rate (ORR) were 90% and 60%, 
respectively, in patients with EGFR mutation in plasma, and 53.57% 
and 17.86%, respectively, in patients with wide-type EGFR (DCR, 
p=0.059; ORR, p=0.019).The DCR and ORR were 66.67% and 
33.33%, respectively, in patients with wide-type KRAS in plasma, 
and 40% and 0%, respectively, in patients with KRAS mutation. 
Patients with EGFR activating mutations in plasma had a favoring 
median PFS of 10.5 months, significantly longer than the patients 
with wild-type EGFR (5.0 months) (p=0.228). The median PFS was 
2.5 months for patients with KRAS mutation and 9 months for pati-
ents with wild-type KRAS, respectively (p=0.000).
Conclusion: A high consistency exists between EGFR/KRAS mu-
tation detection in plasma/pleural effusion and tumor tissues. 
Plasma/pleural effusion could be used as a substitute for tumor 
tissues for detecting gene mutations. EGFR and KRAS mutations 
in plasma are highly associated with the treatment response and 
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P2.06-002 PROTEIN TYROSINE KINASE SUBSTRATES 
PROFILING TO DETECT SHORT-TERM SURVIVORS IN 
EARLY STAGE LUNG ADENOCARCINOMA
Stephan Arni1, Nhung Le1, Rik De Wijn2, Martjin Dankers2, Walter 
Weder1, Sven Hillinger1
1Thoracic Surgery, University Hospital Zuerich/Switzerland, 2Pamgene/
Netherlands
Background: With existing therapeutic efforts, patients with lung 
cancer have a poor prognosis. Assessment of tumor size, lymph 
node status and presence of metastases is currently applied for 
determining prognosis and treatment modality, but predicted and 
real outcomes can vary significantly. Biomarkers with reliable pro-
gnostic significance are therefore of utmost importance but due 
to a lack of immediate correlation between levels of protein and 
their corresponding mRNA, a screen based on the kinase activity 
become a promising option to circumvent this limitation with the 
tremendeous advantage of focusing on therapeutically targetab-
le enzymatic activities. Several protein tyrosine kinase inhibitors 
already clinically approved for the treatment of lung cancer are 
targeting some of the 400 types of DNA signatures described in 
silico in the human genome. The aim of this study is to clarify the 
following hypothesis: Is the in vitro multiplexed tyrosine phospho-
rylation of substrates a possible approach to molecularly classify 
the kinome of early stage lung adenocarcinoma biopsies and ob-
tain a diagnostic /prognostic signature correlating with the survival 
of patients?
Methods: We have built a tumor bank of frozen malignant and 
non-neoplastic lung surgically obtained specimen and recorded all 
clinical interventions, follow up treatments and outcome for each 
of our patients. We incubated TNM stage 1 and 2 lung adenocarci-
noma kinomes on PamChip®4 microarrays and followed the kine-
tics of the multiplexed tyrosine phosphorylation for 144 peptides 
substrates. Image quantification, quality control, statistical analysis 
and interpretation of data were performed with the BionavigatoR 
software.
Results: We screened 84 paired malignant TNM stage 1 and 2 
lung adenocarcinoma and non-neoplastic lung biopsies for the 
multiplex tyrosine phosphorylation of substrates immobilized on a 
PamChip®4microarrays. Based on a 76-point ‘response-signature’ 
we obtained 73 % of correct prediction with a 10 fold cross valida-
tion PLS-DA analysis in TNM stage 1 lung adenocarcinoma biop-
sies. Moreover, we detected 26 peptides substrates significantly 
more inhibited in kinomes of long-term survivors than in kinomes 
of the short-term survivors.
Conclusion: In frozen biopsies of TNM stage I adenocarcinoma 
and with a PLS-DA analysis applied to a 76-point ‘response-signa-
ture’ we present the feasibility to discriminate between long-term 
and short-term survivors. Furthermore, the found differences in 
enzymatic activities in lung biopsies may result in the identification 
of new targets in future anti lung cancer therapy efforts.
Keywords: protein tyrosine kinase, Lung cancer, proteomics, prog-
nostic biomarker
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stage: 0% (0/13), 13.8% (4/29),28.6% (6/21) and 52.9% (9/17) for 
stages I, II, IIIA and IIIB-IV, respectively (I-II vs. IIIB-IV, p<0.001). In 
patients with SCC aged 65 years or older the serum MUC1/ICO25 
³60 U/ml was found in 0% (0/19), 30.0% (3/10), 7.7% (1/13) and 0% 
(0/14) of cases for stages I, II, IIIA and IIIB-IV, respectively. In the 
entire group of patients the rate of the serum MUC1/ICO25 ³60 U/
ml did not depend on the tumor histological grade, local tumor 
extension, location of distant metastases or comorbidities.  
Conclusion: The abnormal MUC1/ICO25 serum levels correlate 
with unfavorable prognostic clinical characteristics of the lung 
cancer, and its potential clinical significance is not restricted to the 
cases of lung adenocarcinoma.
Keyword: lung cancer, MUC1 serum level, prognosis
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P2.06-005 THE HIGH INCIDENCE OF OVERLAP BET-
WEEN ACTIONABLE BIOMARKERS IN NSCLC: POTENTI-
AL IMPACT ON FUTURE CLINICAL TRIAL DESIGN
David S. Shames1, Yuanyuan Xiao2, Younjeong Choi2, Luisa M. 
Solis3, Carmen Behrens4, Franklin Peale5, Hartmut Koeppen2, Ron 
Firestein2, Howard Stern6, Yulei Wang2, Marcin Kowanetz2, Mark 
Lackner2, Simonetta Mocci2, Robert L. Yauch2, Garret Hampton2, 
Theresa Boyle7, Manolo D’Arcangelo7, Fred R. Hirsch8, Christopher 
J. Bowden2, Lukas C. Amler2, Ignacio I. Wistuba4
1Oncology Biomarker Development, Genentech, Inc./United States Of 
America, 2Genentech, Inc./United States Of America, 3University Of 
San Francisco Xavier/Bolivia, 4The University Of Texas MD Anderson 
Cancer Center/United States Of America, 5Pathology, Genentech, Inc./
United States Of America, 6Infinity Pharmaceuticals/United States Of 
America, 7University Of Colorado/United States Of America, 8Universi-
ty Of Colorado Cancer Center/United States Of America
Background: Recent advances in molecular profiling of non-
small cell lung cancer (NSCLC) have led to the replacement of 
platinum-based chemotherapy with targeted therapies for certain 
genetic subsets of NSCLC (ALK rearrangements, some EGFR 
activating mutations). It is also known that myriad pathways can 
drive resistance, the unfortunate norm for most patients. A greater 
understanding of the overlap across multiple biomarker subsets, 
including activating mutations, signal transduction pathways, and 
immune system markers, might aid in prognostic assessment, pre-
dictive biomarker development and the design of combination or 
sequential treatment regimens.
Methods: The prevalence and prognostic significance of nine bio-
markers (TTF1, p63, EGFR mutation, KRAS mutation, MET immuno-
histochemistry [IHC], PDL1 IHC, PTEN IHC, NaPi2B IHC, ECDH IHC) 
across two independent sample sets (Set 1, n=561; Set 2, n=300) 
were tested. With the exception of ECDH, all assays were IVD or 
companion diagnostics. Set 1 was collected from patients who 
were eligible for surgery with curative intent from 2003–2005 at 
MD Anderson Cancer Center in the USA. Samples from Set 2 were 
part of a collaboration between the University of Colorado Cancer 
Center, USA and The Norwegian Radium Hospital, and contained 
surgically-resected NSCLC tissues collected from 2006–2011.
Results: The prevalence of each biomarker varied significantly by 
histology. For adenocarcinoma samples, the prevalence of each 
prognosis of TKI-treated patients. It is feasible to detect EGFR and 
KRAS mutations in plasma/pleural effusion by pyrosequencing. 
The detection sensibility of EGFR mutations can be increased by 
ME-PCR, facilitating choosing patients for TKI treatment.
Keywords: NSCLC, EGFR/KRAS mutation, tyrosine kinase inhibi-
tor, pyrosequencing
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P2.06-004 SERUM LEVELS OF MUC1 GLYCOPROTEIN 
(ICO25) IN PRIMARY LUNG CANCER PATIENTS
Tatyana Karmakova1, Valentin Scripnik1, Raisa Yakubovskaya1, 
Oleg Pikin2, Ali Amiraliev2, Dmitriy Vursol2, Mariya Vorontsova1
1Immunology Laboratory, P.a.hertzen Research Institute Of Oncology/
Russian Federation, 2Thoracic Surgery, P.A.Hertzen Research Institute 
Of Oncology/Russian Federation
Background: The elevated serum level of MUC1 (KL-6, CA15.3) in 
lung cancer patients is considered to be a marker for advanced 
adenocarcinoma and a prognostic factor for disease progression 
after treatment. The aim of this study was to evaluate the serum 
MUC1 levels in primary lung cancer patients in the Russian Federa-
tion, a large portion of which are patients with squamous cell lung 
cancer (SCC).
Methods: Serum samples were obtained from 346 patients at ad-
mission. Two hundred ninety three patients were diagnosed with a 
malignant lung tumor (MLT), i.e. SCC (n=136); adenocarcinoma, AC 
(n=89); adenosquamous cancer, ASqC (n=21); bronchioloalveolar 
carcinoma, BAC (n=12); large cell carcinoma, LCC (n=3); small cell 
cancer (n=4); anaplastic cancer (n=8); carcinoid (n=17); sarcoma 
(n=3). A non-malignant lung disease (NMLD) was confirmed his-
tologically in 53 patients: benign tumors (n=10), pneumofibrosis 
(n=13), tuberculosis (n=9), a resolution stage of pneumonia (n=21). 
Anti-MUC1 ICO25 monoclonal antibody-based and validated 
inhibition enzyme-linked immunosorbent assay was used (normal 
range 9 - 38 U/ml, median 24 U/ml).  
Results: An occurrence of the elevated serum MUC1/ICO25 levels 
(³40 U/ml) 
in patients with MLTs was significantly higher than in patients with 
NMLDs (151 [51.5%] vs. 7 [13.2%] cases, correspondingly; р<0.001), 
and it positively correlated with clinically aggressive tumor histolo-
gy: AC, 61.0%; ASqC, 61.9%; SqCC, 44.9%; BAC, 25.0%; LCC and 
small cell cancer, 100%; anaplastic cancer, 50.0%; carcinoid, 23.5%; 
sarcoma, 0%. The significantly elevated serum MUC1/ICO25 levels 
(³60 U/ml) were found in 81 (27.6%) patients with MLTs and 1 (1.9%) 
patient with NMLDs. In patients with nonsquamous non-small cell 
lung cancers (AC, BAC, LCC) and ASqC the serum MUC1/ICO25 
³60 U/ml were found in 44.0% (55/125) of cases. The rate of these 
cases positively correlated with the advanced TNM stage and de-
pended on the patients’ age: statistically significant difference bet-
ween stages I-II and stages IIIB-IV was found in patients aged 65 
years and older (15.8% [3/19] vs. 84.2% [16/19]; p<0.001), but not 
in patients aged less than 65 years (28.6% [8/28] vs. 48.6% [17/35]; 
p=0.127). In patients with SCC the overall rate of serum MUC1/
ICO25 ³60 U/ml was 16.9% (23/136), and the reversed 
age-related dependence of those levels on the tumor stage was 
bserved. In patients aged less than 65 years the higher rate of the 
serum MUC1/ICO25 ³60 U/ml correlated with more advanced TNM 
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Results: The median serum XIAP levels were similar in patients and 
the controls (p=NS). USP8 level was higher in patients compared to 
the control group (p<0.0001). In univariate analysis, there was no 
significant relationship between XIAP and USP8 serum levels and 
age, sex, performance status, weight loss, stage of disease, histo-
patological type and response to chemotherapy. In the low and 
high XIAP and USP8 groups, there was no significant difference in 
progression-free survival (PFS) (p=0.432 and p=0.50, respectively) 
and overall survival (OS) (p=0.989 and p=0.90, respectively).
Conclusion: No relationship was found with serum XIAP and USP8 
levels and clinical parameters, response to chemotherapy, PFS and 
OS in patients with advanced stages of NSCLC.
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P2.06-007 META-ANALYSIS OF STAT3 AND P-STAT3 EX-
PRESSION AND SURVIVAL IN NON-SMALL-CELL LUNG 
CANCER
Yunhua Xu, Linping Gu, Baijun Cheng, Shun Lu
Lung Tumor Clinic Medical Center, Shanghai Chest Hospital/China
Background: The prognostic role of signal transducer and activa-
tor of transcription 3 (STAT3) and phosphorylated STAT3(p-STAT3) 
in non-small-cell lung cancer (NSCLC) remains controversial. To 
clarify its impact on survival, we performed a meta-analysis to 
quantitatively assess STAT3 and p-STAT3 expression on prognosis 
of NSCLC.
Methods: Published studies were identified using a systematic and 
thorough literature search.To be eligible, a study had to investigate 
STAT3 or p-STAT3 expression rates of NSCLC patients in different 
characteristics and survival data of STAT3 or p-STAT3 expression.
Results: A total of 17 retrospective trials were chosen for meta-
analysis, including 1793 patients.We showed that the estimated 
pooled HR (0.67, 95%CI: 0.57-0.77) of 9 trials (STAT3: HR 0.71, 
95%CI 0.38-1.04; p-STAT3: HR 0.67 ,95%CI 0.56-0.77) for NSCLC 
was statistically significant (P<0.0001), suggesting that high STAT3 
or p-STAT3 expression is a strong predictor of poor prognosis 
among patients with NSCLC.For the risk factors, pooled analysis 
of patients with STAT3 positivity, demonstrated a statistically sig-
nificant OR (3.82, 95%CI: 2.37-6.16) between poorly differentiated 
carcinoma and well-moderately, OR( 5.68, 95%CI: 3.16-10.21)bet-
ween patients in stage III-IV and patients in stage I-II, and OR (3.41, 
95%CI: 2.12-5.49 ) between patients with lymph node metastasis 
and patients without lymph node metastasis. However, pooled 
analysis of patients with p-STAT3 positivity, only demonstrated a 
statistically significant OR (4.51, 95%CI: 1.57-12.96) between poorly 
differentiated carcinoma and well-moderately(P<0.05).
Conclusion: High STAT3 or p-STAT3 expression is a strong predic-
tor of poor prognosis among patients with NSCLC. The conclusion 
should be confirmed by large prospective studies with long-term 
follow-up.
Keywords: signal transducer and activator of transcription 3, phos-
phorylated STAT3, non-small-cell lung cancer, Meta-analysis
biomarker was: EGFR mutation (13%), KRAS mutation (29%), TTF1 
IHC (83%), p63 IHC (7%), MET IHC (50%), PDL1 IHC (45%), PTEN 
loss IHC (11%), NaPi2B IHC (76%), EGFR IHC (FLEX cut-off, 11%). In 
squamous-cell carcinoma, the prevalence of each biomarker was: 
TTF1 IHC (2%), p63 IHC (87%), MET IHC (13%), PDL1 IHC (50%), 
PTEN loss IHC (13%), NaPi2B IHC (3%), EGFR IHC (FLEX cut-off, 
40%). In addition, more than 67% of patients were positive for 
more than one biomarker and >33% were positive for at least three 
biomarkers. The diagnostic criteria for each biomarker and correla-
tions with patient characteristics will be described in further detail. 
Figure 1. Biomarker Overlap in Adenocarcinoma in Set 1 (n=337) 
Conclusion: Collectively, these data suggest that the biomarker 
landscape in NSCLC is complex and will be increasingly dynamic 
as more experimental agents approach pivotal testing. Grant sup-
port: this study was partially funded by UT Lung Specialized Pro-
grams of Research Excellence grant (P50CA70907; IIW)
Keywords: NSCLC, Biomarkers
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P2.06-006 CLINICAL AND PROGNOSTIC IMPORTANCE 
OF XIAP AND USP8 IN ADVANCED STAGES OF NON-
SMALL CELL LUNG CANCER
Suleyman Buyukberber, Meltem Baykara, Melek Yaman, Umut 
Demirci, Gulnihal Tufan, Mustafa Benekli, Ugur Coskun, Ahmet 
Ozet, Emin U. Bagriacik
Gazi University/Turkey
Background: Apoptotic pathways are controlled by activation or 
inhibition of the intracellular caspases. Inhibitor of apoptosis prote-
ins (IAPs) are endogenous inhibitors of caspase activity. We aimed 
to investigate the relationship of the apoptosis regulators X-linked 
inhibitor of apoptosis (XIAP) and ubiquitin specific protease 8 
(USP8) with clinical parameters, survival and response to chemo-
therapy in advanced stages of non-small cell lung cancer (NSCLC).
Methods: A total of 34 NSCLC patients (28 males, 6 females) and 
44 healthy volunteers were included in the study. Most of the 
patients had squamous cell histology (62%), while others had ade-
nocarcinoma (29%) and unclassified (8%) types. All patients had 
locally advanced stage IIIA-IIIB (50%) or metastatic (50%) disease. 
XIAP and USP8 levels were measured by ELISA method.
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P2.06-009 SIMULTANEOUS PROFILING OF MULTIGENE 
MUTATIONS FOR THE EFFECTIVE AND EFFICIENT DIAG-
NOSIS OF NON-SMALL CELL LUNG CARCINOMA
Bing Yu1, Belinda Mercorella1, Darryl Irwin2, Chiu C. Ng1, Priscilla 
Hunt2, Po Y. Yip3, Maija Kohonen-Corish4, Lisa G. Horvath3, Wendy 
A. Cooper5, Ronald J. Trent1, Sandra O‘Toole5
1Molecular And Clinical Genetics, Royal Prince Alfred Hospital/Austra-
lia, 2Asia Pacific, Sequenom/Australia, 3Medical Oncology, Sydney Can-
cer Centre, Royal Prince Alfred Hospital/Australia, 4Kinghorn Cancer 
Centre, Garvan Institute Of Medical Research/Australia, 5Tissue Patho-
logy And Diagnostic Oncology, Royal Prince Alfred Hospital/Australia
Background: Identification of actionable driver mutations in non-
small cell lung carcinoma (NSCLC) has become increasingly impor-
tant for the prioritisation of targeted therapies. Mutational analysis 
of formalin-fixed paraffin embedded (FFPE) tissues presents seve-
ral challenges including generally limited and fragmented DNA, 
the need to identify a range of biologically significant mutations 
and a pressing need for a fast turn around time at a cost-effective 
way. Our aim was to determine optimal methods for quantification 
of DNA for mutational analysis in NSCLC and to develop a new 
custom assay that could perform multigene mutational analysis on 
the limited quantity of DNA available in the small NSCLC samples 
frequently submitted for testing.
Methods: DNA was extracted from FFPE tissues including cytolo-
gy specimens. Spectrophotometry quantification was compared 
with Qubit 2 Fluorometer measurements and the Sequenom Sam-
pleID assay for accurate and meaningful assessment of extracted 
DNA for diagnostic mutational profiling. We have previously es-
tablished a diagnostic protocol for somatic mutation profiling in 
NSCLC using a commercial DNA mass spectrometry kit (Oncocarta 
v1.0) and compared it with a new custom kit “OncoFocus” deve-
loped in collaboration with Sequenom. These assays utilise target 
amplicons of small sizes for efficient amplification in fragmented 
DNA and simultaneously profile a range of actionable mutations 
in EGFR, KRAS, BRAF and NRAS. Preliminary verification of the 
“OncoFocus” assay was performed in 27 NSCLC samples, 3 lung 
cancer cell lines and 2 control genomic DNA samples.
Results: We found spectrophotometry significantly overestimated 
DNA quantity particularly at low concentrations. We also studied 
the correlation of DNA quantities with estimated copies of DNA 
templates as determined by SampleID. The results suggested that 
a minimum of 300 ng DNA is needed to achieve the required 300 
– 500 amplifiable genomic copies per reaction for the OncoCarta 
analysis, which remains difficult to achieve for many diagnostic 
NSCLC samples. We developed a more focused diagnostic panel 
“OncoFocus” which could be performed reliably with less DNA 
but which includes key actionable mutations in 159 hotspots in 
EGFR (n=109), KRAS (n=17), BRAF (n=15) and NRAS (n=18) requiring 
only 150 ng of DNA. Somatic mutations were identified in 23 sam-
ples and 3 cell lines including EGFR (n=22), KRAS (n=6) and BRAF 
(n=1). No false positive results were observed in 4 FFPE and 2 con-
trol samples. The whole process from the receipt of FFPE samples 
to issuing a report can be completed within 5 working days and 
the “OncoFocus” panel has increased our capacity per chip (iPLEX 
II) from 15 to 31 samples. The “OncoFocus” panel also results in 
decreased per sample testing costs.
Conclusion: The Qubit fluorometer is a more reliable and accurate 
method to quantify DNA derived from FFPE for mutational ana-
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P2.06-008 POLYMORPHISMS IN THE EXON 20 OF EGFR 
GENE IN METASTATIC LUNG ADENOCARCINOMA: PRO-
GNOSTIC RELEVANCE AND SENSITIVITY TO ERLOTINIB.
Gilberto Castro Jr.1, Iberê C. Soares2, Tiago K. Takahashi1, Manuel 
C.D.F. Maia1, Rafael Caires-Lima1, Bruno M. Protasio1, Teresa Y. 
Takagaki3, Christina Shiang2, Evandro S. Mello2, Paulo M. Hoff1, 
Venâncio A. Alves2
1Medical Oncology, Instituto Do Cancer Do Estado De Sao Paulo (ICE-
SP)/Brazil, 2Pathology, Instituto Do Cancer Do Estado De Sao Paulo 
(ICESP) And Lim-14 Fmusp/Brazil, 3Pneumology, Instituto Do Cancer 
Do Estado De Sao Paulo (ICESP)/Brazil
Background: EGFR-activating mutations are predictive of high 
response rates and overall survival gains in patients (pts) with 
pulmonary adenocarcinoma, treated with EGFR- tyrosine-kinase 
inhibitors (EGFR-TKIs), as erlotinib. Mutations in the EGFR gene, 
especially in the exon 20 (T790M), are related to resistance to EG-
FR-TKIs. We investigated if a polymorphic DNA sequence in exon 
20 (Q787Q, NCBI database 162093G>A, SNP ID: rs1050171) was 
associated with clinical outcomes in pulmonary adenocarcinomas, 
treated with erlotinib.
Methods: It is a prospective, observational study on all consecu-
tively pts whose tumors were genotyped for EGFR-activating mu-
tations. Tumor samples were formalin-fixed and paraffin-embed-
ded. Tumor areas were selected and macrodissected, followed by 
whole DNA extraction and amplification by PCR. EGFR genotyping 
was performed through DNA sequencing (exons 18, 19, 20 and 21) 
by Sanger´s methodology. Pts with adenocarcinomas harbouring 
EGFR-activating mutations were treated with erlotinib.
Results: 191 pts had tumor samples genotyped between 
Aug/2011 and Apr/2013. Median age was 64 y (17-90), 106 (56%) 
female. According to ethnicity, 154 pts were Caucasian (81%), 26 
African-American (14%) and 11 Asian (6%). Seventy pts were clas-
sified as never-smokers (37%), 23 (12%) as light-smokers (≤ 10 p.y.) 
and 95 as current smokers (51%). EGFR activating mutations could 
be identified in 54 out of 191 samples (28%): 35 were exon 19 de-
letions (65%), 15 were L858R mutation in exon 21 (30%), and three 
were rare mutations (G719S and G719A in exon 18, and V774M 
in exon 20). Polymorphism Q787Q in EGFR gene (exon 20) was 
detected in 108 samples (56.5%). The polymorphic status did not 
correlate with gender (p=0.324), smoking status (p=0.810) or EGFR 
mutational status (p=0.238), but it was more frequently detected 
in Caucasian pts (p=0.0002). Considering all 191 studied pts, no 
difference in median overall survival was detected according to 
polymorphic status (19.6 mo. vs. 24.3 mo., HR 0.86; 95% CI 0.54-
1.38, p=0.541). There was no difference in response rate to erlo-
tinib according to the polymorphic status (p=0.248). In addition, 
no difference in median overall survival was detected according 
to polymorphic status among the 38 pts treated with erlotinib and 
presenting EGFR-activating mutations (not reached in both groups, 
HR 2.44; 95% CI 0.31-16.01, p=0.425).
Conclusion: Polymorphism Q787Q in EGFR gene (exon 20) was 
commonly detected in pulmonary adenocarcinomas (56.5%), being 
more frequent in Caucasian pts. The presence of polymorphic 
status was neither related to sensitivity to erlotinib, nor to survival 
outcomes in our pts.
Keywords: Polymorphisms, Epidermal growth factor receptor, 
non-small cell lung cancer, erlotinib
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Our results show a high concordance rate (97.3%) of cobas EGFR 
with an existing IVD product, the therascreen EGFR assay. In this 
study, one double mutant, T790M in combination with L858R, was 
only identified by the cobas EGFR assay. The cobas EGFR assay 
appears to give the most accurate and appropriate results for NS-
CLC patients.
Keywords: EGFR, mutation assay, IVD
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P2.06-011 PHOSPHORYLATED-AKT EXPRESSION IS A 
PROGNOSTIC MARKER IN EARLY STAGE NON-SMALL 
CELL LUNG CANCER (NSCLC)
Po Yee Yip1, Wendy A. Cooper2, Maija Kohonen-Corish3, Brian Mc-
caughan4, Michael Boyer1, James Kench2, Lisa G. Horvath1
1Medical Oncology, Sydney Cancer Centre/Australia, 2Tissue Patholo-
gy And Diagnostic Oncology, Royal Prince Alfred Hospital/Australia, 
3Kinghorn Cancer Centre, Garvan Institute Of Medical Research/Aust-
ralia, 4Cardiothoracic Surgery, Royal Prince Alfred Hospital/Australia
Background: The 5-year survival for stage IB non-small cell lung 
cancer (NSCLC) is only 55%, but the benefit of adjuvant chemothe-
rapy in this setting remains equivocal. Numerous prognostic markers 
have been examined, but none to date have moved into clinical 
practice. There is an urgent need to identify novel molecular mar-
kers that can select high risk patients, who may potentially benefit 
from adjuvant chemotherapy.
Methods: We identified 471 consecutive patients with stage IB pri-
mary NSCLC according to the American Joint Commission on Can-
cer, (AJCC) 6th edition tumour-node-metastasis staging system, who 
underwent surgical resection between 1990 and 2008. Patients who 
received neoadjuvant or adjuvant treatments were excluded. Patho-
logy reports were reviewed and pathologic characteristics were ex-
tracted. Expression of phosphorylated Akt (pAkt) in both cytoplas-
mic and nuclear locations was assessed by immunohistochemistry, 
and clinicopathologic factors were analyzed against 10-year overall 
survival using Kaplan-Meier and Cox proportional hazards model.
Results: 455 (96.6%) cancers were adequate for pAkt immuno-
histochemical analysis. The prevalence of pAkt expression in the 
cytoplasm and nucleus of the cancers was 60.7% and 43.7% res-
pectively. Patients, whose cancers expressed higher levels of pAkt 
in the cytoplasm, had a trend towards longer overall survival than 
those with lower levels of cytoplasmic pAkt (p=0.06). Conversely, 
patients whose cancers expressed higher levels of pAkt in the nuc-
leus had a poorer prognosis than those with lower levels of nuclear 
pAkt expression (p=0.02). Combined low cytoplasmic/high nuclear 
expression of pAkt was an independent predictor of overall survival 
[HR=2.86 (95% CI:1.35-6.04); p=0.006] when modeled with age [HR= 
1.05 (95% CI: 1.03-1.07); p<0.001], extent of operation [HR= 2.11 
(95% CI: 1.48-3.01); p<0.001], visceral pleural invasion [HR=1.63 (95% 
CI: 1.24-2.15); p<0.001], gender, tumour size, histopathologic type 
and grade (p>0.05).
Conclusion: Levels of expression of pAkt in the cytoplasm and nu-
cleus and visceral pleural invasion are independent prognostic fac-
tors that can help to select patients with high risk disease, who may 
potentially benefit from adjuvant chemotherapy.
Keyword: PAkt, lung cancer, prognostic marker
lysis than spectrophotometry. We also conclude that DNA mass 
spectrometric analysis using a new custom “OncoFocus” panel is 
an effective and efficient test that simultaneously detects 159 mu-
tational hotspots, in the generally lower quantity of DNA obtained 
from routine FFPE NSCLC samples.
Keywords: mutation profiling, mass spectrometry, multigene ana-
lysis, FFPE DNA
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P2.06-010 ANALYTICAL PERFORMANCE OF THE COBAS 
EGFR MUTATION ASSAY FOR JAPANESE NON-SMALL 
CELL LUNG CANCER
Tatsuo Ohira1, Hideharu Kimura2, Osamu Uchida3, Jun Matsuba-
yashi4, Shinichirou Shimizu5, Toshitaka Nagao4, Norihiko Ikeda1, 
Kazuto Nishio2
1Department Of Surgy, Tokyo Medical University/Japan, 2Department 
Of Genome Biology, Kinki University Faculty Of Medicine/Japan, 3De-
partment Of Respiratory Surgery, Funabashi Municipal Medical Center/
Japan, 4Department Of Anatomic Pathology, Tokyo Medical University/
Japan, 5Department Of Pathology, Funabashi Municipal Medical Center/
Japan
Background: Patients’ EGFR mutation status prior to treatment 
impacts outcomes and, EGFR testing has been developed as a 
companion diagnostic; this relationship between therapeutic and 
diagnostic agents is known as personalized healthcare. Recently, it 
was reported that about half of patients may acquire resistance to 
EGFR-TKIs following therapy, mainly by appearance of EGFR mu-
tations, such as T790M. Thus, it is important to assess EGFR mu-
tation status before and during treatment to determine the most 
appropriate treatment regimens for patients. A number of PCR-
based techniques are used in the assessment of EGFR mutations. 
In Japan, the “Scorpion-ARMS” therascreen® EGFR Rotor-Gene Q 
PCR Kitis (therascreen EGFR assay) the only available in vitro dia-
gnostic (IVD) test. The cobas® EGFR Mutation Test (cobas EGFR 
assay) is the only FDA-approved kit for IVD testing in the US.In this 
study, we compared the performance of the cobas EGFR assay and 
the therascreen® EGFR assay using FFPE tissue specimens from 
NSCLC patients.
Methods: We extracted DNA from 149 FFPE tissues of NSCLC, 
according to the manufacturer’s instructions and performed a 
comparative study of cobas EGFR and therascreen EGFR methods.
Results: EGFR mutations were identified in 63 NSCLC specimens 
(42.3%) using the cobas EGFR assay and 61 samples (41.2%) using 
the therascreen EGFR assay. The concordance rate between the 
cobas EGFR assay and therascreen EGFR assays was 145/149 
(97.3%). Only three discordants between these EGFR assays were 
observed. One T790M mutation in combination with an L858R 
mutation was identified by the cobas EGFR assay. No invalid assay 
results occurred with the cobas EGFR assay.
Conclusion: The cobas EGFR assay has two advantages. One is 
that the process is easily performed by stable methods. It takes 
only 8 hours, from tumor specimen to results generated using the 
semi-automated system. Thus, patients assessed using the cobas 
EGFR assay can begin the most appropriate treatment quickly. The 
other advantage is that only a very small amount of DNA (150 ng) 
is required to detect mutation status using the cobas EGFR assay. 
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P2.06-013 GENETIC PROFILING OF LUNG CANCER IN 
YOUNG ADULTS PATIENTS: EARLY DATA ASSESSMENT 
USING NEXT-GENERATION SEQUENCING.
Tiziana Vavala‘, Valentina Monica, Marco Lo Iacono, Simona Vat-
rano, Sara Demichelis, Simona Carnio, Paolo Bironzo, Luisella 
Righi, Silvia Novello
Department Of Oncology, University Of Turin/Italy
Background: In 3% of cases, lung cancer is diagnosed in patients 
younger than 45 years. The epidemiology, biology and clinical history 
of young lung cancer patients is generally different from the adult 
counterpart: the higher percentage of mutations has the potential to 
influence both tolerability and response to treatment with consequent 
impact on quality of life and survival. The biomolecular characterizati-
on of the disease in this subgroup will allow the design of clinical stu-
dies dedicated to young patients, that will lead to the identification of 
specific items that are not deducible from trials opened to the general 
adult population. In this study, Next-Generation Sequencing (NGS) 
technology has been applied to archival tissue samples to enhance 
tumor-specific genomic profile knowledge in this selected cohort of 
young patients (pts).
Methods: A retrospective analysis has been performed at the Tho-
racic Unit of San Luigi Hospital from January 2007 to March 2013, 
collecting 13 lung cancer-diagnosed pts (10 completely sequenced; 
in 3 cases the analysis is ongoing), aged between 15-39 years. Ge-
nomic DNA was extracted by microdissected formalin-fixed and 
paraffin embedded (FFPE) tumor samples of all pts and by lympho-
cytes of three healthy controls (ctrl). Amplicons NGS libraries for 46 
oncogenes included in the Ion Torrent Cancer Panel were generated, 
following manufacture guidelines, and sequenced in Personal Geno-
me Machine (PGM) Ion Torrent instrument. Variant Caller included in 
Torrent Suite Software was used to identify mutations.
Results: Twenty-two non-synonymous, 3 frameshifts, 3 stop-gain 
and 55 synonymous somatic sequence variations were found in 10 
young adult patients (allelic frequency ≥ 10%). Excluding synonymous 
mutations, the most frequently altered genes in patients were TP53 
(7 mutations; 25%), followed by EGFR and KDR (5 mutations; 18%), 
PI3K (3 mutations; 11%), KIT (7 mutations; 14%), FGFR3-ABL1-MET-
ATM-RB1-SMO (1 mutation; 3.6%). Furthermore, 14 of these mutations 
are annotated in SIFT or in PolyPhen databases as “mutations that 
could damage affected protein”. Overall, we identified 28 mutations 
annotated in COSMIC database, among which the most frequent 
were COSM149673, COSM28026 and COSM6223-COSM22413 with 
5,4 and 2 counts, respectively. We also found 93 SNPs in our cohort, 
including the most frequent rs7688609, rs1873778 and rs1050171 with 
13 counts (10 pts; 3 ctrl) followed by rs1800861 (9 pts; 3ctrl); rs41115 (8 
pts; 2ctrl); rs1870377 (4 pts; 1ctrl); rs3822214 (2 pts; 2ctrl); rs3729687 (2 
pts; 1ctrl); rs2228230 (2 pts) and rs3730358-rs3135898 (1 pt; 1ctrl).
Conclusion: The development of new biological techniques, such as 
the next-generation sequencing, could allow to collect a wide number 
of mutations. From these preliminary results, some interesting data 
have been discovered concerning SNPs or mutations. This pivotal ret-
rospective analysis is the basis for the ongoing prospective collection. 
A better definition of molecular-genetic pattern in this selected young 
population of patients could increase the knowledge about the lung 
cancer etiology and suggest age-related new trials design.
Keywords: young adults, next generation sequencing, genomics, 
non-small cell lung cancer
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P2.06-012 IMPACT OF EGFR T790M MUTATIONS AND 
BIM MRNA EXPRESSION ON PROGRESSION-FREE SUR-
VIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS 
WITH EGFR-MUTANT NON-SMALL-CELL LUNG CANCER 
(NSCLC) TREATED WITH ERLOTINIB OR CHEMOTHERA-
PY IN THE RANDOMIZED PHASE III EURTAC TRIAL
Rafael Rosell1, Miguel Angel Molina-Vila2, Ana Drozdowskyj3, Car-
lota Costa2, Ana Gimenez-Capitan2, Jordi Bertran-Alamillo2, Niki 
Karachaliou2, Radj Gervais4, Bartomeu Massuti5, Jia Wei6, Teresa 
Moran1, Margarita Majem7, Enriqueta Felip8, Enric Carcereny1, 
Rosario Garcia-Campelo9, Santiago Viteri2
1Catalan Institute Of Oncology/Spain, 2Quiron-dexeus University Hos-
pital, Pangaea Biotech, Molecular Oncology Research (MORE) Foundati-
on/Spain, 3Pivotal/Spain, 4Medical Oncology, Centre François Baclesse/
France, 5Medical Oncology, Hospital General De Alicante/Spain, 6On-
cology, Affiliated Drum Tower Hospital To Nanjing University/China, 
7Servei D’Oncologia, Hospital De Sant Pau/Spain, 8Medical Oncology, 
Hospital Valle Hebron/Spain, 9Medical Oncology, Complejo Hospitalario 
A Coruña/Spain
Background: Activating EGFR mutations confer sensitivity to 
EGFR tyrosine kinase inhibitors (TKIs) in patients with NSCLC, but 
responses are transient, with delay in disease progression but no 
impact on survival. Concomitant genetic alterations could account 
for these incomplete clinical responses. Erlotinib-treated EGFR-
mutant NSCLC patients harboring the EGFR T790M mutation had 
shorter PFS than those without the mutation (12 vs 18 months [m]). 
Low BIM levels were associated with gefitinib resistance in EGFR-
mutant NSCLC.
Methods: The efficacy results of the EURTAC trial were updated at 
January 24, 2013. We have evaluated the frequency and potential 
impact of pretreatment EGFR T790M mutations and BIM mRNA 
expression in 95 patients with EGFR-mutant NSCLC included in the 
EURTAC trial.
Results: T790M mutations were detected in 65.26% of patients. 
PFS to erlotinib was 9.7 m for those with T790M mutations and 15.8 
m for those without, while among patients receiving chemothera-
py, it was 6 and 5.1 m, respectively (P<0.0001). BIM expression was 
successfully analyzed in 83 patients. PFS to erlotinib was 12.9 m for 
those with high BIM levels and 7.2 m for those with low/intermedi-
ate BIM levels, while among chemotherapy-treated patients, it was 
5.8 and 5.5 m, respectively (P=0.0003). OS was 28.6 m for patients 
with high BIM expression and 22.1 m for those with low/intermedi-
ate BIM expression (P=0.0364). The multivariate analyses showed 
that erlotinib was a marker of longer PFS (HR, 0.35; P=0.0003), 
while high BIM expression was a marker of longer PFS (HR, 0.49; 
P=0.0122) and OS (HR, 0.53; P=0.0323).
Conclusion: BIM mRNA expression is a biomarker of PFS and OS 
in EGFR-mutant NSCLC. T790M mutations and BIM mRNA expres-
sion can potentially be used for designing combination therapeutic 
strategies for use in lieu of EGFR TKI monotherapy.
Keywords: EGFR T790M mutations, NSCLC, Phase III EURTAC 
trial, BIM mRNA expression
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P2.06-015 NOVEL PLASMA PROTEINS ASSOCIATED 
WITH PROGNOSIS IN MALIGNANT PLEURAL MESOTHE-
LIOMA
Steven Kao1, Michaela B. Kirschner1, Ardeshir Amirkhani2, Dana 
Pascovici2, Xiaomin Song2, Rozelle Harvie3, Nick Pavlakis3, Ste-
phen Clarke3, Mark P. Molloy2, Nico Van Zandwijk1, Glen Reid1
1Asbestos Disease Research Institute/Australia, 2Australian Proteome 
Analysis Facility, Macquarie University/Australia, 3Medical Oncology, 
Royal North Shore Hospital/Australia
Background: The search for novel biomarkers to define more suc-
cessful and individual treatment approaches represent an important 
challenge for those involved in the care for patients with malignant 
pleural mesothelioma (MPM). In this exploratory study, we have 
systematically investigated the proteins present in plasma of MPM 
patients and correlated their levels with disease outcomes.
Methods: Plasma samples from twelve MPM patients (6 ‘short-’ and 
6 ‘long-term’ survivors from parallel phase II studies investigating 
thalidomide) were used for proteomic analyses. Our series included 
samples from 9 patients with epithelial MPM and 3 patients with 
biphasic MPM. Plasma samples were immuno-depleted of the 14 
most abundant proteins prior to labelling for isobaric tag for relative 
and absolute quantitation (iTRAQ) analysis using mass spectromet-
ry. The most promising candidates and mesothelin were chosen for 
selected reaction monitoring mass spectroscopy (SRM-MS) quantifi-
cation and enzyme-linked immunosorbent assay (ELISA) validation. 
Statistical analyses using T-Test of peak areas were used to identify 
proteins that were differentially expressed between the short- and 
long-term survivor groups.
Results: Median survival of short- and long-term survivors (1.2 and 
38.3 months, respectively) differed significantly (p = 0.001). This was 
also the case for the neutrophil-to-lymphocyte ratio (NLR) that was 
significantly higher in the group of short-term survivors (p=0.03). 
Other baseline characteristics did not reveal major differences bet-
ween the short- and long-term survivors. The total number of prote-
ins identified was 226 (1% false discovery rate) in iTRAQ. A number 
of those were found to be differentially expressed between short- 
and long-term survivors (≥1.2-fold change; p≤0.05) by iTRAQ: se-
lenoprotein P; tetranectin; insulin-like growth factor-binding protein 
2 (IBP2); osteonectin (SPARC); platelet basic protein (CXCL7); and 
attractin. Mesothelin was assessed to validate the proteomic metho-
dology: SRM-MS quantification was highly correlated with the ME-
SOMARK ELISA values with a Pearson correlation of 0.82 (p=0.001). 
SRM-MS quantification revealed that the concentrations of attractin 
(p=0.02), tetranectin (p=0.003) and selenoprotein P (p=0.001) were 
higher in long-term survivors. In contrast, there was a trend for an 
increase in the concentration of SPARC (p=0.32), IBP2 (p=0.12) and 
CXCL7 (p=0.19) to be correlated with shorter survival. Furthermore, 
quantification by ELISA demonstrated an association between long 
survival and low concentration of SPARC (p=0.07) as well as high 
tetranectin (p=0.13).
Conclusion: We have demonstrated the feasibility of using the 
iTRAQ and SRM-MS proteomic techniques to investigate potential 
prognostic protein markers in plasma of MPM patients. Potential 
prognostic biomarkers worthy of further studies include SPARC and 
tetranectin and we plan to validate these in a larger clinical cohort.
Keyword: malignant pleural mesothelioma; proteomics; prognostic 
marker
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P2.06-014 QUANTITATIVE TEST OF MUTANT EGFR AND 
ITS EFFECT ON EFFICACY OF EGFR TKI IN ADVANCED 
NSCLC
Xuefei Li1, Shengxiang Ren1, Chao Zhao1, Jiayu Li1, Guohua Yang2, 
Wei He2, Caicun Zhou1
1Department Of Medical Oncology; Lung Cancer And Immunology 
Laboratory, Shanghai Pulmonary Hospital, Tongji University; Tongji 
University Medical School Cancer Institute/China, 2Genosaber Biotech 
Co. Ltd/China
Background: It is reported that abundance of EGFR mutations is 
related with efficacy of EGFR TKI in advanced NSCLC patients with 
mutant EGFR. This study was designed to investigate influence of 
EGFR mutations and their abundance on efficacy of EGFR TKI by a 
quantitative method.
Methods: 190 NSCLC treated with EGFR TKI and available tissue 
for EGFR mutations were enrolled into the study; 113 were FFPE 
specimen, and 62 were fresh tissue. EGFR mutation was detected 
with the kit of AmoyDx ARMS and percentage of mutant EGFR was 
tested with the method of an Allele Specific PCR with Competitive 
Blocker (ASB-PCR). In this assay, copies of EGFR mutants were ca-
librated by standard curve, and the mutation rates were estimated 
through normalizing by copies of a conserved sequence in EGFR 
exon2. The relationship between abundance of EGFR mutations 
and efficacy of EGFR TKI was analyzed.
Results: Of 190 samples, 15 were censored due to EGFR exon2 
copies less than 100; finally, 175 enrolled into data analysis. Mutant 
percentage less than 0.1% was defined as wild-type, 0.1%~2% as 
low abundance, 2%~20% as moderate abundance, and more than 
20% as high abundance. The mutant rate was 56.6% and 62.3% 
by using AmoyDx ARMS and ASB-PCR methods, respectively. The 
accordance rate of EGFR mutations was 89.7% by two methods. Of 
175 samples, 20, 27 and 62 harbored low, moderate and high ab-
undances of mutant EGFR, respectively; 66 were wild-type EGFR. 
Median progress free survival (mPFS) was 4.9 (95% CI, 3.4 to 6.4), 
8.3 (95% CI, 3.3 to 13.3) and 16.0 months (95% CI, 10.4 to 21.7) in 
patients with low, moderate and high abundances of mutant EGFR 
(p =0.012). The mPFS of low abundance was not longer than that 
of those patients with wild-type EGFR (2.0 months, 95% CI, 0.2 to 
4.1; p=0.261). Objective response rate (ORR) was 67.7%, 44.4%, 
25.0% and 19.7%, and disease control rate (DCR) was 90.3%, 
81.5%, 55.0% and 45.5% in patients with high, moderate, low ab-
undance and wild-type EGFR, respectively (p<0.001). But ORR and 
DCR were no difference between low abundance and WT groups 
(p=0.754; p=0.610, respectively).
Conclusion: The abundance of EGFR mutations could affect the 
efficacy of EGFR-TKI, and quantitation of mutant EGFR could bet-
ter predict for efficacy of EGFR TKI in advanced NSCLC.
Keywords: NSCLC, EGFR TKI, EGFR mutation, mutant EGFR abun-
dance
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21% cases in this series express a pattern associated with potential 
sensitivity to MCT1 inhibition. Higher expression of MCT1 is an 
adverse prognostic factor in univariate analysis reinforcing further 
evaluation of MCT1 inhibition in this disease.
Keywords: SCLC, monocarboxylate transporter, Prognosis
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P2.06-017 LONG NON CODING RNAS (LNCRNAS) ARE 
DYSREGULATED IN MALIGNANT PLEURAL MESOTHE-
LIOMA (MPM)
Casey Wright1, Michaela B. Kirschner1, Yuen Yee Cheng1, Kenneth 
O‘Byrne2, Steven Gray2, Karin Schelch3, Mir Alireza Hoda3, Sonja 
Klebe4, Brian Mccaughan5, Nico Van Zandwijk1, Glen Reid1
1Asbestos Diseases Research Institute/Australia, 2Department Of 
Medical Oncology, St. James‘s Hospital/Ireland, 3Institute Of Cancer 
Research And Divison Of Thoracic Surgery, Comprehensive Cancer Cen-
ter/Austria, 4Department Of Anatomical Pathology, Flinders University 
And Sa Pathology/Australia, 5Cardiothoracic, Royal Prince Alfred Hos-
pital/Australia
Background: Malignant Pleural Mesothelioma (MPM) is an ag-
gressive disease, often diagnosed at an advanced stage. It is cha-
racterized by a long latency period and prior asbestos exposure. 
Currently accurate diagnosis of MPM is difficult due to the lack of 
sensitive biomarkers, and despite minor improvements in treat-
ment, median survival rates rarely exceed 12 months. Accumula-
ting evidence suggests that aberrant expression of long non-co-
ding RNAs (lncRNAs) plays an important functional role in cancer 
biology. LncRNAs are a class of recently discovered non-protein 
coding RNAs >200 nucleotides in length with a role in regulating 
transcription. The aims of this study were to characterize the ex-
pression and function of these lncRNAs in MPM.
Methods: To identify novel lncRNAs involved in MPM, microarray 
profiling was performed on five cell lines - the immortalized nor-
mal mesothelial cell line (MeT-5A) and four MPM lines (two epi-
thelioid H28 and H226 and two biphasic MM05 and MSTO) using 
Invitrogen’s NCode lncRNA microarrays. These allow simultaneous 
assessment of mRNA and lncRNA content. High priority candidate 
lncRNAs were selected on the basis of statistical (P<0.05) and bio-
logical (>3-fold difference) significance. Expression of high priority 
candidates were technically validated using RT-qPCR, and biolo-
gically validated in three independent test sets. Pathway analyses 
were performed to interrogate the relationship between lncRNA 
and mRNA expression. Cell proliferation and colony formation 
assays were used to investigate lncRNA function.
Results: Microarray profiling and real-time qPCR validation identi-
fied 9 lncRNA candidates with significant differential expression in 
MPM compared with normal mesothelial cells Validation in three 
independent test sets by RT-qPCR analysis demonstrated consis-
tent up-regulation of four of these lncRNAs. Receiver Operating 
Curve analysis showed that two of these candidates were able to 
separate benign pleura and MPM with high sensitivity and specifi-
city. In addition, high expression of AK054908 was associated with 
nodal metastases with lower levels of AK130275 and AF268386 
observed in patients receiving induction chemotherapy. Cases 
with higher EF177379 levels also demonstrated a trend to impro-
ved survival. The majority of mRNAs co-expressed with candidate 
lncRNAs were associated with cellular and metabolic processes 
POSTER SESSION 2 - PROGNOSTIC AND PREDICTIVE BIOMARKERS  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.06-016 EXPRESSION AND CLINICAL SIGNIFICANCE 
OF THE MONOCARBOXYLATE TRANSPORTER MCT1 AS 
A NOVEL THERAPEUTIC TARGET IN SMALL-CELL-LUNG-
CANCER (SCLC)
Alberto Fusi1, Radosław Polański2, Daisuke Nonaka1, Fiona Black-
hall1, Lynsey Priest2, Francesca Trapani2, Paul Bishop3, Caroline 
Dive2, Christopher Morrow2
1The Christie NHS Foundation Trust/United Kingdom, 2Paterson Insti-
tute For Cancer Research, University Of Manchester/United Kingdom, 
3Pathology, University Hospital South Manchester/United Kingdom
Background: Small cell lung is a rapidly proliferating disease. 
Because of its high proliferation index, cancer cells rely on glyco-
lysis, rather than oxidative phosphorylation, for ATP generation. 
Furthermore SCLC tumours often contain regions of hypoxia which 
switches tumour cells to a glycolytic phenotype. Increased glyco-
lysis leads to increased lactate production which is effluxed from 
the cell in order to prevent reduced intracellular pH or inhibition 
of metabolic pathways via the monocarboxylate transporter (MCT) 
proteins MCT1 and MCT4. Inhibition of these transporters has 
been proposed as a method of selectively targeting highly glyco-
lytic cancer cells. AZD3965 is an orally bioavailable MCT1 specific 
inhibitor currently under evaluation in phase I clinical trials. In an in 
vitro model of SCLC we have recently shown that in hypoxic con-
ditions resistance to AZD3965 is associated with increased MCT4 
levels (Polanski et al. submitted). Aim: To examined the expression 
and clinical significance of MCT1 and MCT4 in SCLC.
Methods: Archival SCLC biopsy specimens and clinical data from 
78 patients presenting to the University Hospital of South Man-
chester and the Christie Hospital between 1994 and 2005 were 
analyzed. Nine representative cores from the tumour specimens 
were used to generate three TMAs. Sections were then stained 
for the markers MCT1, MCT4 and for the hypoxic marker CAIX. 
Staining was evaluated by two independent scorers and extent 
and intensity of the staining were estimated. A combined score 
for each case was calculated as the mean product of extent and 
intensity for all the cores in a case. The association between MCT1, 
MCT4 or CAIX and known prognostic factors was evaluated by 
Fisher’s exact test. Kaplan-Meier analysis was used to assess over-
all survival rates and Log Rank test was used for the comparison of 
the survival distributions.
Results: The proportion of tumours with any expression of MCT1, 
MCT4 or CAIX was 99%, 99%, 90% respectively. Higher levels of 
expression (intensity x extent) were observed for MCT1 (medi-
an=8.17) compared to MCT4 (median=2.21; p<0.001). A positive 
correlation was observed for CAIX expression and MCT4 expres-
sion. Tumours with CAIX expression, high MCT1 expression (>me-
dian) and low MCT4 expression (<median) represented the 21% of 
the cases defining a putative subpopulation of SCLC with higher 
chance of response to MCT1 inhibition. For 39 patients clinical 
data were available. No significant correlation was observed for 
MCT1, MCT4 or CAIX with known clinical prognostic factors (stage, 
Hb < 9 g/L, WBC > 10 x 109/L, platelets < 150 x 109/L, Na < 135 
mmol/L; LDH > 550 IU/L). However, high MCT1 expression score 
was associated with worse survival (14 vs. 32 months; p=0.019). 
Neither MCT4 nor CAIX expression was prognostic. Of the known 
prognostic factors assessed, extensive stage was significantly as-
sociated with shorter overall survival (6 vs. 27 months; p<0.001).
Conclusion: MCT1 and MCT4 are often expressed in SCLC and 
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Conclusion: Immunostaining is a useful method for measuring TS 
level when TS is being considered as an appropriate biomarker for 
postoperative adjuvant chemotherapy with 5-FU delivertives.
Keyword: TS mRNA, 5-FU delivertives
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P2.06-019 EGFR MUTATION DETECTION IN CTDNA 
ISOLATED FROM NSCLC PATIENT PLASMA; A CROSS-
PLATFORM COMPARISON OF LEADING TECHNOLOGIES
Kenneth S. Thress1, Simon P. Dearden2, Suzanne JeNKIns2, Helen 
Brown2, Roz Brant3, Alain Horvais2, Ruth March2, J Carl Barrett1
1Translational Sciences, Astrazeneca/United States Of America, 2PHB, 
Astrazeneca/United Kingdom, 3Translational Sciences, Astrazeneca/
United Kingdom
Background: The diagnosis and treatment of non-small cell lung 
cancer (NSCLC) was revolutionised with the discovery of epider-
mal growth factor receptor (EGFR) activating mutations and the 
corresponding treatment of mutation-positive cancers with EGFR 
tyrosine kinase inhibitors (EGFR-TKI, i.e. gefitinib, erlotinib). While 
EGFR-TKI’s are highly effective in this setting, patients invariably 
relapse due to acquired resistance to the targeted therapy. In ap-
proximately 50% of the cases, resistance to gefitinib and erlotinib 
is associated with a T790M mutation that renders the EGFR tumor 
molecule unresponsive to these inhibitors. A number of 2nd and 3rd 
generation inhibitors are currently in development to address the 
primary T790M resistance mechanisms (afatinib, AZD9291, Clovis 
1686). Identifying the relevant patient population for such drugs 
may rely on diagnostic analysis of re-biopsy material to determine 
the mechanism of acquired resistance. However, such invasive 
surgical procedures may present a significant challenge in a pro-
portion of patients with EGFR TKI-resistant disease. Availability of 
a reliable, minimally invasive method to assess the EGFR mutation 
status of NSCLC patients could have major clinical benefits for 
patients and support access to novel targeted therapies. Recently, 
several highly sensitive technologies have been described for de-
tection of EGFR mutations in the small amount of tumor DNA that 
is shed into the circulating plasma (ctDNA). ctDNA has potential 
as a minimally-invasive alternative to surgical biopsies and as such, 
holds promise for disease diagnosis and early assessment of di-
sease progression.
including cell cycle, cell death and apoptosis. In functional studies, 
siRNA knockdown of AK130275 showed suppression of cell growth 
and colony formation in MPM cells with moderate changes obser-
ved following knockdown of EF177379.
Conclusion: To our knowledge this is the first systematic study of 
lncRNA expression profiles in MPM. We have found that lncRNA 
expression profiles can distinguish malignant mesothelium from 
normal pleural tissue, and that some lncRNAs are associated with 
nodal metastasis and long term survival. We also demonstrate 
that lncRNAs have potential prognostic and diagnostic utility with 
functional roles in regulating cell growth. Further work is required 
to evaluate whether these lncRNAs are capable of differentiating 
mesothelioma from lung cancer and benign asbestos-related di-
seases, and to reveal their specific functions in MPM pathogenesis.
Keywords: mesothelioma, long noncoding RNA, microarray, func-
tion
POSTER SESSION 2 - PROGNOSTIC AND PREDICTIVE BIOMARKERS  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.06-018 CORRELATION OF TS MRNA EXPRESSION LE-
VEL AND TS PROTEIN LEVEL DETECTED BY IMMUNOS-
TAINING FOR USE IN POST-OPERATIVE PRIMARY LUNG 
CANCER THERAPY
Noriyuki Matsutani, Hitoshi Dejima, Yusuke Takahashi, Masafu-
mi Kawamura
Surgery, Teikyo University School Of Medicine/Japan
Background: There has been a focus on the use of thymidylate 
synthase (TS) as a biomarker for the long term administration of 
metabolic antagonists for lung cancer. TS mRNA levels have been 
measured by real time RT-PCR in tumors collected using a micro-
dissection method; however, this method has not been applicable 
for general use and its clinical use has been problematic. Therefo-
re, this study investigated the correlation of TS mRNA expression 
level and a commonly used semiquantitative immunohistochemical 
method.
Methods: Resected lung specimens were collected from 47 pati-
ents with Stage IA (T1b) and IIB primary non-small-cell lung cancer 
who had undergone lobectomy between 2006 and 2012 at our 
Hospital. Levels of mRNA expression were measured using the 
Danenberg Tumor Profile method while TS immunostaining with 
anti-TS mouse IgG MoAB was graded into 4 levels.
Results: Of 47 patients, 24 patients were male and 23 patients 
were female. Thirty six people had adenocarcinoma while 11 pati-
ents exhibited squamous cell carcinoma. The number of patients at 
each IA, IB, IIA and IIB stage were 20, 20, 5, and 2, respectively. TS 
mRNA expression levels of these patients were between 0.69 and 
12.68 (a median value of 2.47). Immunostaining indicated that Gra-
de 0, 1, 2, and 3 were observed in 3, 17, 15 and 12, respectively. 
A moderate positive correlation was observed at a correlation 
coefficient of r=0.4880 between mRNA expression levels and im-
munostain levels (A). Moreover, a significant correlation between 
mRNA expression levels and immunostain levels was observed 
when mRNA expression levels were divided into two groups, one 
with higher than median values and the other with lower than 
median values, where Grade 0 and 1 were assigned as negatively 
stained and Grade 2 and 3 were assigned as positively stained (B).
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observed between diagnostic biopsies and subsequent surgical re-
sections of primary tumors in either the OP-group (p=0.186) or the 
NAC-group (p=0.542). Primary tumors were discordant between 
diagnostic biopsies and resection specimens when TS expression 
was dichotomized into high (H-score>150) and low (H-score ≤150), 
in 45% and 33% in the OP-group and NAC-group, respectively 
(p=0. 288).
Conclusion: The discordance observed between paired serial 
samples likely reflects intratumoral heterogeneity of TS expression 
and highlights the need of sufficient representative material for TS 
expression analysis if this biomarker is to be used for treatment se-
lection.. TS expression in primary tumors remained unchanged and 
new biopsies for deciding on 2nd line pemetrexed do not seem 
warranted based on the current results.
Keywords: biomarker, thymidylate synthase, NSCLC
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P2.06-021 IS RRM1 A PREDICTIVE MARKER FOR VINO-
RELBINE EFFICACY - THE RESULTS FROM A COHORT 
OF MALIGNANT PLEURAL MESOTHELIOMAS TREATED 
WITH CISPLATIN AND VINORELBINE.
Zarah G. Zimling1, Eric Santoni-Rugiu2, Cecilia Bech1, Jens B. So-
rensen1
1Oncology, National University Hospital/Denmark, 2Pathology, National 
University Hospital/Denmark
Background: In a recently published study our group proposes 
a possible predictive impact of immunohistochemically detected 
RRM1 on vinorelbine efficacy in advanced NSCLC. This thesis was 
based on results from a randomized phase III trial comparing tri-
plet-chemotherapy (paclitaxel, cisplatin, gemcitabine) to standard 
doublet-therapy (cisplatin, vinorelbine). We found that increased 
expression of RRM1 was associated with significantly decreased 
progression-free survival (PFS) and overall survival (OS) only in the 
patients receiving cisplatin-vinorelbine therapy. These findings 
were suprising since the overexpression of RRM1 is conventionally 
associated with resistance towards the chemotherapeutic agent 
gemcitabine, which is a potent inhibitor of ribonucleotide reduc-
tase (RNR). RNR is an essential enzyme for DNA synthesis that 
converts ribonucleoside di-phosphates into deoxyribonucleoside 
di-phosphates. The enzyme consists of a large sub-unit (RRM1) 
and a small sub-unit (RRM2). Vinorelbine is a spindle-poison and 
resistance towards this agent has never been associated with 
RRM1 over-expression. It has however been shown that vinorelbine 
can reduce the repair of radiotherapy-induced DNA damage in 
small-cell lung-cancer cell-lines, pointing to a possible interaction 
between vinorelbine and the DNA repair system. This study aimed 
at further exploring the possible predictive value of immunohis-
tochemically detected RRM1 in patients receiving vinorelbine 
therapy. For this purpose we chose a cohort of malignant pleural 
mesothelioma patients treated with cisplatin and vinorelbine in a 
phase II trial.
Methods: Fifty-four consecutive patients with MPM, were enrolled 
between February 2003 and September 2006 into a phase II trial 
with cisplatin and vinorelbine. The formalin-fixed paraffin-embed-
ded bioptic tumor specimens from these MPM patients were ret-
rospectively evaluated for RRM1 expression by immunohistoche-
mistry (IHC) using an H-score. The cut-off point was chosen as the 
Methods: We undertook a comprehensive cross-technology 
comparison of three technology platforms for detection of T790M 
mutation in ctDNA extracted from patient plasma: 1) ARMS-based 
detection using the Roche cobas® EGFR mutation detection kit; 
2) digital droplet PCR using the BioRad ddPCR instrument (by 
MolecularMD); and 3) bead-based digital PCR using the Inostics 
BEAMing technology. In total, 140 frozen plasma samples (appro-
ximately 80 EGFR mutation +ve and 60 EGFR mutation -ve), obtai-
ned from EGFR-TKI resistant patients enrolled on two AstraZeneca 
clinical studies were used to assess mutation prevalence, false 
negative, and false positive rates. Each individual patient plasma 
sample was split and evaluated across multiple platforms. ctDNA 
was extracted and tested by operators blinded to the EGFR tumor 
mutation result for 3 common mutations (Exon 19 deletion E746_
A750delELREA, L858R and T790M). The EGFR mutations status of 
patient-matched tumor biopsies was available for all plasma samp-
les to allow for ctDNA-tumor concordance testing.
Results: Overall, concordance of EGFR mutation status was high 
between all 3 methods. In addition, the false positive rate in the 
known EGFR mutation -ve cases was low for all 3 methods. Howe-
ver, differences were seen in the rate of false negative results (as-
say sensitivity) between methods, with digital PCR showing incre-
ased assay sensitivity compared with the ARMS based method. A 
comprehensive comparative analysis for all 3 technologies will be 
presented.
Conclusion: Digital droplet and BEAMing PCR platforms both pro-
vide sensitive detection of EGFR mutations in ctDNA isolated from 
circulating plasma. Importantly, both platforms also provide results 
in relation to wild-type EGFR molecules, allowing for quantification 
EGFR mutation load
Keywords: EGFR mutation, ctDNA, digital PCR, T790M
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P2.06-020 PRETREATMENT THYMIDYLATE SYNTHASE 
PROTEIN EXPRESSION LEVELS REMAINS STABLE DU-
RING PACLITAXEL AND CARBOPLATIN TREATMENT IN 
NON-SMALL CELL LUNG CANCER
Jan N. Jakobsen1, Eric Santoni-Rugiu2, Jens B. Sorensen1
1Oncology, National University Hospital/Denmark, 2Pathology, National 
University Hospital/Denmark
Background: Thymidylate synthase (TS) is a potential predictive 
marker for efficacy of treatment with pemetrexed. The current stu-
dy aimed at investigating whether TS expression changes during 
non-pemetrexed chemotherapy of non-small cell lung cancer (NS-
CLC) thus making rebiopsy necessary for deciding on pemetrexed 
second line treatment.
Methods: TS immunohistochemístry was performed on biopsies 
and available resection specimens from 65 NSCLC patients stage 
T1-3N0-2 treated with preoperative carboplatin and paclitaxel 
(NAC-group) and 53 NSCLC patients stage T1-4N0-1 treated with 
surgery without preceding chemotherapy (OP-group) served as 
controls. The diagnostic biopsies and subsequent resection samp-
les were compared in order to evaluate for concordance in TS ex-
pression in groups with and without preoperative chemotherapy.
Results: No statistically significant change in TS expression was 
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278 adenocarcinoma ( NSCLC FFPE and cytology) samples using 
Real-Time PCR technology with modified taqman probes to detect 
29 EGFR mutations in exon 18, 19, 20 and 21 and Multiplex Liga-
tion-dependent Probe Amplification (MLPA) to detect the most 
common deletion in exon 19, substitutions in exon 21 (L858R), 20 
(T790M) and 18 (G719X), and insertion in exon 20 (S768I). Second-
ly, we evaluated MET and HER2 amplification in all 278 samples by 
MLPA only.
Results: EGFR mutation analysis demonstrated identical results 
in 97.5% cases between qRT-PCR and MLPA; 2.5% of discrepancy 
came from limit detection between those two methods (1% Limit 
of Detection for qRT-PCR; and 10-15% for MLPA). The fluorescent 
signals to cross the threshold for those 2.5% cases were detected 
in late cycles and positively correlated with small percentage of 
tumour cells in the sample. Both methods are more sensitive than 
traditional Sanger Sequencing which limit of detection is in a range 
15%-25%. Additional MET and HER2 amplification analysis indi-
cated that 10% of NSCLC samples carried MET and 1.8% - HER2 
amplification.
Conclusion: Both Real-Time PCR and MLPA are accurate tools to 
detect point mutations or chromosomal aberration, respectively 
- as an alternative method to time consuming Sanger sequencing 
and FISH analysis for NSCLC biomarker detection. As MET amplifi-
cation is known negative prognostic factor, in particular for patient 
treated with TK inhibitors, we suggest to use both technologies in 
NSCLC diagnostics: qRT-PCR for EGFR somatic mutation analysis 
and MLPA to detect MET amplification.
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P2.06-023 GENE EXPRESSION SIGNATURE AND IMMU-
NOHISTOCHEMICAL ASSESSMENT OF NRF2 PATHWAY 
ACTIVATION FOR ADJUVANT CHEMOTHERAPY BENEFIT 
IN LUNG SQUAMOUS CELL CARCINOMA (SQCC)
Shingo Sakashita, Desmond She, Chang Q. Zhu, David Ceacon, 
Melania Pintilie, Frances A. Shepherd, Ming S. Tsao
Princess Margaret Hospital, University Health Network, University Of 
Toronto/Canada
Background: Genomic profiling of SqCC has identified somatic 
alterations in NRF2 or its negative regulators (NFE2L2 mutations/
amplifications, KEAP1 or CUL3 mutations/deletions) in ~1/3 of 
tumors. These alterations result in activation of the NRF2 transcrip-
tional program, but the clinical significance of this pathway in lung 
SqCC patients is unknown. We hypothesize that a gene expression 
signature that reflects somatic NRF2-activating alterations may be 
identified and correlated with NRF2 protein over-expression. Fur-
thermore, such gene expression or its immunohistochemical cor-
relates may have prognostic significance and/or may be predictive 
of adjuvant chemotherapy benefit in early stage resectable lung 
SqCC patients.
Methods: Logistic regression (LR) and SAM analysis were applied 
independently to 104 SqCC cases from The Cancer Genome Atlas 
(TCGA) that had both microarray gene expression and mutation 
data to identify genes associated with NRF2 pathway mutational 
status. Overlapping genes were used to define the signature, 
which was then tested in 3 independent SqCC microarray datasets 
to evaluate its prognostic value. Correlation of the signature with 
NRF2 and KEAP1 mutations and with NRF2 and KEAP1 immunore-
upper quartile value of the H-scores to separate positive (H-score 
≥upper quartile) from negative (H-score <upper quartile) tumors. 
Bioptic tumor specimens from 17 additional MPM patients treated 
with carboplatin and pemetrexed during the period 2008 – 2010 
were also evaluated for RRM1 expression.
Results: Sixty-six patients had enough tumor tissue for IHC. The 
upper quartile H-score was 3 yielding 15 positive and 34 (69%) 
negative tumors in the cisplatin-vinorelbine treated group. In the 
carboplatin-pemetrexed treated group there were 6 positive and 
11 (64%) negative tumors. There was a significant overall survival 
advantage only in the RRM1-negative patients treated with cispla-
tin and vinorelbine (log rank p= 0.002). This group had a two-year 
survival rate of 47% opposed to 13 % for the RRM1-positive tumors 
treated with this combination. In the carboplatin-pemetrexed-tre-
ated group there were no differences in overall survival according 
to marker status, with two-year survival rates of 0% and 9% in the 
RRM1-positive and –negative group respectively.
Conclusion: Patients with RRM1-negative tumors treated with 
cisplatin-vinorelbine combination therapy had a prolonged overall 
survival. There was no survival advantage in the RRM1-negative 
group when patients were treated with carboplatin and pemet-
rexed. Our study suggest a possible role of RRM1 in predicting 
efficacy of cisplatin-vinorelbine combination chemotherapy ,also in 
MPM, which supports the similar finding from our group in NSCLC 
patients. Thus, RRM1 may be a biomarker for vinorelbine though 
the results require further validation.
Keywords: predictive marker, vinorelbine, RRM1, malignant pleural 
mesothelioma
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P2.06-022 USE OF THE REAL-TIME PCR AND MULTIPLEX 
LIGATION-DEPENDANT PROBE AMPLIFICATION (MLPA) 
ASSAY IN THE MOLECULAR DIAGNOSIS FOR NSCLC 
BIOMARKER DETECTION.
Janusz Kowalewski1, Ma Lewandowska2, K Czubak3, W Jóźwicki2, 
Mariusz Kowalewski4, P Kozłowski3
1Department Of Thoracic Surgery And Tumours, Franciszek Lukaszczyk 
Oncology Centre, Bydgoszcz, Poland/Poland, 2Department Of Tumour 
Pathology And Pathomorphology, Molecular Oncology And Genetics 
Unit, Franciszek Lukaszczyk Oncology Centre, Bydgoszcz, Poland/
Poland, 3European Centre Of Bioinformatics And Genomics (ecbag), 
Institute Of Bioorganic Chemistry, Polish Academy Of Sciences, Poznań, 
Poland/Poland, 4Department Of Thoracic Surgery And Tumours, Colle-
gium Medicum, In Bydgoszcz, Nicolaus Copernicus University In Toruń, 
Poland/Poland
Background: Variety of molecular methods for somatic mutations 
detection in NSCLC demonstrate discrepancies in sensitivity, cost 
and performance. Presence of activating mutation in TK domain 
of EGFR gene qualifies NSCLC patients to targeted therapy with 
TK inhibitors. Sanger sequencing is still a ‚gold standard‘ for EGFR 
point mutation analysis and FISH is the primary method for detec-
ting copy number of specific genes in tissue sections. Alternative 
methods like qRT-PCR, CISH or MLPA are more and more com-
monly used to detect EGFR point mutations or MET or HER2 amp-
lification, yet results on their accuracy remain inconclusive.
Methods: We compared EGFR mutation analysis performed on 
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stageof NSCLC with KRAS mutation(p=0.015, Χ2-test). Furthermo-
re, the overall survival of the patients with RALB overexpression 
was significantly shorter than that of the patients without RALB 
overexpression (2.7 vs. 7.3 months, P<0.001; Mann-Whitney U 
test). In metastatic lung tumor tissues from KRAS mutant colorectal 
cancer patients, RALB protein overexpression showed only a trend 
toward shortened disease free survival.
Conclusion: RALB overexpression might be related to rapid di-
sease progression and poor prognosis in NSCLC patients with 
KRAS mutations.
Keyword: RALA/RALB, small GTPase, KRAS, non-small cell lung 
cancer
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P2.06-025 PROGNOSTIC IMPACT OF CXCL16 AND 
CXCR6 IN TWO NON-SMALL CELL LUNG CANCER CO-
HORTS: COMBINED HIGH STROMAL AND TUMOR CELL 
CXCL16 EXPRESSION YIELDS AN IMPROVED SURVIVAL
Sigurd M. Hald1, Roy M. Bremnes1, Samer Al-Saad2, Elin Richard-
sen2, Yury Kiselev2, Sigve Andersen1, Helge Stenvold1, Marte Ei-
lertsen1, Khalid Al-Shibli2, Lill Tove Busund2, Tom Dønnem1
1Dept Clinical Medicine, University Of Tromsø/Norway, 2Dept Medical 
Biology, University Of Tromsø/Norway
Background: The chemokine CXCL16 and its receptor CXCR6 are 
expressed on a variety of immune cells, and have been shown to 
influence angiogenesis. Hence, these markers are potentially inte-
resting markers in NSCLC treatment. The expression of CXCR6 and 
CXCL16 has been examined in a variety of human cancers; however 
no studies have investigated their influence on prognosis in non-
small cell lung cancer (NSCLC). We therefore wanted to explore 
their prognostic significance in NSCLC, in addition to examining 
associations with our previously investigated immunologic and 
angiogenic markers.
Methods: Resected tumor tissue from consecutive unselected 
stage I-IIIA NSCLC patients (1990-2005) were collected in two 
different cohorts; Nordland Central Hospital, NCH (n = 176), and 
University Hospital of North Norway, UNN (n = 159). Tissue mi-
croarrays were constructed from duplicate cores of neoplastic 
epithelial and stromal areas of each specimen. Immunohistoche-
mistry was used to evaluate the expression of CXCR6 and CXCL16. 
Correlation analyses with well-known adaptive immunological 
(CD4, CD8, CD20), innate immunological (CD68, CD56, CD1A) and 
angiogenic (vascular endothelial growth factors and receptors, pla-
telet derived growth factors and receptors and fibroblast growth 
factor-2 and receptor-1) markers were done. Disease-specific survi-
val was used as endpoint, and survival analyses were performed in 
each cohort separately and in the combined total population.
Results: In univariate analysis, ↑stromal cell CXCL16 expressi-
on was a significant positive prognostic factor in the combined 
patient cohort (P = 0.016), supporting the similar trends in each 
cohort separately (NCH, P = 0.045; UNN, P = 0.137). Interestingly, 
the combinations (Figure 1) increased (↑stromal and ↑cancer cell), 
mixed (↑↓ and ↓↑) and reduced (↓stromal ↓cancer cell) CXCL16 
expression patterns showed 5-year survival rates of 71%, 58% 
and 48%, respectively (P = 0.016). CXCR6 was expressed in can-
cer cells, but did not show any significant prognostic impact. 
active protein expression by immunohistochemistry (IHC) was eva-
luated. We also tested the gene expression signature as a potenti-
al predictor of adjuvant chemotherapy benefit in a subset of NCIC 
JBR.10 adjuvant chemotherapy trial patients with microarray data.
Results: A 28-gene signature that distinguished SqCC with or 
without aberration of the NRF2 pathway genes (NFE2L2/KEAP1/
CUL3) in the TCGA dataset was identified. This gene signature that 
putatively represents NRF2 pathway activation status separates 
consistently SqCC into 2 groups in independent datasets. Both 
NRF2/KEAP1 mutation and NRF2 protein expression by IHC were 
significantly correlated with the NRF2 pathway activation signature 
(p<0.001 for each comparison). KEAP1 protein expression was not 
associated with the gene expression signature. No prognostic ef-
fect of the activated signature was observed in three independent 
datasets. In the JBR.10 patient cohort, a trend toward improved 
survival with adjuvant chemotherapy was observed in patients with 
the NRF2 “wild type” signature (HR 0.32, 95%CI 0.065-1.6 p=0.16), 
but not in patients with the “activated” signature (HR 2.28, 95%CI 
0.24–22, p=0.48; interaction p=0.15).
Conclusion: A gene expression signature based on mutational 
activation of the NRF2 pathway may be predictive of benefit 
from adjuvant cisplatin/vinorelbine in SqCC. Patients with NRF2 
pathway activating somatic alterations may have reduced benefit 
from this therapy. NRF2 immunohistochemistry could potentially 
be useful to identify NRF2-activated lung SqCC patients who may 
not benefit from adjuvant chemotherapy but this requires further 
validation.
Keywords: NRF2 pathway, KEAP1, squamous cell carcinoma, pre-
dictive marker
POSTER SESSION 2 - PROGNOSTIC AND PREDICTIVE BIOMARKERS  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.06-024 PROGNOSTIC VALUE OF RALA AND RALB 
OVEREXPRESSION IN KRAS MUTANT LUNG CANCER
Eun Young Kim, Se Kyu Kim, Joon Chang, Yoon Soo Chang
Department Of Internal Medicine, Yonsei University College Of Medici-
ne/Korea
Background: Oncogenic mutations of KRAS play important roles 
in cancer progression and resistance to chemotherapy in non-small 
cell lung cancer (NSCLC). Ras-related proteins, RALA and RALB, 
are members of the RAS superfamily of small GTPases and act as 
downstream effectors of KRAS. Therefore RAL proteins may be 
involved in cancer cell survival, invasion and metastasis. In this 
study, authors investigated the prognostic role of RALA and RALB 
overexpression in non-small cell lung cancer (NSCLC) patients with 
KRAS mutations.
Methods: Expression status of RALA and RALB in the tumor tissue 
of NSCLC patients whose tumor harbors KRAS mutations were 
evaluated by immunohistochemistry(n=12). In addition, we investi-
gated 11 metastatic lung tumor tissue samples from KRAS mutant 
colorectal cancer patients. Predictive factors for survival were 
calculated using Kaplan-Meier estimator and Cox proportional 
hazards model.
Results: There was no statistically significant relation between 
RALA/RALB overexpression and KRAS mutation subtypes. Howe-
ver, RALB was frequently overexpressed in the tumor of advanced 
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Methods: We reviewed the clinicopathological data for patients 
with pathological N2 NSCLC treated with surgical resection follo-
wed by either observation or adjuvant chemotherapy, if treated 
after 2004. Genomic DNA from formalin fixed paraffin embedded 
(FFPE) samples were purified and bisulfite converted according to 
the manufacturer’s (QIAGEN) instructions. Mutational status was 
determined in genomic DNA using Sequenom‘s Oncocarta panel 
v1.0. Tumour samples were cut and stained with NY-ESO-1 antibo-
dy (E978). Previously described protocols for methylation-specific 
NY-ESO-1 primers2 and beta-actin3 control probes were used. 
Using real-time quantitative methylation-specific polymerase chain 
reaction (qMS-PCR), the level of NY-ESO-1 methylation was deter-
mined and expressed as the ratio of methylated to unmethylated 
molecules (M/UM). We used a cut-off fold-difference of 5 (Log2, 
M/UM) to separate tumour samples into hypomethylated and hy-
permethylated groups. Survival estimates were obtained using the 
Kaplan-Meier method. Comparison across groups was performed 
using the Chi-squared or Fisher‘s test.
Results: NY-ESO-1 PM MS-PCR was successful in 92/100 (92%) 
of specimens. NY-ESO-1 was hypermethylated in 86% (79/92) of 
samples. Age, smoking history, gender, histology and oncogenic 
mutations were not associated with presence of NY-ESO-1 PM. 
NY-ESO-1 hypomethylation was inversely associated with protein 
expression (p<0.0001). In multivariate analysis, hypomethylation 
of the NY-ESO-1 promoter was an independent poorer prognostic 
marker in patients not treated with chemotherapy (HR 2.97, 95%CI 
1.06-8.29, p=0.038), after adjusting for age, gender, stage IIIA/B 
and histology. Conversely, in patients treated with chemotherapy 
there were no differences in survival associated with NY-ESO-1 PM, 
suggesting hypomethylated tumours remain chemosensitive.
Conclusion: NY-ESO-1 hypomethylation was an independent ad-
verse prognostic marker in patients not treated with chemothera-
py. Given their poorer outcome, association with chemosensitivity 
and known immunogenicity, CTAs may make attractive targets for 
immunotherapy, demethylating agents and immune checkpoint 
inhibition. References 1.John et al. PLOS One, In press. 2.James et 
al. Oncogene 2006. 3.Eads et al. Cancer Res 2001. .
Keywords: Promoter methylation, New York-Esophageal Antigen-1 
(NY-ESO-1), Cancer testis antigens, Treatment outcome
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P2.06-027 LOW FREQUENCY KRAS MUTATIONS IN 
COLORECTAL CANCER PATIENTS AND THE PRESENCE 
OF MULTIPLE MUTATIONS IN ONCOGENIC DRIVERS IN 
NON-SMALL CELL LUNG CANCER PATIENTS
Liyan Jiang1, Jiaqi Huang2, Chris Morehouse2, Brandon W. Higgs2, 
Wei Zhu2, Susana Korolevich2, Kim Lehmann2, Philip Brohawn2, 
Zheng Liu2, Christine Kiefer2, Xinying Su1, Yi Gu3, Yao Yihong2
1Shanghai Chest Hospital Affiliated To Shanghai Jiaotong University/
China, 2Translational Sciences, Medimmune Llc/United States Of Ame-
rica, 3Innovation Center China, Astrazeneca Global R&D/China
Background: Intra-tumor heterogeneity can confound mutational 
status in oncodriver genes and challenge targeted cancer therapy 
strategies. Ultra-deep sequencing can detect low-frequency and 
expanded clonal mutations in primary tumors to better inform 
treatment decisions
There were no strong correlations between CXCR6/CXCL16 and 
immunological or angiogenic markers. In the multivariate analy-
sis, combined ↓cancer and ↓stromal cell CXCL16 expression was 
an independent negative prognostic factor in the total cohort 
when compared to ↑stromal and ↑cancer cell expression (ha-
zard ratio: 2.41; 95% confidence interval: 1.14 – 5.12, P = 0.022). 
Conclusion: We have shown that combined ↑cancer and ↑stromal 
cell CXCL16 expression is an independent positive prognostic 
factor in NSCLC. Further studies are warranted to elucidate the 
biological mechanism underlying this finding.
Keyword: CXCL16 CXCR6 prognosis stroma
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P2.06-026 ASSOCIATION OF NEW YORK-ESOPHAGEAL 
ANTIGEN-1 (NY-ESO-1) PROMOTER METHYLATION AND 
SURVIVAL IN STAGE III NON-SMALL CELL LUNG CAN-
CER
Mun Sem Liew, Anderly C. Chueh, Marzena Walkiewicz, Jonathan 
Cebon, Paul Mitchell, John Mariadason, Thomas John
Ludwig Institute For Cancer Research/Australia
Background: Cancer-Testis antigens (CTAs) are immunogenic mo-
lecules exclusively expressed in normal testes but with aberrant 
expression in up to 30% of NSCLC. NY-ESO-1, is a CTA whose 
expression is associated with poorer survival but improved re-
sponse to chemotherapy.1 The promoter regions for many CTA 
genes contain CpG islands which are predominantly methylated in 
most tissues. In cancer, hypomethylation of CTA gene promoters 
hsvr been shown to be determining factor for the frequent re-ex-
pression of these genes. Herein we sought to correlate NY-ESO-1 
promoter methylation (PM) with protein expression in lung cancers 
and test whether methylation status can be used as a predictive 
and prognostic marker in NSCLC.
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62 years (35-84), 36.9% were male, 63.9% were stage IV, 78.3% 
were PS 0 or 1, 87.3% were ever-smokers, and 71.1% had received 
a first-line platinum-based chemotherapy. More ever-smokers 
were present in the KRAS-mutant subgroup compared with WTs 
(90% versus 76.5%, respectively, P = 0.08). ERCC1 average scores 
ranged from 0.1 to 26.7, the values being not normally distributed 
(Kolmogorov-Smirnov test, P<0.0001). Median and mean overall 
ERCC1 values for all patients were 1.3 and 2.2 [standard deviation 
(SD) 3.4], respectively. There was no statistically significant diffe-
rence in terms of ERCC1 median values betwen KRAS-mutants and 
KRAS WTs (1.4 vs. 1.3, respectively, P = 0.27). Nevertheless, mean 
ERCC1 expression levels were found to be significantly higher in 
KRAS-mutants compared with KRAS WTs [2.9 (SD 4.5) vs. 1.4 (SD 
0.8), respectively, P = 0.02]. This finding was due to 7 KRAS-mutant 
patients (ERCC1 high) coming out with ERCC1 levels higher than 
5.0, thus notably incresing mean ERCC1 values. In the group of 
patients treated with first-line platinum-based chemotherapy (n 
= 79), median progression-free survival was 1.9 months for KRAS-
mutant, ERCC1 high patients (n = 6), 5.1 months for KRAS-mutant, 
ERCC1 low patients (n = 38), and 7.1 months for KRAS WT patients 
(n = 35) (P = 0.003).
Conclusion: KRAS-mutant NSCLCs may express higher levels of 
ERCC1 compared with KRAS WTs, which could translate into poor 
sensitivity to first-line platinum-based chemotherapy. Combination 
strategies of platinum-based chemotherapy plus KRAS-targeting 
agents may represent an appealing upfront strategy for KRAS-mu-
tants advanced NSCLCs, particularly in presence of concomitant 
expression of high ERCC1 levels.
Keywords: EGFR wild type, KRAS, non-small cell lung cancer, 
ERCC1
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P2.06-029 ALTERATIONS DETECTED IN GLYCEROPHOS-
PHOLIPID PROFILE OF LUNG CANCER TISSUE SAMPLES 
BY MASS SPECTROMETRY
Argo Aug1, Katre-Helena Käppa1, Bruno Sarana2, Tanel Laisaar2, 
Kalle Kilk1, Ursel Soomets1
1Department Of Biochemistry, Institute Of Bio- And Translational Medi-
cine, Faculty Of Medicine, University Of Tartu/Estonia, 2Thoracic Surge-
ry, Tartu University Hospital/Estonia
Background: Metabolomics is an approach that is increasingly 
used in research of different types of cancer as it reflects the most 
proximate deviations in metabolism of cells and tissues. It has 
been shown before that untargeted metabolomics can effectively 
distinguish diseased tissue samples from healthy ones and di-
seased individuals from healthy ones regarding the general meta-
bolite pattern of the samples.
Methods: In this study lung cancer tissue and macroscopically 
non-cancer tissue were obtained from lung cancer patients (n=45) 
and analysed using liquid chromatography combined with tandem 
mass spectrometry to acquire full spectra of metabolites between 
mass-to-charge ratio (m/z) 50-1000 extracted in hydrophobic and 
hydrophilic phase in positive and negative ionisation mode. Princi-
pal component analysis (PCA), sparse partial least squares discrimi-
nant analysis (SPLS-DA), paired t-test were used for data analysis. 
Fragmentation and comparison of fragment spectra to public and 
in-house databases were used for metabolite identification.
Methods: KRAS coding exons in 61 treatment-naïve colorectal 
cancer (CRC) tumors were sequenced, along with KRAS, EGFR, 
ALK, and MET in lung tumors from 3 Chinese non-small cell lung 
cancer (NSCLC) patients
Results: Forty-two percent of CRC patients (28/61) harbored mu-
tations in the KRAS active domain, 12 patients harbored >1 muta-
tion, and eleven patients (18%), of which 5 had frequencies <10%, 
were not detected by Sanger sequencing. Low frequency KRAS 
active (G12R) and EGFR kinase domain mutations (G719A) were 
identified in one NSCLC patient. Multiple low frequency mutations 
in KRAS, EGFR, and MET and ALK gene copy number increases 
were found in a second NSCLC patient; a third NSCLC patient had 
EML4-ALK fusion with ALK, EGFR, and MET mutations. Multiple 
low frequency mutations occurred within individual gene in all 
three patients.
Conclusion: A complex pattern of intrinsic low frequency driver 
mutations in well-known tumor oncogenes may exist prior to 
treatment, potentially resulting in resistance to targeted therapies. 
Ultra-deep sequencing can characterize intra-tumor heterogeneity 
and identify such mutations which could ultimately impact treat-
ment decisions.
Keyword: KRAS, EGFR, mutation, NSCLC
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P2.06-028 ERCC1 MRNA EXPRESSION AND KRAS MU-
TATION STATUS IN EGFR WILD TYPE (WT) ADVANCED 
NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Giulio Metro1, Matteo Cenci1, Annamaria Siggillino1, Rita Chiari1, 
Francesca R. Tofanetti1, Diana Giannarelli2, Lorenza Pistola1, An-
tonella Flacco1, Chiara Bennati1, Guido Bellezza3, Sara Baglivo1, 
Angelo Sidoni3, Vienna Ludovini1, Lucio Crino1
1Medical Oncology, Santa Maria Della Misericordia Hospital/Italy, 
2Regina Elena National Cancer Institute/Italy, 3Pathology, Santa Maria 
Della Misericordia Hospital/Italy
Background: In a previous report of EGFR WT advanced NSCLC 
patients treated with first-line platinum-based chemotherapy we 
observed a worse clinical outcome for KRAS-mutants compared 
with KRAS WT patients (Metro et al. ESMO 2012). Here, we as-
sessed whether this phenomenon could be due to different levels 
of ERCC1 expression.
Methods: From a prospectively maintained database of EGFR WT 
advanced NSCLC patients diagnosed at a single Institution bet-
ween January 2006 and November 2012, we identified the indivi-
duals who had a known KRAS mutation status and tissue available 
for assessment of ERCC1 mRNA expression. Total RNA was isola-
ted from paraffin-embedded tumor specimens using RNeasy Mini 
kit and automatically purified by QiaCube instrument (Qiagen). 
Quantification of mRNA expression levels of ERCC1 was analyzed 
by real-time one-step RT-PCR using QuantiFast technology by 
RotorGeneQ instrument (Qiagen), and the results were compared 
considering β-actin as the internal reference gene.
Results: One hundred and eleven patients were evaluable, 60 
of which were KRAS-mutants. Among KRAS-mutants, the rate of 
codon 12/13/61 mutations were 80%/13.3%/6.7% respectively. 
Baseline patients characteristics were as follows: median age was 
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Methods: Delta HU/Gy and delta HU/Gy x MLD (Mean Lung Dose), 
the latter to take into account a volume factor for RILD, were cor-
related with 314 SNPs related to fibrosis and inflammation. The 
outcome variables were square root transformed because both 
were not normally distributed. Univariate ANOVA analyses were 
performed for comparisons of means. P-values of less than 0.01 
were considered to be significant.
Results: Eighty-nine lung cancer patients were studied, 63 men 
and 26 females. Twenty patients were treated with radiothera-
py alone, 31 with sequential chemo-RT and 38 with concurrent 
chemo-RT. Twenty percent of the patients developed grade 2 
or more clinical dyspnoea after treatment. Three SNPs were si-
gnificantly correlated with delta HU/Gy: rs2252070 (p=0.006, 
MMP13), rs2230588 (p=0.009, JAK1) and rs12901071 (p=0.009, 
SMAD3) [Table 1A]. For delta HU/Gy x MLD, significant associ-
ations were found for rs3819122 (p=0.008, SMAD4), rs2230529 
(p=0.009, ITGB2) and rs2230588 (p=0.009, JAK1) [Table 1B]. 
Conclusion: Quantification of CT density changes due to radiothe-
rapy, measured as HU changes over time as a specific and quan-
titative endpoint for RILD correlates with specific SNPs in genes 
involved in signal transduction of cytokines (SMAD3/4, JAK1), in 
the extracellular matrix (MMP13) and in cell adhesion (ITGB2). Ex-
ternal validation will follow.
Keywords: non-small cell lung cancer, SNP, Radiation-induced 
lung damage
Results: PCA and SPLS-DA indicated the existence of systematic 
differences in between the two types of tissue based on the data 
matrix extracted from mass-spectra. All together 496 signals (13% 
of all measured signals) were found to have significant (p<0.001) al-
teration by t-test between cancer and non-cancer spectra. Eleven 
most prominent of them were selected for fragmentation. Their 
mass-to-charge ratios (m/z) were in hydrophilic phase as follows: 
+86, -147, +168, -171, -201, and in hydrophobic phase +735, +736, 
-774, -775, -888 and -889. Signals with m/z of -171, +735, +736, -774 
and -775 were found more abundant in non-cancer tissue and the 
signals with m/z of +86, +168, -147, -201, -888 and -889 in the can-
cer tissue compared to non-cancer tissue. From hydrophobic pha-
se signals +735 and +736 were identified as unspecified species of 
phosphatidylcholines. M/z -888 was identified as phosphatidylino-
sitol 18:0-20:3 (stearic acid and Mead acid as lipid acid residues) 
having on average two-fold stronger signal in the spectra of cancer 
tissue compared to non-cancer tissue. The phosphatidylinositols 
are, in addition to structural purposes in membranes, known to be 
used as a depot for PUFA-s, such as arachidonic acid (AA; 20:4). 
As the increase of free Mead acid in blood has been linked to the 
deficiency of essential fatty acids (as AA) in food, we suggest our 
finding indicates that lung cancer cells have significantly increased 
demand for inflammatory mediators synthesized from AA.
Conclusion: Cancer tissue is clearly distinguishable from non-can-
cer tissue with mass spectrometry. From all low-molecular weight 
metabolites 13% are differing in cancerous and non-cancer tissue. 
Most striking changes were assigned to phospholipids and in par-
ticular to Mead acid containing phosphatidylinositols, which are 
upregulated in cancer tissues by 100%. The results imply differen-
tial regulation of polyunsaturated fatty acids in lung cancer, which 
improves our knowledge of molecular mechanisms of cancer and 
opens new ways for accurate prognostic markers and personalized 
approach to postoperative treatment.
Keywords: cancer tissue, untargeted metabolomics, Mead acid, 
phosphatidylinositol
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P2.06-030 RADIATION-INDUCED LUNG DAMAGE 
QUANTIFICATION WITH CT SCANS: CORRELATION 
WITH SINGLE NUCLEOTIDE POLYMORPHISMS
Dirk De Ruysscher1, Hoda Sharifi2, Wouter Van Elmpt2, Katrien 
Vandecasteele3, Philippe Lambin4, Yolande Lievens5, Wilfried De 
Neve5, Kim De Ruyck6
1Radiation Oncology, University Hospitals Leuven/ KU Leuven/Belgium, 
2Radiation Oncology, Maastro Clinic/Netherlands, 3Radiation Oncology, 
Gent University/Belgium, 4Department Of Radiation Oncology (Maas-
tro), Maastricht University Medical Center/Netherlands, 5Radiation 
Oncology Department, University Hospital Ghent/Belgium, 6University 
Ghent/Belgium
Background: Radiation-induced lung damage (RILD) is a dose-
limiting toxicity of lung radiotherapy. Individual sensitivity can be 
measured by changes in Hounsfield Units over time (delta HU) on 
CT scans (De Ruysscher et al. Acta Oncol 2013). This endpoint is 
specific for lung damage and does not correlate with dyspnoea, 
which is multi-factorial. In this study, we investigated the associati-
on between density changes over time and SNPs aiming at finding 
individual sensitivity for RILD.
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establishment of multidisciplinary teams to ensure the coordination 
between clinicians, radiologists and pathologists, makes routine pa-
thological and molecular diagnosis on bone metastasis specimens a 
fast, reliable and safe procedure.
Keywords: Bone Metastasis, genotyping, Adenocarcinoma
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P2.06-032 SMO MUTATIONS OCCUR IN NON-SMALL 
CELL LUNG CANCER (NSCLC) AND MAY RESPOND TO 
HEDGEHOG INHIBITORS
Anne Tsao1, Lauren A. Byers1, Lixia Diao2, Jing Wang3, John N. 
Weinstein3, Funda Meric-Bernstam4, Ken Aldape4, John V. Hey-
mach1
1Thoracic Head And Neck Medical Oncology, Univ Of Texas M.D. Ander-
son Cancer Center/United States Of America, 2Bioinformatics & Computa-
tional Biology, The University Of Texas MD Anderson Cancer Center,/Uni-
ted States Of America, 3Bioinformatics & Comp Biology, The University Of 
Texas MD Anderson Cancer Center/United States Of America, 4University 
Of Texas M.D. Anderson Cancer Center/United States Of America
Background: Smoothened (SMO) is a 7-membrane spanning recep-
tor involved in the hedgehog signaling pathway. In the absence of 
Patched inhibition, SMO accumulates and inhibits proteolytic clea-
vage of transcription factors. We previously identified a lung cancer 
patient with SMO mutation (Patient A, Table 1) and successfully trea-
ted him with erivedge, a hedgehog inhibitor. We therefore sought to 
determine the incidence of SMO mutations in The Cancer Genome 
Atlas (TCGA) lung cohorts, identify additional NSCLC patients with 
SMO mutations, and initiate therapy with hedgehog inhibition as 
proof-of-concept.
Methods: TCGA databases for lung adenocarcinoma (n=230) and 
squamous cell carcinoma (n=178) were interrogated for SMO muta-
tions and hedgehog pathway dyregulation. Mutations were deter-
mined by whole exome sequencing. Copy number was assessed by 
GISTIC 2.0 (scores of 2 considered high level amplification). The lung 
SMO mutation patients were undergoing treatment at M.D. Ander-
son Cancer Center Thoracic Clinic for metastatic/refractory disease. 
Mutations in hotspot regions of 46 cancer-related genes including 
SMO was performed as part of their clinical diagnostic evaluation 
(Ion AmpliSeq Cancer Panel; Life Technologies, CA).
Results: In TCGA lung adenocarcinomas, alterations in SMO (mutati-
on, amplification, mRNA overexpression) were observed in 12.2% of 
tumors. The incidence of SMO mutations was 2.6% and SMO gene 
amplifications 5%. SMO mutations and amplifications strongly corre-
lated with sonic hedgehog gene dysregulation (p<0.0001). In TCGA 
squamous cell, SMO was altered in 10.1% of tumors, primarily via 
mRNA upregulation. Only 1 SMO missense mutation was identified 
in the Lung SCC cohort (D209Y). We identified 3 NSCLC patients 
with SMO mutations (Table 1) by the 46-gene panel. Patient A was 
treated with erivedge as he had a concomitant localized basal cell 
carcinoma (BCC) with a significant reduction in tumor burden. He 
continues to respond to therapy after 14 weeks. It is possible that 
Patient A’s NSCLC-SCC was misidentified and that this was metasta-
tic BCC or that this is a germline variant. Germ-line mutation analysis 
is underway. However, the precise SMO mutation in Patient A was 
also identified in a lung adenocarcinoma Patient C (Table 1). Two 
additional SMO-mutated patients have just initiated erivedge and 
updates on their status will be provided at WLCC. 
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P2.06-031 MUTATIONAL PROFILING OF SYNCHRONOUS 
BONE METASTASES FROM LUNG ADENOCARCINOMA: 
FEASIBILITY AND RESULTS IN A PROSPECTIVE COHORT 
OF 46 PATIENTS (POUMOS STUDY)
Marie Brevet1, Cyrille B. Confavreux2, Jean-Baptiste Pialat3, Mojgan 
Devouassoux-Shisheboran4, Sylvie Isaac5, Jean-Charles Rousseau6, 
Pierre-Paul Bringuier1, Philippe Clézardin6, Françoise Thivolet-
Béjui7, Nicolas Girard8
1Pathology Department, Hôpital Edouard Herriot, Hospices Civils De Lyon/
France, 2Rheumatology Service, Hôpital Edouard Herriot, Hospices Civils 
De Lyon/France, 3Radiology Service, Hôpital Edouard Herriot, Hospices 
Civils De Lyon/France, 4Pathology Department, Hôpital De La Croix-Rousse, 
Hospices Civils De Lyon/France, 5Pathology Department, Centre Hospitalier 
Lyon Sud, Hospices Civils De Lyon/France, 6Inserm UMR 1033, Université 
Claude Bernard Lyon 1/France, 7Pathology Department, Hôpital Louis Pra-
del, Hospices Civils De Lyon/France, 8Respiratory Medicine Service, Hôpital 
Louis Pradel, Hospices Civils De Lyon/France
Background: Mutational profiling for targetable oncogenic drivers is 
systematically recommended in the pretherapeutic workup of meta-
static lung adenocarcinoma. Pathological and molecular diagnoses 
may be performed on specimens from metastatic lesions, when the 
primary pulmonary tumor is not accessible, either because of proxi-
mal location increasing the risk of transthoracic procedures, or when 
the material collected is insufficient in size. The feasibility of perfor-
ming molecular diagnoses on small specimens from bone metastases 
has been questioned over time. To prospectively study patients with 
bone metastases from lung cancer, we set up a multidisciplinary 
group at the Hospices Civils de Lyon, including rheumatologists, 
pulmonologists, oncologists, interventional radiologists, pathologists 
and molecular biologists.
Methods: POUMOS was a prospective observational study aiming 
at evaluating the feasibility of routine percutaneous biopsy of syn-
chronous bone metastases from lung adenocarcinoma, to perform 
pathological diagnosis and mutational profiling on the bone lesion. 
Results were correlated with that obtained on specimens from the 
primary tumor, if available. Technically, bone metastasis specimens, 
usually multiple, were sent fresh for immediate formalin-fixation, and, 
if possible, snap-freezing. Decalcification of bone was performed 
using EDTA for a better preservation of cell morphology and DNA. 
Mutational profiling of EGFR, KRAS, HER2, BRAF, and PIK3CA, as well 
as testing for ALK rearrangements, was conducted as recommended 
by the French National Cancer Institute (INCA) for all adenocarcinoma 
cases. DNA extraction was performed after laser microdissection 
of cancer cells; genotyping was based on direct sequencing and/or 
SNaPshot. Complete description of the process will be presented at 
the meeting.
Results: Starting April 2011, 46 patients with lung adenocarcinoma 
and synchronous bone metastasis were enrolled. No grade 3-4 adver-
se effects were reported after the bone biopsy. Mutational profiling 
was obtained in 45 (98%) cases; one specimen did not provide with 
sufficiently good quality DNA for the analysis. EGFR mutation was ob-
served in 6 (13%) patients, KRAS mutation in 14 (30%) patients, HER2, 
BRAF and PIK3CA mutations in 1 (2%) patient each. Updated results, 
especially correlations between the mutational profiles of primary 
lung tumors and bone metastases, will be reported at the meeting.
Conclusion: Our data demonstrate the feasibility of percutaneous 
biopsy of synchronous bone metastasis from lung adenocarcinoma to 
conduct mutational profiling for common oncogenic alterations. The 
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Background: KRAS mutations are common driver mutations in 
30% of non-small cell lung cancer. However, treatment for lung 
cancer patients with KRAS mutations remains unestablished. 
Therefore, to screen other targetable receptor tyrosine kinases 
(RTKs) in lung cancers with KRAS mutations, we performed phos-
pho-RTK array analyses using 6 KRAS mutated lung cancer cell 
lines.
Methods: Sixteen NSCLC cell lines were analyzed using Human-
Phospho-RTK Array Kit (R&D Systems, MN) and relative phospho-
rylation levels of 42 RTKs were examined. Phosphorylation levels 
Table 1
Patient Biopsy site SMO mutation 
Reported  
Histology
Duration of Erivedge  
Therapy Response to Erivedge 
A Lung
Codon 641, exon 
11 (CCT to GCT) p. 
Pro641Ala 
NSCLC SCC 14 weeks PR
A Skin lesion
Codon 641, exon 
11 (CCT to GCT) p. 
Pro641Ala
BCC 14 weeks CR
B
AP window 
lymph node
Codon 525, exon 
9 (ATG to TTG) 
p.Met525Leu
NSCLC Adenoca pending pending
C
Axillary lymph 
node
Codon 641, exon 
11 (CCT to GCT) 
p.Pro241Ala 
NSCLC Adenoca pending pending
Conclusion: SMO mutations and pathway alterations occur in NS-
CLC and may be an actionable target with hedgehog inhibitors; a 
clinical trial is under development. Screening lung SCC tumors for 
SMO mutations is recommended to prevent misdiagnosis of me-
tastatic BCC. Additional analysis of hedgehog signaling pathway 
alterations is underway and will subsequently be reported.
Keywords: Smoothened mutation, NSCLC, hedgehog inhibition, 
TCGA
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P2.06-033 IDENTIFICATION F IGF-1R ACTIVATION AS A 
CANDIDATE MOLECULAR TARGET IN KRAS-MUTATED 
LUNG CANCER
Hiroshi Mizuuchi, Kenichi Suda, Katsuaki Sato, Toshiki Takemoto, 
Takuya Iwasaki, Kenji Minami, Tetsuya Mitsudomi
Division Of Thoracic Surgery, Department Of Surgery, Kinki University 
Faculty Of Medicine/Japan
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60 patients who provided EGFR mutated status, 29 patients harbo-
red EGFR mutation and the other 31 without EGFR mutation. The 
PFS of the subgroup with EGFR mutation after EGFR-TKIs showed 
prolonged trend compared with that of the subgroup without 
EGFR mutation, however, the statistics failed to amount to signifi-
cant difference (2.4 months vs. 1.8 months, p=0.071). No statistical 
differences were observed in PFS ORR, DCR and OS between the 
two subgroups. IHC results demonstrated that most of lung SCC 
patients harboring EGFR mutation showed P63 positive and TTF-
1 negative (15/18). We then constructed lung SCC cell lines with 
EGFR mutation (Beas-2B/EGFR 19DEL cell line and Beas-2B/EGFR 
21L858 cell line), which showed resistant to erlotinib with the IC50 
of 3.43±0.56µM和11.9±1.18µM. After the treatment of erlotinib, the 
mainly up-regulated signaling pathways included TGFβ pathway 
and hedgehog pathway, and RNA levels of some mesenchymal 
genes were also up-regulated.
Conclusion: Lung SCCs with EGFR mutation were not uncommon, 
who showed insensitivity and even resistance to EGFR-TKIs. The 
likely molecular mechanisms included TGFβ related epithelial-me-
senchymal transition (EMT) and tumor stem cell like differentiation, 
and the upregulation of bone morphogenetic protein 4 (BMP4).
Keyword: EGFR mutations,Lung squamous cell carcinoma,EGFR-
TKIs,TGFβ,BMP4
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P2.06-035 ACQUIRED RESISTANCE IN NSCLC WITH 
EGFR MUTATION TREATED WITH TKI‘S: SINGLE CENTER 
EXPERIENCE AND TREATMENT OUTCOME
Frank -. Griesinger1, Volker Halbfass2, Imme Conradi2, Cora Hal-
las3, R P Henke4, Markus -. Falk3, Markus Tiemann3
1Hematology And Oncology, Pius-Hospital Oldenburg, University Of 
Oldenburg/Germany, 2Hematology And Oncology, Pius-Hospital/Ger-
many, 3Pathology, Hemopathology Hamburg/Germany, 4Institute Of 
Pathology/Germany
Background: Acquired resistance in NSCLC with activating EGFR 
mutations has been defined by Jackman et al. The molecular me-
chanisms have been studied in small series of patients: in about 
50% of cases, T790M mutation confers acquired resistance, in 25% 
c-Met overexpression detected by IHC. Other as of yet unknown 
mechanisms might also play a role. Here we present the acquired 
resistance mechanisms in a cohort of 12 patients (out of 33 pts.) with 
activating EGFR mutations treated with TKI and identified at our 
center (see Halbfass et al.). Treatment methods and outcome are 
also described
Methods: 159 consecutive patients (s. abstract Halbfass et al.) were 
molecularly studied for EGFR mutations in exons 18-21. EGFR mu-
tation analysis was performed by Sanger Sequencing or by hybridi-
zation based COBAS methodology after microdissection of tumor 
tissue to ascertain a high percentage of tumor tissue. c-Met IHC was 
performed automatized by standard procedure (BondMax, Menari-
ni). ALK rearrangement was studied using a break apart FISH-Probe 
(Abbott). Remission was measured by RECIST 1.1 criteria.
Results: Of 159 patients tested, 33 had an EGFR mutation, of which 
3 had primary resistance mutations (T790M 1 case, Exon 20 inser-
tions 2 cases). Of these 30 pts., 20 had acquired resistance and 12 
were rebiopsied. 8 were not rebiopsied for various reasons, the 
of RTKs were quantified relative to the average of positive controls 
using image analysis software JustTLC (Sweday, Lund, Sweden). 
We also examined growth inhibitory effect of small interfering 
RNA (siRNA) and erlotinib in KRAS mutant lung cancer cell lines. In 
addition, we developed erlotinib-resistant cell lines from erlotinib-
sensitive H358 cells by chronic drug exposure for 3 months.
Results: In the phospho-RTK array analysis, phosphorylation levels 
of EGFR were lowest in the cell lines with KRAS mutation (Table1). 
Three of six cell lines with KRAS mutation showed IGF-1R phospho-
rylation and the difference was statistically significant compared 
with 0 of ten cell lines without KRAS mutation (P=0.03, Fisher‘s Ex-
act test). KRAS siRNA did not induce apoptosis in 5 cell lines with 
KRAS mutation but mild apoptosis in H358 cells. Moreover, only 
H358 showed mild sensitivity to erlotinib (IC50 120nmol/L). Analysis 
for erlotinib-resistant H358 cells identified increased phosphoryla-
tion of IGF-1R compared with H358 parent cells (18.0 times).
Conclusion: These results suggest IGF-1R may be a candidate 
molecular target in lung cancers with KRAS mutation.
Keywords: NSCLC, KRAS mutation, IGF-1R
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P2.06-034 ANALYSIS OF SENSITIVITY OF LUNG SQUA-
MOUS CARCINOMA WITH EGFR MUTATION TO EGFR-
TKIS AND RESISTANT MECHANISM
Zhijie Wang, Zhenxiang Li, Xiaodan Yang, Hua Bai, Minglei Zhuo, 
Jianchun Duan, Jie Wang
Peking University Cancer Hospital/China
Background: Epidermal growth factor receptor (EGFR) gene 
variation is one common driver mutation in lung cancer. In lung 
adenocarcinoma, EGFR mutations are the powerful predictors to 
the efficacy of EGFR-TKIs. However, the phenomenon seemed to 
be inconsistent in lung squamous carcinoma. The present study 
aims to investigate the sensitivity of lung squamous cell carcinoma 
(SCC) harboring EGFR mutation to EGFR-TKIs, and explore the like-
ly molecular mechanisms through constructing EGFR mutant lung 
SCC cell lines and analyzing the results transcriptomics.
Methods: This study retrospectively enrolled 91 patients with 
advanced lung SCC who received EGFR-TKIs in Beijing University 
Cancer Hospital. Denaturing high-performance liquid chromato-
graphy (DHPLC) and immunohistochemistry (IHC) were used for 
the detection of EGFR mutations and protein expressions of P63 
and TTF-1, respectively. Stable cell lines were constructed through 
lipofectamine and confirmed by western-blot, soft agar cloning 
formation and tumoregeneity in nude mice. Cell titer Glo was used 
for cell number counting. RNASeq was used for the analysis of 
transcriptomics and related signaling pathways were screened in 
KEGG website. SPSS (17.0 version) was used for statistics.
Results: The frequency of EGFR mutation was 16.2% (64/396) in 
lung SCC. In lung cancer patients with EGFR mutation, lung SCC 
patients accounted for 7% (64/863), commonly in male (71.9%), 
smoker (59.4%) and EGFR exon 19DEL (64.1%). In total 91 pati-
ents who received EGFR-TKIs, the objective response rate (ORR) 
and the disease control rate (DCR) were 11.0% (10/91) and 56.0% 
(51/91) respectively and the progression-free survival (PFS) and the 
overall survival (OS) were 2.9 months and 16.3 months. In terms of 
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analysed at 4 weeks of radiotherapy suggests an impaired radia-
tion response after multiple radiotherapy fractions. By contrast, 
the mean number of observed hair follicle gamma-H2AX foci was 
not different from baseline to 1-hour post first-fraction (p=0.42), 
elevated at 24 hrs (p=0.10) and 4 weeks (p=<0.01) but was not 
different from baseline at 3 months (p=0.31). The scattered dose 
at the eyebrow was recorded at <0.01 Gy per fraction and was 
insufficient to directly induce the observed gamma-H2AX signal 
Figure 1 - a brisk DNA damage response in out-of-field eyeb-
row hair 24-hours post radiation (gamma-H2AX foci in green)
Conclusion: The Gamma-H2AX assay on peripheral blood at 
1-hour may be a useful as a human in-vivo biodosimeter. To our 
knowledge, this study is the first report of abscopal DNA damage 
response in hair follicles associated with radiotherapy in cancer 
patients. Further validation of our findings on a larger patient co-
hort is warranted.
Keywords: DNA damage, radiation therapy, gamma-H2AX, Non 
small cell lung cancer
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P2.06-037 TRANSFORMING GROWTH FACTOR-Β1 GE-
NETIC POLYMORPHISMS RELATE TO ERLOTINIB INDU-
CED DIARRHEATRANSFORMING GROWTH FACTOR-Β1 
GENETIC POLYMORPHISMS RELATE TO ERLOTINIB 
INDUCED DIARRHEATRANSFORMING GROWTH 
FACTOR-Β1 GENETIC POLYMORPHISMS RELATE TO ER-
LOTINIB INDUCED DIARRHEA
Tatsuo Kimura1, Tomohiro Suzumura2, Shinzoh Kudoh1, Kuniomi 
Matsuura1, Toshiyuki Nakai1, Naoki Yoshimoto1, Takako Oka1, Shi-
geki Mitsuoka1, Naruo Yoshimura1, Yukimi Kira3, Kazuto Hirata1
1Respiratory Medicine, Osaka City University/Japan, 2Medical Oncology, 
Izumi Municipal Hospital/Japan, 3Central Laboratory, Osaka City Uni-
versity/Japan
Background: Rash, liver dysfunction, diarrhea and pneumonitis are 
known as adverse events of epidermal growth factor receptor ty-
rosine kinase inhibitors (EGFR-TKIs). Transforming growth factor-β1 
(TGF-β1) is a cytokine and acts as an anti-proliferative factor in 
normal epithelial cells and epithelial-mesenchymal transition (EMT) 
most common being progress in the CNS. Of the 12 rebiopsied 
pts, c-Met was successfully studied in 8, T790M in 12 and ALK in 6. 
In 5/8 pts., c-Met was amplified, in 4/12 pts. the T790M mutation 
was found and in 1/6 pts., an ALK rearrangement was observed. 
4 pts. received afatinib, 2 pts. chemotherapy, 2 pts. afatinib and 
cetuximab, 1 pt. afatinib and crizotinib and 2 pts. other treatments. 
Detailed treatment results will be presented at the meeting.
Conclusion: The understanding of resistance mechanisms in acqui-
red TKI resistance is of academic interest and might be important 
for subsequent treatment options. Therefore, rebiopsy at progress 
while on TKI therapy should be discussed with patients. As targeted 
treatment options are available for c-Met, ALK as well as T790M, 
resistance mechanisms potentially may guide therapeutic strategies 
in EGFR mutated patients with acquired resistance.
Keywords: EGFR mt NSCLC, acquired resistance mutations
POSTER SESSION 2 - PROGNOSTIC AND PREDICTIVE BIOMARKERS  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.06-036 DNA DAMAGE RESPONSE DURING CURATIVE 
RADIOTHERAPY OF NON-SMALL CELL LUNG CANCER: 
IN-VIVO BIODOSIMETRY WITH PERIPHERAL BLOOD 
LYMPHOCYTES AND SYSTEMIC EFFECTS MEASURED  
IN HAIR FOLLICLES
Shankar Siva1, Pavel Lobachevsky2, Nickala Best2, Jai Smith2, Tho-
mas Devereux3, Michael Hofman4, Tomas Kron5, David Ball1, Mi-
chael Macmanus1, Olga Martin2
1Radiation Oncology, Peter MacCallum Cancer Centre/Australia, 2Mo-
lecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre/
Australia, 3Radiation Therapy Services, Peter MacCallum Cancer Cen-
tre/Australia, 4Nuclear Medicine, Peter MacCallum Cancer Centre/Aus-
tralia, 5Physical Sciences, Peter MacCallum Cancer Centre/Australia
Background: The interactions between radiation dose, toxicity 
and systemic responses are poorly understood during radiothera-
py of patients with NSCLC). The purpose of this study was to mo-
nitor DNA damage using the gamma-H2AX assay in tissues inside 
and outside irradiated volumes of patients with NSCLC.
Methods: This prospective ethics approved study assessed 12 pa-
tients receiving radiotherapy was planned to 60 Gy in 30 fractions 
over 6 weeks. Six patients receive concurrent platinum doublet 
chemotherapy (chemoRT), and six patients had radiotherapy alone. 
The number, distribution and kinetics of gamma-H2AX foci were 
compared with the irradiated volume. Lymphocytes and eyebrow 
hairs were processed for gamma-H2AX staining and microscopy at 
each of 5 time-points; baseline, 1 and 24 hours post-first fraction, 4 
weeks into radiotherapy, and 3 months after treatment completion.
Results: The mean irradiated target volume was 384 cm3 (range 
87-1137 cm3). We observed the presence of a small subpopulation 
of lymphocytes with multiple (>5) gamma-H2AX foci at 1-hour 
post-first fraction. There was no difference in this subpopulation 
between patients receiving chemoradiotherapy or radiotherapy 
alone at baseline (p=0.26) nor at 1-hour (p=0.24) There was a 
strong correlation between the size of this subpopulation and ir-
radiated volume (r=0.84, p<0.01), indicating direct radiation expo-
sure. This suggests potential utility of the gamma-H2AX assay as a 
human in-vivo biodosimeter. This subpopulation was not detected 
at 24 hours due to DNA damage repair. A trend for reduction of 
this subpopulation and the average number of foci in lymphocytes 
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P2.06-038 COMPARISON OF EXPRESSION PROFILING 
OF CIRCULATING AND TISSUE MIRNAS LOOKING 
FOR POSSIBLE NON-INVASIVE BIOMARKERS FOR THE 
TREATMENT OF METASTATIC NSCLC PATIENTS: PRELI-
MINARY RESULTS.
Stefania Tommasi1, Daniela Petriella1, Katia Danza1, Rosamaria 
Pinto1, Annamaria Catino2, Barbara Barrettara3, Francesco Alfredo 
Zito3, Massimo Carella4, Orazio Palumbo4, Giovanni Simone5, Do-
menico Galetta2
1Molecular Genetics, National Cancer Research Centre “Giovanni Paolo 
Ii“/Italy, 2Medical Oncology, National Cancer Research Centre “Giovanni 
Paolo Ii“/Italy, 3Ospedale San Paolo Asl Bari/Italy, 4IRCCS Casa Sollievo 
Della Sofferenza/Italy, 5Pathological Anatomy, National Cancer Re-
search Centre “Giovanni Paolo Ii“/Italy
Background: Non-small cell lung cancer (NSCLC) is the most com-
mon type of lung cancer. Although some progress has been made 
in the development of its treatment, most patients are diagnosed 
at advanced stage and have a short overall survival rate. Just as 
specific genes have to be analyzed before selecting a targeted 
therapy, microRNAs (miRNAs) are emerging as biomarkers for NS-
CLC diagnosis and prognosis. miRNAs are small oligonucleotides 
that regulate target mRNAs in the post-transcriptional step driving 
the expression of some genes involved in the tumorigenesis of NS-
CLC. Due to their resistance to nuclease digestion, miRNAs can be 
detected both in lung tissue samples and in body fluids as circu-
lating factors. Our aim was to identify specific non-invasive cancer 
biomarkers involved in NSCLC tumorigenesis regulation.
Methods: 33 NSCLC patients, 19 male and 14 female, were en-
rolled. The mean age was 63.3 and 66% were smokers. 88% of 
patients had advanced stage (IIIb-IV) tumors of which 23 were 
adenocarcinoma and 10 squamous cell carcinoma. We collected 
serum before chemotherapy and, when available, tissue samples 
from biopsy. MiRNA expression profiling of 33 serum and 10 tissue 
paired samples and 10 serum samples from normal volunteers 
were investigated by Affymetrix GeneChip miRNA Array. meV 
software was used for statistical analysis, and target genes identi-
fied by deregulated miRNAs were analyzed through the miRWalk 
database.
Results: Statistical analysis revealed 47 miRNAs differentially 
expressed in NSCLC serum samples compared to control serum 
(p<0.05) and 29 miRNAs deregulated in NSCLC tissue samples 
compared to their normal counterparts. 326 miRNAs resulted dif-
ferentially expressed between the serum and the tissue of NSCLC 
patients. Among these deregulated miRNAs, the Venn diagram 
comparing tumor/normal serum, tumor/normal tissue and tumor 
serum/tissue samples showed that the serum of NSCLC patients 
was characterized by 22 miRNAs, while 10 miRNAs identified the 
tumor tissue of NSCLC patients. Only one miRNA, miR-133a, was 
detected both in NSCLC serum samples and in tissue ones. Focu-
sing on miRNAs involved in NSCLC pathogenesis, of 22 miRNAs 
miR-486-5p had a lower mean expression ratio (MER) in tumor vs 
normal serum (8.70±3.28 vs 10.78±1.35), as did let7b which had 
a MER of 5.28±2.63 in tumor serum vs 7.14±1.8 in normal serum 
samples. Of 10 miRNAs, miR-200c had the lowest MER in tumor vs 
normal tissue (1.25±0.10 vs 2.37±0.09 respectively) as did miR-29c* 
which had a MER of 2.18±0.08 in tumor tissue samples vs 2.34±0.11 
in normal tissues. miR-133a had a comparable MER in tumor se-
rum vs tumor tissue (2.41±0.17 vs 2.46±0.17 respectively). These 
miRNAs are able to target PIK3CA and PTEN genes, according 
with invasion and metastasis in cancer cells. TGF-β1 mediated 
Smad activation caused EMT, and activation of the EGFR. TGF-
β1-mediated EGFR activation was abolished by EGFR suppression 
or extracellular EGF depletion pathway. TGF-β1 genotypes are 
associated with serum level of TGF-β1. It has been hypothesized 
that TGF-β1 genotypes may be implicated in clinical outcomes of 
EGFR-TKIs.
Methods: Patients were identified through a query of patient infor-
mation for subjects enrolled in the Medical Information System in 
Osaka City University Hospital between January 1999 and Februa-
ry 2012. The associations between three genetic polymorphisms of 
TGF-β1 (C-509T, T869C, and G915C) and adverse events of erloti-
nib and gefitinib have been studied. Genomic DNA was extracted 
from peripheral blood or formalin-fixed and paraffin-embedded 
tissues. TGF-β1 genotypes were determined using RT-PCR me-
thod. The primers were designed to amplify the target fragments 
of TGF-β1 rs1800469, rs1800471, and rs1982073, respectively. In 
order to identify the risk factors for the adverse events, gender, 
age, stage and three genetic polymorphisms of TGF-β1 were selec-
ted and estimated for their potential confounding effects on rash, 
diarrhea, and liver dysfunction by multivariate analysis. Uncondi-
tional logistic regressions were used to compute the odds ratios 
(ORs) and their 95% confidence intervals (CIs). All analyses were 
two-sided, and p values of less than 0.05 were considered statisti-
cally significant. This study was approved by the ethics committee 
of Osaka City University (approval number, 1700).
Results: A total of 255 patients received gefitinib, and 75 pati-
ents received erlotinib. In the gefitinib group, the rates of rash, 
diarrhea, and liver dysfunction of grade 1 or more were 66.7%, 
26.0% and 48.5%, respectively. In the erlotinib treatment group, 
the rates of rash diarrhea, and liver dysfunction of grade 1 or more 
were 84.1%, 43.5% and 33.3%, respectively. The C-509T consisted 
of TT in 26.6%, CT or CC in 73.3% of patients (n=289), respectively. 
The T869C consisted of CC in 26.1%, TC or TT in 73.9% of pati-
ents (n=272), respectively. The G915C consisted of GG in 100% 
of (n=313) patients. TT of the C-509T and CC of the T869C were 
significantly associated diarrhea of grade 1 or more in erlotinib 
group (OR 0.21, 95% confidence interval [CI] 0.054-0.72, p < 0.001, 
and OR 0.21, 95% CI 0.05-0.73, p = 0.014, respectively). No associ-
ations were observed between TGF-β1 genotypes and any adverse 
events in gefitinib group.
Conclusion: Minor alleles of TT of the C-509T and CC of the 
T869C were associated with erlotinib induced diarrhea. These alle-
les are generally associated with high level of TGF-β1 in serum. The 
increase level of TGF-β1 may be a risk factor for mucosal damage 
of the gastrointestinal tract in patients treated with erlotinib.
Keywords: NSCLC, EGFR-TKI, TGF-β1, Polymorphism
S801Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Conclusion: EGFR protein overexpression and gene amplification 
in ESCC were correlated with the malignant biological behavior, in-
cluding tumor differentiation and lymph node metastasis. Further 
studies should be conducted to analyze the prognostic value of 
EGFR protein overexpression and gene amplification in patients 
with ESCC.
Keyword: epidermal growth factor receptor, esophageal squa-
mous cell carcinoma, prognosis
POSTER SESSION 2 - PROGNOSTIC AND PREDICTIVE BIOMARKERS  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.06-040 CIRCULATING CYTOKINES AND ANGIO-
GENIC FACTORS (CAFS) AS MARKERS OF CLINICAL 
RESPONSE IN A RANDOMIZED PHASE II STUDY OF 
TRAMETINIB VS DOCETAXEL FOR PATIENTS WITH 
KRAS-MUTANT NON-SMALL CELL LUNG CANCER (NS-
CLC) (MEK114653, NCT01362296)
Hai T. Tran1, Yuan Liu2, Robert C. Gagnon2, Erica Rappold2, George 
R. Blumenschein1, Vijay G.R. Peddareddigari2, Frank S. Wu2, John 
Heymach1
1The University Of Texas MD Anderson Cancer Center/United States Of 
America, 2GlaxoSmithKline/United States Of America
Background: Trametinib is a reversible and highly selective alloste-
ric inhibitor of MEK1/MEK2. In a 2:1 randomized, open-label phase 
2 study, trametinib showed an overall response rate of 12% but 
did not show improvement in progression-free survival (PFS) over 
docetaxel as second-line treatment in patients with KRAS-mutant 
NSCLC. Median overall survival (OS) was 8 months in the trame-
tinib arm and has not been reached in the docetaxel arm (ASCO 
2013 abstract #8029). Several CAF markers were identified as pro-
gnostic and predictive of clinical benefit in patients with renal cell 
carcinoma (Tran, Lancet 2012), and of tumor shrinkage in patients 
with NSCLC (Nikolinakos, Cancer Research 2010), after receiving 
targeted therapy.
Methods: Of 134 patients randomized, plasma samples (n = 116 
baseline [113 KRAS-mutant], n = 89 day 22) from patients who 
consented for this optional study were analyzed for 38 CAFs using 
SearchLight multiplex assays in a CLIA-certified laboratory. Base-
line CAF levels were tested for association with PFS using propor-
to the miRWalk database, which are involved in the EGFR-related 
pathway.
Conclusion: Our results highlighted specific miRNA expression 
profiles, both in the serum and in the tissue of NSCLC patients, 
able to identify circulating miRNAs that could be used as non-
invasive biomarkers for early diagnosis, or to predict prognosis in 
NSCLC patients thus improving personalized therapy. These data 
are preliminary to a prospective clinical validation in a multicentric 
trial.
Keyword: miRNA, NSCLC, biomarkers, serum
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P2.06-039 THE STATUS OF EPIDERMAL GROWTH FAC-
TOR RCEPTOR (EGFR) MUTATION, PROTEIN OVEREX-
PRESSION AND GENE AMPLIFICATION IN ESOPHAGEAL 
SQUAMOUS CELL CARCINOMAS
Yaping Xu, Xiaojiang Sun, Wei Wu, Jialei Gu, Gu Zhang, Jinlin Hu, 
Yuanda Zheng, Weimin Mao
Zhejiang Cancer Hospital/China
Background: Epidermal growth factor receptor (EGFR) is widely 
distributed in human epithelial cell membrane, including esopha-
geal squamous cell carcinoma (ESCC). The purpose of this study 
was to evaluate the relationship between malignant biological 
behavior and EGFR status in ESCC.
Methods: We investigated tumor specimens from 56 patients with 
surgically resected ESCC from 2004 through 2008. Immunohisto-
chemistry (IHC) was performed to analyze the expression of EGFR. 
Fluorescence in situ hybridization (FISH) was performed to assess 
the EGFR gene amplification. EGFR mutations in exons 19-21 
were detected by pyrosequencing technology. A chi-square test 
or Fisher exact test for independence was used to examine the 
correlation among the status of EGFR protein, gene and the se-
veral clinicopathological factors. Overall survival and disease-free 
survival were constructed using the Kaplan-Meier method, and 
the log-rank test was used to evaluate the statistical significance 
of differences. Multivariate analysis was performed using the Cox 
proportional hazard method.
Results: EGFR was overexpressed in 30 of 56 ESCC (53.6%) and 
was correlated with tumor differentiation (p=0.047) (Figure 1.). 
EGFR gene amplification was found in 13(23.2%) cases and was 
correlated with the presence of lymph node metastasis (p=0.001) 
and higher pathological tumor-node-metastasis (pTNM) stage 
(p=0.042). There was no EGFR mutation in the clinical samples of 
56 patients with ESCC. In univariate analysis, there was no corre-
lation between the prognosis and EGFR protein expression, but 
EGFR gene amplification was a significant predictor of better prog-
nosis (p=0.031). The multivariate analysis revealed that EGFR gene 
amplification was significantly correlated with better disease-free 
survival (p=0.037) and overall survival (OS) (p=0.026). However, 
patients with EGFR gene amplification did more likely receive ag-
gressive treatment in clinical practice.
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Conclusion: Plasma VEGF 165 is a potential diagnostic marker in 
advanced NSCLS.
Keywords: NSCLC, VEGF
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P2.06-042 THYMIDYLATE SYNTHASE EXPRESSION AS 
PREDICTIVE BIOMARKER OF PEMETREXED SENSITIVITY 
IN ADVANCED THORACIC CANCER PATIENTS.
Manuel Domine, Federico Rojo, Sandra Zazo, Cristina Chamizo, 
Gloria Serrano, Cristina Caramés, Nuria Pérez González, Tatiana 
Hernández, Carolina Ortega, Carmen Laura Auz, Irene Moreno, 
Jose Ignacio Martín Valades, Yann Izarzugaza, Nerea Carvajal, 
Juan Luis Arranz, Juan Madoz, Ana León, Francisco Lobo, Victoria 
Casado, Gustavo Rubio, Brezo Martinez-Amores, Alberto Lendi-
nez, Mauro Oruezabal, Natalia Ramirez, Maria Jesús Fernández-
Aceñero, Jesús García Foncillas
Translational Oncology Division, ISS-Hospital Universitario Fundación 
Jiménez Díaz/Spain
Background: Although a high level of thymidylate synthase (TS) 
expression in malignant tumours has been suggested to be rela-
ted to a reduced sensitivity to the antifolate drug pemetrexed, no 
direct evidence for such an association has been demonstrated in 
routine clinical samples from patients treated with this drug. The 
purpose of this study was to evaluate the impact of quantitative 
TS expression in tumor cells as predictor of the efficacy in patients 
with advanced non-small cell lung cancer, small cell lung cancer 
(SCLC) and mesothelioma treated with pemetrexed in our institu-
tion.
Methods: 54 patients were included in this study: 40 stage IV 
NSCLC (26 adenocarcinomas, 11 large cell, and 3 squamous cell 
carcinoma), 3 SCLC and 11 mesothelioma. 21 patients received 
platins-pemetrexed as first line NSCLC, 20 pemetrexed in mono-
therapy as second and further lines and 3 carboplatin-pemetrexed 
fo extensive disease SCLC. Total RNA was isolated by RNeasy 
FFPE procedure (Qiagen). The expression of TS was analyzed by 
RT-qPCR using appropriate mRNA specific primers and probes in 
LightCycler 480II platform at 45 cycles. TS levels was calibrated to 
expression in normal tissue.
Results: From 54 cases, TS expression data were available in 32 
cases, detecting overexpression in 23 (71.8%) and low expression 
in 9 (28.2%) patients. The response rate for patients with low TS 
expression was 0.63 compared with 0.15 in patients with overex-
pression (p=0.015). A significant benefit in time to progression 
was observed in patients with low expression (median TTP 12 vs. 2 
months respectively, p= 0.002), whereas did not impact on overall 
survival (median OS 20 vs. 19 months respectively, p= 0.595).
Conclusion: TS overexpression in tumor cells correlated with a 
reduced response to pemetrexed-containing chemotherapy and 
might be used as a predictive biomarker in advanced lung and 
mesothelioma cancer patients.
Keywords: Biomarkers, thymidylate synthase, Advanced Thoracic 
Cancer
tional hazards regression within and between arms. Correlation 
between baseline CAFs and baseline tumor burden was assessed 
using the Spearman rank correlation test. Change from baseline 
was assessed using Wilcoxon signed rank tests. P < .01 was consi-
dered significant; for treatment arm by CAF-level interaction, P < 
0.05 was considered significant.
Results: Lower baseline levels of IL-6 and OPN and higher baseline 
levels of TRAIL were associated with longer PFS in patients treated 
with trametinib but not those treated with docetaxel. Interaction 
between CAFs and trametinib or docetaxel treatment was signi-
ficant for IGFBP-1, MMP-9, E-selectin, and VEGF. There was a po-
sitive correlation between IL-6 levels and baseline tumor burden. 
At day 22, decreases (trametinib: ANG-2, IGF-1, IGFBP-3, IL-10, 
IL-2R, TIMP-1; docetaxel: IL-6, MIP-1A, MIP-1B, SDF-1) and increases 
(trametinib: IGFBP-1, IL-6, MMP-2, PIGF, VEGF) in CAF levels were 
observed. Additional results (pairwise correlation, CAF levels and 
OS, change from baseline CAF levels and PFS and OS) will be re-
ported.
Conclusion: Circulating baseline CAF levels may be predictive of 
PFS for patients treated with trametinib or docetaxel. CAF levels 
are modulated by each treatment. The impact of circulating base-
line CAFs on PFS warrants additional investigation in well-desig-
ned clinical trials. Plasma CAF profiling may aid in the prognostic 
evaluation of patients and determine potential therapeutic respon-
se to trametinib treatment in patients with NSCLC.
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P2.06-041 PLASMA VASCULAR ENDOTHELIAL GROWTH 
FACTOR 165(VEGF 165) IN ADVANCED NON-SMALL 
CELL LUNG CANCER
Ahmed Abdallah1, Mohamed Belal1, Ahmed El Bastawisy2, Rabab 
Gaafar2
1Faculty Of Pharmacy, Al Azhar University/Egypt, 2Medical Oncology, 
National Cancer Institute, Cairo University/Egypt
Background: Lung cancer is the leading cause of death among 
malignant tumors worldwide therefore it is important to develop 
novel diagnostic techniques.
Methods: This is a prospective case control study including two 
groups of patients: Group I: healthy volunteers as control .Group II: 
Patients with advanced non-small cell lung cancer (NSCLC). Plasma 
VEGF 165 levels were measured at baseline by ELISA before first 
line Gemcitabine-Cisplatin regimen. High VEGF 165 cutoff taken 
was >703 pg/ml .Primary end point was comparison of plasma 
VEGF 165 levels in cases and controls. Secondary endpoint was 
correlation between High VEGF 165 and clinical response (CR), 
Progression free survival (PFS) and overall survival (OS) in advan-
ced NSCLC patients.
Results: 35 patients with advanced NSCLC and 34 age and sex 
matched normal subjects as control were included and followed 
up during the period from 10/2009 to 10/2012 with median follow 
up of 10.5 months. Median plasma VEGF 165 level was 707 pg./
ml in cases versus 48 pg./ml in controls, (p < 0.001).No significant 
correlation was found between plasma VEGF 165 level and clinical 
response(p < 0.5).No significant correlation was found between 
plasma VEGF 165 level and Median PFS and OS (p=1 and 0.7 res-
pectively.
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P2.06-044 THE INFLUENCE OF TP53 MUTATION ON THE 
PROGNOSIS OF PATIENTS WITH EARLY 
STAGE NON-SMALL CELL LUNG CANCER MAY DEPEND 
ON THE INTRATUMOR 
HETEROGENEITY OF THE MUTATION
Shin Yup Lee1, Ji Yun Jeong2, Keum Ju Choi3, Mi Young Kim3, Hyo-
Sung Jeon4, Eun Jin Lee4, Jin Eun Choi4, Ji Young Park2, Seung Soo 
Yoo1, Eung Bae Lee1, Jae Yong Park1
1Lung Cancer Center, Kyungpook National University Medical Center/
Korea, 2Department Of Pathology, Kyungpook National University 
Medical Center/Korea, 3Department Of Internal Medicine, Kyungpook 
National University Hospital/Korea, 4Department Of Biochemistry, 
Kyungpook National University, School Of Medicine/Korea
Background: A large number of studies have evaluated the impact 
of TP53 mutation on the prognosis of patients with non-small cell 
lung cancer (NSCLC); however, the results of these studies are still 
controversial. Recently, considerable intratumor heterogeneity for 
genetic alterations has been demonstrated in various human can-
cers, including lung cancer.
Methods: In the present study, we evaluated TP53 mutations in 
NSCLCs by direct sequencing and observed remarkable variation 
in the values of the relative intensity (RI, the height of the peak of 
mutated allele/the height of the peak of non-mutated allele) of 
TP53 mutation. We also examined whether the RI values were as-
sociated with intratumor heterogeneity of TP53 mutation. In ad-
dition, we evaluated the relationship between TP53 mutation and 
survival outcome.
Results: The patients with TP53 mutation did not have significantly 
worse survival compared to those without the mutation. Howe-
ver, when tumors with TP53 mutation were categorized into two 
groups, those with a low and those with a high RI, the latter group 
had significantly worse survival compared to those with wild-type 
TP53 (adjusted hazard ratio = 2.58, 95% confidence interval = 1.21-
5.48, P = 0.01), whereas the former group did not.
Conclusion: These results suggest that intratumor genetic hete-
rogeneity may be an important factor in determining the role of 
TP53 mutation on the prognosis of NSCLC patients.
Keyword: TP53 mutation, intratumor heterogeneity, non-small cell 
lung cancer, prognosis
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P2.06-043 CYP1A1*2A POLYMORPHISM IS CORRELATE 
WITH EGFR EXON 19 MUTATION AND IS AN INDEPEN-
DENT PROGNOSTIC INDICATOR FOR THE ADVANCED 
LUNG CANCER PATIENTS TREATED WITH EGFR-TKI
Qiang Nie, She-Juan An, Xue-Ning Yang, Wenzhao Zhong, Ri-Qi-
ang Liao, Jin-Ji Yang, Xuchao Zhang, Jian Su, Zhi Xie, Yi-Long Wu
Guangdong Lung Cancer Institute, Guangdong General Hospital & Gu-
angdong Academy Of Medical Sciences/China
Background: The EGFR mutated status becomes a very important 
factor for NSCLC patients considering of the treatment, but the 
mechanism of the mutation is still unknown.Our study aimed to de-
tect the correlations among EGFR mutations and polymorphisms 
of EGFR and CYP1A1 genes and their associations with clinical 
outcome of NSCLC patients treated with EGFR-TKI.
Methods: We evaluated the EGFR mutations, the genotypes for 
EGFR Intron1 (CA) n, R497K and CYP1A1 *2A, *2C polymorphisms 
in 70 Chinese patients with NSCLC. Genetic polymorphisms were 
correlated to EGFR mutations. As to subgroup of 36 patients who 
accepted the EGFR-TKI treatment and had systemic 5 years follow 
up data, the associations among the somatic EGFR mutations, the 
genomic polymorphisms of EGFR and CYP1A1 and clinical out-
come of the EGFR-TKI were analyzed.
Results: The data show that EGFR Intron1 (CA) n and CYP1A1*2A, 
*2C polymorphisms were correlated with EGFR mutations 
(P=0.006, P=0.001, and P=0.008, respectively) and all the three 
polymorphisms were also associated with EGFR 19 exon delection 
(P=0.007, P=0.033, and P=0.006, respectively); whereas the multi-
variate analysis demonstrated that only CYP1A1*2A polymorphism 
was associated with EGFR somatic mutations (P=0.021). For 36 pa-
tients treated with EGFR-TKI, the EGFR mutation and CYP1A1*2A 
polymorphism showed correlation with clinical response of EGFR-
TKI(P=0.001, and P=0.011, respectively); However, the multivariate 
analysis confirmed that the EGFR mutation is still the most effecti-
ve predictive factor (P=0.006) ; Either the log-rank test and Cox re-
gression analysis demonstrated that the CYP1A1*2A polymorphism 
is independent prognostic factor for patients’ overall survival trea-
ted with EGFR-TKI( P=0.000 for both statistical analysis).
Conclusion: The results demonstrate that the CYP1A1*2A poly-
morphism is correlated with EGFR somatic mutation; for advanced 
NSCLC patients with EGFR-TKI therapy, the EGFR mutation status 
is still most effective predictor for clinical response of EGFR-TKI, 
whereas the CYP1A1*2A polymorphism is an independent prog-
nostic factor. The inner mechanisms deserve thorough study.
Keyword: CYP1A1 polymorphisms; EGFR somatic mutations; EGFR 
targeted treatment; Molecular marker
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P2.06-046 EML4-ALK MONITORING OF CRIZOTINIB RE-
SPONSE IN BLOOD PLATELETS AND PLASMA OF NSCLC 
PATIENTS
Jonas Nilsson1, Carlota Costa2, Niki Karachaliou2, Miquel Taron2, 
Bakhos Tannous3, Erik Thunnissen4, Thomas Wurdinger1, Rafael 
Rosell2, Egbert Smit5
1Neurosurgery, Vrije Universiteit VU Medical Centre/Netherlands, 
2Catalan Institute Of Oncology/Spain, 3Harvard Medical School/United 
States Of America, 4Pathology, VU University Medical Center/Nether-
lands, 5VU Medical Centre/Netherlands
Background: The discovery of various genetic alterations that 
underlie lung cancer has opened-up a new era in the development 
of specifically targeted therapies employing specific alteration-de-
pendent inhibitors. In the vast majority of NSCLC patients genetic 
alterations occur in EGFR (20-25%), BRAF (3%), and ALK (3-10%), 
seemingly in a predominant mutual exclusive manner. Hence, pa-
tient stratification for EGFR, KRAS, BRAF, and ALK alterations is 
becoming common practice among oncologists. The mutational 
status of NSCLC patients is considered dynamic and can change 
in due course of the disease and selection in response to therapy. 
Longitudinal monitoring of the mutational status of NSCLC pati-
ents is of crucial importance to tailor targeted therapy by adapting 
treatment regimens according to mutational status. However, tech-
nical challenges associated with serial tumor biopsy constitute a 
major challenge in longitudinal molecular monitoring and targeted 
treatment of NSCLC patients. Blood-based assays may overcome 
such limitations and allow for frequent assessment of the mutatio-
nal status.
Methods: Here, tumor tissue, platelets, and/or plasma of NSCLC 
patients were collected and analyzed for the presence of translo-
cated ALK using FISH, IHC, and/or RT-PCR. Monitoring of EML4-
ALK in platelets and plasma was performed by RT-PCR on EML4-
ALK positive patients treated with crizotinib and correlated to the 
clinical response as measured by serial radiographic CT.
Results: From a multicenter cohort of NSCLC patients we iden-
tified EML4-ALK positive patients by FISH, IHC, and RT-PCR, for 
blood platelet and/or plasma isolation. In blood platelets of ALK 
positive NSCLC patients (n=24) and ALK negative control subjects 
(n=54) we demonstrated an EML4-ALK test sensitivity of 70-80% 
and specificity of 100%. We detected EML4-ALK in plasma of ALK 
positive NSCLC patients (n=22), however with inferior sensitivity of 
20-30%. In addition, longitudinal EML4-ALK monitoring in blood 
platelets of an ALK positive NSCLC patient correlated with the 
crizotinib response.
Conclusion: We demonstrate here that blood platelets of NSCLC 
patients are a biosource for the detection of the EML4-ALK trans-
location and may proof useful for longitudinal monitoring of ALK 
inhibitors in NSCLC patients, with superior outcome over plasma.
Keywords: longitudional monitoring, EML4-ALK, platelets
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P2.06-045 C-MET EXPRESSION IN MALIGNANT MESO-
THELIOMAS
Peter Illei, Rajni Sharma, Morgan Cowan
Pathology, Johns Hopkins Medical Institutions/United States Of Ame-
rica
Background: Met is a receptor tyrosine kinase that is encoded 
by c-Met a proto-oncogne. Abnormal c-met expression has been 
described in several solid tumors most notably in non small cell 
lung carcinoma and gastric carcinoma where tumor growth and 
survival is driven by met signaling. Furthermore, met is also a re-
sistance pathway for EGFR tyrosine kinase inhibitors. Met-targeted 
therapies are currently being tested in clinical trials and met IHC 
is being used as one of the methods to evaluate met expression. 
Malignant mesothelioma is an aggressive tumor with limited treat-
ment options and short survival. Met-based therapies could be 
considered in mesotheliomas with deregulated c-Met expression.
Methods: The study cohort included 39 malignant mesothelioma 
(Age 15-91 years; Sex: 11 female and 28 male; Histologic type: 1 
sarcomatoid, 7 biphasic and 21 epithelioid, primary location: 8 
peritoneal and 31 pleural). Immunohistochemistry was performed 
using an anti-total c-Met rabbit monoclonal antibody (clone SP-44, 
Ventana Medical Systems, Tucson, AZ, USA) using 4 micron sec-
tions of large biopsies or resection specimens and an automated 
platform (Ventana Benchmark Ultra, Ventana Medical Systems, 
Tucson, AZ, USA). The staining was evaluated for intensity (none, 
week, moderate, strong) and extent (percent of tumor staining) 
and a score was assigned to each tumor on a scale from 0 to 3+ (0: 
no staining, 1+: any staining in less than 50% of tumor, 2+: modera-
te to strong staining in >50% of tumor, 3+: strong staining in >50% 
of tumor). Tumors with and IHC score of 3+ and 2+ were conside-
red positive.
Results: Twenty (20) tumors were scored negative and 19 tumors 
positive. Strong (3+) staining was seen in 3 epithelioid mesothelio-
mas (all pleural), 2+ staining was seen in 1 biphasic and 15 epitheli-
oid mesotheliomas, while the remaining 6 biphasic, 1 sarcomatoid 
and 13 epithelioid mesotheliomas were negative (1+: 19; 0: 1).
Conclusion: c-Met positivity (3+ or 2+) is seen in the majority of 
epithelioid mesothelomas (18 of 21) and in the minority of biphasic 
mesotheliomas (1 of 7), while the single sarcomatoid mesothelioma 
was negative. Since the majority of malignant mesotheliomas are 
of the epithelioid subtype we expect the majority of malignant 
mesotheliomas be considered met positive as determined by im-
munohistochemistry and potentially amenable to met-targeted 
therapy. Correlation with met amplification and activating c-met 
mutations needs to be investigated to better understand the me-
chanisms of c-met over expression in malignant mesotheliomas.
Keyword: mesothelioma, c-met, immunohistochemistry
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P2.06-048 MALIGNANT MESOTHELIOMA LACKING 
MERLIN SHOWS ENHANCED SENSITIVITY TO THE FAK 
INHIBITOR VS-6063: EVALUATION OF MERLIN/NF2 STA-
TUS IN CLINICAL SAMPLES
Mitchell Keegan1, Irina M. Shapiro1, David T. Weaver1, Yuwaraj Ka-
dariya2, Christian M. Vidal1, Quentin G. Wright1, Jennifer E. Ring1, 
Joanna C. Horobin1, Qunli Xu1, Craig Menges2, Joseph R. Testa2, 
Daniel W. Paterson1, Jonathan A. Pachter1
1Verastem Inc./United States Of America, 2Fox Chase Cancer Center/
United States Of America
Background: Malignant pleural mesothelioma (MPM) is an ag-
gressive tumor in the pleural lining of the lung often resulting from 
prior exposure to asbestos. Median overall survival following front-
line chemotherapy with pemetrexed/cisplatin is approximately 12 
months. There is no established second line treatment. New thera-
peutic modalities are urgently needed to improve the prognosis of 
MPM patients. Approximately 50% of MPM patients exhibit homo-
zygous disruption of the NF2 tumor suppressor gene by mutation 
and/or deletion resulting in lack of expression of functional merlin 
protein. VS-6063 is a potent, orally active, inhibitor of focal adhesi-
on kinase (FAK).
Methods: Proliferation of drug-treated mesothelioma cell lines 
in 3-dimensional (3D) Matrigel culture was assessed by MTS, and 
orthotopic MPM xenograft growth in the lungs was measured in 
vehicle- vs. VS-6063-treated SCID mice. Since absence of merlin 
expression can theoretically result from several mechanisms in-
cluding NF2 mutation and chromosome 22 abnormalities, we as-
sessed NF2 gene deletion by FISH and merlin protein levels by IHC 
in the same human mesothelioma tumor samples.
Results: Among a panel of mesothelioma cell lines in 3D culture, 
MPM lines lacking expression of merlin protein were found to be 
especially sensitive to the selective FAK inhibitor VS-6063. In con-
trast, MPM cell lines with wild-type merlin were less sensitive with 
EC50 values greater than 1 µM. Accordingly, oral dosing of VS-6063 
induced significant tumor growth inhibition in a merlin-negative 
mesothelioma model pre-implanted in the lungs of mice. To ena-
ble the planned stratification of MPM patients by merlin status, an 
immunohistochemistry (IHC) assay has been optimized to quantify 
merlin protein levels. A merlin IHC H-score below the defined cu-
toff was associated with loss of at least one copy of chromosome 
22, indicating that chromosomal deletion is an important mecha-
nism of merlin loss in mesothelioma patients.
Conclusion: These data support the clinical development of VS-
6063 for treatment of malignant pleural mesothelioma patients 
stratified by merlin/NF2 status. VS-6063 is being studied in a 
registration-directed mesothelioma trial.
Keywords: mesothelioma, FAK, NF2, Merlin
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P2.06-047 BLOCKER SEQUENCING - AN IMPROVEMENT 
IN SANGER SEQUENCING WHICH SUPERCHARGES LOW 
LEVEL MUTATION DETECTION
Benjamin Legendre, Jr., Anthony Dowers, Phil Krzycki, Stephanie 
Peterson, Jason Stoddard, Mindy Kuebler, Jaclyn Pope, Amy Kru-
empel, Phil Eastlake, Katherine Richardson
Transgenomic, Inc/United States Of America
Background: Epidermal growth factor receptor (EGFR) antagonists 
are therapeutic agents that can be effective in colorectal cancer 
(CRC) treatment. It has been shown that 40% of CRC tumors have 
activating KRAS exon 2 codon 12 and 13 mutations and that these 
mutations are associated with a poor response to EGFR antago-
nists. Recent studies have shown that mutations in KRAS exons 3 
and 4 as well as NRAS exons 2, 3, and 4 also predict poor response 
to EGFR agonists such panitumumab. Sensitive detection (down 
to 1%) with Sanger sequencing of such diagnostic biomarkers is 
necessary to determine the presence or emergence of drug resis-
tant tumor cell populations. Locked Nucleic Acid (LNA) containing 
oligonucleotides (oligos) have been used in microRNA (sample 
preparation), RNA (in situ hybridization) and DNA (SNP detection 
using allele-specific PCR) analysis applications. Incorporation of 
LNA into oligos has the advantage of increasing the melting tem-
perature of the LNA/complementary template duplex after hybri-
dization as compared to duplexes using standard oligos.
Methods: To improve the mutation detection limits of Sanger se-
quencing, an LNA-based approach has been developed to cycle 
sequence the mutant allele selectively in the presence of the wild-
type allele. During cycle sequencing, an additional annealing step 
is added to hybridize the LNA-containing oligo (BLOCker-oligo) 
to the template DNA. A denaturing step is then performed at a 
temperature at which the BLOCker-oligo remains annealed to the 
wild-type sequence while the LNA oligo denatures from the mu-
tant sequence. The sequencing primer then anneals to the mutant 
sequence and is subsequently extended. Both forward and reverse 
strand BLOCker oligos can be developed enabling sensitive en-
richment for bidirectional sequencing.
Results: To show applicability of this methodology in CRC samp-
les, the limit of detection in both the forward and reverse sequen-
cing directions for multiple codon 12 and codon 13 KRAS exon 2 
mutations with and without the addition of the KRAS exon 2 wild-
type specific BLOCker-oligo will be demonstrated. To date, the 
increase in sensitivity is ~10 fold. In addition, a series of FFPE sam-
ples will be analyzed for mutations in NRAS and KRAS exons 2 – 4 
with and without BLOCker-oligos to show the increase sensitivity 
of this approach.
Conclusion: BLOCker sequencing is an efficient methodology for 
the detection of any mutation present in a sample using standard 
laboratory equipment and Sanger sequencing. The assays being 
developed at Transgenomic will be offered as CE IVD kits for the 
detection of all TKI-response associated mutations in KRAS and 
NRAS Exons 2, 3 and 4.
Keywords: BLOCker sequencing, Sensitive mutation detection, 
Sanger Sequencing improvement, Patient monitoring
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Conclusion: TTF1 is a better predictor of benefit to E than histolo-
gy, sex and smoking status. The very low median PFS and OS for 
patients with TTF1 –ve tumours would suggest that such patients 
derive no benefit from E, hence TTF1-ve status acts as a negative 
predictor of benefit to E.
Keyword: TTF1, predictive, Erlotinib
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P2.06-049 TTF1 NEGATIVE STATUS IS A NEGATIVE PRE-
DICTOR OF BENEFIT TO ERLOTINIB (E) IN METASTATIC 
NON SMALL CELL LUNG CANCER (NSCLC)
Haris Charalambous1, Charis Charalambous2, Demetrios Vomvas1, 
Nicos Katodritis1, Elias Porphyrides3, Marios Decatris1
1Oncology, Boc Oncology Centre/Cyprus, 2Histopathology, Nicosia Gene-
ral Hospital/Cyprus, 3Respiratory Medicine, Nicosia General Hospital/
Cyprus
Background: Erlotinib (E) is currently indicated as first line thera-
py in patients with EGFR mutations, and as second and third line 
treatment for patients with advanced metastatic NSCLC. In Cyprus 
comprehensive EGFR testing started in January 2011. In this study 
we reviewed all the patients that received E between 2007-2010, 
without having undergone EGFR mutation testing, looking at pre-
dictive factors of response to E. In view of evidence suggesting 
that EGFR mutations are found in predominantly TTF1 +ve tu-
mours, TTF1 status as well as clinical factors (i.e. adenocarcinoma 
histology, female sex and non smoking status) were assessed as 
potential predictive factors of response to E.
Methods: 100 consecutive patients are included. 3 patients recei-
ved this as 1st line, 49 patients as 2nd line and 48 patients as 3rd line 
and beyond. Previous treatments included gemcitabine platinum 
doublet as first line, and either pemetrexed or docetaxel as 2nd line 
therapy. Patients had regular Chest x-rays (every 2-3 cycles) and CT 
scans (every 3-4 cycles) and were assessed clinically on a monthly 
basis. Survival outcomes for both progression free survival (PFS) 
and overall survival (OS) were calculated with Kaplan Meier. Subset 
analyses using smoking status, sex, histology type and TTF1 and 
finally Cox regression was undertaken.
Results: 40 female and 60 male were treated with E. Median age is 
66 years (range 32-79). 45 patients were WHO performance status 
(PS) 0-1, 47 PS 2-3. For 8 patients PS was not recorded. Median 
progression-free survival (PFS) for all patients was 95 days (95% CI 
68-118). Median overall survival (OS) from starting E was 144 days 
(95% CI 103-185). Toxicity was predominantly grade 0-2. Ten (10) 
patients had a partial response and 34 patients had stable disease. 
Subset analyses were undertaken based on smoking status, sex, 
histology type and TTF1. Univariate analysis for PFS using KM plots 
showed a statistically significant difference for sex, smoking and 
TTF1. On Cox regression only gender and TTF1 were statistically 
significant (0.007 and 0.006). There was a striking difference in 
median OS between patients with TTF1-ve tumours (33 days) and 
TTF1 +ve tumours (149 days). See table underneath.  
Median PFS (days) 95% CI (days) Log Rank Median OS (days) 95% CI (days) Log Rank 
All patients 95 68-118 ------- 144 103-185 ------- 
Female 165 46-284 0.0137 236 45-427 0.1470 
Male 80 40-120 104 60-148 
< 10 Pack Yrs 203 149-257 0.0009 291 193-389 0.0034 
> 10 Pack Yrs 54 15-93 84 53-115 
TTF1 – ve 28 11-45 0.0002 33 28-38 0.0001 
TTF1 +ve 109 34-184 149 35-263 
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P2.06-051 CLINICAL SIGNIFICANCE OF PRETREATMENT 
PLASMA BIOMARKERS IN ADVANCED NON-SMALL 
CELL LUNG CANCER PATIENTS
Xiaohong Han, Shuai Wang, Xingsheng Hu, Xiaoyuan Wang, Ling 
Di Zhao, Le Tang, Yun Feng, Di Wu, Yan Sun, Yuankai Shi
Medical Oncology, Department Of Medical Oncology Laboratory Cancer 
Institute/ Hospital Chinese Academy Of Medical Sciences(CAMS) & 
Peking Union Medical College(PUMC)/China
Background: The use of biomarkers for selecting patients with 
non-small cell lung cancer (NSCLC) for treatment with epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is 
essential for achieving a satisfactory therapeutic outcome. EGFR 
mutations have been found to be predictive of response to EGFR-
TKIs. The aim of this study was to explore whether biomarkers 
which can be identified in plasma, such as EGFR mutations, circula-
ting free DNA, and levels of expressed cytokines are predictive for 
response to EGFR-TKIs and patient survival time.
Methods: Formalin-fixed and paraffin-embedded biopsies from 
tumor tissues and paired plasma samples were collected from 134 
patients with advanced NSCLC, EGFR mutations in both types of 
specimens were assessed by an ARMS/Scorpion assay using real-
time PCR. Expression levels of transforming growth factor-alpha 
and beta one (TGF-α and TGF-β1) were assessed using an enzyme-
linked immunosorbent assay (ELISA). Concentrations of circulating 
free DNA were detected in both NSCLC patients and healthy 
subjects by a colorimetric assay using ultraviolet spectrometry. The 
clinical significance of EGFR mutations, levels of cytokines, and 
circulating free DNA was assessed in advanced NSCLC patients 
treated with EGFR-TKIs.
Results: EGFR somatic mutations were detected in the tumors 
from 68 of 134 (50.7%) advanced NSCLC patients, and EGFR 
mutations were detected in the plasma samples from 17 (12.7%) 
NSCLC patients. Also, the concentrations of circulating free DNA 
were higher in NSCLC patients than in healthy subjects (P<0.01). 
EGFR-TKI treatment produced significant effects on progression-
free survival (PFS) and overall survival (OS) that were related to 
the presence of EGFR mutations detected in the tumor tissues 
(P<0.01).Patients with high levels of TGF-β1 showed shorter OS 
and worse response to EGFR-TKI treatment than patients with low 
TGF-β1 levels (P<0.01); however, patients with different expression 
levels of TGF-α showed no difference in either PFS or OS (P>0.05). 
Multivariate analysis showed that younger age, adenocarcinoma, 
never smoking and EGFR somatic mutation were associated with a 
longer PFS time, and adenocarcinoma, never smoking, low perfor-
mance status (PS) score, EGFR somatic mutation and low levels of 
TGF-β1 were associated with greater OS (P<0.05).
Conclusion: Plasma levels of TGF-β1 may be a marker for predic-
ting response to EGFR-TKIs and survival time in NSCLC patients, 
and levels of circulating free DNA could be a biomarker for diffe-
rentiating between NSCLC patients and healthy individuals.
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P2.06-050 VALIDATION AND UTILIZATION OF A CLI-
NICAL NEXT GENERATION SEQUENCING ASSAY TO 
IDENTIFY MUTATIONS AND GENOMIC COPY NUMBER 
CHANGES IN LUNG CANCER
Robert Daber, Charuhas Deshpande, Alan Fox, Shrey Sukhadia, 
David Roth, Jennifer Morrissette
Pathology And Laboratory Medicine, University Of Pennyslvania/United 
States Of America
Background: Recent advances in next generation sequencing 
provide us with the ability to simultaneously analyze both mutation 
status and copy number changes across a large number of cancer 
related genes. Here we discuss our experience in developing, vali-
dating and applying a 47 gene panel across our lung tumor patient 
population in a clinical laboratory.
Methods: Genomic DNA was extracted from 20 Formalin Fixed 
Paraffin embedded (FFPE) tissue samples from lung tumors for 
validation and over 80 patient samples upon clinical implemen-
tation. Extracted DNA was analyzed for quality and amplifiable 
quantity with suitable performance criteria established during 
validation. Between 10 and 250 ng of total genomic DNA was then 
subjected to the Truseq Amplicon (Illumina) assay for enrichment 
of the target regions across 47 different genes. Libraries were 
then sequenced on the Miseq (Illumina) to an average depth of 
coverage between 2000 and 4000x with 186 basepair, paired end 
reads. Data was then analyzed using analysis pipelines composed 
of various in house and open source tools, to detect insertions, 
deletions, amplifications and single nucleotide variants to an allele 
frequency of 5%.
Results: Across the clinical sample set, 67% of samples were found 
to have at least one disease associated mutation, 8% had only an 
unclear variant, 13% were ‘normal’, while 12% had DNA that was 
not adequate for testing. The average number of mutations seen 
in samples with disease associated changes was 1.6, with a range 
from 1 to 4. Half of the samples analyzed were found to have Tp53 
mutations, followed by EGFR changes seen in 11%. While only 16 
patients had EGFR changes, nearly half (7) of these had co-muta-
tions, including changes at positions 709, 719, 768 and 790. Many 
of the EGFR changes were complicated insertion/deletions found 
in exons 19 and 20, which were missed by standard bio-informatic 
algorithms and only captured by in house tools. KRAS changes 
were seen in 21% of patients followed by PTEN, MET, STK11 and 
APC mutations seen in at least 2 patients. Other known somatic 
mutations were also identified in ATM, BRAF, CTNNB1, FBXW7, 
FLT3, GNAS, HRAS, NRAS, PIK3CA and ALK in at least one patient. 
This included the hotspot mutation F1174L in ALK, which is seen 
with high frequency in neuroblastoma.
Conclusion: The mutation status of many clinically relevant genes 
can be reliably detected in FFPE samples using a single molecular 
assay followed by high throughput sequencing. Using this ap-
proach known somatic mutations seen frequently in other tumor 
types can be readily identified in lung tumors, and highlights the 
future benefits of tumor profiling.
Keywords: genomics, Tumor Profile, next generation sequencing, 
molecular pathology
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Conclusion: NSCLC patients suffer from permanently reduced 
long-term HRQoL compared to the age- and gender-matched 
normal population. Factors associated with reduced HRQoL were 
presence of comorbidity, postoperative complications and redu-
ced FEV1-status preoperatively. The occurrence of complications 
was also associated with a significantly reduced survival rate. 
Adjuvant-therapy was associated with a higher HRQoL. Age and 
gender were not associated with significant differences in the total 
15D-score or the QLQ-C30 global health score.
Keywords: Lung neoplasms, surgery, quality of life
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P2.07-002 SENTINEL NODE BIOPSY REDUCES THE 
NEED FOR SYSTEMATIC MEDIASTINAL LYMPHADENEC-
TOMY IN STAGE IA NSCLC
Josko Juricic1, Nenad Ilic2, Josip Banovic1, Dragan Krnic1, Nives 
Frleta Ilic3, Darko Ilic1, Vinko Markovic4
1Thoracic Surgery Dept., University Surgical Hospital/Croatia, 2Thoracic 
Surgery Department, University Surgical Hospital/Croatia, 3Oncology 
Dept., Cito Policlinic/Croatia, 4Nuclear Division, Clinical Hospital Cen-
ter/Croatia
Background: Systematic mediastinal lymphadenectomy is still es-
sential for an adequate postoperative staging of NSCLC. We tried 
to investigate the controversial role of sentinel node biopsy (SNB) 
in early stage non small cell lung cancer (NSCLC) surgery
Methods: A total of 52 patients with clinical T1N0MO NSCLC un-
derwent SN navigation lobectomy using Tc-99 labeled tin colloid 
followed by systematic mediastinal lymphadenectomy (SML) in two 
years time period (2010-2012). Mapping of the mediastinal lymph 
nodes by their number and station followed by histopathological 
evaluation was performed. Patients data were statistically analy-
zed.
Results: Intraoperative SN was identified in 45 (87%) of these pati-
ents with 92% of accuracy. We found lobe specific skip nodal me-
tastases in 5 (10%) patients resulting in upstaging. The incidence 
of ML metastases seemed to be more often in adenocarcinoma 
patients (p<0.05), but skip nodal metastases showed higher rate 
in squamous cell carcinoma patients. Intraoperative frozen section 
was not confirmed accurate for detecting micrometastases in two 
(4%) patients. Operative time was prolonged for 10 (8-25) minutes 
showing no difference in complication rate.
Conclusion: Procedure showed absolute safety and high accuracy. 
Our results indicated that SN identification could reduce medias-
tinal lymph node dissection in early stage NSCLC. Further clinical 
studies should be carried out in order to prove that minimally inva-
sive surgical procedures could be curative for T1N0MO NSCLC.
Keywords: Early stage NSCLC, surgery, sentinel node biopsy, 
mediastinal lymphadenectomy
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P2.07-001 LONG-TERM LUNG CANCER SURVIVORS 
HAVE PERMANENTLY DECREASED QUALITY OF LIFE 
FOLLOWING SURGERY
Ilkka Ilonen1, Ville Rauma2, Jari Räsänen2, Jarmo Salo2
1Surgery, Päijät-Häme Central Hospital/Finland, 2Heart-Lung Centre, 
Helsinki University Central Hospital/Finland
Background: Long term health related quality of life (HRQoL) 
among patients operated for non-small cell lung cancer (NSCLC) 
has not been extensively studied, as most studies has end-point 
within 24 months following surgery. Endpoints ike progression-free 
survival and overall survival, postoperative HRQoL could be more 
important to the patient.
Methods: A total of 586 patients were operated for NSCLC in the 
Department of Cardiothoracic surgery of the Helsinki University 
Hospital between January 2000 and June 2009. Two validated 
quality of life â€“questionnaires, the 15D and the EORTC QLQ-
C30 with its lung cancer specific module QLQ-LC13, were sent to 
patients alive in June 2011. Results of the 15D were compared with 
those of an age- and gender-standardized general population. Pa-
tient and treatment features predicting higher or lower long-term 
HRQoL were identified.
Results: Of the 276 patients who were sent the questionnaires, 
230 (83.33%) answered. The median follow-up time was 4.85 ye-
ars. When compared with the general population (picture), our 
patient group had significantly lower scores in the 15D total score, 
representing the total HRQoL of the patients, and in the dimen-
sions Mobility, Breathing, Usual activities, Depression, Distress 
and Vitality. The patient group scored significantly higher in the 
dimensions Hearing and Mental function. Features predicting 
lower long-term HRQoL were comorbidity, measured with the 
Charlson comorbidity index (CCI), post-operative complications 
and pre-operative FEV1% 70% of the predicted value. Adjuvant-
therapy was observed to predict higher long-term HRQoL.
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local recurrence, disease-free survival, and five-year survival rates.
Methods: Thirty four prospective and retrospective studies registered 
in PubMed and Scopus electronic databases during the last twenty 
five years were reviewed. Bibliographies and handsearching of journals 
were used to identify trials. Studies’ authors, citations, objectives, and 
results were extracted. No meta-analysis was used. Validation of results 
was discussed.
Results: Segmentectomies were superior to wedge resections in terms 
of local recurrence and cancer-related survival rates. Sublobar resec-
tions were superior to lobectomy concerning preservation of pulmona-
ry parenchyma. It was recommended that high-risk patients undergo 
segmentectomy. Lobectomies were superior to segmentectomies only 
for tumors >2 cm (T2bN0M0) as regarding disease-free and overall 
5-year survival. There was no significant difference for tumors <2 cm in 
most studies. Free surgical margins were crucial for local control rates. 
Systematic lymphadenectomy was mandatory regardless of type of 
resection. In cases of pure bronchoalveolar carcinoma, segmentectomy 
was recommended. Shorter hospital stay was achieved with sublobar 
resections.
Conclusion: The choice of type of resection for T1aN0M0 tumors 
should rely on specific patient and tumor characteristics. Patient age 
and tumor size are the most important factors. Further prospective 
randomized trials are needed to determine minimal resections in early 
lung cancer patients.
Keywords: Non-small-cell lung carcinoma, Thoracic surgery
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P2.07-005 A COMPARATIVE STUDY OF DIAGNOSING 
AND STAGING BY MEDIASTINOSCOPY OR EBUS ON 
LUNG CANCER
Yang Shen-Tu, Liang Zhang
Thoracic Surgery, Shanghai Chest Hospital/China
Background: Endobronchial ultrasound-guided transbronchial 
needle aspiration (EBUS) has been gradually application in clinic, 
but its value in staging of lung cancer and dignosing of mediastinal 
mass need to be evaluated. We intends to study comparatively the 
clinical value of EBUS and mediastinoscopy, and, want to provide a 
basis for the rational choice applications.
Methods: Between July 2009 and December 2012, 361 patients 
accepted mediastinoscopy, including 199 cases of lung cancer 
and 162 of mediastinal mass. During the same period, 348 pati-
ents accepted EBUS , including 216 cases of lung cancer and 132 
of mediastinal mass. All of the biopsy samples were tested in the 
pathological department of Shanghai chest hospital. Analyzing the 
data of two groups and comparing the clinical value of mediastino-
scopy and EBUS both on preoperative staging of lung cancer and 
diagnosing of mediastinal mass.
Results: With the pathological results as a gold diagnosis stan-
dard, the accuracy, sensitivity and specificity of mediastinoscopy 
diagnostic efficacy are 98.28%, 98.03% and 100%, respectively on 
lung cancer, and, 98.11%, 97.62% and 100%, respectively on medi-
astinal mass. For EBUS, the accuracy, sensitivity and specificity of 
diagnostic efficacy are 95.69%, 94.74% and 100%, respectively on 
lung cancer, and, 82.64%, 77.42% and 100%, respectively on medi-
POSTER SESSION 2 - SURGERY  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.07-003 SAMPLING VS. SYSTEMATIC FULL LYMPHATIC 
DISSECTION IN SURGICAL TREATMENT OF NON-SMALL 
CELL LUNG CANCER
Konstantinos N. Syrigos, Fotis Psarros, Elias Karampelas, Korina 
Lymberopoulou, Eleftheria Dalakou, Grigorios Karagkiouzis, Geor-
gios Koulaxouzidis
Oncology Unit Gpp, Sotiria General Hospital/Greece
Background: The extent of mediastinal lymph node assessment du-
ring surgery for non-small cell cancer remains controversial. Different 
techniques are used, ranging from simple visual inspection of the un-
opened mediastinum to an extended bilateral lymph node dissection. 
Furthermore, there are different terms to define these techniques: 
Sampling is the removal of one or more lymph nodes guided by pre-
operative finding. Systematic (full) nodal dissection is the removal of 
all mediastinal tissue containing the lymph nodes systematically within 
anatomical landmarks.
Methods: A Medline search was conducted to identify articles in Eng-
lish, addressing the role of mediastinal lymph nodes resection in the 
treatment of NSCLC
Results: Opinions favoring full lymphatic dissection include complete 
resection, improved nodal staging and better local control due to re-
section of undetected micrometastasis. Arguments against routine full 
lymphatic dissection are increased morbidity, increased operative time 
and lack of evidence of improved survival. For complete resection of 
non-small cell lung cancer a systematic nodal dissection is recommen-
ded for many authors, as the standard approach during surgery: it as-
certains both adequate nodal staging and completeness of resection.
Conclusion: Whether extending the lymph node dissection influences 
survival or recurrence rate remains to be determined. There are valuab-
le arguments in favor of not only an improved local control but also an 
improved long-term survival. However, the impact of lymph node diss-
ection in long-term survival should be further assessed by large-scale 
multicenter randomized trials.
Keywords: surgery, complete resection, systematic lymph node diss-
ection, sampling
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P2.07-004 WEDGE RESECTION AND SEGMENTECTOMY 
IN PATIENTS WITH STAGE I NON-SMALL CELL LUNG 
CANCER
Konstantinos N. Syrigos, Paraskevi Boura, Charris Tsapas, Aris-
tidis Nikolaou, Georgios Kalavrouziotis, Konstantinos Reveliotis, 
Andriani Charpidou
Oncology Unit Gpp, Sotiria General Hospital/Greece
Background: The use of resections lesser than lobectomy as definitive 
management of a stage I non-small cell lung carcinoma (NSCLC) is a 
topic that creates controversy in the global medical community. To 
describe the current conclusions concerning the relative indications of 
each type of resection in the surgical treatment of stage I NSCLC, as 
well as the international results from their application concerning the 
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P2.07-007 SURGICAL TREATMENT OF ELDERLY PATI-
ENTS WITH RESECTABLE LUNG CANCER
Yo Kawaguchi1, Takuya Fujita1, Ryosuke Kaku2, Tomoyuki Igara-
shi2, Masayuki Hashimoto2, Koji Teramoto2, Jun Hanaoka2
1Thoracic Surgery, Kohka Public Hospital/Japan, 2General Thoracic 
Surgery, Shiga University Of Medical Science/Japan
Background: The incidence of lung cancer in the older population 
is increasing. In case of resectable primary lung cancer, surgery 
remains the best treatment for cure, independent of age. However, 
the prevalence of co-morbidities among elderly lung cancer pati-
ents is significantly higher. A presumed fear of increased postope-
rative morbidity and mortality in the elderly patients has resulted 
in the delivery of sub-optimal cancer surgery. We believe all elder-
ly cancer patients should be offered optimal treatment depending 
on their functional status not on their age; a major step in ensuring 
this would be to establish the appropriate surgical management 
protocol for elderly cancer patients. Thus it is important to de-
termine whether the elderly would indeed benefit from the same 
management standards as their younger counterparts. This study 
aimed to determine the suitable operative procedures for elderly 
patients with primary lung cancer.
Methods: Between January 2006 and December 2012, 98 patients 
aged over 75 years with primary lung cancer received lobectomies 
in our hospital. We divided the patients into group A (75-79 years 
old) and group B (over80 years old) and analyzed their relapse-free 
survival and postoperative complication incidence.
Results: The patients in group A (46 men and 17 women) had a 
mean age of 76.8 years, 36 patients had adenocarcinomas, 24 had 
squamous cell carcinomas, and 3 had other tumors. A mediastinal 
lymph node dissection (MLND) was performed in 52 patients but 
not in 11 patients. The patients’ pathological stages were 1A (21), 
1B (13), 2A (5), 2B (12), 3A (11), and 4 (1). The 3-year relapse-free 
survival was 66.3 % (MLND-positive, 62.6 %; MLND-negative, 90.9 
%). Postoperative complications occurred in 30.8 % of the MLND-
positive patients and 18.2 % of the MLND-negative patients. 
The patients in group B (26 men and 9 women) had a mean age of 
82.4 years, 17 patients had adenocarcinomas, 12 had squamous 
cell carcinomas, and 6 had other tumors. An MLND was performed 
in 24 patients but not in 11 patients. The patients’ pathological 
stages were 1A (12), 1B (10), 2A (5), 2B (3), 3A (1), and 3B (4). The 
3-year relapse-free survival was 73.3 % (MLND-positive, 75.7 %; 
MLND-negative, 68.2 %). Postoperative complications occurred 
in 16.7 % of the MLND-positive patients and 9.1 % of the MLND-
negative patients. 
Conclusion: This study showed a survival benefit in elderly lung 
cancer patients who underwent lobectomies. In clinically well-do-
cumented early nodal stage disease (N0 patients and N1 patients 
with limited hilar disease), an MLND did not have a therapeutic 
effect and thus may not be necessary. Omitting MLNDs in elderly 
lung cancer patients also provided fewer postoperative complica-
tions. In this study, we proved that elderly patients with resectable 
lung cancer who received lobectomies without MLNDs could 
achieve long-term survival and be a safe procedure.
Keywords: Elderly Patient, Lung cancer, surgery, Postoperative 
complication
astinal mass. Two techniques have not significant difference on di-
agnosing and staging of lung cancer (P>0.05), but have statistically 
difference on mediastinal mass (P<0.05), especially on sarcoidosis 
(P=0.0109), tuberculosis(P=0.0135) and lymphoma(P=0.0036).
Conclusion: Mediastinoscopy and EBUS have a similar clinical va-
lue in diagnosing and staging on lung cancer, but mediastinoscopy 
is superior to EBUS in diagnosing on mediastinal mass.
Keyword: lung cancer, mediastinal mass, mediastinoscopy, EBUS
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P2.07-006 PREDICTING FACTORS FOR EARLY AND 
LONG TERM MORTALITY AND COMPLICATIONS AFTER 
THORACOTOMY IN PATIENTS WITH PRIMARY LUNG 
CANCER
Cynthia V. Arkel, Ben Van Den Borne, Daphne Dumoulin, Joost Ter 
Woorst, A Van Straten, S Houterman
Pulmonlogy, Catharina Ziekenhuis Eindhoven/Netherlands
Background: To determine factors predicting early and long term 
mortality and complications in patients who underwent a thoracotomy 
because of primary lung cancer.
Methods: Data of patients who underwent a thoracotomy in the Catha-
rina Hospital Eindhoven between January 1995 and January 2011 have 
been collected retrospectively from the medical files. Early mortality 
was defined as mortality <30 days after surgery. Last date of follow up 
was January 1, 2013. Patients were divided in three groups according 
to date of surgery (1: 1995-1999, 2: 2000-2004 and 3: 2005-2010). Com-
plications were divided into major and minor complications. Predicting 
factors were assessed with uni- and multivariate logistic regression 
analysis. For long-term mortality and survival predicting factors were 
assessed using the Cox proportional hazards model.
Results: In total 501 patients underwent a thoracotomy due to primary 
lung cancer. Overall 30 day mortality (early mortality) was 5.6% (n=28). 
Multivariate analysis showed that age over 70 (p=0.002), pneumonecto-
my (p=0.008) and a pre-operative VO2max of <15 ml/kg/min (p=0.02) 
were significant predictors of early mortality. With respect to long term 
survival, 308 (61%) patients had died at the end of the follow-up period. 
Median survival time was 44 months, with an overall 5- and 10- year 
survival of 45% and 27%, respectively. The 5-year survival for stage I, II 
and III-IV was 61%, 46% and 16%, respectively (p<0.0001, log rank test). 
Furthermore Cox regression analysis showed that stage (stage I, stage 
II compared to stage III-IV), FEV1% ≤70%, a history of cerebrovascular 
disease (CVD) and surgery in an earlier time period (1, 2 compared to 3) 
were significant predictors of long term mortality. Finally, the only signi-
ficant predictor for major postoperative complications was a history of 
COPD (OR 2.32; 95% CI 1.38-3.91).
Conclusion: In this cohort, mortality and complication rates in lung 
cancer patients after thoracotomy were in line with literature. Significant 
predictors of early mortality were age, pneumonectomy and pre-
operative VO2max. Significant predictors of long term mortality were 
disease stage, FEV1%, a history of CVD and surgery in an earlier time 
period.
Keywords: Non-small-cell lung carcinoma, surgery, Mortality, predic-
ting factors
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P2.07-009 WHAT IS AN APPROPRIATE TREATMENT 
STRATEGY FOR SUPERIOR SULCUS TUMORS?
Takuma Tsukioka, Ryoji Yamamoto, Makoto Takahama, Ryu Na-
kajima, Keiko Tei, Hirohito Tada
General Thoracic Surgery, Osaka City General Hospital/Japan
Background: Superior sulcus tumors (SST) comprise a subgroup of 
non-small-cell lung cancers that arise near the pulmonary apex or 
superior sulcus. They generally invade the chest wall and brachial 
plexus, and occasionally the subclavian vessels. Induction chemo-
radiation therapy followed by surgery is the recommended treat-
ment for SST. However, surgical approaches for SST remain contro-
versial, partly because of their infrequent use. Several approaches 
to resecting these tumors have been described, depending on the 
precise localization and involvement of the surrounding organs. 
These include posterolateral thoracotomy, hemi-clamshell and 
transmanubrial osteomuscular-sparing approaches. It is necessary 
to establish the appropriate multimodality therapy for SST, inclu-
ding the optimal surgical approaches.
Methods: We retrospectively analyzed the clinical courses of pati-
ents with SST treated with surgery at our institution. A total of 2765 
patients with non-small-cell lung cancer were treated surgically at 
Osaka City General Hospital, Japan, from January 1995 to Decem-
ber 2012. Among these, 34 patients with SST were investigated in 
this study.
Results: The mean age of the patients was 62 years (range, 42–90 
years). There were 32 men and two women. Seventeen patients 
had squamous cell carcinoma, 12 had adenocarcinoma, and five 
patients had tumors of other histological types. There were 21 
patients with stage 2B, 10 with stage 3A, and three patients with 
stage 3B disease. Two patients received induction chemotherapy, 
and 22 patients received induction chemoradiotherapy. Posterola-
teral thoracotomy was performed in 11 patients and anterior tho-
racotomy (hemi-clamshell, transmanubrial osteomuscular-sparing 
approaches) in 22 patients. A combination of anterior and lateral 
thoracotomies was applied in one patient. Pulmonary lobectomy 
was performed in 25 patients, segmentectomy in one patient, and 
pulmonary partial resection in nine patients. The resected surroun-
ding organs, other than the chest wall, were the subclavian artery 
in two patients, the superior vena cava in two, and the aortic arch 
and vertebral body in two patients each. The median follow-up 
period was 16 months (range, 3–154 months). Postoperative 1-, 
3- and 5-year survival rates were 72%, 46%, and 34%, respectively. 
Investigation of clinicopathological factors with potential impacts 
on postoperative outcome identified pathological nodal extension 
as the only significant factor indicating poor prognosis (p < 0.01). 
Tumor markers, surgical approach, type of pulmonary resection, 
and type of resected surrounding organ had no effect on post-
operative outcome. No viable tumor was observed in seven of 
22 patients treated with induction chemoradiotherapy, and the 
postoperative 5-year survival rate in these seven patients was 86%. 
Recurrent disease was observed in 17 patients during the postope-
rative follow-up period. Local recurrence was observed in five pati-
ents and recurrence in distant organs was observed in 13 patients.
Conclusion: Patients with node-positive SST have a poor progno-
sis, and surgical indications should be investigated fully in these 
patients. Induction chemoradiotherapy is necessary to treat SST. 
The major sites of recurrence are in distant organs, and the type 
of pulmonary resection does not affect postoperative outcome. 
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P2.07-008 RADIOLOGICAL-PATHOLOGICAL CORRELATI-
ON FOR RESECTED SMALL LUNG NODULES WITH PURE 
GROUND GLASS OPACITY DETECTED BY HIGH-RESOLU-
TION COMPUTED TOMOGRAPHY
Masafumi Yamaguchi1, Eiko Inamasu2, Gouji Toyokawa2, Tsuki-
hisa Yoshida1, Yoshimasa Shiraishi2, Fumihiko Hirai2, Tomohiro 
Takenaka2, Ryo Toyozawa1, Kenichi Taguchi3, Akio Furuya4, Taka-
shi Seto2, Mitsuhiro Takenoyama2, Yukito Ichinose2
1Department Of Thoracic Oncology, National Kyushu Cancer Center/
Japan, 2Thoracic Oncology, National Kyushu Cancer Center/Japan, 3De-
partment Of Pathology, National Kyushu Cancer Center/Japan, 4Depart-
ment Of Diagnostic Imaging And Nuclear Medicine, National Kyushu 
Cancer Center/Japan
Background: The term "ground glass opacity (GGO)“ on high-
resolution computed tomography (HRCT) is defined as “hazy incre-
ased attenuation in the lung that does not obliterate the bronchial 
and vascular margins” by Fleischner Society. The identification of 
small lung nodules of GGO on HRCT often implies lung cancer, 
especially well differentiated adenocarcinoma or atypical adeno-
matous hyperplasia; however, there is no objective definition of 
GGO, such as the computed tomography number.
Methods: A single institutional retrospective study. To access the 
correlation between radiological and pathological diagnosis of 
the patients with small pure GGO on HRCT. Thirty-nine consecu-
tive surgically resected patients with pure GGO less than 30 mm 
detected by HRCT between July 2008 and March 2013 in our de-
partment were retrospectively examined. The median follow-up of 
these patients was 28.7 (1.9 - 92.7) months.
Results: The median age of the patients was 64 (range 42-82) 
years old, 19 patients were male and 20 were female. The median 
size of major axis of lung nodules was 11 (range 5-25) mm, and 29 
(74.4%) were less than 15 mm and 10 were between 15 and 30 mm 
in diameter. Twenty-eight (71.8%) patients had a single nodule, 
whereas 11 patients had multiple nodules. Six of the 39 patients 
had a previous history of malignancy (three lung cancers and 
three other cancers). During the follow-up period, 22 patients had 
nodules that were stable in size or appearance, and five patients 
had nodules that either became enlarged or in which the opacity 
increased, as determined by HRCT. The other twelve patients were 
operated based on the findings of their first HRCT, basically by the 
attending surgeons’ decision. Partial resection was performed in 
seven patients, segmentectomy in 11 patients and lobectomy was 
performed in 21 patients. Histologically, thirty-seven patients had 
adenocarcinoma, one had small cell carcinoma and one had a be-
nign tumor. Among the 37 patients with adenocarcinoma, 14 were 
adenocarcinoma in situ, five tumors were minimally invasive and 18 
were invasive according to the IASLC/ATS/ERS classification. There 
was no postoperative recurrence during the follow-up period.
Conclusion: Even if the small pulmonary nodules present as pure 
GGO, they may still be adenocarcinoma with an invasive nature. 
The timing of surgery should be considered carefully so that a 
chance to achieve a cure of such patients is not missed.
Keywords: Pathology, pure ground glass opacity, surgical r 
esection
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P2.07-011 A PILOT STUDY ON THE EFFECTS OF PERI-
OPERARTIVE ADMINISTRATION OF THE NEUTROPHIL 
ELASTASE INHIBITOR, SIVELESTAT, TO NON-SMALL 
CELL LUNG CANCER PATIENTS WITH PREOPERATIVE 
RISK FACTORS OF ACUTE RESPIRATORY DISTRESS SYN-
DROME AFTER PULMONARY RESECTION
Takuro Kometani1, Tatsuro Okamoto2, Shigetoshi Yoshida3, Ichiro 
Yoshino3
1Department Of Thoracic Surgery, National Hospital Organization Oita 
Medical Hospital/Japan, 2Department Of Surgery And Science, Gradu-
ate School Of Medical Sciences, Kyushu University/Japan, 3Department 
Of General Thoracic Surgery, Graduate School Of Medicine, Chiba Uni-
versity/Japan
Background: Postoperative acute respiratory distress syndrome 
(ARDS) is a recognized complication of pulmonary resection. ARDS 
following lung resection has a miserable prognosis, with overall 
hospital mortality rates over 25%. Previous studies demonstrated 
that there were risk factors of ARDS after pulmonary resection 
including age, chronic obstructive pulmonary disease (COPD), 
interstitial pneumonia, concurrent cardiac disease, prior therapy, 
remaining lung perfusion, duration of operation, increased blood 
loss and so on. Neutrophils and neutrophil elastase (NE) are be-
lieved to play a key role in the endothelial injury and increased 
vascular permeability characteristic of ARDS. Sivelestat sodium 
hydrate is a selective NE inhibitor and has been shown to improve 
respiratory status in cases of ARDS. It has not been well known 
whether or not NE inhibitors are beneficial for prevention of ARDS 
after lung resection.
Methods: We conducted a pilot study to investigate the efficacy 
of perioperative administration of sivelestat sodium hydrate to 
prevent postoperative ARDS in 34 non-small cell lung cancer (NS-
CLC) patients who had the various preoperative risk factors of the 
incidence of ARDS after pulmonary resection in Chiba University 
between 2009 and 2011. They received sivelestat sodium hydrate 
(5mg/kg/day) intravenously for 7 days starting at the beginning of 
operation.
Results: The patient demographics were as follows: median age, 
68 years of age (range 47 to 83 years), male/female ratio, 31/3, 
clinical stage I/II/III, 9/6/19. The histology was adenocarcinoma (n 
=19), squamous cell carcinoma (n=10) and others (n =5). Risk fac-
tors of ARDS included induction chemotherapy (n=3), induction 
chemoradiotherapy (n=17), interstitial pneumonia (n=10), COPD 
(n=3) and medical history of ARDS (n=1). All 34 patients underwent 
complete resection. The operations included 2 partial resections, 
31 lobectomies, and 1 pneumonectomy. Of the 31 patients who 
received lobectomy, bronchial or arterial plasty was performed in 
9 patients. The postoperative mortality rate was 2.9%. One patient 
died of heart failure on the nineth postoperative day. There was no 
incidence of ARDS after pulmonary resection in all patients.
Conclusion: Perioperative administration of sivelestat sodium hy-
drate can be beneficial to prevent postoperative ARDS in NSCLC 
patients. Prospective studies are required.
Keywords: acute respiratory distress syndrome, neutrophil elasta-
se, Sivelestat, pulmonary resection
Partial resection may be an acceptable option in patients with no 
detectable viable tumor after induction chemoradiotherapy.
Keywords: Superior sulcus tumor, surgical approach, chemoradio-
therapy
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P2.07-010 SURGICAL TREATMENT AND OUTCOME OF 
MULTIPLE PRIMARY LUNG CANCERS
Shizu Saito1, Takao Morohoshi1, Masanori Hashimoto1, Hiroyuki 
Adachi1, Munetaka Masuda2, Yukio Tsuura3, Masahiro Tsuboi4
11-16, Yokosukakyosai Hospital/Japan, 2Department Of Surgery, Yo-
kohama City University School Of Medicine/Japan, 3Department Of 
Pathology, Yokosuka Kyosai Hospital/Japan, 4Surgery, Yokohama City 
University Medical Center/Japan
Background: Recently, multiple primary lung cancer is inreasing 
with progress of imaging diagnostic technology and improvement 
in treatment results. We assesed the selection of the type of pul-
monary resection, operative morbidity, mortality and the outcome 
of our cases which enforced surgical treatment for multiple primary 
lung cancer.
Methods: Of 840 patients who underwent operation for primary 
lung cancer between January 2001 and May 2013.We consider 
57(6.7%) to have a multiple primary lung cancer. We use the criteria 
of Martini and Melamed as a diagnosis of multiple primary lung 
cancer.
Results: The group comprised 27 men and 30 women. Median 
age was 66.7 years (48-80). It occured synchronous in 21 cases and 
metachronous in 36 cases. Cell type combination was adenocar-
cinoma-adenocarcinoma in 37 cases, adenocarcinoma-squamous 
cell carcinoma in 10 cases, squamous cell carcinoma-squamous cell 
carcinoma in 6 cases, adenocarcinoma-large cell carcinoma in 3 ca-
ses and large cell carcinoma-large cell carcinoma in 1 case. Opera-
tive procedures was lobectomy-lobectomy in 13 cases, lobectomy-
segmentectomy in 12 cases, lobectomy-edge resectionin 19 cases, 
edge resection-edge resection in 5 cases and lobectomy/edge 
resection-radio therapy in 3 cases. Pathological stage for the first 
cancer was IA/IB/IIA/IIB/III = 35/14/4/0/4. The 5 year survival rate 
after first surgery was 81.7%, and second surgery was 72.2%.
Conclusion: With this result, we consider that surgical resection 
may prove beneficial in cases which postoperative good survival 
can be expected by the aggressive surgical approach, despite it is 
difficult to distinguish multiple primary lung cancers and metasta-
tic cancers preoperatively.
Keywords: metachronous, multiple primary lung cancer, metasta-
tic lung cancer, synchronous
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P2.07-013 RISK FACTORS FOR LOCOREGIONAL FAILURE 
IN COMPLETELY RESECTED N1 NON-SMALL CELL LUNG 
CANCER WITHOUT POSTOPERATIVE RADIOTHERAPY
Sukki Cho1, Samina Park2, Sanghoon Jheon1, Kwhanmien Kim1, 
Hee Chul Yang1, Eunjue Yi1, Yangki Seok1, Dongsub Noh1, Sung 
Won Yeom1
1Thoracic And Cardiovascular Surgery, Seoul National University 
Bundang Hospital/Korea, 2Department Of Thoracic And Cardiovascular 
Surgery, Seoul National University Hospital/Korea
Background: N1 disease is a subset of non-small cell lung cancer 
(NSCLC) with a different prognosis than other subsets. Although 
the NCCN guideline recommends adjuvant chemotherapy alone in 
completely resected N1 disease, locoregional failure, which could 
have been prevented by postoperative radiotherapy (PORT), may 
not be uncommon. Using PORT with modern techniques has resul-
ted in significantly higher rates of local control, disease-free survi-
val, and overall survival. Therefore, this study aimed to evaluate the 
actuarial rates of locoregional failure in patients with pathologic N1 
NSCLC and to identify the risk factors associated with an increased 
risk of locoregional failure, which could have been potentially pre-
vented by PORT after complete resection.
Methods: Between 2003 and 2010, we enrolled 136 patients who 
underwent complete resection with pathologically confirmed N1 
disease through the prospective lung cancer database of Seoul 
National University Bundang Hospital. Patients who underwent 
neoadjuvant therapy, adjuvant radiotherapy, or operative mortality 
were excluded. Multiple factors potentially related to outcomes 
including patient-related factors, surgery-related factors, and 
pathologic factors were extensively evaluated. Locoregional fai-
lure, which could have been potentially prevented by PORT, was 
defined as recurrence at either a bronchial stump, or a resected 
margin of the lung, hilum, and mediastinum. Other failures were 
ipsilateral lung recurrence, pleural seeding, and metastasis of dis-
tant organs. Univariate analysis by a log rank test and multivariate 
analysis by the Cox proportional hazards model were performed to 
identify risk factors independently associated with a higher risk of 
locoregional failure.
Results: The median follow-up duration was 45 months (6-114) and 
recurrence developed in 54 (40%) patients. The actuarial 5-year ra-
tes of disease-free survival and overall survival were 56% and 66%, 
respectively. From the perspective of first site recurrence, 23 (17%) 
locoregional failures, which could have been potentially prevented 
by PORT, included recurrence in the mediastinum in 10, bronchial 
stump in 5, regional lymph nodes in 4, and mediastinum + others 
in 4. The 31 (23%) other failures included a distant organ in 17, 
ipsilateral lung in 12, and pleural seeding in 2. The median survival 
time from locoregional failure and other failures was 41 and 57 
months, respectively; however, there was no significant difference. 
Risk factors of locoregional failure were squamous cell carcinoma, 
number of involved node (>1), pathologic stage (IIIA), interlobar 
node involvement, more than 2 node stations of involvement, and 
a lymph node ratio greater than 10% by univariate analysis. Patho-
logic stage (HR=4.768, 95% CI=1.641-13.859, p=0.01), interlobar 
node involvement (HR=2.783, 95% CI=1.057-7.327, p=0.04), and 
squamous cell carcinoma (HR=2.449, 95% CI=0.929-6.454, p=0.07) 
were independent risk factors by multivariate analysis.
Conclusion: Locoregional failure was more common than expec-
ted, and pathologic stage, interlobar node involvement, and cell 
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P2.07-012 LONG-TERM RESULTS OF LIMITED RESEC-
TION FOR SMALL ADENOCARCINOMA SHOWING 
GROUND-GLASS OPACITY
Takehiro Watanabe, Akira Okada, Tatsuhiko Hirono
Chest Surgery, Nishi-Niigata Chuo National Hospital/Japan
Background: In 2005, we reported the study of intentional limited 
resection for small peripheral lung cancer based on intraoperative 
pathologic exploration. At that time, only 14 patients with a small 
adenocarcinoma showing ground-glass opacity (GGO) had un-
dergone limited resection. After that, we have continued limited 
resection and follow-up. The median follow-up time from the ope-
ration has reached 80 months, so we analyze the long-term results 
of this procedure.
Methods: Between 1996 and 2013, we enrolled 56 patients in this 
study. Entry criteria were: 1) cT1aN0M0 peripheral adenocarci-
noma, 2) High resolution computed tomography (HRCT) findings 
suspected of having a Noguchi type A or B adenocarcinoma, and 
3) pulmonary function adequate to permit lobectomy. When the 
tumor consisted of GGO only or GGO with a solid component 
that accounted for less than 50% of the surface area on HRCT, 
the tumor was suspected to be Noguchi type A or B adenocarci-
noma. Wedge resection or segmentectomy was performed, and 
was followed by an intraoperative pathologic exploration. After 
confirming the diagnosis of Noguchi type A or B by intraoperative 
pathologic exploration, operation was completed. No systematic 
lymph node dissection or sampling was performed. If the lesion 
was not Noguchi type A or B, extended segmentectomy or lo-
bectomy with systematic lymph node dissection was performed 
instead.
Results: Between 1996 and 2013, we enrolled 56 patients in this 
study. Limited resection was performed in all patients, wedge 
resection in 52, and segmentectomy in 4. Intraoperative patholo-
gic exploration revealed that the lesion was not Noguchi type A 
or B in 11 patients. In these 11patients, we underwent extended 
segmentectomy in 2 and lobectomy in 9 with systematic lymph 
node dissection. Intentional limited resection was completed in 
45 patients. Of these, 7 had Noguchi type A tumors, and 38 had 
Noguchi Type B tumors based on intraoperative pathologic explo-
ration. Postoperative pathologic examination revealed 10 patients 
with Noguchi type A, 31 patients with Noguchi type B, and 4 
patients with Noguchi type C. We recommended reoperation to 
4 patients with Noguchi type C, but all refused reoperation and 
has been carefully followed at 3-month intervals. There was no 
postoperative and 30-day mortality or in-Hospital mortality. There 
were no morbidities. All patients but one are alive without recur-
rence of lung cancer at the time of writing. Only one patient died 
of malignant lymphoma without recurrence. The follow-up periods 
have ranged from 6 to 195 months, and median follow-up period is 
80 months. The overall 5- and 10-year survival rates were 96% and 
96%, respectively. The 5- and 10-year recurrence –free proportions 
were 100% and 100%, respectively.
Conclusion: When patients are carefully selected by preoperative 
HRCT and intraoperative pathologic exploration, limited resection 
can be an acceptable option for the treatment of T1aN0M0 ade-
nocarcinoma showing GGO lesion.
Keywords: Adenocarcinoma, GGO, limited resection, intraoperati-
ve pathologic exploration
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P2.07-015 CLINICAL OUTCOME OF 16 EXTREMELY EL-
DER PATIENTS (85-YEAR-OLD OR OVER) WITH SURGI-
CALLY RESECTED NON-SMALL CELL LUNG CANCER
Takahiro Yoshioka, Osamu Kawamata
Department Of Surgery, Onomichi Municipal Hospital/Japan
Background: In Japan, an aging society, the number of surgical ope-
rations performed in the elderly has been increasing. In this study, to 
investigate whether the surgical resection of non-small cell lung can-
cer benefits extremely elder patients (85-year-old or over), we analy-
zed the clinical outcome of our patients.
Methods: Sixteen consecutive patients aged 85 years or older who 
underwent surgical resection of primary non-small cell lung cancer in 
our hospital from May 2002 to September 2012 were enrolled in this 
study. The patients’ operative procedure, respiratory function before 
operation, histological type, tumor size, clinical stage, comorbidity, 
surgery-related complications, prognosis, and recurrence were retros-
pectively reviewed.
Results: There were 11 males and 5 females. Their mean age was 86.6 
years (range: 85-93 years). The mean follow-up period after operation 
was 1290 days (range: 249-4029 days). Operative procedures include 
lobectomy (N=4), segmentectomy (N=6), and wedge resection (N=6). 
Among them, thoracoscopic surgeries were performed in 14 patients. 
Patients treated by segmentectomy had poorer pulmonary function 
than others in terms of the forced expiratory volume in 1 second 
(FEV1.0) (mean±SD: 1.43±0.40 vs 1.94±0.39 L, p<0.05) and vital capa-
city (VC) (mean±SD: 2.02±0.51 vs 2.55±0.53 L, p=0.06). Histological 
type include adenocarcinoma (N=11) and squamous cell carcinoma 
(N=5). The tumor size ranged 11 mm to 48 mm. All 16 patients were 
negative for lymph node metastasis. Pathological stage was IA in 11 
patients, IB in 4 patients, and IIB in 1 patient. Seven patients had co-
morbidity (e.g. COPD, post-bypass grafting for coronary aretery, and 
others). Seven patients were smokers. Mortality rate was 0% and mor-
bidity rate was 25% (e.g. pulmonary fistula treated with pleurodesis in 
1 patient, atrial fibrillation in 2 patients, heart failure in 1 patient, and 
delirium in 1 patient). Fourteen patients are alive, whereas 2 patients 
died from other diseases than lung cancer. The 2 patients died after 
1950 days and 1344 days after operation, respectively. No patients 
had recurrence during the follow-up period.
Conclusion: No patients died from surgery or post-surgical complica-
tions. Our study indicates that the surgical resection of non-small cell 
lung cancer benefits patients, even with extremely elder age (85-year-
old or over). For our institution’s principal indications for pulmonary 
surgery, patients with elder age (75-years-old or older) have to (i) 
be able to undergo pulmonary physiotherapy, (ii) have good perfor-
mance status (0-1 in ECOG scale), and (iii) be free from psychological 
disorder such as dementia. Additionally, in cases with extremely older 
age (85-year-old or over), we consider patients with clinical stage I or 
patients without lymph node metastasis are good candidates. Lobec-
tomy can be performed in patients with better pulmonary function, 
whereas patients with worse pulmonary function should undergo 
segmentectomy. Wedge resection is selected only if the lesion is jud-
ged to be completely resectable. We consider these inclusion criteria 
and the manner of selecting operative procedures will provide a good 
prognosis, even though the patient is 85 years or older.
Keywords: elderly lung cancer, pulmonary function, indication of 
surgery, selection of operative procedures
type were independent risk factors for locoregional failure after 
complete resection of N1 NSCLC. A prospective clinical trial may 
be necessary to evaluate the effectiveness of adjuvant radiothera-
py in patients with these risk factors.
Keywords: Non small cell lung cancer, N1 disease, Recurrence, risk 
factors
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P2.07-014 INTRAPLEURAL PERFUSION HYPERTHERMIC 
CHEMOTHERAPY IN MALIGNANT PLEURAL EFFUSION 
AND PLEURAL SEEDING
Dongsub Noh, Hee Chul Yang, Eunjue Yi, Kwhanmien Kim, Sang-
hoon Jheon, Yangki Seok
Thoracic & Cardiovascular Surgery, Seoul National University Bundang 
Hospital/Korea
Background: Malignant pleural effusion or pleural seeding is de-
tected in advanced non-small cell lung cancer (NSCLC) patients, 
and they are generally associated with poor prognosis. Systemic 
chemotherapy is the mainstay modality in these patients. However, 
it is not enough to improve the survival. Intrapleural perfusion hy-
perthermic chemotherapy (IPHC) provides direct effect to pleural 
seeding cancer cells. This study attempted to evaluate the efficacy 
and safety of IPHC.
Methods: From 2003 to 2012, 41 patients who underwent IPHC 
for malignant pleural effusion or pleural seeding for NSCLC in our 
institute. The IPHC was performed with cisplatin (dose:150-200mg/
m2) for 90 minutes after resection of primary tumor. Efficacy was 
determined by computed tomography and Positron Emission To-
mographic (PET) standardized uptake value (SUV) postoperatively.
Results: The IPHC group consisted of 25 males and 16 females. 
The mean age was 60.98±9.80 year ranging from 33 to 78. Preope-
rative pleural mean SUV was 1.46±1.88 (R: 0-6) and postoperative 
pleural mean SUV was 1.58±1.72 (R: 0-5) (p= 0.933). Sixteen pati-
ents were received adjuvant systemic chemotherapy. The 2-year 
and 5-year survival rate were 82.1% and 44.9%, respectively. Major 
post-IPHC complications are acute renal insufficiency (n=4, 9.76%) 
and arrhythmia (n=2, 4.88%). There were no difference in sex, age, 
adjuvant systemic chemotherapy, tumor size, nodal statues bet-
ween the patients who survived more than 2 years and less than 2 
years. There was no difference in SUV of preoperative main mass 
and pleura between the patients who survived more than 2 years 
and less than 2 years. However, the SUV of postoperative pleura in 
the patients who survived more than 2 years (SUV: 2.92±1.98) was 
less than that of the patients who survived less than 2 years (SUV: 
1.16±1.45) (p=0.031).
Conclusion: IPHC would be safety procedure for malignant pleural 
effusion or pleural seeding. IPHC may provide better survival com-
pared with the systemic chemotherapy only in the highly selected 
patients. Low post-IPHC SUV uptake would be provide longer 
survivor.
Keywords: malignant pleural effusion, intrapleural hyperthermic 
chemotherapy, Lung cancer, malignant pleural seeding
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treatment such as adjuvant chemotherapy.
Keywords: non-small cell lung cancer, Nutrition, induction chemo-
radiotherapy
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P2.07-017 PULMONARY RESECTION FOR LUNG CANCER 
PATIENTS WITH CEREBROVASCULAR AND CARDIOVAS-
CULAR COMORBIDITIES
Nobuhiro Izumi, Shinjiro Mizuguchi, Shoji Hanada, Hiroaki Ko-
matsu, Hidetoshi Inoue, Hiroko Oka, Satoshi Okada, Kantaro Hara, 
Noritoshi Nishiyama
Thoracic Surgery, Osaka City University Hospital/Japan
Background: Patients with cerebro- and cardio-vascular comor-
bidities (CCVC) who undergo surgery represent a high-risk group 
and require careful perioperative management. In the present 
study, we aimed to retrospectively analyze the postoperative 
complications (POC) of patients with CCVC who had undergone 
pulmonary resection for lung cancer. Patients with cerebro- and 
cardio-vascular comorbidities (CCVC) who undergo surgery repre-
sent a high-risk group and require careful perioperative manage-
ment. In the present study, we aimed to retrospectively analyze the 
postoperative complications (POC) of patients with CCVC who had 
undergone pulmonary resection for lung cancer.
Methods: Among 288 patients who underwent pulmonary resec-
tion at our institution from January 2009 to December 2011, we 
examined the records of 51 patients with CCVC (17.7%) to identify 
the risk factors for developing POC. Among the analyzed patients, 
we noted the presence of 34 POC, including tachyarrhythmia in 9, 
prolonged pulmonary fistula in 9, pyothorax in 2, cerebral infarc-
tion in 2, requirement of long-term oxygen therapy in 2, interstitial 
pneumonia in 2, delirium in 2, and other POC in 4. Several patients 
had multiple POC.
Results: We examined 43 male patients (84.3%); the median age 
was 72 years and the median preoperative forced expired volume 
in 1s (FEV1) was 2200 mL (range, 1120–3420). The patients with 
CCVC included 12 with cerebral infarction, 2 with transient cerebral 
ischemic attacks, 2 with cerebral hemorrhage, 1 with subarachnoid 
hemorrhage, 4 with cerebral aneurysm, 10 with arrhythmia, 17 with 
ischemic heart disease, 1 with valvular heart disease, 8 with aortic 
aneurysm/dissection, 11 with peripheral arterial disease, and 1 with 
a left atrial myxoma; several of these patients had multiple CCVC. 
Moreover, 2 patients underwent pneumonectomy, 37 underwent 
lobectomy, 3 underwent segmentectomy, and 9 underwent wedge 
resection. Postoperative morbidity rates were 21.4% in cerebrova-
scular comorbidity patients (p = 0.015), 53.5% in the cardiovascular 
comorbidity patients (p < 0.0001), 71.4% in CCVC patients (p = 
0.0028), and 12.3% in patients without CCVC. No operative or 
in-Hospital mortality was noted. Gender, age, smoking status, and 
smoking index were not found to be significantly related to the 
incidence of POC. However, patients with an FEV1 < 2200 mL were 
found to be significantly more likely to develop POC (p = 0.036).
Conclusion: We noted that patients with CCVC and low FEV1 were 
more likely to develop POC.
Keywords: Lung cancer, comorbidity, Postoperative complication, 
pulmonary resection
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P2.07-016 PERIOPERATIVE NUTRITION OF INDUCTION 
CHEMORADIOTHERAPY FOLLOWED BY SURGERY IN 
LOCALLY ADVANCED NON-SMALL LUNG CANCER PATI-
ENTS
Junichi Soh1, Yusuke Konishi1, Shinichi Toyooka1, Kazuhiko 
Shien1, Hiromasa Yamamoto1, Masanori Okada1, Kentaroh Mi-
yoshi1, Seiichiro Sugimoto1, Makio Hayama1, Masaomi Yamane1, 
Takahiro Oto1, Katsuyuki Kiura2, Shinichiro Miyoshi1
1Thoracic Surgery, Okayama University Hospital/Japan, 2Department 
Of Respiratory Medicine, Okayama University Hospital/Japan
Background: Induction chemoradiotherapy (CRT) followed by 
surgery (iCRT) is one of treatment strategies for locally advanced 
non-small cell lung cancers (NSCLCs). We have previously reported 
its feasibility and good clinical outcome with approximately 60% of 
5-year overall survival rate. .Perioperative nutritional status,is con-
sidered as one of important factors for improved clinical outcome 
after surgery and other treatments. Here, we investigated the 
perioperative nutritional status in NSCLC patients treated by iCRT 
(CRT group) to evaluate the influence of nutritional variables on 
clinical outcome by comparing that in NSCLC patients with simple 
pulmonary resection without CRT (non-CRT group) .
Methods: Thirty-three consecutive patients with locally adcanced 
NSCLC who underwent iCRT from January 1, 2009, until December 
31, 2011 at our institute were included in this study. The regimen 
of CRT was two cycles of docetaxel (40 mg/m2) plus cisplatin (40 
mg/m2) with concurrent radiotherapy (46 gray) and the surgery was 
performed within 6 weeks of completing induction CRT. We com-
pared nutrition-related factors and clinical outcome in 33 iCRT pa-
tients with those in 58 consecutive NSCLC patients who underwent 
lobectomy during January 1 to December 31, 2011 at out institute. 
.As for blood nutritional factors, total lymphocyte count (TLC), al-
bumin (Alb), total cholesterol (T-cho), choline esterase (ChE), were 
examined. The prognostic nutritional index (PNI) was also calcula-
ted by Alb and TLC. Each nutrition-relatd factors were examined 1) 
before CRT, 2) before surgery and 3) one month after surgery.
Results: Median age of CRT group (61 years old) was significantly 
younger than that of non-CRT group (69 years old). Twenty-one 
males and 12 females and 44 males and 14 females were enrolled 
in CRT and non-CRT groups, respectively. Before any treatment, 
no significant difference was observed in body mass index and 
any blood nutritional factors in both groups. After induction CRT, 
TLC was significantly decreased, and additionally, Alb, T-cho, and 
ChE were significantly decreased after surgery comparing with 
those before surgery (after CRT). As for preoperative status in both 
groups, TLC, Alb and PNI were significantly lower in CRT group 
than in non-CRT group. Regard with surgery, extended surgery, 
operating time, and blood loss was significantly heavier in CRT 
group than in non-CRT group. Perioperative mortality rate was 0% 
in both groups and the frequency of post-operative complication 
was similar in both groups (51% and 41% in CRT and non-CRT 
groups, respectively). The length of hospital stay after surgery was 
significantly longer in CRT group (median 23 days) than in non-CRT 
group (median 14 days). Among CRT group, patients with loiw PNI 
index could not administrate adjuvant chemotherapy.
Conclusion: Perioperative nutritional status, especially TLC, is 
suppressed after CRT and moreover after surgery. Suppression of 
nutritional status continued one month after surgery with induction 
CRT and severe suppression of nutritional status disturbs further 
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P2.07-019 POSTOPERATIVE OUTCOME OF PATIENTS 
WITH PULMONARY LARGE-CELL NEUROENDOCRINE 
CARCINOMA
Terumoto Koike1, Toru Shirato1, Seijiro Sato1, Takehisa Hashimo-
to1, Masayuki Saito2, Akira Okada3, Takehiro Watanabe3, Masanori 
Tsuchida1
1Thoracic And Cardiovascular Surgery, Niigata University Graduate 
School Of Medical And Dental Sciences/Japan, 2Thoracic And Cardio-
vascular Surgery, Niigata Prefectural Shibata Hospital/Japan, 3Chest 
Surgery, Nishi-Niigata Chuo National Hospital/Japan
Background: Although large-cell neuroendocrine carcinoma 
(LCNEC) was categorized as a variant of large cell carcinoma on the 
WHO histologic classification of lung carcinomas, the clinical and 
biological features of LCNEC resemble those of small cell lung car-
cinoma. Therefore, there is no consensus on the treatment strategy 
for LCNEC, and an indication of surgical treatment for LCNEC is 
still controversial. Even though preoperative accurate diagnosis of 
LCNEC is difficult, the aim of this study was investigating patients 
with pulmonary LCNEC in whom better postoperative outcome is 
expected.
Methods: We retrospectively reviewed patients with pulmonary 
LCNEC on permanent pathologic diagnosis who underwent pul-
monary resection at the 3 institutions between 1999 and 2011. We 
reviewed the medical records of each patient for demographic, 
clinical, and pathologic data including age, sex, smoking status, 
preoperative serum CEA, radiologic tumor size, c-stage, surgical 
procedure, extent of lymphadenectomy, p-stage, lymph node me-
tastasis, visceral pleural invasion, lymphatic permeation, vascular 
invasion, and adjuvant chemotherapy. Disease-free survival (DFS) 
was calculated using the Kaplan-Meier method, and factors associ-
ated with DFS were analyzed with the log-rank test.
Results: Of the 18 patients eligible for this study, 14 were male and 
4 were female. The median age was 74 years (range, 53 to 85). Ac-
cording to the current TNM classification, 12 patients had c-stage 
I disease, 4 had c-stage II disease, and 2 had c-stage IIIA disease. 
The majority of patients (13 patients, 72%) underwent lobectomy, 
1 underwent pneumonectomy, 1 underwent bilobectomy, and 3 
underwent wedge resection. On pathologic diagnosis, 8 patients 
had p-stage I disease, 5 had p-stage II disease, and 5 had p-stage 
IIIA disease. Following surgical treatment, cisplatin-based adjuvant 
chemotherapy was applied for 3 patients. The 1-year and 2-year 
DFS were 39% and 39%, respectively, with the median follow-up 
period of 9 months (range, 2 to 80). During the follow-up period, 
10 patients (56%) developed recurrence, and the recurrence was 
identified within the first year post-resection in all the 10 patients. 
By the log-rank test, smoking status (non- or former, vs. current) 
and surgical procedure (lobectomy or greater, vs. limited resec-
tion) were identified as significant factors associated with DFS.
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P2.07-018 CURATIVE SURGERY IN LUNG CANCER: CA-
SES PRESENTED AT MULTIDISCIPLINARY MEETINGS 
COMPARED WITH A CONTEMPORANEOUS CONTROL 
GROUP.
Philippa J.T. Bowers1, Kumid Dhital2, Emily Granger2, Paul Jansz2, 
Phillip Spratt2, Emily Stone1
1Department Of Thoracic Medicine, St Vincent‘s Public Hospital/Aust-
ralia, 2Department Of Cardiothoracic Surgery, St Vincent‘s Public Hos-
pital/Australia
Background: Multidisciplinary team (MDT) meetings have develo-
ped to enhance disease-specific interdisciplinary communication 
towards accelerating the initiation of appropriate therapy and 
improving both patient care and survival. They have long been a 
mainstay in the management of patients with cancer. This study 
aims to compare resection rates, surgical cure (based on post-
resection pathological status) and co-morbidity status in consecu-
tive lung cancer cases (stages IA-IIB, IASLC TNM staging 6th or 7th 
ed.), as presented at our institution’s Lung Cancer MDT meeting, 
compared with a similar contemporaneous control group not pre-
sented at the MDT meeting.
Methods: Data for this study was drawn from the Clinical Cancer 
Registry Project (ClinCR) database in NSW, which captures all 
cases of lung cancer managed in the public health system as well 
as databases used by the Lung Cancer MDT and Cardiothoracic 
Surgery. Cases of non-small cell lung cancer (NSCLC) appropriate 
for curative surgery based on pre-operative stage IA-IIB were ana-
lysed for MDT presentation, resection rate, surgical cure rate and 
for pre-operative Charlson co-morbidity score.
Results: Data were analysed from the time period 2006-2011. 
During this time 755 cases of NSCLC were diagnosed, 377 were 
presented at MDT (49.9%) and 378 were not (50.1%). A total of 138 
cases of early stage disease (stages IA-IIB) were identified, 90 of 
which were presented at MDT (65.2%) and 48 were not (34.8%). 
Significantly more cases of early stage disease presented at MDT, 
33/90 (36.7%) had resection than cases of early stage disease not 
presented at MDT 13/48 (27.1%) (p=0.015). Overall resection rate in 
early stage disease (MDT and non-MDT) was 46/138 (33.3%). In re-
sected cases the surgical cure rate (according to surgical margins) 
did not differ significantly between the two groups with 30/33 
(90.9%) in the MDT group and 12/13 (92.3%) in the non-MDT group 
achieving surgical cure (p=0.75). For cases of early stage NSCLC 
presented at MDT the odds ratio for surgical resection was 2.5. 
Further analysis of Charlson co-morbidity score will clarify associa-
ted co-morbidities, which may help explain this difference.
Conclusion: Surgical resection rates are statistically higher in early 
stage NSCLC cases presented at MDT than in contemporaneous 
cases not presented at MDT in our study population. Surgical cure 
rates for resected patients appear high in both groups. Further 
data on co-morbidities and identifiable referral patterns, including 
patients managed outside the public hospital system, may clarify 
reasons for the disparity in resection rates and enable identifica-
tion of potentially reversible barriers to treatment.
Keywords: multidisciplinary, non-small cell lung cancer, surgical 
resection
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Results: Between January 2007 and December 2012, 533 patients 
with lung cancer underwent (surgical resection at our institution. 
Among them, we reviewed 182 patients who had available preope-
rative PET/CT data and underwent a curative-intent operation with 
systematic or selective lymph node dissection. One hundred fifty-
one patients (83%) had lung cancer with expected lymph node 
status, whereas, 31 patients (17%) were found to have lung cancer 
with unexpected lymph nodes metastasis, consisting of 12 (39%) 
unexpected pN1 and 19 (61%) unexpected pN2 diseases. There 
were 16 men and 15 women with a median age of 67 years. Seven-
teen patients were current- or past- smokers, and 14 were never-
smokers. Tumor size ranged from 12 to 52 mm, and pathological 
T factor was pT1a in 3, pT1b in 5, pT2a in 19, pT2b in 3, and pT3 in 
1. Histological type of the primary tumor were adenocarcinoma in 
28 (90%), squamous cell carcinoma in 2, and large cell carcinoma 
in 1. Among 28 adenocarcinomas, the most common predominant 
subtype was papillary (20 patients; 71%), followed by acinar (5 
patients), solid with mucin, micropapillary, and invasive mucinous 
(one patient, respectively). Of these patients, 7 patients had micro-
papillary component in varying proportions in their tumors. EGFR 
gene mutation status was available in 22 patients, and of these, 12 
patients (55%) had tumors with EGFR gene mutation, consisting of 
exon 19 deletion in 5, exon 21 point mutation in 5, and other minor 
mutation in 1. In univariate analysis, tumor size (> 3cm), pleural, 
and lymphatic invasion were significant predictive factors for un-
expected pN1 and pN2 diseases. Only in 151 adenocarcinomas, 
papillary predomiant tumor and having micropapillary component 
were significant predictive factors for unexpected lymph node 
metastasis.
Conclusion: We should take care that false-negative rate is re-
latively high on preoperative PET/CT for lymph node status in 
NSCLC. Histological findings of the primary tumor are often im-
portant because they can provide predictive information for lymph 
nodes status even if there is no FDG uptake in regional lymph 
nodes on preoperative PET/CT. We hope new accurate imaging 
modality which can reflect tumor histology and lymph nodes mi-
crometastasis.
Keywords: Unexpected pathological N1 and N2, Lung cancer, 
PET/CT
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P2.07-021 RESULTS OF SURGICAL TREATMENT FOR 
LUNG CANCER IN PATIENTS AGED 80 YEARS OR OVER - 
SINGLE INSTITUTION OVER 20 YEAR EXPERIENCE
Takuro Miyazaki, Naoya Yamasaki, Tomoshi Tsuchiya, Keitaro 
Matsumoto, Takeshi Nagayasu
Surgical Oncolgy, Nagasaki Graduate School Of Medicine/Japan
Background: The average age of the general population is in-
creasing in the worldwide. Therefore, there is also an increasing 
number of elderly patients presenting with potentially-resectable 
lung cancer. We retrospectively reviewed the outcomes of octo-
genarians or over who underwent pulmonary resection for primary 
non-small cell lung cancer (NSCLC) to identify the independent 
factor of overall survival.
Methods: We conducted a retrospective single-Institution review 
of patients aged 80 years or over who underwent pulmonary re-
section for primary NSCLC from 1990 to 2012 at Nagasaki universi-
Conclusion: Of patients with pulmonary LCNEC undergoing 
surgical treatment, a long-term prognosis might be expected if 
no recurrence is identified within the first year post-resection. If 
diagnosis of LCNEC is preoperatively obtained, surgical treatment 
is recommended for patients without current smoking status, and 
lobectomy or greater resection should be the surgical procedure 
of first choice.
Keywords: Non–Small-Cell Lung Cancer, Large-cell Neuroendocri-
ne Carcinoma, surgery, lobectomy
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P2.07-020 CLINICOPATHOLOGICAL CHARACTERISTICS 
OF PATIENTS WITH UNEXPECTED PATHOLOGICAL N1 
AND N2 LUNG CANCER
Tomohiro Haruki, Yoshiteru Kidokoro, Makoto Wakahara, Yuki 
Matsuoka, Yuzo Takagi, Ken Miwa, Kunio Araki, Yuji Taniguchi, 
Hiroshige Nakamura
Department Of Surgery, Division Of General Thoracic Surgery, Tottori 
University, Faculty Of Medicine/Japan
Background: Although positron emission tomography/computed 
tomography (PET/CT) seems to be able to provide accurate infor-
mation of lymph nodes status in non-small cell lung cancer (NSCLC) 
patients, we sometimes experience surgical cases with unexpected 
lymph nodes metastasis. The objective of this study is to demonstrate 
clinicopathological characteristics of patients with unexpected patho-
logical (p) N1 and N2 NSCLC.
Methods: All patients with lung cancer underwent enhanced CT of 
the chest and PET/CT preoperatively for evaluating of lymph node 
status. Mediastinoscopy or EBUS-TBNA was not routinely performed. 
Unexpected pN1 and pN2 diseases were defined as surgical cases 
which were proved to have hilar or mediastinal lymph nodes metasta-
sis postoperatively in spite of negative 18-fluoro-2-deoxy-D-glucose 
(FDG) uptake in hilar or mediastinal lymph nodes on preoperative 
PET/CT. We retrospectively reviewed clinical features of these patients 
and analyze predictive factors for these unexpected diseases.
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P2.07-022 PROGNOSTIC IMPLICATION OF CYTODIAG-
NOSIS OF MINUTE PLEURAL EFFUSION FOUND AT THO-
RACOTOMY IN NSCLC PATIENTS
Mitsutoshi Shiba1, Takahide Toyoda1, Taiki Fujiwara1, Tomohiko 
Iida1, Eiji Kunimatsu2, Osamu Matsuzaki2
1Dep. Of Thoracic Sugery, Kimitsu General Hospital/Japan, 2Dep. Of 
Pathology, Kimitsu General Hospital/Japan
Background: In order to clarify clinical implication and therapeutic 
strategies managing minute malignant pleural effusion unexpec-
tedly found at thoracotomy, we analyzed diagnostic results of cyto-
diagnosis of pleural effusion found at thoracotomy and prognosis 
of the patients treated in our institute retrospectively.
Methods: From 2004 to 2013, 502 non-small cell lung cancer pa-
tients were surgically treated in our institute. At the time of thora-
cotomy pleural effusion cytology (PEC) was performed in the cases 
that small amount of subclinical, minute pleural effusion was found 
unexpectedly. In some cases pleural lavage cytology (PLC) was 
performed simultaneously.
Results: In 254 patients (50.6%) out of 502, minute pleural effusion 
was detected and PEC was performed. In 25 patients (9.8%), ma-
lignant pleural effusion was demonstrated. PLC was performed in 
191 cases, and positive results were obtained in 16 cases (8.3%). In 
these 16 cases, PEC was also performed in 12 cases and positive 
results were obtained in 11 cases. And in 4 cases no pleural effusi-
on was found but PLC was positive for malignancy. Post operative 
5 yrs survival of malignant pleural effusion group was 43.7%. In 
p-N0 cases, post operative survival of PEC positive cases was tend 
to poorer than surgically treated PEC negative cases (p=0.13), but 
in p-N1, N2 cases, post operative survival was almost equal bet-
ween these groups (p=0.66).
Conclusion: Cytodiagnosis of minute pleural effusion found at 
thoracotomy was performed in 51% of surgical cases of NSCLC. 
Subclinical malignant pleural effusion found at thoracotomy may 
be a prognostic factor in clinical stage one case. PLC at the time of 
thoracotomy may become a complementary examination of PEC.
Keywords: Thoracotomy, Non small cell lung cancer, Cytodiagno-
sis, pleural effusion
ty hospital. The various clinicopathological data, including gender, 
histological type, body mass index, comorbidity, clinical stage, 
surgical procedure, extent of lymph node dissection, and patholo-
gical stage were analyzed.
Results: 119 octogenarians or over underwent pulmonary resec-
tion. The median age was 82 years (range 80-92 years). Of the 
total patient number, 56 (47.1%) had respiratory and 44 (33.6%) had 
cardiovascular comorbidity diagnosed preoperatively. The clinical 
stage was I in 97 (81.5%) patients, II in 13, III in 6, IV in 3. Opera-
tions included 82 (68.9%) lobectomies, 2 (1.7%) bilobectomies, 
15 (12.6%) segmentectomies, and 19 (16.0%) partial resections. 
Only 31 (26.1%) were performed mediastinal lymph node diss-
ection. The pathological stage was I in 79 (81.5 down to 66.4 %) 
patients, II in 16 (13.4%), III in 21 (17.7%), IV in 3 (2.5%). 26 (21.8%) 
patients presented with postoperative respiratory complications, 
and 11 (9.2%) were cardiovascular, and the operative mortality 
was 1 (0.8%). The 5-year survival rates were 46.0% for all patients, 
60.8% for stage I patients. The disease specific 5-year survival 
rates were 60.1% for all patients, 79.5% for stage I patients, re-
spectively. In univariate analysis, female (p<0.04), clinical stage 
(p<0.002), and pathological stage (p<0.000) was independent 
and cardiovascular comorbidity was marginally (p<0.05) factor for 
overall survival. In multivariate analysis, only advanced pathologic 
stage (stage II, more) was independent predictor of overall survival 
[p<0.0001, Hazard ratio: 3.17, 95% confidence interval 1.76-5.73]. 
Conclusion: Surgical treatment for selected patients aged 80 years 
or over or with primary NSCLC can be performed safely with low 
morbidity and mortality in this study. We recommend that limited 
operation might be the best surgical treatment, especially for sta-
ge I NSCLC. In the future, establishment of accurate clinical sta-
ging as well as early detection for lung cancer, and the appropriate 
treatment for advanced stage NSCLC for aged people should be 
studied for the upcoming aged society.
Keyword: lung cancer, surgery, aged people
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lobectomy after induction CRT is feasible, but careful patient se-
lection and perioperative management is mandatory.
Keywords: induction chemoradiotherapy, extended sleeve lobec-
tomy
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P2.07-024 PREDICTIVE FACTORS FOR POSTOPERATIVE 
MORBIDITY IN PATIENTS UNDERGOING ESOPHAGEC-
TOMY FOR ESOPHAGEAL CANCER:
Swamyvelu Krishnamurthy1, Prashanth Shivappa2
1Surgical Oncology, Kidwai Memorial Institute Of Oncology/India, 2Kid-
wai Memorial Institute Of Oncology/India
Background: Oschner and DeBakey in 1940, reviewed the world 
literature of 191 esophageal resections with a 72% mortality 
rate. Later on with advent of better preoperative, intaoperative 
and postoperative management advances, the risk of mortali-
ty had decreased to less than 10%. Various radical resections 
were described both in resection of primary (Eg: Transhiatal 
esophagectomy(THE), transthoracic esophagectomy (TTE),enbloc 
esophagectomy,etc..,) and lymph node dissection (two field, three 
field , etc.,). The role of radical surgery is still controversial and its 
becomes necessary to decide which patient can tolerate a radical 
procedure in the preoperative setting itself.
Methods: We retrospectively analyzed surgical and medical re-
cords of 154 patients of carcinoma esophagus operated in a single 
unit at our center to assess the predictive factors for postoperative 
morbidity for the period 2006-2012.
Results:  
Table 1: Demographic 
profile of the Pati-
ents: 
Characteristics Number of patients ( Total N = 154) 
Age Mean Range 55.857 ± 10.3989 20-79 years 
Sex Male Female 92 62 
Histopathological Ex-
amination Squamous 
cell carcinoma Ade-
nocarcinoma Adenos-
quamous carcinoma 
124 28 2 
Site of lesion Middle 
third esophagus Lower 
third thoracic esophagus 
and Gastroesophageal 
tumors 
36 118 
Duration of symptoms 
( Mean ± S.D) Preope-
rative albumin (gm/dl)
( Mean ± S.D) Comor-
bidities Neoadjuvant 
treatment 
2.481± 1.7684 (Range 1 -12) 3.938 ± 
0.3684 (Range 3-4.9) 25 ( COPD-12, 
Diabetes Mellitus-10, Hypertensi-
on-8, Ischemic heart disease-3; Hy-
pothyroidism-3, Previous history of 
pulmonary Koch’s-3) 10 (6 patients 
- NACTRT, 4 patients- NACT) 
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P2.07-023 EXTENDED SLEEVE LOBECTOMY AFTER IN-
DUCTION CHEMORADIOTHERAPY FOR LOCALLY AD-
VANCED NON-SMALL CELL LUNG CANCER
Hiromasa Yamamoto, Shinichi Toyooka, Junichi Soh, Masaomi 
Yamane, Kazuhiko Shien, Kentaroh Miyoshi, Seiichiro Sugimoto, 
Takahiro Oto, Shinichiro Miyoshi
Department Of Thoracic Surgery, Okayama University Graduate School 
Of Medicine, Dentistry And Pharmaceutical Sciences/Japan
Background: An extended sleeve lobectomy is a useful procedure 
so as to spare the lung parenchyma. However, the resection of the 
bronchus can cause an increment in the tension at the site of the 
anastomosis and mismatches in the size of the bronchial orifices. 
Induction chemoradiotherapy (CRT) followed by surgery is a the-
rapeutic option for locally advanced non-small cell lung cancer 
(NSCLC). Induction CRT, especially radiotherapy, has a negative 
effect on bronchial healing in the bronchial stump or anastomosis 
in a pulmonary resection.
Methods: The medical records were reviewed for nine NSCLC 
patients who underwent extended sleeve lobectomy after CRT 
between December 2007 and January 2013. Disease stage was 
evaluated with imaging analyses, including enhanced chest com-
puted tomography (CT) scan, brain magnetic resonance imaging, 
positron emission tomography-CT scan and bronchoscopy. Induc-
tion CRT was performed for eight cases using cisplatin and doce-
taxel with concurrent thoracic radiation. For one patient who had 
synchronous laryngeal cancer, 5-fluorouracil and nedaplatin were 
used as chemotherapy. The radiation dose was 46 or 40 Gy using a 
conventional fractionation (2 Gy/day). Patients without progressive 
disease or good general condition underwent surgery. The bron-
chial anastomosis was basically wrapped with an omental pedicled 
flap or pericardial fat pad with prophylactic intent. The pre- and 
postoperative first-second forced expiratory volume was measu-
red. The overall survival (OS) and the disease-free survival (DFS) 
were calculated from the date of initialing induction CRT until 
the date of death or the last follow-up for OS and until confirmed 
death of any cause or recurrence at local or distant site for DFS. 
The survival curve was calculated by the Kaplan-Meier method.
Results: The median patient age was 60 years (range, 50 to 73 
years). There were seven men and two women. The histological 
subtype was squamous cell carcinoma in six patients and ade-
nocarcinoma in three patients. Five patients had clinical stage 
(c-stage) IIIA, two patients had c-stage IIIB, and two patients had 
c-stage IIB. The radiation dose was 46 Gy in seven patients and 40 
Gy in two patients. An extended sleeve lobectomy was performed 
for the left lingular division and the lower lobe in four patients, the 
right upper lobe and trachea in one patient, the right upper lobe, 
carina and trachea in one patient, the right middle and lower lobe 
in one patient, the right upper and middle lobe and the carina in 
one patient, and the right upper lobe and superior segment of the 
lower lobe in one patient. While no postoperative 90-day deaths 
occurred in this series, one case developed a bronchopleural 
fistula on postoperative day (POD) 25 and one case developed a 
bronchovascular fistula on POD 163. No cases of local recurrence 
occurred. The first-second forced expiratory volume before surge-
ry was 2.52 ± 0.58 L (mean ± standard deviation), while that after 
surgery was 1.80 ± 0.66 L. The 2-year overall survival and disease-
free survival rates were 63.5% and 47.6%, respectively.
Conclusion: Our experience suggests that an extended sleeve 
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period. Preoperative serum albumin and histological subtype were 
associated with increased postoperative mortality. Neoadjuvant 
therapy was not associated with increased complication rate.
Keyword: Carcinoma esophagus, perioperative morbidity, trans-
hiatal esophagectomy, esophagectomy
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P2.07-025 NEW PATHOLOGICAL CLASSIFICATION OF 
LUNG ADENOCARCINOMA IS USEFUL FOR SELECTING 
LIMITED CASES UNDERGOING SUBLOBAR RESECTION 
AS A CURATIVE SURGERY.
Akira Shimamoto1, Motoshi Takao1, Katsunori Uchida2, Makiko 
Fujita3, Hironori Tempaku1, Hiroshi Kodama3, Shuichi Murashi-
ma3, Hideto Shimpo1
1Thoracic And Cardiovascular Surgery, Mie University Graduate School 
Of Medicine/Japan, 2Pathologic Oncology, Mie University Graduate 
School Of Medicine/Japan, 3Radiology, Mie University Graduate School 
Of Medicine/Japan
Background: A new lung adenocarcinoma classification is being 
proposed by the International Association for the Study of Lung 
Cancer, American Thoracic Society, and European Respiratory 
Society (IASLC/ATS/ERS), which was based on histomorphologic 
subtype and had recently been validated in a North American se-
ries of 514 stage I lung adenocarcinomas. However, its distribution 
of patient number was biased, especially adenocarcinoma in situ 
(AIS), minimally invasive adenocarcinoma (MIA), and non-mucinous 
lepidic predominant groups, compared with in Japan. We evalu-
ated an appropriateness of new classification in a series in Japan 
and whether the classification could be useful for selecting limited 
cases undergoing sublobar resection.
Methods: We retrospectively reviewed clinical records of all pati-
ents operated on for non-small cell lung cancer from 1997 to 2011 
(n=825). 292 patients (35.4%) had pathological stage IA adenocar-
cinoma of the lung classified according to the Union for Internatio-
nal Cancer Control/American Joint Committee on Cancer 7th Edi-
tion. Some pathologists, blinded to patient outcome, performed 
histopathologic subtyping according to the proposed new IASLC/
ATS/ERS classification. Statistical analyses were made including 
Kaplan–Meier and Cox regression analyses.
Results: There were 160 females (54.8%) and 132 males (45.2%) 
with a median age of 67 years (29–84 years) and 212 pT1a and 80 
pT1b patients (tumor size: 16.7±7.1 [2-30] mm). Three overall prog-
nostic groups were identified: low grade: AIS (n=103, 35.3%) and 
MIA (n=24, 8.2%) had 97.1% and 95.1% of disease-free survival at 5 
years (DFS, median follow-up was 54 months); intermediate grade: 
non-mucinous lepidic predominant (n=61, 20.9%), acinar predomi-
nant (n=38, 13.0%), and papillary predominant (n=48, 16.4%), with 
80.1%, 86.5%, and 62.4% of DFS; and high grade: invasive muci-
nous adenocarcinoma (n=5, 1.7%), solid predominant (n=12, 4.1%) 
and micropapillary predominant (n=1, 0.3%), with 88.9% of DFS. 
DFS in low grade was significant better than in other two grades 
(P<0.005), however, there was no significant difference between in 
intermediate and high grade groups due to lower DFS in papillary 
predominant or insufficient patient number in high grade group. 
Preoperative imaging examinations such as consolidation/tumor 
(C/T) ratio on high resolution CT and maximum standardized 
uptake value (SUVmax) by FDG-PET were correlated with histopa-
Surgery performed 
Transhiatal esophagec-
tomy Transthoracic eso-
phagectomy 
140 14 
Complications Pul-
monary complications 
Anastamotic leak Morta-
lity Abdominal infection 
Chyle leak 
18 11 12 ( 7 had pulmonary compli-
cation also) 3( All 3 had pulmonary 
complication ) 2 1( also had pulmo-
nary complication) 
 
NACTRT- Neoadjuvant chemoradiotherapy, NACT-Neoadjuvant 
chemotherapy Of 154 patients who underwent esophagectomy at 
our center, 140 patients underwent THE and 14 underwent TTE. 
Mean duration of dysphagia was 2.4 months. One hundred and 
twenty four patients had squamous cell carcinoma and 30 patients 
had other histological types. Twenty five patients had comorbidi-
ties as described in Table.1. Eighteen patients developed postope-
rative complication of which three died - one case due to massive 
pulmonary embolism and two cases due topulmonary infection 
and septicaemia). Twelve patients had anastamotic leak (7.7%), all 
were managed conservatively. When multivariate regression analy-
sis was performed for the predicted risk factors and development 
of complication, preop albumin ( less than 4gm/dl) and histological 
type (non squamous cell carcinoma) were associated significantly 
with increased post operative complications (Table.2). Abnormal 
pulmonary function tests though showed increased risk of compli-
cations it didn’t attain statistical significance.  
Table 2: Multivariate logistic regression analysis of predic-
tive factors for early postoperative complications:
Independent 
variables 
Coeffici-
ent 
Standard 
Error 
t P 
Albumin (Less 
than 4 gm/dl) 
-0.1505 0.07519 -2.001 0.0472*(sig-
nificant) 
Comorbidity 
(Yes) 
0.1012 0.06716 1.507 0.1339 
Duration of 
dysphagia 
(Absolute 
dysphagia) 
0.004364 0.01576 0.277 0.7823 
Histopatholo-
gical exami-
nation ( Non 
squamous cell 
carcinoma) 
-0.1877 0.07332 -2.559 0.0115*(Sig-
nificant) 
Neoadjuvant 
treatment ( 
Yes) 
0.1043 0.1147 0.910 0.3645 
Site of lesion ( 
Middle 3rd) 
0.06701 0.06641 1.009 0.3146 
Pulmonary 
function tests 
(Abnormal) 
0.04156 0.02232 1.862 0.0646 
 
Conclusion: We achieved a 2% mortality rate during the study 
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p=0.749), median ICU (both 0 days) and hospital stay (both 5 days) 
were also similar in the two groups.
Conclusion: Early postoperative outcomes after major lung re-
section for primary lung tumors are independent of the level of 
training of the operating surgeon. These results are qualified by 
the fact that operations performed by trainees were closely super-
vised and assisted by experienced consultant thoracic surgeons in 
a teaching tertiary level cancer centre.
Keywords: surgeon grade, lung resection, postoperative  
outcomes
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P2.07-027 RETROSPECTIVE ANALYSIS OF 236 CONSE-
CUTIVE ROBOTIC-ASSISTED PULMONARY LOBECTO-
MIES AT A SINGLE INSTITUTION: A BI-PHASIC LEAR-
NING CURVE
Kathryn L. Rodriguez1, Frank O. Velez-Cubian1, Wei Wei Zhang1, 
Matthew R. Thau1, Jacques-Pierre Fontaine2, Joseph R. Garrett2, 
Carla C. Moodie2, Lary A. Robinson2, Eric M. Toloza2
1University Of South Florida College Of Medicine/United States Of 
America, 2Thoracic Oncology, Moffitt Cancer Center/United States Of 
America
Background: The treatment of choice for early-stage lung cancer 
is surgical resection. Over the years, there has been an increase in 
minimally-invasive surgical (MIS) options for lung resection, inclu-
ding video-assisted thoracoscopic (VATS) lobectomy and robotic-
assisted thoracoscopic (RATS) lobectomy. These MIS approaches 
have reformed lobectomies, decreased overall morbidity as well 
as decreased post-operative pain and hospital length of stay (LOS) 
when compared to traditional thoracotomy lobectomies. In spite 
of the recent rapid surgical expansion of MIS lobectomy, little is 
known about the learning curve of RATS lobectomy. In order to 
move forward in this new surgical technologic era while enhancing 
patient safety, determination of this learning curve is crucial.
Methods: We retrospectively analyzed the perioperative outco-
mes of 236 consecutive patients who underwent robotic lobec-
tomy at our institution between September 2010 and June 2013. 
Patients were grouped chronologically into four quartiles, with 59 
patients in each quartile. A comparison was performed between 
quartiles with respect to operative times, intraoperative estimated 
blood loss (EBL), hospital LOS, and in-Hospital mortality. Statistical 
analysis was undertaken using analysis of variance (ANOVA), linear 
regressions, and t-tests. Significance was set at p-value <0.05.
Results: A total of 236 patients with a mean age of 67 ± 10 years 
underwent RATS lobectomy between September 2010 and June 
2013. Each of the four quartiles had overall conversion-to-thoraco-
tomy rates of ≤10% and emergency conversion rates of ≤5%. Alt-
hough intraoperative EBL and hospital LOS were not significantly 
different among the quartiles, both EBL and hospital LOS showed 
a decreasing trend over each chronologic quartile. Operative times 
increased during the 2nd quartile, but also showed a decreasing 
trend with subsequent quartiles. There was an overall pathologic 
upstaging in 39% of the RATS lobectomy patients. Lastly, the in-
Hospital mortality rate was 5.1% for the 1st quartile and 0% for 
each subsequent quartile.
thologic grade according to new classification (P<0.01). Moreover, 
sublobar resection was undergone for 144 cases (49.3%), more ca-
ses had been identified small tumor, low C/T ration, low SUVmax, 
and low grade subtypes, and DFS in sublobar resection was 96.4% 
which was significant better than in lobectomy (78.6%, P=0.0002).
Conclusion: In this study, we can evaluate with enough number 
of patients classified to AIS, MIA, or non-mucinous lepidic predo-
minant according to the new IASLC/ATS/ERS classification. Most 
of subtypes correlated with DFS, except of papillary predominant 
and subtypes in high grade clinical aggressiveness, which may 
need more clinical investigation. Patients in low grade subtypes 
who underwent sublobar resection had better DFS, which can be 
predicted using tumor size and preoperative imaging examinations 
such as C/T ratio and SUVmax. So, the new classification has ad-
vantages for better selection of limited cases undergoing sublobar 
resection as a curative surgery.
Keywords: adenocarcinoma in situ, minimally invasive adenocarci-
noma, sublobar resection
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P2.07-026 DOES SURGEON GRADE INFLUENCE EARLY 
POSTOPERATIVE OUTCOMES IN MAJOR RESECTION 
FOR LUNG TUMORS?
C S. Pramesh1, George Karimundackal1, Sabita Jiwnani1, Parveen 
Yadav1, Marzi Mehta2
1Thoracic Surgery, Surgical Oncology, Tata Memorial Centre/India, 
2Tata Memorial Hospital/India
Background: Postoperative complications are common after major 
lung resections for cancer. Although there have been important 
advances in operative technique and perioperative care, lung re-
section for cancer is still a major surgery with higher incidence of 
complications in centres with a low case volume. We undertook a 
retrospective analysis of a prospectively maintained surgical da-
tabase to ascertain whether the grade of the operating surgeon 
influenced the occurrence of postoperative complications and 
mortality in a tertiary level teaching cancer centre.
Methods: Data from a prospectively maintained database (Aug 
2004 to May 2013) was analysed and the following parameters 
were retrieved: age, sex, type of surgery, grade of surgeon (Con-
sultant vs trainee), postoperative major complications including 
pulmonary complications, air leak, bronchopleural fistula and mor-
tality. ICU and hospital stay were also compared between surge-
ries performed by consultants and trainees. Categorical variables 
were analysed by the Chi square or Fischer’s exact test and nume-
rical variables using the unpaired Student t test. P values less than 
0.05 were considered statistically significant.
Results: A total of 654 patients (494 male, 160 female; mean age 
54.4, range 14 to 83 years) underwent lung resection for prima-
ry lung tumors in the study period. The overall major morbidity 
and postoperative mortality was 10.6% and 1.7% respectively. 
Consultant thoracic surgeons performed 532 surgeries while trai-
nees performed 122 procedures. Major morbidity was 11.2% and 
8.2% (p=0.336) and postoperative mortality was 1.9% and 0.8% 
(p=0.628) when lung resection was performed by consultants and 
trainees respectively. The incidence of pulmonary complications 
(10.2% vs 9.9%, p=0.916) and bronchopleural fistula (2.2% vs 1.8%, 
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Results: To date, nearly 900 patients have been enrolled at the 
twelve Collaborative sites. Certain elements have proven more dif-
ficult than others to accomplish reliably, namely adherence to post-
operative pain control and pulmonary toilet regimens. Even so, the 
redesign of the complex care required by the lung resection pati-
ent to embed evidence-based best practices into everyday patient 
flow, has resulted in high adherence to the prescribed elements of 
care, ranging from 92 to 100%. A comparison of the ProvenCare® 
study group to the STS Database control will be undertaken once 
an additional 200 patients are enrolled.
Conclusion: Quality and reliability represent frontiers of cancer 
care, and have the potential to improve patient outcomes as much 
as blockbuster medications or innovative radiation or surgical tech-
niques, and perhaps more cost-effectively. We present an example 
of a national, collaborative, multidisciplinary model of reliable care 
that represents the first attempt to test patient care outcomes in 
this context.
Keyword: Surgery, Quality, Reliability, NSCLC
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P2.07-029 CLINICAL FEATURES AND OUTCOME OF SUR-
GICALLY RESECTED SECONDARY PRIMARY NON-SMALL 
CELL LUNG CANCER
Masatoshi Kakihana, Yoshinori Sakata, Yoshihisa Shimada, Nao-
hiro Kajiwara, Tatsuo Ohhira, Norihiko Ikeda
First Department Of Surgery, Tokyo Medical University/Japan
Background: The incidence of a second primary lung cancer has 
been reported with 1-2% per patient year. Still, relatively few data 
has been published about this selected group of patients with 
sometimes conflicting results. Most data has been included low 
patient numbers that derived either from multiple institutions or 
from a long time period that may have rendered conclusions dif-
ficult caused by varying diagnostic procedures and therapeutic 
developments. Moreover, data regarding clinical characteristics is 
lacking for patients with first primary lung cancer who might be at 
risk for developing second primary lung cancer
Methods: From January 1999 to December 2008, 65 patients with 
Conclusion: In contrast to the steep learning curves associated 
with other MIS procedures, RATS lobectomy may result in only a 
modest learning curve for surgeons with extensive VATS lobecto-
my experience, as is suggested from the unchanging and low hos-
pital LOS, intraoperative EBL, and conversion to open lobectomy 
rates across all quartiles. Additionally, the increase in operative 
time in the 2nd quartile is most likely associated to the extension 
of the RATS approach to more difficult lobectomy cases after re-
lative comfort with RATS lobectomy has been achieved. The high 
percentage of overall pathologic upstaging is likely due to more 
complete mediastinal lymph node dissection than would be achie-
ved with either deliberate lymph node sampling only or else in-
adequate lymph node dissection due to limitations in visualization, 
instrumentation, or technical experience with VATS lobectomy. The 
decrease in mortality rate from the 1st to subsequent quartiles can 
be attributed to increased proficiency in RATS lobectomy. Thus, a 
bi-phasic learning curve is demonstrated by increased operative 
times after establishment of comfort with RATS lobectomy after 
initial success and subsequent extension of RATS to more compli-
cated patients (1st phase), while operative times, EBL, hospital LOS, 
and mortality decrease with improved patient selection and more 
RATS experience (2nd phase).
Keywords: Robotic, pulmonary, lobectomy, learning curve
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P2.07-028 PROVENCARE®: EVIDENCE BASED CARE TO 
OPTIMIZE LUNG CANCER RESECTION OUTCOMES
Nikhilesh M. Korgaonkar1, Matthew A. Facktor2, Douglas Wood3, 
Karen E. Mckinley2, David Winchester4
1Sinai Hospital Of Baltimore/United States Of America, 2Geisinger 
Health System/United States Of America, 3University Of Washington/
United States Of America, 4American College Of Surgeons/United Sta-
tes Of America
Background: Lung cancer remains by far the biggest cause of 
cancer deaths worldwide, exceeding the next four cancers com-
bined. Meanwhile, health systems struggle with ballooning costs 
and an unclear relationship between cost and outcomes. Within 
this context, there exists a great need for reliable, goal-oriented, 
and cost-effective care. ProvenCare® Lung Cancer is a national, 
multi-Institutional care improvement collaborative that identifies 
and prescribes best practice elements of care in order to improve 
outcomes of pulmonary resection for lung cancer.
Methods: Incorporating principles of reliability science, the Pro-
venCare® group established a protocol to promote adherence 
to and completion of best practice elements of care for patients 
undergoing pulmonary resection for lung cancer. Thirty-eight 
care elements span the continuum from preoperative assessment 
through intraoperative and inpatient postoperative care, and on 
to post-discharge follow-up. An original 6 thoracic surgical teams, 
subsequently expanded to twelve institutions, prospectively mea-
sured adherence to the prescribed elements of care in an “all or 
none” measure of success (adherence to all 38 elements is requi-
red for “compliance”). These data are to be compared both in a 
pre- and post-ProvenCare® involvement within participating sites, 
as well as to contemporaneous data within the Society of Thoracic 
Surgeons (STS) General Thoracic Database, to compare operative 
morbidity and mortality between the two groups. 
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female, and the age at the first pulmonary metastasectomy ranged 
from 13 to 82 years (median, 56 years). Primary tumor pathologies 
included colorectal cancer (n=104, 49.8%), hepatobiliary cancer 
(n=38, 18.2%), kidney cancer (n=17, 8.1%), sarcoma (n=14, 6.7%), 
and the others (n=36, 17.2%). Disease-free interval from initial 
primary tumor treatment to the first metastasis ranged from 1 to 
94 months (median, 25 months). Overall 5 year recurrence-free 
survival rate was 30.1%. There was no difference in recurrence 
rates between the MLND group and the non-MLND group (5 year 
recurrence-free survival: 30.0% vs. 24.5%, p=0.927). On multivaria-
ble analysis, primary tumor histopathology (p<0.001), disease-free 
interval (p=0.016), and the number of nodules (p<0.001) emerged 
as significant and independent prognostic factors for recurrence. 
After adjustment by these three significant variables, mediastinal 
lymph node dissection did not affect recurrence-free survival (ha-
zard ratio, 0.924; 95% confidence interval, 0.641-1.333; p=0.672).
Conclusion: Tumor recurrence after pulmonary metastasectomy 
was affected by the histopathology of the primary tumor, disease-
free interval, and the number of metastatic nodules. However, the 
role of mediastinal lymph node dissection as a part of pulmonary 
metastasectomy is obscure in patients with no evidence of medias-
tinal lymph node metastasis based on CT and PET.
Keywords: lung metastasis, metastasectomy, Mediastinal lymph 
node dissection
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P2.07-031 LOCALLY ADVANCED LUNG CANCER WITH 
LOW NODAL INVOLVEMENT AND CONCOMITANT  
TUBERCULOSIS IN A TERTIARY CARE CANCER CENTRE 
OF INDIA
Palaniappan Ramanathan, Nk Shukla, Svs Deo, Sunil Kumar, Dur-
gatosh Pandey, Shivam Vatsal, Ashish Jakhetiya
Surgical Oncology, All India Institute Of Medical Sciences/India
Background: Lung cancer generally presents in an advanced stage 
and tuberculosis(TB) is a common disease in the subcontinent. This 
study describes locally advanced lung cancer showing low nodal 
involvement by cancer and concomitant TB.
Methods: Retrospective analysis of lung cancer database of De-
partment of Surgical Oncology , BRA IRCH , AIIMS (2012 -2013 
) was performed and 28 cases were identified who underwent 
surgeries for lung mass. Only primary lung cancers were included. 
The clinical features , histopathology and management of these 
patients were analyzed.
Results: A total of 1293 cancer patients were operated between 
2012 and 2013 in the department of surgical oncology. Out of 
which 28 patients were diagnosed to have lung mass with an inci-
dence of 2.1%. Lung cancer was common in fifth decade. Predo-
minant in males [M:F - 3.6:1]. Equal incidence of left and right lung. 
Five had old Koch‘s disease. Eighteen were smokers and majority 
were diagnosed to have lung cancer by computed tomography 
guided tissue diagnosis. Bronchoscopy detected 9 central tumors. 
All underwent R 0 resection except one case which was unresec-
table. Majority were in stage III [ 18 cases]but only 2 patients had 
nodal invovlement. Chest wall was resected in 4 patients with an 
average of three ribs resected. Final histopathology showed majo-
rity of adenocarcinoma [ 12 cases] followed by squamous cell carci-
second primary lung cancer, classified by the criteria proposed by 
Martini and Melamed, were treated at our Institution. We had 34 
patients with a synchronous tumour and 31 with metachronous. As 
second treatment, we performed 11 lobectomies and 54 segmen-
tectomies and widewedge resections. Histology was adenocarci-
noma in 58, squamous in 4, adenosquamous in 8, large cells in 2 
and pleomorphic in 1.
Results: Overall 5-year survival from second surgery was 69%; 
overall operative mortality was 0.65% (1 patient). Regarding the 
interval of surgery, the second operation had performed later than 
2 years group showed a better 5-year survival than within 2 years 
group (80.6% and 69.2%, respectively, P = 0.008). Compared with 
lobectomies, segmentectomy showed a no significantly changes in 
survival rate(69 and 60%, respectively, P >0.051).
Conclusion: From our experience, lobectomy should still be con-
sidered as the treatment of choice in the management of second 
primary lung cancer, but sublobar resection remains a valid option 
in high-risk patients with limited pulmonary function.
Keyword: synchronous and metachronous lung cancer, follow-up, 
surveillance, NSCLC
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P2.07-030 THE ROLE OF MEDIASTINAL LYMPH NODE 
DISSECTION DURING PULMONARY METASTASECTOMY 
IN PATIENTS WITH NO EVIDENCE OF MEDIASTINAL 
LYMPH NODE METASTASIS BASED ON PREOPERATIVE 
COMPUTED TOMOGRAPHY AND POSITRON EMISSION 
TOMOGRAPHY
Joo Yeon Kim, Geun Dong Lee, Se Hoon Choi, Hyeong Ryul Kim, 
Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park
Department Of Thoracic And Cardiovascular Surgery, Asan Medical 
Center/Korea
Background: The clinical impact of mediastinal lymph node 
dissection (MLND) during pulmonary metastasectomy remains 
controversial. Especially the prognostic contribution of MLND on 
the prevention of tumor recurrence in patients with no evidence of 
mediastinal lymph node metastasis has not been clearly defined. 
We aimed to clarify the role of MLND during pulmonary metas-
tasectomy in this population.
Methods: We retrospectively reviewed 632 patients who under-
went pulmonary metastasectomy from January 2006 to December 
2010 in Asan Medical Center. Among them, two hundred nine pa-
tients were identified to meet the following criteria and comprised 
the current study population: the presence of preoperative com-
puted tomography (CT) and positron emission tomography (PET) 
within 2 months before pulmonary metastasectomy, definite con-
trol of the primary tumor, and no evidence of mediastinal lymph 
node metastasis. Of 209 patients, sixty-seven patients underwent 
MLND during pulmonary metastasectomy (MLND group), where-
as 142 patients underwent pulmonary resection only (non-MLND 
group). Between-group recurrence-free survival was compared, 
and risk factors for tumor recurrence were evaluated. The data on 
tumor recurrence were obtained through a median follow-up dura-
tion of 42 months (range 2-83 months).
Results: The study population was composed of 119 male and 90 
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stage non-small cell lung cancer (NSCLC).
Methods: Four relevant studies with propensity score-matched 
patients were identified from six electronic databases. Endpoints 
included perioperative mortality and morbidity, individual post-
operative complications and duration of hospitalization.
Results: indicate that all-cause perioperative mortality was similar 
between VATS and open thoracotomy. However, patients who 
underwent VATS were found to have significantly fewer overall 
complications, and significantly lower rates of prolonged air leak, 
pneumonia, atrial arrhythmias and renal failure. In addition, pa-
tients who underwent VATS had a significantly shorter length of 
hospitalization compared to patients who underwent open thora-
cotomy. 
Conclusion: In view of a paucity of high level clinical evidence in 
the form of large, well-designed randomized controlled trials, pro-
pensity score matching may provide the highest level of evidence 
to compare VATS with open thoracotomy for patients with NSCLC. 
The present meta-analysis demonstrated superior perioperative 
outcomes for patients who underwent VATS, including overall 
complication rates and duration of hospitalization.
Keywords: Propensity score matching, Meta-analysis, NSCLC, 
VATS
noma [ 8 cases]. Five patients showed features of concomitant TB.
Conclusion: Due to high prevalence of TB in this subcontinent , 
nodal staging in pre-operative imaging assessment might be fal-
lacious. Imaging and positron emission tomography results should 
be interpreted more cautiously while making surgical decisions 
regarding operability.
Keywords: low nodal invovlement, locally advanced lung cancer, 
Concomitant tuberculosis
POSTER SESSION 2 - SURGERY  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.07-032 VIDEO-ASSISTED THORACIC SURGERY VER-
SUS OPEN THORACOTOMY FOR NON-SMALL CELL 
LUNG CANCER - A META-ANALYSIS OF PROPENSITY 
SCORE MATCHED PATIENTS
Christopher Cao1, Con Manganas2, Su Ang1, Sheen Peeceeyen2, 
Tristan D. Yan1
1Systematic Reviews Unit, Collaborative Research Group/Australia, 
2Cardiothoracic Surgery, St. George Hospital/Australia
Background: This meta-analysis aims to compare the perioperati-
ve outcomes of video-assisted thoracic surgery (VATS) versus open 
thoracotomy for propensity score-matched patients with early-
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surgeons as MLND, none of which met pathology criteria, only 9% 
of all resections met SS criteria, 50% of all resections had random 
sampling (RS) and 42% had no sampling (NS) of MLN. An indepen-
dent surgeon audit suggested that 29% of operation notes descri-
bed a MLND, but 26% were RS and 45% NS. The concordance rate 
for MLND or SS between surgeon claims and pathology report 
audit was only 11%. We examined the impact of corrective inter-
vention with a pre-labeled lymph node specimen collection kit and 
a checklist on the verifiable quality of MLN examination in a repeat 
audit of surgeon claims.
Methods: Prospective cohort study of NSCLC resections per-
formed with the kit at 4 Memphis, TN hospitals from 11/2010 - 
01/2013. Surgeons, operating room and pathology staff received 
training on the value of rigorous MLN examination and proper kit 
use. Surgeons marked the stations harvested on a checklist du-
ring the operation. Resections were classified into 4 pre-defined 
groups based on MLN stations marked on the checklist (surgeon 
claims), and the pathology report: MLND, SS (both by ACOSOG 
Z0030 trial criteria), RS (>0 MLN present, but MLND/SS criteria not 
met), NS (0 MLN present). Audited operation notes were catego-
rized by surgeons from two independent academic cancer centers 
into one of the 4 MLN examination groups. The primary endpoints 
were the verifiable rate of MLND + SS and the concordance rate 
between observers.
Results: N = 161; 51% female, median Charlson comorbidity score 
2 (IQR 1-3), 58% right-side resections. Clinico-demographic cha-
racteristics were similar between patients in each MLN category. 
Surgeons claimed MLND in 49%, SS in 9% of cases; vs 76% and 
14% in the independent surgeon audit. The kappa score bet-
ween independent surgeons was 0.44 (‚moderate agreement‘). 
Conclusion: The verifiable MLND+SS rate increased from 9% in 
the previous pathology audit to 83%; and from 29% in the previ-
ous independent surgeon audit to 89%. Concordance between 
operating surgeon claims and the pathology report increased from 
11% to 83%. The improved lymph node yield and verifiable quality 
of MLN mapping indicates that implementing a corrective inter-
vention with a pre-labelled specimen collection kit and checklist 
improves surgical MLN collection practice, fosters better commu-
nication with pathologists and improves the quality of pathologic 
nodal staging of NSCLC.
Keywords: quality of care, mediastinal lymph node evaluation, 
Lung cancer surgery, pathologic staging
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P2.07-033 A COMPARATIVE STUDY OF COMPLETE 
VIDEO-ASSISTED THORACOSCOPIC LOBECTOMY AND 
VIDEO-ASSISTED MINI-THORACOTOMY IN TREATMENT 
OF LUNG CANCER
Yi Zhang, Yuanbo Li
Thoracic Surgery, Xuanwu Hospital, Cmu/China
Background: To explore the clinical application value of complete 
video-assisted thoracoscopic(cVATS) lobectomy in the mini-invasi-
ve treatment of lung cancer.
Methods: 90 patients with non-small cell lung cancer(NSCLC) 
who had undergone lobectomy were reviewed. According to 
surgical approach, complete video-assisted thoracoscopic lobec-
tomy group (cVATS,n=47) and video-assisted mini-thoracotomy 
group(VAMT,n=43) were studied. Numbers of dissected lymph 
nodes,operation duration,volumes of intraoperative bleeding, 
duration of postoperative catheter drainage, length of postopera-
tive hospital stay, incidence rates of postoperative complications, 
postoperative pain scores of patients were compared between the 
two groups retrospectively.
Results: There were no significant differences in numbers of diss-
ected lymph nodes, operation duration, bleeding during opera-
tion, incidence rates of postoperative complication between the 
two groups(P>0.05).Duration of postoperative catheter drainage 
and length of postoperative hospital stay of patients in cVATS 
group were shorter than those in VAMT group(P<0.05).Pain scores 
of patients in cVATS group were lower than those at the same time 
in VAMT group(P<0.05).
Conclusion: Complete video-assisted thoracoscopic lobectomy 
is safe and effective surgical strategy for lung cancer patients with 
advantage of rapid recovery.
Keywords: Thoracoscopy, surgical approach, lobectomy, NSCLC
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P2.07-034 AUDIT OF MEDIASTINAL LYMPH NODE (MLN) 
EXAMINATION IN NON-SMALL CELL LUNG CANCER 
(NSCLC) RESECTIONS USING A SPECIMEN COLLECTION 
KIT AND CHECKLIST INTERVENTION.
Raymond U. Osarogiagbon1, Srishti Sareen1, Robert Ramirez2, Lau-
ra E. Miller3, Christopher G. Wang4, Sharon Phillips5, Kemp Kerns-
tine6, Joe B. Putnam7, Edward T. Robbins1
1Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center/
United States Of America, 2Louisiana State University/United States 
Of America, 3Medical Oncology, Tulane University/United States Of 
America, 4Medical Oncology, University Of Alabama/United States Of 
America, 5Biostatistics, Vanderbilt Ingram Cancer Center/United States 
Of America, 6Surgery, University Of Texas Southwestern/United States 
Of America, 7Surgery, Vanderbilt University/United States Of America
Background: Optimal pathologic nodal staging of NSCLC requires 
MLN dissection (MLND) or systematic sampling (SS). In our prior 
audit of a citywide database, 45% of resections were claimed by 
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Characteristics of open versus MIS groups
OPEN 
(N=107)
MIS 
(N=107)
p-
Value
Pathologic Stage <0.001
IA 38 (36%) 68 (63%)
IB 41 (38%) 32 (30%)
IIA 16 (15%) 3 (3%)
IIB 2 (2%) 1 (1%)
IIIA 9 (8%) 3 (3%)
IV 1 (1%) 0
Pathologic T size (cm) 
(median)
2.8 2.1 0.003
Pathologic N0 status 87 (81%) 102 (95%) 0.001
Conclusion: In the same time period, nodal upstaging after open 
lobectomy for early stage NSCLC was significantly higher compa-
red to MIS. However, there were no differences in local, regional 
or distant recurrence rates. Disease-free and overall survival was 
equivalent at median follow up of 38 months despite the diffe-
rence in upstaging rates.
Keywords: NSCLC, lobectomy, MIS, survival
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P2.07-036 LOWER-THAN-EXPECTED FEV1 AFTER UPPER 
LOBE RESECTION FOR LUNG CANCER IN THE EARLY 
POSTOPERATIVE PERIOD
Yuji Hirami1, Katsuhiko Shimizu2, Riki Okita2, Shinsuke Saisho2, 
Takuro Yukawa2, Ai Maeda2, Kouichiro Yasuda2, Masao Nakata2
1General Thoracic Surgery, National Hospital Organization Fukuyama 
Medical Center/Japan, 2Kawasaki Medical School/Japan
Background: After pulmonary resection, the immediate postope-
rative observed forced expiratory volume at 1 second (FEV1) is 
expected to be more correlated with the incidence of postoperati-
ve complications than the postoperative predicted FEV1. However, 
the clinical factors that affect the decrease in postoperative FEV1 
have not been reported in detail.
Methods: Seventy patients who underwent lobectomy or segmen-
tectomy for lung cancer were prospectively enrolled in this study. 
Of these patients, 25 who performed all pulmonary function tests 
in the preoperative period and in the early (at 3 or 4 days), middle 
(3 weeks later), and late (> 3 months later) postoperative periods 
were analyzed. At each postoperative period, the ratio of the post-
operative observed FEV1 to the postoperative predicted FEV1 
(po/ppFEV1) was evaluated according to the clinical factors.
Results: The mean po/ppFEV1 in the early / middle / late postope-
rative periods in all cases was 0.83 / 1.02 / 1.11. In the early period, 
the mean po/ppFEV1 of the resected upper / middle/ lower lobes 
was 0.74 / 0.97 / 0.88. The early poFEV1 after upper lobe resection 
was significantly lower than the ppFEV1 after middle or lower lobe 
resection (P=0.019). In the middle and late periods, no significant 
relationships were found between po/ppFEV1 and the resected 
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P2.07-035 COMPARISON OF CANCER-SPECIFIC OUT-
COMES BETWEEN OPEN AND MINIMALLY INVASIVE 
SURGERY (MIS) LOBECTOMY FOR EARLY STAGE NON-
SMALL-CELL LUNG CANCER (NSCLC)
Candice L. Wilshire, Brian E. Louie, Ralph W. Aye, Alexander S. 
Farivar, Jed A. Gorden, Eric Vallieres
Thoracic Surgery, Swedish Medical Center/United States Of America
Background: The optimal surgical approach for early stage NSCLC 
continues to be debated. Nodal upstaging could be a surrogate 
measure for the quality of surgery and may help define superiority 
of a particular approach. However, nodal upstaging is only one 
measure of oncologic equivalence and may not translate into can-
cer recurrence or survival. Additionally, recent publications focu-
sing on oncologic equivalence have compared approaches from 
different time periods. This study compares nodal upstaging, re-
currence rates, disease-free and overall survival between matched 
groups of open and MIS (VATS/Robotic) lobectomy performed 
concurrently in a single time period.
Methods: We retrospectively compared patients undergoing 
lobectomy via thoracotomy to MIS for primary, clinical stage I/II 
NSCLC from 01/04-05/11. Patients were matched for age, gender, 
comorbidities, PFTs and clinical TNM status.
Results: Two hundred and fourteen patients were evaluated with 
107 in each group. Preoperatively the MIS group had more T1a 
tumors (Table). The rate of nodal upstaging was significantly higher 
in the open group compared to the MIS group [N0 to N1: 12% (13) 
vs 4% (4), p=0.02; N0 to N2: 7% (7) vs 1% (1), p=0.03]. At median 
follow-up of 38 and 33 months respectively, recurrence rates for 
open vs MIS were similar: local 4% (4) vs 2% (2), regional 8% (9) vs 
3% (3) and distant 13% (14) vs 12% (13), p=0.23. Disease-free sur-
vival was 74% (79) and 83% (88) for open and MIS groups respec-
tively at 36 and 28 months, p=0.14. Overall 2 year survival was 89% 
(95) for the open group and 91% (97) for the MIS group, p=0.65.  
Characteristics of open versus MIS groups
OPEN 
(N=107)
MIS 
(N=107)
p-
Value
Age (median) 69 68 0.574
Female 63 (59%) 71 (66%) 0.260
Smoker 82 (77%) 84 (79%) 0.340
# Comorbidities (me-
dian)
1 1 0.589
FEV1% (median) 83 85 0.835
DLCO/VA% (median) 79 83 0.700
Investigations
PET Scan 93 (87%) 103 (96%) 0.264
Mediastinoscopy 78 (73%) 85 (79%) 0.264
Clinical Stage 0.150
IA 73 (68%) 82 (77%)
IB 33 (31%) 24 (22%)
IIA 1 (1%) 1 (1%)
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P2.07-038 ELDERLY PATIENTS WITH NON-SMALL CELL 
LUNG CANCER ARE OFTEN NOT OPERATED ON -  
RESULTS FROM A POPULATION-BASED STUDY
Tomas Gudbjartsson1, Kristjan Baldvinsson1, Andri W. Orrason1, 
Martin I. Sigurdsson1, Hunbogi Thorsteinsson1, Steinn Jonsson2
1Cardiothoracic Surgery, Landspitali University Hospital/Iceland, 2Pul-
monology, Landspitali University Hospital/Iceland
Background: We have previously reported favorable outcomes 
in elderly patients treated with surgery for NSCLC. In this study 
we have evaluated all elderly patients that were diagnosed with 
NSCLC in Iceland and specifically studied those that were not ope-
rated on.
Methods: A whole nation study has been conducted that included 
all patients diagnosed with NSCLC in Iceland between 1991 and 
2010 according to the Icelandic Cancer Registry. Data on staging, 
functional status and survival was obtained from medical records. 
All tumors were staged clinically (cTNM) and the reasons for exclu-
sion from surgery were registered for elderly patients with cTNM 
stages IA – IIIA.
Results: Of 2263 patients with NSCLC, 735 (32.5%) were defined 
as elderly. Resection rate for the elderly was 15% compared to 
26% for younger patients (p<0.001). Out of 627 elderly patients 
55% had localized/regional disease that was considered potentially 
resectable, and of that group 42% were not operated on. The most 
common reasons for exclusion from surgery were poor pulmonary 
function (40%) ECOG-performance status (15%), central tumor 
location (14%), underlying heart disease (11%) or that the patient 
rejected treatment (9%).
Conclusion: Elderly patients with potentially resectable NSCLC are 
frequently excluded from surgery due to co-morbid conditions. 
Their favorable 30-day and long-term survival may reflect bias in 
selection of lower risk patients.
Keyword: NSCLC, elderly, non-surgical, outcome
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P2.07-039 SURVIVAL OUTCOME OF PATIENTS UNDER-
GOING SURGICAL RESECTION OF NSCLC IN BRUNEI 
DARUSSALAM
Chee Fui Chong
Thoracic Unit, Department Of Surgery, Raja Isteri Pengiran Anak Sa-
leha Hospital/Brunei
Background: Lung cancer is the leading cause of cancer deaths in 
Brunei Darussalam for the past 5 years. Curative surgical resection 
in early stage non-small cell lung cancer (NSCLC) have been shown 
to improve survival. This study aimed to assess the 5-yr survival of 
patients undergoing surgical resection of NSCLC in Brunei Darus-
salam.
Methods: From 2000 to 2013, 64 patients underwent surgical 
resection of NSCLC at the RIPAS Hospital in Brunei Darussalam. 
lobe. No other clinical factors showed significant relationships with 
po/ppFEV1 in any postoperative period. The postoperative forced 
volume capacity (FVC) did not show a significant relationship with 
any clinical factor.
Conclusion: Resection of the upper lobe leads to a decrease of 
the FEV1 in the early postoperative period that is lower than the 
postoperative predicted FEV1. Therefore, in the early postoperati-
ve period after upper lobe resection, careful management is nee-
ded in order to avoid pulmonary complications.
Keywords: pulmonary function test, pulmonary resection, Lung 
cancer, Complication
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P2.07-037 MINIMALLY INVASIVE ANATOMIC SEGMEN-
TECTOMY AS PRIMARY TREATMENT FOR LUNG  
LESIONS
Eserval R. Júnior, Paula Ugalde, Sergio T. Pereira, Maria Kalil, Yuki 
T.H. Vieira
Cirurgia Torácica, Santa Casa De Misericórida De Salvador/Brazil
Background: Lobectomy is considered the gold standard curative 
treatment for early lung cancer. Its indication does not only rely 
only on the extent of the disease but also on postoperative lung 
capacity. With the new adenocarcinoma classification for lung 
cancer peripheric lesions smaller than 2cm might be treated with 
anatomic segmentectomy.
Methods: We performed a retrospective analysis of 29 patients 
submitted to anatomic segmentectomy by VATS technique in the 
period of 05/07/2009 to 31/05/2013 in Salvador, Bahia, Brazil due 
to peripheral lung lesion suspected of malignancy. A total of 30 
procedures were performed by two surgeons (Ugalde PA, Pereira 
ST). The purpose of this study is to analyze the indications, length 
of stay, surgical complications and final pathology.
Results: Of the 29 patients 17 (58,62%) were female, the age 
ranged from 13 to 89 years with an average of 53 years (± 20.49). 
53,3% of cases final pathology revealed neoplastic disease, 10 
adenocarcinomas in situ, 4 metastatic diseases, 1 carcinoid tumor, 
and 1 spindle cell tumor proliferation. The postoperative hospi-
talization ranged from 1 to 6 days with an average of 2.73 days (± 
1.44), the timing of chest drain varied 1 to 6 days with an average 
of 2.80 days (± 1.52). Two patients had to be submitted to bron-
choscopy due to postoperative atelectasis.
Conclusion: Anatomic segmentectomy although controversial 
in the treatment of primary early stage lung cancer, in our series 
when performed through VATS was safe and effective with mini-
mum rate complication. The advantages of a minimally invasive 
procedure resulted in a shorter hospital stay and recovery time, 
enabling patient early return to their activities.
Keywords: VATS, segmentectomy, Anatomical, Anatomic segmen-
tectomy
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following intravenous injection of 175 MBq of 99mTc-MAA, using 
geometric means method to determine left and right sided contri-
bution. QS-poFEV1 was the product of preop FEV1 x (1- number 
of resected segments/total number of segments in operated 
lung x perfusion in this lung). Pneumotach controlled CT scan at 
maximum expiration (RV) and inspiration (TLC) allowed to seg-
ment lobar volumes and calculated regional expansion (EXP). 
Resistances (iRaw before and after virtual resection) were acquired 
through computational fluid dynamics. FRI-poFEV1 equation: 
Results: Data of 14 patients are available: 8 male, median age 63 y 
(51-73), median preop FEV1 2490 ml (1660-4070), 10 lobectomy, 2 
bilobectomy, 2 pneumonectomy. Median actual poFEV1 was 2100 
ml (1210-3210). The Pearson correlation coefficient (R2) paired t-test 
and root mean square error (RMSE) between actual and predicted 
poFEV1 are shown below. FRI-poFEV1 underestimated fewer cases 
with respect to the actual- 7% variation corrected-poFEV1 (Oost-
veen,2013 in press) than the other methods.  
Method 
Predicted 
median 
poFEV1 
(ml)  
(range) 
Unde-
resti-
mated 
cases (n) 
R2 Slope 
RMSE 
(ml) 
P 
(paired 
t-test) 
ASM 
1660 
(1240-
2970) 
11/14 0.77 1.06 436 <0.001 
QS 
1980 
(1320-
3040) 
7/14 0.84 1.10 309 0.007 
FRI 
2050 
(1450-
3440) 
4/14 0.86 0.98 213 0.76 
Conclusion: FRI seems a superior predictor of actual poFEV1 in re-
sected lung cancer pts than either conventional method, allowing 
for 20% more functionally operable patients. Confirmation in a 
larger serie is ongoing.
Keywords: postoperatieve FEV1, Functional Respiratory Imaging, 
Estimation, surgery
Demographic and Clinical data of these 64 patients were retros-
pectively retrieved from the clinical notes. All deaths and date of 
death were obtained and cross-check with the National birth and 
death registry at the Imigration Department. Data were analysed 
using SPSS statistical software and 5-yr Kaplan-Meier survival cur-
ves were derived. Predictors of 5-yr survival were analysed using 
Cox regression analysis.
Results: Mean age of the 64 patients was 60.6 ± 12.2 (27.4 – 80.0 
years) with male to female ratio of 39:25. Racial distribution con-
sisted of 82.9% (53/64) Malay, 15.6% (10/64) Chinese and 1 foreign 
national. Histological types of NSCLC consisted of 57.8% (37/64) 
adenocarcinoma, 12.5% (8/64) Squamous cell carcinoma, 4.7% 
(3/64) large cell carcinoma, 18.8% (12/64) bronchioalveolar carci-
noma and 6.3% of other origin. Overall 5-yr Kaplan-Meier survival 
curves according to stage of disease were 67.9% for Stage 1A, 
51.1% for Stage 1B, 30.0% for Stage 2B, 29.0% for Stage 3A, 20.8% 
for Stage 3B and 33.3% for Stage 4. 5-yr disease-free survival were 
59.6% for stage 1A, 43.5% for stage 1B, 20.8% for Stage 3B and 
33.3% for stage 4. 5-yr survival for Stage 1A was better in patients 
who had systematic mediastinal lymphnodes dissection carried 
out as routine procedure (72.5%). Only Stage of NSCLC at the time 
of surgery was a significant independent predictor of 5-yr survival 
(p=0.01).
Conclusion: Overall 5-yr survival of patients with treated early sta-
ge 1A NSCLC is good and comparable to the surrounding region. 
This is further improve if routine SMLD were performed. Stage of 
NSCLC at time of diagnosis was the only significant independent 
predictor of 5-yr survival.
Keywords: Non small cell lung cancer, Survival Analysis, Cancer 
staging, Kaplan-Meier survival curves
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P2.07-040 IS POSTOPERATIVE FEV1 (POFEV1) MORE AC-
CURATELY ESTIMATED BY FUNCTIONAL RESPIRATORY 
IMAGING (FRI) THAN BY CONVENTIONAL METHODS?
Annelies Janssens1, Cedric Van Holsbeke2, Wim Vos2, Paul Van 
Schil3, Laurens Carp4, Elly Oostveen5, Wilfried De Backer5, Jan P. 
Van Meerbeeck1
1Thoracic Oncology / Moca, Antwerp University Hospital/Belgium, 
2Fluidda Nv/Belgium, 3Thoracic Surgery, Antwerp University Hospital/
Belgium, 4Nuclear Medicine, Antwerp University Hospital/Belgium, 
5Respiratory Medicine, Antwerp University Hospital/Belgium
Background: Accurate estimation of poFEV1 remains challenging. 
Underestimation excludes patients with early stage lung cancer 
from a potential curative resection, overestimation gives more 
postoperative complications. The anatomic segment method 
(ASM) and the perfusion scintigraphy (QS) are standard methods, 
although both underestimate actual poFEV1 (Holvoet 2011). FRI, 
describing flow characteristics in the lungs, estimates poFEV1 after 
virtual resection (De Backer 2010). We compared the accuracy of 
FRI with ASM and QS in the estimation of poFEV1 in patients plan-
ned for resection of lung cancer.
Methods: 23 consecutive patients underwent pre- and post-
operative FEV1 measurements by spirometry, ASM, QS and FRI. 
ASM-poFEV1 was estimated by the product of preop FEV1 with 
(1-number of resected segments /19). QS-images were obtained 
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P2.07-042 IS PLASMA FIBRINOGEN A NOVEL INDEPEN-
DENT PROGNOSTIC FACTOR IN PATIENTS UNDERGO-
ING SURGERY FOR NON-SMALL CELL LUNG CANCER?
Matthew O. Smith1, Robert George1, Annabel J. Sharkey1, Richard 
Hubbard2, Jagan N. Rao1, John Edwards1
1Department Of Cardiothoracic Surgery, Northern General Hospital/
United Kingdom, 2University Of Nottingham/United Kingdom
Background: Plasma fibrinogen levels have been shown to corre-
late with outcomes in various extra-thoracic malignancies. In pati-
ents with NSCLC, positive associations have been shown between 
fibrinogen levels and tumour pathology, but the clinical correlates 
are unclear. We aimed to examine whether pre-operative fibrino-
gen levels are a prognostic factor in patients undergoing surgical 
resection for suspected NSCLC.
Methods: All NSCLC patients undergoing surgery between 
29/8/2007 and 30/3/11 were included. Pre-operative plasma fibri-
nogen levels were measured and correlated with clinicopathologi-
cal factors, pathological TNM stage and survival. Survival analysis 
was performed on 17/06/13.
Results: 722 patients underwent surgery for suspected NSCLC. In 
519 (71.9%) patients (54.5% males, median age 68.5 (range 37.8 - 
90.8) years), pTNM stage and preoperative fibrinogen level were 
available. Median fibrinogen level was 4.1 (range 1.7 - 10.2) g/dL. 
330 (63.6%) of patients had fibrinogen level > reference range 
(2-4g/dL). Fibrinogen correlated with tumour size (p<0.001) and 
pTNM stage (p<0.001), but not with nodal stage, histological gra-
de or cell type. At the time of analysis, 309 (59.5%) patients were 
alive. Fibrinogen > 4g/dl (p=0.01), pTNM stage (p<0.001), Nstage 
(p=0.001) and tumour size (p=0.003) were univariate prognostic 
factors. In Cox multivariate analysis, fibrinogen level (p=0.02), 
pTNM stage (p<0.001), age (p<0.001) and gender (p=0.023) were 
independent predictors of prognosis.  
Fibri-
nogen 
<4g/dL
Fibri-
nogen 
>4g/
dL
p
n
Median 
Survival
n
Median  
Survival
StageI 125
Not 
reached
176 63.0 0.011
Stage II 45 55.4 97 Not reached 0.677
Stage III 19 42.3 57 34.5 0.396
Conclusion: Fibrinogen is associated with tumour size and pTNM 
stage. Whilst survival data are not yet mature, pre-operative fib-
rinogen > 4 g/dl may be a novel independent prognostic factor 
following surgical resection of NSCLC. Further work is required to 
determine the clinical implications of high fibrinogen levels, and to 
investigate the underlying mechanisms.
Keywords: non-small cell lung cancer, Fibrinogen, Prognostic fac-
tors for survival
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P2.07-041 TALC PLEURODESIS OR IPC FOR MALIGNANT 
PLEURAL EFFUSION. IS IT TIME TO CHANGE?
Annabel J. Sharkey, Matthew O. Smith, Jagan N. Rao, John Edwards
Department Of Cardiothoracic Surgery, Northern General Hospital/
United Kingdom
Background: Indwelling pleural catheters (IPCs) have a role in the 
management of pleural effusions. The TIME-2 trial demonstrated 
equivalence in dyspneoa relief for first time pleurodesis. This sing-
le centre study aimed to compare experience of patients receiving 
talc pleurodesis versus IPC.
Methods: A retrospective review of all patients undergoing IPC 
insertion or talc pleurodesis within a single Trust between October 
2007 and September 2012. We had a policy of selective IPC inser-
tion for trapped lung or recurrent pleural effusion, with talc pleu-
rodesis the procedure of choice for expansile lungs. We examined 
resource utilisation including pre-operative intervention, length of 
stay (LOS), re-accumulation and re-intervention.
Results: 130 patients were identified. 61 (47%) patients underwent 
talc pleurodesis; 69 had an IPC inserted. 13.1% of talc patients 
and 59.4 % in the IPC group had received a previous pleural inter-
vention (p<0.001). 23.0% of the talc and 29.0% of the IPC group 
received their procedure on an urgent basis (p=0.44 ). Significantly 
more patients underwent a general anaesthetic in the talc group 
(IPC 26 (37.7%), talc 57 (93.4%) p<0.001). Patients treated with IPC 
had a significantly shorter post-operative stay than those treated 
with talc (IPC median 2 (range 2-46) days; talc 5 (0-36), p<0.001). 
Significantly fewer patients experienced re-accumulation fol-
lowing IPC than talc pleurodesis at 30 days (8 (11.6%) vs 19 (31.3%) 
p=0.006), and overall (12 (17%) vs 27(44%) p<0.001). There were 
no differences in post-procedure mortality (IPC 3 (4.35%), talc 1 
(1.64%) p=0.372); effusion requiring re-admission to hospital (IPC 
5(7.25%), talc 7 (11.5%) p=0.406, or re-intervention rates (IPC 6 
(8.7%), talc 7 (11.5%) p=0.60).
Conclusion: Despite being used in patients with more complicated 
pleural effusion, IPC placement was associated with a significantly 
shorter post-operative length of stay and fewer cases of effusion 
re-accumulation. IPC placement should be considered for the 
treatment of pleural effusion.
Keywords: Indwelling pleural catheter, malignant pleural effusion, 
Talc pleurodesis
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Conclusion: While women had a slightly higher conversion rate to 
open lobectomy than men, female gender was not associated with 
increased intraoperative or postoperative complications nor with 
increased hospital LOS or in-Hospital mortality. Our study sug-
gests that robotic-assisted pulmonary lobectomy is feasible and 
safe in women.
Keywords: outcomes, gender, Robotic, lobectomy
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P2.07-044 RISK FACTORS FOR RECURRENCE AFTER PA-
THOLOGICAL STAGE IA NON-SMALL CELL LUNG CAN-
CER RESECTION
Yoshimi Otani1, Hiroki Shomura1, Yujiro Toyoshima1, Kensuke 
Ishida2, Yutaka Nishigaki2, Yuji Akiba2
1Thoracic Surgery, Hokkaido Pwfac Asahikawa-Kosei General Hospital/
Japan, 2Respiratory Medicine, Hokkaido Pwfac Asahikawa-Kosei Gene-
ral Hospital/Japan
Background: Adjuvant chemotherapy is not required for patho-
logical stage (p-stage) IA non-small cell lung cancer (NSCLC). 
And the prognosis of p-stage IA NSCLC is comparatively good. In 
the Japanese Joint Committee for Lung Cancer Registration, the 
5-year survival rate for p-stage IA NSCLC was reported with 86.8% 
[J Thorac Oncol 2011; 6: 1229-35]. But, there are some cases to 
cause recurrences more than expected among them. The purpose 
of this study was to evaluate the risk factors for recurrence in p-
stage IA NSCLC patients who had undergone complete resection.
Methods: A total of 409 primary NSCLC patients underwent pul-
monary resections between January 2003 and December 2012. 
Among them, 145 patients with p-stage IA NSCLC completely 
excised tumors in surgical procedures of segmentectomy or more 
were evaluated. All patients were divided into two groups : the 
group with recurrence (group R, n=15) and the group with no-re-
currence (group NR, n=130). We compared the both groups regard 
to the patient-related factors (age, sex, smoking habits, previous 
history, consultation motivation, timing of definitive diagnosis), 
the tumor-related factors (tumor markers, histologic type and dif-
ferentiation, tumor size, lymphatic permeation, vascular invasion, 
EGFR gene mutation) and the treatment-related factors (extent 
of resection and nodal dissection, thoracoscopic surgery or open 
thoracotomy, skill levels of operators, operative duration, amount 
of bleeding, postoperative hospital stay, adjuvant chemotherapy). 
The postoperative 5-year survival rate was calculated with the 
Kaplan-Meier method. The differences of significance between the 
two groups were compared using the Chi-square test. P values less 
than 0.05 were considered statistically significant.
Results: The 5-year survival rate was 45.0% in the group R and 
92.3% in the group NR (p<0.001). In the patient-related factors, the 
smoker/non-smoker ratio was 7/8 in the group R and 95/35 in the 
group NR (p<0.05). The previous history of hypertension/no-hy-
pertension ratio was 9/6 in the group R and 44/86 in the group NR 
(p<0.05) and that of diabetes/non-diabetes ratio was 4/11 in the 
group R and 10/120 in the group NR (p<0.05). There were no signi-
ficant differences in other patient-related risk factors. In the tumor-
related factors, the pathological lymphatic permeation ly1/ly0 ratio 
was 3/6 in the group R and 3/76 in the group NR (p<0.001). There 
were no significant differences in other tumor-associated risk fac-
tors. In the treatment-related factors, the enforcement of adjuvant 
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P2.07-043 EFFECT OF FEMALE GENDER ON PERI-OPE-
RATIVE OUTCOMES AFTER ROBOTIC-ASSISTED PULMO-
NARY LOBECTOMY: RETROSPECTIVE ANALYSIS OF 180 
CONSECUTIVE CASES
Frank O. Velez-Cubian1, Wei Wei Zhang1, Tawee Tanvetyanon2, 
Kathryn L. Rodriguez1, Matthew R. Thau1, Jacques-Pierre Fontai-
ne2, Joseph R. Garrett2, Carla C. Moodie2, Lary A. Robinson2, Eric M. 
Toloza2
1University Of South Florida College Of Medicine/United States Of 
America, 2Thoracic Oncology, Moffitt Cancer Center/United States Of 
America
Background: Female gender has been associated with worse 
outcomes in cardiovascular surgery, including vein bypass for limb 
salvage and coronary artery bypass grafting. Women have also 
been found to prefer to suffer arthritis pain rather than risk ortho-
pedic surgery and to delay surgery to await better technology and 
to avoid disrupting caregiving roles for spouses and other depen-
dents. We investigated the effect of gender on perioperative out-
comes after robotic-assisted lobectomy.
Methods: We retrospectively analyzed 180 consecutive patients 
who underwent robotic-assisted lobectomy by one surgeon bet-
ween September 2010 and February 2013. Intraoperative estima-
ted blood loss (EBL), operative times (skin incision to skin closure), 
conversion to open lobectomy, chest tube days, hospital length of 
stay (LOS), and in-Hospital mortality were analyzed. All clinically 
significant perioperative complications were noted, including mi-
nor complications, such as wound infection and anemia, to more 
serious major complications, such as empyema and DVT/PE. Com-
parison of perioperative outcomes between men and women was 
significant at p-value <0.05.
Results: Of 180 total patients, there were 90 men (mean age 68yr; 
range 37-86yr) and 90 women (mean age 68yr; range 29-85yr; 
p=0.19). Skin-to-skin operative times were 191+12 min for men and 
174+12 min for women. Men had median (+SEM) EBL of 235+60mL 
compared to 150+48mL for women (p=0.79). Intraoperative com-
plication rates were 7/90 (8%) in men and 10/90 (11%) in women 
(p=0.45). The most common intraoperative complication in men 
was bleeding not requiring conversion in 2/90 (2%), compared to 
pulmonary artery (PA) bleeding in 5/90 (6%) of women. The over-
all conversion rate to open lobectomy was 14/90 (16%) in women 
versus 6/90 (7%) in men (p=0.06); although the emergent conversi-
on rate was 5/90 (6%) in women versus 1/90 (1%) in men. The most 
common reasons for conversion to open lobectomy in women 
was PA bleeding in 5/90 (6%) and dense hilar pleural and/or tumor 
adhesions in 5/90 (6%); while the latter was the most common rea-
son for conversion in men, occurring in 3/90 (3%). A minor and/or 
major postoperative complication occurred in 48/90 (53%) of men, 
compared to 39/90 (43%) in women (p=0.18). The most common 
postoperative complications in men were prolonged air leak 20/90 
(22%), atrial fibrillation 14/90 (16%), pneumonia 11/90 (12%), and 
mucus plugs requiring intervention 7/90 (8%), while the most com-
mon in women were prolonged air leak 14/90 (16%; p=0.25), pneu-
monia 12/90 (13%; p=0.82), atrial fibrillation 8/90 (9%; p=0.12), and 
mucus plugs requiring intervention 7/90 (8%; p=1.00). Women had 
4.0+0.5 chest tube days (median+SEM) and 5.0+0.5 hospital days, 
compared to 4.0+1.1 chest tube days and 5.5+0.6 hospital days for 
men (p=0.14 and p=0.44, respectively). In-Hospital mortality was 
4/90 (4%) in men compared to 1/90 (1%) in women (p=0.17).
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tionality, and capability. According to statements from patients the 
interdisciplinary intervention of physiotherapist, nurse and doctor in 
this project is very valuable. Professional experience has shown that 
the collection of data from surgical lung cancer patients is difficult 
due to the fact that a lot of patients disappear from the program of 
rehabilitation. A large group of the patients transfer to oncological 
treatment, aborts the rehabilitation offer or dies. This influences the 
results of the study and therefore also the conclusion.
Keyword: specialized, rehabilitation, interdisciplinary
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P2.07-046 EFFECT OF AIRWAY STENTING ON QUALITY 
OF LIFE (QOL) IN PATIENTS WITH MALIGNANT AIRWAY 
OBSTRUCTION: A SINGLE INSTITUTIONAL EXPERIENCE 
AT MAYO CLINIC ARIZONA (MCA)
Harshita R. Paripati, Amylou C. Dueck, Helen J. Ross, Dawn E. 
Jaroszewski
Mayo Clinic/United States Of America
Background: Malignant airway obstruction is associated with severe 
respiratory distress and poor outcome. Airway stents have been used 
to relieve malignant airway obstruction and may provide significant 
palliation of symptoms, but quality of life data after airway stenting is 
lacking. We report the Mayo Clinic Arizona experience with the Bos-
ton Scientific Ultra Flex stent in the management of malignant airway 
obstruction.
Methods: A single center study evaluating quality of life before and 
after placement of the Boston Scientific Ultra Flex stent for malignant 
airway obstruction. Quality of life data (SF-36 questionnaires) before 
and after stent placement were obtained prospectively. Charts were 
reviewed retrospectively. Patients were enrolled from 2007-2011 at 
Mayo Clinic Arizona. The study was approved by the Mayo Found-
ation IRB. Informed consent was obtained and documented in the 
clinical record. SF-36 questionnaires were completed by the patients 
in the outpatient clinic before (baseline) and after stent placement.
Results: From 2007 to 2011, 19 patients underwent placement of 
Boston Scientific Ultraflex non covered tracheobronchial stents for 
airway obstruction. 3 of the 19 patients underwent stent placement 
for benign etiologies and were excluded from the analysis. Of the 
remaining 16 patients, 8 were male and 8 were female. The median 
age was 64.5 years. Non-small cell lung cancer was the most common 
underlying diagnosis (11 patients). The remaining patients had head 
and neck cancer (2 patients), esophageal cancer (1 patient), metastatic 
Hurthle cell thyroid cancer (1 patient) and metastatic renal cell carci-
noma (1 patient). The most common presenting symptom of airway 
obstruction was dyspnea. Data from SF36 forms were available in 8 
of 16 patients. There was a significant improvement in the physical 
component score (PCS) (10.4±10.1, P=0.02), and a non-significant 
improvement in the mental component score (MCS) (1.4±6.2, P=0.54) 
after stent placement.
Conclusion: Placement of airway stents for malignant bronchial ob-
struction resulted in significant palliation of symptoms and improve-
ment in patient quality of life.
Keywords: bronchial stent, malignant airway obstruction, quality  
of life
chemotherapy/nothing ratio was 2/13 in the group R and 3/127 in 
the group NR (p<0.05). There were no significant differences in 
other treatment-related risk factors.
Conclusion: A history of hypertension or diabetes, lymphatic 
permeation and adjuvant chemotherapy were risk factors for re-
currence, respectively. And aggressive enforcement of adjuvant 
chemotherapy is desirable in p-stage IA NSCLC patients both with 
pathologically lymphatic permeation and with a history of diabetes 
or hypertension.
Keywords: p-stage IA, non-small cell lung cancer, risk factors for 
recurrence, operation
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P2.07-045 POST LUNG SURGERY REHABILITATION
Susanne Petersen, Pernille Mikkelsen, Inge Marie Aagaard
Thoracic, Cardiac And Vascular Surgery, Odense University Hospital/
Denmark
Background: Due to a recommendation from The Danish Board of 
Health, the department for Heart, - Lung, - and Vascular Surgery on 
Odense University Hospital, Denmark has developed a specialized 
program of rehabilitation for lung cancer patients who have recently 
undergone lung surgery.
Methods: Purpose The patient is offered a specialized and precise-
ly targeted physical lung rehabilitation program supplemented with 
nurse intervention with the goal of an improved quality of life, func-
tionality and capability. Method The project is conducted as a qua-
litative study e.g. with questionnaires about life quality and smoking 
habits. Spirometry, walking test after the Borg 10 scale, and also 
VAS-score related to pain, are conducted. A preoperative FEV1 is 
also measured. The physical rehabilitation begins three weeks post 
surgery and takes place twice a week throughout the total length of 
the program of 4-10 weeks. A specially trained physiotherapist is re-
sponsible for tests and physical exercise. The physical rehabilitation 
is accompanied by patient interviews conducted by a specially trai-
ned nurse and also by supervision from other health professionals. 
The areas of focus of the nurse intervention are dyspnea, coughing, 
nausea, loss of appetite, pain, fatigue, smoking habits, and other 
psychological symptoms, and consultation with specially trained 
nurse is offered 3, 6, 9, and 12 months postoperative. At the same 
time the patient is offered a CT scan. Due to ethical standards no 
control group of patients was established in this study.
Results: The nurse intervention has shown a clear positive effect on 
the patients smoking habits. The results on the effect on dyspnea, 
coughing, nausea, loss of appetite, pain, fatigue, smoking habits 
and psychological symptoms will be presented on the poster. Data 
show improvement in FEV1, and significant improvement in 6-minu-
te walk test after finishing the physical rehabilitation program.
Conclusion: In the beginning of the program the patients are very 
motivated. Statements from patients and relatives show that they 
choose rehabilitation offers which are available in the Health Care 
System with the anticipation of a future positive influence on their 
prognoses. The patients are expressing that the tests which are a 
part of the physical rehabilitation program have a huge effect on 
their motivation. Data shows that physical and emotional rehabili-
tation has a very positive effect on the patients’ life quality, func-
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Conclusion: This technique represents a safe, effective and mini-
mally invasive way to access a fused pleural space. This technique 
has proven useful in extending eligibility for pleural mesothelioma 
gene therapy, but could be used to safely access a fused pleural 
space for any purpose. This would include obtaining a biopsy in 
a patient who had undergone pleurodesis without an established 
diagnosis or placement of a catheter for any type of intrapleural 
therapeutic.
Keywords: mesothelioma, gene therapy, surgical techniques, 
pleural space
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P2.07-048 CAUSES, PREDICTORS AND CONSEQUENCES 
OF CONVERSIONS IN VATS LOBECTOMY FOR NSCLC
Johannes Bodner1, Stefanie Kerber1, Martin Reichert1, Wilhem 
Stertmann1, Ibrahim Alkoudmani1, Florian Augustin2
1Division Of Thoracic Surgery, University Hospital Giessen/Germany, 
2Visceral, Transplant, Thoracic Surgery, University Hospital Innsbruck/
Austria
Background: To analyze causes, predictors and consequences of 
conversions to open surgery in VATS lobectomy.
Methods: Retrospective analysis of a prospectively maintained 
database.
Results: Since February 2009, 297 patients with NSCLC were sche-
duled for VATS anatomical resections. Conversion to open surgery 
was necessary in 22 patients (7.4%). Reasons for conversion were 
bleeding in 10, oncologic reason in 8 and technical considerations 
in 4 patients (adhesions after pleuritis or radiotherapy for other 
tumors: 3, limited space: 1). In univariate analysis, conversion rate 
was significantly higher in patients after neoadjuvant therapy (21% 
vs 4.3%, p=0.002). There was a statistical trend for higher con-
version rate in patients during the first half of the series (9.5% vs 
3.4%, p=0.062) and larger tumor size (T1 vs >T1, 4.8% vs 12.9%, 
p=0.098). The conversion rate was not influenced by age of the 
patient, nodal stage (pN0 vs pN+), body mass index, COPD, FEV1, 
or benign disease. Conversion did not translate into higher overall 
postoperative complication rates (33.3% vs 29.5%), longer chest 
drain duration (median 5 vs 5 days), or mortality (0% vs 2%). Howe-
ver, length of hospital stay was significantly longer in the conversi-
on group (median 10 vs 6 days, p=0.0066).
Conclusion: Neoadjuvant therapy is an independent risk factor for 
conversion to thoracotomy in this VATS lobectomy series. Patients 
after neoadjuvant therapy should be selected carefully for a VATS 
approach. Conversion to thoracotomy did not increase the post-
operative complication or mortality rate, but significantly increased 
the length of stay.
Keywords: VATS lobectomy, NSCLC
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P2.07-047 A NEW MINIMALLY INVASIVE SURGICAL 
TECHNIQUE TO ACCESS A FUSED PLEURAL SPACE FOR 
BIOPSY, GENE THERAPY OR OTHER NOVEL INTRAPLEU-
RAL THERAPEUTICS - A REPORT OF 34 PATIENTS
Joseph Friedberg1, Steven M. Albelda2, Andrew R. Haas2, Susan 
Metzger2, Melissa Culligan1, Daniel Sterman2
1University Of Pennsylvania/United States Of America, 2Medicine, Di-
vision Of Pulmonology, University Of Pennsylvania/United States Of 
America
Background: Gene therapy has shown promise as a novel treat-
ment for pleural mesothelioma. This treatment requires intrapleu-
ral placement of a catheter, a routine procedure if a patient has an 
effusion. After surgery or pleurodesis, however, the pleural space 
will be fused and access can be difficult. Previously these patients 
were excluded from gene therapy. The objective of this study was 
to develop a minimally invasive technique that would allow place-
ment of a catheter into a fused pleural space.
Methods: Over the past 50 months 34 patients with fused chest 
cavities were enrolled in a gene therapy clinical trial. Utilizing a 
videoscopic saphenous vein-harvesting device, a new surgical 
technique was developed to safely create a space in the chest 
cavity for biopsy of tumor, creation of space to accommodate 
vector instillation and placement of a tunneled catheter. Often the 
procedure required tunneling directly between the lung and the 
chest wall, where there was no visible disease, in order to access a 
pleural nodule that was detectable on CT scan. In every case this 
procedure was performed through a single 15 mm incision (fig 1). 
Figure 1 a) The videoscopic saphenous vein tunneling device b) 
The device in use – not transillumination in the chest approximate-
ly 10cm distal to the incision c) Closure of the single video port 
with the catheter emerging from a proximally tunneled site
Results: All 34 patients had successful catheter placement, with 
27 as outpatients. The only surgical complication was a transient 
air leak in 1 patient requiring overnight admission. 5 patients were 
admitted for urinary retention and 1 for resumption of anticoagu-
lation. One patient had a local wound infection at the catheter site 
requiring readmission and 2 more were treated as outpatients, all 
clearing with antibiotics. All patients received gene therapy.
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P2.08-001 START OF PHASE TRANSITION "NORM---
EARLY LUNG CANCER“ SIGNIFICANTLY DEPENDED ON 
BLOOD IMMUNE CELL CIRCUIT
Oleg Kshivets
Surgery, Central City Hospital/Russian Federation
Background: Significance of blood immune cell circuit for start of 
phase transition (PT) “norm---early lung cancer” (LC) was investi-
gated.
Methods: In trial (1987-2012) consecutive cases after radical 
surgery (R0, bi/lobectomies=48, N2-lymphadenectomies=48; 
squamous=21, adenocarcinoma=25, large cell=2; G1=16, G2=21, 
G3=11), monitored 48 early LC patients (LCP) (age=59±6.5 years, 
m=40, f=8; T1AN0M0=48, tumor size=1.7±0.3 cm, 5-year survi-
val=100%) and 120 healthy donors (m=69, f=51) were reviewed. 
Variables selected for study were input levels of immunity blood 
parameters. The percentage, absolute count and total populati-
on number (per human organism) of T, B, CD4, CD8, CD16, CD1, 
CDw26, monocytes, CD4+2H, CD8+VV, leukocytes, lymphocytes, 
monocytes, eosinophils, stick and segmented neutrophils were 
estimated. The laboratory blood studies also included input 
levels of NST (tests of oxygen dependent metabolism of neutro-
phils spontaneous and stimulated by Staphylococcus aureus or 
by Streptococcus pyogenes), index of stimulation of leukocytes 
by Staphylococcus aureus or Streptococcus pyogenes, index of 
thymus function, phagocytic number, phagocyte index, index of 
complete phagocytosis. Differences between groups were eva-
luated using discriminant analysis, clustering, structural equation 
modeling, Monte Carlo, bootstrap simulation and neural networks 
computing.
Results: It was revealed that start of PT “norm---early lung can-
cer” significantly depended on T-, B-, CD16-, CD8- cell circuit, 
neutrophils, monocyte circuit (P=0.000-0.027). Neural networks 
computing, genetic algorithm selection and bootstrap simulation 
revealed relationships of PT “norm---early lung cancer” and neu-
trophils (rank=1), CD16 (rank=2), monocytes (3), lymphocytes (4), 
CD4 (5), CD8 (6), B-cells (7), T-cells (8), eosinophils (9). Correct de-
tection of start of PT “norm---early lung cancer” was 100% by neu-
ral networks computing (error=0.000; urea under ROC curve=1.0).
Conclusion: Start of phase transition “norm---early lung cancer” 
significantly depended on blood immune cell circuit.
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P2.07-050 SHORT TERM PREOPERATIVE EFFICACY OF 
TIOTROPIUM FOR PATIENTS WITH RESECTABLE LUNG 
CANCER AND CHRONIC OBSTRACTIVE PULMONARY 
DISEASE: PRELIMINARY RESULTS OF ONE ARM PROS-
PECTIVE STUDY
Takeshi Matsunaga1, Kenji Suzuki2, Aritoshi Hattori1, Yukio Tsu-
shima1, Kazuya Takamochi1, Shiaki Oh1
1Department Of General Thoracic Surgery, Juntendo University School 
Of Medicine/Japan, 2General Thoracic Surgery, Juntendo University/
Japan
Background: It was reported that in chronic obstructive pulmo-
nary disease (COPD) patients, tiotropium improves lung function. 
However diagnosis of COPD is often made during evaluation of 
patients with lung cancer for surgical intervention and the efficacy 
of tiotropium for these patients is unclear. Thus a prospective stu-
dy is needed to investigate it.
Methods: A prospective study was conducted on patients under-
going pulmonary resection for lung cancer with COPD (ratio of 
forced expiratory volume in 1 second (FEV1)/ forced vital capacity 
(FVC) less than 70%) between July 2011 and January 2012. Patients 
with a known history of asthma, chronic respiratory disease other 
than COPD were excluded. Primary endpoint was evaluating the 
incidence of postoperative complication. Secondary endpoints 
were improvement of pulmonary function tests after more than 
1-week treatment using tiotropium preoperatively.
Results: Of 168 lung cancer patients for six months, 21 (12.5%) 
patients with COPD were enrolled. Pulmonary complications 
(prolonged air leak; 4 (19.0%), sputum retention; 2 (9.5%), hypoxia 
needing transient home oxygen therapy; 2 (9.5%)) were observed 
in seven (33.3%), although there was no critical complication such 
as acute respiratory failure and no side-effect related tiotropium. 
Treatment of tiotropium resulted in a significant improvement of 
FVC (pre-FVC 2.96±0.70 vs post-FVC 3.18±0.58; p=0.005) and 
FEV1 (pre-FEV1 1.78±0.44 vs post FEV1 1.91±0.18; p=0.0003), but 
there was no significant difference between pre-RV (residual volu-
me) / TLC (total lung capacity)% and post-RV/TLC% ( 108.8±20.1 vs 
102.4±16.1; p=0.237).
Conclusion: In this prospective study, we were safely able to use 
tiotropium without critical complication and it improved FVC and 
FEV1 in patients with COPD. But it did not improve RV/TLC% sta-
tistically and there remains doubt about efficacy of titropium. We 
thought that there is a problem of compliance in inhalation drug 
and need to reveal the population in which tiotropium was effecti-
ve, and then we should perform a prospective randomized control 
trial.
Keywords: pulmonary resection, chronic obstructive pulmonary 
disease, tiotropium, Lung cancer
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Background: Whether IFRT could replace ENI or not has been a 
controversial topic for years because of rare data from large samp-
le sizes, prospective, randomized studies were available. This study 
is to evaluate the locoregional failure and its impact on survival by 
prospectively comparing involved field radiotherapy (IFRT) with 
elective nodal irradiation (ENI) for locally advanced non-small cell 
lung cancer with concurrent chemoradiotherapy.
Methods: Patients were randomized into IFRT or ENI arm,treated 
with 2 cycles of carboplatin combined with paclitaxel. Those wit-
hout distant metastasis continued to receive chemoradiotherapy. 
The target volumes for IFRT included primary tumor, ipsilateral 
hilum and positive mediastinal lymph nodes, while that for ENI 
included the primary lesion, ipsilateral hilum, bilateral mediastinal 
lymph node drainage areas and bilateral supraclavicular fossa. The 
radiation dose was prescribed as high as possible if the restrictions 
could be met: percent volume of bilateral lung receiving ≥ 20Gy 
(V20) was ≤35% and the maximum dose to spinal cord was ≤50Gy.
Results: 99 consecutive patients were assigned (45 IFRT vs. 54 
ENI), with more patients in IFRT iiradiated with >60Gy than those 
in ENI (48.9% vs. 25.9%, P=0.018). the local failure rates were 34.1% 
and 30.0% (P=0.673) , Of which the isolated ENF was 0.0% and 
2.0%, respectively (P=0.363). The median survival time was 27.8 
months (95% CI, 18.0-37.5 months) and 16.7 months (95% CI, 15.0-
18.4 months); the 1-, 2- and 3-year local tumor progression-free 
survival rates were 78.1%, 72.6%, 62.9% and 85.5%, 61.2%, 56.1%  
(P=0.895) , respectively; the 1-, 2- and 3-year overall survival rates 
were 80.0%, 53.3%, 36.6% and 70.4%, 34.9%, 30.3%  (P=0.08) , 
respectively.
Conclusion: Preliminary results indicated that IFRT did not increa-
se locoregional failure related to ENF. With IFRT, higher radiation 
dose could be administered compared with ENI and it is expected 
to improve survival. Further investigation is warranted.
Keywords: Concurrent chemoradiotherapy, radiotherapy target, 
prospective study, Lung neoplasms
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P2.08-004 IMPACT OF MEDICAL CO-MORBIDITIES ON 
SURVIVAL IN PATIENTS TREATED WITH STEREOTACTIC 
BODY RADIOTHERAPY FOR EARLY STAGE NON-SMALL 
CELL LUNG CANCER
Mei Ling Yap, Andrew Hope, Soha Atallah, Meredith Giuliani, 
Andrea Bezjak, Anthony Brade, Elantholi Parameswaran Saibish-
kumar, Alexander Sun, Byoung Chun J. Cho
Department Of Radiation Oncology, University Of Toronto, Princess 
Margaret Cancer Centre/Canada
Background: Stereotactic body radiotherapy (SBRT) is an effective 
treatment for early stage inoperable non-small cell lung cancer 
(NSCLC), with loco-regional control of 80-90%. However, the me-
dian overall survival of these patients is limited. We evaluate the 
impact of co-morbidities on patient survival and whether a subset 
of patients who may not benefit from SBRT can be identified.
Methods: Patients treated on a prospective protocol at a single 
cancer center with SBRT for T1-T2N0 NSCLC from Oct 2004-May 
2012 were evaluated. The most common doses delivered were 
48Gy/4fr and 54Gy/3fr. The presence of significant medical co-
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P2.08-002 MODERN POST-OPERATIVE RADIOTHERAPY 
FOR STAGE III NON-SMALL CELL LUNG CANCER MAY 
IMPROVE LOCAL CONTROL AND SURVIVAL: A PUBLICA-
TION-BASED META-ANALYSIS
Charlotte Billiet1, Herbert Decaluwé2, Stephanie Peeters1, Johan 
Vansteenkiste3, Christophe Dooms3, Paul De Leyn2, Dirk De 
Ruysscher1
1Radiation Oncology, Universitary Hospitals KU Leuven/Belgium, 2Tho-
racic Surgery, Universitary Hospitals KU Leuven/Belgium, 3Respiratory 
Oncology, Universitary Hospitals KU Leuven/Belgium
Background: We hypothesized that modern postoperative radio-
therapy (PORT) could decrease local recurrence (LR) and improve 
overall survival (OS) in patients with stage IIIA-N2 non-small-cell 
lung cancer (NSCLC).
Methods: To investigate the effect of modern PORT on LR and 
OS, we identified published phase III trials for PORT and stratified 
them according to use or non-use of linear accelerators. We mo-
delled the potential benefit of modern PORT in stage IIIA-N2 NS-
CLC treated with induction chemotherapy and resection.
Results: Of the PORT phase III studies, eleven trials (2387 patients) 
were included for OS analysis and eight (1677 patients) for LR. 
PORT decreased LR, whether given with cobalt, cobalt and linear 
accelerators, or with linear accelerators only. An increase in OS was 
only seen when PORT was given with linear accelerators, along 
with the most significant effect on LR (relative risk for LR and OS 
0.31 (p=0.01) and 0.76 (p=0.02) for PORT vs. controls, respectively). 
Four trials (357 patients) were suitable to assess LR rates after sur-
gery and/or induction chemotherapy in stage III NSCLC. LR as first 
relapse was 30 % (105/357) after 5 years. In the modelling part, 
PORT with linear accelerators was estimated to reduce LR rates to 
10 % as first relapse and to increase the absolute 5-year OS by 13 
%.
Conclusion: This modelling study generates the hypothesis that 
modern PORT may increase both LR and OS in stage IIIA-N2 NS-
CLC even in patients being treated with induction chemotherapy 
and surgery.
Keywords: local tumour control, post-operative radiotherapy, non-
small cell lung cancer, survival
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P2.08-003 INVOLVED-FIELD RADIOTHERAPY VERSUS 
ELECTIVE NODAL IRRADIATION IN COMBINATION 
WITH CONCURRENT CHEMOTHERAPY FOR LOCALLY 
ADVANCED NON-SMALL CELL LUNG CANCER: A PROS-
PECTIVE RANDOMIZED STUDY
Hong L. Ma1, Yong Bao2, Xiao Hu2, Jin Wang1, Fang Peng2, Qi C. 
Zhou2, Xiao W. Deng2, Ming Chen1
1Department Of Radiotherapy Oncology, Zhejiang Cancer Hospital/
China, 2Department Of Radiotherapy Oncology, Sun Yat-Sen University 
Cancer Center/China
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Three alternative dose escalated IMRT plans were developed 
offline based on the week 0, 2 and 4 scans. The PET avid primary 
(PET-T) and nodal disease (PET-N) volumes were auto-contoured 
using the 50%SUVmax metric. PET-T and PET-N were dose escalated 
to as high as possible while respecting OAR constraints and ensu-
ring coverage of the clinical plan PTV. The D95% and Dmax of the 
PET-T and PET-N were calculated and compared between week 
0-2-4.
Results: Thirty-two patients were recruited, with 27 completing all 
scans. Sixteen patients were stage IIIA (60%), 9 were IIIB (33%) and 
2 were IIA (7%). Eight patients (30%) had been prescribed a clinical 
dose of 60 Gy, 17 (63%) had 66 Gy, 1 patient 70Gy and 1 patient 
74Gy. 25 patients (93%) were boosted successfully above the cli-
nical plan doses at week 0; this reduced to 23 (85%) at week 2 and 
20 (74%) at week 4. For all weeks combined, the D95 for PET-T was 
higher than that delivered to clinical PTV by a median of 16.2 Gy 
(4.2-37.4Gy). The D95 for PET-N exceeded that delivered to clini-
cal PTV by 13.4Gy (6.8-29.7Gy). The median D95% to the PET-T at 
week 0, 2 and 4 were 74.4 Gy, 75.3Gy and 74.1Gy respectively. The 
median Dmax to PET-T at week 0, 2 and 4 were 85.9Gy, 83.8Gy and 
81.2Gy. The median D95% to PET-N at week 0, 2 and 4 was 74.3Gy, 
71.0Gy and 69.5Gy. The median Dmax to PET-N at week 0, 2 and 4 
were 82.7Gy, 82.5Gy and 78.9Gy.
Conclusion: Using 4DPET/CT derived volumes, it is feasible to 
dose escalate a majority of patients, either at the onset or during 
RT. Though the PET-T was able to be escalated to higher doses 
than PET-N, nodal disease can still be boosted to significant doses. 
More patients were able to be dose escalated at the onset of RT; 
however mid-RT dose escalation allows the additional potential for 
adaptation.
Keywords: 4DPET/CT, dose escalation, non-small cell lung cancer, 
radiotherapy
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P2.08-006 EFFICACY OF SINGLE DOSE 8-GY PALLIATIVE 
CHEST IRRADIATION IN PAIN PALLIATION OF PATIENTS 
WITH LOCOREGIONALLY RECURRENT STAGE IV NON-
SMALL CELL LUNG CANCER
Erkan Topkan1, Cem Parlak1, Berrin Pehlivan2, Ozgur Ozyilkan3, 
Ugur Selek4
1Department Of Radiation Oncology, Baskent University Medical Fa-
culty/Turkey, 2Department Of Radiation Oncology, Medstar Antalya 
Hospital/Turkey, 3Department Of Medical Oncology, Baskent University 
Medical Faculty/Turkey, 4Department Of Radiation Oncology, American 
Hospital, University Of Texas MD Anderson Radiation Oncology Cen-
ter/Turkey
Background: To investigate the efficacy of single dose 8-Gy pal-
liative chest re-irradiation (PCRI) in metastatic non-small cell lung 
cancer (M-NSCLC) patients with painful recurrences in previously 
irradiated thoracic region.
Methods: Clinical data of 63 M-NSCLC patients, who received 
single dose 8-Gy PCRT due to painful thoracic recurrences from 
February 2007 to June 2010 were retrospectively analyzed. All 
patients had previously received upfront definitive 60-66 Gy 
concurrent chemoradiotherapy (C-CRT), and 52 of them had also 
received salvage chemotherapy. Primary endpoint was change in 
morbidities including cardiac disease, COPD, cerebro-vascular 
disease, diabetes, previous pneumonectomy and oxygen depen-
dence were recorded at baseline. Patient, tumor, and treatment 
data as well as outcomes were prospectively collected. Log rank 
tests were performed for survival analysis and chi squared tests 
used to analyze deaths within 1 year from radiotherapy treatment 
(D<1y). Cancer specific deaths (CSD) were defined as any death 
following a recurrence of the previously treated NSCLC.
Results: There were 279 patients identified, 134 female (48%) and 
145 male (52%). The median age was 76 years (range 48-93). The 
performance status was ECOG 0 in 87 patients (31%), ECOG 1 in 
127 patients (46%), ECOG 2 in 53 patients (19%) and ECOG 3 in 9 
patients (3%). There were 212 (76%) with T1 tumors, the remain-
der (24%) T2 tumors. The median follow up was 1.3 years. At last 
follow up, 111 patients (40%) had died, including 42 (15%) patients 
with D<1y. Of all deaths, 25 (22.5%) were CSD, the remainder from 
other causes. There were 222 patients (80%) identified as having 
a significant co-morbidity, collectively these conditions did not 
influence deaths from any cause (DAC) or CSD. The presence of 
cardiac disease (N=67) led to an increased risk of DAC (HR 4.1, p = 
0.04) but not CSD (HR 1.2, p=0.28). These results were more pro-
nounced for D<1y, patients with cardiac disease having increased 
D<1y, (HR 7.34, p=0.007), but not CSD<1y, (HR 2.9, p=0.09). Other 
co-morbidities were not correlated of survival. ECOG status was 
correlated with both DAC (HR 15.1, p=0.005) and CSD (HR 9.3, 
p=0.05).
Conclusion: The presence of respiratory and vascular co-morbidi-
ties should not necessarily preclude a patient from receiving SBRT. 
ECOG status and prognosis from a cardiac point of view may be 
associated with poorer overall survival at 1 year and should be 
considered when assessing a patient’s suitability for SBRT.
Keywords: Stereotactic Ablative Body Radiotherapy (SABR), co-
morbidities, Stereotactic body radiotherapy (SBRT), Non small cell 
lung cancer
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P2.08-005 4D-PET/CT-BASED ADAPTIVE DOSE ESCA-
LATED RADIOTHERAPY (RT) IN LOCALLY ADVANCED 
NON-SMALL CELL LUNG CANCER (LA-NSCLC)
Mei Ling Yap, Alexander Sun, Andrea Marshall, Nathan Becker, 
Jane Higgins, Lisa Le, Douglass Vines, Katy Clarke, Andrea Bezjak, 
Jean-Pierre Bissonnette
Department Of Radiation Oncology, University Of Toronto, Princess 
Margaret Cancer Centre/Canada
Background: There has been recent interest in dose escalation in 
LA-NSCLC, with the aim to improve both loco-regional control and 
overall survival. Attempts to dose escalate CT-defined volumes for 
radiotherapy (RT) for LA-NSCLC have been limited due to organ 
at risk (OAR) toxicity. We investigated the potential for adaptive 
dose-escalation to PET-defined volumes, using 4DPET/CT scans 
acquired prior to and during a course of radical chemo/RT (CRT).
Methods: This single institution study prospectively enrolled pati-
ents with NSCLC receiving CRT to a dose ≥60Gy, delivered in daily 
2Gy treatments. 4DPET/CT scans were acquired prior to (week 0) 
and at weeks 2 and 4 during RT. RT was delivered using the inten-
sity modulated RT (IMRT) plan developed from the week 0 scans. 
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Table 1. Pretreatment patient characteristics 
Conclusion: Results of this study has shown that, in line with the 
literature, surgical or radiosurgical treatment modalities directed 
to SSBM in NSCLC patients could not demonstrate any superiority 
over each other. Therefore, management of BM should be tailored 
according to the facilities available, and patient or disease-specific 
conditions. Moreover, although larger prospective data are nee-
ded, survival outcome in such patients similar to locally advanced 
patients indicates the potentially curative role of definitive CRT.
Keywords: synchronous single brain metastasis, surgical resection, 
radiosurgery, non-small cell lung cancer
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P2.08-008 A PROSPECTIVE STUDY TO DETERMINE 
INTER-OBSERVER VARIABILITY OF GROSS TUMOR VO-
LUME WITH FDG-PET/CT COMPARED TO CT ALONE 
IN STAGE III NON-SMALL CELL LUNG CANCER USING 
THREE-DIMENSIONAL ANALYSIS.
David J Peterson1, Naseer Ahmed1, Ryan Rivest2, Bashir Bashir1, 
Shahida Ahmed1, Sandor Demeter3, Zoann Nugent4, Pam Brechin1, 
Boyd Mccurdy2, William Hunter1, Ahmet Leylek1, Amit Chowdhu-
ry1
1Radiation Oncology, Cancer Care Manitoba, University Of Manitoba/
Canada, 2Medical Physics, Cancer Care Manitoba/Canada, 3Nuclear 
Medicine, Health Sciences Center, University Of Manitoba/Canada, 
4Epidemiology & Cancer Registry, Cancercare Manitoba/Canada
Background: There are no randomized trials comparing CT versus 
FDG-PET/CT based radiotherapy planning for lung cancer or any 
other disease site.Based on phase II studies, a convincing body of 
data has emerged within the last 10 years incorporating the use 
of FDG-PET scans for radiotherapy planning in lung cancer.Publis-
hed data comparing changes in volume measured with FDG-PET/
visual analogue score (VAS), and secondary endpoints were time 
to lowest VAS record and duration of pain control.
Results: Treatment was well tolerated with only 3 (4.8%) grade III 
radiation-induced pneumonitis. For all patients median, 1-, 2-year 
survival were 9.2 months, 28.4%, and 12.3%. Median pre-PCRI and 
minimum achievable post-PCRI VAS values were 6.7 (range: 5-8) 
and 3.4 (range: 0-8), and the decline in VAS values was statistically 
significant (p<0.001). Objective response defined as reduction of 
at least 2 points in VAS value was achieved in 54 (85.7%) patients. 
Median time to lowest VAS and duration of pain control were; 27 
(95% CI: 21 - 33) days and 7.1 (95% CI: 6.3 - 7.9) months, respec-
tively.
Conclusion: Single dose 8-Gy PCRI is safe and highly efficient in 
palliating moderate to severe pain in locoregionally recurrent M-
NSCLC patients, who have previously received upfront definitive 
C-CRT
Keywords: non-small cell lung cancer, palliative chest re-irradiati-
on, Metastatic stage, thoracic recurrence
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P2.08-007 IMPACT SURGICAL RESECTION AND RADIO-
SURGERY DIRECTED TO BRAIN METASTASIS ON SURVI-
VAL OUTCOMES IN NON-SMALL CELL LUNG CANCER 
PATIENTS WITH SYNCHRONOUS SINGLE BRAIN META-
STASIS
Cem Parlak1, Ozan C. Guler1, Ozgur Ozyilkan2, Erkan Topkan1
1Department Of Radiation Oncology, Baskent University Medical Fa-
culty/Turkey, 2Department Of Medical Oncology, Baskent University 
Medical Faculty/Turkey
Background: Aim of this study was to compare surgical resection 
and radiosurgical treatment modalities directed to brain metas-
tasis (BM) in terms of survival outcomes in newly diagnosed non-
small cell lung cancer (NSCLC) patients with synchronous single 
brain metastasis (SSBM).
Methods: Medical records of medically fit NSCLC patients with 
SSBM treated at our department were retrospectively evaluated. A 
total of 64 patients were staged with PET-CT besides conventional 
staging tools. TRT to a total dose of 66 Gy in 2 Gy fx was delivered 
with 2 cycles of concomitant cisplatin –based chemotherapy (CT) 
following surgery+30 Gy whole-brain RT (WBRT) (n:33) or 30 Gy 
WBRT+stereotactic radiosurgery (SRS) (n:31) for their BM.
Results: Pretreatment patient characteristics were given in Table. 
Whole study population could complete planned treatment to 
their BM and thoracic primaries. At median 20.7 months (7.1-58.7) 
of follow-up, Median overall (OS), neurological progression-free 
(NPFS), locoregional progression-free (LRPFS) and progression-free 
survival (PFS) were 23.4, 22.8, 14.9, ve 9.4 months, respectively. 
There was no statistically significant survival difference between 
two groups (p>0.05 for each survival parameter) (Figure 1). On 
univariate analyses, patients with ECOG performance status of 0-1 
(p<0.001), younger than median 50 years (p=0.031) and with no 
weight loss (p=0.001) revealed superior OS. On multivariate ana-
lyses performed with these factor, all factors except age retained 
their independent prognostic value (p<0.05 for each parameter). 
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P2.08-009 STEREOTACTIC ABLATIVE BODY RADIOTHE-
RAPY (SABR) OUTCOMES FOR PRIMARY AND METASTA-
TIC NON-SMALL CELL LUNG CANCER (NSCLC) PULMO-
NARY TUMOURS
Isabelle Thibault1, Ian Poon1, Darby Erler1, Anthony Kim1, Brian 
Keller1, Latifa Yeung2, Suneil Jain3, Hany Soliman1, Fiona Lochray1, 
Patrick Cheung1
1Department Of Radiation Oncology, Sunnybrook Odette Cancer Cen-
tre, University Of Toronto/Canada, 2Department Of Paediatrics And 
Institute Of Health Policy, Management And Evaluation, University Of 
Toronto/Canada, 3Centre For Cancer Research And Cell Biology, Queen‘s 
University Belfast/United Kingdom
Background: To evaluate the clinical outcomes following SABR to 
early-stage NSCLC and pulmonary metastases (Mets) from NSCLC, 
including potential predictive factors and a focus on chest wall 
(CW) toxicities.
Methods: From our prospective lung SBRT database, we iden-
tified 240 NSCLC lung tumors in 209 patients treated with SABR 
between 2008 and 2011. 228 were primary NSCLC and 12 were 
NSCLC Mets. The institutional policy was to deliver 48-52 Gy in 4 
fractions (fx) for peripheral tumors and 50 Gy in 5 fx for central tu-
mors. Local control (LC) was defined as the absence of recurrence 
within or ≤1 cm beyond the planning target volume (PTV). Lobar 
LC was defined as absence of recurrence within the same lobe. All 
tumors were categorized as adjacent to the CW (PTV touching the 
CW) or not, to determine if this localisation can predict for rib frac-
ture. Age, comorbidities, lobe of the target lesion, stage, tumor 
size, maximal tumor standardized uptake value (SUV), total dose 
and various dose-volume histogram metrics were also evaluated 
for their predictive significance.
Results: The median follow-up was 20.8 and 18.1 months (range, 
0.2–52.1 and 15.3–46.2) for primary NSCLC and Mets, respectively. 
168/240 tumors (70%) were biopsy-proven NSCLC. Of the 228 pri-
mary NSCLC, the majority were stage I (192/228; T1a=136, T1b=21, 
T2a=35). Among all primary tumors, the 2-year LC was 94.8%. LC 
did not differ between biopsy-proven or presumed tumor, and did 
not differ between primary NSCLC and NSCLC Mets. For the who-
le cohort, only the presence of a respiratory comorbidity predicted 
for better local control (p=0.021) on multivariate analysis. In stage 
I NSCLC, the 2-year LC, lobar LC, regional control, distant control 
(DC) and overall survival (OS) were 95.5%, 91.3%, 89.3%, 74.7% and 
77.9%, respectively. The 2-year OS rates for non-stage I primary 
NSCLC and Mets from lung were 69.2% and 48.6%, respectively. 
The 2-year DC rates in all primary NSCLC and NSCLC Mets were 
73.6% and 20.8%, respectively. Among primary NSCLC, upper 
lobe tumors predicted for a better DC compared to lower lobe 
tumors (p=0.009). Of the 240 lung tumors, 132 (55%) were adjacent 
to the CW and had a significant greater risk of rib fracture. The 
2-year risk of fracture was 29.6% versus 8.1%, for tumors adjacent 
and not adjacent to the CW, respectively (p<0.001). The median 
time to fracture was 15.9 months. 51% of rib fractures were sym-
ptomatic. There was a suggestion that a higher conformity index 
(ratio of the 95% isodose volume to the PTV) predicted for a higher 
risk of rib fracture (p=0.067).
Conclusion: The excellent LC rate post-SABR seems similar in pri-
mary NSCLC and in NSCLC Mets, and having a respiratory comor-
bidity predicted favourably for LC. Patients with lower lobe tumors 
had higher risk of distant relapse. Patients with tumors adjacent to 
CT to CT alone indicates that the magnitude of treatment volume 
changes with incorporation of PET in radiotherapy planning for 
lung cancer varies from 27% - 100%. However, volumetric data 
only provides information on changes in size and does not account 
for potential changes in position and shape of the target, thereby 
affecting variability of the GTV in NSCLC. In this study we describe 
influence of FDG-PET/CT or CT alone for the primary and medi-
astinal nodal disease in radiation planning for stage III NSCLC in 
relation to changes in volume, position and overlap of the GTV. We 
also report the interobserver variability between radiation onco-
logists for FDG-PET/CT and CT alone-derived GTV. In addition to 
volumetric measurements, we have used a vector displacement 
method for three-dimensional (3D) positional analysis. We have 
further evaluated the overlap of the primary and nodal GTV with 
Dice Similarity Coefficient (DSC) method
Methods: Patients (n=29) underwent Three Dimensional Confor-
mal Radiotherapy (3DCRT) planning by three different radiation 
oncologists. Simultaneous co-registered CT and FDG-PET/CT were 
obtained in the same treatment planning position. Gross Tumor 
Volume (GTV) for lung tumor and mediastinal lymphadenopathy 
was contoured and compared for changes in volume and position. 
Interobserver variability was determined using three-dimensional 
analysis with vector displacement and the Dice Similarity Coeffici-
ent (DSC). Concordance for the number of lymph nodes contoured 
was performed.
Results: Mean GTV for lung tumor with FDG-PET/CT and CT alone 
was 62.0 cm3 and 74.64 cm3, respectively (p=0.0005), resulting in a 
17% reduction by FDG-PET/CT. Mean GTV for mediastinal lymph-
adenopathy was 15.72 cm3 and 19.02 cm3 (p=0.084), equalling a 
17% reduction GTV for FDG-PET/CT. Mean vector displacement of 
lung tumor was 2.0 mm with FDG-PET/CT versus 7.1 mm with CT 
alone (p = 0.0016), equating to a 3.6 fold reduction in interobser-
ver variability of position. Mean vector displacement of the medi-
astinal lymphadenopathy was 1.53 mm with FDG-PET versus 10.2 
mm for CT alone (p= 0.0005), resulting in a 6.7 fold reduction in 
interobserver variability. Median Dice Similarity Coefficient (DSC) 
for the primary GTV contours was 0.87 for FDG-PET/CT and 0.74 
for CT alone. For the nodal GTV DSC were 0.79 and 0.59, respec-
tively. Physician agreement on the number of lymph nodes con-
toured was 15/29 on CT and 27/29 patients for FDG-PET/CT. Only 
two of the three physicians agreed on the number of lymph nodes 
contoured for CT alone in 12/29 versus only 2/29 patients for FDG-
PET/CT (p=0.0018).
Conclusion: FDG-PET/CT significantly reduces mean lung tumor 
and mediastinal nodal GTV, is more precise for size and position 
in defining target volumes, and reduces interobserver variability. 
There was greater agreement for the number of lymph nodes con-
toured on FDG-PET/CT compared to CT alone.
Keyword: PET/ CT, Radiotherapy Planning, Lung Cancer
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P2.08-011 UTILITY OF MRI IN LUNG CANCER RADIO-
THERAPY: A LITERATURE REVIEW
Shivani Kumar1, Lois C. Holloway2, Shalini Vinod2
1University Of New South Wales/Australia, 2Liverpool Hospital, Cancer 
Therapy/Australia
Background: Lung cancer remains a challenging site to treat in 
radiotherapy. For tumour delineation CT combined with FDG PET 
is the current gold standard for delineating lung cancer volumes. 
MRI has been utilized in a limited number of cases such as superior 
sulcus tumours. However its use has been limited due to reduced 
MRI signal as a result of low proton density in lung, inhomogeneity 
of the magnetic field in lung and cardiac and respiratory motion. 
As technology improves, the utility of MRI in imaging lung cancer 
has become plausible. The aim of this literature review was to iden-
tify evidence to support the use of MRI in lung cancer imaging for 
radiotherapy.
Methods: Pubmed and Google Scholar were used to identify li-
terature on MRI in Lung cancer using the keywords Lung Cancer, 
MRI, MR, thoracic imaging and radiotherapy. Articles were limited 
to human and phantom subjects. A total of 22 articles were identi-
fied between 1995 and 2013 and reviewed to assess the potential 
of MRI for lung radiotherapy imaging.
Results: Eighteen studies were performed on 1.5T and two on 3T 
magnets with magnet strength not specified in two studies. Gra-
dient echo sequence and TrueFISP were most common sequences 
utilised. Thirteen articles examined tumour motion and nine con-
centrated on tumour volume analysis. One study illustrated mini-
mal geometric distortion and inter-cycle reproducibility of tumour 
volume on free breathing MRI sequence. The possibility of defi-
ning tumour internal target volume for radiotherapy treatment was 
demonstrated in three studies Two further studies demonstrating 
variability of lung tumour motion based on location and variability 
of motion between tumour and non-tumour bearing lung. There 
was conflicting evidence on pulmonary node detection based on 
results from two studies. Four comparative studies with FDG PET 
and functional MRI sequences demonstrated diffusion weighted 
image (DWI) had higher specificity for lesion detection in the pre-
sence of inflammation. Correlation was seen between SUV and 
DWI value. Two studies demonstrated the potential for radiothe-
rapy planning based on biological function by avoiding functional 
lung tissue.
Conclusion: This literature review indicates that improvement in 
MRI technology has overcome some of the initial limitations of 
utilising MRI for lung cancer imaging. MRI can not only provide the 
morphological information required for identifying lung cancer 
based on anatomical sequences but also functional information to 
identify both tumour activity and surrounding healthy or pathologi-
cal structures. There is potential for MRI to be utilised in the clini-
cal setting for defining tumour volumes for radiotherapy planning 
and in evaluating tumour response during and after treatment. 
However further research is required to determine protocols with 
defined standard sequences specific for lung cancer imaging.
Keyword: Lung Cancer, MRI, Radiotherapy
the CW are at significantly greater risk of rib fracture post-SABR 
and should be well informed prior to treatment.
Keywords: non-small cell lung cancer, stereotactic body radiothe-
rapy, rib fracture
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P2.08-010 OUTCOME OF EPIDERMAL GROWTH FACTOR 
RECEPTOR MUTATED (EGFRM) NON-SMALL CELL LUNG 
CANCER (NSCLC) PATIENTS (P) WITH BRAIN METAS-
TASES (BM) IN A SINGLE INSTITUTION: VALUE OF THE 
LUNG-GPA CLASSIFICATION
Maria Jove1, Arturo Navarro2, Maria Dolores Arnaiz2, Maria Plana1, 
Isabel Brao1, Núria Codorniu1, Valentí Navarro-Pérez3, Ramon Pal-
mero1, Felipe Cardenal1
1Medical Oncology, Instititut Català D’Oncologia/Spain, 2Radiation Onco-
logy, Institut Català D’Oncologia/Spain, 3Clinical Research Unit, Instititut 
Català D’Oncologia/Spain
Background: In February 2012 a specific GPA scale for assessing the 
prognosis of BM in NSCLC was published (JCO, 2012; 30(4): 419-426). 
Retrospective series have showed longer survival for patients with 
cerebral metastases and EGFR sensitizing mutations (m) compared 
with those without them.
Methods: Charts from EGFRm NSCLC p with BM were reviewed. We 
classified p with the lung-GPA prognosis scale at the time of diagnosis 
of BM and compared the expected GPA overall survival (GPA-OS) 
with the Observed OS (OS) for each group.
Results: 24p were diagnosed from January 2007 to December 2012. 
15 p were treated with whole-brain radiotherapy (WBRT), total dose 
30Gy (2p GPA 0-1; 10p GPA 1.5-2; 3p GPA 2.5-3), 1 p with stereotactic 
radiosurgery (SRS), mean dose 18Gy (GPA 3.5-4), 1p with SRS and 
WBRT (GPA 2.5-3) and 2p with surgery (S) and WBRT (1p GPA 2.5-3; 
1p GPA 3.5-4). 5p receive no treatment (3p GPA 0-1; 2p GPA 1.5-2). 
Outcomes were [Expected median (m) GPA-OS vs Observed m OS]:  
GPA 
Expected 
m GPA-
OS(months) 
Observed m OS 
(months) 
Number of p 
0-1 3.4 <1 5 
1.5-2 4.7 6 12 
2.5-3 8.8 34 5 
3.5-4 14.8 
Not reached (100% 
OS at 40 months) 
2 
 
Two p did not receive any EGFR tyrosine kinase inhibitor (TKI). 5p 
were receiving an EGFR TKI when they were diagnosed with BM and 
12p were treated with EGFR TKI after the diagnosis of BM. Sixteen p 
have died. Further details of p characteristics and treatment received 
will be presented at the meeting.
Conclusion: Observed m OS of p with EGFR m-NSCLC and brain 
mets was much longer than expected by GPA-OS. The GPA subsets 
might predict prognosis in patients with mutated tumors as well.
Keywords: GPA, brain metastases, EGFR
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P2.08-013 PROTON RADIOTHERAPY FOR LOCALLY-
ADVANCED NON-SMALL CELL LUNG CANCER, A COST-
EFFECTIVE ALTERNATIVE TO PHOTON RADIOTHERAPY 
IN BELGIUM?
Yolande Lievens1, Nick Verhaeghe2, Wilfried De Neve1, Indira 
Madani2, Barbara Vanderstraeten1, Jan Verstraete3, Lieven Anne-
mans2
1Radiation Oncology Department, University Hospital Ghent/Belgium, 
2Faculty Of Medicine And Health Sciences, Ghent University/Belgium, 
3Radiation Oncology Department, University Hospital Leuven/Belgium
Background: As part of a feasibility study for a Hadron Therapy 
Centre in Belgium, an economic evaluation was performed to as-
sess the potential cost-effectiveness of proton radiotherapy (PT) 
delivered concurrently with chemotherapy for locally-advanced 
non-small cell lung cancer (LA-NSCLC), compared to concurrent 
chemoradiotherapy employing photon therapy, either 3D-confor-
mal (3D-CRT) or intensity-modulated (IMRT) radiotherapy.
Methods: A Markov decision-analytic model was developed 
using Microsoft Excel 2007 software. The model was defined for 
a time horizon of 10 years, allowing patients to transition between 
5 health states (treatment, controlled disease, loco-regional pro-
gression, distant progression and death) using transition cycles 
of 3 months. Transition probabilities were derived from photon 
and proton literature on LA-NSCLC and from nationally available 
data. Results were to be expressed in cost per (quality adjusted) 
life years (LY and QALY). The occurrence of grade 3 toxicity or 
higher in terms of radiation pneumonitis, radiation esophagitis/
dysphagia and pulmonary radiation fibrosis was accounted for in 
the calculation of QALYs. Treatment costs of the standard 3D-CRT 
and IMRT treatments were obtained from an Activity-Based Cos-
ting (ABC) exercise in Belgian radiotherapy centers (KCE report 
198). Similarly, the cost of PT was calculated using ABC in different 
technical (proton-only vs. combined proton and carbon-ion center) 
and financing (private vs. public) scenarios. Toxicity and follow-up 
costs were based on literature evidence but adapted to the Belgi-
an context.
Results: The base case analysis used the scenario of a publicly 
financed combined center. The survival curves generated by the 
model demonstrated it accurately predicts survival of published li-
terature and of the Belgian Cancer Registry. Compared to 3D-CRT 
res. IMRT, PT generates 0.837 res. 0.664 extra LYs and 0.549 res. 
0.452 extra QALYs. When combined with the higher cost (18,875€ 
res. 14,257€), this translates into an incremental cost-effectiveness 
ratio (ICER) of 22,543€/LY for PT compared to 3D-CRT and of 
21,489€/LY compared to IMRT. Expressed in cost per QALY, the 
ICERs amount to 34,396€/QALY and 31,541€/QALY respectively. 
Assessing the effect of different technical scenarios and/or finan-
cing methods, the ICER ranges between 21,489€ to 53,685€/LY 
and 31,541€ to 78,873€/QALY, with the highest figures found for a 
combined center with private financing. One-way sensitivity analy-
ses reveal that the results are most sensitive to the effect of proton 
therapy on disease control, loco-regionally as well as at distance, 
and to the quality of life pre-progression.
Conclusion: Based on a public financing scenario for a combined 
center, PT delivered concurrently with chemotherapy is found bor-
derline cost-effective in the Belgian health care context, compa-
red to the best available photon radiotherapy alternatives. These 
results are however highly sensitive to the cost of PT (hence the 
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P2.08-012 TREATMENT OF MULTIPLE PRIMARY LUNG 
CANCERS (MPLC) WITH STEREOTACTIC ABLATIVE RA-
DIOTHERAPY (SABR)
Gwendolyn H. Griffioen1, Frank Lagerwaard1, Cornelis J. Haas-
beek1, Egbert Smit2, Ben J. Slotman1, Suresh Senan1
1Radiation Oncology, VU University Medical Center/Netherlands, 2Pul-
monary Diseases, VU University Medical Center/Netherlands
Background: Multiple primary lung cancers (MPLC) are not an 
uncommon clinical presentation, with an incidence in the surgical 
literature of 1-8%. ESMO guidelines state that synchronously de-
tected lesions should be treated as multiple primary tumors, and 
a curative approach for both lesions has been associated with im-
proved survival in the surgical series. However, many patients with 
MLCP are elderly and have multiple co-morbidities, which can ren-
der them unfit to undergo surgery for both lesions. We analyzed 
clinical outcomes in such patients who were treated with SABR.
Methods: SABR was performed in 62 patients diagnosed with 
MPLC at the VUmc from 2003 – 2012. Staging included a man-
datory FDG-PET scan, and all patients were discussed in a multi-
disciplinary tumor board. A pathological diagnosis was available 
for both lesions in 3%, and for one lesion in 48%. Invasive nodal 
staging was performed in 13% of patients. SABR was used as a sin-
gle modality for both lesions (n=56), or in combination with surgery 
for the second lesion (n=6). SABR was delivered to a total dose of 
54-60 Gray (Gy) in 3-8 fractions, depending on tumor size and lo-
cation. Clinical outcome, including survival, patterns of relapse and 
toxicity (CTC v4.0) was evaluated. A sub-analysis was performed 
for ipsilateral and bilateral lung lesions.
Results: Median overall survival was 31 months, with an actuarial 
survival of 56% at 2 years. Overall lesion local control rate was 
84% at 2 years. Local control correlated significantly with number 
of fractions (p=0.013) and lesion location (p=0.004) on univariable 
Cox regression analysis. Lesion control at 2 years for bilateral lesi-
ons was 92% versus 74% for ipsilateral lesions (p=0.009). Regional 
failures at two years were observed in 13% (n=6) of all patients, 
and in 0% versus 31% in patients with respectively bilateral and 
ipsilateral lesions. Of the patients who developed a subsequent 
regional recurrence, only one had undergone EUS/EBUS prior to 
treatment, and others did not as pre-treatment FDG-PET-scans 
showed no nodal uptake. Distant failures were observed in 27% of 
all patients, at two years. No grade ≥3 early toxicity was observed. 
Late grade 3 toxicity was reported in 3 patients (5%), consisting of 
pneumonitis (n=1), rib fracture (n=1) and chest wall pain (n=1). No 
grades 4-5 late toxicity was reported.
Conclusion: Curative treatment of MPLC using SABR, either alone 
or combined with surgery, can lead to long-term survival with limi-
ted toxicity. The disappointing local control rates observed after 
SABR for ipsilateral double lesions merits further investigation. The 
higher rate of nodal recurrences in patients presenting with multip-
le ipsilateral lesions suggests that systematic nodal staging may be 
appropriate in such cases.
Keywords: Multiple primary lung cancers, Stereotactic Radiothe-
rapy, survival
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the only significant factor among patients ≤65, while CRT was an 
insignificant factor among patients >65. The patients treated with 
CRT had significantly lower frequency of local relapse (33%) com-
pared with patients treated without (46%, p = 0.016), while the rate 
of distant metastases was unaffected by the use of CRT. Patients 
≤65 years had a low complication death rate (1-2%) independent of 
CRT, while the complication death rate among patients >65 years 
was 6-8%, also independent of CRT.
Conclusion: Patients ≤65 years had a very positive effect of CRT 
while CRT did not influence survival in older patients. The reason 
for this is unknown
Keywords: elderly, Concurrent chemo-radiation, locally advanced 
NSCLC
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P2.08-015 STEREOTACTIC BODY RADIOTHERAPY WITH 
HELICAL TOMOTHERAPY FOR LUNG TUMOR: TREAT-
MENT OUTCOME AND FEASIBILITY
Sung Hwan Kim1, Yun Hee Lee2, Dae Gyu Kang1, Deog Gon Cho3
1Radiation Oncology, St. Vincent’s Hospital, College Of Medicine, The 
Catholic University Of Korea/Korea, 2Radiation Oncology, Uijeongbu St. 
Mary‘s Hospital, College Of Medicine, The Catholic University Of Korea/
Korea, 3Thoracic And Cardiovascular Surgery, St. Vincent‘s Hospital, 
College Of Medicine, The Catholic University Of Korea/Korea
Background: In this study we evaluated the feasibility and out-
come of stereotactic body radiotherapy (SBRT) for lung tumors 
treated with helical tomotherapy.
Methods: Between December 2007 and January 2013, 26 Patients 
with a total of 49 lung tumors were treated with helical tomothe-
rapy at a median 75 Gy of 10 fractions over 2 weeks. Thirteen lung 
lesions of primary lung tumors (group 1) and 36 of recurrent or 
metastatic lung tumors (group 2) were analyzed. Three patients 
received re-SBRT due to local recurrence after first SBRT were 
included. (Total 29 cases were analyzed). Radiation pneumonitis 
was graded according to the Common Terminology Criteria for 
Adverse Events V 4.0.
Results: The patients’ age was median 72 years (range, 47-82). Me-
dian follow up was 16 months (range, 2-57 months). Total 13 cases 
(45%) showed progressive disease after SBRT, and one of them was 
distant metastasis. Of 12 thoracic recurrences, in-field recurrences 
were noted in 5 patients and out-field recurrences in 7 patients. In 
group 1 (13 cases), there were 3 recurrences with 1 in-field thoracic 
recurrence, 1 out-field thoracic recurrence and 1 distant metasta-
sis. Grade≥2 radiation pneumonitis was noted in 8 patients (30%). 
One patient died due to radiation pneumonitis at 2 months follow 
up after second SBRT.
Conclusion: The preliminary findings of our study suggest SBRT 
with helical tomotherapy is feasible for lung tumor treatment. But 
further studies with more patients and longer follow-up duration 
are required.
Keywords: stereotactic body radiotherapy, radiation pneumonitis, 
helical tomotherapy, lung tumors
financing scenario) and the expected clinical advantage of PT, both 
in terms of improved survival and decreased long-term toxicity 
impacting on quality of life. Apart from clinical appropriateness 
and budgetary possibilities, such results support decision-making 
on the feasibility and desirability of introducing hadron therapy in 
Belgium.
Keyword: non-small cell lung cancer, proton radiotherapy, photon 
radiotherapy, cost-effectiveness
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P2.08-014 THE INFLUENCE OF AGE ON THE OUTCOME 
OF CONCURRENT CHEMO-RADIOTHERAPY IN LOCALLY 
ADVANCED NSCLC
Olfred Hansen1, Tine Schytte1, Morten Nielsen2, Carsten Brink2
1Oncology, Odense University Hospital/Denmark, 2Laboratory Of Radia-
tion Physics, Odense University Hospital/Denmark
Background: Concomitant chemo-radiotherapy (CRT) has been 
shown to be superior to single modality radiotherapy (RT) and to 
neoadjuvant chemotherapy (NeoCT) followed by RT. In this retro-
spective study we report the influence of age on survival in two 
groups of patients with locally advanced radiotherapy treated from 
1995 to June 2012: 1) NoCRT-group: RT +/- NeoCT without CRT 
and 2) CRT-group: NeoCT followed by CRT.
Methods: Data for 446 patients that completed 3-D conformal RT 
or IMRT in planned doses of 60-66 Gy at 2 Gy/F without elective 
nodal irradiation was obtained. CRT was used for 114 patients with 
the regimens: weekly Docetaxel (N=43), Carboplatin-Vinorelbine 
(N=70) and Cisplatin-Vinorelbine (N=1). The NoCRT group consis-
ted of 332 patients
Results: 
The median and 5 year survival was 17.2 months and 15% for No-
CRT, and 21.4 months and 29% for CRT (p<0.02). The data was 
analyzed in the age groups ≤65 and >65 years. For NoCRT, no 
differences in survival was found (17.2 vs. 17.1 months), but in the 
CRT group significant longer survival was found in the younger age 
group, 29.2 vs. 20.0 months in the older group (p=0.03). CRT was 
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P2.08-017 INCREASING EXPECTED LOCAL CONTROL 
FOR LOCALLY ADVANCED NSCLC PATIENTS WITH  
INHOMOGENEOUS DOSE-ESCALATION
Tine B. Nielsen1, Tine Schytte2, Olfred Hansen2, Carsten Brink3
1Laboratory Of Radiation Physics, Odense University Hospital/Den-
mark, 2Department Of Oncology, Odense University Hospital/Denmark, 
3Institute For Clinical Research, University Of Southern Denmark/
Denmark
Background: Radiotherapy treatments of locally advanced NSCLC 
patients are associated with poor local control and low overall 
survival rates. Local recurrence often occurs within the initial pri-
mary tumour. Therefore, higher doses to locally advanced NSCLC 
tumours with conventional fractionation are required in order to 
increase the local control. However, current tumour dose levels are 
limited by the toxicity levels of the surrounding normal tissue, e.g. 
healthy lung tissue and mediastinal region. This study presents the 
concept of clinically applicable inhomogeneous dose plans that 
distribute higher doses in the tumour without compromising the 
expected lung toxicity, not only for isolated lung tumours, but also 
for patients with involved lymph nodes.
Methods: Twenty consecutive NSCLC patients previously treated 
with conventional radiotherapy treatment with a prescribed dose 
of 66Gy/33F were included in this planning study. The patients 
were staged T1b-T4 N0-N3 with a median tumour size of 56.7 cm3 
(range 3.2-399.2 cm3). Highly modulated IMRT plans were used 
for treatment with standard dose coverage of 95%-107% of the 
prescribed dose. For each patient, a new dose-escalated treat-
ment plan was created with the same mean lung dose as obtained 
in the standard plan using an inhomogeneous dose distribution 
with minimum dose coverage of ≥95% of the prescribed dose. The 
maximum tumour dose was only limited by conservative tolerance 
levels of the surrounding healthy tissue: maximum doses of 45 to 
spinal canal, 66 Gy to oesophagus, and 74 Gy to less than 1 cm3 
within the mediastinal region. Two different tumour control proba-
bility (TCP) models were used to evaluate the homogeneous and 
inhomogeneous treatment plans. Furthermore, in order to estima-
te the reliability of the calculated doses in comparison to actual 
delivered doses, the treatment plans were re-calculated in 4D by 
accounting for uncertainties arisen from respiration, delineation, 
setup, and baseline shift.
Results: Dose escalation was possible for all patients. TCP values 
increased approximately 15 and 10 percentage points based on 
calculations related to the GTV and CTV, respectively, from an ini-
tial level of 18%. This increase in expected local control was obtai-
ned without increasing the mean lung dose. However, small incre-
ases in maximum doses to the mediastinum were observed: 2.5 Gy 
for aorta, 4.4 Gy for the connective tissue, 1.6 Gy for the heart, and 
2.6 Gy for trachea and bronchi. The increase in TCP predictions 
from 4D calculations differed only slightly from the corresponding 
3D calculation.
Conclusion: Increased target doses and TCP values using dose-es-
calated inhomogeneous dose distributions could be achieved for 
all patients, regardless of lymph node involvement, tumour stage, 
location, and size. These new treatment plans have the potential 
to increase the local tumour control with 10-15 percentage points 
without increasing the mean lung dose, which is often regarded as 
a measure for the expected lung toxicity. The conservative dose 
constraints used for the organs at risk ensures clinical applicable 
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P2.08-016 USE OF PALLIATIVE RADIOTHERAPY IN LUNG 
CANCER DURING THE LAST WEEKS OF THE LIFE.
Amela Tursunovic, Tine Schytte, Olfred Hansen
Oncology, Odense University Hospital/Denmark
Background: Radiotherapy (RT) is commonly used for palliation of 
symptoms in patients with lung cancer. However, the time before 
onset of relief may be several weeks. It is therefore of interest to 
study how many patients who die within few weeks after the in-
itiation RT since these patients are not likely to benefit from the 
treatment.
Methods: This is a retrospective review of the overall survival rate 
of 293 patients with lung cancer who received palliative RT in 2010 
at our institution. If patients had received more than one course of 
RT, only data from the last course was included in the study.
Results: The planned fractionation (F) schedules were 
8Gy/1F(N=34), 10Gy/1F(N=34), 20Gy/4-5F(N=16), 20Gy/10F(N=2), 
25Gy/5F(N=44), and 30Gy/10F(N=167). The median survival was 
11.9 weeks. The two-week mortality rate 10.2% and the four-week 
mortality rate was 22.2%.  
N 
2 week 
mortality 
4 week 
mortality 
Median survival 
8-10 Gy/1F 64 15 (23%) 26 (41%) 5.6 w 
20-25Gy/4-
5F 
60 8 (13%) 20 (33%) 6.0 w 
20-30Gy/10F 169 7 (4%) 19 (11%) 21.7 w 
Total 293 30 (10%) 65 (22%) 11.9 w 
 
Among the patients planned for 4-5F, only one patients (2%) did 
not receive the planned number of fractions, while 13 patients 
(8%) of the patients planned for 10F did not receive the planned 
number of fractions. In a logistic regression analysis using 2-week 
mortality as endpoint, only planned number of fractions <10F and 
bone metastases as indication of RT were significant factors for 
poor survival, while gender, CNS metastases, age, performance 
status and histology were not. The results are strikingly similar to 
Gupta et al. Radiother. Oncol. 2012;103 suppl.1(PO-0744).
Conclusion: Although 10% of the patients receiving palliative RT 
die within 2 weeks from the start of RT, the results indicate that 
prolonged treatment regimens were reserved for patients with 
longer life expectation. Nearly 1 of 4 of patients receiving 1F died 
within two weeks after start of RT indicating that the RT was futile 
in these patients.The radiation oncologists seem to expect a palli-
ative effect of RT for bone metastases even in patients with short 
life expectations.
Keywords: radiotherapy, palliation
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Conclusion: 
Several conclusions can be drawn from this study. At first it is very 
challenging to define postoperative volume, when there is no 
gross tumor volume as is the case when RT it is due to microscopic 
non-radical operation. Secondly, it is important to have guidelines 
in order to define the approximate size of the CTV, this in context 
of the large difference in the size of the volume between the on-
cologists. Thirdly, surgeon and oncologist should delineate the 
postoperative target volume in collaboration to ensure the correct 
conclusion is drawn on the basis of operation and pathological re-
ports, in order to hit the right target and reduce irradiated volume.
Keywords: radiotherapy, NSCLC, postoperative, Delineation
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P2.08-019 PALLIATIVE RADIATION DURING PEMETREX-
ED PLUS CISPLATIN FIRST-LINE TREATMENT OR PEMET-
REXED CONTINUATION MAINTENANCE TREATMENT IN 
ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG 
CANCER (NSCLC): A REPORT OF PATIENT SAFETY IN 
THE PARAMOUNT TRIAL
Filippo De Marinis1, Cesare Gridelli2, Mircea Dediu3, Michael 
Thomas4, Jean-Lois Pujol5, Olivier Molinier6, Martin Reck7, Tarini 
P. Sahoo8, Belen San Antonio9, William J. John10, Annamaria H. 
Zimmermann10, Nadia Chouaki11, Carla Visseren-Grul12, Luis G. 
Paz-Arez13
1Azienda Ospedaliera San Camillo-forlanini/Italy, 2S. G. Moscati 
Hospital/Italy, 3Institiute Of Oncology/Romania, 4Thoraxklinik Im 
Universitätsklinikum Heidelberg/Germany, 5Montpellier Academic 
Hospital/France, 6Le Mans Regional Hospital/France, 7Onkologischer 
Schwerpunkt, Krankenhaus Großhansdorf, Zentrum Für Pneumologie 
Und Thoraxchirurgie/Germany, 8Jawaharlal Nehru Cancer Hospital 
And Research Center/India, 9Eli Lilly And Company/Spain, 10Eli Lillyand 
Company/United States Of America, 11Eli Lilly And Company/France, 
12Medical Oncology, Eli Lilly And Company/Netherlands, 13University 
Hospital/Spain
Background: Patient (pt) safety is of utmost concern to radiation 
oncologists. Pemetrexed (Pem) is an effective and well-tolerated 
treatment for advanced nonsquamous NSCLC. The safety of pal-
liative radiation (XRT) during Pem treatment was studied in this 
subset of pts in the PARAMOUNT trial.
Methods: In PARAMOUNT, a randomized, double-blind study, 939 
pts received 4 cycles of induction Pem (500 mg/m2) + cisplatin (Cis) 
(75 mg/m2) on day 1 every 21 days. Patients without progressive 
disease (PD) and with an Eastern Cooperative Oncology Group 
performance status (ECOG PS) of 0/1 (n=539) were then rando-
mized (2:1) to maintenance Pem (500 mg/m2, day 1) + best suppor-
treatment plans that can be implemented today. Based on these 
promising results, a national randomised phase III study is under 
development.
Keywords: Tumour Control Probability, locally advanced NSCLC, 
Dose-escalated radiotherapy, Inhomogeneous dose distribution
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P2.08-018 INTEROBSERVER VARIABILITY IN TARGET 
VOLUME DELINEATIONS IN POSTOPERATIVE RADIO-
THERAPY FOR NSCLC.
Tine Schytte1, Tine B. Nielsen2, Peter Licht3, Lars Ladegaard3, Cars-
ten Brink2, Olfred Hansen1
1Department Of Oncology, Odense University Hospital/Denmark, 2La-
boratory Of Radiation Physics, Odense University Hospital/Denmark, 
3Cardiothoracic Surgery, Odense University Hospital/Denmark
Background: The aim of this study is to determine the interobser-
ver variability between thoracic surgeons and radiation oncologists 
in defining and delineating target volume for postoperative radio-
therapy for patients with non small cell lung cancer (NSCLC). These 
patients were offered postoperative RT due to microscopic non-
radical operation.
Methods: Between 2002 and 2010, 48 NSCLC patients were of-
fered postoperative radiotherapy at Department of Oncology, 
Odense University Hospital due to microscopic non-radical ope-
ration. Two thoracic surgeons (S1 and S2) and two clinical oncolo-
gists (O1 and O2) were retrospectively asked to delineate clinical 
target volume (CTV) on the 3D CT scanning used for radiotherapy 
planning in each patient. Instruction were given to include the 
non-radical site on basis of surgical-, pathological-, and radiolo-
gical reports. The delineation was done independently by each 
physician. There are no local guidelines for delineation postope-
rative volume after non radical microscopic operation. The spatial 
volume discrepancy between the different physicians was the end-
point.
Results: The mean volumes were very different between the phy-
sicians: S1 20.5 (SD 17.4) cm3, S2 21.5 (28.1) cm3, O1 14.4 (20.5) 
cm3, and O2 32.9 (SD 35.6) cm3. A large spatial volume discrepan-
cy between the different physicians was observed as well. Mean 
discrepancies were O1-O2 18.5 (SD 25.3) cm3 (p<0.0001), O1-S1 
6.1 (SD 21.4) cm3 (p=0.06), S1-S2 1.3 (SD 22.9) cm3 (p=0.7). Mean 
Soerensen-Dice index O1-O2 0.27 (SD 0.19), O1-S1 0.27 (SD 0.16), 
S1-S2 0.29 (SD 0.18). There was a reasonable overlap in 25 patients 
(52%) between all 4 physicians. In another 9 cases (19%) 3 physici-
ans had a reasonable overlap and one “outlier”. Figure 1 illustrates 
one case with reasonable overlap, and another case with one “out-
lier”.
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P2.08-020 PROGNOSITC PARAMETERS FOR LOCAL AND 
REGIONAL CONTROL IN LOCALLY ADVANCED NSCLC 
PATIENTS TREATED WITH CONCURRENT CHEMO-RA-
DIOTHERAPY
Chun Chen, Michel Van Den Heuvel, Josien De Bois, Judi Van Dies-
sen, Jose Belderbos, Jan Jakob Sonke
Radiation Oncology, Netherlands Cancer Institute/Netherlands
Background: Traditionally, the same radiotherapy dose is prescri-
bed to the primary tumor (PT) and involved lymph nodes (LN) for 
locally advanced NSCLC patients, independent of volume and 
metabolic activity of each lesion. On the other hand, the PT and 
lesions with a high 18F-FDG uptake are often believed to have a 
higher recurrence rate. The purpose of this study was therefore 
to find prognostic parameters for the lesion control probability in 
locally advanced NSCLC.
Methods: A total of 279 patients treated between 2007 and 2011 
with 24×2.75Gy IMRT and concurrent daily low dose cisplatin 
were included in this retrospective analysis. Patients had a staging 
FDG-PET scan within 6 weeks prior the start of treatment. For 
follow-up, CT thorax was performed 4-6 weeks after treatment 
and at 3-monthly intervals chest x-ray or CT scans were made up 
to 2 years after CCRT. Medical records of the patients were retros-
pectively reviewed. The PT and/or LN progression were classified 
based on follow-up records and scans by two physicians. The volu-
me of each separate lesion on the planning CT and their SUVmax 
from the pre-RT staging PET scan were then tested as prognostic 
factors for disease progression using Cox proportional hazard 
model with patient as random effect. Data were analyzed using R, 
package “coxme”.
Results: A total of 291 PTs (8 patients had no PT, 252 had 1 PT, 
18 had 2 PTs, 1 had 3 PTs) and 627 LNs (59 patients without LN, 
57 had 1 LN, 57 had 2 LNs and 106 had >=3 LNs involved) were 
analyzed. The majority (92%) of the patients had TNM stage III and 
86% patients had ≥N2. At a median follow-up of 30 months (95%CI 
27-35) and median OS of 25 months (95% CI 21-29), 47 PTs had 
progression and 14 LNs had progression, 38% patients had syste-
mic relapse. The log(Vol), SUVmax and lesion type (TP vs. LN) were 
each significant (p<0.001) as prognostic factor for progression in 
the univariate cox regression. In the multivariate analysis, log(Vol) 
remains as a significant predictor (p<0.001) with a trend toward 
significance for lesion type (p=0.07) (Figure 1). 
tive care (BSC) (Arm A) or placebo + BSC (Arm B) until PD. Best 
supportive care (BSC) was defined as treatment without a specific 
antineoplastic regimen and included palliative XRT to extrathoracic 
structures. Safety was assessed via the incidence of adverse events 
(AEs) by maximum grade (Gr; CTCAE, v3).
Results: The 55 pts who received palliative XRT to extrathoracic 
structures during treatment had stage IV nonsquamous NSCLC. 
The majority of pts were male (58%), with an ECOG PS of 1 (75%). 
Patients’ median age was 61 yrs (range, 32-74) yrs, with 13% of pts 
≥70 yrs. The most common location irradiated was bone (43/55 
pts). Non-bone locations were: lymph node (3), mediastinum (2), 
chest (2), and adrenal gland, intraocular, lung, brain, and abdomen 
(1 each). Forty-five pts received XRT during Pem+Cis induction, 3 
of whom also received XRT during maintenance. Seven pts (Arm A) 
and 6 pts (Arm B) received palliative XRT during maintenance. To-
tal XRT doses ranged from 8-66 Gy. The time interval between day 
1 of last chemotherapy cycle and the start of palliative XRT ranged 
from 0-28 days. Of 55 pts, 12 (22%) had ≥1 AE(s) during XRT consi-
dered possibly related to Pem and/or XRT (Table 1). All pts except 
1 experienced the AE during induction. The most common AE was 
Gr 2 anemia. Three pts had Gr 3/4 anemia. Five pts had nonhema-
tologic toxicities. One pt in Arm B, who received a total dose of 20 
Gy in the hip during maintenance treatment, had pneumonitis. No 
AEs were reported for pts who received palliative XRT during Pem 
maintenance treatment.  
Table 1: AEs during palliative 
XRT or within 2 weeks after 
the end of the last fraction 
in both phases of the PARA-
MOUNT trial. 
Pts receiving palliative XRT 
(N=55) 
Patients with AEs during in-
duction and/or maintenance 
(n=12, 22%) 
Toxicity Gr 1, n (%) 
Gr 2, n 
(%) 
Gr 3-4, n 
(%) 
Hematologic 
Hemoglobin 1 (1.8) 4 (7.3) 3 (5.5) 
Leukocytes 0 2 (3.6) 1 (1.8) 
Platelets 0 1 (1.8) 0 
Nonhematologic 
Rash/dermatitis 1 (1.8) 1 (1.8) 0 
Rash/desquamation 1 (1.8) 1 (1.8) 0 
Pneumonitis 0 0 1 (1.8)* 
*Pneumonitis was the only 
event reported for a pt during 
the maintenance phase. The 
pt was assigned to placebo. 
Conclusion: In PARAMOUNT, palliative XRT is well tolerated and 
can be safely administered at low and high doses during Pem+Cis 
chemotherapy or Pem monotherapy to pts with advanced nons-
quamous NSCLC.
Keywords: radiotherapy, patient safety, non-small cell lung cancer, 
nonsquamous
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patients who had previously been treated with 3DCRT for stage 
IIIA or IIIB Non-Small Cell Lung Cancer at NCCC, and had undesi-
rably high healthy lung doses when prescribed 60Gray (Gy) in 30 
fractions. The original treatment volumes (planning target volu-
me (PTV), clinical target volume/gross tumour volume) and total 
prescribed dose for each planning method was left unchanged for 
this study. The original 3DCRT plans utilised, on average, 4 static 
beams with 8mm field margins. Angles, wedges, weighting and 
energy were selected as a best fit to treat the target volume and 
avoid spinal cord irradiation and healthy lung tissue. Each VMAT 
replan comprised of one 352° arc, with 89 control points, delivered 
over a maximum of 90 seconds, with all radiotherapy dose deli-
vered through this dynamic arc. This study compared the two plan-
ning methods based on PTV coverage, Conformity Index (CI), V20 
(volume of normal lung receiving 20Gy) <30% and V30 (volume of 
normal lung receiving 30Gy) <20% of the combined healthy lung 
volume and mean lung dose.
Results: Improved coverage of the PTV by 60Gy is achieved with 
VMAT, with an average of 92.5%, whilst 3DCRT plans achieved an 
average of 77.7% 60Gy PTV coverage. VMAT combined lung doses 
were reduced when compared to 3DCRT, with an average V20 
of 29.9% for VMAT plans compared to 34.1% for conformal plans, 
and V30 of 18.4% for VMAT plans, compared to 27% for 3DCRT 
plans. Combined mean lung dose was also lower for VMAT plans, 
with an average reduction of 2Gy, with average mean lung dose of 
18.01Gy for VMAT plans compared to 20.09Gy for 3DCRT plans. 
The CI of the D95% was improved in all three cases, with an ave-
rage 100% CI of 1.01 for VMAT plans, and an average CI of 1.2 for 
3DCRT plans.
Conclusion: VMAT is a viable planning method to achieve radical 
treatment intent to 60Gy in 30 fractions, adequate PTV coverage 
by D95% and improved healthy lung doses for patients with stage 
IIIA and IIIB NSCLC.
Keywords: radiotherapy, non-small cell lung cancer, conformal 
radiotherapy, Volumetric Modulated Arc Therapy
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P2.08-022 NON-SMALL CELL LUNG CANCER (NSCLC): 
CHANGES IN VOLUME DURING RADIOTHERAPY AND 
POTENTIAL ADAPTIVE RADIOTHERAPY PLANNING
Ge Kai Ho, Shivani Kumar, Sankar Arumugam, Michael Jameson, 
Skye Degruyter, Penny D.T. Phan, Lois C. Holloway, Shalini Vinod
Radiation Oncology, Liverpool And Macarthur Cancer Therapy Centres/
Australia
Background: Curative radiotherapy for non-small cell lung can-
cer (NSCLC) is usually delivered over a time period of 5-7 weeks. 
Tumour regression has been observed over the course of curative 
radiotherapy. Currently, the entire radiotherapy treatment is deli-
vered based on the original tumour volume. An evolving approach 
is adaptive radiotherapy planning whereby the radiotherapy plan 
is modified during a course of treatment to account for tumour and 
patient changes. This has the potential to reduce the size of radio-
therapy fields, allowing dose escalation and normal tissue sparing.
Methods: A cohort of 20 consecutive NSCLC patients receiving a 
curative course of radiotherapy and who had weekly kV cone beam 
computer tomography (CBCT) images was identified. The gross 
Conclusion: Our regimen of 66 Gy in 24fx results in excellent local-
regional control in locally advanced NSCLC patients. The PT yields 
a significantly higher risk of progression than LNs. A larger lesion 
volume and higher SUVmax were associated with an increased risk 
of progression.
Keywords: local-regional control, SUV, prognostic factor, tumor 
volume
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P2.08-021 COMPARISON OF TWO RADIOTHERAPY PL-
ANNING TECHNIQUES FOR STAGE IIIA AND IIIB NSCLC: 
VOLUMETRIC MODULATED ARC THERAPY (VMAT) VS 
3D CONFORMAL RADIOTHERAPY (3DCRT)
Katherine Small, Kylie Unicomb, Fiona Hegi-Johnson, Kevin Van 
Tilburg, Roland Yeghiaian-Alvandi, Jeffrey Barber, Sean White
Radiation Oncology, Nepean Cancer Care Centre/Australia
Background: The treatment of locally advanced lung cancer with 
radiation therapy has traditionally utilised multiple beam conformal 
plans. On occasions, the curative intent is compromised due to 
excessive normal tissue dose, especially to healthy lung tissue. This 
necessitates a reduction in total delivered dose to a more palliative 
regimen. With the advent of Volumetric Modulated Arc Therapy 
(VMAT) at Nepean Cancer Care Centre (NCCC), the question arises 
of whether VMAT plans can be utilised in these circumstances in 
order to deliver curative tumour dose, whilst still delivering accep-
table normal tissue doses. This study shows a planning comparison 
of the VMAT and traditional 3D Conformal Radiotherapy (3DCRT) 
planning techniques. Hypothesis: It is expected that VMAT plans 
will produce equivalent target volume coverage, whilst resulting in 
lower toxicities to surrounding healthy tissue, when compared to 
3DCRT plans.
Methods: This study was conducted retrospectively on three 
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locoregional relapse, ten patients (23.3%) had in-field or mar-
ginal failure, while three (7.0%) had recurrence at initially unin-
volved lymphatic regions. Grade 3 TRP and esophagitis occur-
red in one (2.3%) and ten (23.3%) patients. The one-year LRC, 
PFS, and OS rates were 75.0%, 33.7%, and 81.7%, respectively. 
Conclusion: The early experience of IMRT for the patients with ad-
vanced NSCLC, who are poor candidates for conventional RT tech-
niques, seems favorable with respect to locoregional control and 
toxicity. Further studies will be directed to address the issues on 
the elective lymphatic irradiation extent, radiation dose escalation, 
long-term clinical outcomes, and comparison with conventional RT 
techniques. Authors hope to develop optimal clinical indications of 
IMRT that can be reimbursed by the national insurance system in 
Korea.
Keywords: non-small cell lung cancer, intensity-modulated radia-
tion therapy
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P2.08-024 A NEW DOSE CONSTRAINT REDUCE THE 
INCIDENCE AND SEVERITY OF RADIATION-INDUCED 
PNEUMONITIS IN LOCALLY ADVANCED NSCLC TREA-
TED WITH INTENSITY-MODULATED RADIOTHERAPY
Azza A. Khalil1, Ditte S. Møller2, Katherina P. Farr1, Lone Hoff-
mann2, Marianne M. Knap1
1Oncology Department, Aarhus University Hospital/Denmark, 2Medical 
Physics Department, Aarhus University Hospital/Denmark
Background: Applying Intensity-Modulated Radiotherapy (IMRT) 
techniques to patients with stage III NSCLC allows treating large 
tumour volumes and bulky mediastinal lymph nodes while respec-
ting the usual normal tissue constraints to the lungs and organs at 
risks. IMRT techniques lead to irradiating a large lung volume with 
low doses (lung bath). The volume of lung receiving doses of 5 Gy 
or more (V5) may estimate the toxicity related to low dose irradiati-
on. In the current study, an analysis was performed to test whether 
the introduction of IMRT was associated with increased incidence 
tumour volume (GTV) and anatomical reference points were de-
lineated on all CBCT scans. Volume and positional changes were 
recorded and analyzed.
Results: Six patients with non-small cell lung cancer who received 
curative radiotherapy were assessed so far. Five patients had suf-
ficient image quality for contouring. There was a mean percent de-
crease of 24.8% by fraction 16 and 37.2% by fraction 26. Average 
tumour migration was 0.4cm. Progressive anatomical changes were 
more prominent where there was tumour associated with atelecta-
sis. Updated results for the whole cohort will be presented.
Conclusion: Tumour regression was observed in all patients and a 
proportion showed significant reduction. Adaptive planning was a 
feasible option in selected patients.
Keyword: Adaptive radiotherapy planning, lung
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P2.08-023 INTENSITY-MODULATED RADIATION THERA-
PY FOR INOPERABLE NON-SMALL CELL LUNG CANCER: 
EXPERIENCE AT SAMSUNG MEDICAL CENTER
Jae Myoung Noh, Jin Man Kim, Yong Chan Ahn, Hongryull Pyo, 
Bokyoung Kim, Dongryul Oh, Sang Gyu Ju, Jin Sung Kim, Jung Suk 
Shin, Chae-Seon Hong, Hyojung Park, Seung Won Seol
Department Of Radiation Oncology, Samsung Medical Center, Sungky-
unkwan University School Of Medicine/Korea
Background: Intensity-modulated radiation therapy (IMRT) is not 
covered by national health insurance in Korea until yet. This study 
is to retrospectively evaluate the clinical outcomes following IMRT 
in the patients with inoperable non-small cell lung cancer (NSCLC).
Methods: From May 2010 to November 2012, 43 patients with 
newly diagnosed, pathologically confirmed NSCLC, who seemed 
to be at excessive risk of pulmonary toxicity if treated with con-
ventional radiation therapy (RT) techniques based on their disease 
extent and pulmonary function status, received IMRT. The median 
age was 58 (35~80) years. Clinical stages were IIIA in 7 (16.3%) and 
IIIB in 36 (83.7%) patients, where 26 patients (65.1%) had supracla-
vicular nodal metastases. Thirty-six (83.7%) received concurrent 
chemotherapy during IMRT. The most common chemotherapy 
regimen was weekly docetaxel plus cisplatin (N=18), followed by 
weekly paclitaxel plus cisplatin (N=11). Simulation with 4-dimen-
sional CT was done in 27 patients (62.8%). RT was delivered with 
6-MV photon beams using step-and-shoot IMRT method. The me-
dian RT dose was 66 Gy in 33 fractions. The median clinical target 
volume was 357.5 (89.3~881.2) cm3, and elective irradiation to the 
uninvolved lymphatics was not added. Normal tissue constraints 
were as follow: maximum spinal cord dose was <46 Gy; relative 
lung volumes receiving 20 Gy/5 Gy were <35%/65%; and mean 
lung dose was <20 Gy. Early toxicities including treatment-related 
pneumonitis (TRP) and esophagitis were graded using the CTCAE 
version 4.0. In-field locoregional control (LRC), progression-free 
survival (PFS), and overall survival (OS) were estimated by the 
Kaplan-Meier method.
Results: At median follow-up of 11.6 (2.3~39.6) months, 30 
patients (69.8%) experienced disease progression: distant me-
tastases in 23 patients (53.5%); and locoregional relapse in 13 
patients (30.2%) (Figure). Among 13 patients who experienced 
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intent radiotherapy for lung cancer. All 4DCT scans accessible 
from patients scanned between December 2009 and May 2013 
were included. Images were analysed using the MIM v5.6 software. 
Tumour volumes were delineated by a single observer and propa-
gated to include all 10 phases of the respiratory cycle. Movements 
were tracked in the superior-inferior (SI), anterior-posterior (AP) 
and medio-lateral (ML) directions by changes in the gross tumour 
volume centroid coordinates. Tumour motion characteristics were 
correlated with anatomical lobe, pulmonary zone, tumour volume, 
histopathology, spirometry and T-stage. Tumours with chest wall or 
mediastinal invasion were excluded. Statistical analyses were per-
formed using Prism v6.0.
Results: Preliminary data from 82 patients showed the greatest 
mean movement in the SI direction among lower lobe tumours 
compared to those located in the upper lobes [Left lower, 8.0mm, 
n = 13, vs. Left upper, 1.3mm, n = 24] [Right lower, 6.4mm, n = 
19, vs Right upper, 1.9mm, n = 28], p < 0.01. In all lobes, mean 
movements were similar in the AP [1.6mm, Right lower; 2.1mm, 
Right middle; 1.8mm, Right upper; 2.3mm, Left lower; 1.6mm, 
Left upper] and lateral directions [0.9mm, Right lower; 2.4mm, 
Right middle; 1.2mm, Right upper; 1.5mm, Left lower; 1.2mm, 
Left upper]. 35 patients were staged as T1, 30 as T2 and 14 as 
T3. Mean lung tumour motion decreased with increasing T stage 
in the SI direction [3.9mm, T1; 3.7mm, T2; 3.5mm, T3], however 
this was not statistically significant. Assessment of the associati-
on between tumour motion and spirometry findings is ongoing. 
Conclusion: The degree of lung tumour motion varies widely ac-
cording to its position within the lung. The largest differences in 
tumour motion was between the upper and lower lobes in the SI 
direction. Analysis of all 100 patient datasets is ongoing.
Keywords: four dimensional computed tomography, Radical radio-
therapy, Respiratory induced tumour motion, Anatomical lobe
of severe radiation pneumonitis (RP) compared to three-dimensi-
onal conformal radiotherapy (3D-CRT) and whether introducing a 
new dose constraints to the V5 (V5 = 60%) would reduce the inci-
dence and/or severity of radiation pneumonitis.
Methods: The control group included 105 patients with patho-
logically confirmed inoperable stage III NSCLC receiving radical 
radiotherapy (60-66Gy in 2Gy/fraction) between 2007 and 2009, at 
our department using 3D-CRT. The Study group included ninety 
consecutive matching patients receiving the same radical dose of 
radiotherapy using IMRT in the period January 2011 to June 2012. 
The first 35 patients (group I) were treated with standard dose 
constrains on MLD (maximum 20 Gy) and V20 (Maximum 40%). In 
group II including 55 patients, a new dose constraint to V5 was 
introduced (maximum 60%). All patients were seen weekly under 
radiotherapy, 6 weeks after, and then with 3 months intervals. Ra-
diation Pneumonitis was graded using CTC 3.3. The clinical and 
dosimetric parameters related to RP were analysed using SPSS.
Results: IMRT was delivered using 4 to 8 beam arrangements. The 
incidence of grade 3 or more RP in the control group reciving 3D 
conformal radiotherapy was 16.3% (2% lethal). This was increased 
to 33% (14% lethal) in group I. Introducing a new dose constrain for 
the volume receiving low dose (V5) reduced the incidence of se-
vere radiation pneumonitis to less than 10% (0% lethal) in group II. 
Neither the Mean Lung Dose nor the volume receiving 20 Gy (V20) 
values were significantly different in the 3 groups.
Conclusion: Irradiating large lung volumes with low radiation do-
ses of 5 Gy or more is associated with higher incidence of severe 
pneumonitis that is potentially lethal despite respecting the V20 
and MLD constraints. Using IMRT in patients with large tumours 
especially if receiving concurrent chemotherapy should be perfor-
med with caution. The cut level of V5 of 60% was applied in our 
department and was found feasible.
Keywords: radiation pneumonitis, Stage III NSCLC, clinical re-
search, chemo-radiotherapy
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P2.08-025 A STUDY OF RESPIRATORY-INDUCED TU-
MOUR MOTION BASED ON ANATOMICAL LUNG LOCA-
TION USING 4DCT IN LUNG CANCER PATIENTS
Kevin V.S. Tan1, Roshini Thomas1, Nicholas Hardcastle1, Daniel 
Pham1, Tomas Kron2, Farshad Foroudi1, David Ball3, Shankar Siva1
1Radiation Oncology, Peter MacCallum Cancer Centre/Australia, 2Medi-
cal Physics, Peter MacCallum Cancer Centre/Australia, 3Division Radia-
tion Oncology, Peter MacCallum Cancer Centre/Australia
Background: Respiratory induced tumour motion is one of several 
challenges encountered when delivering radical radiotherapy to 
lung cancer patients. In recent years, four-dimensional computed 
tomography (4DCT) has improved our ability to accurately define 
lung tumour motion during breathing. Using 4DCT images, our 
study aims to compare the magnitude of lung tumour motion due 
to respiration, amongst different anatomical lobes and pulmonary 
zones. This may help guide personalised radiotherapy margins for 
patients with lung cancer.
Methods: This is a retrospective study of 100 consecutive patients 
from the Peter MacCallum Cancer Centre treated with curative 
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P2.08-027 ATLAS SEGMENTATION FOR LUNG STEREOT-
ACTIC ABLATIVE RADIOTHERAPY
Jeffrey Barber, Jonathan Sykes, Sean White, Roland Yeghiaian-
Alvandi, Fiona Hegi-Johnson, Kylie Unicomb, Katherine Small, 
Kevin Van Tilburg
Radiation Oncology, Nepean Cancer Care Centre/Australia
Background: With the high radiation dose used in stereotactic 
ablative body radiotherapy (SABR), it is vital to accurately delineate 
radiosensitive normal tissues in the planning process such that the 
dose distributions can be optimised to avoid these regions. This 
can become a time consuming process. It is also well understood 
that there is variation in how these volumes are delineated and this 
has influence on the plan and follow-up data. This work aims to 
determine if the use of automatic atlas segmentation can help to 
quickly and accurately delineate CT volumes for SABR planning - 
saving time, reducing complexity and improving the uniformity of 
process between patients.
Methods: From a retrospective sample of 5 patients delineated 
by an oncologist, each patient’s CT scan and contours was used 
as an atlas for a deformable image registration to map volumes to 
the other patients. A range of quantitative metrics (based on both 
overlap and distance) were used to evaluate the agreement bet-
ween the expert contours and the atlas contours for each.
Results: The Dice similarity co-efficient showed overlap varied de-
pending on the structure – lungs and heart performed well with a 
mean of 90% (range 71 – 99%) while the airway structures (trachea, 
oesophagus, proximal bronchi) performed poorer, with a mean of 
52% (range 17 – 99%). This indicates while some structures are well 
suited to atlas segmentation, some are not. The mean Hausdorff 
distance, indicated that contours requiring editing after applying 
the atlas, had mean Hausdorff distances on the order of 1 mm. Ty-
pically, atlases that did not perform acceptably had a mean Haus-
dorff distance > 3 mm indicating it was better to start again with 
manual delineation. From the sample of 5 atlases, none performed 
significantly better than the others across all cases.
Conclusion: The use of atlases could potentially encourage con-
sistency in delineation and could reduce the laborious task of 
delineation for lung SBRT treatment planning, however editing of 
contours is still required. Larger structures performed well, how-
ever they could also be easily delineated with threshold-based 
automatic segmentation. Further investigation to develop a bank 
of representative atlases may improve performance.
Keywords: Stereotactic ablative body radiotherapy, radiotherapy 
treatment planning, atlas segmentation
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P2.08-026 PROSPECTIVE STUDY OF STAGE I NON-
SMALL-CELL LUNG CANCER TREATED WITH HYPO-
FRACTIONATED SIB IMRT
Wei Zhang, Baosheng Li, Tao Zhou, Zhongtang Wang
Radiation Oncology, Shandong Tumor Hospital/China
Background: To analyze the effects of hypofractionated-simul-
taneous integrated boost-intensity modulated radiation therapy 
(Hypo-SIB-IMRT) on medically inoperable patients with stage I 
non–small-cell lung cancer (NSCLC).
Methods: 65 qualified patients from December 2003 to Novem-
ber 2012 at three centers in China were included, with a median 
follow-up time of 39 months. Hypo-SIB-IMRT was delivered in 15 
fractions with iGTV 75Gy, CTV 60Gy, and PTV 45Gy in 3 weeks. 
The slow computer tomography (CT) scan, conventional planning 
CT scan with active breath control (ABC), 18fluorodeoxyglucose-
position emission tomography (18FDG-PET) scan, or four dimensi-
onal CT scan (4D CT) were employed to do simulation. During the 
treatment, electrical port imaging device (EPID) or cone beam CT 
(CBCT) were performed 2-3 times per week to verify the reprodu-
cibility of the targets. All IMRT plans were optimized with Pinnacle 
or Eclipse systems using heterogeneity correction.
Results: The 1-, 3- and 5-year overall survivals (OS) were 100%, 
87% and 58%, respectively with a median survival of 66.5 months. 
The 1-, 3- and 5-year progression free survivals (PFS) were 98%, 
83% and 74%, while cancer-specific survivals (CSS) were 100%, 
92% and 73%, respectively. The distant metastasis-free survivals 
(DMFS) were 98%, 85% and 76%, meanwhile local control (LC) were 
100%, 93%, and 91%, respectively. There were no significant dif-
ferences in OS, PFS, CSS, DMFS and LC compared with stage (IA 
vs. IB) or gross tumor volume (GTV>20 cm
3 vs.≤20 cm3). However, 
patients with T1 tumors (stage IA) were inclined to better survivals 
than those with T2a (stage IB) ones, and local relapses were more 
frequent for larger GTVs. 18.5% (12/65) had grade 1or 2 radiation 
pneumonitis (RP), and only 1.5% (1/65) grade 1 esophagitis. Of 12 
patients with RP, 10.8% (7/65) developed grade 1 radiation pulmo-
nary fibrosis (RPF).
Conclusion: Due to the favorable long-term OS, PFS, CSS, DMFS, 
LC in addition to the minimal toxicities for medically inoperable 
stage I NSCLC patients, Hypo-SIB-IMRT presented in this prospec-
tive study may be an option to stereotactic body radiotherapy.
Keywords: non-small cell lung cancer, hypofrantionation radiothe-
rapy, SIB IMRT, early stage
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judged that toxicities were acceptable and consistent with what 
was expected. Study is ongoing with 44 enroled patients currently.
Conclusion: The interim analysis of a phase II study of CRT in fit el-
derly patients with no resecable locally advanced NSCLC assessed 
by SGA showed an acceptable toxicity. Results will be upgraded 
for the congress.
Keywords: locally advanced NSCLC, Elderly Patient, concurrent 
chemo-radiothérapy
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P2.09-002 PROGNOSTIC IMPACT OF CONVENTIONAL 
AND MODIFIED MEASUREMENT OF MEDIASTINAL 
LYMPH NODE INVOLVEMENT IN THE OUTCOME OF 
PATIENTS WITH RESECTED LOCALLY ADVANCED NON-
SMALL CELL LUNG CANCERS PREVIOUSLY TREATED 
WITH INDUCTIVE CHEMO OR CHEMORADIATION
Diego Marquez-Medina1, Ariadna Gasol-Cudos1, Antonio Martin-
Marco1, Jose Miguel Duran Alhama2, Angeles Montero-Fernandez3
1Medical Oncology, University Hospital Arnau De Vilanova/Spain, 
2Pneumology, University Hospital Arnau De Vilanova/Spain, 3Patholo-
gy, Royal Brompton And Harefield Trust/United Kingdom
Background: Mediastinal lymph node involvement (MLNI) is the 
strongest prognostic factor of resected locally advanced non-small 
cell lung cancers (LA-NSCLC). The 7th edition of the TNM is based 
in purely topographic criteria: N2 is applied for ipsilateral MLNI 
and N3 for contralateral and unresectable MLNI. Different authors 
have proposed many other prognostic classifications of MLNI
Methods: We retrospectively reviewed 45 resected LA-NSCLC 
previously treated with inductive chemo or chemoradiation in our 
center between October-2004 to June-2012. Three patients died 
due to early surgical complication were not analyzed. Systematic 
mediastinal dissection was performed in all of them. The pro-
gnostic impact of pN2 was statistically compared to number of 
resected nodes; number of affected areas; number of metastatic 
nodes; and ratio of metastatic/resected nodes
Results: Our series included 37 men and 5 women with a mean 
age of 64.64 years-old. There were diagnosed eight non-specified 
NSCLC, two adenocarcinomas, and 32 squamous carcinomas. Cis- 
and carboplatin-based chemotherapy was administered in 35 and 
seven patients, respectively. Concurrent radiation was administe-
red in 21. pN2 MLNI clearly worsened both disease free (DSF) and 
overall survival (OS) of the patients (p= 0.006; and p= 0.018, res-
pectively). Proportion of patients with pN2 MLNI was lower when 
radiation was applied (p= 0.033) and did not significantly vary ac-
cording to chemotherapeutic regimen or histology. The number of 
resected nodes did not impact on survival (DFS p= 0.261, and OS 
p= 0.277), but OS was better in patients with a lower rate of pa-
thologically detected nodes (p= 0.046). The number of metastatic 
nodes according to the Tokio score did not impact on survival. The 
Regina Elena and the Mount Sinai ratios of metastatic nodes accor-
ding to the number of resected nodes neither impacted
Conclusion: The presence of pN2 MLNI according to the 7th 
edition of the TNM classification is the strongest mediastinal 
prognostic factor in our series of resected LA-NSCLC previously 
treated with inductive chemo or chemoradiation. No other tes-
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P2.09-001 PHASE II STUDY OF CONCURRENT CHEMO-
RADIOTHERAPY (CRT) WITH WEEKLY CISPLATINUM 
PLUS ORAL VINORELBINE IN FIT ELDERLY PATIENTS 
WITH NONRESECTABLE LOCALLY ADVANCED NON-
SMALL-CELL LUNG CANCER (NSCLC) ASSESSED BY 
STANDARDIZED GERIATRIC ASSESSMENT (RACCOSA, 
GFPC 08-06 STUDY): INTERIM ANALYSIS.
Chrystele Locher1, Nicolas Pourel2, Herve Le Caer3, Henry Berard4, 
Jean-Bernard Auliac5, Laurent Greillier6, Isabelle Monnet7, Lionel 
Falchero8, Gilles Quere9, Jacky Crequit10, Pascal Thomas11, Alain 
Vergnenegre12
1Service De Pneumologie, Centre Hospitalier Saint Faron/France, 2Ra-
diation Oncology, Institut Sainte-Catherine/France, 3Centre Hospitalier 
De Draguignan/France, 4Pneumology, Hôpital D‘instruction Des Ar-
mées Sainte-Anne/France, 5Pneumology, Centre Hospitalier F. Quesnay/
France, 6Multidisciplinary Oncology And Therapeutic Innovations, 
Assistance Publique-Hôpitaux De Marseille, Aix Marseille University/
France, 7Service De Pneumologie, Centre Hospitalier Intercommunal De 
Creteil/France, 8Pneumology, Centre Hospitalier De Villefranche Sur 
Saône/France, 9Institut De Cancérologie De Bretagne Occidentale, Chru 
Brest/France, 10Pneumology, Ch Laennec-Creil/France, 11Centre Hos-
pitalier De Gap/France, 12Service De Pneumologie, Centre Hospitalier 
Universitaire De Limoges/France
Background: Few studies are dedicated to elderly patients with 
unresectable stage IIIA/B. We used a Standardized Geriatric As-
sessment (SGA) to select fit elderly patients and assess if this po-
pulation can benefit from standard of care, namely concurrent CRT.
Methods: The aim of this multicentric phase II opened-study 
was to assess CRT in patients older 70 years with locally advan-
ced NSCLC, evaluated as “fit” according to SGA.CRT associated 
oral vinorelbine (30 mg/m²/week) and IV cisplatinum (30 mg/m²/
week) during 6 weeks concurrently with radiotherapy (66 Gy, 33 
fractions, 6,5 weeks). Main inclusion criterias were : PS ≤ 1, weight 
loss < 10%, creatinine clearance ³ 50 ml/mn abreviated, VEMS ³ 
40%, PaO2 ³ 60 mm Hg, KCO ³ 60% and patient classified as fit 
according to SGA. The principal end-point was early treatment 
tolerance (number of patients with adverse event grade ³ 3 (except 
nausea and vomiting) or grade 4 for hematologic toxicity and as-
thenia. Secondary end-points were RECIST response 4 weeks after 
treatment, quality of life, tolerance, progression-free survival and 
overall survival. Using a Simon‘s optimal plan in 2 steps, the total 
number of patients to be included was 59 with an intermediate 
analysis after 19 patients. Toxicities and serious adverse events 
were monitored by an independent peer committee.
Results: Interim analysis was done after 23 inclusions in 19 evalua-
ble patients: males 84% , mean age 74.6 (70 to 83) years, 3 patients 
didn’t end the treatment (1 disease progression, 1 cons-indication 
for radiotherapy, 1 patient choice). Four patients had adverse 
event ≥ 3 (except nausea and vomiting) or grade 4 hematologic 
toxicity and asthenia. Treatment efficacy was: 1 RC, 10 RP, 5 SD, 
1 PD. Two patients were not evaluable (1 early death, 1 patient’s 
refusal to further treatment). The independent peer committee 
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P2.09-003 CONCURRENT CHEMORADIATION (CCHRT) 
FOR STAGE III NON-SMALL CELL LUNG CANCER  
(NSCLC): A PHASE II STUDY FROM THE GALICIAN  
LUNG CANCER GROUP.
Joaquin Casal1, C Ponte2, C Senin1, B Campos3, Xl Fírvida4, M Carmo-
na5, E Hernández6, Md López7, I Formoso2, M Lázaro1, S Vázquez3,  
Mc Areses4, C Rodriguez5, C Pena8, Mj Villanueva1
1Oncoloxía Médica, Complexo Hospitalario Universitario De Vigo/Spain, 
2Oncoloxia Radioterápica, Complexo Hospitalario Universitario De Santia-
go/Spain, 3Oncoloxia Médica, Hospital Universitario Lucus Augusti/Spain, 
4Oncoloxia Médica, Complexo Hospitalario Universitario De Ourense/Spain, 
5Oncoloxia Médica, Complexo Hospitalario Universitario De Santiago/Spain, 
6Oncoloxia Radioterápica, Complexo Hospitalario Universitario De Vigo/
Spain, 7Oncoloxia Radioterápica, Complexo Hospitalario Universitario De Ou-
rense/Spain, 8Oncoloxia Médica, Complexo Hospitalario De Pontevedra/Spain
Background: Combined cytotoxic chemotherapy and radiation thera-
py is established as the standard treatment for patients with medically 
inoperable or technically unresectable stage III NSCLC. Multiple ran-
domized studies and meta-analyses demonstrate that CChRT results 
in improved survival compared with sequential chemo-radiotherapy or 
radiotherapy alone. The aim of our study was to evaluate the effective-
ness and toxicities of CChRT with bi-weekly Docetaxel (D) and Cisplatin 
(C) and thoracic radiotherapy, after one cycle D-C induction chemothe-
rapy.
Methods: Between May 2009 and November 2012, 53 chemo-naive p 
with histologically confirmed inoperable locally advanced NSCLC, sta-
ge IIIAN2/IIIB (no pleural T4), PS 0-1 and adequate lung function (FEV1 
> 1.1, V20 < 25%) were included: one cycle of D 75 mg/m2 on day 1 
and C 40 mg/m2 days 1-2 followed at 21 days by CChRT with bi-weekly 
D 40 mg/m2 and C 40 mg/m2 for four courses, during conformal thora-
cic radiotherapy (66 Gys, 180 cGy/day). The primary objective was ove-
rall survival (OS); secondary objectives were progression free survival 
(PFS), response rate (RR) and toxicity. Median follow-up: 17,8 months.
Results: The p characteristics were: mean age 59,4 years (34-75); male/
female 47/6; ECOG PS 0/1 in 17/36 p; squamous/adeno/large cell car-
cinoma: 53%/34%/13%; stage IIIAN2 15 p (28.3%) and stage IIIB 38 p 
(71.7%). All p were evaluable for response and toxicity. RR: 6 CR, 37 PR 
(RR 81.8%; 95% CI:71-92), 4 SD (7.6%) and 6 PD (11.3%). The median PFS 
was 14 months (95% CI:11-17) and median OS was 21 months (95% CI:9-
32). The PFS at 1/2 years were 55%/32% and the OS at 1/3 years were 
82%/50%. A total of 53 cycles of D-C induction chemotherapy were 
given; main toxicities (NCI-CTC 3.0) per p Grade (g) 1-2/3-4 (%) were as 
follows: neutropenia 1.8/15; anemia 11.3/0; nausea/vomiting 26.4/1.8; 
diarrhea 22.6/3.7; fatigue 35.8/0; there were three episodes of hospita-
lization: febrile neutropenia 2 p and g3 diarrhea 1p. Main toxicities per 
p in CChRT (D-C doses: 203, 3.8 per p; mean doses RT: 64,6 Gys) were 
g1-2/3 (%): neutropenia 28.3/5.6; anemia 62.2/0; esophagitis 50.9/3.7 
and pneumonitis 32/0; nausea/vomiting 20.7/0; fatigue 37.7/3.7; there 
were four episodes of hospitalization: febrile neutropenia, 2 p and g3 
esophagitis, 2 p.
Conclusion: CChRT with bi-weekly Docetaxel and Cisplatin and tho-
racic radiotherapy is a feasible treatment option for inoperable locally 
advanced stage III NSCLC, showing good clinical efficacy and tolerabi-
lity with acceptable long-term survival.
Keywords: Concurrent Chemoradiation, Stage III non-small cell lung 
cancer
ted classification of MLNI could predict significant differences in 
survival. The prognostic significance of the lower detection rate 
of resected nodes after inductive treatment should be explored. 
Figure 1. DFS and OS Kaplan-Meier curves according to MLNI. 
Keywords: non-small cell lung cancer, Combined modality, lymph 
node invasion, Prognosis
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therapy and radiotherapy, and was feasible, very well tolerated, 
and provided efficacy. The survival outcome with concurrent che-
moradiotherapy was notably longer than anticipated.
Keywords: poor-risk patients, Stage III NSCLC, chemoradiation
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P2.09-005 CISPLATIN, S-1 AND CONCURRENT THORA-
CIC RADIOTHERAPY FOR LOCALLY ADVANCED NON-
SMALL-CELL LUNG CANCER: A PHASE II STUDY OF 
OKAYAMA LUNG CANCER STUDY GROUP 0501
Hiroshi Ueoka1, Katsuyuki Hotta2, Tadashi Maeda1, Keisuke Aoe1, 
Kenichi Chikamori1, Daizo Kishino1, Naoyuki Nogami3, Nagio Ta-
kigawa4, Mitsune Tanimoto2, Katsuyuki Kiura2
1Medicine, National Hospital Organization, Yamaguchi-Ube Medical 
Center/Japan, 2Department Of Respiratory Medicine, Okayama Uni-
versity Hospital/Japan, 3Department Of Thoracic Oncology, Shikoku 
Cancer Center/Japan, 4Medicine, Kawasaki Medical School, Kawaski 
Hospital/Japan
Background: Concurrent chemoradiotherapy is the standard 
treatment for locally advanced non-small-cell lung cancer (LA-
NSCLC). However, its cure rate remains unsatisfied, and further 
improvement in the treatment outcome is strongly warranted. S-1 
(S), an oral fluoropyrimidine, is a new active agent possessing a 
radio-sensitizing effect. Additionally, combining S and cisplatin (P) 
offered an active and safe regimen for metastatic non-small-cell 
lung cancer. The objective of this study was to assess the efficacy 
and safety of S plus P with concurrent thoracic radiotherapy (TRT) 
for LA-NSCLC.
Methods: Patients with stage IIIA/IIIB, aged ≤75 years and PS 0-1, 
and without any prior chemotherapy were eligible for this study. 
Patients were treated with P (40 mg/m² on day 1, 8, 29 and 36) and 
S (40 mg/m²/dose b.i.d. on days 1-14 and 29-42) and TRT (60 Gy/30 
fr over 6 weeks starting on day 1). Primary endpoint was respsonse 
rate, and required sample size was 48 patients.
Results: Between 2006 and 2009, 48 patients were enrolled (37 
men; median age, 66 years; PS 0/1, 36/14; IIIA/IIIB, 23/25; sq/non-
sq, 22/26). Partial response was observed in 37 patients (77%; 95% 
confidence interval: 63-88%). At a median follow-up of 54 months 
for the surviving patients, median progression-free survival and 
median survival time were 9.3 months and 31.3 months, respec-
tively. No difference in efficacy (response and survivals) was obser-
ved stratified by histology (sq vs. non-sq). Toxicities were generally 
mild, including G3/4 neutropenia (44%), G3/4 thrombocytopenia 
(13%), G3 febrile neutropenia (8%) and G3 pneumonitis (4%). No 
one developed Gr3/4 esophagitis. No toxic deaths have occurred.
Conclusion: This chemoradiotherapy regimen yielded a favorable 
overall survival data. Also, it was well-tolerated in patients with 
LA-NSCLC as compared with concurrent docetaxel plus P with TRT 
therapy especially in term of TRT-related toxicities.
Keywords: cisplatin, S-1, non-small-cell lung cancer, chemoradio-
therapy
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P2.09-004 PHASE II STUDY OF SEQUENTIAL VERSUS 
CONCURRENT CHEMOTHERAPY AND RADIOTHERAPY 
IN POOR RISK PATIENTS WITH INOPERABLE STAGE III 
NON-SMALL CELL LUNG CANCER (NSCLC): FINAL RE-
SULTS OF THE SPANISH LUNG CANCER GROUP 00-05 
STUDY
Felipe Cardenal1, Maria Dolores Arnaiz2, Dolores Isla3, Javier Va-
lencia4, Manuel Domine5, Ana Maria Perez-Casas6, Nuria Viñolas7, 
Francesc Casas8, Inmaculada Maestu9, Carlos Mesia10, Ramon 
Garcia-Gomez11, Javier Perez Martin12
1Medical Oncology, Institut Català D’Oncologia/Spain, 2Radiation On-
cology, Institut Català D’Oncologia/Spain, 3Medical Oncology, Hospital 
Clinico Lozano Blesa/Spain, 4Radiation Oncology, Hospital Clinico 
Lozano Blesa/Spain, 5Medical Oncology, Fundación Jimenez Diaz/Spain, 
6Radiation Oncology, Fundación Jimenez Diaz/Spain, 7Medical Oncolo-
gy, Hospital Clinic/Spain, 8Radiation Oncology, Hospital Clinic/Spain, 
9Medical Oncology, Hospital Virgen De Los Lirios/Spain, 10Medical On-
cology, Hospital Del Mar/Spain, 11Medical Oncology, Hospital Gregorio 
Marañón/Spain, 12Clinical Research Unit, Institut Català D’Oncologia/
Spain
Background: Inoperable stage III NSCLC is increasingly diagnosed 
in poor-risk patients for whom there is not yet a standard treat-
ment. We conducted a randomized two-stage phase II study to 
assess whether sequential or concurrent chemoradiation was feasi-
ble, tolerable and showed efficacy.
Methods: Patients with inoperable stage IIIA and B NSCLC and at 
least one of the following conditions: age ≤ 75 years, ECOG PS=2, 
weight loss > 5%, creatinine clearance < 60 ml/min, a comorbid 
condition precluding the patient from being treated in a protocol 
for fit patients,were randomized to receive either carboplatin AUC 
2.5 and vinorelbine 15 mg /m2 both on days 1,8,22, and 29, and 
thoracic radiotherapy (TRT) total dose 60 Gy starting day 1 (CT 
arm) or, carboplatin AUC 5, days 1 and 22 and vinorelbine 25 mg/
m2 days 1, 8, 22, and 29, followed by TRT 60 Gy starting day 43 to 
50 (ST arm). The primary end-point was response rate.
Results: From June 2001 to June 2006, 70 patients from 8 centers 
were included : 47 in CT arm and 23 in ST arm. Forty-eight of the-
se patients were randomized during the first stage of the trial. By 
September 2004, due to a decrease in treatment compliance and 
an increase in early deaths in the ST arm, accrual was continued 
in the second stage of the trial only in the CT arm. Patient charac-
teristics: median age 74 (49-84), Male 96%, Stage IIIB 65%; ECOG 
=2, 28%; Weight loss >5%, 29%; Creatinine clearence <60, 26%; 
Comorbidity, 70%. More than one poor risk inclusion criteria: 59 
%. Fifty-eight patients completed treatment 93 % in CT arm, and 
73% in ST arm. There were 2 CR and 25 PR (RR 60%) in CT arm, 
and 10 PR (RR 45.5%) in ST arm. Grade 3- 4 hematological toxicity 
was absent in CT arm and was 14% (neutropenia) in ST arm. Grade 
3 and 4 non-hematological toxicities experienced by more than 5% 
of patients were asthenia (7%) and dyspnea (9%) in CT arm and an-
orexia (9%), asthenia(14%), and dyspnea (14%) in ST arm. Only one 
patient developed grade 3 esophagitis (CT arm) There were five 
deaths during treatment: two in CT arm and three in ST arm. Medi-
an PFS and overall survival rate were 6.7 (95% CI:4.9-8.5) and 16.8 
months (95% CI 9.5-24), and 7.9 (95% CI:3.9-16.2) and 5.6 months 
(95% CI:2.7-8.9 ), for the CT arm and ST arm, respectively.
Conclusion: In poor-risk patients with inoperable stage III NSCLC, 
concurrent chemoradiotherapy outperformed sequential chemo-
S851Copyright © 2013  by the International Association for the Study of Lung Cancer
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P2.09-007 COMPARISON OF TOXICITY AND OUTCOMES 
OF CONCURRENT RADIOTHERAPY WITH CARBOPLA-
TIN/PACLITAXEL AND CISPLATIN/ETOPOSIDE IN STAGE 
III NON-SMALL CELL LUNG CANCER
Mun Sem Liew1, Joseph Sia2, Maud H.W. Starmans3, Ali Tafreshi1, 
Sam Harris1, Malcolm Feigen2, Shane White1, Allan Zimet1, Philip-
pe Lambin4, Paul Boutros3, Paul Mitchell1, Thomas John1
1Joint Austin-ludwig Oncology Unit, Austin Health/Australia, 2Depart-
ment Of Radiation Oncology, Austin Health/Australia, 3Informatics And 
Biocomputing Platform, Ontario Institute For Cancer Research/Canada, 
4Department Of Radiation Oncology (Maastro), Maastricht University 
Medical Center/Netherlands
Background: Concurrent chemoradiotherapy (CCRT) has become 
the standard of care for patients with unresectable stage III non-
small cell lung cancer (NSCLC). The comparative merits of two 
widely used regimens: carboplatin/paclitaxel (PC) and cisplatin/
etoposide (PE), each given with concurrent radiotherapy, remain 
largely undefined.
Methods: Records for consecutive patients with stage III NSCLC 
treated with PC or PE and ≥60Gy chest radiotherapy between 
2000-2011 were reviewed for outcomes and toxicity. Survival was 
estimated using the Kaplan-Meier method and Cox modeling with 
the Wald test. Comparison across groups was done using the stu-
dent t and chi-squared tests.
Results: 75 (PC: 44, PE: 31) patients were analyzed. PC patients 
were older (median 71 vs 63 years; p=0.0006). Other characteris-
tics were comparable between groups. With PE, there was signifi-
cantly increased grade ≥3 neutropenia (39% vs 14%, p=0.024) and 
thrombocytopenia (10% vs 0%, p=0.039). Radiation pneumonitis 
was more common with PC (66% vs 38%, p=0.033). Five treatment 
related deaths occurred (PC: 3 vs PE: 2, p=1.000). With a median 
follow up of 51.6 months, there were no significant differences in 
relapse free survival (median PC 12.0 vs PE 11.5 months, p=0.700) 
or overall survival (median PC 20.7 vs PE 13.7 months; p=0.989). In 
multivariate analyses, no factors predicted for improved survival 
for either regimen. Table 1: Non-hematological and hematologi-
cal adverse events, by grade (CTCAE 4.0)  
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P2.09-006 LONG-TERM RESULTS OF A PHASE II TRIAL 
OF S-1 AND CISPLATIN WITH CONCURRENT THORACIC 
RADIOTHERAPY FOR LOCALLY ADVANCED NON-SMALL 
CELL LUNG CANCER
Tateaki Naito1, Nobuyuki Yamamoto2, Fumiyoshi Ohyanagi3, 
Takeshi Horai3, Atsushi Horiike3, Takuyo Kozuka4, Haruyasu 
Murakami1, Hideyuki Harada5, Toshiaki Takahashi1, Yukiko Naka-
mura6, Makoto Nishio3
1Division Of Thoracic Oncology, Shizuoka Cancer Center/Japan, 2Third 
Department Of Internal Medicine, Wakayama Medical University/Ja-
pan, 3Department Of Thoracic Medical Oncology, The Cancer Institute 
Hospital Of JFCR/Japan, 4Radiation Oncology, The Cancer Institute 
Hospital/Japan, 5Radiation Oncology, Shizuoka Cancer Center/Japan, 
6Yokohama Municipal Hospital/Japan
Background: Concurrent chemoradiotherapy is the standard treat-
ment for unresectable stage III non-small cell lung cancer (NSCLC). 
S-1 has been shown to be significant efficacious for treating ad-
vanced NSCLC. Our previous phase II study reported short-term 
outcomes of cisplatin (CDDP)/S-1 chemoradiotherapy. Because 
CDDP/S-1 chemoradiotherapy is considered to have advantages 
over others in overall survival (OS) and toxicity, we analyzed its 
long-term outcomes by following up patients included in the pha-
se II study.
Methods: Forty-eight patients (aged <75 years) with unresectable 
stage III NSCLC were evaluated. They were treated with CDDP (60 
mg/m2 on day 1) intravenously and oral S-1 (40 mg/m2 twice daily 
on days 1–14); this regimen was repeated every 4 weeks for four 
cycles. A 60-Gy thoracic radiation dose was delivered in 30 frac-
tions beginning on day 2.
Results: After a median follow-up of 6.3 years (range, 5.7–7.4 ye-
ars), the median OS was 2.8 years [95% confidence interval (CI); 
1.04–4.63 years], and the 3- and 5-year OS rates were 49.7% (95% 
CI: 35.6%–63.8%) and 33.0% (95% CI: 20.0%–46.6%), respectively. 
Out of the several variables evaluated as predictors of OS, inclu-
ding gender, age, stage, histology, and performance status (PS), 
only PS proved to be a statistically significant predictor in both 
univariate and multivariate analyses.
Conclusion: CDDP/S-1 concurrent thoracic radiotherapy is clini-
cally feasible and highly efficacious. Despite our relatively small 
sample size, the benefits of this regimen revealed in this study 
warrant further research.
Keywords: non-small cell lung cancer, chemoradiotherapy, S-1
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Methods: This was a single-Institution prospective phase II stu-
dy. Treatment comprised cisplatin (50 mg/m2 days 1, 8, 29, 36), 
etoposide (50 mg/m2 days 1-5 and 29-33) and concurrent tho-
racic radiotherapy starting on day 1 chemotherapy (66 Gy in 33 
daily fractions; 3D conformal radiotherapy or IMRT) followed by 
consolidation pemetrexed (500 mg/m2 on days 71, 92 and 133). 
The primary endpoint was 1 year OS. Secondary endpoints were 
progression-free survival (PFS), 2 yr OS, acute/late toxicity (CTCAE 
v3.0), compliance to treatment.
Results: 35 patients were recruited between March 2008 and 
October 2010. Median age was 61 years (range 42-76). M:F ratio 
was 23(66%):12(34%). ECOG PS was 0:1 11(31%):24(69%). Histolo-
gy: squamous 21(60%), adenocarcinoma 8(23%), undifferentiated 
4(11%), other 2(6%). Stage: IIB 1(3%), IIIA 19(54%), IIIB 15(43%). All 
35(100%) had PETCT staging. All 35 patients received concurrent 
chemotherapy (dose reduction in 3 patients) and 32 (91%) recei-
ved the planned 66Gy (range 56-66 Gy). The number of patients 
who completed pemetrexed were: cycle 1=25 (71%), cycle 2=22 
(63%), cycle 3=16 (46%). Radiation parameters: Gross Tumour 
Volume (GTV) was median 60.2 cm3 (range 11.4-274.4 cm3), V20Gy 
median 30.4% (range 10.5-35.3%), During the concurrent phase, 
grade 3/4 toxicity was noted for: neutropenia 17(49%) anaemia 
1(3%), thrombocytopenia 1(3%), infection 8(23%), fatigue 6(17%), 
nausea±vomiting 4(11%), mucositis 3(9%), anorexia 3(9%). During 
the pemetrexed consolidation phase, the only grade 3/4 toxicities 
were: infection 5(20%), anaemia 3(12%), neutropenia 2(8%) and fa-
tigue 2(8%). Acute radiotherapy toxicity (<3months): oesophagitis 
grade 3/4 10(29%) and late toxicity (>3months): pneumonitis grade 
3/4 2(7%), oesophageal stricture 2 (7%), pulmonary fibrosis 1(3%). 
Median follow up was 25months. Median OS was 34months, with 
1yr OS 77% (95% CI 60-88%), and 2yr OS 61% (95% CI 37-72%). 
Median PFS was 22months, with 1yr PFS 62% (95% CI 43-76%) and 
2yr 49% (95% CI 31-65%). Of the 14 deaths, causes were, 1 suicide 
during radiotherapy, 2 treatment-related deaths (1 grade 5 pneu-
monitis and 1 grade 5 haemoptysis) and 13 due to lung cancer.
Conclusion: In an unselected locally advanced NSCLC population, 
staged with PETCT a median survival of 34 months can be achie-
ved. The study reinforces the challenge of delivering consolidation 
chemotherapy and suggests that improved staging contributes 
to improved outcomes. Although there was failure to deliver all 
planned cycles of consolidation pemetrexed after cCTRT in 54% of 
patients, these are encouraging results that warrant further inves-
tigation.
Keywords: phase II, chemo-radiotherapy, consolidation chemo-
therapy, stage III
Adverse events PC (n = 44) PE (n = 31) 
n (%) n P
Χ2 
Esophagitis 1 
2 3 4 
3 (7) 19 (43) 10 
(23) 5 (11) 
5 (16) 7 (23) 10 
(32) 1 (3) 
0.151 
Pneumonitis 1 2 
3 4 5 
21 (48) 6 (14) 0 (0) 
1 (2) 1 (2) 
4 (13) 6 (19) 1 (3) 
1 (3) 0 (0) 
0.033 
Neuropathy 1 2 1 (2) 1 (2) 0 (0) 0 (0) 0.485 
Nephropathy 
1 2 3 
3 (7) 0 (0) 0 (0) 4 (13) 0 (0) 1 (3) 0.314 
Nausea/vomiting 
1 2 3 
7 (16) 8 (18) 0 (0) 7 (23) 2 (6) 1 (3) 0.291 
Chest infection 1 
2 3 4 5 
1 (2) 1 (2) 11 (25) 
1 (2) 1 (2) 
0 (0) 3 (10) 5 (16) 
2 (6) 1 (3) 
0.534 
Neutropenia 1 
2 3 4 
4 (9) 5 (11) 6 (14) 
0 (0) 
2 (6) 0 (0) 8 (26) 
4 (13) 
0.024 
Febrile neutro-
penia 3 4 
5 (11) 0 (0) 5 (16) 1 (3) 0.394 
Anemia 1 2 3 4 
12 (27) 5 (11) 1 (2) 
0 (0) 
10 (32) 9 (29) 0 
(0) 1 (3) 
0.117 
Thrombocytope-
nia 1 2 3 
1 (2) 3 (7) 0 (0) 4(13) 1 (3) 3 (10) 0.039 
Treatment-rela-
ted deaths 
3 (7) 2 (6) 1.000 
Conclusion: PC was more likely to be used in elderly patients. 
Despite this, PC resulted in significantly less hematological toxicity 
but achieved similar survival outcomes as PE. PC is an acceptable 
CCRT regimen, especially in older patients with multiple comorbi-
dities.
Keywords: Cisplatin/Etoposide, Carboplatin/Paclitaxel, locally 
advanced NSCLC, Concurrent chemoradiotherapy
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P2.09-008 CONCURRENT CHEMORADIOTHERAPY 
(CCTRT) FOR LOCALLY ADVANCED NON SMALL CELL 
LUNG CANCER (NSCLC) FOLLOWED BY CONSOLIDATI-
ON PEMETREXED: A PHASE II STUDY
Corinne Faivre-Finn, Paula Mccloskey, Jonathan Helbrow, Neil 
Bayman, Paul Burt, Abbas Chittalia, Maggie Harris, Lip W. Lee, 
Laura Pemberton, Hamid Sheikh, Jo Coote, Paul Taylor, Linda 
Ashcroft, Craig Scharf, Emma Halkyard, Jackie Fenemore, Tracy 
Coyne, Fiona Blackhall
The Christie NHS Foundation Trust/United Kingdom
Background: cCTRT is the current standard treatment for good 
Performance Status (PS) unresectable locally advanced NSCLC. A 
phase III study demonstrated that Docetaxel consolidation does 
not improve overall survival (OS) after cCTRT (Hanna. JCO 2008). 
The role of consolidation chemotherapy after cCTRT is still inves-
tigational and our study was set up to evaluate the role of pemet-
rexed in this setting. A less toxic consolidation chemotherapy may 
enable a higher proportion of patients to comply to planned treat-
ment which may improve outcome.
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P2.09-010 VARIATION IN THE UPTAKE OF THE COM-
BINED MODALITY PRACTICE GUIDELINE FOR SURGI-
CALLY UNRESECTABLE STAGE III NSCLC IN ONTARIO
William Evans1, Yee C. Ung2, Jennifer Stiff3, Anna Chyjek4, Aryn 
Gatto5, Angelika Gollnow6, Catherine Inibhuna7, Rebecca Anas3, 
Carol Sawka8
1Administration, Juravinski Cancer Centre And Mcmaster University/
Canada, 2Radiation Oncology, Odette Cancer Centre/Canada, 3Cancer 
Quality Council Of Ontario, Cancer Care Ontario/Canada, 4Disease Pa-
thway Management Secretariat, Cancer Care Ontario/Canada, 5Project 
Coordinator, Disease Pathway Management Secretariat, Cancer Care 
Ontario/Canada, 6Disease Pathway Secretariat, Cancer Care Ontario/
Canada, 7Informatics - Centre Of Excellence, Cancer Care Ontario/
Canada, 8Clinical Programs & Quality Initiatives, Cancer Care Ontario/
Canada
Background: Cancer Care Ontario’s (CCO) Program in Evidence-
based Care has been developing lung cancer practice guidelines 
since 1997. Based on randomized clinical trials and published 
meta-analyses, a modest but clinically significant benefit for the 
use of concurrent chemo-radiotherapy treatment (CCRT) in selec-
ted inoperable stage III NSCLC (good performance status, limited 
weight loss), was recommended in a guideline published in 2005 
and revised in 2006.
Methods: In 2008, CCO began to measure concordance with 
guidelines and to publically report regional results through the 
Cancer System Quality Index (CSQI),a web-based public reporting 
tool released annually by the Cancer Quality Council of Ontario 
(CQCO), Guideline concordance is a measure within the Effective 
quality domain of CSQI and is used to track the consistency of 
cancer treatment services across Ontario. This measure links data 
within Cancer Care Ontario’s Activity Level Reporting Enterprise 
Data Warehouse and the Ontario Cancer Registry with information 
from the Canadian Institute for Health Information’s Discharge 
Abstract Data and National Ambulatory Care Reporting System.
Results: Of 1312 patients with unresected stage III disease dia-
gnosed in 2010 and 1259 in 2011, only 30.3% and 31.8% respec-
tively received CCRT defined as radiation and chemotherapy 
given within 180 days of diagnosis. An additional 33.9% received 
an alternative form of treatment in 2011: 83.6% of these patients 
were treated only with radiation, 66% of whom had palliative 
radiotherapy while 33.4% had radical (curative) radiotherapy. In 
2010, a similar pattern of treatment was observed with 33.5% of 
cases receiving alternate treatment: 81.3% of whom received only 
radiation; 70% of these patients received palliative treatment while 
27.5% received radical radiotherapy. In 2011, 34.2% received no 
treatment, a decrease of 2% from 2010. Variation in guideline con-
cordant practice was evident between the 14 health service regi-
ons of the province (range from 23.3% to 44.5%) but only one was 
significantly greater than the Ontario rate (95% Confidence Interval 
(CI); effect size (d =0.56). Six of 14 regions had a decline in the 
concordance rate between 2010 and 2011. There was no difference 
in the rate of CCRT use by gender (28.4%) but there was a sharp 
decline in CCRT after age 65 (45% < 65 yr vs. 25% > 65 yr), (95% 
CI, 21.5-28.5; p=0001). Less CCRT was given to the lowest income 
quintile (Q)(22.9% vs. 29.9% for Q4, 95% CI 23.9-35.9; p=0.0001), 
to urban vs. rural populations (22.9% vs. 34.8%; 95% CI, 28.6-40.9; 
p=0.0001) and in those areas of the province with higher popula-
tions of immigrants (lowest tercile 28.4% vs. 18.6% for middle and 
19.0% for the highest tercile, p=0.0001).
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P2.09-009 IMPACT OF CHANGE IN HEMOGLOBIN LE-
VELS DURING TREATMENT ON PROGNOSIS IN NON-
ANEMIC LOCALLY ADVANCED NON-SMALL CELL LUNG 
CANCER PATIENTS TREATED WITH CONCURRENT CHE-
MORADIOTHERAPY
Erkan Topkan1, Cem Parlak1, Ozan C. Guler1, Berrin Pehlivan2, 
Ozgur Ozyilkan3, Ugur Selek4
1Department Of Radiation Oncology, Baskent University Medical Fa-
culty/Turkey, 2Department Of Radiation Oncology, Medstar Antalya 
Hospital/Turkey, 3Department Of Medical Oncology, Baskent University 
Medical Faculty/Turkey, 4Department Of Radiation Oncology, American 
Hospital, University Of Texas MD Anderson Radiation Oncology Cen-
ter/Turkey
Background: Purpose of this study was to evaluate the association 
between change in hemoglobin (Hb) levels during treatment and 
disease control and survival in locally advanced non-small cell lung 
cancer (LA-NSCLC) patients treated with concurrent chemoradio-
therapy (CRT).
Methods: Medical records of 368 LA-NSCLC patients, who had 
been treated with definitive CRT at our department between dates 
January 2007 and December 2011, and whose pretreatment Hb 
levels were ≥12.0 g/L, and who had at least 3 Hb measurements 
during CRT, were retrospectively evaluated. All patients received 
60-66 Gy thoracic 3-dimentional conformal radiotherapy concur-
rently with 1-3 cycle cisplatin/carboplatin-vinorelbine/taxane (q21) 
doublet chemotherapy. For all analyses, patients were divided 
into groups according to their nadir Hb level, percent Hb change, 
development of anemia (Hgb<12) and nadir Hb cut-off defined 
from ROC analysis. Primary end point was overall survival (OS), 
and secondary end points were progression-free survival (PFS) and 
locoreginal PFS (LRPFS).
Results: At a median follow-up of 24.7 months (range 19.7-27.5), 
Median OS, PFS and LRPFS for whole group were 23.8 (%95 
CI=22.8-24.8), 11.7 (%95 CI=11.0-12.5) and 15.3 months (%95 
CI=14.7-15.9), respectively. During CRT course, 138(37.5%) patients 
developed anemia, and median OS, PFS, and LRPFS were signi-
ficantly worse in these patients [(27.3 vs. 18.3; p<0.001), (12.7 vs. 
9.2; p<0.001), and (16.4 vs. 11.2 months; p<0.001)]. While there was 
no statistically significant survival difference according to median 
nadir Hb level and % Hb change, patients with Hb levels above the 
cut-off point defined from ROC curves (12.4 g/L) revealed better 
OS (27.7 vs. 20.4; p<0.001), PFS (12.8 vs. 10.2; p<0.001) and LRPFS 
(16.4 vs. 13.8 months; p<0.001). On multivariate analyses, only 
these two factors found to be independent prognostic factors 
(p<0.001 for Hb > vs. < 120 g/L, p<0.03 for Hb> vs. <ROC Hb 
cut-off).
Conclusion: Results of this study has shown that 37.5% NSCLC 
patients with normal pretreatment Hb levels had developed ane-
mia during the course of CRT, which was found to be a worse pro-
gnostic factor independent from other co-existing factors in terms 
of locoregional tumor control and survival outcome.
Keywords: change in hemoglobin (Hb) levels during treatment, 
locally advanced non-small cell lung cancer, Concurrent chemora-
diotherapy
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with induction CRT. The status of tumor location should be consi-
dered in stratification in randomized trails that estimate the impact 
of the trimodality therapy.
Keywords: N2, non-small cell lung cancer, induction chemoradio-
therapy, surgery
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P2.09-012 PROGNOSTIC VALUE OF TUMOR SURVIVIN 
EXPRESSION IN STAGE III NON-SMALL CELL LUNG CAN-
CER PATIENTS TREATED WITH PLATINUM-BASED CHE-
MORADIATION THERAPY FOLLOWED BY SURGERY
Hyeong Ryul Kim1, Hyun Jin Cho1, Young Soo Park2, Yong-Hee 
Kim1, Dong Kwan Kim1, Sang-We Kim3, Se Jin Jang2, Seung-Il Park1
1Department Of Thoracic And Cardiovascular Surgery, Seoul Asan 
Medical Center/Korea, 2Pathology, Asan Medical Center, University Of 
Ulsan College Of Medicine/Korea, 3Department Of Oncology, Asan Me-
dical Center/Korea
Background: The potential prognostic value of survivin is variably 
reported in various stage of lung cancer. This study evaluated the 
correlation between tumor survivin expression before and after 
chemoradiation therapy (CRT) and prognosis in stage III non-small 
cell lung cancer (NSCLC) patients treated with platinum-based 
chemoradiation therapy followed by surgery
Methods: Medical records from 53 patients whose tissues were 
suitable for study were reviewed. Tissues were stained by immu-
nohistochemistry and were estimated the degree of stain with 
scoring for survivin. Clinicopathologic parameters and survivin 
expression score were evaluated for a prognostic relationship with 
overall survival (OS) and time to recurrence (TTR).
Results: Pathologic complete response, residual nodal involve-
ment and radiologic response after CRT were not related with OS 
or TTR. Tumor survivin expression on pre-treatment tissues was 
presented in 47 patients (88.7%). Pre-treatment survivin score was 
not related with TTR and OS (p = 0.249 and p = 0.601, respec-
tively). There was no correlation between pre-treatment and post-
treatment survivin score (p = 0.309). Downregulation of survivin 
and post-treatment survivin score (0 – 1) after chemoradiation 
showed significant improvement in OS (p = 0.04 and p = 0.033, 
respectively). Age, downregulation of survivin score, and post-
treatment survivin score (0 – 1) were significant prognostic factors 
for survival by multivariate analysis.
Conclusion: Downregulation of survivin score and post-treatment 
low survivin score in stage III NSCLC treated with platinum-based 
chemoradiation therapy followed by surgery has a value of prog-
nostic factor regardless pre-treatment survivin score. Further stu-
dies to evaluate the relation of survivin expression and platinum-
based chemoradiation therapy are warranted in NSCLC.
Keywords: stage III, chemoradiation, survivin, Prognosis
Conclusion: Concordance with the CCO guideline on CCRT in 
Stage III unresectable NSCLC is particularly low in older, lower 
income, urban and immigrant populations. The absence of weight 
loss and performance status data makes interpretation of this data 
difficult. Further study of the reasons for these variations in practi-
ce will be necessary to inform appropriate strategies to reduce 
these inequities.
Keyword: guideline concordance, non-small cell lung cancer, 
chemo-radiotherapy
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P2.09-011 TUMOR ARISING FROM LOWER LOBES IS 
A POOR PROGNOSTIC FACTOR IN NON-SMALL CELL 
LUNG CANCER PATIENTS WITH N2 DISEASE TREATED 
WITH INDUCTION CHEMORADIOTHERAPY
Ken Suzawa1, Shinichi Toyooka1, Kazuhiko Shien1, Junichi Soh1, 
Hiromasa Yamamoto1, Kentaroh Miyoshi1, Seiichiro Sugimoto1, 
Masaomi Yamane1, Takahiro Oto1, Kuniaki Katsui2, Katsuyuki 
Kiura3, Shinichiro Miyoshi1
1Thoracic Surgery, Okayama University Hospital/Japan, 2Radiology, 
Okayama University Hospital/Japan, 3Respiratory Medicine, Okayama 
University Hospital/Japan
Background: Trimodality therapy consisting of induction chemora-
diotherapy (CRT) followed by surgery can be one of the treatment 
options for locally advanced non-small cell lung cancer (NSCLC). 
While recent randomized phase III trials failed to demonstrate a 
benefit from the addition of surgery in the entire population, the 
subset analysis of the intergroup trial 0139 indicates that trimodali-
ty therapy is beneficial for population who did not undergo pneu-
monectomy. This result strongly suggests that the status of disease 
may influence the prognosis even in same stage population. Thus, 
identifying prognostic factors and their inclusion in stratification 
are critical for the appropriate randomized study. In this study, we 
retrospectively examined the prognostic impact of tumor location 
in NSCLC patients with clinical (c-) N2 disease who underwent 
trimodality therapy in our institute.
Methods: Among patients who underwent induction CRT followed 
by surgery between 1999 and 2011 at our institution, a total of 76 
NSCLC patients with c- N2/3 stage III were enrolled for this retros-
pective study. Induction CRT basically consisted of docetaxel and 
cisplatin with concurrent radiation at a dose of 40 - 60 Gray.
Results: A total of 76 patients consisted of 53 male and 23 female, 
43 adenocarcinomas and 33 non-adenocarcinomas, and 44 c-
Stage IIIA and 32 c-Stage IIIB. Primary tumors were located in right 
upper lobe for 33 patients, right middle lobe for 5, right lower 
lobe for 11, left upper lobe for 20, and left lower lobe for 7. For all 
population, lower lobe tumors showed significantly shorter overall 
survival (OS) and disease-free survival (DFS) times compared to 
non-lower lobe tumors (OS, p = 0.022; DFS, p = 0.0007). In a multi-
variate analysis, tumor location was independent prognostic factor 
for poor prognosis. Limited to pathologically proven N2/3 disease 
before induction CRT (n = 36), location of lower lobe tend to be 
poor prognosis compared to other location (OS, p = 0.068; DFS, p 
= 0.0075).
Conclusion: We showed that tumor arising from lower lobes is a 
poor prognostic factor in NSCLC patients with N2 disease treated 
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Figure 2. Overall survival stage III < 380cc and > 380cc 
Survival: 1=PTV1 < 380 cc, 2=PTV1>380 cc (p=0.018) 
Keywords: PTV, Non small cell lung cancer, Concurrent Chemora-
diation, Overall Survival
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P2.09-014 CONCOMITANT CHEMORADIOTHERAPY 
USING DOCETAXEL AND CISPLATIN FOR UNRESECTAB-
LE STAGE III LUNG SQUAMOUS CELL CARCINOMA
Yaping Xu, Xinmin Yu, Xiaojiang Sun, Yuanda Zheng, Xianghui 
Du, Weimin Mao
Zhejiang Cancer Hospital/China
Background: Concomitant chemoradiotherapy is the standard 
treatment of unresectable stage III non-small cell lung cancer 
(NSCLC). However, the optimal chemotherapy regimen is still con-
troversial, particularly in lung squamous cell carcinoma. We have 
conducted a phase II clinical trial in a Chinese population to evalu-
ate concomitant treatment using docetaxel/cisplatin chemotherapy 
and thoracic radiotherapy followed by docetaxel/cisplatin consoli-
dation chemotherapy in unresectable stage III lung squamous cell 
carcinoma. The purpose of this study is to evaluate the feasibility 
and activity, and also assess its impact on progression-free survival 
(PFS).
Methods: A total of 32 patients were enrolled between January 
2011 and January 2013. Patients received concomitant docetaxel 
30mg/m2 on day 1 and day 8, cisplatin 25mg/m2 on day 1 to day 3 
repeated every 3 weeks for 2 cycles and thoracic radiotherapy, fol-
lowed by docetaxel/cisplatin for 2 cycles as consolidation therapy 
(docetaxel 60mg/m2 on day 1, cisplatin 25mg/m2 on day 1 to day 
3 repeated every 3 weeks). Objective response rate according to 
the RECIST criteria was recorded and toxicity was evaluated using 
the NCI Common Toxicity Criteria. The Kaplan–Meier method was 
used to evaluate patient survival. Univariate analysis of patient 
characteristics and tumor responses was conducted using the Chi-
square and Fisher’s exact test.
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P2.09-013 TREATMENT OUTCOME IN 136 PATIENTS 
(PTS) WITH INOPERABLE OR IRRESECTABLE NON-
SMALL CELL LUNG CANCER (NSCLC), STAGED WITH 
PET-SCAN, TREATED WITH CONCURRENT (CC) LOW-DO-
SE DAILY CISPLATIN AND HIGH-DOSE RADIOTHERAPY
Edith Dieleman1, Lon Uitterhoeve1, Rob V. Os1, Willemijn Kolff1, 
Caro Koning1, J T Annema2, Judith Adam3, P Symerski4, Coen 
Rasch1
1Radiation Oncology, AMC Amsterdam/Netherlands, 2Pulmonary 
Disease, AMC Amsterdam/Netherlands, 3Nuclear Medicine, AMC 
Amsterdam/Netherlands, 4Cardio-Thoracic Surgery, AMC Amsterdam/
Netherlands
Background: to analyse survival data, treatment results, toxicity 
and prognostic factors, the influence of PET-staging in the combi-
nation of daily low-dose cisplatin with high-dose radiotherapy in 
stage III NSCLC patients.
Methods: retrospective study between 2005 -2012 of PET staged 
patients with mainly stage III irresectable, locally advanced non 
small cell lung cancer. Concurent chemoradiation is given by using 
daily low-dose cisplatin (6mg/m2) combined with 24 fractions 2,75 
Gy to a total dose of 66 Gy.
Results: mean follow-up 20 months, median follow-up 15 months 
(1, 7-88). Prognostic factors at multivariate analysis are for survival: 
PTV1 < 380 cc (p=0.018), ECOG scale (p=0.09). For local control: 
PTV1 < 380 cc (p=0.031). Our data show a linear relationship bet-
ween the size of the PTV1 and survival. The median survival was 36 
months and the 5-year survival rate is 33%. The incidence of dis-
tant free survival of 5 years is 27%. The local relapse free survival 
of 5 years is 51%.
Conclusion: results for survival and local control are good and 
show a 100% increase in 5 yr overall survival compared to our 
historical control series. In our data toxicity is low. In multivariate 
analysis a low PTV volume (<380 cc) is the only significantly favo-
rable prognostic factor for local disease-free and overall survival. 
Possibilities to increase the biological radiation dose (EQD2= 74 
Gy) and/or in combination with biological response modifiers 
should be studied in the near future. Figure 1. Overall survival for 
all patients Mean follow-up 20m, median follow-up 15 m (1,7-88) 
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metastasis (5yr DFS 42.8% vs. 16.6%, p = 0.023). Grade 3 radiation 
pneumonitis and esophagitis was seen in only one patient, respec-
tively.
Conclusion: In pathological stage N2 NSCLC patients, more than 
half eventually developed distant metastasis despite adjuvant che-
motherapy. PORT increased LRC in these propensity-matched pa-
tients, but did not DFS. However, patients with multiple stations of 
mediastinal lymph node metastasis appear to benefit from PORT.
Keywords: non-small cell lung cancer, propensity score, postope-
rative radiotherapy, adjuvant chemotherapy
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P2.09-016 A FEASIBILITY STUDY OF NEOADJUVANT 
CHEMOTHERAPY WITH CISPLATIN, PEMETREXED AND 
BEVACIZUMAB FOLLOWED BY SURGERY FOR NONS-
QUAMOUS NON-SMALL CELL LUNG CANCER
Kazuya Takamochi1, Yoshihiro Miyata2, Yasuhiro Tsutani2, Kenji 
Suzuki1, Fumihiro Tanaka3, Haruhiko Nakayama4, Yoshinori Ya-
mashita5, Makoto Oda6, Masahiro Tsuboi7, Morihito Okada2
1Department Of General Thoracic Surgery, Juntendo University School 
Of Medicine/Japan, 2Department Of Surgical Oncology, Hiroshima 
University/Japan, 3Second Department Of Surgery, University Of Oc-
cupational And Environmental Health/Japan, 4Department Of Thoracic 
Surgery, Kanagawa Cancer Center/Japan, 5Department Of General 
Thoracic Surgery, Kure Medical Center/chugoku Cancer Center/Japan, 
6Department Of General And Cardiothoracic Surgery, Kanazawa Uni-
versity/Japan, 7Respiratory Disease Center (Surgery), Yokohama City 
University Medical Center/Japan
Background: Bevacizumab and pemetrexed/cisplatin improves 
the response and survival in patients with advanced or metastatic 
non-small cell lung cancer (NSCLC); however, the role of these me-
dications in the setting of induction therapy for NSCLC is not well 
defined. The purpose of this study was to evaluate the feasibility 
of induction combination therapy with cisplatin, pemetrexed and 
bevacizumab followed by surgery in patients with clinical stage II/
IIIA nonsquamous NSCLC.
Methods: Patients with clinical stage II/IIIA nonsquamous NSCLC 
were enrolled. The induction chemotherapy consisted of three 
cycles of cisplatin (75 mg/m2), pemetrexed (500 mg/m2) and beva-
cizumab (15 mg/kg) on Day 1, administered every 21 days. At least 
six weeks after the last administration of bevacizumab, the patients 
underwent surgical resection. The primary endpoint was the com-
plete resection rate after the completion of three cycles of induc-
tion chemotherapy. The sample size was set at 30. The feasibility 
of the treatment was considered to be confirmed if the complete 
resection rate was 80% (24/30) or more.
Results: A total of six institutions in Japan participated in this trial. 
The study was initiated in June 2010, and patient enrollment was 
completed in November 2012. Thirty-one patients were recruited, 
30 of which were eligible. The median age was 64 years (range: 
54-71), and the male/female ratio was 17/13. The PS0/PS1 ratio was 
29/1, the adenocarcinoma/large cell carcinoma ratio was 30/0 and 
the clinical stage IIA/IIB/IIIA ratio was 5/3/22. Grade 3 toxicities 
included neutropenia (7%), nausea (7%), appetite loss (13%), hyper-
tension (23%) and pulmonary embolism (3%). There were no grade 
4 events, and 27 (90%) patients completed three cycles at the full 
Results: Eight (25.0%) and 20 patients (62.5%) had a complete or 
partial response, respectively, while 3 patient’s disease remained 
stable and 1 patient had progression of the disease. The overall 
response rate (87.2%, 95% confidence interval (CI): 63–97%) excee-
ded the goal per study design. The median PFS was 11.0 months 
(95% CI: 5.6–16.4 months). This approach obtained likely better ef-
fects than history control group. Main toxicity (grade 3 or greater, 
%): neutropenia 10 (31.3%); thrombocytopenia 7 (21.9%); anaemia 
8 (25.0%); nausea/vomiting 5 (15.6%); anorexia 7 (21.9%), dysphagia 
4 (12.5%), radiation pneumonitis 3 (9.4%) and fatigue 4 (12.5%).
Conclusion: This data suggests that concomitant treatment with 
docetaxel/cisplatin and thoracic radiotherapy was well tolerated, 
with promising activity in a Chinese population with unresectable 
stage III lung squamous cell carcinoma. Although the data presen-
ted herewith appears promising, this study is relatively small, and 
more data from randomized trials are needed to further validate 
this regimen.
Keyword: Non-small cell lung cancer; Locally advanced; Concomi-
tant chemoradiotherapy; Docetaxel
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P2.09-015 ROLE OF POSTOPERATIVE RADIOTHERAPY 
AFTER CURATIVE RESECTION AND ADJUVANT CHEMO-
THERAPY FOR PATIENTS WITH PATHOLOGICAL STAGE 
N2 NON-SMALL CELL LUNG CANCER: A PROPENSITY 
SCORE MATCHING ANALYSIS
Hak Jae Kim1, Byoung Hyuck Kim1, Hong-Gyun Wu1, Chang Hyun 
Kang2, Young Tae Kim2, Se-Hoon Lee3
1Radiation Oncology, Seoul National University Hospital/Korea, 2Tho-
racic And Cardiovascular Surgery, Seoul National University Hospital/
Korea, 3Department Of Internal Medicine, Seoul National University 
Hospital/Korea
Background: To evaluate the role of postoperative radiotherapy 
(PORT) after curative resection and adjuvant chemotherapy for 
patients with pathological stage N2 non-small cell lung cancer 
(NSCLC).
Methods: We performed a retrospective review of 219 consecuti-
ve patients who underwent curative surgery followed by adjuvant 
chemotherapy between 2000 and 2011. Among 219 patients, 41 
received PORT additionally. Propensity scores for PORT receipt 
were calculated for each patient and used for matching to patients 
without PORT. 118 patients in non-PORT group and 39 patients in 
PORT group were matched. Clinical and pathologic characteristics 
were well-balanced after matching. PORT was delivered using 
conventional technique (n=13) or three-dimensional conformal 
technique (n=26) with median dose of 54 Gy (range, 50-60). The 
median follow-up duration for matched patients was 47 months.
Results: During the follow-up, 58 patients (49.2%) experienced 
loco-regional failure in the non-PORT group and 12 patients 
(30.8%) in the PORT group. Distant metastasis occurred in 68 pa-
tients (57.6%) in non-PORT group and 22 patients (56.4%) in PORT 
group. PORT was associated with improved loco-regional control 
rate (LRC) (5yr LRC 67.0% vs. 48.4%, p = 0.047), but not disease-
free survival (DFS) (5yr DFS 43.3% vs. 32.3%, p = 0.257). An ex-
ploratory subgroup analysis suggested a potential DFS benefit of 
PORT in patients with multiple stations of mediastinal lymph node 
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and toxicities. Kaplan–Meier analyses were used to assess survival, 
and toxic effects were examined using the Pearson Chi-Square 
test. All statistical tests were two-sided.
Results: A total of 104 patients were enrolled with 100 ones ana-
lyzed for 3 in arm 1 and 1 in arm 2 were not finished treatment 
according to the protocol. The characteristics of study population 
between the two arms were well balanced. The median PFS were 
15 and 23 months , respectively  (p=0.014) , while median OS 
were 25 and 25.5 months for arms 1–2, respectively  (p= 0.270) . 
In arms 1 and 2, the median OS of squamous cell carcinoma was 
22.5m and 23m, while non-squamous cell carcinoma 27m and not 
reached, respectively (p=0.216). The median PFS of squamous cell 
carcinoma was 17m and 20m, while non-squamous cell carcinoma 
15m and not reached, respectively (p=0.020). Compared with 
lower radiation doses, patients treated with more than or equal 
to 70 Gy had a better OS and PFS (p=0.002) for both arms. Con-
cerning toxicities, for arms 1 and 2, grade 3-4 depression of white 
blood cell was 20/48 and 11/52 (p=0.027), grade 2-3 hemotoblatin 
8/48 and 5/52 (p=0.047), grade 1-3 radiation induced pneumoni-
tis 40/48 and 31/52 (p=0.032). The differences of other adverse 
events including esophagitis, nausea, vomiting, platelet were not 
statistical difference.
Conclusion: Comparing with NP, concurrent pem/DDP at full sys-
temic doses and LCAHRT was well tolerated, with promising activi-
ty and milder side effects in a Chinese population with inoperable 
stage III NSCLC in spite of histology types.
Keywords: randomized study, local adwanced stage, non-small 
cell lung cancer, concurrent chemo-radiothérapy
POSTER SESSION 2 - COMBINED MODALITY  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.09-018 INCORPORATING ERLOTINIB INTO INDUC-
TION CHEMOTHERAPY FOLLOWED BY CONCURRENT 
CHEMORADIATION OF UNRESECTABLE STAGE III NON-
SMALL CELL LUNG CANCER ACCORDING TO EGFR MU-
TATION STATUS: PRELIMINARY RESULT OF A RANDO-
MIZED PHASE II STUDY
Youngjoo Lee1, Jin Soo Lee1, Sung Ho Moon2, Byung-Ho Nam3, Kun 
Young Lim1, Geon Kook Lee1, Sehee Oh1, Heung Tae Kim1, Tak 
Yun1, Kwan Ho Cho2, Ji-Youn Han1
1Center For Lung Cancer, National Cancer Center/Korea, 2Center For 
Proton Therapy, National Cancer Center/Korea, 3Cancer Biostatistics 
Branch, National Cancer Center/Korea
Background: EGFR tyrosine kinase inhibitors (TKIs) showed great 
survival benefit in the selected patients with stage IV non-small cell 
lung cancer (NSCLC) harboring TKI-sensitive EGFR mutations. As-
suming that if the cases were properly selected, EGFR-TKIs would 
be integrated into treatment paradigms of stage III NSCLC as more 
effective systemic therapy, we designed this study to evaluate the 
efficacy and toxicity of erlotinib and chemotherapy in the com-
bined-modality treatment of unresectable stage III NSCLC patients 
according to EGFR mutation status.
Methods: Patients over 18 years with unresectable stage IIIA (N2) 
or stage IIIB NSCLC, ECOG performance status 0–1, and adequate 
organ function are eligible. The mutational analysis of EGFR (exon 
18–21) is performed using direct sequencing in tissue sample. 
EGFR mutation-positive patients initially receive 3 cycles of erloti-
dose of chemotherapy. All but one patient exhibited radiologic 
tumor reduction based on the RECIST criteria. The objective res-
ponses to chemotherapy was CR in 0% of the patients, PR in 37%, 
SD in 50% and PD in 10% (due to new lesions). The disease control 
rate (CR+PR+SD) was 87%. Five patients dropped out from the 
study before surgery due to the patient’s decision in one patient, 
adverse events in three and disease progression in one. The com-
plete resection rate after the completion of three cycles of induc-
tion chemotherapy was 83% (25/80). Therefore, the results met our 
criterion for feasibility.
Conclusion: Induction chemotherapy using a combinati-
on of cisplatin, pemetrexed and bevacizumab in patients 
with resectable clinical stage II/IIIA nonsquamous NSCLC is 
therefore considered to be a feasible treatment modality. 
Keywords: Lung cancer, Induction therapy, clinical trial, feasibility
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P2.09-017 PHASE III STUDY OF CONCURRENT CISPLA-
TIN WITH PEMTREXED VERSUS VINORELBINE AND 
LCAHRT FOR UNRESECTABLE STAGE III NSCLC
Baosheng Li1, Zhongtang Wang1, Zhenying Wu2, Shuzeng Yu3, 
Qiang Wang4
1Radiation Oncology, Shandong Tumor Hospital/China, 2Radiation On-
cology, Dezhou Tumor Hospital/China, 3Radiation Oncology, Liaocheng 
People Hospital/China, 4Radiation Oncology, Linzi People Hospital/
China
Background: To evaluate pemetrexed in combination with cispla-
tin in these patients, a randomized phase III study of concurrent 
cisplatin with pemtrexed or vinorelbine and late course accelera-
ted hyperfractionated radiotherapy (LCAHRT) was performed.
Methods: Patients with unresectable stage III non–small cell lung 
cancer  (NSCLC)  were randomly assigned to two concurrent regi-
mens. Arm1 included cisplatin at 25 mg/m2 on days 1-3, 22-24 and 
vinorelbine at 25 mg/m2 on days 1,8 and 22,29 with concurrent 
LCAHRT. Arm 2 used cisplatin at 25 mg/m2 on days 1-3, 22-24 and 
pemtrexed at 500 mg/m2 on days 1 and 22 with the same radio-
therapy protocol. The primary endpoint was progression free sur-
vival (PFS), and secondary endpoints included overall survival (OS ) 
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P2.10-001 MODELLING OF COST EFFECTIVENESS IN 
ADVANCE NSCLC OF A FOUR ARM TREATMENT SE-
QUENCE WITH BIOMARKERS. USING A FILEMAKER APP
John A. Davidson
Medical Oncology, Royal Perth Hospital/Australia
Background: The addition of treatment predicitive biomarkers and 
the sequencing of treatments should effect outcomes in terms of 
survival and cost. in NSCLC. Clinical trials are expensive in time 
and resources. Generally one biomarker and a treatment at a 
particular sequence is tested in a clinical trial. Estimating the cost 
benefit of combining biomarkers and sequencing of treatment in 
a computer model as a teaching tool and for the design of trials 
would be useful. The adaption of a STATA model into a Filemaker 
program suitable for use on a personal computer or tablet would 
provide greater use for this modelling.
Methods: A decision analysis model in STATA 9 has been adapted 
to run on Filemaker which can be run on an IPAD. Biomarkers used 
in the model are histology and Epidermal Growth Factor Receptor 
mutation status . The model uses reported response rates and di-
sease free survival for platinum doublet, erlotinib, Pemetrexed and 
Vinorelbine. Two trials of two hundred patients are created half are 
treated with a platinum agent first followed by treatments selected 
using no additional biomarker information. The other half are trea-
ted using the best suitable treatment as informed by knowing the 
biomarker information where 75% of the patients have Adenocar-
cinoma and 15% are EGFR mutation positive. Costs for treatments 
and the use of biomarker are used to establish cost benefits.
Results: The modelling has 5.9 months improved survival for Ade-
nocarcinomas for the use of biomarkers but no significant improve-
ment for Squamous cell cancer. The added cost per life year saved 
for the arm which used histology and EGFR1 mutation testing to 
control the sequence of therapy from first to fourth line therapy 
was $37,401.
Conclusion: The model showed a meaningful educational and 
design of a trial outcome for managment of NSCLC. The result 
was specific for the parameters in the model but can be adapted 
quickly to investigate other hypothesis. The adaption to Filemaker 
a data tool suitable for tablets should allow clinicians, students and 
researches to access the modelling to simulate other senarios.
Keywords: Modelling, Biomarkers, Filemaker, Cost
nib and then are treated by concurrent chemoradiotherapy (CRT) 
with either erlotinib (Arm A) or irinotecan-cisplatin (IP) (Arm B). 
After CRT, patients in Arm A receive consolidation therapy with 6 
cycles of erlotinib while those in Arm B are observed until progres-
sion. EGFR mutation-negative or unknown patients are treated eit-
her with 3 cycles of IP followed by CRT with IP (Arm C) or vice versa 
(Arm D). Erlotinib is given at 150mg daily with 3-week cycle. IP is 
given with cisplatin 30mg/m2 (day 1 and 8) and irinotecan 60mg/
m2 (day 1 and 8) during radiotherapy (total 60 Gy/ 2.4 Gy/fr) or with 
cisplatin 30mg/m2 (day 1 and 8) and irinotecan 65mg/m2 (day 1 and 
8) during induction or consolidation therapy with 3-week cycle. 
The primary endpoint is response rate (RR), toxicity, and survival 
estimation. Erlotinib and irinotecan were provided by Roche Korea 
and Pfizer, Inc., respectively
Results: From February 2008 to February 2013, 62 patients were 
screened and 50 patients were randomized into Arm A (n= 6), 
Arm B (n= 4), Arm C (n= 19), and Arm D (n= 21). The EGFR mu-
tation status was positive in 10 (20.0%) patients, negative in 23 
(46.0%), and unknown in 17 (34%). The median age was 65 years. 
The proportion of never smoker and adenocarcinoma histology 
was 80% (event/ total No. = 8/10) and 90% (9/10) in the EGFR 
mutation-positive group, 13% (3/23) and 48% (11/23) in the EGFR 
mutation-negative group, and 6% (1/17) and 18% (3/17) in the 
EGFR mutation-unknown group. The median follow-up time was 
34.7 months (range, 3.8−53.8 months). The completion rate of 
planned treatment was 66.7% (4/6), 100% (4/4), 78.9% (15/19), and 
76.2% (16/21) from Arm A to Arm D. For induction therapy, the RR 
to elrotinib of the EGFR mutation-positive group was 70.0% (7/10). 
Moreover, the subgroup harboring TKI-sensitive EGFR mutations 
(exon 19 deletion and exon 21 L858R mutations) showed the RR to 
erlotinib of 87.5% (7/8). The RR to IP induction therapy was 41.7% 
(5/12) in the EGFR mutation-negative group, 0% (0/4) in the EGFR 
mutation-unknown group, and thus 31.1% (5/16) in the EGFR muta-
tion-negative or unknown patients.
Conclusion: The combined-modality treatment by molecular diag-
nostics was feasible in stage III NSCLC and accrual is ongoing.
Keywords: non-small cell lung cancer, Concurrent chemoradiothe-
rapy, induction chemotherapy, EGFR tyrosine kinase inhibitors
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P2.10-003 A MULTICENTER, PROOF-OF-CONCEPT STU-
DY OF SHORT-TERM SUPPLEMENTATION OF FOLIC 
ACID AND VITAMIN B12 PRIOR TO CISPLATIN-PEMET-
REXED THERAPY FOR NON-SMALL CELL LUNG CAN-
CER.
Yusuke Takagi1, Yukio Hosomi1, Kuniko Sunami2, Yoshiro Naka-
hara1, Yusuke Okuma1, Makiko Yomota1, Tsuneo Shimokawa3, 
Makoto Nagamata1, Mari Iguchi4, Hiroaki Okamoto3, Tatsuru Oka-
mura1, Masahiko Shibuya1
1Department Of Thoracic Oncology And Respiratory Medicine, Tokyo 
Metropolitan Cancer And Infectious Diseases Center Komagome Hospi-
tal/Japan, 2National Cancer Center Hospital/Japan, 3Yokohama Munici-
pal Citizen‘s Hospital/Japan, 4Tokyo Metropolitan Matsuzawa Hospital/
Japan
Background: Pemetrexed, a multi-targeted antifolate, requires 
supplementation with folic acid and vitamin B12 prior to its first 
administration in order to reduce toxicity. The lead-in time for this 
vitamin supplementation is advised to be at least seven days on 
the drug package insert. Previous studies suggested that paren-
teral vitamin B12 pervades the major organs in 24 hours, while oral 
folic acid supplementation usually takes much longer than seven 
days to correct folic acid deficiency. We hypothesized that the 
lead-in time for vitamin supplementation can be shortened to 24 
hours, enabling earlier administration of standard chemotherapy 
and potential avoidance of treatment alterations due to rapid di-
sease progression before starting chemotherapy. Since only a few 
retrospective analyses related to early initiation of pemetrexed 
have been conducted, the first prospective study evaluating shor-
tened vitamin supplementation for pemetrexed-based chemothe-
rapy was planned.
Methods: A multicenter, single-arm phase 2 study was conducted. 
Patients with advanced non-squamous non-small cell lung cancer 
were enrolled. Major eligibility criteria were adequate organ func-
tion, performance status 0-1, no symptomatic brain metastasis, 
and no prior cytotoxic chemotherapy. Patients who had provided 
written informed consent were administered 1000 µg of vitamin 
B12 by intramuscular injection and started taking 350-500 µg of 
folic acid per day. Cisplatin (75 mg/m2) plus pemetrexed (500 mg/
m2) therapy was commenced 24-48 hours after vitamin B12 injec-
tion and repeated for four cycles unless disease progression or 
unacceptable toxicity was observed. The primary endpoint was the 
proportion of patients experiencing neutropenia ≥grade 3. Thirty 
patients were to be accrued to detect the difference between the 
expected 30% of patients with neutropenia ≥grade 3 and the null 
hypothesis of 50%, using a two-stage design with 70% power and 
5% alpha. Clinical trial registry number UMIN000006546.
Results: From November 2011 to March 2013, 31 patients were 
enrolled. Their median age was 66 years (range, 34-74 years), with 
32% female. Most patients had adenocarcinoma (87%) and stage 
IV disease (90%). Performance status was 0 in 16 (52%) and 1 in 
15 (48%) patients. Of the 30 patients who started chemotherapy 
within 48 hours from vitamin administration, 21 (70%) patients 
completed four cycles of cisplatin/pemetrexed therapy. Six (20%) 
patients discontinued chemotherapy due to disease progression, 
and the treatment of three (10%) patients was stopped due to ad-
verse events. No treatment-related deaths or grade 4 toxicity oc-
curred. Grade 3 neutropenia was observed in 7% (95%CI, 2-21%) of 
patients. Other grade 3 toxicities were anemia (two patients), de-
creased white blood cell count, diarrhea, thromboembolic event, 
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P2.10-002 PHASE I DOSE ESCALATION STUDY OF PE-
METREXED AND CARBOPLATIN IN CHEMOTHEARPY-
NAIVE ELDERLY PATIENTS WITH ADVANCED NON-
SQUAMOUS NON-SMALL CELL LUNG CANCER.
Hiroaki Takeoka, Kazuhiko Yamada, Yoshiaki Zaizen, Fumie 
Shimamatsu, Koichi Azuma, Tomoaki Hoshino
Kurume University School Of Medicine/Japan
Background: The subgroup analyses in several phase III trials have 
suggested that overall survival after platinum-doublet chemothe-
rapy in elderly patients with non-small cell lung cancer (NSCLC) 
can be similar to those in younger patients. The combination of 
carboplatin (CBDCA) with pemetrexed (PEM) is expected as a sui-
table treatment for carefully selected elderly patients with advan-
ced non-squamous (non-Sq) NSCLC.
Methods: Patients with ≥75 years, PS of 0-1, chemotherapy-naïve 
advanced non-Sq NSCLC were enrolled in this study. They re-
ceived escalated doses of CBDCA at AUC 4 (cohort 1) or AUC 5 
(cohort 2) and PEM 500 mg/m2 every 3 weeks for six cycles. Dose 
escalation was decided by dose-limiting toxicity (DLT) occurred 
in the first cycle of chemotherapy. Study protocol stipulated that 
additional number of patients, up to maximum of 20 patients, was 
enrolled to receive the recommended dose of study treatment. 
The primary objectives were to evaluate feasibility and determine 
the recommended dose of this combination.
Results: A total of 20 patients (6 patients in cohort 1, 14 patients 
in cohort 2) were enrolled in this study. Median age was 77 (range 
75-83). No DLTs were observed in the patients with cohort 1 and 
the first 6 patients of cohort 2 during the first cycle of chemothera-
py, thus the combination of PEM 500 mg/m2 plus CBDCA at AUC 
5 was determined as the recommended dose. Median number of 
cycles was 4 (range 1-6). The major toxicities were neutropenia, 
thrombocytopenia and anemia. During the entire period of study, 
2 and 5 patients needed to have platelet transfusion and RBC 
transfusion, respectively. Liver dysfunction, fatigue and anorexia 
were also common, but these were generally manageable. Six 
partial responses and 9 stable diseases were observed, giving an 
overall response rate of 30% and a disease control rate of 75%. 
Median progression-free survival time was 4.8 months (95% CI, 4.1 
– 5.4 months).
Conclusion: The combination of PEM 500 mg/m2 plus CBDCA at 
AUC 5 was determined as the recommended dose. This combi-
nation therapy is generally tolerable, and may have encouraging 
antitumor activity in chemotherapy-naïve elderly patients with 
advanced non-Sq NSCLC.
Keywords: non-small cell lung cancer, elderly, Carboplatin, peme-
trexed
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interest regarding BEV. 2 patients died from study-drug related to-
xicity (GI hemorrhage, pneumonia aspiration; during induction CT). 
Conclusion: In this study of PEM+CIS+BEV induction CT followed 
by PEM+BEV maintenance, median PFS was 6.9 months. The ad-
dition of BEV to PEM-CIS induction and PEM maintenance was 
associated with acceptable and expected toxicities. Main G3/4 
toxicities included neutropenia and fatigue, hypertension was less 
common.
Keywords: pemetrexed, non-squamous NSCLC, radiotherapy, 
bevacuzimab
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P2.10-005 ERLOTINIB (E) CAN BE SAFELY ADMINISTE-
RED IN PTS > 80 YEARS OLD
Ioannis Gkiozos, Paraskevi Boura, Dimitrios Vassos, Antonios 
Vassias, Antonios Bastas, Anastasios Boufas, Konstantinos N. 
Syrigos
Oncology Unit Gpp, Sotiria General Hospital/Greece
Background: Besides chemotherapy, E is another option in NSCLC 
pts especially in those with EGFR mutations. Elderly pts enrolled 
in trials are fit without cM, but in clinical practice most suffer from 
cM.
Methods: Medical records of 1221 pts diagnosed with NSCLC 
between 2008-2012 were screened. We examined pts ≥75 yrs for 
demographics, clinical data and Tx details.
hypertension, and myocardial infarction (one patient, respectively). 
The plasma homocysteine level before vitamin administration, a 
marker for vitamin B12 and/or folate deficiency, was elevated in four 
patients, but none of the patients experienced grade 3 toxicities. 
The response rate and the disease control rate of chemotherapy 
were 43% (95%CI, 27-61%) and 77% (95%CI, 59-88%), respectively.
Conclusion: This study met its primary endpoint. Absence of re-
lationship between baseline homocysteine levels and toxicities of 
chemotherapy suggests the efficacy of short-term vitamin supple-
mentation. A pragmatic study with a larger cohort that can detect 
uncommon toxicities is being conducted.
Keywords: folic acid, non-small cell lung cancer, pemetrexed, 
vitamin B12
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P2.10-004 ADDITION OF BEVACUZIMAB (BEV) TO PEME-
TREXED (PEM) PLUS CISPLATIN (CIS) INDUCTION AND 
PEM MAINTENANCE THERAPY IN 1ST LINE SETTING 
FOR TREATMENT OF ADVANCED NONSQUAMOUS 
NON SMALL CELL LUNG CANCER (NS-NSCLC) - FINAL 
RESULTS AND SAFETY UPDATE FROM A PHASE 2  
STUDY
Gunnar Hillerdal1, Jens B. Sorensen2, Gert Hoeffken3, Adolfo Fa-
varetto4, Ramon Perez Carrion5, Carla Visseren-Grul6, Sophie 
Ameryckx7, Victoria Soldatenkova8, Nawel Bourayou9, Armando 
Santoro10
1Pulmonary Medicine, Karolinska Hospital/Sweden, 2Oncology, Nati-
onal University Hospital/Denmark, 3Center Of Pneumology, Thoracic 
And Vascular Surgery, Fachkrankenhaus Coswig/Germany, 4Second 
Medical Oncology, Istituto Oncologico Veneto/Italy, 5Hospital Quirón/
Spain, 6Medical Oncology, Eli Lilly And Company/Netherlands, 7Lilly 
S.A. Eli Lilly Benelux N.v./Belgium, 8European Statistics, Oncology, Lilly 
Deutschland GmbH/Germany, 9Medical Oncology, Eli Lilly And Compa-
ny/France, 10Humanitas Cancer Center IRCCS, Rozzano/Italy
Background: 1st line PEM+CIS induction chemotherapy (CT) fol-
lowed by PEM maintenance and 1st line BEV-based CT followed 
by BEV maintenance offer clinical benefit (progression-free and 
overall survival; PFS and OS) in NS-NSCLC. This study explored 
efficacy and safety of 1st line induction PEM+CIS+BEV followed by 
maintenance PEM+BEV.
Methods: Patients with advanced NS-NSCLC and ECOG perfor-
mance status (PS) 0-1 were planned to receive 4 cycles PEM 500 
mg/m2, CIS 75 mg/m2, BEV 7.5 mg/kg, given every 3 weeks. In the 
absence of progressive disease (PD) and in the case of ECOG PS 
0-1, patients could continue on PEM+BEV until PD or unacceptable 
toxicity. All patients received vitamin supplementation as per PEM 
label. Primary endpoint was PFS; secondary endpoints included 
OS, response rate and toxicity. PFS without Grade (G)4 toxicity was 
additionally assessed.
Results: 109 patients were enrolled in 5 countries. Characteristics: 
median age 61 years, males/females 59/41%, ECOG PS 0/1 54/46%, 
stage IIIB/IV 9/91%, adenocarcinoma 91%. 72 patients (66%) recei-
ved maintenance CT. Overall median (maximum) number of cycles 
were 8(34) for PEM+BEV and 4(4) for CIS. Median PFS was 6.9 
months (90% CI 5.7, 8.3). Table 1 summarizes efficacy data; Table 
2 presents G1-4 adverse event (AE) data, including AEs of special 
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first-line therapy for advanced(III/IV) non-small cell lung cancer 
(NSCLC) was performed. Response was assessed by CT Response 
Evaluation Criteria in Solid Tumors (RECIST) at after every two cy-
cles or emerge symptoms relate to disease progression . Overall 
survival(OS), progression-free survival (PFS), and post-progression 
survival(PPS) were Recorded. Primary tumor maximum standar-
dized uptake value (SUVmax), primary tumor size were all derived 
from the PET/CT data. Survival curves stratified by median SUVmax 
and SUVmax to tumor size ratio by the Kaplan-Meier method and 
statistical differences were assessed using the log-rank test. Mul-
tivariate proportional hazards (Cox) regression analyses were ap-
plied to test the SUVmax’s and SUVmax to tumor size ratio’s inde-
pendency of other prognostic factors for the prediction of survival.
Results: Total 186 patients were enrolled into the current study. 
Median OS was 14.9 m (range, 3.1–64.0 m), PFS was 5.6 m (range, 
0.8–41.1 mo), and PPS was 7.9m(range, 0–51.3 m). The statistical 
analysis data indicated that Low pretreatment SUV≤7.9(P=0.026), 
and SUVmax to tumor size ratio<2.2(0.000) were associated with 
response to first-line therapy. Clinical response was independent 
prognostic factors for PFS (OR= 3.152, P=0.000), low stage(III) was 
associated with PPS independently, with OR=1.700, P= 0.027,and 
for OS, low SUVmax to tumor size ratio(OR= 1.764, P=0.027), tumor 
diameter (OR= 1.743, P=0.013)and clinical response(OR= 1.678, 
P=0.002) were all independent prognostic factors.
Conclusion: The ratio of SUVmax to tumor size may be a more 
important indicator of prognosis than SUVmax alone in patients 
with NSCLC.
Keywords: non–small cell lung cancer, 18F-FDG PET/CT;SUVmax, 
therapeutic response, survival
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P2.10-007 PHASE II TRIAL OF PEMETREXED AND CAR-
BOPLATIN FOLLOWED BY PEMETREXED CONTINUATI-
ON-MAINTENANCE THERAPY IN PREVIOUSLY UNTREA-
TED ADVANCED NON-SMALL CELL LUNG CANCER
Kazumi Nishino1, Takashi Kijima2, Seigo Minami3, Kiyoshi Komu-
ta3, Toru Kumagai1, Fumio Imamura1, Soichiro Yokota4, Yoshiko 
Takeuchi3, Takeshi Nakatani3, Junji Uchida1, Takako Okuyama1, 
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Background: Survival benefits of pemetrexed for advanced non-
squamous non-small cell lung cancer (NSCLC) have been demons-
trated in both switch- and continuation-maintenance settings after 
platinum-based induction. A phase III trial (PARAMOUNT) com-
paring pemetrexed maintenance with best supportive care after 
4 cycles of induction pemetrexed plus cisplatin in non-squamous 
NSCLC patients demonstrated benefits both in progression-free-
survival (PFS) and overall survival (OS) by pemetrexed continua-
tion-maintenance. However, it remained undetermined whether 
pemetrexed could improve survival when it was continued to admi-
nister after carboplatin plus pemetrexed induction. We conducted 
Results: 233/1221 NSCLC pts received E at any line. 53/233 (23%) 
were ≥75 yrs old. Male:female ratio was 34:19 and median age 79 
yrs (range 75-88). NSCLC subtypes included 31 adenoca, 8 squa-
mous cell, 9 NOS and 5 others. 50/53 pts had cM (≥2 in 46 pts, 1 
in 4pt). Main cM were cardiovascular disease (n=41), COPD (n=14), 
other cancer (n=10) and diabetes (n=8). 8 pts were tested for 
EGFR mutations (5 -ve, 3 +ve). Performance Status was satisfactory 
(ECOG 0-1) in 8 pts and poor (2-3) in 45pts. 8pts were treated with 
E 100mg and 45 pts with E 150mg (12 pts needed dose reduction). 
Complete follow up data were found in 46pts. Mean duration of 
treatment was 79 days (range 9-662). 35/46 pts experienced side 
effects (s.e) [rash n=29, diarrhea n=17] which led to treatment 
discontinuation in 12pts. Pts with abnormal creatinine clearance 
(n=13) were more likely to stop treatment due to s.e (6/13 versus 
6/33). 17/46 pts (37%) achieved disease control (5 PR, 12 SD) and 
a time to progression (TTP) of 157 days (range 106-662, 95% CI 
132.79-270,74) while 22/46 pts had PD as best response (TTP 49d, 
range 19-88, CI 44,67-64,97). 7pts were not evaluable (stopped Tx 
due to s.e). All EGFR+ve pts had disease control (2PR, 1SD).
Conclusion: E is a valuable option in elderly NSCLC patients with 
co-morbidities, especially if they harbor EGFR mutations. Impaired 
renal function might be associated with propensity to side effects 
and earlyTx discontinuation.
Keywords: EGFR mutations, elderly, co-morbidities, non-small-cell 
lung cancer
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P2.10-006 PROGNOSTIC VALUE OF THE RATIO OF POSI-
TRON EMISSION UPTAKE TO PRIMARY TUMOR SIZE IN 
ADVANCED NON-SMALL CELL LUNG CANCER
Yong Song
Department Of Respiratory Medicine, Nanjing Jinling Hospital/China
Background: In Surgically Resected Non–Small Cell Lung Cancer,a 
previous study has shown ratio of maximum standardized uptake 
value to primary tumor size is a more important indicator of prog-
nosis than SUVmax alone. The objective of this study was to assess 
the prognostic value of patients with advanced non-small cell lung 
cancer (NSCLC). We have investigated whether SUVmax to tumor 
size ratio is associated with response to first-line therapy and survi-
val in advanced Non–Small Cell Lung Cancer.
Methods: A retrospective review of 186 consecutive patients 
who had a pretreatment 18F-FDG PET/CT done before receiving 
first-line therapy for advanced(III/IV) non-small cell lung cancer 
(NSCLC) was performed. Response was assessed by CT Response 
Evaluation Criteria in Solid Tumors (RECIST) at after every two cy-
cles or emerge symptoms relate to disease progression . Overall 
survival(OS), progression-free survival (PFS), and post-progression 
survival(PPS) were Recorded. Primary tumor maximum standar-
dized uptake value (SUVmax), primary tumor size were all derived 
from the PET/CT data. Survival curves stratified by median SUV-
max and SUVmax to tumor size ratio by the Kaplan-Meier method 
and statistical differences were assessed using the log-rank test. 
Multivariate proportional hazards (Cox) regression analyses were 
applied to test the SUVmax’s and SUVmax to tumor size ratio’s 
independency of other prognostic factors for the prediction of 
survival.A retrospective review of 186 consecutive patients who 
had a pretreatment 18F-FDG PET/CT done before receiving 
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Background: Chemotherapy drugs have still the major disadvan-
tage of non-specific cytotoxic effects. Although, new drugs targe-
ting the genome of the tumor are already on the market, doublet 
chemotherapy regimens still remain the cornerstone of lung cancer 
treatment. Novel modalities of administration are under investiga-
tion such as; aerosol, intratumoral and intravascular.
Methods: In the present study five chemotherapy drugs; paclita-
xel, docetaxel, gemcitabine, carboplatin and cisplatin were nebu-
lized with three different jet nebulisers (Maxineb®, Sunmist®, Inva-
care®) and six different residual cups at different concentrations. 
The purpose of the study was to identify the ``ideal`` combination 
of nebulizer-residual cup design-drug-drug loading for a future 
concept of aerosol chemotherapy in lung cancer patients. The 
Mastersizer® 2000 was used to evaluate the aerosol droplet mass 
median aerodynamic diameter.
Results: The drug, nebulizer and residual cup design greatly in-
fluences the producing droplet size (p<0.005, in each case). How-
ever; the design of the residual cup is the most important factor 
affecting the produced droplet size (F=834.6, p<0,001). The drug 
loading plays a vital role in the production of the desired droplet 
size (F=10.42, p<0.001). The smallest droplet size was produced at 
8ml loading (1.26µm), while it remained the same at 2, 4 and 6 mls 
of drug loading.
Conclusion: The ideal nebulizer would be Maxineb®, with a large 
residual cup (10 ml maximum loading capacity) and 8 mls loading 
and the drug with efficient pulmonary deposition would be doce-
taxel.
Keyword: aerosol cisplatin, lung cancer, cytoviva, hyperspectral 
microscope system.
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P2.10-009 INTRINSIC AND ACQUIRED RESISTANCE PAT-
TERNS IN NON-SMALL CELL LUNG CANCER (NSCLC) 
PATIENTS TREATED WITH PLATINUM-BASED CHEMO-
THERAPY
David J. Stewart1, Pierre Saintigny2, Charles Lu2, Glenwood Goss1
1Medical Oncology, University Of Ottawa/Canada, 2Thoracic/Head & 
Neck Medical Oncology, MD Anderson Cancer Center/United States Of 
America
Background: Platinum-based chemotherapy (PBC) yields clinical 
benefit in some but not all patients with advanced NSCLC. All 
patients eventually become resistant to treatment. We assessed 
degree and timing of onset of tumor regression (TR) and tumor 
growth (TG) as a surrogate indicator of sensitivity and resistance 
patterns.
Methods: In 130 NSCLC patients on PBC, we assessed percent 
change in tumor diameter (TG or maximum TR on treatment) com-
a phase II study to evaluate the efficacy and safety of this regimen.
Methods: Thirty-four chemonaïve patients with stage IIIB/IV or 
postoperative recurrent non-squamous NSCLC received carbo-
platin (area under the concentration-time curve 6 mg/mL/min, 
day 1) plus pemetrexed (500 mg/m2, day 1) every 3 weeks. Non-
progressive patients after 4 cycles of induction received pemet-
rexed maintenance (500 mg/m2, day 1) every 3 weeks until disease 
progression or unacceptable toxicity. The primary objective was 
to investigate 1-year survival rate. Secondary objectives were to 
investigate the safety, the objective response rate (ORR) during 
induction chemotherapy and PFS, defined as the time from enroll-
ment to disease progression or death.
Results: From December 2009 to March 2011, a total of 34 pati-
ents were enrolled. The median follow-up time was 20.9 months 
(range, 2 to 32.3). At the time of the data collection, 19 patients 
were dead, 13 still alive, 2 lost follow-up. Twenty-five patients 
(73.5%) completed induction and 22 patients (64.7%) received 
maintenance therapy. The 1-year survival rate was 70.3% (95% CI, 
53.0 to 83.2). The 2-year survival rate was 45.5% (95% CI, 28.7 to 
63.5). The median PFS and OS were 5.2 months (95% CI, 4.1 to 8.2) 
and 23.0 months (95% CI, 15.5 to not available) from enrollment 
in all 34 patients, in addition 9.0 months (95% CI, 5.2 to 12.1) and 
24.3 months (95% CI, 17.8 to not available) from the start of main-
tenance therapy in 22 patients who proceeded to maintenance 
therapy. The objective response rate and the disease control rate 
were 32.4% and 88.2%. The incidental rates of grade 3 or more 
severe adverse events were low except for one case of grade 5 
pneumonitis. A multivariate analysis of 21 patients who received 
maintenance therapy with any tumor regression showed that the 
longer time to the best response achievement, positive epidermal 
growth factor receptor mutation status and better Karnofsky per-
formance status contributed to achieve longer PFS.
Conclusion: Pemetrexed continuation-maintenance following 
pemetrexed plus carboplatin induction is a promising treatment 
for chemonaïve patients with advanced non-squamous NSCLC 
because of its good efficacy and less cumulative toxicities. This 
regimen could be substitutable for pemetrexed continuation-main-
tenance following cisplatin-based induction.
Keywords: pemetrexed, Carboplatin, continuation-maintenance
POSTER SESSION 2 - CHEMOTHERAPY  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.10-008 ESTABLISHING THE OPTIMAL NEBULIZATION 
SYSTEM FOR PACLITAXEL, DOCETAXEL, CISPLATIN, 
CARBOPLATIN AND GEMCITABINE; BACK TO DRAWING 
THE RESIDUAL CUP.
Konstantinos Zarogoulidis1, Paul Zarogoulidis2, Kaid Darwiche3, 
Lutz Freitag3, Robert Browning4, Jay F. Turner5, Qiang Li6, Christos 
Ritzoulis7, Dimitris Petridis8
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Hospital, Aristotle University Of Thessaloniki/Greece, 2Pulmonary 
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totle University Of Thessaloniki, Thessaloniki/Greece, 3Department Of 
Interventional Pneumology, Ruhrlandklinik, West German Lung Center, 
University Hospital, University Duisburg-Essen/Germany, 4Director Of 
Interventional Pulmonology, Commander, Medical Corps, U.S. Navy/
United States Of America, 5Professor Of Medicine University Of Nevada 
School Of Medicine Senior Research Fellow, National Supercomputing 
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Republic, 5University Hospital Olomouc/Czech Republic, 6Pneumology, 
University Hospital/Czech Republic, 7Oncology, Masaryk Memorial 
Cancer Institute/Czech Republic, 8Usti Nad Labem Hospital/Czech Re-
public, 9Charles University Hospital/Czech Republic
Background: Lung cancer is the leading cause of cancer mortality 
in the Czech Republic. Approximately 80%are NSCLC and 65% of 
patients have advanced disease at the time of diagnosis. Most pa-
tients who receive first-line chemotherapy experience disease pro-
gression within 3 to 6 months of initiating therapy and the median 
survival time observed is 8 to 10 months. In this situation, there is a 
need to find effective therapeutic regimen with an administration 
as simple as possible and the most favorable toxicity profile. The 
purpose of this study was to evaluate the activity and feasibility of 
CBDCA together with full oral vinorelbin (NVBO).
Methods: Patients with advanced NSCLC received NVBO 80 mg/
m² on D1 and D8 with CBDCA AUC5 on D1 every three weeks. In 
stage III, chemotherapy was followed by external radiotherapy. 
The outcomes include following: response, median overall survival 
(mOS) and median progression free survival (mPFS). Response was 
assessed by imaging techniques after 4-6 weeks of treatment and 
was confirmed one month later by chest X-ray and/or CT scanning. 
The difference in response relative to baseline characteristics was 
determined using Pearson Chi-square test. Differences in OS and 
PFS relative to baseline characteristics were evaluated for signifi-
cance using Log-rank test.
Results: 396 patients were treated: 311 men (78,5) and 50 women 
(21,5%), median age 65 years. ECOG performance status at in-
clusion was PS 0 in 51 (12,9% patients, PS 1 in 287 (72,7%) and PS 
2 in 57 (14,4%) patients. Most patients had stage IIIB 116 (29,3%) 
and stage IV NSCLC 257 (64,9), only 32 (5,84%) were stage IIIA . 
Adenocarcinoma was confirmed in 90 patients (22,7%), squamous-
cell carcinoma in 238 (60,1%), large-cell carcinoma 11 and other in 
57 (17,2%). Complete response was confirmed in 2 (0,5%) patient, 
partial response in 136 (34,3%), stable disease in 104 (26,3%), 154 
(38,9%) patients progressed. The regimen was well tolerated. 
Median cycles was 4, the dosage of NVBO was without changes 
in 268 (67,7%) patients, the dosage of NVBO was reduced in 28 
(7,1%) and escalated in 77 (19,48%). In 23 (5,8%)of patients was the 
dosage of NVBO reduced after escalation. Major toxicities (Grade 
3-4) were neutropenia in 29%, leucopenia in 20,8%, anemia in 
3,3% and thrombocytopenia in 1,8% patients. Febrile neutropenia 
was observed in 6,1% patients. Gastrointestinal toxicity grade 3-4 
was observed in 4,6% patients. The mPFS was 7,4 moths and mOS 
was 9,92 months by median follow-up 8,5 months. The differences 
between groups of pts according to PS (0+1 vs. 2) were statistically 
significant (p < 0,001) better for patiens with PS 0+1. The differen-
ces between groups of pts according histology were not statisti-
cally significant (p=0,3975).
Conclusion: In this group of 396 unselected patients with advan-
ced NSCLC was the treatment with full NVBO and-CBDCA in first 
line more convenient and well tolerated with evidence of high anti-
tumour activity. This combination was active in all groups patients 
according histology (mOS was 9,92 and mPFS was 7,4 months). Sta-
tistically significant better were the results in patients with PS 0+1.
Keywords: oral vinorelbine, non-small-cell lung cancer, Treatment, 
advanced diseases
pared to pre PBC, and also assessed incremental percent further 
TR or TG in serial scans compared to the most recent prior scan on 
treatment.
Results: Of the 130 patients, 32 (25%) had intrinsic resistance, with 
TG at 1st repeat scan after 2 cycles of PBC. Only 1 patient with 
initial TG had later TR on PBC. Among those with TR at 1st re-eva-
luation, pattern of onset of acquired resistance varied: 81 had a 2nd 
repeat scan after 4 cycles of PBC, of whom 20 (25%) had TG. Of 41 
patients with earlier TR who then had a 3rd repeat scan <4 weeks 
post PBC cycle 6, 13 (32%) had TG compared to prior scans. In 76% 
of those with TR, the greatest TR compared to most recent prior 
scan was seen at the first re-evaluation, with TG or a lower percent 
TR on later scans. 26 patients had progressive further TR over each 
of >4 re-evaluation scans, of whom 11 had initial rapid TR at 1st 
re-evaluation, with subsequent more gradual further TR over later 
scans (a pattern that we designated as “Incremental TR pattern 1”). 
The other 15 patients with progressive TR over >4 re-evaluation 
scans had modest initial TR followed by greater TR on a later scan 
(a pattern that we designated as “Incremental TR pattern 2”). By 
Spearman coefficients, maximum percent TR from pre PBC (with 
TG coded as a negative value for TR) correlated with OS (r=0.46, 
p<0.0001), time to progression (TTP) (r=0.69, p<0.0001) and post-
progression survival (PPS) (r=0.30, p=0.001). OS also correlated 
with TTP (r=0.63, p<0.0001), and PPS correlated with TTP (r=0.44, 
p<0.0001), and with OS (r=0.95, p<0.0001). Median OS was 11.0 
months, and varied with TR pattern (p<0.0001): for patients with 
first TG at 1st, 2nd, 3rd and 4th repeat scans, median OS was 5.9, 10.8, 
10.5 and 15.1 months, respectively. Median OS was 18.2 months in 
patients with “Incremental TR pattern 1”, and was 30.5 months in 
patients with “Incremental TR pattern 2”. Median OS with RECIST 
partial response (23% of patients), minor TR (52%), minor TG (13%) 
and RECIST progressive disease (13%) was 16.9, 12.4, 9.8 and 4.0 
months, respectively (p<0.0001).
Conclusion: Intrinsic resistance was noted in 25% of patients. De-
gree of TR vs TG and patterns of intrinsic and acquired resistance 
correlated strongly with OS, TTP and PPS, with longest median 
OS in patients with “Incremental TR pattern 2”. Our observations 
require confirmation. While numerous biological factors correlate 
with resistance preclinically, it remains unclear which are most rele-
vant clinically, and it is also unclear what factors may be responsib-
le for the different patterns of clinical resistance observed.
Keywords: resistance, tumor regression patterns, NSCLC, plati-
num based chemotherapy
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P2.10-010 FULL ORAL VINORELBINE (NVBO) ON D1 
AND D8 WITH CARBOPLATIN (CBDCA) AS FIRST LINE 
TREATMENT IN ADVANCED NON-SMALL LUNG CAN-
CER (NSCLC) PATIENTS: RESULTS OF A PROSPECTIVE 
STUDY IN NONRANDOMIZED AND UNSELECTED POPU-
LATION OF 396 PATIENT
Jana Skrickova1, Bohdan Kadlec1, Ondrej Venclicek1, Lenka Jakubi-
kova1, Tereza Janaskova2, Jiri Chalupa3, Jiri Bartos4, Vitezslav Ko-
lek5, Ivona Grygarkova6, Helena Coupkova7, Pavel Reiterer8, Milada 
Zemanova9
1Department Of Respiratory Diseases And TB, University Hospital Brno 
And Masaryk University/Czech Republic, 2Hospital Vitkovice/Czech 
Republic, 3Hospital Liberec/Czech Republic, 4Hospital Tabor/Czech 
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Conclusion: In a group of 233 patients with advanced non-squa-
mous NSCLC who were treated with pemetrexed in first line and in 
combination with cisplatin, the therapy was well tolerated: termina-
tion of treatment due to adverse events was reported only in 3.8% 
of patients. Median overall was 11.6 months, median progression-
free survival was 4.2 months
Keywords: non-squamous NSCLC, Pemetrexed and cisplatin, First 
line treatment, advanced diseases
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P2.10-012 EVALUATION OF AMRUBICIN AS A THIRD 
OR LATER LINE OF CHEMOTHERAPY FOR ADVANCED 
NON-SMALL CELL LUNG CANCER
Satoshi Igawa, Yujiro Nagashima, Yasuhiro Hiyoshi, Mikiko 
Ishihara, Michiko Kimura, Masashi Kasajima, Jiichiro Sasaki, 
Noriyuki Masuda
Respiratory Medicine, Kitasato University School Of Medicine/Japan
Background: Currently, there are no standard cytotoxic treatments 
for non-small-cell lung cancer (NSCLC) patients beyond third-line 
or further line therapy. Previous studies of amrubicin in patients 
with previously untreated advanced NSCLC in succession demons-
trated an overall response rate of 18.3-27.9%, and a median survi-
val time of 8.2-9.8 months. Accordingly, amrubicin was equivalent 
to anticancer agents such as taxanes, gemcitabine, vinorelbine, 
and pemetrexed in terms of single-agent activity against NSCLC. 
The purpose of this study was to evaluate the efficacy of amrubicin 
monotherapy as a salvage treatment in heavily pretreated NSCLC 
patients.
Methods: The records of NSCLC patients who received amrubicin 
monotherapy as a third or later line of chemotherapy at a Kitasato 
University Hospital between January 2009 and December 2012 
were retrospectively reviewed. Amrubicin was administered to pa-
tients by intravenous injection in a dose of 35 mg/m2 or 40 mg/m2 
daily on 3 consecutive days, and cycles were repeated at 3-week 
intervals.
Results: There were 36 patients who met the inclusion criteria. 
Their median number of prior chemotherapy was 4 (range: 2 to 7), 
and the median number of cycles of chemotherapy per patient was 
4 (range: 1 to 9). Grade 3 or 4 hematologic toxicities included neu-
tropenia (61.1%), leukopenia (58.3%), thrombocytopenia (22.2%), 
and anemia (11.1%). Febrile neutropenia occurred in 8 patients 
(22.2%). Non-hematologic toxicities were mild. Treatment related 
death was not observed. The overall response rate, median pro-
gression-free survival time, and median survival time were 8.3%, 
1.7 months, and 6.3 months, respectively. Progression-free survival 
time was the same, 1.7 months, in both the 35 mg/m2 dose group 
and the 40 mg/m2 dose group.
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P2.10-011 PEMETREXED IN COMBINATION WITH 
CISPLATIN IN THE FIRST-LINE TREATMENT OF NON-
SQUAMOUS NSCLC: CZECH EXPERIENCE WITH 233 
PATIENTS
Jana Skrickova1, Zdenek Bortlicek2, Karel Hejduk2, Milos Pesek3, 
Vitezslav Kolek4, Leona Koubková5, Jaromir Roubec6, Marcela 
Tomiskova1, Monika Satankova1, Zdenka Povolna1, Libor Havel7, 
Helena Coupkova8, Frantisek Salajka3, Michal Hrnciarik3, Milada 
Zemanova9, Dimka Sixtova9, Marketa Cernovska10
1Department Of Respiratory Diseases And TB, University Hospital 
Brno And Masaryk University/Czech Republic, 2Institut Biostatistiky A 
Analýz, Masaryk University/Czech Republic, 3Pneumology, University 
Hospital/Czech Republic, 4University Hospital Olomouc/Czech Republic, 
5Pneumology, University Hospital Motol/Czech Republic, 6Pneumology 
Department, University Hospital/Czech Republic, 7Pneumology, Hospi-
tal Na Bulovce/Czech Republic, 8Oncology, Masaryk Memorial Cancer 
Institute/Czech Republic, 9Charles University Hospital/Czech Republic, 
10Thomayer University Hospital/Czech Republic
Background: Pemetrexed in combination with cisplatin in the first-
line treatment of advanced non-squamous NSCLC (non-smal-cell 
lung cancer) has been administered in the Czech Republic since 
10/2010. The purpose of this study was to evaluate the activity and 
feasibility of pemetrexed in first-line treatment of NSCLC in combi-
nation with cisplatin.
Methods: Patients with advanced non-squamous NSCLC were tre-
ated with pemetrexed in first line and in combination with cisplatin 
between 10/2012 and 03/2013 in 12 institutions. Retrospective ana-
lyses were carried out to assess the effectiveness of treatment and 
applied regimens, and to evaluate the safety of targeted therapy. 
The outcomes include following: response, median overall survival 
(mOS) and median progression free survival (mPFS). Response was 
assessed by imaging techniques after 4-6 weeks of treatment and 
was confirmed one month later by chest X-ray and/or CT scanning. 
The difference in response relative to baseline characteristics was 
determined using Pearson Chi-square test. Differences in OS and 
PFS relative to baseline characteristics were evaluated for signifi-
cance using Log-rank test.
Results: Out of 233 treated patients, 125 were men (53.6%) and 
108 were women (46.4%). At the time of treatment initiation with 
pemetrexed, the following characteristics were recorded. The me-
dian age of patients was 61 years. 97 patients (41.6%) were smokers, 
72 patients (30.9%) were former smokers, 64 patients (27.5%) were 
non-smokers. Performance status (PS) was 0 in 53 patients (22.7%), 
1 in 172 patients (73.8%) and 2 in 8 patients (3.4%). Adenocarcino-
ma) was confirmed in 226 patients (97.0%), large-cell carcinoma was 
reported in 7 patients (3.0%). Most of the patients were diagnosed 
in stage IV (186 patients, 80.2%) and treatment of most patients was 
also initiated in stage IV (84.5%). As on the date of data analysis (18 
March 2013), treatment was terminated in 185 patients (79.4%), and 
the median duration of treatment in these patients was 12.1 weeks. 
Adverse effects during treatment with pemetrexed were reported 
in 73 patients (31.3%). Complete response was achieved in 4 pati-
ents (1.7%), partial response in 58 patients (24.9%), stable disease in 
79 patients (33.9%) and progressive disease in 38 patients (16.3%); 
treatment response was not evaluated in 54 patients (23.2%). Medi-
an overall survival (OS) starting from treatment initiation with peme-
trexed was 11.6 months (95% CI: 7.0; 16.3). Median progression-free 
survival (PFS) starting from treatment initiation with pemetrexed was 
4.2 months (95% CI: 3.4; 5.1).
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Et D’hématologie, Chu Morvan/France, 9Clinique Pneumologique, 
Hôpital Charles Nicolle/France, 10Pneumology, Hôpital D‘instruction 
Des Armées Sainte-Anne/France, 11Département De Médecine Oncolo-
gique, Centre Paul Strauss/France, 12Pneumology, Centre Hospitalier 
Départemental/France, 13Département D’oncologie Médicale, Institut 
De Cancérologie De La Loire/France, 14Centre François Baclesse/France, 
15Peumology, Centre François Baclesse/France, 16Service De Pneumolo-
gie, Chu D’angers/France, 17Ch René Dubos-Pontoise/France, 18Service 
De Pneumologie, Chu De Rouen Hôpital Bois Guillaume/France, 19Hôpi-
tal Robert Boulin/France, 20Service De Pneumologie, Centre Hospitalier 
Saint Faron/France, 21Unité Fonctionnelle De Recherche Clinique Et 
Biostatistique, Facultés De Médecine Et De Pharmacie/France, 22Service 
De Pathologie Respiratoire, Hôpital Du Cluzeau/France
Background: Erlotinib and docetaxel are approved in second line 
treatment of advanced NSCLC. Concomitant administration of a 
tyrosine kinase inhibitor (TKi) of EGFR with standard chemotherapy 
in first line did not improve survival compared to chemotherapy 
alone. Preliminary studies support a possible efficacy of sequential 
administration of EGFR TKi and chemotherapy. Objective: This 
open randomized phase II trial (Tarseq) was designed to assess 
the efficacy and tolerability of second-line sequential erlotinib plus 
docetaxel in advanced NSCLC.
Methods: Patients were randomized (1/1, stratified by center, di-
sease status: recurrent or refractory (no response observed after 
4 cycles of first-line chemotherapy))between sequential erlotinib 
150 mg/d (day 2-16) + docetaxel (75 mg /m2 d1- 21) (arm A) versus 
docetaxel (75mg/m2 d1) alone (arm B) until disease progression 
or unacceptable toxicity. Primary endpoint was the rate of pati-
ents with progression-free survival at 15 weeks (PFS15) ; second 
endpoints included progression-free survival (PFS), overall survival 
(OS), overall response rate (ORR), and tolerability. Main eligibili-
ty criteria were advanced NSCLC, EGFR wild type or unknown, 
performance status 0 to 2, failure of first line cisplatin based che-
motherapy; main exclusion criteria were more than 2 lines of treat-
ment, previous anti-EGFR or docetaxel treatment. Statistical analy-
sis was based on a Simon’s optimal two stage design . The primary 
endpoint is rejected if the number of efficacy is less 33 over 66 pts 
(25+ 41) at the end of the two stages.
Results: 147 patients were randomized by 33 centers: median age: 
60 ± 8 years, PS 0/1/2 (44/83/20 pts) ; male: 78%, EGFR status: 
wild type 66%, unknown: 34%; recurrent patients: 65% (arms A/B 
:66%/65%), nonsquamous: 86% (arms A/B : 84%/90%), smoking 
status: smokers 35%, formers 57,5%, never 7,5%. Baseline charac-
teristics were balanced between 2 arms. In ITT, the primary objec-
tive was not meet with 18/66 pts without progression at 15 weeks 
in arm A, 17 /66 pts in arm B. In arm A and B, median PFS was 2,2 
(CI95% 1,6-2,8) and 2,5 (CI 95% 1,7-2,8) months and median OS 
was 6,6 (CI 95% 4,3-10,3) and 8,4 (CI 95% 4,5-11,3) months respec-
tively. Toxicity was acceptable in both arms with 60.2 % and 54% of 
G3/4 toxicity in arms A and B, respectively.
Conclusion: The sequential combination of erlotinib with doceta-
xel did not demonstrate any benefit in second-line treatment of 
EGFR wild type or unknown advanced NSCLC, despite acceptable 
toxicity. The Pharmacological hypothesis of synergism between 
erlotinib given sequentially and standard chemotherapy is not con-
firmed in the present study. Clinical trial information: NCT01350817 
/ Supported by an academic grant from Roche, Chugai, Sanofi 
Aventis,with the help of clinical research direction ( Limoges Uni-
versity Hospital)
Keyword: chemotherapy , sequential treatment, Tyrosine kinase 
inhibitors , second line
Conclusion: Amrubicin exhibits modest activity and acceptable 
toxicity when used as a third or later line of chemotherapy for ad-
vanced NSCLC.
Keywords: Third or later line, amrubicin, non-small cell lung can-
cer, Chemotherapy failure
POSTER SESSION 2 - CHEMOTHERAPY  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.10-013 RANDOMIZED NON COMPARATIVE MULTI-
CENTER PHASE II STUDY OF SEQUENTIAL ERLOTINIB 
WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PA-
TIENTS WITH NON SMALL CELL LUNG CANCER (NSCLC) 
AFTER FAILURE OF FIRST LINE CHEMOTHERAPY (TAR-
SEQ): A GFPC 10.02 STUDY.
Jean Bernard Auliac1, Laurent Greillier2, Chrisots Chouaid3, Isa-
belle Monnet4, Herve Le Caer5, Lionel Falchero6, Romain Corre7, R 
Descourt8, Suzanna Bota9, Henry Berard10, Rolland Schott11, Acya 
Bizieux-Thaminy12, Pierre Fournel13, Radj Gervais14, Cecile Dujon15, 
Nathalie Baize16, Ghislaine Fraboulet17, Dominique Paillotin18, M S 
Abdiche19, Chrystele Locher20, Benoit Marin21, Alain Vergnenegre22
1Department Pneumology, Hopital Quesnay/France, 2Multidisciplinary 
Oncology And Therapeutic Innovations, Assistance Publique-Hôpitaux 
De Marseille, Aix Marseille University/France, 3Department Pneumo-
lgy, Hopital Saint Antoine/France, 4Service De Pneumologie, Centre 
Hospitalier Intercommunal De Creteil/France, 5Centre Hospitalier De 
Draguignan/France, 6Centre Hospitalier/France, 7Pneumology, Chu 
Pontchaillou/France, 8Oncologie Thoracique Institut De Cancérologie 
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P2.10-015 LESS TOXIC CHEMOTHERAPY IMPROVES UP-
TAKE OF ALL LINES OF CHEMOTHERAPY IN ADVANCED 
NON SMALL CELL LUNG CANCER, PARTICULARLY IN 
THE ELDERLY: A TEN YEAR RETROSPECTIVE POPULATI-
ON-BASED REVIEW
Nevin Murray, Janessa Laskin, Katherine Ramsden, Sophie Sun, 
Barbara Melosky, Cheryl Ho
Medical Oncology, BC Cancer Agency/Canada
Background: The platinum doublet is standard first-line therapy in 
advanced NSCLC. Over the past decade, well tolerated second-
line therapies have been approved including erlotinib and peme-
trexed. We hypothesize that the introduction of less toxic chemo-
therapy has increased treatment of advanced NSCLC resulting in 
improved survival.
Methods: The BC Cancer Agency provides cancer care to a popu-
lation of 4.5 million. A retrospective review was conducted of all 
referred Stage IIIB/IV patients in four 1 yr time cohorts; C1 baseline 
(1998) and 6 months after the provincial approval of C2 docetaxel 
(2001), C3 erlotinib (2006) and C4 pemetrexed (2007).
Results: 2, 623 patients were referred and 720 had systemic thera-
py. Characteristics: M/F 55%/45%, median age 67 (33-101), ECOG 
<=1/>=2/unknown 33%/56%/11%, never/former/current/unknown 
smoker 9%/35%/36%/20%, squam/nonsquam/NOS 18%/41%/41%. 
More patients received first line chemotherapy over time; 16%, 
23%, 34%, 33% C1-4 respectively. In C1 to C4 uptake of second 
line (21%, 27%, 38%, 55%) and third line (10%, 10% 14%, 18%) 
increased. In C1 the most common first line doublet was cis/vino 
(70%) and in C4, cis/gem (45%). Second line doce was frequently 
used in C2 (51%) but usage decreased in C4 to 7% vs. erlo 50% 
and pem 26%. In the >=70 group (n=1118), 1st line usage increa-
sed from C1 9% to C4 19% and 2ndline in the C2 (doce) 4% to C4 
(erlo+pem avail) 56%. The increased use of systemic therapy was 
associated with improved survival in all patients: C1 4.56 m vs C4 
4.98 m (p=0.004) and treated patients; C1 9.48 m vs C4 12.07 m 
(p=0.014) and the >= 70 group; C1 9.7 m vs C4 12.5 m (p=0.07).
Conclusion: This population-based data set represents the trend 
of treatments over time in a large geographical area, including 
community and tertiary care cancer treatment sites. The introduc-
tion of less toxic systemic therapy for advanced NSCLC resulted in 
an increased proportion of patients treated with first-line chemo-
therapy and an even greater increase in 2nd/3rd line treatment. 
This trend was particularly evident in the elderly. Associated with 
this was a significant improvement in overall survival for all subsets.
Keywords: Second line, population based, elderly
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P2.10-014 A PHASE II STUDY OF BEVACIZUMAB IN 
COMBINATION WITH CARBOPLATIN AND PACLITAXEL 
IN PATIENTS WITH NON-SQUAMOUS (NON-SQ) NON-
SMALL-CELL LUNG CANCER (NSCLC) HARBORING MU-
TATIONS OF EPIDERMAL GROWTH FACTOR RECEPTOR 
(EGFR) GENE AFTER FAILING FIRST-LINE EGFR-TYRO-
SINE KINASE INHIBITORS (TKIS) HANSHIN ONCOLOGY 
GROUP 0109
Yoshinobu Namba1, Takehiro Hattori2, Miyako Satouchi2, Soichiro 
Yokota1, Toru Kumagai3, Fumio Imamura3, Shiro Fujita4, Nobuyuki 
Katagami4, Takashi Nishimura5, Hironobu Sunadome5, Motoko 
Tachihara6, Satoshi Morita7, Shunichi Negoro2
1Department Of Thoracic Oncology, Nho National Toneyama Hospital/
Japan, 2Hyogo Cancer Center/Japan, 3Department Of Thoracic Oncology, 
Osaka Medical Center For Cancer And Cardiovascular Diseases/Japan, 
4Integrated Oncology, Institute Of Biomedical Research And Innovation/
Japan, 5Kyoto-Katsura Hospital/Japan, 6Kobe University Hospital/Ja-
pan, 7Yokohama City University Graduate School Of Medicin/Japan
Background: EGFR-TKIs’ mono-therapy is one of the standard 1st 
line therapy for NSCLC harboring EGFR gene mutations. Although 
platinum doublet ± bevacizumab recommended for 2nd line therapy 
after failing EGFR-TKIs in National Comprehensive Cancer Network 
guideline, there is little information of these setting. Therefore, we 
planned prospective phaseII study to evaluate the efficacy and safety 
of bevacizumab in combination with carboplatin and paclitaxel(PCB) 
for EGFR-TKIs resistant Non-Sq NSCLC.
Methods: In multicenter phase II trial, we recruited non-squamous 
NSCLC harboring EGFR gene mutation after failing EGFR-TKIs. Key 
eligibility criteria were as follows: Non-Sq NSCLC with EGFR mutation, 
failure of 1st line EGFR-TKIs, stageIIIB or IV or recurrence after surgery, 
measurable lesion, age 20 or over, ECOG Performance status (PS) 0 
or 1, adequate organ function. Clinically significant hemoptysis, sym-
ptomatic brain metastasis, uncontrollable hypertension, interstitial 
pneumonia were excluded. Patients received carboplatin (AUC=6/5), 
paclitaxel (200mg/m2), bevacizumab (15mg/kg) intravenously on 
day1 every 3 weeks for three to six cycles, and bevacizumab was 
administered every 3 weeks until disease progression or intolerable 
toxic effects. Primary endpoint was response rate (RR) and secondary 
endpoints were progression free survival (PFS), overall survival (OS), 
disease control rate (DCR) and safety.
Results: A total of 31 patients were assigned between March 2010 
and February 2013. One patient was excluded because of unfitted 
eligibility criteria. Therefore, we analyzed thirty patients’ data. Median 
age was 60 years (45~74), male/female : 11/19, PS 0/1 : 9/21, non-
smoker/smoker : 18/12, EGFR mutation status exon19 del/exon21 
L858R : 20/11, 1st line EGFR-TKIs gefitinib/erlotinib/other : 22/7/1. RR : 
40% (95%CI:22%-58%), DCR : 83% (95%CI:70%-97%), PFS : 6.0 month 
(95%CI:4.8-12.2). Major severe adverse event (Grade 3,4) were one pa-
tient with dyspnea (G4), 6 with fever neutropenia (G3) and 3 patients 
with hyper tension (G3). There was no grade 5 adverse event.
Conclusion: In patients with Non-Sq NSCLC harboring EGFR gene 
mutation failed 1st line EGFR-TKIs, RR of 2nd line PCB therapy was lo-
wer than it was in 1st line phase II study of PCB in Japan, but same RR 
of E4599 study. Safety was similar to previous reports. We considered 
PCB therapy is one of the treatment option in 2nd-line for patient with 
EGFR-TKIs resistant Non-Sq NSCLC.
Keywords: EGFR, Bevacizumab, NSCLC
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P2.10-017 EFFICACY OF PEMETREXED IN ADVANCED 
NON-SMALL CELL LUNG CANCER WITH ASYMPTOMA-
TIC BRAIN METASTASES
Hidenori Kitai, Hajime Asahina, Taichi Takashina, Yasuyuki Ike-
zawa, Jyunn Sakakibara-Konishi, Naofumi Shinagawa, Satoshi 
Oizumi, Masaharu Nishimura
Hokkaido University School Of Medicine/Japan
Background: Conventionally, the role of chemotherapy in brain 
metastases (BM) from non-small cell lung cancer (NSCLC) remains 
limited. However, some cases in which brain metastases (BM) are 
responsive to Pemetrexed (PEM) have been recognized recently.
Methods: We conducted a retrospective analysis of 74 advanced 
NSCLC patients who had received PEM-containing regimens in our 
institution from January 2006 to May 2013.
Results: Twenty-seven patients had been diagnosed as having 
BM before starting chemotherapy of PEM-containing regimens. 
The patient characteristics were: male/female = 12/15; median 
age (range) = 63 (25-85) years; smoking status: ever/never = 13/14; 
performance status: 0/1/2 = 0/26/1; histology: adenocarcinoma/
NSCLC-NOS = 26/1; EGFR mutation status: positive/negative/unk-
nown = 12/12/3; prior EGFR-TKI therapy: yes/no = 13/14 ; response 
to prior EGFR-TKI: CR/PR/SD/PD = 1/8/3/1. Fourteen patients had 
received any local treatments for BM, consisting of 7 whole brain 
radiotherapy (WBRT), 6 stereotactic radiotherapy (SRT), 2 stereot-
actic radiosurgery (SRS) and 2 brain surgery. The PEM-containing 
regimens administered were; CDDP+PEM/CBDCA+PEM/PEM 
alone = 2/9/16. The lines of chemotherapy was; 1st/2nd/3rd/4th 
or later = 5/7/9/6. They received the chemotherapy for a median 
cycle of 3 cycles (range 1-15). The overall response rate (ORR) 
was 14.8% (4/27) in total and the cranial response rate regarding 
BM was 14.8%(4/27), consisting of 1 CR and 3 PR. Of 13 patients 
who received prior EGFR-TKI, the cranial response rate was 23.1% 
(3/13). Of 17 patients without any prior local treatments for BM or 
with disease progression of BM after the prior local treatment, the 
cranial response rate was 23.5% (4/17).
Conclusion: The PEM-containing regimens might be a promising 
therapy for asymptomatic BM in NSCLC including those who show-
ed resistance to EGFR-TKI.
Keywords: pemtrexed, NSCLC, brain metastasis
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P2.10-016 PHASE II STUDY OF GEFITINIB AND INSERTED 
CISPLATIN PLUS DOCETAXEL AS A FIRST-LINE TREAT-
MENT FOR ADVANCED NON-SMALL-CELL LUNG CAN-
CER HARBORING AN EPIDERMAL GROWTH FACTOR 
RECEPTOR ACTIVATING MUTATION
Yuichiro Ohe1, Shintaro Kanda2, Hidehito Horinouchi2, Yutaka 
Fujiwara2, Hiroshi Nokihara2, Noboru Yamamoto2, Ikuo Sekine3, 
Hideo Kunitoh4, Kaoru Kubota5, Tomohide Tamura2
1Department Of Thoracic Oncology, National Cancer Center Hospital 
East/Japan, 2Department Of Thoracic Oncology, National Cancer Center 
Hospital/Japan, 3Department Of Medical Oncology, Graduate School 
Of Medicine, Chiba University/Japan, 4Respiratory Medicine, Mitsui 
Memorial Hospital/Japan, 5Medical Oncology Division, Nippon Medical 
School/Japan
Background: Gefitinib yields a longer progression-free survival 
(PFS) period than platinum-doublet chemotherapy as a first-line 
treatment for patients with advanced non-small-cell lung cancer 
(NSCLC) harboring an epidermal growth factor receptor (EGFR) 
activating mutation, but most patients develop resistance against 
gefitinib after the initial response. We hypothesized that the inser-
tion of platinum-doublet chemotherapy during the initial response 
could prevent the emergence of acquired resistance and prolong 
survival, compared with gefitinib monotherapy.
Methods: We performed a phase II study of the following first-line 
treatment for patients with advanced NSCLC with EGFR mutation. 
Gefitinib (250 mg) was administrated on days 1-56. After a two-
week rest, three cycles of cisplatin (80 mg/m2) and docetaxel (60 
mg/m2) were administered on days 71, 92, and 113. Gefitinib was 
re-started on day 134 and was continued until progression. The 
primary endpoint was the two-year PFS rate. The sample size was 
estimated at 33, and this treatment was considered worthy for 
further development if more than 11 of the 33 patients who started 
treatment had a 2-year PFS.
Results: Thirty-three Japanese patients were enrolled. Twenty-
five patients could recieve the second gefitinib, 12 achieved a PFS 
period of over 2 years, and 7 continued to receive the protocol 
treatment without experiencing progression. The 1-, 2-, and 3-year 
estimated PFS rates were 67.0%, 40.2%, and 36.9%, respectively, 
and the median PFS time was 19.5 months. The 1-, 2-, and 3-year 
estimated survival rates were 90.6%, 71.9%, and 64.8%, respec-
tively, and the median survival time had not been reached at the 
time of analysis. Treatment-related deaths and unexpected severe 
toxicities were not seen.
Conclusion: Our results indicated that first-line treatment consis-
ting of gefitinib and inserted cisplatin plus docetaxel is promising 
in patients with advanced NSCLC with EGFR mutation. A phase III 
study of this treatment compared with gefitinib monotherapy is 
warranted.
Keywords: EGFR mutation, gefitinib, platinum-doublet chemothe-
rapy, non-small-cell lung cancer
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ved for NSCLC in autumn of 2009 in Japan, there are not enough 
data regarding the efficacy and toxicity with Bev treatment in real-
world clinical practice in Japan. We have evaluated the efficacy 
and safety of the combination chemotherapy with Bev in patients 
with non-sq NSCLC at four major hospitals in Shinjuku area, Tokyo, 
Japan.
Methods: From August 2010 to July 2012, 102 patients planned to 
treat with Bev was prospectively enrolled in this study with written 
informed consent. Eligible patients were histlogically or cytolo-
gically documented non-sq NSCLC with advanced stage (IIIB-IV) 
or recurrence, ECOG-PS 0-2, and adequate organ function for 
cytotoxic chemotherapy. Patients received Bev (15mg/kg, every 
3 weeks) plus any chemotherapy (physician’s choice) followed by 
maintenance Bev. The primary endpoints were safety and efficacy 
(PFS). Patients were treated at four major hospitals (three university 
hospitals and one national center) participating in Shinjuku Thora-
cic Oncology Group (STOG).
Results: Patients characteristics: median age (range) 64 (36-85) 
years, male/female = 60/42, clinical staging: IIIB/IV/post-operation 
recurrence/others ＝ 8/77/15/1, ECOG-PS 0/1/2 = 66/34/2, ade-
nocarcinoma/others = 98/4, non-smoker/smoker = 40/60, EGFR 
mutation (+)/(-)/unknown ＝ 43/56/3, 1st line /2nd line />=3rd line ＝ 
56/23/23, Bev combination regimen: CBDCA+PEM/ CDDP+PEM/ 
CBDCA+PTX/ others ＝ 40/22/18/22. At the time of April 2013, 
median Bev administration number (range) was 7 (1-29) in total; 7.5 
(1-29) in 1st line, 8 (1-24) in 2nd line, 7 (1-21) in >= 3rd line. With evalu-
able 102 cases, response rate (RR) was 39.2%, disease control rate 
(DCR) was 90.2%, median PFS was 321 (95%CI: 195-410) days (10.6 
months (M)). Median overall survival was not reached. RR, DCR, 
and PFS were 46.4%, 96.4%, 10.9M with 1st line, 39.1%, 87.0%, 9.1M 
with 2nd line, 21.7%, 78.3%, 9.3M with >= 3rd line. Hematological 
toxicities (>=G3): leucocytopenia 24%, neutropenia 40%, anemia 
8%, thrombocytopenia 5%, febrile neutropenia 3%. Bev related 
adverse events (>=G3): Hypertension 28%, proteinuria 5%, throm-
boembolism 5%, hemosputum 1%. There was no treatment related 
death.
Conclusion: Combination chemotherapy with Bev was effective 
for the patients with non-sq NSCLC in real-world clinical practice in 
Japan, as similar or superior efficacy as clinical trials. Also, adverse 
events were well tolerated. The efficacy was good at 1st line and 
also at 2nd line and thereafter.
Keywords: chemotherapy, non-squamous, NSCLC, Bevacizumab
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P2.10-020 DOSE ESCALATION AND PHARMACOKINETIC 
STUDY OF CARBOPLATIN AND PEMETREXED FOR EL-
DERLY PATIENTS WITH ADVANCED NON-SQUAMOUS, 
NON-SMALL-CELL LUNG CANCER: KUMAMOTO THO-
RACIC ONCOLOGY STUDY GROUP TRIAL 1002
Sho Saeki1, Jiichiro Sasaki2, Akinobu Hamada3, Shinya Sakata1, 
Hiroto Kishi4, Kazuyoshi Nakamura5, Ryo Sato1, Toyohisa Iriki6, 
Hideyuki Tanaka7, Daisuke Notsute8, Kimitaka Akaike8, Koichi 
Saruwatari1, Hiroshi Semba6, Hirotsugu Kohrogi1
1Respiratory Medicine, Kumamoto University Hospital/Japan, 2Respira-
tory Medicine, Kitasato University School Of Medicine/Japan, 3Division 
Of Integrative Omics And Bioinformatics, National Cancer Center Re-
search Institute/Japan, 4Respiratory Medicine, Kumamoto City Hospi-
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P2.10-018 DRUG SELECTION IN NON-SMALL CELL  
LUNG CANCER PATIENTS: PERSPECTIVE OF KOREAN 
PHYSICIAN
Choonhee Son, Mee-Sook Roh
Dong-a University Medical Center/Korea
Background: The main purpose of chemotherapy in patients of 
non-small cell lung cancer (NSCLC) is similar in both physician and 
patients, prolonging survival time and improve quality of life. But, 
priority of the criteria for selection of regimen is different. To inves-
tigate types of systemic anticancer therapy in patients with NSCLC, 
to describe regimen-wise characteristics of patients’ clinical profile, 
and to examine factors influencing the selection of regimen.
Methods: This observational study was conducted at 19 study 
centers in Korea from June 2008 to July 2010. Patients above 18 
years of age with histologically confirmed NSCLC stage IIIa, IIIb, 
or IV, who received systemic chemotherapy for lung cancer for the 
first time and were willing to provide written consent, were inclu-
ded in the study. Descriptive statistics were performed on the data 
collected.
Results: In total, 435 patients were included and evaluated in the 
study. Docetaxel (85.1%) was the most common drug prescribed 
followed by carboplatin (46.4%) and cisplatin (37.9%). Across regi-
mens, no difference in the distribution of patients for tumor-node-
metastasis stage, histology of the disease as well as previous che-
motherapy and radiation therapy was observed. Of all the reasons 
for selecting chemotherapy, efficacy as measured by disease free 
survival/overall survival was reported as being “most important” in 
the highest proportion (28.1%, 122/435) of patients.
Conclusion: For the physicians, the first priority of regimen selec-
ting chemotherapy was efficacy, different from patients’ perspecti-
ve, adverse effects. We should evaluate this again in the era of new 
drugs with less side effects.
Keywords: quality of life, selection of regimen
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P2.10-019 A PROSPECTIVE COHORT STUDY OF NON-
SQUAMOUS NON-SMALL CELL LUNG CANCER PATI-
ENTS TREATED WITH BEVACIZUMAB
Katsuhiko Naoki1, Kenzo Soejima2, Seisuke Nagase3, Toshinori 
Kanemura4, Tatsuo Ohhira3, Yuichiro Takeda5, Norihiko Ikeda6
1Keio Cancer Center, Keio University School Of Medicine/Japan, 2Pul-
monary Medicine, Keio Univerisy School Of Medicine/Japan, 3Surgery 
I, Tokyo Medical University/Japan, 4Chemotherapy And Palliative Care, 
Tokyo Women‘s Medical University/Japan, 5Department Of Respiratory 
Medicine, National Center For Global Health And Medicine/Japan, 6Tho-
racic Surgery, Tokyo Medical University Hospital/Japan
Background: In several clinical trials, first line combination chemo-
therapies with bevacizumab (Bev) have been reported to improve 
clinical outcomes in patients with advanced non-squamous non-
small cell lung cancer (non-sq NSCLC). Although Bev was appro-
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pectively reviewed. The baseline patient characteristics, response 
to gefitinib, and survival were compared between patients with 
postoperative recurrent NSCLC (postoperative group) and patients 
with stage IV NSCLC at diagnosis (stage IV group). Patients were 
not included if they had received other EGFR tyrosine kinase inhi-
bitors before administration of gefitinib.
Results: A total of 169 patients met the eligibility criteria for this 
study (postoperative group; 50, stage IV group; 119). The base-
line characteristics (sex, age, histology, EGFR mutations status, 
prior cytotoxic chemotherapy) were well balanced between both 
groups, with the exception of performance status (PS). Patients in 
postoperative group had better PS than those in stage IV group 
(p = 0.044). At the start of treatment with gefitinib, bone and liver 
metastases were more common in stage IV group (p = 0.002 and p 
= 0.032), and pulmonary metastases were more common in post-
operative group (p = 0.004). There was no significant difference 
in number of metastatic sites between two groups. The response 
rate of gefitinib in postoperative group was similar to that in stage 
IV group (58 vs 61%, p = 0.685). In contrast, progression free sur-
vival (PFS) (median PFS 16.7 vs 9.8 months, p < 0.001) and overall 
survival (OS) (median OS 63.3 vs 23.9 months, p < 0.001) were 
significantly longer in postoperative group than in stage IV group. 
Additionally, postoperative recurrent disease, PS (0-1) and single 
metastatic site were independent prognostic factors in the multi-
variate analysis of survival.
Conclusion: PFS and OS were superior in patients with postope-
rative recurrent NSCLC harbouring EGFR mutations treated by 
gefitinib than in those with stage IV disease. These results suggest, 
postoperative recurrent disease may be considered to be a stratifi-
cation factor in clinical trial for NSCLC with EGFR mutations.
Keywords: non-small cell lung cancer, postoperative recurrent, 
mutations of the epidermal growth factor receptor, gefitinib
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P2.10-022 PROSPECTIVE OBSERVATIONAL COHORT 
STUDY OF SECOND-LINE CHEMOTHERAPY ADMINIST-
RATION AFTER FIRST-LINE PLATINUM-BASED CHEMO-
THERAPY FOR PATIENTS WITH ADVANCED NSCLC IN 
JAPAN (SAPPHIRE STUDY)
Yasushi Goto1, Kiyotaka Yoh2, Kazuma Kishi3, Yasuo Ohashi4, Hi-
deo Kunitoh5
1Department Of Respiratory Medicine, The University Of Tokyo/Japan, 
2Division Of Thoracic Oncology, National Cancer Center Hospital East/
Japan, 3Department Of Respiratory Medicine, Respiratory Center, To-
ranomon Hospital/Japan, 4Department Of Biostatistics, University Of 
Tokyo/Japan, 5Respiratory Medicine, Mitsui Memorial Hospital/Japan
Background: In advanced non- small cell lung cancer (NSCLC), 
second-line chemotherapy (second-CT) after the progression of 
the first-line platinum-based chemotherapy (first-CT) is the stan-
dard of care. More recently, maintenance therapy after the first-CT 
has been reported to be beneficial. However, its impact on overall 
survival appears to be marginal or negligible, when most patients 
could receive timely active second-CT after progression. The pur-
poses of this study are to investigate the proportion of those who 
actually received the second-CT, and to elucidate factors associa-
ted with its administration in advanced NSCLC patients.
tal/Japan, 5Kumamoto Saishunso National Hospital/Japan, 6Kumamoto 
Regional Medical Center/Japan, 7National Hospital Organization Kuma-
moto Medical Center/Japan, 8Miyazaki Prefectural Nobeoka Hospital/
Japan
Background: This study was designed to determine the recom-
mended dose of carboplatin-pemetrexed in elderly(≧70 years 
old), chemotherapy-naïve patients with advanced non-squamous 
non-small-cell lung cancer. Also, we measured the blood level of 
pemetrexed in order to explore significant factors associated with 
toxicity or efficacy.
Methods: The patients were treated with carboplatin and peme-
trexed every three weeks from 4 to 8 cycles. The dose of the anti-
cancer drug escalated according to protocol.
Results: Grade 3 infection was observed as DLT at a dose of car-
boplatin AUC 5 and pemetrexed 500 mg/m2, and we determined 
this phase as a recommended dose. Overall response rate was 
15.3%, and the disease control rate was 76.9% in all cases. The 
median duration of progression-free survival was 3.9 months. The 
AUC of pemetrexed was associated with hematotoxicity, but not 
the efficacy. We observed that renal dysfunction induced high 
blood concentration of pemetrexed.
Conclusion: The combination of carboplatin AUC5 and 500mg/m2 
of pemetrexed is promising for elderly chemo-naïve patients with 
advanced non-squamous NSCLC, but dose reduction of pemetrex-
ed may be required for patients with renal dysfunction in further 
study.
Keyword: erderly, carboplatin, pemetrexed, pharmacokinetics
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P2.10-021 THE EFFECT OF GEFITINIB IN PATIENTS WITH 
POSTOPERATIVE RECURRENT NON-SMALL CELL LUNG 
CANCER HARBOURING MUTATIONS OF THE EPIDER-
MAL GROWTH FACTOR RECEPTOR.
Ryo Ko1, Hirotsugu Kenmotsu1, Yasushi Hisamatsu1, Hiroaki 
Akamatsu1, Shota Omori1, Kazuhisa Nakashima1, Takuya Oyaka-
wa1, Kazushige Wakuda1, Hisao Imai1, Akira Ono1, Tetsuhiko Tai-
ra1, Haruyasu Murakami1, Tateaki Naito1, Keita Mori2, Masahiro 
Endo3, Toshiaki Takahashi1
1Division Of Thoracic Oncology, Shizuoka Cancer Center/Japan, 2Clinical 
Trial-Coordination Office, Shizuoka Cancer Center/Japan, 3Division Of 
Diagnostic Radiology, Shizuoka Cancer Center/Japan
Background: For patients with postoperative recurrent non-small 
cell lung cancer (NSCLC) harbouring mutations of the epidermal 
growth factor receptor (EGFR), EGFR tyrosine kinase inhibitor, such 
as gefitinib, is frequently used in clinical practice, in accordance 
with the treatment for patients with stage IV NSCLC. However, it is 
unclear whether there is a difference in effect of gefitinib between 
patients with postoperative recurrent NSCLC and patients with 
stage IV NSCLC, harbouring EGFR mutations.
Methods: We reviewed consecutive patients with postoperative 
recurrent or stage IV (at diagnosis) NSCLC harbouring EGFR muta-
tions, who were treated with gefitinib at the Shizuoka Cancer Cen-
ter between September 2002 and March 2012. The clinical data of 
the patients were obtained from their medical records, and retros-
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Japan, 4Department Of Oncology, Japanese Red Cross Medical Center/
Japan, 5Department Of Biostatistics And Epidemiology, Yokohama City 
University Medical Center/Japan, 6Thoracic Oncology Research Group/
Japan
Background: The addition of BV to cytotoxic agent(s) prolonged 
survival for non-Sq NSCLC patients (pts). However, there is no defi-
nitive evidence for the cytotoxic agent(s) plus BV is superior to the 
cytotoxic agent(s) alone for elderly non-Sq NSCLC. We conducted 
the feasibility study of PEM plus BV as the first-line treatment for 
elderly advanced or recurrent non-Sq NSCLC.
Methods: Major eligibility and exclusion criteria were followings; 
chemotherapy-naïve; unfit for bolus combination chemotherapy; 
stage III/IV or relapsed non-Sq NSCLC; age≥70; PS 0-1; no evi-
dence of brain metastasis; no history of hemoptysis and irradiation 
for thorax. PEM (500mg/m2) and BV (15mg/kg) were administrated 
intravenously on day 1 every 3 weeks. The primary endpoint was 
toxicity and the secondary endpoints were objective response rate 
(ORR), progression-free survival (PFS), overall survival (OS), and the 
percentage of pts who completed more than 3 cycles.
Results: From November 2010 to April 2012, total 12 pts were en-
rolled. Patients characteristics were following; Male/Female=6/6; 
Median age (range) 78 (72-81); Histology was all adenocarcinoma; 
Activating EGFR mutation No/Yes/unknown=9/2/1; Stage IIIB/
IV/Recurrence=2/8/2; ECOG PS 0/1=6/6; Smoking History Yes/
No=6/6. Severe toxicities (Grade 3≥) were leukopenia (25%), 
neutropenia (25%), anemia (8%), thrombocytopenia (8%), febrile 
neutropenia (8%), anorexia (8%), hypertension (8%), fatigue (8%), 
nausea (8%), and perforation (colon) (8%). No dose-limiting toxicity 
and treatment-related death was occurred. Three patients achie-
ved PR and the ORR was 25%. The median PFS and OS were 5.6 
months (mo) (95% C.I. 1.1-7.9 mo) and 10.3 mo (95% C.I. 6.9-15.6 
mo) in 11 evaluated pts, respectively. The 1-year survival rate was 
49% (95% C.I. 12-79%). Seven of 12 pts (58%) received more than 3 
cycles.
Conclusion: PEM plus BV as first-line treatment for elderly non-Sq 
NSCLC was well tolerable and promising.
Keywords: chemotherapy, Bevacizumab, elderly, NSCLC
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P2.10-024 USEFULNESS OF CREATININE/CYSTATIN C 
RATIO AS A PREDICTIVE MARKER FOR ADVERSE EF-
FECTS OF CHEMOTHERAPY.
Kensuke Suzuki1, Minehiko Inomata1, Kotarou Tokui1, Seisuke 
Okazawa1, Toru Yamada1, Ryuji Hayashi1, Toshiro Miwa2, Kazuyu-
ki Tobe1, Tatsuhiko Kashii2
1First Department Of Medicine, Toyama University/Japan, 2Department 
Of Medical Oncology, Toyama University Hpspital/Japan
Background: Cystatin C has often been used as a marker of renal 
function and rarely is influenced by muscle mass, whereas the 
Creatinine/cystatine C ratio (Cr/CysC) is influenced by muscle 
mass. However, it is unknown if the Cr/CysC ratio can be used as a 
predicitive marker for adverse side effects of chemotherapy. The 
aim of this study is to if the Cr/CysC ratio can be used as a predicti-
ve marker for adverse effects of chemotherapy.
Methods: From April 2010 to September 2011, patients with ad-
vanced NSCLC who received platinum-based first-CT at 30 insti-
tutions in Japan were enrolled in this prospective observational 
study. Baseline characteristics, regimens and responses to the 
first-CT, presence or absense of the second-CT administration, and 
if not administered, its reasons were recorded. This is an interim 
report describing patients with at least 6 months of follow up. This 
study was supported by the Public Health Research Center Found-
ation CSPOR and registered at UMIN#000006393.
Results: A total of 865 eligible patients with advanced NSCLC 
provided patient characteristics and details of the first-CT. Median 
age was 65 (range: 24-86), proportion of patients with adenocar-
cinoma/squamous/NOS/others were 70/20/8/2%, and with EGFR 
mutant/wild/unknown were 10/60/30%. Platinum compound used 
in the first-CT were: cisplatin in 38.3% of the cases, carboplatin in 
57.9%, and nedaplatin in 2.8%. Of the patients with non-squamous 
histology, 24% received bevacizumab. At the time of cut off, 797 
patients were assessable for response of the first-CT. Among 
them, 225 patients had either disease progression or inadequate 
data (NE) to the first-CT and 572 patients were evaluated CR/PR/
SD; 194 (22%) received maintenance therapy, including bevaci-
zumab. Of the 572 patients, 51 have no disease progression after 
the first-CT, and data are not yet available in another 13. Therefore, 
508 patients were further analyzed for the administaration of the 
second-CT. Among those, 132 patients (26%) failed to receive the 
second-CT. The reasons for not receiving were as follows: declined 
PS, 79 (60%); patient refusal, 28 (21%); death of any cause, 6 (5%); 
loss of follow-up and others, 19 (14%). Explorative analysis of asso-
ciation between characterisics and administration of the second-
CT revealed age (<65 vs ≥65, odds ratio [OR], 0.59; 95% CI, 0.39-
0.90, p=0.01), PS (0 vs 1-4, OR 0.33, 95% CI 0.22-0.53, p<0.0001), 
and smoking status (never vs ever, OR 0.47, 95% CI 0.26-0.85, 
p=0.01) as possible factors.
Conclusion: Preliminary results of this large observational study 
in Japan suggested that around one-fourth of the patients missed 
an opportunity to receive appropriate the second-CT. Further 
investigation is needed to clarify optimal management of the pati-
ents after the first-CT, particularly on how to identify the patients 
that would be less likely to receive the second-CT after disease 
progression and thus would be more likely to receive benefit from 
maintenance therapy strategy.
Keywords: maintenance chemotherapy, Non small cell lung cancer
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P2.10-023 FEASIBILITY STUDY OF PEMETREXED (PEM) 
PLUS BEVACIZUMAB (BV) AS THE FIRST-LINE TREAT-
MENT FOR ELDERLY ADVANCED OR RECURRENT NON-
SQUAMOUS (NON-SQ) NON-SMALL CELL LUNG CAN-
CER (NSCLC): TORG1015.
Toshiyuki Kozuki1, Naoyuki Nogami1, Hiromoto Kitajima1, Tet-
su Shinkai1, Fumiaki Kato2, Emiko Sakaida2, Yuichi Takiguchi2, 
Satoshi Ikeda3, Masahiro Yoshida3, Yasunori Enomoto3, Terufu-
mi Kato3, Takashi Ogura3, Shingo Miyamato4, Satoshi Morita5, 
Koshiro Watanabe6
1Dept. Of Thoracic Oncology And Medicine, National Hospital Organiza-
tion, Shikoku Cancer Center/Japan, 2Department Of Medical Oncology, 
Graduate School Of Medicine, Chiba University/Japan, 3Division Of Re-
spiratory Medicine, Kanagawa Cardiovascular And Respiratory Center/
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Results: From January, 2010 to October 2012 a consecutive series 
of 43 pts was treated with wPCT. The median age was 62 yrs (ran-
ge 32-74); all but two presented metastatic disease at the diagno-
sis. Thirty-three, 5, and 5 pts received wPCT as second, third and 
fourth line treatment, respectively. Five pts received only 1 wPCT 
course, 30 pts 2 courses, 3 pts 3 courses, and 5 pts 4 courses, for a 
total number of 94 administered courses. wPCT was well tolerated: 
only 2 pts experienced a grade 3 toxicity (1 pt liver and 1 pt di-
arrhea). No toxicity-related treatment interruptions were recorded. 
Nine pts (21%) achieved a partial response and 9 a stable disease. 
After a median follow-up of 9 mos, the median PFS and OS were 4 
and 11 mos, respectively. The 1-y OS was 30.2%.
Conclusion: From our experience wPCT in daily clinical practice 
may represent a reasonable chemotherapeutic option for pre-
treated aNSCLC pts, with a manageable toxicity profile, and may 
provide disease control rates comparable to those of docetaxel 
and pemetrexed.
Keywords: paclitaxel, Second line, Non small cell lung cancer
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P2.10-026 FINAL RESULTS OF EGFR MUTATION REANA-
LYSIS AND KRAS MUTATION SCREENING BY SCORPION 
ARMS METHOD: PHASE II STUDY OF ERLOTINIB FOR 
EGFR WILD TYPE NON-SMALL CELL LUNG CANCER PA-
TIENTS. CENTRAL JAPAN LUNG STUDY GROUP (CJLSG) 
0903 TRIAL.
Eiichi Maruyama1, Masahiro Morise1, Tetsunari Hase1, Hiroyuki 
Taniguchi2, Hideo Saka3, Joe Shindoh4, Ryujiro Suzuki5, Eiji Koji-
ma6, Kenji Ogawa7, Takuya Ikeda8, Yasuhiro Nozaki9, Masahiko 
Ando10, Masashi Kondo1, Hiroshi Saito11, Yoshinori Hasegawa1
1Department Of Respiratory Medicine, Nagoya University Graduate 
School Of Medicine/Japan, 2Department Of Respiratory Medicine And 
Allergy, Tosei General Hospital/Japan, 3Department Of Respiratory 
Medicine And Medical Oncology, National Hospital Organization, Nago-
ya Medical Center/Japan, 4Department Of Respiratory Medicine, Ogaki 
Municipal Hospital/Japan, 5Department Of Respiratory Medicine, Toyo-
hashi Municipal Hospital/Japan, 6Department Of Respiratory Medicine, 
Komaki Municipal Hospital/Japan, 7Department Of Respiratory Medici-
ne, National Hospital Organization Higashi Nagoya National Hospital/
Japan, 8Department Of Respiratory Medicine, Yokkaichi Municipal 
Hospital/Japan, 9Department Of Respiratory Medicine, Social Insurance 
Chukyo Hospital/Japan, 10Center For Advanced Medicine And Clinical 
Research, Nagoya University Hospital/Japan, 11Aichi Cancer Center 
Aichi Hospital/Japan
Background: Erlotinib might benefit non-small cell lung cancer 
(NSCLC) patients with EGFR wild-type (WT) genotype based on 
the subgroup analysis of the BR21 trial and SATURN trial. How-
ever, the sensitivity of methods for detection of EGFR mutation 
can influence the evaluation of erlotinib efficacy. We conducted 
CJLSG0903 trial, a phase II study of erlotinib for previously treated 
EGFR WT NSCLC patients screened by peptide nucleic acid-locked 
nucleic acid (PNA-LNA) PCR clamp method. The efficacy and sa-
fety results of CJLSG0903 were previously reported at the ESMO 
meeting 2012. Here we present the final results of EGFR mutation 
reanalysis and KRAS mutation screening by S-ARMS method.
Methods: Stage IIIB or IV NSCLC patients were eligible. EGFR mu-
tation status was screened by PNA-LNA PCR clamp method, which 
Methods: We measured cystatin C levels in 25 patients with either 
non-small cell cancer (NSCLC) or small cell lung cancer (SCLC) as a 
marker of renal function at the initial commencement of chemothe-
rapy and conducted a retrospective comparative study utilizing the 
Cr/CysC ratio and clinical data.
Results: Patient characteristics were as follows: median age = 
67 years (age range 54-84 years; age 70 ≤ 10 out of 15 cases); 
male:female = 23:3; NSCLC:SCLC = 18:7; ECOG PS 0-1:2 = 22:3. 
Epidermal growth factor receptor (EGFR) genetic mutation was 
observed in one case, was not present in 13 cases, and the remai-
ning 11 cases were unknown. Twenty two cases were in the first 
line therapy, and 3 cases were in the second line therapy. The ratio 
of platinum-based combination to single agent therapy was 20:5 
cases. NSCLC patients with toxicity grades over 3 had hematolo-
gical toxicity (n = 4, 22.2%) and non-hematological toxicity (n = 3, 
16.7%). All SCLC patients with toxicity grades over 3 had hematolo-
gical toxicity (n = 7, 100%) while non-hematological toxicity wasn’t 
present (n = 0, 0%). There were no significant differences between 
the Cr/CysC ratios in patients > 70 years. There was a highly signi-
ficant difference in the Cr/CysC ratios in patients with NSCLC and 
patients with SCLC (0.92 vs 0.78, p < 0.05). There was significant 
difference between Cr/CysC ratios in patients with toxicity grade 
over 3 and under 2 (0.84 vs 0.70, p<0.05), and this trend was also 
shown in the confined platinum-based combination therapy group 
(0.85 vs 0.69, p < 0.05).
Conclusion: The Cr/CysC ratio could prove useful as a predictive 
marker for adverse effects of chemotherapy in patients with NS-
CLC.
Keywords: chemotherapy, supportive care, adverse effect
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P2.10-025 WEEKLY PACLITAXEL (WPCT) FOR PRE-TRE-
ATED PATIENTS (PTS) WITH ADVANCED NON-SMALL 
CELL LUNG CANCER (ANSCLC): A SINGLE INSTITUTION 
EXPERIENCE IN THE DAILY CLINICAL PRACTICE.
Orazio Caffo, Mariachiara Dipasquale, Viviana Murgia, Antonello 
Veccia, Sonia Brugnara, Alessia Caldara, Antonella Ferro, Michela 
Frisinghelli, Francesca Maines, Lucianna Russo, Barbara Soini, 
Francesco Valduga, Enzo Galligioni
Santa Chiara Hospital/Italy
Background: Pemetrexed and docetaxel represent the reference 
treatments as second line chemotherapy for pts with aNSCLC after 
failure of a platinum-based treatment, with a response rate (RR) < 
10%. However, non-squamous aNSCLC pts could have received 
pemetrexed into the first line setting and docetaxel may present 
a relevant side effects burden, in both 3-week and weekly sche-
dules. wPCT is a well tolerated drug which proved to be active in 
aNSCLC. In the attempt to improve pts compliance we adopted 
wPCT in the daily practice.
Methods: From January, 2010, all pts with aNSCLC progressing 
after platinum-based chemotherapy and eligible for further che-
motherapy received wPCT at 80 mg/sqm for 6 consecutive weeks, 
followed by a 2-week rest. In absence of clinical evidence of pro-
gressive disease at least two courses of wPCT were planned before 
instrumental re-staging. Responders pts continued the treatment 
up to a maximum of 4 courses.
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Results: EGFR gene mutations were detected in 2 of 50 (4%) sam-
ples. Common characteristics of two patients were male, elderly, 
high level of CEA, and good PS. One patient was an on-smoker 
and the other was a heavy smoker. The type of the EGFR gene 
mutation was both exon 21 point mutation. Gefitinib was adminis-
tered to two patients and PRs were observed. Their progression-
free-suvival were 9 months and 20 months.
Conclusion: The frequency of the EGFR gene mutation in Sq was 
low. However, it was suggested that gene mutation positive Sq is 
responded to EGFR-TKI. It is necessary to analyze the EGFR gene 
mutation in Sq.
Keywords: gefitinib, mutation, squamous cell carcinoma, EGFR-
tyrosine kinase inhibitor
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P2.10-028 EFFICACY AND SAFETY OF ERLOTINIB IN 
ELDERLY VERSUS NON-ELDERLY PATIENTS: ANALYSIS 
OF THE POLARSTAR STUDY OF 9,909 JAPANESE NON-
SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREA-
TED WITH ERLOTINIB.
Taro Koba1, Kiyoshi Komuta1, Hiroshige Yoshioka2, Fumio Imamu-
ra3, Shoji Kudoh4, Masahiro Fukuoka5, Akihiro Seki6
1Department Of Respiratory Medicine, Osaka Police Hospital/Japan, 
2Department Of Respiratory Medicine, Kurashiki Central Hospital/Ja-
pan, 3Department Of Thoracic Oncology, Osaka Medical Center For Can-
cer And Cardiovascular Diseases/Japan, 4Double-Barred Cross Hospital 
Japan Anti-tuberculosis Association/Japan, 5Izumi Municipal Hospital/
Japan, 6Chugai Pharmaceutical/Japan
Background: Compared with younger patients, elderly NSCLC pa-
tients are often considered unfit for standard chemotherapy due to 
increased chemotherapy-related toxicity, more comorbidities, and 
the consequent deterioration in patient quality of life. Erlotinib, an 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor 
(TKI), has demonstrated survival benefits with good tolerability in 
previously treated NSCLC patients regardless of EGFR mutation 
status. Erlotinib has become a standard treatment for this indica-
tion. As it is well tolerated compared with cytotoxic agents, erloti-
nib is also expected to be a valid treatment option for previously 
treated elderly NSCLC patients. This analysis of the POLARSTAR 
surveillance study compared the efficacy and safety of erlotinib 
treatment for elderly versus non-elderly patients.
Methods: From December 2007 to October 2009 all recurrent/
advanced NSCLC patients in Japan treated with erlotinib were 
enrolled onto the POLARSTAR surveillance study. Erlotinib effi-
cacy and safety data were analyzed by age group: Group A <75 
years; Group B 75–84 years; and Group C ≥85 years. Kaplan–Meier 
methods were used to estimate median progression-free survival 
(PFS). All adverse event reports were collected and graded using 
the NCI-CTCAE version 3.0 and coded using MedDRA version 
14.1.
Results: Of 9,909 patients evaluated, 9,907 were eligible for safety 
assessment (Group A, n=7,848; Group B, n=1,911; Group C, n=148). 
Baseline characteristics (including histology, smoking status and 
performance status [PS]) were well-balanced between groups. 
Non-hematologic toxicities are shown (Table). Grade 1–4 hemato-
logic toxicities (neutropenia/leukopenia/anemia/thrombocytope-
is known to be a highly sensitive. Primary endpoint was objective 
response rate (ORR). Oral erlotinib 150 mg was given daily until 
progression or unacceptable toxicity.
Results: From February 2010 and April 2012, 53 evaluable patients 
were enrolled. ORR was 11.3% (95% confidence interval: 4.3–
23.0%). We performed preplanned reanalysis of EGFR mutation 
status and KRAS mutation by Scorpion ARMS (S-ARMS) methods 
if remaining samples from participants were available. Samples 
from 26 patients (49%) were available for EGFR mutation reana-
lysis. Only one patient who achieved partial response (PR) was 
EGFR mutation positive (exon 19 deletion). In 25 patients, EGFR 
WT genotype was reconfirmed by S-ARMS method. Two of them 
achieved PR. ORR was 8.0 % in patient with EGFR WT genotype 
confirmed by both PNA-LNA PCR clamp and S-ARMS methods. 
Samples from 42 patients (79%) were available for KRAS mutation 
screening. KRAS mutations were detected in 4 of 42 patients, and 
progressive disease (PD) was observed in all of KRAS mutation 
positive patients.
Conclusion: Erlotinib still shows activity in patients with EGFR WT 
genotype confirmed by two different highly sensitive methods. 
Activating KRAS mutation might be negative predictive factor for 
erlotinib efficacy in patients with EGFR WT genotype. (UMIN Clini-
cal Trials Registry: UMIN000002692)
Keyword: NSCLC
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P2.10-027 MUTATION OF EPIDERMAL GROWTH FAC-
TOR RECEPTOR GENE AND EFFICACY OF GEFITINIB IN 
SQUAMOUS CELL CARCINOMA OF LUNG
Toshiro Miwa1, Tatsuhiko Kashii1, Kensuke Suzuki2, Minehiko 
Inomata2, Takeshi Tsuda2, Kotaro Tokui2, Chihiro Taka2, Seisuke 
Okazawa2, Kenta Kanbara2, Toru Yamada2, Ryuji Hayashi2, Shoko 
Matsui2, Masayoshi Toge3, Kazutaka Senda3, Yoshinori Doki3, Kun-
inori Nomura4
1Department Of Medical Oncology, Toyama University Hospital/Japan, 
2First Department Of Medicine, Toyama University/Japan, 3Department 
Of General Thoracic And Cardiovascular Surgery, Toyama University/
Japan, 4Depatment Of Diagnostic Therapeutic Radiology, Toyama Uni-
versity/Japan
Background: The epidermal growth factor receptor (EGFR) gene 
mutation has been reported as an important predictive factor for 
EGFR-tyrosine kinase inhibitor (TKI) efficacy in NSCLC. In "The 
Lung Cancer Diagnosis and Treatment Guideline published by The 
Japan Lung Cancer Society 2012 edition“, the EGFR gene mutation 
is strongly recommended to be analyzed in deciding the treatment 
policy of advanced non- squamous cell carcinoma. In addition, it 
is known that the EGFR gene mutation is frequently observed in 
adenocarcinoma (Ad), but very rare in squamous cell carcinoma 
(Sq). Efficacy of EGFR-TKI in EGFR gene mutation positive Sq has 
not examined enough.
Methods: We obtained tumor samples from 50 patients diag-
nosed as Sq (excluded Ad-Sq carcinoma) by two or more patho-
logist between January 2008 to March 2013. The EGFR gene 
mutation status was determined by PCR-Invader assay (BML Incor-
poration) and direct sequencing method.
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P2.10-029 EDUCATING COMMUNITY HEALTH PROFES-
SIONALS ABOUT LUNG CANCER: A PILOT EVALUATION 
OF A WEB-BASED EDUCATIONAL TOOL
Peter M. Ellis1, Cheyenne Thannikkotu2, Adrianne Van Dam3, 
Shelley Chambers3, Sally Hapke1, Lorraine Martelli-Reid4, John R. 
Goffin1
1Juravinski Cancer Centre/Canada, 2Medical University Of The Ameri-
cas/Saint Kitts And Nevis,Canada 3Supportive Cancer Care Research 
Unit, Mcmaster University/Canada, 4St Josephs Hospital/Canada
Background: Previous research demonstrated significant de-
lays from the onset of lung cancer symptoms to diagnosis and 
commencement of treatment. This has potential to influence the 
outcome of treatment. However, the diagnosis of lung cancer is 
complicated by considerable overlap between lung cancer sym-
ptoms and those of other common respiratory illnesses such as 
COPD. We sought to evaluate the impact of education of com-
munity health professionals about lung cancer on perception of 
knowledge.
Methods: A web-based educational program was developed by 
expert panel, to disseminate information about lung cancer. Inter-
active small group workshops were organized within local commu-
nities targeting primary care physicians and primary care nurses 
involved in the initial evaluation of patients with suspected lung 
cancer. The web-based application covered lung cancer statistics, 
presenting symptoms, frequently asked questions, links to the new 
diagnostic assessment program, and key advances in treatment. 
Invitations were sent to all family physicians in the Hamilton and 
Haldimand regions of Ontario to attend a pilot session. Pre and 
post questionnaires were administered to assess the utility of the 
educational program. Follow up questionnaires were mailed out 
after six months to evaluate the value of the educational program.
Results: Education sessions were conducted in six family practice 
offices and one occupational health practice, involving 67 health 
professionals. There were 46 pre and 40 post intervention ques-
tionnaires completed (24 physicians, 10 nurses and 12 other). Re-
sponses were similar between city (n=20) and rural-based (n=26) 
health professionals. All respondents felt the educational session 
was beneficial to attend. Over 85% of respondents agreed the 
information was clear and easy to understand, of sufficient detail 
and relevant to practice. Most respondents (88%) felt they would 
use the web-based tool personally and 90% felt they would use 
it for patient education. Following the educational intervention, 
there was some improvement in respondents’ assessment of their 
knowledge about lung cancer: understanding and background 
knowledge about lung cancer (79% v 90%); common presenting 
symptoms of lung cancer (81% v 92%); understand steps needed 
to diagnose lung cancer (79% v 80%), standard approach to treat-
ment of lung cancer (52% v 95%); recent advances in treatment of 
lung cancer (19% v 92%). Six month follow up questionnaires were 
sent to 45 individuals, with 31 replies. Only 4 respondents (13%) 
had used the web-based tool. The most commonly used section 
was on the treatment of lung cancer. The majority of respondents 
(52%) had not seen a lung cancer patient during this time period. 
Other reasons included for not using the program included: no 
need (7%), insufficient time (15%), and did not think about it (11%). 
Respondents’ assessment of their lung cancer knowledge was 
lower at six months (range 45%-80%).
Conclusion: have shown that it is feasible to implement a web-
nia) were observed at <1.0% in each group. One patient had grade 
5 anemia (Group A) and one patient had grade 5 thrombocytope-
nia (Group B). A total of 9,651 patients were eligible for efficacy 
assessment. The median PFS was 65 days for Group A (n=7,701), 
74 days for Group B (n=1,815) and 72 days for Group C (n=135). 
In patients with clinical features associated with better EGFR TKI 
efficacy (adenocarcinoma/non-smoker/PS 0–2/second- or third-line 
setting/EGFR TKI naïve) the median PFS was 176 days (Group A, 
n=651), 213 days (Group B, n=180), and 341 days (Group C, n=14). 
Conclusion: Efficacy and tolerability of erlotinib treatment for el-
derly patients (≥75 years) with previously treated NSCLC was simi-
lar to that seen in younger patients. Erlotinib could be considered 
as standard therapy for elderly NSCLC patients in second- or later 
line treatment settings.
Keyword: erlotinib, elderly, efficacy, safety
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logist (n=39), a worse survival was associated with a poorer patient 
assessed PS (median survival 16.7 vs. 18.2 months for patient as-
sessed ECOG >0 vs. ECOG=0 respectively; p=0.31).
Conclusion: Both physician and patient-assessed ECOG scores 
are predictive of overall survival. In this study, there was only fair 
agreement in ECOG assessed by NSCLC patients and their onco-
logists, with patient scores usually poorer. A number of patients 
would have excluded themselves from therapeutic interventions 
including clinical trials based on their ECOG PS rating. Patient-as-
sessed ECOG scores of > 0 may be associated with worse survival 
despite their oncologist’s more optimistic scoring, a finding which 
may be incorporated to benefit clinical decision-making.
Keywords: clinical decision making, performance status, Non 
small cell lung cancer
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P2.10-031 CHINESE RANDOMIZED PHASE II TRIAL OF 
CUSTOMIZED CHEMOTHERAPY BASED ON BRCA1-
RAP80 MRNA EXPRESSION IN ADVANCED NON-SMALL-
CELL LUNG CANCER (NSCLC) PATIENTS (P) (CHICTR-
TRC-12001860/BREC-CHINA)
Jia Wei1, Xiaoping Qian1, Zhengyun Zou1, Lifeng Wang1, Lixia Yu1, 
Maria Sanchez-Ronco2, Chuanwen You3, Yong Song4, Huiyu Lu5, 
Wenjing Hu1, Jing Yan1, Xingxiang Xu6, Xiaofei Chen7, Xingya Li8, 
Qinfang Wu9, Yan Zhou9, Feiling Zhang10, Rafael Rosell11, Baorui 
Liu1
1The Comprehensive Cancer Center, Affiliated Drum Tower Hospital To 
Medical School Of Nanjing University/China, 2Statistics, University Of 
Alcala De Henares/Spain, 3Suqian General Hosp/China, 4Nanjing Jinling 
Hospital, Nanjing Jinling Hospital/China, 5Taizhou General Hosp/China, 
6Subei General Hosp/China, 7Huaian General Hosp/China, 8Zhengzhou 
No.1 Hosp/China, 9Yixing General Hosp/China, 10Maanshan General 
Hosp/China, 11Medical Oncology, Catalan Institute Of Oncology/Spain
Background: BRCA1 serves as a differential modulator of che-
mosensitivity to docetaxel (doc) and cisplatin (cis). RAP80 targets 
the BRCA1-BARD1 E3 ligase at double-strand breaks. A Spanish 
Lung Cancer Group (SLCG) phase II customized chemotherapy 
trial (NCT00883480) indicated that RAP80 and BRCA1 jointly influ-
enced outcome in NSCLC p treated with cis- or doc-based chemo-
therapy. Based on these findings, the SLCG initiated a randomized 
phase III trial (NCT00617656/GECP-BREC), and we have performed 
a parallel phase II trial comparing non-customized cis/doc with 
customized therapy in metastatic NSCLC p in China.
Methods: Since October 2010, 104 p have been randomized 1:3 to 
control and three experimental arms. p in the control arm receive 
cis/doc; p in the experimental arm receive treatment according 
to their BRCA1 and RAP80 levels: p with low RAP80, regardless 
of BRCA1 levels, cis/gemcitabine (gem); p with intermediate/high 
RAP80 and low/intermediate BRCA1, cis/doc; p with intermediate/
high RAP80 and high BRCA1, doc alone. The primary endpoint is 
progression-free survival (PFS).
Results: PFS was 4.15 months (m) in the control and 3.59 m in the 
experimental arm (P=0.68). Overall survival (OS) was 10.82 m in the 
control and 11.74 m in the experimental arm (P=0.68). Response 
rate (RR) was 23.3% in the control and 32.4% in the experimental 
arm (P=0.48). In ancillary analyses of p with low, intermediate and 
based lung cancer interventional program in family practice. This 
may improve short term knowledge about lung cancer, but this 
does not appear sustained at six months. One limitation to the 
utility of this program is the relative infrequency of lung cancer 
patients seen by individual family physicians.
Keywords: Lung cancer, family physician, education, knowledge
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P2.10-030 EASTERN COOPERATIVE ONCOLOGY GROUP 
(ECOG) SCORE: AGREEMENT BETWEEN NON-SMALL-
CELL LUNG CANCER (NSCLC) PATIENTS AND THEIR ON-
COLOGISTS AND CLINICAL IMPLICATIONS
Marie A. Malalasekera1, Cindy Tan2, Viet Phan3, Po Yee Yip4, Janet-
te Vardy3, Stephen Clarke5, Steven Kao3
1Medical Oncology, Liverpool Hospital/Australia, 2Department Of Nut-
rition And Dietetics, Concord Repatriation General Hospital/Australia, 
3Department Of Medical Oncology, Concord General Repatriation Hos-
pital/Australia, 4Medical Oncology, Macarthur Cancer Therapy Centre/
Australia, 5Department Of Medical Oncology, Royal North Shore Hospi-
tal/Australia
Background: Oncologists use ECOG score to assess patients’ per-
formance status (PS) and guide treatment decisions, but patients 
and doctors do not necessarily agree on their score. We compared 
ECOG scores assessed by NSCLC patients and their oncologists to 
determine if this has implications on treatment and survival predic-
tion.
Methods: NSCLC patients who underwent chemotherapy in pro-
spective inter-ethnic difference and nutrition studies at Concord 
Hospital were included. Patients self-assessed their ECOG score 
as part of the Patient-Generated Subjective Global Assessment 
questionnaire prior to chemotherapy. Kappa was used to assess 
agreement of ECOG score between patients and oncologists. 
Survival was calculated from date of chemotherapy, using Kaplan 
Meier method.
Results: 79 patients (median age 63 years, 86% Stages IIIB/IV, 
median survival of 15.5 months) were included. ECOG scores 
differed in 34 (43%) cases (Table).The interrater reliability bet-
ween patients and their oncologists was Kappa = 0.35 (p <0.001). 
If patient ECOG scores were used, 11 patients (14%) would be 
deemed unfit for chemotherapy (ECOG≥3) and 21 patients (27%) 
would be excluded from clinical trials (ECOG≥2). ECOG status (0 
versus >0) irrespective of assessor was predictive of overall survival 
(18.7 vs. 12.1 months with p=0.023 and 17.4 vs. 11.1 months with 
p=0.017 for patient and oncologist-assessed ECOG respectively). 
In patients whose ECOG score was assessed to be 0 by their onco-
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P2.10-033 PHASE II STUDY OF WEEKLY AMRUBICIN 
IN PATIENTS WITH REFRACTORY OR RELAPSED NON-
SMALL CELL LUNG CANCER
Masahiro Iwasaku1, Akihiro Nishiyama1, Naoki Watanabe1, Kei 
Kunimasa1, Kazuya Tsubouchi1, Saori Oka2, Hiroshige Yoshioka1, 
Chiyoe Kitagawa3, Hideo Saka3
1Department Of Respiratory Medicine, Kurashiki Central Hospital/
Japan, 2Department Of Respiratory Medicine, National Hospital Orga-
nization, Nagoya Medical Center/Japan, 3Department Of Respiratory 
Medicine And Medical Oncology, National Hospital Organization, Nago-
ya Medical Center/Japan
Background: Amrubicin (AMR) is a potent topoisomerase II inhibi-
tor, and promising agent for both small cell and non-small cell lung 
cancer. AMR is usually administered on days 1-3 of a 21-day course 
by intravenous infusion. However, it causes severe, occasionally 
fatal, toxicity of febrile neutropenia. Otherwise, previous trials re-
vealed that a weekly schedule of chemotherapy had a higher dose 
intensity, less severe adverse effects and anti-tumor activity as 
effective as other treatments. We conducted a phase I study, and 
reported the safety and recommended dose in a weekly schedule 
(60 mg/m2 weekly on 1st and 8th day with a rest on day 15).
Methods: Refractory or relapsed non-small cell lung cancer pati-
ents after 1 or 2 regimens, with older than 20 and with adequate 
main organ functions were eligible. AMR was administered at the 
dose of 60 mg/m2 weekly (on days 1 and 8 every 3weeks). Primary 
endpoint was objective response rate. Secondary endpoints were 
adverse events, progression-free survival, and disease control rate 
(CR, PR, and SD).
Results: Thirty-three patients were enrolled. Twelve were female, 
21 were male, and their median age was 67 years (range, 38-80). 
Twenty-four were adeno- carcinoma, 7 were squamous cell carci-
noma, and 2 were non-small cell carcinoma. One hundred twenty-
nine courses were given (median: 3, range: 1-20). The objective 
response rate was 6.0%, and the disease control rate was 51.5%. 
Median follow-up time was 9.3 months, and median progression-
free survival was 2.7 months. Common grade 3/4 adverse events 
were white blood cell decreased (63.6%), neutrophil count decrea-
sed (45.5%), anemia (15.2%), anorexia (15.2%), and fatigue (12.1%). 
Febrile neutropenia was noted in two patients. There was no 
treatment-related death.
Conclusion: Primary endpoint was not met in this study. However, 
weekly AMR showed high disease control rate and good tolerabi-
lity. Weekly AMR is promising in refractory or relapsed non-small 
cell lung cancer patients.
Keywords: amrubicin, chemotherapy, non-small cell lung cancer, 
weekly amrubicin
high BRCA1 levels, PFS in the control arm was 2.66, 4.15 m and 7.5 
m, respectively, while PFS in the experimental arm was 10.66 m, 
3.45 m and 3.06 m, respectively. In the multivariate analysis inclu-
ding PS, treatment arm, BRCA1, RAP80, histology and smoking 
status, only ex-smokers were associated with an increased risk of 
progression (HR, 1.906; P=0.029).
Conclusion: Customized chemotherapy based on BRCA1/RAP80 
expression does not improve PFS. The predictive value of BRCA1 
alone seems to be stronger than that of BRCA1/RAP80 combined.
Keywords: non-small cell lung cancer, BRCA1, Customizing Che-
motherapy
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P2.10-032 PALLIATIVE CHEMOTHERAPY OF LUNG CAN-
CER IN ELDERLY : SINGLE CENTER EXPERIENCES
Jaemin Jo1, Sungheon Song2, Sanghoon Han1
1Jeju National University Hospital/Korea, 2Cheju Halla General Hospi-
tal/Korea
Background: Elderly patients with cancer are significantly under-
represented in all clinical trials, including those for lung cancer. 
However, there is a general agreement that age alone cannot be 
the only parameter to be taken into consideration for decision 
making. We investigated feasibility and efficacy of palliative che-
motherapy for elderly patients with lung cancer.
Methods: We reviewed medical record based on database of Jeju 
National University Hospital. Between January,2007, and Decem-
ber,2012, Elderly patients (aged 70 or more) with lung cancer who 
began to receive palliative chemotherapy were 28 persons. Pro-
gression-free survival(PFS) and overall survival(OS) in terms of Non-
small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) 
were investigated respectively.
Results: Median age of patients were 75 year-old (range, 70-82) 
and 20 patients were male. 20 patients were non-small cell lung 
cancer and eight patients were small cell lung cancer. In overall 
patients, median PFS of 1st line palliative chemotherapy and me-
dian OS were 5.0 months (95% confidence interval[CI], 4.43-9.86 
months) and 18 months (95% CI, 14.99-26.80 months), respec-
tively. In NSCLC patients, mPFS was 5.0months (95% CI, 3.77-11.23 
months) and mOS was 21.5 months (95% CI, 16.63-31.21 months).In 
SCLC patients mPFS and mOS were 5.5 months (95% CI, 2.97-9.53 
months) and 11.0 months (95% CI, 3.46-23.04 months), respec-
tively. 19 patients with NSCLC received sequential second line che-
motherapy after progresssion. median number of chemotherapy 
regimen they received after progression was 1 (range, 1-6, 95% CI, 
0.90-2.40). There was no significant difference of survival between 
age group of 70-74, 75-79 and more than 80.
Conclusion: Palliative chemotherapy for elerly patients with lung 
cancer is feasible. Even patients aged more than 70 would expect 
similar survival benefit compared to younger patients.
Keywords: Lung cancer, chemotherapy, elderly
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P2.10-035 EGFR MUTATION (M) STATUS IN SERUM ONLY 
TO TREAT NON SMALL CELL LUNG CANCER (NSCLC) 
PATIENTS (P)
Enric Carcereny1, Teresa Moran1, Laia Capdevila2, Anna Estival1, 
Olga Fernandez1, Crsitina Queralt1, Alberto Indacochea1, Itziar De 
Aguirre1, Crisitina Buges1, Laia Vilà1, Miquel Taron1, Rafael Rosell1
1Catalan Institute Of Oncology/Spain, 2Medical Oncology, Hospital De 
Sant Pau I Santa Tecla/Spain
Background: Treatment of EGFR mutated NSCLC p with EGFR 
TKIs in phase III trials has shown improved efficacy to standard 
chemotherapy.However, it can be difficult to obtain sufficient tu-
mor tissue for analysis of EGFR m status in a large proportion of p. 
Nevertheless,so far,no data exists for NSCLC p treated according 
to EGFR m status in serum alone.
Methods: We reviewed our database to identify EGFR mutated p, 
excluding those for whom status was available in both serum and 
tissue.We analyzed p treated with an EGFR TKI for whom EGFR 
mutation status was known in serum only(status in tissue unk-
nown due to insufficient material).At the same time, we reviewed 
p in whom EGFR m status in tissue was available over the same 
period in order to compare clinical characteristics and efficacy 
parameters,PFS,ORR and Overall Survival(OS). EGFR m analysis 
was performed in cell free circulating DNA(cfDNA)isolated from 
serum and plasma using the QIAmp DNA blood mini kit.
Results: 9 p with EGFR m detected in serum and 33 p with EGFR 
m in tissue were included. In EGFR mutated p in serum, median 
age 63; male 55.6%; non-smokers 33.3%; former smokers 44.4%; 
ECOG PS 0-1 66.7%; adenocarcinoma 77.8%; deletion19 33.3%, 
L858R 66.7%; EGFR TKI treatment in 1st line 44.4%; 2nd or 3rd line 
55.6%. ORR: complete response (CR) 22.2%; partial response (PR) 
22.2%; stable disease (SD) 22.2%; progressive disease (PD) 11.1%. 
2p had poor PS and died prior to evaluation. mPFS 4.7 months 
(mo). mOS 18 mo. In p with EGFR m in tissue, median age 61; male 
36.4%; non-smokers 75.8%; former smokers 24.2%; adenocarci-
noma 87.9%; deletion19 75.8%; L858R 24.2%; 1st line 54.5%; 2nd 
or 3rd line 45.5%. ORR: CR 15.2%; PR 57.6%; SD 12.1%; PD 15.2%. 
mPFS 8.9 mo. mOS 32.7 mo. The multivariate analysis for OS con-
sidering EGFR m in serum differed according to PS (PS 0-1 16.6 mo 
vs PS > 2 5.2 mo)
Conclusion: Obtaining sufficient tissue from NSCLC p for analysis 
of EGFR m status and other molecular alterations can be difficult. 
Determination of EGFR m in serum alone is feasible, yields similar 
results to mutation status in tissue, and could permit us to take 
treatment decisions.
Keywords: EGFR mutation, serum, Treatment
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P2.10-034 IS SECOND LINE SYSTEMIC CHEMOTHERAPY 
BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG 
CANCER (NSCLC)? : A MULTICENTER DATA EVALUATI-
ON OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY 
(ASMO)
Hatice Odabas1, Arife Ulas2, Kubra Aydin1, Mevlude Inanc3, Asude 
Aksoy4, Dogan Yazilitas5, Mehmet Turkeli6, Sinemis Yuksel1, Ali 
Inal7, Ahmet S. Ekinci2, Alper Sevinc8, Nebi S. Demirci9, Mukremin 
Uysal10, Necati Alkis2, Faysal Dane11, Mahmut Gumus1
1Medical Oncology, Kartal Dr.Lutfi Kirdar Research And Training Hospi-
tal/Turkey, 2Medical Oncology, Abdurrahman Yurtaslan Oncology Hos-
pital/Turkey, 3Medical Oncology, Erciyes University Hospital/Turkey, 
4Medical Oncology, Inonu University Hospital/Turkey, 5Medical Oncolo-
gy, Konya Research And Training Hospital/Turkey, 6Medical Oncology, 
Ataturk University Hospital/Turkey, 7Medical Oncology, Dicle Universi-
ty Hospital/Turkey, 8Medical Oncology, Gaziantep University Hospital/
Turkey, 9Medical Oncology, Ankara Numune Research And Training 
Hospital/Turkey, 10Medical Oncology, Kocatepe University Hospital/Tur-
key, 11Medical Oncology, Marmara University Hospital/Turkey
Background: Although NSCLC patients have a very poor prog-
nosis, they generally need a second line therapy. Studies have 
shown that both systemic chemotherapy and targeted therapies 
are useful in this setting. To determine the patients who would get 
benefit from second line therapy may increase the success rate of 
the treatment. In this multicenter study, we aimed to evaluate the 
parameters that determine the benefit of second line treatment in 
NSCLC.
Methods: Records of NSCLC patients who received second line 
systemic therapy in 11 centers from Turkey were evaluated retro-
spectively. Age, gender, histological subtype, stage at diagnosis, 
performance status, serum hemoglobin level, serum lactate dehy-
drogenase level, response to first line therapy, platinum sensitivity, 
and progression free survival after first line therapy were investi-
gated whether they have any role in detecting the usefulness of 
second line therapy. Additionally, PFS and OS after second line 
therapy were analyzed.
Results: Overall, the data of 904 patients (31% female and 75% 
< 65 years old) were evaluated. Median follow up was 13 (2-197) 
months. The rate of adenocarcinoma, squamous cell carcinoma, 
and NSCLC-NOS were 47%, 32%, and 23%, respectively. At diag-
nosis, 22% of patients had stage 3B, and 78% had stage 4 disease. 
Single agent docetaxel was preferred the most as a second-line 
therapy (21%). The survival analysis showed that median PFS and 
median OS were 4 months (SE: 0.2; 95% CI: 3.6-4.3), and 7 months 
(SE:1: 95% CI: 6-8), respectively. In univariate analysis, performance 
status, normal hemoglobin level, having stage 3B at diagnosis, res-
ponse to first line therapy, and PFS of 3 months or longer after first 
line therapy were found to be significant for overall survival after 
second line therapy (p values <0.05). In multivariate cox regression 
analysis, good performance status, normal hemoglobin level, and 
response to first line therapy were independent prognostic factors 
for survival (p<0.0001, p<0.0001, and p=0.001, respectively).
Conclusion: Our findings revealed that second-line therapy is 
beneficial in patients who have good performance status and who 
responded to the first-line therapy. Detecting the parameters that 
predict the usefulness of second-line therapy may increase the 
success rate and guide the selection of patients for this therapy.
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Conclusion: In this retrospective analysis of updated SEER-Medi-
care data, first-line therapy with BCP was associated with longer 
median survival and reduced hospitalizations compared to CP in 
patients > 65 years of age.
Keyword: NSCLC, survival, hospitalizations, first-line therapy
POSTER SESSION 2 - CHEMOTHERAPY  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.10-037 EFFICACY AND SAFETY OF MAINTENANCE 
PEMETREXED IN PATIENTS WITH ADVANCED NONS-
QUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) 
AFTER COMPLETING AT LEAST 4 CYCLES OF PEMET-
REXED PLUS CISPLATIN INDUCTION TREATMENT: A 
CROSS-TRIAL ANALYSIS OF TWO PHASE III TRIALS
Giorgio V. Scagliotti1, Cesare Gridelli2, Filippo De Marinis3, Michael 
Thomas4, Mircea Dediu5, Jean-Lois Pujol6, Christian Manegold7, 
Belen San Antonio8, Patrick M. Peterson9, William J. John9, Nadia 
Chouaki10, Carla Visseren-Grul11, Luis G. Paz-Ares12
1San Luigi Hospital, Univerisy Of Torino/Italy, 2S.G.Moscati Hospital/
Italy, 3High Specialization Hospitals , Oncological Pulmonary 1st Unit, 
San Camillo-Forlanini/Italy, 4Thoraxklinik Im Universitätsklinikum Hei-
delberg/Germany, 5Institute Of Oncology/Romania, 6Montpellier Acade-
mic Hospital/France, 7Heidelberg University Medical Center/Germany, 
8Eli Lilly And Company/Spain, 9Eli Lilly And Company/United States Of 
America, 10Eli Lilly And Company/France, 11Medical Oncology, Eli Lilly 
And Company/Netherlands, 12University Hospital/Spain
Background: In a phase III trial, JMDB, the subgroup of patients 
with nonsquamous histology showed a significant improvement in 
survival after treatment with first-line pemetrexed + cisplatin (pem 
500 mg/m2 + cis 75 mg/m2 every 21 days for a maximum of 6 cyc-
les). In PARAMOUNT, a double-blind, placebo-controlled, phase 
III trial, 539 patients with advanced nonsquamous NSCLC and an 
Eastern Cooperative Oncology Group performance status (ECOG 
PS) of 0 or 1 were randomized to maintenance pem or placebo 
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P2.10-036 OVERALL SURVIVAL AND HOSPITALIZATION 
RATES IN MEDICARE PATIENTS DIAGNOSED WITH AD-
VANCED NSCLC TREATED WITH BEVACIZUMAB- PACLI-
TAXEL-CARBOPLATIN VS PACLITAXEL-CARBOPLATIN: A 
RETROSPECTIVE COHORT STUDY
Corey J. Langer1, Arliene Ravelo2, Sebastien Hazard2, Annie Gue-
rin3, Dominick Latremouille-Viau3, Raluca Ionescu-Ittu3, Eric Q. 
Wu4, Suresh S. Ramalingam5
1Abramson Cancer Center, University Of Pennsylvania/United States Of 
America, 2Genentech, Inc./United States Of America, 3Analysis Group/
Canada, 4Analysis Group/United States Of America, 5Department Of 
Hematology And Medical Oncology, Winship Cancer Institute Of Emory 
University/United States Of America
Background: The study aimed to compare overall survival and 
hospitalization rates for Medicare patients diagnosed with advan-
ced nonsquamous non-small cell lung cancer (NSCLC) and treated 
with first-line bevacizumab-carboplatin-paclitaxel (BCP) vs. carbo-
platin-paclitaxel (CP).
Methods: Patients aged ≥65years first diagnosed with nonsqua-
mous NSCLC stage IIIB/ IV between 2006 and 2009 and treated 
with first-line BCP or CP therapy were identified in the SEER-Medi-
care database that links cancer registry and Medicare claims data 
from United States. Outcomes were measured from the treatment 
initiation date to the end of data availability on 12/31/2010 for 
hospitalizations and 12/31/2011 for survival. Survival and hospi-
talization rates are reported from Kaplan-Meier analyses over the 
follow-up period. Bootstrap methodology was used to test treat-
ment groups differences in median time to death and first hospita-
lization. Age-stratified survival analyses were conducted using age 
75 as a cut point. Inpatient utilization rates are also reported per 
100 patient-days for each treatment group and compared in terms 
of incidence rate ratios (IRR) estimated from negative binomial 
models adjusted for potential confounders.
Results: Of 1,706 patients, 592 (34.7%) received BCP and 1,114 
(65.3%) received CP by inclusion criteria, while 692 (40.6%) were 
≥75 years of age. Patient characteristics were balanced between 
arms for age, sex, disease stage. The BCP group had fewer pre-
treatment comorbidities, greater proportion of adenocarcinoma 
histology, and differences in ethnicity, SEER region, and income 
compared to the CP group. The median survival time was 10.5 
months in the BCP group vs. 8.4 months in the CP group (2.1 
months difference, p=0.0007). The difference in median overall 
survival favoring BCP over CP groups was 1.3 months for patients 
aged 65-74 years (p=0.11), and 3.3 months for those aged ≥75years 
(p=0.006). At 6-months and 1 year of follow-up, survival rates for 
all subjects were, respectively, 70.3% and 43.8% of BCP patients 
vs. 60.6% and 37.0% of CP patients. After 1 year of follow-up, 
69.5% of BCP vs. 75.1% of CP had ≥ 1 hospital admission. Hospi-
talization rates were significantly lower for BCP patients (adjusted 
IRRs: 0.82, p=0.003 and 0.77, p=0.002 for hospital admission and 
hospitalization days). The difference in median time to first hospi-
talization was 2.1 months (p <.0001). Additional statistics are pre-
sented in the Table. 
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Conclusion: The PARAMOUNT placebo arm showed results con-
sistent with the JMDB homogeneous group treated with pem+cis. 
The addition of pem continuation maintenance treatment results 
in a statistically significant increase in OS and PFS. Although there 
was an increase in the incidence of grade 3/4 toxicities with longer 
exposure to pem+cis or maintenance pem, the overall incidence 
remains low, underscoring the relative safety of these treatment 
regimens.
Keyword: efficacy,safety,pemetrexed maintenance,nonsqamous 
NSCLC
after completing 4 cycles of pem+cis without disease progression.
Methods: We compared patients from the two randomized arms 
of PARAMOUNT with a selected homogeneous population from 
JMDB: 346 patients with advanced nonsquamous NSCLC and an 
ECOG PS of 0 or 1 who completed at least 4 cycles of pem+cis 
without disease progression. Efficacy outcomes included overall 
survival (OS) and progression-free survival (PFS) measured from 
the start of treatment with pem+cis and analyzed by Kaplan-Meier 
and Cox methods. Rates of toxicities were calculated without for-
mal statistical comparison.
Results: Outcomes for the JMDB homogeneous group were simi-
lar to the PARAMOUNT placebo arm (PFS: 6.24 vs 5.59, p=0.117; 
OS: 14.23 vs 13.96, p=0.979). The PARAMOUNT pem group had 
statistically superior efficacy compared with the JMDB homo-
geneous group (PFS: 7.46 vs 6.24 p<0.00001; OS: 16.89 vs 14.23 
p=0.003). Patients who received pem maintenance displayed nu-
merically higher incidences of drug-related serious adverse events 
(SAEs) compared with JMDB patients who received ≥4 cycles of 
pem+cis (10.6% vs 2.9%); grade 3/4 anemia and fatigue were hig-
her in the pem arm of PARAMOUNT. A comparable number of 
patients (approximately 2/3) on both arms of PARAMOUNT and 
on JMDB received post-discontinuation systemic therapy (PDT). 
Results are summarized in Table 1. Table 1: Summary of survival, 
post-discontinuation systemic therapy , and selected drug-related 
adverse events in the PARAMOUNT pem and placebo arms and 
the JMDB homogeneous group  
PARAMOUNT pem 
arm (n=359) 
PARAMOUNT placebo 
arm (n=180) 
JMDB homogeneous 
group (n=346) 
PFS 
Median (95% CI), mos 7.46 (6.90-8.57) 5.59 (5.45-5.95) 6.24 (5.91-6.54) 
Cox unadjusted HR (95% CI) 0.66 (0.56-0.77)* 0.86 (0.72-1.04)** 
Unadjusted log-rank p-value <0.00001* 0.117** 
OS 
Median (95% CI), mos 16.89 (15.77-18.99) 13.96 (12.88-15.51) 14.23 (12.94-15.05) 
Cox unadjusted HR (95% CI) 0.75 (0.63-0.91)* 1.00 (0.81-1.24)** 
Unadjusted log-rank p-value 0.003* 0.979** 
Received any PDT, n % 231 (64.3) 129 (71.7) 207 (59.8) 
Patients with ≥1 drug-related 
SAE, n (%) 
38 (10.6) 8 (4.4) 10 (2.9) 
Hematologic grade 3/4 toxici-
ties, n (%) 
Anemia Hemoglobin decreased 
Hemoglobin 
16 (4.5) 2 (0.6) 0 (0.0) 2 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 10 (2.9) 
Neutropenia Neutophils/granulo-
cytes 
17 (4.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 18 (5.2) 
Nonhematologic grade 3/4 to-
xicities, n (%) 
Fatigue 11 (3.1) 2 (1.1) 5 (1.4) 
 
*PARAMOUNT pem arm vs JMDB homogeneous group; **PARA-
MOUNT placebo arm vs JMDB homogeneous group. Abbrevia-
tions: PDT=post-discontinuation systemic therapy; PFS: progressi-
on-free survival; OS: overall survival; SAE: serious adverse event
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Paclitaxel
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P2.10-039 OUTCOMES OF FIRST LINE BEVACIZUMAB-
BASED CHEMOTHERAPY FOR NSCLC RELATIVE TO THE 
MEDICATIONS USED TO CONTROL HYPERTENSION 
(HTN).
Haythem Ali1, Muath Dawod2, Diana Kostoff2, Danielle L. Heide-
mann2, Meredith Mahan2
1Hematology And Oncology, Henry Ford Hospital/United States Of 
America, 2Henry Ford Hospital/United States Of America
Background: Several studies have suggested a correlation bet-
ween development of hypertension and response to bevacizumab 
therapy. Most studies have suggested a prolongation of progres-
sion free survival and possibly overall survival in patients who 
develop emergent hypertension during therapy. Preclinical data 
suggests an interaction between the renin-angiotensin “RA” sys-
tem and the vascular endothelial growth factor (VEGF) system. This 
interaction between the two systems may lead to activation of the 
RA system when the VEGF system is inhibited. Studies have sugge-
sted an activated RA system induces a pro-proliferative response 
in tumor tissue. We hypothesize that this interaction between the 
RA and VEGF systems results in a differential response to VEGF 
therapy when angiotensin modifying drugs (AMD) are used in the 
treatment of bevacizumab induced HTN.
Methods: We evaluated patients treated at our institution with 
bevacizumab containing chemotherapy in the first line setting 
for locally advanced or metastatic non small cell lung cancer and 
continued bevacizumab therapy until progression, development 
of adverse events or death. The primary endpoint was Time to 
Treatment Failure (TTF) defined as the time from initiation of beva-
cizumab therapy until discontinuation for progression, adverse 
events or death. Patients were compared based on history of pre-
existing HTN, emerging HTN, exposure to antihypertensive drugs 
(AHD) or exposure to AMD (ace inhibitors “ACEi” or angiotensin 
receptors blockers “ARB”)
Results: 75 patients met the inclusion criteria. 38 patients (51%) 
had preexisting hypertension, 41 (55%) patients were taking an 
antihypertensive drug prior to the start of chemotherapy and 24 
(32%) patients developed emergent hypertension. The median 
TTF for patients with emergent HTN was 13.1(95% CI: 10.1, 19.9) 
months versus for those without exposure to AHD was 4.7 (95% CI: 
3.5, 5.6) months (p= 0.076). The median TTF for patients with HTN 
who were treated with AMD was 4.9 (95% CI: 29, 7.5) months com-
pared to 6.2( 95% CI:4.0, 12.3) months for patients treated with all 
other AHD ( P=0.716) and 4.7( 95% CI:3.5, 5.6) months for patients 
without exposure to AHD (p=0.438).
Conclusion: We did not observe a statistically significant diffe-
rence in TTF between any of the groups studied. We specifically 
did not observe an advantage to using an AMD over other AHDs 
for the treatment of HTN during bevacizumab therapy. We did 
observe a trend towards longer TTF in patients who developed 
emergent HTN commensurate to currently published data.
Keyword: Bevacizumab, hypertension, angiotensin
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P2.10-038 NAB-PACLITAXEL IN COMBINATION WITH 
CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS 
WITH ADVANCED NON-SMALL CELL LUNG CANCER 
(NSCLC): ANALYSIS OF PREDICTIVE FACTORS
Vera Hirsh1, Ray Page2, Amy Ko3, Markus F. Renschler3, Mark A. 
Socinski4
1McGill University Health Center/Canada, 2The Center For Cancer 
And Blood Disorders/United States Of America, 3Celgene Corporation/
United States Of America, 4Hematology/Oncology, University Of Pitts-
burgh/United States Of America
Background: Identification of predictive factors is critical for appro-
priate selection of patients and chemotherapy regimen. In a phase 
III trial, nab-paclitaxel (nab-P, 130 nm albumin-bound paclitaxel 
particles) + carboplatin (C) vs solvent-based paclitaxel (sb-P) + C 
significantly improved ORR (primary endpoint; 33% vs 25%, P = 
0.005), with a trend toward improved OS and PFS in patients with 
advanced NSCLC. nab-P/C vs sb-P/C was associated with less severe 
peripheral neuropathy, arthralgia, and myalgia, but more anemia and 
thrombocytopenia. This exploratory analysis examined the correlation 
between several key patient and clinical factors and clinical outcomes 
with nab-P/C vs sb-P/C.
Methods: Patients with untreated stage IIIB/IV NSCLC were rando-
mized 1:1 to nab-P 100 mg/m2 on d 1, 8, 15 or sb-P 200 mg/m2 d 
1 q21d; both arms received C AUC 6 d 1 q21d. ORR and PFS were 
assessed by blinded, centralized review. P values for ORR were 
based on chi-square test, and those for OS and PFS were based on 
log-rank test. Factors, including sex, age (< 70 and ≥ 70 y), histology 
(squamous and nonsquamous), stage (IIIB/IV), and geographic region 
(North America, Eastern Europe, and Asia/Pacific), baseline ECOG 
score, smoking status, diabetes, body mass index, number and loca-
tion of metastatic sites, were analyzed for association with outcomes; 
of these, the first 5 were prespecified stratification factors for the trial.
Results: The hazard ratio (HR)/risk ratio favored nab-P/C for ORR, PFS, 
and OS for most factors analyzed. Significant quantitative treatment-
by-predictive factor interactions were noted for several key factors, 
including number of metastatic sites, diabetes, histology, and age, 
with respect to outcomes, and the comparative treatment effect was 
maintained in all other subgroups. In patients with ≥ 4 metastatic 
sites, significant treatment differences favoring nab-P/C were noted 
for ORR (response rate ratio [RRR] 3.40; P = 0.003) and OS (HR 0.562; 
P = 0.009) and trended in favor of nab-P/C for PFS (HR 0.735; P = NS). 
In patients with diabetes, significant treatment differences favoring 
nab-P/C were noted for ORR (RRR 1.935; P = 0.046) and PFS (HR 0.416; 
P = 0.016) and trended in favor of nab-P/C for OS (HR 0.553; P = NS). 
In patients with squamous NSCLC, significant treatment differences 
favoring nab-P/C were noted for ORR (RRR 1.68; P < 0.001) and tren-
ded in favor of nab-P/C for OS (HR 0.890; P = NS). In patients ≥ 70 y, 
significant treatment differences favoring nab-P/C were noted for OS 
(HR 0.583; P = 0.009) and trended in favor of nab-P/C for ORR (RRR 
1.385; P = 0.196) and PFS (HR 0.687; P = NS). No treatment differen-
ces significantly favoring sb-P/C were observed.
Conclusion: A trend toward improved outcomes was noted with nab-
P/C vs sb-P/C in most factors analyzed. Squamous NSCLC, diabetes, 
age ≥ 70 y, and ≥ 4 metastatic sites were predictive of improved 
outcomes with nab-P/C vs sb-P/C. These predictive factors should be 
taken into consideration when selecting the appropriate treatment for 
patients with advanced NSCLC.
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0.86-0.95, p<0.001) accounting for all other independently signi-
ficant predictors, namely: estimated neutrophil-lymphocyte ratio 
>5 (HR 3.15, 95% CI 1.76-5.64, p<0.001); haemoglobin <120g/L (HR 
1.93, 95% CI 1.3-2.9, p=0.001) and total white cell count >11x109/L 
(HR 1.55, 95% CI 1.05-2.27, p=0.03).
Conclusion: Oncologists‘ estimates of survival time were inde-
pendently associated with observed survival time and provided a 
reasonable basis for estimating worst-case, typical and best-case 
scenarios for survival. Oncologists’ estimates provide useful addi-
tional prognostic information, above and beyond that provided by 
established prognostic factors.
Keyword: Prognosis, Survival time, advanced non-small-cell lung 
cancer
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P2.10-041 OPTIMISING REGULATORY T CELL (TREG) DE-
PLETION IN COMBINATION WITH CHEMOTHERAPY FOR 
ENHANCED ANTI-TUMOUR IMMUNITY
Alistair M. Cook, Alison Mcdonnell, Bruce Robinson, Michael Mill-
ward, Richard Lake, Anna K. Nowak
School Of Medicine And Pharmacology, University Of Western Austra-
lia/Australia
Background: Cytotoxic chemotherapy is widely used to palliate 
malignant pleural mesothelioma (MM) and non small cell lung 
cancer (NSCLC). While originally considered detrimental to the 
immune system, there is now abundant preclinical data showing 
that chemotherapy can enhance anti-cancer immunotherapy. Tregs 
are immunosuppressive CD4+ T cells thought to inhibit anti-tumour 
immune responses; murine data suggests that Treg eradication 
may augment existing anti-tumour immunity. Cyclophosphamide 
(CTX) is immunostimulatory and at low doses selectively depletes 
Tregs in mice and humans. The primary objective of this study is to 
identify an optimum dose and schedule of iterative low dose oral 
CTX for Treg depletion in the context of pemetrexed-based che-
motherapy, and to determine how treatment affects the function 
and phenotype of the cellular immune response.
Methods: In this single centre phase 1b study we investigate an 
optimum dose and schedule of iterative low dose oral CTX for Treg 
depletion, in the context of pemetrexed-based chemotherapy, and 
how treatment affects the function and phenotype of the cellular 
immune response. Thirty-one patients with advanced malignant 
pleural mesothelioma (MM) or non-small cell lung cancer (NSCLC) 
received standard doses of pemetrexed ± cisplatin or carboplatin 
on a 21 day schedule (6 cycles max.). From the second cycle, es-
calating doses of oral CTX were administered, initially with 50 mg 
daily. Weekly peripheral blood samples were collected, and the 
proportion of Tregs within the CD4+ population (Treg%) determi-
ned by flow cytometry, amongst other immunological parameters.
Results: 31 participants enrolled on the study (27 MM, 4 NSCLC). 
The mean number of treatment cycles completed was 4.2 from 
a potential total of 6 cycles, with 20 participants on-study for at 
least 4 cycles, and the combination was safe and feasible. Contrary 
to our initial hypothesis, CTX treatment did not reduce the Treg 
proportion of CD4+ T cells in peripheral blood, with baseline Treg 
(CD127loCD25+Foxp3+) proportion of CD4+ T cells at 4.44±1.56% 
and no significant change observed when comparing values from 
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P2.10-040 PROGNOSTIC SIGNIFICANCE, ACCURACY 
AND USEFULNESS OF ONCOLOGISTS‘ ESTIMATES OF 
SURVIVAL TIME FOR PATIENTS STARTING FIRST-LINE 
CHEMOTHERAPY FOR ADVANCED NON-SMALL-CELL 
LUNG CANCER (ANSCLC)
Belinda E. Kiely1, Anne-Sophie Veillard1, John A. Davidson2, 
Mateya E. Trinkaus3, Karen P. Briscoe4, Brett Hughes5, Stephen 
Begbie6, Nick Pavlakis7, Michael Millward8, Michael Boyer9, Chris 
Brown1, Nick Muljadi1, Xanthi Coskinas1, Martin Stockler1
1Nhmrc Clinical Trials Centre, University Of Sydney/Australia, 2Medical 
Oncology, Royal Perth Hospital/Australia, 3Markham Stouffville Hos-
pital, University Of Toronto, Markham/Canada, 4Coffs Harbour Health 
Campus/Australia, 5Oncology, The Prince Charles Hospital Brisbane/
Australia, 6Port Macquarie Base Hospital/Australia, 7Department Of 
Medical Oncology, Royal North Shore Hospital/Australia, 8University Of 
Western Australia/Australia, 9Medical Oncology, Sydney Cancer Cen-
tre/Australia
Background: Oncologists are frequently required to provide esti-
mates of survival time for their patients with advanced cancer. The 
aims of this study were to determine the accuracy and prognostic 
significance of oncologists’ estimates of survival time above and 
beyond conventional prognostic factors.
Methods: Medical oncologists from 26 sites in Australia and New 
Zealand recorded the “expected survival time in months” for in-
dividual patients with ANSCLC prior to randomisation in a trial of 
first-line chemotherapy with a platinum-based doublet. Blood sam-
ples, demographics, tumour and treatment characteristics were 
collected at baseline along with the oncologist’s rating of each 
patient using Spitzer’s Quality of Life Index (SQLI). Based on previ-
ous studies, we deemed estimates within 0.75-1.33 times observed 
survival as precise, and expected 50% of patients to live longer 
(or shorter) than their oncologist’s estimate, 50% to live from half 
to double their oncologist’s estimate (typical scenario); 5-10% to 
live ≤¼ of their estimate (worst-case scenario); and, 5-10% to live 
≥3 times their estimate (best-case scenario). Associations between 
estimated and observed survival times in months were assessed 
with Cox proportional hazards regression before and after ad-
justment for baseline prognostic factors including age, gender, 
Eastern Cooperative Oncology Group performance status (ECOG 
PS), cancer extent, histology, co-morbidities, laboratory results and 
SQLI.
Results: Estimates of survival were available for 244 (98%) of the 
first 250 patients randomised. Patient characteristics were: median 
age 64 years; female 40%; adenocarcinoma 64%; ECOG PS 0-1 
92%; and distant metastases 71%. After a median follow-up of 21 
months there were 172 deaths (69%). The median (interquartile 
range, IQR) for observed survival was 10 months (5-20) and for 
estimated survival was 11 months (9-12). Oncologists’ estimates 
were imprecise (22% from 0.75-1.33 times observed) but well cali-
brated (47% of patients lived shorter than expected and 53% lived 
longer than expected). The proportions of patients with observed 
survival times falling within ranges bounded by simple multiples of 
their estimated survival times corresponded closely with our a-
priori hypotheses: 10% lived ≤1/4 of their estimated survival time, 
53% lived from half to double their estimated survival time, and 
13% lived ≥3 times their estimated survival time. The oncologist’s 
estimate of survival time at baseline was the strongest predictor 
of observed survival in both univariable analysis (HR 0.90, 95% CI 
0.86-0.95, p<0.001) and multivariable analysis (HR 0.90, 95% CI 
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PS 0-2 and 14,3% resp 15,9% had PS 3-4. Chemotherapy given to 
387(32,4%) of the Swedish and 58(36,9%) of the immigrants, conco-
mitant chemo-radiotherapy to 90(7,5%) resp 16(10,2%), radiothe-
rapy against the tumor 8,4% resp 8,3%, SBRT to 2,7% resp 1,3%. 
Surgery were performed among 9,1% of the Swedish and 10,8% 
of the immigrants, 5,9% resp 4,5% given adjuvant chemotherapy. 
Approximately 20% of the Swedish and 15,9% of the immigrants 
given no therapy at all. There was no significant differences in 
treatment between the two groups p<0.551.The median survival 
time for the Swedish patients was 245 days and for other nationa-
lities it was 269 days with no statistical significant difference. For 
Swedish female patients the median survival time was 273 days 
and for females from other nationalities it was 329 days with no sig-
nificant difference.No significant differences in survival and staging 
between the swedish and the imigrants. There was no significant 
difference in survival between Swedish and non-Swedish patients 
within performance status groups.
Conclusion: In this study, we used cohort of patients with lung 
cancer (except carcinoid), with a focus on ethnicity, to determine 
whether racial/ethnic disparities exist in overall survival. Another 
objective of our analysis was to determine whether any differences 
in survival could be attributed to disease-associated variables. To 
our best knowledge no previous study has investigated the inci-
dens of lung cancer in immigrants in Sweden. This study showed 
no significant difference in survival between immigrants and Swe-
dish patients with lung cancer.
Keyword: Imigrants, lung cancer, treatment, survival
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P2.10-043 PHASE II STUDY OF BIWEEKLY IRINOTECAN 
PLUS BEVACIZUMAB IN HEAVILY TREATED ADVANCED 
NON-SMALL CELL LUNG CANCER (NSCLC)
Andres F. Cardona1, Oscar Arrieta2, Mauricio Cuello3, Luis Cor-
rales4, Carlos Vargas1, Claudio Martin5, Hernán Carranza1, Jorge 
M. Otero1, July Katherine Rodriguez6, Luis Más7, Pilar Archila6, 
Guillermo Bramuglia8, Zulay Pastrán9, Elizabeth Curcio10, Leonar-
do Rojas2, Laura Bernal1, Alma D. Campos Parra2, Petros Gianni-
kopoulos11, Rafael Rosell12
1Clinical And Translational Oncology Group, Fundación Santa Fe De 
Bogotá/Colombia, 2Thoracic Oncology Clinic And Laboratory Of Experi-
mental Oncology, Instituto Nacional De Cancerología (INCAN)/Mexico, 
3Clinical Oncology, Hospital De Clínicas, Udelar/Uruguay, 4Clinical 
Oncology, Hospital San Juan De Dios-ccss/Costa Rica, 5Oncology, Alex-
ander Fleming/Argentina, 6Fundation For Clinical And Applied Cancer 
Research – Ficmac/Colombia, 7Clinical Oncology, Instituto De Enfer-
medades Neoplásicas/Peru, 8Fundación Investigar/Argentina, 9Clinical 
Oncology, Policlínica Metropolitana/Venezuela, 10Grupo De Trabajo De 
Oncologia Médica/Venezuela, 11Cancer Therapeutics Innovation Group/
United States Of America, 12Medical Oncology, Catalan Institute Of 
Oncology/Spain
Background: Irinotecan and bevacizumab are effective against 
non-small cell lung cancer (NSCLC) and synergism with non-cross-
resistance has been demonstrated in preclinical studies.
Methods: Twenty-four patients having heavily treated metastatic 
NSCLC were enrolled from March 2011 to November 2012. Sixteen 
of these subjects had never been exposed to bevacizumab and 
8 had received antiangiogenic therapy as part of their first-line 
the end of each treatment cycle. Doses above 50/100 mg did not 
improve depletion. However, analysis of the T-effector cell popula-
tion has demonstrated an increased frequency of CD38hiHLA-DRhi 
cells within the total CD8+ T cell pool. From the perspective of 
biological relevance, the ratio of activated T-effector cells to Tregs 
changes minimally during the first cycle of standard care chemo-
therapy (baseline = 0.21±0.15 T-effectors per Treg); however, from 
mid-way through cycle 2 (when CTX treatment begins) onward a 
notable and variable increase in the proportion of activated T-ef-
fector cells is observed (end of cycle 3 = 2.21±3.83 T-effectors per 
Treg). Detailed immunological data will be presented.
Conclusion: These data suggests that CTX with chemotherapy can 
increase the proportion of activated T-effector cells, an observati-
on that has the potential to improve anti-tumour immunity or che-
mo-immunotherapy efficacy. We postulate that CTX may affect the 
function rather than numbers of Treg cells, decreasing their ability 
to suppress the proliferation of CD8+ effector T cells.
Keywords: mesothelioma, immunotherapy, Treg, chemoimmuno-
therapy
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P2.10-042 LUNG CANCER AMONG SWEDISH AND IMI-
GRANTS. INCIDENS, HISTOPATHOLOGY, TREATMENT 
AND SURVIVAL.
Hirsh Koyi1, Eva Brandén1, Gunnar Hillerdal1, Olov Andersson2, 
Hans Högberg3
1Department Of Respiratory Medicine, Gävle Hospital/Sweden, 2De-
partment Of Respiratory Medicine And Allergy, Karolinska Institutet/
Sweden, 3Centre For Research And Development, Uppsala University/
county Council Of Gävleborg, Sweden/Sweden
Background: Lung cancer represents the leading cause of cancer-
related death world wide. Several studies have shown that the risk 
of developing lung cancer is associated with socioeconomic status. 
Recently a Swedish study showed that socioeconomically disad-
vantaged groups with NSCLC receive less intensive care. Low edu-
cation remained an independent predictor of poor survival only in 
women with early stage disease. Foreign-born people constitute 
12.5% of the Swedish population in Sweden.
Methods: A retrospective analysis of all patients with lung cancer 
at the Department of Respiratory Medicine and Allergy, Karolinska 
University Hospital - Solna during 030101—061231. In all, 1353 
cases of lung cancer were diagnosed in which 157 (11.6%) were 
immigrants. The mean age in Swedish patients was 69, median 70 
and range 38-96 years. The figures for the immigrants was 65, 66 
respectively 38-90 years.91,3% of the Swedish and 92,3% of the 
immigrant patients were either smoker or former smoker. There 
was no significant differences between the groups.
Results: In 105 (8,8%) Swedish and 7 (4,5%) of the immigrants the 
diagnosis was clinical Adenocarcinoma was the most common 
subtype found in both Swedish and immigrant patients 44,7% 
respectively 40,1%, squamous cell carcinoma 17,5% resp 21,7% 
and small cell lung cancer 12,2% respectively 14% . No significance 
differences between the groups.19,1% of the Swedish and 14% of 
the immigrants were diagnosed as stage I, 2,4% resp 4,4% as stage 
II, 7,9% resp 7% as stage IIIa and 70,4% resp 74,5% as stage IIIB/
IV. Nearly 86% of the Swedish and 84,1% of the immigrants had 
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years. Thirty patients (19,4%) had stage I disease, 17 (11%) had sta-
ge II, 46 (29,9%) had stage III, and 61 (39,6%) had stage IV disease. 
Fifty patients had at least one comorbid disease (min; 0 max; 6). 
CCI scores of the patients were as follows ; 22 patients (14,2 %) had 
0 point, 59 patients (38,3 %) had 1 point, 39 patients (25,3 %) had 
2 points, 22 patients (14,3%) had 3 points, 8 patients (5,2%) had 4 
points, 3 patients (1,9%) had 5 points and 1 patient (0,6%) had 6 
points. When patients were classified into 2 groups according to 
CCI scores (Group 1; CCI 0 and 1, group 2; CCI≥2), DFS of group 1 
and group 2 were 13,2 and 16,9 months respectively, and OS were 
21,9, and 23,1 months respectively. There was no statistically sig-
nificant difference between 2 groups (p>0,1 for all comparisons). 
Survival rates were also similar when compared according to age-
adjusted CCI scores of the two groups. The only significant predic-
tors of both dfs and os were disease stage, Eastern Cooperative 
Oncology Group (ECOG) performance status and the presence of 
weight loss in multivariate Cox regression analysis.
Conclusion: In conclusion, comorbid diseases stratified according 
to the CCI were found not to be associated with DFS or OS in el-
derly patients with NSCLC in our study. The only predictive factors 
of survival were performance status, weight loss and disease sta-
ge. Negative results may be due to low validity of the CCI score in 
NSCLC, underreporting of comorbidities in patient files or aggres-
sive biology of NSCLC which overrides comorbidities being the 
most imortant predictor of survival. Prospective studies with larger 
number of patients are needed to clarify these points.
Keyword: elderly, lung cancer, comorbidities
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P2.10-045 PHASE II STUDY OF PEMETREXED (PEM) + 
CARBOPLATIN (CB) + BEVACIZUMAB (BEV) AS FIRST 
LINE THERAPY FOR NON-SQUAMOUS NON SMALL 
CELL LUNG CANCER (NSCLC) WITHOUT EGFR MUTA-
TION. CENTRAL JAPAN LUNG STUDY GROUP (CJLSG) 
0909 TRIAL.
Yasuhiro Goto1, Tomoki Kimura2, Hiroyuki Taniguchi2, Mai Iwaki3, 
Masashi Yamamoto1, Ryujiro Suzuki4, Masashi Kondo5, Takashi 
Abe6, Osamu Hataji7, Eiji Kojima8, Norio Yoshida9, Kazuyoshi Imai-
zumi10, Takuya Ikeda11, Yoshimasa Tanikawa12, Takayuki Ando13, 
Hiroshi Saito14
1Nagoya Ekisaikai Hospital/Japan, 2Tosei Genaral Hospital/Japan, 3Ja-
panese Red Cross Nagoya Daini Hospital/Japan, 4Toyohashi Municipal 
Hospital/Japan, 5Nagoya University Graduate School Of Medicine/
Japan, 6Ogaki Municipal Hospital/Japan, 7Matsusaka Municipal Hospi-
tal/Japan, 8Komaki Municipal Hospital/Japan, 9Kariya Toyota General 
Hospital/Japan, 10Fujita Health University/Japan, 11Yokkaichi Municipal 
Hospital/Japan, 12Toyota Kosei Hospital/Japan, 13Okazaki Municipal 
Hospital/Japan, 14Aichi Cancer Center Aichi Hospital/Japan
Background: In advanced non-squamous non-small cell lung 
cancer (NSCLC), epidermal growth factor receptor (EGFR) status 
is important to determine the treatment. However many previous 
studies of NSCLC were investigated regardless of EGFR mutation 
status. Chemotherapy with bevacizumab (Bev) showed higher res-
ponse rate (RR), and maintenance therapy with Bev or pemetrexed 
(Pem) showed longer progression free survival (PFS) (E4599, AVAiL, 
PARAMOUNT). But, there has been few report of chemotherapy 
with Pem and Bev including maintenance therapy in patients with 
EGFR-WT. 
(all had achieved a previous response for more than 6 months). 
Treatment consisted of a 90-min intravenous infusion of 125 mg/
m2 irinotecan on day 1 and 8 plus 7.5 mg/kg bevacizumab on day 
1. The treatment was repeated every 3 weeks and all patients un-
derwent genotype evaluation (including EGFR and KRAS mutation 
screening).
Results: One patient (4.2%) achieved a complete response and six 
(25%) had a partial response. Objective response rate (ORR) was 
29.2% (4.6 months median response duration). Seven patients had 
stable disease, and disease control rate (DCR) was 58.3%. After a 
median follow-up of 12.8 months, median progression-free survival 
(PFS) rate was 4.8 months (95%CI 1.8-9.2) and median overall sur-
vival (OS) rate was 19.8 months (95%CI 9.2-30.2). Major toxicity was 
myelosuppression (grade 3-4 neutropenia occurred in 43% of pa-
tients and thrombocytopenia in 8.3%). Two patients experienced 
febrile neutropenia and non-haematological toxicity was usually 
mild. One patient suffered grade 4 diarrhoea, and four patients 
harbouring EGFR mutations had a long-lasting, partial response 
(>7 months after at least 4 prior lines).
Conclusion: The irinotecan pus bevacizumab combination resul-
ted in favourable activity and manageable toxicity profiles as third 
or fourth line for patients suffering advanced NSCLC. Our results 
suggested that such regimen can represent a reasonable chemo-
therapeutic option, especially for subjects having EGFR mutations. 
This hypothesis can be partly supported because of topo I activity 
resulting from increased topo I mRNA and protein expression 
caused by MET signalling.
Keyword: Lung cancer, irinotecan, bevacizumab, response, pro-
gression free survival
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P2.10-044 IMPACT OF COMORBIDITIES ON SURVIVAL 
IN ELDERLY PATIENTS WITH NON SMALL CELL LUNG 
CANCER.
Metin Kaya1, Omer Dizdar2, Samed Rahatli2, Nadire Kucukoztas2, 
Selim Yalcin2, Ozden Altundag2, Ozgur Ozyilkan3
nternal Medicine, Baskent University/Turkey, 2Medical Oncology, 
Baskent University/Turkey, 3Department Of Medical Oncology, Baskent 
University Medical Faculty/Turkey
Background: Lung cancer comprises 14% of all cancers and 29% 
of cancer related deaths. Mean age at diagnosis is 60, therefore 
it’s a disease of elderly. Comorbidities are common in this group of 
age. Comorbidities can affect survival, quality of life, and patients’ 
tolerability for therapy, as well. Nevertheless, data on the effects 
of comorbidities over lung cancer are limited. What we aimed with 
this study is to use Charlson comorbidity index (CCI) in order to 
define and stratify the comorbidities of our elderly patients (i.e ≥65 
years) with non small cell lung cancer (NSCLC) and analyze its ef-
fect over disease-free survival (DFS) and overall survival (OS).
Methods: 154 patients with NSCLC aged 65 and over were inclu-
ded in this study. Data were retrospectively collected from pati-
ents’ files. Patients’ comorbidities were classified using CCI and 
its effect on DFS and OS along with other prognostic factors were 
evaluated.
Results: Mean age of patients for diagnosis in this study was 70 
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sults when rexinoids are combined with chemotherapy or targeted 
agents. We designed a phase I/II study to evaluate the tolerability 
and activity of the rexinoid, bexarotene in combination with weekly 
paclitaxel and every 4 week carboplatin to allow for closer interac-
tion between the agents.
Methods: Patients with confirmed stage IIIB or IV NSCLC and ade-
quate organ function were enrolled. Prior chemotherapy was allo-
wed for the phase I portion of this study. All patients were sche-
duled to receive paclitaxel 100 mg/m2 weekly for 3 doses every 4 
weeks and carboplatin AUC = 6 monthly. Bexarotene oral capsules 
were administered daily starting on initial day of chemotherapy. 
Two dose levels of bexarotene were evaluated (300 mg/m2/day and 
400 mg/m2/day). The recommended phase II dose of bexarotene 
was 400 mg/m2/day.
Results: 33 patients (pts) were enrolled, 14 pts received 300 mg/
m2/day and 19 pts received 400 mg/m2/day of bexarotene. Patient 
characteristics: age (median 59), gender (female 39%), stage (85% 
stage IV), Karnofsky performance status (KPS) (37% with KPS 60-
70%), prior chemotherapy (30%), prior radiation (33%), and prior 
surgery (33%). Hematologic toxicity was mild with grade 3 anemia 
in 5 pts and grade 3 neutropenia in 7 pts. Non-hematologic toxi-
cities consisted primarily of hyperlipidemia and hypothyroidism 
which were medically managed. No cases of pancreatitis were 
observed. With a median follow-up of nearly 9 years, the median 
survival time (MST) for all pts was 8.5 months with 1-year survival 
of 43%. MST for the 300mg dose was 6.5 months while the MST 
for the 400mg dose was 10.2 months. The median survival time 
for chemotherapy-naive pts (n = 24) was 8.3 months with a 1-year 
survival of 47%. There was no statistically significant difference in 
survival between those pts with or without dose modifications for 
side effects. MST was 8.4 months for the subset of pts who expe-
rienced hypertriglyceridemia compared to 4.9 months for the pts 
who did not develop hypertriglyceridemia.
Conclusion: The 43% 1-yr survival for chemotherapy-naive pts 
treated with bexarotene in combination with weekly paclitaxel and 
every 4 week carboplatin is encouraging. However, two reported 
phase III trials found no benefit from adding bexarotene to con-
ventional chemotherapy. Our study dose confirmed the subgroup 
analysis for a significant positive correlation between bexarotene-
induced hypertriglyceridemia and survival. Thus, our study which 
utilizes a different chemotherapy should be confirmed in future 
trials. Further research on biomarkers to identify subsets of pati-
ents that may benefit from bexarotene is warranted.
Keywords: bexarotene, paclitaxel, Carboplatin, non-small cell lung 
cancer
This study is designed to evaluate the efficacy and safety of com-
bination therapy with Pem, carboplatin (Cb) and Bev followed by 
Pem plus Bev maintenance therapy for non-squamous NSCLC pati-
ents with EGFR-WT.
Methods: This study was multicenter, phase II trial. Chemo-naive, 
stage IIIb/IV or recurrent disease after surgery (rec), non-squamous 
NSCLC pts with performance status 0-1, and without EGFR muta-
tion in exon 19 deleion or 21 L858R and without brain metastases 
were eligible. Pts were treated with Pem 500mg/m2, Cb AUC=6, 
and Bev 15mg/kg intravenously on day 1 every 3 weeks. After 4-6 
cycles, pts who achieved disease control receive Pem 500mg/m2 
and Bev 15mg/kg on day 1 every 3 weeks until progressive disease 
or unacceptable toxicity. To determine the EGFR mutation, we use 
the peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp 
assay. Response was determined by CT scans after every 2 cycles 
(RECIST ver1.1), and toxicity was assessed with CTCAE ver3.0. 
Primary endpoint was RR. Secondary endpoint included safety, 
disease control rate (DCR), overall survival, PFS. We planned the 
sample size was 47 patients and recruited 52 patients (pts).
Results: Fifty eligible patients were enrolled between July 2010 
and July 2012. Of 50 evaluable for analysis, the median age was 64 
years (range, 37–74); 40/10 males/females; 6/40/4 with IIIB/IV/rec; 
47/1/2 with adenocarcinoma/large cell carcinoma/NSCLC. In the 
triplet therapy, the median number of cycles was 5. There were 24 
partial responses with an RR of 48.0% (95% CI, 33.7-62.6). SD was 
observed in 21 pts and DCR was 90% and 35 pts (70%) followed by 
maintenance therapy. NE and PD were observed in 4 pts and 1 pts, 
respectively. Major adverse event was grade 3-4 neutropenia in 19 
pts (38.0%), grade 3-4 thrombocytopenia in 12 pts (24.0%). Alt-
hough grade 3-4 infection was observed in 2 cases (4.0%). There 
was no treatment-related death.
Conclusion: This is the first report of treatment with Pem, Cb, 
and Bev in EGFR-WT pts. This first line chemotherapy regimen 
demonstrated good efficacy and acceptable toxicity profile , and 
many pts could transfer to Pem plus Bev maintenance therapy. In 
the future, we will report the data containing maintenance therapy. 
Unique trial Number; UMIN000003736
Keywords: Carboplatin, Bevacizumab, EGFR-WT, pemetrexed
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P2.10-046 A PHASE I/II STUDY OF BEXAROTENE WITH 
WEEKLY PACLITAXEL AND CARBOPLATIN FOR THE 
TREATMENT OF PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER
Jeremy D. Whyman, Peter E. Kebbekus, Sarah K. Fink, James R. 
Rigas, Konstantin H. Dragnev
Department Of Medicine, Section Of Thoracic Oncology, Dartmouth-
Hitchcock Medical Center, Geisel School Of Medicine At Dartmouth/
United States Of America
Background: The combination of weekly paclitaxel and every 4 
week carboplatin as first-line therapy for advanced non-small cell 
lung cancer (NSCLC) has been report to result in a median survival 
time of 8.8 months and a 1-year survival of 39.5%. Retinoids and 
rexinoids are derivatives of vitamin A with anti-proliferative and dif-
ferentiation inducing activity in a variety of cancer types, including 
NSCLC. Preclinical and early clinical work has shown promising re-
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P2.10-048 THERAPEUTIC EFFICACY OF GEFITINIB FOR 
POSTOPERATIVE RECURRENT CANCER IN PATIENT 
WITH EGFR MUTATION
Takefumi Oikawa, Tatsuo Ohira, Junichiro Osawa, Masaru Hagi-
wara, Masatoshi Kakihana, Naohiro Kajiwara, Norihiko Ikeda
Thoracic Surgery, Tokyo Medical University/Japan
Background: Epidermal growth factor receptor (EGFR) -tyrosine 
kinase inhibitor (TKI) responds to approximately 80% of the non-
small cell lung cancer (NSCLC) patients with EGFR mutation. In 
other words, about 20% of the patients with EGFR mutations don’t 
respond. It was reported that resistance to EGFR-TKI is caused by 
secondary mutation at codon 790 (exon 20 mutation), Met ampli-
fication and hepatocyte growth factor (HGF)-MET signaling. The 
aim of this study is to explore the type of EGFR mutation, phos-
phorylated MET and HGF expression in tissues surgically removed 
for NSCLC with EGFR mutation impact on the sensitivity to gefiti-
nib.
Methods: We studied 44 surgically resected NSCLC from 2001 
to 2012. 43 cases were adenocarcinoma and 1 case was large cell 
neuroendocrine carcinoma. These surgical resections were taken 
from patients who were treated with gefitinib as first or second or 
third line therapy for postoperative recurrent cancer. The patients’ 
age ranged from 27 to 78years old (average 63.1 years old). There 
were 19 male and 25 female patients. There was 1 case of exon 18 
point mutation, 23 cases of exon 19 deletion, 2 cases of exon 20 
point mutation, 16 cases of exon 21 point mutation, and 2 cases of 
both exon 20 and 21 point mutation. We assessed non-responders 
progression within 2 months. Intermediate responders were con-
sidered as being effectively treated (at least stable disease) with 
gefitinib between 3 and 11 months. And long-term responders 
were considered to be effectively treated with gefitinib for over 12 
months.
Results: Non-responders were 4 cases. Intermediate responders 
were 26 cases (including 11 cases of ongoing treatment). Long-
term responders were 14 cases (including 1 case of ongoing treat-
ment). Non-responders had two secondary mutation, one exon 19 
deletion and exon 21 mutation. Intermediate responders had one 
exon 18 mutation, 14 exon 19 deletion, 10 exon 21 mutation and 
one both exon 20 and 21 mutation. long-term responder had eight 
exon 19 deletion, five exon 21 mutation and one both exon 20 and 
21 mutation.
Conclusion: In our data, NSCLC with exon 20 mutaiton will res-
pond to gefitinib if this NCCLC with another EGFR mutation. We 
will report the findings of non-responders excluding analyzed exon 
20 mutation phosphorylated MET and HGF expression.
Keywords: gefitinib, Efficacy, postoperative, EGFR
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P2.10-047 THE THREE-DRUGS REGIMEN CPBEV (CIS-
PLATINUM, PEMETREXED AND BEVACIZUMAB) IS VERY 
ACTIVE WHEN USED AS FIRST-LINE THERAPY FOR 
LOCALLY ADVANCED OR METASTATIC ADENOCARCI-
NOMA OF THE LUNG: FINAL RESULTS OF A PHASE III 
TRIAL.
Roberto Bordonaro1, Hector Soto-Parra2, Concetta Sergi1, Carmelo 
Giannitto-Giorgio3, Saverio Cinieri4, Fiorenza Latteri1, Stefano Cor-
dio1, Concetta Martines1, Giovanni Burrafato1, Daniela Sambataro1, 
Enrico Potenza1
1Oncology, Arnas Garibaldi/Italy, 2Vittorio Emanuele - Policlinico/Italy, 
3Asp 3 Gravina Hospital/Italy, 4U.O.C. Oncology And Breast Unit, "An-
tonio Perrino“ Hospital/Italy
Background: During the past seven years paradigms of advan-
ced lung cancer therapy dramatically changed; Bevacizumab and 
Pemetrexed, when administered separately in association with 
platinum salts, demonstrated to improve survival in patients with 
non-squamous histologies. In the aim to investigate activity and 
safety of a three-drugs regimen containing both these agents plus 
cis-platinum, we conducted a multi-Institutional phase II trial.
Methods: Eligible criteria were: chemo-naive patients with proven 
histology of non-squamous non-small celle lung cancer, PS-ECOG-
WHO equal or lesser than 2, adequate hematological, liver and 
renal functions, no previous history of hemoptysis, stage III/B or 
IV without brain metastases, at least one measurable lesion, no 
uncontrolled hypertension or other severe comorbidities, no ana-
mnestic episodes of venous thromboembolism. We adopt a two-
stage of Simon model as statistical design of the study; the main 
end-point was overall response rate. No maintenance therapy was 
allowed.
Results: Thirty-two patients were enrolled; their main characteris-
tics were: male/female: 20/12, median age (years): 59, ECOG-WHO 
PS 0/1: 21/11. We administered 183 cycles of CPBev: main grade 
3 adverse events were neutropenia (28%), emesis (19%), asthenia 
(9%), and hypertension (9%). In terms of overall response rate 
we registered 20/32 (62.5%) partial responses, 8/32 (25%) stable 
diseases and 4/32 (12.5%) progressive diseases, with a clinical be-
nefit rate of 28/32 (87.5%). The median overall survival of the entire 
series was 16.9 months; 1 and 2-years-overall survival were respec-
tively 61.4 and 32.1%; the median progression-free-survival was 9.3 
months, with a 1 and 2-progression-free-survival of 43.2 and 7%, 
respectively.
Conclusion: On the basis of our data, we may affirm that CPBev 
regimen have a good toxicity profile and is extremely active iwhen 
administered to advanced non-squamous, non-small celle lung 
carcinomas. Data concerning outcome parameters seems to be 
very interesting: CPBev deserves to be compared to actual stan-
dard regimens in a phase III trial in this population of patients.
Keywords: non-squamous non-small cell lung cancer, Bevaci-
zumab, pemetrexed, advanced stages
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Conclusion: For patients with adenocarcinoma of lung, bone me-
tastasis is associated with decreased disease control rate in those 
with classic EGFR mutation and received first-line chemotherapy, 
and lung metastasis is associated with decreased response and 
disease control rate in those received first-line TKI therapy no mat-
ter of with or without classic EGFR mutation.
Keywords: Adenocarcinoma, first-line therapy, Bone Metastasis, 
lung metastasis
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P2.10-050 EFFICACY OF DENOSUMAB IN PATIENTS 
WITH METASTATIC LUNG CANCER WITH EGFR MUTA-
TIONS
Yoshihiro Suido, Terufumi Kato, Atsuhito Nakazawa, Hajime 
Sasano, Norikazu Matsuo, Yasunori Enomoto, Akimasa Sekine, 
Hideya Kitamura, Tomohisa Baba, Takeshi Shinohara, Ryuuichi 
Nishihira, Shigeru Komatsu, Eri Hagiwara, Takashi Ogura
Dept. Of Respiratory Medicine, Kanagawa Cardiovascular And Respira-
tory Center/Japan
Background: Denosumab, a fully human monoclonal antibody to 
RANKL, is expected to improve overall survival better than zoled-
ronic acid when administered in the treatment of bone metastasis 
from lung cancer. Although the mechanism of prolongation of 
survival by denosumab for lung cancer patients is unknown, deno-
sumab may have an additional effect other than bone-protective 
effects. We examined relevance between efficacy of denosumab 
and EGFR mutation status which is tend to be causal of multiple 
bone metastasis.
Methods: Patients treated by Denosumab with metastatic lung 
cancer were eligible for the study. We retrospectively analyzed 
their histological type, EGFR mutation status, chemotherapy, the 
change of primary lesion and bone metastasis before and after 
treatment of denosumab.
Results: From July 2012 to June 2013, there were 18 patients mat-
ched in the analysis.Patients’ characteristics: median age 68.5 ye-
ars, male/female 9/9, PS0/1/2/3 2/10/4/2, adenocarcinoma/others 
15/3, EGFR mutation status Ex19del./L858R/wt or unknown 9/2/7). 
Seven patients were treated by gefitinib, and in the three of them, 
reossifications by computed tomography were observed without 
ostalgia.In none of 11 patients treated by other anticancer drug or 
followed-up, reossification was seen. 
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P2.10-049 LUNG AND BONE METASTASIS ARE ASSOCI-
ATED WITH DIFFERENT RESPONSE AND DISEASE CON-
TROL RATE OF FIRST-LINE THERAPY IN PATIENTS WITH 
ADENOCARCINOMA OF LUNG.
Chieh-Hung Wu1, Yung-Hung Luo1, Chu-Yun Huang1, Wen-Shuo 
Wu1, Chih-Wei Wu1, Chun-Ming Tsai1, Yu-Chin Lee1, Reury-Perng 
Perng1, Jacqueline Whang-Peng2, Yuh-Min Chen1
1Department Of Chest Medicine, Taipei Veterans General Hospital/
Taiwan, 2Centre Of Excellence Cancer Research (CECR), Taipei Medical 
University/Taiwan
Background: Bone and lung are frequent metastatic sites for ade-
nocarcinoma of lung. Chemotherapy and tyrosine-kinase inhibitor 
(TKI) are standard first-line therapies for stage IV adenocarcinoma 
of lung according to the epidermal growth factor receptor (EGFR) 
mutation status. This study aimed at evaluating the relationship 
between bone, lung metastasis, with or without classic EGFR muta-
tion, response rate and disease control rate of first-line chemothe-
rapy and TKI therapy.
Methods: We retrospectively reviewed 206 patients who were 
diagnosed of adenocarcinoma of lung at our hospital. The pati-
ents’ bone and lung metastatic status at diagnosis, with or without 
classic EGFR mutation, response and disease control status of first-
line chemotherapy and TKI therapy were collected for chi-square 
analysis.
Results: Fifty-five (26.7%) patients had bone metastasis and 82 
(39.8%) patients had lung metastasis. 107 (51.9%) patients had clas-
sic EGFR mutation. There was no significant difference between 
bone, lung metastatic status and with or without classic EGFR 
mutation (p=0.65 for bone, p=0.46 for lung). For the patients wit-
hout classic EGFR mutation and received first-line chemotherapy, 
33(57.9%) patients were without response (13, 20 patients were 
without, with bone metastasis, respectively), 24(42.1%) patients 
were with response (21, 3 patients were without, with bone metas-
tasis, respectively), p<0.01; 21(36.8%) patients were not controlled 
(9, 12 patients were without, with bone metastasis, respectively),36 
(63.2%) patients were controlled (25, 11 patients were without, with 
bone metastasis, respectively), p=0.048. For the patients with clas-
sic EGFR mutation and received first-line chemotherapy, 27(60%) 
patients were without response (14, 13 patients were without, with 
bone metastasis, respectively), 18(40%) patients were with respon-
se (16, 2 patients were without, with bone metastasis, respectively), 
p=0.01; 10(22.2%) patients were not controlled (4, 6 patients were 
without, with bone metastasis, respectively), 35(77.8%) patients 
were controlled (26, 9 patients were without, with bone metastasis, 
respectively), p=0.043. There were no significant difference bet-
ween response status of TKI and lung metastatic status (p=0.469), 
control status of TKI and lung metastatic status(p=0.855), response 
status of TKI and bone metastatic status(p=0.673), control status 
of TKI and bone metastatic status(p=0.58), response status of 
chemotherapy and bone metastatic status(p=0.533), control status 
of chemotherapy and bone metastatic status(p=0.777) in patients 
without classic EGFR mutation. For patients with classic EGFR mu-
tation, there were also no significant difference between response 
status of TKI and lung metastatic status(p=0.077), control status 
of TKI and lung metastatic status(p=0.332), response status of TKI 
and bone metastatic status(p=0.76), control status of TKI and bone 
metastatic status(p=0.05), response status of chemotherapy and 
bone metastatic status (p=0.143), except for control status of che-
motherapy and bone metastatic status(p=0.017).
S886 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 2 - CHEMOTHERAPY  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.10-051 THE FINAL ANALYSIS OF PROSPECTIVE, 
FEASIBILITY STUDY OF S-1 AND CARBOPLATIN COM-
BINATION CHEMOTHERAPY FOR THE PATIENTS WITH 
INTERSTITIAL PNEUMONIA (IP) AND ADVANCED NON 
SMALL CELL LUNG CANCER (NSCLC).
Terufumi Kato, Tomohisa Baba, Hideya Kitamura, Chiaki Hoso-
da, Haruki Kobayashi, Hiroyuki Ito, Midori Sugisaki, Hiroyoshi 
Yamauchi, Hajime Sasano, Norikazu Matsuo, Yasunori Enomoto, 
Yoshihiro Suido, Atsuhito Nakazawa, Akimasa Sekine, Takeshi 
Shinohara, Ryuichi Nishihira, Shigeru Komatsu, Eri Hagiwara, 
Takashi Ogura
Division Of Respiratory Medicine, Kanagawa Cardiovasucular And 
Respiratory Center/Japan
Background: IP is commonly concomitant disorder with lung can-
cer. Because IP sometimes deteriorates and results unfavorable 
clinical course, patients with IP are excluded from most cancer 
clinical trials. S-1 is a novel active oral fluoropyrimidine antican-
cer agent consisting of tegafur, gimeracil and oteracil potassium. 
Although most anti-cancer agent has pulmonary toxicity, post 
marketing surveillance reported S-1 has lower pulmonary toxicity 
incidence. We have conducted feasibility study of S-1 and car-
boplatin combination for patients with advanced or ineligible for 
other treatment modality of NSCLC patients.
Methods: Patients with confirmed NSCLC, clinical and radiological 
diagnosed interstitial pneumonia, aged 80 years old or younger, 
performance status 0-2 and chemo-naive patients were eligible for 
the study. Carboplatin (AUC 5) was administered on day 1 and S-1 
(80mg/m2/day) on day 1 to 14 for four to six cycles. Study objec-
tives are safety estimation especially pulmonary adverse events, 
and efficacy evaluation as tumor response and survival. Pulmonary 
adverse events were evaluated by CTCAE ver.4.0 and acute exa-
cerbation criteria.
Results: From March 2009 to December 2011, 21 patients were 
enrolled. Male/female: 19/2, age: 67(55 to 77), adeno/squamous/
adenosquamous: 10/10/1, stage IIB/IIIA/IIIB/IV/rec.: 1/2/10/4/4, 
PaO2 at rest: 70.6(51.4 to 96.7) mmHg, %VC: 91.0 (69.0 to 119.0), 
%DLco; 63.4(48.1 to 90.4). Treatment delivery cycles 1/2/3/4/5/6: 
3/3/2/10/2/1. PR/SD/PD/NE: 7/7/4/3 (RR 33%, DCR 67%), the me-
dian progression free survival was 4.0 months and the median 
overall survival was 10.4 months. During the treatment, two patient 
experienced moderate level of acute deterioration of IP, one pa-
tient experienced infectious pneumonia, all these patients reco-
vered from the event. Acute exacerbation rate were estimated as 
9.5% with 22.1% of upper limit of 95% C.I. There was no treatment 
related death. After first line treatment, four patients experienced 
acute exacerbation of IP, two during second line treatment, one 
during immune therapy, and another during no treatment period. 
From begging of first line chemotherapy, 6 out of 21 patients (29%) 
experienced some forms of acute exacerbation of IP during any 
treatment or observational periods. Besides pulmonary toxicity, 
the profile of hematological and non hematological toxicities was 
similar to past studies.
Conclusion: First and largest prospective trial for the patients with 
IP and NSCLC was completed. The study revealed S-1 and carbo-
platin combination was feasible and active even in patients with 
IP and NSCLC who are usually excluded from clinical trials. Acute 
exacerbation of IP was observed during not only fist line treatment 
but also latter line or observational period.
Conclusion: Patients treated with gefitinib may be beneficial by 
denosumab treatment. Further investigation exploring synergistic 
effect of denosumab and gefitinib is warranted.
Keywords: reossification, gefitinib, denosumab
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P2.11-001 ALK GENOTYPING VIA LIQUID BASED THIN-
PREP SLIDES PREPARED FROM FINE NEEDLE ASPIRATES 
IN NSCLC
Raymond R. Tubbs1, Eugen Minca2, Christophen Lanigan1, Jordan 
Reynolds3, Zhen Wang2, Patrick Ma4, Francisco Almeida5, Nathan 
Pennell4
1Molecular Pathology Ll2-2, Cleveland Clinic/United States Of America, 
2Molecular Pathology, Cleveland Clinic/United States Of America, 3Ana-
tomic Pathology, Cytopathology Section, Cleveland Clinic/United States 
Of America, 4Taussig Cancer Center, Cleveland Clinic/United States 
Of America, 5Cleveland Clinic, Respiratory Institute/United States Of 
America
Background: Rearrangements at chromosome locus 2p23 encom-
passing the Anaplastic Lymphoma Kinase (ALK) gene in non-small 
cell lung carcinomas (NSCLC) drive expression of the oncogenic 
ALK encoded protein and provide a target for crizotinib and other 
ALK inhibitors. A companion diagnostic assay, fluorescence in-situ 
hybridization (FISH) using conventional formalin-fixed paraffin-em-
bedded (FFPE) tissue samples, was approved for identifying pati-
ents eligible for treatment and has been the commonly employed 
method for identification of ALK rearrangements. The FISH assay 
assessing ALK rearrangments may fail due to absence of enume-
rable FISH signals, insufficient number of tumor cells, or autofluo-
rescence obscuring specific FISH signals, especially for cytoblocks 
obtained as part of staging or diagnostic fine needle aspiration 
(FNA) biopsy. FISH performed on liquid based ThinPrep slides 
(ThinPrepFISH) may represent a robust alternative to conventional 
FFPE-FISH.
Methods: ThinPrep slides obtained by FNA biopsy from 156 pati-
ents with advanced NSCLC were evaluated at Cleveland Clinic by 
ThinPrep-FISH using a standard ALK break-apart two color probe 
set (Abbott Molecular Vysis, Des Plaines; AMV). Cell pellets were 
not available for preparation of FFPE cytoblocks from the cell 
pellet in 7/156 (4%), and the FFPE cytoblock slides did not contain 
tumors cells for evaluation in 33/156 (21%) despite the presence 
of abundant tumor cells in the ThinPrep slide. Given the failure 
rate for FFPE-FISH using cytoblocks (>30% in our preliminary ex-
perience) we chose to use ultrasensitive immunohistochemistry 
(IHC) for ALK expression in corresponding cytoblocks {D5F3 
antibody (Cell Signaling) coupled with enhanced detection sensi-
tivity (OptiView with signal amplification (Ventana; Tucson)} as the 
reference data set [J Mol Diagn 2013 May; 15(3):341-6] The same 
ThinPrep slide used for cytopathology diagnosis was probed using 
ThinPrep-FISH. Specific areas of the ThinPrep-FISH slide having 
abundant tumor cells were etched with a diamond tip pen on the 
reverse side of the slide prior to removal of the cover slip; all areas 
of the ThinPrep slide were screened qualitatively and signals enu-
merated selectively for tumor cells. Interpretative criteria used for 
ThinPrepFISH were the same criteria as is used for the IVD AMV 
probe set.
Results: ThinPrepFISH ALK signals were robust and not compro-
mised by nuclear truncation inherent in FFPE tissue FISH in 155 / 
156 cases. One of 156 cases displayed no signals, but was probed 
Keywords: Acute exacerbation, Non small cell lung cancer, Inter-
stitial pneumonia, S-1
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P2.10-052 A FEASIBILITY STUDY OF VINORELBINE AND 
BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY TREA-
TED ADVANCED NON-SQUAMOUS NON-SMALL CELL 
LUNG CANCER
Kyohei Kaburaki1, Kazutoshi Isobe1, Ai Yamamoto1, Naobumi 
Tochigi2, Yoshinobu Hata2, Kazutoshi Shibuya2, Akira Iyoda2, Sa-
kae Homma2 
1Toho University Omori Medical Center, Tokyo/Japan, 2Toho University, 
School of Medicine, Tokyo/Japan
Background: In recent clinical trials for non-squamous non-small 
cell lung cancer (NonSq-NSCLC), platinum regimens with bevaci-
zumab (BEV) resulted in better prognosis and acceptable toxicity 
profile. However, there have been few studies on their feasibility 
or efficacy of BEV in NonSq-NSCLC patients who were previously 
treated with a platinum regimen. Therefore, we conducted a pro-
spective study of combination therapy with vinorelbine (VNR) and 
BEV in NonSq-NSCLC patients who were previously treated with a 
platinum regimen.
Methods: Eligible patients had recurrent NonSq-NSCLC, PS 0-1, 
and adequate organ functions. The primary endpoint was feasibi-
lity. Secondary endpoints were response rate and safety. Patients 
received combination therapy with VNR (25mg/kg on day 1, 8) and 
BEV (15mg/kg, day 1). The treatment cycles were repeated every 3 
weeks until progressive disease (PD)
Results: From June 2011 to January 2013, 15 NSCLC patients were 
eligible for this study. The patients consisted of 7 men and 8 wo-
men, and their median age was 68 (range 57-82) years. The pati-
ents received the treatment with a median of 4 (range 1-12) cycles. 
The histological classification was adenocarcinoma in all. The PS 
(ECOG) was 0 in 2, 1 in 11, and 2 in 2, respectively. The incidence 
of grade 3-4 neutropenia, anemia, thrombocytopenia and febrile 
neutropenia was 26.7%, 6.7%, 6.7%, and 13.3%, respectively. Res-
ponse rate and disease control rate in the overall study population 
(n=15) were 26.7% and 73.3%, respectively. Median PFS was 2.8 
months. Grade 3-4 phlebitis occurred in 3 patients; phlebitis im-
proved by central venous catheter in 1, and by administration with 
corticosteroid in other two patients.
Conclusion: Combination therapy with VNR and BEV was safe and 
effective in NonSq-NSCLC patients who were previously treated 
with a platinum regimen. However, a few patients had a risk of 
developing phlebitis.
Keywords: Bevacizumab, Previously treated, combination therapy
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pathology or cytology after radical operation and with EGFR exon 
19 deletion mutation or exon 21 L858R single base substitution 
were enrolled (n=94). Within 4 weeks post radical surgery, the en-
rolled patients would randomly allocated for adjuvant therapy, re-
ceiving either erlotinib (n=47) 150mg/day for 2 years or NP (n=47) 
chemotherapy (vinorelbine 25mg/m2 on day 1, 8 and cisplatinum 
75mg/m2 on day 1 of a 3-week schedule ) for 4 cycles. Duration 
of trial recruitment is estimated to 18 months. Primary endpoint 
is 2-year disease free survival rate (DFSR). Secondary endpoints 
are disease free survival (DFS), 3-year and 5-year overall survival 
(OS), Quality of Life (QOL) and Safety. Biomarker profile will be the 
exploratory research. Patients after surgery and therapy will re-
ceive long-term follow-up including chest and abdominal CT scan 
every 3 months, brain MRI every 6 months and bone scan every 12 
months for up to 2 years.
Results: Current recruitment: twenty-five patients have been en-
rolled since FPI in August, 2012.
Conclusion: Adjuvant erlotinib therapy in IIIA-N2 NSCLC with 
EGFR activating mutation is a promising strategy.
Keyword: NSCLC,EGFR mutation,post surgery,erlotinib
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P2.11-003 HOW TO MAKE THE CHOICE IN THE REUSE 
OF EGFR-TKI FOR ADVANCED NSCLC PATIENTS WHO 
BENEFITED FROM PRIOR GEFITINIB THERAPY: THE ORI-
GINAL DRUG OR SWITCHING TO A SECOND EGFR-TKI?
Chuanhao Tang, Wanfeng Guo, Jianjie Li, Weixia Wang, Xiaoqing 
Liu
Department Of Lung Cancer, Affiliated Hospital Of Academy Of Milita-
ry Medical Sciences/China
Background: For advanced NSCLC patients who benefited from 
prior EGFR-TKI therapy, the choice of a second TKI therapy has 
gradually become a new strategy for the treatment. Some investi-
gators recommend that the second therapy should be continued 
with the original TKI; however, other investigators recommend the 
administration of another TKI. This study aims to discuss which 
choice is more reasonable.
Methods: In retrospect, patients with advanced NSCLC or with 
postoperative relapse of advanced NSCLC achieved CR, PR or SD 
in prior Gefitinib therapy, PFS≥3 months. They received repeated 
Gefitinib or Erlotinib at an interval of at least one month. The ana-
lysis was carried out with respect to efficacy and optimal populati-
on of the two groups.
Results: A total of 61 patients were enrolled into the study, 30 in 
Gefitinib group and 31 in Erlotinib group. Baseline characteris-
tics of the two groups were comparable. Among these patients, 
overall response rate was 16.4% (10/61), disease control rate was 
67.2% (41/61), median PFS was 3.5 months (95%CI 3.0-4.0 months), 
median OS was 8.5 months (95%CI 7.0-11 months). In the compari-
son between patients treated with Gefitinib and with Erlotinib, no 
statistical differences were seen for response rate (10% vs 22.6%, 
P=0.3006), disease control rate (60% vs 74.2%, P=0.2378), me-
dian PFS (3.0 vs 3.5 months, P=0.4945), or median OS (8.3 vs 8.5 
months, P=0.1408). Multivariate analysis showed that in the initial 
dose of Gefitinib, PFS≥6 months (HR 0.317, 95%CI 0.102-0.984, 
11 months after the ThinPrep slide had been prepared. Overall, 
9/156 cases (6%) were ALK rearranged. For 116 ThinPrep slides suc-
cessfully paired with FFPE cytoblocks containing tumor cells, 7/116 
cases (6%) were ThinPrep-FISH positive and IHC positive for ALK 
rearrangements/expression, 2/116 cases (1.7%) were ThinPrep-FISH 
positve but IHC negative, and 107/116 cases were ThinPrep-FISH 
negative and IHC negative (sensitivity 100%, specificity 98.2%, 
overall agreement 98.3%).
Conclusion: Detection of ALK gene rearrangements in liquid cy-
tology ThinPrep slides prepared from fine needle aspiration cyto-
pathology specimens derived from patients with NSCLC can be 
confidently used for clinical ALK molecular testing.
Keyword: ALK ThinPrep FISH Crizotinib
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P2.11-002 A PROSPECTIVE, OPEN-LABELED, RANDO-
MIZED, MULTICENTER PHASE II STUDY TO EVALUATE 
EFFICACY AND SAFETY OF ERLOTINIB VS NP CHE-
MOTHERAPY AS ADJUVANT THERAPY IN POST RADI-
CAL OPERATION STAGE IIIA NSCLC PATIENTS WITH 
EGFR 19 OR 21 EXON MUTATION (EVAN, ML28280, 
NCT01683175)
Dongsheng Yue1, Shidong Xu2, Qiang Li3, Junfeng Liu4, Xiaofei Li5, 
Haitao Ma6, Weimin Mao7, Yue Yang8, Qun Wang9, Chun Chen10, 
Lanjun Zhang11, Yongyu Liu12, Yi Shen13, Zheng Wang14, Heng 
Zhao15, Changli Wang1
1Tianjin Medical University Cancer Institute And Hospital/China, 2The 
Third Affiliated Hospital Of Harbin Medical University/China, 3The 
Second People‘s Hospital O Sichuan/China, 4Hebei Provincial Tumor 
Hospital/China, 5The Fourth Military Medical University/China, 6The 
First Affiliated Hospital Of Soochow University/China, 7Zhejiang 
Cancer Hospital/China, 8Beijing Cancer Hospital/China, 9Zhongshan 
Hospital Fudan University/China, 10Fujian Medical University Union 
Hospital/China, 11Sun Yat-Sen University Cancer/China, 12Liaoning 
Cancer Hospital & Institute/China, 13The Affilated Hospital Of Medical 
College Qingdao University/China, 14Shenzhen People‘s Hospital/China, 
15Shanghai Chest Hospital Affiliated To Shanghai Jiaotong University/
China
Background: Stage IIIA NSCLC represents a relatively heterogene-
ous group, which the relative roles of treatment modalities are not 
clearly defined. Adjuvant chemotherapy remains the most impor-
tant treatment for stage IIIA NSCLC after radical operation, but the 
drug-related toxicities limit its use and benefits for patients. The 
tyrosine-kinase inhibitor might provide a promising treatment for 
NSCLC patients with EGFR19 or 21 exon mutation. In the OPTIMAL 
study comparing first-line erlotinib with carboplatin/gemcitabine 
in advanced NSCLC patients with EGFR activating mutations, the 
primary analysis showed significantly prolonged progressive free 
survival in erlotinib treatment in comparison to carboplatin/gemci-
tabine (p<0.0001). The aim of this study is to investigate the effica-
cy and safety of erlotinib in comparison to vinorelbin plus cisplatin 
(NP) chemotherapy as adjuvant therapy in post radical operation 
stage IIIA NSCLC patients with EGFR19 or 21 exon mutation to 
explore a new treatment strategy for this subset.
Methods: The study was designed as a prospective, open-labeled, 
randomized, multicenter phase II clinical trial. Patients aged bet-
ween 18 and 75 with ECOG PS 0–1 IIIA NSCLC confirmed by histo-
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tigue (31%), dehydration (15%) and hypertension (15%). The MTD/
MAD in Arms A, B and C is 340 mg GDC-0941 in combination with 
either Carbo + Pac +/- Bev or with Cis + Pem + Bev, respectively. 
PK characteristics in all Arms were similar to historical profiles for 
the respective chemotherapy agents, as well as to the single-agent 
GDC-0941 profile. Confirmed partial responses (PRs) for patients 
with at least one post-baseline scan are as follows: 6 of 10 (60%) Sq 
patients; 11 of 28 (39%) NSq (Arms A and B) and 9 of 12 (75%) NSq 
patients (Arm C).
Conclusion: The combinations of GDC-0941 with either Pac + Car-
bo (+/- Bev), or Cis + Pem + Bev have been well tolerated at doses 
consistent with target PK exposures based on preclinical activity. 
Promising responses rates have been observed with all combina-
tions evaluated. Evaluation of GDC-0941 + Cis + Pem is ongoing. 
A randomized Phase 2 study of GDC-0941 + Pac + Carbo (+/- Bev) 
in NSq and Sq patients is ongoing.
Keywords: combination chemotherapy, Phase 1b, PI3K, NSCLC
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P2.11-005 RANDOMIZED PHASE II STUDY OF PEMET-
REXED V. PEMETREXED/BEVACIZUMAB V. CARBOPLA-
TIN/PEMETREXED/BEVACIZUMAB IN PATIENTS WITH 
PREVIOUSLY UNTREATED ADVANCED NON-SQUA-
MOUS NON-SMALL-CELL LUNG CANCER AND POOR 
PERFORMANCE STATUS
Rogerio Lilenbaum1, John Hainsworth2, Matthew Joseph3, Dianna 
Shipley3, Kelly Hagan4, Dana Thompson3, F Anthony Greco2, How-
ard Burris2, David Spigel2
1Mount Sinai Medical Center/United States Of America, 2Sarah Cannon 
Research Institute/United States Of America, 3Tennessee Oncology, 
Pllc/United States Of America, 4Virginia Cancer Institute/United States 
Of America
Background: Pemetrexed (Pem) and bevacizumab (Bev) have each 
been shown to improve survival in patients (pts) with advanced 
non-squamous non-small-cell lung cancer (NSCLC) (Scagliotti 
JCO 2008, Sandler NEJM 2006). Recent evidence suggests these 
agents can be safely combined and given with carboplatin (Cb) in 
the first-line setting with encouraging activity (Patel, ASTRO 2012). 
However, the efficacy and safety of these agents in pts with poor 
performance status (PS) are unknown. Herein, we report a pros-
pective randomized phase II study of first-line pem v. pem/bev v. 
cb/pem/bev in pts with advanced NSCLC and poor PS.
Methods: Key eligibility included: pts with newly diagnosed ad-
vanced non-squamous NSCLC (IIIB or IV), an Eastern Cooperative 
Oncology Group (ECOG) PS of 2, and measurable disease per 
RECIST v.1.1. Pts were randomized 1:1:1 to receive either Pem 
500mg/m2 IV (Arm 1), Pem 500mg/m2 IV and Bev 15mg/kg IV (Arm 
2), or Pem 500mg/m2 IV, Bev 15mg/kg IV, and Cb AUC=5 IV (Arm 
3). Cycles were 21 days, with reimaging every 2 cycles. Pts on Arm 
3 received a maximum of 4 cycles (12 weeks) of Cb. All pts conti-
nued Pem or Pem/Bev until disease progression or unacceptable 
toxicity. The primary endpoint was progression-free survival (PFS). 
Secondary endpoints included objective response rate (ORR), 
overall survival (OS), and safety.
Results: Between June 2009 and May 2013, 155 pts were rando-
mized. Summary demographic data are available for 142 pts (medi-
P=0.0469). With an interval ≥3 months (HR 0.224,95%CI 0.071-
0.713,P=0.0113) between two doses of TKI, the risk of disease pro-
gression was reduced; but if with an interval ≥3 months (HR 0.262, 
95%CI 0.097-0.705,P=0.0080), the risk of death was reduced.
Conclusion: Advanced NSCLC patients who benefited from prior 
Gefitinib therapy can benefit again either with the original drug 
Gefitinib or the alternative drug Erlotinib when a second TKI thera-
py is resumed. Such benefit is related to PFS of initial TKI therapy 
and time interval between two doses of TKI.
Keywords: gefitinib, erlotinib, Lung neoplasms, HER
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P2.11-004 A PHASE IB, OPEN LABEL, DOSE ESCALATI-
ON STUDY OF THE SAFETY AND PHARMACOLOGY OF 
PI3-KINASE (PI3K) INHIBITOR GDC 0941 IN COMBINATI-
ON WITH EITHER PACLITAXEL (PAC) AND CARBOPLATIN 
(CARBO) WITH OR WITHOUT BEVACIZUMAB (BEV), OR 
PEMETREXED (PEM), CISPLATIN (CIS), AND BEV IN PATI-
ENTS WITH ADVANCED NON–SMALL CELL LUNG CAN-
CER (NSCLC).
Grace K. Dy1, Alex Adjei1, Harry J.M. Groen2, Joseph A. Ware3, Gee-
tha Shankar3, Wei Lin3, Benjamin Besse4, Rastilav Bahleda4, David 
Planchard4, Jean-Charles Soria4
1Roswell Park Cancer Institute/United States Of America, 2Dept Of Pul-
monology, UMC Groningen/Netherlands, 3Genentech Inc/United States 
Of America, 4Institut Gustave Roussy/France
Background: The PI3K pathway has been implicated as a mecha-
nism for cell survival and resistance to chemotherapy. PI3K may 
be an important target in NSCLC based on genetic alterations 
such as PIK3CA amplification, PTEN loss and PI3K mutations. Pre-
clinical NSCLC models show that concurrent dosing of GDC-0941 
improved activity of taxanes, platinums, and anti-VEGF therapy. 
This Phase 1b study aims to establish the safety and tolerability of 
GDC-0941 in combination with four frontline standard of care regi-
mens in patients with advanced NSCLC.
Methods: This study contains two Carbo/Pac containing arms: 
Arm A (GDC-0941 + Carbo + Pac), open to squamous (Sq) patients 
and Bev-ineligible non-squamous (NSq) patients; and Arm B (GDC-
0941 + Carbo + Pac + Bev) for NSq patients. The study also aims 
to evaluate two Cis/Pem containing arms in NSq patients: Arm C 
(GDC-0941 + Cis + Pem + Bev); and Arm D (GDC-0941 + Cis + 
Pem). Study objectives are to evaluate safety and pharmacokinetics 
(PK), and to determine the maximum tolerated/administered dose 
(MTD or MAD) of GDC-0941 in combination with chemotherapy re-
gimens in all arms. Patients received GDC-0941 with 4-6 cycles of 
chemotherapy every 3 weeks (Q3W): Pac (200 mg/m2), Carbo (AUC 
6 mg/mL·min), Cis (75 mg/m2), Pem (500 mg/m2), and Bev(15 mg/
kg) . In all arms, GDC was given PO qd on Days 1-14 of a 21-day 
cycle. GDC-0941 +/- Bev were given until progression or toxicity.
Results: As of 1 February 2013, Arms A, B and C have completed 
enrollment, with 18, 24 and 13 patients, respectively; no patients 
have been enrolled in Arm D to date. The most common Grade 
3/4 treatment-related adverse events (TAEs) reported in ≥10% of 
patients were as follows: Arm A: neutropenia (50%), anemia (17%), 
febrile neutropenia (17%), leukopenia (11%) and thrombocytopenia 
(11%); Arm B: neutropenia (38%), lymphopenia (13%); Arm C: fa-
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P2.11-006 REVIEW OF 10 YEARS OF ASCO ABSTRACTS 
FOR NON-SMALL CELL LUNG CANCER (NSCLC) AND 
THE IMPACT OF MOLECULAR BIOMARKERS (MB) IN CLI-
NICAL TRIAL SELECTION CRITERIA
Ryan D. Gentzler1, Sarah E. Yentz2, Alfred Rademaker3, Melissa L. 
Johnson1, Jyoti D. Patel1
1Division Of Hematology/Oncology, Northwestern University Feinberg 
School Of Medicine/United States Of America, 2Department Of Medici-
ne, Northwestern University Feinberg School Of Medicine/United States 
Of America, 3Preventive Medicine, Northwestern University Feinberg 
School Of Medicine/United States Of America
Background: Over the last decade, incorporation of new cytotoxic 
chemotherapeutics, introduction of maintenance therapy, and in-
tegration of targeted therapies have altered treatment paradigms 
for patients with metastatic NSCLC (mNSCLC). In a disease that 
was largely treated empirically, therapy is now tailored based upon 
histology and MB. We sought to analyze whether outcomes of cli-
nical trials in mNSCLC reported over 10 years at the ASCO Annual 
Meeting reflected perceived gains in the treatment of patients with 
mNSCLC.
Methods: Data were collected from ASCO abstracts of Phase II–IV 
clinical trials for patients with mNSCLC from 2004–2013. Trials in 
Progress abstracts were excluded. Data collected included author 
names, histology and MB selection criteria, phase, primary end-
point, outcomes, and drugs used. We hypothesized that rates of 
positive clinical trial outcomes would increase over time and that 
trials using MB selection criteria would have higher rates of posi-
tive outcomes. Statistical comparisons were made using Fisher’s 
exact test with two-sided p-values. Trends were compared using 
Spearman’s rank correlation.
Results: 711 of 2,540 identified mNSCLC category abstracts met 
selection criteria. Over 50% were published by the top 10% of 
841 unique first/last authors. Annual abstracts fitting selection 
criteria declined from 107 to 41 from 2004–2013. Common pri-
mary endpoints were: not specified (31%), response rate (24%), 
progression-free survival (PFS, 22%), and overall survival (OS, 14%). 
Few phase II trials had primary endpoints of PFS or OS (20.4%, 
6.0%). The proportion of trials with positive PFS outcomes increa-
sed from 3.7% to 26.8% despite decreases in total annual abstracts 
(correlation coefficient = –0.67, p=0.033) (see Figure). Positive OS 
outcomes increased from 0.9% to 4.9%. Trials with MB selection 
criteria (5.6%) or non-squamous (NS) histology (13% of trials wit-
hout MB selection) increased from 0% to 22% and 18% annually, 
respectively, and were more likely to result in an improvement in 
PFS (20.0% vs. 9.2%, p=0.0482 and 23.0% vs. 7.3%, p=0.0001, 
respectively). These criteria had no significant association with OS 
or QOL outcomes. 
an age: 72 years, adenocarcinoma, 80%, males, 59%) in Arms 1, 2, 
and 3; 97%, 98%, and 88% of pts were current or former smokers, 
respectively. The most common treatment-related grade 3/4 toxi-
cities are presented below. ORRs for Arms 1, 2, and 3 were 15%, 
24%, and 40%, respectively. While modest efficacy was observed 
in Arm 1, recent data (Lilenbaum, et al. 2012) suggesting a signifi-
cant OS advantage in pts receiving Pem in combination with Cb vs. 
Pem alone led to closure of this arm in early 2013. A subset ana-
lysis examining pts older or younger than 70 years found that the 
younger population treated on Arm 1 had inferior ORRs to older 
pts treated on Arm 3 (7% v. 26%, respectively).  
Grade 3/4 Toxicity Arm 1 (N=48) 
Arm 2 
(N=49) 
Arm 3 
(N=45) 
Hematologic 
Hemoglobin 5 (10%) 1 (2%) 5 (11%) 
Leukocytes 0 1 (2%) 4 (9%) 
Neutrophils 3 (6%) 4 (8%) 8 (18%) 
Platelets 0 2 (4%) 10 (22%) 
Non-hematologic 
Anorexia 1 (2%) 0 0 
Cardiac ischemia/infarction 0 1 (2%) 0 
CNS ischemia 0 1 (2%) 1 (2%) 
Deep vein thrombosis 0 1 (2%) 1 (2%) 
Dehydration 2 (4%) 2 (4%) 0 
Diarrhea 0 2 (4%) 1 (2%) 
Dyspnea 0 2 (4%) 2 (4%) 
Fatigue 10 (21%) 9 (18%) 9 (20%) 
Epistaxis 0 1 (2%) 0 
Hypertension 0 2 (4%) 2 (4%) 
Muscle weakness 4 (8%) 3 (6%) 4 (9%) 
Nausea 0 0 2 (4%) 
Proteinuria 0 0 1 (2%) 
Pulmonary embolism 1 (2%) 1 (2%) 2 (4%) 
Vomiting 0 2 (4%) 1 (2%) 
Conclusion: This is the largest prospective trial of bevacizumab in 
poor PS pts with advanced NSCLC. All three regimens were safe 
and well-tolerated. ORRs with Pem/Bev +/- Cb were encouraging 
and comparable to historical outcomes in patients with better PS. 
PFS and OS data will be presented.
Keywords: non-squamous, poor performance status, non-small-
cell
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test CEA level. The patients with positive EGFR mutation receive 
EGFR-TKI treatment. The EGFR mutation status of these patients’ 
blood was analyzed by HRM and ARMS. Then we tested their CEA 
level on the third, seventh, fifteenth and thirtieth day after EGFR-
TKI treatment respectively. We evaluated the efficacy on the first 
month and confirm it on the second month.
Results: 44/70 cases were found with EGFR gene mutations.In-
cluding 25 cases of exon19,18 cases of L858R mutation and 1 case 
of exon20 mutation. EGFR mutation rate of serum CEA high-level 
group was significantly higher than low-level group (EGFR gene 
mutation rate of patients with serum CEA level <5ng/ml vs. ≥ 5ng/
ml was 40.9% vs. 70.8%, p=0.017). Multivariate analysis showed 
that CEA high-level is independently associated with EGFR gene 
mutation rate. (p=0.020,OR=3.508, 95%CI：1.223-10.059).The sen-
sitivity, positive predictive value and accuracy of high CEA level to 
predict EGFR mutation is 79.1%,70.8% and 67.1%.The sensitivity of 
HRM and ARMS is 13.9% and 51.2% respectively. 43 patients recei-
ved EGFR-TKI treatment, 2 patients quit the study due to severe 
adverse reaction. We evaluate the efficacy and follow up their 
PFS.The total ORR is 41.9%, DCR is 74.4%.We divided the patients 
through the variation types of CEA into three groups: descending 
type, first increased then decreased type and ascending type. 
Analysis the relevance between clinical characteristics and efficacy 
of EGFR-TKI shows that the variation types of CEA is the only influ-
encing factor (P=0.001). Univariate analysis of NSCLC patients who 
received EGFR-TKI first-line treatment shows that patients with de-
scending type have longer PFS (P=0.001, HR 6.981, 95%CI: 2.534-
19.237). Multivariate Cox proportional hazards model analyses of 
various factors affecting PFS shows the same result (P=0.001, HR 
9.82, 95%CI: 3.322-26.031).
Conclusion: Patients with high CEA levels have a higher rate of 
EGFR mutations in NSCLC. Using high CEA level for predicting 
EGFR mutation is more sensitive than using peripheral blood to 
test EGFR mutation; the variation types of CEA could help us to 
predict the efficacy of EGFR-TKI for a short time (one month).
Keywords: Adenocarcinoma, Carcinoembryonic Antigen, EGFR 
Gene, ARMS
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P2.11-008 HIGH PROPORTION OF UNUSUAL EGFR MU-
TATIONS IN AN AUSTRALIAN POPULATION OF NON-
SQUAMOUS NSCLC
Henry W. Ainge-Allen1, Tajalli Saghaie2, Alistair Abbott2, Scott 
Mead3, Robyn Daniels2, Lucy Morgan2, Emily Stone1
1Lung Cancer MDT, St Vincent‘s Hospital/Australia, 2Nepean Lung 
Cancer Group, Nepean Blue Mountains Local Health District/Australia, 
3Department Of Anatomical Pathology, St Vincent‘s Hospital/Australia
Background: EGFR mutations have previously been reported in 
10-15% of non-squamous NSCLC in European populations. The 
rate of mutations and the proportion of mutations considered to 
be classical activating, known to confer resistance or unusual is yet 
to be determined in the Australian population. The influence of 
unusual mutations on disease progression is not yet clear.
Methods: We conducted a retrospective audit of cases of non-
squamous NSCLC lung cancer presenting to two metropolitan 
multidisciplinary teams in Sydney, Australia. All had EGFR testing 
Conclusion: Despite fewer phase II–III clinical trials presented 
at ASCO annually, there was a significant increase in those with 
positive PFS outcomes. Increases in trials selective for MB or NS 
histology may account for the improved PFS results. These data 
suggest better trial design and efficient use of resources. These 
data may also reflect bias in selecting abstracts for presentation, 
which could result in missed learning opportunities for future trial 
design. Additionally, it is unclear whether PFS endpoints are as 
meaningful as OS.
Keywords: NSCLC, metastatic, clinical trials, biomarker
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P2.11-007 RELEVANCE BETWEEN CEA LEVEL AND EGFR 
MUTATION, EFFICACY OF EGFR-TKI IN PATIENTS WITH 
LUNG ADENOCARCINOMA
Wei Y. Zhang, Hui B. Han, Bo Jin, Hua M. Shao, Yu Dong, Mi A. 
Huang
Departments Of Pulmonary Medicine, Chest Hospital Affliliated To 
Shanghai Jiaotong University/China
Background: EGFR-TKI has been widely used in the treatment of 
advanced NSCLC with positive EGFR mutation. However, tumor 
tissues may not always be available in patients with inoperable 
NSCLC. Although peripheral blood can be used to test the mu-
tations, but the sensitivity are not satisfactory.Studies have found 
that the CEA level are higher in patients with positive EGFR muta-
tion. And it also have been reported that the variation of CEA level 
before and after EGFR-TKI therapy was closely related with therapy 
efficacy. So if we use high CEA level to predict the EGFR mutati-
on, could we get a higher sensitivity than use peripheral blood to 
test the mutation? Are the variation types of CEA related with the 
efficacy of EGFR-TKI? To solve these questions, we designed this 
study and hope to find a marker to predict EGFR mutation and 
efficacy of EGFR-TKI.
Methods: 70 cases of newly diagnosed non-smoking adenocar-
cinoma of NSCLC were included in the study. We detected their 
EGFR mutation status, record their clinical characteristics and 
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Methods: It is a prospective, observational study on all consecu-
tively pts whose tumors were genotyped for EGFR-activating mu-
tations. All studied pts were treated in a single institution (ICESP) 
with erlotinib 150 mg PO daily. Tumor samples were formalin-fixed 
and paraffin-embedded. Tumor areas were selected and macro-
dissected, followed by whole DNA extraction and amplification by 
PCR. EGFR genotyping was performed through DNA sequencing 
(exons 18, 19, 20 and 21) by Sanger´s methodology.
Results: 49 pts were treated with erlotinib from Nov/2010 to 
May/2013, as first-line (11 pts, 22%), second-line (31 pts, 63%) or 
third-line therapy (7 pts, 14%). Erlotinib was administered during 
a median time of 4 mo. (0.2-23.6 mo.). Among these 49 pts, 38 
(78%) were diagnosed with adenocarcinomas harbouring EGFR-
activating mutations: 26 with exon 19 deletions, 10 with L858R 
mutation in exon 21 and one presented a rare mutation in exon 18 
(G719S). As expected, erlotinib was well tolerated, and acneiform 
rash and diarrhea were the most commonly observed toxicities. 
No treatment-related deaths were seen. Tumor response assess-
ment was done in 42 pts: progressive disease was observed in 15 
pts (36%) and 27 pts (64%) presented either partial response or 
disease stabilization. In a mean follow-up of 14 mo., 13 pts were 
dead. Median overall survival was not reached for the 38 pts with 
EGFR-mutated adenocarcinomas, and 1-year overall survival rate 
was 94% in these pts. In those pts with wild-type EGFR tumors, 
median overall survival was 15.6 mo (HR 0.17; 95% CI 0.02-0.33, 
p=0.0004). No difference in overall survival was observed between 
pts with EGFR-mutated adenocarcinomas if treated with erloti-
nib either as first-line therapy or later (HR 1.11; 95% CI 0.20-6.15, 
p=0.895). No difference in overall survival was observed between 
pts with EGFR-mutated adenocarcinomas according to the type of 
mutations (exon 19 deletions or others, p=0.147).
Conclusion: High rate of disease control (64%) and an impres-
sive 1-year overall survival rate (94%) were observed among pts 
with metastatic pulmonary adenocarcinomas harbouring EGFR-
activating mutations, as expected, with a favorable toxicity profile. 
These results do reinforce the importance of the correct identifi-
cation of this subgroup of pts with EGFR-activating mutations and 
their treatment with an EGFR-TKI as a targeted therapy.
Keywords: erlotinibe, non-small cell lung cancer, Epidermal 
growth factor receptor activating mutations
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P2.11-010 PHASE I STUDY OF HM61713, A NOVEL EPI-
DERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT 
SELECTIVE INHIBITOR, IN NON-SMALL CELL LUNG CAN-
CER (NSCLC) PATIENTS HAVING AN ACTIVATING EGFR 
MUTATION BUT FAILED TO PRIOR EGFR TYROSINE KI-
NASE INHIBITOR (TKI) THERAPY.
Dong-Wan Kim1, Sang-We Kim2, Tae Min Kim1, Se-Hoon Lee1, 
Chang-Min Choi2, Bhumsuk Keam1, Jae Cheol Lee2, Dae-Seog Heo1, 
Jungshin Lee2, Kyung-Sang Yu3, In-Jin Jang3, Kyung Joon Lim4, Jee-
woong Son4, Dae Ho Lee2
1Department Of Internal Medicine, Seoul National University Hospital/
Korea, 2Department Of Oncology, University Of Ulsan College Of Medi-
cine, Asan Medical Center/Korea, 3Department Of Clinical Pharmacolo-
gy, Seoul National University Hospital/Korea, 4Hanmi Pharmaceutical 
Co., Ltd./Korea
conducted between October 2010-March 2013. EGFR mutations 
were identified using PCR and DNA sequencing.
Results: 134 patient samples were tested for EGFR mutation. 
Samples were obtained by surgical resection (n=50), FNA (n=31), 
Core Biopsy (n=31), pleural fluid aspirate (n=3) and EBUS FNA (19). 
Of these, 32 (24%) were positive for an EGFR mutation. 23/32 had 
classical activating mutations, with 16/32 Exon 19 deletions and 
7/32 Exon 21 L858 substitutions. 4/32 had non-activating/resis-
tance mutations, with 3 exon 20 insertions and 1 exon 20 T790M 
(L858 + T790M complex de novo mutation). The remaining 6/32 
had unusual mutations (1 Exon 20 ala 767-Val769 duplication, 1 
Exon 21 p. Pro848Leu, 2 Exon 18 p. G719x, 1 exon 20 S761, D770 
insertion and 1 exon 20 deletion V774 insertion). 72 patients in 
the cohort were female. 8 were Asian, 8 were Pacific Islander, 1 
was Indian and 15 were Caucasian. Smoking history was confir-
med in all cases. 18/32 were non-smokers, 3/32 were Asian and 
24/32 were female. Of the patients with EGFR mutation positive 
tumours, 16/32 received TKI as first-line therapy, 5/32 received TKI 
as second-line therapy, 6/32 did not receive TKI and 5/32 were 
lost to follow-up in other institutions. Of the 6 who did not receive 
TKI, 5 cases were early-stage treated surgically; the other case 
received palliative radiotherapy but co-morbidity prevented TKI 
therapy. Information regarding disease progression was available 
in 20/32 cases. Of these cases 11/20 had classical activating mu-
tations, were treated with EGFR TKI and, to date have a mean (SD) 
progression free survival (PFS) of 315 (± 208) d. Those with other 
mutations had a PFS of 117 (±86) d. This difference was statistically 
significant at p<0.01(Mantel-Cox).
Conclusion: EGFR mutations occur more commonly in an Austra-
lian population of non-squamous NSCLC than previously reported 
in European populations. Most in this series have classical acti-
vating mutations. Almost one third of this series had a mutation 
other than classically activating and in all of these cases the PFS 
was significantly reduced. We report six unusual mutations of unc-
lear clinical significance, which are also associated with poor PFS.
Keywords: Epidermal growth factor receptor mutation, Non small 
cell lung cancer
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P2.11-009 ERLOTINIB IN METASTATIC PULMONARY 
ADENOCARCINOMAS HARBOURING EGFR ACTIVATING 
MUTATIONS, IN SAO PAULO - BRAZIL.
Rafael Caires-Lima1, Bruno M. Protasio1, Tiago K. Takahashi1, Mi-
lena P. Mak1, Denyei Nakazato1, Cristiane S. Mesquita1, Teresa Y. 
Takagaki2, Iberê C. Soares3, Evandro S. Mello3, Venâncio A. Alves3, 
Paulo M. Hoff1, Gilberto Castro Jr.1
1Medical Oncology, Instituto Do Cancer Do Estado De Sao Paulo (ICE-
SP)/Brazil, 2Pneumology, Instituto Do Cancer Do Estado De Sao Paulo 
(ICESP)/Brazil, 3Pathology, Instituto Do Cancer Do Estado De Sao Paulo 
(ICESP) And Lim-14 Fmusp/Brazil
Background: EGFR-activating mutations are predictive of high 
response rates and overall survival gains in patients (pts) with pul-
monary adenocarcinomas, treated with EGFR- tyrosine-kinase in-
hibitors (EGFR-TKIs), as erlotinib. Our objectives in this study were 
to analyze the efficacy and safety of erlotinib as first-line therapy 
or later in pts with adenocarcinomas harbouring EGFR-activating 
mutations.
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played nanomolar inhibitory activity in proliferation assays using 
lung adenocarcinoma cell lines expressing mutant EGFRL858R/T790M 
(NCI-H1975 EC50 92 nM).
1 In NSCLC patients with prior erlotinib/
gefitinib failure and one/two previous lines of chemotherapy, 
50mg afatinib once daily produced confirmed objective respon-
ses in 7% of patients and a median PFS of 3.3 months.2 Preclinical 
models suggested that administering afatinib using a high-dose 
intermittent (HDI) schedule, leading to higher maximal plasma 
concentrations, may provide an alternative means to block T790M-
harbouring cells effectively. It may also potentially reduce wild-
type EGFR-mediated adverse events noted with continuous dosing 
of EGFR TKIs. In this ongoing open-label study, the maximum 
tolerated dose (MTD), safety and pharmacokinetics (PKs) of HDI 
afatinib are being assessed in Part A in patients with advanced 
solid tumours. The MTD of HDI afatinib will be evaluated in Part B 
in patients with T790M-mutated advanced NSCLC following prior 
EGFR TKI therapy. Preliminary results from Part A are presented.
Methods: In Part A, patients with metastatic/unresectable solid tu-
mours and adequate organ function were administered 90–200mg 
afatinib on Days 1–3 every 14 days in each 28-day cycle using a 
3+3 dose-escalation design. Doses are escalated until MTD (pri-
mary endpoint), defined as the dose at which less than two of up 
to six patients develop dose-limiting toxicities (DLTs) in Cycle 1. PK 
sampling was conducted on Days 1–3, 8, 15–17, 29, 43 and 57, with 
Cmax of afatinib on Day 3 of Cycle 1 being the secondary endpoint. 
In Part B, the MTD cohort will be expanded to specifically include 
EGFR TKI-pretreated advanced NSCLC patients with T790M mu-
tations. Exploration of baseline and on-therapy plasma levels of 
detectable T790M is planned.
Results: To date, 16 patients have been recruited in Part A (90mg 
n=6; 120mg n=3; 150mg n=4; 200mg n=3; male/female n=8/8; 
median age 65 years; never smokers/ex-smokers n=10/6; primary 
tumour site lung n=9; known T790M mutation n=7). The most com-
mon drug-related adverse events (DRAEs) were diarrhoea, rash, 
dermatitis acneiform and nausea. DRAEs of Grade ≥3 were seen 
in one patient at 90mg (Grade 3 worsening cellulitis [Cycle 1; DLT] 
and urosepsis [Cycle 2]) and one patient at 150mg (Grade 3 dehy-
dration, hypokalaemia, hypophosphataemia, diarrhoea [Cycle 2]). 
Preliminary response data on evaluable T790M-mutated NSCLC 
patients will be presented as available. Preliminary PK analyses 
suggest 150mg afatinib once daily for 3 days is sufficient to achie-
ve total plasma Cmax concentrations at or above the predicted IC50 
value for T790M. Afatinib trough plasma concentrations will also 
be presented.
Conclusion: HDI afatinib elicited a manageable safety profile up 
to 200mg on Days 1–3 every 14 days. Total plasma Cmax concent-
rations at or above the predicted efficacious threshold for T790M 
inhibition were already achieved in the 150mg cohort. Treatment in 
the 200mg cohort is ongoing. Additional cohorts may be included 
to explore shorter drug-free dosing periods. 1. Solca F, et al. JPET 
2012;343:342–50. 2. Miller V, et al. Lancet Oncol 2012;13:528–38.
Keywords: T790M, EGFR, afatinib, NSCLC
Background: NSCLC patients having an activating EGFR mutation 
initially responded well to EGFR TKI but most of them experienced 
progressive disease due to various resistance mechanisms inclu-
ding T790M (~50% of cases) mutation. HM61713 is an orally active, 
novel EGFR mutant selective inhibitor showing a strong anticancer 
activity in many lung cancer cell lines including T790M mutation 
harboring cell line. Therefore, HM61713 might provide the poten-
tial clinical benefit to those who have an activating EGFR mutation 
but have failed previous EGFR TKI treatment.
Methods: This is a phase I study using a standard 3+3 dose esca-
lation scheme. NSCLC Patients with activating EGFR mutation and 
progressed after at least 2 prior chemotherapy regimens including 
EGFR TKI were eligible. The objective of this study is to determine 
the recommended phase II dose as well as to assess the prelimina-
rily efficacy.
Results: To date, a total of 23 patients were treated with at doses 
of 75-250 mg/day. One patient at a dose of 200 mg/day experi-
enced grade 3 drug induced idiosyncrasy and grade 4 elevation of 
amylase. The drug induced idiosyncrasy was skin rash of non-EGFR 
TKI type. The most common drug-related adverse events were 
desquamation, diarrhea, pruritus, and nausea; most were grade 
1 or 2. The maximum tolerated dose (MTD) and recommended 
phase II dose were not determined yet. Plasma concentration of 
HM61713 reached the peak 2-4 hr after administration and decli-
ned with the half-life of 8-12 hr. Among 21 evaluable patients, 2 
patients achieved partial response (PR) and one of them had con-
firmed T790M mutation while 12 patients had stable disease (SD) 
including 11 patients showed tumor shrinkage. Accrual to this stu-
dy is ongoing and updated data will be presented at the meeting.
Conclusion: HM61713 showed good safety profile and promising 
anticancer activity in NSCLC patients with EGFR mutation who 
failed to prior EGFR TKI therapy. These results support the the-
rapeutic potential of HM61713 for NSCLC patients with activating 
EGFR mutations after development of resistance to EGFR TKI the-
rapy.
Keywords: EGFR mutant selective inhibitor, Phase I clinical trial, 
NSCLC with EGFR mutation, HM61713
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P2.11-011 A PHASE IB STUDY OF HIGH-DOSE INTERMIT-
TENT (HDI) AFATINIB IN EGFR T790M MUTATION-POSI-
TIVE NON-SMALL CELL LUNG CANCER PATIENTS WITH 
ACQUIRED RESISTANCE TO REVERSIBLE EGFR TKIS
D Ross Camidge1, Pasi A. Jänne2, Lecia V. Sequist3, Vikram Chand4, 
Elizabeth Dowling5, Yu Gu6, David Schnell7, Geoffrey R. Oxnard8
1Medical Oncology, University Of Colorado/United States Of America, 
2Lowe Center For Thoracic Oncology, Dana Farber Cancer Institute/Uni-
ted States Of America, 3Hematology/Oncology, Massachusetts General 
Hospital/United States Of America, 4Clinical Development – Oncology, 
Boehringer Ingelheim Pharmaceuticals, Inc./United States Of America, 
5Boehringer Ingelheim Pharmaceuticals, Inc./United States Of America, 
6Biometrics And Data Management, Boehringer Ingelheim Pharmaceu-
tical Inc./United States Of America, 7Boehringer Ingelheim Pharma 
GmbH & Co. KG/Germany, 8Lowe Center For Thoracic Oncology, Dana-
Farber Cancer Institute/United States Of America
Background: Afatinib, an irreversible ErbB Family Blocker, dis-
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P2.11-013 A RANDOMISED PHASE II TRIAL OF OLAPA-
RIB MAINTENANCE VERSUS PLACEBO MONOTHERAPY 
IN PATIENTS WITH CHEMOSENSITIVE ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC)
Dean Fennell1, Angela Casbard2, Jason Lester3, Sarah Bridges2, 
Gareth Griffiths2
1University Of Leicester/United Kingdom, 2Wales Cancer Trials Unit/
United Kingdom, 3Velindre NHS Trust/United Kingdom
Background: In the UK approximately 35,000 people die from 
lung cancer annually, the majority from NSCLC. Chemotherapy is 
one of the main treatments for advanced NSCLC but those treated 
will still only live for an average of 9 or 10 months after diagnosis. 
Chemotherapy damages tumour cell DNA, and NSCLC tumours 
that respond to chemotherapy are less able to repair this damage. 
Olaparib blocks the Poly (ADP-ribose) polymerase (PARP) enzyme 
which is essential for DNA repair. It is hypothesized that if DNA 
repair is prevented then this will cause cancer cell death. The UK 
National Cancer Research Institute Lung Clinical Studies Group, as 
part of the National Cancer Research Network/AstraZeneca initia-
tive, have developed this clinical trial to investigate whether or not 
giving Olaparib following chemotherapy will benefit patients with 
NSCLC who have responded to initial chemotherapy treatment 
by prolonging the time before the tumour re-grows. The study 
is funded by a research grant from Cancer Research UK (C16728/
A14917) and an investigator sponsored grant and free drug from 
AstraZeneca. The trial is sponsored by Velindre NHS Trust, and 
coordinated by the Wales Cancer Trials Unit, Cardiff, UK.
Methods: A UK multicentre randomised phase II trial. Eligible 
patients include histological diagnosis of stage IIIB/IV squa-
mous/non-squamous non small cell lung cancer, ECOG PS0-1, 
age>=18, chemonaive and having given informed consent. 
Patients are initially registered before induction chemotherapy 
after which if there is evidence of radiological response (partial or 
complete) they will be randomised to either Olaparib (300mg po 
bd q21) until disease progression, or placebo. Those with stable 
disease or progression will not be eligible for the main trial and 
will receive local standard treatment. The primary endpoint of 
the randomised trial is progression-free survival based on RECIST 
v1.1 with secondary endpoints of safety, tolerability, feasibility of 
use, response, overall survival and tumour volume reduction. The 
median PFS for patients with CR/PR after 3 – 4 cycles of induction 
chemotherapy treatment is expected to be 3 months. With 90% 
power and a one-sided α of 0.2, 114 participants are required to 
demonstrate statistical significance between the arms if the true 
hazard ratio for Olaparib compared to placebo is 0.65, based on 
the logrank test. We therefore aim to recruit 57 participants into 
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P2.11-012 PHASE IA/IB STUDY OF THE ANTI-MET ANTI-
BODY ONARTUZUMAB (METMAB) IN PATIENTS WITH 
SOLID TUMORS OR MET-POSITIVE LUNG CANCER
Hidehito Horinouchi1, Shinji Nakamichi1, Hiroshi Wakui1, Hiroshi 
Nokihara1, Noboru Yamamoto1, Yasuhide Yamada1, Atsushi Hori-
ike2, Fumiyoshi Ohyanagi2, Keita Kudo2, Noriko Yanagitani2, Yuko 
Kawano2, Toshio Sakatani2, Azusa Tanimoto2, Makoto Nishio2, Ma-
saichi Abe3, Hideki Doura3, Takashi Tahata3, Tomohide Tamura1
1National Cancer Center Hospital/Japan, 2Cancer Institute Hospital, 
Japanese Foundation For Cancer Research/Japan, 3Chugai Pharmaceuti-
cal Co., Ltd.,/Japan
Background: MET, a receptor tyrosine kinase, and its ligand, he-
patocyte growth factor (HGF), play a key role in cancer progressi-
on and prognosis. Aberrant activation of the HGF/MET pathway 
can enhance invasion, proliferation, and survival of cancer cells, 
providing a rationale for developing therapeutics that block MET 
activation. Onartuzumab was engineered as a unique recombinant 
humanized one-armed anti-MET monoclonal antibody that inhibits 
HGF-induced MET signaling without agonistic activity.
Methods: This 2-stage study was the first in Japanese patients 
to evaluate efficacy, safety, and pharmacokinetics (PK) of onartu-
zumab or onartuzumab in combination with erlotinib. In Stage 1—a 
3+3 dose-escalation stage—patients with advanced solid tumors, 
refractory to the standard of care or for which there is no stan-
dard of care, received onartuzumab at doses of 4, 15, or 30 mg/
kg IV once every 3 weeks until disease progression. In Stage 2—a 
combination stage—onartuzumab at a dose of 15 mg/kg IV once 
every 3 weeks was given in combination with erlotinib 150 mg/day 
to patients with advanced MET-positive non–small-cell lung cancer 
who had received at least 1 prior platinum-containing regimen (as 
regards EGFR-TKI, only 1 regimen was permitted); this regimen 
was continued until disease progression. Exploratory biomarker 
analyses were also conducted.
Results: In Stage 1, 9 patients (male/female: 6/3) were enrolled. 
Median age was 68 years. There were no dose-limiting toxicities 
(DLTs) and the maximum tolerated dose was not reached at 30 mg/
kg. Hypoalbuminemia (33.3%) and constipation (33.3%) were the 
most frequent adverse events (AEs). Hypoalbuminemia was the 
only AE occurring at grade 3 severity, indicating that onartuzumab 
was well tolerated up to 30 mg/kg. In Stage 2, 6 patients were 
enrolled (male/female: 1/5; adeno/squamous: 5/1; EGFR wild type/
mutant: 3/3; median age 69 years). There were no DLTs. The most 
frequent AE was diarrhea (83.3%). Grade 1/2 AEs occurred in all 
patients. There was one grade 3 case of each of deep vein throm-
bosis, pulmonary embolism, rash, hypoxia, dermatitis acneform, di-
arrhea, and neutropenia. No grade 4/5 AE was observed. PK ana-
lysis from patients in Stages 1 and 2 indicated dose proportionality 
of Cmax and AUC. No drug–drug interaction between onartuzumab 
and erlotinib was observed. In Stage 2, progression-free survival 
was beyond 6 months in 2 patients (7.2 and 12.2 months); 1 patient 
achieved a partial response. Median circulating HGF concentration 
after onartuzumab was elevated to approximately three times the 
baseline level.
Conclusion: Onartuzumab alone or with erlotinib was well tolera-
ted in Japanese patients. The PK profile of onartuzumab was not 
affected by co-administration with erlotinib.
Keywords: MET inhibitor, ADVANCED NSCLC, erlotinib, HGF
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red for successful development.
Conclusion: Physicians that enroll patients in NSCLC trials should 
prioritize their participation in programs that involve either a bio-
marker or receptor targeted therapy, which appear to carry the 
best chances for a successful treatment response. Given the high 
adjusted cost of clinical testing alone in NSCLC, efforts to mitigate 
the risk of trial failure need to explore these factors more fully.
Keywords: biomarker, Cost, clinical trial, drug development
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P2.11-015 COMPARATIVE EFFECTIVENESS OF GEFITI-
NIB, ERLOTINIB, AFATINIB AND CHEMOTHERAPY IN 
THE FIRST LINE TREATMENT OF PATIENTS WITH AD-
VANCED NON SMALL CELL LUNG CANCER (NSCLC) 
AND EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) 
MUTATIONS
Gilberto Lopes1, Benjamin Haaland2
1Johns Hopkins University/United States Of America, 2Centre For Quan-
titative Medicine, Office Of Clinical Sciences, Duke-Nus Graduate Medi-
cal School/Singapore
Background: EGFR tyrosine kinase inhibitors (TKI) have revolutio-
nized the treatment of patients with advanced NSCLC who harbor 
activating EGFR mutations. No large prospective trial has compa-
red gefitinib, erlotinib and afatinib face-to-face. We did a network 
analysis comparing the three drugs against chemotherapy and 
among themselves.
Methods: We searched PUBMED, EMBASE, google scholar da-
tabases and abstracts from ASCO, ESMO and WCLC abstracts 
between 2000 and 2013 using relevant search terms. Prospective, 
randomized clinical trials comparing erlotinib, gefitinib, or afatinib 
to chemotherapy or one another as first-line therapy in patients 
with non-small-cell lung cancer were selected. Studies were inclu-
ded if they included only patients with EGFR activating mutations 
or if they reported relative efficacy within the EGFR positive sub-
group. Endpoints of interest were progression-free survival (PFS), 
overall survival (OS), and overall response rate (ORR). Direct and 
indirect meta-estimates were generated in the context of linear 
mixed effects models, similar to the model of DerSimonian and 
Laird, with fixed effects for each relative comparison and random 
effects for each study. Heterogeneity across studies was tested 
using chi-squared and I2 statistics in the manner of Higgins and 
Thompson. Confidence (CI) and Predictive intervals (PIs) were 
calculated using the study-to-study variance estimates from each 
linear mixed-effects model. Results were considered statistically 
significant if the CI and PI did not cross unity.
Results: Eight studies fulfilled search and inclusion criteria: OP-
TIMAL, EURTAC, LUX-Lung 3, LUX-Lung 6, IPASS, West Japan, 
North-east Japan, and First-SIGNAL. The pooled hazard ratio 
(HR) meta-estimate for PFS were as follows: erlotinib vs. chemo-
therapy - 0.25 (95% CI 0.14-0.43; 95% PI 0.11-0.58), afatinib vs. 
chemotherapy - 0.44 (95% CI 0.25-0.77; 0.19-1.03), gefitinib vs. 
chemotherapy - 0.43 (95% CI 0.29-0.63; 95% PI 0.21-0.90), erlotinib 
vs. afatinib - 0.57 (95% CI 0.26-1.23; 95% PI 0.21-1.55), erlotinib vs. 
gefitinib - 0.58 (95% CI 0.30-1.13; 95% PI 0.23-1.46), and afatinib 
vs. gefitinib - 1.02 (95% CI 0.52-2.00; 95% PI 0.41-2.58). The test of 
heterogeneity (for PFS) indicated moderately high study-to-study 
each arm, over a 12 month accrual period, with minimum partici-
pant follow-up of at least 6 months. The primary analysis of data 
will be performed after 98 PFS events.
Results: Not applicable
Conclusion: Not applicable
Keyword: Olaparib PARP NSCLC
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P2.11-014 BIOMARKERS REDUCE CLINICAL TRIAL RISK 
AND THE COST OF DRUG DEVELOPMENT IN NON-
SMALL CELL LUNG CANCER (NSCLC)
Gilberto Lopes1, Adam Falconi2, Jayson Parker2
1Johns Hopkins University/United States Of America, 2University Of 
Toronto/Canada
Background: We evaluated the risk of clinical trial failure and the 
cost of drug development for patients with NSCLC between 1998 
and 2012
Methods: For assessment of drug development we used trial dis-
closures from publically available resources, such as clinicaltrials.
gov and others. Compounds were excluded from the analysis if 
they began phase I clinical testing before 1998 and if they did not 
use clinically significant, treatment-relevant endpoints, such as 
response rate, progression-free and overall survival. Analysis was 
conducted in regards to treatment indication, compound classifi-
cation and mechanism of action. A compound that had completed 
a phase I clinical trial was classified as successful if there was an 
ongoing, completed, or currently recruiting phase II clinical trial 
found. A compound that had completed a phase II clinical trial was 
similarly classified as successful if there was an ongoing, comple-
ted or currently recruiting phase III found. A compound that had 
completed a phase III clinical trial was classified as successful if 
there was an official FDA approved indication in our study popu-
lation. In addition, a phase I/II trial was classified as a phase II trial 
and a phase II/III trial was classified as a phase III trial for analysis 
purposes. Follow up was completed until January 1, 2012. Costs 
of clinical drug development for advanced NSCLC were calculated 
using industry data and assumptions, a 9% yearly discount rate 
and assuming a clinical trial length of 2.5 years for phase I trials, 4 
years for phase II trials, 5 years for phase III trials and an average of 
5 phase I trials, 7 phase II trials, and 4 phase III trials per approved 
drug. All funding costs are in US dollars (USD).
Results: 2,407 clinical trials met search criteria. 676 trials and 199 
unique compounds met our inclusion criteria. The likelihood, or 
cumulative clinical trial success rate, that a new drug would pass 
all phases of clinical testing and be approved was found to be 11% 
(less than the expected industry aggregate rates of 16.5%). The 
biggest obstacle for approval was the success of phase III trials: 
success rate was only 28%. Biomarker-guided targeted therapies 
(with a success rate of 62%) and receptor targeted therapies (with 
a success rate of 31%) were found to have the highest likelihood of 
success in clinical trials. The risk-adjusted cost for NSCLC clinical 
drug development with biomarkers was US$1.4 billion, a 26% re-
duction when compared to overall lung cancer drug development 
costs of US$1.89 billion, which is within industry expectations. Po-
tential savings may be even higher if fewer clinical trials are requi-
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Conclusion: Administration of TKI agents with conventional the-
rapy might be benefit for patients with BMs from NSCLC on MOS, 
MPFSI and MPFSE compared with conventional therapy. Patients 
harboring EGFR mutation not only had significant improvement for 
PFSE with TKI plus conventional treatment compared with EGFR 
negative patients, but also non-significantly better outcome of OS 
and PFSI as well.
Keywords: TKI, non-small cell lung cancer, brain metastasis, EGFR 
mutation
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P2.11-017 ICOTINIB IN ADVANCED LUNG ADENOCARCI-
NOMA PATIENTS PRETREATED WITH PEMETREXED
Yulong Zheng1, Weijia Fang1, Haiping Jiang1, Chenyu Mao1, Peng 
Zhao1, Yi Zheng1, Jiong Qian1, Jianying Zhou2, Nong Xu1
1Medical Oncology, The 1st Affiliated Hospital, Zhejiang University, 
College Of Medicine/China, 2Respiratory Medicine, The 1st Affiliated 
Hospital, Zhejiang University, College Of Medicine/China
Background: In non-small cell lung cancer (NSCLC), the well-deve-
loped epidermal growth factor receptor (EGFR) is important thera-
peutic target. EGFR activating gene mutations have been proved 
strongly predictive of response to EGFR-tyrosine kinase inhibitors 
in NSCLC. However, both in daily clinical practice and clinical trials, 
patients with unknown EGFR gene status (UN-EGFR-GS) are very 
common. In this study, we assessed efficacy and tolerability of 
sequential treatment of first-line pemetrexed followed by icotinib 
in Chinese advanced lung adenocarcinoma with UN-EGFR-GS.
Methods: We retrospectively analyzed 15 patients with advanced 
lung adenocarcinoma, who were treated first-line chemotherapy 
with pemetrexed and sequential using icotinib. The clinical cha-
racteristics, toxicity and survival status were collected through 
reviewing medical records, electronic preserved data, interviewing 
with patients or their family members. The overall survival (OS) was 
defined as the time of starting pemetrexed treatment to death or 
lost to follow up. The clinical course of included patients and treat-
ment were prospectively monitored.
Results: Totally, 15 patients with advanced lung adenocarcinoma 
were included, 9 females, 6 males. The median age is 57 years old 
(ranges: 40-73y). Of the 15 patients, 11 were non-smokers and 4 
were smokers. All the patients at least received one cycle of peme-
trexed chemotherapy, and then were administered with icotinib. 
Four cases were received pemetrexed combined with carboplatin, 
8 combined with cisplatin, and 3 as single use. The mean cycles of 
pemetrexed given to patients were 3.8(1-6cycles). The response 
rate to pemetrexed was 20.0% (3/15), stable disease 33.3% (5/15), 
progressive disease 40% (6/15). The icotinib use of 4 patients was 
for the purpose of maintenance therapy, 11 for second line. The re-
sponse rate to icotinib was 40% (6/15), stable disease 26.7% (4/15), 
progressive disease 33.3% (5/15). There was no grade 3-4 toxicities 
observed during icotinib treatment phase. The most common 
grade 1-2 toxicities were rashes (26.7%), diarrheas (30%), elevated 
aminotransferase (13.3%) and elevated BUN (6.7%). At the end of 
follow up, 8 patients were dead, 7 alive. The median OS was 22.6 
months. Two patients were still on icotinib treatment.
Conclusion: The sequence of first-line pemetrexed-based chemo-
therapy followed by icotinib treatment is a promising option for 
variability with Q = 17.7 on 5 degrees of freedom (p = 0.003) and 
I2 of 72%. For ORR, The pooled odds ratio (OR) meta-estimate for 
erlotinib vs. chemotherapy was 8.2 (95% CI 4.5-15.1; 95% PI 3.9-
17.5), afatinib vs. chemotherapy was 5.5 (95% CI 3.4-8.8; 95% PI 
2.9-10.5), gefitinib vs. chemotherapy was 4.1 (95% CI 2.7-6.3; 95% 
PI 2.3-7.6), erlotinib vs. afatinib was 1.5 (95% CI 0.7-3.3; 95% PI 0.6-
3.7), erlotinib vs. gefitinib was 2.0 (95% CI 0.9-4.1; 95% PI 0.8-4.7), 
and afatinib vs. gefitinib was 1.3 (95% CI 0.7-2.5; 95% PI 0.6-2.8). 
The test of heterogeneity indicated moderate study-to-study vari-
ability with Q = 7.32 on 5 degrees of freedom (p = 0.198) and I2 of 
32% (For ORR). There were no statistically significant differences 
for overall survival.
Conclusion: Erlotinib, gefitinib and afatinib improved clinical out-
comes when compared with chemotherapy. There were no stati-
stically significant differences in the comparison among erlotinib, 
afatinib, and gefitinib.
Keywords: Epidermal growth factor receptor, comparative effec-
tiveness, tyrosine kinase inhibitor, indirect comparison
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P2.11-016 A COMPARATIVE ANALYSIS OF EGFR MUTA-
TION STATUS IN ASSOCIATION WITH THE EFFICACY OF 
TKI IN COMBINATION WITH WBRT/SRS/SURGERY PLUS 
CHEMOTHERAPY IN BRAIN METASTASIS FROM NON-
SMALL CELL LUNG CANCER
Lanjun Zhang1, Ling Cai2
1Thoracic Surgery, Sun Yat-Sen University Cancer Center/China, 2Radi-
ation Oncology, Sun Yat-Sen University Cancer Center/China
Background: The outcomes of brain metastasis (BM) from non-
small cell lung cancer (NSCLC) remain poor even with optimized 
option of stereotacic radiosurgery (SRS), whole brain radiotherapy 
(WBRT), surgery, chemotherapy or a combination. We purposed to 
identify the efficacy of tyrosine kinase inhibitor (TKI) of epidermal 
growth factor receptor (EGFR) using with conventional therapy on 
BM patients from NSCLC and clarify the association between treat-
ment outcome and EGFR gene mutation status.
Methods: Totally 282 cases treated basically with conventional 
therapy alone or in addition to TKI were enrolled in our study from 
2003-2012. Among these patients, 178 cases were treated with 
conventional therapy (Non-TKI group) and 104 cases were treated 
with TKI plus conventional therapy (TKI group). EGFR mutation 
analysis was performed in 107 patients with tissue samples.
Results: With a median follow-up of 28 months (range, 22-34 
months), the median overall survival (MOS), median progression-
free survival of intracranial disease (MPFSI), and median progres-
sion-free survival for extracranial disease (MPFSE) in TKI group 
was 31.9, 19.8, and 19.6 months compared with 17.0 (P<0.0001), 
12.0 (P<0.0001), and 12.3 (P<0.0001) months in Non-TKI group, 
respectively. Within TKI group, patients harboring EGFR mutation 
had longer time of 20.4 months to extracranial disease progression 
than 14.1 months in EGFR negative patients (P=0.032). In additi-
onal, EGFR positive patients had nonsignificant but potential im-
provements of 37 and 22.7 months for MOS and MPFSI compared 
with 23.4 and 16.9 months in EGFR negative patients (P=0.094, 
P=0.382 respectively).
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quamous carcinomas, 7% squamous cell carcinomas, 9% NSCLC 
NOS and 3% others; tumor stages I-II, III and IV in 15.5%, 24% and 
60.5% of the patients. EGFR mutations were found in 163 (16%) 
patients. Patients with mutations had the following characteristics: 
age median 66 (range 34-89) years, 46% male, 54% female, 47% 
never-smokers, 38% former smokers, 15% current smokers; perfor-
mance status was recorded in 153 patients and was 0, 1, 2 and 3 in 
30%, 50%, 14% and 6% of the patients. The mutation-positive tu-
mors had the following characteristics: 85% adenocarcinomas, 4% 
adenosquamous carcinomas, 4% squamous cell carcinomas, 2% 
NSCLC NOS, and 5% others. Among patients with mutations, exon 
18 mutations were seen in 7% of the patients, exon 19 mutations in 
50% of the patients including deletions in 39%, exon 20 mutations 
in 12%, exon 21 mutations in 39% including L858R in 28% of the 
patients. Detailed data on systemic treatment were available for 
122 patients with advanced EGFR mutation-positive NSCLC and 
most of these patients received EGFR-directed tyrosine kinase 
inhibitors during the course of their disease.
Conclusion: The INSIGHT observational study demonstrated that 
EGFR mutation testing has been established in the participating 
centres in Central Europe. The mutation rate of 16% is on the 
upper limit of the range seen in Western European countries but 
a potential selection bias for testing of patients with higher likeli-
hood of harboring EGFR mutations cannot be excluded. Systemic 
treatment in patients with EGFR mutations is similar to treatment 
patterns observed in other countries. This study was supported by 
Boehringer Ingelheim Regional Center Vienna.
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P2.11-019 TREATMENT STRATEGIES IN PATIENTS WITH 
ADVANCED EGFR MUTATION-POSITIVE NSCLC IN CEN-
TRAL EUROPE: FINDINGS FROM THE INSIGHT OBSER-
VATIONAL STUDY
Tanja Cufer1, Rafal Dziadziuszko2, Peter Berzinec3, Anna Kowal-
czyk2, Ladislav Dusek4, Helmut Popper5, Izidor Kern6, Wlodzimierz 
Olszewski7, Janus Milanowski8, Zoltan Lohinai9, Katarzyna Ram-
lau10, Joanna Chorostowska-Wynimko11, Marcela Tomiskova12, 
Juraj Kultan12, Milos Pesek12, Rodryg Ramlau10, Wolfgang Eisterer13, 
Lenka Medvecova14, Alicia Maciejewska – Izdebska2, Juraj Mazal15, 
Paolo Bajcic16, Vit Kandrnal4, Robert Pirker17
1Medical Oncology Unit, University Clinic Golnik/Slovenia, 2Department 
Of Radiotherapy & Oncology, Medical University Of Gdansk/Poland, 
3Department Of Oncology, Specialised Hospital Of St Zoerardus Zobor/
Slovak Republic, 4Institute Of Biostatistics And Analyses, Masaryk Uni-
versity/Czech Republic, 5Department Of Pathology, Medical University 
Of Graz/Austria, 6Laboratory Of Cytology And Pathology, University 
Clinic Golnik/Slovenia, 7Department Of Pathology, Oncology Institute 
Of Maria Skłodowska-Curie/Poland, 8Department Of Pneumology, 
Oncology & Allergology, Medical University/Poland, 9Department Of 
Pneumology, National Korányi Institute/Hungary, 10Department Of 
Oncology, Poznań University Of Medical Sciences/Poland, 11Laboratory 
Of Molecular Diagnostics & Immunology, National Institute Of Tubercu-
losis And Lung Diseases/Poland, 12Department Of Pulmonary Diseases 
And Tuberculosis, University Hospital/Czech Republic, 13Department 
Of Medicine, Medical University Of Innsbruck/Austria, 14Department 
Of Oncology, Adus Healthcare Centre/Slovak Republic, 15Department Of 
Pneumology, University Hospital F. D. Roosevelt/Slovak Republic, 16Me-
dical Affairs Department, Boehringer Ingelheim Rcv/Austria, 17Depart-
ment Of Medicine 1, Medical University Of Vienna/Austria
advanced lung adenocarcinoma with UN-EGFR-GS in China. The 
sequence yielded promising results with acceptable toxicity. The 
role of the sequential model for advanced NSCLC patients with 
adenocarcinoma histology should be further investigated in stu-
dies with larger sample sizes.
Keywords: chemotherapy, EGFR-TKI, non-small cell lung cancer
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P2.11-018 EGFR MUTATIONS IN NSCLC PATIENTS IN 
CENTRAL EUROPE: THE INSIGHT OBSERVATIONAL  
STUDY
Robert Pirker1, Rafal Dziadziuszko2, Peter Berzinec3, Ladislav 
Dusek4, Tanja Cufer5, Paolo Bajcic6, Helmut Popper7, Wlodzimierz 
Olszewski8, Joanna Chorostowska-Wynimko9, Jana Skrickova10, 
Vitezslav Kolek11, Milos Pesek12, Gyula Ostoros13, Izabela Chmie-
lewska14, Lenka Medvecova15, Wolfgang Eisterer16, Vit Kandrnal4, 
Juraj Mazal17, Helmuth Popper7, Wlodzimierz Olszewski18, Rodryg 
Ramlau19
1Department Of Medicine 1, Medical University Of Vienna/Austria, 
2Department Of Radiotherapy & Oncology, Medical University Of 
Gdansk/Poland, 3Department Of Oncology, Specialised Hospital Of St 
Zoerardus Zobor/Slovak Republic, 4Institute Of Biostatistics And Analy-
ses, Masaryk University/Czech Republic, 5Medical Oncology Unit, Uni-
versity Clinic Golnik/Slovenia, 6Medical Affairs Department, Boehringer 
Ingelheim Rcv/Austria, 7Department Of Pathology, Medical University 
Of Graz/Austria, 8Department Of Pathology, Oncology Institute Of Ma-
ria Sklodowska-Curie/Poland, 9Laboratory Of Molecular Diagnostics & 
Immunology, National Institute Of Tuberculosis And Lung Diseases/Po-
land, 10Department Of Pulmonary Diseases And Tuberculosis, Universi-
ty Hospital/Czech Republic, 11Department Of Respiratory Medicine, Uni-
versity Hospital Olomouc/Czech Republic, 12Department Of Pulmonary 
Diseases And Tuberculosis, University Hospital Plzeň/Czech Republic, 
13Department 8, National Koranyi Institute Of Pulmonology/Hungary, 
14Department Of Pneumology, Oncology & Allergology, Medical Univer-
sity/Poland, 15Department Of Oncology, Adus Healthcare Centre/Slovak 
Republic, 16Department Of Medicine, Medical University Of Innsbruck/
Austria, 17Department Of Pneumology, University Hospital F. D. Roo-
sevelt/Slovak Republic, 18Department Of Pathology, Oncology Institute 
Of Maria Skłodowska-Curie/Poland, 19Department Of Oncology, Poznań 
University Of Medical Sciences/Poland
Background: Central European countries are among those with 
the highest incidence rates of lung cancer and most of these can-
cers are smoking-related. The INSIGHT observational study aimed 
at assessing prevalence and treatment of patients with EGFR mu-
tations in clinical practice in Central Europe. Here we report on the 
overall findings of this study.
Methods: Patients with NSCLC and tested for EGFR mutations 
between 15 November 2011 and 31 March 2013 in 14 centers from 
6 Central European countries (Austria, Czech Republic, Hungary, 
Poland, Slovakia, Slovenia) were enrolled. EGFR mutations were 
determined by sequencing, PCR or other techniques.
Results: Here we report data on 1009 NSCLC patients who had 
been enrolled into the INSIGHT study. The patients had the fol-
lowing characteristics: median age 64 (range 29-93), 62% male, 
38% female, 99.9% Caucasians, ECOG performance status 0-1, 
2 and 3-4 in 79%, 17% and 4%; 19% never-smokers, 46% former 
smokers, 35% current smokers; 79% adenocarcinomas, 2% adenos-
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P2.11-020 SORAFENIB IN PATIENTS WITH RET FUSION-
POSITIVE NON-SMALL CELL LUNG CANCER
Atsushi Horiike1, Kengo Takeuchi2, Takeshi Uenami1, Yuko Ka-
wano1, Azusa Tanimoto1, Kyohei Kaburaki1, Hiroshi Kobayashi1, 
Hiroshi Gyotoku1, Hironari Nishizawa1, Yuichi Tambo1, Katsumi 
Nakatomi1, Noriko Yanagitani1, Fumiyoshi Ohyanagi1, Sachiko 
Hagiwara1, Noriko Motoi3, Yuichi Ishikawa3, Takeshi Horai1, Mako-
to Nishio1
1Department Of Thoracic Medical Oncology, Cancer Institute Hospital 
Of Japanese Foundation For Cancer Research/Japan, 2Pathology Project 
For Molecular Targets, Japanese Foundation For Cancer Research/Japan, 
3Division Of Pathology, The Cancer Institute, Japanese Foundation For 
Cancer Research/Japan
Background: RET fusions were recently identified in non-small cell 
lung cancer (NSCLC) and considered to be a druggable target of 
NSCLC. There are several small molecules which can potentially 
inhibit RET kinase activity. Among them, sorafenib, sunitinib and 
vandetanib are clinically available, and sorafenib is the most promi-
sing agent which showed potent anti-RET activity (the IC50 against 
RET is 0.0059-0.047 µM) in preclinical studies. However, it is difficult 
to evaluate the efficacy of this agent in RET-positive NSCLC in large 
clinical trials, because RET-positive NSCLC makes up only 1% to 2% 
of NSCLC cases. Therefore, we conducted a pilot study to evaluate 
the efficacy and feasibility of sorafenib treatment in a small number 
of patients with RET fusion-positive NSCLC.
Methods: Eligible patients had advanced or recurrent NSCLC, were 
more than 20 years old, had undergone treatment with one or more 
previous chemotherapy regimens, had an ECOG performance status 
(PS) 0–2, adequate organ function and provided informed consent. 
The RET fusion gene was confirmed by a split FISH assay. Patients 
received 400 mg of sorafenib orally twice daily. The treatment was 
continued until disease progression or unacceptable toxicity.
Results: From March 2012 to April 2013, three patients were en-
rolled. The first patient was a 62-year-old female who had stage IV 
NSCLC and had received three prior chemotherapy regimens (pe-
metrexed with cisplatin, docetaxel and erlotinib) and two courses of 
palliative radiation (thorax and whole brain) before being enrolled 
this study. The second patient was a 38-year-old male who had 
recurrence after thoracic surgery and had received two prior che-
motherapy regimens (pemetrexed with cisplatin and docetaxel) and 
whole brain radiation before enrolling this study. The third patient 
was a 75-year-old female who had recurrence after thoracic surgery 
and had received one prior chemotherapy regimen (Docetaxel). The 
pathological diagnoses were adenocarcinoma in two patients and 
NSCLC not otherwise specified in one patient. Their tumors did not 
demonstrate any EGFR mutations or ALK fusion. The RET partner 
genes were KIF5B in two patients and unknown in one patient. All 
three patients were treated with sorafenib at 400 mg orally twice 
daily. Unfortunately, there was no response. The best responses to 
sorafenib in the patients were PD, SD and SD. In the third patient, 
sorafenib treatment was continued for over seven weeks. The most 
common toxicities were hand-foot syndrome, hypertension and 
diarrhea. The third patient needed a dose reduction to 400 mg once 
daily due to grade 3 hand-foot syndrome.
Conclusion: Sorafenib seems to have some efficacy for the RET 
fusion-positive NSCLC, but no dramatic response was observed.
Keywords: RET, Sorafenib
Background: The INSIGHT observational study aimed at assessing 
the management of NSCLC patients with EGFR mutations in clini-
cal practice in 10 centres from 6 Central European countries. As 
part of this project, the treatment strategies used in these patients 
have been determined.
Methods: Between 15 November 2011 and 31 March 2013, EGFR 
mutations were determined by one of the established methods 
in 1009 patients with NSCLC. The systemic treatments of patients 
with EGFR mutation positive NSCLC were assessed.
Results: Comprehensive data on systemic treatment were availab-
le for 122 patients with EGFR mutation-positive tumors. Mutations 
were located in exon 19 (52.5%), exon 21 (38.5%), exon 20 (10.7%), 
and exon 18 (6.6%). In 8 patients, mutations were present in 2 or 
3 exons. Patients with mutation-positive tumors had the following 
characteristics: median age 66 (range 41-83) years; 58 (48%) ma-
les, 64 (52%) females; 51 (42%) never smokers, 51 (42%) former 
smokers, and 19 (16%) current smokers; performance status at 
diagnosis ECOG 0, 1, and equal or above 2 in 28 (23%), 60 (49%), 
20 (16.5%) of patients; in 14 (11.5%) patients PS was not recorded; 
adenocarcinomas 98 (80%), adenosquamous 6 (5%), squamous 7 
(6%), not otherwise specified 2 (2%) and 9 (7%) patients had other 
types of carcinoma. A total of 116 patients presented with stage 
IIIB or IV and received the following first-line therapy: gefitinib in 
66 (57%), erlotinib in 4 (3%), chemotherapy in 43 (37%), and che-
motherapy plus bevacizumab in 3 (3%) patients, respectively. In 22 
(19%) patients EGFR test results were obtained after initiation of 
first-line therapy and the majority of these patients (n=20) received 
chemotherapy as first-line therapy. For patients tested before the 
first-line treatment initiation, median time between the date of test 
result and initiation of first-line therapy was 16 days. Regardless 
of the lines of treatment, EGFR-directed tyrosine kinase inhibitors 
were administered to 90 out of 116 (78%) patients. No major dif-
ferences in treatment strategies between various countries were 
observed.
Conclusion: The INSIGHT observational study demonstrated that 
most patients with advanced EGFR mutation-positive NSCLC had 
been treated with EGFR-directed tyrosine kinase inhibitors either 
in the first- or second-line setting. This study was supported by 
Boehringer Ingelheim Regional Center Vienna.
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P2.11-022 PHASE IV, SINGLE-ARM STUDY OF FIRST-LINE 
GEFITINIB IN CAUCASIAN PATIENTS WITH EPIDERMAL 
GROWTH FACTOR RECEPTOR (EGFR) MUTATION-PO-
SITIVE, ADVANCED NON-SMALL-CELL LUNG CANCER 
(NSCLC): POST-HOC EXPLORATORY ANALYSES OF EGFR 
MUTATIONS IN PLASMA-DERIVED CFDNA SAMPLES
Jean-Yves Douillard1, Gyula Ostoros2, Manuel Cobo3, Tudor Ciulea-
nu4, Rose Mccormack5, Alan Webster6, Tsveta Milenkova7
1Medical Oncology, Ico R Gauducheau/France, 2Korányi National Insti-
tute Of TB And Pulmonology/Hungary, 3Medical Oncology, Hru Carlos 
Haya/Spain, 4Medical Oncology, Prof. Dr. Ion Chiricuta Institute Of 
Oncology/Romania, 5Personalised Healthcare, Astrazeneca/United 
Kingdom, 6Biometrics And Information Sciences, Astrazeneca/United 
Kingdom, 7Research & Development, Astrazeneca/United Kingdom
Background: Study NCT01203917 assessed the efficacy and sa-
fety/tolerability of the EGFRTKI gefitinib in Caucasians with EGFR 
mutation-positive NSCLC (previously reported). Here we report 
post-hoc EGFR mutation analyses of plasma-derived, circulating-
free DNA (cfDNA), including efficacy (objective response rate 
[ORR] and progression-free survival [PFS]) by mutation subtype 
(Exon 19 deletions; L858R point mutations).
Methods: Patients: Caucasians; ≥18 yrs; PS 0-2; histologically con-
firmed Stage IIIA/B/IV EGFR mutation-positive NSCLC eligible for 
first-line treatment. Treatment: 250mg gefitinib once-daily until 
disease progression. Primary endpoint: ORR (investigator assess-
ment); secondary endpoints: disease control rate, PFS, overall 
survival, and safety/tolerability (previously reported). Mandatory 
tumor and plasma samples were collected at baseline (all scree-
ned patients). Post-hoc exploratory analyses: correlation between 
clinical characteristics and baseline plasma cfDNA EGFR mutation 
status; concordance of plasma cfDNA mutation subtype determi-
nation (Exon 19 deletions; L858R) with tumor; gefitinib efficacy by 
plasma cfDNA mutation subtype (Exon 19 deletions; L858R).
Results: Of 1060 screened patients with NSCLC, 118 presented 
with activating, sensitizing EGFR mutations, 106 of whom were 
enrolled and treated with gefitinib (Full Analysis Set; 71% fema-
le; 97% adenocarcinoma; 64% never-smoker). Mutation rate for 
samples with known mutation status: 14% (118/859) in tumor, 10% 
(82/784) in plasma. Among 784 patients with baseline plasma sam-
ples of known mutation status, histology (adenocarcinoma vs non-
adenocarcinoma; odds ratio [OR] 5.54; p=0.0012), smoking status 
(never- vs ever-smoker; OR 4.39; p<0.0001), and gender (female vs 
male; OR 2.68; p=0.0004) independently predicted plasma cfDNA 
mutation status. Concordance in 652 matched tumor and plasma- 
Exon 19 deletions: 96% (confidence interval [CI]: 95-98); L858R: 
98% (CI: 96-99). Using tumor mutation status as reference, EGFR 
mutation test sensitivity in cfDNA (Exon 19 deletions) was 68% (CI: 
56-78), specificity was 100% (CI: 99-100); positive predictive value: 
100% (CI: 93-100); negative predictive value: 96% (CI: 94-98); re-
sults were similar for L858R, with numerically lower sensitivity (62%; 
CI 44-78%). ORR for patients with both EGFR mutation-positive 
tumor and plasma for Exon 19 deletions (n=45): 82% (CI: 69-91); 
L858R (n=20): 65% (CI: 41-85) (Table). Median PFS for patients with 
both EGFR mutation-positive tumor and plasma for Exon 19 deleti-
ons (25 events): 10.3 months (CI: 8.5-12.4); L858R (11 events): NC. 
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P2.11-021 INTERIM OUTCOME ANALYSIS OF PHASE II 
STUDY OF NEOADJUVANT BEVACIZUMAB PLUS PEME-
TREXED AND CARBOPLATIN IN UNRESECTABLE, LO-
CALLY ADVANCED LUNG ADENOCARCINOMA
Ning Li, Si-Yu Wang, Wei Ou, Liang Zhang, Song-Liang Zhang
Thoracic Surgery, Sun Yat-Sen University Cancer Center/China
Background: Locally advanced (III A-bulky N2, III B) lung cancer 
is often treated with chemotherapy with or without radiotherapy. 
The VEGF inhibitor bevacizumab has demonstrated clinical activity 
in advanced lung adenocarcinoma. To explore the role of bevaci-
zumab in the neoadjuvant setting, we performed the phase II trial 
to assess the safety and efficacy of neoadjuvant bevacizumab plus 
pemetrexed and carboplatin followed by surgery in conventionally 
unresectable, locally advanced (III A-bulky N2, III B) lung adenocar-
cinoma. Here we report interim outcomes.
Methods: The single-center, single-arm, phase II study investiga-
tes neoadjuvant bevacizumab (7.5mg/kg) plus pemetrexed (500 
mg/m2) and carboplatin (AUC=5) followed by surgery for patients 
with unresectable, locally advanced (III A-bulky N2, III B) lung ade-
nocarcinoma. Four cycles of neoadjuvant therapy were planned 
and neoadjuvant therapy was administered on day 1 of every 21-
day cycle. Patients’ resectability was assessed by a medical team 
(including thoracic surgeons, medical oncologists, and radiolo-
gists) and surgery was scheduled 3-4 weeks after last neoadjuvant 
therapy. Primary and secondary endpoints were resectability rate 
and perioperative complications.
Results: 20 patients were enrolled. All patients received bevaci-
zumab plus pemetrexed and carboplatin. Neoadjuvant-related 
toxicities included: epistaxis (5%), fatigue (30%), infusion reaction 
(5%), nausea (5%), diarrhea (10%), insomnia (5%), headache (5%); 
neutropenia (25%), anemia (10%), thrombocytopenia (5%). Grade 3 
or above toxicities included fatigue (10%); neutropenia (5%), throm-
bocytopenia (5%). Complete response was observed in 1 patient, 
partial response in 8, stable disease in 10, and progressive disease 
in 1. After neoadjuvant therapy, 14 (70%) patients underwent sur-
gery. Median time between last neoadjuvant therapy and surgery 
was 25 days (22-28). R0 resection was achieved in 10 patients. 
No patient died in the perioperative phase. Postoperative com-
plications were manageable and included pneumonia (1 patient), 
atelectasis (1), subcutaneous emphysema (2), arrhythmia (1). No 
perioperative hemorrhage events, thromboembolic events and 
wound-healing problems were observed.
Conclusion: The treatment modality of neoadjuvant bevacizumab 
plus pemetrexed and carboplatin followed by surgery appears to 
be safe and feasible in patients with unresectable, locally advan-
ced (III A-bulky N2, III B) lung adenocarcinoma. Clinical trial infor-
mation: NCT01588704.
Keywords: non-small cell lung cancer, Neoadjuvant therapy
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P2.11-023 BE-POSITIVE: GEFITINIB IN FIRST-LINE TREAT-
MENT OF ADVANCED NON-SMALL CELL LUNG CANCER 
(NSCLC) PATIENTS HARBORING ACTIVATING EPIDER-
MAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS. 
A COMBINED RETROSPECTIVE AND PROSPECTIVE 
ANALYSIS FROM ITALIAN PATIENTS.
Silvia Novello1, Follador Alessandro2, Alessandro Morabito3, Mat-
teo Giaj Levra1, Jessica Menis2, Emilio Bria4, Olga Martelli5, Dome-
nico Galetta6, Gianluca Spitaleri7, Orazio Caffo8, Marcello Tiseo9, 
Fabiana Cecere10, Erika Rijavec11, Nicoletta Zilembo12, Giuseppe 
Banna13, Antonio Rossi14
1Department Of Oncology, University Of Turin/Italy, 2Dipartimento Di 
Oncologia. Azienda Ospedaliero - Universitaria S. M. Misericordia Udi-
ne/Italy, 3Medical Oncology, Istituto Tumori Di Napoli/Italy, 4Medical 
Oncology, Az. Osp. Univ. Integr. (A.O.U.I.), University Of Verona/Italy, 
5Medical Oncology, Azienda Ospedaliera San Giovanni Addolorata/Ita-
ly, 6Medical Oncology, National Cancer Research Centre “Giovanni Paolo 
Ii“/Italy, 7Istituto Europeo Di Oncologia/Italy, 8Santa Chiara Hospital/
Italy, 9Medical Oncology Unit, University Hospital Of Parma/Italy, 10Me-
dical Oncology Unit, Aou Careggi/Italy, 11Lung Cancer Unit, IRCCS Aou 
San Martino - Ist Istituto Nazionale Per La Ricerca Sul Cancro/Italy, 
12Medical Oncology, IRCCS Istituto Nazionale Dei Tumori/Italy, 13Divi-
sion Of Medical Oncology, A.O. Cannizzaro Hospital/Italy, 14Division Of 
Medical Oncology, S.G. Moscati Hospital/Italy
Background: Advanced NSCLC patients have an extremely poor 
prognosis with a 5-year survival rate of less than 5%. In 2009, the 
European Medicines Agency approved gefitinib, a reversible EGFR 
tyrosine kinase inhibitor, at the dose of 250 mg daily for the treat-
ment of adult patients with locally advanced or metastatic NSCLC 
with EGFR activating mutations. As the first-line EGFR mutation 
positive data at that time were mainly in Asian populations a pros-
Table 
ORR with gefitinib: baseline tumor vs plasma samples
Tumor Plasma
N Responders ORR, %
95% 
CI N Responders
ORR, 
%
95% 
CI
All mutations 106 74 70 61-78 65 50 77 65-86
Exon 19 deleti-
ons
69 50 73 61-82 45 37 82 69-91
L858R point mu-
tations
33 21 64 47-78 20 13 65 41-85
Median PFS with gefitinib for baseline tumor vs plasma samples
Tumor (FAS, N=106) Plasma (N=65)
Events, 
N PFS, months 95% CI
Events, 
N PFS, months 95% CI
All mutations 61 9.7 8.5-11.0 36 10.2 8.5-12.5
Exon 19 deleti-
ons
41 9.6 8.0-11.0 25 10.3 8.5-12.4
L858R point mu-
tations
19 NC NC 11 NC NC
 
NC, not calculated
Conclusion: EGFR mutation status assessment of common muta-
tions from plasma-derived cfDNA can be considered when tumor 
tissue is unavailable. In this context, cfDNA might be used to 
guide treatment decisions with EGFRTKI therapy, as patients with 
mutation-positive cfDNA, regardless of mutation subtype, appear 
to have similar ORR to tumor mutation-positive patients.
Keyword: EGFR mutation; gefitinib; NSCLC; Caucasian; circula-
ting-free DNA
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P2.11-024 EFFICACY ANALYSIS FOR MOLECULAR SUB-
GROUPS IN MARQUEE: A RANDOMIZED, DOUBLE-
BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF 
TIVANTINIB (ARQ 197) PLUS ERLOTINIB VERSUS PLACE-
BO PLUS ERLOTINIB IN PREVIOUSLY TREATED PATIENTS 
WITH LOCALLY ADVANCED OR METASTATIC, NON-
SQUAMOUS, NON- SMALL CELL LUNG CANCER (NSCLC)
Silvia Novello1, Giorgio Scagliotti1, Rodryg Ramlau2, Adolfo Fa-
varetto3, Fabrice Barlesi4, Wallace Akerley5, Joachim Von Pawel6, 
Sergey Orlov7, David R. Spigel8, Armando Santoro9, Frances She-
pherd10, Vera Hirsh11, Lecia V. Sequist12, Dale Shuster13, Hamim Za-
hir13, Qiang Wang13, Brian Schwartz14, Reinhard Von Roemeling13, 
Allan B. Sandler15
1Department Of Oncology, University Of Turin/Italy, 2Department 
Of Oncology, Poznań University Of Medical Sciences/Poland, 3Second 
Medical Oncology, Istituto Oncologico Veneto/Italy, 4Aix Marseille 
University – Assistance Publique Hôpitaux De Marseille/France, 5The 
University Of Utah School Of Medicine, Huntsman Cancer Institute/
United States Of America, 6Asklepios-fachkliniken München-gauting/
Germany, 7St. Petersburg State Medical University Named After Acad. 
I.p. Pavlov Roszdrava/Russian Federation, 8Tennessee Oncology, Sarah 
Cannon Research Institute/United States Of America, 9Medical Onco-
logy Department, Istituto Clinico Humanitas/Italy, 10Department Of 
Medical Oncology, Princess Margaret Cancer Centre, University Health 
Network, University Of Toronto/Canada, 11McGill University Health 
Center/Canada, 12Cancer Center, Massachusetts General Hospital/Uni-
ted States Of America, 13Daiichi Sankyo, Inc./United States Of America, 
14Arqule, Inc./United States Of America, 15Oregon Health & Science 
University/United States Of America
Background: MARQUEE, a Phase 3 study which investigated the 
role of tivantinib, a c-MET inhibitor, in previously treated non-
squamous NSCLC, collected EGFR and KRAS genotype on >90% 
of randomized patients, and MET expression was determined 
for 42%. In the ITT population, addition of tivantinib to erlotinib 
significantly improved PFS and ORR but did not show benefit in 
OS. Additional efficacy analyses in the pre-defined molecular sub-
groups are presented.
Methods: Patients with locally advanced or metastatic non-
squamous, EGFR inhibitor naive NSCLC previously treated with 1 
or 2 lines of systemic therapy, including a platinum-doublet, were 
stratified by number of prior therapies, sex, smoking history, and 
EGFR and KRAS mutation status, then randomized to oral tivanti-
nib (360 mg twice daily) + erlotinib (150 mg once daily) or placebo 
+ erlotinib until disease progression. Primary endpoint was OS 
with one interim analysis for futility/superiority. MET was assessed 
centrally by IHC using CONFIRM (SP44) antibody. Based upon a 
stability study, tumor tissue must have been sectioned within 90 
days prior to MET immunostaining to be considered reliable. MET 
High was pre-specified as ≥50% of tumor cells staining with 2+ or 
3+ intensity.
Results: From 1/2011 to 7/2012, 1048 patients were randomized to 
tivantinib + erlotinib (TE, n=526) or placebo + erlotinib (PE, n=522). 
Baseline characteristics were median age = 62 years (range, 24-89), 
prior therapies = 1 (66%) or 2 (34%), ECOG performance status = 0 
(32%) or 1 (68%), EGFR mutant (10.4%), and KRAS mutant (27.1%). In 
9/2012, the data monitoring committee recommended trial discon-
tinuation because the pre-planned interim analysis of OS crossed 
the futility boundary. At the 12/2012 data cutoff, median OS was 
8.5 months and 7.8 months for TE and PE, respectively (hazard 
pective phase IV, open-label, single-arm study of first-line gefitinib 
in Caucasian patients was presented: this trial confirmed the activi-
ty and efficacy of gefitinib in 106 Caucasian patients (Douillard EM-
CTO 2013). In the same way, we initially collected retrospectively, 
continuing then prospectively, the data of NSCLC EGFR-mutation 
positive Italian patients treated with first-line gefitinib, with the aim 
to evaluate the therapeutic outcomes and the approaches beyond 
progression in a “real life population”.
Methods: We collected data of patients who started gefitinib from 
June 2009 until May 2013. Primary endpoint was the evaluation of 
first line outcomes, in terms of: objective response rate (ORR), du-
ration of treatment, progression-free survival (PFS), overall survival 
(OS) and safety. Secondary endpoint is the evaluation of the outco-
mes beyond progression to gefitinib. Here we report the results of 
first-line gefitinib of a large number of Caucasian patients.
Results: Data of 203 patients from 23 Italian Institutions were 
collected. The main patients characteristics were: median age 67 
(range: 33-87), male/female 76/127, ECOG performance status (PS) 
0/1/2/3/4 in 89/92/18/2/2 patients, 90.6% adenocarcinoma (in our 
study the percentage of carcinoma non otherwise specified was 
1.5%), never/former/current smoker in 129/64/10, del19/L858R/un-
common in 128/57/18. In one case a T790M mutation ex novo was 
found in association with the deletion of the exon 19 (not all the 
patients were tested for this mutation at baseline). A median time 
for obtaining the EGFR test result was 8-15 days (more than 30% 
of the patients got the results in less than one week). Patients eva-
luable at the time of data lock were 168, of these 3 (1.8%) patients 
achieved a complete response, 72 (42.9%) a partial response for an 
ORR of 44.7%, 54 (32.1%) patients were stable. Median treatment 
with gefitinib was 38 weeks. Main toxicities were: grade 3-4 skin 
rash and diarrhea in 1.8% and 4.2%, respectively. Treatment was 
definitely stopped due toxicity in 4.2% of patients. After progres-
sion in 5 cases a re-biopsy was performed and 94 (56%) received a 
second-line treatment.
Conclusion: BE-Positive is the first study reporting results of first-
line gefitinib in a large "real life population“ of Caucasian patients. 
Data were firstly collected in a retrospective fashion, than in a pro-
spective way. This study shows that Caucasian patients reported 
lower ORR when indirectly compared to Asian counterparts, but 
this is probably due to the partial analysis of the patients, exclu-
ding at this time those who are still on treatment. However, the 
tolerability profile was excellent and the median time of treatment 
is quite overlapping to literature data. The outcomes of PFS, OS 
and treatment beyond gefitinib progression will be reported when 
mature.
Keywords: EGFR mutation, gefitinib, caucasian patients, non-small 
cell lung cancer
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never-smokers (61%), RPA class II (87%), and neurologically asym-
ptomatic (82%). Patients had a median of 4 BM (range 1-30) with a 
median largest diameter of 10mm. In the erlotinib group, erlotinib 
was given as monotherapy in 91% and combined with chemothera-
py in 9% of patients. 38% of these patients (n=24) eventually recei-
ved WBRT or PBI a median of 17 mos after diagnosis of BM (range 
5-40 mos). Median OS for the whole cohort was 29 mos with a 
2-yr OS of 59%. There was no significant difference in OS between 
the WBRT (median 35 mos) and erlotinib (median 26 mos) groups 
(p=0.59 by Cox model) though patients treated with PBI had a 
longer OS (median 64 mos). On univariate analysis, KPS (p<.001), 
RPA class (p<.001) and PBI (vs. erlotinib, p=.005) were significant, 
with only RPA class (p=.007) and KPS (p<.001) remaining significant 
on multivariate analysis. Median time to intracranial progression 
(ICP) was 17 months for the entire cohort. There was a longer time 
to ICP in patients who received WBRT (median 24 mos) vs. erlotinib 
upfront (median 16 mos, p<.05), though this effect was no longer 
significant on multivariate analysis. Patients in the erlotinib or PBI 
group were more likely to fail intra-cranially as a component of first 
failure (58% and 71%, respectively), while upfront WBRT patients 
were more likely to fail extracranially first (76%).
Conclusion: The survival of EGFR-TKI naïve patients with EGFR-
mutated NSCLC with BM is notably long, whether they receive 
upfront erlotinib or brain RT. We observed longer intracranial con-
trol with WBRT, but this effect is potentially due to other confoun-
ding variables. Though retrospective, this analysis suggests that 
deferring brain RT in favor of EGFR-TKI is a reasonable strategy for 
patients with EGFR-mutated NSCLC with BM.
Keywords: EGFR, erlotinib, whole brain radiotherapy, brain meta-
stasis
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P2.11-026 RET FUSION-POSITIVE ADVANCED LUNG 
CANCERS: RESPONSE TO FIRST-LINE CHEMOTHERAPY 
AND SURVIVAL IN COMPARISON TO ROS1 AND ALK 
FUSION-POSITIVE AND EGFR- AND KRAS-MUTANT 
LUNG CANCERS
Alexander Drilon1, Lu Wang2, Philippe Joubert2, Alexandra Sny-
der1, Eun Jung Cho1, Gregory Riely1, Mark Kris1, Marc Ladanyi2, 
Naiyer Rizvi1
1Department Of Medicine, Memorial Sloan-Kettering Cancer Center/
United States Of America, 2Department Of Pathology, Memorial Sloan 
Kettering Cancer Institute/United States Of America
Background: RET fusions are novel targetable drivers in non-small 
cell lung cancers. While the clinicopathologic profile of patients 
with RET fusion-positive tumors has been described in early-stage 
disease, little is known regarding clinical behavior in advanced 
unresectable disease.
Methods: Patients with advanced unresectable (stage IIIB/IV) pan-
negative lung adenocarcinomas (absence of mutations in EGFR, 
KRAS, NRAS, BRAF, MAP2K1, ERBB2, PIK3CA, and AKT, and fusi-
ons of ALK or ROS1) were screened for RET fusions via dual-probe 
break apart FISH testing. Upstream partners were identified via 
RT-PCR and next-generation sequencing whenever possible. A 
retrospective review of patient records was conducted to deter-
mine response to systemic therapy and overall survival (OS). OS 
was calculated from diagnosis of metastatic disease and compared 
ratio [HR] = 0.98; 95% CI, 0.84-1.15; p = 0.81). Median PFS was 3.6 
months and 1.9 months, respectively (HR = 0.74; 95% CI, 0.62-
0.89; p < 0.0001). Overall response rate (ORR) improved to 10.3% 
for TE compared with 6.5% for PE (p < 0.05). MET expression was 
obtained for 445 patients. In the pre-specified, MET High sub-
group (n = 211), median OS improved to 9.3 months for TE vs 5.9 
months for PE (HR = 0.70; 95% CI, 0.49-1.01; p = 0.03). In the MET 
Low subgroup (n = 234), median OS was 8.5 months for TE and 
7.7 months for PE (HR=.90, 95% CI, 0.64-1.26, p=.53). OS did not 
differ between treatments in KRAS wildtype (n=702), KRAS mutant 
(n=284), and EGFR wildtype (n=937) subgroups; OS was immature 
for the EGFR mutant (n=109) subgroup at the cut-off time. Consis-
tent with ITT, PFS was increased with TE vs PE across all molecular 
subgroups. Common adverse events (TE vs PE, respectively) inclu-
ded rash (33.1% vs 37.3%), diarrhea (34.6% vs 41.0%), and asthenia/
fatigue (43.5% vs 38.1%), which occurred at similar rates between 
treatments; neutropenia (Grade 3/4: 10.0% vs 1.0%) was more com-
mon with TE.
Conclusion: Tivantinib significantly improved PFS and OS in the 
prospectively defined MET High subgroup. Further investigation 
of tivantinib in MET High selected, non-squamous NSCLC is war-
ranted.
Keywords: tivantinib, erlotinib
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P2.11-025 ERLOTINIB VERSUS RADIATION THERAPY 
FOR BRAIN METASTASES IN PATIENTS WITH EGFR-MU-
TANT LUNG ADENOCARCINOMA
Naamit K. Gerber1, Yoshiya Yamada1, Weiji Shi2, Zhigang Zhang2, 
Gregory Riely3, Kathryn Beal1, Helena A. Yu3, Timothy A. Chan1, 
Andreas Rimner1, Abraham J. Wu1
1Radiation Oncology, Memorial Sloan-Kettering Cancer Center/United 
States Of America, 2Biostatistics, Memorial Sloan-Kettering Cancer 
Center/United States Of America, 3Medical Oncology, Memorial Sloan-
Kettering Cancer Center/United States Of America
Background: Radiation therapy (RT) is a principal modality in the 
treatment of patients with brain metastases (BM). However, given 
the activity of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in the 
central nervous system, it is uncertain whether upfront brain RT is 
necessary for EGFR mutated lung adenocarcinoma patients with 
BM treated with EGFR-TKIs.
Methods: We identified all patients treated from 2006-2012 with 
EGFR-mutated NSCLC with BM at our institution. We evaluated the 
clinical outcomes of these patients who developed brain metas-
tases and received EGFR-TKI and/or CNS radiotherapy. Endpoints 
included intracranial progression (ICP), extracranial progression 
(ECP) and overall survival (OS). All endpoints were measured from 
development of BM.
Results: 222 patients were identified. Patients were excluded if 
they were on an EGFR-TKI prior to the development of BM (n=57), 
if they possessed a de novo EGFR-TKI resistance mutation (n=6), 
or if there was incomplete data (n=48). Of the remaining 111 pati-
ents, 64 were treated initially with erlotinib, 32 with whole brain RT 
(WBRT), and 15 with partial brain radiation (PBI). Median follow-up 
was 20 months (mos). Median age was 61 years (range 26-89). Pati-
ents were predominantly female (68%), stage IV at diagnosis (92%), 
S903Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Japan, 3Iizuka Hospital/Japan, 4Nho Fukuoka-Higashi Medical Center/
Japan, 5Miyazaki Prefectural Miyazaki Hospital/Japan, 6Nho Kumamoto 
Medical Center/Japan, 7Kitakyushu Municipal Medical Center/Japan, 
8Saiseikai Fukuoka General Hospital/Japan, 9Nho Omuta Hospital/
Japan, 10Koga Hospital 21/Japan, 11Department Of Pathology, National 
Kyushu Cancer Center/Japan, 12Department Of Pathology, Fukuoka Uni-
versity/Japan, 13Kyushu University Hospital/Japan, 14Clinical Research 
Institute, National Kyushu Cancer Center/Japan, 15Logik/Japan
Background: The epidermal growth factor receptor tyrosine kina-
se inhibitors (EGFR-TKIs) such as gefitinib and erlotinib, are used to 
treat non-small cell lung cancer with EGFR sensitive mutations. The 
response rates to EGFR-TKI for mainly adenocarcinoma patients 
with EGFR mutations are very high, ranging from 62-85%, with a 
median progression-free survival (PFS) of 8.0-13.1 months and a 
median overall survival of 21.6-35.5 months. EGFR mutations can 
also be detected in a few non-adenocarcinoma tumors, however, 
the response of such cases to EGFR-TKIs is controversial. This 
study assessed the effectiveness of EGFR-TKIs in non-adenocar-
cinoma non-small cell lung cancer (non-adeno NSCLC) with EGFR 
mutations.
Methods: Nine institutions of the Lung Oncology Group in Ky-
ushu (LOGIK) joined in this study. The primary endpoint was the 
response rate (RR), and the secondary endpoints were the disease 
control rate (DCR), overall survival, duration of disease control and 
the incidence of adverse events. A total of 43 cases of non-adeno 
NSCLC who were treated with EGFR-TKIs were retrospectively 
enrolled in this study.
Results: This study included 28 males and 15 females, and 18 of 
the 43 were never smokers. The ages of the patients ranged from 
42 to 83 years, with a mean of 67 years. The pathological types 
were squamous cell carcinomas in 26 patients, adenosquamous 
cell carcinomas in six, large cell carcinomas in six, and others in five 
patients. Of these 43 cases, 18 with EGFR mutations were included 
in the analysis. The incidence of EGFR mutations was significantly 
higher in females than in males (80.0% vs. 21.4%, p<0.01), and 
in never smokers than in smokers (72.2% vs. 20.0%, p<0.01). The 
EGFR-TKIs administered were gefitinib in 27 patients and erlotinib 
in 16. In the patients with EGFR mutations, the RR and DCR were 
83.8% and 93.8%, which were significantly superior to the rates 
in patients without EGFR mutations, which were 4.1% and 20.1%, 
respectively (p<0.01).
Conclusion: Even in patients with non-adeno NSCLC, the mutation 
of EGFR gene was a predictive factor for the response to EGFR-TKI 
treatment. In this meeting, we will show a detailed report based on 
the pathological analysis performed by the pathological commit-
tee of the LOGIK.
Keywords: EGFR, EGFR-TKI, non-adenocarcinoma, non-small cell 
lung cancer
to patients with ALK and ROS1 fusion-positive, and EGFR- and 
KRAS-mutant lung cancers. Survival curves were estimated using 
the Kaplan-Meier method. Differences in survival between groups 
were assessed by the log-rank test.
Results: A RET fusion was found in 16% (n=12/76, 95%CI 8%-
24%) of pan-negative tumors and 19% (n=10/48, 95%CI 10%-33%) 
of pan-negative tumors from never-smokers. Patients with RET 
fusion-positive tumors were predominantly never-smokers (83%, 
n=10/12, 2 patients with 7 and 10 pack-year histories, respectively) 
with advanced-stage disease at diagnosis (92%, n=11/12 stage IIIB/
IV). Fusion partners were identified in 6 patients (4 KIF5B-RET, 1 
TRIM33-RET, 1 NCOA4-RET). Eight patients (67%) received first-line 
platinum-based therapy, 6 of whom (50%) received maintenance 
pemetrexed and/or bevacizumab. Partial responses (PRs) were 
seen in 3 patients (38%) and stable disease (SD) in 5 patients (62%). 
1-year OS on chemotherapy and median progression-free survival 
were 47% and 7.3 months, respectively. 1-year and 2-year OS for 
patients whose tumors harbored RET, ROS1, or ALK fusions, or 
EGFR or KRAS mutations is summarized below (Table). OS was not 
significantly different between RET, ROS1, ALK, or EGFR cohorts 
when RET was compared to each of the latter three cohorts sepa-
rately. The presence of a RET fusion was associated with improved 
OS compared to the presence of a KRAS mutation (HR 0.39, 95%CI 
0.21-0.74, p=0.004). Of the 11 patients with RET fusion-positive 
lung cancers, 4 patients (36%) were treated with cabozantinib on a 
phase 2 protocol (NCT01639508) with disease shrinkage of -66%, 
-32%, -23%, and -19% via RECIST v1.1.  
Driver Detected OS 1-year [95%CI] OS 2-year [95%CI] 
RET (n=12) 100% 71% [25%-92%] 
ROS1 (n=9) 88% [39%-99%] 88% [39%-99%] 
ALK (n=44) 91% [77%-97%] 73% [55%-85%] 
EGFR (n=102) 85% [76%-91%] 58% [47%-67%] 
KRAS (n=117) 60% [50%-66%] 26% [18%-35%] 
Conclusion: Response to platinum-based first-line therapy in pa-
tients with RET fusion-positive tumors is comparable to historical 
controls. Survival in patients with RET fusion-positive disease is 
comparable to patients with EGFR mutations and other recurrent 
gene fusions (ROS1 and ALK) and improved compared to patients 
with KRAS mutations. Cabozantinib is worthy of further study in 
RET fusion-positive lung cancers.
Keywords: RET, fusion, chemotherapy, survival
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P2.11-027 THE RESPONSE OF NON-ADENOCARCINO-
MA NON-SMALL-CELL LUNG CANCER PATIENTS WITH 
EGFR MUTATIONS TO EGFR-TKI: A RETROSPECTIVE 
MULTICENTER STUDY (LOGIK 1104)
Kenji Sugio1, Taro Ohba2, Noriyuki Ebi3, Noriaki Nakagaki4, Dai-
suke Himeji5, Kosuke Kashiwabara6, Koji Inoue7, Hiroshi Wataya8, 
Masayuki Kawasaki9, Yukihiro Misumi10, Kenichi Taguchi11, Kazu-
ki Nabeshima12, Junji Kishimoto13, Yukito Ichinose14, Logik: Lung 
Oncology Group In Kyushu15
1Department Of Thoracic And Breast Surgery, Oita University/Japan, 
2Department Of Thoracic Oncology, National Kyushu Cancer Center/
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P2.11-029 EGFR-MUTATIONS AND RESULTING TREAT-
MENT IN A NSCLC POPULATION-BASED COHORT IN 
CENTRAL SWEDEN
Martin Sandelin1, Anders Berglund2, Magnus Sundström3, Christer 
Janson1, Johan Botling3
1Dept Of Respiratory Medicine, Uppsala University Hospital/Sweden, 
2RCC, Uppsala/Sweden, 3Department Of Immunology, Genetics And 
Pathology, Uppsala University/Sweden
Background: Since the IPASS-study was published in 2009, EGFR-
TKI has been the recommended first line treatment for EGFR-muta-
tion positive (EGFR-m+) non-small cell lung cancer (NSCLC) patients. 
In Sweden, the indication for EGFR-mutation testing of NSCLC, 
based on national and regional consensus guidelines, has gradually 
shifted from clinical characteristics (age, sex and smoking status) to 
histological subtypes (non-squamous cell lung cancer). The aim of 
this study was to characterise the EGFR-mutation spectrum in a re-
presentative Swedish NSCLC cohort in relation to patient demogra-
phics, histology, prognosis and sample quality parameters. We also 
wanted to assess the adherence to guidelines regarding molecular 
testing and treatment recommendations.
Methods: NSCLC patients tested for EGFR mutations 2010-2012 
(n=669) were identified in records at the molecular pathology unit 
in Uppsala that serves five regional hospitals in central Sweden. 
Histopathology and molecular reports were reviewed, and age, sex, 
stage, smoking, performance status and overall survival data were 
retrieved from regional and national lung cancer registries. For the 
EGFR-mutated sub-group a medical chart follow-up was performed 
to evaluate TKI-treatment and chemotherapy response. In addition, 
for estimation of potential clinical selection bias and true molecular 
testing coverage, we compared the study cohort, referred for EGFR-
analysis, to the entire source NSCLC population (n=2527) in the five 
covered counties.
Results: The EGFR-tested cohort consisted of 83% adenocarcino-
mas (AdC), 5% squamous cell carcinomas (SqCC), 11% large cell 
carcinomas not otherwise specified (LC) and 1% where histology was 
not reported. The EGFR mutation frequency was 10% (n=66), with 
an expected frequency distribution within exons 18-21. Mutations 
were enriched in women, never smokers and AdC. The analysed 
tissue was collected using bronchoscopic px (29%), core needle 
biopsy (46%), cytology (1%), and surgical specimens (22%), with 
mean tumor cell fraction of 30% (range 5–85%). With regard to the 
subgroup in focus for TKI-treatment, i.e. patients in stage IIIb/IV with 
non-squamous histology, 36% were referred for EGFR-testing, with 
an increasing trend between 2010 and 2012 (27.9–40.1%). Of the pa-
tients with EGFR-m+ and advanced disease 38% received EGFR-TKI 
in first line, 46% in later lines and 16% had not received EGFR-TKI at 
time of follow up. There was a trend for worse overall survival in the 
subgroup not receiving TKI-treatment, however this difference did 
not reach statistical significance.
Conclusion: The results regarding the EGFR mutation frequency 
and patient demographics is similar to previously published data on 
western populations. Surprisingly, despite guidelines regarding mo-
lecular testing, the majority of patients in advanced stage with non-
squamous histology were not referred for EGFR-analysis and only 
a minority of the EGFR-m+ patients received TKI-treatment in first 
line. Our results highlight the need for follow-up of treatment and 
diagnostic algorithms in population-based real life patient cohorts 
combining quality registries, pathology review and clinical records.
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P2.11-028 ERLOTINIB SALVAGE THERAPY IN PULMONA-
RY ADENOCARCINOMA PATIENTS WHO HAD DISEASE 
PROGRESSED AFTER PREVIOUS EGFR-TKI TREATMENT 
AND PLATINUM-BASED CHEMOTHERAPIES
Wen-Shuo Wu1, Chun-Ming Tsai2, Yu-Chin Lee1, Reury-Perng 
Perng1, Jacqueline Whang-Peng3, Yuh-Min Chen2
1Department Of Chest Medicine, Taipei Veteran General Hospital/Tai-
wan, 2Division Of Thoracic Oncology, Department Of Chest Medicine, 
Taipei Veterans General Hospital/Taiwan, 3Taipei Medical University/
Taiwan
Background: Erlotinib is an EGFR tyrosine kinase inhibitor with 
promising efficacy in treating lung adenocarcinoma. However, 
after the failure of two lines of EGFR-TKI and chemotherapy, the 
remaining treatment choices are few. The purpose of this study is 
to demonstrate the efficacy of erlotinib as ≥ third-line treatment in 
this kind of patients.
Methods: We retrospectively reviewed the chart records of our 
stage IV pulmonary adenocarcinoma patients who were diagnosed 
and treated in our hospital between July 2004 and June 2013. 
Clinical data, type of response to the treatment, time to disease 
progression, the duration between starting erlotinib treatment and 
end of first line EGFR-TKI treatment, and overall survival time were 
collected.
Results: Seventy-four patients were enrolled and they all had been 
treated with EGFR-TKI, either as a first-line therapy or following 
platinum-based chemotherapy. Thirty-nine patients had response 
to initial EGFR-TKI treatment and thirty-five of them did not. The 
median progression free survival (PFS) of front-line EGFR-TKI is 8.2 
months. All received erlotinib as salvage treatment after they had 
disease progressed to both chemotherapy and front-line EGFR-
TKI. The median PFS of erlotnib as salvage treatment for patients 
with and without response to front-line EGFR-TKI are 5.1 months 
and 4.9 months (p=0.768), respectively. Detailed data of subgroup 
analysis regarding EGFR mutation status and clinical characteristics 
will be presented in the meeting.
Conclusion: In pulmonary adenocarcinoma patients who were 
heavily treated, erlotinib is still a choice whether or not the patient 
was responsive to previous EGFR-TKI.
Keywords: erlotinib, EGFR-TKI, Adenocarcinoma, pulmonary
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P2.11-031 RADIOFREQUENCY ABLATION OF LIVER 
METASTASES MAY PROLONG THE SURVIVAL OF PUL-
MONARY ADENOCARCINOMA PATIENTS WITH LIVER 
METASTASIS
Shih-En Tseng1, Yi-You Chiou2, Yu-Chin Lee3, Reury-Perng Perng4, 
Yuh-Min Chen5
1Internal Medicine, Zhongxing Branch, Taipei City Hospital/Taiwan, 
2Radiology, Taipei Veterans General Hospital/Taiwan, 3Department Of 
Chest Medicine, Taipei Veterans General Hospital/Taiwan, 4Department 
Of Chest Medicine, Taipei Veteran General Hospital/Taiwan, 5Division 
Of Thoracic Oncology, Department Of Chest Medicine, Taipei Veterans 
General Hospital/Taiwan
Background: In patients with non-small cell lung cancer (NSCLC), 
the development of liver metastasis (LM) is a poor prognostic 
factor that compromises survival time. Whether combine systemic 
treatment with local treatment for liver metastases has benefit for 
NSCLC patients with LM is unknown. How to select a suitable pati-
ent for receiving local treatment is also unclear.
Methods: We retrospectively reviewed 713 pulmonary adenocar-
cinoma patients and 85 patients that developed LM at any time 
point in the course of the disease were identified for analysis. We 
use radiofrequency ablation (RFA) for local treatment of liver me-
tastases. The indication of RFA were liver metastases number less 
than three with maximal size less than 5cm. RFA was performed 
with real-time ultrasonography guidance. Dynamic computed 
tomography (CT) scan was done 1 month after RFA for evaluating 
local therapeutic efficacy. An SPSS version 19 statistical software 
package (SPSS INC, Chicago, IL, USA) was used for data analysis.
Results: The independent prognostic factors after LM were Perfor-
mance status, epidermal growth factor receptor (EGFR) mutation 
and LM numbers. There were 47 patients (54.7%) have LM nodules 
number less than three. The median overall survival (OS) in pati-
ents with LM nodules number less than three was 7.9 months com-
paring with 2.9 months in patients with nodules number over three 
( P < 0.001). The independent prognostic factors for LM nodules 
number less than three patients were performance status and pre-
sence of brain metastasis. There were total six patients received 
RFA. Patients who received RFA treatment had better median OS 
after LM than those not ( 19.1 v.s 6.0 months, P = 0.04)
Conclusion: We recommend patients with better performance 
status (ECOG <2) without brain metastasis can consider RFA for 
liver metastases.
Keywords: Pulmonary adenocarcinoma, liver metastasis, radiofre-
quency ablataion
Keywords: advanced stage, molecular pathology, EGFR, NSCLC
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P2.11-030 IS THERE ANY PREDICTOR FOR CLINICAL 
OUTCOME IN EGFR MUTANT 
NSCLC PATIENTS TREATED WITH EGFR TKIS ?
Ji Yun Lee, Sung Hee Lim, Moonjin Kim, Sungmin Kim, Hyunae 
Jung, Won Jin Chang, Moon Ki Choi, Jung Yong Hong, Su Jin Lee, 
Jong-Mu Sun, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Division Of Hematology-Oncology, Department Of Medicine, Samsung 
Medical Center/Korea
Background: Tyrosine kinase inhibitors (TKI) of the epidermal 
growth factor receptor (EGFR) have demonstrated dramatic res-
ponse rate and prolonged progression-free survival (PFS) in ad-
vanced non-small cell lung cancer (NSCLC) patients with activating 
EGFR mutation. However, PFS and overall survival (OS) among 
those patients who were treated with EGFR TKIs are variable. In 
this study, we evaluated predictors of clinical outcome in EGFR 
mutant NSCLC patients treated with EGFR TKIs.
Methods: From January 2008 to December 2010, a total of 148 
patients who had metastatic or recurrent NSCLC with activating 
EGFR mutation treated with either erlotinib or gefitinib as a first-
line (n=10) and a second-line or more treatment (n=138) were re-
trospectively reviewed. The first analysis with a total 148 patients 
and subgroup analysis with patients who had received EGFR TKIs 
as second-line treatment (n=105) were undertaken to identify any 
difference in the clinical and molecular features among those pati-
ents who were treated with EGFR TKIs.
Results: Median follow-up duration was 21.9 months (range, 1.1-
62.5) and median number of cycles was 7 (range, 1-44). The me-
dian PFS and OS for a total 148 patients were 10.6 months (95% 
CI, 9.0-12.2) and 21.8 months (95% CI, 18.5-25.1), respectively. The 
survival outcomes were similar between first-line and second-line 
or more line of treatment of EGFR TKIs (p=0.512 for PFS, p=0.699 
for OS). A high number of metastasis sites (3-6 versus 1-2) was as-
sociated with shorter PFS and OS (median PFS 9.9 vs. 11.9 months, 
p=0.019; median OS 16.4 vs. 22.2 months, p=0.021, respectively) 
in univariate analysis, but not in multivariate analysis. According to 
the clinical and molecular markers by multivariate analysis, there 
were no significant differences in PFS. When PFS was dichotomized 
by median 11 months for 105 patients treated with EGFR TKIs as 
second-line therapy, no significant differences in any clinical or 
molecular features were found between longer PFS and shorter 
PFS groups.
Conclusion: Despite the heterogeneity in PFS among EGFR mu-
tant patients treated with EGFR TKIs, no significant differences of 
clinical features were noted, suggesting more understanding of 
the variability of underlying biology should be needed.
Keywords: Epidermal growth factor receptor, tyrosine kinase inhi-
bitors, non-small cell lung cancer
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study 1028, clinically meaningful improvements from baseline (>10 
points difference on a 0–100-point scale) in key NSCLC symptoms 
(cough, dyspnea, pain in chest, pain in arm/shoulder, fatigue, and 
physical function) were reported by patients receiving dacomitinib. 
The difference in mean change from baseline was more favorable 
with dacomitinib at most time-points.
Conclusion: Dacomitinib demonstrated consistent improvements 
in common NSCLC symptoms across three clinical trials in pret-
reated patients with advanced NSCLC. PROs such as cough and 
pain improved within 3 weeks of initiating treatment, with benefits 
sustained throughout the course of therapy. Dacomitinib also de-
monstrated greater improvements in key NSCLC symptoms than 
erlotinib.
Keywords: patient-reported outcomes, erlotinib, dacomitinib, 
non-small cell lung cancer
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P2.11-033 ALK-EML4-TESTING IN NON-SMALL CELL 
LUNG CANCER: EXPERIENCES FROM KAROLINSKA  
UNIVERSITY HOSPITAL IN SWEDEN
Stephanie Mindus1, Kenbugul Jatta2, Göran Elmberger2, Luigi De 
Petris3, Karl Kölbeck1
1Respiratory Medicine And Allergology, Karolinska University Hospital/
Sweden, 2Department Of Pathology, Karolinska University Hospital/
Sweden, 3Department Of Oncology, Karolinska University Hospital/
Sweden
Background: Overall survival (OS) in lung cancer is poor but not 
without heterogeneity. Molecular pathways and “driver mutations” 
have been identified in the struggle to improve prognosis and 
treatment outcome. Some constitute predictive factors for the use 
of new drugs: tyrosine kinase inhibitors (TKI) such as erlotinib and 
gefitinib target mutations within the EGFR-gene and crizotinib 
ALK-translocations. The presence of the two molecular features are 
usually mutually exclusive. Crizotinib is a newly registered drug in 
Sweden. Our aim was to define the clinical importance of molecu-
lar pathological testing for ALK-EML4-translocations in non-small 
lung cancer (NSCLC).
Methods: We have retrospectivly examined all histological and 
cytological sampling for molecular testing on NSCLC-patients at 
Karolinska University Hospital since 2010. 3 complementary me-
thods to identify ALK-EML4-translocations were used: fluorecense-
in-situ-hybridisation (FISH) with Vysis ALK break apart probe, im-
munohistochemistry (IHC) with ALK-EML4 specific AB and real time 
PCR with an in-house developed method able to detect the five 
most common fusiontranscripts with inversion INV(2)(p21p23).
Results: 211 FISH-test were conducted, whereof 70 performed 
on 160 consecutive surgically removed NSCLC. A total of 30 ALK-
EML4-translocations were identified, 3 of which amongst the 70 
surgical samples. No case of concomittant ALK-EML4-translocation 
and mutation in the EGFR-gene was identified. The characteristics 
of ALK-EML4 positive patients were as follows: 19 were women and 
11 men with an average age of 58.2 years. 20 were never smokers, 
1 current smoker, 9 ex smokers with an average time of 20.5 years 
since smoking cessation. Adenocarcinomas represented 29 cases 
and adenosquamous cancer 1 case (currently smoking woman). 
Staging according to IASLC 7th edition showed : 4 patients in stage 
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P2.11-032 PATIENT REPORT OF DACOMITINIB 
(PF-00299804)-ASSOCIATED SYMPTOM AND HRQOL 
BENEFIT IN PREVIOUSLY TREATED ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC)
Jim P. Doherty1, Karen L. Reckamp2, Joseph O‘Connell1, Stephen 
Letrent1, Suresh S. Ramalingam3, Michael Boyer4, Pasi A. Jänne5, 
Keunchil Park6, Dong-Wan Kim7, Shirish Gadgeel8, Andrew Bot-
tomley9
1Pfizer Oncology/United States Of America, 2City Of Hope/United Sta-
tes Of America, 3Department Of Hematology And Medical Oncology, 
Winship Cancer Institute Of Emory University/United States Of Ame-
rica, 4Medical Oncology, Sydney Cancer Centre/Australia, 5Lowe Center 
For Thoracic Oncology, Dana Farber Cancer Institute/United States Of 
America, 6Department Of Medicine, Division Of Hematology-Oncology, 
Samsung Medical Center, Sungkyunkwan University School Of Medici-
ne/Korea, 7Department Of Internal Medicine, Seoul National University 
Hospital/Korea, 8Karmanos Cancer Institute/Wayne State University/
United States Of America, 9Quality Of Life Department, EORTC/Belgium
Background: Decreasing tumor burden may reduce/delay cancer-
related symptoms experienced by patients with NSCLC and favo-
rably impact global health-related quality of life (HRQoL). Daco-
mitinib is an irreversible small-molecule inhibitor of all catalytically 
active members of the human epidermal growth factor receptor 
(HER) family of tyrosine kinases (EGFR/HER1, HER2, and HER4), 
and has shown anticancer activity and manageable toxicity in NS-
CLC clinical trials [Janne et al 2009; Park et al 2010; Ramalingam 
et al 2012; Mok et al 2012]. Qualitative assessment of the adverse 
event (AE) burden from the patient’s perspective helps to provide 
a greater understanding of the overall impact of treatment-related 
AEs than grading of AEs alone. Here we report the impact of daco-
mitinib on core lung cancer symptoms in patients with previously 
treated, advanced NSCLC in three phase II clinical trials [Janne et 
al 2009; Park et al 2010; Ramalingam et al 2012].
Methods: Dacomitinib was evaluated in advanced NSCLC, in pa-
tients who had received prior chemotherapy and erlotinib (study 
1002; n=66) [Janne et al 2009], in Korean patients who had re-
ceived prior chemotherapy and erlotinib or gefitinib (study 1003; 
n=43 in phase II) [Park et al 2010], and in comparison with erlotinib 
in patients who had received prior chemotherapy (study 1028; 
n=188) [Ramalingam et al 2012]. In each of the trials, HRQoL was 
evaluated using validated patient-reported outcome (PRO) mea-
sures. Disease/treatmentrelated symptoms were recorded using 
the European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire core module (EORTC QLQ-C30) and 
its lung cancer module (LC13). Scores were summarized using the 
mean (and 95% CI) for each group and plotted over time. Mean 
changes from baseline were also reported.
Results: On-study questionnaire mean completion rates were high 
(>90% of patients answered at least 1 question across treatment 
cycles) in each of the studies. Across the three trials, patients re-
ported a rapid onset (typically ≤3 weeks of starting therapy) of 
improvement in key lung cancer symptoms (e.g. cough, pain in 
chest, and pain in arm/shoulder) relative to baseline scores, with 
symptomatic improvements remaining durable over the course of 
therapy. Diarrhea and sore mouth were the most commonly repor-
ted class-related AEs (for dacomitinib in studies 1002 and 1003, 
and for both dacomitinib and erlotinib in study 1028). These AEs 
peaked at weeks 3–6, were manageable, and remained stable or 
improved over time with intervention. Compared with erlotinib in 
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0.20-0.51), E vs A 0.38 (95%CI 0.24-0.62); for rash G vs E 1.0 (95%CI 
0.82-1.22), G vs A 0.31 (95%CI 0.15-0.65), E vs A 0.31 (95%CI 0.15-
0.65); for hypertransaminasemia G vs E 2.29 (95%CI 1.63-3.23). Nail 
disorders affected 57% of patients treated with A, 15% with G, and 
4% with E.
Conclusion: Results of our analysis showed that all treatments 
have similar activity and efficacy while the toxicity profile was less 
favorable for A with a significant higher risk of diarrhea, rash, and 
nail disorders. Based on these safety results, we suggest that A 
may not be the first choice for upfront treatment in EGFR mutated 
patients. Confirmation is warranted by ongoing prospective head 
to head RCTs.
Keywords: first line, EGFR-TKI, Metanalysis
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P2.11-035 ASSOCIATION OF TUMOR PD-L1 EXPRESSION 
AND IMMUNE BIOMARKERS WITH CLINICAL ACTIVITY 
IN PATIENTS WITH NON-SMALL CELL LUNG CANCER 
(NSCLC) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-
936558; ONO-4538)
Scott J. Antonia1, Joseph F. Grosso2, Christine E. Horak2, Christo-
pher T. Harbison2, John F. Kurland2, H David Inzunza2, Ashok Gup-
ta2, Vindira Sankar2, Jong-Soon Park2, Maria Jure-Kunkel2, James 
Novotny2, John Cogswell2, Xiaoling Zhang3, Therese Phillips3, Pau-
line Simmons3, Jason Simon2
1H. Lee Moffitt Cancer Center & Research Institute/United States Of 
America, 2Bristol-Myers Squibb/United States Of America, 3Dako North 
America/United States Of America
Background: The immune checkpoint receptor programmed 
death-1 (PD-1) negatively regulates T-cell activation upon in-
teraction with its ligands, PD-L1 and PD-L2. In a Phase 1 dose-
escalation/cohort expansion study (CA209-003; NCT00730639), 
nivolumab, a fully human PD-1 receptor blocking antibody, 
delivered durable responses in patients with solid tumors, inclu-
ding advanced NSCLC. Immunohistochemistry (IHC) analysis of 
tumor samples from this study suggested an association between 
pre-treatment tumor PD-L1 expression and clinical response to 
nivolumab in patients with melanoma (Grosso JF J Clin Oncol. 
2013;31(suppl):abs 3016; Topalian SL NEJM 2012;366:2443-54). 
Here we investigate the association between PD-L1 expression 
by IHC and response to nivolumab in patients with NSCLC, and 
patient response with pre-/post-dose absolute lymphocyte counts 
(ALC) and selected lymphocyte cell subsets.
Methods: 129 patients with NSCLC from the CA209-003 trial re-
ceived nivolumab between 2008 and 2012 (1–10 mg/kg IV every 2 
weeks) during dose escalation and/or cohort expansion. Archived 
formalin-fixed paraffin-embedded pre-treatment tumor tissue and 
pre-treatment and on-treatment peripheral whole blood samples 
were analyzed to explore potential pharmacodynamic/predictive 
biomarkers associated with nivolumab therapy. Pre-treatment tu-
mor PD-L1 expression was evaluated by IHC using an automated 
assay developed by Dako based on a sensitive and specific anti-
PD-L1 monoclonal antibody (28-8). Tumors were defined as PD-L1 
positive (PD-L1+) when ≥5% of the tumor cells had membrane stai-
ning at any intensity. Lymphocyte subsets in the periphery were 
measured using flow cytometry.
I, 1 in stage II, 7 in stage III and 18 in stage IV. 16 patients, all with 
metastatic disease, were treated with crizotinib (15 with 250mg 1x2 
and 1 patient with 200mg 1x1). Crizotinib was given to: 0 patients 
as 1st line, 4 patients as 2d line, 6 as 3d line, 5 as 4th line and 1 as 5th 
line. At time of data collection 9 patients had discontinued crizo-
tinib-therapy. 7 patients had ongoing treatment with an average 
duration of 125 days. 12/16 patients obtained partial remission, 3 
stable disease and 1 disease progression. 3/9 discontinued crizo-
tinib-therapy due do severe side effects: 1 due to persistant visus 
toxicity grade ≥2, 1 due to pneumonitis occuring at treatment day 
42 and 1 due to liver toxicity with CTCAE grade ≥2 occurring at 
treatment day 37. Only the case with pneumonitis resultated in 
death at day 43. No QTc-syndromes and no hematological toxicity 
CTCAE grade ≥3 occurred.
Conclusion: Identifying patients with ALK-EML4-translocations, 
the predictive factor for crizotinib-treatment, offers new treatment 
options and realistically balanced hope in the severe setting of 
metastatic NSCLC. In our experience, the predictive value of a po-
sitive ALK-EML4-test is high on histological material and crizotinib 
offers good treatment outcomes after progression on platinum-
based chemotherapy but for shorter time than what is expected 
for TKIs in patients with activating EGFR-mutations.
Keyword: ALK-EML4-translocations, metastatic NSCLC, predictive 
factors
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P2.11-034 INDIRECT COMPARISONS OF HARM/BENEFIT 
PROFILE OF EGFR TYROSINE KINASE INHIBITORS AS 
FIRST LINE TREATMENT IN EGFR MUTATED NSCLC PATI-
ENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Eva R. Haspinger1, Francesco Agustoni1, Francesco Gelsomino1, 
Valter Torri2, Marina C. Garassino1, Michela Cinquini2
1Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori/
Italy, 2Laboratorio Di Metodologia Per La Ricerca Biomedica, IRCCS - 
Istituto Di Ricerche Farmacologiche "mario Negri“/Italy
Background: To date, three EGFR Tyrosine Kinase inhibitors (TKIs) 
gefitinib (G), erlotinib (E), and afatinib (A) have been compared to 
standard chemotherapy as first line treatment in patients with ad-
vanced NSCLC harboring EGFR mutations. We performed a syste-
matic review and meta -analysis in order to estimate through indi-
rect comparisons the relative risk benefit associated to each drug.
Methods: The major databases were searched for published and 
unpublished randomized control trial up to March 2013. Data ext-
raction was performed by two independent reviewers and focused 
on benefit (ORR, PFS) and selected harm outcomes (diarrhea, rash, 
nail disorders, hypertransaminasemia). The adjusted indirect com-
parisons were performed using the random effect method descri-
bed by Bucher and Glenny approach for Hazard Ratio (HR) for PFS 
and relative risk (RR) for the other outcome measures.
Results: All EGFR TKIs fared better when compared with chemo-
therapy in terms of PFS: overall HR 0.40 (95%CI 0.30-0.54); G vs E 
HR 1.34 (95%CI 0.63-2.86), G vs A HR 0.74 (95%CI 0.53-1.04), E vs 
A HR 0.55 (95%CI 0.31-0.99). The relative probability of ORR was 
G vs E 0.96 (95%CI 0.69-1.34), G vs A 0.79 (95%CI 0.49-1.28), E vs 
A 0.82 (95%CI 0.49-1.38). Indirect comparisons for safety showed 
RR for diarrhea G vs E 0.8 (95%CI 0.63-1.01), G vs A 0.32 (95%CI 
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type tumors. The relationship between EGFR activating mutations 
and their primary tumor location in the lungs was not reported 
before.
Methods: We retrospectively reviewed the data of our pulmonary 
adenocarcinoma patients who had received complete staging and 
received tumor EGFR mutation analysis. The association between 
EGFR mutation status, patients smoking status, patient’s gender 
and primary tumor location were analyzed.
Results: 205 cases were reviewed. There are 126 patients with 
tumor EGFR mutations, including 115 patients with classic EGFR 
mutations (exon 19 deletions or L858R), and 79 patients were wit-
hout EGFR mutation. There are statistically significant association 
between tumor EGFR mutations and primary tumor location in 
right upper lobe (P=0.007); especially in RB1 segment (P=0.018), 
and primary tumor location of exon 19 deletions occurred more 
frequently in right upper lobe (P<0.001). There were no significant 
associations between patients smoking status and primary tumor 
location(P=0.659), nor was patients gender and primary tumor 
location (P=0.473).
Conclusion: There are statistically significant association between 
EGFR mutation and primary tumor location in right upper lobe of 
patients with adenocarcinoma 
of the lungs.  
Keywords: adenocarcinoma of lung, Tumor EGFR Mutation, tumor 
location
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P2.11-037 EGFR ACTIVATING MUTATION AND BONE 
METASTASIS HAVE ASSOCIATION WITH CNS METASTA-
SIS AT DIAGNOSIS IN PATIENTS WITH NON-SMALL CELL 
LUNG CANCER
Ki Hwan Kim, Hyo-Jeong Lim, Jin Hyun Park, Jin-Soo Kim, In Sil 
Choi
Department Of Internal Medicine, Seoul National University Boramae 
Medical Center/Korea
Background: CNS metastasis happens not infrequently in patients 
with non-small cell lung cancer, reaching upto 25%. The presence 
of CNS metastasis is a major decision factor of planning primary 
treatment. Furthermore, predictors for CNS metastasis could be 
used for selecting patients who may get the potential benefit of 
prophylactic cranial irradiation.
Methods: We retrospectively analyzed the clinicopathologic data 
of 233 patients with non-small cell lung cancer who underwent 
brain MRI at the time of diagnosis between Jan 2008 and Dec 
2012. Chi-square analysis and multivariate logistic regression mo-
del was used to find risk factors for CNS metastasis.
Results: Forty-five (19.3%) patients had initial CNS metastasis (41 
brain parenchymal metastasis and 4 leptomeningeal seeding). 
Chi-square analysis revealed that never-smoking (28.7% vs. 13.7%, 
P=0.005), lung metastasis (29.6% vs 14.8%, P=0.009), bone me-
tastasis (35.7% vs 13.1%, P<0.001), adenocarcinoma (24.8% vs 
10.9%, P=0.008), and EGFR activating mutation (44.4% vs 18.3%, 
P=0.004) were associated with CNS metastasis. However, pleural, 
Results: Tumor membrane PD-L1 expression was measured in 
63 patients with NSCLC (29 squamous; 34 non-squamous). 31/63 
(49%) NSCLC biopsies were PD-L1+. There was no apparent associ-
ation between PD-L1 protein expression and NSCLC histology: for 
squamous and non-squamous tumors, 52% (15/29) and 47% (16/34) 
were PD-L1+, respective. Objective response rates for PD-L1+ and 
PD-L1- NSCLC patients with non-squamous and squamous histolo-
gy are shown in the Table. Objective responses were observed in 
patients with squamous and non-squamous NSCLC who were ne-
gative for PD-L1 expression. Since increases in on-treatment ALC 
and activated T-cell phenotypes have been shown to positively 
associate with favorable clinical outcomes in ipilimumab monothe-
rapy (Ku GY Cancer 2010;116:1767-75; Carthon BC Clin Cancer Res 
2010;16:2861-71), results from an analysis correlating patient res-
ponse with pre-/post-dose ALC and T-cell populations in patients 
with NSCLC receiving nivolumab will be presented.  
Table. Patient response according to PD-L1 expression status in 
patients with NSCLC
Tumor type PD-L1 expression status
Objective  
response rate, 
n/N (%)
NSCLC  
(all patients)
+ 5/31 (16.1)
– 4/32 (12.5)
NSCLC  
(squamous)
+ 2/15 (13.3)
– 3/14 (21.4)
NSCLC (non-
squamous)
+ 3/16 (18.8)
– 1/18 (5.6)
Conclusion: Further evaluation of PD-L1 as a molecular marker 
of nivolumab therapy is required. Association of PD-L1 protein 
expression with clinical outcome is currently being prospectively 
assessed in ongoing Phase 3 trials. Clinical Trial Registration Num-
ber: NCT00730639
Keywords: nivolumab, non-small cell lung cancer, programmed 
death-1 receptor ligand 1, biomarker
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P2.11-036 ASSOCIATION BETWEEN TUMOR EGFR MU-
TATION AND PRIMARY TUMOR LOCATION IN PATIENTS 
WITH ADENOCARCINOMA OF THE LUNGS
Chu-Yun Huang1, Yung-Hung Luo1, Chieh-Hung Wu1, Chih-Wei 
Wu1, Wen-Shuo Wu1, Chun-Ming Tsai2, Yu-Chin Lee2, Reury-Perng 
Perng1, Jacqueline Whang-Peng3, Yuh-Min Chen2
1Department Of Chest Medicine, Taipei Veterans General Hospital/
Taiwan, 2Division Of Thoracic Oncology, Department Of Chest Medi-
cine, Taipei Veterans General Hospital, School Of Medicine, National 
Yang-Ming University/Taiwan, 3Centre Of Excellence Cancer Research 
(CECR), Taipei Medical University/Taiwan
Background: Lung cancer is the leading cause of cancer death in 
the world, and the non-small cell lung cancer accounts for more 
than 80% of the lung cancer. Among patients with non-small cell 
lung cancer, tumor epidermal growth factor receptor (EGFR) acti-
vating mutations were mostly found in patients with adenocarcino-
ma and were associated with a better prognosis than EGFR wild-
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Results: 129 patients with NSCLC (non-squamous [n=74], squa-
mous [n=54], unknown histology [n=1]) received nivolumab at 1, 3, 
or 10 mg/kg as of March 2013 (Table). Association of clinical acti-
vity with baseline characteristics will be assessed for the following 
subgroups: age ≥70 and <70 years, gender, ECOG PS 0 and ≥1, 
number of prior therapies 1–2 and ≥3, prior tyrosine kinase inhibi-
tor (TKI) therapy, EGFR-mutation status, and KRAS-mutation status. 
Table
Baseline characteristica NSCLC patient population (n=129)
Median age (range), y 65 (38–85)
Gender, n (%)
Male 79 (61)
Female 50 (39)
ECOG PS, n (%)
0 27 (21)
1 100 (78)
2 2 (2)
Number of prior therapies, n (%)
1 25 (19)
2 34 (26)
3 27 (21)
≥4 43 (33)
Prior therapy, n (%)
Platinum-based chemotherapy 128 (99)
TKI 36 (28)
aData on EGFR- and KRAS-mutation status are pending. 
Conclusion: Nivolumab demonstrated encouraging clinical activity 
in patients with previously treated advanced NSCLC. Clinical acti-
vity by patient subgroups may provide insights into the influence 
of patient and tumor characteristics on response to nivolumab. An 
update of the data regarding clinical activity of nivolumab therapy 
in these subgroups of the NSCLC cohort will be presented.
Keywords: programmed death-1 receptor, nivolumab, NSCLC, 
subpopulations
pericardial, adrenal, liver metastasis, gender, age, and T/N staging 
did not have correlation with CNS metastasis. Multivariate analysis 
indicated that only EGFR activating mutation status (adjusted HR, 
4.3; 95% CI, 1.6-11.2; P=0.003) and bone metastasis (adjusted HR, 
4.0; 95% CI, 1.5-10.6; P=0.005) had independent association with 
CNS metastasis.
Conclusion: In the current study, EGFR activating mutation status 
and presence of bone metastasis are independently associated 
with initial CNS metastasis. Initial staging work-up for patients with 
these clinicopathologic features should include brain MRI. Results 
of this study can be used for selecting candidates for prophylactic 
cranial eradiation or adjuvant EGFR tyrosine kinase inhibitor treat-
ment.
Keywords: EGFR mutation, CNS metastasis, non-small cell lung 
cancer, Bone Metastasis
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P2.11-038 EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-
936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY 
TREATED ADVANCED NON-SMALL CELL LUNG CANCER 
(NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A 
PHASE 1 TRIAL
Scott Gettinger1, Leora Horn2, Scott J. Antonia3, David R. Spigel4, 
Leena Gandhi5, Lecia V. Sequist6, Vindira Sankar7, Christoph M. 
Ahlers7, Jon M. Wigginton7, Georgia Kollia7, Ashok Gupta7, Julie R. 
Brahmer8
1Yale Cancer Center/United States Of America, 2Vanderbilt-ingram Can-
cer Center/United States Of America, 3H. Lee Moffitt Cancer Center & 
Research Institute/United States Of America, 4Sarah Cannon Research 
Institute/tennessee Oncology/United States Of America, 5Dana-Farber 
Cancer Institute/United States Of America, 6Massachusetts General 
Hospital/United States Of America, 7Bristol-Myers Squibb/United Sta-
tes Of America, 8Sidney Kimmel Comprehensive Cancer Center At Johns 
Hopkins/United States Of America
Background: Lung cancer is the leading cause of cancer deaths 
globally, and NSCLC comprises 85% of lung cancers. Patients with 
advanced (stage IIIB or IV) NSCLC have a poor prognosis. Current 
second-line chemotherapeutics demonstrate a median overall sur-
vival (OS) of 8 months and 1-year survival of 30%. Factors that may 
influence clinical activity include age, ECOG performance status 
(PS), number of prior therapies, and EGFR- and KRAS-mutation 
status. The immune checkpoint receptor programmed death-1 
(PD-1) negatively regulates T-cell activation upon interaction with 
its ligands PD-L1 and PD-L2. Nivolumab, a fully human IgG4, PD-1 
receptor blocking monoclonal antibody, was evaluated in a phase 
1 study (CA209-003; NCT00730639) in patients with various tu-
mors, including previously treated advanced NSCLC. In this study, 
treatment with nivolumab demonstrated durable objective respon-
ses and prolonged stable disease in a portion of patients from this 
NSCLC cohort (Topalian S, et al. N Engl J Med. 2012;366:2443-54). 
We present the updated findings from assessment of clinical acti-
vity to nivolumab in subpopulations of the NSCLC cohort from this 
study.
Methods: Patients received nivolumab (1–10 mg/kg IV Q2W) for 
≤12 cycles (4 doses/8W cycle) or until discontinuation criteria were 
met. An analysis of clinical activity by select patient characteristics 
was performed from the NSCLC cohort of this trial.
S910 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Hazard ratio (HR) for recurrence: 0.384; 95:CI = 0.1736 - 0.8510; p = 
0.018. The most pronounced changes in the immune system have 
been defined only after fourth DC-vaccine administration. These 
changes consist in the significant reduction of T-reg number and 
their ability to secrete TGF-β, significant increasing the CD8+IFN+ 
CTL number and functionality and CD4+ memory cell number, 
Th1–polarization of immune responses, significant increasing of the 
RANTES/MIP-1α mRNA ratio (p<0,001). ROC analysis revealed that 
CD8+IFN+ number (Se=66,67%;Sp=100%; AUC=0,83; p=0,0066), 
CD4+ memory cell number (Se=100%;Sp=75%; AUC=0,875; 
p=0,0094), TGF-β mRNA level (Se=75%;Sp=100%; AUC=0,889; 
p=0,017), RANTES/MIP-1a mRNA ratio (Se=100%;Sp=83,33%; 
AUC=0,83; p=0,0066) are the most important immune response 
markers which associated with clinical outcome after DC-vaccine 
therapy in NSCLC patients.
Conclusion: Adjuvant therapy with DC-vaccine in IIB-IIIA stage NS-
CLC patients is highly effective approach for prevention metastasis 
development and recurrence of disease in post-operative period. 
Patients with low volume disease constitute a target group for the 
development of effective immune and clinical responses after DC-
vaccine therapy.
Keywords: non-small-cell lung cancer, dendritic cell vaccine, clini-
cal benefits, immune response markers
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P2.11-039 RESULTS FROM PHASE III TRIAL OF DEN-
DRITIC CELL BASED VACCINE IMMUNOTHERAPY IN 
PATIENTS WITH -IIIA STAGE NON-SMALL-CELL LUNG 
CANCER
Natalia Khranovska1, Oksana Skachkova1, Andrey Ganul2, Olexan-
dr Gorbach1, Volodimir Sovenko2, Nataliia Svergun1, Valeriy Orel3
1Research Laboratory Of Experimental Oncology, National Cancer Insti-
tute Mph Of Ukraine/Ukraine, 2Thoracic Oncology Department, Natio-
nal Cancer Institute Mph Of Ukraine/Ukraine, 3Research Laboratory Of 
Medical Physics And Bioengineering, National Cancer Institute Mph Of 
Ukraine/Ukraine
Background: Antitumor immunotherapy to target tumor antigens 
is considered reasonable and promising in lung cancer (LC). In our 
early phase of clinical investigation, the safety and efficacy of dend-
ritic cell (DC) based vaccine therapy in patients with non-small-cell 
lung cancer (NSCLC) have been shown. Following successful early 
phase results, we designed a phase III trial of DC- vaccine in IIB-IIIA 
stage NSCLC patients to investigate clinical benefits as the primary 
endpoint, and immune response markers as secondary endpoint.
Methods: One hundred and twenty eligible patients with IIB-IIIA 
stage NSCLC, ECOG 0-1, without autoimmune disorders were 
enrolled into the study. Patients were randomly allocated into two 
groups: 1 st - patients who received DC-vaccine as immunotherapy 
after surgery (lobectomy or pneumonectomy), 2nd - comparison 
group of patients who received surgery only. Original construction 
of DC-vaccine have been used: autologous DCs of monocytic origin 
loaded with mechanically heterogenized microparticles of tumor 
cells. Maturation state and functional activity of DCs were evaluated 
by the expression of cell surface markers CD83/86, HLA-DR and IL-
12 p35/p40 mRNA levels. DC in amount 4,62±0,37x106 per injection 
were injected intravenously in 1-3 courses with 6 months interval. 
One course consisted of 5 injections with one-month interval. Cli-
nical and immunological monitoring of DC-vaccine immunotherapy 
was performed.
Results: The table summarizes median overall survival (OS) and di-
sease free survival rates at 1, 2, 3, 4 and 5 years for NSCLC patients. 
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P2.11-041 EFFECT OF TREATMENT DURATION ON IN-
CIDENCE OF ADVERSE EVENTS (AES) IN A PHASE III 
STUDY OF CRIZOTINIB VERSUS CHEMOTHERAPY IN 
ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG 
CANCER (NSCLC)
Alice T. Shaw1, Benjamin J. Solomon2, Tony Mok3, Dong-Wan Kim4, 
Keith D. Wilner5, Paulina Selaru5, Anna Polli6
1Massachusetts General Hospital/United States Of America, 2Peter 
MacCallum Cancer Centre/Australia, 3Chinese University Of Hong 
Kong/China, 4Seoul National University Hospital/Korea, 5Pfizer Oncolo-
gy/United States Of America, 6Pfizer Oncology/Italy
Background: In the ongoing global randomized phase III study 
PROFILE 1007, the oral ALK inhibitor crizotinib improved progressi-
on-free survival, response rate, and global quality of life compared 
with single-agent chemotherapy in patients with advanced, pre-
viously treated ALK-positive NSCLC. While hematologic toxicities 
were more common with chemotherapy, a greater number of non-
hematologic toxicities were reported with crizotinib. Several fac-
tors may have complicated the comparison of AEs, including lon-
ger treatment duration with crizotinib, standard use of prophylactic 
medications with chemotherapy but not with crizotinib, and a high-
er rate of continuing treatment beyond RECIST-defined progressi-
ve disease with crizotinib. Here we examine whether differences in 
treatment duration may have impacted the incidences of selected 
AEs and non-fatal serious AEs (SAEs) observed in this study.
Methods: In PROFILE 1007, 172 patients received crizotinib 250 
mg orally BID and 171 patients received chemotherapy (pemet-
rexed 500 mg/m2 or docetaxel 75 mg/m2, both IV q3w). AEs were 
classified and graded using CTCAE v4.0. For this analysis, AEs of 
interest included those occurring in ≥10% of patients with ≥5% 
absolute difference between treatment groups, as well as non-fatal 
SAEs. To evaluate the potential impact of differential treatment 
duration on these AEs, exposure-adjusted incidence rates were 
calculated using person-years of exposure (PYE; the sum of the 
individual person-years at risk for a particular AE).
Results: Median treatment duration was almost three-fold longer 
with crizotinib (31 weeks) versus chemotherapy (12 weeks). Inciden-
ces and exposure-adjusted incidence rates of AEs of interest are 
shown in the table below. After accounting for treatment duration, 
the rates of nausea, constipation, elevated transaminases, ede-
ma, upper respiratory infection, dizziness, pulmonary embolism, 
hypokalemia, and non-fatal SAEs were comparable between the 
crizotinib and chemotherapy groups. The rates of diarrhea, vision 
disorder, vomiting, dysgeusia, and syncope were significantly high-
er with crizotinib. Exposure-adjusted incidence rates for other AEs, 
as well as additional analyses to account for treatment duration will 
be presented.  
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P2.11-040 PHASE 1 STUDY OF IPILIMUMAB IN COMBI-
NATION WITH PACLITAXEL/CARBOPLATIN IN PATIENTS 
WITH NON-SMALL CELL LUNG CANCER
Hihoshi Nokihara1, Hidehito Horinouchi1, Shigehiro Yagishita1, 
Satoru Kitazono1, Hidenori Mizugaki1, Shintaro Kanda1, Yutaka 
Fujiwara1, Noboru Yamamoto1, Mayumi Iida2, Takuto Tokudome2, 
Tomohide Tamura1
1Department Of Thoracic Oncology, National Cancer Center Hospital/
Japan, 2Bristol-Myers Squibb/Japan
Background: Ipilimumab is a fully human IgG1 monoclonal antibo-
dy which blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4) and 
augments antitumor T-cell responses. In a global phase 2 study 
in subjects with non-small cell lung cancer (NSCLC) and small cell 
lung cancer (SCLC), ipilimumab administrated in a phased schedu-
le in combination with paclitaxel/carboplatin, improved immune-
related progression-free survival with an acceptable safety profile. 
A pronounced benefit was observed in squamous NSCLC. We 
conducted the phase 1 study of ipilimumab in combination with 
paclitaxel/carboplatin in Japanese patients with NSCLC.
Methods: Target population was Japanese subjects with stage IIIB 
without indication for definitive radiotherapy, stage IV, or recur-
rent NSCLC. Patients received ipilimumab 3 mg/kg or 10 mg/kg 
(starting at Cycle 3) in addition to paclitaxel 175 mg/m2 and carbo-
platin AUC=6 every 3 weeks for up to 6 cycles. Dose limiting toxi-
city (DLT) was evaluated during the first two cycles of ipilimumab 
administration (Cycle 3 and Cycle 4). The recommended dose (RD) 
was defined as the highest dose at which no more than 2 out of 6 
ipilimumab-treated patients experienced a DLT.
Results: A total 15 patients were enrolled and 12 patients received 
ipilimumab (female/male=1/11, range of age =53-70, stage IIIB/
IV/recurrent=0/9/3, squamous/non-squamous= 1/ 11, ipilimumab 
3 mg/kg / 10 mg/kg=6/6). DLTs were observed in 2 out of 6 ipili-
mumab-treated patients in ipilimumab 3 mg/kg arm (febrile neu-
tropenia, amylase increased / 1patient, thrombocytopenia / 1pati-
ent) and 1 out of 6 ipilimumab -treated patients in ipilimumab 10 
mg/kg arm (entercolitis, total-bilirubin increased, lipase increased). 
Of 10 patients evaluable for tumor response based on RECIST 
criteria, partial response and stable disease were achieved in 6 and 
4 patients, respectively.
Conclusion: For Japanese patients with NSCLC, the RD of ipili-
mumab in combination with chemotherapy was identified as 10 
mg/kg and it demonstrated acceptable safety profile and potential 
efficacy. Two global Phase 3 studies are ongoing in subjects eva-
luating ipilimumab 10 mg/kg in combination with chemotherapy 
in advanced squamous NSCLC (with carboplatin/paclitaxel) and 
extensive stage SCLC (with etoposide/platinum).
Keywords: phase 1 study, ipilimumab, paclitaxel/carboplatin
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P2.11-042 ACID SUPPRESSION THERAPY IMPAIRS ERLO-
TINIB EFFICACY IN NON-SMALL CELL LUNG CANCER
Michael P. Chu1, Sunita Ghosh1, Carole Chambers2, Naveen Bas-
appa1, Charles A. Butts1, Quincy Chu1, David Fenton3, Anil A. Joy1, 
Randeep Sangha1, Michael Smylie1, Michael B. Sawyer1
1Medical Oncology, Cross Cancer Institute/Canada, 2Cancer Care, Alberta 
Health Services/Canada, 3British Columbia Cancer Agency/Canada
Background: Erlotinib is a key treatment option in all advanced or 
metastatic non-small cell lung cancer (mNSCLC) subtypes regardless 
of epidermal growth factor receptor (EGFR) status. Despite side 
effect advantages over cytotoxic chemotherapy, a shortcoming of 
erlotinib is pH-dependent absorption. Recent evidence highlights 
this inconsistency further by showing reduced plasma levels of vari-
ous oral tyrosine kinase inhibitors (TKIs) in the presence of acid sup-
pression therapy. Given the prevalence of gastroesophageal reflux 
disease (GERD) and diseases that use acid suppression, goals of this 
study are to determine if coadministration of acid suppressants and 
erlotinib affected clinical outcomes in advanced NSCLC patients.
Methods: A cohort of patients with mNSCLC from 2007-2012 who 
received erlotinib through our institution was retrospectively revie-
wed. In addition to stage, age, gender, performance status, and 
NSCLC subtype, patients were then identified as receiving acid 
suppression (AS) if their pharmacy records included either proton 
pump inhibitors (PPIs) or histamine blockers (anti-H2). Patients were 
considered taking these medications concomitantly if dates for acid 
suppressants overlapped their erlotinib prescription by ≥ 20% of 
the treatment duration. Patients who received erlotinib for ≥ 1 week 
were analyzed for progression free survival (PFS) and overall survival 
(OS).
Results: 544 stage IIIB/IV NSCLC patients were identified. Of tho-
se, 507 were eligible for review. Median age was 64 years, gender 
235 male, and 272 female. By subtype, 318 were adenocarcinoma, 
106 squamous, 43 poorly differentiated, 11 large cell, and 29 not 
otherwise specified (NOS). 124 patients received concomitant AS 
therapy with the most common type being PPIs. Analysis unselected 
for EGFR mutational status yielded median PFS and OS in the AS 
versus no-AS group as 1.4 v 2.3 months (p<0.001) and 12.9 v 16.8 
months (p=0.003), respectively. In multivariate analysis with gender, 
NSCLC subtype, and performance status, Cox proportional hazards 
ratios for PFS and OS for AS and non-AS groups were 1.83 (95% CI 
1.48-2.25) and 1.37 (95% CI 1.11-1.69) respectively. Subgroup ana-
lysis by subtype in the AS and non-AS groups was significant in the 
following types (p<0.05): adenocarcinoma, PFS 1.8 v 2.7 months, 
OS 13.2 v 17.5 months; squamous PFS 1.5 v 2.3 months, OS 13.4 v 
15.9 months; poorly differentiated PFS 0.8 v 2.0 months, OS 7.6 v 
15.5 months, and NOS PFS 1.2 v 1.7 months, OS 10.8 v 14.5 months. 
Effects of AS in EGFR mutated patients are being studied.
Conclusion: Despite limitations of retrospective analyses, this large 
population based study demonstrates erlotinib efficacy is depen-
dent on gastric acidity and OS can be adversely affected. This is the 
first study the authors are aware of that demonstrates an impact on 
clinical outcomes by co-administration of acid suppression and TKI 
therapy. Caution should be taken with co-administration of other 
TKIs and acid suppressive therapy.
Keywords: acid suppression, NSCLC, erlotinib
Crizo-
tinib 
(n=172) 
Che-
mothe-
rapy 
(n=171) 
AE 
Inci-
dence 
(%) 
Incidence 
rate/1000 
PYE 
Inci-
dence 
(%) 
Incidence 
rate/1000 
PYE 
P  
valuea 
Diarrhea 60 1848 19 592 <0.0001 
Vision 
disor-
derb 
60 2449 9 268 <0.0001 
Nausea 55 1577 37 1527 0.842 
Vomi-
ting 
47 1083 18 561 0.001 
Consti-
pation 
42 832 23 789 0.789 
Ele-
vated 
transa-
mina-
sesb 
38 716 15 470 0.056 
Edemab 31 568 16 473 0.430 
Dysgeu-
sia 
26 463 9 269 0.045 
Upper 
respi-
ratory 
infec-
tionb 
26 419 13 401 0.865 
Dizzi-
nessb 
22 346 8 236 0.195 
Pulmo-
nary 
embo-
lismb 
6 78 2 62 0.686 
Hypoka-
lemia 
5 70 2 63 0.846 
Syn-
cope 
3 39 0 0 0.025 
Non-
fatal 
SAEs 
29 440 21 640 0.105 
 
aFor differences in incidence rates, twosided. 
bClustered term.
Conclusion: This initial analysis suggests that differences in treat-
ment duration between two drugs may have a significant impact 
when comparing AE profiles. Depending on the safety profiles of 
the two drugs, analyses to account for treatment duration may be 
appropriate when a large disparity has been observed.
Keywords: Crizotinib, treatment duration, adverse events, safety
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Comparisons of patient characteristics according to genotype
EML4-
ALK gene
Characteris-
tics Total,n Positive,n Negative,n P value
56 122
Age(years)
Median 53 48 55 <0.001
Range 25-76 25-74 27-76
Sex
Male 78 20 58 0.140
Female 100 36 64
Smoking  
history
Never/light 
smokers
143 49 94 0.103
Smokers 35 7 28
Pathological 
type
Adenocarci-
noma
161 52 109 0.438
Non- ade-
nocarcinoma
17 4 13
Biopsy  
method 
Tumor and 
metastatic 
lymph nodes 
resection
158 49 109 0.003
Needle biopsy 20 7 13
Site of biopsy
Lung tumor 99 27 72 0.217$
Metastatic 
lymph nodes
72 26 46
Pleura 2 1 1
Others 5 2 3
Interval bet-
ween biopsy 
and the iden-
tification of 
EML4-ALK fu-
sions (months)
≤48 167 55 112 0.020
>48 11 1 10
EGFR  
mutation 
(n=103)
Mutant type 16 1 15 0.005
Wide type 87 37 50
 
$:lung tumor compared with lymph nodes
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P2.11-043 ANALYSIS OF CLINICOPATHOLOGICAL FEA-
TURES FOR CHINESE PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER HARBORING EML4-ALK 
FUSION GENES
Yuankai Shi, Yutao Liu, Xuezhi Hao, Lin Wang, Xiaohong Han, 
Dan Li, Yujie Zhou, Le Tang
Department Of Medical Oncology, Cancer Institute/Hospital, Peking 
Union Medical College & Chinese Academy Of Medical Sciences; Beijing 
Key Laboratory Of Clinical Study On Anticancer Molecular Targeted 
Drugs/China
Background: The echinoderm microtubule-associated protein 
like-4—anaplastic lymphoma kinase (EML4--ALK) fusion oncoge-
ne defines a novel molecular subset of non-small cell lung cancer 
(NSCLC). Crizotinib (Xalkori) has been approved for patients with 
locally advanced or metastatic NSCLC that is ALK positive. How-
ever, the clinicopathological characteristics of patients with the 
EML4-ALK gene have not been identified completely.
Methods: The clinicopathological characteristics of 200 
Chinese patients with advanced NSCLC were analyzed 
retrospectively．Clinical factors including age, sex, smoking histo-
ry, pathological type, biopsy method, site of biopsy and interval 
between biopsy and the identification of EML4-ALK fusions and 
the status of epidermal growth factor receptor (EGFR) mutation 
were analyzed to investigate possible correlations with EML4-ALK 
fusions.
Results: Among the 200 patients with NSCLC enrolled, 56 (28.0%) 
harbored the EML4-ALK gene in this retrospective study. EML4-
ALK fusions could not be detected in 22 of 200 patients (11.0%) 
because of insufficient tissue. The median age was 53 as a whole. 
The median ages of ALK positive and negative groups were 48 
and 55 years, respectively. Patients with the EML4-ALK gene were 
significantly younger than patients without EML4-ALK (p<0.001). 
The detection rate of EML4-ALK rearrangement in patients with 
tumor or metastatic lymph nodes resection was significantly 
higher than patients with needle biopsy(p=0.003). If the interval 
between biopsy and the identification of EML4-ALK fusions was 
less than 48 months, the detection rate of EML4-ALK rearrange-
ment was significantly higher compared with the interval more 
than 48months(p=0.020). Among the 200 patients, 103(51.5%) 
patients had received EGFR mutation detection. Only 1 case har-
bored both EML4-ALK rearrangement and EGFR mutations. The 
incidence of EML4-ALK rearrangement in patients with EGFR wide 
type (42.5%,37/87) was significantly higher than EGFR mutant type 
(6.3%,1/16) . No significant difference in the distribution of sex, 
smoking history, pathological type, and site of biopsy(lung tumor 
compared with metastatic lymph nodes) was observed between 
ALK positive and negative groups (p = 0.140, 0.103, 0.438 and 
0.217, respectively).  
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responses (PR) were observed in 8P (72,2%), stable disease (SD) in 
3P (27,27%) and no progressive disease (PD) (0%). In previously TKI 
treated P, 3 (37,5%) PR were observed, 3 (37,5%) SD, and 2 (25,5%) 
PD. Durable PR and SD were observed in both EGFR TKI-naïve and 
previously treated P.10P are still on treatment. The derived PK pa-
rameters were the following: 100mg bid: Olaparib Cmaxss(ug/ml): 
Day 7:4.60; Day 14:3.53; TR(range) 0.77. AUCss(ug.h/ml) Day 7:24.4; 
Day 14:18.9; TR:0.79. 200mg bid: Cmaxss(ug/ml): Day 7:7.68; Day 
14:6.60; TR:0.89. AUCss(ug.h/ml) Day 7:48.6; Day 14:40.0; TR:0.85; 
200mg tds: Cmaxss(ug/ml): Day 7:8.35; Day 14:8.01; TR:0.96. 
AUCss(ug.h/ml) Day 7: 34.9*; Day 14: 32.7*; TR: 0.94; 250mg tds: 
Cmaxss(ug/ml): Day 7:9.85; Day 14:9.46; TR:0.97. AUCss(ug.h/ml) 
Day 7: 44.2*; Day 14: 43.3*; TR: 0.99. *AUC quoted is AUC0-6 not 
AUCss.
Conclusion: This phase IB trial of gefitinib plus olaparib, confirms 
the tolerability of the combination and the anti-tumor activity seen 
warrants further exploration in treatment-naïve patients. MTD of 
olaparib was 200mg TDS. Co-administration of gefitinib does not 
appear to have altered steady state exposure to olaparib. A phase 
II randomized trial in treatment-naïve EGFR-mutant advanced NS-
CLC is planned to start in 2013. The final recommended dose of 
olaparib will be 200 mg TDS
Keyword: egfr mutated nsclc, therapeutic approaches
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P2.11-045 TRY: A PHASE II STUDY TO EVALUATE SAFETY 
AND EFFICACY OF COMBINED TRASTUZUMAB AND 
AUY922 IN ADVANCED NON-SMALL-CELL LUNG CAN-
CER (NSCLC) WITH HER2 OVEREXPRESSION OR AMPLI-
FICATION OR MUTATION.
Lucia Nogova1, Marc Bos1, Masyar Gardizi1, Matthias Scheffler1, 
Irini Papachristou1, Claudia Wompner1, Lukas C. Heukamp2, Hans-
Ulrich Schildhaus2, Uwe Fuhr3, Martin L. Sos1, Wilfried E.E. Eber-
hardt4, Marcel Wiesweg4, Kurt Werner Schmid4, Martin Schuler4, 
Reinhard Büttner2, Jürgen Wolf1
1Lung Cancer Group Cologne, Department I Of Internal Medicine And 
Center For Integrated Oncology Köln-Bonn, University Hospital Colo-
gne/Germany, 2Institute Of Pathology, University Hospital Cologne/
Germany, 3Center For Integrated Oncology, University Hospital Cologne, 
Department Of Pharmacology/Germany, 4West German Cancer Center, 
Dept. Of Medical Oncology, University Hospital Essen/Germany
Background: HER2 amplifications and/or mutations are rare ge-
netic alterations in NSCLC accounting for approximately 4%. Preli-
minary clinical data suggested efficacy of trastuzumab in patients 
with HER2 IHC3+ status or FISH positivity. The heat shock protein 
HSP90 is a molecular chaperone that modulates stability and/or 
transport of intracellular client proteins including HER2. In breast 
cancer HSP90 inhibition has shown anticancer activity in HER2-
positive patients after trastuzumab failure. Here we are investiga-
ting the efficacy of the combination of trastuzumab and the HSP90 
inhibitor AUY922 in lung cancer patients with aberrant HER2.
Methods: This phase II study recruits metastatic NSCLC patients 
with HER2 overexpression (immunohistochemistry, DAKO-score 
3+) or amplification (fluorescence in situ hybridization) or activating 
mutation after at least one previous standard treatment. In the first 
part of the study, patients are treated with trastuzumab only. CT 
scans are scheduled every 6 weeks during treatment. In case of 
Conclusion: We identified younger age and EGFR wide type as 
clinicopathological features of patients with advanced NSCLC 
harboring EML4-ALK fusion genes. The detection rate of EML4-
ALK rearrangement was significantly higher in patients with tumor 
or metastatic lymph nodes resection and the interval less than 48 
months between biopsy and the identification of EML4-ALK fusi-
ons.
Keywords: non-small cell lung cancer, EML4-ALK, EGFR
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P2.11-044 PHASE IB STUDY TO EVALUATE THE EFFICA-
CY AND TOLERABILITY OF OLAPARIB (AZD2281) PLUS 
GEFITINIB IN PATIENTS (P) WITH EPIDERMAL GROWTH 
FACTOR RECEPTOR (EGFR) MUTATION POSITIVE AD-
VANCED NON-SMALL CELL LUNG CANCER (NSCLC) PA-
TIENTS (P). (NCT=1513174/GECP-GOAL)
Rosario Garcia Campelo1, Enriqueta Felip2, Bartomeu Massuti3, 
Margarita Majem4, Enric Carcereny5, Ramon Palmero5, Miguel 
Angel Molina-Vila6, Rosana Cajal7, Maria Sanchez-Ronco8, Rafael 
Rosell5
1Medical Oncology, Complejo Hospitalario Universitario A Coruña/
Spain, 2Hospital Universitario De La Vall D‘hebron/Spain, 3Medical On-
cology, Hospital General De Alicante/Spain, 4Medical Oncology, Hospital 
De La Santa Creu I Sant Pau/Spain, 5Medical Oncology, Catalan Insti-
tute Of Oncology/Spain, 6Quiron-Dexeus University Hospital, Pangaea 
Biotech/Spain, 7Astra Zeneca/Spain, 8Statistics, University Of Alcala 
De Henares/Spain
Background: Progression-free survival (PFS) and response rate 
(RR) to EGFR tyrosine kinase inhibitors (TKIs) vary in P with NSCLC 
driven by EGFR mutations, suggesting that other genetic altera-
tions may influence oncogene addiction. In our experience, high 
BRCA1 mRNA expression negatively influenced PFS among EGFR 
mutant P treated with erlotinib. We hypothesiszed that since olapa-
rib can attenuate and/or prevent BRCA1 expression, the addition 
of olaparib to gefitinib could improve PFS in these P.
Methods: This is a Phase IB dose escalation study to identify the 
maximum tolerated dose (MTD), dose limiting toxicity (DLT), phar-
macokinetics (PK), and clinical activity of orally administered olapa-
rib in combination with gefitinib in EGFR mutant advanced NSCLC. 
In a standard 3+3 design based on toxicity, P were treated with 
gefitinib 250mg once daily plus olaparib tablets at escalating do-
ses ranging from 100mg BID to 250mg TDS during a 28-day cycle. 
Steady state Cmax and AUC (AUC0-12) were determined following 
dosing on Day 7 and 14 of the study and the Day 14:Day 7 treat-
ment ratio calculated to assess the impact on olaparib steady state 
exposure of dosing in combination with gefitinib
Results: 22P have been included across four dose levels of olapa-
rib: 100mg BID (3), 200mg BID (6), 200mg TDS (6) and 250mg TDS 
(7). Median age, 65 (range 39-84); male, 6P; PS 0-1, 20P; EGFR TKI 
treatment-naïve, 13P; Most toxicities were G1-2, including anemia, 
leucopenia, nausea, diarrhea, asthenia, rash and anorexia; G3 
drug-related events included lymphopenia (1) and anemia (3). No 
DLT at dose levels 1, 2, and 3; 3 DLT at dose level 4 (G3 anemia 
and repeated blood transfusion within 4-6 weeks). Few dose re-
ductions or interruptions for both drugs were needed. 1P died due 
to pulmonary embolism unrelated to study treatment. 19P were 
evaluated for response: For those not previously treated P, partial 
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Methods: Use of sample size determination software allows for 
comparison of phase II trials with a target survival proportion at a 
given time T based upon Kaplan-Meier (KM) versus exponential (E) 
survival methods. This comparison was made in instances where 
the exponential distribution assumption is valid.
Results: The use of exponential survival fitting methods, in lieu of 
the currently implemented KM trial designs, to single arm phase 
II studies can routinely reduce patient numbers by 25-40% (Table) 
without compromising the statistical power. Another substantial 
advantage is that the variability in the survival information for the 
exponential fit estimate both before and after the median survival 
points is reduced. Since patient accrual is staggered ,this reduced 
variability allows for obtaining robust survival information with 
shorter follow up times T. Any additional follow-up beyond T only 
further improves the E estimate, but not the KM estimate. Thus, 
compared to the KM approach, the E approach will allow us to do 
single arm phase II trials with smaller numbers of patients without 
compromising statistical power. Robust survival estimates can also 
be achieved with shorter follow up periods. 
Conclusion: When conducting single arm phase II clinical trials 
with rare molecular entities of lung cancer, the exponential survi-
val fitting method could replace the current standard approach. 
Robust survival information can be obtained with smaller numbers 
of patients and with shorter survival times. Detailed examples and 
analysis will be presented.
disease progression, patients receive the combination of trastu-
zumab and AUY922.
Results: The study was initiated this year and NSCLC patients are 
screened within the Network of Genomic Medicine Lung Cancer 
on HER2 overexpression, amplifications and mutations. Until now, 
we tested 720 tumor samples by FISH and 63 by genomic sequen-
cing. We identified 55 patients with HER2 amplification, 34 with 
HER2 overexpression (Dako score 3+) and 7 patients showed a 
mutation in the HER2 gene (1 exon 19; 6 exon 20).
Conclusion: HER2 overexpression, amplification or mutation is a 
rare genetic alteration in NSCLC patients. Data on treatment with 
HER2 antibody trastuzumab and HSP90 inhibitor AUY922 will be 
presented.
Keyword: HER2, trastuzumab, AUY922
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P2.11-046 A NOVEL APPROACH TO INCREASE THE EF-
FICIENCY OF SURVIVAL-ENDPOINT PHASE II TRIALS.
George R. Simon1, Michael Schell2, Jongphil Kim3, Gang Han4, Eric 
B. Haura5
1Medical Oncology, MD Anderson/United States Of America, 2Biosta-
tistics, Moffitt Cancer Center/United States Of America, 3Biostatistics, 
H. Lee Moffitt Cancer Center And Research Institute/United States Of 
America, 4Department Of Biostatistics, H Lee Moffitt Cancer Center/
United States Of America, 5Thoracic Oncology, H. Lee Moffitt Cancer 
Center And Research Institute/United States Of America
Background: Lung cancer is the second most common cancer in 
United States. However, new molecular information whether ari-
sing from identification of key mutations, or Next Gen Sequencing 
(NGS) has lead to the fragmentation of this common disease into 
multiple and often very rare molecular subtypes. Even though this 
has enabled us to substantially improve survival in specific mole-
cular subtypes with targeted agents, having sufficient numbers of 
patients to demonstrate the effectiveness of novel targeted thera-
pies for each subtype has therefore become challenging, essenti-
ally impeding progress.
Table: Sample Size Requirements For the Survival Proportion at a Given Time T for the 
Kaplan-Meier and Exponential Estimators T 
HR 0.5 0.67 1 1.5 2 3 4 ∞ 
2.20 54|50 42|39 33|28 26|21 22|18 
19|14
18|13  --|11 
2.00 66|62 55|48 37|35 31|26 26|22 24|18 25|16  --|15 
1.83 81|78 67|61 48|44 36|33 33|28 31|23 35|21 --|19
1.67 112|106 91|83 66|60 51|45 43|38 43|31 47|29 --|26 
1.50 168|161 135|126 98|92 79|69 70|59 64|49 73|45 --|42 
1.40 234|228 187|179 136|130 110|99 96|84 91|70 109|64 60 
1.30 375|363 295|286 218|209 176|159 154|135 153|114 177|105 97
Note: The left- and right-side sample sizes are based on the Kaplan-Meier and Exponential 
Estimators
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P2.11-048 NUTRITIONAL STATUS, BODY SURFACE AND 
SARCOPENIA ARE ASSOCIATED TO DOSE REDUCTION 
AND SEVERE GASTROINTESTINAL TOXICITY RELATED 
TO AFATINIB IN PATIENTS WITH ADVANCED NSCLC
Oscar Arrieta, Martha Cecilia D.L.T. Vallejo, Diego L. Macias, Car-
los Enrique R. Marin, Eleazar O. Macedo, David O. Cortez
Thoracic Oncology Clinic, National Cancer Institute Of Mexico/Mexico
Background: Afatinib, an irreversible tyrosine kinase inhibitor of 
ErbB-family, has shown clinical benefits and prolonged progressi-
on free survival in EGFR mutated patients. Adverse effects related 
to afatinib such as diarrhea, stomatitis and rash can negatively im-
pact on QoL and survival by interrupting treatment. Dose of TKI´s 
of EGFR are fixed regardless of weight or body surface (BS), which 
could affect the severity of treatment related toxicity.
Methods: We prospectively studied patients with advanced Non-
small cell lung cancer (NSCLC ) treated with afatinib in order to de-
termine if malnutrition and clinical factors are associated to higher 
incidence of severe toxicity. This study was approved by Ethics and 
Investigation Committees Prior treatment with afatinib (40mg), 84 
patients was assessed. Nutritional status was assessed by Subjec-
tive Global Assessment (SGA) and muscle volume was determined 
by CT scan analysis using L3 as anatomic landmark (-29 +150 HU). 
Toxicity was obtained during 2 cycles by CTCAE 4.0, severe toxici-
ty is defined as grades 3 and 4.
Results: Mean age was 59.3±14.8 years, 70.2% were women, 
94% had adenocarcinoma, 91.7% had a good performance status 
(ECOG 0-1). Median weight and BS were 59.8±13.4 kg and 1.6±0.21 
m2). Afatinib was indicated as 2nd, 3rd and 4th line of treatment in 
54.8%, 38.1%, and 7.12% of patients, respectively. Sixty percent 
of patients had some grade of malnutrition (SGA B+C). Severe 
diarrhea, mucositis and overall GI toxicity were present in 38.9%, 
28.8% and 57.5% respectively. Fifty percent of patients required 
dose reduction, only 6 patients presented severe diarrhea and 
mucositis simultaneously with no statistical association (p=0.929). 
Factors associated to severe diarrhea, mucositis, overall gastroin-
testinal toxicity and dose reduction are shown in Table 1. Table 1 
Related factors to Afatinib toxicity. 
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P2.11-047 SEQUENTIAL TREATMENT WITH ERLOTINIB 
AND PEMETREXED IN PRETREATED PATIENTS WITH 
LUNG ADENOCARCINOMA.
Ondrej Fiala1, Milos Pesek2, Jindrich Finek1, Lucie Benesova3, Zby-
nek Bortlicek4, Marek Minarik3
1Department Of Oncology And Radiotherapy, Medical School And 
Teaching Hospital In Pilsen, Charles University In Prague/Czech Repu-
blic, 2Department Of Tuberculosis And Respiratory Diseases, Medical 
School And Teaching Hospital In Pilsen, Charles University In Prague/
Czech Republic, 3Center For Applied Genomics Of Solid Tumours (CE-
GES), Genomac Research Institute/Czech Republic, 4Institute Of Biosta-
tistics And Analyses, Masaryk University/Czech Republic
Background: Erlotinib and pemetrexed are novel agents used for 
the treatment of patients with advanced-stage NSCLC. Both are 
frequently used for the treatment of patients after failure of first-
line chemotherapy. Sequential treatment strategies have become 
a very interesting topic in current oncology research. The role of 
sequential treatment in NSCLC has not been elucidated yet. Thus, 
we conducted this retrospective study to compare the efficacy of 
second-line pemetrexed monotherapy followed by third-line erloti-
nib (P-E) to treatment with the reverse sequence (E-P).
Methods: Clinical data of 57 patients with advanced (IIIB/IV) lung 
adenocarcinoma harboring wild-type epidermal growth factor 
receptor (EGFR) gene were analysed. 31 patients were treated 
with P-E and 26 patients with E-P sequence. Genetic testing was 
performed using PCR direct sequencing. The terminations of PFS 
and OS, as well as the estimations of survival probabilities, were 
performed using Kaplan Meier survival curves; all point estimates 
were accompanied by 95% confidence intervals. The differences in 
survival were tested using the log-rank test.
Results: The median progression-free survival (PFS) for patients 
treated with the P-E sequence was 3.6 months compared to 7.8 
months for patients treated with E-P sequence (p=0.029). The 
median overall survival (OS) for patients treated with P-E sequence 
was 7.9 months compared to 26.3 months for patients treated with 
E-P sequence (p=0.006).
Conclusion: The study results proved significant improvement of 
both PFS and OS for patients treated with the E-P sequence as 
compared to the P-E sequence. Although the study was limited, its 
findings could have a great impact on the treatment of advanced-
stage NSCLC. Thus, the role of the sequential treatment of NSCLC 
should be confirmed in a prospective randomised study in the 
future.
Keyword: NSCLC, erlotinib, pemetrexed, sequence, adenocarci-
noma
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P2.12-001 ERLOTINIB AS NEOADJUVANT TREATMENT 
IN PATIENTS WITH STAGE IIIA-N2 NON-SMALL CELL 
LUNG CANCER (NSCLC) WITH ACTIVATING EPIDER-
MAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION 
(NCT01217619, EASTERN): STUDY UPDATE
Baohui Han, Liwen Xiong, Jiayuan Sun, Rong Li, Yuqing Lou, Yan-
wei Zhang, Aiqing Gu, Liyan Jiang, Jianxin Shi, Wentao Fang, Heng 
Zhao
Shanghai Chest Hospital Affiliated To Shanghai Jiaotong University/
China
Background: Approximately 15% of patients with NSCLC are di-
agnosed with stage IIIA-N2 disease, the treatment modalities of 
which are not clearly defined due to its heterogeneous character. 
Patients with stage IIIA N2 NSCLC have poor outcomes with 5-year 
survival rate of approximately 15% after treatment with surgical 
resection or chemo-radiotherapy. Tyrosine kinase inhibitor mono-
therapy as the first line treatment could significantly improve 
tumor response rate and disease progression free survival (PFS) 
for metastatic NSCLC patients with activating EGFR mutation. The 
objective of this trial is to explore the efficacy and safety profile 
of erlotinib as neoadjuvant treatment in patients of stage IIIA-N2 
NSCLC with activating EGFR mutation.
Methods: This is a prospective, single arm, phase II clinical trial. 
Patients with Endobronchial Ultrasound(EBUS) confirmed stage 
IIIA-N2 NSCLC with activating EGFR mutation in exon 19 or 21 will 
be enrolled into the study. All the recruitment patients will be tre-
ated by erlotinib 150mg orally per day for 56 days for neoadjuvant 
period. Patients will be assessed after erlotinib treatment and tho-
se who get response from neoadjuvant therapy and are technically 
resectable will undergo surgery treatment. The adjuvant regime 
is decided by the investigator taking patients’ benefits into consi-
deration. The primary endpoint is radical resection rate. The se-
condary endpoints are pathological complete resection rate(pCR), 
objective response rate(ORR), disease free survival(DFS), overall 
survival(OS), quality of life(QoL) and safety profile. Patients after 
surgery and therapy will receive long-term follow-up including 
regular chest CT and ultrasound examination.
Results: Eighty-eight(88) patients have been screened and 15 pa-
tients have been enrolled since first patients in (FPI) on 30th April, 
2011. Excluded reasons including ineligible pathological diagno-
sis (n=23), ineligible stage (n=36), without EGFR mutation (n=10) 
and poor compliance (n=4). Ineligible stage including T1-3N0M0 
(n=11), T1-3N1M0 (N=8), T1-3N3M0 (N=8), T1-3N2M1 (N=7) and 
T4N2M0 (N=2). 41% patients who were diagnosed with stage 
IIIA-N2 non-small cell lung cancer when in chest CT examinations 
were not in the stage after endobronchial ultrasound(EBUS) , and 
became the main reason for screening failure in this study. Seven 
patients had partial response, 3 patients with stable disease and 2 
patients were still on treatment (DCR 66.6%). 3 patients with pro-
gress disease. Due to active hepatitis and technical infeasibility, 2 
patients with partial disease didn’t receive surgery. However, one 
stable disease patient and five partial response patients (40%) 
received R0 surgery.
Diarrhea 
G3/4 (%) 
Mucositis 
G3/4 (%) 
All GI toxi-
city G3/4 
(%) 
Dose  
reduction % 
Female Male 
p 
44.4 22.2 
p=0.094 
33.3 15.8 
p=0.146 
64.8 36.8 
p=0.034 
59.3 36.8 
p=0.092 
ECOG 0-1 
>1 P 
36.9 57.1 
p=0.419 
24.2 
71.4 
p=0.018 
53.1 100 
p=0.017 
53.0 57.1 
p=0.836 
BMI ≤18.5 
>18.5 P 
47.1 31.6 
p=0.179 
38.5 17.6 
p=0.05 
55.9 59 
p=0.79 
50 56.4 
p=0.584 
Body sur-
face ≤1.7m2 
>1.7m2 p 
40.7 33.3 
p=0.572 
0 38.9 
p=0.001 
36.8 64.8 
p=0.0034 
36.8 59.3 
p=0.092 
Malnutrition 
SGA A SGA 
B+C p 
36.3 29 
p=0.136 
16.1 38.1 
p=0.04 
38.7 71.4 
p=0.005 
32.3 69 
p=0.002 
Hemoglobin 
(mg/dl) 
<12mg/dl 
>12mg/dl p 
68.8 
30.4 
p=0.005 
28.1 31.2 
p=0.804 
50.9 81.2 
p=0.03 
47.4 75 
p=0.05 
GI: Gastrointestinal. SGA : Subjective Global Assessment. ECOG: 
Eastern Cooperative Oncology Group Performance Scale.
Conclusion: The performance status, malnutrition and body sur-
face are independent factors related to severe gastrointestinal 
toxicity to Afatinib. The only independent factor associated with 
dose reduction was malnutrition. This study suggests that for the 
initial dose selection of TKI´s of the EGFR these factors should be 
considered in order to reduce the risk of severe toxicity.
Keyword: Non-small cell lung cancer , Afatinib,Nutritional status, 
Toxicity.
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Conclusion: The overall driver gene positive rate in this series 
detected by Q-PCR is 66.3%. Each type of drive gene corresponds 
to different clinical and pathological features. Patients with ALK or 
RET gene translocations are more younger, and more likely to be 
solid predominant invasive adenocarcinoma. EGFR-mutant group 
has shorter OS than wild-type group among stage IIIB-IV paitents 
without targeting therapy. KRAS mutations implicate poor progno-
sis only in patients with stage IIIA.
Keywords: Driver gene, lung adenocarcinoma, Prognosis
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P2.12-003 POSTOPERATIVE RECURRENCE AND THE 
PERSONALIZED POSTOPERATIVE SURVEILLANCE FOR 
RESECTED LUNG CANCER PATIENTS
Satoshi Shiono1, Naoki Kanauchi2, Masami Abiko1, Toru Sato1
1Department Of Thoracic Surgery, Yamagata Prefectural Central Hospi-
tal/Japan, 2Department Of Thoracic Surgery, Nihonkai General Hospi-
tal/Japan
Background: Half of the patients who have a complete lung cancer 
resection have a recurrence. However, advances in radiographic 
modalities and chemotherapy enable physicians to achieve better 
outcomes for postoperative lung cancer recurrence. Yet, for cases 
with recurrence, postoperative follow-up methods have not been 
adequately assessed and there is currently no evidence-based 
postoperative surveillance method. We evaluated cases with post-
operative recurrence and the personalized postoperative surveil-
lance periods and methods used.
Methods: Follow-up after surgery consisted of a regular outpati-
ent clinic check-up, including physical examination, history taking, 
blood tests, and chest X-ray, which were done three or four times 
per year for five years. During the follow-up period, annual chest 
and brain computed tomography scanning was done. If the pati-
ents were completely followed for 5 years, then surviving patients 
continued to be followed using chest X-ray or CT. Between May 
2004 and December 2011, 547 patients had completely resected 
lung cancers in our institution. We retrospectively reviewed their 
prospectively collected database.
Results: We selected 106 patients (19.4%) who had a postoperative 
recurrence for an analysis of associations between recurrence and 
clinical factors. Regarding pathological stages, 24 of 257 (9.3%) 
with stage IA, 23 of 115 (20.0%) with stage IB, 18 of 61 (29.5%) with 
stage IIA, 10 of 25 (40.0%) with stage, IIB 30 of 50 (60.0%) with sta-
ge IIIA, and 1 of 2 (50.0%) with stage IV developed a recurrence. 
Sixty-eight patients (64%) were found to have a recurrence during 
follow-up surveillance and 38 patients (36%) were found to have 
a recurrence based on symptoms. The median time to recurrence 
was 12 months (1–72 months). Cumulative recurrence rates after 
surgery were 53% at 1 year, 81% at 2 years, and 98% at 5 years. 
Multivariate analysis showed that an advanced stage (stage II-IV; 
p < 0.01) and lymphovascular invasion positive (LVI; p = 0.01) were 
independent factors for earlier recurrence. Comparing those pati-
ents who were advanced stage and LVI positive with those who did 
not have these factors, 90.8% of high-risk patients had a relapse 
and 55.1.% of the other patients had a relapse within 2 years after 
surgery (p < 0.01). Five-year survival after surgery for patients with 
recurrence was 31.6% and 5-year survival after recurrence was 
9.0%. Multivariate analysis showed that recurrence with symptoms 
Conclusion: Neoadjuvant erlotinib therapy might be a promising 
treatment for IIIA-N2 NSCLC patients with EGFR activating mutati-
on. EBUS helps the judgment of mediastinal lymph node metasta-
sis and is better than CT scan.
Keywords: IIIA N2 NSCLC, Tyrosine-kinase inhibitor, neoadjuvant
POSTER SESSION 2 - NSCLC EARLY STAGE  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.12-002 CLINICAL CHARACTERISTICS AND PROGNO-
SIS OF LUNG ADENOCARCINOMA DRIVER MUTATIONS 
FROM CHINESE POPULATION
Yu Dong1, Ying Li1, Bo Jin1, Hong Peng2, Hui Xiong3, Baohui Han1
1Departments Of Pulmonary Medicine, Chest Hospital Affliliated To 
Shanghai Jiaotong University/China, 2Departments Of Propaganda Sec-
tion, Chest Hospital Affliliated To Shanghai Jiaotong University/China, 
3Shanghai Yuanqi Biotechnology Company/China
Background: Driver gene mutation in lung adenocarcinoma varies 
greatly among different populations, and lacks of large sample 
study on Chinese population. The purpose of this study was to 
identify driver gene mutations or translocations, and to evaluate 
their association with clinicopathological features and prognosis in 
Chinese lung adenocarcinoma.
Methods: Gene mutations or translocations were detected by 
fluorescence quantitative PCR in tumor tissues of 762 lung ade-
nocarcinoma patients, including mutations of EGFR, KRAS and 
BRAF, and translocations of ALK and RET. The correlation of gene 
mutations/translocations with clinicopathological features was 
retrospectively analyzed by Chi-square test and logistic regression. 
Kaplan-Meier survival curves were used to evaluate the correlation 
of these genes with disease-free survival(DFS) in 314 patients and 
overall survival(OS) in 564 patients respectively.
Results: In the 762 patients with lung adenocarcinoma, the po-
sitive rate of gene mutations/translocations involving EGFR, 
KRAS, ALK, RET and BRAF was 49.6%, 10.0%, 4.5%, 1.7%, 0.5%, 
respectively, among which there was no mutations of polygenes. 
This study showed that EGFR mutations were more common in 
non-smokers or light smokers, lepidic predominant invasive ade-
nocarcinoma subtype, and patients without distant metastasis. 
KRAS mutations were more common in heavy smokers, mucinous 
invasive adenocarcinoma subtype, and early stage patients. ALK 
translocations were more common in patients younger than 55 ye-
ars old, with solid predominant invasive adenocarcinoma subtypes. 
RET translocations were more common in patients younger than 52 
years old, with solid predominant invasive adenocarcinoma sub-
types and patients who have family history of lung cancer. BRAF 
mutations were more common in mucinous invasive adenocarci-
noma subtype. The survival analysis showed that the median OS 
of EGFR-mutant group was shorter than wild-type group among 
stage IIIB-IV paitents without targeting therapy(P=0.019); Although 
KRAS gene mutations in patients with early stage was not related 
to disease recurrence and survival either, KRAS mutations in stage 
IIIA patients do contribute to shorter DFS and OS(P=0.018, 0.039); 
ALK translocations in each stage subgroup were not related to 
recurrence and survival; Patients with mutations of either EGFR, 
KRAS, or translocations of ALK as a group showed no significant 
difference in DFS and OS as compared to those without involve-
ment of any of these genes.
S919Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 2 - NSCLC EARLY STAGE  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.12-005 RESULTS OF RADICAL TREATMENT OF NON-
SMALL CELL LUNG CANCER PATIENTS WITH A SINGLE 
SYNCHRONOUS METASTASIS
Margriet Kwint1, Chun Chen1, Joost Knegjens1, Haike Peulen1, 
Sjaak Burgers2, Houke Klomp3, Marcel Verheij1, Jose Belderbos1
1Radiation Oncology, The Netherlands Cancer Institute/Netherlands, 
2Pulmonology, The Netherlands Cancer Institute/Netherlands, 3Thoracic 
Surgery, The Netherlands Cancer Institute/Netherlands
Background: Stage IV non-small cell lung cancer (NSCLC) patients 
are considered incurable and mainly treated for palliation. The 
purpose of this study is to investigate the overall survival (OS) and 
disease free survival (DFS) of NSCLC patients, diagnosed with syn-
chronous oligometastatic disease treated with curative intent of 
the intrathoracic disease as well as the metastasis.
Methods: Patients treated between 2008 and 2013 were included 
in this retrospective analysis. Main inclusion criteria were: synchro-
nous presentation of NSCLC and oligometastatic disease at diag-
nosis with only 1 extra-thoracic metastasis, and multidisciplinary 
consent on a radical treatment of both the intrathoracic disease 
and the solitary metastasis. Treatment of the intrathoracic disease 
consisted of radical radiotherapy (> 55 Gy biological effective 
dose) or surgical resection. Treatment of the metastasis consisted 
of radical/stereotactic radiotherapy or surgical resection or radio-
frequency ablation (RFA).
Results: Twenty-two patients, 13 men and 9 women, were inclu-
ded. The mean age was 61 years (range 41-79) and all were in 
good condition (WHO 0-1). The sites of the solitary metastases 
were brain (13), bone (6), liver (1), soft tissue (1) and adrenal gland 
(1). The intrathoracic tumor stage (ignoring M-status) was IA in 2 
patients, IB in 1 patient, IIA in 4 patients, IIB in 1 patient, IIIA in 
8 patients and IIIB in 6 patients. Nineteen patients were treated 
with radiotherapy and 3 patients had a surgical intervention for the 
primary tumor. Eighteen patients (82%) received chemotherapy, 3 
concurrently and 15 sequentially. The metastases were treated with 
ablative/stereotactic radiotherapy (19), surgical intervention (2) 
and RFA (1). The median follow-up was 47 months (95% CI 24-69). 
Seventeen patients developed recurrent disease of whom 12 died. 
Only 2 recurrence occurred within the irradiated area. Both infield 
recurrences were brain metastasis after a stereotactic irradiation of 
15 Gy and 18 Gy. The other recurrences where mostly pulmonary 
(7) and brain metastases (6). The median DFS was 14 months (ran-
ge 1-47, 95% CI 9 – 19) and the median OS was 32 months (95% 
CI 12– 52). The 1- and 2-year OS was 78.7% (95% CI 52.7-91.5) and 
59.5% (95% CI 32.8-78.5), respectively. The 1- and 2-year DFS was 
54.5% (95% CI 30.5-73.2) and 24.9% (95% CI 8.1-46.3), respectively.
Conclusion: Radical treatment of a highly selected group of NS-
CLC patients in good condition presenting with a single synchro-
nous extra-thoracic metastasis resulted not only in adequate local 
control, but also in favorable long-term DFS and OS.
Keywords: Non small cell lung cancer, Oligometastatic disease, 
radical treatment
(p < 0.01) and shorter time to recurrence (< 24 months; p < 0.01) 
were independent prognostic factors after recurrence.
Conclusion: Although this study was retrospective and included 
some biases, advanced stage and LVI positive patients should be 
intensively followed-up. Personalized follow-up programs for re-
sected lung cancer patients should be considered.
Keywords: Lung cancer, Recurrence, surgery, follow-up
POSTER SESSION 2 - NSCLC EARLY STAGE  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.12-004 PERCUTANEOUS CRYOABLATION FOR THE 
TREATMENT OF INOPERABLE STAGE I NON-SMALL 
CELL LUNG CANCER: MID-TERM OUTCOME
Yoshikane Yamauchi1, Masafumi Kawamura2, Hideki Yashiro3, 
Masanori Inoue4, Seishi Nakatsuka3
1Department Of General Thoracic Surgery, Keio University School Of 
Medicine/Japan, 2Teikyo University School Of Medicine/Japan, 3Keio 
University School Of Medicine/Japan, 4Hiratsuka Munincipal Hospital/
Japan
Background: To evaluate the midterm results of percutaneous 
cryoablation for medically inoperable stage I non-small cell lung 
cancer.
Methods: Between January 2004 and June 2010, 160 patients un-
derwent computer tomography guided percutaneous cryoablation 
for lung tumors at our institution. Of these patients, histologically 
proven stage I primary lung cancer patients with more than one 
year of follow-up, were retrospectively reviewed. All of these pati-
ents were considered to be medically inoperable. Follow-up was 
based primarily on computed tomography.
Results: There were 22 patients with 34 carcinoma who underwent 
25 sessions of cryoablation treatment. Complications were pneu-
mothoraces in 7 treatments (28%, chest tube required in one treat-
ment), and pleural effusions in 8 treatments (31%). The observation 
period ranged from 12 to 92 months, average 44±22 months, 
median 38 months. Local tumor progression was observed in two 
carcinomas (3%). Mean local disease progression-free interval 
was 88±8 months. Median local disease progression-free interval 
was not achieved. The overall 3-year survivals were 90.7%. Mean 
overall survival was 88±8 months. Median overall survival was not 
achieved. The disease-specific 3-year survivals were 100%. Mean 
overall survival was 81±14 months. Median overall survival was 
not achieved. The disease-free 3-year survivals were 77%. Mean 
disease-free survival was 64±19 months. Median disease-free 
survival was 89 month. Pulmonary function tests were done in 16 
patients (18 treatments) before and more than 3 months after cry-
oablation. Percentage of predicted vital capacity, and percentage 
of predicted forced expiratory volume in 1 second, did not differ 
significantly before and after cryoablation (93±23 versus 90±21, 
and 70±11 versus 70±12, respectively).
Conclusion: Although further accumulation of data is necessary 
regarding efficacy, cryoablation may be a feasible option in inope-
rable stage I primary lung cancer patients.
Keywords: cryoablation, primary lung cancer
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P2.12-007 PET/CT FINDINGS OF ADENOCARCINOMA 
PATIENTS
Fatma Kutluhan1, Aylin Ozgen Alpaydin1, Cagnur Ulukus2, Nezih 
Ozdemir3, Berna Degirmenci Polack4, Atila Akkoclu1
1Pulmonary Diseases, Dokuz Eylul University Medical Faculty/Turkey, 
2Pathology, Dokuz Eylul University Medical Faculty/Turkey, 3Thoracic 
Surgery, Dokuz Eylul University Medical Faculty/Turkey, 4Nuclear Me-
dicine, Dokuz Eylul University Medical Faculty/Turkey
Background: AIM: New classification of adenocarcinoma subtypes 
cannot be discriminated by PET/CT findings. The aim of this study 
was to evaluate the features of operable adenocarcinoma patients 
according to PET/CT findings.
Methods: Medical records of 49 adenocarcinoma patients to 
whom PET-CT was applied for clinical staging between November 
2009 and December 2011 were evaluated retrospectively.
Results: Mean tumor size was 3,51±1,70 and mean tumor SUV max 
value was 8,18±4,50. Tumor size and tumor SUV max values were 
not different between subtypes. Seventeen of the patients had 
positive and 8 had suspicious positive mediastinal lymph nodes, 
however only 16 of the positive N2 lymph nodes were determined 
to be pathologically positive by mediastinoscopy or thoracotomy. 
Tumor SUV max values were found to be correlated with tumor size 
(r=0,493, p<0,001). The most frequent subtype was unclassified 
(32 patients). The others were mixed (6), acinar (4), lepidic (3), muci-
nous (2), solid (1) and papillary (1) subtypes.
Conclusion: We need studies involving more patients to evaluate 
the differences between PET/CT uptakes of adenocarcinoma sub-
types, although we observed an association with tumor size and 
SUV max values of the adenocarcinomas regardless from the histo-
pathological subtypes.
Keyword: PET/CT, NSCKLC, ADENOCARCINOMA
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P2.12-008 DO PET/CT FINDINGS PREDICT CLINICAL STA-
GING IN NSCLC ?
Fatma Kutluhan1, Aylin Ozgen Alpaydin1, Berna Degirmenci Po-
lack2, Ahmet Onen3, Duygu Gurel4, Atila Akkoclu1
1Pulmonary Diseases, Dokuz Eylul University Medical Faculty/Turkey, 
2Nuclear Medicine, Dokuz Eylul University Medical Faculty/Turkey, 
3Thoracic Surgery, Dokuz Eylul University Medical Faculty/Turkey, 
4Pathology, Dokuz Eylul University Medical Faculty/Turkey
Background: AIM: Staging of lung cancer determines the choice 
for treatment. Currently, PET/CT has been used widely in the sta-
ging NCSLC. We aimed to investigate the changes in clinical sta-
ging of NSCLC patients after PET/CT procedure.
Methods: Clinical and pathological data of 124 operable NSCLC 
patients to whom PET-CT was applied for clinical staging between 
November 2009 and December 2011 were evaluated retrospec-
tively. PET-CT was positive for N2 lymph nodes in 60 of 124 pa-
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P2.12-006 FACTORS IMPACTING THE MANAGEMENT OF 
SOLID LUNG TUMORS BY PERCUTANEOUS RADIOFRE-
QUENCY ABLATION IN NON-SURGICAL PATIENTS
Peter Andrew1, Stephen O‘Connor2, Richard Lee-Ying3, Sandra 
Jerat4
1Internal Medicine, The Ottawa Hospitals/Canada, 2City University/
United Kingdom, 3Tom Baker Cancer Center/Canada, 4Atlas Medical 
Research Inc/Canada
Background: By 2010, the estimated number of percutaneous 
radiofrequency ablation (RFA) procedures to treat solid thoracic 
malignancies approached 150,000 per annum. But limited data 
exists regarding factors that impact local recurrence following 
RFA of solid lung tumors in non-surgical patients. The objective 
of this meta-analysis was to compare pooled estimate data of LTP 
for small (<3cm diameter) versus large (≥3cm diameter) solid lung 
tumors following CT-guided percutaneous RFA. Moreover, sensiti-
vity analyses were used to consider whether lung lobular site (RUL, 
RML, RLL, LUL, lingula, and LLL), histology (primary versus metasta-
tic), and adjuvant chemotherapy modified local tumor recurrence.
Methods: Study design: Based on meta-analysis. Evidence was 
gathered from PubMed, the Cochrane Library, EMBASE, and CAN-
CERLIT databases from January 2000 to December 2012; additional 
interrogation of abstracts from scientific meetings, bibliographies 
of identified studies, and clinical trial registries [e.g., clinicaltrials.
gov] was undertaken in an effort to identify all available evidence. 
Blinded duplicate screening was used to extract data from cap-
tured clinical studies involving patients with non-surgical solid 
lung tumors, both primary and/or metastatic. Aggregate effect 
estimates from constituent studies for single outcome (local tumor 
progression; [LTP]) was the basis for comparing pooled estimates. 
Population: non-surgical patients with solid lung tumors, either 
primary and/or metastatic. Intervention: RFA +/- PAC. Compara-
tors: small (<3cm diameter) versus large (≥3cm diameter) tumors. 
Outcomes: LTP at 1 year follow-up; sensitivity analyses for tumor 
location in lung lobules, tumor histology, and post ablation chemo-
therapy (PAC).
Results: Pooled estimate analysis involved 87 small tumors versus 
96 large tumors; 106 primary versus 48 metastatic. LTP 6% for small 
tumors versus 19% for large tumors following percutaneous RFA 
at 1 year follow-up; odds ratio (OR) 4.7 (95% CI: 1.5-14.9, p=0.009). 
Tumor location and histology did not significantly perturb LTP 
(p>0.1). RFA plus PAC yielded LTP of 15% over median follow-up of 
31 months [range 12 to 59]) whereas RFA alone yielded 19% over 
median follow-up of 21 months [range 12 to 29]); OR 0.73 (95% CI: 
0.61-0.86, p<0.05) at 1 year follow-up.
Conclusion: RFA is a relatively new tool for local control of solid 
lung tumors. To our knowledge, our meta-analysis is the first to 
purposely demonstrate factors that impact the management of 
solid lung tumors by percutaneous RFA in non-surgical patients. 
Our pooled analysis revealed that locoregional control of lung ma-
lignancy by percutaneous RFA is most effective for tumors <3cm in 
diameter, is independent of lung lobular site and tumor histology, 
but is optimized with a therapeutic strategy of RFA plus PAC. Pa-
tients most likely to benefit from a RFA plus PAC strategy would 
be non-surgical candidates with solid lung tumors that have a rela-
tively good performance status and could tolerate RFA plus PAC.
Keywords: radiofrequency, ablation, Meta-analysis, Lung cancer
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Results: ACT was applied to 104 eligible patients (72 men, 32 wo-
men, median of age 64 years). Out of them 41 were smokers, 57 
ex-smokers and 5 non smokers. Surgically determined stages were 
IB in 32 pts, II in 36 pts and IIIA in 36 pts. Altogether 399.5 cycles 
(mean no 3.82) were administered, 86,5 % of patients finished four 
cycles of planned ACT. The reasons for 14 (13.5%) patients ending 
ACT prematurely were hematological toxicity in 8 pts, non-hema-
tological toxicity in 3 pts, other reasons in 3 pts . Relative dose 
intensity (RDI) was 80.8% for vinorelbine and 95.4% for CBDCA. 
The most frequent WHO grade 3/4 of toxicity were neutropenia 
in 10.6%, leucopenia in 5.6%, anemia in 1.3%, thrombocytopenia 
in 1.3%, alopecia in 3.3%, nausea in 4.8%, neurotoxicity, nephro-
toxicity, diarrhoea and mucositis in 0.3%. During the median of 
follow-up period, 45 (43.2%) pts died and 38 (36.5%) out of them 
died on lung cancer. Median DFS was 29.1 months, 2-year survival 
was 70.6%, 2.5-year survival was 63.9%. Predictors of significantly 
better DFS and 2.5 year survival were stage IB (p = 0.0045) and 
lobectomy (p = 0.0465). Trend of better DFS and 2.5 year survival 
was observed in cases without angioinvasion and pleural invasion.
Conclusion: Applied ACT had excellent tolerability, high RDI was 
achieved and preliminary parameters of survival are acceptable. 
Study is ongoing and long term survival results will be evaluated in 
the future. This study was supported by Grant NT- 13569 and NS-
9959-3 of the Czech Ministry of Health
Keyword: NSCLC - adjuvant chemotherapy - vinorelbine
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P2.12-010 DOES PRESENCE OF CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE (COPD) INFLUENCE CLINICAL 
BEHAVIOR IN PATIENTS WITH EARLY STAGE NON-
SMALL CELL LUNG CANCER (ES-NSCLC)?
Satomi Yamamoto1, Taro Tamura2, Akihide Matsumura3, Shinji 
Atagi4, Masanori Kitaichi5, Tomoya Kawaguchi1, Kazuto Hirata6
1Dept Of Internal Medicine, Kinki Chuo Chest Medical Center/Japan, 
2Dept Of Environmental Health, School Of Medicine, University Of Fu-
kui/Japan, 3Dept Of Surgery, Kinki Chuo Chest Medical Center/Japan, 
4Clinical Research, Kinki-Chuo Chest Medical Center, Sakai/Japan, 
5Dept Of Pathology, Kinki Chuo Chest Medical Center/Japan, 6Respirato-
ry Medicine, Osaka City University/Japan
Background: CDPD and lung cancer sometimes occurs simulta-
neously. COPD has been recognized as an inflammatory disease 
mainly by smoking effects and may potentially affect biology of the 
accompanying tumor. It is not fully understood whether presence 
of CDPD influences clinical characteristics, pathological findings 
and/or clinical outcomes in patients with operable ES-NSCLC.
Methods: Retrospective and consecutive data were collected from 
the medical records of patients who underwent surgical resec-
tions of lung cancer at Kinki-chuo Chest Medical Center, Japan, 
between January 2009 and December 2010. CDPD status was 
classified as absence of COPD, stage I and II COPD based on the 
criteria of Global Initiative for Chronic Obstructive Lung Disease 
(GOLD2009). Histology, vascular / lymphatic invasion and the sta-
tus of epidermal growth factor receptor (EGFR) were determined 
using the surgical materials.
Results: A total of 319 surgical cases was included in this study 
with median age of 67 (range, 36 - 89). There were 81 cases of 
tients. Thirty of them underwent mediastinoscopy, 4 underwent 
mediastinotomy and 2 underwent thoracotomy and the remaining 
24 were operated without any prior invasive procedure for the 
evaluation of mediastinal lymph nodes. Among the 64 PET/CT 
negative patients 59 were directly operated, 4 underwent medias-
tinoscopy and 1 to thoracotomy.
Results: Stage 3A was the most frequent stage in both clinical and 
pathological staging. T staging was the same for both clinical and 
pathological stages in 48%of the patients, while this was 58% for 
mediastinal lymph nodes. Overall clinical and pathological stages 
were the same in 42% of the patients, while in 34% clinical staging 
was lower and in 24% higher than the pathological staging. The 
most compliant stage between clinical and pathological stages 
was 1A while the least one was stage 1B.
Conclusion: Clinical staging with the assistance of PET/CT was 
observed to be moderate compliant with pathological staging 
in most of the patients. Therefore, clinical staging with PET/CT 
should not replace pathological staging in NSCLC
Keyword: PET/CT, NSCLC
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P2.12-009 ADJUVANT CHEMOTHERAPY WITH ORAL VI-
NORELBINE USED IN DOUBLET WITH CARBOPLATIN IN 
NON-SMALL CELL LUNG CANCER AFTER RADICAL RE-
SECTION - TOLERABILITY AND SHORT TERM SURVIVAL.
Vitezslav Kolek1, Ivona Grygarkova1, Jiri Chalupa2, Leona Koub-
kova3, Tereza Janaskova4, Jaromir Roubec5, Dimka Sixtova6, Jana 
Skrickova7
1Department Of Respiratory Medicine, University Hospital/Czech Re-
public, 2Oncology, Hospital Liberec/Czech Republic, 3Pneumology, Praha 
Motol/Czech Republic, 4Pneumology, Hospital Vitkovice/Czech Repub-
lic, 5Pneumology, Hospital Ostrava/Czech Republic, 6General Hospital 
Praha/Czech Republic, 7Pneumology, University Hospital/Czech Repu-
blic
Background: Adjuvant cisplatinum-based chemotherapy is recom-
mended for routine use in patients with stages IIA, IIB, and IIIA of 
non small-cell lung cancer (NSCLC) after radical resection. Results 
in stage IB were not conclusive. Vinorelbine is a preferable drug 
in this indication and a randomized study proved the comparable 
effectiveness and tolerability of vinorelbine given both orally or 
intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine 
gives better comfort to patients. Only few studies evaluated the 
position of vinorelbine in doublet with carboplatin (CBDCA) none 
of them used oral vinorelbine in this doublet as adjuvant chemo-
therapy (ACT).
Methods: This prospective multicentre study evaluates the feasibi-
lity, toxicity and short time survival of ACT based on CBDCA (AUC 
5) with oral vinorelbine after radical resection. Vinorelbine was 
applied orally 80 mg/m2 D1 and D8 after the first cycle of 60mg/
m2. ACT (4 cycles of 21 day regimen) was applied to patients with 
stage IB, II, and IIIA of NSCLC (6th TNM revision) in 16 centres. The-
rapy was applied from the 1st of April 2009 to the 28th of February 
2010. Median of follow-up period was 31 months Histology of 
tumor, type of surgery, grading, visceral pleura and angio-invasion 
were evaluated as potencial predictors of survival.
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On multivariate analysis, older age, tumor size, and squamous his-
tology predicted for higher rates of any failure (p=0.034, <0.001, 
0.016, respectively). Conversely, larger absolute reduction in 
SUVm post-SBRT predicted for improved rates of disease control 
(p=0.005). Median OS was 14.65 months. On multivariate Cox pro-
portional hazards analysis of predictors of overall survival, higher 
pre-SBRT SUVm, larger size, squamous cell histology, and staging 
mediastinoscopy predicted for worse OS (all p<0.05).
Conclusion: PET is a powerful tool in the work-up of newly diag-
nosed NSCLC. SUVm values appear to also have prognostic impor-
tance, as absolute change in SUVm after SBRT predicts for failure 
and pre-SBRT SUVm predicts for overall survival.
Keywords: NSCLC, SBRT, PET, survival
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P2.12-012 PROGNOSTIC IMPACT OF VISCERAL PLEURAL 
INVASION IN RESECTED TUMORS OF NON-SMALL CELL 
LUNG CANCER
Kenji Sugio, Michiyo Miyawaki, Takafumi Hashimoto, Yohei Ta-
kumi, Shuji Suehiro
Department Of Thoracic And Breast Surgery, Oita University/Japan
Background: A standardized definition of visceral pleural invasion 
(VPI) has been incorporated into the 7th edition of TNM, and the 
recommendations include the use of elastic stains to determine 
the VPI. PL0, defined as a lack of pleural invasion beyond the elas-
tic layer, is not regarded as a T factor. In tumors of 3 cm or less, 
PL1 was defined as invasion beyond the elastic layer, and PL2 was 
defined as invasion to the surface of the visceral pleura, both of 
which are classified as indicators of T2 disease. The purpose of this 
retrospective study was to evaluate the validity of this definition.
Methods: We retrospectively reviewed 493 NSCLC patients with 
pathological N0M0 with a size of 5 cm or less with PL0-2 who un-
derwent curative resection by lobectomy or segmentectomy bet-
ween 1999 and 2013. We evaluated the disease-free survival (DFS) 
and overall survival (OS) in relation to the grade of VPI.
Results: The median follow-up for overall survival was 39 months 
after the operation. There were 282 males and 211 females inclu-
ded in the study. The age of the patients ranged from 31 to 90 
years, with a mean of 69 years old. There were 347 patients in sta-
ge IA and 146 in Stage IB, and the histological type was adenocar-
cinoma in 374 patients (75.8%), squamous cell carcinoma in 91 pati-
ents (18.4%) and others in 28 patients (5.8%). The 5-year survival 
rates by PL grade were as follows: 85.0% for PL0 (n=425), 73.3% for 
PL1 (n=50) and 70.8% for PL2, respectively. In patients with tumors 
3 cm or less in diameter, the 5-year survival rates and 5-year DFS 
rates were as follows: 87.9% and 88.2% for PL0 (n=342), 71.6% and 
86.9% (n=30) for PL1 and 90.7% and 80.0% (n=11) for PL2, respec-
tively. The 5-year survival rate of cases with PL0-T2a (> 3 cm, ≤ 5 
cm) was 71.2%, and that for PL1-T2a was 71.6%, which did not differ 
significantly. Postoperative recurrence was observed in 47 patients 
(9.5%). Distant metastases were observed in 3.1% of PL0 patients, 
10.0% of PL1 patients and 11.1% of PL2 patients, which showed 
significant difference between PL0 and PL1/2. However, no diffe-
rence was found in the local recurrence rates between PL0 and 
PL1/2 patients.
relapse and 40 cases of death during the median follow up of 28 
months (11 days to 49 months). According to the subgroups of no 
COPD, stage I and II COPD, the median age, the number of case 
in gender (male/female), performance status (PS, 0/1), histology 
(squamous cell carcinoma [SQ] /non SQ), smoking status (never/
ever), and EGFR status (wild type/mutant) were as follows respec-
tively; 67, 72, 72 (p<0.001) and 105/110, 48/12, 38/6 (p<0.001) and 
170/40, 53/7, 27/14 (p=0.029) and 31/184, 12/48, 14/28 (p<0.001) 
and 89/122, 7/53, 2/39 (p=0.002) and 47/37, 21/3, 9/3 (p=0.013), re-
spectively. No significant difference was observed in disease-free 
survival (DFS, log-rank p=0.411) and overall survival (OS, log-rank 
p=0.127) between the patients with and without COPD. In multi-
variate analysis adjusted for age, gender, PS, histology, smoking 
status, pathological stage, vascular / lymphatic invasion and EGFR 
status, presence of COPD did not affect DFS (HR=1.457, p = 0.279) 
nor OS (HR=0.993, p = 0.990).
Conclusion: Although COPD was significantly associated with the 
elderly, male gender, presence of symptoms, SQ histology, ever 
smoking, and wild type EGFR, it did not add values of prognostic 
factors in patients with operable ES-NSCLC.
Keywords: chronic obstructive pulmonary disease, surgical resec-
tion, non-small cell lung cancer
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P2.12-011 PRE-RADIOTHERAPY PET SUV MAXIMUM 
PREDICTS FOR OVERALL SURVIVAL IN PATIENTS WITH 
EARLY-STAGE NSCLC TREATED WITH STEREOTACTIC 
BODY RADIATION THERAPY
Brandon R. Mancini1, Nicholas J. Giacalone2, Sanjay Aneja1, Charles 
E. Rutter1, Zain A. Husain1, Roy H. Decker1
1Department Of Therapeutic Radiology, Yale School Of Medicine | Yale 
University/United States Of America, 2Vanderbilt School Of Medicine | 
Vanderbilt University/United States Of America
Background: The prognostic importance of positron emission 
tomography (PET) standardized uptake value maximum (SUVm) 
scores for patients with early stage non-small cell lung carcinoma 
(ES-NSCLC) treated with stereotactic body radiotherapy (SBRT) is 
unclear. This study aims to address this uncertainty.
Methods: Records of patients diagnosed with ES-NSCLC and 
treated with SBRT between September 2007 and May 2012 were 
retrospectively reviewed. Mediastinoscopy was used to stage pa-
tients with synchronous primary lesions, centrally located lesions, 
and those larger than 3 cm. SBRT was delivered via 3-5 fractions 
to a dose of 40-60 Gy, with the vast majority of patients receiving 
54 Gy in 3 fractions. Univariate and multivariate Cox proportional 
hazards analyses were used to compare disease progression and 
overall survival on the basis of pre- and post-SBRT SUVm, absolute 
change in SUVm, age, tumor size, and histology.
Results: 127 patients with a median follow-up of 14 months were 
identified. Median age was 73.9 years and 54% were male. Histolo-
gy was adenocarcinoma in 39%, squamous cell carcinoma in 20%, 
unspecified NSCLC in 20%, and unbiopsied in 21%. Pre-SBRT PET 
was available in 98% and median pre-SBRT SUVm was 4.8. Post-
SBRT PET was performed in 33% and median post-SBRT SUVm 
was 2.3. SUVm declined by a median of 3.7 units post-SBRT. There 
were 5, 4, and 12 local, regional, and distant failures, respectively. 
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Results: Between July 2006 and June 2012, 206 patients under-
went surgical resection, with a median follow-up of 30 months. 
Median age was 69 years (range 46–84), with a male:female ratio 
of 65 vs 35%. There were 113 (55%), 52 (25%) and 39 (19%) stage 
I, II and III tumours respectively. One patient had a pathologic 
complete response to neoadjuvant chemoradiotherapy. Adjuvant 
chemotherapy was delivered to three (3%), 20 (39%) and 28 (72%) 
patients with stage I, II and III disease respectively. Nine of 39 
(23%) stage III patients received adjuvant radiotherapy. 73 of 206 
(35%) patients relapsed at a median of 10.5 months from surgery 
(range 0.7–46.4). A further 15 (7%) patients were diagnosed with 
new primary lung cancers and four (2%) with second, non-pulmo-
nary malignancies. Relapses were more frequent in patients with 
higher stage tumours (Table 1). Of the patients receiving adjuvant 
or neoadjuvant chemotherapy, 55% developed recurrent disease. 
Among patients who recurred, 46 (63%) were symptomatic, with 
32 of these (70%) requiring emergency or early clinical reviews. 
In contrast, new primary tumours were significantly more likely to 
be detected on routine surveillance imaging (87% vs 29% of re-
currences, p=0.0001). One-year post-relapse survival was 40% for 
disease recurrences vs 53% for new primary lung cancers. 
 
Conclusion: The goals of routine surveillance imaging following 
curative treatment of NSCLC are two-fold; early detection of: 
1) asymptomatic disease recurrence and, 2) new primary lung 
cancers. Our data demonstrate that the majority of disease recur-
rences are symptomatic at the time of diagnosis, thus negating 
the value of routine imaging. In contrast, the high proportion 
of asymptomatic new primary cancers detected on surveillance 
imaging supports this approach for patients fit for curative-intent 
treatment.
Keywords: follow-up, NSCLC
Conclusion: The grade of VPI defined by the TNM 7th edition is 
reasonable. Namely, PL1 indicates visceral pleural invasion, and 
can be regarded as T2a disease.
Keywords: TNM staging, visceral pleural invasion, non-small cell 
lung cancer, Prognosis
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P2.12-013 PATTERNS OF RECURRENCE FOLLOWING 
SURGICAL RESECTION OF STAGE I-III NON-SMALL CELL 
LUNG CANCER (NSCLC)
Hui-Li Wong1, Betty Zhang1, Richard De Boer2, Phillip Parente1, 
Phillip N. Antippa3, Dishan Gunawardana2, Andrew Barling4, Ra-
chel Wong1
1Department Of Medical Oncology, Eastern Health, Monash Universi-
ty, Faculty Of Medicine, Nursing And Health Sciences, Eastern Health 
Clinical School/Australia, 2Department Of Medical Oncology, The Royal 
Melbourne Hospital/Australia, 3Department Of Cardiothoracic Surgery, 
Royal Melbourne Hospital/Australia, 4Department Of Cardiothoracic 
Surgery, Eastern Health/Australia
Background: Despite receiving curative treatment, a significant 
proportion of patients with locoregional non-small cell lung cancer 
(NSCLC) will develop recurrent disease. The role of routine surveil-
lance imaging following curative treatment remains controversial, 
as there is no definitive evidence that early detection and treat-
ment of asymptomatic metastases improves survival. The aim of 
this study was to explore the patterns of recurrence in stage I-III 
NSCLC patients treated in routine clinical care.
Methods: Retrospective analysis of 218 patients across two tertia-
ry centres in Melbourne, Australia, who underwent surgical resec-
tion of stage I-III NSCLC over a 5-year period. Patients who died 
within 30 days of surgery or with no follow-up data were excluded. 
Clinicopathologic, treatment and outcome data were collected.
Table 1 – Clinicopathologic features and patterns of relapse in 206 patients with resected stage I-III NSCLC1
Total N 
Disease-
free n 
(%)
Relapsed NSCLC n (%)
New primary 
lung cancer n 
(%)
TOTAL 206 104 (51%) 73 (35%) 15 (7%)
Stage 0 I II III 
1 113 52 
39
1 (100%) 
70 (62%) 
21 (40%) 
10 (26%)
0 25 (22%) 21 (40%) 25 
(64%)
0 10 (9%) 2 (4%) 
3 (8%)
Chemotherapy receipt Yes No 53 145
17 (32%) 
84 (58%)
29 (55%) 42 (29%) 3 (6%) 12 (8%)
Histology Adenocarcinoma Squamous cell 
Large cell Other 
112 57 15 
21
53 (47%) 
32 (56%) 
6 (40%) 
13 (62%)
41 (37%) 18 (32%) 8 (53%) 
6 (29%)
9 (8%) 5 (9%) 1 
(7%) 0
Method of relapse detection2 Routine ima-
ging Symptomatic 
34 51 N/A N/A 21 (62%) 46 (90%) 13 (38%) 2 (4%)
1Data for second non-pulmonary malignancies not shown 2Method of relapse detection not documented in six pati-
ents 
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Table 1 – Clinicopathologic features in total and brain relapse 
populations
Total population 
N Brain relapse n (%)
TOTAL 206 22 (11%)
Median age (yrs) 69 (46-84) 69 (50-84)
Sex M F 134 72 15 (11%) 7 (10%)
Stage 0 I II III 1 113 52 39
0 7 (6%) 7 (13%) 8 
(21%)
Histology Ade-
nocarcinoma Squa-
mous cell Large 
cell Other
112 57 15 21
16 (14%) 0 3 (20%) 3 
(14%)
Chemotherapy 
Adjuvant Neoadju-
vant None
50 3 145
6 (12%) 1 (33%) 14 
(10%)
Radiotherapy 
Adjuvant Neoadju-
vant None
12 2 185 5 (42%) 0 16 (9%)
Conclusion: In this small retrospective series, the majority of pa-
tients who developed brain metastases after curative treatment 
for NSCLC were symptomatic at the time of relapse. Post-relapse 
survival was worse in patients with coexistent extracranial disease. 
None of the incidentally detected asymptomatic brain metastases 
could be treated curatively, suggesting a limited role for including 
brain imaging in routine surveillance for resected NSCLC.
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P2.12-015 INVESTIGATION OF THE FDG PET-DERIVED 
TOTAL GLYCOLYTIC ACTIVITY (TGA) AS PROGNOSTIC 
TOOL IN PATIENTS WITH EARLY STAGE RESECTED 
NON-SMALL CELL LUNG CANCER
Maria Werner-Wasik1, Sarah Hegarty1, Mark Ashamalla1, Ewa 
Strus1, Sarah Pirozzi2, Benny Weksler3, Nathaniel Evans1, Scott 
Cowan1, Aaron Nelson2, Dennis Nelson2, Rita Axelrod1, Barbara 
Campling1, Carey Myers1, Charalambos Solomides1
1Thomas Jefferson University/United States Of America, 2Mimsoftware 
Inc./United States Of America, 3University Of Pittsburgh Medical Cen-
ter/United States Of America
Background: While the maximum standardized uptake values (SUV 
max) on the preoperative positron emission tomography (FDG 
PET-CT) have been associated with tumor recurrence in patients 
(pts) with resected early stage non-small cell lung cancer (ES-NS-
CLC), we investigated the prognostic role of tumor volume, using 
the Total Glycolytic Activity (TGA).
Methods: Pts with resected ES- NSCLC and single primary tumors 
without intrathoracic dissemination, staged with FDG PET-CT 
scans from 2006-2011 were included. Anonymized images of tu-
mors were contoured with a commercially available semi-automatic 
gradient-based tool in order to derive the Metabolic Tumor Volu-
me (MTV) and the SUV max/mean. The TGA (a product of the MTV 
and the SUV mean), was calculated. Patient-related, PET-derived 
and pathologic tumor characteristics were evaluated in univariable 
Cox proportional hazards models for association with Disease Free 
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P2.12-014 BRAIN METASTASES FOLLOWING SURGICAL 
RESECTION OF STAGE I-III NON-SMALL CELL LUNG 
CANCER (NSCLC)
Betty Zhang1, Andrew Wirth2, Rachel Wong1, Phillip Parente1, 
 Dishan Gunawardana3, Richard De Boer3, Phillip N. Antippa4, 
Andrew Barling5, Hui-Li Wong1
1Department Of Medical Oncology, Eastern Health, Monash Universi-
ty, Faculty Of Medicine, Nursing And Health Sciences, Eastern Health 
Clinical School/Australia, 2Department Of Radiation Oncology, Peter 
MacCallum Cancer Centre/Australia, 3Department Of Medical Onco-
logy, The Royal Melbourne Hospital/Australia, 4Department Of Cardi-
othoracic Surgery, Royal Melbourne Hospital/Australia, 5Department Of 
Cardiothoracic Surgery, Eastern Health/Australia
Background: The brain is a common site of relapse following cu-
rative treatment of stage I-III non-small cell lung cancer (NSCLC). 
Retrospective series estimate actuarial risk of brain recurrence at 
~10% for stage I-II and ~30% for stage III tumours. Possible risk 
factors are young age, non-squamous histology and higher tu-
mour/nodal stage, with survival typically dictated by the presence 
of extracranial disease. The aim of this study was to review pat-
terns and treatment of brain metastases in patients with relapsed 
stage I-III NSCLC.
Methods: Retrospective analysis of 218 patients with surgically 
resected stage I-III NSCLC at two tertiary centres in Melbourne, 
Australia over a 5-year period. Patients who died within 30 days 
of surgery or with no follow-up data were excluded. Treatment 
and outcome data for patients who subsequently developed brain 
metastases are reported.
Results: 206 eligible patients underwent surgical resection bet-
ween July 2006 and June 2012. None received prophylactic cranial 
irradiation. At a median follow-up of 30 months, 73 (35%) patients 
had relapsed. Twenty-two (30%) had intracranial metastases, ten 
with brain-only metastases at the time of relapse. The other 12 had 
concurrent extracranial disease. Median time to brain relapse was 
7.7 months (range 0.7-38.6). The incidence of brain relapse incre-
ased with higher stage: 6%, 13% and 21% of patients with stage I, 
II and III disease respectively (Table 1). Relapses occurred at a me-
dian of 10.9 (stage I), 8.8 (stage II) and 6.4 (stage III) months from 
surgery. Brain metastases were noted more frequently in patients 
with adenocarcinoma. Although 18/57 patients with squamous cell 
histology relapsed, none were noted to have intracranial metasta-
ses. In five patients, asymptomatic brain metastases were detected 
on routine surveillance imaging and treated with palliative whole-
brain radiotherapy. Three of the five had coexistent extracranial 
disease and died within four months of relapse. The other two had 
brain-only metastases and remain alive at nine and 16 months from 
relapse. For all patients, one-year survival following diagnosis of 
brain metastasis was higher in those with brain-only disease (50%) 
compared to those with concurrent extracranial metastases (9%).  
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Methods: Between Jan.2006 and Jun.2012, 419 cases of lung ade-
nocarcinoma presented as SPN underwent completely resection 
in our hospital. Of which, we identify 216 cases that follow-up for 
more than 1-year and assigned to three group according to pN 
status and recurrence. Group A, 49 cases with pathological diag-
nosis of lymphatic metastasis; Group B, 23 pN0 cases with early re-
currence; Group C, 144 pN0 cases have no recurrence or metasta-
sis; Group D, combine Group A and B. All the pN0 patients in this 
study have not received adjuvant therapy. Chi-square test is used 
to analyze each factors’ difference. Multivariate logistic regression 
analysis was used to identify independent factors.
Results: Incidents of preoperative elevated CEA, Poorly differen-
tiated of cancer cells, vascular invasion in Group A, B and D were 
significantly higher than those of Group C. Besides, tumor size 
>2cm were frequently observed in Group A(p<0.001). And more 
males in group D than in group C. See Table-1. Tumor size, cancer 
cell differentiation and vascular invasion identified as independent 
factors by multivariate logistic analysis.
Conclusion: cT1pN0 Stage I lung adeocarinoma patients with 
male, preoperative elevated CEA, poorly differentiated cancer 
cells, vascular invasion were associated with early failure. Adjuvant 
therapy in patients with these factors need further study.
Keywords: Adenocarcinoma, Lung cancer, Recurrence, surgery
Survival, DFS. Factors significantly associated with DFS were inclu-
ded in multivariable models with either TGA or SUV max. Akaike 
Information Criterion (AIC) was used to compare the fit of the mo-
dels. LogTGA was used due to a skewed distribution.
Results: 170 pts with 121 PET scans were initially identified; 76 
images were uploadable and 13 pts were excluded (1, small-cell 
lung cancer; 12, biopsy), leaving 63 analyzable pts. Median age 
was 69 (50-87) and 46% were males. Average time from FDG PET 
to surgery was 39 days (0-152). There were 55 (87 %) lobectomies/
pneumonectomies and 8 (13%) wedge resections. Tumor histo-
logy was: 42 (66.7%) adenocarcinoma; 13 (20.6%) squamous cell 
carcinoma (SCCa); 4 (6.3%) adenosquamous (ASCa); 4 (6.3%) large 
cell (LCCa). Median tumor largest dimension was 2 cm (0.7-10.0); 
12 (21.1%) tumors had lymphovascular invasion; 10 (18.5%) were 
node-positive (10 [17.2%] N1 and 2 [3.4%] N2); 3 pts had positive 
resection margin. Adjuvant treatment was given to 15 (24%) pts (13, 
chemotherapy; 4, radiation therapy). Median follow-up (FU) time 
was 32.2 months (mo) (0-83.8). Eighteen pts experienced disease 
progression and the first failure sites were: local (2); regional (4) 
and distant (16). Mean time to recurrence was 23.8 mo (median 
time, not reached) and 14 pts died. Median survival time (ST) was 
not reached; mean ST was 46.3 mo. Median MTV, median SUV 
max, median SUV mean and median TGA were as follows: 3.48 
cc (range: 0.72-110.43); 6.25 (1.24-29.04); 3.56 (0.84-12.55); 10.22 
(1.68-723.66). In univariable analysis, ASCa and LCCa were signifi-
cantly (p = 0.011) associated with recurrence, compared to SCCa, 
and increasing logTGA showed a trend (p=0.12) for worse DFS. In 
multivariable analysis, log TGA and SUV max failed to reach sta-
tistical significance (p = 0.167 and 0.445, respectively); however, 
the log TGA model was found to fit the data slightly better than 
the SUV max model (AIC = 131.2 vs. 132.5, respectively). In the log 
TGA model, pts with ASCa and LCCa were 7.6 times more likely to 
have recurrence than those with SCCa (p = 0.04).
Conclusion: ASCa and LCCa histologies were associated with wor-
se DFS . Log TGA may be a more informative measure for disease 
free survival than SUV max; however, further study of a larger size 
is needed.
Keywords: Total Glycolytic Activity, non-small cell lung cancer, 
resected lung cancer, PET scan
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P2.12-016 PREDICT FOCTORS OF LYMPHATICS METAS-
TASIS OR EARLY DISTANT AND REGIONAL FAILURE  
AFTER COMPLETE RESECTION IN CT1 LUNG  
ADENOCARCINOMA
Xiang-Chan Hong1, Xue-Ning Yang2, Xin-Yue Wang2, Jun-Xiong 
Liao2, Lu-Wen Ren2
1Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong 
General Hospital & Guandong Academy Of Medical Sciences/China, 
2Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong 
General Hospital& Guangdong Academy Of Medical Sciences/China
Background: cT1 lung cancer presented as solitary pulmonary 
nodule(SPN) tends to be stage I disease. Nevertheless, early recur-
rences were observed in these patients. The purpose of this study 
is to identify clinicopathological factors associated with early failu-
re in cT1 adenocarcinoma after complete resection.
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P2.12-018 BRAIN METASTASES AS A FIRST SITE OF 
RECURRENCE IN SURGICALLY RESECTED NON-SMALL-
CELL LUNG CANCER
Won Jin Chang, Moon Ki Choi, Jung Yong Hong, Moonjin Kim, Su 
Jin Lee, Silvia Park, Sungmin Kim, Ji Yun Lee, Sung Hee Lim, Jong-
Mu Sun, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Division Of Hematology-Oncology, Department Of Medicine, Samsung 
Medical Center/Korea
Background: With improved survival after multimodality treatment 
in surgically resected non-small-cell lung cancer (NSCLC), the 
incidence of brain metastases as a first site of recurrence has in-
creased. We analyzed the characteristics and prognostic factors in 
patients with postoperative brain metastases as a first site of relap-
se in surgically resected NSCLC, focusing on difference between 
patients with brain only metastases (B) and patients with brain and 
extracranial systemic metastases (BS) simultaneously.
Methods: We retrospectively analyzed patients with surgically 
resected NSCLC at Samsung Medical Center (SMC) between 2004 
and 2010. Clinicopathological parameters and prognostic factors 
between two groups (brain only metastases vs brain and extracra-
nial sites) were reviewed. Interval to brain metastases as a first site 
of relapse after surgery and overall survival after brain recurrence 
was calculated.
Results: Of the 3134 patients with surgically resected NSCLC, 106 
(3.4%) patients developed postoperative brain metastases as a 
first site of recurrence. Among them, 73 patients (2.3%) relapsed 
in B and 33 patients (1.1%) were in BS simultaneously. Median time 
to brain metastases as a first site of relapse after surgery was 11 
months (range 0-54 months). Most common histologic subtype 
was adenocarcinoma (n=65, 61.3%) and large number of patients 
had IIIa disease (n=56, 52.8%). Single brain metastases were ob-
served in 42 patients (39.4%) and local treatments were performed 
in 102 patients (96.2%). The baseline characteristics between two 
groups (B vs BS) were not significantly different. Among 73 (brain 
only), 8 patients (11%) received systemic treatment as well as local 
treatment and 16 patients (21.9%) developed extracranial systemic 
metastases after brain relapse. The median interval time to ext-
racranial systemic metastases after brain relapse was 10 months 
(range 0-27 months). The overall survival following B and BS was 30 
months and 13 months, respectively (P=0.004). Significantly favora-
ble prognostic factor for survival in patients with brain only meta-
stases included single brain metastases whereas adenocarcinoma 
was associated with good prognosis in patients with BS.
Conclusion: Our results suggested that brain metastasis is com-
mon site of metastasis after surgery and patients who develop 
brain only metastases after curative resection of NSCLC show favo-
rable prognosis with local treatment.
Keyword: brain metastases , first site of recurrence , brain only 
metastases, brain and extracranial systemic
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P2.12-017 CLINICAL IMPACT OF DYNAMIC CONTRAST-
ENHANCED CT IN STAGE IA NON-SMALL CELL LUNG 
CANCER: NET ENHANCEMENT IS AN INDEPENDENT 
PREDICTOR OF RECURRENCE.
Eun Young Kim1, Chin A Yi1, Jung Won Moon1, Kyung Soo Lee2,  
O Jung Kwon1, Joungho Han3
1Samsung Medical Center/Korea, 2Radiology, Samsung Medical Cen-
ter, Sungkyunkwan University School Of Medicine/Korea, 3Pathology, 
Samsung Medical Center, Sungkyunkwan University School Of Medici-
ne/Korea
Background: Microvessel density is known as a prognostic in-
dicator for patients with solid organ malignancy and the extent 
of enhancement on CT is positively correlated with the extent of 
microvessel density. The purpose of this study is to investigate the 
prognostic significance of dynamic contrast-enhanced (DCE) CT in 
patients with stage IA non-small cell lung cancer (NSCLC).
Methods: From January 2003 through December 2006, we retro-
spectively enrolled 118 patients (men: women = 67:51; mean age, 
58.6 years) with stage IA NSCLC who underwent DCE CT with 
helical technique (unenhanced images and series of dynamic en-
hanced images covering primary lung cancer at 30, 60, 90 and 120 
seconds and 5 and 10 minutes) after intravenous contrast medium 
injection and followed by curative surgery. Data were collected on 
age, pathologic subtype, and size, peak attenuation and net en-
hancement of primary lung cancer and then correlated with ove-
rall, metastasis-free, and recurrence-free survivals that occurred 
through December 31, 2011.
Results: In multivariate analysis, net enhancement of primary lung 
cancer was independently associated with recurrence (hazard ra-
tio [HR] 1.024, P=.013), metastasis (HR 1.027, P=.023), and overall 
survival (HR 1.025, P=.044). Net enhancement of 80 HU predicted 
significantly higher risk for the recurrence (P=.028) and metastasis 
(P=.025) after curative surgery of stage IA lung cancer. The signifi-
cance of tumor size was proved only in the correlation with recur-
rence (HR 1.069, P=.038) .
Conclusion: Our study confirmed the prognostic significance of 
net enhancement as an indirect biomarker of tumor angiogenesis 
for patients with stage IA NSCLC.
Keywords: Dynamic Contrast-Enhanced CT, non-small cell lung 
cancer, Net Enhancement, Recurrence
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P2.12-020 THE IMPACT OF ADJUVANT THERAPY IN 
RESECTED PATIENTS WITH EARLY STAGE NON-SMALL 
CELL LUNG CARCINOMA: THE ERCC1 AND EGFR EX-
PRESSIONS ARE ASSOCIATED WITH SURVIVAL.
Aysun Aynaci1, Akif Turna2, Atilla Gürses3, Filiz Kosar1, Nur Ürer4, 
Kamil Kaynak5
1Department Of Chest Diseases, Yedikule Teaching Hospital For Chest 
Diseases And Thoracic Surgery/Turkey, 2Department Of Thoracic 
Surgery, Istanbul University, Cerrahpasa Medical Faculty/Turkey, 3De-
partment Of Thoracic Surgery, Yedikule Teaching Hospital For Chest 
Diseases And Thoracic Surgery/Turkey, 4Department Of Pathology, 
Yedikule Teaching Hospital For Chest Diseases And Thoracic Surgery/
Turkey, 5Department Of Thoracic Surgery, Istanbul University Cerrah-
pasa Medical Faculty/Turkey
Background: The aim of study was to investigate the impact of is 
searching effect of tumor ERCC-1 and EGFR expression levels on 
survival, metastasis and recurrence in patients with non-small cell 
lung cancer (NSCLC) who had undergone resectional surgery follo-
wed by adjuvant chemotherapy.
Methods: In this study, 140 patients with NSCLC who underwent 
resectional surgery between 2005 and 2009 were analyzed. The 
patients’ pTNM were constructed according to latest staging sys-
tem and the specimens were analyzed by both conventional histo-
pathological analysis (hematoxylin-eosin) and immunohistochemi-
cal staining for ERCC-1 and EGFR expression. Survival analysis was 
calculated according to Kaplan-Meier method.
Results: Thirtysix (25%) of patient had EGFR expression wheras 
and 98 (68%) patients were negative for EGFR. The 5-year survival 
rates of patients with or without EGFR expression were 52% and 
54.8% respectively (p=0,717). In patients who had not adjuvant 
chemotherapy, the 5-year survival rates were 46.7% and 82.1% in 
patients with EGFR+ and EGFR- tumors respectively (*p=0.035). 
Tumor ERCC-1 expression level were evaluated in 128 patients. It 
was found that in 88 patients (61.1%) tumor showed ERCC-1 ex-
pression whereas no ERCC-1 expression was found in 40 patients 
(27.8%). We also found that 5-year survival rate was 65.2% in pati-
ents who had ERCC-1(+) tumors while it was 46.1% in patients with 
tumors not expressing ERCC-1(p=0.047).
Conclusion: ERCC-1 expression in tumor tissue seemed to be a 
good prognosticator in resected non-small cell lung cancer pati-
ents. On the other hand, EGFR expression indicated poor survival 
in these patients. Further studies are needed to clarify this issue.
Keywords: ERCC1, adjuvant therapy
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P2.12-019 COMPLIANCE, TOXICITY AND SUCCESSFULL 
GOALS IN ADJUVANT SETTING. RESULTS FROM TWO 
REFERAL CENTERS IN SOUTH AMERICA.
Edgar N. Olguin1, Karina O´leary1, Wilson Golomar2, Atahualpa 
Campos2, Mariano Gallo Questa1, Mauricio Luongo2, Néstor Spiz-
zamiglio3, Miguel Galmés3, Gustavo JaNKIlevich1
1Oncology Unit, Hospital Carlos G. Durand/Argentina, 2Thoracic Divisi-
on, Instituto Nacional Del Cáncer/Uruguay, 3Surgery Division, Hospital 
Carlos G. Durand/Argentina
Background: Cisplatin based chemotherapy is the treatment of 
choice in the adjuvant setting of non small cell cancer (NSCLC) 
stages (IB)II-IIIA. Compliance, toxicity and follow up are issues of 
paramount importance. Series from Latinamerica were infrecuent.
Methods: We retrospectively analyzed all patients with NSCLC 
diagnosis and adjuvant treatment at two referal center since 2008 
to present. Toxicity, compliance and follow up were the end point.
Results: The medical records of forty five consecutive patients 
were reviewed. Median Age was 60 (r.40-76).From 45 patients 
twenty five (55,6%) were male and twenty (44,4%) female. Sta-
ge IB four patients (8,8%), teen patients were stage IIA (22,2%), 
15(33,3%) were IIB and 16 (35,56%) patients stage IIIA . Pathology 
was adenocarcinoma 33 patients (pts) , squamous cell carcinoma 
in teen cases and other pathology in 2 cases.Perfomance Status 
at start of treatment were 0 in teen pts, 1 thirty two pts and 2 in 
three. All patients had accessibility (with or without insurance). 
The median days to start chemotherapy since surgery was 37.Re-
gimes indicated were Cisplatin-Vinorelbine (29), Cisplatin-VP-16 
(9), Carboplatin-Paclitaxel (4) and others 3.The median number of 
cycles were 4 (3-6). The Cisplatin-Vinorelbine regimen was com-
pleted in 62% of pts and related with more adverse events,others 
combo were completed with mild toxicity in 66,6% of cases. No 
Grade 5 toxicity were recorded. Toxicity were recorded in 35 me-
dical records.Grade 3-4 were seen in 16 pts (45,7%), the toxicity 
more frequent was asthenia (12pts),neurotoxicity (8pts),pain at 
administration site (5pts) all with vinorelbine,febril neutropenia in 
7 pts, trombocytopenia and neutropenia in 12 pts and anemia 10 
pts. Recurrence was seen in 10/45 pts ,the pattern of recurrence 
were locoregional 4 pts and distant 6 pts. No second tumors were 
reported and three lung cancers with different histology were re-
corded at follow up in 3pts.
Conclusion: Adjuvant treatment of NSCLC were feasible, with high 
compliance and mild toxicity in the community setting. The multi-
disciplinary approach for thoracic oncology teams in the follow up 
and surveillance of adverse events is the target in this population.
Keywords: Compliance, Non small lung cancer, Adjuvant treat-
ment, Toxicity
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P2.12-022 A FEASIBILITY STUDY OF POSTOPERATIVE 
ADJUVANT CHEMOTHERAPY WITH FLUOROPYRIMI-
DINE S-1 IN PATIENTS WITH STAGE II-IIIA NON-SMALL 
CELL LUNG CANCE
Mitsuhiro Tsuboi1, Hiromitsu Takizawa1, Kazuya Kondo2, Hisashi 
Ishikura3, Suguru Kimura3, Koichiro Kajiura1, Yasushi Nakagawa1, 
Yukikiyo Kawakami1, Mitsuteru Yoshida1, Shoji Sakiyama1, Akira 
Tangoku1
1Department Of Thoracic, Endocrine Surgery And Oncology, The Uni-
versity Of Tokushima Graduate School/Japan, 2Department Of Onco-
logical And Regenerative Surgery, University Of Tokushima, School Of 
Medicine/Japan, 3Department Of Surgery, Tokushima Red Cross Hospi-
tal/Japan
Background: S-1 is an orally active combination of tegafur, gimera-
cil and oteracil in a molar ratio of 1:0.4:1. We conducted a feasibili-
ty study of S-1 as postoperative adjuvant chemotherapy in patients 
with curatively resected pathologically stage II-IIIA non-small cell 
lung cancer (NSCLC).
Methods: Patient eligibility required compliance with the following 
criteria: histologically proved NSCLC; pathologic stage II-IIIA (ac-
cording to the Union for International Cancer Control 6th edition) 
after complete resection; no previous treatment except for surge-
ry; age >=20 and <80 years; performance status (PS) 0 or 1; no or-
gan dysfunction; no concurrent malignancy; and written informed 
consent. Chemotherapy comprised 9 courses (4-week administra-
tion, 2-week withdrawal) of S-1 at 80-120 mg per day according to 
body surface area and renal function. The primary end point was 
the completion rate of scheduled adjuvant chemotherapy. Secon-
dary end points were safety, overall survival and relapse-free sur-
vival. From November 2007 through December 2010, 24 patients 
were enrolled in this trial.
Results: Patient characteristics were as follows: median age of 68 
(range: 49-79); male/female: 16/8; surgical procedure lobectomy/
pneumonectomy: 21/3; pathologic stage IIA/IIB/IIIA: 8/6/10; and 
histologic type adenocarcinoma/squamous cell carcinoma/other: 
19/4/1. Three patients were censored due to the disease recur-
rence, and the completion rate of 9 courses was calculated to be 
42.9% (9/21). Completion rate of more than 70% of scheduled 9 
courses was 61.9% (13/21). Most common adverse events were 
grade 1 or 2 anorexia (54.2%) or fatigue (20.8%), which were rea-
sons of discontinuation of S-1 administration. Although grade 3 
elevated total bilirubin (4.2%) and pneumonitis (4.2%) were obser-
ved, no grade 4 or 5 adverse events occurred. Overall and relapse-
free survival rates at 3 years were 69.5% and 51.1%, respectively. 
Patients who completed more than 70% of scheduled 9 courses 
showed better relapse-free survival than 70% uncompleted pati-
ents (p=0.01).
Conclusion: Postoperative administration of S-1 seems feasible 
with few severe adverse events as adjuvant chemotherapy for pati-
ents with curatively resected pathologically stage II-IIIA NSCLC.
Keywords: NSCLC, adjuvant chemotherapy, S-1
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P2.12-021 SELECTIVE MEDIASTINAL LYMPH NODE DISS-
ECTION FOR CN0 NON-SMALL CELL LUNG CANCER
Taichiro Ishizumi, Tatsuya Inoue, Jitsuo Usuda
Thoracic Surgery, Nippon Medical University/Japan
Background: As lobe-specific patterns of nodal metastases of lung 
cancer have become recognized, selective lymph node dissection 
(LND) based on metastatic pathways is increasingly common. The 
aim of this study was to evaluate the effectiveness of selective LND 
for cN0 lung cancer.
Methods: We retrospectively evaluated 1602 patients with pre-
viously untreated cN0 lung cancer resected with systematic LND 
between January 2001 and December 2012. We evaluated nodal 
metastatic patterns and frequency according to the primary loca-
tion and pathology.
Results: Primary tumor locations were the right upper lobe (RUL) 
in 553, the right middle lobe (RML) in 110, the right lower lobe 
(RLL) in 343, the left upper lobe (LUL) in 364, and the left lower 
lobe (LLL) in 232. The tumor cell types were adenocarcinoma in 
1272, squamous cell carcinoma in 228, large cell carcinoma in 50, 
adenosquamous cell carcinoma in 8 and others in 44. Among the 
patients with cN0 lung cancer who underwent operation, 8.1% had 
pN1 (129/1602) and 9.6% had pN2 (154/1602). In the cases of cN0 
lung cancer, except cases of adenocarcinoma, the right and left 
upper lobe (RUL and LUL) tumors did not have subcarinal metasta-
ses and the right and left lower lobe tumors did not have superior 
mediastinal metastases. On the other hand, 4.2% of RUL and 2.8% 
LUL-superior segment cN0 adenocarcinoma had subcarinal meta-
stases. The RUL and LUL-superior segment cN0 adenocarcinomas 
except 2 patients did not have subcarinal metastases when the 
superior mediastinal nodes were negative, whereas 7.7% of left lin-
gular segment adenocarcinomas metastasized to subcarinal nodes 
even when the superior mediastinal nodes were negative. 3.1% of 
right and 3.3% of left basal segment cN0 adenocarcinomas had 
superior mediastinal metastases. The right and left basal segment 
cN0 adenocarcinomas did not have superior mediastinal metas-
tases when the subcarinal nodes were negative, whereas 3.7% of 
right S6 and 5.6% of left S6 adenocarcinomas had metastatic supe-
rior mediastinal nodes even when the subcarinal nodes were ne-
gative. All the above-mentioned patients with lingular segment or 
right or left S6 adenocarcinoma had hilar lymph node metastases.
Conclusion: Lobe-specific selective LND is feasible for patients 
with cN0 lung cancer, except cases of adenocarcinoma. In cN0 RUL 
and LUL-superior segment adenocarcinomas, subcarinal dissection 
may be unnecessary if the superior mediastinal node is negative. 
In cN0 right and left basal segment adenocarcinomas, superior 
mediastinal dissection may be unnecessary if the subcarinal node 
is negative. On the other hand, as left lingular segment adenocar-
cinomas might metastasize to subcarinal nodes even if the superior 
mediastinal node is negative, and right and left S6 adenocarcino-
mas might metastasize to superior mediastinal nodes even if the 
subcarinal node is negative, selective LND requires confirmation of 
hilar LN-negative status.
Keyword: cN0 lung cancer, Selective lymph node dissection
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Conclusion: In early stage NSCLC managed with radiation alone, 
patients with high SUVmax ≥7 on FDG-PET/CT scan have poorer 
outcomes and high risk of progression, possibly due to aggressive 
biology. Pre-treatment FDG-PET/CT is an effective and non-invasi-
ve method to identify patients with higher risk of distant metastasis 
and possible candidates for adjuvant therapy studies.
Keywords: early stage lung cancer, PET SUVmax, distant metasta-
ses, radiotherapy
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P2.12-023 PRE-TREATMENT 18FDG-PET SUVMAX AS A 
PREDICTOR OF DISTANT METASTASIS IN EARLY STAGE 
NSCLC TREATED WITH DEFINITIVE RADIOTHERAPY
Vimoj J. Nair, Robert Macrae, Peter Cross, Jason Pantarotto
Division Of Radiation Oncology, University Of Ottawa/Canada
Background: Positron emission tomography (PET) using [18F]-
fluoro-2-deoxy-glucose (FDG) is a standard staging investigation 
for patients with non-small cell lung cancer (NSCLC). The maximum 
standardized uptake value (SUVmax) is a semi-quantitative measure 
of FDG uptake that correlates with tumor doubling time and pro-
liferation rates, which in turn are known to correlate with tumor 
aggressiveness. The aim of this study was to determine whether 
the pre-radiation SUVmax of the primary tumor for FDG has a prog-
nostic significance in patients with T1 or T2N0 NSCLC treated with 
curative radiation therapy.
Methods: Between April 1993 and December 2011, a total of 
406 patients with medically inoperable histologically proven T1 
or T2N0 NSCLC treated with radiotherapy (either conventional 
fractionation or stereotactic ablative radiotherapy (SABR)) were 
entered in an ethics-approved database. Minimum radiation dose 
delivered was 50Gy. 180 tumors (163 patients) with pre-treatment 
FDG-PET/CT scan satisfied the eligibility criteria. We stratified the 
patients above and below the median SUVmax value on the pre-
treatment PET/CT scan and analysed the survival data, measured 
from date of diagnosis. Statistical analysis (including multivariate) 
was done using SPSS v15. Survival data was analysed using Kap-
lan-Meier method, and comparisons of survival were done using 
Mantel-Cox log-rank test.
Results: Of the 180 tumors, 68.9 % were T1; 24.6% centrally lo-
cated (RTOG definition); 64.4% of treated with SABR. Median 
follow-up time was 15 months. Overall survival (OS) at 2 and 3 
years for the entire cohort was 76% and 67% respectively. Mean 
and median SUVmax were 8.1 and 7 respectively. Progressi-
on free survival at 3 years with SUVmax < 7 was approximately 
double that of those patients with tumor SUVmax ≥ 7 (55% vs. 
28%; p=0.0096). Tumors with SUVmax ≥ 7 were associated with 
a worse regional recurrence free survival but no difference was 
seen for local recurrence. In the multivariate analysis SUVmax≥7 
was an independent prognostic factor for distant metastasis 
free survival (DMFS) [Figure 1], in addition to a higher T status 
being an independent prognostic factor for worse overall sur-
vival. Figure 1: Results of univariate and multivariate analysis 
demonstrating the prognostic factors associated with DMFS 
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P2.13-002 RANDOMIZED PHASE II STUDY OF SINGLE 
AGENT OSI-906, AN ORAL, SMALL MOLECULE, TYROSI-
NE KINASE INHIBITOR (TKI) OF THE INSULIN GROWTH 
FACTOR-1 RECEPTOR (IGF-1R) VERSUS TOPOTECAN 
FOR THE TREATMENT OF PATIENTS WITH RELAPSED 
SMALL CELL LUNG CANCER (SCLC)
Alberto A. Chiappori1, Gregory Otterson2, Afshin Dowlati3, Anne 
Traynor4, Leora Horn5, Christine Hann6, Taofeek Owonikoko7, Ta-
her Abu Hejleh8, Helen J. Ross9, Jorge Nieva10, Xiuhua Zhao11, Mi-
chael Schell11, Daniel Sullivan12
1Thoracic Oncology, Moffitt Cancer Center/United States Of America, 
2Ohio State University/United States Of America, 3University Hospitals 
Case Medical Center/United States Of America, 4University Of Wiscon-
sin/United States Of America, 5Vanderbilt University/United States Of 
America, 6Johns Hopkins University/United States Of America, 7Emory 
University/United States Of America, 8University Of Iowa Hospitals/
United States Of America, 9Mayo Clinic/United States Of America, 
10Billings Clinic Cancer Center/United States Of America, 11Biostatistics, 
Moffitt Cancer Center/United States Of America, 12Experimental Thera-
peutics, Moffitt Cancer Center/United States Of America
Background: SCLC typically presents with advanced (extensive 
stage) disease. Despite an initial response to chemotherapy, they 
all relapse and rarely survive beyond 2 years. Treatment of relapsed 
SCLC is limited (topotecan) and dependent on the response to initial 
chemotherapy (sensitive vs. refractory relapse). Downstream acti-
vation of PI3K-AKT, through IGF-1R pathway signaling plays a role 
in both, growth/survival and resistance to chemotherapy in SCLC. 
Growth inhibition and chemosensitization with IGF-1R inhibitors 
correlates with the PI3K-AKT inhibitory signaling and suggests AKT 
activation as a potential biomarker. OSI-906, is a well tolerated oral, 
small molecule, potent inhibitor of IGF-1R
Methods: A phase II randomized study comparing the efficacy 
of OSI-906 vs topotecan in patients with rSCLC is currently being 
conducted. Primary endpoint is PFS, summarized with the K-M me-
thod. An increase in median PFS from 2.5 to 4.175 months (in the 
experimental arm B) is proposed. A total of 95 patients are plan-
ned. Biomarkers of IGF-1R inhibition are explored in plasma, PBMC 
and using Radiomics. Eligible patients must have proven rSCLC, 
platinum sensitive (sen) or resistant (res) disease, ECOG PS 0-2 and 
adequate hematologic, renal and hepatic function. Fasting glucose 
<160 mg/dl, QTc < 450 msec and measurable disease by RECIST 
v1.1 are required. Pregnant, breast-feeding, diabetic and cirrhotic 
patients as well as those taking insulin/insulinotropic agents are 
excluded. Patients are randomized (2:1) to the experimental arm (B): 
OSI-906, 150 mg PO BID, until progression or to the standard arm 
(A): topotecan, 1.5 mg/m2 IV daily x5 OR 2.3 mg/m2 PO daily x5, for 
4 cycles. Crossover to OSI-906 is allowed.
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P2.13-001 ADDITIVE FIRST-LINE CHEMOTHERAPIES IM-
PROVE PROGRESSION-FREE SURVIVAL FOR COMBINED 
SMALL CELL LUNG CANCER IN A PHASE II RANDO-
MIZED TRIAL.
Jie Zhang
Oncology Department, Shanghai Pulmonary Hospital/China
Background: We aimed to compare the efficacy of alternating 
etoposide-cisplatin and vinorelbine-cisplatin (EP-NP) versus etopo-
side-cisplatin (EP) only regimens for combined small cell carcino-
mas (C-SCLC) in a phase II randomized trial.
Methods: Eighty-two histologically proven C-SCLC patients were 
assigned to receive either the EP-NP regimen (Group A) or the EP 
regimen (Group B). Patients were followed up until either death 
occurred or exit study. The response rate (RR), progression-free 
survival (PFS), overall survival (OS), and toxicity were recorded and 
analyzed.  
Results: The overall 1-year survival rate was 40% and the median 
OS and median PFS was 11.47 and 6.08 months, respectively. Ad-
ditionally, 1-year PFS in Group A was significantly better than that 
in Group B (18% vs. 3%, p = 0.041). There were 18 (42.9%) Partial 
response (PR), 19 (45.2%) Stable disease (SD), and 5 Progressive 
disease (PD) in Group A and 13 (32.5%) PR, 25 (62.5%) SD, and 2 
PD cases in Group B. The median survival time was 11.47 months, 
1-year and 2-year overall survival rates were 43% and 13% in Group 
A and 38% and 10% in Group B, respectively. No significant survi-
val differences were found between two groups (p = 0.866). Mul-
tivariate analysis showed that chemo-response was predictive of 
longer survival (hazard ratio: 2.635; 95% CI: 1.681-4.131; p < 0.001, 
respectively).
Conclusion: The addition of NP to EP regimen for C-SCLC impro-
ved progression-free survival as compared to EP-only administra-
tion.
Keywords: Clinical respiratory medicine, Histology/Cytology, Lung 
cancer, Pathology
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P2.13-003 PROGNOSTIC FACTORS FOR EXTENSIVE  
STAGE SMALL CELL LUNG CANCER.
Choonhee Son, Mee-Sook Roh
Dong-a University Medical Center/Korea
Background: Despite a high cheomosensitivity, the long term survival 
of extensive stage small cell lung cancer is poor. But the individual 
prognosis is variable. We want to evaluate prognostic factors in exten-
sive small cell lung cancer..
Methods: We retrospectively analyzed clinical and laboratory charac-
teristics of 129 patients who were diagnosed extensive stage small 
cell lung cancer. Clinical and laboratory characteristics were analyzed.
Results: The median survival time is 196 days (95% confidence 
interval[CI], 162 to 229 days). Univariate analysis showed that gender, 
body mass index(BMI), performance status(PS), the presence of supe-
rior vena cava(SVC) syndrome, diabetes, and anemia were associated 
survival.(all P-value≤0.031). Multivariate Cox regression analysis indi-
cate that survival time was independently associates with BMI(<18.5) 
(hazard ratio [HR];6.56, 95% CI 2.83–15.21; p = 0.000), the presence of 
SVC syndrome([HR];3.54, 95% CI 1.50–8.36; p = 0.004) and the pre-
sence of anemia ([HR];1.83, 95% CI 1.01–3.34; p = 0.047).
Conclusion: In this study, lower BMI, the presence of SVC syndrome 
and the presence of anemia were poor prognostic factor for survival.
Keywords: small cell lung cancer, Prognosis
Results: 
Thirty-three patients have been enrolled; A=10 (res=6, PS 2=2) and 
B=23 (res=15, PS 2=4). M/F= 13/20; ECOG PS 0/1/2 = 8/19/6. Pla-
tinum sen/res = 12/21. Two patients were not treated (A/B = 1/1). 
Adverse events are described in Table 1. No responses have been 
observed. Only 2/6 and 1/15 patients in arms A and B respectively 
achieved SD at 6 weeks. Median PFS (A/B) was 2.1 (95% CI; 0.6, 3.6) 
and 1.3 (95% CI; 1.0, 1.4) months respectively (p = 0.0149). OS was 
not reached in arm A and 2.7 (95% CI; 1.5, …) months in arm B (p = 
0.1716).
Conclusion: OSI-906 is safe in rSCLC patients. In our unselected, 
high risk population, efficacy in both arms, but particularly in arm 
B appears suboptimal. The study continues to accrue to reach the 
sample size and follow up time needed for more robust conclusions.
Keywords: small cell lung cancer, insulin growth factor 1 receptor, 
tyrosine kinase inhibitor, recurrent disease
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P2.13-005 PALONOSETRON (ALOXI®) EFFECTIVELY PRE-
VENTS NAUSEA AND EMESIS IN SCLC PATIENTS RECEI-
VING PLATINUM-BASED THREE DAYS REGIMEN.
Ioannis Gkiozos, Dimitrios Vassos, Meropi Panagiotarakou, Anto-
nios Vassias, Sotirios Tsimpoukis, Elias Kainis, Konstantinos N. 
Syrigos
Oncology Unit Gpp, Sotiria General Hospital/Greece
Background: We evaluated retrospectively the safety and effectiveness 
of single dose administration of palonosetron (Aloxi®) in SCLC patients 
receiving platinum-based three days regimen.
Methods: We retrospectively recorded the nausea and emesis of 417 
SCLC patients (337 men and 80 women) with mean age 69.1 years 
(SD=9.0 years). Of those 63.3% had Extensive Disease (ED) and 36.7% 
Limited Disaese (LD). 318 pts (76.3%) received six cycles of chemothe-
rapy and 229 pts (67%) received also radiotherapy, either concurrent or 
sequential. With regard to the chemotherapy regimen, 290 pts (69.5%) 
received Carboplatin (D1) & etoposide (D1-3), 99 pts (23.7%) received 
Carboplatin (D1), Irinotecan (D1) & etoposide(D1-3), and 28 pt (6.7%) 
received Cicplatin (D1) and etoposide (D1-3). The antiemetic treatment 
was i.v. administration of 0.25mg palonosetron on D1.
Results: 315 (75.5%) of 417 patients didn’t experience any acute nau-
sea and 329 (78.9%) patients remained free of nausea in the delayed 
phase . Free of vomit was 380 (91%) patients in the acute phase and 
390 (93.5%) in the delayed phase. In compination 314 (75.3%) patients 
was free of vomit or nausea in the acute phase and 326 (78.2%) in the 
delayed phase with the use of palonosetron. No signs or symptoms 
due to toxicity from palonosetron observed in acute or delayed phase 
. Both univariate and multiple analyses indicated that the odds of nau-
sea decreases as age increases and that woman had greater odds for 
nausea. No smoking related differences were recorded, but 94.8% of 
the patients were smoker. Addition of radiotherapy did not increase the 
probability of nausea or emesis and patients receiving cisplatin instead 
of carboplatin were more likely to experience nausea or emesis.
Conclusion: Our data indicate that single dose of palonosetron on 
D1 effectively controls acute and delayed nausea and emesis in SCLC 
patients receiving platinum based three days regimen.
Keywords: chemotherapy, adverse effects prevention
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P2.13-004 LITHIUM AS A NEUROPROTECTIVE AGENT 
IN PATIENTS UNDERGOING PROPHYLACTIC CRANIAL 
IRRADIATION (PCI) FOR SMALL CELL LUNG CANCER 
(SCLC): THE TULIP STUDY
Mustafa Khasraw1, Violet R. Mukaro2, Michael Berk1, Greg Whee-
ler3, Madhu Singh2, Chris Brown4, Michael Francis2, Graham Pit-
son2, Andrew Hui2, Dickson Ma5, Adam Broad2, Inger Olesen2, Feli-
cia May Lee Leow2, Peter Brotchie5, Paul Marruff6, Robert Ramsay7, 
David Ashley1
1School Of Medicine, Deakin University/Australia, 2Andrew Love Cancer 
Centre, Barwon Health/Australia, 3Division Of Radiation Oncology And 
Cancer Imaging, Peter MacCallum Cancer Centre/Australia, 4National 
Health And Medical Research Council Clinical Trials Centre/Australia, 
5Department Of Nuclear Medicine, Geelong Hospital/Australia, 6Cogstate 
Ltd/Australia, 7Differentiation And Transcription Laboratory, Peter Mac-
Callum Cancer Centre/Australia
Background: Somnolence syndrome and cognitive dysfunction are 
devastating complications of cranial irradiation. Lithium (Li) has 
neuroprotective properties, such as induction of neuroglial growth 
after radiation and reduction of cognitive loss in models of cranial ir-
radiation (PCI). It has a well-understood safety profile. PCI is offered 
to SCLC responders to chemo and radiotherapy. We are assessing 
feasibility and subsequently efficacy of lithium as a neuroprotective 
agent in people receiving cranial irradiation.
Methods: Twenty SCLC patients treated with PCI are randomised 
in an open label multicentre stratified feasibility study, (TULIP), to 
PCI +/- Li. Li is commenced after PCI at 250mg daily, and increased 
by 250 – 500 mg based on plasma levels for a period of 6 weeks, 
the average time to develop somnolence syndrome. Patients with 
histologically or cytologically confirmed SCLC with complete or 
partial response to chemotherapy and lung irradiation with no major 
comorbidities and good performance are eligible. Cognitive assess-
ments are done at baseline, after Li therapy, at 3, 6 and 12 months 
using CogState interactive tools assessing aspects of executive 
function, memory and attention. Additionally, the Cognitive Failures 
Questionnaire, Centre for Epidemiological Studies Depression Sca-
le, and Epworth Sleepiness Scale evaluation are completed. Feasi-
bility is the primary endpoint of TULIP. Secondary endpoints include 
neurocognition and safety. FDG-PET and gadolinium MRI before 
and 6 weeks after Li or placebo assessing grey matter volumetrics 
within the hemispheres before and after Li. Differences in regional 
cerebral metabolic rate for glucose consumption, between baseline 
and after Li will be evaluated using Parametric Mapping.
Results: N/A
Conclusion: There are currently 5 patients enrolled in TULIP. Subse-
quent to TULIP, the definitive 2nd Li Protection Study (2LiP) will com-
mence, aiming to randomise 138 patients with various malignancies 
and brain metastases treated with whole brain radiotherapy +/- Li to 
measure impact of Li on cognition, mood and quality of life.
Keywords: cognitive function, cranial irradiation, lithium, small cell 
lung cancer
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P2.13-007 IMPACT OF AGE ON TREATMENT AND SURVI-
VAL IN PATIENTS WITH SMALL CELL LUNG CANCER.
Harminder S. Takhar, Shawgi Sukumaran, Marleesa Ly, Chris 
Karapetis, Amitesh Roy, Ganessan Kichenadasse, Bogda Koczwara
Medical Oncology, Flinders Medical Centre/Australia
Background: Elderly patients account for a significant proportion of 
patients with small cell lung cancer (SCLC). Intuitively advanced age 
may be associated with worse outcomes. We examined the impact of 
age of the patients, <70 years versus >70 years, on survival.
Methods: Patients with small cell lung cancer (SCLC) were identified 
by searching the hospital cancer registry from 1999 to 2009. Patient 
characteristics, management and outcome data were collated by 
reviewing clinical records. Analysis was performed using SPSS version 
20.
Results: 168 patients with SCLC with a median age of 71 years (range 
37-94) were identified of which 49 had limited stage (LS) and 113 had 
extensive stage (ES) SCLC. Staging was indeterminate in 6 patients. 
Within the overall cohort 82 patients were <70 years in age and 86 
were > 70 years of age. the median survival was 8.5 months in the 
<70 year cohort (95% CI 5.9 -11.0.) and 5.2 months in the > 70 months 
cohort (95% CI 3.0-7.3) with p value of 0.02. However, when analysed 
separately for each stage the survival difference was not significant 
within the 2 cohorts. Median survival were 12.5 months vs 9.1 month 
in the LS cohort (p= 0.53) and 5.9 months vs 4.5 months within the ES 
cohort ( p=0.08). In the LS cohort, there was no significant difference 
in proportion of patients who received active treatment or comple-
ting treatment between the two groups (92.8% vs 95.2% p =1.0) and 
(70.8% vs 54.5% p = 0.53). In the ES cohort patients higher proportion 
of patients <70years received active treatment, including chemo-
radiotherapy, chemotherapy alone or radiotherapy alone, (78% versus 
69%, p= 0.2). Significantly less patients >70years vs <70years com-
pleted treatment (20% versus 39% p = 0.032). In an adjusted model 
using Cox regression, the patient age was not significant prognostic 
factor when adjusted for ECOG performance status, sex and whether 
the patients received active treatment or not (p=0.8)
Conclusion: Age was not an independent prognostic factor and 
should not be used as the sole criteria for making therapeutic  
decisions.
Keyword: Age survival SCLC
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P2.13-006 A PHASE IIA STUDY OF HA-IRINOTECAN, A 
CD44-TARGETED FORMULATION OF HYALURONIC ACID 
AND IRINOTECAN, IN THE TREATMENT OF EXTENSIVE 
STAGE SMALL CELL LUNG CANCER AND ITS EFFECT ON 
CANCER STEM-LIKE CELLS.
Muhammad Alamgeer1, Tracey J. Brown2, Peter Briggs1, Peter 
Midolo1, Ben Markman1, Kieren Marini3, Ilia Banakh2, David Neil 
Watkins3, Vinod Ganju1
1Medical Oncology, Monash Medical Centre/Australia, 2Biochemistry And 
Molecular Biology, Monash University/Australia, 3Centre For Cancer Re-
search, Monash Institute Of Medical Research/Australia
Background: Preclinical studies in small cell lung cancer cell lines and 
xenograft models have shown that Hyaluronic acid (HA) can be effec-
tively used to deliver Irinotecan (IR) and selectively decrease CD44 
expressing (stem cell-like) tumour cells and prolong duration of res-
ponse. This “proof of principle” study aims to replicate these findings 
in the clinical setting and obtain data on safety and response rates.
Methods: Extensive Small Cell Lung Cancer (ESCLC) patients with 
measurable disease (suitable for biopsy), PS 0-2, medically fit and able 
to give informed consent were screened for this study. A safety co-
hort (n=5) were treated with HA-IR (150mg/m2) and Carboplatin(C) at 
5 AUC, q3 weekly with subsequent patients stratified as 1st or 2nd line. 
All 2nd line patients received open label HA-IR+C while 1st line patients 
were randomized to receive either HA-IR+C or equivalent dosing regi-
men of IR+C. Sequential tumour biopsies were obtained at baseline 
and after 1 or 2 cycles. Tumour response was measured by CT/PET 
scan at baseline, after 1 cycle and every 2 cycles subsequently. A final 
biopsy at disease progression was planned. Blood samples for circula-
ting tumour cells (CTCs) were obtained at baseline, and at every cycle.
Results: Patients N=16, Age: median= 60; Range 39-78. Three 2nd 
line patients were not evaluated due to rapid early disease progres-
sion after Cycle 1. Overall toxicity profile of HA-IR+C was similar to 
IR+C with grade III/IV diarrhoea and neutropenia seen in 15% and 
20% respectively. One patient (7%) had grade III anaemia, while no 
grade III/IV nausea or vomiting was observed. No biopsy related com-
plications were observed. Of 13 patients evaluated for tumour res-
ponse, the overall response rate was 60% with 1 (7%) complete and 7 
(53%) partial responses. Three patients (24%) achieved stable disease 
while 2 patients (16%) progressed during the treatment. To date medi-
an progression-free survival is 5.9 months (7.6 months in first line and 
3.1 months in the second line cohort). Preliminary CTCs data shows 
close correlation between the number of CTCs and tumour response 
and relapse. Patients with CD44+ tumours appear to have obtained 
most durable response. Analysis of sequential biopsies is underway 
and will be presented.
Conclusion: HA-IR+C appears to be an active option for ESCLC. This 
regimen is designed to target CD44+ve subpopulation within the tumour.
Keyword: SCLC, CD44, Hyaluronic acid, irinotecan
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and 90-day mortality rates were 2 pateients (4%) and 5patients 
(8%), respectively. Postoperative complications occurred in 25 % 
and were major in 3 patients (6%). Re-operation was necessary in 
3 case (6%) for one of the following reasons:pleural fistula (n = 1), 
bleeding (n = 1), and empyaema (n = 1). The mean hospital stay 
was 20 days. The median survival was 16 months, while the overall 
1-, 2- and 5-year survival rates were 60%, 30% and 10%, respec-
tively.
Conclusion: These results concur with the published data of the 
most experienced centre with regards to the mortality and mor-
bidity after EPP for MPM. If a patient with epithelioid MPM is fit 
enough to tolerate a thoracotomy then macroscopic clearance of 
the tumour is the preferred option as part of a multimodality re-
gime including chemotherapy.
Keyword: Malignant pleural mesothelioma; Radical surgery;  
Pleurectomy/decortications.
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P2.14-002 VALIDATION OF THE CALGB AND EORTC 
PROGNOSTIC MODELS FOR MESOTHELIOMA BASED 
ON MULTIPLE CALGB TRIALS (ALLIANCE)
Herbert Pang1, Lydia Hodgson1, Robert Kratzke2, Jeffrey Crawford3, 
Hedy Kindler4, Everett Vokes4, Xiaofei Wang1
1Department Of Biostatistics And Bioinformatics, Duke University 
School Of Medicine/United States Of America, 2Department Of Medici-
ne, University Of Minnesota/United States Of America, 3Department Of 
Medicine, Duke University School Of Medicine/United States Of Ameri-
ca, 4Department Of Medicine, University Of Chicago/United States Of 
America
Background: Prognostic models play an important role in the de-
sign and analysis of mesothelioma treatment trials. The European 
Organisation for Research and Treatment of Cancer (EORTC) and 
the Cancer and Leukemia Group B (CALGB) prognostic models 
are two well-known tools to predict survival in patients with mali-
gnant mesothelioma. In this retrospective validation study, we aim 
to assess the performance of these two mesothelioma prognostic 
models for overall survival (OS) with multiple clinical trials data from 
CALGB.
Methods: Using 204 patients with malignant pleural mesothelioma, 
the EORTC model (Curran et al 1998) was developed using a Cox 
regression with white blood cell (WBC) count, ECOG performance 
status (PS), diagnosis, histological type, and gender as prognostic 
variables. Using 337 patients with malignant mesothelioma, the 
CALGB model (Herndon et al 1998) was developed using a cross-
validated exponential regression tree with PS, age, haemoglobin 
(Hgb) level, WBC count, chest pain indicator, and weight loss indica-
tor as prognostic variables. In this validation study, 602 mesothelio-
ma patients from fifteen completed CALGB treatment trials accrued 
between June 1984 and August 2009 were included. As the CALGB 
model was developed using the seven earlier studies, 266 patients 
from eight recent studies were included in the validation. For the 
EORTC model, we analysed all studies as well as just those eight 
recent studies. The concordance of predicted survival times and risk 
scores was estimated by c-index (Harrell et al 1996). Secondary end-
point of interest includes progression-free survival (PFS). Sensitivity 
analysis and multiple imputations were used to handle missing data. 
We also compared our results with PS alone.
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P2.14-001 TRIMODALITY TREATMENT OF MALIGNANT 
PLEURAL MESOTHELIOMA (MPM). A REVIEW OF 53 
CONSECUTIVE PATIENTS WITH MALIGNANT PLEURAL 
MESOTHELIOMA, PERIOD 10-YEARS JANUARY 2002- 
DECEMBER 2012.
Fadil Gradica1, Lutfi Lisha2, Epaminonda Fype3, Fahri Kokici3, 
Dhimitraq Argjiri4, Alma Cami3, Alban Hatibi3, I Skenduli2, Perlat 
Kapisyzi4, Gojard Cerga5
1Thorax Surgery, University Hospital “Shefqet Ndoqi“/Albania, 2Thorax 
Surgery Department, University Hospital “Shefqet Ndoqi“/Albania, 
3Anestesie Reanimation Department, University Hospital “Shefqet Ndo-
qi“/Albania, 4Pneumology, University Hospital “Shefqet Ndoqi“/Alba-
nia, 5Patologist, University Hospital “Shefqet Ndoqi“/Albania
Background: Malignant pleural mesothelioma (MPM) is an ag-
gressive neoplasm arising from the surface serosal cells of the 
pleural cavity. It is a highly lethal disease with a poor prognosis. 
The incidence of MPM has been predicted to increase rapidly in 
certain countries until approximately 2020 .Different staging sys-
tems for MPM exist . Although mainly related to surgical data, the 
TNM (tumour, nodes, metastasis)-based classification proposed by 
the International Mesothelioma Interest Group is the most widely 
used . MPM has long been surrounded by therapeutic nihilism, as 
chemotherapy, radiotherapy and surgery have not been proven 
to be effective as a single treatment modality. The role of surgery 
in providing maximal debulking is controversial and has not yet 
been determined. A major breakthrough was obtained with two 
randomised trials showing significant activity of the combination of 
cisplatin and a folate antagonist, pemetrexed or raltitrexed, with a 
significantly improved median survival time (MST) in patients with 
MPM. The European Organisation for Research and Treatment of 
Cancer (EORTC) initiated a phase II trial to evaluate the feasibility 
of trimodality therapy in a multicentre international setting (EORTC 
protocol 08031). 
Objective: To report on the experience with radical surgery, with 
emphasis on the long-term outcome, for malignant pleural meso-
thelioma (MPM) at a single institution. 
Methods: From our database over a 20-year period, we reviewed 
53 consecutive patients undergoing radical surgery for MPM in a 
multimodality programme. The long-term overall survival was ana-
lysed using the Kaplan–Meier method.
Results: A total of 53 patients (35 males, median age: 60 years) 
underwent an pleurectomy /Decorticacion 20(37%),pleural drena-
ge and pleurodesis 30(55%) , extra-pleural pneumonectomy (EPP) 
5(8%) with a palliativ/ curative intent . Epitheliod MPM was the 
most frequent (82%) cause. A right-sided disease was present in 
half of the cases 28 patients (52%). The International Mesothelioma 
Interest Group (IMIG) stage of the disease was stage I in 5 patients 
(8%) ,stage II in 19 patients (37%),stage III në 24 patient ( 47%) dhe 
stadi IV in 5 patients (8%). Preoperative chemotherapy consisting 
of a doublet cisplatin–pemetrexed (mean of three cycles) was of-
fered to 3 patients (6%). Postoperative therapies, either chemothe-
rapy or radiotherapy, were given in 15 patients (28%). The 30-day 
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200 mg/m2 in a step-wise dose escalation manner. The pharmaco-
kinetic parameters were calculated by model independent analysis 
and the dose proportionality was investigated on Cmax and AUC 
(0-t) values.
Results: 58 patients were screened and a total of 17 patients were 
enrolled consisting of seven colorectal cancer, six pancreatic ade-
nocarcinoma, two mesothelioma and two head and neck cancer 
(seven patients in 50 mg/m2, three in 100 mg/m2 and seven in 200 
mg/m2, respectively). Two DLTs were observed (grade 3 cytokine 
release syndrome in 50 mg/m2 and grade 5 interstitial lung disease 
in 200 mg/m2). Treatment related adverse events were observed 
in 13 of 17 patients, and the most common events were grade 1 
fatigue (five patients) and pyrexia (four patients). Amatuximab was 
eliminated from serum biphasically after reached Cmax. Estimated 
mean T1/2 on Cycle 1 Day 1 was 92.3 to 108 h and CL was 11.7 to 
15.2 mL/h/m2. It was found that the Cmax and AUC (0-t) values on 
Cycle 1 Day 1 increased in an almost dose proportional manner 
and these were similar to those in US patients. HACA was detected 
in eight of 17 patients. Of 53 patients whose tissue samples were 
evaluated by IHC, 24 patients (45.3%) were mesothelin-positive (10 
of 19 patients in colorectal cancer, four of eight in biliary cancer, 
four of five in pancreatic adenocarcinoma and six of 21 in other 
cancers).
Conclusion: Amatuximab was well tolerated in patients with ad-
vanced solid tumors, and MTD was not reached up to 200 mg/m2. 
Pharmacokinetic profile of amatuximab in Japanese patients was 
similar to that in US patients. Amatuximab is currently being inves-
tigated for its potential treatment of mesothelioma.
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P2.14-004 EORTC AND CALGB PROGNOSTIC MODELS, 
BUT NOT NEUTROPHIL-TO-LYMPHOCYTE RATIO, ARE 
PROGNOSTIC IN UNSELECTED PATIENTS WITH NEWLY 
DIAGNOSED MALIGNANT MESOTHELIOMA
Tarek Meniawy1, Jenette Creaney2, Richard Lake2, Anna K. Nowak1
1School Of Medicine And Pharmacology, University Of Western Austra-
lia/Australia, 2National Centre For Asbestos Related Disease/Australia
Background: Neutrophil-to-lymphocyte ratio (NLR), a marker of 
systemic inflammation, was proposed as a prognostic biomarker in 
a number of malignancies, including malignant pleural mesothe-
lioma (MPM). We examined baseline variables predictive of overall 
survival (OS) in patients with newly diagnosed MPM, including NLR 
and the established EORTC and CALGB prognostic models.
Methods: Consecutive patients with newly diagnosed MPM 
between 1st January 2005 and 31st December 2010 at Sir Charles 
Gairdner Hospital, Western Australia were included in this retros-
pective study. Eligible patients had a confirmed diagnosis of MPM, 
neutrophil and lymphocyte count within 90 days of diagnosis, no 
concurrent haematological malignancy, and follow-up more than 
90 days from diagnosis. Any subsequent treatment, including 
supportive care alone, was allowed. Variables to be analysed and 
cut-off determination was predetermined according to previous 
reports. Multiple imputation was performed for missing values, 
and univariate analyses and multivariate Cox models were calcula-
ted for OS.
Results: 274 of 369 patients screened met the eligibility crite-
Results: (1) For OS, the EORTC model produced c-indices equal 
to 0.592 and 0.610 for the fifteen and eight studies respectively. 
For the eight recent studies, the CALGB model produced c-indices 
equal to 0.618 and 0.593 without and with imputation respectively. 
PS alone produced c-indices equal to 0.591 and 0.564 for the fifteen 
and eight studies respectively. (2) For PFS, the EORTC model pro-
duced c-indices equal to 0.569 and 0.598 for the fifteen and eight 
studies respectively. For the eight recent studies, the CALGB model 
produced c-indices equal to 0.585 and 0.560 without and with im-
putation respectively. PS alone produced c-indices equal to 0.568 
and 0.553 for the fifteen and eight studies respectively. See Table 1. 
Conclusion: The EORTC and CALGB models perform similarly, 
with little improvement in prognostic ability from either compared 
to using PS alone. Further improvement on these existing prog-
nostic models is warranted.
Keywords: EORTC, CALGB, Prognostic models, mesothelioma
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P2.14-003 PHASE I AND PHARMACOKINETIC STUDY 
OF AMATUXIMAB, A NOVEL CHIMERIC ANTIBODY TO 
MESOTHELIN, IN PATIENTS WITH ADVANCED SOLID 
TUMORS
Takayasu Kurata1, Yasuhito Fujisaka1, Kaoru Tanaka1, Toshihiro 
Kudo1, Kunio Okamoto1, Junji Tsurutani1, Hiroyasu Kaneda1, Isamu 
Okamoto1, Masayuki Namiki2, Chifumi Kitamura2, Kazuhiko Na-
kagawa1
1Department Of Medical Oncology, Kinki University Faculty Of Medici-
ne/Japan, 2Eisai Co., Ltd./Japan
Background: Amatuximab is a chimeric monoclonal antibody to 
mesothelin. Mesothelin, a membrane protein, is a potential target 
for molecular targeted therapy due to its high expressions in vir-
tually all pancreatic cancers and mesotheliomas as well as several 
cancers, while showing little expression in normal tissues, except 
for normal mesothelium. Amatuximab inhibits the growth of 
mesothelin-expressing human tumors in vitro and in vivo xenograft 
model.
Methods: To investigate dose-limiting toxicities (DLTs) and estima-
te the maximum tolerated dose (MTD) of amatuximab in Japanese 
patients with advanced solid tumors. In addition, pharmacoki-
netics of amatuximab, human anti-chimeric antibody (HACA) 
and mesothelin expression by immunohistochemistry (IHC) were 
investigated. Patients with pancreatic cancers, mesotheliomas, or 
mesothelin-positive solid tumors as assessed by the IHC test, who 
have no other appropriate treatment were eligible in the study. 
Amatuximab was administered weekly until disease progression or 
occurrence of a DLT, and administered to 3 cohorts at 50, 100 and 
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ria and were included in this retrospective study. 159 received 
systemic chemotherapy, 10 underwent tri-modality therapy; 2 
underwent surgery only, and 103 received supportive care alone. 
Prognostic factors predictive of shorter survival in univariate ana-
lysis were: age ≥ 65 years, non-epithelioid histology, sarcomatous 
histology, AJCC stage III-IV, ECOG performance status (PS) 2-3, 
weight loss, chest pain, low haemoglobin and high platelet count. 
An NLR ≥ 5 at diagnosis did not predict for shorter OS (hazard 
ratio (HR) 1.25; p=0.122). On multivariate analysis, age, histology, 
PS, weight loss, chest pain, and platelet count remained signifi-
cant. The EORTC and CALGB prognostic groups were highly sta-
tistically significant as predictors for OS (HR 1.62; p<0.001 and HR 
1.65; p<0.001, respectively). On preplanned subgroup analyses, 
baseline NLR was not prognostic in chemotherapy-treated or non-
chemotherapy treated patients.  
Univariate and multivariate analyses of association of prognostic factors with overall survival
Univariate analysis Multivariate analysis
Baseline prognostic factor HR (95% CI) P-value HR (95% CI) P-value
Baseline NLR <5* vs. ≥5 1.25 (0.94-1.66) 0.122 1.02 (0.76-1.37) 0.893
Age <65* vs. ≥65 years 1.64 (1.24-2.17) <0.001 1.41 (1.05-1.90) 0.023
Female* vs. Male 1.23 (0.86-1.77) 0.262 1.24 (0.85-1.81) 0.269
Epithelioid* vs. non-epilthelioid 1.40 (1.08-1.80) 0.009 1.38 (1.05-1.82) 0.023
Non-sarcomatous* vs. sarc. 2.37 (1.62-3.48) <0.001 1.86 (1.22-2.84) 0.004
AJCC Stage I-II* vs. III-IV 1.52 (1.17-1.97) 0.002 1.27 (0.97-1.66) 0.087
ECOG PS 0-1* vs. 2-3 2.35 (1.59-3.46) <0.001 1.81 (1.21-2.70) 0.004
Weight loss absent* vs. present 2.11 (1.62-2.74) <0.001 1.62 (1.22-2.15) <0.001
Chest pain absent* vs. present 1.58 (1.21-2.07) <0.001 1.34 (1.02-1.76) 0.038
Hb difference <10* vs. >10 1.87 (1.41-2.49) <0.001 1.32 (0.96-1.80) 0.087
WCC (x 109/L) ≤8.30* vs. >8.30 1.22 (0.96-1.57) 0.110 0.95 (0.73-1.25) 0.745
PLT (x 109/L) ≤400* vs. >400 1.96 (1.49-2.58) <0.001 1.71 (1.26-2.33) <0.001
Abbreviations: *=referent; AJCC=American Joint Committee on Cancer Staging System; ECOG= Eastern Cooperative Oncology 
Group, WCC=White cell count; NLR=Neutrophil-to-lymphocyte ratio
 
Conclusion: Our findings validate established baseline prognostic 
variables as well as the EORTC and CALGB models, but not base-
line NLR in unselected patients with newly diagnosed MPM. In gui-
ding treatment decisions for patients at time of diagnosis, multiple 
variables should be considered that jointly predict survival
Keywords: malignant mesothelioma, prognostic factors, neutro-
phil-to-lymphocyte ratio
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included in a prospective trial at specialized centers.
Keywords: malignant pleural mesothelioma, Extrapleural pneu-
monectomy, induction chemotherapy, Postoperative complication
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P2.14-006 IS PLEURECTOMY-DECORTICATION A VIABLE 
MANAGEMENT OPTION IN THE TREATMENT OF MALI-
GNANT PLEURAL MESOTHELIOMA?
Henrietta Wilson, Emma Beddow
Thoracic Surgery, Royal Brompton And Harefield NHS Trust/United 
Kingdom
Background: Malignant pleural mesothelioma remains a signifi-
cant cause of morbidity and mortality in individuals exposed to 
asbestos. At present, around 2000 deaths per year in Britain are 
attributed to malignant mesothelioma, with numbers predicted 
to continue to increase until at least 2020. There is currently no 
known curative treatment. A number of management strategies 
have been advocated including chemotherapy, radiotherapy and 
surgical resection. The optimal management however remains 
elusive. In light of the results from the recent Mesothelioma and 
Radical Surgery trial there has been a move away from extra-pleu-
ral pneumonectomy (EPP) in the UK, with the majority of centres 
advocating a less radical approach. Pleurectomy-decortication 
may provide a safer alternative to EPP in patients with early stage 
disease as part of multi-modality treatment. Some authors, howe-
ver, remain concerned about the morbidity of this operation. The 
aim of this study was to review patients undergoing pleurectomy-
decortication for pleural mesothelioma within our institution to 
assess the safety and efficacy of this surgical approach.
Methods: A review of the thoracic surgical database identified 
eighteen patients who had undergone pleurectomy-decortication 
in the management malignant pleural mesothelioma between May 
2009 and May 2013. Patient notes were analysed retrospectively 
to collect patient demographics and histological data. All surgical 
procedures were carried out by a single surgeon. The outcomes 
included were post-operative length of stay, complications and 
overall survival.
Results: The average age within this cohort was 68.8 years (range 
54-82) and there was a higher percentage of men (M:F = 14:4). The 
pre-operative diagnosis of malignant mesothelioma had been con-
firmed in all cases, with the majority having previously undergone 
VATS pleural biopsy with or without talc pleurodesis. In 4 patients 
cytology alone was used for diagnosis and 1 patient had undergo-
ne image guided biopsy. All patients underwent surgical resection 
via a postero-lateral thoracotomy. The mean length of stay was 8.1 
days (range 5-17). 67% of patients had an uncomplicated recovery. 
Of those where complications did occur, 3 patients had a persis-
tent airleak and 3 had renal impairment requiring conservative 
management only. There were no in hospital deaths and the mean 
survival at follow-up was 17.0 months (range 2.3 – 38.7).
Conclusion: The role of surgical resection in the management of 
malignant pleural mesothelioma remains controversial. Although 
encouraging results following EPP have been reported in some 
large case series, these have not been replicated in randomised 
trials. Some researchers have suggested that the high rates of 
morbidity and mortality following EPP, without significant survival 
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P2.14-005 ASSESSMENT OF POSTOPERATIVE COMPLI-
CATIONS AFTER THE FIRST ALL JAPAN MULTI-INSTITU-
TIONAL TRIAL OF INDUCTION CHEMOTHERAPY FOL-
LOWED BY EXTRAPLEURAL PNEUMONECTOMY FOR 
MALIGNANT PLEURAL MESOTHELIOMA
Noriyasu Usami1, Kohei Yokoi1, Kenta Murotani2, Akihiko Hiraka-
wa2, Chiharu Tabata3, Toshinori Soejima4, Norihiko Kamikonya5, 
Fumihiro Tanaka6, Takeharu Yamanaka7, Morihito Okada8, Seiki 
Hasegawa9, Takashi Nakano3
1Department Of Thoracic Surgery, Nagoya University Graduate School 
Of Medicine/Japan, 2Center For Advanced Medicine And Clinical Re-
search, Nagoya University Graduate School Of Medicine/Japan, 3Res-
piratory Medicine, Hyogo College Of Medicine/Japan, 4Radiation Onco-
logy, Hyogo Cancer Center/Japan, 5Department Of Radiation Oncology, 
Hyogo College Of Medicine/Japan, 6Second Department Of Surgery, 
University Of Occupational And Environmental Health/Japan, 7Clinical 
Development Center, National Cancer Center Hospital East/Japan, 8De-
partment Of Surgical Oncology, Hiroshima University/Japan, 9Depart-
ment Of Thoracic Surgery, Hyogo College Of Medicine/Japan
Background: The first all Japan multi-Institutional trial was com-
pleted to evaluate the feasibility of induction chemotherapy using 
pemetrexed plus cisplatin, followed by extrapleural pneumonec-
tomy (EPP) and postoperative hemithoracic radiation in patients 
with resectable malignant pleural mesothelioma (MPM). The main 
results were presented at the ASCO 2013. In this study, we espe-
cially reviewed major postoperative complications and mortality 
of patients who underwent EPP and determined the risk factors 
responsible for adverse outcomes.
Methods: From 2008 to 2010, 42 patients with MPM were enrolled 
in this study. Thirty-nine patients received planed chemotherapy. 
Thirty-three patients proceeded to EPP, which was completed in 
30 patients. These patients were candidates in this study. Major 
complications were defined by grade 3, 4, 5 events according to 
National Cancer Institute Common Terminology Criteria for Adver-
se Events version 4.0. Treatment-related death was defined as any 
death occurring within 84 days after operation. Logistic regression 
analysis was performed on preoperative variables for major adver-
se outcomes.
Results: A total of 17 institutions in Japan with certified specialists 
in oncology, surgery and radiation therapy participated in this 
trial. Thirty patients (29 male, 1 female; median age of 66 years, 
range 43–74) completed EPP (14 right-sided and 16 left-sided), and 
macroscopic complete resection was accomplished in all patients. 
Histology of the tumors was epithelial in 22, biphasic in 4, sarco-
matous in 1, and others in 3. Median operation time and blood loss 
were 437 minutes (range, 335-655) and 1461 gram (range, 390-
4530), respectively. Major postoperative complications developed 
in 73.3% of the patients, and treatment-related death occurred in 
4 patients (13.3%), which causes were cardiac herniation (n = 1), 
ARDS (n = 2), bronchial fistula and ARDS (n = 1). There were no 
significant predictors for major postoperative complications and 
treatment related death in both univariate and multivariate analy-
sis.
Conclusion: We cannot find the predictor of major adverse events 
and treatment related death in MPM patients treated with induc-
tion chemotherapy followed by EPP. Although that is why sample 
size is small, we also recognize that multimodality treatment in-
cluding EPP for MPM has more than 10% mortality and should be 
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pectively. The estimated incidence pooled across all IARC regions 
between 1998 and 2002 is 1.47 per 100,000 for males (95% CI 1.46, 
1.48) and 0.31 per 100,000 (95% CI 0.30, 0.32) for females. There 
was little change in the female incidence rate from the 1988-1992 
to 1998-2002 period. However, there was a non-statistically signi-
ficant difference increase in the male incidence rate over the same 
periods.
Conclusion: We found that males made up 79% of all mesothelio-
ma cases reported between 1988 and 2002. The majority of cases 
were from the European, North American and Oceania regions but 
this maybe an artefact of better diagnosis and reporting in those 
regions. Pooled across countries and calendar periods, we also 
found that the male incidence rate was almost 5 times higher than 
the female incidence rate. Continued assessment of patterns in the 
proportion of cases in each region and time trends in incidence by 
sex and region will help to evaluate trends in disease occurrence.
Keywords: malignant mesothelioma, Incidence, Global, Patterns
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P2.14-008 EFFECT OF AQUAPORIN 1 MODULATION IN 
MALIGNANT PLEURAL MESOTHELIOMA: INHIBITION OF 
CELL PROLIFERATION AND COLONY FORMATION IN 
VITRO AND TUMOUR GROWTH IN VIVO USING A HETE-
ROTOPIC MOUSE MODEL
Jack Driml1, Kim Griggs1, Yuen Y. Cheng2, Glen Reid2, Ngan C. 
Cheng2, Douglas W. Henderson3, Sonja Klebe3
1Anatomical Pathology, Flinders University/Australia, 2Asbestos Disea-
ses Research Institute/Australia, 3Department Of Anatomical Patholo-
gy, Flinders University And Sa Pathology/Australia
Background: Aquaporin 1 (AQP1) has been shown to be an in-
dependent prognostic marker for survival in malignant pleural 
mesothelioma (MPM). AQP1 is a trans-membrane protein normally 
expressed in mesothelial cells and is part of a family of proteins 
involved in fluid homeostasis, cell proliferation and motility. AQPs 
have been implicated in various aspects of tumour development. 
The aim of the current study was to determine the functional role 
of AQP1 in MPM, using in vitro and in vivo models.
Methods: Primary MPM cells obtained from patient’s pleural effu-
sions and the MPM cell line NCI-H226 were subjected to a specific 
pharmacological AQP1 blocker and AQP1 siRNA knockdown and 
examined for proliferation and colony formation using MTS and 
anchorage independent assays. Levels of AQP1 expression were 
determined by immunohistochemistry and RT-PCR. The influence 
of AQP1 on tumour growth in vivo was studied using a heterotopic 
mouse model. Briefly, 5 x 106 NCI-H226 cells were injected sub-
cutaneously in the hind flank of BALB/C nude mice and allowed 
to grow to 100 mm3 before daily intra-tumour injections of AQP1 
blocker. Tumour size was measured daily.
Results: AQP1 expression correlates with cell proliferation in pri-
mary MPM cells (R2 = 0.69). Blockade of AQP1 with pharmacolo-
gical blocker or siRNA knockdown in MPM cells was shown to sig-
nificantly decrease cell proliferation, both in NCI-H226 (p < 0.05) 
and primary MPM cells expressing AQP1 (p < 0.05). Primary MPM, 
where more than 20% of tumour cells expressed AQP1, showed 
greater reduction in proliferation compared to cells having AQP1 
expression <20%. Application of AQP1 blocker decreased both 
benefit, make this an unacceptable approach in the majority of pa-
tients. In our experience, pleurectomy-decortication can provide 
an alternative in patients with early stage disease and good per-
formance status. At follow-up, 67% of patients were still alive and 
mean survival was 17 months. In patients with epitheliod subtype 
the mean survival was 21.6 months. This data supports previous 
studies which have identified a survival benefit with pleurectomy-
decortication, although numbers are too small to draw firm con-
clusions. The procedure was however well tolerated in all patients 
with no major post-operative complications and no in hospital 
deaths.
Keywords: mesothelioma, Pleurectomy/decortication
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P2.14-007 GLOBAL PATTERNS IN THE INCIDENCE OF 
MALIGNANT MESOTHELIOMA, 1988-2002, USING DATA 
PUBLISHED BY THE INTERNATIONAL AGENCY FOR RE-
SEARCH ON CANCER (IARC)
Matthew J. Soeberg1, Ken Takahashi2, Mehrnoosh Movahed2, Ying 
Jiang2, Nico Van Zandwijk3
1Cancer Epidemiology And Services Research, The University Of Syd-
ney/Australia, 2University Of Occupational & Environmental Health/
Japan, 3Asbestos Disease Research Institute/Australia
Background: Malignant mesothelioma is a rare but aggressive 
form of cancer which has a strong causal link to asbestos expo-
sure. While descriptive analyses have been undertaken of global 
patterns of mesothelioma deaths, the global pattern of malignant 
mesothelioma incidence is unclear. Since 1988, the International 
Agency for Research on Cancer (IARC) has been reporting count 
and incidence data for malignant mesothelioma. The aim of this 
study was to improve understanding of the global patterns of mali-
gnant mesothelioma.
Methods: We extracted mesothelioma incidence count data by 
sex recorded in Volumes VII (1988-1992, 150 registries in 50 coun-
tries), Volume VIII (1993-1997, 186 registries in 57 countries) and 
Volume IX (1998-2002, 225 registries in 60 countries) of the IARC 
Cancer Incidence in Five Continents reports. We also extracted 
the related age-standardised incidence rates and their standard 
errors. The data extraction was done for each reporting cancer 
registry or country in the six IARC regions (Africa, Asia, Central and 
South America, Europe, North America, and Oceania). The number 
of incident cases was summed by region and stratified by calendar 
period and sex. To provide accurate and conservative estimates, 
we removed sub-regional data from summary counts where total 
regional data were provided. The male to female ratio of incident 
count data was calculated for each combination of sex, region and 
calendar period. From the standard errors, we calculated lower 
and upper 95% confidence intervals. Inverse variance weighting 
was then used to provide a pooled estimate for each IARC region 
in each combination of calendar period by sex.
Results: We identified a total 120,544 cases of mesothelioma 
reported by IARC in the calendar period 1988-2002. There were 
95,466 males and 25,068 females with a male to female ratio of 
3.8. Of the total number of cases, 58% of these were from North 
American region, 33% from European region, 5% from the Oceania 
region, and 3% from the Asian region. The African and Central and 
Southern American regions made up less than 1% of cases res-
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Overall  
Survival
Time To  
Recurrence
#  
Positive
#  
Negative
HR 95% C.I. HR 95% C.I.
All 213 193 2.4 (1.9-3.0) 2.2 (1.7-2.7)
EPP 167 111 1.9 (1.5-2.6) 2.0 (1.5-2.5)
PDC 46 82 3.3 (2.1-5.2) 2.9 (1.9-4.4)
Conclusion: Pathologic ILS involvement is a T2 classification criteri-
on characteristic of 85% of EPP cases. It is most accurately predic-
ted by measured thickness >2mm on CT. However, ILS thickness of 
>5mm is a more discriminant and clinically useful indicator of poor 
outcome, particularly for patients undergoing PDC. As such, this 
measurement represents an available clinical prognostic marker 
not currently included among TNM staging criteria or standard 
radiology reports.
Keywords: Clinical T status, malignant pleural mesothelioma, TNM 
staging, T2 critereon
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P2.14-010 INTRAPLEURAL PERFUSION HYPERTHERMO-
CHEMOTHERAPY WITH CISPLATIN IN PATIENTS WITH 
MALIGNANT PLEURAL MESOTHELIOMA.
Hirozo Sakaguchi, Hironori Ishida, Hiroyuki Nitanda, Nobuhiro 
Yamazaki, Kunihiko Kobayasi, Koichi Kaneko
General Thoracic Surgery, Saitama Medical University International 
Medical Center/Japan
Background: For patients with malignant pleural mesothelioma 
(MPM), intensive local regulations are needed,whether patients will 
be treated with EPP or not. In order to obtain adequate control of 
malignant effusion and expect temporary anti-tumor effect, we 
have introduced intrapleural perfusion hyperthermo-chemothera-
py (IPHC) with cisplatin.
Methods: Twenty-six patients with MPM underwent IPHC at the 
time of pleural biopsy with thoracoscope. Hyperthermo(42.5 
℃)-perfusion was performed with cisplatin (80mg/m2) during 60 
minutes under the general anesthesia. Complications, control of 
pleural perfusion, treatment followed by IPHC, and survival time, 
were studied.
Results: Median age was 68 years (range, 56-82). Twenyy-four pati-
ents were male. Eiteen patients had epitherial, 5 had biphasic,and 
3 had sarcomatoid histology. Fifteen had left-sided disease. There 
were no serious clinical complications associated with this pro-
cedure. The pleural effusion was well controlled in all patients. 
Adjuvant chemotherapies (CT) were performed immediately in 24 
patients. Nine patients were treated by EPP after 2 course of CT: 
One/2/5 year survival rates were 87.5/50.0/37.5 %, respectively. 
MST was 19.5 months.Seventeen patients were treated by CT (pla-
tinum + Pem) : One/2 year survival rates were 81.9/29.8 %, respec-
tively. MST was 14.0 months.
Conclusion: IPHC with cisplatin is easy to perform, and relatively 
safe. This method had brought an ideal pleural adhesion. IPHC 
may offer excellent local control and good survival for patients 
the number and size of colonies formed after NCI-226 cells were 
subjected to anchorage independent growth (p < 0.05). In a pilot 
study using the heterotopic mouse model the size of tumours was 
decreased after 5 days using 20 µM of AQP1 blocker compared to 
an untreated control (n=6 for each group).
Conclusion: Results indicate that AQP1 plays a functional role in 
MPM. Modulation of AQP1 decreases cell proliferation and colony 
formation as well as the growth of MPM tumours in a heterotopic 
mouse model. Larger scale animal studies are required to further 
understand the role of AQP1 in MPM and the potential clinical 
implications of an AQP1 blocker in the treatment of MPM
Keywords: malignant pleural mesothelioma, Aquaporin 1
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P2.14-009 NOVEL CLINICAL ASSESSMENT OF MALIG-
NANT PLEURAL MESOTHELIOMA
Ritu R. Gill1, William Richards2, Beow Y Yeap3, Raphael Bueno2, 
David J. Sugarbaker2
1Radiology, Brigham And Women‘s Hospital/United States Of America, 
2Surgery, Brigham And Women‘s Hospital/United States Of America, 
3Massachusetts General Hospital/United States Of America
Background: Clinical TNM staging of MPM is suboptimal for pre-
dicting prognosis of individual patients. Accurate clinical assess-
ment of T classification is limited by poor contrast resolution of the 
tumor from adjacent structures. Involvement of interlobar septae 
(ILS) is a T2 classification criterion that is amenable to quantitative 
measurement owing to high contrast with surrounding lung paren-
chyma.
Methods: All patients who underwent primary extrapleural pneu-
monectomy (EPP) or pleurectomy (PDC) between 2001-2012 with 
preoperative CT scan available for retrospective review were in-
cluded. ILS were measured at their maximum thickness evident on 
axial CT images. ILS thickness representing the optimal threshold 
for predicting pathologic involvement was determined by ROC 
analysis among patients who underwent EPP with complete patho-
logic analysis including microscopic examination of the ILS. Cox 
regression was used to determine the threshold associated with 
the maximal hazard ratio for death among all patients in the study 
cohort.
Results: 406 patients met criteria for inclusion (278 EPP, 128 PDC; 
319 male; 260 epithelial histology; median age 64). Maximal ILS 
thickness ranged 0 - 50mm, median 5.75mm. Among 269 EPP pa-
tients with ILS pathologically evaluated (229 positive), predictive 
accuracy was optimized at a threshold of >2mm on CT (83% sensi-
tivity, 57% specificity, 79% accuracy). Among 406 patients, hazard 
ratios for death were optimized at threshold of >5mm on CT. The 
table lists the numbers of patients within the entire cohort and 
for the subsets undergoing EPP and PDC who scored positive for 
at the 5mm threshold, as well as the associated hazard ratios for 
death and disease recurrence.  
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of biospecimens and data using standard operating procedures 
based on best practices. A steering committee will have overall 
control of MesobanK. An independent scientific advisory board 
will review applications for samples and advise the steering com-
mittee. Prioritisation for access to samples will be based solely on 
scientific merit. All researchers, whether in the UK National Health 
Service, universities, charities, government agencies or commercial 
companies, and whether based in the UK or abroad will be subject 
to the same application process and approval criteria.
Results: Not applicable
Conclusion: It is anticipated that initial tissue (TMA and cell lines) 
will be available in 2014.
Keywords: Tissue baNKIng, Bioresource, tissue microarray, meso-
thelioma
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P2.14-012 ONCOLYTIC HERPES VIRUS THERAPY FOR 
MESOTHELIOMA- A PHASE I STUDY OF INTRAPLEURAL 
ONCOLYTIC VIRUS HSV1716 (NCT01721018)
Penella Woll1, Sarah Danson1, John Edwards1, Susan Goldsbo-
rough2, Patricia Fisher3, Joe Conner2
1University Of Sheffield, Sheffield Teaching Hospitals/United Kingdom, 
2Virttu Biologics/United Kingdom, 3Weston Park Hospital/United King-
dom
Background: Malignant pleural mesothelioma (MPM) remains 
a major challenge, with limited therapeutic options. Multifocal 
intrapleural disease can cause disabling symptoms of pain and 
breathlessness in the absence of distant metastases, so an intra-
pleural treatment approach is attractive. HSV1716 is a mutant her-
pes simplex virus type 1 deleted in the RL1 gene which encodes 
the protein ICP34.5, a specific determinant of virulence. Mutants 
lacking the RL1 gene are capable of replication in actively dividing 
cells but not in terminally differentiated cells – a phenotype exploi-
ted to selectively kill tumor cells. Activity against mesothelioma 
has been demonstrated in animal models. Studies in adult patients 
with high grade glioma, melanoma and squamous cell carcinoma 
report that HSV1716 is safe and well tolerated when administered 
by intra-tumoral injection. We have therefore designed a phase I 
study to determine the safety, tolerability and potential for efficacy 
of HSV1716 given intrapleurally to patients with MPM.
Methods: The study is an open label, dose escalation, phase I/IIa 
study in a single clinical centre. Patients with a histological diag-
nosis of MPM and an indwelling pleural catheter are eligible if they 
have performance status ≤ 2 and adequate hematologic, renal 
and liver function. Patients will receive 1x107iu HSV1716 through 
their pleural catheter on one, two or four occasions a week apart, 
in three separate patient cohorts. The primary objectives are to 
determine the safety and tolerability of HSV1716 given intrapleu-
rally in patients with inoperable MPM. Detailed safety analyses will 
be undertaken. The secondary objective is to obtain evidence of 
HSV1716 replication and lysis of mesothelioma cells through analy-
sis of pleural fluid by determining the number of viral particles on 
alternate days for one week, after the last Seprehvir administration, 
then weekly. An exploratory objective will be to assess tumour 
response by CT using modified RECIST criteria.
with MPM as a part of multi-modality therapy.
Keywords: cisplatin, malignant pleural mesothelioma, Extra pleuro 
pneumonectomy, Hyperthermo-Chemotherapy
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P2.14-011 MESOBANK: A UK BASED BIORESOURCE FOR 
MALIGNANT PLEURAL MESOTHELIOMA
Robert C. Rintoul1, Doris M. Rassl2, Nick A. Maskell3, Peter W. Sz-
losarek4, Keith M. Kerr5, Richard Booton6, Victoria Hughes1, Dean 
Fennell7, Stefan J. Marciniak8
1Thoracic Oncology, Papworth Hospital/United Kingdom, 2Histopatholo-
gy, Papworth Hospital NHS Foundation Trust/United Kingdom, 3School 
Of Clinical Sciences, Southmead Hospital/United Kingdom, 4Medical 
Oncology, St Batholomew‘s Hospital/United Kingdom, 5Department Of 
Pathology, Aberdeen University Medical School/United Kingdom, 6North 
West Lung Centre, Wythenshawe Hospital/United Kingdom, 7Univer-
sity Of Leicester/United Kingdom, 8Cambridge Institute For Medical 
Research (CIMR), University Of Cambridge, Wellcome Trust/MRC Buil-
ding/United Kingdom
Background: Availability of quality assured, fully annotated meso-
thelioma tissue collected to rigorous standard operating procedu-
res will facilitate better understanding of mesothelioma biology. 
Currently, few bioresources of mesothelioma tissue exist, the lar-
gest being the National Mesothelioma Virtual Bank hosted by the 
University of Pittsburgh (http://www.mesotissue.org/). A few other 
clinical/research groups hold fresh tissue from small numbers of 
mesothelioma patients but these collections are not formally linked 
and often do not involve collection of tissue and data to Standard 
Operating Procedures. The British Lung Foundation/Mick Knighton 
Mesothelioma Research Fund has recently funded MesobanK, a UK 
based bioresource of malignant mesothelioma tissue samples.
Methods: Tissue Microarray: MesobanK will construct a tissue 
microarray (circa 1000 cases) using historical formalin fixed paraffin 
embedded blocks of tissue taken at thoracoscopy/surgical resec-
tion. Inclusion criteria requires sufficient tissue to permit multiple 
0.5 mm cores (to allow for tumour heterogeneity) and a clinical 
minimum data set. Fresh tissue: Fresh frozen mesothelioma tissue 
(300 cases over 3 years) will be collected prospectively from multi-
ple centres across the UK together with parallel pleural fluid, whole 
blood, serum and plasma. Each case will have a detailed anony-
mised linked clinical data set with follow up data. Cell lines: Meso-
banK plans to create 20 new fully annotated mesothelioma primary 
cell lines. The bioresource will be supported by a web-based IT 
infrastructure for annotating and searching the collection. Clinical 
data will be collected on each case and supplemented by labora-
tory and pathology results, Hospital Episode Statistics data and UK 
Cancer Registry data in order to achieve as complete a data set as 
possible. MesobanK will follow the Guiding Principles laid out by 
the NCRI Confederation of Cancer Biobanks and the UK Medical 
Research Council Operational and Ethical Guidelines on Human 
Tissue and Biological Materials for Use in Research. It will also be 
managed within the scope of all relevant regulatory frameworks 
and quality management/quality assurance systems. In addition, 
we share the aim of the US National Cancer Institute (NCI) National 
Biospecimen Network Blueprint: to create a comprehensive frame-
work for sharing and comparing research results through a robust, 
flexible, scalable and secure bioinformatics system that supports 
the collection, processing, storage, annotation and distribution 
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logrank test. The primary analysis of data will be analysed after 111 
OS events.
Results: not applicable
Conclusion: not applicable
Keyword: mesothelioma, clinical trial, phase II,
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P2.14-014 A PHASE 2 RANDOMIZED, DOUBLE-BLIND, 
PLACEBO-CONTROLLED, MULTICENTER STUDY OF VS-
6063 AS MAINTENANCE THERAPY IN SUBJECTS WITH 
MALIGNANT PLEURAL MESOTHELIOMA WHICH HAS 
NOT PROGRESSED ON AT LEAST 4 CYCLES OF PEMET-
REXED/PLATINUM THERAPY
Mitchell Keegan1, Paul Baas2, Dean Fennell3, Richard J. Gral-
la4, Hedy Kindler5, Lee M. Krug6, Anna K. Nowak7, Lawrence H. 
Schwartz8, Joanna C. Horobin1
1Verastem/United States Of America, 2The Netherlands Cancer Insti-
tute/antoni Van Leeuwenhoek Hospital/Netherlands, 3University Of 
Leicester/United Kingdom, 4Albert Einstein College Of Medicine, Jacobi 
Medical Center/United States Of America, 5University Of Chicago/
United States Of America, 6Memorial Sloan-Kettering Cancer Center/
United States Of America, 7School Of Medicine And Pharmacology, Uni-
versity Of Western Australia/Australia, 8Columbia University College 
Of Physicians And Surgeons/United States Of America
Background: Malignant pleural mesothelioma (MPM) is an ag-
gressive tumor in the pleural lining of the lung usually caused by 
asbestos exposure. Median OS following frontline chemotherapy 
with pemetrexed/cisplatin is ~12 months. There is no established 
second line therapy. Approximately 50% of MPM patients exhibit 
homozygous disruption of the NF2 tumor suppressor gene by mu-
tation and/or deletion resulting in lack of expression of functional 
merlin protein. Preclinical data have indicated that mesothelioma 
cell lines that lack NF2/Merlin are especially sensitive to focal ad-
hesion kinase (FAK) inhibition in both cellular and animal models. 
Interestingly, pemetrexed and cisplatin increase cancer stem cells 
(CSCs), while FAK inhibitors have been found to decrease CSCs in 
mesothelioma models. Given the sensitivity of mesothelioma cells 
lacking NF2/Merlin and the effect on CSCs, the use of a FAK inhi-
bitor in a maintenance setting after first line chemotherapy may be 
an attractive strategy to extend survival of MPM patients. VS-6063 
is an orally bioavailable selective inhibitor of FAK. In a phase 1 trial 
VS-6063 was generally well tolerated, with grade 1/2 nausea, vo-
miting and fatigue as the most frequent adverse events (Jones SF J 
Clin Oncol 2011 29:1 suppl; abstr 3002).
Methods: A multinational, randomized, double-blind, placebo 
controlled, phase 2 clinical trial was designed to determine if VS-
6063 provides superior clinical benefit compared with placebo as 
a maintenance treatment in patients with MPM following frontline 
therapy with pemetrexed/platinum therapy. The study aims to 
assess whether VS-6063 improves median OS and median PFS 
over placebo. Randomization will be stratified by Merlin status 
(high versus low) and patients will receive either VS-6063 400mg 
BID continuously or matched placebo (1:1). The study follows an 
adaptive enrichment design where, pending results from an inte-
rim analysis, sampling may be restricted to patients with low Merlin 
protein expression if promising results are observed among the 
Results: The study is open and the first two patients have been 
treated with a single dose of HSV1716 with no dose limiting toxicity 
(DLT) or serious adverse events (SAEs) reported. HSV1716 DNA has 
been detected in pleural fluid samples from one of the patients 
up to one month post treatment.Up to 12 patients will be recrui-
ted and, if successful, a randomised phase II study of intrapleural 
HSV1716 is planned.
Conclusion: Not applicable.
Keyword: oncolytic herpes virus mesothelioma
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P2.14-013 A RANDOMISED PHASE II TRIAL OF ORAL VI-
NORELBINE AS SECOND-LINE THERAPY FOR PATIENTS 
WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 
EXPRESSING BRAC1 - VIM TRIAL
Dean Fennell1, Angela Casbard2, Jason Lester3, Kirsty A. Roberts2, 
Gareth Griffiths2
1University Of Leicester/United Kingdom, 2Institute For Translation, 
Innovation, Methodology And Engagement (Time), Wales Cancer Trials 
Unit/United Kingdom, 3Velindre NHS Trust/United Kingdom
Background: Mesothelioma is increasing worldwide. However the-
re is no approved therapy in the second-line setting. Vinorelbine 
exhibits promising activity, however there has been no randomised 
evaluation or validation of biomarkers to support patient stratifica-
tion. We have recently reported that BRCA-1 is an essential regu-
lator of mesothelioma sensitivity to vinorelbine, and its expression 
is lost in approximately 38%. The UK National Cancer Research 
Institute Lung Clinical Studies Group have therefore developed 
this clinical trial to investigate whether or not giving second-line 
vinorelbine in addition to active symptom control (ASC) will be-
nefit patients in terms of overall survival. The study is funded by a 
research grant from Cancer Research UK (CRUK/12/056) and free 
vinorelbine, labeling and distribution from Pierre Fabre Ltd. The 
trial is sponsored by Leicester University, and coordinated by the 
Wales Cancer Trials Unit, Cardiff, UK.
Methods: A UK multicentre open-label randomised phase II trial. 
Eligible patients include histological diagnosis of mesothelioma, 
received at least one line standard platinum doublet based chemo-
therapy, age >=18 years, measurable lesions by modified RECIST, 
radiological evidence of disease progression and informed con-
sent. Patients will be randomised to either control of active sym-
ptom control (ASC) or ASC plus vinorelbine using a 1:2 allocation 
ratio. ASC will be administered as per local practice, continuing 
follow-up until evidence of radiological progression. Vinorelbine 
will administered at a dose of 60mg/m2 po od on day 1 (equiva-
lent to 25mg/m2 iv day 1) weekly for 3 weeks for the first cycle, 
incrementing to 80mg/m2 weekly (equivalent to 30mg/m2 iv) in the 
absence of haematological toxicity for subsequent cycles. Patients 
will continue chemotherapy until evidence of radiological progres-
sion (or unacceptable toxicity or patient withdrawal). The primary 
endpoint of the trial is overall survival with secondary endpoints 
of tolerability, response rate, change in tumour volume and pro-
gression-free survival. BRCA1 expression IHC will be evaluated as a 
stratification factor. The median OS for patients in the control arm 
is expected to be 1.5 months. With 90% power and a one-sided α 
of 0.2, 114 participants are required (76 in the vinorelbine arm and 
38 in the control arm) to detect a hazard ratio of 0.65, based on the 
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receive either treme or placebo. Randomization will be stratified 
by EORTC status (low-risk vs high-risk), line of therapy (second vs 
third), and anatomical site (pleural vs peritoneal). A total of 180 
subjects will be enrolled at approximately 150 study centers in 
multiple countries. Endpoints: Primary endpoint: Overall Survival 
(OS). Secondary endpoints: durable disease-control rate (DCR); 
progression-free survival (PFS); effect of treme on patient-reported 
outcomes (PROs) including disease-related symptoms, pain sym-
ptoms, and time to deterioration of disease-related symptoms; 
overall response rate (ORR) and duration of ORR; safety and to-
lerability of treme, immunogenicity and pharmacokinetics (PK) of 
treme in treated subjects. Exploratory objectives: DCR, PFS, ORR, 
and duration of response based on immunerelated response crite-
ria (irRC); health-related QoL, disease-related symptoms, pain, and 
health status in subjects with durable clinical activity; biomarkers 
and their association with treme treatment and clinical outcome.
Results: not applicable
Conclusion: Current status: The study started recruiting in 
May 2013. More info is available at ClinicalTrials.gov Identifier 
NCT01843374.
Keyword: CTLA4, mesothelioma, immunotherapy, tremelimumab
subpopulation. Approximately 370 eligible patients with patho-
logically confirmed MPM, who have PR or SD following at least 
4 cycles of pemetrexed with either cisplatin or carboplatin, Kar-
nofsky PS ≥70%, will be enrolled. Patients will continue treatment 
until disease progression. Archival tumor tissue will be used for 
the analysis of Merlin status and is therefore required for partici-
pation. Secondary endpoints include patient-reported outcomes 
of health-related quality of life and disease- or treatment-related 
symptoms utilizing the LCSS-meso scale, objective response and 
safety and tolerability. Clinical trial information: NCT01870609.
Results: not applicable
Conclusion: not applicable
Keywords: cancer stem cells, NF2/Merlin, mesothelioma, FAK
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P2.14-015 A RANDOMIZED, DOUBLE-BLIND STUDY 
COMPARING TREMELIMUMAB TO PLACEBO IN  
SECOND AND THIRD LINE TREATMENT OF SUBJECTS 
WITH UNRESECTABLE PLEURAL OR PERITONEAL  
MESOTHELIOMA
Hedy Lee Kindler1, Alessandra Di Pietro2, Paul B Robbins2, Shengy-
an Hong2, Aiman Shalabi2, Ramy Ibrahim2, Luana Calabro3, Miche-
le Maio3
1The University Of Chicago/United States Of America, 2Medimmune/
United States Of America, 3University Hospital Of Siena/Italy
Background: Malignant mesothelioma (MM) is an uncommon can-
cer, caused principally by asbestos exposure. There is no approved 
treatment after first-line platinum-pemetrexed (Vogelzang, 2003), 
as no agents have shown survival benefit in this setting (Ceresoli, 
2010). Novel approaches are clearly needed. Asbestos exposure 
induces immunosuppression and immune dysfunction in the me-
sothelium environment, mainly by a hyper-activation of regulatory 
T lymphocytes (T-reg) and an over-production of cytokines inhi-
biting cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells 
(Maeda, 2010; Kumagai-Takei, 2011; Robinson, 2011). This suggests 
that agents that target the immune microenvironment may be 
appropriate to evaluate in MM. Cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4, CD152) is expressed upon T-cell activation, 
modulating and eventually switching off T-cell activation. Tremeli-
mumab (treme) binds to CTLA-4 antigen, preventing its negative 
regulatory signal to T cells. Treme has been investigated in more 
than 1000 patients in various tumor types. An Italian investigator-
sponsored Phase 2 study of Treme in 29 MM patients who pro-
gressed on platinum-pemetrexed showed encouraging activity, 
including promising 1- and 2-year survival rates and a safety profile 
consistent with that observed across the clinical development pro-
gram for treme (Calabro et al, 2012). Currently this study has been 
expanded and is exploring an optimized dosing schedule 10mg/kg 
on Day 1, every 4 weeks for 6 doses in induction phase, then every 
12 weeks in maintenance phase until disease progression or severe 
toxicity.
Methods: Study design: This is an international, Phase 2, ran-
domized, double-blind, placebo-controlled study. Subjects with 
unresectable pleural or peritoneal MM who have progressed fol-
lowing 1 (first line regimen containing platin plus pemetrexed) or 2 
prior chemotherapy regimens will be randomized in a 2:1 ratio to 
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P2.15-002 PATTERNS AND PREDICTORS OF RECUR-
RENCE AFTER RADICAL RESECTION OF THYMOMA
Cai Xu, Qinfu Feng, Chengcheng Fan, Yirui Zhai, Yidong Chen, 
Hongxing Zhang, Zefen Xiao, Zongmei Zhou, Jun Liang, Zhougu-
ang Hui, Dongfu Chen, Jie He, Lvhua Wang
Radiation Department, Cancer Institute & Hospita Chinese Academy Of 
Medical Sciences, Peking Union Medical College/China
Background: Even after complete resection, recurrence of thymo-
ma is not uncommon, but the recurrent patterns remain contro-
versial. This study sought to define the patterns and predictors of 
relapse after complete resection of thymoma.
Methods: A single-Institution retrospective study was performed 
of 331 patients who underwent radical resection of thymoma from 
1991 through 2012.
Results: After a median follow-up of 59 months (range, 3-256), the 
recurrence rates was 6.9% (23/331). Overall 5- and 10-year survival 
rates were 92.3% and 84.9%. Cancer specific survival rates were 
95% and 89.4% at 5 and 10 years, respectively. Recurrence-free 
survival rates were 93.6% and 87.2% at 5 and 10 years, respec-
tively. Among the 23 patients, relapses were found in the following 
sites: pleura (thirteen cases), tumor bed (six), lung (six), chest wall 
(four), lymph node metastasis (two) , abdominal node metastasis 
(one),liver (one), pleural effusion (three), and over-lapped recur-
rence (nine). According to the definition of the International Thymic 
Malignancy Interest Group, 10 (43.5%) patients had local recur-
rence, 15 (65.2%) had regional recurrence, 10 (43.5%) had distant 
recurrence (six lung, one liver, one abdominal node metastasis, 
and two lymph node metastasis), and 9 (39.1%) had over-lapped 
recurrence. The difference in survival after recurrence between 
lung and regional relapse was statistically significant (p=0.027), but 
it was insignificant between lung and distant relapse (p=0.808). 
Recurrence rates correlated with the initial Masaoka stage: I, 1.0% 
(2/196); II, 9.7% (9/93) ; III, 24.2% (8/33); IVa, 42.9% (3/7); and IVb, 
100% (1/1). The difference in recurrence between Masaoka stage 
I and II was stastically significant (p=0.000). And they also correla-
ted with World Health Organization tumor type: A and AB, 3.2% 
( 5/154 ); B1, 6% ( 4/67 ); B2, 6% ( 3/50 ); and B3, 22.7% ( 10/44). 
Tumor size demonstrated a step-up of recurrence at 8 cm (<8 
cm, 62.8%; ≥8 cm, 37.2%; P=0.007). In multivariate analysis, Ma-
saoka stage (p=0.005), tumor size (p=0.033), and WHO histology 
(p=0.046) were predictive of recurrence.
Conclusion: Pleura are the most common recurrent sites. Recur-
rence in the lung had poorer survival than the regional relapse, it 
should be included in the distant recurrence. Regional recurrence 
is the most common pattern of relapse, but local and distant recur-
rences are not infrequently observed. Advanced Masaoka stage, 
larger tumor size, and Type B3 were risk factors of recurrence.
Keyword: Thymoma, Recurrence, Patterns of Relapse, Predictors.
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P2.15-001 PREDICTORS OF LONG-TERM SURVIVALS IN 
PATIENTS WITH MASAOKA STAGE III THYMOMAS
Qinfu Feng1, Chengcheng Fan1, Yidong Chen2, Yirui Zhai1, Zong-
mei Zhou1, Dongfu Chen1, Zefen Xiao1, Hongxing Zhang1, Zhougu-
ang Hui1, Jun Liang1, Jima Lv1, Lvhua Wang1
1Radiation Oncology, Chinese Academy Of Medical Scinse And Peking 
Union Medical School, Cancer Hospital/China, 2Radiation Oncology, 
Beijing Shijitan Hospital/China
Background: To analyse long-term survival rates, reccurence rates 
and prognostic factors of patients with Masaoka stage III thymomas.
Methods: A total of 111 patients with stage III thymoma treated in 
our hospital between September 1965 and December 2010 were 
retrospectively analysed. Sixty-eight patients(61.3%) were with com-
plete resection, while 23 patients(20.7%)with incomplete resection 
and 20 patients(18%)with pure biopsy(18 patients wih thoracic ex-
ploration surgery and 2 patients with CT-guidied fine needle punc-
ture biopsy). Fifty-six patients with complete resection(50.5%)and 10 
patients with incomplete resection(9%) had postoperative radiation. 
Twenty patients with pure biopsy received post or preoperative 
radiation or chemotherapy with or without surgery.
Results: The median follow-up time was 66 months(5-540). The 
total overall survival (OS) rates, disease free survival(DFS)rates and 
disease specific survival (DSS) rates at 5 and 10 year were 75.3%, 
60.8%, 81.9% and 54.7%, 41.3%, 67.1%, respectively. Postoperative 
radiotherapy did not improve OS, DFS, DSS compared to surgery 
alone (p=0.316, p=0.729 and p=0.601). The OS at 5 and 10 year 
among the patients with complete resection, incomplete resection 
and pure biopsy were 88%, 59%, 56.7% and 69.3%, 30.6%, 47.3%, 
repectively (p=0.002). The DFS at 5 and 10 year among the patients 
with complete resection, incomplete resection and pure biopsy 
were 73.9%, 40.1%, 41.2% and51.5%, 26.7%, 30.9%, repectively 
(p=0.003). The DSS at 5 and 10 year were 93.9%, 69.2%, 59.7% and 
78.9%, 46.2%, 59.7%, respectively (p=0.004). The total failure rate 
was 36% (40/111), including 30.6% locoregional recurrence and 
9% distant metastasis (including multisite failure). Local recurrent 
rates in patients with postoperative radiotherapy was lower than 
patients with surgery alone (9.4% and 19.2%), but the result was not 
statistically significant (p=0.173). On multivariate analysis, resection 
completeness (p=0.000) and lung involvement (p=0.024) were in-
dependent prognostic factors for DFS, and resection completeness 
(p=0.002), age (p=0.028) and myasthenia gravis (p=0.038) were 
independent prognostic factors for DSS.
Conclusion: Patients with completely resected Masaoka stage III 
thymoma had a better survival and lower recurrence rates than pa-
tients with tumor incompletely resected. The role of postoperative 
radiation needs further investigation. Resection completeness and 
lung involvement were prognostic factors for DFS, and resection 
completeness, age and myasthenia gravis were prognostic factors 
for DSS.
Keywords: radiotherapy, survival, thymoma, surgery
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thymic tumors and controls. In a subset analysis, we found no signi-
ficant differences by WHO histology compared to controls.
Conclusion: AQUA® was used to help overcome limitations of 
analyzing protein expression in histologically heterogeneous thy-
mic tumors with small sample sizes. We found no clinically or statis-
tically significant increased expression of gli1, notch1, and CTNNB1 
in thymoma compared to benign thymic tissue. Thus, this study 
provides no evidence for upregulation of the sonic hedgehog, 
notch or wnt pathways in thymic tumors.
Keywords: tissue microarray, thymoma, stem-cell
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P2.15-004 MANAGEMENT OF PRIMARY TUMOURS 
OF THE THYMUS AND USEFULNESS OF 18F-FLUORO-
DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY 
(FDG-PET).
Sotirios D. Moraitis1, Ioannis Gkiozos2, Konstantinos Kanakakis1, 
Dimitrios S. Moraitis1, Konstantinos N. Syrigos2
1Cardiothoracic Surgery Dpt./ Oncology Unit G‘pp, Naval And Veterans 
Hospital Of Athens/ "Sotiria“Gen. Hospital Of Athens/Greece, 2Oncolo-
gy Unit Gpp, Sotiria General Hospital/Greece
Background: Thymic epithelial tumours are the predominant lesi-
ons that arise in the anterior mediastinum, represent 0.2—1.5% of 
all malignancies and overall, it is an uncommon malignancy with 
an incidence of 0.15 cases per 100,000 population. Recent studies 
have shown the usefulness of 18F-fluorodeoxyglucose positron 
emission tomography (FDG-PET) in differentiating between World 
Health Organization (WHO) histological subgroups of thymic epi-
thelial tumours. We present our experience in the management of 
patients with primary thymic tumours.
Methods: We evaluated retrospectively the medical records of 
21 consecutive patients (pts) who underwent thymectomy in our 
department. All but one patients underwent radical thymectomy 
through a median sternotomy. One female patient was subjected 
to transcervical procedure. In all procedures, the upper and lower 
thymic poles were traced as far into the neck and down toward the 
diaphragm as necessary to ensure complete resection, and all fatty 
tissue between the phrenic nerves was included in the resection. 
Myasthenia gravis was present in 3 pts (14.28 %), while 9 pts (42.85 
%) were asymptomatic.Diagnostic procedures included contrast 
enhanced Computed Tomography of the thorax (21 pts) and/or 
Magnetic Resonance Imaging (3 pts) and in the case of 7 patients, 
an FDG PET-CT was performed. The maximum standardized up-
take value (SUVmax) of the tumor, the mean SUV of mediastinum, 
and the tumor/mediastinum (T/M) ratio (ratio of peak SUV of the 
tumor to mean SUV of mediastinum) were compared to determine 
whether primary thymic tumours could be distinguished by 18F-
FDG PET/CT.
Results: There were 11 male and 10 female pts with a mean age of 
46.09 years. The histopathology examination revealed 13 thymo-
mas, 1 endocrine carcinoma and 7 hyperplasias. 
Type A thymomas were found in 2 pts (15.38 %), AB in 5 pts (38.46 
%), B1 in 2 pts (15.38%), B2 in 1 pt (7.7 %) and B3 in 2 pts (15.38 %), 
while 2 thymomas were unclassified. The mean diameter of the re-
sected masses was 7.03 cm. Three pts were classified as Masaoka 
IIA stage (23.07%) and two as Masaoka IIB (15.38%), who received 
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P2.15-003 GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY 
AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE 
(AQUA) IN A THYMIC MALIGNANCY TISSUE MICROAR-
RAY (TMA)
Jonathan W. Riess1, Robert West2, Sukhmani K. Padda1, Michelle 
Dean3, Alexander Klimowicz3, Chuong Huong4, Joel W. Neal1, Hea-
ther A. Wakelee1
1Medicine, Division Of Oncology, Stanford University School Of Medici-
ne/United States Of America, 2Pathology, Stanford University School Of 
Medicine/United States Of America, 3Functional Tissue Imaging Unit, 
University Of Alberta, Tom Baker Cancer Center/Canada, 4Cardiothora-
cic Surgery, Division Of Thoracic Surgery, Stanford University School Of 
Medicine/United States Of America
Background: Thymoma is a rare malignancy, with a paucity of data 
on its biology and on the role of targeted therapeutics. Wnt, notch 
and sonic hedgehog pathway interactions between thymocytes 
and thymic stroma are important to both thymus and T-cell deve-
lopment. AQUAnalysis® is a digital image analysis software that 
continuously measures multiplexed protein expression and has the 
potential to overcome limitations of small sample sizes and tissue 
heterogeneity in the tumor microenvironment. We analyzed a thy-
moma TMA for gli1, notch1 and CTNNB1 (β-Catenin) expression 
by AQUA® as surrogate markers of activity of the sonic hedgehog, 
notch and wnt pathways, respectively. We hypothesized this pre-
clinical screen may provide rationale for attacking these pathways 
with targeted therapeutics in thymoma.
Methods: A TMA was constructed from 68 patients with thymic 
malignancies and 8 benign thymic controls at Stanford Universi-
ty School of Medicine (Stanford, CA). Gli1, notch1 and CTNNB1 
expression were assayed using quantitative fluorescent immuno-
histochemistry at the Tom Baker Cancer Center (Alberta, Cana-
da). The TMA was stained with anti-gli1 rabbit mAb (monoclonal 
antibody), clone EPR4523 (Epitomics, Burlingame, CA, USA); anti-
Notch1 rabbit mAb, clone EP1238Y (Epitomics, Burlingame, CA, 
USA); and anti-beta-catenin mouse mAb, clone β-Catenin-1 (Dako 
Mississauga, ON, Canada) using a Dako autostainer. To isolate 
expression of these stem-cell pathway proteins separately in the 
tumor and the lymphocytes, the TMA was also stained with anti-
pan-cytokeratin guinea pig mAb (Acris, San Diego, CA, USA); anti-
vimentin rat mAb, clone 280618 (R&D Systems, Minneapolis, MN, 
USA); and anti-CD45 rabbit mAb, clone EP322Y (Epitomics, Bur-
lingame, CA, USA). Automated image acquisition was performed 
using an Aperio Scanscope FL (Aperio Inc., Vista, CA, USA). Ima-
ges were then analyzed using the AQUAnalysis® program, version 
2.3.4.1. A tumor-specific mask and a tumor cytoplasmic mask were 
generated to distinguish thymoma cells from surrounding stro-
mal tissue by thresholding the pan-cytokeratin images to identify 
pan-cytokeratin positive cells as tumor cells and define the tumor 
cytoplasm. Statistical analysis was performed using SAS Enterprise 
Guide v5.0 (Cary, NC). Two-tailed t-tests were used to compare 
the differences between thymic tumor and benign control tissue. 
ANOVA and Dunnett’s t-test was used to compare differences in 
gli1, notch1, and CTNNB1 expression by WHO histology.
Results: Demographics for 68 patients: M:F (53%/47%), Mean 
age at diagnosis: 55 years, WHO Histology: A (10%), B (57%), AB 
(24%), C (4%), unclassified (4%), Pathologic Masaoka Stage: I (46%), 
IIa (18%), IIb (4%), III (18%), IVa (9%) IVb (6%). No difference in gli1 
(mean 201 vs. 211, p=0.31), CTNNB1 (mean 396 vs. 418, p=0.66) or 
notch1 expression (mean 317 vs. 325, p=0.82) was noted between 
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was better than those of 33 patients who were received chemothe-
rapy with or without radiotherapy alone (5 year survival rate, 84.8% 
vs. 10.4%, p<0.001). On multivariate analysis, the extent of surgical 
resection (complete resection vs. unresectable tumors: hazard ra-
tio [HR] =0.117; 95% CI 0.038-0.365; p<0.001, incomplete resection 
vs. unresectable tumors: HR=0.200; 95% CI 0.075-0.536; p=0.001) 
was the sole independent prognostic factor in this study.
Conclusion: The prognosis of patients with thymic carcinoma is di-
stinct according to the extent of surgical resection. Initial chemora-
diotherapy followed by surgical resection may produce long-term 
survival even at advanced stages of disease. Surgical resection of 
regressed tumors at loco-regional disease after initial chemothera-
py with or without radiotherapy should have attempted.
Keywords: Masaoka-Koga stage, surgical resection, Chemoradia-
tion therapy, Thymic carcinoma
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P2.15-006 RETROSPECTIVE STUDY ON THE EFFICACY 
OF MULTIDISCIPLINARY THERAPY FOR THYMIC CAN-
CERS
Masayuki Hashimoto, Jun Hanaoka, Koji Teramoto
Division Of General Thoracic Surgery Department Of Surgery, Shiga 
University Of Medical Science/Japan
Background: Thymic cancer is relatively rare malignant disease, 
and the therapeutic strategy remains to be explored. The purpose 
of this study is to evaluate the clinical features of thymic cancers 
after multidisciplinary therapy.
Methods: From January 2004 to December 2012, 13 patients were 
diagnosed with thymic cancer in our hospital. Clinical features of 
12 cases except 1 case who was given best supportive care from 
the beginning were evaluated retrospectively.
Results: The mean age of patient was 62 years old, ranging 41 
to 79 years old. Stages of tumors according to Masaoka sta-
ging system were as follows; the number of patients with stages 
1/2/3/4A/4B was 1/2/4/0/5, respectively. The pathological subty-
pes of the tumor according to the WHO histological criteria inclu-
ded squamous cell carcinomas in 7 cases, adenocarcinomas in 3, 
large cell neuroendocrine carcinoma (LCNEC) in 1 and undifferen-
tiated carcinoma in 1. Of 12 patients, 6 patients (50.0%) underwent 
complete resection of both tumor and thymic tissues (Surgery 
group, the number of patients with stage 1/2/3/4A/4B=1/2/2/0/1) 
and others (50.0%) received chemo-radiotherapy (Non-surgery 
group, the number of patients with stage 1/2/3/4A/4B = 0/0/2/0/4). 
In Surgery group, 5 patients (83.3%) received adjuvant radio- or 
chemotherapy. Despite of multidisciplinary therapy, recurrences 
of the tumor were observed in 2 cases (33.3%) with pathological 
subtypes of adenocarcinoma and LCNEC. The median disease 
free survival after surgery in Surgery group was not reached at the 
time of this analysis. Kaplan-Meier analysis revealed that the me-
dian survival times after the treatment in Surgery and Non-surgery 
groups were 53.0 and 18.0 months, respectively, indicating that 
patients in Surgery group had significant longer survival than those 
in Non-surgery group (P=0.049, log-lank test).
Conclusion: Multidisciplinary therapy including complete resec-
tion of tumors can achieve better therapeutic outcomes. Non-
adjuvant radiotherapy. All the others were classified as Masoka I. 
All tumours were totally resected. The 5 year survival was 100%. 
There was recurrence of the endocrine carcinoma within 5 years 
and the pt underwent a reoperation.The SUVmax values of 
thymomas were 2.31+/- 0.59, while the SUVmax values of mediasti-
num were 1.74 +/- 0.08.
Conclusion: Tumours of the thymus are an heterogeneous group 
of tumours, ranging from relatively “benign”thymomas to highly 
aggressive carcinomas. Surgery continues to be the mainstay of 
treatment and complete resection of the tumour remains the most 
important prognostic factor. A recurrence should be completely 
resected whenever possible, because this approach is associated 
with good long-term survival. FDG-PET can help characterize vari-
ous thymic lesions, however, larger prospective studies are further 
required to substantiate these findings.
Keywords: Thymic tumours, 18F-fluorodeoxyglucose positron 
emission tomography (FDG-PET)., thymoma, Median sternotomy
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P2.15-005 LONG-TERM SURVIVAL AFTER THE MULTIMO-
DAL TREATMENT OF THYMIC CARCINOMAS: A SINGLE 
CENTER EXPERIENCES IN 90 CASES.
Geun Dong Lee, Dong Kwan Kim, Hee Suk Jung, Se Hoon Choi, 
Hyeong Ryul Kim, Yong-Hee Kim, Seung-Il Park
Department Of Thoracic And Cardiovascular Surgery, Asan Medical 
Center/Korea
Background: Thymic carcinomas are rare aggressive tumors. We 
reviewed our experiences to evaluate the long-term prognosis 
regarding the multimodal treatment of thymic carcinoma.
Methods: A retrospective analysis was made of a total number 
of 90 patients who diagnosed with thymic carcinomas between 
December 1997 and July 2012. Among patients, 33 patients were 
treated with surgical resection followed by radiotherapy with or 
without chemotherapy. Of the remaining 57 patients treated initi-
ally with chemotherapy with or without radiotherapy for advanced 
thymic carcinoma, 24 patients could have surgical resections. The 
survival rate was compared between the groups. Stage was mea-
sured according to the Masaoka-Koga system.
Results: The study group was composed of 57 men and 33 wo-
men, with a mean age of 51.5 (±1.2 years). At the time of diag-
nosis, 10 patients (11.1%) had stage I disease, 14 (15.6%) stage II, 
21 (23.3%) stage III, and 45 (50.0%) stage IV. Histologic subtypes 
included 50 squamous cell carcinoma (55.6%), 10 poorly-differenti-
ated neuroendocrine carcinoma (11.1%), 5 well-differentiated neu-
roendocrine carcinoma (carcinoid tumors, 5.6%), and 4 other types 
(4.4%) among 69 patients whose histologic classification were 
made by pathologic study. Overall survival rates were 55.1% at 5 
years and 32.3% at 10 years. Five year survival rates were 100% 
in stage I or II, 68.8% in stage III, and 39.8% in stage IV (p=0.012). 
Five year survival rates of the patients had treated with complete 
resection, the patients with incomplete resection, and the patients 
with unresectable tumors were 95.0%, 84.4%, 10.4%, respectively 
(p<0.001). In regard to the role of chemoradiotherapy, the survival 
rate of 24 patients had treated with initial chemotherapy followed 
by surgical resection, consisted of 13 cases of complete resection 
and 11 cases of incomplete resection and 4 cases of exploration, 
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glass slides. Digital imaging is a good tool for remote consultation 
and educational purposes. In the majority of specimens, patho-
logists are able to make the correct diagnosis. Major challenges 
include distinguishing B3 tumors and carcinomas and tumors with 
morphologic heterogeneity. The overall agreement can be impro-
ved after training. This technology could be used to establish a 
digital slide bank which could provide a method for training patho-
logists with less experience in the pathology of thymic epithelial 
tumors, to foster collaborative work in the field, and diagnostic 
consultation.
Keywords: thymoma, digital microscopy, classification
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P2.15-008 COMPARISON OF OUTCOMES AFTER EXTEN-
DED THYMECTOMY FOR MYASTHENIA GRAVIS BY PRE-
SENCE OF THYMOMA
Shoko Kadoma, Yuichi Ozeki
Thoracic Surgery, National Defense Medical Collage/Japan
Background: Thymoma occurs in about 10-20% of myasthenic 
patients and in turn, 20-25% of patients with a thymoma have my-
asthenia gravis. The patients with myasthenia gravis are treated by 
extended thymectomy. The aims of this study were to analyze the 
clinical outcomes of myasthenic patients after extended thymecto-
my by presence of thymoma.
Methods: Forty one patients with myasthenia gravis (27 patients 
without thymoma: Group A and 14 patients with thymoma: Group 
B) underwent extended thymectomy between 1995 and 2013. In 
patients with thymoma, the WHO histological classification was: A 
in 2 cases, B1 in 3, B2 in7, and B3 in 2. The Masaoka clinical staging 
was: I in 4 cases, II in 7, IVa in 3. A change of clinical manifestation 
was examined with QMG score. Reduction of anti-acetylcholine 
receptor antibody titer (anti-AchR) was evaluated before and at 3 
months after thymectomy.
Results: Mean follow-up period was 8.7 years (range, 0.3 to 17.8). 
The frequency of postoperative re-aggravation was significantly 
high in group B (5/14) in comparison with group A (1/27). The anti-
AchR were reduced from 170.9 to 76.7 (p=0.029) in Group A, and 
were increased from 22.4 to 35.8 (n.s.) in Group B. Re-elevation of 
anti-AchR after surgery was recognized to 7.4% (2/27) in Group A 
and 42.9% (6/14 ) in Group B, respectively.
Conclusion: These data suggest that extended thymectomy for 
myasthenia gravis is more effective in patients without thymoma 
than in those with thymoma.
Keywords: myasthenia gravis, thymoma, extended thymectomy
squamous cell carcinomas are likely to be subtypes with poor pro-
gnosis despite of multidisciplinary therapy.
Keywords: Thymic Cancer, Multidisciplinary therapy, squamous 
cell carcinoma
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P2.15-007 DIGITAL MICROSCOPY REPRODUCIBILITY 
STUDY OF THYMIC EPITHELIAL NEOPLASMS
Andre L. Moreira1, Wang Hangjun1, Camelia S. Sima2, Mary Beth 
Beasley3, Peter Illei4, Anjali Saqi5, Daisuke Nonaka6, Kim Geisinger7
1Pathology, Memorial Sloan Kettering Cancer Center/United States 
Of America, 2Biostatistics, Memorial Sloan-Kettering Cancer Center/
United States Of America, 3Pathology, Mount Sinal School Of Medicine/
United States Of America, 4Dept Of Pathology, Johns Hopkins/United 
States Of America, 5Pathology, Columbia University Medical Center/
United States Of America, 6The Christie NHS Foundation Trust/United 
Kingdom, 7Piedmont Pathology Associates; Universitiy Of North Caroli-
na At Chapel Hill/United States Of America
Background: Thymic epithelial tumors are rare and morphologi-
cally heterogeneous which constitutes interpretive challenges to 
practicing pathologists. Advances in digital imaging provide an 
opportunity to disseminate knowledge of these rare tumors, and 
can be potentially useful as diagnostic and educational tools. How-
ever the diagnostic reproducibility utilizing digital slide imaging 
needs to be validated.
Methods: Twenty cases of thymomas or thymic carcinomas with 
characteristic morphologic features were scanned into the APERIO 
system. The images were sent to pathologists with expertise in 
thoracic pathology in 6 different centers. The pathologists were 
asked to classify the tumors according to the World Health Orga-
nization (WHO) 2004 classification and to evaluate invasion on the 
scanned material. In addition, they were asked to indicate their 
confidence in the diagnosis using the imaging system. Interob-
server agreement was evaluated. After discussions of the first 20 
cases, a second round representing 10 cases were evaluated by 
digital images by the participating pathologists.
Results: In the initial phase, there was agreement among patho-
logists for the diagnosis of thymoma and thymic carcinoma in 75 
% of cases (n= 14), in the remaining 6 cases, the disagreement 
was between cases of B3 thymoma and thymic carcinoma in five 
and between Type A thymoma and thymic carcinoma in one (kap-
pa=0.43, moderate agreement). Perfect agreement was seen in 4 
thymoma cases, where all pathologists diagnosed the same WHO 
type. These were classical cases with pushing borders and large 
fibrous bands. In other cases there were disagreements among the 
classification of the tumor as B2, B3, and AB. The cases with most 
disagreement were histologically heterogeneous with combined 
patterns. When invasion was evaluated, the overall k coefficient 
is 0.49 for the presence of invasion. In the second round of cases, 
we observed an improvement in interobserver agreement for 
diagnosis thymoma vs thymic carcinoma (kappa = 0.63) and for 
determination of invasion (present versus absent) (k=0.57). Most 
pathologists found that the digital images were comparable with 
glass slides and the overall confidence in the diagnosis was good.
Conclusion: The diagnostic accuracy of thymic epithelial tumors by 
digital images is equivalent to that reported in prior studies using 
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P2.16-002 LONG-TERM TREATMENT RESULTS IN SOFT 
TISSUE SARCOMAS OF THE THORACIC WALL TREATED 
BY PRE-OR-POSTOPERATIVE RADIOTHERAPY IN A MUL-
TIDISCIPLINARY APPROACH- 
RESULTS OF THE CTF SARCOMA GROUP
H Fazilet Dincbas1, Nil Mandel2, Sevim Ozdemir1, Nuri Kaydıhan1, 
Didem Colpan Oksuz1, Sergulen Dervisoglu3, Murat Hız4, Hasan 
Tuzun5, Sedat Koca1
1Radiation Oncology, Istanbul University Cerrahpasa Medical School/
Turkey, 2Medical Oncology, VKV American Hospital/Turkey, 3Pathology, 
Istanbul University Cerrahpasa Medical School/Turkey, 4Orthopedic 
Surgery, Istanbul University Cerrahpasa Medical School/Turkey, 5Car-
diovasculary And Thoracic Surgery, Istanbul University Cerrahpasa 
Medical School/Turkey
Background: To evaluate the long term treatment results and the 
prognostic factors among patients with soft tissue sarcoma of the 
thoracic wall who were treated with pre-or postoperative radiothe-
rapy
Methods: Forty two cases were referred to our clinic between 
December 1980- December 2007 with the diagnosis of soft tissue 
sarcoma of the thoracic wall, and 13 of them were excluded from 
further evaluation due to the absence of radiotherapy indication 
or the predilection of the patients to receive radiotherapy at ano-
ther center. The mean age was 44 (14-85) and 15 of them were 
male and 11 female. Malignant fibrous histiocytoma was the most 
common histopathology (27.6%). 7 patients had well differentiated, 
6 had moderately differentiated and 13 had poorly differentiated 
tumor. Tumor size varied between 1- 25 cm (mean 7.8 cm). Twenty 
one of the patients admitted to our clinic after primary surgery, 5 
after local recurrence. Seventeen of the cases had marginal and 9 
had wide local resection. The surgical margin was positive in 11 of 
the patients. Four cases received postoperative radiotherapy with 
a mean dose of 60 Gy (50-66 Gy) and 22 received preoperative 
radiotherapy with a mean dose of 46 Gy. adjuvant chemotherapy 
with Doxorubicin, Ifosfamide and Holoxan was given to 6 patients.
Results: Mean follow-up time was 97 (9-309 months) months. Nine 
patients (34.6%) developed local recurrence with a median time 
to recurrence of 20 months (2-53 months). the surgical margin was 
positive in 6 of them. All patients with recurrent disease had un-
dergone surgery. And 4 of them were treated with chemotherapy, 
1 of them received external radiotherapy, and 1 patient received 
brachytherapy afterwards. 11 (42.3%) patients developed distant 
metastasis after a median of 40 months (4-92 months). The most 
common metastases sites were the lungs (38.5%) and the bones 
(3.8%). Three cases developed both local and distant metastasis. 
Five-year local control (LC), disease-free survival (DFS), overall 
survival (OS), and disease-specific survival (DSS) rates were 62%, 
38%, 69%, and 76% respectively. Chemotherapy was given to all 
cases developing distant metastasis. Seventeen cases died due to 
disease progression, 2 patients died due to cardiac disorders. On 
univariate analysis, although LC was approximately twice worse for 
the patients with positive surgical margin, the difference was not 
significant. 5-year DFS and DSS rates were significantly worse for 
the patients with poorly differentiated tumors than well and mode-
rately differentiated tumors (0%, 66% and 60%, 92% respectively. 
DFS was significantly better for the patients who received chemo-
therapy (p=0.01) and there was a trend for DSS (p=0.09). On multi-
variate analysis, no factor affected the results significantly.
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P2.16-001 DIAGNOSIS AND SURGICAL RESECTION OF 
SOLITARY PULMONARY NODULES IN PATIENTS WITH 
BREAST CANCER
Kimihiro Shimizu1, Kazumi Tanaka1, Toshiteru Nagashima1, 
Yoichi Ohtaki1, Seiichi Kakegawa1, Jun Atsumi1, Takashi Ibe1, Kai 
Obayashi1, Masayuki Sugano1, Mitsuhiro Kamiyoshihara,1, Osamu 
Kawashima1, Kyoichi Kaira2, Izumi Takeyoshi1
1Division Of Thoracic And Visceral Organ Surgery, Gunma University 
Graduate School Of Medicine/Japan, 2Department Of Medicine And Mo-
lecular Science, Gunma University Graduate School Of Medicine/Japan
Background: The differential diagnosis of solitary pulmonary no-
dules (SPNs) in patients with breast cancer is vital but difficult using 
radiological features. We assessed the nature of SPNs in these 
patients and the role of surgery in diagnosis and treatment.
Methods: Thirty consecutive patients who underwent surgery for 
an SPN between 2002 and 2011 after curative surgery for breast 
cancer were retrospectively evaluated.
Results: Most (93%) SPNs were malignant. Pathological diagno-
ses in patients with SPNs were primary lung cancer (n = 20, 67%), 
pulmonary metastasis from breast (n = 7, 23%) or colon (n = 1, 3%) 
cancer, and benign conditions (n = 2, 7%). Among the 20 patients 
with primary lung cancer, 15 (75%) had stage IA tumors (T1aN0M0). 
The average disease-free interval was significantly longer in pati-
ents with primary lung cancer than in those with pulmonary meta-
stases from breast cancer (P = 0.031). The five-year survival rates 
after pulmonary resection for lung metastasis from breast cancer 
patients and primary lung cancer patients were 100 and 61.1%, 
respectively.
Conclusion: SPNs found in patients with breast cancer have a high 
probability of malignancy, especially primary lung adenocarcino-
ma. Early resection of SPNs in patients who were diagnosed with 
both primary and metastatic lung cancer led to a good prognosis. 
We suggest that early pathological diagnosis by surgical resection 
should be conducted for the early diagnosis and appropriate treat-
ment of SPNs in patients with breast cancer.
Keywords: Solitary pulmonary nodule, Lung cancer, Breast cancer, 
metastasectomy
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Conclusion: Outcomes from VATS are comparable to, if not better 
than, open thoracotomy. VATS is a suitable choice for pulmonary 
metastasectomy.
Keywords: open thoracotomy, survival, pulmonary metastasecto-
my, VATS
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P2.16-004 MEDICAL MANAGEMENT OF PULMONARY 
CARCINOID TUMORS
Curtis Chong1, Lori Wirth2, Aileen Chen1, Lynette Sholl1, Pasi Jan-
ne1, Bruce Johnson1
1Dana-Farber Cancer Institute/United States Of America, 2Massachu-
setts General Hospital/United States Of America
Background: The optimal medical management of pulmonary 
carcinoid tumors, which comprise 1-2% of all lung cancers, remains 
to be determined.
Methods: We conducted a retrospective review of patients with 
typical and atypical pulmonary carcinoid tumors treated at our 
institution between 1990-present.
Results: We identified 34 patients treated with chemotherapy, 
including 26 patients with metastatic disease (22 atypical), and 8 
patients treated with adjuvant platinum-etoposide chemoradia-
tion (6 atypical, 2 typical, 6 stage IIIA, 2 stage IIB). At an average 
follow-up of 12 months there were 2 recurrences in the 8 patients 
receiving adjuvant treatment, both of whom had atypical carcinoid 
(1 stage IIIA, 1 stage IIB). Of patients with metastatic disease, the 
principal sites of metastasis were the liver (70%), bone (40%), and 
brain (25%); median survival after diagnosis of metastatic disease 
was 3.4 years with a 5 year survival of 29%. Regimens showing effi-
cacy in metastatic disease include octreotide (77% stable disease), 
etoposide-cisplatin (29% disease control, 4 partial response, 1 
stable disease), and temozolomide (44% disease control, 2 partial 
responses, 2 stable disease).
Conclusion: These results support our previous finding that pul-
monary carcinoid tumors are responsive to chemotherapy and that 
adjuvant therapy should be offered to patients with stage II or IIIA 
resected disease.
Keywords: Atypical Carcinoid, Neuroendocrine lung cancer, Pul-
monary Carcinoid, typical carcinoid
Conclusion: In our series, high grade found to be the most impor-
tant factor affecting prognosis. Although we couldn’t show statisti-
cally, it seems that radiotherapy helped to achieve better LC, even 
in margin positive patients. In addition to this, while a definitive 
conclusion is not possible due to the small number of cases, che-
motherapy improved the treatment results.. Thoracic wall sarcomas 
should be approached in a multidisciplinary manner as with sarco-
mas in other regions.
Keyword: thoracic wall sarcomas, radiotherapy,prognostic factors
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P2.16-003 THE EFFICACY OF VATS VERSUS OPEN THO-
RACOTOMY: A SYSTEMATIC REVIEW
Mun Yoong Cheang, Pradyumna Herle, Marzi Mehta, Phillip An-
tippa
Cardiothoracic Surgery, The Royal Melbourne Hospital/Australia
Background: VATS has become an increasingly popular technique 
for the cardiothoracic surgeon. Its use in the treatment of malig-
nancy has been an issue of debate previously. Whilst its use has 
been documented for the treatment of primary lung cancers, its 
use in metastasectomy has been brought under question for se-
veral reasons. The low sensitivity of pre-operative CT in diagnosis 
of metastatic disease in the lungs, compared to palpation means 
that VATS may miss resection of metastatic lesions. VATS has also 
been associated with pleural and port site seeding. Whilst there 
have been several studies demonstrating roughly equivalent sur-
vival and more rapid post-operative recovery in minimally invasive 
approaches, there remains no randomised trials and other high 
level evidence regarding the oncological outcomes of VATS versus 
open thoracotomy for pulmonary metastases. This article attempts 
to provide a systematic review of studies which have directly com-
pared open and VATS resection of pulmonary metastasis in terms 
of outcome.
Methods: The study followed the PRISMA protocol for systematic 
reviews and meta-analyses. The search strategy included an elec-
tronic literature review using the PubMed database. The MeSH 
terms utilised were pulmonary metastasectomy, VATS, thoraco-
scopic and open. The inclusion criteria for the studies are that they 
had to have 2 limbs for direct comparison of VATS and open thora-
cotomies. The studies should also provide data regarding overall 
survival data or recurrence free survival data separately for the 2 
limbs of the study.
Results: Nine studies with 777 patients fulfilled the inclusion cri-
teria. The VATS groups had slightly higher odds of 1, 3 and 5 year 
survival with OR of 1.53, 1.69 and 1.41 respectively. All these re-
sults demonstrated no heterogeneity on testing. However, only 3 
year survival was statistically significant for overall effect. The VATS 
group also had higher odds of 1, 3 and 5 year recurrence free sur-
vival with OR of 1.29, 1.54 and 1.54 respectively for each of these 
outcomes. Once again the tests demonstrated no significant he-
terogeneity on testing. None of the outcomes demonstrated sta-
tistical significance in testing for overall effect. Overall pulmonary 
recurrence had lower odds in the VATS group with an odds ratio 
of 0.55. This data was not significantly heterogenous (p = 0.15) and 
did not demonstrate statistical significance in testing for overall 
effect also (p = 0.28).
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P2.17-002 RETROSPECTIVE STUDY OF 5-YEAR  
EXPERIENCE WITH ENDOBRONCHIAL CRYOBIOPSY  
IN REPUBLIC OF ESTONIA.
Tõnu Vanakesa1, Ingemar Almre1, Sirje Marran2
1North Estonia Medical Center/Estonia, 2Tartu University Clinics/ 
Estonia
Background: We report North Estonia Medical Center and Tartu 
University Clinic 5-year experience with cryobiopsy in diagnosing 
endobronchial malignancies. The purpose of this study is to assess 
the diagnostic efficacy of the procedure, sampled tissue size and 
side effects of cryobiopsy in patients with central airways malig-
nances.
Methods: The freezing system which operates according to the 
principle of the Joule-Thomson effect was used for cryobiopsy (CB) 
during fiberoptic videobronchoscopy (FVB) under local anaestesia 
(Erbokryo CA, ERBE Elektromedizin GmbH, Germany) with use of 
2.4 mm cryoprobe.
Results: Three hundred and thirteen patients (mean age 65.5 yr, 
range 17- 88) with clinical and radiological suspicion of endobron-
chial malignancy underwent FVB with routine collection of CB sam-
ples from February 2007 to January 2013. A total of 385 cryobiop-
sies, ranging from 1 to 4 for a patient, with median sample size of 
9.86 mm, were obtained from the trachea, main bronchi or lobar 
bronchi. The CB specimens were free of artefacts, contained suf-
ficient tissue for the definite pathological diagnosis and had well-
preserved surface epithelium, if visible in the biopsy, according to 
the pathology reports. The diagnosis of endobronchial malignancy 
was verified in 298 patients (95,5.%) with CB-s. In 3 cases, all CB-s 
taken from segmental and subsegmental airways, re-bronchoscopy 
with new CBs was successfully applied to verify the cancer diag-
nosis. In 15 cases (4, 79 %), the use of CB was unable to confirm 
the malignancy: the morphology was confirmed by using other 
minimally invasive endoscopic methods (TBNA, EBUS-TBNA or 
EUS-FNA). No CB associated complications requesting special 
intervention were observed. In 35 cases, immediate re-canalization 
of the bronchi obstructed by the endobronchial tumor was achie-
ved in parallel to CBs for the diagnosis. No difference in diagnostic 
results was observed regardless the number of collected tissue 
samples for a patient.
Conclusion: CB is superior human bronchial tissue biopsying me-
thod; biopsying efficiency is very high, sampled tissue size and 
morphological quality cryo-bioptates is excellent, and no proce-
dure related complications were observed. CB during FVB has also 
paramount value in terms of preserving high quality tissue for the 
genetic mutations testing in the era of rapidly evolving persona-
lized medicine in lung cancer.
Keyword: bronchoscopy, cryobiosy, endobronchial malignancies.
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P2.17-001 A COMBINATION USE OF MULTI-GUIDED 
DEVICES IN THE BASIS OF THE OBTAINED DATA FROM 
VIRTUAL BRONCHOSCOPIC NAVIGATION LUNGPOINT 
SYSTEM USING THIN VIDEO-BRONCHOSCOPE FOR DIA-
GNOSING SMALL (≤ 30 MM) PERIPHERAL PULMONARY 
LESIONS SUSPECTED LUNG CANCER
Masafumi Misawa, Motohisa Takai, Yu Munakata, Haruki Koba-
yashi, Kei Nakashima, Naoko Katsurada, Hideki Makino, Norihiro 
Kaneko, Masahiro Aoshima
Pulmonary Department, Kameda Medical Center/Japan
Background: The concept of“Guided Bronchoscopy”has been 
gradually notable because of the contribution to increasing the 
diagnostic yields for small peripheral pulmonary lesions (PPLs). 
Navigation systems such as electromagnetic navigation (EMN) and 
virtual bronchoscopic navigation 
(VBN) have been fundamental equipments for that concept. We 
have been consistently used this navigation software LungPoint 
(Broncus Technologies, Inc., Mountain View, CA) since it was gone 
on sale in Japan. We aimed to furthermore increase of diagnostic 
yields for small (≦30 mm) PPLs by diversified approach case by 
case in the basis of the LungPoint data using thin video-broncho-
scope (P260F, 4-mm outer diameter; Olympus, Tokyo, Japan)
Methods: Between October 2010 and January 2013, a new com-
bination diagnostic technique was all performed for the first time 
for the consecutive 132 patients (139 lesions) at our hospital. All 
of the patients had small PPLs with diameters of 30 mm or less 
as determined by chest computed tomography which were sus-
pected of primary lung cancers. We used all of the data obtained 
from LungPoint system such as VB-image, navigating pathway and 
virtual fluoroscopic image to determine how to approach to the 
target bronchus into which the bronchoscope should be advanced. 
The other guided devices such as 20-MHz mechanical radial-type 
probe EBUS (RP-EBUS) and a guide sheath (GS) kit (Olympus, To-
kyo, Japan) with an external diameter of 1.95 mm including forceps 
and brushing were used in combination case by case. Primary 
endpoints were overall diagnostic yield and diagnostic yield of 
malignancy.
Results: The variation of a combination use of multi-guided de-
vices was VBN/VBN-EBUS/VBN-EBUS-GS. The number of lesion 
using each method was 34/47/58. The overall diagnostic yield of 
132 cases (139 PPLs) was 74.8%. Diagnostic yield of malignancy 
was 66.7%.
Conclusion: A new combination of multi-guided devises technique 
via thin video-bronchoscope following the obtained data from 
LungPoint system was useful to determine what devices we should 
choice for approaching to the target and contribute to increasing 
the diagnostic yield for small (≦30 mm) peripheral pulmonary  
lesions.
Keyword: virtual bronchoscopic navigation, LungPoint, EBUS, thin 
video-bronchoscope,
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Conclusion: EBUS-MP is a relatively novel technique in broncho-
scopy. Our early experience has demonstrated some potential 
usefulness of the procedure. EBUS-MP allows good visualisation 
of lesions, can deliver a tissue diagnosis and provide reassurance. 
No complications have occurred to date. We believe that EBUS-MP 
sampling may have a role in investigation of peripheral pulmonary 
mass lesions. In a well selected cohort of patients it appears to be 
a safe alternative to CT-guided biopsy.
Keywords: EBUS-Miniprobe, Non-surgical investigation, Lung 
Cancer alternative investigation, Peripheral Pulmonary Mass Lesi-
ons
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P2.17-004 ENDOBRONCHIAL ULTRASOUND GUIDED 
TRANSBRONCHIAL NEEDLE ASPIRATION (EBUS-TBNA) 
INVESTIGATION OF MEDIASTINAL LYMPHADENOPA-
THY OF UNKNOWN AETIOLOGY
Philip A. Reid1, William Wallace2, Kristopher M. Skwarski3
1Respiratory Department, Royal Infirmary Of Edinburgh/United King-
dom, 2Department Of Pathology, Royal Infirmary Of Edinburgh/United 
Kingdom, 3Respiratory Medicine, Royal Infirmary Of Edinburgh/United 
Kingdom
Background: Endobronchial ultrasound guided transbronchial 
needle aspiration (EBUS-TBNA) now offers an accurate and mini-
mally invasive alternative to cervical mediastinoscopy for the pa-
thological assessment of mediastinal and hilar lymphadenopathy. 
We aimed to establish amongst patients with mediastinal and hilar 
lymphadenopathy of unknown aetiology and without a radiological 
identified primary tumour; the yield from EBUS-TBNA for benign 
and malignant pathologies and the requirement for subsequent 
investigations in order to confirm a pathological diagnosis in non 
diagnostic TBNA samples.
Methods: We retrospectively reviewed 418 endobronchial ul-
trasound examinations performed between 03/01/2011 and 
01/03/2013 at the Royal Infirmary of Edinburgh. All patients had a 
pre-sampling CT thorax and a maximum lymph node diameter of 
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P2.17-003 EARLY EXPERIENCE OF ENDOBRONCHIAL 
ULTRASOUND-MINIPROBE (EBUS-MP) FOR INVESTIGA-
TION OF PERIPHERAL PULMONARY MASS LESIONS
James F. Tiernan1, William Wallace2, Kristopher M. Skwarski1
1Respiratory Medicine, Royal Infirmary Of Edinburgh/United Kingdom, 
2Department Of Pathology, Royal Infirmary Of Edinburgh/United King-
dom
Background: The frequency of detection of peripheral pulmonary 
mass lesions is rising with increasing availability of radiological 
imaging. Their aetiology may need to be established, particularly 
in cases of suspected malignancy. Traditional means of obtaining 
tissue include CT-guided biopsy, bronchoscopic biopsy, endosco-
pic ultrasound with fine needle aspiration and surgery. Each moda-
lity has potential complications. Endoscopic ultrasound miniprobe 
(EBUS-MP) is established as a valuable tool, particularly in the sta-
ging of early GI tumours. EBUS-MP has been used for qualitative 
assessment of bronchial structures post lung transplant but data is 
sparse regarding the role of EBUS-MP sampling of peripheral pul-
monary mass lesions. The paper illustrates our experience with this 
technique to date.
Methods: Procedures were carried out in a tertiary respiratory 
centre over 18 months. Patients were referred for suspected pul-
monary malignancy. CT images for each case were reviewed prior 
to selection. All procedures were undertaken by the same con-
sultant bronchoscopist, assisted by a respiratory trainee. Samples 
(biopsies / endobronchial brushings / washings) were taken from 
the identified subsegmental bronchus. Each case was reviewed 
with respect to diagnostic rate, management, complications and 
potential alternative non-surgical investigations.
Results: 45 EBUS-MP procedures were performed on 43 pa-
tients. Age range 40 – 87 years (mean 69.2 years +/- 10.8). 
FEV1 ranged from 0.8L to 3.3L. Lesions from all lobes were 
targeted. No complications occurred in study populati-
on. Figures 1 and 2 show detailed outcomes for EBUS-MP. 
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performed only when biplane fluoroscopy confirmed that forceps 
were in contact with the lesion. In the ultrathin bronchoscope 
group, biopsies were only performed when an endoluminal lesion 
was seen; if there were no endobronchial lesion, then bronchial 
brushing was performed.
Results: both groups were similar in the main variables, except 
for the number of brushes performed in the conventional group 
(total 31 vs. 66; p <0.05)). Conventional (n=27): age 67.6; gender 
(M) 66.7%; diameter 20.1 (SD 5.9); SUVm (n=20) 9.1; localization 0% 
(inner), 50% (middle), 50% (outer); left lower lobe (11.1%), bronchus 
sign (45%); visualized by fluoro (88.9%); biopsy performed (40.9%); 
brushes (2 in 55%, 3 in 44.4%). Ultrathin (n=39): age 66.9; gender 
(M) 79.5%; diameter 21.5 (SD 6.0); SUVm (n=32) 7.7; localization 11.1 
(inner), 55.6% (middle), 33.3% (outer); left lower lobe (12.8%), bron-
chus sign (68.4%); visualized by fluoro (69.2%); biopsy performed 
(59.1%); brushes (non2 20%, 1 in 69.2%, 2 in 7.5%%, 3 in 2.6%). The 
final diagnosis were achieved in 44.4% in the conventional group 
vs. 38.5% in the ultrathin group (p=0.6)
Conclusion: the ultrathin bronchoscope is equally effective as the 
conventional bronchoscopy under fluoroscopy guidance in the 
diagnosis of SPN.
Keyword: Ultrathin bronchoscopy, peripheric noduls, lung cancer 
diagnosis
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P2.17-006 LONG TERM OUTCOME OF INITIAL BRON-
CHOSCOPIC TREATMENT STRATEGY IN PATIENTS WITH 
BRONCHIAL CARCINOIDS
Hes A.P. Brokx1, Marinus A. Paul2, Johannes M A Daniels1, Koen J. 
Hartemink3, Katrien Grünberg4, Erik Thunnissen4, Wolter A. Oos-
terhuis3, Tom Sutedja1, Pieter E Postmus1
1Pulmonary Diseases, VU University Medical Center/Netherlands, 
2Cardiothoracic Surgery, VU University Medical Center/Netherlands, 
3Surgery, VU University Medical Center/Netherlands, 4Pathology, VU 
University Medical Center/Netherlands
Background: Bronchial carcinoids are considered low-grade ma-
lignancies and, traditionally, are treated surgically. Tumor biology 
and advances in diagnostic and therapeutic techniques, however, 
enable a less invasive approach such as surgical bronchoplasty can 
preserve normal lung parenchyma. We previously reported favou-
rable outcome for initial bronchoscopic treatment (BT) strategy in 
patients with intraluminally located bronchial carcinoids. We now 
present our long term results.
Methods: In patients presenting with a bronchial carcinoid, an 
initial diagnostic therapeutic bronchoscopy is attempted for 
complete tumor eradication for sampling sufficient tissue for the 
proper differentiation between typical (TC) and atypical (AC) histo-
logic type apart from to optimally improve pre-surgical condition. 
A high resolution computed tomography is performed six weeks 
later, to determine intra- versus extraluminal tumor growth. In case 
of intraluminal growth of TC bronchoscopic removal attempt can 
be repeated. We perform surgical resection in case of extraluminal 
disease, or failure to bronchoscopic radical resection (i.e. recur-
rence or persistent residual tumor). Complete bronchoscopic re-
section of AC histological type is currently not followed by surgical 
resection.
> 10mm. All cases without a radiological identified primary were 
included in the study. Final clinical diagnosis in relation to patholo-
gical diagnosis was achieved from the medical records as was the 
need for further investigations in order to achieve a pathological 
diagnosis.
Results: Of 418 EBUS procedures 340 were to stage lymph nodes 
with radiological primary lesion. 78 EBUS procedures were perfor-
med for the investigation of lymphadenopathy of unknown origin. 
Nodal sampling was achieved in 112 of 118 aspirates (95%). 32 
patients (41%) had non diagnostic lymph node sampling. 72 (35.1%) 
had malignancy diagnosed by EBUS-TBNA (21 bronchogenic) with 
a further 5 suspicious of malignancy. A false negative for malig-
nancy occurred in 1 patient who had lymphoma. Of 19 patients 
with a clinical suspicion of sarcoidosis 14 had non-caseating gra-
nulomatous lymphadenitis confirmed on TBNA and 3 patients had 
subsequent confirmation with invasive investigations. The yield 
then of EBUS FNA for sarcoidosis was 88% when considering those 
with subsequent pathological confirmation. Of 24 patients with 
negative sampling, 10 were considered reactive to underlying lung 
disease, although 11 remained without clear explanation. Follow 
up was variable within this group. 9 patients required further inves-
tigations to confirm disease. 3 patients required mediastinoscopy 
and 2 went on to have endoscopic ultrasound with core biopsy
Conclusion: EBUS-TBNA has an excellent yield for both begin and 
malignant pathologies causing mediastinal lymphadenopathy and 
should be considered as a non invasive alternative to mediastino-
scopy where lymphoma is thought less likely.Where TBNA or FNA 
is non-diagnostic but the suspicion of malignancy is high, further 
investigations are indicated. Given the availability of CT scanning 
in today’s practice, lymphadenopathy of uncertain significance is 
an increasing clinical dilemma. Protocols have had to be develo-
ped for the management of incidental solitary pulmonary nodules 
and similar guidelines could be produced for the management of 
intra-thoracic lymphadenopathy incidental or otherwise to ensure 
a standardised investigative cycle and follow up.
Keyword: EBUS, mediastinal, lymphadenopahy, cytology
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P2.17-005 CONVENTIONAL VS ULTRATHIN BRONCHO-
SCOPY IN THE DIAGNOSIS OF SOLITARY PULMONARY 
NODULES (SPN).
Juan A. Botero Zaccour, Antoni Rosell Gratacos, Noelia Cubero 
Frutos, Rachid Tazi Mezalek
Pulmonary Intervention, Bellvitge Hospital/Spain
Background: Ultrathin bronchoscopes can be guided under fluo-
roscopy to reach solitary pulmonary nodules. The aim of this study 
is to compare its diagnostic yield against conventional broncho-
scope.
Methods: two hospitals have prospectively collected patients re-
ferred to study solitary pulmonary nodules by bronchoscopy under 
fluoroscopy guidance. One centre performed the procedures with 
a conventional bronchoscope (Olympus BF Q-180, outer diameter 
5.5 mm, working channel 2.0mm) and the other an ultrathin (Olym-
pus XP 160, outer diameter 2.8; working channel 1.2 mm). In both 
groups bronchial washings were routinely collected. In the conven-
tional group, brushing was always performed and biopsies were 
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P2.17-007 MISCLASSIFICATION OF MEDIASTINAL 
LYMPH NODES BY ENDOBRONCHIAL ULTRASOUND 
(EBUS)
Cho S. Leem1, Ho-Il Yoon2, Choon-Taek Lee2, Sanghoon Jheon3, Jae 
Ho Lee2
1Respiratory Center, Seoul National University Bundang Hospital/Ko-
rea, 2Internal Medicine, Seoul National University Bundang Hospital/
Korea, 3Thoracic And Cardiovascular Surgery, Seoul National Univer-
sity Bundang Hospital, Seoul National University College Of Medicine/
Korea
Background: Endobronchial ultrasound-guided transbronchial 
aspiration(EBUS-TBNA) is reported to show relatively high sensitivi-
ty and specificity in mediastinal node staging of non-small cell lung 
cancer (NSCLC). But discrepancies exist between bronchoscopic, 
radiologic, and surgical classification of mediastinal lymph nodes 
and thus can lead to misclassification. However, the impact of the 
misclassification on diagnostic performance of EBUS-TBNA has 
never been evaluated.
Methods: Medical records of NSCLC patients who underwent 
surgery after EBUS-TBNA for mediastinal staging from November 
2010 until March 2013 in a tertiary hospital were reviewed. Of tho-
se, only lymph nodes which have been aspirated by EBUS-TBNA 
and removed by surgery were analyzed. Patients who received 
neoadjuvant chemotherapy between EBUS-TBNA and surgery 
were excluded. Detailed review of medical records and radiolo-
gical imaging was done to infer the causes for false negative or 
positive results.
Results: A total of 105 lymph nodes from 96 patients were in-
cluded in our analysis. Median interval between EUB-TBNA and 
surgery was 11 days. A total of 8 lymph nodes(7.6%) showed false 
negative results and only one lymph node (0.9%) showed false po-
sitive result. Sensitivity, specificity, accuracy, positive and negative 
predictive value (PPV and NPV) of EBUS-TBNA for malignancy were 
65.2%, 97.5%, 88.5%, 88.5%, 90.6%, respectively. After detailed 
review of cases who had false positive or negative results, 3 false 
negative lymph nodes and 1 false positive lymph node (44%) were 
recognized to be due to misclassification. Other false negative 
cases were due to sampling errors.
Conclusion: Misclassification of lymph nodes can cause false posi-
tive or false negative results of EBUS-TBNA.
Keywords: staging of lung cancer, EBUS, NSCLC, misclassification
Results: So far, 133 patients have been treated; 76 females, 67 
males, median age 46 (range 16 – 85 years). Median follow up was 
87 (range 2 – 264) months. Ninety-nine patients (84%) had TC, and 
34 (26%) had AC. Bronchoscopic eradication was successful in 57 
(43%) patients (51 TC, 6 AC). Detailed treatment results are shown 
in table 1. Table 1. Initial bronchoscopic treatment strategy in pati-
ents with bronchial carcinoids  
BT Completion Surgery 
Remark 
Number of 
patients 
62 71 
Histology TC 
AC 
56 (90%) 
6 (10%) 
43 (61%) 28 
(39%) 
Follow up (me-
dian) in months 
87.5 (2-
223) 
87 (12-264) 
Completely 
resected 
57 (92%) 64 (90%) 
Residual after 
CT/recurren-
ces Additional 
treatment 
bronchoscopy 
Additional 
treatment sur-
gery 
3 4 0 0 
Interval in 
months: 10,13,63 
47,104,115,192 
Alive with di-
sease 
5 0 
2 unfit for surgery 
3 refused surgery 
Alive with me-
tastatic disease 
0 1 40 months 
Carcinoid rela-
ted mortalities 
0 2 
Pulmonary meta-
stases 
Treatment rela-
ted mortalities 
0 1 
Non-carcinoid 
related morta-
lities 
8 3 
Conclusion: Initial bronchoscopic treatment strategy in patients 
with bronchial carcinoids is justifiable with excellent long term 
outcome. It should be implemented in the standard algorithm for 
patients with bronchial carcinoids.
Keywords: Outcome, bronchial carcinoids, bronchoscopic treat-
ment, Surgical Treatment
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P2.17-009 HOW TO PERFORM EBUS TBNA AND WHEN 
IS IT SUFFICIENT ?
Mark Krasnik
Thoracic And Cardiovasc. Surgery, Rigshospitalet/Denmark
Background: When a new diagnostic or staging method is imple-
mented, the new method should at least produce results of the 
same level as the old method Mediastinoscopy has for decades 
been the golden standard in the preoperative diagnosis and sta-
ging of lung cancer. Guidelines from ESTs recommend that at me-
diastinoscopy biopsies from stations 2R, 2L, 4R, 4L and 7 should be 
the result of the procedure, but the procedure may be accepted if 
there is biopsies from the stations 4R, 4L and 7 Should it be deci-
ded to replace mediastinoscopy with endoskospic ultrasound this 
procedure should be based on the principles of mediastinoscopy. 
The purpose of this project is an assessment of the Endoscopic 
Ultrasound follow the part of the guidelines for mediastinoscopy 
dealing which stations recommended biopsied.
Methods: Abstracts from ERS 2012 were reviewed in order to loca-
te projects where EBUS TBNA has been used. In Medline were the 
keywords EBUS TBNA, EBUS, endoscopic ultrasound endobronchi-
al ultrasound and lung cancer sought
Results: 20 relevant abstracts from ERS 2012 were found. Of the-
se 13 abstract did not contain information that made it possible 
to estimate how many stations there were biopsied. The other 7 
abstracts provides 526 patients (53-129) and there is biopsied 950 
lymph nodes which corresponds to t mean 1.8 lymph nodes bi-
opsied (range 1.2 to 2.5) In Medline were 18 relevant publications 
were located dealing with 2068 patients (22 - 190). 4188 lymph 
nodes were biopsied (32 - 928) mean 1.7 per patient (range 0.8 to 
3.0) Unfortunately, it is only a small part of the publications which 
describe either the number of stations, or at least the number of 
nodes that were biopsied compared with the number of patients 
involved. Just a simple calculation of the ratio between the number 
of lymph nodes and patients that were included in these projects 
suggests that a large proportion of lung cancer patients diagnostic 
and staging procedure is of lower standard than if they had been 
offered the golden standard ( mediastinoscopy )
Conclusion: There is a big task in developing and implementing 
guidelines for the diagnostic and staging process of lung cancer 
when mediastinoscopy is not used. Since an increasing share of the 
staging process for the patients included in oncology projects are 
based on Endoscopic ultrasound can cause uncertainty about the 
results of these studies
Keywords: staging, EBUS TBNA, Lung cancer
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P2.17-008 A NEW PROCEDURE FOR SAMPLING FINE 
NEEDLE ASPIRATIONS ENABLES ISOLATION OF HIGH 
QUALITY MRNA
Birgitte S. Paulsen1, Christina Demuth2, Birgitte Folkersen3, Tor-
ben R. Rasmussen3, Steffen F. Sorense1, Boe Sorensen2, Peter Mel-
dgaard1
1Department Of Oncology, Aarhus University Hospital/Denmark, 
2Department Of Clinical Biochemistry, Aarhus University Hospital/
Denmark, 3Department Of Pulmonary Disease, Aarhus University Hos-
pital/Denmark
Background: Fine needle aspirates (FNA) are widely used in the 
diagnostics of non-small cell lung cancer (NSCLC). As relevant 
oncogenic drivers have emerged, the demand for molecular tests 
is increasing. To investigate mRNA expression fresh frozen tissue 
is required. In an everyday setting isolation of snap-frozen tissue is 
rarely a possibility and new procedures are needed to allow use of 
FNA material for mRNA expression studies.
Methods: Tumour samples from patients under suspicion of ha-
ving lung cancer were isolated. Routine diagnostic procedures of 
FNA and/or transbronchial needle aspiration (TBNA) were perfor-
med and smears used for routine diagnostics were prepared. The 
remaining sample in the needle and syringe was mixed with 10 ml 
Cytolyt©. 9.5 ml was used for routine diagnostics, while 0.5 ml was 
mixed with 4.5 ml RNAprotect©. mRNA was isolated, transcribed 
into cDNA and quantified with quantitative reverse transcription 
quantitative PCR (RT-qPCR).
Results: Analysis of four reference genes in the first 50 samples 
consecutively collected showed that the most stable reference 
gene was β-actin. 211 tissue samples from 81 patients were then 
examined for β-actin mRNA expression. 92 % of the samples 
contained sufficient material for mRNA quantification containing 
mRNA corresponding to 100 HCC827 NSCLC cells or more. Fur-
thermore 100 HCC827 NSCLC cells were sufficient to quantify the 
mRNA splice variant of BIM conferring erlotinib sensitivity.
Conclusion: We describe a novel procedure that optimizes the use 
of diagnostic FNA and TBNA and demonstrate that these samples 
contain enough material for isolation of high quality mRNA without 
influencing routine procedures.
Keyword: FNA, TBNA, mRNA, biomarkers
S954 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 2 - PATHOLOGY  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.18-002 A COMPREHENSIVE COMPARATIVE ANALYSIS 
OF THE HISTOMORPHOLOGICAL FEATURES OF ALK-RE-
ARRANGED LUNG ADENOCARCINOMA BASED ON DRI-
VER ONCOGENE MUTATIONS : FREQUENT EXPRESSION 
OF EPITHELIAL-MESENCHYMAL TRANSITION MARKERS 
THAN OTHER GENOTYPE
Hyojin Kim1, Se Jin Jang2, Doo Hyun Chung3, Seol Bong Yoo4, Ping-
Li Sun5, Yan Jin1, Jin-Haeng Chung1
1Pathology, Seoul National University Bundang Hospital/Korea, 2Patho-
logy, Asan Medical Center, University Of Ulsan College Of Medicine/
Korea, 3Pathology, Seoul National University College Of Medicine/Ko-
rea, 4Pathology, Presbyterian Medical Center/Korea, 5Thoracic Surgery, 
Seoul National University Bundang Hospital/Korea
Background: Molecular classification of lung cancer correlates 
well with histomorphologic features. However, detailed histo-
morphologic features which differentiate ALK rearranged tumors 
from ALK wild type has not been fully evaluated. To investigate 
histomorphologic features of tumors harboring ALK rearrangement 
to evaluate the predictive significance of morphologic characte-
rization, we compared the histomorphological analysis between 
ALK-rearranged and ALK negative lung adenocarcinomas based 
on driver oncogene mutations.
Methods: Eighty resected ALK rearranged lung adenocarcinomas 
and two hundred thirteen resected ALK negative adenocarcino-
mas (91 EGFR mutated, 29 K-ras mutated and 93 triple-negative) 
were analyzed for several histomorphological parameters and 
histologic subtype based on newly proposed IASLC/ATS/ERS clas-
sification.
Results: ALK rearranged tumors were associated with a younger 
age at presentation, frequent nodal metastasis and higher stage at 
diagnosis, compared with patients with other genotypes. ALK rear-
ranged tumors were more likely to show solid predominant pattern 
(43.8%, 35/80) than other genotypes (p<0.001) and a lepidic pre-
dominant histology was not observed in ALK rearranged tumors 
(p<0.001). In ALK rearranged tumors, considerable number of 
the tumors (67.5% , 54/80) contained at least 5% solid pattern but 
only small number of the tumors (12.5%, 12/80) contained at least 
5% lepidic pattern, compared with other genotypes (p<0.001). 
The most significant morphological features distinguishing ALK 
rearranged tumors from ALK negative tumors were cribriform 
formation (OR: 3.253, p=0.028), presence of mucin-containing 
cells (OR: 4.899, p=0.008), close relation to adjacent bronchioles 
(OR: 5.361, p=0.001), presence of psammoma body (OR: 4.026, 
p=0.002) and solid predominant histological subtype (OR: 13.685, 
p=0.023). ALK-rearranged tumors exhibited invasive histomorpho-
logical features, aggressive behavior and frequent expression of 
epithelial-mesenchymal transition markers (loss of E-cadherin and 
expression of vimentin) compared with other genotype (p =0.015). 
Spatial proximity between bronchus and ALK-rearranged tumors 
and frequent solid histologic subtype with p63 expression may 
cause diagnostic difficulties to differentiate squamous cell carcino-
ma in the small biopsy, whereas p40 was rarely expressed in ALK-
rearranged adenocarcinoma.
Conclusion: Knowledge of these features may improve the diag-
nostic accuracy and lead to a better understanding of the charac-
teristic behavior of ALK-rearranged tumors.
Keywords: anaplastic lymphoma kinase, Lung cancer, histology
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P2.18-001 RETROSPECTIVE ANALYSIS OF THE CLINICO-
PATHOLOGICAL PROFILE OF ALK POSITIVE PATIENTS IN 
THE SOUTH OF SPAIN (ANDALUSIAN AREA)
Jesus Corral1, Miriam Gonzalez De La Peña2, Michele Biscuo-
la2, Maria Dolores Mediano2, Miriam Alonso2, Amparo Sánchez 
Gastaldo2, Lourdes Gomez Izquierdo2
1Medical Oncology, University Hospital Virgen Del Rocio/Spain, 2Uni-
versity Hospital Virgen Del Rocio/Spain
Background: The anaplastic lymphoma kinase (ALK) fusion gene 
is a key oncogenic driver in a subset of patients with advanced non 
small cell lung cancer (NSCLC). ALK rearragement is detected in 
2-7% of NSCLC patients. Fluorescence in situ hybridization (FISH) 
is the recommended method of detection. The clinical features 
of lung cancer that harbors ALK include light- or never-smokers, 
younger age, adenocarcinomas with acinar pattern or signet ring 
adenocarcinoma, and a lack of EGFR or KRAS mutations. Crizotinib 
has shown an important benefit in terms of overall response rate 
(ORR) and progression free survival (PFS) in the 2nd/3rd line set-
ting. Treatment related adverse events were gastrointestinal and 
visual disorders.
Methods: Retrospective analysis of the clinico-pathological profile 
of ALK NSCLC patients between May 2011 and December 2012 in 
our Institution.
Results: 10 cases (6,7%) were identified from 150 screened pati-
ents with adenocarcinoma histology and EGFR wild-type status. 7 
(70%) patients were women. Median age at diagnosis was 62 years 
old (range=36-77). 90% patients were light-or-never smokers. All 
tumours were adenocarcinomas with EGFR wild type status: acinar 
growth pattern was detected in 4 cases (40%); 4 (40%) patients 
showed mucous cells and previous described signet-ring cells were 
detected in the last 2 (20%) cases. Only 5 (50%) patients received 
crizotinib therapy: 2 patients were treated during first line with 
partial response, 1 patient was treated in second line with stable 
disease and 2 patients received therapy in third line with partial 
response and no response, respectively. Only one patient required 
a dose reduction (200 mg bd) due to gastrointestinal toxicity.
Conclusion: Most of the patients with ALK rearregements in our 
serie have clinical and pathological characteristics to previously 
described. More women and older population were showed. In 
stead of the small sample size, pathological pattern based on aci-
nar growth and mucous or signet-ring cells in adenocarcinomas 
with no EGFR mutation should guide the ALK screening process. 
ORR and toxicity profile confirmed Crizotinib benefit as soon as 
ALK status was detected.
Keyword: NSCLC, ALK, crizotinb
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P2.18-003 SPREAD THROUGH ALVEOLAR SPACES 
(STAS): A NEWLY RECOGNIZED PATTERN OF INVASI-
ON IN LUNG ADENOCARCINOMA ASSOCIATED WITH 
INCREASED RECURRENCE IN PATIENTS UNDERGOING 
LIMITED RESECTION FOR ≤2CM TUMORS
Junichi Nitadori1, Kyuichi Kadota2, Camelia S. Sima2, Hideki Uji-
ie2, Nabil P. Rizk2, Valerie W. Rusch2, William D. Travis2, Prasad S. 
Adusumilli2
1Department Of Thoracic Surgery, The University Of Tokyo Hospital/
Japan, 2Memorial Sloan-Kettering Cancer Center/United States Of Ame-
rica
Background: We have recently demonstrated that presence of the 
micropapillary pattern increases the risk of local recurrence after 
limited resection for ≤2 cm lung adenocarcinoma (ADC). In cases 
of tumors with the micropapillary pattern, a detached collection of 
tumor cells is frequently identified within an alveolar space sepa-
rate from the main tumor, which we have named “Spread Through 
Alveolar Spaces” (STAS). However, the prognostic significance of 
this finding is not known. The purpose of this study is to investiga-
te whether the presence of STAS correlates with an increased risk 
of recurrence after limited resection versus lobectomy.
Methods: All available tumor slides from patients with therapy-na-
ive, surgically resected solitary lung ADC ≤2 cm in size (1995-2009) 
were reviewed (n=697; stage IA/IB, 600/97; limited resection/
lobectomy, 226/471). Comprehensive histologic subtyping was 
performed according to the IASLC/ATS/ERS classification. STAS 
was defined as isolated tumor islands (morphologically solid or 
micropapillary pattern) or single cells within alveolar spaces sepa-
rate from the main tumor. The distance between the tumor surface 
and the STAS was measured by a ruler (mm) and by the number of 
alveolar spaces. Recurrence-free probability (RFP) was estimated 
using the Kaplan-Meier method.
Results: STAS was identified in 224 cases (32%). The morpholo-
gic types of STAS were as follows: 119 micropapillary, 91 solid, 
and 14 single cell. Presence of the micropapillary or solid pattern 
(>5%) in the main tumor and presence of lymphatic invasion were 
significantly associated with presence of STAS (p<0.001 for each). 
Presence of STAS correlated with an increased risk of recurrence 
(5-year RFP, 75.6%), compared with absence of STAS (5-year RFP, 
83.5%; p=0.022). In the limited resection group, tumors with STAS 
were associated with an increased risk of recurrence, compared 
with those without STAS (5-year RFP, 58.3% vs 81.9%; p=0.004); 
this did not follow in the lobectomy group (5-year RFP, 84.1% vs 
84.2%; p=0.658) (Figure). The distance between the tumor surface 
and the STAS did not correlate with risk of recurrence (p=0.992). 
Conclusion: Presence of STAS correlated with an increased risk of 
recurrence in patients treated with limited resection for ≤2 cm lung 
ADC. This finding may guide surgeons to choose lobectomy over 
limited resection for the treatment of these patients.
Keywords: lung adenocarcinoma, limited resection, Micropapilla-
ry, Spread Through Alveolar Spaces
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P2.18-005 MORPHOLOGICAL AND GENETIC CLASSIFI-
CATION OF LUNG CANCER: VARIATION IN PRACTICE 
AND IMPLICATIONS FOR TAILORED TREATMENT
John R. Gosney1, Paul Cane2, Michael D. Peake3, Karen M. Linkla-
ter4, Andrew Nicholson5, Henrik Moller6
1Dept Of Cellular Pathology, Royal Liverpool University Hospital/United 
Kingdom, 2Dept Of Histopathology, Guy‘s And St Thomas‘ Hospital/
United Kingdom, 3Department Of Respiratory Medicine, Glenfield Hos-
pital/United Kingdom, 4National Cancer Registration Service/United 
Kingdom, 5Histopathology, Royal Brompton NHS Foundation Trust/Uni-
ted Kingdom, 6King‘s College London/United Kingdom
Background: The rational use of tailored therapy for lung cancer 
depends crucially on high quality pathology. Not only must sub-
typing of the tumour be achieved consistently and with accuracy, 
but as much material as possible from increasingly small speci-
mens must be preserved for the genetic analysis upon which such 
treatment is increasingly predicated. Although there is a general 
presumption that pathologists have risen to this challenge, reliable 
data is sparse and the nature and degree of variation in practice 
and quality is unknown.
Methods: We collected and scrutinised anonymised information, 
including pathology reports, on all consecutive, newly-diagnosed 
patients with lung cancer referred to 19 lung cancer units across 
the UK for a period of 6 months commencing late 2011, a total of 
1507 cases. Centres surveyed ranged from district general hospi-
tals to specialist regional cardiothoracic units.
Results: Achievement of a positive tissue diagnosis of malignancy 
ranged from 53 to 88%, figures accompanied by ‘suspicious but 
non-diagnostic’ rates of 10 and 2% respectively. Despite apparent 
adherence to the diagnostic criteria and terminology of the WHO 
classification of tumours of the lung, variation in proportions of 
tumour subtypes was wide, the prevalence of squamous carcino-
ma, for example, varying from less than 10 to greater than 50%. 
The proportion of tumours unclassified beyond ‘non-small cell lung 
cancer not otherwise specified’ varied from 3 to 20% despite the 
almost universal use of immunochemistry (most often TTF-1, class 
7 cytokeratins and p63) to aid in this differential diagnosis. Testing 
for EGFR gene mutations was directly instigated by the pathologist 
at diagnosis in only 4 of the 19 centres and the proportion of tu-
mours tested ranged from 12 to 92%.
Conclusion: Variations in practice amongst pathologists and ar-
guably in the quality of pathology ranged widely across the cen-
tres surveyed, raising important questions about variable expertise 
of pathologists, adherence to guidelines, applicability and rigour 
of external quality assessment and, ultimately, the reliability of the 
pathology that crucially underpins the management of lung cancer.
Keyword: pathology diagnosis classification genetics
POSTER SESSION 2 - PATHOLOGY  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.18-004 CLINICAL APPLICATION OF IMMUNOCYTO-
CHEMICAL DETECTION OF ALK REARRANGEMENT ON 
CYTOLOGY SLIDES FOR DETECTION OR SCREENING OF 
LUNG ADENOCARCINOMA
Hisashi Tanaka1, Kiyoshi Tone1, Akihito Hayashi2, Takeshi Mori-
moto2, Kageaki Taima2, Yoshihito Tanaka2, Kunihiko Nakamura2, 
Hideyuki Nakagawa3, Shingo Takanashi2, Akira Kurose1, Ken Oku-
mura2
1Department Of Anatomic Pathology, Hirosaki University Graduate 
School Of Medicine/Japan, 2Cardiology, Respiratory Medicine And Ne-
phrology, Hirosaki University Graduate School Of Medicine/Japan, 3De-
partment Of Respiratory Medicine, Hirosaki National Hospital/Japan
Background: Immunohistochemical screening of anaplastic lym-
phoma kinase (ALK) rearrangement has been regarded essential 
and routinely carried out to select the treatment for lung ade-
nocarcinoma. However, due to difficulty to approach a tumor by 
transbronchial lung biopsy (TBLB), it often fails to obtain tumor tis-
sues whereas tumor cells are contained in cytology specimens si-
multaneously obtained when the bronchoscopy is done. Therefore 
we evaluated the expression of ALK protein by using immunohis-
tochemistry (IHC) on TBLB specimens and immunocytochemistry 
(ICC) on brushing smear cytology slides in the same cases, and 
compared the concordance rate of IHC and ICC results. ICC was 
carried out on routine Papanicolaou-stained slides after cytology 
diagnosis and decolorization.Background: Immunohistochemical 
screening of anaplastic lymphoma kinase (ALK) rearrangement has 
been regarded essential and routinely carried out to select the 
treatment for lung adenocarcinoma. However, due to difficulty to 
approach a tumor by transbronchial lung biopsy (TBLB), it often 
fails to obtain tumor tissues whereas tumor cells are contained 
in cytology specimens simultaneously obtained when the bron-
choscopy is done. Therefore we evaluated the expression of ALK 
protein by using immunohistochemistry (IHC) on TBLB specimens 
and immunocytochemistry (ICC) on brushing smear cytology slides 
in the same cases, and compared the concordance rate of IHC and 
ICC results. ICC was carried out on routine Papanicolaou-stained 
slides after cytology diagnosis and decolorization.
Methods: IHC was done using the commercially available antibody 
against ALK (dilution 1:100, clone 5A4; Novocastra, Newcastle, 
UK), and signals were detected using the EnVision FLEX Mini-kit 
(Dako, Tokyo, Japan). Papanicolaou-stained bronchoscopic brus-
hing smear cytology slides containing cells cytologically diagnosed 
as adenocarcinoma were used. ICC was carried out by using the 
same antibody and the detection kit as used in IHC. IHC and ICC 
expressions were quantified by three cytopathologists. Cytoplas-
mic ALK expressions were quantified using a three-value intensity 
score (0, 1+, 2+) and the intensity scores 1+ and 2+ are defined 
positive.
Results: Eighteen patients with adenocarcinoma were extracted in 
the Hirosaki University Hospital and the Hirosaki National Hospital. 
IHC and ICC results showed a very high concordance rate: sensiti-
vity of ICC in comparison with IHC was 85.7% (6/7), specificity was 
100% (11/11), positive predictive value was 100% (6/6), and negati-
ve predictive value was 91.6% (11/12).
Conclusion: Detection of ALK rearrangement using ICC on routine 
Papanicolaou cytology slides is considered to be advantageous for 
lung cancer treatments.
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P2.18-007 CORRELATING HISTOLOGIC AND MOLE-
CULAR FEATURES IN THE LUNG ADENOCARCINOMA 
TCGA PROJECT
William Travis1, Matthew Wilkerson2, Natasha Rekhtman1, Ri-
chard Cheney3, Belinda Clarke4, Sanja Dacic5, Edwina Duhig6, 
Carol Farver7, William K. Funkhouser8, Peter Illei9, Gabriel Sica10, 
James Suh11, Ming S. Tsao12, Tcga The Cancer Genome Atlas Re-
search Network13
1Pathology, Memorial Sloan-Kettering Cancer Center/United States Of 
America, 2Lineberger Comprehensive Cancer Center/United States Of 
America, 3Pathology, Roswell Park Cancer Institute/United States Of 
America, 4Dept Of Pathology, Prince Charles Hospital/Australia, 5Dept 
Of Pathology, University Of Pittsburgh/United States Of America, 6Sul-
livan Nicolaides Pathology/Australia, 7Dept Of Pathology, Cleveland 
Clinic/United States Of America, 8Dept Of Pathology, Univ. Of North 
Carolina/United States Of America, 9Dept Of Pathology, Johns Hopkins/
United States Of America, 10Dept Of Pathology, Emory University/Uni-
ted States Of America, 11Dept Of Pathology, New York University/Uni-
ted States Of America, 12Dept Of Pathology, Princess Margaret Cancer 
Centre/Canada, 13National Cancer Institute/United States Of America
Background: Our understanding of the molecular landscape of 
lung adenocarcinoma (ADC) is evolving rapidly. Furthermore, 
the IASLC/ATS/ERS lung ADC classification was recently publis-
hed. The histologic and molecular correlations have not yet been 
thoroughly explored in this rapidly changing field. We sought to 
investigate the molecular findings according to the IASLC/ATS/ERS 
classification. .
Methods: Aperio© scanned H&E stained slides were reviewed 
from 230 tumors according to the 2011 IASLC/ATS/ERS lung 
adenocarcinoma classification criteria. Molecular profiling was 
performed on 230 resected, untreated lung adenocarcinomas, 
using mRNA, miRNA and DNA sequencing integrated with copy 
number, methylation and proteomic analyses. Histologic molecular 
correlations focused on mRNA and DNA sequencing and TTF-1 
proteomic findings.
Results: We found 12 lepidic predominant ADC (5%), 21 papillary 
predominant (9%), 77 acinar predominant (33%), 33 micropapil-
lary predominant (14%), and 58 solid predominant (25%) as well 
as, 9 invasive mucinous (4%), and 20 unclassifiable ADCs (9%). 
EGFR mutation and KRAS mutations were found in 8% and 17% 
of lepidic ADC, respectively. Nine of 12 lepidic ADC (75%) were 
of the terminal respiratory unit (TRU) gene expression subtype 
(GES) and 3 (25%)were in the 19p-depleted transcriptional GES, 
but none were found in the solid-enriched GES (Figure; p=0.007). 
Most of the papillary ADC were of the TRU (10/21, 47.6%) and 19p-
depleted transcriptional (9/21, 42.9%) GES (p=0.026). 46% (41/89) 
of acinar ADC tumors were in the TRU-GES compared to the solid 
enriched (18/78, 23.1%) and 19p-depleted transcriptional (18/63, 
28.6%) GES (p=0.005). When the oncogene positive group was 
defined including KRAS, EGFR, ALK, RET, ROS1, BRAF, ERBB2, 
HRAS and NRAS, there was a higher percentage of solid ADC in 
the oncogene negative (30/93, 32.3%) compared to the oncogene 
positive group (28/137, 20.4%, p=0.046). The highest percentage 
of solid ADC was found in the solid-enriched GES (47/78, 47.4%) 
compared to the 19p-depleted transcriptional (17/63, 27%) and 
TRU GES (4/89, 4.5%) (p<0.001). Invasive mucinous ADC correlated 
with KRAS (but no EGFR) mutations (67%) compared to other ADC 
(28%, p=0.02) and also lacked elevation of TTF-1 (p=0.007). GES 
was associated with histologic grade: high grade with solid-enri-
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P2.18-006 HER2 AND BRAF MUTATIONS IN NON-
SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P).
Anna Estival1, Enric Carcereny1, Alberto Indacochea1, Jose Luis 
Ramirez2, Teresa Moran1, Jose Luis Cuadra1, Laia Vila1, Maria Gil1, 
Mónica Botia2, M Perez2, M Tierno2, Laia Capdevila3, Rafael Rosell1
1Medical Oncology, Hospital Germans Trias I Pujol/Spain, 2Molecular 
Biology, Hospital Germans Trias I Pujol/Spain, 3Medical Oncology, Xar-
xa Sanitaria Santa Tecla/Spain
Background: Treatment of non-small-cell lung cancer (NSCLC) 
has changed drastically in recent years with an increase in rates 
of detection of driver mutations in a subgroup of NSCLC patients 
(p); the most recent mutations described in NSCLC are HER2 and 
BRAF. Overexpression of HER-2 (insertion in exon 20) occurs in 
2-6% of NSCLC patients and is more common in women, never-
smokers, Asian and adenocarcinoma hystology (adc). BRAF is 
found in 1.6-4.9% of p, with a higher rate of V600E mutations in 
smokers, and non-V600E mutations in non-smokers.
Methods: We systematically analyzed HER2 and BRAF mutations 
in EGFR wild type and non-translocated ALK p and retrospectively 
reviewed the results. Forty six NSCLC p were included between 
December 2011 to June 2013. Clinical characteristics such as his-
tological subtype, sex, age, smoking status, and mutational status 
were analyzed. BRAF mutation was assessed by Taqman based 
assay (5’ nuclease activity) in an AB 7900HT system, with specific 
primers and probes for V600E positions. HER2 insertion was as-
sessed using Sanger sequencing. All samples were PCR amplified 
and sequenced in AB 3130, using specific primers for exon 20.
Results: All patients were Caucasian; 25 p (54.3%) were women 
and 21 p (45.7%) men. Fourteen p (30.4%) were never-smokers, 
11 (23.9%) former smokers and 19 (41.3%) smokers. Median age 
was 58.74 years. Forty one p (89.1%) had adc, 2 had squamous cell 
histology and 3 had another histology (1carcinod tumour, 1 large 
cell lung cancer and 1 poorly differentiated NSCLC) . Two p (4.3%) 
had BRAF V600E mutation: 1 female and 1 male, with median age 
of 56.5, both smokers. One 65 year old, female, never-smoker p 
(2.2%) had HER-2 insertion. All mutations were found in adc.
Conclusion: Analysis of less common driver mutations such as 
BRAF and Her2 mutations is feasible for daily clinical practice and 
could be useful to decide treatment. In our European population, 
incidence of BRAF and HER-2 mutation is similar to that previously 
reported (4.3% and 2.2%). Both p with BRAF V600E mutation were 
smokers, and the p with mutation in HER-2 was a 65 year-old fema-
le never-smoker.
Keyword: HER-2, BRAF, non small cell lung cancer, smoker, fema-
les.
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Methods: not applicable
Results: A 32-year-old man presented with cough and bloody 
sputum. Computed tomography (CT) showed a mass in the S6 
segment and diffuse consolidation throughout the lower lobe of 
the left lung. Transbronchial lung biopsy revealed adenocarcinoma 
with lymphangiosis. Immunohistochemistry (IHC) showed ALK pro-
tein expression and break-apart fluorescent in-situ hybridization 
(FISH) showed ALK gene rearrangement. First-line chemotherapy 
with cisplatin and docetaxel was started. After tumor progression, 
the patient was enrolled in the clinical trial and was allocated to the 
pemetrexed arm. Subsequently, he was enrolled in other trial to 
receive crizotinib in July 2011. After partial response was observed, 
a nodule in the S9 segment developed to 2cm in February 2012, 
and crizotinib was discontinued. CT scans performed after 4 cycles 
of carboplatin and gemcitabine showed a mixed response, with 
improvements in lymphadenopathy and lymphangiosis but pro-
gression of the mass in S9. CT-guided core-needle biopsy revealed 
ALK-positive atypical cells but it was impossible to distinguish his-
tological types because of degeneration and necrosis. Thereafter, 
carboplatin, paclitaxel, and bevacizumab were administered, but 
the same mixed response was observed. The mass in S9 increased 
rapidly and reached 7 cm.  (Left lower lobectomy was performed. 
The primary tumor in S6 was diagnosed as adenocarcinoma positi-
ve for thyroid transcription factor (TTF)-1 immunostaining, whereas 
the tumor in S9 was TTF-1-negative sarcomatoid carcinoma. ALK 
was positive with IHC in both tumors, and FISH revealed high-level 
gene amplification of the ALK fusion gene only in the sarcoma-
toid carcinoma. Reverse transcriptase polymerase chain reaction 
revealed the same variant of echinoderm microtubule-associated 
protein like 4-ALK (E13; A20) and it indicated that these tumors 
have the same origin. Moreover, in the sarcomatoid carcinoma, 
DNA sequencing revealed no additional resistance point mutations 
from ALK exon 20 to exon 23. Brain metastases occurred 2 months 
after pulmonary resection and he underwent brain surgery. The 
tumor was diagnosed as sarcomatoid carcinoma. Ten days later, 
he died due to exacerbation of lymphangiosis To discuss poten-
tial epithelial-to-mesenchymal transition (EMT), we performed 
E-cadherin and keratin staining as epithelial markers, and vimentin 
staining as a mesenchymal marker in 4 specimens. The specimens 
were pre-crizotinib specimen in S6, surgical specimen in S6, re-
biopsied specimen in S9 after carboplatin and gemcitabine, and 
surgical specimen in S9. Rebiopsied specimen in S9 was unevalu-
able for IHC staining because of degeneration and necrosis. All of 
the 3 evaluable specimens showed positive expression of vimentin 
and only surgical specimen in S9 showed negative of epithelial 
markers.
Conclusion: The transformation from adenocarcinoma to sarco-
matoid carcinoma could be interpreted as kind of EMT. This trans-
formation might represent a novel acquired resistance mechanism 
to crizotinib, although there is another possibility that subsequent 
chemotherapies induced this transformation.
Keywords: acquired resistance, epithelial-to-mesenchymal transiti-
on, ALK-rearranged adenocarcinoma, Crizotinib
ched GES and intermediate/low grade with TRU GES (p<0.001). 
Conclusion: Our data reveal multiple correlations between mo-
lecular (mutation and GES) and histologic (subtyping and grade) 
features. This reveals insights into the biology of these tumors in 
particular genetic characteristics of the high grade tumors which 
may lead to better understanding of why these are more aggressi-
ve tumors.
Keywords: Lung cancer, genetics, Adenocarcinoma, histologic 
classification
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P2.18-008 TRANSFORMATION TO SARCOMATOID CAR-
CINOMA IN ALK-REARRANGED ADENOCARCINOMA 
WHICH DEVELOPED ACQUIRED RESISTANCE TO CRIZO-
TINIB AND RECEIVED SUBSEQUENT CHEMOTHERAPIES
Yoshihisa Kobayashi1, Yukinori Sakao1, Simon Ito2, Jangchul Park3, 
Tetsuya Mizuno1, Hiroaki Kuroda1, Noriaki Sakakura1, Noriyasu 
Usami4, Tetsuya Mitsudomi5, Yasushi Yatabe6
1Department Of Thoracic Surgery, Aichi Cancer Center Hospital/Japan, 
2Department Of Thoracic Surgery, Nagoya Daini Red Cross Hospital/Ja-
pan, 3Department Of Thoracic Oncology, Aichi Cancer Center Hospital/
Japan, 4Department Of Thoracic Surgery, Nagoya University Graduate 
School Of Medicine/Japan, 5Department Of Surgery, Kinki University, 
Faculty Of Medicine/Japan, 6Dept. Of Pathology And Molecular Diag-
nostics, Aichi Cancer Center/Japan
Background: Non-small-cell lung cancers (NSCLC) with anaplas-
tic lymphoma kinase (ALK) rearrangement are highly sensitive to 
the ALK kinase inhibitor crizotinib, but drug resistance invariably 
emerges. Morphological transformation from adenocarcinoma to 
SCLC represents one acquired resistance mechanism to epidermal 
growth factor receptor tyrosine kinase inhibitors. We present the 
case of transformation to sarcomatoid carcinoma in ALK-rearran-
ged adenocarcinoma which developed acquired resistance to 
crizotinib.
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P2.18-010 COPY NUMBER CHANGES IN CHROMOSOME 
2P ARE UNIQUE EVENTS AMONG ALK FUSION POSITI-
VE LUNG ADENOCARCINOMAS
Hironori Ninomiya1, Motohiro Kato2, Masashi Sanada3, Kengo Ta-
keuchi4, Yuichi Saito1, Eisaku Miyauchi1, Noriko Motoi1, Hiroyuki 
Mano5, Seishi Ogawa3, Yuichi Ishikawa1
1Division Of Pathology, Japanese Foundation For Cancer Research/Ja-
pan, 2Department Of Pediatrics, The University Of Tokyo/Japan, 3Can-
cer Genomics Project, The University Of Tokyo/Japan, 4Pathology Pro-
ject For Molecular Targets, Japanese Foundation For Cancer Research/
Japan, 5Division Of Functional Genomics, Jichi Medical University/Japan
Background: ALK fusion is a unique gene transversion detected 
among lung adenocarcinomas. It emerged as a target for cancer 
therapy, but little is known how this genomic abnormality is crea-
ted. To unveil the underlying mechanisms leading to gene fusion, 
we compared the genomic structures of the two groups using 
SNP-array allelokaryotyping analysis.
Methods: 35 ALK fusion positive and 95 ALK fusion negative cases 
were involved in this study. Immunohistochemical staining and 
multiplex RT-PCR was employed for screening and confirmation. 
Chromosome 2p were closely examined using SNP-array based 
allelokaryotyping.
Results: Copy number changes of the regions including ALK and 
EML4 were detected among ALK fusion positive tumors (10/35, 
29%) in contrast with ALK fusion negative tumors (0/95, 0%). In 
other words, the genomic regions unnecessary to constitute each 
fusion gene variants were deleted in ALK fusion positive tumors. 
And some of them showed copy number gain of fusion gene. In 
addition, clustered genomic number changes within 2p were more 
frequently encountered in ALK fusion positive tumors compared 
with fusion negative ones.
Conclusion: Copy number changes within the genomic region in-
cluding EML4 and ALK are particular findings in ALK fusion positive 
tumors. In addition, genomic structure of the short arm of chromo-
some 2 was more unstable than ALK fusion negative tumors. We 
speculate that clustered chromosomal rearrangements of the short 
arm of chromosome 2 contribute to EML4-ALK gene fusion.
Keyword: ALK, SNP-array, allelokaryotyping, lung cancer
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P2.18-009 MUTATION TESTING IN NON-SMALL CELL 
LUNG CANCER - SUITABILITY OF SMALL BIOPSY AND 
CYTOLOGY SPECIMENS
Shu Wang1, Bing Yu2, Chiu C. Ng2, Belinda Mercorella2, Sandra 
O‘Toole1, Wendy A. Cooper1
1Tissue Pathology And Diagnostic Oncology, Royal Prince Alfred Hos-
pital/Australia, 2Molecular And Clinical Genetics, Royal Prince Alfred 
Hospital/Australia
Background: Patients with non-small cell lung cancer (NSCLC) harbo-
ring sensitizing mutations in epidermal growth factor receptor (EGFR) 
benefit from treatment with EGFR tyrosine kinase inhibitors. As most 
patients with NSCLC present with advanced-stage disease and are 
not candidates for surgical resection, somatic mutation testing is of-
ten performed on small biopsy and cytology specimens. Compared 
to resection specimens, the suitability of these specimens is not well 
established. We aimed to explore the suitability of small biopsy and 
cytology specimens for mutation testing in NSCLC.
Methods: We undertook a retrospective review of NSCLC mutation 
testing cases performed at Royal Prince Alfred Hospital, Sydney, from 
March 2012 to May 2013. Mutation testing was requested by the 
treating physician. DNA was extracted from formalin-fixed, paraffin 
embedded tissue and a multiplex PCR assay (OncoCarta Panel v1.0) 
used to identify mutations in 19 oncogenes including EGFR, KRAS, 
and BRAF. The results were analyzed on the Sequenom MassArray 
platform. Fragment analysis was also undertaken to assess for exon 19 
deletions.
Results: Mutation testing was undertaken on 151 NSCLC specimens, 
including 44 (29.1%) resection specimens (27 lung resection speci-
mens and 17 metastatic site resections), 67 (44.4%) small biopsy spe-
cimens, and 40 (26.5%) cytology specimens. Overall, EGFR mutations 
were detected in 32/151 (21.2%) cases, KRAS mutations in 29/151 
(19.2%) cases, and BRAF mutations in 3/151 (2%) cases. Mutations 
were detected in 25/44 (56.8%) resection specimens, principally lung 
resection specimens (19/27, 70.4%), 26/67 (38.8%) small biopsies and 
13/40 (32.5%) cytology specimens. The mutation rate was significantly 
lower in small biopsies (p=0.006) and cytology specimens (p=0.002), 
compared to lung resection specimens. Specifically, EGFR mutations 
were identified in 13/44 (29.5%) resection specimens, again mainly 
in lung resection specimens (10/27, 37%), 9/67 (13.4%) small biopsies 
and 10/40 (25%) cytology specimens. Compared to lung resection 
specimens, the proportion of EGFR mutation positive cases was signi-
ficantly lower in small biopsy (p=0.01), but not in cytology specimens 
(p=0.29). One paired cytology and lung resection specimen from a 
single patient was available and both specimens confirmed the pre-
sence of an L858R EGFR mutation.
Conclusion: Mutations, including EGFR mutations, were most fre-
quently detected in lung resection specimens. Compared to lung 
resection specimens, the EGFR mutation rate was significantly lower 
in small biopsy, but not in cytology specimens. This suggests that 
cytology specimens are more likely to be adequate for mutation tes-
ting than small biopsies such as core and bronchial biopsies. However, 
we cannot exclude bias in this study from differing referral patterns 
which may affect these results. Careful assessment of DNA quality 
and quantity is important for all specimens, particularly small biopsy 
specimens, to reduce the risk of false positive or negative results.
Keywords: EGFR, Cytology, non-small cell lung cancer
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Conclusion: The following pathological features should be evalu-
ated in diagnosis of AC: localization, the infiltrative growth, solid 
and insular pattern, high grade atypia, oncocytic and spindle-cell 
components, mitotic figures and IP (Ki-67). We proposed for TC 
0-2 mitosis/2mm2 and PI ≤4%, for AC ≥3 mitosis/2mm2 and PI >4% 
and/or foci of necrosis.
Keywords: microscopic criteria, Immunohistochemistry, Pulmonary 
Carcinoid, proliferative index
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P2.18-012 BRONCHIAL WASHING/BRUSHING SAMPLES 
ARE COMPARABLE TO BIOPSY SAMPLES FOR EGFR MU-
TATION TESTING IN NON-SMALL CELL LUNG CANCER
Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim, Kyu-Sik Kim, Kook-Joo 
Na, Sung-Ja Ahn, Sang-Yun Song
Lung Cancer Clinic, Chonnam National University Hwasun Hospital/
Korea
Background: Bronchial washings/brushings (BW/B) are often used 
for early screening and cytological diagnosis of lung cancer. We 
examined the possibility of EGFR testing on cytology samples, as 
compared to bronchial biopsy sample.
Methods: 116 BW/B samples with non-squamous histology 
were submitted to our department for EGFR mutation testing at 
Chonnam National University Hospital within 8-month period. Bi-
opsy samples was concurrently submitted for histologic diagnosis. 
We used the PNA clamping method for EFGR mutation test.
Results: Histologic diagnosis were 103 cases of adenocarcinomas 
and 13 cases of NSCLC, not otherwise specified (NOS). Each sam-
ple was assessed by a pathologist for adequacy and DNA content. 
At BW/B samples, 22 cases showed exon 19 deletion, 13 exon 21 
mutation, 79 were wild type and 2 failed. The EGFR mutation rate 
using BW/B sample was 30.2%. At bronchial biopsy samples, 23 
cases showed exon 19 deletion, 13 exon 21 mutation, 72 were wild 
type and 12 failed. The EGFR mutation rate using bronchial biopsy 
sample was 31.0%. Mutation detection cases were nearly identi-
cal in both samples. But, in only one case, exon 21 mutation was 
detected in biopsy sample, not in BW/B sample. The median DNA 
content for BW/B samples compared to biopsy samples were 3.7ug 
and 3.2ug. The failure rate for cytology samples was lower than 
biopsy samples.
Conclusion: BW/B samples are superior to bronchial biopsy samp-
les in terms of DNA quantity and rate of failure. Moreover, in case 
of inadequate biopsy sample, BW/B samples were a substitute 
material for EGFR mutation test.
Keywords: Epidermal growth factor receptor, non-small cell lung 
cancer, Bronchial Brushing, Bronchial washing
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P2.18-011 BRONCHOPULMONARY CARCINOID TUMOR 
(BPC) - IS IT TIME TO CHANGE MICROSCOPIC CRITERIA 
OF DIAGNOSIS?
Renata Langfort1, Malgorzata Szolkowska1, Piotr Rudzinski2, Ewa 
Szczepulska-Wójcik1, Beata Maksymiuk1, Dorota Giedronowicz1, 
Tadeusz Orlowski2
1Pathology Dpt., National Tuberculosis And Lung Diseases Research 
Institute/Poland, 2Thoracic Surgery, National Tuberculosis And Lung 
Diseases Research Institute/Poland
Background: The distinction between typical (TC) and atypical 
carcinoids (AC) is currently based on histologic criteria reported 
by Travis and al., then accepted by WHO classification and widely 
used today. The crucial microscopic features that distinguish TC 
from AC are mitotic activity and necrosis. TC has fewer than 2 mi-
totic figures/2mm2 , whereas AC has 2 to 10 mitoses/2mm2 and/or 
small foci of necrosis. The aim was to analyze the microscopic fea-
tures and immunohistochemical (IHC) profile of TCs and ACs, and 
to identify the other pathological criteria that could be simple, and 
reproducible, as well as helpful in daily practice of surgical patho-
logy and usefulness in differentiation between both of them.
Methods: We retrospectively collected 236 cases of resected BPC 
from 1998 to 2011 at National Tuberculosis and Lung Diseases 
Research Institute. All tumors were reclassified according to the 
2004 WHO classification. The clinicopathological features were 
correlated and survival analysis were performed. We evaluated size 
and location of tumors (central or peripheral), depth of bronchial 
invasion, destruction of bronchial cartilage, tumor invasiveness, the 
infiltrative growth of the adjacent normal architecture, presence of 
pleural, perineural and vascular invasion. We also assessed cellular 
atypia, growth pattern, cellular morphology, especially oncocytic 
and clear cell, as well as spindle-cell components. The expression 
of a range of antigens including markers of epithelial differentiati-
on (cytokeratins: AE1/AE3 and 19, TTF-1, napsin A), neuroendocri-
ne markers (chromogranin A, synaptophysin, NCAM/CD56), pep-
tide products (calcitonin, serotonin) and antigens involved in cell 
proliferation and death (Ki-67, p53, Bcl-2, CD117) were studied.
Results: After reclassification, 8 cases were diagnosed as LCNEC, 
102 tumors (44,7%) were classified as TC and 126 (55,3%) as AC. 
Most tumors are localized centrally (73,7%) and occurred in fema-
les (69%). AC were larger than TC (2,54 vs 1,9 cm). Solid and insular 
pattern, medium and high cellular atypia, oncocytic component, 
centrally located tumors with cartilage destruction, invasion of pe-
ribronchial tissue and/or adjacent lung parenchyma correlated with 
AC. Mitotic activity was one of most accurate method of diagnosis 
TC and AC but more advantageous would be increasing a number 
of mitoses figures to 2 for TC and to ≥3/2mm2 for AC. AC more 
often revealed positive reaction with CK19 and higher cellular in-
dex for p53. Routinely staining for proliferative index (PI) with Ki-67 
is recommended, for TC ≤4% and for AC >4%. Immunoreactivity 
of broad-spectrum cytokeratin was observed in 95% cases, more 
then 50% showed "dot-like“ reactivity. Peripherally located tumors 
were distinctly different morphologically and IHC than centrally 
carcinoids. Peripherally tumors were smaller (1,9 vs 2,4cm), usually 
not-well demarcated, with solid or insular pattern and spindle-
cell component as well as fibrosis. In contrast to centrally tumors, 
they showed expression of TTF-1, serotonin and Bcl-2 but sparsely 
CK19.
S961Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 2 - PATHOLOGY  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.18-014 IMPACT OF NON SMALL CELL LUNG CANCER 
(NSCLC) IMMUNOPHENOTYPING IN CHEMOTHERAPY 
RESPONSE.
Luisella Righi, Silvia Novello, Jessica Giorcelli, Arianna Votta, 
Matteo Giaj Levra, Enrica Capelletto, Giorgio V. Scagliotti, Mauro 
Papotti
Department Of Oncology, University Of Turin/Italy
Background: The vast majority of non small cell lung cancers 
(NSCLC) presents as advanced disease and histological diagnosis 
is widely based on small biopsy or cytological samples. Recently, 
the adoption of new pharmaceutical agents targeting individual 
histotypes requires a precise subtyping of NSCLC. This task is of-
ten difficult according to morphological criteria only and the use 
of immunohistochemistry (IHC) is recommended for small samples 
or undifferentiated tumors to define the most probable histotype. 
However, the real impact of IHC characterization of NSCLC-Not 
otherwise Specified (NOS) in terms of response to therapy and 
outcome (compared to cases classified by morphology, only) is not 
well established.
Methods: A large series of 224 advanced "non-squamous“ NSCLC 
diagnosed from year 2005 to 2010 on small biopsy or cytological 
samples and homogeneously treated, was retrospectively se-
lected, all with adequate follow-up data available. All diagnoses 
were reviewed resulting in two groups of adenocarcinoma (ADC) 
and NSCLC-NOS. The latter were further characterized by IHC to 
identify the most probable differentiation lineage. Disease Control 
Rate (DCR) and Response Rate (RR) were calculated and Overall 
Survival (OS) curves were analyzed by Kaplan Meier.
Results: After review 120/224 (53.6%) cases were ADC based 
on morphological examination, only (“ADC morphology”) and 
104/224 (46.4%) remained NSCLC-NOS. In terms of response 
to therapy no significant difference was found between the two 
groups (“ADC morphology” had DCR= 0.66 and RR=0.31; NSCLC-
NOS had DCR=0.64 and RR=0.35; Chi-Square p=0.83). The 
NSCLC-NOS cases that underwent IHC profiling resulted in 66/104 
(63.5%) cases that had an ADC phenotype (“NSCLC favor ADC”) 
and 38/104 (36.5%) cases that lack ADC features (including 5 “NS-
CLC favor squamous carcinoma” and 33 “NSCLC null phenotype”). 
The “NSCLC favor-ADC” had DCR and RR similar to “ADC mor-
phology” group (Chi-Square p=0.23), while the “non-ADC” NSCLC 
group had significantly different both DCR=0.47 and RR=0.29 
(Chi-Square p=0.006). Survival curves confirmed no difference in 
terms of survival between the “ADC morphology” and the “NSCLC 
favor-ADC” groups, while showed a significantly poorer survival for 
the “non-ADC” NSCLC group with respect the other two groups 
(median survival: 8.5 vs 12.3 months, respectively; HR=0.5999; 
p=0.018).
Conclusion: These preliminary findings indicate that the practice 
of minimizing the NSCLC-NOS diagnoses by means of IHC has an 
impact on chemotherapy response. Stratifying such tumors by IHC, 
cases having an ADC immunoprofile had response rates compara-
ble to those of morphologically diagnosed ADC, thus supporting 
the value of IHC to maximize lung cancer histological typing in the 
perspective of obtaining the best response to therapy.
Keywords: Treatment response, non-small cell lung cancer, Ade-
nocarcinoma, Immunohistochemistry
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P2.18-013 INCIDENCE OF EGFR, KRAS, BRAF, ALK, AND 
P53 ALTERATIONS IN A COHORT OF 159 CONSECU-
TIVELY TESTED PATIENTS FROM A CERTIFIED LUNG 
CANCER CENTER, CORRELATION WITH CLINICAL CHA-
RACTERISTICS AND TREATMENT OUTCOME.
Volker Halbfass1, Regina Prenzel2, Douglas Scriba3, Kay Willborn4, 
Markus Falk5, Cora Hallas5, Markus Tiemann5, Frank Griesinger6
1Hematology And Oncology, Pius-Hospital/Germany, 2Pneumology, 
Pius-Hospital/Germany, 3Thoracic Surgery, Pius-Hospital/Germany, 
4Radiotherapy, Pius-Hospital/Germany, 5Pathology, Hemopathology 
Hamburg/Germany, 6Hematology And Oncology, Pius-Hospital Olden-
burg, University Of Oldenburg/Germany
Background: The incidence of EGFR mutations has been systema-
tically analyzed in a large cohort in Germany within the REASON 
trial. However, systematic data on KRAS, BRAF, ALK, and p53 
within the same cohort have not been published in German co-
horts of patients with lung cancer. Therefore we studied the inci-
dence of these alterations in 159 patients from a single center and 
correlated these with clinical characteristics and survival.
Methods: 159 patients from a single center diagnosed with lung 
cancer were studied for the presence of EGFR mutations, ALK re-
arrangements, KRAS codon 12/13/61 and BRAF V600E and G469A, 
as well as inactivating p53 mutations. Methods for the detection 
of EGFR mutations included Sanger Sequencing and hybridization 
based COBAS testing. ALK rearrangements were either tested by 
RT-PCR or ALK-FISH (break apart probe, Vysis). BRAF mutations 
were detected by allele specific PCR, KRAS and p53 by Sanger 
Sequencing
Results: 159 consecutive patients at the lung cancer center of the 
Pius-Hospital Oldenburg were studied. In all cases EGFR mutations 
status was successfully determined. 33/159 (21%) had EGFR mu-
tations, of which 3 had primary resistance mutations. 5/132 suc-
cessfully studied pts had ALK rearrangements (3,7%). 29/142 (20%) 
successfully studied for KRAS mutations had codon 12 or 13 mu-
tations. 2/136 (1,4%) successfully studied for BRAF mutations had 
G469A (2) mutations, V600E mutations were not observed. p53 
mutations were observed in 47% of successfully studied pts (21/45 
pts). Just analyzing the 60 never or light smokers (< 100 cigarettes 
lifelong or < 10 packyears and ex-smoker), revealed 23/60 (38%) 
EGFR mutations, 4/44 (9%) ALK rearrangements, 4/49 (8%) KRAS 
mutations, 1/49 (2%) BRAF mutations and 7/19 (37%) p53 muta-
tions, demonstrating that EGFR and ALK were overrepresented in 
never-light smokers, whereas BRAF, KRAS and p53 mutations were 
overrepresented in smokers. ALK, EGFR, KRAS and BRAF muta-
tions were mutually exclusive in this patient population. However 
p53 mutations were observed in pts with activating EGFR muta-
tions in 7/15 successfully studied cases. Outcome in the different 
subgroups will be presented at the meeting.
Conclusion: EGFR and ALK mutations were overrepresented in 
never-light smokers, BRAF and KRAS mutations were underrepre-
sented. P53 mutations occurred independently of smoking status 
in combination with EGFR mutations, but not ALK- translocations. 
OS data will be presented at the meeting.
Keywords: KRAS mt NSCLC, ALK translocation, BRAF mt NSCLC, 
EGFR mt and p53 mt NSCLC
S962 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
 ( FNA CNB 
EGFR WT 74 45 
 ( Exon 19 Del 8 2 
 ( Exon 20 Ins 0 1 
 ( L858R 5 1 
 ( Exon 18 G719X 1 0 
 ( Invalid 3 0 
KRAS WT 51 40 
 ( 12/13 Mutation 29 8 
 ( 61 Mutation 1 0 
 ( Invalid* 8 1 
 
* By sequencing 6 WT and 3 mutated
Conclusion: In addition to FFPE samples, identification of EGFR 
and KRAS mutations in FNA and CNB samples using cobas EGFR 
and KRAS Mutation Tests is faster, easier to use, and reproducible. 
Although DNA concentrations were lower from FNA, DNA quality 
was similar to CNB and provided valid results. Sequencing had 
lower sensitivity and was more time-consuming. Careful sample 
management, especially for FNA, by the pathologist is critical to 
ensure quality and to optimize DNA yields.
Keyword: Cytological smears, FNA, CNB, mutations.
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P2.18-016 HIGH THROUGHPUT SOMATIC MUTATION 
PROFILING IN PARAFFIN EMBEDDED NON-SMALL CELL 
LUNG CANCER BIOPSIES USING THE LUNGCARTA™ 
PANEL IN CLINICAL ROUTINE PRACTICE
Antoinette Lemoine1, Raphaël Saffroy2, Jocelyne Hamelin3, Nelly 
Bosselut3, Jean-Francois Morere4
1Oncogenetics, Hôpital Paul Brousse/France, 2Hôpital Paul Brousse/
France, 3Oncogenetics, Aphp/France, 4Oncology, Hôpital Paul Brousse/
France
Background: The identification of EGFR mutations as a driver for 
oncogenic proliferation in Non-Small Cell Lung Adenocarcinoma 
(NSCLC), in parallel with the development of the tyrosine kinase 
inhibitors has opened the way to “theranostics”. However, as more 
targets are identified and more targeted inhibitors are marketed, 
the medical community now needs to interrogate multiple genes 
to generate an accurate molecular profile for each individual tumor 
and determine matching targeted therapeutics. The development 
of the Next Generation Sequencing (NGS) has opened a new area 
offering for more comprehensive screening of somatic mutations 
across 10s to 100s of genes. However, its application in routine 
clinical practice within the individual therapeutic setting remains 
impractical due to the large data sets produced, as well as the 
high potential for generating false positive mutations Therefore 
atargeted approach seems more appropriate when screening for 
actionable somatic mutations. MALDI-TOF mass spectrometry 
(MassARRAY® System) is a flexible high-throughput solution that 
can easily adapt to newly discovered mutations as well as detect 
minority alleles of mutated DNAof large sample sets.
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P2.18-015 EGFR AND KRAS MUTATIONAL ANALYSIS 
USING SMALL AMOUNTS OF DNA FROM FNA AND 
SMALL CNB IS FEASIBLE AND REPRODUCIBLE USING A 
COMMERCIAL REAL TIME PCR METHOD. VALIDATION 
OF THIS PCR METHOD IN CYTOLOGICAL SAMPLES.
Maria D. Lozano1, Tania Labiano1, Myriam Montañana1, Nerea 
Gomez1, M Aguirre1, Ji Echeveste1, John F. Palma2, Teresa Ramos3, 
Alfonso Gurpide4, Salvador Martin-Algarra4
1Pathology, Clínica Universidad De Navarra/Spain, 2Roche Molecular 
Systems/United States Of America, 3Roche Diagnostics/Spain, 4Medical 
Oncology, Clinica Universidad De Navarra/Spain
Background: EGFR and KRAS mutations guide treatment selection 
in NSCLC patients. With 75% of newly diagnosed cases at advan-
ced stages, mutational analysis is performed in small samples: core 
needle biopsies (CNB) and fine needle aspiration (FNA). Both the 
cobas EGFR and KRAS test are CE-IVD. No validation studies of 
the cobas tests have been performed using cytological smears but 
it is important to extend the benefits of molecular targeted thera-
py while preserving tissue for additional marker testing.
Methods: EGFR and KRAS mutation status were studied in 140 
non-selected samples from NSCLC patients: 49 CNB, 91 FNA. 
DNA was extracted directly from one stained smear in FNA samp-
les and one 5-micron section in CNB using the cobas DNA Sample 
Preparation Kit. All samples contained ≥ 50% tumor cells. DNA 
concentration and ratio (A260/280) were recorded. All cases were 
studied using the cobas EGFR and KRAS mutation tests. Moreover, 
123 and 125 cases were analyzed respectively for EGFR and KRAS 
mutational status using Sanger sequencing.
Results: CNB diagnosis was: 29 SqCC, 17 AC, 1 BAC, 1 adenos-
quamous, 1 NSCLC-NOS. FNA diagnosis was: 64 AC, 13 SqCC, 
3BAC, 2 LCC, 2 adenosquamous, 7 NSCLC-NOS. DNA concentra-
tions from CNB were higher and significantly different than DNA 
from FNA (p<0.001,U Mann Whitney). DNA quality was similar 
between sample types. Mutational analysis is shown in Table 1. 
Mutation rate for EGFR was 15.9% and 8.2 % and for KRAS 37% 
and 16.7% in FNA and CNB, respectively, but should be conside-
red within the context of tumor type. 8.6% and 36.4% of the cases 
were below the manufacturer’s recommendations of 2ng/µl and 
4ng/µl for EGFR and KRAS testing, respectively. Invalid rates were 
2.1% (3) for EGFR and 5.5% (9) for KRAS. These results may be due 
to low DNA concentration (EGFR) or technical performance (KRAS) 
that was resolved with later samples. Sequencing invalid results 
were 42.3% for EGFR and 0.8% for KRAS. Table 1. 
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P2.18-017 MULTIPLEXED-BASED MUTATION PROFILING 
OF NON SMALL CELL LUNG CANCER SMALL BIOPSY 
SAMPLES USING THE SEQUENOM LUNGCARTA™ PA-
NEL AND MASSARRAY® SYSTEM
Anne Marie Quinn1, Nicholas Hickson1, Megan Adaway1, Lynsey 
Priest2, Catherine Keeling3, Andrew Wallace1, Daisuke Nonaka4, 
Richard Byers3, William Newman1, Fiona Blackhall4
1Dept. Of Genetic Medicine, St. Mary‘s Hospital/United Kingdom, 2Pa-
terson Institute For Cancer Research, University Of Manchester/United 
Kingdom, 3Pathology, Manchester Royal Infirmary/United Kingdom, 
4The Christie NHS Foundation Trust/United Kingdom
Background: The advent of specific therapies for non small cell 
lung cancer (NSCLC) based on individual tumour genotype has 
impacted the development of high throughput genomic profiling 
strategies. A single platform designed for the synchronous scree-
ning of multiple mutations across different genes can potentially 
enable molecular profiling in samples of limited tumour tissue such 
as small biopsy samples.
Methods: Haematoxylin and eosin-stained sections and accompa-
nying reports were reviewed from patients diagnosed with NSCLC 
(2008 to 2012) in Greater Manchester, U.K. Samples with less than 
20% tumour cell content (TCC) were macrodissected to increase 
the final TCC. In each case DNA was extracted manually from 1 
5µM curl/section using the cobas® DNA Sample Preparation Kit. 
Mutation analysis was performed with the Sequenom LungCarta™ 
Panel which enables screening of 214 mutations in 26 genes, and 
utilises multiplexed polymerase chain reactions, single base exten-
sion reactions and mass spectrometry (Sequenom MassARRAY® 
platform).
Results: Results Sixty cases comprising 47 lung biopsies, 1 wedge 
resection, 6 lymph node biopsies, 4 pleural biopsies, 1 brain bio-
psy and 1 pericardial effusion were classified as 21 adenocarcino-
mas (ACA), 17 squamous cell carcinomas (SCC), 8 NSCLC favour 
ACA, 10 NSCLC favour SCC, 1 adenosquamous carcinoma and 3 
NSCLC not otherwise specified (NOS). Mutations were success-
fully detected at a mutant allele frequency of 10% and definite 
mutations were reported in 28 cases (47%). Possible mutations of 
low allele frequency or uncertain significance were detected in an 
additional 15 cases (25%) and also in 10 cases with a definite mu-
tation. In total 32 definite and 39 equivocal mutations have been 
detected and are currently being validated by a combination of 
pyrosequencing, next-generation sequencing and immunohisto-
chemistry (IHC).  
Methods: We have evaluated the LungCarta™ Panel, a panel tar-
geting 213 somatic mutations in 26 genes. The method relies on 
multiplex PCR followed by single base extension and analysis using 
MALDI-TOF Mass Spectrometry.Genes such as EGFR, KRAS, BRAF, 
ERBB2 or PI3KCA,MAP2K1, EPHA3, NTRKs, STK11, TP53 and DD-
R2are well-represented.
Results: For verification of this panel we have screened a set of 37 
lung metastatic adenocarcinoma DNA isolated from formalin fixed 
paraffin embedded (FFPE) biopsies.These samples were previously 
characterized for EGFR, KRAS, ERBB2, PIK3CA and BRAF. We iden-
tified a total of 26 mutations in 23 of the 37 samples (62%) loca-
lized in 10 genes. 100% of the previously known mutations were 
verified and an additional 12 mutations were identified, 10 of these 
mutations were located in genes not previously screened. We were 
able to significantly reduce the DNA amount to as little as 24ng. To 
further validate the LungCarta panelresults we selected 15 of the 
samples to be analyzed using NGSand theTruSeqAmplicon - Can-
cer Paneland11 of the samples generated high quality libraries that 
could be sequenced. Using this NGS approach we validated the 
hits obtained by LungCarta. When comparing the two methods, 
NGS has a quite complicated workflow and we identified more 
than 50 positive hits for each sample requiring a large bioinforma-
tics effort in order to separate true positives hits from false positive 
hits. This problem was not seen using the LungCarta where the 
standard turnaround time for each sample batch was less than 24 
hours and the panel showed excellent robustness using DNA ob-
tained from FFPE.
Conclusion: We have now applied the LungCarta™ panel to more 
than 400 patients with NSCLC and were able to not only treat 
patients promptly, but also enter some others in clinical trials We 
have identified targets that could be very interesting in the future. 
Compared to the NGS approach,LungCarta offers a relatively sim-
ple workflow with quick turnaround time and minimal sample input 
requirements.
Keywords: SOMATIC MUTATION PANEL, HIGH THROUGHPUT 
SEQUENCING
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P2.18-018 OUTCOMES OF LUNG ADENOCARCINOMA 
PATIENTS WITH SIGNET RING CELL TUMORS: A THREE-
WAY EVALUATION
Ping Yang1, Jennifer Boland2, Marie Christine Aubry2, Jason 
Wampfler1, Randolph Marks3, Stephen Cassivi4, Dennis A. Wigle4, 
Aminah Jatoi3, Francis Nichols4, Jin Jen5, Mariza De Andrade1, K 
Robert Shen4, Mark Allen4, Yolanda I. Garces6, Julian Molina3, Clau-
de Deschamps4, Joanne Yi2
1Health Sciences Research, Mayo Clinic/United States Of America, 
2Anatomic Pathology, Mayo Clinic/United States Of America, 3Medical 
Oncology, Mayo Clinic/United States Of America, 4Thoracic Surgery, 
Mayo Clinic/United States Of America, 5Department Of Laboratory 
Medicine And Pathology, Mayo Clinic/United States Of America, 6Radi-
ation Oncology, Mayo Clinic/United States Of America
Background: Pathologically, signet ring cells (SRC) describe singly 
dispersed tumor cells with intracytoplasmic mucin vacuoles, which 
eccentrically displace and compress the nucleus. SRCs are traditio-
nally associated with adenocarcinoma of the gastrointestinal tract 
and are rare in lung adenocarcinoma (LACA). Patients with primary 
LACA with SRC features (SRC+) have been associated with poor 
clinical outcome and ALK gene rearrangement (ALK+). However, 
the impact of SRC+ on clinical outcome is not well delineated. We 
systematically studied LACA survival outcomes for the impact of 
SRC status.
Methods: Three distinct groups of surgically treated patients with 
LACA (n=763) that were followed for ≥5 years were reviewed: never 
smokers (n=266), 2006-2007 cohort (n=222), and smokers enriched 
Table 1. Unequivocal mutations detected according to histological subtype. (aIncludes double mutant; TP53 and 
MAP2K1, bincludes triple mutant; 2 TP53 and 1 KRAS, cincludes double mutant; KRAS and MET)
No. of 
definite 
mutations 
detected
No. of 
mutated 
samples
ACA
NSCLC 
favour 
ACA
SCC
NSCLC 
favour 
SCC
NSCLC 
NOS
% of mu-
tations 
detected in 
all ACA or 
SCC
Comment
13 TP53 12 3a 2b 5 1 1
17 % ACA 
22% SCC
1 confirmed by next 
generation sequen-
cing. 7 of 8 tested 
cases were strongly 
positive for P53 IHC
12 KRAS 12 8c 1b 3
31% ACA 
11% SCC
7 confirmed by pyro-
sequencing
3 MET 3 2c 1
10% ACA 0% 
SCC
1 confirmed by next 
generation sequen-
cing
2 EGFR 2 2
7% ACA 0% 
SCC
2 previously detected 
by Sanger sequen-
cing
1 EPHA5 1 1
0% ACA 4% 
SCC
Moderately differen-
tiated SCC
1 MAP2K1 1 1
3% ACA 0% 
SCC
Poorly differentiated 
ACA TTF1+
 
Conclusion: The MassARRAY® system of testing for multiple mu-
tations is a sensitive method that facilitates the optimal use of tu-
mour DNA present in small specimens, and can detect concurrent 
mutations with the potential to influence responses to targeted 
therapies. Unequivocal mutations were reported in 59% and 37% 
of cases diagnosed/favoured as ACA and SCC respectively. This 
may reflect the LungCarta™ panel design, which was based on 
mutations detected in ACA.
Keyword: NSCLC mutation profiling Sequenom
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clinicopathological features in NSCLC.
Methods: A total of 383 consecutive patients with NSCLC under-
went complete resection from 2006 to 2008 were examined retro-
spectively. The expression of EGFR and KRAS were evaluated by 
tissue microarray.
Results: The mutations of EGFR and KRAS were detected in 
181/383 (47.3%) and 32/383 (8.4%) patients, respectively. On ana-
lysis of EGFR mutations, female were 107/181 (59.1%) and 51/202 
(25.2%), adenocarcinoma were 177/181 (97.8%) and 123/202 
(60.9%), no vascular invasion were 147/181 (81.2%) and 110/202 
(54.5%), and non-smoker were 99/181 (54.7%) and 41/202 (20.3%) 
patients in EGFR mutation and wild type patients, respectively. As 
a result, EGFR mutation was found more frequently in female, ade-
nocarcinoma, no vascular invasion, and non-smoker. The number 
of patients with pathological T1a were 49/181 (27.0%) and 42/202 
(20.8%), T1b were 63/181 (34.8%) and 41/202 (20.3%) in EGFR 
mutation and wild type patients, respectively. Moreover, average 
tumor diameter was smaller in patients with EGFR mutation (2.68 
cm±0.92) than wild type (3.34cm±1.70) (P<0.001). There were no 
differences in clinicopathological characteristics between exon19 
and 21 EGFR mutations. In contrast, there were no significant dif-
ferences between KRAS mutation and gender, histopathological 
type, vascular invasion and.smoking. Although KRAS status was 
not correlated with pathological T factors, average tumor diameter 
was larger in patients with KRAS mutation (3.49 cm±2.00) than wild 
type (2.98 cm±1.35) (P<0.001).
Conclusion: Our results suggest that EGFR mutation may suppress 
vascular invasion, and tumor growth, on the other hand, KRAS 
mutation may correlate with activation of tumor growth.
Keywords: non-small cell lung cancer, Epidermal growth factor 
receptor, KRAS
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P2.18-020 APPROPRIATENESS EVALUATION OF HAND-
LING METHOD FOR THE SMALL LUNG ADENOCAR-
CINOMA IN THE FROZEN SECTION DIAGNOSIS BY 
RADIOLOGICAL-PATHOLOGICAL CORRELATION
Tetsuya Isaka1, Tomoyuki Yokose1, Kouzo Yamada2, Hiroyuki 
Ito2, Masato Watanabe2, Naoko Imamura2, Kentaro Imai2, Teppei 
Nishii2, Fumi Karino2, Shuji Murakami2, Tetsuro Kondo2, Haruhiro 
Saito2, Fumihiro Oshita2, Haruhiko Nakayama2, Munetaka Masu-
da3
1Pathology, Kanagawa Cancer Center Hospital/Japan, 2Thoracic Oncolo-
gy, Kanagawa Cancer Center Hospital/Japan, 3Department Of Surgery, 
Yokohama City University School Of Medicine/Japan
Background: The frozen section diagnosis is often performed in 
the sublobar resection of lung tumor. As no standard of prepara-
tion method for the frozen section is proposed, its methodology 
differs depending on institutions. In this study, we examine appro-
priateness of our preparation method for a resected specimen with 
a small adenocarcinoma by comparing between radiological and 
pathological tumor size.
Methods: We retrospectively reviewed the records of 59 resected 
lung specimens for the frozen section diagnoses (54 wedges and 
5 segmentectomies) of lung adenocarcninomas from January to 
for various degrees of lepidic growth pattern (LGP, n=275). Two 
pulmonary pathologists reviewed all cases; SRC+ tumors were 
defined as having >10% SRCs, agreed by both pathologists. SRC+ 
tumors were TTF1+, and generally cytoplasmic mucin+ and CDX2-. 
ALK immunostain was performed on all SRC+ cases, and ALK sta-
tus was confirmed by FISH for cases with any degree of immuno-
reactivity. Impact of SRC+ on patients’ survival outcomes (overall 
and disease-free, OS and DFS) were analyzed using Cox models 
(by hazard ratio, HR) separately for the three groups, with careful 
evaluation of known prognostic factors: age at diagnosis; gender; 
smoking status; lung cancer history; tumor subtype; grade and 
stage; and treatment (surgery, chemotherapy and/or radiation).
Results: In the total of 763 patients (61% women, mean age at 
diagnosis 68 years), 53 (7%) were SRC+. In never smokers (73% wo-
men), 9% were SRC+; 33% of the SRC+ were ALK+ vs. 5% among 
the SRC- cases (p<0.0001). In the 2006-2007 cohort (55% women), 
9% were SRC+; in LGP-smokers (54% women), 3% were SRC+. 
Across all three groups, SRC+ tumors were more likely to occur 
in men and have higher stage. Univariate analysis showed SRC+ 
never smokers had shorter survival: median DFS was 2.4 years (vs. 
5.2 in SRC- never smokers, p=0.0004), and median OS was 3.7 
years (vs. 7.6, p=0.0064). However, multivariate analysis did not 
confirm a significant impact of SRC+ on survival. In contrast, for the 
other two groups, crude 5-year survival was 6%-27% decreased in 
SRC+ cases compared to SRC- cases (none reached statistical sig-
nificance); however, multivariate analysis revealed a 2-fold higher 
mortality (HR=2.30, 95% CI=1.01-5.27, p=0.048) for smokers with 
SRC+ tumors.
Conclusion: Based on results from three patient groups, we confir-
med that SRC+ is significantly associated with ALK+. Worse survival 
in patients with SRC+ tumors was observed in never smokers by 
univariate analysis. A potential negative impact of SRC+ tumors on 
OS in LGP-smokers was only uncovered after adjusting for known 
prognostic factors. These results need to be furthered confirmed.
Keywords: Outcome, lung adenocarcinoma, Signet Ring Cell  
Tumors
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P2.18-019 CLINICOPATHOLOGICAL FEATURES IN NON-
SMALL CELL LUNG CANCER PATIENTS WITH EGFR AND 
KRAS MUTATIONS.
Teppei Nishii1, Tomoyuki Yokose2, Yohei Miyagi3, Hiroyuki Ito1, 
Masato Watanabe1, Naoko Imamura1, Tetsuya Isaka2, Kentaro 
Imai1, Fumi Karino1, Shuji Murakami1, Tetsuro Kondo1, Haruhiro 
Saito1, Fumihiro Oshita1, Kouzo Yamada1, Haruhiko Nakayama1, 
Munetaka Masuda4
1Thoracic Oncology, Kanagawa Cancer Center/Japan, 2Pathology, Kana-
gawa Cancer Center/Japan, 3Molecular Pathology And Genetics Divisi-
on, Kanagawa Cancer Center Research Institute/Japan, 4Department Of 
Surgery, Yokohama City University School Of Medicine/Japan
Background: Some of molecular pathways have been shown to 
have prognostic impact in non-small cell lung cancer (NSCLC). Epi-
dermal growth factor receptor (EGFR) mutations predict the effect 
of EGFR tyrosine kinase inhibitors. KRAS is also critical oncogene, 
and it has been reported that KRAS pathway might interact with 
EGFR. But, the role of KRAS in NSCLC is unclear. We investigated 
the relationship between EGFR and KRAS mutation status and 
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P2.18-021 HOW ACCURATE ARE WE IN DIAGNOSING 
SQUAMOUS CELL CARCINOMA OF THE LUNG IN CYTO-
LOGY SPECIMENS AND RELEVANCE TO MOLECULAR 
TESTING? AN INSTITUTIONAL EXPERIENCE.
Rashmi Tondon, Michelle Pramick, Zubair Baloch, Charuhas 
Deshpande
Dept. Of Pathology & Laboratory Medicine, University Of Pennsylvania/
United States Of America
Background: Distinction between different subtypes of non–small 
cell lung carcinoma (NSCLC) particularly separating squamous cell 
carcinoma (SCC) from non-SCC is important due to the availability 
of specific targeted therapy based on histologic subtypes. Recent 
molecular testing guideline for selection of lung cancer patients for 
epidermal growth factor (EGFR) and anaplastic lymphoma kinase 
(ALK) tyrosine kinase inhibitor therapy from the College of Ame-
rican Pathologists (CAP), International Association for the Study 
of Lung Cancer (IASLC) and Association for Molecular Pathology 
(AMP), recommend that in the setting of fully excised lung cancer 
specimens, EGFR and ALK testing is not recommended in lung 
cancers that lack any adenocarcinoma component, such as pure 
SCC (Lindeman et al, J Mol Diagn 2013, 15:1-39). However, more 
than two-thirds of lung cancer presents as advanced stage disease 
and cytology specimens may only be available in most of these 
cases. Accurate distinction between SCC and non-SCC can be 
challenging in these cytology specimens due to limited cellularity. 
We report our institutional experience regarding the diagnostic 
accuracy of classifying SCC in cytology preparations compared 
with histopathological follow-up.
Methods: A retrospective review of the cytology specimens diag-
nosed as squamous cell carcinomas was carried out from January 
2011 – June 2012 from our cytopathology and surgical pathology 
databases. All cases were correlated with subsequent histopa-
thological diagnoses, immunohistochemical (IHC) and molecular 
analyses.
Results: A total of 200 histopathological specimens diagnosed as 
squamous cell carcinoma (SCC) were retrieved from our electronic 
medical records. 30 were excluded due to multiple specimens 
from the same patient. Corresponding cytology specimens inclu-
ding fine needle aspiration (FNA) specimens, bronchial brushings 
and bronchial washings were available in 88/170 (52%) cases. Out 
of these 88 cytology specimens, a diagnosis of malignancy was 
made in 58 (66%) specimens; these were subcategorized into (1) 
definite diagnosis of malignancy (32/58=55.2%), (2) favor tumor 
subtype (14/58=24.1%), (3) unclassified (9/58=15.5%) and (4) suspi-
cious for malignancy (3/58=5.2%). Overall, the diagnoses of malig-
nancy was made in 57/58 (98.3%) while the accurate diagnoses of 
squamous cell carcinoma was made in 52/55 (95%) cytology speci-
mens. IHC was employed in cases 21/88 (23.9%). Molecular testing 
was performed on 12/170 (7%) specimens. Molecular testing was 
successful in these cases with mutations identified in two cases.
Conclusion: Our study demonstrates that cytology specimens 
are an excellent source of making a reliable, quick and accurate 
diagnosis of lung squamous cell carcinomas in 95% of cases and 
can serve as an excellent source for IHC and molecular analyses, if 
necessary.
Keyword: Squamous cell carcinoma, lung, cytology, histopatholo-
gy, correlation
December 2008. After the specimen was well inflated with saline 
using injector, the pathologist cut it into segments with a width of 
3-5mm and immersed them in saline. Taking the segment with ma-
ximum diameter of tumor as a sample, the pathological tumor sizes 
were measured (I) macroscopically by using metal straight ruler, 
(II) microscopically on the frozen section, and (III) microscopically 
on the permanent paraffin section. For obtaining the stereoscopic 
tumor size (II and III), we used a stereoscopic image analysis soft-
ware, Leica Application Suite (Leica Microsystems; Tokyo, Japan). 
CT tumor size was measured by using 1-2mm thin-section CT (X-
Vigor/Real or Aquillion, Toshiba Medical Systems, Tokyo, Japan). 
We obtained the tumor shadow disappearance rate (TDR) by 
comparing tumor size on the lung and mediastinal window image, 
to classify 59 cases into two groups according to TDR; TDR≧50% 
defined as the air-containing type (Group A, n=44) and TDR<50% 
as the solid-containing type (Group S, n=15). We also calculated 
the diremption rate (DR%) between the pathological and the CT 
tumor size (DR% = |CT tumor size － each pathological tumor size|/
CT tumor size×100(%)) and compared Group A and Group S.
Results: Mean CT tumor size and its standard deviation(SD) were 
18.36±5.23mm, and mean pathological tumor sizes and SD of I, II, 
and III were 17.17±6.12, 14.29±3.66, and 14.23±4.38mm, respec-
tively. Mean CT tumor size was statistically larger than that of II and 
III (p<0.001 using Paired t-test). All the three pathological tumor 
sizes were correlated to the CT tumor size by Pearson’s correlati-
on analysis (correlation coefficient were 0.766, 0.700, and 0.682, 
respectively). DR% of II and III were significantly higher in Group 
A than Group S by Mann-Whitney U-test (Mean DR% of group A 
/ S (p-values) of I, II, and III were 17.0/13.8% (p=0.196), 25.8/19.3% 
(p=0.093), and 27.3/15.5% (p=0.032) , respectively).
Conclusion: There was a strong correlation between CT tumor size 
and each pathological tumor size, which shows that our preparati-
on method of the specimen for the frozen section is appropriate to 
obtain sufficient information about the lung tumor. Furthermore, 
we found that the pathological tumor size is considerably unde-
restimated by measuring tumor size on the frozen or permanent 
paraffin section, especially the tumor classified as “air-containing 
type” including adenocarcinoma with good prognosis. It is there-
fore important to inflate the lung specimen sufficiently and to 
transfer it to microscopical examination without tissue shriNKIng.
Keywords: CT tumor size, Adenocarcinoma, pathological tumor 
size, frozen section diagnosis
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Methods: We included 313 patients with stage IIIB and IV histolo-
gically confirmed lung ADC from the Instituto Nacional de Cance-
rología (INCan). All patients received platinum-based chemothera-
py (CT) and only 30% received EGFR-TKIs. ADCs were re-classified 
using the new IASLC/ATS/ERS criteria. Clinical characteristics, 
mutational profile, response and progression-free survival (PFS) to 
CT and overall survival (OS) were analyzed.
Results: ADCs were classified as lepidic 6.1%, acinar 36.7%, pa-
pillary 8.3%, micropapillary 2.9%, solid 28.1% and 17.9% were un-
classifiable. We divided them into two groups: intermediate-grade 
(lepidic and acinar-predominant) and high-grade (micropapillary, 
papillar and solid-predominant). The response rate and PFS to CT 
were better in the high grade group (36.9% vs 25.4% p= 0.034; 6.4 
vs 5.5 months p= 0.009, respectively). The OS was better in the 
high grade group (25 vs 16.8 p= 0.023). In multivariate analysis, 
factors associated with better OS were ECOG of 0-1, EGFR muta-
tions and high grade group histology. We did not find association 
between EGFR mutations and this classification.
Conclusion: Unlike early stages, patients with advance disease and 
with high-grade ADC according to the new classification have lon-
ger OS compared with intermediate grade ADC, probably due to a 
better response to CT.
Keyword: Lung adenocarcinoma, IASLC/ATS/ERS classification, 
advanced disease 
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P2.18-022 DO EGFR- AND KRAS-MUTATIONS OCCUR IN 
SQUAMOUS CELL LUNG CARCINOMAS?
Julien P.L. Vincenten1, Egbert F Smit2, Katrien Grünberg3, Pieter E. 
Postmus2, Peter J F Snijders3, Birgit I. Witte4, Daniëlle A M Heide-
man3, Erik Thunnissen3
1Pulmonary Diseases, Albert Schweitzer Hospital/Netherlands, 2Pulmo-
nary Diseases, VU University Medical Center/Netherlands, 3Pathology, 
VU University Medical Center/Netherlands, 4Epidemiology And Biosta-
tistics, VU University Medical Center/Netherlands
Background: Adenocarcinoma (ADC) of the lungs may harbor 
EGFR- and KRAS-mutations, which are relevant for treatment deci-
sions. Approximately 35% of non-small cell lung cancer (NSCLC) bi-
opsies are diagnosed as not-otherwise-specified (NOS).To improve 
segregation between ADC and squamous cell carcinoma (SqCC), 
the classification of lung cancer was updated in 2011, adding 
immunohistochemistry (IHC) for p63 and TTF-1 to the diagnostic 
algorithm. The aim of our study was to investigate the hypothe-
sis, that additional IHC reliably delineates lung cancer harboring 
EGFR- and KRAS-mutations.
Methods: From an institutional lung cancer database of specimens 
routinely analyzed for the presence of EGFR- or KRAS-mutations 
(n=816), cases harboring a mutation were selected (n=343) and 
corresponding original histological diagnoses and IHC for TTF-1, 
p63 and PAS-D were collected. Cases with a pattern compatible 
with SqCC were histologically reassessed.
Results: From the 343 cases 25% were resection specimen, 70% 
biopsy and 5% cytology specimens. 69% of cases had a KRAS-
mutation and 31% an EGFR-mutation. IHC-data were conclusive in 
89%. The combination of positive TTF-1 and/or mucin stain and a 
negative p63 stain, favoring ADC, was found in 264 cases (77%). 
Six (1.7%) specimens were positive for p63 only, favoring SqCC.
Conclusion: The current 2011 classification of lung tumors, based 
on histology and immunohistochemistry for TTF-1, p63 and mucin, 
segregates specimens of ADC and SqCC sufficiently well. Our stu-
dy results support the use of IHC in the diagnosis of lung cancer.
Keyword: EGFR-mutation, KRAS-mutation, immunohistochemistry
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P2.18-023 RELEVANCE OF THE NOVEL IASLC/ATS/ERS 
CLASSIFICATION OF LUNG ADENOCARCINOMA IN AD-
VANCED-DISEASE NON-SMALL CELL LUNG CANCER.
Alma D. Campos Parra1, Alejandro Avilés1, Susana Contreras-
Reyes1, Carlos Rojas Marín1, Hugo Domínguez Malagón1, Diana 
Flores-Estrada1, José Borbolla2, Oscar Arrieta1 
1Instituto Nacional de Cancerología (INCan), Mexico City/Mexico, 2On-
cology, Bristol-Myers-Squibb, Mexico City/Mexico
Background: Since IASLC/ATS/ERS reported their new classifica-
tion for lung adenocarcinoma (ADC), several groups have validated 
its association with prognosis in early stage. We know do not any 
study in advanced disease.
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P2.19-002 PULMONARY TULAREMIA: A RARE DISEASE 
WHICH CAN BE MISTAKEN FOR LUNG CANCER
Gunnar Hillerdal1, Karl Kölbeck1, Hans Jacobsson2
1Pulmonary Medicine, Karolinska Hospital/Sweden, 2Nuclear Medicine, 
Karolinska Hospital/Sweden
Background: Acute infections can sometimes radiologically be 
suspected to be lung cancer. Only rarely are, however, the medi-
astinal lymph nodes enlarged. Tularemia is a disease in rodents 
caused by the bacterium Fransiscella tularensis but it can also in-
fect humans if infective material is inhaled, and typically lung infil-
trates and PET-positive nodes persist for a few months. We have 
not found any good description of this entity in the literature and 
therefore we describe three such cases.
Methods: During two years, three patients were referred for sus-
pected lung cancer. One was a farmer and two who had cleaned 
out their summer house after the winter invasion of mice. PET 
investigation with 18F-fluorodeoxyglycose (FDG) was strongly po-
sitive both in the "tumor“ and in the enlarged mediastinal lymph 
nodes. Bronchoscopy showed inflammatory cells only.
Results: There was a spontaneous regression of the lesions during 
the investigations and serology proved the etiology.
Conclusion: Like the classical plague, there are two variants of 
tularemia: peripheral wounds or insect bites can cause the ulcerog-
landular form, with an ulceration and enlarged local lymph nodes 
nodes which can suppurate, and inhalation of infectious material 
(for example, mouse excrements) can cause a localized pulmonary 
infiltrate and enlarged mediastinal lymph nodes which will readily 
be mistaken for lung cancer. Diagnosis is by serology; treatment is 
mainly by tetracyclines, but by the time investigation is started the 
disease is usually already healing spontaneously. History is very im-
portant: has the patient has any contact with mice or other rodents 
or their droppings?
Keywords: Infection, Differential diagnosis, Lung cancer, PET CT
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P2.19-001 THE IMAGING CHARACTERISTICS OF F-18 
FDG PET-CT ON EPIDERMAL GROWTH FACTOR RECEP-
TOR MUTATIONS IN NON-SMALL CELL LUNG CANCER
Berna Degirmenci Polack1, Yasemin Baskin2, Nazli Pinar Karahan1, 
Gizem Calibasi2, Recep Bekis1, Olcun Umit Onal3, Ilhan Oztop3, 
Atilla Akkoclu4
1Nuclear Medicine, Dokuz Eylul University Medical School/Turkey, 
2Basic Oncology, Dokuz Eylul University Institute Of Oncology/Turkey, 
3Oncology, Dokuz Eylul University Medical School/Turkey, 4Chest Du-
sease, Dokuz Eylul University Medical School/Turkey
BackgroundWe aimed to compare F-18 FDG PET-CT imaging cha-
racterictics in non-small cell lung cancer (NSCLC) with and without 
epidermal growth factor (EGFR) reseptor mutation.
Methods: A total of 47 NSCLC patients (38 male, 9 female, mean 
age : 47±10.45 )were included in this retrospective study. All pa-
tients underwent EGFR mutation resting and pretreatment F-18 
FDG PET-CT scan. The maksimum standardized uptake (SUVmax) 
of the primary tumor and metastases was calculated for all lesions 
in all patients. We compared the SUVmax values for primary tumor 
and metastatic lesions in patients with and without EGFR receptor 
mutation.
Results: In our study group, there were 17 adeno, 10 squamous, 2 
large cell, 1 mixt-type and 17 non-small cell cancer patients. Seven 
patients had EGFR-mutant and 40 patients had EGFR wild-type 
tumors. There was a trend for higher SUVmax in primary tumors 
among patients with EGFR-mutant (mean SUVmax: 14.20±10.40) 
versus patients with wild-type EGFR (mean SUVmax:11.53±6.46). 
In patients with wild-type EGFR, the mean SUVmax was 7.05±3.39, 
7.83±4.66, 6.10±4.44, 12.83±4.89 for hilar(17 pts), unilateral medi-
astinal (23 pts), contralateral mediastinal (13pts) and supraclavicular 
(3 pts) lymph node metastates (LNM), respectively. In 5 patients 
with EGFR-mutant , SUVmax was 6.48±3.39 for unilateral medi-
astinal LNM. There was no hilar, contralateral and supraclavicular 
LNM which can be demonstrated by F-18 FDG PET-CT in EGFR-
mutant patients. The mean SUVmax was 7.97±6.67, 8.98±4.31 and 
5.85±3.39 for lung (6 pts), bone (9 pts) and adrenal (6 pts) metasta-
ses in wild- type EGFR patient group. In EGFR-mutant group , one 
patient had lung, bone and adrenal metastases in which SUVmax 
was 4.20, 11.20 and 22.20, respectively.
Conclusion: Higher FDG uptake was found in primary tumors 
among EGFR-mutant patients than wild-type EGFR patients. In 
this study group, the incidence of hilar, contralateral mediastinal 
and supraclavicular LNM were higher in wild-type EGFR group 
than that in EGFR-mutant group. Bone and adrenal metastases 
in a patient with EGFR-mutant showed markedly increased FDG 
uptake. Further analyses with large number of patients are needed 
to describe a predictive role of FDG uptake on EGFR mutations in 
NSCLC patients.
Keywords: F-18 FDG, F-18 FDG PET-CT, EGFR, Non small cell lung 
cancer
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tissue of each post-treatment scan. An experienced radiologist 
compared the severity of change in each ROI from pre-treatment 
to post-treatment and categorized each as containing: 1) no 
abnormality, 2) mild abnormality, 3) moderate abnormality, or 4) 
severe abnormality. Twenty texture features that characterized 
gray-level intensity, region morphology, and gray-level distribution 
were calculated in all post-treatment ROIs and compared with 
anatomically matched ROIs mapped to the pre-treatment scan 
using demons registration. Fitted coefficients for the percent 
feature value change (ΔFV) between pre-treatment and post-
treatment ROIs at each category of visible radiation damage were 
calculated using linear regression.
Results: Most ROIs contained no abnormality (66%) or mild abnor-
mality (30%). ROIs with moderate (3%) or severe (1%) abnormalities 
were observed in 9 patients. For 19 of 20 features, significant 
differences (p<0.05) in ΔFV existed among ROIs assigned to vari-
ous severity levels. For 12 features, significant differences in ΔFV 
existed among all four categories of radiation damage (see figure). 
Compared with regions with no abnormality, ΔFV for these 12 
features increased, on average, by 1.6% (95% CI: 1.3-2%), 12% (95% 
CI: 9-15%), and 30% (95% CI: 19-41%), respectively, for the mild, 
moderate, and severe abnormality ROI categories.
Conclusion: For 12 of the 20 features, ΔFV was significantly 
different among all categories of visible radiation damage. As 
severity increased, the mean feature value change from the pre-
treatment scan also increased. In future studies, this approach may 
be used as a quantitative indicator of the severity of acute normal 
lung tissue damage following RT.
Keyword: lung CT image analysis, texture analysis, deformable 
registration, lung cancer radiation therapy
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P2.19-003 A TEXTURE ANALYSIS APPROACH TO ASSESS 
THE SEVERITY OF ACUTE NORMAL TISSUE CHANGES IN 
THORACIC CT SCANS FOLLOWING RADIATION THERA-
PY FOR LUNG CANCER
Alexandra Cunliffe1, Samuel G. Armato1, Christopher Straus1, 
Renuka Malik2, Hania A. Al-Hallaq2
1Dept. Of Radiology, The University Of Chicago/United States Of Ame-
rica, 2Dept. Of Radiation & Cellular Oncology, The University Of Chica-
go/United States Of America
Background: Quantitative analysis of thoracic computed tomo-
graphy (CT) scans may be used to assess response to radiation 
therapy (RT). The purpose was to (1) identify a set of mathematical 
descriptors of image texture that correlate with the severity of 
radiologic normal lung tissue changes following RT and (2) quan-
titatively measure the extent of severity-dependent change in the 
values of these texture features.
Methods: Twenty-four patients who underwent definitive 
RT (median dose: 66 Gy, 2 Gy/fraction) for lung cancer were 
retrospectively identified. For each patient, three CT scans were 
collected: pre-treatment scan, post-treatment (median: 34 days, 
range: 8-82 days) scan, and RT planning scan with an associated 
dose map. Four dose regions (0-10 Gy, 10-30 Gy, 30-50 Gy, and 
>50 Gy) in the RT dose map were identified and mapped to the 
post-treatment scan through demons deformable registration. 
Sixty regions of interest (ROIs) distributed evenly among the four 
dose regions were automatically identified in the normal lung 
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P2.19-005 TUMOR GROWTH RATE OF GROUND-GLASS 
NODULES AFTER LONG-TERM FOLLOW-UP: THE USE-
FULNESS OF A COMBINATION OF INITIAL COMPUTED 
TOMOGRAPHY ATTENUATION AND TUMOR SIZE AS A 
PREDICTOR FOR TUMOR GROWTH
Takashi Eguchi1, Ryoichi Kondo2, Satoshi Kawakami3, Akihiko 
Yoshizawa4, Daisuke Hara1, Shunichiro Matsuoka1, Tetsu Takeda1, 
Kentaro Miura1, Hiroyuki Agatsuma1, Takao Sakaizawa1, Yoshiaki 
Tominaga1, Masayuki Toishi1, Masahiro Hashizume1, Takayuki 
Shiina1, Jun Amano5, Mina Matsushita3, Tomonobu Koizumi6, Keii-
chiro Takasuna7, Kazuo Yoshida1
1Thoracic Surgery, Shinshu University/Japan, 2Thoracic Surgery, Matsu-
moto Medical Center Chushin Hospital/Japan, 3Radiology, Shinshu Uni-
versity/Japan, 4Pathology, Shinshu University/Japan, 5Surgery, Shinshu 
University/Japan, 6Comprehensive Cancer Center, Shinshu University/
Japan, 7Thoracic Surgery, Ina Central Hospital/Japan
Background: Pulmonary ground-glass nodules (GGNs) often grow 
over a long period of time. Elucidating the growth rate of GGNs 
is of great importance in deciding on follow-up intervals in clinical 
practice. The objective of this study was to clarify the natural histo-
ry and tumor growth rate of GGNs after a long-term follow-up.
Methods: We retrospectively studied 121 cases of patients with 
GGNs, who had more than 50% of ground-glass opacity com-
ponent and were monitored using high-resolution computed 
tomography (CT) for >2 years. Factors affecting the time to tumor 
progression were evaluated using the Kaplan–Meier method and 
Cox proportional hazard model analysis. Tumor growth rate was 
evaluated using specific growth rate (SGR), which was calculated 
using volume-doubling time (VDT) data (SGR = ln 2/VDT).
Results: During a median follow-up period of 59.7 months, GGNs 
showed enlargement or increase in attenuation in 66 patients and 
no change in 55 patients. In multivariate analysis using Cox pro-
portional hazard model, the initial mean CT attenuation value > 
–670 Hounsfield unit (HU) and initial tumor size > 8 mm were inde-
pendent predictive factors for time to tumor growth (p < 0.0001 
and p = 0.0006, respectively). The Kaplan-Meier curves evaluating 
time to tumor progression, which was divided into 4 parts accor-
ding to the initial mean CT attenuation value and initial tumor size, 
showed that the final estimated probability for patients with GGNs 
with a mean CT attenuation value < –670 HU and tumor size < 8 
mm was 14.5%, whereas that for the other 3 groups was more than 
50%, and with a significant difference (p < 0.0001). Comparing 
the tumor growth rates in these 4 groups, the SGR in GGNs with a 
mean CT attenuation value < –670 HU and tumor size < 8 mm was 
significantly lower than that in GGNs with a mean CT attenuation 
value > –670 HU and tumor size > 8 mm (p < 0.0001) and with a 
mean CT attenuation value > –670 HU and tumor size < 8 mm (p = 
0.0005).
Conclusion: A combination of the measurement of the mean CT 
attenuation and the tumor size in the initial CT examination may be 
useful for predicting GGN growth. Lower-attenuation and smaller-
size GGNs grow, but with slow growth rate, and, for patients with 
such GGNs, longer follow-up intervals may be useful in clinical 
practice.
Keywords: Ground-glass nodule, Computed tomography attenua-
tion, Tumor growth rate
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P2.19-004 CHARACTERIZATION OF SOLITARY PULMO-
NARY LESIONS COMBINING VISUAL PERFUSION AND 
QUANTITATIVE DIFFUSION MR IMAGING
Johan J. Coolen1, Frederik De Keyzer1, Herbert Decaluwé2, 
Walter De Wever1, Johan Vansteenkiste3, Christophe Dooms3, 
Eric Verbeken4, Paul De Leyn2, Dirk Van Raemdonck2, Steven 
Dymarkowski1, Kristiaan Nackaerts5, Johny Verschakelen1
1Radiology, UZ Gasthuisberg/Belgium, 2Thoracic Surgery, Universitary 
Hospitals KU Leuven/Belgium, 3Pneumology, Respiratory Oncology 
Unit, University Hospitals Leuven/Belgium, 4Pathology, UZ Gasthuis-
berg/Belgium, 5Pulmonology, UZ Gasthuisberg/Belgium
Background: To evaluate the diagnostic accuracy of dynamic 
contrast enhanced (DCE)magnetic resonance (MR) and diffusion 
weighted imaging (DWI) sequences for defining benign or malig-
nant character of solitary pulmonary lesion (SPL) in a preoperative 
setting.
Methods: This study was approved by the local ethics committee; 
all patients provided written informed consent. First, 54 consecu-
tive patients with SPL, clinically staged (CT and PET or integrated 
PET-CT) as N0M0, were included in this prospective study. An 
additional MR examination including DCE and DWI was performed 
one day before the surgical procedure. Histopathology of the sur-
gical specimen served as standard of reference. Subsequently, this 
functional method for SPL characterization was validated with a 
second cohort of 54 patients.
Results: In the feasibility group, 11 benign and 43 malignant SPL 
were included with a maximal diameter that varied from 3 to 71 
mm (mean 23.2 mm). Using the conventional MR sequences with 
visual interpretation of DCE-MR curves sensitivity, specificity, accu-
racy were respectively 100%, 55% and 91%. By additional interpre-
tation of quantitative apparent diffusion coefficient (ADC) values 
(with a cutoff value of 1.52x10-3 mm2/sec for ADC calculated from 
high b-values (ADChigh) these results improved to 98%, 82% and 
94% respectively. In the validation group, with 14 benign and 40 
malignant SPL (diameter ranged between 7 mm and 10 cm - mean 
26.5 mm), these results were confirmed with a sensitivity, specifici-
ty and accuracy of 95%, 79%, and 91%, respectively.
Conclusion: Visual DCE-MR-based curve interpretation can be 
used for initial differentiation of benign from malignant SPL, while 
additional quantitative DWI-based interpretation can further im-
prove the specificity.
Keywords: Single pulmonary lesion, Characterization of lung no-
dule or mass, Magnetic resonance imaging, DWI and DCE-MRI
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P2.19-007 PULMONARY NODULE DETECTION BY JUNI-
OR MEDICAL STAFF IS IMPROVED BY DIGITAL TOMO-
SYNTHESIS COMPARED TO CHEST X-RAY
Xiang-Wen Lee1, Steven Leong2, Henry Marshall2, Jonny Ayres3, 
Osman Mohamed3, Rayleen Bowman2, Ian Yang2, Kwun Fong2
1University Of Queensland/Australia, 2Department Of Thoracic Medici-
ne, The Prince Charles Hospital/Australia, 3Department Of Radiology, 
The Prince Charles Hospital/Australia
Background: Junior doctors may fail to detect subtle pulmonary 
pathology on plain chest X-ray (CXR). Digital tomosynthesis (DT) 
is an emerging radiographic technique that provides multiple co-
ronal chest images at only 2% of the radiation of a standard chest 
CT. Previous studies have demonstrated that pulmonary nodule 
detection sensitivity is three times greater with DT compared to 
CXR. We investigated whether DT can increase nodule detection 
rates by junior doctors compared to CXR.
Methods: Ten volunteer junior doctors (post-graduate years 1-3) 
at The Prince Charles Hospital in Brisbane, Australia, a secondary 
and tertiary referral hospital, were recruited to view CXR and DT 
images of 11 patients. All patients had CXR, DT and CT images 
acquired within a 30 day period for the evaluation of lung nodu-
les. CT images (Philips Brilliance, Philips Medical Systems, Best, 
Netherlands), with collimation 0.625 mm and reconstructed slice 
width 0.9 mm, reported by experienced radiologists, served as the 
gold standard. DT images, consisting of 60 exposures through a 
30° arc, were acquired using the GE Definium 8000 Xray Unit (GE 
Healthcare, Little Chalfont, United Kingdom), with simultaneous 
CXR as a scout image. Nine of these patients had at least one no-
dule >10 mm on CT, with two control patients without nodules. All 
participants undertook brief training to familiarise them with DT 
images one week prior to the study. In the study session, partici-
pants were showed anonymised CXR and DT images in random 
order and asked to mark “definite” or “possible” pulmonary no-
dules electronically. The markings were compared to CT detected 
“true” nodules. Markings made where there were no true nodules 
on CT were recorded as false positives. The time taken to view 
each image was measured. Participants completed a brief survey 
after viewing the images.
Results: Nodule detection sensitivity, represented by the pro-
portion of true nodules marked “definitely” present, was signifi-
cantly higher using DT than CXR (28/65 [43%] versus 3/70 [4%], Χ2, 
p<0.001), as was the proportion of nodules marked either “defi-
nitely” or “possibly” present (32/65 [49%] versus 13/70 [19%], Χ2, 
p<0.001). When considering instances where a nodule was marked 
either “definitely” or “possibly” present, where there was no true 
nodule on CT, significantly fewer false positives were made, on 
average, when viewing DT compared to CXR (0.36 versus 1.18 false 
positives per image, t-test, p<0.001). Although the time taken to 
view each DT image was statistically significantly longer than for 
each CXR image (86.9 seconds versus 67.9 seconds, t-test, p<0.01), 
the absolute difference was small. Ninety percent of participants 
agreed that they could identify nodules more confidently with DT 
than CXR.
Conclusion: In this study, junior doctors correctly identified more 
pulmonary nodules using DT compared to CXR and reported fe-
wer false positive results. The time taken to view DT images was 
slightly longer than for CXR images, but this difference was small. 
Despite the small sample size, this pilot experiment has shown that 
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P2.19-006 NOVEL COMPUTED TOMOGRAPHY WIN-
DOWS FOR PREDICTING PATHOLOGICAL INVASION 
AREA IN PULMONARY SUBSOLID TUMORS
Takashi Eguchi1, Satoshi Kawakami2, Akihiko Yoshizawa3, Daisu-
ke Hara1, Shunichiro Matsuoka1, Tetsu Takeda1, Kentaro Miura1, 
Hiroyuki Agatsuma1, Takao Sakaizawa1, Yoshiaki Tominaga1, 
Masayuki Toishi1, Masahiro Hashizume1, Takayuki Shiina1, Jun 
Amano4, Mina Matsushita2, Tomonobu Koizumi5, Ryoichi Kondo6, 
Keiichiro Takasuna7, Kazuo Yoshida1
1Thoracic Surgery, Shinshu University/Japan, 2Radiology, Shinshu Uni-
versity/Japan, 3Pathology, Shinshu University/Japan, 4Surgery, Shinshu 
University/Japan, 5Comprehensive Cancer Center, Shinshu University/
Japan, 6Thoracic Surgery, Matsumoto Medical Center Chushin Hospital/
Japan, 7Thoracic Surgery, Ina Central Hospital/Japan
Background: Preoperatively distinguishing non-invasive or mini-
mally invasive lung adenocarcinomas from invasive lung adenocar-
cinomas on the basis of the classification proposed by the Interna-
tional Association for the Study of Lung Cancer, American Thoracic 
Society and European Respiratory Society (IASLC/ATS/ERS) is 
essential. However, in some cases, this distinction is potentially 
difficult to make by using the conventional computed tomography 
(CT) settings, i.e., lung and mediastinal windows. The objective of 
this study is to evaluate novel CT window settings for preoperative 
detection of pathologically invasive adenocarcinomas.
Methods: We retrospectively investigated 112 pathological T1a 
adenocarcinomas with a ground-glass opacity pattern ratio on 
preoperative CT of more than 50%. In the CT performed before 
an operation, the window level/window width was set as follows: 
-300/600, -250/500, -200/400, -150/300, and 30/400 (conventional 
mediastinal window). Under these viewing conditions, a maximum 
diameter of residual tumor was defined as the predictive invasion 
diameter. Receiver operating characteristic curve analyses were 
used to verify whether each viewing condition could be used to 
predict pathologically invasive adenocarcinomas that have a maxi-
mum invasion diameter of more than 5 mm.
Results: The area under the curve values for the -300/600, 
-250/500, -200/400, -150/300, and 30/400 settings were 0.87, 0.91, 
0.86, 0.84, and 0.78, respectively. The sensitivity and specificity in 
the window setting of -250/500 was 98.1% and 67.8%, when the 
cut-off value for the predictive invasion diameter was set at 6 mm.
Conclusion: We determined novel CT window settings. The win-
dow level/window width setting of -250/500 might be useful for 
predicting pathological invasion of more than 5 mm in T1a lung 
adenocarcinomas.
Keywords: Computed tomography window, Pulmonary adenocar-
cinoma, Invasive adenocarcinoma
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Results: 
Of all clinical variables as well as the tumor metabolism quantifiers, 
the TMV was found to be the only standalone statistically signifi-
cant prognostic factor for both overall (log-rank test p=0,048) and 
progression-free survival (p=0,014). Its value was confirmed in both 
Kaplan-Meier (shown) and Cox models. No co-relation was found 
between TMV and SUVmax, tumor type, sex or the pattern of failu-
re. Tumor stage in PET-CT studies (after or during chemotherapy) 
was co-related to TMV, yet its prognostic value was not significant.
Conclusion: TMV is a simple parameter to calculate during routine 
analysis of PET-CT study, which provides - independently on the 
clinical variables and more accurately than radiological re-staging - 
relatively reliable prognostic information for patients who are to be 
treated with definite radiotherapy for NSCLC. Prospective studies 
on larger number of patients need to be undertaken to answer 
whether and how to alter the treatment regime (dose escalation, 
hypofractionation) in order to improve the outcome for patients 
with unfavorably high TMV.
Keywords: PET, NSCLC, metabolic volume
DT may potentially improve identification of pulmonary nodules by 
junior doctors and a larger study is underway.
Keywords: Chest X-ray, Pulmonary nodule, Junior medical staff, 
Digital tomosynthesis
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P2.19-008 THE PROGNOSTIC VALUE OF TUMOR META-
BOLIC VOLUME IN PET-CT STUDY FOR UNRESECTABLE 
NON-SMALL-CELL LUNG CANCER TREATED WITH DEFI-
NITE RADIOTHERAPY
Maciej J. Pelak1, Andrea D‘Amico2, Barbara Bobek-Billewicz3, 
Małgorzata Kaszuba3, Dorota Syguła1, Katarzyna Pecka4
1Department Of Radiotherapy, Maria Skłodowska-Curie Memorial Can-
cer Center And Institute Of Oncology, Gliwice Branch/Poland, 2Depart-
ment Of Pet Diagnostics, Maria Skłodowska-Curie Memorial Cancer 
Center And Institute Of Oncology, Gliwice Branch/Poland, 3Department 
Of Radiology, Maria Skłodowska-Curie Memorial Cancer Center And 
Institute Of Oncology, Gliwice Branch/Poland, 4Department Of General 
Surgery, St Elisabeth Hospital/Poland
Background: Over the recent years, PET-CT studies have become 
the golden standard for the planning of high-dose definite radio-
therapy of non-small-cell lung cancer (NSCLC). This is justified by 
their proven superiority over computer tomography in both sensiti-
vity and specifity to determine the location of all tumor sites, hel-
ping avoid underirradiation of active malignancy as well as using 
unnecessarily large field sizes. Numerous reviews have pointed out 
that the quantifiers of tumor metabolism, primarily the maximal 
Standard Uptake Value (SUVmax) of 18F-deoxyglucose as measu-
red in PET-CT studies can as well serve as a prognostic factor in 
NSCLC. As we were expecting this to be particularily significant 
for patients with unresectable tumors yet irradiated with intention 
to cure, we decided to retrospectively investigate the prognostic 
value of tumor metabolism quantification for this group.
Methods: The material of our study consists of 53 patients, trea-
ted with definite radiotherapy (with sequential chemotherapy in 
50 cases) for locally advanced, unresectable NSCLC. The doses 
prescribed for radiotherapy ranged from 60 to 71,2 Gy; all patients 
completed the intended radiation treatment. We assessed the 
tumor metabolism on PET-CT studies used for radiotherapy plan-
ning; in addition to measuring the SUVmax value, we quantified 
the tumor metabolic volume (TMV) using three different algorithms 
varying by the threshold above which voxels within the tumor were 
considered its volume. Results were co-related to various clinical 
parameters and the therapeutic outcome, measured as progressi-
on-free and overall survival at 36 months of follow-up.
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Conclusion: Our PET-CT based clinical prediction model has bet-
ter accuracy in estimate the pretest probability of malignancy 
in patients with SPNs.
Keywords: Solid Pulmonary Nodules, model, PET-CT, Lung cancer
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P2.19-010 THE ASSOCIATION BETWEEN BASELINE 
CLINICAL-RADIOLOGICAL CHARACTERISTICS AND 
GROWTH OF PULMONARY NODULES WITH GROUND-
GLASS OPACITY
Yoshihisa Kobayashi1, Yukinori Sakao1, Gautam A. Deshpande2, 
Takayuki Fukui3, Tetsuya Mizuno1, Hiroaki Kuroda1, Noriaki Saka-
kura1, Noriyasu Usami3, Yasushi Yatabe4, Tetsuya Mitsudomi5
1Department Of Thoracic Surgery, Aichi Cancer Center Hospital/Japan, 
2St. Luke’s International Hospital/Japan, 3Department Of Thoracic Sur-
gery, Nagoya University Graduate School Of Medicine/Japan, 4Dept. Of 
Pathology And Molecular Diagnostics, Aichi Cancer Center/Japan, 5De-
partment Of Surgery, Kinki University, Faculty Of Medicine/Japan
Background: Pulmonary nodules with ground-glass opacity (GGO) 
are frequently encountered. We previously reported that, based 
on natural history of 108 pulmonary nodules that were 3 cm or less 
and had 50 % or more GGO component, these nodules should be 
followed for at least 3 years to accurately evaluate lesion growth. 
However, it remains unclear whether all GGOs should be followed 
for as long as 3 years. To establish reasonable follow-up plan, it 
would be useful to if we could predict which of GGO lesions tend 
to grow by any of clinical-radiographic characteristics. The purpo-
se of this study was to clarify which baseline clinical and radiologi-
cal characteristics were associated with growth of these nodules.
Methods: We retrospectively studied patients between 1999 and 
2013 with pulmonary nodules that met the following criteria: (1) 
lesion diameter of ≤ 3 cm, (2) GGO proportion of ≥ 50%, and (3) 
observation without treatment in the prior 6 months. We evaluated 
the changes in lesion size on serial computed tomography. Two 
endpoints, “Time to 2-mm growth” and “2-mm growth incidence”, 
were analyzed using Cox proportional hazards and logistic regres-
sion models, respectively.Variables for univariate analysis were as 
follows: age; gender; smoking history; past history of lung cancer; 
lesion multiplicity; lesion diameter; and solid proportion. Factors 
for which p-value was < 0.05 in univariate analysis, as well as past 
history of lung cancer which was reported as a predictor in previ-
ous reports, were included in multivariate analysis. To strictly defi-
ne “no growth”, we excluded lesions which had been observed for 
less than 3 years in logistic regression analyses.
Results: 120 pulmonary lesions in 67 patients fulfilled inclusion 
criteria. At the median observation period of 4.2 years, 34 lesions 
had become larger by 2mm or more, whereas the remaining 86 
had persisted without changing in size. Smoking history and initial 
lesion diameter were statistically significant in both regression and 
time-to-event analyses. In terms of time to 2mm growth, hazard 
ratio (HR) for smoking history was 3.67 (P < 0.01). Compared to 
those ≤ 1 cm, HRs for 1.1–2 cm and 21-3 cm lesions were 2.23 (P = 
0.08) and 5.08 (P = 0.04), respectively. In contrast, odds ratio (OR) 
for the likelihood of 2mm growth for smoking history was 6.51 (P < 
0.01), and OR for lesion diameter of 1.1–3 cm in comparison to ≤ 1 
cm was 4.06 (P = 0.02).
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P2.19-009 A PREDICTION MODEL TO ESTIMATE THE 
PROBABILITY OF MALIGNANCY OF SOLITARY PULMO-
NARY NODULES INTERGRATING PET-CT AND CLINICAL 
DATA.
Jun-Xiong Liao1, Xin-Yue Wang1, Xiang-Chan Hong1, Lu-Wen Ren1, 
Xue-Ning Yang2
1Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong 
General Hospital & Guandong Academy Of Medical Sciences/China, 
2Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong 
General Hospital& Guangdong Academy Of Medical Sciences/China
Background: Most solitary pulmonary nodules(SPN) discovered by 
CT scan are benign. 18F-FDG PET has been reported better diffe-
rentiated benign from malignant pulmonary nodules. Three previ-
ous developed clinical prediction models (Mayo model,VA model 
and Peking University model) are based on CT scan. We intergra-
ting PET-CT and Clinical Data to increase accuracy in estimate the 
probability of malignancy of SPN.
Methods: From January 2009 to December 2012, 365 consecutive 
patients diagnosed SPN by PET-CT have been identified and re-
viewed. Clinical data were collected retrospectively. The data set 
was split into two groups: training set (305 patients) and testing 
set (60 patients). Independent factors associated with benign and 
malignancies were identified using training set by logistic regressi-
on analysis, and a prediction model has been established. Patients 
from the testing set were then used to validate the predictive value 
of this model, and compared accuracy with Mayo model and Pe-
king University model.
Results: Logistic analysis showed three clinical 
characteristics(gender,age, smoking data) and six radiologi-
cal characteristics(diameter, upper lobe,speculation, lobu-
lation, pleural tail, FDG uptake) were independent predic-
tors for malignancy. The area under the evaluated receiver 
operating characteristics curve was 0.854±0.043. Compa-
red to Mayo model,VA model and Peking University model, 
this PET-CT based model showed better predictive value. 
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with the ratio of the VCL in the resected lobes. These data may 
provide more precise prediction of postoperative lung function in 
patients who underwent lung resection.
Keywords: Lung cancer, pulmonary function, Computed tomogra-
phy volumetry
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P2.19-012 INTER-METHOD COMPARISON OF 18F-FDG 
PET METABOLIC RESPONSE ASSESSMENT IN NON-
SMALL CELL LUNG CANCER
Jingbo Wang1, Ka Kit Wong2, Piert Morand2, Stanton Paul3, Kirk 
Frey2, Feng-Ming (Spring) Kong4
1Radiation Oncology, Cancer Hospital & Institute, Chinese Academy Of 
Medical Sciences/China, 2Nuclear Medicine, University Of Michigan/
United States Of America, 3Department Of Radiation Oncology, Univer-
sity Of Michigan And Veteran Administration Hospital/United States 
Of America, 4Department Of Radiation Oncology, University Of Michi-
gan And Veteran Administration Hospital, Currently At Gru Cancer 
Center, Georgia Regent University/United States Of America
Background: This study aimed to: 1) compare qualitative and 
semi-quantitative assessment of 18F-fluorodeoxyglucose PET based 
categorical metabolic response in patients with NSCLC and deter-
mine their value for prognosis prediction; 2) investigate the relati-
onship between semi-quantitative assessments of post-treatment 
change of metabolic activity and survival and explore an optimal 
cutoff to distinguish a subset of responders with more favorable 
outcome.
Methods: This is a secondary analysis of prospective studies with 
IRB approval. Enrolled patients with NSCLC underwent PET/CT 
imaging within 2 weeks prior to (pre-RT PET/CT), at 4 weeks during 
and after radiation treatment (post-RT PET/CT). Post-RT metabo-
lic therapeutic response was assessed using 1) visual assessment 
and 2) semi-quantitative measurement based on reduction in tu-
mor FDG uptake; SUVmax normalized to mediastinal blood pool 
(NSUV-A). Interpretation of PET/CT scans was performed by three 
nuclear medicine physicians, blinded to clinical information. The 
three physicians did independent reads of the patients, perfor-
ming a single read for each patient’s set of PET studies. Kappa 
coefficient was used to evaluate the agreement between categori-
cal variables. Survival analysis and Cox proportional hazard regres-
sion model were adopted to analyze the effect of various response 
criteria on overall survival (OS) and progression free survival (PFS).
Results: Forty-four patients (36 male: 8 female) were eligible for 
analysis. The median interval between end of RT and post-RT PET/
CT scan was 93 days. A poor agreement was observed between 
visual and semi-quantitative responses (Kappa coefficient = 0.393). 
Categorical responses were significantly correlated with both OS 
and PFS independent of employed response assessment criteria 
(either visual or semi-quantitative, p < 0.001) and patients with 
complete metabolic response (CMR) obtained the longest survi-
val. As a continuous variable, reduction percentage of NSUV-A 
showed significant correlations with OS (hazard ratio, HR = 0.980, 
p < 0.001) and PFS (HR=0.984, p < 0.001). Analysis of OS and PFS 
consistently recommended NSUV-A reduction of sixty percent 
(60%) as another discriminative cutoff to distinguish patients with 
different outcome (p < 0.01).
Conclusion: Smoking history and initial lesion diameter are signifi-
cantly associated with the growth of these nodules. These results 
suggested that closer follow up of larger size GGO in smoking 
patients be recommended.
Keywords: ground-glass opacity, Smoking, follow-up, small lung 
lesion
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P2.19-011 COMPENSATION OF VITAL CAPACITY OF RE-
SIDUAL LOBES AFTER LUNG RESECTION IN PATIENTS 
WITH LUNG CANCER
Masako Matsutani1, Mariko Honda2, Takuya Ohashi2, Haruka 
Nishiguchi2, Rie Nakamura2, Yoshimitsu Hirai2, Mitsumasa Kawa-
go2, Yozo Kokawa2, Tatsuya Yoshimasu2, Shoji Oura2, Yoshitaka 
Okamura2
1Wakayama Medical University/Japan, 2Department Of Thoracic And 
Cardiovascular Surgery, Wakayama Medical University/Japan
Background: Major lung resection may induce expansion of the 
remaining lung, accompanied by some gain in the function of this 
lung. Pulmonary function studies have been performed in thoraco-
tomy patients mainly for the purpose of predicting postoperative 
morbidity and mortality. Lobectomy is the standard operative 
procedure for lung cancer. However, the impact of this compen-
satory response of the residual lobes remains unclear, because 
spirometry cannot evaluate pulmonary function of individual lobe 
as single units.
Methods: Thirty-one patients who underwent lobectomy were 
included in this study. They were consisted of 15 males and 16 
females, and 67 years old in average. Surgical procedures were 30 
lobectomies and 1 bilobectomy. Chest CT scans at inspiratory and 
expiratory levels were performed at the same time using 40-slice 
MDCT (Brilliance 40, Philips, Netherlands). Scan conditions were 
120 kV, ≤ 250 mAs, 0.5 sec./rotation, 32x1.25 configuration, pitch 
0.906, and 5 sec. scan time. We then calculated the volume of 
individual lobes using graphic workstation (Virtual Place Lexus 1.0, 
AZE, Japan). Voxels with -215 HU or less were regarded as the air 
in the lung. VC of each lobe (VCL) was calculated as lobar volume 
at the inspiratory level subtracted by lobar volume at the expirato-
ry level. This CT volumetry was performed before and 1 year after 
surgery.
Results: VCLs of the residual lobes in the operated side were 
1.01±0.47L before surgery, and significantly (p=0.0094) increased 
to 1.22±0.74L after surgery. There was 22.3±43.6% gain in VCL 
of the lobes in the operated side after surgery compared with 
that before surgery. However, there was no significant difference 
(p=0.7040) in VCLs of the lobes in the unoperated side between 
before (1.71±0.71L) and after (1.69±0.63L) surgery. The rate of com-
pensatory response of VCL of the residual lobes in the operated 
side was significantly (p=0.0002) correlated with the percentage 
of the VCL of the resected lobes. Statistical analysis revealed that 
the rate of compensatory response (%) could be calculated as the 
ratio of VCL in resected lung (%) before surgery multiplied by the 
constant of 1.556.
Conclusion: The compensatory response in pulmonary function af-
ter lobectomy appeared to occur only in the lobes in the operated 
side. The rate of this functional gain was significantly correlated 
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seven cases (22.6 %), subsegmental atelectasis in 14 cases (45.2 
%), traction bronchiectasis in four cases (12.9 %), and a lung cyst in 
one case with subcentimeter lymphadenopathy in 26 cases (83.9 
%). The average size of the mediastinal lymph node was 0.7 cm in 
diameter (range 0.2-0.9 cm).
Conclusion: This study reported initial findings from low-dose CT 
and chest radiography. These results demonstrated that low-dose 
CT screen may be a valuable method for screening in the first re-
lative of lung cancer patients compared with chest radiography. 
However, all of the positive cases need to be worked up for a de-
finite tissue diagnosis in order to have an earlier diagnosis of lung 
cancer and potentially more curative treatment or at least to be 
closely monitored. This study will be continued and more partici-
pants will be recruited and evaluated.
Keywords: First relative, Low-dosed CT, Lung cancer screening
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P2.19-014 WHOLE-BODY DIFFUSION-WEIGHTED MRI 
FOR STAGING NON-SMALL CELL LUNG CANCER PATI-
ENTS
Jefferson L. Gross, Rubens Chojniak, Marcos D. Guimarães, Eduar-
do N.P. Lima, Fabio J. Haddad
Thorax, Ac Camargo Cancer Center/Brazil
Background: Therapeutic decision and prognosis in non-small 
cell lung cancer (NSCLC) relies on accurate staging. Currently, 
Positron Emission Tomography/Computed Tomography (PET/CT) 
appears to have better efficacy, and is considered the gold stan-
dard method for staging lung cancer. Diffusion-weighted Magnetic 
Resonance Imaging (DWI) for the whole body has become feasible 
and provides images with good resolution. Some investigators 
have suggested that DWI could be used for assessment of prima-
ry tumor, lymph nodes and distant metastases in lung cancer. To 
date there are few data assessing DWI for staging of NSCLC. The 
purpose of this study is to compare the role of DWI and PET/CT for 
staging NSCLC patients.
Methods: This is a prospective study. Institutional review board 
approval and written informed consent was provided by all pa-
tients. From May 2011 to April 2012, thirty-two patients were 
included. Twenty (62.5%) were men, and the mean age was 62.4 
years old. Non-small cell lung cancer (NSCLC) was proved at pa-
thological examination. PET/CT and brain MRI was performed as a 
routine staging work up. DWI was studied as an alternative method 
for staging. Final stage in each patient was defined by pathologi-
cal examination when available or through radiologic and clinical 
examinations/follow-up. Sensitivity, specificity, and accuracy were 
evaluated and were compared between both groups.
Results: Preliminary results demonstrate that WB MRI and PET/CT 
have satisfactory levels of sensitivity, specificity and accuracy, with 
no significant difference (p>0.05), as disclose in Table 1. Table 1 – 
Sensibility, specificity and accuracy of WB MRI and PET/CT.  
Conclusion: There is a great discrepancy in metabolic response 
rates between qualitative and semi-quantitative methods. Cate-
gorical metabolic response criteria, either from qualitative visual 
assessment or a semi-quantitative method, demonstrate significant 
association with overall survival and progression free survival. Visu-
al method offers a simpler approach that provides good informati-
on with regard to predicting OS and PFS, while the semi-quantita-
tive method provides ordinal value that correlates with prolonged 
OS. As a continuum, the numerical percentage reduction in the 
normalized SUV is positively correlated with longer overall survival, 
reinforcing the prognostic value of metabolic change on FDG PET/
CT. A sixty percent reduction of SUV may be the optimal cutoff for 
metabolic response to identify subsets of the PMR population with 
distinct outcomes, pending validation by an independent popula-
tion.
Keyword: PET/CT; non-small cell lung cancer; therapeutic respon-
se; overall survival
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P2.19-013 PILOT STUDY OF LOW DOSE COMPUTED TO-
MOGRAPHY SCREENING IN FIRST RELATIVE OF LUNG 
CANCER PATIENT (PRELIMINARY REPORT)
Somcharoen Saeteng1, Apichat Tantraworasin1, Juntima -. Euat-
hrongchit2, Yutthaphan Wannasopha3, Nirush Lertprasertsuke4
1Surgery, Chiang Mai University Hospital/Thailand, 2Radiology, Chiang 
Mai University/Thailand, 3Radiology, Chiangmai University/Thailand, 
4Pathology, Chiang Mai University/Thailand
Background: Screening lung cancer with low dose computed to-
mography (CT) improved the likelihood of detection of small non-
calcified nodules, and thus lung cancer might be detected earlier 
with more potential for a cure. The National Lung Screening Trial 
(NLST) showed that screening with low-dose helical computed to-
mography (CT) rather than with chest radiography reduced morta-
lity from lung cancer. However, the cost-effectiveness of using low 
dose CT screening was still debatable in the normal population 
even in the smoking population. The Northern Thailand Thoracic 
Oncology Group (NT-TOG) would like to study focusing on the first 
relative of lung cancer patients which may benefit from low dose 
CT screening.
Methods: From January 2013 to May 2013, a prospective cohort 
study was performed at Chiang Mai University Hospital. We en-
rolled asymptomatic participants, 20 to 65 years of age who were 
the first relative of lung cancer patients and received a structural 
interview and informed consent. Low-dose CT scan and chest ra-
diography were performed on the same day for each participant. 
Nodules or other suspicious findings were classified as positive 
results. Nodules or suspicious findings from either low-dose CT 
or chest radiography which have a high risk of malignancy will be 
worked up rapidly for tissue pathology whereas low risk nodules 
will be followed up with low-dose CT and chest radiography eve-
ry six months, for two years. This study reports findings from the 
initial screening examination.
Results: There were 14 (45.2%) cases of positive nodule from 
low- dose CT screening out of a total of 31 cases, whereas, there 
were no positive nodules from the chest radiography. The average 
number of nodules was 2.1 nodules and the average size of nodule 
was 0.4 cm in diameter. There was ground-glass opacity (GGO) in 
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P2.20-001 EFFECT OF REPEATED ANNUAL SPUTUM 
CYTOLOGY SCREENING ON HIGH RISK POPULATION: 
CHANGE OF INCIDENCE OF SQUAMOUS CELL CARCI-
NOMA
Akira Sakurada1, Chiaki Endo1, Yasuki Saito2, Hirotsugu Notsuda1, 
Takashi Kondo1
1Thoracic Surgery, Tohoku University Hospital/Japan, 2Thoracic Surge-
ry, Sendai Medical Center/Japan
Background: Sputum cytology is a widely accepted non-invasive 
diagnostic method for lung cancer. However, the efficacy to redu-
ce lung cancer mortality has not been clearly proven in mass scree-
ning setting. To understand the potential value of sputum cytology 
to detect squamous cell carcinoma (SCC) of the lung, we evaluated 
its sensitivity and specificity. We simultaneously attempted to cla-
rify the effect of repeated screening on the incidence of SCC.
Methods: In total, 104,872 sputum cytology tests combined with 
miniature chest X-ray were performed on 44,809 people belon-
ging to the high-risk population of Miyagi Prefecture in Japan from 
1990 to 1996. The sensitivity and specificity were calculated based 
on the information from the Cancer Registry. The incidence of 
SCC in the year after sequential annual repeat or sequential annual 
absences was analyzed.
Results: In total, 183 SCC-positive cases were diagnosed. The 
sensitivity and specificity of sputum cytology for SCC were 66.7% 
and 99.9%, respectively. Among cases with known localization, 
sensitivity for the central type was 90.7%, while that for peripheral 
type was 64.2%. Similarly, significantly decreased screen-detected 
SCC was observed in the third repeated test . A significant increa-
se in screen-detected SCC cases was observed in the third year of 
sequential absence from screening.
Conclusion: Annual screening by sputum cytology for the high-risk 
group showed high sensitivity for SCC of the lung, particularly for 
central type SCC. Significantly reduced incidence of central type 
SCC was observed by repeating annual sputum cytology scree-
ning.
Keywords: Sputum Cytology, Mass screening, squamous cell car-
cinoma, Sensitivity
WB MRI PET/CT 
Sensibility 72.3% 73.5% 
Specificity 91.6% 94.5% 
Accuracy 86.8% 88.2% 
Conclusion: PET/CT has shown to be an excellent tool for the clini-
cal staging of lung cancer. DWI has been considered an alternative 
method for staging these patients. Advantages of whole-body 
DWI include absence of ionizing radiation exposure, excellent con-
trast resolution and information from different sequences allowing 
a better characterization of lesions, mainly brain and liver metasta-
sis. Our preliminary results demonstrate no significant difference in 
accuracy between both methods for staging patients with NSCLC.
Keywords: Lung cancer, staging, PET-CT, MRI
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P2.20-003 DIAGNOSTIC WORK-UP AND SURGERY IN 
PARTICIPANTS OF GDANSK LUNG CANCER SCREENING 
PROGRAM - THE EXTENT OF FUTILE PROCEDURES IN 
NON-MALIGNANT CONDITION
Witold Rzyman1, Malgorzata Jelitto-Górska2, Robert Dziedzic2, 
Janina Ksiazek2, Tomasz Marjanski2, Piotr Chwirot2
1Medical Univerity Of Gdansk/Poland, 2Medical University Of Gdansk/
Poland
Background: Low-dose computed tomography (LDCT) screening 
improves lung cancer prognosis, but also results in diagnostic 
work-up and surgical treatment in many individuals without cancer. 
We therefore analyzed procedures that screening participants 
underwent to better understand the extent of overdiagnosis.
Methods: Between 2009 and 2011, 8649 healthy volunteers in the 
age 50-75 with 20 pack-years smoking history underwent LDCT 
screening with two years control in individuals with lung nodules. 
Participants with nodules diameter >10 mm or with suspected tu-
mor morphology underwent diagnostic work-up. It was performed 
in 283(6%) of 4694(54%) screening participants with detected lung 
nodules. One hundred four individuals were operated, 27 were un-
derwent oncological treatment and in 154 patients without cancer 
diagnosis further follow up with LDCT was applied.
Results: Our results showed that in 75% of the participants accep-
ted for diagnostic work-up those procedures were futile. The same 
holds for 25% receiving surgery. Only in 70(24,7%) participants a 
specific diagnosis was obtained. That was mainly due to low effica-
cy of Fine Needle Aspiration Biopsy (Sensitivity 65,2%, NPV 95,9%) 
and bronchofiberoscopy (sensitivity 71,4%, NPV 50%) caused by 
overinterpretation of LDCT (PPV 2%). Of 104(36.7%) participants 
that were accepted for surgery, forty-three patients (41,4%) had 
preoperative cancer diagnosis and 61(58,6%) underwent opera-
tions without obtained pathology. In the latter group intervention 
was justified in 35(57,3%) patients. Complications occurred in 49 
(17.3%) participants subjected to diagnostic work-up. In patients 
accepted for surgery 67 (64.4%) malignant and 37 (35.6%) benign 
lesions were resected. In the latter group intervention was justified 
in only 11 (29,7%) patients. No patient died as a result of diagnostic 
or treatment procedures during the study. The complication rate 
was 14,5% in the malignant and 10,8% in the benign groups. Fi-
nally in 94 screening participants a neoplasm was found. Of those, 
67(71.3%) patients underwent operation; the remaining 27(28.7%) 
patients were not candidates for surgery. Adenocarcinoma accoun-
ted for 49/67(73%) operated NSCLC patients; 56/67(84%) patients 
had stage I non-small cell lung cancer, and 26/67(38%) underwent 
video-assisted thoracoscopic surgery lobectomy.
Conclusion: Futile diagnostic work-ups and operations must be 
reduced before LDCT screening can be broadly used. Stage I ade-
nocarcinoma dominated in the operated NSCLC patients.
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P2.20-002 INVESTIGATING SUSPECTED LUNG CANCER: 
FAST TRACK IN STOCKHOLM
Gunnar Hillerdal1, Karl Kölbeck1, Susan Kamareji2, Hans Jacobs-
son3
1Pulmonary Medicine, Karolinska Hospital/Sweden, 2Lung, Karolinska 
Hospital/Sweden, 3Nuclear Medicine, Karolinska Hospital/Sweden
Background: Doctors´ delays can sometimes be very large in in-
vestigations of suspected lung cancer. The main problem seems 
to be the many steps involved, with delays at all levels. In order 
to speed up the process within the available limited resources we 
have in Stockholm constructed a “fast track”.
Methods: The majority of suspected lung cancers in the Northern 
Stockholm area are referred to the Lung Clinic in Solna from GP:s 
and other clinics. Patients who from this information were judged 
to suffer from potentially curable lung cancer were admitted to the 
fast track, where the first visit should occur within a week and the 
investigations (broncoscopy, PET-CT, spirometry etc) was planned 
by a special nurse within the next week.
Results: From December, 2009, to march, 2013, 219 patients, 109 
women and 110 men, have been investigated. The mean age was 
67 years (55-82). The mean time from referral to first visit was 6,1 
days and 77% were seen within one week. From referral to treat-
ment decision, the mean was 17.8 days. There were 149 primary 
lung cancers, thereof 105 adenocarcinomas, 18 squamous, and 13 
small cell cancers. Stage I-II were 74, III 35, and IV 41. Surgery was 
performed on 65 patients, 17 of whom the diagnosis was made at 
surgery. Potentially curative radiotherapy or chemoradiotherapy 
was given in 44 patients. Three lymphomas, one sarcoma, and 6 
metastases from earlier unknown cancers were also seen. Thus, 
109 (73%) received a potentially curative therapy. Benign lesions 
were seen in 56 persons (26%), mostly hamartomas or infections 
but only one active TB. Two granulomas were operated. PET-CT 
also disclosed 6 concurrent and earlier unknown cancers in other 
organs among the cancer patients and in two with a benign diag-
nosis. During the period, approximately 900 primary lung cancers 
were diagnosed at the clinic, so about 17% went in the fast track, 
which was limited by available resources.
Conclusion: A fast track is feasible and possible even without ad-
ded resources. PET-CT gives very valuable information on spread 
of disease but also other cancers.
Keywords: investigation, fast track, Lung cancer, PET CT
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P2.20-005 VOLUME DOUBLING TIMES OF SUBSOLID 
NODULES DETECTED USING LOW-DOSE CT LUNG CAN-
CER SCREENING BASED ON AN EIGHT-YEAR PROSPEC-
TIVE OBSERVATION
Ryutaro Kakinuma1, Masahiko Kusumoto2, Takaaki Tsuchida3, 
Koji Tsuta4, Hisao Asamura5
1National Cancer Center, Research Center For Cancer Prevention And 
Screening/Japan, 2Department Of Diagnostic Radiology, National Can-
cer Center Hospital/Japan, 3Department Of Endoscopy, Respiratory 
Endoscopy Division, National Cancer Center Hospital/Japan, 4Division 
Of Pathology, National Cancer Center Hospital/Japan, 5Division Of 
Thoracic Surgery, National Cancer Center Hospital/Japan
Background: To evaluate the volume doubling times (VDTs) of 
subsolid nodules (SNs) detected using low-dose CT lung cancer 
screening.
Methods: Patients with SNs detected between February 2004 and 
January 2005 were enrolled. Among the SNs that were detected 
after February 2005, increasing SNs and resected SNs after follow-
up were also included in this study. After confirming the persisten-
cy of the SNs at 3 months after screening, a follow-up thin-section 
CT examination was performed every year, in principle. Dedicated 
software was developed to analyze the SNs. The volumes of the 
subsolid nodules were calculated based on the summation of the 
area of each CT slice multiplied by the CT slice thickness (i.e., 1 
mm). The area of a SN on each CT slice was determined semiau-
tomatically. The measurement of each area was performed twice, 
and the average of the first and second measurements was used 
for the volume calculation. VDTs were calculated using the fol-
lowing formula; (T1-T0)*log2/log(V1/V0).
Results: As of June 14, 2013, the measurements of 81 SNs in 72 ca-
ses had been completed. The interim results were as follows. VDTs 
were classified into positive values (n = 56) and negative values (n 
= 25). VDTs with positive values ranged from 333 to 83384 days 
(median, 1981 days; VDT >4500 days, n = 13), while the VDTs with 
negative values ranged from -110007 to -1014 days (median, -13317 
days; VDT <-4500 days, n = 20). The initial volumes for the positive 
VDTs ranged from 45 to 3486 mm3 (median, 199 mm3), while the 
initial volumes for the negative VDTs ranged from 45 to 1037 mm3 
(median, 189 mm3); the difference in initial volume between the 
positive VDTs and the negative VDTs was not statistically significant 
(P = 0.468). Among the 72 cases, 9 SNs in 9 cases (12.5%) were 
resected and diagnosed as adenocarcinomas (adenocarcinoma in 
situ [AIS], n = 4; minimally invasive adenocarcinoma [MIA], n = 3; 
and invasive adenocarcinoma [IA], n = 2). The VDTs for AIS ranged 
between 726 and 1723 days (median, 1154 days), the VDTs for MIA 
ranged between 333 and 806 days (median, 536 days), and the 
VDTs for IA ranged between 348 and 448 days (median, 398 days). 
The measurements of other SNs are ongoing.
Conclusion: The interim results showed that adenocarcinomas 
with a higher degree of invasiveness had a shorter VDT. Tentatively 
assuming that absolute values of VDTs >4500 days indicate clinical 
stability in volume despite the inherent variability of semiautomatic 
volumetry, 40% of the SNs were stable after an eight-year observa-
tion period.
Keyword: Volume doubling time, subsolid nodules, low-dose CT 
lung cancer screening, prospective observation
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P2.20-004 DNA COPY NUMBER ABERRATIONS IN EN-
DOBRONCHIAL LESIONS: A VALIDATED PREDICTOR 
FOR CANCER
Robert A A Van Boerdonk1, Johannes M A Daniels2, Peter J F Snij-
ders1, Katrien Grünberg1, Erik Thunnissen1, Mark A Van De Wiel3, 
Bauke Ylstra1, Pieter E Postmus2, Chris J L M Meijer1, Gerrit A Mei-
jer1, Egbert F Smit2, Tom Sutedja2, Daniëlle A M Heideman1
1Pathology, VU University Medical Center/Netherlands, 2Pulmonary 
Diseases, VU University Medical Center/Netherlands, 3Epidemiology & 
Biostatistics, VU University Medical Center/Netherlands
Background: Individuals who present with squamous metaplastic 
and dysplastic lesions are considered at high risk of lung cancer. 
However, these lesions behave erratically and only a minority pro-
gresses towards lung cancer. Therefore, biomarkers need to be 
discovered that can aid in assessing an individual’s risk for subse-
quent cancer. We recently identified a DNA copy number aberrati-
on (CNA)-classifier, including changes at 3p26.3-p11.1, 3q26.2-29, 
and 6p25.3-24.3, as a risk predictor for cancer in individuals pre-
senting with endobronchial squamous metaplasia (van Boerdonk 
et al, AJRCCM, 2011). The current study was set out to validate 
this classifier in an independent series of endobronchial squamous 
metaplastic and dysplastic lesions.
Methods: DNA copy number profiles (i.e., chromosomal gains and 
losses) were determined in a set of endobronchial lesions (8 squa-
mous metaplasia (SqM), and 28 dysplasias (Dys) of various grades), 
identified and biopsied during autofluorescence bronchoscopy, of 
36 high-risk subjects using a nested case-control design. Of the 36 
patients, 12 cases had a carcinoma in situ or invasive carcinoma at 
the same site at follow-up (median 11 months, range 4-24), while 
24 controls remained cancer-free (median 78 months, range 21-
142). DNA copy number profiles were related to lesion outcome. 
The prediction accuracy of the predefined CNA-based classifier to 
predict endobronchial carcinoma (in situ) in this series was deter-
mined.
Results: All SqM and Dys lesions of controls showed no or a rela-
tively low number of CNAs (i.e., quiescent profile with on average 
0.2% altered probe features, range 0.0 – 2.4%), while the majority 
of lesions of cases showed multiple CNAs (i.e. highly aberrant 
profile with on average 38.8% altered probe features, range 0.0 – 
76.7%). The previously defined CNA-classifier demonstrated 92% 
accuracy for cancer (in situ) prediction in the current series. All 
nine subjects with CNA-classifier-positive endobronchial lesions 
at baseline had cancer as final outcome (i.e., a positive predictive 
value of 100%). The negative predictive value of the classifier was 
89%, i.e., all 24 controls and 3 cases were classified as being low-
risk.
Conclusion: CNAs are a highly accurate biomarker for assessing 
the progression risk of endobronchial squamous metaplastic and 
dysplastic lesions. This classifier could assist in selecting subjects 
with endobronchial lesions who might benefit from more aggressi-
ve therapeutic interventions.
Keywords: arrayCGH, squamous metaplasia, dysplasia, molecular 
classifier
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≥8mm. More data are required for lung nodules <8mm size. Refe-
rences: (1) Boyle P, et al. Ann Oncol. 2011;22:383-389. (2) Jett JR, et 
al. J Thoracic Oncology 2012;7:S222. (3) Chapman CJ, et al. Tumor 
Biol. 201;33(5):1319-1326.
Keywords: indeterminate pulmonary nodule, autoantibody, nodu-
le, Lung cancer
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P2.20-007 COMPUTED TOMOGRAPHY (CT) SCREENING 
FOR LUNG CANCER: DOES THE MORTALITY ENDPOINT 
PROVIDE DEFINITIVE EVIDENCE FOR CT SUPERIORITY 
IN THE NATIONAL LUNG SCREENING TRIAL (NLST)?
Gary M. Strauss1, Lorenzo Dominioni2
1Medical Oncology, Tufts Medical Center/United States Of America, 
2Thoracic Surgery, University Of Insubria/Italy
Background: NLST generated excitement reporting that CT-
screening reduces lung cancer mortality in comparison to CXR-
screening. In randomized population trials (RPTs) on cancer 
screening, disease-specific mortality is assumed to provide an 
unbiased measure of screening effectiveness. This is based upon 
the assumption that randomization produces comparison groups 
with equal probability of death from the target cancer, unless the 
intervention reduces risk. However, these assumptions have often 
been violated in the RPT setting, leading to uncertainty about the 
effectiveness of several screening interventions. Objectives of this 
analysis are to assess whether the mortality endpoint provides an 
unbiased measure of screening efficacy in NLST.
Methods: In NLST, 53,454 current/former smokers, age 55-74 ye-
ars, were randomized to CT or CXR-screening. Participants were 
offered a prevalence screen followed by two annual incidence 
screens.
Results: There was a highly significant 20% lung cancer mortality 
reduction in the CT-group (TABLE). There was also a significant 
12% increase in lung cancer incidence in CT-group. Because CT is 
more sensitive than CXR, higher lung cancer incidence is predicta-
ble based upon lead-time and length-biases, and possibly overdi-
agnosis. The significant three-fold excess of BAC in the CT-group 
may reflect some overdiagnosis. Moreover, the highly significant 
two-fold excess of stage I cancers may reflect conventional biases. 
However, incidence of the most virulent lung cancers, including 
small-cell lung cancer and NSCLC-not-otherwise-specified was 
16% lower in experimental-group. There exists no plausible hypo-
thesis to explain lower incidence of highly biologically aggressive 
lung cancers in the CT-group. These differences strongly suggest 
imbalances in randomization. This is not to suggest that CT is not 
superior to CXR. While survival has not been reported, there is a 
significant 29% reduction in case-fatality in CT-group. Moreover, 
despite higher incidence, there was a highly significant one-third 
reduction in the absolute number of stage IV cancers in CT-group.  
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P2.20-006 AUTOANTIBODIES TO A PANEL OF LUNG 
CANCER-ASSOCIATED ANTIGENS CAN PROVIDE SIGNI-
FICANT DISCRIMINATION BETWEEN MALIGNANT AND 
NON-MALIGNANT LUNG NODULES
Pierre Massion1, Laura J. Peek2, Lynn Fredericks2, William Jewell2, 
William W. Pingleton2, John F..R. Robertson3
1Vanderbilt University/United States Of America, 2Oncimmune Usa Llc/
United States Of America, 3University Of Nottingham/United Kingdom
Background: EarlyCDT®-Lung, a clinical blood test that detects 
autoantibodies to lung cancer-associated antigens, has shown high 
specificity in case-control validation studies(1).The performance 
of this test in routine clinical use was audited in an initial series of 
1612 patients tested by EarlyCDT-Lung who signed HIPAA authori-
zation permitting disclosure of their health information to Oncim-
mune®; the reported specificity and sensitivity (91%/41%) of the 
test was as predicted by case-control studies(2).
Methods: A prospective audit was conducted of 423 individuals 
known to have a lung nodule for whom lung cancer-associated 
autoantibodies were measured by EarlyCDT-Lung. Physicians were 
contacted following patient testing by EarlyCDT-Lung to deter-
mine whether a cancer diagnosis had been made or a pulmonary 
nodule identified by imaging. Imaging and pathology reports were 
reviewed. This report focuses on patient outcomes at 6 months 
following EarlyCDT-Lung, and specifically on the 318/423 individu-
als for whom a lung nodule was detected prior to EarlyCDT-Lung 
testing. The EarlyCDT-Lung panel was modified in November 2010 
from a 6 autoantibody (AAB) panel to 7AAB to improve specificity 
of the test(3) ; there were 152/318 individuals with nodules who 
had the 6AAB test and 166/318 who had the 7AAB test. Analyses 
comparing EarlyCDT-Lung results by malignant and non-malignant 
nodules were made using chi-squared tests.
Results: Of the 423 individuals with nodules, there were 77 pa-
tients diagnosed with a lung cancer, and 346 were deemed to 
have a non-malignant nodule; 32/77 and 76/346 were positive for 
EarlyCDT-Lung, respectively (p=0.0004). Overall, this represented 
a 2-fold increased incidence of lung cancer with a positive result. 
Of the 318 individuals with lung nodules known prior to testing 
by EarlyCDT-Lung, the number of positive tests were 27/62 lung 
cancers and 43/256 non-malignant nodules (p= 0.000005); there-
fore, a positive result reflected a 2.7-fold increased incidence in 
this group. Considering nodule size, there was no difference for 
nodules <8mm, but the number of lung cancers in this group was 
small at only n=3. For nodules between 8-20mm and ≥20mm, a 
positive EarlyCDT-Lung test was statistically more likely to signify 
a lung cancer (p=0.06 & p=0.002, respectively; p=0.00008 com-
bined). When only the 7AAB test was assessed, which has greater 
specificity, for 8-20mm and ≥20mm nodules a positive EarlyCDT-
Lung test remained significantly more likely to indicate a lung 
cancer even though the numbers in each group were relatively 
small, n=58 & n=52, respectively (p=0.01 & p=0.004, respectively; 
p=0.0001 combined). For the 7AAB test overall and also for inde-
terminate nodules (8-20mm), a positive result represented a 3.5-
fold increased incidence of lung cancer.
Conclusion: EarlyCDT-Lung positivity reflects a statistically signi-
ficant increased risk of malignancy for lung nodules ≥8mm. This 
varies from 2-fold to 3.5-fold depending on nodule size. These 
data confirm that EarlyCDT-Lung adds to the armamentarium of 
the pulmonologist in assessing the risk of malignancy in nodules 
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P2.20-008 INVESTIGATING SYMPTOMS OF LUNG 
CANCER: AN EVIDENCE-BASED GUIDE FOR GENERAL 
PRACTITIONERS
Lauren Deutsch1, Elizabeth King1, Sue Sinclair1, Phillipa Hastings1, 
Danielle Mazza2, Samantha Chakraborty2, Donna Southern2, He-
len Zorbas1
1Cancer Australia/Australia, 2Monash University/Australia
Background: Early diagnosis and referral to specialist treatment 
are critical factors in the management of lung cancer. Survival is 
improved when lung cancer is diagnosed at an early stage and 
the patient is referred to a multidisciplinary specialist lung cancer 
team for diagnosis, staging and treatment planning. However, as 
symptoms can be non-specific and often present similarly to other 
chronic health issues, an early diagnosis of lung cancer may be 
missed. Patients with symptoms of lung cancer are likely to present 
to their general practitioner (GP). Therefore, it is important to en-
hance awareness of the risk factors, signs and symptoms of lung 
cancer, and provide GPs with the most recent evidence to facilitate 
timely and effective assessment and appropriate referrals. Cancer 
Australia commissioned Monash University (MU) to develop an 
evidence-based guide for GPs (the Guide), and to develop strate-
gies for promoting uptake of the Guide.
Methods: An Expert Advisory Panel (EAP) was established to 
oversee development of the Guide, using the ADAPTE framework 
for guideline adaptation. Following a search of the literature to 
identify potentially relevant guidelines and shortlisting using the 
Appraisal of Guidelines for Research and Evaluation instrument 
(AGREE), three international guidelines (UK, NZGG, USA) were 
selected to inform development of the GP Guide. MU conducted 
interviews with GPs to assess the feasibility of incorporating the 
Guide into a computerised decision support tool for the GP set-
ting. An evidence-based, multifaceted approach to promoting the 
Guide and supporting uptake of best practice cancer care within 
the general practice setting is ongoing, in consultation with a Pro-
ject Working Group. The approach includes development and im-
plementation of an Active Learning Module (ALM) and workshops 
for primary care providers and organisations.
Results: The Guide includes 24 recommendations focusing on 
key topics including: risk factors and symptoms of lung cancer; 
appropriate investigations in primary care; and effective referral 
to a specialist linked to a lung cancer multidisciplinary team and 
services. The Guide was published on the Cancer Australia website 
and disseminated to GPs throughout Australia. The feasibility as-
sessment found that GPs’ consultation styles did not support ad-
ditional online ‘pop-up’ reminders, preferring to access the Guide 
external to patient consultations. Incorporation of the Guide into 
an appropriate format is ongoing. The ALM provides a structured 
learning activity in an online, interactive format, providing further 
detail and context to using the Guide in the primary care setting. 
The ALM includes case-based learning, literature for further rea-
ding, and reflection and reinforcing activities. Workshops for GPs 
have been held to promote and support implementation of the 
Guide, including strategies to adopt the Guide’s recommendations 
in practice. Train-the-Trainer workshops have commenced with 
primary care providers. Evaluation of the uptake of the Guide into 
clinical practice is currently unavailable.
Conclusion: A new evidence-based guide is available to support 
GPs to assess symptoms that may be lung cancer, to undertake 
CT Group CXR Group p value
Relative 
Risk (95% 
Confidence 
Interval) 
Population 26,722 26,732
LUNG CAN-
CER DEATHS
mortality
356 
(1.33%)
443 (1.66%) 0.0022
0.80 (0.70-
0.92)
fatality
356/1060 
(33.6%)
443/941 
(47.1%)
<0.0001
0.71 (0.64-
0.80)
LUNG CAN-
CER INCI-
DENCE AND 
STAGE
incidence
1,060 
(3.97%)
941 (3.52%) 0.0067
1.12 (1.03-
1.23)
stage I lung 
cancer
416 (1.56%) 196 (0.73%) <0.0001
2.12 (1.79-
2.51)
stage IV lung 
cancer
226 
(0.85%)
335 (1.25%) <0.0001
0.67 (0.57-
0.80)
LUNG CAN-
CER HIS-
TOLOGIC 
SUBTYPES
bronchioal-
veolar carci-
noma (BAC) 
incidence
110 (0.41%) 35 (0.13%) <0.0001
3.14 (2.15-
4.60)
adenocarci-
noma, squa-
mous cell 
carcinoma, 
or large cell 
carcinoma 
incidence
664 
(2.48%)
527 (1.97%) <0.0001
1.26 (1.12-
1.41)
small cell 
carcinoma or 
nonsmall cell 
carcinoma-
not otherwi-
se specified 
(NSCLC-
NOS) inci-
dence
268 
(1.00%)
317 (1.18%) 0.046
0.84 (0.72-
0.99)
carcinoid 
incidence
6 (0.022%) 2 (0.007%) 0.18
3.00 (0.61-
14.87)
Conclusion: In NLST, lower incidence of lethal lung cancer sub-
types in CT-group predicts for lower lung cancer mortality, inde-
pendent of CT-screening efficacy. Accordingly, lower lung cancer 
mortality does not provide an unbiased measure of CT-screening 
efficacy in NLST. While stage distribution and case-fatality advan-
tages strongly support that CT is superior to CXR, further analysis, 
which must include survival, is required to judge the true effect 
of CT-screening. While a simple survival comparison of CT versus 
CXR would also be biased, an analysis comparing survival stratified 
by histologic subtype or other outcome predictors, would be use-
ful in judging the effectiveness of CT-screening in NLST.
Keywords: CT screening, Mortality, Fatality/Survival, Bias
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P2.20-010 RAMAN SPECTROSCOPY BASED BREATH 
ANALYSIS WITH POTENTIAL FOR LUNG CANCER  
DETECTION
Kam K. Chow, Michael Short, Stephen Lam, Annette Mcwilliams, 
Haishan Zeng
Imaging Unit - Integrative Oncology Department, British Columbia 
Cancer Agency Research Centre/Canada
Background: Lung cancer is the top cancer killer in North Ameri-
ca and worldwide. Current lung cancer detection tools involving 
X-ray, CT and bronchoscopy are relatively time-consuming and 
costly. Breath analyses done by mass spectrometry have shown 
that certain endogenous volatile organic compounds (VOCs) are 
related to lung cancer and revealed the potential of breath analysis 
for lung cancer detection. But mass spectrometry is costly and has 
slow turnaround times. In another interesting development, elec-
tronic noses were made for breath analysis, however the signals 
generated from semiconductor array cannot accurately quantify 
nor correlate with VOCs. Raman spectroscopy is a promising can-
didate for breath analysis because it can offer unique fingerprint-
type signals for molecular identification. Our objective is to deve-
lop a simple, cost-effective and non-invasive tool based on Raman 
spectroscopy for breath analysis and potentially for lung cancer 
screening.
Methods: A Raman-gas analyzer was designed and built, based 
on photonic technologies. We employed a hollow core-photonic 
crystal fibre (HC-PCF), a novel light guide that allows light to be 
guided in a small hollow core and it can be filled with a gaseous 
sample (i.e., human breath) for spectral analysis. A gas supply sys-
tem was built to provide a sealed environment for the loading and 
unloading of gaseous samples. A 785 nm diode laser was used for 
Raman excitation. Stokes Raman signals generated in the hollow 
core of the HC-PCF were guided to the collection optics and were 
analyzed by a Raman spectrometer for molecular identification.
Results: Raman spectra have been obtained successfully from air, 
reference gases (hydrogen gas, oxygen gas, carbon dioxide gas), 
and human breath. The limit of detection of the system was found 
to be approximately 15 parts per million by CO2 concentration in 
the ambient air, characterized by the Raman peaks at 1286 cm-1 
and 1388 cm-1. This is a more than 100-fold improvement over the 
recently reported detection limit with a reflective capillary fibre-
based Raman cell. The detection limit can be further improved by 
changes to the optical configurations, optimizing the interaction 
length of the HC-PCF and the use of sample pre-concentration 
method to enhance signal-to-noise ratio.
Conclusion: This work demonstrated a working prototype of a sim-
ple, compact, and cost-effective breath analyzer based on hollow 
core photonic crystal fibre and Raman spectroscopy. With further 
improvement in the detection sensitivity, this method can potenti-
ally be used for lung cancer screening.
Keywords: Lung cancer screening, breath analysis, Raman spect-
roscopy, Volatile Organic Compounds (VOCs)
appropriate investigations, and to support rapid referral into the 
cancer care pathway. The evidence-based, multifaceted implemen-
tation strategy supports the translation of the evidence into best 
practice cancer care.
Keywords: Early assessment of symptoms and referral to a lung 
cancer specialist, Early diagnosis, Non-specific nature of symptoms 
of lung cancer, Evidence-based guide for general practitioners
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P2.20-009 EARLY DETECTION OF MEDIASTINAL  
TUMORS USING LOW-DOSE SPIRAL COMPUTED  
TOMOGRAPHY.
Ikuma Kasuga1, Kaname Kubota1, Hiromi Maezawa1, Daisuke Ta-
kahashi2, Kazuyo Wakabayashi2, Osamu Ohtsubo2, Shigeru Yama-
moto2, Ichita Kawamura1
1Healthcare Center, Shinjuku-oiwake Clinic/Japan, 2Seikoukai Health-
care Center/Japan
Background: Chest radiographic screening is a commonly used 
conventional method for the detection of lung and mediastinal 
tumors. However, more than half of the tumors detected by chest 
radiography are those that have already progressed to the advan-
ced stage. Recent studies have shown that low-dose spiral compu-
ted tomography (CT) is effective for the early stage detection of 
lung cancer, and this facilitates better resectability and long-term 
survival. The present study was performed to evaluate the useful-
ness of chest radiography and spiral CT in the diagnosis of medias-
tinal tumors.
Methods: More than 50000 consecutive asymptomatic individuals 
had undergone a health check-up at our institution during a 1-year 
period (from December 2011 to November 2012). Of these indivi-
duals, approximately 45000 had undergone chest radiography or 
low-dose spiral CT. The presence of mediastinal tumors was inves-
tigated in these individuals.
Results: Five mediastinal tumors were detected (2 thymoma, 1 te-
ratoma, 1 liposarcoma, and 1 neurofibroma with Recklinghausen’s 
disease). Two cases were detected using both chest radiography 
and CT, whereas the other 3 were detected using chest CT only. In 
these 3 cases, no abnormal opacity was observed on chest radio-
graphs. The tumors in all 5 cases were successfully resected, and 
to date, no tumor recurrence has been observed.
Conclusion: These results suggest that screening using low-dose 
spiral CT is more useful than chest radiography and might contri-
bute to the early detection and treatment of mediastinal tumors, 
although further studies to confirm of these findings will be nee-
ded.
Keyword: mediastinal tumor computed tomography
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P2.21-001 SOLITARY PULMONARY SQUAMOUS CELL 
CARCINOMA IN PATIENTS WITH A HISTORY OF SQUA-
MOUS CELL CARCINOMA: METASTASIS OR SECOND 
PRIMARY TUMOUR?
Tomohiro Murakawa, Junji Ichinose, Tomonori Murayama, Chihi-
ro Konoeda, Yuta Inoue, Kentaro Kitano, Haruaki Hino, Kazuhiro 
Nagayama, Junichi Nitadori, Masaki Anraku, Jun Nakajima
Department Of Thoracic Surgery, University Of Tokyo/Japan
Background: Primary and metastatic squamous cell carcinomas 
(SCC) in the lung are often histologically indistinguishable, and 
the differential diagnosis between them is primarily dependent 
on clinical information such as the location of the lung lesion, the 
tumour stage, and the disease-free interval, particularly when the 
pulmonary nodule is solitary. The management of solitary pulmo-
nary SCC in patients with a history of SCC may pose diagnostic 
and therapeutic challenges.
Methods: A retrospective chart review analysis was conducted. 
The study included 244 consecutive patients with antecedent can-
cer histories who subsequently underwent pulmonary resections 
for newly discovered solitary pulmonary nodules (new SPNs) from 
January 1998 to December 2007 at our institute.
Results: Of the 244 patients, 36 had a history of SCC (neck: 14, 
oesophagus: 9, neck and oesophagus: 3, lung: 5, anal canal: 1, unk-
nown: 1, uterine cervix: 3), and 208 had no history of SCC. A his-
tory of SCC was significantly associated with the squamous patho-
logy of new SPNs (22 of 36, p < 0.0001). Of the 22 new SPNs with 
a squamous pathology, 14 of them were diagnosed as metastatic 
(mSCC), and 8 were diagnosed as primary carcinomas (pSCC). The 
mSCC showed a more advanced initial disease (p = 0.0109) and a 
marginally shorter disease-free interval (p= 0.0818) than the pSCC. 
The overall survival (OS) and recurrence-free survival (RFS) of pati-
ents with pSCC were superior to those of patients with mSCC (OS: 
p = 0.0413, RFS: p = 0.0282) (Figure 1). Notably, 6 intra-thoracic 
recurrences were observed in the mSCC group.
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P2.20-011 A PROSPECTIVE CLINICAL STUDY EVALU-
ATING STAGE DEPENDENT SPUTUM MICRO-RNA EX-
PRESSION PROFILES FOR THE DETECTION OF NON-
SMALL CELL LUNG CANCER
Rene Razzak1, Eric L.R. Bédard1, Julian O. Kim2, Sayf Gazala1, Ling-
hong Guo2, Sunita Ghosh2, Anil A. Joy2, Tirath Nijjar2, Eric Wong3, 
Wilson H. Roa2
1Division Of Thoracic Surgery, Department Of Surgery, University Of 
Alberta/Canada, 2Department Of Oncology, Cross Cancer Institute/Ca-
nada, 3Pulmonary Medicine, University Of Alberta/Canada
Background: Lung Cancer accounts for the greatest cancer related 
mortality worldwide. To date, no effective screening tool for Non-
Small Cell Lung Cancer (NSCLC) exists. For patients with operable 
stage IA NSCLC, the 5-year survival can be as high as 80%. Early de-
tection is crucial in improving long-term survival. MicroRNAs (miR-
NAs), a class of short noncoding RNA molecules. miRNA expression 
in biological fluid samples such as sputum has shown promise as a 
potential means of detecting NSCLC. Our objective was to utilize an 
efficient, cost-effective panel consisting of 3 miRNAs (miR-21, miR-
210 and miR-372) for prospective validation as a potential means 
of accurately detecting NSCLC. This panel was selected based on 
retrospective analysis of 11 miRNAs our group had previously un-
dertaken using separate NSCLC and control cohorts.
Methods: 21 early NSCLC (≤ Stage II) patients, 22 advanced NSCLC 
(≥ Stage III) patients and 10 control subjects were prospectively 
accrued. A single sputum sample was obtained through sponta-
neous expectoration from each study participant. Detailed study 
participant and tumor characteristics were obtained. miR-21, miR-
210 and miR-372 expression was conducted on each sputum sample 
and normalized to an endongenous control (U6) relative to a MRC-5 
reference sample, using RNA reverse transcription and Quantitative 
real-time Polymerase Chain Reaction (RT-qPCR). Statistical evalu-
ation consisted of unsupervised hierarchical cluster analysis of the 
experimental-normalized miRNA expression profiles using within-
group linkage.
Results: The median ages of the early NSCLC cases, advanced NS-
CLC cases and controls were 68, 68 and 58.5 respectively. The ma-
jority of the early and advanced NSCLC patients had smoking histo-
ries (>90%). 60% of the controls had smoking histories. Mean tumor 
size (± standard deviation) for early and advanced NSCLC cases 
were 3.4 cm (± 2.1 cm) and 4.8 cm (± 1.7 cm) respectively. Adenocar-
cinoma and squamous cell carcinoma comprised 62% and 23.8% of 
early NSCLC cases. Adenocarcinoma and squamous cell carcinoma 
comprised 45.5% and 22.7% of advanced NSCLC cases. Comparing 
early NSCLC to controls, the use of miR-21, miR-210 and miR372 
expression yielded a diagnostic sensitivity of 66.7% and a specificity 
of 90.0%. Advanced NSCLC patients had an improved sensitivity of 
81.8% with the same specificity of 90.0%.
Conclusion: The utilization of miR-21, miR-210 and miR372 sputum 
expression might provide a sensitive and specific means of detec-
ting NSCLC. The potential linkage between their expression and 
NSCLC stage may account for the higher sensitivity observed in the 
advanced NSCLC group. Future use of this promising panel on a 
larger population will be required to establish its potential applica-
tion as a screening tool.
Keywords: miRNA, NSCLC, sputum, detection
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P2.21-002 IDENTIFICATION OF MALIGNANT PLEURAL 
EFFUSIONS (MPES) SECONDARY TO LUNG CANCER BY 
TUMOUR MARKERS: A NATIONAL MULTI-CENTRE TRIAL
Stefano Elia1, Salvatore Griffo2, Renato Massoud1, Uliano Moran-
di3, Antonio Vetrani4, Alessandro De Stefano1, Francesco Pacelli2, 
Claudio Cortese1, Giuseppe Petrella1
1Experimental Medicine And Surgery, Tor Vergata University/Italy, 
2Surgical Sciences, Anaesthesiology And Emergency, Federico Ii Univer-
sity/Italy, 3Medical And Surgical Sciences, University Of Modena And 
Reggio Emilia/Italy, 4Biomorphological Sciences, Federico Ii University/
Italy
Background: Malignant pleural effusions (MPEs) are a common 
and important cause of cancer-related mortality and morbidity. 
Prompt diagnosis using minimally invasive procedures is a key 
point in the evolution of disease since the overall median survival 
after diagnosis is only 4-9 months. Tumour markers analysis has 
been proposed as a less invasive alternative for categorizing mali-
gnant and non-malignant pleural effusions. This multi-centre study 
aimed at establishing diagnostic cut-offs for a panel of markers in 
pleural fluid and plasma to identify patients with lung cancer.
Methods: Pleural fluid specimens and plasma samples from 112 
patients (46 malignant, 66 non-malignant) consecutively admitted 
over one year in three Italian university hospitals were analyzed for 
Ca 125, Cyfra 21.1, NSE, CEA, M2PK. The diagnosis of malignant 
or non-malignant effusion was based on cytology, pleural biopsy, 
thoracoscopy, video-assisted thoracic surgery (VATS). Statistical 
evaluation included Kolmogorov-Smirnov, Mann-Whitney, Chi-
square and Fisher’s exact tests. Non parametric (Spearman) cor-
relations were determined. ROC curve analysis was performed to 
determine analyte cut-offs, sensitivity, specificity and AUC values 
of each marker. A p-value <0,05 was considered statistically signi-
ficant.
Conclusion: The current policy for differentiation between mSCC 
and pSCC, which is based on clinical information, appears to be 
acceptable. In cases in which the origin of the pulmonary lesion is 
unclear, it might be better to treat solitary lung SCC as a primary 
lung cancer because it might offer the best chance for a cure.
Keywords: Lung cancer, diagnosis, Metastases, Pathology, squa-
mous cell carcinoma
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There were 53 (62%) patients with unresectable NSCLC and 32 
(38%) patients with postoperative recurrent disease. The number 
of patients with adenocarcinoma is 75 (87%). The bone metastasis 
type was OL group in 39 (46%) patients, OB group in 37 (43%) 
patients, and mixed type in 9 (11%) patients. Survival analysis incor-
porating mixed type bone metastasis into OB group revealed me-
dian survival time of 20.3 months and 30.9 months for OL and OB 
group, respectively. The difference was not significant (p=0.314), 
but OB group seems to have better prognosis than OL group. 
The prevalence of activating EGFR gene mutation was marginally 
significance in OB group (58%) than in OL group (36%) (p = 0.052). 
There are no significant relationship between the type of bone 
metastasis, and sex and smoking history.
Conclusion: This study shows that evaluating the type of bone 
metastasis by CT image enable prediction of EGFR gene mutation 
status and prognosis in NSCLC patients with bone metastases 
separately from sex, smoking habit, and race. The presence of os-
teoblastic metastases or the evolution to metastases should always 
be noted since it might represent an important predictive factor of 
response to EGFR-TKI treatment.
Keywords: osteoblastic, EGFR, NSCLC, metastasis
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P2.21-004 INFRARED SPECTRAL CYTOPATHOLOGY OF 
THE RESPIRATORY TRACT: 
A PILOT STUDY
Jim Brown, Sam Janes
University College London Hospital/United Kingdom
Background: Vibrational infrared (IR) spectroscopy is a powerful 
chemical analytical tool that can be used to detect and analyse 
many types of chemicals and materials including complex mix-
tures. Absorptions in this region arise from molecular vibrational 
properties and most molecules have characteristic IR spectra. 
There is a growing literature on its possible medical diagnostic use 
to distinguish cell types and states by characterising their IR ‘mo-
lecular fingerprints’ in the 1800 -900 cm-1 range. Such spectra are 
complex since they represent an overlapping mixture of proteins, 
lipids, carbohydrates, DNA and cellular metabolites. Hypothesis: 
IR spectroscopy will differentiate histological grade of bronchi-
al biopsies by identifying spectral changes corresponding to 
the stepwise progression from dysplasia to invasive cancer.  
Methods: 52 biopsy specimens were obtained bronchoscopically 
from 38 patients representing 21 normal, 9 low grade dysplasia, 
18 high grade dysplasia and 7 invasive squamous cell carcinomas. 
Matched histopathological samples were examined by H&E stai-
ning and microscopy for pathological classification. In all cases, IR 
data were collected in the 4000 – 900cm-1 region using a Bruker 
IFS66s FTIR spectrometer, both absolute absorbance spectra and 
their second derivatives were calculated. Biopsies are analysed 
fresh; time taken to capture each reading is approximately 1  
minute.  
Results: There were minimal changes to differentiate low grade 
changes from normal epithelial cells however there were signi-
ficant and reproducible changes corresponding to high grade 
Results: Cytological negative samples were analyzed to ensure 
that they truly represented non-malignant effusions related to 
other diseases such as congestive heart failure (CHF), renal imba-
lance, pneumonia, tuberculosis or post-traumatic. Patients with a 
history of malignancy or subsequent diagnosis of malignancy with 
a cytological negative pleural sample were excluded from the stu-
dy. All examined concentrations were significantly higher in mali-
gnant effusions compared to non-malignant effusions. The value 
of AUC of pleural samples was always higher than in plasma for all 
malignant cases. The best AUC value in both pleural samples and 
plasma was detected for Cyfra 21.1 (0,91 vs 0,695) and CEA (0,836 
vs 0,681).
Conclusion: Tumour markers assay in pleural fluid complements 
cytology and other classifying tests. A few tumour markers over-
expressed in pleural fluid of patients with known malignancy have 
been identified. Therefore the use of a panel including the best 
performing markers may prevent patients with suspected malig-
nancy from undergoing invasive procedures such as thoracoscopy 
or VATS. Our study shows a significant performance of pleural 
fluid vs plasma samples when comparing AUC values. Tailoring a 
specific marker assay in pleural fluid for a specific malignancy is 
highly advisable especially in patients with relevant comorbidity. 
Moreover, the evaluation of tumor markers in pleural fluid may well 
be considered as a prognostic factor in those patients with known 
malignancy undergone surgery and/or chemoradiotherapy during 
follow up.
Keywords: Lung cancer, Thoracoscopy, pleural effusion, Tumor 
markers
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P2.21-003 THE RELATIONSHIP BETWEEN THE TYPE OF 
BONE METASTASIS AND EGFR GENE MUTATION IN 
NON-SMALL CELL LUNG CANCER
Kumi Akanabe1, Yoshihisa Shimada1, Soichi Akata2, Sachika 
Nogi2, Masatoshi Kakihana1, Naohiro Kajiwara1, Tatsuo Ohira1, 
Norihiko Ikeda1
1Department Of Surgery I, Tokyo Medical University/Japan, 2Depart-
ment Of Radiology, Tokyo Medical University/Japan
Background: The bone is the most common distant site of metas-
tasis in non-small cell lung cancer (NSCLC), and patients with bone 
metastasis have a markedly poor prognosis. There are three types 
of bone metastasis; such as osteolytic type, osteoblastic type, and 
mixed type. Assessment of bone metastatic type may be impor-
tant as a part of therapeutic strategy because it has been noted 
that osteoblastic tumors would have lead to both a better progno-
sis and activating epidermal growth factor receptor (EGFR) mutati-
on presence. The aim of this study was to examine the relationship 
between the type of bone metastasis and clinical characteristics 
including EGFR gene mutation status in NSCLC patients.
Methods: We reviewed the records of 85 unresectable or post-
operative recurrent NSCLC patients with at least one site of bone 
metastasis. The type of bone metastasis was classified by two 
radiologists reviewing the radiological examination as osteolytic 
type (OL), osteoblastic type (OB), and mixed-type from the CT 
findings.
Results: Median follow-up time for survivors was 25.4 months. 
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overall survival in the United States Military who receive equal and 
open access to healthcare in the Department of Defense (DoD) 
medical system.
Methods: We identified patients (military service members and 
their dependents) ≥18 years old, with an initial diagnosis of NS-
CLC from January 2003- March 2013 in the DoD Cancer Registry 
(N=4,751). Descriptive statistics were generated for demographic 
and clinical characteristics. Kaplan Meier (KM) curves and Cox pro-
portional hazards regression assessed overall survival (OS).
Results: Military service members comprised 63% of the cohort. 
The mean age at diagnosis was 66, 64% were male and 72% were 
Caucasian. Adenocarcinoma (AC) histology was the majority (45%), 
followed by 31% NSCLC not otherwise specified (NOS), 21% squa-
mous cell (SC), and 2% Large Cell (LC). A majority (57%) were dia-
gnosed at advanced stage and tended to be younger (mean age 
65 vs. 67; p<.0001) and more likely male (66% vs. 61%; p<.0001) 
compared to patients diagnosed with earlier stage disease. In the 
early stage cohort 78% had stage I disease. Patients with advanced 
stage disease presented predominately with either AC (41%) or 
NOS (38%) compared to SC (20%) or LC (2%). Most of the cohort 
were either currently using or had a history of tobacco use (82%). 
The unadjusted OS for the cohort was 14.97 months (95% confi-
dence interval (CI): 13.9-15.7) with significantly decreasing survival 
as stage increased (Table). In the multivariate survival analysis, 
older age, male gender, increasing stage (Table), squamous cell 
histology, higher number of comorbidities, and tobacco history 
were associated with a higher risk of death.
Conclusion: In this DoD cohort, NSCLC patients were diagnosed 
at a younger age and had a higher proportion of Stage I disease 
than often seen in the general US civilian population, perhaps 
due to more open access to health care. Stage at diagnosis was a 
significant predictor of mortality and further research comparing 
factors influencing survival relative to the general population is 
warranted including the role of open access to care.  
Table: Unadjusted and Adjusted Survival by Stage
Unadjusted Adjusted
Stage N
Median 
Survival 
(Months) 
95% CI HR 95% CI
I 1141 64.2 58.4-70.1 ref
II 324 29.5 26.2-34.1 1.78 1.49-2.12
III 1049 13.5 12.5-15.2 3.31 2.94-3.73
IV 1678 6.5 6.0-7.0 7.15 6.38-8.02
Keywords: Military Lung Cancer, Younger Age Diagnosis
dysplasia and cancer (Fig 1). We have developed an algorithm 
analysing the relative size of IR peaks in the 1290-1270cm-1 ran-
ge that differentiates with 100% accuracy between normal/ low 
grade and high grade/ cancer in this small pilot study. We have 
observed differences in regions suggesting changes in intracellular 
glycoproteins and lipids and work continues to define the exact 
cause of the observed differences. More subtle spectral changes 
also discriminate between high grade dysplasia and cancer and 
are the subject of further algorithm development and validation.
Conclusion: 
• High quality mid-IR spectra of ex-vivo biopsies do reveal diffe-
rences between normal and dysplastic/ cancerous cells in bronchi-
al tissues.
• This technology has the potential to provide real-time near pati-
ent cytopathological diagnosis for the bronchoscopist or 
thoracic surgeon for instance to confirm clear resection margins at 
surgery.
• Identification of the chemical changes occurring at a cellular level 
may lead to reverse translation and better understanding of the 
processes driving progression to malignant transformation.
• Future work will refine and validate the 
observed changes.
Keyword: Infrared spectroscopy, preinvasive,
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P2.21-005 NON-SMALL CELL LUNG CANCER (NSCLC) IN 
THE UNITED STATES DEPARTMENT OF DEFENSE
Corey A. Carter1, Sacha Satram-Hoang2, Ashok Gunuganti2, Caroli-
na Reyes3, Hans-Peter Goertz3, Christopher Gallagher1
1John P. Murtha Cancer Center, Walter Reed National Military Medical 
Center/United States Of America, 2Q. D. Research Inc/United States Of 
America, 3Genetech, Inc/United States Of America
Background: Lung cancer is the leading cause of cancer-related 
death in the United States, with non-small cell lung cancer (NSCLC) 
accounting for 87% of cases. Roughly half of all patients present 
with advanced disease and the majority with earlier stage disease 
eventually develop disease recurrence. The objectives of this study 
were to characterize patients diagnosed with NSCLC and assess 
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Conclusion: Small samples such as LBC by bronchoscopy may be 
used to molecular analysis. Especially, our results suggest that LBC 
from EBUS-TBNA is very usefulness.
Keyword: Bronchoscopy, lung cancer, liquid based cytological 
samples, molecular analysis
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P2.21-007 COMPUTED TOMOGRAPHY-GUIDED NEEDLE 
ASPIRATION AND BIOPSY OF PULMONARY LESIONS: 
A SINGLE-CENTER EXPERIENCE ON 750 BIOPSIES IN 
JAPAN
Jumpei Takeshita, Nobuyuki Katakami, Akito Hata, Reiko Kaji, 
Katsuhiro Masago, Shiro Fujita
Integrated Oncology, Institute Of Biomedical Research And Innovation/
Japan
Background: Computed tomography (CT)-guided fine needle as-
piration (FNA) and biopsy is a well-established diagnostic method 
for pulmonary lesion.The aim of our study was to update the diag-
nostic outcomes and the safety profile of CT-guided lung biopsies.
Methods: We retrospectively analyzed the results of the CT -gui-
ded FNA and biopsies for 750 pulmonary lesions in 696 patients, 
and investigated the diagnostic yield, and complication rates.The 
independent risk factors for the diagnostic failure (ie, nondiag-
nostic, false-positive, and false-negative results) and the complica-
tions (severe pneumothorax) were determined using multivariate 
logistic regression analysis.
Results: The study included 417 male patients and 279 female 
patients, with a mean age of 71 years.The mean lesion size was 2.0 
cm in maximal diameter.The biopsy results were nondiagnostic in 
1.4% of the lesions (11 of 750 cases).The diagnostic accuracy was 
92.6% (685/739cases).The sensitivity and specificity for the diag-
nosis of malignancy was 91.7% (534 of 582 cases) and 99.3% (156 
of 157 cases), respectively.The significant independent risk factor 
for diagnostic failure was Lesions measuring < 2.0 cm (OR, 3.94; p 
<0.0001).Pneumothorax was the most common complication, and 
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P2.21-006 MOLECULAR ANALYSIS OF LIQUID BASED 
CYTOLOGICAL SAMPLES BY BRONCHOSCOPY IN LUNG 
CANCER PATIENTS
Yukiko Nakamura1, Shinji Sasada1, Takehiro Izumo1, Takaaki Tsu-
chida1, Hiroaki Okamoto2, Koji Tsuta3, Koh Furuta4, Takashi Koh-
no5, Hiroshi Nokihara6
1Division Of Endoscopy, National Cancer Center Hospital/Japan, 2Divi-
sion Of Respiratory Medicine And Medical Oncology, Yokohama Muni-
cipal Citizen‘s Hospital/Japan, 3Division Of Pathology, National Cancer 
Center Hospital/Japan, 4Division Of Clinical Laboratories, National 
Cancer Center Hospital/Japan, 5Division Of Genome Biology, National 
Cancer Center Research Institute/Japan, 6Division Of Thoracic Oncolo-
gy, National Cacner Center Hospital/Japan
Background: In advanced lung cancer, for the treatment based on 
one specific driver mutation, it is important to make diagnosis by 
the use of small biopsy or cytological samples obtained from bron-
choscopy examination. With the development of multiple molecu-
lar target agents, we need to simultaneously examine several kinds 
of genetic alterations in small samples.
Methods: Patients who were considered necessary to examine 
bronchoscopy for diagnosis of lung cancer were prospectively en-
rolled. Between November 2012 to March 2013, 123 patients were 
enrolled, and molecular analysis were performed in 115 patients. 
Liquid based cytological samples (LBC) by bronchoscopy were 
divided equally into routine pathological examination and mole-
cular examination. After extraction of DNA and RNA from LBC, we 
evaluated EGFR, KRAS and BRAF mutations and ALK fusions.
Results: Patients characteristics were as follows: the median age 
69 (range: 42-83); female 43 (37%); never smoker 40 (22%). Finally, 
80 patients were pathologically diagnosed as lung cancer (Ad/Sq/
NSCLC/Sm/Unclassified; 50/14/8/6/2). Fifty-nine patients showed 
class V of LBC, and 16 patients had molecular change (11 EGFR 
mutation and 5 KRAS mutation). Moreover, 1 patient of class III 
had an EGFR mutation. In a procedure of bronchoscopy (EBUS-
TBNA, bronchoscopy for peripheral lesions and bronchoscopy for 
central lesions), median quantities of DNA in class V patients of 
LBC were 1.19, 0.67 and 0.16µg, respectively (Fig1 shown). Median 
quantities of RNA were 1.24, 0.37 and 0.49µg respectively (Fig2 
shown). The quantity of DNA and RNA extracted from EBUS-
TBNA were more than that of other bronchoscopy procedures. 
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analysis. Considering that the expected prevalence is no greater 
than 10%, this sample permits this estimation with a half-width of 
the 95% confidence interval < 1.7%. Tissue samples will be ship-
ped to INCA (the coordinator center) for central analysis. Clinical 
data will be collected by local investigators and retrieved by the 
coordinator center. The primary goal of the study is to estimate 
the prevalence of ALK fusion gene in LATAM nonsquamous NSCLC 
patients and build a stable LATAM network for future molecular 
epidemiology studies. The secondary objective is to perform a 
comparison of FISH, PCR and IHC methods for ALK fusion gene 
detection. FISH will be considered the standard method for com-
parison and performed using the ALK Dual Color Break-Apart 
probe (Abbott Molecular Inc.). Real time PCR will be performed 
in collaboration with Fundación Santa Fé, Colombia (probes and 
primers synthesized at TIB MOLBIO, LLC and designed with Primer 
3 software) and IHC performed with VentanaTM reagents.
Results: The protocol was planned in 2011. Since then, the first 
LATAM molecular epidemiology network was established with 
LACOG collaboration, and molecular analysis methodology stan-
dardization completed.
Conclusion: This trial represents the first cooperative effort for 
genotype patients in LATAM using sample shipment for central 
analysis. Enrollment of patients is still pending, waiting for final 
approval from country regulatory agencies which have different 
requirements and timeframes for review. Moreover, additional data 
on tumor specific biomarkers and diagnostic testing across the 
region may provide a basis to guide future decisions by regulators 
and treating physicians.
Keyword: non-small cell lung cancer; ALK fusion gene; diagnostic; 
epidemiology
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P2.21-009 RESULTS OF EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) REFLEX TESTING IMPLEMENTATI-
ON IN THE BRAZILIAN NATIONAL CANCER INSTITUTE 
(INCA)
Clarissa Baldotto1, Alexssandra Lima1, Mariana Siqueira1, Tatiane 
Montella2, Pedro M. Domingues2, Daniel Herchenhorn1, Mauro 
Zukin1
1Clinical Oncology, Instituto Nacional De Câncer/Brazil, 2Clinical Research, 
National Institute Of Cancer (INCA)/Brazil
Background: Patients with advanced lung cancer and EGFR mu-
tations can derive significantly benefit by receiving first line EGFR 
tyrosine kinase inhibitor (TKI) therapy. Multiple trials have showed 
that clinical selection is not sufficient and that EGFR mutations test 
should be requested for all non-squamous patients. Moreover there 
is a suggestion that a lag time between diagnosis and molecular 
test could harm patients. In this retrospective trial we describe EGFR 
mutation analysis after the implementation of reflex testing in a 
cohort of Brazilian patients.
Methods: After May 2011 EGFR reflex testing was recommended 
for all stage IVA and IVB non-squamous lung cancer patients treated 
at INCA. EGFR exons 18, 19, 20 and 21 were examined using a com-
mercially available Polymerase chain reaction and Sanger sequenci-
ng assay. We retrospectively reviewed clinical and EGFR tests cha-
racteristics from medical charts of all patients with available results.
occurred in 36% (272 cases), pneumothorax requiring temporal 
drainage or chest tube insertion in 7.3% (55 cases), and tension 
pneumothorax, in 0.2% (2 cases).There were 27 cases (3.6%) with 
pulmonary hemorrhage, 63 cases (8.4%) with hemoptysis, 2 cases 
(0.2%) with air embolism , 5 cases (0.6%) with hypertension re-
quiring antihypertensive treatment , 1 case (0.1%) with posterior 
reversible encephalopathy syndrome (PRES) , and 8 cases (1.0%) 
with others, including pain, shock, subcutaneous emphysema, 
subcutaneous hematoma, epilepsy, and bradycardia or tachycardia 
spell.From a total of 13 patients with severe complications, 12 pa-
tients recovered without sequela, however 1 patient recovered but 
developed paraplegia due to spinal cord infarction; there were no 
fatalities.The significant independent risk factors for pneumothorax 
requiring drainage were the depth from pleura < 3.0 cm (OR, 3.60; 
p <0.001), lesions in the middle lobe (OR, 2.25; p 0.0284), (and 
COPD patients(OR, 4.38; p <0.001).
Conclusion: CT-guided lung FNA and biopsy have a high diag-
nostic yield, but factors such as the acquisition of lesions measu-
ring <2.0 cm significantly increased the rate of diagnostic failure.
The complication rates were acceptable and comparable to previ-
ously published figures.The rate of pneumothorax requiring draina-
ge was correlated with the depth from pleura < 3.0 cm, lesions in 
the middle lobe, and COPD patients.
Keywords: Complication, Computed tomography-guided needle 
aspiration, Computed tomography-guided biopsy, Pneumothorax
POSTER SESSION 2 - DIAGNOSIS AND STAGING  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.21-008 CLINICAL AND EPIDEMIOLOGIC STUDY OF 
ALK FUSION GENES IN LUNG CANCER PATIENTS IN  
LATIN AMERICA: CHALLENGES AND PERSPECTIVES
Clarissa Baldotto1, Cinthya Sternberg2, Carolyn Blanckmeister3, 
Dalia B. Wajsbrot4, Isabele Small2, Carlos Gil Ferreira2
1Clinical Oncology, Instituto Nacional De Câncer/Brazil, 2Clinical Re-
search, Instituto Nacional De Câncer/Brazil, 3Embu Development On-
cology, Pfizer Inc./United States Of America, 4Emep Bu Development 
Oncology, Pfizer Inc./United States Of America
Background: Anaplastic Lymphoma kinase (ALK) alterations play 
a significant role in the pathogenesis of non-small-cell lung cancer 
(NSCLC), and the ALK pathway has become an important target for 
novel NSCLC treatment. Despite strong participation in industry-
sponsored and recently investigator-initiated multicenter clinical 
trials, little is known about the prevalence, clinic-pathological 
parameters and clinical outcomes related to ALK fusion in Latin 
American (LATAM) NSCLC patients. Preliminary data from previous 
small studies suggest that the prevalence of other NSCLC driver 
genes such as EGFR and BRAF may be more frequent in LATAM 
than in other non-Asian populations. This highlights a clear need 
for a comprehensive molecular epidemiology investigation in this 
genetically heterogeneous region.
Methods: Collaboration with the Brazilian National Cancer Institu-
te (INCA) and Latin America Oncology Group (LACOG), through a 
research agreement with Pfizer Inc., was established and 11 sites 
from 5 different LATAM countries were contacted for participation 
(Brazil, Mexico, Argentina, Peru and Bolivia). Countries and site 
selection was based on ethnic, social and cultural characteristics 
in order to (appropriately) represent the continent’s population. A 
total of 1,154 patients will be retrospectively enrolled for molecular 
S988 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
y (41-87 y). The most frequent histology reported was adenocar-
cinoma. All adenocarcinomas were analyzed for EGFR mutations 
(exon 18, 19, 20, and 21). 33.3% of adenocarcinoma patients had an 
EGFR mutation. Smoking history was statistically associated with 
the occurrence of an EGFR mutation. Patient characteristics are 
summarized in Table 1.  
Table 1: Characteristics of patients diagnosed with NSCLC in HS-
JD-Costa Rica during 2012 
Total NS-
CLC po-
pulation 
n=40 
Adenocar-
cinoma 
populati-
on n=27 
EGFR 
mut 
positive 
populati-
on n=9 
Median 
age 
68 y (41-
87 y) 
Sex p=0.504 
M (%) 24 (60) 15 (55.6) 4 (44.4) 
F (%) 16 (40) 12 (44.4) 5 (55.6) 
Smoking 
history 
(PY) 
p=0.022 
Non smo-
ker (%) 
14 (35) 12 (44.4) 7 (77.8) 
5-20 (%) 3 (7.5) 3 (11.1) 0 
21-40 (%) 4 (10) 1 (3.7) 0 
41-60 (%) 9 (22.5) 4 (14.8) 1 (11.1) 
>60 (%) 10 (25) 7 (26) 1 (11.1) 
Adenocar-
cinoma 
histology 
(%) 
27 (67.5) 
Stage of 
diagnosis 
I-II 3 (7.5) 2 (7.4) 0 
IIIA 9 (22.5) 4 (14.8) 0 
IIIB 5 (12.5) 2 (7.4) 0 
IV 23 (57.5) 19 (70.4) 9 (100) 
% EGFR 
mutation 
positive 
22.5 33.3 
% of type 
of EGFR 
mutation 
Exon 18 0 0 0 
Exon 19 17.5 25.9 77.8 
Exon 20 2.5 3.7 11.1 
Exon 21 2.5 3.7 11.1 
Conclusion: In Costa Rica, the incidence of EGFR mutations in 
adenocarcinoma patients tends to be higher to that of the Caucasi-
an population and lower than the Asian population. This incidence 
might be similar in other Latin American countries. Epidemiologi-
Results: From May 2011 to May 2013 samples from 189 patients 
(56.2%) out of 336 were screened for EGFR mutations. Main reason 
for non-testing was insufficient material. Turn around time for EGFR 
mutation processing substantially improved over this period, from 
over three weeks to less than 5 working days. Of those patients 
tested 58.8% were women and 22% were non-smokers or light 
smokers. Results were obtained from cytological specimen in 33 
cases (17.4%). Most patients had adenocarcinoma (95.2%) with only 
6 cases (3.2%) of unspecified carcinoma. EGFR mutations were 
detected in 52 patients (27.5%). The incidence of mutations was 
higher in females (58.8%) and non-or light smokers (56%). Of the 
mutations identified 18 (34.6%) were in frame deletions in exon 19, 
and 8 (15.3%) were exon 21 L858R. Exon 18 G719A and exon 20 in-
sertions were detected in only 1 (1.9%) and 2 (3.9%) cases respec-
tively. We found a high incidence of atypical mutations (44.3%). All 
of them were single aminoacidic substitutions in exon 18 (7 cases; 
30.5%), exon 19 (5 cases; 21.7%), exon 20 (5 cases; 21.7%), exon 21 
(5 cases; 21.7%), and a single case of double mutation (exons 19 
and 20). We did not detect any de novo T790M exon 20 mutation.
Conclusion: The results of the first 2 years of reflex molecular tes-
ting at a single Brazilian institution reported demonstrate the feasi-
bility and potential for a non-clinical selective approach. This high 
frequency of atypical mutations must be further investigated since 
to date there are no published data regarding EGFR mutations in 
the Brazilian population.
Keyword: EGFR; molecular epidemioloy; reflex testing
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P2.21-010 EGFR MUTATION FREQUENCY IN PATIENTS 
DIAGNOSED WITH NSCLC FROM COSTA RICA
Luis Corrales-Rodriguez, Allan Ramos-Esquivel, Mónica Araya, 
Ernesto Jiménez, Sofía Antillón, Randall Guadamuz, Christian 
Campos-Fallas, Manuel Caballero, Carlos Arce-Lara, Melissa 
Juárez-Villegas
Grupo De Oncología Torácica, Hospital San Juan De Dios-CCSS/Costa 
Rica
Background: Histological differentiation in NSCLC has been 
addressed recently due to the importance regarding prognosis 
and treatment options. Adenocarcinoma is considered the most 
frequent histology and recent guidelines recommend the EGFR 
mutation testing. Epidemiological characteristics of EGFR muta-
tion positive patients have been widely described in Caucasian 
and Asian population. Given the differences between these po-
pulations, it is important to evaluate the epidemiology in other 
populations. More than 90% of Costa Rica’s population is treated 
in a government-based hospital. Hospital San Juan de Dios (HSJD) 
attends approximately a 40% of Costa Rica’s population. Starting 
at the end of 2011, all patients with lung adenocarcinoma are eva-
luated for EGFR mutations.
Methods: We conducted a retrospective analysis of all patients 
diagnosed with NSCLC in HSJD between January and December 
2012. A total of 42 patients were diagnosed with a NSCLC but 2 
patients were excluded from the study due to insufficient clinical 
information. Epidemiologic data was obtained and EGFR mutation 
status was analyzed.
Results: The NSCLC population analyzed had a median age of 68 
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P2.22-001 JAPANESE NATION WIDE LUNG CANCER RE-
GISTRIES CONDUCTED BY THE JAPANESE JOINT COM-
MITTEE OF LUNG CANCER REGISTRY (JJCLCR)
Noriyoshi Sawabata, Hisao Asamura, Yoichi Nakanishi, Kenji Egu-
chi, Masaki Mori, Ichiro Yoshino, Yoshitaka Fujii, Hirohito Tada, 
Hideo Kobayashi, Etsuo Miyaoka, Meinoshin Okumura, Kohei 
Yokoi
Japanese Joint Committee Of Lung Cancer Registry/Japan
Background: The Japanese Joint Committee of Lung Cancer 
Registry (JJCLCR) is jointly established by the Japan Lung Cancer 
Society, the Japanese Respiratory Society, the Japanese Associati-
on for Chest Surgery and the Japan Society for Respiratory Endo-
scopy, conducting Japanese nation-wide registries of lung cancer 
patients
Methods: In 1999, 2004 and 2009, registries were conducted for 
surgical patients in 1994, 1999 and 2004, respectively. In 2002, 
both surgical and non-surgical (non-biased) patients in 2002 were 
registered with a follow up period of 3 years or more. In 2012, a 
registry has been conducted for non-surgical patients in 2012 with 
a follow up period of 3 years. In 2016, surgical patients in 2010 will 
be registered. These registries were observationally assessed.
Results: Registries for surgical cases in 1994, 1999 and 2004 which 
were conducted in 1999, 2004 and 2009 revealed the trend of 
increase in mean age, rates of female, the aged, small sized lesion, 
adenocarcinoma and stage I, and that of decrease in the rate of 
perioperative death. Furthermore proposals for TNM classification 
were stated as peer reviewed papers- invasion to visceral pleura, 
chest wall and fat tissue in the mediastinum for T factor. In addi-
tion, status of N2 disease were assessed resulting in that highly 
selected cases (3.8%) were subjected to surgery or surgery-inclu-
ded multimodal therapy with a 5-year survival rate of 30.1% in cN2/
pN2-Stage IIIA and it was better than previous registries. Registry 
for surgical and non-surgical patients in 2002 revealed that stage-
specific prognosis was within a range similar to other reports and 
stage, gender, surgery and performance status were independent 
prognostic indicator of both non-small and small cell lung cancer. 
Registry of non-surgical cases in 2012 was conducted and greater 
than 8,000 cases were registered. In this study, status of usage of 
FDG-PET scan for staging, EGFR gene mutation and individual 
therapy were, and prognosis of patients will be registered. In up-
coming registry for surgical cases in 2010 which will be performed 
in 2016, new parameters- the size of tumor regarding non-invasive 
regions in adenocarcinoma (ground grass opacity in computed 
tomography), quantitative assessment of lymph node metastasis 
(the number of metastasized lymph node) as a prognostic indi-
cator, which may be assessed as factors of TNM classification in 
the future. Besides, the TNM classification will be revised in 2016 
according to the proposal from IASLC staging project, to which the 
JJCLCR offered data of 47,306 cases (approximately 25% of whole 
world wide cases) from the recent 4 registries.
Conclusion: The JJCLCR conducted nation-wide lung cancer re-
gistry in Japan, revealing the condition of the treatment of lung 
cal characteristics of EGFR mutation positive patients are similar to 
that reported in the literature.
Keywords: Adenocarcinoma, EGFR, mutation, NSCLC
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P2.21-011 PERSISTENT GROUND-GLASS OPACITY LUNG 
NODULES < 20 MM IN DIAMETER AT CT: HISTOPATHO-
LOGIC COMPARISONS WITH IMAGING FEATURES
Lihua Yang1, Shengxiang Ren1, Jingyun Shi2, Cunyan Wu1, Caicun 
Zhou3
1Shanghai Pulmonary Hospital, Tongji University/China, 2Imaging 
Department, Shanghai Pulmonary Hospital, Tongji University/China, 
3Department Of Medical Oncology, Shanghai Pulmonary Hospital, 
Tongji University School Of Medicine, Tongji University Medical School 
Cancer Institute/China
Background: Differentiation of atypical adenomatous hyperplasia 
(AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarci-
noma (MIA), and invasive adenocarcinoma(IA) on computed tomo-
graphy (CT) is useful for determining ‘‘follow-up or resection’’ stra-
tegies for lesions displaying ground-glass opacity nodules(GGN). 
The purpose of this study is to compare the morphologic features 
of persistent GGNs of <20 mm in diameter at thin-section CT 
(TSCT) with histopathology.
Methods: Jan 2010 and Dec 2012, a total of 200 nodules in 191 re-
sected GGNs that were evaluated with TSCT were included in this 
study. Correlations between histopathology and CT characteristics 
were examined.
Results: The nodules included 45 AAH (22.5%), 99AISs (49.5%), 11 
MIAs (5.5%), and 45 invasive adenocarcinomas (22.5%). The mean 
CT value (P < .0001), size of nodule (P < .0001) were significant 
factors that differentiated AAH lesions from invasive adenocarci-
noma or AIS or MIA. While the size of nodule (P < .0001) and mass 
of nodule (P < .0.001) were significant factors that differentiated 
invasive adenocarcinoma from AIS or MIA.
Conclusion: Size of nodule less than 10 mm and mean CT value 
less than -510Hu are determinants of AAH, while size and mass of 
the nodule are determinants of invasive adenocarcinoma in Chine-
se population.
Keywords: Lung cancer, Ground-glass nodule, Differential diagno-
sis, lung adenocarcinoma
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P2.22-003 BIM (BCL2L11) DELETION POLYMORPHISM IS 
ONE OF MAJOR RISK FACTORS OF LUNG CANCER IN 
KOREAN POPULATION.
Eun Na Cho, Eun Young Kim, Arum Kim, Hyung Jung Kim, Chul 
Min Ahn, Yoon Soo Chang
Department Of Internal Medicine, Yonsei University College Of Medicine/
Korea
Background: BIM (BCL2L11), which encodes a BH3-only prote-
in, is one of major pro-apoptotic factors that facilitate cell death. 
A 2,903-bp genomic deletion polymorphism in intron 2 of BIM 
showed 12.3% carrier frequency in East Asian population. This 
polymorphism results in expression of BIM isoforms lacking the 
pro-apoptotic BH3. We evaluated whether the presence of the BIM 
deletion polymorphism is a major risk factors of lung cancer in Kore-
an population.
Methods: We designed 1:1 matched case-control study between 
lung cancer and control subjects. Lung cancer patients and age, 
gender and smoking status matched control subjects without other 
types of malignancies were prospectively enrolled from Feb. 2013 to 
now. Subjects under 18 years old and who denied to present infor-
med consent were excluded. The presence of 2,903-bp genomic 
DNA deletion polymorphism in intron 2 of BIM were analyzed by 
PCR and validated by sequencing. BIM deletion polymorphism sta-
tus and relationship with clinical and pathological parameters were 
analyzed using chi-square test, t-test, Kaplan-Meyer estimator, and 
Log-Rank test.
Results: There were no statistically significant differences in age, 
gender and smoking status between lung cancer and control sub-
jects. Twenty-three out of 102 (22.5%) lung cancer patients revealed 
a BIM deletion polymorphism whereas 9 out of 75 (12%) control 
subjects showed polymorphism. The odd ratio for the association 
of BIM deletion polymorphism and lung cancer was 2.139 (p=0.076). 
Sixty-nine out of 102 (67.6%) lung cancer patients were male and 52 
(51%) were smoker. Among them 97 (95%) were non-small cell lung 
cancer (NSCLC) and 5 (5%) were small cell lung cancer. Adenocar-
cinoma was the most common histological subtype accounting for 
69 out of 97 (71%) in NSCLC. When lung cancer patients were cate-
gorized according to the presence of polymorphism status, there 
was no difference in the age between subjects with and without 
polymorphism (mean age; 63.3 vs. 63.4 year). Among the lung can-
cer patients harboring BIM deletion polymorphism, there were more 
female (9 out of 23, 39%) and non-smokers (15 out of 23, 65%) when 
compared to those without polymorphism showing 24 out of 79 
(30%) female and 35 out of 79 (44%) non-smokers. The histological 
subtypes between the two groups were not significantly different. 
A total of 64 out of 102 lung cancer patients had been tested EGFR 
mutation status. The odd ratio for the association of BIM deletion 
polymorphism and EGFR activating mutation was 0.87. In lung can-
cer patients, the BIM deletion polymorphism did not have a statisti-
cally significant impact on the clinical outcome of the patients.
Conclusion: Our results indicate that BIM deletion polymorphism 
may be one of major lung cancer risk factors in Korean population. 
To strengthen our results, we are extending the sample size and 
are going to perform hierarchical analysis prospectively. To validate 
our results, we are performing a validation analysis with an external 
validation dataset from the national cohort.
Keywords: Lung cancer, risk factors, BIM deletion polymorphism
cancer and contributing to the TNM staging program.
Keywords: TNM, Lung cancer, Registry, Japan
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P2.22-002 STUDY OF SOME FACTORS RELATED TO EPI-
DEMIOLOGY IN MALIGNANT PLEURAL MESOTHELIOMA
Nguyen S. Lam1, Tran D. Thanh2
1Pathological Department, Pham Ngoc Thach Hospital/Vietnam,  
2Department Of Oncology, Pham Ngoc Thach Hospital/Vietnam
Background: Malignant Pleural Mesothelioma (MPM) is a rare di-
sease and often associated with a history of long-term exposure 
to asbestos. Recently, It’s related to Simian virus 40 (SV-40). The 
determination is related to exposure to asbestos based on clinical 
history and possible asbestos in tissue pathology specimens. Di-
agnosis related to SV-40 based on immunohistochemical staining 
The Simian Virus 40 Large T Antigen.
Methods: Retrospective descriptive statistics. Survey by interview-
ing patients and pathological examine specimens can find asbes-
tos and immunohistochemistry with The Simian Virus 40 Large T 
Antigen.
Results: From Jan, 2008 to Dec, 2012 at the Pham Ngoc Thach 
Hospital, we have take diagnosis of 60 cases of malignant pleural 
mesothelioma, including 29 men and 31 women, with histopa-
thological classification: 28 cases of epitheliod MPM (46.7%), 11 
cases with biphasic MPM (18.3%), 09 cases with sarcomatoid MPM 
(15%), 06 cases with Desmoplastic MPM (10%), 04 cases with Well-
Differentiated Papillary Mesothelioma (6.7%) and 02 cases with 
Anaplastic MPM (3.3%). 
§ Elements related to contact asbestos: 22cases (44.4%). 
§ Confirm the diagnosis of asbestos in tissue 
specimens:12cases(20%). 
§ Presence of The Simian Virus 40 Large T Antigen: 11 cases 
(18,3%). 
§ Only one case (1,7%) with both two factors positive asbestos and 
SV-40. 
§ And having 16 cases (26,7%) did not identify epidemiological 
factors. 
Conclusion: Through the the study series cases of Malignant Pleu-
ral Mesothelioma, initially issued a warning about the causative 
factors in those tumors, including long-term exposure to asbestos 
and can be caused by infections with Simian virus 40.
Keyword: Malignant Pleural Mesothelioma, Asbestos, Simian Virus 
40
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Odds ratio 95% CI p-value
Year of diagnosis
2000 1 (Ref)
2010 0.84 0.77-0.91 <0.0001
Age (years)
<60 1 (Ref)
60-75 1.03 0.94-1.13 0.55
>75 1.53 1.35-1.42 <0.0001
Sex
Female 1 (Ref)
Male 1.28 1.15-1.42 <0.0001
Smoking status
Never-smoker 1 (Ref)
Former-smoker 1.02 0.87-1.19 0.84
Active-smoker 1.23 1.05-1.44 0.01
Performance 
status
0- Asymptomatic 1 (Ref)
1- Symptomatic 
but completely 
ambulatory
2.45 2.23-2.69 <0.0001
2- Symptomatic, 
< 50% in bed
6.49 5.73-7.36 <0.0001
3- Symptomatic, 
> 50% in bed
15.2 12.6-18.3 <0.0001
4- Bedbound 39.0 23.5-64.8 <0.0001
Small cell lung 
cancer
Yes 1 (Ref)
No 0.83 0.74-0.93 0.002
Conclusion: In 10 years, 1-year mortality decreased in patients 
with primary lung cancer. The improvement in survival was not 
solely due to epidemiological changes in patient characteristics 
(age, sex, smoking habits, or PS) and tumor characteristics (histo-
logical type) over the 10-year period. This supports the hypothesis 
of improved management of lung cancer in patients followed up in 
French general hospitals.
Keywords: Epidemiology, Lung neoplasms, Mortality, hospitals, 
general
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P2.22-004 SURVIVAL IMPROVEMENT IN PRIMARY LUNG 
CANCER PATIENTS IN A 10-YEAR PERIOD: RESULTS OF 
THE FRENCH KBP-2000-CPHG AND KBP-2010-CPHG 
COHORTS
Chrystele Locher1, Sandrine Loutski2, Pierre Le Lann2, Nicolas 
Just2, Serge Jeandeau2, Serge Lacroix2, Eric Goarant2, Daniel San-
dron2, Christine Mouroux-Rotomondo2, Gérard Berthiot2, Pascal 
Thomas2, Michel Grivaux1
1Service De Pneumologie, Centre Hospitalier Saint Faron/France, 2Ser-
vice De Pneumologie, Centre Hospitalier/France
Background: Due to its high incidence and bad prognosis, lung 
cancer is a major health problem. In the 2000s, several social and 
scientific changes (such as decreased smoking, improved diagnosis 
methods, or the development of new drugs and therapeutic stra-
tegies) may have changed the epidemiology and prognosis of this 
cancer. The objective of the present study was to compare 1-year 
mortality in adult patients with primary lung cancer at a 10-year 
interval.
Methods: In 2000 and 2010, the French College of General Hos-
pital Respiratory Physicians (CPHG) performed 2 prospective 
multicenter cohort studies collecting information on all new cases 
of lung cancer diagnosed histologically or cytologically from 01 
January 2000 to 31 December 2000, and from 01 January 2010 to 
31 December 2010, and managed in the respiratory department 
of one of the participating general hospitals. A standardized form 
was completed for each patient. A steering committee checked 
recruitment exhaustiveness.
Results: 137 hospitals in 2000 and 104 hospitals in 2010 included 
respectively 5667 and 7051 patients. The 2 cohorts represented 
about 1 in 5 lung cancers diagnosed in France in 2000 and 2010. 
The characteristics of patients and lung cancer changed during 
the 10-year period in France. In 2010, compared to 2000, pati-
ents were older (mean (SD): 65.5 (11.3) years vs. 64.3 (11.5) years; 
p<0.0001), more frequently women (24.3% vs. 16.0%; p<0.0001) 
and more frequently never-smokers (10.9% vs. 7.2%; p<0.0001); 
they had a lower performance status score (PS) at diagnosis (PS 3 
or 4: 12.7% vs. 17.7%; p<0.0001); their tumor was more frequently 
an adenocarcinoma (45.4% vs. 29.0%; p<0.0001). One-year morta-
lity also changed, decreasing from 61.8% in 2000 to 56.4% in 2010. 
Multivariate analysis showed that the year of diagnosis was an 
independent risk-factor for death. Other independent risk-factors 
were older age, male sex, higher PS, active smoking, and small cell 
lung cancer (please see the table hereafter). 
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P2.22-006 RETROSPECTIVE ANALYSIS OF NON SMALL 
CELL LUNG CANCER PATIENTS SUBMITTED TO RESSEC-
TION OR RADIOSURGERY FOR BRAIN METASTASIS (BM) 
AT BRAZILIAN NATIONAL CANCER INSTITUTE
Clarissa Baldotto1, Ana Licia M. Silva1, Felipe Erlich2, A H I Garcês1, 
Luiz Henrique De Lima Araujo1
1Clinical Oncology, Instituto Nacional De Câncer/Brazil, 2Radiotherapy, 
Instituto Nacional De Câncer/Brazil
Background: Lung cancer is the leading cause of death from can-
cer in the world and 70 to 85% of these tumors are non-small cell 
(NSCLC) type. Up to 50% of patients have metastatic disease at the 
diagnosis, and the brain is one of the most common sites of me-
tastasis. Prognosis of patients with central nervous system (CNS) 
involvement is usually dismal and is determined by performance 
status (PS), systemic disease status and age. Recently there is a 
growing amount of evidence suggesting that aggressive treatment 
for patients with brain oligometastasis may improve prognosis.
Methods: In this retrospective cohort, forty-nine charts of patients 
with non-small cell lung cancer (NSCLC) metastatic to the brain 
and treated with neurosurgery (NS) or radiosurgery, between 1996 
and 2008, were reviewed at the Brazilian National Cancer Institute. 
The primary outcome was overall survival (OS), defined as the in-
terval from the diagnosis to death or last follow-up.
Results: Median age was 54 years (range 32-82), 61% were male 
and more than 95% had PS 0-1. Most patients were smokers 
(95.7%) and had adenocarcinoma (77.6%). Twenty-three patients 
(47.9%) presented with metastatic disease at diagnosis, and 13 
(38.8%) with BM upfront. Imaging for the diagnosis of BM varied 
between computed tomography (CT) (n=19;38.8%), magnetic reso-
nance (MRI) (n=12;24.5%), both CT and MRI (N=15;30.6%) and po-
sitron emission tomography (n=1;2%). Forty-three patients (87.8%) 
were submitted to NS and only one was treated with radiosurgery. 
Patients had more often single metastasis (84.8%), and none had 
more than three lesions. Most patients (80%) still received adjuvant 
whole brain radiotherapy (WBT) after NS. The median OS was 15.8 
months (95% CI 9.4-22.2).
Conclusion: Our data confirmed that compared to historical con-
trol patients with good PS and brain oligometastasis could derive a 
better survival when submitted to aggressive local therapy. In our 
center, until 2008 NS was the most common procedure used and 
adjuvant WBT was still frequently indicated.
Keyword: Non small cell lung cancer, Metastasis, Central nervous 
system, Surgery
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P2.22-005 CLINICOPATHOLOGIC CHARACTERISTICS OF 
LUNG CANCER ASSOCIATED WITH PLEURAL PLAQUES
Ryujiro Sugimoto1, Shoichi Kuyama2, Atsushi Shimoda1, Masa-
moto Nakanishi2, Takahiro Umeno2, Daisuke Nohjima2, Kazuhiko 
Kataoka1
1Thoracic Surgery, National Hospital Organization Iwakuni Clinical 
Center/Japan, 2Respiratory Medicine, Iwakuni Clinical Center/Japan
Background: In Japan, crocidolite had been used for asbestos 
cement pipe and spraying and amosite had been used for building 
board and spraying. These two types of asbestos had stopped 
to use in Japan in the late 1970s. Asbestos exposure will increa-
se the risk of lung cancer, mesothelioma and nonmalignant lung 
parenchymal and pleural disorders, including asbestosis, pleural 
plaques, pleural thickening, and pleural effusions. Asbestosis is a 
form of diffuse interstitial pulmonary fibrosis and pneumoconiosis 
caused by the inhalation of excessive amounts of asbestos fibers. 
By contrast, pleural plaques are the most frequent response to 
asbestos exposure, appearing even with low-dose, often intermit-
tent, exposures. Plaques occupy irregular, discrete areas on the 
parietal pleura and are often found as incidental chest radiogra-
phic findings. Therefore, radiographic evidence of pleural plaques 
in lung cancer patients indicates the history of asbestos exposure.
Methods: Between 2003 and 2011 in our hospital, there were 979 
patients in whom pleural plaque was confirmed by computed to-
mography (CT) scanning of the chest. Among those patients, 62 
were histologically diagnosed as primary lung cancer.
Results: Grouped according to sex, there were 61 men and an 
woman. The frequent histologic types of the cancers were ade-
nocarcinoma ( 21 patients ) and squamous cell carcinoma ( 22 pati-
ents ), followed by small cell carcinoma (8 paients). 16 patients had 
Stage1A disease, 8 patients had stage 1B disease, 3 patients had 
stage 2B disease, 8 patients had stage 3A disease, 6 patients had 
stage 3B disease and 21 patients had stage 4 disease. The medi-
an overall survival was 23.0 months and 1 year, 2 year and 5 year 
survival rate of all the patients were 56.0 %, 49.0 % and 23.7 %, 
respectively. Based on the primary treatment, 28 patients received 
surgery, 4 patients received radiation therapy, 5 patients received 
chemoradiotherapy, 19 patients received chemotherapy and 6 
patients received best supportive care. The median overall survival 
of the patients treated by surgery, radiation therapy, chemora-
diotherapy, chemotherapy, and best supportive care, were 96.0 
months, 40.9 months, 6.3 months, 8.4 months and 3.0 months, re-
spectively. Six patients showed radiographic findings of asbestosis 
accompanied with pleural plaques. Five patients received surgery 
and a patients received chemotherapy as a primary treatment, but 
the median overall survival of these 6 patients was as short as 6.5 
months.
Conclusion: Among the lung cancer patients associated with pleu-
ral plaques alone, early stage patients showed favorable progno-
sis. But the lung cancer patients in whom pleural plaque and as-
bestosis were detectable in chest CT showed poor prognosis even 
after diagnosis at early stage. Therefore, the early detection of 
lung cancer may contribute to a better outcome in the population 
which has pleural plaque alone, not accompanied with asbestosis.
Keywords: Lung cancer, asbestos, pleural plaque
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Results: The main study results are summarized in the table and 
figure. Patient characteristics changed over time, with patients in 
the 2006-2009 vs. 1991-1995 cohorts being older (26.1 vs. 17.5% 
aged ≥80 years), more patients being females (47.6 vs. 42%) and 
having stage IV cancer (74.1 vs. 64.7 %) at their first diagnosis. Me-
dian survival was 4.03 months for the 1991-1995 cohort and incre-
ased to 4.30, 4.62 and 4.98 months for the 1996-2000, 2001-2005 
and 2006-2009 cohorts. From the earliest (1991-1995) to the latest 
(2006-2009) cohort the 6-month and 1-year survival rates have in-
creased by 23% (from 37.4 to 46.0%) and 63% (from 16.6 to 27.0%) 
respectively. After adjustment for potential confounding factors, 
the 5-year hazard of death decreased by 11%, 21% and 30% res-
pectively for the patients diagnosed in 1996-2000, 2001-2005 and 
2006-2009 vs. those diagnosed in 1991-1995. 
 
Conclusion: The last 20 years witnessed a steady improvement 
in extending the survival of the patients ≥65years diagnosed with 
advanced NSCLC.
Keyword: non-small cell lung cancer, survival, temporal trends
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P2.22-007 SURVIVAL ADVANCEMENTS IN ADVANCED 
NON-SMALL CELL LUNG CANCER IN THE PAST 20 YE-
ARS: A STORY OF HOPE
Arliene Ravelo1, Annie Guerin2, Dominick Latremouille-Viau2, 
Raluca Ionescu-Ittu2, Eric Q. Wu3
1Genentech, Inc./United States Of America, 2Analysis Group/Canada, 
3Analysis Group/United States Of America
Background: New drug developments in the past decades have 
improved the prognosis of patients with advanced non-small cell 
lung cancer (NSCLC). This study aimed to quantify the change in 
5-year overall survival of patients ≥65years diagnosed with advan-
ced NSCLC from 1991 to 2009 in United States (US).
Methods: Patients aged ≥65years that were first diagnosed with 
NSCLC stage IIIB/ IV between 1991 and 2009 (n= 83,930) were 
identified in the Surveillance, Epidemiology and End Results 
database that collects data from several US cancer registries. 
Four cohorts were defined based on patients’ diagnosis year: 
1991-1995, 1996-2000, 2001-2005 and 2006-2009. For each co-
hort, median survival time from diagnosis and 6-month, 1-year, 
and 5-year survival rates were reported. The 5-year hazard 
of death was compared between cohorts using Cox multiva-
riable regression adjusted for age, sex, tumor ‘s differentia-
tion level, cancer stage and patient’s socio-economic status.
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No clinical or pathologic characteristic differences were observed 
between patients with or without family history of cancer. The pre-
sence of EGFR mutations was similar, although WLC patients with 
family history of cancer had a higher rate of exon 21 mutation. The 
median overall survival was significantly higher in WLC patients 
with family history of cancer and LC. Family history of cancer, es-
pecially of LC, might have a role in LC development and deserves 
further studies focused in inherited genetic alterations related with 
an increased susceptibility to LC.
Keywords: Familiy history of cancer, Lung Cancer in women
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P2.22-009 QUALITY IN LUNG CANCER CARE: THE DE-
VELOPMENT OF A POPULATION BASED LUNG CANCER 
REGISTRY
Robert Stirling1, Peta Mclaughlin2, Meera Senthuren2, Sue Evans2, 
Neil Watkins3, John Mcneil2
1Department Of Medicine, Monash University/Australia, 2Department 
Of Epidemiology & Preventive Medicine, Monash University/Australia, 
3Centre For Cancer Research, Monash Institute Of Medical Research/
Australia
Background: Lung cancer is the fourth most common cancer in 
Victoria and the leading cause of cancer mortality. Little local 
knowledge exists of the factors which influence outcome in lung 
cancer. A pressing need exists to describe regional structure, pro-
cess and outcome in lung cancer care to improve quality of care 
and to inform translational research and health care planning. We 
aim to develop and pilot a population-based lung cancer clinical 
quality registry to describe clinical assessment, diagnosis, staging, 
management and outcomes in lung cancer in Victoria.
Methods: The establishment of the Victorian Lung Cancer Registry 
Pilot Project commenced with the appointment of a Steering Com-
mittee to provide project governance. Review of current literature 
and evidence-based national and international clinical practice 
guidelines was undertaken by an expert working group. Included 
data items were epidemiologically sound, reproducible and valid. 
The data set enables the capture of identified quality indicators 
designed to describe the structural quality, process quality and 
indicators of outcome in lung cancer management. Case ascer-
tainment is derived from institutional ICD-10 coding of small and 
non-small cell lung cancer. Consent to recruitment to the registry 
occurs via an “opt-off” system. Follow up and outcome measures 
are collected 6 and 12 months after initial diagnosis capturing sur-
vival, treatment and quality of life assessments. Survival will be re-
confirmed at 2 and 5 years post diagnosis. Institutional recruitment 
was designed to sample from metropolitan public, metropolitan 
private and regional hospitals. A quantitative, case finding audit 
was employed to evaluate the case ascertainment methodology at 
a major metropolitan hospital.
Results: Ethics approval was received for 8 pilot sites and a me-
chanism for rapid case ascertainment and secure data transfer 
has been established. A web enabled data collection tool has 
been developed and data has been collected on 576 eligible and 
consenting patients. Evidence of distress screening was available 
for 13.02% of subjects. Diagnosis was confirmed < 28 days from 
referral in 56-86% of cases across institutions. A statement of 
ECOG status was available in 52.51% of cases and clinical T staging 
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P2.22-008 ANALYSIS OF FAMILY HISTORY OF CANCER 
IN WOMEN WITH LUNG CANCER (WLC) FROM THE  
SPANISH WORLD07 DATABASE
Margarita Majem1, Dolores Isla2, Pilar Garrido3, Enriqueta Felip4, 
Nuria Viñolas5, Angel Artal6, Enric Carcereny7, Rosario Garcia-
Campelo8, Pilar Lianes9, Ramon De Las Peñas10, Isabel Bover11, 
Silvia Catot12, Javier D. Castro Carpeño13, Ana Blasco14, Josefa 
Terrasa15, Jose Luis Gonzalez Larriba16, Vicente Alberola17, Oscar 
Juan18, Mariano Provencio19
1Medical Oncology, Hospital De La Santa Creu I Sant Pau/Spain, 2Medi-
cal Oncology, Hospital Clinico Lozano Blesa/Spain, 3Medical Oncology, 
Irycis,hospital University Ramon Y Cajal/Spain, 4Medical Oncology, 
Hospital Valle Hebron/Spain, 5Hospital Clinic/Spain, 6Medical Oncolo-
gy, Hospital Universitario Miguel Servet/Spain, 7Catalan Institute Of 
Oncology/Spain, 8Medical Oncology, Complejo Hospitalario A Coruña/
Spain, 9Hospital De Mataró/Spain, 10Oncology, Hospital De Castellon/
Spain, 11Oncology, Hospital Son Llatzer/Spain, 12Hospital Althaia/Spain, 
13Hospital Universitario La Paz/Spain, 14Department Of Medical Onco-
logy, Hospital General Universitario De Valencia/Spain, 15Hospital Son 
Espases/Spain, 16Medical Oncology, Hospital Clínico San Carlos/Spain, 
17Hospital Arnau De Vilanova/Spain, 18Hospital La Fe/Spain, 19Oncolo-
gy, Hospital Puerta De Hierro/Spain
Background: Gender differences in lung cancer (LC) have been 
reported, but with many unresolved issues . Family history of can-
cer might play an important role in lung cancer, especially in never-
smoker patients. The aim of this study was to analyze potential 
clinical, molecular and epidemiological differences between WLC 
with or without family history of cancer.
Methods: WORLD07 is a Spanish prospective, multicenter, epi-
demiologic female-specific LC database sponsored by ICAPEM, 
a professional association committed with WLC research. Clinico-
pathologic data, tumor genotype, family and personal history of 
cancer were collected and analyzed in order to detect differences 
between both groups.
Results: From October/2007 to November/2012, 2081 WLC were 
included in an e-database from 32 centers. Family history of can-
cer was common (49.4%, in first-degree was 77%), family history 
of lung cancer was present in 33%, of breast cancer in 25% and of 
colorectal cancer in 17%. No differences in median age of diagno-
sis of LC, previous hormonal therapy, number of children, menst-
rual status, tumor histology or stage at diagnosis were observed 
between WLC with or without family history of cancer. WLC with 
family history of cancer were ever smokers in a higher percentage 
(63% vs 56%, p=0.006), with no differences in passive smokers. The 
presence of EGFR mutations was similar in WLC with family history 
of cancer versus WLC without family history (38% vs 37%), although 
WLC patients with family history of cancer had a higher rate of 
exon 21 mutation (36% vs 28%), both in smokers WLC (32% vs 16%, 
p=0.220) and in never smokers WLC (43% vs 32%, p=0.094). The 
median overall survival was 25 months (CI95% 21.0-29.0) for WLC 
with family history of cancer and 22.0 months (CI95% 19.4-24.5) for 
patients without family history of cancer (p=0.027). Of note, the 
median overall survival was 34.8 months (CI95% 22.9-46.6) for WLC 
with family history of LC and 22.5 months (CI95% 20.5-24.5) for 
patients without family history of LC (p< 0.001).
Conclusion: The presence of familiar history of cancer in WLC 
patients included in the WORLD07 database was high (49.4%), 
being lung cancer the most common, followed by breast cancer. 
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proportion of sub types of lung cancers was not statistically dif-
ferent compared to national and world data. Only 11.2% of cases 
were diagnosed at early stage of the disease but surgical resection 
rate for early stage lung cancer was similar to international data. 
More than 50% of the patients with NSCLC and more than 80% of 
patients with SCLC received some form of Chemotherapy. More 
than 80% of patients received radiotherapy at some point of their 
treatment cycle. 10% with stage IV disease did not receive treat-
ment and 85% of patients of patients with late stage disease were 
referred to palliative care. Average mortality from lung cancer in 
Illawarra and Shoalhaven region was not statistically different to 
national data and international data. Only 42 % of cases were dis-
cussed in the Multi Disciplinary Team (MDT) Meeting.
Conclusion: This study confirms a higher incidence of thoracic 
malignancy in regional and rural Australia compared to metropo-
litan areas. A significantly higher percentage of lung cancer was 
diagnosed in late stage of disease compared to national and inter-
national data but outcomes were not statistically different. We also 
found that a significant proportion of the cases were not discussed 
in MDT meeting
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P2.22-011 RACIAL/ETHNIC VARIATION AMONG NON-
SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN THE 
UNITED STATES DEPARTMENT OF DEFENSE
Corey A. Carter1, Sacha Satram-Hoang2, Christina Brzezniak1, As-
hok Gunuganti2, Carolina Reyes3, Hans-Peter Goertz3, Christopher 
Gallagher1
1John P. Murtha Cancer Center, Walter Reed National Military Medical 
Center/United States Of America, 2Q.D. Research/United States Of 
America, 3Genetech, Inc/United States Of America
Background: Non-small cell lung cancer (NSCLC) comprises 87% 
of all lung cancer in the United States with the vast majority diag-
nosed in advanced stage. Military personnel have higher smoking 
rates compared to the general population and consequently an 
increased incidence of lung cancer. We set out to examine whether 
there were variations in smoking rates and outcomes among pati-
ents diagnosed with NSCLC, based on self described ethnicity, in 
the United States Military and their dependents who receive equal 
and open access to healthcare in the Department of Defense 
(DOD) medical system.
Methods: We identified 4,547 patients ≥18 years, with an initial 
diagnosis of NSCLC from January 2003- March 2013 in the DOD 
Cancer Registry and categorized into the following self described 
ethnic groups: Caucasian, African American, Hispanic and Asian/
Pacific Islander (PI). Differences in patient characteristics by race 
were compared using Chi-square and t-test. Kaplan Meier curves 
and Cox proportional hazards regression assessed overall survival.
Results: There were 3434 (76%) Caucasian, 533 (12%) African Ame-
ricans, 468 (10%) Asian/PI, and 112 (2%) Hispanics who met the 
study inclusion criteria. Mean age at diagnosis was highest among 
Caucasians (67 yrs) followed by Asian/PI (64 yrs), Hispanics (63 
yrs) and African Americans (62 yrs). A large majority of Caucasians 
(87%) and African Americans (86%) had a history of tobacco use, 
followed by Hispanics (74%) and Asian/PI (65%). Asian/PIs were 
also more likely to be female, married, have adenocarcinoma histo-
logy and were more likely to be sporadic cases (no family history) 
in 48.43% prior to treatment. A record of multidisciplinary team 
meeting presentation was available in 48.43% of cases. Curative 
surgery was provided for 27.78% of subjects, curative chemothe-
rapy <5% and curative radiotherapy < 5%. Curative surgery was 
provided < 14 days from diagnosis in 82-100% of cases. 30 day 
post curative surgery mortality was 3.12% following 160 curative 
surgical procedures.
Conclusion: Cancer registries have proven capacity for improving 
process in the delivery of cancer care and the ensuing outcomes. 
The development of rapid case ascertainment and “opt off” 
recruitment strategies appear viable and should ensure broad 
recruitment from eligible patients diagnosed with lung cancer in 
Victoria. For registries to inform quality of care and benchmark 
performance, high quality data is needed on all eligible cases. 
Our study has identified significant gaps in the documentation of 
this information in the patient’s medical record. Efforts to improve 
documentation are required to ensure that registries can perform 
their important function.
Keyword: Registry, lung cancer, quality, outcome
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P2.22-010 THE INCIDENCE, TREATMENT AND SURVIVAL 
OF LUNG CANCER IN A REGIONAL AUSTRALIAN  
CANCER CENTRE FROM 2006 TO 2011.
Andrew Jones1, Prabaharan Manoharan2
1Respiratory, Wollongong Hospital/Australia, 2Medicine/respiratory, 
Wollongong Hospital/Australia
Background: According to a Lung cancer report by The Austra-
lian Institute of Health and Welfare, between 2003 and 2007 the 
highest number of lung cancer diagnosed in New South Wales. 
The incidence of in lung Cancer in NSW was 59 per 100 000 po-
pulation, the second highest in Australia. This report also found 
that the incidence of lung cancer was higher in those living in outer 
regional, remote and very remote area compared to males living 
in major cities and inner regional areasAccording to a Lung cancer 
report by The Australian Institute of Health and Welfare, between 
2003 and 2007 the highest number of lung cancer diagnosed in 
New South Wales. The incidence of in lung Cancer in NSW was 
59 per 100 000 population, the second highest in Australia. This 
report also found that the incidence of lung cancer was higher in 
those living in outer regional, remote and very remote area compa-
red to males living in major cities and inner regional areas
Methods: Retrospective and descriptive study.
Results: In this study a total of 1245 new cases were included. 
Mean age at diagnosis was 70 years and 67% were men. 63 % of 
the cases were from the Illawarra region. The age adjusted in-
cidence of lung cancer in Illawarra region was 70.7/100,000 and 
42.5/100,000 for males and females respectively, which was not 
statistically different compared to the rest of Australia and the 
world. However, the age adjusted incidence for Shoalhaven region 
was 103/100,000 and 76.5/100, 000 for male and female respec-
tively which was higher and statistically significant compared to 
Australian data (P = 0.0239 for NSW and 0.0369 for Australia). 
Non-Small Cell Lung Carcinoma comprise 73% and 70 % of cases 
in the Illawarra and Shoalhaven region respectively. The incidence 
of pleural Mesothelioma was similar to rest of the Australia. The 
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sex, tumour stage, tumour morphology, emergency presentation, 
performance staus and co-morbidity by modelling deprivation 
category-specific relative survival.
Results: Preliminary results confirm that survival remains lower 
in patients with lung cancer from deprived areas of residence. In 
multivariate modelling, this finding does not seem to be explained 
by competing causes of death or stage of disease at diagnosis. 
The main explanatory variables seem to be performance status 
and treatment.
Conclusion: Preliminary analysis suggests that performance status 
and treatment are the most important explanations for the ‚depri-
vation gap‘ in survival from lung cancer in Scotland.
Keyword: survival deprivation Scotland
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P2.22-013 EVALUATION OF ELDERLY PATIENTS WITH 
NON-SMALL-CELL LUNG CANCER IN A PRIVATE CAN-
CER CENTER IN BRAZIL.
Tatiane Montella, Clarissa Baldotto, Luiz Claudio Thuler, Leticia 
Maciel, Mauro Zukin, Nelson Teich, Carlos Gil Ferreira
Clinical Research, Clinicas Oncológicas Integradas/Brazil
Background: At diagnosis approximately 25-40% of patients with 
non-small-cell lung cancer (NSCLC) are older 70 years. There is a 
scarcity of data on this elderly subpopulation. The aim of this study 
was to report clinical characteristics of this subpopulation, high-
lighting some challenges in their clinical management.
Methods: In this retrospective cohort, data from 631 patients with 
lung cancer diagnosed from 1995 to 2011 at a private Cancer Cen-
ter in Brazil were analyzed.
Results: At diagnosis, 33% patients (n=214) were older than 70 
years. Within this elderly group most patients (n=193; 90%) were 
classified as NSCLC and became the focus of our analysis. As 
expected, performance status (PS), staging and smoking were 
associated with survival (table1). Metastatic disease was present in 
60% of this subpopulation, and most patients had good PS (PS0-1: 
83%) and 84% were smokers. Additionally, 70% of this group with 
NSCLC had at least one comorbidity. The median overall survival 
time was 15 compared to 22 months for patients aged <70 years 
(p<0.001). In the metastatic group the majority of patients (62%) 
received only one cycle of chemotherapy (CT) and only 10% re-
ceived more than 3 cycles. Of note, in patients with stage II and III 
adjuvant CT was correlated with survival (14 months vs 69 months 
in no adjuvant CT and adjuvant CT group respectively; p=0,02), 
although this therapy was administered in only 30% of patients 
with stage II and 20% of those with stage III. 
compared to the other self described ethnic groups. Asian/PIs 
had significantly higher unadjusted overall survival (Log rank p = 
0.0012) and in the multivariate survival analysis, adjusting for age, 
sex, race, stage, histology, comorbidity, tobacco history, alcohol 
history, family history, and marital status, Asian/PI patients de-
monstrated a 20% lower risk of death (Table 1) compared to Cau-
casian patients. There was no difference in mortality risk between 
Caucasian and African Americans, and Caucasian and Hispanics.
Conclusion: In this military cohort, equal open access to care in 
NSCLC patients resulted in similar overall survival among Cauca-
sian, African Americans and Hispanics with significantly higher OS 
among Asian/PIs. Racial disparities in survival often seen in US 
civilian populations were not seen in this study of patients treated 
in the military health system, perhaps due to more equal access 
to health care. Continued research evaluating treatment patterns 
and outcomes in the military relative to the general population is 
warranted.  
Table: Cox Proportional Hazards Regression of Overall 
Survival
RACE N HR 95% CI
Caucasian 3434 ref
African American 533 1.001 0.89-1.12
Asian/Pacific Islander 468 0.803 0.71-0.91
Hispanic 112 0.984 0.77-1.26
Keywords: Overall Survival, Race
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P2.22-012 WORSE SURVIVAL OUTCOMES IN PATIENTS 
WITH LUNG CANCER FROM DEPRIVED AREAS OF RESI-
DENCE IN SCOTLAND: WHY?
Marianne C. Nicolson1, David Brewster2, Sharon Kennedy2, Ron 
Fergusson3, Richard Jones4, Robert Milroy5, Catherine Thomson2
1Oncology, Aberdeen Royal Infirmary/United Kingdom, 2Isd/United 
Kingdom, 3Respiratory Medicine, Royal Infirmary Edinburgh/United 
Kingdom, 4Beatson Oncology Centre/United Kingdom, 5Respiratory 
Medicine, Glasgow Royal Infirmary/United Kingdom
Background: Lung cancer survival remains poor with only modest 
progress in absolute terms in recent years. Survival has been lower 
in the UK than many comparable European countries. There is 
some evidence that this survival deficit is particularly apparent ear-
ly during follow-up. Within the UK, survival has been lower among 
deprived patients. Recent evidence suggests that this ‚derivation 
gap‘ in survival also predominates early during follow-up. Although 
early deaths could reflect advanced disease, previous research in 
both Scotland and England does not support the hypothesis that 
deprived patients with lung cancer present with more advanced 
disease.
Methods: Using Scottish lung cancer audit records linked to can-
cer registrations, hospital discharge records and mortality records, 
the aims of this project were 1) to describe patterns of survival 
from lung cancer by socio-economic position 2) to explore the 
influence of the ‚deprivation gap‘ in survival factors such as age, 
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P2.23-001 DOES DISSATISFACTION WITH BODY IMAGE 
IN ADOLESCENTS A DETERMINANT OF SMOKING BE-
HAVIOR?
Henrique C. Queiroga1, Diana Silva2, Julia A. Fernandes3, Ana 
Valente3, Claudia Dias4, Altamiro Costa-Pereira4, Caldas Afonso2, 
António Guerra2
1Pulmonology Unit, Centro Hospitalar S.joão/Portugal, 2Pediatric Ser-
vice, Centro Hospitalar S.joão/Portugal, 3Faculty Of Nutrition And Food 
Sciences/Portugal, 4Department Of Bioestatistics And Medical Informa-
tics/Portugal
Background: Smoking appears to start at ever earlier ages, occur-
ring in the great majority of adolescents between 13 and 15 years 
old. It is often associated with body image dissatisfaction and ea-
ting behaviors disorders. 
Objective: Assess tobacco consumption and its influence on body 
image dissatisfaction among high school Portuguese students, 
aged 15 and 19 years old.
Methods: Based on all students attending 3 high schools from 
the northern Portugal, the sample was randomly selected and 100 
students were recruited from each high school. The adolescents 
smoking behavior was evaluated according to a protocol adapted 
from the Global Youth Tobacco Survey (Centers for Disease Con-
trol and Prevention, 2001) and body image dissatisfaction was also 
assessed.
Results: The mean age of the total sample (n=285) was 16.6 ± 1.2 
years (min = 15, max = 19) and 46% were male. More than half 
(55.8%) were dissatisfied with their body image and had already 
started smoking (59.6%), with greater incidence among girls (54%). 
More than a half of these students who have tried smoking refer-
red that it had happened between 12 and 15 years old. In all the 
three schools, 41.1% of adolescents think that smoking leads to 
weight loss (EA = 40.4%; EB = 41.7%, EC = 41.2%). There was not 
found any association between body image dissatisfaction and 
onset of tobacco use (p=0.388), although a stronger association 
was seen between the wish to be thinner and the fact that they 
had tried smoking.
Conclusion: Tobacco consumption is increasingly associated with 
diet behaviors and body image dissatisfaction among adolescents, 
particularly in girls. Such behavior points to the need for an early, 
clarifying and effective educational intervention.
Keyword: adolescence, body dissatisfaction, tobacco
Conclusion: These data show that in this cohort elderly patients 
with NSCLC do constitute a special subpopulation with associa-
ted comorbidities. However, despite most of them had good PS 
at diagnosis, limited oncology treatment options were offered 
leading to suboptimal treatment. The fact that oncologists do 
not feel confortable to offer standard oncology treatment for this 
population may be due to the fact most of clinical trials exclude 
elderly patients. Although these data were generated in a private 
Cancer Center in Brazil we believe it mirrors the stiatuation across 
the country. These results highlight the urgent need for clinical 
trials focused on elderly patients, in order to provide a better care 
for those patients.
Keywords: erderly, Lung cancer, NSCLC
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P2.24-001 LUNG CANCER IN RURAL AND REMOTE AB-
ORIGINAL AND TORRES STRAIT ISLANDER COMMUNI-
TIES IN QUEENSLAND
Barbara J. Page1, Deb C. Hill2, Ian A. Yang3, Rayleen Bowman3, 
Kwun Fong3
1Indigenous Respiratory Outreach Care Program The Prince Charles 
Hospital, Queensland Health/Australia, 2Department Of Health, Indi-
genous Respiratory Outreach Care Program/Australia, 3Department Of 
Thoracic Medicine, The Prince Charles Hospital/Australia
Background: The status of lung cancer in rural and remote Abori-
ginal and Torres Strait Islander ( from this point referred to as Indi-
genous) communities in Queensland is unclear. It is not known how 
much of a problem lung cancer is in these communities nor how 
much awareness exists regarding lung cancer risk factors and early 
symptoms. Several factors contribute to the uncertainty of lung 
cancer status in rural and remote communities. Factors include 
the quality of reporting Indigenous status and cancer registration, 
cultural influences affecting treatment decisions, access to health 
services and availability of culturally appropriate lung cancer in-
formation resources . Research on lung cancer in rural and remote 
Indigenous communities in Queensland is needed to improve lung 
cancer diagnostic and referral pathways and develop culturally 
appropriate and effective lung cancer information resources. Study 
Aims: 1. Describe the local and regional health care facilities for 
Indigenous people who may be referred for suspected lung cancer 
across the state of Queensland. 2. Interview Indigenous people 
and health workers in 3 population sample groups from six rural 
and remote Indigenous communities in Queensland to identify if 
there are variations in patient flow relative to predicted utilisation 
of local and regional health care facilities.
Methods: 1. Using publically available information, identify 
relevant health care facilities including those with diagnostic 
bronchoscopy (with or without endobronchial ultrasound (EBUS) 
services across Queensland to predict expected referral pathways 
for suspected lung cancer. 2. Using quantitative and qualitative 
approaches to learn preferred referral pathways from 3 target po-
pulation groups including patients referred for medical treatment 
with symptoms suspicious of lung cancer or confirmed lung cancer, 
Indigenous health workers, Indigenous community members aged 
18 years and older. Frequency distributions in terms of the fol-
lowing will be analysed: demographics, current health status, soci-
al situation, access to health services, social and financial impact of 
treatment and information resources. Frequency distributions will 
be cross tabulated with age, education attainment, socio-econo-
mic characteristics, cultural influences, lung cancer awareness and 
knowledge. The responses to narrative questions will be analysed 
to identify main themes. These themes will be categorised by 
issues relating to lung cancer knowledge, cultural influences and 
beliefs, the patient experience and access to lung cancer medical 
and support services.
Results: We identified a spectrum of health care services across 
Queensland where patients may be referred for lung cancer ma-
nagement, ranging from public to private facilities. There are 
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P2.23-002 PROTECTING FROM SECOND HAND SMOKE: 
AN ASSESSMENT OF SHS EXPOSURE IN PUBLIC PLACES 
IN TWO STATES OF INDIA
Urvashi Kaushik1, Gaurang P. Nazar2, Amit Yadav2, Monika Arora2, 
Srinath K. Reddy2
1Health Promotion And Tobacco Control, Public Health Foundation Of 
India/India, 2Public Health Foundation Of India/India
Background: Lung cancer caused 1.37 million deaths in 2008 
worldwide, 71% of which are caused due to tobacco smoking. 
Secondhand smoke (SHS) exposure can lead to lung cancer. 60% 
of the global lung cancer deaths occur in low and middle income 
countries (WHO). Despite the existing prohibition on smoking in 
public places in India (Section 4, COTPA), the prevalence of SHS 
exposure is 40% in homes, 30% in workplaces and 17-48% in other 
public places. The objective of this study was to describe air qua-
lity through PM2.5 and air nicotine levels, as well as smoking beha-
vior, in public places and hospitality venues in two Indian states, 
Gujarat and Andhra Pradesh (AP).
Methods: A random sample of 400 public places was recruited; 
stratified into hospitality venues (N=200) and other public places 
(N=200). The air nicotine study was conducted in a subsample of 
38 venues out of those recruited. Air nicotine monitors were put 
in place for 1 week according to standard protocol. PM 2.5 side 
packs, indicative of ambient SHS, were used with 30 minutes spent 
each in several rooms including restrooms and offices at each ve-
nue. Median and range were reported as the data was skewed.
Results: Air Nicotine monitoring - Detectable levels of air nicotine 
were found in all building types. In Gujarat, the highest recorded 
air nicotine concentrations were found in Hospitals (3.319 ug/m3), 
however the highest median air nicotine concentration was recor-
ded in Tea Shops (0.214 ug/m3), followed by Railway Station, Wai-
ting Rooms and Restaurants. In AP, air nicotine was highest in Bars/
Pubs (median value: 4.445 ug/m3), followed by the Tea Shop and 
Hospitals. 90% of the hospitals monitored in Gujarat and 80% in 
AP registered smoking on the premises. PM2.5 monitoring – Over-
all, across the states, the highest median PM2.5 concentrations were 
found in recreational venues (44 µg/m3), followed by auditoriums 
(25 µg/m3) and offices (20 µg/m3). Transportation (19 µg/m3), hos-
pitals (15 µg/m3) and educational venues (14 µg/m3) also recorded 
PM2.5 concentrations. PM2.5 levels were significantly higher in places 
where smoking was observed. PM2.5 levels were significantly high-
er in hospitality venues as against other public places.
Conclusion: Concentration of tobacco smoke and nicotine was 
found in most public places including hospitals and government 
offices. Apart from violation of Section 4 of COTPA these results 
also suggest that the smoke-free policy as currently implemented 
is not effectively protecting the masses from SHS and the resulting 
adverse effects including lung cancer. There is an urgent need to 
strengthen compliance with smokefree laws at all levels, while pro-
vision of designated smoking areas should be removed from the 
law to ensure 100% protection from SHS.
Keywords: Second hand smoke, Monitoring for compliance 
strengthening, Tobacco Control and Lung Cancer, Air Quality Mo-
nitoring
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stages 1b (size >40mm) and 3a. 20 of these patients received ad-
juvant chemotherapy. Of the remaining 28 patients, four declined 
treatment, five were not medically fit enough for chemotherapy, 
and four developed cancer recurrence shortly after their operation. 
15 (54%) patients were mistakenly not offered chemotherapy when 
it may have been of potential benefit.
Conclusion: This audit would suggest lower utilisation of adjuvant 
chemotherapy than predicted, and no improvement in toxicity 
rates by reducing the dose of Cisplatin used per cycle. A higher 
likelihood of completing all planned chemotherapy was found. It 
highlights the prolonged waiting times to access chemotherapy 
and identifies barriers that inhibit suitable patients from accessing 
this important treatment. Several areas for improvement are iden-
tified. Our main recommendation would be to present all patients 
and review their pathology at multidisciplinary meeting following 
surgery. Our data is limited by its retrospective nature and small 
study population.
Keyword: adjuvant chemotherapy lung cancer
POSTER SESSION 2 - SUPPORTIVE CARE  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.24-003 THIRD-LINE THERAPY AND BEYOND FOR 
PATIENTS WITH ADVANCED/METASTATIC NON-SMALL 
CELL LUNG CANCER (NSCLC)
Jesus Corral, Carlos Robles, Maria Dolores Mediano, Amparo Sán-
chez Gastaldo, Miriam Gonzalez De La Peña, Miriam Alonso
Medical Oncology, University Hospital Virgen Del Rocio/Spain
Background: Lung cancer is the leading cause of cancer-related 
deaths globally, with a 15% 5-year survival rate. Platinum-based 
chemotherapy constitutes the main treatment modality, with a me-
dian overall survival (OS) of approximately 10-12 months. The cur-
rent National Comprehensive Cancer Network (NCCN) guidelines 
recommend several options for first-line and second-line therapies 
but endorse only erlotinib/gefitinib as third-line therapy in unselec-
ted patients, as well as crizotinib in ALK-positive selected patients.
The paucity of approved agents for third-line therapy and beyond 
for patients with non-small cell lung cancer (NSCLC) constitutes an 
important unmet medical need.
Methods: Retrospective analysis of 22 patients with advanced/
metastatic NSCLC in progression after a minimum of 3 lines of 
therapy.
Results: Between January 2009 and October 2012, 22 patients 
were analysed. Median age at diagnosis was 62 years old. 15% of 
patients were never smokers and 72.7% had non squamous NS-
CLC histology. Stage at diagnosis resulted: 6 (27.3%) stage IIIA, 3 
(13.6%) stage IIIB and 13 (59.1%) stage IV. 3 (13.6%) patients were 
EGFR mutation carriers and 1(1%) patient had ALK translocation. 
Third line therapy options resulted a clinical trial (27.3%), erlotinib 
(22.7%), paclitaxel/gemcitabine (13.6%), docetaxel (9.1%) and crizo-
tinib (4.5%). Estimated median progression-free survival (PFS) bet-
ween first and second line therapy was 5.3 months; PFS between 
second and third line resulted 4.4 months. Median PFS and overall 
survival (OS) beyond third line treatment has not been reached yet.
Conclusion: Currently, erlotinib/gefitinib and crizotinib, which 
target EGFR and ALK, are the only recommended agents for 
third-line therapy in patients with advanced/metastatic NSCLC. 
seventeen discrete Indigenous communities in Queensland. Com-
pared to the nearest health care facility which offer diagnostic 
bronchosopy, 5 discrete Indigenous communities are situated > 
200km away, 9 > 500km away and 2> 1000km away. Only one is 
situated 50km away.
Conclusion: The research findings will provide a clear understan-
ding of the affect of lung cancer in rural and remote Indigenous 
communities in Queensland. Knowledge gained from research will 
enable better health service planning and help reduce any health 
disparities experienced by Indigenous people; particularly those 
who live in less advantaged areas compared to other Australians 
when facing a diagnosis of possible or confirmed lung cancer.
Keyword: Indigenous, rural, remote, cancer
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P2.24-002 TOLERABILITY AND BARRIERS TO DELIVERY 
OF ADJUVANT CISPLATIN/VINORELBINE CHEMOTHE-
RAPY IN NON SMALL CELL LUNG CANCER
Abbey Jebb
Auckland City Hospital/New Zealand
Background: Adjuvant Cisplatin and Vinorelbine chemotherapy 
has been shown to improve overall survival for patients with resec-
ted non-small cell lung cancer. In the Auckland region, we admi-
nister 400mg/m2 of Cisplatin over 5 cycles in an attempt to reduce 
toxicity. The aim of this audit is to review the number of patients 
treated with this chemotherapy at our centre, assess the rates of 
toxicity, examine patient outcomes, and identify barriers to adju-
vant chemotherapy administration.
Methods: Patients starting Cisplatin and Vinorelbine between 
1 January 2008 and 31 December 2010 were identified by the 
Auckland Hospital oncology pharmacy department. Their clinical 
records were reviewed with respect to demographics, details of 
chemotherapy received, and toxicities encountered. Cancer outco-
mes were also analysed, including recurrence and mortality rates. 
Subsequently a review of our local thoracic multidisciplinary team 
meetings held over the same time period was undertaken to iden-
tify barriers to adjuvant chemotherapy access.
Results: A total of 29 patients received Cisplatin and Vinorelbine 
over the 3 years as adjuvant treatment for non-small cell lung can-
cer. 24 patients had stage 2 or early stage 3 cancer, four patients 
had stage 1B, and one patient had stage 4 cancer with an isolated 
brain metastasis which had been resected. 23 (79%) patients re-
ceived all planned cycles of chemotherapy. Five patients did stop 
early due to toxicity and one because of travel plans. The average 
number of cycles given was 4.58 and the average dose of Cisplatin 
received was 349mg/m2. The average time from surgery to chemo-
therapy initiation was 87 days. There were no treatment related fa-
talities in our group. 25 (86.2%) patients had at least grade 3 toxici-
ty requiring either dose reduction or deferral. The majority of side 
effects were haematological in origin. As of the 31/05/2013, 14 of 
29 patients have had cancer recurrences (48.3%) and 14 patients 
have died (48.3%), the lung cancer specific mortality was 37.9%. 
One patient has been lost to follow-up. One, two, and three year 
survivals were 89.7%, 79.3%, and 56% respectively. Over the three 
years examined, 48 patients discussed at our thoracic multidisci-
plinary meeting had resection of a primary lung cancer between 
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P2.24-005 ORAL EGFR TKIS AS FIRST LINE TREATMENT 
FOR NSCLC: EXPERIENCE FROM A TERTIARY CARE 
CENTRE IN NORTH INDIA
Digambar Behera, Navneet Singh, Gela Viswanath, Ashutosh N. 
Aggarwal
Pulmonary Medicine, Postgraduate Institute Of Medical Education And 
Research/India
Background: Therapeutic armamentarium for advanced NSCLC 
includes oral EGFR-TKIs. There is paucity of data from India on 
experience with oral EGFR-TKIs in newly diagnosed NSCLC. The 
current study sought to assess demographic profile and treatment 
outcomes for NSCLC patients receiving first line treatment with 
oral EGFR-TKIs at a tertiary care institute in North India.  
Methods: Retrospective analysis of data on newly diagnosed 
NSCLC patients initiated on treatment with oral EGFR-TKIs over 
a 4 year period (January 2008 to December 2011). Demographic 
characteristics, histology, disease stage and smoking status were 
noted. Radiological response to treatment was assessed using 
RECIST. Toxicity was graded as per Common Toxicity Criteria (CTC 
v3.0). Numerical and categorical data were compared between 
groups using Mann Whitney U test and chi-square test respec-
tively. Survival probabilities and median survivals were calculated 
by 
Kaplan-Meier method and group differences analyzed using the 
log-rank test.
Results: Of the 76 patients who comprised the study population, 
the percentage of males and current/ex-smokers was 67.1% (n=51) 
and 51.3% (n=39) respectively. Histological distribution was as fol-
lows: Adenocarcinoma 59.2% (n=45), Squamous cell 23.7% (n=18), 
NSCLC-NOS 11.8% (n=9) and Large cell carcinoma 5.3% (n=4). 
Majority of patients were in stages IV 64.5% (n=49) and IIIB 26.3% 
(n=20) while only 9.2% (n=7) were in stages I-IIIA. Malignant pleural 
effusion was present in 20 (26.3%) patients. Baseline Karnofsky 
performance status (KPS) was 80-100 in 25.5%, 60-70 in 42.6% and 
≤50 in 31.9%. Gefitinib (n=70, 92.1%) was the most frequently used 
EGFR-TKI. Most common indications for use of oral EGFR-TKI were 
poor PS/physiological status in 65.8% (n=50) and unwillingness for 
chemotherapy in 27.6% (n=21). Overall, 47 patients had atleast one 
follow up visit after one month and were eligible for assessment 
for response and toxicity. There were no complete responses while 
partial response (PR), stable disease (SD) and progressive disease 
(PD) were documented in 36.2%, 29.8% and 34.0% respectively 
of assessable patients. The most common side effects were skin 
rash and diarrhoea that developed in 17.0% and 10.6% of patients 
respectively. These were mild (grade 1/2) in all except one patient 
each with grade 3. Objective PR was observed in all (100%) pa-
tients with skin rash as compared to 23.1% among those without 
skin rash (p<0.001). Among patients without skin rash, the median 
OS was 178 days (IQR 53-320 days) while among those with skin 
rash the median OS had not been reached (figure 1). 
Real-world clinical practice reveals a variety of chemotherapeutic 
agents used in this setting. Additional systemic and/or targeted 
therapeutic under development, with complementary biomarker 
analysis, should be the key in identifying those patients most likely 
to benefit from newer agents.
Keyword: third line, advanced/metastatic, NSCLC
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P2.24-004 CHEST WALL TOXICITY FOLLOWING SABR 
FOR EARLY LUNG CANCER: A DOSIMETRIC ANALYSIS.
Pooja Jain, Rachel Brooker, John Littler, Alison Scott, Helen Wong
Clinical Oncology, Clatterbridge Cancer Centre/United Kingdom
Background: SABR is well established in medically inoperable 
patients with early lung cancer. These patients are usually elderly 
with multiple comorbidities. Chest wall toxicity is seen in 15% of 
cases, however in radiotherapy planning no chest wall constraints 
are used to minimise this risk. Some centres actively exclude the 
chestwall from PTV margin and some feel that the risk of sustaining 
a fracture is as high with 3 as with 5 fractions as rib is likely to be-
have similar to a serial structure.
Methods: Of the 85 patients treated with SABR from 2009 to 2013, 
cases with at least one year follow up were audited. Patients were 
treated with 18 Gy x 3# and 11 Gy x 5# on alternate days. Chest 
wall was defined as 3cm from the ipsilateral lung border excluding 
the skin. For the chest wall, the maximum dose and volume getting 
30, 40 and 50 Gy was recorded. Patients were followed up three 
monthly for the first year with CT imaging and toxicity was scored 
using CTCAE v3.0. Dosimetric parameters were correlated against 
chest pain and rib fracture.
Results: 50 patients with a median age of 70 (range 56-89) and 
follow up of 16.8 (range 1.2-44.9) months were audited. The majo-
rity (62%) of the patients had a PS of 2 and 66% had a T1 tumour. 
6 patients developed a rib fracture and patients complained of 
dysaesthesia/chest pain. One patient sustained fractures in three 
adjacent ribs at two different time points. The rate of any grade 
rib fracture and chest pain was 12% and 16% respectively with 
median time to development of respective toxicities of 15.6 and 
4.6 months. Grade 3 rib fracture was seen in one patient. All of the 
patients that sustained rib fracture/chest pain had SABR delivered 
over 5 fractions as the PTV overlapped the chest wall. Median sur-
vival is 34 months with a 1 year survival of 88%. No correlation was 
seen between rib fracture and chest wall dosimetric parameter. 
However chest pain correlated well to all dosimetric parameters.
Conclusion: Our series shows a similar rate of chest wall toxicity 
to that reported in the literature, which is largely less than grade 3 
in severity. However it is important to minimize this side effect as 
much as possible as the patient population currently being treated 
with SABR is elderly with multiple comorbidities. As the incidence 
of this toxicity is low, large patient data is needed to identify useful 
dosimetric parameters to predict chest wall toxicity. Developing 
SABR in the UK within the consortium structure with national gui-
delines opens up the potential to obtain and analyse such data. 
However there are logistical challenges of pooling data across 
various hospitals.
Keyword: SABR, lung cancer, rib fracture, chest pain
S1001Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 2 - SUPPORTIVE CARE  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.24-006 BRONCHIAL ASSOCIATED LYMPHOID TISSUE 
(BALT) LYMPHOMA - IS RITUXIMAB ALONE A VIABLE 
OPTION INSTEAD OF AGGRESSIVE LOCAL THERAPY 
AND HIGH DOSE CHEMOTHERAPY EVEN IN THE RE-
LAPSED SETTING FOR THIS RATHER RARE ENTITY?
Rajitha Sunkara, David Lee, Douglas Schnieder, Samaan Rafeq, 
Dorcas Chi
Hematology/Oncology, St. Elizabeth Medical Center/United States Of 
America
Background: BALT Lymphoma accounts for only 1% of Non 
Hodgkin’s Lymphoma leading to the paucity of randomized clinical 
trials to outline the treatment options (1). There are a few recently 
published case reports in the literature claiming success with sin-
gle agent rituximab therapy but none in the relapsed setting with 
repeat rituximab treatment.
Methods: A 67-year-old woman was initially diagnosed with BALT 
lymphoma involving the left lower lobe 10 years prior, for which 
she underwent wedge resection alone. Five years later, she deve-
loped recurrence with multiple bilateral lung nodules noted on her 
annual CT scan. She was then treated with chemotherapy using 
Rituximab, cyclophosphamide, vincristine and prednisone given 
for 12 cycles. She achieved completed remission. Her annual sur-
veillance CT scan four years later showed a left lower lobe lesion. 
Staging PET/CT scan showed isolated uptake in the left lower lobe 
lesion with SUV of 4.7 with no evidence of disease elsewhere. The 
biopsy showed recurrent BALT lymphoma. Immunostains were 
positive for CD20 and CD79a. Bone marrow biopsy showed no evi-
dence of lymphoma. She was then treated with four weekly doses 
of Rituximab at 375mg/m2. Follow up CT scan after completion of 
the treatment showed complete resolution of the left lower lobe 
Gender, histology and smoking status did not differ amongst 
patients with and without skin rash. However, skin rash occurred 
in 25.0% and 5.4% of patients with and without malignant pleural 
effusion (MPE) respectively (p=0.26). On multivariate logistic re-
gression analysis, only MPE was associated with occurrence of rash 
[odds ratio=0.19 (95% CI=0.04-0.95); p=0.04].
Conclusion: Oral EGFR-TKIs are a useful treatment option for clini-
cally selected patients with advanced NSCLC who have either poor 
PS or are unwilling for chemotherapy. Occurrence of skin rash has 
an independent association with objective treatment response and 
with better OS. Presence of MPE is associated with occurrence of 
skin rash.
Keyword: EGFR, TKIs, NSCLC, India
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among different regimens. Histotype, maintenance therapy (m) 
and quality of life (QoL) have been explored to improve patients 
(pts) outcome. The ERACLE trial (NCT01303926), a QoL-oriented 
phase III trial, was designed to compare the QoL for two CT regi-
mens.
Methods: Pts with stage IIIB/IV NS-NSCLC (ECOG 0/1) were ran-
domized (1:1) to receive first-line CT. Arm A received 6 cycles of 
Cisplatin (C) (75 mg/m2)/Pemetrexed (P) (500 mg/m2) q3w, followed 
by mP (500 mg/m2), while Arm B received Carboplatin (Cb) AUC 6/
Paclitaxel (T) 200 mg/m2 plus Bevacizumab (Be) 15 mg/kg q3w for 
6 cycles, followed by mBe 15 mg/kg. Both treatments were admi-
nistered until progression, unacceptable toxicity or death. Stratifi-
cation was based on Study Centre and disease stage. Co-Primary 
endpoints were EQ5D Index (EQ5D-I) and EQ5D-VAS (Euro-QoL 
questionnaire). Quality of life data were collected at three time 
points during the induction phase and at 12 and 18 weeks during 
the maintenance phase. Secondary endpoints were QoL over 
time, safety and activity of CT arms. A sample size of 49 pts per 
arm (that have not progressed during initial CT and during main-
tenance therapy for at least 12 weeks) would have 91% chance to 
have 12-point Minimal Interesting Difference (MID) between arms 
for EQ5D-VAS, and 87% chance to find 0.137 MID between arms 
for EQ5D-I. It is assumed that about 20% of pts in both arms ex-
perience progressive disease before the evaluation of the primary 
endpoint. The study sample was then increased to 118.
Results: From 1/2011 to 3/2012, 118 pts were randomized to Arm A 
(n=60) or Arm B (n=58). Baseline demographics were well balanced 
across arms; Arm A/Arm B male: 70%/77.6%, PS 0: 78.3%/79.3%, 
stage IV 95%/93%, smokers: 63%/52% . Seventy four pts (62,7%) 
received maintenance chemotherapy. Treatment differences (mean 
change from baseline), EQ5D-VAS = 1.82 (95%CI -8.60 to 12.24; 
P=0.73), EQ5D-I = 0.15 (95%CI 0.01 to 0.29), favoured arm A. Sa-
fety was as expected without relevant haematological toxicity and 
with a significant impact of G3/4 alopecia (p=0.002) and G 1-3 
neurotoxicity in ARM B (p=0.008) during induction. Response rates 
were (Arm A/Arm B) partial responses 40%/51%; stable disease 
48.3%/27.6%. The Hazard Ratio (HR) for Progression Free Survival 
Arm A/Arm B [Cox‘s analysis] was 0.62 (95%CI 0.41 to 0.95) p=0.03 
and HR for Overall Survival Arm A/Arm B [Cox‘s analysis] was 0.69 
(95%CI 0.61 to 1.04) p=0.08.
Conclusion: Arm A showed better (over the MID) health profile 
(EQ5D-I) as compared to Arm B. EQ5D-VAS didn’t find any sig-
nificant difference between treatment arms. By assuming equal 
activity, the choice of a treatment for advanced NSCLC should be 
mainly based on QoL.
Keywords: quality of life, Euro QoL, metastatic, maintenance
lesion. She was started on maintenance treatment with Rituximab 
to be given every 3 months.
Results: There are no set guidelines for treatment of BALT lym-
phoma but general consensus has been local therapy with either 
surgery or radiation for early stage disease, and chemotherapy 
for late stages. Also resection might not possible for patients 
with poor lung function (1). A phase II study of monoclonal anti-
body rituximab showed overall response rate of 73% (2). Several 
case reports also suggested completed remission (CR) with 4 to 
8 weekly doses of rituximab (3). However, high relapse rate of 
36% , observed in a phase II study (2) suggests that perhaps the 
4-weekly-doses regimen may not represent the best schedule. 
Recent meta-analysis showed improvement in the overall survival 
with maintenance rituximab treatment in the relapsed setting in 
patients with follicular lymphoma (4). Given that BALT lymphoma is 
a subtype of Non-Hodkins Lymphoma, we extrapolated the data 
to our patient and started her on maintenance treatment.
Conclusion: Although longer follow-up is needed in our case, the 
demonstration of minimal toxicity and considerable activity of this 
biologic agent in the relapsed setting is promising. 1. Ferraro P et 
al. Primary non-Hodgkin’s lymphoma of the lung. Ann Thorac Surg 
2000;69: 993-7. 2. Conconi A et al. Clinical activity of rituximab in 
extranodal marginal zone B-cell lymphoma of MALT type. Blood 
2003;102: 2741-5 3. Ahmet Bilici et al. Pulmonary BALT lymphoma 
successfully treated with eight cycles of weekly Rituximab: Report 
of first case and F-18 FDG PET/CT Images. J Korean Med Sci. 2011 
April; 26(4): 574–576. 4. Vidal L et al. Rituximab maintenance for 
the treatment of patients with follicular lymphoma: an updated 
systematic review and meta-analysis of randomized trials. J Natl 
Cancer Inst. 2011 Dec 7;103(23):1799-806.
Keyword: BALT lymphoma, rituximab, relapse, lung
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P2.24-007 FIRST-LINE PEMETREXED PLUS CISPLA-
TIN FOLLOWED BY MAINTENANCE PEMETREXED VS 
CARBOPLATIN-PACLITAXEL PLUS BEVACIZUMAB FOL-
LOWED BY MAINTENANCE BEVACIZUMAB (ERACLE) 
IN ADVANCED NON SQUAMOUS NON-SMALL CELL 
LUNG CANCER : A QUALITY OF LIFE-ORIENTED, MULTI-
CENTER RANDOMIZED PHASE III TRIAL OF THE GOIM 
(GRUPPO ONCOLOGICO ITALIA MERIDIONALE).
Domenico Galetta1, Salvatore Pisconti2, Saverio Cinieri3, Vittorio 
Gebbia4, Alessandro Morabito5, Nicola Borsellino6, Evaristo Maiel-
lo7, Antonio Febbraro8, Annamaria Catino1, Michele Montrone2, 
Angelo Nacci3, Giovanni Simone1, Andrea Misino1, Daniele Rizzi1, 
Giovanni L. Pappagallo9, Giuseppe Colucci1
1Medical Oncology, National Cancer Research Centre “Giovanni Paolo 
Ii“/Italy, 2Oncology, “G. Moscati“ Hospital/Italy, 3U.O.C. Oncology And 
Breast Unit, "antonio Perrino“ Hospital/Italy, 4La Maddalena Oncology 
Centre/Italy, 5Medical Oncology, Istituto Tumori Di Napoli/Italy, 6Medi-
cal Oncology Unit, Buccheri-La Ferla Hospital/Italy, 7Division Of Medi-
cal Oncology, “Casa Sollievo Della Sofferenza” Hospital/Italy, 8Division 
Of Medical Oncology, “Fatebenefratelli” Hospital/Italy, 9Clinical Trials 
Office, Department Of Medical Sciences, Azienda Ulss 13/Italy
Background: Chemotherapy (CT) for advanced non-squamous 
non-small cell lung cancer (NS-NSCLC) without oncogenic drivers 
remains palliative with suggested similar efficacy and survival 
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Conclusion: Every health professional engaged in cancer care has 
a responsibility to ensure work practice systems are optimised 
to ensure best patient outcomes. As a unique evidence- based 
online resource, eviQ contributes to reducing this variability. By 
harnessing the collective expertise of health care professionals in 
Australia, eviQ has developed an efficient, safe, quality national 
resource of evidence-based cancer treatment information for use 
at the point of care.
Keywords: evidence-based, cancer treatment protocols, online 
resource, eviQ
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P2.24-009 ATYPICAL CT FINDINGS IN A PATIENT WITH 
A BRAF V600E MUTATED PULMONARY LANGERHANS 
CELL HISTIOCYTOSIS (PLCH)
Ella Willenbacher1, Wolfgang Willenbacher1, Claudia Manzl2, And-
rea Brunner2, Renate Frank3, Judith Loeffler-Ragg4
1Haematology & Oncology, Medical University/Austria, 2Pathology, 
Medical University/Austria, 3Radiology, Medical University/Austria, 
4Pneumology/USPH, Medical University/Austria
Background: PLCH is an orphan disease of unknown etiology, 
occurring almost exclusively in smokers, histopathologically cha-
racterized by focal Langerhans cell granulomas infiltrating and des-
troying distal bronchioles and lung parenchyma. Unlike other types 
of histiocytosis, PLCH was considered to be a polyclonal disease, 
but recently the monoclonal presence of the BRAF V600E mutation 
was demonstrated in some patients.
Methods: A 51-year old caucasian male smoker was referred due 
to lymphadenopathy and disseminated, progressive, apical accen-
tuated pulmonary nodules (up to 12 mm) with beginning cavitation 
on CT-scans and elevated 18F-FDG uptake on PET/CT. The patient 
negated any B symptoms, while complaining of frequent coughs. 
Lung function tests showed a worsening restrictive pattern He-
matological work up proved the diagnosis of a stage IV A SCL-
NHL with marrow infiltration by a CLL-like lymphocyte population 
(Matutes score 4/5).No extrapulmonary involvement of PLCH was 
observed. Due to the CT findings suspicious of infectious disease, 
lymphoma infiltration or metastasis a CT-guided lung biopsy was 
performed. For BRAF analysis DNA was extracted from formalin-
fixed paraffin-embedded lung biopsies and subsequent pyrose-
quencing.
Results: The biopsy revealed a granulomatous infiltration with 
CD1a positive Langerhans cells, molecular analysis confirmed a 
BRAF V600E mutation. Treatment with steroids and nicotine abs-
tinence was initiated with impressive regression of pulmonary no-
dules after 1 month of therapy, as well as a decrease of F-18 FDG 
uptake on PET-CT. Lung function returned to normal.
Conclusion: PLCH should be considered in smokers with upper 
lobe predominant small nodules associated with cysts on high-
resolution CT scans. These characteristic radiologic features are 
sufficient to establish a presumptive diagnosis. In case of doubt a 
lung biopsy should be performed. Our patient did not show typi-
cal PLCH HRCT aspects, presenting with large randomly distribu-
ted pulmonary nodules (up to 12 mm). The histological diagnosis 
of PLCH was clinically unexpected. The FDG uptake is compatible 
with this diagnosis, but unspecific. Predominant nodular patterns 
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P2.24-008 EVIQ - A WEB BASED, POINT OF CARE 
TREATMENT RESOURCE - ITS ROLE IN LUNG CANCER
Lisa King, Catherine Johnson, Natalie Cook, Aisling Kelly
Eviq, Cancer Institute New South Wales/Australia
Background: eviQ Cancer Treatments Online, launched in Octo-
ber 2009, is a Cancer Institute NSW flagship program. Its primary 
remit is to improve service delivery, standardise cancer treatment 
and improve patient outcomes. The primary audience is health 
professionals involved in delivering cancer care. Tailored infor-
mation is also available for people with cancer and their carers, 
and other non-cancer health professionals. This open-access, 
web-based repository provides approximately 600 peer-reviewed 
cancer treatment protocols designed to support the way in which 
cancer care is implemented. eviQ treatment protocols and nursing 
resources provide detailed and extensive instructions on how to 
deliver evidence-based cancer treatments safely and appropriate-
ly. Provision of eviQ information promotes equity of access to the 
same information across rural, remote and metropolitan settings. 
eviQ provides reference standards that support the measurement 
and reporting of cancer treatment delivery to further determine 
strategies to reduce variation and improve patient outcomes.
Methods: Treatment protocols are developed according to the 
eviQ Governance Framework. Content specific reference commit-
tees, made up of clinical experts, discuss and review protocols at 
face to face meetings, and endorse them for publication on the 
site. Content is reviewed and updated in accordance with strict 
risk stratification criteria. This work is underpinned by the use of a 
tailor-made bibliometrics system, ensuring that the latest publis-
hed evidence drives protocol development.
Results: eviQ includes a mechanism to record de-identified usage 
of the website. Usage has increased significantly; from 1932 in 
December 2009 to 27,853 (2,386 international) registered users in 
May 2013. Registered users by primary role: Australia (+ internati-
onal) 
• Medical 4,192 (+ 536)
• Nursing 11,377 (+653)
• Radiation therapy 1,031(+185)
• Allied Health 840 (+38)
• Other 4,889 (+486)
There are currently 31 chemotherapy and 7 radiation respiratory 
cancer treatment protocols available on the site which were last re-
viewed and updated in 2012. The most frequently accessed respi-
ratory treatment protocols (NSCLC carboplatin & gemcitabine and 
SCLC cisplatin & etoposide) are visited on average over 1000 times 
per month (based on figures from 2012-2013), this being compa-
rable to similar breast treatment protocols (adjuvant adriamycin & 
paclitaxel and docetaxel & cyclophosphamide). Statistics confirm 
eviQ is accessed by a wide range of users in both public and pri-
vate health care settings. eviQ is utilised in the tertiary setting as 
a teaching tool, further embedding the use of evidence based 
practice in the clinical setting. Independent evaluation undertaken 
in 2012 concluded eviQ is an easily usable, quality resource that 
supports evidence based practice in cancer care.
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noclonal anti body maintenance- 2 pts, premetreksed maintence-7 
pts, taxenes maintenance- 8 pts. 
Patients recieved from 1 up to 4 lines of treatment. Median survival 
time was 34 months.
Conclusion: Survival time depends on various factors including 
usage of targeted drug therapies and maintenance treatment. 
Good performance status during treatment initialization still is one 
of the most important prognostic factors.
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P2.24-011 LEFT VENTRICULAR THORMBOSIS DUE TO 
CHEMOTHERAPY USING BEVACIZUMAB FOR LUNG 
CANCER.
Kazuhiro Yanagihara1, Hidekazu Tachi2, Toru Tanaka2, Shinya Ito2
1Medical Oncology, Kansai Electric Power Hospital/Japan, 2Thoracic 
Surgery, Kansai Electric Pawer Hospital/Japan
Background: Thoromboembolism has been reported as one of 
side effects of bevacizumab (BEV). An occurrence frequency of 
venous thoromboembolism caused by BEV is 0.2%. Specifically, 
it increases to approximately 4% within 1 to 3 months soon after 
chemotherapy. However, a ventricular thormbosis caused by BEV 
has almost never reported as far. We report a case of a ventricular 
thormbosis that occurred during chemotherapy using BEV for the 
lung cancer.
Methods: (case) 55 year-old, Japanese woman, who suffered 
myocardial infarction at 27 year-old and had a history of smoking 
(B.I.:350), complained of left.hemiplegia for brain tumor at first. Af-
ter surgical treatment for brain tumor, she was diagnosed as lung 
adenocarcinaoma, cT1aN3M1b stage IV and was referred to our 
hospital. The first line pemetrexed(500 mg/m2) / carboplatin (AUC 
6) /BEV (15 mg/kg) chemotherapy for two cycles every 3 weeks was 
performed. A partial response was found in the initial computed 
tomography (CT) evaluation, whereas the examination showed a 
thrombus of 26 × 25 mm in diameter in the left ventricle. D-dimer 
is 2.0 µg / mL at this point (D-dimer before treatment is 1.5 µg 
/ mL). The anticoagulation therapy by using heparin continuous 
infusion and sequential oral agent therapy of warfarin and aspirin 
reduced the thrombus to 11 × 22 mm in diameter.
Results: (Discussion) Thromboembolism is clinically diagnosed 
by clinical findings, ultrasonography, contrast CT, and D-dimer. 
D-dimer is a simple indicator even for asymptomatic thrombus 
formation and has been reported to be valid for the evaluation of 
thrombus formation. In this case, D-dimer value was almost con-
served through this event. We cannot be undeniable the relation 
the chemotherapy including BEV and left ventricular thrombosis. 
Also, since there is no evaluation of left ventricular function before 
chemotherapy treatment, it can not be denied the possibility of 
thrombus formation by reduced left ventricular function.
Conclusion: (conclusion) We have experienced a case that develo-
ped ventricular thrombosis during chemotherapy for lung cancer. It 
is believed to be evaluated, such as ultrasonography before using 
BEV in the case passing a long period of time after myocardial 
infarction.
Keywords: Left ventricular thormbosis, chemotherapy, Bevaci-
zumab
of PLCH have been described and may determine the early phase 
of the disease, whereas cystic patterns prevail later on. To the best 
of our knowledge, it has still to be determined how cystic lesions 
are formed, and how rapidly the dynamics of lung parenchymal 
abnormalities evolve. We demonstrate within a surprising short cli-
nical course progressive nodular lesions, beginning with cavitation 
and partial regression after one month of therapy. Low incidence 
and spontaneous recovery of PLCH hamper the performance of cli-
nical trials. Glucocorticoid therapy is successful only in a subgroup 
of patients and is advocated on empirical grounds in the treatment 
of nodular PLCH to accelerate the resolution of inflammation. 
Because of the predominantly macronodular pattern our patient 
received steroids in addition to nicotine abstinence and showed 
impressing regression within one month. The long-term impact of 
this strategy in BRAF V600E positive PLCH patients and the pos-
sible superiority of a targeted therapy with vemurafenib remain to 
be elucidated. But early therapeutic intervention, before conversi-
on into cystic stages of PLCH may have the largest benefit.
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P2.24-010 ADVANCED NON SMALL LUNG CANCER 
LONG TERM SURVIVORS - CLINICAL DATA ANALYSIS. 
SINGLE CENTER EXPERIENCE
Ewa Chmielowska, Maciej Studzinski, Anna Krause, Mariusz Kwi-
atkowski
Clinical Oncology, Oncology Center/Poland
Background: Patients with advanced non-small cell lung cancer 
are qualified to chemotherapy treatment with palliative intentions. 
Median survival time of those patients is 10 months and 24% live 
longer than 12 months. Current treatment modalities with tar-
geted drugs and maintenance treatment extend survival time in 
limited group of patients beyond 24 months.The aim of the paper 
is to analyze selected patient-related factors, tumor factors and 
treatment regimens among patients who survived more than 24 
months.
Methods: 47 patients selected among 390 patients with advanced 
non-small cell lung cancer whose data were previously presen-
ted on WCLC 2011, not qualified to radical chemoradiotherapy 
treatment, who survived more than 24 months. Patients were 
treated with various platinum-based chemotherapy regimens 
– CDDP+Navelibine, CDDP+Gemcitabine, CDDP+Pemetrexed, 
Paclitaxel+Carboplatin and targeted drugs like erlotinib, gefitinib 
and bevacizumab. Usage of specific treatment regimen depended 
on clinical situation. 
 
Retrospective analysis of selected host factors, tumor factors and 
treatment regimen.
Results: Host-dependent factors: sex – 30 women, 17 men, age – 
range 39-67, median age 58 yrs, stage – IIIB – 15 patients, IV – 21 
pts, reccurence after radical treatment – 9 pts; active smokers – 11 
pts, former smokers – 32, non-smokers – 4; ECOG performance 
status – 0 – 32 pts, 1 – 15pts. 
Tumor-related factors: NSLC subtypes – not-otherwise specified – 
28 pts, adenocarcinoma – 14, squamous cell carcinoma – 5 pts. 
Number of metastatic sites – 1- 30 pts, 2 – 17 pts; Metastatic loca-
tions – bone – 17 pts, lymph nodes – 20 pts, liver – 21 pts, brain – 0 
pts. 
Treatment related factors – antyEGFR treatment – 6 patients, mo-
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(NSCLC). Here we report safety and efficacy data from open label, 
phase IV trial of erlotinib in Croatian population.
Methods: Patients with advanced NSCLC who had failed prior 
chemotherapy were treated with oral erlotinib 150 mg daily until 
disease progression or unacceptable toxicity.
Results: A total of 384 patients (276 men and 108 women, mean 
age 62) with advanced NSCLC were enrolled in the study from 
2006 to 2012 in 10 centers in throughout Croatia. Patient charac-
teristics: Non-squamous NSCLC had 57% of patients, squamous 
NSCLC 32% and NOS 11%; active smokers 41%, former and/or ne-
ver smokers 57%; ECOG 0 36%, ECOG 1 54%, ECOG 2 7%, ECOG 
3 1%. Most of the patients (83%) received erlotinib in third line of 
treatment. Progression-free survival (PFS) was 2,3 months showed 
trend to improved PFS in patients with squamous compared to 
non-squamous NSCLC (3,7 vs. 2,1 months). PFS in non-smokers 
was longer than in smokers (2,6 vs. 2,1 months). Disease control 
rate after two cycles of treatment was 40%; most patients had sta-
ble disease. Most common adverse event (AE) was rash which de-
veloped in 58% of patients and diarrhea in 28%. Most of AEs were 
grade I and II. Grade III rash developed only in 10% of patients.
Conclusion: These data confirmed favorable efficacy and safety 
profile even in non-selected NSCLC Croatian patients, including 
patients with squamous cell lung cancer.
Keyword: erlotinib, squamous-cell lung cancer, rash, efficacy
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P2.24-014 PRIMARY LUNG CANCER COEXISTING WITH 
LUNG METASTASES FROM OTHER MALIGNANCIES
Noritoshi Nishiyama, Nobuhiro Izumi, Shinjiro Mizuguchi, Shoji 
Hanada, Hiroaki Komatsu, Hidetoshi Inoue, Hiroko Oka, Satoshi 
Okada, Kantaro Hara
Thoracic Surgery, Osaka City University Hopspital/Japan
Background: Various tumors metastasize to the lung and they are 
often detected as multiple nodules. Regardless of recent advances 
in computed tomography for detecting small pulmonary nodules 
and ground-glass opacity components which indicate possible 
primary lung cancer, preoperative differential diagnosis of either 
metastatic or primary lung cancer is usually difficult.
Methods: Four cases of such multiple lung metastases that co-
existed with primary lung cancer were retrospectively examined: 
in three of the cases (case 1 is a myxoid liposarcoma in the right 
thigh, case 2 is a colon cancer, and case 3 is a renal cell carcinoma), 
a pulmonary metastasectomy revealed that one of the tumors was 
primary lung cancer. In case 4, the patient had a proven lung can-
cer that was combined with small nodules in the ipsilateral lung, 
one of which was pathologically diagnosed as a metastasis from 
rectal cancer.
Results: In case 1, the patient was diagnosed with clinical stage IA 
primary lung cancer (a well differentiated adenocarcinoma in the 
left lower lobe), and a left lower lobectomy was performed 17 days 
after the initial surgery. In case 2, a postoperative pathological 
examination revealed that one of the resected pulmonary tumors 
in the left upper lobe, measuring 5 mm in diameter, was Noguchi 
type B bronchioloalveolar carcinoma. In case 3, two nodules in the 
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P2.24-012 PUBLIC ATTITUDES ABOUT LUNG CANCER: 
STIGMA, SUPPORT, AND PREDICTORS OF SUPPORT
Jared Weiss1, Briana Stephenson2, Lloyd Edwards2, Maureen Rig-
ney3, Amy Copeland3
1Hematology And Oncology, Lineberger Comprehensive Cancer Center 
At The University Of North Carolina/United States Of America, 2Biosta-
tistics, University Of North Carolina/United States Of America, 3Lung 
Cancer Alliance/United States Of America
Background: Lung cancer is the leading cause of cancer death yet 
public engagement with efforts against lung cancer is low. Public 
engagement with a cancer is critical to efforts to combat it yet the 
reasons for low support for efforts against lung cancer have not 
been systematically characterized.
Methods: We conducted a telephone survey of 1,071 people to 
determine levels of engagement and attitudes that might poten-
tially drive engagement. These were then analyzed by univariate 
and multivariate analysis.
Results: 8% of participants were involved with a lung cancer 
organization and 12% chose it among cancers to receive more 
support. Most participants felt that lung cancer was principally 
caused by external factors, that it could be cured if caught early, 
and that lung cancer patients were at least partly to blame for their 
illness. In multivariate analysis, participants who were supportive 
in some way of efforts against lung cancer were more likely to be 
employed, live in suburbia, and to be unsure of the cause of lung 
cancer. Potential supporters were more likely to be employed, 
female, younger, have higher income, to believe that genetics is 
the primary cause of lung cancer and to believe that lung cancer 
can be cured when caught early. Participants frequently noted that 
they supported a particular cancer because of knowing someone 
affected. Full demographic, univariate, and multivariate data will 
be presented.
Conclusion: As the lung cancer movement attempts to grow and 
increase its impact, the most successful recruitment efforts will be 
targeted to these groups.
Keyword: stigma, support, engagement
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P2.24-013 EFFICACY AND SAFETY OF ERLOTINIB IN 
CROATIAN PATIENTS
Marko Jakopovic1, Branka Cucevic1, Sanja Plestina1, Marta Korsic1, 
Neven Rakusic1, Zarko Vrbica2, Miranda Canadic3, Damir Gugic3, 
Miroslav Samarzija1
1Department For Respiratory Diseases Jordanovac, University Hospital 
Center Zagreb/Croatia, 2General Hospital Dubrovnik/Croatia, 3Univer-
sity Hospital Center Osijek/Croatia
Background: Erlotinib is inhibitor of epidermal growth factor re-
ceptor tyrosine-kinase activity that has been shown to significantly 
increase survival, delayed symptom progression and improve qua-
lity of life in previously treated advanced non-small cell lung cancer 
S1006 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
WALCE started its collaboration with “La forza e il sorriso – L.G.F.B. 
Italia” in 2009. From March 2009 to June 2013, 68 make-up work-
shops were organised at the San Luigi Hospital (Orbassano, Italy) 
in collaboration with five local cancer centres. 487 ladies attended, 
guided by 7 voluntary beauticians, with the support of a psycho-
oncologist. - Relaxation technique sessions may be helpful to 
face with stress. They are intended to promote physical, emotional 
and mental relaxation to get a better recovery of energies. From 
March 2012 to May 2013, 12 sessions were organised and 28 peop-
le attended. - Natural cooking classes are a good opportunity for 
patients and caregivers to learn that the health is closely related 
with nutrition and actively get involved during the preparation of 
food. The natural cuisine plays a key role in healthcare and these 
lessons provide useful tips for a balanced diet. Participating in 
these classes can empower people affected by cancer to learn 
vital skills that enable them to regain control, reduce isolation and 
restore hope. - Mindfulness Based Intervention (MBI) based on 
the assumption that a non-judgmental awareness and acceptance 
of one’s moment-to-moment experience have an effect on the dis-
tressing tendencies to escape from or to over-engage with one’s 
disturbing feelings, emotions and thoughts. MBI can positively 
impact on coping strategies and on the adaptation to the disease, 
by encouraging patients to relate differently to their physical and 
psychological symptoms.
Results: NOT APPLICABLE
Conclusion: Cancer patients tend to cope better with the illness 
and daily-life when self-confidence is regained. The sense of well-
being shared in a relaxed atmosphere a acknowledging social, 
emotional and psychological needs, whilst being amongst other 
people with the same fears or anxieties, is an incentive to fight 
against cancer. It is important to know that there are ways to re-
lieve the discomfort of most treatment-related side effects and to 
prevent them from becoming severe.
Keyword: advocacy, emotional support, self esteem, relieve the 
discomfort
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P2.24-016 WHY DO WE TREAT LUNG CANCER PATIENTS 
WITH CHEMOTHERAPY UNTIL THE END OF LIFE?
Fabio C. Lopes1, Nuno Guerra2, Manuel Machado2, Igor Gloria2, 
Maria Brilhante1, Carlos Carvalho1, Sofia Braga3
1Oncology Unit, Hospital Professor Doutor Fernando Da Fonseca/Por-
tugal, 2Departamento Ciências Biomédicas, Universidade Do Algarve/
Portugal, 3Jose De Mello Saude/Portugal
Background: We have previously characterized chemotherapy 
(CT) administration in the end of life (EOL) of solid tumor patients 
(pts) and found that close to 40% of them are treated with CT in 
the last month of life (LMOL). With this work we want to under-
stand the reasons for CT administration in the EOL and chose lung 
cancer as a model.
Methods: We used a population of dead lung cancer pts that were 
treated by one oncologist in one hospital from 2004 to 2012. The 
oncologist was blinded to study design, data collection and analy-
sis. We collected data retrospectively in the pt clinical charts and 
hospital electronic medical records. For group comparisons we 
used Chi square and Mann-Whitney tests and logistic regression 
right lower lobe increased in size. An intra-operative pathological 
examination revealed that one of the pulmonary tumors in seg-
ment S9 measuring 7 mm in diameter was adenocarcinoma, and 
the other tumor in segment S8 located deeply near the pulmonary 
artery. Subsequently, a right lower lobectomy was performed. A 
postoperative pathological examination revealed that the tumor 
in segment S9 was Noguchi type A bronchioloalveolar carcinoma, 
and the other tumor measuring 8 mm in segment S8 of the resec-
ted lobe was metastatic clear cell carcinoma from renal cell carci-
noma. In cases 2 and 3, the patients were diagnosed with clinical 
stage IA primary lung cancer and no additional treatment for lung 
cancer was required. In case 4, the patient, who had a history of 
rectal cancer, underwent left upper lobectomy with mediastinal 
lymph node dissection, combined with partial resection of the left 
lower lobe. A postoperative pathological examination using immu-
nohistological staining revealed that the nodule in the left lower 
lobe and a hilar lymph node were metastasis from lung cancer 
(pT4N1M0, stage IIIA). The remaining nodule besides the tumor in 
the left upper lobe was diagnosed as metastasis from rectal can-
cer. The patient recovered uneventfully and was discharged with 
a treatment plan involving postoperative chemotherapy for lung 
cancer.
Conclusion: Possible coexistence of primary lung cancer should be 
considered in multiple metastases from other organs. On the other 
hand, the stage of the lung cancer depends on a definitive tissue 
diagnosis of the coexisting small nodules, and the importance of 
active tissue diagnosis including surgery should therefore be em-
phasized, especially in patients with previous malignancies.
Keywords: metastatic pulmonary tumor, pulmonary resection, 
surgical diagnosis, lung cancer diagnosis
POSTER SESSION 2 - SUPPORTIVE CARE  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.24-015 THE ROLE OF WALCE (WOMEN AGAINST 
LUNG CANCER IN EUROPE) IN HELPING PATIENTS AND 
THEIR CAREGIVERS TO COPE WITH CANCER.
Stefania Vallone1, Raffaella Ronchetta1, Maria Vittoria Pacchiana2, 
Simonetta Rapetti2, Benedetta Crida2, Simona Carnio2, Sara Demi-
chelis2, Elisa Gobbini2, Gianluca Fora2, Silvia Novello2
1Walce/Italy, 2Department Of Oncology, University Of Turin/Italy
Background: The diagnosis and treatment of cancer are traumatic 
events for patients with cancer and their families. It can be a time 
of a emotional distress for both and can evoke a wide range of 
emotions related to poor quality of life. The expression of these 
feelings is crucial in order to cope with a diagnosis of cancer and 
with treatment side effects and any action where people perceive 
that they’re moving those feelings outside may be beneficial to 
them emotionally and physically. Even patients who receive the 
best support from family and friends may need to connect with 
other patients, who are facing the same challenges. Patients may 
seek emotional and/or practical support from cancer patient orga-
nizations and find programs designed with the aim to help them 
and their families to alleviate the emotional concerns.
Methods: During the last five years, WALCE addressed their emo-
tional care needs designing programs to ameliorate the cancer 
patient quality of life during the treatments. These projects are 
addressed to caregivers too and are observational studies. - The 
Look Good ... Feel Better® is active in 25 countries worldwide. 
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vement of neurological symptoms of paralysis. It was possible to 
maintain a relatively well ADL.
Conclusion: There may be an excessive burden to perform the 
surgery for the patients with vertebral metastasis in advanced lung 
cancer, the surgery for selecting patients may have been able to 
improve neurological symptoms such as paralysis. Therefore, we 
thought that the surgical procedure for the patients who are pos-
sible to survive long term period might have been one of the im-
portant treatment methods because of maintaining possibly their 
ADL well.
Keywords: vertebral metastasis, Lung cancer, posterior spinal 
fixation
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P2.24-018 PRIMARY MEDIASTINAL CASTLEMAN‘  
DISEASE; SURGICALLY CURABLE ANEMIA: A CASE  
REPORT
Si Young Choi1, Young Du Kim2, Yong Hwan Kim1, Deog Gon Cho3, 
Chan Beom Park4, Sang Young Roh5, Sook Hee Hong5, Ok Ran Shin6
1Thoracic And Cardiovascular Surgery, Uijeongbu St. Mary’s Hospital, 
The Catholic University Of Korea, College Of Medicine/Korea, 2Thoracic 
And Cardiovascular Surgery, Bucheon St. Mary’s Hospital, The Catholic 
University Of Korea, College Of Medicine/Korea, 3Thoracic And Cardio-
vascular Surgery, St. Vicent Hospital, The Catholic University Of Korea, 
College Of Medicine/Korea, 4Thoracic And Cardiovascular Surgery, 
Incheon St. Mary’s Hospital, The Catholic University Of Korea, College 
Of Medicine/Korea, 5Internal Medicine, Seoul St. Mary’s Hospital, The 
Catholic University Of Korea, College Of Medicine/Korea, 6Clinical 
Pathology, Uijeongbu St. Mary’s Hospital, The Catholic University Of 
Korea, College Of Medicine/Korea
Background: Castleman’s disease, an uncommon disease that 
causes benign lymph node hyperplasia, must be distinguished 
from reactive lymph node hyperplasia and malignancies. Unicentric 
Castleman’s disease in patients with anemia is rarely described.
Methods: We describe the case of a 25-year-old woman with plas-
ma cell type of unicentric Castleman’s disease presenting as iron 
deficiency anemia. We report the clinical course from the initial 
presentation to diagnosis and surgical cure and review the litera-
ture.
for multivariate analysis.
Results: We identified 223 pts. The median age of the cohort was 
65 years and 83% were males. The histology was NSCLC in 88% 
of the pts and the stage distribution was stage I or II in 6%, stage 
IIIA in 9%, stage IIIB in 23% and stage IV in 62%. The median sur-
vival of the cohort was 12 months. Of these, 190 pts were treated 
with CT, 74 (40%) in the LMOL and 50 (26%) in the last two weeks. 
Univariate analysis shows 11 variables significantly associated with 
CT administration in the LMOL: (1) dying in the hospital, (2) no 
asymptomatic interval after first therapeutic modality, (3) no opioid 
use, (4) less than 7 month survival, (5-6) progression to first and to 
last CT line, (7-8) worse performance status (PS) at first and at last 
CT line, (9) PS of 3 at last CT line, (10) having had less total time on 
CT and (11) having a low median duration of response to CT. In the 
logistic regression model, living less than 7 months, undergoing 
more than 3 lines of CT, dying in the hospital, no opioid use, pro-
gression to last CT line and PS of 3 at last CT line were considered 
predictors of CT administration in LMOL.
Conclusion: We show that CT administration in the EOL occurs in 
symptomatic pts that have short survival and chemoresistant di-
sease. It is known that pts, families and society have unreasonable 
expectations on the efficacy of EOL CT and oncologists feel obli-
ged to try to obtain disease control in poor PS pts with aggressive 
disease. Additionally, the subjective nature of the bond between 
oncologists, pts and families in the EOL is impossible to capture in 
this report.
Keyword: Chemotherapy, End-of-Life, Palliative, Lung
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P2.24-017 5 CASES OF LONG-TERM SURVIVAL IN POS-
TERIOR SPINAL FIXATION SURGERY AGAINST VERTEB-
RAL METASTASIS OF LUNG CANCER
Tomoyuki Igarashi1, Kazuki Hayashi1, Ryosuke Kaku1, Masayuki 
Hashimoto1, Koji Teramoto2, Noriaki Tezuka1, Jun Hanaoka1
1Thoracic Surgery, Shiga University Of Medical Science/Japan, 2Medical 
Oncology, Shiga University Of Medical Science/Japan
Background: Recently, with the progress of treatment, the pati-
ents showing prolonged survival has increased in advanced lung 
cancer. Even though local treatments for the patients with verteb-
ral metastasis, such as radiation therapy and/or surgery, are consi-
dered with effective, the indication of the treatment has not been 
determined. We report 5 cases who underwent posterior spinal 
fixation, they could maintain ADL(Activities of Daily Livings) well 
and could keep a long-term prognosis.
Methods: Between December 2012 and June 2004, we objectively 
evaluate postoperative state and prognosis of the 5 cases that 
underwent the posterior spinal fixation surgery for vertebral meta-
stasis in advanced lung cancer.
Results: 5 patients were underwent this surgery, 3 were male and 
2 were female and the average age was 58.9 years. We added the 
surgery to remove the pressure of the spine in 3 cases, fortuna-
tely there was no spinal invasion in these 5 cases. We preformed 
chemoradiotherapy in 4 cases and chemotherapy alone in 1 case. 
EGFR mutation was positive in 2 cases. All patients were possible 
to ambulate in early postoperative day, and they showed impro-
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P2.24-019 PLEURODESIS WITH BLEOMYCIN IN ADVAN-
CED NON SMALL CELL LUNG CANCER: A SINGLE CEN-
TRE EXPERIENCE FROM SOUTHERN INDIA
Krishnakumar Rathnam1, Kirushnakumar Kosanam Subrama-
niam2, Vijayabhaskar Ramakrishnan3
1Medical Oncology, Meenakshi Mission Hospital And Research Centre/
India, 2Radiation Oncology, Meenakshi Mission Hospital And Research 
Centre/India, 3Surgical Oncology, Meenakshi Mission Hospital And 
Research Centre/India
Background: Pleurodesis is an accepted therapy for patients with 
recurrent and massive pleural effusion in patients with advanced 
non small cell lung cancer.Bleomycin is safe and effective for che-
mical pleurodesis in several studies.The aim of this study was to 
study the effectiveness of bleomycin pleurodesis in advanced non 
small cell lung cancer.
Methods: Seventy five cases of proven non small cell lung cancer 
; with recurrent and symptomatic pleural effusion admitted to our 
hospital between 2006 - 2012 were included in the study. All pati-
ents received chemical pleurodesis with 60 units of bleomycin after 
pleurocentesis using intercostals drainage.All patients received 
systemic chemotherapy following pleurodesis.
Results: The clinical control of pleural effusion by 4 weeks of pro-
cedure and the need for a repeat pleurodesis was analysed.The 
success rate was 76.7 per cent (95% CI,68.6 – 88.7 %). The only sig-
nificant complication reported was chest pain of varying degrees. 
There were no deaths associated with bleomycin pleurodesis.
Conclusion: Bleomycin pleurodesis may be considered as safe 
and cost effective treatment in patients with advanced non small 
cell lung cancer with symptomatic pleural effusion in developing 
countries.
Keyword: NSCLC Pleurodesis bleomycin
Results: 
A 25-year-old woman was referred with abnormal chest X-ray 
which was found during pre-employment screening. She had no 
other complaints, and her previous medical history was unremar-
kable, as was her family medical history. No fever, acute infectious 
symptoms and signs, or any other abnormalities were found in the 
physical examination. 
Normocytic anemia was found based on initial blood tests (hemo-
globin 7.7 g/dl, mean corpuscular volume 88.9 fl, with normal white 
blood cells, red blood cell distribution width, liver renal functions, 
and electrolytes). Further laboratory examinations (ferritin 89.0 ng/
ml; serum iron 23 mg/dl; and total iron binding capacity 206 mg/dl) 
demonstrated that she was iron deficient. 
Chest X-ray and chest CT scan confirmed a mass (6x4x4 cm) at 
right superior and mid-mediastinum (Fig. 1). PET/CT showed para-
tracheal mass shows inhomogeneously high FDG uptake. In suspi-
cion of lymphoma, diagnostic thoracoscopic surgery was planned. 
However, intraoperative frozen section diagnosis of a specimen 
was benign. Thus, the mass was completely removed and diag-
nosis was consistent with unicentric plasma cell type Castleman’s 
disease. 
Three months after surgery, without any medical intervention, the 
laboratory data had recovered to normal range (hemoglobin 14.5 
g/dl). She receives regular follow ups and no recurrence has been 
found for 4 years since surgery.
Conclusion: The surgical resection would appear to be the optimal 
treatment modality, and constitutional symptoms may be resolved. 
The prognosis following complete surgical resection appears to be 
good.
Keywords: mediastinal tumor, castleman‘s disease, video-assisted 
thoracoscopic surgery, giant lymph node hyperplasia
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some cases superior, to other developed countries. Only a very 
small number, 12.9% of patients, are diagnosed early enough to 
undergo surgery. This would suggest that it is not the treatment 
provided in England that is inferior, but our ability to diagnose lung 
cancer at an early stage.
Keywords: Lung cancer, lobectomy, survival
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P2.24-021 ADJUVANT OR INDUCTION CHEMOTHERAPY 
FOR NON SMALL CELL LUNG CANCER TREATED WITH 
CHEMORADIOTHERAPY: AN INVIDUAL DATA META-
ANALYSIS OF PHASE II TRIALS
Paul Van Houtte1, Marianne Paesmans1, Hak Choy2, Pierre Four-
nel3, Pilar Garrido4, Jan P. Van Meerbeeck5, Thierry Berghmans1, J 
P Sculier1
1Institut Jules Bordet/Belgium, 2University Of Texas Southwestern Me-
dical Center/United States Of America, 3Institut De Cancerologie De La 
Loire/France, 4Medical Oncology, Irycis,hospital University Ramon Y 
Cajal/Spain, 5Thoracic Oncology / Moca, Antwerp University Hospital/
Belgium
Background: it is well known that combining chemotherapy and 
radiation therapy is beneficial to patients with locally advanced 
non small cell lung cancer compared to radiation alone or compa-
red to a sequential approach using chemotherapy and radiation 
therapy. However, it is not obvious what is the best schedule. A 
few randomized trials assessed chemotherapy as induction before 
chemoradiotherapy (CT -> CTRT) versus chemotherapy as consoli-
dation, after chemoradiotherapy (CTRT -> CT). Most of those trials 
are phase II trials with moderate sample sizes and were not desig-
ned to demonstrate treatment effect in terms of overall survival.
Methods: the study coordinators of those trials (T. Berghmans, H. 
Choy, P. Fournel, P. Garrido, J. Van Meerbeeck) agreed on a pro-
tocol for carrying out a meta-analysis of individual patients data 
and for sharing the individual patients data that were sent to the 
coordinating institution. Overall survival was the primary outcome, 
progression-free survival and toxic death occurrence were among 
the secondary outcomes. The treatment effect was assessed 
through the estimation of the hazard ratio of the survival distribu-
tions using CTRT -> CT as reference. Combined hazard ratio was 
obtained through Cox regression models (fixed effects) with a stra-
tification by trial. Preplanned interactions between baseline covari-
ates (age, sex, performance status, stage, histology) and treatment 
effect were assessed. Toxic death rates were analyzed per trial and 
odds ratios have been estimated to assess the treatment effect. 
Combined odds ratio was obtained by the Peto method.
Results: the data bases of the 5 eligible identified trials (3 with 
cisplatin based chemotherapy regimens, 2 with carboplatin based 
regimens) were shared for a total of 534 patients (CT -> CTRT 
271, CTRT -> CT 263). Median ages were 60 and 61 years, stage 
IIIB represented 69%/70% of the patients and EOCG PS > 1 was 
rare (3%/2%). Median follow-up ranged from 12 months up to 66 
months and rates of events from 44% to 88%. No significant dif-
ference was detected either for overall survival with an estimated 
HR of 0.96 (95% CI : 0.79-1.17) without heterogeneity between the 
5 trials (I2=0) or for progression-free survival (analysis restricted to 
4 out of the 5 trials), HR=0.91 (95% CI : 0.75-1.11) and absence of 
heterogeneity (I2=2%). For both outcomes, no interaction between 
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P2.24-020 UK LUNG CANCER SURVIVAL: WHERE ARE 
WE GOING WRONG?
Henrietta Wilson1, Vladimir Anikin2, Emma Beddow2
1Thoracic Surgery, Royal Brompton And Harefield NHS Trust/United 
Kingdom, 2Thoracic Surgery, Harefield Hospital/United Kingdom
Background: A number of recent studies have reported poor 
cancer survival in England when compared to other developed 
countries worldwide. In particular, lung cancer has been highligh-
ted as amongst the worst, with only Scotland and Malta showing 
poorer survival rates in Europe. The aim of this study was look for 
an explanation for these findings by assessing our post-operative 
survival in patients undergoing surgery for lung cancer. Through 
this we hope to establish whether the management of patients 
with curative disease is inferior or whether other key factors, such 
as stage and timing of diagnosis, are to blame.
Methods: 501 patients were identified who had undergone lo-
bectomy, bilobectomy or pneumonectomy for non-small cell lung 
cancer between January 2003 and January 2011. Information re-
garding patient demographics and histological stage of disease 
was collected. NHS number tracing was used to obtain patient 
status at follow-up. Survival data was plotted using the Kaplan-
Meier method with comparison of stage 1 and 2 disease. In additi-
on, information was collected from the NHS lung cancer database 
to identify the percentage of patients diagnosed with non-small 
cell lung cancer who underwent surgical management during the 
research period.
Results: Of the 501 patients within this cohort, 263 had stage 1 
disease, 147 stage 2 disease and 91 stage 3 or 4 disease. Ave-
rage age at the time of surgery was comparable between the 
groups (mean 67 years) and there were considerably more men 
within the study than women (M:F = 303:198). 5 year survival in 
patients with stage 1 or 2 disease was 75% or 40% respectively 
(Figure 1). On average, 12.9% of patients diagnosed with NSCLC 
underwent surgical resection. Figure 1: Comparison of survival 
following lung resection in patients with stage 1 and 2 NSCLC 
Conclusion: Cancer survival is an important measure of the effec-
tiveness of both management strategies and healthcare systems. 
These findings demonstrate that in patients with early, operable 
lung cancers we are achieving survival rates comparable, and in 
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pful resource for their patients. Challenges encountered during the 
project were lower than expected recruitment due to lack of clini-
cal engagement from busy clinicians, multiple additional visits that 
sometimes conflicted with other scheduled patient visits to the 
RCC, and declining performance status of the patients precluding 
in-person attendance for training in DM techniques.
Conclusion: DM can be effectively implemented and tailored to 
local needs of a RCC or program. Key factors for success included 
a clinical champion and a multidisciplinary team approach in or-
der to build the necessary knowledge and expertise for DM. The 
lessons learned as a result of these pilot projects have led to a new 
initiative to improve the quality and consistency of DM across the 
province of Ontario. This new initiative will incorporate novel ap-
proaches for knowledge transference with the possibility of enga-
ging healthcare providers beyond the RCC.
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P2.24-023 A DESCRIPTIVE PILOT STUDY TO EVALUATE 
THE CURRENT PRACTICES OF DETERMINING "DO NOT 
RESUSCITATE STATUS“ IN PATIENTS WITH INCURABLE 
LUNG CANCER AT CANCER CARE MANITOBA,  
CANADA.
Naseer Ahmed1, Pamela Johnston2, Michelle Lobchuk3, William 
Hunter1, Jeffrey J Sisler4
1Radiation Oncology, Cancer Care Manitoba, University Of Manitoba/
Canada, 2Nursing, Cancer Care Manitoba/Canada, 3Faculty Of Nursing, 
University Of Manitoba/Canada, 4Family Medicine, University Of Ma-
nitoba/Canada
Background: At Cancer Care Manitoba (CCMB), Canada, lung can-
cer patients when considered incurable, are often enrolled into the 
palliative care program. One of the most important pre-requisites 
for patients to enroll into this program is to have a Do Not Resusci-
tate (DNR) status determined and signed by an authorized cancer 
care provider.Currently there are no guidelines on how and when 
to address advanced care planning and more specifically when to 
discuss DNR status. At this time the issue appears to be addressed 
on an individual basis depending on the patient’s unique circum-
stances and the personal practice of the physician involved. DNR 
discussions in the context of incurable lung cancer can be difficult 
for a number of reasons that include but are not limited to: social 
or family complexities such as dysfunctional dynamics or conflicted 
goals for medical attention, cultural differences, limited patient 
and/or family understanding of the patient’s prognosis, a recent 
diagnosis, limited time for discussion, physician preferences, and 
questionable patient cognitive competence secondary to pain, 
medications, brain metastases, whole brain radiotherapy, and 
emotional stress caused by the disclosure of incurable nature of 
the disease . Lung cancer team at CCMB has identified a need to 
explore the current practice and opinions around DNR discussion 
and future development of advance care planning guidelines. The 
findings from the current pilot study may serve the basis for a pro-
spective randomized trial that tests an intervention that incorpo-
rates the timing of DNR discussions.
Methods: From January 2012 to November 2012 a total of 10 lung 
cancer patients who had previously discussed and determined 
their DNR status, 9 family members, and 10 health care providers 
were identified and agreed to participate. A mixed quantitative 
and qualitative methodology including a written questionnaire 
the above specified covariates and treatment effect was found. 
Toxic deaths occurred overall in 3% of the patients, no detectable 
impact of treatment arm was found with a combined odds ratio of 
0.40 and a 95 % CI overlapping 1 (0.15-1.06).
Conclusion: our results suggest that there is no argument in favour 
of one of the two therapeutic schedules when looking at overall 
survival or at progression free survival; however, in the absence of 
benefit in terms of prognosis, a more detailed evaluation of toxicity 
is warranted and is ongoing.
POSTER SESSION 2 - SUPPORTIVE CARE  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.24-022 IMPLEMENTING DYSPNEA MANAGEMENT: A 
QUALITY IMPROVEMENT PROJECT FOR PATIENTS WITH 
LUNG CANCER IN ONTARIO, CANADA
Yee C. Ung1, William Evans2, Aryn Gatto3, Angelika Gollnow3, Lor-
raine Martelli-Reid4, Cathy Kiteley5, Alice Chen3
1Radiation Oncology, Odette Cancer Centre/Canada, 2Juravinski Cancer 
Centre/Canada, 3Cancer Care Ontario/Canada, 4St Josephs Hospital/
Canada, 5Cns Oncology And Palliative Care, Credit Valley Hospital/
Canada
Background: Dyspnea is a distressing symptom that occurs in up 
to 75% of patients with lung cancer as measured by the Edmon-
ton Symptom Assessment System (ESAS). Appropriate dyspnea 
management (DM) can improve the patient’s quality of life, perfor-
mance status and emotional well-being. However DM is not uni-
form or standard across Regional Cancer Centers (RCC). A quality 
improvement intiative on DM was implemented through the Di-
sease Pathway Management (DPM) of Cancer Care Ontario (CCO). 
DPM is a unifying approach to quality improvement that integrates 
program activity across the cancer continuum in order to advance 
system-wide improvements. This initiative provided advice on 
various delivery models and strategies for DM.
Methods: Seven RCCs received funding from CCO to undertake 
one year pilot projects in DM. These projects had to have potential 
for significant impact, be innovative and be cost effective. Each 
RCC project was required to address the physical and psychologi-
cal aspects of dyspnea that affect the patient, their families and/
or caregivers. The precise methodology was left to each RCC to 
develop and initiate within the specified criteria. Approaches inclu-
ded educational sessions for patients and family members, indivi-
dual counseling and treatment plans, and symptom management 
clinics. Four measures were tracked: ESAS for patient-reported 
symptom severity, Palliative Performance Status (PPS) for evalua-
tion of functional status, European Organization for Research and 
Treatment Quality of Life Questionnaire (EORTC-QOL) to measure 
quality of life and a Patient Survey to evaluate the patient’s know-
ledge of dyspnea, preparedness for self-management and overall 
satisfaction with the DM initiative.
Results: 188 patients were evaluable. 45% of patients with an 
initial severe dyspnea score on ESAS reported a shift to either a 
moderate or mild score by the last visit. 32% of patients with an 
initial moderate dyspnea score on ESAS reported a shift to a mild 
score. Patient satisfaction was high, with feelings of empowerment 
to carry on daily activities as a result of the interventions offered; 
caregivers reported a better understanding of dyspnea and better 
ability to support their loved ones; clinicians noted a difference in 
patients attending the dyspnea care initiative and valued the hel-
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les of EP (etoposide 130 mg/m2, days 1–3; cisplatin 30 mg/m2, day 
1) with concurrent mediastinal irradiation were enrolled. SUVmax 
of primary tumor was revised with the SUV of liver (SUVlivermax). 
Differences between pre- and post-treatment average SUV uptake 
of the primary tumor and intrathoracic lymph nodes were presen-
ted as ∆SUVliveravg. Thirty-one tumor biopsy specimens were 
immunostained for glucose transporter-1 (GLUT-1), Bcl-2, and hy-
poxia inducible factor-1α (HIF-1α).
Results: Objective response rates (ORRs) after CCRT were 92.7% 
and 87.8% on chest CT and FDG-PET, respectively. Median overall 
survival (OS) and RFS were 13.7 (range 4.4–54.1) months and 10.4 
(range 0.97–54.1) months, respectively. In multivariate analysis, pre-
treatment lactate dehydrogenase (LDH) and ∆SUVliveravg correla-
ted significantly with RFS (hazard ratio [HR] 2.8, P = 0.043 and HR 
0.3, P = 0.004, respectively). Gender, pretreatment LDH, objective 
tumor metabolic response, and SUVlivermax correlated significant-
ly with OS (HR 12.1, P = 0.006; HR 3.7, P = 0.037; HR 10.1, P = 0.008 
and HR 0.2, P = 0.014, respectively). High GLUT-1-positivity (>75%) 
and pretreatment LDH levels (>400 U/L) correlated significantly 
with better ORR (P = 0.012) and HIF-1α immunoreactivity score 
(IRS, P = 0.029), respectively.
Conclusion: ∆SUVliveravg and GLUT-1, with respect to tumor 
glucose metabolism, might predict RFS and ORR, respectively, in 
definitive CCRT-treated LD-SCLC patients.
Keywords: GLUT-1, HIF-1α, Limited disease of small cell lung can-
cer, FDG-PET
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P2.24-025 APPLYING THE RESULTS OF THE FRAGMATIC 
TRIAL TO REAL LIFE: LONGITUDINAL QUALITATIVE STU-
DY EXPLORING THE EXPERIENCES OF PATIENTS PART-
CIPATING IN A RANDOMISED PHASE III CLINICAL TRIAL 
INVESTIGATING THE EFFECT OF FRAGMIN ADDED TO 
STANDARD THERAPY IN LUNG CANCER
Simon Noble1, Emily Harrop1, Michelle Edwards1, Stephanie Sivell1, 
Kerenza Hood2, Gareth Griffiths3, Anthony Byrne1, Barbara Moore4, 
Sheik Ahmed3, Annmarie Nelson1
1Marie Curie Palliative Care Research Group, Cardiff University/United 
Kingdom, 2South East West Trials Unit, Cardiff University/United King-
dom, 3Wales Cancer Trials Unit/United Kingdom, 4Cancer Research Uk/
United Kingdom
Background: Clinical data suggests low molecular weight heparin 
(LMWH) may produce a survival benefit when given to cancer pati-
ents. Several studies are being conducted in different cancer pri-
maries to explore this hypothesis including FRAGMATIC, which will 
be presented at the World Lung Conference. The FRAGMATIC trial 
is an open label multi-centre Phase III randomised controlled trial 
in patients with lung cancer comparing anticancer treatment accor-
ding to local practice plus dalteparin (Fragmin®), with anticancer 
treatment according to local practice alone. The primary outcome 
measure is overall survival and the secondary outcome measures 
include; toxicity, VTE-free survival, metastasis-free survival, quality 
of life, patient experience and cost utility. 2202 patients have been 
recruited in order to detect an advantage of 5% in overall survival 
at 1 year (to 30%). Fragmin is given as a daily subcutaneous injec-
tion for six months by the patients themselves or a willing partner/ 
carer. This may raise practical challenges regarding how applicable 
followed by a nurse directed audio recorded interview was emplo-
yed to determine participant’s views. Interviews were transcribed 
and then content analysis and constant comparison techniques 
were used to identify, code, and categorize primary patterns in the 
collected data.
Results: Major themes identified from the patient and caregiver’s 
perspective include their trust in the health care system, the need 
for clear communication, the desire to be respected, and the 
benefit of having family present during discussion. Health care 
provider’s commonly expressed the importance of having ade-
quate clinic time for discussions and the need for the process to 
be adaptable. Admission into a palliative care program is the most 
common trigger for initiating discussions but other points earlier in 
the disease course may also be appropriate. The presumed level of 
stress that patients are thought to undergo with DNR discussions 
is less than they actually report. Fnal data analysis is pending and 
subject to refinement before final presentation.
Conclusion: DNR status decision-making is a complex process, 
influenced by patient, family, and health care provider factors. 
The implementation of a standard approach to DNR discussions 
could potentially be restrictive. Potential areas of improvement 
include additional resources, and the specific guidelines. A need 
for a prospective trial addressing the timing of DNR discussion was 
identified but may not be feasible.
Keyword: Lung Cancer, DNR
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P2.24-024 METABOLIC ACTIVITY ON [18F]-
FLUORODEOXYGLUCOSE-POSITRON EMISSION TOMO-
GRAPHY/COMPUTED TOMOGRAPHY AND GLUCOSE 
TRANSPORTER-1 EXPRESSION MAY PREDICT CLINICAL 
OUTCOMES IN PATIENTS WITH LIMITED DISEASE OF 
SMALL CELL LUNG CANCER RECEIVING CONCURRENT 
CHEMORADIATION
Jieun Lee1, Jung Oh Kim1, Chan Kwon Jung2, Yeon Shil Kim3, Ie Ry-
ung Yoo4, Woo Hee Choi5, Eun Kyung Jeon1, Sook Hee Hong1, Sang 
Hoon Chun6, Seung Joon Kim7, Young Kyoon Kim7, Jin Hyoung 
Kang1
1Medical Oncology, Seoul St. Mary‘s Hospital, Catholic University Of 
Korea/Korea, 2Hospital Pathology, Seoul St. Mary‘s Hospital, Catholic 
University Of Korea/Korea, 3Radiation Oncology, Seoul St. Mary‘s Hos-
pital, Catholic University Of Korea/Korea, 4Nuclear Medicine, Seoul St. 
Mary‘s Hospital, Catholic University Of Korea/Korea, 5Nuclear Medici-
ne, St. Vincent’s Hospital, Catholic University Of Korea/Korea, 6Medical 
Oncology, Bucheon St. Mary‘s Hospital, Catholic University Of Korea/
Korea, 7Pulmonology, Seoul St. Mary‘s Hospital, Catholic University Of 
Korea/Korea
Background: Limited disease of small cell lung cancer (LD-SCLC) 
respond well to concurrent chemo-radiation (CCRT), but have 
high relapse rates and short relapse-free survival (RFS). We ai-
med to evaluate tumor metabolic activities measured by [18F]-
fluorodeoxyglucose-positron emission tomography/computed 
tomography (FDG-PET) as a prognostic factor and analyze its rela-
tionships with markers of tumor biologic behavior.
Methods: Forty-one LD-SCLC patients receiving 4 cycles of EP 
(etoposide 120 mg/m2, days 1–3; cisplatin 60 mg/m2, day 1), 2 cyc-
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palliative care before calculating median intervals between these 
points.
Results: 
52% of patients were urban and 48% rural. 45% of patients were 
treated with curative intent and 55% with palliative intent. Perti-
nent median intervals include: referral to appointment (appt): 4 
days (inpt: 0 days, outpt: 7 days); appt to diagnosis (a) rural outpt 
:16 days, urban outpt: 10 days (p=0.58); (b) surgical: 21 days, cu-
rative outpt CH-R: 7 days (P<0.001); (c) surgical rural 30.5 days, 
surgical urban 13 days (p<0.001); referral to treatment: 41 days 
(UK 2006: 41 days, RAH 2010: 48 days, (a) outpt: 54 days, inpt: 21 
days (p<0.0001), (b) surgical: 62 days, outpt curative CH-R: 34 days 
(p=0.81), curative outpt CH-R: 34 days, palliative outpt CH-R: 46.5 
days (p=0.79)). Inpts met both UK targets. There are a number 
of factors contributing to the delays in surgical cases including a 
higher proportion of cases needing multiple biopsy attempts and 
requiring CT-FNA, which takes twice as long to obtain as a bron-
choscopy. Rural location did not impact on overall time to treat-
ment but delays seen in appointment to diagnosis, in particular the 
surgical cases.
Conclusion: For 2011, the RAH achieved the first UK targets for 
first appointment to a specialist but did not meet the target set for 
referral to commencing treatment. Delays were seen in some rural 
subgroups, necessitating the need for a streamlined rural pathway 
to assist in managing investigations and appointments. In turn, this 
will also reduce the number of rural elective admissions. Initiatives 
to improve time to treatment with curative intent include pre-
booking investigations, utilising EBUS for staging and improving 
access to CT-FNA. A follow up audit including analysis of mortality 
is being conducted.
Keywords: timeliness of care, time interval in lung cancer care
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P2.24-027 CISPLATIN PLUS PEMETREXED AND CON-
CURRENT RADIATION WITH CONSECUTIVE SURGERY 
IN LOCALLY ADVANCED ADENOCARCINOMA OF THE 
RIGHT LUNG - CASE REPORT
Milada Zemanova1, Tomas Buchler2, Jan Schutzner3, Lubos Petru-
zelka1
1Dept Of Oncology, 1st Medical Faculty Of Charles University/Czech 
Republic, 2Dept Of Oncology, Thomayer Hospital, 1st Medical Faculty Of 
Charles University/Czech Republic, 33rd Dept Of Surgery, 1st Medical 
Faculty Of Charles University/Czech Republic
Background: Locally advanced non-small cell lung cancer has poor 
prognosis with less than 20% probability of 5-year survival despite 
the results of the main trial will be to clinical practice especially 
with regard to quality of life and thus compliance. We conducted 
a longitudinal quality of life study to explore the experiences of 
patients participating in the FRAGMATIC trial to better inform 
the patient journey and practicalities of applying results to clinical 
practice.
Methods: Semi-structured interviews were held at up to three time 
points, with two groups of patients recruited from the intervention 
(n=4) and control (n=6) arms of the FRAGMATIC trial.A total of 
twenty interviews were analysed using Interpretative Phenome-
nological Analysis to identify emergent themes that reflect parti-
cipants‘ lived experience. We report data focusing on participant 
views and experiences of self injection for six months.
Results: No discernable difference in quality of life was identified 
between patients in the control or intervention arm who repor-
ted similar experiences of the cancer journey and its treatments. 
Patients on the intervention arm found daily Fragmin injections 
to be acceptable and a small consequence of having additional 
treatment as they saw it. Patients developed processes in order to 
administer Fragmin at similar times and described adaptive tech-
niques to reduce discomfort and bruising. Minimal training was 
required to be able to inject Fragmin and few side effects were 
reported. The most common side effect was stinging which was 
short lived and bruising around injection sites. Patients reported 
these events did not impact upon quality of life. Overall, Fragmin 
was found to be an acceptable intervention, which did not pose 
any compliance problems.
Conclusion: The FRAGMATIC trail will report the impact of daily 
subcutaneous LMWH on overall survival in lung cancer. In this trial 
1100 patients self injected Fragmin or had it administered to them. 
Based on qualitative interview data, Fragmin injections were well 
tolerated and the experiences of patients suggest that it would be 
relatively simple to introduce self-injecting into standard lung can-
cer therapy should the results of the FRAGMATIC study demonst-
rate a survival benefit.
Keyword: FRAGMATIC, patient experience, qualitative
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P2.24-026 LUNG CANCER PATHWAY AT THE ROYAL 
ADELAIDE HOSPITAL: IMPACT OF TREATMENT INTENT 
AND PATIENT LOCATION.
Justin R. Ng, Telena Eastley, Peter Robinson, Maree Oborn, Phan 
Nguyen, Brendan Dougherty, Chien-Li Holmes-Liew
Thoracic Medicine, Royal Adelaide Hospital/Australia
Background: A previous 2010 audit at the Royal Adelaide Hospital 
(RAH) found delays in treatment initiation when compared to tar-
gets set in the United Kingdom (UK) National Cancer Plan. The aim 
of this study was to review our performance in 2011 and to explore 
the impact of curative or palliative treatment intent and rural or 
urban based location, in order to guide future improvement.
Methods: Using a pathology database, we retrospectively revie-
wed 128 case notes of patients referred to the RAH in 2011 with 
new histologically confirmed lung cancer. We identified treatment 
intent, patient location and key dates in diagnosis and treatment 
by radiation oncology, medical oncology, cardiothoracic surgery or 
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approved outcomes registry. Data was abstracted from the me-
dical record and the cancer registry. Photofrin was used as the 
photosensitizer at a dose of 2 mg/kg IV . Light dosimetry ranged 
from 100 - 200 J. Light was delivered at 630 nm. All patients were 
treated under general anesthesia for light application and airway 
debridement. Autofluorescent bronchoscopy was used to delinea-
te extent of endobronchial disease.
Results: Between 1998 and 2013, we have performed PDT on 910 
patients; 519 procedures (57%) have involved the tracheobronchial 
tree. The average age was 62 years with a range of 18 -92 years.
The cell types managed by PDT included NSCLC, SCLC, carcino-
id, and metastases to the airway. Indications for tracheobronchial 
PDT included symptom management/ palliation (63%), induction 
therapy (27%), and definitive therapy with curative intent (10%). 
Dyspnea and post obstructive pneumonia from airway obstruction 
were the most common symptoms. Photosensitivity rate was < 2%. 
There were no perforations of the tracheobronchial tree. There was 
a single stricture in this cohort; this occurred in a patient who had 
been previously resected.
Conclusion: PDT for primary or metastatic lesions to the tra-
cheobronchial tree is safe. Early and advanced lesions can be trea-
ted. PDT can be used prior to surgical resection and may increase 
resectability by reducing endoluminal disease. PDT may be used 
after radiation therapy with good efficacy. PDT can be utilized 
during multiple courses of treatment to palliate obstructing or 
bleeding lesions. Photosensitivity is an infrequent complication. 
Our experience demonstates the utility of PDT across all stages of 
NSCLC when there is a visible endoluminal component. In order to 
more specifically define the utility of PDT in NSCLC, we have esta-
blished a prospective multi center registry to delineate indications, 
contraindications and the role of PDT in treatment algorhythms for 
airway malignancies.
Keywords: photodynamic therapy, Lung cancer, PDT
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P2.24-029 PATTERNS OF PALLIATIVE CARE INVOLVE-
MENT IN METASTATIC NON-SMALL CELL LUNG CAN-
CER PATIENTS: LIMITATIONS OF EARLY PALLIATIVE 
CARE IN A RURAL AUSTRALIAN CENTRE
Amy Prawira1, Mathew George1, Srinivas Kondalsamy-Chennake-
savan2, Kerry Bowden1
1Medical Oncology, North West Cancer Centre/Australia, 2Rural Clinical 
School, The University Of Queensland/Australia
Background: A number of studies have demonstrated that early 
palliative care involvement in the care of metastatic non-small cell 
lung cancer patients leads to significant improvements in quality 
of life, symptom control, and survival. Most studies, however, were 
performed in large centres where palliative care service is readily 
available. The North West Cancer Centre is a comprehensive rural 
Australian cancer centre. In this study, we reviewed our patterns of 
palliative care involvement, seeking to examine the current practi-
ces in the light of our limitations.
Methods: Retrospective analysis of patients with metastatic ade-
nocarcinoma of the lung in the North West Cancer Centre bet-
ween January 2008 to December 2012.
the use of concurrent chemoradiotherapy. Last generation chemo-
therapy regimen, high dose of radiotherapy, and surgery if feasible 
are options to achieve better outcomes in highly selected cases.
Methods: A case report of a 25-year woman with non-mutated 
adenocarcinoma of the right lung is presented in this work.
Results: The young woman, age 25 years, smoker of 1 pack/day 
since the age of 18 years, without family cancer history presented 
with right lung perihilar mass. CT scan showed tumor infiltration 
of the right upper lobe of 73x65x80 mm involving mediastinum as 
well as enlargement of right hilar and mediastinal lymph nodes. 
Suspicion of left aortic arc lymph nodes infiltration was described 
on FDG-PET/CT but no distant metastases were seen. Transbron-
chial biopsy confirmed adenocarcinoma. EGFR mutation and ALK 
translocation were not found. TNM stage (UICC7) was T4N2-3M0 – 
clinical stage IIIB. Performance status 1, cough, dyspnoea and mild 
weight loss at time of diagnosis were noted. Treatment consisted 
of 5 cycles of chemotherapy with cisplatin and pemetrexed in stan-
dard doses every 3 weeks and concurrent radiotherapy given in 
the dose of 72Gy/36 fraction/7.5 weeks during 3-5th cycle. Resta-
ging after CRT showed substantial partial remission with negative 
mediastinal lymph nodes on PET/CT scan, therefore surgery was 
proposed, resulting in right upper lobectomy and mediastinal 
lymphadenectomy. The histology showed residual adenocarcino-
ma 35x20x45mm with regressive signs, stage ypT2 ypN0. Whole-
body and brain FDG-PET/CT two months after surgery confirmed 
complete remission. No additional chemotherapy nor prophylactic 
cranial irradiation were indicated but close follow-up has been 
planned because of the high risk of recurrent distant metastases.
Conclusion: This case report showed successful multimodal the-
rapy of advanced NSCLC in a very young woman whose age and 
good PS warranted aggressive treatment approach. This abstract 
was supported by a grant from the Ministry of Health of the Czech 
Republic – IGA MZ CR NT12331-5/2011 and by a grant from the 
Charles University Prague PRVOUK - P27.
Keywords: Concurrent chemoradiotherapy, surgery, pemetrexed/
cisplatin, lung adenocarcinoma
POSTER SESSION 2 - SUPPORTIVE CARE  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.24-028 PHOTODYNAMIC THERAPY FOR AIRWAY 
MALIGNANCIES: A 15-YEAR SINGLE INSTITUTION EXPE-
RIENCE
Patrick Ross1, Patsy L. Skabla1, Susan Moffatt-Bruce1, Edmund Kas-
sis1, Vincent Daniel1, Kate Glass1, John Wilson2
1Division Of Thoracic Surgery, Ohio State University/United States 
Of America, 2Division Of Thoracic Surgery, The Ohio State University 
Medical Center/United States Of America
Background: Photodynamic therapy (PDT) is a unique combination 
of photosensitizing drug and laser light for drug activation which 
results in tissue destruction by direct cellular damage and small 
vessel thrombosis. We have utilized PDT to manage airway malig-
nancies since 1998. This large, single institution case series will de-
scribe technical considerations of airway PDT,incorporation of PDT 
into multi modality therapy, patient selection, patient management 
and clinical outcomes.
Methods: All patients receiving PDT were entered into an IRB 
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the basis of CRP to a maximum of 1200mg.
Results: Overall Response seen in 4 patients (VT-122 arm) and 2 
patients (docetaxel arm). 6 patients in VT-122 arm completed 6 
cycles of docetaxel while in non-VT-122 4 patients completed the 
6 cycles. 1 year survival was 30% vs 10%; p=0.025. Grade III/IV 
hematologic toxicity was decreased by 50% ie 6 cases in docetaxel 
arm and 3 in VT-122. In non-hematological toxicity this trend was 
seen for asthenia, neuropathy, skin and nail changes and weight 
loss.
Conclusion: Addition of VT-122 (propranolol and etodolac) increa-
ses efficacy of docetaxel and is cost effective.
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P2.24-031 PRE-TREATMENT SYMPTOM PROFILES PRE-
DICT SURVIVAL IN PATIENTS WITH NON-SMALL CELL 
LUNG CANCER
Mei-Ling Chen1, Chih-Teng Yu2
1School Of Nursing, Chang Gung University/Taiwan, 2Department Of 
Thoracic Medicine, Chang Gung Memorial Hospital/Taiwan
Background: Fatigue, depression, sleep disturbance, and dyspnea 
are symptoms frequently reported by patients with non-small cell 
lung cancer before anti-cancer treatment. The purposes of this 
study were to identify latent subgroups of patients with NSCLC 
using the above four symptoms assessed at pre-chemotherapy 
and to determine whether different patient subgroups based on 
their symptom profiles can predict their survival.
Methods: Patients with stage III or IV NSCLC were recruited from 
a large teaching hospital located in northern Taiwan. Fatigue subs-
cale of the European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC QLQ-C30) was used 
to measure fatigue. The Hospital Anxiety and Depression-De-
pression subscale was used to measure depressive symptom. The 
Pittsburg Sleep Quality Index (PSQI) was used to measure sleep 
disturbance. Four items from EORTC QLQ-C30 and QLQ-LC13 was 
used to measure dyspnea. All patients were followed up until the 
end of the study. The follow-up time ranged from 10 to 30 months. 
Latent class analysis was used to identify patient subgroups. Cox 
regression was used to examine the effect of patient subgroup on 
survival after adjusting the effect of covariates.
Results: The study sample consisted of 127 NSCLC patients. Two 
distinct patient subgroups were identified. The first group (30%) 
was characterized with high severity on all four symptoms (high 
symptom group), the second groups (70%) showed low severity 
on all four symptom (low symptom group). Before adjusting co-
variates, the “high symptom group” had significantly shorter sur-
vival time (median = 11.1 months) than the “low symptom group” 
(median = 21.1 months) (P = 0.016). After controlling for gender 
and disease stage, the group membership remain significantly 
associated with survival time (P=0.047). The risk of early death was 
1.81 times higher in the “high symptom group” as compared to the 
“low symptom group” (HR=1.81, 95% CI=1.01 to 3.23).
Conclusion: The finding suggests that pre-treatment symptom 
profile has additional prognostic prediction in patients with advan-
ced NSCLC. Early symptom assessment is recommended.
Results: We identified 35 patients with stage IV adenocarcinoma 
of the lung. The median duration to first review by palliative care is 
126 days (range 28 - 669 days). Median duration from first review 
by palliative care to time of death is 22 days (range 11 - 152 days). 
Both are calculated from time of first review in medical oncology 
clinic. Further analysis revealed only 10 patients reviewed by a 
palliative care physician, with a median duration to first review of 
227 days (range from 76 to 670 days). 25 patients were reviewed 
by specialist palliative care nurses, with a median duration to first 
review of 382 days (range from 76 to 676.5 days). 30 patients requi-
red inpatient palliative care, however only 7 were admitted under 
a specialist palliative care unit. 8 patients are currently alive. 5 pati-
ents received no palliative care input.
Conclusion: Lung cancer patients in rural and remote communi-
ties are known to have poorer prognosis compared to their urban 
counterparts. Our study further highlights this disparity. Early 
palliative care is becoming a standard of care. However, there are 
unique challenges facing a rural cancer centre that limits feasibility 
of early palliative care involvement in rural and remote lung cancer 
patients. A limited number of specialist palliative care health care 
providers service a large area (map). Currently we have 1 part-time 
specialist palliative care physician and 2 specialist palliative care 
nurses, catering for inpatient, ambulatory, and community palliati-
ve care patients. Our study found significant involvement of non-
palliative care specialist health care providers assisting in provision 
of palliative care services. It is our impression that increasing awa-
reness and education of the supporting health care providers is 
imperative to improving delivery of palliative care in a rural setting.
Keyword: metastatic non-small cell lung cancer, adenocarcinoma, 
palliative care, rural
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P2.24-030 INCREASING THERAPEUTIC EFFICACY AND 
SAFETY OF DOCETAXEL IN LUNG CANCER
Gouri Shankar Bhattacharyya1, A A B Ranade2, G Biswas3, Hemant 
Malhotra4, Kanaka Govindbabu5, Shailesh Bondarde6, Saumen 
Basu7, Sushmita Roychoudhury8, Raja Dhar8, Newell Bascomb9
1Medical Oncology, H.O.D. Medical Oncology, Fortis Hospital Ananda-
pur, Amri Hospital And Orchid Nursing Home,/India, 2Medical Oncolo-
gy, Deenanath Mangeshkar Hospital,/India, 3Medical Oncology, Sparsh 
Hospital/India, 4Medical Oncology, Sms Medical College & Hospital/
India, 5Medical Oncology, Kidwai Memorial/India, 6Medical Oncology, 
Shatabdi Super Specialty Hospital/India, 7Radiation Oncology, Amri, 
Dhakuria/India, 8Pulmonology, Fortis Hospital/India, 9Drug Develop-
ment, Vicus Therapeutics/United States Of America
Background: Docetaxel is an accepted second line drug for NS-
CLC not used frequently for its side effects. VT-122 (propranolol 
and etodolac) which has anti-angiogenic COX-2 inhibition pro-
perties. Modifying the tumor-microenvironment and sympathetic 
system has anticancer activity as well as ameliorates toxicity of 
anticancer drugs. Docetaxel efficiency can be improved with VT-
122 which possesses the above property. To increase efficacy of 
docetaxel and safety profile using VT-122.
Methods: 20 (10 in each arm) patients (55-65 years) were treated 
with docetaxel (75mg/m2) with or without VT-122. VT-122 was star-
ted 7 days before giving docetaxel. Propranolol doses were titra-
ted to maintaining heart rate around 60. Etodolac was titrated on 
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dobronchial ultrasound, autofluorescence), including a comparison 
with previous surveys will be given in the lecture or on the poster.
Conclusion: The level of bronchological service offered in the 
Czech Republic is comparable with the most developed countries 
and serves a prompt and exact diagnostics of patients with respi-
ratory disorders including lung cancer.  
"Supported by Projects (Ministry of Health) of conceptual develop-
ment of research organization 00064203 (FN Motol, Prague, Czech 
Republic)“.
Keyword: bronchoscopy, survey, diagnostics, lung cancer
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P2.24-033 THE VALUE OF ASSESSING MUSCLE DEPLE-
TION IN LUNG CANCER (SARCOPENIA) RATHER THAN 
BODY SURFACE AREA, IN THE WORK-UP TO CHEMO-
THERAPY. REFLECTIONS FROM A SYSTEMATIC REVIEW.
Jemima Collins1, Simon Noble2, John Chester2, Anthony Byrne2
1University Hospital Of Wales, Cardiff University/United Kingdom, 
2Marie Curie Palliative Care Research Group, Cardiff University/United 
Kingdom
Background: Dosing of many chemotherapy drugs is currently 
based on body surface area (BSA), which is partly derived from 
body weight. However, BSA has been shown to result in large 
inter-patient variability in drug exposure. Another measurement of 
body composition is fat free mass (FFM), which includes hepatic, 
renal and muscle metabolic tissue. Depletion of FFM is termed 
sarcopenia, which in breast and renal cancer populations is asso-
ciated with increased chemotherapy toxicity and time to disease 
progression. Sarcopenia can occur regardless of weight or BSA. In 
order to explore the value of FFM assessment in lung cancer pati-
ents undergoing chemotherapy, we performed a systematic review 
to explore this relationship. We present an analysis of relationships 
between sarcopenia, body weight, BSA, chemotherapy toxicities 
and outcomes in lung cancer patients.
Methods: Two search strings (‘muscle mass loss’ AND ‘lung can-
cer’) were used as a basis for formulating specific literature search 
strategies in five databases. We included all publication types and 
the search was limited to articles written in English. From this lar-
ger review, we then narrowed our focus to chemotherapy-specific 
studies.
Results: Our systematic review of FFM loss in lung cancer consis-
ted of 29 studies, from which 7 studies considered specifically the 
relationship between FFM and chemotherapy. One study of 250 
obese patients found 15% were sarcopenic, FFM poorly correlated 
with BSA (r2=0.37), and variation in FFM per unit of BSA could ac-
count for up to three-times variation of chemotherapy volume of 
distribution, potentially indicating increased risk of chemotherapy 
toxicity. A further population-based study (N=441) found 46.8% 
were sarcopenic, despite only 7.5% being underweight. A further 
two smaller studies (N=40, 41) found the prevalence of sarcopenia 
to be 61% and 46% (despite approximately half being overweight 
or obese). Prospective evaluation of the effect of chemotherapy on 
FFM in 3 small studies (N<22) showed no significant change. Sar-
copenia was also associated with poorer performance status and 
reduced median survival.
Keywords: latent class analysis, survival, non-small cell lung can-
cer, symptom profile
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P2.24-032 BRONCHOSCOPY IN THE CZECH REPUBLIC, 
2012
Miloslav Marel1, Vitezslav Kolek2, Pavel Barton3, Jana Skrickova4, 
Pavel Reiterer5, Martina Vasakova6, Jiri Votruba7, Frantisek Salaj-
ka2, Norbert Pauk8, Milos Pesek2, Frantisek Petrik1
1Pneumological Department, 2nd Medical Faculty, University Hospital/
Czech Republic, 2Pneumology, University Hospital/Czech Republic, 
3Pneumology, Olu Trn JevíČko/Czech Republic, 4Department Of Respira-
tory Diseases And Tb, University Hospital Brno And Masaryk Univer-
sity/Czech Republic, 5Usti Nad Labem Hospital/Czech Republic, 6De-
partment Of Respiratory Medicine, Thomayer Hospital/Czech Republic, 
7Pneumological Department, 1st Medical Faculty, University Hospital/
Czech Republic, 8Pneumological Department, 3rd Medical Faculty, Uni-
versity Hospital/Czech Republic
Background: The incidence of lung cancer in the Czech Republic 
has been unacceptably high for decades. It has reached 91/100 
000 in men and 31/100 000 in women. Bronchoscopy plays an 
important role in the diagnostic process. To assess the quality and 
density of the bronchological net and to determine the current 
situation in the implementation of bronchoscopy in the Czech Re-
public we decided to carry out a national survey.  
Methods: A bronchological questionnaire was sent by e-mail to 
every pneumologist performing bronchoscopy. With the help of 
repeated e–mails and additional telephone interviews we achieved 
a response rate of more than 95%.
Results: In 2012 there were 56 centers performing bronchoscopy 
in adults and 9 in children in the Czech Republic. 
The bronchological units of adult clinics employed 169 broncholo-
gists using 231 fiberscopes, out of which 88 were video broncho-
scopes and 79 rigid bronchoscopes. Altogether 30 354 broncho-
scopies were performed in adults. General anesthesia was used in 
2 146 cases, the rest was carried out under local anesthesia. The 
total number also includes 1767 bronchoscopies performed using 
rigid instrumentation. Cytological examination of the material 
obtained during bronchoscopy was carried out by a pathologist 
(Department of Clinical Pathology) at 34 centers, by a pneumolo-
gist trained in cytology at 13 centers and by both the pathologist 
and the pneumologist at 9 centers. Interventional bronchoscopic 
procedures (laser, electrocautery, stenting, brachytherapy, cryo-
cautery and the introduction of endobronchial valves) were used 
in 17 departments. Altogether the above mentioned procedures 
were performed 654 times during one year. 
All 9 children‘s bronchological departments employed 12 bron-
choscopists, using a total number of 29 fiberscopes, out of which 
17 were video bronchoscopes. Seven pediatric bronchoscopy 
centers also used rigid instrumentation. The total number of pedi-
atric bronchoscopies performed in 2012 was 682, the majority of 
them (621) under general anesthesia. Out of all bronchoscopies, 
the rigid bronchoscopy was performed in 32 cases. At five centers 
cytology examination was performed by a pathologist, at 3 centers 
by a pneumologist trained in cytology and at one center by both 
specialists together. 
Further analysis of the specialized bronchological procedures (en-
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and platinum 60%, gemcitabine and carboplatin 20%, single 
agent pemetrexed 8%, vinorelbine 8%, gemcitabine 4%. Third line 
therapy was received by 40% of those who had received 2nd line 
treatment.
Conclusion: Patients with EGFR activating mutations often derive 
a significant clinical benefit and marked reduction in tumour bur-
den with oral EGFR TKI therapy, which results in a reluctance, from 
both patients and clinicians, to stop therapy at the time of radio-
logical progression if the patient is still experiencing symptomatic 
improvement. Our results show that treatment beyond disease 
progression is common (34%) in ‘real –life’ clinical practice with 
some patients continuing to derive benefit for more than a year 
beyond the time of disease progression. .
Keywords: NSCLC, EGFR TKI, Disease progression
POSTER SESSION 2 - SUPPORTIVE CARE  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.24-035 DESCRIPTION OF LUNG CANCER PATIENTS 
WITH ECOG 2 AT DIAGNOSIS. EXPERIENCE OF OUR 
HOSPITAL
Angel Artal, Lourdes Calera, Alba Hernández, María Alvarez, Ana 
Cebollero, Jorge Hernando, Irene Torres, Isabel Pajares, Carmen 
Santander, Antonio Anton-Torres
Medical Oncology, Hospital Universitario Miguel Servet/Spain
Background: Patients with advanced lung cancer presenting with 
ECOG 2 at diagnosis trend to be no longer included in large, ran-
domized, registration trials and then recommendations for their 
treatment are more difficult. Nonetheless, they account for a sig-
nificant percentage of the cases attended in a Medical Oncology 
Department. We describe their characteristics and outcomes in 
our experience.
Methods: Medical records of lung cancer patients with ECOG 2 
that were seen in our Department between april 2009 and april 
2013 have been reviewed.
Results: 124 patients (p) were found. They account for a 15.3% of 
the overall number of lung cancer patients attended. 106p were 
male (85.5%). Median age 66 years (44-83). By histology: adenocar-
cinoma 41p (33.1%), EGFR+ adenocarcinoma 4p (3.2%), squamous 
36p (29.0%), small-cell 23p (18.5%), other 19p (15.3%), no histologic 
diagnosis 1p (0.8%). By stage: III 39p (31.5%), IV 85 (68.5%). By the 
time of analysis, 76p (61.3%) hade died, other 31p (25.0%) continu-
ed palliative care and 17 (13.7%) were still on active therapy. Initial 
intention of therapy was palliative in 94p (75.8%), radical/adjuvant 
in 9 /.3%) and 21p did not receive any active therapy beyond 
supportive care. Drugs administered at first line: carboplatin 43p 
(34.7%), cisplatin 12p (9.7%), EGFR-TKI 6p (4.8%), non-platinium 
chemotherapy 39p (31.5%), no Chemotherpy 24 (19.4%). No diffe-
rences by gender existed in the drugs given, except for TKI which 
were more frequently given to women (5/6). Median overall survival 
was 34 weeks (IC: 26.0-41.9). No differences existed by gender 
(male 32 weeks, female 39 weeks) or stage (III 30 weeks, IV 36 
weeks) but they differed by histology: adenocarcinoma 34 weeks, 
squamous 22 weeks, EGFR+ aenocarcinoma Not Reached, small 
cell 59 weeks.
Conclusion: A significant percentage of lung cancer patients are 
diagnosed with ECOG 2 performance status in every histological 
Conclusion: A more refined understanding of body composition 
is needed in lung cancer patients, in order to minimise toxicities 
of chemotherapy, whilst ensuring optimal chemotherapy dosage. 
The current literature suggests that a more detailed prospective 
study is required in order to explore the validity and advantage 
of measuring FFM rather than BSA in lung cancer patients, in the 
work-up to chemotherapy. It also suggests that targeting sarcope-
nia may offer a novel approach to improving chemotherapy tole-
rance and overall survival.
Keywords: body surface area, fat free mass, sarcopenia, chemo-
therapy dose calculation
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P2.24-034 TREATMENT BEYOND PROGRESSION IN 
PATIENTS WITH NON-SMALL CELL LUNG CANCER HAR-
BOURING EGFR MUTATIONS - THE MANCHESTER LUNG 
CANCER GROUP EXPERIENCE
Emma Halkyard1, Rahul Peck2, Elizabeth Connolly3, Andrew Wal-
lace4, Fiona Blackhall1, Paul Taylor1, Raffaele Califano1, Paul Burt1, 
Margaret Harris1, Neil Bayman1, Hamid Sheikh1, Abbas Chittalia1, 
Lip W. Lee1, Corinne Faivre-Finn1, Jo Coote1, Yvonne J. Summers1
1The Christie NHS Foundation Trust/United Kingdom, 2Oncology, Uni-
versity Hospital Of South Manchester/United Kingdom, 3Oncology, 
Belfast City Hospital/United Kingdom, 4Genetic Medicine, Regional 
Molecular Genetics Service/United Kingdom
Background: The presence of EGFR activating mutations in NS-
CLC and sensitivity of these tumours to EGFR tyrosine kinase 
inhibitors (TKI) was first described in 2005. For NSCLC patients 
harbouring an activating EGFR mutation the treatment of choice is 
an EGFR TKI which is better tolerated and easier to administer than 
chemotherapy. However, questions remain about duration of the-
rapy and optimal management on radiological progression.
Methods: A retrospective case note review was undertaken 
with the aim of establishing current practice in prescription and 
discontinuation of EGFR-TKIs, subsequent therapies and clinical 
outcomes. We identified consecutive patients from the database 
of the genetic testing laboratory (from Q4 2009 when routine 
testing commenced to a cut-off point of February 2013). 171 case- 
notes were reviewed for demographic and clinical data including 
survival.
Results: Of 171 cases 116 (69%) had received treatment with an 
EGFR TKI (Gefitinib 79%, Erlotinib 19%, both 2%). The reasons 
for not receiving treatment included: patient received radical 
therapy, patient died before oncology assessment and patient 
preference. 63% of patients were female, 26% never smokers, 
44% ex-smokers, 6% current smokers and smoking history was 
not documented in 23%. 76% of patients had Stage IV disease 
and performance status was 0-1 in 47%, 2 in 22%, 3 in 7%, 4 in 2% 
and not documented in 23%. The average length of treatment on 
EGFR TKI was 10.5 months (range 0.5-40) and 36 (31%) patients 
were still on treatment at the time of analysis. Disease progression 
on the EGFR-TKI (PD) had occurred in 82 (71%) of patients and 
28 (34%) of these continued EGFR TKI treatment beyond PD. The 
average length of time on treatment beyond PD was 5.6 months 
(range 1-16) and TKI treatment was ongoing in 9 of the 28 patients. 
25 of the 73 patients (34%) with PD who had stopped EGFR TKI 
went onto receive a second line systemic treatment: pemetrexed 
S1017Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 2 - SUPPORTIVE CARE  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.24-037 FEASIBILITY OF CREATIVE ART THERAPY AS 
A SUPPORTIVE CARE MODALITY FOR PATIENTS WITH 
METASTATIC LUNG CANCER TREATED WITH CHEMO-
THERAPY
Bénédicte Etienne-Mastroianni, Louise Natoli, Jean-François Cor-
dier, Nicolas Girard
Respiratory Medicine Service, Louis Pradel Hospital, Hospices Civils De 
Lyon/France
Background: Creative art therapy (CAT) consists in the use of arti-
stic activities to help patients manage physical and emotional pro-
blems in a therapeutic setting. In oncology, CAT has mostly been 
practiced in palliative-care units. CAT has not been used in lung 
cancer patients so far, especially when chemotherapy treatment 
is still delivered. Our objectives were to prospectively assess the 
feasibility of integrating CAT in the management of patients with 
metastatic lung cancer treated with chemotherapy.
Methods: From 2011/11 to 2013/05, CAT was offered to in- and 
out-patients who received chemotherapy for metastatic lung can-
cer in our department. Creative activities included the production 
of paintings, drawings, and/or sculptures. Patients were assessed 
by a trained art therapist for anxiety levels, self-awareness and 
satisfaction, before and after each art session.
Results: 84 patients were included in the study, among whom 41 
(55%) accepted CAT and received a mean number of 3 sessions. 
In this cohort of 13 men and 28 women, 31 (75%) and 17 (41%) pa-
tients reported improvements in anxiety levels and cancer-related 
symptoms after the art session, respectively. CAT gave satisfaction 
to 37 (90%) patients. These benefits were transient in all cases. 
Main reasons for refusing CAT in the remaining 33 patients inclu-
ded fatigue and lack of interest for arts. Painting and drawings 
from lung cancer patients along the disease management will be 
presented at the meeting.
Conclusion: Our study reports on the feasibility of CAT in lung 
cancer patients receiving chemotherapy. CAT may be considered 
part of the multimodal supportive care management of lung can-
cer patients. This study was supported by an unrestricted grant 
from Hoffmann-La Roche.
Keywords: art therapy, supportive care, chemotherapy
subtype. Minor differences existed with respect to clinical charac-
teristicas and they benefit from receiving active therapy. This ad-
vantage seemed to be lesser in squanous carcinoma.
Keywords: ECOG 2, chemotherapy, clinical outcome
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P2.24-036 ERLOTINIB IN METASTATIC, EGFR WILD-
TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS 
SECOND OR FURTHER LINE OF THERAPY.
Alba Hernández, Lourdes Calera, María Alvarez, Jorge Hernando, 
Irene Torres, Isabel Pajares, Julia Madani, Ana Cebollero, Antonio 
Anton-Torres, Angel Artal
Medical Oncology, Hospital Universitario Miguel Servet/Spain
Background: Erlotinib (E) is a EGF-receptor tyrosine kinase inhibi-
tor (TKI) approved for the treatment of NSCLC after progression 
to first-line chemotherapy irrespective of EGFR status. Currently 
EGFR mutation is usually performed upfront upon diagnosis and 
most mutated patients are treated with first-line TKI‘s. Nowadays, 
patients candidates for second line therapies are EGFR-wild-type.
Methods: Medical records of EGFR-wild-type patients treated with 
E in second or further linesbetween March/2008 and March/2013 
were reviewed.
Results: 85 patients (p) were found. Characteristics: Median age 
61 years (38-83), 76.5% were male. Tobacco: 42.4% were smokers 
and 45.9% former smokers. PS 0, 16p; 1, 50p; 2, 19p; by stage: 
IIIb 27p, IV 58 p. Histology: adenocarcinoma 48p, squamous-cell 
25p, undifferentiated or non-specified 11p, adenosquamous 1p. E 
was given: 40% as second, 44.7% as third and 15.3% as fourth or 
subsequent line. Effectivity: Partial response 9.4%, Stable disease 
48.2%, Progressive disease 41.2%, Not assessable 1%. Overall 
Survival (OS): median 22 weeks (w) (95% CI, 17.4-26 .7), progression 
free survival (PFS) 12w (95% CI ,9.8-14 .2). In smokers PFS was 12w 
also. In squamous carcinomas 10w. In males 11w (these differences 
were non significant). 
Toxicity: 92.9%p presented some side-effect: 70.5% rash (49p, 
G1; 11p, G2); diarrhea 34.1%p (25p, G1; 3p, G2; 1p, G3); asthenia 
29.4%p (12p, G1; 6p, G2; 7p, G3); ocular 2.4%p (2p, G1) and diges-
tive 9.5% (2p, G1; 1p, G2; 1p, G3). Dose was reduced in 12.9%p 
(7p 100 and 4p 125 mg/day). Treatment was interrupted in 7.1%p 
(median 14 days (range 7-23)); most common causes were G3 skin 
rash and diarrhea.
Conclusion: We described the efficacy of Erlotinib in day-to-day 
clinical practice when was given beyond the first-line treatment 
in advanced and metastatic NSCLC without EGFR mutation. Our 
results are in accordance with has been reported from clinical trials 
and may reflect its efficacy in clinical practice.
Keyword: erlotinib, second line, wild-type EGFR
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sents a specific entity characterized by very strong association with 
tobacco-smoking and male gender, peculiar histological-radiologi-
cal presentation, poor prognosis due to major limitations and risks 
to conduct standard-of-care diagnostic and therapeutic interven-
tions in a significant proportion of patients, and possible interest 
of screening. Lung cancer in CPFE syndrome further represents the 
most characteristic and severe model of tobacco-related disease.
Keywords: emphysema, Lung cancer, interstitial disease, pulmona-
ry fibrosis
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P2.24-039 RENAL FAILURE IS THE FIRST CAUSE OF 
DOUBLE MAINTENANCE (BEVACIZUMAB + PEMETREX-
ED) DISCONTINUATION FOR TOXICITY IN REAL WORLD 
SETTING
Marion Sassier1, Paul Lesueur1, Virginie Avrillon1, Acya Bizieux-
Thaminy2, Jean-Bernard Auliac3, Laure Kaluzinski4, Julie Tillon4, 
Gilles Robinet5, Herve Le Caer6, Isabelle Monnet7, Anne Madrozyk1, 
Gabriella Boza4, Lionel Falchero8, Pierre Fournel9, Thomas Ege-
nod10, Anne-Claire Toffart11, Catherine Dubos12, Radj Gervais12
1Centre De Lutte Contre Le Cancer/France, 2Pneumology, Centre Hos-
pitalier Départemental/France, 3Pneumology, Centre Hospitalier F. 
Quesnay/France, 4Ch/France, 5Oncology-pneumology, Hôpital Morvan/
France, 6Centre Hospitalier De Draguignan/France, 7Service De Pneu-
mologie, Centre Hospitalier Intercommunal De Creteil/France, 8Pneu-
mology, , Centre Hospitalier De Villefranche Sur Saône/France, 9Institut 
De Cancerologie De La Loire/France, 10Chu/France, 11Institute Albert 
Bonniot Inserm Grenoble University/France, 12Centre François Baclesse/
France
Background: Maintenance treatment, with either bevacizumab or 
pemetrexed, has been shown to increase PFS and overall survi-
val. Two trials have compared double maintenance (DM) therapy 
(pemetrexed + bevacizumab), to single drug maintenance (bevaci-
zumab in AVAPERL and POINTBREAK studies). Conflicting results 
were found. Before definitive conclusions can be driven from 
these studies and other ongoing study (ECOG 5508), the purpose 
of our retrospective study was to determine in real world setting 
the frequency of double maintenance discontinuation for adverse 
event, and to describe the main toxicities occurring during double 
maintenance.
Methods: All patients who received at least one cycle of pemet-
rexed and bevacizumab as maintenance treatment were identified 
from the Oncology Pharmacy database of participating centers 
since year 2011. All the charts were analyzed retrospectively to ob-
tain clinical data. Lab results were noted for haemoglobin, creati-
nine and liver enzymes before starting and after receiving multiple 
doses of pemetrexed and bevacizumab.
Results: Included were 87 patients treated with two to six cycles 
of induction chemotherapy (median 4), combining platinum with 
pemetrexed and bevacizumab, followed by at least one cycle 
of bevacizumab and pemetrexed as maintenance treatment. All 
patients received supplementation of vitamin B12 and folic acid 
during chemotherapy. Baselines characteristics (%): male 54: stage 
IV 96,5; adenocarcinoma 96,5; median age 58 yr. 57,8% of patients 
had objective response after induction chemotherapy, and 42,2% 
had stable disease after induction chemotherapy. At cut off date: 
treatment was still ongoing for 17 patients (19,8%); 40,6% of pati-
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P2.24-038 LUNG CANCER AND COMBINED PULMONA-
RY FIBROSIS AND EMPHYSEMA SYNDROME IN WES-
TERN PATIENTS: A SERIES OF 47 PATIENTS
Nicolas Girard1, Sylvain Marchand-Adam2, Jean-Marc Naccache3, 
Raphaël Borie4, Thierry Urban5, Stéphane Jouneau6, Eric Mar-
chand7, Anne-Claire Ravel8, Lize Kiakouama-Maleka1, Bénédicte 
Etienne-Mastroianni1, Jacques Cadranel3, Vincent Cottin1, Jean-
François Cordier1
1Hôpital Louis Pradel, Hospices Civils De Lyon/France, 2Hôpital Bre-
tonneau, Centre Hospitalier Régional Universitaire/France, 3Hôpital 
Tenon, Assistance Publique-hôpitaux De Paris/France, 4Groupe Hospi-
talier Bichat-claude Bernard, Assistance Publique-hôpitaux De Paris/
France, 5Centre Hospitalier Universitaire/France, 6Hôpital Pontchaillou, 
Centre Hospitalier Universitaire/France, 7Cliniques Universitaires De 
Mont Godinne, Université Catholique De Louvain/Belgium, 8Centre 
Hospitalier/France
Background: The syndrome of combined pulmonary fibrosis and 
emphysema (CPFE) is characterized by imaging features consisting 
of the association of centrilobular and/or paraseptal emphysema 
and pulmonary fibrosis, associated with subnormal spirometry, 
contrasting with severe impairment of gas exchange with strong 
decrease in carbon monoxide diffusing capacity, and hypoxaemia 
at exercise. Virtually all patients presenting with CPFE are smokers 
and may be at high-risk to develop lung cancer; limited data have 
been made available on such association, mostly from Japanese 
cohorts.
Methods: This retrospective multicentre study was conducted by 
the Groupe d’Etudes et de Recherche sur les Maladies “Orpheli-
nes” Pulmonaires (GERM”O”P), a collaborative group of about 200 
French physicians dedicated to the study of rare pulmonary disea-
ses. Patients presenting with CPFE syndrome and lung cancer at 
the referring centers from 2003 to 2012, were included. The clini-
cal, pathological, and therapeutic features, as well as the outcome 
of patients, were collected and analyzed.
Results: A total of 47 patients presenting with lung cancer and 
CPFE syndrome were identified. All patients but one were men, 
with a mean age of 68 years. All patients were smokers, with a 
mean of 47 pack-years. The CPFE syndrome was diagnosed syn-
chronously with lung cancer in 27 (57%) patients. Detection of 
lung cancer was incidental in 22 (47%) patients. The tumour was 
diagnosed at an early-stage, i.e. stage I-II, in 55% of cases. A pa-
thological diagnosis of lung cancer was obtained for only 38 (81%) 
patients. Histological type was squamous cell carcinoma in 17 
(36%) patients, adenocarcinoma in 14 (30%) patients, non-small cell 
lung cancer not otherwise specified in 3 (6%) patients, small cell 
lung cancer in 3 (6%) patients, and sarcomatoid carcinoma in one 
(2%) patient. There was no significant relation between tumor his-
tology and location in the lung parenchyma (p=0.32). Overall, 20 
of the 47 patients could not receive standard-of-care treatment for 
lung cancer, as per international recommendations and guidelines; 
this limitation was considered to be directly related to the CPFE 
syndrome in 8 (40%) cases. After a mean follow-up of 17 months, 
35 patients were dead, and 12 patients were alive. Causes of death 
included locoregional or systemic tumor progression in 5 (14%) 
and 17 (49%) patients, respectively, respiratory failure in 8 (23%) 
patients, treatment-induced toxicity in 4 (11%) patients, and post-
operative exacerbation of pulmonary fibrosis in 1 (3%) patient.
Conclusion: Lung cancer in patients with CPFE syndrome repre-
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records. Patients identified as having been discussed more than 
once at an MDT meeting were analysed in relation to the docu-
mented reason for re-discussion.
Results: There were 533 patients presented in an MDT meeting 
within the six year period analysed. 463 were discussed once; 57 
twice; 12 three times; and 1 four times. Of those discussed more 
than once, 10 had pathological diagnosis confirmed after the in-
itial MDT presentation, and were re-presented to discuss these 
results and formulate a treatment plan. Of the 10 patients, reasons 
for presentation without pathological diagnosis included: non-
diagnostic tissue sample or origin not specified (4); issues around 
comorbidities and most appropriate avenue for obtaining diagno-
sis (3); and protracted inpatient stay prior to pneumonectomy (1). 
Two patients were discussed prior to pathological diagnosis for no 
apparent reason. 31 cases were re-presented, as initial discussion 
recommended further investigation/staging. Of these, 18 had ini-
tial diagnosis/presumed stage confirmed, 8 were up-staged. After 
initial treatment was completed, 13 patients were rediscussed 
with regard to future treatment/monitoring, 10 due to an increase 
in symptoms and 15 due to disease progression. 50 of the cases 
discussed more than once resulted in the patient being referred to 
additional Specialists.
Conclusion: A review of five years of Lung Cancer MDT data has 
shown that the MDT meeting is performing its role as a central 
point for discussion of treatment options for lung cancer patients. 
In a small number of cases (1.9%) pathological diagnosis had not 
been confirmed prior to the MDT. For the majority of these pati-
ents (8), the meeting provided expert guidance in regards to the 
most appropriate timing and procedure to obtain tissue diagnosis. 
The MDT may benefit from the development of a template/pa-
thway to ensure a reduction in the number of patients presented 
without pathological diagnosis and avoid discussion of some of the 
patients recommended for further investigation/staging. A templa-
te/pathway may enable the MDT to have a more complete picture 
of the patient’s diagnosis and reduce re-presentation/delays in 
treatment.
Keywords: MDT, Pathological Diagnosis, Repeat Presentation
ents stopped DM for progressive disease; 33,3% of patients stop-
ped DM for toxicity (out of these 33% of patients, 42% went on 
single maintenance with Pemetrexed and 58% with Bevacizumab); 
11,6% of patients stopped DM for patient/physician decision, and 
14,4% for other reasons. The most common toxicity responsible for 
DM discontinuation was renal failure (52%).  
Reason for disconti-
nuation (%) 
POINTBREAK AVAPERL This study 
Progressive disease 61,0 54,7 40,6 
Adverse event 13,7 21,6 33,3 
Others reasons 19,8 23,5 25,8 
Conclusion: This retrospective study suggests that in real world 
setting, double maintenance is frequently discontinued for adverse 
event (33,3% of patients). The most frequent adverse event was 
renal failure (half of the cases). Further analyses are ongoing in 
order to identify any predictive factors for renal failure occurrence 
and will be presented at meeting. These results suggest that par-
ticular caution should be taken in order to preserve renal function 
whenever double maintenance (pemetrexed + bevacizumab) is 
considered in a patient with stable or responding tumour after 
induction chemotherapy consisting in platinum, pemetrexed and 
bevacizumab.
Keyword: pemetrexed, bevacizumab, double maintenance,  
toxicity
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P2.24-040 ANALYSIS OF WHY CERTAIN RESPIRATORY 
CANCER PATIENTS DIAGNOSED AND/OR RECEIVING 
CANCER DIRECTED TREATMENT HAVE REPEAT PRE-
SENTATIONS AT MULTIDISCIPLINARY TEAM MEETINGS.
Stephen Dunn1, June A. Rose2
1Cancer Services Wollongong Hospital, Illawarra Shoalhaven Local 
Health District/Australia, 2Cancer Care Centre, Wollongong Hospital/
Australia
Background: Multidisciplinary team (MDT) meetings are seen as 
vital to delivering a coordinated approach to the care of patients 
who have been diagnosed with cancer. Use of an MDT model of 
care has been shown to increase patient recruitment to clinical 
trials, ensure a shortened patient journey from diagnosis to treat-
ment, and result in a higher likelihood that the patient receives 
evidence-based treatment, ensuring better survival outcomes. 
Additionally, MDT’s are essential in ensuring correct diagnosis and 
staging, appropriate treatment modalities, and timely referrals to 
different disciplines within the team. The aim of this study was to 
analyse the reasons why respiratory cancer patients diagnosed 
within the Illawarra Shoalhaven Local Health District (ISLHD) have 
repeat presentations at MDT meetings.
Methods: Patients diagnosed with lung cancer (diagnosis inclu-
ded Small Cell Lung Cancer (SCLC), Non Small Cell Lung Cancer 
(NSCLC) and Mesothelioma) and discussed in the Lung Cancer 
MDT meeting in the ISLHD between 1st January 2006 and 31st 
December 2011 were identified. These identified patients were 
then cross-referenced against MDT meeting data stored in patient 
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as topical use of a steroid sulfatase inhibitor could be considered 
for further investigation.
Keyword: rash, EGFR, NSCLC, supportive care
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P2.24-042 ROLE OF COMORBIDITY ON SURVIVAL AF-
TER RADIO- AND CHEMOTHERAPY FOR NON-SURGI-
CALLY TREATED LUNG CANCER
Anders Mellemgaard1, Maria Iachina2, Anders Green2, Mark Kras-
nik3, Erik Jakobsen4, Margreet Luchtenborg5, Henrik Moller6
1Department Of Medical Oncology, Herlev Hospital, University Of 
Copenhagen/Denmark, 2Center For Clinical Epidemiology, Odense Uni-
versity Hospital/Denmark, 3Rigshospitalet/Denmark, 4Danish Lung 
Cancer Registry, Odense University Hospital/Denmark, 5Knowledge & 
Intelligence Team (London), Public Health England/United Kingdom, 
6Cancer Epidemiology And Population Health, King‘s College London/
United Kingdom
Background: Comorbidity, such as diseases of the cardiovascular, 
pulmonary, and other systems may influence prognosis in lung 
cancer as well as complicate its treatment. The performance sta-
tus of patients, which is a known prognostic marker, may also be 
influenced by comorbidity. Due to the close link between tobacco 
smoking and lung cancer, and because lung cancer is often dia-
gnosed in advanced ages (median age at diagnosis is 70 years), 
comorbidity iwill be present in a substancial proportion of lung 
cancer patients.
Methods: Patients with any stage lung cancer who did not have 
surgical treatment were identified in the Danish Lung Cancer Re-
gistry (DLCR). DLCR collects data from clinical departments, the 
Danish Cancer Registry, Danish National Patient Registry (DNPR) 
and the Central Population Register. A total of 22,999 patients 
with lung cancer were identified. Due to missing variables, 19,561 
patients were available for analysis. Comorbidity was sought in 
the DNPR which is a register of all in and out patient visits to hos-
pitals in Denmark. By record linkage, all lung cancer patients who 
had previously been diagnosed with any of a number of comorbid 
conditions was recorded using the Charlsson comorbidity score 
CCS. First treatment was categorized as chemotherapy, chemo-
radiotherapy, radiotherapy or no therapy. Data on CCS, perfor-
mance status, age, sex, stage, pulmonary function (Fev1), histology 
and type of first treatment (if any) were included in univariable and 
multivariable Cox proportional hazard analyses.
Results: For patients receiving chemotherapy as first treatment 
for lung cancer, survival was increasing worsened by increasing 
comorbidity (HR=1,00,1.10, 1.17, 1,15 for CCS scores 0, 1, 2, 3+ 
respectively). After adjustment for potential confounders, risk esti-
mates was reduced somewhat (HR: 1.00, 1.05, 1.11, 1.11 for CCS 
scores 0, 1, 2, 3+ respectively). For patients receiving radiotherapy 
as first therapy, a different pattern was seen with better survival for 
patients with comorbidity (HR=1.00, 0.99, 0.94, 0.87 for CCS scores 
0, 1, 2, 3+ respectively). After adjustment, this effect disappeared 
and survival was unaffected by CCS. For patients receiving com-
bined radio/chemo therapy there was no significant association 
between CCS and survival.Throughout the analysis, performance 
score remained a strong and highly significant risk factor for sur-
vival, and was robust in multivariate analysis (HRunivariate, all 
patients= 1.0, 1.40, 1.95, 3.23, 5.91 for ECOG performance score 
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P2.24-041 A PILOT STUDY OF A STEROID SULPHATASE 
INHIBITOR (BN83495) IN PATIENTS WITH RASH DUE TO 
TREATMENT WITH AN ORAL EPIDERMAL GROWTH FAC-
TOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-
TKI) FOR NON-SMALL CELL LUNG CANCER (NSCLC)
Linda Mileshkin, Chris Mccormack, Michael Michael, Ben Solo-
mon, Damien Urban, Emma Link, Linda Cowan, John Zalcberg
Division Of Cancer Medicine, Peter MacCallum Cancer Centre/Australia
Background: Treatment with inhibitors of the Epidermal Growth 
Factor Receptor (EGFR) commonly results in rash, which causes pa-
tients significant symptoms and embarrassment, and is not always 
easy to manage with existing treatments. BN83495 is a first in class 
inhibitor of steroid sulphatase (STS), which has been used in early 
phase studies as treatment for steroid-dependent cancers such 
as breast, prostate and endometrial cancer, with one side-effect 
noted to be dry skin. STS converts oestrone sulphate to oestrone, 
a precursor of oestradiol; and dehydroepiandrosterone sulphate 
(DHEA-S) to dehydroepiandrosterone (DHEA), a precursor of ad-
renal testosterone. Blocking these pathways can be helpful in the 
treatment of acne, and patients with X-linked ichthyosis, who have 
an inherited deficiency of STS, do not get acne. Hence we hypo-
thesized that use of BN83495 could help to treat EGFR-associated 
rash.
Methods: Eligible patients had histologically proven, locally recur-
rent or metastatic NSCLC and were continuing to experience rash 
during treatment with an EGFR-TKI (Erlotinib or Gefitinib), despite 
standard management. Patients were treated with BN83495 at 
a dose of 40 mg/day orally for a period of 12 weeks and able to 
continue on standard treatment for rash such as topical steroids or 
antibiotics. For patients with no or minimal toxicity and minimal or 
no rash at 12 weeks, treatment with BN83495 could continue for an 
additional 3 months before being discontinued. If rash worsened 
on discontinuation of treatment at 6 months BN83495 could be 
resumed. The primary objective was to describe changes in the 
frequency and grade of EGFR-related rash and other cutaneous 
side-effects of the EGFR-TKI with the combination. A pragmatic 
sample size of 20 patients was proposed.
Results: Nine patients were registered but 2 withdrew prior to 
commencing BN83495. All patients had grade 2 rash at study 
entry. Of the 7 patients who commenced study treatment, 5 had 
an improvement in rash by one CTC grade. Patients received 
BN83495 for a median of 12 weeks (range 1 – 52) with 2 patients 
recommencing drug after rash worsened when BN83495 was stop-
ped after 6 months of treatment as per protocol. BN83495 was 
generally well tolerated with no grade 3 or 4 toxicity. However, 
all participants experienced grade 2 dry skin related to BN83495 
which was generally manageable with moisturizers, but 2 patients 
stopped study drug early for this reason. 3 patients discontinued 
study drug when the EGFR-TKI was stopped due to disease pro-
gression, and 2 other patients elected to cease the drug at 3 and 6 
months respectively because rash was mild. The study was closed 
early due to poor accrual as many patients were not keen to enter 
a study which involved treating rash by taking an additional tablet.
Conclusion: Treatment of EGFR-TKI related rash with the steroid 
sulfatase inhibitor BN83495 improved the severity of rash in the 
majority of patients but commonly resulted in grade 2 dry skin. 
Accrual to a study which involved treating rash with an additional 
oral medication proved challenging. Alternative approaches such 
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stages of lung cancer. Health service consultation highlighted 
challenges and best practice approaches along with a range of 
systemic issues that influence how care is delivered. Challenges 
included streamlining a complex diagnostic pathway, managing 
multidisciplinary teams that include cancer and non-cancer specia-
lists, early referral to palliative care, coordinating care, involvement 
of primary care, and a lack of standard guidelines for follow-up 
care. Best practice examples were identified across the diagnostic 
and treatment pathway. Results informed a set of national princip-
les including: patient-centred care; timely diagnosis and staging; 
multidisciplinary care; appropriate treatment and supportive care; 
coordinated care; and collection and monitoring of data.
Conclusion: This research identified gaps and variations in the de-
livery of lung cancer care and has built the evidence base to inform 
the development of best practice approaches to support the con-
sistent diagnosis and management of lung cancer in Australia.
Keywords: Patterns and models of care, Gaps and variations in 
care and service delivery, National principles and best practice 
elements of treatment and care, Best practice management of lung 
cancer
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P2.24-044 USE AND COMPARISON OF ERYTHROPOIE-
SIS-STIMULATING AGENTS (ESAS) FOR THE TREATMENT 
OF CHEMOTHERAPY-INDUCED ANAEMIA (CIA) IN PATI-
ENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
Analia Rodriguez Garzotto1, Susana Cortijo2, Santiago Ponce Aix1, 
Cristina Pernaut1, Irene Otero1, Gustavo Ruiz Ares1, Lucia Parrilla1, 
Maria Blázquez1, Franscico Rebollo3, Hernan Cortes-Funes1
1Medical Oncology, Hospital 12 De Octubre/Spain, 2Pharmacy Depart-
ment, Hospital 12 De Octubre/Spain, 3Sandoz España/Spain
Background: There are limited data on the relative effectiveness 
of biosimilar ESAs and other available ESAs for the treatment of 
CIA. In addition, it is unclear whether the most recent recommen-
dations for more conservative use of ESAs to treat CIA are reflec-
ted in real-world clinical practice
Methods: We analysed 73 patients with NSCLC who were inclu-
ded in a retrospective audit of CIA treatment with ESAs in a large 
oncology centre in Spain, with patients treated by multiple physi-
cians. The patients were treated for CIA with Binocrit® 40,000 IU 
QW (n=12), Binocrit® 30,000 IU QW (n=6), darbepoetin alfa 500 µg 
Q3W (n=36) or darbepoetin alfa 150 µg QW (n=19). In addition to 
overall haemoglobin (Hb) outcomes, comparisons were performed 
according to the different ESA treatments given
Results: The mean overall haemoglobin (Hb) at start of ESA treat-
ment was 9.4 g/dL; the mean overall Hb level at the end of treat-
ment was 10.6 g/dL. 36/73 patients (49%) achieved a Hb increase 
of at least 1 g/dL. There were no significant differences (p>0.05) 
between the groups in terms of Hb levels at the start of ESA treat-
ment. At the end of treatment, however, the mean Hb level in the 
group treated with darbepoetin alfa 500 µg Q3W was significantly 
lower than that in the other three groups (Table). No drug-related 
adverse events were recorded 
0,1,2,3 and 4 respectively).
Conclusion: Comorbidity has a limited effect on survival and only 
for patients treated with chemotherapy. It is rather the perfor-
mance of the patient at diagnosis than the medical history that 
prognosticates survival in this patient group.
Keywords: comorbidity, performance status, register linkage  
study
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P2.24-043 DEVELOPING AN OPTIMAL BEST PRACTICE 
MODEL OF CARE FOR THE MANAGEMENT OF LUNG 
CANCER IN AUSTRALIA: A NATIONAL APPROACH
Elizabeth King1, Lauren Deutsch1, Sue Sinclair1, Alison Evans2, 
Sheila Hirst3, Helen Zorbas1
1Cancer Australia/Australia, 2Zest Health Strategies/Australia, 3Sheila 
Hirst Consulting/Australia
Background: In 2007, lung cancer was the leading cause of cancer-
related mortality and morbidity in Australia for both men and 
women. Only 14% of those diagnosed with lung cancer survive five 
years beyond their diagnosis. People living in rural areas, those 
from lower socio-economic status or from certain cultural and lin-
guistic backgrounds have poorer outcomes. Factors contributing 
to differences in survival and outcomes are varied. Cancer Austra-
lia is developing a best practice model of care for the management 
of lung cancer that has national relevance and can be implemented 
locally, with the aim of achieving consistency in approach and 
improving lung cancer outcomes. This abstract describes how the 
evidence base has been built to inform the model of care.  
Methods: A systematic review of international and national lite-
rature on patterns and models of care for lung cancer informed 
themes explored through qualitative and quantitative research. A 
tiered approach to data collection included: (i) mapping of lung 
cancer services across Australia; (ii) health service consultation 
through interviews and site visits; and (iii) consumer consultation 
through a national survey and targeted interviews. Findings were 
presented and discussed at a national workshop with clinical lea-
ders, consumers, researchers and service delivery experts to re-
view and define principles and elements of best practice care.
Results: The patterns of care literature for lung cancer identified 
variations in time to diagnosis, access to active treatment, re-
treatment and palliative care. Service delivery themes identified 
through the review and research included multidisciplinary care, 
specialist involvement in diagnosis and treatment, care coordina-
tion, early integration of palliative care, uptake of guidelines and 
quality measures, involvement of primary care and consideration 
of supportive care needs. Lung cancer service mapping identified 
192 services across Australia providing some elements of lung 
cancer care. Approximately two-thirds were public and one third 
private. Multidisciplinary teams were identified in 58 services 
(30%), the majority in metropolitan locations (n=41, 71%). Con-
sumer consultation identified variations in time to first specialist 
appointment (two weeks to two months), definitive diagnosis (two 
weeks to three months); and treatment (one week to two months). 
Consumers identified that improvements could be made in the 
way information about lung cancer is communicated across all 
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mood fluctuations, loss and grief issues, relationship and existenti-
al concerns.
Conclusion: The revised model made a significant impact on 
meeting the previously unmet needs of this patient group through 
providing timely assessments and interventions. This highlights the 
potential effectiveness of integrating psychology services within 
medical cancer streams. We received no funding and there was no 
duality or conflict of interest
Keywords: model of care, distress, psychological need
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P2.24-046 QUALITY OF LIFE IN PATIENTS WITH MALIG-
NANT PLEURAL EFFUSION UNDERGOING PLEURODESI
Ricardo M. Terra1, Alessandro W. Mariani2, José D.A. Neto3, Milena 
M. Suesada2, Paulo M. Pêgo-Fernandes2
1Instituto Do Câncer Do Estado De São Paulo (ICESP) Fmusp/Brazil, 
2Thoracic Surgery, Incor Hcfmusp/Brazil, 3Hospital Aristides Maltez/
Brazil
Background: Pleurodesis is a palliative procedure which main pur-
pose is to alleviate respiratory symptoms of patients with malignant 
pleural effusion. Nevertheless, quality-of-life is an outcome rarely 
explored in literature. The main purpose of this study was to evalua-
te the quality-of-life before and 30 days after pleurodesis in patients 
with malignant pleural effusion. The secondary objective was to 
identify predictors of quality-of-life improvement after pleurodesis.
Methods: Retrospective study including all patients with recurrent 
malignant pleural effusion who underwent pleurodesis at Hospital 
das Clinicas (University of Sao Paulo) and Hospital Aristides Maltez 
from 2008 until 2012 and who filled out quality-of-life questionnaires 
before and 30 days after the procedure. In both institutions the 
World Health Organization-bref general quality-of-life questionnaire 
has been regularly applied to all patients undergoing pleurodesis 
since 2007. Paired T-test was used to compare before and after 
scores and multivariable regression models were used to identify 
predictors.
Results: During the study period 132 patients were included (26 
men, 106 women, mean age 58.1 +- 11.8). The primary tumors were: 
breast (84), lung (25), ovary (4), lymphoma (11) and other (8). The 
mean prepleurodesis quality-of-life scores were: physical domain 
35.8+-17.7, psychological domain 58.8+-17.7, social domain 52.8+-
14.8, and environmental domain 65.4+-18.8. Thirty days after pleu-
rodesis, the physical aspect (8.1 pts, p=0.0001) and the environmen-
tal domain (3.6 pts, p=0.008) improved significantly while the other 
two domains remained unchanged. Predictors of improvement of 
quality-of-life in this sample were: ovary cancer (p=0.015), pleural 
fluid glucose (p=0.012), and low physical aspect score before pleu-
rodesis (p=0.001).
Conclusion: All aspects of quality-of-life are deeply compromised 
in patients with recurrent malignant pleural effusion. Pleurodesis 
improves quality-of-life thirty days after the procedure particularly in 
patients with ovary cancer and with very low physical status scores.
Keywords: pleural effusion, pleurodesis, quality-of-life, palliative 
care
ESA 
Mean 
treatment 
duration 
(weeks) 
Mean Hb at 
start of treat-
ment (g/dL) 
Mean Hb at end of 
treatment (g/dL) 
Darbepo-
etin 150 
µg QW 
4.16 9.2 11.3 
Darbepo-
etin 500 
µg Q3W 
4.59 9.4 10.1 
Binocrit 
30,000 IU 
3.50 9.4 11.1 
Binocrit 
40,000 IU 
3.67 9.5 10.7 
Conclusion: Our data indicate that Hb outcomes in a real-world 
clinical practice setting are similar for the ESA treatments used 
with the exception of Darbepoetin 500 µg Q3W, which achieved a 
significantly lower Hb at the end of treatment. We consider the use 
of ESAs in our centre to be conservative and safe, and to reflect 
the most recent change in ESA prescribing information and recom-
mendations for more moderated use in patients with CIA (that is, 
use the lowest possible dose and duration of treatment necessary 
to avoid transfusions)
Keywords: anemia, erithropoyetin, Lung cancer
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P2.24-045 ENHANCING PSYCHOLOGICAL SERVICES 
FOR PEOPLE WITH LUNG CANCER
Maria Ftanou1, Tessa Jones1, Annabel Pollard1, Mary Duffy2, David 
Ball3
1Clinical Psychology, Peter MacCallum/Australia, 2Ambulatory Care, 
Peter Mac Callum Cancer Centre/Australia, 3Dept. Of Radiation Oncolo-
gy, Peter MacCallum Cancer Centre/Australia
Background: Lung cancer patients have a higher level of disease 
burden, higher unmet psychosocial needs and lower uptake of 
psychological services compared with other cancer groups. The 
Department of Clinical Psychology, in collaboration with the lung 
cancer service at PeterMac, revised the model of psychological 
care to optimise access and improve psychosocial well-being.
Methods: This revised model of care involved realigning the Psy-
chology Outpatient Clinic to run in parallel with the Lung Outpati-
ent Clinic. The aims were to: 1) provide a timely and early interven-
tion service; 2) increase patient access to psychology services; 3) 
reduce the burden of accessing psychology services; and 4) assess 
psychological needs of patients and provide appropriate psycholo-
gical interventions. Patient demographics, uptake, referral informa-
tion and session data were collected for a three month period and 
compared to data from the same period in the previous year.
Results: Our sample included a total of 37 patients with lung can-
cer. The results indicated that the revised model of service delivery 
led to: a 21% increase in new lung patient referrals for psychology 
services; an almost 100% uptake of services; and a 186% increase 
in the number of scheduled sessions attended by lung patients. 
The main reasons that patients attended sessions were to address 
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P2.24-048 PREVALENCE OF PULMONARY EMBOLISM 
IN PATIENTS WITH ONCOGENE ADDICTED ADVANCED 
LUNG ADENOCARCINOMA
Lucio Crino1, Rita Chiari1, Melina Verso2, Chiara Bennati1, Laura 
Franco2, Luca Paglialunga1, Mattias Fischer3, Stefano Mosca3, Vale-
ria Marconi3, Giancarlo Agnelli2
1Medical Oncology, Santa Maria Della Misericordia Hospital/Italy, 2Di-
vision Internal And Vascular Medicine - Stroke Unit, Santa Maria Della 
Misericordia Hospital/Italy, 3Radiology Department, Santa Maria Della 
Misericordia Hospital/Italy
Background: Non-small cell lung cancer is associated with a 
higher risk of thromboembolic events in comparison with SCLC. 
Adenocarcinoma represent roughly 75% of NSCLC patients. Lung 
adenocarcinomas harboring EGFR and KRAS mutations as well 
as EML4/ALK rearrangements represent distinct subsets of this 
disease. No data are available concerning the prevalence of pul-
monary embolism in lung adenocarcinoma patients with these 
mutations. The aim of the study was to evaluate the prevalence 
of pulmonary embolism in patients with stage IIIB and IV lung 
adenocarcinomas harboring EGFR and KRAS mutations as well as 
EML4/ALK traslocations.
Methods: Patients with stage IIIB or IV NSCLC referred to Division 
of Medical Oncology at the Hospital of Perugia between 2008 
and 2012 were included in the study. In these patients, contrast-
enhanced CT scans of the chest were reviewed for the presence of 
pulmonary embolism by a panel composed by three radiologists. 
In the same patients, data regarding the molecular characteristics 
(EGFR exons 18-21 and KRAS exon 2 mutations as well as EML4/
ALK traslocations) were collected.
Results: A total of 209 patients with stage IIIB or IV NSCLC were 
included in the study. A histologic diagnosis of lung adenocarci-
noma was done in 173 patients (82.7%). In 127 of these patients 
sequence analysis for known EGFR (exon 18-21) and KRAS (exon 
2) mutations was performed. In this population 31/173 patients 
were EGFR mutated (17.9%), 27/173 were K-RAS mutated (15.6 %) 
and 17/173 were EML4/ALK positive (9.8%). 41 patients with lung 
adenocarcinoma had a diagnosis of pulmonary embolism at CT 
scan (23.7%). Of these, 34.1% had no oncogene mutations in com-
parison with 28.8% of the patients without pulmonary embolism. 
Of the 41 patients with a diagnosis of pulmonary embolism 12.1% 
had an EGFR mutation and 12.1% a KRAS mutation, in comparison 
with 19.7% and 16.6% of patient without pulmonary embolism, 
respectively. In patients with lung adenocarcinoma, EML4/ALK re-
arrangements was observed in 19.5% among patients with pulmo-
nary embolism and in 6.8% among patients without it. The risk of 
pulmonary embolism was 3.3-fold higher in presence of EML4/ALK 
rearrangements in comparison with no EML4/ALK rearrangements 
[OR: 3.3 (95%CI 1.2-9.2)].
Conclusion: In lung adenocarcinoma patients, the presence of 
EML4/ALK traslocation seems to be associated with a high risk 
of pulmonary embolism and could help in identifying patients at 
particular high risk who might benefit from an antithrombotic pro-
phylaxis. These preliminary data need to be confirmed by further 
studies.
Keywords: pulmonary embolism, lung adenocarcinoma, driver 
mutations
POSTER SESSION 2 - SUPPORTIVE CARE  
TUESDAY, OCTOBER 29, 2013 - 09:30-16:30
P2.24-047 PALLIATIVE CARE UNITS IN THE MANAGE-
MENT OF PATIENTS WITH ADVANCED LUNG CANCER 
- THE EXPERIENCE OF THE MEDICAL UNIVERSITY OF 
VIENNA
Sophie Schur1, Eva K. Masel1, Romina Nemecek2, Herbert Watzke1, 
Robert Pirker1
1Department Of Medicine I, Medical University Of Vienna/Austria, 
2Department Of Dermatology, Medical University Of Vienna/Austria
Background: Patients with advanced lung cancer suffer from a 
high burden of tumor-related symptoms. Thus palliative care is an 
important treatment modality in these patients. Palliative care units 
have been established in many comprehensive cancer centers in 
order to achieve this. Here we report on the experience we have 
obtained at the Palliative Care Unit of the Medical University of 
Vienna in the management of patients with advanced lung cancer.
Methods: We retrospectively reviewed medical records of 86 pati-
ents with advanced lung cancer who were treated at our Palliative 
Care Unit between June 2010 and March 2013. We determined 
reasons for admission, duration of hospitalization, non-invasive as 
well as invasive medical interventions, and clinical outcome.
Results: We report on 86 patients with advanced lung cancer 
(74 % NSCLC, 26 % SCLC) who had been admitted to our 
Palliative Care Unit within a period of 34 months. Lung cancer 
patients comprised the largest group of cancer patients who are 
admitted to our unit. Reasons for admissions were deterioration 
of performance status (41 %), dyspnea (13 %), pain (38 %), 
psychosocial reasons (7 %), and other (1 %). Re-admissions 
occurred in 20 % of all patients. The patients had the following 
characteristics: median age 62 years (range 42-85 years), 38 % 
females and 62 % males, ECOG performance status 0-2 38 % 
and >2 62%, median body mass index (BMI) 24 (range 14-39). 
Median duration of hospitalization was 16 days (range 1-101 days). 
The following treatments were delivered during hospitalization: 
analgesic treatment according to the WHO I-III ladder (85 %), 
palliative radiotherapy (31 %), palliative chemotherapy (7 %), and 
invasive procedures (such as thoracocentesis, pleurX drainage 
system, pleurodesis, bronchial stenting, invasive neurolysis and 
other in 26%). Antibiotic therapy was delivered in 33 % and 
antipressants or antipsychotropic drugs in 38 % of all patients. 
Palliative sedation by means of a continuous intravenous or 
subcutaneous infusion with midazolam was administered in 25%. 
Dietary counseling and spiritual as well as psychosocial support 
was offered to all patients and accepted by most of them. 77 
% of all patients died during their stay, mostly due to disease 
progression. The remaining 23 % of all patients were discharged 
with improvements in their tumor related symptoms or stable 
disease and were offered home care or hospice access.
Conclusion: Patients with advanced lung cancer did benefit from 
admission to the Palliative Care Unit. Medical as well as non-
medical interventions resulted in improvements of cancer-related 
symptoms and better coping with the disease. Thus Palliative 
Care Units should be part of the multidisciplinary management 
of patients with advanced lung cancer. Schur S and Masel EK 
contributed equally to this work
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Keywords: non-small cell lung cancer, zoledronate, fever, prog-
nostic factor
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P2.24-050 TREATMENT PATHWAYS OF PATIENTS  
DIAGNOSED WITH NON-SMALL CELL LUNG CANCER 
- AN AUDIT OF PRACTICE AT A REGIONAL TEACHING 
HOSPITAL.
Cameron J. Hunter1, Louise M. Nott2
1Respiratroy Medicine, Royal Hobart Hosptial/Australia, 2Medical Onco-
logy, Royal Hobart Hospital/Australia
Background: Lung cancer is the main cause of cancer death for 
both men and women in Australia. Non-small cell lung cancer (NS-
CLC) usually presents late in the disease when treatment options 
are limited. Surgery remains the main stay of curative treatment 
with definitive radiotherapy or chemoradiotherapy used in some 
patients unfit for surgery or with locally advanced disease. In-
creasing use of chemotherapy with introduction of new targeted 
therapies has broadened the therapeutic choices for patients. We 
wished to look at what happened to patients with NSCLC in our 
hospital (RHH)
Methods: An audit was performed of patients presenting at our 
MDT (at which all patients with lung cancer in southern Tasmania 
are discussed) in 2010 and 2011 with a diagnosis of NSCLC. We 
looked at the type of therapy assigned (or not) and where they had 
chemotherapy the number of lines and types of treatment given.
Results: 177 patients presented with NSCLC. Histology showed 99 
adenocarcinomas, 48 squamous cell, 20 NSCLC-NOS, 5 large cell 
neuroendocrine, 3 adenosquamous cell and 2 with synchronous 
primaries. 48 (27%) patients received no treatment beyond palli-
ative care. Mostly this was due to comorbidities or patient wishes 
(8) but 13 (7%) patients died around the time of diagnosis. 38 (21%) 
patients underwent surgery (3 pneumonectomies, 31 lobectomies 
and 4 wedge resections). 3 had adjuvant radiotherapy and 5 had 
adjuvant chemotherapy. 79 (45%) patients under went radiothe-
rapy: 59 had palliative radiotherapy, 12 chemoradiotherapy, 4 
definitive radiotherapy, 1 brachytherapy and 3 had adjuvant radio-
therapy to surgery. 84 (47%) were reviewed by medical oncologist 
of whom 56 (32% of total, 67% of those reviewed) received some 
form of 1st line chemotherapy. There were 13 different regimens 
of first line therapy, most common being carboplatin/gemcitabine 
(n=19) and carboplatin/vinorelbine (n=10). The reason for choice of 
therapy was not usually stated and varied between specialists but 
individual specialists also varied regimens used. 22 patients had 
2nd line therapy, 12 patients had 3rd line and 5 patients had 4th line. 
16 patients had pemetrexed maintenance therapy (1 in combinati-
on with carboplatin) of which 9 received 3 or less cycles, 1 patient 
received 26 cycles. 13 (7%) patients received erlotinib. The patients 
were reviewed by 7 different specialists (3 were seen elsewhere in 
the state) with one specialist seeing 36 patients but 4 seeing less 
than 10 over the 2 year period.
Conclusion: The majority of our patients received some form of 
therapy. Our radiotherapy usage is below expected numbers and 
chemotherapy usage is particularly low. This may reflect our pati-
ents’ demographics. The wide variety of first line regimens used 
makes over all conclusions about the effect of chemotherapy dif-
ficult. A number of medical oncologists treat less than 5 patients 
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P2.24-049 THE SIGNIFICANCE OF FEVER AFTER THE 
FIRST ADMINISTRATION OF ZOLEDRONATE AS A PRO-
GNOSTIC FACTOR IN PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER.
Hiroki Izumi, Kennichi Takeda, Tomohiro Sakamoto, Shizuka Ito, 
Kosuke Yamaguchi, Hirokazu Touge, Jun Kurai, Haruhiko Makino, 
Masahiro Kodani, Masaki Nakamoto, Hiroki Chikumi, Tadashi 
Igishi, Eiji Shimizu
Molecular Respirology, Tottori University/Japan
Background: Nitrogen-containing bisphosphonates(N-BPs) are 
usually administered to patients with advanced cancer harboring 
bone metastases to prevent skeletal related events(SREs). 
Preclinical studies have demonstrated the anticancer activity of 
N-BPs in vitro and in vivo. Zoledronate (ZOL) is a type of N-BP, 
and clinical trials of ZOL have demonstrated survival benefits in 
breast cancer and multiple myeloma. However, the benefit of ZOL 
to overall survival for lung cancer patients is still controversial. The 
first administration of intravenous N-BPs are occasionally induced 
fever, which is due to the activation of γΔ T cells. γΔ T cells are 
a small subset of T lymphocytes that play an active role in the 
immunosurveillance against infections and tumors as components 
of innate immunity. However, the significance of ZOL-induced fever 
is not clear in patients with advanced non-small cell lung cancer 
(NSCLC). The aim of this study was to estimate the prognostic 
value of fever after N-BP administration in advanced NSCLC 
patients.
Methods: We retrospectively reviewed 46 patients with advan-
ced NSCLC who recerved ZOL treatment from March-2009 to 
March-2011 in the department of respiratory medicine in Tottori 
University hospital. ZOL-related fever was defined as body tempra-
ture more than 37.5℃ within 48 hours after the first administration 
of ZOL. Fever that persister for > 2 days, or treated with antibiotics 
were not defined as ZOL-related fever. Even if there were records 
of ZOL administration, we excluded the case with no record in 
terms of fever after treatment with ZOL. We analysed patients who 
had Eastern Cooperative Oncology Group (ECOG)-performance 
status (PS) ≦ 1. Clinicopathological factors such as age, gender, 
smoking history, disease stage, histological type, and epidermal 
growth factor receptor (EGFR) mutation status were analyzed using 
univariate and multivariate analyses, and these factors were com-
pared between the fever group and non-fever group.P-value of < 
0.05 were considered statistically significant.
Results: Fifteen out of 46 patients (32.6%) experienced fever after 
the first administration of ZOL. No significant differences in clini-
copathological characteristics were seen between the two groups. 
The mean survival time (MST) observed in the fever group [MST 
1003 vs. 471 day, hazard ratio (HR) 2.15, p=0.04] was significantly 
longer than the non-fever group. Univariate analyses for the pro-
bability of overall survival indicated that a positive EGFR mutation 
status (p=0.016), non-squamous type of cancer (p=0.02), no smo-
king history (p=0.001), and female gender (p=0.036) were predic-
tors of significantly longer survival time. Comparatively, the pre-
sence of fever after ZOL administration [HR, 2.73; 95% confidence 
interval (CI) 1.17-6.34, p=0.020] and having no smoking history [HR, 
0.13; 95%CI 0.20-0.85, p=0.033] were still significant predictors for 
longer survival time in multivariate analyses.
Conclusion: Fever after the first administration of ZOL was an in-
dependent prognostic factor in patients with advanced NSCLC.
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stump margin were suspected to a local recurrence. It has increa-
sed uptakes in PET-CT imaging, like as cancer recurrence. It should 
be completely excised as soon as possible because it is growing 
infiltrative to surrounding tissues and it would recur sometimes.
Keywords: Cicatricial fibromatosis, Desmoid fibromatosis, PET-CT
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P2.24-052 A SINGLE CENTRE REVIEW OF ENDOTHELIAL 
GROWTH FACTOR RECEPTOR (EGFR) MUTATION  
TESTING: A REGIONAL AUSTRALIAN EXPERIENCE.
Scott Twaddell1, Yolande Cox2
1Department Of Medicine, Calvary Mater Newcastle/Australia, 2De-
partment Of Nursing, Cancer Care Coordinator, Calvary Mater New-
castle/Australia
Background: Endothelial Growth Factor Receptor (EGFR) mutation 
testing is now recommended practice for lung adenocarcinoma. 
Those patients with EGFR mutations are eligible for targeted 
agents which offer survival and quality of life advantages with re-
duced toxicity in some. Several reports have suggested particular 
samples are more likely to give reliable EGFR mutation results than 
others. We were interested in investigating the types of samples 
locally that were viable for testing and to assess the population 
rate of EGFR mutation positivity in adenocarcinoma for which there 
is little published data in Australian (mainly Caucasian) populati-
ons.
Methods: Data was systematically collected for tissue samples 
sent for EGFR mutation testing over a three year period. Basic 
demographic data, sample type and test results were recorded. 
Testing was performed as part of the routine workup for patients 
with lung adenocarcinoma. Chart review was undertaken to clarify 
sampling methods and test results if required.
Results: 214 sequential specimens from patients with proven ade-
nocarcinoma were sent for analysis of the presence of EGFR mu-
tation. 197 specimens were of adequate quality for analysis (>20% 
of specimen composed of tumour cells). There were 22 positive 
tests for EGFR mutations (16 female; 11 non- or never-smokers). 
Table 1 outlines the types and adequacy of specimens collected 
for testing. There was no association between specimen type and 
adequacy for analysis. 27 specimens were unable to be analysed. 
Of these 12 were labelled failed tests and 15 returned incomplete 
results for at least one of four exons. 17 specimens were labelled 
inadequate for testing; 9 of those were reported as negative for 
EGFR mutations despite being reported as having less than 20% 
tumour cells in the specimen. 6 of 12 failed tests were adequate for 
testing. 14 of 15 incomplete tests were adequate for testing.  
with lung cancer a year. Consolidation of care to a smaller number 
of specialists should be considered.
Keywords: NSCLC, chemotherapy, radiotherapy, surgery
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P2.24-051 CICATRICIAL FIBROMATOSIS WITH HIGH 
SUV WERE SUSPECTED BY A LOCAL RECURRENCE OF 
BRONCHIAL STUMP IN PATIENT WITH LUNG CANCER
Yoo Sang Yoon1, Soon Hyo Park2, Daewook Yeh3
1Thoracic Surgery, Dirams/Korea, 2Pulmonology, Dirams/Korea, 3Radio-
logy, Dirams/Korea
Background: Cicatricial fibromatosis arises in a surgical scar is a 
well-known clinical condition. However, its occurrence after thora-
cic surgery, especially at bronchial stump. is extremely rare.
Methods: 42 years old male patient had undergone video assisted 
thoracoscopic right lower lobectomy 18 months earlier for primary 
lung cancer. There was no evidence of recurrence in last chest CT 
examination until 9 months ago. A 33mm sized mass was found be-
side right lower lobe stump margin in subcarinal space in chest CT 
examination. It had increased uptakes (SUVmax 6.5) in F-18 FDG 
PET/CT imaging. There were not any findings of distant metastasis 
in chest CT and F-18 FDG PET/CT imaging. Therefore we thought 
it would be a local recurrence of lung cancer at bronchial stump 
site. We performed biopsy of a mass using EBUS and EUS to con-
firm the diagnosis. The results were only fibrotic tissue without evi-
dence of malignancy. So he had undergone a complete excision of 
subcarinal mass through thoracotomy. It was very hard and tightly 
adhesive to surrounding tissues, as bronchus and esophagus. 
Results: Pathologic report was that it was myofibroblast prolife-
ration with infiltrative margin, which was diagnosed as cicatricial 
fibromatosis.
Conclusion: In this case, Cicatricial fibromatosis beside bronchial 
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P2.24-053 11-YEAR SURVIVAL OF A PATIENT WITH UN-
TREATED, EGFR POSITIVE, PULMONARY ADENOCARCI-
NOMA
Nicolas C. Kahn1, Arne Warth2, Roland Penzel2, Claus-Peter Heus-
sel3, Felix Herth1, Alicia Morresi-Hauf4, Philipp Schnabel5
1Pulmonary And Respiratory Critical Care Medicine, Thoraxklinik At 
Heidelberg University Hospital/Germany, 2Institute Of Pathology, 
University Of Heidelberg/Germany, 3Diagnostic And Interventional 
Radiology, Thoraxklinik At Heidelberg University Hospital/Germany, 
4Institue For Pathology, Asklepios Hospital Gauting/Germany, 5Sektion 
Thoraxpathologie, Pathologisches Institut/Germany
Background: Lung cancer is the most common cancer related 
death and the fourth most common cause of death in Germany. 
The five-year survival rate in European and North American coun-
tries is in between 5,5% and 15,7%. In the last couple of years 
though, significant progress has been made concerning persona-
lized medicine in this disease entity. Novell targeted therapies with 
tyrosin kinase inhibitors (TKI) for patients with a mutation in the 
EGFR gene offer a new treatment option.
Methods: A 78-year old male patient was referred to the Tho-
raxklinik Heidelberg with atypical thoracic pain after cardiologic 
assessment. In 2001 he was given the diagnosis of pulmonary 
adenocarcinoma of the right upper lobe in the Asklepios Hospital 
Munich-Gauting. Because of his overall good clinical condition the 
patient had declined any treatment to this point. A new PET- CT 
was conducted and compared to the computer tomography of 
2001 revealed a significantly grown lesion in the right upper lobe 
as well as new, small bipulmonar lesions suspicious of lung metas-
tasis.
Results: A new histological assessment was performed on an en-
dobronchial forceps biopsy of the now occluded right upper lobe. 
The diagnosis of a partial lepidic differentiated adeno-carcinoma 
was consistent with the diagnosis as well as the preserved speci-
mens of 2001. We were able to perform an EGFR mutation analysis 
of the 2001,- as well as of the new tumor specimens through PCR-
amplification and bidirectional sequencing of exons 18, 19 and 21. 
In each of the probes we detected a deletion combined with an 
Specimen Type 
Number collec-
ted (% of total) 
Number of specimens with >20% 
of tumour cells in specimen  
(% of number collected) 
Number of failed or 
incomplete tests 
Image guided FNA Bx 27 (12.5) 25 (93) 5 
Image guided core Bx 16 (7.5) 15 (94) 3 
Bronchial Bx/TBNA/EBUS/TBLB (bron-
choscopy) 
89 (42) 78 (88) 11 
Lung/Pleura/Pericardium/ Mediastinal 
LN Bx (surgical) 
49 (23) 48 (98) 5 
Pleural fluid 9 (4) 8 (89) 0 
Surgical LN Bx 4 (2) 4 (100) 0 
Abdominal/oesophageal node 3 (1.5) 3 (100) 0 
Brain/ cerebellar metastasis 11 (5) 10 (91) 1 
Musculoskeletal metastasis (surgical) 6 (3) 6 (100) 2 
214 (100) 197 (92) 27 (13%) 
Conclusion: In our population (majority Australian born Caucasi-
ans), the percentage and profile of EGFR positivity is similar to that 
reported in other studies. Representative samples can be obtained 
from many different types of tissue, in particular, fine needle aspi-
rates and core biopsies of lung parenchyma and lymph nodes as 
well as from pleural fluid.
Keywords: Lung cancer, Treatment, EGFR mutation, Pathology
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Of those patients, 58.3% were male. They were between 54-81 
years old (M = 66.2; SD = 6.6); 62.5% were married; 54.2% had at 
least college degree. The NSCLC were 87.5% adenocarcinoma and 
12.5% epidermoid. The survival rate was 10.7 months for all pati-
ents (range from 1 to 50 months; SD = 10.7); being 6.4 months for 
moderate to severe distress and 14.2 for mild distress. Seven types 
of chemotherapy regimen were prescribed: Cisplatin+Gemcitabine 
(45.8%); Alimta+Carboplatin (16.7%); Carboplatin+Taxol+Avastin 
(8.3%); Erlotinib (8.3%); Taxol+Carboplatin (8.3%); Cisplatin+Alimta 
(8.3%); Cisplatin+Gemcitabine+Avastin (4.2%). Half of patients 
(54.2%) reported moderate to severe distress (DT ≥ 4). The most 
problems reported at PL were worry (70.8%), sadness (66.7%), fears 
(45.8%), sleep (70.8%), fatigue (66.7%), pain (58.3%), eating (50%) 
and breathing (50%). Considering the survival curves, patients with 
mild distress showed better survival rate than patients with mode-
rate to severe distress (x2 = 4.16; p = .04).
Conclusion: Despite the limited sample size, the data suggest that 
mild distress is a prognostic factor in survival rate. The high preva-
lence of patients with moderate to severe distress, as well as, the 
problems-related distress, highlighted the importance of the dis-
tress screening and also to create an advanced care planning for 
patients with lung cancer, from the time of diagnosis until the last 
phase of illness, helping them to cope with this reality. More stu-
dies are thus needed to investigate the implication of distress level 
at diagnosis as a prognostic factor, increasing and diversifying the 
sample in order to make the data more generalizable.
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P2.24-055 REALCARE: RECOVERY AFTER LUNG RESEC-
TION. STUDY DESIGN AND PRELIMINARY RESULTS.
Josien G. Timmerman1, Michel W.J.M. Wouters2, Marit G.H. Dek-
ker-Van Weering1, Thijs M. Tönis1, Hermie J. Hermens3, Miriam 
M.R. Vollenbroek-Hutten1
1Telemedicine Research Group, Roessingh Research And Development/
Netherlands, 2Netherlands Cancer Institute - Antoni Van Leeuwenhoek/
Netherlands, 3Faculty Of Electrical Engineering, Biomedical Signals And 
Systems, Telemedicine Group, University Twente/Netherlands
Background: Although lung resection still provides the best long-
term outcome for lung cancer, it is also associated with a consi-
derable decay of physical and psychosocial health status. Physical 
activity (PA) is considered beneficial for post-surgery recovery, and 
patients often are encouraged to increase PA in daily life. Surpri-
singly, only few studies objectively assessed daily PA in lung cancer 
patients, and none of these studies examined possible associa-
tions between daily PA and recovery of health status following lung 
resection. Therefore, our study aims to explore the relationship 
between daily PA and recovery of physical and psychosocial health 
status in lung cancer patients treated with lung resection.
Methods: Lung cancer patients undergoing curative lung resec-
tion at the Nederlands Canker Institute-Antoni van Leeuwenhoek 
Hospital in Amsterdam are enrolled in the study before surgery 
(T0). Follow-up measurements are scheduled at 1 (T1), 3 (T2) and 
6 months (T3) post-surgery. PA levels are measured for three days 
on all occasions using a triaxial accelerometer and expressed as 
amount of activity in counts per minute. Secondary outcome mea-
sures include VO2max, pulmonary function, six-minute-walking-di-
stance, times standing on the 30-seconds-chair-stand test, quality 
of life, mental distress, fatigue, and pain. The aim is to include 60 
insertion c.2127_29del (p.E709_T710delinsD) in exon 18.
Conclusion: The above mentioned mutation has already been 
described in the literature but there is no information concerning 
the responsiveness of tyrosine kinase inhibitors in this particular 
mutation. Now that the cancer had spread we decided to start 
treatment with erlotinib. Due to cutaneous side effects the patient 
decided to discontinue this therapy. Since then he has been in 
regular follow-up showing a stable disease and good general state 
of health.
Keywords: Lung cancer, EGFR mutation, survival
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P2.24-054 RELATIONSHIP BETWEEN DISTRESS LEVEL 
AND SURVIVAL RATE AMONG NEWLY DIAGNOSED STA-
GE IV NON-SMALL CELL LUNG CANCER (NSCLC): PILOT 
STUDY
Cristiane D. Bergerot1, Augusto P. Prata2, Marco M. Buso2
1Psycho-Oncology Service, Centro De Cancer De Brasilia (CETTRO)/
Brazil, 2Medical Oncology Service, Centro De Cancer De Brasilia (CET-
TRO)/Brazil
Background: Lung cancer is one of the most appalling diagnoses, 
associated with significant patient distress, poured quality of life 
and often limited survival. Moreover, the current literature empha-
sizes the effect of distress level on survival rates. The purpose of 
this study was to explore the survival curve, considering the dist-
ress level reported by patients with advanced NSCLC cancer at the 
beginning of the treatment.
Methods: A sample of 24 patients with newly diagnosed stage IV 
NSCLC, answered the Distress Thermometer (DT) and the Problem 
List (PL) before start the first chemotherapy infusion. They treated 
at a private cancer center, located at Brasília, Brazil. Survival was 
calculated from time of the histopathological diagnosis. The data 
was analyzed with descriptive evaluation, followed by Kaplan-Mei-
er models, to test associations with survival and distress.
Results: 
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P2.24-056 A TERTIARY CANCER EXPERIENCE IN USE  
OF TKI IN METASTATIC LUNG CANCER
Vanita Naronha1, Vijay M. Patil2, Amit Joshi2, Bhavesh P. Poladia2, 
Gautam Goyal2, N Purandare3, Abhishek Mahajan4, Anuradha 
Chougle2, Nirmala Jambekar5, Saral Desai5, K Prabhash2
1Medical Oncology, Tata Memorial Centre/India, 2Medical Oncology, 
TMH/India, 3Bio Imaging, Tata Memorial Hospital/India, 4Radiodiagno-
sis, TMH/India, 5Pathology, Tata Memorial Hospital/India
Background: Use of tyrosine kinase inhibitors is a attractive op-
tion due to its predicatble profile of side effects & it been a oral 
tablet. Its efficacy and toxicities have been well described in both 
east asian and western population. However not much literature is 
available on its use from India. The aim of this paper was to audit 
the population which received TKI (Erlotinib or Gefinib) in a tertiary 
cancer center in India.
Methods: All patients who received TKI in lung cancer were identi-
fied from our OPD database. There case records, electronic medi-
cal records & our OPD databases were utilized. The demographic 
profile, the staging details , details of EGFR mutations, the RECIST 
patients by October 2015.
Results: So far, fourteen lung cancer patients (6 male; mean 
age 65.4±10.4 yrs) are included in the study. Ten patients un-
derwent lobectomy, four segment resection, while no patients 
underwent pneumectomy. Four patients dropped out due 
to comorbidity (n=1), disinterest (n=1), and inability to per-
form the measurements (n=2). First analyses show that both 
physical and psychosocial health are worse one month post-
surgery, but improve during the following five months (table 
1). Activity patterns from pre-surgery to 6 months post-surgery 
of the included patients are being analysed at the moment. 
Conclusion: As was expected from earlier research, physical and 
psychosocial outcome measures worsened following lung resec-
tion, but returned to baseline levels at 6 months post-surgery, ex-
cept of VO2max. At this moment, we cannot calculate associations 
between daily PA and secondary outcome measures yet. However, 
patients are actively recruited and enrolled, and at the time of the 
conference we will be able to draw more firm conclusions about 
possible associations between daily PA and recovery of health 
status following lung resection.
Keywords: lung resection, Physical Activity, accelerometry, quality 
of life
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to deliver a total dose of 48Gy, in four fractions of 12Gy, in alterna-
te days, with support of Image-Guided Radiation Therapy (IGRT) 
technology. There was a good clinical and haematological toleran-
ce, no acute or late complications were referred, and the 6 months 
follow-up CT-scans showed partial response, according to RECIST 
criteria.
Conclusion: SBRT is nowadays a valid alternative for lung cancer 
treatment in patients with medical contraindications to surgical 
treatment, demonstrating a high local control of the lesion, associ-
ated with low toxicity effects. 
Keyword: SBRT lung cancer
response rates, the toxicities, progression free survival (PFS) & 
overall survival (OS). SPSS 16 was used for statistical analysis.
Results: Total of 105 patients were identified with a median age of 
58 years (35-77 years). There were 56 females (52.8%). The 15.2 % 
(16) of patients were smokers & 22.3 % (18) were tobacco chewers. 
The median duration of smoking & tobacco chewing was 25 & 15 
years respectively. All patients had stage IV disease. There were 2 
cases of squamous cell carcinoma (1.9%)& rest all were adenocar-
cinomas. (98.1%) Extrathoracic disease was present in 42 patients 
(39.6 %) The EGFR mutation invoved exon 19 , 21 & 18 in 25, 72 & 
8 patients respectively. The ECOF PS was 0 & 1 in 14 (13.2%) & 51 
(48.1%) patients respectively.The incidence of any grade skin and 
mucosal toxicites were 53% & 38% respectively. The median PFS 
& OS overall were 11.1 & 21 months respectively. The PFS & OS 
were not affected by the performnce status, comorbidities & sites 
of metastasis
Conclusion: Use of TKI in Indian population had similar toxicity & 
efficacy as reported in literature.
Keyword: EGFR mutation, Oral TKI, NSCLC , Palliative
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P2.24-057 STEREOTACTIC BODY RADIATION THERA-
PY (SBRT) - THE SUCCESS OF A NEW TECHNIQUE IN A 
COMPLEX CLINICAL CASE
Ana R. Figueredo1, Mariana Mendes1, Paulo Costa2, Joaquim Moi-
ta3, Álvaro Brandão4, Fernando Barata1
1Chest Oncology, Coimbra‘s University Hospital Centre/Portugal, 2Ra-
diation Unit, Barreiro Montijo Hospital Centre/Portugal, 3Functional 
Respiratory Rehabilitation Unit, Coimbra‘s University Hospital Centre/
Portugal, 4Urology, Coimbra‘s University Hospital Centre/Portugal
Background: SBRT is an emerging technique, with numerous ad-
vantages over classical radiotherapy, namely in high surgical risk 
patients.
Methods: Critical review of a clinical case
Results: The authors report the case of a 37 year-old man, type 
1 Neurofibromatosis patient, with dorsal paraplegia secondary to 
paravertebral tumours, severe kiphoscoliosis, and chronic hyper-
capnic respiratory failure requiring continuous non-invasive ventila-
tion (NIV) since 2007. He was also medicated with Baclofen 125mg/
day and botulinum toxin for severe spasticity, with poor response. 
In May 2010, he was diagnosed with testicular malignancy, which 
has undergone radical resection under local anaesthesia. In June 
2010 he was submitted to a follow-up CT scan, which revealed a 
9mm pulmonary nodule on the right upper lobe that remained 
under supervision, due to the risks of invasive diagnostic proce-
dures. In January 2012, because of a significant size increase, a CT 
scan-guided biopsy of the lesion was performed, which revealed a 
lymphoepithelioma-like carcinoma. Subsequent CT-scans demons-
trated progressive growth of the neoformation (4.9cm in July 2012) 
with invasion of the thoracic wall, and the PET/CT scan revealed 
FDG-F18 hyper fixation. Due to the comorbidities, and the need 
for continuous NIV, he had no surgical, chemotherapy or classical 
radiotherapy conditions. The remaining treatment option was 
SBRT. Therefore, a planning 4D-CT scan with a vacuum mattress 
for immobilization was performed, and a therapy plan was defined 
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P2.24-059 RESULTS OF TREATING ADVANCED STAGE 
NON SMALL CELL LUNG CANCER BY ERLOTINIB AT THE 
PULMONARY DEPARTMENT, CHO RAY HOSPITAL: FIRST 
VIETNAMESE CASE REPORT
Le Thuong Vu, Tran V. Ngoc
Pulmonary Medicine And Respiratory Care, Cho Ray Hospital/Vietnam
Background: Lung cancer is the second cause of cancer death in 
Vietnam. Most of patients with lung cancer are non small cell (90%) 
and present at advanced stage. Erlotinib was the first EGFR TKI 
permitted to be used for advanced stage non small cell lung can-
cer in Vietnam since 2007. Safety and efficacy of this treatment has 
never been reported in Vietnamese patients. We present the first 
case report of erlotinib in Vietnamese advanced-stage non small 
cell lung cancer patients to study the safety and the efficacy of this 
treatment.
Methods: From 12/2007 to 12/2011 advanced stage (wet IIIB and 
IV) non small cell lung cancer patients diagnosed at Cho Ray hos-
pital were prescribed erlotinib as (1) second/third line treatment or 
as (2) first line treatment only if they could not use standard, state 
of the art chemotherapy after well informed about different treat-
ment options.
Results: High overall response 35.5%, median progression free 
survival of 7 months, median overall survival of 11 months and 1 
year survival rate 50% were seen in 31 patients using erlotinib. 
These results were similar to East Asia patients but better than 
ones of Caucasian patients. Common adverse events were rash 
and diarrhea, severe adverse events were rare.
Conclusion: Erlotinib had high efficacy and low toxicity in Vietna-
mese patients like East Asian patients.
Keywords: non small cell lung cancer treatment, erlotinib, vietna-
mese, EGFR TKI
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P2.24-060 VATS LOBECTOMY USING SUBCOSTAL INCIS-
ION IN NSCLC
Jinwook Hwang, Byug-Ju Min, Won-Min Jo, Jae Seung Shin, In Sung 
Lee
Thoracic And Cardiovascular Surgery, Korea University Ansan Hospi-
tal/Korea
Background: VATS lobectomy for Non-small cell lung cancer usu-
ally can be performed using one working window, and two or more 
ports for endoscopic instruments. The working window are made 
on the intercostal space space. However, these narrow Intercostal 
space could be the obstacle for the extraction of congested or 
huge resected lung lobe. So, we performed VATS lobectomy using 
3 interocostal ports and the 3 cm subcostal incision.
Methods: Since March 2012, In Korea University Ansan Hospital, 
20 VATS lobectomies was done for lung cancer. Of 20, we per-
formed 4 cases of subcostal incision VATS lobectomy. At first, we 
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P2.24-058 THORACIC MULTIDISCIPLINARY MEETING 
DISCUSSION OUTCOMES AT AUCKLAND CITY HOSPI-
TAL: CONCORDANCE WITH ACTUAL PATIENT MANAGE-
MENT FOR LUNG MALIGNANCIES
Laura Cossar, Tim Christmas, Christopher A. Lewis
Respiratory Services, Auckland City Hospital/New Zealand
Background: Discussion of patients at multidisciplinary meetings 
(MDMs) is now considered the standard of care for management 
of thoracic malignancies. However, there is limited evidence regar-
ding concordance of decisions made at MDMs with subsequent 
actual treatment. This study aimed to assess the concordance 
between MDM outcomes and subsequent treatment received by 
patients with thoracic malignancy at our centre, and to identify 
factors that contributed towards any deviation from the MDM ma-
nagement plan.
Methods: In this retrospective audit, patients discussed at 12 
Auckland City Hospital MDMs between 1st May and 31st July 2012 
were identified, using the MDM lists for each session and chairper-
son summaries of discussion and decisions. The electronic cases 
records of these patients were then reviewed for demographical 
data, information on the MDM outcome and to ascertain the even-
tual treatment received by these patients. Any discrepancies bet-
ween MDM recommendations and eventual patient management 
were noted, and the reasons stated for this.
Results: There were 121 cases identified from 138 documented 
patient presentations; 17 patients were re-presented within the 
study period, and the presentation at which anti-cancer treatment 
was determined was analysed (if achieved). Of the 121 cases, 93 
included a pathologically confirmed diagnosis (80 primary lung or 
pleural tumours, 13 other tumours or pulmonary metastases), and 
28 did not, including 4 with suspected malignant pleural effusions. 
A decision for radical therapy was made for 22 cases at the MDM. 
18 of these cases received treatment as determined at MDM: 13 
of 15 surgical resection, 1 of 3 radical radiotherapy, 3 of 3 radical 
chemo-radiotherapy, and 1 was deemed not to need adjuvant 
chemotherapy. A decision for one or more palliative treatments 
was made for 72 cases. Of these, the MDM determined treatment 
was actually received in 41 (57% of cases): 5 of 7 palliative surgery 
cases (1 died pre-op, 1 patient declined), 18 of 28 chemotherapy 
as initial treatment, and 13 of 23 radiotherapy as initial treatment. 
In 14 cases with an MDM decision recorded recommending both 
palliative chemotherapy and radiotherapy, 5 received both moda-
lities, 7 radiotherapy alone and 2 neither. Reasons for discordance 
between MDM decision and treatment included patient deteri-
oration or poor performance status (n=14), patient choice (n=8), 
patient and doctor agreed choice (n=5) and did not attend/lost to 
follow up (n=4) In the remaining 27 cases, best supportive care was 
recommended in 7 and no definitive treatment decision was able 
to be made in 20.
Conclusion: This study demonstrated excellent concordance bet-
ween decisions made for radical therapy at the MDM and actual 
treatment. Concordance was less for palliative therapies, and this is 
likely to reflect on the poorer performance status of these patients 
at presentation and the perceived benefit versus adverse effects of 
palliative measures to the patient and the clinician. Since this stu-
dy, a standardised electronic MDM template has been introduced 
to ensure accurate and complete information is available.
Keywords: lung cancer management, multidisciplinary meeting
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Conclusion: The subcostal incision for extraction of lung specimen 
was useful in VATS lobectomy.
Keywords: VATS lobectomy, Lung cancer, minimally invasive sur-
gery, post thoracotomy pain
performed entire procedure through the intercostal ports (10mm). 
After resection of lung, the subcostal incision (3cm ) was made 
anterior to the 10th rib. Because the 11th costal cartilage is ab-
scent, there is no limitation during spreading the 10th intercostal 
space for the extraction of resected lung (Fig 1). And then, we 
dissect mediastinal lymph nodes systemically. During the subcos-
tal incision, rectus muscle is resected partially. And the chest cavity 
was entered through the costophrenic junction. So,at the end the 
repair of diaphragm is needed. The chest tube can be placed pro-
perly through one of the intercostal ports.
Results: The characteristics of patients is summerized in Table 1.Of 
4 cases of subcostal incision lobectomy, one case should be con-
versed to the anterior thoracotomy.That case was 6.5cm sized right 
middel lobe tumor.In the third case, we used two intercostal ports 
and one subcostal incision. In the question of post operative inter-
costal pain at operation day, patients did not complain severe pain 
(more than VAS score 5). However, we did not compare the pain 
score after this operation with conventional VATS lobectomy. 
Talble 1.The patient’s characteristics
Case No. G/A Lobe Tumor size LND pTNM 3 ports subcostal
1 M/67 LLL 3.5cm 30 T2aN0M0 5th/6th/7th 3cm
2 M/62 LUL 3.5cm 16 T2aN0M0 4th/6th/6th 3cm
3 F/69 RUL 1.8cm 47 T1aN1M0 5th/6th 3cm
4 F/43 RML 6.5cm 29 T2bN2M0 5th/6th/6th 1cm
 
Fig 1. Three intercostal ports (10mm) and one Subcostal 
incision (3cm)
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Conclusion: Standardization of the surgical procedures improved 
the workflow, enabled safe and efficient surgery among the affilia-
ted hospitals, and increased awareness of the importance of work-
flow improvement. Change in awareness toward thoracic surgery 
was observed among participating members, suggesting that the 
present approach is highly useful.
Keywords: standardization, Surgical Procedure, team medicine, 
workflow improvement
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P2.25-002 HOW DO PATIENTS WITH LUNG CANCER 
EXPERIENCE RADIATION INDUCED OESOPHAGITIS?
Mary Duffy1, Donna Milne2, David Ball3, Sanchia Aranda2
1Ambulatory Care, Peter MacCallum Cancer Centre/Australia, 2Depart-
ment Cancer Experiences Research, Peter MacCallum Cancer Centre/
Australia, 3Division Radiation Oncology, Peter MacCallum Cancer Cen-
tre/Australia
Background: Radiation induced oesophagitis (RIO) is a signifi-
cant toxicity of lung cancer treatment that has profound clinical, 
social and economic implications. The literature suggests there is 
minimal evidence to support current analgesic regimes with the 
exception of systemic analgesia. More information is required to 
better understand the patient experience of RIO and how it can 
be managed. Aim: To identify the properties and characteristics of 
RIO experienced by patients having radiotherapy to the chest for 
lung cancer.
Methods: A qualitative exploratory study conducted with patients 
with lung cancer receiving radiotherapy to the chest. Patients par-
ticipated in semi-structured interviews exploring their experience 
of RIO. Interviews were recorded, transcribed and content ana-
lysed.
Results: Twenty six patients participated: six with grade 1; 14 with 
grade 2 and eight with grade 3 RIO. Patients were interviewed 
following recovery from grade 3 RIO. Four key domains were iden-
tified: 1.Pain descriptors such as “feels raw “, “burning”, “like reflux 
but worse” were reported 2. Swallowing difficulties varied over 
time and were described as “felt like there was a blockage, “afraid 
I would choke,” “unable to get anything through”. 3. Self care ef-
forts employed by the patients to manage these difficulties ranged 
from diet modification, allowing food and drinks to go cold before 
eating and eating slowly. 4. An aversion to taking regular analgesia 
was also evident. The overall impact on participants’ lives was of-
ten understated, even in the context of hospital admissions, inser-
tion of nasogastric tubes and poorly controlled pain.
Conclusion: This study demonstrates the complexity of RIO and 
suggests clinicians may underestimate the effect and severity of 
RIO. Given patients appear to continue to experience problems, 
despite treatment, better prophylaxis and management regimes 
are required.
Keyword: qualitative, patient experience, oesophagitis
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P2.25-001 WORKFLOW IMPROVEMENT AND RESULTS 
OF STANDARDIZATION OF THORACIC SURGERY PRO-
CEDURES AMONG SIX HOSPITALS
Yasushi Iwasaki1, Kazuhiro Itoh2, Motohiro Nishimura3, Masashi 
Yanada4, Kunihiko Terauchi5, Masanori Shimomura6, Hiroaki Tsu-
nezuka6, Daishiro Kato6, Junichi Shimada6
1Respiratory Surgery, Nantan General Hospital/Japan, 2Kyoto Ya-
mashiro General Medical Center/Japan, 3Thoracic Surgery, Saiseikai 
Suita Hospital/Japan, 4Thoracic Surgery, Ayabe City Hospital/Japan, 
5Department Of Chest Surgery, Nara City Hospital/Japan, 6Division Of 
Chest Surgery, Department Of Surgery, Kyoto Prefectural University Of 
Medicine/Japan
Background: Five full-time doctors are sent to 5 affiliated hospitals 
from University Hospital of Kyoto Prefectural University of Medici-
ne. To conduct a surgery in the affiliated hospitals, a doctor is sent 
from the university, for ensuring an efficient and secure medical 
care with limited members. Until now, each hospital performed 
surgeries in its own way. However, to perform safer and efficient 
surgery with a limited number of operating room nurses and thora-
cic surgeons, they need to work as one team. We report the stan-
dardization of thoracic surgery procedures.
Methods: First, to understand the current situation at each affilia-
ted hospital, we survey all aspects of surgical procedures. Subse-
quently, we held 5 meetings among the group and standardized 
the surgical procedures. A thoracic surgeon and 3–4 operating 
room nurses from each hospital joined in the discussion. The to-
pics of the discussion covered all aspects of surgery and methods 
from each hospital were analyzed and standardized. We have al-
ready standardized the thoracoscopy system and energy device in 
all hospitals. We also standardized the main surgical instruments 
and methods in these meetings. The content of the standardized 
main surgical procedure was thoroughly explained in a video distri-
buted to each hospital in DVD format. We evaluated the frequency 
of use of the surgical instruments and excluded rarely used items. 
To increase the understanding on automatic suture instruments 
and energy device, the important usage points were shared in the 
meeting. Nurses were trained on the usage. In the 6th affiliated 
hospital meeting, a questionnaire was conducted to survey the 
awareness of this approach.
Results: The amount of time required from entering the opera-
ting room to starting the surgery was shortened from 62 to 55.5 
minutes (average). The time required from the end of surgery to 
exiting the operating room was also shortened from 46.1 to 38.7 
minutes (average). The difference among hospitals was successful-
ly reduced. Because the main surgical instruments and methods 
were standardized, almost the same level of surgery could be per-
formed in each hospital. Surgical instruments were reduced from 
48.3 to 41.1 types (average). Total number of surgical instruments 
was successfully reduced from 91.8 to 73.5 items (average). In the 
questionnaire, all members referred to other hospitals devices, and 
they will attempt productions of their own device. All members 
confirmed improved understanding on thoracic surgery and 88% 
confirmed increased interest in thoracic surgery．
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Methods: A panel of seven NSCLC cell lines (NCI-H23, NCI-H358, 
HCC827, NCI-H1650, NCI-H1975, HCC2935 and HCC4006, from 
ATCC) was used to determine the effects of ATO treatment on cell 
viability, TYMS protein and mRNA expression, E2F1 protein ex-
pression and TYMS activity. TYMS knockdown and overexpression 
were performed to confirm the importance of TYMS in cell survival 
and resistance to ATO respectively. Tumor growth inhibition in vivo 
was studied using a nude mice xenograft model.
Results: ATO showed antiproliferative effects with clinically achie-
vable concentrations (around 1.1-6.9 µM after 72 hours incubation) 
in NSCLC cell lines. Baseline TYMS protein expression was detec-
ted in H23, H358, H1650 and H1975 cells. Among them, downregu-
lation of TYMS protein and mRNA expression, reduced total TYMS 
activity, and suppressed E2F1 expression were demonstrated in 
H23, H358, and H1650 cells with ATO. Cell viability was reduced by 
15-50% with TYMS knockdown (to less than 30% protein expres-
sion) (Fig. 1). Overexpression of TYMS led to a 2.7-fold increase in 
IC50 value with ATO treatment for 72 hours in H358 cells, but not 
H23 cells. Using a xenograft model with H358 cell line, relative 
tumor volume was reduced to 44% that of control after 8 days of 
treatment with 7.5 mg/kg intraperitoneal ATO, and associated with 
significant downregulation of TYMS protein expression in tumor 
xenografts (Fig. 2). 
Conclusion: ATO has potent in vitro 
and in vivo activity in NSCLC, and is 
partially mediated by transcriptional 
downregulation of TYMS.
Keywords: Non-small cell lung 
carcinoma, Arsenic trioxide, thymidylate 
synthase, xenograft
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P3.01-001 DOWNREGULATION OF THYMIDYLATE SYN-
THASE WITH ARSENIC TRIOXIDE IN NON-SMALL CELL 
LUNG CANCER: IN VITRO AND IN VIVO
Sze Kwan Lam, Yuan Yuan Li, Chun Yan Zheng, James Chung Man 
Ho
Department Of Medicine, The University Of Hong Kong/Hong Kong
Background: Thymidylate synthase (TYMS) is an important chemo-
therapeutic target in non-small cell lung cancer (NSCLC). Recently, 
arsenic trioxide (ATO) has been shown to downregulate TYMS in a 
colonic cancer model. Therefore, we examined the effect of TYMS 
suppression by ATO in NSCLC.
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nists and/or EP3 antagonists may become one of the options to 
suppress the lymph node metastasis.
Keyword: Lung cancer, Lymph node metastasis, Premetastatic 
niche, Dendritic cells
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P3.01-003 IDENTIFICATION AND TUMORIGENIC ROLE 
OF MESENCHYMAL STEM CELLS FROM HUMAN LUNG 
CANCER
Luca Ampollini1, Gallia Graiani2, Caterina Frati2, Denise Madeddu2, 
Bruno Lorusso2, Costanza Lagrasta3, Francesco Facchinetti2, Ange-
la Falco2, Francesca Saccani2, Roberta Alfieri2, Piergiorgio Petroni-
ni2, Eugenio Quaini4, Michele Rusca1, Paolo Carbognani1, Federico 
Quaini2
1Thoracic Surgery - University Hospital Of Parma/Italy, 2Clinical And 
Experimental Medicine - University Hospital Of Parma/Italy, 3Depart-
ment Of Biomedical, Biotechnology And Translational Science - Univer-
sity Hospital Of Parma/Italy, 4Cardiothoracic Department Heart Hospi-
tal “G. Pasquinucci“ Fondazione Toscana “G. Monasterio“, Massa/Italy
Background: A hierarchical model in which a small population of 
stem cells or Cancer Initiating Cells (CIC) may be responsible of 
tumour growth has been proposed. CIC is defined as a cell able 
to regenerate detectable neoplastic populations in xenografted 
immunodeficient mice. By this experimental approach, convincing 
data have led to the identification of CIC in solid tumours including 
breast, brain, colorectal, melanoma and lung. However, the auto-
nomous growth ability of CIC is allowed in specialized structures, 
called niches, in which a microenvironmental control is exerted 
by several stromal elements including mesenchymal cells. These 
attractive pathogenetic mechanisms encompass innovative thera-
peutic implications because the limited success of the actual treat-
ment of lung cancer may be attributable to the lack of targeting on 
CICs and their niches. The aim of the present study was to identify 
mesenchymal stem cells (MSC) from Non Small Cell Lung Cancer 
(NSCLC) and to investigate their biological properties and in vivo 
tumorigenic potential.
Methods: Small fragments of NSCLC (53 Adeno- and 24 Squa-
mous carcinoma) surgically removed from 77 patients (46 male) 
were subjected to enzymatic digestion whereas most of the ori-
ginal sample was processed for diagnostic purpose. To identify 
mesenchymal cells from human lung cancer (hLc-MSC) we used 
different conditioning media and immunomagnetic selection to 
separate neoplastic epithelial cells frequently growing together 
with adherent stromal cells at early passages. To determine their 
tumorigenic properties, female immunodeficient BALB/c nude 
mice were subcutaneously injected with either 106 hLc-MSCs (from 
male donors) alone or in combination with 106 Calu-3, a human 
adenocarcinoma cell line lacking Y chromosome and able to repro-
ducibly induce xenografted tumours.
Results: We have been able to obtain stable primary cultures of 
hLc-MSC, expandable for at least 14 passages, from 62% of NSCLC 
samples. This cell population uniformly expressed the typical MSC 
markers CD90, CD105, CD73, CD13 and CD44 at FACS analysis. 
hLc-MSC were negative for EpCAM, CD45, CD14 and CD34 where-
as CD117 and CD133 were expressed at low frequency. Clones and 
subclones were documented by limiting dilution analysis. The nuc-
lear expression of transcription factors involved in stemness (OCT 
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P3.01-002 DENDRITIC CELLS PROMOTED THE SDF-
1-EXPRESSING PREMETASTATIC NICHE FORMATION IN 
MEDIASTINAL LYMPH NODE METASTASIS FOR LUNG 
CANCER VIA COX-2-DERIVED PGE2-EP3 SIGNALING.
Fumihiro Ogawa1, Hideki Amano2, Yukitoshi Satoh1, Yuji Kuma-
gai2, Masataka Majima3
1Department Of Thoracic Surgery, Kitasato University School Of Medi-
cine/Japan, 2Department Of Clinical Research Center, Kitasato Univer-
sity School Of Medicine/Japan, 3Department Of Pharmacology, Kitasato 
University School Of Medicine/Japan
Background: Lung cancer is the most widespread cause of cancer 
death in the world. COX-2 derived prostaglandin E2 (PGE2) is well 
known to induce tumor growth and metastasis, and thus is associ-
ated with a poor prognosis. Lymph node metastasis is also one of 
the major determinant of the prognosis and is facilitated by lymph-
angiogenesis, however the precise of the mechanisms is not well 
understood. In the presenr atudy, we investigated the role of COX-
2-derived PGE2 on formation of premetastatic niche facilitate the 
lymph node metastasis in Lung Cancer. Lung cancer is the most 
widespread cause of cancer death in the world. COX-2 derived 
prostaglandin E2 (PGE2) is well known to induce tumor growth and 
metastasis, and thus is associated with a poor prognosis. Lymph 
node metastasis is also one of the major determinant of the prog-
nosis and is facilitated by lymphangiogenesis, however the precise 
of the mechanisms is not well understood. In the presenr atudy, 
we investigated the role of COX-2-derived PGE2 on formation of 
premetastatic niche facilitate the lymph node metastasis in Lung 
Cancer.
Methods: Male C57BL/6 (6-8 weeks-old, Wild type; WT) and EP3 
knockout mice (EP3-/-), one of PGE2 receptor subtype, were used. 
Orthotopic intrapulmonary implantation model was made by in-
jecting Lewis Lung Carcinoma (LLC 5.0X106 cells/ml) cells into the 
lung. We estimated the expressions of lymphangiogenic factors, 
SDF-1/CXCR4, subtypes of EP receptors by immunehistochemical 
staining, ELISA and real time PCR. The accumulation of immature 
dendritic cells (iDCs) and regulatory T cells (Tregs) were estimated 
by immunofluolecent analysis. Furthermore, we estimated the role 
of iDC on lymph node metastasis by injecting iDCs.
Results: The expression of COX-2 and SDF-1, and accumulation 
of iDCs and Tregs were increased before LLC cell accumulated in 
lymph node. Compared to vehicle mice, mediastinal lymph node 
metastasis formations were suppressed with a COX-2 inhibitor 
(celecoxib, 100mg/kg/day, p.o., P<0.05). Compared to other PGE2 
subtype receptors, the expression of EP3 receptor was significantly 
suppressed in celecoxib treated mice (P<0.05). The expression 
of lymphangiogenesis markers and lymph node metastasis were 
suppressed in EP3-/-. The expression of SDF-1 and accumulations 
of CD11c+DCs and FOXP3+Tregs in lymph nodes were significantly 
suppressed in EP3-/- (P<0.05). In vitro study, under PGE2 stimula-
tion, the SDF-1 conentration and expression of EP3 in culutured 
iDCs were significanltly enhanced compared to control. Furthrmo-
re, WT transplanted with EP3-/-BM were significantly suppressed 
mediastinal lymph node metastasis formation compared to WT 
transplanted with WT mice.
Conclusion: These results suggested that premetastatic niche 
formation in mediastinal lymph node was induced by bone marrow 
derived immatured dendritic cells via PGE2-EP3 signaling by induc-
tion of SDF-1-expression. Thus, COX-2 inhibitors, CXCR4 antago-
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of activation of its specific receptors, DR4 and DR5, while display-
ing low toxicity towards normal cells. We sought to investigate if 
DRs activation could subvert the relative resistance to cisplatin 
intrinsically presented by NSCLC cell lines. NSCLC cell lines trea-
ted with suboptimal concentrations of cisplatin (IC30) for 48h had 
their gene expression analyzed by qPCR and the results showed 
an increased expression of DR4 and DR5 in these cells. These 
results were confirmed at protein level by Western blot analysis. 
NSCLC cells are naturally regarded as resistant to TRAIL-induced 
cell death. Such resistance can rise, among other reasons, from 
low expression of DRs or increased expression of decoy receptors 
and/or anti-apoptotic proteins. LBY135 (Novartis) is a DR5 agonist 
monoclonal antibody that mimics TRAIL and induces cell death in 
DR5 expressing cells. As cisplatin modulated DR5 protein expressi-
on, we have combined it with LBY135 as a strategy to improve cell 
death induction upon NSCLC cells. LBY135 monotherapy did show 
some effects when analyzed by MTT assay, although it did not 
induce cell death accessed by Annexin/PI FACS analysis. However, 
when cisplatin IC30 and LBY135 were combined, we observed a si-
gnificant decrease in MTT measurements and increased cell death 
incidence, suggesting a synergistic effect of these drugs. Such 
pro-apoptotic effect was blocked by zVAD-fmk, a pan-caspase 
inhibitor.
Conclusion: The synergistic effect observed was more pro-
nounced in cell lines bearing the classical G12K-ras mutation, 
suggesting an alternative way to subvert chemo-resistance of K-ras 
mutated NSCLC and restore cisplatin-induced apoptotic signaling 
leading to cell death.
Keywords: NSCLC, Death Receptor 5, K-ras, Apoptosis
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P3.01-005 EFFICACY OF ARSENIC TRIOXIDE IN THE 
TREATMENT OF MALIGNANT PLEURAL EFFUSION 
CAUSED BY PLEURAL METASTASIS OF LUNG CANCER
Yuan-Sheng Zang1, She-Ling Xie2, Xue-Wei Zhao2, Bing Li2
1Department Of Respiratory Medicine, Changzheng Hospital/China, 
2Changzheng Hospital/China
Background: Arsenic trioxide (As2O3), an ancient drug used in 
traditional Chinese medicine with the characteristics of high effec-
tiveness and low toxicity, was used to treat acute promyelocytic 
leukemia at the beginning. Over the past decade, in our clinical 
practice, local injection of As2O3 into pleural cavity has been suc-
cessfully used for more than 80 patients with malignant pleural 
effusions(MPE) caused by pleural metastasis of lung cancer. And 
interestingly, after local administration of As2O3, the composition 
of blood cells in pleural effusion was reduced and the color of MPE 
changed from red to light yellow in the majority of patients, indi-
cating that As2O3 could be considered as an effective approach 
for the treatment of MPE, but the underlying mechanism remains 
unclear . The aim of this study was to investigate the mechanism of 
arsenic trioxide (As2O3) in the treatment of malignant pleural effusi-
on (MPE) caused by pleural metastasis of lung cancer.
Methods: A mouse model of MPE caused by pleural metastasis 
of lung cancer was first established in our study, and then As2O3 
was intraperitoneally injected to treat MPE. Those mice treated 
with bevacizumab and bleomycin were included as positive control 
animals, and placebo equivalents were also employed as negative 
3/4 and SOX2), and in bronchio-alveolar (TTF1) or squamous (p63) 
lineage commitment was consistently present in hLc-MSC isolated 
from Adeno- or Squamous cell carcinomas. In vivo xenotransplan-
tation demonstrated that although hLc-MSC administered alone 
did not generate tumours, their co-injection with Calu-3 develo-
ped in all animals subcutaneous nodules that were 10-fold larger 
than those induced by equal doses of Calu-3 injected alone. To 
detect the fate of both injected cells on sections of xenografted 
tumours, FISH analysis of human specific sex chromosomes was 
combined with immunohistochemistry. We documented that cyto-
keratin positive adenocarcinoma structures showing X chromoso-
mes only (Calu-3 derived) were surrounded by a thin layer of non 
neoplastic cells carrying XY chromosomes (hLc-MSC derived). The 
cross talk and phenotypic changes of E-Cadherin positive neoplas-
tic cells co-cultured with hLc-MSC were also documented.
Conclusion: Our study demonstrates that the reciprocal inductive 
interactions between the mesenchyme and the neoplastic epitheli-
um are essential for the fate induction of lung cancer.
Keywords: cancer stem cell, non-small-cell lung cancer, nude 
mice, cancer initiating cells
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P3.01-004 PRE-CLINICAL EVALUATION OF DEATH RE-
CEPTOR-5 ACTIVATION AS A FEASIBLE OPTION FOR 
K-RAS MUTANT NSCLC THERAPY
Cinthya Sternberg, Mauricio D.S. Caetano, Carlos Gil Ferreira
Clinical Research, National Cancer Institute Of Brazil/Brazil
Background: Activating mutations of K-ras are one of the most 
common alterations associated with tobacco exposure-related 
lung cancer(LC). There are two major types of LC - small-cell 
LC(SCLC) and non-small cell LC(NSCLC) - and the later accounts 
for 80% of the cases. NSCLC can be divided into three histolo-
gical subtypes: Adenocarcinoma, large cells and squamous cell 
carcinoma. First-line treatment comprises surgical resection of 
tumor, followed or not by chemo/radiotherapy. In non-surgical 
cases, platinum compounds remain the cornerstone for both early 
and advanced NSCLC stages management, in spite of its toxicity, 
high rate of chemo-resistance and poor long term results. Several 
attempts to develop therapies based on molecular targets, such 
as K-ras, have been developed and thus far failed, clearly stating 
the need for new approaches to bring clinical benefits to patients. 
Among its several aberrations, NSCLC harbors alterations in the 
apoptotic pathways, leading to impaired pro-apoptotic signaling 
and positive modulation of anti-apoptotic pathways. Therapeutic 
strategies targeting such pathways can emerge as an alternative to 
the cytotoxic therapies selected to wild-type EGFR-patients – es-
pecially for K-ras mutated patients, comprising about 20% of this 
population.
Methods: Here we have analyzed a representative panel of NS-
CLC cell lines (A549, H460, Calu-1 and LC319), that display distinct 
sensitivities towards cisplatin, mutational profiles and histological 
subtypes, to test a pre-clinical therapeutic strategy engaging the 
TNF-related apoptosis-inducing ligand (TRAIL) receptor (Death 
receptor 4 and 5).
Results: TRAIL is a member of the TNF family of cytokines that 
induces apoptotic cell death in a variety of tumor cells by means 
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Those included 137 different proteins identified by tandem MS. 
IPA revealed that these proteins were overrepresented in the cel-
lular assembly, organization, morphology, and tissue morphology 
networks. DPYL2, GNAQ, RSSA, RUVB1, and STMN1 were found 
to be the most discriminatory candidate biomarkers among the 
membrane-associated proteins overexpressed in SCLC as com-
pared with NSCLC and normal bronchial airway cell lines. Overex-
pression of DPYL2, GNAQ, and STMN1 was verified in SCLC cell 
lines by WB. Intense protein expression of DPYL2, GNAQ, RUVB1, 
and STMN1 was also confirmed in SCLC by IHC on tissue microar-
rays (TMA). These proteins’ expression levels measured by IHC 
were significantly associated with the SCLC subtype and survival in 
a univariable analysis but could not be verified as independent in a 
multivariable analysis.
Conclusion: Proteomic analysis of membrane-associated proteins 
in lung cancer and bronchial airway epithelial cell lines revealed 
137 proteins differentially expressed in SCLC. These proteins were 
enriched for cellular assembly, organization, morphology, and tis-
sue morphology networks. Of the five proteins selected for clinical 
validation, DPYL2, GNAQ, RUVB1, and STMN1 overexpression in 
SCLC was verified by WB and IHC, suggesting that these results 
need to be tested for functional implication in SCLC progressi-
on. The association with survival requires further validation in a 
larger clinical dataset. Funding This work was supported by a VA 
Merit review award 1I01CX000242 to PPM. SO was supported by 
a Télévie Grant, a Fondation Mont-Godinne Grant and a Clinician-
Researcher Mandate from Secteurs des Sciences de la Santé, Uni-
versité Catholique de Louvain (UCL), Belgium.
Keyword: Small-cell lung cancer, biomarker, proteomics
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P3.01-007 ENERGY METABOLISM IN LUNG ADENOCAR-
CINOMA
Chuong Hoang1, Yue Xu1, Zhenliang Shi1, Yongbin Lin1, Robert E. 
Merritt1, Joseph Shrager1, Millie Das2, Joel W. Neal2, Heather A. 
Wakelee2
1Division Of Thoracic Surgery, Stanford University/United States Of 
America, 2Division Of Oncology, Department Of Medicine, Stanford Uni-
versity School Of Medicine/United States Of America
Background: Cancer cells have defects in regulatory circuits 
governing proliferation and homeostasis. Consequently, cell meta-
bolism is altered to meet the demand for accelerated, deregulated 
growth. Metabolic perturbations arising from malignant transfor-
mation have not been well characterized in human lung cancers in 
situ. The most well known metabolic derangement(s) in tumors is 
that of enhanced glycolysis and a decrease in mitochondrial oxida-
tive phosphorylation. We wanted to characterize this phenomenon 
more accurately in human lung adenocarcinomas by metabolomic 
profiling.
Methods: We performed metabolomic analysis of matched pairs 
of solid, non-small cell lung adenocarcinomas and normal lung tis-
sue from 25 surgically resected patients. Metabolites were extrac-
ted by a methanol-chloroform-water technique. The resulting ex-
tracts were divided into multiple fractions. Ultrahigh performance 
liquid chromatography/ mass spectrometry coupled with tandem 
mass spectrometry and gas chromatography/ mass spectrometry 
experiments were conducted. Agilent MassHunter Qualitative 
control. The effects of As2O3 on MPE volume, pleural vessel densi-
ty, vascular permeability, expression of angiogenic function related 
factors including VEGF and TNF-α, as well as NF-κB activity in 
pleural carcinomatosis were observed.
Results: Intraperitoneal injection of As2O3 could reduce the volu-
me of MPE and decrease vascular density and vascular permea-
bility in pleural metastatic nodules, in a dose-dependent manner. 
Moreover, the dose-dependent decrease in VEGF and TNF-α ex-
pression in MPE and NF-κB activity in pleural carcinomatosis were 
also found after As2O3 treatment.
Conclusion: Our work demonstrated that As2O3 could down-
regulate the VEGF expression through NF-κB inhibition, and then 
decrease vascular density and permeability in pleural metastatic 
nodules, thereby playing its effects on MPE caused by pleural 
metastasis of lung cancer. Our results could provide a foundation 
for As2O3-based clinical treatment program.
Keywords: malignant pleural effusion, Arsenic trioxide, Treatment, 
Lung cancer
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P3.01-006 DISCOVERY OF NEW MEMBRANE-ASSOCIA-
TED PROTEINS PREFERENTIALLY EXPRESSED IN SMALL-
CELL LUNG CANCER
Sebahat Ocak1, David B. Friedman2, Heidi Chen3, Jamie A. Aus-
born4, Mohamed Hassanein4, Bruno Detry1, Birgit Weynand5, 
Charles Pilette1, Yves Sibille1, Pierre P. Massion4
1Institut De Recherche Expérimentale Et Clinique (IREC), Pôle Pneumo-
logie, Orl Et Dermatologie, Université Catholique De Louvain (UCL)/
Belgium, 2Department Of Biochemistry, Vanderbilt University/United 
States Of America, 3Cancer Biostatistics Center, Vanderbilt University/
United States Of America, 4Division Of Allergy, Pulmonary, And Cri-
tical Care Medicine, Vanderbilt University/United States Of America, 
5Department Of Pathology, Chu UCL Mont-Godinne/Belgium
Background: Small-cell lung cancer (SCLC) is the most aggres-
sive subtype of lung cancers, with no early detection strategy or 
targeted therapy currently available. We hypothesized that diffe-
rence gel electrophoresis (DIGE) may allow the identification of 
membrane-associated proteins specific to SCLC, the advancement 
of our understanding of SCLC biology, and the discovery of new 
candidate diagnostic or therapeutic biomarkers.
Methods: Membrane-associated protein lysates were prepared in 
quadruplicate from three SCLC, three non-small-cell lung cancer 
(NSCLC), and three immortalized normal bronchial epithelial cell 
lines. The 36 samples were co-analyzed by DIGE and subsequent 
protein identification was performed by mass spectrometry (MS). 
Identified proteins were submitted to Ingenuity pathway analysis 
(IPA). Candidate biomarkers were validated by Western blotting 
(WB) and immunohistochemistry (IHC), and tested against clinical 
outcomes.
Results: Principle component analysis on the global DIGE data-
set demonstrated that the four replicates derived from each of 
the nine cell lines clustered very closely from one another, as did 
samples within the same histological group. A total of 135 distinct 
protein features were differentially expressed in SCLC as compa-
red with NSCLC and bronchial airway epithelial cell lines (P<0.001). 
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well characterized in the progression of colon cancer, is associated 
with chronic inflammation. As antagonists of Wnt pathways, the 
SFRPs are functional tumour suppressors of colon, gastric, breast, 
ovarian and lung cancers, with some members methylated in me-
sothelioma. In this study, we aimed to investigate the functional si-
gnificance of the SFRP2 and 5 in MPM, and the effect of long-term 
asbestos exposure on epigenetic alteration in the immortalised 
mesothelial cell MeT-5A.
Methods: Gene expression and promoter DNA methylation of 
the SFRP family were analysed in MPM lines and MeT-5A with and 
without 5’Azacitidine treatment using RT-qPCR, MSP and COBRA. 
The effect of SFRP2 and SFRP5 re-expression on MPM cells was 
determined by cell growth and clonogenic assays in 2D and 3D 
culture. The expression and promoter DNA methylation of SFRP 
genes was also assessed in MPM patient samples using RT-qPCR 
and MSP. MeT-5A cells were cultured long-term (12 months) in the 
presence of asbestos, and SFRP mRNA expression and promoter 
DNA methylation was analysed.
Results: SFRP2 and SFRP5 were either absent or down-regulated 
MPM lines, and restored after 5’Azacitidine treatment. SFRP1 was 
highly expressed and unmethylated in MeT-5A line. Expression 
of the SFRP family was down-regulated in MPM patient samples 
and this correlated with methylation of promoter CpG islands. 
Ectopic expression of SFRP2 or SFRP5 inhibited MPM cell growth 
and colony formation in both 2D and 3D culture. SFRP1 was down-
regulated and methylated following prolonged asbestos exposure 
in MeT-5A cells.
Conclusion: Our results indicate that both SFRP2 and SFRP5 func-
tion as tumour suppressor genes in MPM and long-term asbestos 
exposure induce gene silencing via DNA hypermethylation.
Keywords: tumour suppressor genes, DNA methylation, malignant 
pleural mesothelioma, Secreted Frizzled-Related Protein (SFRP)
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P3.01-009 FGF-2 INDUCES CHEMORESISTANCE IN 
MODEL AND LUNG CANCER CELLS THROUGH S6K2/
HNRNPA1-MEDIATED ENHANCED TRANSLATION OF 
ANTI-APOPTOTIC PROTEINS
Michael J. Seckl1, Rajat Roy1, Francesco Mauri1, Li Hue2, Lindsay 
Jordan3, Mark Skehel4, Guo Lin2, Martin Holcik3, Olivier Pardo1
1Imperial College London/United Kingdom, 2Wuhan University/China, 
3Children’s Hospital Of Eastern Ontario Research Institute/Canada, 
4London Research Institute/United Kingdom
Background: Most patients die from lung cancer because of che-
moresistant metastatic disease. We have previously identified the 
importance of fibroblast growth factor 2 (FGF2) /S6 kinase 2 (S6K2) 
signalling in mediating multidrug resistance in lung cancer through 
enhanced translation of antiapoptotic proteins, such as BCL-XL and 
XIAP. Here we investigate the downstream mediator(s) of this trans-
lational response and demonstrate its relevance in a lung cancer 
tissue array.
Methods: We used tandem affinity purification using S6K2 as bait 
as well as quantitative phospho-proteomics in the presence and 
absence of FGF2 stimulation in small cell lung cancer and HEK 293 
cells to identify new S6K2 interactors and downstream mediators 
software was utilized. The Molecular Feature Extractor was utilized 
to find features in raw data files. Extracted peaks were retention 
time aligned using Mass Profiler Professional and unique features 
detected by least squares analysis. The Agilent version of the Met-
lin database was utilized to identify metabolites. Matched pairs 
t-test identified biochemicals significantly altered between tumor 
and normal specimens. The false discovery rate method assessed 
for significance; p-value ≤ 0.05 and q-value < 0.10.
Results: Based on known library standards to identify biochemi-
cals, our global metabolomic profiling found 204 overexpressed 
and 42 underexpressed metabolites in tumors relative to normal 
lung (p< 0.05). We observed altered metabolite levels in lung 
tumors that mapped to not one, but two glucose utilization pa-
thways. Glucose-6-P (2.7-fold), fructose-6-P (2.6-fold), fructose-1,6-
bisP (6.9-fold), lactate (2.7-fold), and NAD+ (1.4-fold) were signifi-
cantly upregulated in tumors consistent with an aerobic glycolysis 
(i.e. Warburg) biosignature, the major source of ATP. Concurrently, 
pentose phosphate pathway (PPP) metabolites were upregulated in 
tumors: ribulose-5-P (2.6-fold), ribulose (3.6-fold), ribitol (4.6-fold), 
ribose (4-fold), and sedoheptulose-7-P (3-fold). Our data reveals 
evidence of multiple active pathways to explain glucose utilization 
in lung adenocarcinomas. The PPP is important to protect against 
oxidative stress as it serves to generate NADPH, and is a key ana-
bolic pathway of nucleotide synthesis by generating the ribose-5-P 
backbone for proliferating cells. Observing both pathways simul-
taneously in lung adenocarcinomas suggests they are coupled to 
give tumors a growth advantage over normal tissue. Consistent 
with this, we observed an overall increasing nucleotide biosynthe-
sis signature in tumors: multiple metabolites (range 2 to 17-fold) in 
purine and pyrimidine pathways were significantly elevated.
Conclusion: Metabolomic analysis identified a unique glucose 
energetic biosignature in lung tumors that is more complex that 
just a single process/ pathway. Our results suggest a specific 
strategy to target lung adenocarcinomas by exploiting their high 
glucose uptake.
Keywords: Lung cancer, metabolomics, glycolysis
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P3.01-008 THE IMPORTANCE OF THE SECRETED FRIZZ-
LED-RELATED PROTEIN (SFRP) TUMOUR SUPPRESSOR 
GENE FAMILY AND THE EFFECT OF LONG-TERM ASBES-
TOS EXPOSURE ON SFRP EXPRESSION IN MALIGNANT 
PLEURAL MESOTHELIOMA (MPM)
Yuen Yee Cheng1, Chris Mclaughlin2, Hong Chuan Jin3, Francis Kl 
Chan4, Brian Mccaughan5, A M George2, Glen Reid1, Nico Van Zand-
wijk1
1Asbestos Diseases Research Institute/Australia, 2School Of Medical & 
Molecular Biosciences Institute For Biotechnology Of Infectious Disea-
ses, University Of Technology Sydney/Australia, 3Biomedical Research 
Center, Sir Runrun Shaw Hospital, Zhejiang University/China, 4Depart-
ment Of Medicine And Therapeutics, The Chinese University Of Hong 
Kong/Hong Kong, 5Cardiothoracic Unit, Royal Prince Alfred Hospital/
Australia
Background: The etiology of malignant pleural mesothelioma 
(MPM) is closely linked with asbestos exposure. Asbestos is capab-
le of inducing chronic inflammation which potentiates tumour sup-
pressor gene silencing. Epigenetic silencing of the Wnt pathway, 
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py for size and intact structure, and characteristic TMV markers 
(CD81 and ezrin) were verified by western blot analysis. Cytotoxic 
assay was done using XTT assay and EGFR mutation testing was 
done using PNA-clamping method.
Results: Incubation of PC-9 cells with TMV (40 µg/ml) derived from 
PC-9/GR cells confer PC-9 cells gefitinib-resistant. EGFR genoty-
ping of TMV in both cells revealed as the same with cellular DNA 
and this means that TMV carry cell-specific DNA. Passage study 
after PC-9/GR cell derived TMV transfer showed, however, regai-
ned gefitinib sensitivity suggesting that TMV-mediated gefitinib 
resistance is phenotypically transient. Genotyping after T790M-
containing TMV revealed EGFR WT.
Conclusion: T790M-associated gefitinib resistance in lung cancer 
cells might be horizontally transferred via TMV but this type trans-
fer of gefitinib resistance was phenotypically transient in cell-line 
system and there was no genotype transfer. Further investigation 
for TMV-mediated transfer of gefitinib resistance is necessary.
Keywords: tumor microvesicle, gefitinib resistance, T790M, EGFR 
mutation
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P3.01-011 HETEROGENEITY IN TUMOUR CONTENT AND 
NECROSIS IN PRIMARY LUNG CANCERS: IMPLICATIONS 
FOR MOLECULAR ANALYSIS
Felicia Goh1, Edwina Duhig2, Belinda Clarke2, Andrew Dettrick2, 
David Godbolt2, Kayla Tran2, Louise Franz3, Jeremy Barr3, Kylie 
Parsonson3, Maria Martins3, Morgan Davidson3, Casey Wright3, 
John De Laat3, Janet Shaw3, Jennifer Martin3, Brielle Parris3, Eloise 
Shaw3, Laura De Souza3, Jane Tjahjadi3, Marissa Daniels3, Jill E. 
Larsen3, Annalese Semmler3, Rachel Stockwell3, Santiyagu Sava-
rimuthu3, Vandana Relan3, Krishna Sriram3, Jennifer Campbell3, 
Samuel Kim3, Maxine Tan3, Leanne Morrison3, Kelly Chee3, Emily 
Impey3, Annalicia Vaughan3, Sasha A. Rahman3, Nick Chang3, 
Morgan Windsor4, Rishendran Naidoo4, Kevin Matar5, Robert 
Tam5, Peter Cole4, Ian A. Yang3, Rayleen Bowman3, Kwun Fong3
1University Of Queensland Thoracic Research Centre At The Prince 
Charles Hospital/Australia, 2Department Of Anatomical Pathology, The 
Prince Charles Hospital/Australia, 3Thoracic Research Centre, Univer-
sity Of Queensland, Prince Charles Hospital/Australia, 4Cardiothroacic 
Surgery, Prince Charles Hospital/Australia, 5Cardiothoracic Surgery, 
The Prince Charles Hospital/Australia
Background: Lung adenocarcinoma (AC) and squamous cell carci-
noma (SCC) tumours have a large variance in tumour cell content. 
This heterogeneity is a concern for genomic studies, as it is difficult 
to distinguish mutational differences between tumour and non-
tumour if low percentage tumour is used for analysis. In addition 
to this, tumour samples are affected by the amount of necrosis 
present, as the overall number of viable cells is decreased. We 
assessed tumour and necrotic content in lung tumour specimens 
from AC and SCC patients and aimed to identify possible implica-
tions for the suitability of these samples in molecular characterisa-
tion studies using next generation sequencing technology.
Methods: Lung tissue specimens were collected during the pe-
riod of 1990 to 2013 from patients at The Prince Charles Hospital 
who consented to donate their surgically resected lung tissues for 
research. Tissues were macroscopically dissected, snap frozen in 
of the FGF2 pathway. Interactors were validated by co-immunopre-
ciptation experiments and their functional significance examined 
by siRNA and expression of wild-type or phosphomutant forms. 
The clinical significance of our in vitro findings were examined in 
lung cancer tissue arrays.
Results: Here, we show that S6K2 interacts with and phosphoryla-
tes the heteronuclear ribonuclear protein hnRNPA1 on Ser 4 and 6. 
This increases the association of this protein with BCL-XL and XIAP 
mRNAs to promote their nuclear export while de-repressing their 
translation. A non-phosphorylatible S4/6A hnRNPA1 mutant pre-
vented this process from occurring and impaired the pro-survival 
activity of FGF2/S6K2 signalling. Following phosphorylation and 
transfer to the cytoplasm in complex with mRNAs, phospho-
hnRNPA1 associates with 14-3-3 to be sumoylated on K189 within 
a multi-protein complex involving UBC9. This targets hnRNPA1 for 
re-import into the nucleus in a caryopherin-dependent manner, 
a step that is essential for translational derepression of target 
mRNAs. Our in vitro findings predicted that in cancer cells where 
FGF2/S6K2 signalling is switched on, hnRNPA1 would be predo-
minantly localised to the nucleus and cytoplasmic expression of 
anti-apoptotic proteins such as BCL-XL would be increased. To test 
this hypothesis, we stained a NSCLC tissue array for S6K2, hnRN-
PA1 and BCL-XL expression. Strikingly, this revealed that increased 
S6K2 expression tightly correlated with decreased cytoplasmic 
hnRNPA1 and increased BCL-XL levels.
Conclusion: FGF-2/S6K2 signalling promotes the nucleo-cytoplas-
mic cycling of hnRNPA1 to promote tumour cell survival through 
increased translation of the anti-apoptotic proteins BCL-XL and 
XIAP. Our immunohistochemical findings in NSCLC suggests that 
tumours which show absence of cytoplasmic hnRNPA1 in the pre-
sence of increased S6K2 and Bcl-XL expression might respond 
better to FGF receptor inhibitors.
Keyword: Fibroblast growth factor, hnRNPA1, immunohistoche-
mistry, S6K2
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P3.01-010 TUMOR-DERIVED MICROVESICLES MEDIATE 
THE TRANSFER OF GEFITINIB RESISTANCE IN LUNG 
CANCER CELLS HARBORING T790M EGFR MUTATION
Jae Young Heo1, Do-Young Choi1, Hee Joung Kim2, Kwang Pyo Kim1, 
Kye Young Lee2
1Department Of Molecular Biotechnology, Institute Of Biomedical Sci-
ence And Technology/Korea, 2Department Of Internal Medicine, Konkuk 
University Hospital/Korea
Background: Tumor-derived microvesicles (TMV) contain bioactive 
molecules including proteins, RNA, microRNA, and DNA, and shed 
TMV propagate the horizontal transfer of their cargo in tumor mi-
croenvironment. TMV play important roles in cancer biology such 
as tumor progression, angiogenesis, escape from immune surveil-
lance, metastasis and drug resistance. In this study, we investiga-
ted whether T790M EGFR mutation-related gefitinib resistance 
could be transferred via TMV using lung cancer cells harboring 
exon 19 del mutation (PC-9 cells) ± exon 20 T790M mutation (PC-
9/GR cells).
Methods: TMV were isolated from the culture medium by serial 
centrifugations. Isolated TMV were checked by electron microsco-
S1039Copyright © 2013  by the International Association for the Study of Lung Cancer
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P3.01-012 CO-TARGETING THE PI3K AND MEK  
PATHWAYS IN NSCLC: AN IN VITRO EVALUATION  
AND MUTATION PREVALENCE IN AN IRISH PATIENT 
COHORT.
Susan Heavey1, Martin Barr1, Brian Hennessy2, Sinead Toomey2, 
Aoife Carr2, John Crown3, Anthony Davies1, Kenneth O‘Byrne4, 
Kathy Gately1
1Clinical Medicine, Trinity College Dublin/Ireland, 2Royal College Of 
Surgeons In Ireland/Ireland, 3St. Vincent‘s Hospital/Ireland, 4Princess 
Alexandra Hospital/Australia
Background: PI3K pathway activation in NSCLC has been shown by 
us and others to lead to a more aggressive disease correlating to poor 
prognosis for patients. Unfortunately, the success of PI3K targeted 
inhibition has been hampered by a high rate of innate and acquired 
resistance. Mutations in KRAS and B-RAF, ERK hyperactivation as well 
as extensive PI3K-MEK pathway cross-talk allow the MEK pathway to 
provide a bypass track. Preclinical studies demonstrate a rationale for 
a PI3K-MEK co-targeted treatment strategy which may provide a more 
effective response. A Phase I clinical trial is underway investigating the 
combination of GDC-0941, a pan-PI3K inhibitor, with GDC-0973, a MEK 
inhibitor. GDC-0980 is a dual PI3K-mTOR inhibitor which may offer im-
proved pathway inhibition compared to GDC-0941. No data has been 
published to date on the combination of GDC-0980 and GDC-0973, 
which we believe may offer improved overall inhibition of survival sig-
naling in NSCLC cells. We aim to elucidate the role of mutation status 
in response to this co-targeted inhibition approach in vitro, as well as 
investigating the frequency of PI3K and MEK pathway mutations in a 
well characterized Irish NSCLC patient cohort.
Methods: The effects of GDC-0941, GDC-0980 and GDC-0973 on 
proliferation and apoptosis in a panel of four NSCLC cell lines were ana-
lysed by BrdU Assay and HCA Apoptosis Assay, respectively. The four 
cell lines investigated were H460 (adenocarcinoma, PIK3CA mutant 
& KRAS mutant), A549 (adenocarcinoma, PIK3CA wild type & KRAS 
mutant), H1975 (adenocarcinoma, PIK3CA mutant, KRAS wild type & 
EGFR TKI resistant) and SKMES-1 (squamous cell carcinoma, PIK3CA 
wild type & KRAS mutant). Further investigation involved expression 
analysis of pAkt, pGSK-3β, pp70S6K, pS6RP, ERK and pERK in cell lines 
treated with each inhibitor alone or in combination using Mesoscale 
technology and Western blot. DNA was extracted from 120 NSCLC 
patient tissue samples, and screened for 547 mutations in 59 genes 
(including PI3K and MEK pathway members) using the Sequenom.
Results: GDC-0941 and GDC-0980 treatment induced dose-depen-
dent anti-proliferative and pro-apoptotic responses across all four 
NSCLC cell lines, while GDC-0973 treatment induced only anti-prolife-
rative responses. Protein expression analysis showed that GDC-0980 
& GDC-0973 combination treatment induced significantly improved 
phosphoprotein inhibition compared to treatment with either inhibitor 
alone in cell lines harbouring PIK3CA mutations, while in one cell line 
bearing WT PIK3CA (SKMES-1), combination treatment actually increa-
sed pathway signalling. NSCLC patient mutational profiling data will be 
presented.
Conclusion: This research underpins the importance of mutation sta-
tus in sensitivity to targeted therapies. While combination treatment 
approaches may be beneficial in certain molecular subtypes, in others 
they may be detrimental. In the era of personalised medicine, patient 
genotyping is crucial to improve patient survival and reduce toxicities.
Keywords: PI3K, MEK, co-targeted inhibition, sequenom
liquid nitrogen and stored at -80°C. A tissue section was taken and 
stained with haematoxylin and eosin (H&E) for two pathologists to 
independently assess tumour cell and necrotic content. Tumour 
cell content (TC) in each specimen was scored as percentage of 
viable cells as seen on the H&E slide, where necrotic content (NC) 
was recorded as a percentage of the whole slide section. Statis-
tics were calculated using SPSS v21 software. Tumour specimens 
screened for eligibility to The Cancer Genome Atlas sequencing 
project are presented here.
Results: Tumours from 62 AC and 104 SCC subjects were scored 
(specimen characteristics in Table 1). Scoring between the two 
pathologists was highly correlated, with a high intraclass reliability 
(0.94 and 0.96 for TC and NC respectively).  
Table 1: Clinical and Pathological Characteristics of  
Specimens
AC SCC
Number of Specimens 384 609
Number of Males/Females 36/26 84/20
Median Specimens per Subject 4 4
Range of Specimens per Subject 1-25 1-27
Median TC 35% 30%
Range of TC 0-88% 0-90%
Median NC 0% 6%
Range of NC 0-90% 0-100%
Median Age 62 yrs 68 yrs
Range of Age 45-85 yrs 46-91 yrs
Median Smoking Pack Years 40 56
Range of Smoking Pack Years 0-115 0-158
 
TC varied from 0-~90% for both subtypes. Comparing AC and 
SCC, the median TC was higher in AC than SCC (35% vs 30% 
respectively, p<0.05). NC varied from 0-~100%, but was gene-
rally low. The median NC was statistically significantly different 
between AC and SCC (0% and 6% respectively, p<0.001). TC was 
weakly correlated with NC (Spearman Rank r = 0.32, p<0.01). There 
were no clinically important correlations between smoking pack 
years, gender or age with TC and NC of specimens.
Conclusion: Lung AC and SCC specimens are heterogeneous in 
terms of TC and NC. Therefore, only a small proportion of resec-
ted lung cancer specimens meet the criteria required for massively 
parallel sequencing projects that require high quality tumour DNA 
and RNA (ie low NC) and relatively low stromal contamination (ie 
high TC).
Keywords: squamous cell carcinoma, molecular, Lung cancer, 
Adenocarcinoma
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Program/Australia, 4Medicine, Vercelli Hospital/Italy
Background: The PI3K/AKT signaling pathway is aberrantly active 
and has an important biologic impact in malignant pleural me-
sothelioma (MMe) cell cycle progression and chemo-resistance. 
Akt consists of three isoforms, Akt1, Akt2, and Akt3. Despite 
the growing amount of research demonstrating the existence of 
isoform-specific regulation, many papers still draw generalized 
conclusions about AKT without focusing on functional specificity 
of each isoforms. Recent data have clearly demonstrated a role of 
SIRT1 in the modulation of AKT1 activation and a role of PARP1 as 
a gatekeeper for SIRT1 activity by limiting NAD+ availability.
Methods: We explored the expression of AKT isoforms in MMe in 
vivo and in vitro and the balancing between their acetylation and 
phosphorylation status in human MMe derived cell lines in vitro.
Results: We firstly described that MMe tumors in vivo and MMe 
derived cell lines express both AKT1 and AKT3 isoforms but not 
AKT2, and their expression results significantly increased in the 
biphasic histotype. Furthermore, we demonstrated an inverse 
correlation between AKTs acetylation and phosphorylation modu-
lated by PARP1/SIRT1 activation status. By immunoprecipitation 
experiments, we evidenced that in basal conditions AKT1 is in part 
acetylated and in part phosphorylated and became highly phos-
phorylated and completely de-acetylated upon PARP1 inhibition. 
Interestingly, AKT1 activation, related to PARP1 inhibition, is unab-
le to modulate pro-survival signals, because the downstream pa-
thway is interrupted at the level of its effector mTOR. Conversely, 
SIRT1 inhibition or silencing result in a more evident AKT1 and its 
interactors acetylation.
Conclusion: In conclusion, our results clearly show how both 
PARP1 and SIRT1 affect critical cellular pathways involved in MMe 
progression and offer a model of a regulatory inter-relationship 
between these proteins. These data could be helpful for designing 
new effective therapeutic strategies.
Keywords: Acetylation, Phosphorylation, AKT mesothelioma,  
mesothelioma
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P3.01-015 OUTCOME IN PEMETREXED/CISPLATIN-TRE-
ATED NON-SMALL-CELL LUNG CANCER (NSCLC) PATI-
ENTS ACCORDING TO MRNA EXPRESSION LEVELS OF 
BRCA1, TS, AEG1 AND REV3 
Bartomeu Massuti1, Guillermo Lopez-Vivanco2, Thomas M. Marti3, 
Ilya Kotov4, Imane Chaib5, Santiago Ponce-Aix6, Rosario Garcia-
Campelo7, Jose Miguel Sanchez8, Angel Artal9, Isabel Bover10, Mi-
quel Taron5, Maria Sanchez-Ronco11, Christian Rolfo12, Rolf Stahel4, 
Rafael Rosell5
1Medical Oncology, Hospital General De Alicante/Spain, 2Oncology, 
Hospital De Cruces De Barakaldo/Spain, 3Lab Of Thoracic Surgery, Dpt 
Of Clinical Research, University Hospital Bern/Switzerland, 4Clinic And 
Policlinic Of Oncology, University Hospital Zurich/Switzerland, 5Catalan 
Institute Of Oncology/Spain, 6Medical Oncology, Hospital 12 De Octub-
re/Spain, 7Medical Oncology, Complejo Hospitalario A Coruña/Spain, 
8Medical Oncology, MD Anderson Cancer Center/Spain, 9Medical Onco-
logy, Hospital Universitario Miguel Servet/Spain, 10Oncology, Hospital 
Son Llatzer/Spain, 11Statistics, University Of Alcala De Henares/Spain, 
12Medical Oncology, University Hospital Antwerp/Belgium
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P3.01-013 KAT5 MAY BE A CANDIDATE THERAPEUTIC 
TARGET IN MALIGNANT PLEURAL MESOTHELIOMA
Sian Cregan1, Yun Gao2, Kenneth O‘Byrne3, Steven G. Gray4
1Clinical Medicine, Trinity College Dublin/Ireland, 2Department Of 
Oncology, Aerospace Central Clinical Medical College Of Peking Univer-
sity/China, 3Queensland University Of Technology, Cancer & Ageing 
Research Program/Australia, 4Clinical Medicine, Trinity College Dublin/
st Jame‘s Hospital/Ireland
Background: Malignant pleural mesothelioma (MPM) is a rare 
aggressive cancer of the pleura. Asbestos exposure (through in-
halation) is the most well established risk factor for mesothelioma. 
The current standard of care for patients suffering from MPM is a 
combination of cisplatin and pemetrexed (or alternatively cisplatin 
and raltitrexed). Most patients however, die within 24 months of 
diagnosis. New therapies are therefore urgently required for this 
disease. Lysine acetyltransferases (KATs) including KAT5 have been 
linked with the development of cisplatin resistance. This gene may 
therefore be altered in MPM and could represent a novel candida-
te target for intervention
Methods: A panel of MPM cell lines inluding the normal pleural 
cells LP9 & Met5A were screened for expression of KAT5 variants 
by RT-PCR. Levels were subsequently examined in a cohort of 
snap-frozen patient samples isolated at surgery comprising beni-
gn, epithelial, biphasic, and sarcomatoid histologies by RT-PCR. 
The effects of a small molecule inhibitor of KAT5 (MG-149) on cel-
lular proliferation were examined.
Results: We show that the expression of KAT5A is dramatically 
increased in MPM. When separated according to histological sub-
type, KAT5A was significantly overexpressed in both the the sar-
comatoid and biphasic subgroups for all transcript variants. Treat-
ment of cells with the small molecule MG-149 caused significant 
inhibition of cellular proliferation (p<0.0001). We continue to asess 
this compound by other methodologies to confirm its potential 
utility in the treatment of MPM.
Conclusion: KAT5, a lysine acetyltransferase associated with ci-
splatin resistance in cancer is significantly altered in MPM. A small 
molecule inhibitor of this protein shows significant anti-proliferative 
effects in MPM cell lines. Targeting this protein may have impor-
tant future implications for the management of MPM.
Keywords: mesothelioma, epigenetics, lysine acetyltransferase, 
KAT5A
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P3.01-014 EXPRESSION AND POST-TRANSLATIONAL 
MODIFICATIONS OF AKT ISOFORMS IN MALIGNANT 
PLEURAL MESOTHELIOMA CELLS
Giulia Pinton1, Arcangela G. Manente1, Steven G. Gray2, E Borroni1, 
Kenneth O‘Byrne3, Luciano Mutti4, Laura Moro1
1Dept. Of Pharmacological Sciences, University Of Piemonte Orientale/
Italy, 2Clinical Medicine, Trinity College Dublin/st Jame‘s Hospital/Ire-
land, 3Queensland University Of Technology, Cancer & Ageing Research 
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chanism of cytotoxicity, the exact mechanism of action of ATO in 
SCLC is not fully elucidated. In this study, we further explore the 
potential genetic changes and biological properties of acquired 
resistance to ATO in SCLC.
Methods: Using H841 SCLC cell line as a model, a daughter cell 
line resistant to ATO (H841AR) was established by culturing H841 
cells in medium with progressively increasing concentrations 
of ATO for 12 months. Resistant clones were then selected and 
cultured in HITIS medium containing 20 µM ATO. Total RNA was 
extracted from both H841 and H841AR cells, followed by reverse 
transcription and hybridization with Affymetrix EXON 1.0 ST array. 
Gene chip signals were analyzed by Gene Spring 12 software. Cell 
proliferation (MTT) assay, wound healing (migration) experiment 
and invasion assay were performed to compare between H841 and 
H841AR cells.
Results: Exponential growth of H841AR cells was shown in HITIS 
medium with 20 µM ATO. Comparing with H841 cells, 17 genes 
were upregulated by at least 5-fold in H841AR cells, consisting of 
stress response factors, immune system regulators and prolifera-
tion-associated or transcriptional factors. Similarly, 45 genes were 
downregulated by more than 5-fold in H841AR compared with 
H841 cells, mainly involving angiogenesis, signal transduction and 
neurodifferentiation. Apart from resistance to ATO (resistant index 
(RI) = 12.5 comparing H841AR cells with H841 cells), H841AR cells 
were also slightly resistant to cisplatin (RI = 2) compared with H841 
cells. H841AR cells demonstrated faster proliferation, with greater 
migration and invasion properties.
Conclusion: There are distinct genetic alterations and biological 
properties in SCLC cell line (H841AR) with acquired resistance to 
ATO. Further analysis of the functional significance of various ge-
netic alterations in ATO-resistant SCLC cell line is warranted. This 
study is partly funded by the CRCG Small Project Funding from the 
University of Hong Kong
Keywords: Acquired Arsenic Resistance, small cell lung cancer
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P3.01-017 NITRIC OXIDE ADAPTED LUNG TUMOR CELLS 
EXPRESS TUMOR STEM CELL-LIKE MARKERS
Arkadiusz Dudek1, Madeeha Aqil2, Kim Elseth2, Lawrence Feld-
man1, Gabor Tarjan3, James A. Radosevich2
1Hematology/Oncology, University Of Illinois At Chicago/United States 
Of America, 2CMBOD, University Of Illinois At Chicago/United States 
Of America, 3Pathology, John H. Stroger, Jr Hospital Of Cook County/
United States Of America
Background: Recent studies in our laboratory show that tumor 
cells exposed to progressively higher concentrations of DETA-
NONOate grow more aggressively than the parent cells. The cur-
rently accepted tumor stem cell model proposes that rare tumor 
stem cells produce both tumor cells (TCs) and rare tumor stem 
cells (TSCs). A number of TSC markers have been proposed, inclu-
ding CD antigens expression, Hoerscht 33342 exclusion, ALDH1/2 
expression, and ALDH1/2 activity. In this study, we compare the 
TSC-like properties of parent and HNO cells. We hypothesized that 
human lung tumor cells adapted to high nitric oxide (HNO) levels 
will exhibit enhanced tumor stem cell-like properties relative to 
analogous cells not adapted to NO (“parent” cells).
Background: REV3, the catalytic subunit of the translesion synthe-
sis (TLS) polymerase x, can continue replication past DNA adducts. 
Depletion of REV3 sensitizes A549 lung cancer cells to cisplatin. 
REV3 expression is part of a gene signature that predicted pe-
metrexed sensitivity in 17 NSCLC cell lines. BRCA1, TS, AEG1 and 
RAP80 are involved in DNA damage repair through homologous 
recombination. The homologous recombination and TLS pathways 
have non-redundant functions in response to cisplatin. We hypo-
thesized that low mRNA expression of these genes – either alone 
or in combination – could confer improved outcome to cisplatin/
pemetrexed in NSCLC patients.
Methods: REV3, BRCA1, RAP80, TS and AEG1 mRNA expression 
was examined by quantitative RT-PCR and categorized by terciles. 
Expression of each gene was correlated with outcome in 47 cispla-
tin/pemetrexed-treated NSCLC patients.
Results: 63.8% male; 47% smokers; 80.9% ECOG PS 1; 80.8% ade-
nocarcinoma. Overall response rate was 51%, with no differences 
according to expression levels of any of the genes. Progression-
free survival (PFS) for patients with low, intermediate and high 
BRCA1 levels was 13.4, 5.5 and 3.9 months (m), respectively 
(P=0.005). Similar differences in PFS were observed according to 
TS (P=0.003) and AEG1 (P<0.001) expression. The hazard ratio 
(HR) for PFS for patients with high BRCA1 levels was 4 (P=0.002). 
Overall survival (OS) for patients with low, intermediate and high 
BRCA1 levels was 29.7, 7.4 and 6.3 m, respectively (P=0.05). Si-
milar differences in OS were observed according to TS (P=0.005) 
and AEG1 (P=0.001) expression. HR for OS for patients with high 
BRCA1 levels was 3.6 (P=0.004). There were no differences in PFS 
or OS according to REV3 or RAP80 levels. However, the joint effect 
of BRCA1 and REV3 was significant for predictive modeling. PFS 
for patients with low, intermediate and high levels of both genes 
was 14.9, 7.2 and 2.8 m, respectively (P=0.001). OS for patients with 
low, intermediate and high levels of both genes was 29.7, 7.8 and 
6.3 m, respectively (P=0.04).
Conclusion: Low BRCA1 expression predicts longer PFS and OS in 
pemetrexed/cisplatin-treated NSCLC p. Low TS and AEG1 levels 
have similar predictive value. The combination of low BRCA1 and 
REV3 expression confers longer PFS and OS. Analysis of these 
genes could be useful for customizing pemetrexed/platinum che-
motherapy.
Keywords: REV3, BRCA1, NSCLC, AEG1
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P3.01-016 GENETIC ALTERATIONS AND CELLULAR PRO-
PERTIES OF ACQUIRED ARSENIC RESISTANCE IN SMALL 
CELL LUNG CANCER
Chun Yan Zheng, Sze Kwan Lam, Yuan Yuan Li, James Chung Man 
Ho
Department Of Medicine, The University Of Hong Kong/Hong Kong
Background: Small cell lung cancer (SCLC) is notoriously a highly 
fatal disease, with rapid emergence of resistance to first-line che-
motherapy. Arsenic trioxide (ATO) has been used as a standard 
treatment for acute promyelocytic leukemia for the past decade. 
Our recent data have demonstrated in vitro activity of ATO, with 
clinically relevant concentrations, in SCLC cell line model. Although 
induced oxidative stress has been implicated as a possible me-
S1042 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
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Results: The FACS-sorted “pure” TCs, after being cultured, resul-
ted in a TSC population re-immerging within days.
Conclusion: Collectively, these data support the idea that TSCs 
are not rare cells and that NO can drive TC populations to express 
properties of TSCs. This plasticity means that any TC can become 
a TSC.
Keywords: Tumor Stem Cell, Adenocarcimas, Nitric Oxide
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P3.01-019 ANALYSIS OF INTEGRINS IN MALIGNANT ME-
SOTHELIOMA (MM).
Ngan Ching Cheng, Nico Van Zandwijk, Glen Reid
Asbestos Diseases Research Institute/Australia
Background: Malignant mesothelioma (MM), strongly associated 
with exposure to asbestos, is a growing worldwide problem (1). 
This aggressive tumour is largely resistant to oncological treat-
ments and new approaches to therapy are urgently needed. Inte-
grins are a class of adhesion molecules composed of an α and a β 
chain. Combinations of 18 α and 8 β subunits form the 24 members 
of the integrin family. The αv subunit can dimerize with β1, β3, β5, 
β6 and β8. Aberrant expression of αv integrins was reported in 
MM, and the integrins αv β3 and αv β5 have been implicated in 
tumour progression and metastasis. We have investigated the ex-
pression and function of αv integrins in MM cell lines and the effect 
of gene knockdown on cell invasion.
Methods: Expression of the integrin (ITG) genes was analysed by 
qPCR in 7 MM cell lines. Expression of the heterodimers was deter-
mined by Western blot, immunofluorescence and immunocytome-
try (monoclonal antibodies kindly provided by Simon Goodman, 
2). In addition, we knocked down the genes potentially involved 
in tumour progression (ITGB3 and ITGB5) and analysed the in vitro 
2D and 3D invasiveness with an agarose spot invasion assay (3) and 
MM spheroids.
Results: All 7 MM cell lines showed high ITGB1 expression, mode-
rate ITGB5 expression, and a general low ITGB6 and ITGB8 expres-
sion. ITGB3 was expressed in one cell line, which accordingly had 
high αv β3 expression. ITGB3 knockdown of this cell line resulted in 
suppression of invasion both in 2D and 3D cultures.
Conclusion: We have found evidence that integrin αv β3 may 
play a role in MM invasion. Presently, we are testing cilengitide, a 
peptide antagonist of integrin αv, in MM cell lines. References: 1. 
Delgermaa F, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Glo-
bal mesothelioma deaths reported to the World Health Orga-
nization between 1994 and 2008. Bull World Health Organ. 2011, 
89:716-724. 2. Goodman SL, Grote HJ, Wilm C. Matched rabbit 
monoclonal antibodies against αv-series integrins reveal a no-
vel αvβ3-LIBS epitope, and permit routine staining of archival 
paraffin samples of human tumors. Biol Open. 2012, 1:329-340. 
3. Wiggins H and Rappoport J. An agarose spot assay for che-
motactic invasion. Biotechniques. 2010, 48:121-124.
Keywords: mesothelioma, integrin, Invasion, 3D spheroids
Methods: The human lung adenocarcinoma cell line A549-Parent 
and the previously reported A549-HNO adapted cell lines were 
used in these studies. Immunohistochemistry was used to measure 
the expression of ALDH1/2 and six different CD antigens. Gene 
expression was measured using chip microarray analysis. FACS 
analysis was used to measure the population of H33342-positive 
and H33342-negative cells. ALDH activity was assessed using the 
ALDEfluor assay.
Results: The ALDEFLUOR assay demonstrated that ALDH activity 
of A549-HNO has increased compared to that of A549-parental. 
Relative to the A549-parental cells, A549-HNO cells showed mar-
kedly higher H33342-exclusion in the FACS analysis and greater 
ALDH1/2 expression in the immunostaining studies. Shocking the-
se cells with 700 mM NO donor prior to treatment produced even 
more pronounced stem cell-like properties, suggesting that NO 
might be able to influence TCs into becoming more TSC-like. Gene 
chip results show that CD44, ALDH1A1, and ALDH2 are more high-
ly expressed in A549-HNO cells than in A549-Parent cells. Cytospin 
results showed that ALDH1/2, CD44, and CD133 were more highly 
expressed in the A549-HNO cells, relative to A549-Parent cells.
Conclusion: The TSC markers tested in this study are consistent 
with the A549-HNO cells being more TSC-like than the A549-Pa-
rent cells. Having a large population of TSC-like cells would allow 
for improved drug screening of therapeutic candidates specifically 
designed to target TSCs.
Keywords: Nitric oxide level, Tumor stem cells, human lung ade-
nocarcinoma
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P3.01-018 SUPPORTING EVIDENCE FOR A NEW TUMOR 
STEM CELL PLASTICITY MODEL BASED ON ADAPTION 
TO NIRTIC OXIDE
Kim Elseth1, James A. Radosevich1, Madeeha Aqil1, Arkadiusz Du-
dek2, Lawrence Feldman2
1CMBOD, University Of Illinois At Chicago/United States Of America, 
2Hematology/Oncology, University Of Illinois At Chicago/United States 
Of America
Background: Hypothesis: Tumor stem cells (TSCs) are not rare 
cells and tumor cells TCs) have the plasticity to become TSCs. Ob-
jectives: Currently the rate limiting step in these efforts is the use 
of fluorescence-activated cell sorting (FACS) instrumentation to 
physically sort TSCs from TCs. We have shown that tumor cell lines 
could be adapted to comparatively high Nitric Oxide (NO) levels 
and that these cells had properties similar to TSCs. These cells 
were tested for various TSC properties using cellular, immunologi-
cal, and molecular biology methods which included ALDH expres-
sion, ALDH activity, CD antigen expression, and H33342 dye exclu-
sion. Proving that these are in fact TSCs would mean that we can 
produce large quantities of these cells to study. In a similar fashion, 
proving that TCs can become TSCs, would be very important.
Methods: We used the A549 and several Head & Neck SCC cell 
line in this study. They were FACS sorted five to seven times conse-
cutively using H33342, to remove any chance of TSCs being pre-
sent. The resulting TCs were cultured, and retested using H33342 
at various times (several days to several weeks), for the presence of 
TSCs. The cells were cultured with or without NO.
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P3.01-021 A3 ADENOSINE RECEPTOR-MEDIATED P53- 
DEPENDENT APOPTOSIS IN LU-65 HUMAN LUNG CAN-
CER CELLS
Taiichiro Otsuki1, Tomoyuki Nishizaki2, Eriko Fujimoto1, Yuichi 
Koda1, Daisuke Horio1, Eisuke Shibata1, Eriko Masachika1, Hitomi 
Kamiya1, Hisaya Okuwa1, Miki Honda1, Risa Maeda1, Koji Mikami1, 
Yoshitaka Nogi1, Takayuki Terada1, Kunihiro Tamura1, Chiharu 
Tabata1, Takashi Nakano1
1Respiratory Medicine, Hyogo College Of Medicine/Japan, 2Division Of 
Bioinformation, Department Of Physiology, Hyogo College Of Medicine/
Japan
Background: A3 adenosine receptor mediates apoptosis in cancer 
cells via diverse signaling pathways. The present study examined 
A3 adenosine receptor-mediated apoptosis in Lu-65 cells, a human 
giant cell lung carcinoma cell line.
Methods: MTT assay, TUNEL staining, real-time RT-PCR, Western 
blotting, and assay of caspase-3, -8, and -9 activities were carried 
out in Lu-65 cells, and A3 adenosine receptor or p53 was knocked-
down by transfecting each siRNA into cells.
Results: Extracellular adenosine induces Lu-65 cell apoptosis in a 
concentration (0.01-10 mM)-dependent manner, and the effect was 
inhibited by the A3 adenosine receptor inhibitor MRS1191 or by 
knocking-down A3 adenosine receptor or p53. Like adenosine, the 
A3 adenosine receptor agonist 2-Cl-IB-MECA also induced Lu-
65 cell apoptosis. Adenosine upregulated expression of p53 and 
Noxa mRNAs and activated caspase-3 and -9, but not caspase-8. 
Those adenosine effects were still inhibited by knocking- down A3 
adenosine receptor or p53.
Conclusion: The results of the present study show that adenosine 
upregulates p53 expression via A3 adenosine receptor, to promote 
p53-dependent Noxa gene transcription, causing activation of cas-
pase-9 and the effector caspase-3 to induce Lu-65 cell apoptosis.
Keywords: Apoptosis, A3 adenosine receptor, p53, Lu-65 lung 
cancer cell
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P3.01-020 BONE MARROW MESENCHYMAL STEM 
CELLS DELETERIOUSLY AFFECT LUNG CANCER CELL 
LINES.
Victoria Zismanov1, Liat Drucker2, Maya Gottfried3
1Lung Cancer Research Laboratory, Meir Medical Center/Israel, 2Onco-
genetic Laboratory, Meir Medical Center/Israel, 3Oncology, Meir Medical 
Center/Israel
Background: Lung cancer remains the most common cause of 
cancer-related death in the world. The major advances in treat-
ment of lung cancer have brought only minor improvements in sur-
vival; therefore novel strategic treatment approaches are urgently 
needed. Accumulating data allocate a central role for the cancer 
microenvironment including mesenchymal stem cells (MSCs) in 
acquisition of drug resistance and disease relapse. Therefore, we 
decided to study the effect of bone marrow (BM) MSCs on non 
small cell lung cancer (NSCLC) cell lines. Recent studies indicate 
that translation initiation factors are over expressed in multiple 
cancers and negatively impact NSCLC prognosis. Interestingly, 
translation initiation is highly modulated by microenvironmental 
cues. Hence, special emphasis will be attributed to the role of 
translation initiation in the crosstalk between the malignant lung 
cells and the BM-MSCs.
Methods: Specifically, we will determine the influence of MSCs 
(co-culture) and MSCs conditioned media on the proliferation, 
viability, migration of NSCLC cell lines (A549, H1299, and H460). 
We will also explore the effect on translation initiation factors im-
plicated in cancer progression (eIF4E, eIF4GI, DHX29).
Results: Preliminary results demonstrate that 48h co-culture of 
NSCLC cell lines with MSCs conditioned media significantly de-
creased cell number (A549: 60%, H1299: 50%, H460: 10%, p<0.05) 
and viability (A549: 70%, H1299: 50%, H460: 60%, p<0.01) yet 
had no effect on cell cycle or death. Moreover, MSCs conditioned 
media decreased NSCLC cells motility (H1299: 60%, H460: 70%, 
p<0.05) and attenuated eIF4GI expression and activity as indicated 
by the levels of its targets (H1299: peIF4G 65%, total eIF4G 40%, 
SMAD5 30%, cMyc 80%; H460: peIF4G 90%, SMAD5 85%, cMyc 
40%, p<0.05).
Conclusion: Ongoing work in our lab is aimed at dissecting whe-
ther the effects are dependent on direct cell-cell contact or medi-
ated by soluble factors. Results that indicate translation initiation is 
modulated by MSCs derived components will mark new therapeu-
tic targets for lung cancer treatment.
Keywords: mesenchymal stem cells, Non small cell lung cancer, 
translation initiation
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P3.02-002 IDENTIFICATION OF CPG ISLAND METHYLA-
TOR PHENOTYPE PREDICTS THE PROGNOSIS OF SMALL 
CELL LUNG CANCER
Yuichi Saito1, Eisaku Miyauchi1, Hironori Ninomiya1, Noriko Mo-
toi1, Masayuki Nakao2, Hirofumi Uehara2, Mingyon Mun2, Sakae 
Okumura2, Ken Nakagawa2, Genta Nagae3, Hiroyuki Aburatani3, 
Yukitoshi Satoh4, Yuichi Ishikawa1
1Pathology, Japanese Foundation For Cancer Research/Japan, 2Thoracic 
Surgical Oncology, The Cancer Institute Hospital Of Japan Foundation 
For Cancer Research/Japan, 3Genome Science Division, Research Center 
For Advanced Science And Technology/Japan, 4Department Of Thoracic 
Surgery, Kitasato University School Of Medicine/Japan
Background: Small cell lung cancer (SCLC) accounts for 13-15% of 
new lung cancer cases in worldwide and has the poor therapeu-
tic outcomes with a median survival of just over one year. A CpG 
island methylate phenotype (CIMP) is well known as a methylator 
phenotype with characteristic promoter DNA methylation alte-
rations, in colorectal cancers, glioblastoma and breast cancers, 
although there has been no report about any CIMP of SCLC. We 
investigated whether DNA methylation profiles can provide useful 
molecular subtyping of SCLC in terms of etiology and prognosis of 
SCLC.
Methods: We analyzed 28 fresh frozen samples from pure SCLC 
patients and 13 noncancerous lung tissues. All patients underwent 
surgical lung resection at the Cancer Institute Hospital, nine pati-
ents among them were treated with chemotherapy before surgery. 
After genomic DNA was treated with sodium bisulfite, bisulfite-
converted genomic DNA was analyzed using Illumina’s Infinium 
HumanMethylation27 BeadChip. And, total RNA was extracted 
from twenty-five SCLC tumor samples and mRNA expression of 
these samples were analyzed by Agilent’s SurePrint G3 Human 
CGH Microarray. Next, we matched these two data sets by Gene 
Symbol, and identified fifty-five most differentially methylated CpG 
sites (corresponding to 46 genes) with a FDR p value cut off of 
0.05. Gene ontology analysis was performed using DAVID Bioinfor-
matics Resources.
Results: We selected a total of 1741 most differentially methylated 
CpG sites (s.d. > 0.20) across the 28 SCLC tumor tissues in each 
DNA methylation platform, after an elimination of the probes re-
lated with the X- and Y- chromosome. Unsupervised hierarchical 
clustering of methylation data from SCLC samples reveals two 
major subgroups with different prognosis: the 5 years disease-free 
interval (DFI) rate of patients in cluster 1 (11.1%) was lower than 
that of patients in cluster 2 (61.57%) (p = 0.001). By multivariate 
analysis for DFI, both postoperative chemotherapy and cluster 1 
were a significant prognostic factor (p = 0.002 and 0.002; respec-
tively). Next, among 1220 genes with methylation and expression 
data both available, the CpG sites were ranked on the basis of the 
spearman’s correlation coefficient between cluster 1 and cluster 2 
into an ascending order. Finally, we identified that fifty-five CpG 
sites were nagetively correlated and found that apoptosis pathway 
was a most differentially expressed.
Conclusion: By comprehensive DNA methylation profiling, two 
distinct subgroups with different molecular and clinical phenotype 
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P3.02-001 KIF5B/RET FUSION GENE IN SURGICALLY-
TREATED JAPANESE ADENOCARCINOMA OF THE 
LUNG
Hidefumi Sasaki1, Shigeki Shimizu2, Yoichi Tani3, Katsuhiro Oku-
da1, Yu Hikosaka1, Satoru Moriyama1, Motoki Yano1, Yoshitaka 
Fujii1
1Oncology, Immunology And Surgery, Nagoya City University Graduate 
School Of Medical Sciences/Japan, 2Pathology, National Hospital Or-
ganization, Kinki-chuo Chest Medical Center/Japan, 3Dako Japan Inc/
Japan
Background: Recently, a novel fusion gene resulting from linkage 
between the kinesin family member 5B gene (KIF5B; 10p11.22) and 
rearranged during transfection gene (RET; 10q11.21) was identi-
fied in non-small cell lung cancer (NSCLC). RET translocation was 
previously reported in thyroid cancer, as CCD6/RET translocation. 
However, the correlation between KIF5B/RET fusion gene status 
and clinicopathologic features of surgically-treated lung cancer has 
not been well characterized.
Methods: We have investigated KIF5B/RET fusion gene status in 
371 surgically treated NSCLC (270 were adenocarcinoma and 101 
were squamous cell carcinoma), 60 breast cancers, 11 metastatic 
lung cancers from colon cancers and thyroid papillary adenocar-
cinoma case at Nagoya City University Hospital. The fusion gene 
and CCD6/RET statuses were analyzed by RT-PCR based assay 
and direct sequencing. We have performed immunohistochemical 
(IHC) analysis using C-ternimal specific anti RET antibody (EPR2871, 
1:250) (Epitomics Inc., Burlingame, CA, USA, n=86) with Dako linker 
kit using intercalated antibody-enhanced polymer (iAEP) method. 
Cytoplasm was stained either granular (G1) or diffuse (G2). G2 stai-
ning was defined as positive staining.
Results: We detected 3 of 270 cases of KIF5B/RET fusion genes in 
adenocarcinomas (1.5 %) from the present study; all were mixed 
subtype adenocarcinomas and three were female and never-smo-
kers. The fusion genes were exclusive with the other mutations, 
such as EGFR, Kras, Braf, erbB2 mutations, and EML4-ALK fusion. 
KIF5B/RET fusion was not detected in the cases with squamous cell 
carcinoma or other types of cancers. Of the 3 cases, 2 cases were 
KIF5B (exon15): RET (exon12) fusions with papillary dominant and 1 
cases were KIF5B (exon22): RET (exon12) fusion with solid dominant 
adenocarcinoma. Matched normal lung tissues did not show trans-
location. In the present study, we did not detect CCD6/RET fusion 
genes. as a driver somatic mutation of lung adenocarcinomas. 
Although all 3 had positive IHC staining, 35/86 had more than 10% 
staining and 15/86 had more than 50% staining.
Conclusion: In the present study, we reported KIF5B/RET fusion 
genes as a possible new driver somatic mutation of lung adenocar-
cinomas. Cinico-pathological backgrounds of the KIF5B/RET fusion 
positive patients were similar with that of the EML4/ALK fusion 
positive patients. The chimeric oncogene might be as a promising 
molecular target for the personalized diagnosis and treatment of 
NSCLC. However, the chimeric oncogene might not be determined 
using IHC analysis.
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Conclusion: The study associated various SNPs to drug pharmaco-
kinetics, patient toxicities and response which could be integrated 
into future personalisation efforts of paclitaxel and carboplatin. 
Furthermore, SNPs with interethnic differences may provide clues 
to understand interethnic variability in drug efficacy. Finally, a no-
vel SNP identified in ATP7A associated with patient response and 
toxicity. The ATP7A gene encodes a protein that has been linked 
to resistance to platinum based drugs, however, the SNP has unk-
nown functional effects which require further elucidation.
Keywords: Pharmacogenomics, Drug variability, Ethnic variability, 
ATP7A
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P3.02-004 DYSREGULATION OF HIPPO TUMOR-SUP-
PRESSIVE PATHWAY IN MALIGNANT MESOTHELIOMA
Yoshitaka Sekido, Ichidai Tanaka, Makiko Fujii, Hirotaka Osada
Division Of Molecular Oncology, Aichi Cancer Center Research Institu-
te/Japan
Background: Malignant pleural mesothelioma (MPM) is a highly 
aggressive tumor caused by asbestos exposure after a long la-
tency. The neurofibromatosis type 2 (NF2) tumor suppressor gene 
is mutated in around 50% of MPM cases, which encodes Merlin 
that regulates the Hippo tumor-suppressive signaling pathway. 
We previously reported occasional genetic alteration in the LATS2 
and SAV1 genes in MMs, which encode components of the Hippo 
pathway. The LATS2 inactivation was shown to lead to constitutive 
activation of YAP, a prooncogenic protein and transcriptional coac-
tivator, which enhances multiple cell cycle regulation genes inclu-
ding cyclin D1 (CCDN1). To further delineate the exact inactivation 
mechanism of this pathway in MMs, we analyzed MM cell lines for 
other multiple components that regulate activation or inactivation 
of this pathway.
Methods: We studied several new components that have been 
identified to be involved in the Hippo signaling pathway including 
a LIM protein Ajuba. Expression analyses such as conventional 
western blot and real time RT-PCR were performed. Using MPM 
cell lines and their transplanted mouse models, biological assays 
were conducted to study the effects of cell proliferation, motility 
and invasion after the induction of overexpression or knockdown 
of candidate genes. Immunohistochemical analysis with primary 
MPM tissues and xenografts was also carried out.
Results: We found that the expression of Ajuba was significantly 
down-regulated in 6 of 20 MM cell lines compared to an immorta-
lized normal mesothelial cell line, MeT-5A. Interestingly, the 6 cell 
lines with low Ajuba expression showed decreased phosphorylati-
on (activation) levels of YAP. We infected the MM cells with Ajuba-
expressing lentivirus and found that exogenous Ajuba increased 
phosphorylation (inactivation) of YAP and inhibited cell prolife-
ration. Dual-luciferase reporter assays demonstrated that Ajuba 
suppressed the promoter activities of YAP-transcriptional targets 
including CCND1. Knockdown of LATS2 effectively increased these 
promoter activities, suggesting the mediation of LATS2 for Ajuba 
to inhibit this cascade. Immunohistochemical analysis also showed 
frequent downregulation of Ajuba in primary MMs.
Conclusion: Inactivation of Hippo signaling is a key mechanism for 
MPM cell proliferation and progression. Our findings suggest that 
were identified to evoke a CIMP of SCLC. We found some promo-
ter markers in the apoptosis pathway could make a difference bet-
ween the two groups, and we hope that our data can contribute to 
provide a useful resource for the construction of therapeutic strat-
egy and the development of a new chemotherapeutic agent.
Keywords: DNA methylation, small cell lung cancer, CpG island 
methylator phenotype, genome wide DNA methylation profiling
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P3.02-003 ATP7A IS A NOVEL DETERMINANT OF TOXI-
CITY AND RESPONSE IN ADVANCED NON-SMALL CELL 
LUNG CANCER PATIENTS RECEIVING PACLITAXEL AND 
CARBOPLATIN
Benjamin D. Harris1, Vidya Perera2, Viet Phan3, Andrew Mclach-
lan4, Stephen Clarke5, Kellie Charles1
1Pharmacology, The University Of Sydney/Australia, 2School Of Phar-
macy And Pharmaceutical Sciences, Suny At Buffalo/United States Of 
America, 3Department Of Medical Oncology, Concord General Repa-
triation Hospital/Australia, 4Centre For Education And Research On 
Ageing, Concord General Repatriation Hospital/Australia, 5Department 
Of Medical Oncology, Royal North Shore Hospital/Australia
Background: Genetic variability can influence the pharmacoki-
netics and pharmacodynamics of paclitaxel and carboplatin in 
patients with non-small cell lung cancer (NSCLC). Additionally, 
the prevalence of genetic variations often differs between ethnic 
groups and may account for observed interethnic variability in 
drug efficacy. We aimed to undertake a pharmacogenomic investi-
gation to account for patient variability in order to improve dosing 
and patient selection in NSCLC.
Methods: 76 advanced NSCLC patients from Caucasian (n = 50) 
and Asian (n = 26) ethnicity were prospectively recruited into the 
study at Concord Repatriation General Hospital from 2007-2011. 
All patients received paclitaxel (175mg/m2) and carboplatin (target 
AUC 6 mg/mL•min) for an intended 6 cycles. A candidate gene ap-
proach was used to select single nucleotide polymorphisms (SNPs) 
for pharmacogenomic analysis. HPLC with population pharmaco-
kinetic modelling (NONMEM) was used to obtain pharmacokinetic 
data (n = 61). Toxicities were assessed according to CTCAE v 4.0 
and response was measured by CT scans according to RECIST 
criteria. Blood DNA was genotyped by the Australian Genetics 
Research Facility using a MassARRAY® iPLEX Gold system on a Se-
quenom mass spectrometer. SNPs were assessed for linkage dise-
quilibrium, Hardy-Weinberg equilibrium and interethnic differences 
in allele frequency. Regression analysis was undertaken to associa-
te SNPs with drug pharmacokinetics, toxicities and response.
Results: 42 SNPs from 21 genes were selected and genotyped 
in patients. Regression analysis identified 12 SNPs significantly 
associated to paclitaxel pharmacokinetics, patient toxicities and 
response. SNPs rs2306283 and rs11615, in SLCO1B1 and ERCC1 re-
spectively, associated with paclitaxel clearance. Previously publis-
hed SNPs in CYP2C8, CYP1B1, ABCB1, ABCC10, SLCO2B1, GSTP1, 
ATP7A, ERCC1 and CCND1 were found to be associated with pa-
tient toxicities. Three SNPs, rs2306283, rs1056836 and rs2306168, 
encoded by SLCOB1, CYP1B1 and SLCO2B1 respectively, had 
interethnic difference in SNP prevalence and associated to patient 
outcomes. SNP rs2227291 in ATP7A associated with patient res-
ponse and to nausea and anaemia.
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P3.02-006 DOWNREGULATION OF THE CANDIDATE TU-
MOR SUPPRESSOR GENE SIRPA INDUCES SENESCENCE 
MEDIATED BY RB AND P27 AND IS ASSOCIATED WITH 
MUTATION OF EGFR
Larissa Pikor1, Raj Chari2, Jennifer Y. Kennett1, Luisa M. Solis3, Ilse 
Valencia4, Ignacio Wistuba3, Adi F. Gazdar4, Stephen Lam1, Wan L. 
Lam1
1Integrative Oncology, BC Cancer Research Centre/Canada, 2Depart-
ment Of Genetics, Harvard Medical School/United States Of America, 
3The University Of Texas MD Anderson Cancer Center/United States Of 
America, 4Hamon Center For Therapeutic Oncology Research, Univer-
sity Of Texas Southwestern Medical Center At Dallas/United States Of 
America
Background: The epidermal growth factor receptor (EGFR) si-
gnaling pathway is involved in numerous biological processes 
including proliferation and apoptosis, migration/invasion, and 
angiogenesis, and has emerged as one of the most important 
and frequently deregulated pathways in NSCLC. The discovery 
of oncogenic, activating mutations in the tyrosine kinase domain 
of EGFR and DNA amplification of EGFR have led to the deve-
lopment of multiple targeted therapeutics against this pathway. 
While effective at prolonging survival, these targeted therapies 
are only applicable to a subset of patients (~15-20%) that harbour 
these alterations and resistance to treatment ultimately develops. 
As multiple genomic and epigenomic mechanisms can disrupt 
genes, a comprehensive understanding of the genetic alterations 
affecting genes within this pathway is required. An integrative, 
multi-dimensional genomics approach can detect genes disrup-
ted by multiple mechanisms which may otherwise be overlooked 
if only a single genomic dimension were assessed, improving the 
ability to identify causal genetic events and decipher downstream 
consequences.
Methods: A multi-dimensional integrative analysis of copy num-
ber, DNA methylation and gene expression profiles on 77 ade-
nocarcinomas and matched non-malignant tissue, was performed 
to investigate the complement of genetic alterations affecting the 
EGFR pathway. Novel candidate genes were validated in external 
datasets and immunohistochemical analysis of a tissue microarray 
was used to verify disruption at the protein level and to correlate 
expression with clinical features. The tumor suppressive effects of 
SIRPA were assessed by stable knockdown and in vitro assays on a 
panel of lung cancer cell lines. The effect of SIRPA downregulation 
on TKI sensitivity was assessed by dose response assays.
Results: Of the 35 genes examined, 11 were aberrantly expressed 
in over 50% of tumors, with 6 (RRAS, SIRPA, PIK3R1, TGFA, ERBB2 
and EGFR) raNKIng in the 95th percentile of altered genes. Of 
these genes, all but SIRPA are known to be frequently disrupted in 
NSCLC and play a role in tumorigenesis. SIRPA is a transmembrane 
protein that negatively regulates receptor tyrosine kinsase activity 
and is frequently downregulated at both the mRNA and protein 
level in NSCLC tumors and cell lines. Underexpression of SIRPA 
is associated with EGFR mutations and is more prominent in ade-
nocarcinoma than squamous cell carcinoma. Downregulation of 
SIRPA enhanced colony formation and wound healing but impaired 
viability and suppressed proliferation. Interestingly, SIRPA knock-
down induced a senescent phenotype through the accumulation 
of p27 and Rb in its unphosphorylated state thereby blocking pro-
gression of the cell cycle. These results suggest senescence indu-
ced by SIRPA downregulation is a tumor suppressive mechanism 
Ajuba is also one of the target components for Hippo signaling 
inactivation; Ajuba negatively regulates YAP in the presence of 
LATS2, and thus the downregulation of Ajuba serves to enhance 
constitutive activation of YAP in MM cells. Our study also indicates 
that a strategy to normalize this signaling cascade may be the rati-
onale for developing a new target therapy against MPMs.
Keywords: oncogene, malignant mesothelioma, signal transduc-
tion cascade, tumor suppressor gene
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P3.02-005 GENOME-WIDE IDENTIFICATION OF GENES 
WITH AMPLIFICATION AND/OR FUSION IN SMALL CELL 
LUNG CANCER
Jun Yokota1, Reika Iwakawa1, Masataka Takenaka1, Koji Tsuta2, 
Masayuki Noguchi3, Takashi Kohno1
1Division Of Genome Biology, National Cancer Center Research Insti-
tute/Japan, 2Division Of Pathology And Clinical Laboratories, National 
Cancer Center Hospital/Japan, 3Faculty Of Medicine, University Of 
Tsukuba/Japan
Background: Most of small cell lung cancer (SCLC) cases are di-
agnosed after metastatic spread of the diseases, and only 5% of 
SCLC patients survive beyond 5 years after diagnosis. Therefore, 
for the improvement of patients’ outcome in this disease, it is ne-
cessary to identify druggable targets that are activated by genetic 
alterations in SCLC cells.
Methods: To obtain a landscape of gross genetic alterations in 
SCLC, genome-wide copy number analysis and whole-transcripto-
me sequencing were performed in 58 and 42 SCLCs, respectively.
Results: Focal amplification of known oncogene loci, MYCL1 
(1p34.2), MYCN (2p24.3), and MYC (8q24.21), was frequently and 
mutually exclusively detected. MYCL1 and MYC were co-amplified 
with other regions on either the same or the different chromoso-
me in several cases. In addition, the 9p24.1 region was identified 
as being amplified in SCLCs without amplification of MYC family 
oncogenes. Notably, expression of the KIAA1432 gene in this 
region was significantly higher in KIAA1432 amplified cells than 
in non-amplified cells, and its mRNA expression showed strong 
correlations with the copy numbers. Thus, KIAA1432 is a novel 
gene activated by amplification in SCLCs. By whole-transcriptome 
sequencing, a total of 60 fusion transcripts, transcribed from 95 
different genes, were identified as being expressed in SCLC cells. 
However, no in-frame fusion transcripts were recurrently detec-
ted in 2 SCLCs, and genes in the amplified regions, such as PVT1 
neighboring MYC and RLF in MYCL1 amplicons, were recurrently 
fused with genes in the same amplicons or with those in different 
amplicons on either the same or different chromosome.
Conclusion: Amplification and fusion of several genes on chro-
mosomes 1 and 8 were likely to occur simultaneously but not 
sequentially through chromothripsis in the development of SCLC. 
Amplification rather than fusion of genes was indicated to play an 
important role in its development.
Keywords: small cell lung cancer, genome-wide analysis, gene 
amplification, gene fusion
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Sample 
Source 
Clinical Trial OA-
M4558g Vendor-Procured 
Histology 
Adenocar-
cinoma 
Squa-
mous-cell 
Carcinoma 
Adenocar-
cinoma 
Squamous-
cell Carci-
noma 
Cases (n) 75 36 95 110 
MET- 
positive 
(%) 
61 28 24 9 
Conclusion: These results demonstrate preferential MET expressi-
on for adenocarcinoma compared with the squamous-cell carcino-
ma subtype of NSCLC. The lower proportion of MET-positive cases 
in the vendor samples suggests that tissue quality is crucial for 
adequate MET assessment by IHC.
Keywords: MET expression, NSCLC, histology, Biomarkers
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P3.02-008 TRIM14 IS A NOVEL TUMOR SUPPRESSOR 
GENE IN NON-SMALL-CELL LUNG CANCER
Josephine Hai, Chang Q. Zhu, Ming S. Tsao
Princess Margaret Cancer Centre/Canada
Background: Non-small-cell lung carcinoma (NSCLC) accounts 
for 85% of all malignant lung tumors. Our group previously iden-
tified Tripartite Motif-Containing 14 (TRIM14) as a component of 
a prognostic multigene expression signature for NSCLC patients. 
TRIM14 belongs to a conserved family of Tripartite Motif-encoding 
genes involved in a broad range of biological processes, such as 
transcriptional regulation, cell proliferation, and apoptosis. How-
ever, TRIM14 itself is poorly understood. Here we investigate the 
functional and prognostic role of TRIM14 in NSCLC.
Methods: Cox proportional hazards regression analysis was done 
on published mRNA expression datasets of primary NSCLCs to 
identify whether TRIM14 expression is associated with patient sur-
vival. The expression of TRIM14 was modified in human NSCLC cell 
lines (NCI-H1395, NCI-H1650, NCI-H520 and NCI-H157) by lenti-
virus-mediated overexpression and short-hairpin RNA (shRNA)-
mediated silencing. Effects were assessed by examining in vitro 
cell proliferation and anchorage-independent growth, and in vivo 
tumorigenicity in mice.
Results: Univariate analyses demonstrated that TRIM14 expression 
is significantly associated with patient survival, with loss of expres-
sion correlated with poorer prognosis in resectable early stage 
NSCLC patients. In vitro studies showed that TRIM14 overexpres-
sion in H1395 cells suppressed proliferation and anchorage-inde-
pendent growth, whereas shRNA knockdown of TRIM14 expression 
in H1650, H520, and H157 cells promoted cell proliferation and 
colony formation. In vivo studies demonstrated that suppressing 
TRIM14 expression in H1650 and H157 cells significantly promotes 
tumor growth in immunodeficient mice.
Conclusion: We show that TRIM14 may function as a tumor sup-
pressor gene in NSCLC affecting cell proliferation and anchorage-
independent growth in vitro and tumor growth in mice. We provi-
de evidence that prognostic genes identified in microarray based 
that must be overcome to develop tumors.
Conclusion: Our integrative analysis of the EGFR pathway revealed 
SIRPA as one of the most frequently deregulated genes within the 
pathway. SIRPA functions as a tumor suppressor gene, controlling 
a number of biological functions through the inhibition of singaling 
pathways downstream of EGFR. To our knowledge, this is the first 
study to report a role for SIRPA in NSCLC tumorigenesis.
Keywords: EGFR, SIRPA, Rb, Senescence
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P3.02-007 PREFERENTIAL EXPRESSION OF MET IN 
LUNG ADENOCARCINOMA VS LUNG SQUAMOUS-CELL 
CARCINOMA
Sandra Rost1, Sara Chan1, Chenery Lowe1, Eloisa Fuentes1, Robert 
Yauch2, Hartmut Koeppen1
1Research Pathology, Genentech/United States Of America, 2Research 
Oncology Diagnostics, Genentech/United States Of America
Background: MET is a tyrosine kinase receptor expressed on 
the cell surface of numerous cell types, including normal and 
malignant epithelial cells. MET is expressed on a proportion of 
non-small cell lung cancer (NSCLC) cases of adenocarcinoma and 
squamous-cell differentiation. In a phase II clinical trial evaluating 
the anti-MET monovalent antibody onartuzumab, patients with 
advanced MET-positive NSCLC – as determined by immunohisto-
chemistry (IHC) – derived clinical benefit from onartuzumab and er-
lotinib. The prevalence of MET expression in two separate sample 
cohorts of NSCLC – vendor-procured and phase II clinical trial sam-
ples – is compared and correlated with MET gene copy number.
Methods: Formalin-fixed, paraffin-embedded NSCLC tissues were 
obtained from commercial sources or from the phase II clinical trial 
OAM4558g. Tumor histology was determined by morphology; IHC 
for TTF1 and p63, respectively; or both. MET IHC was performed 
with the SP44 rabbit monoclonal antibody (CONFIRM anti-Total 
c-MET) on a Ventana Benchmark XT platform. Patients were selec-
ted based on expression of MET by IHC as defined by moderate or 
strong staining in at least 50% of tumor cells (clinical score 2+/3+); 
MET gene copy number was determined by fluorescence in-situ 
hybridization (FISH) or by chromogenic in-situ hybridization (CISH) 
(INFORM® MET DNA probe, Ventana Medical Systems).
Results: Adenocarcinomas and squamous-cell carcinomas accoun-
ted for 46% (n=95) and 54% (n=110) of the vendor-procured sam-
ples and for 59% (n=75) and 28% (n=36) of clinical trial samples, 
respectively. In total, 16% (n=33) of vendor-procured and 52% of 
clinical trial samples were scored as MET-positive. The proportions 
of MET-positive cases among adenocarcinomas and squamous-cell 
carcinomas were 24% and 9% for vendor samples and 61% and 
28% for clinical trial samples. FISH analysis of the OAM4558g clini-
cal trial samples showed MET gene amplification in 8 of 96 cases 
(8%) with a high positive correlation to MET-positive IHC status; 6 
of 8 gene-amplified cases were MET-positive by IHC (p<0.0001). 
Evaluation of MET copy number by CISH is ongoing and will be 
reported.  
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erlotinib-treated patients harbored concomitant T790M mutations; 
for these patients, PFS was10.8 m for those with low/intermediate 
ROR1 levels vs 2.7 m for those with high levels (P=0.0138).
Conclusion: ROR1 expression has a differential effect on outcome 
to erlotinib and chemotherapy in EGFR-mutant NSCLC patients. 
High ROR1 expression significantly limits PFS in erlotinib-treated 
patients with T790M mutations and ROR1-directed therapies can 
enhance the efficacy of treatment. In contrast, high ROR1 expres-
sion confers longer PFS to chemotherapy in the same group of 
patients. The role of chemotherapy and erlotinib in EGFR-mutant 
NSCLC patients with high ROR1 expression warrants further inves-
tigation.
Keywords: ROR1, EGFR, NSCLC, T790M
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P3.02-010 A PCR-BASED TEST DETECTING ECTOPIC 
EXPRESSIONS OF PLACENTA/GERMLINE GENES CAN 
PREDICT AGGRESSIVE LUNG TUMOURS
Christian G. Brambilla, Sophie Rousseaux, Alexandra De Bernardi, 
Baptistin Jacquiau, Anne-Laure Vitte, Francois Arbib, Nicolas Le-
maitre, Sylvie Lantuejoul, Hélène N. Mignotte, Denis Moro-Sibilot, 
Anne-Claire Toffart, Elisabeth M. Brambilla, Saadi Kochbin
Institute Albert Bonniot Inserm Grenoble University/France
Background: Cell transformation and tumour progression are as-
sociated with severe alterations of the epigenetic control of gene 
expression. Although the abnormal repression of tumour sup-
pressor genes has been thoroughly investigated, the concept of 
tissue-specific gene aberrant reactivations in cancer is only starting 
to emerge. The extent of this process has not been reported yet, 
mainly because of the difficulties in detecting these expressions by 
the currently used transcriptomic analyses
Methods: We have developed a simple approach, exploiting ge-
nome wide expression data, which has enabled us to demonstrate 
that these "off-context“ gene activations occur in any cancer, 
providing a universal source of cancer biomarkers. By applying this 
analysis to our series of lung cancer patients (n=297) with the cor-
responding precise clinical annotations and 5 to 10 years patient 
follow-up, we found that hundreds of germline-specific genes are 
ectopically expressed in the tumours and that a subset of 26 genes 
are specifically activated in a subgroup of highly aggressive me-
tastatic-prone tumours, even at an early stage of the disease. This 
approach has enabled us to define and isolate a homogeneous 
group of very aggressive tumours called P3 with at least 3 genes 
ectopically expressed, independently of other prognosis parame-
ters (histo-pathological or stage) (Rousseaux et al. Sci Transl Med 
2013, 5 (186): 186ra66).
Results: Based on these data we setup a PCR based test to di-
rectly rank lung tumours by detection of the prognosis associated 
gene activations. This test was first validated on a series of 60 
tumour samples from the same cohort (also analyzed by an affy-
metrix transcriptomic approach), which revealed the remarkable 
robustness of the PCR approach and showed a higher sensitivity of 
the PCR-based detections in tumour raNKIng. We then extended 
these PCR-based analyses to include additional patients with pre-
cise clinical and pathological annotations and 10 years follow-up 
but for whom transcriptomic data were not available. Here again 
gene expression analyses may have a strong biological rationale.
Keywords: prognostic marker, xenograft models, tumor suppres-
sor gene, non-small-cell lung cancer
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P3.02-009 ROR1 AS A NOVEL THERAPEUTIC TARGET 
FOR EGFR-MUTANT NON-SMALL-CELL LUNG CANCER 
(NSCLC) PATIENTS WITH THE EGFR T790M MUTATION
Niki Karachaliou1, Ana Drozdowskyj2, Carlota Costa1, Miguel 
Angel Molina-Vila1, Ana Gimenez-Capitan1, Alain Vergnenegre3, 
Bartomeu Massuti4, Teresa Moran5, Margarita Majem6, Enriqueta 
Felip7, Enric Carcereny5, Rosario Garcia-Campelo8, Santiago Viteri1, 
Cordula Heidecke9, Roger Estrada-Tejedor10, Jordi Teixido10, Trever 
Bivona11, Petros Giannikopoulos12, Mayumi Ono13, Rafael Rosell5
1Quiron-dexeus University Hospital, Pangaea Biotech, Molecular Onco-
logy Research (MORE) Foundation/Spain, 2Pivotal/Spain, 3Service De 
Pneumologie, Centre Hospitalier Universitaire De Limoges/France, 4On-
cology, Hospital General De Alicante/Spain, 5Catalan Institute Of Onco-
logy/Spain, 6Servei D’Oncologia, Hospital De Sant Pau/Spain, 7Medical 
Oncology, Hospital Valle Hebron/Spain, 8Medical Oncology, Complejo 
Hospitalario A Coruña/Spain, 9Oncology, Ctu Tarragona/Ichhco Tarra-
gona/Spain, 10Universitat Ramon Llull, IQS-Institut Quimic De Sarria/
Spain, 11UCSF Helen Diller Family Comprehensive Cancer Center/United 
States Of America, 12Cancer Therapeutics Innovation Group/United 
States Of America, 13Medical Biochemistry, Kyushu University/Japan
Background: Molecular cross-talk between EGFR and other sig-
naling pathways creates alternative means of tumor cell prolife-
ration and promotes resistance to single-agent erlotinib therapy 
in NSCLC driven by EGFR mutations. ROR1 knockdown inhibited 
the growth of NCI-H1975 cells (harboring EGFR L858R and T790M 
mutations). A pro-survival function for ROR1/MEK/ERK signaling in 
cooperation with AKT has been demonstrated. We have assessed 
ROR1 expression in 45 patients from the EURTAC trial (clinicaltrials.
gov NCT00446225), 27 of whom harbored pretreatment concomi-
tant EGFR T790M mutations, and correlated results with outcome.
Methods: ROR1 mRNA expression was examined by quantitative 
RT-PCR and categorized by terciles; patients were classified as 
having low/intermediate or high ROR1 expression. The T790M 
mutation was determined by Taqman with a PNA to inhibit amplifi-
cation of the wild-type (wt) allele. Tumor samples were run in oc-
tuplicates; this method can detect 1 mutated allele among 10,000 
wt alleles.
Results: Median age 65; 68.9% female; 57.8% never-smokers; 
95.6% ECOG PS <2; 91.1% adenocarcinoma; 68.9% exon 19 deleti-
on. No differences in baseline characteristics were observed accor-
ding to ROR1 expression levels. 24 patients (53.3%) were treated 
with erlotinib and 21 (46.7%) with chemotherapy. 10 (41.7%) erloti-
nib-treated patients and 6 (28.6%) chemotherapy-treated patients 
had high ROR1 mRNA levels. Among erlotinib-treated patients, 
response rate (RR) was 40% for the 10 patients with high ROR1 
levels vs 71.4% for the 14 with low/intermediate levels (P=0.058). 
Among chemotherapy-treated patients, RR for the 15 patients with 
low/intermediate ROR1 levels was 6.7%; the 6 patients with high 
ROR1 levels did not respond. Progression-free survival (PFS) was 
11.8 months (m) for erlotinib-treated patients with low/intermediate 
ROR1 levels vs 5.8 m for those with high levels. PFS for chemothe-
rapy-treated patients was 5.6 and 9 m, respectively (P=0.0165). 15 
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P3.02-011 QUANTITATIVE DETERMINATION OF ME-
THYLATION PATTERNS IN FHIT AND APC GENES IN 
NON SMALL CELL LUNG CANCER (NSCLC): A COMPA-
RATIVE ANALYSIS IN TUMOR TISSUE, NORMAL LUNG 
TISSUE, PERIPHERAL BLOOD, SPUTUM AND BRONCHI-
AL ASPIRATE. CORRELATION WITH CLINICAL VARIAB-
LES.
Manuel A. Cobo Dols1, Rocio L. Valenzuela2, Ricardo A. Sanchez3, 
Jose Luis De La Cruz Rios4, Roberto M. Ponce3, Carlos P. Navarrete3, 
F P. Codeso4, Enrique B. Casero3, Dolores Bautista5, Miguel Angel 
Berciano Guerrero1, Manuel Benavides Orgaz1
1Medical Oncology, Hru Carlos Haya/Spain, 2Research Laboratory, Ima-
bis Foundation, Hru Carlos Haya/Spain, 3Thoracic Surgery Department, 
Hru Carlos Haya/Spain, 4Pneumology Department, Hru Carlos Haya, 
Malaga/Spain, 5Pathology Department, Hru Carlos Haya/Spain
Background: Quantifying and comparing the degree of methyla-
tion in the promoter region of APC gene and coding region of 
FHIT gene in patients (p) with non small cell lung cancer (NSCLC) in 
different samples. Correlate these methylation patterns with clini-
cal variables.
Methods: DNA was extracted from peripheral blood simples (B), 
sputum (S) and bronchial aspirate (BA), obtained from patients with 
NSCLC prior to the completion of surgery, as well as resected lung 
tumor tissue (TT) and normal lung tissue (TN). Methylation patterns 
were analyzed by bisulfito conversion and subsequent pyrose-
quencing (QIagen PyroMark System).We analyzed 5 CpG islands 
in the promoter region of the APC gene and 5 CpG islands in the 
coding region of the FHIT gene.
Results: We analyzed 20p, with a median age of 64 years (range 
48-70), 16 men and 4 women. Smoking status: 2p never smokers, 
11p former smokers, 7p current smokers. Histology: 10p adenocar-
cinoma, 9p squamous, 1p large cell. Stage: I 8p, II 8p, III 4p. No 
statistically significant differences were observed between the 
samples studied to any of the islands analyzed. The degree of me-
thylation in TT CpG1 was higher in smokers and former smokers <5 
years, compared to never smokers and ex-smokers >5 years, mean 
4 (0-10) vs 0, p=0.022. There was no other difference when analy-
zing the degree of methylation as a function of the variables age, 
sex, smoking status, cumulative tobacco consumption, histological 
type and clinical stage. Respect FHIT gene, no statistically signifi-
cant differences were found between the tissues studied respect 
to any of the CpG islands analyzed and like wise, no differences 
were observed when analyzed for degree of methylation depen-
ding on the clinical variables studied.
Conclusion: The area of  the APC gen promoter and FHIT coding 
region analyzed showed a low degree of methylation, with no si-
gnificant difference observed between the samples studied. The 
degree of methylation in the TT CpG1 island of the APC gene was 
higher in current smokers and former smokers <5 years. However, 
these findings have to be confirmed in a larger sample. *This study 
was funded by the Carlos III Health Institute (PS09/00308), Spain.
Keywords: FHIT gene, Lung cancer, methylation, APC gene
we could show that our test successfully ranked the patients into 
groups with significantly different survival probabilities. we show 
here the intermediate analysis on a first group of 88 patients wit-
hout lymph node metastasis treated by surgery 
Conclusion: In conclusion we are ready to launch a prospecti-
ve study based on this PCR test to evaluate its ability to predict 
tailored follow up of patients after surgery and also tumour sensiti-
vity to design specific targeted therapies including immunotherapy 
since this ectopic activation may lead to very innovative treatment .
Keyword: epigenetics, testis genes , biomarkers, tailored therapy
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P3.02-013 ATF2 CONTRIBUTES TO PLATINUM RESIS-
TANCE IN NON SMALL CELL LUNG CANCER AND CJUN/
ATF2 CELASTROL MEDIATED MODULATION RESTORES 
PLATINUM SENSITIZATION.
Marco Lo Iacono, Valentina Monica, Tiziana Vavala‘, Mara Gisa-
bella, Silvia Saviozzi, Enrico Bracco, Silvia Novello, Mauro Papotti, 
Giorgio V. Scagliotti
Department Of Oncology, University Of Turin/Italy
Background: ATF2 is a member of the basic helix-loop-helix (b-
ZIP) transcription factor family playing important roles in Stress and 
DNA damage. Several studies reported correlation between ATF2/
JNK-mediated activation and resistance to damaging agents. Ce-
lastrol is an ATF2 inhibitor extracted from a Chinese plant known 
as “Tunder of God Vine”. Celastrol is used in traditional Chinese 
medicine for anti-inflammatory properties. In addition, Celastrol 
is a triterpene with promising anticancer activity in several cancer 
models both in vivo and in vitro. The purpose of the present study 
was to investigate whether ATF2 might play a role in inducing drug 
resistance in Non-Small Cell Lung Cancer (NSCLC).
Methods: In NSCLC cell lines ATF2 expression levels were evalua-
ted by quantitative PCR (qPCR) and Western Blot (WB) and correla-
ted to cisplatin (CDDP) resistance. Celastrol mediated ATF2/cJUN 
activity was assessed by Luminometry, qPCR and western blotting 
(WB). Furthermore, matched tumors and corresponding normal 
tissues of 88 surgically resected NSCLC specimens, were collected 
and both qPCR and immunohistochemical analyses for ATF2 were 
performed.
Results: NSCLC cell lines CDDP-resistant (H522 and H1395) ex-
pressed high levels of ATF2 protein. Moreover, CDDP treatment 
increased ATF2 phosphorylation levels leading to an enrichment 
within the nuclear cell compartment. In our study, Celastrol redu-
ced ATF2 activity by decreasing the production of ATF2 mRNA and 
blocking the CDDP-mediated phosphorylation/mRNA expression 
of cJUN, a main ATF2 partner. Furthermore, ATF2/cJUN functional 
inhibition mediated by Celastrol restored the response to CDDP 
in resistant lung cell Lines. ATF2, at both protein and mRNA level, 
was significantly up-modulated in NSCLC tumor samples com-
pared to the paired normal lung tissue (mRNA: p<<0.01, mean 
Log2(FC)=+4.7). Moreover, high expression of ATF2 mRNA was 
correlated with the smoking status of the patients. Relevantly, 
smoker or former smoker patients expressed significantly high 
ATF2 mRNA levels compared to non-smokers (p=0.02 and p=0.04, 
respectively).
Conclusion: This study shows that in NSCLC cell lines a correlation 
between ATF2 protein expression and CDDP resistance occurs. 
Furthermore, our results suggest a potential increase of CDDP sen-
sitivity, following the Celastrol-mediated ATF2/cJUN inhibition. For 
the first time it has been shown in NSCLC an up-regulation of ATF2 
mRNA/protein levels compared to normal tissues and consistent 
with that detected in CDDP resistant cell lines. This data suggest a 
possible involvement of ATF2 in NSCLC CDDP-resistance.
Keywords: Cisplatin-resistance, ATF2, cJUN, NSCLC
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P3.02-012 CYSTEINE DIOXYGENASE 1 (CDO1) :  
A NOVEL TUMOR SUPPRESSOR GENE REGULATED BY 
HYPERMETHYLATION.
Hae-Won Lee, Jun-Hye Kwon, Moon-Chul Kang, Jong-Ho Park
Thoracic Surgery, Korea Cancer Center Hospital/Korea
Background: Lung cancer is one of the most common causes of 
cancer-related deaths worldwide. Effective early diagnosis and 
targeted therapies for lung cancer to reduce mortality and inci-
dence would benefit from in-depth study on molecular mechanism 
of lung carcinogenesis, but these are largely unknown. In our pre-
vious study, we reported a novel hyper-methylated gene, CDO1, 
encoding cysteine dioxygenase 1 that involved in the conversion of 
cysteine to cysteine sulfinate, and plays a key role in taurine bio-
synthesis. In this study, we evaluated the functional characteristics 
of CDO1 in Lung squamous cell carcinoma (LSCC).
Methods: We analyzed expression levels of CDO1 mRNA and 
protein in tumor and normal tissue pairs from 12 LSCC patients 
were determined by RT-PCR and Western blot analysis. In order to 
determine whether high levels of CDO1 expression contributed to 
the LSCC cell proliferation, migration, invasion and colony formati-
on, we employed a CDO1-expressing vector pEGFP_C3_CDO1 to 
transfect CDO1 into LSCC cell lines (HCC-95, HCC-1588). Further-
more, we performed gene expression profile analysis using human 
whole genome oligonucleotide chip (Agilent).
Results: Downregulation of CDO1 mRNA level was observed in 
LSCC cell lines and tumors derived from patient tissues. In cell pro-
liferation assay, the number of HCC-95 and HCC-1588 cells trans-
fected with pEGFP_C3_CDO1 decreased to 58-70% compared 
with pEGFP_C3 (p<0.05). Moreover, the forces expression of CDO1 
in two different types of LSCC cell lines significantly decreased the 
cell migration, invasion, and colony formation ability (p<0.05). Fur-
thermore, we showed that overexpression of CDO1 make change 
of several signal molecules in lung cancer cells using microarray 
analysis.
Conclusion: In this study, we found that CDO1 expression was re-
gulated by DNA methylation, and this epigenetic regulated CDO1 
might be a novel tumor suppressor gene and potentially valuable 
biomarker for lung squamous cell carcinoma.
Keywords: tumor suppression gene, epigenetic regulation, CDO1
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P3.02-015 GENOMIC ALTERATION IN SPUTUM SAMPLES 
AND DNAFC OF LUNG CANCER HIGH RISK CHILEAN 
POPULATION.
Marta Adonis1, Ulises Urzúa2, Lorena Contreras3, Carolina Tama-
yo3, Lorena Lorca4, Marco Chahuan5, Verónica Miranda6, Mónica 
Campos5, Hugo Benitez7, Alcides Zambrano7, Pedro Marín7, Lionel 
Gil2
1Cellular And Molecular Biology Programme, University Of Chile Facul-
ty Of Medicine Cetecáncer/Chile, 2University Of Chile Faculty Of Medi-
cine/Chile, 3Faculty Of Medicine University Of Chile/Chile, 4Cetecáncer 
Faculty Of Medicine University Of Chile/Chile, 5Hospital San Borja Arri-
arán/Chile, 6Hospital Barros Luco Truddeau/Chile, 7Hospital Regional 
De Antofagasta/Chile
Background: Antofagasta region in northern Chile shows the high-
est lung cancer (LC) mortality rate in the country. This population 
was exposed to arsenic (As) in driNKIng water of concentrations 
as high as 870 mg/L. Between 2003 and 2007, Antofagasta region 
showed a mortality rate of 30.8/100,000. It has been suggested 
that variation in As susceptibility among individuals might be part-
ly due to differences in As biotransformation in addition to other 
genomic factors associated to the carcinogenic process. Objecti-
ve: To determine the association of genomic variations (SNPs, and 
DNA copy-number alterations (CNAs) and susceptibility to LC, in 
blood and induced sputum samples collected from a LC risk samp-
le population.
Methods: The 400 high-risk volunteers from Antofagasta and 
Metropolitan region was split in 2 groups, controls and cases, 
according to the result of early detection assays including auto-
matic quantitative cytometry (AQC), DR70 and autofluorescence 
bronchoscopy (AFB). Copy number variants (CNVs) and single nu-
cleotide polymorphisms (SNPs) were determined in genomic DNA 
of peripheral blood using TaqMan QPCR assays. Odd ratios (OR) 
were estimated by conditional likelihood and significance as exact 
mid-p values. Whole genome CGH profiles were generated with 
HEEBO 70-mer oligonucleotide microarrays.
Results: Among 8 polymorphisms assayed (5 SNPs and 3 CNVs), 
CYP1A1 SNP rs1048943 was associated both to pre-neoplastic 
lesions (PNL) and cancer histopathology (OR 2.66, p=0.02). The 
CYP1B1 SNP rs1056836 was associated to LC, although no sig-
nificantly. Some differences in the AS3MT SNP rs11191439 were 
observed between individuals from Antofagasta and Santiago. 
Additionally, the genomic profiles of sputum DNA and circulating 
cell-free DNA (cfDNA) from serum samples showed discrete diffe-
rences among LC cases, pre-neoplastic lesions (PNL) and healthy 
controls. Chromosome 7p arm showed a significant gain in sputum 
DNA from cancer patients.
Conclusion: Our results suggest that SNPs associated to CYP450, 
like to CYP1A1 and 1B1, might be related to LC etiology. Additi-
onally, genomic profiles from sputum DNA and cfDNA might be 
useful to detect PNL as complementary tools. Finally, this panel of 
genomic biomarkers in addition to DR70, AQC and AFB could be 
helpful to identify individuals susceptible to develop LC, and as 
complementary tools for LC early detection. These findings might 
be relevant in prevention and early detection of LC. Supported by 
INNOVA CORFO Chile: Grants 07CN13B48 and 11IDL2-10634.
Keywords: Lung cancer, sputum biomarkers, ADNfc, genomic 
biomarkers
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P3.02-014 INTERACTION BETWEEN ENVIRONMENTAL 
EXPOSURE AND HPV INFECTION ON DEVELOPING 
LUNG CANCER AMONG TAIWANESE NONSMOKERS
Ya-Wen Cheng, Nan-Yung Hsu, Huei Lee
Graduate Institute Of Cancer Biology And Drug Discovery, Taipei Medi-
cal University/Taiwan
Background: Majority of investigation is focused on lung tumori-
genesis in smokers, little in nonsmokers. Previously, Benzo[a]pyre-
ne (B[a]P)-DNA adducts levels in nonsmoking female patients were 
higher than in nonsmoking male patients. However, p53 mutation 
rate in female patients did not differ from male patients. Moreover, 
HPV16/18 infection rate in female patients was much higher than in 
male patients. We therefore hypothesized that HPV infection could 
synergistically increased chromosomal instability (CIN) induced by 
B[a]P-DNA adducts and might contribute to lung tumorigenesis.
Methods: Herein, three HPV-positive and five HPV-negative lung 
cancer cells were enrolled to test the hypothesis. FISH analysis 
was used to determine the micronuclei formation when these cells 
were treated with various concentrations of B[a]P for different time-
intervals.
Results: The efficacy of micronuclei and DNA adduct formation in-
duced by B[a]P in HPV-positive cells were significantly higher than 
HPV-negative cells. Mechanistically, the micronuclei and DNA ad-
duct formation are dependent on HPV E6 oncoprotein expression. 
We next questioned whether B[a]P-induced CIN enhanced by E6 
could be through altering DNA repair gene expressions. The pro-
moter hypermethylation and mRNA expression of six DNA repair 
genes including hMLH1, hMSH2, BRCA1, and BRCA2, and XRCC3, 
and XRCC5 were evaluated by MSP and real-time RT-PCR, and 
data indicated that XRCC3 and XRCC5 expressions in E6-positive 
cells were markedly lower than in E6-negative cells and the reduc-
tion of both genes was caused by promoter hypermethylation.
Conclusion: Collectively, the promoter hypermethylation of 
XRCC3 and XRCC5 induced by E6 may increase B[a]P-induced CIN 
and contribute to lung tumorigenesis in nonsmokers.
Keywords: Benzo[a]pyrene, Lung cancer, HPV
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lung cancer cells and directly interacted with ILK. Here, we further 
investigated the effect of α-catulin/ILK interaction in lung cancer 
metastasis and evaluated whether this interacting axis could be a 
potential therapeutic target.
Methods: Knockdown and overexpression of α-catulin and ILK 
genes were performed in non-small cell lung cancer (NSCLC) cell 
lines. Cell invasion and migration assays were done in 24-well 
Transwell polycarbonate filters coated with or without Matrigel. 
Spontaneous and experimental metastasis assays were performed 
in xenograft mice models to determine the effects of α-catulin on 
lung cancer cell metastasis in vivo. The public NSCLC cohort da-
tasets were used for validation of the expression of α-catulin/ILK 
associated with patient survival.
Results: In the present study, we demonstrated that α-catulin 
promoted the migration and invasion of NSCLC cells through the 
ILK/NF-κB/integrin network. α-Catulin directly interacted with 
ILK, which in turn activated the ILK/Akt/NF-κB signaling pathway. 
This led to increased expression of the NF-κB downstream genes 
fibronectin and integrin αvβ3, which sequentially activated NF-κB 
signaling and resulted in cancer cell migration, invasion and meta-
stasis. The ILK plus CTNNAL1 two-gene signature was even more 
strongly associated with clinical outcomes of NSCLC patients.
Conclusion: Our data suggest that the alpha-catulin/ILK signaling 
axis is strongly associated with lung cancer cell migration and in-
vasion and correlated with clinical outcome of NSCLC. Thus, this 
novel signaling axis could be a potential therapeutic target for 
treating NSCLC metastasis.
Keywords: α-catulin, ILK, lung cancer metastasis, integrin
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P3.02-018 EGFR MUTATION AND ITS SUBTYPES IN INDI-
AN POPULATION: A STUDY FROM SINGLE ACADEMIC 
CENTRE- TATA MEMORIAL CENTRE
Anuradha Choughule1, Vanita Naronha2, Amit Joshi2, Nirmala 
Jambhekar3, Saral Desai3, Amit Dutt4, K Prabhash5
1Medical Oncology-molecular Laboratory, Tata Memorial Centre/In-
dia, 2Medical Oncology, Tata Memorial Centre/India, 3Department Of 
Histopathology, Tata Memorial Centre/India, 4Molecular Laboratory, 
Actrec- Tata Memorial Centre/India, 5Medical Oncology, Tata Memorial 
Hospital/India
Background: Tyrosine Kinase (TK) domains are central regulators 
of signaling pathways that control differentiation, transcription, cell 
cycle progression, apoptosis, motility and invasion. EGFR TK mu-
tations represent bona fide somatic mutations in NSCLC. Patients 
with specific mutations respond better to targeted therapy.Mu-
tation analysis is known to be evaluated by several methods. Real 
time PCR using allele specific TaqMan primer probes is a simple, 
robust, highly sensitive, and selective method that is compatible 
with standard processes used for known gene expression analysis. 
The main objective of our study was to detect EGFR mutations in 
NSCLC patients registered in Tata Memorial Hospital (TMH) by 
using rapid and sensitive technique of RQ-PCR with In-house Taq-
Man primer probes. There is limited data regarding EGFR mutation 
in Indian population with variable mutation rate reported. This is 
an attempt to get actual mutation rate in our population, correlate 
the frequency of EGFR mutation and their subtypes and analyze 
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P3.02-016 PROTEINASE INHIBITION REGULATES THE 
ANTI-TUMOR ACTIVITY OF PAI-1 TOWARDS LUNG AND 
PROSTATE CANCER CELLS
Joanna Chorostowska-Wynimko1, Adriana Rozy1, Marta Kedzior1, 
Paulina Jagus1, Adam Szpechcinski1, Ewa Skrzypczak-Jankun2, 
Jerzy Jankun2
1Laboratory Of Molecular Diagnostics And Immunology, National In-
stitute Of Tuberculosis And Lung Diseases/Poland, 2Urology Research 
Center, Health Science Campus, University Of Toledo/United States Of 
America
Background: Plasminogen activator inhibitor type 1 (PAI-1) plays 
an important role in tumor growth and metastasis formation, di-
rectly via specific urokinase complexing or indirectly due to its 
affinity to vitronectin.
Methods: The aim of this study was to analyze the impact of the 
mutant forms of PAI-1: very long half-life (VLHL PAI-1) or devoid 
of affinity towards vitronectin (Vn neg PAI-1) and wild form (wPAI 
-1) on proliferation of lung cancer (A549 and H1299 ) and prostate 
cancer (LNCaP and DU145) cells characterized by different protei-
nase (urokinase) production.
Results: The dose- and time-dependent inhibition of cell prolifera-
tion in the presence of VLHL PAI-1 was evident in A549 and LNCaP 
cultures. In H1299 cells inhibitory effect was only dose-depended 
(p<0.001), while in DU145 only 100 mg/ml of VLHL PAI-1 in 72 hrs 
cultures suppresed prostate cancer cells proliferative activity (p 
<0.001). No significant effect of Vn neg PAI-1 on the proliferation 
of A549 and H1299 was observed while in prostate cancer lines 
(DU145, LNCaP) only the inhibitory effect of the highest Vn neg 
PAI-1 concentration (100µg/ml) was evident (p <0.001) but not 
time-dependent. wPAI-1 did’t affect A549 and LNCaP proliferati-
on while in highest concentration it had the stimulating effect on 
H1299 and Du145 (24,48 hrs cultures).
Conclusion: PAI-1 is a negative regulator of cancer cells prolifera-
tion due to its anti-proteinase activity. Its biological effect on lung 
cancer cells is time and dose-dependent.
Keywords: Lung cancer, Plasminogen activator inhibitor type 1, 
PAI-1, anti-tumor activity
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P3.02-017 ALPHA-CATULIN/ILK SIGNALING AXIS COULD 
A POTENTIAL THERAPEUTIC TARGET FOR TREATING 
NSCLC METASTASIS
Yuh-Ling Chen1, Tse-Ming Hong2
1Institute Of Oral Medicine, National Cheng Kung University/Taiwan, 
2Graduate Institute Of Clinical Medicine, National Cheng Kung Univer-
sity/Taiwan
Background: Alpha-catulin is a cytoskeletal linker protein. Integ-
rin-linked kinase (ILK) is a serine/threonine protein kinase implica-
ted in cancer cell proliferation, anti-apoptosis, invasion and angio-
genesis. Our previous study found that α-catulin is upregulated in 
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Methods: A cohort of histopathologically-defined and clinically-
annotated resected SQCLCs was tested for FGFR1 amplification 
by FISH (Zytovision Dual Color Probe). Amplification was defined 
by FGFR1 copy number ≥2.2x CEP8 control copy number and was 
assessed by two evaluators (MW, LW) who were blinded to clini-
cal results. Disease-free survival (DFS) defined as date of surgical 
resection until disease recurrent, relapse, or death, which ever 
occured first. DFS was estimated using Kaplan-Meier method. The 
association between FGFR1 status and clinical features (unpaired 
T-test, Fisher’s exact, Chi-square tests) and DFS (log-rank test for 
unadjusted analysis; Cox proportional hazards regression for multi-
variate analysis) were assessed.
Results: 63 resected SQCLCs were evaluated. FGFR1 amplifi-
cation was detected in 16 (24%). 56% were stage I, 24% were 
stage II, and 20% were stage IIIA. There was no association 
between FGFR1 amplification and age (p=0.86), sex (p=0.80), 
smoking status (p=0.37), or stage of disease (p=0.16). Median 
DFS was significantly longer in FGFR1-amplified cases com-
pared to non-amplified cases: not reached vs 2.3 yrs (95% CI 
1.1-3.4 yrs), p=0.02, with a corresponding unadjusted hazard 
ratio of 0.41 (95%CI: 0.19-0.88). Adjusted for sex and stage, 
multivariate analysis found FGFR1 amplification significantly as-
sociated with improved DFS (HR 0.31, 95%CI 0.1-0.89, p=0.03). 
Conclusion: FGFR1 amplification is associated with improved pro-
gnosis in this cohort of resected SQCLCs. The distinctive natural 
history substantiates FGFR1amplified SQCLCs as a unique, onco-
gene-defined subgroup. There was no association between FGFR1 
status and sex, age, smoking status, or stage. FGFR1 amplification 
is common in SQCLCs.
Keyword: FGFR1, SQCLC, early-stage, oncogene
across different variables of age, gender, habits and histology with 
different ethnicity groups.
Methods: 1018 patients of NSCLC were referred for EFGR testing 
as a routine service over a 1.5-year period. Extracted DNA from 
FFPE blocks was amplified for the exons 18, 19, 20 and 21 using 
the specific TaqMan primer probes with the End point genotyping 
method on LC-480 II platform. Chi-square test was performed to 
reveal any significant correlation between the mutation status and 
age, gender and habits of the patient and tumor histology.
Results: Overall Mutation Rate (MR) was 25.0% with a higher mu-
tation rate in females than males (34 vs.21) with a p value of 0.002. 
Within the age group, MR was high in > 60 yrs group as com-
pared to <60 years (47.6 % vs. 31%). Total population of smoker 
vs. never-smoker was 37.5% vs. 58.6 %. (p value <0.001). MR was 
significantly higher in Never Smoker (NS) as compared to Smoker 
(S) (31.5 % vs.16 %), MR in Adenocarcinoma (ADC) was significantly 
higher than squamous (27.7 %vs. 5.6%) with a p value of <0.001. 
MR is higher in ADC NS female as compared to ADC NS male (37.2 
%vs.29 %). MR of Exon 19 , 21, 18, & 20 was 53%, 38 %, 5.8 % & 2.4 
% respectively. In the cohort of ADC NS gender, Exon 19 positivity 
was predominantly higher in male than female (61.8% vs.34 %) , 
whereas Exon 21 was marginally higher in ADC NS female than 
male (39 % vs 34 %). Exon 20 expressed 2.4%.
Conclusion: There is a heterogenous EGFR MR in diferent geo-
graphical population. We are in close association with East Asian 
countries than Western countries. In our data though the MR is 
high in NS, 16 % of EGFR MR in smokers is also startling reality. 
Another possibility of variation in EGFR mutation rate could be due 
to application of different technologies. Each technique differs in 
their sensitivity and specifictiy. EGFR tyrosine kinase domain defi-
ne a new molecular marker for lung carcinoma.
Keywords: NSCLC, EGFR mutation analysis , Real time PCR, NS-
CLC Adenocarcinoma EGFR mutations Real time PCR, NSCLC, 
EGFRmutations,RealtimePCR, NSCLC, EGFR mutations, RQPCR
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P3.02-019 FGFR1 AMPLIFICATION IS ASSOCIATED WITH 
IMPROVED SURVIVAL IN PATIENTS WITH EARLY-STAGE 
SQUAMOUS CELL CARCINOMAS OF THE LUNG (SQCLC)
Matthew D. Hellmann1, Melissa Wynne2, Lu Wang2, Mark G. Kris1, 
Camelia S. Sima3, Andre L. Moreira2, Natasha Rekhtman2, Paul K. 
Paik1
1Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center/
United States Of America, 2Department Of Pathology, Memorial Sloan-
Kettering Cancer Center/United States Of America, 3Department Of 
Biostatistics, Memorial Sloan-Kettering Cancer Center/United States Of 
America
Background: The spectrum and frequency of oncogenes in squa-
mous cell lung cancers (SQCLCs) is actively being defined. Ampli-
fication of fibroblast growth factor receptor 1 (FGFR1) is the most 
common targetable oncogenic driver in SQCLCs, occurring in 
~20%. Clinical trials of FGFR1 inhibitors for advanced SQCLCs are 
ongoing. The frequency, clinicopathologic features, and prognosis 
of FGFR1 amplification in early-stage SQCLCs have been reported 
but with discrepant results.
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P3.02-021 INTERDEPENDENT ROLE OF MUC16/TSPYL5 
IN LUNG CANCER CELL PROLIFERATION
Apar Kishor Ganti1, Imayavaramban Lakshmanan1, Prabin Dhan-
gada Majhi1, Srustidhar Das2, Sukhwinder Kaur2, Dhanya Haridas2, 
Satyanarayana Rachagani2, Moorthy P. Ponnusamy2, Maneesh 
Jain2, Surinder K. Batra2
1Internal Medicine, Va Nebraska Western Iowa Health Care System/United 
States Of America, 2University Of Nebraska Medical Center/United States 
Of America
Background: Lung cancer is the leading cause of cancer-related 
mortality in the world. These patients usually present at an advanced 
stage where treatment is mostly palliative. Hence, there is an urgent 
need to investigate the various pre-neoplastic pathways to identify 
suitable therapeutic targets to decrease lung cancer mortality. The 
expression patterns of mucins are drastically altered during lung 
cancer development, and these alterations facilitate lung cancer cell 
proliferation and metastasis. MUC16 mucin and Testis specific Y-like 
protein TSPYL5 are two proteins that are overexpressed in lung can-
cer and appear to promote growth of lung cancer cells. In addition 
overexpression of TSPYL5 facilitates chemoresistance and regulates 
aromatase (CYP19A1) enzyme expression. This study was conducted 
to assess the interplay between these two markers and evaluate their 
effect of cisplatin induced cytotoxicity in lung cancer cells.
Methods: Expression of MUC16 in normal lung as well as lung carci-
noma tissues in a commercially available tissue array was assessed by 
immunohistochemical (IHC) analysis using MUC16 antibody (DAKO 
Company-M11 clone). MUC16 levels were semi-quantified using a 
composite score based on the intensity and extent of staining. Endo-
genously expressed MUC16 and TSPYL5 were stably knocked down 
using a MUC16 shRNA construct (pSUPER-Retro-MUC16-sh) and TS-
PYL5 ShRNA construct in H292 and H827 lung cancer cells by stable 
transfection method for investigating the oncogenic functions. Lung 
cancer cells were treated with cisplatin to examine the role of MUC16 
and TSPYL5 on chemoresistance and survival in lung cancer cells.  
 
Results: MUC16 is highly expressed in lung carcinoma and is not ex-
pressed in non-neoplastic lung tissues. MUC16 composite IHC scores 
increased progressively from stage I to stage III NSCLC. Knockdown 
of MUC16 led to decreased proliferation (due to G1 accumulation), in-
vasion and motility in H292 lung cancer cells. TSPYL5 was significantly 
downregulated in MUC16 knockdown cells. TSYPL5 knockdown in 
H292 lung cancer cells resulted in decreased expression of MUC16 as 
well as aromatase. The knockdown studies suggested that silencing 
of MUC16 and TSPYL5 affected each other. These results indicate that 
there may be a feedback regulation between these two molecules 
during lung cancer cell proliferation. Furthermore, cisplatin treatment 
of these cells significantly abrogated MUC16 and TSPYL5 expression.
Conclusion: MUC16 is overexpressed in non small cell lung cancer. 
MUC16 plays an important role in lung cancer proliferation, through 
rapid G1/S transition in the cell cycle. MUC16 and TSPYL5 regulate 
each other during lung cancer cell proliferation, possibly through the 
aromatase pathway. One of the possible mechanisms through which 
cisplatin may decrease lung cancer proliferation is by downregulation 
of MUC16 and TSPYL5.
Keywords: Lung cancer, MUC16, Testis specific Y-like protein (TS-
PYL5), cisplatin
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P3.02-020 NSCLC MOLECULAR PORTRAIT OF THE SAM-
PLE OF CZECH POPULATION AND INDICATIONS OF 
TARGETED THERAPY
Milos Pesek1, Petr Grossman2, Petr Mukensnabl3, Frantisek Bruha1, 
Ondrej Fiala4, Lucie Benesova5, Marek Minarik5
1Department Of Tuberculosis And Respiratory Diseases, Medical School 
And Teaching Hospital In Pilsen, Charles University In Prague/Czech 
Republic, 2Department Of Pathology, Medical School And Teaching Hospi-
tal In Pilsen, Charles University In Prague,/Czech Republic, 3Department 
Of Pathology, Medical School And Teaching Hospital In Pilsen, Charles 
University In Prague/Czech Republic, 4Department Of Oncology And 
Radiotherapy, Medical School And Teaching Hospital In Pilsen, Charles 
University In Prague/Czech Republic, 5Center For Applied Genomics Of 
Solid Tumours (CEGES), Genomac Research Institute/Czech Republic
Background: Molecular therapy targeted on tumour driving muta-
tions should improve quality of life, PFS and overal survival in NSCLC 
patients. While EGFR mutations are widely accepted as targets for 
gefitinib and erlotinib in the first line treatment of advanced NSCLC, 
recently, translocation of EML4-ALK as well as amplification of ROS1, 
are used as guides for indication of crizotinib. Some other genetic 
changes, such as EGFR amplification, c-Met amplification, PIK3CA 
mutations and KRAS mutations are expected to serve as prognostic 
or predictive factors of targeted therapy currently or in near future.
Methods: We analyzed molecular predictors which were routinely 
tested at our department starting in 2004. We focus on EGFR muta-
tions, EGFR gene amplifications, KRAS mutations, EML4-ALK trans-
locations, c-Met amplifications and PIK3CA mutations. We analyzed 
the frequency of genetic changes and , where applicable, their 
impact on PFS and OS. We have also analysed comparability of PCR 
based detection (multiplex ligation-dependent probe amplification, 
MLPA) an FISH for EGFR gene amplifications.
Results: In the group of 890 NSCLC patients we found EGFR mu-
tations on exon 19 in 62 cases, EGFR mutations on exon 21 in 24 
patients. KRAS mutations were found in 141/819. Translocations of 
EML4-ALK were found in 7/203, c-Met amplifications in 5/104, EGFR 
amplifications in 11/34 and PIK3CA mutations in 8/220 patients. We 
confirmed a high correlation between FISH and MLPA-based testing 
of EGFR amplifications, as well as agreement of PFS and OS of both 
groups. However, EGFR gene amplifications were not prognostic, 
nor predictive marker of TKI therapeutic efficacy. Positive predictors 
of such treatment were in accordance with the literature and our 
expectiations, EGFR mutations for the treatment with gefitinib and 
erlotinib, and EML4-ALK translocations for crizotinib. We identified 
KRAS G12C mutation as the only negative predictor of EGFR inhibi-
tor treatment. One hundred patients were defined as triple negative 
tumors (EGFR, EML4-ALK, KRAS negative). Some of our patiens had 
some combinations of genetic changes, such as concurrent EGFR 
and KRAS mutations, mutations and amplifications of EGFR gene 
and, in one patient, mutations and amplifications of EGFR, EML4-
ALK translocation and c-Met amplification.
Conclusion: Precious morphologic and genetic investigations of 
NSCLC tumour tissue should serve as a guide for targeted therapy. 
However, in our population of non-squamous tumour lesions, we 
found predominantly a triple negative tumour type which should 
continue to be treated by first line chemotherapy.
Keyword: NSCLC, , EGFR, KRAS, ALK, ROS1
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and to predict response to therapeutic treatments.
Keywords: Mutational Analysis, ATM, Next-Gen Sequencing, NS-
CLC
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P3.02-022 DEEP-SEQUENCING MUTATIONAL ANALYSIS 
OF ATM IN NSCLC CELL LINES
Lars F. Petersen1, John B. Mcintyre1, Anifat A. Elegbede1, Susan P. 
Lees-Miller2, D G. Bebb1
1Oncology, Tom Baker Cancer Centre, University Of Calgary/Canada, 
2Biochemistry And Molecular Biology, University Of Calgary/Canada
Background: Ataxia telangiectasia-mutated (ATM) is a DNA repair 
protein that is functionally absent in patients with A-T. Individuals 
with heterozygous or somatic homozygous mutations are pre-
disposed to developing various cancers. Previous attempts to 
sequence ATM in cancer cell lines or in patient tissue samples have 
not identified any mutational hot-spots that are linked to the A-T 
phenotype or cancer predisposition, however much of the sequen-
cing analysis performed to date has used traditional Sanger-based 
methodology, which is limited in its depth of coverage. Our lab has 
identified two non-small cell lung cancer (NSCLC) cell lines, NCI-
H23 and NCI-H1395, which appear to be deficient for ATM. While 
H23 cells display sensitivity to ionizing radiation, typical of ATM 
deficiency, H1395 do not and moreover show downstream activa-
tion of several ATM targets. These previous results are important 
because the hallmark radiation sensitivity, and possible chemosen-
sitivity of ATM-deficient patients may suggest that these patients 
would be more responsive to low-dose therapies. However, if 
cells show no detectable ATM but maintain an intact DNA repair 
mechanism, the usefulness of ATM as a biomarker is questionable. 
To assess if these observed differences were intrinsic to the ATM 
gene, we performed next-gen sequencing (NGS) to characterize 
the mutational spectra of H23 and H1395.
Methods: We used the semiconductor-based Ion Torrent PGM to 
sequence the coding region of ATM from genomic DNA isolated 
from H23, H1395, and H460 (ATM normal) cells. Variants were iden-
tified and mapped to the ATM gene. Additional western blots were 
performed to confirm mutation analysis.
Results: Several missense SNP mutations were identified in both 
H23 and H1395, however only one was shared by both, c.5948A>G, 
corresponding to amino acid substitution N1983S, which has pre-
viously been identified as a phosphovariant due to its proximity to 
the activation phosphorylation site, S1981. Interestingly, this SNP 
was not identified in H1395 in past sequencing attempts, demons-
trating the power of NGS. Few of the other SNPs have previously 
been annotated in the COSMIC database, and it is as yet unknown 
whether they confer functional disruptions in the protein. Interes-
tingly, the N1983S SNP is located in the same region of ATM used 
as the epitope for antibodies to both the phosporylated and un-
phosphorylated forms of ATM, raising the question of whether the 
antibodies are unable to bind to these variants and thus limiting 
detection. We performed western blots with antibodies to diffe-
rent epitopes to address this question.
Conclusion: We have yet to determine whether the mutations we 
identified in H23 and H1395 NSCLC cells are the cause of deficien-
cy in these cells. However, use of deep-sequencing methodology 
has rapidly identified previously unknown mutations in these cell 
lines, and expansion of these studies to include a cohort of NSCLC 
patient samples may identify hot-spot mutations that were previ-
ously undetected by traditional sequencing methods. Moreover, 
these results imply that current methods for ATM detection may 
be insufficient; however supplementary deep-sequencing of these 
samples could be used to determine the nature of ATM deficiency, 
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P3.03-002 HETEROGENITY OF ADENO CARCINOMA OF 
LUNG - CHANGE IN IMMUNOHISTOCHEMISTRY AND 
HISTOPATHOLOGY CHACTER IN PATIENTS TREATED 
WITH CHEMOTHERAPY OR EGFR-TKIS
Gouri Shankar Bhattacharyya1, Hemant Malhotra2, Purvish M. 
Parikh3, Kanaka Govindbabu4, Tanweer Shahid5, Vikash Agarwal6, 
Saumen Basu7, Raja Dhar8, Sushmita Roychoudhury8, Raman 
Deshpande9
1Hod, Medical Oncology, Fortis Hospital, Anandapur/India, 2Medical 
Oncology, Sms Medical College & Hospital/India, 3Icon-Aro,/India, 4Kid-
wai Memorial/India, 5Tata Memorial Center/India, 6Oncology, Apollo 
Gleneagles Hospitals/India, 7Radiation Oncology, Amri, Dhakuria/
India, 8Pulmonology, Fortis Hospital/India, 9Oncology, Fortis Hospital/
India
Background: Adenocarcinoma of the lung is a heterogenous 
group of disease. Even within the same patient, the tumor may 
show, various patterns of histopathology. In fact published data 
suggest that only 1/3rd of lung cancer are homogenous. Although 
known this factor is not taken into account in treatment planning 
and management. It is also known that treatment induces hetero-
genity and change in character of the tumor.
Methods: 46 patients of Stage IV Adenocarcinoma of Lung were 
studied. All patients were confirmed as Adenocarcinoma by doing 
IHC TTF p63. All slides were viewed by two pathologists and all 
patients had EGFR mutation done.IHC marker for neuro-endocrine 
differentiation was done i.e. Chromogranin-A and Synaptophysin. 
Patients were treated with chemotherapy or EGFR-TKI. Patients 
were re-biopsied on progression. The same set of IHC studies was 
done.
Results: 
IHC marker 
for adenocar-
cinoma
IHC marker for 
squamous cell
Neuro-endocri-
ne marker
n=46
Pre-chemo-
therapy/TKI
41 (89%) 15 (32%) 17 (37%)
Post-che-
motherapy/
TKI
25 (54%) 25 (54%) 29 (63%)
n=18
Pre TKI 16 (89%) 5 (28%) 4 (22%)
Post TKI 8 (44%) 9 (50%) 14 (78%)
n=28
Pre-chemo-
therapy
25 (89%) 10 (36%) 13 (46%)
Post-che-
motherapy
17 (61%) 16 (57%) 15 (54%)
 
Median duration of chemotherapy - 10 months Median duration of 
TKI - 16 months Change in character on IHC - seen in approximate-
ly 30% patients Infact change in post TKI occurring in upto 50% 
of patients with gain in Small Cell characters. Of the 50% patients 
who gained i.e. 10 patients - 7 of them also showed microscopic 
features of Small Cell Carcinoma of Lungs.
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P3.03-001 THE OVERXPRESSION OF TS PROTEIN  
INDUCED BY NPE6-PDT
Sachio Maehara, Keishi Ohtani, Hideyuki Furumoti, Yosihisa 
Shimada, Kouichi Yoshida, Naohiro Kajiwara, Tatsuo Ohira, Nori-
hiko Ikeda
Tokyo Medical University Hospital/Japan
Background:  
Malignant pleural mesothelioma(MPM) is a locally aggressive 
disease characterized by a poor prognosis and increasing. MPM 
tumors are usually related to asbestos exposure, and the incidence 
is anticipated to peak between 2020 and 2030 because of the lag 
time between asbestos expousere and the development of the 
malignancy. MPM is difficult to detect at an early stage, and sur-
gical and radiotherapeutic approaches are ineffective when used 
independently, because MPM spreads diffusely in the surrounding 
chest wall. No universally accepted treatment approach currently 
exists. 
Methods: We examined whether combination treatment consis-
ting of pemetrexed chemotherapy and photodynamic therapy 
(PDT) using the photosensitizer, NPe6, enhanced the antitumor 
effect in vitro and in vivo models. We also investigated preclinical 
treatment schedules.Four human malignant mesothelioma cell line, 
(MSTO-211H, H2052, H2452and H28) were assayed using the WST 
assy after treatment with pemetrexed and NPe6-PDT. The treat-
ment schedule for the combination treatment was examined using 
nude mice.
Results: In nude mice injected with MSTO-211H cells and then tre-
ared using a combination of pemetrexed and NPe6-PDT (10 mg/kg 
NPe6, 10 J/cm2 laser irradiation), the tumor volume decreased by 
50% but subsequently increased, reaching the pretreatment value 
after 14 days. Pemetrexed treatment followed by NPe6-PDT resul-
ted in an 80% reduction in the tumor size and inhibited re-growth. 
NPe6-PDT followed by pemetrexed treatment resulted in a 60% 
reduction in tumor size but did not inhibit re-growth. 
Conclusion: Pemetrexed reportedly inhibits multiple enzymes in 
the folate metabolic pathway, with TS being the main target. In 
non-small cell lung cancer cell line, high baseline TS expression 
levels confer resistance to pemetrexed, and the TS level is corre-
lated with pemetrexed efficacy in a variety of solid tumors. These 
results suggest that the overexpression of TS protein induced by 
NPe6-PDT may be associated with the failure of pemetrexed to 
exert a tumoricidal action. Therefore, we concluded that NPe6-
PDT followed by pemetrexed did not enhance tumor cell lethality 
in the in vivo model. Combination treatment, consisting of peme-
trexed followed by NPe6-PDT, should be further investigated as a 
new treatment modality for malignant pleural mesothelioma. In the 
future, this combination treatment may contribute to a reduction in 
local recurrence and a prolonged survival period in patients with 
malignant pleural mesothelioma.
Keywords: PDT, malignamt pleural mesothelioma, TS, NPe-6
S1057Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
than those with tight connection (58.3% vs 21.7%, p=0.028). The 
median survival times are not reached in both groups.
Conclusion: Macroscopically loose connection specimens can 
afford to provide adequate amount of samples for diagnosis with 
sensitivity of 77.3%, and this appearance was negatively correlated 
with amount of fiber. Furthermore, the patients with loose con-
nection tissue were associated with distal metastasis. The loose 
connection specimens may represent the status of EMT acquisition 
which is induced tumor initiation, growth, and metastasis. These 
findings suggest that the macroscopic appearance of tissue speci-
mens obtained from CT guided biopsy can be an effective evalua-
tion for prediction of metastasis in patients with NSCLC.
Keywords: epithelial-mesenchymal transition (EMT), Azan stain, 
CT-guided lung needle biopsy, NSCLC
Conclusion: The study suggests that patients with advanced lung 
cancer have benefit from chemotherapy and TKI. On treatment 
and on progression there is a change in IHC and histopathology 
character in the patients. It occurs in close to 40% in such patients. 
These changes also call for changes in treatment. Hence re-biopy 
in such patients is essential.
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P3.03-003 THE RELATIONSHIP BETWEEN FRESH MAC-
ROSCOPIC APPEARANCE OF TISSUE SPECIMEN BY CT 
GUIDED BIOPSY AND ITS CLINICOPATHOLOGICAL FEA-
TURE IN 58 PATIENTS WITH NSCLC.
Toshiyuki Nakai1, Tatsuo Kimura1, Shigeki Mitsuoka1, Norio 
Yamamoto1, Naoki Yoshimoto1, Yoshihiro Tochino1, Gakuya Ta-
magaki1, Shinzoh Kudoh1, Toshiyuki Matusoka2, Kazuto Hirata1
1Respiratory Medicine, Osaka City University/Japan, 2Radiology, Osaka 
City University/Japan
Background: The CT-guided lung needle biopsy is a well-establis-
hed and safety technique for diagnosis. A biopsy specimen often 
had loose connection and broke to tiny pieces before formalin 
fixation. Tumor invasion often involves the epithelial-mesenchymal 
transition (EMT) during which cells lose the lateral attachments to 
their neighbors and become more motile. The hypothesis is the 
fresh macroscopic appearance of specimens may relate patho-
logical features and predict clinical features in patients with lung 
cancer.
Methods: The correlations between fresh macroscopic appea-
rance of specimens and pathological findings or clinical outcomes 
were examined in patients who underwent CT-guided lung needle 
biopsy in our institution between May 2009 and May 2013. The 
intensity of fiber stained Azan staining (0, 1+, 2+, and 3+) and the 
percentage of positive cells (<1%, <25%, <50%, <75, and >75%) 
were assessed. The score of each case was multiplied to give a 
final score and the fibrosis was finally classified as low (<200) or 
high (>200). Comparisons of variables were performed by using 
Fisher exact tests.
Results: A total of 93 (86.1%) of 108 patients had adequate sam-
ples for diagnosis. The mean nodule diameter was 26 mm (range 
4-75mm). CT findings revealed only three of 93 lesions showed 
ground-glass opacity, and all of them were in tight connection 
group. Macroscopically, 21.3% (n=23) specimens had loose con-
nection, and 78.7% (n=85) specimens had tight connection. In 
loose connections, 73.9% (n=17) diagnosed as malignant and 
26.1% (n=6) as benign, with sensitivity of 77.3%, specificity of 
100%, and accuracy of 78.3%. In tight connections, 75.3% (n=64) 
as malignant and 24.7% (n=21) as benign, with sensitivity of 86.5%, 
specificity of 100%, and accuracy of 88.2%. There were 58 NSCLC 
samples, including 30 well or moderate (w/d or m/d), and 8 poorly 
differentiated (p/d) adenocarcinomas (Ad), 7 w/d or m/d, and 6 p/d 
squamous cell carcinomas (Sq), and 7 undifferentiated carcinoma. 
In 58 samples, 20.7% (n=12) specimens had loose connection and 
79.3% (n=46) specimens had tight connection. In Azan staining, 
the tight connection group had 32 samples of high and 14 of low 
scores with the mean score of 213.6, and the loose connection 
group had 4 of high and 8 of low scores with the mean score of 
118.6. The tight connection group had significantly higher scores 
than the loose connection group (p=0.042). The patients with loo-
se connection had significantly higher rate of distant metastasis 
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Conclusion: The autologous tumor lysate-transduced DC vaccina-
tion is effective to induce tumor specific cellular immune response 
in some of such patients. Establishment of CTL clones recognizab-
le autologous tumor cells can lead to identification of specific Ag 
coding genes which can be used as immunological targets.  
Keywords: resectable NSCLC, Autologous tumor lysate, DC vacci-
nation, adjuvant chemoimmunotherapy
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P3.04-002 A PHASE II TRIAL TO ASSESS THE SAFETY 
AND IMMUNOLOGICAL ACTIVITY OF TROVAX PLUS PE-
METREXED/CISPLATIN IN PATIENTS WITH MALIGNANT 
PLEURAL MESOTHELIOMA - SKOPOS TRIAL
Jason Lester1, Zsuzsanna Tabi2, Hayley Timmins3, Angela Cas-
bard3, Gareth Griffiths3
1Velindre NHS Trust/United Kingdom, 2Institute Of Cancer And Gene-
tics, Cardiff University/United Kingdom, 3Wales Cancer Trials Unit/
United Kingdom
Background: Malignant pleural mesothelioma (MPM) is an incu-
rable and fatal malignancy of the pleural membranes. MPM has a 
poor prognosis and patients have a median survival of 9-13 months 
in clinical studies, with above 1,500 cases in the UK per year. No 
surgical approach has been shown to prolong survival and pemet-
rexed-cisplatin is now seen as the chemotherapy standard of care 
in the UK. However it is clear that new therapeutic strategies are 
urgently needed for MPM. Immunotherapy is potential new treat-
ment approach to be considered in MPM, as the disease has been 
shown to respond to various immunotherapeutic strategies tested 
in animal models and early phase clinical trials. TroVax® consists 
of a highly attenuated vaccinia virus containing the human TAA 
5T4 glycoprotein gene under regulatory control of a modified VV 
promoter, mH5. Velindre NHS Trust and the Wales Cancer Trials 
Unit (WCTU) have developed the SKOPOS trial to evaluate whether 
TroVax® is active in the treatment of MPM. SKOPOS is funded by 
the June Hancock Mesothelioma Research Fund, and the Velindre 
Cancer Centre Stepping Stones Appeal. Oxford BioMedica (UK) 
Ltd. is providing TroVax® vaccine free of charge, and also labeling 
and distribution costs. The trial is sponsored by Velindre NHS 
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P3.04-001 COMBINED ADJUVANT CHEMOIMMUNO-
THERAPY WITH CBDCA+GEM AND AUTOLOGOUS TU-
MOR LYSATE-TRANSDUCED DENDRITIC CELL VACCINA-
TIONS IN PATIENTS WITH OPERABLE NSCLC
Kosei Yasumoto1, Tetsuya So1, Naohiro Nose2, Takashi Yoshimat-
su3, Takeaki Miyata3, Atsushi Sekimura4, Keiko Naitoh5, Takashi 
Kamigaki6, Mai Tomiyama7, Ryuji Maekawa7
1General Thoracic Surgery, Shinkomonji Hospital/Japan, 2Shinyukuh-
ashi Hospital/Japan, 3Fukuokawajiro Hospital/Japan, 4Shintakeo Hos-
pital/Japan, 5Seta Clinic Fukuoka/Japan, 6Seta Clinic Shinyokohama/
Japan, 7Medinet Medical Institute, Medinet Co.,Ltd/Japan
Background: Surgical adjuvant chemotherapy with platinum 
doublet is effective but not enough to suppress recurrence of 
NSCLC. We have applied combination chemoimmunotherapy with 
CBDCA+GEM and autologous tumor lysate transduced dendritic 
cell vaccination in patients with operable NSCLC in order to clarify 
that such a treatment can induce tumor specific immune response.
Methods: Eight patients with NSCLC whose pathological stages 
ranging from IB~IV were included in this study. The main purpose 
of the study is to obtain the principle of concept in which such 
vaccination can induce cellular immune response against autolo-
gous tumor cells detected by ELISPOT assay and establishment of 
CTL clones to recognize the tumor cell. Autologous tumor lysate 
was prepared from the surgical specimen aseptically by 5 times 
of freeze-thaw and sonication . DC cells were prepared from peri-
pheral blood mononuclear cells obtained by apheresis, and in vitro 
culture with IL-4 and GM-CSF. Matured DC was induced by culture 
with TNF-α. Autologous tumor lysate-transduced DC was prepared 
by electroporation using MaxCyte cell loading system(MaxCyteR). 
More than 7x106 of the DC were injected intradermally at groin bi-
weekly at 1, 3, 5, 7, 9 and 11week. Combination chemotherapy with 
CBDCA+GEM was administered at 0, 2, 4, 6, 8 and 10 week.
Results: Delayed type hypersensitivity skin reaction to the DC 
was observed in 5 of 8 patients after completion of the vaccina-
tion(6 times). ELISPOT assay revealed specific IFN-γ production 
in response to autologous tumor lysate-transduced DC following 
completion of the vaccination in 3 of the 5 patients. In one patient 
among them, CTL clones could be induced successfully in vitro, 
and identification of the Ag recognized by the CTL is now under-
way. No serious adverse effect was observed. Six patients have 
recurrent disease at 6, 6, 8, 10, 12 and 18months after operation. 
One patient(N0.6) died of the disease at 13 months after the ope-
ration due to systemic metastasis. However, the other patients are 
alive with(5 patients) or without(2 patients) evidence of the recur-
rent disease(ranging from 10~22 months as of February, 2013). 
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Methods: Peripheral blood from 112 chemotherapy-naive patients 
with stage III/IV NSCLC and 27 healthy donors was analyzed with 
flow cytometry for the presence of monocytic and granulocytic 
subpopulations of MDSCs, CD4+ Tregs, as well as the frequencies 
of distinct immune cells such as CD4+ and CD8+ cells, dendritic 
cells (DC) and B cells. The frequencies of these cells in the patients 
were compared to the healthy donors. The patients’ clinical out-
come (PFS and OS) was compared according to the frequency of 
MDSCs and Tregs (high vs low expression as defined by their per-
centage above healthy donors).
Results: Two monocytic (CD14+CD15-CD11b+CD33+HLA-DR-Lin- 
and D14+CD15+CD11b+CD33+HLA-DR-Lin-), and a granulocytic 
(CD14-CD15+CD11b+CD33+HLA-DR-Lin) subpopulations as well as 
CD4+ Tregs (CD3+CD4+CD25+highCD152+CD127-Foxp3+) were increa-
sed in patients compared to healthy donors (p<0.001 and p<0.007, 
respectively). Levels of MDSCs and CD4+ Tregs did not associated 
with tumor histology or stage of the disease. The levels of both 
subpopulations of monocytic but not of granulocytic MDSCs were 
reversely correlated with the levels of dendritic cells (DC) (r2=-
0.3, p≤0.04) whereas the granulocytic subpopulation of MDSCs 
was reversely correlated with the levels of CD4+ T cells (r2=-0.3, 
p=0.006). Increased baseline levels of both monocytic MDSCs’ 
subpopulations was associated with early relapse despite front-line 
platinum-based chemotherapy (p=0.05). The detection of baseline 
CD14+CD15+CD11b+CD33+HLA-DR-Lin- MDSCs within the normal 
levels was associated with longer OS compared to those with high 
levels (p=0.0035). Finally, patients with normal CD4+ Tregs frequen-
cies had a higher OS than those with high frequencies (p=0.05).
Conclusion: The data show that increased levels of monocytic MD-
SCs and CD4+ Tregs in the peripheral blood of NSCLC patients are 
reversely correlated to the other normal immune cells. These cells 
could represent potential predictive/prognostic biomarkers since 
their increased levels were negatively correlated to the treatment 
outcome.
Keyword: immunosuppression, MDSCs, CD4+ Tregs, clinical out-
come
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P3.04-004 INTERLEUKIN-15: A POTENTIAL FACTOR IN 
ESTABLISHMENT AND PROGRESSION OF LUNG CAN-
CER
Jason C. Steel, Charmaine A. Ramlogan-Steel, Brittany A. Black, 
Faisal Adhami, John C. Morris
Hematology-Oncology, University Of Cincinnati/United States Of America
Background: Interleukin-15 (IL-15) is a potent pro-inflammatory cy-
tokine, that plays a major role in stimulating immune effector cells 
following microbial and viral infection. IL-15 exhibits broad activity 
and induces the differentiation and proliferation of T, B and natural 
killer (NK) cells. IL-15 is primarily expressed by antigen presenting 
cells; however, in areas where there are high microbial loads, such 
as the lungs and colon, epithelial cells may also express IL-15 and its 
receptor (IL-15Rα). The expression of IL-15 and IL-15Rα by the lung 
epithelium facilitates immune responses by inducing local prolifera-
tion of NK and CD8+ T-cells in response to infection. Here we deter-
mine the status of IL-15 and IL-15Rα on lung cancers and assess their 
ability to stimulate the proliferation of these immune cells.
Trust, and coordinated by the WCTU.
Methods: A UK single centre, single arm, phase II trial. Eligible 
patients include locally advanced or metastatic, histologically or 
cytologically proven MPM, WHO performance status 0-1, life ex-
pectancy > 6months, at least four weeks since any previous thera-
py (surgery, radiotherapy). Enrolled patients will be treated with: 
TroVax® - intramuscular injection, dose 1 x 109 TCID 50/ml in 1ml, 
given on Day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24. 
Folic Acid - 400µg oral daily from Day 2 of week 3 to Day 2 of week 
16 
B12 Vitamin – 1000µg intramuscular, Day 2 of weeks 3 and 12 
Dexamethasone –4mg BD, Days 2-6 of weeks 4, 7, 10, 13 
Pemetrexed - 500 mg/m2 over 10 min, given on day 3 of weeks 4, 
7, 10, 13 
Cisplatin - 75mg/m2 over 1h, given on day 3 of weeks 4, 7, 10, 13 
The co-primary endpoints of the trial are i) cellular response to 
5T4 and MVA antigens measured by intracellular cytokine staining 
(ICCS); and ii) antibody response to 5T4 and MVA antigens as 
measured by ELISA. Secondary outcome measures include safety, 
progression free survival, objective response rate and overall sur-
vival. The sample size was determined using Fleming’s single arm 
design. The outcome measure is the immune response to the 5T4 
antigen. A success in this trial is defined as an increased response 
(at least a doubling in the 5T4 antibody or T-cell response) from 
that measured at baseline at any of the six follow-up time points. 
If an increased response is seen in at least 64% of patients then 
we will research the vaccine further in this group of patients. Using 
Fleming’s single-stage design, p1=0.40 and p2=0.64, setting al-
pha=0.05 (1-sided) and 80% power, 26 participants are required.
Results: Not Applicable
Conclusion: Not applicable
Keywords: mesothelioma, clinical trial, trovax
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P3.04-003 HIGH LEVELS OF CIRCULATING IMMUNOSUP-
PRESSIVE CELLS PREDICT WORST CLINICAL OUTCOME 
IN NON-SMALL LUNG CANCER (NSCLC) PATIENTS
Eleni K. Vetsika1, Filippos Koinis2, Despoina Aggouraki1, Anna 
Koutoulaki1, Dimitris Mavroudis2, Vassilis Georgoulias2, Athana-
sios Kotsakis2
1Laboratory Of Tumor Cell Biology, University Of Crete, School Of Me-
dicine/Greece, 2Department Of Medical Oncology, University General 
Hospital Of Heraklion/Greece
Background: The immune cells can prevent and inhibit tumour de-
velopment but also may contribute to growth and progression of 
cancer. Myeloid-derived suppressor cells (MDSCs), a heterogene-
ous population of immature cells with immune suppressive proper-
ties, have been correlated with worse prognosis in several tumors. 
In addition, high levels of circulating CD4+ T regulatory (Tregs) cells 
exhibit suppressive functional activity against anti-tumour T-cell 
responses and correlated with worse recurrence-free survival in 
NSCLC patients. In the present study, we investigated the expres-
sion and levels of MDSCs’ subpopulations and CD4+Tregs, their 
correlation to distinct immune cells, as well as to the clinical out-
come of patients with advanced NSCLC.
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P3.05-001 METFORMIN SENSITIZES EGFR-TKI-RESIS-
TANT HUMAN LUNG CANCER CELLS IN VITRO AND IN 
VIVO THROUGH INHIBITION OF IL-6/STAT3 AXIS AND 
EMT REVERSAL
Li Li, Yong He
Department Of Respiratory Medicine, Daping Hospital Of Third Military 
Medical University/China
Background: Tyrosine kinase inhibitors (TKIs) that target the 
epidermal growth factor receptor (EGFR) has become standard 
therapy in patients with EGFR activating mutations. Unfortuna-
tely, acquired resistance eventually limits the clinical effects and 
application of EGFR-TKIs. Although main mechanisms of acquired 
resistance have been detected with varying frequencies, including 
T790M mutation, amplicfication of other kinases and epithelial to 
mesenchymal transition(EMT), potential therapies for these tumors 
have not been modeled in vivo. Researches have shown that sup-
pression of EMT and IL-6/STAT3 pathway may abrogate this acqui-
red mechanism of drug resistance of TKI.
Methods: By using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium (MTT), immunofluorescence, Western blot, cell tracking, 
invasion assay, ELISA assay and xenograft experiments, we ana-
lyzed the effect of metformin and TKIs on TKI resistance of tumor 
cells both in vitro and in vivo.
Results: Metformin, which is widely used as an antidiabetic agent, 
effectively increased sensitivy of TKI-resistant lung cancer cells to 
erlotinib or gefitinib. Metformin reversed EMT and decreased IL-6/
STAT3 activation in TKI-resistant cells, while IL-6 addition in those 
cells bypassed the antitumor effect of metformin. Furthermore, 
overexpression or addition of IL-6 in TKI sensitive cells induced TKI 
resistance, which can be overcomed by metformin. Lastly, metfor-
min-based combinatorial therapy effectively block tumor growth in 
xenografts involving TKI-resistant cancer cells, which is associated 
with EMT reversal and decreased IL-6/STAT3 activation.
Conclusion: Thus, the unexpected ability of metformin to reverse 
EMT and inactivate IL-6 axis further reveals that this biguanide, ge-
nerally considered non-toxic and remarkably inexpensive, might be 
used in combination with TKIs in NSCLC patients harboring EGFR 
mutations to overcome TKI resistance. Our findings therefore offer 
preclinical proof of principle that combination of TKI and metfor-
min may benefit patients with NSCLC.
Keywords: Non small cell lung cancer, tyrosine kinase inhibitors, 
drug resistance, Metformin
Methods: Western blotting, ELISA and qPCR were used to deter-
mine the expression of IL-15 and IL-15Rα in 6 human lung cancer 
cell lines and 1 normal human bronchial epithelial cell (HBEC) line. 
Further, mRNA from 146 primary lung cancers of all stages and 
tissues from 45 normal lungs were examined by multiplex qPCR 
for the expression of IL-15 and IL-15Rα. NK and T-cell proliferation 
assays were performed to determine the effects of IL-15 expressi-
on by the cell lines on these immune cells.
Results: IL-15 expression by lung cancer cell lines was significantly 
reduced compared to the HBEC cell line. Similar results were seen 
when we examined the expression of IL-15 in primary tumors, with 
lung cancer expressing less IL-15 than normal lung (P<0.001). When 
we compared IL-15 expression between stages, we found that 
increased stage correlated with a decrease in IL-15 expression with 
normal lung> stage I> stage II> stage III> stage IV. In contrast, 
IL-15Rα expression levels in the tumor samples were found to be 
largely unchanged across stage, P=0.417. Decreases in IL-15 with 
increasing stage may represent one mechanism in which lung can-
cers limit the immune response directed at the tumor and may aid 
in metastatic progression. In order to assess the immune effects of 
a reduction in IL-15 expression, we examined the ability of the lung 
cancer cell lines and HBEC to induce the proliferation of NK and 
T-cells following co-incubation. We found that the lung cancer cell 
lines significantly inhibited the proliferation of either NK or T-cells 
compared to HBEC.
Conclusion: Pro-inflammatory cytokines such as IL-15 are impor-
tant for the induction of lung immunity. Decreases in IL-15 expres-
sion may reduce immune responses thereby aiding in the escape 
of lung cancer from immune detection and the dissemination of 
tumor. The differential expression of IL-15 across lung cancer sta-
ges and retention of IL-15Rα expression may make lung cancer a 
target for IL-15-based treatments and opens the potential for IL-15 
to be used as a predictive biomarker in early stage patients.
Keywords: Interleukin 15 receptor alpha, Interleukin 15, lung can-
cer immunology
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P3.05-003 ROLE OF ATM IN RESPONSE OF NON-SMALL 
CELL LUNG CANCER CELL LINES TO THERAPEUTIC 
AGENTS
Anifat A. Elegbede1, D G. Bebb1, Lars F. Petersen1, Eiji Kubota2, Sus-
an P. Lees-Miller3
1Oncology, Tom Baker Cancer Centre, University Of Calgary, Alberta 
Canada/Canada, 2Nagoya City University Graduate School Of Medicine 
Sciences/Japan, 3University Of Calgary/Canada
Background: Lung cancer is the leading cause of cancer death 
worldwide. Non-Small Cell Lung Cancer (NSCLC) which is the 
predominant type is mostly advanced stage disease at diagnosis. 
Cytotoxic agents including chemotherapeutic drugs and radiation 
therapy, the mainstay of advanced NSCLC treatment are neither 
specific nor curative and are significant causes of morbidity in 
patients. This poor NSCLC outlook therefore requires a novel 
therapy as well as predictive markers of treatment response for an 
improvement. We propose Ataxia Telangiectasia Mutated (ATM), 
a critical player in the DNA double strand break repair pathway, as 
a potential predictor of treatment response in NSCLC. Radiation 
sensitivity is one of the hallmarks of ataxia telangiectasia (A-T), a 
condition due to ATM mutations. Our lab has previously demonst-
rated ATM deficiency in about 20% of resected NSCLC tumors and 
this is associated with poorer survival outcomes; however, no treat-
ment guidelines currently take this into consideration.
Methods: We assessed in vitro the altered sensitivity of ATM de-
ficient NSCLC cell lines to both targeted agents (e.g. Poly (ADP) 
ribose polymerase (PARP) inhibitors) and non-targeted agents (e.g. 
DNA damaging agents including ionizing radiation (IR) and the 
commonly used cytotoxic chemotherapies in NSCLC) using the 
clonogenic survival assay. A panel of NSCLC cell lines (NCI-H23, 
NCI-H226, NCI-H460, NC1-H522, NCI-H1793, NCI-H1395 and HCC 
4006) were characterised for pre-existing ATM deficiency in terms 
of ATM protein expression levels and functionality using western 
blot. By examining the cells’ responses to IR, confirmation of ATM 
deficiency was achieved with clonogenic assay to assess cellular 
viability and western blot for the expression of IR inducible ATM-
dependent phosphorylation sites on target proteins including 
phosphorylation of serine 1981 of ATM (p-S1981 ATM), serine 15 of 
p53 (p-S15 p53) and serine 824 of KAP1 (KRAB-associated protein 
1).
Results: We identified NCI-H23 cells with pre-existing low ATM 
protein levels (11% relative to BT cells) and undetectable ATM 
protein in NCI-H1395 cells compare to our positive (BT cells) and 
negative (L3 cells) control lymphoblastoid cells derived from nor-
mal and A-T patients respectively. In addition, H23 and H1395 cells 
display altered ATM signaling as evidenced by no detectable level 
of p-S1981 ATM expression post-irradiation. There is increased 
sensitivity of H23 cells to DNA-damaging agents (such as IR, topo-
tecan and cisplatin) and PARP inhibition compare to ATM proficient 
NSCLC cell lines.
Conclusion: Our results seem to delineate the therapeutic sen-
sitivity of ATM deficient versus ATM proficient cell lines to both 
non-targeted agents (chemotherapy and radiation therapy) and to 
targeted agents (PARP inhibitors). ATM could serve as a potential 
marker in guiding the use of 1) targeted agents such as PARP inhi-
bitors, and 2) conventional chemo-radio therapeutic agents in the 
treatment of NSCLC. We are in the process of establishing ATM 
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P3.05-002 RESISTANCE TO BH3 MIMETIC S1 IN NON-
SMALL CELL LUNG CANCER CELLS THAT PHOSPHO-
RYLATE BIM THROUGH ERK1/2 AND LEAD TO ITS PRO-
TEASOMAL DEGRADATION
Yubo Liu, Zhichao Zhang
School Of Chemistry, Dalian University Of Technology/China
Background: Lung cancer is the leading cause of all cancer deaths 
worldwide. Non-small cell lung cancer (NSCLC) is the most com-
mon type, accounting for 75–80% of all lung cancers. Bcl-2 is a 
central regulator of cell survival that is overexpressed in NSCLC 
and contributes to both malignant transformation and therapeutic 
resistance. We previously identified a small-molecule BH3 mimetic 
named S1 that exhibits nanomolar affinity towards Mcl-1, Bcl-2 and 
Bcl-XL. The purpose of this work was to study the key factors that 
determine the sensitivity of NSCLC cells to S1 and the mechanism 
underlying the resistance of this drug.
Methods: Acquired resistant cells were derived from initially sen-
sitive NCI-H1975 cells. Western blot and co-immunoprecipitation 
were used to evaluate the contribution of Bcl-2 family members to 
the cellular response of several NSCLC cell lines to S1. Quantitative 
PCR and gene silencing were performed to investigate Bim down-
regulation. PD98059 and MG-132 was used to inhibit the degrada-
tion of Bim.
Results: S1 can disrupt Bcl-2/Bim, Mcl-1/Bim and Bcl-XL/Bim 
complexes regardless of the levels of the anti-apoptotic proteins 
NSCLC cell lines. A progressive decrease in the relative levels 
of Bim characterized the increased de novo and acquired resis-
tance of NSCLC cell lines. Furthermore, in resistant cells, acute 
treatment of S1 induced Bim phosphorylation on serine 69 and 
degradation via the proteasome pathway. ERK inhibitor PD98059 
abrogated Bim phosphorylation and degradation and induced 
caspase activation and apoptosis. We showed that BH3 mime-
tics including S1 and ABT-737 induced ER stress and then acti-
vated MEK/ERK pathway in NSCLC cells. The function of MEK/
ERK pathway in defining BH3 mimetics was illustrated: Bim was 
released from anti-apoptotic proteins by S1, ERK1/2 activation 
leaded to Bim sustained phosphorylation and then degraded 
by proteasome in naïve and acquired resistant NSCLC cells.
Conclusion: We describe here a new mechanism for the regulation 
of Bim expression by phosphorylation protects NSCLC cells from 
BH3 mimetics induced apoptosis. These results provide significant 
novel insights into the molecular mechanisms for ERK1/2 mediated 
the crosstalk between the Bim regulation and ER stress to define 
BH3 mimetics in NSCLC cells.
Keywords: ERK1/2, Bim phosphorylation, BH3 mimetics, NSCLC
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ceramide metabolism may overcome or substantially reduce ac-
quired cisplatin drug resistance. Targeting the functional interplay 
between Gb3 and MDR1 might aid in the development of new 
drug therapies against acquired drug resistance in MPM and lung 
cancer.
Keyword: Cisplatin, ceramide, glucosylceramide synthase, globot-
riaosylceramide (Gb3, lung cancer, multidrug r
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P3.05-005 DEREGULATION OF BCL-2 FAMILY PROTEIN 
EXPRESSION AND PRESERVED POST-TARGET APOPTO-
SIS RESISTANCE TO THE BH3-MIMETIC GX15-070 ON 
ACQUISITION OF CISPLATIN-RESISTANCE IN A MALIG-
NANT MESOTHELIOMA CELL LINE
Andreas Tyler1, Camilla Sandberg1, Amanda Blom1, Anders Jo-
hansson2, Veronica Rondahl3, Kjell Grankvist1
1Medical Biosciences/Sweden, 2Odontology/Sweden, 3Pathology/Sweden
Background: Platinum-based drugs, such as cisplatin, are the 
standard treatment for aggressive malignant pleural mesothelioma 
(MPM) and non-small-cell lung cancer (NSCLC), but inherent as well 
as acquired resistance are major clinical problems leading to thera-
py failure and low median survival after diagnosis. Cisplatin expo-
sure initiates the mitochondrial signaling pathway of apoptosis, by 
activation of BH3-only proteins i.e. pro-apoptotic members of the 
Bcl-2 family of proteins. Therapy failure may be the result of decre-
ased apoptosis due to caspase-9-deactivation or over-expression 
of the anti-apoptotic proteins Bcl-XL and Mcl-1. Affecting cisplatin 
resistance by targeting post- and off-target apoptosis signalling 
proteins with pro-apoptotic BH3-mimetics, would possible sensiti-
ze cancer cells to cisplatin treatment.
Methods: We investigated the expression of Bcl-2 family and other 
proteins involved in apoptosis signal transduction and the diffe-
rence between the response to equiapoptotic cisplatin concent-
rations as well as the response to the pro-apoptotic BH3-mimetics 
ABT-737 and GX15-070, alone or in combination. To separate 
mitochondrial-dependent from –independent signalling we com-
pared initiator-caspase-dependent parental P31 MPM cells with 
its acquired cisplatin-resistant (P31res) sub-line which has initiator-
caspase-independent caspase-3-activated apoptosis,
Results: On acquisition of cisplatin-resistance, the expression of 
the pro-apoptotic and anti-apoptotic Bcl-2-family proteins was eit-
her not changed or slightly decreased in P31res cell compared to 
parental P31 cells. A 6-h exposure to equiapoptotic concentrations 
of cisplatin, on the other hand, increased the expression of potent 
pro-apoptotic BH3-only proteins as well as the anti-apoptotic Bcl-x 
protein in P31 but not P31res cells whereas Bcl-x expression was 
almost annihilated in P31res cells. TUNEL results showed a synergic 
effect on apoptosis when cisplatin was combined with the BH3-
mimetic GX15-070 in P31res, but only an additive effect in P31. The 
BH3-mimetic ABT-737 did not augment cytotoxicity or apoptosis 
either per se or when combined with cisplatin and/or GX15-070. 
GX15-070 efficiently inhibited anti-apoptotic Bcl-2-family-, inhi-
bitors of apoptosis (IAP) - and heat shock protein (HSP) - family 
protein expression both with and without cisplatin in P31 cells, 
whereas preserved protein expression was noted in P31res cells 
after 6 h incubation with cisplatin. Sub-toxic concentrations of the 
knock-down cells from ATM proficient NSCLC cell lines. Results of 
the altered sensitivity of established ATM deficient NSCLC cells to 
our investigative agents will be discussed and presented.
Keyword: DNA damaging agents, PARP inhibitor, Lung cancer
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P3.05-004 TARGETING GLUCOSYLCERAMIDE SYNTHA-
SE INDUCTION OF CELL SURFACE GLOBOTRIAOSYL-
CERAMIDE (GB3) CO-EXPRESSED WITH MULTIDRUG 
RESISTANCE 1 (MDR1) PROTEIN AS NEW TREATMENT 
APPROACH IN ACQUIRED CISPLATIN-RESISTANCE OF 
MALIGNANT PLEURAL MESOTHELIOMA AND NON-
SMALL CELL LUNG CANCERCISPLATIN-RESISTANCE IN 
A MALIGNANT MESOTHELIOMA CELL LINE
Parviz Behnam Motlagh1, Andreas Tyler2, Anders Johansson3, Te-
rese Karlsson4, Thomas Brännström1, Kjell Grankvist1
1Medical Biosciences/Sweden, 2Clinical Chemistry/Sweden, 3Odontolo-
gy/Sweden, 4Oncology/Sweden
Background: Development of acquired resistance to cisplatin 
treatment is a major problem when treating patients with malig-
nant pleural mesothelioma (MPM) and non-small cell lung cancer 
(NSCLC). Chemotherapy leads to tumor cell stress activation of 
glucosylceramide synthase (GCS) to eliminate ceramide by glyco-
sylation and formation of glycosphingolipids (GSLs) such as globot-
riaosylceramide (Gb3), the functional receptor of verotoxin-1. Cera-
mide elimination leads to stimulated cell proliferation and blocked 
apoptosis, thus stimulating tumor progression. GSLs also transac-
tivate multidrug resistance 1/P-Glycoprotein (MDR1) and possibly 
multidrug resistance protein 1 (MRP1) expression which confers 
tumour cell resistance by further preventing ceramide accumula-
tion and stimulating drug efflux. We investigated if Gb3, MDR1 
and MRP1 are co-expressed and co-localized in MPM and NSCLC 
cells with acquired cisplatin resistance and if GSC activity inhibitors 
DL-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol 
(PPMP) and cyclosporin A would reduce their expression and relie-
ve cisplatin-resistance.
Methods: Cell surface as well as intracellular expression of Gb3, 
MDR1 and MRP1 was analysed by flow cytometry and confocal mi-
croscopy using specific protein antibodies on P31 MPM and H1299 
NSCLC cell lines and corresponding sub-lines (P31res, H1299res) 
with acquired cisplatin resistance.
Results: Gb3 and MDR1, but not MRP1 were co-expressed and 
partly co-localized on the cell surface, and Gb3 and MDR1 as well 
as MRP1 intracellular co-expressed but not co-localized in P31res 
and H1299res cells. P31 cells expressed minute cell surface Gb3 
and the non-resistant cells had less cell surface and but similar 
intracellular expression of Gb3 and MDR1. Glycosphingolipid 
synthesis inhibitors PPMP and cyclosporin A radically decreased 
intracellular Gb3, MDR1 and MRP1-expression in all cell sub-lines 
whereas cell surface Gb and MDR1 expression was decreased only 
by PPMP but not by cyclosporin A.
Conclusion: These results indicate that cell surface Gb3 that is 
co-expressed and co-localised with MDR1 is a likely tumour bio-
marker for acquired cisplatin resistance in MPM and NSCLC and 
that therapy with GCS activity inhibitors or Gb3 blockers affecting 
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P3.05-007 EPIDERMAL GROWTH FACTOR RECEPTOR 
TARGETED GOLD NANOPARTICLES FOR THE RADIATI-
ON TREATMENT OF NON-SMALL CELL LUNG CANCER
Rene Razzak1, Wilson H. Roa2, Raimar Löbenberg3, Alexander Mce-
wan2, Eric L.R. Bédard1
1Division Of Thoracic Surgery, Department Of Surgery, University Of 
Alberta/Canada, 2Department Of Oncology, Cross Cancer Institute/Ca-
nada, 3Faculty Of Pharmacy And Pharmaceutical Sciences, University 
Of Alberta/Canada
Background: Lung cancer accounts for the greatest cancer related 
mortality world wide, with two thirds of all patients receiving radi-
ation therapy as part of their cancer care. Despite advancements 
made, the overall 5-year survival in Canada remains less than 20%. 
Developments in nanotechnology have proven to possess exciting 
potential in the treatment of various malignancies. Nanoparticles 
with high atomic number, such as Gold (GNPs), facilitate surprising 
local enhancement secondary to gold’s strong photoelectric ab-
sorption coefficient. GNPs are capable of forming covalent bonds, 
enabling the creation of “targeted” radio-sensitizing agents. The 
goal of this study is to evaluate the in vitro and in vivo radiation 
potential and biodistribution profile of GNPs targeted against the 
epidermal growth factor receptor (EGFR) using the monoclonal 
antibody Cetuximab (GNP-cetuxumab) stabilized with thiolated 
polyethylene glycol (SH-PEG) for the treatment of non-small cell 
lung cancer (NSCLC). To date a comprehensive evaluation of such 
a platform has not been undertaken.
Methods: We examined the radiation enhancement of 50nm GNPs 
in vitro using SKMES-1 (High wild type EGFR expression) and h460 
(low wild type EGFR expression) NSCLC cell lines, both possessing 
Kras mutations. MTS, clonogenic assays and flow cytometry were 
used to assess radiation effect using 4 groups (no GNPs, GNPs, 
GNPs bound to SH-PEG stabilizer, GNP-Cetuximab). In vivo bio-
distribution was conducted on balb-c nude mice bearing two flank 
subcutaneous SKMES-1 xenografts. One tumor received a single 
radiation exposure (200 kVp, 8 Gray) prior to tail vein injection of 
GNP-cetuximab or GNP-PEG in order to assess the effect radiation 
induced inflammation may have on GNP tumor uptake. Tumors and 
organs were harvested at various time points with GNP concentra-
tion determined using inductively coupled mass spectroscopy. In 
vivo radiation experiments were conducted on 3 flank tumor bea-
ring groups (each group = 7): 1) radiation only, no nanoparticles 2) 
GNP-PEG, GNP stabilized by bound PEG and 3) GNP-Cetuximab. 
Four weekly radiation fractions (4Gy, 200 kVp) with weekly tail vein 
injection timing based on the biodistribution results were adminis-
tered. Tumor growth kinetics was then evaluated.
Results: Significant in vitro radiation effect was observed in the 
GNP groups compared to the radiation only group. GNP-cetu-
ximab and GNP-PEG demonstrated enhanced radiation effect 
as compared to unfunctionalized GNPs. In the biodistribution 
experiment, the peak intra-tumor concentration without pre-
administered radiation in the GNP-PEG group was twice that of 
the GNP-Cetuximab group 5 days after tail vein injection. Tumor 
pre-irradiation resulted in a doubling of intra-tumor nanoparticle 
uptake in both groups. At the end of radiation therapy experiment, 
the GNP-PEG group demonstrated the greatest reduction in tu-
mor growth as compared to the radiation alone group (52mm3 vs 
180mm3 respectively, p<0.01).
IAP-inhibitor AT-406 and the HSP90-inhibitor 17-AAG with GX15-
070 markedly potentiated cisplatin cytotoxicity in P31res cells.
Conclusion: P31 malignant mesothelioma cell acquisition of cispla-
tin-resistance led to deregulated Bcl-2 family protein expression 
and induced post-target apoptosis resistance to the BH3-mimetic 
GX15-070. GX15-070 had a synergistic effect on cisplatin-induced 
apoptosis in P31res cells. The synergy was due to efficient GX15-
070 inhibition of expression of the anti-apoptotic Bcl-x protein 
despite apoptosis resistance by preserved IAP and HSP protein 
expression. Cisplatin therapy combined with GX15-070 in acquired 
cisplatin resistance was even more efficacious when combined also 
with inhibitors of IAP- and HSP- apoptosis signalling pathways.
Keyword: Key words: apoptosis, Bcl-2 proteins, cisplatin, acquired 
cisplatin resistance,
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P3.05-006 INHIBITION OF TUMOR CELL GROWTH, MI-
GRATION BY SIM-89, A NOVEL INHIBITOR OF C-MET 
TYROSINE KINASE
Jun Pei1, Tianqing Chu1, Minhua Shao1, Aiqing Gu1, Rong Li1, Jialin 
Qian1, Weifeng Mao2, Jiajun Teng1, Huifang Sha3, Yin Li1, Baohui Han1
1Department Of Pulmonary, Shanghai Chest Hospital , Shanghai Jiao Tong 
University/China, 2Department Of Biology, East China Normal University, 
Shanghai, People’s Republic Of China/China, 3Department Of Basic Research, 
Shanghai Chest Hospital , Shanghai Jiao Tong University/China
Background: It has been found that HGF-dependent c-Met (HGFR) 
autocrine is activated in a wide variety of human primary and second 
malignancies. On the other hand, the metastatic growth potential of 
tumors can be activated through paracrine mechanism. c-Met dysregu-
lation leads to lung cancer development through overexpression and 
mutation.
Methods: 70 kinase enzymogram screening was proceeded by Z-lyte 
technique. MOA analysis was completed on the inhibited kinases. Cell 
vitality was determined at 24h, 48h, 72h after treatment through CCK8 
method. Transwell system was used to observe the inhibition of cell 
migration. Difference of special gene expression was evaluated by 
Real-time PCR. Westernblot assay was used to compare the expression 
difference of c-MET and p-MET. HGF level in culture medium is deter-
mined by ELISA.
Results: SIM-89 can inhibit 3 kinases including c-Met (IC50=297nM, 
AMPK, TRKA (IC50=150.2nM). SIM-89 has an ATP competive inhibition 
on c-Met. By Real-time PCR, SIM-89 has been found to inhibit STAT1, 
JAK1, c-Met gene expression in H460 cell. P-Met expression of A549, 
H441, H1299 and B16F10 cell can be inhibited by SIM-89. HGF level of 
supernatant in culture is significantly lower than control group. Vitality 
of NSCLC cell lines is inhibited dependent on time and concentration 
by SIM-89. Induced by HGF, migration of H460, H1299 cell is inhibited.
Conclusion: SIM-89 has significant inhibitive effect on c-Met, TRKA 
kinases. It also can inhibit proliferation, migration and HGF autocrine 
of NSCLC cell significantly. Further study in vivo should be carried to 
explore the pharmacokinetics of SIM-89.
Keywords: c-Met, small molecular inhibitor, Lung cancer, cell  
proliferation
S1064 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
cancer treatment by MPS peptide through the sequestration of 
PIP2 pool and the suppression of MARCKS phosphorylation and 
PI3K/AKT pathway.
Keywords: MARCKS phosphorylation, PI3K/AKT signaling, Lung 
cancer, peptide drug
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P3.05-009 METABOLIC REPROGRAMMING OVERCOMES 
RESISTANCE TO ABT-737 -INDUCED APOPTOSIS IN PRE-
CLINICAL MODELS OF MALIGNANT PLEURAL MESO-
THELIOMA
Xiao Ming Sun1, Tatyana Chernova1, Stefano Grosso1, Fiona Mur-
phy1, Jonathan Bennett2, Apostolos Nakas2, Martin Bushell1, Kel-
vin Cain1, Anne E. Willis1, Marion Macfarlane1
1Toxicology Unit, Mrc/United Kingdom, 2Glenfield Hospital, University 
Hospitals Of Leicester, NHS Trust/United Kingdom
Background: Malignant mesothelioma (MM) is an aggressive, 
fatal, tumour of the pleura or peritoneum and is strongly related 
to asbestos exposure. Clinically, there is no curative therapy for 
MM and the profound chemoresistance of MM is well documen-
ted, reportedly being due to the ability of MM cells to escape cell 
death. Unravelling the molecular mechanisms employed by MM 
cells to evade cell death will therefore provide new insights into 
key cell death pathways that may be targeted for successful thera-
py. Currently, the Bcl-2 repertoire is an undervalued and attractive 
pharmacological target for mesothelioma therapy. The aims of this 
study were to investigate the sensitivity of MM to the BH3-mime-
tic, ABT-737, and identify mechanisms of overcoming resistance to 
support personalized therapy.
Methods: Sensitivity to the highly selective BCL-2/BCL-XL anta-
gonist, ABT-737, was investigated using FACs-based analysis and 
immunoblotting techniques in a panel of MM cell lines and tumour 
cells isolated from freshly resected MM tumours. In addition, 
patient-derived tumour explants were similarly analysed, providing 
a clinically relevant 3D mesothelioma model. Furthermore, to ex-
plore the possibility that tumour cell metabolism may modulate 
the sensitivity of MM cells to ABT-737, we investigated the effect of 
inhibiting glycolysis with 2-deoxyglucose (2-DG) on ABT-737 -indu-
ced apoptosis in relevant pre-clinical models of MM.
Results: The majority of MM cell lines and freshly-derived cultured 
tumour cells were resistant to ABT-737, suggesting a deregulation 
of cell death signalling at the level of mitochondria. Aerobic glyco-
lysis (Warburg effect) is a process by which tumour cells gain not 
only growth advantage (providing much needed “building blocks”) 
but also an increased survival potential. Importantly we report 
that, in MM, glycolysis can be inhibited by 2-deoxyglucose(2-DG), 
a competitive inhibitor of hexokinase. Although exposure to 2-DG 
did not induce cell death, 2-DG induced a time- and concentrati-
on-dependent potentiation of ABT-737 -induced apoptosis in eit-
her established mesothelioma cell lines or newly-derived tumour 
cells from patients. BCL-2-family member profiling revealed that, 
while the predominant pro-survival members expressed in MM 
were MCL-1 and BCL-XL, 2-DG selectively decreased MCL-1 prote-
in levels, a leading cause of resistance to ABT-737 in other tumour 
models.
Conclusion: Despite the superiority of GNPs bound to cetuximab 
in vitro as a radiation enhancer, the favorable tumor biodistribution 
of the GNP-PEG accounted for the most dramatically reduced tu-
mor growth kinetics observed. The future utility of targeted nano-
particles requires further investigation in light of these findings. In 
this study we demonstrate the exciting in vitro and in vivo potential 
of GNPs in the radiation treatment of NSCLC.
Keywords: radiation, Gold nanoparticles, non-small cell lung  
cancer
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P3.05-008 NOVEL ANTI-CANCER PROPERTIES OF A 
MARCKS ED DOMAIN PEPTIDE OCCUR THROUGH 
UNIQUE ALTERATIONS OF PI3K/AKT SIGNALING
Ching-Hsien Chen, Phillip Thai, Reen Wu
Department Of Internal Medicine And Center For Comparative Respi-
ratory Biology And Medicine, University Of California Davis/United 
States Of America
Background: Constitutive activation of the phosphoinositide 
3-kinase (PI3K)/Akt pathway has been found in non–small cell lung 
cancer (NSCLC) and promotes cancer progression. Myristoylated 
alanine-rich C kinase substrates (MARCKS) is a substrate of protein 
kinase C (PKC), and acts as a key regulatory protein controlling 
cell motility and signaling. We previously reported that elevated 
MARCKS phosphorylation (pSer159/163) potentiates lung cancer 
cell malignancy by upregulation of AKT/Slug axis.
Methods: Tissue array and immunohistochemistry were performed 
to analyze MARCKS phosphorylation in 110 pairs of NSCLC tumor 
cells and corresponding normal tissues. The enforced and silenced 
expressions of MARCKS were performed in lung cancer cells to 
verify the role of MARCKS expression and its phosphorylation. 
In vitro and in vivo anticancer activities of a MARCKS ED domain 
peptide (MPS) were confirmed by MTS, colony formation, flow cy-
tometry, invasion, migration assays and in vivo subcutaneous and 
orthotopic implantation. The molecules regulated by MPS peptide 
were determined by Western blotting, PIP3 pool assay and co-
immunoprecipitation.
Results: We demonstrated that elevated MARCKS phosphoryla-
tion is correlated with advanced-stage and lymph node metas-
tasis of lung cancer. siRNA knockdown of MARCKS expression 
confirmed the importance of MARCKS and its phosphorylation in 
modulating PIP3 pool and cancer cell survival. Furthermore, we 
have identified that a small peptide, MPS, which mimics the basic 
effector domain (ED) of MARCKS is very effective in suppressing 
phospho-MARCKS and PIP3 levels in lung cancer cells. MPS pep-
tide treatment is able to inhibit cancer cell viability, colony forma-
tion, migration and invasion in vitro, as well as tumorigenesis and 
metastasis in vivo. Interestingly, MPS peptide is very cytotoxic to 
cancer cells with highly activating PI3K/AKT signaling and mali-
gnant phenotypes, while MPS has no cytotoxic effect on normal 
human bronchial epithelial cells. In addition, a co-treatment of MPS 
peptide with epidermal growth factor receptor inhibitor erlotinib 
could reverse drug sensitivity of these tyrosine kinase inhibitor 
(TKI) resistant cells, H1650 and H1975, toward erlotinib.
Conclusion: These results suggest a therapeutic potential in lung 
S1065Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Conclusion: These results provide novel evidence on an important 
role of Met-dependent EMT in the adverse clinical behavior of 
SCLC and support clinical trials of Met inhibitors and chemothera-
py in this fatal disease.
Keywords: Met, Hepatocyte growth factor, small cell lung cancer, 
epithelial to mesenchymal transition
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P3.05-012 POTENTIAL BIOMARKERS OF GROWTH IN-
HIBITION OF AFATINIB (BIBW-2992) IN COMBINATION 
WITH DASATINIB (BMS-354825) IN GEFITINIB RESIS-
TANT NON SMALL CELL LUNG CANCER CELLS (NSCLC)
Alex Y. Chang1, Miao Wang2
1Medical Oncology, Johns Hopkins Singapore International Medical 
Centre/Singapore, 2Research, Johns Hopkins Singapore International 
Medical Centre/Singapore
Background: Gefitinib or Erlotinib (EGFR-TKI) is the first choice 
of treatment for advanced NSCLC patients harbouring activating 
EGFR mutations. In addition to primary resistance, acquired resis-
tance to EGFR-TKI eventually occurred in patients after an initial 
response. New agents have been developed to specifically inhibit 
the signaling pathways involved in mediating resistance. Because 
of heterogeneous resistant mechanisms, single agent usually had 
limited efficacy. Thus drug combination therapy may offer more 
benefits by synergistic interactions and avoidance of resistance 
emergence. We studied the combination of afatinib (an irreversible 
ErbB family inhibitor) and dasatinib (an inhibition of Src, BCR-ABL, 
PDGFR, Eph) in 8 different genetically characterized NSCLC cell 
lines to evaluate resistance mechanisms and molecular predicting 
biomarkers.
Methods: Growth inhibition was assessed by MTS assay. The inter-
action between two different drugs was evaluated by the method 
of Chou and Talalay. EGFR and k-Ras mutations were tested by 
direct DNA sequencing. EGFR, HER2, Src and downstream prote-
ins FAK, Akt, MAPK42/44, Stat3, Stat5 expressions were measured 
by western blot.
Results: The efficacy of dasatinib against NSCLC cells in vitro is 
significantly more potent than gefitinib (p<0.001) and anti-EGFR 
monoclonal antibody cetuximab (p<0.05). Afatinib demonstrated 
increased activity against gefitinib and cetuximab resistance cell 
lines. Synergistic interaction (combination index, CI< 1) between 
dasatinib and afatinib was found in 7 NSCLC cell lines except A549. 
The efficacy of dasatinib in combination with afatinib is significant-
ly stronger than that of cetuximab in combination with afatinib 
(p<0.001). In gefitinib resistant cell lines, growth inhibition by da-
satinib was correlated with the ratio of p-Akt/t-Akt (p<0.05); total 
FAK expression is correlated to the growth inhibition by afatinib 
(p<0.05); CI results between dasatinib and afatinib were correlated 
with the active ratio of p-FAK925/t-FAK (p<0.05). In H1650 cell line, 
which was resistant to both dasatinib and afatinib, the combination 
of both drugs significantly inhibited the activity of p-EGFR845, 
p-FAK925, p-Src416, p-Akt473 and p-MAPK42/44 when comparing 
with that treated by afatinib or dasatinib alone (p<0.05). No sig-
nificant inhibition was found on p-Stat3 and p-Stat5 by dasatinib. 
Afatinib was able to reduce the activity of Stat3 but not Stat5. No 
significant effect was shown on p-Stat3 and p-Stat5 by the combi-
Conclusion: High constitutive levels of MCL-1 most likely explain 
the inherent resistance of MM cells to the highly selective BCL-2/
BCL-XL antagonist, ABT-737. Importantly, 2-DG-dependent down-
regulation of MCL-1 provides a potential mechanism for overco-
ming resistance to ABT-737 in the clinical setting.
Keyword: Malignant Pleural Mesothelioma, ABT-737, Tumour Me-
tabolism, Apoptosis
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P3.05-011 TARGETING EPITHELIAL TO MESENCHYMAL 
TRANSITION WITH MET INHIBITORS REVERTS CHEMO-
RESISTANCE IN SMALL CELL LUNG CANCER
Israel Cañadas1, Federico Rojo2, Alvaro Taus3, Iria González3, Oriol 
Arpí1, Lara Pijuan4, Silvia Menéndez4, Sandra Zazo2, Manuel Domi-
ne5, Marta Salido4, Antonio García De Herreros6, Ana Rovira1, Joan 
Albanell3, Edurne Arriola3
1Cancer Research Program, Imim/Spain, 2Pathology, Iis-fundación Jimé-
nez Díaz/Spain, 3Medical Oncology, Hospital Del Mar/Spain, 4Patholo-
gy, Hospital Del Mar/Spain, 5Oncology, Fundacion Jiménez-Díaz/Spain, 
6Epithelial To Mesechymal Transition Laboratory, Imim/Spain
Background: Met receptor phosphorylation is associated with 
poor prognosis in human SCLC. Several Met inhibitors are being 
tested for the treatment of different neoplasms. Met activation 
has been shown to be an inductor of epithelial to mesenchymal 
transition (EMT) in a number of tumor models. The aim of our work 
was to investigate the effects of hepatocyte growth factor (HGF)/
Met induced EMT in SCLC, to evaluate the role of Met inhibition 
in mesenchymal/chemorefractory SCLC models and to investigate 
the significance of EMT in human SCLC.
Methods: Biological features (growth, invasiveness, tumorogene-
sis) and chemosensitivity of SCLC models (H69) of HGF-induced 
EMT (H69M) were evaluated in vitro and in vivo (subcutaneous 
xenografts in BALB/c nude mice). Mice with mesenchymal chemo-
resistant SCLC xenografts were treated with etoposide, the Met 
inhibitor PF-2341066 (Crizotinib) and the combination. Human 
SCLC samples at diagnosis and relapse were evaluated by immu-
nohistochemistry and immunofluorescence for EMT markers and 
Met status and correlated these with patient outcome. Association 
between clinical-pathological characteristics were tested with 
Chi-Square and Fisher tests. Differences in survival according to 
biomarker status were evaluated by log-rank and Cox regression 
models, assuming a 2-sided statistical significance p< 0.05.
Results: We identified that the activation of the Met receptor 
through HGF induced expression of mesenchymal markers (Snail1, 
SPARC, vimentin) and downregulation of E-cadherin. This derived 
in increased tumorogenesis, local invasion and chemoresistance in 
xenograft models. The combination of etoposide and PF-2341066, 
but not the Met inhibitor alone significantly decreased tumor 
growth in this chemoresistant/mesenchymal models. Moreover, 
Snail1, SPARC and vimentin expression in human SCLC specimens 
(N:87) was significantly associated with Met activation (co-localiza-
tion by immunofluorescence). Expression of mesenchymal markers 
predicted worse survival (all p-values <0.05) in the multivariate 
analysis. In 5 paired biopsies, we observed upregulation of mesen-
chymal markers and p-Met in chemorefractory disease.
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P3.05-014 ERIBULIN, A TUBLIN TARGETED CHEMOTHE-
RAPEUTIC AGENT, INHIBITS THE IN VITRO GROWTH OF 
SMALL CELL LUNG CANCER CELL LINES.
Paul Bunn, Barbara Helfrich
Medical Oncology, University Of Colorado Denver-AMS/United States 
Of America
Background: New therapeutic strategies are urgently needed for 
small cell lung cancer (SCLC) which accounts for approximately 
29,000 cases annually in the U.S. SCLC tumors have rapid doubling 
times and a propensity for early development of widespread meta-
static disease. There have been no therapeutic advances in recent 
decades. The microtubule-targeting agent eribulin is a mechanisti-
cally-unique inhibitor of microtubule dynamics. Eribulin binds with 
high affinity to a maximum of 15 distinct beta-tubulin binding sites 
inhibiting microtubule growth by depolymerization and sequestra-
tion of tubulin into non-productive aggregates. Eribulin is currently 
FDA approved for the treatment of metastatic breast cancer pati-
ents with a demonstrated significant increase in overall survival in 
patients that are refractory or resistant to multiple chemotherapy 
agents. We investigated the effects of eribulin in a panel of 15-hu-
man SCLC lines.
Methods: Growth inhibition by eribulin was assessed by tetrazoli-
um based assays at 5-days post treatment with varying drug con-
centrations and the growth inhibitory (GI50) was calculated. Erbulin 
induced cell cycle arrest was monitored following propidium iodi-
ne staining and analysis by FACS. Apoptosis was determined by 
using the DNA binding dyes YOPRO and PI and analysis by FACS.
Results: Eribulin inhibited the growth of 13 of the cell lines. Four 
SCLC lines had GI50s of < 1 nM and 9-lines had eribulin GI50 va-
lues of 1-6 nM. These GI50 are similar to those reported in breast 
cancer cell lines. The eribulin IC50 value in the remaining 2-lines 
was > 100 nM. We are currently exploring clinical and gene ex-
pression differences that may explain the high sensitivity and resis-
tance of different cell lines. A two to three-fold increase in the % 
cells in the G2/M phase of the cell cycle were observed following 
an 18-hour exposure to eribulin at concentrations of ≤ 5 nM in all 
cell lines growth inhibited by eribulin. Apoptosis assays are ongo-
ing and in vitro studies of eribulin in combination with radiation are 
planned.
Conclusion: s: Erbulin inhibited the growth of SCLC lines and in-
duced a significant G2/M arrest. Confirmation of growth inhibition 
of SCLC cell lines in an in vivo nude mouse model would support 
human studies in SCLC patients.
Keyword: SCLC eribulin microtubule-tageting agent
nation of afatinib and dasatinib.
Conclusion: Our study showed synergistic combination of afatinib 
and dasatinib is more potent than cetuximab plus afatinib against 
gefitinib resistant NSCLC cells; it inhibited cell proliferation in 
H1650 cell line via affecting SFK/FAK, PI3K/PTEN/Akt, and Ras/
Raf/MEK/ERK, but not JAK/Stat pathways. The level of p-FAK925/t-
FAK may be a useful biomarker predicating synergism between 
afatinib and dasatinib for the treatment of gefitinib resistant NS-
CLC cells. P-Akt/t-Akt and total FAK expression may be related to 
sensitivity to dasatinib and afatinib respectively.
Keyword: Mechanism, Dasatinib, Afatinib, Biomarker
POSTER SESSION 3 - PRECLINICAL MODELS OF THERAPEUTICS/
IMAGING  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.05-013 EFFECT OF PSA DERIVATIVES ON DNA ME-
THYLTRANSFERASE (DNMT) INHIBITION AND RADIO-
SENSITIZATION IN A549 LUNG CANCER CELL LINE
Hak Jae Kim1, Eun Sook Ma2, Jin Ho Kim1, Beom Soo Shin2, Il Han 
Kim1
1Radiation Oncology, Seoul National University Hospital/Korea, 2College 
Of Pharmacy, Catholic University Of Daegu/Korea
Background: Psammplin A (PsA), a novel DNA methyltransferase 
(DNMT) inhibitor and histone deacetylase (HDAC) inhibitor, was 
reported to induce radiosensitivity in lung cancer cell line. Concer-
ning in vivo tissue distribution characteristics, PsA was found to be 
highly distributed to lung tissues. However, it appeared to be un-
stable in biological matrices. Here we report the DNMT inhibitory 
effect of PsA derivatives and their potential for radiation sensitiza-
tion in lung cancer cell line.
Methods: A549 lung cancer cell line was used in verification of 
DNMT inhibitory effect with cultured cell DNA extraction kit. A549 
cell line was exposed to radiation with or without a total of 9 PsA 
derivatives for 18 hours prior to radiation, after which cell survival 
was evaluated via clonogenic assays.
Results: These 9 PsA derivatives all showed DNMT inhibito-
ry effect and inhibited cell proliferation at the ranges of IC50 
30–120µM. Furthermore, radiation clonogenic assays revealed that 
these compound shows radiosensitizing properties in A549 lung 
cancer cell line.
Conclusion: This preliminary data support the further investigati-
on of these derivatives for use as radiation sensitizing agents with 
potential for clinical application.
Keywords: DNMT inhibitor, Psammaplin, radiation, lung cancer 
cell line
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P3.05-016 EFFECTIVE COMBINATION THERAPIES WITH 
MEK INHIBITORS FOR THE TREATMENT OF MUTANT-
BRAF LUNG CANCERS.
Emmanuel Matti1, Rachel Ramsdale2, Aparna Rao1, Grant Mcar-
thur1, Petranel T. Ferrao1
1Cancer Research, Peter MacCallum Cancer Centre/Australia, 2Universi-
ty Of Melbourne/Australia
Background: Targeted therapeutics to mutant-BRAF and MEK 
have demonstrated remarkable efficacy in BRAFV600E metastatic 
melanomas. Unexpectedly, similar responses to the BRAF inhibitor 
vemurafenib (PLX4032) were not observed in BRAFV600E colorectal 
cancers (CRCs). Approximately 3% of lung cancers carry BRAF 
mutations, with only half being BRAFV600E. Recent case studies 
have reported responses to vemurafenib in patients with BRAFV600E 
NSCLC, suggesting that inhibition of the MAPK pathway with tar-
geted therapeutics may be a feasible treatment strategy for BRAF-
mutant lung cancers.
Methods: A panel of NSCLC cell lines carrying BRAFV600E, BRAF-
G469A, BRAFG466V and BRAFL597V mutations were assessed for res-
ponses to the MEK inhibitors Selumetinib (AZD6244), Trametinib 
(GSK1120212) and PD-325901 using standard drug response 
assays. Cell lines were also analysed by Western Blot analysis at 
various time-points following treatment with MEK inhibitors to 
determine the effects on the signalling pathways within the cells.
Results: Although all the cell lines displayed some sensitivity to 
MEK inhibition, the level of cell death observed with MEK inhibi-
tors as single agents was minimal. The responses to MEK inhibition 
varied in cell lines carrying the same BRAF mutation indicating that 
other genetic differences could influence responses to inhibition of 
the MAPK pathway. Inherent co-expression of specific Receptor Ty-
rosine Kinases such as EGFR was detected in some of the cell lines 
and an increase in P-EGFR was observed following MEK inhibition. 
Increase in P-EGFR has been reported as the mechanism of resis-
tance to vemurafenib in BRAF-mutant CRCs. In cell lines carrying 
non-V600E BRAF mutations, MEK inhibitor treatment also resulted 
in an increase in P-MEK, revealing a release of the MAPK pathway 
negative feedback resulting in upstream activation of MEK. We 
are currently focusing on assessing various combination therapies 
with MEK inhibitors, such as RTK inhibitors or second generation 
RAF inhibitors to overcome the feedback effect and drug-induced 
enhanced RTK activity. We have observed synergy in some cases, 
such as with the BRAF inhibitor AZ628 and the MEK inhibitor PD-
901 in the H1755 cell line carrying the BRAFG469A mutation. In other 
cases we have observed additive effects suggesting co-existing 
oncogenic signalling.
Conclusion: Our findings suggest that different combination thera-
pies are effective in the various mutant-BRAF cell lines and efficacy 
may depend on co-existing oncogenic ‘drivers’ and compensatory 
signalling mechanisms. We predict that combination treatment 
strategies for effective responses in BRAF-mutant NSCLCs may 
need to be determined on a personalised basis following tumour 
characterisation for co-expression of additional activators of the 
MAPK signalling pathway.
Keywords: BRAF mutant, MEK inhibitors, Combination therapies, 
MAPK signalling pathway
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P3.05-015 POSITRON-EMISSION TOMOGRAPHY-COM-
PUTED TOMOGRAPHY WITH THE GLUCOSE ANALOGUE 
[18F] FLUORODEOXYGLUCOSE IN ORTHOTOPIC IM-
PLANTATION SCID MOUSE MODEL OF LUNG CANCER
Hiromitsu Takizawa1, Kazuya Kondo2, Tamaki Otani3, Ali M. Mo-
hammed2, Hideki Otsuka4, Mitsuhiro Tsuboi1, Koichiro Kajiura1, 
Yasushi Nakagawa1, Yukikiyo Kawakami1, Mitsuteru Yoshida1, 
Shoji Sakiyama1, Akira Tangoku1
1Department Of Thoracic, Endocrine Surgery And Oncology, The Uni-
versity Of Tokushima Graduate School/Japan, 2Department Of Onco-
logical And Regenerative Surgery, University Of Tokushima, School Of 
Medicine/Japan, 3Program In Biomedical Information Science, The Uni-
versity Of Tokushima Graduate School/Japan, 4Department Of Radiolo-
gy, The University Of Tokushima Graduate School/Japan
Background: In vivo evaluation is essential for development of 
lung cancer treatment. However, the subcutaneous xenograft mo-
dels are not closely reproducing microenvironment of lung cancer. 
Although orthotopic implantation SCID mouse model of lung 
cancer presents lymphatic metastasis to mediastinum or pleuritis 
carcinomatosa with progression of disease, it has been difficult 
to evaluate the efficacy of treatment without sacrifice of model 
mouse. Positron-emission tomography-computed tomography 
(PET-CT) with the glucose analogue [18F] fluorodeoxyglucose 
(FDG) has been recently applied for evaluating tumor response to 
anticancer therapy. We have evaluated the utility of FDG PET-CT in 
orthotopic implantation SCID mice model of lung cancer.
Methods: Animals: 6 weeks male SCID mice (n=12). Cell line: 
Ma44-3 cloned from Ma44 (human squamous cell lung cancer 
cell line). Under sufficient anesthesia, mice were placed in the left 
lateral decubitus position. A 1-cm transverse incision was made in 
the right lateral skin just below the inferior border of the scapula. 
After intercostal muscles were exposed, 2 x 106 tumor cells/ml with 
400 µg/ml Matrigel® was injected into the right lung in a volume 
of 10 µl (2.0x104 cells) of medium. Four or 5 days after implantation 
(6 mice on day 4 and other 6 mice on day 5), the SCID mice were 
examined with FDG PET-CT and mice whose lung tumors were 
identified were randomized to treatment group and control group. 
Treatment group mice received intraperitoneal injection of cispla-
tin (7mg/kg) on day 6 after implantation. All mice were examined 
with FDG PET-CT on day 8 and 13 after implantation. Tumor volu-
me and maximal standardized uptake value (SUV max) of the lung 
tumor were calculated for all mice. All SCID mice were sacrificed 
on day 13 after implantation for histopathologic analysis.
Results: Six mice whose lung tumors were identified at the first 
FDG PET-CT were randomized to treatment group (n=3) and con-
trol group (n=3). The average growth rates (day 13 versus day 5 
or 6) of tumor volume and SUV max of the treatment group were 
144% and 108%, respectively, whereas the average growth rates of 
tumor volume and SUV max of the control group were 1470% and 
271%, respectively.
Conclusion: Tumor growth and inhibition were evaluated by FDG 
PET-CT in orthotopic implantation SCID mice model of lung can-
cer. This in vivo evaluation system is useful for development of lung 
cancer treatment.
Keywords: PET-CT, Non small cell lung cancer, orthotopic implan-
tation SCID mouse model
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Methods: Human lung cancer cell lines, H460 and H1299, were 
irradiated with 6MV photons using Varian 21EX linear accelerator in 
two different delivery models. Cells of conventional model irradi-
ated continuously while the other cells irradiated with gated deli-
very. Doses of 2 Gy, 4 Gy and 8 Gy were studied. In conventional 
model, treatment times were 0.5 min for 2 Gy and 3min for 8 Gy 
including latency for multiple field. In gated delivery model, treat-
ment times were 2.5 min for 2 Gy and 11 min for 8 Gy with 20% 
gating efficacy.
Results: H1299 cells were radioresistant than H460 cells (P<0.001). 
Elongation of treatment time caused significant increase in survival 
fraction in H1299 cell line (p=0.046). In H460 cell line survival frac-
tions also increased but differences were not statistically significant 
(p=0.107). Relative differences between two delivery models in log 
scale survival fraction were not increased in higher dose.
Conclusion: The biologic effects of protracted delivery with gated 
technique were different between cell lines, suggesting influence 
of diversity of sublethal damage repair. More radioresistant cell 
lines were affected by elongation of treatment time. These results 
suggest that potential risk of sparing tumor in prolonged delivery 
time with gated radiotherapy should be considered in resistant 
tumor at the clinic.
Keywords: Respiratory gating, radiotherapy, In vitro, Cell survival
POSTER SESSION 3 - PRECLINICAL MODELS OF THERAPEUTICS/
IMAGING  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.05-019 BIM EXPRESSION IN EGFR-MUTANT LUNG 
CANCER 3D SPHEROIDS PREDICTS RESPONSIVENESS 
TO TYROSINE KINASE INHIBITORS
Hyun-Kyung Lee1, Dario Barbone2, Trever Bivona3, V C. Broaddus2
1Division Of Pulmonary And Critical Care Medicine, Inje University 
Busan Paik Hospital/Korea, 2Lung Biology Center, San Francisco Ge-
neral Hospital, University Of California San Francisco/United States 
Of America, 3UCSF Helen Diller Family Comprehensive Cancer Center/
United States Of America
Background: The pro-apoptosic Bcl-2 family member BIM is 
known to be a critical mediator of targeted therapy-induced apo-
ptosis in lung cancer. Also, pretreatment level of BIM strongly 
predicted the capacity of EGFR inhibitors to induced apoptosis in 
EGFR-mutant cancers. But prevous studies were mostly done in 
two-dimensional (2D) cell cultures (monolayers).
Methods: So we used three-dimensional(3D) spheroid culture 
model that were proved to be a valuable platform to study acqui-
red multicellular apoptotic resistance and effectively recapitulate 
some of the complexity of solid tumors such as mesothelioma. 3D 
spheroids with EGFR-mutant cell lines (H3255, HCC827, H1650, 
11-18, H4006) were generated in polyHEMA-coated plates and TKI 
treatments were done both in 2D and 3D. The degree of apoptosis 
and expressions of BIM by immunoblotting before and after treat-
ment were compared.
Results: Contrary to other solid tumors, spheroids showed more 
prominent apoptosis to TKI than monolayer. Spheroids expressed 
more BIM than did monolayers except H4006. BIM was not ex-
pressed in H4006 (2D, 3D), but BIM expression was found to be 
elevated after TKI treatment only in spheroids. Higher level of BIM 
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P3.05-017 LKB1 LOSS INDUCES CHARACTERISTIC PA-
THWAY ACTIVATION IN HUMAN TUMORS AND CON-
FERS SENSITIVITY TO MEK INHIBITION DUE TO AT-
TENUATED PI3K-AKT-FOXO3 SIGNALING.
Jacob Kaufman1, Joseph Amann2, Kyungho Park1, Haotian Li1, Yu 
Shyr3, David P. Carbone2
1Cancer Biology, Vanderbilt University/United States Of America, 
2James Thoracic Center, The Ohio State Wexner Medical Center/United 
States Of America, 3Vanderbilt University School Of Medicine/United 
States Of America
Background: Inactivation of STK11/LKB1 is one of the most com-
mon genetic events in lung cancer, and understanding the cellular 
phenotypes and molecular pathways altered as a consequence 
will aid the development of therapeutic strategies targeting LKB1-
deficient cancers.
Methods: We report the comprehensive analysis of gene and 
protein expression patterns associated with LKB1 loss in lung 
adenocarcinomas, through which we identify hallmarks of altered 
tumor metabolism and down-regulation of the PI3K/AKT pathway.
Results: Significant differences are observed between human 
tumors and those derived from a genetically engineered mouse 
model of LKB1 loss. A 16-gene signature is predictive of both mu-
tational and non-mutational LKB1 loss in human tumors. Cell lines 
expressing this signature show increased sensitivity to MEK inhibi-
tion, independent of mutations in RAS and RAF family members. 
Restoration of LKB1 in lung cancer cell lines down-regulates the 
gene expression pattern, attenuates FOXO3, and induces resis-
tance to MEK inhibition.
Conclusion: These findings identify characteristic phenotypic fea-
tures of LKB1-deficient tumors and identify LKB1 loss as a novel 
determinant of MEK sensitivity.
Keywords: Lung cancer, LKB1, MEK, Expression analysis
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P3.05-018 DOES ELONGATION OF TREATMENT TIME 
IN RESPIRATORY GATED RADIOTHERAPY ALTER CELL 
SURVIVALS?
Sanghyuk Song, Hong-Gyun Wu
Department Of Radiation Oncology, Seoul National University Hospi-
tal/Korea
Background: Respiratory gated radiotherapy (RGRT) is a modern 
radiotherapy technique, which is increasingly used technique to 
take account of respiratory motion. One potential risk of RGRT is 
the possibility of sublethal repair during treatment leading more 
tumor cell survival. This study assessd the influence of elongation 
of treatment time in respiratory gated radiotherapy by measuring 
cell survival in vitro.
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anti-inflammatories or other nutrient-specific dietary supplements 
will moderate the rate of mesothelioma in asbestos exposed popu-
lations.
Keyword: mesothelioma, cancer prevention, animal model
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P3.05-021 TARGETING HDACS TO OVERCOME CISPLA-
TIN RESISTANCE IN MALIGNANT PLURAL MESOTHELIO-
MA
Anne-Marie Baird1, Cormac J. Jennings2, Lauren Mcdonagh1, Lou-
ise Flynn1, Eimear O‘Donnell1, Martin Barr1, Eric Santoni-Rugiu3, 
Finn K. Hansen4, Thomas Kurz4, Yuichi Takiguchi5, Warren Tho-
mas2, Zarah G. Zimling6, Kenneth O‘Byrne7, Steven Gray1
1Thoracic Oncology Research Group, St. James‘s Hospital/Trinity College 
Dublin/Ireland, 2Molecular Biology, Royal College Of Surgeons In Ireland/
Ireland, 3Pathology, National University Hospital/Denmark, 4Institute 
Of Pharmaceutical And Medicinal Chemistry, Heinrich-Heine-University 
Of Duesseldorf/Germany, 5Department Of Medical Oncology, Graduate 
School Of Medicine, Chiba University/Japan, 6Oncology, University Hos-
pital Of Copenhagen, Rigshospitalet/Denmark, 7Queensland University 
Of Technology, Cancer & Ageing Research Program/Australia
Background: Malignant pleural mesothelioma (MPM) is an aggres-
sive cancer of the mesothelial cells and is becoming a worldwide 
health burden. Progress in the treatment of MPM remains difficult, 
underscored by the fact that no single treatment option has proven 
particularly effective and chemo-resistance is a common problem. 
However, epigenetic modifiers, such as histone deacetylase inhibi-
tors (HDi) have emerged as a novel class of anti-cancer agent and 
are currently undergoing clinical trials in numerous cancers. There is 
also evidence to suggest that HDAC expression may play a role in 
the development of chemo-resistance. We investigated the levels 
of HDACs in MPM cell lines, patient samples and determined the 
effect of HDi on MPM cisplatin sensitive and resistant cell lines.
Methods: A panel of MPM cell lines (n=16) was screened for 
the expression of HDAC11, Class I (HDAC1/2/3/8) and Class II 
(HDAC4/5/6/7/9/10) HDACs at the mRNA level (RT-PCR) and at 
the protein level (Western Blot). The HDAC expression profile was 
determined in an isogenic cell line model consisting of a cisplatin 
sensitive (Parent) and resistant (CisR) MPM cell line, P31. In addition, 
HDAC expression was examined in panel of twenty patient samples 
(benign/biphasic/sarcomatoid/epithelial). Also, MPM TMAs were 
stained by imummo-histochemistry for HDAC5 expression. Further-
more proliferation assays (BrdU ELISA) were performed to determi-
ne the effect of two HDi on the p31 cell lines. The HDi used were 
Vorinostat (pan HDAC inhibitor) and 19i (selective HDAC5 inhibitor).
Results: HDAC11, Class I and II HDACs were detected to varying 
degrees at the mRNA and protein level within our cell line panel. In 
the P31 isogenic parent/cisplatin resistant, HDAC protein expressi-
on was decreased (HDAC2/3/4/5/7) in the CisR compared with the 
Parent. HDAC5 was significantly reduced at both the protein and 
the mRNA level (p<0.05). The expression of HDACs 1/2/3/5 were 
increased in the MPM patient samples (n=15) compared with beni-
gn (n=5) (HDAC2/3/5, p<0.05). HDAC5 staining in a cohort of MPM 
samples, demonstrated no significant association between survival 
and a low HDAC5 score. However females had a greater median 
survival than their male counterparts. Vorinostat and 19i significant-
in spheroids had the tendency of higher apoptotic response to TKI.
Conclusion: 3D spheroids cultures are useful in studying apoptotic 
mechanism in EGFR-mutant lung cancer. BIM expression before 
and after treatment of TKI might be useful predictor in EGFR-mu-
tant spheroids model. So therapies that upregulated BIM expressi-
on can improve the efficacy of TKI therapy.
Keywords: tyrosine kinase inhibitor, BIM, EGFR mutant lung  
cancer
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P3.05-020 STRATEGIES FOR THE PREVENTION OF ME-
SOTHELIOMA IN MEXTAG MICE
Cleo Robinson1, Samantha Woo1, Amy Walsh1, Helman Alfonso2, 
Anna K. Nowak1, Richard Lake1
1University Of Western Australia, National Centre For Asbestos Related 
Diseases/Australia, 2University Of Western Australia/Australia
Background: Current treatments for mesothelioma typically incre-
ase median survival by a matter of months. Progress in treatment 
has been hampered by lack of a suitable small animal model, which 
could guide clinical advances, given limited numbers of patients 
eligible for clinical trials. To this end we recently developed a trans-
genic mouse model of mesothelioma in which the viral oncogene, 
SV40TAg (TAg) is directed to mesothelial cells by use of the cell 
type specific mesothelin promoter. MexTAg mice develop meso-
thelioma rapidly and uniformly, but only following exposure to the 
natural carcinogen, asbestos. The model closely mimics the human 
disease and is thus ideal for both rapid analysis of novel therapeutic 
studies and for investigating factors that might act synergistically 
with asbestos to cause disease. Since all MexTAg mice develop me-
sothelioma following asbestos exposure the model is highly suitable 
for early intervention and cancer prevention studies. An effective 
cancer prevention strategy for the millions of people who have been 
exposed to asbestos could have enormous benefit worldwide. Epi-
demiological evidence indicates that supplementation with some 
dietary factors or use of common drugs such as statins and non-ste-
roidal anti-inflammatory drugs is associated with a lower incidence 
of cancer.
Methods: not applicable
Results: We previously reported that dietary supplementation with 
a number of antioxidants did not alter the time to develop disease 
nor overall survival, despite the widely accepted hypothesis that 
asbestos catalyzed production of reactive oxygen and nitrogen 
species contribute to the development of this cancer. We have 
extended these studies to test whether vitamin D, non-steroidal 
anti-inflammatories, statins and some other candidate diets could 
alter the pattern of disease in the MexTAg model. Supplemented 
diets were provided at levels based on published data and began 2 
weeks prior to asbestos exposure in order to maximize our chance 
of detecting a benefit. Preliminary data suggests a single agent or 
nutraceutical may not be enough to prevent the multiple pathways 
involved in tumorigenesis. This is somewhat supported by epide-
miological data from the Wittenoom cohort of asbestos exposed 
workers and residents.
Conclusion: In conclusion, we think it is unlikely that antioxidants, 
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of targeting four RTKs whose expression are significantly elevated in 
maligant MPM. Given the many indications that these RTKs are asso-
ciated with “addicted” RTK networks, this compound may therefore 
have potential clinical utility in the clinical management of MPM.
Keywords: BSM-777607, Receptor Tyrosine Kinase
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P3.05-023 TREATMENT WITH THE MTOR KINASE INHIBI-
TOR CC-223 OVERCOMES RESISTANCE TO THE EPIDER-
MAL GROWTH FACTOR RECEPTOR TYROSINE KINASE 
INHIBITOR ERLOTINIB IN NON-SMALL CELL LUNG CAN-
CER CELLS
Simon Ekman1, Daniel Chan2, Murry W. Wynes2, Zhiyong Zhang2, 
Leslie Rozeboom2, Heather Raymon3, Kristen Hege3, Shuichan Xu3, 
Ellen Filvaroff3, Fred R. Hirsch2
1Dept Of Medicine, Division Of Medical Oncology/United States Of 
America, 2Dept Of Medicine, Divison Of Medical Oncology/United Sta-
tes Of America, 3Celgene Corporation/United States Of America
Background: Activation of the mTOR pathway is a common down-
stream mechanism of resistance to Epidermal Growth Factor 
receptor (EGFR) tyrosine kinase inhibitors. CC-223 (Celgene) is an 
mTOR kinase inhibitor under clinical development. We evaluated 
CC-223 in combination with erlotinib to overcome resistance to 
EGFR tyrosine kinase inhibition in non-small cell lung cancer (NS-
CLC) cell lines and xenografts in nude mice.
Methods: A panel of 18 NSCLC cell lines was used to evaluate the 
effect of erlotinib and CC-223 treatment on cell growth using an 
MTT assay. Intermediately (IC50 >1 and <10 mM) and highly (IC50 
>10 mM) resistant cell lines to erlotinib were used in analyses of 
additive/synergistic effects for the combination treatment with 
CC-223.
Results: CC-223 demonstrated anti-proliferative activity in NSCLC 
cell lines with various degrees of sensitivity as reflected in different 
IC50 values, ranging from 0.15 to 12 mM. In combination with er-
lotinib, CC-223 showed synergistic anti-proliferative effects in NS-
CLC cells resistant to erlotinib with combination indices as low as 
0.1-0.2. In vivo studies in mice xenografts demonstrated a strong 
synergistic effect of the combination treatment of erlotinib and 
CC-223 with a 90% decrease of tumor volume compared to unt-
reated and 88% compared to erlotinib treated for A549 cells. IHC 
analyses of apoptosis and proliferation in the tumors are ongoing; 
mature data will be presented at the meeting.
Conclusion: The mTOR kinase inhibitor CC-223 demonstrated anti-
proliferative activity in a panel of NSCLC cell lines. In NSCLC cells 
resistant to the EGFR tyrosine kinase inhibitor erlotinib, combining 
erlotinib with CC-223 demonstrated a synergistic anti-proliferative 
effect. In vivo studies of tumors in xenografted mice also demons-
trated synergistic anti-tumor effects with the combination treat-
ment even in erlotinib resistant tumors. The present data suggest 
that mTOR inhibition using the mTOR kinase inhibitor CC-223 may 
be a therapeutic strategy to overcome resistance to EGFR tyrosine 
kinase inhibitors in NSCLC.
Keyword: mTOR,non-small cell lung cancer,erlotinib, resistance
ly reduced the proliferative capacity of the p31 Parent and CisR. 
SAHA was more effective in the Parent cells compared with CisR. 
The effect of 19i was similar in both cell lines.
Conclusion: Altered HDAC expression was observed in an isogenic 
Parent and CisR MPM cell model. Work ongoing in non-small cell 
lung cancer (NSCLC) has also demonstrated significantly reduced 
HDAC5 levels in CisR compared with Parent. This may suggest that 
a reduction in HDAC expression is involved in cisplatin resistance. 
Reduced levels of HDAC5, in an MPM TMA, were not associated 
with survival. It should be noted, however that patient numbers 
were small and biphasic and sarcomatoid sub-types had the lowest 
expression levels of HDAC5. We are currently increasing our patient 
numbers for an additional IHC study. HDi significantly reduced the 
proliferative capacity of CisR and Parent MPM cells. HDAC levels 
may represent an important biomarker in stratifying patients for 
future epigenetic targeted therapies in MPM.
Keywords: mesothelioma, HDAC, chemoresistance, epigenetics
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P3.05-022 BMS-777607 AS A CANDIDATE THERAPEUTIC 
AGENT IN MALIGNANT PLEURAL MESOTHELIOMA
Kenneth O‘Byrne1, Steven G. Gray2
1Queensland University Of Technology, Cancer & Ageing Research 
Program/Australia, 2Clinical Medicine, Trinity College Dublin/st Jame‘s 
Hospital/Ireland
Background: Malignant pleural mesothelioma (MPM) is an aggres-
sive inflammatory cancer associated with exposure to asbestos. 
Untreated, MPM has a median survival time of 6 months, and most 
patients die within 24 months of diagnosis. There is an urgent unmet 
need to identify new therapies for this disease. Receptor tyrosi-
ne kinases (RTK) are an area of active research in cancer therapy. 
The identification of “addicted” signalling networks could rapidly 
lead to candidate inhibitors (RTKi) that could potentially be uused 
to target MPM. We have previously identified RON/MST1R as a 
candidate therapeutic target in MPM. Additional RTKs identified 
by other studies include Axl and c-MET. The agent BMS-777607 
is an orally bioavailable small molecule with the capacity to inhibit 
c-MET, RON/MST1R, Axl and Tyro3 (at nanomolar concentrations) 
and has just completed a Phase I/II trial (ClinicalTrials.gov Identifier: 
NCT00605618). This drug may therefore have applicability in MPM.
Methods: A panel of MPM cell lines inluding the normal pleural cells 
LP9 & Met5A were screened for expression of Tyro3, c-MET, RON/
MST1R and Axl by RT-PCR. A cohort of snap-frozen patient samp-
les isolated at surgery comprising benign, epithelial, biphasic, and 
sarcomatoid histologies were subsequently examined for the ex-
pression of these RTKs. The effects of BMS-777607 on MPM cellular 
proliferation and viability are being assessed.
Results: Expression of various RON/MST1R isoforms, c-MET, Tyro3 
and Axl were observed in all cell lines. Significantly higher expressi-
on of all genes were found in the malignant tumour material versus 
benign pleura. The effects of BMS-777607 on cellular proliferation/
viability are ongoing and the results will be presented at the mee-
ting.
Conclusion: BMS-777607 represents a unique compound capable 
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P3.06-002 RLIP76 EXPRESSION IS PROGNOSTIC AND 
PREDICTIVE OF CHEMOTHERAPY BENEFIT IN RESEC-
TED NSCLC
Damien Urban1, Richard J. Young1, Zoe Wainer1, Matthew Conron2, 
Prudence A. Russell2, Gavin Wright1, Ben Solomon1
1Peter MacCallum Cancer Centre/Australia, 2St. Vincent‘s Hospital/
Australia
Background: Despite adjuvant chemotherapy improving overall 
survival of resected Stage II and III non-small cell lung cancer (NS-
CLC), acute and late toxicities of chemotherapy have highlighted 
the need to better predict which patients will benefit from treat-
ment. RLIP76 is a ubiquitously expressed multi-functional transpor-
ter that is associated with cisplatin and vinorelbine resistance. Our 
aim was to analyse the prognostic and predictive value of RLIP76 
expression in NSCLC.
Methods: We identified 367 NSCLC patients resected between 
1996 and 2009. A tissue microarray was created and immunohisto-
chemistry (IHC) performed with an anti-human RLIP76 rabbit poly-
cloncal antibody (Millipore, Temecula, CA). The intensity (0-3) and 
proportion of tumour cells (0-100) with staining was scored. The 
product of RLIP76 intensity and proportion of tumour cells staining 
was calculated (range 0-300) and divided into high (>100) and no/
low expression (≤100). RLIP76 expression was correlated with clini-
cal features and patient outcome.
Results: IHC was available for 285 patients, 173(60.7%) of which 
were male. Number of patients according to stage I, II, III and 
IV was 150(52.6%), 83(29%), 44(15.4%) and 8(3%), respectively. 
RLIP76 was overexpressed in 117(41%) specimens. There was no 
relationship between RLIP76 expression and stage, histology, sex 
or age. High RLIP76 expression was associated with an improved 
prognosis on univariate (HR 0.62, CI 9.44-0.90, p=0.012,Figure 1) 
and multivariate analysis (HR 0.57, CI 0.39-0.83, p=0.003). Adju-
vant chemotherapy was also associated with an improved survival 
on multivariate analysis (HR 0.52, CI 0.33-0.82, p=0.005). When 
stratifying by RLIP76 expression, the benefit of chemotherapy was 
limited to patients with no/low expression (HR =0.44, CI 0.24-0.8, 
p=0.008)(Figure 2). No benefit of chemotherapy was seen in pa-
tients with high RLIP76 expression (HR=0.75, CI 0.34-1.63, p=0.5). 
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P3.06-001 SERUM NESFATIN-1 LEVEL AS A BIOMARKER 
IN NON-SMALL CELL LUNG CANCER
Bulent Karagoz1, Hakki Cetinkaya2, Oguz Bilgi1, Alpaslan Ozgun1, 
Tolga Tuncel1, Levent Emirzeoglu1, Rauf Gorur3
1Medical Oncology, Gata Haydarpasa Training Hospital/Turkey, 2Ne-
phrology, Gata Hospital/Turkey, 3Thoracic Surgery, Gata Haydarpasa 
Training Hospital/Turkey
Background: Nesfatin-1 is an anorexigenic neuropeptide. We have 
previously reported that serum nesfatin-1 level is decreased in 
lung cancer patients. In this study, we aimed to investigate possi-
ble effects of serum nesfatin-1 level in survival and chemotherapy 
response of non-small cell lung cancer patients.
Methods: Twenty-eight non-small cell lung cancer patients were 
included in this study. Data were obtained from clinical records 
and our previously study about nesfatin-1. The patients were divi-
ded into two groups according to high nesfatin-1 level or low. Sur-
vival data were compared between these groups. Moreover, serum 
nesfatin-1 levels were investigated in chemotherapy responder and 
non-responder patients.
Results: Three of patients received supportive care alone. Twenty-
five patients were treated with platinum-based doublet chemothe-
rapy. In chemotherapy non-responder patients, serum nesfatin-1 
level was more lower than in the patients achieved clinical benefit 
(0.38 ng/ml ±0.12 ng/ml vs 0.55 ng/ml ±0.21 ng/ml; p:0.044). Pa-
tients with low nesfatin-1 level had shorter overall survival (OS), 
but it is not statistically significant (median OS 7.3 months vs 13.8 
months, respectively; p: 0.829). Serum nesfatin-1 levels were not 
also different in between patients survived more than 12 months 
and not (0.62 ng/ml ±0.22 ng/ml vs 0.46 ng/ml ±0.19 ng/ml; 
p:0.077).
Conclusion: This preliminary study suggests that serum nesfatin-1 
level is not prognostic factor in non-small cell lung cancer, but may 
be a predictive marker for chemotherapy response.
Keywords: predictive, nesfatin-1, Lung cancer
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P3.06-003 CORRELATIVE ANALYSIS OF CIRCULATING 
BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CA-
BOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) 
IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC 
NON-SMALL CELL LUNG CANCER (NSCLC)
Sukhmani K. Padda1, Yael Rosenberg-Hasson2, Joel W. Neal1, Scott 
N. Gettinger3, Jeffrey A. Engelman4, Pasi A. Jänne5, Howard L. 
West6, Deepa Subramaniam7, Joseph W. Leach8, Primo N. Lara9, 
Michael B. Wax10, Heather A. Wakelee1, Douglas O. Clary11, Lisa 
Zhou1
1Stanford Cancer Institute/stanford University School Of Medicine/
United States Of America, 2Stanford University School Of Medicine/
Institute For Immunity, Transplantation And Infection/United States Of 
America, 3Yale Cancer Center/yale University School Of Medicine/Uni-
ted States Of America, 4Massachusetts General Hospital/harvard Me-
dical School/United States Of America, 5Dana Farber Cancer Institute/
harvard Medical School/United States Of America, 6Swedish Cancer In-
stitute/United States Of America, 7Lombardi Cancer Center/georgetown 
University/United States Of America, 8Virginia Piper Cancer Institute/
United States Of America, 9University Of California Davis Comprehen-
sive Cancer Center/United States Of America, 10Summit Medical Group/
United States Of America, 11Exelixis, Inc./United States Of America
Background: Cabozantinib (C) is a potent ATP-competitive inhibi-
tor of MET and vascular endothelial growth factor receptor 2 (VEG-
FR2) along with KIT, RET, AXL, TIE2, and FLT3. Hepatocyte growth 
factor (HGF), the ligand of MET, and VEGF act synergistically to 
promote angiogenesis. There are currently no widely accepted 
prognostic or predictive biomarkers for anti-angiogenic agents.
Methods: This is a retrospective correlative biomarker study from 
the phase 1b/2 trial of C+/-E in stage IIIB-IV NSCLC. All pts had to 
fail prior therapy with E. Both drugs are oral and dosed daily. C do-
sing is in the free-base equivalent weight. In phase I, there was a 2 
week lead in with E and the cohorts included: 1A (60 mg C+150 mg 
E), 2A (60 mg C+100 mg E), 3A (100 mg C+100 mg E), 4A (100 mg 
C+50 mg E), and 2B (40 mg C+150 mg E). In phase II, both drugs 
started simultaneously: Arm A (100 mg C) and Arm B (100 mg 
C+50 mg E). Pts were included in the study if a pre-E+C and post-
C > day 29 plasma sample was available. The Milliplex 13-plex and 
Conclusion: High RLIP76 expression is associated with an impro-
ved prognosis in resected NSCLC.Interestingly no/low RLIP76 
expression may predict for benefit of adjuvant chemotherapy. 
Further studies are needed to confirm these results.
Keywords: predictive, RLIP76, NSCLC, Prognostic
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without T790M.
Results: Out of 70 cases, 36 (51%) were identified to have the 
T790M mutation in the rebiopsy specimen. There was no dif-
ference in the pattern of disease progression, progression-free 
survival for initial TKIs (12.8 and 11.3 months), post-progression 
survival (14.7 and 14.1 months), or overall survival (43.5 and 36.8 
months) in patients with and without T790M. In total, 34 patients 
received afatinib after post-progression biopsy as a subsequent 
treatment. Among them, six (18%) achieved objective response. 
The median progression-free survival for afatinib was 3.7 months 
for the entire group, and 3.2 and 4.6 months for the groups with 
(n = 21) and without (n = 13) T790M, respectively (p = 0.33). 
Conclusion: Although T790M had no prognostic or predictive 
role in the present study, further research is necessary to identify 
patients with T790M-mutant tumors who might benefit from new 
treatment strategies.
Keywords: Epidermal growth factor receptor, T790M, tyrosine 
kinase inhibitor, afatinib
Luminex 51-plex assays were used. For this preliminary analysis, 
select markers previously implicated in angiogenesis (bFGF, VEGF, 
sVEGFR1-3, IL-6, IL-8, IL-12, IL-17, PDGF-BB, ICAM-1, VCAM-1) and 
those of interest (ligands of KIT and MET- SCF and HGF, respec-
tively) were analyzed. Log transformed mean fluorescence intensity 
(MFI) values and Wilcoxon Rank paired sum tests were used to 
detect changes from day 1-29. A change from baseline was noted 
to be significant if at least 15% (median) with α<0.05 (2-sided) and 
a trend if 10-15% (median) with α<0.08 (2-sided).
Results: 73 pts included: 52 phase I and 21 phase II; median age 
60 years; 23M/50F; 56.2% nonsmoker; 91.8% adenocarcinomas. 
The pts with samples from both time points were divided into two 
groups due to limited sample size and included: Group R (com-
plete/partial response and stable disease> 6 months; n=22) and 
Group NR (stable disease< 6 months and progressive disease; 
n=51). The only marker that changed in a single direction in all sub-
jects within a group was sVEGFR2 in group R. Overall, significant 
decreases were noted in sVEGFR1-3, IL-6, PDGF-BB, and trended 
in IL12p70 and IL-17. By subgroups: Group R had significant decre-
ases in bFGF, VEGF, sVEGFR1-3, IL-6, IL-8, IL-12(p40+p70), IL-17, 
PDGF-BB, SCF, and trended in HGF (median 10.1% ↓, p=0.0275); 
and Group NR had significant decreases in sVEGFR2-3, IL-6, PDGF-
BB, and trended in sVEGFR-1, IL-6, and IL-17.
Conclusion: Both groups R+NR had a decrease in sVEGFR-2, 
suggesting that this is a marker of treatment with C rather than a 
marker of response. However, overall group R had larger dynamic 
decreases of immune markers than group NR. HGF, which is tar-
geted downstream by C and plays a role in angiogenesis and E 
resistance, had a trend to decrease in group R but not group NR. 
This study is retrospective with a small sample size, imbalanced 
numbers per response subgroup, and is exploratory in nature.
Keyword: cabozantinib, biomarker, erlotinib
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P3.06-004 T790M MUTATION IN PATIENTS WITH AC-
QUIRED RESISTANCE TO EGFR TYROSINE KINASE INHI-
BITORS: IS IT ASSOCIATED WITH CLINICALLY DISTINCT 
FEATURES?
Jun Ho Ji1, Jong-Mu Sun1, Myung-Ju Ahn1, Yoon-La Choi2, Jin Seok 
Ahn1, Keunchil Park1
1Division Of Hematology-Oncology, Samsung Medical Center, Sungky-
unkwan University School Of Medicine/Korea, 2Department Of Patho-
logy, Samsung Medical Center, Sungkyunkwan University School Of 
Medicine/Korea
Background: The T790M mutation is considered to be the major 
mechanism of acquired resistance to epidermal growth factor re-
ceptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its clinical 
implication in patients with non-small cell lung cancer (NSCLC) is 
yet determined.
Methods: NSCLC patients with acquired resistance to initial EGFR 
TKIs such as gefitinib or erlotinib were identified, and post-pro-
gression tumor specimens were prospectively collected for T790M 
mutation analysis. Clinical features including the pattern of disease 
progression (intrathoracic only versus extrathoracic), treatment 
outcomes for initial or subsequent TKIs, post-progression survival, 
and overall survival were compared between patients with and 
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Conclusion: We have demonstrated that it is feasible to incorpo-
rate this protocol into the routine analysis of thoracic samples. The 
pattern of retesting to achieve full analysis in all samples suggests 
that, while EGFR testing is easily achievable with a one-section 
approach, the analysis of KRAS and ALK may require another round 
of testing in a small percentage of cases. Our results thus provide 
a pre-analytical and analytical rationale for comprehensive genoty-
ping in patients with NSCLC.
Keywords: EGFR, ALK, KRAS
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P3.06-006 INTEGRATED GENOMIC ANALYSIS OF EGFR-
MUTANT NON-SMALL CELL LUNG CANCER IMMEDIATE-
LY FOLLOWING ERLOTINIB INITIATION IN PATIENTS
Petros Gianikopoulos1, Rosario Garcia-Campelo2, Margarita Ma-
jem3, Carlota Costa4, John St. John1, Aleah F. Cauhlin1, Matthew 
Wilkerson5, Niki Karachaliou6, Oscar Westesson1, Santiago Viteri4, 
Nathan Boley1, Enriqueta Felip7, Enric Carcereny8, Cordula Heide-
cke9, Urvish Parikh1, Nick Hahner1, Anne Wellde1, Bartomeu Mas-
suti10, Jonathan Barry1, George W. Wellde Jr.1, Joel Parker5, William 
R. Polkinghorn1, Trever G. Bivona1, Jonathan Weissman1, Rafael 
Rosell6
1Cancer Therapeutics Innovation Group/United States Of America, 
2Medical Oncology, Complejo Hospitalario A Coruña/Spain, 3Servei 
D’Oncologia, Hospital De Sant Pau/Spain, 4Quiron-dexeus University 
Hospital, Pangaea Biotech, Molecular Oncology Research (MORE) Foun-
dation/Spain, 5University Of North Carolina/United States Of America, 
6Quiron-Dexeus University Hospital, Pangaea Biotech/Spain, 7Medical 
Oncology, Hospital Valle Hebron/Spain, 8Catalan Institute Of Oncology/
Spain, 9Oncology, Ctu Tarragona/Ichhco Tarragona/Spain, 10Hospital 
General De Alicante/Spain
Background: Major obstacles limiting the clinical success of EGFR 
TKI therapy in EGFR mutant non-small cell lung cancer (NSCLC) 
patients are heterogeneity and variability in the initial anti-tumor 
response to treatment. The underlying molecular basis for this 
heterogeneity has not been explored in patients immediately after 
initiation of therapy.
Methods: We conducted CT-guided core needle biopsies imme-
diately prior to erlotinib treatment initiation and at 6 days and 60 
days post erlotinib initiation in a patient with histologically confir-
med NSCLC harboring an established activating mutation in EGFR. 
DNA and RNA from each of the frozen biopsies were analyzed by 
whole exome sequencing and whole transcriptome sequencing, 
respectively. High-resolution CT images were also obtained at the 
time of each biopsy to assess the degree of molecular and radio-
graphic responses observed.
Results: Two established activating somatic mutations were identi-
fied in EGFR (p.G719A and p. R776H). Gene expression analysis re-
vealed that several proapoptotic genes including BID, CASP3 and 
several growth inhibitory genes including GADD45B, GADD45G 
were upregulated at 6 days post erlotinib treatment, while at 60 
days their expression levels decreased to below pretreatment 
levels. Other proapoptotic genes such as BAD and BAX and were 
noted to be upregulated most significantly 60 days, as was growth 
inhibitory gene CDKN1A. In contrast, the growth-promoting genes 
CCNB1 and CCND3 exhibited a progressive decrease in expres-
sion across time points. Whole exome sequencing demonstrated 
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P3.06-005 A PROSPECTIVE PROTOCOL FOR SIMULTA-
NEOUS GENOMIC TESTING IN PATIENTS WITH NON-
SMALL CELL LUNG CANCER
Fernando Lopez-Rios1, Esther Conde1, Barbara Angulo1, Rebeca 
Martinez1, Claire Mcgready2, Graeme O´ Hara2, Neil Anderson2, 
Perry Maxwell2, Manuel Salto-Tellez2
1Laboratorio De Dianas Terapeuticas, Hospital Universitario Sanchinar-
ro/Spain, 2Queen‘s University/United Kingdom
Background: Molecular testing in lung cancer has dramatically 
evolved over the past few years with a large number of targeted 
therapies and associated biomarkers. This has created a demand 
for tissue preservation. A careful consensus for prioritization of 
the different assays is needed to identify the right therapy for the 
patient. It is necessary to have protocols available that give access 
to results rapidly and accurately without depleting the sample 
throughout the process. We have designed a prospective study to 
demonstrate an efficient biomarker testing workflow (EGFR, ALK 
and KRAS) in a real clinical setting that preserves limited, valuable 
clinical samples
Methods: This prospective study was conducted at two indepen-
dent pathology laboratories (Laboratorio de Dianas Terapeuticas 
of Madrid, Queen’s University of Belfast). Each site performed 
tissue sectioning for diagnosis and molecular testing according to 
laboratory protocols or to the assay specific package insert. Digital 
pathology was used to annotate specimens. NSCLC specimens 
were obtained by each lab (surgical resections and small biopsies 
of primary and metastatic lesions), excluding cytology specimens, 
with the exception of cells blocks. EGFR and KRAS mutation tes-
ting was performed using the cobas® EGFR Mutation Test and 
the cobas® KRAS Mutation Test (both CE-IVD), using a single 5µm 
section per test. FISH analysis was performed using the Vysis LSI 
ALK probe. 
Results: A total of 103 cases were included. 100% of the speci-
mens were successfully tested for EGFR mutation status. Failure 
rates were 1.9% for ALK and KRAS analysis. Failed DNA extraction/
PCR amplification was 3.9%/2.9% for EGFR and 5.8%/12.6% for 
KRAS. The prevalence of molecular alterations identified in EGFR 
(4% and 13.2%), ALK (4% and 7.8%) and KRAS (26% and 29.4%) was 
somewhat similar to that described in earlier studies. ALK rearran-
gements were mutually exclusive with EGFR and KRAS mutations. 
The median turnaround time was almost identical between sites: 
6-7 days for all biomarkers (EGFR range 1-12 days, ALK range 2-14 
days and KRAS range 1-17 days).
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capturing CTCs by On-chip Sort. ARMS/Scorpion PCR assay detec-
ted the EGFR deletion mutation from two of the samples (50%).
Conclusion: The preclinical study and the results of the clinical 
feasibility study suggested the possibility of the On-chip Sort as-
say to detect EGFR mutations from peripheral blood of patients 
with lung cancer. Further investigation is going to be conducted to 
evaluate the correlation of EGFR mutations in captured CTCs and 
primary lesions.
Keywords: liquid biopsy, Circulating Tumor Cell, EGFR
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P3.06-008 PROGNOSTIC AND PREDICTIVE VALUE OF 
KRAS MUTATIONS IN ADVANCED NON-SMALL CELL 
LUNG CANCER
Deok Won Hwang1, Jong-Mu Sun1, Jin Seok Ahn1, Myung-Ju Ahn1, 
Keunchil Park2
1Medicine, Samsung Medical Center/Korea, 2Hematology-Oncology, 
Samsung Medical Center/Korea
Background: Clinical implications of KRAS mutations in advanced 
non-small cell lung cancer remain unclear.
Methods: Kras mutation status was identified by direct sequen-
cing test in 844 specimens that were diagnosed of NSCLC at 
Samsung Medical Center from 2006 to 2011. This study included 
stage IV NSCLC patients who were treated with systemic chemo-
therapy. We retrospectively evaluated the prognostic and predicti-
ve value of KRAS mutations in patients with advanced NSCLC.
Results: Among 484 patients with available results for both KRAS 
and EGFR mutations, 39 (8%) had KRAS and 182 (38%) EGFR mu-
tations, with two cases having both mutations. The median overall 
survivals for patients with KRAS mutations, EGFR mutations, or 
both wild types were 7.7, 38.0, and 15.0 months, respectively (P 
< 0.001). The KRAS mutation was an independent poor prog-
nostic factor in the multivariate analysis (hazard ratio=2.6, 95% CI: 
1.8–3.7). Response rates and progression-free survival (PFS) for the 
pemetrexed-based regimen in the KRAS mutation group were 14% 
and 2.1 months, inferior to those (28% and 3.9 months) in the KRAS 
wild type group.
Conclusion: KRAS mutation tended to be associated with inferi-
or treatment outcomes after gemcitabine-based chemotherapy, 
while there was no difference regarding taxane-based regimen. 
Although the clinical outcomes to EGFR tyrosine kinase inhibitors 
(TKIs) seemed to be better in patients with KRAS wild type than 
those with KRAS mutations, there was no statistical difference in 
response rates and PFS according to KRAS mutation status when 
EGFR mutation status was considered. Two patients with both 
KRAS and EGFR mutations showed partial response to EGFR TKIs. 
Although G12D mutation appeared more frequently in never smo-
kers, there was no difference in clinical outcomes according to 
KRAS genotypes. These results suggested KRAS mutations have 
an independent prognostic value but a limited predictive role for 
EGFR TKIs or cytotoxic chemotherapy in advanced NSCLC.
Keyword: KRAS mutation, Prognosis, Predictive factor, Non-small 
cell lung cancer
the progressive evolution of global copy number abnormalities. 
High-resolution CT scans revealed no interval radiographic change 
in tumor size after 6 days of erlotinib treatment, and a decrease 
in tumor size 60 days into therapy. No clinical complications were 
encountered.
Conclusion: This study is the first reported longitudinal integrated 
genomic analysis of EGFR-mutant NSCLC in a patient treated with 
an EGFR TKI. We documented the feasibility, safety and utility of 
this strategy to establish initial drug efficacy at the molecular level 
prior to any radiographic evidence of response (6 days), as well as 
evidence that acquired resistance can emerge early in the course 
of TKI therapy. Serial integrated genomic analysis is ongoing in 
other TKI treated patients to enhance the management of NSCLC 
patients on targeted therapy.
Keyword: Genomics, lung cancer, targeted therapy
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P3.06-007 CLINICAL FEASIBILITY STUDY OF A NOVEL 
SORTING SYSTEM FOR DETECTING EGFR MUTATIONS 
FROM CAPTURED CIRCULATING TUMOR CELLS IN PATI-
ENTS WITH LUNG CANCER
Takeshi Sawada1, Masaru Watanabe2, Yasuhiro Koh2, Yuu Fuji-
mura3, Hidehito Horinouchi4, Shintaro Kanda4, Yutaka Fujiwara4, 
Hiroshi Nokihara4, Noboru Yamamoto4, Tomohide Tamura4, Fu-
miaki Koizumi1
1Shien-laboratory, National Cancer Center Hospital/Japan, 2Division Of 
Drug Discovery And Development, Shizuoka Cancer Center, Shizuoka/
Japan, 3On-Chip Biotechnologies Co., Ltd./Japan, 4Department Of Inter-
nal Medicine And Thoracic Oncology, National Cancer Center Hospital/
Japan
Background: Circulating tumor cells (CTCs) are cells that originate 
from a primary solid tumor and are found transiting the circulatory 
system. CTCs are expected to provide useful clinical information 
on biology of their primary, as ”liquid biopsy.” We have developed 
a novel cell-sorting system equipped with a disposable microflui-
dic chip (On-chip Sort, On-Chip Biotechnologies, Tokyo, JAPAN). 
At American Association for Cancer Reseach meeting 2013, we 
previously reported about its CTCs enumeration capability when 
performed in a clinical setting. Currently, On-chip Sort enables 
recovery of more CTCs than conventional cell sorting systems for 
further characterization.
Methods: In a preclinical study, PC-9 and H1975 human lung can-
cer cells harboring EGFR mutations (E746_A750del and L858R, 
T790M, respectively) were spiked into the blood from healthy 
donors. After samples were negatively enriched using anti-CD45-
coated magnetic beads, the spiked cancer cells in the samples 
were captured by On-chip Sort. The captured tumor cells were 
subjected to mutation detection by ARMS/Scorpion PCR assay. A 
clinical feasibility study was then conducted in lung cancer patients 
harboring EGFR mutations.
Results: On-chip Sort performed recovery of the spiked PC-9 
and H1975 cancer cells (5 cells in 4 ml of blood) in a preclinical 
experiment. Successively, we were able to detect the EGFR muta-
tions from the captured cells. In a clinical feasibility study, 4 blood 
samples from lung cancer patients harboring EGFR mutation were 
collected and were evaluated. All the samples were successful in 
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Conclusion: In this cohort of patients, there was a paradoxical 
“meaningful” increase in Ki67 index after neoadjuvant chemo-
therapy in ~20% of patients, without a clear association between 
histology or platinum doublet administered. For patients receiving 
neoadjuvant chemotherapy, the Ki67 index decline rate was not as-
sociated with radiographic response. Approximately 1/5 of NSCLC 
may have selection of tumor cells for a higher proliferative index 
when undergoing neoadjuvant platinum-based chemotherapy. 
The effect of this on progression-free and overall survival is being 
evaluated.
Keywords: neoadjuvant chemotherapy, Ki67, paradoxical respon-
se, non-small cell lung cancer
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P3.06-011 THE IMPACT OF E-CADHERIN TRANSCRIP-
TIONAL FACTORS ON THE SURVIVAL OF PULMONARY 
PLEOMORPHIC CARCINOMA
So Miyahara1, Makoto Hamasaki1, Daisuke Hamatake2, Shin-Ichi 
Yamashita2, Takeshi Shiraishi2, Akinori Iwasaki2, Takayuki Shira-
kusa3, Kazuki Nabeshima1
1Department Of Pathology, Fukuoka University Hospital And School Of 
Medicine/Japan, 2Department Of General Thoracic, Breast And Pediatric 
Surgery, Fukuoka University Hospital And School Of Medicine/Japan, 
3Fukuseikai Hospital/Japan
Background: Pleomorphic carcinoma of the lung is a rare epitheli-
al tumor, and its clinicopathological characteristics and prognostic 
factors are still controversial. Up-regulation of E-cadherin repres-
sors is known to increase tumor cell invasion and motility in non-
small cell lung cancer cells. The aim of this study was to clarify the 
clinicopathological characteristics and prognostic factors, such as 
E-cadherin repressors (e.g., Zinc finger E-box-binding homeobox 
[ZEB], Snail, and Twist), in pleomorphic carcinoma.
Methods: We reviewed 2,328 cases of resected lung cancers that 
occurred between 1988 and 2011 and identified 62 patients with 
pulmonary pleomorphic carcinoma. Immunohistochemical staining 
for ZEB, Snail, and Twist was performed, and nuclear expression 
was estimated by the percentage of positive cells. The patients 
were divided into two groups; a diffuse expression group (≥75%) 
or a focal expression group (<75%). Clinicopathological variables 
and the expression of E-cadherin repressors were investigated re-
trospectively to analyze prognostic factors for the disease-specific 
survival rate of 42 patients after lung resection.
Results: The TNM pathological stages of pleomorphic carcinoma 
were classified as follows: 7 (11.2%) cases with stage IA, 15 (24.1%) 
with stage IB, 3 (4.8%) with stage IIA, 20 (32.2%) with stage IIB, 10 
(16.1%) with stage IIIA, 4 (6.4%) with stage IIIB, 3 (4.8%) with stage 
IV. The 5-year disease-specific survival rate after pulmonary resec-
tion was 68.3%. Forty-seven (75.8%) tumors contained at least 10% 
spindle and/or giant cells, and the other fifteen (24.1%) consisted 
entirely of spindle cells and giant cells. An adenocarcinoma com-
ponent was found in 34 (54.8%) cases, a squamous cell carcinoma 
component in 7 (11.2%) cases, an adenosquamous cell carcinoma 
component in 4 (6.4%) cases, and a large cell carcinoma compo-
nent in 2 (3.2%) cases. The pleomorphic carcinoma patients were 
divided into five groups according to the predominant epithelial 
component, and there were no significant differences in the di-
sease-specific survival rate between the groups. Those with a pre-
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P3.06-009 PARADOXICAL INCREASE IN KI67 WITH NEO-
ADJUVANT CHEMOTHERAPY IN NSCLC
Glen J. Weiss1, Judit Moldvay2, Balazs Dome3, Katalin Fabian2, 
Eszter Podmaniczky2, Judit Papay4, Marton Gyulai5, Jozsef Furak6, 
Ildiko Szirtes7, Jizhou Ai1, Ryan Mccabe1, Janine Lobello8, Balazs 
Hegedus3
1Cancer Treatment Centers Of America/United States Of America, 2De-
partment Of Pulmonology, Semmelweis University/Hungary, 3Medical 
University Of Vienna/Austria, 4Ist Institute Of Pathology And Expe-
rimental Cancer Research, Semmelweis University/Hungary, 5County 
Hospital Of Pulmonology/Hungary, 6Department Of Thoracic Surgery, 
Medical University Szeged/Hungary, 72nd Institute Of Pathology, Sem-
melweis University/Hungary, 8The Translational Genomics Research 
Institute/United States Of America
Background: Neoadjuvant chemotherapy is used to help downs-
tage cancer, and is widely used in locally-advanced breast cancer. 
Studies of Ki67 proliferation index in breast cancer have been fairly 
extensively evaluated. Comparison of core and surgical specimens 
in breast cancers without exposure to chemo- or radiotherapy 
revealed technical variation of up to 20% in the Ki67 index score. 
In non-small cell lung cancer (NSCLC), however, little is known 
about the association of rate of change of Ki67 after neoadjuvant 
chemotherapy with radiographic response and clinical outcomes. 
We surveyed NSCLC from patients treated with neoadjuvant che-
motherapy.
Methods: NSCLC patients treated with neoadjuvant chemothe-
rapy were identified from 3 Hungarian hospitals and 1 community 
hospital in the United States. Matched pre-chemotherapy and 
post-surgical resection formalin-fixed, paraffin-embedded (FFPE) 
tumor specimens were collected and the Ki67 index was scored 
under an IRB exemption. We set an absolute difference of 20% 
between pre-chemotherapy and post-resection Ki67 scores as 
“meaningful” to avoid possible technical variation reported in the 
literature. Radiographic response to neoadjuvant chemotherapy by 
RECIST 1.0 criteria was also measured. Fisher’s exact test was used 
to measure the relationship between gender, histology, and type 
of chemo with “meaningful” Ki67 index. Logistic regression was 
used to test the relationship between Ki67 index decline rate and 
outcome subgroup (response/no response). Decline rate was defi-
ned as a ratio of decrease of Ki67 to its level at baseline.
Results: 63 matched cases were identified. 46 cases were analyz-
able for pre-chemotherapy and post-operative Ki67, and chemo-
therapy regimen; 40 cases also had response criteria by RECIST. Of 
the 46 cases, the median patient age was 59 years (range 40-77), 
23 were men, and 30 of 34 had a smoking history. There were 24 
adenocarcinomas and 22 squamous cell carcinomas. Stages I, II, 
III, and IV were 2, 9, 31, and 4; respectively. All but two patients 
received a platinum-doublet, with 24 containing gemcitabine. 5 
patients also received neoadjuvant radiotherapy. The mean Ki67 
index scores were 35% (range 1-100%) pre-chemotherapy and 
32% (0-100%) post-resection. 9 patients (19.6%) had a paradoxical 
“meaningful” increase in Ki67 index after neoadjuvant chemothe-
rapy. Of the 40 patients with RECIST response data, there was 1 
complete response, 34 partial responses, 4 stable diseases, and 
1 disease progression. There were no statistically significant dif-
ferences between gender, histology subtype, or type of platinum 
doublet administered associated with this paradoxical increase. 
There was no statistically significant difference in Ki67 decline rate 
between responders and nonresponders.
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years; 57.1% were male, 96.4% had an Eastern Cooperative On-
cology Group Performance Status of 0–1, 96.4% had stage IV di-
sease, and 94.6% had adenocarcinoma. The response rate, disease 
control rate, and median PFS were 32.2%, 78.6%, and 4.7 months, 
respectively. Of the 38 polymorphisms tested, none were associ-
ated with response or toxicity, but 2 single nucleotide polymor-
phisms (SNPs) (in the gamma-glutamyl hydrolase [GGH 452C>T] 
and methionine synthase [MTR 2756A>G] genes) were significantly 
associated with PFS. Patients harboring the GGH-C452C variant 
had significantly longer PFS (5.6 vs 2.8 months; p < 0.0001) than 
those with the C452T or T452T variants. Further, patients harboring 
the MTR-A2756A variant had significantly longer PFS (5.3 vs 3.7 
months; p = 0.036) than those with the A2756G variant. In additi-
on, among patients with the GGH-C452C variant, those harboring 
the MTR-A2756A variant had significantly longer PFS (5.9 vs 4.3 
months; p = 0.044) than those with the A2756G variant.
Conclusion: SNPs in GGH and MTR seem to predict differences 
in PFS in NSQ-NSCLC patients treated with PEM plus CIS, and a 
combination of these 2 SNPs may predict differences in PFS more 
accurately. These results should be validated in larger, adequately 
designed prospective studies.
Keywords: non-small cell lung cancer (NSCLC), Pharmacogeno-
mics, Polymorphism, pemetrexed
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P3.06-013 ICE COLD-PCR COMBINED WITH NEXT-GE-
NERATION SEQUENCING: INCREASED SENSITIVITY FOR 
HIGH THROUGHPUT DETECTION OF MUTATIONS.
Katherine Richardson, Rui Lin, Ariel Tarrell, Sarah Cherubin, Ben-
jamin Legendre, Jr., Mindy Kuebler, Grant Wu, Phil Eastlake
Transgenomic, Inc/United States Of America
Background: The ICE COLD-PCR (Improved and Complete Enrich-
ment COamplification at Lower Denaturation Temperature PCR) 
technology is capable of high sensitivity mutation detection. The 
ICE COLD-PCR (ICP) reaction contains a reference sequence oligo-
nucleotide (RS-oligo) that hybridizes to both alleles but will dissocia-
te from the mutant strand at the critical temperature for all mutation 
types: point mutations, insertions, deletions and indels. Following 
ICP, samples with mutations present at 0.1% in the original sample 
can be enriched and determined using standard Sanger sequen-
cing. Next-Generation Sequencing (NGS) allows high-throughput 
analysis of somatic mutations in cancer using targeted resequencing 
panels of genes. Thus a broad mutation signature of tumors can be 
determined. However, the level of detection is ~4% for mutations 
unless a higher depth of coverage is used; this comes at the price of 
reducing the number of samples that can be analyzed on a chip. ICP 
enrichment of mutations prior to NGS mimics an increased "depth 
of coverage“ without reducing the throughput per chip.
Methods: Proof of concept experiments were performed using low 
level mutations: KRAS G12R (0.5, 0.1, 0.05%) PIK3CA E542K and 
E545K (1.0, 0.5, 0.1%) and EGFR Exon 19 E746_A750del (0.5, 0.1, 
0.05%). In addition, DNA isolated from FFPE tissues and matched 
plasma were amplified by standard PCR or enriched by ICP and sub-
sequently analyzed for PIK3CA, KRAS, BRAF and EGFR mutations 
using the Ion AmpliSeq Cancer Hotspot Panel on the Ion Torrent 
Personal Genome Machine (PGM) with the Variant Caller Plugin.
dominance of spindle-cell or giant-cell components also showed 
no difference in disease-specific survival. Nuclear ZEB-1 expression 
was positive only in the pleomorphic component. Diffuse expressi-
on of ZEB1 was found in seven patients. Snail and Twist were posi-
tive in epithelial and pleomorphic components, but at various le-
vels; however, expression tended to be higher in the pleomorphic 
component. Thirteen patients had diffuse expression of Snail, and 
eight had diffuse expression of Twist. Using multivariate analysis, 
lymph node metastasis, pleural invasion, and diffuse expression of 
ZEB1 in the pleomorphic component all predicted poorer disease-
specific survival (p=0.007, 0.022, and 0.016, respectively). Nuclear 
ZEB1 expression was higher in cases with lymphatic permeation 
compared to those without lymphatic permeation, but this associa-
tion was not statistically significant (p=0.107).
Conclusion: Several unfavorable prognostic factors for pulmonary 
plemorphic carcinoma have been reported, such as massive ne-
crosis, TNM stages, lymph nodes metastasis, pleural invasion, and 
complete resection. Our current study showed that lymph node 
metastasis, pleural invasion, and diffuse expression of ZEB1 in the 
pleomorphic component suggested a worse prognosis for pulmo-
nary pleomorphic carcinoma. ZEB1 may promote the aggressiven-
ess and invasiveness of this malignant tumor.
Keywords: Lung cancer, pleomorphic carcinoma, ZEB1, survival
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P3.06-012 PHARMACOGENETIC STUDY OF JAPANESE 
PATIENTS WITH ADVANCED NON-SQUAMOUS NON-
SMALL CELL LUNG CANCER TREATED WITH PEMETREX-
ED PLUS CISPLATIN
Hisao Imai1, Toshiaki Takahashi1, Masakuni Serizawa2, Keita 
Mori3, Akira Ono1, Hiroaki Akamatsu1, Tetsuhiko Taira1, Yuki-
ko Nakamura1, Hirotsugu Kenmotsu1, Tateaki Naito1, Haruyasu 
Murakami1, Yasuhiro Koh2, Masahiro Endo4, Takashi Nakajima5, 
Nobuyuki Yamamoto6
1Division Of Thoracic Oncology, Shizuoka Cancer Center/Japan, 2Di-
vision Of Drug Discovery And Development, Shizuoka Cancer Center, 
Shizuoka/Japan, 3Clinical Trial-Coordination Office, Shizuoka Cancer 
Center/Japan, 4Division Of Diagnostic Radiology, Shizuoka Cancer Cen-
ter/Japan, 5Division Of Diagnostic Pathology, Shizuoka Cancer Center/
Japan, 6Third Department Of Internal Medicine, Wakayama Medical 
University/Japan
Background: Pemetrexed (PEM) inhibits multiple enzymes in the 
folate (F) pathway. Several studies show that genetic polymor-
phisms in these enzymes influence the efficacy and toxicity of PEM. 
We aimed to investigate the relationship between genetic poly-
morphisms associated with the F pathway and clinical outcomes 
of Japanese patients with advanced non-squamous non-small cell 
lung cancer (NSQ-NSCLC) treated with PEM plus cisplatin (CIS).
Methods: We analyzed 34 polymorphisms in 14 genes associated 
with the F pathway in NSQ-NSCLC patients treated with PEM plus 
CIS: ABCC11, ADA, ATIC, DHFR, ERCC1, FPGS, GGH, MTHFD1, 
MTHFR, MTR, MTRR, SHMT1, SLC19A1, and TYMS. These polymor-
phisms were compared with clinical outcomes such as response, 
toxicity, and progression-free survival (PFS) using Pearson’s Χ2 test 
and the log-rank test.
Results: All 56 patients were Japanese, with a median age of 62 
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Results:  
ICE COLD-PCR 
Amplification of 
FFPE DNA with 
Sequence Confir-
mation by Sanger 
Sequencing or 
Next Generati-
on Sequencing 
using the Ion 
Torrent PGM 
Gene Mutation in Sample 
% Starting 
Mutant 
% Variant 
Frequen-
cy (San-
ger) 
% Variant 
Frequen-
cy (NGS) 
P-value Co-verage Ref Cov Var Cov 
EGFR Exon 19 #1 E746_A750_Del 0.50% 30 9.1* 1.00E-10 2,000 1,812 182 
#2 E746_A750_
Del 0.10% 10 3* 7.82E-10 2,000 1,940 60 
#3 E746_A750_
Del 0.05% 
Back-
ground 
No Vari-
ant 
KRAS #1 G12R 0.50% 70 69.18 1.00E-10 19,174 5,819 13,264 
#2 G12R 0.10% 10 23.58 1.00E-10 10,004 7,513 2,359 
#3 G12R 0.05% Back-ground 2.86 5.01E-04 11,027 10,603 315 
PIK3CA #1 E542K 1.0% 15 16.48 1.00E-10 28,899 24,113 4,763 
#1 E545K 1.0% 25 24.23 1.00E-10 30,027 22,700 7,275 
#2 E542K 0.5% 10 9.19 1.00E-10 15,680 14,225 1,441 
#2 E545K 0.5% 10 11.78 1.00E-10 15,267 13,405 1,798 
#3 E542K 0.1% Back-ground 2.02 1.00E-10 15,358 15,045 310 
#3 E545K 0.1% Back-ground 3.17 1.00E-10 15,154 14,657 481 
* difficult to de-
tect deletions by 
NGS 
Conclusion: ICP is a flexible technology that results in a PCR pro-
duct enriched for any mutation present in the sample analyzed. 
This upstream enrichment of low level somatic mutations com-
bined with high throughput analysis by NGS brings NGS one step 
closer for use in high throughput screening of circulating mutations 
for patient treatment selection and monitoring of disease.
Keywords: ICE COLD-PCR, cfDNA, next generation sequencing
S1079Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
del of pathological stage and the CCP expression score in order to 
maximize the prognostic utility of both markers.
Methods: Cox proportional hazards models with pathological 
stage and the CCP expression score were created from two data 
sets: 256 patients (190 stage I, 66 stage II) from the Director’s Con-
sortium microarray cohort and 381 adenocarcinomas (337 stage I, 
44 stage II) from a clinical study set analyzed by qPCR. Expression 
microarray data were scaled to adjust for differences in experimen-
tal platforms. The primary outcome measure was cancer-specific 
death, defined as death from lung cancer or death with recurrence 
within five years of surgery. Coefficients for modeling were derived 
from the hazard ratio in the Cox PH model.
Results: Both pathological stage and CCP score were independent 
predictors of lung cancer death in both cohorts. The coefficients 
for pathological stage and CCP score were consistent across both 
data sets and did not differ significantly between the analysis of 
all patients and a subset of untreated patients. A combined score 
(CS) of stage and CCP score (0.33 * CCP score + 0.52 * stage) was 
created from the subset of untreated patients. When applied to 
untreated patients in the clinical ADC cohort, pathological stage 
alone provided estimates of five-year risk of cancer-specific death 
of 12.6% (stage IA), 22.6% (stage IB), 38.4% (stage IIA) and 60% 
(stage IIB). In the same cohort, the combined score could separate 
stage IA patients with five-year risk estimates ranging from 6% to 
24%. Similarly increased discrimination of risk estimates were ob-
served for stage IB (10% to 42%), stage IIA (21% to 63%) and stage 
IIB patients (32% to 75%).
Conclusion: A combination of pathological stage and the CCP 
expression score is a more effective predictor of post-surgical risk 
of cancer-specific death than either marker alone. A more precise 
risk assessment provides better guidance in balancing treatment 
related risks with disease-specific survival.
Keywords: Prognostic Assay, Resectable Lung Adenocarcinoma
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P3.06-016 ALDEHYDE DEHYDROGENASE 1 EXPRES-
SION IN CANCER CELLS COULD HAVE PROGNOSTIC 
VALUE FOR PATIENTS WITH NON-SMALL CELL LUNG 
CANCER WHO ARE TREATED WITH NEOADJUVANT 
THERAPY: IDENTIFICATION OF PROGNOSTIC MICROEN-
VIRONMENTAL FACTORS AFTER CHEMORADIATION
Yoshitaka Zenke1, Genichiro Ishii2, Yuichiro Ohe1, Kaoru Kaseda2, 
Tatsuya Yoshida1, Shingo Matsumoto1, Shigeki Umemura1, Kiyo-
taka Yoh1, Seiji Niho1, Koichi Goto1, Hironobu Ohmatsu1, Takeshi 
Kuwata2, Atsushi Ochiai2
1Division Of Thorcic Oncology National Cancer Center Hospital East/
Japan, 2Division Of Pathology, Research Center For Innovative Oncology, 
National Cancer Center, Hospital East/Japan
Background: Prognostic biomarkers for patients with non-small 
cell lung cancer (NSCLC) who have been treated with neoadjuvant 
therapy have not been fully assessed. Identifying biological pro-
gnostic markers may help to distinguish patients who are likely to 
benefit from additional postoperative chemotherapy. The purpose 
of this study was to analyze prognostic biomarkers in surgically 
resected NSCLC after treatment with neoadjuvant therapy, with 
special reference to the immunophenotypes of both the cancer 
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P3.06-014 POSITIVE PROGNOSTIC IMPACT OF MIR-210 
IN NON-SMALL CELL LUNG CANCER
Marte Eilertsen1, Samer Al-Saad2, Elin Richardsen2, Tom Dønnem1, 
Lill Tove Busund2, Roy M. Bremnes1
1Dept Clinical Medicine, University Of Tromsø/Norway, 2Dept Medical 
Biology, University Of Tromsø/Norway
Background: As non-small cell lung cancer (NSCLC) is a leading 
cause of cancer death, new prognostic and predictive markers are 
highly warranted. miR-210 is an essential regulator of the hypoxia 
pathway. The biological and prognostic importance of miR-210 
has not been thoroughly studied in NSCLC. We aimed to explore 
miR-210 expression in both cancer and tumor stromal cells in a 
large representative NSCLC patient cohort to assess its impact on 
disease-specific survival (DSS).
Methods: Tissue micro arrays (TMAs) were constructed, represen-
ting both cancer cells and tumor stromal cells from 335 unselected 
patients diagnosed with stage I-IIIA NSCLC. In situ hybridization 
was used to evaluate the expression of miR-210.
Results: In univariate analyses, high cancer cell (p=0.039) and high 
stromal cell expression (p=0.008) of miR-210 were both significant-
ly associated with an improved DSS. Co-expression of miR-210 in 
cancer and stromal cells combined was also a positive prognostic 
factor for DSS (p=0.010). In multivariate analysis, miR-210 in stro-
mal cells (p=0.011), and miR-210 co-expressed in cancer and stro-
mal cells (p=0.011) were independent prognosticators for DSS.
Conclusion: High expression of miR-210 in tumor stromal cells, and 
high miR-210 co-expressed in cancer cells and tumor stromal cells 
mediates an independent favorable prognostic impact in NSCLC. 
miR-210 may be a candidate marker for prognostic stratification 
and therapeutic interventions in NSCLC.
Keywords: Prognosis, NSCLC, miR-210
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P3.06-015 INTEGRATED PROGNOSIS IN EARLY STAGE 
RESECTABLE LUNG ADENOCARCINOMA
Edward Kim1, Elisha Hughes2, Alexander Gutin2, Carmen Behrens3, 
Susanne Wagner2, Jerry Lanchbury2, Massimo Barberis4, Ignacio 
Wistuba3
1Levin Cancer Institute/United States Of America, 2Myriad Genetics, 
Inc./United States Of America, 3The University Of Texas MD Anderson 
Cancer Center/United States Of America, 4Istituto Europeo Di Oncolo-
gia/Italy
Background: Treatment decisions in stage I and II resectable lung 
adenocarcinoma (ADC) are heterogeneous due to low efficacy of 
treatment and a high frequency of co-morbidities in the patient 
population. Currently, pathological stage is the main determinant 
of adjuvant treatment recommendations. The cell cycle progressi-
on (CCP) score is a proliferation based expression profile that has 
been shown to add significant prognostic stratification within stage 
I and II patients. We have developed an integrated prognostic mo-
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Background: The insulin-like growth factor (IGF) pathway is in-
volved in the development and progression of many tumours and 
there is growing preclinical evidence that blockade of this pathway 
has anti-tumour effects in NSCLC. IGF receptors (IGFR) are another 
potential target for targeted treatment of NSCLC and a number of 
agents are already undergoing clinical trial. Biomarkers are needed 
to select patients most likely to derive clinical benefit from these 
agents. The downstream pathway components of IGF1R and MET 
activation include PI3K and AKT, which are other potential bio-
markers currently being investigated in this patient cohort. IGF1R 
has also been implicated in acquired resistance to EGFR-TKI treat-
ments. Only a few small retrospective studies have investigated 
the prognostic role of IGF1R in NSCLC and the relationship with 
EGFR mutations is not known.
Methods: IGF1R status was evaluated by chromogenic silver in 
situ hybridization (ISH) and immunohistochemistry (IHC) in tissue 
microarray sections from a retrospective cohort of 264 surgically 
resected NSCLCs and results were compared to clinicopathologi-
cal features and patient survival. Patients were classified as IGF1R 
gene amplification (either presence of tight gene clusters, IGF1R to 
CEN15 ratio ≥ 2, or ≥ 15 copies of IGF1R per cell in ≥ 10% of ana-
lysed cells); high polysomy (≥ 4 copies of IGF1R in ≥ 40% of tumour 
cells); low copy number (< 4 copies of IGF1R in < 40% of cells). 
Patients were also grouped as IGF1R-positve (amplification or high 
polysomy) or IGF1R-negative (low copy number).
Results: High IGF1R gene copy number was identified in 77 cases 
(29.2%) in which there were 32 amplified IGF1R cases (12.1%) and 
45 high-polysomy IGF1R cases (17%). Increased copy number of 
IGF1R was more common in squamous cell carcinomas (SCC) com-
pared to large cell carcinomas (LCC) or adenocarcinomas (ADC) 
(p<0.05). There was no correlation between IGF1R gene copy num-
ber status and other clinicopathological features including patient 
age, gender, smoking status, tumour size, vessel, perineural or 
lymphatic invasion, grade or stage. IGF1R copy number alteration 
in primary tumours was highly correlated with IGF1R copy number 
status in metastatic tumours (p<0.01). 
High IGF1R protein expression was observed in 61/259 (23.6%) 
primary tumours and 14/215 (6.5%) normal adjacent bronchial 
mucosae. High expression of IGF1R protein was significantly asso-
ciated with SCC in comparison with non-SCC primary tumours, as 
well as with lymphatic and vessel invasion. There was a moderate 
correlation between IGF1R copy number status (positive versus 
negative) and IGF1R protein expression (high versus low) (Cramer’s 
V=0.3, p-value <0.001). Both IGF1R copy number status and pro-
tein expression were not associated with patient overall survival in 
univariate analyses (p>0.05). 
Conclusion: High IGF1R gene copy number and its protein ex-
pression are frequent in NSCLC, particularly in SCC. However, 
alterations of IGF1R are not associated with patient prognosis. 
IGF1R gene copy number can readily be assessed in formalin fixed 
paraffin embedded tissue and warrants further investigation as a 
potential biomarker of targeted therapy in NSCLC.
Keywords: in situ hybridisation, immunohistcchemistry, Non-small 
cell lung carcinoma, IGF1R
cells and the stromal cells.
Methods: A series of 66 patients with NSCLC who were treated 
with neoadjuvant chemotherapy, chemoradiotherapy, or radiothe-
rapy followed by complete resection at our hospital between April 
1992 and December 2009 were reviewed. Among the 66 surgically 
resected specimens, case with viable tumor cells remained in the 
specimens were included in this study (n =52). We examined the 
expressions of geminin and cleaved caspase 3 (proliferation and 
apoptosis markers), E-cadherin and vimentin (epithelial mesenchy-
mal transition related molecules), ALDH1 and CD44v6 (Stem cells 
related molecules) in the cancer cells. Furthermore in the stromal 
cells, the expressions of podoplanin and CD90 in cancer associa-
ted fibroblasts (CAFs) and CD204 in tumor associated macropha-
ges (TAMs) were also examined.
Results: The 5-year disease-free survival rate of patients with high 
ALDH1 expression levels in their cancer cells was significantly lower 
than those with a low ALDH1 level (47.3% vs. 21.5%, respectively; 
P =0.023). The expression statuses of geminin, cleaved caspase 3, 
E-cadherin, vimentin, and CD44v6 in the cancer cells had no prog-
nostic impact. The 5-year disease-free survival rate of patients with 
low or high podoplanin and CD90 levels in CAFs and CD204 levels 
in TAMs expression levels were not any prognostic impact in the 
stromal cells (37.9% vs. 29.1%, 33.8% vs. 37.5%, 38.4% vs. 29.0%, P 
=0.90, P = 0.75, P =0.98). In NSCLC without neoadjuvant therapy 
matching for clinical stage and histopathology (case control, n 
=104), the 5-year DFS rate of the patients with a high ALDH1 ex-
pression level was 48.3%, while that of the cases with a low ALDH1 
expression level was 59.8%. The expression of ALDH1 in cancer 
cells was not correlated with the prognosis in NSCLC without 
neoadjuvant therapy (P =0.507). A multivariate analysis identified 
ALDH1 expression in cancer cells as significantly independent pro-
gnostic factors for disease-free survival in patients who received 
neoadjuvant therapy (P =0.045).
Conclusion: The presence of ALDH1-positive cancer cells was an 
independent recurrence predictor in patients who received neoad-
juvant therapy, while CAFs and TAMs did not provide any predic-
tors. Although prospective studies with a larger number of patients 
are required to confirm the prognostic significance of ALDH1 ex-
pression in cancer cells in validation populations with neoadjuvant 
therapy, our results suggest that the immunophenotypes of ALDH1 
expression can serve as a guide to additional treatment after surgi-
cal resection in patients who received neoadjuvant therapy.
Keywords: cancer stem cells, non-small cell lung cancer, Neoadju-
vant therapy, ALDH1
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P3.06-017 DISTINCTIVE INSULIN-LIKE GROWTH FACTOR 
1 GENE COPY NUMBER AND PROTEIN EXPRESSION IN 
NON-SMALL CELL LUNG CANCER
Thang N. Tran1, Christina I. Selinger1, Maija Kohonen-Corish2, 
Brian Mccaughan3, Catherine Kennedy3, Sandra O‘Toole1, Wendy 
A. Cooper1
1Tissue Pathology And Diagnostic Oncology, Royal Prince Alfred Hos-
pital/Australia, 2Kinghorn Cancer Centre, Garvan Institute Of Medical 
Research/Australia, 3Cardiothoracic, Royal Prince Alfred Hospital/
Australia
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P3.06-019 MDM2 309T>G POLYMORPHISM AND RISK 
OF LUNG CANCER IN A JAPANESE POPULATION
Seiichi Kakegawa1, Kimihiro Shimizu2, Yasuaki Enokida2, Osamu 
Kawashima1, Mitsuhiro Kamiyoshihara,2, Masayuki Sugano2, Ta-
kashi Ibe2, Toshiteru Nagashima2, Yoichi Ohtaki2, Jun Atsumi2, Kai 
Obayashi2, Izumi Takeyoshi2
1Thoracic Surgery, National Hospital Organization Nishigunma Hos-
pital/Japan, 2Thoracic And Visceral Organ Surgery, Gunma University 
School Of Medicine/Japan
Background: The MDM2 protein plays an important role in regu-
lating cell proliferation and apoptosis by interaction with multiple 
proteins including p53 and Rb. c.309 (rs2279744) polymorphism 
(T>G) in the MDM2 promoter has been shown to result in higher 
levels of MDM2 RNA and protein. In order to evaluate the associa-
tion of the MDM2 309T>G polymorphism and lung cancer risk, we 
carried out a case-control study in a Japanese population.
Methods: The MDM2 genotypes were determined in 469 lung 
cancer patients and in 682 healthy control subjects using Smart 
Amplification Process (SmartAmp). Statistical adjustment was 
made for sex and age.
Results: The distribution of the MDM2 309T>G genotypes was 
not significantly different between control and overall lung cancer 
cases. Subgroup analysis of KRAS G to T transversion adenocarci-
noma indicated that G/G genotype of SNP309 may be associated 
with lung cancer carcinogenesis (adjusted OR = 2.42 95% C.I. = 
1.01-5.82 p = 0.05) compared to T/T + T/G genotypes. G/G geno-
type has lower-level exposure to cigarette smoke than T/T + T/G 
genotypes (p=0.03) among squamous cell lung cancer patients. 
There was however no effect of either polymorphism on age at 
diagnosis of lung cancer or on overall survival.
Conclusion: Our results indicate that the MDM2 309T>G polymor-
phism is not significantly associated with lung carcinogenesis but 
may be associated with smoking related cancer of the lung.
Keywords: Lung cancer, MDM2, KRAS, case-control study
POSTER SESSION 3 - PROGNOSTIC AND PREDICTIVE BIOMARKERS  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.06-020 PROGNOSTIC MARKERS FOR MESOTHELIO-
MA PATIENTS TREATED WITH INDUCTION CHEMOTHE-
RAPY FOLLOWED BY EXTRAPLEURAL PNEUMONECTO-
MY
Byron Bitanihirwe1, Mayura Meerang1, Emanuela Felley-Bosco2, 
Martina Friess1, Alex Soltermann3, Burkhardt Seifert4, Holger 
Moch3, Rolf Stahel2, Walter Weder1, Isabelle Opitz1
1Division Of Thoracic Surgery, University Hospital Zurich/Switzerland, 
2Laboratory Of Molecular Oncology, University Of Zurich/Switzerland, 
3Institute Of Surgical Pathology, University Hospital Zurich/Switzer-
land, 4Institute For Social And Preventive Medicine, University Of Zu-
rich/Switzerland
Background: Multimodal treatment provides the best outcome for 
some but not all malignant pleural mesothelioma (MPM) patients. 
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P3.06-018 ECT2 OVEREXPRESSION AND GENE ALTE-
RATION ARE ASSOCIATED WITH THE OUTCOME OF 
EARLY-STAGE LUNG ADENOCARCINOMA
Yuko Minami1, Yoshihiko Murata2, Reika Iwakawa3, Jun Yokota3, 
Masayuki Noguchi1
1Faculty Of Medicine, University Of Tsukuba/Japan, 2Graduate School 
Of Comprehensive Human Sciences, University Of Tsukuba/Japan, 
3Division Of Genome Biology, National Cancer Center Research Institu-
te/Japan
Background: In order to evaluate gene abnormality in lung ade-
nocarcinoma at an early stage, genomic DNAs of six in situ ade-
nocarcinomas (Ad) and nine small but invasive adenocarcinomas 
(INVAd) were examined by array-comparative genomic hybridiza-
tion. Finally, 3q26 was detected as a significantly amplified region 
in INVAd relative to in situ Ad. Among the genes located at 3q26, 
we selected the epithelial cell transforming sequence 2 oncogene 
(ECT2) and examined it for abnormality in lung Ad, since ECT2 is 
related to Rho-specific exchange factors and cell cycle regulators, 
and is also thought to have an important role in the regulation of 
cytokinesis.
Methods: The clinical implications of ECT2 abnormality were 
examined by quantitative real-time genomic PCR (qPCR) and im-
munohistochemistry (IHC) using 158 cases of varies types of LAd, 
resected at Tsukuba University Hospital. The results were verified 
by cDNA microarray and 10k SNP array using another set of early-
stage LAds, resected at the National Cancer Center Hospital.
Results: qPCR and IHC analyses revealed overexpression of ECT2 
in INVAd, and this was correlated with the MIB-1 index. ECT2 
overexpression was significantly associated with lymph node me-
tastasis, pathological stage, vascular invasion and the histological 
subtype of Ad. Patients with LAd overexpressing ECT2 showed an 
unfavorable outcome in terms of both disease-free and overall sur-
vival (Figure). These results were verified using another set of 144 
early-stage Ads resected at the National Cancer Center Hospital. 
Conclusion: ECT2 is a new marker that can be used for prognosti-
cation of patients with early-stage LAd.
Keywords: early stage lung adenocarcinoma, new prognostic 
marker, ECT2
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reveal the EGFR expression and EGFR expression may also change 
during chemotherapy.
Methods: EGFR expression in diagnostic biopsies and resection 
specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 
treated with surgery without preceding chemotherapy (OP-group) 
and from 65 NSCLC patients stage T1-3N0-2M0 (NAC-group) tre-
ated with preoperative carboplatin and paclitaxel were analyzed 
regarding EGFR expression to evaluate the concordance of EGFR 
expression between samples.
Results: No significant change in EGFR expression H-score was 
observed when comparing serial samples from either the OP-
group (p=0.934) treated with surgery or the NAC-group (p=0.122) 
treated with preoperative chemotherapy. Discordance between 
tumors dichotomized according to EGFR expression (high: H-
score≥200; low: H-score<200) in diagnostic biopsies and immedi-
ate resection specimens was 25% in the OP-group and 33% in the 
NAC-group (p=0.628).
Conclusion: EGFR expression in 25% of diagnostic biopsies may 
potentially not be accurate compared to the prevailing pattern in 
the whole tumor based on the larger resection specimens. This 
may potentially be an obstacle for proper use of antibodies tar-
geting the EGFR in NSCLC. EGFR expression does however not 
change significantly during paclitaxel and carboplatin and rebiop-
sies in order to decide on anti-EGFR antibody therapy following 
chemotherapy does not seem warranted.
Keywords: NSCLC, biomarker, EGFR
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P3.06-022 POPULATION BASED STUDY OF THE PRE-
VALENCE OF EGFR MUTATIONS IN NON-SMALL CELL 
LUNG CANCER (NSCLC)
Birgit G. Skov1, Estrid Høgdall2, Paul Clementsen3, Mark Krasnik4, 
Klaus R. Larsen5, Jens B. Sørensen6, Anders Mellemgaard7
1Pathology, Rigshospitalet, University Hospital Copenhagen/Denmark, 
2Pathology, Herlev University Hospital/Denmark, 3Pulmonary, Gentofte 
University Hospital/Denmark, 4Rigshospitalet, University Hospital, 
Copenhagen/Denmark, 5Pulmonary, Bispebjeg University Hospital/
Denmark, 6Oncology, Rigshospitalet, University Hospital, Copenhagen/
Denmark, 7Oncology, Herlev University Hospital, Copenhagen Universi-
ty/Denmark
Background: Activating mutations in the EGFR gene identifies 
NSCLC patients sensitive to treatment with EGFR tyrosine kinase 
inhibitors. EGFR mutations are more prevalent in Asians compared 
to Caucasian. However, estimates of mutation frequencies are only 
available from selected patient cohorts and the incidence in an un-
selected Caucasian population is unknown. This study assess the 
prevalence of EGFR mutations in an unselected population based 
cohort, and the correlation between mutation and gender, age, 
ethnicity, smoking habits, as well pathological data.
Methods: Patients diagnosed with NSCLC June 1, 2010 - Sep-
tember 30, 2011 in a well-defined population of 1.7 million in the 
Capital Region, Denmark, were included in this single center study. 
The type and location of the diagnostic material was registered. All 
specimens were pretreatment, no residual tumors were included. 
Smoking data were also available. The mutation analyses were 
Therefore the identification of prognostic markers helping to se-
lect patients remains a subject of key importance. Frequent loss 
of NF2 tumor suppressor gene, a regulator of Hippo pathway and 
mammalian target of rapamycin (mTOR) has been well documented 
in MPM. We recently observed loss of expression of phosphatase 
and tensin homologue (PTEN), a tumor suppressor gene of the 
phosphatidylinositol 3-kinase (PI3K)/mTOR pathway, in 62% of 
MPM patients. In this regard, increased activity of these pathways 
stemming from loss of abovementioned tumor suppressor genes 
may serve as potential prognosticator as well as therapeutic target. 
Here we aim to assess prognostic significance of PI3K/mTOR and 
Hippo pathways for MPM patients treated with a multimodal ap-
proach.
Methods: Large cohort of MPM patients uniformly treated with 
induction chemotherapy followed by extrapleural pneumonectomy 
was employed in this study. Tissue micro arrays were constructed 
composing of paired samples from patients (n = 153) collected 
pre- and post-induction chemotherapy. All tissues were evaluated 
for apoptotic index (cleaved caspase-3) and proliferation index 
(Ki-67). Expression levels of biomarkers of PI3K/mTOR (PTEN, 
p(phosphorylated)-mTOR and p-S6) and Hippo signaling pathway 
(nuclear-YAP and nuclear-Survivin) were evaluated by immunohisto-
chemistry and correlated with overall survival (OAS) and progressi-
on free survival (PFS).
Results: Survival analysis showed that high p-S6 expression and 
high Ki-67 index in samples of treatment naïve patients was asso-
ciated with shorter PFS (p = 0.02 and p = 0.04, respectively). High 
Ki-67 index after chemotherapy remained associated with shorter 
PFS (p = 0.03) and OAS (p = 0.02). Paired comparison of marker 
expression in samples prior and post induction chemotherapy 
revealed that decreased cytoplasmic PTEN as well as increased p-
mTOR expression was associated with a worse OAS (p = 0.04 and 
0.03, respectively). No correlation was observed between expressi-
on level of nuclear-YAP with PFS or OAS.
Conclusion: Ki-67 proliferation index has prognostic value for 
MPM patients treated with multimodality approach in when ana-
lyzed both pre- and post- induction chemotherapy specimens. 
Our results further reveal the prognostic significance of expression 
changes of PI3K/mTOR pathway components during induction 
chemotherapy. If confirmed, these data suggest PI3K/mTOR pa-
thway to be a target for selected MPM patients.
Keywords: mesothelioma, Prognostic markers, Multimodal thera-
py, tissue microarray
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P3.06-021 CHANGES IN EPIDERMAL GROWTH FACTOR 
RECEPTOR EXPRESSION DURING CHEMOTHERAPY IN 
NON-SMALL CELL LUNG CANCER
Jan N. Jakobsen1, Eric Santoni-Rugiu2, Jens B. Sorensen1
1Oncology, National University Hospital/Denmark, 2Pathology, National 
University Hospital/Denmark
Background: Antibodies targeting epidermal growth factor recep-
tor (EGFR), such as cetuximab, may potentially improve outcome 
in non-small cell lung cancer (NSCLC) patients with high EGFR 
expression. The EGFR expression may be heterogeneously distri-
buted within tumors and small biopsies may thus not accurately 
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blocks, pleural effusions, and sera. The diagnostic performance of 
pleural effusion was investigated.
Results: Among the 57 patients with malignant effusion, 37 pa-
tients were NSCLC, 11 were SCLC and 9 were extrapulmonary 
cancer. Twenty patients including 11 SCLC and 9 extrapulmonary 
cancer showed negative for EGFR mutational status. Among the 
37 NSCLC patients, the diagnostic performance of pleural effusion 
compared with the combination of tumor tissue and cell blocks 
showed 89% sensitivity, 100% specificity, positive predictive value 
of 100%, and negative predictive value of 95% by PNA clamping, 
and 67% sensitivity, 90% specificity, positive predictive value of 
75%, and negative predictive value of 86% by directing sequenci-
ng. A patient in whom an EGFR mutation was identified in pleural 
effusion only by PNA clamping showed a significant response to 
EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment.
Conclusion: Pleural effusion had a diagnostic performance for the 
detection of EGFR mutations in NSCLC that was comparable to 
that of tumor tissues and cell blocks. The diagnostic performance 
of PNA clamping was good compared with that of direct sequen-
cing. A more sensitive and accurate detection of EGFR mutations 
would benefit patients by allowing a better prediction of the res-
ponse to EGFR-TKI treatment.
Keywords: EGFR mutation, Direct sequencing, PNA clamping, 
malignant pleural effusion
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P3.06-024 RETROSPECTIVE ANALYSIS OF REBIOPSIES 
 IN A COHORT OF EGFR-MUTATED NSCLC-PATIENTS 
WITH TKI-RESISTANCE; INCIDENCE OF THE T790M  
MUTATION.
Justine L. Kuiper1, Erik Thunnissen2, Danielle A.M. Heideman2, 
Marinus A. Paul3, Egbert F Smit1
1Pulmonary Diseases, VU University Medical Center/Netherlands, 2Pa-
thology, VU University Medical Center/Netherlands, 3Cardiothoracic 
Surgery, VU University Medical Center/Netherlands
Background: Epidermal Growth Factor Receptor mutated (EGFR+) 
NSCLC patients have a median progression free survival (PFS) of 
approximately 12 months when treated with EGFR-tyrosine kinase 
inhibitors (TKI). One of the resistance mechanisms described is the 
T790M mutation. This mutation is reported in 49-65% of patients 
who are rebiopsied at disease progression. Here, we report on 
the incidence of T790M mutation in a cohort of patients who were 
sequentially rebiopsied.
Methods: EGFR+ patients or with TKI-response>24weeks and 
progressive disease on TKI’s were retrospectively analysed. Pati-
ents should have had at least 2 separate biopsies. All biopsies and 
treatments were collected from the medical record and patholo-
gical reports. Survival was calculated according to Kaplan-Meier. 
Overall survival (OS) was calculated from date of 1st diagnosis until 
death or June 2013, which ever was first
Results: 68 patients with 2 biopsies or more were available 
for analysis. In the first biopsy at TKI-resistance; T790M muta-
tion was detected in 34 patients (50,0%). 26/68 patients had 
later biopsies available; showing gain and loss of T790M in 
later biopsies (figure 1). Overall development of T790M was 
investigated by therascreen EGFR RGQ PCR Kit (detection of 29 
somatic mutations in the EGFR oncogene, Qiagen) (n =1121) or 
direct sequencing (n=62). Twenty-two patients were analyzed with 
both methods.
Results: 658 men and 598 women were included. All but 4 were 
Caucasians. 6.2% were never smokers, 38.9% were ex- smokers 
and 54.9% were current smokers. 1161 (92.4%) patients had materi-
al sufficient for mutation analysis. More than 50% malignant tumor 
cells were available for analyses in 68%, 76% and 56% of the his-
tological, cytological clot, and cytological smear material respec-
tively. Manual macro dissection to ensure this high concentration 
of tumor cells was done on 32%, 4%, and 10% of the histological, 
cytological clots, and cytological smears material, respectively. 
Cytological material was used for 38 % of the mutation analyses. 
5.4 % of tested patients harbored mutation in the EGFR gene 
(4.3% men/ 6.7 % women). The majority of mutations (55 cases= 
87%) were activating mutations (29 exon 19 deletions, 24 L858R 
mutations and 2 G719X mutations), 3 were rare mutations (two 
L861Q and one S768I) with unclear clinical response to TKI, five 
were insertions in exon 20 (resistance mutation). Three of the mu-
tations (all exon 19 deletions) were detected in the three included 
Asian women. 8.0 % of adenocarcinomas, 1.9% of squamous cell 
carcinomas and one single case of adenosquamous cell carcinoma 
were mutated. No other tumor types were mutated. DNA yield 
was similar whether extracted from cytological or histological sam-
ples and these material types yielded similar mutation percentages 
(6.55% in cytology and 4.66% in histology of material analyzed). 
29.4%, 4.4% and 2.9 % of never, ex- and current smokers, respec-
tively, were mutated (p<0.001). No significantly difference between 
ex- and current-smokers was observed. Mutation status was not 
related to age.
Conclusion: EGFR mutations analysis on cytological as well as on 
histological material was possible in 92% of patients with NSCLC. 
5.4% of the patients harbored EGFR mutation. Adenocarcinomas 
were mutated more often (8.0%) than squamous cell carcinomas 
(1.9%). Mutations were found in never smokers as well as in former 
and current smokers. No difference in gender and age regarding 
mutation status was observed.
Keywords: EGFR mutations, Cytology, population based, NSCLC
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P3.06-023 USEFULNESS OF PLEURAL EFFUSION FOR 
THE DETECTION OF EGFR MUTATION BY USING DIRECT 
SEQUENCING AND PNA CLAMPING
Seung Joon Kim
Internal Medicine, The Catholic University Of Korea/Korea
Background: Pleural fluid samples are useful when tumor tissues 
are not available for mutation analysis. Moreover, the advantages 
of using pleural fluid are that it is easily accessible, can be sampled 
by relatively non-invasive methods, and can be repeatedly samp-
led. Approaches for examining molecular biomarkers in body fluids 
such as effusion may be clinically helpful in predicting the respon-
se to EGFR-TKI treatment.
Methods: Fifty-seven patients with malignant pleural effusion 
were enrolled in the study. EGFR mutations were assessed by 
direct sequencing and PNA clamping using tumor tissues, cell 
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Conclusion: 57.4% of patients developed T790M. OS in patients 
developing T790M was longer than in patients not developing 
T790M, however the difference was not significant. Sequential 
data show that some patients ‘loose’ the T790M later on in the 
course of the disease. Data from this cohort suggests that T790M 
development is a dynamic process.
Keyword: NSCLC EGFR T790M rebiopsy
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P3.06-025 T790M MUTATION ASSOCIATED WITH BET-
TER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT 
IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RE-
SISTANCE TO EGFR-TKI
Shengxiang Ren1, Wei Li2, Aiwu Li3, Xiaoxia Chen2, Guanghui Gao2, 
Yayi He4, Xuefei Li5, Caicun Zhou6
1Shanghai Pulmonary Hospital, Tongji University/China, 2Department 
Of Medical Oncology, Tongji University Affiliated Shanghai Pulmonary 
Hospital/China, 3Outpatient Department, Tongji University Affiliated 
Shanghai Pulmonary Hospital/China, 4Department Of Medical Onco-
logy, Shanghai Pulmonary Hospital, Tongji University Medical School 
Cancer Institute, Tongji University School Of Medicine/China, 5De-
partment Of Lung Cancer And Immunology, Tongji University Medical 
School Cancer Institute/China, 6Department Of Medical Oncology; Lung 
Cancer And Immunology Laboratory, Shanghai Pulmonary Hospital, 
Tongji University; Tongji University Medical School Cancer Institute/
China
Background: The strategy for EGFR-TKI acquired resistance inclu-
ding continuous EGFR-TKI with chemotherapy or local therapy or 
chemotherapy alone. The aim of this study was to investigate the 
association of T790M mutation status with the efficacy of different 
modalities after acquired resistance to EGFR-TKI.
Methods: From Mar 2011 to Mar 2013, the advanced NSCLC pati-
ents who performed a rebiopsy after acquired resistance to EGFR-
TKI in Shanghai Pulmonary Hospital were included into this study, 
Scorpion ARMS was used to detected the EGFR mutation status. 
SPSS 13.O was used to perform the statistical analysis.
Results: 53 patients were enrolled in the study with a median age 
of 51.2 years old. 45.3% (25/53) were females and 54.7% (29/53) of 
patients had T790M mutation. Among them, 16 people with local 
disease progression received local therapy combined with TKI 
therapy, while 21 with a slow progress received chemotherapy plus 
TKI therapy. The median progression-free survival time (PFS1) of all 
patients according to RECIST criteria was 11.8 months. The median 
progression-free survival time (PFS2) of patients who received con-
tinuous EGFR-TKI treatment was 3.5 months (95% CI 2.689-4.311). 
Patients with T790M mutation had significantly longer PFS2 than 
those without T790M mutation (6.3 vs 3.0 months, p = 0.001), while 
there were no significant differences found in PFS1 between the 
two groups (13.0 vs 8.5 months, p = 0.999).
Conclusion: NSCLC patients who had T790M mutation after ac-
quired resistance to EGFR-TKI benefited more from the continuous 
EGFR-TKI treatment and should be recommend to adopt this mo-
dality.
Keywords: T790M mutation, NSCLC, Accquired resistance, Treat-
ment
57.4% (39/68). 7 patients had >3 biopsies available (figure 2). 
Patients developing T790M had numerically longer medi-
an OS of 3.8 years (range 2.8 – 4.9) as compared to median 
OS in T790M-patients (2.5 years, range 1.0 – 3.9) (P = 0.204).
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ed in first line of treatment. Patients with low nuclear TS expression 
showed prolonged overall survival and better response to therapy. 
Such preliminary results define TS assessment as a potential tool 
which may select the most appropriate group of patients to be 
treated with pemetrexed.
Keywords: thymidylate synthase, non-small cell lung cancer, pe-
metrexed
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P3.06-027 A COMPARISON OF FISH AND IMMUNOHIS-
TOCHEMISTRY IN THE DETECTION OF ALK REARRAN-
GEMENT IN LUNG ADENOCARCINOMA
John Le Quesne1, Manisha Maurya2, David Gonzalez De Castro2, 
Sanjay Popat3, Andrew Wotherspoon4, Andrew Nicholson1
1Department Of Histopathology, Royal Brompton Hospital/United King-
dom, 2Centre For Molecular Pathology, The Royal Marsden Hospital/
United Kingdom, 3Department Of Oncology, Royal Marsden Hospital/
United Kingdom, 4Histopathology, The Royal Marsden Hospital/United 
Kingdom
Background: Personalised treatments for lung cancer are being 
increasingly employed. Around 4% of pulmonary adenocarcino-
mas have rearrangements of the ALK gene resulting in oncogenic 
fusion proteins. Such cases are sensitive to the small molecule 
tyrosine kinase inhibitor Crizotinib, and detection of the ALK rear-
rangement is crucial to the treatment of these patients. Currently 
the only approved test for the detection of ALK-positive NSCLC is 
FISH. Various immunohistochemical assays have been proposed 
as alternatives or screening tools, which are cheaper, quicker and 
easier to perform and interpret than FISH. Validation of these im-
munohistochemical tests is therefore important.
Methods: 15 FISH positive cases were obtained from local archives 
at the Royal Marsden and Royal Brompton Hospitals, with accom-
panying data on crizotinib therapy and clinical response. A further 
14 FISH negative and FISH uncertain cases were also retrieved. 3 
antibodies were optimised for immunohistochemical detection of 
ALK: D5F3, marketed by Ventana and using their proprietary auto-
mated system, ALK1 (Dako), and 5A4 (Abcam). All three antibodies 
were applied to sections from the archival cases. Antibodies were 
semiquantitatively scored on their intensity (0-3) and proportion of 
malignant cells stained (0-100%). Cutoffs for positivity/negativity 
were set by ROC analysis to optimise correct classification.
Results: Positivity according to the Vysis FISH assay (i.e. approp-
riately abnormal FISH signal in at least 15% of cells) was taken as 
the gold standard. The Ventana assay (D5F3) was markedly more 
intense but showed higher background than the other two antibo-
dies. ROC analysis of staining intensity showed that the Ventana 
and Dako antibodies should be considered positive when staining 
is of ‚moderate‘ intensity or above. The Abcam assay was discri-
minatory when any positivity was seen. Scoring of proportion did 
not improve specificity or sensitivity with any of the antibody tests. 
Subsequent analyses were of intensity scoring. Taking all cases 
together, all 3 antibodies were highly specific (100%) and sensitive 
(Ventana 86%, Abcam 79% and Dako 71%). In excision specimens, 
all 3 assays showed sensitivity of 83%. In cytology and small biopsy 
specimens, Ventana performed the best (specificity of 88% com-
pared to 75% for Dako and 63% for Abcam) although the numbers 
are small. No ‘false positive’ (-ve FISH, +ve IHC) cases were seen; 
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P3.06-026 THYMIDYLATE SYNTHASE (TS) MRNA AND 
PROTEIN EXPRESSION IN ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH 
PEMETREXED-BASED THERAPY.
Valentina Monica1, Silvia Novello1, Michele Milella2, Tiziana Va-
vala‘1, Sabrina Vari2, Marco Lo Iacono1, Simone Busso1, Gianluca 
Fora1, Mauro Papotti1, Giorgio V. Scagliotti1
1Department Of Oncology, University Of Turin/Italy, 2Division Of Medi-
cal Oncology A, Regina Elena National Cancer Institute/Italy
Background: In NSCLC, higher Thymidylate Synthase (TS) levels 
have been reported in both squamous and large cell carcinomas 
compared to adenocarcinoma. In clinical practice, Pemetrexed, a 
potent antifolate inhibitor of TS, showed a selective benefit in pati-
ents with "non-squamous“ NSCLC. Two retrospective studies have 
shown that low TS protein levels are associated with better clinical 
outcome in NSCLC patients treated with pemetrexed. Aim of this 
study was to explore, in a series of advanced stage IV patients 
receiving pemetrexed-based regimens in first line of treatment, the 
association between TS mRNA and protein expression with overall 
survival (OS) and therapeutic response.
Methods: Two series of histologically confirmed non squamous-
NSCLC, assessed in formalin-fixed and paraffin embedded speci-
mens from patients treated with pemetrexed-based regimens were 
collected: the first series at San Luigi Hospital (n=64), the second 
series at Regina Elena National Cancer Institute (n=8). Due to the 
limited amounts of tissue specimens available, total RNA extrac-
tion was possible in 52 out of 72 cases. TS protein expression was 
performed using immunohistochemistry (mouse monoclonal TS106 
antibody) and scored through H-SCORE method, considering 
both staining intensity (0 no staining; +1 weak; +2 moderate; or +3 
strong) and percentage of tumor cells stained, resulting in semi-
quantitative H-scores ranging from 0 to 300. TS nuclear and cyto-
plasmic staining, respectively, were separately scored. Statistical 
analyses were performed using the STATISTICA10 software.
Results: The differential H-SCORE assessment showed a strong 
importance of TS localisation for clinical outcome prediction: in 
Cox regression analysis, a statistically significant association was 
observed between nuclear TS expression and OS (p < 0.009) indi-
cating that lower nuclear TS expression levels were associated with 
longer OS. In addition, lower nuclear TS levels were significantly 
associated with a better response to therapy (p<0.001). On the 
contrary, TS cytoplasmic staining did not affect patients’ survival 
or clinical response (p>0.05). Four subgroups of patients, based 
on the dichotomized low/high TS expression in both nucleus and 
cytoplasm, were obtained: both high, both low, nucleus high/
cytoplasm low and nucleus low/cytoplasm high. Significant diffe-
rences in overall survival among these four groups were detected 
(p=0.017), confirming the strong and selective influence of nuclear 
TS, as compared to cytoplasmic TS, expression in clinical outcome. 
Moreover, Chi2 test revealed a significant association between low 
nuclear TS and partial response to pemetrexed treatment, inde-
pendently of cytoplasmic TS expression (p<0.001). No correlation 
between TS protein expression data and clinico-pathological data 
(age, gender) were identified. TS gene expression analyses are 
ongoing.
Conclusion: This retrospective study suggests that TS protein 
expression, selectively assessed at nuclear level, has a potential 
predictive role in advanced stage IV patients, receiving pemetrex-
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This includes defining the population to be tested, timing, and the 
tests to be performed. This may be facilitated by including more 
information on diagnostic sample requisitions, such as clinical 
suspicion of lung cancer primary (versus metastasis from another 
site), other cancer history, and other samples collected (and tested) 
previously or planned (e.g. planned resection). Pathologists need 
to incorporate routine EGFR, ALK testing into diagnostic lung 
cancer algorithm. This and greater clinical information on sample 
requisitions will minimize unnecessary tissue sections and allow the 
most efficient use of available tumour tissue for molecular testing. 
Incremental laboratory funding is required throughout the Cana-
dian public healthcare system in order to provide the current stan-
dard of molecular testing required for NSCLC. Turnaround times 
need to be clearly established and monitored. Implementation of 
the College of American Pathologists (CAP) guidelines for trans-
port from diagnostic lab to molecular testing lab (3 days), and tur-
naround for test results (10 days) will also improve the proportion 
of patients with test results available at initial consultation. Finally, 
feedback to clinicians, including sample quality, volume, whether 
or not testing was successful, and molecular results is necessary in 
a timely manner.
Keywords: non-small cell lung cancer, EGFR, Biomarker testing, 
Non-small cell lung cancer, EGFR, Biomarker testing
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P3.06-029 PREDICTIVE ROLE OF SERUM TUMOR MAR-
KERS IN NSCLC PATIENTS TREATED WITH ERLOTINIB
Ondrej Fiala1, Milos Pesek2, Jindrich Finek1, Lucie Benesova3, Ma-
rek Minarik3, Zbynek Bortlicek4, Ondrej Topolcan5
1Department Of Oncology And Radiotherapy, Medical School And 
Teaching Hospital In Pilsen, Charles University In Prague/Czech Repu-
blic, 2Department Of Tuberculosis And Respiratory Diseases, Medical 
School And Teaching Hospital In Pilsen, Charles University In Prague/
Czech Republic, 3Center For Applied Genomics Of Solid Tumours (CE-
GES), Genomac Research Institute/Czech Republic, 4Institute Of Biosta-
tistics And Analyses, Masaryk University/Czech Republic, 5Department 
Of Nuclear Medicine - Immunoanalytic Laboratory, Medical School And 
Teaching Hospital In Pilsen, Charles University In Prague/Czech Repu-
blic
Background: Erlotinib is an epidermal growth factor receptor 
(EGFR) tyrosine-kinase inhibitor. Clinical trials proved its efficacy in 
patients with advanced-stage NSCLC. Although, activating EGFR 
gene mutations are currently the strongest predictor of erlotinib 
efficacy, the majority of NSCLC patiens harbor wild-type EGFR 
gene and moreover there is still a large proportion of patients in 
whom it is not feasible to acquire an adequate tissue for EGFR 
mutation analysis. We conducted this retrospective study aiming 
to prove the predictive role of tumor markers in patients with 
advanced-stage NSCLC treated with erlotinib.
Methods: 144 patients with advanced-stage (IIIB, IV) NSCLC were 
treated with erlotinib (150 mg daily). Pretreatment serum levels 
of CEA, CYFRA 21-1, NSE and TK were assessed. Comparison of 
patients’survival (PFS and OS) according to the level of assessed 
tumor markers was performed using the log-rank test.
Results: Median PFS and OS for patients with normal CEA levels 
was 2.9 and 16.1 vs. 1.9 and 8.6 months in patients with high CEA 
levels (p = 0.046 and p = 0.116). Median PFS and OS for patients 
the only disparity between FISH and IHC were ‚false negative‘ 
cases. Two cases were FISH-positive but universally IHC-negative 
(with all 3 assays). Of these, one was treated with crizotinib, and 
failed to respond.
Conclusion: IHC is a highly specific (100%) and sensitive (71%-
86%) test for ALK rearrangement in archival FFPE tumour tissue. In 
this study of 15 ALK-rearranged tumours, the Ventana D5F3 assay 
performed the best, despite having relatively high background 
staining. Occasional cases are FISH-positive but IHC-negative. 
One such case was not responsive to Crizotinib, further supporting 
IHC as a test predictive of drug response. IHC has the potential to 
replace FISH for the detection of candidates for Crizotinib therapy. 
However, further work is required to direct the treatment of tu-
mours with discordant FISH and immunohistochemical tests.
Keywords: ALK, FISH, IHC, Crizotinib
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P3.06-028 APPROACH TO BIOMARKER TESTING:  
PERSPECTIVES FROM VARIOUS SPECIALTIES
Natasha Leighl1, Peter Ellis2, Sunil Verma3
1Princess Margaret Hospital/Canada, 2Mcmaster University/Canada, 
3University Of Toronto/Canada
Background: Currently, biomarker testing for lung cancer is not 
uniformly integrated into the Canadian public healthcare system, 
despite its clear importance for patient outcomes. In order to 
better understand the current practice pattern for lung cancer 
biomarker testing, we assessed physician perspectives by specialty 
and region.
Methods: A national survey of Canadian specialists was conducted 
to understand their perspective on biomarker testing in lung can-
cer. An 11-item survey was developed to assess current practice 
and challenges related to biomarker testing. The survey was sent 
to 375 specialists (150 medical oncologists, 75 pathologists, 150 
respirologists/thoracic surgeons) with a focus or interest in the 
management of lung cancer.
Results: The overall response rate for the survey was 36%, (38% of 
medical oncologists, 24% of pathologists, and 40% respirologists). 
It is understood that knowing tumour genotyping results at the 
time of the initial medical oncology consultation impacts patient 
outcome and influences the treatment decision (98%). To date, 
medical oncologists most commonly initiate molecular testing 
(67%), however, most respondents suggested a shared model for 
initiating the testing involving medical oncologists and patholo-
gists is needed. The current perception is that less than two-thirds 
of patients have testing results available at the time of initial medi-
cal oncology consultation. Barriers identified to routine testing for 
all advanced lung cancer patients include cost, lack of funding for 
molecular testing, tissue availability and the quality of the tumour 
sample.
Conclusion: There was clear agreement that biomarker testing is 
important in determining the most appropriate initial treatment for 
patients with advanced NSCLC. There is a need for national con-
sensus on who should initiate molecular testing. Moving forward, 
clear clinical guidance for pathologists needs to be established for 
molecular testing as part of the lung cancer diagnostic process. 
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(demonstrated by IF). CTCs and CT images were assessed in 19 
pts after at least two CHT cycles; the best response was a partial 
response (PR) in 2 pts, progressive disease (PD) in 3 pts and stable 
disease (SD) in 13 pts. The CTC number varied with the tumor size 
in 77.8% (14/18) of pts; decreased CTC counts were observed in 
87.5% (7/8) of pts with reduced tumor size, whereas increased CTC 
counts were found in 70% (7/10) of pts with increased tumor size. 
Notably, variations in CTC count and tumor size were concordant 
in 100% (5/5) of pts achieving a PR or with PD as the best response.
Conclusion: This study demonstrates the feasibility of isolating 
CTCs in all advanced lung ADK pts using a low-cost, size-based 
technique. Interestingly, the concordance between the CTC ana-
lysis and CT suggests that CTCs may represent an early predictive 
marker of disease outcome. To our knowledge, this is the first stu-
dy suggesting a relationship between CTC variation and treatment 
response in lung cancer.
Keywords: pemetrexed, NSCLC, Circulating TUmor Cells, RECIST 
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P3.06-031 MRNA AND SPLICE VARIANT ANALYSIS IN 
ENDOBRONCHIAL LINING FLUID COLLECTED BY BRON-
CHOSCOPIC MICROSAMPLING IN PROXIMITY OF PUL-
MONARY NODULES
Nicolas C. Kahn1, Michael Meister2, Ralf Eberhardt1, Thomas Mu-
ley2, Philipp Schnabel3, Felix Herth1, Holger Sueltmann4, Ruprecht 
Kuner4
1Pulmonary And Respiratory Critical Care Medicine, Thoraxklinik At 
Heidelberg University Hospital/Germany, 2Translational Research, 
Thoraxklinik At Heidelberg University Hospital/Germany, 3Sektion 
Thoraxpathologie, Pathologisches Institut/Germany, 4Unit Cancer Geno-
me Research, Division Of Molecular Genetics, German Cancer Research 
Center And National Center Of Tumor Diseases/Germany
Background: Molecular biomarkers in tissues and body fluids 
represent a promising source to improve cancer diagnostics. Bron-
choscopic Microsampling (BMS) of endobronchial epithelial lining 
fluid (ELF) is a potent method to investigate potential biomarkers 
in lung diseases. Recent studies report that mRNA derived from 
ELF can be used to improve the differentiation of malignant and 
benign pulmonary nodules. Tenascin C (TNC) is an important com-
ponent of the extracellular matrix involved in tissue remodeling 
and cell signaling. It has been reported that TNC is differentially 
expressed in malignant pulmonary nodules. We investigated whe-
ther specific splice variations of TNC are differentially expressed 
in ELF collected by the BMS method in proximity of pulmonary 
nodules.
Methods: ELF was collected by the BMS method from subseg-
mental bronchi close to the indeterminate pulmonary nodule and 
from the contralateral lung. Diagnosis was confirmed by transbron-
chial biopsy or surgery. In this study 176 ELF samples were inclu-
ded from a total of 88 patients (65 NSCLC and 23 benign cases) 
with indeterminate pulmonary nodules detected by computed 
tomography. Quantitative real-time PCR (RT-PCR) assays were used 
to detect different TNC variant patterns.
Results: All patients underwent BMS without complications. Quan-
titative RT-PCR was reliably applied to all ELF samples. A signifi-
with normal CYFRA 21-1 levels was 3.4 and 23.8 vs. 1.9 and 6.1 
months in patients with high CYFRA 21-1 levels (p < 0.01 and p < 
0.01). Median PFS and OS for patients with normal NSE levels was 
2.1 and 9.8 vs. 1.1 and 3.8 months in patients with high NSE levels 
(p = 0.051 and p = 0.022). Median PFS and OS for patients with 
normal TK levels was 2.1 and 23.7 vs. 2.0 and 8.5 months in pati-
ents with high TK levels (p = 0.110 and p = 0.037).
Conclusion: The study proved that high pretreatment levels of 
CEA, CYFRA 21-1 and NSE predict low efficacy of erlotinib treat-
ment in patients with advanced-stage NSCLC. Assessment of the-
se tumor markers is a good predictive tool for erlotinib treatment 
efficacy especially for those patients with unknown EGFR mutation 
status.
Keyword: NSCLC, tumor marker, prediction
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P3.06-030 CIRCULATING TUMOR CELLS AS A NOVEL 
PREDICTIVE MARKER IN PATIENTS WITH ADVANCED 
ADENOCARCINOMA OF THE LUNG TREATED WITH PLA-
TINUM AND PEMETREXED
Francesco Grossi, Anna Truini, Carlo Genova, Erika Rijavec, Clau-
dio Sini, Giulia Barletta, Giovanni Burrafato, Maria Giovanna Dal 
Bello, Simona Coco, Angela Alama
Lung Cancer Unit, National Institute For Cancer Research/Italy
Background: Circulating tumor cells (CTCs) are cells that have 
spread from the primary tumor into the bloodstream, and they play 
a crucial role in the development of distant metastases. CTCs have 
been detected in several cancers and associated with aggressive 
disease. The aim of this study was to evaluate the correlation bet-
ween the numeric variation of CTCs in the blood of patients (pts) 
with advanced adenocarcinoma (ADK) of the lung during chemo-
therapy (CHT) and the radiological response to explore their po-
tential role as an early predictive indicator of treatment response. 
Methods: Peripheral blood samples and computed tomography 
(CT) scans were obtained before any treatment (baseline) from 
25 pts with advanced ADK who were candidates for first-line CHT 
(platinum-based combination with pemetrexed). Blood samples 
were collected every two CHT cycles, and radiological responses 
were concomitantly assessed by CT according to the RECIST v. 
1.1 criteria. CTCs were isolated from blood and diluted in a buffer 
containing formaldehyde to lyse red blood cells and fix CTCs using 
a filtration-based device (ScreenCell®, France) to sort CTCs by size. 
CTCs were isolated by size using a microporous membrane filter 
composed of polycarbonate material containing circular pores that 
are calibrated (7.5±0.36 µm) and randomly distributed throughout 
the filter (1×105 pores/cm2). At the end of filtration, hematoxylin and 
eosin (HE) staining and immunofluorescence (IF) using CK7 were 
performed to enumerate and characterize the CTCs. Moreover, va-
riations in the CTC count were compared with tumor size variations 
observed in CT scans. 
Results: Baseline CTC counts and CT scans were obtained from 
25 pts, including 18 males and 7 females, with a median age of 68 
(range: 45-81) years. H&E staining revealed that the CTCs were 
morphologically compatible with tumor cells and were present 
in all 25 pts at baseline (range: 2-25 CTCs/ml). Furthermore, the 
epithelial origin of the CTCs was confirmed by CK7 positivity 
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P3.06-033 SUBCELLULAR LOCALIZATION OF NRF2 PRO-
MOTES TUMOR AGGRESSIVENESS, POOR OUTCOME, 
AND UNFAVORABLE RESPONSE TO CHEMOTHERAPY 
VIA INCREASED IKKΒ STABILITY IN NSCLC
Huei Lee1, Po-Lin Lin2, Tzu-Chin Wu3, Jeng-Yuan Wu4, Ming-Ching 
Lee5
1Graduate Institute Of Cancer Biology And Drug Discovery, Taipei Me-
dical University/Taiwan, 2Institute Of Medicine, Chung Shan Medical 
University/Taiwan, 3Department Of Internal Medicine, Chung Shan Me-
dical University/Taiwan, 4Buddhist Tzu Chi General Hospital/Taiwan, 
5Department Of Surgery, Aichung Veteran General Hospital/Taiwan
Background: Dysfunction of Nrf2-Keap1 interaction by Keap1 or 
Nrf2 mutations may promote tumor growth, drug resistance, and 
poor outcomes in non-small cell lung cancer (NSCLC). However, 
both gene mutations are uncommon in Asian patients, suggesting 
that a different mechanism might be involved in lung tumor pro-
gression via altering Nrf2-Keap1 pathway.
Methods: Two strategies—treatment of NO scavenger and a 
nuclear location sequence (NLS)-mutated Nrf2 expression vector 
transfected into Nrf2-knockdown stable clones—were used to 
explore whether IKKβ could be elevated by cytoplasmic Nrf2 and 
promotes cell invasion. The prognostic values of cytoplasmic Nrf2 
and IKKβ mRNA levels in tumors from NSCLC patients were esti-
mated by Kaplan Meier and Cox regression model.
Results: We showed that mutated p53 upregulated Nrf2 transcrip-
tion by de-repression of Sp1 binding to the Nrf2 promoter. Inte-
restingly, cytoplasmic Nrf2 expression was markedly increased 
in p53-mutated cells compared with p53 wildtype cells due to 
a decrease in iNOS-mediated NO production. The stability of 
IKKβ protein was also increased by the interaction of cytoplasmic 
Nrf2 with Keap1, which blocked IKKβ degradation by the Keap1-
mediated proteasomal pathway. An increase in IKKβ expression 
due to cytoplasmic Nrf2 was responsible for soft agar growth and 
invasion capability. Positive cytoplasmic Nrf2 immunostaining or 
high IKKβ mRNA expression in tumors from NSCLC patients may 
predict poorer overall survival and relapse free survival. Moreover, 
patients with cytoplasmic Nrf2 positive tumors had unfavorable 
responses to cisplatin-based chemotherapy.
Conclusion: Cytoplasmic Nrf2 may promote tumor aggressiven-
ess, poor outcome, and unfavorable response to chemotherapy in 
NSCLC.
Keywords: Lung cancer, Nrf2, IKKβ, clinical outcome
cant increase of TNC transcript variants close to malignant nodules 
was observed for most of the used qPCR assays. A better accuracy 
was observed for two protein-coding variants and an untranslated 
transcript indicating a distinct tumor-associated TNC variant pat-
tern and a lower intraindividual variance.
Conclusion: Our results indicate that the analysis of individual TNC 
variants might improve the accuracy in detecting malignant nodu-
les compared to the detection of whole TNC transcripts.
Keywords: Bronchoscopic Microsampling, Endobronchial Lining 
Fluid, Pulmonary Nodules
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P3.06-032 EVALUATION OF ANAPLASTIC LYMPHOMA 
KINASE (ALK) REARRANGEMENTS USING ALK/EML4 
TRICHECK FLUORESCENCE IN SITU HYBRIDISATION 
(FISH) IN NON-SMALL CELL LUNG CANCERS (NSCLC) 
AND ITS UTILITY FOR EQUIVOCAL CASES.
Christina I. Selinger1, Wendy A. Cooper1, Trina Lum1, Anthony 
Gill2, Sandra O‘Toole1
1Tissue Pathology And Diagnostic Oncology, Royal Prince Alfred Hospi-
tal/Australia, 2Pathology, Palms, Royal North Shore Hospital/Australia
Background: Accurate assessment of ALK gene rearrangement in 
NSCLCs is critical to identify patients likely to respond to crizotinib. 
Currently, the gold standard for identifying ALK gene rearrange-
ments is FISH and the Abbott Molecular ALK break apart probe 
is commonly used. We evaluated a new ALK/EML4 TriCheck FISH 
Probe for the detection of ALK rearrangements and confirmation 
of EML4 as the inversion partner. In addition, we evaluated its use 
as an ancillary FISH probe for use in cases with subtle, equivocal or 
atypical ALK FISH patterns.
Methods: ALK FISH was prospectively performed on 29 routine 
diagnostic cases using the ALK/EML4 TriCheck Probe (ZytoVision) 
and the Vysis ALK Break Apart FISH Probe (Abbott Molecular). ALK 
immunohistochemistry (IHC) was performed using the 5A4 clone 
antibody (Novocastra) and D5F3 clone antibody (Cell Signaling 
Technology).
Results: Both probes were concordant in all cases, except for one 
case which showed an atypical signal pattern using the Abbott 
Molecular ALK probe. This case was technically negative using 
standard scoring criteria for the Abbott probe, despite positive 
ALK IHC, but was confirmed as positive using the ZytoVision Tri-
Check probe. Two additional cases which were equivocal (10-16% 
ALK rearrangement), were confirmed to be positive for ALK rear-
rangement using the ALK/EML4 TriCheck probe. Of the 10 ALK 
rearranged cases, 4 showed evidence of EML4 translocation.
Conclusion: The ALK/EML4 TriCheck FISH Probe is useful for the 
detection of ALK gene rearrangements, including those involving 
EML4 as the translocation partner, especially for borderline cases 
or cases displaying atypical signal patterns, where an additional 
unique ALK FISH probe can provide further confirmation of rear-
rangement.
Keyword: ALK rearrangement, FISH, ALK/EML4
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bined detection of APE1 and ERCC1 expression might better 
individualize the efficacy of chemotherapy and improve survival in 
advanced NSCLC.
Keywords: cisplatin resistance, APE1, BRCA1, ERCC1, ADVANCED 
NSCLC, Customized Chemotherapy
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P3.06-035 STUDY OF THE CORRELATIONS BETWEEN 
SNPS IN ANGIOGENIC GENES AND TREATMENT RES-
PONSE/ OUTCOME IN PATIENTS WITH ADVANCED NS-
CLC (NON-SQUAMOUS HISTOLOGY) TREATED IN FIRST 
LINE WITH CARBOPLATIN, PACLITAXEL AND BEVACI-
ZUMAB (CPB). THE ANGIOMET STUDY.
Bartomeu Massuti1, Jose Luis Gonzalez Larriba2, Eloisa Jantus 
Lewintre3, Delvys Rodriguez Abreu4, Oscar Juan5, Maria Sanchez-
Ronco6, Manuel Domine7, Mariano Provencio8, Javier Garde9, 
Ramon Garcia-Gomez10, Inmaculada Maestu11, Ramon Perez Car-
rion12, Angel Artal13, Christian Rolfo14, Josefa Terrasa15, Juana Ora-
mas16, Ramon De Las Peñas17, Lioba Ferrara18, Mar Soto3, Natividad 
Martinez-Banaclocha19, Olbia Serra20, Javier De Castro21, Rafael 
Rosell22, Carlos Camps23
1Hospital General De Alicante/Spain, 2Hospital Clínico San Carlos/
Spain, 3Fundación Para La Investigación Del Hospital General Universi-
tario De Valencia/Spain, 4Hospital Insular Gran Canaria/Spain, 5Hos-
pital La Fe/Spain, 6Statistics, University Of Alcala De Henares/Spain, 
7Fundación Jimenez Diaz/Spain, 8Hospital Puerta De Hierro/Spain, 
9Hospital Arnau De Vilanova/Spain, 10Hospital Gregorio Maranon/
Spain, 11Hospital Dr. Peset/Spain, 12Hospital Quirón/Spain, 13Hospital 
Miguel Servet/Spain, 14Clínica Rotger/Spain, 15Hospital Son Espases/
Spain, 16Hospital Universitario De Canarias/Spain, 17Hospital Provin-
cial De Castellón/Spain, 18Hospital Ntra. Sra. De La Candelaria/Spain, 
19Hospital General De Elche/Spain, 20Hospital General De L‘hospitalet/
Spain, 21Hospital La Paz/Spain, 22Catalan Institute Of Oncology/Spain, 
23Htal. Gral. Univ. Valencia- Universitat De Valencia/Spain
Background: It has been demonstrated that the addition of beva-
cizumab to paclitaxel plus carboplatin (CPB) in the treatment of 
advanced NSCLC improves survival. Even though, there is a high 
variability in drug efficacy between patients, leading to different 
response rates. ANGIOMET is an exploratory study promoted by 
the SLCG in advanced NSCLC, non-squamous histologies (NS-
NSCLC) treated in first line with a combination scheme based in 
CPB, designed to investigate the relationship between angiogenic 
mediators and the outcome and response to treatment. The pri-
mary end-point was progression-free survival (PFS), and the secon-
dary end-points are the follows: OS, response-rates and toxicity 
profiles.
Methods: In this multicentric study, patients with stage IIIB/IV 
NS-NSCLC (ECOG status 0–2) were included and treated in first 
line with CPB. Peripheral blood samples were collected before 
treatment administration and DNA was purified from the leukocyte 
fraction. Ten SNPs of VEGF-pathway genes were genotyped in 186 
samples by RT-PCR in duplicate. SNPs were related to PFS and OS 
(Kaplan-Meir method, log-rank test) and to response rate.
Results: 10 SNPs were determined in 186 DNA samples. In this 
preliminary analysis there were data from 108 patients valid for 
PFS and OS analysis. Baseline characteristics of the patients were: 
median age, 63 years [37-80]; 74.5% male; 94.1% ECOG PS 0-1; 
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P3.06-034 DUAL-FUNCTION PROTEIN APE1 IS A NOVEL 
BIOMARKER TO PREDICT TUMOR RESPONSE IN CHINE-
SE PATIENTS WITH STAGES IIIB TO IV NON-SMALL-CELL 
LUNG CANCER.
Zheng Li, Wei Guan, Yi Qing, Shi-Heng Zhang, Yu Peng, Yan-Li 
Xiong, Meng-Xia Li, Xue-Qin Yang, Zhaoyang Zhong, Dong Wang
Cancer Center, Daping Hospital And Research Institute Of Surgery, 
Third Military Medical University/China
Background: More than 70% of patients with lung cancer are 
diagnosed with advanced-stage, with short survival times. The 
discovery of epidermal growth factor receptor (EGFR) mutations is 
a major scientific breakthrough; tyrosine kinase inhibitor (TKI) treat-
ment for patients with EGFR mutations reported a median overall 
survival of more than 2 years. Nevertheless, chemotherapy has 
steadfastly remained the most validated therapies in non-small-cell 
lung cancer (NSCLC) not only for vast majority of patients without 
EGFR mutations, but for those with EGFR-TKI resistance. There are 
many influence factors in platinum resistance, among them DNA 
repair genes have been extensively explored. Excision repair cross 
complementing 1 (ERCC1) and/or breast cancer susceptibility gene 
1 (BRCA1) is generally associated with sensitivity to platinum, but 
the results were inconclusive and controversial. Apurinic/apyrimidi-
nic endonuclease 1 (APE1), a bifunctional AP endonuclease/redox 
factor, is important in DNA repair and redox signaling, may be 
associated with chemoresistance.
Methods: In total, 172 patients with advanced NSCLC who recei-
ved platinum-based doublet chemotherapy, ages 34 to 84 years 
at diagnosis from 2007 to 2012 were enrolled into this study. We 
evaluated the impact of APE1, BRCA1, ERCC1 expression levels 
on response to platinum-based chemotherapy and median pro-
gression-free survival (mPFS) and/or median overall survival (mOS) 
outcomes, and protein expression levels were determined by im-
munohistochemistry (IHC).
Results: The mPFS was 8.8 months, mOS 12.8 months. A partial 
treatment response was found in 55 patients (31.98%). No signi-
ficant association was found between BRCA1 protein expression 
and response rate, mPFS or mOS. Interestingly, patients whose 
tumors did not express APE1 had 50.00% response rate compared 
to 25.00% whose tumors expressed the protein (OR 0.34; 95% CI 
0.17-0.69; P=0.002). Patients negative for APE1 had a significantly 
longer mPFS (10.3 vs. 8.0 months, P=0.016), but not mOS (17.1 vs. 
10.9 months, P=0.263), than those positive for APE1. Patients ne-
gative for ERCC1 expression experienced better response to che-
motherapy (OR 0.36; 95% CI 0.18-0.72; P=0.003), longer mPFS (9.8 
vs. 6.8 months, P=0.001), and longer mOS (14.4 vs. 10.3 months, 
P=0.011). In particular, the expression of ERCC1 had a positive 
trend of correlation with APE1 expression (r2=0.23, P<0.01), and 
patients negative for both APE1 and ERCC1 had significantly high-
er response rate (OR 0.18; 95% CI 0.07-0.45; P<0.001), longer mPFS 
(12.0 vs. 6.8 months, P<0.001) and mOS (18.8 vs. 10.1 months, 
P=0.010), than those positive for both APE1 and ERCC1. Multivaria-
te analysis adjusting for possible confounding factors showed that 
negative APE1 and/or ERCC1 expression was a significantly favo-
rable factors for mPFS (HR 1.86, P=0.002 and HR 1.83, P=0.001; 
respectively) and mOS (HR 2.02, P=0.002 and HR 1.78, P=0.007; 
respectively).
Conclusion: The results suggest that dual-function protein APE1 
may be a novel prognostic and predictive factor, and the com-
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that classifies Non Small Cell Lung Cancer (NSCLC) patients in 2 
categories VS Good or VS Poor according to the overall survival 
(OS) of patients treated with EGFR-TKIs. Recently, the prospective 
Phase III PROSE study showed that the VS algorithm is predictive 
of differential OS benefit for erlotinib (E) vs second line standard 
chemotherapy (CT): VS Poor classified patients had worse OS on E 
compared to CT, while there was no significant difference between 
treatments outcome in the VSG group. Aim of the current study 
was to evaluate if baseline Standardized Uptake Value (SUV) of 
FDG-PET may help to optimize treatment choice between E or CT 
IN VS Good classified pts.
Methods: Plasma samples were collected before the beginning of 
E from metastatic NSCLC patients. Acquired spectra were classi-
fied according to the VS algorithm. The FDG-PET was performed 
tha day before the beginning of E. Survival curves were estimated 
using the Kaplan-Meier method.
Results: Thirty eight NSCLC patients on E therapy with the fol-
lowing characteristics were analyzed: median age 62 years old, 
63% were males, 53% had adenocarcinoma histology, response 
rate was 26%, median OS 10 mos and TTP 3.4 mos. Twenty-six 
(68%) were classified as VS Good, 12 (32%) as Poor. TTP and OS for 
VS Good and Poor were 4.1 vs 2.1 mos (HR 0.86, log-rank p=0.6) 
and 11.1 vs 4.1 mos (HR 0.45,log-rank p=0.02), respectively. All VS 
Poor classified patients had SUV ≥ 7 and had the worst TTP and 
OS; VS Good classified patients with baseline SUV level ≥ 7 had 
worse OS (10 mos) and worse TTP (2.1 mos) compared to those 
who were VS Good and had SUV<7 (OS 16 mos) (TTP 13.8 mos).
Conclusion: The study confirmed that VS Poor classified patients 
had significantly shorter OS than those classified as VS Good. Pati-
ents with VS Good profile and with baseline FDG-PET SUVs levels 
<7 may benefit more from EGFR-TKIs than VS Good patients with 
higher FDG-PET SUV, suggesting that FDG-PET analysis may be a 
clinically useful tool for EGFR-TKIs therapy selection.
Keywords: NSCLC, EGFR-TKIs, Proteomic
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P3.06-037 EXPRESSION OF STEMNESS FACTORS OCT4 
AND NANOG IN RESECTABLE NON-SMALL CELL LUNG 
CANCER.
Raquel Requena1, Eloisa Jantus Lewintre1, Rut Lucas2, Rosa Farràs3, 
Miguel Martorell4, Marta Usó1, Sandra Gallach1, Ana Blasco5, Car-
los Camps6
1Molecular Oncology Laboratory, General University Hospital Research 
Foundation/Spain, 2Departamento De Historia De La Ciencia Y Docu-
mentación, Universitat De Valencia/Spain, 3Oncogenic Signalling, Prince 
Felipe Research Centre/Spain, 4Pathology Department, Universitat De 
Valencia/Spain, 5Department Of Medical Oncology, General University 
Hospital Of Valencia/Spain, 6Htal. Gral. Univ. Valencia- Universitat De 
Valencia/Spain
Background: Epithelial–mesenchymal transition (EMT) and ex-
pression of stemness features are key issues for tissue invasion 
and metastasis during cancer development. OCT4 and NANOG 
are homebox transcription factors essential to the self-renewal of 
stem cells and are expressed in several cancers. The role of OCT4/
NANOG signaling in tumorigenesis and as biomarkers in non-small 
cell lung cancer (NSCLC) is still elusive.
14% never-smokers, 100% caucasian; 89.7% adenocarcinomas, 
2.8% large cell carcinomas; median number of CPB cycles was 4. 
There was no response assessment in 27 patients (25%), 30.6% 
PR, 31.5% SD and 13.0% PD. The SNP rs833061 (CC) in VEGFA 
correlated with lower response rates to CPB than the other geno-
types (p=0.07). SNPs in KRAS and VEGFR2 were associated with 
PFS and/or OS in our cohort. The KRAS SNP rs10842513 (TT+CT) 
was associated with shorter PFS compared with the CC genotype 
(median: 5.39 vs 6.81 months; p=0.04, respectively). The VEGFR2 
SNP rs2071559 (AA) was significantly associated with longer PFS 
and OS (Table 1). No significant differences in PFS or OS were ob-
served according to other SNPs analyzed. Table 1: PFS and OS for 
VEGFR2 SNPrs2071559.  
PFS 
% Median 
(months) 
95%CI p 
VEGFR2 
(rs2071559) 
AA 25.6 9,408 5,084 - 13,732 0.01 
GG+AG 74.0 5,724 4,902 - 6,546 
OS 
% Median 
(months) 
95%CI p 
VEGFR2 
(rs2071559) 
AA 25.6 NR ---- 0.001 
GG+AG 74.0 12,270 8,760 – 15.780 
Conclusion: These preliminary data indicate that genetic variation 
in VEGFR2, SNP rs2071559 variant AA, is associated with prog-
nosis in advanced NS-NSCLC patients treated with CPB and may 
have predictive implications as biomarkers in patients treated with 
chemotherapy with bevacizumab. On behalf of the Spanish Lung 
Cancer Group (SLCG)
Keywords: angiogenesis, Bevacizumab, biomarker, advanced  
stage
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P3.06-036 PROSPECTIVE CORRELATIVE STUDY OF FDG-
PET SUV AND PROTEOMIC PROFILE (VERISTRAT) OF 
NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS 
TREATED WITH ERLOTINIB
Chiara Lazzari1, Marcello Tiseo2, Vanesa Gregorc1, Fiorenza Lat-
teri3, Massimo Ippolito4, Sergio Baldari4, Sebastiano Cosentino4, 
Maura Scarlattei5, Silvia Foti1, Heinrich Roder6, Roberto Bordona-
ro3, Andrea Ardizzoni2, Hector J Soto Parra7
1Oncology, Ospedale San Raffaele/Italy, 2Medical Oncology Unit, Uni-
versity Hospital Of Parma/Italy, 3Medical Oncology, Garibaldi Hospital/
Italy, 4Nuclear Medicine, Cannizzaro Hospital/Italy, 5Medicina Nucleare, 
Azienda Ospedaliero Universitaria/Italy, 6Biodesix Inc/United States Of 
America, 7University Hospital Policlinico Vittorio Emanuele/Italy
Background: VeriStrat (VS) is a multivariate protein serum test 
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Results: Based on previous results, the most important features 
distinguishing between neoplastic and benign pe were: cardiac 
tamponade on echocardiographic examination, HR>90 beats/min 
on ECG, enlarged mediastinal lymph nodes (>1cm) on chest CT 
scan, CEA> 5ng/ml in pe, Cyfra 21-1>95 ng/ml in pe, bloody pe. 
The sensitivity, specificity, PPV and NPV are listed in table 1.  
Parame-
ter Diag. 
value 
HR>90/
min 
Car-
diac 
tam-
pona-
de 
CEA>5 
ng/ml 
(pe) 
Cyfra 
21-
1>95 
ng/ml 
(pe) 
Bloo-
dy pe 
Lymph 
no-
des>1 
cm (CT) 
sensitivity 0.82 0.67 0.63 0.64 0.86 0.93 
specificity 0.55 0.65 0.94 0.95 0.57 0.70 
PPV 0.60 0.61 0.91 0.93 0.66 0.66 
NPV 0.79 0.70 0.71 0.71 0.80 0.94 
 
The original scoring system (-3 up to + 3 points) was developed 
based on PPV and NPV of the above mentioned parameters. The 
diagnostic value of the proposed scoring system was high, ( ROC: 
AUC 0.926 95%CI 0.85-0.96) and exceeding the value of single 
parameters (at a cut off of 0 points – sensitivity was 0.84 and speci-
ficity - 0.91).
Conclusion: Assessment of the probability of malignant pe accor-
ding to the proposed original scoring system was able to improve 
the diagnostic algorithm based on single parameters, thus indi-
cating pts in whom more invasive diagnostic methods should be 
applied to recognize malignant pe.
Keywords: neoplastic pericardial effusion, probability, scoring 
system, Lung cancer
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P3.06-039 EXPRESSION OF MUCIN 1 IN NON-SMALL 
CELL LUNG CANCER: RELATIONSHIP BETWEEN IM-
MUNOHISTOCHEMISTRY, TUMOUR CHARACTERISTICS 
AND SURVIVAL
Paul L. Mitchell1, Shane Battye2, Thomas John3, Carmel Murone4, 
Simon Knight5, Gerd Bode6, Sonia Quaratino7, Andreas Schröder7, 
Khashayar Asadi2
1Ludwig Medical Oncology Unit, Olivia Newton-john Cancer And 
Wellness Centre, Austin Health/Australia, 2Department Of Anatomi-
cal Pathology, Austin Health/Australia, 3Ludwig Institute For Cancer 
Research/Austin Health/Australia, 4Ludwig Institute For Cancer Re-
search/Australia, 5Austin Hospital/Australia, 6Consultant To Merck 
Serono/Germany, 7Merck Kgaa/Germany
Background: Mucin 1 (MUC1), a glycoprotein highly expressed in 
many malignancies, is being explored as an antigen for immuno-
therapy. How best to measure MUC1 expression in non-small cell 
lung cancer (NSCLC) and its prognostic value in NSCLC are under 
discussion.
Methods: Tissue microarrays (TMAs) were constructed using tri-
plicate 1mm cores of formalin-fixed paraffin-embedded tumour 
and stained with 214D4 (recognizes protein core) and MA695 
(recognizes carbohydrate epitope) anti-MUC1 antibodies. TMAs 
Methods: mRNA was isolated from 177 frozen samples, corres-
ponding to tumoral and normal parenchyma of NSCLC patients 
in resectable-stage. OCT4 and NANOG relative expression was 
determined by RTqPCR using hydrolysis probes. Expression levels 
were normalized using GUSB as endogenous housekeeping gene. 
Statistical significance was considered for p<0.05.
Results: Patient’s median age was 64 years [26-87], 87.6 % were 
males, 75.2 % presented performance status (PS=0) and 47.3% 
had squamous histology. We found a significant positive correla-
tion between OCT4 and NANOG expression (r2 =0.61 p<0.0001, 
Pearson test). Higher levels of expression of NANOG were related 
to poor differentiation grade (p= 0.04). Survival analysis revealed 
that there is a trend to a poorer progression free survival in the 
subgroup of patients with higher levels (> median) of expression of 
OCT4 levels
Conclusion: The transcription factor OCT4 may have a role as 
prognostic biomarker in resectable NSCLC. (Supported in part by 
ISCIII (PI12/02838), RTICC (RD12/0036/0025), Ministry of Economy 
and Competitiveness and SEOM Grants 2012)
Keywords: OCT4, NANOG, early-stage NSCLC, biomarker
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P3.06-038 NEW SCORING SYSTEM ASSESSING THE 
PROBABILITY OF MALIGNANCY AS THE CAUSE OF LAR-
GE PERICARDIAL EFFUSION IS ABLE TO IMPROVE THE 
DIAGNOSTIC ALGORITHM OF NEOPLASTIC PERICARDI-
TIS.
Monika Szturmowicz1, Witold Tomkowski2, Anna Pawlak-Cieslik3, 
Agnieszka Skoczylas4, Katarzyna Blasinska5, Juliusz Gatarek6, 
Renata Langfort7
1I Dept. Of Lung Diseases, National Institute Of Tuberculosis And Lung 
Diseases/Poland, 2Cardio-Pulmonary Intensive Care Unit, National 
Institute Of Tuberculosis And Lung Diseases/Poland, 3Outpatients 
Clinic/Poland, 4Medical Centre Pulawska/Poland, 5Dept. Of Radiology, 
National Institute Of Tuberculosis And Lung Diseases/Poland, 6Dept. Of 
Thoracic Surgery, National Institute Of Tuberculosis And Lung Disea-
ses/Poland, 7Dept. Of Pathology, National Institute Of Tuberculosis And 
Lung Diseases/Poland
Background: Neoplastic pericarditis is found in 60-80% of patients 
(pts) with large pericardial effusion (pe) (>2 cm on echocardiogra-
phy). The most frequent causes of neoplastic pe are metastatic 
lung or breast cancer. Malignant pe is combined with high relapse 
rate after pericardiocentesis and poor prognosis. Early recognition 
of malignant pe and intensive local (+/-) systemic treatment is able 
to improve life expectancy. Nevertheless in 30-40% of pts the 
malignant cause of pe is not recognized during the first episode 
of disease. The aim of the study was to introduce the new scoring 
system assessing the probability of malignant pe in the pts requi-
ring pericardial fluid drainage due to large pe/tamponade.
Methods: 146 pts, median age 57 years (21-88), 80 with benign 
cause of pe, 66 with neoplastic cause of pe ( positive pe cytology 
or neoplastic infiltration in pericardial biopsy specimen) treated in 
the National Institute of Tuberculosis and Lung Diseases in 1982 - 
2008 entered the study. Metastatic lung cancer was diagnosed in 
67% of neoplastic pe.
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P3.06-040 CHARACTERIZATION OF PD-L1 EXPRESSION 
AND ASSESSMENT OF ASSOCIATION WITH TUMOR 
HISTOLOGY AND GENE EXPRESSION STATUS IN PRET-
REATMENT NON-SMALL CELL LUNG CANCER (NSCLC) 
TUMOR SPECIMENS
Christopher T. Harbison, John F. Kurland, John Cogswell, Xiaolan 
Hu, Xia Han, Christine E. Horak, H David Inzunza, James F. Novot-
ny, Jason S. Simon, Maria N. Jure-Kunkel
Bristol-Myers Squibb/United States Of America
Background: The immune checkpoint receptor programmed 
death-1 (PD-1) negatively regulates T-cell activation. In a phase 1 
study, nivolumab (PD-1 blocking antibody) delivered durable re-
sponses in patients with advanced NSCLC, melanoma, and renal 
cell carcinoma. Immunohistochemistry (IHC) analysis suggested 
association between pretreatment tumor PD-1 ligand (PD-L1) ex-
pression and response to nivolumab in patients with melanoma 
(Grosso ASCO 2013 abstract 3016; Topalian New Engl J Med. 
2012;366:2443). There is little published information associating 
PD-L1 expression with gene profiles, mutational status, or patient 
characteristics in NSCLC. Such data may be relevant in understan-
ding which patient subgroups may be more likely to benefit from 
nivolumab therapy.
Methods: 60 NSCLC formalin-fixed paraffin-embedded tumor 
tissue samples (Asterand: 30 squamous; 30 non-squamous) with 
matching RNA, frozen tissue samples, and patient characteristics/
outcomes were utilized. Tumor cell membrane PD-L1 expression 
was evaluated by IHC using an automated assay based on a sensi-
tive and specific PD-L1 monoclonal antibody (28-8). Tumors were 
defined as PD-L1 positive (PD-L1+) when ≥5% of the tumor cells 
had membrane staining at any intensity. PTEN/EGFR expression 
was analyzed by IHC. Mutations in isolated DNA were analyzed on 
the AmpliSeqTM cancer panel using the Ion Torrent platform. Gene 
expression was conducted on the Affymetrix platform and associa-
tion with PD-L1 status analyzed using ANOVA.
Results: Of 59 tumor samples with available data assessed by 
IHC, 42% (25/59) were PD-L1+ and 58% (34/59) were PD-L1 ne-
gative (PD-L1-). There was no apparent association between PD-
L1 protein expression and NSCLC histology: for squamous and 
non-squamous tumors, 38% (11/29) and 47% (14/30) were PD-L1+, 
respectively. No association was observed between PD-L1 status 
and PTEN or EGFR expression. PD-L1+ tumors, compared with 
PD-L1- tumors, showed higher expression of several immune-
related genes, including interferon-gamma (IFNγ), IFNγ-induced 
cytokine, and other genes involved in immune-cell regulation. 
The PD-L1 gene was differentially expressed between IHC PD-
L1+ and PD-L1- samples, with no continuous relationship noted. 
Genes associated with tumor progression and signaling pathways 
were over-expressed in PD-L1+ versus PD-L1- tumors, including 
proto-oncogene tyrosine kinase (MET), EGFR ligands, neuropilin-2, 
and alpha E-catenin. Analysis of key mutations from the Ampliseq 
panel indicated that rates of detectable mutations in our tumor 
panel differed from those reported in COSMIC (Catalog of Somatic 
Mutations in Cancer; http://cancer.sanger.ac.uk/cancergenome/
projects/cosmic/), as p14/CDKN2A and CBL mutations were not 
observed. However, KRAS and TP53 mutation rates were consis-
tent with COSMIC. IHC PD-L1 positivity was observed amongst 
KRAS mutation-positive (8/10) and KRAS wild-type tumors (15/43), 
and importantly amongst EGFR mutation-positive and EGFR wild-
type tumors.
were assessed for polarization, cytoplasmic and membranous stai-
ning intensity (scored 0–3) and proportion cells positive (0–100%; 
scored 0–5), averaged for multiple cores. A composite score (in-
tensity x cells positive) was derived (range 0–15).
Results: TMAs from 518 patients were analyzed: 69% male, 95% 
Caucasian, 7% never-smoking; 49% adenocarcinoma, 35% squa-
mous cell, 7% large cell; 43% stage I NSCLC, 33% stage II, 23% sta-
ge III. Immunohistochemistry staining intensity, proportion positive 
cells and depolarization were very similar between antibodies, with 
high concordance in composite score (R2=0.71, p<0.0001). Pola-
rization was discordant in 8%. Similar scores were seen for N0, N1 
and N2 when assessed by either antibody. For 77 cases with paired 
primary/N2 nodal tissue, mean 214D4 composite scores were 10.7 
and 10.1 and MA695 scores 9.5 and 9.4, respectively. Discordant 
staining in primary but not node was seen in 5.2% and 10.4% with 
214D4 and MA695, respectively. For 27 cases with neoadjuvant 
chemotherapy vs no chemotherapy, mean 214D4 scores were 
10.2 vs 10.1 and MA695 9.3 vs 9.6, respectively. Higher scores with 
each antibody trended toward improved survival (non-significant). 
Polarization was associated with improved survival (whole cohort) 
with 214D4 (80.6 vs 47.8 months; HR 1.37 [95%CI 1.078–1.742], 
p=0.01 log rank test) and MA695 (95.8 vs 45.7 months; HR 1.48 
[95%CI 1.159–1.878], p=0.002). Polarization with 214D4 was stron-
gly associated with improved survival for adenocarcinoma (HR 1.92 
[95%CI 1.385–2.668], p<0.0001) but not for non-adenocarcinoma. 
Similarly, polarization with MA695 conferred a survival advantage 
in adenocarcinoma (HR 1.68 [95%CI 1.225–2.311], p=0.001) but not 
non-adenocarcinoma cases. Data on MUC1 immunohistochemistry 
and circulating soluble MUC1 will be presented.  
214D4 MA695
No staining 3.5% 6.2%
Mean intensity
- Cytoplasmic 1.8 1.7
- Membranous 2.1 2.2
Mean cells positive 3.9 3.6
Mean composite score 10.1 9.6
- Adenocarcinoma 13.1 12.0
- Squamous cell 7.1 7.0
- Large cell 7.2 7.7
Depolarization 66.7% 62.4%
Conclusion: Over 93% were MUC1 immunohistochemistry po-
sitive, with higher scores in adenocarcinoma. Composite scores 
for the two antibodies were highly correlated and depolarization 
largely concordant. MUC1 expression was generally maintained 
in paired primary/nodal tumour and was similar across nodal sta-
ges and following neoadjuvant chemotherapy. Polarization was 
associated with improved survival in adenocarcinoma. Further 
investigation is needed to determine which antibodies best predict 
outcomes.
Keywords: non-small cell lung cancer, immunotherapy, Immuno-
histochemistry, MUC1
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dataset for unresectable/inoperable NSCLC treated with RT. This 
circulating miRNA signature may be used as a non-invasive biomarker, 
which may have prognostic or therapeutic implications for the future 
management of locally advance NSCLC patients. Larger sample size 
studies are needed to further validate our findings.
Keywords: NSCLC, MicroRNAs/blood, Prognosis, Gene expression 
profiling
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P3.06-042 PLEURAL FLUID ADA IS ASSOCIATED WITH 
SURVIVAL OF PATIENTS WITH MALIGNANT PLEURAL 
EFFUSION
Ricardo M. Terra1, Alessandro W. Mariani2, Leila Antonangelo3, 
Milena M. Suesada3, Paulo M. Pêgo-Fernandes2
1Instituto Do Câncer Do Estado De São Paulo (ICESP) Fmusp/Brazil, 
2Thoracic Surgery, Incor Hcfmusp/Brazil, 3Incor Hcfmusp/Brazil
Background: Estimating survival is desirable to determine the best 
palliative approach for patients with malignant pleural effusion (MPE). 
Previous studies have shown that some pleural fluid biochemical 
parameters as glucose or pH are predictors of survival in such a po-
pulation. Inflammatory infiltrate profile was already determined as a 
relevant predictor in solid tumors. However, inflammatory cells profile 
and lymphocyte activity was not systematically assessed as a survival 
predictor in MPE patients. Therefore, our objective was to evaluate 
whether cytology profile and Adenosine Deaminase (ADA) levels are 
relevant predictors of overall survival in patients with MPE who under-
go pleurodesis.
Methods: Retrospective cohort study carried out in a tertiary univer-
sity-based hospital. We included all patients who underwent pleuro-
desis for MPE treatment in our institution during the period: Jan/08 
to Jun/11. We excluded patients that had no pleural fluid analysis 
registered in our database. The following data regarding pleural fluid 
analysis were retrieved from our database: glucose, LDH, total prote-
ins and ADA, total cell count, leukocytes, macrophages, neutrophils, 
lymphocytes and oncotic cytology. All patients were followed up in 
our outpatient clinic until death, those who were lost to follow-up 
were contacted by telephone. Cox regression models were built to 
identify predictors of overall survival
Results: 156 patients were included in this study (44 men, 112 women, 
mean age 58.9+-12 years). Primary neoplasms were: breast (83), lung 
(39), lymphoma (10), other (24). Median survival was 9 months. The 
final regression model was built using forward stepwise selection and 
the overall survival predictors identified that levels of ADA below 15 
IU/L (HR:2.3, p=0.0008) or above > 40 IU/L. (HR 2.3, p=0.01) are asso-
ciated with a shorter survival. An association with shorter survival was 
also found for patients with primary neoplasms different from breast, 
lung or lymphoma. (HR: 2,1, p= 0.007). No other predictor analyzed 
was associated with worse prognosis. Exploratory analysis showed 
that patients with ADA < 15 IU/L had low pleural fluid lymphocytes 
count and low protein concentration; paradoxically, those with ADA > 
40 IU/L also had low lymphocytes count while other parameters were 
normal.
Conclusion: We concluded that ADA is a relevant predictor of survival 
in patients with MPE who undergo pleurodesis.
Keywords: pleural effusion, survival, pleurodesis, pleural fluid analysis
Conclusion: Current data suggest PD-L1 protein expression on 
NSCLC tumors may be associated with several factors, including 
expression of immune genes, expression of tumor progression 
markers, and driver mutations. Ongoing analyses within this tumor 
panel are exploring putative associations of PD-L1 expression with 
patient characteristics and outcomes. Findings could help define 
additional factors that may influence the likelihood of response to 
nivolumab therapy. Correlates to PD-L1 will be explored in greater 
detail as part of ongoing phase 3 trials of nivolumab in NSCLC.
Keywords: nivolumab, non-small cell lung cancer, programmed 
death receptor ligand 1, Gene expression
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P3.06-041 SERUM MIRNA SIGNATURE PREDICTS SURVI-
VAL IN PATIENTS WITH UNRESECTABLE/INOPERABLE 
NON-SMALL CELL LUNG CANCER TREATED WITH DEFI-
NITIVE RADIATION THERAPY
Nan Bi1, Matthew Schipper1, Paul Stanton1, Weili Wang1, Feng-
Ming (Spring) Kong2
1University Of Michigan/United States Of America, 2Department Of Ra-
diation Oncology, University Of Michigan And Veteran Administration 
Hospital, Currently At Gru Cancer Center, Georgia Regent University/
United States Of America
Background: The expression profiles of serum micro RNAs (miRNAs) 
are known to predict overall survival (OS) of metastatic and operable 
non-small cell lung cancer (NSCLC). We hypothesized that circulating 
miRNAs is also correlated with survival in unresectable/inoperable 
NSCLC treated with radiation therapy (RT).
Methods: 134 patients with inoperable/unresectable NSCLC treated 
with definitive RT (18-month minimum follow-up) were eligible. Serum 
samples were collected prospectively before RT commencement. 100 
patients with enough serum and reliable miRNA profile quality were 
randomly divided into training and validation sets (50 patients each). 
MiRNA profiling was performed using real-time PCR-based array, 
containing a panel of 84 miRNAs detectable in human bodily fluids. 
Spiked-in cel-miR-39 was used for normalization. Stepwise regressi-
on Cox model building was used to build a miRNA signature on the 
training set, which was then assessed on the validation set both alone 
and with clinical factors.
Results: The median age was 67 years; 76% were stages III and 79% 
received chemoradiation; the median physical dose was 70 Gy. Step-
wise regression modeling identified five miRNAs as jointly significant 
predictors. Using coefficients from Cox model fit, the miRNA signa-
ture was 0.53*log(hsa-miR-15b)+0.21*log(hsa-miR-34a)-0.27*log(hsa-
miR-221)-0.27*log(hsa-miR-224) -0.07*log(hsa-miR-130b). This signa-
ture was a significant predictor of OS in the validation set (p=0.011). 
It retained statistical significance in a model also containing terms 
for GTV Volume and KPS, the only two significant clinical factors in 
univariate analysis in the validation set (p=0.012). Using computational 
methods (TargetScan6.2) for miRNA target prediction, the putative 
targets of these five miRNAs are known to modulate apoptosis, cell 
cycle control, DNA damage response and repair process (including 
nucleotide excision repair and DNA translesion synthesis), angiogene-
sis and epithelial-mesenchymal transition.
Conclusion: In this study, we developed a prognostic miRNA sig-
nature consisting of five miRNAs and validated in an independent 
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P3.06-044 KRAS, EGFR MUTATIONS AND EGFR GENE 
COPY STATUS AS PREDICTIVE MARKERS OF RESPONSE 
AND TIME TO PROGRESSION IN EGFR WILD-TYPE  
STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC) 
PATIENTS TREATED WITH EGFR TYROSINE-KINASE  
INHIBITORS.
Manuel Domine, Federico Rojo, Tatiana Hernández, Sandra Zazo, 
Gloria Serrano, Cristina Chamizo, Cristina Caramés, Juan Mad-
oz, Irene Moreno, Nuria Pérez González, Carolina Ortega, Nerea 
Carvajal, Francisco Lobo, Carmen Laura Auz, Victoria Casado, 
Gustavo Rubio, Ana León, Jose Ignacio Martín Valades, Yann Izar-
zugaza, Juan Luis Arranz, Maria Jesús Fernández-Aceñero, Alberto 
Lendinez, Mauro Oruezabal, Brezo Martinez-Amores, Natalia Ra-
mirez, Jesús García Foncillas
Translational Oncology Division, ISS-Hospital Universitario Fundación 
Jiménez Díaz/Spain
Background: KRAS mutations on codons 12, 13 and 61 result in 
the constitutive activation of protein, which may render tumor cells 
independent of Epidermal Growth Factor Receptor (EGFR) signal-
ling and thereby resistant to tyrosine-kinase inhibitor (TKI) therapy 
in NSCLC patients. This study was aimed to evaluate the associ-
ations of KRAS and EGFR copy number alteration and mutations 
with response and time to progression (TTP) in EGFR TKI treated 
patients.
Methods: KRAS mutations on codons 12, 13 and 61 result in the 
constitutive activation of protein, which may render tumor cells in-
dependent of Epidermal Growth Factor Receptor (EGFR) signalling 
and thereby resistant to tyrosine-kinase inhibitor (TKI) therapy in 
NSCLC patients. This study was aimed to evaluate the associations 
of KRAS and EGFR copy number alteration and mutations with res-
ponse and time to progression (TTP) in EGFR TKI treated patients.
Results: KRAS mutation was detected in 15 (17.8%) cases, EGFR 
mutation in 27 (32.1%) and EGFR amplification in 8 (9.5%). Signi-
ficant differences were detected in response rates for wild-type 
compared with mutant KRAS ( 20 vs 0%, p=0.023), mutant compa-
red with wild-type EGFR (59 vs 8%, p=0.007), and EGFR-amplified 
compared with non-amplified (71 vs 18%, p=0.005). Additionally, 
significant benefit from TKI therapy was observed for KRAS wild-
type compared with KRAS mutated patients (median TTP 7 vs. 3 
months, p=0.001), for EGFR-mutated compared with wild-type 
patients (14 vs. 4 months, p=0.004) and for EGFR-amplification in 
contrast to non-amplified cases (11 vs. 5 months, p=0.001). KRAS 
and EGFR mutations or EGFR amplification did not correlated with 
overall survival (18 vs. 19 months, p=0.406; 16 vs. 21 p=0.094; 25 
vs. 17 months, p=0.103, respectively). Combined analysis of favou-
rable status of three biomarkers strongly predicted benefit to TKI 
therapy (median TTP 15 vs. 3 months, p<0.001).
Conclusion: Combined analysis of KRAS mutation, EGFR mutation 
and EGFR amplification in EGFR TKI treated NSCLC might provi-
de superior predictive information than single biomarker study in 
these patients
Keywords: Biomarkers, Tirosine-kinase inhibitors, NSCLC, metas-
tatic
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P3.06-043 MODULATION OF THE CYCLOOXYGENASE 
PATHWAY IS ASSOCIATED WITH EFFICACY IN A RAN-
DOMIZED PHASE II TRIAL OF ERLOTINIB AND CELE-
COXIB OR PLACEBO IN ADVANCED NON-SMALL CELL 
LUNG CANCER (NSCLC)
Michael C. Fishbein1, Brian Gardner1, Ginder L. Milne2, Marianna 
Koczywas3, Mihaela Cristea3, Jonathan E. Dowell4, Hejing Wang1, 
Robert A. Figlin5, Robert M. Elashoff1, Steven M. Dubinett1, Karen 
L. Reckamp3
1David Geffen School Of Medicine At Ucla/United States Of America, 
2Vanderbilt University/United States Of America, 3City Of Hope/United 
States Of America, 4University Of Texas Southwestern/United States 
Of America, 5Cedars Sinai/United States Of America
Background: Combined epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitor (TKI) therapy and cyclooxygenase-2 (COX-
2) inhibition has been shown to potentiate responses in NSCLC, 
and may overcome resistance in wild type EGFR tumors. Several 
biomarkers have been used to evaluate effective targeting of the 
COX-2 pathway. COX-2 expression by immunohistochemistry (IHC) 
and urinary 11α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-
dioic acid (uPGEM) have identified patients who may derive benefit 
from COX-2 inhibition. We evaluated these markers in association 
with PFS and tumor response in our randomized, placebo cont-
rolled trial of erlotinib and high dose celecoxib in advanced NSCLC 
patients.
Methods: Pts with stage IIIB/IV NSCLC who progressed following 
at least one line of therapy or refused standard chemotherapy 
were randomized to erlotinib (150mg/day)/high dose celecoxib 
(600mg/2x day) v E/P. Urinary prostaglandin E2-metabolite (uP-
GEM) was assessed at baseline, week 4 and week 8 of therapy. 
Immunohistochemical evaluation of COX-2 was performed on ar-
chival tissue.
Results: 87 pts had urine assessed and 38 pts had additional 
evaluable tissue following EGFR mutation analysis. PFS was signifi-
cantly improved in patients with wild type EGFR tumors (3.2 v 1.8 
months, HR = 0.54, p = 0.03). Previously established normal uP-
GEM levels for men and women were used to determine high and 
low baseline values. 59 pts (67%) had high and 29 pts (33%) had 
low uPGEM at baseline. Elevated baseline uPGEM was associated 
with improved PFS for patients who received high dose celecoxib 
(5.6 v 2.2 months, p = 0.09). Pts with low baseline uPGEM did not 
benefit from celecoxib. Further assessment of COX-2 and E-cadhe-
rin was performed by IHC and correlations will be presented.
Conclusion: UPGEM is an easily assessed biomarker that is asso-
ciated with improved outcomes in patients treated with high dose 
celecoxib and erlotinib with advanced NSCLC. Tumor levels of 
COX-2 and E-cadherin may refine our ability to best define a po-
pulation who will benefit from COX-2 and EGFR targeted therapy 
in future studies. Supported by NIH 1P50 CA90388, K12 CA01727, 
Phase One Foundation and medical research funds from the Dept 
of Veterans’ Affairs.
Keywords: Targeted therapy, Cyclooxygenase, Epidermal growth 
factor receptor, Biomarkers
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P3.06-046 THE TUMOR SUPPRESSOR INTEGRIN-ALPHA 
7 IS FREQUENTLY DOWNREGULATED IN MALIGNANT 
PLEURAL MESOTHELIOMA: BIOLOGICAL AND PROG-
NOSTIC CONSEQUENCES
Mir A. Hoda1, Viktoria Laszlo1, Christine Pirker2, Bahil Ghanim1, 
Thomas Klikovits1, Marko Jakopovic3, Miroslav Samarzija3, Sabine 
Zöchbauer4, Balazs Dome5, Luka Brcic6, Walter Berger2, Michael 
Grusch2, Walter Klepetko1, Balazs Hegedus5
1Division Of Thoracic Surgery, Medical University Vienna/Austria, 
2Institute Of Cancer Research, Medical University Vienna/Austria, 
3Department For Respiratory Diseases Jordanovac, University Hospital 
Center Zagreb/Croatia, 4Division Of Oncology, Medical University Vi-
enna/Austria, 5Translational Thoracic Oncology Laboratory, Division Of 
Thoracic Surgery, Medical University Of Vienna/Austria, 6Department 
Of Pathology, University Hospital Center Zagreb/Croatia
Background: Malignant pleural mesothelioma (MPM) is a malig-
nancy characterized by therapy resistance and poor outcome. The 
high mortality of MPM is largely due to its invasive growth, local 
recurrence and locoregional spread. The identification of molecu-
lar changes that lead to this phenotype is indispensable. ITGA7 is a 
laminin binding receptor and has been identified as a novel tumor 
suppressor based on its frequent mutation in other malignancies. 
However, the alterations of ITGA7 have not yet been studied in 
MPM.
Methods: ITGA7 mRNA levels of normal mesothelial and MPM 
cells were measured by q-RT-PCR. ITGA7 promoter silencing in 
mesothelioma cell cultures was quantified by methylation-specific 
PCR analysis and by sequencing. Migratory activity of MPM cells 
has been investigated by 2D videomicroscopy. In vitro cell prolife-
ration and adhesion assays were performed on siRNA transfected 
cells to demonstrate the biological consequence of decreased 
ITGA7 expression. ITGA7 expression in MPM tissue specimens was 
analysed by immunohistochemistry (IHC) and correlated to clinical 
outcome data.
Results: ITGA7 is highly expressed by normal mesothelial cells 
while decreased in MPM cells. In most MPM cells the expression 
of ITGA7 was reduced through promoter hypermethylation. ITGA7 
promoter is hypermethylated in a number of tested MPM cell cul-
tures (n=13) and the ratio of promoter methylation inversely corre-
lates with ITGA7 expression. MPM cells with high in vitro migratory 
activity demonstrated a significantly lower ITGA7 expression when 
compared to slow migrating MPM cells. Proliferation of normal 
mesothelial cells is inhibited by laminin and this inhibitory effect 
is abolished by downregulation of ITGA7 expression via siRNA 
transfection. Adhesion of normal mesothelial and MPM cells is 
enhanced by laminin, however, it is not decreased by downregula-
tion of ITGA7. The clinical significance of ITGA7 protein expression 
was investigated by IHC in a cohort of 89 MPM surgical specimens. 
Importantly, patients with high ITGA7 expression had significantly 
longer median overall survival (448 days) than patients with low 
expression (247 days, log rank test: p=0,0281).
Conclusion: ITGA7 is a novel tumor suppressor in MPM and its 
expression is down-regulated in MPM cells by promoter hyperme-
thylation. Moreover, low ITGA7 expression in tumor cells influences 
clinical outcome as a negative prognostic factor in human MPM.
Keyword: Pleural mesothelioma, Integrins, Prognostic factor, tu-
mor suppressor gene
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P3.06-045 E-CADHERIN AND VIMENTIN AS BIOMAR-
KERS OF CLINICAL OUTCOMES AMONG EGFR+ LUNG 
ADENOCARCINOMA (LA) PATIENTS TREATED WITH ER-
LOTINIB (CLICAP)
Andres F. Cardona1, Claudio Martin2, Oscar Arrieta3, Hernán Car-
ranza1, Carlos Vargas1, Luis Corrales-Rodriguez4, Jorge M. Otero1, 
Pilar Archila5, July Katherine Rodriguez1, Luis Más6, Guillermo 
Bramuglia7, Laura Bernal1, Diana Torres8, Leonardo Rojas3, Petros 
Giannikopoulos9, Rafael Rosell10
1Clinical And Traslational Oncology Group, Fundación Santa Fe De 
Bogotá/Colombia, 2Oncology, Alexander Fleming/Argentina, 3Thoracic 
Oncology Clinic And Laboratory Of Experimental Oncology, Instituto 
Nacional De Cancerología (INCAN)/Mexico, 4Medical Oncology, Hospi-
tal San Juan De Dios-ccss/Costa Rica, 5Fundation For Clinical And Ap-
plied Cancer Research – Ficmac/Colombia, 6Clinical Oncology, Instituto 
De Enfermedades Neoplásicas/Peru, 7Fundación Investigar/Argentina, 
8Foundation For Clinical And Applied Cancer Research - Ficmac/Colom-
bia, 9Cancer Therapeutics Innovation Group/United States Of America, 
10Medical Oncology, Catalan Institute Of Oncology/Spain
Background: Epithelial-mesenchymal transition (EMT) has been 
known to play a key role in stromal invasion of lung adenocarcino-
ma. Loss of E-cadherin and acquisition of vimentin are two critical 
steps in EMT, that are induced by Snail-1 and TWIST upregulation 
associated with overexpression of epidermal growth factor receptor 
(EGFR). However, roles of EMT-related proteins in EGFR mutants 
have not been fully elucidated. We investigated the inmunoexpres-
sion of EMT-related proteins in EGFR lung adenocarcinoma to de-
monstrate their key roles in tumor progression.
Methods: E-Cadherin and vimentin expression was assessed in 84 
patients with EGFR+ LA to determine if these markers had the po-
tential to predict clinical outcomes in patients treated with Erlotinib. 
The percentage of tumor cells with grades 0, 1, 2, or 3 membrane 
staining of E-Cadherin and cytoplasmic staining of vimentin was 
measured. We selected previously reported cut-off points shown to 
provide optimal stratification: ≥40% of tumor cells with staining of 
+2 and +3 for E.cadherin and ≥10% of tumors cell with any staining 
for vimentin. Overall response rates (ORR), clinical benefit (CB), time 
to progression (TTP), and overall survival (OS) were estimated, as 
well as variables that influenced OS.
Results: Mean age was 59.6 years (SD +/- 13.1) and 79.8% of patients 
were women. Mutations of EGFR, L858R and G719X in exon 19 were 
present in 61%, 31% and 6% respectively. Vimentin expression was 
strong in 9.5% (n=8) and E-cadherine expression was weak in 51.2%, 
moderate in 23.8% and strong in 23.8%. Highest positivity of E-Cad-
herin was related to exon 19 deletion (p=0-001) but not to L858R 
mutations (p=0.14). Strong vimentin reactivity was associated with 
history of smoking (p=0.03). OS was 12.3 [10-14], 27.0 [23-31],26.1 
[20-32] and 33.5 [30-36] months when E-cadherine expression was 
negative, weak, moderate and strong (p=0.05). OS was 33 months 
[31-35] in vimentin-negative and 8.2 months [6-10] in vimentin-po-
sitive (p=0.001). Similar trends were observed for progression-free 
survival and response rate.
Conclusion: E-Cadherin and vimentin are valuable predictive bio-
markers for EGFR+ patients. These results warrant further research 
on EMT in selected populations exposed to erlotinib.
Keywords: Vimentin, E-cadherin, epithelial to mesenchimal transiti-
on, EGFR, prognosis., Vimentin, E-cadherin, EMT, EGFR, prognosis.
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tions in NSCLC. NanoString assays were subsequently developed 
for the signatures and used in: i) cell line based cross-platform 
comparisons with Affymetrix technology ii) formalin-fixed paraffin-
embedded (FFPE) NSCLC samples to determine measurable ge-
nes, variation in gene expression and the limit of quantification for 
the signatures iii) matched tumour samples from the same patients 
iv) a blinded cohort of 50 NSCLC samples with known KRAS muta-
tion status.
Results: In silico data confirmed the published correlations of 
transcriptome signatures with KRAS status in NSCLC samples. 
NanoString data appear to be robust, demonstrating a strong cor-
relation with the Affymetrix platform and reproducible signature 
scores across separate samples from the same tumour. Reproduci-
bility is maintained across dilutions of the same isolated RNA sam-
ple and supports previous observations regarding the sensitivity of 
these signatures for detecting KRAS mutations in clinical samples. 
In addition, we showed that high expression of these signatures is 
not restricted to samples with KRAS mutation, confirming previous 
observations that RAS or MEK activation is not exclusively linked to 
KRAS mutation.
Conclusion: We have developed a clinically relevant, robust assay 
platform, determined biological variation within tumours and con-
firmed the link to KRAS mutation status in a cohort of blinded NS-
CLC samples. The NanoString assays provide a means to test the 
prognostic and predictive capabilities of the gene signatures in the 
samples routinely provided in clinical practice. We intend to test 
the concordance of the gene signature indices between primary 
and metastatic tumours from the same patients, the prognostic 
relevance of the signatures in first- and second-line NSCLC pati-
ents treated with standards of care and wherever possible in future 
clinical trials of MEK inhibitors.
Keywords: MEK, NSCLC, KRAS
POSTER SESSION 3 - PROGNOSTIC AND PREDICTIVE BIOMARKERS  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.06-049 DETECTION OF EGFR MUTATION IN BRON-
CHIAL LAVAGE FLUID AFTER TRANSBRONCHIAL BIOPSY 
USING A NOVEL HIGH-SPEED REAL-TIME PCR SYSTEM.
Tomohiro Sakamoto, Miyako Takada, Masahiro Kodani, Hiroki 
Izumi, Shizuka Itou, Kosuke Yamaguchi, Kennichi Takeda, Jun 
Kurai, Hirokazu Touge, Haruhiko Makino, Masaki Nakamoto, 
Hiroki Chikumi, Tadashi Igishi, Eiji Shimizu
Division Of Medical Oncology And Molecular Respirology, Tottori Uni-
versity Hospital/Japan
Background: Epidermal growth factor receptor (EGFR) mutation 
testing is essential to determine treatment regimens for patients 
with advanced non-squamous non-small cell lung cancer (non-Sq 
NSCLC). However, it requires at least two weeks until the results 
of commercialized EGFR testing are available. Therefore, we de-
veloped a novel high-speed real-time PCR system to reduce the 
time required for EGFR mutation detection. The reaction time of 
this system is only 5 minutes, and EGFR mutation status is found 
out within a few hours after diagnostic bronchoscopy. We tried 
to detect exon 19 deletion and exon 21 point mutation(L858R) in 
bronchial lavage fluid (BLF) after transbronchial biopsy (TBB) using 
this system. The aim of this study is to assess the performance of 
this novel high-speed real-time PCR system.
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P3.06-047 PROGNOSTIC VALUE OF NEUTROPHIL LYM-
PHOCYTE RATIO IN SECOND LINE ADVANCED MALIG-
NANT PLEURAL MESOTHELIOMA
Ahmed El Bastawisy, Maha Yahia, Rabab Gaafar
Medical Oncology, National Cancer Institute, Cairo University/Egypt
Background: Malignant pleural mesothelioma is a lethal disease 
and hence the strong need for identifying new prognostic factors.
Methods: This is a retrospective study including all eligible pati-
ents with advanced malignant pleural mesothelioma (MPM) pre-
senting to National Cancer Institute, Cairo University. Neutrophil 
lymphocyte (N/L) ratio was assessed before second line chemothe-
rapy.2.5 was used as the cutoff point. Endpoints were assessment 
of correlation between N/L ratio and clinical response (CR), pro-
gression free survival (PFS) and overall survival (OS).
Results: 52 patients (19 stage III and 33 stage IV) MPM were inclu-
ded and followed up during the period from July 2009 till Novem-
ber 2012 with a median follow up period of 2.6 months. 87.5% of 
patients with N/L ratio > 2.5 showed progressive disease versus 
91.7% in patients with N/L ratio <2.5. (P-value=0.66).6 months PFS 
was 11% for patients with N/L ratio > 2.5 versus 14% for patients 
with N/L ratio <2.5. (P-value =0.001). 6 months OS was 72% for 
patients with N/L ratio > 2.5 versus 66% for patients with N/L ratio 
<2.5. (P-value =0.4).
Conclusion: N/L ratio is a potential prognostic marker for advan-
ced MPM treated with second line chemotherapy.
Keywords: N/L ratio, MPM
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P3.06-048 PROGRESS WITH CANDIDATE PREDICTIVE 
GENE EXPRESSION SIGNATURES FOR MEK INHIBITORS 
IN NON-SMALL CELL LUNG CANCER (NSCLC)
Roz Brant1, Tom Liptrot1, Claire Rooney1, Helen Brown1, Robert 
Mcewen1, Gael Mcwalter1, Brian Dougherty2, Jill Walker1, Maria 
C. Orr1, Liz Harrington1, Carl Barrett2, Jonathan Dry1, Paul Smith1, 
Darren Hodgson1
1Astrazeneca/United Kingdom, 2Astrazeneca/United States Of America
Background: Several MEK inhibitors are in late-stage clinical trials 
in mutant BRAF melanoma, where novel patient selection biomar-
kers are not major impediments to clinical development. In non-
mutant BRAF disease, there is a presumption that the optimum 
patient population may also be selected according to gain of func-
tion mutations in key genes, resulting in pathway activation. In the 
present work we have taken a different approach, based on two 
publications (Dry et al. Cancer Res 2010;70:2264–2273; Loboda et 
al. BMC Med Genomics 2010;3:26), attempting to define NSCLC 
patient populations for MEK inhibitors based on gene expression 
signature measurements of pathway output.
Methods: In silico analyses were performed to test the sensitivity 
of candidate transcriptome signatures for detecting KRAS muta-
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expression than the lepidic, papillary, and acinar components 
(P\\0.001, P\\0.001, and P = 0.016, respectively). The fibronectin 
and vimentin expression levels were also significantly higher in the 
solid subtype component than in other components. This immu-
nostaining character was validated by using mixed-subtype ade-
nocarcinomas containing all four components in the same tumor.
Conclusion: This study concluded that the solid subtype compo-
nent in lung adenocarcinomas exhibit the invasive immunophe-
notype, including increased laminin-5 expression, compared with 
the other components, which may be associated with a poorer 
prognosis.
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P3.06-051 CIRCULATING BIOMARKERS MAY HELP GUI-
DE SELECTION OF ERLOTINIB VERSUS CHEMOTHERAPY 
IN PRETREATED ADVANCED NSCLC PATIENTS.
Jeffrey A. Borgia1, Marta Batus2, Mary Jo Fidler2, J A. Gangaram3, 
Sanjib Basu4, Cristina Fhied5, Kelly Kaiser-Walters5, Brett Mahon5, 
Philip Bonomi2
1Pathology And Biochemistry, Rush University Medical Center/United 
States Of America, 2Department Of Medical Oncology, Rush Univer-
sity Medical Center/United States Of America, 3Biochemistry, Rush 
University Medical Center/United States Of America, 4Department Of 
Preventive Medicine, Rush University Medical Center/United States Of 
America, 5Pathology, Rush University Medical Center/United States Of 
America
Background: Recent data suggests a trend for prolonged progres-
sion-free survival (PFS) in patients with wild-type EGFR (wtEGFR) 
non-small cell lung cancer (NSCLC) treated with second-line do-
cetaxel over erlotinib. In this same study, however, overall survival 
(OS) appeared unaffected. In the maintenance setting, erlotinib 
was also shown to improve both PFS and OS in wtEGFR advanced 
NSCLC patients. More recently, evaluating serum protein patterns 
by mass spectroscopy revealed inferior PFS with erlotinib compa-
red to docetaxel in patients with a particular protein pattern. The 
individual proteins in the mass spectroscopy peaks were not iden-
tified. The objective of this study was to develop a multi-analyte 
serum panel of specific proteins with predictive value for erlotinib 
versus palliative chemotherapy in pretreated advanced NSCLC 
patients that were unselected for EGFR mutation status.
Methods: 74 biomarkers were evaluated using Luminex immuno-
bead assays against a total of 120 patients with stage IV NSCLC 
that were previously treated with chemotherapy and were unse-
lected for EGFR mutation status. Patients were treated either with 
single agent erlotinib or platinum-based chemotherapy at the 
discretion of the treating physician. Patients were evaluated for di-
sease progression using RECIST criteria and association of biomar-
ker with survival outcomes was assessed using Cox proportional 
hazards regression model. The differential association of the bio-
markers in the two treatment groups (erlotinib or chemotherapy) 
with survival outcomes was assessed using a proportional hazards 
(PH) interaction model.
Results: In univariate PH regression analysis, we identified 7 serum 
biomarkers (osteopontin, CA-125, sTNF-RII, PlGF, leptin, IGFBP5, 
and amphiregulin) which were strongly associated (p<0.01) and 
nine additional biomarkers (IGFBP4, sTNF-RI, CA 15-3, IGFBP1, sIL-
2Rα, sFAS, VEGF-A, sIL-1RI, and sIL-4R) which had significant asso-
Methods: Seventy five consecutive patients who underwent TBB in 
our hospital from November 2012 to May 2013 were enrolled. Sam-
ples were obtained from BLF after TBB. DNA was extracted using 
QIAamp Blood Mini Kit (QIAGEN Japan, Tokyo, Japan). EGFR 
mutations were detected with high-speed real-time PCR system 
(TRUST medical, Hyogo, Japan) (Method A). Once the patient was 
diagnosed NSCLC with histology of TBB samples, EGFR mutation 
status was validated with PCR-invader method (BML, Inc. Tokyo, 
Japan) (Method B). We evaluated the sensitivity and concordance 
between (A) and (B).
Results: Lung cancer was histologically diagnosed in 51 patients 
(adenocarcinoma/squamous cell carcinoma/others=42/6/3), while 
not in 24 patients. Detection rate of EGFR mutation in patients 
with lung cancer was 29.4%(15/51) with (A) and 31.4%(16/51) with 
(B), respectively. Concordance rate between two methods was 
94%. Discordance was found in one (6%) sample, where minor 
mutation of Exon19 L747-P753 deletion and insertion S was found 
only with (B). When (B) was used as a standard, sensitivity and 
specificity of (A) were 94% and 100%, respectively. Time to detect 
EGFR mutation by (A) and (B) were 2 hours and 18 days (6-45 days), 
respectively.
Conclusion: A novel high-speed real-time PCR system enables us 
to apply rapid EGFR mutation detection for clinical use.
Keyword: EGFR mutation, real-time PCR, PCR-invader, TBB
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P3.06-050 CHARACTERISTIC IMMUNOPHENOTYPE OF 
SOLID SUBTYPE COMPONENT 
IN LUNG ADENOCARCINOMA
Teruhisa Takuwa1, Genichiro Ishii2, Kanji Nagai3, Junji Yoshida3, 
Tomoyuki Hishida3, Shinya Neri3, Seiki Hasegawa1, Atsushi Ochi-
ai2
1Department Of Thoracic Surgery, Hyogo College Of Medicine/Japan, 
2Pathology Division, Research Center For Innovative Oncology, National 
Cancer Center Hospital East/Japan, 3Department Of Thoracic Oncology, 
National Cancer Center Hospital East/Japan
Background: Lung adenocarcinomas represent a morphologically 
heterogeneous tumor composed of an admixture of different his-
tologic subtypes (lepidic, papillary, acinar, and solid subtype). The 
presence of a solid subtype component is reported to be associa-
ted with a poorer prognosis. The aim of this study was to evaluate 
the characteristic immunophenotype of the solid subtype compo-
nent compared with the immunophenotypes of other components.
Methods: We analyzed the clinicopathological characteristics of 
stage I adenocarcinoma patients with predominant solid subtype 
disease. Furthermore, we immunostained adenocarcinomas with 
predominant lepidic, papillary, acinar, and solid subtype compo-
nents (n = 23 each) for 10 molecular markers of tumor invasiveness 
and scored the results.
Results: Patients showing predominance of the solid subtype com-
ponent (solid subtype adenocarcinoma) had a poorer prognosis 
than those showing predominance of the lepidic, papillary, or aci-
nar component. Lymphovascular invasion was more often detected 
in solid subtype tumors than in others. The solid subtype compo-
nent showed a significantly stronger staining intensity of laminin-5 
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Conclusion: This technique can distinguish FFPE artifacts from 
true variants and therefore provides increased accuracy for the 
detection of low-frequency variants by NGS. *Research Use Only
Keywords: DNA based assay, Next Generation Sequencing NGS, 
Solid tumors, Somatic Mutations
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P3.06-053 A DIAGNOSTIC STUDY TO DETERMINE THE 
PREVALENCE OF EPIDERMAL GROWTH FACTOR RECEP-
TOR (EGFR) MUTATIONS IN ASIAN AND RUSSIAN PATI-
ENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) 
OF ADENOCARCINOMA AND NON-ADENOCARCINO-
MA HISTOLOGY: IGNITE STUDY DESIGN
Baohui Han1, Sergei Tjulandin2, Nicola Normanno3, Koichi Hagi-
wara4, Martin Reck5, Gael Mcwalter6, Rose Mccormack6
1Department Of Respiratory Medicine, Shanghai Chest Hospital, Jiao 
Tong University/China, 2Department Of Clinical Pharmacology And 
Chemotherapy, Russian Cancer Research Center/Russian Federation, 
3Cell Biology And Biotherapy Unit, Int-fondazione Pascale/Italy, 4De-
partment Of Respiratory Internal Medicine, Saitama Medical Univer-
sity/Japan, 5Onkologischer Schwerpunkt, Krankenhaus Großhansdorf, 
Zentrum Für Pneumologie Und Thoraxchirurgie/Germany, 6Persona-
lized Healthcare And Biomarkers, Astrazeneca/United Kingdom
Background: EGFR mutation status is widely accepted as an im-
portant biomarker in NSCLC. To assess the current status of EGFR 
mutation testing, including testing procedures, sample types, 
mutation prevalence across demographic/histological subgroups 
(adenocarcinoma and non-adenocarcinoma histologies), and im-
pact of EGFR mutations on personalized therapy choice, a large, 
multinational, diagnostic, non-comparative, interventional study 
(NCT01788163; IGNITE) of EGFR mutation status in patients with 
locally advanced/metastatic NSCLC of adenocarcinoma and non-
adenocarcinoma histology will be conducted across centers in the 
Asia Pacific region and Russia.
Methods: Approximately 3500 patients (age ≥18 years) with che-
motherapy naïve, Stage IIIA/B/IV NSCLC (newly diagnosed or re-
current disease after surgical resection) that is not suitable for cu-
rative treatment will be recruited over ~18 months from Asia Pacific 
(including 25 centers in China) and Russia. To give similar precision 
for the estimation of EGFR mutation frequency in the key non-ade-
nocarcinoma subgroup in Asia Pacific and Russia, 2500 patients 
from Asia Pacific (assumptions: 20% patients non-adenocarcinoma 
histology, with 10% EGFR mutation frequency [one-fifth of the 50% 
prevalence in adenocarcinoma]; precision ±3%) and 1000 patients 
from Russia (assumptions: 20% patients non-adenocarcinoma 
histology, with 4% EGFR mutation frequency [one-fifth of the 20% 
prevalence in adenocarcinoma]; precision ±4%) need to be scree-
ned. Provision of diagnostic tumor samples for testing will be man-
datory for all patients; additionally, plasma samples, which contain 
circulating-free tumor derived DNA (cfDNA), will be collected for 
EGFR mutation testing of plasma from a subset of 2500 patients in 
Russia, China, Taiwan and Korea. EGFR testing will be performed 
according to local practices, with Exon 19 deletions and L858R 
point mutations assessed as a minimum. The first-line (all patients) 
and second-line (patients with mutation-positive NSCLC; estima-
ted 50% will progress to second-line treatment by study cutoff) 
therapy choices will be recorded. The primary objective is to de-
termine EGFR mutation (and subtype) frequency in patients with 
ciation (p<0.05) with PFS in the erlotinib subgroup (n=92). Similarly, 
9 biomarkers (osteopontin, sTNF-RI, sTNF-RII, CA 15-3, sIL-2Rα, 
epiregulin, PILG, IL6 and CA 125) were found to be strongly asso-
ciated with OS. In our assessment of differential association with 
PFS, we found eight serum biomarkers (sIL-2Rα, IL-8, sIL-1RI, Ten-
sascin C, FGF2, HGF, Leptin, and TGF-α) with significant to strongly 
significant positive interaction terms, thus indicating differentially 
increased hazard of progression in the chemotherapy subgroup 
with high biomarker levels. Four markers (IL-8, TGF-α, HGF, VEGF-
A) were found to have significantly positive interaction, indicating 
a decreased hazard of death in the erlotinib group with high bio-
marker levels; whereas two (sTNF-RII, PSA) had significant negative 
interaction with OS, demonstrating a increased hazard of death in 
the erlotinib group.
Conclusion: We identified a series of circulating surrogate biomar-
kers associated with epithelial-to-mesenchymal transition (EMT) 
that have promise for algorithm development to help physicians 
determine whether erlotinib as a single agent of chemotherapy is 
capable of improving outcomes in patients that progressed after 
first-line platinum-based chemotherapy. Current efforts focus on 
evaluating biomarker relationships with EGFR mutation status and 
algorithm validation in an effort to enhance survival in advanced 
stage NSCLC.
Keywords: biomarker, erlotinib, treatment selection, serum
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P3.06-052 A NOVEL TECHNIQUE THAT DISTINGUISHES 
LOW-LEVEL SOMATIC DNA VARIANTS FROM FFPE-
INDUCED ARTIFACTS IN LUNG AND OTHER SOLID TU-
MORS BY NEXT-GENERATION SEQUENCING (NGS)
Nitin Udar1, Robert Haigis1, Thomas Gros1, Nick Kerry1, Bret Bar-
nes1, Dmitry Pokholok1, Mark Ross1, Agda K. Lucio-Eterovic2, Qing-
xiu Zhang2, Maryam Zenali2, Erich Jaeger1
1Diagnostics, Illumina/United States Of America, 2MD Anderson Can-
cer Center, Institute Of Personalized Cancer Therapy/United States Of 
America
Background: Next generation sequencing is a powerful tool to 
investigate somatic changes in tumor DNA. However the challenge 
is to detect low-frequency variants (< 10% minor allele frequency, 
MAF) in DNA extracted from formalin-fixed-paraffin-embedded 
(FFPE) tissue. DNA extracted from FFPE is highly fragmented and 
chemically modified. To overcome these challenges, we have de-
veloped a novel technique that can distinguish true variants from 
fixation artifacts with high sensitivity and specificity by investiga-
ting each of the two DNA strands independently.
Methods: TruSeq Custom Amplicon technology was used to gene-
rate sequencing libraries and deep sequencing was carried out to 
an average depth of 20,000X with a minimum of 1000X. The targe-
ted re-sequencing assay* investigates ~14 kb of exons in 26 genes 
commonly mutated in solid tumors.
Results: Testing of more than 200 samples with a MAF 
≥5%threshold revealed the presence of a large number of potenti-
ally false positive calls when data from only one strand of DNA was 
analyzed, but this number was significantly reduced (e.g. >50% for 
G>A) when both strands were considered.
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mcL but was poor with higher or lower cfDNA concentrations. 
Serial assessment on erlotinib (Figure 2) demonstrated pret-
reatment detection of EGFR mutations with ddPCR, complete 
plasma response on erlotinib, and subsequent reemergence 
of plasma EGFR up to 16 weeks prior to objective progression. 
Conclusion: Plasma genotyping of cfDNA using ddPCR has 100% 
specificity when using a rigorously defined threshold for a positi-
ve result. Sensitivity is highest in specimens with optimal cfDNA 
concentration. Clinical development is underway to use this non-
invasive assay to guide genotype-directed therapy.
Keywords: digital droplet PCR, NSCLC, EGFR, plasma DNA
adenocarcinoma and non-adenocarcinoma NSCLC (overall and by 
country/region). Secondary objectives are: to describe first-line 
therapy following EGFR mutation testing and second-line therapy 
following discontinuation of first-line treatment in patients with 
EGFR mutation-positive NSCLC confirmed by tissue/cytology; to 
determine concordance between EGFR mutation status determi-
ned using tissue/cytology versus plasma; to summarize current 
EGFR testing practices (methods, sample types, mutation detec-
tion rate, turnaround time, and reasons for not performing testing); 
to determine correlations between EGFR mutation status (derived 
from tumor or plasma) and demographic data and disease status. 
The secondary analyses in this study will provide information on 
current testing and therapeutic practices in advanced NSCLC ac-
ross the Asia Pacific region and Russia, as well as an assessment of 
the utility of cfDNA as a less invasive methodology for the assess-
ment of EGFR mutation status in patients with NSCLC.
Results: Not applicable.
Conclusion: Not applicable.
Keyword: EGFR mutation testing; cfDNA; NSCLC
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P3.06-054 DEVELOPMENT OF A CLINICAL-GRADE 
QUANTITATIVE ASSAY FOR NON-INVASIVE MEASURE-
MENT OF TUMOR GENOTYPE IN CELL-FREE PLASMA 
DNA (CFDNA) USING NEXT-GENERATION QUANTITATI-
VE GENOTYPING
Geoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang, Melissa M. 
Messineo, Allison O‘Connell, Stacy L. Mach, Mohit Butaney, Peter 
C. Lo, David M. Jackman, Pasi A. Jänne
Dana-Farber Cancer Institute/United States Of America
Background: Non-invasive genotyping of cfDNA has been shown 
to be feasible using highly sensitive assays. However, for detection 
of uncommon genomic events, specificity must approach 100% or 
false positive results impair clinical utility. Digital droplet PCR (ddP-
CR) is a quantitative genotyping technology that emulsifies input 
DNA into ~20,000 droplets which are PCR amplified, fluorescently 
labeled, and read as mutant or wildtype in a droplet flow cyto-
meter. Using this quantitative technology, we aimed to develop a 
clinical-grade assay for non-invasive plasma genotyping and serial 
disease monitoring.
Methods: Patients with advanced NSCLC known to harbor EGFR 
or KRAS mutations were studied in an IRB-approved fashion. 
Plasma was collected in 10cc EDTA-tubes. Extracted DNA was 
quantified with a PCR for LINE1 and genotyped using ddPCR. Spe-
cificity of EGFR genotyping was determined using patients with 
KRAS-mutant lung cancer as gold standard negative cases. Serial 
assessment was piloted on EGFR-mutant cases receiving first-line 
erlotinib.
Results: To minimize risk of false positive results, we identi-
fied the “normal range” for EGFR L858R and exon 19 deleti-
ons in specimens from KRAS-mutant lung cancers as 0-1 and 
0-8 copies/mL of plasma, respectively. Using this threshold 
for positive, ddPCR for EGFR sensitizing mutations had 67% 
sensitivity and 100% positive predictive value (Figure 1). Sen-
sitivity was 100% with LINE-1 levels between 60-60000 pg/
S1100 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Keywords: VATS (Video-Assisted Thoracic Surgery), Thoracotomy, 
clinical stage IA NSCLC, Prognosis
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P3.07-002 PLEURAL LYMPH FLOWS EXCEEDING THE 
LUNG SEGMENT
Yui Watanabe, Aya Harada, Toshiyuki Nagata, Masaya Aoki, Ka-
zuhiro Wakida, Go Kamimura, Soichi Suzuki, Masashi Umehara, 
Naoya Yokomakura, Kota Kariatsumari, Yoshihiro Nakamura, 
Masami Sato
Department Of General Thoracic Surgery, Graduate School Of Medical 
And Dental Sciences, Kagoshima University/Japan
Background: Limited pulmonary resections including lung seg-
mentectomy for peripheral small lung cancer have attracted 
attention in recent years. However, a surgical consensus has not 
been established. It has been pointed out that there are not only 
lymph flows to pulmonary hilum along pulmonary vessels or bron-
chi but also pleural lymph flows directory into the mediastinum or 
adjacent lung lobe. There are some lung cancer cases with pleu-
ral indentation less than twenty millimeters. In these cases, it is 
concerned that lymph flows carry metastases from the pulmonary 
segment directly into the mediastinal lymph nodes without passing 
through the hilar lymph nodes. In other words, skip metastases 
might be caused. However, there have been few reports investiga-
ting pleural lymph flows exceeding the lung segment. The present 
study was designed to evaluate whether pleural lymph flows ex-
ceeding the lung segment could be detected using indocyanine 
green (ICG) and a fluorescence imaging system intraoperatively.
Methods: Fourteen patients undergoing lung segmentectomy or 
lobectomy for a tumor were enrolled in this study. A jet ventilation 
is selectively applied under bronchofiberscopy to the burdened 
bronchus to develop an anatomic border between the inflated 
segment to be evaluated and the deflated area. A 1.0 ml solution 
containing the fluorescent dye ICG (2.5 mg/ml) was injected into 
three to five subpleural sites of the segment. Fluorescence imaging 
device (HyperEye Medical System, MIZUHO IKAKOGYO CO.,LTD. 
Tokyo, Japan) was used to monitor the ICG-containing lymph flows 
from the injection site for five minutes. We evaluated the presence 
of pleural lymph flows exceeding the lung segment.
Results: We observed pleural lymph flows in eight of fourteen 
cases (57.1%), and pleural lymph flows exceeding the lung segment 
in seven of fourteen cases (50.0%). There is no pleural lymph flow 
from superior segment of bilateral lower lobe exceeding the seg-
ment in studies of several segments. 
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P3.07-001 LONG-TERM OUTCOME AND CURRENT PRO-
BLEMS OF VATS VERSUS OPEN LOBECTOMY FOR CLINI-
CAL STAGE IA NON-SMALL CELL LUNG CANCER
Mitsunori Higuchi1, Goichi Endo1, Osamu Konno1, Ryuzo Kanno1, 
Akio Ohishi1, Hiroyuki Suzuki2
1Thoracic Surgery, Fukushima Red Cross Hospital/Japan, 2Thoracic 
Surgery, Fukushima Medical University/Japan
Background: The oncologic efficacy of lobectomy for lung cancer 
by means of video-assisted thoracic surgery (VATS) compared with 
conventional thoracotomy has been reported, and VATS lobecto-
my is now considered to be one of the standard surgical procedu-
res for lung cancer. In this study, we retrospectively evaluated the 
long-term prognosis and some problems after VATS lobectomy, 
comparing with conventional thoracotomy, for clinical stage IA 
non-small cell lung cancer (NSCLC) in our institution.
Methods: From July 2002 to June 2012, 160 patients were diag-
nosed as clinical stage IA NSCLC and they underwent lobectomy. 
Of those 160 patients, 114 patients underwent VATS lobectomy 
and 46 patients underwent lobectomy under conventional thora-
cotomy. Patients’ clinical characteristics, recurrent status and ove-
rall survival were recorded. Disease free survival (DFS) and overall 
survival (OS) were calculated by means of Kaplan-Meier analysis 
and statistical significance between the groups was analyzed by 
using log-rank tests. Cox proportional hazard regression was used 
to ascertain independent predictors of recurrence.
Results: Median follow-up time was 44.8 months. 5-year DFS was 
88.0% in VATS group and 77.1% in thoracotomy group in clinical 
stage IA (p=0.1504), and 91.5% in VATS group and 93.8% in tho-
racotomy group in pathological stage IA (p=0.2662). 5-year OS 
was 94.1% in VATS group, whereas 81.8% in thoracotomy group in 
clinical stage IA (p=0.0268), and 94.8% in VATS group and 96.2% in 
thoracotomy in pathological stage IA (p=0.5545). Cox proportional 
hazard analysis demonstrated a lower risk of recurrent disease in 
patients without lymph nodes metastases in this series (p=0.0026). 
The accurate diagnostic rate of preoperative staging was 71.9% in 
VATS group and 56.5% in thoracotomy group (p=0.2611). Inconsis-
tent factors between clinical and pathological stage were largely 
tumor size (12.3% and 17.4%), nodal statement (10.0% and 21.1%) 
and pleural involvement (15.0% and 15.8%) in VATS group and 
thoracotomy group, respectively. There were 27 recurrent lesions 
(22 cases) at the first time of recurrence after surgery in this study. 
Twelve lesions (11 cases) with distant metastases were detected in 
VATS group, whereas 8 lesions (5 cases) were occurred distant me-
tastases in thoracotomy group. Interestingly, only one lesion with 
local recurrence was detected in VATS group, whereas 6 lesions (5 
cases) in thoracotomy group were detected (p=0.0495).
Conclusion: There was no significant inferiority for DFS and OS in 
VATS group, and local control was also significantly better in VATS 
group, compared with thoracotomy group. On the other hand, the 
significant difference of OS between two groups in clinical stage 
IA and multivariate analysis for recurrence showed the insufficiency 
of accurate staging before surgery.
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(83%), methylmethacrylate (25.4%), bioprosthetic mesh (5.1%). Soft 
tissue reconstruction required free tissue transfer (6.8%) and local 
muscle flaps (45.7%). Diaphragm reconstruction was required in 
18.6% patients. The overall complication rate was 62%; which was 
subdivided into pulmonary complications (48%), cardiac complica-
tions (12%), and wound complications (17%). On average, patients 
were ventilator dependent for 3.9 days, required ICU monitoring 
for 4.9 days, and were discharged after 15.6 days. Mean follow-up 
time was 36 months. The 90-day overall survival rate of patients 
after initial procedure was 89.4%; all deaths occurred within supe-
rior resections (p=.03). Average postoperative decreases in FEV1 
and FVC were 6.8% and 5.3%, respectively. Patients with superior 
resections and those older than 60 years were more likely to have 
post-operative complications.
Conclusion: In patients with massive oncologic thoracic defects, 
complex reconstructions are associated with a high rate of com-
plications. However, creation of a stable construct is possible to 
prevent debilitating respiratory impairment and minimize pleural 
complications. Frequently, massive defects may be reconstructed 
with local muscle flaps obviating the need for free flaps. Prospec-
tive multicenter trials are warranted to differentiate and establish 
superiority of specific techniques and implant devices within these 
rare but challenging cases.
Keyword: Thoracic Reconstruction, Muscle Flaps
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P3.07-004 A NOVEL SOFT-COAGULATION SYSTEM FOR 
LUNG CANCER SURGERY: MINIMIZATION OF SURGE-
ONS‘ RISK
Akihiko Uchiyama1, Kei Miyoshi1, Katsuya Nakamura2
1Department Of Surgery, Kyushu Kosei-neNKIn Hospital/Japan, 2Surge-
ry And Oncology, Kyushu University Hospital/Japan
Background: The soft-coagulation system VIO is a new device 
for tissue coagulation in which the output voltage is automatically 
regulated. This system controls the temperature below the boiling 
point, without generating sparks, thereby causing minimal damage 
to surrounding tissues. This study was designed to evaluate the 
usefulness of a soft-coagulation system for lung cancer surgery in 
the viewpoint of minimizing surgeons’ risk.
Methods: We used soft-coagulation system VIO (ERBE Elektrome-
dizin, Tubingen, Germany) for major pulmonary resections in 223 
consecutive patients with primary lung cancer from January 2009 
through April 2013. Bipolar soft-coagulation mode was used for tis-
sue coagulation around lobar vessels, fissure dissection, and lymph 
node dissection. Three general thoracic surgeons were enrolled in 
this study. The checkpoints included blood loss, incidence of int-
raoperative complications, and surgeons’ stress. The data among 
the 223 patients who underwent major pulmonary resections using 
the VIO system (VIO group) were compared with data on 122 pa-
tients with primary lung cancer who underwent major pulmonary 
resection in our institution between January 2006 and December 
2008 using conventional electrocautery (CE group). Student’s t-
test was used to examine intergroup difference in blood loss. The 
threshold of significance was set at P<0.05).
Results: The patients consisted of 116 men and 107 women with 
a median age of 70.3 years. The type of resection was lobectomy 
Conclusion: Pleural lymph flows exceeding the lung segment can 
be observed in vivo. Skip metastases may occur through subpleu-
ral lymph channels in subpleural lung cancer cases. We should pay 
attention to skip metastases when we perform limited pulmonary 
resections for such cases.
Keywords: skip metastasis, limited resection, Lung cancer, Pleural 
Lymph Flow
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P3.07-003 FUNCTIONAL OUTCOMES IN RECONSTRUC-
TION OF MASSIVE CHEST WALL DEFECTS: A 17-YEAR 
EXPERIENCE
Mark Clemens, Patrick Garvey, Joseph Corkum, Jun Liu, Elizabeth 
David, Donald Baumann, Wayne Hofstetter, Charles Butler
Plastic Surgery, MD Anderson Cancer Center, University Of Texas/Uni-
ted States Of America
Background: Large chest wall resections with significant loss of 
the skeletal framework can result in flail chest, prolonged ventilator 
dependence, and major respiratory impairment. Limited case re-
ports address the extreme situation of massive chest wall defects, 
defined as oncologic resection of 5 or more ribs. We review our 
institutional experience and compare patient demographics, surgi-
cal techniques, and clinical outcomes to evaluate which factors are 
predictive or protective of complications.
Methods: Patients information was prospectively entered into 
a departmental database and then retrospectively reviewed. All 
consecutive patients who underwent immediate reconstruction of 
massive thoracic neoplastic or oncologic-related defects (≥5 ribs 
resected) between 1994 – 2011 were included. Tumor defect and 
reconstructive factors were evaluated for possible relationships 
with complications. Logistic regression analysis evaluated predicti-
ve factors for surgical outcomes.
Results: A total of 59 patients (median age 53) were available for 
review. Rib resections ranged from 5 to 10 ribs (defect area 80-
690cm2). Indications included lung malignancy (52.5%), sarcoma 
(33.9%), and squamous cell carcinoma (5.9%). Types of rigid and 
semi-rigid reconstruction included use of prosthetic implants 
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Conclusion: The long-term follow-up of patients with completely 
resected NSCLC revealed that recurrence-free survival was related 
to the pathological stage of the original lung cancer, but postre-
currence survival was not. Only pleural invasion of the original lung 
cancer was related to both recurrence-free and postrecurrence 
survival. Moreover, postrecurrence survival was related to both site 
and treatment of the initial recurrence. In brief, the more advan-
ced stage a lung cancer is at, the earlier it recurs. However, after 
recurrence, postrecurrence survival is related to the recurrence site 
or type of treatment of recurrent disease, rather than original lung 
cancer stage. The incidence of metachronous primary lung cancer 
was stable over time after the initial surgery.
Keywords: recurrence-free survival, multiple primary lung cancer, 
non-small cell lung cancer, post-recurrence survival
in 200 patients, bilobectomy in 5, pneumonectomy in 6, and seg-
mentectomy in 12. All pulmonary resections were performed by 
thoracotomy. Thoracoscopy was used in all cases for assistance. 
The pathological stage was stage IA in 129, IB in 43, IIA in 8, IIB 
in 14, IIIA in 24, IIIB in none, and IV in 4. With the VIO system, co-
agulation of tissues around the lobar vessels was effective without 
injury to the pulmonary vessels or bronchus. The mean blood loss 
in the VIO group was 76.1 g (range 5-700 g), which was significantly 
lower than that in the CE group (mean 175.3 g, range 5-1580 g) 
(P<0.0001). There was no intraoperative complication. The inter-
view has shown that all three surgeons experienced less stress in 
surgery with soft-coagulation system, compared to surgery with 
CE.
Conclusion: The results of this study showed that the VIO soft-
coagulation system is safe and feasible for major pulmonary re-
sections in patients with primary lung cancer. This device could 
contribute to improve safety during dissection of the lobar vessels 
and decrease the surgeons’ risk in lung cancer surgery.
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P3.07-005 RECURRENCE-FREE AND POST-RECURRENCE 
SURVIVAL AND THE INCIDENCE OF METACHRONOUS 
PRIMARY LUNG CANCER AFTER COMPLETE RESECTION 
OF NON-SMALL CELL LUNG CANCER
Chiaki Endo, Hirotsugu Notsuda, Akira Sakurada, Takashi Kondo
Thoracic Surgery, Tohoku University Hospital/Japan
Background: In patients with completely resected non-small cell 
lung cancer, recurrence-free and postrecurrence survival, and me-
tachronous primary lung cancer, have not been well studied at the 
same time.
Methods: A total of 315 patients with non-small cell lung cancer 
who underwent complete resection between 2001 and 2005 were 
examined. Patients were routinely assessed with chest computed 
tomography scan and physical checkups every 4 months for the 
first 2 years, and every 6 months from the third to fifth year. After 
that, they were examined annually. Accordingly, surviving patients 
can be followed up for five years or more after surgery.
Results: Median recurrence-free survival was 15.7 months. Multiva-
riate analysis showed that pathological stage and pleural invasion 
were associated with decreased recurrence-free survival (Fig1). 
Median postrecurrence survival was 18.7 months. Multivariate 
analysis indicated that male gender, pleural invasion, extrathoracic 
recurrence and supportive care for recurrence were associated 
with decreased postrecurrence survival (Fig 2). The cumulative rate 
of metachronous primary lung cancer at 5 years was 3.7 %, and it 
developed at even eight years after initial surgery. 
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P3.07-007 INDUCTION TREATMENT FOR LOCALLY AD-
VANCED LUNG CANCER DETERIORATES PULMONARY 
FUNCTION
Hiroshi Niwa, Masayuki Tanahashi, Haruhiro Yukiue, Eriko Suzu-
ki, Naoko Yoshii, Hiroshi Haneda
Division Of Thoracic Surgery, Respiratory Disease Center, Seirei Mi-
katahara General Hospital/Japan
Background: Preoperative induction treatment combining chemo-
therapy or chemoradiotherapy with surgical treatment may impro-
ve the prognosis of locally advanced lung cancer patients. On the 
other hand, induction treatment is associated with a higher inci-
dence of postoperative pulmonary complications. We investigated 
the patients who received preoperative induction treatment to as-
sess the respiratory function before and after induction treatment, 
and association with postoperative respiratory complications.
Methods: Preoperative induction therapy followed by surgery was 
performed for cT3-4 or cN2-3 locally advanced lung cancer in 118 
of the 1,820 patients undergoing lung cancer resection between 
January 1997 and December 2012. Sixty-nine patients with com-
plete data on the respiratory function before and after preoperati-
ve induction therapy were analyzed. 
Pulmonary functions before and after induction therapy were 
analyzed. Predicted postoperative those pulmonary functions 
also analyzed in the patients with pulmonary complication (group 
PORC) and without pulmonary complications (group NPORC). 
Independent group t tests were performed and p value<0.05 was 
considered statistically significant.
Results: There were 58 males and 11 females and median age was 
61 years old. There were 38 adenocarcinomas, 20 squamous cell 
carcinomas, and 11 other pathologies. There were 11 stage IIB 
patients, 41 stage IIIA, and 17 stage IIIB. All patients received mul-
tidisciplinary induction treatment. Forty-three patients received 
induction chemoradiotherapy and 26 patients received induction 
chemotherapy. There was no significant change in %VC, %FEV1 
before and after induction therapy. %DLCO (p<0.05) and DLCO/
VA (p<0.01) were significantly decreased after induction treatment. 
More decrease of %DLCO was observed after induction chemo-
radiotherapy than chemotherapy (p<0.03). After the induction 
treatment lobectomy was performed in 51 patients, bi-lobectomy 
in 7, pneumonectomy in 10, and segmentectomy in 1. Combined 
resection of chest wall was performed in 16 patients, vertebra in 
5, left atrium in 5, superior vena cava in 2, and diaphragm in 1. 
Sleeve lobectomy performed in 6 patients, sleeve bi-lobectomy 
in 3 and sleeve pneumonectomy in 1. Complete excision rate was 
91.3%. Pathological analysis revealed that the ratio of patients 
obtained Ef 2-3 response were 56% after chemo-radiotherapy and 
27% after chemotherapy (p<0.01). Median survival rate was 44.7 
months and 5-year survival rate was 36％ for all patients. Especially 
5-year survival rate of patients who obtained Ef 2-3 response after 
chemo-radiotherapy was 67%. There was no operative death and 
morbidity rate was 35%. Respiratory complications occurred in 12 
patients. There were 8 pneumonia patients and 4 persistent hypo-
xemia patients. Ppo%VC, ppo%FEV1, ppo%DLCO, and ppoDLCO/
VA were significantly low in the PORC group.
Conclusion: Higher proportion of patients obtained Ef 2-3 respon-
se after induction chemoradiotherapy and these patients showed 
a more favorable prognosis. DLCO should be evaluated to select 
candidates for induction therapy. Predicted postoperative pulmo-
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P3.07-006 ROBOTIC ASSISTED LOBECTOMY: A  
PLATFORM FOR INCREASING MINIMALLY INVASIVE 
PULMONARY RESECTIONS
Patrick Ross, Patsy L. Skabla, Edmund Kassis, Susan Moffatt-Bru-
ce, Kate Glass, Vincent Daniel
Division Of Thoracic Surgery, Ohio State University/United States Of 
America
Background: Minimally invasive pulmonary resection has been 
accepted as a technique for performing lobectomy since the mid 
1990s; however, despite a number of effectiveness studies, the 
percentage of VATS lobectomies remains low. By some estimates, 
VATS lobectomy accounts for only 8 to 20 % of all lobectomy ca-
ses. We evaluated the development of a robotic assisted lobecto-
my program and short term outcomes. We assessed the impact of 
this platform on the rate of minimally invasive resections.
Methods: All patients undergoing robotic lobectomy were con-
sented and entered into an IRB approved outcomes registry at the 
time of initial surgical consent. Multiple variables including length 
of operation, hospital stay, duration of chest tubes, complications, 
and mortality were evaluated. Medical records of patients under-
going robotic-assisted lobectomy between September 2011 and 
May 2013 were reviewed. Case logs for the years 2010 through 
20123 were tallied to provide aggregate data on pulmonary resec-
tion.
Results: Histology for these patients included adenocarcinoma 
(45), squamous cell (20), benign disease (13), carcinoid (7), metasta-
ses from other primary (7). Stages of NSCLC were: I (56%), II (16%), 
IIIa (14%) and IV (6%). Ten of 87 patients with NSCLC had induc-
tion therapy (9 chemo/rad, 1 chemo). Conversion to thoracotomy 
occurred in 10% overall, but was performed in 3 of 10 induction 
patients. LOS (6d v 5d) and operative time (275 min v 221min) were 
longer in the induction group. When analyzed by quartile, average 
duration of robotic assisted lobectomy decreased from 280 min to 
170 min. LOS decreased by 2 days over the initial 100 cases. Mor-
tality rate was 1%. The minimally invasive case percentage prior to 
robotic assisted resection was 24%. During the first year of robotic 
assisted surgery, this minimally invasive value increased to 78%. In 
the second year of robotic assisted lobectomy, 86% of resections 
were performed with minimaly invasive approach.
Conclusion: In 2011, we added a robotic assisted surgery program 
into a multi-surgeon comprehensive thoracic oncology service. As 
expected, procedure times and need to convert to thoracotomy 
decreased as experience was acquired despite the increasing com-
plexity of procedures. Robotic assisted resection has applicability 
to all stages of NSCLC including patients receiving induction thera-
py. Most importantly, robotic assisted surgery provided a platform 
for significantly increasing the rate of minimally invasive lobectomy 
in our institution.
Keywords: robotics, general thoracic, lobectomy, minimally inva-
sive
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other illness in 75-79 years old male is the most important.
Keyword: NSCLC, elderly, surgery
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P3.07-009 COMBINED USE OF VIRTUAL PUNCTURE BY 
SIMULATOR WITH METHYLENE BLUE STAIN LOCALIZA-
TION OF THE PULMONARY PERIPHERAL NODULES
Liang Zhang, Yang Shen-Tu
Shanghai Chest Hospital/China
Background: To explore the new technique of combined use of 
virtual puncture by simulator with methylene blue stain localization 
of the pulmonary peripheral nodules. And, evaluate the efficacy on 
focus localization and the clinical useful value of this method. To 
explore the new technique of combined use of virtual puncture by 
simulator with methylene blue stain localization of the pulmonary 
peripheral nodules. And, evaluate the efficacy on focus localization 
and the clinical useful value of this method.
Methods: During July 2011 to February 2013, total 80 pulmonary 
peripheral nodules of 75 patients were virtually punctured before 
operation. The methylene blue injected after anesthesia according 
to the identified skin point, angle and depth of preoperative virtual 
puncture. Then, marked lung tissue wedge resected under VATS. 
The samples were examined by pathologist during operation. The 
proper surgical style was decided to the pathological results. All 
of the data, including focus diameter, distance of colored spot and 
the lesions, localization time, interval time from injection finished 
to stain spot observed , successful localization and complication 
rate, were recorded and analyzed.
Results: 75 of 80 pulmonary peripheral noudles were successfully 
localized. The accuracy rate of localization is 92.65%. Forty two no-
dules were primary lung cancer, those patients were accepted the 
lobectomy and systematic lymph node dissection. Twenty five no-
dules were benign lesion, one was metastatic tumor. Focus diame-
ter was 10.15±3.57mm, distance of stain spot and the lesions was 
5.54±2.83mm, localization time was 22.44±5.19min, interval time 
of injection finished to stain spot observed was 16.93±2.17min. All 
cases had no complication.
Conclusion: The new technique, combined preoperative virtual 
puncture by simulator with methylene blue stain localization of the 
pulmonary peripheral nodules, has high accuracy rate and safety. 
It is useful to localize the pulmonary peripheral nodules, especially 
for the early stage lung cancer lesion which hard to be seen or 
palpated during VATS.
Keyword: lung cancer, pulmonary nodules, simulator, methylene 
blue
nary function should be assessed before surgery to select patients 
and to avoid critical pulmonary complications.
Keywords: DLCO, locally advanced lung cancer, induction chemo-
radiotherapy, pulmonary function test
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P3.07-008 SURGERY OF NON-SMALL CELL LUNG CAN-
CER IN THE ELDERLY, COMPARISON BETWEEN 75-79 
YEARS OLD CASES AND 80 YEARS OR OLDER CASES
Osamu Kawamata
Surgery, Onomichi Municipal Hospital/Japan
Background: Non-small cell lung cancer (NSCLC) is a typical di-
sease of the elderly, and is becoming increasingly. Surgical resec-
tion is standard treatment for early-stage NSCLC. Our objective 
was to evaluate on surgery of NSCLC in the elderly, and assess the 
problem after surgical resection for NSCLC. We analyzed type of 
operation, postoperative complication, overall survival and cause 
of death for older patients undergoing surgical resection for NS-
CLC. We compare the clinical features of surgery of NSCLC in 75-
79 years old patients and 80 years or older patients.
Methods: Of a total 140 patients aged 75 years or older who 
underwent surgery for NSCLC at our hospital between 2000 and 
2012, there were classified into 75-79 years old and 80 years or 
older.
Results: Surgery of NSCLC in 75-79 years old and 80 or greater 
was 83 cases and 57 cases. 56(67.5%) patients in 75-79 years old 
and 36(63.2%) patients in 80 or greater were men. Adenocarci-
noma constituted the most common pathologic subtype in two 
groups, 56(67.5%) cases in 75-79 years old, 42(73.7%) cases in 80 or 
greater. 55(66.3%) patients in 75-79 years old and 47(82.5%) pati-
ents in 80 or greater had stage IA/IB disease. 56(67.5%) patients in 
75-79 years old and 32(56.1%) patients in 80 or greater underwent 
lobectomy. 19(22.9%) patients in 75-79 years old and 14(24.6%) 
in 80 or greater underwent segmentectomy. 7(8.4%) patients in 
75-79 years old and 11(19.3%) in 80 or greater underwent wedge 
resection. Only one patient in 75-79 years old underwent pneu-
monectomy. Morbidity rate in 75-79 years old was 26.5%, and in 
80 or greater was 22.8%. Atrial fibrillation was the most common 
postoperative complications in two groups. Mortality rate in 75-79 
years old was 3.6%, and in 80 or greater was 3.5%. 30 patients in 
75-79 years old and 12 patients in 80 or greater died within post-
operative five years, 11 of 30 patients died for lung cancer and 19 
patients died for the other illness. 15 of 19 patients were men, 3 of 
15 were another organ cancer and 4 of 15 were respiratory failure. 
6 of 12 patients died for lung cancer and other patients died for 
the other illness. Overall survival at 5 years in 75-79 years old was 
58.5%, and in 80 or greater was 66.8%. Overall survival at 5 years 
in 75-79 years old male was 54.1%, and in female was 67.1%. Over-
all survival at 5 years in 80 or greater male was 68.6%, and in fema-
le was 64.3%. Overall survival at 5 years of stage IA in 75-79 years 
old was 80.8% and in 80 or greater was 78.7%.
Conclusion: Surgical resection of NSCLC in 75 years or older is 
permitted, especially in particular good indication for stage IA. 
However, long-term survival rate in 75-79 years old male was the 
poorest. The reason is that the ratio to die of the other illness was 
the highest. We thought that the decrease of the death by the 
S1105Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Non-Emergent 
Case Hospital 
Death
8% 6% 0.7
Stage 1&2 Survival 
(mo -median)
26 26 0.74
Conclusion: Attempting VATS pneumonectomy appears to be a 
safe strategy that does not compromise short-term or long-term 
oncologic goals.
Keywords: pneumonectomy, VATS, Thoracoscopy
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P3.07-011 PROGNOSTIC AND PREDICTIVE FACTORS 
FOR RECURRENCE-FREE SURVIVAL IN PATIENTS WITH 
COMPLETELY RESECTED PN2 NON-SMALL CELL LUNG 
CANCER
Hirofumi Uehara1, Masayuki Nakao1, Mingyon Mun1, Yuichi 
Ishikawa2, Ken Nakagawa1, Sakae Okumura1
1Thoracic Surgical Oncology, The Cancer Institute Hospital Of Japan 
Foundation For Cancer Research/Japan, 2Division Of Pathology, The 
Cancer Institute, Japanese Foundation For Cancer Research/Japan
Background: The role of surgical resection remains controversial 
for pathologic N2 (pN2) non-small cell lung cancer (NSCLC). The 
objective of our study was to determine the prognostic and pre-
dictive factors for recurrence-free survival (RFS) in patients with 
completely resected pN2 NSCLC.
Methods: Between 1990 and 2009, 2439 patients with NSCLC 
underwent curative surgical resection at the Cancer Institute Hos-
pital. Of these patients, 311 (12.8%) were diagnosed as having pN2 
NSCLC. Surgical resection was performed in 79, 71, 70, and 91 
patients in 1990–1994, 1995–1999, 2000–2004, and 2005–2009, 
respectively. Overall survival (OS) and RFS were calculated using 
the Kaplan-Meier method, and survival outcomes were assessed 
using the log-rank test. Univariate and multivariate Cox proportio-
nal hazards models were used to identify factors influencing RFS.
Results: The patient population comprised 199 male and 112 
female patients, with ages ranging from 16 to 84 years (median, 
61.4). Lobectomies or bilobectomies were conducted in 263 cases, 
and pneumonectomies were performed in 48 cases. For the entire 
cohort, 5-year OS and 5-year RFS rates were 46% and 24%, res-
pectively. The median follow-up time was 44 months. OS and RFS 
rates were 34% and 23% in 1990–1994, 42% and 34% in 1995–1999, 
45% and 20% in 2000–2004, and 59% and 20% in 2005–2009, 
respectively. The recent improvement in OS was remarkable, whe-
reas the RFS rate did not improve. Multivariate analysis identified 
4 independent predictors for poor RFS: multiple-zone mediastinal 
lymph node metastasis (hazard ratio [HR], 1.551; P = .002), ipsilate-
ral intrapulmonary metastasis (HR, 1.038; P = .002), tumor size > 30 
mm (HR, 1.007; P = .046), and clinical N1 or N2 stage (HR, 1.039; P 
= .041). Patients were grouped according to the number of risk fac-
tors for poor RFS. Patients with none of the identified risk factors 
had an RFS rate of 32%, those with 1–2 factors had an RFS rate of 
25%, and those with 3–4 factors had an RFS rate of 7% (P < .001).
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P3.07-010 THORACOSCOPIC PNEUMONECTOMY -  
AN 11 YEAR EXPERIENCE
Todd L. Demmy, Ariba Jahan, Athar Battoo, Sai Yendamuri, Elisa-
beth Dexter, Mark Hennon, Anthony Picone, Chuwumere Nwogu
Thoracic Surgery, Roswell Park Cancer Institute/United States Of America
Background: While VATS lobectomy yields enhanced recovery and 
fewer complications than open approaches, outcomes for thoraco-
scopic pneumonectomy are understood less well.
Methods: 107 consecutive pneumonectomy cases performed at a 
comprehensive cancer center from 1/2002 to 12/2012 were studied 
retrospectively. 40 cases were open, while 50 Successful and 17 
VATS conversions were grouped together for an intent-to-treat  
analysis.
Results: Preoperative characteristics were similar except for greater 
age (64±10 vs. 60±10, p=0.07), female sex (57 vs. 30% p=0.007) and 
preoperative comorbidities in the VATS group (Table 1). Right side 
was similar (46% vs. 45% open, p=0.9) as was disease extent (Early 
Stage 1&2, 72 vs. 61% open, p = 0.24). Neoadjuvant chemotherapy 
use also was similar (34 vs. 40% open). All VATS pneumonectomy 
pulmonary arteries were controlled safely and there were no intra-
operative deaths from bleeding or other technical mishaps. Pursuing 
a VATS approach yielded a similar number of complications (3.1±2.6 
vs. 3.0±2.6, p=0.8). Completion pneumonectomy (13%VATS/8% 
open) patients stayed longer (median 7.5 vs. 5 days, p=0.05) but had 
better survival (median not reached vs 27 months, p=0.05) largely 
because of more favorable stage distribution. A learning curve was 
evident as the rate of successful VATS pneumonectomy rose from 
26% to 63% by the second half of the series (p<0.001). VATS pati-
ents started adjuvant chemotherapy an average of 39 days earlier. 
Excluded from long-term analyses were 7 pneumonectomies (3% 
VATS/13% open) for emergent indications like hemoptysis that led 
to 3 deaths. Stage-matched pneumonectomy cases had similar 
survival curves between the two groups. Multivariate logistic regres-
sion analyses found only age and pathologic stage as independent 
predictors of overall and disease-free survival. While the subset 
of patients who required conversion from VATS stayed longer (7 
vs. 6 days, p=0.07), their survival curves were superimposable on 
open operations for all stages. In fact, achieving a successful VATS 
pneumonectomy demonstrated a trend toward improved survival 
compared to open/converted cases for early stage patients (median 
survival 80 vs. 27 months, p=0.07).  
Procedure VATS n=67 Open n =40 p
Predicted Post-
resection Diffusing 
Capacity
38±10% 36±12% 0.6
Comorbidities 
(number)
3.2±1.7 2.3±1.3 0.001
Nodes retrieved 25±14 24±11 0.87
OR time (min -me-
dian)
289 225 0.001
EBL (ml -median) 400 325 0.84
ICU (days -median) 3 2 0.24
Hospital Stay (days 
-median)
5 6 0.2
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Background: With the increase in life expectancy, surgical treat-
ment of non-small cell lung cancer (NSCLC) in elderly patients 
became more frequent. The aim of this study is to evaluate the risk 
factors for short and long-term outcomes after pulmonary resec-
tion in the elderly patients with stage I NSCLC.
Methods: From October 1994 to December 2011, the patients 
who were surgically treated with curative intent and pathologically 
diagnosed as stage I NSCLC were included. The patients were 
divided into two groups; elderly group (≥70 years) and younger 
group (<70 years). Comorbidity and surgical factors were analyzed 
for thirty-day mortality, hospital stay and overall survival in both 
groups.
Total 1,340 patients were enrolled and 285 patients (21.3%) were 
classified as the elderly group and 1,055 patients (78.7%) as the 
younger group. The thirty-day mortality was 8 of 1,340 patients 
(0.6%) and all of the patients were elderly. The only independent 
factor for thirty-day mortality in elderly group was diffusing capaci-
ty for carbon monoxide (DLCO) less than 70% of predicted (hazard 
ratio, 12.9; p = 0.001). The elderly group had significantly longer 
hospital stay (11.2 12.2 vs. 8.0 6.7 days, p < 0.001). Open thoraco-
tomy (p < 0.001), DLCO less than 70% of predicted (p < 0.001) and 
percentage of one second forced expiratory volume over forced vi-
tal capacity (FEV1/FVC) less than 70% (p = 0.005) were significantly 
associated with longer hospital stay. In-Hospital complication rate 
in elderly patients was also significantly higher (47.7 vs. 26.9%, p 
< 0.001). 5-year overall survival rates were 91.1% in the younger 
group and 66.2% in the elderly group. In the elderly group, pre-
vious history of tuberculosis (p = 0.004) and interstitial pulmonary 
fibrosis (IPF; p = 0.015), DLCO less than 70% of predicted (p = 
0.004), preoperative creatinine higher than 1.5 mg/dL (p = 0.022), 
and more extensive pulmonary resection (p = 0.012) were the inde-
pendent risk factors for overall survival. On the other hand, previ-
ous history of IPF (p < 0.001) and pathologic stage IB over IA (p < 
0.001) were the independent risk factors in the younger group.
Conclusion: Pulmonary resection for the elderly patient requires 
caution, particularly in case of low diffusing capacity (DLCO < 70%) 
or airflow limitation (FEV1/FVC < 70%).
Keywords: non-small cell lung cancer, Elderly Patient, surgery
Conclusion: In patients with surgically resected pN2 NSCLC, OS 
tended to improve in recent years, whereas RFS was fairly constant 
over the study period. The overall prognosis of patients with sur-
gically resected pN2 NSCLC remains poor. However, prognosis is 
considerably better in those patients with fewer risk factors. Accor-
dingly, surgical resection could be beneficial in select patients.
Keywords: pathologic N2, surgery, recurrence-free survival, non-
small cell lung cancer
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P3.07-012 PULMONARY RESECTION FOR STAGE I NON-
SMALL CELL LUNG CANCER IN ELDERLY PATIENTS
Byungjoon Park, Jhingook Kim, Young Mog Shim, Jae Il Zo, Yong 
Soo Choi, Genehee Lee
Cadiovascular And Thoracic Surgery, Samsung Medical Center, Sung-
kyunkwan University School Of Medicine/Korea
Results: The Risk factors for short and long term outcome after pulmonary resection in elderly patients with stage I 
NSCLC
Risk factor 
30-day mortality (Pearson’s 
Chi-Square Test) 
Hospital stay (Linear Re-
gression Model) 
5-year survival (Cox Ha-
zard Model) 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
DLCO less than 70% 12.9 (1.8-93.6) 0.001 5.0 (2.7-7.3) < 0.001 3.4 (1.5-8.0) 0.004 
FEV1/FVC less than 70% NS 2.5 (0.8-4.3) 0.005 NS 
Open thoracotomy NS 3.6 (2.3-4.8) < 0.001 NS 
Pulmonary tuberculosis NS NS 3.3 (1.5-7.5) 0.004 
Interstitial pulmonary 
fibrosis NS NS 5.0 (1.4-18.0) 0.015 
Creatinine higher than 
1.5mg/dL NS NS 5.7 (1.3-25.3) 0.022 
Extensive resection NS NS 4.4 (1.4-14.0) 0.012 
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Keyword: chylothorax, video-assisted thoracoscopic pulmonary 
resection
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P3.07-014 POST-RECURRENCE SURVIVAL OF SURGI-
CALLY RESECTED NON-SMALL CELL LUNG CANCER  
PATIENTS IN THE ERA OF EGFR-TKI
Yuki Matsumura1, Junji Yoshida2, Tomoyuki Hishida1, Keiju  
Aokage1, Genichiro Ishii3, Yuichiro Ohe2, Kanji Nagai1
1Division Of Thoracic Surgery, National Cancer Center Hospital East/Japan, 
2Department Of Thoracic Oncology, National Cancer Center Hospital East/
Japan, 3Pathology Division, Research Center For Innovative Oncology, Natio-
nal Cancer Center Hospital East/Japan
Background: Although surgical resection is the standard treatment of 
choice for early stage non-mall-cell lung cancer (NSCLC), not a small 
percentage of patients recur even after complete resection, and post-
recurrence survival (PRS) is dismal. Since epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitor (TKI) was approved for pati-
ents with advanced or recurrent NSCLC in 2002 in Japan, the number 
of long-term survivors after recurrence seems to be increasing. There 
have been few reports on post-recurrence survival in the era of EGFR-
TKI. In the present study, we analyzed PRS in patients with completely 
resected NSCLC after EGFR-TKI was introduced in clinical practice.
Methods: From 1992 to 2010, 3058 NSCLC patients underwent 
complete resection in our hospital. Among them, 938 (31%) patients 
recurred. Of them, 503 patients, who recurred in 2002 or later and 
received anticancerous treatment, were the subject of this analysis. 
We retrospectively analyzed their clinicopathological characteristics, 
PRS, and identified favorable prognostic factors.
Results: The median age at recurrence was 68 years (range: 23-91), 
and 332 (58%) of them were men. There were 347 (69%) adenocar-
cinoma patients and 101 (20%) squamous cell carcinoma patients. 
The pathological stages of the primary cancers were I in 183 patients 
(36%), II in 120 (24%), and III in 200 (40%), respectively. Fifty-six pa-
tients (11%) underwent reoperation for recurrent lesions. Of the 216 
patients whose EGFR mutation was examined, mutation was positive 
in 97 patients (45%). The median period of follow-up after recurrence 
was 49 months (range: 7-124). The overall 3- and 5-year PRS were 27% 
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P3.07-013 CHYLOTHORAX COMPLICATING VIDEO- 
ASSISTED THORACOSCOPIC PULMONARY RESECTION 
IN NON-SMALL CELL LUNG CANCER
Chao-Yu Liu1, Wen-Hu Hsu2, Chien-Sheng Huang2, Yu-Chung Wu2, 
Yung-Han Sun3, Po-Kuei Hsu2
1Division Of Thoracic Surgery, Department Of Surgery, Far Eastern Me-
morial Hospital/Taiwan, 2Division Of Thoracic Surgery, Department Of 
Surgery, Taipei Veteran General Hospital/Taiwan, 3Graduate Institute 
Of Business And Management, Chang Gung University/Taiwan
Background: Chylothorax complicating pulmonary resection 
(CCPR) is an infrequent but well-known complication in lung can-
cer surgery. Previous published studies on this topic were limited 
and standard thoracotomy for pulmonary resection (STPR) was 
the surgical approach. Video-assisted thoracoscopic pulmonary 
resection (VATPR) has become prevalent in the lung cancer surgery 
nowadays. The purpose of this study is to analyze the clinical data 
of CCPR after VATPR and evaluate their outcome after treatment.
Methods: Between January 2010 and May 2013, we retrospec-
tively reviewed 728 primary non-small cell lung cancer patients 
who undergone VATPR and mediastinal lymph node dissection 
(MLND) in our institute. CCPR were noted in 18 patients (2.47%) 
who constitute the subjects of our study. We initially treated these 
patients conservatively with oral intake cessation and parenteral 
nutrition. If conservative treatment failed, reoperation with video-
assisted thoracic surgery (VATS) for thoracic duct ligation would be 
performed. Daily pleural drainage amount, timing of surgical inter-
vention, and treatment responses were recorded and investigated. 
The data collected were compared to other studies in which STPR 
was the main operative method.
Results: Among the 18 CCPR cases, all of them were adenocarci-
noma on the right side of lung. Thirteen of patients received con-
servative treatment and 5 patients received reoperation for CCPR. 
All of them were successfully treated with cessation of CCPR wit-
hout mortality. The average pleural drainage amounts per day in 
conservative treatment group and reoperation group were 206 ml 
and 433 ml. The presented study suggests that CCPR with pleural 
drainage amount less than 400 ml in the first postoperative day will 
subsided after conservative treatment. CCPR with pleural drainage 
amount more than 400 ml in the first or second postoperative day 
can also resolve if drainage amount below 400 ml was seen in the 
postoperative day 4 and thereafter. Reoperations would be under-
taken for CCPR in cases with increasing amount of pleural drainage 
in the postoperative 4 after conservative treatment.
Conclusion: chylothorax, video-assisted thoracoscopic pulmonary 
resectionVATPR did not incur more CCPR than did STPR in NSCLC 
surgery. The average pleural drainage amount of CCPR in reope-
ration cases was less in our study than that in other studies. The 
timing of surgical intervention for CCPR following VATPR can be 
earlier if pleural drainage didn’t show trend of decrease after con-
servative treatment. 
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Total N=70 Clinical Stage : N(%) 
Pathologic Stage: 
N(%) 
Ia 49 (70%) 34 (48.6%) 
Ib 6 (8.6%) 16 (22.9%) 
IIa 8 (11.4%) 6 (8.6%) 
IIb 3 (4.3%) 4 (5.7%) 
IIIa 3 (4.3%) 9 (12.8%) 
IIIb 0 0 
IVa 0 0 
IVb 1 (1.4%) 1 (1.4%) 
 
Table 2: Intraoperative and postoperative outcomes  
N % 
Intraoperative data 
OR extubation 66 94 
Conversion to open 13 18 
Blood transfusion 1 1.4 
Death 0 0 
Average EBL 83 
Postoperative data 
Atrial fibrillation 10 14 
Bronchoscopy 9 12.8 
Prolonged air leak (>7days) 8 11.4 
Blood transfusion 7 10 
Pneumonia 5 7.1 
Respiratory failure (reintubation) 2 2.8 
Reoperation within 30 days 2 2.8 
Readmission within 30 days 2 2.8 
Pulmonary embolism 1 1.4 
DVT 1 1.4 
Average Chest Tube Days 4.1 
 
EBL: estimated blood loss; DVT: deep vein thrombosis
Conclusion: This is the first report on feasibility and outcome of 
robotic thoracic surgery in a high risk veteran population. Our data 
suggest that robotic-assisted pulmonary resection for NSCLC can 
be performed with acceptable morbidity and mortality in this co-
hort.
Keywords: Robotic surgery, Veteran Population, High Risk, Lung 
cancer
and 16%, respectively and their median PRS length was 19 months. 
The multivariate analysis revealed that adenocarcinoma, negative 
pleural invasion, locoregional recurrence, surgical resection of re-
current lesion, positive EGFR mutation were independent favorable 
prognostic factors. The 3-year PRS rate and median PRS length of 
the patients undergoing surgery and those with EGFR mutation were 
60% (55 month) and 46% (35 month), respectively.
Conclusion: The PRS was still poor, but longer survival can be expec-
ted in selected patients, who have resectable recurrence or EGFR 
mutation.
Keywords: surgery, non-small cell lung cancer, post-recurrence survi-
val, EGFR-TKI
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P3.07-015 ROBOTIC-ASSISTED PULMONARY RESECTION 
FOR NON-SMALL CELL LUNG CANCER IN HIGH RISK  
VETERAN POPULATION: A SINGLE INSTITUTION  
EXPERIENCE
Amir Abolhoda, Vincent Kirkpatrick, Raja Narayan, May Thein, 
Ian Gordon
Surgery, Long Beach Veterans Administration Healthcare System/Uni-
ted States Of America
Background: The value of robotics in surgical treatment of lung can-
cer is not well-defined. Our goal was to examine the surgical results 
of robotic-assisted pulmonary resections in a high risk profile veteran 
population. .
Methods: A retrospective analysis of a single VA facility’s robotic 
thoracic surgical experience from January 2011 to May 2013 was 
performed. A total of 70 consecutive patients had undergone robotic 
pulmonary resections, by a single surgeon, for treatment of non-small 
cell lung cancer (NSCLC). All preoperative, intra- and postoperative 
data including length of stay (LOS) and readmission rates were collec-
ted.
Results: 60 lobar and 10 sublobar (wedge) pulmonary resections plus 
mediastinal/hilar lymph node staging had been performed. Mean 
number of lymph node stations sampled were 3.5 (range 2-7). Mean 
age was 68 (40-86). 33 (47%) patients were active smokers. 42 (60%) 
patients had hypertension, 34 (48%) had COPD, 15 (21%) had BMI 
>30, 14 (20%) had DM, 13 (19%) had documented coronary artery 
disease, 11 (16%) had history of alcohol abuse, 7 (11%) had renal insuf-
ficiency defined as creatinine > 1.3, and 3 (4%) had received induction 
therapy. Average preoperative FEV1 and DLCO were 76% and 68% of 
predicted, respectively. Stage distribution is shown in Table 1. Intra- 
and postoperative data are summarized in Table 2. Thirty day mortali-
ty was 1.4% (1). 20 patients sustained at least one complication (28.5% 
morbidity). Mean LOS for the entire cohort was 7 days; mean LOS for 
those 57 patients having undergone completely robotic resection was 
6 days. Prolonged air leak was the most prevalent reason for an exten-
ded LOS. Table 1: Clinical and pathologic stage distribution.  
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Table 1. Cardiovascular and respiratory events in the chronic 
phase for the patients with and without postoperative cardio-
pulmonary complications in the acute phase after lung cancer 
surgery.
Variables
With  
cardiopulmo-
nary compli-
cations (N=90) 
Without  
cardiopul-
monary com-
plications 
(N=370) 
P  
Value
All events 13 (14%) 14 (4%) <0.001
Cardiovascular 
events
7 (8%) 7 (2%)
Acute heart  
failure
3 1
Arrhythmias 1 2
Coronary artery 
disease
0 3
Peripheral vascu-
lar disease
2 0
Cerebrovascular 
disease
1 1
Respiratory 
events
6 (7%) 7 (2%)
Pneumonia 5 6
Acute  
respiratory  
distress  
syndrome
0 1
Chronic  
respiratory  
failure
1 0
Conclusion: Postoperative cardiopulmonary complications in the 
acute phase were associated with the incidence of cardiovascular 
and respiratory events in the chronic phase after lung cancer sur-
gery. It is important for those with postoperative cardiopulmonary 
complications to be careful about not only cancer recurrence but 
also cardiovascular and respiratory events in the long-term period.
Keywords: Lung cancer surgery, Postoperative complications, 
long-term outcome
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P3.07-016 CLINICAL IMPACT OF POSTOPERATIVE CAR-
DIO-PULMONARY COMPLICATIONS ON LONG-TERM 
OUTCOME IN LUNG CANCER PATIENTS
Takashi Nojiri1, Yukiyasu Takeuchi2, Hajime Maeda2, Yasushi 
Shintani1, Masayoshi Inoue1, Noriyoshi Sawabata1, Meinoshin 
Okumura1
1General Thoracic Surgery, Osaka University Graduate School Of Medi-
cine/Japan, 2General Thoracic Surgery, National Hospital Organization 
Toneyama Hospital/Japan
Background: Postoperative cardiopulmonary complications repre-
sent a major source of morbidity and mortality in the acute phase 
after lung cancer surgery. However, clinical impacts of postopera-
tive cardiopulmonary complications on long-term outcome were 
not well studied. The objective of this study was to investigate the 
effects of postoperative cardiopulmonary complications in the 
acute phase on cardiovascular and respiratory events in the chro-
nic phase after lung cancer surgery.
Methods: From a prospective single-Institution database of 496 
consecutive patients who underwent a lung cancer surgery bet-
ween August 2008 and December 2011, we retrospective analysed 
medical charts of all patients with curative surgery for non-small 
cell lung cancer. Patients with limited surgery (n=32) and postope-
rative mortality (n=4) were excluded from the analysis. The remai-
ning 460 patients were analysed for the incidence of cardiovascular 
and respiratory events in the chronic phase after surgery. Results 
were compared between the patients with and without postopera-
tive cardiopulmonary complications in the acute phase.
Results: Postoperative cardiopulmonary complications were iden-
tified in 90 (20%) patients; these patients included more advanced 
patients with pathological stage IB-III compared to those without 
cardiopulmonary complications (60% vs. 48%; p < 0.05). There 
were significantly higher cardiovascular and respiratory events in 
those with postoperative cardiopulmonary complications than 
those without (Table 1, 14% vs. 4%; p < 0.001). Also, there was 
significantly higher incidence of cancer recurrence in those with 
postoperative cardiopulmonary complications than those without 
(27% vs. 20%; p < 0.05).  
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P3.07-018 ASSESSING SURVIVAL AND GRADING THE 
SEVERITY OF COMPLICATIONS IN OCTOGENARIANS 
UNDERGOING PULMONARY LOBECTOMY
Elizabeth N. Mckeown1, Brian E. Louie2, Eric Vallieres2, Ralph W. 
Aye2, Jed A. Gorden2, Alexander S. Farivar2
1Surgical Residency, Swedish Medical Center/United States Of America, 
2Department Of Thoracic And Foregut Surgery, Swedish Medical Cen-
ter/United States Of America
Background: Previous papers have demonstrated that pulmonary 
lobectomy on octogenarians is safe and feasible. However, there is 
little data characterizing the survival or the severity of complications 
in these frail patients after lobectomy. Therefore we reviewed our 
experience with patients aged eighty and above undergoing lobec-
tomy.
Methods: We performed a retrospective review of consecutive pa-
tients aged 80 or above that underwent lobectomy between 2004 
and 2012. Chart reviews were performed evaluating comorbidities, 
clinical stage, perioperative and postoperative course, time to recur-
rence, and date and cause of death. All complications were graded 
per the Seely Thoracic Surgery morbidity and mortality classification 
schema.
Results: 45 patients (mean 82.2 years) underwent lobectomy. PFTs 
averaged 86% predicted for FEV1. Pathologic stage IA comprised 
26% (10 of 39) of our patients; IB 33%(13), IIA 8% (3), IIB 8% (3), IIIA 
18% (7), IIIB 3% (1), and IV 5% (2). Of the 45 patients, 28 had com-
plications (60%), but only 18% (8 of 45) were significantly morbid to 
the patient (grade IIIB or above). Perioperative mortality was 2% (1 
of 45). The most common complication was arrhythmia. Median LOS 
was 6 days for thoracotomy patients, 5.5 days for VATS patients, 
and 4.5 days for robot. 78% were discharged home, and 16% were 
readmitted to hospital within thirty days. Six patients had recurrent 
disease that occurred at an average of 768 days. 50% of our patients 
are still alive. Only three of the seven known causes of death were 
from metastatic disease. Five year actuarial survival was 52.3%. 
Mean survival was 53 months, and median survival was 72 months.  
Complications Separated by Grade
Grade Definition Example Incidence
Grade I
Clinically Insig-
nificant
Asymptomatic 
vocal cord pa-
ralysis, urinary 
retention
4% (2 of 45)
Grade II
Medical Thera-
py Only
AFib, esopha-
gitis, new home 
O2
26.7%  
(12 of 45)
Grade IIIA
Interventions 
not requiring 
anesthesia
Percutaneous 
pleural catheters
13.3%  
(6 of 45)
Grade IIIB
Interventions 
requiring anes-
thesia
Return to OR 8.8% (4 of 45)
Grade IV
Critical illness, 
reintubation, 
organ failure
MI, PNA, chyle 
leak
6.7% (3 of 45)
Grade V Death 2.2% (1 of 45)
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P3.07-017 EXAMINATION OF THE SURGICAL PROCE-
DURES FOR METASTATIC PULMONARY TUMORS (CON-
FIRMATION OF THE TUMOR LOCAL EXISTENCE BY THE 
PALPATION)
Shozo Fujino1, Masato Watanabe2, Takehiro Okumura1
1Surgery, University Hospital Mizonokuchi, Teikyo University School Of 
Medicine/Japan, 2Thoracic Surgery, Kanagawa Cancer Center/Japan
Background: The small pulmonary lesions, the localization of 
which cannot be confirmed by the sight, are often removed sur-
gically with help of markers. But it is the most certain to confirm 
local existence of tumors with help of palpation and remove them 
surgically. I examine the metastatic pulmonary tumor operation 
cases in our hospital and identify the usefulness of hand assisted 
thoracoscopic surgery (HATS).
Methods: Thirty nine patients underwent surgery from July 2007 
to November 2012 (colorectal cancer 24 cases, soft tissue tumor 
5 cases, gynecology territory malignancy 3 cases, others 7 cases). 
Tumors which existed in the hilum of lung, multiple tumors in the 
same lobe or segment of lung and tumors which were diagnosed 
as primary lung cancers before surgery were removed by lobec-
tomy or segmentectomy. The localization of small tumors which 
cannot be seen by sight were tried to confirm by palpation in all 
cases. Ten lobectomies, 2 segmentectomies and 27 partial resec-
tions were performed. Standard thoracotomy was done in 5 cases, 
video-assisted thoracic surgeries were done in 30 cases and HATS 
was done in 4 cases. In HATS cases, a hand of surgeon was inser-
ted into the thoracic cavities of patient through a subxiphoid skin 
incision.
Results: Localized confirmation was possible in all cases using 
an ocular inspection and palpation without markers. Fifty seven 
tumors were excised in 39 cases (an average of 1.46) and 9 other 
lesions (including intrapulmonary lymph nodes and granuloma) 
were excised simultaneously. The maximum tumor diameters are 
3-75mm (an average of 15.7mm).
Conclusion: New lesions which cannot be discovered by preope-
rative CT were confirmed by HATS. Local existence confirmation 
by the palpation with a finger from a small open chest wound and 
palpation by HATS is very important to remove pulmonary lesions 
without fail.
Keywords: Metastatic Pulmonary Tumors, local existence confir-
mation, palpation, hand assisted thoracoscopic surgery
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Conclusion: Sex-based differences in the morbidity associated 
with resection for NSCLC were noted, with a significant impro-
vement in several important short –term outcomes for women 
compared to men. As the percent of female NSCLC patients in-
crease, these data carry significant implications in procedural risk 
stratification and in comparison of modern surgical trials to historic 
controls.
Keywords: gender, surgery, non-small cell lung cancer, morbidity
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P3.07-020 NONINTUBATED THORACOSCOPIC LOBEC-
TOMY FOR LUNG CANCER: EXPERIENCE OF TWO ME-
DICAL CENTERS FROM TAIWAN AND CHINA
Ming-Hui Hung1, Ya-Jung Cheng1, Ke-Cheng Chen1, Jun Liu2, Fei 
Cui2, Jin-Shing Chen1, Jianxing He2
1National Taiwan University Hospital/Taiwan, 2The First Affiliated 
Hospital Of Guangzhou Medical College/China
Background: General anesthesia with single-lung ventilation is 
considered mandatory for thoracoscopic lobectomy for non-small 
cell lung cancer (NSCLC). Nonintubated thoracoscopic lobectomy 
has rarely been reported previously. The objective of this study 
was to evaluate the feasibility and safety of thoracoscopic lobecto-
my without endotracheal intubation.
Methods: From August 2009 through March 2013, 196 patients 
with clinical stage I or II NSCLC were treated by non-intubated 
thoracoscopic lobectomy using epidural anesthesia, intrathoracic 
vagal blockade, and sedation at National Taiwan University Hospi-
tal, Taiwan, and The First Affiliated Hospital of Guangzhou Medical 
College, China.
Results: The mean age of the patients were 59 years and 128 
(65.3%) were female. Collapse of the operative lung and inhibiti-
on of coughing were satisfactory in the non-intubated patients, 
induced by spontaneous breathing and vagal blockade. Sixteen 
patients (8.2%) required conversion to intubated-single lung ven-
tilation because of significant mediastinal movement, persistent 
hypoxemia, dense pleural adhesions, and bleeding. Two patients 
were converted to standard thoracotomy because of bleeding. The 
mean postoperative chest tube drainage and postoperative hos-
pital stay were 3.6 days and 6.8 days, respectively. Postoperative 
complications were noted in 23 (11.7%) patients, including prolon-
ged air leaks, arrhythmia, pneumonia, and bleeding. No operation 
mortalities were noted.
Conclusion: Non-intubated thoracoscopic lobectomy is technically 
feasible and safe. It can be a valid alternative of single-lung venti-
lated thoracoscopic lobectomy in managing selected patients with 
early-stage NSCLC.
Keywords: Lung cancer, Nonintubated Thoracoscopic Lobectomy, 
VATS, surgery
Conclusion: Lobectomy on carefully selected octogenarians can 
be done safely regardless of approach with a low mortality. 60% 
experienced a complication but when graded in a validated sys-
tem only 18% were considered significant.
Keywords: Lung cancer, lobectomy, Octogenarians, complications
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P3.07-019 SEX-BASED DIFFERERNCES IN MORBIDITY 
AND MORTALITY ASSOCIATED WITH NON-SMALL CELL 
LUNG CANCER RESECTIONS
Audrey Pendleton, Harvey Pass, Gerardo Gonzalez, Judith Gold-
berg, Ryan Harrington, Bernard Crawford, Micheal Zervos, Costas 
Bizekis, Jessica Donington
New York University School Of Medicine/United States Of America
Background: Stage for stage, women have superior survival com-
pared to men with non-small cell lung cancer (NSCLC). This inclu-
des women undergoing resection, but little is reported regarding 
sex-based differences in operative morbidity, mortality, and length 
of hospital stay (LOS) following NSCLC resection.
Methods: We retrospectively evaluated all patients undergoing 
primary NSCLC resections at our institution from 01/07-12/08 to 
evaluate the prognostic significance of female sex on morbidity, 
mortality and LOS.
Results: A total 259 patients were included, 155 females and 104 
males. The majority of resections were lobectomy (162/259) and 
by VATS (161/259). Women were significantly younger (70.6 vs. 
74.0 years, p=0.006), reported fewer pack years smoked (30 vs. 
44 years, p=0.001), had more adenocarcinoma histology (86% vs. 
63%, p<0.001) and had higher percent predicated forced expi-
ratory volume in 1 second (FEV1%)(84 vs. 77, p=0.014) than men. 
No other significant differences in pre-treatment demographics, 
tumor characteristics or surgical procedures were noted. A signifi-
cantly reduced rate of post operative atrial fibrillation (5% vs. 13%, 
p=0.031), prolonged air leak (8% vs 16%, p=0.044), any complica-
tion (28% vs. 44%, p=0.007), and LOS (5.0 vs. 5.98 days, p=0.031) 
was noted for women. In multivariate analysis, which included age, 
pack years and FEV1%, male sex remained a significant predictor 
for the occurrence of a post-operative complication (p= 0.007). 
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from 76% to 43% (P = 0.003).
Conclusion: Encouraging long-term survival can be achieved even 
with an increasingly aggressive surgical approach to pulmonary 
metastasis. Although sarcoma patients tend to present with rapidly 
progressive and extensive pulmonary disease, a tendency toward 
confinement of metastasis to the lungs may justify an even more 
aggressive surgical strategy for these patients.
Keyword: Surgery, Metastasis, Sarcoma, Aggressive
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P3.07-022 PREOPERATIVE LIPIODOL MARKING FOR 
SMALL-SIZED LUNG TUMORS
Junichi Shimada, Daishiro Kato, Masanori Shimomura, Hiroaki 
Tsunezuka, Satoru Okada, Shunta Ishihara, Hirofumi Suzuki
General Thoracxic Surgery, Kyoto Prefectural University Of Medicine/
Japan
Background: Recent advances in imaging modalities have enabled 
detection of small-sized lung tumors at earlier stages with resultant 
dramatic changes in therapeutic strategies. However, if preopera-
tive pathological diagnosis is not possible, video-assisted thoracic 
surgery (VATS) for therapeutic resection as well as diagnostic exci-
sional biopsies may be indicated. Small-sized lung tumors, such as 
bronchioloalveolar carcinoma, are difficult to localize during surgery 
by visualizing or palpating the lung surface because the lung is a 
soft and deformable organ and contains air. Accurate intraoperative 
localization of the tumor is critical to surgeons. We usually perform 
preoperative lipiodol marking for small-sized tumors, particularly 
those located deep in the lung, to create a “visible target” from an 
invisible and impalpable tumor. This visualization technique enables 
resection of marked lesions under X-ray fluoroscopy.
Methods: From May 2006 through March 2013, we performed 
preoperative lipiodol marking for 356 lesions in 215 cases in which 
unconfirmed lung tumors were less than 10 mm in diameter, loca-
ted deep to the visceral pleura, or of ground-glass opacity. One to 
five markings with lipiodol were performed in each case. The mean 
diameter of the lesions was 7.7 ± 5.1 mm (2–33 mm), and they were 
located 10.1 ± 9.5 mm (0–54 mm) below the surface of the visceral 
pleura. CT-fluoroscopy guidance was used to inject 0.1–0.5 mL lipi-
odol in the vicinity of the tumor before surgery. During VATS, X-ray 
fluoroscopy was used to confirm lesion location and to guide resec-
tion of the lipiodol-marked lesion.
Results: The average duration of the marking procedure was 18.4 
minutes per lesion. Regarding complications, pneumothorax occur-
red in 40 cases (18.6%), but there were no cases of air embolization 
and no histological modifications in or around lipiodol markings. Of 
the 356 lesions, 354 (99.4%) were detectable and safely resected. 
Pathological examinations revealed lung cancer in 54 lesions, aty-
pical adenomatous hyperplasia in 8, metastatic lung tumor in 165, 
organized pneumonia in 115 and other benign lesions in 12.
Conclusion: Lipiodol marking with CT-fluoroscopy guidance before 
VATS is a useful technique for small and impalpable lung tumors.
Keywords: CT fluoroscopy, lipiodol, lung tumor
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P3.07-021 PULMONARY METASTASIS, PARTICULARLY 
OF SARCOMAS, AMENABLE TO AGGRESSIVE SURGICAL 
MANAGEMENT
Joseph A. Reza1, Amanda Sammann1, Chengshi Jin2, Matthew 
Hudnall1, Andrew Horvai3, Thierry Jahan4, David M. Jablons1, John 
Kornak2, Michael J. Mann1
1Division Of Cardiothoracic Surgery, University Of California, San 
Francisco/United States Of America, 2Department Of Epidemiology 
And Biostatistics, University Of California, San Francisco/United States 
Of America, 3Department Of Pathology, University Of California, San 
Francisco/United States Of America, 4Division Of Hematology & Onco-
logy, University Of California, San Francisco/United States Of America
Background: Metastatic lesions are the most common malignancy 
of the lungs. In the past, pulmonary metastatectomy was reserved 
for cases of solitary or oligo-metastasis. Over the past decade, 
however, indications for surgical treatment of pulmonary metasta-
sis have broadened for many cancers. Sarcomas have a predilec-
tion for spread to the lungs, often in the absence of metastasis to 
other organs. We examined our experience with an increasingly 
aggressive approach to pulmonary metastasis, to help define evol-
ving parameters and expectations for clinical outcomes, exploring 
the perceived differences in the clinical patterns between sarcoma 
and other cancers.
Methods: We identified 262 patients who underwent a total of 361 
R0 pulmonary metastatectomies, 336 of which were performed at 
UCSF Medical Center between 1996 and 2009. Sarcoma was the 
primary tumor in 118 patients undergoing 180 of these operations. 
Survival estimates were based on Kaplan-Meier analysis and com-
pared using either a log-rank or Wilcoxon test. Predictors included 
surgical procedure; number/size of lesions; repeat resection; inter-
vals to metastasis (DFI) and to recurrent metastasis; chemotherapy; 
cancer type; distribution of pulmonary and extra-pulmonary me-
tastasis; patient age/sex. These predictors were compared using 
univariate and multivariate Cox proportional hazards modeling; 
multiple-predictor modeling started with a set of predictors based 
on historical/clinical significance, and stepwise forward selection 
determined which additional predictors were included until all p-
values in the model were less than 0.1.
Results: Despite an increasingly aggressive surgical approach, 
reflected in an increase in number of lesions, the percentage of 
patients with > 8 lesions, the number of patients with lesions < 1 
cm, and in a decrease in DFI, the overall 5-year survival was 48% 
(median survival 4.7 years, 95%CI 3.5-5.5), and did not differ bet-
ween the early and late periods of the study. Sarcoma patients, 
however, tended to be significantly younger (46 ± 16 yrs vs. 59 
± 14, P<0.001), and to have more lesions (4.0 ± 4.3 vs. 2.3 ± 2.3, 
P<0.001), a shorter DFI (2.5 ± 3.3 yrs vs. 3.6 ± 3.9, P = 0.004), more 
diffuse pulmonary involvement (43% bilateral disease vs. 29%, P 
= 0.02), and more frequent recurrence rate (80% vs. 51%, <0.001) 
than the non-sarcoma patients. Whereas lesion size (HR 1.2, 
P=0.004), age (HR 1.4, P<0.001), DFI (HR 2.1, P=0.008), and extra-
pulmonary disease (HR 1.9, P=0.04) were all independent predic-
tors of survival for non-sarcomas, only metastasis synchronous to 
the primary tumor (HR 2.7, P=0.007) and a need for anatomic re-
section (HR 2.5, P=0.006) independently predicted a higher morta-
lity among sarcomas. Furthermore, a need for repeat resection did 
not impact the survival of sarcoma patients as long as complete 
resection remained feasible, whereas the 5-year survival of patients 
even with resectable recurrent non-sarcoma metastases dropped 
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P3.07-024 THE ENDO-FINGER TECHNIQUE FOR THE LO-
CALIZATION OF SMALL PULMONARY GROUND GLASS 
NODULES UNDER THORACOSCOPIC SURGERY
Kazuhiro Sakamoto1, Kohei Ando1, Daisuke Noma1, Shinya G. 
Amano1, Shigeto Sudo2, Hideto Goto2, Yasushi Yamakawa2, Moto-
fumi Tsubakihara2, Masahiro Tsuboi3, Munetaka Masuda4
1Department Of Respiratory Surgery, National Yokohama Medical Cen-
ter/Japan, 2Department Of Respiratory Medicine, National Yokohama 
Medical Center/Japan, 3Department Of Respiratory Surgery, Yokohama 
City University Medical Center/Japan, 4Department Of Surgery, Yoko-
hama City University School Of Medicine/Japan
Background: Small pure ground glass nodules (GGNs) have someti-
mes been detected by high resolution computed tomography (CT). 
Pathologically, most of these pure GGNs are bronchioloalveolar 
carcinoma (BAC) or atypical adenomatous hyperplasia (AAH). In pu-
blished papers, the thoracoscopic resection of the pure GGNs was 
reported to be difficult, because they cannot usually be palpated. 
Therefore, various marking techniques, such as those using a hook 
wire, colored collagen, barium, lipiodol and so on, have been descri-
bed for the localization of pure GGNs. However, these techniques 
are associated with the development of several complications, such 
as pneumothorax, hemorrhage, and serious air embolism. Moreover, 
they requires a lot of time. In this study, we evaluated the localiza-
tion of small pure GGNs in thoracoscopic surgery using the endo-
finger technique.
Methods: Patients with peripheral pure GGNs that were 20 mm and 
less in diameter who planned to undergo resection in our institute 
were candidates for this study. Preoperatively, no marking technique 
was performed. Thoracoscopy was performed in the lateral position 
under single lung anesthesia. Thoracoports were placed near the 
GGNs based on the CT findings. One finger was inserted through 
the port into the pleural cavity to palpate the lung to localize the 
GGNs (the endo-finger technique). After the GGNs were detected, 
they were resected by endostaplers with adequate safety margin.
Results: Since January 2005, twenty patients with thirty-four GGNs 
were enrolled in this study. The size of the GGNs was 5 mm or less 
in eight lesions, 6 – 10 mm in 14 lesions, 11 – 15 mm in nine lesions 
and 16 – 20 mm in three lesions. The depth of the lesions from the 
visceral pleura ranged from 0 – 14 mm. The main reasons for the 
resection were a need for another ipsilateral simultaneous operation 
in six cases, the patients’ requests in five cases and enlargement of 
the GGNs during the follow-up period in three cases. All but one 
GGN could be detected using the endo-finger technique with two 
or three thoracoports, and were resected. Some of the GGNs adja-
cent to the visceral pleura were visualized by thoracoscopy as color 
changes in the visceral pleura. There was one conversion to thora-
cotomy in one patient who had a severe pleural adhesion due to a 
previous ipsilateral lobectomy of the lung. No complications occur-
red in association with this procedure. The pathological diagnoses 
of the GGNs were BAC in 23 nodules, AAH in nine, hyperplasia of 
the alveolar epithelium in one and an inflammatory lesion in one. 
The surgical margins of all of the resected specimens were patholo-
gically negative.
Conclusion: The endo-finger technique is safe and useful for the 
localization and resection of peripheral GGNs during thoracoscopic 
surgery. We suggest that the preoperative marking to detect GGNs 
can be replaced by the endo-finger technique in some cases.
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P3.07-023 CHANGES IN SYMPTOM OCCURRENCE RA-
TES AND SEVERITY RATINGS BEFORE AND FOLLOWING 
LUNG CANCER SURGERY
Trine Oksholm1, Tone Rustoen1, Bruce Cooper2, Christine Mias-
kowski2, Johny Kongerud1
1Oslo University Hospital/Norway, 2School Of Nursing, University Of 
California/United States Of America
Background: Knowledge about symptoms is an important out-
come to evaluate following lung cancer surgery because patients 
want information about the usual course of recovery of their 
physical and mental health. Patients need information at hospital 
discharge about when they need to contact their clinician if sym-
ptoms persist. Because to our knowledge only three studies have 
evaluated the occurrence of symptoms in patients prior to and 
following lung cancer surgery, the purpose of this study was to 
evaluate for changes in symptom occurrence ratings and severity 
scores from the preoperative period to 1 month after surgery using 
a multidimensional symptom assessment scale (i.e., Memorial Sym-
ptom Assessment Scale (MSAS)).
Methods: Patients were recruited from three university hospitals 
in Norway. They completed a number of self-report questionnaires 
prior to and again at 1 month following surgery. The question-
naires provided information on demographic and clinical characte-
ristics and symptoms. Patients’ medical records were reviewed for 
disease and treatment information. Descriptive statistics were used 
to present demographic and clinical characteristics. McNemar‘s 
test was used to evaluate for changes over time in symptom oc-
currence rates. Paired t-tests were done to evaluate for changes 
in severity scores for patients who reported severity scores either 
preoperatively, postoperatively, or on both occasions. Because the 
severity ratings were skewed, 1000 bootstrapped samples were 
taken for each analysis to provide unbiased estimates.
Results: The sample consisted of 129 (57%) men and 99 (43%) 
women who had a mean age of 65.8 years (SD=8.5, range 30 to 
87). The total number of symptoms increased significantly from 
the preoperative ( =9.4, SD=7.2) to the postoperative ( =13.1, 
SD=6.8, p<.001) assessment. Of the 11 symptoms that occurred 
in more than 50% of the patients at 1 month, 8 of them increased 
significantly from the preoperative to the postoperative period. 
Eight of the symptoms increased in both their occurrence rates and 
severity scores (i.e., lack of energy, pain, feeling bloated, lack of 
appetite, shortness of breath, feeling drowsy, dry mouth, sweats). 
Only one symptom had a significant reduction in its severity score, 
namely cough. Four symptoms were experienced by more than 
80% of the patients at the 1 month assessment, namely: shortness 
of breath (85.5 %), lack of energy (83.8%), pain (83.8%), and feeling 
drowsy (82.5%).
Conclusion: Findings from this study suggest that patients experi-
ence a high number of symptoms after surgery. These findings can 
be used to educate patients about the normal course of postope-
rative recovery. In addition, clinicians need to assess for these sym-
ptoms and develop effective interventions to improve symptom 
management for this vulnerable group of patients.
Keyword: surgery; symptoms; preoperative; postoperative
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Conclusion: 
In the clinical practice, the modified ACCP risk flow chart may be 
easier to apply and useful for the perioperative risk assessment of 
the patients with lung cancer being considered for standard resec-
tion.
Keywords: perioperative risk, Lung cancer surgery, preoperative 
physiologic assessment, ACCP guidelines
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P3.07-026 A NON-INTERVENTIONAL STUDY ON EGFR 
MUTATION STATUS AND CLINICAL OUTCOMES OF  
CHINESE PATIENTS WITH COMPLETELY RESECTED 
LUNG ADENOCARCINOMA (ICAN STUDY)
Yi-Long Wu1, Jun Wang2, Xiang-Yang Chu3, Zhi-Dong Liu4, Yi 
Shen5, Haitao Ma6, Xiang-Ning Fu7, Jian Hu8, Nai-Kang Zhou3, 
Yongyu Liu9, Xinming Zhou10, Jian-Jun Wang11, Kang Yang12, Jian 
Li13, Lin Xu14, Si-Yu Wang15, Qun Wang16, Lun-Xu Liu17, Shun Xu18, 
Shanqing Li19, Zhongyuan Chen20, Honghe Luo21, Ying Chen22, 
Changli Wang23
1Guangdong Lung Cancer Institute, Guangdong General Hospital/
China, 2Peking University People‘s Hospital/China, 3301hospital/Chi-
na, 4Beijing Chest Hospital, Capital Medical University/China, 5The 
Affilated Hospital Of Medical College Qingdao University/China, 6The 
First Affiliated Hospital Of Soochow University/China, 7Tongji Hos-
pital, Tongji Medical College, Huazhong University Of Science And 
Technology/China, 8The First Affiliated Hospital Of Medical School Of 
Zhejiang University/China, 9Liaoning Cancer Hospital & Institute/Chi-
na, 10Zhejiang Cancer Hospital/China, 11Union Hospital, Tongji Medical 
College, Huazhong University Of Science And Technology/China, 12The 
First Affiliated Hospital Of Third Military Medical University/China, 
13Peing University First Hospital/China, 14Jiangsu Cancer Hospital/Chi-
na, 15Thoracic Surgery, Sun Yat-Sen University Cancer Center/China, 
16Zhongshan Hospital Fudan University/China, 17West China Hospital, 
Keywords: ground glass nodule, THORACOSCOPIC SURGERY, 
endo-finger technique
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P3.07-025 PREOPERATIVE PHYSIOLOGIC ASSESSMENT 
OF LUNG CANCER SURGERY USING THE MODIFIED 
ACCP GUIDELINES
Tatsuo Nakagawa, Naohisa Chiba, Masao Saito, Yasuto Sakaguchi, 
Shinya Ishikawa
Thoracic Surgery, Tenri Hospital/Japan
Background: The American College of Chest Physicians(ACCP) 
has published the revised guidelines on preoperative physiologic 
assessment of lung cancer surgery. However, the relevance of the 
guidelines has not yet evaluated enough, partially because cardi-
opulmonary exercise testing recommended for achieving to the 
patients with poor predicted postoperative lung function is availa-
ble in only limited institutions.
Methods: Initial analysis was conducted to examine the 
relationship between the maximum oxygen consumption (VdotO2 
max) measured from cycling ergometer and the minimum 
saturation level (SpO2min) or maximum desaturation level (ΔSpO2) 
during 6 minute walking test (6MWT). In the next analysis, we 
modified the risk assessment flow chart in ACCP guidelines using 
SpO2min and ΔSpO2 instead of VdotO2 max. The patients with 
lung cancer who underwent lobectomy or more resection were 
retrospectively assessed using the modified flow chart.
Results: Using the data obtained from 39 patients with cardiac 
diseases and five healthy volunteers, we analyzed the correlation 
between VdotO2 max and variables of 6MWT. VdotO2max was 
significantly correlated to SpO2min and ΔSpO2 (r=0.469,p=0.001 
and r=-0.458, p=0.002,respectively). Receiver operating 
characteristic (ROC) analysis revealed that both SpO2min and 
ΔSpO2 was available for the detection of the patients with 
VdotO2max of <15 mL/kg/min which is the borderline value 
between the average and increased risk group in ACCP guidelines 
(AUC 0.802, p=0.001 and AUC 0.802, p=0.001, respectively). 
When the cut-off value was set as SpO2min <91%, sensitivity and 
specificity was 85.2％ and 70.6％,respectively. When the cut-off 
value was set as ΔSpO2>4%, sensitivity and specificity was 74.1
％and 76.5％,respectively. We introduced a new decision criteria 
of SpO2min <91% or ΔSpO2>4% instead of VdotO2max of <15 
mL/kg/min in the final step of the flow chart in ACCP guidelines. 
A total of 965 patients were evaluated according to the modified 
flow chart and 883 (91.5%) patients were classified to the average 
risk group and 31 (3.2%) patients were classified to the increased 
risk group. Fifty-one (5.3%) patients were excluded because of 
the lack of 6MWT data. In regard to surgical outcome, there was 
a significant difference between the average risk group and the 
increased risk group in introduction rate of home oxygen therapy 
(0.7% vs. 25.8%,p<0.001) and cardiopulmonary oriented 90-day 
mortality rate (0.8% vs. 9.7%,p<0.001).
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complications was assessed. Mean follow up was 22, 8 months.
Results: The number of left pneumonectomies was slightly higher 
(62.5%) than the right ones. Most of the patients were diagnosed 
of squamous cell carcinoma (57, 1%). 24 patients (37.5%) had N2 
disease. Twenty-eight patients (44.4%) were treated with neoad-
juvant chemotherapy and 6 (9.4%) with concomitant radiotherapy. 
Mean VEF1 was 74% (r: 38-125). Diabetes, hypertension and smo-
king were not significant risk factors. Four patients (6.3%) died 
within 30 days of surgery. Atrial fibrillation appeared in 9 patients 
(14%), major pulmonary complications in 4 (6.3%). Late broncho-
pleural fistula appeared in 4 patients (6, 3%) and the presence of 
brochopleural fistula was not related to an increase in mortality 
(p=0. 78). Mean overall survival was 38 months (1-year 72%, 3-ye-
ars 50% and 5-years 24.7%). Mean survival was higher for a right 
pneumonectomy (31 vs 38 months). Survival according to size was 
T1: 33.3 months, T2: 46.3 months, T3: 28.1 months and T4 15.7 
months. There was no difference between TNM stage, histological 
type, neoadjuvant or adjuvant treatment in survival. Survival was 
lower in patients who underwent chest wall resection (37.4 vs 9.9 
months, p=0.035). Body mass index, diabetes, hypertension and 
arrhythmia didn´t show differences in overall survival.
Conclusion: The side of the pneumonectomy was not related to 
mortality. Bronchopleural fistula, hypertension and diabetes and 
arrhythmia were not related to an increase in mortality.
Keyword: NSCLC, pneumonectomy, survival
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P3.07-028 LONG-TERM RESULT OF ROBOT-ASSISTED 
ESOPHAGECTOMY FOR ESOPHAGEAL CANCER: TECH-
NICAL FEASIBILITY AND ONCOLOGICAL RELIABILITY.
Chang-Hyun Kang, You Hwa Whang, Hye Sun Kim, Jae Hyun Jeon, 
In Kyu Park, Young Tae Kim
Thoracic And Cardiovascular Surgery, Seoul National University Hospi-
tal/Korea
Background: Whether robot-assisted esophagectomy is a techni-
cally feasible and oncologically reliable operation for esophageal 
cancer has not been proven. This study aimed to evaluate short-
term and long-term outcomes of robot-assisted esophagectomy.
Methods: Robot-assisted esophagectomy was performed in prone 
position for cervical anastomosis or lateral position for intrathora-
cic anastomosis. Thoracic procedures were performed by totally 
robotic technique and abdominal procedures were performed by 
robot or laparotomy. Two field lymph node dissection was perfor-
med in all patients and dissection along both recurrent laryngeal 
nerves was performed in the patients with T1b or more stages. 
Retrospective review on short-term and long-term outcomes for 
robot-assisted esophagectomy was performed.
Results: Robot-assisted esophagectomy was performed in 46 
patients between 2008 and 2013, which was 16% of total esopha-
gectomy cases during the same period. There were 43 men and 3 
women and mean age was 63.9 ± 8.2 years. Preoperative clinical 
stages were IA in 19 patients (41%), IB in 8 (17%), IIA in 6 (13%), 
IIB in 9 (20%), and IIIA in 4 (9%). Neoadjuvant chemoradiation 
was performed in 5 patients (11%). Abdominal procedures were 
performed by robot in 29 patients (63%) and by laparotomy in 16 
Sichuan University/China, 18The First Hospital Of China Medical Uni-
versity/China, 19Peking Union Medical College Hospital/China, 20Ruijin 
Hospital, Jiaotong University/China, 21The First Affiliated Hospital, Sun 
Yat-Sen University/China, 22Jilin Cancer Hospital/China, 23Tianjin Medi-
cal University Cancer Institute And Hospital/China
Background: ICAN study (NCT01106781) investigated EGFR muta-
tion status, clinical outcomes and recurrent risk factors in Chinese 
lung adenocarcinoma (ADC) patients after complete resection. 
Here we report analysis results for the profile of surgery, adjuvant 
therapy and 2-year disease free survival (DFS) rate in the real-world 
practice.
Methods: Patients were aged ≥18 years, with histological diag-
nosed lung ADC, and received surgical complete resection. Tumor 
sample EGFR mutation status was determined according to clini-
cal routine practice. All eligible patients would be followed up to 
collect the clinical information and the outcomes till 3 years after 
operation.
Results: Of 571 patients from 26 sites, 315 (55.2%) patients were 
EGFR mutation positive. The most common mutations were exon19 
deletion and L858R mutation found in 140 (24.52%) and 132 
(22.59%) patients respectively. There were 50.79% of patients who 
received adjuvant therapy, in which 45.37% received chemothera-
py, 4.55% received radiotherapy and 1.93% received TKI therapy, 
respectively. The 2-year DFS rate was 68.83%. There was statisti-
cally significant difference of 2-year DFS among the patients with 
different postoperative pathologic stage (P <0.0001). There was no 
statistically significant difference of 2-year DFS among the patients 
with age, gender, smoking history and EGFR mutation status. Ope-
ration method and adjuvant therapy correlated significantly with 
2-year DFS, but was not significant when adjusted for postoperati-
ve pathologic stage.
Conclusion: The overall EGFR mutation positive rate in operable 
Chinese ADC was 55.2%. 2-year DFS rate was 68.83%. Postopera-
tive pathologic stage had a statistically significant association with 
2-year DFS, while age, gender, smoking history and EGFR mutation 
status didn’t show statistically significant association.
Keywords: adjuvant therapy, DFS, Chinese lung adenocarcinoma, 
EGFR mutation
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P3.07-027 RISK FACTORS AND OUTCOME OF PNEU-
MONECTOMY IN LUNG CANCER PATIENTS
Manuel Wong Jaen, Laura Romero Vielva, Ricardo Zapata Gonza-
lez, María Deu Martín, Joan Solé Montserrat, Javier Pérez Vélez, 
Iker López Sanz, Alberto Jáuregui Abularach, Irene Bello Rod-
riguez, Mercedes Canela Cardona
Thoracic Surgery, Vall D‘hebron University Hospital/Spain
Background: The purpose of the study was to evaluate complica-
tions, risk factors and outcome of pneumonectomy for the surgical 
treatment of lung cancer patients.
Methods: We reviewed retrospectively the hospital records of 64 
consecutive patients who underwent a pneumonectomy between 
January 2007 and December 2012. The majority were male (87, 
5%), with a mean age of 63, 7 years (r: 38-80). Comorbidities and 
S1116 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
cal staple line. The 5-year overall survival rates were 100% in Type 
1 and Type 2, 98% in Type 3, and 88% in Type 4. Patients with Type 
4 had a significantly worse prognosis than those with other types.
Conclusion: s. Subcentimeter lung cancers with a GGO compo-
nent on preoperative HRCT (Type 1 to 3) can be considered “ear-
ly” lung cancers. Thus, in these cases, limited resection may be 
warranted to achieve a cure because patients with Type 1 to 3 did 
not have lymph node metastasis. On the other hand, lobectomy 
should still be considered the standard operation of choice for 
Type 4 tumors.
Keywords: Prognosis, subcentimeter lung cancer, high-resolution 
CT, Thoracic surgery
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P3.07-030 SURGICAL TREATMENT OF BRONCHOPUL-
MONARY CARCINOID TUMORS - A SINGLE INSTITUTI-
ON EXPERIENCE
Piotr Rudzinski1, Renata Langfort2, Małgorzata Szołkowska2, Beata 
Maksymiuk2, Ewa Szczepulska-Wójcik2, Tadeusz Orlowski1
1Thoracic Surgery, Institute Of Tuberculosis & Lung Diseases/Poland, 
2Pathology Dpt., National Tuberculosis And Lung Diseases Research 
Institute/Poland
Background: Bronchopulmonary carcinoid (BPC) comprise about 
2-5% of lung tumors. BPC are malignant neoplasms with indolent 
course. Surgical treatment is the gold standard therapy.
Methods: We present our experience of 228 patients treated sur-
gically for typical (TC) and atypical carcinoid (AC) from1998 to 2011 
in National Tuberculosis and Lung Diseases Research Institute. We 
tried to determine the variables influencing the long-term survival 
of patients with BPC. Among 4467 patients, treated surgically for 
non-small cell carcinoma, BPC encompassed 5,1%. All cases were 
reviewed and classified according to the latest WHO classification 
(2004). The clinical course and survival analysis were performed.
Results: The number of BPC during last 14 years gradually growth, 
from 13,4 cases per year between 1998-2004 to 19,1 cases bet-
ween 2005-2011. 102 cases (44,7%) were classified as TC and 126 
(55,3%) as AC. There were 158 females (69%) and 70 men (31%) 
and the mean age was 52 ys. Men were significantly younger then 
females (49 vs 53). Symptoms were present in 143 patients, the 
most commonly were cough (31%), respiratory tract infection (31%), 
then haemoptysis (18%), dyspnoe (12%) and atelectasis (3,5%). No 
patients showed a carcinoid syndrome. There were no correlation 
between smoking status and BPC. Most of the tumors were central 
(73,7%), the remaining were peripheral. The mean diameter of BPC 
was 2,25cm (range 0,6-7,0cm). AC were significantly larger (2,54 vs 
1,9) and centrally located were also larger the peripheral. Surgical 
treatment consisted of: 146 standard lobectomies (64%), 19 pneu-
monectomies (8%), 23 bilobectomies (10%), 23 sleeve lobectomies 
(10%), 2 sleeve-pneumonectomies (1%), 7 anatomic segmentecto-
mies (3%), 2 wedge resections (1%), 6 – bronchoplastic procedures 
without lung resection (2,6%). Radical mediastinal lymphadenec-
tomy was added in all cases exept 1. Involvement of lymph nodes 
was present in 35 cases (15,4%), N1 -22 (9,7%) and N2 – 13(5,7%). 
Infiltration of bronchial or vessel margin (R1) was revealed in 8 ca-
ses. The postoperative TNM stage contained IA (50%) disease, IB 
(31%), IIA (10%), IIB (2,6%), IIIA (6,1%), IV (0,4%). The stages IB, IIIA 
(35%). R0 resection was accomplished in 45 patients (98%) and 
mean operation time including robot docking time were 512 ± 104 
minutes. Total 2-field lymph node dissection along bilateral recur-
rent laryngeal nerve was performed in 32 patients (70%) and mean 
number of dissected lymph nodes were 29.1 ± 14.1. Cell types of 
esophageal cancer were squamous cell carcinoma in 45 patients 
(98%) and melanoma in 1 patient (2%). Pathologic stages were IA in 
9 patients (20%), IB in 19 (41%), IIA in 2 (4%), IIB in 11 (24%), IIIA in 4 
(9%), and IIIB in 1 (2%). There were one 30-day mortality (2%) and 
postoperative complication occurred in 15 patients (33%); respira-
tory complication in 5 patients (11%), anastomosis site leakage in 
5 (11%), and vocal cord palsy requiring treatment in 3 (7%). Overall 
5-year survival was 88% and 5-year freedom from recurrence was 
73%. Locations of recurrence were regional in 4 patients (9%), dis-
tant in 4 (9%), and there was no local recurrence.
Conclusion: Robot-assisted esophagectomy was technically feasi-
ble and oncologically reliable surgery in this study. Further studies 
based on large series of data are necessary to prove advantages of 
robot-assisted esophagectomy.
Keywords: robot, esopahgeal cancer, survival, surgery
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P3.07-029 CLINICOPATHOLOGICAL FEATURES OF  
RESECTED SUBCENTIMETER LUNG CANCER
Hiroyuki Sakurai, Kazuo Nakagawa, Shun-Ichi Watanabe, Hisao 
Asamura
Thoracic Surgery, National Cancer Center Hospital/Japan
Background: . Subcentimeter lung cancers are still rare and their 
pathobiological behavior and management have not yet been fully 
clarified. In this retrospective study, we investigated the clinico-
pathological characteristics of patients with subcentimeter lung 
cancers.
Methods: . From among 7,463 patients with primary lung cancers 
that were surgically resected at the National Cancer Center Hospi-
tal, Tokyo, from 1993 through 2011, 291 (4%) patients with periphe-
ral lung cancers of 1.0 cm or less in diameter were studied retro-
spectively with regard to their clinicopathological characteristics 
including prognosis. Of these 291 patients, 141 (48%) were male 
and 150 (52%) were female, and they had a mean age of 62.0 years. 
According to the proportion of consolidation component within 
the tumor in preoperative imaging on high-resolution computed 
tomography (HRCT), the tumors were classified into 4 types; Type 
1 (n = 50): non-solid ground-glass opacity (GGO) lesion, Type 2 (n 
= 89): part-solid GGO lesion including 50% or more GGO within 
the lesion, Type 3 (n = 62): part-solid GGO lesion including less 
than 50% GGO within the lesion, and Type 4 (n = 90): solid lesion 
with no GGO component.
Results: . Patients with Type 4 included significantly greater per-
centages of males and smokers than those with the other types. 
Pleural invasion and vascular/lymphatic permeation were signifi-
cantly more frequent in Type 4 than in the other types. While none 
of the patients with Type 1 to 3 had lymph node metastases, these 
were found in 10% of the patients with Type 4. Overall, recurrence 
was observed in 13 patients (4.5%). Almost all of these patients 
with recurrence had Type 4 tumors. The lone exception was a Type 
3 patient in whom local recurrence developed adjacent to a surgi-
S1117Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
58.6% /61.8% /72.9%/ 81.5%. Within CPFE patients, multivariable 
analysis of hazard ratio for prognosis showed following significant 
factors; pO2<70 (HR 13.52, p=0.001), lymph node metastasis (HR 
10.89, p=0.002).
Conclusion: Surgery for patients with CPFE is feasible. Postopera-
tive complications were frequently and prognosis is poor compa-
red with either emphysema or fibrosis. 
Not only the status of lung cancer but also respiratory status is a 
risk factor of prognosis after surgery for primary lung cancer with 
CPFE.
Keywords: Combined pulmonary emphysema and fibrosis, Surgi-
cal outcome, Prognosis
POSTER SESSION 3 - SURGERY  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.07-032 SYSTEMIC EXTENDED BILATERAL MEDIASTI-
NAL LYMPH NODE DISSECTION THROUGH A MEDIAN 
STERNOTOMY WITH NON-SMALL CELL CARCINOMA 
OF THE RIGHT UPPER LOBE.
Toshiya Yokota, Shin Ikeda
Surgery Respiratory Center, Mitsui Memorial Hospital/Japan
Background: Metastasis to mediastinal lymph nodes is a signifi-
cant negative prognostic factor for NSCLC in spite of a localized 
presentation. According to the results of Hata’s study on the vital 
lymphdrainage from each segmental bronchus, the predictable N3 
stations of lymphatic spread of cancer cells are the contra-lateral 
mediastinal nodes. Therefore, we have considered that it would 
be valuable to perform Systemic extended bilateral mediastinal 
dissection and lung resection through a median sternotomy (ND3 
operation, Hata’s method). And we had devised ND3 operation for 
patient with NSCLC of the left lung. So far, we reported effectiven-
ess of N3α operation (Hata’s method) in patients with lymph node 
metastasis to the mediastinum in NSCLC of the left lung. From 
January 1990 ,we have also applied N3α operation (Hata’s method) 
to patients with NSCLC of the right upper lobe.
Methods: We retrospectively analyzed the clinical records of pa-
tients who underwent ND3 operation (R0 resection) for NSCLC 
of the right upper lobe. Patients who had incomplete resection 
(R1,R2), stageIV disease were excluded from this analysis. The 
patients with NSCLC who are estimated to be able to conventio-
nal radical operation and aged 75 year-old or less becomes the 
adaptation of ND3 operation. From January 1990 to December 
2012, 195 patients of the right upper lobe primary underwent ND3 
operation completely (R0 resection) and we reviewed these cases. 
Survival estimates were calucurated by The Kaplan-Meier method 
and compared using the log-rank test.
Results: Overall 5-year survival rate in 195 patients, including ope-
ration-related deaths and deaths due to unrelated diseases, was 
55.4%. In these 195 patients, the five-year survival rate according 
to pathological stages were 90% in 35 pts of stageIA, 70.6% in 48 
pts of p-stageIB , 57.5% in 19 pts of stageIIA, 47.9% in 18 pts of p-
stageIIB, 42.1% in 45 pts of p-stageIIIA, 18.1% in 30 pts of p-stag-
eIIIB. And the 5-year survival rate according to nodal involvement, 
70.9% in 109 pts of N0, 46.2% in 22 pts of N1, 41.5% in 41 pts of 
N2, and 19% in 14 pts of N3γ. Operative mortality in 195 patients 
of right upper lobe primary NSCLC was 5 patients (2.6%).
and IV more often related to AC. Four patients died in short time 
after operation (0,2 -2 months). Three of them were after pneu-
monectomies, one – sleeve-lobiectomie. In most cases tumor was 
localized centrally. The mean follow-up time for all patients was 
69,3 months (range 0,2-172), with 204 still alive. Four patient died 
of tumor progression (3 from A, 1 from TC), remaining 8 patients 
from other causes, from 12 – the cause of death was unknown. 
Lymph nodes metastasis were seen in 5 cases (20,8%). Overall, 5, 
10 and 14-years survival for TC was respectively 95%, 92,1% and 
90,2%, for AC – 93%, 90,6% and 88,9%.
Conclusion: BPC demonstrate gradual growth during last years. 
Lung carcinoids are tumors with an excellent prognosis in most 
cases, even in the presence of metastases in lymph nodes and 
positive surgical margin (bronchial or vessel). Histologic subtypes 
did not infleunce on survival. Surgery currently represents the best 
treatment with good results and long survival but long-time obser-
vation is necessary.
Keyword: carcinoid, lung cancer
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P3.07-031 SURGICAL OUTCOME OF RESECTED LUNG 
CANCER PATIENTS COMPLICATED WITH COMBINED 
PULMONARY FIBROSIS AND EMPHYSEMA
Mariko Fukui, Kenji Suzuki, Takeshi Matsunaga, Yukio Tsushima, 
Kazuya Takamochi, Shiaki Oh
Department Of General Thoracic Surgery, Juntendo University School 
Of Medicine/Japan
Background: Combined pulmonary fibrosis and emphysema 
(CPFE) has been recently reported as a prognostic factor for pa-
tient with respiratory disorders. It might increase the risk of lung 
cancer. However controversisies remain as to surgical outcome in 
this population.
Methods: Retrospective study was performed on 981 patients 
who underwent surgical resection of lung cancer at our institute 
between 2008 and 2012. Findings on thin-section computed tomo-
graphy which was available for all patients were reviewed. Based 
on the findings, patients complicated with CPFE were selected and 
clinicopathological features were investigated. Surgical outcome 
and prognosis following lung resection were also examined.
Results: CPFE was observed in 97 (9.1%) patients with resected 
lung cancer. (Patients with pulmonary fibrosis alone were 43 pa-
tients (43.8%), patients with emphysema alone were 148 patients 
(15.1%) and patients without abnormal shadow were 649 patients. 
Lung function test were as follows (CPFE/ Fibrosis/ Emphysema): 
vital capacity (VC); 3.3L/ 2.9L/ 3.5L, forced expiratory volume in 
one second (FEV1); 71.5%/ 77.4%/ 67.9%, diffuse capacity (DLco); 
44.6%/ 58.1%/ 58.6%. 
Ninety day-mortality(CPFE/ Fibrosis/ Emphysema) was 10.2%/ 
2.3%/ 1.1%. Risk factor of ninety day mortality in patients with 
CPFE was operative blood loss. 
CPFE patients also have higher risk of major complication after 
surgery (CPFE 44.3%, non-CPFE 8.1%). 
The statistically significant difference in survival was found with 
the Kaplan-Meier method (p<0.001). Survival at 2 years(CPFE/ 
Fibrosis/ Emphysema/ Normal) was 74.6%/ 88.2%/ 91.4%/ 93.6% 
and survival at 5 years (CPFE/ Fibrosis/ Emphysema/ Normal) was 
S1118 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
would have contributed to the better prognosis of them after sur-
gery. In the NSCLC patients under 50 years old, the prognosis of 
female patients who received curative surgery is likely to be better 
than that of male patients.
Keywords: NSCLC, Female, under 50 years old, Surgical Treatment
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P3.07-034 THERAPEUTIC OUTCOMES IN 24 CASES OF 
POSTOPERATIVE BRONCHOPLEURAL FISTULA IN LUNG 
CANCER SURGERY
Kentaro Imai1, Haruhiko Nakayama1, Hiroyuki Ito1, Tetsukan 
Woo1, Naohiro Aruga1, Norihiko Ikeda2
1Thoracic Oncology, Kanagawa Cancer Center/Japan, 2Thoracic Surgery, 
Tokyo Medical University/Japan
Background: Bronchopleural fistula (BPF) after lung resection is 
a life-threatening complication. Thoracic surgeons should always 
consider the risk of postoperative BPF and the management to 
avoid worst scenario, but it is still controversial of which is the best 
way to manage BPF. We herein describe the results of BPF and 
explore optimal treatment.
Methods: Data on 2270 patients with lung resection for NSCLC 
over a period from 2000 to 2012 were retrospectively reviewed. 
Details regarding surgery and subsequent treatment were carefully 
reviewed. Followed information was recorded; age, sex, clinical 
diagnosis, associated condition, TNM stage, time from primary 
operation to rethoracotomy, and postoperative outcome.
Results: The overall BPF incidence was 1.1% (24/2270). There were 
20(83.3%) male and 4(16.7%) female, mean age was 67.1 years. 
BPFs occurred after pneumonectomy in 2(8.3%), lobectomy in 
20 (83.3%) and sleeve resections in 2 (8.3%). In side right was in 
20 (83.3%) and left was in 4 (16.7%). The histological types were 
9 adenocarcinomas, 9 squamous cell carcinomas, 6 others. The 
pathological stage were stage IA in 6 cases, IB in 4, IIA in 3, IIB 
in 4, IIIA in 6 cases. Mean postoperative day was 19.8. In initial 
treatment, fenestration was 12 cases, primary closure using various 
techniques was 8 cases, and completion pneumonectomy was a 
case. Massive hemoptysis causing death owing to bronchial pul-
monary artery fistula (BPAF) was in 3 cases. Primary closure using 
various techniques succeeded in 3 cases, while the repair failed in 
the other 5 case and 2 cases subsequently developed further fatal 
complications. The mortality rate of primary closure was 25% (2/8) 
and success rate was 38% (3/8). The mortality rate of fenestration 
was 8.3% (1/12), and success rate was 91.6% (11/12). The overall 
mortality rate for postoperative BPF was 25% (6/24); 3 cases were 
BPAF, 3 cases were aspiration pneumonia.
Conclusion: BPF remains a major complication in the surgery 
of lung cancer because of its high mortality and morbidity rate. 
Especially, the mortality rate of primary closure using various tech-
niques was high, and aspiration pneumonia with consequent ARDS 
is fatal complication. To avoid death related to BPF, the surgeons 
should consider the fenestration as soon as the BPF was diag-
nosed.
Keywords: bronchopleural fistula, Lung cancer, Postoperative 
complications
Conclusion: In this nonrandomized comparison, the post-opera-
tive survival of patients with p-N2 NSCLC of the right upper lobe 
would be improved by our Systemic Bilateral Mediastinal Dissec-
tion. To improve survival rate, it is important to perform curative 
operation with complete (dissection of all station of mediastinal 
lymph nodes.
Keywords: N2 disease, Lymphadenectomy, NSCLC
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P3.07-033 SURGICAL TREATMENTS FOR NSCLC OF  
FEMALE PATIENTS UNDER 50 YEARS OLD
Ryosuke Kaku1, Koji Teramoto2, Kazuki Hayashi1, Tomoyuki Igara-
shi1, Masayuki Hashimoto1, Noriaki Tezuka1, Jun Hanaoka1
1Department Of Surgery, Shiga University Of Medical Science/Japan, 
2Department Of Medical Oncology, Shiga University Of Medical Sci-
ence/Japan
Background: The number of patients with non-small cell lung can-
cer (NSCLC) has been increasing for some decades. The patients 
are predominantly male and over 50 years old in age, whereas 
female patients under 50 years old are relatively small cohort in 
NSCLC. Therefore, the characteristics of these female patients 
remain to be unclear.
Methods: In this study, we examined the clinico-pathological cha-
racteristics of female patients under 50 years old who had received 
surgical treatments for NSCLC. 
Female patients who had been under 50 years old and received 
curative surgical resection for NSCLC in our hospital from January 
2000 to December 2010 were involved in this study. The clinico-
pathological characteristics of them were examined retrospectively 
and compared with those of relative male patients in the similar 
criteria. Both overall survival (OS) and disease-free survival (DFS) 
times after surgery were obtained by Kaplan-Meier analysis, and 
differences between two cohorts were analyzed by log-lank test.
Results: In total, 13 female patients with median age of 43 years 
old (range: 40-49 years old) and 12 male patients with median age 
of 43years old (range: 31-49 years old) were received curative sur-
gical resection for NSCLC in this period. All of the female patients 
were never-smokers, whereas 11 male patients (91.7%) were cur-
rent smokers. Twelve female patients were free from symptoms at 
the diagnosis of NSCLC, however, 5 male patients had some sym-
ptoms related to NSCLC (a rate of symptom-free patients; female 
vs male = 92.3% vs 58.3%). Pathological stages of female NSCLC 
were as follows; 1A: 9, 1B: 1, 2A: 1, 3A: 1, 3B: 1. All cases of female 
NSCLC (100.0%) were diagnosed with adenocarcinomas histologi-
cally; mixed subtype: 6, papillary: 2, bronchiolo-alveolar cell carci-
nomas (BAC): 5 cases. In males, 8 patients (66.7%) were diagnosed 
with adenocarcinomas including 1 BAC case. The rates of OS and 
DFS at 5 years after surgery of female patients were 100.0% and 
74.6%, respectively, with the median observation period was 69.0 
months (range: 17-148 months). On the other hand, the rates of OS 
and DFS at 5 years after surgery of male patients were 74.6% and 
58.3%, respectively, demonstrating that OS in female patients see-
med to be long as compared with that in male patients (P=0.302).
Conclusion: More patients who were free from symptoms, never-
smokers and with BAC subtype were included in female than male 
patients in this study. These characteristics of female patients 
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P3.07-036 POSTRECURRENCE SURVIVAL OF SURGI-
CALLY RESECTED PULMONARY ADENOCARCINOMA 
PATIENTS ACCORDING TO EGFR AND KRAS MUTATION 
STATUS
Yoichi Ohtaki1, Kimihiro Shimizu1, Seiichi Kakegawa1, Toshiteru 
Nagashima1, Kai Obayashi1, Tetsuhiro Nakano1, Jun Atsumi1, Hito-
shi Igai1, Takashi Ibe1, Masayuki Sugano1, Mitsuhiro Kamiyoshiha-
ra,1, Osamu Kawashima1, Kyoichi Kaira2, Izumi Takeyoshi1
1Division Of Thoracic And Visceral Organ Surgery, Gunma Graduate 
School Of Medicine/Japan, 2Department Of Medicine And Molecular 
Science, Gunma University Graduate School Of Medicine/Japan
Background: The aim of this study was to clarify the prognosis of 
pulmonary adenocarcinoma patients after postoperative recur-
rence according to EGFR and KRAS mutations and recurrence site.
Methods: Between July 2002 and December 2011, a total of 297 
consecutive patients underwent surgical resection for primary 
pulmonary adenocarcinoma. Among all the patients, we retrospec-
tively evaluated 58 recurrent adenocarcinoma patients. They were 
divided into the groups according to presence of EGFR mutation 
and KRAS mutation, and compared clinicopathological features, 
recurrence sites and postrecurrence survival.
Results: EGFR, KRAS mutations were detected in 26 patients 
(45%), 11 patients (19%), respectively. Of the cases with EGFR 
mutations, L858R point mutation in exon 21 was most frequently 
observed in 18 cases, secondly deletion in exon 19 was in 8 cases. 
Initial recurrence was detected in distant in 25 (43%), local in 17 
(29%), and both in 16 (28%). In EGFR mutant (EGFR+) cases, bila-
teral/contralateral lung recurrences were significantly frequently 
occurred. EGFR+ cases had significantly better outcome than 
KRAS+ cases and EGFR-KRAS- (Wild) cases. 2-year postrecur-
rence survival rate were 81%, 18%, and 47% in EGFR+, KRAS+, and 
Wild cases, respectively. Patients with distant organ recurrence 
(D+) showed significantly worse survival than those without dis-
tant recurrences in only Wild cases, but not significant in EGFR+ 
cases and entire cohort. Multivariate analysis revealed that only 
EGFR mutation and number of recurrent lesions were statisti-
cally significant independent postrecurrence prognostic factors. 
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P3.07-035 BENEFIT OF PREOPERATIVE LOCALIZATION 
USING FRAGMENTED PLATINUM MICROCOIL FOR FLU-
OROSCOPY-AIDED THORACOSCOPIC RESECTION OF 
SOLITARY PULMONARY NODULES
Deog Gon Cho1, Yong Jin Chang1, Kyu Do Cho1, Hyun Jin Park2, Chi 
Hong Kim3, Sung Hwan Kim4, Jinyoung Yoo5, Hoon-Kyo Kim6
1Thoracic Surgery, St. Vincent‘s Hospital, The Catholic Univ. Of Korea/
Korea, 2Radiology, St. Vincent‘s Hospital, The Catholic Univ. Of Korea/
Korea, 3Pulmonology, St. Vincent‘s Hospital, The Catholic Univ. Of Ko-
rea/Korea, 4Radiation Oncology, St. Vincent‘s Hospital, The Catholic 
Univ. Of Korea/Korea, 5Pathology, St. Vincent‘s Hospital, The Catholic 
Univ. Of Korea/Korea, 6Medical Oncology, St. Vincent‘s Hospital, The 
Catholic Univ. Of Korea/Korea
Background: Preoperative localization is necessary to perform 
thoracoscopic resection of small or deeply located solitary pul-
monary nodules (SPNs). We recently developed a new localization 
technique using a self-made, fragmented platinum microcoil, and 
retrospectively compared the effectiveness of our technique with 
that of lipiodol.
Methods: Fifty two patients underwent thoracoscopic pulmonary 
wedge resections for 57 SPNs between January 2006 and June 
2013. Self-made, fragmented platinum microcoils (Easimarker) 
were targeted to localize 30 SPNs [17 solid nodules, and 13 ground 
glass opacities (GGOs)] in 28 patients (Group A), and lipiodol was 
injected in 27 SPNs (17 solid nodules, and 10 GGOs) of 22 patients 
(Group B). Preoperative localization using both targeting materials 
was performed into, or just around the pulmonary lesions on the 
day of thoracoscopic surgery in the room of chest CT scanner. Lo-
calized SPNs were then, wedgely resected using fluoroscopy-aided 
thoracoscopic surgery (FATS). The intraoperative fluoroscopic ex-
posure (radiation) time, diagnostically detecting rate of pathologic 
lesions, and other clinical data were collected.
Results: Mean size and depth of SPNs in group A and B were 10.6 
± 4.7 mm (range: 0.9 to 23) versus 7.9 ± 4.9 mm (1 to 21), and 10.9 
± 7.9 mm (1 to 30) versus 9.7 ± 8.4mm (1 to 28.2), respectively. CT-
guided localizations were successfully performed in both groups. 
No mortality and major morbidity were observed in both groups. 
All lesions in both groups were completely resected and diag-
nosed histopathologically. The intraoperative fluoroscopic expo-
sure time of group A (55.0±40.8 seconds) was significantly shorter 
than that of group B (105.7±109.0 seconds).
Conclusion: Our preoperative localization procedure using frag-
mented platinum microcoils appears to be effective and feasible 
in that it has shorter intraoperative time, less radiation exposure, 
and better accuracy of detecting SPNs. Once inserted fragmented 
microcoil into the pulmonary lesions stays firmly and more visible 
radiologically, through lipiodol tends to diperse outside the targe-
ting lesion.
Keywords: microcoil, Pulmonary nodule, preoperative localization, 
Thoracoscopy
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Conclusion: Our results indicate there were distinct survival diffe-
rences in recurrent adenocarcinoma patients according to driver 
mutations. Patients with EGFR mutated tumors could be expected 
of long survive regardless of presence of distant site recurrences, 
and patients with KRAS mutated adenocarcinoma had poor out-
come after postoperative recurrence. The examination of driver 
mutations is essential for prediction of postrecurrence survival 
after surgical resection.
Keywords: Adenocarcinoma, EGFR, KRAS, postrecurrence survival
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Results: All institutions used the same master-slave robotic system 
(da Vinci, Intuitive Surgical, Sunnyvale, California) and most pati-
ents underwent lobectomies for early-stage non-small cell lung 
cancers. Perioperative mortality rates for patients who underwent 
pulmonary resection by RVATS ranged from 0 – 3.8%, whilst overall 
morbidity rates ranged from 10 – 39%. Two propensity-score ana-
lyses compared patients with malignant disease who underwent 
pulmonary resection by RVATS or thoracotomy, and a meta-analy-
sis was performed to identify a trend towards fewer complications 
after RVATS. In addition, one cost analysis and one quality of life 
study reported improved outcomes for RVATS when compared to 
open thoracotomy. 
Conclusion: Results of the present systematic review suggest 
that RVATS is feasible and can be performed safely for selected 
patients in specialized centers. Perioperative outcomes including 
postoperative complications were similar to historical accounts of 
conventional VATS. A steep learning curve for RVATS was identi-
fied in a number of institutional reports, which was most evident in 
the first 20 cases. Future studies should aim to present data with 
longer follow-up, clearly defined surgical outcomes, and through 
an intention-to-treat analysis.
Keywords: NSCLC, systematic review, Meta-analysis, Robotic as-
sisted thoracoscopic surgery
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P3.07-037 A SYSTEMATIC REVIEW AND META-ANALYSIS 
ON PULMONARY RESECTIONS BY ROBOTIC VIDEO-
ASSISTED THORACIC SURGERY
Christopher Cao1, Con Manganas2, Su Ang1, Tristan D. Yan1
1Systematic Reviews Unit, Collaborative Research Group/Australia, 
2Cardiothoracic Surgery, St. George Hospital/Australia
Background: Pulmonary resection by robotic-video assisted tho-
racic surgery (RVATS) has been performed for selected patients 
in specialized centers over the past decade. Despite encouraging 
results from case-series reports, there remains a lack of robust 
clinical evidence for this relatively novel surgical technique. The 
present systematic review aimed to assess the short- and long-
term safety and efficacy of RVATS.
Methods: Nine relevant and updated studies were identified from 
12 institutions using five electronic databases. Endpoints included 
perioperative morbidity and mortality, conversion rate, operative 
time, length of hospitalization, intraoperative blood loss, duration 
of chest drainage, recurrence rate and long-term survival. In addi-
tion, cost analyses and quality of life assessments were also syste-
matically evaluated. Comparative outcomes were meta-analyzed 
when data were available.
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Reference: de Perrot M, Rampersaud R. Surgical approaches to 
apical thoracic malignancies. J Thorac Cardiovasc Surg. 2012 
Jul;144(1):72-80.
Keywords: thoracic inlet, surgery, non-small cell lung cancer
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P3.07-039 VIDEO-ASSISTED MEDIASTINOSCOPIC 
LYMPHADENECTOMY IS ASSOCIATED WITH BETTER 
SURVIVAL THAN MEDIASTINSOCOPY IN PATIENTS WITH 
OPERABLE AND INOPERABLE NON-SMALL CELL LUNG 
CANCER PATIENTS.
Akif Turna1, Ahmet Demirkaya2, Elvin Hekimoğlu2, Ezel Ersen2, 
Serkan Ozkul3, Buge Oz4, Kamil Kaynak1
1Department Of Thoracic Surgery, Istanbul University, Cerrahpasa 
Medical Faculty/Turkey, 2Department Of Thoracic Surgery, Istanbul 
University Cerrahpasa Medical Faculty/Turkey, 3Department Of Thora-
cic Surgery, Tekirdag State Hospital/Turkey, 4Department Of Pathology, 
Istanbul University Cerrahpasa Medical Faculty/Turkey
Background: Video-assisted mediastinoscopic lymphadenectomy 
(VAMLA) has been developed to reduce the false-negativity rate 
of mediastinoscopy. We aimed to analyze the impact of VAMLA on 
survival in patients with operable IA-IIIA disease and inoperable 
IIIB (N2) tumor.
Methods: Between May 2005 and June 2013, 421 N2 patients with 
non-small cell lung cancer who had undergone standard mediasti-
noscopy or VAMLA were evaluated. Of these, 105 patients (24.9%) 
underwent VAMLA, whereas 316 patients (75.1%) underwent stan-
dard mediastinoscopy. The median number of resected lymph 
node was 29.1 in VAMLA group , while the median was 10.3 in 
mediastinoscopy group.All patients with N2 disease were referred 
to medical oncology and/or radiation oncology departments. The 
survival rates were calculated using Kaplan-Meier test. Of those, 
26 patients (6.2%) were referred to neoadjuvant treatment.
Results: The 5-year survival rate of N2 patients who had VAM-
LA was 34.0%, whereas it was 18.0% in patients who underwent 
mediastinoscopy (p=0.03)in all patients. Survival analyses re-
vealed T factor (p=0.04), N factor (p=0.01), multiplicity of nodal 
status(p=0.04), and lymphatic invasion (p=0.03), type of medi-
astinoscopy (VAMLA vs standard mediastinoscopy) statistically 
significant in entire study population. Multivariable Cox analysis 
confirmed N stage(p=0.01, hazard ratio, 4.1, 95% confidence inter-
val;1.125-8.661)T stage (p=0.045, hazard ratio, 1.4, 95% confidence 
interval: 1.050-4.112)and type of mediastinoscopy as independent 
prognostic factors (p=0.02, hazard ratio, 2.1; 95% confidence inter-
val:1.11-11.03)
Conclusion: VAMLA seemed to provide longer survival in opera-
ble and inoperable (T3-4N2) non-small cell lung cancer patients. 
This effect could be due to complete resection of mediastinal 
lymph nodes. Further studies in order to clarify the possible survi-
val impact are warranted.
Keywords: video-assisted mediastinoscopic lymphadenectomy, 
mediastinoscopy, staging
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P3.07-038 LONG-TERM OUTCOME AFTER RESECTION 
OF NON-SMALL CELL LUNG CANCER INVADING THE 
THORACIC INLET
Stephane Collaud1, Tiago Machuca1, Olaf Mercier1, Thomas Wad-
dell1, Kazuhiro Yasufuku1, Andrew Pierre1, Gail E. Darling1, Marce-
lo Cypel1, Yoga Rampersaud1, Stephen Lewis1, Frances Shepherd2, 
Natasha Leighl2, John Cho2, Andrea Bezjak2, Shaf Keshavjee1, Marc 
De Perrot1
1Toronto General Hospital/Canada, 2Princess Margaret Hospital/Cana-
da
Background: Non-small cell lung cancer (NSCLC) of the thoracic 
inlet accounts for less than 5% of all lung cancers. Due to the lack 
of efficient treatment and the complexity of the anatomical struc-
tures commonly invaded, these tumors were deemed historically 
unresectable and fatal. In this study, we reviewed our surgical 
experience and long-term outcome after resection of NSCLC inva-
ding the thoracic inlet
Methods: All consecutive patients from a single center who under-
went resection of NSCLC invading the thoracic inlet were reviewed 
with data retrieved retrospectively from the charts.
Results: A total of 65 consecutive patients with a median age of 
61 years (range 32 to 76) underwent resection of NSCLC invading 
the thoracic inlet from 1991 to 2011. Tumors were located in the 
previously described (Reference) five zones of the thoracic inlet as 
follows: zone 1 or anterolateral (n=5, 8%), zone 2 or anterocentral 
(n=7, 11%), zone 3 or posterosuperior (n=12, 18%), zone 4 or poste-
roinferior (n=22, 34%) and zone 5 or inferolateral (n=7, 11%). Fifty-
two (80%) patients had induction therapy, mostly two cycles of 
cisplatin-etoposide and 45 Gy of concurrent radiation. All patients 
underwent en bloc resection of the lung and chest wall. Lobec-
tomy was performed in 60 patients (92%). A median of three ribs 
were resected (range 1 to 5) and included the first rib in all pati-
ents. Twenty-four patients (37%) had an additional vertebral resec-
tion of up to five levels (median 3). Considering the most extended 
vertebral resection, total vertebrectomy with anterior-posterior 
spinal stabilization was required in 6 patients (25%), hemi-verte-
brectomy with posterior spinal stabilization in 15 (62%), and partial 
vertebrectomy without stabilization in 3 (13%). Arterial resections 
were performed in seven patients (11%) and included subclavian 
artery (n=5), vertebral artery (n=1) and combination of sublclavian 
and carotid arteries (n=1).The median postoperative length of stay 
was 11 days (range 4 to 173). Postoperative morbidity and morta-
lity were 46% and 6%, respectively. Pathologic response to induc-
tion treatment was complete (n=19) or near complete (n=12) in 31 
patients (49%). Pathologic stages were 0 in 19 patients (29%), IB in 
1 (2%), IIB in 28 (43%), IIIA in 15 (23%) and IIIB in 2 (3%) patients. 
After a median follow-up of 20 months (range 0 to 193), 34 patients 
were alive without recurrence. The overall 3- and 5-year survivals 
reached 58% and 52%, respectively. Results of the Cox regression 
and log-rank/Breslow tests identified the site of tumor (zone 1/3 
vs 2/4/5, p=0.050) and the response rate to induction treatment 
(complete/near complete vs partial, p=0.004) as significant predic-
tors of survivals. A trend toward shorter survival was found in case 
of arterial resection (p=0.063).
Conclusion: Survival after resection of NSCLC invading the thora-
cic inlet in highly selected patients reached 52% after five years. 
Tumor location within the thoracic inlet and pathologic respon-
se to induction therapy were significant predictors of survivals. 
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Conclusion: Temporal trends in patient characteristics in this series 
mirror recent epidemiological data for non-small cell lung cancer. 
After controlling for known confounders and background mortality 
variation, improved survival was demonstrated for more recent 
patients. Advances in clinical staging and adjuvant therapy may 
explain these findings.
Keywords: non-small cell lung cancer, surgical outcomes, tempo-
ral trends, relative survival
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P3.07-041 STUDY ON SURGICAL CASES FOR SIMULTA-
NEOUS MULTIPLE GGNS IN BILATERAL LUNG
Hironori Ishida1, Hirozo Sakaguchi1, Hiroyuki Nitanda1, Nobuhiro 
Yamasaki1, Koichi Kaneko1, Yoshihiko Shimizu2
1General Thoracic Surgery, Saitama Medical University International 
Medical Center/Japan, 2Pathology, Saitama Medical University Interna-
tional Medical Center/Japan
Background: In recent years, the opportunity to encounter a 
ground glass opacity nodule (GGN) by high-resolution CT is incre-
ased, and simultaneous multiple GGNs also are not uncommon. 
A GGN has been usually classified as pure GGN and part-solid 
GGN, the former seems to correspond to atypical adenomatous 
hyperplasia (AAH) or adenocarcinoma in situ (AIS) and the latter 
seems minimally invasive adenocarcinoma (MIA) or invasive ade-
nocarcinoma (IA), but CT image and pathological findings do not 
necessarily match. Some GGNs are diseases unrelated to primary 
lung adenocarcinoma. We have examined the resected cases for 
simultaneous multiple GGNs on both sides of the lung.
Methods: Adaptation of resection for GGNs on our hospital is as 
follows. 1)10-15mm or more size, 2) larger solid component, 3) just 
below the pleura, 4) increase over time in size or density, 5) the 
purpose of pathological diagnosis, etc. The prevention of lung 
function is noted in the resection on both sides of the lung. In this 
four years, we performed surgery on seven patients with bilateral 
multiple GGNs for diagnosis and treatment. We investigated the 
clinical features and histopathological findings of the resected 
lung.
Results: The seven patients consisted of 40 to 70 years old, five 
women and two men. We performed lobectomy and partial 
(wedge) resection of three patients. Four patients underwent se-
veral wedge resections for pathological diagnosis and treatment. 
Two women did the two-term surgery on both sides of the lungs. 
Pathological diagnosis was adenocarcinoma (AIS, MIA, IA) in five 
cases, AAHs in one, and lymphoproliferative disease in one. In one 
patient, all three lesions from four wedge resections had different 
mutated patterns of EGFR. There was no recurrence or death in 13 
to 58 months of the observation period.
Conclusion: Simultaneous multiple GGNs was more frequent in 
women than men. Surgical biopsy (wedge resection) seems to be 
necessary for definitive diagnosis because a GGN may not be re-
lated to lung cancer. Even if multiple cancers in bilateral lung are 
supposed, prognosis may be able improved by surgical removal of 
more invasive (advanced) lesions in GGNs.
Keywords: ground glass opacity nodule, adenocinoma, bilateral 
lung, surgery
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P3.07-040 TEMPORAL TRENDS IN SURGICAL  
OUTCOMES FOR EARLY STAGE NON-SMALL CELL  
LUNG CANCER
Benjamin M. Robinson1, Catherine Kennedy1, Jocelyn Mclean2, 
Brian C. Mccaughan2
1Baird Institute/Australia, 2Cardiothoracic Unit, Royal Prince Alfred 
Hospital/Australia
Background: There has been little investigation of temporal trends 
in outcomes following resection of early non-small cell lung cancer. 
Analyses are easily confounded by changes in patient charac-
teristics and variations in background mortality when assessing 
all-cause survival. This study aimed to evaluate changes in patient 
characteristics, tumour factors and survival over time.There has 
been little investigation of temporal trends in outcomes following 
resection of early non-small cell lung cancer. Analyses are easily 
confounded by changes in patient characteristics and variations in 
background mortality when assessing all-cause survival. This study 
aimed to evaluate changes in patient characteristics, tumour fac-
tors and survival over time.
Methods: A retrospective analysis of 2816 consecutive pathologi-
cal stage 1A to 3A patients, treated by surgical resection between 
1984 and 2007 was performed. Patients were divided into four 
6-year eras by date of surgery. Relative survival probabilities were 
estimated by era and TNM stage. Expected survival was calculated 
from national age, sex and period specific mortality rates. Multi-
variable regression using a generalised linear model with Poisson 
error was used to estimate the excess hazard of death in each era, 
using the 1984-1989 cohort as the baseline, controlling for age, 
sex, extent of resection, margin status, tumour stage and cell type.
Results: In later eras, patients were older, had a greater pro-
portion of adenocarcinomas and stage 1A tumours. Relative 
5-year survival rates for 1984-1989, 1990-1995, 1996-2001 and 
2002-2007 were 45.4, 49.6, 48.5 and 57.9% respectively. The-
re was a significant improvement in 5-year relative survival in 
the 2002-2007 cohort (Excess hazard ratio 0.62, p<0.001). Age 
≥75, increasing TNM stage, positive margins and mixed cell 
type were also significant prognostic factors. The increased 
survival demonstrated in the most recent era can be attributed 
primarily to survival gains in stage IIa/b and stage 3a (Figure). 
S1124 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 3 - SURGERY  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.07-043 PNEUMONECTOMY, BRONCHOPLASTY, PUL-
MONARY ARTERIOPLASTY, AND COMBINED RESEC-
TIONS OF THE SUPERIOR VENA CAVA ARE FEASIBLE 
EVEN IN SALVAGE SURGERY AFTER TREATED LUNG 
CANCER
Yukio Tsushima, Kenji Suzuki, Mariko Fukui, Takeshi Matsunaga, 
Shiaki Oh, Kazuya Takamochi
General Thoracic Surgery, Juntendo University School Of Medicine/
Japan
Background: Salvage therapy could be indicated for residual tu-
mor and local recurrence of treated lung cancer. However, there 
is no report of the meaning of making full use of bronchoplasty, 
pulmonary arterioplasty, and combined resections of superior 
vena cava (SVC) in salvage surgery for lung cancer. In this study, we 
investigated perioperative complications of the salvage surgery for 
lung cancer according to the mode of operations.
Methods: We retrospectively reviewed 1320 consecutive patients 
who underwent lung resection for lung cancer at our institution 
from January 2008 to May 2013 and surveyed 18 salvage surgery 
cases among them. The mode of operation, perioperative compli-
cation and long-term outcome were investigated in detail.
Results: Twelve salvage surgical therapies were indicated for resi-
dual tumor after 10 chemotherapy and two chemoradiotherapy ca-
ses, and another six salvage surgeries were indicated for local re-
currence after chemoradiotherapy. Radiation dose was 45 – 66Gy 
in seven chemoradiotherapy cases and 140Gy of proton therapy 
in one case. The number of mode of operation was as follows; one 
pneumonectomy with carinal resection, three pneumonectomies, 
one lobectomy with bronchoplasty and pulmonary arterioplasty 
and combined resection of the SVC (triple plasty), one lobectomy 
with bronchoplasty and combined resection of the SVC (double 
plasty), one sleeve bilobectomy, two sleeve lobectomies, eight 
lobectomies and one wedge resection(Table 1). Median operation 
time was 178.5 minutes (range 80-395). Median intra-operative 
blood loss was 130ml (range 5-1720). Average duration of hospi-
talization days after salvage surgery was 10.5 days. Regarding to 
operation time, intra-operative blood loss, and hospitalization days 
after operation, there was no significant difference between salva-
ge surgery and conventional lung resection at our institute. Post-
operative complications were as follows; three empyemas, three 
pneumonias, two pleural fistulas, and one chylothorax. We had to 
make an open window for one empyema case, but another compli-
cations were recovered safely and there was no 30-day mortality. 
Median follow-up was 9.5 months. There was no local recurrence 
but there were three distant metastases cases after salvage surge-
ry. The longest survivor without recurrence after salvage surgery 
survives for 31 months.
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P3.07-042 PROPHYLACTIC LANDIOLOL ADMINISTRATI-
ON CAN PREVENT ATRIAL FIBRILLATION AFTER  
LOBECTOMY?
Koichiro Kajiura1, Shoji Sakiyama1, Hiromitsu Takizawa1, Yasushi 
Nakagawa1, Kazuya Kondo2, Akira Tangoku1
1Department Of Thoraci,endocrine Surgery And Oncology, Institute Of 
Health Biosciences The University Of Tokushima Graduate School/Ja-
pan, 2Department Of Oncological And Regenerative Surgery, University 
Of Tokushima, School Of Medicine/Japan
Background: It is said that atrial fibrillation(Af) after lobectomy is 
seen in about 20%, sometimes difficulty in postoperative manage-
ment. Landiolol is very short acting selective β1-blocker. It is repor-
ted that landiolol have the usefullness of not only treatment for Af, 
but also the prevention of Af after lobectomy. We had randamized 
control study about preventation of Af after lobectomy or more.
Methods: We divided into control group and landiolol administ-
ration group for patients to perform lobectomy or more. The pati-
ents of administration group are subjected prophylactic landiolol 
to 24hr continuous infusion from the start of surgery at 5γ. We 
analysed the 93 cases with informed consent in this clinical trial 
from June 2010 to April 2013. Finally, 2cases dropped out because 
of changing operative procedure for dissemination of lung cancer.
Results: 45 cases is in landiolol administration group and 46 ca-
ses is in control group of 91 cases. Postoperative Af was occurred 
10 cases. But, there were no occurrence of Af during landiolol 
infusion. 9 cases of 10 cases had Af during the 3days after sur-
gery. The data is following: (administration group, control group) 
Event of Af=(6,4), postoperative days of Af=(1.5, 3.), age(years-
old)=(70±8.7, 66.3±9.4), gender(M:F)=(25:20, 29:17), pasthistory of 
Af=(0, 5), operative site(R:L)=(29:16, 31:15), bleeding=(286±463ml, 
212±308ml), operation time=(290±86min,272±87min), in-out 
balance in operation=1816±827ml, 1414±732ml), the rate of 
concomittant use of epidural anethesia=(91%:95%), operatibe 
approach(open:VATS)=(6:39, 10:36), operative procedure(lobecto
my:bilobectomy:pneumonectomy)=(45:0:0, 40:3:3), upper medi-
astinal LN disection rate=(67%, 63%), #7 LN disection rate=(73%, 
70%). Adverse effect of landiolol is hypotension(BP<80) in 3 ca-
ses(7%) and bradycardia(HR<60) in 1 case.
Conclusion: Landiolol administration group had more occurrence 
of postoperative Af, compared to control group. Considering the 
incidence of Af is high up to 3days after surgery, only 24hr conti-
nuous administration can not suppress Af after stopping infusion. 
β- action, by exciting sympathetic nerve, is important for the 
occurrence of postoperative Af. β- action is inhibited by landiolol 
during administration, for positive feedback, β-receptor are upre-
gulation. It is thought that Af occurrence after stopping landiolol 
is increasing in administration group than control group, because 
the β-agonist binds to the upregulated receptor. It is possible that 
turned out to be different result, if prophylactic landiolol administ-
ration would continue until 3days after surgery, for Af is high up to 
3days after surgery.
Keywords: landiolol, postoperative atrial fibrillation
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part of the local procedure. Patients with mediastinal lymph node 
involvement detected by the preoperative CT or PET scan and 
patients with metastatic lung cancer were excluded from the study.
Results: There were 101 lung metastasectomies, for metastatic 
carcinoma in 87 patients, for metastatic sarcoma in 14 cases. Surgi-
cal procedures were as follows: 71 wedge resections, 27 lobecto-
mies, 8 segmentectomies. Bilateral metastases were present in 22 
patients; solitary metastatic lesion was found in 57 cases. Average 
diameter of the metastasis was 25.3 mm. Average number of the 
lymph nodes yielded by lymphadenectomy was 16.4. Metastatic 
involvement of the mediastinal lymph nodes was found in 9 cases 
(8.9%), metastatic carcinoma (colorectal in 4 cases) in 7 cases and 
sarcoma in 2 cases. Average DFI was 37.5 months. 3-years survival 
according Kaplan-Meier was 76% (0.76±0.06), for metastatic car-
cinoma 81% (0.81±0.06), sarcoma 46% (0.46±0.15); for colorectal 
carcinoma 92% (0.92±0.06). 3-years survival for patients with ne-
gative lymph nodes was 78% (0.78±0.06), with metastatic involve-
ment 53% (0.53±0.25). Statistical analysis with two-sided log-rank 
test at the 0.05 level of significance showed better survival for the 
patients with metastatic carcinoma in comparison with sarcoma 
(p=0.0007) and better survival for patients without metastatic 
lymph node involvement (p=0.044).
Conclusion: Even in carefully selected group of patients, incidence 
of the mediastinal lymph node metastases is high and systematic 
lymphadenectomy should be considered in all cases. Because of a 
lack of robust data, we recommend routine nodal dissection only 
as a part of a clinical study. Due to the small numbers available, 
lymphadenectomy remains questionable in bilateral cases, for 
sarcoma metastases and in patients in high operative risk.
Keyword: lung metastasectomy, systematic nodal dissection
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P3.07-045 THIN-SECTION COMPUTED TOMOGRAPHY 
FINDINGS OF LUNG ADENOCARINOMA INHERENT 
WITH METASTATIC POTENTIAL
Keiju Aokage, Junji Yoshida, Yuki Matsumura, Tomoyuki Hishida, 
Kanji Nagai
Division Of Thoracic Surgery, National Cancer Center Hospital East/
Japan
Background: Pulmonary solid nodules on chest computed tomo-
graphy (CT) included inflammatory nodule, benign tumor, carci-
noid tumor, small cell lung cancer, large cell carcinoma, large cell 
neuroendocrine carcinoma, squamous cell carcinoma, and poorly-
differentiated adenocarcinoma, and so on. If the solid nodule was 
highly suspicious of malignant tumor or diagnosed as being prima-
ry lung cancer, a surgical resection would be recommended as ex-
peditiously as practicable because of its metastatic potential. On 
the other hand, most well-defined ground-glass nodules including 
part-solid nodules were atypical adenomatous hyperplasias or lung 
adenocarcinomas. The development of spatial resolution on CT 
had provided improvement in predicting malignancy of these no-
dule shadow suspected of lung cancer. The aim of this study was 
to elucidate the preoperative chest thin-section CT (TSCT) findings 
of lung nodules which were inherent with metastatic potential from 
the perspective of recurrence and long term results.
Methods: We reviewed 392 primary lung adenocarcinomas with 
Conclusion: There were no critical complications and mortality in 
salvage surgeries after chemotherapy and chemoradiotherapy for 
lung cancer. Pneumonectomy, bronchoplasty, pulmonary arterio-
plasty and combined resections of the SVC are feasible even in 
salvage surgery for treated lung cancer.
Keywords: Salvage surgery, bronchoplasty, pulmonary arterio-
plasty
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P3.07-044 SYSTEMATIC NODAL DISSECTION DURING 
PULMONARY METASTASECTOMY: RESULTS OF A CLINI-
CAL STUDY
Jan Dolezel1, Vaclav Jedlicka2, Adam Pestal1, Josef Vodicka3, Marek 
Szkorupa4, Karel Vesely5, Vaclav Zvonicek6, Ivan Capov2
11st Department Of Surgery, St Anne´s Hospital/Czech Republic, 2First 
Department Of Surgery, St. Anne´s Hospital, Masaryk University/
Czech Republic, 3Department Of Surgery, University Hospital Plzen/
Czech Republic, 4Department Of Surgery, University Hospital Olomouc/
Czech Republic, 5Department Of Pathology, St. Anne´s Hospital/Czech 
Republic, 6Department Of Anesthesiology And Critical Care, St Anne´s 
Hospital/Czech Republic
Background: Systematic nodal dissection has become a standard 
part of a curative resection for the non-small cell lung cancer. Its 
value in lung metastasectomy is unknown. The aim of our study 
was to assess the frequency of lymph node metastases in the pa-
tients undergoing lung metastasectomy, survival of the patients 
with and without lymph node involvement and to consider, if and 
when routine nodal dissection should be recommended. Study 
was supported by the grants of the Ministry of Health of the Czech 
Republic IGA MZ ČR NS10095-4, NT/12085-3.
Methods: All consecutive patients selected for lung metastasec-
tomy in 3 surgery departments from 7/2008 to 12/2011, were 
operated by standard technique of the lung metastasectomy with 
systematic nodal dissection according to the ESTS guidelines for 
intraoperative lymph node staging in non-small cell lung cancer. 
If wedge resection was done, N1 nodes were removed only as a 
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gnant pleural effusions. In all cases, after assuring their effusions 
could be drawn through a 19 gauge needle, they were taken 
to the operating room where a tunneled catheter was placed, 
leaving the fibrous polyester cuff in place for tissue ingrowth, 
but trimming the valve and connecting that end of the catheter 
to a standard implantable single lumen infusion port (Figure 1). 
Figure 1 A) The configuration of the cuffed catheter connected to 
a single lumen infusion port B) The port-accessed catheter being 
tested after implantation of the catheter and prior to implantation 
of the port C) Accessing the catheter as it is done at home
Results: All procedures were performed uneventfully and without 
complications. The catheters continue to work well and are ac-
cessed by the patients at home.
Conclusion: This novel technique offers a safe palliative option 
for any effusion that can be aspirated through a 19 gauge needle, 
benign or malignant. The patients have been able to maintain their 
normal life style without the risk and inconvenience of serial out-
patient thoracenteses or the limitations imposed by the presence 
of an exterior tube. Specifically, the proven benefits are that it 
enhances quality of life for those patients who wish to maintain the 
activities of swimming or tub bathing or have compelling concerns 
about the appearance of an external tube. There is also the theo-
retical benefit that this port-accessed drainage system may be less 
prone to infectious complications.
Keywords: pleural effusion, palliation
clinical T1N0M0 who underwent surgery between 2003 and 2007. 
Independent recurrence predicting parameters were extracted 
from the following ten parameters by using logistic regression 
analysis; sex, age, smoking index, preoperative serum carcinoemb-
ryonic antigen level, tumor location, maximum tumor size, consoli-
dation tumor ratio (C/T ratio), tumor disappearance rate (TDR), the 
maximum size of consolidation at lung window setting (lung conso-
lid), and the maximum size of consolidation at mediastinal window 
setting (med consolid). We evaluated extracted parameters by 
using receiver operating characteristic area under the curve (ROC-
AUC) for recurrence prediction and identified these optimal cut-off 
levels of these parameters for prediction of whether patients had a 
good chance of being cured by surgical resection from their recur-
rence rate and survival.
Results: The median follow-up period was seven years. The 75 of 
392 patients recurred. C/T ratio, lung consolid, and TDR were ext-
racted as an independent recurrence predictor. ROC-AUC of these 
parameters was 0.70, 0.71, and 0.64 for predicting recurrence, 
respectively. If C/T ratio was 0.5 or less, distant metastatic recur-
rence was observed in only one of 75 patients and if lung consolid 
was 10 mm or less, it was also observed in only one of 82 patients. 
There were significant differences in overall survival and recurrence 
free survival among two populations divided by these cut-off levels 
of C/T ratio and lung consolid.
Conclusion: If the C/T ratio was 0.5 or less and/or lung consolid 
size was10 mm or less in cT1N0M0 lung adenocarcinoma pati-
ents, the recurrence rate was extremely low if they underwent a 
standard surgical resection. But when TSCT parameters of lung 
nodules exceeded these cut-off values, the recurrence rate wound 
increase and the prognosis would become worse even if they 
underwent complete resection. In these cases a prompt surgical 
resection would be recommended.
Keywords: Adenocarcinoma, thin-section computed tomography, 
consolidation tumor ratio, ground glass nodules
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P3.07-046 A NOVEL TECHNIQUE FOR PALLIATING 
RECURRENT PLEURAL EFFUSIONS WITH A PORT-AC-
CESSED TUNNELED CATHETER
Joseph Friedberg1, Andrew R. Haas2, Melissa Culligan1, Daniel 
Sterman2
1University Of Pennsylvania/United States Of America, 2Medicine, Di-
vision Of Pulmonology, University Of Pennsylvania/United States Of 
America
Background: The cuffed tunneled catheter has revolutionized out-
patient management of recurrent pleural effusions. Some patients, 
however, refuse these tubes on the basis of prohibition of swim-
ming/tub bathing or cosmetic considerations. The objective of this 
study was to develop a technique to serve such patients.
Methods: Four patients with recurrent effusions refused tun-
neled catheter placement and were not candidates or refused 
pleuro-peritoneal shunts. All required multiple thoracenteses, 
one weekly for over a year. One patient had a chronic benign 
symptomatic transudative effusion after successful nonoperative 
treatment of NSCLC. The second patient had recurrent chylotho-
races secondary to Yellow Nail Syndrome. Two patients had mali-
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leadership & support. The TSI serves as a model for other regions 
and systems to define & implement high quality thoracic surgery. 
Clinical data is required to monitor success.
Keywords: Thoracic surgery, Quality, Quality improvement, Health 
system
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P3.07-048 VATS LOBECTOMY FOR NSCLC IN GERMANY 
- RESULTS OF A NATIONWIDE SURVEY
Johannes Bodner1, Wilhem Stertmann1, Martin Reichert1, Stefanie 
Kerber1, Ibrahim Alkoudmani1, Florian Augustin2
1Division Of Thoracic Surgery, University Hospital Giessen/Germany, 
2Visceral, Transplant, Thoracic Surgery, University Hospital Innsbruck/
Austria
Background: Despite increasing evidence of safety and efficacy of 
VATS lobectomy for early stage NSCLC, there has been persistent 
reluctance for this technique among thoracic surgeons in central 
Europe. Concerns have existed with regard to oncologic safety and 
the feasibility and accuracy of hilar and mediastinal lymph node 
dissection. Only recently the VATS approach has gained some 
increasing acceptance but no data exist regarding application and 
indication of the VATS approach for NSCLC in Germany.
Methods: A survey (12 questions) was performed among the tho-
racic surgical units in Germany. Questions focused on volume, in-
dication, technique and distribution of VATS lobectomy for NSCLC.
Results: The response rate was 65% (25 units). Most units started 
the VATS lobectomy program only within the last 5 years and sofar 
performed up to 100 procedures, only 4 centers performed more 
than 300 procedures. Most centers consider NSCLC stages IA-IIB 
for a VATS approach, 4 units (16%) approach tumors up to stage 
IIIA by VATS. All units operate via an anterior approach, most (80%) 
use 3 incisions. In addition to standard lobectomies, 15 (60%) units 
also perform anatomical segmentectomies, 2 (8%) centers bronchi-
al sleeve resections and 1 (4%) center pneumonectomies by VATS. 
24 (96%) units perform systematic lymph node dissection, 3 cen-
ters perform VAMLA (Video Assisted Mediastinal LympAdenecto-
my). In most units (14, 56%) 2-3 surgeons participate in the VATS 
lobectomy program.
Conclusion: In Germany, the VATS approach for anatomical re-
sections for NSCLC has been increasingly adopted only within the 
last 5 years. However, even in 2013, only approximately 15% of 
all lobectomies are performed by VATS, which is a low rate when 
compared to the US, Great Britain and some Asian countries.
Keywords: VATS lobectomy, NSCLC
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P3.07-047 DEVELOPING THORACIC SURGERY QUALITY 
ACROSS A BROAD REGION OF WESTERN UNITED STA-
TES: THORACIC SURGERY INITIATIVE (TSI)
John R. Handy1, Kimberly Costas2, Eric Vallieres3, Kenton Ste-
phens4, Raymond Schaerf5, Calvin Harrison6, Kasia Konieczny7, 
Catherine Betzer1, Katherine Lothrop1, Maureen Angel8
1Thoracic Surgery, Providence Cancer Center/United States Of America, 
2Providence Physician Group Cardiac And Thoracic Surgery, Providence 
Regional Medical Center Everett/United States Of America, 3Depart-
ment Of Thoracic And Foregut Surgery, Swedish Medical Center/United 
States Of America, 4Providence Alaska Medical Center- Anchorage/
United States Of America, 5Providence St. Joseph Medical Center/United 
States Of America, 6Providence Health & Services/United States Of 
America, 7Oncology Services Sw Region, Providence St. Peter Hospital/
United States Of America, 8Providence Strategic Management, Provi-
dence Health & Services/United States Of America
Background: In the United States, thoracic surgery quality, as 
measured in mortality, morbidity or processes (eg lymphadenec-
tomy after lung cancer resection), is very heterogeneous between 
institutions and surgeons. Despite barriers involving surgeon spe-
cialties, payors and administrative systems, health care quality is 
measurable & implementable. We describe the Thoracic Surgery 
Initiative (TSI), a grass roots quality improvement effort within 
Providence Health & Services (PHS), which consists of 34 facilities 
providing healthcare over a large Western region (Alaska, Califor-
nia, Montana, Oregon & Washington).
Methods: The TSI was conceived and driven by a thoracic sur-
geon. A core team (surgeons, administrators, data manager) was 
formed, thoracic surgery (TS) service line specifics defined & 
identified (of 34 facilities, 14 perform TS), stakeholders identified 
& surveyed regarding interest & resources. A series of meetings, 
agreements and collaborations were formed to define and imple-
ment quality care with the following goals: decrease mortality & 
morbidity, clinical standardization & cost savings.
Results: 2011- Feb 2012: (1) intra-mural grant for TSI development 
obtained, (2) development activities described above, (3) organi-
zing meeting of stakeholders (40 attendees-12 hospitals) accom-
plished: (a) persuasion of site-specific & system leaders/physicians/
administrators, (b) executive committee (EC), (c) operational ca-
lendar (bimonthly phone conferences). Surgeon-leader spent 265 
hrs on project Aug 2011-Mar 2012. 2012 EC accomplishments: (1) 
formulated charter & mission statement, (2) agreed upon & defi-
ned TS clinical data elements, (3) determined system/site-specific 
data system costs, (4) endorsed electronic health record (EHR) as 
platform for standardization, (5) endorsed development of TS best 
practice. Dec 2012 meeting (42 attendees; 12 hospitals): (1) estab-
lished data system requirements, (2) began system wide TS practi-
ce standardization using EHR (TS consult, op note, daily rounding 
note, discharge summary, clinic note, multidisciplinary thoracic on-
cology conference note), (3) consensus regarding required compo-
nents of lung cancer screening program. 2013: Executive commit-
tee established best practice component candidates (performance 
status, clinical staging, lymphadenectomy, etc). Surgeons surveyed 
for importance of possible components. 38 components chosen 
for incorporation into EHR templates. Data system and EHR temp-
lates developed. Quarterly newsletter informs all TSI stakeholders.
Conclusion: Health care quality can be defined & implemented 
across a broad geographic area but requires dedicated physician 
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Keywords: Elderly Patient, Stereotactic Body Radiation Therapy, 
Concurrent Chemotherapy
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P3.08-002 AN EVIDENCE-BASED ESTIMATION OF  
SURVIVAL AND LOCAL CONTROL BENEFIT OF  
RADIOTHERAPY FOR LUNG CANCER
Jesmin Shafiq, Timothy Hanna, Geoff Delaney, Shalini Vinod, 
Michael Barton
University Of Nsw/Australia
Background: Evidence-based Radiotherapy utilisation benchmarks 
[Delaney G et al, Cancer 2003] have been used as the basis for 
planning radiotherapy services both nationally and internationally. 
These utilisation models have been further expanded to estimate 
the benefit for each radiotherapy indication in individual cancer 
sites using evidence-based approach [Shafiq J et al, Radiotherapy 
and Oncology 2007].
Methods: Our study aimed at estimating the benefit of definitive 
or adjuvant radiotherapy to overall survival and local control of 
lung cancer patients if the entire lung cancer population are trea-
ted according to evidence-based treatment guidelines. The opti-
mal radiotherapy utilization model previously reported for small-
cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) was 
extended to incorporate overall survival and local control benefit 
from radiotherapy (radiotherapy vs no radiotherapy, radiotherapy 
and concurrent chemotherapy vs radiotherapy alone) from publis-
hed data (1990-2010). Palliative benefits were not considered.
Results: The overall gains in 5-year local control and survival were 
11% (95% CI 9.5%-12.3%) and 5% (95% CI 3.6%-6.7%) respectively if 
optimal radiotherapy was applied for all lung cancer patients. The 
optimal gains for all lung cancer from concurrent chemotherapy 
and radiotherapy over radiotherapy alone were 5% (95% CI 1.7%-
7.6%) for local control and 4% (95% CI 1.0%-6.0%) for survival. The 
overall local control benefit for radiotherapy including concurrent 
chemotherapy for SCLC and NSCLC were 10% and 17%; 5 year 
survival benefit proportions were: SCLC 2% and NSCLC 10%.
Conclusion: Our model provides a quantitative estimate of benefit 
of curative radiotherapy for lung cancer at the population level if 
evidence-based guidelines were applied. The model predicted 
that guidelines-recommended application of radiotherapy treat-
ment could save 900 extra lives per 10 000 cases of lung cancer for 
up to 5 years and prevent 1600 local recurrences in that period.
Session P3.08: Poster Session 3 -  
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P3.08-001 FEASIBILITY OF STEREOTACTIC BODY RADI-
ATION THERAPY WITH CONCURRENT CHEMOTHERA-
PY FOR PATIENTS OVER 75 YEARS OLD WITH STAGE I 
NON-SMALL-CELL LUNG CANCER.
Masaki Kokubo1, Takahiro Kishi1, Megumi Uto1, Takashi Shintani1, 
Nami Ueki1, Shiro Fujita2, Reiko Kaji2, Akito Hata2, Kenji Takaya-
ma1, Nobuyuki Katakami2
1Radiation Oncology, Institute Of Biomedical Research And Inovation/
Japan, 2Integrated Oncology, Institute Of Biomedical Research And Inno-
vation/Japan
Background: Stereotactic body radiation therapy (SBRT) is now 
the standard treatment for elderly patients with inoperable Stage I 
non-small-cell lung cancer (NSCLC). However SBRT with concurrent 
chemotherapy may be feasible and effective to selected elderly 
patients with NSCLC. This retrospective study was aimed to evalu-
ate the safety and tolerability of concurrent SBRT and chemothera-
py in patients aged 75 years or older.
Methods: We reviewed the records of 11 NSCLC patients who 
were 75 years or older when treated with SBRT and concurrent 
chemotherapy with curative intent from 2009 to 2012. Five patients 
had T1 tumor, the others had T2 tumors. The median age was 81 
years with a range of 76 to 88 years. Eight (72%) patients had chro-
nic obstructive pulmonary disease. The median number of Eastern 
Cooperative Oncology Group (ECOG) performance status of the 
cases in the beginning of treatment was 1 with a range from 0 to 
2. The median delivered radiation dose was 48 Gy in 4 fractions. 
Concurrent chemotherapy regimen was carboplatin plus paclitaxel, 
carboplatin plus docetaxel, paclitaxel alone, pemetrexed alone, 
and S1 alone.
Results: All patients received SBRT on schedule. Out of 11 pati-
ents, concurrent chemotherapy was successfully accomplished as 
originally planned in 8 (72%) patients. Initial effect of SBRT plus 
chemotherapy could be evaluated in all cases. Complete local 
remission was achieved in 10 patients. One patient alone had 
local recurrence. Distant metastases observed in 4 patients. In 2 
patients, chemotherapy was intermitted due to grade 3 neutrophil 
count decreased and anemia (Common Terminology Criteria for 
Adverse Events version 4.0). In another, chemotherapy was broken 
off because of Grade 2 radiation pneumonitis. During the treat-
ment, no other adverse event was shown. No treatment-related 
death was observed.  
Grade 2 Grade 3
Neutrophil count decreased 6 (55%) 1 (9%)
Anemia 1 (9%) 2 (10%)
Radiation pneumonitis 1 (9%) 0
Conclusion: SBRT plus concurrent chemotherapy might be feasib-
le in selected patients aged 75 years or older with Stage I NSCLC.
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P3.08-004 SIGNIFICANCE OF LOW DOSE DISTRIBUTI-
ON IN DEVELOPING RADIATION PNEUMONITIS AFTER 
HELICAL TOMOTHERAPY BASED HYPOFRACTIONATED 
RADIOTHERAPY FOR PULMONARY METASTASES
Chul Seung Kay1, Seok Hyun Son1, Yong Nam Kang2, In Young Jo1, 
Ji Young Jung1, Ki Jun Kim3
1Radiation Oncology, The Catholic University Of Korea Incheon St. Mary 
Hospital/Korea, 2Radiation Oncology, The Catholic University Of Korea 
Seoul St. Mary Hospital/Korea, 3Diagnostic Radiology, The Catholic 
University Of Korea Incheon St. Mary Hospital/Korea
Background: Hypofractionated radiotherapy (HRT) for pulmonary 
malignancies has been now commonly used, as a tumorcidal dose 
can be accurately delivered to the target without any consequenti-
al dose to adjacent normal tissues. However, radiation pneumonitis 
(RP) is still a major problem after HRT. To determine the significant 
parameters in developing RP, we retrospectively investigated data 
from patients treated with HRT using helical tomotherapy for lung 
metastases.
Methods: A total of 45 patients were included in the study and the 
median age was 53 years old. The median prescriptive doses were 
50 Gy to internal target volume and 40 Gy to planning target volu-
me in 10 fractions over 2 weeks. RP was diagnosed by chest X-ray 
or computed tomography after HRT and its severity was determi-
ned by CTCAE version 4.0.
Results: The incidence of symptomatic RP was 26.6%. Univariate 
analysis showed that mean lung doses, V5, V10, V15, V20 and 
V25 were statistically significant in developing symptomatic RP 
(P<0.05). However, only V5 was statistically significant in develo-
ping symptomatic RP in multivariate analysis (p=0.019). In the ROC 
curve, V5 was the most powerful predictor of symptomatic RP, and 
its AUC was 0.780 (p=0.004). In addition, the threshold value of V5 
to develop symptomatic RP was 65%. The large distribution of a 
low dose resulted in a higher risk of lung toxicity.
Conclusion: To prevent symptomatic RP, we should limit the V5 to 
less than 65%, in addition to considering conventional dosimetric 
factors. However, a further clinical study must be done in oreder to 
confirm this result.
Keywords: low dose distribution, radiation pneumonitis, hypofrac-
tionated radiotherapy, helical tomotherapy
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P3.08-003 FDG-PET PARAMETERS AS PREDICTORS FOR 
OUTCOME IN NON SMALL CELL LUNG CANCER NSCLC 
TREATED WITH STEREOTACTIC ABLATIVE RADIOTHE-
RAPY (SABR) AT THE ST JAMES‘S INSTITUTE OF ONCO-
LOGY
Mymoona Alzouebi1, Manil Subesinghe1, Helene Thegesen2, Mark 
Teo1, Mike Snee1, Kevin Franks1, Rob Turner1, Rob Stuart1, Caroline 
Young1, Katy Clarke3
1St James Hospital/United Kingdom, 2Leeds University/United Kingdom, 
3Oncology, St James Hospital/United Kingdom
Background: To identify predictive FDG-PET imaging factors for 
outcomes following Stereotactic Ablative Radiotherapy in early 
stage Non Small Cell Lung Cancer
Methods: Patients with inoperable T1 and T2 NSCLC and a base-
line FDG PET-CT at a single centre (St James Institute of Onco-
logy) treated with SABR for a single tumour between 2009 and 
2012 were included. Prospective data was collected on a range of 
FDG-PET parameters (Tumour SUVmean, SUVmax, Tumour:Liver 
SUVmax and SUVmean ratios, Tumour:Mean Blood Pool SUVmax 
and SUVmean ratios and TLG –Total lesion glycolysis). Patient cha-
racteristics and outcome variables including stage, histology, PTV 
volume, performance status, dose, time interval between PET and 
SABR, response to treatment and patterns of failure collected and 
analysed. The PET parameters were analysed initially as a conti-
nuous variable.
Results: 125 patients (72 female, 53 male), median age 75, 94 were 
T1 and 31 T2. Median follow-up 1.2yrs (range 0.28-3.3). Histology 
confirmation was possible in 40 patients. Relapse free survival at 
2 years was 55%. Local (LR), regional (RR) and distant relapse (DR)-
free rates were 94%, 89% and 83% respectively. Overall (OS) and 
cause-specific survival at 2 years was 57% and 81% respectively. 
On multivariate analysis, pre-treatment SUVmax was the only PET 
parameter that consistently predicted for recurrence (p<0.01), DR 
(p=0.012) and OS (p=0.026). This was consistent amongst patients 
with and without diagnostic pathology and no statistical difference 
was found between the two groups. Patients with SUVmax > 17.9 
had significantly worse DR and OS (HR 9.99 and 6.68 respectively). 
SUVmax however did not correlate with LR or RR rates. The only 
other PET parameter with any statistically significant correlation 
was the TLG20 which showed some association with RR (p=0.038). 
Once SUVmax was established as the strongest predictor for out-
come this was assessed as a dichotomised variable to assess pre-
dictability for DR. Patients with an SUVmax above17.9 were found 
to have significantly higher rates of DR (p=0.03)
Conclusion: In our population SUVmax is the strongest FDG-PET 
parameter to correlate with outcome following SABR for NSCLC. 
Number of events of DR were small and a cut off point predicting 
for this is difficult to interpret. This is consistent with previously 
published data. With SABR an emerging treatment modality for 
early stage disease, this may have future implications on the use of 
adjuvant chemotherapy.
Keyword: SABR PET-FDG SUVmax NSCLC
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• Formation of regional training hubs
Specific goals identified for Australia were the need to standardise 
protocols, advocacy for access to funding through Medicare for 
advanced radiotherapy technologies, and the safe implementation 
of SABR in regional centres. The Tripartite Collaboration being 
developed at a national level between RANZCR, AIR and ACPSEM 
and the NSW SABR Collaboration will address these concerns.
Results: Australia has already contributed physics expertise to 
facilitate the success of the first regional training course, held in 
Singapore in December 2012. Sydney will host the final regional 
training course in 2015 on SABR for lung and spine. We continue to 
contribute our technical and clinical expertise in developing trai-
ning materials and resources for the project.
Conclusion: Collaboration between well-resourced and develo-
ping countries in Asia is helping to sustainably develop resources 
and expertise to improve access to SABR for lung cancer patients. 
This networking provides future opportunities for large scale cli-
nical trials and research in diseases with a high prevalence in the 
region. 1. Pan H et al. Cancer 2011 117(19):4566 2. Palma D et al. 
J Clin Oncol. 2010;28(35):5153 3. Teshima T al. J Radiati. Res 53.5 
(2012): 710
Keywords: Stereotactic, Lung cancer
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P3.08-006 RESPIRATORY FUNCTION CHANGES AFTER 
STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) IN 
STAGE I NON-SURGICAL NSCLC: PRELIMINARY RESULTS 
FROM A SINGLE INSTITUTION PROSPECTIVE STUDY.
Cinzia Ferrero1, Andrea R. Filippi2, Matteo Giaj Levra3, Roberto 
Torchio4, Simonetta G. Rapetti3, Alessia Guarneri2, Cristina Man-
tovani2, Ilenia Potenza2, Francesco Moretto2, Luana Focaraccio1, 
Silvia Novello3, Umberto Ricardi2
1University Of Turin, Postgraduate School Of Respiratory Disease/Italy, 
2Department Of Oncology, University Of Turin, Italy/Italy, 3Department 
Of Oncology, University Of Turin/Italy, 4Respiratory Function And Sleep 
Laboratory Service/Italy
Background: Stereotactic Ablative Radiotherapy (SABR) is an 
alternative to surgery in patients with early stage non-small cell 
lung cancer (NSCLC) inoperable for medical co-morbidities (mainly 
cardiovascular or respiratory diseases) or who refuse surgery. We 
performed a prospective evaluation of lung function parameters, 
treatment-related radiological and clinical toxicity in a cohort of 
patients treated with SABR.
Methods: We prospectively recruited 26 patients from July 2012 
to May 2013. All patients had a histological or cytological diagno-
sis of NSCLC (n=20) or a lung lesion in dimensional growth with 
PET positivity (SUV>2.5) (n=6). All patients had stage IA– IB and 
were judged unfit for surgery or refused it. Each patient did a 4D-
TC with slice of 2.5mm/2.5mm, treatment consisted of a single 
Volumetric Modulated Arc Therapy and the fractionation sche-
dule was dependent on tumor location. Pulmonary toxicity was 
assessed through the execution of pulmonary function tests and 
on chest Computed Tomografy (CT). All tests were synchronously 
performed before treatment and at regular intervals after SABR 
(the first control at 45 days, then every 90 days until progression). 
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P3.08-005 IAEA RCA 6065: IMPROVING ACCESS TO 
STEREOTACTIC ABLATIVE BODY RADIOTHERAPY (SABR) 
FOR LUNG CANCER PATIENTS IN ASIA.
Fiona Hegi-Johnson1, Shankar Siva2, Matthew Foote3, Daniel Tan4, 
Mi-Sook Kim5
1Radiation Oncology, Nepean Cancer Care Centre/Australia, 2Peter 
MacCallum Cancer Centre/Australia, 3Radiation Oncology, Princess 
Alexandria Hospital/Australia, 4Radiation Oncology, National Universi-
ty Hospital/Singapore, 5Radiation Oncology, Korean Institute Of Radio-
logical And Medical Sciences ( Kirams)/Korea
Background: The IAEA/RCA Project “Strengthening the Applica-
tion of Stereotactic Body Radiotherapy” aims to increase the capa-
city to deliver SABR in Asia. Lung cancer is one of the most com-
mon cancers in Asia. Most patients present with locally advanced 
or metastatic disease, but increased access to diagnostic scanning 
will result in earlier detection of lung cancers suitable for SABR. 
The shorter treatment time is beneficial in reducing the burden of 
treatment and economic costs of radiotherapy treatment. The clini-
cal efficacy and socio-economic benefits of SABR have led to rapid 
implementation in the US1, Europe2 and parts of Asia3. SABR lung 
demands specialised expertise, physical infrastructure, and a long-
term commitment to rigorous quality assurance. There is significant 
heterogeneity in the resources and expertise between the RCA 
Member States. This project aims to identify and ameliorate obsta-
cles to the safe and effective implementation of SABR within Asia. 
Methods: Each country developed a work-plan specific to their 
capacities and needs. Key strategies for implementation of the 
project are: 
• Development of treatment protocols
• Regional training courses
• Advocacy with Government bodies responsible for policy-ma-
king and funding, and education of the wider medical community 
and public about the benefits of SABR
• Expert missions with on-site training
• Publications including educational materials and the results of 
implementation( utilisation rates, local control and clinical outco-
mes)
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linac-based volumetric modulated arc therapy (VMAT), in a cohort 
of patients actually treated on 0813. The comparison is limited to 
target coverage and organ-at-risk (OAR) sparing capability for this 
technically challenging group of patients.
Methods: All 5 patients from our institution accrued to RTOG 0813 
were selected for this study. Eight planners (4 VMAT, 4 RRS) with 
combined experience of >500 lung SABR cases re-planned each 
case for 60 Gy in 5 fractions. Patient setup, contouring details, and 
planning constraints were as per 0813. Monte Carlo planning was 
performed on Monaco v3.20 (Elekta Inc., MI, USA) for VMAT and 
Multiplan v4.5.0 (Accuray Inc., Sunnyvale, USA) for RRS on Cyber-
Knife. An objective scoring system was designed that included 
each dose-volume 0813 protocol criterion. For each target require-
ment or OAR constraint a “structure score” was assigned whereby 
[Actual Plan parameter /Expected 0813 parameter] X priority factor 
= structure score. Priority factors (high 0.9, intermediate 0.6, and 
low 0.3) were assigned by 3 experienced lung SABR radiation on-
cologists for each of the 5 patients given that different OARs were 
of greater concern depending on exact target location. A ‘final 
plan score’ was the sum of all structure scores, with a lower overall 
score indicating a plan that best achieved target coverage and 
OAR avoidance in keeping with radiation oncologist priority. To re-
duce inter-planner bias more than one plan was created for each of 
the 5 patients using both modalities and only the best plans were 
selected for comparison.
Results: A total of 15 VMAT and 10 RRS plans were submitted for 
analysis, each satisfying the minimum 0813 protocol requirements. 
Using the scoring system, a final plan score was obtained for all 25 
plans with a median VMAT score of 8.02 (range 5.52 to 10.09) and 
RRS score of 7.1 (range 4.98 to 12.41). The lowest scoring VMAT 
plan was then compared with the lowest scoring RRS plan for each 
patient. Analysis of target coverage parameters showed that both 
modalities had similar scores, indicating an equivalent ability to 
conformally cover the target. RRS plans had lower OAR scores 
(mean reduction of 1.3) compared to VMAT plans. Overall the plan 
scores for each patient (RRS: VMAT) were: Patient 1 (6.74:9.2), Pati-
ent 2 (6.69:7.32), Patient 3 (4.98:5.94), Patient 4 (7.69:8.92), Patient 5 
(5.78:7.36).
Conclusion: When using a scoring system based on RTOG 0813 
planning criteria to compare patient plans from two different lung 
SABR delivery systems, 5 of 5 patients planned using a robotic 
radiosurgery system had more favourable overall scores compared 
to VMAT linac delivery for centrally located tumours.
Keywords: Cyberknife, Early lung cancer, vmat, central lung tu-
mors
Lung function parameters were obtained performing spirometry, 
body plethysmography, determination of the diffusion lung capaci-
ty of carbon monoxide (DLCO) and arterial blood gas analysis.
Results: Of 26 patients enrolled, 17 performed the first evaluation 
at 45 days, 5 at 135. At 45 days the total lung capacity (TLC) slight-
ly decreased from 5.87±1.50 Liters (L) to 5.62±1.42 (t=1.87; NS), 
whereas VC, FEV1 and FEV1/VC ratio showed minimal changes. At 
135 days TLC in the 5 patients who ultimate this step showed a 
slight recovery to 5.75±1.75 L. The pulmonary diffusion capacity for 
carbon monoxide (DLCO), corrected for hemoglobin (Hb) levels, si-
gnificantly decreased from 14.4±4.9 to 12.9±5.2 (mL min-1·mmHg-1) 
at 45 days (p<0.019) with a slight recovery at 135 day to 13.9±2.7. 
When DLCO was corrected for the measured Alveolar Volume 
(DLCO/VA) the change was not significant. The difference between 
plethysmographic TLC and the dilution VA (TLC-VA) increased at 
45 days from 1.24±0.7 to 1.49±0.8 L, suggesting an increase in 
ventilation inhomogeneity of the lung. Arterial oxygen pressure 
decreased from 75.8±7.2 to 71.6±10.4 mmHg (p=0.056 NS) and 
the variation correlated with TLC-VA (r=-0.72, p<0.001) and DLCO 
variations (r=-0.67, p<0.03). We observed a low toxicity profile du-
ring the first evaluation at 45 days, with only 1 RTOG grade 2 and 1 
grade 3 post actinic pneumonia, both treated with systemic corti-
costeroids. Only three patients reported fatigue as the only adver-
se event. At the first radiological re-evaluation we didn’t observe 
any progression disease, with a 59% rate of partial response.
Conclusion: Preliminary findings suggest that no major changes 
in lung function can be detected at 45 days after SABR. A slight 
reduction in DLCO can be observed, and this could reflect a tran-
sitory increase in pulmonary ventilation inhomogeneity caused by 
RT rather than a direct membrane damage. Study prosecution will 
hopefully clear the physiopathological evolution at several months 
after SABR, and further analyses will be carried out investigating 
for a potential correlation with radiological toxicity and dosimetric 
profiles.
Keywords: Non small cell lung cancer, Stereotactic ablative radio-
therapy, Respiratory function, Lung toxicity
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P3.08-007 STEREOTACTIC ABLATIVE RADIOTHERAPY 
(SABR) OF CENTRALLY LOCATED EARLY STAGE LUNG 
CANCER ACCRUED TO RTOG 0813: NOVEL SCORING 
SYSTEM TO COMPARE PLAN QUALITY OF VOLUMETRIC 
MODULATED ARC THERAPY (VMAT) VERSUS ROBOTIC 
RADIOSURGERY
Vimoj J. Nair1, Jason Pantarotto1, Robert Macrae1, Elizabeth Hen-
derson2, Gillian Wright1, Margaret Mcmanus1, Margaret Ciesiel-
ski1, Manon Lacelle1, Janice Doody1, Janos Szanto2, Nicholas Plo-
quin2
1Division Of Radiation Oncology, University Of Ottawa/Canada, 2Medi-
cal Physics, The Ottawa Hospital/Canada
Background: Central lung tumours pose a challenge for stereot-
actic ablative radiotherapy (SABR) due to proximity to vital organs 
and risk of potentially fatal toxicity. RTOG 0813 is an attempt to 
determine a safe dose for these tumours in an era where many 
institutions have multiple technologies that can deliver lung SABR. 
The purpose of this study is to use a novel scoring system to com-
pare two different SABR platforms, robotic radiosurgery (RRS) and 
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P3.08-009 RADIOTHERAPY FOR POSTOPERATIVE THO-
RACIC LYMPH NODE RECURRENCE IN PATIENTS WITH 
NON-SMALL CELL LUNG CANCER WITHOUT DISTANT 
METASTASIS
Jiro Okami1, Kinji Nishiyama2, Ayako Fujiwara1, Koji Konishi2, Ta-
kashi Kanou1, Toshiteru Tokunaga1, Teruki Teshima2
1General Thoracic Surgery, Osaka Medical Center For Cancer And Car-
diovascular Diseases/Japan, 2Radiation Oncology, Osaka Medical Cen-
ter For Cancer And Cardiovascular Diseases/Japan
Background: Thoracic lymph node recurrence after complete 
resection is common in non-small cell lung cancer but it mostly 
occurs along with distant metastases. The recurrent disease might 
be localized and curative intent radiation therapy is therefore the 
treatment of choice if no evidence of hematogenous spreading 
of the disease is observed. However, the treatment effect and the 
long-term outcomes of radiotherapy for lymph node recurrences 
have not been well reported. We sought to describe the treatment 
effect and the long-term outcomes of radiotherapy for postopera-
tive lymph node recurrences.
Methods: Fifty patients that had developed thoracic lymph node 
recurrence after complete resection received curative intent radio-
therapy between 1997 and 2009. The nodal stage at recurrence 
was N1 in 10 patients, N2 in 28 patients, and N3 in 12 patients. 
The diagnosis of lymph node recurrence was based on chest CT, 
FDG-PET, physiological examination, the value of CEA, and/or 
bronchoscopic sampling for cytology. The cytological evidence 
was obtained in 10 (20%) patients. Thirteen patients had symptoms 
associated with recurrent disease. Patients were treated using 3D 
conformal techniques. Conventional fractionation was used (2-3 
Gy/fraction), and the total prescribed dose ranged from 50 to 80 
Gy. The clinical endpoints included the tumor response, overall 
survival, progression-free survival, locoregional recurrence within 
the irradiated field, and any other recurrence.
Results: The planned total radiotherapy was completed in 49 pati-
ents. One patient refused further therapy at 56Gy/60Gy due to ra-
diation esophagitis. The median follow-up time after radiotherapy 
was 41 (19-98) months among the survivors. The response to treat-
ment was complete response in 65%, partial response in 24%, and 
progressive disease in 10% of the evaluated patients. The 1-year, 
the 3-year, and the 5-year progression-free survival rates were 
49.1%, 28.2%, and 22.2%, respectively. The median progression-
free interval was 12.0 months after radiotherapy. In ten patients, no 
additional recurrence was detected for longer than 3 years after ra-
diotherapy. The median overall survival after radiotherapy was 37.3 
months. Fourteen patients survived more than three years after 
radiotherapy. The 5-year overall survival rate was 36.1% (Figure). A 
multivariate analysis revealed that the absence of symptoms and 
the involvement of a single lymph node station were significant 
factors associated with a better overall survival.
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P3.08-008 COMPARISON OF AUTO- SEGMENTED PET 
VOLUMES IN DISCRETE LUNG TUMORS WITH CT BASED 
MANUAL CONTOURS: IMPLICATIONS IN RADIOTHERA-
PY PLANNING.
Madhava R. Kanakamedala, John K. Ma, Shankar P. Giri, Sriniva-
san Vijayakumar, William N. Duggar, Satyaseelan Packianathan
Radiation Oncology, University Of Mississippi Medical Center/United 
States Of America
Background: The aim of this study was to compare the GTV volumes 
drawn manually on CT scans with GTV delineation on FDG PET scans 
utilizing automatic threshold (SUV 3) and gradient-based (PET Edge) 
auto-segmentation methods in lung tumors and discuss implications in 
radiation planning.
Methods: Twenty two patients with lung carcinoma treated with radia-
tion therapy having discrete lesions with no adjacent consolidation or ate-
lectasis and having PET scan done within 30 days of simulation CT were 
enrolled in this study. FDG-PET/CT and planning CT were transferred to 
the MIM software and fused using the deformable registration algorithm. 
For each patient three GTV’s were defined. GTV CT manually contoured 
on CT scan using lung window in lesions adjacent to lung parenchyma 
and mediastinal window when adjacent to mediastinum or chest wall. 
For GTV SUV3, circle of interest was created with a margin around the 
lesion, excluding blood pool (heart) and auto segmented with SUV value 
of 3. GTV-PET Edge was auto segmented using PET Edge tool centered 
on the hyper metabolic area. Statistical Methods: Spearman correlation 
coefficients were constructed to view relationships between variables, 
and sign tests were used for inference.
Results: Among 22 patients, only one was small cell and 21 were with 
non-small cell carcinomas (8 squamous cell, 11 adenocarcinoma and 2 
poorly differentiated). As per the AJCC 7th Ed, 16-stage I, 3 stage II and 
3 belong to IIIA. Median CT volume for all lesions was 4.385, (range 0.68-
173.74), PET Edge median 4.235 (range 0.474-113.00), SUVs 3 median 
4.845 (0.659-109.1). Correlation between CT and SUV 3, SUV 3 and PET 
edge, CT and PET Edge were 0.8690, 0.9105 and 0.8585 respectively. 
No significant differences between CT and SUV 3 volumes (p=0.5235) 
as well as CT and PET Edge volumes (p=0.3833). But PET edge volumes 
were significantly less compared to SUV 3 volumes (p=0.0525).
Conclusion: Lobectomy is the treatment of choice for early stage non-
small cell lung cancers. In medically inoperable patients stereotactic 
body radiation therapy has become the new standard of care with 3 year 
overall survival of 60%, similar to lobectomy. For conventional Radiation 
therapy GTV’s are expanded to generate CTV for presumed microscopic 
disease (CTV). In SBRT GTV and CTV are identical. In phantom studies 
auto segmentation using PET edge tool shown to be superior to other 
methods and better correlated with pathology. In our study the median 
volume by PET edge is smaller compared to other two modalities. The 
difference is statistically significant between PET edge and SUV 3 but not 
between CT and PET edge. Hence, adaptation of PET edge tool may 
decrease the GTV and PTV volumes that will enable to spare the normal 
structures better in SBRT. Surgical pathologic studies determined CTV 
margins of 6mm for squamous and 8mm for adeno, beyond gross patho-
logical tumor (Giraud et al). CT overestimates GTV volume in lung tumors 
with no additional or negative margins required to create CTV (Chan et 
al). We allude that adaptation of SUV 3 may be enough to generate CTV 
volumes for conventional radiation therapy.
Keywords: Radiation, contour, PET, CT, Radiation therapy, contour,  
PET, CT
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based on four categories; tumour edge detection, image artefacts, 
noise affecting edge detection and overall image quality. A score 
of 2 or below was considered clinically acceptable
Results: Both magnet strengths provided reasonable image qua-
lity to define tumour volume on lung MRI. The average score for 
overall image quality between the two scanners was 1.8 for 1.5T 
and 1.3 for the 3T scanner. For the 1.5T scanner the sagittal and 
coronal T2 weighted scan scored the best for overall image quality 
for tumour delineation (1.53), due to limited respiratory motion dis-
tortion. However these image planes are not compatible with ra-
diotherapy planning systems. For the 3T scanner the axial T2 ima-
ges scored best for overall image quality (1.05). For tumour edge 
detection the sagittal and coronal and T1 weighted images scored 
best (1.75) for the 1.5T scanner. The axial T2 weighted image and 
the sagittal cine mode performed best for tumour edge detection 
(1). Overall sequences on the 3T scanner were rated higher than 
those on the 1.5T scanner
Conclusion: It is feasible to utilise commercially available MRI se-
quences to acquire images of acceptable quality for the purposes 
of lung cancer delineation in radiotherapy. Both magnet strengths 
gave acceptable image quality for clinical use in radiotherapy, with 
the 3T magnet displaying slightly better image quality. A future 
study will compare lung cancer delineation between the current 
standard practice of CT&PET with MRI.
Keyword: Lung Cancer, MRI, Image Quality
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P3.08-011 STEREOTACTIC ABLATIVE RADIOTHERAPY:  
A POTENTIALLY CURABLE APPROACH TO MULTIPLE 
PRIMARY LUNG CANCER
Joe Y. Chang1, Yung-Hsien Liu1, Zhengfei Zhu1, James W. Welsh1, 
Daniel Gomez1, Ritsuko Komaki1, Jack Roth2, Stephen G. Swisher2
1Radiation Oncology, The University Of Texas MD Anderson Cancer 
Center/United States Of America, 2Thoracic & Cardiovascular Surgery, 
University Of Texas MD Anderson Cancer Center/United States Of 
America
Background: Lung parenchymal recurrent or multiple lobe cancer 
is typically considered to have metastatic disease and treated with 
palliative approach such as chemotherapy. However, some of these 
patients may have multiple primary lung cancer (MPLC) that could 
be potential curable. Surgical resection has been the standard 
treatment for early-stage multiple primary lung cancer (MPLC). 
However, a significant proportion of patients with MPLC cannot 
undergo surgery. We explored here the role of stereotactic ablati-
ve radiotherapy (SABR) for patients with MPLC.
Methods: We reviewed MPLC cases treated with SABR (50 Gy in 4 
fractions) for the second tumor. Four-dimensional CT–based plan-
ning/volumetric image-guided treatment was used for all patients. 
Patients underwent chest CT scanning every 3 months for 2 years 
after the SABR and then every 6 months for another 3 years. PET 
scans were recommended at 3–12 months after SABR. Toxic ef-
fects were scored according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Effects version 4.
Results: For the 101 patients treated with SABR, at a median 
follow-up interval of 36 months and median overall survival of 46 
Conclusion: Radiation therapy for thoracic lymph node recurrence 
after complete resection is safe and provides acceptable disease 
control. Early detection of lymph node recurrence may improve 
better disease control and increase the chance of curing the di-
sease.
Keywords: radiotherapy, lymph node recurrence
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P3.08-010 THE POTENTIAL USE OF MRI TO DELINEATE 
LUNG CANCER VOLUMES FOR RADIOTHERAPY
Shivani Kumar1, Lois C. Holloway2, Daniel Moses1, Gary Liney3, 
Shalini Vinod2
1University Of New South Wales/Australia, 2Liverpool Hospital, Cancer 
Therapy/Australia, 3Inghams Institute Of Applied Medical Research/
Australia
Background: The use of MRI for lung cancer volume delineation 
for radiotherapy is rare. This has been due to poor image quality 
as a result of physical and physiological factors such as low proton 
density, susceptibility effects and respiratory and cardiac motion. 
However as MRI technology has improved, imaging of lung abnor-
malities has become more feasible. A prospective study was there-
fore conducted to evaluate image quality for lung tumour delinea-
tion on a 1.5T (Tesla) and 3T MRI scanner. The aim of the study was 
to identify potential scan sequences that could be used clinically 
for tumour delineation for radiation therapy treatment.
Methods: Ten patients with lung cancer underwent MRI, five on a 
1.5T GE scanner using a body phased array coil and five on a 3T 
Phillips scanner. Scans on the 1.5T scanner were undertaken with 
breath hold and scans on the 3T scanner were performed with 
respiratory and peripheral pulse gating to give optimal image qua-
lity. The thorax was imaged with T2 and T1 weighted sequences on 
both field strengths. Cine mode imaging to compare tumour mo-
tion was also acquired. Scan sequence was matched for the 1.5T 
and 3T scanners. The quality of images for lung cancer delineation 
was assessed by an experienced thoracic radiologist and thoracic 
radiation oncologist using a four point scale. A consensus score 
ranging from 1(superior) to 4 (inferior) was given for each sequence 
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lity and effectiveness of a novel approach to dose escalation in 
LA-NSCLC. The study is funded by Cancer Research UK (C25518/
A11535), sponsored by Velindre NHS Trust and coordinated by the 
Wales Cancer Trials Unit.
Methods: Patients with histologically or cytologically confirmed 
stage II to IIIb NSCLC, suitable for radical radiotherapy, are eligible 
for the trial. Enrolled patients will receive 20 fractions of radiothe-
rapy over 4 weeks. The trial is split into two phases: Phase I: To 
establish the maximum tolerated (MTD) dose of radiotherapy to 
the oesophagus in patients where the oesophagus overlaps with 
the planning target volume (PTV). Phase I patients will be split 
into 2 groups depending on the length of the oesophagus lying 
within the PTV (Group 1A is where the overlap ≤6.5cm and Group 
1B is where the overlap >6.5cm). Cohorts of 6 or 12 patients are 
recruited to both groups at sequentially increasing dose levels (58, 
61, 63, 65Gy). Progression to the next oesophageal dose level will 
depend on the number of patients in a cohort with grade 3 or 4 
acute oesophagitis, or other grade 3 or 4 toxicity, occurring up to 
2 months after radiotherapy. Once the MTD to the oesophagus is 
established for each group, all participants will follow the Phase II 
protocol with the determined oesophageal dose limit. Phase II: Pa-
tients will receive a maximum of 65Gy in 20 fractions and the dose 
prescribed will be the highest dose achievable without exceeding 
defined safe dose limits for organs at risk. Where the oesophagus 
does not overlap with the PTV, patients can immediately be trea-
ted in Phase II, whereas patients whose oesophagus overlaps with 
the PTV can only be entered into Phase II once Phase I is complete, 
i.e. the MTD to the oesophagus has been established. The primary 
outcome of Phase II is the toxicity rate (grade 3 or 4) at 3 months. 
The I-START trial will determine whether this novel method of in-
creasing the radiotherapy dose in patients with NSCLC patients 
is tolerable, safe and effective. If the results are positive, then this 
new treatment may be compared against the best currently availa-
ble standard treatment in a future larger randomised (Phase III) 
trial.
Results: Not applicable.
Conclusion: Not applicable.
Keywords: radiotherapy, non-small cell lung cancer, dose escalla-
tion, clinical trial
POSTER SESSION 3 - RADIOTHERAPY  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.08-013 HIGH LOCAL CONTROL RATES WITH POST-
OPERATIVE RADIATION THERAPY IN INCOMPLETELY 
RESECTED NON-SMALL CELL LUNG CANCER (NSCLC) 
PATIENTS
Shaun U. Din1, Abraham J. Wu1, Daphna Y. Gelblum1, Amanda 
Foster1, Jamie E. Chaft2, Nabil P. Rizk3, James Huang3, Andreas 
Rimner1
1Radiation Oncology, Memorial Sloan-Kettering Cancer Center/United 
States Of America, 2Thoracic Oncology Service, Memorial Sloan-Ket-
tering Cancer Center/United States Of America, 3Division Of Thoracic 
Service, Department Of Surgery, Memorial Sloan-Kettering Cancer 
Center/United States Of America
Background: Post-operative radiation therapy (PORT) is frequently 
given to patients with NSCLC who have microscopically positive 
margins (R1 resection) or gross residual disease (R2 resection) 
months, 2-year and 4-year in-field local control rates were 97.4% 
and 95.7%. 2- and 4-year rates of overall survival (OS) were 73.2% 
and 47.5% and progression-free survival (PFS) were 67.0% and 
58.0%. Patients with metachronous tumors had higher OS and 
PFS than did patients with synchronous tumors (2-year OS 80.6% 
metachronous vs. 61.5% synchronous; 4-year OS 52.7% vs. 39.7%; 
p=0.047; 2-year PFS 84.7% vs. 49.4%; 4-year PFS 75.6% vs. 30.4%; 
p=0.0001). For patients whose tumors were both of the same his-
tology (meaning that the second lesion could have been a satellite, 
a metastasis, or a recurrent lesion), the 2-year and 4-year OS rates 
were 76.4% and 51.2%, which were no different from the OS rates 
for patients with tumors of different pathology (2-year OS: 66.7% 
and 4-year OS: 40.5%; p=0.406). The 2- and 4-year OS of patients 
in whom both tumors were classified as stage I were 76.1% and 
55.2%, which was better than the OS rates for the patients whose 
index tumors were of higher stage (2-year OS 66.7%, 4-year OS 
26.6%; p=0.049). For patients whose index tumor was treated with 
surgery or SABR, the incidence of grade ≥3 radiation pneumonitis 
was 3% (2/71), but this increased to 17% (5/30) for patients whose 
index tumor was treated with conventional radiotherapy. Other 
grade ≥3 toxicities included grade 3 chest wall pain (3/101, 3%) 
and grade 3 skin toxicity (1/101, 1%).
Conclusion: 1. SABR achieves an excellent long-term tumor control 
and promising PFS and OS in early-stage MPLC. 2. Toxicity could 
happen but within the scope of SABR in stage I disease. 3. Caution 
should be taken integrating SABR with prior conventional radiothe-
rapy for stage II/III disease. SABR could be an effective alternative 
to surgery for curative treatment of early-stage MPLC tumors.
Keyword: multiple primary lung cancer; stereotactic ablative ra-
diotherapy; stereotactic body radiotherapy;ea
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P3.08-012 I-START TRIAL: A UK PHASE I/II TRIAL OF 
ISOTOXIC ACCELERATED RADIOTHERAPY IN LOCALLY 
ADVANCED NON-SMALL CELL LUNG CANCER
Jason Lester1, Lisette S. Nixon2, Chinnamani Eswar3, Nazia Mo-
hammed4, Zafar Malik3, Robert Cowles2, Emma Parsons5, Philip 
Mayles3, Helen Mayles3, Alina Ionescu6, Nicholas Courtier2, Alan 
Nahum3, John Fenwick7, Gareth Griffiths2
1Velindre NHS Trust/United Kingdom, 2Wales Cancer Trials Unit, Car-
diff University/United Kingdom, 3Medical Physics, Clatterbridge Cancer 
Centre/United Kingdom, 4Beatson Cancer Centre/United Kingdom, 5Na-
tional Trials Qa Team, Mount Vernon Hospital/United Kingdom, 6Respi-
ratory Medicine, Royal Gwent Hospital/United Kingdom, 7Department 
Of Oncology, University Of Oxford/United Kingdom
Background: Approximately 35,000 people die from lung cancer 
each year in the UK, the majority from non-small cell lung cancer 
(NSCLC). Patients with locally advanced (LA) NSCLC are often not 
suitable for chemotherapy or combined chemo-radiotherapy treat-
ment because of patient or tumour factors. In these cases radical 
radiotherapy alone is used. Increased radiation dose may improve 
both local tumour control and survival. The radiotherapy dose 
is limited by surrounding organs, which include the lungs, heart, 
spinal cord and oesophagus. The maximum radiotherapy dose that 
can safely be delivered to the oesophagus is not known. The I-
START trial was therefore developed, on behalf of the UK National 
Cancer Research Institute Lung Clinical Studies Group, to establish 
oesophageal radiation dose limits and to investigate the feasibi-
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Background: Locoregional failure rates are high in patients with 
locally advanced non-small cell lung cancer (NSCLC), even when 
using concurrent chemoradiation. Recurrences have been shown 
to be predominantly located in the primary tumor, more specifi-
cally in areas with a high FDG-uptake that can be identified on a 
pre-treatment FDG PET-CT scan. Improved tumor control could 
be accomplished by dose escalation. The PET-boost trial is an 
ongoing randomized phase II trial investigating radiation dose-es-
calation using an individualized, accelerated schedule either to the 
entire primary tumor or to the regions of high FGD-uptake (>50% 
SUVmax) within the primary tumor. We present a preliminary analy-
sis of the acute toxicity of the first 45 patients.
Methods: Patients with NSCLC stage IB-III with a primary tumor 
diameter ≥4 cm are eligible. Patients are treated with concurrent 
or sequential chemoradiation or radiotherapy only. Permitted regi-
mens are: daily dose cisplatin (only in concurrent chemoradiation) 
or cisplatin-etoposide in concurrent and sequential chemoradi-
ation. Eligible patients receive a planning PET-CT scan on which 
an IMRT plan is constructed up to a dose of 66 Gy in 24 fractions 
of 2.75 Gy to the involved lymph nodes and the primary tumor. In 
patients where normal tissue constraints allow further dose esca-
lation to the primary tumor up to a minimal dose of 72 Gy of ≥ 3 
Gy-fractions, 2 plans (with equal mean lung dose) are constructed: 
either giving the integrated boost to the entire primary tumor (Arm 
A) or redistributing the boost to areas of high FGD-uptake (>50% 
SUVmax) in the tumor (Arm B), up to a maximal prescribed dose of 
129.6 Gy in 24 fractions of 5.4 Gy. All pts are followed according to 
study protocol. Toxicity is scored according to the CTCv3.0 criteria. 
Primary endpoint of this study is local progression-free survival 
at 1 year. Secondary endpoints are acute and late toxicity, overall 
survival and quality of life.
Results: Between 2010 and 2013 71 patients were registered of 
which 45 were randomized: 22 pts to arm A and 23 to arm B. In 
both arms, median follow up was 13.3 months. Patient and tumor 
characteristics were equally distributed in both arms. Thirty-seven 
patients (82.2%) had stage III lung cancer. Concurrent chemoradio-
therapy was given in 25 patients (55.6%). Mean GTV was 154.2 cm 
³ (range 26-416 cm³). Mean fraction size in both arms was 3.46 Gy 
(range 3.0-5.4 Gy). Baseline toxicity grade 3 occurred in 4 patients 
(8.8%) consisting of dyspnea in 1 patient, cough in 2 patients and 
renal dysfunction in 1 patient. During treatment grade ≥3 hema-
tologic toxicity was seen in 6 patients (13.3%), whereas 2 patients 
(4.4%) suffered from cardiac toxicity grade 4 (ischemia/infarction). 
Seven patients (15.6%) had grade ≥3 dysphagia. 82.2% of the pa-
tients finished treatment according to study protocol. Radiation 
treatment was completed in all patients. Seven patients have died 
of which 3 (6.6%) due to pulmonary hemorrhage.
Conclusion: This first toxicity analysis of the multicenter phase II 
randomized PET-boost trial at a median follow up of 13.3 months 
did not reveal any unexpected acute or late toxicity.
Keywords: Individualized radiation dose-escalation, locally ad-
vanced lung cancer, First toxicity results, Phase II randomized Pet-
boost trial
based on oncologic first principles. However, the data to support 
this practice is scarce. Here we report our institutional experience 
comparing patients who received PORT in the setting of R0, R1 or 
R2 resections.
Methods: Between 1999 and 2012, 203 patients with NSCLC were 
treated with PORT in 25-39 fractions to 45-70 Gy. All surgery and 
PORT were performed at our institution. Twenty-one patients had 
a sublobar resection, 158 had a lobectomy, and 24 underwent a 
pneumonectomy. PORT was given to R0 patients with pathologic 
N2 disease, R1 or R2 resections. Patients with negative margins 
were compared to patients with residual disease (R1 and R2 re-
sections). Patients with tumor recurrence within the PORT field 
were recorded as local failures. Local failure-free survival (LFFS), 
disease-free survival (DFS) and overall survival (OS) were calculated 
using the Kaplan-Meier method. Univariate analysis was performed 
using the log-rank test.
Results: Fifty-five of 203 patients had residual disease after re-
section; 45 had R1 and 10 had R2 resections. The predominant 
histology was adenocarcinoma (80%). Stage at diagnosis was 
stage I-II in 17 patients, stage III in 186 patients. One-hundred 
and twenty-six (62%) patients received neoadjuvant and 39 (19%) 
adjuvant chemotherapy. Median age was 60 years and median KPS 
before PORT was 80. Median interval from surgery or adjuvant 
chemotherapy to PORT initiation was 1.6 months (range of 0-3.7 
months). With a median follow up of 21 months, local failure occur-
red in 33/148 (22%) without and 14/55 (25%) patients with residual 
disease. Two- and 5-year actuarial LFFS rate were 79%/66% for R0 
and 75%/58% for R1/R2 resections. Two- and 5-year actuarial DFS 
rate were 44%/30% for R0 and 48/26% for R1/R2 resections. Two-
year and 5-year overall survival (OS) for all patients were 62.4% 
and 33.1%. LFFS, DFS and OS were not significantly different when 
comparing R0 to R1/R2 resections. Radiation dose, KPS, T-stage, 
N-stage, lymphovascular invasion, histology and chemotherapy 
were all not found to be significantly associated with any endpoint. 
OS was significantly worse for patients with R2 resection compared 
to R0/R1 resection (2-year OS 20% vs 64%; p= 0.002) and patients 
with age >65 (p=0.03). Multivariate analysis will be presented.
Conclusion: PORT results in equivalent local control rates after R1 
and R2 resections when compared to R0 resections. This suggests 
that PORT has a significant role in local control of residual disease. 
However, OS was significantly worse for patients with gross residu-
al disease postoperatively.
Keywords: post operative radiation therapy, Lung cancer, Incom-
plete resection
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P3.08-014 VERY HIGH RADIATION DOSE ESCALATION 
IN NSCLC DOES NOT LEAD TO UNEXPECTED TOXICITY: 
A PLANNED TOXICITY ANALYSIS OF THE PET-BOOST 
STUDY (NCT01024829)
Judi Van Diessen1, Jose Belderbos1, Jan Jakob Sonke1, Harm Van 
Tinteren2, Wouter Vogel1, Eugene Damen1, Bart Reymen3, Wouter 
Van Elmpt3, Dirk De Ruysscher4
1Radiation Oncology, The Netherlands Cancer Institute/Netherlands, 
2Biostatistics, The Netherlands Cancer Institute/Netherlands, 3Radiati-
on Oncology, Maastro Clinic/Netherlands, 4Radiation Oncology, Univer-
sitary Hospitals KU Leuven/Belgium
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P3.08-016 CLINICAL OUTCOME OF [18F] FDG-PET/CT 
VERSUS CONVENTIONAL CT BASED PLANNING FOR 
RADIOTHERAPY IN LOCALLY ADVANCED NSCLC PATI-
ENTS: A PROPENSITY-SCORE MATCHING STUDY
Wenwen Zhang1, Jingbo Wang2, Ning Wu3, Rong Zheng3, Luhua 
Wang2
1Peking Union Medical College/China, 2Department Of Radiation Onco-
logy, Cancer Institute And Hospital, Chinese Academy Of Medical Sci-
ences And Peking Union Medical College/China, 3Pet-ct Center, Cancer 
Hospital, Chinese Academy Of Medical Sciences, Peking Union Medical 
College/China
Background: To evaluate the clinical outcome and toxicity after 
radiotherapy using [18F] FDG-PET/CT based target volume deli-
neation instead of conventional CT for locally advanced non-small 
cell lung cancer (LA-NSCLC).
Methods: Between January 2007 and May 2011, 248 patients with 
stage IIIA or IIIB NSCLC were referred to our institution for radio-
therapy. Among them, twelve patients were excluded, including 
four patients upstaged to stage IV after PET/CT and eight patients 
lost follow-up. The remaining 236 patients were investigated, inclu-
ding 67 patients received RT with PET/CT-based planning and 169 
patients with CT-based planning. Propensity-score matching (PSM) 
method was utilized to obtain two matched groups (1:1) with similar 
baseline clinical characteristics. Kaplan-Meier method was conduc-
ted to calculate the overall survival (OS), progression-free survival 
(PFS), and locoregional control (LRC). Log-rank test was performed 
to compare the survival between two groups. Response to initial 
treatment was also compared, as well as acute radiation toxicity, 
especially the radiation-induced lung injury (RILI).
Results: Two matched groups with comparable baseline clinical 
characteristics were created using the PSM method, including 67 
patients with PET/CT-based planning (PET/CT group) and 67 pati-
ents with CT-based planning (CT group). The covariates that we se-
lected for the propensity score model were gender, age, Charlson 
comorbidity index, Karnofsky performance status, smoking history, 
FEV1 (%), VC (%), location of the primary tumor (central or periphe-
ral), presence of atelectasis, histology type, T stage, N stage and 
TNM stage. Patients in the PET/CT group received a higher total 
radiation dose than those in the CT group (60.7 Gy vs. 59.0 Gy, P 
= 0.067). After initial treatment, 55 (82.1%) patients in the PET/CT 
group and 41 (62.1%) patients in the CT group achieved complete 
remission (CR) or partial remission (PR), respectively (P = 0.010). 
After a median follow-up of 24.7 months, a significant superior 
locoregional control was observed in the PET/CT group compa-
red with the CT group (P = 0.036), with a 2-year LRC of 54.2% and 
40.1%, respectively. Log-rank test showed no statistical difference 
in respect to OS (P =0.319) and PFS (P =0.582) between the two 
groups. However, patients in the PET/CT group tended to have a 
slightly longer median survival time (25.4 mo vs. 21.7 mo) and me-
dian progression-free survival time (12.7 mo vs. 10.7 mo). Patients 
in the PET/CT group were less likely to develop grade ≥ 2 RILI than 
those in the CT group (9.0% vs. 19.4%, P = 0.083). Other acute toxi-
cities were all comparable between the two groups.
Conclusion: Using PET/CT instead of CT for target volume deline-
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P3.08-015 DOSIMETRIC FACTORS ASSOCIATED WITH 
WEIGHT LOSS DURING RADIOTHERAPY TREATMENT 
FOR NON-SMALL CELL LUNG CANCER
Nicole Kiss1, Mei Krishnasamy1, Sarah Everitt2, Karla Gough1, 
Mary Duffy3, Elisabeth Isenring4
1Department Of Cancer Experiences Research, Peter Macallum Cancer 
Centre/Australia, 2Radiation Therapy, Peter MacCallum Cancer Centre/
Australia, 3Peter MacCallum Cancer Institute/Australia, 4School Of 
Human Movement Studies, University Of Queensland/Australia
Background: Thoracic radiotherapy is associated with significant 
acute toxicities including oesophagitis, anorexia and fatigue which 
can impact on the ability to achieve adequate nutritional intake, 
subsequently leading to weight loss and malnutrition. Malnutri-
tion during cancer treatment is associated with poorer patient 
and treatment outcomes. Understanding factors associated with 
weight loss assists with the early identification and intervention of 
patients at nutritional risk. This study aimed to identify radiothe-
rapy dosimetric factors associated with clinically significant weight 
loss (greater than or equal to 5%) in patients receiving treatment 
for non-small cell lung cancer (NSCLC). 
Methods: A retrospective analysis of an existing cohort of 54 
NSCLC patients treated with concurrent chemoradiotherapy for 
whom oesophageal dose distributions had previously been cal-
culated. Weight change was calculated at any time point from the 
start up to 90 days from radiotherapy commencement to determi-
ne those with clinically significant weight loss. Chi-squared tests, 
Pearson correlation, Mann-Whitney U-test and logistic regression 
were used to examine associations. 
Results: Four patients for whom weight was not available at the 
start or end of treatment were excluded leaving 50 patients for 
analysis. The prevalence of clinically significant weight loss was 
22% (median weight loss 9.1%, range 5.9 – 22.1). Dosimetric factors 
associated with clinically significant weight loss were maximum 
dose to the oesophagus (z= -1.99, p=.046), absolute oesophageal 
length receiving 40Gy (r=.32, p=.03), 50Gy (r=.36, p=.01) and 60Gy 
(r=.45, p=.001) to the partial circumference, relative oesophageal 
length receiving 50Gy (r=.32, p=.02) and 60Gy(r=.44, p=.001) to 
the partial circumference. The odds of a patient receiving 40Gy 
(median length 10.6cm), 50Gy (median length 10.2cm) or 60Gy 
(median length 7.2cm) to the partial oesophagus experiencing 
clinically significant weight loss were 1.18 (95%CI 1.01,1.37, p=.04), 
1.20 (95%CI 1.03,1.41, p=.02) and 1.32 (95%CI 1.09,1.60, p=.005) 
greater, respectively, than those with less oesophagus in the treat-
ment field. Nine (82%) of the eleven patients who had clinically 
significant weight loss received a dose of 60Gy to at least 5cm of 
the partial circumference of the oesophagus. 
Conclusion: The strongest dosimetric association with clinically 
significant weight loss was absolute oesophageal length receiving 
60Gy to the partial circumference. A previous study identified an 
association between concurrent chemotherapy and late stage di-
sease (stage III or IV) and clinically significant weight loss. Findings 
from both studies have been used to develop a model, currently 
undergoing validation, to assist clinicians in predicting NSCLC 
radiotherapy patients at high nutritional risk.
S1137Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Results: 24 patients were identified, 13 (54%) had recurrent di-
sease, and 46% a new primary. Most (63%) had stage III NSCLC 
at initial and second treatments; median reirradiation interval was 
51 months, and median follow-up from reirradiation 19.1 months. 
Median overall survival (OS) after reirradiation was 13.5 months, 
with 1-year survival 51%, median local progression-free survival 
(LPFS) 14.1 months and median distant progression-free survival 
(DPFS) 18.5 months. One-year disease-free survival was 47%. 
Three patients died from bleeding (2/3 had high-dose overlap in 
the mediastinum, of whom one had prior hemoptysis and was an-
ticoagulated, the 3rd patient had extensive endobronchial therapy 
prior to reirradiation). Other post-retreatment toxicity was uncom-
mon. The size of the second PTV (median 250cc) was prognostic. 
OS was 17.4 versus 8.2 months for patients with a 2nd PTV <300cc 
and >300cc respectively (p=0.02). Differences in DPFS (p=0.007) 
and for DFS (p=0.03) were also significant. LPFS was shorter when 
reirradiation interval was <24 months (p=0.02), however it was not 
different when groups were defined by the median interval of 51 
months. Magnitude of PTV and dose overlap between the two 
treatments did not influence survival. Figure 1: Example of reirradi-
ation for a new primary lung cancer. Planning target volume (PTV) 
and dose-cloud shown from treatment in 2004 (A, 23 fractions of 
2.6Gy) and 2010 (B, 33 fractions of 2Gy) and the overlap of both 
treatments (C).
Conclusion: High-dose, conventionally fractionated reirradiation 
for new primary or recurrent lung cancer can deliver meaningful 
survival, especially for patients with a smaller PTV at the time of 
reirradiation. A shorter reirradiation interval may be associated 
with less chance of loco-regional control. Prospective studies are 
needed to confirm these findings, and establish reliable normal 
tissue tolerances for reirradiation.
Keywords: High dose reirradiation, survival, conventionally  
fractionated
ation in radiotherapy for LA-NSCLC was associated with a better 
LRC and lower incidence of grade≥2 RILI. A possible explanation 
was that the more accurate target delineation in PET/CT-based pl-
anning allowed for an escalated total dose delivered to a relatively 
small target volume.
Keywords: locally advanced non-small cell lung cancer (LA-
NSCLC), 18F-FDG Positron emission tomography/Computed 
Tomography ([18F] FDG-PET/CT), radiotherapy, target volume 
delineation
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P3.08-017 HIGH-DOSE, CONVENTIONALLY FRACTIONA-
TED THORACIC REIRRADIATION FOR SECOND PRIMARY 
LUNG TUMORS OR RECURRENT DISEASE
Gwendolyn H. Griffioen1, Max Dahele1, Patricia F. Haan De1, Peter 
Ven Van De2, Ben J. Slotman1, Suresh Senan1
1Radiation Oncology, VU University Medical Center/Netherlands, 2Epi-
demiology And Biostatistics, VU University Medical Center/Nether-
lands
Background: Although loco-regional recurrences and second 
primary lung tumors are not uncommon following prior high-dose 
thoracic radiotherapy, only a minority of patients undergo reirradi-
ation. Reirradiation performed at short intervals, and to low total 
doses, is generally associated with median overall survival (OS) of 
only 5-7 months. Few studies report outcomes following high-dose 
reirradiation. We describe institutional experience after high-dose, 
conventionally fractionated reirradiation.
Methods: High-dose conventional reirradiation was defined as 
fraction sizes of 2-3Gy and minimum total dose of 39Gy. A retro-
spective chart review of patients treated between Feb 2004-Feb 
2013 was performed. Where possible, overlap in planning target 
volumes (PTV) and radiation doses were determined. New primary 
tumors were defined as new histology or reirradiation interval ≥5 
years.
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lung lesions or oligometastatic disease limited to the chest, survi-
val was encouraging. We will continue to utilize SBRT in this popu-
lation of oligometastatic disease with careful patient selection.
Keywords: Stereotactic Radiotherapy, outcomes, lung metastases, 
Oligometastatic disease
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P3.08-019 VISUAL ASSESSMENT OF THE PRESENCE 
OF CENTRAL PHOTOPENIA ON FDG-PET IMAGING IN 
NON-SMALL CELL LUNG CANCER (NSCLC) AND ITS 
PROGNOSTIC INFLUENCE ON SURVIVAL IN PATIENTS 
TREATED WITH RADIOTHERAPY. A SUBSET ANALYSIS 
OF TROG 99.05.
Timothy Akhurst1, Richard A. Cox2, Mathias Bressel3, David Ball2, 
Michael Macmanus2
1Centre For Cancer Imaging, Peter MacCallum Cancer Centre/Australia, 
2Department Of Radiation Oncology, Peter MacCallum Cancer Centre/
Australia, 3Biostatistics Centre For Biostatistics And Clinical Trials, 
Peter MacCallum Cancer Centre/Australia
Background: Cavitation in NSCLC has anecdotally been associ-
ated with worse prognosis and survival. It has been postulated 
that rapid tumour growth and disordered angiogenesis leads to 
necrosis, cavitation and central hypoxia, with associated reduction 
in tumour radiosensitivity. This study investigated central photo-
penia on FDG-PET imaging (indicating reduced metabolic activity 
in necrotic areas) as an independent prognostic factor in patients 
with NSCLC treated by definitive radiotherapy.
Methods: Pre-treatment PET images for 172 patients (single ins-
titution, enrolled in multicentre prospective observational study 
TROG 99.05) with pathologically proven stage I-III NSCLC planned 
for definitive radiotherapy (minimum 50 Gy in 20 fractions) or che-
moradiotherapy (93.4%) were independently analysed by two in-
vestigators at two time points one month apart. The presence and 
percent of tumour demonstrating central photopenia were scored 
using visual assessment. Central photopenia was defined as a non-
peripheral volume within the primary tumour with an SUV <40% of 
the SUVmax. Survival was adjusted for known prognostic factors 
including performance status, T and N stage.
Results: Inter-observer agreement for the presence (Kappa=0.822, 
p<0.001) and proportion (intraclass correlation coefficient 
(ICC)=0.913 with 95% CI, 0.862-0.946, p<0.001) of photopenia and 
were good. Intra-observer reassessment showed fair agreement 
(Kappa=0.600, p<0.001 and ICC=0.752 with 95% CI, 0.634-0.836, 
p<0.001). Photopenia, present in 43% of the tumours was associa-
ted with larger tumour volumes (mean volume 197.3cm3 vs 56.2cm3 
in solid tumours, p<0.001) and weight loss (51% of patients vs 31%, 
p=0.029). Median survival was shorter in the presence of photope-
nia but there was no significant difference in overall survival (OS) 
on univariate (HR=1.25, 95% CI, 0.89-1.77, p=0.200) or multivariate 
analysis (HR=1.14, 95% CI, 0.80-1.61, p=0.465) after adjusting for 
stage and performance status. Correlations of OS and the percent 
of photopenia were not statistically significant. 
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P3.08-018 STEREOTACTIC BODY RADIOTHERAPY FOR 
OLIGOMETASTATIC DISEASE TO THE LUNG
Jonathan Ashman1, Uma Goyal1, Sujay Vora1, Edward Clouser1, 
Dawn Jaroszewski2, Amylou Dueck3, Harshita Paripati4, Lewis 
Wesselius5, William Rule1, Helen J. Ross4, Steve Schild1
1Radiation Oncology, Mayo Clinic/United States Of America, 2Cardio-
vascular And Thoracic Surgery, Mayo Clinic/United States Of America, 
3Biostatistics, Mayo Clinic/United States Of America, 4Hematology 
And Oncology, Mayo Clinic/United States Of America, 5Pulmonary And 
Critical Care, Mayo Clinic/United States Of America
Background: With the increasing penetration of stereotactic body 
radiotherapy (SBRT) into cancer practice, there is growing interest 
in applying this technique to patients with limited metastatic di-
sease. We reviewed our single institution experience using SBRT in 
the treatment of oligometastatic pulmonary disease.
Methods: A retrospective review was performed to identify pati-
ents treated at our institution with SBRT for pulmonary metastases 
between 3/2008 and 1/2013. Treatment decisions were multidis-
ciplinary and a biopsy was performed when feasible. The gross 
tumor volume (GTV) was non-uniformly expanded to create an 
internal target volume (ITV) to encompass tumor motion based on 
4-dimensional computed tomography (CT). A 5 mm uniform ex-
pansion of the ITV was then applied to create the planning target 
volume (PTV). The most common dose/fractionation schedule was 
48-50 Gy in 4-5 fractions. Cone beam CT was used for daily image 
guidance. Overall survival (OS), time to distant failure (TTDF), and 
local control (LC) were estimated from the end of the first SBRT 
procedure using the Kaplan-Meier method. Toxicity was scored 
based on CTCAEv4. Median follow up was 15 months (range 3-60).
Results: 64 patients underwent 66 SBRT procedures to treat 74 
lesions. There were 36 males (56%) and 28 females (44%) with a 
median age of 71 years (range 42-90). The most common primary 
disease sites were lung (n=23; 36%), colorectal (n=10; 16%), me-
lanoma (n=9; 14%), and head and neck (n=5; 8%). The target lesi-
on represented the only site of metastatic disease in 32 patients 
(50%); 20 patients (31%) had additional pulmonary metastases but 
no extra-thoracic disease; 12 patients (19%) had both pulmonary 
and non-pulmonary sites of metastases. Median lesion size was 2.3 
cm (range 0.6-6.8). Median, 1-year, and 2-year OS was 21 months, 
73%, and 49%, respectively. Distant metastatic disease progres-
sion was observed in 37 patients (58%) at a median time interval 
of 12 months. Patients (n=52) with no extra-thoracic disease at the 
time of SBRT had a significantly longer TTDF compared to pati-
ents (n=12) with concurrent extra-thoracic disease (median 13 vs. 
5 months; 1-year failure rate 47 vs. 73%; p = 0.02) without a diffe-
rence in OS (median OS not reached vs. 20 months; 1-year OS 75 
vs. 63%; p=0.1). Local failure was observed for 4 lesions resulting in 
an 18-month LC rate of 88%. There were 11 toxicities observed in 
10 patients including fatigue (n =1, grade 1), dyspnea (n=1, grade 
1), dermatitis (n=1, grade 2), rib fracture (n=1, grade 2), and pneu-
monitis (n= 5, grade 2; n=2, grade 3).
Conclusion: SBRT is a reasonable treatment for patients with pul-
monary metastases. High rates of local control can be achieved 
with acceptable toxicity. Only 2 patients (3%) developed grade 3 
pneumonitis (oxygen indicated). In this high risk population, new 
distant metastatic progression was common, especially among 
patients who present for SBRT with known extra-thoracic sites of 
disease at the time of SBRT. However, among patients with solitary 
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diagnosed with NSCLC lesions staged IIIA or B previously treated 
at NCCC. The original 3D CRT plans were used for comparison. 
Gross Tumour Volume/ Clinical Target Volume (GTV/CTV and PTV) 
contours have remained unchanged. Original 3D CRT utilised on 
average 4 static beams, 8mm field margins, and dosed 60Gy in 
30 fractions. The hybrid VMAT technique consists of AP/PA static 
beams, 8mm field margin only dosed to a portion of the prescri-
bed dose, the remaining dose delivered using a partial VMAT arc. 
The two techniques were compared using PTV coverage, V20 < 
30% and V30 <20% of the combined lung volume and mean lung 
doses.
Results: Average results from the first two planning comparisons 
show coverage of the PTV by D95% is achieved with both hybrid 
VMAT (96.6%), and 3D CRT (99.2%). However improvements in 
coverage by D100% are seen using the hybrid VMAT technique 
compared to 3D CRT (88.7% vs. 79.5%). Hybrid VMAT combined 
lung doses were reduced, average results V30 = 19.5% and V20 
= 24.8% compared to 3DCRT 23.9% and 30% respectively. Mean 
lung doses using the hybrid technique were also lower in compa-
rison to 3D CRT, 15.6Gy vs. 18.5Gy, reduced on average by 2.9Gy. 
Average contralateral mean lung dose also followed this trend with 
hybrid VMAT 7.3Gy vs. 3D CRT with 9.4Gy average reduction by 
2.01Gy.
Conclusion: Hybrid VMAT is a viable treatment option to achieve 
radical treatment intent to 60Gy in 30 fractions, adequate PTV 
coverage by D95% whilst obtaining acceptable V20 and V30 lung 
doses for patients with stage IIIA and B NSCLC.
Keywords: non-small cell lung cancer, Volumetric Modulated Arc 
Therapy, conformal radiotherapy, radiotherapy
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P3.08-021 PATIENT SPECIFIC QUALITY ASSURANCE FOR 
LUNG CANCER STEREOTACTIC ABLATIVE BODY RADIO-
THERAPY
Nicholas Hardcastle1, Natalie Clements1, Shankar Siva2, David 
Ball2, Tomas Kron1
1Physical Sciences, Peter MacCallum Cancer Centre/Australia, 2Peter 
MacCallum Cancer Centre/Australia
Background: Hypofractionated image guided radiotherapy of 
extracranial targets has become increasingly popular as a treat-
ment modality for inoperable patients with one or more small 
lesions, often referred to as Stereotactic Ablative Body Radio-
therapy (SABR). Our institution is using SABR for lung, liver, spine 
and kidney tumours and is the lead in a multicentre clinical trial of 
radical SABR for early stage lung cancer. Current and future trends 
in patient safety and quality assurance (QA) programs are towards 
ensuring patient safety using the most efficient methods. There is 
limited published work on patient specific QA for lung SABR treat-
ments on which to base risk management QA programs. Thus, we 
have performed a review of the first two years of lung SABR patient 
specific QA process with the aims of highlighting specific areas 
of uncertainty in lung SABR delivery with the aims of improving 
efficiency and effectiveness of our QA program. This presentation 
will detail the results of the review and the evolution of the QA 
program to a risk-management based approach.
Methods: SABR involves one or few fractions of high radiation 
Conclusion: The presence and proportion of photopenia on FDG-
PET imaging can be reproducibly measured using visual analysis 
without requiring specialist workstation software. Central photo-
penia was associated with larger tumours, weight loss, and shorter 
median survival, but there was no statistically significant effect on 
overall survival after adjusting for known prognostic factors.
Keywords: non-small cell lung cancer, survival, radiotherapy, posi-
tron emission tomography
POSTER SESSION 3 - RADIOTHERAPY  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.08-020 COMPARISON OF TWO RADIOTHERAPY 
PLANNING TECHNIQUES FOR STAGE IIIA AND IIIB NS-
CLC: HYBRID VOLUMETRIC MODULATED ARC THERAPY 
(VMAT) VS 3D CONFORMAL RADIOTHERAPY (3D CRT)
Kylie Unicomb, Katherine Small, Fiona Hegi-Johnson, Kevin Van 
Tilburg, Jeffrey Barber, Sean White, Roland Yeghiaian-Alvandi
Radiation Oncology, Nepean Cancer Care Centre/Australia
Background: Radiotherapy for Stage IIIA and B non-small cell 
lung cancer at Nepean Cancer Care Centre (NCCC) consists of 
a 3D conformal radiotherapy (3D CRT) plan dosed to 60Gy in 30 
fractions. However, due to the size and location of many stage IIIA 
and B NSCLC lesions radical radiotherapy is not always clinically 
deliverable, with the limiting factor often being healthy lung toxici-
ty. In these cases the prescribed dose may be reduced to 50Gy, or 
the treatment intent altered to palliation. One solution to achieve 
treating these lesions with a radical intent at NCCC is a hybrid 
(Volumetric Modulated Arc Therapy) VMAT planning technique. 
We present a comparison planning study of the Hybrid Volumetric 
Modulated Arc Therapy (VMAT) vs. 3D Conformal Radiotherapy 
(3D CRT). Hypothesis: It is expected that the hybrid VMAT tech-
nique will achieve better coverage of the Planning Target Volume 
(PTV) by 95% (57Gy) of the prescribed dose (PD) in addition to 
reducing the combined lung V20 (volume of lung receiving 20 Gy) 
and V30 (volume of lung receiving 30 Gy) doses when compared to 
3D CRT technique.
Methods: This study was conducted retrospectively on 3 patients 
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radiation and adjuvant radiotherapy after surgical resection were 
excluded. The records were updated using the national registry of 
death in Wales. Univariate analyses of the effects of different sub-
groups on overall survival were performed.
Results: 
Table 1. Stage and Histological distribution
No of patients
stage IA 27
IB 35
IIA 8
IIB 30
IIIA 52
IIIB 66
IV 1
Unknown 3
Histology NOS 37
Non-Squamous 44
Squamous 95
Unknown 46
 
Total 222 patients (128 males, 94 females) underwent radical radio-
therapy between 2001 and 2011. Median follow up period was 267 
weeks (range 74-637). Mean age at diagnosis was 68 yr (41-91). The 
stage and histological distribution is shown in table 1. Of the stage 
III patients 81 had induction chemotherapy before the radiothera-
py. The median survival of the whole group was 124 weeks (95% 
CI 105-141) and the survival by histology and stages is shown in 
table 2. The good 2 yr but poor 5 yr OS of the Stage I patients may 
reflect their poorer general health at presentation that rendered 
them medically inoperable.  
Table 2. Overall survival by Stage and Histological Subgroups
Median 
OS in 
Weeks 
(95% 
C.I.)
2 yr 
OS
5 yr 
OS
stage stage 1 135 (116-210) 68% 28% p= 0.47
stage 2
135 (80-
264)
58% 42%
stage 3
105 (85-
141)
50% 27%
Histology NOS
73 (60-
102)
30% 10% p= 0.0004
Non-
Squamous
131 (114-
216)
67% 25%
Squamous
130 (97-
162)
57% 35%
dose typically delivered in many small fields or arcs. Tight margins 
are often applied to mobile targets through heterogeneous tissue 
density with non-coplanar beams. We have conducted thorough 
QA for individual patients similar to the more common IMRT QA 
with particular reference to motion management. Individual patient 
QA was performed in a Perspex phantom (Modus Medical) using a 
point dose verification and radiochromic film for verification of the 
dose distribution. The results for the first 33 plans were analysed 
with the aim of revising QA procedures for future lung SABR plans. 
The results from these plans were then used to highlight particular 
areas of delivery uncertainty which require attention during patient 
specific QA.
Results: While individual beams could vary by up to 7%, the total 
dose in the target was found to be within ±2% of the prescribed 
dose for all 33 plans. The QA process verified all aspects of the 
plan delivery including non-coplanar geometry, isocentre accuracy 
under couch rotation and internal target volume construction. The 
QA process highlighted the importance of accounting for couch 
transmission and demonstrated the need for accurate motion ma-
nagement strategies. The review of the first 33 plans lead to the 
creation of a risk-management based approach to QA of subse-
quent treatment plans. Particular emphasis is now placed on verifi-
cation of small field dosimetry and motion management strategies 
for lesions with large motion.
Conclusion: QA is essential for complex radiotherapy deliveries 
such as SABR. We found individual patient QA helpful in setting up 
the technique and understanding weak points in the process chain. 
Ongoing review of the patient specific QA results has lead to im-
provements in efficiency in the process, facilitating a risk-manage-
ment based approach to patient specific QA for SABR.
Keywords: stereotactic body radiotherapy, quality assurance
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P3.08-022 SURVIVAL ANALYSIS OF HYPO-FRACTIONA-
TED RADICAL RADIOTHERAPY FOR THE TREATMENT 
OF NON-SMALL-CELL LUNG CANCER USING 55GY IN 
20 FRACTIONS: THE NORTH WALES CANCER CENTRE 
EXPERIENCE
Niladri Ghosal, Nafisa Chowdhury, Mark O‘Beirn, Ravi Kodavati-
ganti, Glyn Thomas, Nick Smith, Angel Garcia
Department Of Oncology, North Wales Cancer Treatment Centre, Glan 
Clwyd Hospital/United Kingdom
Background: Hypo fractionated radical radiotherapy using 55 Gy 
in 20 fractions is one of the most commonly used radical radiothe-
rapy regimens in the UK. The shorter overall treatment time has 
the radio-biological advantage of minimal re-population. Despite 
its popularity in UK, there is paucity of supporting data in the 
reported literature. We present the mature outcome data of this 
regimen based on the single centre experience in North Wales 
Cancer Centre,UK.
Methods: A retrospective case note analyses of Non-Small-Cell 
Lung Cancer patients who underwent radical radiotherapy using 
55Gy in 20 fraction (fraction size that 2.75 Gy/fraction), between 
2001 and 2011, was carried out. We included the patients who 
had the total dose reduced to 52.5 Gy in 20 fractions to allow for 
normal tissue constraints. Patients receiving concurrent chemo-
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Table 1 Number %
Performance 
status
0 59 50
1 57 49
missing 1 1
Gender Male 68 58
Female 49 42
Histology Squamos cell carcinoma 41 35
Adenocarcinoma 54 46
Conclusion: From this study we conclude, that the risk of develo-
ping grade 2 esophagitis is related to dose 66 Gy but the severity 
is manageable. Acknowledgements Supported by CIRRO- The 
Lundbeck Foundation Center for Interventional Research in Radia-
tion Oncology.
Keywords: NSCLC, Definitive Radiotherapy, esophagitis, side  
effects
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P3.08-024 PRELIMINARY EXPERIENCE IN BRONCHO-
SCOPIC PLACEMENT AND IN-TREATMENT IMAGING OF 
TWO DIFFERENT FIDUCIAL MARKERS FOR GUIDANCE 
OF LUNG CANCER RADIATION.
Daniel P. Steinfort1, Shankar Siva2, Tomas Kron3, Chris Fox3, Louis 
Irving1, David Ball4
1Respiratory Medicine, Royal Melbourne Hospital/Australia, 2Radiation 
Oncology, Peter MacCallum Cancer Centre/Australia, 3Medical Physics, 
Peter MacCallum Cancer Centre/Australia, 4Department Of Radiation 
Oncology, Peter MacCallum Cancer Centre/Australia
Background: During conventional radiation therapy, treatment 
image guidance is largely indirect relying on slow acquisition 3D 
volumetric imaging or the use of bony surrogates. Fiducial marker 
placement within/adjacent to lung tumours facilitates image gui-
ded radiation therapy by Marker placement has been attempted 
Table 2. Overall survival by Stage and Histological Subgroups
Median 
OS in 
Weeks 
(95% 
C.I.)
2 yr 
OS
5 yr 
OS
Unknown
191 (131-
325)
67% 38%
Conclusion: Radical Radiotherapy using 55 Gy in 20 fractions is a 
highly effective form of treatment for early and locally advanced 
stages of Non-Small-Cell Lung Cancer with results comparable to 
isofractionated radiotherapy published in the literature.
Keywords: Radical radiotherapy, non-small-cell lung cancer, hypo-
fractionated radical radiotherapy, 55 Gy 20 fractions
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P3.08-023 ACUTE ESOPHAGITIS AND CONCOMITTANT 
CHEMORADIOTHERAPY WITH NAVELBINE. RESULTS 
FROM NARLAL, A PHASE II RANDOMIZED TRIAL.
Tine Schytte1, Marianne M. Knap2, Azza A. Khalil2, Christa H. Ny-
hus3, Tine Mcculloch4, Bente Holm5, Carsten Brink6, Olfred Han-
sen1
1Department Of Oncology, Odense University Hospital/Denmark, 
2Oncology, Aarhus University Hospital/Denmark, 3Oncology, Vejle 
Hospital/Denmark, 4Oncology, Aalborg University Hospital/Denmark, 
5Oncology, Herlev Hospital/Denmark, 6Laboratory Of Radiation Physics, 
Odense University Hospital/Denmark
Background: Radiotherapy (RT) for non-small cell lung cancer 
(NSCLC) is associated with important side effects with acute 
esophagitis (AE) as one of the main acute toxicities. RT dose and 
concomitant chemo-radiotherapy as well as volume of oesophagus 
treated are known risk factors for development of AE.
Methods: This is a multicentre national protocol on RT for locally 
advanced NSCLC. From 2009-2013 117 patients were randomized 
between 60 Gy/ 30 F (arm A) and 66 Gy/ 33 F (Arm B), 5 FW. Na-
velbine® 50 mg 3 days a week was given concomitant with RT. 
Before randomization patients were treated with 2 cycles of carbo-
platin and Navelbine® as induction chemotherapy. During RT, pati-
ents were registered for side effects once a week. After RT follow 
up schedule was every 3th month from RT start. Side effects were 
registered according to NCI CTCAE version 3.
Results: A total of 117 patients were randomized in this protocol. 
Baseline characteristics are summarized in table 1. Since last pati-
ent was randomized August 2013, all CRF are not available for the 
moment. There are complete esophagitis data on 103 patients. 
Grade 0-1 AE were seen in 66 patients (37 in arm A vs. 29 in Arm 
B), grade 2 in 27 patients (11 vs. 16), 10 patients experienced grade 
3 (3 vs. 7), and none grade 4 AE. In a logistic regression analysis 
with N2/3, age ≥64 years, histology, gender and dose as covari-
ates; treatment arm B was the only significant covariate (p=0.02) 
for developing grade 2 esophagitis. Dose volumetric data will be 
ready for WCLC.
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P3.08-025 LUNG TUMORS WITH BIG SIZE OR IRREGU-
LAR SHAPE OR HIGH-MOBILITY CAN BETTER BENEFIT 
FROM FOUR-DIMENSIONAL RADIOTHERAPY
Ming Chen1, Yan Wang2, Yong Bao3, Xiao Hu1, Xiaowu Deng4, Wei 
Fan5
1Department Of Radiation Oncology, Zhejiang Cancer Hospital/China, 
2Department Of Oncology,and Tomotherapy Cancer Center, General 
Hospital Of Guangzhou Military Command Of Pla/China, 3Department 
Of Radiation Oncology, Sun Yat-Sen University Cancer Center/China, 
4Department Of Radiation Physics, Sun Yat-Sen University Cancer 
Center/China, 5Department Of Nuclear Physics, Sun Yat-Sen University 
Cancer Center/China
Background: Consideration of respiration-induced motion based 
on 4DCT for lung cancer yields individualized margin. The purpose 
of our study was to quantify the gain from 4DCT based radiothera-
py in lung cancer and to identify the tumor characteristics of better 
benefit.
Methods: 51 patients with 52 lung tumors who underwent 4DCT 
based radiotherapy were included. GTVs on 10 respiratory pha-
ses were contoured by single radiation oncologist. Internal gross 
tumor volume (IGTV) was obtained by combining the GTVs at ten 
phases of the respiratory cycle. No separate margins were used to 
account for microscopic tumor extension. Additional isotropic se-
tup margin of 3mm to derived the PTV-4D from the IGTV. PTV-3D 
was generated by adding a isotropic margin of 10mm to the GTV 
in a single phase (20%) for upper or middle lobe tumor, and a mar-
gin of 10,10,15mm in later, AP and SI direction for tumor in lower 
lobe. The target coverage on PTV-4D and PTV-3D were compared 
respectively. Using linear regression, clinical and anatomic factors 
for the reduction of PTV-4D vs PTV-3D were identified.
Results: PTV-4D was significantly smaller than PTV-3D, by 89cm3 
on average. Approximately 17% PTV-3D (in 9 of 52 tumors) were 
not fully covered PTV-4D with up to 2%-18% slices lost. For the 
cases of target missed in PTV-3D, tumors were either irregular or 
had a larger mobility of ≥ 1cm in SI direction. For the cases of tar-
get encompassed in PTV-3D (43 tumors), the volume reduction of 
PTV-4D vs PTV-3D was associated with the GTV size and the tumor 
movement in SI direction. Taken median GTV (48cm3, the corres-
ponding diameter of around 4.5cm) as a cutoff, big or small tumors 
had an average PTV reduction of 141 cm3 (77-304 cm3) or 42cm3 
(11.5-107 cm3 ), respectively.
Conclusion: 4D plan has a more accurate and safe target coverage 
than that of empirical estimated margins in 3D plan. Patients with 
tumor character one of irregular shape, big size or high-mobility 
can better benefit from 4DCT based radiotherapy. It will be of 
clinical significance when administration a higher dose to a bulky 
tumor at equal normal tissue constraint, or high-precision radiation 
was delivered. A small benefit in a large PTV should be paid more 
attention especially when 4D based radiotherapy transforming a 
palliative intent to a curative one.
Keyword: 4DCT; lung cancer; respiratory; radiotherapy
percutaneously but is associated with pneumothorax in up to 45%, 
with frequent use of chest drain tubes. Furthermore, in-treatment 
imaging protocols are not standardized, and the impact of marker 
characteristics on accuracy of in-treatment imaging has not previ-
ously been reported. We describe our preliminary experience in 
bronchoscopic implantation and in-treatment tracking/imaging of 
two different types of lung fiducial marker.
Methods: Study design: Prospective observational case series of 
NSCLC patients undergoing radical radiation treatment . Broncho-
scopic implantation: performed under conscious sedation using 
radial probe endobronchial ultrasound and fluoroscopic guidance 
to achieve tumour localization and placement within/adjacent 
to peripheral tumours. Post-implantation/ in-treatment imaging: 
Time-resolved 4D CT (Philips Brilliance+bellows system) for treat-
ment planning and after completion of treatment to investigate 
marker movement. Throughout treatment delivery MV electronic 
portal images (EPI) were acquired plus kV planar and Cone Beam 
CT (CBCT) (Varian Medical System) images.
Results: Four patients with T1N0 NSCLC underwent broncho-
scopic implantation of fiducial markers (two using VisicoilTM linear 
fiducial 10x0.75mm, two using SuperDimension® superLock™ 
2-band 13x0.9mm markers. Confirmation of tumour localization 
was achieved with EBUS in all four patients. Two markers were 
placed in adjacent airways in one patient, and the remainder had 
a single marker placed within/adjacent to their peripheral tumour. 
No complications related to bronchoscopy or marker implantation 
were observed. No marker migration was observed over the treat-
ment time for both marker types. Visibility of the markers in EPI 
was only possibly in selected beam directions though they were 
easily discernible in kV planar images (Figure 1a). While diagnostic 
CT scanning was able to demonstrate the markers in great clari-
ty (Figure 1b), they caused significant image artefacts in CBCT. 
Figure 1: Image-guided radiotherapy images demonstrating: a) 
4DCT image showing visicoil fiducial on maximum intensity projec-
tion images, tumour+motion contoured in red, & b) kV orthogonal 
image showing superLock™ 2-band marker.
Conclusion: Our preliminary experience indicates bronchoscopic 
implantation of fiducial markers is safe, and is achievable with a 
high degree of accuracy on initial imaging, and stability on sub-
sequent in-treatment imaging. There is a fine balance of marker 
size minimising CBCT artefacts while allowing visualisation in EPI 
imaging which would be an ideal tool to verify gated radiotherapy 
delivery.
Keywords: Stereotactic, endobronchial ultrasound, early stage 
lung cancer
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P3.08-027 RADIATION PNEUMONITIS IN IMRT VS. 3D 
CONFORMAL RADIATION THERAPY
Marina Heskel1, Eric P. Xanthopoulos2, Michael N. Corradetti3, 
Surbhi Grover1, Annemarie Fernandes1, Greg Conway1, Abi Orisa-
molu1, Lilie Lin1, Charles B. Simone1, Ramesh Rengan4
1Department Of Radiation Oncology, University Of Pennsylvania/United 
States Of America, 2Department Of Radiation Oncology, Columbia Uni-
versity/United States Of America, 3Department Of Radiation Oncology, 
Harvard University/United States Of America, 4Department Of Radiati-
on Oncology, University Of Washington/United States Of America
Background: Radiation pneumonitis is a common cause of morbi-
dity and is a radiation dose-limiting toxicity in patients with locally 
advanced NSCLC treated with definitive radiotherapy. NSCLC 
patients are increasingly receiving intensity modulated radiation 
therapy (IMRT), in part in an attempt to reduce irradiation doses 
to organs at risk, like the lungs. It is unclear whether the incidence 
of pneumonitis in IMRT patients differs from that in patients recei-
ving the more commonly available 3D conformal radiation therapy 
(3DCRT). This retrospective study reports on outcomes at the Uni-
versity of Pennsylvania.
Methods: All consecutive patients with non-metastatic locally 
advanced NSCLC treated with curative intent at the University 
of Pennsylvania between January 2003 and October 2011 with 
3DCRT (n=208) and IMRT (n=58) were graded for post-treatment 
radiation pneumonitis using Common Toxicity Criteria (CTC) and 
SWOG criteria in this IRB-approved study. Any short- or long-
course initiation of prednisone for dyspnea 1-10 months following 
treatment was scored as grade 3 pneumonitis. Associations bet-
ween type of treatment and clinical and demographic factors and 
outcomes were assessed using Χ2 and non-parametric equality-of-
medians tests. Logistic regression was used to determine predic-
tors of pneumonitis.
Results: Patient characteristics, including age, gender, race, mar-
ital status, smoking history and pulmonary function were well ba-
lanced across treatment groups (p = 0.18 – 0.97). Patients also had 
similar tumor TNM-stage, histology, differentiation, and involved 
lobe (p = 0.26 – 0.62). No differences in the proportion receiving 
concurrent chemotherapy, radiation prescription, lung V5, lung 
V20 and mean lung doses, or planning target volume (PTV) were 
identified (p >0.05 for all). Pneumonitis rates did not differ bet-
ween the IMRT and 3DCRT patients. In 3DCRT patients, 54% had 
grade 2+ and 27% had grade 3+ CTC pneumonitis compared to 
59% and 34% in IMRT patients, respectively (p >0.05). Additionally, 
45% and 17% of 3DCRT patients had grade 2+ and 3+ SWOG 
pneumonitis compared to 45% and 16% in IMRT patients, respec-
tively (p> 0.05). Lower lung lobe, single marital status, pack-years 
smoked, low pre-treatment pulmonary function DLCO status, in-
creased lung V5, increased lung V20 and mean lung dose all asso-
ciated with pneumonitis on univariate logistic regression for both 
3DCRT and IMRT patients (p <0.05 for all). A multivariate analysis 
was performed but yielded no significant results.
Conclusion: Our findings suggest that treatment with IMRT is 
associated with similar rates of pneumonitis as treatment with 
3DCRT for locally advanced NSCLC patients treated with definiti-
ve radiation therapy. As opposed to treatment modality, several 
factors were identified that were associated with pneumonitis risk, 
included lung lobe, marital and smoking status, pre-treatment 
lung function, and irradiation dose received by the lung. Thus, 
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P3.08-026 FACTORS INFLUENCING ONE YEAR SUR-
VIVAL IN RADICAL RADIOTHERAPY TREATED LUNG 
CANCER PATIENTS DECEMBER 2010-NOVEMBER 2011, 
BEATSON WEST SCOTLAND CANCER CENTRE
Hiwot W. Chemu, Stephen Harrow, John Maclay, Elaine Mccartney
Clinical Oncology, Beatson West Of Scotland Cancer Centre/United 
Kingdom
Background: Radical radiotherapy, with or without chemotherapy, 
is a treatment modality for early and late stage inoperable lung 
cancer. We investigated patients treated with curative intent over 
the course of one year.
Methods: Patients who received radical radiotherapy for lung can-
cer from Dec 2010 to Nov 2011 at the Beatson West of Scotland 
Cancer Centre were reviewed retrospectively. Information was 
gathered from the patient clinical records and the radiotherapy 
planning records (ARIA). All patients with lung cancer who received 
radical conventional radiotherapy (a total dose of 45- 66Gy) with 
or without sequential or concurrent chemotherapy were included. 
Patient demographics, disease characteristics, radiotherapy pl-
anning treatment parameters and overall survival were analysed 
using standard statistical methods.
Results: A total of 179 lung cancer patients received conventional 
radical radiotherapy. Median age 70 years, 55% were female, with 
ECOG 0 25%, ECOG 1 62%, ECOG 2 13%. Patients Deprivation 
Score as per Scottish Index of Multiple Deprivation score 2012: 
44% are 1 (most deprived), 26% are 2, 13% are 3, 9 % are 4 and 
8% are 5(least deprived). 22%(39/179) are stage I, 19%(34/179) 
stage II, 58%(104/179) stage III, and 0.6%(2/179) are stage IV. 
51%(91/179) squamous cell carcinoma, 25%(44/179) adenocarcino-
ma, 7%(13/179) small cell carcinoma, 12%(22/179) had no histology 
and 5%(4/179) were neuroendocrine and others. 99% completed 
their prescribed radiotherapy. The mean whole lung V20 and who-
le lung V5 were 22.1% and 49.4% respectively. Mean PTV was 409.6 
ml. 62/179(35%) died within the first year of receiving their radical 
radiotherapy. Out of those who died 33/62 PTV <500ml, 26/62 PTV 
500-1000ml, 3/62 PTV>1000. 26/62 were treated with radiotherapy 
alone and 36/62 had received chemoradiotherapy. On univariate 
analysis using log-rank, age (p=0.663), sex (p=0.437), performance 
status (p=0.403), deprivation score (p=0.133), stage (p=0 .117), V20 
(p=0.084) and V5 (p=0.064) were not significant factors affecting 
survival. PTV (p=0.020) and chemoradiotherapy (p=0.001) were 
statistically significant variable affecting survival. On multivariate 
analysis using Cox-regression PTV remained significant with res-
pect to overall survival.
Conclusion: The outcome of this audit demonstrates that PTV is a 
significant variable affecting the survival of the patients in the first 
year after treatment. It was of interest to us that clinical stage, who-
le lung V20 and V5 were not significantly associated with survival. 
We also observed a significant one year survival difference in pa-
tients who were treated with radical radiotherapy alone compared 
with chemoradiotherapy. Overall survival was also not associated 
with deprivation score with survival outcomes similar across the 
whole population. The radiotherapy PTV may be an important va-
riable when deciding treatment independent of other radiotherapy 
planning parameters.
Keyword: lung cancer, radical radiotherapy, mortality, PTV
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P3.09-001 NSCLC IN ELDERLY PATIENTS WITH BRAIN 
METS: ROLE OF COMBINED ERLOTINIB AND TEMOZO-
LOMIDE WITH RADIATION THERAPY.
Manoj K. Behera, Pramod K. Julka, Goura K. Rath
Clinical Oncology, All India Institute Of Medical Sciences (aiims)/India
Background: Non small cell lung cancer with brain metastases 
are usually associated with poor outcomes and survival and about 
40-50% of all patients with lung cancer develop brain metastases 
during the course. The poor outcomes and relapses following 
WBRT alone indicate a need for new therapeutic options. As some 
patients with NSCLC have mutations in the EGFR and treating with 
WBRT with the anti-EGFR agent erlotinib in patients of NSCLC 
with brain metastases may benefit the patients in terms of disease 
regression and possible improvement in quality of life. Temozolo-
mide has been already used alone or in combination with radio-
therapy in the treatment of primary brain tumors and there are few 
studies showing its benefits in metastatic brain with WBRT. In this 
study we test the feasibility and efficacy of both of the drugs with 
WBRT.
Methods: A total of 12 elderly patients of biopsy proven ade-
nocarcinoma lung with brain metastases (on MRI) were analyzed 
from July 2010 to March 2012. All the patients were planned for 
palliative radiation of 30 Gy/10#/2 weeks to local disease with 
WBRT of 20 Gy/5#/1 week with concurrent Temozolomide@ 75mg/
m2 followed by assessment for further therapy after 3 weeks of 
radiation. All the patients were evaluated 3 weekly for assessment 
of symptom relief and improvement or progression. After 3 weeks 
all the patients were started on Erlotinib@ 150 mg, daily and Te-
mozolamide@ 150-200 mg/m2, D1-5, 4 weekly.
Results: The patient‘s age ranged from 58 to 75 years. All the pa-
tients completed the scheduled radiation with oral steroids. Five 
patients progressed and died between 3 and 10 months. One 
patient defaulted during the radiation therapy and another after 
completion of 6 cycles of oral chemotherapy. Only 5 patients could 
complete the 12 cycles of oral chemotherapy with Temozolamide 
and Erlotinib, 4 weekly. Only two patient needed dose reduction 
of Erlotinib to 100 mg due to grade III rashes in 3rd cycle. The pati-
ents who improved after local and brain RT have shown to tolerate 
the further oral chemotherapy. These patients are still alive with 
the metastatic disease.
Conclusion: The combination of Erlotinib with temozolomide ap-
pears to be a promising therapy for treating brain metastases in 
NSCLC in terms of tolerability and efficacy. Further studies need to 
be done in our set up of patients.
Keywords: Adenocarcinoma, brain metastases, erlotinib, temozo-
lomide
care should be taken to limit the lung V5, lung V20, and mean lung 
doses when administering curative-intent radiotherapy, regardless 
of treatment with IMRT or 3DCRT.
Keywords: pneumonitis, IMRT
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P3.09-002 I WANT IT ALL! THE BETTER OUTCOME OF 
PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL 
LUNG CANCER RECEIVING CHEMORADIATION FOLLO-
WED BY SURGERY OVER ANY OTHER COMBINATION 
OF INDUCTIVE CHEMOTHERAPY, RADIATION OR  
SURGERY
Diego Marquez-Medina1, Ariadna Gasol-Cudos1, Antonio Martin-
Marco1, Juan Carlos Samame Perez-Vargas1, Juan Felipe Cordoba-
Ortega1, Elena Garcia-Alonso2, Ricard Pifarre-Teixido3, Antonieta 
Salud-Salvia1
1Medical Oncology, University Hospital Arnau De Vilanova/Spain, 2Ra-
diation Oncology, University Hospital Arnau De Vilanova/Spain, 3Pneu-
mology, University Hospital Arnau De Vilanova/Spain
Background: Half of Non-small cell lung cancers are diagnosed in 
locally advanced stage (LA-NSCLC) and warrant multidisciplinary 
treatments including chemotherapy, radiation, and surgery (S) in 
a not well-defined combination and sequence. We compared to-
lerance and effectiveness of different combos of inductive chemo 
(iCT) or chemoradiotherapy (iCRT) followed by S or consolidative 
radiation (RT)
Methods: We retrospectively reviewed 108 consecutive LA-NSCLC 
diagnosed in our center between October-2004 and June-2012 
and treated with: 1) iCRT+S (N= 24); 2) iCT+S (N= 31); 3) iCRT+RT 
(N= 36); 4) iCT+RT (N= 17). Their tolerance, response, and out-
come were statistically compared. Survival of five patients that 
progressed during inductive therapy was not analyzed
Results: Mean age of the patients was 66.2 years-old, 92% were 
male, and 85.1% ECOG-0. Histology was squamous carcinoma in 
71.3%, non-specified NSCLC in 15.7%, and adenocarcinoma in 
12%. iCT included platin-doublets with taxanes, vinorelbine, and 
gemcitabine. CBDCA-combinations were commonly used in el-
derly patients (15.6% vs. 31.8%, p= 0.001). Grade 3-4 toxicity was 
observed in 14.8% of inductive therapies, without significant diffe-
rences between iCT and iCRT arms (p= 0.976). No patient interrup-
ted therapies due to toxicity. Progression rate was higher with iCT 
than iCRT (8.3% vs. 0; p= 0.023). S was performed in 51 patients 
(pneumonectomy 30%, bi/lobectomy 56%). Severe S complications 
appeared in 13.7% of cases. Three patients in the iCRT+S arm died 
due to early postoperative complications. Complete pathologic re-
sponses were higher with iCRT than iCT (25% vs. 11.5%, p= 0.049). 
Resected patients presented better disease free (DFS) and overall 
survivals (OS) than those definitively radiated (27.9 vs. 12 months, 
p= 0.000; and 37.8 vs. 25.9 months, p= 0.009). Higher DFS and OS 
was found among patients of the iCRT+S arm (p= 0.000 and p= 
0.049, respectively)
Conclusion: Those LA-NSCLC that achieved S after inductive the-
rapy presented a better outcome that those non-resected. iCRT+S 
was tolerable, feasible, and obtained the higher response and 
survival rate of our series, although these results are biased by the 
better prognosis of resectable patients. Anyway, prospective trials 
are warranted to confirm the benefits of triple multidisciplinary 
approach. Figure 1. DFS and OS Kaplan-Meier curves of patients 
according to the treatment arm. 
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phase III trial.
Keywords: chemoradiotherapy, molecular targeting, nimotu-
zumab, locally advanced non-small cell lung cancer
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P3.09-004 OLIGOMETASTATIC NON-SMALL CELL LUNG 
CANCER: A SIMULATION EXPERT MULTIDISCIPLINARY 
TUMOR BOARD.
Christophe Dooms1, Paul De Leyn1, Christophe Deroose1, Dirk De 
Ruysscher1, Anne-Marie Dingemans2, Joachim Pfannschmidt3, 
Keith M. Kerr4, Frank Lagerwaard5, Jose Luis Lopez Guerra6, 
Ramon Rami-Porta7, Egbert Smit8, Johan Vansteenkiste1
1University Hospitals Leuven/Belgium, 2Maastro/Netherlands, 3Thorax-
klinik/Germany, 4Aberdeen University Medical School/United Kingdom, 
5Radiation Oncology, VU University Medical Center/Netherlands, 6Hos-
pital Universitario Virgen Del Roco/Spain, 7Thoracic Surgery, Hospital 
Universitari Mutua Terrassa/Spain, 8VU Medical Centre/Netherlands
Background: Series on aggressive local treatment in selected pa-
tients with oligometastatic non-small cell lung cancer (NSCLC) are 
mostly retrospective, and prospective data are scarce (De Ruys-
scher et al, JTO 7:1547-1555, 2012). Although a precise definition 
is lacking, ‘oligometastatic NSCLC’ is considered an intermediate 
biologic state of restricted metastatic capacity with a limited num-
ber of metastases. The turning point between oligometastatic and 
polymetastatic is merely based on personal opinion and situated 
somewhere between 1 and 5 distant metastases. In the absence of 
clear definitions or clinical practice recommendations, a treatment 
decision is mainly driven by the opinion of each local multidiscipli-
nary tumor board (MDTB).
Methods: As the consideration of and the treatment modality for 
oligometastatic NSCLC is a controversial area in respiratory onco-
logy, in preparation of a recent dedicated workshop, we simulated 
a MDTB with international experts in the field. Multiple discipli-
nes from 7 different centers participated in the MDTB, including 
pathology (1), nuclear medicine physician (1), thoracic surgery (3), 
radiation oncology (3), and respiratory oncology (3). Participants 
were asked to assess an electronic file describing 10 clinical ‘oli-
gometastatic NSCLC’ cases, with 2 simple questions per case: 1. 
Do you consider this case ‘oligometastatic’ (Yes/No) and 2. What is 
your preferred treatment proposal.
Results: A full response was returned by all 11 specialists taking 
part in the simulated MDTB. Only 1 case was considered ‘oligome-
tastatic NSCLC’ by all MDTB members. The presented cases were 
considered by a median of 78% (range 36-100%) of responders as 
true oligometastatic disease. Despite the fact that each responder 
gave only one treatment proposal, a median of 4 different treat-
ment proposals (range 2-6) was made per case. Except for brain 
metastases, most team members would treat the locoregional 
thoracic disease before the distant metastases. No preference 
towards neo-adjuvant or adjuvant chemotherapy could be found. 
The option for surgery or radiation therapy as part of a combined 
modality treatment was mainly driven by the physicians’ prefe-
rence.
Conclusion: Our simulated MDTB shows that oligometastatic NS-
CLC is an entity with many unanswered questions, and thus a major 
challenge for clinicians. Patients with oligometastatic NSCLC are in 
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P3.09-003 PHASE II STUDY OF NIMOTUZUMAB IN COM-
BINATION WITH CONCURRENT CHEMORADIOTHERAPY 
(CRT) IN PATIENTS WITH LOCALLY ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC).
Kazushige Hayakawa1, Yasumasa Nishimura2, Hideyuki Harada3, 
Toshinori Soejima4, Kayoko Tsujino4, Takuyo Kozuka5, Masahiro 
Tanaka6, Tomonari Sasaki7, Nobuyuki Yamamoto8, Kazuhiko Na-
kagawa9
1Kitasato University School Of Medicine/Japan, 2Radiation Oncology, 
Kinki University Faculty Of Medicine/Japan, 3Radiation Oncology, Shi-
zuoka Cancer Center/Japan, 4Radiation Oncology, Hyogo Cancer Center/
Japan, 5Radiation Oncology, The Cancer Institute Hospital/Japan, 6Radi-
ation Oncology, Osaka City General Hospital/Japan, 7Clinical Radiology, 
Kyushu University Hospital/Japan, 8Third Department Of Internal Me-
dicine, Wakayama Medical University/Japan, 9Medical Oncology, Kinki 
University Faculty Of Medicine/Japan
Background: Nimotuzumab, a humanized IgG1 monoclonal anti-
EGFR antibody, is approved and widely used in patients (pts) with 
head and neck cancer or malignant glioma in combination with 
radiotherapy (RT) in several countries. In previous clinical studies, 
nimotuzumab has demonstrated a very mild and low incidence of 
skin toxicity compared to other anti-EGFR antibodies. On in-vitro 
and in-vivo experiments using NSCLC cell lines, nimotuzumab 
showed a radio-sensitizing effect.
Methods: This open-label, multicenter phase II study evaluated 
the tolerability and efficacy of nimotuzumab in combination with 
concurrent CRT in pts with unresectable locally advanced NSCLC. 
All eligible pts received concurrent thoracic RT (60 Gy, 2 Gy/day, 6 
weeks from day 1) and 4 cycles of chemotherapy (cisplatin 80 mg/
m2 on day 1, vinorelbine 20 mg/m2 on days 1 and 8) once every 4 
weeks as scheduled. Nimotuzumab (200 mg) was administrated 
once a week from cycle 1 to 4. The primary endpoint was tolera-
bility in combination with concurrent CRT, which was measured by 
the percentage of pts who completed 60 Gy of RT within 8 weeks, 
completed 2 cycles of chemotherapy and received more than 75% 
of nimotuzumab.
Results: Between June 2009 and May 2010, 40 pts were enrolled 
from 7 institutions in Japan, and 39 eligible pts received the study 
treatment. The pts characteristics (n = 39) were as follows: 62 years 
(median); male/female, 34/5; stage IIIA/B, 21/18; PS0/1, 25/14. Thir-
ty-four pts (87%) met the criteria for treatment tolerability, and 38 
pts (97%) completed 60 Gy of RT within 8 weeks. Infusion reaction, 
>grade 3 skin rash, >grade 3 radiation pneumonitis, or >grade 4 
nonhematological toxicity were not observed. The 2-year overall 
survival rate for the 39 pts was 76% (95% CI; 59-87%). The median 
PFS was 16.7 months; and 30 pts were alive at the cutoff date (Nov 
2011). The 1-year PFS rate for pts with squamous cell carcinoma 
(Sq; n = 16) was 75%, while that for pts with non-squamous cell car-
cinoma (non-Sq; n = 23) was 41%. In terms of the first relapse site, 
in-field relapse rates were low for both Sq (3/16; 19%) and non-Sq 
(3/23; 13%). However, the distant relapse rate was significantly 
higher for non-Sq (15/23; 65%) than that for Sq (2/16; 13%) (p<0.01, 
chi-square test with Yates correction).
Conclusion: Addition of nimotuzumab to the concurrent CRT in 
this setting was well tolerated with clinical benefit to the patients. 
The low in field relapse rates may be attributed to the radio-
sensitizing effect of nimotuzumab. These findings warrant further 
clinical evaluation of nimotuzumab/cisplatin/vinorelbine/RT in a 
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The CONSORT diagram below descri-
bes the treatment patients ultimately received. 
The median EFS and OS were 16 (95% CI 13-22) and 44 (95% CI 
36-NA) months. OS at 1, 2 and 3-years were 77%, 55%, and 32%. 
EFS plateaued at 23%, estimating the rate of cure. Overall survival 
strongly favored surgical resection over salvage radiation (HR=0.5, 
95% CI 0.16-1.05).
Conclusion: These data provide unique perspective on the out-
comes of patients with IIIA adenocarcinoma treated with neoadju-
vant chemotherapy with intent of surgical resection. EFS and OS 
compare favorably to historical outcomes in this stage of disease, 
demonstrating the value of the neoadjuvant approach. The inferior 
survival in patients treated with radiation as a “salvage” approach 
emphasizes the recommendation for definitive concurrent chemo-
radiation in those unlikely to be resectable.
Keyword: neoadjuvant, chemotherapy, NSCLCs, resectable
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P3.09-006 OUTCOMES OF ELDERLY PATIENTS WITH 
LOCALLY-ADVANCED NON-SMALL CELL LUNG CANCER 
(LA-NSCLC) TREATED WITH RADIATION +/- CHEMOTHE-
RAPY AT THE OTTAWA HOSPITAL CANCER CENTRE
Brian D. Healy1, Kent Russell2, Paul Wheatley-Price2, Robert Mac-
rae2, Jason Pantarotto2, Ranjeeta Mallick2, Scott Laurie2
1Medical Oncology, Juravinski Cancer Centre/Canada, 2The Ottawa 
Hospital Cancer Centre/Canada
Background: Concurrent chemoradiation (C-CRT) is standard the-
rapy for fit patients with unresectable, LA-NSCLC. We evaluated 
outcomes of patients treated with curative intent at our centre for 
quality assurance, and to compare outcomes between elderly (≥75) 
and younger patients.
Methods: Patients with stages IIIA/ IIIB NSCLC from 2002 to 2008 
were identified, and those planned for curative-intent radiation 
the need of 1. discussion at an experienced multidisciplinary tumor 
board to select patients for a radical combined modality approach; 
2. multidisciplinary prospective research protocols to set better 
definitions of oligometastic NSCLC, evaluate the validity of a radi-
cal approach, and to optimize therapeutic modalities.
Keywords: oligometastatic, non-small cell lung cancer, multidisci-
plinary treatment
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P3.09-005 "INTENTION-TO-TREAT“ OUTCOMES OF 
SEQUENTIAL PATIENTS WITH STAGE IIIA LUNG ADE-
NOCARCINOMAS TREATED WITH NEOADJUVANT CHE-
MOTHERAPY WITH INTENT OF SURGICAL RESECTION
Matthew D. Hellmann1, Jamie E. Chaft1, Patrick D. Hilden2, Valerie 
W. Rusch3, Mark G. Kris1
1Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center/
United States Of America, 2Department Of Biostatistics, Memorial 
Sloan-Kettering Cancer Center/United States Of America, 3Thoracic 
Service, Department Of Surgery, Memorial Sloan-Kettering Cancer 
Center/United States Of America
Background: Neoadjuvant chemotherapy followed by surgical 
resection is uniquely permits assessment of the in vivo response 
to therapy in patients with IIIA non-small cell lung cancer. Studies 
of neoadjuvant chemotherapy often focus only on those who are 
ultimately resected. We describe an “intention-to-treat” analysis 
of sequential patients with stage IIIA adenocarcinomas receiving 
neoadjuvant chemotherapy with intent of surgical resection.
Methods: Using natural language processing software, we 
searched the electronic medical record at Memorial-Sloan Kette-
ring Cancer Center for “neoadjuvant,” “preoperative,” or “induc-
tion” in physicians’ notes. Cases were limited to those with stage 
IIIA lung adenocarcinoma deemed resectable by a thoracic surge-
on and treated with neoadjuvant chemotherapy (without radiation), 
including those enrolled in prospective clinical trials. Event-free 
survival (date of diagnosis to recurrence, relapse or death) and 
overall survival (date of diagnosis to death) were assessed using 
Kaplan-Meier methods.
Results: From 2007 until 08/2012, 129 patients were identified. 
Median follow up is 25 months (range 1-76). The patient details are 
described. 94/129 (73%) were treated with cisplatin-based therapy.
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P3.09-007 UPDATE DATA OF BIOMARKER ANALYSIS OF 
WJOG4107 (A RANDOMIZED PHASE II TRIAL OF ADJU-
VANT CHEMOTHERAPY WITH S-1 VERSUS CDDP+S-1 
FOR RESECTED STAGE II-IIIA NON-SMALL CELL LUNG 
CANCER (NSCLC))
Hirohito Tada1, Yasuo Iwamoto2, Kazuto Nishio3, Takeharu 
Yamanaka4, Tetsuya Mitsudomi5, Hiroshige Yoshioka6, Masahiro 
Yoshimura7, Ichiro Yoshino8, Masayuki Takeda9, Shunichi Suga-
wara10, Shinzoh Kudoh11, Toshiaki Takahashi12, Mitsunori Ohta13, 
Yukito Ichinose14, Shinji Atagi15, Morihito Okada16, Hideo Saka17, 
Shuichi Tsukamoto18, Kohei Yokoi19, Nobuyuki Katakami20, Kazu-
hiko Nakagawa21, Yoichi Nakanishi22
1Department Of General Thoracic Surgery, Osaka City General Hospi-
tal/Japan, 2Hiroshima City Hospital/Japan, 3Department Of Genome 
Biology, Kinki University Faculty Of Medicine/Japan, 4Biostatistics, 
National Cancer Center. East/Japan, 5Department Of Surgery, Kinki 
University, Faculty Of Medicine/Japan, 6Department Of Respiratory Me-
dicine, Kurashiki Central Hospital/Japan, 7Hyogo Cancer Center, Hyogo 
Cancer Center/Japan, 8Department Of General Thoracic Surgery, Chiba 
University Graduate School Of Medicine/Japan, 9Medical Oncology, 
Kinki University Faculty Of Medicine/Japan, 10Sendai Kousei Hospital/
Japan, 11Department Of Respiratory Medicine, Osaka City University/
Japan, 12Division Of Thoracic Oncology, Shizuoka Cancer Center/Japan, 
13Department Of General Thoracic Surgery, Osaka Prefectural Medical 
Center For Respiratory And Allergic Diseases/Japan, 14Thoracic Oncolo-
gy, National Kyushu Cancer Center/Japan, 15Thoracic Oncology, Kinki-
chuo Chest Medical Center/Japan, 16Department Of Surgical Oncology, 
Hiroshima University/Japan, 17Department Of Respiratory Medicine, 
Nagoya Medical Center/Japan, 18General Thoracic Surgery, Steel Me-
morial Yawata Hospital/Japan, 19Department Of Thoracic Surgery, 
Nagoya University Graduate School Of Medicine/Japan, 20Division Of 
Integrated Oncology, Institute Of Biomedical Research And Innovation/
Japan, 21Department Of Medical Oncology, Kinki University Faculty Of 
Medicine/Japan, 22Department Of Clinical Medicine, Research Institute 
For Diseases Of The Chest, Faculty Of Medical Sciences, Kyushu Uni-
versity/Japan
Background: We conducted a randomized phase II trial for pati-
ents with resected stage II-IIIA NSCLC comparing postoperative 
oral S-1 (80 mg/m2/day for consecutive 2 weeks q3w for 1 year) (S) 
(N=100) or cisplatin (CDDP) (60 mg/m2 day1) plus oral S-1, (80 mg/
m2/day for 2 weeks) q3w for 4 cycles (PS)(N=100). We reported 
that disease free survival rate at 2 years (DFS@2) (95% confidence 
interval: CI), a primary endpoint, was 66 (55-74) % for S and 58 (48-
67)% for PS. Here, we report the preliminary results of preplanned 
biomarker analysis, a co-primary endpoint, to identify molecules 
whose expression is significantly associated with patient outcome.
Methods:  (cDNA extracted from macro-dissected formalin-fixed 
paraffin-embedded specimens were available for 197/200 patients. 
Thirty-one genes including those whose expressions have been 
potentially associated with (CDDP (e.g. ERCC1, XRCC1, BRCA1, 
GSTpi, HMG1, TBP) or fluorouracil (FU) sensitivity (TS, DHFR, DPD, 
UMPS, UPP1) were measured by QGE analysis (MassArray, Se-
quenom, CA). Additional analysis are being performed to assess 
ERCC1 isoform expression with an isoform-specific TaqMan probe 
(Applied Biosystems, CA). The expression of each gene was dicho-
tomized according to its median value.
Results: Molecules such as ERCC1 and GSTpi whose expression 
have been previously associated with CDDP sensitivity did not 
emerge as predictive markers (P=0.7908, 0.6406, respectively). 
(minimum 50Gy) included, irrespective if therapy was actually com-
pleted. Charts were reviewed for patient demographics, baseline 
prognostic factors, treatments planned and administered, hospita-
lizations and outcomes. Multivariable analyses were performed to 
determine factors associated with survival.
Results: 329 patients were included: median age 66 (range 
40-89), 60% male, 15% ECOG 2+, 60% IIIB, 35% weight loss 
>5%. 20% (66/329) were ≥75. C-CRT, sequential CRT and ra-
diation alone were delivered in 85%, 5%, and 10% of cases, 
respectively; the elderly were less likely to receive C-CRT (61% 
vs. 91%). Median survival (all patients) was 18.4 months; for < 
and ≥75 cohorts, MS were 20.8 and 16.4 months (p=0.0533). 3 
and 5 year OS (all patients) were 29% and 17%; for the < and 
≥75 cohorts values were 31/21% and 19/8%. Elderly patients 
had lower treatment-related hospitalization (6% vs. 20%) and 
death (2% vs. 5%). Radiation compliance was equivalent howe-
ver chemotherapy completion was higher in younger patients 
(78% vs. 45%). In multivariate analysis, age ≥75 (HR=1.68, 95% CI 
1.03-2.75, p=0.038), female gender (HR=0.60, 95% CI 0.41-0.87, 
p=0.008), and completion of radiation therapy (HR=0.39, 95% CI 
0.25-0.62, p<0.0001) were independent predictors of outcome. 
Conclusion: Outcomes of patients with LA-NSCLC offered curative 
therapy at the Ottawa Hospital Cancer Centre are comparable 
to those obtained in clinical trials of C-CRT, despite a more un-
selected population with a higher proportion of poor prognostic 
features. Those ≥75 were less likely to be offered C-CRT and were 
less likely to complete planned chemotherapy. However fit patients 
≥75 offered radical therapy still have reasonable MS and 3-year 
OS.
Keyword: Curative, Outcomes, Elderly, NSCLC.
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to those reported for similarly staged patients without SVCS sug-
gest treatment of such patients with aggressive C-CRT protocols.
Keywords: superior vena cava syndrome, Concurrent chemoradio-
therapy, non-small cell lung cancer, locally advanced stage
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P3.09-009 SURVIVAL OUTCOME IN STAGE IIIB NON-
SMALL CELL LUNG CANCER PATIENTS YOUNGER THAN 
45 YEARS: RETROSPECTIVE ANALYSIS OF 145 PATI-
ENTS.
Erkan Topkan1, Cem Parlak1, Ozan C. Guler1, Ugur Selek2
1Department Of Radiation Oncology, Baskent University Medical Fa-
culty/Turkey, 2Department Of Radiation Oncology, American Hospital, 
University Of Texas MD Anderson Radiation Oncology Center/Turkey
Background: Purpose of this study was to assess clinical outcomes 
of concurrent chemoradiotherapy (CRT) in Stage IIIB non-small 
cell lung cancer (LA-NSCLC) patients younger than 45 treated with 
concurrent chemoradiotherapy (CRT).
Methods: Medical records of 145 ≤45 years old patients out of 
942 LA-NSCLC patients, who had been treated with definitive CRT 
[60-66 Gy thoracic radiotherapy (TRT) concurrently with 1-3 cycle 
cisplatin-based doublet (vinorelbine/docetaxel/etoposite/gemci-
tabine) chemotherapy] at our department between dates January 
2007 and December 2011 were retrospectively evaluated. . Primary 
end point was overall survival (OS), and secondary end points were 
progression-free survival (PFS) and locoreginal PFS (LRPFS).
Results: At the time of analyses, 58 (40%) patients were alive, and 
median follow-up for these patients was 30.5±11.2 months. For 
whole study group, median, 3- and 4-year OS, LRPFS and PFS were 
24.8 months, 38% and 24%, 15.7 months, 26.3% and %18.9, and 12 
months, 18.2% and 11.2%. On univariate analyses, CRT duration 
(≤50 vs. >50 days; p<0.001), pretreatment anemia (Hb<12 g/dl 
vs. ≥12; p<0.001) were significantly associated with survival while 
there was a statistical trend for nodal stage (N2 vs N3; p=0.09). On 
multivariate analyses, longer CRT duration and pretreatment ane-
mia retained their prognostic significance.
Conclusion: Median OS of 24.8 months for younger stage IIIB 
NSCLC patient treated with CRT is promising, and superior OS in 
patients with no pretreatment anemia and in patients completing 
their CRT earlier than 50 days suggest that pretreatment anemia 
should be corrected and all preventive measures should be perfor-
med to complete CRT at planned period of time.
Keywords: Concurrent chemoradiotherapy, non-small cell lung 
cancer, Stage IIIB, younger age
We quantitated ERCC1 by isotype (202 and 204 cannot be distin-
guished). There was a trend in patients with high 201 or 202/204, 
CDDP/S-1 was worse than S-1.
Conclusion: Quantitation of ERCC1 by isotype may define a pati-
ent subset that would benefit from postoperative platinum  
therapy.
Keywords: S-1, biomarker, adjuvant chemotherapy, Non small cell 
lung cancer
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P3.09-008 PROGNOSIS OF STAGE III NON-SMALL CELL 
LUNG CANCER PATIENTS INITIALLY PRESENTING WITH 
SUPERIOR VENA CAVA SYNDROME TREATED WITH 
PARTIALLY ACCELERATED DEFINITIVE CONCURRENT 
CHEMORADIOTHERAPY
Erkan Topkan1, Cem Parlak1, Berrin Pehlivan2, Ugur Selek3, Ozgur 
Ozyilkan4
1Department Of Radiation Oncology, Baskent University Medical Facul-
ty/Turkey, 2Department Of Radiation Oncology, Medstar Antalya Hos-
pital/Turkey, 3Department Of Radiation Oncology, American Hospital, 
University Of Texas MD Anderson Radiation Oncology Center/Turkey, 
4Department Of Medical Oncology, Baskent University Medical Faculty/
Turkey
Background: To retrospectively investigate the prognosis of lo-
cally advanced non-small cell lung cancer (LA-NSCLC) patients 
initially presenting with superior vena cava syndrome (SVCS) fol-
lowing partially accelerated definitive concurrent chemoradiothe-
rapy (C-CRT).
Methods: Forty-seven LA-NSCLC patients presented with SVCS 
between June 2007 and December 2011 were included. All pa-
tients received an initial daily 4 Gy radiotherapy (RT) followed by 
weekly cisplatin-based chemotherapy given concurrently with 2 Gy 
daily RT for additional 26 fractions, which corresponds to a biolo-
gically equivalent dose (BED10) of 79.2 Gy. Primary endpoint was 
overall survival (OS).
Results: Median follow-up time was 20.3 months for whole cohort, 
and 37.4 months for surviving patients. Median age was 63 years. 
Squamous cell- and adenocarcinoma rates were 54 and 46%, res-
pectively. Stage distribution was 29.8% stage IIIA and 70.2% stage 
IIIB. Treatment was relatively well tolerated. All patients were able 
to receive planned RT, and 39 (83%) received 4 or 5 courses of 
prescribed chemotherapy. There were no treatment related deaths 
at acute phase while 8 (17%) grade 4 hematologic toxicity was 
reported, with no grade 4 non-hematologic toxicity. At long term 
2 patients died of tracheoesophageal fistula and caval rupture. 
Median, 2-, and 3-year OS were 19.4 months, 36.2%, and 25.5%, 
respectively. On univariate analyses; cause of SCVS (nodal vs. pri-
mary tumor; p<0.001), status of SVC (infiltrated vs. compressed; 
p<0.001), and tumor stage (IIIA vs. B; p<0.03) were the factors 
significantly associated with prognosis. Of these, cause of SCVS 
(p<0.001) and status of SVC (p<0.001) retained their significance 
on multivariate analyses.
Conclusion: Partially accelerated C-CRT regimen utilized here is 
reasonably safe and efficient in LA-NSCLC patients initially presen-
ting with SVCS. Present survival rates, which are almost equivalent 
S1150 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 3 - COMBINED MODALITY  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.09-011 CONCURRENT CHEMORADIATION FOR  
LOCALLY ADVANCED NON SMALL CELL LUNG CANCER 
(NSCLC) USING WEEKLY CISPLATIN AND DOCETAXEL: 
RETROSPECTIVE ANALYSIS OF TOXICITY AND  
SURVIVAL DATA .
Pinky Baghi1, Fiona Abell2, Yolande Cox2
1Medical Oncology, Calvary Mater Newcastle/Australia, 2Medical Onco-
logy, Calvary Mater/Australia
Background: Concurrent chemoradiation is the standard of care 
for majority of medically fit patients with locally advanced (IIIA and 
IIIB) NSCLC. Whilst the optimal radiation dose and schedule is well 
established (66Gy in 30#) the optimal chemotherapy regimen is 
less certain due to a paucity of phase III chemotherapy trials in this 
context. Phase II studies have demonstrated high disease response 
rates with acceptable toxicities when weekly cisplatin and doce-
taxel were administered concurrently with radiotherapy.SWOG 
chemoradiotherapy regimen with cisplatin and etoposide which is 
commonly used has not been compared to modern cisplatin dou-
blet in phase III setting. Furthermore, in our experience the SWOG 
regimen is associated with significant toxicity. In 2004 we adopted 
a local chemoradiation protocol using weekly low dose cisplatin 
and docetaxel.
Methods: We searched oncology pharmacy dispensing records to 
identify community based patients treated with weekly cisplatin 
(20mg/m2) and docetaxel (20mg/m2) doublet regimen between 
2004 and 2011. This data was cross referenced with radiation on-
cology database to identify a cohort of patients with locally ad-
vanced NSCLC who received concurrent radical radiation.Disease 
stage was recorded as documented in medical records. Toxicity 
data was collected and graded according to the NCI criteria. Pro-
gression free survival(PFS) was calculated from commencement 
of treatment until radiologically confirmed recurrence.Overall 
survival(OS) was calculated from commencement of treatment until 
death from any cause.
Results: Sixty eligible patients were identified. Median age was 
63 yrs. 75% patients were male. Predominant histologies were 
squamous (43%) and adenocarcinoma (35%).The majority of pa-
tients were current or ex smokers (57% and 37% respectively) 
and were ECOG 1 at start of treatment (72%). 58% patients had 
stage IIIA disease and 40% stage IIIB. In addition to concurrent 
chemoradiation, 42% received either induction or consolidation 
chemotherapy. Grade 3/4 non haematological toxicities included 
oesophagitis (36%) and pneumonitis (1 patient).Significant haema-
tological toxicities were rare with grade 3/4 anaemia,neutropenia 
and thrombocytopenia seen in 1, 2 and 1 patient respectively.
Grade 3 /4 esophagitis seen in 36% cases. Treatment compliance 
was good with 73% of patients completing planned 6 weeks of 
chemotherapy. Chemotherapy delay due to toxicity occurred in 
20 % patients.At least one hospital admission was seen in 36% 
patients. One treatment related death occurred. Median PFS was 
10 months. Median OS was 20 months. In patients who relapsed 
,chest was the most common site (n=15) followed by brain (n=13). 
As on February 2013,17 patients remain alive whilst an additional 8 
patients have been lost on followup.
Conclusion: Low dose cisplatin and docetaxel when given con-
currently with definitive radiotherapy for locally advanced NSCLC 
is a feasible regimen with negligible haematological toxicity. The 
incidence of esophagitis whilst relatively high is main non haema-
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P3.09-010 LONG TREATMENT DURATION IS ASSOCIA-
TED WITH POOR PROGNOSIS IN PATIENTS RECEIVING 
CONCURRENT CHEMORADIOTHERAPY WITH THE DIAG-
NOSIS OF STAGE IIIB NON-SMALL CELL LUNG CANCER
Erkan Topkan1, Cem Parlak1, Berrin Pehlivan2, Ozgur Ozyilkan3, 
Ugur Selek4
1Department Of Radiation Oncology, Baskent University Medical Fa-
culty/Turkey, 2Department Of Radiation Oncology, Medstar Antalya 
Hospital/Turkey, 3Department Of Medical Oncology, Baskent University 
Medical Faculty/Turkey, 4Department Of Radiation Oncology, American 
Hospital, University Of Texas MD Anderson Radiation Oncology Cen-
ter/Turkey
Background: Aim of this study is to investigate the relationship 
between the treatment duration on prognosis in stage IIIB non-
small cell lung cancer (NSCLC) patients treated with definitive con-
current chemoradiotherapy (CRT).
Methods: Medical records of 824 18-70 years old stage IIIB NSCLC 
patients treated at our department between dates January 2007 
and December 2011 were retrospectively evaluated. Patients re-
ceived 60-66 Gy thoracic radiotherapy concurrently with at least 1 
cycle cisplatin-vinorelbine/docetaxel (q21) regimen chemotherapy. 
Primary end point was the evaluation of association between treat-
ment duration and overall survival (OS), and secondary end points 
were progression-free survival (PFS) and locoreginal PFS (LRPFS).
Results: At a median follow-up of 22.8 months (range 17.4-25.2), 
Median OS, PFS and LRPFS for whole group were 21.2 (%95 CI: 
20.2-22.2), 9.9 (%95 CI: 9.4-10.3) and 13.7 months (%95 CI: 13.1-
14.3), respectively. The most significant cut off point for CRT 
duration defined in ROC (receiver operating characteristic) curve 
analysis was 50.5 days, and patients were dichotomized into two 
groups; namely Group 1: ≤50 (n=420) and Group 2: ≥ 50 (n=404). 
On comparative survival analyses, patients completing their CRT in 
shorter period of time revealed superior OS (26.6 vs.15.5 months; 
p<0.001), PFS (12.8 vs.7.7 months; p<0.001), and LRPFS (16.4 
vs.10.2 months; p<0.001) than the others. Duration of CRT retained 
its significant association with OS, PFS, and LRPFS on multivariate 
analyses (p<0.001).
Conclusion: Results of this study has demonstrated that completi-
on of CRT in longer than 50 days was associated with significantly 
shorter survival. Therefore, treatment delays due to religious or 
official holidays should be avoided, and all comprehensive palliati-
ve measures should be performed in order to minimize treatment-
related toxicities that might potentially prevent shorter delivery of 
CRT.
Keywords: non-small cell lung cancer, Stage IIIB, treatment durati-
on, Concurrent chemoradiotherapy
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Conclusion: Curative intent RT +/- chemotherapy is well tolerated 
and effective treatment for inoperable or locally advanced NS-
CLC. Tumour outcomes and toxicities were comparable to those 
reported in clinical trials. Higher SCS was not correlated with worse 
survival in this cohort.
Keywords: chemotherapy, Non small cell lung cancer, comorbidity 
score, radiotherapy
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P3.09-013 OUTCOMES AND PREDICTORS FOR RE-
CURRENCE AND SURVIVAL AFTER NEOADJUVANT 
CONCURRENT CHEMORADIATION FOLLOWED BY 
OPERATION IN PATIENTS WITH CLINICAL STAGE III-N2 
NON-SMALL-CELL LUNG CANCER
Hyun-Ju Lim1, Ho Yun Lee1, Kyung Soo Lee2, Joungho Han3, O Jung 
Kwon4, Young Mog Shim5, Myung-Ju Ahn6, Yong Chan Ahn7, Keun-
chil Park6, Byung-Tae Kim8
1The Department Of Radiology And Center For Imaging Science, 
Samsung Medical Center, Sungkyunkwan University School Of Medi-
cine/Korea, 2The Department Of Radiology And Center For Imaging 
Science, Sungkyunkwan University Of School Of Medicine, Seoul, 
Korea/Korea, 3The Department Of Pathology/Korea, 4The Division Of 
Respiratory And Critical Medicine Of The Department Of Internal Medi-
cine, Samsung Medical Center, Sungkyunkwan University Of School Of 
Medicine/Korea, 5The Department Of Thoracic Surgery, Samsung Medi-
cal Center, Sungkyunkwan University School Of Medicine/Korea, 6The 
Division Of Hemato-oncology Of The Department Of Internal Medicine, 
Samsung Medical Center, Sungkyunkwan University School Of Medici-
ne/Korea, 7The Department Of Radiation Oncology, Samsung Medical 
Center, Sungkyunkwan University Of School Of Medicine/Korea, 8The 
Department Of Nuclear Medicine, Samsung Medical Center, Sungky-
unkwan University Of School Of Medicine/Korea
Background: This study assessed the impact of imaging, surgical, 
histopathologic and patient-related factors on the risks of local and 
distant recurrence and overall survival for patients with stage III-N2 
non small cell lung carcinoma (NSCLC) undergoing definitive re-
section after neoadjuvant concurrent chemoradiation (neoCCRT).
Methods: We retrospectively examined 129 consecutive patients 
with stage III-N2 NSCLC received neoCCRT followed by curative 
surgery between 2008 and 2011. We reviewed clinical data and 
operation method. We also analyzed histopathologic factors such 
as subtype, pathologic invasive tumor characteristics, differenti-
ation, residual tumor size, or the number of residual LNs as well 
as imaging characteristics on chest CT and PET/CT. Disease free 
survival (DFS) and overall survival (OS) were estimated using the 
Kaplan-Meier method, and predictive factors for recurrence and 
survival were identified by univariate and multivariate Cox-propor-
tional analyses.
Results: 112 (87%) patients were pathologically staged for N2-
positive status (82 patients by mediastinoscopic biopsy and 30 
patients by EBUS). The 5-year recurrence rate was 28.3 %, and 
the 5-year survival rate was 43.4 %. Five-year OS for patients with 
recurrence compared with those without was 29.5 versus 59.1 % 
(P = 0.028). Based on the multivariate Cox-proportional analysis 
and log-rank test, history of adjuvant therapy was the only signi-
ficant prognostic predictor for prolonged OS (HR 0.134, 95 % CI 
0.039–0.455, P = 0.001). As for recurrence, less size decrease on 
tological toxicity seen and is comparable to that of other published 
data using this chemoradiation regimen. Furthermore this toxicity 
had minimal impact on treatment compliance and was without 
longterm sequelae. We believe our regimen is an acceptable alter-
native to the SWOG regimen.
Keyword: combined chemoradiotherapy .Tolerance
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P3.09-012 A DECADE OF COMMUNITY-BASED OUTCO-
MES OF PATIENTS TREATED WITH CURATIVE RADIO-
THERAPY (RT) +/- CHEMOTHERAPY FOR NON-SMALL 
CELL LUNG CANCER (NSCLC).
Ariyanto Pramana1, Joseph Descallar2, Shalini Vinod1
1Liverpool And Macarthur Cancer Therapy Centres, Liverpool Hospital/
Australia, 2Ingham Institute For Applied Medical Research, Liverpool 
Hospital/Australia
Background: There are many clinical trials reporting good out-
comes of patients treated with curative RT. However, clinical trials 
populations are highly selected and there are limited data on whe-
ther these outcomes are seen in community practice in the Aust-
ralian setting. The aim of the study was to evaluate the outcomes 
and toxicity of patients treated with curative RT +/- chemotherapy 
for NSCLC.
Methods: Electronic medical records at Liverpool and Macarthur 
Cancer Therapy Centres, NSW, Australia were queried to retrieve 
data on patients with Stage I-III NSCLC who were treated with 
curative RT (minimum dose 60Gy) between 1/1/2000-31/12/2010. 
Patient death records were available up until 16/1/2013 with a mi-
nimum follow up time for patients of 2 years. Patient demographic 
data, tumour, and treatment details were retrieved. The records 
were retrospectively reviewed to collect data on patient comorbi-
dities and treatment toxicities. The Simplified Comorbidities Score 
(SCS) was used to score comorbidity. The median follow up time 
was 22 months. For Cancer Specific Survival (CSS), patients were 
censored if they had died from another cause or survived until the 
last date of follow up, and for Overall Survival (OS), patients were 
censored if they survived until the end of the study. Univariate and 
multivariate Cox proportional hazards models were used to assess 
predictors of CSS and OS.
Results: One hundred and sixty patients were treated with curative 
RT over this period. The median age was 69 years (range 36-89). 
Seventy-six patients received RT alone, 59 received concurrent 
chemo-radiation, and 25 received sequential chemo-radiation. 
Twenty-nine patients had stage I disease, 28 had stage II, and 103 
had stage III. Median overall survival was 29 months for patients 
with stage I NSCLC, 26 months for stage II, and 18 months for sta-
ge III. For stage II and III patients treated with concurrent chemo-
radiation, median survivals were 29 and 18 months and 2-year OS 
were 64 and 42% respectively. On multivariate analysis, stage II or 
III and weight loss ≥5% were predictive of cancer specific survival 
with hazard ratio 4.47 (95% CI: 10.8-18.55, p=0.039) and 2.23 (95% 
CI: 1.13-4.39, p=0.021). Toxicity was acceptable with 2% grade ≥3 
radiation pneumonitis, 6% grade ≥3 oesophagitis, and 2% grade 
≥3 febrile neutropenia. There was no treatment-related death. 
Performance status, age, SCS, respiratory function, pathology, and 
grade were not predictive of survival.
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sitate more aggressive adjuvant treatment.
Keywords: N2, neoadjuvant chemoradiation, Prognosis, locally 
advanced non-small-cell lung cancer
POSTER SESSION 3 - COMBINED MODALITY  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.09-014 CONCURRENT CHEMORADIOTHERAPY FOR 
PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL 
CELL LUNG CARCINOMA; A REAL-LIFE EXPERIENCE
Ufuk Yilmaz1, Esra K. Kıraklı2, Gulru Polat1, Ilker Karadogan2, Ci-
men Akcay2
1Dept Of Chest Disease, Izmir Dr. Suat Seren Chest Disease And Sur-
gery Training And Research Hospital/Turkey, 2Dept. Of Radiation On-
cology, Izmir Dr. Suat Seren Chest Disease And Surgery Training And 
Research Hospital/Turkey
Background: Investigators from the Hoosier Oncology Group 
reported that there was no survival advantage but significant to-
xicity from the addition of docetaxel consolidation to immediate 
radiation and concurrent cisplatin (P)–etoposide (E) for treatment 
in patients with unresectable stage III non-small-cell lung carci-
noma (NSCLC). Concurrent chemoradiotherapy alone is standard 
treatment for fit patients in this group. The aim of this prospective 
study is to investigate the survival rates of standard treatment for 
these patients in a real-life.
Methods: Eligible patients had unresectable stage IIIA or IIIB NS-
CLC, baseline performance status of 0 to 1, less than 5% weight 
loss and adequate organ function. Patients received P 50 mg/m2 
intravenously (IV) on days 1, 8, 29, and 36 and E 50 mg/m2 IV on 
days 1-5 and 29-33 concurrently with chest XRT to 63.00 Gy (1.8 Gy 
per fraction and 5 fractions per week).
Results: From January 2008 until December 2010, 59 patients 
were entered into the trial, 57 were evaluated. Patient characte-
ristics were as follows: 94,7% male; median age, 56 years; 40,3% 
stage IIIA; and 59,7% stage IIIB; 64,9% squamous cell carcinoma, 
17,5% adenocarcinoma. Objective response rate was 61,4% (com-
plete response 19,3%). Grade 4 neutropenia was the most com-
mon toxicity (35,1%). 19,3% of patients experienced grade 2-3 pul-
monary- late toxicity. 44 patients have died. 12,2% of patients had 
febrile neutropenia. One patient died due to renal toxicity. With 
a median follow-up time of 18 months, median progression-free 
survival (PFS) was 10,5 months, median overall survival (OS) was 18 
months (11,7 to 24,2, 95% confidence interval), and two-, 3- and 
4-year OS rates were 36,1%, 23,2%, and 16,9%, respectively. Two-, 
3- and 4-year PFS rates were 17,4%, 13,2%, and 9,9%, respectively.
Conclusion: The survival rates in real-life studies as the current stu-
dy can be expected to be mildly shorter than those in controlled 
clinical trials.
Keywords: chemoradiotherapy, Real-life, survival, Lung cancer
CT (HR 1.030, 95 % CI 1.005–1.056, P = 0.017), higher T stage (HR 
2.450, 95 % CI 1.322–4.540, P = 0.004), larger residual tumor size 
on the pathologic specimen (HR 1.124, 95 % CI 1.010–1.252, P = 
0.016), and presence of lymphovascular invasion (HR 4.180, 95 % 
CI 1.093–15.984, P = 0.037) were the significant predictors in both 
the multivariate Cox-proportional analysis and the log-rank test. 
Conclusion: Recurrence remains high in resected stage III-N2 NS-
CLC patients after neoCCRT and nodal downstaging, and patients 
who received adjuvant therapy had longer overall survival rate than 
patients who did not. Size decrease on CT, T stage, residual tumor 
size on the pathologic specimen, and presence of lymphovascular 
invasion would be predictive for higher recurrence and may neces-
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P3.09-016 A PHASE II STUDY OF CISPLATIN AND ORAL 
VINORELBINE CONCOMITANTLY WITH RADIOTHERAPY 
IN LOCALLY ADVANCED NON-SMALL-CELL LUNG CAN-
CER TREATMENT: EFICACY AND SAFETY RESULTS.
Oscar Juan1, Sergio Vazquez2, Jose Garcia3, José Luis Fírvida4, 
Francisco Aparisi5, Jose Muñoz6, Joaquin Casal7, Vicente Giner8, 
Regina Gironés9, Martin Lazaro7, Javier Garde3, Alfredo Sánchez-
Hernández10
1Medical Oncology, Hospital Universitari I Politècnic La Fe/Spain, 2Me-
dical Oncology, Hospital Universitario Lucus Augusti/Spain, 3Medical 
Oncology, Hospital Arnau De Vilanova/Spain, 4Medical Oncology, Com-
plexo Hospitalario Universitario De Ourense/Spain, 5Medical Oncology, 
Hospital Virgen De Los Lirios/Spain, 6Medical Oncology, Hospital Uni-
versitario Doctor Peset/Spain, 7Medical Oncology, Complexo Hospitala-
rio Universitario De Vigo/Spain, 8Medical Oncology, Hospital De Sagun-
to/Spain, 9Medical Oncology, Hospital Lluís Alcanyís/Spain, 10Medical 
Oncology, Consorcio Hospitalario Provincial De Castellón/Spain
Background: It has been shown an improvement in survival with 
concurrent chemoradiation versus the sequential administration of 
both treatment modalities. In patients with unresectable stage III 
disease, chemotherapy may best be started soon after the diagno-
sis of unresectable NSCLC has been made. Cisplatin (CDDP) plus 
oral vinorelbine (OV) as induction and concomitant regimen with 
radiotherapy (RT) has shown good efficacy outcomes and safety 
profile (Vokes, Fournel, Krzakowski). The objective of this study 
was to evaluate the effectiveness and toxicities of the combination 
of CDDP and OV given at full doses concomitantly with RT in lo-
cally advanced (LA) non-small-cell lung cancer (NSCLC).
Methods: Between February 2010 and December 2011, 48 chemo-
naïve patients (p) with histologically confirmed unresectable stage 
IIIA/IIIB LA NSCLC were treated. Treatment consisted of 4 cycles 
(cy) of OV 60 mg/m2 on days 1 and 8 and CDDP 80 mg/m2 every 3 
weeks plus RT 66 Gy starting on day 1, cy 2. The primary objective 
is the overall response rate (ORR) using RECIST 1.0. A standard 
Fleming two stage design was used. The sample size calculated 
with a type 1 error of 0.05 and type 2 error of 0.01, taking P0 20% 
and P1 40%. The study was approved by the local Ethical Commit-
tees of the participating institutions.
Results: Patient’s characteristics were: Median age 61 years (range 
34-72); ≥ 65y 42%; males 89.6%; PS0 42% / PS1 58%; smokers 52%; 
adenocarcinoma 30% / squamous 64%; stage IIIA 46% / IIIB 54%. 
Median of days between initial diagnosis and study start was 28 
days. 75% p completed the treatment as per protocol. Relative 
dose intensities of OV and CDDP were 97%/98%, respectively. 
14.7% of cy were delayed, 11.8% due to toxicity. Dose of day 8 OV 
was canceled or delayed in 8.2% of cy. Hematological toxicities 
(% p): grade (g) 3/4 neutropenia 33.3%; g3 anemia 12.5%; g3/4 
thrombocytopenia 16.6%; febrile neutropenia concomitant during 
CT-RT 14.6%. Non-hematological toxicities (% p): g3 esophagitis 
12.5%; g3 dyspnea 4.2%, g3 vomiting 4.2%, g3-4 infection 4.2%. 
2 treatment-related deaths were reported, both during cycle 1. 42 
p (87.5%) received RT, 7.1% under 60 Gy, 23.8% with RT delays or 
interruptions due to adverse events. 44 p were evaluable for res-
ponse. ORR 77.3% [CI 95%, 62.2-88.5], DCR 88.6% [CR 2 p (4.5%), 
PR 32 p (72.7%), SD 5 p (11.4%)]. Median follow-up was 19 months 
(m) (range 0.47-39.4). Median progression free survival (PFS), 12 m 
[CI 95%, 7.3-16.6]; 1-year PFS, 48.3% [CI 95%, 33.6-63], 2-year PFS, 
30% [CI 95%, 15.8-44.2]. Median time to progression (TTP), 13.3 m 
[CI 95%, 9.7-16.9]; 1-year TTP, 51.7% [CI 95%, 36.9-66.6], 2-year TTP, 
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P3.09-015 THE ROLE OF ADJUVANT TREATMENT IN N2 
POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS 
TREATED WITH NEOADJUVANT CHEMORADIATION 
FOLLOWED BY SURGERY: A RETROSPECTIVE SINGLE 
CENTER EXPERIENCE.
Jung Yong Hong, Ji Yun Lee, Joungho Han, Hojoong Kim, O Jung 
Kwon, Yong Chan Ahn, Jhingook Kim, Young Mog Shim, Jong-Mu 
Sun, Myung-Ju Ahn, Keunchil Park, Jin Seok Ahn
Samsung Medical Center/Korea
Background: The optimal management of locally advanced N2 
positive non-small cell lung cancer (NSCLC) is still controversial. 
Some studies have shown promising results of neoadjuvant con-
current chemoradiotherapy (CCRT) followed by surgical resection 
in terms of survival benefit without increasing morbidity and mor-
tality. However, the role of adjuvant treatment after completion of 
neoadjuvant CCRT followed by surgery in N2 positive NSCLC pati-
ents has not defined yet.
Methods: From March 2006 to December 2011, 249 N2 positive 
NSCLC patients received neoadjuvant CCRT (weekly docetaxel/
cisplatin with 45Gy/25Fx of thoracic radiotherapy) followed by 
curative surgery. Patients who died with post-operative complica-
tions within a month after surgery (n=5) were excluded to minimize 
selection bias.
Results: Among 244 patients, 80 patients (32.8%) receieved ad-
juvant radiotherapy alone, 26 patients (10.7%) received adjuvant 
chemotherapy alone, 57 patients (23.4%) received both of adju-
vant radiotherapy/chemotherapy, and 80 patients (32.8%) did not 
receive adjuvant treatment. Survival was compared according to 
adjuvant treatment (any kind of adjuvant treatment [n=164, 67.2%] 
vs. no adjuvant treatment [n=80, 32.8%]). There was no significant 
differences between two groups in age over 60 years, ECOG per-
formance, initial T stage, initial multistation N2 disease, completion 
of neoadjuvant CCRT, R0 resection, and pathologic down staging 
of N2 disease. In the univariate analysis, median overall survival 
(OS) and progression-free survival (PFS) were 54.1 months vs. 37.9 
months (P=0.016) and 23.4 months vs. 17.7 months (P=0.239) in 
adjuvant treatment group and no adjuvant treatment group, res-
pectively. In subgroup analysis, adjuvant treatment group showed 
significantly better OS than no adjuvant treatment group in pati-
ents who achieved N2 down staging by neoadjuvant CCRT (n=146, 
59.8%) (78.1 months vs. 44.7 months, P=0.027) but not in patients 
who did not achieve pathologic N2 down staging (n=98, 40.2%) 
(32.3 months vs. 21.6 months, P=0.125).
Conclusion: This results suggest that adjuvant treatment may 
contribute survival benefit even after completion of neoadjuvant 
CCRT following curative surgery in N2 positive NSCLC. The role of 
adjuvant treatment should be seeked further in carefully selected 
patients who benefit most, such as CCRT sensitive patients who 
achieved pathologic N2 down staging.
Keywords: N2 positive non-small cell lung cancer, trimodality 
treatment, Adjuvant treatment, N2 down staging
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tropenic sepsis. The incidence of grade 3-4 oesophagitis or pneu-
monitis was < 10% and manageable. Detailed toxicity data will be 
presented in the full publication.
Conclusion: This regimen has produced encouraging results in a 
patient cohort with predominantly IIIB disease and with a signifi-
cant minority of poor PS=2 patients, with close to 90% being able 
to complete the treatment. The 17.2 month median OS achieved 
in this cohort is similar to that reported previously from larger ran-
domized phase III studies of ConCRT. Finally 11% of patients had 
pathological pCR, whist it appears that about 35% patients treated 
with this regime can achieve long-term survival.
Keyword: concurrent chemoradiation, advanced NSCLC
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P3.09-018 IFCT-0803 TRIAL: A PHASE II STUDY OF CETU-
XIMAB, PEMETREXED, CISPLATIN AND CONCURRENT 
RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVAN-
CED, UNRESECTABLE, STAGE III, NON SQUAMOUS, 
NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINA-
RY SAFETY ANALYSIS
Jean Tredaniel1, Francoise Mornex2, Fabrice Barlesi3, Cecile Le 
Pechoux4, Eric Pichon5, Delphine Lerouge6, Sylvestre Le Moulec7, 
Virginie Westeel8, Lionel Moreau9, Lidia Petit10, Sylvie Friard11, Lau-
rence Baudrin12, Marie Paule Lebitasy12, Gerard Zalcman13
1Pneumology, Hôpital Saint Joseph/France, 2Dept. Radiation Oncology, 
Centre Hospitalier Lyon-sud/France, 3Aix Marseille University – As-
sistance Publique Hôpitaux De Marseille/France, 4Radiotherapy Dept, 
Institut Gustave Roussy/France, 5Centre Hospitalier Universitaire/
France, 6Clcc Baclesse/France, 7Hia Val-de-grace/France, 8Centre Hospi-
talier Régional Universitaire/France, 9Centre Hospitalier/France, 10Chu/
France, 11Hôpital Foch/France, 12Ifct/France, 13Respiratory Diseases And 
Thoracic Oncology, Caen University Hospital/France
Background: Cisplatin-based chemotherapy and concurrent ra-
diotherapy are the standard treatments for locally advanced unre-
sectable NSCLC. New therapeutic combinations using molecular 
targeted drugs are needed. IFCT-0803 Trial is a phase II study 
evaluating the benefit of adding cetuximab to a combination of 
concomitant radio-chemotherapy with cisplatin and pemetrexed in 
patients with stage III, non-squamous NSCLC. Data on safety and 
tolerance during the first 16 weeks of treatment, available after the 
inclusion of the first 62 eligible patients, are presented.
Methods: Based on a two-stage Simon approach, 106 patients will 
be included in IFCT-0803 trial. An interim analysis of the first 34 
patients authorized the continuation of the study. Eligible patients 
receive conformal thoracic radiation with no elective nodal irradi-
ation (66 Gy in 33 fractions, ICRU) along with cisplatin (75 mg/m2) 
and pemetrexed (500 mg/m2) on day 1 administered intravenously 
every 21 days for four cycles; weekly cetuximab (400 mg/m2 for the 
first week, then 250 mg/m2) is added from the first week of thera-
py for a total of 12 doses. The primary objective is to assess the 
disease control rate at the 16th week, one month after treatment 
completion
Results: 62 patients were included (37 male, 56 years mean age), 
PS 0 = 39 and PS 1 = 23, ever smoker = 57, stage IIIA = 31 and IIIB 
= 31, adenocarcinoma = 50. Compliance for the first 62 patients 
included was as follows: Day 1 chemotherapy was administered 
33.3% [18.5-48.1]. Median overall survival was not reached; 1-year 
and 2-year survival rates were, 72.3% [CI 95%, 59.6-85.1] and 49.4% 
[CI 95%, 33.8-64.9], respectively.
Conclusion: This prospective phase II trial shows that the schedule 
of cisplatin plus oral vinorelbine concomitant with radiotherapy from 
2nd cycle obtains a good efficacy with an acceptable safety profile. 
Clinical trial information: EudraCT Number: 2009-010436-17
Keyword: cisplatin, vinorelbine, radiotherapy, non-small-cell lung 
cancer
POSTER SESSION 3 - COMBINED MODALITY  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.09-017 CONCURRENT CHEMORADIOTHERAPY (CON-
CRT) USING CISPLATIN-VINORELBINE IN LOCALLY AD-
VANCED (LA) NON-SMALL CELL LUNG CANCER (NSCLC)
Haris Charalambous1, Nicos Katodritis1, Demetrios Vomvas1, 
Michalis Maimaris2, Marios Decatris1
1Oncology, Boc Oncology Centre/Cyprus, 2Thoracic Surgery, Nicosia 
General Hospital/Cyprus
Background: ConCRT is considered to be the standard of care 
in LA NSCLC. We adopted ConCRT as our standard of care for 
appropriately selected patients since 2005. This is an analysis of a 
register of all patients consecutively assigned ConCRT since 2005 
(in an intent to treat analysis).
Methods: From Feb 2005 to Feb 2013 we assigned ConCRT for 
56 consecutive patients with LA NSCLC, who were deemed unre-
sectable; this included T4/N3/ “bulky” N2 disease or locally recur-
rent disease after initial surgery. Patients had ECOG performance 
status (PS) 0-2 and were treated with Cisplatin 75mg/m2 d1 and 
Vinorelbine 30mg/m2 d1-8, 3-weekly during the induction che-
motherapy phase (i.e. full doses for the first 1-2 cycles) whilst with 
the addition of radical RT delivered concurrently with subsequent 
chemotherapy cycles, Vinorelbine was reduced to 12.5mg/m2 d1-
8. After ensuring acceptable toxicity with the first 11 patients tre-
ated, subsequent patients received Vinorelbine at 15mg/m2 d1-8 
during ConCRT and the number of treatment cycles was escalated 
to a maximum of 6. Patients received definitive CRT (59.4-64.8 Gy) 
unless surgery was planned, in which case restaging evaluation for 
potentially resectable patients was performed at 45-50.4 Gy. PET 
staging was only available in a minority of these patients, since 
2011.
Results: 56 patients: 51 men and 5 women. Median age was 63 
(43-81); PS 0-1 n=47, PS 2 n=9. Radiological stage IIIB n=34 (61%), 
IIIA n=16 (29%), IIB n=6 (11%). Histology, squamous n=31, ade-
nocarcinoma n=13, unspecified/other NSCLC n=12. Treatment 
delivered: median 4 cycles of chemotherapy (range 1-6) delivered. 
50 patients (89%) completed ConCRT. Radiological response ra-
tes: Objective responses n=34 (29 partial, 5 complete) yielding a 
response rate of 61%; stable disease (SD) n=7; progressive disease 
(PD) n=7; of the remaining 8 non-evaluable patients, 6 patients did 
not complete ConCRT, either due to toxicity/death or disease pro-
gression. 7/50 patients who received ConCRT underwent surgery 
(5 lobectomies, 2 pneumonectomies). 6 of these 7 patients had 
a complete pathologic response (pCR) and 1 a near pCR. Kaplan 
Meier survival figures: median progression-free survival (PFS) 12.2 
months (95% C.I. 8.8-15.6) and median overall survival (OS) 17.2 
months (95% C.I. 11.8-22.6). There were 2 toxic deaths from neu-
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P3.10-001 TRANSGLUTAMINASE 2 CAN BE PREDICTIVE 
OF EPIDERMAL GROWTH FACTOR RECEPTOR TYRO-
SINE KINASE INHIBITOR EFFICACY AND CYTOTOXIC 
CHEMOTHERAPY SUCCESS IN NON-SMALL CELL LUNG 
CANCER
Jae-Heon Jeong1, Hyo Sup Shim2, Sun-Min Lim3, Se Kyu Kim3, Ky-
ung Young Chung4, Byoung Chul Cho3, Joo Hang Kim3
1Medical Oncology And Hematology, Kyung Hee University/Korea, 
2Department Of Pathology, Yonsei University College Of Medicine/
Korea, 3Department Of Internal Medicine, Yonsei University College Of 
Medicine/Korea, 4Department Of Thoracic And Cardiovascular Surgery, 
Yonsei University College Of Medicine/Korea
Background: Transglutaminase 2 (TG2), a cross-liNKIng enzyme, is 
involved in drug resistance and the constitutive activation of NF-
κB, a pro-inflammatory transcription factor. We investigated the 
association of the EGFR-TKI or cytotoxic chemotherapy clinical ef-
ficacy with transglutaminase 2 and NF-ĸB expression in non-small 
cell lung cancer (NSCLC).
Methods: TG2 and NF-ĸB expression was immunohistochemically 
studied in 120 patients with NSCLC who received an operation. 
Kaplan-Meier survival analysis and Cox regression analysis were 
used to estimate the effect of TG2 and NF-ĸB expression on che-
motherapy clinical efficacy.
Results: Median age of patients was 64 years (41–82). There were 
102 (85%) cases of adenocarcinoma and 18 patients (15%) had 
other histologies. Eight patients received adjuvant chemotherapy, 
29 received platinum-based doublet chemotherapy and another 
29 patients received EGFR-TKI. Smoking status was as follows: 
25 current, 16 former and 79 never. There were 55 patients with 
an EGFR mutation. TG2 median value was 50 (0 to 300) and NF-
kB median value was 20 (0 to 240). Response to platinum-based 
doublet was as follows: Overall response rate (ORR) was 13.8% 
and disease control rate (DCR) was 69% (Complete response (CR) 
0%, partial response (PR) 13.8%, stable disease (SD) 55.2% and 
progressive disease (PD) 24.1%). Responses to EGFR-TKI was as 
follows: ORR was 24.1% and DCR was 58.6% (CR 3.4%, PR 20.7%, 
SD 34.5% and PD 34.5%). Among the 88 patients who received 
adjuvant chemotherapy, disease-free survival (DFS) did not differ 
between the low and high TG2 groups. Among patients (n=29) 
who received palliative platinum-based doublet chemotherapy, 
progression free survival (PFS) was significantly longer in the low 
TG2 group when compared with the high TG2 group (34.0 versus 
15.0 months, p = 0.003). Among those who received EGFR-TKI 
(n=29) (first line 7, second line 18, third line 3, fourth line 1), PFS 
was significantly longer in the low TG2 group when compared with 
high TG 2 group (11.0 versus 2.0 months, p = 0.013). In patients 
with EGFR wild-type mutations treated with EGFR-TKI, progression 
free survival was longer in patients with low TG2 expression (9.0 vs 
2.0 months, p=0.013).
Conclusion: This study suggests that TG2 expression can be pre-
dictive of success of cytotoxic chemotherapy and EGFR-TKI for 
patients with non-small cell lung cancer, particularly in patients 
to 100% of patients on cycles 1 and 2, to 98.4% on cycle 3 and to 
96.6% on cycle 4. Radiotherapy protocol was respected: median 
was 33 for number of fractions, 66 Gy for total dose, 46 days for 
duration of treatment, 39 patients had a maximal toxicity of grade 
3 and 6 of grade 4. Table 1 lists the number of patients for the 
main categories of toxicity.  
n=62 grade 1/2 grade 3 grade 4
anemia 32 4 0
neutropenia 24 20 5
thrombocytopenia 30 4 2*
general toxicity 42 13 0
skin toxicity 51 9 0
digestive toxicity 
(nausea and vomiting)
42 6 0
esophageal toxicity 43 10 0
febrile neutropenia - 5 0
renal toxicity 4 3 0
neurologic toxicity 11 0 0
 
* :One patient died consecutively to a subdural hematoma caused 
by a fall, he had a grade 4 thrombocytopenia
Conclusion: IFCT-0803 trial is ongoing, the end of the inclusions is 
scheduled for October 2013. This combination therapy is feasible 
without any unexpected side effects.
Keywords: non-small cell lung cancer, chemoradiotherapy
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and 24% in the vinorelbine cohort). Nearly all (94%) of these pati-
ents received packed red blood cells. Nineteen percent of patients 
received ≥1 colony stimulating factor (CSF), which included G-CSF 
(69%), or erythropoietin (39%). During therapy, 82% of patients 
used antiemetics and antinauseants, 58% used steroids, 40% used 
analgesics, and 24% used antibiotics. Twenty-eight percent of 
patients received radiation during FLT and most often radiation 
was delivered concurrently with chemotherapy (66% overall, 66% in 
the pemetrexed cohort, 54% in the gemcitabine cohort, 68% in the 
taxanes cohort, and 73% in the vinorelbine cohort).
Conclusion: The FRAME study provides unique, real-life data re-
flecting prospectively collected information on resource use not 
accessible in a clinical trial setting. This study revealed several 
important findings regarding real-world resource use during NS-
CLC therapy including data on hospitalizations, outpatient visits, 
transfusions, concomitant treatments, and radiation.
Keywords: observational study, pemetrexed, resource use, NSCLC
POSTER SESSION 3 - CHEMOTHERAPY  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.10-003 A RANDOMIZED PHASE 2 TRIAL OF PEMET-
REXED (P) AND GEFITINIB (G) VERSUS G AS FIRST-LINE 
TREATMENT FOR PATIENTS WITH STAGE IV NON-SQUA-
MOUS (NS) NON-SMALL CELL LUNG CANCER (NSCLC) 
WITH ACTIVATING EPIDERMAL GROWTH FACTOR RE-
CEPTOR (EGFR) MUTATIONS
Tarun Puri1, Mauro Orlando2, Helen Barraclough3, Sotaro Enatsu4
1Eli Lilly And Company India Pvt. Ltd/India, 2Eli Lilly Interamérica Inc./
Argentina, 3Asia-pacific Statistical Sciences, Eli Lilly Australia Pty 
Limited/Australia, 4Eli Lilly Japan K.k./Japan
Background: G has been established as a standard first-line the-
rapy in patients with advanced NSCLC harboring activating EGFR 
mutations. Results from preclinical and clinical studies have shown 
synergistic cytotoxic effects of EGFR tyrosine kinase inhibitors and 
P, and that P is a key cytotoxic agent for NS NSCLC. Therefore, 
combination of P and G may offer benefits that exceed the inhibi-
tion of tumor progression with G monotherapy in patients with NS 
NSCLC harboring activating EGFR mutations.
Methods: This randomized, multicenter, open-label, parallel-arm, 
Phase 2 East-Asian study has been initiated to test the hypothesis 
that G + P will prolong progression-free survival (PFS) compared to 
G in patients with NS NSCLC with EGFR mutation. Eligible patients 
must have stage IV NS NSCLC, an Eastern Cooperative Oncology 
Group performance status (ECOG PS) of 0-1 and an activating 
EGFR mutation. Approximately 188 patients will be randomized in 
a 2:1 ratio (G+P:G) stratified by gender, ECOG PS and prior neo-/
adjuvant treatment. Study treatment will continue until progres-
sion, unacceptable toxicity or another discontinuation criterion is 
met. Patients in the G + P arm are required to take prophylactic 
folic acid and vitamin B12 supplementation as stated on the P label. 
With a one-sided significance level of 0.2, 145 events (objective 
disease progression/death) will provide 70% power, assuming a 
true hazard ratio of 0.79 (about 26% prolongation in PFS time). It is 
expected that 145 events will be observed if 188 pts are enrolled 
within an accrual period of 12 months and followed-up over 18 
months. The primary endpoint of PFS will be analyzed after 145 
events have been observed by using a multivariate Cox model. 
Secondary endpoints include time to progressive disease, overall 
with EGFR wild-type mutations.
Keyword: transglutaminase 2, NF-kB, lung cancer
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P3.10-002 RESOURCE UTILIZATION OF NSCLC PATIENTS 
RECEIVING PLATINUM-BASED THERAPIES ACROSS EU-
ROPE; RESULTS FROM THE FRAME OBSERVATIONAL 
STUDY
Denis Moro-Sibilot1, Javier D. Castro Carpeño2, Philipp Schnabel3, 
Krzysztof Lesniewski-Kmak4, Joachim Aerts5, Kees Kraaij6, Carla 
Visseren-Grul6, Karim Nacerddine7, Yulia D‘Yachkova8, Kaisa Tai-
pale9, Allicia Girvan10, Egbert Smit11
1Unité D’oncologie Thoracique–pneumologie/France, 2Hospital Universi-
tario La Paz/Spain, 3Sektion Thoraxpathologie, Pathologisches Institut/
Germany, 4Medical University Of Gda´nsk/Poland, 5Dept Of Pulmonolo-
gy, Erasmus Mc, Amphia Hospital/Netherlands, 6Eli Lilly And Compa-
ny/Netherlands, 7Eli Lilly And Company/France, 8Eli Lilly And Compa-
ny/Austria, 9Oy Eli Lilly/Finland, 10Eli Lilly And Company/United States 
Of America, 11VU Medical Centre/Netherlands
Background: FRAME was a non-interventional, prospective obser-
vational study of advanced or metastatic non-small cell lung cancer 
(NSCLC) patients initiating first-line treatment (FLT) with platinum-
based therapies in a routine practice setting across 11 European 
countries.
Methods: Patient enrollment occurred between April 2009 and 
February 2011. Consenting adults with Stage IIIB or IV NSCLC 
receiving platinum-based doublet chemotherapy with or without 
an additional targeted agent as FLT were eligible for this study. 
Patients were under routine treatment for NSCLC by their doctors 
and treatment choice and resource use were at the discretion of 
the treating physician. Secondary objectives of the study included 
determining resource use during FLT. Hospitalizations, outpatient 
visits, concomitant therapy use, transfusions and the use of colony 
stimulating factors (CSFs) are reported here. Cohorts were not 
adjusted for multivariate parameters prohibiting statistical compa-
risons.
Results: Evaluable patients (n=1564) were categorized into 4 main 
cohorts based on their FLTs: pemetrexed + platinum (n=569), 
gemcitabine + platinum (n=360), taxanes + platinum (n=295) or 
vinorelbine + platinum (n=300). Forty of the evaluable patients 
received other platinum-doublet treatments and were excluded 
from the analyses presented here.Across the four main cohorts, 
55% of patients were hospitalized.A majority (61%) of hospitaliza-
tions were preplanned (71% in the pemetrexed cohort, 45% in the 
gemcitabine cohort, 67% in the taxanes cohort and 53% in the 
vinorelbine cohort). Among the unplanned hospitalizations, 54% 
were related to an adverse event (54% in the pemetrexed cohort, 
54% in the gemcitabine cohort, 55% in the taxanes cohort, and 
55% in the vinorelbine cohort). The mean (95%-confidence interval) 
duration of hospitalizations was 13 days (11.6 to 14.6) for pemet-
rexed (median=9 days), 11 days (9.4 to 12.8) for gemcitabine (me-
dian=7 days),17 days (14.0 to 19.7) for taxanes (median=12 days), 
and 13 days (11.3 to 15.0) for vinorelbine (median=9 days). Nearly 
half of patients (47%) were seen in an outpatient setting with most 
outpatient visits (82%)planned for scheduled treatments. Nineteen 
percent of patients received ≥1 transfusion (16% in the pemetrexed 
cohort, 24% in the gemcitabine cohort, 15% in the taxanes cohort 
S1157Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
with dental problems were further referred to their family dentists.
Conclusion: Osteonecrosis of the jaw, in the present series, was 
the most common oral complication. The dental oncology expert 
within in the multidisciplinary team contributed to the diagnosis of 
oral pathoses and of the osteonecrosis at the early Stage 0.
Keywords: Lung cancer, oral complications, chemotherapy, treat-
ment and prevention
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P3.10-005 A PHASE II STUDY OF AMRUBICIN AND CAR-
BOPLATIN FOR PREVIOUSLY UNTREATED PATIENTS 
WITH EXTENSIVE-DISEASE SMALL CELL LUNG CANCER
Takaya Ikeda1, Hirokazu Taniguchi1, Hiroshi Soda1, Minoru Fu-
kuda2, Akihito Kinoshita3, Masaaki Fukuda4, Yoshifumi Soejima5, 
Daiki Ogawara6, Yoichi Nakamura6, Shigeru Kohno6
1Respiratory Medicine, Sasebo City General Hospital/Japan, 2The Japa-
nese Red Cross Nagasaki/Japan, 3Nagasaki Prefecture Shimabara Hos-
pital/Japan, 4National Hospital Organization Nagasaki Medical Center/
Japan, 5Ureshino Medical Center/Japan, 6Second Department Of Internal 
Medicine , Nagasaki University Hospital/Japan
Background: Amrubicin and cisplatin are active in the treatment 
of small cell lung cancer (SCLC), and carboplatin is an analogue 
of cisplatin with less nonh ematological toxicity. To determine the 
efficacy and toxicity of amrubicin and carboplatin for previously 
untreated patients with extensive-disease (ED) SCLC.
Methods: Patients and methods: Thirty-five patients fulfilling the 
following eligibility criteria were enrolled: chemotherapy-naive, 
good performance status (PS 0-1), age < 76, extensive-disease, 
and adequate organ function. Based on the phase I study (J Tho-
rac Oncol 4:741, 2009), the patients received amrubicin35mg/m2 
i.v. on days 1,2 and 3, and carboplatin AUC 5 i.v. on day 1. Four 
cycles of chemotherapy were repeated every 3 weeks.
Results: Thirty-five patients we re eligible and 34 patients were 
assessable for response, toxicity and surviva l. Patients’ charac-
teristics were as follows: male/female=27/8; PS 0/1=4/31; median 
age(range)=64(41-75); stage IV=35. The overall response was 81% 
(CR5, P R21, SD4, PD2, NE3). Grade 4 leukopenia, neutropenia, 
and thrombocytopenia occ urred in 11%, 60%, and 11%, respec-
tively. There were no treatment-related deat h and pneumonitis. 
Three patients experienced hypotension for amrubicin infusi on 
reaction and two were terminated the study. The median overall 
survival tim e, and the 1-, 2- and 3-year survival rates were 15.6 
months, 63%, 33% and 8%, respectively. The median progression-
free survival time was 6.5 months.
Conclusion: Amrubicin and carboplatin was effective in untreated 
extensive-disease small cell lung cancer.
Keywords: Extensive-Disease Small Cell Lung Cancer, amrubicin, 
chemotherapy, Carboplatin
survival (OS), overall response rate, disease control rate, duration 
of response, biomarkers and treatment-emergent adverse events. 
To ensure mature OS data, the criteria to end the study will be the 
earlier of 130 OS events or 30 months from the last patient entered 
treatment milestone. Enrollment started in early 2012. The trial is 
sponsored by Eli Lilly and Company (NCT01469000).
Results: Not Applicable.
Conclusion: Not Applicable.
Keywords: non-squamous non-small cell lung cancer, EGFR muta-
tion, clinical trial, pemetrexed
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P3.10-004 JAW OSTEONECROSIS IN LUNG CANCER PA-
TIENTS: A RETROSPECTIVE ANALYSIS
Konstantinos N. Syrigos, Fotis Psarros, Elias Karampelas, Korina 
Lymberopoulou, I Zontanos, Maria Kiayia, Sofia Tsagkouli, Ioannis 
Gkiozos
Oncology Unit Gpp, Sotiria General Hospital/Greece
Background: Lung cancer patients may develop oral complica-
tions related to conventional chemotherapy or targeted and anti-
resorptive agents. Early diagnosis of those complications, within 
a multidisciplinary team, can lead to effective treatment and the 
maintenance of patient’s quality of life. The aim of the current 
study is to present our 4-year experience (2009-2012) in the treat-
ment and prevention of oral complications in lung cancer patients.
Methods: Forty three patients (21 women, 22 men, mean age 
62.6 years) were included in the analysis. Thirty patients received 
active chemotherapy treatment; 9/30 (30%) received conventional 
chemotherapy in combination with targeted therapy, 11/30 (36.7%) 
targeted therapy and 10/30 (33.3%) conventional chemotherapy. 
Twenty-one patients received i.v. bisphosphonates (zoledronate 
76.2%). Eleven patients received bishosphonates combined with 
bevacizumab; 4 of them had interrupted bevacizumab at the time 
of referral. Oral clinical and radiographic evaluation, using periapi-
cal and panoramic x-rays were performed. Dental scan was perfor-
med in 2 patients. Oral hygiene instructions were introduced and 
patients were educated about the importance of the maintenance 
of optimal oral health.
Results: Thirty three patients were referred by their medical onco-
logist (25 patients, 58.1%, by the SOTIRIA Hospital), 1 was referred 
by his dentist and 10 were self referred. Twelve patients (27.9%) 
presented with jaw osteonecrosis (Stage 0: 6, 50%, Stage I: 4, 
33.3%, Stage II: 2, 16.7%); of those 4 received bevacizumab con-
currently with zoledronic acid, 2 received the same combination in 
the past, 5 received zoledronate alone and 1 received zoledronate 
followed by denosumab. Six patients were diagnosed with oral 
candidiasis, 4 with herpes infection, and 2 with necrotizing ulcera-
tive gingivitis. Nine patients had dental problems, while 5 patients 
were introduced to the Unit for preventive measures. Jaw osteone-
crosis was treated with long term antibiotics, while local ozone oil 
was applied in 3 patients. Three dental extractions were perfor-
med in one patient with osteonecrosis stage 0. Today, 6 patients 
with osteonecrosis remain in partial remission, 3 are in complete 
remission, 2 were lost of follow up and 1 worsened. Of the 3 dental 
extractions, 2 healed and one led to osteonecrosis stage I. Patients 
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P3.10-007 AVASTIN® FOR ADVANCED OR RECURRENT 
NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: A 
NESTED CASE CONTROL STUDY EXPLORING RISK FAC-
TORS FOR HEMOPTYSIS IN JAPAN
Koichi Goto1, Nobuyuki Yamamoto2, Yuichiro Ohe1, Masahiko Kus-
moto3, Masahiro Endo4, Yui Toratani5, Masahiro Fukuoka6
1Division Of Thoracic Oncology, National Cancer Center Hospital East/
Japan, 23rd Department Of Medicine, Wakayama Medical University/
Japan, 3Department Of Diagnostic Radiology, National Cancer Center 
Hospital/Japan, 4Department Of Diagnostic Radiology, Shizuoka Cancer 
Center/Japan, 5Chugai Pharmaceutical Co., Ltd./Japan, 6Cancer Center, 
Izumi Municipal Hospital/Japan
Background: A nested case control (NCC) study was conducted 
to assess the incidence of hemoptysis (Grade 2 cases that used an 
injectable hemostatic or Grade 3+ cases) and to explore risk fac-
tors for hemoptysis in patients receiving Avastin® (bevacizumab) in 
real-life-practice in Japan.
Methods: From November 2009 to August 2011 patients inten-
ding to use bevacizumab were pre-enrolled, and we calculated 
incidence of hemoptysis in the 6774 patients actually receiving 
bevacizumab. Excluding one patient of unspecified age, we se-
lected a control group from the 6773 patients by matching each 
patient who developed hemoptysis (cases) to four patients who did 
not (controls) by sex and age. We selected 92 controls for the 23 
cases and performed conditional logistic regression analysis of a 
total 113 patients (23 cases and 90 controls) to investigate risk fac-
tors for hemoptysis. A third party including radiologists performed 
blind assessment of imaging characteristics for the 104 patients 
with evaluable baseline computerized tomography images.
Results: In the 6774 patients receiving bevacizumab, incidence of 
hemoptysis was 0.33%. To perform conditional logistic regression 
analysis of the 113 patients in the case control study, we included 
the following factors in the model: smoking history, stage (7th 
ed.), PS (baseline), present metastasis, previous lung disease, 
concurrent lung disease, previous thoracic radiotherapy, conco-
mitant drugs (anticoagulant, aspirin preparation, non-steroidal 
anti-inflammatory drug, antiplatelet drug), concomitant thoracic 
radiotherapy, treatment line, macrovascular (arterial) invasion, and 
central airway tumor exposure extending to segmental bronchus. 
Analysis using the stepwise method identified presence of previ-
ous thoracic radiotherapy (odds ratio [OR], 2.76; 95% confidence 
interval [CI], 0.61–12.43), concomitant thoracic radiotherapy (OR, 
6.19; 95% CI, 0.63–60.47), and central airway tumor exposure ex-
tending to segmental bronchus (OR, 5.29; 95% CI, 1.22–22.89).
Conclusion: At 0.33%, the incidence of hemoptysis in this study 
was low, and three risk factors were identified. Because this was a 
case control study in patients receiving Avastin, these risks cannot 
necessarily be attributed to Avastin treatment, and further study of 
safety risks is needed.
Keywords: hemoptysis, Bevacizumab, case control study, risk fac-
tor
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P3.10-006 POST-PROGRESSION SURVIVAL AFTER 
TREATMENT WITH EPIDERMAL GROWTH FACTOR RE-
CEPTOR-TYROSINE KINASE INHIBITOR FOR ADVANCED 
NON-SMALL CELL LUNG CANCER PATIENTS HARBO-
RING EPIDERMAL GROWTH FACTOR RECEPTOR MUTA-
TIONS
Yoshihito Kogure, Yuko Ise, Yasushi Murakami, Kazumi Hori, 
Masashi Nakahata, Saori Oka, Misaki Ryuge, Masatoshi Tokojima, 
Chiyoe Kitagawa, Masahide Oki, Hideo Saka
Department Of Respiratory Medicine, Nagoya Medical Center/Japan
Background: Non-small cell lung cancer (NSCLC) patients harbo-
ring the epidermal growth factor receptor (EGFR) mutation show 
a survival benefit on treatment with EGFR-tyrosine kinase inhibitor 
(EGFR-TKI); however, few studies report on post-progression tumor 
behavior after treatment with EGFR-TKI. We investigated the post-
progression clinical course after treatment with EGFR-TKI in NS-
CLC patients harboring the EGFR mutation. We also evaluated the 
correlation between the site of relapse after EGFR-TKI treatment 
and prognosis.
Methods: We retrospectively reviewed clinical data of stage IV 
or recurrent NSCLC patients harboring the EGFR mutation, who 
received EGFR-TKI as first-line treatment in our institute from 2009 
to 2011.
Results: Thirty-six patients received EGFR-TKI as first-line therapy. 
Thirty of these patients with recurrent NSCLC were enrolled in this 
study. The median age of the patients was76 years (range, 38–97), 
and the male/female ratio was 4/26. The median progression-free 
survival (PFS) after EGFR-TKI treatment was 8.2months and the 
median overall survival (OS) was 20.4months. Sites of relapse in 
patients with progressive disease (PD) were the brain, pleural effu-
sion, bone, and lung (n=5, 13, 6, and 8, respectively). Twenty-one 
patients received sequential therapy: 11 patients received con-
tinued EGFR-TKI treatment beyond PD and 10 patients received 
second-line therapy. Second-line therapies were platinum-based 
doublet therapy, monotherapy, and another cycle of EGFR-TKI (n = 
6, 2, and 2 patients, respectively). Post-progression survival (PPS) 
of all the patients after treatment with EGFR-TKI was 9.2 months, 
whereas that of patients who received second-line therapy was 14 
months. Subgroup analysis according to the site of relapse showed 
that after first-line EGFR-TKI treatment, PFS tended to be higher 
for patients with a relapse in the brain (11.6 months) than for pati-
ents with sites of relapse other than the brain (8.2 months).
Conclusion: PPS of all the patients after treatment with EGFR-TKI 
was 9.2 months, whereas that of patients who received second-line 
therapy was 14 months. Subgroup analysis showed that patients 
with a relapse in the brain might survive longer.
Keywords: post-progressison survival, EGFR-TKI, NSCLC, EGFR 
mutation
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P3.10-009 PHASE II STUDY OF BEVACIZUMAB IN COM-
BINATION WITH CARBOPLATIN PLUS PACLITAXEL AS 
FIRST-LINE CHEMOTHERAPY FOR NON-SQUAMOUS 
NON-SMALL CELL LUNG CANCER WITH MALIGNANT 
PLEURAL EFFUSION
Akihiro Tamiya1, Motohiro Tamiya2, Tadahiro Yamadori2, Tomo-
mi Yasue3, Keiko Nakao1, Takayuki Shiroyama2, Kazuhiro Asami1, 
Naoko Morishita2, Hidekazu Suzuki2, Norio Okamoto2, Kyoichi 
Okishio4, Tomoya Kawaguchi1, Tomonori Hirashima2, Shinji Atagi4
1Internal Medicine, Kinki-chuo Chest Medical Center/Japan, 2Thoracic 
Malignancy, Osaka Prefectural Hospital Organization Osaka Prefectural 
Medical Center For Respiratory And Allergic Diseases/Japan, 3Clinical 
Laboratory, Osaka Prefectural Hospital Organization Osaka Prefectural 
Medical Center For Respiratory And Allergic Diseases/Japan, 4Clinical 
Research, Kinki-chuo Chest Medical Center, Sakai/Japan
Background: Vascular endothelial growth factor (VEGF) plays an 
important role in non small cell lung cancer (NSCLC) with malig-
nant pleural effusion (MPE), but there are little evidence regarding 
the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) 
for treatment of NSCLC with MPE. Therefore, we prospectively 
evaluated the efficacy and safety of Bev and CP in non-squamous 
(SQ) NSCLC patients with MPE.Vascular endothelial growth fac-
tor (VEGF) plays an important role in non small cell lung cancer 
(NSCLC) with malignant pleural effusion (MPE), but there are little 
evidence regarding the efficacy of bevacizumab (Bev) with carbo-
platin-paclitaxel (CP) for treatment of NSCLC with MPE. Therefore, 
we prospectively evaluated the efficacy and safety of Bev and CP 
in non-squamous (SQ) NSCLC patients with MPE.
Methods: Chemotherapy-naive non-SQ NSCLC patients with MPE 
were eligible to participate. Pleurodesis before chemotherapy was 
not allowed. In the first cycle, the treated patients received only CP 
to prevent Bev-induced wound healing delayed after chest draina-
ge. Subsequently, they received 2–6 cycles of CP with Bev. Patients 
who completed more than 4 cycles of CP and Bev without disease 
progression or severe toxicities continued to receive Bev alone as 
a maintenance therapy. The primary endpoint was overall respon-
se, although an increase in MPE was allowed in the first cycle. The 
VEGF levels in plasma and MPE were measured at baseline and the 
VEGF levels in plasma were measured after 3 cycles of chemothe-
rapy.
Results: Between September 2010 and June 2012, 23 patients 
were enrolled. The overall response rate was 60.8%, the disease 
control rate was 87.0%, and one patient was not evaluated respon-
se because of sudden death after 1 cycle treatment. Sixteen pati-
ents received maintenance therapy, following a median of 3 cycles. 
The median progression-free survival and the median overall 
survival were 7.1 months (95% CI, 5.6 - 9.4 months) and 11.7 months 
(95% CI, 7.4 – 16.6 months). Almost all patients experienced severe 
hematological toxicities, including ≥ grade 3 neutropenia. And 
there was no patient who experienced severe bleeding events. 
The median baseline VEGF levels in MPE was 1798.6 (range; 223.4 
- 35,633.4) pg/mL. The VEGF levels in plasma showed a significant 
decrease after 3 chemotherapy cycles (baseline; 513.6 ± 326.4 pg/
mL, post chemotherapy; 25.1 ± 14.1 pg/mL, p < 0.01), regardless of 
efficacy of CP with Bev.
Conclusion: The combination of CP with Bev was confirmed to 
be effective and tolerable in chemotherapy-naïve non-SQ NSCLC 
patients with MPE.
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P3.10-008 A PHASE I STUDY EVALUATING THE CON-
TINUATION OF GEFITINIB BEYOND PROGRESSIVE DI-
SEASE FOLLOWED BY THE ADDITION OF DOCETAXEL
Satoshi Watanabe1, Junta Tanaka2, Ko Sato2, Yu Saida2, Masaaki 
Okajima2, Rie Kondo2, Satoru Miura2, Hiroshi Kagamu2, Masato 
Makino3, Kazuhiko Ito3, Akira Iwashima3, Kazuhiro Sato3, Akira 
Yokoyama3, Hirohisa Yoshizawa1
1Bioscience Medical Research Center, Niigata Universiy Medical And 
Dental Hospital/Japan, 2Department Of Medicine (ii), Niigata Universi-
ty Medical And Dental Hospital/Japan, 3Niigata Lung Cancer Treatment 
Group/Japan
Background: Despite the high disease control rate in EGFR-
mutated patients, gefitinib treatment is not curative and eventually 
there is disease progression. Recent studies report that disconti-
nuation of EGFR-TKIs result in rapid disease progression in NSCLC 
patients who had developed acquired resistance. These findings 
suggest that patients with acquired resistance could have sensitive 
and resistant tumor clones to EGFR-TKIs. We designed a phase I 
trial to assess the safety and efficacy of docetaxel combined with 
gefitinib in NSCLC patients who acquired resistance.
Methods: Patients with metastatic NSCLC who had responded to 
gefitinib treatment and then developed progressive disease were 
treated with docetaxel in combination with the continuation of 
gefitinib. Docetaxel was administered on day 1 of 21-day cycle and 
escalated from 50 to 70 mg/m2. Gefitinib was given at a fixed dose 
of 250mg/day. Dose limiting toxicities (DLT) were assessed after 
the first cycle, and doses were escalated in 3 to 6 patient cohorts.
Results: Fourteen patients were treated at doses of 50 (n=4), 60 
(n=5) and 70 mg/m2 (n=5). All 14 patients were evaluable for safety 
and efficacy. At a docetaxel dose of 60 mg/m2, 1 patient experi-
enced a DLT (grade 4 neutropenia for 4 days), and at a dose of 70 
mg/m2 1 patient experienced a DLT (grade 4 neutropenia for 4 
days and febrile neutropenia). Because all 5 patients treated at a 
docetaxel dose of 70 mg/m2 had grade 4 neutropenia, this dose 
level was determined to be the maximum-tolerated dose. The 
overall response rate was 43%, median progression free survival 
was 183 days (95% CI, 157 to 215 days), and median overall survival 
was 575 days (95% CI, 220 to 816 days). At the recommended dose 
of 60 mg/m2, the overall response rate was 40%.
Conclusion: Recommended dose of docetaxel is 60 mg/m2 in 
combination with gefitinib. This combination was well tolerated 
and demonstrated activity in NSCLC patients with acquired resis-
tance to gefitinib.
Keywords: gefitinib, docetaxel, beyond PD, NSCLC
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P3.10-011 WHICH DO PATIENTS PREFER AS A FIRST-
LINE THERAPY, EGFR-TKI OR CHEMOTHERAPY, IF THEY 
HAVE NSCLC HARBORING EGFR MUTATION? A VIGNET-
TES STUDY (LOGIK0903).
Noriyuki Ebi1, Takayuki Suetsugu2, Minoru Fukuda3, Nobuhiko 
Nagata4, Koichi Takayama5, Nobuko Tsuruta6, Masayuki Ishida7, 
Chinatsu Nishida8, Kosuke Kashiwabara9, Shinji Akamine10, Kazu-
toshi Komiya11, Noriaki Nakagaki12, Hiroto Kishi13, Shoji Tokuna-
ga14, Jiichiro Sasaki15, Yukito Ichinose16
1Respiratory Medicine, Iizuka Hospital/Japan, 2Respiratory Medicine, 
Sendai Medical Association Hospital/Japan, 3Respiratory Disease, 
Japanese Red Cross Nagasaki Genbaku Hospital/Japan, 4Respiratory 
Medicine, Fukuoka University Chikushi Hospital/Japan, 5Research Insti-
tute For Diseases Of The Chest, Kyushu University/Japan, 6Respiratory 
Diseases, Hamanomachi General Hospital/Japan, 7Clinical Medicine, 
Institute Of Tropical Medicine, Nagasaki University/Japan, 8Respiratory 
Medicine, University Of Occupational And Environmental Health/Japan, 
9Respiratory Medicine, National Hospital Organization Kumamoto Me-
dical Center/Japan, 10Chest Surgery, Oita Prefectural Hospital/Japan, 
11Hematology, Respiratory Medicine And Oncology, Faculty Of Medicine, 
Saga University/Japan, 12Respiratory Disease, National Hospital Orga-
nization Fukuoka-higashi Medical Center/Japan, 13Respiratory Medicine, 
Kumamoto City Hospital/Japan, 14Medical Information Center, Kyushu 
University Hospital/Japan, 15Respiratory Medicine, Kitasato University 
School Of Medicine/Japan, 16Clinical Research Institute, National Kyus-
hu Cancer Center/Japan
Background: Treatment decision-making is associated with poten-
tial decisional conflict of patients. Aim of this study was to deter-
mine the preferences of advanced NSCLC patients for EGFR-TKI or 
chemotherapy as first-line therapy if they were in the situation of 
having a lung cancer harboring EGFR mutation, and to investigate 
the variables considered important to that preference.
Methods: Three vignettes were designed to assess the patients’, 
the physicians’ or medical staff members’ preferences for treat-
ment decision-making and the reasons classified into five category 
such as “evidence level”, “type of drug administration”, “thera-
peutic efficacy”, “adverse events”, and “influence to ordinary life” 
behind the decision. HADS, FACT-L and characteristics of partici-
pants including gender, age, and performance status (PS) are also 
investigated in this analysis.
Results: Total 377 individuals containing 100 patients, 100 phy-
sicians, and 177 medical staff members were analyzed in this 
study, and 322 participants (85.4%) preferred to EGFR-TKI than 
chemotherapy as a first-line therapy. Preference rate of EGFR-TKI 
in patients was statistically significantly lower than those in physi-
cians and medical staffs, 73%, 88% and 91%, respectively. Among 
the reasons we investigated, “therapeutic efficacy” was the only 
marginal significant reason for preference in patients (odds ratio: 
3.88, p=0.06). In addition to “therapeutic efficacy”, “type of drug 
administration” and “influence to ordinary life” was the significant 
reasons for their preference in physicians (odds ratio: 11.57, 22.57 
and 20.5, respectively). In pre-planned analysis, we found the dif-
ference of value between the patients and the physicians in “influ-
ence to ordinary life”.
Conclusion: If the patients have an advanced lung cancer with 
EGFR mutation, they may prefer EGFR-TKI as a first-line therapy to 
chemotherapy as well as physicians and medical staff members. 
However the reasons of those preferences among them may be 
Keywords: non-small cell lung cancer, Bevacizumab, VEGF, malig-
nant pleural effusion
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P3.10-010 A STUDY OF PEMETREXED MONOTHERAPY 
IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG 
CANCER WITH IMPAIRED RENAL FUNCTION
Norihiko Funaguchi, Yasushi Ohno, Daizo Kaito, Komei Yanase, 
Fumitaka Ito, JuNKI Endo, Fumihiko Kamiya, Megumi Morishita, 
Masahiro Asano, Shinya Minatoguchi
Second Department Of Internal Medicine, Regeneration And Advanced 
Medical Science, Graduate School Of Medicine, Gifu University/Japan
Background: Pemetrexed (Alimta) plasma clearance positively 
correlated with glomerular filtration rate (GFR), resulting in incre-
ased drug exposures in patients with impaired renal function. In 
US Food and drug administration guidances, pemetrexed is not 
recommended for patients with a creatinine clearance (CrCl) less 
than 45 mL/min. Insufficient numbers of patients have been stu-
died with creatinine clearance < 45 mL/min to give a dose recom-
mendation. Here, we investigated the toxicity and effectiveness of 
pemetrexed in patients with impaired renal function.
Methods: Patients with nonsquamous non-small cell lung cancer 
who received chemotherapy with pemetrexed as a single-agent, 
were divided into two groups of CrCl<45 mL/min and ≥45 mL/min, 
and were analyzed retrospectively, between May 2009 and May 
2012. Patients received a 10-minute infusion of 375 to 500mg/m2 
of pemetrexed every 3 weeks. Estimated CrCl was calculated using 
Cockcroft-Gault formula.
Results: Twenty-seven patients were ascessed in this study, 10 
patients with a CrCl < 45 mL/min and 17 patients with a CrCl ≥ 45 
mL/min. The rate of grade 3/4 neutropenia was higher in patients 
with a CrCl < 45 mL/min than ≥ 45 mL/min. There were no febrile 
neutropenia and treatment related death. Nonhematologic toxici-
ties included fatigue, diarrhea, and nausea, did not correlate with 
renal function. Stable disease was observed in 6 patients (60%) 
in CrCl < 45 mL/min group, and in 12 (70%) in CrCl ≥ 45 mL/min 
group.
Conclusion: Although the risk of grade 3/4 neutropenia was higher 
in patients with impaired renal function (CrCl < 45mL/min) than 
maintained renal function (CrCl ≥ 45 mL/min), treatment with pe-
metrexed should be considered dose reduction in patients with 
impaired renal function.
Keywords: NSCLC, impaired renal function, pemetrexed
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Conclusion: The recommended dose for this combination in future 
study is docetaxel 50 mg/m2 and bevacizumab 15mg/kg.
Keyword: non-small cell carcinoma
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P3.10-013 OPEN-LABEL, RANDOMIZED MULTICENTRE, 
PHASE II TRIAL OF ORAL VINORELBINE (NVBO) OR 
INTRAVENOUS VINORELBINE (NVBIV) WITH CISPLA-
TIN (CDDP) IN PATIENTS (PTS) WITH ADVANCED NON 
SMALL CELL LUNG CANCER (NSCLC): A CHINESE EXPE-
RIENCE (CA225 STUDY)
Li Zhang1, Chang Jianhua2, Cheng Huang3, Jie Wang4, Shu Yongqi-
an5, Yiping Zhang6, Jean-Philippe Burillon7, Nathalie Vaissière7, 
Marcello Riggi7
1Department Of Medical Oncology, Sun Yat-Sen University Cancer 
Center/China, 2Fudan University Cancer Hospital/China, 3Fujian Pro-
vincial Tumor Hospital/China, 4Beijing Cancer Hospital/China, 5Jiangsu 
Provincial People‘s Hospitall/China, 6Zhejiang Cancer Hospital/China, 
7Institut De Recherche Pierre Fabre/France
Background: Aim of the study: to evaluate efficacy (CR, PR) of the 
two formulations with CDDP in advanced NSCLC. Secondary ob-
jectives were progression-free survival (PFS), overall survival (OS) 
and safety.
Methods: NVBo, 60 mg/m² (Arm A) and NVBiv, 25 mg/m² (Arm 
B) were delivered on D1, D8, repeated every 3 weeks. Doses were 
increased at cycle 2 (NVBo 80 mg/m2, NVBiv 30 mg/m2) according 
to hematological tolerance. CDDP doses were 80 mg/m2 D1 every 
3 weeks in both arms. Pts received a maximum of 4 cycles in ab-
sence of progression.
Results: Between 1/2008 and 6/2009, 132 pts were randomized 
at 6 investigational centres (cut-off date for final analysis: August, 
31st 2012 - Arm A 67 pts, Arm B 65 pts). One patient in Arm A was 
not treated. Among the 131 pts analyzed by an independent panel 
review, PR was 25.8% (95% CI [15.8-38.0]) in Arm A and 23.1% (95% 
CI [13.5-35.2]) in Arm B, and disease control (PR+SD) 72.7% (95% 
CI [60.4-83.0]) in Arm A and 72.3% (95% CI [59.8-82.8]) in Arm B. 
PFS (months) was 6.2 [3.8-7.7] for Arm A and 6.2 [4.9-7.8] for Arm 
B. One Year Survival was 59% and 61.6 in Arm A and Arm B, res-
pectively, Two Years Survival: 39% Arm A, 38.7% Arm B, and 30 
months Survival 29.2% Arm A, 26.9% Arm B. Median dose intensity 
(DI): NVBo 44.7 mg/m²/week, NVBiv 15.6 mg/m²/week. Relative 
dose intensity (RDI): NVBo 89.3%, NVBiv 81.5%. The CDDP median 
DI was 24.6 mg/m2/week in Arm A and 24.5 mg/m2/week in Arm 
B, with a RDI of 92.1% and 91.6% respectively. Grade 3/4 neutro-
penia: 29 pts and 43 cycles Arm A, 56 pts and 106 cycles Arm B. 
Febrile neutropenia : 4 (6.1%) pts Arm A, 6 (9.2%) pts Arm B. Grade 
3 anaemia : 6 (9.1%) pts and 10 cycles Arm A, 13 pts (20%) and 18 
cycles Arm B, with grade 4 anaemia in 3 (4.6%) pts and 5 cycles 
only in arm B. The most frequent non hematological disorders 
were nausea (8 pts Grade 3 - 12.1% Arm A; 6 pts Grade 3 - 9.2% 
Arm B) and vomiting (10 pts Grade 3 - 15.2%, 1 pt Grade 4 - 1.5% 
Arm A; 9 pts Grade 3 - 13.8%, 1 pt Grade 4 - 1.5% Arm B). Diarrhea 
was reported in 15 (22.7%) and 9 (13.8%) pts in Arm A and Arm B, 
respectively.
Conclusion: Both arms testing NVBo and NVBiv with CDDP repor-
ted similar efficacy results in term of Response Rate, PFS and OS, 
different. We should consider continuation of patients’ ordinary life 
when we discuss about treatment decision-making with patients.
Keywords: chemotherapy, Vignettes study, treatment decision-
making, EGFR-TKI
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P3.10-012 FEASIBILITY STUDY OF DOCETAXEL AND 
BEVACIZUMAB IN ELDERLY PATIENTS WITH ADVANCED 
NONSQUAMOUS NON-SMALL CELL LUNG CANCER: 
THORACIC ONCOLOGY RESEARCH GROUP (TORG) 
1014.
Makiko Yomota1, Yukio Hosomi1, Yusuke Takagi1, Fumihiro Os-
hita2, Kouzo Yamada2, Naoya Hida3, Hiroaki Okamoto3, Nobuhiko 
Seki4, Kouichi Minato5, Hideo Kunitoh6, Satoshi Morita7, Masahiko 
Shibuya1, Koshiro Watanabe8
1Department Of Thoracic Oncology And Respiratory Medicine, Tokyo 
Metropolitan Cancer And Infectious Diseases Center Komagome Hos-
pital/Japan, 2Kanagawa Cancer Center/Japan, 3Yokohama Municipal 
Citizen‘s Hospital/Japan, 4Division Of Medical Oncology, Department Of 
Internal Medicine, Teikyo University School Of Medicine/Japan, 5Pulmo-
nary Medicine, Gunma Prefectural Cancer Center/Japan, 6Respiratory 
Medicine, Mitsui Memorial Hospital/Japan, 7Yokohama City Univer-
sity Graduate School Of Medicin/Japan, 8Thoracic Oncology Research 
Group/Japan
Background: A series of Japanese trials indicate docetaxel (DTX) 
monotherapy is a standard of care in elderly patients with advan-
ced non-small cell lung cancer (NSCLC), and that the addition 
of platinum does not significantly improve the outcomes. Beva-
cizumab (BEV) has been shown to be beneficial when added to 
standard platinum-doublet chemotherapy in good-risk NSCLC 
patients. BEV toxicity is a major concern for elderly patients.
Methods: Patients with chemotherapy-naïve advanced non-squa-
mous NSCLC who were >70 year old with performance status (PS) 
0/1 and adequate organ function were enrolled. Eligible patients 
received DTX 60 (Level 0) or 50 (Level -1) mg/m2 and BEV 15 mg/
kg on day 1, every 3 weeks. Toxicity was the primary endpoint and 
secondary endpoints were response rate, progression free survival 
(PFS), overall survival (OS), and completion rate of the 3 cycles of 
treatment. The planned sample size was 12 to 24, with at least 6 
subjects treated at each level.
Results: Between December 2010 and September 2012, 21 elderly 
patients (9 in level 0 and 12 in level -1) were enrolled in the study 
(median age, 75 years; 43% male; 90% adenocarcinoma; 67% PS 1). 
Two of the 9 patients in level 0 had a dose limiting toxicities (DLTs). 
After 9 patients enrolled on level 0, two severe adverse events 
were reported. One patient had grade 4 sepsis in cycle 4 and 
another patient had grade 4 sepsis in cycle 5. We decided to stop 
enrollment to level 0 and reduce dose to level -1. Two of 12 pati-
ents in dose level -1 experienced DLTs. Grade 3 or 4 of toxicities 
among all patients were neutropenia (86%), anemia (5%), hyperten-
sion (19%), anorexia (10%), and increased aminotransferase levels 
(10%). Three out of 9 patients in level 0 achieved partial response 
(PR) and 3 out of 11 assessable patients in level -1 obtained PR. 
Completion rates of the 3 cycles of treatment were 78% (7/9) in 
level 0 and 67 % (8/12) in level -1. The median PFS and OS were 5.4 
and 11.1 months, respectively.
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P3.10-015 FINAL ANALYSIS OF DOSE ESCALATION STU-
DY OF CARBOPLATIN PLUS PEMETREXED FOLLOWED 
BY MAINTENANCE PEMETREXED FOR ELDERLY PATI-
ENTS (≥75 YEARS OLD) WITH ADVANCED NON-SQUA-
MOUS NON-SMALL CELL LUNG CANCER
Motohiro Tamiya1, Akihiro Tamiya2, Takayuki Shiroyama1, Masa-
ki Kanazu2, Aya Hirooka2, Taisuke Tsuji2, Naoko Morishita1, Kazu-
hiro Asami2, Hidekazu Suzuki1, Norio Okamoto1, Kyoichi Okishio3, 
Tomoya Kawaguchi2, Tomonori Hirashima1, Shinji Atagi3, Ichiro 
Kawase1
1Thoracic Malignancy, Osaka Prefectural Hospital Organization Osaka 
Prefectural Medical Center For Respiratory And Allergic Diseases/Ja-
pan, 2Internal Medicine, Kinki-chuo Chest Medical Center/Japan, 3Clini-
cal Research, Kinki-chuo Chest Medical Center, Sakai/Japan
Background: This study was designed to determine the recom-
mended dose of carboplatin plus pemetrexed in elderly (≥75 years 
old), chemotherapy-naive patients with advanced non-squamous 
non-small cell lung cancer (NSCLC).Patients and methods: Patients 
received escalated doses of carboplatin and pemetrexed every 3 
weeks for 4 cycles. Patients with an objective response and stable 
disease continued pemetrexed therapy until disease progression 
or unacceptable toxicity was observed.
Methods: Patients received escalated doses of carboplatin area 
under the concentration–time curve (AUC) of 4 (cohort 0) or 5 (co-
hort 1) or 6 (cohort 2) and pemetrexed 500mg/m2 every 3 weeks 
for 4 cycles. Patients with an objective response and stable disease 
continued pemetrexed therapy until disease progression or unac-
ceptable toxicity was observed.
Results: In cohort 0, a dose-limiting toxicity (DLT) was not ob-
served in three patients, and no DLTs were seen in the first three 
patients of cohort 1. In cohort 2, DLTs were observed in three of 
the seven patients: two of grade 4 thrombocytopenia and one of 
grade 3 febrile neutropenia. And in additional cohort 1, no DLTs 
were seen in the next four patients. Therefore, the combination of 
carboplatin at an area under the concentration–time curve (AUC) 
of 5, plus 500 mg/m2 pemetrexed, was determined to be the re-
commended dose for elderly patients (≥75 years old) with advan-
ced non-squamous NSCLC. Of a total of 17 patients, 10 received 
a median of 5 cycles of pemetrexed maintenance therapy without 
unexpected or cumulative toxicities. No complete responses and 
8 partial responses were observed, and the study had an overall 
response rate of 47.1%. The median progression-free survival time 
was 5.5 monthes (95% confidence interval [CI], 2.4–8.9 monthes) 
and the median overall survival time was 12.6 monthes (95% CI, 
7.4–17.9 monthes) in he final analysis of this study.
coupled with an optimal safety profile. NVBo is a step forward in 
the treatment of NSCLC since it optimises treatment convenience 
thanks to its oral formulation while maintaining a high level of effi-
cacy.
Keyword: Non Small Cell Lung Cancer, Advanced disease, Oral 
vinorelbine, chemotherapy
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P3.10-014 EFFICACY AND SAFETY OF DOCETAXEL PLUS 
OXALIPLATIN AS A FIRST-LINE CHEMOTHERAPY IN PA-
TIENTS WITH ADVANCED OR METASTATIC NON-SMALL-
CELL LUNG CANCER
Young-Chul Kim, Heejung Ban, Kyu-Sik Kim, In-Jae Oh, Kook-Joo 
Na, Sung-Ja Ahn, Sang-Yun Song, Yoo-Duk Choi, Seong-Hoon 
Yoon, Boram Lee, Jinyeong Yu
Lung Cancer Clinic, Chonnam National University Hwasun Hospital/
Korea
Background: Platinum doublets are standard first-line treatment 
of stage IV non-small-cell lung cancer (NSCLC) without targetable 
driver mutations such as EGFR or ALK. Oxaliplatin is known to be 
more potent than cisplatin, requiring fewer DNA adducts to provi-
de equivalent cytotoxicity. The objective of this study is to evaluate 
the efficacy and safety of oxaliplatin combined with docetaxel as a 
first line treatment of stage IV NSCLC.
Methods: This is prospective, single-center, phase II trial. Patients 
with chemotherapy-naive NSCLC received docetaxel 60mg/㎡ (day 
1) and oxaliplatin 70mg/㎡ (day 2) every 3 weeks for up to 6 cycles. 
The primary endpoint was objective response rate (ORR) and the 
secondary endpoints were progression-free survival (PFS), overall 
survival (OS) and safety. Treatment response was evaluated accor-
ding to RECIST version 1.1.
Results: Thirty three patients were enrolled and response evalua-
tion is available in 30 patients at the present time. There were 10 
partial responses, 16 stable diseases. ORR was 33.3% and disease 
control rate was 86.7%. Median PFS was 127 days (95% confidence 
interval, 59~195) and median OS was 394 days (95% confidence 
interval, 264~524). Grade 3-4 toxicities occurred in 45% of pati-
ents, and the most common hematologic toxicity was neutropenia. 
There were two cases of hyperglycemia and sepsis.
Conclusion: This study suggests that the combination of oxalipla-
tin and docetaxel is effective in patients with NSCLC, with reasona-
ble toxicities. (ClinicalTrials.gov Identifier: NCT01243775)
Keywords: non-small-cell lung cancer, docetaxel, Oxaliplatin
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surgery or those with postoperative recurrence, 3) patients having 
received 2 or fewer prior regimens of chemotherapy (at least one 
regimen being platinum-based), 4) patients with no history of 
treatment with EGFR-TKI and drugs of the fluoropyridimine family. 
This combination chemotherapy consisted of two 3-week cycles of 
S-1 treatment and once daily erlotinib at a dose of 150 mg/body. 
In phase I study, the initial dose of S-1 was 60 mg/m2/day, and 3 
patients were registered for each level of S-1 treatment. In phase II 
study, S-1 at recommended dose and erlotinib were administered 
similarly to the phase I study.
Results: In phase I study, seven patients (one man and 6 women) 
with a median age of 66 years (range: 52-70 years) were enrolled. 
All patients had ECOG PS of 0-1, six patients had adenocarcino-
mas, and one had large cell carcinoma. All patients were at clinical 
stage IV. No patient had grade 2 or more neutropenia, and each 
1 had grade 2 leukocytepenia, anemia, mucositis, general fatigue, 
skin rash, and diarrhea; however, none experienced DLT. The RD 
for the phase II study was determined as 80 mg/m2 S-1 and 150 
mg/m2 erlotinib. The phase II study was conducted in 10 patients, 
9 men and 1 woman, with a median age of 60.5 years (range 
42–75). PS was 0 in 2, 1 in 6, and 2 in 2 patients. The histological 
subtype was adenocarcinoma in 5 patients, squamous-cell car-
cinoma in 4, and others in 1. One patient had grade 3 diarrhea, 
grade 4 colitis, and grade 4 septic shock, and the other had grade 
4 dehydration and acute respiratory failure which resulted in two 
treatment-related deaths. With these findings, the trial was closed 
to additional enrollment.
Conclusion: Erlotinib(150mg) and S-1(80 mg/m2 for 14 days every 
21 days) therapy seemed to be toxic for pretreated patients with 
EGFR-wt NSCLC patients.
Keywords: erlotinib, S-1, non-small cell lung cancer, EGFR gene 
mutation wild type
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P3.10-017 THE ROLE OF CYTOKERATIN FRAGMENT 
ANTIGEN 21-1 ( CYFRA21-1 ) AS A PREDICTIVE MARKER 
FOR THE PATIENTS WITH NON-SMALL-CELL LUNG CAN-
CER TREATED WITH PEMETREXED
Hiroyuki Minemura1, Hiroshi Yokouchi1, Ken-Ichiro Hirai1, Satoko 
Sekine1, Kengo Oshima1, Kenya Kanazawa1, Takashi Ishida2, Yos-
hinori Tanino1, Mitsuru Munakata1
1Department Of Pulmonary Medicine, Fukushima Medical University/
Japan, 2Department Of Pulmonary Medicine, Clinical Oncology Center, 
Fukushima Medical University Hospital/Japan
Background: Pemetrexed plays an important role in the treatment 
of advanced non-small-cell lung cancer (NSCLC). The expression 
of thymidylate synthase in NSCLC has been reported to be a pre-
dictive marker for patients treated with pemetrexed; however, no 
practical marker has been established except for histopathological 
features. Thus we attempted to select a practical predictive marker 
for pemetrexed treatment from clinical characteristics.
Methods: We retrospectively reviewed the charts of patients with 
advanced non-squamous NSCLC treated with pemetrexed in our 
hospital from January 2009 to December 2012. We investigated 
clinical variables such as smoking history, gender, clinical stage, se-
rum tumor marker levels at the diagnosis (CEA, CYFRA21-1, ICTP, 
Conclusion: 
This combination was a tolerable and effective regimen, and re-
commended dose was carboplatin (AUC of 5) / pemetrexed (500 
mg/m2) every 3 weeks, in chemotherapy-naïve, elderly (≥75 years 
old) patients with advanced non-squamous NSCLC.
Keywords: elderly, maintenance therapy, non-small cell lung can-
cer, carboplatin pemetrexed
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P3.10-016 A PHASE I/II STUDY OF COMBINATION CHE-
MOTHERAPY WITH ERLOTINIB AND S-1 IN PRETREATED 
NON-SMALL CELL LUNG CANCER (NSCLC): THORACIC 
ONCOLOGY RESEARCH GROUP (TORG) 0808/0913
Naoyuki Nogami1, Toshiyuki Kozuki1, Naoya Hida2, Yukio Hoso-
mi2, Nobuhiko Seki2, Hiroaki Okamoto2, Kenji Eguchi2, Masahiko 
Shibuya2, Satoshi Morita2, Tetsu Shinkai2, Koshiro Watanabe2
1Thoracic Oncology, National Hospital Organization Shikoku Cancer 
Center/Japan, 2Thoracic Oncology Reseach Group/Japan
Background: In BR.21 Study, erlotinib was shown to significantly 
prolong OS, PFS and the time to progression of NSCLC-associated 
symptoms. The study reported that the RR was 7% for EGFR-wt 
cases but the MST was longer than placebo. S-1 is a fourth-genera-
tion oral fluoropyrimidine that contains tegafur, a prodrug of 5-flu-
orouracil (5-FU). The consecutive administration of S-1 at 80 mg/
m2/day was well tolerated. The objective RR and MST were 22.0% 
and 10.2 months. Regarding the EGFR-TKI and 5-FU-based che-
motherapy, EGFR-TKI has been shown in basic studies to reduce 
the expression of thymidilate synthase, the target enzyme for the 
5-FU-based chemotherapy, at the protein and mRNA levels, and 
synergistic effects of gefitinib used in combination with S-1 have 
been reported in basic study. Thus, we conducted a phase I study 
to find the maximum tolerated doses of erlotinib/ S-1 combination 
therapy, and a phase II study to evaluate the efficacy and toxicity 
of this combination strategy as a 2nd/3rd-line therapy for recur-
rent/advanced NSCLC in the absence of EGFR gene mutations.
Methods: Eligibility criterias were as follows: 1) patients with his-
tologically or cytologically diagnosed NSCLC, 2) patients at clini-
cal stage IIIB or IV not indicated for radical radiotherapy/radical 
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ents were composed of 3 negative, 34 unknown, and 46 positive 
patients with EGFR mutations. The median follow-up time was 7 
months, ranging 1 to 141 months. The median OS was 34 months 
in all patients (n=83) and 43 months in the patients with EGFR mu-
tation in exon19 or exon21 (n=44). The median PFS was 11 months 
in the former and 19 months in the latter.
Results: As previously reported, the factors such as female (hazard 
ratio [HR] 0.46, 95% confidence interval [CI] 0.26 to 0.81, P=0.007) 
or smoker (HR 2.55, 95%CI 1.46 to 4.47, P=0.001) influenced PFS in 
all patients. However, they did not in the patients with EGFR muta-
tion. As for the administration timing of the gefitinib, the later star-
ting date of its administration (HR 0.97, 95%CI 0.94 to 1.00, P=0.02) 
slightly improved the OS in all patients, which might be influenced 
by other factors, because the later therapy line (HR 1.55, 95%CI 
1.17 to 2.05, P=0.002) worsened PFS. Its administration timing did 
not significantly influence OS or PFS in the patients with EGFR mu-
tations. As for the dosage of gefitinb, the increase of body surface 
area significantly influenced PFS in the all patients (HR 7.12, 95%CI 
1.05 to 49.1, P=0.045). Paradoxically, the prolonged administration 
intervals improved OS (HR 0.39, 95%CI 0.20 to 0.76, P=0.006) and 
PFS (HR 0.35, 95%CI 0.19 to 0.65, P=0.001) in all patients and PFS 
(HR 0.34, 95%CI 0.14 to 0.83, P=0.018) in the patients with EGFR 
mutations.
Conclusion: In summary, the administration timing did not influ-
ence OS or PFS in the patients with EGFR mutations. Moreover, the 
alternate-day administration might not decrease the effect on the 
patients with EGFR mutations. Given the adverse effects, the pro-
vision of appropriate dosage is required for these patients.
Keywords: gefitinib, NSCLC, EGFR mutation, dosage
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P3.10-019 ORAL S-1 AND CARBOPLATIN FOLLOWED BY 
MAINTENANCE S-1 FOR CHEMO-NAIVE PATIENTS WITH 
ADVANCED SQUAMOUS CELL LUNG CANCER (OSAKA-
LCSG 1102)
Takayuki Shiroyama1, Takashi Yokoi2, Kiyoshi Komuta3, Suguru 
Yamamoto3, Seigo Minami3, Tomonori Hirashima1, Yoshinobu 
Namba4, Osamu Morimura5, Ichiro Kawase1, Takashi Kijima5
1Department Of Thoracic Malignancy, Osaka Prefectural Hospital Orga-
nization Osaka Prefectural Medical Center For Respiratory And Allergic 
Diseases/Japan, 2First Department Of Internal Medicine, Kansai Me-
dical University Hirakata Hospital/Japan, 3Department Of Respiratory 
Medicine, Osaka Police Hospital/Japan, 4Department Of Thoracic On-
cology, Nho National Toneyama Hospital/Japan, 5Department Of Res-
piratory Medicine, Allergy And Rheumatic Diseases, Osaka University 
Graduate School Of Medicine/Japan
Background: The subset analysis of LETS study suggested that 
S-1 plus carboplatin was more beneficial than paclitaxel plus car-
boplatin in overall survival (OS) in squamous cell lung cancer. We 
previously showed the validity of tailored dose S-1 adjusted by 
BSA and Ccr. No maintenance study focusing on squamous cell 
lung cancer has been reported yet. Here, we conducted a phase II 
study to evaluate the efficacy and safety of tailored dose S-1 plus 
carboplatin followed by S-1 maintenance in chemonaïve patients 
with advanced and recurrent squamous cell lung cancer.
Methods: Patients receive carboplatin (AUC = 5, day1) plus S-1 
and SLX), and epidermal growth factor receptor (EGFR) mutation 
status. The relationships between those variables and the patients 
survival or response to pemetrexed were evaluated.
Results: We identified 60 patients, 37 male, and the average age 
was 65 (range, 22-83) years. There were 59 patients with adenocar-
cinoma. The clinical stages were; IIIA/IIIB/IV = 3/3/54 (UICC TNM 
ver.7). Pemetrexed with platinum (cisplatin or carboplatin) was 
administered to 46 patients (bevacizumab was concurrently em-
ployed in 5 patients) and 14 patients underwent pemetrexed mo-
notherapy. When the serum CYFRA21-1 cut-off level was set at 2.1 
ng/ml, the patients with low serum levels had a significantly longer 
progression free survival (PFS) than those with high serum levels 
(130 versus 263 median days; p=0.038). There was no significant 
difference in overall response rate and overall survival between the 
two groups.
Conclusion: High serum levels of CYFRA21-1 might reflect the 
higher degree of biological characteristics of squamous cell carci-
noma in a tissue; therefore they could be used to identify the indi-
viduals with short PFS among patients treated with pemetrexed. 
Serum levels of CYFRA21-1 may become a predictive marker for 
advanced NSCLC patients treated with pemetrexed.
Keywords: pemetrexed, CYFRA21-1, NSCLC
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P3.10-018 AN ADMINISTRATION TIMING AND DOSAGE 
OF THE GEFITINIB IN THE ADVANCED NON-SMALL-
CELL LUNG CANCER PATIENTS WITH EPIDERMAL 
GROWTH FACTOR RECEPTOR MUTATION
Sakae Fujimoto1, Yosuke Miura1, Tsutomu Yoshida2, Atsushi Fuji-
ta2, Kouichi Minato1
1Pulmonary Medicine, Gunma Prefectural Cancer Center/Japan, 2Thora-
cic Surgery, Gunma Prefectural Cancer Center/Japan
Background: In the patients who had locally advanced or metasta-
tic non-small-cell lung cancer with epidermal growth factor recep-
tor (EGFR) mutation, progression-free survival (PFS) was prolonged 
by first line therapy of gefitinib than those of chemotherapy. How-
ever, overall survival (OS) was not prolonged due to the crossover 
administration of tyrosine kinase inhibitor. In such patients, the 
administration timing of gefitinib becomes a clinically interesting 
issue. Moreover, it is unknown whether effect of gefitinib was at-
tenuated or not by alternate-day administration for the adverse 
effects such as exanthema, 
diarrhea, and liver function disorder. The suitable dosage of gefiti-
nib to the 
patients with EGFR mutation is thought to be actually unidentified, 
because of the setting dosage before proving the EGFR mutation. 
Therefore, we retrospectively analyzed the population of patients 
receiving gefitinib at our hospital to solve these questions and exa-
mine the prognostic factors in the patients with EGFR mutations.  
Methods: Eighty three patients (median age 66 years, 51 females), 
except ten patients with combined chemotherapy, have begun to 
be received gefitinib in our hospital between January 1, 2007 and 
December 31, 2012. These data were collected at May 31, 2013 
and analyzed using Cox proportion hazard model with covariance 
which may influence OS and PFS of gefitinib therapy. These pati-
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We performed the growth inhibition assay for NSCLC cell lines and 
made two-dimension isobolograms to estimate the synergy of the 
combination. The combination of amrubicin and erlotinib had sig-
nificant synergistic effect on EGFR wild type NSCLC cell line A549, 
and additive effect on EGFR mutant cell line PC-9. We conducted 
a phase I trial of this combination. The aim was to determine the 
maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs) 
and pharmacokinetics of this combination in patients with non-
small cell lung cancer (NSCLC) who had previous chemotherapy.
Methods: Nine patients with stage IV disease were treated at 
3-week intervals with erlotinib once daily on days 1-21 plus amrubi-
cin 5-min intravenous injection on days 1-3.
Results: The dose levels evaluated were erlotinib (mg/day)/am-
rubicin (mg/m2): 100/30 (n = 3), 100/35 (n = 3) and 150/30 (n = 3). 
The MTD of erlotinib and amrubicin was 100 mg/day and 35 mg/
m2 since two of the three patients experienced DLTs during the 
first cycle of treatment at the third dose level of 150 mg/day and 
30 mg/m2. Cessation of erlotinib administration for 8 days due to 
grade 3 leukopenia and grade 3 skin infection (erysipelas) were 
the DLTs. No drug-drug interactions between erlotinib and amru-
bicin were observed in this study. The overall response rate was 
33%, including three partial responses, in the nine patients. The 
median progression-free survival for all patients was extraordinary 
long 11.3 months, and the median overall survival has not yet been 
reached.
Conclusion: Combined erlotinib plus amrubicin therapy seems to 
be highly effective, with acceptable toxicity, against NSCLC. The 
recommended dose for phase II studies was erlotinib 100 mg once 
daily on days 1-21, and amrubicin 35 mg/m2 on days 1-3 administe-
red every 21 days.
Keywords: amrubicin, phase I study, non-small cell lung cancer, 
erlotinib
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P3.10-021 PHASE II MULTICENTER TRIAL OF ERLOTINIB 
FOR ADVANCED NON-SMALL-CELL LUNG CANCER 
WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTA-
TIONS
Kazutoshi Isobe1, Sakae Homma1, Kazuhisa Takahashi2, Ryo Ko-
yama2, Kiyoshi Mori3, Takashi Kasai3, Shigeru Tominaga4, Kenji 
Kido5, Hisashi Takaya6, Kazuma Kishi6
1Department Of Respiratory Medicine, Toho University Omori Medical 
Center/Japan, 2Division Of Respiratory Medicine, Juntendo University 
Hospital/Japan, 3Department Of Medical Oncology, Tochigi Cancer 
Center/Japan, 4Division Of Respiratory Medicine, Juntendo University 
Urayasu Hospital/Japan, 5Division Of Respiratory Medicine, Juntendo 
University Nerima Hospital/Japan, 6Department Of Respiratory Medici-
ne, Respiratory Center, Toranomon Hospital/Japan
Background: Erlotinib is effective for non-small-cell lung cancer 
(NSCLC) with epidermal growth factor receptor (EGFR) mutations 
and also recommended in NCCN guidelines. However, there has 
been a few study done on second-line therapy in NSCLC with 
EGFR mutations in Japan. The aim of this phase II study was to 
evaluate the efficacy and safety of erlotinib therapy as second-line 
treatment in EGFR-mutated NSCLC who was previously treated 
with platinum doublet.
(tailored dose b.i.d., days 1-14) every 21 days. Non-progressive pa-
tients after 4 cycles of induction continued to receive S-1 until di-
sease progression or unacceptable toxicity. The primary endpoint 
was objective response rate (ORR) with a threshold value of 15%. 
The secondary endpoints were progression-free survival (PFS) and 
OS from enrollment, PFS in maintenance phase, and safety.
Results: Between April 2011 and October 2012, 35 patients were 
enrolled. Thirty-three patients excluding 2 patients with protocol 
violations were analyzed. The median age was 72 years (range, 
44-82), The ORR was 30.3% (95% CI: 15.6-48.7%) that met the pri-
mary endpoint. Disease control rate was 75.8%, and 10 patients 
(30.3%) received maintenance therapy. The median PFS was 3.7 
months. The median OS and maintenance PFS are under follow-
up. 10 patients received maintenance S-1 (median: 3 cycles, range: 
1-9 cycles); median PFS from the beginning of induction treatment 
was 5.6 months. Grade 3/4 toxicities with the frequency more than 
5% included 4 neutropenia (12.1%), 7 thrombocytopenia (21.2%), 2 
anemia (6.1%), 4 appetite loss (12.1%), 2 nausea (6.1%) and 2 fatigue 
(6.1%). All of them were controllable and febrile neutropenia was 
not experienced.
Conclusion: This is the first trial of S-1 plus carboplatin followed by 
maintenance S-1 for chemo-naïve advanced and recurrent squa-
mous cell lung cancer. This treatment strategy was effective and 
feasible.
Keyword: lung cancer, maintenance therapy, S-1, squamous cell 
carcinoma
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P3.10-020 PHASE I AND PHARMACOKINETIC STUDY 
OF ERLOTINIB ADMINISTERED IN COMBINATION WITH 
AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED, 
ADVANCED NON-SMALL CELL LUNG CANCER
Sakiko Otani1, Akinobu Hamada2, Jiichiro Sasaki1, Michiko Yama-
moto1, Shinichiro Ryuge1, Akira Takakura1, Tomoya Fukui1, Ma-
sanori Yokoba3, Hisashi Mitsufuji1, Issei Toyooka4, Sachiyo Maki1, 
Masaru Kubota1, Masato Katagiri3, Hideyuki Saito4, Noriyuki Ma-
suda1
1Respiratory Medicine, Kitasato University/Japan, 2Division Of Inte-
grative Omics And Bioinformatics, National Cancer Center Research 
Institute/Japan, 3Department Of Clinical Physiology, Kitasato Universi-
ty School Of Allied Health Sciences/Japan, 4Department Of Pharmacy, 
Kumamoto University Hospital/Japan
Background: Standard second-line chemotherapy against advan-
ced non-small-cell lung cancer (NSCLC) is a single agent such as 
docetaxel, pemetrexed, or erlotinib. The response rate of each 
agent as second-line setting are from 10% to 15% in Japanese 
NSCLC without EGFR mutation. Amrubicin, a totally synthetic 
9-aminoanthracycline, is active as second-line chemotherapy for 
advanced NSCLC. The reported response rate to amrubicin as 
second-line treatment for advanced NSCLC is 11.5%. Erlotinib is an 
orally active reversible inhibitor of epidermal growth factor recep-
tor tyrosine kinase activity (EGFR-TKI), which induces rapid tumor 
shrinkage if the tumor harbors EGFR activated mutation. Erlotinib 
is also effective for NSCLC without EGFR mutation, but the res-
ponse rate is around 8%. We considered it worthwhile to explore 
if a doublet regimen consisting of amrubicin and erlotinib may 
provide therapeutic benefit and have a favorable toxicity profile. 
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nephropathy (3.0%). One patient had tracheoesophageal fistula.
Conclusion: The efficacy of regimens in which bevacizumab was 
included was similar. The combined therapy of bevacizumab plus 
pemetrexed as a maintenance therapy significantly improved the 
overall progression free survival compared to therapy with bevaci-
zumab alone.
Keywords: maintenance therapy, retrospective study, Bevaci-
zumab-based therapy
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P3.10-023 PHASE II STUDY OF PEMETREXED + CAR-
BOPLATIN AS FIRST LINE THERAPY FOR ADVANCED 
NON-SQUAMOUS NON-SMALL CELL LUNG CANCER 
WITHOUT EGFR MUTATION. : CENTRAL JAPAN LUNG 
STUDY GROUP (CJLSG) 0906 TRIAL
Tomoki Kimura1, Hiroyuki Taniguchi1, Hideo Saka2, Yousuke Yu-
kita3, Eiji Kojima4, Tomohiko Ogasawara5, Masashi Yamamoto6, 
Masashi Kondo7, Ryujiro Suzuki8, Kazuyoshi Imaizumi9, Takuya 
Ikeda10, Fumio Nomura11, Yoshimasa Tanikawa12, Hiroshi Saito13
1Tosei General Hospital/Japan, 2National Hospital Organization, Nago-
ya Medical Center/Japan, 3Ogaki Municipal Hospital/Japan, 4Komaki 
Municipal Hospital/Japan, 5Japanese Red Cross Nagoya Daini Hospital/
Japan, 6Nagoya Ekisaikai Hospital/Japan, 7Nagoya University Graduate 
School Of Medicine/Japan, 8Toyohashi Municipal Hospital/Japan, 9Fujita 
Health University/Japan, 10Yokkaichi Municipal Hospital/Japan, 11Japa-
nese Red Cross Nagoya Daiichi Hospital/Japan, 12Toyota Kosei Hospital/
Japan, 13Aichi Cancer Center Aichi Hospital/Japan
Background: In advanced non-squamous non-small cell lung 
cancer (NSCLC), epidermal growth factor receptor (EGFR) status 
is important to determine the treatment. However, many previous 
studies of NSCLC were investigated regardless of EGFR mutation 
status. Therefore, we thought that the trial only for EGFR wild-type 
(WT) patients (pts) is required. We evaluated the efficacy and safe-
ty of combination therapy with pemetrexed (Pem) and carboplatin 
(Cb) for advanced non-squamous NSCLC EGFR-WT pts.
Methods: This study was multicenter, phase II trial. We recruited 
non-Sq NSCLC patients without EGFR mutation. Eligibility criteria 
were as follows; stage IIIB or IV, or recurrent disease after surgery 
(rec), no prior chemotherapy, age 20 to 74, ECOG PS: 0-1, and ade-
quate organ function. We evaluated the efficacy and safety of Pem 
500mg/m2 and Cb AUC 6 on day1, every 3 weeks, for 3 to 6 cyc-
les. The primary endpoint was response rate (RR) and secondary 
endpoints were safety and disease control rate (DCR). We planned 
the sample size was 48 patients and recruited 54 pts. (Unique trial 
Number; UMIN000003393)
Results: From March 2009 to February 2012, 54 pts were enrolled 
from 18 centers. Of 53 evaluable for analysis, the median age was 
65 years (range, 45–73); 41/12 males/females; 6/44/3 with IIIB/IV/
rec; 47/3/3 with adenocarcinoma/large cell carcinoma/NSCLC. The 
median number of cycles was 4 (range, 1–6). There were 19 partial 
responses with an RR of 35.8% (95% CI, 23.6–51.0%). SD was ob-
served in 20 pts and DCR was 73.6%. Median PFS was 5.2 months 
and median OS was 12.months. Major adverse event was grade 
3–4 neutropenia in 19 pts (35.8%), anemia in 16 pts (30.2%), throm-
bocytopenia in 17 pts (32.1%). There was no treatment-related 
death.
Methods: NSCLC patients with EGFR mutations (exon19 or 21) who 
were treated with platinum doublet previously as first-line therapy 
were treated with daily erlotinib (150mg/ day). The primary end-
point in this phase II study was response rate (RR), and the secon-
dary endpoints were progression-free survival time (PFS), overall 
survival time (OS), and safety.
Results: From August 2009 to February 2012, 31 NSCLC patients 
were eligible in this phase II study. The patient’s demographics 
were a median age of 65 years (range 50-75 years), 21 men and 
10 women, 30 adenocarcinomas and 1 other type of cancer, 9 
never-smokers and 22 former smokers, PS (ECOG) were 0 in 15, 1 
in 14, 2 in 2 patients, exon19 mutation in 15 and exon21 mutation 
in 16, respectively. Total RR of erlotinib treatment was 61.3%. The 
disease control rate was 93.5%. Median PFS was 308 days and OS 
was not reached. Toxicities such as acne, rush and diarrhea were 
less than Grade 2. Treatment-related death caused by pneumonitis 
in one patient.
Conclusion: Erlotinib therapy as second-line treatment in EGFR-
mutated NSCLC patients who were treated with platinum doublet 
previously was effective with an acceptable toxicity profile.
Keywords: erlotinib, non-small-cell lung cancer, EGFR mutation, 
second-line treatment
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P3.10-022 EFFICACY AND SAFETY OF BEVACIZUMAB-
BASED THERAPY IN ADVANCED NON-SQUAMOUS 
NON SMALL CELL LUNG CANCER : A RETROSPECTIVE 
STUDY.
Kentaro Ito1, Osamu Hataji1, Masahiro Naito1, Fumiaki Watanabe1, 
Motoshi Takao2, Esteban C. Gabazza3, Osamu Taguchi3
1Respiratory Center, Matsusaka Municipal Hospital/Japan, 2Thorasic 
And Cardiovascular Surgery, Mie University Graduate School Of Me-
dicine/Japan, 3Pulmonary And Critical Care Medicine, Mie University 
Graduate School Of Medicine/Japan
Background: Bevacizumab (BEV) improves clinical response in 
patients with advanced NSCLC when it is used in combination with 
platinum-based chemotherapy. This study assesses the efficacy of 
bevacizumab as a maintenance therapy.
Methods: We retrospectively reviewed 67 patients with NS-NSCLC 
that were treated with bevacizumab (15mg/kg) in combination with 
any standard chemotherapy at Matsusaka Municipal Hospital (Ja-
pan) from November, 2009 through December, 2011. The therapy 
with bevacizumab was continued till the occurrence of disease 
progression or unacceptable toxicity; 45 patients received bevaci-
zumab as a maintenance therapy. Survival was evaluated using the 
Kaplan-Meier curve.
Results: The median overall survival was 24.9 months, progression 
free survival was 7.0 months, and the overall response rate was 
70.5%. No significant differences in overall survival or progression 
survival were found among regimens in which bevacizumab was 
used. As a maintenance therapy, the median progression survival 
was 6.0 months in the bevacizumab alone group and 9.9 months in 
the bevacizumab plus pemetrexed group (P=0.012). Grade 3/4 ad-
verse events included neutropenia (44.8%), thrombopenia (9.0%), 
hypertension (14.9%), anorexia (4.5%), hepatopathy (4.5%), and 
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8) severe drug allergy, 9) receiving anticoagulant drug (except as-
pirin under 325mg/day), 10) active GI bleeding or inflammation in 
the abdominal cavity, 11) pregnancy or lactation, 12) patients who-
se participation in the trial is judged to be inappropriate by the 
attending doctor. Primary endpoint was RR. Secondary endpoint 
included safety, disease control rate, overall survival, PFS. (Unique 
trial Number; UMIN000003737)
Results: not applicable.
Conclusion: not applicable.
Keywords: pemetrexed, Carboplatin, Bevacizumab, EGFR  
mutation
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P3.10-025 TAXANE-PLATINUM INDUCTION CHEMOTHE-
RAPY IN LOCOREGIONALLY ADVANCED NON-SMALL-
CELL LUNG CANCER: OUTCOMES AND PROGNOSTIC 
FACTORS
Hee Yeon Lee1, Woo Hee Choi2, Eun Kyung Jeon1, Sook Hee Hong1, 
Jae Kil Park3, Young Pil Wang3, Sook Whan Sung3, Young Kyoon 
Kim1, Seung Joon Kim1, Hoon K. Kim4, Jin Hyoung Kang1
1Department Of Internal Medicine, Seoul St.mary‘s Hospital/Korea, 
2Nuclear Medicine, St. Vincent’s Hospital, Catholic University Of Korea/
Korea, 3Thoracic And Cardiovascular Department, Seoul St. Mary‘s 
Hospital/Korea, 4St. Vincent‘s Hospital, Department Of Internal Medi-
cine/Korea
Background: Induction chemotherapy (IC) in locoregionally advan-
ced non-small-cell lung cancer (LA-NSCLC) has shown survival bene-
fit. This retrospective study aimed to assess clinical outcomes and to 
identify prognostic factors in the LA-NSCLC patients who received 
taxane-platinum IC (TP-IC).
Methods: We reviewed medical charts, imaging studies, and pa-
thologic reports in 51 LA-NSCLC pts who were treated with TP-IC 
between January 2003 and June 2012 at Seoul St. Mary’s Hospital 
and St. Vincent’s Hospital.
Results: Mean age at diagnosis was 63.1 years (range, 43-77). Forty-
two pts (82.4%) were male. ECOG performance status was 0 in 17 
pts (33.3%) and 1 in 34 (66.7%). Histology was squamous cell in 30 
pts (58.8%), adenocarcinoma in 20 (39.2%), and large cell in 1. Thirty-
four pts (66.7%) had stage IIIA disease, 13 (25.5%) IIIB and 4 (7.8%) 
IIB. All pts were treated with docetaxel 75 mg/m2 or paclitaxel 175 
mg/m2, and cisplatin 75 mg/m2 or carboplatin AUC 5 on day 1 every 
3 weeks. Forty-four pts (86.3%) received docetaxel-cisplatin IC, 4 
(7.8%) docetaxel-carboplatin, and 3 (15.7%) paclitaxel-cisplatin. The 
median number of IC cycles was 3 (range, 2-4). Mean relative dose 
intensity was 90.4% (±10.8) and RDI ≥90% was achieved in 31 pts 
(60.8%). During TP-IC, asthenia (88.1%), anorexia (89.1%), neutro-
penia (84.4%), alopecia (80.4%), nausea (71.7%) and myalgia (57.1%) 
were frequent. Most common grade 3/4 toxicity was neutropenia 
(80%) and febrile neutropenia occurred in 3 pts (5.9%). All toxicities 
were manageable with supportive care with no treatment-related 
death. Tumor response was assessed according to the RECIST and 
PERCIST criteria. According to RECIST, 3 pts (5.9%) achieved com-
plete responses (CR), 32 (62.7%) partial responses (PR), 14 (27.5%) 
stable diseases (SD), and 2 (3.9%) progressive disease (PD). In addi-
tion, response evaluation by PERCIST was available in 38 pts, 5 pts 
Conclusion: Combination chemotherapy with Pem and Cb showed 
efficacious and well tolerated in advanced non-Sq NSCLC without 
EGFR mutation. This combination could include one of the options 
in standard regimen for 1st line therapy for advanced non-Sq NS-
CLC.
Keywords: EGFR wild type, pemetrexed, Carboplatin
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P3.10-024 PHASE II STUDY OF PEMETREXED + CARBO-
PLATIN + BEVACIZUMAB AS FIRST LINE THERAPY FOR 
NON-SQUAMOUS NON-SMALL CELL LUNG CANCER 
WITH EGFR MUTATION: CENTRAL JAPAN LUNG STUDY 
GROUP (CJLSG) 0910 TRIAL
Tomoki Kimura1, Hiroyuki Taniguchi2, Tomohiko Ogasawara3, 
Ryujiro Suzuki4, Masashi Kondo5, Joe Shindoh6, Norio Yoshida7, Eiji 
Kojima8, Yoshiyuki Yamada9, Osamu Hataji10, Motoshi Ichikawa11, 
Hiroshi Saito12
1Tosei General Hospital/Japan, 2Tosei Genaral Hospital/Japan, 3Japa-
nese Red Cross Nagoya Daini Hospital/Japan, 4Toyohashi Municipal 
Hospital/Japan, 5Nagoya University Graduate School Of Medicine/
Japan, 6Ogaki Municipal Hospital/Japan, 7Kariya Toyota General Hospi-
tal/Japan, 8Komaki Municipal Hospital/Japan, 9Konan Kosei Hospital/
Japan, 10Matsusaka Municipal Hospital/Japan, 11Gifu Prefectural Tajimi 
Hospital/Japan, 12Aichi Cancer Center Aichi Hospital/Japan
Background: In advanced non-squamous non-small cell lung 
cancer (NSCLC) with activating epidermal growth factor receptor 
(EGFR) mutation (MT), EGFR-tyrosine kinase inhibitor (TKI) show-
ed better response rate (RR) and longer progression free survival 
(PFS) than standard chemotherapy, but showed almost same ove-
rall survival (OS) in recent studies. Recently, chemotherapy with 
bevacizumab (Bev) showed higher RR, and maintenance therapy 
with Bev or pemetrexed (Pem) showed longer PFS (E4599, AVAiL, 
PARAMOUNT). But, there has been few report of chemotherapy 
with Pem and Bev including maintenance therapy in patients with 
EGFR-MT. According to the result of IPASS study, response to stan-
dard chemotherapy in patients with EGFR-MT is also better than 
patients without EGFR mutation. Therefore, we thought chemothe-
rapy containing Pem and Bev may be more effective in EGFR-MT 
pts. This study is designed to evaluate the efficacy and safety of 
combination therapy with Pem, carboplatin (Cb) and Bev followed 
by Pem plus Bev maintenance therapy for non-squamous NSCLC 
patients with EGFR-MT.
Methods: This study was multicenter, phase II trial. Patients recei-
ve Pem 500mg/m2 day1 + Cb AUC6 day1 + Bev 15mg/kg day1, 
every 3 weeks, 4-6 cycles. Patients who achieved disease control 
receive Pem 500mg/m2 day1 + Bev 15mg/kg day1, every 3 weeks 
until disease progression. Key inclusion criteria are as follows; 1) 
histologically or cytologically proven non-squamous NSCLC, 2) pa-
tients with EGFR mutation (exon 19 deletion or L858R revealed by 
peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp as-
say), 3) patients with stage IIIB or IV, or recurrent disease after sur-
gery and was not a candidate for curative radiotherapy, 4) no prior 
chemotherapy, 5) patient who has measurable lesion by RECIST, 
6) age: 20-74, 7) ECOG PS: 0-1, 8) adequate organ function, 9) life 
expectancy more than 3 months,10) written informed consent. Key 
exclusion criteria are as follows; 1) brain metastasis, 2) hemoptysis 
(>=2.5ml), 3) active infection, 4) fever, 5) serious disease condition, 
6) active double cancer, 7) cavity fluid retention difficult to control, 
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P3.10-027 SELECTION OF PATIENTS WITH ADENOCAR-
CINOMA OF THE LUNG FOR GEFINITIB BY FDG PET ME-
TABOLIC RESPONSE
Jungmin Jo1, Dae Ho Lee1, Chang-Min Choi1, Jae Cheol Lee1, Jung 
Shin Lee1, Jeong-Sook Hong1, Jin-A Kim1, Hye Ok Kim2, Sun-Young 
Chae2, Jin-Sook Ryu2, Dae Hyuck Moon2, Woo Sung Kim3, Sang-We 
Kim1
1Department Of Oncology, Asan Medical Center/Korea, 2Department Of 
Nuclear Medicine, Asan Medical Center/Korea, 3Pulmonary And Critical 
Care Medicine, Asan Medical Center/Korea
Background: Gefitinib is the standard therapy for non-small cell 
lung cancer patients harboring activating EGFR mutation. Howe-
ver, there are some limitations; 1) we need sufficient tumor tissue 
to analyze EGFR mutation test; 2) we have to wait result of the test, 
causing delay of treatment; and 3) we can evaluate the response 4 
weeks later but some of the patients do not respond to EGFR TKIs 
even though they have an activating EGFR mutation. Therefore, 
we investigated the role of FDG PET as a method overcoming the 
limitations to evaluate the response to EGFR TKIs.
Methods: Key eligibility is as follows; advanced/metastatic ade-
nocarcinoma of the lung; never smoker; no prior chemotherapy; 
ECOG PS of 0-1; and main lesion > 2cm. The patients performed 
two times of FDG PET; before starting gefitinib and after 7 days 
of gefitinib 250mg/d therapy. If % decrease of peak standardized 
uptake value (pSUV) of main lesion was 20% or more, gefitinib was 
continued till progression (Group A). After 6 weeks of the treat-
ment, conventional response evaluation using chest CT was done. 
But, if % decrease of pSUV less than 20% or increase, treatment 
changed from gefitinib to pemetrexed/cisplatin (Group B). Primary 
endpoint was to see the response rate of gefitinib in the patients 
of Group A. EGFR mutation test using direct sequencing method 
was also performed but the result was not available or unknown to 
investigators before the report of second PET result.
Results: Between Apr 2012 and Apr 2013, 50 patients participated. 
After 7 day-treatment of gefitinib, 28 out of 50 patients showed 
decrease of pSUV of main lesion ≥ 20 % (47.4±15.8%) (Group A). 
Out of the 28 patients in Group A, 27 patients were evaluable; PR 
in 24 (85.7%), SD in 2 and PD in 1 (Table). EGFR mutation was iden-
tified later in 24 patients (85.7%) and 4 patients showed wild type 
EGFR with 2 PRs, 1 PD and 1 NE. Twenty-two patients showed 
decrease of pSUV < 20 % or increase (-0.3±15.3%). Interestingly, 19 
patients (86.4%) had wild type EGRF while two had an activating 
EGFR mutation. One patient who showed mutated EGFR in Group 
B was given gefitinib continuously as physician’s decision. But the 
patient did progressed after all.  
(13.2%) achieved CR, 26 (68.4%) PR, 5 (13.2%) SD, and 2 (5.3%) PD. 
Thirty-one pts (60.8%) underwent surgery, 12 (23.5%) concurrent 
chemo-radiation (CCRT), 2 (4.3%) radiotherapy alone, 5 (9.8%) 2nd 
line chemotherapy or best supportive care and 1 lost follow-up. In 
31 pts undergone surgical resection, 27 (87.1%) achieved R0 resec-
tion while 30-day postoperative death was reported in 2 pts. Me-
dian relapse-free survival (RFS) and overall survival (OS) were 10.7 
months (95% CI, 8.1-13.2 months) and 25.5 months (95% CI, 20.4-
30.6 months), respectively. The pts. with MD histology and objective 
metabolic response (CR+PR) by PERCIST showed significant longer 
RFS with HR of 6.27 (P=.002) and 3.23 (P=.04), respectively.
Conclusion: The TP-IC in LA-NSCLC showed remarkable tumor 
regression activity, leading to high R0 resection rate. MD histology 
and tumor response (CR+PR) by PET (PERCIST) were significant pro-
gnostic factors for RFS. Further study is ongoing to identify molecu-
lar markers affecting clinical outcomes.
Keywords: induction chemotherapy, Taxane, Platinum, non-small-
cell lung cancer
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P3.10-026 OUTCOMES OF PATIENTS UNDERGOING 
ADJUVANT PLATINUM-VINORELBINE CHEMOTHERAPY 
FOR RESECTED NON-SMALL CELL LUNG CANCER (NS-
CLC)
Alexandra Pender1, Jim Coward2, Ranga Gunapala1, Mary O‘Brien1, 
Jaishree Bhosle1, Sanjay Popat1
1Medical Oncology, The Royal Marsden NHS Foundation Trust/United 
Kingdom, 2Cancer Therapeutics Group, Mater Medical Research Institute/
Australia
Background: Cisplatin-vinorelbine adjuvant chemotherapy signifi-
cantly improves survival in resected NSCLC. We evaluated outco-
mes of patients receiving adjuvant chemotherapy in our institution 
between 2006-2011.
Methods: Outcomes of stage IB -IIIA NSCLC patients who received 
platinum-vinorelbine following radical lung surgery were collected 
and analysed to assess overall survival (OS), progression-free survi-
val (PFS), and treatment intensity.
Results: 53 patients were identified (23:30, M:F), mean age 62, and 
35% were adenocarcinoma. Resected stage was 1B-3A, with one-
third stage 3A. When tested, EGFR mutation prevalence was 33% 
(39% never smokers; 61% ever smokers). There was one death from 
chemotherapy toxicity. Median chemotherapy cycles given was 4. 
There was no difference in PFS or OS in patients having carboplatin 
compared with cisplatin. A significantly improved OS in patients 
that received ≥3 cycles of chemotherapy was observed (HR=0.25, 
0.07-0.97, p=0.04). 60.4% patients had relapsed at last follow-up. 
Radically treatable disease on relapse was detected by surveillance 
imaging.
Conclusion: Our small dataset indicates that four cycles of adjuvant 
platinum-vinorelbine chemotherapy is deliverable in the real world 
setting, and that less than 3 chemotherapy cycles is associated with 
poorer outcomes.
Keyword: chemotherapy, non-small cell lung cancer, platinum-
vinorelbine
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P3.10-028 PATHOLOGIC COMPLETE REMISSION AFTER 
INDUCTION CHEMOTHERAPY AND INTERCALATED ER-
LOTINIB IN EGFR-MUTATED ADENOCARCINOMA STAGE 
IIIA: CASE REPORT.
Frank -. Griesinger1, Markus -. Falk2, Imme Conradi1, Volker Halb-
fass1, Michael Reinhardt3, Alexander Kluge4, Kay Willborn5, Regina 
Prenzel6, Douglas Scriba7, R P Henke8, Wilfried E.E. Eberhardt9, 
Cora Hallas2, Markus Tiemann2
1Hematology And Oncology, Pius-Hospital/Germany, 2Pathology, He-
mopathology Hamburg/Germany, 3Nuclear Medicine, Pius-Hospital/
Germany, 4Radiology, Pius-Hospital/Germany, 5Radiotherapy, Pius-
Hospital/Germany, 6Pneumology, Pius-Hospital/Germany, 7Thoracic 
Surgery, Pius-Hospital/Germany, 8Institute Of Pathology/Germany, 
9Medical Oncology, University Of Duisburg-Essen/Germany
Background: EGFR TKI treatment is standard of care in patients 
with metastasized NSCLC carrying an activating EGFR mutation. 
However, induction concepts in locally advanced NSCLC with 
EGFR mutation including TKI have not been studied extensively. 
Recently new focus has been shed on intercalated regimens of 
chemotherapy and TKI, showing improved PFS as well as OS. This 
concept was used as induction regimen in a female patient with 
activating EGFR mutation as well as p53 mutation and stage IIIA 3 
multilevel.
Methods: Patient was diagnosed and worked up according to 
standard imaging, histology and immunohistology methods. 
EGFR, KRAS, BRAF, ALK and P53 mutation analysis was performed 
as described by Halbfass et al. Remission induction was measured 
by RECIST 1.1, regression grading by Junker criteria.
Results: A female caucasian 62 y.o. never smoker was diagnosed 
with TTF1+ adenocarcinoma G3 of the upper lobe of the lung, 
c2T3 (extension to mediastinal pleura) c2N2 (LN 2R and 4R) c2M0, 
UICC7 IIIA4 (Robinson). Molecular analysis after microdissection 
revealed WT for ALK, KRAS and BRAF, but an activating EGFR 
mutation Exon19 (p.Leu747_Ala750delinsPro), as well as a TP53 
mutation in exon 8 (p.Val272Met (c.814G>A) (Sanger Sequencing). 
Induction therapy was started with erlotinib 150 mg/die p.o. days 
-12 to -2 in order to prove responsiveness of the tumour to TKI. 
On day 0 partial response was achieved. Therapy was continued 
with 3 cycles of Docetaxel 75 mg/m2 d1 and Cisplatin 50 mg/m2 
d 1 and 2 qd22 with intercalated Erlotinib 150 mg/die p.o on days 
4-19. Almost complete radiologic remission was achieved after 2 
cycles The patient underwent R0 resection (upper lobe resection 
and radical lymphadenectomy) 4 weeks after day 1 of the 3rd cycle 
of chemotherapy, pathologic examination revealed T0N0 (mic+) 
with only one insula of tumor cells in an N2 lymph node, demons-
Group A (gefitinib, n=28) Group B (pem/cis, n=22)
Response
EGFR mutation EGFR mutation
Postive (n=24) Negative (n=4) Total (n=28) Postive (n=2) Negative (n=19) NE (n=1) Total (n=22)
CR - - 0 - - - 0
PR 22 2 24 (85.7%) 1 13 - 14 (63.6%)
SD 2 - 2 (7.1%) - 4 - 4 (18.2%)
PD - 1 1 (3.6%) - 1 - 1 (4.5%)
NE - 1 1 (3.6%) 1 1 1 3 (13.6%)
 
Conclusion: The % decrease of pSUV of ≥ 20 % after 7 days of 
gefitinib treatment would be a good indicator to predict tumor 
response to EGFR TKI therapy in this clinical setting.
Keywords: gefitinib, FDG PET, NSCLC
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up every 6 to 8 weeks, about 1/3 of patients do not receive 2nd 
line therapy. The application of maintenance therapy raised the 
chances of receiving 2nd line therapy. Multiple metastases, espe-
cially bone and CNS, requiring radiation therapy, were associated 
with not receiving 2nd line therapy. These data suggest that main-
tenance therapy should be considered for pts after 1st line therapy 
and that radiation therapy for bone and CNS metastases should if 
possible be accompanied by systemic treatment.
Keywords: second line therapy, maintenance therapy, NSCLC
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P3.10-030 A PHASE II STUDY OF PEMETREXED/CARBO-
PLATIN FOR PREVIOUSLY UNTREATED PATIENTS WITH 
ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG 
CANCER: ANALYSIS OF THE CORRELATION BETWEEN 
THE ANTI-TUMOR EFFICACY/TOXICITY AND SNPS OF 
MTHFR.
Takashi Kasai1, Kokichi Sugano2, Eri Haneda2, Yukari Kamiyama1, 
Kenya Kohyama3, Naoto Fueki3, Kiyoshi Mori1
1Department Of Medical Oncology, Tochigi Cancer Center/Japan, 2Onco-
gene Res. Unit / Cancer Prevention Unit, Tochigi Cancer Res Institute/
Japan, 3Department Of Respiratory Medicine, Dokkyo Medical Universi-
ty Koshigaya Hospital/Japan
Background: Previous studies investigating a combination of 
Pemetrexed (P)/Carboplatin (C) showed promising efficacy in the 
treatment of non-squamous (Sq) non-small cell lung cancer (NS-
CLC). However, there is no sufficient data of biomarkers. In the 
present study, we determined the efficacy and toxicity of 6 cycles 
of P/C for previously untreated patients with advanced non-Sq 
NSCLC. In addition, we investigated the correlation between the 
anti-tumor efficacy/toxicity and single nucleotide polymorphisms 
(SNPs) of the methylenetetrahydrofolate reductase (MTHFR).
Methods: Eligibility criteria were no prior chemotherapy, StageII-
IB without any indications for radiotherapy or IV, non-Sq NSCLC 
patients, performance status (PS) 0-1, age <76 yrs, and adequate 
hematological, hepatic, and renal function. Patients received 6 cy-
cles of P (500mg/m2)/C (AUC6) on day 1, repeated every 3 weeks. 
Primary end-point was the assessment of tumor response rate 
measured by RECIST criteria. The SNPs of the MTHFR gene were 
analyzed from the genomic DNA extracted from the peripheral 
blood cells drawn prior to the chemotherapy.
Results: Thirty-nine patients (pts) were enrolled and all pts evalu-
able for toxicity and response. Male/Female: 30/9; PS 0/1: 11/28; 
median age 62(45-75); Path: adeno 37(95%), NSCLC unclassified 
2(5%); EGFR mutation: positive 2(5%), negative 35(90%), unknown 
2(5%). Evaluations of responses were 1CR, 17PR, 16SD, 5PD (re-
sponse rate 46.2%). The median progression free survival time 
(PFS) was 6.8 months, and the median survival time (MST) was 18.1 
months. Grade 3/4 toxicities in the first cycle included: leukope-
nia(3/1), anemia(1/1), thrombocytopenia(4/2), neutropenia(2/1), and 
AST/ALT elevation(2/0). SNPs of the MTHFR at codon 677 were 
examined in 28 pts. MTHFR genotypes were as follows: C677C; 
8 cases, C677T; 14 cases and T677T; 6 cases. Response rates and 
disease control rates of MTHFR codon677 genotypes were as fol-
lows: C677C (50%/75%), C677T (36%/79%) and T677T (50%/100%). 
Median PFS and MST of MTHFR codon677 genotypes were as 
follows: C677C; 4.8/7.6 months, C677T; 6.4/20.6 months and T677T; 
trating regression grade III in the primary tumor and Grade IIB in 
the lymph nodes, according to the Junker classification. Molecular 
analysis of residual tumor cell insula revealed the same EGFR and 
p53 mutations as the primary tumour. The patient underwent post-
operative radiotherapy of the mediastinum. No additional therapy, 
including TKI was administered postoperatively.
Conclusion: Intercalated TKI treatment might be a promising 
treatment choice in patients with EGFR mutated locally advanced 
NSCLC. A phase II trial is currently being planned to expand know-
ledge in this challenging field.
Keywords: Induction therapy, intercalated TKI-chemotherapy, 
EGFR mt NSCLC, stage III
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P3.10-029 SECOND LINE CHEMOTHERAPY EXPOSURE 
IN A GERMAN CANCER SOCIETY CERTIFIED LUNG CAN-
CER CENTER: SINGLE CENTER EXPERIENCE OF 3 YEARS 
AND RELEVANCE FOR MAINTENANCE THERAPY
Frank -. Griesinger1, Regina Prenzel2, Volker Halbfass3, Douglas 
Scriba4, Kay Willborn5
1Hematology And Oncology, Pius-Hospital Oldenburg, University Of 
Oldenburg/Germany, 2Pneumology, Pius-Hospital/Germany, 3Hemato-
logy And Oncology, Pius-Hospital/Germany, 4Thoracic Surgery, Pius-
Hospital/Germany, 5Radiotherapy, Pius-Hospital/Germany
Background: One of the strongest rationale for maintenance the-
rapy in NSCLC is the fact that exposure to 2nd line therapy is only 
40-60% in clinical trials in specialized treatment centers. Even with 
follow-up intervals of 6 weeks, the 2nd line treatment rate does not 
seem to increase in clinical trials. One of the main arguments for 
maintenance treatment not widely adopted in Germany is that 2nd 
line exposure in international clinical trials does not reflect the situ-
ation of treatment management in Germany. Therefore, we analy-
zed the exposure of patients with stage IV NSCLC in one German 
Cancer Society certified Lung Cancer Center since certification, as 
long term follow-up data are available.
Methods: All primary lung cancer cases stage IV in the lung cancer 
center were analyzed based on the documentation files between 
2009 and 2013. Patients were followed between 1st and 2nd line 
therapy every 6-8 weeks according to S3 guidelines.
Results: 203 patients were diagnosed with NSCLC IV (UICC7), or 
had systemic relapse of localized disease and were treated with 1st 
line therapy for metastatic disease. Of these, 130 (64 %) received 
1st line combination therapy with Carboplatin, 44 (22%), 21 (10%) 
with TKI 1st line therapy and 8 (4%) with platin-free single agent 
therapy. 32 (16%) of all patients received maintenance therapy, 
most of them with bevacizumab. Of 203 patients, 168 progressed 
after 1st line therapy or 1st line and maintenance therapy. 111/163 
(66%) pts. received 2nd line therapy. 57 pts (34%) did not receive 
2nd line chemotherapy. Reasons for not receiving 2nd line the-
rapy were mostly associated with intercurrent bone metastases 
that needed surgery and or radiotherapy and CNS metastases 
requiring radiation, as well as non-cancer related causes. Of 23 pts 
receiving maintenance therapy and requiring 2nd line therapy, 20 
(87%) received 2nd line therapy.
Conclusion: In a certified lung cancer center and stringent follow-
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P3.10-032 EFFICIENCY AND SAFETY OF ERLOTINIB IN 
THE SECOND AND THE FURTHER LINES OF TREATMENT 
FOR PATIENTS (CAUCASIAN ETNIC) WITH ADVANCED, 
NON-SMALL-CELL LUNG CANCER IN EASTERN SLOVA-
KIA.
Igor Andrasina1, Andrea Cipkova1, Pavel Matula1, Valeria Tkacova2, 
Bibiana Ziarna3, Jozef Chovanec4, Renata Sikrova5
1Dept. Clinical Oncology, East Slovakia Oncology Institute/Slovak 
Republic, 2Faculty Hospital Presov/Slovak Republic, 3County Hospital 
Trebisov/Slovak Republic, 4County Hospital Bardejov/Slovak Republic, 
5S.kukura County Hospital Michalovce/Slovak Republic
Background: Erlotinib is indicated in first line treatment of patients 
with advanced or metastatic non-small cell lung cancer (NSCLC) 
with EGFR positive mutation, then in maintenance treatment of 
patients with NSCLC, and in second line after failure of at least one 
chemotherapy regimen. Its efficiency is comparable with chemo-
therapy, but erlotinib has better adverse-event profile, it is better 
tolerated, with no haematological toxicity.
Methods: We evaluated data of 154 patients treated in 5 hospi-
tals in Eastern Slovakia between January 01,2008, and October 
31,2012. The primary endpoint was overall survival (OS) and se-
condary endpoints were progression-free survival (PFS) overall 
response and safety. Statistical analysis was performed using Ka-
plan Meier method and logrank test. The overall population had a 
median age of 63,6 years (range +-10,7 year).The group included 
higher percentage of: males (70,8%); patients with squamous-cell 
histology (52%); patients with stage IV disease 85,7% and patients 
with ECOG performance status O-1 53%. In total 62 % patients 
were treated in second-line and 38% in further lines of treatment.
Results: Median overall survival (OS) was 8,3 months. In multiva-
riate analysis, significantly better OS was in group of patients with 
stage IIIB vs, IV (p =0.033), with PS 0-1 vs. 2 ( 0.011) and previous 
response on chemotherapy (p=0.011). There was no significant 
difference in multivariate analysis caused by histological subtype, 
smoking status and sex. Median of PFS was 4,96 months. Response 
rate (CR +PR) was observed in 24% of population (mainly PR), but 
clinical benefit was observed in 70% of patients. Most common 
toxicity of erlotinib treatment was skin rash (70%) but grade III and 
IV was only in 4 % of cases. Grade III and IV diarrhea was observed 
in 1,3 % of patients.
Conclusion: Erlotinib is acceptable treatment (with acceptable 
OS,PSF and toxicity profile) for patients either with unknown EGFR 
mutation status or patients unsuitable for chemotherapy.
Keywords: erlotinib, non-small-cell lung cancer
6.9/18.5 months. Although there were no significant differences 
of PFS and overall survival between MTHFR genotypes, those of 
C677C subjects were shorter as compared to the others.
Conclusion: In patients with previously untreated advanced non-
Sq NSCLC, P/C appears to be well tolerated and demonstrates 
encouraging activity. PFS and overall survival of the MTHFR C677C 
subjects were shorter than those of the C677T or T677T subjects, 
while the disease control rate of the T677T subjects was higher 
than that of the C677C or C677T subjects.
Keywords: non-small cell lung cancer, MTHFR, Phase II study, 
pemetrexed
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P3.10-031 COMPARATIVE STUDY BETWEEN BELOTE-
CAN/CISPLATIN AND ETOPOSIDE/CISPLATIN (COMBAT) 
IN PATIENTS WITH PREVIOUSLY UNTREATED, EXTENSI-
VE STAGE SMALL CELL LUNG CANCER
In-Jae Oh, Kyu-Sik Kim, Young-Chul Kim, Kook-Joo Na, Sung-Ja 
Ahn, Sang-Yun Song, Yoo-Duk Choi, Seong-Hoon Yoon, Boram 
Lee, Jinyeong Yu
Lung Cancer Clinic, Chonnam National University Hwasun Hospital/
Korea
Background: Belotecan (camtobell™) is a topoisomerase I in-
hibitor, and effective in small cell lung cancer (SCLC). The ob-
jective of this study is to compare the efficacy and safety of 
belotecan+cisplatin (BP) and etoposide+cisplatin (EP) in first line 
setting.
Methods: This is a multicenter, randomized, prospective cont-
rolled trial to prove non-inferiority of BP compared to standard 
EP regimen. The primary endpoint is overall response rate (ORR), 
and secondary endpoints are toxicity, overall survival (OS) and 
progression-free survival (PFS). BP was administrated by belotecan 
0.5 mg/㎡ for 4 days combined with cisplatin 60 mg/㎡ only for first 
day. Treatment response was evaluated according to version 1.0 of 
Response Evaluation Criteria in Solid Tumors.
Results: A total of 147 (BP: 71, EP: 76) patients were randomly assi-
gned and received study drug at least once. In BP arm, there were 
1 complete response, 41 partial responses (PR), 17 stable diseases 
(SD), and there were 35 PR and 28 SD in EP arm. Non-inferiority 
of BP compared to the EP arm was confirmed by the ORR (BP: 
59.2%, EP: 46.1%, 90% confidence interval -0.3 to 26.5, meeting 
the predefined non-inferiority criterion). Median OS (BP: 360, EP: 
305 days, p=0.21) and PFS (BP: 190, EP: 172 days, p=0.37) were not 
significantly different. The mean relative dose intensity was signifi-
cantly different (BP: 0.79, EP: 0.86, p<0.01). The frequency of grade 
≥ 3 anemia (BP: 34.3%, EP: 13.0%, p<0.01) and thrombocytopenia 
(BP: 54.3%, EP: 16.9%, p=<0.01) were higher in BP arm.
Conclusion: In extensive stage SCLC, ORR of BP was not inferior to 
EP and there was no difference of survival. But anemia and throm-
bocytopenia were more frequent in BP arm. (ClinicalTrials.gov 
number, NCT00826644)
Keywords: belotecan, small cell lung cancer, topoisomerase I in-
hibitor
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temozolomide. As MGMT methylation has been found in lung can-
cers, there is an increasing interest on the clinical utility of temozo-
molide in the treatment of human cancers. However, it is essential 
to use appropriate quantitative or semi-quantitative method me-
thods to definitively establish the methylation status of the tumour.
Methods: We critically assessed MGMT methylation status in 6 
lung cancer cell lines and 56 lung tumours using three different 
methodologies. We first assessed the MGMT methylation pattern 
using methylation sensitive – high resolution melting (MS-HRM). 
The methylation status at each CpG dinucleotide was assessed 
bisulfite pyrosequencing of methylated clones. The level of MGMT 
methylation was quantified using quantitative methylation specific 
PCR.
Results: MGMT methylation was found in 3 lung cancer cell lines 
by MS-HRM. The melting profiles of all methylated samples were 
indicative of heterogeneous methylation pattern by melting curve 
analysis. To examine the methylation status at each CpG sites of 
individual template, two MGMT methylated lung cell lines (H1666 
and H69) were further tested by limiting dilution analysis and bisul-
fite pyrosequencing. The number and site of methylated CpG di-
nucleotides greatly varied in each template, confirming the hetero-
geneous methylation pattern in both cell lines. In 56 lung tumours, 
heterogeneous MGMT methylation was detected in seven samples 
(13%) by MS-HRM. The level of MGMT methylation was then esti-
mated. 17 lung tumours, including the 7 MS-HRM positives and 10 
additional tumours, were positive. However, the methylated level 
in all of the methylated samples was low, ranging from below 1% 
(12 samples) and up to 12%.
Conclusion: The level of MGMT promoter in lung cancer is difficult 
to estimate. Ideally clonal analysis should be used to estimate 
the proportion of methylated alleles. Alternatively, methylation 
profiling using MS-HRM followed by pyrosequencing can be used 
to identify tumours showing significant levels of methylation. If 
MGMT methylation is found only in a small proportion of tumour 
cells, it is unlikely to be a useful target for therapy. Overcalling of 
MGMT methylated tumours may provide the explanation for the 
lack of survival benefit with temozolomide treatment in MGMT-
methylated lung cancer patients in a recent phase II clinical trial 
(NCT00423150). This indicates that incorporation of immunohisto-
chemistry for the MGMT protein should also be part of the assess-
ment of the MGMT status of lung cancer.
Keyword: MGMT, DNA methylation, targeted chemotherapy, per-
sonalised medicine
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P3.10-035 USEFULNESS OF IHC FOR DETECTION OF 
THE ALK-FUSION GENE IN NON-SMALL CELL LUNG 
CANCER
Eri Sugiyama1, Koichi Goto1, Genichiro Ishii2, Shigeki Umemura1, 
Shingo Matsumoto1, Kiyotaka Yoh1, Seiji Niho1, Hironobu Ohmat-
su1, Yuichiro Ohe1
1Division Of Thoracic Oncology, National Cancer Center Hospital East/
Japan, 2Pathology Division, Research Center For Innovative Oncology, 
National Cancer Center Hospital East/Japan
Background: Diagnostic guidelines on CAP-IASLC-AMP recom-
mend the use of the ALK fluorescence in situ hybridization (FISH) 
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P3.10-033 PROGNOSTIC FACTORS IN STAGE III NON-
SMALL CELL LUNG CANCER PATIENTS WITH POSTOPE-
RATIVE BRAIN METASTASES
Masatoshi Kakihana, Yoshinori Sakata, Seisuke Nagase, Naohiro 
Kajiwara, Tatsuo Ohira, Norihiko Ikeda
Thoracic Surgery, Tokyo Medical University/Japan
Background: The brain is the most frequent site of distant metas-
tases in patients with non-small cell lung cancer (NSCLC). In stages 
I-IIIA NSCLC, after complete resection of the primary tumor, brain 
metastases account for 9.4% to 36.8% of all recurrences. This study 
assessed the risk factors for brain metastasis and the prognostic 
factors for survival after brain recurrence in patients whose advan-
ced NSCLC was resected.
Methods: A total of 101 patients with brain metastases occurring 
after resection of stage III NSCLC tumors at Tokyo Medical  
University Hospital between 1995 and 2010 were retrospectively 
reviewed.
Results: The median time to onset of brain metastasis was 11.2 
months (1-72 months) and the median survival time from the diag-
nosis of brain metastasis was 18.5 months (1-60 months). Multiva-
riate analysis revealed that the risk factors for brain metastasis in 
postoperative stage III NSCLC included the following parameters: 
adenocarcinoma,age <65 years at recurrence, N2-N3, incomplete 
resection, and vascular invasion. In addition, the significant favo-
rable prognostic factors included the absence of neurologic signs 
and symptoms, single and small size of brain metastasis, age <65, 
and treatment with epidermal growth factor receptor tyrosine 
kinase inhibitors.
Conclusion: It was possible to identify patientsat high-risk for brain 
metastases after surgery. For these patients, careful follow-up is 
needed after surgery. It is important to detect brain recurrence in 
patients with NSCLC before neurologic signs or symptoms deve-
lop, as early detection improves prognosis.
Keywords: prognostic factors, postoperative, non-small cell lung 
cancer, brain metastases
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P3.10-034 IS LOSS OF MGMT A THERAPEUTIC TARGET 
IN LUNG CANCER?
Hongdo Do1, Paul Mitchell2, Thomas John2, Carmel Murone3, Benja-
min Solomon4, Alexander Dobrovic1
1Peter MacCallum Cancer Centre/Australia, 2Joint Austin-ludwig 
Oncology Unit, Austin Health/Australia, 3Austin Hospital/Australia, 
4Department Of Medical Oncology, Peter MacCallum Cancer Centre/
Australia
Background: MGMT is a DNA repair protein which removes alky-
lating DNA adducts from the O6 position of guanine. Expression 
of MGMT is often silenced by promoter methylation in human 
cancers. MGMT methylation is a predictive marker for prolonged 
survival in glioblastoma patients treated with an alkylating agent, 
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P3.10-036 AFATINIB IN PLATINUM- AND GEFITINIB OR 
ERLOTINIB-PRETREATED PATIENTS WITH NSCLC. A SIN-
GLE INSTITUTION EXPERIENCE IN A COMPASSIONATE-
USE-PROGRAM
David F. Heigener, Simone Hildebrandt, Niels Reinmuth, Martin 
Reck
Thoracic Oncology, Lungenclinic Grosshansdorf/Germany
Background: The inhibition of the Epidermal Growth Factor Re-
ceptor (EGFR) is a treatment option in patients with non-small cell 
lung cancer (NSCLC). Afatinib is an inhibitor of EGFR as well as 
the other members of the ErbB family. This compassionate use 
program was initiated to offer a treatment option for patients after 
failure of platinum-based chemotherapy and reversible TKI. 
Methods: Patients with NSCLC who had had platinum-based 
chemotherapy and therapy with gefitinib or erlotinib for at least 6 
months or who had an activating mutation in the EGFR-gene were 
eligible to enter this compassionate use program. Patients were gi-
ven 50 mg (or 40 mg at the investigators´ decision) of afatinib daily 
until progression or intolerable adverse events. Here we report on 
our clinical experience at our institution.
Results: 18 Patients were enrolled at our center. 6 had an acti-
vating mutation, 1 had proven wild type and 11 had an unknown 
EGFR-status. The median duration of therapy was 2.4 months 
(range 0.5 to > 19 months). Interestingly, one of the remissions was 
observed in a patient with proven EGFR wild-type. Most adverse 
events were EGFR-TKI class-specific and manageable by dose-
adaption.
Conclusion: Afatinib is an appropriate treatment option for pati-
ents who benefitted from treatment with gefitinib or erlotinib.
Keywords: afatinib, EGFR
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P3.10-037 DRUG THERAPY FOR PATIENTS WITH BRAIN 
METASTASES FROM NON-SMALL CELL LUNG CANCER.
David R. Naskhletashvili1, Vera A. Gorbounova2, Mark B. Bychkov2, 
Ekaterina A. Moskvina1
1Neurooncology, Russian N.N.blokhin Cancer Research Center/Russian 
Federation, 2Chemotherapy, Russian N.N.blokhin Cancer Research Cen-
ter/Russian Federation
Background: About 30–40% of all patients (pts) with non-small 
cell lung cancer (NSCLC) develop brain metastases (BM), leading 
to a poor prognosis and a median survival of <6 months after 
whole brain radiotherapy. There have not been standards of drug 
therapy for treatment for pts with BM. The main goal of this trial is 
to assess the efficacy of different schemes of drug therapy in pts 
with BM from NSCLC.
Methods: 87 pts were included in this study. 56 pts with NSCLC 
were treated with gemcitabine (Gem) - 1000 mg/m2 intravenous on 
assay for selecting suitable patients for ALK-TKI therapy. However, 
based on some reports of the usefulness of immunohistochemistry 
(IHC) for the detection of ALK, it was considered that it may be 
possible to use IHC instead of FISH, which is more time-consuming 
and technically difficult, for the select suitable patients for ALK-TKI 
therapy in FFPE specimens. The purpose of this study was to inves-
tigate the usefulness of IHC as compared to FISH for the diagnosis 
of ALK-fusion gene-positive NSCLC in clinical practice.
Methods: A total of 52 patients with NSCLC who were examined 
for the ALK-fusion gene by both IHC (Envision Flex+, Dako) and 
FISH (break-apart probe) at the National Cancer Center Hospital 
East from March 2012 to March 2013 were included in this study. 
The reliability and usefulness of IHC as compared to those of FISH 
were examined for the diagnosis of ALK-fusion gene-positive NS-
CLC.
Results: There were 26 men and 26 women, with a median age 63 
years (range, 25-78 years). The pathological diagnosis, based on 
the examination of 20 resected specimens and 32 biopsy speci-
mens, was adenocarcinoma in 47 cases and poorly-differentiated 
NSCLC in the remaining 5 cases. ALK protein overexpression was 
detected by IHC in 11 patients, in contrast, ALK rearrangement 
was detected by FISH in 9 patients. When the results of the FISH 
assay were considered as true-positive, the sensitivity, specifi-
city, accuracy, positive predictive value and negative predictive 
value of IHC were 78%, 100%, 74%, 64%, and 93%, respectively. 
There were 7 patients with discordant ALK status, consisting of 2 
patients who were IHC-negative/ FISH-positive, 4 patients who 
were IHC-positive/ FISH-indeterminate and 1 patient who was 
IHC-negative/FISH-indeterminate. Of these patients with discor-
dant ALK status, three received ALK-TKI (crizotinib) therapy. The 
best response rate according to assessment by the RECIST was 
SD in the patient who was IHC-negative/ FISH-positive, and PR 
in both the patients who were IHC-positive / FISH-indeterminate. 
Conclusion: Although the ALK-true positive result remained unc-
lear, based on the responses to crizotinib, it might be judged that 
the result was true-positive in the patients who were IHC-positive/ 
FISH-indeterminate and true-negative in the patient who was IHC-
negative/ FISH-positive. Thus, it appeared that FISH could not de-
termine the ALK status in approximately 10% of the patients, and it 
can therefore not be considered an absolute diagnostic method.
Keywords: ALK-fusion gene, IHC, FISH
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ber of treatment cycles was 3.15±2.1 cycles. Overall response rate 
was 2.6% (95% confidence interval, 0%-7.9%) and disease control 
rate was 23.7% (95% confidence interval, 10.5%-39.4%). Grade 
3/4 hematological toxicities were neutropenia (5.2%), leucopenia 
(5.2%), anemia (5.3%), and thrombocytopenia (2.6%). Grade 4 non-
hematological toxicities and chemotherapy related death were not 
observed.
Conclusion: Pemetrexed shows unfavorable result to patients with 
acquired drug resistance after EGFR-tyrosine kinase inhibitor treat-
ment. We will have to study the efficacy of pemetrexed after EGFR-
TKI treatment prospectively.
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P3.10-039 IMPACT OF XANTHINE OXIDOREDUCTASE 
AND BRCA1 ON PROGNOSIS OF ADVANCED NON-
SMALL CELL LUNG CANCER
Selim Yalcin, Nadire Kucukoztas, Samed Rahatli, Omer Dizdar, 
Dalokay Kilic, Ozden Altundag, Huseyin Abali
Medical Oncology, Baskent University/Turkey
Background: Lung cancer is the leading cause of cancer-related 
deaths over the world. Treatment in locally advanced non small cell 
lung cancer (NSCLC) is heterogeneous. The cure rate after compla-
te surgical resections not good as expected. Additional treatment 
have come into question. Cisplatin based chemotherapy adjuvant 
or neoadjuvant increases overall survival in stage III NSCLC. The 
better understanding of the biology of NSCLC, may allow selection 
of appropriate treatment. Only a few research is made about prog-
nostic value of xanthine oxidoreductase (XOR) and BRCA-1 in lung 
cancer.
Methods: In our study, stage IIIA and stage IIIB 35 patients who 
had been followed in Baskent Universty medical oncology and of 
thoracic surgery departments, operated in Baskent Ankara and 
Adana hospitals, and who received neoadjuvant chemotherapy 
were included. Clinical and histopatological parameters (age, 
gender, stage, smoking history, performans status, neoadjuvant 
chemotherapy) along with immunohistochemical BRCA1and XOR 
staining were examinated and corelated with survival.
Results: Median overall survival time was 38.5 months and 5 year 
survival rate was 33% Patients with ECOG PS 0 had better overall 
survival than the patients with ECOG PS 2 (p= 0.004) According 
to results of the analyses for overall survival BRCA1 positivity was 
significant P=0.047, XOR was 0.039. The only significant associated 
parameter with overall survival was ECOG PS. There was no signi-
ficant relation between overall survival and XOR expression in our 
patients.
Conclusion: BRCA1 positivity was associated with shorter overall 
survival in stage III lung cancer in patients to whom neoadjuvant 
platinium based chemotherapy was given.
Keyword: Nonsmall cell lun cancer, Xanthine oxidoreductase, 
BRCA1
days 1 and 8 + cisplatin (Cis) – 50 mg/m2 intravenous on days 1 and 
8, every 3-4 weeks. 10 pts with NSCLC (adenocarcinoma, without 
epidermal growth factor receptor (EGFR) mutations) were treated 
with paclitaxel (Pacl) -175 mg/m2 intravenous on day 1 + Carbo-
platin (Carb) – AUC=6 intravenous on day 1, every 3 weeks. 21 pts 
with NSCLC (adenocarcinoma, with EGFR mutations – 12 pts; ade-
nocarcinoma, without EGFR mutations – 9 pts) received treatment 
with epidermal growth factor receptor tyrosine kinase inhibitors 
(EGFR TKIs) gefitinib (Gef) - 250mg/day (15 pts) or erlotinib (Erl) - 
150 mg/day (6 pts) until radiologically-verified progressive disease. 
The main aims of this study were objective response (OR) – com-
plete response (CR) + partial response (PR) in the brain and in the 
extracranial sites (ES), median of survival (MoS), 1-year survival.
Results: Observations were as follows: in the Gem + Cis treated 
pts, 26 OR (46,4%) in 56 pts group in the brain and 22 OR (40,0%) 
in 55 pts group in ES. The MoS was 9.0 months, 1-year survival was 
30,3%. In the Pacl + Carb treated pts, there were 3 OR (30,0%) in 
10 pts group in the brain and 4 OR (40,0%) in 10 pts group in ES. 
The MoS was 7,5 months, 1-year survival was 30,0%. In the EGFR 
TKIs treated pts (with EGFR mutations), there were 9 OR (75,0%) in 
12 pts group in the brain and 7 OR (70,0%) in 10 pts group in ES. 
The MoS was 14,5 months, 1-year survival was 66,6%. In the EGFR 
TKIs treated pts (without EGFR mutations), there were no OR in 9 
pts group in the brain and in ES. The MoS was 4 months, 1-year 
survival was 11,1%.
Conclusion: Previous results of our study showed that efficacy of 
drug therapy in patients with BM from NSCLC depends on biology 
of tumor and scheme of treatment. The best results achieved in pts 
with EGFR mutations who received EGFR TKIs (Gef or Erl). Further 
investigation is to be expected.
Keyword: Brain metastases, non-small cell lung cancer, drug  
therapy
POSTER SESSION 3 - CHEMOTHERAPY  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.10-038 THE EFFICACY AND SAFETY OF PEMETREX-
ED AFTER THE FAILURE OF GEFITINIB IN PATIENTS 
WITH ADENOCARCINOMA WITH EGFR MUTATION.
Kyu-Sik Kim, Young-Chul Kim, In-Jae Oh, Kook-Joo Na, Sung-Ja 
Ahn, Yoo-Duk Choi, Seong-Hoon Yoon, Boram Lee, Jinyeong Yu
Lung Cancer Clinic, Chonnam National University Hwasun Hospital/
Korea
Background: Patients with epidermal growth factor 
receptor(EGFR) mutation positive adenocarcinoma exhibited 
marked response to gefitinib. In most cases, the patients showed 
disease progression after EGFR-tyrosine kinase inhibitor treat-
ment. We evaluated the efficacy and safety of pemetrexed after 
the failure of gefitinib in patients with adenocarcinoma with EGFR 
mutation.
Methods: Patients harvoring EGFR-mutant stage IV adenocarcino-
ma that progressed during gefitinb were administered pemetrexed 
after discontinuing of gefitinib treatment. We retrospectively ana-
lysed the efficacy of pemetrexed monotherapy.
Results: Retrospectively, we analysed the 41 patients in this study. 
All patients were treated with gefitinib as the first line and treated 
as the 2nd line with pemetrexed monotherapy. The median num-
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P3.10-041 IMPACT OF A COMPREHENSIVE GERIATRIC 
ASSESSMENT ON MANAGEMENT STRATEGIES IN EL-
DERLY PATIENTS WITH ADVANCED NO SMALL CELL 
LUNG CANCER (NSCLC): A POLLED ANALYSIS OF TWO 
PHASE 2 PROSPECTIVE STUDY OF THE GFPC GROUP.
Isabelle Borget1, Romain Corre2, Herve Le Caer3, Chrystele Locher4, 
Christine Raynaud5, Chantal Decroisette6, Henri Berard7, Claris-
se Audigier-Valette8, Cecile Dujon9, Jean-Bernard Auliac10, Jacky 
Crequit11, Isabelle Monnet12, Alain Vergnenegre13, Christos Chou-
aid12
1Etudes Et Recherches En Economie De La Santé, Institut Gustave 
Roussy/France, 2Pneumology, Chu Pontchaillou/France, 3Ch Draguig-
nan/France, 4Service De Pneumologie, Centre Hospitalier Saint Faron/
France, 5Pneumologie, Centre Hospitalier Argenteuil/France, 6Ch An-
necy/France, 7Service De Pathologie Respiratoire, Hôpital D‘instruction 
Des Armées Sainte-anne/France, 8Department Of Pneumology, Chits 
Toulon/France, 9Ch Versailles/France, 10Pneumology, Centre Hospitalier 
F. Quesnay/France, 11Pneumology, Ch Laennec-creil/France, 12Service 
De Pneumologie, Centre Hospitalier Intercommunal De Creteil/France, 
13Service De Pneumologie, Centre Hospitalier Universitaire De Limoges/
France
Background: The impact of a systematic use of a Comprehensive 
Geriatric Assessment (CGA) on management strategies in elderly 
patients with no small cell lung cancer (NSCLC) is not well establis-
hed. The objective of this study was to analyze if items of CGA may 
predict overall survival of elderly patients with NSCLC treated by 
chemotherapy or erlotinib in first or second lines setting.
Methods: Individuals data’s of GFPC 0504 study (population of fit 
elderly patients) and GFPC 0505 study (population of frail elderly 
patients) were pooled. The aim of these two prospective phase 2 
trials were to compare a strategy using chemotherapy (doublet in 
fit patients, monotherapy in frail patients) in first line followed by 
erlotinib in second line to the reverse strategy (erlotinib in first line, 
followed by chemotherapy), in terms of progression-free survival 
(PFS) in second line period. Secondary outcomes were to compare 
first-line PFS, overall survival (OS), tolerance and costs. All patients 
had a complete comprehensive geriatric assessment, evaluating 
diverse areas as functional status, nutritional status, cognition, 
psychological functioning, and social support, at randomization. 
Predictive factors associated with OS were searched using Kaplan-
Meier curves and logrank tests in the univariate analysis. A Cox 
model was used for the multivariate analysis.
Results: 195 patients were included. Mean age was 77 years. 135 
(70%) patients were males, 172 (89%) were stage IV and 109 (56%) 
were no or ex-smokers. At CGA assessment, 176 patients (70%) 
had an IADLD score of 3 or 4, 129 pts (66%) had a 0 or 1Charlson 
score, 167 pts (86%) had a simplified Charlson score < 8, 19 pts 
had a MMS score < 30, 146 pts (75%) had a situational score >10, 
33 (17%) had a nutritional score <8. Factors predicting OS in the 
univariate analysis were 1-3 PS scores (1.5 [1.1 – 2.0], p=0.01); no 
or ex-smoker (0.70 [0.52–0.95], p = 0.02); 2-4 Charlson score (2.0 
[1.4 – 2.7], p<0.0001, Simplified Charlson score ≥ 8 (1.50 [1.10–
2.07],p=0.03), nutritional score>8 (0.60 [0.42 – 0.91], p= 0.01); 2 
level mobility score (0.15 [0.04 – 0.62], p = 0.009). In the multivaria-
te analysis, remained 1-3 PS (1.4 [1.02 – 1.9], p = 0.04), 2-4 Charlson 
score (1.46 [1.07 – 1.99], p=0.02), >8 nutritional score (0.69 [0.46 
– 1.04], p= 0.07), level 2 mobility score level (0.25 [0.06 – 1.01], p = 
0.06)
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P3.10-040 OPTIMAL DURATION OF CHEMOTHERAPY 
FOR ADVANCED NON-SMALL CELL LUNG CANCER.  
A PROSPECTIVE POPULATION-BASED AUDIT.
Fouzia Andleeb, Noelle O‘Rourke
Beatson Cancer Centre/United Kingdom
Background: Chemotherapy trials for stage IIIB/IV NSCLC have esta-
blished that 3 cycles was better than 6. International guidelines stipu-
late 4-6 cycles but recent studies addressing maintenance or switch 
therapy suggest benefits with prolongation of treatment. Our regio-
nal protocol for chemotherapy in stage IIIB/IV NSCLC recommends 
platinum doublet chemotherapy first line to a total of four cycles with 
interim CT scan after two to assess response. This audit was under-
taken to establish what additional benefit in response was achieved 
by cycles three and four. Our primary outcomes were response rate 
to chemotherapy after two cycles and change in response between 
interim imaging and end of treatment scan after four cycles.
Methods: During 2011/2012 all advanced non-small cell lung can-
cer patients referred for chemotherapy to our regional centre had 
treatment and outcomes recorded. We excluded from our audit any 
patients receiving non-first line chemotherapy, oral TKIs or clinical trial 
agents. We included patients who had received minimum two cycles, 
recording at baseline: age, gender, pathology, ECOG performance 
status and chemo regimen. Interim CT scans were classed as stable 
disease SD, partial response PR, mixed response MR( response at one 
site of disease with either stable or progressive disease at other sites) 
or progressive disease PD. CT following four cycles was compared to 
interim imaging and categorised as stable disease, increased respon-
se relative to interim scan, mixed response or progressive disease.
Results: 188 patients fulfilled audit entry criteria: 96 men, 92 women: 
age range 36-83 years (median 67y). There were 107 adenocarcinoma 
(57%), 53 squamous carcinoma (28%) and 21 undifferentiated/ not 
otherwise specified (11%). ECOG: PS0-1 44%, PS2 6%, PS3 1% but 
49% not recorded. Most common chemo regimens were cisplatin/
pemetrexed (22%), carboplatin/pemetrexed (20%), gemcitabine/car-
boplatin (22%) and carboplatin/paclitaxel (14%). After 2 cycles che-
motherapy 25 patients (13%) had progressive disease but 66(35%) PR, 
72(38%) SD and 15(8%) MR. 25 patients stopped or changed therapy 
following 2 cycles with a further 25 stopping after 3 cycles. Of the 
138 completing 4 cycles 26(19%) had PD on end of treatment scan. 
62(45%) had stable disease compared to interim scan and 25(18%) 
had minor improvement relative to interim scan. Of those showing 
continuing response most (84%) had had initial PR.
Conclusion: Our response rates to chemotherapy after two cycles 
compare well with published series. Evaluation of interim and end of 
treatment scans has demonstrated that most of the radiological res-
ponse to chemotherapy is achieved by the first two cycles. The num-
ber of patients responding after 2, if SD at 2, was low and the additio-
nal benefit in the minority of PR patients who did continue to respond 
was marginal. Our audit is limited by lack of quality of life data but 
if patients experience increased fatigue and toxicity with third and 
fourth cycles then our data would suggest that early stopping of 
platinum chemotherapy may not be detrimental to overall response 
rates. The optimal number of cycles of platinum based chemotherapy 
remains uncertain and worthy of further research.
Keywords: chemotherapy, duration, response
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rapy is associated with similar long-term survival but lower rates 
of severe toxicity when used in combination with radiotherapy to 
treat elderly patients with stage III NSCLC. These data suggest 
that carboplatin may be the preferred therapy for elderly patients 
with locoregional NSCLC.
Keywords: Lung cancer, elderly, chemotherapy, Toxicity
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P3.10-043 NAB-PACLITAXEL IN COMBINATION WITH 
CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS 
(PTS) WITH ADVANCED NON-SMALL CELL LUNG CAN-
CER (NSCLC): AN ECONOMIC ANALYSIS
David Spigel1, William Harwin2, George Dranitsaris3, Gary Binder4, 
Paul Weber4, Markus F. Renschler4, Mark A. Socinski5
1Sarah Cannon Research Institute/United States Of America, 2Sarah 
Cannon Research Institute, Forida Cancer Specialists/United States Of 
America, 3Augmentium Pharma Consulting/Canada, 4Celgene Corpo-
ration/United States Of America, 5Hematology/Oncology, University Of 
Pittsburgh/United States Of America
Background: In a phase III trial in first-line, advanced NSCLC, nab-
paclitaxel + carboplatin (nab-P/C) significantly increased tumor res-
ponse rates, with comparable overall survival (OS) vs solvent-based 
paclitaxel + carboplatin (sb-P/C). However, nab-P/C improved OS 
in prespecified, stratified subgroups of pts, including those aged 
≥ 70 y (19.9 vs 10.4 mo; P = 0.009) and in North American pts, (12.7 
vs 9.8 mo; P = 0.008). Based on the data from this trial, nab-P/C 
was approved by the US Food and Drug Administration (FDA) as 
a first-line treatment in advanced NSCLC, a condition for which no 
drug has demonstrated a clinically meaningful survival advantage 
vs platinum doublets in an unselected population in FDA registra-
tion trials. Here, we report results of a cost-effectiveness analysis 
that was conducted from the US payer perspective, with resource 
use data collected during the trial.
Methods: Cost-of-care estimates were applied to patient-level 
data on chemotherapy, drug delivery, patient monitoring, suppor-
tive care drugs, and treatment of dose-limiting toxicity. Cost-effec-
tiveness outcomes were presented as incremental cost per life year 
($/LY) gained with nab-P.
Results: Use of colony stimulating factors and treatment disconti-
nuations due to toxicity were comparable between experimental 
and control arms. Taxane dose intensity was higher with nab-P vs 
sb-P (79.6% vs 61.8%). For all pts, the nab-P/C group had a $25,868 
higher cost compared with sb-P/C ($35,179 vs $9,310) and an in-
cremental $/LY gained in excess of $100K, comparable with $/LY 
gained estimates published for other recently approved NSCLC 
agents. However, in the subsets of pts aged ≥ 70 y and those from 
North America, the cost differential was reduced to $18,244 and 
$19,941, respectively. $/LY gained was reduced to $23,000 and 
$83,000, respectively, which compares favorably with published 
incremental $/LY gained for other NSCLC agents based on their 
OS advantage in patient subpopulations. Similar results were ob-
served in a post hoc analysis of the subgroup of pts aged ≥ 60 y.
Conclusion: Weekly nab-P/C can be considered a clinically and 
economically attractive treatment option for US payers for first-line 
advanced NSCLC, particularly in the North American and elderly 
subsets. Future clinical trials are needed to validate these findings.
Conclusion: Comorbidities, nutritional and mobility scores, in this 
specific elderly population are predictive of OS. Prospective stu-
dies using large prospective cohort are needed to better select 
the more relevant management for elderly with advance NSCLC.
Keywords: Overall Survival, Comprehensive Geriatric Assessment, 
elderly
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P3.10-042 CISPLATIN VS. CARBOPLATIN-BASED CHE-
MORADIOTHERAPY IN ELDERLY PATIENTS WITH UNRE-
SECTED STAGE III NON-SMALL CELL LUNG CANCER
Juan P. Wisnivesky, Grace Mhango
Medicine, Mount Sinai School Of Medicine/United States Of America
Background: Combined chemoradiotherapy (CRT) is the standard 
therapy for unresectable stage III non-small cell lung cancer (NS-
CLC). The most commonly used (~80%) chemotherapy regimens 
are platinum (cisplatin or carboplatin)-based. While carboplatin 
has been favored in older patients with comorbidities, there is very 
limited data regarding tolerability of these regimens in the elderly. 
In this study, we used population-based data to compare survival 
and toxicity of elderly stage III NSCLC patients treated with car-
boplatin vs. cisplatin-based chemotherapy in combination with 
radiotherapy.
Methods: Using the Surveillance, Epidemiology and End Results 
(SEER) database linked to Medicare records we identified 2,057 
patients >65 years of age with histologically confirmed, unresec-
ted stage III NSCLC that received concurrent chemoradiotherapy 
between 2002 and 2009. We limited the cohort to patients treated 
with platinum-based regimens. We used logistic regression to fit a 
propensity score model predicting use of cisplatin-based therapy. 
Overall and lung-cancer specific survival of patients treated with 
cisplatin vs. carboplatin was compared after adjusting for propen-
sity scores. We identified severe treatment-related toxicity requi-
ring hospitalization and compared these rates among patients 
treated with cisplatin vs. carboplatin after controlling for propensi-
ty scores.
Results: Overall, 347 (16%) patients received cisplatin, most 
commonly (70%) in combination with taxanes. Patients treated 
with cisplatin were younger (p<0.001), more likely to be married 
(p=0.01), and had lower comorbidity burden (p=0.008). There were 
no significant differences in other sociodemographic characteris-
tics, tumor location, and T or N status among patients treated with 
cisplatin vs. carboplatin (p >0.05 for all comparisons). Cox models 
adjusting for propensity scores showed that overall (hazard ratio 
[HR]: 0.98, 95% confidence interval [CI]: 0.86-1.11) and lung cancer-
specific (HR: 1.01, 95% CI: 0.86-1.18) survival were similar for cispla-
tin compared with carboplatin-treated stage III patients. Adjusted 
analyses also showed that cisplatin-treated patients had increased 
risk of severe neutropenia (odds ratio [OR]: 2.70, 95% CI: 1.61-4.51), 
anemia (OR: 1.32, 95% CI: 1.01-1.73), and thrombocytopenia (OR: 
1.62, 95% CI: 1.01-2.62). Rates of infection (OR: 1.10, 95% CI: 0.76-
1.58), fever (OR: 1.07, 95% CI: 0.43-2.64), dehydration (OR: 1.11, 
95% CI: 0.84-1.49), emesis/diarrhea (OR: 1.77, 95% CI: 0.98-3.20), 
and renal failure (OR: 1.58, 95% CI: 0.91-2.76) were not significantly 
different among groups.
Conclusion: Carboplatin, compared to cisplatin-based, chemothe-
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ents were enrolled to R1 and 179 patients (46.8%) were enrolled 
to R2 (61 vs. 118). The median follow-up time for OS was 23.5 
months (range 20.5, 28.1 months) for patients receiving BSC and 
24.4 months (range 22.6, 25.3 months) for patients receiving 
maintenance docetaxel of 60mg/m2 for up to 6 cycles. Median 
OS of BSC group (13.7months, [95%CI:12.0, 15.7]) was not signi-
ficantly different from that of docetaxel group(12.3months,[95%
CI:11.2,14.1]) (p=0.77). No difference was found in the subgroup 
analysis. Post-discontinuation therapy was given at the discretion 
of the investigator. Numerically more patients in BSC group (n=35, 
57.4%) received second-line treatments, including docetaxel, 
EGFR-TKI or pemetrexed, than those in maintenance group (n=56, 
45.5%), although the difference is statistically insignificant (p=0.13). 
The failure observation of PFS gains translating into OS gains is 
partially related to post-progression therapy. Preliminary pharma-
cogenomics analysis demonstrated the CYP3A5*3C(6986 AG/GG) 
genotype associated with poor PFS and ABCB1:2677 GG genotype 
demonstrated less neutropenia in Chinese NSCLC patient treated 
with Docetaxel/DDP regiment, which did not correlated with OS.
Conclusion: Although there is no significant benefit in terms of OS 
with Docetaxel maintenance treatment, our finding for better tole-
rability suggest that Decetaxel maintenance treatment could be of 
some benefit to patients with advanced non-small cell lung cancer.
Keywords: chemotherapy, docetaxel, non-small-cell lung cancer, 
maintenance therapy
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P3.10-045 COMBINATION CHEMOTHERAPY WITH BEVA-
CIZUMAB, DOCETAXEL AND CARBOPLATIN FOR CHE-
MOTHERAPY-NAIVE PATIENTS WITH NON-SQUAMOUS 
CELL LUNG CARCINOMA: PHASE II STUDY.
Masaru Matsumoto1, Yuichi Takiguchi2, Kouichi Minato3, Kozo 
Yoshimori4, Hiroaki Okamoto5, Hidehiko Kuribayashi6, Masahiro 
Ando7, Masato Shingyoji8, Rintaro Noro9, Akihiko Gemma9
1Department Of Pulmonary Medicine And Oncology, Graduate School Of 
Medicine, Nippon Medical School/Japan, 2Medical Oncology, Chiba Univ. 
Hosp/Japan, 3Pulmonary Medicine, Gunma Prefectural Cancer Center/
Japan, 4Antituberculosis Association Fukujuji Hospital/Japan, 5Depart-
ment Of Respiratory Medicine And Medical Oncology, Yokohama Muni-
cipal Citizen‘s Hospital/Japan, 6Nippon Medical School, Chiba Hokusoh 
Hospital/Japan, 7Tsuboi Cancer Center/Japan, 8Department Of Thoracic 
Disease, Chiba Cancer Center/Japan, 9Department Of Pulmonary Medi-
cine And Oncology, Nippon Medical School/Japan
Background: Some clinical studies suggested a possible advan-
tage of bevacizumab combined with taxanes. Although carbopla-
tin is slightly inferior to cisplatin in terms of survival, addition of 
bevacizumab to carboplatin may overcome this disadvantage. The 
aim of this study was to clarify the efficacy and safety of combina-
tion chemotherapy consisting of bevacizumab, docetaxel and car-
boplatin in the 1st line chemotherapy for non-squamous non-small 
cell lung cancer.
Methods: Patients who are untreatable with thoracic curative ra-
diotherapy, with stage IIIB/IV non-squamous non-small cell lung 
cancer, age ranging from 20 to 74 years, PS 0 or 1, adequate organ 
functions, measurable lesions, and written informed consents were 
eligible. Combination chemotherapy consisting of bevacizumab (15 
mg/kg), docetaxel (60 mg/m2) and carboplatin (AUC=6) on day 1 
Keywords: economic analysis, nab-Paclitaxel, non-small cell lung 
cancer
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P3.10-044 OVERALL SURVIVAL ANALYSIS RESULTS OF 
TFINE STUDY (CTONG 0904): DIFFERENT DOSE DOCE-
TAXEL PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY 
AND THEN MAINTENANCE THERAPY WITH SINGLE 
AGENT DOCETAXEL FOR ADVANCED NON-SMALL CELL 
LUNG CANCER
Shun Lu1, Li Zhang2, Yi-Long Wu3, Ying Cheng4, Zhihuang Hu2, 
Zhiwei Chen1, Gongyan Chen5, Xiaoqing Liu6, Jin-Ji Yang3, Li 
Zhang7, Jia Chen8, Meijuan Huang9, Min Tao10, Gang Cheng11, Cheng 
Huang12, Caicun Zhou13, Weimin Zhang14, Hong Zhao15
1Shanghai Lung Cancer Center, Shanghai Chest Hospital/China, 2Can-
cer Center, Sun Yat-Sen University/China, 3Guangdong Lung Cancer 
Institute, Guangdong General Hospital And Guangdong Academy Of 
Medical Sciences/China, 4Jilin Cancer Hospital/China, 5Cancer Hospital 
Of Harbin Medical University/China, 6Internal Medicine Tumor De-
partment, 307 Hospital Of The Academy Of Military Medical Sciences/
China, 7Perking Union Medical Hospital/China, 8Jiangsu Province Tu-
mor Hospital/China, 9West China Hospital, Sichuan University/China, 
10The First Affiliated Hospital Of Suzhou Medical University/China, 
11Oncology Department, Beijing Hospital Of The Ministry Of Health/
China, 12Fujian Provincial Tumor Hospital/China, 13Department Of 
Oncology,shanghai Pulmonary Hospital, School Of Medicine, Tongji Uni-
versity/China, 14General Hospital Of Guangzhou Military Command Of 
Pla/China, 15Chinese People‘s Liberation Army General Hospital/China
Background: Docetaxel (75mg/m2) has been reported as first-line 
and maintenance treatment for Western population with advan-
ced NSCLC. Different doses of docetaxel (60mg/m2) are currently 
delivered in Asian population. Pharmacogenomics alterations in 
taxanes disposition in different ethnic groups may explain this 
difference. TFINE study was to evaluate the efficacy, safety, and 
tolerability of Docetaxel in the maintenance setting, and to identify 
the preferable dose of docetaxel in Asian population. TFINE study 
demonstrated significant superiority in tolerability and similar ef-
ficacy for dose of 60mg/m2 of Docetaxel versus that of 75mg/m2 
in first-line Chinese advanced NSCLC patients. And maintenance 
treatment with docetaxel significantly prolonged PFS compared 
with BSC. Here we report Overall Survival (OS) data from TFINE 
(ClinicalTrials.gov NCT01038661).
Methods: Previously untreated patients, aged between 18 and 75 
years, histologically or cytologically confirmed advanced NSCLC 
with PS of 0-1 were included. Patients were initially randomized 
(R1, 1:1) to receive cisplatin (75mg/m2) plus docetaxel of 75 mg/
m2 or 60mg/m2 for 4 cycles. Patients with disease control after the 
initial treatment were subsequently randomized (R2, 1:2) to best 
supportive care (BSC) or maintenance docetaxel of 60mg/m2 for 
up to 6 cycles. Genomic DNA was prospectively collected from 
all enrolled patients. The primary endpoint was PFS since R2, and 
the secondary endpoints included ORR, overall survival (OS), and 
toxicity. OS was defined as the time lasting from R2 to death of any 
cause. The subgroup analysis about OS included gender, historical 
category, smoking, ECOG PS. The maintenance treatments of eve-
ry patient were recorded.
Results: This randomized study was undertaken in 15 centers 
in China. Between Dec 2009 and Aug 2011, a total of 382 pati-
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noma had more opportunities to receive more drugs(P<0.05). The 
therapy regimen was decided by the Chinese medical insurance. 
Combined with platinum, gemcitabine was 29.3% and Taxanes was 
26.5%. Either of these two regimens was the preferred choice. Ty-
rosine kinase inhibitors(TKI) including those offered by clinical trail 
and pemetrexed which were paid at patients’ own expense were 
14%, 22.8%, respectively. In patients received 1, 2 and multi-line 
therapy(more than 2 lines), the partial response rate was 14.4%, 
3.8%, 0, respectively. The stable disease rate was 28.8%, 32.1%, 
30%, respectively. OS of patients with multi-line therapy(more than 
2 lines) was longer than those with 1 and 2 lines treatment but the 
data was not mature.
Conclusion: Patients with advanced non-small cell lung cancer had 
multi-line treatment had better disease control. Their regimens 
mainly covered the chemotherapy and TKIs. Limited of the Chi-
nese medical insurance, the first choice was gemcitabine/taxanes 
combined with platinum. Tailored therapy may explore the rational 
therapy sequence to get much better efficacy.
Keywords: non-small cell lung cancer, , multi-line treatment
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P3.10-047 WEIGHT GAIN DURING FIRST-LINE CHEMO-
THERAPY FOR LOCALLY ADVANCED AND METASTATIC 
NON-SMALL-CELL LUNG CANCER IS ASSOCIATED WITH 
IMPROVED SURVIVAL
Iva Ferreira1, Mohammed Azeem2, Sanjib Basu3, Shannon Sims4, 
Marta Batus1, Philip Bonomi1, Mary Jo Fidler1
1Department Of Medical Oncology, Rush University Medical Center/United 
States Of America, 2Department Of Internal Medicine, Rush University 
Medical Center/United States Of America, 3Department Of Preventive 
Medicine, Rush University Medical Center/United States Of America, 4De-
partment Of Quality Services/information, Rush University Medical Center/
United States Of America
Background: Two previous studies from our institution have shown 
that weight gain in the course of chemoradiotherapy for locally advan-
ced or oligomestastatic NSCLC is associated with improved survival 
(Sher et al, 2013 and Gielda et al, 2010). This study aimed to deter-
mine the prognostic value of weight and serum albumin changes in 
patients with locally advanced and metastatic NSCLC receiving first-
line platinum doublet chemotherapy.
Methods: Patients with newly-diagnosed locally advanced or metas-
tatic NSCLC treated in the first-line setting with platinum doublet che-
motherapy from June, 2011 to August, 2012 at RUMC were included 
for analysis. Weight and albumin values were recorded at baseline, 3, 
6, and 12-week intervals from initiation of therapy. Their association 
with overall survival (OS) was assessed using Kaplan Meir methods 
and Cox proportional hazards regression.
Results: A total of 139 patients were included. Median age was 68 ye-
ars (range 31-85). ECOG performance status (PS) was 0 in 29.5%, 1 in 
46.7%, and 2 or greater in 16.5% of patients. Median baseline weight 
was 68.17 kg (range 40.1-123.4). Patients who experienced weight gain 
at 6 weeks had a significantly higher OS compared to those who lost 
weight, 20.4 months versus 13.6 months median survival respectively 
(log-rank p=0.025), Fig 1. In Cox regression analysis the hazard ratio 
(HR) for 1 kg of weight gain at 6 weeks was 0.84 (p <0.001). A mar-
ginal improvement in OS was seen for those who gained weight at 
was administered every 3 weeks up to 6 cycles (induction phase). 
Unless PD, bevacizumab maintenance therapy was performed until 
PD (maintenance phase). The primary endpoint was median PFS 
to prove its superiority to the previous standard combination che-
motherapy consisting of docetaxel and cisplatin with its historical 
median PFS of 4.6 months. With a=0.05 and b=0.20, calculated 
minimum sample size was 37, and the final determined sample 
size was 40. This trial was registered to the clinical trial registration 
system with the ID of UMIN000004524.
Results: Forty patients enrolled and 39 patients were analyzed. 
They included women in 31%, patients with PS of 0 in 67%, stage 
IV in 92%, EGFR mutations in 13% and unknown EGFR status in 8%. 
The median age was 62 years. The induction phase was delivered 
for 4 cycles in median (range: 1-6), and 21 patients (54%) received 
maintenance phase with median 4 cycles (range: 2-24). Frequent 
toxicities ≥ grade 3 during the induction phase in completely 
analyzed patients (n=32) included neutropenia (50.0%), anemia 
(9.4%), thrombocytopenia (9.4%), febrile neutropenia (25.0%) and 
hypertension (37.5%). Other toxicities ≥ grade 3 were cholecystitis, 
increased ALP, hyperpotassemia, proteinuria, diarrhea, appetite 
loss, nausea, constipation, infection, stomatitis, and cancer pain in 
3.1%, respectively. Interim external reviews of 35 pts revealed ORR 
of 74% (26/35) and median PFS of 6.4 months (95% CI: 4.8-9.9).
Conclusion: The primary endpoint was met because the lower end 
of the 95%CI exceeded the threshold of 4.6 months. This combina-
tion chemotherapy seems promising in terms of safety and effec-
tiveness, warranting phase III studies.
Keywords: non-squamous non-small cell lung cancer, Bevaci-
zumab, first line chemotherapy
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P3.10-046 PATIENTS WITH ADVANCED NON-SMALL 
CELL LUNG CANCER(NSCLC) RECEIVED MULTI-LINE 
TREATMENTS HAD BETTER EFFICACY
Xiaochen Zhang, Nong Xu, Yulong Zheng, Jiong Qian, Haiping 
Jiang, Yi Zheng, Peng Zhao
Medical Oncology, The 1st Affiliated Hospital, Zhejiang University, 
College Of Medicine/China
Background: Efficacy of advanced non-small cell lung cancer 
treatment has been in platform. How to integrate the limited drugs 
and design the sequence of regimens is the key point in clinical 
practice.
Methods: Clinical data of 215 patients of pathologically confirmed 
advanced non-small cell lung cell from January 2010 to December 
2012 was analyzed retrospectively. The clinical features, patholo-
gical diagnosis, numbers of treatment lines and the efficacy were 
analyzed. Efficacy and adverse events were evaluated according 
to the RECIST 1.1 Criteria, NCI Common Terminology Criteria v3.0, 
respectively.
Results: Among 215 patients treated in our cancer center, 135 
were men and 84 were women. The squamous cell carcinoma and 
adenocarcinoma was 50 and 74 in man ; 8 and 70 in women, res-
pectively. 111 cases had 1 line treatment, 53 had 2 lines, 31 had 3 
lines, 10 had 4 lines and 9 had more than 4 lines. In all lines, pati-
ents with adenocarcinoma compared to the squamous cell carci-
S1179Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
squamous/NOS 34%/21%/46%. 710 (51%) patients were assessed by a 
MO and of these, 382 (54%) received chemotherapy. 1225 (89%) were 
assessed by a radiation oncologist (RO), and 1025 (84%) received ra-
diation. MLR showed that patients referred to MO were more likely to 
be younger, from an urban area, and have a better ECOG. Median OS 
for the entire cohort was 9.6 months (CI 8.5-10.7). There was a statisti-
cally significant improvement in OS in patients who received chemo-
therapy at 14.2 months (CI 12.5-15.9) in comparison to 7.6 months (CI 
6.6-8.6) who did not receive chemotherapy (p<0.0001). This remained 
statistically significant in the CPH model, controlling for ECOG, sex, 
age, histology (HR 0.80, CI 0.65-0.92). In comparison, OS was 8.6 
months (CI 7.4-9.8) for patients who received only radiotherapy, and 5 
months (CI 3.1-6.8) for those treated with best supportive care.
Conclusion: Only half of the referred patients were assessed by a me-
dical oncologist and only 54% of them received chemotherapy. This is 
despite the awareness that chemotherapy significantly improves OS. 
Strategies to improve upon this 51% referral rate should be evaluated, 
such that patients do not miss out on life-prolonging therapy.
Keywords: Treatment delivery, Referral patterns, Population-based 
analysis, advanced non-small cell lung cancer
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P3.10-049 COMBINATION CHEMOTHERAPY AND AU-
TOPHAGY INHIBITION WITH HYDROXYCHLOROQUINE 
FOR ADVANCED NON-SMALL CELL LUNG CANCER
Joseph Aisner, Biren Saraiya, Sujani Surakanti, Janice Mehnert, 
Eileen White, Robert S. Dipaola
Cancer Institute Of New Jeresey/United States Of America
Background: Autophagy (ATG) preserves tumor growth potential 
during cellular stresses, and may thus promote chemotherapy resis-
tance. Hydroxychloroquine (HCQ) inhibits ATG in in-vitro and in-vivo 
models.
Methods: We thus initiated a phase II study of HCQ (200 mg/d p.o, 
twice daily) plus I.V. paclitaxel 200 mg/M2 and carboplatin AUC=6 
every 21 days (group [GRP] 1) plus I.V. bevacizumab (GRP2; 15 mg/kg 
every. 21days as per Bev criteria).
Results: We entered 25 PS 0-1 patients (Pts), 14M/11F; 19 (5/4) in 
GRP1, 16 (9/7) GRP2. Median PS =1. Median age =70. Overall: 0 
CRs; 13/25 (52%, 90% CI 40,64) Pts achieved PR (4/9 GRP1; 9/16 
GRP2); 5/25 achieved SD (2/9 GRP1, 3/16 GRP2); 5/25 had PD, and 
2/25 remain too early. Median F/U is 16 months, median TTP was 6+ 
months, and median OS was 10+ months. Pharmacokinetic analysis 
of CINJ phase I HCQ studies, showed results similar to studies in 
arthritis: HCQ was membrane bound at doses up to 800 mg/day, 
but free HCQ levels were seen at 1200 mg/day. In parallel labora-
tory studies, engineered murine k-ras -/- lung cancer models were 
dependent on ATG, and ATG inhibitors blocked tumor development 
and progression. K-ras data, available on 4/25 Pts showed 1/1 k-ras 
wt had PD. Among 3 Pts with k-ras-mutant tumors, 2 achieved PR 
and 1 SD
Conclusion: Further k-ras assessment on available tissue is in pro-
cess. This study continues with HCQ at 1200 mg/day and required 
k-ras assessment.
Keywords: Autophagy, chemotherapy
12 weeks, median survival not reached versus 15.5 months in those 
who lost weight (log-rank p=0.07). The HR for 1 kg weight gain by 
12 weeks was 0.91 (p=0.002). Baseline albumin level was available 
for 97 patients. Median baseline albumin was 3.5 (range 1.5-4.7). A 
higher baseline albumin was found to be significantly associated with 
longer survival (HR 0.31, p<0.001). In a multivariate analysis, weight 
gain in 6 weeks was strongly associated (HR 0.81, p=0.003), and 
higher baseline albumin was associated (HR 0.49, p=0.03) with im-
proved OS after adjusting for age, PS, and baseline weight. Figure 1: 
Conclusion: Higher baseline albumin and weight gain during first-
line chemotherapy for locally advanced and metastatic NSCLC, 
appear to be associated with improved overall survival and may 
constitute important predictors of outcome. Study of molecular 
mechanisms involved in weight gain during anti-neoplastic treat-
ment might provide ideas for novel therapeutic strategies.
Keyword: Weight, albumin, NSCLC, survival
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P3.10-048 REFERRAL PATTERNS IN ADVANCED NON 
SMALL LUNG CANCER: IMPACT ON DELIVERY OF 
TREATMENT AND SURVIVAL IN BRITISH COLUMBIA
Krista Noonan, Cheryl Ho, King Mong Tong, Nevin Murray, Barba-
ra Melosky, Sophie Sun, Janessa Laskin
Medical Oncology, BC Cancer Agency/Canada
Background: Chemotherapy improves overall survival in advanced 
non-small cell lung cancer (NSCLC). We sought to evaluate clinical 
effectiveness of chemotherapy in the general population by looking 
at referral patterns, and outcomes.
Methods: The British Columbia (BC) Cancer Agency is a publicly fun-
ded system that serves a population of over 4.5 million. All referred 
cases of stage IIIb/IV non-small cell lung cancer were identified using 
the BC Outcomes and Surveillance Integrated System and retrospec-
tively reviewed. Patient demographics, tumour characteristics and 
treatments were extracted. Overall survival (OS) was estimated using 
the method of Kaplan-Meier. Cox Proportional Hazards (CPH) mode-
ling was used to control for possible confounders. Multiple logistic re-
gression (MLR) was used to compare characteristics between patients 
who were referred and not referred to a medical oncologist (MO).
Results: 1384 patients were diagnosed with Stage IIIb/IV NSCLC 
between January 1 to December 31, 2009. Median age 70 years (29-
96), male 53%, ECOG 0-1 38%, rural/urban 17%/83%, non-squamous/
S1180 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
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function change of the patients before and after chemotherapy 
were analyzed by dividing them into two groups: adenocarcinoma 
(ADC) and squamous cell carcinoma (SCC).
Results: Sixty-four patients with stage III and IV NSCLC were inclu-
ded for analysis. Thirty-nine out of 64 patients had SCC. The SCC 
patient group had more males (p = 0.001), higher pack-years in 
smoking history (p < 0.001), and a higher rate of chronic obstructi-
ve pulmonary disease (COPD) as the baseline disorder at cancer di-
agnosis (p = 0.005). With respect to the baseline pulmonary func-
tions, the SCC group showed significantly lower spirometric values 
of forced vital capacity (FVC; 79.4% vs 90.2%, p = 0,031), forced 
expiratory volume in 1 sec. (FEV1; 69.4% vs 90.5%, p=0.002), FEV1/
FVC (59.2% vs 70.3%, p <0.001) and maximum midexpiratory flow 
rate (MMFR; 38% vs 60.2%, p=0.002). Variables associated with 
lung volume, TLC showed no differences between the SCC and 
ADC groups. However, residual volume (RV; 107.6% vs 84.6%, p = 
0.012) and RV/total lung capacity (RV/TLC; 43% vs 34.8%, p=0.009) 
were significantly higher in the SCC group. The baseline DLCO 
level was significantly lower in the SCC group (82.8% vs 100.8%, 
p=0.013). After chemotherapy, pulmonary functions related to 
spirometry significantly improved while DLCO reductions were 
not significant in patients with SCC (-0.22%, p = 0.972). The ADC 
group revealed no change in variables relating to spirometry, but 
DLCO was reduced significantly (-16.6%, p = 0.021).
Conclusion: The baseline pulmonary functions and the changing 
pattern of pulmonary function after chemotherapy were different 
between these two groups. The pathogenesis and biological be-
havior of these respective histologic types of lung cancer would be 
attributable to these pulmonary functional alterations.
Keyword: Lung cancer, Pulmonary function, Chemotherapy
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P3.10-052 TAXANE MONOTHERAPY IN ADVANCED 
EGFR MUTATION POSITIVE LUNG CANCER: 
A SINGLE INSTITUTION EXPERIENCE
Christina Baik1, Manjiri Dighe2, Keith Eaton1, Laura Chow1, Bernar-
do Goulart1, Sarah Wallace1, Renato Martins1
1Medical Oncology, University Of Washington/United States Of Ameri-
ca, 2Radiology, University Of Washington/United States Of America
Background: Lung cancers harboring epidermal growth factor re-
ceptor (EGFR) activating mutations are sensitive to EGFR tyrosine 
kinase inhibitor (TKI) therapy with tumor response rates of 70-80%. 
However, patients eventually develop resistance requiring the use 
of cytotoxic chemotherapy. Currently, the optimal chemotherapeu-
tic agent in this molecular subtype is unknown. We have observed 
at our institution that EGFR mutation positive lung cancers are 
sensitive to subsequent taxane therapy. Here we present a single 
institutional experience of EGFR mutation positive lung cancer 
patients who have been treated with a taxane monotherapy after a 
prior TKI therapy.
Methods: This retrospective case series includes patients with 
advanced lung cancer with a documented EGFR mutation who 
have been treated with an EGFR TKI and who received subsequent 
taxane monotherapy between November 2006 and April 2013. 
The response rate was analyzed using RECIST 1.1. The overall di-
sease control rate was evaluated at 8 weeks. Only the patients who 
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P3.10-050 CHANGES OF PULMONARY FUNCTION AF-
TER PLATINUM BASED CHEMOTHERAPY IN SMALL CELL 
LUNG CARCINOMA
Wooho Ban
The Catholic University Of Korea/Korea
Background: Platinum based combination chemotherapy is 
the mainstay of treatment in patients with small cell lung cancer 
(SCLC). However, changes of pulmonary function after the chemo-
therapy in these patients have not been well characterized.
Methods: We reviewed the data from patients with SCLC treated 
with platinum based chemotherapy as a first-line treatment at St. 
Paul’s Hospital, The Catholic University of Korea, retrospectively. 
The basal clinical features and the outlook of changes in pulmona-
ry function test (PFT) values of the patients before and after 2 or 3 
cycles of chemotherapy were analyzed. Also, we surveyed factors 
affecting such pulmonary function changes.
Results: Eighteen patients were enrolled in this study. Baseline 
PFT values were measured and forced expiratory volume in 1 se-
cond (FEV1, 80.4%), forced vital capacity (FVC, 87.4%), and FEV1/
FVC ratio (62.5%) showed an obstructive pattern. After the che-
motherapy, overall spirometric values and lung volumes were not 
significantly changed, but diffusing capacity of the lung for carbon 
monoxide (DLCO) was significantly decreased ( p = 0.023). In mul-
tivariate analysis, peripheral tumor location was the only significant 
factor associated with DLCO reduction (HR 21.00; 95% CI 1.504-
293.253; p=0.024). Patients with limited disease had a declining 
tendency of DLCO (p = 0.058) compared to the patients with ex-
tensive disease.
Conclusion: Platinum based chemotherapy could reduce DLCO in 
patients with SCLC. Tumor location was the only independent fac-
tor associated with DLCO reduction.
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P3.10-051 CHANGE IN PULMONARY FUNCTION AFTER 
CHEMOTHERAPY IS DIFFERENT BETWEEN SQUAMOUS 
CELL CARCINOMA AND ADENOCARCINOMA OF THE 
LUNG
Wooho Ban
The Catholic University Of Korea/Korea
Background: Chemotherapy is a mainstay of therapy for lung 
cancer, and lung is an organ that manifests adverse reactions of 
chemotherapy. Also, owing to association with smoking, lung can-
cer is often seen in cases with compromised lung functions. Never-
theless, the baseline pulmonary functions and the manifestations 
of pulmonary function change after chemotherapy in patients with 
lung cancer have largely been unknown.
Methods: This retrospective study analyzed the data from patients 
who had been diagnosed as having non-small cell lung cancer 
(NSCLC) and treated at St. Paul’s Hospital, The Catholic University 
of Korea. The basal clinical features and the outlook of pulmonary 
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P3.10-053 PHASE II STUDY OF A NOVEL TAXANE 
(CABAZITAXEL-XRP 6258) IN PREVIOUSLY TREATED 
ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) 
PATIENTS: TOXICITY REPORT
Rodolfo Bordoni1, Francisco Robert2, Mansoor Saleh2, Pamela Di-
xon2, Barbara Howell1, Candice Griffith1
1Georgia Cancer Specialists Affiliated With Northside Cancer Insititue/
United States Of America, 2Uab/United States Of America
Background: Cabazitaxel-XRP6258 is a novel semisynthetic taxane 
derived from the European yew. In vitro, it has similar microtubules 
stabilization properties to docetaxel, even against resistant cell li-
nes, due to its lower affinity for P-glycoprotein. Additionally, precli-
nical models indicated that cabazitaxel was able to cross the blood 
brain barrier. In addition to prostate cancer, data available from 
completed phase I, II and III trials showed activity in lung cancer. 
Based on these data we designed and conducted a phase II trial of 
Cabazitaxel in the second line treatment of NSCLC.
Methods: In this open-label, pilot Phase II trial, subjects with stage 
IV NSCLC [7th Edition of the TNM staging classification, 2009], who 
have failed first line chemotherapy (platinum doublet or non-plati-
num doublets, including previous taxane exposure) were randomly 
treated with either treatment Schedule A (20 mg/m2 every 3 weeks 
as a 1 hour IV infusion, f/b 25 mg/m2, if no DLTs) or B (8.4 mg/m2 
as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5 week cycle, 
f/b 10mg/m2, if no DLTs). The primary endpoint was to assess the 
objective response rate (ORR) of Cabazitaxel-XRP6258. Secondary 
Objectives were to assess the time to progression (TTP), progressi-
on free survival (PFS), overall survival (OS) and safety.
Results: Overall the treatment was well tolerated. Among the so 
far 22 patients enrolled onto the trial, the most commonly found 
side effects to cabazitaxel were fatigue (18%), anemia (9%), hema-
turia (8%), neuropathy (6.5%), neutropenia (6%), nausea (6%), and 
dyspnea (6%), reported as a percentage of the total 141 censored 
events, compared with the previously most commonly described 
side effects to cabazitaxel of neutropenia, leukopenia, anemia, 
diarrhea, fatigue, and asthenia. Most side effects (76%) were grade 
1/2 while 23% were grade 3/4; only one patient (4.5%) experienced 
grade 5 toxicity and succumb to sepsis. The most common adver-
se effects leading to treatment discontinuation were hematuria 
and sepsis. Often reported toxicities (over 10%) not found in this 
cohort includes diarrhea, vomiting, constipation, alopecia, arthral-
gia and mucosal inflammation. Inversely, the report of hematuria 
in almost one third of the patients (73% grade 1/2 and 27% grade 
3/4) was significant, even more because contrary to the experience 
with prostate cancer (17% incidence) our population of patients 
lack the presence of blood in urine at baseline.
Conclusion: This Phase II study of cabazitaxel in second line ad-
vanced NSCLC showed good tolerance to the drug when admi-
nistered in two different schedules. The observed side effects are 
in general consistent with prior reports but hematuria, developed 
upon exposure to the drug in almost one third of patients. We 
speculate that cabazitaxel may induce hematuria in cancer patients 
by direct injury of the urothelial mucosa.
Keywords: cabazitaxel, phase II, Second line, Advanced
received treatment for at least 4 weeks and who were evaluable for 
response were included in the analysis.
Results: Among the 19 patients identified, 17 patients were inclu-
ded in the analysis. Ten (59%) patients were found to have exon 
19 deletion and five (29%) had exon 21 L858R point mutation. The 
median age of patients was 68 (range 46 – 78) and 65% were wo-
men. Sixteen (94%) patients received weekly paclitaxel 90mg/m2 d 
and one patient (6%) received docetaxel 60mg/m2 every 3 weeks. 
Patients had received a median of 3 previous lines of therapy 
(range 1-5) which included prior TKI therapy. Median duration of 
treatment was 4.0 months (range 1.0 – 9.6). Partial responses (PR) 
were observed in 4 (24%) patients with a median tumor reduction 
of 59.8% (range 37.7 – 76.4%) and the median duration of response 
was 6.9 months (range 6.5 - 7.0). Stable disease (SD) at 8 weeks was 
observed in 10 (59%) patients with a median tumor reduction of 
18.7%. Median duration of stable disease was 4.0 months (range 
3.3 - 9.6). The overall disease control rate (PR + SD) at 8 weeks was 
82% (14/17). 
Conclusion: Patients with EGFR mutation positive lung cancers 
exhibit excellent disease control with taxane monotherapy in this 
case series, even in heavily pretreated patients. The role of taxane 
monotherapy in this patient population is currently being evalua-
ted in a prospective phase II trial at our institution. Further investi-
gation of the biological mechanism of this finding is warranted.
Keyword: EGFR, Non-small cell lung cancer, chemotherapy,  
taxane
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P3.10-055 LONG PROGRESSIVE FREE SURVIVAL TO PAC-
LITAXEL AND CISPLATIN IN FIRST LINE IS ASSOCIATED 
WITH BETTER RESPONSE AND PROGRESSION FREE 
SURVIVAL TO DOCETAXEL IN SECOND LINE IN ADVAN-
CED NON-SMALL CELL LUNG CANCER
Eleazar O. Macedo1, Oscar Arrieta1, David Orta2
1Thoracic Tumors, Instituto Nacional De Cancerologia/Mexico, 2Thoracic 
Tumors, Insituto Nacional De Cancerologia/Mexico
Background: Lung cancer is the leading cause of cancer death 
worldwide. Approximately 85% are of the non–small-cell lung 
cancers (NSCLC) histology and the majority have locally advanced 
or metastatic stage IV disease at diagnosis (85%). Cisplatin-based 
combination chemotherapy (CT) is the standard treatment in 
first line. Cisplatin plus paclitaxel (PT) it´s one of the most used 
combinations. Docetaxel (D) is approved for FDA in second line 
in NSCLC based in 3 phase III trials. Patients with breast cancer 
treated with paclitaxel (T) can respond to D. However, there is little 
information on lung cancer. We evaluate factors associated with 
response to D in patients previously treated with PT.
Methods: We analized consecutive patients treated in the thoracic 
tumors clinic of the Instituto Nacional de Cancerologia in Mexico 
between January 2007-december 2012 with NSCLC IV stage that 
previously were treated with PT and that at progression received D 
as second line (75mg/m2 each 3 weeks). We define as period free 
of Paclitaxel (PFT) the interval between the last cycle of PT and 
the progression of the disease, progression free survival (PFS) as 
interval since first cycle of CT and progression disease, and overall 
survival (OS) as the period from the diagnosis and death from any 
cause. The rate response (RR) was evaluated with RECIST criteria.
Results: Fifty-five patients were eligible for entry onto the stu-
dy. Median age was 57.6 years (±15.1), female 54.5%, ECOG 0-1 
(89.1%), cigarettes-smoking 45.5%, never smokers 54.5%; ade-
nocarcinoma histology 74.5% and epidermoid 25.5%. The PFS 
to first-line was 6.7 months (IC 95% 5.8-7.6) and PFS to D was 4.3 
months (IC 95% 2.8-5.9 months). The median period between last 
cycle of CT and progression disease was 2.99 months (IC 95% 2.1-
3.9 months). The RR to D was 21.8% in all population. In patients 
with PFT >3 months compared with PFS <3months, the RR and 
PFS were 29% vs 14.3% (p 0.186) and 2.7 vs 6.7 months (p 0.021), 
respectively. We not found differences for type of response to first 
line CT neither histology subtype. The patients with partial respon-
se to D had were PFS prolonged in relation to patients with stable 
disease (5.3 versus 2.6 months, p 0.069).
Conclusion: Prior used of T not excluded for used D. Our results 
demonstrate that the PFT is the best predictive factor for response 
to D. Patients with PFT >3 months and response to D have better 
prognostic in relation with PFT <3months and with stable disease 
to D. This results must be validated in others prospective studies 
and Phase III trials that compared docetaxel with others therapies.
Keywords: NSCLC, metastasis, Interval free paclitaxel, response 
toDocetaxel
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P3.10-054 METASTATIC NSCLC OUTCOMES AT A SINGLE 
CANADIAN INSTITUTION OVER A DECADE
Shannon Otsuka, William Boland, Desiree Hao, Don Morris, Gwyn 
Bebb
University Of Calgary/tom Baker Cancer Centre/Canada
Background: In the past 10 years, the standard of care in non 
small cell lung cancer has seen the adoption of several less toxic 
and better tolerated therapies, allowing a greater proportion of 
metastatic patients the opportunity to receive 2nd and even 3rd line 
treatment. We investigated whether this improvement in the num-
ber of available therapies for metastatic NSCLC had any bearing 
on overall patient survival, by retrospectively analyzing patients 
diagnosed in 1999/2000, 2004/2005 and 2009/2010 at our centre.
Methods: After ethical approval was obtained demographic 
details, clinical variables and outcome data were gathered retro-
spectively via chart review, on NSCLC patients diagnosed at the 
Tom Baker Cancer Centre (TBCC) in 1999/2000, 2004/2005 and 
2009/2010 (Glans-Look Lung Cancer Database). All patients were 
restaged according to the new 7th Edition of the American Joint 
Committee on Cancer TNM system for NSCLC staging. Stage IV 
patients and early stage patients with subsequent metastatic re-
currence were included in the analysis. Survival was analyzed using 
the Kaplan-Meier method and differences measured by a log rank 
test.
Results: 1290 patients were included in the preliminary analysis 
(data only from 1999, 2004/2005 and 2009/2010), 1018 of which 
were stage IV at diagnosis, 272 who recurred with metastatic di-
sease. The median overall survival (MOS) of patients increased 
slightly from 1999 to 2009/2010, from 4.5 months in 1999, to 5.7 
months in 2004/2005 to 4.6 months in 2009/2010, as did the pro-
portion of patients who received systemic treatment (21.3% in 
1999, 28.9% in 2004/2005 and 28.1% in 2009/2010). However, the 
proportion of patients who received 2 or more lines of chemo dou-
bled from 1999 to 2009/2010 (7.3% in 1999, 12.1% in 2004/2005 
and 14.6% in 2009/2010)(p = 0.04). In addition, there was a trend 
towards increasing median overall survival (MOS) of systemically 
treated patients over 1999-2009, from 9.6 months (95% CI: 7.6-11.6) 
in 1999 to 12.7 months (95%CI: 11.0-14.4) in 2009/2010 (p=0.25).
Conclusion: Our analysis suggests that there are an increasing 
proportion of metastatic NSCLC patients being treated systemi-
cally at our centre, specifically, the proportion being treated with 
two or more lines of systemic therapy has significantly increased 
over the decade from 1999-2009/2010. This study also suggests a 
trend toward an increased MOS for systemically treated patients 
diagnosed in 2009/2010 compared to those diagnosed in 1999. 
However, the vast majority of patients (>3/4) are still not being 
treated with systemic therapy, despite the increase in available 
therapies now compared to a decade ago. The reasons for this are 
not clear but may include poor ECOG performance status, rapid 
decline, sub-optimal referral pathways and rural residence. Further 
analyses will be presented.
Keywords: Systemic Therapy, Metastatic NSCLC, outcomes
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NSCLC. CART can be used to identify homogeneous patient po-
pulations in clinical practice and future clinical trials.
Keyword: non-small-cell lung cancer (NSCLC); Classification and 
regression tree(CART); Gefitinib
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P3.11-002 NEW TOXICITY PROFILE AS RADIOLOGICAL 
RESPONSE MARKER IN THE CONTEXT OF MTOR THE-
RAPY IN ADVANCED/METASTATIC NON SMALL CELL 
LUNG CANCER (NSCLC)
Jesus Corral, Julia Martinez, Maria Dolores Mediano, Miriam Alon-
so, Miriam Gonzalez De La Peña, Amparo Sánchez Gastaldo
Medical Oncology, University Hospital Virgen Del Rocio/Spain
Background: mTOR pathway plays a key role in most of solid tu-
mors. Its blockage has shown clinical and survival benefit in the 
context of advanced/metastatic breast, kidney and neutroendocri-
ne cancer. Multiple preclinical and early clinical trials are ongoing 
to demonstrate mTOR inhibition role as monotherapy as in chemo 
combo in NSCLC.
Methods: Retrospective analysis of advanced and/or metastatic 
NSCLC patients treated in our Institution with mTOR monotherapy 
or combined chemotherapy and correlation between radiological 
cavitation pattern mTOR therapy induced as early response mar-
ker.
Results: Four patients with advanced/metastastic NSCLC in pro-
gression after more or equal 2 lines of standard chemotherapy 
were treated in our center during 2012 in the context of early cli-
nical trials. Three patients had squamous NSCLC and one patient 
adenocarcinoma. All ones were evaluated at 6-8 weeks by CT scan: 
cavitation as early response marker was seen in all of them but 
measurement by RECIST 1.1 criteria only showed stable disease.
Conclusion: Preliminary data suggest that cavitation may be a 
marker of stable disease by RECIST and the therefore, a therapeu-
tic benefit. Overinfection and haemoptysis are currently complica-
tions in this context. Careful patient assessment should be under-
taken while the drug is being administered.
Keyword: NSCLC, mTOR therapy, response marker
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P3.11-001 CLASSIFICATION AND REGRESSION TREE 
ANALYSIS OF PATIENTS WITH NON-SMALL-CELL  
LUNG CANCER TREATED WITH GEFITINIB AFTER  
CHEMOTHERAPY
Hongyan Sun1, Jingfeng Guo2, Yu-Tao Liu1, Zi-Ping Wang1
1Medical Oncology Department, Cancer Institue & Hospital, Chinese 
Academy Of Medical Sciences & Peking Union Medical College/China, 
2Medical Oncology Department, Hexian Affiliated Memorial Hospital Of 
Southern Medical University/China
Background: Many randomized studies have shown that epider-
mal growth factor receptor (EGFR-) tyrosine kinase inhibitors (TKIs) 
are apparently advantageous over standard chemotherapy in 
non-small-cell lung cancer (NSCLC) patients with EGFR active mu-
tation in front-line treatment. But the EGFR mutation status is not 
a compulsory guideline for second- or third-line treatment in cli-
nical practice. which subgroup of advanced NSCLC could benefit 
from EGFR-TKIs in the second-or third-line setting remains elusive. 
To explore predictive factors of advanced NSCLC patients with 
the unknown status of EGFR mutation treated by gefitinib in the 
second-or third-line setting is warrant.
Methods: 155 cases with advanced NSCLC who failed in previous 
platinum-based chemotherapy and received gefitinib as part of the 
Expanded Access Program (EAP) of the China Charity Federation 
were included in this study. Fifteen clinical variables were analyzed 
within the following general categories: demographic variables, 
smoking history, pathological and differentiation, involvement of 
specific metastasis sites, the number of comorbidities, and prior 
thoracic radiotherapy. Multivariate analysis of progression-free sur-
vival (PFS) was performed using recursive partitioning referred to 
as classification and regression tree (CART) analysis. This method 
uses recursive partitioning to assess the effect of specific variables 
on PFS, thereby ultimately generating groups of patients with simi-
lar clinical features on PFS.
Results: The median PFS in 155 patients with NSCLC who were 
treated with gefitinib after prior chemotherapy was 14 months 
(95% CI 13.4–18.6). CART was performed with an initial split on 
adenocarcinoma differentiation, followed by brain metastasis and 
prior thoracic radiotherapy. According to the analysis, four terminal 
subgroups were produced, and the median PFS was significantly 
different between the four terminal subgroups (P=0.011). The lon-
gest PFS subgroup was located in those patients with well-diffe-
rentiated adenocarcinoma without brain metastasis, and received 
prior thoracic radiotherapy (mPFS 42 m). The poorest median PFS 
of 12 months was found in subgroup of patients with moderately 
and poorly-differentiated adenocarcinoma. The other two sub-
group patients were well-differentiated adenocarcinoma without 
brain metastasis, and didn‘t receive prior thoracic radiotherapy 
(mPFS 18 m), and well-differentiated adenocarcinoma with brain 
metastasis (mPFS 13 m) respectively.
Conclusion: Adenocarcinoma differentiation, brain metastasis and 
prior thoracic radiotherapy are predictors of benefit of gefitinib in 
second- or third- line treatment after chemotherapy in advanced 
S1184 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 3 - NSCLC NOVEL THERAPIES  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.11-004 A PROSPECTIVE STUDY OF THE USE OF CIR-
CULATING MARKERS AS PREDICTORS FOR EPIDERMAL 
GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHI-
BITOR TREATMENT IN PULMONARY ADENOCARCINO-
MA
Yuh-Min Chen1, Pei-Chun Tseng2, Yung-Hung Luo2, Teh-Ying 
Chou3, Yu-Chin Lee2, Reury-Perng Perng2, Jacqueline Whang-Peng4
1Department Of Chest Medicine, Taipei Veterans General Hospital/
Taiwan, 2Taipei Veterans General Hospital/Taiwan, 3Department Of 
Pathology And Laboratory Medicine, Taipei Veterans General Hospital/
Taiwan, 4Taipei Medical University/Taiwan
Background: The use of liquid tissue, such as circulating cells or 
free DNA, to predict treatment response is attracting more atten-
tion.
Methods: Patients with stage IV adenocarcinoma of the lungs 
who were going to receive gefitinib or erlotinib treatment were 
included. Both tumor tissue and plasma specimens were prospec-
tively collected before treatment and analyzed using the ARMS-
Scorpions method for EGFR mutation status analysis. The numbers 
of circulating CD146+/CD3- cells (as circulating endothelial cells, 
CECs), CD34+/CD45- cells (as endothelial progenitor cells, EPCs), 
and CD133+ cells (as circulating cancer stem cells, CSCs) were 
measured with flow cytometry. From June 2010 to July 2012, 112 
consecutive patients were enrolled.
Results: Eighty of the 112 patients had tissue EGFR (tEGFR) acti-
vating mutations. Plasma EGFR (pEGFR) activating mutations were 
detected in 24 of 80 patients with tEGFR activating mutations. 
There were lower CEC, EPC, and CSC counts in tEGFR mutated 
patients than in wild-type patients (p=0.001, 0.012, and 0.001, 
respectively). Progression-free survival (PFS) was best in those with 
only tEGFR mutations (n=56, median 16.8 months), followed by 
those with both tEGFR and pEGFR mutations (n=24, median 7.9 
months), and worst in EGFR wild-type patients (n=32, median 2.1 
months) (p<0.0001). PFS was significantly longer in patients with 
low CEC and low CSC counts than in those with high cell counts 
(p=0.0023 and 0.0053, respectively). Multivariate analysis showed 
that the presence of pEGFR was a poor prognostic factor, but not 
the presence of other markers.
Conclusion: The presence of pEGFR mutation is a poor prognostic 
factor for patients with tEGFR mutations when they receive EGFR-
TKI treatment. EGFR wild-type patients had higher counts of CECs, 
EPCs, and CSCs. These circulating markers are useful in predicting 
EGFR-TKI treatment efficacy, but less useful than pEGFR detection.
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P3.11-003 THE USE OF EPIDERMAL GROWTH FACTOR 
RECEPTOR TYROSINE KINASE INHIBITORS IN TREAT-
MENT OF ADVANCED EGFR WILD-TYPE NON-SMALL 
CELL LUNG CANCER: A META-ANALYSIS STUDY
Kit Man Wong1, Charles Victor2, Lawson Eng3, Sunil Verma4
1Medical Oncology, University Of Toronto/Canada, 2Institute Of Clinical 
Evaluative Sciences/Canada, 3Faculty Of Medicine, University Of Toronto/
Canada, 4Medical Oncology, Sunnybrook Health Sciences Centre/Canada
Background: The epidermal growth factor receptor (EGFR) oral 
tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, improve 
progression-free survival (PFS) compared to chemotherapy in the 
first-line treatment of patients with advanced non-small cell lung can-
cer (NSCLC) with activating EGFR mutation. Previous trials of TKIs in 
unselected patients suggest that they may have some activity in EGFR 
wild-type (WT) patients, but the magnitude of benefit is unclear. We 
conducted a meta-analysis to determine the outcomes of EGFR WT 
patients with advanced NSCLC treated with gefitinib or erlotinib.
Methods: MEDLINE was searched for phase 2 and 3 clinical trials of 
gefitinib or erlotinib in advanced NSCLC published between January 
2000 and May 2012. Trials using TKI as treatment arm (i.e. compared 
against placebo or chemotherapy), control arm or maintenance the-
rapy were included. In addition, studies must have tested for EGFR 
mutation by polymerase chain reaction and analyzed EGFR WT 
patients. Random effects meta-analysis using the DerSimonian and 
Laird method was performed to pool survival estimates (hazard rati-
os (HR), risk ratios) and objective response rate (ORR). Placebo- and 
chemotherapy-controlled phase 3 trials were evaluated separately in 
a subgroup analysis.
Results: Six randomized controlled trials (RCTs) with a total of 1,180 
EGFR WT patients (709 on TKI, 471 on control with placebo or che-
motherapy) were available for meta-analysis. Pooled overall survival 
(OS) from 5 RCTs was not significantly different for patients in the TKI 
arm compared to control arm (HR 1.00; 95% CI 0.86-1.16). Subgroup 
analysis according to type of control showed that TKI offered no OS 
benefit compared to either placebo (HR 0.92, 95% CI 0.63-1.35) or 
chemotherapy (HR 1.02, 95% CI 0.86-1.22) (interaction p=0.63). Like-
wise, pooled PFS was similar between TKI and control in 4 RCTs (HR 
1.35; 95% CI 0.79-2.31). However, the use of TKI significantly increa-
sed PFS compared to placebo (HR 0.78, 95% CI 0.63-0.97), but not 
compared to chemotherapy (HR 1.64, 95% CI 0.96-2.79) (interaction 
p=0.01). The rate of patients in the control arm who subsequently re-
ceived TKI upon progression ranged from 3% to 52%. ORR estimated 
from 51 studies (1,872 EGFR WT patients) was 8.4% (95% CI 6.0-10.8), 
and was similar for gefitinib and erlotinib. Sensitivity analysis removing 
studies with estimated effect sizes did not affect these findings.
Conclusion: In this meta-analysis, gefitinib and erlotinib significantly 
increase PFS compared to best supportive care for advanced NS-
CLC with EGFR WT status. The lack of OS gain may be explained by 
significant crossover in these trials. TKIs may have a potential role in 
the management of EGFR WT patients who are not candidates for 
chemotherapy. There is a lack of studies on TKIs in EGFR WT patients, 
and more data with new generation TKIs are needed in this populati-
on.
Keywords: non-small cell lung cancer, wild-type EGFR, Meta-analysis, 
EGFR inhibitors
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ve for PFS with gefitinib.
Keywords: dose-escalation, NSCLC, stable disease, gefitinib
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P3.11-006 ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN 
PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL 
LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKI-
NETIC (PK) INTERACTION
Millie Das1, Sukhmani K. Padda1, Lisa Zhou1, Adam Frymoyer2, Joel 
W. Neal1, Heather A. Wakelee1
1Medicine, Division Of Oncology, Stanford University School Of Medi-
cine/United States Of America, 2General Pediatrics/neonatal And De-
velopmental Medicine, Stanford University School Of Medicine/United 
States Of America
Background: Dovitinib (TKI 258) is an oral antiangiogenic agent 
that targets PDGFR, KIT, FLT3, VEGF, RET, and FGFR. Dovitinib 
induces CYP1A1/A2, CYP2C19, CYP2C9, and it inhibits CYP3A4. 
Dovitinib is metabolized mainly by FMO, CYP3A4, and CYP1A1/
A2. Erlotinib is metabolized mostly by CYP3A4 (70%) but also by 
CYP3A5, CYP1A1, and CYP1A2.
Methods: This is a phase I 3+3 trial of E+D in patients with EGFR 
wild-type or mutated metastatic NSCLC who could have previ-
ously received E. Four cohorts were planned with E given daily 
and D given 5 days on/2 days off, starting after a 2-week lead-in 
of E alone. Only two cohorts enrolled due to dose limiting toxicity 
(DLT): cohort 1 [150 mg E +300 mg D] and cohort -1 [150 mg E+200 
mg D]. Plasma concentrations of E and its metabolite OSI-420 
were measured on day 14+/-4 (E alone; pre-dose, 2, 4, 6, 8, and 24 
hours) and day 29 +/- 4 (D+E, at same time points). Pharmacoki-
netic (PK) samples were analyzed by a validated liquid chromato-
graphy-tandem mass spectrometry assay. PK parameters for E and 
OSI-420 were estimated from the plasma concentration data via 
noncompartmental analysis. Paired-t tests on log transformed PK 
parameters were used to detect a statistical difference (α < 0.05, 
2-sided) between E alone versus E+D treatment days.
Results: Nine patients enrolled (3 in cohort 1 and 6 in cohort (-1)). 
The study was suspended due to excess of DLTs. Best response 
was evaluable in seven patients. Two unevaluable patients on 
follow-up scan were on E monotherapy for ~1 month. Four patients 
discontinued due to grade 3 AEs (syncope (n=1), fatigue (n=1), and 
pulmonary embolism (n=2)). Three patients had progressive di-
sease and 4 had stable disease (duration: 6 cycles(C), 8 C, and 1-2 
C for two patients who stopped due to AE). Two patients required 
a dose delay in D (one for grade 2 LFT elevation, the other for gra-
de 3 fatigue) and one required dose reduction of E to 100 mg prior 
to initiation of D (dose-corrected for PK analysis). Six patients had 
data available for PK analysis. During E alone, erlotinib exposure 
(average Cmax 2308 +/- 697 ng/ml and AUC 0-24 41.0 +/- 15.6 µg*h/
ml) was similar to previous reports for multiple daily doses of 150 
mg. During D co-administration, the concentrations of E were re-
duced. Cmax on average decreased by 83% (p= 0.022) and AUC0-24 
by 94% (p= 0.0039). OSI-420 exposure was also reduced during D 
co-administration.
Conclusion: Our small study demonstrates a potential significant 
PK interaction with decrease of E and its metabolite in the pre-
sence of D. This decrease is higher than that reported in combi-
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P3.11-005 RANDOMIZED, OPEN-LABEL, MULTI-CENTER 
STUDY OF GEFITINIB DOSE-ESCALATION (500MG/D 
VERSUS 250MG/D) IN ADVANCED NSCLC PATIENT 
ACHIEVED STABLE DISEASE (SD) AFTER ONE-MONTH 
GEFITINIB TREATMENT
Li Zhang1, Cong Xue1, Ning Li2, Weineng Feng3, Jun Jia4, Jiewen 
Peng5, Daren Lin6, Xiaolong Cao7, Siyang Wang8, Weimin Zhang9, 
Hongyu Zhang8, Wei Dong10
1Medical Oncoloty, Sun Yat-Sen University Cancer Center/China, 2Me-
dical Oncology, Guangzhou Chest Hospital/China, 3Oncology, The First 
People‘s Hospital Of Foshan/China, 4Dongguan People‘s Hospital/Chi-
na, 5Zhongshan People‘s Hospital/China, 6Jiangmen Central Hospital/
China, 7Panyu District Central Hospital/China, 8The Fifth Affiliated 
Hospital Of Sun Yat-Sen University/China, 9General Hospital Of Gu-
angzhou Military Command Of Pla/China, 10The First People‘s Hospital 
Of Shunde/China
Background: Some retrospective studies revealed that higher 
drug exposure of EGFR-TKIs was associated with better clinical 
outcome, especially in EGFR mutation-negative patients (pts). This 
randomized, open-label, multi-center study try to confirm whether 
dose-escalation of gefitinib would improve effect and survivals.
Methods: Key eligibility criteria of this study include: ECOG PS 
0-2, stage IIIB/IV NSCLC all histologies, progression after previous 
platinum-based chemotherapy, SD after one-month treatment of 
standard dose gefitinib (250mg/d). Patients were randomized (1:1) 
to received either higher dose (500mg/d, H group) or continue 
standard dose (250mg/d, S group) of gefitinib untill progression 
or toxicities. The primary end-point was objective response rate 
(ORR), and secondary endpoints included progression-free survival 
(PFS), overall survival (OS) and safety. The sample size was deter-
mined based on the assumption that H group was superior to S 
group in ORR (15% vs 5%, a one-sided alpha of 0.1, 1 - beta = 0.8) 
and 50 pts per arm was needed. Paired plasma was collected for 
detection of gefitinib concentration with high-performance liquid 
chromatographic method with tandem mass spectrometric (LC–
MS/MS) method in consented patients at baseline (randomization, 
D1) and first evaluation (D60). (NCT01017679)
Results: From May 2009 to Jan 2012, 466 pts treated with gefitinib 
were included in this study. Among these pts, 155 achieved SD af-
ter one-month gefitinib treatment and 96 pts were randomly assi-
gned to H group (48 pts) or S group (48 pts), respectively. Baseline 
factors including age (55.5 vs 57.5 years), gender (M/F: 24/24 vs 
19/29), histology (adenocarcinoma/others: 44/4 vs 41/7), smoking 
status (Y/N: 18/30 vs 15/33) and EGFR mutantion rate (20% vs 31%) 
were balanced between two arms. ORR were same (12.5%) in two 
groups (p=1.000); median PFS were 159 days (H group) vs 187 days 
(S group, p=0.077); and median OS were 411 days (H group) vs 743 
days (S group, p=0.098), respectivedly. Significantly more grade 
3/4 acne-like rash was seen in H group (14.6% vs 0%, p=0.012). PFS 
was significantly longer in EGFR mutation pts than wild type pts 
(344 d vs 135 d, p =0.001 ). Plasma gefitinib concentration increa-
sed significantly in the H group (n=12, D1 vs D60: 217.02 ng/ml vs 
397.25 ng/ml, p=0.017) while it remained stable in S group (n=7, 
312.59 ng/ml vs 310.33 ng/ml, p=0.972). However the gefitinib con-
centration increase did not translate to survival improvement.
Conclusion: Gefitinib 500mg/d did not confer a response or survi-
val advantage over gefitinib 250mg/d in patients achieved SD with 
one-month gefitinib treatment. EGFR mutation remained predicti-
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ratio to motesanib or placebo. Stratification factors include EGFR 
mutation status, weight loss of ≥ 5% in the previous 6 months, and 
region. This MONET-A trial will be assessed twice by the Indepen-
dent Data Monitoring Committee (IDMC), at the time 50 and 150 
patients complete their first cycle for unblinded safety data.
Results: This study initiated in July 2012 and is being conducted 
in Japan, Korea, Taiwan, and Hong Kong. The enrollment is on-
going. First evaluation by IDMC was performed using the data as 
of 26 December 2012. A total of 64 patients were enrolled and 
63 patients (63 Japanese; median age, 64.5 years) received study 
treatment. All the blinded patients who received study treatment 
experienced adverse events (AEs); Grade 3 to 5 AEs were reported 
in 38 patients (60.3%). Common AEs included alopecia (63.5%), 
peripheral sensory neuropathy (57.1%), and decreased appetite 
(50.8%). 7 patients had 8 serious AEs (SAEs). SAEs considered to 
be related to blinded study drug were cholecystitis in 2 patients, 
gastric ulcer haemorrhage, nausea, and upper gastrointestinal 
haemorrhage in 1 patient. A treatment-related fatal AE (interstitial 
lung disease) was reported in one patient (blinded). AEs leading to 
permanent discontinuation of unblindedunblinded study drug (mo-
tesanib or placeco) were cholecystitis (Grade 2), liver injury (Grade 
3), purpura (Grade 2), rash (Grade 3), eye haemorrhage (Grade 2), 
upper gastrointestinal haemorrhage (Grade 3), and gamma-gluta-
myltransferase increased (Grade 4).
Conclusion: The first IDMC recommended continuation of the stu-
dy after the review of unblinded data of 63 patients. Updated safe-
ty data will be presented after the second IDMC (JapicCTI-121887).
Keywords: NSCLC, VEGFR, Asian phase 3 trial, Motesanib
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P3.11-008 PHASE II STUDY OF METRONOMIC CHEMO-
THERAPY (MC) WITH BEVACIZUMAB (B) IN PATIENTS 
WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL 
LUNG CANCER (NS-NSCLC)
Francisco Robert1, Stefan C. Grant2, Mary Jerome2, Debi Miley2, 
Vishnu Reddy2, Alan Cantor2
1Comprehensive Cancer Center, University Of Alabama Of Birmingham/
United States Of America, 2Comprehensive Cancer Center, University Of 
Alabama At Birmingham/United States Of America
Background: Platinum-based chemotherapy regimens using 
maximum-tolerated dosing schedules are the standard of first-line 
treatment for advanced non-small cell lung cancer (NSCLC) and are 
associated with a modest survival benefit and substantial toxicity. 
Targeting vascular endothelial growth factor (VEGF) has shown mo-
dest improvement in patients with advanced NS-NSCLC. Frequent 
administration of low dose chemotherapy agents (metronomic che-
motherapy [MC]) is thought to target endothelial cells of the tumor 
vasculature as well as tumor cells. The hypothesis of this pilot phase 
2 study is that the combination of bevacizumab and MC will result 
in enhanced antiangiogenic effect and clinical benefit in advanced 
NSCLC.
Methods: Untreated patients with stage 4 non-squamous NSCLC, 
PS 0-1 and measurable disease were treated with a 4-week cycle of 
paclitaxel (80 mg/m2 D1, 8, 15), gemcitabine (200-300 mg/m2 D1, 8, 
15) and bevacizumab (10 mg/kg D1, 15) for 6 cycles. Patients without 
progressive disease received maintenance bevacizumab every 2 
nation studies with other CYP1A1 or CYP3A4 inducers. Dovitinib 
PK data is pending. Given the toxicity and the potential PK inter-
action, further investigation with this drug combination will be 
challenging.
Keyword: dovitinib, erlotinib, phase I, pharmacokinetic
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P3.11-007 PRELIMINARY SAFETY RESULTS OF MONET-A: 
A PROSPECTIVE, ASIAN PHASE 3, RANDOMIZED, PLA-
CEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF THE IN-
VESTIGATIONAL AGENT MOTESANIB IN COMBINATION 
WITH PACLITAXEL AND CARBOPLATIN FOR ASIAN PA-
TIENTS OF ADVANCED NON-SQUAMOUS NON-SMALL 
CELL LUNG CANCER
Hiroshige Yoshioka1, Fumihiro Oshita2, Naoyuki Nogami3, Hiroyasu 
Kaneda4, Kiyotaka Yoh5, Terufumi Kato6, Byoung Chul Cho7, Gee-Chen 
Chang8, Yukito Ichinose9, Kazuhiko Nakagawa4, Keunchil Park10, 
James C. Yang11, Hiroyuki Achiwa12, Takayuki Asato13, Kaoru Kubota14
1Department Of Respiratory Medicine, Kurashiki Central Hospital/
Japan, 2Department Of Thoracic Oncology, Kanagawa Cancer Center/Ja-
pan, 3Thoracic Oncology, National Hospital Organization Shikoku Can-
cer Center/Japan, 4Department Of Medical Oncology, Kinki University 
Faculty Of Medicine/Japan, 5Division Of Thoracic Oncology, National 
Cancer Center Hospital East/Japan, 6Division Of Respiratory Medicine, 
Kanagawa Cardiovascular And Respiratory Center/Japan, 7Department 
Of Internal Medicine, Yonsei University College Of Medicine/Korea, 
8Cancer Center, Taichung Veterans General Hospital/Taiwan, 9Thoracic 
Oncology, National Kyushu Cancer Center/Japan, 10Division Of Hema-
tology/Oncology, Samsung Medical Center, Sungkyunkwan University 
School Of Medicine/Korea, 11Institute Of Oncology And Cancer Research 
Centre, National Taiwan University/Taiwan, 12Medical Sciences Divisi-
on, Takeda Bio Development Center Ltd./Japan, 13Clinical Development 
Division, Takeda Bio Development Center Ltd./Japan, 14Medical Oncolo-
gy Division, Nippon Medical School/Japan
Background: Inhibition of the vascular endothelial growth factor 
receptor (VEGFR) pathway appears to be an effective treatment 
strategy for frontline non-small cell lung cancer (NSCLC), but small 
molecule VEGFR kinase inhibitors have failed to show survival 
benefit. Motesanib is an orally administrated small molecule an-
tagonist of VEGFR 1, 2, and 3, platelet-derived growth factor re-
ceptor (PDGFR), and stem cell factor receptor (c-kit). In a subgroup 
analysis of Asian patients (n = 227) from the global phase 3 study 
(MONET-1), treatment of motesanib in combination with paclitaxel 
and carboplatin demonstrated significant improvements in overall 
survival (HR, 0.65; 95% CI, 0.46-0.91), progression free survival (HR, 
0.59; 95% CI, 0.44-0.79), and overall response rate compared to 
placebo. To prospectively evaluate efficacy and safety of motesa-
nib in Asian patients with NSCLC, this phase 3 study has initiated.
Methods: Stage IV/recurrent non-squamous NSCLC patients 
without prior chemotherapy receive oral motesanib (125 mg) or 
placebo once daily in combination with paclitaxel (200 mg/m2) and 
carboplatin (AUC = 6) every 3 weeks up to 6 cycles and continue 
motesanib or placebo until disease progression, consent withdra-
wal, or unmanageable adverse event. ECOG performance status 
0 or 1 are eligible for this study regardless of epidermal growth 
factor receptor (EGFR) mutation status. Patients with untreated or 
symptomatic central nervous system metastases are excluded. Ap-
proximately 400 patients will be randomized in a double-blind 1:1 
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P3.11-009 TULUNG REGISTRY: DATA ANALYSIS OF  
PATIENTS WITH NON-SQUAMOUS NSCLC (ADENOCAR-
CINOMA, LARGE CELL CARCINOMA) AND PS 0-1  
TREATED WITH ERLOTINIB IN SECOND LINE SETTING
Jaromir Roubec1, Karel Hejduk2, Zdenek Bortlicek2, Jana Skricko-
va3, Milos Pesek4, Petr Zatloukal5, Vitezslav Kolek4, Frantisek Sa-
lajka4, Leona Koubková6, Marcela Tomiskova3, Ivona Grygarkova4, 
Libor Havel5, Michal Hrnciarik4, Milada Zemanova7, Dimka Sixto-
va8, Helena Coupkova9, Katerina Kosatova10
1Pneumology Department, Fakultni Nemocnice Ostrava/Czech Republic, 
2Institut Biostatistiky A Analýz, Masaryk University/Czech Republic, 
3Department Of Respiratory Diseases And Tb, University Hospital Brno 
And Masaryk University/Czech Republic, 4Pneumology, University Hos-
pital/Czech Republic, 5Pneumology, Hospital Na Bulovce/Czech Republic, 
6Pneumology, University Hospital Motol/Czech Republic, 7Oncology, Gene-
ral University Hospital/Czech Republic, 8Pneumology, Thomayer Hospital/
Czech Republic, 9Oncology, Masaryk Memorial Cancer Institute/Czech 
Republic, 10Pneumology, Hospital Na Homolce/Czech Republic
Background: We conducted a systematic review of data from pati-
ents reported in the TULUNG registry (data cut-off 18-Mar-13). The 
TULUNG registry prospectively collects data from all NSCLC patients 
treated by erlotinib in the Czech Republic. 
Methods: Our analysis was performed on a subgroup of patients with 
non-squamous NSCLC (adenocarcinoma or large-cell carcinoma) with 
good performance status (PS 0-1), treated with erloninib in a second-
line setting.
Results: 521 of 2365 patients reported in the the TULUNG registry 
met the above-mentioned criteria. Of 521 patients analyzed, 51,2% 
were female; the median age at erlotinib treatment initiation was 64 
years (range 29-88). The majority of patients were smokers and ex-
smokers (34.4% and 34.0% respectively) and 93.1% of tumours were 
adenocarcinomas by histology. 86.1% patients were at the metastatic 
stage at the initiation of second-line erlotinib treatment, 12.8% of 
patients were in stage IIIb and only 1.1% of patients in stage IIIa. The 
majority of patients (87.7%) was in PS 1 at the initiation of second-line 
erlotinib treatment. From 521 of all analyzed patients, erlotinib thera-
py was terminated in 410 (78.7%) patients at data cut-off (the most fre-
quent reasons for termination were disease progression, in 74.6% and 
death in 11.5% of patients) and treatment was ongoing in 111 (21.3%) 
patients. In 410 of patients with terminated treatment, the median 
duration of treatment was 3.0 months (95% CI 0.7 – 16.9), ORR assess-
ment showed CR in 0.7%, PR in 8.3% and SD in 54.6% of patients. 
Median progression free survival was 4.0 months (95% CI 3.5 – 4.5), 
median overall survival 11.8 months (95% CI 9.6 – 14.0). 1-year survival 
from erlotinib treatment initiation was 49.4%. Adverse events were 
reported in 42.8% of patients, the most frequently reported adverse 
events (in >5% of patients) were skin toxicity (35.3%) and diarrhea 
(13.6%). Grade ≥3 adverse events were reported in 10.5% of patients, 
G≥3 skin toxicity 7.5% and G≥3 diarrhea in 1.3% of patients.
Conclusion: Erlotinib therapy of advanced metastatic adenocarci-
noma or large cell carcinoma in a second-line setting was very well 
tolerated in eligible patients with PS 0-1; only 3.4% of patients had to 
discontinue erlotinib therapy due to adverse effects. In patients with 
completed erlotinib therapy 63.6% disease control rate was reached 
with a median survival of approximately 1 year from initiation of 
second-line erlotinib therapy.
Keywords: NSCLC, non-squamous, erlotinib, performance status
weeks. Primary endpoint: progression-free survival (PFS) with the 
goal to achieve a 30% improvement in the 6.4 months PFS observed 
in ECOG 4599. Secondary endpoints: objective response rate (ORR), 
overall survival (OS), safety, and the evaluation of potential biomar-
kers of angiogenesis. Blood samples for angiogenic and antiangio-
genic biomarkers were collected at different intervals.
Results: 33 evaluable patients were enrolled. Patient characteris-
tics: median age 59 years; 61% female; 70% ≥5% weight loss; 24% 
never/light smoker; 48% genetic testing (mut EGFR-4 patients and 
1 patient ALK+); and 9% brain metastases. Efficacy parameters are 
shown in the table below. Worst hematologic and non-hematologic 
toxicities: grade 3 neutropenia (15%); grade 3 fatigue (6%); grade 3 
nausea (3%); grade 3/4 hypertension (30%); grade 3/4 proteinuria 
(18%); pneumonitis (3 patients); and ischemic events (2 patients). The 
following baseline biomarkers have shown significant correlation 
with response parameters: (VEGF2 (ORR); PLGF (OS); angiopoietin 
-2 (PFS, OS); endocan (ORR); IL-8 (ORR, PFS); TGFβ-1 (ORR); throm-
bospondin-1 (ORR); and angiopoietin-1(ORR).  
Clinical Results 
Patients (N=33) 
PFS (mo) 
Median 9 (95% CI:7; 10) 
OS (mo) 
Median 30 (95% CI: 18; 37) 
1-year survival rate 74% 
2-year survival rate 55% 
ORR 73% (95% CI:0.54; 0.87) 
CR N=1 
PR N=23 
Stable Disease N=6 (18%) 
Progressive Disease N=3 (9%) 
Never or Light Smokers N=8 
Median PFS : 10m 
Median OS : 37m 
Conclusion: MC with a platinum doublet in combination with beva-
cizumab is a feasible, tolerable, and active regimen in advanced 
non-squamous NSCLC. Potential biomarkers were correlated with 
clinical outcome.
Keywords: Metastatic Non-Small Cell Lung Cancer, Metronomic 
Chemotherapy
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P3.11-011 SERUM ALBUMIN AS A POTENTIAL PHARMA-
CODYNAMIC BIOMARKER IN PATIENTS TREATED WITH 
THE ANTI-HEPATOCYTE GROWTH FACTOR MONOCLO-
NAL ANTIBODY FICLATUZUMAB
Wu-Chou Su1, May Han2, Philip Komarnitsky2, Marc Credi2, 
Krista Mckee2, Andrew Strahs2, Amita Patnaik3, Ramesh K. Ra-
manathan4, Eng-Huat Tan5, Keunchil Park6, Sarayut Lucien Gea-
ter7, Tony Shu Kam Mok8, Maria-Elena Elez9, Josep Tabernero9
1National Cheng Kung University Hospital/Taiwan, 2Aveo Oncology/Uni-
ted States Of America, 3South Texas Accelerated Research Therapeutics/
United States Of America, 4Tgen Clinical Research Services/United States 
Of America, 5National Cancer Centre/Singapore, 6Samsung Medical Cen-
ter/Korea, 7Prince Of Songkla University/Thailand, 8Prince Of Wales Hos-
pital/Hong Kong, 9Vall D‘hebron University Hospital/Spain
Background: Ficlatuzumab is an anti-hepatocyte growth factor (HGF) 
monoclonal antibody (mAb) being tested in clinical trials for cancer. 
Hypoalbuminemia has been observed in these trials, as well as in trials 
with other HGF/c-Met inhibitory mAbs. The relationship between 
serum albumin (SA) and ficlatuzumab treatment is examined.
Methods: Ficlatuzumab was studied in P05538, a first-in-human 
dose escalation trial; in P05670, a dose ranging trial investigating 
the pharmacodynamic (PD) effect of ficlatuzumab; and in P06162, a 
phase II study in combination with gefitinib (FG arm) versus gefitinib 
alone (G arm) in NSCLC patients. Patient data from these studies 
were evaluated longitudinally for peripheral edema, changes in SA, 
serum Ca2+ (Ca), liver function tests (LFTs), prothrombin time (PT) 
and proteinuria.
Results: In P05538, all 23 evaluable patients had SA decrease with 
median change to nadir of -29% (-46 to -11%) and median nadir SA 
level of 25 g/L (15 to 33 g/L). In P05670, all 19 evaluable patients had 
decreased SA, with median change to nadir of -20% (-49 to -7%) and 
median nadir SA level of 31 g/L (14 to 40 g/L). In P06162, 88 of 90 
(98%) evaluable patients in FG arm experienced SA decrease, with 
a median nadir change of -27% (range -62 to 8%). No significant SA 
changes were observed in the G arm. LFTs and PT were not signifi-
cantly changed in any of the trials. Peripheral edema was observed 
in 52%, 32%, 38%, and 4% of the patients in P05538, P05670, FG, 
and G arms of P06162, respectively. In P06162, low Ca laboratory 
findings (not corrected for albumin) were reported in 72% of pati-
ents, with median change to nadir of -11% (-24% to 5%). Changes in 
uncorrected Ca were secondary to changes in albumin (% changes 
Pearson correlation=0.68, P<0.0001). No difference in the rate of 
proteinuria was observed across FG and G arms of the 6162 trial.
Conclusion: Decrease in SA during ficlatuzumab treatment was seen 
in almost all patients and appears to be unrelated to hepatotoxicity. 
Decrease in SA resulting from ficlatuzumab treatment may be the 
cause of peripheral edema. Both hypoalbuminemia and peripheral 
edema were frequently observed with other HGF/c-Met inhibitors, 
suggesting they may be class adverse events. Decrease in SA could 
be explored as a PD marker for HGF/c-Met inhibition.
Keywords: NSCLC, hypoalbuminemia, ficlatuzumab, HGF
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P3.11-010 PATTERNS OF RELAPSE AND PROGNOSIS 
AFTER CRIZOTINIB THERAPY FAILURE IN ALK+ NON-
SMALL CELL LUNG CANCER
Noriko Yanagitani1, Hironari Nishizawa1, Ryohei Katayama2, Hiro-
shi Kobayashi1, Hiroshi Gyotoku1, Takeshi Uenami1, Yuichi Tam-
bo1, Keita Kudo1, Fumiyoshi Ohyanagi1, Atsushi Horiike1, Hironori 
Ninomiya3, Noriko Motoi3, Kengo Takeuchi4, Yuichi Ishikawa3, 
Naoya Fujita2, Takeshi Horai1, Makoto Nishio1
1Department Of Thoracic Medical Oncology, Cancer Institute Hospital Of 
Japanese Foundation For Cancer Research/Japan, 2Division Of Experimen-
tal Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation 
For Cancer Research/Japan, 3Pathology, Japanese Foundation For Cancer 
Research/Japan, 4Pathology Project For Molecular Targets, Japanese Foun-
dation For Cancer Research/Japan
Background: Although crizotinib which is a first-in-class oral ALK 
inhibitor shows dramatic response and prolonged PFS in patients 
with ALK(+) NSCLC, most of the patients relapsed within one year. 
However, patterns of relapse, prognosis, and outcome of further 
therapy after crizotinib failure have not been well examined.
Methods: We identified patients at our hospital with ALK(+) NSCLC 
who received and failed in crizotinib therapy.
Results: There were 20 patients (11 females and 9 males, with a 
median age 48 years). ALK fusion gene was confirmed by IHC and/
or FISH (17 patients IHC+/FISH+, 3 patients FISH+). The median 
treatment duration of crizotonib was 4.5 months (range, 1.1-18.6 
months) and the median overall survival (OS) after discontinued on 
crizotinib was 4.8 months; 13 patients died. At the time when cri-
zotinib was discontinued, 2 patients (10%) had progressive disease 
(PD) at the primary site of disease (local recurrence), 18 patients 
(90%) had PD of distant metastasis and one patient had PD at both 
the primary site and distant metastasis. PD in CNS was observed in 
9 patients. Re-biopsies after failure of criztotinib were performed 
in 3 patients. Two secondary mutation were identified in 2 of 3 pts 
(L1196M (n = 1) and G1269A (n = 1). Eleven of 20 patients received 
additional chemotherapy (7 cytotoxic chemotherapies and 4 ALK-
inhibitor). Two of 7 patients who received cytotoxic chemotherapy 
(included docetaxel, S-1, cisplatin+pemetrexed+bevacizumab and 
carboplatin+pemetrexed) after crizotinib had PR (28.5%).
Conclusion: After crizotinib therapy failure, PD most commonly oc-
curred at distant metastasis especially CNS in ALK+ NSCLC patients. 
Cytotoxic chemotherapy after crizotinib failure provide only mini-
mum responses. A New effective therapeutic strategy after failure of 
crizotinib is necessary in ALK+ NSCLC patients.
Keywords: Crizotinib, Non small cell lung cancer, ALK, relapse
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P3.11-013 TREATMENT WITH HIGH-DOSE, WEEKLY 
ERLOTINIB IN EGFR-MUTATED NSCLC-PATIENTS WITH 
EXTRA-CRANIAL PROGRESSIVE DISEASE
Justine L. Kuiper, Egbert Smit
Pulmonary Diseases, Vumc/Netherlands
Background: Progression of disease (PD) in advanced NSCLC pa-
tients with an EGFR mutation (EGFR+) treated with tyrosine kinase 
inhibitors (TKI) is inevitable. Therapeutic options for these patients 
are lacking. Several patients with acquired TKI-resistance who were 
treated with high-dose, weekly erlotinib (‘pulsatile erlotinib’) for 
leptomeningeal metastases showed an evident thoracic response 
(1). We initiated this trial to evaluate the effect of pulsatile erlotinib 
on advanced, EGFR+ NSCLC patients with TKI-resistance.
Methods: This study was developed as a prospective, mono-cen-
ter, open-label, single-arm phase II trial. Primary endpoint was ob-
jective response rate (ORR). Secondary endpoints were PFS, toxi-
city and safety. Eligibility criteria included histologically confirmed 
stage IV, non-squamous, EGFR+ NSCLC-patients who progressed 
on TKI (erlotinib or gefitinib) in standard dose. Biopsy was obtai-
ned before treatment initiation. Patients were treated with erlotinib 
1500mg weekly. Response was assessed according to RECIST 1.1. 
Simon’s 2-stage optimal design was applied (2).
Results: Eleven patients were enrolled. Patient characteristics and 
pathological results are depicted in table 1. When 10 patients were 
assessed to have PD or stable disease, the trial was discontinued, 
according to predefined criteria. Objective response rate (ORR) 
was 9,1%. Median PFS was 1.6 months (95% CI, 0.9-2.0 months). 
One biopsy revealed KRAS mutation, whereas earlier biopsies had 
shown exon 18 + exon 20 mutation. A second primary tumour is 
not excluded in this case. Patients received pulsatile erlotinib as 
3rd -6th treatment. At time of analysis, one patient remains on treat-
ment. One patient had clinical benefit lasting for 3 months beyond 
PD. There were no deaths during the study. Toxicity was mainly 
grade 1-2.  
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P3.11-012 EPIDERMAL GROWTH FACTOR RECEPTOR 
TYROSINE KINASE INHIBITORS IN ADVANCED SQUA-
MOUS CELL CARCINOMA OF THE LUNG.
Malaka Ameratunga1, Adam Broad1, Nick Pavlakis2, Val Gebski3, 
Mustafa Khasraw1
1Andrew Love Cancer Centre, Barwon Health/Australia, 2Department 
Of Medical Oncology, Royal North Shore Hospital/Australia, 3Nhmrc 
Clinical Trials Centre, University Of Sydney/Australia
Background: Tyrosine Kinase inhibitors (TKIs) with gefitinib or erlo-
tinib targeting the epidermal-growth factor receptor (EGFR) are a 
well-established therapy in the treatment of metastatic pulmonary 
adenocarcinoma, particularly in patients with activating EGFR muta-
tions. EGFR mutations are rarely found in squamous cell carcinomas 
(SCC) of the lung. There is conflicting data supporting the efficacy of 
EGFR inhibitors in advanced SCC of the lung. In this analysis we ex-
amined the impact of EGFR TKIs on progression-free survival (PFS) 
and overall survival (OS) in unselected patients with SCC of the lung.
Methods: We searched for Randomised controlled trials (RCTs) 
comparing EGFR-TKIs alone with placebo (PL) in patients with meta-
static non-small cell lung cancer. RCTs in the front-line, maintenance 
and subsequent therapies were included. The primary outcome 
was PFS in the SCC population. We used published hazard ratios 
(HRs), and when not available unpublished data was sought. Non-
adenocarcinoma was used as a surrogate for SCC when analysis was 
available by specific histology. Pooled estimates of treatment effect 
on OS and PFS were calculated using the random-effects inverse 
variance weighted method.
Results: Eight eligible RCTs were included: 2 first line, 6 second-
line or beyond, evaluating 1781 patients (EGFR TKI v PL). Data was 
available for analysis of OS in 4 studies (second-line; N = 1420) and 
for PFS in 4 studies (three second-line, one first-line; N = 788). EGFR 
TKIs significantly prolonged PFS, with a hazard ratio of 0.77 [95% 
CI 0.65 – 0.92]. OS was prolonged with a hazard ratio of 0.88 [95% 
confidence interval (CI) 0.78 – 1.00]. Efforts to obtain further missing 
data from the other studies to complement the analysis are on-
going.
Conclusion: EGFR mutations are rare in SCC of the lung, yet EGFR 
TKIs have a significant PFS benefit and (less certain) OS benefit com-
pared to placebo in unselected patients with advanced pulmonary 
SCC, and should be considered as a therapeutic option in patients 
with advanced SCC of the lung. EGFR mutation independent me-
chanisms may explain efficacy of EGFR inhibitors in this setting. An 
individual patient data meta-analysis is warranted to further charac-
terize the OS benefit.
Keywords: non-small cell lung cancer, EGFR inhibitors, squamous 
cell carcinoma, Meta-analysis
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P3.11-014 SAFETY, PHARMACOKINETICS, AND ACTIVITY 
OF THE ANTI-NAPI2B ANTIBODY-DRUG CONJUGATE 
DNIB0600A: A PHASE I STUDY IN PATIENTS WITH NON-
SMALL CELL LUNG CANCER AND PLATINUM-RESISTANT 
OVARIAN CANCER
David Gerber1, Jeffrey Infante2, Michael Gordon3, Joan Schiller1, Da-
vid Spigel4, Yulei Wang5, David S. Shames5, Younjeong Choi5, Robb 
Kahn5, Jian Xu5, Kedan Lin5, Katie Wood5, Daniel Maslyar5, Howard 
Burris4
1Harold C. Simmons Cancer Center, UT Southwestern Medical Center/United 
States Of America, 2Sarah Cannon Research Institute/tennessee Oncology, 
Pllc/United States Of America, 3Pinnacle Oncology Hematology/United States 
Of America, 4Sarah Cannon Research Institute/United States Of America, 
5Genentech, Inc./United States Of America
Background: NaPi2b (SLC34A2) is a multi-transmembrane, sodium-de-
pendent phosphate transporter highly expressed in non-small cell lung 
cancer (NSCLC) and ovarian cancer (OC). DNIB0600A is an antibody-
drug conjugate consisting of a humanized anti-NaPi2b IgG1 monoclo-
nal antibody and the anti-mitotic agent MMAE.
Methods: This study evaluated safety, pharmacokinetics (PK), and 
pharmacodynamics of DNIB0600A (0.2-2.8 mg/kg) given every 3 weeks 
(q3w) to patients (pts) with non-squamous NSCLC or platinum-resistant, 
non-mucinous OC. A traditional 3+3 design was used for dose escala-
tion followed by expansions in NSCLC and OC at the recommended 
Phase 2 dose (RP2D). Tumor NaPi2b expression was evaluated in ar-
chival tissue by immunohistochemistry (IHC). Anti-tumor activity was 
evaluated per RECIST 1.1.
Results: As of 1 May 2013, 65 pts have enrolled (35 NSCLC; 30 OC), 
median age 62 (range 39-85), PS 0-1, median number of prior regimens 
2 (1-8) in NSCLC pts, and 5 (1-12) in OC pts. Pts received a median of 4 
(range 1-25) doses of DNIB0600A. One pt experienced a DLT (Grade 3 
dyspnea) at 1.8 mg/kg; however, no additional DLTs occurred through 
the maximally administered dose of 2.8 mg/kg. Two patients had Gra-
de 1 and 2 infusion-related reactions. The most common related AEs 
(all grades) were fatigue (55%), nausea (35%), peripheral neuropathy 
(32%), decreased appetite (29%), vomiting (25%), alopecia (20%), and 
diarrhea, dysgeusia, headache, and pain (each 15%). The majority of 
these AEs were Grade 1 and Grade 2. Two patients had serious AEs 
(SAE) which led to discontinuation (dyspnea; dehydration and hyper-
glycemia). Four other related SAEs (nausea, upper respiratory tract 
infection, abdominal pain, and headache) were noted in 2 pts. Prelimi-
nary PK results support a q3w dosing regimen with no accumulation 
observed. Expansion at 2.4 mg/kg was selected based on cumulative 
safety data and a benefit/risk assessment performed at time of expan-
sion. Exposures of analytes monitored were dose-proportional over all 
dose levels, and no PK difference was observed between NSCLC or 
OC pts. Approximately 60% of NSCLC and 90% of OC pts expressed 
high levels (IHC 2+/3+) of NaPi2b. Anti-tumor activity with DNIB0600A 
was associated with tumor NaPi2b expression for both NSCLC and 
OC. Of the 40 pts with NaPi2b IHC Score of 2+ or 3+, treated at dose 
levels 1.8-2.8 mg/kg, 10 pts had a confirmed partial response (PR); 2 of 
18 NSCLC and 8 of 22 OC pts, respectively. Additionally, 3 NSCLC and 
3 OC pts have unconfirmed PRs. No pt was enrolled with NaPi2b IHC 
Score of 1+; no pt responded among the 13 pts with NaPi2b IHC Score 
of 0, treated at dose levels 1.8-2.8 mg/kg
Conclusion: DNIB0600A administered q3w has an encouraging safety, 
tolerability, and PK profile and evidence of anti-tumor activity in NSCLC 
and OC pts whose tumors express NaPi2b detectable by IHC. This data 
Table 1: PATIENT CHARACTERIS-
TICS
Median
N = 11
Range
Age (years) 57 (32-75)
Frequency (%)
Sex
female 11 (100%)
male 0 (0%)
Smoking
Non-smoker 7 (63,6%)
Previous smoker 3 (27,3%)
Current smoker 1 (9,1%)
Performance 
score
PS 0 4 (36,4%)
PS 1 5 (45,5%)
PS 2 2 (18,2%)
Ethnicity Caucasian 11 (100%)
Stage IV - metastatic 11 (100%)
Histology
Adenocarcinoma 10 (90,9%)
1 (9,1%)
Mutation
EGFR-exon 19 2 (18,2%)
EGFR-exon 21 1 (9,1%)
EGFR exon 19 + 
T790M
3 (27,3%)
EGFR exon 21 + 
T790M
2 (18,2%)
KRAS 1 (9,1%)
No mutation 1 (9,1%)
No biopsy 1 (9,1%)
 
Conclusion: Despite some individual successes with pulsatile erlo-
tinib treatment of EGFR+ NSCLC patients, this trial failed to meet 
its primary endpoint and was discontinued prematurely. Pulsatile 
erlotinib was safe and toxicity was manageable. Further investigati-
on of this treatment for this indication is not recommended.
Keyword: Pulsatile, erlotinib, EGFR, NSCLC
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Methods: Patients were enrolled into sequential dose-escalating 
cohorts to receive icotinib orally three times daily (tid) from 225 
mg/day to 1875 mg/day for at least 28 days. Escalation of icotinib 
was based on toxicities observed in the preceding dose cohort. 
Tumor response was assessed every 4 weeks.
Results: 103 patients were enrolled at 11 dose levels, including 
dose escalations and dose expansions. The most common drug-
related adverse events were rash (51.5%, 53/103) and diarrhea 
(19.4%, 20/103), which were generally mild (grade 1/2) and revisa-
ble on symptomatic treatment. Two of six patients at 1875 mg/day 
experienced dose-limiting toxicity (grade 3 rash), and no further 
dose escalation occurred. Tumor responses were observed from 
300 mg/day to 1875 mg/day. Out of 100 patients evaluable for 
tumor responses, the overall objective response rates and disease 
control rates were 27% and 76%, respectively, and the overall pro-
gression-free survival (PFS) was 5.0 months. Dose expansions were 
carried out in 300 mg/day, 375 mg/day and 450mg/day cohorts, 
and the median PFS for each cohort were 5.0 months, 5.6 months, 
and 4.0 months, respectively. 
Conclusion: Icotinib was well tolerated with manageable and revi-
sable AEs at all dose levels. The MTD of icotinib was 1875 mg/day, 
and the tolerable and effective dose range was from 300 mg/day 
to 1875 mg/day. This study demonstrated that icotinib provided 
favorable safety profile and antitumor activity in advanced NSCLC 
patients.
Keywords: Icotinib, non-small-cell lung cancer, dose escalation
supports further clinical evaluation of DNIB0600A in NSCLC and OC 
together with a companion diagnostic.
Keywords: NSCLC, ADC, Phase I, NaPi2b
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P3.11-015 AN OPEN LABEL, DOSE ESCALATION, PHASE 
I TRIAL TO EVALUATE THE TOLERABILITY AND ANTITU-
MOR ACTIVITY OF ICOTINIB IN PATIENTS WITH ADVAN-
CED NON-SMALL-CELL LUNG CANCER
Jianzhong Shentu1, Guolan Wu1, Jian Liu1, Huili Zhou1, Lihua Wu1, 
Xingjiang Hu1, Jing Dou2, Qiong Zhao1, Jianying Zhou1, Nong Xu1, 
Fenlai Tan3, Lieming Ding3
1The First Affiliated Hospital Of College Of Medicine, Zhejiang Universi-
ty/China, 2Guge Pharmaceutical Development Co Ltd/China, 3Zhejiang 
Beta Pharma Inc./China
Background: A phase I, dose escalation study was conducted to 
evaluate the safety and antitumor activity of icotinib, an oral epi-
dermal growth factor receptor inhibitor which was approved for 
treating advanced non-small-cell lung cancer (NSCLC) in China, 
and to explore its tolerable and effective dose range, and the ma-
ximum tolerated dose (MTD) in patients with advanced NSCLC.
Table 1: Safety profile of icotinib at various dose levels. 
Dose (mg/
tid) N
Rash 
(N)
Diarrhea 
(N)
Overall adverse 
events (%)
Overall adverse 
reaction (%)
Grade 
I/II
Grade 
III/IV Grade I/II
Grade 
III/IV
75 7 5 - 1 - 85.7 (6/7) 85.7 (6/7)
100 27 6 1 7 - 70.4(19/27) 55.6(15/27)
125 24 13 1 4 - 75.0(18/24) 70.8(17/24)
150 13 6 - 1 - 69.2 (9/13) 69.2 (9/13)
200 3 1 - 1 - 100 (3/3) 100 (3/3)
250 8 4 - 1 - 75.0 (6/8) 62.5 (5/8)
300 3 2 - - - 100 (3/3) 100 (3/3)
350 3 1 - 1 - 100 (3/3) 100 (3/3)
400 3 3 - - - 100 (3/3) 100 (3/3)
500 6 5 1 1 - 100 (6/6) 100 (6/6)
625 6 3 2 2 - 100 (6/6) 100 (6/6)
Total 103 49 5 20 - 79.6(82/103) 73.8(76/103)
Table 2: Tumor response of icotinib at various dose levels. 
Dose (mg/tid) N CR/PR SD PD ORR (%) DCR (%)
75 6 0/0 6 0 -- --
100 25 2/5 14 4 28 (7/25) 84 (21/25)
125 24 -/7 13 4 29.2 (7/24) 83.3 (20/24)
150 13 1/5 4 3 46.2 (6/13) 76.9 (10/13)
200 3 0/0 2 1 -- --
250 8 0/1 4 3 12.5 (1/8) 62.5 (5/8)
300 3 0/0 2 1 -- --
350 3 0/1 0 2 -- --
400 3 0/2 0 1 -- --
500 6 0/1 1 4 -- --
625 6 0/1 1 4 -- --
Total 100 3/24 49 26 27(27/100) 76(76/100)
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P3.11-017 OBSERVATIONAL POST-AUTHORIZATION 
PROSPECTIVE STUDY TO CHARACTERIZE THE INCI-
DENCE OF EGFR POSITIVE MUTATION (M+) IN ADVAN-
CED OR METASTATIC NON-SMALL CELL LUNG CANCER 
(ANSCLC) PATIENTS (P) AND THEIR CLINICAL MANAGE-
MENT IN GALICIA (NCT01717105): A GALICIAN LUNG 
CANCER GROUP STUDY (GGCP 048-10)
Sergio Vazquez1, Joaquin Casal2, Francisco Javier Afonso3, José 
Luis Fírvida4, Lucía Santomé5, Francisco Barón6, Martin Lazaro2, 
Carolina Pena7, Margarita Amenedo8, Ihab Abdulkader6, Carmen 
González Arenas9, Laura Fachal10, Ana Vega10
1Hospital Universitario Lucus Augusti/Spain, 2Complexo Hospitalario 
Universitario De Vigo/Spain, 3Complexo Hospitalario Universitario De 
Ferrol/Spain, 4Complexo Hospitalario Universitario De Ourense/Spain, 
5Povisa/Spain, 6Complexo Hospitalario Universitario De Santiago/
Spain, 7Complexo Hospitalario De Pontevedra/Spain, 8Centro Oncolóxico 
De Galicia/Spain, 9Astrazeneca/Spain, 10Fundación Pública Galega De 
Medicina Xenómica-sergas/Spain
Background: The presence of mutations in the gene encoding 
the Epidermal Growth Factor Receptor (EGFR) predicts that P with 
aNSCLC may respond better to Tyrosine Kinase Inhibitors (TKIs). 
Recently, the Spanish REASON study has reported that the rate of 
EGFR mutations is 11.6% in Spain; however the mutation rate and 
the clinical management of aNSCLC carrying EGFR mutations in 
Galicia are still unknown.
Methods: All newly diagnosed aNSCLC P in 9 Galician centers 
were prospectively included for a 13-month period. P with M+ di-
sease were followed for at least 9 months (m) in order to characte-
rize their clinical management. Mutation testing was performed on 
available tumor and plasma samples, through a central laboratory 
using the EGFR RGQ PCR Kit™ (Qiagen). Pre-planned exploratory 
objectives included comparison of EGFR mutation status between 
matched baseline tumor and plasma samples.
Results: From February 2011 to March 2012, 198P were included in 
the study. Median age was 65.5 years (range 34-85). 76.3%P were 
men, 21.7% were never-smokers, 45.5% ex-smokers, and 32.8% 
current smokers. PS 0-1: 67.1%. 78.3% had non-squamous histology 
(68.7% adenocarcinoma, 8.1% large-cell carcinoma, 1% adenos-
quamous carcinoma, and 0.5% non-specified) and 21.7% p had 
squamous-cell carcinoma. Sample type provided included: 57.6% 
tissue, 42.4% cytology. Median turnaround time (TAT) was 8 days. 
Mutation rate in evaluable samples: 13.6% in tumor, tissue or cyto-
logy (25P) (11P had exon 19 deletion, 8P L858R mutation, 2P exon 
20 insertions and 1P L861Q mutation); 5.9% in plasma. Tumor and 
plasma EGFR mutation status concordance rate was 90.8%.Plasma 
test sensitivity was 40%. Mutation rate did not vary by sample type 
(13.9% tissue, 13.2% cytology). A higher mutation rate was found 
in never smokers (42.5%), females (38.6%) and adenocarcinoma 
(19.8%). 23 out of 25 M+ P received first line treatment and 2P only 
best supportive care. 21P were treated with TKI (Gefitinib), 1P with 
chemotherapy (CT) (Cisplatin/docetaxel/bevacizumab) and 1P with 
CT+TKI (Carboplatin+Gefitinib). 20P were evaluated for response. 
3P were lost for follow up. At data cut off (31/12/2012), with a me-
dian follow up of 9.8m, 14P had partial response (70%), 2 stable 
disease (10%) and 4P progressive disease (20%). Median progres-
sion free survival was 9.7m. 8 out of 20P (40%) received 2nd line 
treatment (7 CT and 1 TKI). 12 out of 25P had died, 3P were lost for 
follow up and 10P were still alive.
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P3.11-016 USING STATISTICAL MODELS TO IMPROVE 
PHASE II STUDY DESIGNS
Nathan H. Enas1, Valérie A.M. André2, Ji Lin1, Helen Barraclough3
1Eli Lilly & Company/United States Of America, 2Eli Lilly & Company/
United Kingdom, 3Eli-lilly Australia/Australia
Background: Single arm phase II studies have traditionally been 
conducted in oncology, but they rely completely on historical 
information to assess treatment benefits and are associated with 
high bias and false-positive error rates. This has contributed unsus-
tainably high phase III clinical trial failure rates in oncology. On the 
other hand, conventional randomized controlled trials (RCT) invol-
ve more patients, higher cost and longer timelines. Thus, innovati-
ve statistical methods have been developed to try to address this 
challenge. An area of focus has been the use of statistical models 
to improve the design of phase II studies to better mimic what is 
intended for the phase III design, and therefore to predict its out-
comes with greater precision.
Methods: Two statistical innovations have been applied to our 
phase II portfolio. Firstly, the Bayesian Augmented Control (BAC) 
design has been implemented to gain the benefits of using histo-
rical information (“borrowing”) as well as using randomization to a 
concurrent control arm. The BAC design utilizes models to summa-
rize existing knowledge on the standard of care (SOC) in a defined 
patient population. For example, patients can be “borrowed” from 
a previous well-designed phase III RCT which established the SOC. 
The extent of “borrowing” depends on the similarity between the 
response in the new control patients and the historical patients, 
which is evaluated by pre-specified models. Secondly, Change in 
Tumour Size (CTS) from baseline to the end of Cycle 2 has been 
incorporated as an endpoint in our studies because this endpoint 
correlates strongly with progression-free survival (PFS) and ove-
rall survival (OS) in certain tumor types such as Non-Small Cell 
Lung Cancer (NSCLC). The approach consists in using tumor size 
measurements as a continuous variable, rather than a categorical 
endpoint based on Response Evaluation Criteria In Solid Tumors 
(RECIST), for assessing anti-tumor activity.
Results: The BAC design enables randomized controlled trials 
with smaller sample sizes, yet maintains statistical power. It also 
allows disproportionate enrollment to the experimental arm, which 
is often attractive to investigators and patients seeking access to 
novel therapies.
Conclusion: We believe that our phase II data package is now 
more informative whilst still meeting the logistical needs. It is ho-
ped that this will facilitate a better Phase III prediction, which will 
increase our Phase III success rate. To date, insufficient phase III 
trials which were designed based on these improved phase II trials 
have yet been completed to be able to evaluate whether our pha-
se III success rate has ultimately improved.
Keywords: phase II, Statistics, Design, innovation
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values above 10 pg/ml. A general trend of increasing IFN gamma is 
observed in the first 3 vaccinations, followed by a decline and sub-
sequent increase in the fifth and sixth vaccination correlating with 
the introduction of new sets of antigens coming from the result of 
the follow-up CTC gene expression analysis. General observation 
indicated higher IFN gamma values correlate with better patient 
survival.
Conclusion: Thus, the clinical data of the patients who have un-
dergone the DC vaccination therapy have indicated the positive 
effects of autologous DC as an alternative adjunct therapy for lung 
cancer specifically for stages II and III. This data also points to the 
importance of early diagnosis of lung cancer as well as the deve-
lopment of more aggressive immunotherapeutic interventions for 
stage IV cases (e.g. tumor-specific cytotoxic T-cells) which are the 
current directions of the Center.
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P3.11-019 GEFITINIB EFFICACY IN EGFR MUTATED NON 
SMALL CELL LUNG CANCER (NSCLC) PATIENTS BASED 
ON TYPE OF MUTATION: A STUDY FROM THE GALICIAN 
LUNG CANCER GROUP.
Clara Senin1, Xl Fírvida2, Sergio Vazquez3, Mj Villanueva1, Carolina 
Pena4, Francisco Javier Afonso5, Lucía Santomé1, Ihab Abdulkader6, 
Martin Lazaro1, Mc Areses2, B Campos3, Carlos Grande1, Ana Gon-
zález Piñeiro7, Ma Alonso Bermejo2
1Medical Oncology, Complexo Hospitalario Universitario De Vigo/Spain, 
2Medical Oncology, Complexo Hospitalario Universitario De Ourense/
Spain, 3Medical Oncology, Hospital Universitario Lucus Augusti/Spain, 
4Medical Oncology, Complexo Hospitalario Universitario De Pontevedra/
Spain, 5Medical Oncology, Complexo Hospitalario Universitario De Fer-
rol/Spain, 6Pathological Anatomy, Complexo Hospitalario Universitario 
De Santiago De Compostela/Spain, 7Pathological Anatomy, Complexo 
Hospitalario Universitario De Vigo/Spain
Background: Screening for Epidermal Growth Factor Receptor 
(EGFR) mutation is a key molecular test for management of lung 
cancer. Patients who respond well to an EGFR inhibitor harbor 
certain mutations in the EGFR exons 18, 19 or 21. An additional 
mutation in EGFR exon 20 is known to be responsible for acquired 
resistance to this therapy.
Methods: We conducted an analysis of Galician advanced lung 
cancer patients who were tested positive for EGFR kinase domain 
mutations determination and were treated with gefitinib. Frequen-
cy and type of EGFR mutations and the clinical response in our 
area were explored. The aim is to analyse the pattern of response, 
toxicity, progression free survival and overall survival based on the 
type of EGFR mutation.
Results: Forty-six patients with EGFR mutations were collected, 
36 women and 10 men. The median age was 67 years (43-86). Ma-
jority of the patients in the study had PS 0-1 (93%) and adenocar-
cinoma (96%) in the pathological study. The most frequent sites of 
metastasis were lymph nodes (59%), bones (33%), lung (33%) and 
pleura (33%). The median duration of treatment was 6 months. 
Progression disease was the most frequent reason of discontinua-
tion of gefitinib; in 9 patients was discontinued because of toxicity. 
Ten patients were switched to cytotoxic chemotherapy and 10 
patients continued with erlotinib. Twenty patients were detected 
to be positive for mutation in exon 19, 4 patients in exon 20 and 
Conclusion: Mutation analysis is feasible in clinical practice for aN-
SCLC patients in Galicia and allows the customization of treatment 
based on molecular criteria. Despite of the relatively small number 
of patients in this study, EGFR testing in plasma has a low sensiti-
vity and therefore should not substitute tissue testing although it 
could be an alternative for those patients without tissue samples.
Keyword: non-small cell lung cancer, EGFR positive mutation
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P3.11-018 CLINICAL RESPONSE OF LUNG CANCER PA-
TIENTS TO AUTOLOGOUS DENDRITIC CELL VACCINATI-
ON: A COMPILATION OF CASES FROM THE LUNG CEN-
TER OF THE PHILIPPINES
Maria Teresa A. Barzaga1, Francisco M. Heralde2, Carlos Dy3, Guia 
Elena Ladrera4, Jose Luis J. Danguilan5, Samuel D. Bernal6, Nelia S. 
Tan-Liu1
1Molecular Diagnostics And Cellular Therapeutics Laboratory, De-
partment Of Pathology, Lung Center Of The Philippines/Philippines, 
2Department Of Biochemistry And Molecular Biology, University Of The 
Philippines, College Of Medicine/Philippines, 3St. Luke’s Medical Center/
Philippines, 4Department Of Pulmonary Medicine, Lung Center Of The 
Philippines/Philippines, 5Department Of Thoracic And Cardiovascular 
Surgery, Lung Center Of The Philippines/Philippines, 6Globetek Science 
Foundation/Philippines
Background: A number of lung cancer patients at different disease 
stages has availed of the autologous dendritic cell vaccination 
therapy since it was instituted as an adjunct therapy in 2009 at the 
Molecular Diagnostics and Cellular Therapeutics Laboratory of the 
Lung Center of the Philippines.
Methods: Following a protocol approved by the Institutional 
Ethics Review Board of the hospital and after a Safety Evaluation 
Trial involving 3 patients demonstrating patient tolerance to auto-
logous DC with no adverse reaction, at least 19 lung cancer pati-
ents were treated. The protocol involves 1) consultation 2) signing 
of informed consent 3) extraction of blood for circulating tumor 
cells and blood tests 4) hematology clearance 5) growth factor 
administration 6) admission and central line insertion 7) leukaphe-
resis (stem cell collection) 8) dendritic cell culture and maturation 
9) vaccination and 10) IFN-gamma analysis. The compiled clinical 
responses include survival rate at different time points, PET/CT 
scan results, circulating tumor cell (CTC) gene expression profile, 
and plasma interferon gamma levels.
Results: Comparative survival rate at 9 months post-vaccination vs. 
average survival were the following: stage II, 100% vs. 75%; stage 
III, 85.71% vs. 60% and stage IV, 28.57% vs. 23%. The PET/CT Scan 
results showed a general pattern of remission and/or regression 
of the tumor, or stabilization of the disease process in 58% of the 
patients. The circulating tumor cell (CTC) gene expression profile 
using a panel of 14 Tumor Associated Genes (TAGs) showed at 
least two were positive in the patients‘ blood sample which could 
have upregulated expression. ERBB2 appeared as the most po-
sitive gene marker in all the samples (i.e. Rank 1). Livin showed 
the most elevated expression followed by ACTN4. KRT19 showed 
moderate expression while EGFR showed all downregulated ex-
pression. Post-vaccination monitoring showed a decline or com-
plete abrogation of expression of the TAGs. The interferon gamma 
profile showed that majority (90%) of the patients had IFN gamma 
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P3.11-020 EPIDERMAL GROWTH FACTOR RECEPTOR 
(EGFR) MUTATION ANALYSES IN TUMOR AND PLASMA 
SAMPLES FROM A PHASE IV, SINGLE-ARM STUDY OF 
FIRST-LINE GEFITINIB IN CAUCASIAN PATIENTS WITH 
EGFR MUTATION-POSITIVE, ADVANCED NON-SMALL-
CELL LUNG CANCER (NSCLC)
Jean-Yves Douillard1, Gyula Ostoros2, Manuel Cobo3, Tudor Ciulea-
nu4, Rose Mccormack5, Alan Webster6, Tsveta Milenkova7
1Medical Oncology, Ico R Gauducheau/France, 2Korányi National Insti-
tute Of Tb And Pulmonology/Hungary, 3Medical Oncology, Hru Carlos 
Haya/Spain, 4Medical Oncology, Prof. Dr. Ion Chiricuta Institute Of 
Oncology/Romania, 5Personalised Healthcare, Astrazeneca/United 
Kingdom, 6Biometrics And Information Sciences, Astrazeneca/United 
Kingdom, 7Research & Development, Astrazeneca/United Kingdom
Background: Study NCT01203917 assessed the efficacy, and sa-
fety/tolerability of the EGFR tyrosine kinase inhibitor gefitinib in 
Caucasians with EGFR mutation-positive NSCLC, and compared 
mutation status in tumor-derived DNA and plasma-derived circula-
ting-free DNA (cfDNA).
Methods: Patients: Caucasians; ≥18 yrs; PS 0-2; histologically con-
firmed Stage IIIA/B/IV EGFR mutation-positive NSCLC eligible for 
first-line treatment. Treatment: 250mg gefitinib once-daily until 
disease progression. Primary endpoint: objective response rate 
(ORR; investigator assessment). Secondary endpoints: disease 
control rate (DCR; complete/partial response or stable disease ≥6 
wks), progression-free survival (PFS), overall survival (OS) and safe-
ty/tolerability. Pre-planned exploratory objectives: comparison of 
EGFR mutation status in tumor versus mandatory, duplicate plasma 
samples (all screened patients) collected at baseline (plasma1 and 
2) and one optional plasma at progression.
Results: Of 1060 screened patients with NSCLC, 118 presented 
with activating, sensitizing EGFR tumor mutations, 106 of whom 
were enrolled and treated with gefitinib (Full Analysis Set; 71% 
female; 97% adenocarcinoma; 64% never-smoker). ORR (70%), DCR 
(90.6%), median PFS (9.7m), and median OS (19.2m) indicated ge-
fitinib efficacy, with rash (45%), and diarrhea (31%) the most com-
mon adverse events (AEs; any grade; serious AEs: 19%) (previously 
reported at EMCTO 2013). Mutation rate for samples with known 
mutation status: 14% (118/859) in tumor, 10% (82/784) in plasma1. 
In 201 screened patients, tumor mutation status could not be 
detected due to technical reasons; however, 12 had a mutation in 
plasma1. Mutation status concordance in 652 matched tumor and 
plasma1: 94% (CI: 92-96; mutation subtype/frequencies in Table). 
Using tumor mutation status as reference, EGFR mutation test 
sensitivity in cfDNA was 66% (CI: 56-75), specificity was 100% (CI: 
99-100); positive predictive value: 99% (CI: 92-100); negative pre-
dictive value: 94% (CI: 92-96). Mutation status concordance in 224 
duplicate plasma samples: 97% (CI: 94-99) (subtype/frequencies 
in Table). ORR (post-hoc) for patients with both EGFR mutation-
positive tumor and plasma1 or 2 (n=66): 77% (CI: 66-86); ORR for 
patients with EGFR mutation-positive tumor and EGFR mutation-
negative plasma1 or 2 (n=37): 60% (CI: 44-74). Of 12 patients with 
baseline and progression plasma samples, 4 differences were 
observed: no mutations were detected at progression in 3 patients 
in which exon 19 deletions were detected at baseline; one patient 
with an exon 19 deletion at baseline acquired an additional mutati-
on, T790M (75% concordance; CI: 43-95). 
20 patients in exon 21. The L858R point mutation in exon 21 was 
observed in 14 patients and the L833F point mutation in the same 
exon was observed in 1 patient. Thirty-five patients were included 
in the response analysis. The response ratio to gefitinib was 57%. 
Depending on the type of mutation, the response in exon 19 mu-
tation patients was 64%, in exon 20 patients was 0% and in exon 
21 patients was 60%. Rash or acne was the most frequent toxicity 
(48%), only 2% was grade 3-4. Diarrhea and dysnea were the main 
toxicities grade 3-4 (9% both), without statistical differences based 
on type of mutation (p=0.78) . Progression free survival (PFS) of pa-
tients with EGFR mutations was 6 months. Patients with mutation 
in exon 19 had 9 months compared to 6.4 months for patients with 
exon 21 mutation, presenting a statistically significance difference 
(p=0.002). Overall survival (OS) was 17 months for EGFR mutations 
patients (19 months for exon 19 mutation patients and 14 months 
for exon 21 mutation patients; p=0.119)
Conclusion: Pacients in our area with exon 19 EGFR kinase domain 
mutations treated with gefitinib have higher PFS compare to exon 
21 EGFR kinase domain mutations. Exon 20 mutation in our pati-
ents is responsible for resistance to gefitinib.
Keywords: NSCLC, EGFR mutation, gefitinib
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Table  
Baseline tumor EGFR mutation subtype results and corresponding plasma 1 results for 652 patients 
with matched tumor and plasma1 samples
Positive: Exon 19 deletions 
Plasma1,n
TOTAL
Positive: L858R Positive: L858R & T790M Negative
Tumor, n
Positive: Exon 
19 deletions 
48 0 0 23 71
Positive: L858R 0 21 0 12 33
Positive: L858R 
& T790M
0 0 0 1 1
Negative 0 1 0 546 547
TOTAL 48 22 0 582 652
Baseline plasma1 EGFR mutation subtype results and corresponding plasma2 results for 224 patients 
with duplicate plasma1 and 2 samples
Positive: Exon 19 deletions 
Positive: L858R
Plasma2, n
TOTAL
Negative
Plasma1, n
Positive: Exon 19 deletions 43 0 4 47
Positive: L858R 0 20 1 21
Negative 1 1 154 156
TOTAL 44 21 159 224
Conclusion: First-line gefitinib was effective and well tolerated 
in Caucasian patients with EGFR mutation-positive NSCLC. EGFR 
mutation status assessment from plasma-derived cfDNA can be 
considered when tumor tissue is unavailable.
Keyword: EGFR mutation; gefitinib; NSCLC; Caucasian; circula-
ting-free DNA
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P3.11-022 DEEP VEIN TROMBOSIS AMONG LUNG CAN-
CER PATIENTS USING WELLS‘ SCORE: A SINGLE INSTI-
TUTION EXPERIENCE
Elisna Syahruddin, Fadhlia Madjidiah, Sita Andarini
Department Of Pulmonology And Respiratory Medicine, Faculty Of 
Medicine Universitas Indonesia – Persahabatan Hospital, Jakarta, Indo-
nesia/Indonesia
Background: Deep vein thrombosis (DVT) is the common compli-
cation found in malignancy. Currently, there were no current dia-
gnosis guideline which could help to identify DVT in lung cancer. 
This study, is a pilot study to identify and see the magnitude at 
DVT proportion among lung cancer in our hospital. The objective 
of this study is to find proportion of deep vein thrombosis among 
lung cancer patients which is determined by clinical criteria such as 
Wells’ score in Persahabatan Hospital.
Methods: The study design is using a cross-sectional method. We 
examined 147 patients with pathological confirmed lung cancer 
who were hospitalized within September 2012 to February 2013. 
We excluded the lung cancer patients with infection comorbidity. 
The hemostatis function included PT, APTT, and D dimmer were 
conducted along with clinical Wells’ score criteria.
Results: Seventy eight of 147 sobjects were analyze in this study. 
They were mostly male (69,2%) with range of ages were 30 –79 
years old with predominant age group of 51-60 years old (33,3%). 
Adenocarcinoma was found in 57,7%. This study found that deep 
vein thrombosis proportion is 23, 1% using Wells’ score. Clinical 
characteristics such as gender, age, smoking history, cancer cell 
type, stage of the diseases, performance status and homeostasis 
function did not have correlation with DVT whereas the D dimmer 
>500 have correlation with DVT.
Conclusion: The DVT proportion among lung cancer patients in 
Persahabatan Hospital is similar found in some studies in other 
countries which are approximately 21%. This study revealed that 
the simple and practical application of Wells’ score in determining 
DVT is still have valuable role in daily practice, especially in hospi-
tal with limited facility.
Keywords: deep vein thrombosis, Lung cancer, wells’ score
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P3.11-021 BEVACIZUMAB (B) (10 MG/KG) IN COMBI-
NATION WITH CISPLATIN (C) AND DOCETAXEL (D) 
ADMINISTERED EVERY 2 WEEKS IN PATIENTS (P) WITH 
ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG 
CANCER (NSNSCLC): GGCP047/10 STUDY.
Martin Lázaro1, B Campos2, Maria José Villanueva1, Sergio Vaz-
quez2, G Huidobro1, Clara Senin1, Silvia Varela2, Carlos Grande1, 
Paula González Villarroel1, Marta Covela2, Joaquin Casal1, Cristina 
Azpitarte1
1Chuvi/Spain, 2Hula/Spain
Background: B in combination with platinum doublets followed by 
continuation maintenance with B prolongs survival and delays pro-
gression in chemo-naïve pts with advanced nsNSCLC. In a phase II 
trial C, D and B (15 mg/kg) every 3 weeks followed by B showed a 
promising efficacy, in terms of progression free survival (PFS) and 
overall survival (OS), and an acceptable toxicity profile. In addition, 
a biweekly schedule of D and C in p with metastatic NSCLC as a 
front-line CT has demonstrated effective antitumor activity with a 
reduction in hematologic toxicity, comparable to the results of pre-
vious studies using 3-week schedule. Taken together, these data 
suggest that the addition of B to C/D administered every 2 weeks 
could increase the efficacy and reduce the toxicity associated with 
the other schedules.
Methods: GGCP 047-10 is a multicenter study in chemo- naïve p 
diagnosed with advanced nsNSCLC. Eligible p also have measu-
rable disease according to RECIST criteria; age ≥18 years; ECOG 
PS ≤1; adequate hematological, renal and liver function; life expec-
tancy of at least 2 months and signed informed consent. P receive 
C (50 mg/m2), D (50 mg/m2), and B (10 mg/kg) every 2 weeks for 
up to 6 cycles, followed by B alone every 2 weeks until disease 
progression or unacceptable toxicity. PFS is used as the primary 
efficacy endpoint. Secondary endpoints include safety profile, 
overall response rate (ORR), disease control rate (DCR) and OS.
Results: 32 p were enrolled in the study. Median age was 60 years 
(range 44-72; 28.1% > 65 years); male/female (%): 81/19; ECOG 
0/1/2 (%): 28/63/10; adenocarcinoma (%): 84. Median PFS in overall 
population was 6.4 months (95% CI, 4.2-8.7). Among the 22 p eva-
luable for response, the ORR was 63.6% and DCR was 95.4%. Most 
frequent grade 3/4 hematologic toxicity was neutropenia (40.6%) 
and grade 3/4 nonhematologic toxicities was asthenia (12.5%) follo-
wed by mucositis (6.2%) and diarrhea (3.1%). There were no grade 
3/4 hemorrhagic events.
Conclusion: Treatment with B, C and D plus maintenance B every 
2 weeks is effective as front-line treatment of p with advanced 
nsNSCLC with acceptable toxicity. These data provide further evi-
dence that B may be used in combination with multiple standard, 
platinum-based doublets in this setting.
Keywords: biweekly schedule, Bevacizumab, NSCLC
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Drug-related AEs leading to discontinuation were slightly higher in 
Asian patients, but at a rate lower than with chemotherapy (28%). 
Related ILD-like events occurred in four Asian patients (three Gra-
de ≥3) and no non-Asian patients.
Conclusion: Most common drug-related AEs with afatinib were 
EGFR mediated and occurred at similar frequency in Asian and 
non-Asian patients. Treatment discontinuation due to EGFR-
related AEs was low in both groups, indicating that afatinib has a 
manageable safety profile in both populations and is suitable for 
long-term treatment of EGFR M+ NSCLC patients.
Keywords: safety, EGFR, afatinib
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P3.11-024 QUARTZ 
QUALITY OF LIFE AFTER TREATMENT FOR BRAIN ME-
TASTASES FROM NON-SMALL CELL LUNG CANCER: AN 
UPDATE ON THE UK MEDICAL RESEARCH COUNCIL 
QUARTZ TRIAL.
Paula M. Mulvenna1, Richard J. Stephens2, Matthew NaNKIvell2, 
Gosala S. Gopalakrishnan2, Corinne Faivre-Finn3, Rachael Barton4, 
Paula Wilson5, Barbara Moore6, Helen Jones7, Elizabeth Armst-
rong2, Iona Brisbane8, Elaine Mccoll9, Benjamin Sydes2, David 
Ardron10, Mahesh K. Parmar2, Ruth Langley2
1Northern Centre For Cancer Care/United Kingdom, 2Mrc Clinical Tri-
als Unit/United Kingdom, 3The Christie NHS Foundation Trust/United 
Kingdom, 4Castle Hill Hospital/United Kingdom, 5Bristol Haematology 
& Oncology Centre/United Kingdom, 6Cancer Research Uk/United King-
dom, 7St. James University Hospital/United Kingdom, 8Beatson, West 
Of Scotland Cancer Centre/United Kingdom, 9Newcastle Clinical Trials 
Unit/United Kingdom, 10North Trent Cancer Research Network/United 
Kingdom
Background: Approximately one third of all non-small cell lung 
cancer (NSCLC) patients will develop brain metastases. The ma-
jority of such patients are inoperable with a very poor prognosis, 
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P3.11-023 COMPARATIVE SAFETY PROFILE OF AFATINIB 
IN ASIAN AND NON-ASIAN PATIENTS WITH EGFR MU-
TATION-POSITIVE (EGFR M+) NON-SMALL CELL LUNG 
CANCER (NSCLC)
Lecia V. Sequist1, James C. Yang2, Nobuyuki Yamamoto2, Kenneth 
O‘Byrne3, Martin Schuler4, Tony Mok5, Sarayut Lucien Geater6, 
Daniel Massey7, Sven Wind8, Dennis O‘Brien9, Robert Lorence9, 
Yi-Long Wu10
1Massachusetts General Hospital/United States Of America, 2National 
Taiwan University Hospital/Taiwan, 3Princess Alexandra Hospital/Aus-
tralia, 4West German Cancer Center, University Duisburg-Essen/Ger-
many, 5The Chinese University Of Hong Kong/Hong Kong, 6Prince Of 
Songkla University/Thailand, 7Boehringer Ingelheim/United Kingdom, 
8Boehringer Ingelheim Pharma GmbH & Co. KG/Germany, 9Boehringer 
Ingelheim Pharmaceuticals/United States Of America, 10Guangdong 
General Hospital/China
Background: Afatinib is an oral, irreversible ErbB Family Blocker 
which showed superior efficacy to standard first-line chemotherapy 
in two large randomized Phase III trials in global (LUX-Lung 3) and 
Asian (LUX-Lung 6) EGFR M+ patients. In both trials, median pro-
gression-free survival on afatinib was 11 months by independent 
review. This was also reflected in median treatment duration of 
11–12 months in both trials. With long-term treatment duration, the 
safety profile of afatinib becomes particularly relevant to patients 
and physicians, and needs to be well characterized. Furthermore, 
differences in the pattern of some adverse events (AEs; notably 
interstitial lung disease [ILD]) have been previously described in 
Asian and non-Asian patients with reversible EGFR tyrosine kinase 
inhibitors. Here, we present a detailed review of afatinib’s safety 
profile in Asian and non-Asian patients.
Methods: 229 (LUX-Lung 3) and 239 (LUX-Lung 6) EGFR M+ pa-
tients were treated with afatinib 40mg daily until progression or 
intolerable AEs. Afatinib dose could be escalated to 50mg daily or 
reduced to 30mg or 20mg based on predefined study criteria. Pa-
tients from both trials were grouped according to ethnicity: Asian 
vs. non-Asian. On-treatment AEs were summarized by preferred/
grouped terms and graded using NCI-CTCAEv3.0.
Results: 404 Asian (66% China/Taiwan; 16% Southeast Asia; 13% 
Japan; 5% Korea) and 64 non-Asian patients (95% Caucasian; 3% 
American-Indian; 2% African-American) received afatinib, with 
median exposure of 359 and 261 days, respectively. There was no 
difference in afatinib pharmacokinetic exposure in Asian vs. non-
Asian patients. All patients reported at least one AE. Most com-
mon AEs were EGFR-mediated and are summarized in the table. 
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P3.11-025 PROGNOSTIC AND PREDICTIVE ROLE OF 
KRAS MUTATIONS IN PATIENTS WITH ADVANCED NON 
SMALL CELL LUNG CANCER TREATED WITH DOCETA-
XEL OR ERLOTINIB AS SECOND LINE TREATMENT IN 
THE TAILOR TRIAL
Marina C. Garassino1, Valter Torri2, Mirko Marabese2, Elena Copre-
ni2, Gabriella Farina3, Flavia Longo4, Anna Bettini5, Luca Moscetti6, 
Olga Martelli7, Maurizio Tomirotti8, Oscar Alabisio9, Ida Pavese10, 
Maria Giuseppina Sarobba11, Silvio Veronese12, Monica Ganzinelli3, 
Silvia Marsoni13, Massimo Broggini2, Eliana Rulli2
1Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori/
Italy, 2IRCCS- Istituto Di Ricerche Farmacologiche "mario Negri“/Italy, 
3Fatebenefratelli E Oftalmico Hospital/Italy, 4Policlinico Umberto I, Uni-
versity Sapienza/Italy, 5Papagiovanni Xxiii Hospital/Italy, 6Ospedale 
Belcolle/Italy, 7San Giovanni E Addolorata Hospital/Italy, 8Fondazione 
IRCCS Ca‘ Granda - Ospedale Maggiore Policlinico/Italy, 9Ospedale 
Maggiore Della Carità/Italy, 10San Pietro Hospital/Italy, 11Azienda Os-
pedaliera Universitaria/Italy, 12Pathology, Ospedale Ca‘granda Niguar-
da/Italy, 13Institute For Cancer Research And Treatment, IRCCS/Italy
Background: KRAS mutations in NSCLC are supposed to indicate 
a poor prognosis and poor response to anticancer treatment. How-
ever, such evidence is only drawn from retrospective series giving 
controversial results. Aim of this study is to prospectively assess 
the prognostic and predictive value of KRAS mutations in NSCLC 
patients treated with either erlotinib or docetaxel. This is a planned 
ancillary study within the TAILOR trial (NCT00637910 ).
Methods: Main eligibility criteria were a diagnosis of metastatic 
NSCLC, prior platinum-based chemotherapy and mutational status 
of EGFR and KRAS centrally assessed by direct sequencing in two 
independent laboratories. Only patients with wild-type EGFR and 
KRAS status assessed were randomly allocated to receive erlotinib 
or docetaxel until disease progression. Overall survival was the 
primary endpoint. To detect a 33% reduction in mortality with 
an 80% power (2 sided a=0.05), 220 patients were randomized. 
A subgroup analysis aimed at detecting particular subgroups of 
patients, where the differential effect of treatment could be high-
lighted, was planned.
Results: Overall, median survival and progression free survival 
were superior in the docetaxel arm compared to the erlotinib 
arm. Fiftyone out of 220 patients were found to be mutated in 
KRAS. No interaction effect was found according to KRAS status. 
In mutated KRAS the HR for OS was 0.81 (95%CI: 0.45-1.47) in 
favour of chemotherapy, and in wild type KRAS the HR was 0.79 
(95%CI: 0.57-1.10); p value for interaction effect: 0.82. Similar pat-
tern was found for PFS. In mutated KRAS patients the HR for PFS 
was 0.89 (95%CI: 0.51-1.57), while in wild type KRAS the HR was 
0.68 (95%CI: 0.50-0.93), p value for interaction effect: 0.33. No 
evidence of prognostic effect of KRAS could be found. For OS, the 
HR for associations of mutated KRAS status and mortality was 1.24 
(95%CI: 0.87-1.77; p=0.23); for PFS the HR was 1.00 (95%CI: 0.71-
1.41; p=0.98)
Conclusion: Although the study is not sufficiently powered to test 
interaction for KRAS mutations, TAILOR results show that KRAS 
can be considered neither a prognostic nor a predictive factor in 
second line treatment in advanced NSCLC.
Keywords: NSCLC, TAILOR, KRAS, predictive factor
and for several decades the standard treatment has been a com-
bination of steroids and whole brain radiotherapy (WBRT). How-
ever, little evidence exists to support this approach, and there is 
continuing debate over the use of WBRT. The diversity of clinical 
opinion and patient preference makes this a challenging question 
to address.
Methods: The multi-centre randomised QUARTZ trial assesses 
whether optimal supportive care including steroids (OSC) is a 
viable alternative to the current standard of OSC plus WBRT, in 
terms of duration and quality of life (QoL). The primary endpoint 
of Quality Adjusted Life Years (QALYs) reflects that both quality 
and duration of survival are important. Disease status, symptoms 
and QoL data are collected weekly. The impact of the disease and 
treatment on carers is also being assessed. A total of 534 patients 
is required to exclude a detriment in terms of QALYs of >1 week 
with OSC (from 5 weeks with OCS plus WBRT), and the aim was to 
recruit this number in three years.
Results: After four years, only 188 patients had been recruited and 
a decision was taken to present the interim results to participa-
ting clinicians. Interim data (from the first 151 QUARTZ patients)1 
provided no strong evidence that omitting WBRT was detrimental 
in terms of survival or QoL and there were no clear differences in 
steroid usage or toxicity. By June 2013 QUARTZ has recruited 438 
patients (82%) and 336 carers from 78 UK and Australian centres. 
Data collection is excellent with 98% of forms returned.
Conclusion: Patients with brain metastases (and others approa-
ching end of life) represent a difficult group to study, as they often 
have different priorities regarding treatment options, but it is vital 
that we obtain the highest quality evidence possible in order to 
best guide treatment. QUARTZ has demonstrated that good trial 
design (weekly phone assessments, using QALYs as the primary 
endpoint, releasing interim results, etc) makes it possible to con-
duct successful clinical trials in this challenging patient population 
in order to answer important clinical questions. The interim results 
have reassured QUARTZ Investigators that omitting WBRT does 
not appear to lead to any detrimental effect in terms of either 
length or QoL, and have proved very useful when discussing the 
trial with potential patients. Although molecular targeted agents 
can extend treatment options for some patients, QUARTZ remains 
an important trial, which will define the use of WBRT and may im-
pact on practice worldwide. We estimate completing recruitment 
during Summer 2014. Recruitment rates remain constant with 
many centres demonstrating successful recruitment to QUARTZ. 
Acknowledgements Thank you to all the patients and their carers 
for participating in the trial and the recruiting centres for their hard 
work in recruiting patients and helping to achieve the high stan-
dard of data collection. QUARTZ is supported by Cancer Research 
UK (CRUK/07/001). References 1. Langley RE et al. Clin Oncol (R 
Coll Radiol) 2013;25(3):e23-30.
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Conclusion: Overall, enobosarm was safe and well tolerated. Eno-
bosarm had an unambiguous effect on muscle that may translate 
into improvement in physical function and survival in NSCLC pati-
ents.
Keywords: muscle wasting, cachexia, NSCLC, enobosarm
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P3.11-026 RESULTS FROM TWO PHASE 3 RANDOMIZED 
TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RE-
CEPTOR MODULATOR (SARM), FOR THE PREVENTION 
AND TREATMENT OF MUSCLE WASTING IN NSCLC.
Jeffrey Crawford1, Carla M.M. Prado2, Michael L. Hancock3, Mary A. 
Johnston3, James T. Dalton3, Mitchell S. Steiner3
1Department Of Medicine, Duke University School Of Medicine/United 
States Of America, 2Nutrition Food And Exercise Sciences, Florida State 
University/United States Of America, 3Gtx, Inc./United States Of Ame-
rica
Background: Cancer induced muscle wasting is a selective and 
progressive cancer related symptom that begins early in the 
course of malignancy. Greater than 50% of NSCLC patients have 
muscle wasting at diagnosis, increasing to >80% prior to death. 
Previous evidence suggests that a 1kg gain in lean body mass 
(LBM) is beneficial for increasing muscle strength. Enobosarm is a 
first-in-class nonsteroidal oral SARM. We report herein results for 
two Phase 3 enobosarm clinical trials, POWER1 (P1) and POWER2 
(P2), for the prevention and treatment of muscle wasting in patients 
with advanced NSCLC.
Methods: Patients with Stage III or IV NSCLC were randomized 
into the trials at initiation of first-line chemotherapy based upon 
the chemotherapy regimen prescribed; platinum+taxane(P1, 
n=321) or platinum+non-taxane(P2, n=320). Patients (males and 
postmenopausal females ≥30y with ECOG ≤1) received either eno-
bosarm 3mg or placebo for 5 months. LBM was measured by DXA 
and physical function was assessed by stair climb power (SCP) at 
days 84 (primary endpoint) and 147.
Results: Enobosarm had a significant effect on LBM at day 84 
and 147 in both trials (P1:p=0.0003 and < 0.0001; P2: p=0.0227 
and 0.0036 by continuous variable analyses). Additionally, a larger 
proportion of patients receiving enobosarm maintained or incre-
ased LBM at day 84 and 147 in both trials (P1:p=0.036 and 0.026; 
P2:p=0.113 and 0.013) as compared to placebo. Regardless of 
treatment, patients with ≥1kg increase in LBM were more likely to 
demonstrate ≥10% increase in SCP than patients that had lesser 
increases or had decreases in LBM (P1: 43.7% vs 29.3%, p=0.0250 
and P2: 40.5% vs 26.5%, p=0.0321). The percentage improvement 
in SCP from baseline to day 84 differed significantly between 
patients with and without a ≥1kg increase in LBM: 9.1% vs -1.0% 
in P1(p=0.0022) and 7.7% vs -.0.6% in P2(p=0.0046). Importantly, 
patients with ≥1kg increases in LBM were more likely to demons-
trate a ≥10% increase in SCP if they received enobosarm (P1: 
p=0.0698[trend] and P2: p=0.0335) than placebo (P1:p=0.3149 and 
P2:p=0.2852), suggesting that LBM increases in enobosarm-trea-
ted patients were more highly associated with SCP improvements 
in both trials (Figure). In general, patients that maintained or incre-
ased LBM had greater increases in SCP and survived longer (land-
mark analysis) regardless of treatment. The incidence of adverse 
events was similar between enobosarm and placebo in both trials. 
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3/4 febrile neutropenia was seen in 2 (4%) patients in Arm B and 
1 (2%) patient in Arm C. One fatal AE of septic shock (Arm B) was 
considered drug-related; 22%/22%/26% of patients experienced a 
serious AE. Pharmacokinetic analysis of volasertib in Arms A and B, 
together with historical pharmacokinetic data for pemetrexed, did 
not reveal any evidence of pharmacokinetic interactions between 
volasertib and pemetrexed.
Conclusion: Volasertib and pemetrexed could be combined at full 
single-agent doses, with generally acceptable toxicities, and de-
monstrated modest antitumour activity. However, the addition of 
volasertib did not improve PFS compared to single-agent pemet-
rexed in patients with relapsed or refractory NSCLC after platinum-
based first-line therapy.
Keywords: NSCLC, advanced disease, PLK inhibitor, pemetrexed
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P3.11-028 EXPLORATION OF THE RELATIONSHIP BET-
WEEN NEUTROPHIL COUNT AND CLINICAL CONSE-
QUENCES IN PATIENTS WITH ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC) RECEIVING SELUMETINIB 
PLUS DOCETAXEL: PREDICTED EFFECT OF PRIMARY 
PROPHYLACTIC GCSF
Pasi A. Jänne1, Patricia Lorusso2, Delyth Clemett3, Susan Lovick3, 
Catherine Tchinou3, Ian Smith3
1Dana-Farber Cancer Institute/United States Of America, 2Hudson-
webber Cancer Research Center/United States Of America, 3Astra-
zeneca/United Kingdom
Background: Selumetinib (AZD6244, ARRY-142886) is an orally 
available, potent and selective, non-ATP-competitive MEK1/2 inhi-
bitor being investigated with docetaxel for treatment of KRAS mu-
tation-positive advanced NSCLC. A randomised Phase II study of 
selumetinib 75 mg twice daily (bid) plus docetaxel 75 mg/m2 q21d 
(SEL-DOC 75/75), with secondary granulocyte colony-stimulating 
factor (GCSF) prophylaxis if indicated, has shown promising effi-
cacy in this setting but with more diarrhoea, neutropenic events, 
infections, hospitalisations and dose modifications than docetaxel 
alone (Jänne et al. Lancet Oncol 2013;14:38–47; NCT00890825). 
Data from a small number of patients with advanced solid tumours 
in an open-label, Phase I study (NCT00600496) suggested that pri-
mary prophylactic (pp) GCSF reduces the incidence of neutropenic 
events associated with SEL-DOC 75/75 (Kim et al. Mol Cancer Ther 
2011;10[Suppl 1:B225). We evaluated whether pp-GCSF could influ-
ence the incidence of hospitalisation or infection during treatment 
with SEL-DOC 75/75 using bias-reduced logistic regression model-
ling and medical review of data from NCT00890825.
Methods: Neutrophil counts and events of hospitalisation or in-
fection from the safety analysis set of study NCT00890825 were 
used for modelling. This included 86 patients with KRAS mutation-
positive advanced NSCLC randomised to receive second-line 
treatment with SEL-DOC 75/75 or placebo bid plus docetaxel. The 
relationship between maximum reduction in absolute neutrophil 
count (mr-ANC) and infection or hospitalisation events was ex-
plored using bias-reduced logistic regression (Firth. Biometrika 
1993;80:27–38; Kosmidis. brglm, v0.5-6: www.ucl.ac.uk/~ucakiko/
software.html). Starting models included terms for treatment 
group, mr-ANC, interaction between treatment group and mr-
ANC, and baseline ANC. The final fitted models were used to 
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P3.11-027 A RANDOMISED, OPEN-LABEL PHASE II TRIAL 
OF VOLASERTIB AS MONOTHERAPY AND IN COMBI-
NATION WITH STANDARD DOSE PEMETREXED COMPA-
RED WITH PEMETREXED MONOTHERAPY IN SECOND-
LINE NON-SMALL CELL LUNG CANCER (NSCLC)
Peter M. Ellis1, Natasha Leighl2, Vera Hirsh3, M N. Reaume4, Nor-
mand Blais5, Rafal Wierzbicki6, Behbood Sadrolhefazi7, Yu Gu8, 
Dan Liu9, Korinna Pilz9, Quincy Chu10
1Juravinski Cancer Centre/Canada, 2Princess Margaret Cancer Centre/
Canada, 3McGill University Health Center/Canada, 4The Ottawa Hospi-
tal Cancer Centre/Canada, 5Centre Hospitalier De L‘universite De Mon-
treal/Canada, 6Rsm Durham Regional Cancer Centre/Canada, 7Boehrin-
ger Ingelheim Canada Ltd/Canada, 8Boehringer Ingelheim Corporation/
United States Of America, 9Boehringer Ingelheim Pharma GmbH & Co. 
KG/Germany, 10Cross Cancer Centre/Canada
Background: Polo-like kinases (Plks) are overexpressed in many 
cancers including NSCLC. Volasertib (BI 6727; an investigational 
drug) is a selective and potent Plk inhibitor, which induces mitotic 
arrest and apoptosis. This 3-arm trial compared the efficacy, sa-
fety and pharmacokinetics of volasertib monotherapy, volasertib 
combined with pemetrexed and single-agent pemetrexed as 
second-line therapy in patients with advanced/metastatic NSCLC 
(NCT00824408).
Methods: An initial run-in phase was conducted to determine the 
tolerability and dose of volasertib combined with pemetrexed 
500mg/m2. Subsequent patients were randomised to one of three 
arms: (A) volasertib 300mg, (B) volasertib 300mg plus pemetrexed 
500mg/m2, or (C) pemetrexed 500mg/m2. Both drugs were admi-
nistered on Day 1 every 21 days. Eligible patients had advanced/
metastatic NSCLC, ECOG PS 0–2, adequate organ function and 
prior platinum-based chemotherapy. The primary endpoint was 
progression-free survival (PFS) evaluated using a stratified one-
sided log-rank test (Arms B versus C); an exploratory analysis was 
performed for Arms A versus C. Secondary endpoints included 
objective response rate (ORR), overall survival (OS), safety and 
pharmacokinetics.
Results: Twelve patients were included in the run-in phase; the vo-
lasertib dose selected for the randomised phase was 300mg. 131 
patients were then randomised to the three arms (A: n=37, B: n=47, 
C: n=47). Arm A recruitment was stopped early due to an increa-
sed rate of early progression. Demographic data were balanced 
between the arms. One patient per arm did not receive treatment. 
The median number (range) of treatment cycles in Arms A, B and 
C was 2 (1–49), 4 (1–36) and 5.5 (1–38), respectively. Median PFS 
(Arms A/B/C) was 1.4/3.3/5.3 months (HR B versus C =1.141 [95% 
CI: 0.735–1.771; p=0.2804]; HR A versus C =2.045 [95% CI: 1.271–
3.292; two-sided p=0.0030]). ORR (Arms A/B/C) was 8%/21%/9%; 
no complete responses were observed. Disease control rates 
(Arms A/B/C) were 27%/66%/68%. Median OS (Arms A/B/C) was 
22.9/17.1/17.4 months. Median relative dose intensity was 100% 
for both volasertib and pemetrexed in all arms with a range of 
80.6–111.1% in Arm A and 83.3–100.0% in Arm B for volasertib, 
and 87.5–100% in Arm B and 81.3–100% in Arm C for pemetrex-
ed. The most common all-grade adverse events (AEs) were (Arms 
A/B/C): fatigue (56%/74%/70%), nausea (14%/48%/54%), decreased 
appetite (8%/44%/41%), constipation (17%/37%/22%), dyspnoea 
(17%/28%/30%) and vomiting (19%/33%/24%). Most common 
grade 3/4 AEs (>5%) were (Arms A/B/C): fatigue (8%/13%/17%), 
neutropenia (14%/11%/4%) and dyspnoea (3%/9% /13%). Grade 
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Methods: The SELECT-1 study is a randomised, double-blind, 
placebo-controlled Phase III study that will assess the efficacy and 
safety of selumetinib in combination with docetaxel in patients 
receiving second-line treatment for KRAS mutation-positive locally 
advanced or metastatic NSCLC (Stage IIIB–IV). Eligible patients will 
have centrally confirmed KRAS mutation-positive locally advanced 
or metastatic NSCLC, be suitable for second-line treatment and 
have had no prior treatment with docetaxel or a MEK inhibitor. 
Patients must have measurable disease, histologically or cytologi-
cally confirmed locally advanced or metastatic NSCLC and a WHO 
performance status (PS) of 0–1. Patients will be randomised in a 
ratio of 1:1 to receive selumetinib (75 mg, orally twice daily [BID]) 
or matching placebo BID in combination with docetaxel (intrave-
nously 75 mg/m2, on Day 1 of every 21-day cycle) until objective 
disease progression, intolerable toxicity or occurrence of another 
discontinuation criterion. Approximately 4000 patients will need to 
be screened from 220 centres globally to identify 634 KRAS mu-
tation-positive patients for the study. Patients will be stratified at 
randomisation based on their WHO PS (1/0) and tumour histology 
(squamous/non-squamous). Following randomisation, patients will 
attend for visits on Day 8, 15, 22, 43 and every 3 weeks thereafter 
for as long as they are receiving study treatment. Tumour evaluati-
on according to Response Evaluation Criteria in Solid Tumors versi-
on 1.1 guidelines will be performed at screening, Week 6, Week 12 
and every 6 weeks thereafter, relative to the date of randomisation. 
The primary study endpoint is PFS; secondary endpoints include 
overall survival and objective response rate. Efficacy data will be 
analysed on an intent-to-treat basis using randomised treatment. 
Blood samples will be taken to assess the pharmacokinetics of 
selumetinib. The study will also evaluate PROs and safety for the 
selumetinib/docetaxel combination compared with placebo/doce-
taxel. In addition, outcome based on KRAS mutation type will be 
assessed.
Results: Not applicable.
Conclusion: This Phase III study will confirm the efficacy of selume-
tinib in combination with docetaxel in patients with NSCLCs that 
harbour mutations of KRAS and who are eligible for second-line 
treatment.
Keywords: selumetinib, NSCLC, metastatic, KRAS
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P3.11-030 A PHASE I / II TRIAL OF THE HDAC INHIBITOR 
BELINOSTAT IN COMBINATION WITH ERLOTINIB IN PA-
TIENTS WITH NON-SMALL CELL LUNG CANCER.
Jon L. Andersen, Bente Holm, Trine S. Rasmussen, Anders Mel-
lemgaard
Oncology, Copenhagen University Hospital Herlev/Denmark
Background: Belinostat (PXD101), is a histone deacetylase (HDAC) 
inhibitor. HDAC inhibitors, including belinostat, have shown 
marked in vitro and in vivo activity against a number of solid tu-
mors and hematological cancers. Belinostat is efficient as a single 
agent as well as in combination with other anticancer agents such 
as doxorubicin, paclitaxel, carboplatin, fluorouracil, bortezumib. 
Synergistic effect between HDAC inhibitors, incl. belinostat and 
EGFR inhibitors has been observed. Belinostat has been well to-
lerated at doses up to 2000 mg daily in patients. The main side 
effects are fatigue, nausea and vomiting. The trial was designed 
predict the proportion of patients with events across the range of 
mr-ANC. Reported reasons for hospitalisation, dose modification 
and treatment discontinuation were medically reviewed in the con-
text of expected pp-GCSF effect.
Results: The fitted logistic regression model showed some evi-
dence of a relationship between hospitalisation events and mr-
ANC for both treatment groups. A zero mr-ANC (assumed effect 
of pp-GCSF) predicted hospitalisation in 30% of patients (80% 
prediction interval 18–44%) in the SEL-DOC 75/75 group and 10% 
(5–18%) in the placebo plus docetaxel group. The observed inci-
dence of hospitalisations in study NCT00890825 was 48% (80% 
confidence interval [CI] 37–58%) and 19% (11–29%) of patients, 
respectively. There was limited evidence of a relationship bet-
ween events of infection and mr-ANC, suggesting other factors 
(eg immunosuppression and altered integrity of gastrointestinal 
wall) may influence the incidence of infection reported with this 
combination. Medical review indicated that use of pp-GCSF could 
reduce hospitalisation incidence during SEL-DOC 75/75 from ob-
served 48% to a point estimate of 34% (80% CI 25–45%), and dose 
modification due to febrile neutropenia or infection from 23% to 
5% (80% CI 1–12%). Permanent discontinuation of SEL-DOC 75/75 
for reasons other than disease progression did not appear to be 
affected by pp-GCSF use.
Conclusion: Prevention of ANC reduction is predicted to lower the 
incidence of hospitalisation events in patients receiving treatment 
with selumetinib plus docetaxel for NSCLC. These findings support 
pp-GCSF use to reduce the incidence of hospitalisations previous-
ly reported with the SEL-DOC 75/75 regimen.
Keywords: selumetinib, NSCLC, metastatic, KRAS
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P3.11-029 THE SELECT-1 STUDY DESIGN: SELUMETINIB 
IN COMBINATION WITH DOCETAXEL FOR SECOND-
LINE TREATMENT OF KRAS MUTATION-POSITIVE LO-
CALLY ADVANCED OR METASTATIC NON-SMALL CELL 
LUNG CANCER
Pasi A. Jänne1, Helen Mann2, Ian Smith2
1Dana-Farber Cancer Institute/United States Of America, 2Astra-
zeneca/United Kingdom
Background: KRAS mutations are the most common mutation 
type in patients with non-small cell lung cancer (NSCLC) with 
adenocarcinoma histology (Califano et al. Drugs 2012;72[Suppl 
1:]28–36). The presence of the KRAS mutation has been associated 
with a poor prognosis (Mascaux et al. Br J Cancer 2005;92:131–139) 
and a therapy targeting Ras has yet to be proven in clinical trials. 
Selumetinib (AZD6244, ARRY-142886) is an orally available, potent 
and selective, non-ATP-competitive MEK1/2 inhibitor. MEK1/2 are 
proteins downstream of Ras in the Ras/Raf/MEK/ERK pathway. It is 
anticipated that inhibition of MEK activity should inhibit transduc-
tion of the mitogenic and survival signals via this pathway, resulting 
in an inhibition of tumour proliferation, differentiation and survival. 
A randomised Phase II study evaluating docetaxel plus selumetinib 
or placebo in pretreated patients with KRAS mutation-positive 
advanced NSCLC has previously demonstrated a significant impro-
vement in terms of response rate, progression-free survival (PFS) 
and patient-reported outcomes (PROs) in favour of the combinati-
on arm (Jänne et al. Lancet Oncol 2013;14:38–47).
S1202 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Methods: We have retrospectivly examined all histological and cy-
tological sampling for molecular testing on NSCLC-patients in the 
two lung cancer centra in Stockholm, Sweden (Karolinska Universi-
ty Hostpital: sites of Solna and Huddinge) between 2009 and 2011. 
All samples with positive outcome were identified and clinical data 
from all patients in advanced stages of disease were collected.
Results: 565 samples were collected for EGFR-mutation analysis. 
Mutations were identified in 66 cases (11,7%). Both cytological and 
histological material were analyzied (n=23 and 21 respectively). 42 
tumors were adenocarcinomas, 1 was a large cell carcinoma and 1 
was a squamous cell carcinoma. 29 presented deletion in exon 19 
and 14 mutations in exon 21, whereof 21 and 12 respectively were 
women. 1 patient (male) presented a constitutive deletion in exon 
20. 44 patients had metastatic disease. Clinical data from these 
patients were further analyzed. 21 were never smokers, 21 former 
smokers with 28 years in average since smoking cessation and 2 
were current smokers. All patients recieved TKI-treatment, whereof 
24 as 1st line, 14 as 2nd line and 6 as a later line. Partial remission 
was obtained in 77% of cases and stable disease in 11%. 2,2% of 
patients developed progressive disease according to RECIST-cri-
teria during TKI-treatment. At time of data collection, 16 patients 
had died. The remaining 28 patients had ongoing TKI-treatment 
for 400 days on average and a median survival of 21 months.
Conclusion: A positive mutation test on either cytological or his-
tological material carries a high predictive value for TKI-treatment. 
TKIs offer good and durable treatment results in patients with 
advanced NSCLC and activating EGFR-mutations. Thus, identifying 
this subset of patients offers new treatment options and realisti-
cally balanced hope in the severe setting of metastatic NSCLC.
Keyword: NSCLC, EGFR-mutations, TKI, predictive factor
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P3.11-032 A PILOT SINGLE INSTITUTION STUDY OF AU-
TOLOGOUS TUMOR AUTOPHAGOSOME (DRIBBLE) VAC-
CINATION WITH DOCETAXEL IN PATIENTS (PTS) WITH 
STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)
Rachel E. Sanborn1, Helen J. Ross2, Sandra Aung3, Anupama Ku-
rup1, Tarsem Moudgil1, Sachin Puri1, Traci Hilton3, Brenda Fisher1, 
Hong-Ming Hu1, Bernard A. Fox1, Walter J. Urba1
1Robert W. Franz Cancer Research Center, Earle A. Chiles Research 
Institute, Providence Cancer Center/United States Of America, 2Mayo 
Clinic/United States Of America, 3Ubivac/United States Of America
Background: DRibbles are tumor-derived autophagosomes 
containing short-lived proteins (SLiPs) and defective ribosomal 
products (DRiPs). Vaccination with DRibbles produces tumor re-
gression and provides cross-protection against syngeneic MCA 
sarcomas in preclinical models. Docetaxel can expose hidden tu-
mor antigens and induces relative lymphopenia, potentially enhan-
cing specific immune response. Sargramostim (GM-CSF) augments 
priming of tumor-specific T cells when administered at the site of 
DRibble vaccine in mice. This pilot study of autologous NSCLC 
DRibble vaccination with GM-CSF and docetaxel enrolled patients 
with advanced incurable NSCLC with malignant pleural effusion.
Methods: Pts had NSCLC with malignant pleural effusion, ECOG 
PS ≤ 2, and up to 2 prior chemotherapy regimens. Prior cancer-
related vaccine therapy, active autoimmune disease, HIV, viral 
as an open, non-randomized phase I / II trial to assess the efficacy 
and safety of belinostat in combination with erlotinib in patients 
with advanced non-small cell lung cancer, who were eligible for 
treatment with erlotinib.
Methods: The primary endpoint of the phase I part was to esta-
blish the maximum tolerated dose (MTD) and the dose limiting 
toxicity (DLT) of erlotinib (150mg/d) in combination with increasing 
doses of belinostat. The study was designed as a 3+3 phase I trial. 
All patients began with 4 weeks of erlotinib 150 mg/d. If this was 
tolerated, patients started the combination erlotinib and belino-
stat. The belinostat dose steps were 500 mg, 1000 and 1500 mg, 
administered daily in 2 weeks on treatment, 1 week off treatment. 
When one patient was enrolled at one dose level, there would be 
no further dose escalation for that individual patient. Three pati-
ents were planned at each dose level. When the MTD was identi-
fied the trial was planned to expand to a phase II trial, and include 
20 patients with non-small cell lung cancer.
Results: From October 2010 until June 2011 five patients were 
enrolled in the phase I part of the trial. Patient one and two star-
ted belinostat 500 mg after four weeks of erlotinib 150 mg/d.Both 
patients experienced grade 3 diarrhea in spite of supportive care 
with loperamid and antiemitics. The treatment was discontinued 
in both patients and the toxicity quickly resolved. In accordance 
with the trial protocol, patient three was started on belinostat 250 
mg. Patient three experienced only grade 1 diarrhea and grade 
1 nausea. The patient received 2 series of belinostat. Patient four 
experienced grade 2 diarrhea and grade 2 rash in the first series 
belinostat 250 mg. Patient five experienced, in the first series of 
belinostat, grade 3 diarrhea and was hospitalized despite intensive 
supportive care. All patients discontinued treatment and toxicity 
resolved.
Conclusion: The combination of the HDAC-inhibitor belinostat and 
the EGFR inhibitor erlotinib resulted in severe toxicity. The trial has 
been closed. NCT01188707
Keywords: NSCLC advanced, Phase I, Belinostat/Erlotinib
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P3.11-031 THE CLINICAL IMPORTANCE OF EGFR-TES-
TING IN NON-SMALL CELL LUNG CANCER: 
THREE YEAR EXPERIENCE FROM KAROLINSKA UNIVER-
SITY HOSPITAL IN SWEDEN
Stephanie Mindus1, Kenbugul Jatta2, Göran Elmberger2, Karl Köl-
beck1
1Respiratory Medicine And Allergology, Karolinska University Hospital/
Sweden, 2Department Of Pathology, Karolinska University Hospital/
Sweden
Background: Lung cancer remains the most leathal form of cancer. 
Overall five-year survival rate is poor but not without heterogenei-
ty. The struggle to improve prognosis and treatment outcome is 
ongoing. Molecular pathways and “driver mutations” have been 
identified, some of which can be specifically targeted by new 
drugs. Mutations within the APT-binding domain of the EGFR gene 
constitute a predictive factor for the use of tyrosine kinase inhibi-
tors (TKI) such as erlotinib or gefitinib. Our aim was to define the 
clinical importance of molecular pathological testing for activating 
EGFR-mutations in non-small lung cancer.
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P3.11-033 BRAIN METASTASIS FEATURES AND ASSO-
CIATION WITH TUMOR EGFR MUTATION IN PATIENTS 
WITH ADENOCARCINOMA OF THE LUNGS
Yung-Hung Luo1, Chieh-Hung Wu1, Chu-Yun Huang1, Chih-Wei 
Wu1, Wen-Shuo Wu1, Chun-Ming Tsai1, Yu-Chin Lee1, Reury-Perng 
Perng1, Jacqueline Whang-Peng2, Yuh-Min Chen1
1Department Of Chest Medicine, Taipei Veterans General Hospital/Tai-
wan, 2Taipei Medical University/Taiwan
Background: More than half of pulmonary adenocarcinoma pa-
tients present with locally advanced or metastatic disease. Most 
patients with brain metastases suffered from poor quality of life 
and poor survival time. Epidermal growth factor receptor (EGFR) 
mutations were most frequently found in patients with pulmonary 
adenocarcinoma and were associated with a better prognosis than 
patients with EGFR wild-type tumors. However, the association 
between tumor EGFR mutation and whether or not more frequent 
brain metastasis is still unclear.
Methods: We retrospectively reviewed the data of our pulmonary 
adenocarcinoma patients who have brain metastasis, and record 
the characteristics of brain metastasis. The association between tu-
mor EGFR mutation and clinical characteristics of brain metastasis 
were analyzed.
Results: 374 cases were reviewed. There are 239 patients with 
EGFR mutations, 69 patients with initial diagnosis of brain metas-
tasis, and 82 patients with brain metastasis after treatment. Older 
patients (more than 70 years old) had fewer brain metastasis than 
younger (less than 70 years old) patients (25.8% v.s 48%, P<0.001). 
Patients with higher N stage of TNM staging system had higher 
proportion of brain metastasis (P=0.006). Patients with exon 19 
deletion had more chance to suffer from brain metastasis than tho-
se with EGFR wild type (48.1% v.s. 34.1%, P=0.021). Patients with 
exon 19 deletion didn’t have significantly higher chance to have 
initial diagnosis of brain metastasis (P=0.216). However, patients 
with exon 19 deletion had higher chance to suffered from brain 
metastasis after treatment than those with EGFR wild type (35.6% 
v.s. 21.2%, P=0.019). Patients with exon 19 deletion survived longer 
than those with EGFR wild type (1-yr survival rate 95.8% vs. 78.7%, 
P=0.003). Thus, longer survival time may lead to higher proportion 
of brain metastasis occurrence in patients with exon 19 deletion 
than those with EGFR wild type.
Conclusion: There is no significant difference in frequency of ini-
tial brain metastases in patients with EGFR mutation or wild type. 
However, there are statistically significant association between 
brain metastasis and EGFR mutations in pulmonary adenocarcino-
ma patients in their disease process.
Keywords: Adenocarcinoma, EGFR mutation, brain metastasis
hepatitis, or chronic steroid use were not permitted. Pts with rapid 
clinical deterioration after enrollment were not eligible for vacci-
nation. After informed consent, cells from malignant pleural fluid 
were cultured with bortezomib to block degradation of SLiPs and 
DRiPs and ammonium chloride to prevent lysosomal degradation 
of the autophagosome. DRibble vaccines were irradiated and 
passed sterility and endotoxin release criteria. Pts received doce-
taxel 75 mg/m2 IV on day 1 and 29 for antitumor effect and to un-
mask tumor antigens and produce relative lymphopenia. Vaccinati-
on was scheduled for days 14, 43, 57, 71 and 85. GM-CSF (50 ug/d) 
was given via mini pump for 6d after each vaccination with immune 
monitoring pretreatment and at each vaccination.
Results: Six pts (3M, 3F, average age 65) with PS 1 and adenocarci-
noma were enrolled. All received d1 docetaxel. Two did not recei-
ve further therapy due to clinical decline. Four pts were vaccinated 
(2-4 vaccines). One of 4 pts exhibited autologous tumor-specific 
immune response (IFN-γ, TNF-α, IL-5, IL-10) and 3 of 4 pts genera-
ted B cell responses (>5 fold specific antibody), with 1 patient not 
evaluable (Table 1). 
Conclusion: DRibble vaccine given with GM-CSF and chemothe-
rapy is feasible. Small patient numbers preclude further conclu-
sions. In order to translate this strategy to a larger number of pts 
in a more feasible population, we have developed an allogeneic 
DRibble vaccine from two NSCLC cell lines expressing at least 9 
NCI-prioritized cancer antigens and including agonists for TLR 2, 
3, 4, 7 & 9, HSPs and a dendritic cell-targeting molecule. A phase II 
trial of adjuvant DRibble vaccine alone or combined with GM-CSF 
or imiquimod is open in patients with definitively treated stage 
IIIA/B NSCLC. Support R21 CA123864-02 (WJU), R444 CA121612-
01 (SA/TH) and Kuni Foundation (WJU).
Keywords: NSCLC Vaccine, clinical trial, Anti-Cancer Immune Res-
ponse, Autophagosome
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P3.11-035 AN OPEN LABEL COMPASSIONATE USE PRO-
GRAMME OF BIBW 2992/AFATINIB IN ADVANCED NON-
SMALL CELL LUNG CANCER PATIENTS PRE-TREATED 
WITH ERLOTINIB OR GEFITINIB IN KOREA
Moon Ki Choi, Ji Yoon Lee, Jung Yong Hong, Myung-Ju Ahn, Jong-
Mu Sun, Jin Seok Ahn, Keunchil Park
Division Of Hematology-Oncology, Department Of Medicine, Samsung 
Medical Center/Korea
Background: Afatinib is a potent and selective, irreversible ErbB 
family blocker. Previous phase 3 trial demonstrated that afatinib pro-
longed progression-free survival compared with placebo in patients 
with advanced lung adenocarcinoma who progressed after 12 weeks 
of treatment with reversible EGFR tyrosine-kinase inhibitors (TKIs). 
The purpose of this Open Label Compassionate Use Programme is to 
provide afatinib to patients with advanced NSCLC with previous treat-
ment failure on erlotinib or gefinitib and for whom no other approved 
treatment is available.
Methods: who have failed at least one line of platinum-based cytoto-
xic chemotherapy and following at least 6 months on erlotinib or gefi-
nitib were eligible. Thestarting dose of afatinib was 50mg daily.
Results: Between Aug 2011 and Dec 2012, 107 patients were treated 
with afatinib. Most patients were females (60.7%) and never-smokers 
(69.2%) with a median age of 57 years. Of the 95 patients who had 
prior EGFR mutation results, 82 (86.3%) were positive. With afatinib 
treatment 25 (23.4%) of 107 patients had a partial response. Medi-
an progression-free survival was 4.6 months (95% CI 4.1-5.1). The 
most common adverse events were diarrhea (97 [90.7%] patients; 22 
[20.6%] were grade 3) and rash or acne (72 [67.3%] patients; 11 [10.3%] 
were grade 3). No drug-related death was found. Sixty-four (59.8%) 
patients needed a dose reduction because of an adverse event.
Conclusion: Our results suggested that afatinib could be a feasible 
option to patients with advanced lung adenocarcinoma who have 
progressed after clinical benefit on previous EGFR TKIs.
Keywords: non-small cell lung cancer, afatinib, EGFR tyrosine kinase 
inhibitor
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P3.11-036 COMPARISON OF CLINICAL OUTCOME 
BETWEEN GEFITINIB AND ERLOTINIB TREATMENT IN 
PATIENTS WITH NON-SMALL CELL LUNG CANCER HAR-
BORING AN EPIDERMAL GROWTH FACTOR RECEPTOR 
EXON 19 OR EXON 21 MUTATIONS
Sung Hee Lim, Ji Yun Lee, Moonjin Kim, Sungmin Kim, Hyunae 
Jung, Won Jin Chang, Moon Ki Choi, Jong-Mu Sun, Jung Yong Hong, 
Su Jin Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Division Of Hematology-Oncology, Department Of Medicine, Samsung 
Medical Center/Korea
Background: Gefitinib and Erlotinib are oral small-molecule kinase 
inhibitors that inhibit signaling via EGFR and both agents showed 
dramatic response rate and prolonged PFS in patients harboring 
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P3.11-034 ONE-YEAR FOLLOW-UP OF A PHASE I/
II STUDY OF A HIGHLY SELECTIVE ALK INHIBITOR 
CH5424802/RO5424802 IN ALK-REARRANGED ADVAN-
CED NON-SMALL CELL LUNG CANCER (NSCLC)
Akira Inoue1, Makoto Nishio2, Katsuyuki Kiura3, Takashi Seto4, 
Kazuhiko Nakagawa5, Makoto Maemondo6, Toyoaki Hida7, Hiros-
hige Yoshioka8, Masao Harada9, Yuichiro Ohe10, Naoyuki Nogami11, 
Haruyasu Murakami12, Kengo Takeuchi13, Kazue Kikuchi14, Taka-
shi Asakawa14, Shumpei Yokoyama14, Tomohide Tamura15
1Tohoku University Hospital/Japan, 2The Cancer Institute Hospital Of 
JFCR/Japan, 3Okayama University Hospital/Japan, 4National Kyushu 
Cancer Center/Japan, 5Kinki University Faculty Of Medicine/Japan, 6Mi-
yagi Cancer Center/Japan, 7Aichi Cancer Center Hospital/Japan, 8Kuras-
hiki Central Hospital/Japan, 9Hokkaido Cancer Center/Japan, 10National 
Cancer Center Hospital East/Japan, 11National Hospital Organization 
Shikoku Cancer Center/Japan, 12Shizuoka Cancer Center/Japan, 13Japa-
nese Foundation For Cancer Research/Japan, 14Chugai Pharmaceutical 
Company/Japan, 15National Cancer Center Hospital/Japan
Background: CH5424802 is a novel tyrosine-kinase inhibitor that 
selectively inhibits ALK as well as secondary ALK mutations inclu-
ding L1196M. The preliminary results of the Phase I/II study (Lancet 
Oncol. 2013; 14: 590–8) showed that CH5424802 was active in the 
CNS and achieved a 93.5% objective response rate by RECIST in 
crizotinib-naïve NSCLC patients with a median follow-up of 7.6 
months (range, 3.4–11.3). Here we report the 1-year follow-up re-
sults after the last patient enrolled in the Phase II analysis.
Methods: Patients with ALK-rearranged advanced NSCLC, who 
progressed after ≥1 prior chemotherapy regimens and who were 
naïve to any ALK inhibitors, received CH5424802 300 mg orally 
twice daily in the Phase II portion of the study. ALK fusion gene 
expression was confirmed by IHC and FISH or by RT-PCR at central 
laboratories. Tumor assessment was performed every cycle (21 
days) until Cycle 4 and every 2 cycles thereafter with RECIST ver. 
1.1.
Results: As of April 18, 2013, 46 patients had been treated with 
CH5424802 in the Phase II portion: median age, 48 years (range, 
26–75); male/female, 22/24; ECOG PS 0/1, 20/26; never-smoker, 
59%; ≥2 prior chemotherapy regimens, 52%. The objective res-
ponse rate remains the same as previously reported, 93.5% (95% 
CI: 82.1% to 98.6%). At 1-year follow-up, a total of 7 patients (15%) 
had achieved a complete response. The median progression-free 
survival had not been achieved, and the 1-year progression-free 
rate (PFR) was 83% (95% CI: 68% to 92%). 34/46 patients were 
still on study treatment, and the median treatment duration had 
passed 14.8 months. CH5424802 also shows promising efficacy 
in the CNS: of 14 patients with baseline brain metastasis, 9 re-
mained in the study without CNS or systemic progression for >12 
months, with 6 of them exceeding 16 months. The other 5 patients 
with baseline CNS metastasis had no CNS progression during 
CH5424802 treatment. One of these patients discontinued the stu-
dy due to AE, and the remaining 4 patients had systemic progres-
sion. The safety profile remains similar to that previously reported, 
with no patient requiring dose reduction.
Conclusion: CH5424802 demonstrated a high 1-year PFR of 83% 
and promising CNS activity. CH5424802 could be a novel thera-
peutic option for the treatment of ALK-rearranged NSCLC.
Keywords: ALK, CH5424802, RO5424802, ADVANCED NSCLC
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of patients, progression free survival (PFS) and overall survival (OS) 
were disappointing. Concurrent inhibition of multiple pathways 
may improve treatment outcome. Metformin is a save and well 
known antidiabetic drug. It has been described that metformin has 
inhibitory effects against mTOR, downstream of PI3K. An in vitro 
study of our group has shown synergistic effects of sorafenib and 
metformin which provided the rationale for this study [2]. In a post 
hoc analysis of the previous study, metformin users appeared to be 
among the longest survivors.
Methods: Patients with advanced NSCLC with a KRAS mutation, 
pretreated with platinum containing chemotherapy were included. 
Other inclusion criteria were: ECOG performance score (PS) 0-1, 
adequate organ reserve, creatinine clearance >60 ml/min and 
provided written informed consent according to local IRB regula-
tions. A tumor biopsy was mandatory to confirm the presence of a 
KRAS mutation, prior to start of treatment. Treatment consisted of 
sorafenib 400 mg BID and metformin 1000 mg BID until disease 
progression or unacceptable toxicity. Dose reductions and discon-
tinuations were specified per protocol in the face of CTC toxicities 
grade 3 and 4. Primary endpoint: disease control rate (DCR) at 
6 weeks according to RECIST version 1.1. Secondary endpoints: 
duration of response, progression free survival (PFS), overall sur-
vival and treatment related toxicities. A 2-stage design was imple-
mented (Simon‘s optimal design; p0=50%, p1=70%, alpha=0.05, 
beta=0.20) for a total of 45 evaluable patients.
Results: Fifty-five patients were included between 1st of July 2012 
and 1st of June 2013. Median age was 60 (range 34-77) years, 28 
female (51 %), ECOG PS 0/1/2 16/32/1, all patients had stage IV 
disease. Of 47 patients disease evaluation after 6 weeks was availa-
ble (Fig. 1). Two patients had a partial response, 23 stable disease 
and 22 patients had progressive disease. DCR was 53%. Results of 
secondary endpoints will be available at time of the conference.
Conclusion: This preliminary analysis suggests that the addition of 
metformin did not improve DCR, compared to previous reported 
results of sorafenib monotherapy in pretreated stage IV NSCLC 
patients with a KRAS mutation. [1] Dingemans AM et al. Clin Can-
cer Res. 2013 Feb 1;19(3):743-51 [2] Groenendijk FH et al. EJC. 2012 
Nov; 48 (suppl. 6): p 48 
Keywords: non-small cell lung cancer, KRAS, Sorafenib and met-
formin, Phase II study
activating EGFR mutation. We investigated the clinical outcomes bet-
ween gefitinib- and erlotinib-treated patients with recurrent or metas-
tatic non-small cell lung cancer (NSCLC) harboring EGFR mutations.
Methods: A total 375 patients with recurrent or metastatic stage IIIB/
IV NSCLC who had either an exon 19 deletion or L858R mutation on 
exon 21 and received gefitinib(n=228) or erlotinib(n=147) therapy 
between August 2007 and December 2011 were retrospectively re-
viewed. By using a matched-pair case-control study design, 121 pairs 
of gefitinib-treated and erlotinib-treated patients were matched ac-
cording to sex, smoking history, ECOG performance status, and types 
of EGFR mutation.
Results: The median age of all patients was 58 years(range, 30-84) 
and more than half of patients were never smokers(63.6%). Most pa-
tients had adenocarcinoma (98.3%) and good ECOG performance 
status (0, 1) (90.9%). The median number of cycles in TKI treatment 
was 12.7 in gefitinib group and 10.8 in erlotinib group. Of 242 pati-
ents, 64(26.4%) received an EGFR TKI as first line therapy. The overall 
response rates and disease control rates in the gefitinib-treated and 
erlotinib-treated groups were 85.5% versus 79.8 % (p=.375) and 
94.0% versus 89.1%, respectively (p=.242). There was no statistically 
significant difference noted with regard to OS (median, 22.1 vs 25.2; 
p=.546) and PFS (median, 12.5 vs 9.9; p=.114) between the gefitinib-
treated and erlotinib-treated groups. For a subgroup which patients 
were treated with TKI as first line therapy, the overall response rates 
were higher than those of patients who had progressed on prior 
chemotherapy (90.3% vs 79.9%; p=.063). However, there was no signi-
ficant differences in PFS (median, 13.1 vs 10.1; p=.082) between sub-
jects with first line TKI therapy and more than second line treatment. 
Regarding safety and dose adjustment of EGFR TKIs, patients with 
erlotinib more frequently had G3/4 toxicity than ones with gefitinib 
and required dose reduction(18.1% vs 1.65%).
Conclusion: Both gefitinib and erlotinib showed similar effective acti-
vity in selected population of NSCLC that harbored an EGFR mutation 
and further studies are needed to evaluate the efficacy of EGFR TKI 
as first line treatment.
Keywords: gefitinib, erlotinib, Epidermal growth factor receptor  
mutation
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P3.11-037 A PHASE II STUDY OF SORAFENIB AND MET-
FORMIN IN PATIENTS WITH STAGE IV NON-SMALL CELL 
LUNG CANCER (NSCLC) WITH A KRAS MUTATION
Wouter W. Mellema1, Sjaak Burgers2, Harry J.M. Groen3, Anne-
Marie Dingemans4, Erik Thunnissen5, Daniëlle A M Heideman5, 
Jeroen De Jong6, Wim Timens7, Ernst-Jan M. Speel8, Egbert F Smit1
1Pulmonary Diseases, VU University Medical Center/Netherlands, 
2Thoracic Oncology, NKI - Antoni Van Leeuwenhoek Hospital/Nether-
lands, 3Pulmonary Diseases, UMC Groningen/Netherlands, 4Pulmo-
nary Diseases, Maastricht University Medical Center+/Netherlands, 
5Pathology, VU University Medical Center/Netherlands, 6Pathology, 
Netherlands Cancer Institute/Netherlands, 7Pathology, UMC Gronin-
gen/Netherlands, 8Pathology, Maastricht University Medical Center+/
Netherlands
Background: Previously we reported a phase II study of sorafenib, 
a multi tyrosine kinase inhibitor, in advanced NSCLC patients with 
a KRAS mutation [1]. While sorafenib was found active in this group 
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P3.11-039 EXPLORATION OF PATIENT HEALTH STATUS 
AS MEASURED BY THE GENERIC PREFERENCE-BASED 
QUESTIONNAIRE EQ-5D ALONGSIDE THE START TRIAL 
OF TECEMOTIDE (L-BLP25) IN NON-SMALL CELL LUNG 
CANCER
Mark A. Socinski1, Charles A. Butts2, Paul Mitchell3, Nicholas That-
cher4, Giorgio Scagliotti5, Gilles Robinet6, Claudio Martin7, Mauro 
Zukin8, Yury A. Ragulin9, Philip Bonomi10, James C. Yang11, Antoine 
Regnault12, Christoph Helwig13, Enrico De Nigris13, Frances A. She-
pherd14
1Upmc Cancer Pavilion/United States Of America, 2Cross Cancer In-
stitute/Canada, 3Austin Hospital/Australia, 4Christie Hospital NHS 
Trust/United Kingdom, 5Università Di Torino/Italy, 6Oncology-pneumo-
logy, Centre Hospitalier Universitaire - Hôpital Morvan/France, 7Insti-
tuto Especializado Alexander Fleming/Argentina, 8Instituto Nacional 
Do Câncer-inca/Brazil, 9Institution Of The Russian Academy Of Medical 
Sciences/Russian Federation, 10Rush University Medical Center/United 
States Of America, 11National Taiwan University Hospital/Taiwan, 
12Mapi Values/France, 13Merck Kgaa/Germany, 14University Health 
Network, Princess Margaret Hospital/Canada
Background: Tecemotide (L-BLP25) is a mucin 1 (MUC1) antigen-
specific cancer immunotherapy investigated in patients not pro-
gressing after primary chemo-radiotherapy for stage III non-small 
cell lung cancer (NSCLC) in the phase III START study. The objecti-
ve of this analysis was to explore patients’ health status alongside 
the study.
Methods: From January 2007 to November 2011, 1513 patients 
with unresectable stage III NSCLC that did not progress after che-
mo-radiotherapy (platinum-based chemotherapy and ≥50 Gy) were 
randomized (2:1; double-blind) to tecemotide (806 µg lipopeptide) 
or placebo SC weekly x 8 then Q6 weeks until disease progression 
or withdrawal. The analysis population (n=1239) was defined pro-
spectively to account for a clinical hold of the study. The impact 
on patient health status was assessed as an exploratory endpoint 
using the EuroQoL 5 Dimensions (EQ-5D), a widely used generic 
preference-based questionnaire covering 5 dimensions (mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression). 
EQ-5D index score can be calculated for which perfect health is 
given a value of 1 and death a value of 0. EQ-5D was collected 
at baseline, weeks 2, 5 and 8 and then every 6 weeks until end 
of treatment (EOT) visit (i.e. at time of disease progression), the 
EOT visit and every 12 weeks afterwards. Analysis of covariance 
(ANCOVA) was carried out to explore the change of EQ-5D index 
score over time in the overall population for patients on treatment. 
The change of EQ-5D to EOT visit was also estimated. Change of 
EQ-5D index score was explored using all data (i.e. collected both 
before and after EOT visit) using a linear growth curve model, with 
random intercept and slope, considering time as a continuous 
variable.
Results: EQ-5D compliance rates (percentage of patients still in 
the study who completed the questionnaire) were consistently 
above 85% for all visits of the treatment period in both treatment 
arms. Mean baseline EQ-5D score was 0.79 (sd=0.19) for both tece-
motide and placebo arms. The results from ANCOVA on the over-
all population did not show any significant difference between the 
two arms during the treatment phase. Change in the EQ-5D index 
score from baseline to EOT visit was –0.102 (95%CI: –0.134, –0.071) 
for tecemotide and –0.136 (95%CI: –0.177, –0.095) for placebo. The 
linear growth model including the EQ-5D assessments before and 
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P3.11-038 EGFR MUTATIONS IN SQUAMOUS NSCLC - 
PREVALENCE AND TREATMENT RESULTS WITH EGFR 
TYROSINE KINASE INHIBITORS IN SLOVAK REPUBLIC
Peter Berzinec1, Lucia Copakova2, Katarina Hlinkova2, Barbora Pi-
ackova2, Mojmir Konecny3, Katarina Zavodna3, Maria Cerna4, Peter 
Kasan4, Gabriela Chowaniecova1, Miroslava Culagova5, Radovan 
Barila6, Juraj Beniak7, Lenka Medvecova7, Viera Haviarova8, Pavel 
Babal9
1Specialized Hospital Of St Zoerardus Zobor/Slovak Republic, 2National 
Cancer Institute/Slovak Republic, 3St Elizabeth Cancer Institute/Slovak 
Republic, 4Faculty Hospital Of Comenius University/Slovak Republic, 
5Faculty Hospital/Slovak Republic, 6Regional Hospital/Slovak Repub-
lic, 7Adus Healthcare/Slovak Republic, 8Onko Medica/Slovak Republic, 
9Comenius University/Slovak Republic
Background: Wide screening for EGFR mutations in locally advan-
ced or metastatic squamous NSCLC (SQLC) is not recommended 
by internationally accepted guidelines, mainly due to low pre-
valence. However, the COSMIC database shows the increasing 
incidence of EGFR mutations in SQLC, in 2008: 2,6% (upper limit of 
95%CI: less than 3,6%), in 2012: 5%, and in April 2013: 6% (upper 
limit of 95%CI: 6,9%). In spite of this, there are only very limited 
data about the efficacy of EGFR tyrosine kinase inhibitors (TKIs) in 
patients with SQLC containing activating EGFR mutations. The Pur-
pose of this study was to assess the prevalence of EGFR mutations 
in SQLC in the Slovak Republic, and to assess the treatment results 
with TKIs in this group of patients.
Methods: A nationwide multicentre retrospective study was 
designed, and approved by the Ethical Committee of the Nati-
onal Cancer Institute, Bratislava, Slovakia. The databases of the 
participating institutions were searched for patients with locally 
advanced or metastatic SQLC tested for EGFR mutations between 
March 2010 and March 2013. The time limit reflects the fact, that 
the EGFR mutation testing has been available for all patients with 
locally advanced or metastatic NSCLC in the Slovak Republic since 
March 2010.
Results: Altogether 1502 patients with NSCLC were tested for 
EGFR mutations, among them 585 with SQLC. EGFR mutations 
were found in 26 SQLC cases, which give the prevalence 4.4%, 
95%CI: 3.1 – 6.4%. Thirteen patients received treatment with EGFR 
TKIs, 10 with gefitinib, 3 with erlotinib. Patients’ characteristics: 
M/F: 10/3, age: median 65yrs (55 – 83), PS: 1/2/3: 1/10/2, all with 
stage IV SQLC, cytologically and histologically confirmed in 11 
(85%), cytologically only in 2 (15%) patients. Treatment results: RR: 
PR: 7/11 (64%), SD: 2/11 (18%), PD: 2/11(18%), UNK: 2/13, PFS: me-
dian: 5.5 months (1 – 36+). PFS over 12 months was seen in 3 pati-
ents. There were no unexpected or treatment related SAEs.
Conclusion: EGFR mutations in SQLC as well as the treatment 
efficacy of EGFR TKIs in patients with SQLC containing EGFR mu-
tations deserve further attention. EGFR mutation testing should be 
available also for patients with SQLC.
Keyword: EGFR mutations, squamous cell lung cancer, treatment
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ve hazard ratios for TTD using a Cox proportional hazards model.
Results: LUME-Lung 1 showed that nintedanib in combination 
with docetaxel significantly prolonged PFS for all patients regard-
less of histology (3.4 vs 2.7 months; HR 0.79, 95% CI: 0.68–0.92; 
p=0.0019), with a trend for improved median OS (10.1 vs 9.1 
months; HR 0.94, 95% CI: 0.83–1.05; p=0.272) and significantly im-
proved OS in patients with adenocarcinoma (HR: 0.83; p=0.0359; 
median 10.3 to 12.6 months). The most common AEs were di-
arrhoea and reversible ALT elevations. With respect to the QoL 
assessment, there was a high compliance rate of >80% until treat-
ment course 25 for QLQ-LC13 and QLQ-C30 in both treatment 
arms. The addition of nintedanib to docetaxel did not influence 
TTD for cough (HR 0.90; 95% CI: 0.77–1.05; p=0.1858), dyspnoea 
(HR 1.05; 95% CI: 0.91–1.20; p=0.5203) or pain (HR 0.95; 95% CI: 
0.82–1.09; p=0.4373), and maintained global health status/QoL (HR 
0.952; 95% CI: 0.83–1.10). There was a significant deterioration in 
scores for nausea and vomiting, appetite loss and diarrhoea. The 
results were similar for adenocarcinoma patients with respect to 
cough (HR 0.97; 95% CI: 0.78–1.20; p=0.7744), dyspnoea (HR 1.04; 
95% CI: 0.86–1.26; p=0.6813) and pain (HR 0.93; 95% CI: 0.76–1.13; 
p=0.4785); however, there was a trend for improved global health 
status/QoL (HR 0.86; 95% CI: 0.71–1.05). For squamous cell carci-
noma patients, there was a trend for delayed TTD for cough (HR 
0.84; 95% CI: 0.66–1.07; p=0.1561) and a maintained global health 
status/QoL (HR 0.975; 95% CI: 0.788–1.206). Further analyses are 
ongoing and will be presented at the congress.
Conclusion: In second-line NSCLC patients, docetaxel plus nin-
tedanib did not result in any significant improvements in cough, 
dyspnoea or pain compared with placebo and docetaxel. However, 
PFS was improved in patients of all histologies receiving docetaxel 
and nintedanib, and OS was improved in patients with adenocarci-
noma histology without adversely affecting self-reported QoL.
Keywords: NSCLC, nintedanib, phase 3, patient-reported out-
come
POSTER SESSION 3 - NSCLC NOVEL THERAPIES  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.11-041 TREATMENT WITH CRIZOTINIB IN PATIENTS 
WITH IV STAGE NON-SMALL CELL LUNG CANCER (NS-
CLC) WITH ALK TRANSLOCATION: A SINGLE INSTITUTI-
ON EXPERIENCE.
Simona Carnio, Simonetta G. Rapetti, Enrica Capelletto, Tiziana 
Vavala‘, Matteo Giaj Levra, Elisa Gobbini, Benedetta Crida, Sara 
Demichelis, Silvia Novello
Department Of Oncology, University Of Turin/Italy
Background: Crizotinibis is a MET inhibitor, having also an activity 
on ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) 
pathways. The ALK translocation is described in 4% of NSCLC and 
these patients (pts) benefit from crizotinib therapy with a response 
rate (RR) ranging from 51 to 61%.The drug is already approved by 
FDA and EMA; in Italy crizotinib is available in first line within con-
trolled clinical trials and, until April 2013, within expanded access 
program (EAP).
Methods: From June 2010 to February 2013, 155 pts with advan-
ced NSCLC were analyzed for Alk translocation using fluorescence 
in situ hybridization (FISH) at our institution. The selection criteria 
were: adenocarcinoma histology, never or ex smoker, EGFR status 
after EOT showed that the EQ-5D index score decreased signifi-
cantly over time in both treatment arms, but that the decrease was 
slightly slower in the tecemotide than in the placebo arm: –0.0076 
per month in tecemotide patients vs. –0.01 in placebo (p=0.0498).
Conclusion: During treatment, there was no statistical difference in 
health status with tecemotide vs. placebo. This supports the good 
tolerability profile of tecemotide, with a lack of significant toxicity 
as compared to placebo. Disease progression was associated with 
a notable deterioration of patient health status, regardless of the 
treatment. Considering data from both before and after disease 
progression, patients’ health status appeared to worsen slightly 
over time, at a slower rate for patients treated with tecemotide.
Keywords: immunotherapy, EQ-5D, non-small cell lung cancer, 
tecemotide
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P3.11-040 ANALYSIS OF PATIENT-REPORTED OUTCO-
MES FROM THE LUME-LUNG 1 TRIAL: A RANDOMIZED, 
DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 
STUDY IN SECOND-LINE ADVANCED NON-SMALL CELL 
LUNG CANCER (NSCLC) PATIENTS
Silvia Novello1, Anders Mellemgaard2, Rolf Kaiser3, Jean-Yves 
Douillard4, Sergei Orlov5, Maciej Krzakowski6, Joachim Von Pawel7, 
Maya Gottfried8, Igor Bondarenko9, Meilin Liao10, José Barrueco11, 
Birgit Gaschler-Markefski3, Ingolf Griebsch3, Martin Reck12
1Department Of Oncology, University Of Turin/Italy, 2Department Of 
Oncology, Herlev University Hospital/Denmark, 3Boehringer Ingelheim 
Pharma GmbH & Co. KG/Germany, 4Department Of Medical Oncology, 
Centre René Gauducheau/France, 5Department Of Thoracic Oncology, 
St. Petersburg State Medical University/Russian Federation, 6The Maria 
Sklodowska-Curie Institute Of Oncology/Poland, 7Pneumology Clinic, 
Asklepios Fachkliniken/Germany, 8Lung Cancer Unit, Meir Medical 
Center/Israel, 9Clinical Facility, Dnepropetrovsk City Hospital, Medical 
Academy/Ukraine, 10Shanghai Chest Hospital/China, 11Boehringer In-
gelheim Pharmaceuticals Inc./United States Of America, 12Department 
Of Thoracic Oncology, Lung Clinic Grosshansdorf/Germany
Background: Nintedanib is an oral, twice-daily angiokinase inhibi-
tor targeting VEGFR-1–3, PDGFR-α/β and FGFR-1–3. LUME-Lung 
1 is a placebo-controlled phase III trial investigating nintedanib 
plus docetaxel in advanced NSCLC patients after failure of first-line 
chemotherapy.
Methods: Stage IIIB/IV or recurrent NSCLC patients were rando-
mised to receive nintedanib 200 mg bid plus docetaxel 75 mg/
m2 q21d (n=655), or placebo plus docetaxel (n=659). The primary 
endpoint was centrally reviewed progression-free survival (PFS) 
analysed after 714 events; the key secondary endpoint was overall 
survival (OS) analysed hierarchically after 1121 events, first in ade-
nocarcinoma patients and then all patients. Quality of Life (QoL) 
was included as a secondary endpoint. Lung cancer symptoms 
and health-related QoL were assessed every 21 days until the first 
follow-up visit using the EORTC (QLQ-C30/LC13) and EQ-5D ques-
tionnaires. Changes of ≥10 points as compared with baseline were 
considered clinically significant. Analyses of cough, dyspnoea and 
pain symptoms were prespecified. Time to deterioration (TTD, first 
10-point worsening from baseline) was analysed using a stratified 
log-rank test. An exploratory analysis of all subscales/items from 
the EORTC QLQ-C30/LC13 questionnaires estimated the respecti-
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Methods: Patients with EGFR-MT positive tumours were identified 
from a National Multi-Institutional database. Patients with EGFR-
WT tumours matched for age, stage and gender were identified. 
Treatment data including receipt of chemotherapy, EGFR TKI, and 
clinical trial participation were collected. Fisher’s exact and Mann-
Whitney tests were used to compare variables. Cox model was 
used to examine the influence of treatment variables on overall 
survival (OS.) To ascertain the milieu of clinical trials applicable to 
this cohort, www.clinicaltrials.gov was searched for all phase III 
interventional studies in NSCLC between 1/1/2010 and 31/5/2013. 
Trial characteristics were summarized.
Results: We identified 416 patients with NSCLC. Forty (10%) pati-
ents had tumours with EGFR MT’s, of which data were available on 
35 (87%) patients. Twelve (34%) patients had resected disease, and 
23 (66%) had metastatic disease. Nineteen (82%) EGFR-MT positive 
patients with metastatic disease received first line systemic thera-
py, 12 (63%) receiving EGFR TKI (p=0.52.) Fifteen (65%) patients 
with EGFR-WT tumours received first line chemotherapy. The me-
dian number of lines of treatment was 1 (range: 0 – 4; 30% >1 line) 
for patients with EGFR-MT’s and 1 (range: 0 – 3; 13% >1 line) for 
EGFR-WT (p<0.01.) Receipt of second, third and fourth line therapy 
was 26%, 13% and 4.3% for EGFR-MT positive patients respec-
tively, and 8.6%, 4.3% and 0% respectively in EGFR-WT (p<0.01.) 
Six (24%) patients with an EGFR MT and 0 (0%) with EGFR-WT par-
ticipated in clinical trials (p<0.01.) Significant benefits were seen for 
1) receipt of 1 line of treatment vs. 0 (HR=0.2, 95% CI=0.08 – 0.18, 
p=0.03) or 2) >1 line of treatment vs. 0 (HR=0.10, 95% CI= 0.01- 
0.46, p< 0.01) Twenty-four phase III trials in advanced NSCLC were 
identified over the study period. The most commonly investigated 
agents were TKI‘s - 10 (42%) and monoclonal antibodies – 6 (25%). 
Ten (42%) trials required the presence of a driver mutation for eligi-
bility, and 13 (54%) trials were in second line or beyond.
Conclusion: In Irish patients with NSCLC the incidence of EGFR 
MT’s is comparable to other European populations. Our real-world 
experience demonstrates that patients with EGFR MT’s tend to 
receive more lines of therapy and have a higher rate of clinical trials 
participation, reflecting the portfolio of currently available clinical 
trials. While trials should strive to optimise treatment for EGFR-MT 
positive NSCLC, the thoracic oncology community should consider 
that biological heterogeneity can lead to inequalities in clinical trial 
development and subsequent treatment.
Keywords: Treatment, non-small cell lung cancer, Cinical Trials, 
Inequality
WT. Main pts characteristics were: 59% males, median age 57,5 ye-
ars (range 26-76), 77 former smoker (76 pts for more than 15 years). 
Tissue samples were available from primary tumor and metastases 
in 78 and 22%, respectively, having 73% of cases with cytological 
material. In 23,2% of the specimens Alk rearrangement was not 
evaluable due to poor quality and/or quantity issues.
Results: Among the 155 pts, 22 (14%) are ALK translocated: 19 
were treated within PROFILE clinical trials and 3 patients in the 
EAP. 20 pts are currently evaluable for response and toxicity: 6 of 
them received crizotinib as first-line treatment, the others in subse-
quent lines. The response rate was equal to 70%. The total number 
of administered cycles is 235.The reduction of the dose (7% of 
cycles) was necessary in two pts: in 1 case due to bradicardia and 
fatigue G3 (in first line treatment) and in the other one due to neu-
tropenia G3 (in second line).The observed toxicities were mostly 
grade 1-2 (fatigue 47%, bradycardia 5,8%, visual disorder 5,8%, 
anemia 29%, neutropenia 18% and nausea 12%); grade 3-4 was 
less common. The temporary cessation of treatment was required 
in 3 pts (range 4-15 days) for grade 3-4 toxicity (mostly neutropenia 
plus fatigue). No drug interruption for unacceptable toxicity was 
reported. The most common progression sites were brain (37%) 
and bone (27%).
Conclusion: The introduction of a selection criteria (such as negati-
ve EGFR status) leads on an increase of our cases of Alk traslocated 
pts compared to literature data; this selection is moreover recom-
mended in diagnostic algorithm recently proposed by the Italian 
Expert Panel (Marchetti A et al, JTO 2013). Efficacy and tolerability 
profile are consistent with published data.
Keywords: non-small cell lung cancer, ALK translocation, Crizoti-
nib, Efficacy
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P3.11-042 MOLECULAR INEQUALITY IN THE TREAT-
MENT OF NON-SMALL CELL LUNG CANCER (NSCLC) 
AND IMPLICATIONS FOR CLINICAL TRIALS
Jarushka Naidoo1, Sinead Noonan2, Min Yuen Teo3, Young Soo 
Rho1, Janet Clince1, Kathy Gately4, Tony O‘Grady5, Elaine Kaye5, 
Paula Calvert6, Patrick G. Morris7, Cathal O‘Brien4, Kenneth 
O‘Byrne8, Oscar S. Breathnach1
1Medical Oncology, Beaumont Hospital/Ireland, 2Medical Oncology, St. 
James‘s Hospital/Ireland, 3Medical Oncology, The Adelaide And Meath 
Hospital, Incorporating National Children’s Hospital, Tallaght Tallaght, 
Dublin 24, Ireland/Ireland, 4Clinical Medicine, Trinity College Dublin/
Ireland, 5Histopathology, Beaumont Hospital/Ireland, 6Medical Oncolo-
gy, Waterford Regional Hospital/Ireland, 7Medical Oncology, The Her-
mitage Clinic/Ireland, 8Princess Alexandra Hospital/Australia
Background: Activating mutations (MT) in the epidermal growth 
factor receptor (EGFR) gene are found in approximately 10-20% of 
patients with NSCLC. Guidelines recommend therapy with EGFR 
tyrosine kinase inhibitors (TKI’s) in these patients, and in patients 
with EGFR Wild type (WT) tumours beyond second line. Clinical 
trials have focussed on optimising the management of patients 
with an actionable target. The real-world management of patients 
with EGFR MT’s and clinical trial recruitment has yet to be explo-
red. This retrospective study investigated treatment patterns in an 
Irish cohort of patients with non-squamous NSCLC, stratified by 
EGFR-MT status.
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P3.11-044 CLINICAL IMPACT OF EGFR MUTATION FRAC-
TION AND TUMOUR CELLULARITY IN EGFR MUTATION 
POSITIVE NSCLC
Petra Martin1, Carolyn Shiau2, Maria D. Pasic3, Ming-Sound Tsao2, 
Suzanne Kamel-Reid3, Lisa Le4, Brian Higgins5, Susanna Cheng6, 
Ron Burkes7, Matilda Ng8, Saroosh Arif9, Roxana Tudor1, Stephanie 
Lin1, Peter M. Ellis10, Stacy Hubay11, Sara Kuruvilla12, Scott Laurie13, 
Jing Li14, Frances A. Shepherd1, Natasha B. Leighl1
1Princess Margaret Cancer Centre/Canada, 2Department Of Pathology, 
University Health Network, University Of Toronto/Canada, 3Ontario 
Cancer Institute, Princess Margaret/Canada, 4Department Of Biosta-
tistics, Princess Margaret Cancer Centre/Canada, 5Medical Oncology, 
Credit Valley Hospital/Canada, 6Medical Oncology, Sunnybrook Odette 
Cancer Centre/Canada, 7Medical Oncology, Mount Sinai Hospital/Cana-
da, 8Medical Oncology, Mackenzie Health/Canada, 9Medical Oncology, 
Trillium Health Centre/Canada, 10Juravinski Cancer Centre/Canada, 
11Medical Oncology, Grand River Regional Cancer Centre/Canada, 12Me-
dical Oncology, London Regional Cancer Program/Canada, 13The Otta-
wa Hospital Cancer Centre/Canada, 14Medical Oncology, Toronto East 
General Hospital/Canada
Background: We investigated the impact of mutation fraction, 
tumour sample cellularity, and diagnostic specimen type on EGFR 
TKI response, time to treatment failure (TTF) and overall survival 
(OS), as well as patterns of treatment in a population-based cohort 
of advanced EGFR mutation positive NSCLC patients.
Methods: From March 2010 to May 2012, EGFR testing in the 
province of Ontario (Canada) was conducted at a single centre, 
using fragment analysis for exon 19 deletion and Sau961 restriction 
enzyme digest for exon 21 mutations. Patients with EGFR mutation 
positive samples were identified and tumour sample cellularity, 
mutation fraction (percent of tumour cells mutated), demographic, 
treatment and outcome data were collected. Regression analysis 
was undertaken to assess the association between demographic 
variables, mutation fraction, tumour sample cellularity and sample 
type on clinical outcomes.
Results: Among 293 patients identified with EGFR mutation po-
sitive NSCLC, 253 received EGFR TKIs and are included in this 
analysis. Most are female (72%), never smokers (59%), have exon 
19 deletions (53%; 47% exon21 L858R), and median age 65 years 
(range 26 to 96). Tumour specimens tested include resection (32%), 
cytology (30%), and core biopsies (38%). Median EGFR mutation 
fraction is 30% (range 0.4% to 96%); 24% had a low (≤10%) mutati-
on fraction, and 13% had a mutation fraction ≤5%. Responses (any 
tumour reduction) were seen in 62%, mixed response or stable 
disease in 25%, and progression as the best response in 13%. Me-
dian TTF from the start of EGFR TKI therapy is 13.2 months (range 
0-43.7 months). Median OS from TKI start is 22.3 months (95% 
CI: 19.5-28.2 months), with 1-, 2- and 3-year survival rates of 72%, 
49% and 37%. In multivariable analysis, factors associated with TTF 
included female sex (HR 0.69, p=0.03) and sample type (resection 
HR 0.56, cytology HR 0.82, core biopsy as reference, p=0.01). Age 
at metastatic diagnosis (p=0.01), sample cellularity (p=0.01) and 
sample type were significantly associated with OS, (resection HR 
0.51, cytology HR 0.70, core biopsy as reference, p=0.04). Propor-
tional odds logistic regression identified that mutation frequency 
and age at metastatic diagnosis were significantly associated with 
the odds of response, (p=0.047, p=0.04 respectively). Responses 
were seen even in those with lower EGFR mutation fraction, 48% 
(24/50) at a mutation frequency of ≤10% and 33% (9/27) at a muta-
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P3.11-043 SURVIVAL OF PATIENTS WITH ADVANCED 
LUNG ADENOCARCINOMA BEFORE AND AFTER AP-
PROVED USE OF GEFITINIB IN CHINA: A COMPARATIVE 
CLINICAL STUDY IN A SINGLE CENTER
Yutao Liu, Yuankai Shi, Xuezhi Hao, Junling Li, Xingsheng Hu, Yan 
Wang, Zi-Ping Wang, Hongyu Wang, Bin Wang, Xiaohong Han, 
Xiangru Zhang
Department Of Medical Oncology, Cancer Institute/Hospital, Peking 
Union Medical College & Chinese Academy Of Medical Sciences; Beijing 
Key Laboratory Of Clinical Study On Anticancer Molecular Targeted 
Drugs/China
Background: Since approved use of Gefitinib in March 2005 in 
China, more patients with lung cancer, especially those with lung 
adenocarcinoma, have chosen it for treatment. It is of clinical signi-
ficance to compare survival of lung adenocarcinoma patients who 
received Gefitinib treatment after March 2005 and that of those 
who did not receive it so as to provide clinical clues for selection of 
Gefitinib in Chinese lung adenocarcinoma patients.
Methods: Clinical data of 558 patients with advanced lung ade-
nocarcinoma who received palliative chemotherapy from January 
2002 throughout December 2010 were reviewed retrospectively. 
According to the matched-pair case-control study design, 255 pa-
tients who only received palliative chemotherapyand 255 patients 
who received Gefitinib treatment after approved use of Gefitinib 
were stringently matched by age, sex and smoking history and fi-
nally enrolled in this study. Clinical factors including age, sex, smo-
king history, Eastern Cooperative Oncology Group performance 
status (ECOG PS), tumor stage, organ metastasis and the number 
of prior cytotoxic chemotherapies were analyzed to determine 
their correlations with OS.
Results: The median survival time (MST) of the 510 enrolled pati-
ents with advanced lung adenocarcinoma was 22.8 months. MST 
of the patients who received Gefitinib treatment was significantly 
longer than that of the patients without (33.5 months vs. 14.1 
months, p<0.001). OS in patients who received Gefitinib treatment 
was significantly longer than that in patients without receiving Ge-
fitinib treatment in almost all clinical factor-based subgroups, in-
cluding age, sex ,smoking history, ECOG PS 0-1, tumor stage, the 
presence or absence of lung, pleural, bone, brain, adrenal gland 
and liver metastasis, and the number of prior cytotoxic chemothe-
rapies (all p<0.001), except in ECOG PS ≥2 subgroup.
Conclusion: Gefitinib treatment significantly improved the survival 
of patients with advanced lung adenocarcinoma in China.
Keywords: gefitinib, Palliative chemotherapy, non-small cell lung 
cancer, Adenocarcinoma
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Results: A total of 160 patients, including 107 women, 116 light 
or never smokers, 156 patients with adenocarcinomas, and 130 
patients with good performance status, were analyzed. There were 
78 patients with deletions in exon 19, 69 patients with L858R, and 
13 with minor mutations. At the time of the analysis, 111 patients 
showed disease progression by RECIST. No significant difference 
in the PPS was observed between the CNS progression group 
(n=29) and systemic progression group (n=82) (10.6 m vs. 11.2 m, 
p=0.90). Although it was not significant, the continuation group 
(n=43) showed longer PPS than the discontinuation group (n=68) 
(13.0 m vs. 9.7 m, p=0.06). The analysis of Cox hazards model 
including five variables (sex, smoking status, PS, continuation of 
EGFR-TKI, CNS progression or systemic progression) showed that 
the continuation of EGFR TKI beyond PD was the factor associated 
with longer PPS (HR=0.55, 0.31-0.92).
Conclusion: In this retrospective analysis, continued treatment 
with EGFR-TKI after PD resulted in longer PPS. A prospective study 
of continuation EGFR-TKI beyond REIST PD is needed.
Keywords: EGFR tyrosine kinase inhibitor, EGFR mutation, Beyond 
Progressive Disease
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P3.11-046 ROS1 OVEREXPRESSION BY IMMUNOHISTO-
CHEMISTRY IN NON-SMALL CELL LUNG CANCER: CLI-
NICAL CHARACTERISTICS, NATURAL HISTORY AND PO-
TENTIAL NEW THERAPEUTIC TARGET BASED ON TWO 
AUSTRALIAN CASES
Bob T. Li1, Anthony Gill2, Tristan Dodds2, Adrian Lee1, Wendy A. 
Cooper3, Stephen Clarke1, Nick Pavlakis1
1Department Of Medical Oncology, Royal North Shore Hospital, Univer-
sity Of Sydney/Australia, 2Department Of Anatomical Pathology, Royal 
North Shore Hospital/Australia, 3Tissue Pathology And Diagnostic 
Oncology, Royal Prince Alfred Hospital/Australia
Background: Recent years have seen worldwide interest in the 
study of driver mutations in lung cancer, in particular epidermal 
growth factor receptor mutation (EGFR) and anaplastic lymphoma 
kinase gene rearrangement (ALK). ROS1 gene rearrangement is a 
recently identified driver mutation and potential therapeutic target 
for crizotinib and similar agents. However little is known of the 
natural history of patients with ROS1, and moreover the diagnostic 
value of immunohistochemistry (IHC) compared to fluorescent in-
situ hybridization (FISH).
Methods: 12 patients from a single Australian tertiary institution 
with advanced non-small cell lung cancer (NSCLC) were screened 
for ROS1 overexpression and gene rearrangement. Selection was 
based on negative testing for EGFR and ALK, and unusually long 
natural history.
Results: We report 2 patients with ROS1 overexpressed advanced 
NSCLC, their unique characteristics, long natural history and the 
use of IHC as a complementary method to FISH in identifying the-
se patients. Mr GL was a 62 year-old Caucasian man and lifelong 
non-smoker who presented with an incidental 19mm subpleural 
left lower lobe lung nodule found on computed tomography (CT) 
when he was treated for pneumonia in 2008. He was monitored 
with CT for his pulmonary nodule and pre-existing interstitial lung 
disease. In 2011, CT and subsequent positron emission tomogra-
tion frequency of ≤5%. The average cellularity in the high (>10%) 
mutation fraction group was 53% (95%CI 50– 56%), and 36% 
(95%CI 29 – 43%) in those with a low mutation fraction (p<.0001).
Conclusion: Pathologic features may be relevant to clinical outco-
mes in EGFR mutation positive NSCLC, including mutation frac-
tion, sample cellularity, and specimen tested. The clinical relevance 
of sample tumour cellularity and sample type tested remains unc-
lear. In particular, initial stage and prognosis may be confounders 
in the association between resected specimens and favourable 
outcomes. Given that those with mutation fractions ≤5% may have 
significant response from EGFR TKI therapy, treatment should not 
be withheld on the basis of mutation frequency alone.
Keyword: EGFR, Mutation frequency, cellularity, EGFR-TKI
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P3.11-045 EGFR-TKI AFTER DISEASE PROGRESSION 
WITH CENTRAL NERVOUS SYSTEM METASTASIS IN AD-
VANCED NON-SMALL CELL LUNG CANCER WITH EGFR 
MUTATIONS
Kazuo Kasahara1, Takashi Sone1, Kazuhiko Shibata2, Hiroki Shira-
saki3, Toshiyuki Kita4, Asao Sakai5, Shingo Nishikawa6, Taro Yone-
da1, Hideharu Kimura1
1Respiratory Medicine, Kanazawa University Hospital/Japan, 2Medical 
Oncology, Kouseiren Takaoka Hospital/Japan, 3Respiratory Medicine, 
Fukui-ken Saiseika Hospital/Japan, 4Nho Kanazawa Medical Center/
Japan, 5Respiratory Medicine, Keijyu Medical Center/Japan, 6Repiratory 
Medicine, Kanazawa Social Insurance Hospilal/Japan
Background: Several retrospective studies have reported that 
continued treatment with EGFR-TKI after developing progressive 
disease (PD) by RECIST improved survival compared to TKI-free 
treatment in NSCLC patients with EGFR mutations. However, it is 
unclear which patients would benefit from EGFR-TKI after PD. We 
hypothesized that patients with CNS progression only, without 
systemic deterioration, would show a good prognosis with EGFR-
TKI after PD.Several retrospective studies have reported that 
continued treatment with EGFR-TKI after developing progressive 
disease (PD) by RECIST improved survival compared to TKI-free 
treatment in NSCLC patients with EGFR mutations. However, it is 
unclear which patients would benefit from EGFR-TKI after PD. We 
hypothesized that patients with CNS progression only, without 
systemic deterioration, would show a good prognosis with EGFR-
TKI after PD.
Methods: In order to clarify the survival benefits in patients tre-
ated by EGFR-TKI after developing PD, particularly patients with 
CNS metastasis alone, NSCLC patients with EGFR mutations 
who were treated with EGFR-TKI and showed progression were 
analyzed retrospectively. The patients were categorized into two 
groups: patients continuing with EGFR-TKI treatment after pro-
gression (continuation group) and patients switched to chemothe-
rapy or BSC (discontinuation group). Patients were also classified 
into two groups by site of progression: patients who showed dete-
rioration involving only CNS metastasis (CNS progression group) 
and patients who showed progression of the primary lesion, lymph 
nodes, bone, liver, adrenal glands, CNS, or other sites (systemic 
progression group). Differences in post-EGFR-TKI progression 
survival (PPS) and overall survival were compared between the 
groups.
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presence of EGFR, ALK, KRAS, or p53 mutation, and sites of metas-
tatic disease, including brain, bone, liver, and adrenal metastasis. A 
logistic regression model was tested using backward elimination, 
with presence of brain metastasis at diagnosis as the outcome of 
interest.
Results: No statistically significant association was seen between 
the presence of brain metastasis and any of the above covariates. 
We examined the relationship between brain metastasis and KRAS 
mutation, even though this variable was not selected in the model 
selection procedure. The odds ratio for brain metastasis with KRAS 
mutation was 0.3714, indicating that patients with KRAS mutation 
have 63% lower odds of brain metastasis at diagnosis than patients 
without a KRAS mutation (95% exact confidence interval: 0.0825, 
1.3321, p= 0.1184).
Conclusion: No significant association was observed between the 
presence of brain metastasis and various clinical presenting cha-
racteristics in patients with metastatic non-small cell lung cancer, 
including stage, tumor size, histology, age, ethnicity, molecular 
markers including the presence of EGFR, ALK, KRAS, or p53 mutati-
on, and sites of metastatic disease, including brain, bone, liver, and 
adrenal metastasis.
Keyword: brain metastasis
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P3.11-048 COST-EFFECTIVENESS ANALYSIS OF CRIZO-
TINIB IN METASTATIC ALK+ NON-SMALL CELL LUNG 
CANCER (NSCLC)
Alberto J. Montero1, Gilberto Lopes2
1Sylvester Cancer Center, University Of Miami/United States Of Ame-
rica, 2Department Of Medical Oncology, Johns Hopkins Singapore Inter-
national Medical Centr/Singapore
Background: Crizotinib was approved in 2011 by the FDA in for 
treatment of patients with locally advanced or metastatic NSCLC 
that is ALK-positive as detected by an FDA-approved test. In order 
to better inform U.S. policymakers, this study aimed to assess the 
cost-effectiveness, from a payer perspective, of crizotinib compared 
to either pemetrexed or docetaxel.  
Methods: We created a decision model using published data from 
the randomized phase 3 trial that led to its FDA approval, where 
patients with ALK+ NSCLC were randomized to receive one of the 
following: crizotinib (250 mg twice daily), pemetrexed (500 mg/m2), 
or docetaxel (mg/m2). Utilities were derived from available published 
literature. Costs, when available, were obtained from the Center 
for Medicare Services (CMS) drug payment table and physician fee 
schedule and were represented in 2012 U.S. dollars. Because, the 
price of crizotinib was not available from the most recent CMS drug 
payment table, we averaged three different published prices that 
were publically available. The quality-adjusted life-years (QALY) and 
incremental cost-effectiveness ratio (ICER) were calculated. One 
way, two way, and probabilistic sensitivity analyses were performed.
Results: Since the phase 3 trial by Shaw et al. permitted cross-over 
to crizotinib at the time of progression, it is entirely likely that this 
confounded any apparent survival advantage for crizotinib. Therefo-
re, we first evaluated our model with progression-free survival (PFS) 
phy (PET) showed new regional lymphadenopathy and widespread 
sclerotic bone disease with the pulmonary nodule unchanged 
in size but moderately glucose avid. Axillary and supraclavicular 
lymph node biopsies confirmed metastatic adenocarcinoma con-
sistent with a lung primary. EGFR and ALK testing was negative. He 
received induction and maintenance chemotherapy until disease 
progression in 2013. His original biopsy tested negative for ROS1 
rearrangement by FISH but stained strongly positive for ROS1 
overexpression by IHC using the Epitomics rabbit monoclonal 
antibody (D4D6) with diffuse cytoplasmic positivity. He was com-
menced on crizotinib, achieving and maintaining stable disease 
after three months. Mrs MM was a 54 year-old Caucasian woman 
and lifelong non-smoker who presented with an incidental 26mm 
right lower lobe lung nodule found on CT when she presented 
with left sided chest pain in 2009. PET and endobronchial biopsy 
of mediastinal lymph nodes confirmed stage IIIA lung adenocar-
cinoma. EGFR and ALK testing was negative. She received neo-
adjuvant chemotherapy, followed by right lower lobectomy and 
post-operative radiotherapy. In 2010 she developed right supra-
clavicular lymph node recurrence and achieved radiological com-
plete response after radiotherapy. In 2011 she developed another 
isolated nodal recurrence in the right supraclavicular fossa, which 
was surgically resected and confirmed adenocarcinoma. It stained 
strongly positive for ROS1 overexpression by IHC and positive 
for ROS1 rearrangement by FISH. In 2013, PET found an isolated 
hepatic metastasis. She was commenced on crizotinib with plans 
for re-staging and consideration for liver directed therapy. Clinical 
progress of the patients will be updated and presented.
Conclusion: Our cases of ROS1 overexpressed NSCLC illustrate 
unique patient characteristics of never-smoking status, adenocar-
cinoma histology, negative testing for EGFR and ALK, and an unu-
sually long natural history. Our cases highlight the need for greater 
understanding of the predictive value of ROS1 overexpression by 
IHC as opposed to FISH alone for targeted therapy.
Keywords: ROS1, Crizotinib, Immunohistochemistry, fluorescent 
in-situ hybridization
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P3.11-047 FACTORS ASSOCIATED WITH BRAIN METAS-
TASIS IN METASTATIC NON-SMALL CELL LUNG CANCER
Eiko Browning, Xian Lu, Ana Oton
University Of Colorado/United States Of America
Background: The brain is a common site of metastatic spread in 
non-small cell lung cancer that is often associated with morbidity 
and poorer survival. Previously, we have published that ALK, EGFR, 
or KRAS status alone was not associated with the presence of brain 
metastases at diagnosis. Additional methods are needed to pre-
dict which patients are at risk for presenting with brain metastasis 
at diagnosis. The purpose of our study was to develop a more 
detailed predictive model to identify patients at high risk of brain 
metastasis at diagnosis.
Methods: Patients with metastatic non-small cell lung cancer in 
whom molecular analysis was conducted in the Colorado Mole-
cular Correlates Laboratory were identified. Data were collected 
through retrospective review of charts of 120 patients. Characteris-
tics at the time of diagnosis were collected, including stage, tumor 
size, histology, age, ethnicity, molecular markers including the 
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ration was 2 months (range 0 – 26). 21% of patients had a response 
(tumour reduction) to afatinib, 20% stable disease and 50% disease 
progression as their best response. Median survival from the time 
of afatinib start was 5 months (95% CI: 2-12 months). The average 
starting dose of afatinib was 40 mg (6% 50 mg, 94% 40 mg), with 
11% requiring dose reduction. One third of patients (34%) stopped 
treatment for disease progression, 17% for toxicity, 30% for clinical 
deterioration and 19% for other or unknown reasons. The rate of 
grade ≥2 diarrhea, rash, paronychia, or stomatitis with afatinib was 
17%, 20%, 9%, and 9% respectively (grade ≥3 in 10%, 11%, 5% and 
5%). Response (non-RECIST) to afatinib was seen in EGFR wild type 
(2/4) and mutation positive (3/13) patients. Response to erlotinib or 
gefitinib was non-significantly associated with response to afatinib 
(OR 3.3, p=0.22). A similar non-significant association was seen with 
rash (OR 1.7, p=0.22), but not with diarrhea, (OR 0.37, p=0.45).
Conclusion: Afatinib demonstrates activity in clinical practice similar 
to that reported in LUX-Lung 1. While some required dose reduc-
tion, toxicity from afatinib appeared manageable for the majority. 
Although not significant, there was a propensity to experience res-
ponse or rash on afatinib if seen with prior EGFR TKI, although this 
was not seen with diarrhea.
Keywords: EGFR TKI, afatinib, special access program, ADVANCED 
NSCLC
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P3.11-050 SUNITINIB FOR THE TREATMENT OF RET-
TRANSLOCATED NSCLC: A CASE REPORT
Georg Pall1, Reinhard Büttner2, Jürgen Wolf3
1Departement For Internal Medicine V (Hematology/Oncology), Univer-
sity Hospital Innsbruck/Austria, 2Departement Of Pathology, Univer-
sity Hospital Cologne, Germany/Germany, 3Departement For Internal 
Medicine I, University Hospital Cologne, Germany/Germany
Background: RET-translocations have recently been identified as 
oncogenic drivers in a subset of non-small cell lung cancer (NSCLC). 
Up to now, there is limited information on the therapeutic value of 
RET-inhibitors in treating patients with RET-translocated NSCLC. 
Here we report on the clinical course of a patient with RET-trans-
located NSCLC treated with sunitinib, a multitarget tyrosiNKInase-
inhibitor with activity against RET.
Methods: A 65 year old woman with a non smoking history was 
diagnosed with adenocarcinoma of the left upper lobe in octo-
ber 2009. Staging by CT and PET revealed stage II. Therefore the 
patient was referred to lobectomy plus lymphnode dissection. 
Pathologic work up in the following led to an upstaging to stage 
IIIA (pT1N2M0L1V0R0,GIII). The patient refused to get adjuvant 
chemotherapy but postoperative radiotherapy was applied. In may 
2012 the patient developed left-sided pleural carcinomatosis and 
a thoracoscopic biopsy confirmed recurrence of the bronchial ade-
nocarcinoma. Molecular workup of the available tissue showed EG-
FRwt and no evidence for ALK-translocation. As a platinum-based 
chemotherapy was not acceptable for the patient she was treated 
with pemetrexed monotherapy for 3 cycles leading to disease stabi-
lization. At that timepoint the patient opted for a treatment holiday. 
In december 2012 CT-restaging showed progressive disease with 
increasing pleural tumor deposits. As the patient denied further 
cytostatic therapy, additional analyses for potential driver mutations 
were initiated and the existence of a KIF5B/RET-translocation was 
rather than OS. Compared to docetaxel, crizotinib had an incremen-
tal benefit of 0.14 progression-free QALYs, which came at an overall 
cost of $102,420.04, and an incremental cost of $77,138.81, for an 
incremental cost effective ratio (ICER) of $535,956.19/PF-QALYs. The 
results of the model were robust in sensitivity analyses. The two pri-
mary drivers in this model were found to be: crizotinib cost and cri-
zotinib median overall survival. For crizotinib to be cost effective, its 
monthly cost would have to be reduced from approximately $9,300 
to $3,500. When we utilized OS in our model, as expected the ICER 
was even higher, at a cost of $1,197,005/QALY. This is expected, due 
to absence of a significant difference between chemotherapy and 
crizotinib arms in the phase 3 trial.
Conclusion: Crizotinib on our initial decision analytic model did not 
appear to be cost-effective compared to docetaxel at its current 
price of approximately $9,388 per month. Further analysis will be 
performed utilizing a Markov decision model.
Keywords: Crizotinib, cost effectiveness analysis, economic asess-
ment
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P3.11-049 AFATINIB IN ADVANCED PRETREATED NSCLC 
- A CANADIAN EXPERIENCE
Barbara Melosky1, Manstein Kan1, Roxana Tudor2, Stephanie Lin2, 
Anthea Lau3, Tony Panzarella3, Natasha Leighl2
1Medical Oncology, BC Cancer Agency/Canada, 2Dept. Med. Oncology, 
Princess Margaret Cancer Centre/Canada, 3Biostatistics, University 
Health Network/Canada
Background: Afatinib is an oral, irreversible pan-EGFR inhibitor with 
demonstrated superiority over first-line chemotherapy in advanced 
EGFR mutation positive NSCLC. It is also active after failure of che-
motherapy and reversible EGFR tyrosine kinase inhibitor (TKI) the-
rapy, with higher response rate and better progression-free survival 
than placebo (LUX-Lung 1, Miller et al. Lancet Oncol. 2012). Through 
a national special access program (SAP), Canadian patients with ad-
vanced NSCLC, similar to those in the LUX-Lung 1 trial, may access 
afatinib after exhausting all other available therapies. We report our 
Canadian experience with afatinib at the two largest centres partici-
pating in the SAP.
Methods: Retrospective chart review of SAP participants was un-
dertaken at 2 major Canadian cancer centres, the British Columbia 
Cancer Agency (Vancouver) and Princess Margaret Cancer Centre 
(Toronto). Demographic, disease and treatment data were abstrac-
ted, including toxicity, response (clinically documented tumour re-
duction), treatment duration and overall survival.
Results: From July 2010 to the present, 54 patients at the two sites 
were treated with afatinib through the SAP. Median age was 59.5 
(range 37 to 88 years), 57% were female, 52% were never smokers 
(7% current, 35% former smokers), 67% had adenocarcinoma his-
tology and 28% were East Asian. 26% had known EGFR mutations 
(7% wild type, 67% unknown), most commonly exon 19 deletions. 
Patients received a median of 3 previous therapies (range 2 to 5). All 
had received prior EGFR TKI therapy (81% erlotinib, 11% gefitinib, 
6% both, 2% dacomitinib). Half (47%) had a response to prior EGFR 
TKI therapy, and 37% experienced grade ≥2 rash and 9% grade ≥2 
diarrhea on prior EGFR TKI. The median time from metastatic diag-
nosis to starting afatinib was 23.1 months. The median treatment du-
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P3.11-052 PHASE II STUDY OF INTERMITTENT ERLOTI-
NIB (E) PLUS CARBOPLATIN (C), PACLITAXEL (P) AND 
BEVACIZUMAB (B) AS FRONTLINE TREATMENT OF 
PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS 
NON-SMALL CELL LUNG CANCER (NSNSCLC): AVAFAST 
STUDY.
Manuel A. Cobo Dols1, Esperanza Blanco2, Reyes Bernabé3, In-
maculada Fernandez4, Ángel Inoriza5, Ana Laura Ortega6, Javier 
Valdivia7
1Medical Oncology, Hru Carlos Haya/Spain, 2Medical Oncology, Hospital 
Infanta Cristina/Spain, 3Medical Oncology, Hospital Nuestra Señora 
De Valme/Spain, 4Medical Oncology, Hospital De Jerez/Spain, 5Medical 
Oncology, Hospital Juan Ramón Jiménez/Spain, 6Medical Oncology, 
Complejo Hospitalario De Jaén/Spain, 7Medical Oncology, Hospital Uni-
versitario Virgen De Las Nieves/Spain
Background: To improve outcomes of nsNSCLC, investigators 
have empirically combined targeted therapies with conventional 
platinum-based regimens. The potential for combining E with cy-
totoxic drugs was initially investigated in two randomized phase III 
trials. Data from this studies showed that simultaneous EGFR-TKI/
platinum combination resulted in antagonism in NSCLC. First-line 
sequential administration of E with chemotherapy in several stu-
dies, particularly the FAST-ACT trial, has demonstrated promising 
results in patients with nsNSCLC. The aim of this study is to com-
bine E with C/P + B as per a sequential schedule in order to avoid 
the potential cell cycle-based antagonism between E and che-
motherapy. In this study B has been added to the chemotherapy 
regimen since the addition of B has demonstrated improvement in 
response and survival, and should be considered as the most effi-
cacious treatment for patients with nsNSCLC.
Methods: AVAFAST is an ongoing, open-label, multicenter, phase 
II study in chemo-naïve pts diagnosed with unresectable advan-
ced, metastatic or recurrent nsNSCLC. Elegible pts also have 1 
unidimensionally measurable lesion according to RECIST; age ≥ 
18 years; ECOG PS ≤ 1; adequate hematological, renal and liver 
function; treated brain metastasis and signed informed consent. 
Radiological evidence of tumor invasion of major blood vessels, 
EGFR-mutation-positive disease, hemoptysis grade ≥2, significant 
cardiovascular disease or uncontrolled hypertension are exclusion 
criteria. Pts receive sequential combination of C (6 AUC), P (175mg/
m2), B (7,5 mg/kg) on day 1, and intermittent E (150 mg) from day 5 
to18 up to 4 cycles of 21 days. Pts who had not progressed after 4 
cycles continue to receive B (7,5mg/kg) on day 1 until progression 
of disease or unacceptable toxicity. Non Progression Rate (NPR) at 
12 weeks is used as the primary efficacy endpoint. Secondary end-
points include ORR, DCR, NPR at 24 weeks, PFS, OS, Safety profile 
and Quality of Life. 35 of planned 64 patients have been enrolled.
Results: not applicable
Conclusion: not applicable
Keywords: ADVANCED NSCLC, Intermittent Erlotinib, Clinical Trial 
in Progress
detected by FISH-analysis. As, at that timepoint, sunitinib was the 
only available RET-inhibitor at our site the patient was offered suniti-
nib treatment.
Results: Sunitinib was initiated in january 2013 (50mg qd, 4 weeks 
on/2 weeks off) with the patient at that timepoint not suffering from 
any symptoms (WHO 0). Due to severe toxicities (mucositis, fatigue, 
diarrhea) a dose reduction had to be performed allready during 
the first treatment cycle (37,5mg, 4/2 weeks). CT-restaging after 2 
cycles showed stable disease. Treatment was continued, but, due 
to ongoing toxicities, the dose of sunitinib had to be further redu-
ced (25mg qd, continously). In may 2013, with the patient free from 
tumor-associated symptoms, another CT-scan still revealed disease 
stabilization. At that timepoint the patient refused further treatment 
with sunitinib, due to subjectively inacceptable side effects (di-
arrhea, fatigue).
Conclusion: In this case of a patient with recurrent RET-translocated 
NSCLC treatment with sunitinib showed signs of clinical activity by 
inducing disease-stabilization for at least 4 months despite subs-
tantial dose reductions due to toxicities. As the patient withdrew 
further treatment, no further conclusions on the potential long term 
effects of such treatment can be drawn. Based on the preclinical 
evidence and the published case reports so far, testing of RET-
inhibitors for the treatment of patients with RET-translocated NSCLC 
within prospective clinical trials is strongly recommended.
Keywords: RET, Sunitinib, NSCLC
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P3.11-051 VEGFRS PREDICT BEVACIZUMAB BENEFIT IN 
ADVANCED NON SMALL CELL LUNG CANCER PATIENTS
Kai Zhang, Rubo Cao, Shi H. Fei, Li Liu
Cancer Center, Union Hospital, Tongji Medical College, Huazhong Uni-
versity Of Science And Technology/China
Background: Bevacizumab is reported to produce clinical benefit in 
advanced non-squamous non-small-cell lung cancer (NSCLC) patients 
when combined with chemotherapy. However, no biological markers 
have been identified for patient selection of bevacizumab treatment.
Methods: We describe an ongoing observational study in patients 
with advanced non-squamous NSCLC patients. Patients with meta-
static disease will be recruited to receive chemotherapy plus beva-
cizumab 15 mg/kg for 4-6 cycles and radiotherapy when necessary. 
VEGF-A, VEGFR-1, VEGFR-2 levels in peripheral blood of patients will 
be tested before and after the bevacizumab treatments. Cycles are 3 
weeks.The primary endpoint is progression-free survival (PFS) without 
grade 4 toxicity. The secondary endpoint is overall survival (OS). The 
study will enroll 40 patients approximately. The relationship between 
VEGF-A, VEGFR-1, VEGFR-2 levels and the effect of treatment will be 
evaluated.
Results: no
Conclusion: This study will provide results on biomarker options for 
patient selection of bevacizumab treatment.  
Correspondence to Li Liu, E-mail: liulixiehe@163.com
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P3.12-002 PROGNOSTIC SIGNIFICANCE OF THE LYMPH 
NODE INVOLVEMENT IN STAGE II-N1 NON-SMALL CELL 
LUNG CANCER
Shun Lu, Ziming Li
Shanghai Lung Cancer Center, Shanghai Chest Hospital/China
Background: The non-small-cell lung cancer (NSCLC) staging 
system published in the 7th edition of the Union for International 
Cancer Control (UICC) and American Joint Commission on Cancer 
(AJCC) cancer staging manuals in 2009 did not include any chan-
ges to current N descriptors for NSCLC. However the prognostic 
significance of the extent of lymph node (LN) involvement, inclu-
ding the lymph node zones involved (hilar/interlobar or periphe-
ral), cancer-involved lymph node ratios (LNR), and the number of 
involved lymph nodes remain unknown. The aim of this report is 
to evaluate the extent of lymph node involvement and other prog-
nostic factors in predicting outcome after definitive surgery among 
Chinese stage II-N1 NSCLC patients.
Methods: We retrospectively reviewed the clinicopathological 
characteristics of 206 stage II (T1a-T2bN1M0) NSCLC patients who 
had undergone complete surgical resection at Shanghai Chest 
Hospital, Jiao Tong University from June 1999 to June 2009. Ove-
rall survival (OS) and disease-free survival (DFS) were compared 
using Kaplan-Meier statistical analysis. Stratified and Cox regres-
sion analyses were used to evaluate the relationship between the 
lymph node involvement and survival.
Results: Peripheral zone lymph node involvement, cancer-involved 
lymph node ratio(LNR), smaller tumor size, and squamous cell 
carcinoma were shown to be statistically significant indicators of 
higher OS and DFS by univariate analyses. Visceral pleural involve-
ment was also shown to share a statistically significant relationship 
with DFS by univariate analyses. Multivariate analyses showed only 
tumor size and zone of lymph node involvement were to be signifi-
cant predictors of OS.
Conclusion: Zone of N1 lymph node, LNR and tumor size were 
both found to provide independent prognostic information in pati-
ents with stage II NSCLC. This information may be used to stratify 
patients into groups by risk for recurrence.
Keyword: non-small cell lung cancer, stage II, N1
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P3.12-001 LUNG KRUEPPEL-LIKE FACTOR KLF2 IM-
PROVE POST-OPERATIVE PROGNOSIS OF LUNG ADE-
NOCARCINOMA CORRELATION WITH CHEMOKINE RE-
CEPTOR CCR7 AND GENETICAL MUTATIONS OF P53.
Meiji Itakura, Masato Shingyoji, Yasushi Yoshida, Hironori Ashi-
numa, Toshihiko Iizasa, Yasumitsu Moriya, Hajime Tamura
Department Of Thoracic Disease, Chiba Cancer Center/Japan
Background: Chemokines and chemokine receptors not only have 
the powerful ability in cancer metastasis and tumorigenesis, but 
also act as anti-tumorgenic ability. Lung Krueppel-like factor (LKLF, 
KLF2) is a member of the family of the Krueppel-like factors (KLFs). 
(KLF2 was initially described as a lung-specific transcription factor. 
KLF2 is reported to regulate some malignant cells. We examined 
and evaluated the effect of KLF2 on lung adenocarcinoma and the 
relationship of their mRNA expression with CCR7, EGFR and p53 
genetical mutations in lung adenocarcinoma.
Methods: 120 patients of stage I to IV with lung adenocarcinoma 
were included in this retrospective analysis. The expression of 
CCR7 and KLF2 mRNA expression in surgically resected lung ade-
nocarcinoma specimens were examined and evaluated the relation 
to prognosis, the effect of EGFR and p53 genetical mutations. In 
addition the expression of CCR7 and KLF2 exprssion were analy-
zed with immunohistochemical analysis and measured their mRNA 
expression extracted from tissue sections of lung adenocarcinoma 
specimens by laser capture microdissection.
Results: High mRNA expression of KLF2 in lung cancer patients 
indicated significantly good prognosis than the groups of low ex-
pressions (p= 0.0066, HR= 2.008, 95% CI of ratio 1.215 to 3.319). 
The expression of KLF2 mRNA had relationships with CCR7, CCL21 
and CCL19 mRNA expression in lung adenocarcinoma. Moreover 
the mRNA expression of KLF2 in lung adenocarcinoma specimens 
was influenced by the mutation of p53 mutation in lung cancer 
specimens. In addition the expression of KLF2 was confirmed with 
immunohistochemical analysis and was ditected mRNA expression 
extracted from tissue sections of lung adenocarcinoma specimens 
by laser capture microdissection.
Conclusion: We propose KLF2 as clinical good prognostic factors 
and that KLF2 has strong relation with CCR7, the ligands CCL19, 
CCL21 and p53 genetical mutation in lung adenocarcinoma.
Keywords: chemokine, CCR7, KLF2, lung adenocarcinoma
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P3.12-004 A PRACTICE-BASED ANALYSIS TO GAUGE 
THE FEASIBILITY OF GENOTYPE-DIRECTED INDUCTION 
THERAPY FOR STAGE III NON-SMALL CELL LUNG  
CANCER (NSCLC)
Jack Varon1, Raymond H. Mak2, Stephanie H. Cardarella2, Pasi A. 
Jänne2, Geoffrey R. Oxnard2
1Harvard Medical School/United States Of America, 2Dana-Farber Can-
cer Institute/United States Of America
Background: Genotype-directed therapies are transforming the 
care of patients with advanced NSCLC, but these have not yet 
been incorporated into curative therapy for early stage disease. 
Because trials are in development which will study genotype-
directed induction therapy for stage III NSCLC, we retrospectively 
examined practice patterns to identify strategies for maximizing 
the feasibility of this approach.
Methods: Patients with stage IIIA NSCLC who were treated at our 
institution with upfront concurrent chemoradiotherapy between 
1/2004 and 5/2012 were identified from an institutional database. 
Management prior to start of definitive therapy was reviewed. For 
this analysis, biopsies were considered adequate for genotyping 
while cytology specimens were considered inadequate. To gauge 
the feasibility of genotyping, we compared the intervals between 
biopsy and treatment and between first oncologist appointment 
and treatment with a range of hypothetical turnaround times for 
genotyping (i.e. time between when test is ordered and when re-
sults are available).
Results: 150 patients were identified in an initial query. 57 were 
excluded from the analysis: 46 due to treatment at an outside hos-
pital, 5 due to upfront surgery, and 6 due to sequential chemothe-
rapy and radiation. 89 patients were included in the study popula-
tion with the following characteristics: median age at diagnosis 61 
(range 33-86), 45% adenocarcinoma, 25% squamous, 2% neuroen-
docrine, and 28% NSCLC NOS. Clinical stage: 17% T1N2M0, 42% 
T2N2M0, 3% T3N1M0, 24% T3N2M0, 9% T4N0M0, 6% T4N1M0. 
Staging evaluation: 86% underwent bronchoscopy, 86% underwent 
mediastinoscopy; 100% underwent PET-CT, 100% underwent brain 
imaging. Best biopsy for genotyping: 51% surgical biopsy, 20% 
endobronchial biopsy, 7% CT-guided core biopsy, 22% cytology. 
The median time between best biopsy and treatment initiation was 
34 days (IQR: 23-45). The median time between first oncologist 
appointment and treatment initiation was 18.5 days (IQR: 14-25). 
Simulating reflex genotyping versus oncologist-ordered genoty-
ping for a range of hypothetical turnaround times (Figure), reflex 
genotyping may increase the number of patients genotyped in 
time for start of therapy when turnaround time exceeds 8 days. 
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P3.12-003 PREOPERATIVE MANAGEMENT OF NSCLC 
PATIENTS WITH PET/CT N2 POSITIVE MEDIASTINAL 
LYMPH NODES
Fatma Kutluhan1, Aylin Ozgen Alpaydin1, Aydin Sanli2, Berna De-
girmenci Polack3, Atila Akkoclu1, Duygu Gurel4
1Pulmonary Diseases, Dokuz Eylul University Medical Faculty/Turkey, 
2Thoracic Surgery, Dokuz Eylul University Medical Faculty/Turkey, 
3Nuclear Medicine, Dokuz Eylul University Medical Faculty/Turkey, 
4Pathology, Dokuz Eylul University Medical Faculty/Turkey
Background: PET/CT has been widely used in the diagnosis and 
management of lung cancer patients. We aimed to investigate the 
progress of N2 positive NSCLC patients after PET-CT examina-
tions.
Methods: Clinical and pathological data of 124 operable NSCLC 
patients to whom PET-CT was applied for clinical staging between 
November 2009 and December 2011 were evaluated retrospec-
tively.
Results: PET-CT was positive for N2 disease in 60 patients. Among 
them 24 were operated without any prior invasive procedure, 
while the remaining was investigated with different procedures for 
mediastinal lymph node involvement. Thirty of them had cervical 
mediastinoscopy, 4 had anterior mediastinotomy and 2 had tho-
racotomy. N2 positivity determined in nodal stations 5 and 7 was 
also corrected with thoracotomy. However, N2 involvement was 
not observed in one patient who underwent anterior mediastino-
tomy and 13 patients who underwent cervical mediastinoscopy, 
although they had positive PET/CT results. The overall true positi-
vity within these patients who underwent preoperative diagnostic 
procedures for N2 lymph nodes was 22 out of 36 patients (61%). 
N2 lymph node involvement was observed in 6 of the 24 patients 
who were directly operated (25%).
Conclusion: Although PET/CT had an important contribution in 
the preoperative management of NSCLC patients, histopathologi-
cal confirmation remains the golden standard for operable cases.
Keyword: PET/CT, NSCLC
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rative values of FEV1 and DLCO less than 40% is defined as high 
risk in pulmonary function tests. Concerning ABG parameters, the 
normal range for 1) PaO2 is over 75 Torr, 2) PaCO2 is 36-45 Torr 
and 3) pH is 7.36-7.45. The patients were divided into two groups 
according to ABG analysis: normal ABG group (n=167) and abnor-
mal ABG group (n=86). The abnormal ABG group includes those 
whose 1)PaO2 is less than 75Torr (n=39, median 73, range, 63-74.9), 
2)PaCO2 is less than 36 Torr (n=21, median 35.4, range, 32.7-35.9) 
or over 45 Torr (n=33, median 46.2, range, 45.0-50.6) and 3)PH is 
less than 7.36 (n=5, median 7.338, range, 7.332-7.356) or over 7.45 
(n=8, median 7.454, range, 7.451-7.463).
Results: There were no significant differences in gender, perfor-
mance status, Hugh-Jones classification, pathological stage, tumor 
histology, tumor location, surgical procedure, blood loss, operative 
time, and postoperative complications between the two groups. 
The age of patients in the normal ABG group (mean 68 years old) 
was significantly lower than those in the abnormal ABG group 
(mean 71 years old, p = 0.026). The mean follow-up period for the 
entire study population was 5.8 years (range 123-5201 days). No 
operative death occurred. The 3-, 5-, and 10-year survival rates in 
the normal and abnormal ABG groups were 87%, 76%, and 62%, 
and 78%, 64%, and 42%, respectively (p = 0.029). A log-rank test 
using physiological factors revealed that gender, age (>70 years 
old), performance status (0-1 vs 2), Hugh-Jones classification (1-2 
vs 3), postoperative prediction pulmonary function test, and ABG 
were associated with a significant survival rate. By multivariate 
analysis, age, gender, and ABG (risk ratio, 4.03) were independent 
prognostic factors.
Conclusion: Preoperative ABG was a prognostic marker for stage 
I NSCLC. We should consider surgical strategies for patients with 
abnormal ABG analysis not only for immediate or short-term risk, 
which refers to perioperative morbidity and mortality, but also 
long-term survival risk.
Keywords: arterial blood gas, surgical strategies, long-term survi-
val risk, physiological adaptation
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P3.12-006 CLINICAL SIGNIFICANCE OF KI67 EXPRESSI-
ON IN CURATIVELY RESECTED NON-SMALL CELL LUNG 
CANCER
Hee Kyung Ahn1, Minkyu Jung1, Shin Myung Kang2, Inkeun Park1, 
Young Saing Kim1, Jae-Ik Lee3, Eun Kyung Cho1
1Division Of Hematology And Oncology, Gachon University Gil Medical 
Center/Korea, 2Department Of Internal Medicine, Gachon University Gil 
Medical Center/Korea, 3Depeartment Of Thoracic Surgery, Gachon Uni-
versity Gil Medical Center/Korea
Background: Ki67 and p53 were suggested to be associated poor 
survival in stage I-III patients. The aim of this study was to explore 
the association of Ki67 and p53 expression with prognosis in cura-
tively resected non-small cell lung cancer (NSCLC) patients.
Methods: We retrospectively identified patients with stage I-III 
NSCLC who underwent curative surgery in Gachon University Gil 
Medical Center from January 2007 to December 2012. Ki67 and 
p53 expression levels were evaluated by immunohistochemistry. 
Clinicopathologic features and disease free survival (DFS) were 
retrospectively estimated.
Conclusion: In this practice-based analysis of patients with stage 
IIIA NSCLC receiving definitive chemoradiotherapy, 78% of pati-
ents had a biopsy expected to be adequate for genotyping. To 
maximize the feasibility of genotype-directed induction therapy 
for NSCLC, reflex genotyping of staging biopsies may be needed, 
particularly when genotyping turnaround time exceeds 8 days.
Keywords: Locally advanced disease, Practice-based analysis, 
Targeted therapy, non-small cell lung cancer
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P3.12-005 CLINICAL SIGNIFICANCE OF PREOPERATI-
VE ARTERIAL BLOOD GAS IN PATIENTS WITH STAGE I 
NON-SMALL CELL LUNG CANCER
Shinjiro Mizuguchi, Nobuhiro Izumi, Hiroaki Komatsu, Hidetoshi 
Inoue, Hiroko Oka, Satoshi Okada, Kantaro Hara, Noritoshi Nishi-
yama
Thoracic Surgery, Osaka City University Hospital/Japan
Background: Surgical treatment is the most efficient therapy for 
early non-small cell lung cancer (NSCLC). For surgical treatment, 
oncological and physiological indications may be considered. For 
physiological indication, cardiopulmonary function evaluation, 
such as a general respiratory function test, arterial-blood-gas 
(ABG) analysis, an electrocardiogram, and echocardiogram are 
important to be determined. In ABG analysis, PaCO2>45 Torr and 
hypoxemia (< 90% of SaO2) have been reported as risk factors of 
complications after surgery. This study aimed to establish the clini-
cal significance of preoperative ABG analysis in patients with stage 
I NSCLC in aspect of long-term risk.
Methods: The study involved 253 patients (154 male, 99 female; 
median age 68 years) who underwent lobectomy/bilobectomy with 
radical mediastinal lymph node dissection in patients with stage 
I NSCLC in our institution between January 1998 and December 
2008. One hundred and seventy six patients had adenocarcinoma, 
68 had squamous cell carcinoma, five had large cell carcinoma, and 
four had adenosquamous carcinoma. On pathologic staging, 129 
patients were in stage IA, and 124 in stage IB. Predicted postope-
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55 (5.5%) patients. The distribution rate of pl0 was significantly hig-
her in the negative PLC group than in the positive group both of 
pre- and post-resection PLC (p<0.001). The 5-year survival rate was 
61.7% for the positive PLC group and 79.2% for the negative PLC 
group (p<0.01). In regard to the survival stratified according to the 
pleural invasion, the 5-year survival rates was 81.2% for the nega-
tive PLC with pl0 or pl1 group (pl0-1 group) and 61.2% for the ne-
gative PLC with pl2 or pl3 group (pl2-3 group)(p<0.01). The survival 
of the positive PLC group was a significantly worse than that of the 
pl0-1 group (p<0.01) whereas there was no significant difference in 
survival between the positive PLC and the pl2-3 group (p=0.4732). 
A multivariate prognostic analysis adjusted by age, sex, tumor size 
and pathologic nodal status confirmed the superiority of the pl0-1 
group over the pl2-3 and the positive PLC group (HR 0.547,p<0.01 
and HR 0.426,p<0.01, respectively) and the similarity between the 
pl2-3 and the positive PLC group in survival (HR 0.776, p=0.4082). 
A total of 267 patients had recurrent diseases. Regarding the ini-
tial site of recurrence, pleural dissemination occurred in four of 21 
(19%) patients in the positive PLC group, 19 of 197 (9.6%) patients 
in the pl0-1 group and 10 of 49 (20.4%) patients in the pl2-3 group.
Conclusion: The present study demonstrates the clinical relevance 
of intraoperative PLC in non-small cell lung cancer. Positive intra-
operative PLC is of predictive value for adverse survival and has a 
similar impact on survival with the pleural invasion score of more 
than pl2.
Keywords: TNM staging lung cancer, non-small cell lung cancer, 
pleural lavage cytology, subclinical pleural dissemination
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P3.12-008 VARIATIONS IN THE UPTAKE OF PRACTICE 
GUIDELINE RECOMMENDATIONS ON ADJUVANT CHE-
MOTHERAPY USE FOLLOWING SURGICAL RESECTION 
IN ONTARIO
William Evans1, Yee C. Ung2, Jennifer Stiff3, Anna Chyjek4, Aryn 
Gatto5, Angelika Gollnow6, Catherine Inibhuna7, Rebecca Anas3, 
Carol Sawka8
1Administration, Juravinski Cancer Centre And Mcmaster University/
Canada, 2Radiation Oncology, Odette Cancer Centre/Canada, 3Cancer 
Quality Council Of Ontario, Cancer Care Ontario/Canada, 4Disease Pa-
thway Management Secretariat, Cancer Care Ontario/Canada, 5Project 
Coordinator, Disease Pathway Management Secretariat, Cancer Care 
Ontario/Canada, 6Disease Pathway Secretariat, Cancer Care Ontario/
Canada, 7Informatics - Centre Of Excellence, Cancer Care Ontario/
Canada, 8Clinical Programs & Quality Initiatives, Cancer Care Ontario/
Canada
Background: Since 1997, lung cancer practice guidelines have 
been developed through Cancer Care Ontario’s Program in Evi-
dence-based Care. A 2006 CCO guideline (EBS 7-1-2) recommends 
adjuvant chemotherapy (AC) in selected patients with resected 
lung cancer.
Methods: In 2008, CQCO began to measure concordance with 
guidelines and to publically report regional results through the 
Cancer System Quality Index (CSQI),a web-based public reporting 
tool released annually by the Cancer Quality Council of Ontario 
(CQCO). Guideline concordance is a measure within the Effective 
quality domain of CSQI and is used to track the consistency of 
cancer treatment services across Ontario. This measure links data 
Results: One hundred and eighteen consecutive patients with 
Ki67 or p53 results were identified. Median Ki-67 labeling index 
was 30%. P53 expression was positive in 88 (25%) patients. Higher 
Ki67 expression (>30%) was significantly frequent in male(53.0% 
vs 13.3% of female, p<0.001) and non-adenocarcinoma(64.3% vs. 
20.3% of adenocarcinoma, p<0.001) patients. In univariate analysis, 
median DFS had a trend toward worse in patients with higher Ki67 
(55.9 months vs. not reached in those with lower Ki67 expression, 
p=0.113) and with positive p53 (55.9 months vs. not reached in 
those with negative p53 expression, p=0.123). In Cox multivariate 
analysis, higher Ki-67 expression was an signitifant independent 
prognostic factor associated with poorer DFS (HR 3.083, 95% CI 
1.342-7.084), along with histology and stage. Among 44 stage Ib 
patients, 14 patients received adjuvant chemotherapy. In stage 
IB patients with higher Ki67 expression, adjuvant chemotherapy 
administration had a trend toward higher 3-year DFS rate (100% 
vs. 72% in patients without adjuvant chemotherapy). In contrast, 
3-year DFS rate with adjuvant chemotherapy was 69%, compared 
with 79% without adjuvant chemotherapy in stage IB patients with 
lower Ki67 expression. In patients with tumor size≥4cm, there was 
no differences in DFS according to adjuvant chemotherapy.
Conclusion: Higher Ki67 expression was independently associated 
with shorter DFS in resected NSCLC patients. In stage IB, higher 
Ki67 seemed to be associated benefit of adjuvant chemotherapy. 
The value of Ki67 as a predictive biomarker of advantage of ad-
juvant chemotherapy should be further studied in a prospective 
larger cohort.
Keywords: Early stage non-small cell lung cancer, ki-67
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P3.12-007 A CLINICAL RELEVANCE OF INTRAOPERATI-
VE PLEURAL LAVAGE CYTOLOGY IN NON-SMALL LUNG 
CANCER
Masao Saito, Naohisa Chiba, Yasuto Sakaguchi, Shinya Ishikawa, 
Tatsuo Nakagawa
Thoracic Surgery, Tenri Hospital/Japan
Background: Intraoperative pleural lavage cytology (PLC) has 
been reported to be useful in detecting subclinical pleural disse-
mination. However, the result of this examination is not reflected 
on the current TNM staging system.
Methods: A total of 1038 patients with non-small cell lung cancer 
who underwent surgery were retrospectively reviewed and eva-
luated for the clinical relevance of intraoperative PLC. PLC was 
performed by washing the pleural cavity with 200ml of saline solu-
tion and 20ml of lavage was obtained for cytological examination 
immediately after thoracotomy (pre-resection PLC) and just before 
closing the pleural cavity (post-resection PLC).
Results: Thirty five (3.4%) patients were positive for PLC. Among 
them, 27 (2.6%) patients were positive for pre-resection PLC and 
17 (1.6%) patients were positive for post-resection PLC. The pleural 
invasion score was pl0 in 4 (14.8%) patients, pl1 in 10 (37.0%) pati-
ents, pl2 in 9 (33.3%) patients and pl3 in 4 (14.8%) patients in po-
sitive pre-resection PLC group and pl0 in 4(24%), pl1 in 7(41%), pl2 
in 5(29%) and pl3 in 1(6%) in positive post-resection PLC group. On 
the other hand, in the negative PLC group, pl0 in 695 (69.3%) pati-
ents, pl1 in 206 (20.5%) patients, pl2 in 47(4.7%) patients and pl3 in 
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vival outcomes in patients with resected NSCLC receiving adjuvant 
chemotherapy.
Methods: We retrospectively reviewed medical records for pati-
ents with resected, pathologic stages IB-IIIA NSCLC diagnosed 
between 1/1/2005 and 31/12/2012 in SWSLHD. Patients were 
identified using an institutional electronic database. Staging was 
according to the American Joint Commission on Cancer (AJCC) 6th 
edition tumour-node-metastasis (TNM) system. Information was 
extracted on baseline patient and tumour characteristics, treat-
ment modalities, chemotherapy delivery, treatment-related toxici-
ties and patient outcomes. Survival analysis was performed using 
Kaplan-Meier method.
Results: We identified 137 patients who underwent surgical resec-
tion, 63 (46%) received adjuvant chemotherapy and are presented 
in this analysis. The main reasons that patients did not receive 
adjuvant chemotherapy included stage IB disease (32%), advanced 
age/comorbidities (24%), patient preference (14%), prior neoadju-
vant treatment (7%) and non referral (7%). The median age at dia-
gnosis was 64 (range 45 - 77) with 57% male, 81% were ex- or cur-
rent smokers and 80% had an ECOG performance status of 0 or 1. 
Adenocarcinoma and squamous cell carcinoma histology accoun-
ted for 54% and 27%, respectively. Forty one patients (65%) had 
lobectomy and 22 (35%) had pneumonectomy. Pathological stage 
was: 1B 5 patients (7.9%), IIA 11 (17.5%), IIB 13 (20.6%) and IIIA 
34 (54%). Adjuvant chemotherapy commenced within 90 days of 
surgery in 94% with a median time to treatment of 60 days (range 
25-110). Adjuvant radiotherapy was given to 18 patients (29%), with 
52% of patients with N2 disease receiving radiotherapy. Platinum 
doublet chemotherapy was administered to 62 patients (98%) and 
cisplatin/vinorelbine was the most common regimen given to 41 
patients (65%). The number of planned treatment cycles was com-
pleted by 40 patients (63%), and of these, 11 patients (17%) com-
pleted all chemotherapy on schedule without dose modification. 
Eighteen patients (29%) required hospitalisation during treatment. 
Febrile neutropaenia occurred in 10 (16%), with an additional 24 
(38%) developing non-febrile neutropaenia, thrombocytopenia or 
anaemia. Other clinically significant non-haematological toxicities 
included: vomiting (11%); renal impairment (10%); ototoxicity (6%); 
peripheral neuropathy (16%); fatigue (6%); allergy (2%) or myalgias 
(3%). There were no toxic deaths. With a median follow-up of 18.6 
months (range 3.4 to 96 months), 56% had developed recurrent 
disease with a median disease-free survival of 18.9 months. The 
majority (94%) developed recurrent disease within 3 years. The 
median overall survival was 25.6 months. A total of 34 (54%) had 
died, including 3 non-cancer related deaths.
Conclusion: The utilisation of adjuvant chemotherapy rate is mo-
derate but is consistent with other reports. Our results demonstra-
ted a higher rate of febrile neutropenia and shorter median overall 
survival than the clinical trial population. Therefore, careful selec-
tion of patients to undergo adjuvant chemotherapy is essential.
Keywords: adjuvant chemotherapy, Non small cell lung cancer, 
patterns of care
within Cancer Care Ontario’s Activity Level Reporting Enterprise 
Data Warehouse and the Ontario Cancer Registry with information 
from the Canadian Institute for Health Information’s Discharge 
Abstract Data and National Ambulatory Care Reporting System. 
Two cohorts of patients who were diagnosed with Stage II or IIIa 
NSCLC between January and December 2008 to 2009 (cohort 1; 
n=685) and 2010 to 2011 (cohort 2; n=626) and resected within 270 
days of diagnosis and who received cisplatin-based chemotherapy 
within 120 days of surgery are included in this analysis.
Results: In 2011, 60% of stage I, 64% of stage II and 15% of 
stage III NSCLC underwent surgical resection. On average, AC 
use increased in those resected from 54.3% in cohort 1 to 56.7% 
in cohort 2 but with significant variation amongst the 14 health 
service regions of the province (range 42.9 to 72.1%). 3 regions 
were moderately different from the Ontario rate based on Cohen’s 
d effect test at 95% CI, (d = 0.53-0.65). The variation between 
regions was greater in cohort 1 (31.4% to 66.9%; Δ 35.5%) than 
in cohort 2 (42.9% to 72.1%; Δ 29.2%) suggesting that public 
reporting may have driven some modest change. However, 
although the rate of use of AC increased for 10 regions, it actually 
decreased in 4. Men were significantly less likely to be treated 
with AC (38.2%) compared to women (52.7%) (95% CI, 44.6-60.8, 
p=.0001), as were patients over age 65 (65% < 65 yr vs. 34% % > 
65 yr), (95% CI, 27.5-41.2; p=0001). Patients from areas with the 
highest tercile of immigrant population were also significantly 
less likely to be treated 14.3% (95% CI, p=.023) vs 46.0% for the 
middle; and 51.0% (p=.0001) for the lowest tercile. There were no 
differences based on quintiles (Q) of income (lowest Q 48.3% vs 
Q4, 48.3%; Q5, 40.8%) or rural versus urban residence.
Conclusion: Overall guideline uptake appears low for a therapy 
with the potential to improve long term survivorship and there is 
wide variance between regions only partially explained by factors 
such as age, gender and immigrant status. Further study is ne-
cessary to understand the factors driving this variation in practice 
and the best strategies to ensure that patients receive guideline 
recommended therapy.
Keyword: guideline concordance, non-small cell lung cancer, adju-
vant chemotherapy
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P3.12-009 PATTERNS OF CARE IN PATIENTS RECEIVING 
ADJUVANT CHEMOTHERAPY FOR RESECTED NON-
SMALL CELL LUNG CANCER (NSCLC) IN SOUTH WES-
TERN SYDNEY LOCAL HEALTH DISTRICT (SWSLHD)
Annette Tognela1, Stephanie Lim1, Joseph Descallar2, Shalini Vi-
nod3, Po Yee Yip4, Victoria Bray1
1Medical Oncology Department, Liverpool Hospital/Australia, 2Ingham 
Institute For Applied Medical Research, Liverpool Hospital/Australia, 
3Radiation Oncology, Liverpool And Macarthur Cancer Therapy Cen-
tres/Australia, 4Medical Oncology, Macarthur Cancer Therapy Centre/
Australia
Background: Randomised controlled trials have shown that ad-
juvant chemotherapy is the standard of care for patients with re-
sected, stages II and IIIA NSCLC. The benefit in stage IB disease 
remains inconclusive. There are limited data regarding the patterns 
of care, benefits and toxicities of adjuvant chemotherapy in the 
non-clinical trial population. We reviewed patterns of care and sur-
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P3.12-011 SURVIVAL IN RESECTABLE T1 AND T2 STAGE 
NON-SMALL CELL LUNG CANCER
Ricardo Zapata Gonzalez, Laura Romero Vielva, Manuel Wong 
Jaen, Joan Solé Montserrat, María Deu Martín, Iker López Sanz, 
Javier Pérez Vélez, Alberto Jáuregui Abularach, Irene Bello Rod-
riguez, Mercedes Canela Cardona
Thoracic Surgery, Vall D‘hebron University Hospital/Spain
Background: The aim of this paper is to review the pulmonary 
resections for NSCLC and analyze its survival related to the tumor 
size (T1 and T2), lymph nodes (LN) removed and mediastinal relap-
se of the disease.
Methods: We made a retrospective review of mayor lung resec-
tions performed consecutively for T1 and T2 NSCLC at the Vall 
d‘Hebron University Hospital, from October 1995 to December 
2011. Mean follow-up was 50 months.
Results: We analyzed 755 patients, 646 men (85.5%) with a mean 
age of 64 years (r: 21-84). The most common histology was squa-
mous cell carcinoma SCC (45%) followed by adenocarcinoma 
(35%). There were 595 lobectomies, 119 pneumonectomies and 
41 bilobectomies. The number of LN removed was directly pro-
portional to the number of positive nodes (p = <0.001). We found 
significantly more positive nodes in T2 patients (p<0.001). The 
stages were IA: 152 patients (20%), IB: 348 patients (46%), IIA: 24 
patients (3%), IIB: 99 patients (13%), IIIA: 113 patients (15%) and IV: 
18 patients (2%). 193 patients (25.6%) were classified as T1 and 562 
patients (74.4%) as T2. In the last follow-up 377 patients (49.9%) 
were dead. In-Hospital mortality was 2.9%. 73 patients (12.2%) had 
mediastinal LN recurrence. Mean time between surgery and relap-
se was 27 months. Mean overall survival was 7.6 years (1-year: 85%, 
3-year: 65%, 5-year: 51%). Mean survival according to size was, T1: 
9 years, T2: 7 years (p = 0.006), and to LN was N0: 8.3 years, N1: 
6.9 years, N2: 4.9 years. Overall survival was 3.8 years for those 
who had a recurrence and 8.7 years for those who not (p<0.001).
Conclusion: In our series, SCC remains the most common type. 
The mean overall 5-year survival was 51%, significantly affected by 
the size of the tumor, mediastinal nodal involvement and the pre-
sence of recurrence.
Keyword: Survival, NSCLC, T1, T2
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P3.12-010 IMPACT OF PARIETAL PLEURAL INVASION  
AT ADHESION SITES OF LUNG CANCERS AND  
IMPLICATIONS FOR PROGNOSIS IN THE 7TH TNM  
CLASSIFICATION
Masashi Mikubo1, Syoko Hayashi1, Dai Ishii1, Hirotsugu Yamaza-
ki1, Yoshio Matsui1, Hiroyasu Nakashima1, Fumihiro Ogawa1, Ma-
sahito Naito1, Kazu Shiomi1, Yukitoshi Satoh1, Shi-Xu Jiang2
1Thoracic Surgery, Kitasato University School Of Medicine/Japan, 2Pa-
thology, Kitasato University School Of Medicine/Japan
Background: In the 7th tumor, node, metastasis (TNM) classifica-
tion or lung tumors, visceral pleural invasion (VPI) of lung cancers is 
defined as invasion beyond the elastic layer, including invasion to 
the visceral pleural surface, and T1 tumors with VPI are upgraded 
to T2a. Recently, we demonstrated that the microscopic invasion 
beyond elastic fibers of the visceral pleura but no penetration to 
the parietal pleura at tight adhesion sites (we term this p1-3) should 
be managed as a T2 disease in the 6th edition (Virchows Arch. 
2005; 447: 984-9). Thus, this study investigated the prognostic 
value of p1-3 invasion in the current 7th TNM classification.
Methods: Between 2000 and 2012, 976 consecutive patients with 
non-small cell lung cancers (NSCLCs) underwent curative surgical 
resection at the Kitasato University Hospital. Staging definitions for 
T, N, and M components were according to the 7th International 
Staging System for Lung Cancer. Twenty two patients (2.3%) with 
p1–3 pleural invasion were included. These patients were studied 
clinically and pathologically in comparison with cases treated du-
ring the same period. To maximize the power of assessing prog-
nostic potential, we set the significance level at 0.10, one-sided.
Results: The p1–3 condition sites of the 22 cases were the parietal 
pleura for all cases. The 5-year overall survival (OS) rate for these 
p1–3 patients was 62%. No significant differences were observed 
among p1–3, IB, IIA or IIB groups (p=0.185). However, the 5-year 
OS curve of p1-3 and N0 group (n=15) was similar to that of N0 and 
IIB disease.
Conclusion: Our results indicate that p1–3 patients can be ma-
naged as having a T3 (PL3) disease for the present classification, 
and that in such cases, complete tumor removal could improve the 
long-term survival. Because of the small number of patients availa-
ble for this analysis, a large-scale and nationwide study is warran-
ted for validation of p1–3 status as a T3 (PL3) disease for NSCLCs.
Keywords: adhesion site, Lung cancer, TNM classification, Pleural 
invasion
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P3.12-013 RADICAL TREATMENT OF SYNCHRONOUS 
OLIGOMETASTATIC NON-SMALL CELL LUNG CARCINO-
MA (NSCLC): PATIENT OUTCOMES AND PROGNOSTIC 
FACTORS.
Gwendolyn H. Griffioen1, Dan Toguri2, Max Dahele1, Andrew War-
ner2, Patricia F. Haan De1, George Rodrigues2, Ben J. Slotman1, Su-
resh Senan1, Brian P. Yaremko2, David Palma2
1Radiation Oncology, VU University Medical Center/Netherlands, 2De-
partment Of Radiation Oncology, London Regional Cancer Program/
Canada
Background: In general, metastatic NSCLC has a poor prognosis 
and systemic therapy is the cornerstone of treatment. However, 
extended survival has been reported in some patients presenting 
with a limited number of metastases, termed oligometastatic di-
sease. The goal of this study was to assess outcomes for patients 
presenting with NSCLC and synchronous oligometastases, treated 
with radical intent, and to determine predictors of long-term sur-
vival.
Methods: A retrospective chart review was undertaken at two 
cancer centres, on patients with NSCLC presenting with 1-3 meta-
stasis, who received radical intent treatment (surgery and/or radio-
therapy (RT) ± chemotherapy) to the primary lung tumor including 
the pathological regional nodes and all sites of metastatic disease. 
Overall survival (OS), progression-free survival (PFS) and survival 
after first progression (SAPF) were evaluated. Recursive partiti-
oning analysis (RPA) was performed based on significant factors 
from univariable analysis to identify different risk groups.
Results: Between 1999 and 2012, 61 patients were treated with a 
total of 74 metastases. Median follow-up was 26 months. Patients 
had a median age of 62 years, a median performance status of 1 
and intrathoracic disease that was predominately stage III (n=38). 
The majority of patients had a solitary metastasis (n=50). Common 
sites of metastases were brain (n=47 lesions), bone (n=11), adre-
nal (n=4), contralateral lung (n=4) and extrathoracic lymph nodes 
(n=4). Treatment of the primary tumor consisted of RT ± chemo-
therapy in 52 patients and surgery alone or in combination with 
other modalities in 9 patients. Metastases were treated with ste-
reotactic or high-dose RT (n=39) or surgery (n=22). Median OS was 
13.5 months, 2-year OS was 38%. Median PFS was 6.6 months and 
median SAFP was 4.9 months. Predictors of improved survival were 
surgery for the primary lung tumor (p<0.001), and intrathoracic 
PTV size in patients receiving RT (p<0.03). These factors were used 
for RPA (Figure 1). No significant differences in outcomes were 
observed between the two centers. 
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P3.12-012 CLINICAL AND PROGNOSTIC IMPLICATION 
OF ALK AND ROS1 REARRANGEMENT IN NEVER SMO-
KER WITH SURGICALLY RESECTED LUNG ADENOCARCI-
NOMA
Hye Ryun Kim1, Min Hwan Kim1, Sun-Min Lim1, Eun Young Kim2, Ji 
Soo Park1, Joo Hang Kim1, Hyo Sup Shim3, Byoung Chul Cho1
1Division Of Medical Oncology, Department Of Internal Medicine, Yon-
sei University College Of Medicine/Korea, 2Department Of Internal 
Medicine, Yonsei University College Of Medicine/Korea, 3Department Of 
Pathology, Yonsei University College Of Medicine/Korea
Background: Rearrangements of oncogenic kinase proteins, ana-
plastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1), were 
discovered as key oncogenic molecular drivers of lung adenocarci-
noma recently. The aim of this study is to evaluate the prevalence 
and survival outcomes of ALK and ROS fusion in never smoker pati-
ents with surgically resected lung adenocarcinoma.
Methods: We analyzed consecutive stage IB to IIIA never smoker 
lung adenocarcinoma patients who underwent curative surgery 
in our institution. All resected tumors underwent comprehensive 
molecular profiling including EGFR mutation, KRAS mutation test, 
and fluorescence in situ hybridization (FISH) assay for ALK rearran-
gement. ROS1 rearrangement was evaluated by FISH assay in all 
triple-negative tumors (negative for EGFR, KRAS, and ALK).
Results: Of 162 never-smoker patients with lung adenocarcinoma, 
14 (8.6%) and 5 (3.1%) patients had ALK and ROS1 rearrangement, 
respectively. Proportion of ALK or ROS fusion-positive (fusion-
positive) patients was 26.0% (15 out of 73) among patients who 
are negative for EGFR and KRAS mutation. Fusion-positive pati-
ents tend to have a shorter disease free survival (DFS) than fusion 
negative patients, but without statistical significance (p= 0.124). 
However, multivariate analysis showed significantly poorer DFS of 
fusion-positive patients than fusion-negative patients with adjust-
ment for T stage and lymph node metastasis (Hazard ratio 2.26; 
95% Confidence interval, 1.19-4.30; p = 0.013). The 3-year DFS rate 
was 47.0% in fusion-negative patients and 32.7% in fusion–positive 
patients. Fusion-positive patients also showed poorer DFS in stage 
IB to IIB subgroup. (n=123, p= 0.046) Overall survival of patients 
was not different according to ALK or ROS fusion status. (p= 0.535) 
More extrathoracic metastasis was noted in fusion-positive pati-
ents than fusion-negative patients at the first time of recurrence. 
(46.2% vs. 35.8%, p= 0.539) The median progression free survival 
on EGFR tyrosine kinase inhibitor treatment after recurrence was 
0.9 months in fusion-positive patients, which was significantly shor-
ter than 10.2 months in EGFR mutation positive and 6.4 months in 
wild type patients..
Conclusion: This study shows significantly poorer DFS of ALK or 
ROS fusion positive patients in Asian never smoker lung adenocar-
cinoma patients. Development of ALK or ROS targeted adjuvant 
therapies in this subset of patients is needed to improve their poor 
survival after curative surgery.
Keywords: never smoker, ROS, ALK, lung adenocarcinoma
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P3.12-014 PROGNOSTIC IMPACT OF LYMPHOVASCULAR 
INVASION ACCORDING TO THE TUMOR SIZE IN PATI-
ENTS WITH PN0 NON-SMALL CELL LUNG CANCER
Hiroyuki Tao, Kumiko Yoshida, Tatsuro Hayashi, Akihiro Takaha-
gi, Toshiki Tanaka, Eisuke Matsuda, Kazunori Okabe
Thoracic Surgery, Yamaguchi Ube Medical Center/Japan
Background: Lymphovascular invasion (LVI) has been reported to 
be an unfavorable prognostic factor in patients with non-small cell 
lung cancer (NSCLC). We investigated the prognostic impact of LVI 
according to the tumor size in patients with pN0 NSCLC to elucida-
te the candidates for adjuvant chemotherapy.
Methods: Records of a total of 274 patients with pN0 NSCLC 
who underwent lobectomy with hilar and mediastinal lymph-node 
dissection were reviewed. Patients were divided into 3 groups 
according to the tumor diameter; group A: smaller than 20 mm, 
group B: 21 to 30 mm, and group C: greater than 31 mm. The com-
parison between the groups (A, B, and C) and LVI status (positive/
negative) was analyzed by chi-square test. Kaplan-Meier analyses 
and log-rank tests with 95 % confidence intervals were employed 
to evaluate the impact of LVI on overall survival (OS) and relapse-
free survival (RFS) in each group. Cox proportional hazards models 
were applied to assess the independent risk factors.
Results: Group A, B, and C consisted of 99, 86, and 89 patients, 
respectively. The frequency of positive LVI was increased in larger 
tumors (group A: 19.2%, group B: 25.6%, and group C: 36.0%; P = 
0.033). In both group A and B patients, positive LVI was a signifi-
cant risk factor for poor prognosis of OS and RFS in univariate ana-
lysis. In multivariate analysis, positive LVI was an independent risk 
factor for OS in both group A and B patients (hazard ratio = 10.6 
and 10.5, P = 0.005 and 0.006, respectively) and for RFS in group A 
patients (hazard ratio = 14.7, P = 0.001)．LVI status was not shown 
to be a prognostic factor for OS or RFS in group C patients.
Conclusion: The impact of positive LVI on prognosis was more 
significant in the smaller tumors, although the frequency of LVI was 
higher in the larger tumors. Adjuvant chemotherapy for patients 
with pN0 small-sized NSCLC and positive LVI should be conside-
red.
Keywords: Prognosis, non-small cell lung cancer, Lymphovascular 
invasion, Tumor sizeFigure 1. RPA flowchart for OS showing characteristics of risk 
groups (A) with accompanying Kaplan-Meier curves of OS by RPA 
risk groups (B)
Conclusion: Radical treatment of selected NSCLC patients presen-
ting with 1-3 synchronous metastases can result in favorable 2-year 
survival, although progression in the first year was common. Out-
comes were strongly associated with intra-thoracic disease status: 
patients with small radiotherapy treatment volumes or resected 
disease had the best OS. Prospective clinical trials, ideally rando-
mized, should evaluate the role of radical treatment strategies in 
patients with oligometastases.
Keywords: oligometastasis, synchronous, stage IV, radical
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P3.12-016 FREQUENCY IN EGFR, K-RAS, BRAF AND ALK 
MUTATIONS IN A COHORT OF CANCERS: ALK TRANS-
LOCATIONS ARE MORE FREQUENTLY SEEN IN ADVAN-
CED DISEASE
Eric Lim1, David Gonzalez De Castro2, Sanjay Popat3, Emily Shaw4, 
Ian Walker4, Peter Johnson4, Olivia Bamsey1, Anna Higgins1, Tina 
Osadolor1, Louise Renouf2, Andrew G. Nicholson1
1Royal Brompton Hospital/United Kingdom, 2Institute Of Cancer Re-
search/United Kingdom, 3Department Of Oncology, Royal Marsden 
Hospital/United Kingdom, 4Cancer Research Uk/United Kingdom
Background: Routine mutation testing for potential targeted the-
rapy is a challenge in the management of lung cancer. As part of a 
feasibility study on the implementation of molecular testing in the 
United Kingdom, Cancer Research UK (CRUK) set up a stratified 
medicine program testing EGFR, K-RAS, BRAF mutations and ALK 
translocation on lung cancer samples. We present the result from 
the first ten months from two hospitals feeding into one diagnostic 
molecular laboratory.
Methods: Mutations detection in EGFR and KRAS genes was un-
dertaken using cobas®4800 (Roche) and single-strand conformati-
on analysis for BRAF gene. ALK translocations were screened using 
Vysis ALK break apart rearrangement probe.
Results: A total of 94 resections all (but one) in stages I - IIIA were 
analysed, with mutations found entirely within adenocarcinomas 
(n=64), with a frequency of mutations/translocation identification 
of 30% (K-RAS) , 12.5% (EGFR), 1.5% (ALK) and 1.5% (BRAF) (Figure 
1). Over the same period, 360 biopsies from patients with non-
resectable/advanced disease, were analysed, the majority being 
stage 4, with a frequency of 24% (K-RAS), 10%.6 (EGFR), 4.3% and 
1.9% (Figure 2). 
Conclusion: The data suggest that frequency of K-RAS, EGFR and 
BRAF mutations are similar in early and advanced non-small cell 
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P3.12-015 SURGERY FOR EARLY NON-SMALL CELL LUNG 
CANCER WITH PREOPERATIVE ERLOTINIB (SELECT):  
A CORRELATIVE BIOMARKER STUDY
Adrian G. Sacher1, Humberto Lara-Guerra2, Thomas Waddell2, 
Shingo Sakashita3, Zhuo Chen3, Lucia Kim3, Tong Zhang3, Suzanne 
Kamel-Reid3, Alexandra Salvarrey2, Gail E. Darling2, Kazuhiro Ya-
sufuku2, Shaf Keshavjee2, Marc De Perrot2, Frances A. Shepherd1, 
Geoffrey Liu1, Ming-Sound Tsao3, Natasha Leighl1
1Division Of Medical Oncology, Princess Margaret Cancer Center/Cana-
da, 2Division Of Thoracic Surgery, Toronto General Hospital/Canada, 
3Department Of Pathology, Princess Margaret Cancer Center/Canada
Background: Erlotinib has demonstrated major activity in EGFR 
mutation positive NSCLC, but may also benefit those with wild 
type tumours. We conducted a single-arm trial of pre-operative 
erlotinib in early stage NSCLC to assess radiologic and functional 
response as well as correlation with known and investigational 
biomarkers.
Methods: Patients with clinical stage IA-IIB NSCLC received er-
lotinib 150 mg daily for 4 weeks followed by surgical resection. 
Tumor response was assessed using pre- and post-treatment CT 
and PET imaging. Tumor genotype was established using Seque-
nom MassARRAY analysis. EGFR, PTEN, cMET and AXL expression 
levels were determined by immunohistochemistry. Pre- and post-
treatment circulating markers/ligands for EGFR activation (TGF-α, 
amphiregulin, epiregulin, EGFR ECD) were measured by ELISA. 
Tumor MET copy number by FISH and VeriStrat® analysis of pre-
treatment serum samples is ongoing. Secondary endpoints inclu-
ded pathological response, toxicity and progression-free survival.
Results: Twenty-five patients were enrolled; 22 received erlotinib 
treatment with a median follow up of 4.4 years (range 2.2 to 6.4 
years). Histology was predominantly adenocarcinoma (15) with 
smaller numbers of squamous cell carcinoma (7). PET response 
(25% SUV reduction) was observed in 2 patients (9%), both with 
confirmed squamous carcinoma histology. All patients met criteria 
for stable disease by RECIST and several experienced minor ra-
diographic regression with histologic findings of fibrosis/necrosis, 
including 2 with squamous histology. The presence of an EGFR 
activating mutation was detected in two adenocarcinoma cases; 
one patient experienced minor radiographic response to treat-
ment (exon 19 deletion) and the other stable disease (L858R). High 
pre-treatment serum levels of TGF- α correlated with tumor growth 
or primary resistance to erlotinib therapy (p=0.04), whereas high 
post-treatment soluble EGFR levels correlated with tumor respon-
se (p=0.02). Expression of EGFR, PTEN, cMET and AXL did not 
correlate significantly with tumor response.
Conclusion: Erlotinib appears to demonstrate some activity in 
EGFR wild-type tumors including those with squamous histology. 
These findings support that certain EGFR wild-type patients may 
respond to EGFR TKIs. Further research is needed to characterize 
these patients and elucidate the predictive ability of potential bio-
markers such as TGF- α, EGFR copy number and others.
Keywords: NSCLC, biomarker, erlotinib
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Results: 
112/335 patients (33%) had pre-operative staging PET scans. For 
the overall group (n= 335), and for the N0 (n=256) and N1 (n=79) 
subgroups, there was no evidence that the use of a pre-operative 
PET scan was associated with a lesser rate of subsequent distant 
failure, or a slower rate of distant failure (p>0.05 on uni- and multi-
variate analyses) (Figure-1). On multivariate analysis, the predic-
tors of distant failure included lympho-vascular invasion (p=0.02, 
HR=1.3), T stage (T1-2 vs T3) (p=0.009, HR=1.4) and N stage (N0 vs 
N1) (p=0.007, HR=1.5). The predictors for recurrent disease inclu-
ded lympho-vascular invasion (p=0.004, HR=1.8), T stage (p=0.001, 
HR=1.3) and N stage (p=0.004, HR=1.7).
Conclusion: The use of a pre-operative PET scan did not signifi-
cantly alter the rate, or the pace, of distant recurrence or relapse 
of any kind, in patients undergoing surgery for non-small cell lung 
cancer (compared to CT-only staged patients). The retrospective 
nature of this study limits its validity. However, the PET-scanned 
patients were treated more recently, and were therefore perhaps 
more favorable (with both shorter follow up and with access to 
more modern interventions).
Keywords: non-small cell lung cancer, surgery, PET scan, distant 
failure
carcinoma, however ALK translocations were observed to be more 
frequent in patients with advanced disease. This may have implica-
tions when considering which patients should undergo FISH tes-
ting for ALK translocation and entry into clinical trials. This study 
was funded by Cancer Research UK, Astra Zenica and Pfizer.
Keyword: Mutation testing, non-small cell lung cancer
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P3.12-017 THE LACK OF IMPACT OF PRE-OPERATIVE 
PET ON THE RISK, AND PACE, OF SUBSEQUENT FAI-
LURE FOLLOWING SURGERY FOR EARLY STAGE NON-
SMALL CELL LUNG CANCER?
Mert Saynak1, Nirmal K. Veeramachaneni2, Jessica L. Hubbs3, Ti-
mothy Zagar3, Arif Sheikh4, Amir H. Khandani4, Benjamin Haith-
cock2, Bahjat F. Qaqish5, Lawrence Marks3
1Department Of Radiation Oncology, Trakya University Hospital/Tur-
key, 2Division Of Thoracic Surgery, University Of North Carolina/United 
States Of America, 3Department Of Radiation Oncology, University Of 
North Carolina/United States Of America, 4Division Of Nuclear Medi-
cine, University Of North Carolina/United States Of America, 5Division 
Of Biostatistic, University Of North Carolina/United States Of America
Background: PET scans are generally believed to be more sensiti-
ve than are CT in detecting metastatic disease and thus are widely 
used in the pre-operative assessment of patients with early-stage 
lung cancer. Given the increased sensitivity afforded with PET, 
one would expect the PET-staged patients to be “more favorab-
le” than their “CT-staged only” patients (i.e. “stage migration”). 
The PET-staged patients should theoretically have a lower rate 
of subsequent distant failure. Further, among those who fail, the 
PET-staged patients should theoretically fail at a later time post-
operatively (compared to their CT-only-staged patients). We herein 
compare the clinical outcomes in a group of patients with early 
stage lung cancer staged pre-operatively with CT with or without 
PET scan.
Methods: The records of 335 patients undergoing curative sur-
gery at UNC hospital between January 1996 through December 
2006 were retrospectively reviewed, with extensive data extraction 
including staging, treatment, and outcome data. Univariate and 
multivariate analysis were performed to identify predictors for 
clinical outcome. Failure times in sub-groups were calculated with 
the Kaplan–Meier method and compared via log-rank test. The 
rate and pace of recurrence were considered. Independent factors 
adversely affecting failure were determined with Cox regression.
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vessel invasion is high though there were significant differences in 
this investigation because the number of the specimens was small. 
Therefore a large-scaled trial that will make this point clear should 
be planned.
Keywords: stage I, adjuvant therapy, Non Small-cell Lung Cancer, 
vessel invasion
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P3.12-019 FEASIBILITY AND EFFICACY OF RADICAL LO-
CAL THERAPY FOR OLIGO-RECURRENCE OF NSCLC
Ryu Nakajima, Kyukwang Chung, Takuma Tsukioka, Makoto Ta-
kahama, Ryoji Yamamoto, Hirohito Tada
General Thoracic Surgery, Osaka City Genral Hospital/Japan
Background: Oligo-Recurrence (< 5 metastatic lesions) of surgi-
cally resected Non-Small Cell Lung Cancer (NSCLC) patient was 
stage IV disease, but long term survival was expected. Radical 
local therapy may be able to cure a subset of these patients, but 
clinical data has been insufficient.The purpose of this study is to 
evaluate the efficacy and toxicity of local therapy (include surgery 
(OP) and radiation therapy (RT)) according to the recurrence site.
Methods: We retrospectively reviewed surgically resected patients 
of NSCLC at our institution between 1994 and 2009, and extracted 
patients who received local therapy after recurrence. Efficacy and 
toxicity were compared between OP and RT. Significant differen-
ces among treatment groups were compared using the X2-test and 
survival curves were constructed using the Kaplan-Meier method 
and log-rank test.
Results: Of the 1975 patients who underwent surgery during this 
period, and 421 cases were relapsed. Two hundred sixty patients 
were oligo-recurrence case and were received local therapy (OP: 
48/ RT: 143). Primary lesion had been controlled in all cases. Re-
currence sites were lung: 55 (21/ 34), Brain: 52 (3/49), Mediastinal 
and neck LN: 49 (7/38), Born: 33(3/30) and Adrenal gland: 7 (3/4). 
RT for brain metastasis was r-knife: 38 and Whole brain irradiation: 
11. There were no serious adverse events in both treatments. Per-
formance status was not spoiled in both treatment groups. Overall 
median survival time (MST) after recurrence was 17 months (mo.) 
(OP: 27/RT: 11), 3-year survival rate was 22% (29%/19%). Twenty 
patients (OP 6/RT 6) were survived over 5 years. MST according to 
the recurrence site was, lung: 23 mo. (27/11), Brain 18 mo. (16/18), 
mediastinal and neck LN 14 mo. (12/14), born 12 mo. (17/11) and 
adrenal gland 26 mo. (22/47). There was no statistically significant 
difference in survival for overall patients, according to the recur-
rence site, and also treatment modality.
Conclusion: Local therapy for oligo-recurrence NSCLC could be 
safety performed. Overall survival data was not extremely supe-
rior to other Stage IV disease in this data. However, according to 
the recurrence site, MST of lung and adrenal gland were over 20 
months. There was no significant difference between treatment 
modality. To confirm the true efficacy of radical local therapy for 
these patients, prospective study must be needed.
Keywords: non-small cell lung cancer (NSCLC), local therapy, 
Oligo-metastasis
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P3.12-018 EXAMINATION OF THE INFLUENCE THAT 
VESSEL INVASION GIVES PROGNOSIS OF STAGE I NON 
SMALL-CELL LUNG CANCER AND THE TREATMENT EF-
FECT OF ADJUVANT THERAPY FOR THE VESSEL INVASI-
ON-POSITIVE STAGE I CASES
Katsuo Kojima1, Makoto Yano1, Reiko Taki2, Hideki Akamatsu3, 
Tadashi Furuie4, Kenichi Okubo5
1Thoracic Surgery, Musashino Red-cross Hospital/Japan, 2Respiratory 
Internal Medicine, Musashino Red-cross Hospital/Japan, 3Internal Me-
dicine, Aoba Family Clinic/Japan, 4Internal Medicine, Furuie Medical 
Clinic/Japan, 5Thoracic Surgery, Tokyo Medical And Dental University 
Hospital/Japan
Background: We suggested that vessel invasion may be an im-
portant recurrence factor of Stage I non small-cell lung cancer in 
the UICC-TNM 7th classification same as the previous classification 
in the 14th WCLC. On the basis of the result, we have performed 
postoperative adjuvant chemotherapy to the vessel invasion-posi-
tive patients who agreed to our informed consent as pilot study.
Methods: We reexamined the influence that vessel invasion gives 
prognosis of Stage I non small-cell lung cancer. We analyzed 279 
Stage IA-IB cases to whom prognosis is clear and postoperative 
adjuvant therapy was not performed among 711 cases to whom 
radical operation was performed in Tokyo medical and Dental 
University Hospital in Nov.1993-Jun.2008. And we more weighed 
about prognosis 33 vessel invasion-positive Stage IA-IB cases to 
whom postoperative adjuvant therapy was performed in above 
Hospital and Musashino Red-Cross Hospital in May.2004 - Ap-
ril.2011 against 125 vessel invasion-positive cases (:no adjuvant 
group) among above 279 cases. We used Kaplan Meyer analysis 
for survival rate, the chi-square test for comparison of recurrence 
rate and Logistic regression analysis for multivariate analysis.
Results: In 279 cases, p-Stage IA and IB cases were 168 and 111. 
Five year survival rate was 93% and 72% in each stage (p<0.001). 
But in case vessel invasion is negative, there were not significant 
differences between p-Stage IA and IB (95% vs. 87%, p=0.16). On 
the other hand, in case vessel invasion is positive, there were sig-
nificant differences (83% vs. 59%, p=0.01). Multivariate analysis of 
279 cases showed that vessel invasion is the worst factor of death 
from recurrence (p<0.001) in tumor diameter, pleural invasion, 
differentiation, vessel invasion and lymphatic involvement. And it 
was revealed that the recurrence rate is high so that the degree of 
vessel invasion becomes higher (Recurrence rate: V0 6%, V1 14%, 
V2 33%; p<0.001. Five year survival: V0 93%, V1 68%, V2 66%; 
p<0.001). In 33 cases to whom adjuvant therapy was performed, 
an oral treatment of tegafur uracil was performed to 22 cases (:TU 
group), and platinum-based chemotherapy was performed to 11 
cases (:PB group). Platinum-based chemotherapy was performed 
actively to the cases that the degree of vessel invasion is high (V2-
3). In the cases the degree of vessel invasion is low (V1), four year 
survival rate and recurrence rate was 94% in TU group vs. 81% in 
no adjuvant group (p=0.09), and 4% vs. 20% (p=0.43). In the cases 
the degree of vessel invasion is high (V2-3), four year survival rate 
and recurrence rate was 91% in PB vs. 60% in TU vs. 64% in no 
adjuvant (p=0.13) and 10% vs. 40% vs. 36% (p=0.21).
Conclusion: It is supposed that vessel invasion may be an im-
portant prognostic factor of Stage I non small-cell lung cancer. 
Only the platinum-based chemotherapy may improve prognosis 
as adjuvant therapy for the Stage I cases in which the degree of 
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P3.12-021 THE ROLE OF PENTRAXIN 3, AN ACUTE PHA-
SE PROTEIN, AND OF SMOLDERING INFLAMMATION 
AT THE TUMOR SITE IN LUNG CANCER PROGRESSION 
AND PROGNOSIS. A CLINICOPATHOLOGIC STUDY
Maurizio V. Infante1, Cecilia Garlanda2, Manuela Nebuloni3, Daoud 
Rahal4, Daniel Solomon5, Emanuela Morenghi6, Serenella Valaper-
ta7, Marta N. Monari7, Samantha Pesce2, Valentina Errico1, Emanu-
ele Voulaz1, Edoardo Bottoni1, Andrea Morlacchi1, Silvio Cavuto8, 
Paola Allavena2, Marco Alloisio1, Alberto Mantovani2
1Thoracic Surgery, Istituto Clinico Humanitas/Italy, 2Research Labora-
tories, Istituto Clinico Humanitas/Italy, 3Pathology Department, Uni-
versity Of Milan, Ospedale Luigi Sacco/Italy, 4Pathology Department, 
Istituto Clinico Humanitas/Italy, 5Rabin Medical Center/Israel, 6Biosta-
tistics, Istituto Clinico Humanitas/Italy, 7Clinical Labs, Istituto Clinico 
Humanitas/Italy, 8Department Of Infrastructure Research And Statis-
tics, IRCCS-arcispedale Santa Maria Nuova/Italy
Background: The prognosis remains dismal for most lung cancer 
patients, even for early cases, suggesting the existence of sophis-
ticated pathogenetic mechanisms that are not reflected by pa-
thological stage. Although a number of studies have been carried 
out in relatively recent times [], our understanding of the role and 
clinical significance of inflammation and immunity in human lung 
cancer is still limited. We investigated in detail the diagnostic and 
prognostic role of two acute phase proteins, Pentraxin 3 (PTX3) 
and C-reactive protein (CRP), in high-risk subjects and lung cancer 
patients.
Methods: A cohort of high-risk, cancer-free subjects enrolled 
in a lung cancer early-detection trial with spiral CT, a group of 
screening-detected lung cancer patients, and two groups of 
consecutive non-small cell lung cancer patients admitted to our 
Thoracic Surgery Department between January 2009 to June 2010 
were included. Serum CRP and PTX3 levels were determined in the 
high-risk, healthy cohort (N=1434) and in patients with non-small 
cell lung cancer. Pre-treatment blood samples were prospectively 
collected prior to surgical resection in lung cancer patients. PTX3 
expression was determined by immunohistochemistry and scored 
using semiquantitatively. Survival curves were calculated by the 
method of Kaplan and Meyer. Prognostic factors were analyzed by 
multivariate Cox regression.
Results: No significant association was found between PTX3 or 
CRP serum levels and the risk of subsequently developing lung 
cancer or any malignancy in the high-risk-cohort. 119 patients har-
bouring 124 primary lung cancers were evaluable. Screening and 
clinically detected lung cancer patients were comparable as to age 
and comorbidity. There was a significantly higher rate of stage I 
disease among screening patients (p=0.01). Preoperative serum 
CRP and PTX3 levels in lung cancer patients were significantly 
higher than in the tumour-free, high-risk population, p<0.001). In 
the tumour stroma, PTX3 expression was low or moderate in 55% 
and intense in 10%. Tumour cells stained weakly positive in 24%. 
Staining for PTX3 was virtually absent in the normal lung interstice. 
Median follow-up was 27 months (0-140), Median 2-year disease-
free survival was 71 % and median overall 2-year survival was 75% 
Preoperative serum levels of CRP and PTX3 did not correlate with 
survival. Instead, age (p=0.029), stage (p=0.001) and interstitial 
PTX3 expression (p<0.001) were independent prognostic factors
Conclusion: PTX3 and CRP levels are not linked to a higher risk of 
developing lung cancer or any cancer in a healthy high-risk popu-
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P3.12-020 DERAILED ANALYSIS OF LUNG CANCER WITH 
SCATTERED CONSOLIDATION
Ryosuke Tachi, Kenji Suzuki, Takeshi Matsunaga, Yukio Tsushi-
ma, Kazuya Takamochi, Shiaki Oh
General Thoracic Surgery, Juntendo University Hospital/Japan
Background: We have reported that the definition of lung cancer 
with scattered consolidation (LCSC) was difficult to measure the 
size of ground glass opacity (GGO) on thin section computed 
tomography (Matsunaga T, Suzuki K, et al. Interact Cardiovasc 
Thorac Surg. 2013).To add to clinicopathological features, We in-
vestigate in LCSC in detail.
Methods: Between Jan.2009 and Oct.2012, 590 consecutive pa-
tients underwent pulmonary resection for lung cancer with clinical 
stage IA and are performed on thin section computed tomogra-
phy for preoperative evaluation. Among them, 79 patients (13.4%) 
who had lung cancers in which it was difficult to measure the size 
of consolidation tumor ratio (CTR) were investigated in this study. 
LCSC was divided into three categories: tumor with discontinuous 
consolidation like islands (small islands type); tumors with reticulate 
consolidation (reticulation type); tumors with denser GGO (denser 
type). The medical record of each patient was examined for the 
frequency of pathological nodal status, lymphatic invasion, vascu-
lar invasion, and adenocarcinoma in situ (AIS).
Results: All of LCSC patients are adenocarcinoma. No nodal 
involvement was observed in all cohort. Pathological lymphatic 
invasion were found in 5 (17.2%) out of 29 pts with island type, 2 
(7.4%) out of 27 patients with reticular type, 1 (4.3%) out of 23 pa-
tients with denser type.. Vascular invasion was found in 3 (11.5%), 
2 (7.4%), and 0 (0%), respectively. AIS were included in 3 (11.5%), 5 
(13.5%), and 2 (8.6%), respectively. There were no statistically signi-
ficant differences.
Conclusion: s: There were no significant differences in the three 
categories as to pathological invasive factors among LCSC. Vascu-
lar and lymphatic invasions were frequently seen in island or reti-
cular type compared with denser type. On the other hand, AIS was 
frequently seen in denser type.
Keywords: lung cancer with scattered consolidation, thin section 
computed tomography, Ground glass opacity, Adenocarcinoma
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gains however avoidance of emergency admissions is likely to have 
a positive impact on quality of life. Further studies to investigate 
which patients are at highest risk of recurrence and the most ap-
propriate post-surgical follow-up strategies are required.
Keyword: recurrence, surgery, follow-up
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P3.12-023 INTERNATIONAL TAILORED CHEMOTHERAPY 
ADJUVANT TRIAL: ITACA TRIAL
Silvia Novello1, Christian Manegold2, Monika Heidi Serke3, Chris-
tian Grohe4, Michael Geissler5, Ida Colantonio6, Erich Stoelben7, 
Wolfgang Schutte8, Michele Milella9, Andreas Meyer10, Giuseppe 
Valmadre11, Christian Schumann12, Valentina Monica1, Valter Tor-
ri13, Giorgio V. Scagliotti1
1Department Of Oncology, University Of Turin/Italy, 2University Me-
dical Center/Germany, 3Lungenklinik Hemer/Germany, 4Pneumologie 
Evangelische Lungenklinik Berlin/Germany, 5Lung Cancer Centre Ess-
lingen-stuttgart (tess) And Departmet Of Oncology/Germany, 6Medical 
Oncology Unit, Aou Santa Croce E Carle/Italy, 7Lung Clinic, Hospital Of 
The City Of Cologne/Germany, 8Hospital Martha-maria Halle-doelau/
Germany, 9Division Of Medical Oncology A, Regina Elena National 
Cancer Institute/Italy, 10Krankenhaus St. Kamillus, Pneumology De-
partment/Germany, 11E. Morelli Hospital Aaovv/Italy, 12Department Of 
Internal Medicine Ii, Pneumology, University Hospital Ulm/Germany, 
13Department Of Oncology, Mario Negri Institute/Italy
Background: This is an ongoing phase III multicenter randomized 
trial comparing adjuvant pharmacogenomic-driven chemotherapy, 
based on thymidilate synthase (TS) and excision-repair cross-com-
plementing-1 (ERCC1) gene expression versus standard adjuvant 
chemotherapy in completely resected Stage II-IIIA non-small cell 
lung cancer (EudraCT #: 2008-001764-36).
Methods: For all the registered patients (pts) the expression of 
ERCC1 and TS is assessed by qRT-PCR on paraffin-embedded 
tumor specimens in a central laboratory. Randomization is strati-
fied by stage and smoking status. Trial was emended on Feb, 2011 
with the 7th staging system. Primary end point is overall survival; 
secondary end points include recurrence-free survival, therapeutic 
compliance, toxicity profile and comparative evaluation of ERCC1 
and TS mRNA versus protein expression. It is assumed that the 
5-year survival rate in the control arm is 45% and the hazard re-
duction associated to the experimental treatment is 30%. With a 
power of 90% to detect the estimated effect with log-rank test, a 
significant level of 5% (2 tails), 336 events have to be observed; the 
expected total number of pts is 700. The final statistical analysis 
will compare all pts in the control arms versus all those treated in 
the tailored chemotherapies groups. Efficacy analysis will be done 
on an intent-to-treat basis. Cox proportional hazard model will be 
used for estimating hazard ratios after adjusting for relevant vari-
ables. Within 45 days post-surgery, pts in each genetic profile are 
randomized to receive either a standard chemotherapy selected 
by the investigator (cisplatin/vinorelbine, cisplatin/docetaxel or 
cisplatin/gemcitabine) or an experimental treatment (tailored arms) 
selected as follows: 1) high ERCC1 and high TS 4 cycles of single 
agent paclitaxel 2) high ERCC1 and low TS 4 cycles of single agent 
pemetrexed 3) low ERCC1 and high TS 4 cycles of cisplatin/gemci-
tabine 4) low ERCC1 and low TS 4 cycles of cisplatin/pemetrexed. 
All chemotherapy regimens are administered for a total of 4 cycles 
on a 3-weekly basis.
lation. Nonetheless, mean CRP and PTX3 concentrations in pati-
ents with lung cancer are significantly higher than in the blood of 
healthy high risk subjects, and a significant and independent cor-
relation was found for interstitial PTX3 expression with lung cancer 
prognosis after surgery. Altogether this data suggests a connec-
tion between smoldering inflammation in the tumor bed and lung 
cancer progression that warrants further investigation.
Keywords: Prognosis, Pentraxin 3, Lung cancer, Inflammation
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P3.12-022 PATTERNS OF DISEASE RECURRENCE AND 
MODALITY OF DETECTION FOLLOWING SURGERY FOR 
EARLY STAGE LUNG CANCER
Jim Brown1, Stephanie Brazil1, Dorcas Mcasey2, Shahideh Safavi3, 
Ceri Morgan4, Sakib Rokadiya5, Mamta Ruparel6, Dipak Mukher-
jee3, Sarah Doffman4, Sara Lock5, Amit Patel5, Alistair Reinhardt6, 
Jeremy George1, Sam Janes1, Neal Navani1
1University College London Hospital/United Kingdom, 2The Heart Hos-
pital/United Kingdom, 3Basildon Hospital/United Kingdom, 4Brighton 
And Sussex University Hospitals/United Kingdom, 5Whittington Hospi-
tal/United Kingdom, 6Whipps Cross Hospital/United Kingdom
Background: There is a significant risk of disease recurrence fol-
lowing surgery with curative intent for non-small cell lung cancer 
(NSCLC). However, limited data is available on the patterns of re-
currence and best practice for follow up imaging after lung cancer 
surgery. Current practice in the United Kingdom (UK) is to perform 
interval chest x-ray for 5 year following surgery. We aimed to de-
termine the incidence, anatomical site, modality of detection and 
percentage of patient requiring acute admission as a harbinger of 
disease recurrence post thoracotomy for NSCLC
Methods: Records of consecutive patients with NSCLC who un-
derwent thoracotomy and resection of early stage lung cancer at 5 
institutions situated in the South East of the UK between October 
2007 and September 2012 were interrogated. Data collection was 
completed in Jan 2013.
Results: A total of 314 patients were included; 59 (18.8%) patients 
died from disease recurrence during the study period, the site of 
recurrence was lung, central nervous system, bone/ soft tissue, ab-
dominal and lymph node respectively in 24 (40.7%), 17 (28.8%), 10 
(16.9%), 4 (6.8%) and 4 (6.8%) cases. In 45 (76.2%) patients disease 
recurrence was detected during outpatient consultation, modality 
of detection for routine chest x-ray, CT and other modalities were 
respectively 7 (15.5% ), 28 (62.2%) and 10 (22.3%) in every case CT 
was prompted by change in symptoms, a clinically palpable mass 
lesion or clinical suspicion. Other modalities used were MRI, ultra-
sound and lymph node aspiration in 4, 3 and 3 cases respectively. 
Emergency admission accounted for 14 (23.8%) patients pathway 
to detection of recurrence, of these 9 (64.3%) were admitted with 
symptoms relating to cerebral metastases, 4 (28.6%) with sympto-
matic breathlessness and 1 (7.1%) with a pathological fracture.
Conclusion: Almost a quarter of patients with relapsed lung cancer 
following surgery present with acute symptoms requiring emer-
gency admission. Standard chest x-ray follow-up detects very few 
recurrences with most cases being detected once reported sym-
ptoms direct further investigation. It is currently unknown whether 
earlier detection of recurrence may offer symptomatic or survival 
S1227Copyright © 2013  by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
0.05 (1-sided) significance level with 80% power, a total of 168 pts 
(112 in the investigational arm and 56 in the standard arm) will be 
enrolled. The secondary endpoints are overall survival, disease-
free survival, overall survival at 1, 2 and 5 years, overall response 
and safety. The major eligibility criteria are as follows: histologically 
confirmed NSCLC appropriate for surgery; ≥18 years old; ECOG 
performance status (PS) 0-1; sufficient tissue to perform marker 
analyses; medically fit for resection by lobectomy or pneumonec-
tomy; stage IIIA (N2) patients with technically operable disease 
limited to T1a, b, T2a, b N2 M0; T3 (>7 cm) N2 M0 are eligible; 
stage IIIA pts limited to T3 N1 M0, T3 (invasion) N2 M0; T4 N0, N1 
M0 are not eligible; NSCLC confirmed by mediastinoscopy; infor-
med consent. 
This study is open for accrual; further details can be found at Cli-
nicalTrials.gov (NCT01784549). Funded by the Italian Ministry of 
Health – RF 2009-1530324. 
Results: N/A
Conclusion: N/A
Keywords: Neoadjuvant therapy, stage IIIA, customized therapy, 
NSCLC
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P3.12-025 SURVIVAL IN OCTOGENARIANS WITH PATHO-
LOGICAL STAGE I NON-SMALL CELL LUNG CANCER PA-
TIENTS UNDERWENT COMPLETE RESECTION
Yu-Chao Yu1, Cheng-Che Tu2, Chien-Sheng Huang2, Po-Kuei Hsu2, 
Jung-Jyh Hung2, Chih-Cheng Hsieh2, Han-Shui Hsu2, Yu-Chung 
Wu2, Wen-Hu Hsu2
1Taipei Veterans General Hospital, Yang-Ming University Hospital/Tai-
wan, 2Surgical Department, Taipei Veterans General Hospital/Taiwan
Background: For patients older than 80 years old, surgical treat-
ments for resectable lung cancer were usually to a limited extent, 
or even not considered. Few studies evaluated the true effect of 
surgery for these patients. The aim of this study is to compare the 
survival between the octogenarians and younger patients with 
pathological stage I non-small cell lung cncer (NSCLC) underwent 
complete resection using multivariate analysis.
Methods: The clinicopathological characteristics of 870 patients 
underwent complete resection of stage I NSCLC between Jan. 
2002 and Dec. 2011 were retrospectively reviewed. The patients 
were categorized as octogenarians (aged 80~90) or younger (aged 
< 80). Survival under multivariate analysis was examined.
Results: 76 (8.7%) octogenarians were indentified in the 870 
patients, average age was 82.4±2.5 years old. The 794 younger 
patients had average age of 63.0±10.4. Pulomany function test 
including forced expiratory volume in one second (FEV1) and 
FEV1/ forced vital capacity (FVC) were 1.80±0.44 L and 70.5±11.7 
% in the elder group, and were 2.23±0.59 L and 76.3±9.9% in 
the younger patients (p < 0.001). There were 44 (57.9%) lobec-
tomies and 32(42.1%) sublobar resections performed for the 
octogenarians, while 689 (86.8%) lobectomies and 94(11.8%) 
wedge resections/segementectomies were done for the younger 
patients (p < 0.001). Average tumor size was 2.6±1.15 cm and 
2.4±1.12 cm, respectively (p = 0.076). Five surgical mortalities 
Results: Not applicable
Conclusion: Currently, 558 pts have been randomized from 26 in-
stitutions mainly located in Italy and Germany (average enrolment: 
19 patients/month). This is one of the pharmacogenomic-driven 
trial in the adjuvant setting in the European scenario.
Keywords: early stage, pharmacogenomic- driven, adjuvant thera-
py, non-small cell lung cancer
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P3.12-024 A MULTI-CENTER PHASE II RANDOMIZED 
STUDY OF CUSTOMIZED NEOADJUVANT THERAPY VS. 
STANDARD CHEMOTHERAPY (CT) IN NON-SMALL CELL 
LUNG CANCER (NSCLC) PATIENTS WITH RESECTABLE 
STAGE IIIA (N2) DISEASE (CONTEST TRIAL)
Francesco Grossi1, Erika Rijavec1, Giulia Barletta1, Carlo Genova1, 
Claudio Sini1, Maria Giovanna Dal Bello1, Giovanni Battista Ratto2, 
Mauro Truini3, Franco Merlo4
1Lung Cancer Unit, National Institute For Cancer Research/Italy, 2Tho-
racic Surgery, National Institute For Cancer Research/Italy, 3Pathology 
And Cytohistology Division, National Institute For Cancer Research/
Italy, 4Division Of Epidemiology And Biostatistics, National Institute 
For Cancer Research/Italy
Background: Stage IIIA NSCLC constitutes 30% of all NSCLCs. The 
most powerful prognostic factors identified in this stage are medi-
astinal lymph node clearance and a pathologic complete response 
(pCR). A pCR is obtained in 5-15% of patients (pts) with significant 
prolongation of survival. The identification of molecular biomar-
kers, such as excision repair cross-complementation 1 (ERCC1), 
ribonucleotide reductase subunit M1 (RRM1) and thymidylate syn-
thase (TS), may predict the response to CT. Similarly, EGFR muta-
tions may predict the response to EGFR inhibitors.
Methods: CONTEST, a multicenter (19 Italian centers), randomized 
(2:1), 2-arm, phase II study, will recruit pts with resectable stage IIIA 
(N2) NSCLC. Pts will be randomized to receive before resection 
either standard CT with cisplatin (CDDP) 75 mg/m2 + docetaxel 
(Doc) 75 mg/m2 on day (d) 1 q 21 d for 3 cycles (cys) or customized 
therapy using predetermined values for ERCC1, RRM1, TS and 
EGFR mutations. Specimens will be sent to Response Genetics 
(Los Angeles, CA, USA) for the evaluation of ERCC1, RRM1 and TS 
using RT-PCR and EGFR using Sanger sequencing. The customized 
arms are as follows: 
-EGFR+: Gefitinib 250 mg/d for 8 weeks. 
-EGFR-/non-squamous (NS)/TS-/ERCC1-: CDDP 75 mg/m2 + pe-
metrexed 500 mg/m2 d 1 q 21 d for 3 cys. 
-EGFR-/squamous (S) or NS TS+/ERCC1-/RRM1+: CDDP 75 mg/m2 
+ Doc 75 mg/m2 d 1 q 21 d for 3 cys. 
-EGFR-/S or NS TS+/ERCC1-/RRM1-: CDDP 75 mg/m2 d 1+ gemci-
tabine (Gem) 1250 mg/m2 d 1, 8 q 21 d for 3 cys. 
-EGFR-/S or NS TS+/ERCC1+/RRM1+: Doc 75 mg/m2 d 1 + vinorel-
bine 20 mg/m2 d 1, 8 q 21 d for 3 cys. 
-EGFR-/S or NS TS+/ERCC1+/RRM1-: Doc 40 mg/m2 y 1, 8 + Gem 
1200 mg/m2 d 1, 8 q 21 d for 3 cys. 
The primary end point is pCR, and all randomized pts will be com-
pared by treatment arm. Because pCR is a surrogate endpoint and 
given the expected proportion of pCRs in the control group (pc= 
5%), the minimal clinically worthwhile effect of this customized 
treatment is an increase to 20%. To detect such an effect at the 
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P3.13-001 COULD PRETREATMENT PET-CT STANDART 
UPTAKE VALUES HAVE A ROLE IN THE RESPONSE TO 
TREATMENT AND THE SURVIVAL IN PATIENTS WITH 
SMALL CELL LUNG CANCER?
Kubra Aydin1, Hatice Odabas1, Mesut Seker1, Taner Korkmaz1, 
Nurgul Yasar1, Nur Sener1, Dincer Aydin1, Ozlem Ercelep1, Sinemis 
Yuksel1, Aslihan G. Mert1, Mehmet Aliustaoglu1, Alpaslan Maya-
dagli1, Faysal Dane2, Mahmut Gumus1
1Medical Oncology, Kartal Dr.lutfi Kirdar Research And Training Hospi-
tal/Turkey, 2Medical Oncology, Marmara University Hospital/Turkey
Background: It is of great importance for treatment optimization 
to know before the initiation of treatment the different variables 
that may be used to help determine the result in the oncological 
diseases. It has been shown in preveious studies that have been 
performed that standard uptake values obtained in PET-CT carried 
out before the treatment in various cancer types enable us to make 
predictions regarding the tumor’s “aggressiveness”, response to 
treatment and survival. In this study, we researched the predictive 
role of pretreatment SU values of the patients with SCLC in deter-
mining the response to treatment and the survival.
Methods: Ninty patients were enrolled into this study, with whom 
we had follow-up in our center due to SCLC, and in whom pret-
reatment PET-CT was performed. The SU value of primary tumor 
was then determined. The relationship between these values and 
response to treatment is examined through ROC analysis and the 
cut-off value, effective and thus the determination to the response 
to treatment is identified. In the patient group, age, gender, stage, 
performance status, response to treatment, and effect of SU values 
upon response to treatment and survival are studied.
Results: Ninty patients were enrolled into the study. Median 
follow-up period is 11 (1-43) months, and the median age is 58 
(39-83). Ninety percent of patients are male and the diseases in 
37% of were noted to be of limited-stage. All patients received 
platinum+etoposide chemotherapy once every 21 days, as median 
amount of treatments to cure was 6 (3-7). When ROC analysis was 
carried out the SU value, suitable for determining the response, 
is found to be 10. The sensitivity of this value is found 85.7% (CI 
95%; 63-96), the specificity was found to be 61.8% (CI 95%; 49-
73) (AUC: 0.783; p: 0.0001). The overall response rate (complet 
response+partial response) is 59.1% in the other patients, while 
this rate is 93.3% in patients with involvement above the cut-off 
value(p:<0.0001). The response rates are higher in patients with 
age greater than or equal to 60 years old (p:0.047). No significant 
relationship is found between gender, stage and performance sta-
tus, and the response to treatment. In the survival analyses carried 
out, median disease-free survival is found to be 9 months (SE:1; 
95% CI: 8-10), and median general survival was determined to 
be 17 months (SE:3; 95% CI: 12-22). When single and multivariate 
analysis are carried out, the positive impact/effect of limited-stage 
disease and response to treatment upon the progression-free 
survival is determined (p<0.05). The fact that SU value is higher 
than cut-off value, affects the progression-free survival positively 
borderline (p:0.085). As a result, this is effective upon general sur-
were found, 2 (2.63%) were in the elder group and 3 (0.37%) were 
in the younger group. The overall 5-year survivals of the two 
groups were 64.9% and 76.9%, respectively (p = 0.015). Under 
multivariate analysis, male sex, extension of resecion, FEV1 and 
tumor T-status associated with poorer survival. Older than 80 
years old didn’t associated with difference in survival (p = 0.911). 
Conclusion: Octogenarians with pathological stage I NSCLC un-
derwent complete surgical resection had similar survival with their 
younger counterparts. Although they usually had poorer lung func-
tion, thus received more wedge resections or segmentectomies, 
aggressively performing surgical resectionon the elder ones would 
have similar benefits as on the younger ones.
Keywords: non-small cell lung cancer, stage I lung cancer,  
Octogenarians, resection
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loping brain metastases (median: 4 times, range: 2-7 times). The 
median intracranial control time of the 15 patients was 6.8 months. 
The median survival time of the 15 patients was 29.3 months after 
the initial diagnosis, 13.7 months after the development of brain 
metastases, and 12.7 months after the treatment of GKRS. The me-
dian survival time of the patients without extracranial lesions was 
20.2 months after the development of brain metastases and ten-
ded to be longer than that of the patients with extracranial lesions 
(12.6 months). Severe adverse events arising from GKRS were not 
observed in this series.
Conclusion: Stereotactic radiosurgery may be an effective option 
as a salvage therapy for brain metastases after PCI in patients with 
LD-SCLC.
Keywords: Small-cell lung cancer, brain metastases, prophylactic 
cranial irradiation, stereotactic radiosurgery
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P3.13-003 SURVIVAL OF PATIENTS WITH SMALL CELL 
LUNG CARCINOMA IN TAIWAN
Zhong-Zhe Lin1, Yu-Hsuan Kuo2, Yen-Yun Yang3, Yu-Yun Shao1, 
Wen-Yi Shau4, Raymond Nien-Chen Kuo5, James C. Yang1, Mei-Shu 
Lai6
1Oncology, National Taiwan University Hospital/Taiwan, 2Oncology, 
E-da Hospital/Taiwan, 3Center For Comparative Effectiveness Research, 
Clinical Trial Center, National Taiwan University Hospital/Taiwan, 
4Division Of Health Technology Assessment, Center For Drug Evalua-
tion (taiwan)/Taiwan, 5Taiwan Cancer Registry/Taiwan, 6Institute Of 
Preventive Medicine, College Of Public Health, National Taiwan Univer-
sity/Taiwan
Background: Small cell lung cancer (SCLC) is the most aggressive 
form of lung cancer. The prognosis for SCLC patients remains un-
satisfactory, despite advances in chemotherapy. In this study, we 
sought to clarify the prognosis and treatment patterns of patients 
with SCLC.
Methods: A cohort comprising all patients diagnosed with SCLC 
between Jan. 2004 and Dec. 2006 was assembled from the Taiwan 
Cancer Database. Patients were followed up until December 31, 
2009 to determine overall survival. Patient survival was estimated 
using the Kaplan-Meier method, and Cox’s proportional hazard 
model was used to determine the relationship between prognostic 
factors and median survival time.
Results: Among the 1684 patients diagnosed with SCLC, 1215 
(72%) were diagnosed with extensive stage, and 469 (28%) with 
limited stage. Most of the patients were male (90%). The median 
survival time of patients with limited-stage (LS) and extensive-
stage (ES) SCLC was 10.3 months and 5.6 months, respectively. For 
LS patients, surgery, chemotherapy, and combined chemotherapy 
and radiotherapy resulted in better survival than best supporti-
ve care (HR: 0.20, p<0.001; HR: 0.61, p<0.001; HR: 0.37, p<0.001 
respectively). For ES patients, male gender was significantly asso-
ciated with poor prognosis (HR:1.45, p<0.001) and chemotherapy 
was shown to improve overall survival more effectively than best 
supportive care (HR: 0.37, p<0.001).
Conclusion: For LS SCLC patients, surgery, chemotherapy, and 
combined chemotherapy and radiotherapy improved survival com-
vival, and studied using single and multivariate analysis. It is seen 
that only the response rates affect the general survival positively 
(p<0.05).
Conclusion: PET-CT is used in SCLC frequently for staging purpo-
ses. The data obtained in PET-CT may have a role in determining 
the prognostic characteristics of the disease as well as the respon-
se to treatment.
Keywords: small cell lung cancer, positron emission tomography, 
standart uptake value
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P3.13-002 STEREOTACTIC RADIOSURGERY FOR BRAIN 
METASTASES AFTER PROPHYLACTIC CRANIAL IRRADIA-
TION IN LIMITED DISEASE SMALL-CELL LUNG CANCER
Kuniko Sunami1, Hiroshi Nokihara1, Hidenori Mizugaki1, Satoru 
Kitazono1, Hidehito Horinouchi1, Shintaro Kanda1, Yutaka Fujiwa-
ra1, Noboru Yamamoto1, Yoshinori Ito2, Minako Sumi2, Tomohide 
Tamura1
1Department Of Thoracic Oncology, National Cacner Center Hospital/
Japan, 2Department Of Radiation Oncology, National Cancer Center 
Hospital/Japan
Background: Brain metastases are very common in patients with 
small-cell lung cancer (SCLC). Prophylactic cranial irradiation (PCI) 
has been shown to reduce the incidence of brain metastases and 
to improve overall survival in patients with limited-disease SCLC 
(LD-SCLC). However, brain metastases are often observed after 
PCI, and the optimal treatment for these brain metastases is still 
unclear. The present study investigated the recurrence of brain 
metastases after PCI in patients with LD-SCLC and the therapeutic 
efficacy of stereotactic radiosurgery for these metastases.
Methods: Between December 2000 and December 2012, 228 
patients with LD-SCLC were treated and 98 of these patients with 
a complete response (CR) or a near CR to chemoradiotherapy 
underwent PCI at the National Cancer Center Hospital. We retros-
pectively reviewed the medical records and imaging data for these 
98 patients.
Results: Twenty-four (24%) of the 98 patients developed brain 
metastases after PCI. The characteristics of the 24 patients were 
as follows: median age, 62 years (49-72 years), male/female, 21/3; 
performance status 0/1/2, 2/16/6. Twelve (50%) of the 24 patients 
had cranial recurrences only. Twelve patients had single brain 
metastases, and 12 patients had multiple lesions. Nine patients 
had neurological symptoms due to brain metastases. The median 
period after PCI until the appearance of the metastases was 9.9 
months (1.1-34.9 months). Fifteen (63%) of the 24 patients under-
went stereotactic radiosurgery (gamma knife radiosurgery [GKRS]), 
and one patient received whole brain radiotherapy. Six patients 
were treated with chemotherapy plus best supportive care (BSC), 
and two patients underwent BSC alone. The 15 patients who recei-
ved GKRS had brain metastases with/without extracranial lesions 
(7 with, 8 without); three were symptomatic, and 12 were asympto-
matic. The median number of brain metastases at the time of the 
first GKRS was one (range, 1-4). The local control rate of the lesions 
treated with GKRS was 86.7% (complete response in 3 patients, 
partial response in 7 patients, and stable disease in 3 patients). 
Five patients underwent further GKRS because of newly deve-
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P3.13-005 CONVERT - THE CHALLENGES OF OPENING 
CENTRES AND RECRUITING PATIENTS TO AN INTERNA-
TIONAL MULTI-CENTRE CHEMO-RADIOTHERAPY TRIAL 
IN LIMITED-STAGE SMALL CELL LUNG CANCER
Corinne Faivre-Finn1, Linda Ashcroft1, Andrea Bezjak2, Adityan-
arayan Bhatnagar3, Felipe Cardenal4, Sally Falk1, Pierre Fournel5, 
Nicki Groom6, Susan Harden7, Cecile Le Pechoux8, Paul Lorigan1, 
Rhona Mcmenemin9, Nazia Mohammed10, Mary O’Brien11, Laetitia 
Padovani12, Michael Snee13, Veerle F. Surmont14, Elena Wilson15, 
Fiona Blackhall1
1The Christie NHS Foundation Trust/United Kingdom, 2Princess Mar-
garet Hospital/Canada, 3Southampton General Hospital/United King-
dom, 4Duran I Reynals Hospital – Catalan Institute Of Oncology/Spain, 
5Institut De Cancerologie De La Loire/France, 6Mount Vernon Cancer 
Centre/United Kingdom, 7Addenbrooke‘s Hospital/United Kingdom, 
8Institut Gustave Roussy/France, 9Northern Centre For Cancer Care, 
Freeman Hospital/United Kingdom, 10Beatson Cancer Centre/United 
Kingdom, 11The Royal Marsden Hospital/United Kingdom, 12Chu De 
Marseille/France, 13St James‘s Hospital/United Kingdom, 14Ghent Uni-
versity Hospital/Belgium, 15Royal Free Hospital/United Kingdom
Background: CONVERT is a multicentre, randomised, phase III 
trial open in Europe and Canada in limited-stage small cell lung 
cancer. Patients are randomised to twice (45 Gy in 30 fractions) or 
once-daily radiotherapy (66 Gy in 33 fractions) given concurrently 
with 4-6 cycles of chemotherapy. This study is funded by Cancer 
Research UK and involves centres from the UK NCRI, the ‘Grou-
pe Francais de Pneumo-Cancerologie’, the Spanish Lung Cancer 
Group, the EORTC and NCIC CTG.
Methods: To identify and review the challenges in site set-up. To 
review time taken from site initiation to first patient randomised, 
number of centres opened that included 0-2 patients and number 
of centres that recruited the majority of all patients.
Results: In June 2013, 519/532 patients had been recruited in 9 
countries; 299 from 32 UK centres, 100 from 17 French centres, 
39 from 9 Canadian centres, 27 from 6 Spanish centres, 26 from 
3 Belgian centres, 13 patients from 1 centre in Slovenia, 9 from 2 
centres in The Netherlands and 6 patients from 1 centre in Poland. 
Figure 1 shows the number of centres open and patients recruited. 
96 sites are currently open to recruitment (5 sites opened in 2008, 
34 in 2009, 31 in 2010, 17 in 2011, 8 in 2012 & 3 in 2013, 2 sites 
subsequently closed early) of which 74 (77%) have randomised at 
least 1 patient. 24 sites (25%) recruited only 1 or 2 patients. 10 sites 
have recruited 49% of the total number of patients with a single 
site recruiting 18.5% of all patients randomised. Time taken from 
site initiation to 1st patient randomised ranged from 0–1029 days 
with a median of 144 days. Time taken to complete the QA exer-
cise from initial information sent to site ranged from 14-1181 days 
with a median of 290.5 days. 
pared to best supportive care. ES SCLC patients benefited more 
from chemotherapy treatment than best supportive care.
Keywords: small cell lung cancer, Prognosis, chemotherapy, radio-
therapy
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P3.13-004 A MULTICENTER PHASE II STUDY OF BELOTE-
CAN, A NEW CAMPTOTHECIN ANALOGUE, IN ELDERLY 
PATIENTS WITH PREVIOUSLY UNTREATED, EXTENSIVE-
STAGE SMALL CELL LUNG CANCER
Chang Dong Yeo1, Si Young Choi2, Sang Haak Lee3
1Pulmonology, Internal Medicine, Uijeongbu St.mary‘s Hospital/Korea, 
2Thoracic And Cardiovascular Surgery, Uijeongbu St. Mary’s Hospital, 
The Catholic University Of Korea, College Of Medicine/Korea, 3St.paul‘s 
Hospital/Korea
Background: Belotecan is a new camptothecin analogue and a 
potent topoisomerase I inhibitor. The aim of this phase II study was 
to investigate the efficacy and toxicity of belotecan in previously 
untreated elderly patients with small cell lung cancer (SCLC).
Methods: A total of 26 patients, aged ≥65 years, with previously 
untreated, extensive-stage SCLC were enrolled in the study. Belo-
tecan was administered by daily intravenous infusion at 0.5 mg/m2/
day for 5 consecutive days every three weeks.
Results: The overall response rate and disease control rate of 
chemotherapy on an intention-to-treat basis were 35% and 54%, 
respectively. The median overall survival was 6.4 months, and the 
median time to progression was 2.8 months. The most common 
toxicity was hematologic. Grade 3 or 4 neutropenia occurred in 
80.8% of patients, and grade 3 or 4 thrombocytopenia in 15.3%. 
Non-hematologic toxic effects of grade 3 or 4 were uncommon.
Conclusion: Belotecan had modest efficacy and well-tolerated 
toxicity in previously untreated, elderly SCLC patients. Single belo-
tecan could be a promising treatment option, considering its lower 
toxicity in elderly patients who are unsuitable candidates for plati-
num plus etoposide chemotherapy.
Keywords: belotecan, Elderly patients, small cell lung cancer
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the National Cancer Institute.
Results: 50 patients (29 male and 21 female) were included with 
a median (range) age of 67 years (46-82). The majority of patients 
had an Eastern Cooperative Oncology Group performance status 
of 1; median time off first-line treatment was 12 weeks. Average 
number of treatment cycles was 4 (range 1-6). Evaluable for res-
ponse and toxicity were 45 and 48 patients, respectively. A com-
plete response was achieved in 1 patient, a partial response in 24 
patients, stable disease in 16 patients, and progressive disease in 
4 patients (RR 73.5%; 95% confidence interval, 59 to 88). Median 
time to progression was 133 days (range 89-177). Median overall 
survival was 198 days (range 77-322). One-year survival rate was 
34%. Hematologic toxicity grade 3 and 4 was leukopenia 19% 
and 8%, thrombocytopenia 10% and 2%, and anemia 4% and 0%, 
respectively, in a total of 186 cycles. Nonhematologic toxicity was 
diarrhea grade 3-4 (15%), stomatitis grade 3 (4%) and hyponatrie-
mia grade 3 and 4 in one patient each. Seven patients were hospi-
talized due to neutropenic fever; no toxic deaths occurred.
Conclusion: Second-line DC in refractory or relapsing SCLC pa-
tients yielded a high RR and toxicity was relatively mild in these 
poor-prognosis patients. NCT00686985
Keyword: SCLC, second line, chemotherapy
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P3.13-007 PILOT TRIAL OF AN ADJUVANT PENTAVA-
LENT VACCINE FOR PATIENTS WITH SMALL CELL LUNG 
CANCER (SCLC)
Lee M. Krug1, Anna Varghese1, Govind Ragupathi2, Constantine 
George2, Ritsuko Sawada3, Wolfgang W. Scholz3, David Hansen3, 
Philip O. Livingston3, Lukas Delasos1, Maria C. Pietanza1
1Department Of Medicine, Thoracic Oncology Service, Memorial Sloan-
Kettering Cancer Center/United States Of America, 2Memorial Sloan-
Kettering Cancer Center/United States Of America, 3Mabvax Therapeu-
tics/United States Of America
Background: Despite initial responses to chemotherapy, SCLC 
typically progresses within a few months. Targeting residual di-
sease has the potential to improve outcomes. A number of tumor 
specific glycolipid antigens have been identified and are potential 
targets for immune therapies. In a series of phase I clinical trials, 
vaccination with each of these antigens individually was safe and 
induced antibody responses in the majority of patients. Preclinical 
data indicate that combining these antigens will expand the immu-
nogenicity across a broader array of SCLC tumor cells. We conduc-
ted this pilot trial to determine the safety and immunogenicity of a 
vaccine combining five of these antigens.
Methods: Patients with limited or extensive stage SCLC who have 
completed initial chemotherapy +/- thoracic or cranial irradiation 
with a maintained response are eligible. Vaccinations must start 
within 3-8 weeks of the last chemotherapy, and at least 1 week 
after radiation. Patients receive KLH-conjugates of GD2L, GD3L, 
Globo H, fucosyl GM1, and N-propionylated polysialic acid (30mcg 
each) plus OPT-821 adjuvant (150mcg) subcutaneously on weeks 1, 
2, 3, 9, 20, and 32. One cycle of etoposide/platinum chemotherapy 
was administered in week 6. A significant immune response is defi-
ned as an antibody titer of ≥ 1:80 by ELISA against a given antigen 
or a ≥ 8 fold increase over baseline for patients with a detectable 
Conclusion: Recruitment to an academic trial in LS-SCLC is a chal-
lenge but accrual has improved considerably since 2008. This can 
be directly related to the increasing number of sites opened to re-
cruitment. Duration of site set-up and completion of the QA exer-
cise are factors explaining slower than anticipated accrual rates 
particularly between 2008 and 2010. We anticipate that the study 
will close to recruitment in July 2013. International participation 
has been a key factor to the success of the trial and the experience 
gained will be of value to the design of future radiotherapy studies 
to ensure target accrual.
Keywords: chemo-radiotherapy, small cell lung cancer, clinical trial
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P3.13-006 DOCETAXEL-CARBOPLATIN (DC) AS SECOND 
LINE TREATMENT IN PATIENTS WITH SMALL CELL LUNG 
CANCER (SCLC): A PHASE II STUDY.
Sunit Van Riel1, Franz M.N.H. Schramel2, Hans J.M. Smit3, Nico C. 
Van Walree4, Harry J.M. Groen5, Ad J.M. Schreurs1, Bonne Biesma1
1Dept Of Pulmonology, Jeroen Bosch Ziekenhuis/Netherlands, 2Dept Of 
Pulmonology, St. Antonius Ziekenhuis/Netherlands, 3Dept Of Pulmono-
logy, Rijnstate Ziekenhuis/Netherlands, 4Dept Of Pulmonology, Amphia 
Ziekenhuis/Netherlands, 5Dept Of Pulmonology, UMC Groningen/
Netherlands
Background: Patients with relapsing SCLC have a poor prognosis 
and options for treatment are limited. Paclitaxel in combination 
with platinum has demonstrated activity in first and second-line 
treatment. We conducted a phase II study to investigate the anti-
tumor activity and safety profile of Docetaxel/Carboplatin (DC) in 
patients with refractory or relapsing SCLC.
Methods: SCLC patients who were refractory to or relapsed after 
first-line treatment and who did not receive platinum based che-
motherapy within the 3 months before inclusion, were treated with 
Docetaxel (75 mg/m2, day 1 iv) followed by Carboplatin (area under 
the curve 6, day 1 iv.) once every 3 weeks for 4-6 cycles. Primary 
endpoint was response rate (RR) and secondary endpoints were 
time to progression (TTP), overall survival (OS) and safety profile. 
Tumor response was measured according to RECIST version 1.1. 
Toxicity was evaluated according to Common Toxicity Criteria of 
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providing more substages. Slightly better survival of stage IV SCLC 
than that of stage IIIB in the 7th edition is related to malignant pleu-
ral effusion.
Keywords: survival, Lung cancer, staging
baseline titer. The vaccine would be deemed worthy of further stu-
dy if >5 patients had an immune response to 3 or more antigens.
Results: Ten patients were treated, including 9 with extensive sta-
ge, 4 women, 7 with prior brain radiation. The number of vaccina-
tions administered was: 1 (1pt), 3 (2), 4 (3), 5 (2), and 6 (2). Toxicity 
was limited to mild skin reactions. One patient was taken off study 
after he developed aphasia the day after the first vaccination; MRI 
brain was unremarkable and symptoms resolved spontaneously. 
No patients met the predefined criteria for immune response. Six 
patients had increases in IgM titers to 1-2 antigens. The median 
time to progression was 4 months. The two patients with the stron-
gest IgM responses to Globo H and fucosyl GM1, and also the only 
IgG responses to fucosyl GM1, had progression of disease 7 and 9 
months after starting the vaccines, and both progressed initially in 
the brain only.
Conclusion: The polyvalent vaccine is safe, but fewer patients than 
expected had a significant immune response, Two patients with 
immune responses experienced a longer than expected time to 
progression. A second cohort of patients is now receiving the vac-
cinations over a shorter period of time and without the added cyc-
le of chemotherapy. Five out of 10 of those patients have been en-
rolled, and preliminary data will be available on those patients for 
the meeting. Following completion of this pilot trial, a multicenter 
randomized trial is planned. Supported by MabVax Therapeutics’s 
NIH grant R41 CA128363 and a grant from FAMRI.
Keywords: small cell lung cancer, vaccine, immunotherapy
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P3.13-008 LONG-TERM SURVIVAL OF 187 PATIENTS 
WITH SMALL CELL LUNG CANCER BASED ON THE AJCC 
6TH AND 7TH TNM EDITION
Yon Mi Sung, Eun Kyung Cho
 gachon University Gil Medical Center/Korea
Background: The AJCC 7th TNM staging system is recommended 
for both non-small cell and small cell lung cancer (SCLC), although 
SCLC has traditionally been classified using the limited and exten-
sive definition. We evaluated long-term survival of patients with 
SCLC according to the AJCC 6th and 7th TNM edition.
Methods: 239 patients had been pathologically diagnosed with 
SCLC from January 2000 through December 2009 in our hospital. 
We included 187 patients who had initial CT scan of the thorax. We 
analyzed all available data for TNM staging using the AJCC 6th and 
7th edition as well as the long-term survival rates.
Results: According to stages defined by the 6th TNM edition sys-
tem, 5-year stage-specific survivals (5-YSR) were 43% for stage I 
and II, 36% for stage IIIA, 10% for stage IIIB, and 7% for stage IV. 
Applying the 7th edition system, 5-YSR were 46% for stage I and 
II, 24% for stage IIIA, 7% for stage IIIB, and 9% for stage IV. Using 
the 7th edition, 5-YSR of the stage IV was higher than that of stage 
IIIB. The number of changed stage from IIIB in the 6th edition to IV 
in the 7th edition was 22 and all were related to malignant pleural 
effusion.
Conclusion: Application of the TNM staging to SCLC stratifies 
survival more distinctly than limited and extensive definition by 
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fusions, may help to better predict the outcome of patients with 
SFTP.
Keywords: chemotherapy, pleura tumor, Classification of De per-
rot, solitary fibrous tumors
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P3.14-002 SECOND LINE- CHEMOTHERAPY TREATMENT 
OPTIONS, IN MALIGNANT MESOTHELIOMA TUMORS, 
RESISTANT TO PEMETREXED.
Konstantinos N. Syrigos, Antonios Vassias, Georgios Tsironis, 
Anastasios Boufas, Ioannis Ntanos, Alexandra Kopitopoulou, Io-
annis Gkiozos
Oncology Unit Gpp, Sotiria General Hospital/Greece
Background: The number of patients with Malignant Mesothe-
lioma is expected to increase over the next ten years from the 
number of 3.300 new cases that are reported annually nowadays. 
Most of the patients appear with advanced, surgically unresecta-
ble disease at the time of diagnosis and relapse is usual after the 
standard 1st line treatment with a platinum-pemetrexed doublet, 
due to intrinsic and acquired resistance to pemetrexed. This review 
focuses on the treatment options in Malignant Mesothelioma resis-
tant to pemetrexed and is based on trials for possible 2nd line re-
gimens tested the last ten years and ongoing trials of novel agents 
and studies exploring the basis of pemetrexed resistance.
Methods: We searched via PubMed/Medline, Clinicaltrials.gov and 
American Society of Clinical Oncology databases for articles and 
ongoing trials published until 1/2013 using the term: “mesothelio-
ma”, in association with “2nd line chemotherapy”, “pemetrexed 
resistance”, “relapsed”, “pemetrexed-pretreated” and “biomar-
ker”. Primary sources have been quoted.
Results: Data from forty eight conducted and ongoing trials, main-
ly phase II, single-armed, but also retrospective and phase III, are 
shown and discussed. Thirty different agents were tested in these 
trials as possible 2nd line drugs for Malignant Mesothelioma. Cur-
rently, no guidelines for 2nd line chemotherapy in Malignant Meso-
thelioma tumors resistant to pemetrexed are available.
Conclusion: In the absence of a “gold standard” as 2nd line treat-
ment for Malignant Mesothelioma, results of ongoing trials are 
eagerly awaited and the research for novel agents remains critical. 
Furthermore, additional research should be done towards the 
understanding of the mechanisms that lead to pemetrexed resis-
tance, the possible personalization of 1st and 2nd line treatment 
and the use of biomarkers that can be used as factors predicting 
the resistance itself. Finally, more patients should be convinced to 
enroll in clinical trials and more randomized trials have to be con-
ducted.
Keywords: biomarker, relapse, pemetrexed
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P3.14-001 ASSESSING THE ROLE OF CHEMOTHERAPY 
FOR SOLITARY FIBROUS TUMORS OF THE PLEURA IN A 
ROUTINE PRACTICE SETTING
Olivier Bylicki1, Damien Rouviere2, Philippe Cassier3, Jacques Mar-
gery4, Alice Levard3, Jean-Michel Maury5, Lara Chalabreysse6, Juli-
en Mazieres2, Jean-Yves Blay3, Nicolas Girard7
1Pulmonary Department, Hopital D’instruction Des Armées Desgenet-
tes/France, 2Respiratory Medicine Service, Hôpital Larrey, Chu De Tou-
louse, Université De Toulouse Iii (paul Sabatier)/France, 3Department 
Of Medicine, Leon Bérard Cancer Center/France, 4Respiratory Medicine 
Department, Percy Military Hospital/France, 5Department Of Thoracic 
Surgery, Hopital Louis Pradel/France, 6Pathology Department, Louis 
Pradel Hospital, Hospices Civils De Lyon/France, 7Respiratory Medicine 
Service, Louis Pradel Hospital, Hospices Civils De Lyon/France
Background: Solitary Fibrous Tumors of the Pleura (SFTP) refer as 
to a heterogeneous group of mesenchymal malignancies with va-
rious anatomic and histologic features. Upfront surgical resection 
is the standard approach, but the outcome of patients is unpre-
dictable. Recurrences may be aggressive and difficult to treat.The 
most widely accepted staging system has been proposed by De 
Perrot et al., and is based on the anatomy of the tumor implantati-
on (sessile/pedunculated), and the presence of histologic signs of 
aggressiveness, including cellularity with crowding and overlap-
ping of nuclei, cellular pleomorphism, high mitotic count, necrosis, 
or stromal/vascular invasion. Given the rarity of the tumor, limited 
evidence is available about the role and the modalities of periope-
rative and definite chemotherapy for SFTP.
Methods: Multicenter retrospective study of patients (pts) with 
histologically-proven SFTP with complete follow-up from surgical 
diagnostic to tumor recurrence and death.
Results: 68 pts (28 males/40 females) were included. Median age 
at diagnosis was 62 year-old. Tumor stage according to the De 
Perrot system was 0/I for 29 pts, II for 23 pts, III for 7 pts, and IV for 
4 pts. Adjuvant chemotherapy was given to 7 patients, mostly with 
stage III/IV SFTP, consisting of doxorubicin-based regimen. Re-
currence rate and median time-to-progression (TTP) after surgery 
were 3%, 52%, 71%, and 75% (p<0.001), and 107, 70, 29, 11 months 
(p=0.006) for stage 0/I, II, III, and IV tumors, respectively. Besides 
tumor stage, predictors of shorter TTP were incomplete resection 
(p<0.001) and a higher number of histologic signs of malignancy 
(p=0.009). At time of tumor recurrence, 12 pts received chemothe-
rapy. Highest disease control rates were observed with trabecte-
dine (7/9 pts; Disease Control Rate (DCR): 78%; median TTP: 3,4 
months), and gemcitabine-dacarbazine combination (2/3 pts, DCR: 
66%; median TTP: 1,9 months). Median overall survival of the whole 
cohort was 56 months.
Conclusion: This study 1) confirms the prognostic value of the De 
Perrot staging system, 2) indicates a high recurrence rate in pati-
ents with stage II tumors, for which perioperative chemotherapy 
may be considered, and 3) suggests an interest for trabectedine in 
the setting of recurrent tumors. Besides clinical data, further mo-
lecular characterization, including recently identified specific gene 
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Conclusion: Several VOCs of interest were obtained in the breath 
of MPM patients. Two peaks were significantly discriminating bet-
ween both populations. GC-MS analysis and further large cohort 
studies are ongoing in order to validate the accuracy of IMS as a 
diagnostic tool for MPM.
Keywords: mesothelioma, biomarker, breath analysis, ion mobility 
spectrometry
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P3.14-004 ADJUVANT HEMITHORACIC RADIOTHERAPY 
AFTER EXTRAPLEURAL PNEUMONECTOMY FOR MA-
LIGNANT PLEURAL MESOTHELIOMA: EXPERIENCE AT 
THE SYDNEY CANCER CENTRE
Andrej Bece1, Mo Mo Tin1, Brian Mccaughan2, Michael Boyer3, Dar-
ren A. Martin1, Jocelyn Mclean2, Robert H. Lin4
1Department Of Radiation Oncology, Royal Prince Alfred Hospital/Aus-
tralia, 2Cardiothoracic Surgery, Royal Prince Alfred Hospital/Australia, 
3Medical Oncology, Sydney Cancer Centre/Australia, 4Medica Oncology/
Australia
Background: Radiotherapy reduces local recurrence following 
extrapleural pneumonectomy (EPP), and forms part of a potentially 
curative, multimodality treatment of malignant pleural mesothelio-
ma. Hemithoracic radiotherapy poses a significant dosimetric chal-
lenge. Conventional techniques have suffered with marked dose 
uncertainty, while modern IMRT techniques have been associated 
with increased pulmonary toxicity. We conducted a retrospective 
review of all patients referred to our institution for hemithoracic 
radiotherapy following EPP, with the aim of assessing treatment 
toxicity and outcomes. The present study is, to our knowledge, the 
largest Australian series of adjuvant radiotherapy for this disease.
Methods: 53 patients were referred following EPP for malignant 
pleural mesothelioma, with or without neoadjuvant chemotherapy, 
between 2004 and 2012. 4 patients were excluded or did not com-
mence radiotherapy due to poor performance (n = 3) or disease 
progression (n = 1). Radiotherapy involved a 3D conformal, mixed 
photon and electron technique, delivering 45-55 Gy in 25-28 frac-
tions (2004-2009, n=31), and a 9-field IMRT technique, delivering 
50.4-60 Gy in 28-30 fractions (2009-2012, n=18). We assessed 
toxicity, disease progression and survival in all patients who com-
menced radiotherapy (n = 49). Toxicity was assessed using the 
Common Terminology Criteria for Adverse Events version 4.0 and 
survival was calculated from the date of EPP using the Kaplan-
Meier method.
Results: 31 patients (59%) received neoadjuvant chemotherapy, 
with a combination of platinum agent and pemetrexed. 41 patients 
(84%) completed treatment as prescribed. 6 patients stopped pre-
maturely due to toxicity, and 2 due to disease progression. Most 
patients discontinuing due to toxicity (n = 5) received over 90% 
of the prescribed dose. Low grade nausea, anorexia and fatigue 
were near universal, however severe (grade 3) skin toxicity, nausea 
and oesophagitis were 8%, 6% and 2%, respectively. One patient 
developed a grade 4 Pneumocystis carinii infection, however there 
were no cases of radiation pneumonitis. Late toxicities were rare, 
with the exception of a persistent elevation in the liver enzymes 
alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT). 
Of the patients treated with right-sided disease (n = 26), 9 (35%) 
developed grade 2-3 elevations in ALP or GGT. Grade 2-3 liver 
POSTER SESSION 3 - MESOTHELIOMA  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.14-003 VOLATILE ORGANIC COMPOUNDS AS DIAG-
NOSTIC TOOL FOR MALIGNANT PLEURAL MESOTHE-
LIOMA.
Kevin Lamote1, Joris Van Cleemput2, Kristiaan Nackaerts3, Jan P. 
Van Meerbeeck4
1Respiratory Medicine, Ghent University Hospital/Belgium, 2Occup-
ational Health Service, Eternit Nv/Belgium, 3Respiratory Medicine, 
University Hospital Gasthuisberg/Belgium, 4Thoracic Oncology / Moca, 
Antwerp University Hospital/Belgium
Background: Early diagnosis of malignant pleural mesothelio-
ma (MPM) can improve patients’ outcome but is hampered by 
non-specific symptoms and investigations, which delay diagnosis 
and result in advanced stage disease [van Meerbeeck JP, 2011]. 
An accurate non-invasive test allowing early stage diagnosis in 
asbestos-exposed persons is lacking. Breathomics aims at a non-
invasive analysis of volatile organic compounds (VOCs) reflecting 
the cells’ metabolism. The breathogram obtained by the electronic 
nose does however, not allow identification of MPM-related VOCs 
[Chapman EA 2009, Dragonieri S 2011]. Ion mobility spectrometry 
(IMS) combines the advantages of online direct sampling with the 
possibility of VOC identification and liNKIng to MPM pathogenesis 
[Baumbach JI 2009]. We investigated which VOCs could play a role 
in MPM pathogenesis in order to build a possible diagnostic MPM 
tool.
Methods: 10 MPM patients and 10 healthy asbestos-exposed 
individuals (mean asbestos fiberyear count 14,6 (5,5) fibre.years/cc) 
were included after refraining from eating, driNKIng and smoking 
for at least 2 hours before sampling. They breathed tidally for 3 
minutes through a mouthpiece connected to a bacteria filter. Ten 
ml alveolar air was sampled via a CO2-controlled ultrasonic sensor 
and analyzed using the BioScout Multicapillary Column/Ion Mobi-
lity Spectrometer (MCC/IMS, B&S Analytik, Dortmund, Germany) 
[Westhoff M 2009], by using N2 as a carrier gas. Per subject a back-
ground sample was taken. Peaks of interest were visually selected 
and their intensity (V) was analyzed and compared between back-
ground and breath samples via on-board VisualNow 3.2 software 
and SPSS v21 (IBM) using Mann-Whitney-U tests.
Results: Out of 41 peaks of interest, three show a significantly hig-
her intensity in the exhaled breath of MPM patients than healthy 
controls [Table]. The high AUCROC of resp. P12 (0.877) and P24 
(0.863) suggests a possible role of these associated VOCs in MPM 
pathogenesis and as a diagnostic marker in discriminating MPM 
patients from asbestos-exposed healthy controls. 
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improved enjoyment of life. The support group is an important link 
between long term survivors, those currently being treated and a 
valuable resource for new patients deciding about EPP.
Keywords: EPP, support group, well living programme, survivors
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P3.14-006 RADIOTHERAPY FOR THE TREATMENT OF 
PAIN IN MALIGNANT PLEURAL MESOTHELIOMA: A SYS-
TEMATIC REVIEW
Nick J. Macleod1, Noelle O‘Rourke2, Marie Fallon3, Allan Price4, 
Barry Laird3
1Clinical Oncology, Beatson/United Kingdom, 2Beatson Cancer Centre/
United Kingdom, 3Edinburgh Palliative And Supportive Care Group, 
Edinburgh Cancer Research Centre/United Kingdom, 4Clinical Oncology, 
Edinburgh Cancer Research Centre/United Kingdom
Background: To examine the evidence base for radiotherapy in 
the treatment of pain in malignant pleural mesothelioma.
Methods: A systematic search of the Medline (1946-2013), Emba-
se (1974-2013) and Central (The Cochrane Library Issue 9, 2012) 
databases was performed looking for studies which evaluated the 
role of radiotherapy for pain relief in people with malignant pleural 
mesothelioma (MPM). Studies were included if MPM was radiologi-
cally or histologically diagnosed, radiotherapy was given with the 
intent of improving pain and response rates to radiotherapy were 
reported. Documentation of the dose and fractionation of radio-
therapy that was given was required. Finally, the study must have 
explored the relationship between radiotherapy and pain respon-
se. Systematic reviews were ineligible.
Results: Nine studies were eligible. There was marked hetero-
geneity among studies so quantitative synthesis of results was not 
possible. The most recent study reported a clinical response rate 
of 54% two weeks after radiotherapy given at a dose of 36 Gray 
(Gy) in 12 fractions. This was targeted at the area of MPM that was 
felt to be causing the pain. However, this assessment was perfor-
med retrospectively. A radiological response of 43% measured via 
CT scanning two months after irradiation was also reported in this 
study. Another study reported a superior response rate (50%) for 
those treated with a 4 Gy fraction size compared with those trea-
ted with a fraction size of less than 4 Gy (39%). However, this was 
not randomised and reflected a change in policy to treat sites of 
symptomatic disease only rather than covering the entire volume 
of disease. A further study suggested a benefit to hemi-thoracic 
irradiation at a dose of 30 Gy in 10 fractions. However, Cobalt ma-
chines were used in this study. Another study suggested no bene-
fit to hemi-thoracic irradiation at a dose of 40 Gy in 20 fractions. 
However, 27 of the 47 patients in this study had no pain at study 
baseline. The other studies in this review report varying response 
rates, primarily reported in a retrospective fashion.
Conclusion: There are no high quality data to support the use of 
radiotherapy for pain management in MPM. Studies focusing on 
clear pain endpoints, improving target delineation and delivering 
higher equivalent doses using modern day radiotherapy are nee-
ded. Biomarkers which may predict response in a proportion of 
patients should be sought.
Keywords: pain, radiotherapy, mesothelioma
toxicity was more common in patients treated with a conventional 
technique (53%) than with IMRT (11%). No patients developed cli-
nical hepatitis. With a median follow up of 19 months (range 2-102 
months), median progression-free survival and overall survival were 
22 and 30 months, respectively. 2-year overall survival was 53.8%. 
7 patients (14%) were alive beyond 5 years.
Conclusion: Hemithoracic radiotherapy can be safely delivered 
in selected patients following EPP. Although associated with sig-
nificant early toxicity, most patients complete treatment and late 
toxicity is uncommon. Our outcomes compare favourably with 
recently-published international series.
Keywords: radiotherapy, Extrapleural pneumonectomy, trimodali-
ty therapy, mesothelioma
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P3.14-005 INTEGRATING A WELL LIVING PROGRAMME 
INTO A SUPPORT GROUP FOR EPP SURVIVORS AND 
CARERS
Jocelyn Mclean1, Patricia Douglas2, Jane Burger2, Jane Turner3, 
Brian C. Mccaughan1
1Royal Prince Alfred Hospital/Australia, 2Strathfield Private Hospital/
Australia, 3Sydney University/Australia
Background: A brief review of the quality of life of one group of 
survivors and carers identified that after EPP the most common 
symptoms affecting quality of life were fatigue, dyspnoea, insom-
nia and pain. Survivors struggled to return to normal levels of soci-
al and role functioning. Interviews also identified the need to share 
stories with others survivors. In response to this information a well 
living programme was integrated into an EPP survivor support 
group. The aim being: to provide information and develop skills to 
empower survivors and carers to react and improve their quality of 
life; to optimize the physical, emotional, and social functioning of 
survivors; and, to assist carers to perform their role while remaining 
mindful of their own care need.
Methods: Four 1 day support / well living meetings were held 
during 2012. Each involved invited speakers, fitness assessments 
(6-minute walk test), and time allocated for networking over food 
and beverages. Topics included: optimizing living with one lung, 
physical and respiratory assessments, exploring survivor and carer 
experiences, mindfulness healing, exploring survivor and carer 
resilience, creating opportunities for self-attention and nurturing, 
relating science to the living experience, pain management, wri-
ting and music for healing, eating for wellbeing and a goal for 
2013. Physiotherapy staff contributed regularly to the meetings.
Results: The average meeting attendance was 20 participants 
consisting, of 50% survivors and 50% carers. Patients responded 
positively to the physical challenges and set their 2013 goal as 
participation in a community 7 Km fun walk – The Sydney Bay Walk 
in August. In 2013, an exercise physiologist has worked individually 
with some group members, either face-to-face or via telephone. 
This encouraged increased aerobic and resistance training. A num-
ber of survivors report improvements in overall fitness, enjoyment 
of daily living and satisfaction with life.
Conclusion: There appears to be consistent changes in partici-
pant confidence, and attitude toward physical fitness leading to 
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Conclusion: ACT of mRNA engineered CART-meso cells is feasible 
and safe from the perspective of off target toxicity due to low level 
mesothelin expression in normal tissues. mRNA engineered T cells 
can be used to evaluate potential issues of off-target CAR-media-
ted toxicity and support the development of CAR-based strategies 
to target mesothelin.
Keywords: mesothelioma, tumor immunology, chimeric antigen 
receptor, immunotherapy
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P3.14-008 RESECTION AND HEATED PLEURAL CHE-
MOPERFUSION FOR EPITHELIOID MALIGNANT PLEU-
RAL MESOTHELIOMA; A SINGLE CENTER EXPERIENCE
Ronny Ben Avi, David Simansky, Nona Zeitlin, Merav Rokah, Alon 
Ben Nun, Alon Yellin
Thoracic Surgery, Tel Hashomer Medical Center/Israel
Background: Patients with malignant pleural mesothelioma (MPM) 
may be treated aggressively by a multimodality approach inclu-
ding radical resection with a curative intent. Yet, a large proportion 
of them fail locally. One of the measures to reduce local relapse is 
heated pleural chemoperfusion (HPCP) with platinum based com-
pounds. We report the results of a combined treatment consisting 
of resection and HCPC in patients with epitheloid MPM (EMPM).
Methods: A single center retrospective study of 48 patients with 
EMPM scheduled for the combined approach over a 16 years pe-
riod. Surgery consisted of extrapleural pneumonectomy (EPP), or 
lesser resections (LR), followed by HPCP with cisplatinum, 100mg/
m2 at >42oC for 60 min. Survival analysis was done with the Kaplan-
Meier method and comparisons between groups with chi square 
analysis.
Results: Of the 48 pts only 42 had both resection and perfusion. 
Operative mortality was 6.2%; all fatalities occurring after EPP. 
There was no toxicity. EPP was performed in 72% of advanced 
stage (AJCCS III+IV) compared to 54% in early stage (AJCCS I+II) 
disease (p=0.238). Major and minor morbidity were 8(27%) and 
9(32%) Vs. 2(16%) and 3(25%), for EPP and LR respectively. The 
Overall median survival was 14.6 (11.1-18.2, CI-95%); 13.4 months 
(3.4-23.5, CI-95%) and 28.3 (7.7-48.9, CI-95%) months for EPP and 
LR respectively (p=0.079). Patients undergoing EPP+HPCP for ad-
vanced stage EPMP (n=21) had a median survival of 21.6 months 
(2.0-43.0, CI-95%). Local control was achieved in 87.5% of the EPP 
group and 42% of the LR group (p<0.007). The common sites of 
relapse or progression were ipsilateral pleura (n=9), contralateral 
pleura (n= 7) and peritoneum (n=5). Early stage disease (I+II) had a 
survival not significantly better then late stage disease (III+IV).
Conclusion: In a center with low-volume surgery for mesothelioma, 
resection and HPCP can be performed with acceptable mortality 
and morbidity and no toxicity. In EMPM, HPCP does not reduce 
local relapse after resections lesser than EPP. In advanced stage 
EMPM, EPP coupled with HCPC seems to reduce the rate of local 
relapse, and may contribute to a relatively long survival. The role of 
HCPC in conjunction with surgery should be further investigated. 
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P3.14-007 CHIMERIC ANTIBODY RECEPTOR (CAR) 
AUGMENTED ADOPTIVE T CELL THERAPY (ACT) FOR 
PATIENTS WITH PROGRESSIVE MALIGNANT PLEURAL 
MESOTHELIOMA (MPM)
Edmund K. Moon, Michael Kalos, Marcela V. Maus, Yangbing Zhao, 
Bruce L. Levine, Steven M. Albelda, Carl June, Andrew R. Haas
University Of Pennsylvania/United States Of America
Background: ACT using genetically modified T cells has shown 
great promise in different malignancies (eg melanoma, chronic 
lymphoid leukemia.) Our group has recently applied this techno-
logy by creating T cells that express a chimeric antibody receptor 
(CAR) that targets the highly expressed tumor antigen, mesothelin 
to treat malignant mesothelioma (MM), ovarian, and pancreatic 
cancer and has initiated a Phase I trial in MM patients using mRNA 
transfected CAR T cells against mesothelin (CART-meso cells) to 
test its feasibility and safety.
Methods: Three patients with progressive MPM with epithelial or 
biphasic MPM underwent apheresis for T cell isolation/electropo-
ration/expansion. To mitigate concerns about potential off-target 
toxicity due to low levels of mesothelin expression in normal tissu-
es we developed “biodegradable” mesothelin-specific CAR en-
gineered T cells that transiently express CAR transcripts following 
mRNA electroporation. T cells were electroporated with the CAR 
mRNA and then frozen aliquots were thawed and administered to 
the patients. Serum/peripheral blood/marrow mononuclear cells 
were acquired from patients during the trial to detect/quantify 
abundance of transgene and CD3e transcripts, soluble cytokine 
factors, human anti-mouse antibody (HAMA), CAR T cell-induced 
humoral responses against tumor antigens.
Results: Adoptive transfer of mRNA engineered to express “bio-
degradable” CAR that target mesothelin was feasible. CARTmeso 
cells were detected in the blood and demonstrated the predic-
ted transience of persistence in peripheral blood. Infusions were 
safe from the perspective of off target toxicity due to low level 
mesothelin expression in normal tissues. However, in one patient 
who received two courses of T cells, with the second course after 
a 6 week delay developed an anaphylactic reaction after T cell 
infusion, presumably due to IgE antibodies generated against the 
murine single chain antibody that is part of the CAR. We observed 
clinical activity in one patient who showed a 50% reduction in me-
diastinal tumor volume (Figure 1). This patient also developed an-
tibodies against other proteins present in mesothelioma cell lines. 
Fig 1. Greater than 50% reduction in volume of mediastinal MPM 
tumor in one patient after infusion.
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Background: The legacy of occupational and environmental asbes-
tos exposure in Piedmont, Italy, is a continuing epidemic of pleural 
malignant mesothelioma (MPM). MPM still entails a poor prognosis, 
but progresses in its medical and surgical treatment have occurred 
and guidelines started to appear. We aimed to assess: (i) the appro-
priateness of treatment for MPM cases recently diagnosed in the Pi-
edmont population, taking into account patients’ general conditions 
and disease stage at diagnosis, (ii) the end results of treatment.
Methods: We exploited the Registry of Malignant Mesotheliomas 
(RMM) records to identify incident cases from 2008 to 2011. Patients 
diagnosed/treated in hospitals including a thoracic surgery unit and 
in the Casale Monferrato hospital were known to represent about 
70% of all MPM incident cases and were included in this study, as for 
them not only clinical records on diagnostic procedures, but also on 
treatment and follow-up were completely retrieved by RMM. Vital 
status at 31/12/2012 was ascertained for all MPM cases. 
 
Current analyses were limited to incident cases 2008-2009, followed 
at least up to 3 years. Multinomial logistic regression was used to 
estimate the odds ratio (OR) of receiving a specific treatment (ca-
tegories: cytoreductive surgery, CRS, chemo/immunotherapy, CIT, 
best supportive care, BSC), conditional on individual characteristics. 
Survival was assessed with univariate (Kaplan-Meier) and multivaria-
te (Cox) methods.
Results: There were 297 MPM cases. Taking CIT as reference, the 
OR of receiving CRS was decreased by older age and low perfor-
mance status (Table 1). That of receiving BSC alone was increased by 
older age and low performance status as well, and by non-epithelial 
histotype. Median survival was 13.6 months for patients receiving 
CIT and 18.3 for those undergoing CRS 
Conclusion: In participating centres, MPM are currently treated in 
agreement with available guidelines, and treatment outcomes are 
consistent with expectations.
Keywords: mesothelioma, Treatment, Epidemiology
Keywords: Pleural Chemoperfusion, malignant pleural meso-
thelioma, Extrapleural pneumonectomy, locoregional combined 
treatment
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P3.14-009 HIGH RESOLUTION STUDY ON SURVIVAL OF 
PLEURAL MESOTHELIOMA FROM THE RECORDS OF 
THE PIEDMONT REGISTRY OF MALIGNANT MESOTHE-
LIOMAS - REPORT ON INCIDENT CASES 2008-2009
Dario Mirabelli1, Silvia Novello2, Francesco Ardissone3, Caterina 
Casadio4, Mario Botta5, Ezio Piccolini5, Enrica Pazé6, Oscar Alabiso7, 
Carol Brentisci1, Manuela Gangemi1, Antonella Stura1, Alessandra 
Biava1, Enrico Ruffini8, Francesco Guerrera8, Pier Luigi Filosso8
1Epidemiology, Città Della Salute E Della Scienza Di Torino Hospital/Italy, 
2Department Of Oncology, University Of Turin/Italy, 3Thoracic Surgery, 
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finition of minimum measurable tumor adopted by clinical trial and 
staging protocols.
Keyword: Mesothelioma, tumour measurement, imaging, inter-
observer variability
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P3.14-011 GENOMIC PROFILING OF EPITHELIAL MALIG-
NANT PLEURAL MESOTHELIOMA (MPM) USING MASSI-
VELY PARALLEL SEQUENCING.
Tanguy Seiwert, Arun Khattri, Zhixiang Zuo, Michaela K. Keck, 
Aliya Husain, Everett Vokes, Kevin P. White, Ravi Salgia, Hedy 
Kindler
University Of Chicago/United States Of America
Background: Development of targeted therapies in malignant 
pleural mesothelioma has been limited due to the incomplete un-
derstanding of genetic aberrations occurring in this disease. We 
determined mutational and copy number (CN) events in a compre-
hensive fashion in 12 patients with epithelial malignant pleural me-
sothelioma in order to identify characteristic genetic aberrations 
and new potential treatment targets.
Methods: Fresh frozen tumor (≥70% tumor content) and matched 
normal tissue from 12 patients with treatment-naïve epithelial ma-
lignant pleural mesothelioma were evaluated using targeted, mas-
sively parallel sequencing (Illumina HiSeq) for 580 cancer-relevant 
genes using hybrid capture target enrichment and an established 
bioinformatics analysis pipeline. CN analysis was performed using 
sequencing data (CONTRA) and validated on the NanoString 
nCounter. Mutations were modeled bioinformatically using the 
CHASM oncogenic driver prediction algorithm and reviewed for 
prior occurrence in COSMIC and evidence supporting usefulness 
as a treatment target.
Results: Loss of CDKN2A was the most common genetic event oc-
curring in 80% of samples. INPP4B and TRAF6 were lost in 20-30% 
of tumors. No loss of PTEN was observed in any sample. Two BAP1 
small frameshift deletions were observed. Copy number aberra-
tions, in particular amplifications, were rare. The only gene with 
modest increase in copy number was MET (median CN=2.8). We 
identified multiple somatic missense mutations including: two APC 
mutations (K1245E, G2502D; both predicted to be damaging), one 
TSC1 (K587A) and one TSC2 (P952A, predicted driver) mutation, 
one KIT mutation (L799F; predicted driver), one JAK2 (P953A; pre-
dicted driver), as well as single mutations in NF1 (G849R), EPHA1 
(P697S), EPHA4 (T532I), and mTOR (L2208P), all of which had driver 
character. Specific mutations have not been reported in COSMIC. 
No canonical PI3K or MAPK pathway aberrations were identified.
Conclusion: We identified several novel and known mutations and 
copy number events in epithelial malignant pleural mesothelioma: 
deletions in CDKN2A and INPP4B were the most common copy 
number events. Frameshift deletions in BAP1 were identified. Ove-
rall few copy number events were observed. Potentially targetable 
aberrations include missense mutations in NF1, JAK2, EPHA1, 
TSC2, mTOR and KIT, which are predicted to have driver character 
and additional experimental validation is indicated. Additional 
tumor and cell line samples are being processed and will be availa-
ble at the time of presentation.
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P3.14-010 EVALUATION OF MESOTHELIOMA TUMOR 
THICKNESS MEASUREMENT VARIABILITY
Anna K. Nowak1, Roslyn Francis1, Masha Kocherginsky2, Samuel 
G. Armato3
1School Of Medicine And Pharmacology, University Of Western Austra-
lia/Australia, 2Dept. Of Biostatistics, The University Of Chicago/United 
States Of America, 3Dept. Of Radiology, The University Of Chicago/
United States Of America
Background: Single time-point unidimensional tumor thickness 
measurements define measurable disease for clinical trial inclusion 
and also constitute a field in the IASLC prospective mesothelioma 
staging database. The modified RECIST guidelines for mesothelio-
ma did not alter the 10mm minimum tumor measurement recom-
mendation. It is unclear at what minimum thickness interobserver 
variability exceeds 20% of tumor thickness and how morphology, 
and location affect interobserver variability in a single baseline 
measurement.
Methods: 105 thoracic CT scans were collected retrospectively 
from 50 mesothelioma patients. Each scan was reviewed by a me-
dical oncologist, who identified 170 discrete sites of mesothelioma 
tumor across all scans that represented a range of thickness. Lesi-
on morphology (concave rind, convex rind, convex mass, fusiform 
mass), and anatomic location (chest wall, mediastinum, anterior 
angle, or posterior angle; craniocaudal location; bone/soft tissue) 
were categorized. Using a custom computer interface (Abras), re-
ference tumor thickness measurements were obtained by creating 
a line segment that spanned the tumor from the parietal tumor 
margin along the chest wall or mediastinal structures to the inner 
tumor margin. Measurements were selected to capture a range 
of tumor thicknesses and morphologies, rather than the most 
clinically relevant measurement sites. An observer study was con-
ducted in which each of five other physicians was presented with 
the individual CT sections and the same digitally fixed location 
of the outer tumor margin at each of the 170 pre-defined tumor 
measurement sites. Each observer then independently created a 
line segment to capture tumor thickness at all measurement sites. 
Relative differences among the tumor thickness measurements of 
observers were estimated using a random-effects analysis of va-
riance model (ANOVA) to identify the smallest tumor thickness at 
which linear measurements could be made reliably. Comparisons 
were made with the RECIST tumor response criterion of 20% for 
progression.  
 
Results: The median mean measurement across all sites was 
9.68mm, reflecting the study’s aim to investigate measurement 
variability as a function of tumor thickness, given that the current 
standard minimum is set at 10mm. The mean range of observer 
measurements across all sites was 15.1% of the mean per-site mea-
surement (SD 9.1%). Measurements acquired at tumor sites with 
reference thickness less than 7.5 mm demonstrated inter-observer 
variability (as defined by the difference between the maximum and 
minimum measurements of the observers at each site) with a 75th 
percentile that included 20% of the tumor thickness, while mea-
surements acquired at sites with mean tumor thickness >7.5mm 
showed inter-observer variability with a 75th percentile <20% of 
tumor thickness. Inter-observer variability tended to be lower for 
convex mass lesions relative to that associated with the other three 
tumor morphologies.
Conclusion: The results of this study have implications for the de-
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P3.14-013 LONGITUDINAL OBSERVATION OF HEALTH 
RELATED QUALITY OF LIFE FOLLOWING EXTRAPLEU-
RAL PNEUMONECTOMY FOR MALIGNANT PLEURAL 
MESOTHELIOMA
Jason M. Fowler1, Joseph Coll2, Jocelyn Mclean3, Brian Mccaughan3, 
Steven Kao1, Janette Vardy4, Haryana M. Dhillon5
1Asbestos Diseases Research Institute, University Of Sydney/Australia, 
2School Of Psychology, Psycho-oncology Co-operative Research Group/
Australia, 3Cardiothoracic Unit, Royal Prince Alfred Hospital/Australia, 
4Department Of Medical Oncology, Concord Cancer Centre/Australia, 
5Centre For Medical Psychology & Evidence-based Decision-making, 
University Of Sydney/Australia
Background: The aim of this study was to describe the longitudi-
nal picture of Health Related Quality of Life (HQOL) in people with 
Malignant Pleural Mesothelioma (MPM) post Extrapleural Pneu-
monectomy (EPP).
Methods: Participants receiving EPP from 2011- 2013 were as-
sessed pre-operatively, pre and post adjuvant radiotherapy (Rt), 
and at 8, 12 and 24 months following surgery. Here we report Glo-
bal HQOL and HQOL Domain Scores of the EORTC QLQ-C30, and 
Fatigue Scores from FACT-F. Least squares means were obtained 
from a mixed models analysis with time as a fixed effect, the pre-
op assessment as a covariate and a random subject effect.
Results: Twelve men with a mean age of 65 years (range 48-78) 
completed pre-op and at least one post op assessment. Table 1 
and Figure 1 report the mean HQOL domain scores, global HQOL 
and fatigue at baseline as well as the least squares mean and 95% 
confidence intervals at each follow up assessment. Table 1. Health 
related quality of life over time 
Keywords: malignant pleural mesothelioma, next generation se-
quencing, genomics
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P3.14-012 PATHOLOGICAL COMPLETE RESPONSE AF-
TER PLATINUM-BASED CHEMOTHERAPY IN MALIG-
NANT PLEURAL MESOTHELIOMA
Sanjeev S. Kumar1, Michael Boyer1, Cathy Kenney2, Brian Mccaug-
han3, Steven Kao1
1Department Of Medical Oncology, Royal Prince Alfred Hospital/Aust-
ralia, 2University Of Sydney/Australia, 3Department Of Cardiothoracic 
Surgery, Royal Prince Alfred Hospital/Australia
Background: Prior to the demonstration of the efficacy of cispla-
tin/pemetrexed chemotherapy, Malignant pleural mesothelioma 
(MPM) was previously considered a chemotherapy-resistant tu-
mour. In order to assess the efficacy of chemotherapy in the pre-
operative setting, we aimed to: (1) determine the radiological and 
pathological complete response (CR) rate; (2) evaluate any potenti-
al association between pathological CR and patient characteristics; 
and (3) assess if pathological CR is associated with a longer disease 
free survival (DFS) and overall survival (OS) in MPM patients.
Methods: A retrospective review of a prospectively collected 
database of MPM patients treated with induction chemotherapy 
followed by extrapleural pneumonectomy (EPP) at our institutions 
since 2003 were performed. Radiological response was determi-
ned by CT/PET scans while pathological response was assessed by 
examination of the EPP specimen. OS and DFS from the day of EPP 
was determined by the Kaplan Meier method and comparison was 
made by log rank test. Chi square tests were used to determine 
potential association between pathological CR and patient charac-
teristics.
Results: Forty-two patients are included: median age 63 years; 
81% male. Pathology was 91% epithelial and 9% biphasic subtype. 
A median of 3 cycles of induction chemotherapy was administe-
red with either 67% cisplatin-based and 31% carboplatin-based 
treatment. The regimen in the remaining 2% of patients was unk-
nown. All patients proceeded to EPP and 86% of patients received 
adjuvant radiotherapy. The median OS was 30.6 months (95% CI: 
2.9 – 58.2 months), while the median DFS was 19.6 months (95% 
CI: 11.0 – 28.2 months). No-one achieved a radiological CR. Four 
patients (9.5%) had pathological CR and all were male (p=0.31) and 
had epithelial subtype (p=0.50). No association was found bet-
ween pathological CR and the type of chemotherapy (cisplatin vs. 
carboplatin; p=0.76) or the number of cycles administered (≤3 vs. 
>3; p=0.64). Median OS was 30.6 months vs. median not reached 
(p=0.31), while median DFS was 19.4 vs. 36 months (p=0.34), for 
those without pathological CR and those with pathological CR 
respectively.
Conclusion: A 9.5% pathological CR rate was demonstrated after 
induction chemotherapy, indicative of chemo-sensitivity in a sub-
group of MPM patients. There was a trend for longer OS and DFS 
in MPM patients achieving a pathological CR.
Keywords: mesothelioma, chemotherapy, response
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for people with MPM. The analysis was informed by a framework 
approach.
Results: Overall 68 interviews were conducted: 16 people with 
MPM, 14 caregivers, 13 medical oncologists, 4 radiation oncolo-
gists, 7 respiratory physicians, 3 cardiothoracic surgeons and 11 
lung cancer nurses. Health professionals reported varied respon-
ses to our estimate of the chemotherapy under-utilisation rate in 
people with MPM: some suggested it was likely much lower and 
others higher. Patients and caregivers demonstrated mixed views 
about the value of chemotherapy. Many reported choosing che-
motherapy because they felt the need to “do something”; others 
stated that starting and/or continuing chemotherapy was their 
family’s preference, not their own; some believed that their medi-
cal oncologist made the decision about treatment. Those electing 
not to have chemotherapy were satisfied with their decision. Barri-
ers to accessing chemotherapy included: patients’ nihilistic views 
regarding chemotherapy (no benefit, makes you unwell, other 
people have done poorly), distance from treatment centre; health 
professional perceptions such as nihilistic views regarding chemo-
therapy (no benefit, high toxicity), patient frailty, concerns about 
overtreatment, cases not presented at multi-disciplinary team 
meetings (MDTM), low volume MPM centres, lack of availability of 
carboplatin through Pharmaceutical Benefits Scheme. Facilitators 
to accessing chemotherapy included: MDTM discussion, treatment 
in specialist centres, policy to refer all MPM patients to a Medical 
Oncologist, and use of clinical practice guidelines. Other sug-
gestions to improve access to chemotherapy for MPM included: 
increased access to specialist lung cancer nurses and allied health 
professionals, General Practitioner education regarding asbestos 
exposure history and investigating recurrent pleural effusions. 
People with MPM and caregivers highlighted the importance of 
information from health professionals and from others who have 
experienced these treatments.
Conclusion: Reasons for lower than expected rates of chemothe-
rapy utilisation in people with MPM are multifaceted and complex 
to address. These qualitative results will inform the development 
of quantitative surveys of people with MPM, caregivers and health 
professionals to further investigate barriers and facilitators to 
chemotherapy treatment to guide the development of potential 
interventions.
Keywords: chemotherapy, qualitative, barriers to treatment, me-
sothelioma
Figure 1: Health related quality of life over time These results 
suggest that people who elect to have EPP have baseline levels of 
HQOL comparable to the general population. As expected, HQOL 
declines after surgery and during adjuvant radiotherapy. Emotional 
functioning changes least, while physical and social functioning 
closely mirror each other. Role functioning is the domain most 
affected and remains low out to 24 months. Global HQOL is re-
latively stable over time, with an apparent increase at 24 months. 
Fatigue is worst at the conclusion of radiotherapy and gradually 
improves.
Conclusion: People electing to have EPP report a sudden decline 
in HQOL, with the nadir around the end of adjuvant radiotherapy. 
This gradually improves over time, returning to slightly below base-
line in many domains.
Keywords: mesothelioma, Extrapleural pneumonectomy, Health 
Related Quality of Life
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P3.14-014 CHEMOTHERAPY FOR MESOTHELIOMA:  
PATIENT, CAREGIVER AND HEALTH PROFESSIONALS‘ 
PERCEPTIONS OF TREATMENT AND WHAT INFLUENCES 
ACCESS.
Haryana M. Dhillon1, Anne Warby2, Steven Kao2, Janette L. Vardy3
1Centre For Medical Psychology & Evidence-based Decision-making, 
University Of Sydney/Australia, 2Asbestos Diseases Research Institute, 
University Of Sydney/Australia, 3Concord Clinical School, University Of 
Sydney/Australia
Background: Current evidence-based guidelines for management 
of malignant pleural mesothelioma (MPM) suggest the optimal 
rate of chemotherapy utilisation should be around 65%. Reported 
rates of chemotherapy utilisation in Australia are about 54%. This 
reflects an under-utilisation rate of around 11%; i.e.,11% of those 
suitable for chemotherapy do not receive it. Here we explore pati-
ent, caregiver and health professional perceptions of chemothera-
py treatment for MPM, as well as potential barriers and facilitators 
to accessing treatment.
Methods: Semi-structured interviews were conducted with people 
with MPM, caregivers and health professionals, in person or via 
telephone, to explore their perception of chemotherapy treatment 
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neoplastic thymic changes, thymomas, germ cell tumors, neurogenic 
neoplasms and cysts.
Keywords: primary mediastina tumors, Epidemiology, thymoma
POSTER SESSION 3 - THYMOMA  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.15-002 CAN D2-40 ANTIBODY HELP IN IDENTIFYING 
B2 THYMOMAS? PRELIMINARY OBSERVATIONS.
Malgorzata Szolkowska1, Renata Langfort1, Piotr Rudzinski2, Do-
rota Giedronowicz1, Ewa Szczepulska-Wójcik1, Beata Maksymiuk1, 
Tadeusz Orlowski2
1Pathology Dpt., National Tuberculosis And Lung Diseases Research 
Institute/Poland, 2Thoracic Surgery, National Tuberculosis And Lung 
Diseases Research Institute/Poland
Background: WHO histological classification of thymic tumors (2004) 
distinguishes five main histologic types of thymomas: A, AB, B1, B2 
and B3 and several special types. The classification is not easy and the 
diagnosis is not reproducible, because thymomas are heterogeneous 
and often include several different components or the components 
of borderline types. The evaluation is very subjective and more ob-
jective criteria should be found. D2-40 is a monoclonal antibody that 
recognizes podoplanin expressed by lymphatic vessel endothelium, 
mesothelial cells, germ cell tumors and stromal cells of lymphoid 
tissue. Some authors observed, that expression of podoplanin is a 
prognostic factor in thymomas but is less important in histological 
typing of the tumor.
Methods: 30 thymomas were examined immunohistochemically by 
reaction with D2-40 antibody. Morphology of tumors was established 
according to WHO histological classification of thymic tumors (2004), 
stage was based on criteria of Masaoka staging system. Reaction was 
assessed only in epithelial cells as positive or negative, membranous 
or cytoplasmic. When the recognition of epithelial cells was prob-
lematic, AE1AE3 antibody was involved. Normal thymic tissue rem-
nants, lymphatic vessels or lymphoid stroma with reactive lymphoid 
follicles were treated as positive internal control of reaction.
Results: The group of thymomas consisted of type A - 3 cases, AB - 4, 
B1 - 5, B2 - 9, B3 - 2, 4 combined thymomas: B2B3 - 3 cases, B1B2 - 1 
and 3 cases of special types: 2 micronodular and 1 metaplastic thy-
moma. The tumors were staged as I in 4 cases, II - 17, III - 3 and IV - 3 
cases. Podoplanin was expressed in 1 (33%) type A, 1 (25%) AB, 3 
(60%) B1, 9 (100%) B2, 0 (0%) B3, 3 (100%) B2B3, 1 (100%) B1B2, 0 (0%) 
micronodular and 1 (100%) metaplastic type. B2 and B1 types, B2B3 
and B1B2 thymomas showed membranous reaction, other types (A, 
AB and metaplastic) - cytoplasmic. The intensity of reaction was diver-
se from inconspicuous to distinct but usually weaker than observed 
in internal control. Median area of tumor that expressed podoplanin 
ranged between 0 and 40%: A - 0%, AB - 0%, B1 - 1.5%, B2 - 30%, 
B3 - 0%, B2B3 - 40%, B1B2 - 20%, micronodular - 0% and metaplas-
tic - 2%. 3/4 (75%) tumors in stage I, 8/17 (47%) tumors in stage II, 2/3 
(67%) tumors in stage III and 3/3 (100%) tumors in stage IV (100%) 
revealed positive reaction. Median positive area of tumor was 17,5 % 
for stage I, 1% for stage II, 2% for stage III and 17% for stage IV.
Conclusion: Our preliminary observations revealed that positive 
membranous reaction with D2-40 present in epithelial cells that con-
cerns over 20% of tumor area strongly suggests B2 component. The 
reaction can facilitate the recognition of this high-grade thymoma. 
Positive reaction in lymphoid stroma or thymic remnants should not 
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P3.15-001 PRIMARY MEDIASTINAL TUMORS: EPIDEMIO-
LOGICAL ANALYSIS OF 12-YEARS OBSERVATIONS.
Malgorzata Szolkowska1, Renata Langfort1, Piotr Rudzinski2, Ewa 
Szczepulska-Wójcik1, Beata Maksymiuk1, Tadeusz Orlowski2
1Pathology Dpt., National Tuberculosis And Lung Diseases Research 
Institute/Poland, 2Thoracic Surgery, National Tuberculosis And Lung 
Diseases Research Institute/Poland
Background: Primary mediastinal tumors (PMT) can be neoplastic or 
non-neoplastic lesions and originate mostly from thymus. We investiga-
ted epidemiology of these tumors and took into consideration age and 
gender of patients, histologic type of tumor and number of cases per year.
Methods: 1615 cases clinico-radiologically defined as "mediastinal 
tumor” and diagnosed in National Tuberculosis and Lung Diseases Re-
search Institute in Warsaw from the half of 1999 to the beginning of 2013 
was analyzed. The diagnosis was establish by examination of totally re-
sected tumor or biopsy specimens gained by mediastinoscopy or EBUS. 
WHO (2004) histological classification of tumors were applied to analysis.
Results: Material was obtained from 853 (53%) women (median age 49 
years) and 762 (47%) men (median age 53 years). 375 metastatic carci-
nomas and 217 non-diagnostic cases were excluded from further exa-
mination as not "primary tumor”. There were 298 cases (27% of all PMT) 
of non-neoplastic thymic changes, 282 (26%) lymphomas, 147 (14%) thy-
momas, 64 (6%) neurogenic neoplasms, 44 (4%) thymic carcinomas, 44 
(4%) thyroid lesions, 41 (4%) germ cell tumors, 39 (4%) cysts and 125 (12%) 
other tumors. Non-neoplastic thymic changes were dominated by folli-
cular hyperplasia (249, 84%) and was observed mostly in women in 2nd 
- 4th decade. They constituted the most frequent PMT in women. Over 
half of all lymphomas (51%) were classical Hodgkin lymphoma, followed 
by primary mediastinal lymphoma (28%). Both types occurred mainly in 
young women ( the 3rd - 4th decade). The second peak of incidence in 
late life characteristic for Hodgkin lymphoma was not observed. Lympho-
mas were the most common PMT in men. The most frequent types of 
thymomas were AB (28%), B1 (17%) and B2 (11%). 25% of all tumors was 
classified as "combined”. Thymomas occurred more common in women 
(56%). Median age was 57 years. Neurogenic neoplasms were mostly 
schwannomas (58%), neurofibromas and ganglioneuromas (each 16%). 
The tumors were diagnosed more often in middle aged (3rd - 6th de-
cade) female patients. Median age in thymic carcinomas were 58 years. 
They appeared almost equally in both genders. Group of thyroid lesions 
include retrosternal nodular goiter (80%), thyroid carcinomas (18%) and 
one thyroid lipoadenoma (2%). They occurred three times more often in 
women. Peak of incidence fell on the 6th decade. Germ cell tumors con-
cerned mostly young men (M:F = 5:1) beneath 30 years old. There was no 
gender predylection among patients with mediastinal cysts. Median age 
was 52 years. The cysts were usually of thymic origin. The group of other 
tumors comprised sarcomas, haemangiomas, pleural lesions and enlar-
ged mediastinal lymph nodes with granulomatous or reactive changes.
Conclusion: Both number of cases of all mediastinal tumors and percen-
tage of PMT showed growing tendency from 2000 to 2012. The most 
frequent PMT in women are non-neoplastic thymic lesions (hyperplasias), 
followed by lymphomas, thymomas, neurogenic neoplasms and thyroid 
changes. In men, lymphomas are the most common, then are non-
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Results: The patients aged <50 years was 60.8% (n=14) with a male 
preponderance [73.9% (n=17)] and MG was present in 29.6% (n=8). 
Commonest stage at diagnosis was Mosoaka III-43.4% (n=12). 
Commonest type was WHO type AB and B2 [34.7% (n=8) in each]. 
Among patients who underwent surgery [91.3% (n=21)], either up-
front or following neoadjuvant chemotherapy, R0 resection was in 
47.8% (n=11), R1 in 30.4% (n=7), R2 in 13% (n=3) and only biopsy in 
2 patients in stage IV. Postoperative radiation was given to 82.6% 
(n=19) when indicated (tumour more than 6 cm in stage I disease 
and adjuvant in stage II, III and IV). Conformal radiotherapy/IMRT 
was given in 60.8% (n=14). Chemotherapy with either platinum 
or anthracyclines or both given either as neoadjuvant, adjuvant 
or palliative in 56.5% (n=13) and second line chemotherapy with 
Docetaxel, Capecitabine, and or Everolimus was done for recur-
rence or progression. Three of 7 patients with MG who received 
radiotherapy had myasthenic crisis with treatment breaks. Three 
patients developed acute radiation pneumonitis, and 3 patients 
had associated pure red cell aplasia. With a median followup of 
32 months (range: 3-66), recurrence rate was 26% (n=6) and OS 
87%. The median time to recurrence or progression was 27 months 
(range: 1-66). In univariate analysis, the gender, presence of MG, 
stage, and extent of resection were significant prognostic factors 
for progression free survival. The presence of MG and stage were 
significant prognostic factors for overall survival.  
 
Conclusion: Compared to western population studies, our pati-
ents are younger, advanced stage at diagnosis and are with male 
preponderance. The influence of prognostic variables such as sta-
ge and presence of myasthenia and the progression free survival 
was comparable with that of published series. Our study could not 
demonstrate the extent of resection as a significant prognostic 
factor.
Keywords: prognostic factor, resection, stage, thymoma
be treated as diagnostic, but can be useful as a positive internal con-
trol of reaction. Cytoplasmic reaction is not characteristic for B2 type. 
We did not observed any relationship between D2-40 expression and 
stage of tumor.
Keywords: thymomas, D2-40/podoplanin, Immunohistochemistry
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P3.15-003 STAGE AND PRESENCE OF MYASTHENIA  
DETERMINE THE RECURRENCE FREE SURVIVAL IN  
THYMOMA: SINGLE INSTITUTE EXPERIENCE
Patricia Sebastian, Saikat Das, Rajesh Balakrishnan, Rajesh 
Isaiah, Subhashini John
Department Of Radiation Oncology, Christian Medical College/India
Background: In India, thymoma constitutes 0.1 to 0.2% of all mali-
gnancies whereas National Cancer Institute of USA reports 0.2 to 
1.5%. The aim was to audit patients treated for thymomas and to 
associate various prognostic variables with survival and compare 
the same with western population studies to mark out any diffe-
rence.
Methods: Retrospective review of 23 patients with thymoma 
treated from July 2008 to October 2012 was done. The various 
prognostic variables such as Mosaoka stage, WHO type, tumor 
size, extent of resection, presence of myasthenia gravis (MG), and 
treatment modalities were captured. Statistical analyses were done 
using SPSS and Kaplan-Meier method.
Variable Disease free survival Mean (months) Univariate (p value) 
Overall survival 
Mean (months) 
Univariate 
 (p value) 
Age (years) 0.10 0.338 
<50 years 27.5 29.1 
>50 years 27.2 32.6 
Gender 0.003 0.067 
Male 30.17 33.7 
Female 19.5 21.3 
Myasthenia Gravis 0.002 0.031 
Present 25.8 26.1 
Absent 28.2 32.8 
Stage 0.001 0.008 
I AND II 20.1 21.5 
III AND IV 33.0 37.4 
EXTENT OF RESECTION 0.052 0.395 
R0 25.9 27.1 
R1 24.7 26.2 
R2 40.3 43.0 
Biopsy 25.5 45.0 
Tumor size 0.193 0.508 
<6 cm 29.7 34.6 
>6 cm 26.1 28.3 
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clinical behaviors that remain to be fully defined. Although ACC is 
characteristically slow growing and associated with late distant me-
tastasis, our case showed the reverse presentation pattern: early 
recognition of a metastasis and late presentation of the primary 
site. Therefore, peripheral pulmonary ACC should be carefully 
followed and considered in relation to head and neck ACC, even 
after successful management.
Keywords: Adenoid cystic carcinoma, Lung cancer surgery, meta-
stasectomy
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P3.16-002 OUTCOME AND PROGNOSTIC FACTORS OF 
BRONCHOPULMONARY NEUROENDOCRINE TUMORS 
(BNETS): A SINGLE INTITUTIONAL SERIES
Charlotte Verroken1, Birgitta I. Hiddinga2, Liesbeth Ferdinande3, 
Veerle Surmont4, Frederic De Ryck5, Karim Vermaelen4, Karen 
Geboes6, Jan P. Van Meerbeeck2
1Faculty Of Medicine, Ghent University/Belgium, 2Thoracic Oncology, 
Antwerp University Hospital/Belgium, 3Pathology, Ghent University 
Hospital/Belgium, 4Thoracic Oncology, Ghent University Hospital/Belgi-
um, 5Thoracic Surgery, Ghent University Hospital/Belgium, 6Digestive 
Oncology, Ghent University Hospital/Belgium
Background: BNETs consist of typical carcinoids (TC), atypical 
carcinoids (AC) and large cell neuroendocrine carcinomas (LCNEC) 
based on cellular differentiation, mitotic count and the presence or 
absence of necrosis [Travis 2004]. Since 2009, NETs are included in 
the TNM-classification for lung cancer [Sobin 2009]. Whilst increa-
sing evidence points towards the prognostic value of the Ki67 in-
dex (a measure of the proliferative capacity [Rugge 2008, Grimaldi 
2011]), it is unclear which classification method provides the best 
prognostic stratification. In this series, the prognostic value of clini-
copathological characteristics was assessed, including differentiati-
on, stage and proliferation.
Methods: Medical records of pts with a histologically proven 
BNET, treated at Ghent University Hospital between January 2001 
and June 2012, were retrospectively reviewed for clinical, staging, 
histopathological and treatment data. Overall and disease-specific 
survival (DSS) were estimated and correlated to clinicopathological 
features using uni- and multivariate analysis.
Results: Information on differentiation and staging was available 
in 55 of 57 retrieved pts (96.5%). Tumors were mostly TC (49%) or 
LCNEC (42%). Twelve pts (22%) presented with stage IV disease, 7 
(13%) stage III, 9 (16%) stage II and 27 (49%) stage I. The Ki67 index 
was assessed in 14 tumors (25%), with a median of 12.5% (2.0 – 
95.0%). Ki 67 levels were lowest in TCs and highest in LCNECs (p = 
0.014). Forty-one (72%) patients underwent a resection, which was 
R0/1 in 39. Outcome data are in the table. A strong association was 
found between differentiation and stage (p <0.001). With a median 
follow-up of 25 months (0.0 – 132.0), 17 pts (29.8%) died from a 
tumor-related cause. Male gender (p = 0.025), peripheral tumor (p 
= 0.04), LCNEC (p < 0.001), higher Ki 67 index (p= 0.03) and stage 
IV (p < 0.001) were significant predictors of lower DSS in univariate 
analysis. Ki 67 index was not included in the multivariate analysis, 
which identified tumor stage as the independent predictor of DSS. 
Pts with stage IV disease had a 27-fold (95% CI 2.7 – 263.4, p = 
0.005), those with stage III disease a 12-fold (1.3 – 113.1, p = 0.026) 
increased risk of dying from their BNET compared to pts with sta-
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P3.16-001 LATE-DEVELOPING TONGUE ADENOID  
CYSTIC CARCINOMA AFTER PULMONARY  
METASTASECTOMY
Young Jo Sa1, Chan Beom Park1, Sung Bo Sim1, Si Young Choi2, Jong 
Hui Suh1, Seok Whan Moon1
1Department Of Thoracic And Cardiovascular Surgery, College Of Medi-
cine, The Catholic University Of Korea/Korea, 2Thoracic And Cardiova-
scular Surgery, Uijeongbu St. Mary’s Hospital, The Catholic University 
Of Korea, College Of Medicine/Korea
Background: Adenoid cystic carcinoma (ACC) is a malignant neo-
plasm that usually arises in the salivary glands, but can also occur 
in the breast, skin, uterine cervix, upper digestive tract, and lung. 
Primary pulmonary ACC accounts for less than 0.2% of all lung can-
cers, and only 10% of all primary pulmonary ACCs are peripheral 
in origin. To the best of our knowledge, peripheral pulmonary ACC 
detected prior to its appearance in the tongue has not been repor-
ted previously in the literature.
Methods: We report herein a case of peripheral ACC in the right 
lower lobe, which was followed 27 months later by tongue ACC.
Results: A 52-year-old woman was referred to our hospital for 
evaluation of an incidentally found right lower lobe lung mass. 
She had a history of hypertension and denied recent weight loss 
or smoking. Her initial laboratory findings were unremarkable, 
and the results of a pulmonary function test were normal. A chest 
computed tomography (CT) scan revealed a relatively well-cir-
cumscribed and enhanced mass involving the visceral pleura in the 
right lower lobe, and no mediastinal lymphadenopathy. The mass 
was biopsied under video-assisted thoracoscopic surgery, and an 
intraoperative pathologic diagnosis revealed malignant lung can-
cer. The patient underwent right lower lobectomy and mediastinal 
lymph node dissection. A histopathological examination disclosed 
ACC with a cribriform and tubular pattern; metastasis was not 
found in the dissected lymph nodes. For confirmation of a primary 
or metastatic tumor, an otolaryngologic examination and whole-
body positron-emission tomography (PET) were performed after 
lobectomy. The patient was diagnosed with primary peripheral 
pulmonary ACC because of no evidence of salivary gland tumor 
or other metastasis; Neither radiotherapy nor chemotherapy was 
not performed after lobectomy. During follow-up, the patient was 
diagnosed and treated for transitional cell cancer of bladder. Re-
currence of the bladder cancer was suspected at 27 months after 
the pulmonary operation, and a whole-body PET scan showed that 
an enlarged and increased uptake pattern of both parotid nodules 
without recurrence in the lung. The bladder nodule was benign 
and the parotid nodules disclosed ACC of the tongue with metas-
tasis to the parotid lymph node. The otolaryngologist performed 
wide excision of the tongue cancer. The pathologic diagnosis was 
ACC of the tongue; identical to those of the resected right lower 
lobe lung mass taken 27 months previously. After 5 week-adjuvant 
chemo-radiation therapy, she remained in good health and with no 
detectable recurrence at the 7-months follow-up.
Conclusion: We have presented herein a case of ACC with unusual 
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chemotherapy was used in 8 patients (28.6%) and only 1 patient 
received a third line of chemotherapy. Serum tumor markers prior 
to surgery were negative in 19 patients, meanwhile 9 patients un-
derwent surgery with positive serum tumor markers. Surgical ap-
proach was made by median esternotomy in 15 patients, and pos-
terior thoracotomy in 11 patients. Extensive resections (including 
lung resection and/or pericardial resection and/or bone resection) 
were performed in 16 patients. Perioperative mortality was 3.6% 
(one pneumonectomy patient). Median size tumor was 13.3 cm 
(range 4-25 cm) Complete resection was achieved in 23 patients 
(82.1%). Pathology in surgical specimens were viable germ-cell 
tumor in 12 patients (42.9%), mature teratoma in 6 patients (23.4%), 
inmature teratoma in 4 patients (14.3%) , necrosis in 4 patients 
(14.3%) and seminoma in 2 patients (7.1%). Only 7 patients (25%) re-
ceived an additional line of postoperative chemotherapy. Median 
overall survival was 18.32 months (range 1-102 months). Seminoma 
and teratoma were associated with longer survival, meanwhile in 
non-seminoatous tumors preoperative negative serum tumor mar-
kers showed a better prognosis.
Conclusion: Surgical outcomes have improved over time with a 
positive impact in overall survival. Although the prognosis still 
worse for this subgroup of patients with extragonadal germ-cell 
tumors, our results indicates that a proper selection with agressive 
surgery entitles a better prognosis with low mortality. Factors as-
sociated with better survival were histology, serum tumor markers 
status prior to surgery and pathologic report of the surgical speci-
men.
Keywords: germ-cell tumors, chemotherapy, Thoracic surgery, 
mediastinal tumor
ge II disease. None of the 27 pts with stage I disease died from a 
tumor-related cause.  
Median 
(m)
1y 
SR 
(%)
3y 
SR 
(%)
5y 
SR 
(%)
10y 
SR 
(%)
Disease-
specific 
survival
128 81.5 67.3 67.3 67.3
Overall sur-
vival
128 76.6 63.2 63.2 63.2
Conclusion: In this series of BNETS, tumor stage is the only in-
dependent predictor of prognosis. Further research is needed to 
assess the prognostic value of Ki67.
Keywords: Ki67, tumor stage, bronchopulmonary neuroendocrine 
tumors
POSTER SESSION 3 - OTHER THORACIC MALIGNANCIES  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.16-003 OVERALL SURVIVAL AND SURGICAL OUTCO-
MES FOR MEDIASTINAL GERM-CELL TUMORS: THE NA-
TIONAL CANCER INSTITUTE OF MEXICO EXPERIENCE.
Jose F. Corona-Cruz1, Angel Herrera-Gomez2, Edgardo Jimenez-Fu-
entes1, Horacio Vidrio-Morgado2, Omar Macedo3, Jorge Martinez-
Cedillo4, Miguel A. Alvarez-Avitia4, Monika Blake-Cerda5, Oscar 
Arrieta3
1Surgical Oncology And Thoracic Oncology Clinic, Instituto Nacional De 
Cancerologia (INCAN)/Mexico, 2Surgical Oncology, Instituto Nacional 
De Cancerologia (INCAN)/Mexico, 3Thoracic Oncology Clinic And La-
boratory Of Experimental Oncology, Instituto Nacional De Cancerología 
(INCAN)/Mexico, 4Medical Oncology, Instituto Nacional De Cancerolo-
gia (INCAN)/Mexico, 5Radiation Oncology - Thoracic Oncology Clinic, 
Instituto Nacional De Cancerologia (INCAN)/Mexico
Background: Extragonadal germ-cell are rare, most of them ari-
sing in the anterior mediastinum and comprise less than 5% of 
all germ-cell malignancies, Although they also occur in women, 
the men are the most affected. This tumors are considered with a 
worse prognosis than their primary gonadal counterparts. Standar 
treatment includes chemotherapy with bleomycin, etoposide and 
cisplatin, sometimes followed by surgery. Five-year overall survival 
is about 45%
Methods: Retrospective, single institution review from January 
2005 to december 2012. We included patients with mediastinal 
germ-cell tumors treated with chemotherapy plus surgery. We 
reviewed patient characteristics to identify factors associated with 
overall survival.
Results: We included 28 patients in the final analysis, there were 
25 males (89.3%) and 3 females (10.7%), mean age 26.71 years 
(range 15 -39 years). Mediastinal tumor and elevated serum tumor 
markers were present in 22 patients; in 6 patients a pre-treatment 
biopsy was needed because serum tumor markers were negative. 
Non-seminomaotus germ-cell tumor was diagnosed in 22 patients, 
seminoma in 2 patients and mature teratoma in 4 patients. Except 
for the teratoma patients, all received preoperative chemothera-
py, BEP regimen was used in 53.6% of patients. A second line of 
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P3.17-002 VIRTUAL BRONCHOSCOPY AND VIRTUAL 
BRONCHOSCOPIC LUNG BIOPSY USING OSIRIX
Atsushi Sano, Takehiro Tsuchiya
Department Of Thoracic Surgery, Chigasaki Municipal Hospital/Japan
Background: Although the utility of virtual bronchoscopy has been 
reported, the software for virtual bronchoscopy has not been po-
pular due to the high cost. OsiriX® is a reasonably priced software 
that is available to reconstruct virtual endoscopic images. Herein, 
we present the ability of OsiriX to enable virtual bronchoscopy.
Methods: Computed tomography (CT) of the chest was perfor-
med using a 16-row multidetector. Data in 2 mm slices from one 
lung were obtained in 10 patients with a lung nodule. Virtual bron-
choscopic images were established by OsiriX version 5.5 (32-bit). 
To examine the ability to visualize small bronchi, we tried to visu-
alize the distal bronchus possible. We selected B1a and B10c for the 
right lung and B1+2a and B10c for the left lung. In addition, to predict 
whether a pathological diagnosis can successfully made via trans-
bronchial lung biopsy, we reconstructed virtual bronchoscopic 
images toward the lung nodule.
Results: Bronchoscopic images were successfully reconstructed 
for all patients. It takes several seconds to convert CT images 
into bronchoscopic images. The third to the seventh bronchi 
were visualized, except in one patient whose right B10 was occlu-
ded by a tumor. The smallest bronchial diameter visualized was 
approximately 1.5 mm. For all cases, the second-order bron-
chus, such as B1 and B10, were easily visualized. To visualize the 
third and higher-order bronchi, it was sometimes necessary to 
manually adjust brightness and contrast. The pathway can be 
recorded and retrieved using the “Fly Through” function. The 
pathway of the virtual bronchoscopy was reconstructed in only 5 
to 10 minutes. In all cases, the path of the virtual bronchoscopy 
reached the lung nodule (Fig.1). Therefore we predict that bron-
choscopic biopsy would have been successful in all cases. Based 
on transbronchial biopsy, 4 patients were diagnosed with lung 
carcinoma and 1 patient was suspected of having adenocarcino-
ma. In all cases, the lung nodules were successfully diagnosed.
Conclusion: OsiriX is practicable for virtual bronchoscopy at a low 
cost.
Keywords: Virtual bronchoscopy, Transbronchial lung biopsy, 
Three dimensional computed tomography
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P3.17-001 ASSESSMENT OF PULMONARY HEMORRHA-
GE BY BRONCHOSCOPY AND CT FINDINGS IN PATI-
ENTS TREATED WITH BEVACIZUMAB
Naoki Furuya1, Hiromi Muraoka1, Mariko Okamoto1, Ayano Usuba1, 
Teppei Inoue1, Kei Morikawa1, Hirotaka Kida1, Hiroshi Handa1, Hi-
roki Nishine1, Seiichi Nobuyama1, Masamichi Mineshita1, Noriaki 
Kurimoto2, Teruomi Miyazawa1
1Division Of Respiratory And Infectious Diseases, Department Of Inter-
nal Medicine, St. Marianna University School Of Medicine/Japan, 2Divi-
sion Of Chest Surgery, Department Of Surgery, St. Marianna University 
School Of Medicine/Japan
Background: Pulmonary hemorrhage (PH) is a serious adverse 
event for patients treated with bevacizumab (BV). Previous studies 
have identified PH risk factors as tumor cavitation, location, and 
endobronchial invasion confirmed by computed tomography (CT). 
However, for endobronchial invasion, we believe confirmation 
should be judged by bronchoscopy. The aim of this study is to 
demonstrate the relevance of bronchoscopic findings for patients 
with PH and treated with BV.
Methods: Retrospective analysis of non-small cell lung cancer was 
performed on patients treated with combination therapy including 
BV, as a first line chemotherapy at St. Marianna University Hospital 
between April 2010 and June 2013. Clinical data were retrieved 
from medical records and criteria from previous studies were used 
to identify tumor locations. Bronchoscopic findings were classified 
as follows; epithelial, subepithelial, extraluminal, and normal.
Results: Of the twenty-nine patients analyzed in this study, 24 pa-
tents underwent bronchoscopy before BV treatment. The median 
age was 62 years (range 38-78), and adenocarcinoma was confir-
med in all patients histologically. PH was present in 10.3% patients 
(3/29, all Grade1), and the location of tumors (central vs. periphe-
ral), was not a significant risk factor for PH (p=0.63). Bronchoscopic 
classification of patients for epithelial, subepithelial, extraluminal, 
normal were; 0, 18, 0, 6, respectively. Dilatation findings of subepi-
thelial vessels were seen in 2 cases (2/24). There was no significant 
difference for PH in bronchoscopic classifications (subepithelial vs. 
normal, p=0.38); however, patients with dilatation findings of sube-
pithelial vessels were at significantly higher risk for PH (p=0.01).
Conclusion: It might be possible that patients were safely treated 
with BV in spite of central lesions confirmed by CT. However, dila-
tation finding of subepithelial vessels should be observed carefully 
under bronchoscopy, since these findings may predict PH risk fac-
tors for BV.
Keywords: bronchoscopy, Bevacizumab, pulmonary hemorrhage
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P3.17-004 BREATH-HOLD LOW DOSE CT IMMEDIATELY 
FOLLOWING PET/CT ENABLES GOOD QUALITY VIRTUAL 
BRONCHOSCOPY PRIOR TO EBUS GUIDE SHEATH  
BIOPSY
David Fielding1, Farzad Bashirzadeh2, Jye Smith3, Peter Garcia3, 
Sue Frecker3, David Macfarlane3
1Royal Brisbane And Women‘s Hospital/Australia, 2Thoracic Medicine, 
The Royal Brisbane And Women‘s Hospital/Australia, 3Nuclear Medici-
ne, Royal Brisbane And Womens Hospital/Australia
Background: Virtual Bronchoscopy (VB) facilitates localization of 
small lesions at EBUS Guide sheath(GS). A good quality CT to crea-
te the VB can be problematic to obtain in a timely fashion. Most 
lung cancer patients require PET, hence we explored options of 
getting the VB CT at PET upon initial referral prior to EBUS GS.
Methods: We compared VB results for consecutive CTs acquired 
in one of 3 ways. These were: Group1 :reconstructed CT from the 
PET/CT ( tidal breathing), Group 2: a dedicated low dose inspira-
tory breath-hold CT as part of PET/CT, and Group 3 conventional 
diagnostic CT. CTs had volumetric acquisition and 1 mm overlap-
ping cuts were derived giving at least 600 DICOM images per 
scan. DICOM images were loaded onto a Lung Point® VB device 
and VB created. This device gives automated results for the num-
ber of bronchial divisions visible, and nearest distance to lesion in 
question after creation of the VB. Data for Dose Length Product 
(DLP) and CT Dose Index (CTDI) were obtained for each scan. DLP 
for Group 1 included whole body CT whereas DLP for Group 2 is 
stated just for the Thorax CT.
Results: 
Group 1 
Tidal brea-
thing 
Group2 
Breath 
hold 
Group3 Conventional 
CT 
n 18 17 20 
Lesion size 
(mm) 
21.1± 12.0 23.8±11.0 21.6±7.2 
Bronchial 
divisions 
3.25±0.9 
4.49±1.1, 
p<0.01 
4.55±0.5 p<0.01 
proximity to 
target lesi-
on (mm) 
25.8±19.5 
6.7±6.3, 
p<0.001 
cf Gp1 
13.3±9.2, p<0.02 cf Gp1 
DLP 435 ± 31 173 ± 77 
341 ±94, p<0.001 cf 
Gp 2 
CTDI 3.9 ± 1.3 4.1 ± 1.9 8.9±2.9, p<0.001 cf Gp2 
% lesions 
reached at 
EBUS GS 
83 85 90 
% positive 
pathology 
at EBUS GS 
58 54 63 
 
In Group 2 unexpected positive mediastinal nodes were seen 
on PET enabling staging and diagnostic EBUS TBNA confirming 
malignancy to be done instead of EBUS GS in 3 patients. Poor VB 
results with the reconstructed CT were due to underlying COPD 
with small airway closure and hence inability of the software to 
detect these small airways; (scans acquired in both inspiration and 
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P3.17-003 IMPLEMENTATION OF RAPID ON-SITE EVALU-
ATION FOR LINEAR EBUS: LOCAL EXPERIENCE FROM 
THE AUSTIN HOSPITAL, MELBOURNE
Raymond Wong1, Yet H. Khor1, Alesha Thai1, Kerryn Ireland-JeN-
KIn2, Gerardine Mitchell2, Barton Jennings1
1Department Of Respiratory And Sleep Medicine, Austin Hospital/Aust-
ralia, 2Department Of Pathology, Austin Health/Australia
Background: Linear endobronchial ultrasound guided transbron-
chial needle aspiration (EBUS-TBNA) is widely used for tissue 
sampling of mediastinal and hilar lesions. Rapid On-Site Evaluation 
(ROSE) is a technique where TBNA samples are rapidly processed 
and screened for diagnostic material intra-procedure. The use of 
ROSE improves diagnostic yield, cost-effectiveness, and reduces 
procedural time. Until recently, at Austin Health, EBUS TBNA sam-
ples were prepared in the endoscopy room and evaluated off-site. 
Preliminary results were conveyed to the bronchoscopist via tele-
phone leading to significant delay. We propose that the implemen-
tation of ROSE to assist EBUS-TBNA procedures will reduce the 
number of lymph node aspirates performed without reducing the 
quality or diagnostic yield.
Methods: Consecutive EBUS-TBNA cases were prospectively eva-
luated following institution of ROSE. The number of lymph node 
stations sampled and the number of aspirations per lymph node 
station were recorded. This was compared to a retrospective da-
taset of 69 consecutive cases preceeding the commencement of 
ROSE. Specimen Preparation Material obtained from TBNA was 
transferred onto numbered slides with at least one air-dried smear 
and one 95% alcohol fixed smear prepared per puncture. Remai-
ning material was put into a saline pot for cell block preparation. 
A cytologist‘s assessment of specimen adequacy and presence of 
diagnostic material was performed on-site after a rapid H&E stain. 
Lymph node stations sampled and number of aspirations perfor-
med was recorded.
Results: Preliminary results 
Pre-ROSE Post-ROSE p value
Number of cases 69 21 -
Median number 
of punctures
4 4 0.23
Median number 
of punctures per 
lesion
2 2.5 0.46
> 1 lesion investi-
gated (%)
66 48
 
For suspected lung cancer cases, the concordance rate between 
ROSE and final cytologic diagnosis was 92%. Data collection is 
ongoing.
Conclusion: Utilising ROSE during EBUS TBNA lead to a non-sig-
nificant reduction in the number of lymph node stations sampled. 
However, it did not change the number of punctures performed.
Keywords: Endobronchial ultrasound guided transbronchial need-
le aspiration, Rapid On-site Evaluation, bronchoscopy, Lung cancer
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P3.17-006 ENDOBRONCHIAL ULTRASOUND ELASTO-
GRAPHY IN MEDIASTINAL LYMPH NODES: INITIAL EX-
PERIENCES
Takeo Inoue1, Noriaki Kurimoto2, Mariko Okamoto3, Ayano Usu-
ba3, Teppei Inoue3, Kei Morikawa3, Naoki Furuya3, Hiroshi Handa3, 
Hirotaka Kida3, Hiroki Nishine3, Seiichi Nobuyama3, Masamichi 
Mineshita3, Teruomi Miyazawa3
1Division Of Respiratory And Infectious Diseases, St. Marianna Univer-
sity School Of Medicin/Japan, 2Division Of Chest Surgery, Department 
Of Surgery, St. Marianna University School Of Medicine/Japan, 3Divi-
sion Of Respiratory And Infectious Diseases, St. Marianna University 
School Of Medicine/Japan
Background: To determine the feasibility Endobronchial Ultra-
sound (EBUS) Elastography for mediastinal lymph nodes (LNs)
Methods: Mediastinal LNs in sarcoidosis (n=5) and metastatic LNs 
in lung cancer patients (n=7) were examined with B-mode ultra-
sound, Doppler and EBUS elastography. The elasticity distributions 
were classified into homogenous green pattern, Heterogenous 
blue-predominant pattern, ad Homogenous blue pattern. The 
strain ratio (strain of LN/ strain of fatty tissue) was measured in 3 
cases of sarcoidosis and 2 cases of metastatic LNs.
Results: In the elastogram, green on the EBUS images correspond 
to relatively soft tissue and blue correspond to relatively hard tis-
sue. In the elastogram, mediastinal LNs in sarcoidosis of all 5 cases 
were classified in homogenous green pattern. In the elastogram 
of metastatic LNs in 7 lung cancer patients, LNs of 5 cases were 
classified in heterogenous blue-predominant pattern and LNs of 
the residual 2 cases were classified in homogenous blue pattern. 
Homogenous green pattern A blue-predominant pattern, either 
homogenous or heterogenous, supported the diagnosis of mali-
gnant LNs. The strain ratio was 1.31, 3.16, and 5.48 in 3 cases of 
sarcoidosis respectively, and 17.65 and 29.0 in 2 cases of metasta-
tic LNs respectively.
Conclusion: EBUS elastography would be a feasible method to 
visualize the elasticity of mediastinal LNs.
Keywords: Elastography, Strain ratio, Mediastinal lymph nodes, 
EBUS
expiration).
Conclusion: Low dose single breath-hold CT at the time of PET 
gives at least equivalent results to dedicated CT with far less 
radiation exposure, and is technically superior to reconstructed 
CT. Higher visualised bronchial number allows closer proximity to 
lesions by the directed path. Obtaining this CT prior to EBUS GS 
means no additional high dose CT is required and additional nodal 
staging results with the PET can make for better procedural decis-
ion making.
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P3.17-005 DIAGNOSTIC YIELD OF FLEXIBLE BRONCHO-
SCOPY IN EVALUATING PERIPHERAL LUNG LESIONS 
WITHOUT ENDOBRONCHIAL LESIONS
Sang Haak Lee, Woo Ho Ban, Hye Seon Kang, Ah Young Shin, My-
ung Sook Kim, Seung Joon Kim
Department Of Internal Medicine, College Of Medicine, The Catholic 
University Of Korea, Seoul, Korea/Korea
Background: The diagnosis of peripheral lung lesions (PPLs) 
continues to be a commom problem in routine clinical practice. 
Despite bronchoscopy with guidance has evolved from fluoro-
scopy to endobronchial ultrasonography and electromagnetic 
navigation recently, conventional flexible bronchoscopy wit-
hout guidance is still the most widely used because it is more 
readily available and inexpensive. The aim of this study was to 
evaluate the diagnostic yield and factors affecting diagnostic 
yield of flexible bronchoscopy without guidance for peripheral 
lung lesions.
Methods: We retrospectively reviewed the medical records of all 
the patients who underwent flexible bronchoscopy at St. Paul’s 
hospital of the Catholic University of Korea between Jan 2007 and 
Mar 2013. Two hundred four patients had lung lesions without 
endobronchial lesion. Among these, 24 patients were excluded 
due to follow-up loss and additional 11 patients were excluded 
because the lesions were deemed inactive in clinical follow up.
Results: One hundred sixty-eight patients were enrolled in this 
study. The overall diagnostic rate was 58.3%. Sensitivity was 43.2% 
in malignant disease and 78.1% in benign disease. Non-diagnostic 
results of bronchoscopy were compared with subsequent PCNA 
or surgical resection. Nodule location and the distance from the 
pleura did not effect on the diagnostic yield of bronchoscopy. The 
bronchus sign on CT imaging was present in 45.7% of the patients. 
The diagnostic yield was significantly higher for lesions with bron-
chus sign (81.2%) than for lesions not having bronchus sign (39.0%; 
P<0.001). The diagnostic yield of bronchoscopy increased accor-
ding to different ranges of lesion diameter; 10 mm or smaller, 11-
20 mm, 21-30 mm, 31-40 mm, 41-50 mm, and greater than 50mm 
were 16.7%, 32.0%, 50.0%, 57.1%, and 58.8% respectively (linear 
P<0.001). The diagnostic yield was significantly higher for lesions 
>3 cm (67.5%) than for lesions <3cm (47.9%; P < 0.02).
Conclusion: This study suggests that the presence of bronchus 
sign and larger (>30 mm) nodule are useful findings to predict 
outcome of conventional bronchoscopy without guidance.
Keywords: peripheral, lung, flexible, bronchoscopy
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P3.17-008 ELECTROMAGNETIC NAVIGATION BRON-
CHOSCOPY INCREASES DIAGNOSTIC YIELD AFTER 
NON-DIAGNOSTIC ENDOBRONCHIAL ULTRASOUND 
GUIDE SHEATH FOR PERIPHERAL PULMONARY LESI-
ONS
Steven Leong, Henry M. Marshall, Ian Yang, Kwun Fong, Rayleen 
Bowman
Department Of Thoracic Medicine, The Prince Charles Hospital/Australia
Background: Peripheral pulmonary lesions (PPLs) are diagnostic 
challenges. Computed tomography guided transthoracic needle 
aspiration (CT TTNA) has high diagnostic sensitivity but also high 
complication rates1. Endobronchial ultrasound guide sheath (EBUS 
GS) allows confirmation of target localisation but cannot provide 
guidance to the target. Electromagnetic navigation bronchoscopy 
(ENB) allows the bronchoscopist to navigate to target without direct 
vision. We assessed whether ENB could diagnose PPLs that had 
undergone a non-diagnostic EBUS GS.
Methods: We performed 50 ENB procedures for diagnosis of PPLs 
between 3/2011-6/2013, 15 after non-diagnostic EBUS GS. ENB data 
was prospectively collected. ENB (superDimension, Minneapolis, 
US) was performed through a standard 5.9mm bronchoscope under 
general anaesthesia through a laryngeal mask airway after pathway 
planning using iLogic software. Once the locatable guide was close 
to and correctly aligned with the target, it was removed and repla-
ced by EBUS radial probe (EBUS RP) to confirm target localisation. 
Samples were then taken with forceps biopsy, cytology brush, and 
mini bronchoalveolar lavage. If ENB was non-diagnostic patients 
underwent further investigation. Benign diagnoses were followed up 
for a minimum of 6 months to ensure a consistent clinical course. Pri-
mary outcome was diagnostic yield, procedure time, and complica-
tions. Characteristics distinguishing diagnostic from non-diagnostic 
ENB were assessed using the chi-squared test.
Results: 15 patients (mean age 66.67, 9 females, 12 current or ex 
smokers, mean BMI 25.16kg/m2) with 15 PPLs who underwent non-
diagnostic EBUS GS proceeded onto ENB. Lesion location and 
characteristics were as follows: left (7), upper lobe/lower lobe=11/4, 
bronchus sign positive (14), soft tissue density/ground glass=14/1. 
Mean maximal lesion dimension was 25.64mm+/- 12.38mm and 
mean closest distance from pleura was 12.04mm +/- 12.18mm. Ave-
rage total procedure time was 56.83 mins +/- 13.71mins with a mean 
of 4.53 biopsies taken per patient. All except one procedure was 
performed under general anaesthesia with a laryngeal mask airway. 
The target was reached in 12 patients. Median closest distance to 
target was 12.69mm +/- 7.83mm. Target localisation was confirmed 
on EBUS RP without any manipulation in 10 patients; a further 2 
lesions could be localised with minor manipulation. ENB provided 
a diagnosis in 5 of 15 patients (33.33%): adenocarcinoma (2), squa-
mous cell carcinoma (1), fungal infection (1), organising pneumonia 
(1). Non-diagnostic ENB underwent the following additional proce-
dures: CT TTNA (7), repeat EBUS GS (1), and surgical biopsy (2). The 
following conditions were diagnosed: mycobacterial infection (1), 
adenocarcinoma (4), fibrosis (1), hamartoma (1), non-small cell carci-
noma (1), nodular lymphoid hyperplasia (1). There were no complica-
tions. Procedural success was independent of lesion size (p=0.378), 
location (p=0.714), or morphology (p=0.464), but was related to 
confirmation on EBUS RP without manipulation (p=0.053), and the 
ability to view the lesion on Maximal Intensity Projection (MIP) view 
in 360 degrees (p=0.053).
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P3.17-007 RAPID ON-SITE CYTOLOGIC EVALUATION 
(ROSE) OF BRONCHIAL BRUSHINGS DURING BRON-
CHOSCOPIC INVESTIGATION OF PERIPHERAL PULMO-
NARY LESIONS: DIAGNOSTIC ACCURACY AND IMPACT 
ON PROCEDURE TIME
Daniel P. Steinfort1, Tracy Leong1, Anne Beaty2, Irena Laska3, Alpha 
Tsui2, Louis Irving1
1Respiratory Medicine, Royal Melbourne Hospital/Australia, 2Pathology, 
Royal Melbourne Hospital/Australia, 3Royal Melbourne Hospital/Aust-
ralia
Background: Rapid on-site evaluation (ROSE) of transbronchial 
needle aspirates is cost-effective due to its ability to reduce biopsy 
number and complication rates without compromising diagnostic 
yield. Use of ROSE during sampling of peripheral pulmonary lesi-
ons (PPLs) has not previously been examined. We aimed to deter-
mine the ability of ROSE performed on transbronchial brushings of 
peripheral pulmonary lesions to accurately determine final proce-
dural diagnosis. To determine if use of ROSE impacts on procedu-
ral time or procedural complication rates.
Methods: Prospective cohort of patients undergoing radial probe 
endobronchial ultrasound-guided bronchoscopy for investigation 
of PPLs. ROSE was performed using a Rapid Romanowsky stain. If 
ROSE demonstrated diagnostic malignant material the procedure 
was determined to be successful and no further sampling was 
undertaken. Non-diagnsotic ROSE assessment resulted in further 
sampling including transbronchial lung biopsy, and possibly samp-
ling from different locations.
Results: Specimens obtained from 128 lesions in 118 consecutive 
patients in whom radial EBUS successfully localized a peripheral 
pulmonary lesion. Final procedural diagnoses included non-small 
cell lung cancer (n=76), carcinoid (3), metastatic malignancy (n=3), 
benign inflammatory/infective infiltrate (n=46). Positive predictive 
value of ROSE for a malignant bronchoscopic diagnosis was 97% 
(63/65). Two patients had positive diagnoses made on ROSE but 
final procedural diagnosis was “reactive bronchial cells” however 
both of these patients were subsequently confirmed to have NS-
CLC following alternate biopsy procedures. Procedure times were 
significantly shorter in those in whom ROSE specimens demonst-
rated malignancy than in those in whom ROSE was non-diagnostic 
(19+8 minutes vs. 31+11 minutes, respectively. p<0.0001) In four 
procedures, initial negative ROSE results prompted redirection of 
sampling from alternate bronchial segments resulting in positive 
diagnostic tissue being obtained.
Conclusion: ROSE examination of brushings specimen had high 
positive predictive value for bronchoscopic diagnosis of cancer. 
ROSE of brushings specimens has the potential to shorten bron-
choscopy times, reduce complications and is likely to be cost-
effective. It may also improve diagnostic performance via live 
feedback, allowing proceduralists to redirect subsequent sampling 
procedures.
Keywords: radial probe, endobronchial ultrasound
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was conducted and indicated that sampling error accounted for 6 
of the 7 false negative results. This suggests that triplicate sputum 
sample collection could improve the overall sensitivity of this me-
thod for use as a safe, non-invasive screening test for NSCLC or as 
a pre-screening test to select patients for low-dose CT screening.
Conclusion: Hierarchical cluster analysis of 3 expressed miRNAs 
obtained from sputum and brochoalveolar lavage samples are 
highly specific and relatively sensitive methods for the timely diag-
nosis of early stage NSCLC. Larger, population-based studies are 
necessary for further validation of this promising approach in both 
the diagnostic and screening setting.
Keywords: bronchoalveolar lavage, non-small cell lung cancer, 
MicroRNA expression profiling, sputum
Conclusion: ENB can successfully diagnose PPLs that have been 
non-diagnostic on EBUS GS. Lesions that can be confirmed on 
EBUS GS after being navigated to by ENB, as well as those that can 
be visualised in 360 degrees on MIP view, have a higher chance of 
success.
Keywords: bronchoscopy, electromagnetic navigation broncho-
scopy, diagnosis
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P3.17-009 A PROSPECTIVE CLINICAL STUDY OF MI-
CRORNA EXPRESSION PROFILING OF BRONCHOALVE-
OLAR LAVAGE FLUIDS AND SPUTUM AS A MEANS TO 
DISTINGUISH EARLY STAGE NON-SMALL CELL LUNG 
CANCER CASES FROM CANCER-FREE CONTROLS
Julian O. Kim1, Wilson H. Roa1, Rene Razzak2, Sayf Gazala2, Ling-
hong Guo1, Sunita Ghosh1, Anil A. Joy1, Tirath Nijjar1, Eric Wong3, 
Eric Bédard2
1Oncology, Cross Cancer Institute/Canada, 2Surgery, Division Of Tho-
racic Surgery, University Of Alberta/Canada, 3Pulmonary Medicine, 
University Of Alberta/Canada
Background: MicroRNAs (miRNAs) post-transcriptionally regulate 
hundreds of gene targets involved in tumorigenesis and miRNA 
expression profiling is an emerging tool for the early detection of 
malignancy. We assessed the ability of microRNA (miRNA) expres-
sion profiling of bronchoalveolar lavage (BAL) fluids and sputum 
samples to distinguish early stage non-small cell lung cancer (NS-
CLC) cases from cancer-free controls.
Methods: The expression levels of 3 miRNAs (miR-21, miR-210, 
miR-372) were quantified in BAL fluids and sputum, normalized to 
an endongenous control (U6) relative to a MRC-5 reference samp-
le, using RNA reverse transcription and Quantitative real-time Po-
lymerase Chain Reaction (RT-qPCR). All sputum samples were coll-
ected by a single spontaneous expectoration while BAL fluids were 
obtained just prior to surgical resection. Unsupervised hierarchical 
cluster analysis was performed on the experimental-normalized 
miRNA expression profiles using within-group linkage and cosine 
correlation similarity.
Results: From April 2011 to January 2012, twenty-one eligible 
cases and 10 controls were entered into this study. The median 
age of cases was 70 years of which 17 were male and 4 were fema-
les. Thirteen cases had adenocarcinoma, five had squamous cell 
carcinoma, and 3 had large cell carcinoma. Twelve cases had stage 
I and 9 had stage II NSCLC. The median short axis diameter of the 
primary tumour amongst cases was 1.6 cm. With exception of one 
case, endobronchial lesions were not detected on inspection by 
flexible bronchoscopic examination prior to BAL fluid collection. 
The vast majority of cases were smokers (20/21). The median age 
of the control group was 58.5 and five were healthy without active 
medical conditions while five had COPD. Six controls had prior or 
current histories of smoking while 4 were never smokers. Cluster 
analysis of the miRNA expression profiles of BAL samples from 21 
NSCLC cases and sputum samples from 10 cancer-free controls 
yielded a diagnostic sensitivity of 85.7% and specificity of 100%. 
Cluster analysis of sputum samples from the same 21 NSCLC ca-
ses and 10 cancer-free controls yielded a diagnostic sensitivity of 
67.8% and specificity of 90%. A cosine similarity analysis of mat-
ched pairs of concordant and discordant BAL and Sputum samples 
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P3.18-002 PREDICTING STRATIFICATION FOR RECUR-
RENCE OF EARLY LUNG ADENOCARCINOMA BASED 
ON 7TH TNM CLASSIFICATION AND IASLC/ATS/ERS 
CLASSIFICATION
Masaoki Ito1, Kei Kushitani2, Yoshihiro Miyata1, Tomoharu Yoshi-
ya1, Yuta Ibuki1, Keizo Misumi1, Morihito Okada1
1Department Of Surgical Oncology, Research Institute For Radiation 
Biology And Medicine, Hiroshima University/Japan, 2Department Of 
Pathology, Hiroshima University/Japan
Background: Seventh TNM classification for lung cancer and 
IASLC/ATS/ERS classification for pathological subtype of lung 
adenocarcinoma have been released independently. They have 
especially changed classification of small sized (≤ 3.0cm) and nodal 
negative adenocarcinomas. However, when utilizing them simulta-
neously, it is not clear which factors of each classification are useful 
to predict malignant potential of tumor.
Methods: We reviewed 154 pT1a-1bN0M0 adenocarcinoma cases 
resected between 1990 and 2011. Cases with adjuvant chemothe-
rapy were excluded. 154 cases were subdivided into T1a or T1b 
cases according to 7th TNM classification. On the other hand, ac-
cording to IASLC/ATS/ERS classification, reviewed cases were also 
subdivided into adenocarcinoma in situ/minimally invasive ade-
nocarcinoma (AIS/MIA) or invasive adenocarcinoma (invasive Ad). 
Survival outcomes were evaluated based on these subclassfication 
methods.
Results: There were 84 AIS/MIA cases and 75 invasive Ad cases. 
T1a included 77 cases of AIS/MIA and 50 cases of invasive Ad. 
T1b included 7 cases of AIS/MIA and 25 cases of invasive Ad. T1a 
included significantly more AIS/MIA cases compared with T1b 
(p<0.001). 
The significance was confirmed about disease free survival (DFS) 
between T1a and T1b (96.7% vs 72.7, p<0.001). Pathological subty-
pe also reached significance in DFS between AIS/MIA and invasive 
Ad (97.4% vs 85.7%, p<0.001). 
When combining these classifications, DFS of T1a-1b AIS/MIA 
(N=84), T1a invasive Ad (N=50), T1b invasive Ad (N=20) were 
97.4%, 95.6% and 69.2%, respectively. 
The difference of DFS between T1a-1b AIS/MIA and T1b invasive 
Ad were more notable in comparison to single classification me-
thod. Relapse-free probability of T1a-1b AIS/MIA was 100%. 
Conclusion: Combination of 7th TNM classification and IASLC/
ATS/ERS classification were more useful compared with single me-
thod classification to predict T1a-1bN0M0 lung adenocarcinoma 
recurrence. T1b invasive Ad cases were identified as worsen sub-
types than T1a-1b AIS/MIA. AIS and MIS might be handled equally 
regardless of tumor size.
Keywords: Recurrence, TNM staging, IASLC/ATS/ERS classifica-
tion, Adenocarcinoma
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P3.18-001 PROGNOSTIC VALUE OF THE IASLC/ATS/ERS 
CLASSIFICATION IN STAGE I LUNG ADENOCARCINOMA 
PATIENTS
Zhengbo Song1, Yaping Xu2
1Medical Oncology, Zhejiang Cancer Hospital/China, 2Zhejiang Cancer 
Hospital/China
Background: A new lung adenocarcinoma classification proposed 
by the International Association for the Study of Lung Cancer, 
American Thoracic Society and European Respiratory Society 
(IASLC/ATS/ERS) has recently been published in 2011.We investiga-
ted the relationship between predominant subtype, according to 
the (IASLC/ATS/ERS) lung adenocarcinoma classification and prog-
nosis in stage I lung adenocarcinoma in our hospital.
Methods: Two hundred and sixty-one patients with stage I lung 
adenocarcinoma operated in Zhejiang Cancer Hospital were iden-
tified between 2000 and 2010. Survival curves were plotted using 
the Kaplan–Meier method. The Cox proportional hazard model 
was used for multivariate analysis.
Results: The median age of the 261 patients was 59.8 years in cur-
rent cohort. Of the 261 patients, 175 patients (67.1%) were never 
smokers, 86 patients (32.9%) were former or current smokers. The 
surgical procedure employed 245 lobectomy, 12 bilobectomy and 
4 pneumonectomy. The pathologic stage was IA in 92 patients 
(35.2%), IB in 169 patients (64.8%).No cases were adenocarcinoma 
in situ and six were minimally invasive adenocarcinoma. Two hund-
red and fifty-five cases were invasive adenocarcinoma, in which 80 
were papillary predominant, 76 were acinar predominant, 42 were 
micropapillary predominant, 34 were solid predominant, 19 were 
lepidic predominant subtypes, and 4 were variants of invasive ade-
nocarcinoma. The 5-year DFS and OS rates for the all patients were 
66.0%, 78.2%, respectively. Micropapillary predominant subtype 
(p=0.037), solid predominant subtype (p=0.035) were predictive 
of DFS. Patients with micropapillary and solid predominant tumors 
had significantly worse disease-free survival compared with other 
subtypes predominant tumors ( p<0.001).Multivariate analysis re-
vealed that the new classification was an independent predictor of 
disease-free survival and overall survival (p=0.002 and 0.015).
Conclusion: The predominant subtype in the primary tumor was 
associated with prognosis in resected stage stage I lung adenocar-
cinoma.
Keywords: non-small cell lung cancer, IASLC/ATS/ERS classifica-
tion, Prognosis, stage I
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P3.18-004 PULMONARY OSSIFICATIONS: TO BE CONSI-
DERED IN THE DIFFERENTIAL DIAGNOSIS OF SOLITARY 
PULMONARY NODULES.
Jan F. Gielis1, Vasiliki Siozopoulou2, Patrick Lauwers1, Jeroen Hend-
riks1, Paul Van Schil1
1Thoracic And Vascular Surgery, Antwerp University Hospital/Belgium, 
2Pathology, Antwerp University Hospital/Belgium
Background: Hetertopic bone formation in the lung, or pulmonary 
ossification, has been regarded so far as an extremely rare, post-
mortem finding without much clinical significance. Two types of os-
sification are discerned in the literature: nodular ossifications, with a 
smooth and round edge, which are found in the alveoli themselves, 
and dendriform ossifications, branching through the alveolar septa, 
which sometimes even contain marrow formation. Nodular ossifica-
tions are associated with congestive heart failure, while dendriform 
ossification is related to inflammatory and interstitial lung diseases.
Methods: In five years time (January 2008 to March 2013), we have 
diagnosed 17 cases of pulmonary ossifications by awareness of the 
surgeon and the pathologist. The diagnosis was made in each case 
after pathological examination. Neither peroperative palpation nor 
CT by an experienced radiologist were able to differentiate these 
ossifications from solid tumors.
Results: 76% of patients were male with a mean age of 65.7±4.0 
years. Pulmonary ossifications occurred predominantly in the left lo-
wer lobe (35.3%) and the majority were nodular (64.7%) with a mean 
diameter of 3.5±0.88 mm. Pathological diagnosis in 9 cases could 
not reveal any pulmonary neoplasm despite strong pre-and preope-
rative indications. We have observed no clear association between 
specific pathologies and the presence of pulmonary ossifications.
Conclusion: These findings suggest that pulmonary ossifications 
are not as seldom as believed in the past, and may often be over-
looked or mistaken for a malignant space-occupying lesion. Further 
research on the origin and pathogenesis of these ossifications and 
increased awareness may be useful. PO may be included in the dif-
ferential diagnosis of a solitary pulmonary nodule and we expect the 
prevalence to rise in a population that continues to grow older.
Keyword: solitary pulmonary nodule; differential diagnosis
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P3.18-003 ROS1 GENE REARRANGEMENTS IN NON-
SMALL CELL LUNG CARCINOMA - A NEW GENETIC TAR-
GET THAT CAN BE IDENTIFIED BY IMMUNOHISTOCHE-
MISTRY AND FISH
Wendy A. Cooper1, Christina I. Selinger1, Thang N. Tran1, Nick 
Pavlakis2, Po Yee Yip3, Lisa G. Horvath3, Maija Kohonen-Corish4, 
Sandra O‘Toole1
1Tissue Pathology And Diagnostic Oncology, Royal Prince Alfred Hos-
pital/Australia, 2Department Of Medical Oncology, Royal North Shore 
Hospital/Australia, 3Medical Oncology, Sydney Cancer Centre/Austra-
lia, 4Kinghorn Cancer Centre, Garvan Institute Of Medical Research/
Australia
Background: Targeted therapies aimed at specific molecular ge-
netic alterations are revolutionizing cancer treatment, particularly 
in non-small cell lung cancer (NSCLC). ROS1 is an oncogene that 
encodes a transmembrane tyrosine kinase receptor that has high 
homology with the intracellular kinase domain of ALK. Driver muta-
tions involving translocation of the ROS1 gene have recently been 
identified in NSCLC and show promise as a target for tyrosine kina-
se inhibitors. In this study we aimed to: 
(1) Investigate the incidence and clinicopathological features of 
NSCLCs harbouring ROS1 rearrangements in an Australian popu-
lation. 
(2) Investigate the accuracy of immunohistochemistry (IHC) compa-
red to FISH at identifying tumours with ROS1 rearrangements.
Methods: We tested for ROS1 translocations using both a FISH 
breakapart probe (Zytovision and Abbott Molecular) (≥15% cells 
with split signals or single green 3‘ signal considered positive for 
rearrangement), and immunohistochemistry (D4D6 clone, Cell 
Signaling Technology). Testing was undertaken on both 
(1) A retrospective cohort of 316 early stage lung adenocarcinomas 
in tissue microarrays. 
(2) A prospective cohort of 42 NSCLC, selected on clinical grounds 
for mutation testing (eg EGFR/KRAS/ALK negative samples and 
young age or never/light smoker).
Results: In the retrospective cohort, only 1 case was positive for 
ROS1 gene rearrangement by FISH (0.3% incidence). ROS1 IHC 
identified positive staining in 7 (2.0%) cases, including the FISH+ 
case. ROS1 IHC had a sensitivity of 100% and specificity of 98% for 
identifying ROS1 gene rearrangements.In the prospective cohort 
of 42 cases, 4 cases with ROS1 gene rearrangement were identi-
fied by FISH and all 4 cases showed positive ROS1 immunohisto-
chemical staining.Of the total 5 cases with ROS1 gene rearrange-
ment, all occurred in adenocarcinomas from female patients with 
an age range of 33-81 years (mean 58). Four of the five patients 
were non-smokers and two were of Asian ethnicity. All 5 cases 
were negative for ALK rearrangements and in the 4 cases where 
EGFR status was known, they were all wild type.
Conclusion: ROS1 gene rearrangements occur in a very small per-
centage of lung adenocarcinomas with distinctive clinicopathologi-
cal features and appear to be mutually exclusive with other driver 
mutations in the small number of positive cases available for eva-
luation. Screening with IHC may be a suitable method of reducing 
the number of cases requiring FISH testing.
Keywords: ROS1, FISH, predictive biomarker, IHC
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of mutation-positive patients) exon 18 mutations, 82 (50%) exon 19 
mutations including 63 (39%) deletions, 20 (12%) exon 20 mutations 
including 3 (2%) T790M, 63 (39%) exon 21 mutations including 45 
(28%) L858R. Multiple mutations, both common and uncommon, 
were found in 12 (7%) of the patients. Mutations were found in 8% of 
smokers, 14% of former smokers and 43% of never-smokers. Muta-
tions rates varied between centers which most likely reflected diffe-
rent patient selection criteria for EGFR mutation testing.
Conclusion: The INSIGHT project demonstrated that EGFR mutati-
on testing by one of the standard tests in patients with NSCLC has 
been established in participating centers in Central Europe. EGFR 
mutation distribution is similar to other European and American NS-
CLC patient populations. This study was supported by Boehringer 
Ingelheim Regional Center Vienna.
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P3.18-006 NON-TERMINAL RESPIRATORY UNIT LUNG 
ADENOCARCINOMA: CAN HAVE 3 SUBTYPES AND IS 
ASSOCIATED WITH POOR PROGNOSIS
Akihiko Yoshizawa1, Shinji Sumiyoshi2
1Department Of Laboratory Medicine, Shinshu University Hospital/Japan, 
2Department Of Diagnostic Pathology, Kyoto University Hospital/Japan
Background: Terminal respiratory unit (TRU) adenocarcinoma, which 
is proposed as a distinct subset of lung adenocarcinomas, develops in 
periphery of the lung parenchyma, is similar in cell morphology to type 
II pneumocytes or Clara cells, is positive for the expression of thyroid 
transcription factor-1 (TTF-1), and harbors mutations in the gene enco-
ding the epidermal growth factor receptor (EGFR). The clinicopathologi-
cal characteristics are generally well defined. In contrast, few studies have 
focused on non-TRU type adenocarcinomas. We herein analyzed clinico-
pathologic and prognostic findings of non-TRU type adenocarcinomas.
Methods: We selected 244 consecutive patients with lung adenocar-
cinomas underwent pulmonary resection at Kyoto University Hospital 
between January 2001 and December 2007. All cases were classified 
according to IASLC/ATS/ERS criteria. Findings of significant prognostic 
factors for lung adenocarcinomas prompted analyses of lymphatic invasi-
on, vascular invasion, pleural invasion, tumor grade. We annalyzed im-
munohistochemical expression of the mucins MUC5B, MUC5AC, as well 
as TTF-1 using TMA blocks comprising lung adenocarcinoma specimens 
from the 244 patients. The presence of mutations in EGFR and KRAS was 
also determined.
Results: TTF-1, MUC5B, and MUC5AC were detected in 219 (89.6%), 75 
(30.7%) and 33 cases (13.5%), respectively. Cluster analysis of the protein 
expression and EGFR and KRAS mutations yielded four classes of tumors 
as follows: TRU-type (TTF-1(+), MUC5B(-), MUC5AC(-)); Combined-type 
(TTF-1(+), MUC5B(+) and/or MUC5AC(+)); Bronchiolar-type (TTF-1(-), 
MUC5B(+) and/or MUC5AC(+)); and Null-type (TTF-1(-), MUC5B(-), MU-
C5AC(-), EGFR mutations(-), KRAS mutations(-)). TRU-type tumors were 
significantly associated with non-mucinous adenocarcinoma in situ 
(AIS), whereas Bronchiolar-type tumors were associated with mucinous 
AIS. Combined-type cases were intermediate in morphology between 
TRU-type and Bronchiolar-type cases (P < 0.001). TRU-type was associ-
ated with significantly better prognosis (5-year disease free survival rate 
(5y-DFS-rate) = 75.2%, 5-year overall survival rate (5y-OS-rate) = 83.8%), 
followed by Combined-type (5y-DFS-rate = 61.7%, 5y-OS-rate = 73.2%), 
Bronchiolar-type (5 y-DFS-rate = 53.6%, 5y-OS-rate = 53.9%), and Null-
type (5y-DFS-rate = 40.0%, 5 y-OS-rate = 40.0%). Multivariate analyses 
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P3.18-005 EGFR MUTATION TESTING METHODS IN 
CLINICAL PRACTICE IN CENTRAL EUROPE: FINDINGS 
FROM THE INSIGHT OBSERVATIONAL STUDY
Wlodzimierz Olszewski1, Helmut Popper2, Izidor Kern3, Leonhard 
Müllauer4, Rafal Dziadziuszko5, Peter Berzinec6, Ladislav Dusek7, 
Tanja Cufer8, Paolo Bajcic9, Zbynek Bortlicek7, Lucia Copakova10, 
Balazs Dome11, Joanna Chorostowska-Wynimko12, Blanka Robeso-
va13, Vitezslav Kolek14, Milos Pesek15, Rodryg Ramlau16, Wolfgang 
Eisterer17, Lenka Medvecova18, Pawel Krawczyk19, Juraj Mazal20, 
Robert Pirker21
1Department Of Pathology, Oncology Institute Of Maria Skłodowska-
Curie/Poland, 2Department Of Pathology, Medical University Of Graz/
Austria, 3Laboratory Of Cytology And Pathology, University Clinic Gol-
nik/Slovenia, 4Department Of Pathology, Medical University Of Vienna/
Austria, 5Department Of Radiotherapy & Oncology, Medical University 
Of Gdansk/Poland, 6Department Of Oncology, Specialised Hospital Of St 
Zoerardus Zobor/Slovak Republic, 7Institute Of Biostatistics And Analy-
ses, Masaryk University/Czech Republic, 8University Clinic Golnik, Medi-
cal Faculty Ljubljana/Slovenia, 9Medical Affairs Department, Boehringer 
Ingelheim Rcv/Austria, 10Department Of Cancer Genetics, National Can-
cer Institute/Czech Republic, 11Department Of Tumor Biology, National 
Koranyi Institute Of Pulmonology/Hungary, 12Laboratory Of Molecular 
Diagnostics & Immunology, National Institute Of Tuberculosis And Lung 
Diseases/Poland, 13Department Of Pulmonary Diseases And Tuberculosis, 
University Hospital Brno/Czech Republic, 14Department Of Pulmonary 
Diseases And Tuberculosis, University Hospital Olomouc/Czech Republic, 
15Department Of Pulmonary Diseases And Tuberculosis, University Hos-
pital Plzeň/Czech Republic, 16Department Of Oncology, Poznań University 
Of Medical Sciences/Poland, 17Department Of Medicine, Medical Univer-
sity Of Innsbruck/Austria, 18Department Of Oncology, Adus Healthcare 
Centre/Slovak Republic, 19Department Of Pneumology, Oncology & Aller-
gology, Medical University Lublin/Poland, 20Department Of Pneumology, 
University Hospital F. D. Roosevelt/Slovak Republic, 21Department Of 
Medicine 1, Medical University Of Vienna/Austria
Background: The INSIGHT observational study aimed at assessing 
the management of NSCLC patients with EGFR mutations in clinical 
practice in Central Europe. As part of this project, pathological fin-
dings including molecular testing methods were assessed.
Methods: Fourteen Pathology Departments from 6 Central Euro-
pean countries participated. Between 15 November 2011 and 31 
March 2013, EGFR mutations were determined by one of the estab-
lished standard methods in patients with NSCLC.
Results: Here we report data on 1009 patients who had been en-
rolled into the INSIGHT study. These patients consisted of 626 (62%) 
males and 383 (38%) females, 347 (35%) smokers, 452 (46%) former 
smokers and 182 (19%) never-smokers. Pathological diagnosis was 
based on histology (41%), cytology (19%) or both (40%) and revealed 
the following results: 54% non-mucinous adenocarcinomas, 4% 
mucinous adenocarcinomas, 21% unspecified adenocarcinomas, 9% 
NSCLC NOS, 7% squamous cell carcinomas, 2% adenosquamous 
carcinomas, and 2% others. Tumor material was obtained by bron-
choscopy (44%), transthoracic needle biopsy (11%), surgery (19%), 
or other techniques. Specimens were either from primary tumor 
(88%), lymph node metastases (2.5%) or distant metastases (9.5%). 
EGFR mutation testing was done by PCR-RFLP (43%), Roche Cobas 
EGFR mutation test (26%), Sanger sequencing (18%), high resolution 
melting followed by sequencing (13%) or another method (11%). 
EGFR mutations were found in 163 (16%) of the patients. Among 
patients with mutations, the following mutations were found: 12 (7% 
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pathology report. We investigated the relationship between his-
tologic patterns in metastatic sites, overall survival and EGFR and 
KRAS mutations.
Methods: We identified patients who underwent surgical resec-
tion of non-small cell lung carcinoma in metastatic sites from 2000 
to 2011. One biopsy site was selected per patient. A pathologist 
reviewed all slides to confirm the diagnosis of metastatic lung 
adenocarcinoma, recording all adenocarcinoma histologic patterns 
present. EGFR and KRAS mutations were scanned by high resolu-
tion melting, and confirmed by Sanger sequencing. Clinical data 
were extracted from the medical records.
Results: The 100 patients comprised 66 males, with a median age 
of 64 years. 85% had stage IV disease, and 15% had unresected 
stage III disease with mediastinal lymph node sampling. Most were 
current or former smokers (79%) of ECOG 0/1 (67%). Just over half 
the patients received systemic therapy (56%). The overall median 
survival was 10.2 months (95% CI 8.1 – 12.2 months). Metastatic 
sites included brain (30%), pleura (25%), bone/skeletal muscle 
(20%), and lymph nodes (mediastinal 18%; chest wall/neck 7%). It 
was possible in each biopsy to identify a major histologic pattern 
(Table 1). For patients receiving systemic therapy, survival was sig-
nificantly shorter for those with a major component of solid pattern 
tumour in metastases compared to those with major acinar or mi-
cropapillary patterns in metastases (Table 1). No survival difference 
was noted on the basis of ECOG, stage, EGFR or KRAS mutations. 
For patients who did not receive systemic therapy, the major his-
tologic pattern showed no association with overall survival (Table 
1). Worse ECOG was the only significant factor in determining out-
come (ECOG 0/1 vs 2+ – hazard ratio 2.18 (1.14 – 4.16, p=0.018)). 
EGFR mutations were significantly associated with major non-solid 
pattern histology in metastases (Fisher’s exact = 0.006). No associ-
ation was observed by KRAS mutation status (Table 1). 
Conclusion: Our results suggest that patients with a major compo-
nent of solid pattern tumour in metastatic sites may be more resis-
tant to systemic therapy as evidenced by shorter overall survival in 
comparison to those with major micropapillary and acinar pattern 
tumour in metastases. Furthermore, major solid pattern metasta-
ses are unlikely to harbour EGFR mutations. These findings require 
validation in larger patient cohorts.
Keywords: Pulmonary adenocarcinoma, Metastatic disease, histo-
pathology, EGFR mutation
indicated that non-TRU type significantly correlated with poorer progno-
sis for DFS (hazard ratio (HR) = 1.946; 95% confidence interval (CI) 1.139-
3.322; P = 0.015) and OS (HR = 1.933; 95% CI 1.072-3.491; P = 0.030).
Conclusion: The present study demonstrates that lung adenocarcinomas 
expressing MUC5B and MUC5AC could represent the non-TRU type and 
have a poorer prognosis than that of TRU-type lung adenocarcinomas. 
In addition, three distinct subtypes of non-TRU type adenocarcinomas 
were discovered. There are no effective treatments for patients with 
non-TRU type lung adenocarcinoma, while patients with TRU-type lung 
adenocarcinoma can be treated with EGFR inhibitors. Therefore, the 
characterization of non-TRU type lung adenocarcinomas described here, 
suggests that patients with this disease can be identified as candidates 
for receiving treatments that will hopefully be developed in the future.
Keywords: lung adenocarcinoma, terminal respiratory unit (TRU), 
MUC5B, MUC5AC
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P3.18-007 METASTATIC SITES WITH A MAJOR COMPO-
NENT OF SOLID PATTERN PULMONARY ADENOCAR-
CINOMA ARE ASSOCIATED WITH SHORTER SURVIVAL 
WITH SYSTEMIC THERAPY AND INFREQUENT EGFR 
MUTATIONS
Timothy D. Clay1, Hongdo Do2, Vijaya Sundararajan3, Melissa M. 
Moore1, Matthew Conron4, Gavin Wright5, Sue-Anne Mclachlan1, 
Alexander Dobrovic2, Prudence A. Russell6
1Medical Oncology, St Vincent‘s Hospital Melbourne/Australia, 2Depart-
ment Of Pathology, Peter MacCallum Cancer Centre/Australia, 3Depart-
ment Of Medicine, University Of Melbourne/Australia, 4Department Of 
Respiratory Medicine, St. Vincent‘s Hospital/Australia, 5Cardiothoracic 
Surgery, St Vincents Hospital/Australia, 6Anatomical Pathology, St 
Vincent‘s Hospital/Australia
Background: The predominant histologic subtype according to 
the IASCL/ATS/ERS classification has been associated with pro-
gnosis in patients undergoing curative surgical resection. It is 
recommended in the IASLC/ATS/ERS classification that histologic 
patterns present in small specimens be recorded in the final histo-
The major histologic component in sites of metastatic adenocarcinoma – overall survival by the use of systemic therapy; presence of EGFR and 
KRAS mutations (*Comparison across 4 histological types; OS - overall survival, CI - confidence interval, HR - hazard ratio)
Solid Micropapillary Acinar Papillary Comments 
Major Pattern 50% 20% 29% 1% 
Mutations present n = 50 n = 20 n = 29 n = 1 n=100 
EGFR mutation, n (column %) 2 (4%) 5 (25%) 4 (14%) 1 (100%) Fisher’s exact = 0.006 * 
KRAS mutation, n (column %) 18 (36%) 5 (25%) 9 (31%) 0 Fisher’s exact = 0.789* 
Systemic Therapy Given n = 29 n = 13 n = 13 n = 1 n=56 
Median OS, months (95% CI) 9.4 (8.3 - 12.2) 18.9 (11.6 - 24.4) 
15.9 (10.7 
- 24.7) 
Solid vs MPA HR 0.33 (0.16 - 0.67, p = 
0.002) Solid vs Acinar HR 0.32 (0.15 - 
0.67, p=0.003) 
No Systemic Therapy n = 21 n = 7 n = 16 n = 0 n=44 
Median OS, months (95% CI) 4.3 (3.3 - 7.4) 4.7 (1.5 - 11.5) 
4.4 (1.9 - 
16.9) 
No significant differences 
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P3.18-009 CLINICOPATHOLOGICAL CHARACTERISTICS 
OF PRIMARY LUNG MUCINOUS ADENOCARCINOMA IN 
SURGICALLY RESECTED CASES
Hideomi Ichinokawa, Kenji Suzuki, Yukio Tsushima, Kazuya Ta-
kamochi, Shiaki Oh
Division Of General Thoracic Surgery, Juntendo University School Of 
Medicine/Japan
Background: Primary mucinous adenocarcinomas (MA) are rela-
tively rare, and the clinicopathological characterisics have remai-
ned unclear. The aim of this study was to clarify the clinicopatholo-
gical characteristics of MA.
Methods: We selected MA from 1450 cases of surgically resected 
primary lungWe selected MA from 1450 cases of surgically resec-
ted primary lung adenocarcinoma. The clinicopathological charac-
teristics of MA (30 cases) were analyzed.
Results: MA showed a high rate (22/30, 73%) of tumor location in 
the lower lobe. Vascular invasion was observed in 6 cases (20%). 
Pulmonary metastasis was observed in 5 cases (17%). Lymphatic 
permeation was present in 1 case (3%). Pleural invasion was ob-
served in no cases. Lymph node metastasis was present in 1 case 
(tumor size: 75mm, 3%). MA showed a significantly higher rate 
of cases aged 65 and over, tumor location in the lower lobe and 
pathological N0 stage cases, when compared with the other of 
adenocarcinoma. Furthemore, MA displayed a lower frequency 
of plural invasion, lymphatic permeation, and vascular invasion, 
and a high frequency of pulmonary metastasis. We compared the 
frequency of invasive cases in the two groups with respect to their 
size (tumor size; TS). In MA, the frequency of invasive cases in TS 
≦ 3cm, 3cm < TS ≦ 5cm and TS > 5cm was 11% (2/18), 50% (2/4), 
62% (5/8), respectively. In the other types of adenocarcinoma, the 
frequency of invasive cases in TS ≦ 3cm, 3cm < TS ≦ 5cm and TS 
> 5cm was 89% (918/1027), 98% (274/281), 100% (112/112), respec-
tively. Therefore, even as TS became bigger, MA displayed lower 
invasive capacity. We compared the frequency of recurrence cases 
in the two groups.MA showed local recurrence in 3 of 30 cases 
(10%), no incidents of distant metastasis. The tumor size of all 3 
cases showed more than 5 cm. Pulmonary metastasis showed 1 
case (3%) in same side, 2 cases (7%) in the both side. MA showed a 
significantly lower rate of pulmonary metastasis and distant metas-
tasis (P < 0.05), when compared with the other of adenocarcinoma.
Conclusion: The pathogenesis of MA might differ from that of 
lung adenocarcinoma without MA based on higher rate of tumor 
location in the lower lobe and recurrence of pulmonary metastasis. 
MA less than 5cm may be treated as a local disease and could omit 
mediastinum lymph node dissection.
Keywords: Invasive adenocarcinoma, pulmonary metastasis, muci-
nous adenocarcinoma
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P3.18-008 EGFR MUTATION TESTING IN SAUDI  
ARABIAN LUNG ADENOCARCINOMA
Fouad H. Al-Dayel1, Hamad Al Husaini2, Asma Tulbah1, Prashant 
Bavi3, Halah Abalkhail1
1Pathology And Laboratory Medicine, King Faisal Specialist Hospital 
And Research Centre/Saudi Arabia, 2Oncology Center, King Faisal Spe-
cialist Hospital And Research Centre/Saudi Arabia, 3Research Centre, 
King Faisal Specialist Hospital And Research Centre/Saudi Arabia
Background: Lung cancer is the fifth leading cause of cancer in 
males in Saudi Arabia. As per current World Health Organization 
(WHO), lung carcinoma is subdivided into small cell and non-small 
cell carcinoma (NSCLC). The latter compromise 70-80% of lung 
carcinoma and consists of heterogenous groups that is further divi-
ded into adenocarcinoma, squamous cell carcinoma and large cell 
carcinoma. Due to poor prognosis of lung cancer, there is an in-
creasing need to find molecular biomarkers which can be used for 
diagnosis, risk stratification, early detection, treatment selection, 
prognosis and monitoring for recurrence. Increasing interest in 
adenocarcinoma of lung has been raised lately for various reasons. 
One reason is the increasing incidence of adenocarcinoma, which 
is now the most predominant histologic subtype. Other reason is 
the possible use of targeted therapy in cases showing EGFR mu-
tations or ALK rearrangements. Adenocarcinoma comprise appro-
ximately 70% of primary lung cancer in Saudi population. The aim 
of this study is to review the incidence of EGFR mutation in lung 
adenocarcinoma in Saudi patients.
Methods: A cohort of 37 primary lung adenocarcinoma diagnosed 
histologically and confirmed by Immunohistochemistry was collec-
ted. DNA was manually extracted from paraffin embedded tissue 
and was paired with histology-guided tissue macrodissection to 
target tumor cells. The mutation status of EGFR exons 18-21 was 
evaluated using Polymerase chain reaction (PCR) and bi-directional 
sequencing.
Results: EGFR mutation was detected in 10 cases (27%). Of the 10 
cases, 80% of mutations (deletions) were located in exon 19 and 
10% in exons 20 and 21 respectively. All mutations detected con-
ferred increased sensitivity to tyrosine kinase inhibitors (TKI).
Conclusion: The incidence of EGFR mutation in lung adenocarci-
noma in our patients (27%) is slightly higher than western popula-
tion (15-23%). To our knowledge, this is the first molecular analysis 
of EGFR gene mutational analysis in lung adenocarcinoma in Saudi 
Arabia.
Keyword: Lung Adenocarcinoma, EGFR mutation
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P3.18-011 PROGNOSTIC VALUE OF BLOOD AND  
LYMPHATIC VESSELS EMBOLISM (PV, PL) IN EARLY  
STAGE LUNG CANCER (IA, IB).
Piotr Rudzinski1, Wlodzimierz Kupis1, Renata Langfort2, Beata 
Maksymiuk2, Małgorzata Szołkowska2, Tadeusz Orlowski3
1Thoracic Surgery, Institute Of Tuberculosis & Lung Diseases/Poland, 
2Pathology Dpt., National Tuberculosis And Lung Diseases Research 
Institute/Poland, 3Thoracic Surgery, National Tuberculosis And Lung 
Diseases Research Institute/Poland
Background: Stage of lung cancer (TNM) is most valuable prog-
nostic factor. Most of patient in IA and IB stage survive 5 years, 
but in 10% of them the relapse of the disease is noticed. Therefore 
identifying the negative prognostic factors is crucial. The neoplas-
tic emboli in blood and lymphatic vessels seem to be one of them.
Methods: The retrospective analysis of lung cancer patients 
operated on from 2002 thru 2006 at our institution was done. In 
all patient included into the study group the IA or IB stage was 
diagnosed and the neoplastic emboli in both blood and lymphatic 
vessels of the tumor were found. The survival rate in this group was 
compared with those without such findings. Among 1648 patient 
operated on between 2002 and 2006 564 were classified as IA or 
IB (pN0) stage (after rejecting 22 of them due to R1). Among 271 
pts during microscopic detection neoplastic emboli in blood or 
lymphatic vessels were found. The analyzed group consisted of 
208 women and 356 men. The stage IA was established in 212 pts, 
including 115 in pT1a, 97 in pT1b. Stage IB was diagnosed in 352 
pts (pT2a) among whom 149 have infiltration of parenchymal pleura 
detected. All of them underwent the radical resection – all surgical 
margins were negative. The pathological examination revealed 
adenocarcinoma in 230 pts, squamous cell lung cancer in 203 pts, 
large cell lung cancer in 30, carcinoid in 80 pts and other kind of 
NSCLC in remaining 21 pts.
Results: 5-year survival rates recorded were as follow – in stage 
IA 79,9% and 74,1% in pT1A pT1b respectively, in stage IB (pT2a) 
59,9%. The presence of neoplastic emboli in blood and lymphatic 
vessels of tumor correlated with poorer prognosis of survival (V=0 
L=0 – 72%, V=1 L=0 63,3%, V=0 L=1 64,7%, V=1 L=1 58,1%).
Conclusion: Therefore we concluded that such finding should be 
considered a negative prognostic factor and ought to be recorded 
in every pathology report.
Keyword: lung cancer, blood embolism, lymphatic vessels embo-
lism
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P3.18-010 5 DRIVER GENES IN CHINESE FEMALE LUNG 
ADENOCARCINOMA
Baohui Han1, Bing Wei2, Yu Dong1, Zhiyong Ma2, Jie Ma2, Huiqing 
Tao3, Hui Xiong3
1Shanghai Chest Hospital Affiliated To Shanghai Jiaotong University/
China, 2Henan Tumor Hospital An Affiliated Tumor Hospital Of Zheng 
Zhou University/China, 3Shanghai Yuanqi Biomedical Technology Co., 
Ltd./China
Background: Currently, 5 driver genes (EGFR, K-RAS, B-RAF, ALK, 
RET) related to lung cancer have been widely explored and be-
come new targets of NSCLC, however no report has been found 
in Chinese female lung adenocarcinoma, who were prone to EGFR 
mutations and therefore, are the targeted populations for TKIs 
therapy.
Methods: FFPE-tissues from 310 female lung adenocarcinoma 
adopted in Hunan province or Henan province between 2000 and 
2012 were investigated. Oncogenic alterations in newly found 5 
driver genes were analyzed. For EGFR, K-RAS and B-RAF mutation 
detection, ARMS was performed. The reverse transcription and 
real-time PCR were performed either to detect all ALK and RET 
fusions using primers specific to known rearrangement or to detect 
ALK and RET expression by primers specific to TK domain. Se-
quencing was further applied to confirm the subtypes of fusions.
Results: Among 310 samples, 149 (48.1%) EGFR mutations, 16 
(5.2%) KRAS mutations, 0 (0%) BRAF mutations, 23 (7.4%) ALK 
fusions and 5 (1.6%) RET fusions were detected. Deletions in exon 
19 and L858R in exon 21 account for the major EGFR mutations, 
representing 97 (65.1%) and 41 (27.5%), respectively. Only EML4-
ALK fusion but no other ALK fusions were found. Further research 
demonstrated that cases (22, 95.6%) with high ALK expression 
were often accompanied by EML4-ALK fusion and poorly diffe-
rentiated adenocarcinoma. Two RET fusions, namely, KIF5B-RET 
and CCDC6-RET were found, with 2 cases and 3 cases, respec-
tively. The ratio of RET/ABL mRNA levels was significantly higher in 
CCDC6-RET samples with poorly differentiated adenocarcinoma. 
However, with KIF5B-RET fusion, the situation was more complex. 
Relatively high RET/ABL mRNA expression was detected in one 
KIF5B-RET sample with moderately differentiated adenocarcino-
ma, while no RET expression was detected in other two KIF5B-RET 
samples with highly differentiated adenocarcinoma.
Conclusion: This is the first research about the oncogenic altera-
tions of 5 important driver genes in Chinese female lung adenocar-
cinoma, as well as the correlation between ALK fusion and ALK 
expression or between RET fusion and RET expression, thus laying 
good foundation for understanding the genetic mutation spectrum 
in female lung adenocarcinoma.
Keywords: lung adenocarcinoma, mutation, Driver genes, Female
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Table 1 - FISH and IHC summary 
Conclusion: The current FISH based approach to detect ALK gene 
rearrangement misses numerous (50%) patients who might bene-
fit from the most efficient lung cancer therapy for their disease. 
Screening for ALK protein expression by IHC may identify ALK 
positive patients that would otherwise be missed. Borderline IHC 
staining should be further sequenced by NGS to cover other ab-
normalities such as intron19 or other uncommon rearrangements.
Keyword: NSCLC; ALK; NGS
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P3.18-013 DIFFUSE IDIOPATHIC PULMONARY NEURO-
ENDOCRINE HYPERPLASIA AND PULMONARY CARCI-
NOID TUMORS - OWN EXPERIENCES
Renata Langfort1, Malgorzata Szolkowska1, Ewa Szczepulska-Wój-
cik1, Beata Maksymiuk1, Dorota Giedronowicz1, Piotr Rudzinski2, 
Tadeusz Orlowski2
1Pathology Dpt., National Tuberculosis And Lung Diseases Research 
Institute/Poland, 2Thoracic Surgery, National Tuberculosis And Lung 
Diseases Research Institute/Poland
Background: Pulmonary neuroendocrine cells hyperplasia may be 
either reactive and idiopathic type. The latter is defined as diffuse 
idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) 
and sometimes precedes and coexists with carcinoids. According 
to the WHO lung tumor classification, DIPNECH is considered a 
form of preinvasive lung lesion. The available data regarding this 
rare condition are very limited. We would like to present our own 
experience with DIPNECH and carcinoid tumors, describe the 
pathologic features and immunohistochemical profile of both pro-
cesses and to evaluate the frequency of DIPNECH and carcinoid 
tumors.
Methods: The cohort study group consisted of 229 patients dia-
gnosed with carcinoid tumors who underwent surgery at the Na-
tional Tuberculosis and Lung Diseases Research Institute between 
1998-2011. We evaluated all microscopic samples from main tumor 
and adjacent, as well as peripheral parenchyma of the lung. When 
features of neuroendocrine cell proliferation were found, immuno-
histochemical reaction were done using markers of epithelial diffe-
rentiation (cytokeratins, TTF-1, Napsin A), neuroendocrine antigens 
(chromogranin A, synaptophysin, NCAM/CD56). The cell prolifera-
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P3.18-012 THE HIDDEN 50% OF THE ALK POSITIVE  
NSCLC PATIENTS
Marina Pekar1, Murry W. Wynes2, Maya Ilouze1, Mirna Knight2, 
Vincent Miller3, Doron Lipson3, Siraj Ali3, Gary Plamer3, Lior Sous-
san-Gutman4, Addie Dvir4, Fred Hirsch2, Nir Peled1
1Sheba Medical Center, Tel Aviv University/Israel, 2University Of Colo-
rado Cancer Center/United States Of America, 3Foundation Medicine/
United States Of America, 4Oncotest-teva Pharmaceutical Industries/
Israel
Background: Patients with lung adenocarcinoma carrying the ALK 
gene rearrangement show dramatic response to ALK TKIs (e.g. 
crizotinib). The currently approved method for detection of ALK 
gene rearrangements is fluorescence in situ hybridization (FISH), 
however gene sequencing can also be used for detecting ALK 
rearrangement. Aberrant ALK protein expression, as ALK is not 
normally expressed in the lung, can be detected with immunohis-
tochemistry (IHC). Our experience has shown a high rate of false 
negative ALK FISH patients, therefore we retrospectively investiga-
ted 53 cases with IHC and Next Generation Sequence (NGS).
Methods: 53 patients with NSCLC adenocarcinoma were tested 
for ALK rearrangement by FISH (Oncotest-TEVA Ltd, Israel). Re-
trospective IHC (D5F3 antibody, Cell Signaling) was done at the 
University of Colorado Cancer Center. Discordance cases were 
sequenced by "FoundationOne” (Foundation Medicine Inc).
Results: Out of the 53 cases, 4 (7.5%) were FISH positive, and 8 
(15%) were IHC positive with 3 cases both FISH+ and IHC+ (Figure 
1 , Table 1). One specimen was FISH+ and IHC-. NGS was perfor-
med on the 5 IHC+/FISH- mismatched samples and found 4 out 
of the 5 cases positive for ALK rearrangement. The true positive 
incidence of ALK rearrangement in our cohort increased by 100%, 
from 7.5% to 15%. Interestingly, two patients were found to harbor 
a unique ALK rearrangement at intron 19. One of them showed a 
dramatically improvement to crizotinib (PFS=18 months).  
FISH IHC Patients NGS ALK rearrangement + 
+ + 3 3 
- - 44 0* 
+ - 1(1.8%) 0 
- + 5(9.4%) 4 4 
Total 53 4 7 
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NSCLC patient population in order to elucidate progressive clinic-
pathological and genetic abnormalities.
Methods: NSCLC pts with adequate tissue samples before and 
after at least one treatment have been evaluated from July 2006 to 
March 2013, at Department of Oncology of San Luigi Hospital. All 
had ECOG Performance Status of 0, median age of 51,5 years and 
IIIA-IV stage at diagnosis. After histological examination, mutati-
onal analyses for EGFR, K-RAS, PIK3CA, B-RAF, and HER2 genes 
were performed using pyrosequencing or RealtimePCR. ALK and 
c-MET genomic rearrangement were tested by FISH.
Results: A total of 24 (12 males and 12 females) pts were collec-
ted. Histological diagnoses were re-confirmed in all but one (4%) 
case in which morphological and immunophenotypical histology 
of neuroendocrine small cell lung cancer (SCLC) was found. All 
samples were adequate for molecular analyses. At the first biopsy 
EGFR activating mutations were 10/24 (42%) and 3/24 (12,5%) were 
the exon 20 EGFR p.T790M mutation, 2/3 (66%) associated to 
EGFR activating mutations. At the second biopsy 6/10 (60%) EGFR 
activating mutations were maintained and no acquired mutations 
in EGFR wild type pts at first were found at second biopsy. On the 
other hand, 6/24 (25%) p.T790M mutation were detected at second 
biopsy, 5/6 (83%) de novo acquired, 1/6 (17%) maintained and only 
1/5 (20%) associated to EGFR activating mutations. The patient 
who acquired SCLC histology, maintained the L858R EGFR acti-
vating mutation after treatment with no other acquired mutation. 
K-RAS mutations were found in 4/24 (16.7%) first biopsies, while 
5/24 (21%) were found at the second biopsies. No mutations were 
found in BRAF, HER2 and PIK3CA genes. ALK rearrangement was 
assessed in 5/24 (20,8%) patients; otherwise MET amplification was 
seen in 3/24 (12.5%) cases only 1/3 (30%) in EGFR mutant cases.
Conclusion: These preliminary data showed a complex scenario 
of basal and acquired alterations on tumor tissue before and after 
treatment highlighting the need of repeated histological and ge-
notypic assessments to guide at the best treatment decisions.
Keywords: genetic abnormalities, non-small cell lung cancer, his-
tological re-evaluation, genotypic analysis
tion index with Ki-67 and expression of CD117 were estimated.
Results: DIPNECH was confirmed in 15 patients, 14 females and 1 
male with an average age 65,2 (range 32 – 79 ys). In 7 cases, carci-
noid tumors were found in more than one focus, both typical (TC) 
and atypical (AC) carcinoid. The lesions exhibited a diameter with 
an average size of 1,9 (range from 0,6 to 3,0 cm). In one patient, 
apart from TC and AC, numerous foci of sclerosing haemangioma 
were found. Three patients had a history of cancer surgery (mas-
tectomy, kidney resection, and hemicolectomy). In all cases, no 
metastases of primary tumors were evident. Almost all of the dia-
gnosed carcinoid tumors, except one, were located peripherally, 
with mainly spindle-cell morphology, solid and/or insular pattern 
and foci of fibrosis. In 1 case, one of the tumorlet infiltrated the 
pleura but it did not extend beyond its margins. In all patients, the 
neureondocrine cells, tumorlets and carcinoid tumors displayed 
intensive positive reactions to neuroendocrine markers. Silimilarly, 
a positive reaction to cytokeratin was confirmed but in the most 
cases (73%) it was semi-intensive or weak. In all cases the expres-
sion of TTF-1 was positive but in the most cases weak. No positive 
reaction to napsin A and CD117 was detected. The proliferation in-
dex in DIPNECH was 1-2%, but in carcinoid depended of subtype 
of tumor, for TC was lower than 4%, for AC higher than 4%. Bcl-2 
was evident in 9 DIPNECH and carcinoid tumor. Serotonin expres-
sion was found in 8 carcinoid tumors. 13 patients were alive at the 
end of follow-up, there were no information about 2 cases.
Conclusion: DIPNECH is a rare condition predominantly connec-
ted with carcinoid tumors, both TC and AC. Immunohistochemical 
profile is similar to peripherally located carcinoids. We suppose 
that there are biological differences between central and periphe-
ral carcinoids, in that the latter stain more frequently with TTF-1, 
serotonin and Bcl-2. Peripheral are more often spindled in mor-
phology and seen in cases that present with DIPNECH.
Keywords: DIPNECH, pulmonary carcinoids, Immunohistoche-
mistry
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P3.18-014 IMPLEMENTING SYSTEMATIC HISTOLOGICAL 
AND GENOTYPIC RE-EVALUATION OF NON SMALL 
CELL LUNG CANCER (NSCLC) INTO ROUTINE CLINICAL 
PRACTICE: A MONOCENTRIC STUDY
Simona Vatrano, Tiziana Vavala‘, Luisella Righi, Silvia Novello, 
Stefania Izzo, Susanna Cappia, Giorgio V. Scagliotti, Mauro Papotti
Department Of Oncology, University Of Turin/Italy
Background: Cancer is a multistep process in which tumor cells 
progressively harbour genetic alterations that confer growth and 
spread advantages. These observations are also confirmed in 
NSCLCs where specific genetic abnormalities are sensitive to the 
action of targeted drugs, even if secondary mutations could deve-
lop conferring drug resistance. Furthermore, in recent studies, his-
tologic and immunophenotypic changes have been described in 
patients (pts) with a specific molecular alteration re-biopsied after 
receiving a targeted therapy. This finding suggest the possibility of 
a "clonal resistance mechanism“ in which genetic-similar cell po-
pulations had or acquire selective survival features thus escaping 
the inhibitory drug effect. In the present study histological exami-
nation and wide genetic analyses have been performed in tumor 
tissue sampled both before and after treatment in an unselected 
S1258 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
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Conclusion: Our triple marker showed a similar specificity and 
sensitivity as individual markers and yielded optimal conservation 
of tissue for molecular testing.
Keywords: IHC markers, lung cancer subclassification, immunohis-
tiochemistry
POSTER SESSION 3 - PATHOLOGY  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.18-015 THE UTILITY OF A NOVEL TRIPLE MARKER 
(COMBINATION OF TTF, NAPSIN-A AND P40) IN THE 
SUBCLASSIFICATION OF NON-SMALL CELL LUNG  
CANCER (NSCLC).
Hui Zhang1, Ming-Hui Ao1, Peter Illei2, Edward Gabrielson1, Frede-
ric Askin1, Qing Kay Li1
1Pathology, The Johns Hopkins Medical Institutions/United States Of 
America, 2Dept Of Pathology, Johns Hopkins/United States Of America
Background: Personalized treatment of lung cancers necessitates 
the subclassification of NSCLC into adenocarcinoma (ADC) and/
or squamous cell carcinoma (SqCC). In most cases, NSCLC can be 
subclassified by routine histomorphological examination of tu-
mors. However, in poorly differentiated tumors or on small biopsy 
specimens, the subclassification may be difficult by H&E slides 
alone. Therefore, a panel of immunehistochemical (IHC) markers, 
including TTF1, Napsin A for adenocarcinoma (ADC) and CK5/6, 
p63 and p40 for squamous cell carcinoma (SqCC), are usually used 
to aid in the subclassification, These panels need to be performed 
on multiple tissue sections, and may result in the exhaustion of 
tumor tissue for molecular tests. In order to preserve tumor tissue, 
we investigated the utility of a newly developed triple marker (a 
combination of TTF, Napsin A and p40) in the subclassification of 
NSCLC; and compared the sensitivity and specificity of this novel 
triple marker with commonly used individual markers.
Methods: Using pathology archives from Johns Hopkins Hospital, 
three lung cancer tissue microarrays (TMAs) were constructed 
using surgical resection material, including 77 cases of ADC, 75 ca-
ses of SqCC and 46 cases of metastatic lung ADC. Immunostaining 
patterns of the triple marker and individual markers were scored 
semi-quantitatively and compared.
Results: In ADC, the sensitivity and specificity of the triple marker 
showed 93.50% and 77.50%, respectively (Table 1). In SqCC, the 
sensitivity and specificity of the triple marker showed 100% and 
92.50%, respectively (Table 2). In addition, the sensitivity and spe-
cificity of the triple marker in metastatic ADC showed 71.74% and 
77.50%. Table 1. Immunostaining patterns of different markers in 
lung ADC (n=77 cases)  
IHCscores
Markers 0 1 2 3 Sensitivity Specificity P value
Triple marker 6.5% 10.4% 13.0% 70.1% 93.5% 77.5%
TTF 14.3% 5.2% 32.5% 48.1% 85.7% 75.0% 0.185
Napsin A 10.4% 9.1% 22.1% 58.4% 89.6% 90.0% 0.564
 
Table 2. Immunostaining patterns of different markers in lung 
SqCC (n=75 cases) 
IHC scores
Markers 0 1 2 3 Sensitivity Specificity P value
Triple marker 0% 29.3% 33.3% 37.3% 100% 92.5%
p40 0% 32.0% 29,3% 38.7% 100% 90.0% 1.0
p63 0% 24.0% 45.3% 30.7% 100% 80.5% 1.0
CK5/6 5.3% 22.7% 36.0% 36.0% 94.7% 80.0% 0.12
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Results: There were no differences in nodule sizes between two 
groups (1.45±0.6 versus 1.51±0.5, p=0.63). In group A, a correct 
differential diagnosis between malignancies and benign lesions 
were made in 138 nodules. Thirteen nodules were erroneously 
classified and reported as false-positive or false-negative frozen 
section diagnoses (Sensitivity 95.6%, Specificity 53.8%). Three 
nodules were under-diagnosed in FSD. One patient required a 
secondary operation because of false-negative frozen diagnosis 
at the time of initial surgery. In group B, all of 17 nodules were 
correctly classified by frozen section. There were no false-positive 
or false-negative diagnoses in terms of making a diagnosis of ma-
lignancy, resulting in 100%-sensitivity and -specificity. (Figure 1) 
Thirteen nodules were correctly classified as being either minimally 
invasive adenocarcinoma (MIA) or invasive adenocarcinoma. Three 
nodules were diagnosed as MIA by frozen section through measu-
ring invasive tumor size (<5mm) concomitantly. With regards to the 
estimating the size of invasive components of GGN, FSD in group 
B was superior to measurement of solid component in GGO nodu-
les on HRCT. (Table 1)
Conclusion: The accuracy of FSD using the embedding medium 
inflation method in GGO nodules was outstanding compared to 
the conventional frozen method. Furthermore, this method can 
help surgeons plan the appropriate surgical treatment after wedge 
resection of a GGO nodule by providing accurate size estimation 
of the invasive components of the GGN.
Keywords: Frozen diagnostic section, inflation method, Pulmonary 
ground glass nodules, invasive tumor size
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P3.18-016 THE USEFULNESS OF FROZEN SECTION DI-
AGNOSIS AS FOR THE DECISION MAKING MILESTONE 
DURING THE SURGERY FOR PULMONARY GROUND 
GLASS NODULES: EMBEDDING MEDIUM INFLATION 
TECHNIQUE
Yoohwa Hwang1, Jaehyun Jeon1, Jae Moon Koh2, Yong Won Sung3, 
Hyun Joo Lee1, In Kyu Park1, Chang Hyun Kang1, Doo Hyun Chung2, 
Jin Mo Goo4, Young Tae Kim1
1Thoracic And Cardiovasar Department, Seoul National University 
Hospital/Korea, 2Department Of Pathology, Seoul National University 
Hospital/Korea, 3Thoracic Surgery, Smg-Snu Boramae Medical Center/
Korea, 4Radiology, Seoul National University Hospital/Korea
Background: The appropriate intraoperative decision making of 
surgical resection for the pulmonary ground glass nodules (GGN) 
is often difficult. We aimed to evaluate the role of frozen section 
diagnosis (FSD) as for the intraoperative decision making milesto-
ne and compared its accuracy to that of preoperative CT based 
practice as an interim result.
Methods: We retrospectively reviewed FSD of 171 consecutive 
pulmonary GGN from February 2005 to June 2013 and compared 
the diagnostic accuracy. Initially, we used only conventional me-
thod (Group A) but recently, we adapted a embedding medium 
inflation method (Group B) for FSD. The qualities of FSD were 
compared with the final pathologic diagnoses of corresponding 
permanent paraffin sections. Also, we calculated the sensitivity, 
specificity, and predictive values of assessing the size of invasive 
portion in GGN between FSD using the inflation method and pre-
operative CT based practice.
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P3.18-018 RESULTS OF UPFRONT GENOMIC TESTING 
IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS 
(MSN STUDY)
David Planchard1, Ludovic Lacroix2, Laura Faivre3, Maud Ngo Ca-
mus1, Virginie Kahn-Charpy1, Nathalie Auger2, Caroline Caramel-
la4, Valérie Koubi-Pick2, Julien Adam2, Cecile Le Pechoux5, Thierry 
Le Chevalier1, Marianna Macerelli1, Jean-Pierre Pignon3, Arslane 
Rahal1, Valentina Polo3, Jean-Charles Soria1, Benjamin Besse1
1Department Of Medical Oncology, Institut-gustave-roussy/France, 
2Molecular Pathology, Gutave Roussy/France, 3Biostatistics, Gustave 
Roussy/France, 4Department Of Radiology, Institut-Gustave-roussy/
France, 5Radiotherapy Dept, Institut Gustave Roussy/France
Background: Recent advances in lung cancer have identified po-
tential driver mutations that may be targeted. On the basis of rou-
tine screening for EGFR we have initiated a comprehensive large-
scale sequencing analysis of genes potentially mutated in NSCLC.
Methods: Genomic DNA was extracted prospectively from untrea-
ted advanced NSCLC tumors. All materiel was obtained IRB-appro-
ved protocols and after patients’ consent (MSN trial "Melanoma 
– Small-cell lung cancer – Non-small cell lung cancer "). Pathology 
specimens were macrodissected, after DNA extraction, 106 se-
lected exons from 38 genes were analyzed by Sanger sequencing 
(EGFR, KRAS, HER2,4, BRAF, PI3KCA, PIK3R1, TP53, CDK4, CDK-
N2A, cKIT, PDGFRA, MET, FGFR2-4, FCGR2A,3A, FLT3, CTNNB1, 
GNAS, HRAS, NRAS, KDR, PDPK1, TOP1,2A, ERCC1, FBXW7, TSC2, 
PTEN, AKT1-3, MAP2K1-2, STK11, ALK). ALK rearrangements and 
HER2 amplification were detected by FISH. All result therapeutic 
outcomes were discussed monthly in a molecular thoracic multidis-
ciplinary staff.
Results: Thus far (between May 2009 and September 2012), 351 
patients (pts) have been included. The median age was 60 years 
(range 22-87), 212 (60%) were male, 248 (71%) had adenocarcino-
ma, 286 (81%) were former/current smokers. A complete failure of 
the analysis was observed in 78 (22%) pts mostly due to insufficient 
tumor cells in the specimen (<30%) or poor quality DNA. EGFR, 
KRAS, HER2, BRAF, PI3CA and ALK (“standard biomarkers”), ana-
lysis were performed in 235 (67%), 233 (66%), 207(59%), 221(63%), 
139 (40%) and 206 (59%) pts respectively. Depending of markers, 
success rate was between 77% and 86 % (failures include scarce 
tumor sample). Two hundred and sixty three pts had at least one 
result for the EGFR, KRAS or ALK, and 176 pts had all three. 107 
pts had a whole genomic analysis and 244 had at least one (1-6 
biomarkers) standard biomarkers analysis. Ten (3.8%) pts had con-
current oncogenic mutation. The molecular profiles were charac-
terized by 16% EGFR, 26% KRAS, 1% HER2, 0.8% PI3KCA mutated, 
7% HER2 amplification and 11% ALK rearrangement. The pts with 
the while genomic analysis had 12 other genes evaluated for more 
than 80 pts and 13 pts had mutation (STK11, PDPK1, PTEN, NRAS, 
MET, KDR, FGFR4, HER4). A personalized targeted therapy was 
proposed in most of pts with a genomic alteration. Median OS 
of pts with at least one mutation/translocation for EGFR, KRAS, 
BRAF or ALK (n=152) was 13 and 17 months (p=0.006) in wild type 
or mutated pts respectively. In univariate analysis for OS (median 
follow-up: 19 months), KRAS mutated pts had a poor prognosis 
(hazard ratio [HR]=1.56, p=0.037), confirmed in multivariate analy-
sis (HR= 1.78, p=0.008), EGFR mutated pts had a good prognosis 
(HR=0.48, p=0.01), BRAF and ALK mutations/translocation had no 
prognostic value.
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P3.18-017 BIOBANKING IN LUNG RESEARCH -  
QUALITY AND TECHNICAL ASPECTS
Michael Lindner, Anja Stowasser, Christine Friedrich, Laura V. 
Klotz, Rudolf Hatz, Ina Koch
Thoracic Surgery, Center Of Thoracic Surgery Munich, Ludwig Maximi-
lians University Munich, Asklepios Clinic Munich/Germany
Background: The basic aim of a biobank is to provide biomaterials 
of high quality for research purposes including frozen archived 
samples, but also fresh tissue and viable cells, combined with 
relevant clinical data. This study presents workflow and quality 
management.
Methods: Patients are enclosed after signing a broad informed 
consent, allowing use of the samples in future research, and inclu-
ding molecular analysis. Samples are collected independently of a 
defined research project. Double pseudonymisation ensures priva-
cy of donors. After pathological analysis the surplus of the harves-
ted tissue is processed in RNAlater. Tissue samples as well as pre- 
and postoperative sera are archived at -80°C. Corresponding FFPE 
blocks are stored at room temperature. Bronchial lavages, pleura 
fluid, bronchial brush and transbronchial biopsies are integrated. 
In collaboration with researchers, fresh, unpreserved tissue is pro-
cessed according to individual needs, such as filling with Agarose 
for three-dimensional tissue culture or in media for cell isolation.
Results: Between 01/2009 and 12/2012 around 1200 patients do-
nated tissues to the biobank. In general, samples are processed 
within 20 minutes. We compared processing of samples in RNA-
later with direct freezing in liquid nitrogen with times of ischemia 
between 5 minutes and 3 hours. We could not see any differences 
in RNA quality or the expression level of 4 genes tested between 
RNAlater or liquid nitrogen processed samples. Times of ischemia 
of up to three hours had no influence on RNA quality or expressi-
on, possibly due to compartmentalisation of RNAses in still intact 
cells. Samples were appropriate for protein analytical techniques 
such as Western Blot and ELISA. Histological slides from RNAlater 
samples were well evaluable by pathologists and comparable to 
normal cryosections.
Conclusion: The challenge of the biobank is a proactive tissue 
acquisition by pulmonary physicians trained in endobronchial tech-
niques and thoracic surgeons in close collaboration with a patho-
logist. As a result global scientific work is feasible in a network like 
the German lung science center.
Keywords: BiobaNKIng, Biomedical Research
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and heterogeneity underlying NSCLC tumors.
Keyword: molecular profiling, lung cancer
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P3.18-020 THE MUTATIONAL PROFILE OF LUNG  
ADENOCARCINOMA IN KOREAN POPULATION
Yoo Jin Jung1, Heounjeong Go2, Sae Bom Lee1, Samina Park1, Hyun 
Joo Lee1, In Kyu Park1, Chang Hyun Kang1, Doo Hyun Chung2, 
Young Tae Kim1
1Thoracic And Cardiovascular Surgery, Cancer Research Institute, Seoul 
National University Hospital/Korea, 2Department Of Pathology, Seoul 
National University Hospital/Korea
Background: Recent development of molecular target agents 
encouraged us to investigate the presence of driver mutations 
in patients with non-small cell lung cancer. As the prevalence of 
individual driver mutation is different in each ethnic group, under-
standing of mutational profiles of a specific country is important 
for clinical practice as well as for decision-making process of health 
care. Hence, we investigated the genetic profile of lung adenocar-
cinoma in Korean population.
Methods: Among the patients who underwent surgical resection 
for lung adenocarcinoma between 2001 and 2011, we set up a 
total of 477 patients whose fresh frozen lung cancer tissues and 
paraffin blocks were available. We retrospectively searched medi-
cal records of the EGFR exons 18-21 mutation tests results. Then, 
we selected patients who did not harbor EGFR mutations or who 
had not tested for EGFR mutations. DNA was extracted from those 
patients’ samples, and EGFR exons 18-21 and KRAS mutation test 
were performed by Sanger sequencing method. Tissue microarray 
was made for all 477 patients, and the EML4-Alk fusion was tested 
by a break-apart FISH method. We also tested KIF5B-RET fusion 
by using a break-apart FISH method and also by inversion specific 
long-range PCR. We investigated any correlation between muta-
tional status and clinical variables, such as age, gender, smoking 
status, stage, and long term survivals.
Results: Among 477 patients, 321 patients (67.3%) were harboring 
at least one of four driver mutations. The EGFR mutations were the 
most frequently detected (270, 56.6%), followed by KRAS muta-
tions (37, 7.8%), and EML4-Alk fusion (19, 4.0%). We also found five 
patients who had KIF5B-RET fusion mutations (1.0%). There were 
10 patients who had more than two driver mutations; EGFR and 
KRAS mutations in 4, EGFR and EML4-Alk fusion in 4, KRAS and 
EML4-Alk fusion in one, and EGFR and KIF5B-RET fusion in one 
patient. The presences of EGFR mutations were frequently obser-
ved in patients with female gender (p=0.000). Although the EGFR 
mutations were associated with longer overall survival in univariate 
analysis (log-rank test rank test p=0.007), the presence of EGFR 
mutation was not a prognostic factor in multivariate analysis (Cox’s 
regression test p=0.469). The mutational statuses were associated 
with neither the disease-free survival nor fthe reedom from recur-
rence.
Conclusion: Based on our work, we found as high as 67.3% of lung 
adenocarcinoma patients in Korean populations were harboring 
at least one driver mutation, which may get a benefit from target 
agents. We also found as high as 2% of patients harbored multiple 
driver mutations. As the target agent will eventually develop resis-
Conclusion: Routine mutational profiling of advanced NSCLC is 
feasible in the vast majority of the pts but an extensive molecular 
portrait can be performed only in a limited number of pts. The mo-
lecular profile may have an impact on pts treatment strategy at our 
cancer institute. KRAS mutation is associated with poor prognosis. 
Updated results will be presented.
Keywords: NSCLC, EGFR, genomic analysis, mutation
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P3.18-019 PROFILING OF ACTIONABLE ALTERATIONS  
IN LUNG ADENOCARCINOMA
Kumar Prabhash1, Pratik Chandrani2, Jyotirmoi Aich2, Pawan 
Upadhyay2, Anuradha Chougule1, Vanita Noronha1, Amit Joshi1, 
Saral Desai3, Nirmala Jambekar3, Abhishek Thavamani2, Tony 
Jose4, Puneet Chandna5, Amit Dutt6
1Tata Memorial Hospital/India, 2Actrec/India, 3Pathology, Tata Memori-
al Hospital/India, 4Sandor Proteomics Pvt. Ltd/India, 5Aceprobe Techno-
logies Pvt. Ltd/India, 6Actrec, Dutt Lab/India
Background: Lung cancer remains a major unmet medical need 
in India and worldwide. About 63,000 new cases are diagnosed 
each year in India with deaths estimated at approximately 52,000, 
accounting for about 8% of all cancer deaths.Currently available 
cytotoxic chemotherapy is clearly inadequate for treatment of lung 
cancer. Therapies targeting the EGFR and ALK tyrosine kinases 
have proven effective for lung adenocarcinoma patients whose 
tumors harbor genomic alterations of the EGFR and ALK genes, 
respectively. However, most lung adenocarcinomas do not harbor 
these alterations and are not responsive to the relevant treatments. 
Hence, identification of mutationally activated oncogenes in lung 
cancer could result in additional therapeutic targets for this deadly 
disease.
Methods: 676 exons from 196 were capturedin a discovery set 
of 125 Indian lung adenocarcinomasamples (FFPE blocks)using 
microfluidics based RainDance RDT-1000platform. The libraries 
were multiplexed and sequenced on Illumina Genome Analyser 
IIx. to obatin 1000X coverage per samples per base.Sequencing 
data were analysedusing in-house customized informtaicspipe-
line to identify potential driver alterations. 39 significantly altered 
mutations (novel and those known to be altered in NSCLC)were 
genotyped in an additional validation set of 300lung adeomcarci-
nomasamples using Sequenom MassArray.
Results: This is the firstreport of most comprehensive spectrum of 
alterations in 300Indian lung adenocarcinoma patients. We have 
identifiedmutation in genes previously reported as significantly 
mutated in lung adenocarcinoma: TP53, EGFR, KRAS, ERBB2, PIK-
3CA and NRASalong with previously unknown mutation incidence 
in AKT1 and NF2. In addition, we identified statistically recurrent 
mutations in the members of the fibroblast growth factor receptor 
familyin a subset of NSCLC tumors.
Conclusion: We identifyFGFRfamilyas a potential therapeutic 
target, a new avenue of investigation for the treatment of lung 
adenocarcinomas of Indian origin. This study also establishes a 
significant technological advancement for using cutting edge tech-
nologies on FFPE clinical specimens for high definition genomics, 
which has been a major impediment. in clinical research.In over all, 
this study enhances our understanding of the genomic complexity 
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mathematical approach was 35 out of 46 (76%). In 4 cases in which 
the visual judgment was clonal, the mathematical model determined 
clonal as well as non-clonal samples. In 7 cases discordance was no-
ted: the visual outcome was clonal and the mathematical non-clonal.
Conclusion: Array CGH is a useful approach for evaluating clonality 
of synchronic or metachronic tumors.
Keyword: clonality array CGH
tance, it is recommended to test each driver mutation thoroughly 
even if one driver mutation was detected. Furthermore, our obser-
vation suggests future molecular testing should be based on the 
next generation sequencing platform.
Keywords: Lung cancer, Adenocarcinoma, Mutation Profile
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P3.18-021 ARRAY CGH IS USEFUL IN THE EVALUATION 
OF PATIENTS WITH SYNCHRONIC OR METACHRONIC 
TUMORS
Julien P.L. Vincenten1, H F. Van Essen2, Nicole Bulkmans3, O Krijgs-
man4, Katrien Grünberg5, Egbert Smit6, Pieter E. Postmus6, Gerrit A 
Meijer5, Bauke Ylstra2, Erik Thunnissen5
1Pulmonary Diseases, Albert Schweitzer Hospital/Netherlands, 2Micro 
Array Facility, VU University Medical Center/Netherlands, 3Pathology, 
Kennemer Gasthuis/Netherlands, 4Micro Array Facility, VU University 
Hospital/Netherlands, 5Pathology, VU University Medical Center/Nether-
lands, 6Pulmonary Diseases, VU University Medical Center/Netherlands
Background: Synchronic or metachronic tumors may develop in pa-
tients with a lung tumor. Determining whether these tumors origina-
te from the same clone or are separate lesions may be challenging. 
Clinical, morphological and immunohistochemical criteria are often 
not distinctive. The aim of our study was to investigate comparative 
genomic hybridization (array CGH) analysis for the evaluation of 
clonality in patients with metachronic or synchronic tumors, having 
at least one intrathoracic tumor localization.
Methods: A database was constructed of consecutive patients 
(n=77) referred by clinicians or pathologists for assessment of clo-
nality by array CGH from 2007 till 2012. All cases with at least one 
intrathoracic tumor were selected. The array CGH patterns were 
analyzed by a visual comparison of CGH patterns performed by two 
investigators and by two mathematical models on the raw data. One 
model uses a log likelihood ratio as described previously1, the other 
a Pearson correlation between the segmented values. Clonality cut-
off and p-values were set according to copy number profiles from 
individual patients, which are therefore by definition non-clonal. The 
results of the visual evaluation and the mathematical approach were 
correlated. A control group was formed by the specimens of one 
lung tumor from every patient in the database, which were all com-
pared, using the mathematical models. 1. Ostrovnaya I, Seshan VE, 
Olshen AB, et al. Clonality: an R package for testing clonal related-
ness of two tumors from the same patient based on their genomic 
profiles. Bioinformatics. 2011;27:1698-1699.
Results: Specimens of 77 patients were referred for analysis. Sam-
ples of 14 cases were not suited to array CGH due to insufficient 
material or bad quality of DNA. The remaining 63 cases comprised 
of 142 samples. In 8 patients DNA from more than 2 tumors was 
compared. In the mathematical model the outcome of 3 cases was 
missing, 23 cases were determined clonal, 22 non-clonal, 5 with 
clonal as well as non-clonal tumors and 10 were undetermined. In 
the negative control group > 96% of cases were scored as non-
clonal. The visual analysis determined 40 cases clonal, 14 non-clonal, 
1 with clonal as well as non-clonal tumors and 8 were undetermined. 
46 cases were available for comparing the outcomes of the mathe-
matical and visual evaluation, as for 3 cases data were missing and 
in 14 cases the outcome was undetermined. The concordance rate 
for clonal and non-clonal tumors between visual analysis and the 
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P3.19-002 FIBROTIC CHANGES ON LOW-DOSE CHEST 
CT AS A RISK FACTOR OF LUNG CANCER DEVELOP-
MENT IN SUBJECTS WITH ASBESTOS EXPOSURE
Kenichi Gemba1, Nobukazu Fujimoto2, Katsuya Kato3, Kazuto As-
hizawa4, Hiroaki Arakawa5, Takumi Kishimoto2
1Respiratory Medicine, Fukuyama Medical Center/Japan, 2Respirato-
ry Medicine, Okayama Rosai Hospital/Japan, 3Radiology, Okayama 
University Hospital/Japan, 4Radiology, Nagasaki University Hospital/
Japan, 5Radiology, Dokkyo Medical University Hospital/Japan
Background: Asbestos is known for one of the risk factors of lung 
cancer (LC). The subjects with asbestos exposure are considered 
to have increased risk of LC especially if chest X-ray shows fibrotic 
changes of the lung. However, there are few reports about the 
association between the risk of LC and fibrotic changes detected 
by chest CT. The aim of this study was to define the specific CT 
findings of risk of LC among the subjects with asbestos exposure.
Methods: The low-dose chest CT(LD-CT) was taken as LC scree-
ning with written informed consent in subjects with former asbes-
tos exposure in a prone position with the dose less than 30mAs. 
Each image was independently interpreted with more than two 
radiologists especially focused on fibrotic changes including sub-
pleural curvilinear shadow/subpleural dots, reticular shadow, par-
enchymal band, traction bronchiectasis, and honeycombing. These 
findings were scored according to the extent. A chi square test 
was used to investigate the difference of categorical variables, and 
Mann-Whitney U test was applied as a non-parametric test.
Results: Between 2010 and 2012, chest LD-CT was taken in 2,126 
subjects at 8 institutions in Japan. During the period, 38 (1.79%) 
LC was detected. We compared LC group and non-LC group, and 
there was no difference of duration of occupational asbestos ex-
posure, or the prevalence of fibrotic changes on chest LD-CT. The 
extent of the fibrosis determined by scoring of the LD-CT findings, 
however, was more prominent in LC group than in non-LC group, 
though it was not statistically significant (p=0.067). On the other 
hand, LC developed more frequently in subjects with some fibrotic 
change (2.67%) than in those without any fibrotic change (1.44%, 
p=0.067).
Conclusion: The fibrotic changes of the lung detected on LD-chest 
CT might be the risk factor of LC development in subjects with for-
mer asbestos exposure. Further examination is planned with more 
subjects and longer period of observation.
Keywords: risk factor, asbestos exposure, fibrotic change, low-
dose CT
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P3.19-001 CORRELATION BETWEEN WHOLE TUMOR 
SIZE AND SOLID COMPONENT SIZE ON HIGH-RESOLU-
TION COMPUTED TOMOGRAPHY IN THE PREDICTION 
OF THE DEGREE OF PATHOLOGIC MALIGNANCY AND 
THE PROGNOSTIC OUTCOME IN PRIMARY LUNG ADE-
NOCARCINOMA
Hisashi Saji1, Jun Matsubayashi2, Soichi Akata3, Yoshihisa Shima-
da4, Yasufumi Kato4, Yujin Kudo4, Masatoshi Kakihana4, Naohiro 
Kajiwara4, Tatsuo Ohira4, Norihiko Ikeda4
1Chest Surgery, St. Marianna University School Of Medicine/Japan, 
2Anatomic Pathology, Tokyo Medical University/Japan, 3Radiology, 
Tokyo Medical University/Japan, 4Thoracic Surgery, Tokyo Medical 
University/Japan
Background: It is known that in lung adenocarcinoma, ground 
glass nodule (GGN) tumors have a better prognosis than solid 
tumors. The aim of this study is to determine whether it is more 
useful to evaluate the whole tumor size or only the solid compo-
nent size to predict the pathologic malignancy and the prognostic 
outcome in lung adenocarcinoma.
Methods: Using high-resolution computed tomography (HRCT) 
data of 232 patients with adenocarcinoma 7 cm or less who under-
went curative resection, we retrospectively measured the whole 
tumor and solid component sizes with lung window setting (WTLW 
and SCLW) and whole tumor sizes with a mediastinal window set-
ting (WTMW).
Results: There was significant correlation between the WTLW and 
the measurements of pathological specimens (r=0.792, P<0.0001). 
The SCLW and WTMW values significantly correlated with the 
area of pathologically confirmed invasion (r=0.762, P<0.0001 and 
r=0.771, P<0.0001, respectively). The receiver operating cha-
racteristics area under the curve for WTLW, SCLW and WTMW 
used to identify lymph node metastasis or lymphatic or vascular 
invasion were 0.693, 0.817 and 0.824, respectively. Kaplan-Meier 
curves of DFS and OS were better divided according to SCLW and 
WTMW, compared with WTLW. Multivariate analysis of DFS and 
OS revealed that WTMW was an independent prognostic factor 
(HR=0.72, 95%CI=0.58-0.90, P=0.004 and HR=0.74, 95%CI=0.57-
0.96, P=0.022, respectively).
Conclusion: The predictive values of the solid tumor size visualized 
on HRCT especially in the mediastinal window for pathologic high-
grade malignancy and prognosis in lung adenocarcinoma less than 
7 cm were greater than those of whole tumor size.
Keywords: lung adenocarcinoma, Prognosis, solid component, 
ground glass nodule
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P3.19-004 COMPARISON OF OBJECTIVE CRITERIA AND 
EXPERT VISUAL INTERPRETATION TO CLASSIFY BENIGN 
AND MALIGNANT HILAR AND MEDIASTINAL NODES 
ON 18-F FDG PET/CT.
Phan Nguyen1, Manoj Bhatt2, Farzad Bashirzadeh3, Justin Hund-
loe3, Robert Ware4, David Fielding3, Aravind Ravi Kumar2
1Thoracic Medicine, The Royal Adelaide Hospital/Australia, 2Queens-
land Pet Service/Australia, 3Royal Brisbane And Women‘s Hospital/
Australia, 4Queensland Children‘s Medical Research Institute/Australia
Background: Despite the widespread adoption of FDG-PET/CT in 
staging of lung cancer, there are no universally accepted criteria for 
classifying thoracic nodes as malignant. Previous studies have gene-
rally shown high negative predictive values, but there are varying re-
porting criteria and positive predictive values for classifying malignant 
involvement. Using Endobronchial ultrasound transbronchial needle 
aspiration (EBUS-TBNA) histology as the gold standard, we evaluated 
objective 18-F FDG-PET/CT criteria for interpreting mediastinal and 
hilar nodes and compared this to expert visual interpretation (EVI).
Methods: A retrospective review of all patients with proven/suspec-
ted primary lung cancer who had both FDG-PET/CT and EBUS-TBNA 
from 2008-2010 was performed. Scan interpretation was blinded to 
histology. Separate prediction and validation datasets were used. 
104 patients from 2008/2009 formed the prediction set; 48 patients 
from 2010 formed the validation set. Objective FDG-PET/CT criteria 
were: - SUVmax lymph node (SUVmaxLN) - Ratio SUVmaxLN/SUV-
max primary lung malignancy if evident (R-SUVmax primary) - Ratio 
SUVmaxLN/SUVaverage liver (R-SUVavg liver) - Ratio SUVmaxLN/
SUVmax liver (R-SUVmax liver) - Ratio SUVmaxLN/SUVmax blood pool 
(R-SUVmaxBP) An experienced Nuclear Medicine Physician visually 
reviewed all scans and classified each thoracic nodal station as beni-
gn, malignant, or equivocal. For statistical analysis, ‘equivocal’ nodes 
were classified benign.
Results: 87 malignant lymph nodes from 75 patients and 41 benign 
nodes from 21 patients were in the prediction set. All objective 18-F 
FDG-PET/CT criteria analysed were significantly higher in the mali-
gnant group compared to the benign group (p<0.0001 all criteria). 
EVI had 95.3% accuracy, with 83/87(95.4%) malignant nodes and 
39/41(95.1%) benign nodes correctly classified. 34 malignant nodes 
from 34 patients and 19 benign nodes from 14 patients were in the 
validation set. The new proposed cut-off values of the objective cri-
teria from the prediction set correctly classified 44/53(83.0%) nodes, 
with 28/34(82.4%) malignant nodes and 16/19(84.2%) benign nodes 
correctly classified. EVI had 91% accuracy, with 33/34(97.1%) malig-
nant nodes and 15/19 (79.0%) benign codes correctly classified. 
Conclusion: Objective analysis of 18-F FDG PET/CT can differentiate 
between malignant and benign nodes with high accuracy, but is not 
superior to EVI. For objective criteria to perform optimally, there may 
need to be different criteria devised for different patient populations.
Keywords: FDG-PET CT, image analysis, endobronchial ultrasound
POSTER SESSION 3 - IMAGING  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.19-003 THE CORRELATION BETWEEN COMPUTED 
TOMOGRAPHY FINDINGS AND THE CLINICOPATHOLO-
GICAL FACTORS IN SMALL-SIZED ADENOCARCINOMAS 
OF THE LUNG (10 MM OR LESS IN DIAMETER)
Fumi Karino1, Shuji Murakami1, Tetsuro Kondo1, Haruhiro Saito1, Fu-
mihiro Oshita1, Kentaro Imai1, Teppei Nishii1, Hiroyuki Ito1, Haruhiko 
Nakayama1, Tetsuya Isaka2, Tomoyuki Yokose2, Kouzo Yamada1
1Thoracic Oncology, Kanagawa Cancer Center/Japan, 2Pathology, Kana-
gawa Cancer Center/Japan
Background: We previously reported the correlation among the 
thin-section computed tomography (TS-CT) findings, the patho-
logical factors (Noguchi’s classification) and the prognosis of the 
patients. The purpose of this study was to examine the tumor sha-
dow disappearance rate (TDR) on TS-CT findings, clinical course 
and pathological factors of small-sized adenocarcinomas of the lung 
according to the 2011 IASLC/ERS Classification.
Methods: We retrospectively analyzed 111 peripheral non-mucinous 
adenocarcinomas of the lung ≤ 10 mm in diameter that were surgi-
cally resected at our institute between January 1997 and February 
2013. CT scans were obtained by commercially available scanners 
(X-Vigor/Real or Aquilion M/16 CT scanner; Toshiba Medical Sys-
tems; Tokyo, Japan). TS images were obtained with a 1 mm section 
thickness, pitch of 1, section spacing of 1 mm, 512 × 512 pixel re-
solution and 1 second scanning time. TDR was defined as the ratio 
of the maximum diameter of the tumor opacity of the mediastinal 
window to that of the lung window on TS-CT. We also examined the 
relationship among the TDR, the patient backgrounds, pathologi-
cal findings (i.e., lymph node metastasis, pleural invasion, vascular 
invasion and lymphatic invasion) and clinical course. The histologic 
subtypes were analyzed according to the 2011 IASLC/ATS/ERS Inter-
national Multidisciplinary Classification of Lung Adenocarcinoma.
Results: The median age of the patients was 64 (range, 23-83) years, 
and 66 patients (59.5%) were female. Sixty-four patients (57.7%) were 
never-smokers. The average tumor size was 8.7 mm (range, 5-10 
mm). Regarding the histological subtypes, 70 cases were adenocar-
cinoma in situ (AIS) or minimally invasive adenocarcinoma (MIA), 19 
were acinar predominant (AP), 13 were papillary predominant (PP) 
and seven were solid predominant (SP). Two cases could not be 
determined. Seventy cases diagnosed AIS or MIA were all stage IA, 
and none of these patients relapsed. Six cases relapsed after surge-
ry; three cases of AP, two of PP and one of a SP tumor. In a compa-
rison of the clinical course, the pathological differentiation and the 
TS-CT findings, all six cases relapsed after surgery showed ≤ 40% in 
TDR. Four cases diagnosed with lymph node metastasis (i.e., cases 
diagnosed in stage IIA or higher) showed ≤ 22% in TDR. Twelve 
cases with pleural invasion or vascular invasion or lymphatic invasion 
in the pathological factors of the resected lesions showed ≤ 28% in 
TDR. The TDR of AIS and MIA cases were all ≥ 50%.
Conclusion: There are sometimes pathologically invasive lesions 
even in small-sized adenocarcinomas of the lung. We found that 
the TDR is related to the clinical course and pathological factors 
in small-sized adenocarcinomas of the lung (10 mm or less in dia-
meter). The lesions with a TDR ≤ 40% in the TS-CT images may be 
a group of highly malignant with an increased risk of relapse. The 
TDR may contribute to the determination of the optimal therapeutic 
strategy. We need a more robust prospective study to validate the 
efficacy of TDR.
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P3.19-006 PSEUDOPATHOLOGIC VERTEBRAL BODY EN-
HANCEMENT IN THE PRESENCE OF SUPERIOR VENA 
CAVA OBSTRUCTION ON COMPUTED TOMOGRAPHY
Yon Mi Sung, Yoon Kyung Kim, Eun Kyung Cho
 Gachon University Gil Medical Center/Korea
Background: Superior vena cava (SVC) obstruction can cause 
development of collateral vessels. During contrast-enhanced tho-
racic CT, contrast material may reflux into the collaterals such as 
paravertebral venous plexus. However, unusual pseudopathologic 
vertebral body enhancement on CT in the presence of SVC obst-
ruction has not been studied previously. So, the aim of this study 
was to demonstrate clinical presentation and imaging findings of 
pseudopathologic vertebral body enhancement in patients with 
SVC obstruction.
Methods: From March 2009 to September 2012, a retrospective 
radiologic database review was performed to identify patients with 
obstruction of SVC causing contrast reflux into collateral vessels 
and presented with unusual vertebral body enhancement on tho-
racic CT. Thirteen patients (eleven men, mean age 51.4 years) with 
vertebral body enhancement were enrolled. The underlying disea-
ses that caused SVC obstruction were adenocarcinoma of the lung 
in four, non-small cell lung cancer in two, large cell neuroendocrine 
carcinoma, small cell lung cancer, thymic carcinoma, sarcomatoid 
carcinoma, diffuse large B-cell lymphoma, Hodgkin’s lymphoma 
and metastatic lymphadenopathy from pancreatic cancer in one 
patient each. Enhancement patterns, locations and the presence of 
a connection between vertebral body enhancement and the pa-
ravertebral venous plexus were evaluated. Enhancement patterns 
of vertebral bodies were classified as nodular enhancement with 
round shape that occupying < 1/3 of vertebral body or polygonal 
enhancement that occupying ≥ 1/3 of vertebral body on axial 
image. The locations of enhanced areas within vertebral bodies 
were described using right lateral/central/left lateral, anterior/
posterior, and upper/middle/lower in the x-, y-, or z-axis directions, 
respectively.
Results: A total of 39 vertebral body enhancements were found 
in the 13 patients, involving cervical (n = 12), thoracic (n = 25), or 
lumbar (n = 2) vertebrae. Vertebral body enhancements showed 
a nodular (n = 19) or a polygonal (n = 20) pattern. The central 
portions of vertebral bodies were more frequently involved. The 
connection to the paravertebral venous plexus was observed in 34 
lesions (87.2%).
Conclusion: Patients with SVC obstruction with extensive collateral 
vessels might exhibit a pseudopathologic vertebral enhancement. 
They tended to involve the central portion of the vertebral body 
and most of them showed connection to the paravertebral venous 
plexus.
Keywords: superior vena cava, collateral circulation, computed 
tomography, thorax
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P3.19-005 QUANTITATIVE CT PREDICTS HISTOLOGICAL 
TUMOR INVASIVENESS: ANALYSIS ON 211 LESIONS OF 
CT1N0M0 LUNG ADENOCARCINOMA
Kei Shikuma, Toshi Menju, Takao Nakanishi, Hiroyuki Cho, 
Terumasa Sowa, Naoto Imamura, Tetsu Yamada, Masaaki Sato, 
Akihiro Aoyama, Toshihiko Sato, Fengshi Chen, Makoto Sonobe, 
Mitsugu Omasa, Toru Bando, Hiroshi Date
Department Of Thoracic Surgery, Kyoto University/Japan
Background: Biological behavior of small lung adenocarcinoma differs 
in each patient. High intensity area of the tumor on single slice of chest 
CT has been reported as a prognostic factor in several studies. Howe-
ver, because single slice is obviously insufficient to utilize all of the infor-
mation on CT images of a tumor, we applied 3- dimensional volumetric 
evaluation for whole tumor volume. Our study aims to predict lymph 
node metastasis and tumor invasiveness by means of preoperative 
quantitative CT for lung cancer patients.
Methods: From January 2011 to November 2012, 236 lesions of cT-
1N0M0 lung adenocarcinoma were surgically resected in our institute. 
Among them, total 211 lesions of 193 patients were included in this 
study (Age: 67.2±9.5 male/female: 94/99). We analyzed preoperative 
CT images of 211 lesions of resected cT1N0M0 lung adenocarcino-
ma retrospectively. All patients were subjected to helical scanning 
using sections 1mm or less thick during one breath hold. We applied 
threshold of -800 and -300 Hounsfield units (HU) within those CT data, 
calculated the tumor volume, and then, integrated them with clinico-
pathological information. We defined the area -300HU and over as 
“solid tumor volume” and between -800 to-301 HU as “GGO tumor 
volume”. Spearman’s rank test was utilized for statistical analyses.
Results: We divided those lesions into 3 groups by solid tumor volume; 
less than 0.25cm3 (n=61), 0.25 to 1.5cm3 (n=72), and over 1.5cm3 (n=78). 
Solid tumor volume correlated with histological tumor invasiveness; less 
than 0.25cm3, p1to3 (0, 0%) ly1 (0, 0%) v1 (0, 0%); 0.25 to 1.5cm3, p1to3 
(6, 77%) ly1 (1, 1%) v1 (1, 1%); over 1.5cm3, p1to3 (14, 19%) ly1 (4, 6%) v1 
(14, 19%), (p<0.01, p=0.03, p<0.01, respectively). Pathological tumor 
differentiation was also investigated; less than 0.25cm3, well (34, 56%) 
moderate (26, 43%) poor (1, 2%); 0.25 to 1.5cm3, well (17, 22%) modera-
te (57, 73%) poor (4, 5%); over 1.5cm3, well (8, 11%) moderate (51, 71%) 
poor (13, 18%) (p<0.01). Lymph node metastases were found in none 
(0%) of solid tumor volume less than 0.25cm3, in 2 (3%) with 0.25 to 
1.5cm3, in 6 (8%) with over 1.5cm3 (p=0.01). Moreover we calculated the 
proportion of solid tumor volume / (solid tumor volume + GGO tumor 
volume) as “solid tumor ratio”. We divided those lesions into 2 groups 
by solid tumor ratio; 0.3 or less (n=123), and over 0.3 (n=88). Solid tumor 
ratio also correlated with histological tumor invasiveness; 0.3 or less, 
p1to3 (0, 0%) ly1 (0, 0%) v1 (0, 0%); over 0.3, p1to3 (20, 23%) ly1 (5, 6%) 
v1 (15, 17%). (p<0.01, p<0.01, p<0.01, respectively) Strikingly, lymph 
node metastases were found in none (0%) of solid tumor ratio 0.3 or 
less, but in 8 (9%) with over 0.3. (p<0.01)
Conclusion: Both tumor volume -300HU and over “solid tumor volu-
me” and “solid tumor ratio” significantly correlated with tumor invasi-
veness. Preoperative quantitative CT is probably useful for predicting 
tumor invasiveness and lymph node metastases, and, as a result, effec-
tively selecting operative procedure for cT1N0M0 lung cancer whether 
lobectomy or segmentectomy is applicable.
Keywords: Hounsfield unit, solid lesion, quantitative CT, Adenocarci-
noma
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P3.19-008 POSITRON EMISSION TOMOGRAPHY  
SCAN IN LUNG CANCER: NEW INSIGHTS IN TUMOR 
BIOLOGY?
Maria Teresa Almodovar1, Djamila Neves2, Vania Sacramento3, 
Helena Guedes2, Rosario André4, Jsé Duro Da Costa1
1Pulmonology, Instituto Português De Oncologia De Lisboa Francisco 
Gentil/Portugal, 2Pulmonology, Hospital De Faro/Portugal, 3Pulmono-
logy, Hospital Nossa Senhora Do Rosário, C.h Barreiro-montijo, E.P.E/
Portugal, 4Medical Oncology, Instituto Português De Oncologia De Lis-
boa Francisco Gentil/Portugal
Background: 18F-fluoro-2-deoxy-glucose (FDG) uptake on Positron 
Emission Tomography (PET) is highly accurate in the detection of 
mediastinal lymph node metastasis and extrathoracic metastasis 
and plays an important role in the staging of lung cancer. Further-
more, recent studies suggest that PET-CT and Standardized Up-
take Value (SUVmax) reflects tumor metabolism and proliferation 
capacity, and can be used as a prognostic factor as well as to pre-
dict response to therapy.
Methods: Our study aims to detect SUVmax differences between 
different lung cancer histologic sub-types. We conducted a retro-
spective single centre study. All lung cancers diagnosed in 2008-
2009, with a PET-TC evaluation at diagnosis, and with follow-up at 
IPOLFG were included. Data regarding socio-demographic factors, 
smoking habits, histological diagnosis, staging, and performance 
status were obtained from clinical chart reviews. Statistical analysis 
was performed using STATA
Results: A total of 92 patients have been included in this study 
to date. 64 (69.6%) of our patients were male and 28 (30.4%) were 
female. Median age was 64.5 years, standard-deviation of 10.16 ye-
ars, minimum of 36 and maximum of 82 years. 47 patients (51.65%) 
were current smokers, 31 (34.07%) were former smokers, and 11 
(12.09%) were non-smokers. 54% presented ³ 40 Pack years. The 
most frequent histologic sub-type was Adenocarcinoma (ADC) 
(41.3%), followed by Squamous Cell Carcinoma (SCC) (30.4%). 42 
patients had stage I or II lung cancer, 31 had stage III, and 19 with 
stage IV. The median size of the primary tumor lesion was 4.05cm 
(standard-deviation of 2.62cm), and the median SUVmax was 10.11 
(standard deviation of 5.86). SUVmax by primary tumor histological 
sub-type revealed the following characteristics: median SUVmax in 
the SCC group was 12.12 (standard-deviation 6.3), ADC group 8.26 
(standard-deviation 4.5), Non-small Cell Carcinoma group 12.65 
(standard-deviation 7.5), Neuro-endocrine Carcinoma group 7.25 
(standard-deviation 5.4) and Small Cell Carcinoma 10.67 (standard-
deviation 3.6). The observed differences were statistically signifi-
cant between the 5 considered groups (p=0.0233, One-way ANO-
VA) and specifically, we observed a highly significant difference in 
SUVmax between SCC and ADC groups (p=0.005, t-test). We also 
observed a positive correlation between tumor size and SUVmax.
Conclusion: Our preliminary results confirm the effect of tumor 
biology in PET-CT and SUVmax with observed differences bet-
ween different histological sub-types, and suggest that PET-CT 
can be specifically important in the assessment of SCC and ADC 
subtypes. These results support further studies regarding the 
usefulness of PET-CT in tumor biology characterization in SCC and 
ADC subgroups.
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P3.19-007 RELIABILITY ANALYSIS OF VISUAL RANKING 
OF CORONARY ARTERY CALCIFICATION ON LOW-DOSE 
CT OF THE THORAX FOR LUNG CANCER SCREENING: 
COMPARISON WITH ECG-GATED CALCIUM SCORING CT
Yon Mi Sung, Yoon Kyung Kim
 Gachon University Gil Medical Center/Korea
Background: Coronary artery calcification (CAC) is frequently 
detected on low-dose CT of the thorax (LDCT). Concurrent assess-
ment of CAC and lung cancer screening using LDCT is beneficial 
in terms of cost and radiation dose reduction. The aim of our study 
was to evaluate the reliability of visual raNKIng of CAC on LDCT 
compared to Agatston score on ECG-gated calcium scoring CT.
Methods: The subjects were 576 patients who were consecutively 
registered for health screening and undergoing both LDCT and 
ECG-gated calcium scoring CT. We excluded subjects with a calci-
um score of zero. The final study cohort included 117 patients with 
CAC (97 men; mean age, 53.4±8.5). Agatston score on ECG-gated 
calcium scoring CT was used as the gold standard (mean score, 
166.0; range, 0.4-3719.3). Two board-certified radiologists and 
two radiology residents participated in an observer performance 
study. Visual raNKIng of CAC was performed according to four 
categories (1-10, 11-100, 101-400, and 401 or higher) for coronary 
artery disease (CAD) risk stratification. Weighted kappa statistics 
was used to measure the degree of reliability on visual raNKIng of 
CAC on LDCT: kappa values between 0 and 0.40 were considered 
to indicate positive but poor agreement; between 0.40 and 0.75, 
good agreement; greater than 0.75, excellent agreement.
Results: The degree of reliability on visual raNKIng of CAC on 
LDCT compared to ECG-gated calcium scoring CT was excellent 
for board-certified radiologists and good for radiology residents. 
A high degree of association was observed with 71.6% of visual 
raNKIngs in exactly the same category as the Agatston category 
and 98.9% varying by no more than one category.
Conclusion: Visual raNKIng of CAC on LDCT is reliable for predic-
tion of categorization of Agatston score ranks. LDCT is useful for 
both CAD risk stratification and lung cancer screening.
Keywords: Lung cancer screening, low-dose CT, coronary artery 
calcification
S1268 Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
Abstracts Journal of Thoracic Oncology  •  Volume 8, Supplement 2, November 2013
POSTER SESSION 3 - IMAGING  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.19-010 THE STATUS OF EGFR MUTATIONS IN MIXED 
GROUND-GLASS OPACITY (PART-SOLID GGO) ON THIN-
SECTION CT
Haruhiro Saito1, Yuji Sakuma2, Shuji Murakami1, Fumi Karino1, 
Tetsuro Kondo1, Fumihiro Oshita1, Kentaro Imai1, Hiroyuki Ito1, 
Yohei Miyagi3, Tomoyuki Yokose1, Haruhiko Nakayama1, Kouzo 
Yamada1
1Thoracic Oncology, Kanagawa Cancer Center/Japan, 2Pathology, Kana-
gawa Cancer Center/Japan, 3Kanagawa Cancer Center/Japan
Background: Thin-section CT (TS-CT) provides us with a more 
precise image of small pulmonary carcinomas. Thin-slice sections 
with thicknesses of 0.5 mm-1mm reflect, with some accuracy, the 
histopathological findings; mixed ground-glass opacity (part-solid 
GGO) is one characteristic finding of pulmonary adenocarciomas. 
These findings are vary in appearance, for example; some contain 
mainly GGO components, and some contain mainly solid portions. 
CT findings of mixed GGO, pathological findings and prognoses 
have been reported. Presently, we do not fully understand the 
correlation between TS-CT findings of mixed GGO and the status 
of EGFR mutation.
Methods: We retrospectively reviewed the records and TS-CT 
scans of 115 patients with mixed GGO tumors. All patients had 
undergone surgical resection between 2002 and 2008. Tumor 
diameters measured 20mm or less in size. All TS-CT images were 
acquired by Aquillion CT scanner (Toshiba Medical System). TS-
CT images of tumors were obtained at 135kVp at 250mAs with 
0.5-1mm section thickness. All images were photographed using 
mediastinal (level, 40HU; width, 400HU) and lung (level, -600HU); 
width, 1600HU) window settings. All TS-CT images on lung win-
dow setting were classified as: (1) Predominant GGO type (pGGO; 
solid portion areas less than 50% of tumor), (2) Heterogeneous 
type (heterogenous increased density), (3) Predominat solid type 
(pSolid; Solid portion areas took up more than 50% of tumor). We 
analyzed EGFR and Kras mutations, and then studied the correla-
tions between these TS-CT findings and the status of EGFR muta-
tions.
Results: The tumors in all 115 cases were well-differentiated ade-
nocarcinomas. GwS type; 24 cases, Heteogenous type; 30 cases, 
and SwG type 61 cases. The EGFR mutation ratio was 66.6% in 
pGGO type, 90% in Heterogenous type and 52.7% in pSolid type. 
The ratio of EGFR mutation was greater in Heterogenous types 
compared to pGGO and pSolid types. (pGGO/Hetero p=0.045, 
pSolid/Hetero p=0.00038).
Conclusion: There is a correlation between the thin-section fin-
dings of mixed GGO and the status of EGFR mutations.
Keywords: GGO, Lung cancer, CT, EGFR
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P3.19-009 NEWLY DEVELOPED EARLY LUNG CANCER 
DURING FOLLOW-UP OF IDIOPATHIC INTERSTITIAL 
PNEUMONIA: SERIAL HRCT OBSERVATIONS
Mi Young Kim1, Ji-Eun Kim1, Sang Young Oh1, Chang-Min Choi2, 
Tae Sun Shim3, Woo Sung Kim3, Dong Soon Kim3
1Radiology And Research Institute Of Radiology, Asan Medical Center/
Korea, 2Oncology And Pulmonary And Critical Care Medicine, Asan 
Medical Center/Korea, 3Pulmonary And Critical Care Medicine, Asan 
Medical Center/Korea
Background: To describe HRCT findings of newly developed 
peripheral T1 lung cancer in idiopathic interstitial pneumonia (IIP) 
during IIP follow-up
Methods: Between November 2001 and October 2012, 66 con-
secutive patients (62men, 4 women; median age 64, range 40~85 
years) who were diagnosed as IIP, fulfilled the American Thoracic 
Society diagnostic criteria and new cancer (including fourteen 
small cell) simultaneously, were included. Two radiologists inde-
pendently reviewed 132 serial CT scans of 66 patients, determined 
the earliest scan showing lung cancer, and evaluated tumor size 
(mm), lobar location, axial location on transverse image, shape, 
and density of tumor. The median interval between null-IIP to new 
cancer-IIP was measured. Delay in diagnosis was measured from 
the time of the earliest scan showing lung cancer and the subse-
quent clinical diagnosis. Formal radiologic reports as ‘first choice’ 
before diagnosis of cancer were reviewed.
Results: The inter-observer agreement was good (Kappa value > 
0.77). The median smallest tumor size on axial scan at presentation 
was 17mm (± 6.57, range, 5-30mm) with T1a/T1b (48/18). Tumor 
was most commonly located in right lower lobe (29/66, 43.9%), 
followed by left lower lobe (13, 19.7%). Thirty five tumors (53.0%) 
were in the interface between normal and fibrotic lung cysts such 
as honeycomb cysts, twenty two (33.3%) were in the midst of fi-
brotic lung cysts, and nine (13.6%) were in the normal lung. Fifty 
nine (83.3%) tumors had round or oval shape, seven (10.6%) tumors 
had a stellate shape, and two had a band-like shape. Most of the 
tumors (90.3%) presented as solid density rather than part solid, 
ground-glass opacity or consolidation. Lung cancers were found 
during the mean follow-up CT period of 513 days. The median de-
lay in diagnosis was 440 days. Most of the lesions (70%) were inter-
preted as lung cancer, but nine were interpreted as pneumonia or 
fungal infection and seven were missed (10.6%) on HRCT.
Conclusion: About one third of the tumors were misdiagnosed 
including missed in ten percents. Over fifty percent of the can-
cers are located at the interface between normal lung and fibrotic 
cysts. New lung cancers usually show as tumor with a round or oval 
shape and solid density.
Keywords: Lung cancer, interstitial lung, high-resolution CT, CT
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P3.19-012 COMPARISON OF THREE MODELS TO ESTI-
MATE THE PROBABILITY OF MALIGNANCY IN CHINESE 
PATIENTS WITH SOLITARY PULMONARY NODULES
Xuan Zhang1, Xue-Ning Yang2, Jun-Tao Lin2, Ze-Hua Wu2, Jia Liu2, 
Xu-Wei Cao2
1Guangdong Lung Cancer Institute, Guangdong General Hospital& 
Guangdong Academy Of Medical Sciences/China, 2Pulmonary Oncology, 
Guangdong Lung Cancer Institute, Guangdong General Hospital& Gu-
angdong Academy Of Medical Sciences/China
Background: A solitary pulmonary nodule (SPN) is radiologically 
defined as an intraparenchymal lung lesion that is < 3 cm in diame-
ter and is not associated with atelectasis or adenopathy. The dia-
gnosis of SPN is challenging. A prediction model would facilitates 
this task. Until now, three SPN prediction models have been de-
veloped, which are Mayo model, VA model and Peking University 
(PU) model. We compared the accuracy of three models in Chinese 
patients with SPN.
Methods: From July 2003 to December 2011, 154 surgical patients 
with an SPN measuring 3-30mm from Guangdong Lung Cancer 
Institute were included in this study. Data on gender, age, cancer 
history, smoking, nodule size, spiculation, calcification, border and 
final pathological diagnosis were collected retrospectively . Each 
patient’s final diagnosis was compared with probability calculated 
by MAYO model, VA model and PU model. The accuracy of each 
model was assessed by area under the receiver operating charac-
teristics (ROC) curve and calibration curve.
Results: The area under the ROC curve (AUC) of PU mo-
del(0.800; 95% CI 0.708 to 0.891) was larger than that of 
MAYO model(0.753; 95% CI 0.650 to 0.857) and VA mo-
del(0.728; 95% CI 0.623 to 0.833), but this difference 
was not statistically significant. Calibration curves show-
ed that all the three models overestimated malignancy.
 
Figure 1 Receiver operating characteristic curves of Mayo mo-
del, VA model and PU model. AUC(Mayo)= 0.753(95% CI 0.650 to 
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P3.19-011 THE ROLE OF 18F-FDG PET/CT AND 68GA-
DOTANOC PET/CT IN DIFFERENTIATING TYPICAL 
AND ATYPICAL PULMONARY CARCINOIDS
Filippo Lococo1, Vittoria Rufini2, Chiara De Waure2, Guido Rindi2, 
Giorgio Sgarbi1, Angelina Filice1, Giuseppe Cardillo2, Giulio Rossi1, 
Germano Perotti2, Pierluigi Granone2, Annibale Versari1, Paolo 
Graziano2, Alessandro Giordano2
1Thoracic Surgery, Arcispedale Santa Maria Nuova IRCCS/Italy, 2Catho-
lic University Of Sacred Heart, Rome, Italy/Italy
Background: Pulmonary carcinoids are histologically classified 
into typical and atypical. It is important to identify these preope-
ratively for treatment planning and prognosis. Our purpose was to 
calculate the diagnostic sensibility of positron emission tomogra-
phy/computed tomography (PET/CT) using two different tracers 
(18Fluorine-fluorodeoxyglucose [FDG], a glucose analogue and 
68Gallium-DOTANOC, a somatostatin analogue) in a series of pa-
tients with suspected bronchial carcinoids (BCs). Additionally, we 
have evaluated the combination of dual tracer PET/CT findings in 
differentiating typical and atypical pulmonary carcinoids.
Methods: Forty-four patients (16 male/28 female; mean age: 57.8 
y.o.) with suspected BCs (based on radiological findings) under-
went PET/CT with FDG and 68Gallium-DOTANOC in 2 high-volume 
centers. Detection rates of BCs on a per patient-based analysis 
were calculated. Histology was used as reference standard. The 
Chi-square test was used to correlate histology and PET findings.
Results: After surgery, 23 typical carcinoids (TCs), 10 atypical car-
cinoids (ATCs) and 11 benign pulmonary lesions (amartomas) were 
found. Overall and histology-based sensibility rates of both PET-
methods are shown in Table. In particular, no false positive results 
were found and the overall detection rate for BCs was 100% when 
combining both PET methods (one positive at least). DOTANOC-
PET/CT is superior in detecting TCs (sensibility= 91.3%) while FDG-
PET/CT seems to be more useful in ATCs (sensibility= 100%). A 
significant association between histological type and PET findings 
with the two tracers was found (p<0.05). Moreover, the ratio of 
SUVmax values (DOTANOC/FDG) was significantly higher in TC-
group when compared with ATC-group (10.00 vs 0.90; p= 0.027) 
Conclusion: Overall diagnostic performance of PET-CT in detec-
ting BCs is optimal when integrating dual tracer PET-CT findings 
(FDG and DOTANOC). The combination of dual tracer PET/TC 
findings and the ratio of SUVmax values (DOTANOC/FDG) may 
be useful in differentiating TCs and ATCs. Therefore, both PET/CT 
methods should be performed in suspected BCs or when the his-
tological subtype of BCs is unknown.
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P3.19-014 CT MORPHOLOGIC PATTERNS, PATHOLOGIC 
SUBTYPES, AND GENETIC PHENOTYPES: A  
CORRELATION STUDY IN 600 NODULAR LUNG  
ADENOCARCINOMAS
Hyun-Ju Lee1, Young Tae Kim2, Chang-Hyun Kang3, In Kyu Park3, 
Sang Min Lee1, Youkyung Lee4, Mi-Jin Kang5, Hyungjin Kim1, Yoon 
Kyung Jeon6, Jae Moon Koh6, Doo Hyun Chung6
1Radiology, Seoul National University Hospital/Korea, 2Thoracic And 
Cardiovascular Surgery, Cancer Research Institute, Seoul National Uni-
versity Hospital/Korea, 3Thoracic And Cardiovascular Surgery, Seoul 
National University Hospital/Korea, 4Radiology, Smg-snu Boramae Me-
dical Center/Korea, 5Radiology, Inje University Sanggye Paik Hospital/
Korea, 6Pathology, Seoul National University Hospital/Korea
Background: Genotype manifests itself as phenotype and that 
the one may inform the other. In terms of phenotype, imaging has 
the potential to assist in noninvasively characterizing the tumor, 
however, there are very few investigators who have pursued that 
potential connection between imaging features and the genetic 
characteristics of lung cancer. The purpose of this study was to 
retrospectively correlate the CT morphologic patterns of nodular 
lung adenocarcinomas (ADs) with pathological and molecular phe-
notypes in an East-Asian cohort of patients.
Methods: The institutional review board approved this retrospecti-
ve study, and all patients provided informed consent. 600 primary 
lung ADs smaller than 3 cm in diameter that were surgically resec-
ted from 592 patients (M:F=257:335; mean age, 63) were included. 
CT morphologic pattern of ADs was evaluated by three board-
certified thoracic radiologists and was classified into four patterns: 
pure GGN, GGO dominant part-solid nodule (PSN), solid dominant 
PSN, and pure solid nodule. EGFR mutation, ALK rearrangement, 
and KRAS mutation were evaluated using PCR-based direct DNA 
sequencing and FISH. Histologic subtype was classified according 
to IASLC/ATS/ERS classification of lung AD. The Fisher exact test 
and student t-test were used to assess statistical significance.
Results: 
In terms of CT morphologic patterns, 17.2%,15.2%, 31.8%, and 
35.8% of tumors manifested as pure GGN, GGO dominant PSNs, 
solid dominant PSNs, and pure solid nodules, respectively. EGFR 
mutation was significantly more often found in ADs that manifes-
ted as subsolid nodules (69.9%, 269/385) than in ADs presented as 
pure solid nodules (46.7%, 100/214) (P<.0001). ALK rearrangement 
was more frequent in ADs that manifested as pure solid nodule 
(8.5%, 13/153) than in tumors presented as subsolid nodule (1.8%, 
0.857). AUC(VA)= 0.728; 95% CI 0.623 to 0.833. AUC(PU)= 0.800; 
95% CI 0.708 to 0.891.
Conclusion: Three prediction models are sufficiently accurate in 
SPN malignancy prediction in Chinese patients.
Keyword: Solitary pulmonary nodule; Benign and malignant; mo-
del; comparison
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P3.19-013 THE RELATIONSHIP BETWEEN IODINE-
RELATED ATTENUATION OF DUAL-ENERGY CT AND 
STANDARDIZED UPTAKE VALUE OF 18FDG PET-CT IN 
PATIENTS WITH NON-SMALL CELL LUNG CANCER
Eun Young Kim1, Young Saing Kim2, Hae Joon Lee3, Inkeun Park2, 
Hee Kyung Ahn2, Eun Kyung Cho2
1Radiology, Gachon University Gil Medical Center/Korea, 2Division Of 
Hematology And Oncology, Department Of Internal Medicine, Gachon 
University Gil Medical Center/Korea, 3Nuclear Medicine, Gachon Uni-
versity Gil Medical Center/Korea
Background: A recent study revealed that maximum iodine-rela-
ted attenuation (IRAmax) of dual-energy CT (DECT) of primary tu-
mor strongly correlates with maximum standardized uptake value 
(SUVmax) of 
18FDG PET-CT in non-small cell lung cancer (NSCLC) (n 
= 27; r = 0.785; p = 0.001). It suggested that DECT could serve as a 
valuable functional imaging test in NSCLC. The aim of our study is 
to validate the previous results in our NSCLC cohort.
Methods: Twenty-seven patients with NSCLC who underwent both 
DECT and 18FDG PET-CT were analyzed. The maximum and mean 
IRA as well as virtual non-contrast (VNC) images were calculated 
from DECT. Pearson correlation test was used to analyze the re-
lationship between all measurements of DECT and the SUVmax of 
18FDG PET-CT in primary tumors and lymph nodes.
Results: Twenty-seven primary tumors and 51 thoracic lymph no-
des with an SUVmax of >2.5 were included in analyses. In primary tu-
mors, there was a moderate correlation between IRAmax and SUVmax 
(r = 0.565; p = 0.002) whereas no correlation was found between 
other DECT measurements and SUVmax. In lymph nodes, we obser-
ved no correlation between IRAmax and SUVmax (r = 0.197; p = 0.165) 
as well as between other DECT measurements and SUVmax.
Conclusion: In patients with NSCLC, correlation between IRAmax 
and SUVmax was observed in primary tumors but not in lymph 
nodes. Because of relatively small population in our study and 
previous study, further large prospective studies are needed for 
validation.
Keywords: Dual-energy CT, 18FDG PET-CT, non-small cell lung 
cancer
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Conclusion: CB is as safe as FNAB in characterizing LM; particu-
larly, needle size doesn’t impact on MC rate. CB is highly accurate 
in morphological characterization of LM, also providing additional 
tissue for molecular studies, when needed.
Keywords: Lung cancer, Core biopsy, Fine needle aspiration bio-
psy, Diagnostic
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P3.19-016 FAST FOURIER TRANSFORM ANALYSIS FOR 
THE CONTOUR OF PULMONARY NODULES.
Mitsumasa Kawago, Tatsuya Yoshimasu, Shoji Oura, Yozo Ko-
kawa, Yoshimitsu Hirai, Takuya Ohashi, Rie Nakamura, Haruka 
Nishiguchi, Masako Matsutani, Mariko Honda, Yoshitaka Okamu-
ra
Department Of Thoracic And Cardiovascular Surgery, Wakayama Me-
dical University/Japan
Background: Differential diagnosis of primary lung cancer and 
metastatic lung tumor before surgery is important. However, 
histological diagnosis using bronchofiberscopy is often difficult 
in these small peripheral lung nodules. It appears to be useful to 
diagnose pulmonary nodules using chest CT. As already known, 
primary lung cancer presents complicated appearance in chest 
CT. Contour of primary lung cancer is expressed using the words 
such as undulated, irregular, and spiculated. Contrary, metastatic 
lung tumor usually shows simple round shadow. These characte-
ristics are used for the differential diagnosis of tumors. However, 
we often meet tumors with borderline complexity that we are not 
able to clearly classify. Chest CT finding is expressed by words at 
the diagnosis. Therefore, it is difficult to standardize or compare 
the diagnostic properties. Numerical evaluation of complexity of 
tumor outline results in the quantitative evaluation of tumor shape 
and may help the standardization of diagnosis of pulmonary nodu-
les on chest CT. Malignant pulmonary tumors basically show round 
appearance. Therefore, complexity of tumor outline is to be ex-
pressed by the deviation from a circle. And the extent of deviation 
can be expressed numerically. The array data set of the deviation 
is to be regarded as the composition of various kinds of waves. 
Fast Fourier transform (FFT) analysis is suitable to evaluate these 
components of the wave data. In this study, we performed the 
quantitative analysis for the complexity of tumor outline of both 
primary lung cancer and metastatic lung 
tumor utilizing FFT analysis. And then we evaluated the usefulness 
and adequacy of our evaluation method.  
 
Methods: Sequential cases of 72 histologically proven primary 
lung cancers (Group PL) and 54 metastatic lung tumors (Group MT) 
were included. The diameters of tumors in groups PL and MT were 
18.9±7.4 mm and 12.2±6.1 mm, respectively. The outline of each 
tumor on chest CT images was described using polar coordinates, 
and converted to rectangular coordinates, yielding wave data of 
the tumor outline. The FFT was then used to analyze the wave 
data. The complexity index (Cxi) was defined as the sum of the 
amplitude of all harmonics over a fundamental frequency.  
 
Results: The Cxi was higher (P <0.0001) for group PL (10.3±6.7 
mm) than for group MT (3.2±2.4 mm), and it was correlated with 
tumor diameter in both groups: PL (r =0.667, P <0.0001) and MT (r 
= 0.809, P <0.0001). The cut-off equation “Cxi = 0.127 DT + 2.23” 
provided the highest diagnostic accuracy for distinguishing Group 
5/281) (P=.001). KRAS mutation showed no significant difference 
between subsolid nodules (6.6%, 8/121) and pure solid nodules 
(8.5%, 5/59) (P=.760). The ratio of subsolid nodule vs pure solid 
nodule was 72.7% vs 27.3% in ADs with EGFR mutation and was 
27.8% vs 72.2% in ADs with ALK rearrangement. EGFR mutation 
was more frequent in minimally invasive ADs (P=.004) and lepidic 
predominant ADs (P=.018). ALK rearrangement was more frequent 
in solid predominant ADs (P=.002) and invasive mucinous ADs 
(P=.030). KRAS mutation was more frequent in invasive mucinous 
ADs (P=.001).
Conclusion: EGFR mutation was significantly more often found in 
ADs that manifested as subsolid nodules, and ALK rearrangement 
was more frequent in ADs that manifested as pure solid nodule.
Keywords: CT, Adenocarcinoma, Gene, Radiogenomics
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P3.19-015 SHOULD CORE BIOPSY WITH LARGER NEED-
LE REPLACE FNAB IN ASSESSING LUNG MASSES?
Marco Busso, Diego Sardo, Silvia Novello, Irene Garetto, Daniela 
Viglietti, Simonetta G. Rapetti, Enrica Capelletto, Giulia Libero, 
Luisella Righi, Andrea Veltri
Department Of Oncology, University Of Turin/Italy
Background: The distinction between SCLC and NSCLC has been 
recently replaced by a more detailed re-classification. As 70% of 
patients with LC are still not eligible for surgery, tumor characte-
rization is often based on needle biopsy. For the management of 
lung masses (LM), the availability of adequate samples is critical 
not only for pathological diagnosis, but also for additional mole-
cular studies. In this context, our aim was to evaluate the safety 
and accuracy of image-guided core biopsies (CB) in our last 4-year 
series.
Methods: 480 consecutive patients (325 male; 33-87 y, mean 68; 
LM diameter 6-150 mm, m 37,4) underwent 439 CT-guided, 35 US-
guided and 6 US+CT-guided lung biopsies. In 325/480 cases (68%) 
a CB was preferred due to the possible requirement of molecular 
studies. 275 CB were performed with >=18G tru-cut needle, 50 
with <18G, both by a coaxial technique (inserted in a 1G larger sty-
leted cannula). 1 to 6 sampling per patient (m 1.5) were performed. 
Adverse events (including major complications) were recorded 
and correlated with technical issues (namely, with needle size). To 
assess the accuracy of CB, surgical specimens, outcome of non-
surgical therapy and follow-up imaging were considered as gold 
standards. Sensitivity, specificity, diagnostic accuracy and positive 
and negative predictive values of CB were calculated.
Results: 81/325 (24.9%) adverse events occurred, but only 23 (7%) 
were major complications (MC) (22 pneumothorax and 1 hemo-
thorax, requiring drainage and prolonged hospitalization). The 
incidence of MC wasn’t different between either CB and FNAB 
group (11/155, 7%), or larger and smaller CB needle size (20/275 vs. 
3/50, p=n.s). Only the depth of the LM seemed to be significant as 
negative predictor for MC (p=.0061). Pathological diagnosis was of 
benign LM in 60 CB (18.4%), malignancy in 265 (81.5%). According 
to the above gold standard criteria, TP were 265, FN 13, TN 47, 
FP 0. Sensitivity, specificity and diagnostic accuracy were 95.3%, 
100% and 96%, respectively. PPV was 100%, NPV 78.3%.
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of lymph node metastases. Several studies have reported that 
18-fluorodeoxyglucose (FDG) PET-CT plays an important role in 
the assessment of thoracic malignancy such as lung cancer. With a 
small patients experience, we suggest that PET-CT is useful as an 
aid for diagnosis and prognosis of MPM. PET-CT provides useful 
information concerning the extension of the lesions to thoracic 
and abdominal walls not fully evaluated by the initial conventional 
cross-sectional imaging. PET/CT also allows an accurate therapeu-
tic monitoring of the disease.
Conclusion: Our results showed (even with a limited group of pa-
tients experience), PET/CT seems to be superior to convantional 
imaging modalities in identifying more extensive disease involve-
ment, and detecting unexpected occult distant metastases.
Keyword: Malignant pleural mesothelioma, Malignant peritoneal 
mesothelioma, FDG PET-CT,
POSTER SESSION 3 - IMAGING  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.19-018 INCIDENTAL DETECTION ON COMPUTED TO-
MOGRAPHY IS AN INDEPENDANT PROGNOSTIC FAC-
TOR OF SURVIVAL IN PATIENTS OPERATED FOR NON-
SMALL CELL LUNG CARCINOMA
Tomas Gudbjartsson1, Andri W. Orrason1, Martin I. Sigurdsson1, 
Kristjan Baldvinsson1, Hunbogi Thorsteinsson1, Steinn Jonsson2
1Cardiothoracic Surgery, Landspitali University Hospital/Iceland, 2Pul-
monology, Landspitali University Hospital/Iceland
Background: Non-small cell lung carcinomas (NSCLCs) are so-
metimes detected incidentally on imaging for unrelated causes. 
We studied the rate of incidental detection and its impact on 
long-term survival in a nation-wide cohort of patients operated for 
NSCLC.
Methods: This population-based study included all patients who 
underwent pulmonary resection for NSCLC in Iceland between 
1991 and 2010. Demographics and clinicopathological features 
were compared in patients diagnosed incidentally and those pre-
senting due to symptoms. The data was devided into four 5-year 
periods to assess trends, and multivariate analysis used to evaluate 
prognostic factors of cancer-specific survival (CSS), focusing on 
incidental detection.
Results: From a total of 512 patients, 174 (34%) were diagnosed 
incidentally and this proportion remained unchanged during the 
study period. Most tumors were detected by chest X-ray (CXR) 
(26%) or CT (8%), but the proportion of CT diagnoses rose to 15% 
during the last 5-year period. The incidentally detected tumors 
were smaller (3.0 vs 4.3 cm, p<0.0001) and were diagnosed at 
earlier TNM-stages (64 vs. 40% on TNM-stage I, p<0.0001). Fur-
thermore, a higher fraction of the incidentally detected tumors 
were adenocarcinomas. Five-year CSS for patients with symptoms 
was 40%, those incidentally detected on CXR 57% and on CT 80% 
(p<0.001). By multivariate analysis patients detected incidentally 
on CT had significantly better CSS compared to those diagnosed 
incidentally by CXR or for patients with symptoms related to NS-
CLC (HR 0.38, 95% CI 0.16-0.88, p=0.02).
Conclusion: A third of surgically treated NSCLC-patients are de-
tected incidentally, and this fraction has not changed for two deca-
des. However the proportion of CT-detected NSCLCs is increasing 
PL from Group MT such as a sensitivity of 95.8%, a 
specificity of 81.5%, and an accuracy of 89.7%.  
 
Conclusion: Complexity of outline of the pulmonary nodules can 
be evaluated quantitatively using FFT analysis. This analytical pro-
cedure was designed from the beginning as it can be equipped 
on the graphic workstation, and we are now starting to develop it. 
This analytical method will help the diagnosis of primary lung can-
cer. FFT analysis appears useful for quantification of complexity of 
the tumor outline.  
 
Keywords: Fast Fourier transform, primary lung cancer, metastatic 
lung tumor, quantitative evaluation
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P3.19-017 18F-FDG-PET-CT IMAGING IN MALIGNANT 
MESOTHELIOMA
Nil Mandel1, Handan Tokmak2, Onur M. Demirkol2, Kerim Kaban3, 
Şükrü Dilege4
1Medical Oncology, Koç University/Turkey, 2Nuclear Medicine And Mo-
lecular Imaging, American Hospital/Turkey, 3Medical Oncology, Ameri-
can Hospital/Turkey, 4Thoracic Surgery, Koç University/Turkey
Background: Malignant pleural mesothelioma (MPM) is a rare 
and aggressive tumor with a complex growth pattern. Imaging 
plays a crucial role in diagnosis and management. The diagnosis 
of MPM is based on histology using essentially immunohistoche-
mistry on pleural biopsies. Occasional long-term survival results 
are probably due to the biologic characteristics of the disease. 
18F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomogra-
phy (PET)-computed tomography (CT) (FDG PET-CT) has become 
an invaluable tool for the diagnosis, staging, and prognosis of 
this severe disease as it combines both anatomic and functional 
information in a single imaging procedure, allowing for improved 
management of this disease.
Methods: From April 20011 and May 2013, eight patients with his-
tologically proven MPM underwent integrated FDG PET and com-
puted tomography (CT) scanning. These were analyzed: mean age 
was 53.6 years (range: 40-66) and histologic MPM subtypes were 
epithelioid (7 patients) and biphasic (1 patients). We observed a 
significant correlation between high SUV(max) and high-grade 
disease. There were 75 % male patients and 25% female patients. 
PET-CT images showed intense abnormal FDG uptake (SUV-
max>8.0) in the pleural lesions of all 8 MPM patients at delayed 
phase, while it showed abnormal FDG uptake in all (100%) patients 
at early phase. In all patients, the values of SUVmax at delayed 
phase were higher than those at the early phase. PET-CT also in-
dicated metastasis in the lymph node in 4 patients (50%) and in 
the peritoneal lesions in one patient (12.5%) with MPM. The results 
showed that 18F-FDG PET-CT at delayed phase is very useful for 
the diagnosis of pleural diseases and high uptake of 18F-FDG PET-
CT may be a predictive factor of prognosis in MPM patients.
Results: MPM has a limited response to conventional chemothe-
rapy and radiotherapy, thus early diagnosis of MPM is extremely 
critical. In these group patients, PET-CT showed all lesions with 
high sensitivity (%100). CT scans have limited accuracy in the dif-
ferentiation between benign and malignant pleural disease. Also 
CT tends to underestimate early chest wall invasion and perito-
neal involvement and has well-known limitations in the evaluation 
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PERCIST 
RECIST PMR SMD PMD Total 
PR 4 0 0 4 
SD 0 0 0 0 
PD 0 6 4 10 
Total 4 6 4 14 
EORTC 
PMR 4 1 0 5 
SMD 0 5 0 5 
PMD 0 0 4 4 
Total 4 6 4 14 
 
There was a significant difference in the results of response clas-
sification between metabolic classifications and RECIST (p<0.04). 
RECIST and PERCIST (Responders vs. Non-responders) were 
significant factors associated with DFS ( HR =4.070; 95% CI, 1.383-
11.972; p=0.002 for RECIST and HR =0.245; 95% CI, 0.0835-0.722; 
p=0.001 for PERCIST) and OS ( HR =2.620; 95% CI, 0.8806-7.795; 
p<0.046 for RECIST and HR =0.3817; 95% CI, 0.1283-1.1356; 
p=0.046 for PERCIST). EORTC criteria was a significant prog-
nostic factor for predicting DFS ( HR = 0.319; 95% CI, 0.061-1.667; 
p=0.028) but not for OS (p=0.65).
Conclusion: Metabolic and anatomic response were different in 
NSCLC pts treated with Erlotinib. PERCIST can be considered an 
appropriate metabolic evaluation method of therapeutic efficacy 
to discriminate responders from non responders. Mature results 
will be presented.
Keywords: FDG-PET, PERCIST, RECIST, erlotinib
and these patients seem to have a more favorable survival than 
patients detected incidentally on CXR or those who present with 
symptoms.
Keyword: NSCLC, imaging, incidental detection, survival
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P3.19-019 EVALUATION OF ERLOTINIB TREATMENT 
RESPONSE IN NON-SMALL CELL LUNG CANCER USING 
EORTC METABOLIC CRITERIA, PERCIST AND ANATOMIC 
CRITERIA RECIST
Massimo Ippolito1, A Stefano2, Sebastiano Cosentino1, G Mure‘3, G 
Russo2, S Baldari1, Roberto Bordonaro4, M G. Sabini3, D Sardina3, C 
Messa2, M C. Ghilardi2, I Valastro3, Hector J Soto Parra5
1Nuclear Medicine, Cannizzaro Hospital/Italy, 2Ibfm Cnr-lato Cefalu‘/
Italy, 3Medical Physics, Ospedale Cannizzaro/Italy, 4Medical Oncology, 
Garibaldi Hospital/Italy, 5Medical Oncology, Policlinico Vittorio Emanu-
ele University Hospital/Italy
Background: PET for early prediction of tumor response to Erlo-
tinib in patients with advanced non small cell lung cancer NSCLC 
has been evaluated. The aim of this prospective study was to 
compare the early metabolic treatment response using European 
Organization for Research and Treatment of Cancer (EORTC) 1999 
recommendations, PET Response Criteria in Solid Tumors (PER-
CIST), and the standard treatment response using Response Evalu-
ation Criteria in Solid Tumors (RECIST).
Methods: PET was performed before treatment and after 45 days 
of receiving Erlotinib 150 mgrs daily in advanced NSCLC pts. The 
hottest lesion in each patient was evaluated according to the 
EORTC 1999 recommendations, PERCIST and RECIST to assess 
metabolic and anatomic response. Response classifications were 
compared statistically using Wilcoxon signed-rank test. Overall 
survival (OS) and Progression-Free Survival (PFS) time were calcula-
ted by the Kaplan-Meier test.
Results: 14 patients (10 men and 4 women, mean age: 64.1±12.0 
years, range 38 to 79 years) were evaluated. Anatomic responses 
according to RECIST were as follows: 4 Partial Response (PR) and 
10 Progressive Disease (PD). Metabolic responses according to 
EORTC criteria were 5 Partial Metabolic Response (PMR), 5 Stable 
Metabolic Disease (SMD), and 4 Progressive Metabolic Compa-
risons of EORTC and RECIST assessment with PERCIST were as 
follows:  
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(cg27315333; chr2:63285950), L3305 (cg17080163; chr2:123418757), 
(L3310 (cg15347189; chr3:187387999), L3314 (cg03148184; 
chr4:111562513), L3316 (cg16509851; chr4:174430614). Among 
them, L3303 and L3310 are located within the genomic region 
corresponding to orthodenticle homeobox 1 (OTX1) gene and 
somatostatin (SST) 1st exon, respectively.
Conclusion: These 7 CpG sites are possible promising NSCLC-
specific biomarkers for screening and early detection of lung can-
cer, and our goal is the development of the technology to detect 
these novel biomarkers from a blood sample. This technology may 
eventually lead to early detection of lung cancer, which is thought 
as an important opportunity for decreasing lung cancer mortality.
Keywords: DNA methylation profiling, NSCLC-specific biomarkers, 
early detection of lung cancer, diagnostic markers
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P3.20-002 FIRST LOW DOSE CHEST CT LUNG CANCER 
SCREENING PROGRAMS IN POLAND - OVERALL RE-
SULTS
Tomasz Grodzki1, Wojciech Dyszkiewicz2, Witold Rzyman2, Tade-
usz Orlowski3
1Thoracic Surgery, Pomeranian Medical University/Poland, 2Thoracic 
Surgery, Medical University/Poland, 3Thoracic Surgery, Institute Of 
Pneumonology/Poland
Background: To present results of the first four lung cancer (LC) 
screening programs based on low dose chest CT (LDCT) conduc-
ted in Poland.
Methods: Four LC screening programs were conducted in dif-
ferent Polish cities (Gdansk, Poznan, Szczecin, Warsaw) between 
2008 and 2011. Algorithms used for patient`s selection for further 
diagnostics were based on IELCAP protocols with local modifica-
tions. The enrolled patients were ages 50-75, being either active 
smokers or with history of >20 pack years. The following data were 
analyzed: number of LC detected and resected in both protocols, 
and percentage of stage I cancers detected.
Results: 34810 patients were screened in accordance with proto-
cols. Results are presented in table I.  
Parameter G P W Sz All 
No of pati-
ents 
8693 9357 1740 15020 34810 
LC detected 91 96 17 120 324 
LC stage I 58 52 12 83 205 
 
The overall detection rate was 1 cancer per 102 CTs and varied 
from 1/125 to 1/90 (1.05%, 1.03%, 1.0%, 0.86%, 0.98% respec-
tively). The majority of cancers were diagnosed in stage I (64%, 
55%, 70%, 69% 64.5% respectively), while this parameter does not 
exceed 30% in overall population treated by thoracic surgery in 
Poland. The differences between centers regarding both detec-
tion rate and stage I percentage were not significant (p=0.167 and 
p=0.599 respectively). However, if one compares the biggest cen-
ter alone (Szczecin) vs all other ones together, the detection rate in 
Szczecin is significantly lower (p=0.0278).
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P3.20-001 DNA METHYLATION PROFILING IN NSCLC 
IDENTIFIES PUTATIVE DIAGNOSTIC MARKERS FOR 
SCREENING AND EARLY DETECTION OF LUNG CANCER
Arifumi Iwamaru1, Takahiro Kamimoto2, Tatsuya Yamamoto1, 
Koichiro Saito2, Takeru Zama2
1Department Of Surgery, Federation Of National Public Service Person-
nel Mutual Aid Associations Tachikawa Hospital/Japan, 2Department 
Of Otolaryngology-head And Neck Surgery, Keio University School Of 
Medicine/Japan
Background: Lung cancer is a leading cause of the cancer-related 
death in the world, and frequently presents with an advanced di-
sease at diagnosis. Thus, early detection of lung cancer is thought 
as an important opportunity for decreasing mortality. It is willingly 
expected that novel method of early detection of lung cancer 
using biomarkers, such as cancer-specific up-regulation of methyla-
tion levels on genomic DNA. We hereby report that 7 CpG sites 
were found to be highly methylated in Non-Small-Cell-Lung Can-
cer (NSCLC), those which are possible promising NSCLC-specific 
biomarkers.
Methods: Samples for genome-wide DNA methylation analysis 
consisted of 10 surgical specimens including 8 NSCLC (3 ade-
nocarcinomas, 2 squamous cell carcinomas, 2 bronchioalveolar 
carcinomas and 1 large cell carcinoma) and 2 adjacent normal 
lung tissues. Genomic DNAs were isolated from frozen tissue 
sections by using QIAamp DNA mini kit (QIAGEN) followed by 
bisulfite conversion with Epitect bisulfite kit (QIAGEN) according to 
manufacturer’s protocol. Bisulfite converted DNAs were hybridized 
to the Illumina Infinium HumanMethylation 450 BeadChip, which 
screens methylation levels of more than 450,000 CpG sites within 
a single array. Evaluation of the array screening data revealed a 
series of candidate CpG sites that are preferentially methylated in 
cancer samples as compared to normal controls. To further valida-
te cancer-specific up-regulation of methylation levels at candidate 
CpG sites, the QIAGEN Pyromark Q24 system was employed to 
conduct bisulfite pyrosequencing analysis. Pyromark CpG assay 
probes were designed with the aid of PyroMark Assay Design Soft-
ware 2.0 to encompass up to 300 bases region around the CpG 
site of interest, and used to carry out PCR amplification and pyro-
sequencing on bisulfite-converted genomic DNA templates. The 
analyzed samples included 136 surgical specimens consisting of 68 
pairs of NSCLC and adjacent non-cancerous matched tissue, which 
are collected by macrodissection from paraffin-embedded sec-
tions. The 68 NSCLC samples are classified in terms of histological 
types as follows: 54 adenocarcinomas, 10 squamous cell carcino-
mas, 2 adenosquamous cell carcinomas, 2 large cell carcinomas, 
and in terms of cancer staging as follows: 37 of stage I, 15 of stage 
II, 12 of stage III and 4 of stage IV.
Results: Seven CpG sites were found to be highly methylated in 
NSCLC samples compared to adjacent controls in a statistically 
significant manner (two-way ANOVA, p < 0.05). The Illumina CpG 
cluster numbers (cg#) of the 7 CpG sites and their genomic loca-
tions in GRCh37 coordinates are as follows: L3302 (cg26917140; 
chr1:91184770), L3303 (cg04654530; chr2:63282702), L3304 
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optimal screening interval.
Conclusion: The benefits of screening high-risk populations for 
lung cancer with LDCT outweigh the harms if screening is imple-
mented in a strictly controlled manner targeting the high risk po-
pulation. This practice guideline forms the basis for the rationale 
for a screening program. An economic impact analysis will need to 
be done to design an appropriate cost effective lung cancer scree-
ning program prior to implementation.
Keyword: Lung cancer; screening; low-dose computed  
tomography
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P3.20-004 ANALYSIS OF EXHALED BREATH FOR SCREE-
NING OF LUNG CANCER PATIENTS
Jangchul Park1, Toshio Itoh2, Woosuck Shin2, Kazuo Sato3, Yuichi 
Sakumura4, Yoshitsugu Horio1, Toyoaki Hida1
1Thoracic Oncology, Aichi Cancer Center Hosipital/Japan, 2Advanced 
Manufacturing Research Institute, Aist/Japan, 3Mechanical Enginee-
ring, Aichi Institute Of Technology/Japan, 4School Of Information Sci-
ence And Technology, Aichi Prefectural University/Japan
Background: Lung cancer is a leading cause of cancer death. The 
lack of symptoms in this disease and problems associated with 
screening programs for early detection means that patients pre-
sent late with advanced disease. Studies using low-dose computed 
tomography proved to be beneficial, and the efficacy of computed 
tomography scanning as a screening tool for lung cancer is an 
important and contested topic. However, it has been reported 
that the increased incidence of cancer after computed tomogra-
phy scan exposure was mostly due to irradiation. So, computed 
tomography scans should be limited to situations where there is a 
definite clinical indication. The search for non-invasive diagnostic 
methods of lung cancer has led to new avenues of research, inclu-
ding the exploration of the exhaled breath. Previous studies have 
shown that lung cancer can, in principle, be detected through 
exhaled-breath analysis. This study evaluated the potential of 
exhaled-breath analysis for the detection of lung cancer.
Methods: Breath samples were taken from patients with lung can-
cer and from healthy volunteers. The exhaled breath was collected 
in 1L Analytic- BarrierTM bag (OMI ODOR-AIR SERVICE Co. Ltd.). 
Profiles of volatile organic compounds were determined by gas 
chromatography/mass spectrometry (Shimadzu Co. Ltd.).
Results: We collected breath samples from 111 patients with lung 
cancer and 29 healthy volunteers using Analytic-BarrierTM bags. 
The volatile organic compounds were extracted with solid phase 
micro-extraction and analyzed by gas chromatography/mass spec-
trometry. The number of volatile organic compounds detected in 
breath samples was 68. Among the volatile organic compounds 10 
compounds were found in only breath of the lung cancer patients. 
In addition, 11 compounds were found at significantly higher con-
centrations in breath of the lung cancer patients compared to the 
controls.
Conclusion: Our data suggest that compounds in breath could 
possibly be taken as useful breath biomarkers for discerning po-
tential lung cancer patients and volatile organic compounds ana-
lysis could be used as a complementary test for the diagnosis of 
Conclusion: The detection rate of all LC as well as stage I LC in the 
Polish LDCT screening programs is high and comparable in diffe-
rent centers.
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P3.20-003 A PRACTICE GUIDELINE FOR LOW DOSE CT 
SCREENING FOR LUNG CANCER: EVIDENCE BASED 
RECOMMENDATIONS BEFORE IMPLEMENTATION.
Yee C. Ung1, Heidi Roberts2, Cindy Walker-Dilks3, Khalil Sivjee4, 
Kazuhiro Yasufuku5, Amanda Hey6, Nancy Lewis7
1Radiation Oncology, Odette Cancer Centre/Canada, 2Medical Imaging, 
Toronto General Hospital/Canada, 3Program In Evidence-based Care, 
Mcmaster University/Canada, 4Division Of Respirology, Sunnybrook 
Health Sciences Centre/Canada, 5Division Of Thoracic Surgery, Toronto 
General Hospital, University Health Network, University Of Toronto/
Canada, 6Integrated Cancer Screening, Northeast Cancer Centre/Cana-
da, 7Cancer Care Ontario Prevention And Cancer Control/Canada
Background: The National Lung Screening Trial (NLST) compa-
red low dose CT (LDCT) with chest radiography (CXR) in high-risk 
populations and found a 20% reduction in lung cancer mortality 
at 6 years with LDCT after an initial scan and two annual rounds 
of screening. This is the first randomized controlled trial (RCT) to 
show a mortality benefit with lung cancer screening. LDCT scree-
ning is not yet part of the standard of care and no formal process 
currently exists in Ontario, Canada for lung cancer screening. 
Injudicious use of LDCT can potentially cause more harm than 
benefit, including exposure of healthy persons to ionizing radiation 
and subsequent invasive procedures for ultimately benign lesions. 
When used correctly, however, LDCT screening has the potential 
to save lives. A practice guideline was developed to guide clinici-
ans and healthcare policy makers with evidence-based recommen-
dations for screening high-risk populations for lung cancer.
Methods: The guideline was developed using the methods of 
Cancer Care Ontario’s Program in Evidence-Based Care (PEBC). 
The core methodology of the PEBC’s guideline development pro-
cess is a systematic review. A systematic review had recently been 
completed by a collaboration of the American Cancer Society, the 
American College of Chest Physicians, the American Society of 
Clinical Oncology, and the National Comprehensive Cancer Net-
work. The evidence from that systematic review formed the basis 
of the current recommendations, which were reviewed, and amen-
ded where necessary, by clinical experts in the fields of medical, 
radiation, and thoracic oncology; diagnostic radiology; pulmonary 
disease; and population health. The recommendations were revie-
wed by the Provincial Lung Cancer Disease Site Group and under-
went both internal review by an expert panel and external review 
by clinicians with expertise in the topic to achieve consensus.
Results: The systematic review included three RCTs comparing 
LDCT screening with CXR (including the NLST), 5 RCTs comparing 
LDCT screening with usual care (no screening), and 13 single-arm 
studies of LDCT in patients at risk for lung cancer. One large RCT 
reported a statistically significant reduction in lung cancer morta-
lity with low-dose computed tomography at six years compared 
with CXR. The practice guideline recommendations generally align 
with the parameters of the NLST. Deviations were described and 
justified by the guideline working group. The recommendations 
support screening persons at high-risk for lung cancer with advice 
for defining a positive result on LDCT, appropriate follow-up, and 
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P3.20-006 PROTEOMIC ANALYSIS OF THE BRONCHIAL 
EPITHELIUM TO DEVELOP A MOLECULAR SIGNATURE 
OF RISK FOR LUNG CANCER
Jamshed Rahman1, Ming Li1, Yong Zou1, Lisa Zimmermann1, Peng-
cheng Lu1, Robbert Slebos1, Bing Zhang1, Yu Shyr2, Dan Liebler1, 
Pierre Massion1
1Vanderbilt University/United States Of America, 2Vanderbilt Universi-
ty School Of Medicine/United States Of America
Background: A small percentage of at-risk individuals ultimately 
develop lung cancer. This warrants a search for a strategy to iden-
tify individuals who will be developing lung cancer. The bronchial 
epithelium represents the field of carcinogenesis and may serve as 
surrogate tissue for biomarker of risk. Therefore we hypothesized 
that proteomic alterations in the histologically normal airway epi-
thelium from risk stratified individuals allow us to derive a signature 
of risk of developing lung cancer.
Methods: We have collected bronchial brushings specimens from 
risk stratified individuals (Bach PB et al. 2003) and categorized 
them as Control (group 1), low (group 2) and high (group 3) risk 
groups. We collected three bronchial brushings specimens from 
each individual in a single session for acquiring shotgun prote-
omics (n=30). We also collected brushings from cancer patients 
whose risk criteria are similar to low (group 5) and high (group 6) 
risk groups as well as a group of never smoker lung cancer patients 
(group 4). Shotgun proteomics data were acquired from 3 techni-
cal replicates of pooled specimens from 5 individuals. Candidate 
biomarkers were selected based on group comparison and trend 
analysis.
Results: We have acquired shotgun proteomics data from bron-
chial brushings specimen from individuals at-risk for lung cancer 
development. A total of 4973 proteins have been identified. 
Jonchere-Terpestra trend test was performed among control, low 
risk and high risk groups (Groups 1, 2, and 3). Expression level of 
316 proteins were altered (trend p <0.05) with 238 proteins de-
monstrating upward and 78 proteins downward trends. DNA repair 
and oxidative stress and the galactose metabolic enzyme pathway 
were enriched in the upward trend analysis.
Conclusion: We identified a proteomic candidate signature of risk 
of developing lung cancer from histologically normal bronchial 
epithelial cells. Integration of these results with those upcoming 
from two other molecular platforms will allow us to narrow down 
the molecular aberrations most predictive of risk. This signature 
will be validated in an independent cohort. Such signature of risk 
for lung cancer may serve as a powerful tool for lung cancer risk 
assessment and may provide the basis of patient selection for sur-
veillance programs and chemoprevention. This work is funded by 
RO1 CA102353to PPM.
Keyword: proteomics, lung cancer, biomarker, risk
lung cancer. The vision of exhaled breath analysis is that of a broad 
use in clinical routine for personalized screening, diagnosis and 
treatment monitoring.
Keywords: Lung cancer, breath analysis
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P3.20-005 CARDIAC CT AND PULMONARY NODULES; 
INCIDENTAL FINDINGS AND INCIDENCE OF MALIG-
NANCY IN AN AUSTRALIAN POPULATION
James Robertson1, Alistair Miller2, Daniel P. Steinfort2, Philip Bar-
din2, Tony Gabbert3, Steven Stuckey3, Sandra Nichols2
1General Medicine, Monash Health/Australia, 2Respiratory Medicine, 
Monash Health/Australia, 3Radiology, Monash Health/Australia
Background: CT Coronary Angiography provides accurate non-
invasive evaluation of coronary arteries but also images lung pa-
renchyma and other mediastinal structures. Little is known about 
the range and incidence of non-cardiac findings in the Australian 
population and while CT screening has been shown to reduce 
mortality in high risk individuals the significance of identified pul-
monary nodules in this mixed risk population is unknown. A lack of 
data regarding the malignant potential of these incidentally iden-
tified nodules makes evaluation of the relative risk/benefit of both 
initial imaging of the lung and subsequent surveillance scanning is 
difficult.
Methods: A retrospective analysis was performed on reports of 
all cardiac CT scans done in the calendar year 2012. Descriptive 
data was collected including baseline patient characteristics, type 
of nodule and smoking history, as well as whether a full field or 
restricted field view was performed. Surveillance radiological data 
and pathology was collected on a sub-group of the population.
Results: 2500 Cardiac CT scans analysed with 48% females. Re-
ports analysed for presence of lung nodules and type of nodule 
with most common nodule granuloma. Total lung nodules 14% 
(355) with follow up recommended by specialist radiologists; signi-
ficant variation from recommendation in practice was noted. 39% 
of population positive for smoking exposure placing them in high 
risk population. No episodes of malignancy within follow up CT 
scans with the majority of nodules being stable over the follow up 
period. Majority of nodules were <4mm making up 60% of the to-
tal nodules described, 4-8mm 20% nodules of described nodules, 
>8mm making up 12% of nodules. Pulmonary Cysts represented 
4% of nodules. Subpleural nodules described separately and ma-
king up a minority of nodules.
Conclusion: Cardiac CTs are an increasingly common modality 
used to evaluate coronary artery disease. Pulmonary nodules are a 
common finding with a prevalence in this study of 14%; this contri-
butes significantly to a economic burden as well as exposure of the 
community to ionising radiation which there is growing community 
and professional concern around. The findings of this audit are in 
line with published data of a low risk of de novo malignancy in pul-
monary nodules as well as a high prevalence of pulmonary nodules 
across the cohort.
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CXR is more widely accessible and relatively inexpensive. CXR-
screening has the potential to substantially reduce the global bur-
den of lung cancer mortality.
Keywords: Overdiagnosis, survival, Mortality, Screening for Lung 
Cancer
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P3.20-008 PROMPTING EARLIER DIAGNOSIS OF LUNG 
CANCER: EVALUATION OF A PUBLIC EDUCATION CAM-
PAIGN IN NSW TO RAISE AWARENESS OF LUNG CAN-
CER SYMPTOMS
Mayanne Lafontaine1, Melanie Crane1, Nicola Scott2, James Kite1, 
Anita Dessaix1, David Currow1
1Cancer Institute Nsw/Australia, 2Ministry Of Health/Australia
Background: Lung cancer is the leading cause of cancer death 
for both males and females in New South Wales (NSW), Australia. 
Similar to other countries, the five-year relative survival rate for 
lung cancer in NSW is low, reported at 17.6% (2005-07). The poor 
relative survival rate suggests that in most cases, diagnosis occurs 
late, predominantly in stage III or IV. A multi-channel public edu-
cation campaign was implemented in NSW to increase awareness 
of three symptoms consistent with lung cancer (persistent cough, 
change in cough and blood in cough) and prompt people experi-
encing these symptoms to see their General Practitioner (GP) im-
mediately. If people experiencing these symptoms seek a doctor 
as soon as symptoms are experienced, it has the potential to re-
duce diagnostic delay and hence, an improvement in the five-year 
relative survival of lung cancer.
Methods: The public education campaign, comprised mass me-
dia television advertising implemented over 5 weeks (March/April 
2013) at 100 TARPs per week in conjunction with public relations 
activity and a direct mail communication to GPs across NSW. 
Quantitative telephone surveys were conducted in July 2012 (pre-
campaign) and April 2013 (post-campaign) with adults over 45 
years of age residing in NSW (both; n=1000). Unprompted and 
prompted recall of the campaign were measured and levels of un-
prompted awareness of symptoms consistent with lung cancer and 
confidence in recognising symptoms consistent with lung cancer 
were compared between the two surveys.
Results: Overall, 28.7% of the targeted population recalled the 
campaign unprompted, increasing to 60.5% when prompted. Pre- 
and post-campaign results demonstrate an increase in unpromp-
ted awareness of key lung cancer symptoms emphasised by the 
campaign; ‘coughing up blood’ (from 39.1% to 45.4% (p = 0.004)), 
‘cough that does not go away for two or three weeks’ (from 17.0% 
to 40.7% (p = <0.001)) but no significant different in awareness of 
‘worsening or change in cough’ (6.3% to 4.6% (p = 0.096)). Post-
campaign awareness of these symptoms was higher amongst non-
smokers than smokers, particularly for persistent cough. Encoura-
gingly, confidence to recognise a symptom increased from 58.8% 
to 67.4% (p = <0.001).
Conclusion: These findings suggest that a mass media public edu-
cation campaign can be an effective approach to increase aware-
ness of symptoms consistent with lung cancer and confidence in 
recognising these symptoms. Increased awareness and recognition 
of symptoms can lead to earlier diagnosis and treatment.
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P3.20-007 CHEST X-RAY (CXR) SCREENING FOR LUNG 
CANCER: OVERDIAGNOSIS, ENDPOINTS, AND RANDO-
MIZED POPULATION TRIALS (RPTS)
Gary M. Strauss1, Lorenzo Dominioni2
1Medical Oncology, Tufts Medical Center/United States Of America, 
2Thoracic Surgery, University Of Insubria/Italy
Background: CXR-screening has long been considered ineffective 
because RPTs have failed to demonstrate significant mortality re-
ductions in populations randomized to CXR-screening. While these 
studies demonstrate significant survival advantages associated 
with CXR-screening, these advantages are widely believed to be 
spurious, due to the interpretation that CXR-screening leads to 
substantial overdiagnosis. Indeed, the overdiagnosis hypothesis 
is the only alternative to the conclusion that CXR-screening saved 
lives in these trials. The objective of this analysis is to assess the 
magnitude of overdiagnosis in the context of CXR-screening, and 
to determine whether survival or mortality provides the best mea-
sure of efficacy in existing RPTs.
Methods: The Memorial-Sloan-Kettering and Johns-Hopkins Lung 
Projects were designed to assess the effectiveness of sputum cyto-
logy, since participants were randomized to annual CXR-screening 
and sputum cytology every four-months or to annual CXR alone. 
In Mayo-Lung-Project (MLP), following a normal prevalence CXR, 
9,192 smokers were randomized to an experimental group (EG) 
undergoing CXR and cytology every 4-months for 6-years followed 
by 3-years of observation, or to a control group (CG) observed for 
9-years. Controls were advised to obtain annual CXR.
Results: In MSKLP and JHLP, there were no differences between 
EG and CG regarding mortality, survival, or stage distribution. 
However, 5-year survival in both trials was about three-fold supe-
rior to contemporary national statistics. This suggests a beneficial 
effect of CXR, assuming that overdiagnosis did not confound 
survival in EG and CG in both studies. In MLP, lung cancer mor-
tality was 6% higher in EG (p=0.62), although 5-year survival was 
significantly superior in EG (34% vs. 13%; p=0.0021). The fact that 
lung cancer incidence was 30% higher in EG (p=0.013) led to the 
hypothesis that overdiagnosis was responsible for the mortality/
survival discrepancy. However, MLP data are inconsistent with 
overdiagnosis. Long-term survival was achieved only among those 
undergoing resection. Half of resected cancers were apparently 
cured, while no unresected patient was cured (7-year survival: 50% 
vs. 0%: p<0.0001). Indeed, follow-up extended to >20 years in MLP 
continues to show higher incidence and mortality in EG. While in-
terpreted as supporting overdiagnosis, long-term follow-up results 
are primarily informative as to randomization adequacy. Mathema-
tical modeling studies indicate that in MLP-EG higher lung cancer 
incidence and mortality was due to population heterogeneity, due 
to problems with randomization, not to overdiagnosis.
Conclusion: Abundant evidence supports that the magnitude of 
overdiagnosis is minimal in the context of CXR-screening. Moreo-
ver, evidence from RPTs indicates that CXR-screening is superior 
to no screening. The survival endpoint is not meaningless in RPTs 
if one can exclude or adjust for confounding due to overdiagnosis 
and with sufficiently long follow-up. Because overdiagnosis was 
not a confounder of survival in MLP, survival most accurately re-
flected CXR effectiveness. Indeed, long-term survival provided an 
unbiased surrogate for cure. While the National Lung Screening 
Trial demonstrates that CT-screening is superior to CXR-screening, 
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Results: According to histopathology assessment, 42 patients 
(56.7%) had primary lung cancer, 18 patients (24.3%) had metas-
tatic cancer (predominantly of colorectal origin), and 14 patients 
(18.9%) had benign lung diseases. The proportion of patients in 
which cells suspicious for cancer were identified was 39 (52.7%) 
and 42 (56.7%) as reported by two pathologists. Among those 
cases, 6 (15.4%) and 14 (33.3%) were reported as confirmatory. 
The agreement between the pathologists was 77% corresponding 
to a kappa-statistics of 53.7% indicating moderate agreement. In 
metastatic cancer patients, suspicious cells were discovered in 10 
(55.6%) and 9 (50%) cases by two pathologists. In non-cancer pati-
ents, suspicious cell were found in 6 (42.8%) and 5 (35.7%) cases by 
two pathologists, respectively. The test performance for the diag-
nosis of cancer using cytomorphological criteria yielded poor-to-
moderate sensitivity and specificity values, high positive predictive 
values and low negative predictive values (Table).
Conclusion: The results of our study highlight the potential of 
filter-based antibody-independent technology to develop an accu-
rate blood test for the diagnosis of cancer in the peripheral blood. 
However, conventional cytomorphological criteria used for the 
diagnosis provide inadequate sensitivity and specificity. Improved 
performance with immunocytochemistry is still required prior to 
further clinical validation.
Keywords: circulating tumour cells, lung cancer diagnostics
Keywords: symptoms awareness, early detection, early detection, 
mass media campaign, public education
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P3.20-009 DIAGNOSTIC PERFORMANCE OF A FILTER-
BASED ANTIBODY-INDEPENDENT PERIPHERAL BLOOD 
CIRCULATING TUMOUR CELL CAPTURE PAIRED WITH 
CYTOMORPHOLOGIC CRITERIA FOR THE DIAGNOSIS 
OF LUNG CANCER
Dasha V. Freydina1, Andee Tay2, Dimple Chudasama3, Maxim B. 
Freidin1, Andrew G. Nicholson1, Alexandra Rice3, Angeles Monte-
ro-Fernandez1, Sanjay Popat4, Vladimir Anikin3, Eric Lim1
1Royal Brompton Hospital/United Kingdom, 2Imperial College London/
United Kingdom, 3Harefield Hospital/United Kingdom, 4Royal Marsden 
Hospital/United Kingdom
Background: The ability to capture and characterise peripheral 
blood circulating tumour cells (CTCs) has the potential for the de-
velopment of a blood test for cancer. A number of technological 
platforms are available to obtain CTCs including filtration-based 
devices utilising advances of antibody independent capture of 
cells. This technique shows promising results in experimental con-
ditions; however, its performance has not yet been well evaluated 
in a clinical setting. We have evaluated diagnostic performance of 
filtration-based technology using cytomorphologic criteria in pati-
ents undergoing surgery for lung cancer.
Methods: From 06/03/2012 to 24/01/2013 we obtained and pro-
cessed blood from 74 patients undergoing surgery for known or 
suspected lung cancer using ScreenCellTM Cyto devices. Captured 
cells were stained using H&E and independently assessed by two 
pathologists (AGN, AR) for the presence of atypical cells suspicious 
for cancer. Results were reported as confirmed cancer, suspicious 
or no evidence for cancer. Diagnostic performance was evaluated 
against the reference of cancer identified within surgically obtai-
ned specimens reported by a principal pathologist. Sensitivity and 
specificity analyses were undertaken. Inter-observer agreement 
was established by kappa-statistics.
The performance of the diagnosis of cancer using filter-based antibody-independent technique of CTCs trapping
Statistic Pathologist 1 Pathologist 2
Sensitivity (95% CI), % 55.0 (41.6-67.9) 61.7 (48.2-73.9)
Specificity (95% CI), % 57.1 (28.9-82.3) 64.3 (35.1-87.2)
Positive Predictive Value (95% CI), % 84.6 (69.5-94.1) 88.1 (74.4-96.0)
Negative Predictive Value (95% CI), % 
22.9 (10.4-40.1) 28.1 (13.7-46.7)
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P3.20-011 LUNG DENSITY VERSUS EMPHYSEMA AS 
PREDICTOR OF MALIGNANCY RISK OF PULMONARY 
NODULES DETECTED ON FIRST SCREENING CT
Keishi Ohtani1, Rosa Lopez Lisbona1, Martin Tammemagi2, John 
Mayo3, Harvey Coxson4, Stephen Lam1
1Integrative Oncology, British Columbia Cancer Agency/Canada, 2Brock 
University/Canada, 3Department Of Radiology, Vancouver General Hos-
pital/Canada, 4The James Hogg Icapture Centre For Cardiovascular And 
Pulmonary Research/Canada
Background: The association between chronic obstructive pulmo-
nary disease (COPD) and lung cancer has been previously repor-
ted. However, the mechanism whereby emphysema (a destructive 
process) promotes lung carcinogenesis (a proliferative process) 
has not been adequately explained. Emphysema is associated 
with lower lung density while lung inflammation is associated with 
increase in lung density. We hypothesized that lung density and 
emphysema are independent predictors of malignancy risk of lung 
nodules found on screening low dose spiral CT (LDCT).
Methods: Image analysis was performed on a subset of LDCT 
scans (120 kVp, 40 mAs) from the Pan Canadian Early Detection 
of Lung Cancer Study and the BCCA Lung Health Study using the 
VIDA Diagnostics CT image analysis software Pulmonary Worksta-
tion 2. The lobe with the pulmonary nodule was first segmented. 
The average lung density surrounding the nodule was measured. 
Emphysema severity was defined as percentage of the lobe with 
-950 Hounsfield Units (HU). Multivariate logistic regression analysis 
was performed to determine if lung density and degree of emphy-
sema were independently associated with malignant lung nodules.
Results: A total of 161 subjects with lung nodules ≤20 mm were 
studied. The clinical and CT characteristics are shown in the Table 
1. Table 1. Study variables by lung cancer status 
No Cancer Cancer P-value 
N= 95 66 
Age 64±5 63±6 0.52 
Gender : Men: Wo-
men 53% : 47% 38% : 62% 0.078 
Current: Former 
smoker 61% : 39% 45% : 55% 0.051 
Family history % 21% 38% 0.022 
Nodule diameter 10.5 ± 3.0 12.9 ± 4.1 <0.001 
Nodule Type – solid 53% 50% 
- part solid 11% 29% 0.003 
- Non-solid 37% 20% 
Nodule location 
(upper versus midd-
le or lower) 
45% 65% 0.016 
Spiculation (%) 18% 39% 0.017 
Emphysema (visual 
score) % present 67% 78% 0.152 
Density of lobe with 
nodule -848±32 -837±32 0.024 
% emphysema in 
lobe with nodule 9.3%±9.7 7.1%±6.9 0.09 
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P3.20-010 LOW DOSE COMPUTERIZED TOMOGRAPHY 
(LDCT) AS A LUNG CANCER SCREENING TOOL IN AN 
ENDEMIC AREA OF TUBERCULOSIS: A PRELIMINARY 
REPORT
Natthaya Triphuridet1, Sutida Singharuksa2, Thaniya Sricharun-
rat3
1Medical Pulmonology, Chulabhorn Hospital/Thailand, 2Radiology, 
Chulabhorn Hospital/Thailand, 3Pathology, Chulabhorn Hospital/Thai-
land
Background: Thailand is among the countries with a high burden 
of tuberculosis (TB) with 137 new cases per 100,000 persons per 
year reported. The radiographic findings of TB can mimic lung 
cancer even after a complete anti-TB treatment. Currently, no clear 
evidence of benefits from lung cancer screening has been establis-
hed in a high-risk population residing in an endemic area of TB.
Methods: A prospective study was started in July 2012 to deter-
mine the role of low-dose computerized tomography (LDCT) as a 
lung cancer screening tool in Thai heavy smokers (>30 pack-years) 
without a history of active TB within a recent year. Abnormal LDCT 
findings were categorized into 3 groups: negative, indeterminate, 
and suspicious for malignancy according to the baseline nodular 
volume and volume doubling time in a follow-up LDCT.
Results: As of April 2013, 580 subjects were enrolled. At base-
line, 406 cases (70%) had abnormal LDCT findings including 16 
cases (2.8%) suspicious for primary lung cancer. Two hundred 
and forty-five cases (42%) had benign characteristic nodules, 78 
cases (13.4%) had inflammation or infection patterns, and 67 ca-
ses (11.6%) were indeterminate for malignancy. Of the suspicious 
primary lung cancer group, 3 cases had a previous lung nodule 
without any evidence of nodule progression, 13 cases underwent 
tissue biopsy with resulting lung cancers in 7 cases, caseous gra-
nuloma in 2 cases, and negative results in 4 cases. Two cases with 
the inflammation/infection pattern had asymptomatic progressive 
lesions in a 2-month follow-up LDCT and underwent broncho-
scopy. One case was proven pulmonary TB while the other was 
culture-negative TB; both of them responded well to anti-TB 
drugs. Two additional primary lung cancer cases were detected at 
a 3-month follow-up LDCT yielding a total of 9 positive lung cancer 
cases (1.5% of total subjects) which consisted of 4 - stage I cancer, 
1 - stage II cancer, 1 - stage III cancer, and 3 - stage IV cancers. 
Early-stage cases (5/9) received potentially curative surgery. Nota-
bly, 7 and 2 lung cancer cases were detected from suspicious and 
indeterminate group, respectively. Three other malignancies were 
also detected including 1 mediastinal lymphoma, 1 small cell of 
unknown primary and 1 cholangiocarcinoma.
Conclusion: Our preliminary result revealed that despite a high 
burden of TB in Thailand, LDCT screening in heavy smokers could 
yield a high rate of primary lung cancer in this population at risk.
Keyword: Lung Cancer Screening, Low Dose Computerized Tomo-
graphy (LDCT), Tuberculosis, Heavy Smoker
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P3.21-001 METASTATIC LOCATIONS IN NON-SMALL 
CELL LUNG CANCER AND THEIR PROGNOSTIC  
SIGNIFICANCE
Razvan Diaconescu1, Genevieve Payette2, Valerie Rodgers2, 
Bernard Fortin3, Chantal Lafond4, Renaud Whittom1
1Hematology-Oncology, Hopital Sacre Coeur/Canada, 2Internal Me-
dicine, Universite De Montreal/Canada, 3Radiation Oncology, Hopital 
Maisonneuve-rosemont/Canada, 4Pulmonology, Hopital Sacre Coeur/
Canada
Background: For patients with advanced non-small cell lung can-
cer (NSCLC), it is unclear whether the anatomical location of their 
metastases has a different impact on survival. In this project, we 
sought to describe these metastatic sites using the 7th edition of 
the TNM classification and analyse their prognostic implications. 
A special emphasis was placed on brain metastases, as these pa-
tients are commonly excluded from participating in clinical trials, 
based on perceptions of inferior outcomes.
Methods: Consecutive patients diagnosed with NSCLC, between 
2005 and 2009 at Hôpital du Sacré-Coeur de Montréal were in-
cluded in this retrospective analysis. They were re-classified, from 
the TNM 6th edition, in use at the time, to the TNM 7. The following 
metastatic locations were considered: brain, pleura, contra lateral 
lung, extra-thoracic lymph nodes, soft tissues, pericardium, adre-
nal glands and skeleton. The treatments received were classified in 
one of these three groups: standard, non-standard and palliative 
care. Cox proportional hazards analysis was used to identify pre-
dictive factors for survival among the following parameters: age, 
body mass index, gender, histology, smoking history, type of treat-
ment, number and location of metastatic sites.
Results: Five hundred thirty seven patients with stage IV NSCLC 
were identified. Their metastatic sites were, in decreasing order of 
frequency: skeleton (41%), pleura (32%), contra lateral lung (28%), 
brain (26%), liver (18%), extra-thoracic lymph nodes (16%), soft tis-
sues (14%), adrenal glands (14%) and pericardium (6%). Forty-five 
percent of patients had metastases to 1 organ, 33% had 2 and 22% 
had 3 to 6 organs involved. In univariable analyses, metastases to 
the liver, adrenal glands or skeleton were associated with worse 
prognosis (HR=1,37; 1,38 and 1.34, respectively; p < 0.05). The 
patients with liver or adrenal metastases were more likely to have 
at least another metastatic site (90%). In multivariable analyses, 
not surprisingly, better survival was found in patients who could 
receive standard treatment, those having adenocarcinoma histolo-
gy and less metastatic sites. Having contra lateral lung metastases 
conferred a better prognosis (HR=0.74, p=0.0037). Remarkably, 
brain metastases were not a prognostic factor in uni or multivaria-
ble analyses. This group of patients was more likely to have at least 
one of three better-risk factors: age < 65 (68%), brain as a unique 
metastatic site (37%), and more frequent in patients with adenocar-
cinoma than squamous cell cancer (27 vs. 13%). Conversely, they 
were less likely to be treated with palliative care compared to pati-
ents with extra-cerebral metastases (8 vs. 35%).
Conclusion: A history of brain metastases did not have a prog-
While the presence of emphysema of any grade in both lungs by 
visual score was higher in the lung cancer group (78% versus 67%), 
the difference was not statistically significant in the univariate or 
multivariate analysis. Quantitative measurement of emphysema 
severity (area with -950 HU) in the same lobe where the lung no-
dule located showed that the degree of emphysema was less in 
patients with lung cancer (7.1% versus 9.3 %, P = 0.041 in the final 
multivariable logistic regression model consisting of family history, 
nodule size, type and spiculation). Lung density surrounding the 
lung nodule was significantly higher in the lung cancer group com-
pared to the benign nodule group in univariate analysis (P = 0.024) 
but not in multivariable analysis.
Conclusion: Our results suggest lung inflammation as reflected by 
increase in lung density may be a more important factor in lung 
carcinogenesis while emphysema may be more of a dosimeter for 
lung damage by tobacco smoke exposure. Further studies in a 
larger dataset are being performed to determine the incremental 
value of lung density in predicting the malignancy risk of lung no-
dules ≤ 2cm detected by screening LDCT.
Keywords: COPD, low dose CT, Lung cancer screening
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Background: Lung cancer is a major cause of mortality in Russia: 
51,364 deaths in 2008, 18.0% of all cancer-related deaths (GLOBO-
CAN). Mutations in the EGFR gene are known to predict for sensi-
tivity to EGFR tyrosine kinase inhibitors in patients with advanced 
non-small-cell lung cancer (NSCLC). Clinico-pathological characte-
ristics associated with a higher prevalence of EGFR mutations are: 
adenocarcinoma histology, East Asian origin, non-smoking history, 
and female gender. This study aimed to document the characte-
ristics, clinical management and outcomes of Russian patients with 
NSCLC, and to investigate associations between EGFR mutations 
and clinico-pathological parameters.
Methods: A non-interventional, prospective cohort study (ClinTri-
als ID: NCT01069835) carried out in a representative selection of 
hospitals in order to assess lung cancer management in countries 
throughout European and Asian parts of Russia. Patients with 
confirmed NSCLC attending participating centres for the first time 
between 1 February 2010 and 31 March 2011 were enrolled and 
followed-up according to routine practice for a minimum of 12 
months or until death.
Results: A total of 838 patients were enrolled at 33 sites across the 
Russian Federation. Baseline characteristics were: mean age, 58.7 
(SD ±8.5) years; male, 78.4%; European, 98.0%; Russian, 79.6%; 
Tatar, 3.8%; Ukrainian, 3.1%; Byelorussian, 1.3%; current smokers, 
49.4%; never-smokers, 26.5%; ECOG performance status (PS) 1, 
65.6%; disease stage IV, 25.4%; stage III, 37.8%; stage I/II, 36.7%. 
Metastases were found in 38.1% of patients; the most common 
metastatic sites included: respiratory system, 70.2%; pleura, 17.2%; 
bone, 11.9%; liver, 10.3%. EGFR mutations were detected in 85/838 
(10.1%) patients (84/821 [10.2%] European patients and 1/15 [6.7%] 
Asian patients), who were mostly women, 69.4%; <70 years old, 
85.9%; never smokers, 71.8%; PS 1, 59.3%; adenocarcinoma, 58.8%. 
EGFR mutation rates by histological type were: squamous-cell 
carcinoma (SCC), 18/455 (4.0%); adenocarcinoma, 50/260 (19.2%); 
adenocarcinoma bronchioloalveolar, 11/54 (20.4%); large-cell 
carcinoma, 2/24 (8.3%); adenosquamous carcinoma, 2/19 (10.5%); 
other histology, 2/26 (7.7%). Logistic regression analysis of EGFR 
mutations; statistically significant odds ratios: male vs female, 
0.086 (p<0.0001); any smoking history vs no smoking history, 0.110 
(p<0.0001); non-SCC vs SCC, 5.365 (p<0.0001); increase in age (10 
years), 1.391 (p=0.0227). Platinum-containing doublets were the 
most commonly used chemotherapy at first (83.5%) and second 
line (51.0%). In patients who received first- and second-line che-
motherapy, objective response rate, disease progression rate and 
median progression-free survival (PFS) were, respectively, 16.1% 
and 3.6%, 63.8% and 76.8%, 35.0 weeks and 19.4 weeks. Median 
PFS (weeks) after first-line chemotherapy by histology and EGFR 
mutation status was: SCC, 36.3; non-SCC, 34.0; EGFR mutation 
positive, 36.9; EGFR mutation negative, 34.3.
Conclusion: In this cohort, the proportion of patients with EGFR 
mutation-positive NSCLC was similar to other studies of NSCLC in 
Caucasian populations. EGFR mutation status was significantly as-
sociated with female gender and non-smoking history, in-line with 
previous studies of Asian and Caucasian patients with advanced 
NSCLC. This study contributes to a better understanding of prog-
nostic and predictive factors of NSCLC, which will enable optimal 
treatment selection in future clinical practice.
Keywords: NSCLC, EGFR mutation, clinico-pathological, Russia
nostic influence in our NSCLC patient cohort. This finding could 
be explained by the presence of better-risk factors in that group 
of patients. Brain metastases should not be considered by itself an 
exclusion criterion from clinical trials.
Keywords: Prognosis, metastatic sites, brain metastases
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P3.21-002 LUNG-EPICLIN: ANALYSIS OF EGFR MUTA-
TIONS AND ASSOCIATED CLINICO-PATHOLOGICAL 
PARAMETERS IN PATIENTS WITH NSCLC IN RUSSIAN 
FEDERATION
Sergei Tjulandin1, Vladimir Moiseyenko2, Evgeny N. Imyanitov3, 
Elena A. Basova4, Olga Y. Brichkova5, Olga N. Burdaeva6, Nadezda 
V. Cherdyntseva7, Angelina S. Chichkanova8, Irina A. Demidova9, 
Natalia Y. Dobrovolskaya10, Marat G. Gordiev11, Pavel A. Grigo-
ryev12, Ludmila I. Gurina13, Feodosia G. Ivanova14, Apollon I. Karse-
ladze1, Tatiana V. Kekeeva15, Victor A. Khaylenko16, Irina A. Koro-
leva17, Valeri B. Kozhemyako18, Evgeniya S. Kuzmina19, Vladimir A. 
Lubennikov20, Tatiana M. Majatskaya21, Georgy M. Manikhas22, Gu-
zel Mukhametshina23, Alexander P. Pechenyy24, Oleg Pikin25, Igor 
V. Pimenov26, Dmitry M. Ponomarenko27, Viktor V. Prikhodko28, 
Yury A. Ragulin29, Vladimir Shamanin30, Liudmila P. Sheveleva31, 
Sergey V. Sidorov32, Galina B. Statsenko33, Daniel L. Stroioakov-
ski34, Sergei A. Tuzikov35, Olga V. Zharkova36, Vera Karaseva37
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deration, 5Engels Regional Oncological Dispensary/Russian Federation, 
6Arkhangelsk Regional Clinical Oncological Dispensary/Russian Federati-
on, 7Laboratory Of Tomsk Cancer Research Institute/Russian Federation, 
8Nizhny Novgorod Regional Oncologic Dispensary/Russian Federation, 
9Moscow City Oncological Hospital #62/Russian Federation, 10Russian 
Scientific Center Of Radiology Of The Federal Agency Of High-technology 
Medical Care/Russian Federation, 11Tatarstan Cancer Center/Russian 
Federation, 12Regional Clinical Hospital/Russian Federation, 13Primorsky 
Krai’s Oncological Dispensary/Russian Federation, 14Yakutia Republican 
Oncological Dispensary/Russian Federation, 15P.a. Herzen Moscow Onco-
logical Research Institute/Russian Federation, 16Russian Oncological Re-
search Center N.a. N. N. Blokhin/Russian Federation, 17Samara Regional 
Clinical Oncological Dispensary/Russian Federation, 18Pacific Institute Of 
Bioorganic Chemistry/Russian Federation, 19Trans-baikal Regional Clinical 
Oncology Dispensary/Russian Federation, 20Altai Regional Oncological 
Dispensary/Russian Federation, 21Khabarovsk Krai‘s Clinical Center Of 
Oncology/Russian Federation, 22St Petersburg Municipal Oncological Dis-
pensary/Russian Federation, 23Tatarstan Republican Clinical Oncological 
Dispensary/Russian Federation, 24Orel Regional Oncological Dispensa-
ry/Russian Federation, 25P.a. Hertzen Research Institute Of Oncology/
Russian Federation, 26Tula Regional Oncological Dispensary/Russian 
Federation, 27Irkutsk State Medical Academy Of Postgraduate Education/
Russian Federation, 28Sakhalin Regional Oncological Dispensary/Russian 
Federation, 29Obninsk Medical Radiological Research Center/Russian Fe-
deration, 30Biolink, Institute Of Molecular Biology And Biophysics/Russian 
Federation, 31Volgograd Regional Clinical Oncological Dispensary No 1/
Russian Federation, 32Novosibirsk Municipal Clinical Hospital No 1/Russi-
an Federation, 33Omsk Regional Clinical Oncological Dispensary/Russian 
Federation, 34Moscow Municipal Oncological Hospital No 62/Russian 
Federation, 35Tomsk Research Institute Of Oncology/Russian Federation, 
36Kemerovo Regional Clinical Oncological Dispensary/Russian Federation, 
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P3.21-004 THERAPEUTIC DELAY DUE TO MOLECULAR 
TESTING IN PATIENTS WITH STAGE IV NSCLC NEWLY 
DIAGNOSED.
Juan A. Lacava1, Maria Del Valle Geist1, Jose M. Peñaloza1, Romina 
Yapur2, Mariel Zaderadjko2, Juan C. Paez1, Pablo Romera2
1Centro Oncologico San Peregrino/Argentina, 2Fumic/Argentina
Background: The treatment of patients (pts) with advanced non–
small-cell lung cancer (NSCLC) is based on clinical trials experience 
and molecular characteristics. Although molecular testing has be-
come more mainstream, knowledge gaps need to be addressed to 
optimize treatment decision. Delay to treatment may compromise 
palliative efficacy. To evaluate therapeutic delays, procedures for 
71 biopsies from pts with stage IV NSCLC newly diagnosed sub-
mitted to molecular testing were retrospectively analysed.
Methods: Demographic data, site of biopsy, type of first systemic 
treatment, EGFR mutations in exons 18, 19 and 21 using a dual 
technical approach (direct sequencing of polymerase chain reac-
tion (PCR) products followed by bidirectional sequencing by San-
ger method), EML-4-ALK rearrangements by fluorescence in-situ 
hybridization (both done in a single central laboratory sponsored 
by pharmaceutical companies), year of diagnosis, time from first 
consultation to molecular testing results (diagnostic delay, DD), 
and time from first consultation to treatment initiation (therapeutic 
delay, TD) were obtained from 71consecutive pts with stage IV NS-
CLC newly diagnosed seen from 8/2010 to 5/2013 in two general 
oncologic institutions located on Patagonia, Argentina.
Results: Median age was 59 years (range 22-82), 38 % were wo-
men. 86% were adenocarcinoma. 62% of specimens were derived 
from primary tumors, 38% from metastatic sites. EGFR analyses 
was done in all 71 specimens, 13 have insufficient material for 
testing (18%) (group ND) (27% of ND in biopsies obtained during 
2010-2011 versus 10% of those seen during 2012-2013, p: 0.04). 
8 evaluable pts (14%) presented any EGFR mutation, whereas 50 
(86%) were negative. 11 pts were evaluated for ALK translocation 
in 2013. Only 1 pt was positive. As a consequence, 9 pts from the 
entire cohort were able to be treated with molecular directed 
treatments as first line (13%, group POS) Median DD for EGFR ana-
lyses was 18 days (range 8-32). It was 13 days during 2013 probably 
due to a better multidisciplinary approach. Median DD for ALK 
analyses was 18 days (range 14-32). Median TD was 24 days (13-77) 
for the entire cohort. It was 23 days (13-36) for Non-POS pts and 
39 days (21-77) for POS pts (p:0.0001) Despite positivity only 4/9 
POS pts were treated with TKI as first line treatment. Main reasons 
for no treatment were excessive delay for drug accessibility (5) and 
performance status deterioration (1). DD represent 75 % of TD in 
non-POS pts, and 48 % in POS pts
Conclusion: 1- Molecular testing permit to indicate first line TKI 
treatments in 13% of pts 2- DD may compromise treatment in all 
pts, but specially in the numerous non-POS pts who otherwise 
would have been starting therapy after first consultation. 3- With 
a multidisciplinary approach, it is possible to have better testing 
results and to reduce DD. 4- Drug accessibility is an important 
cause of TD in POS pts 5- TD for any preventable reasons should 
be promptly reduced as survival or quality of life may be compro-
mised.
Keywords: Delay, Testing, Accessibility, Developing
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P3.21-003 THE LUNGPATH STUDY: VARIATION IN LUNG 
CANCER DIAGNOSTICS IN ENGLAND. DOES THE AVAI-
LABILITY OF PET SCANNING AND EBUS AFFECT PATI-
ENT CARE?
Paul Cane1, Karen M. Linklater2, George Santis3, John R. Gosney4, 
Henrik Moller3, Michael D. Peake5
1Guy‘s And St Thomas‘ Hospital/United Kingdom, 2National Cancer 
Registration Service/United Kingdom, 3King‘s College/United Kingdom, 
4Cellular Pathology, Royal Liverpool University Hospital/United King-
dom, 5Department Of Respiratory Medicine, Glenfield Hospital/United 
Kingdom
Background: The LungPath study is a national multi-centre survey 
of lung cancer diagnosis and staging practice in England. As part 
of the project, we looked for variation in access to key investiga-
tions such as EBUS and PET-CT scanning and linked this to how 
likely these studies were used to be in different centres and the 
impact these differences may have on patient care.
Methods: Twenty willing English lung cancer centres were ran-
domly selected to participate in the LungPath study. Participating 
centres agreed to submit data on each new lung cancer patient 
seen during the study period of six months from January to June 
2012. Data collected included clinical information such as age, 
gender and performance status, the dates of all radiological in-
vestigations performed and anonymised pathology reports from 
all other investigations performed. The data collected was used to 
map each individual patient’s diagnostic pathway. In addition, we 
collected information about typical waiting times for key investiga-
tions and whether these investigations were available on-site or at 
other institutions. We analysed the patient data to see if the avai-
lability of investigations such as EBUS and PET-CT impacted the 
patient pathways in each centre.
Results: There were significant differences between centres in the 
availability of EBUS and PET-scanning. Approximately half of the 
units surveyed reported waiting times for EBUS and PET-scanning 
of one week or less while the other half reported longer waits, 
typically two weeks and sometimes longer. There were large dif-
ferences in the proportions of patients that underwent EBUS or 
PET-scanning from centre to centre with patients up to six times 
more likely to receive an EBUS and four times more likely to receive 
a PET-scan in some centres than others. There was a clear relati-
onship between the use of the investiagtion and the waiting time. 
We also found that the point in the diagnostic pathways that these 
investigations were used varied and in many cases differed from 
best practice guidelines; several centres routinely performed EBUS 
as a separate procedure after a bronchoscopy had already been 
performed.
Conclusion: There are marked differences in the availability and 
use of EBUS and PET-scanning within different lung cancer units in-
volved in diagnosing and staging lung cancer in England. There is 
a need for commissioners to ensure fairer service provision across 
England and opportunities for education of clinicians to make best 
use of the available resources.
Keywords: Lung cancer, diagnosis and staging, EBUS, PET-CT
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P3.21-006 THE N-CLASSIFICATION BASED ON THE 
NUMBER OF METASTATIC LYMPH NODE IS SUPERIOR 
TO REGIONAL N-CLASSIFICATION IN PREDICTING OUT-
COMES AFTER SURGICAL RESECTION FOR NON-SMALL 
CELL LUNG CANCER.
Sang Yoon Yeom, Hyun Joo Lee, In Kyu Park, Chang Hyun Kang, 
Young Tae Kim
Thoracic And Cardiovascular Surgery, Seoul National University Hospi-
tal/Korea
Background: In many cancers, the N-classification of current TNM 
stage is categorized by the number of positive lymph nodes. 
However, for non-small cell lung cancer (NSCLC), it is classified by 
the involvement of specific regional node groups. The aim of this 
study is to make a new N-classification grouping (nN stage) based 
upon the number of metastatic lymph nodes and to evaluate its 
prognostic significance in predicting outcome after resection of 
NSCLC.
Methods: Between January 2000 and April 2011, 2319 patients 
underwent surgery for NSCLC in our hospital. A total of 1982 pa-
tients was selected by excluding patients who received preopera-
tive induction therapy or did not get curative resection and those 
with pN3 metastatic lymph nodes. Prospectively collected clinical 
information as well as pathologic variables were retrospectively 
analyzed. The recursive partitioning analysis was applied to define 
the most significant cut-off number of metastatic lymph nodes. We 
then analyzed overall and disease-free survival using the new nN 
stage grouping to test if it can provide more accurate classification 
compared to the conventional N stage grouping.
Results: Recursive partitioning analysis identified patients could 
be divided into three distinct groups according to the number of 
metastatic lymph nodes: nN0 (none), nN1 (1-7), nN2 (>7). Among 
1982 patients, 1371 patients were nN0, 538 were nN1, and 73 
were nN2. The 5-year overall survival rates were 79.8%, 62.1% and 
36.1% for nN0, nN1, and nN2, respectively, and they were statisti-
cally different (p < 0.001, log-rank test). For conventional N stage, 
1371 patients were pN0, 284 were pN1, and 327 were pN2. The 
5-year survival rates were 79.8%, 63.8%, and 54.8% for pN0, pN1, 
and pN2 stages, respectively (p < 0.001, log-rank test). The chi-
square value of nN stage was superior to that of pN stage (141.02 
vs. 117.16). When we further analyzed those with pN2 patients, the 
nN1/pN2 group showed a significantly better survival rate than 
nN2/pN2 group (p < 0.001, log-rank test). Moreover, the overall 
survival of nN1/pN2 patients was not different from that of nN1/
pN1 patients. (p = 0.074, log-rank test) 
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P3.21-005 CLINICAL CHARACTERISTICS OF NON-SMALL 
CELL LUNG CANCER WITH EGFR MUTATIONS IN NEVER 
SMOKERS
Young Sik Park1, Ju-Hee Park1, Jinwoo Lee1, Sang-Min Lee1, Chang-
Hoon Lee1, Jae-Joon Yim1, Chul-Gyu Yoo1, Sung Koo Han1, Young 
Tae Kim2, Dae Seog Heo1, Young Whan Kim1
1Internal Medicine, Seoul National University Hospital/Korea, 2Thoracic 
And Cardiovascular Surgery, Seoul National University Hospital/Korea
Background: EGFR mutations are highly associated with pulmo-
nary adenocarcinoma in East Asian never-smoker population. 
The aim of this study is to evaluate the clinical characteristics of 
non-small cell lung cancer (NSCLC) with EGFR mutations in never 
smokers.
Methods: From June 2011 to Dec 2012, consecutive NSCLC pati-
ents who admitted for initial diagnosis of lung cancer without smo-
king habit were recruited in Seoul National University Hospital.
Results: Among 979 of lung cancer patients, 342 never smokers 
with NSCLC (38.6%) were analyzed. Mean age was 62.7 ± 10.6 ye-
ars old and mean BMI was 23.8 ± 3.0 kg/m2. Adenocarcinoma (307, 
89.8%) was the major pathologic diagnosis. The most common 
clinical stage was IV (134, 39.2%), followed by stage Ia (115, 33.6%). 
Among 303 patients who underwent EGFR mutation test, 180 
(59.4%) patients had EGFR mutations. The never smokers with NS-
CLC-EGFR (+) showed better performance status (P=0.006), lower 
uptake of SUV in main mass (8.9 ± 5.9 vs. 11.4 ± 6.8, P=0.003), early 
clinical stage (≤ II, P=0.009), and higher proportion of curative lung 
resection (63.3% vs. 41.2%, P=0.005) compared to the patients 
with NSCLC-EGFR (-).
Conclusion: EGFR mutations are associated with early stage of 
non-small cell lung cancer in never smokers.
Keywords: stage, EGFR, Lung cancer, never-smoker
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Conclusion: The nN-classification seemed to predict long-term 
survival more accurately compared to conventional N stage grou-
ping. Our result suggested the new N stage grouping based on 
the number of metastatic lymph node should be considered for 
the next revision of the TNM classification system for NSCLC.
Keywords: Prognosis, non-small cell lung cancer, staging, Lymph 
node metastasis
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Methods: Sputum samples were collected from 10 lung cancer pa-
tients with confirmed EGFR mutation in their tumour tissue, 10 lung 
cancer patients without evidence of an EGFR mutation, and 10 
patients with chronic obstructive pulmonary disease (COPD). DNA 
was isolated from the sputum and used for mutation analysis by 
Cycleave PCR, COLD-PCR, PangaeaBiotech SL technology (PST), 
and High Resolution Melting, respectively. Targeted resequencing 
(TruSeq Amplicon Cancer Panel) and droplet digital PCR were ad-
ditionally performed on the 10 samples with EGFR mutation.
Results: Dependent on the assay, EGFR mutations could be detec-
ted in 30-50% of the sputum samples of patients with EGFR muta-
tions (Table). The different techniques revealed consistent results, 
with slightly higher sensitivity for PST. Neither the lung cancer 
patients without EGFR mutation nor the COPD controls tested po-
sitive for EGFR mutations in their sputum samples, indicating high 
clinical specificity of all assays. 
Conclusion: EGFR mutations can be detected in sputum samples 
from patients with EGFR-mutated non-small cell lung cancer, which 
may replace biopsy procedure for some patients.
Keywords: diagnosis, non-small cell lung cancer, sputum, EGFR 
mutation
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P3.21-007 EGFR MUTATION ANALYSIS IN SPUTUM OF 
LUNG CANCER PATIENTS: A MULTICENTER MULTITECH-
NIQUE STUDY
A Jasmijn Hubers1, Daniëlle A M Heideman1, Yasushi Yatabe2, Mi-
chelle D. Wood3, Justyna Tull3, Miquel Taron4, Miguel Angel Moli-
na-Vila5, Clara Mayo5, Jordi Bertran-Alamillo5, Gerarda J. Herder6, 
Remco Koning1, Daoud Sie1, Bauke Ylstra1, Gerrit A Meijer1, Peter J 
F Snijders1, Birgit I. Witte7, Pieter E Postmus8, Egbert F Smit8, Erik 
Thunnissen1
1Pathology, VU University Medical Center/Netherlands, 2Pathology And 
Molecular Diagnostics, Aichi Cancer Center/Japan, 3Institute Of Medical 
Genetics, University Hospital Of Wales/United Kingdom, 4Catalan In-
stitute Of Oncology/Spain, 5Pangaeabiotech Sl, Usp Dexeus University 
Institute/Spain, 6Pulmonary Diseases, Sint Antonius Hospital/Nether-
lands, 7Epidemiology And Biostatistics, VU University Medical Center/
Netherlands, 8Pulmonary Diseases, VU University Medical Center/
Netherlands
Background: Mutations in the epidermal growth factor receptor 
(EGFR) gene have been identified in lung adenocarcinomas and 
are associated with a high response to EGFR tyrosine kinase inhi-
bitors. EGFR mutations can be detected in tumour tissue, cytology 
specimens and blood from lung cancer patients. Thus far, EGFR 
mutation analysis has not been systematically demonstrated for 
sputum samples. The aim of the present study was to determine 
whether EGFR mutation analysis is feasible on sputum samples, 
employing different assays in a multicenter study.
Subject Gender Age (years) 
Tumour 
stage 
EGFR mutation 
status of tumour 
tissue1 
EGFR mu-
tation 
analysis 
on sputum 
specimens2 
Cycleave 
PCR 
COLD-
PCR 
PST3 
HRM-se-
quencing Cytology
4 
A F 72 IV Del E746-A750 0 0 0 0 0 
B M 66 I Del E746-A750 0 2 0 0 0 
C6 F 78 IV Del E746-A750 1 1 1 1 2 
D F 46 III Del E746-A750 0 0 1 0 0 
E6 M 54 IV Del E746-A750 1 1 1 1 0 
F F 49 III 
Del E746-A750 & 
c.2369C>T [p.T790M] 
0 0 0 0 0 
G F 54 IV 
Del E746-A750 & 
c.2369C>T [p.T790M] 
0 0 15 0 1 
H F 73 IV c.2753T>G [p.L858R] 0 0 0 0 0 
I F 61 IV c.2753T>G [p.L858R] 0 0 0 0 0 
J6 M 60 IV Del E746-A750 1 1 1 1 2 
1 del E746-A750= deletion exon 19 2 mutation identified: 0=no, 1=yes, 2=dubious 3 exclusively del19 and L858R were assessed 
4 tumour cells: 0=no, 1=yes, 2=in related sample of same patient 5 only del19 detected 6 TSACP and ddPCR both tested EGFR 
mutation (del19) positive.
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uptake value (SUV max) more than 2.5. Rapid on-site cytological 
evaluation was performed during the procedure of EBUS-TBNA for 
convenience and pathological diagnosis was employed by inde-
pendent pathologist. A dedicated 22-gauge needle was used for 
TBNA. Final decision of presence of nodal recurrence was made 
based on pathological findings of cancer recurrence for EBUS-TB-
NA sample, and that of absence of the recurrence was made based 
on radiologic follow-up for more than 6 month.
Results: A total of 40 patients were eligible for this study. The 
mean duration between thoracotomy and EBUS-TBNA was 23.5 
months, and the median follow-up period after EBUS-TBNA was 
21.8 months. Diagnostic sensitivity, specificity and accuracy of 
EBUS-TBNA was 100% for each whereas those of FDG-PET were 
95.8%, 12.5%, and 62.5%, respectively. 24 patients with metas-
tatic lymph node confirmed by EBUS-TBNA showed significantly 
unfavorable prognosis than 16 patients with negative result by 
EBUS-TBNA (p=0.024). 22 out of the 24 patients who diagnosed as 
recurrence received anti-cancer treatments properly. 14 patients 
with positive results by FDG-PET but negative by EBUS-TBNA were 
determined as negative (false positive) since no deterioration of 
the nodal status was confirmed by radiological follow-up. Patholo-
gical findings of these false-positive lymph nodes showed 12 anth-
racosis and 2 non-specific granuloma.
Conclusion: Minimally-invasive diagnosis by EBUS-TBNA should 
be indicated when regional lymph node recurrence is suspected 
since radiologic modalities frequently recognize benign lesions 
as positive. The accurate diagnosis by EBUS-TBNA reduces fertile 
cancer treatment and improves patient management. 
Keywords: postoperative, Histological specimen, Lymph node 
metastasis, Endobronchial ultrasound-guided transbronchial need-
le aspiration
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P3.21-008 EFFECTIVE DIAGNOSIS OF POSTOPERATIVE 
MEDIASTINAL RECURRENCE OF LUNG CANCER BY EN-
DOBRONCHIAL ULTRASOUND-GUIDED TRANSBRON-
CHIAL NEEDLE ASPIRATION
Takayoshi Yamamoto1, Takahiro Nakajima1, Yuuichi Sakairi1, 
Jyunichi Morimoto1, Takamasa Yunn1, Toshiko Kamata1, Hidemi 
Suzuki1, Tetsuzo Tagawa1, Takekazu Iwata1, Teruaki Mizobuchi1, 
Shigetoshi Yoshida1, Michiyo Kannbe2, Yukio Nakatani2, Ichiro 
Yoshino1
1Department Of General Thoracic Surgery, Graduate School Of Medici-
ne, Chiba University/Japan, 2Department Of Diagnotic Pathology, Gra-
duate School Of Medicine, Chiba University/Japan
Background: Diagnosis of postoperative recurrence of lung can-
cer usually depends on radiologic examinations. However, the 
diagnostic yield of radiological examination is limited and it often 
times show false-positive result. Endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA) is well accepted 
modality for the pre-operative lymph node staging in patients with 
lung cancer; however, the efficacy of diagnosis for post-operative 
recurrence still remains unclear. In this study, usefulness of EBUS-
TBNA pathologic confirmation of regional node metastasis was 
investigated in comparison with 18F-fluorodeoxyglucose positron 
emission tomography (FDG-PET).
Methods: The patients who were suspected to have lymph node 
recurrence by routine chest CT follow-up after radical surgery 
for lung cancer were retrospectively investigated, and diagnostic 
yields of FDG-PET and EBUS-TBNA for the recurrence were com-
pared. The cut-off value for positive results by PET was standard 
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mon problem in patients with primary malignant disease in history. 
Not every pulmonary lesion must be just a manifestation of the 
disease, but as we argue in this presentation, it may be a manifes-
tation of sarcoidosis. Therefore, we stress the need of histological 
verification of each newly formed pathological finding. The exclu-
sion of generalized malignancy should have a significant influence 
on the treatment and survival.
Keywords: pulmonary infiltrates, sarcoidosis, intrathoracic lymph-
adenopathy, malignant tumors
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P3.21-010 A RETROSPECTIVE COMPABILITY ASSESS-
MENT OF ALK TRANSLOCATION DIAGNOSIS IN NSCLC
Takashi Yokoi1, Takayasu Kurata1, Yoshitaro Torii1, Yuichi Katas-
hiba1, Maiko Niki1, Yusuke Sawai1, Shosaku Nomura2
1Department Of Thoracic Oncology, Kansai Medical University Hirakata 
Hospital/Japan, 2First Department Of Internal Medicine, Kansai Medical 
University/Japan
Background: A fusion gene between the anaplastic lympho-
ma kinase (ALK) gene and echinoderm microtubule-associated 
protein-like 4 (EML4) occurs in nearly 5% of cases of non-small cell 
lung cancer (NSCLC). This fusion gene leads to the production of 
the EML4-ALK tyrosine kinase, which is considered as one of the 
oncogene driver mutations in NSCLC. The ALK inhibitor, crizotinib, 
showed remarkable antitumor activity in patients with advanced 
ALK-positive NSCLC, and was approved in Japan in 2011. Although 
the break apart FISH is considered as the gold standard to iden-
tify ALK rearrangement, pre-screening by immunohistochemistry 
(IHC) have been proposed in Japan because diagnosable number 
of cases is limited. However, disagreement of IHC and FISH are 
indicated. Therefore, the ALK rearrangements of NSCLC in our 
institute were screened by the IHC, FISH and RT-PCR, and that 
compatibility was examined.
Methods: EML4-ALK rearrangements of 176 examples were scree-
ned by IHC(5A4), FISH, and RT-PCR among 179 patients diagnosed 
as NSCLC in Kansai Medical University Hirakata Hospital from June 
2012 to December 2012.
Results: Ten patients (5.7%) were diagnosed as ALK positive NS-
CLC. Five were male, and median age was 63 (46-81). The results 
by each technique of ten cases are shown in Table. 
patient IHC FISH RT-PCR
1 positive positive positive
2 positive positive negative
3 positive positive negative
4 positive positive negative
5 positive positive negative
6 negative positive negative
7 negative positive negative
8 negative positive negative
9 negative negative positive
10 negative negative positive
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P3.21-009 DIFFERENTIAL DIAGNOSIS OF INTRATHORA-
CIC LYMPHADENOPATHY AND/OR INFILTRATES IN PATI-
ENTS WITH MALIGNANT TUMOURS
Radka Bittenglova1, Milos Pesek1, Frantisek Bruha1, Petr Mukens-
nabl2, Zdenek Chudacek3, Jiri Ferda4
1Pulmonary Diseases, Faculty Hospital Plzen/Czech Republic, 2Patholo-
gy, Faculty Hospital Plzen/Czech Republic, 3Department Of Radiology, 
Faculty Hospital Plzen/Czech Republic, 4Department Of Imaging Met-
ods, Faculty Hospital Plzen/Czech Republic
Background: Patients which are treated due to various malignant 
tumours, should be investigated by pneumologists because of 
having intrathoracic lympadenopathy and/or pulmonary infiltrates. 
We should consider either progression of first malignant tumour, 
secondary and tertiary malignancies, adverse reactions on therapy, 
infectious diseases, or, last but not least, systemic diseases, e.g. 
sarcoidosis. However in sarcoidosis patients, increased risk of he-
matologic and lung malignancies were reported. The occurrence 
of intrathoracic lymphadenopathy with or without pulmonary infil-
trates is subject to frequent diagnostic difficulties in patients with 
cancer history. Accumulation of pulmonary infiltrates and lymph-
adenopathy may be mistakenly interpreted as metastases. We 
present 41 patients with malignancies, who contracted sarcoidosis 
simultaneously, subsequently or before the diagnosis of malig-
nancy. The coincidence of both diseases hasn‘t been published in 
the Czech Republic yet. In these patients, according to a number 
of studies, increased prevalence of malignant diseases was found. 
Sarcoidosis is a non-tumor, chronic, systemic granulomatous di-
sease of unknown etiology and characterized by T-cell dysfunction. 
It affects mainly the lungs and lymphatic system, but also other 
parenchymal organs, the skin, the eyes, the heart. The generally 
accepted hypothesis is some environmental factors may promote 
the development of sarcoidosis in genetically susceptible indivi-
duals. Characteristic lesions are noncaseating granulomas, which 
consist of epithelioid cells and T-lymphocytes.
Methods: During the course of 28 years we have examined around 
500 patients with sarcoidosis. We selected patients with sarcoido-
sis and also malignant diseases from these. 
Using the method of retrospective study, we evaluated the fre-
quency of the coincidence of the period since 1996.
Results: Of all the investigated we follow a group of 41 patients 
with malignancy and sarcoidosis. In 33 patients there was the pri-
mary tumor, in 7 patients primary sarcoidosis, 1 patient had two 
diagnoses simultaneously. These are 18 men and 22 women with 
the mean age of 62,3 years. The spectrum of malignancies covers 
hematological malignancy (6), lung (3), breast (13), head and neck 
(4), intestine (3), melanoma (4), seminoma (3) and other (5). All pa-
tients had sarcoidosis diagnosed by biopsy (23) by CT or PET / CT 
and the bronchioalveolar lavages (18). Mediastinal lymphadeno-
pathy was presented by 37 patients, pulmonary infiltrates and 
nodules were detected in 31 patients, infiltrates only 3 patients, 
extrapulmonary disease in 9 patients. The interval between sarco-
idosis and the primary cancer was 0-552 months with a median of 
36.Treatment with corticosteroids (or in combination with immuno-
suppressive agents) had to be initiated in 28 patients, 12 patients 
were left without treatment. 31 patients showed regression or 
disappearance of lesions, 8 patients were stable and disease didn‘t 
progress, the development of 2 patient is still unknown.
Conclusion: Differential diagnosis of pulmonary lesions is a com-
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P3.21-012 INSTITUTIONAL EXPERIENCE IN OBTAINED 
BIOPSY IN PATIENTS WITH NSCLC IN ONE CENTER IN 
ARGENTINA
Eduardo A. Richardet
Oncology, Instituto Oncologico De Cordoba/Argentina
Background: Lung cancer is one of the most common cancers 
worldwide. It is the leading cause of cancer death in both men 
and women in the West countries and in Latin America too. In Ar-
gentina, 15% of cancer deaths are because of lung cancer (9000 
patients per year). The histology and the analysis of EGFR and ALK 
must be done in all NSCLC. To obtain the tissue, the histological 
diagnosis and the biological studies is particularly difficult in many 
centers in our country because we have to send the tissue to other 
cities. We want to know if we meet the world’s standard in our 
Institutions. Objetive:The primary objective is to assess whether 
the material obtained by different methods is enough for correct 
histopathological diagnosis and molecular biology analysis. We 
also evaluated the prevalence of different histological subtypes, 
the prevalence of EGFR mutations in patients with adenocarcino-
ma, the methodology for obtaining tumor tissue, and the delay in 
evaluation of EGFR mutation status, and currently in ALK translo-
cations.
Methods: A retrospective study analyzed 229 consecutive patients 
with diagnosed NSCLC in Instituto Oncológico de Cordoba. The 
diagnostic method used for obtaining tissue was FNA CT-guided 
in 120 patients (52%), bronchoscopy in 69 (30%), surgery in 29 
(13%) and pleural effusion cytology in 11 (5%). EGFR mutations 
were performed by PCR.
Results: A subtype was determined in 218(95%) out of the 229 
patients studied; 11(5%) were classified as NOS. 147 patients(64%) 
were adenocarcinoma, 59(26%) squamous cell carcinoma, 12(5%) 
large cell carcinoma and 11 carcinoma NOS (5%). In the last peri-
od, 66 patients’ tissues with adenocarcinoma were sent for EGFR 
mutations analysis: In 38 patients (58%), tumor sample was optimal 
and in 28 (42%) patients, it was suboptimal or inappropriate for 
analysis. Of patient with optimal sample, 22(34%) presented diffe-
rent mutations and 16 (24%) patients were Wild Type. The time to 
obtain the result was 1.86 weeks in those with adequate sample 
(2.1 weeks vs 1.6 weeks for those with insufficient or inadequate 
sample).
Conclusion: In 95% of cases, we could determine the histological 
subtype and only 5% were NOS. Out of the 66 patients in whom 
we can evaluate the EGFR, 42% of the samples could not be ana-
lyzed due to insufficient material or inadequate fixation and pro-
cessing techniques. These results are higher but it is not easy to 
compare them with local and Latin American statistics as they are 
not enough. The percentage of TKIs sensitivity was 21%, similar to 
national statistics published (19.3%) and western countries. Latin 
American average is 33.2% in one study. The time to obtain the 
results of EGFR mutation is consistent with recent guidelines pro-
posed by the International Association for the Study of Lung Can-
cer. In our region, we have to work hard in multidisciplinary issues 
to obtain appropriate tissues in NSCLC.
Keywords: Lung cancer, delay in EGFR result
Conclusion: Although IHC is useful as a large-scale screening test, 
many false negative do exist. According to our results, there are 
few cases in agreement between IHC, FISH and RT-PCR. Various 
laboratory tests for ALK rearrangement detection are required for 
effective medication.
Keywords: Lung cancer, EML4-ALK, FISH, IHC
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P3.21-011 PROPOSAL OF AN ALTERNATIVE PROGNOSIS 
PREDICTION METHOD - HAZARD RATIO SCORING SYS-
TEM BASED ON WELL-SUITED NOMOGRAM.
Hae-Won Lee, Moon-Chul Kang, Jong-Ho Park
Thoracic Surgery, Korea Cancer Center Hospital/Korea
Background: The prediction of prognosis has been essential for 
programing cancer treatment strategies. In NSCLC, the TNM sta-
ging system is a worldwide standard form and there have been 
considerate improvements in its accuracy. However, the TNM 
staging system still has many limitations. It cannot reflect all the 
detailed pronostic parameters. In the AJCC system, prognostic 
factors are used to make a mutually exclusive partitioning of pati-
ents and ordering of patients assumes that all the patients receive 
surgery only. Therefore, treatment-specific prognosis cannot be 
predicted in the AJCC system. The prognoses of TNM stages may 
be different between institutes, however the same hazard ratio 
represents the same prognosis. So we propose a hazard ratio sco-
ring system as an alternative prognosis predition method which 
can be used for specific clinical purposes.
Methods: A nomogram was developed and validated using clinical 
data of 2,115 patients who received surgery for NSCLC. Patients 
were randomly divided into the training set (n=1,060) and validati-
on set (n=1,055). Nomogram predictions for 3- and 5-year overall 
survival were calculated for each patient in training set by using 
Cox proportional hazard model and compared with actual survival. 
Validation set was used for evaluating nomogram and AJCC sta-
ging.
Results: The median overall survival was 55.6 months for the trai-
ning set and 58.1 months for validation set. In the prediction of 
5-year survival, the nomogram showed an area under the receiver 
operating characteristic curve of 0.78 (95% CI, 0.76-0.79) in the 
training set. The validation set showed a good discrimination with 
an AUC of 0.85 (95% CI, 0.82-0.89). AJCC TNM staging system 
showed an AUC of 0.74 (95% CI, 0.70-0.79) with a training set.
Conclusion: The nomogram represented the survival results of a 
single institute more accurately than AJCC TNM staging system. 
The hazard scoring system cannot replace the position of the 
AJCC TNM system, however it can be used for programing treat-
ment strategies concerning new or site-specific treatment me-
thods, biomarkers and future clinical parameters.
Keywords: Hazard ratio scoring system, AJCC TNM staging sys-
tem, staging system, Nomogram
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firmed our clinical experience about the more frequent occurrence 
of lung cancer in patients with emphysema (1 in 10) compared with 
those without emphysema (1 in 15).  
"Supported by Projects (Ministry of Health) of conceptual develop-
ment of research organization 00064203 (FN Motol, Prague, Czech 
Republic).“
Keyword: autopsy, lung cancer, emphysema
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P3.22-002 LUNG CANCER: HISTOLOGY, GENDER AND 
AGE CHANGES OVER THE PAST 25 YEARS IN BRAZIL
Maria Teresa Ruiz-Tsukazan1, Alvaro Vigo2, Carlos Barrios3, Jayme 
D.O. Rios4, Noslen Rodrigues5, Jose Antonio L. Figueiredo Pinto4
1Thoracic Surgery, Pucrs, Porto Alegre/brazil, Epidemiology, Ufrgs/Bra-
zil, 2Epidemiology/statistics, Ufrgs/Brazil, 3Oncology, Pontifícia Univer-
sidade Católica Do Rio Grande Do Sul/Brazil, 4Thoracic Surgery, Pucrs/
Brazil, 5Famed, Pucrs/Brazil
Background: Lung cancer is the leading cause of cancer related 
death worldwide when considering both genders. The great effort 
to reduce smoking and introduce of cigarette has changed lung 
cancer epidemiology. In developed countries the increasing inci-
dence of adenocarcinoma and decrease of squamous cell carcino-
ma are well known. Other characteristic reported is the rising num-
ber of women with the disease. Better understanding of current 
lung cancer epidemiology is necessary for the appropriate design 
of public health strategies for prevention, diagnosis and treatment.
Methods: Retrospective analysis of all patients with non-small cell 
lung cancer (NSCLC) treated with lung resection between 1986 
and 2010 in a University Hospital of South Brazil. Analysis was divi-
ded in three periods 1986-1990, 1991-2000 and 2001-2010. Histo-
logical diagnosis was performed by the same pathology group and 
all staging was updated according to the new IASLC 7th edition. 
All analyses were performed using the SAS program version 13.
Results: We studied 817 patients who underwent lung resection 
for NSCLC from 1986 to 2010. 70.0% were males, average age 
61.4 years, 44.2% squamous cell carcinoma and 40.0% adenocar-
cinoma, 26.7% stage IIIA. The female proportion increased from 
22.0% in the first period to 36.0% in the last decade. Mean age at 
surgery treatment was 52.7 years for women and 57.3 for men in 
the first period, and 60.1 for woman and 63.9 for men in the last 
period (p<0.001). The proportion of squamous cell changed from 
49.1% initially to 38.7% on the last period (p=0.017). In comparison, 
the adenocarcinoma prevalence increased from 35.4%, 39.6% and 
most recently 41.21%. Of the total NSCLC patients, females with 
adenocarcinoma represented 9.4% in the first period, 12.5% in the 
second and 16.8% in last period. Patients with stage IIIA represen-
ted 27.9% in the last decade. Type of surgery was predominantly 
lobectomy. Pneumonectomy was the surgical procedure in 21.9%, 
18.8% and 16.8% of cases in each period respectively (p<0.03).
Conclusion: In this cohort of patients in south Brazil, gender analy-
sis shows that rates of lung cancer in females is raising over the last 
three decades but has not surpassed men rates. The proportion of 
adenocarcinoma in females has increased. The significant decrease 
of pneumonectomy rates probably reflects changes on surgical 
management techniques and indication. The mean average age 
for patients undergoing surgical treatment has increased for both 
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P3.22-001 INCIDENCE OF LUNG CANCER AND PULMO-
NARY EMPHYSEMA, A STUDY OF 708 AUTOPSY CASES 
FROM UNIVERSITY HOSPITAL MOTOL, PRAGUE
Miloslav Marel1, Hana Skopcova2, Leona Koubková1, Zuzana 
Kovaříková1, Alzbeta Grandcourtova1, Linda Čapková2, Roman 
Kodet2
1Pneumological Department, 2nd Medical Faculty, University Hospital/
Czech Republic, 2Patological Department, 2nd Medical Faculty, Univer-
sity Hospital/Czech Republic
Background: The incidence of lung cancer in the Czech Republic 
is high. It has reached 91/100 000 in men and 31/100 000 in wo-
men. The TNM stages I and II are diagnosed in less than 20% of all 
patients. Patients with COPD are at higher risk of lung cancer. How 
exactly emphysema affects the development of malignancy and 
how many patients with/without emphysema will suffer from lung 
cancer is unknown. Likewise, we do not know how many patients 
with existing lung cancer are diagnosed post-mortem and we have 
been interested in whether this group of patients shares any com-
mon features. Therefore, we decided to carry out an autopsy study 
which would provide answers to our questions.
Methods: We compared clinical data with autopsy findings in 
patients, both adults and children, from the largest hospital in the 
Czech Republic. During two studied years (2011-2013) we obtained 
complete sets of data on 708 patients.
Results: The studied group included 398 men and 310 women, 
with a median age of 71 years. Autopsies found a total of 55 lung 
cancer cases (7.8% of the set). Out of these, 24 (44%) tumours were 
diagnosed only by autopsy. In 40% of autopsy cases emphysema 
was proved along with a pulmonary malignancy. In the group of 
24 patients with newly diagnosed lung cancer, emphysema was 
more common than in patients with a previously known tumour 
(50% vs. 32%). Patients with lung cancer discovered during autopsy 
died due to CHF in 8 cases, pneumonia in 6 cases, exacerbation 
of COPD in 2 cases, stroke in 2 cases, other tumours in 3 cases, 
and abdominal conditions in 3 cases. Emphysema during lifetime 
has been described less often than post-mortem (84 vs. 197 pati-
ents). The prevalence of autopsy proven emphysema was therefore 
27.8%, the prevalence determined by clinical data was 11.8%. Lung 
cancer was diagnosed in one of every 10 patients with emphysema 
(20/197) and one in every 15 patients without emphysema (35/511).
Conclusion: The number of patients undiagnosed with lung cancer 
during their lifetime (44%) was higher than both literature data and 
our expectations. Studies carried out in the past accounted for 1 
newly diagnosed lung cancer case per 80 autopsies, whereas in 
our group the ratio was 1:30 (Ošťádal, Studia pneumologica, 1994). 
On the other hand 27.8% cases with emphysema confirmed by au-
topsy corresponded with data in literature (15-65%; Thurlbeck, W. 
et Wright, J. L.: Chronic Airflow Obstruction) and results of similar 
previous studies which proved emphysema in 53% of autopsies on 
cases around the age of 70 years (Dalquen, P.: Incidence of Pulmo-
nary Emphysema, and Study of 467 randomised autopsy cases 1, 
Beiträge zur Pathologie, 153, 4, 330-381). Our further results con-
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mutations was 28%, being more frequent in females, and never-
smokers or light smokers, as previously described. Indeed, the 
presence of EGFR activating mutations was a favorable prognostic 
factor. The data here presented does reinforce the importance of 
testing EGFR activating mutations in all pts with TTF-1-positive, 
pulmonary adenocarcinoma.
Keywords: non-small cell lung cancer, Epidemiology, Genotype, 
Epidermal growth factor receptor
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P3.22-004 CANCER AND TUBERCULOSIS, EXPERIENCE 
IN A CHEST HOSPITAL
Rosana Billone, Claudio Martin, Susana Tanco, Cristina Rodriguez
Oncology, Hospital De Rehabilitacion Respiratoria Maria Ferrer/Argen-
tina
Background: Cancer and tuberculosis are two conditions that can 
coexist, and their association is more common in areas of high 
prevalence of tuberculosis like developing countries.
Methods: To report the clinical characteristics of patients with 
cancer and tuberculosis association treated at a chest hospital. In 
this restrospective study, we reviewed the records of 970 patients 
treated for tuberculosis during the period 1998-2010.
Results: There were 16 patients with cancer and tuberculosis 
association. The average age was 55.25 years, 11 males and 5 fe-
males. Cancer was diagnosed before tuberculosis in 12 patients. 
The median time to onset of infection was 24 months. Tuberculosis 
preceded the cancer diagnosis in 3 patients and was obtained 
simultaneously by surgical biopsy in 2 cases. The most frequent 
association was with pulmonary cancer and hematological malig-
nancies, 3 patients each. Pulmonary tuberculosis was present in 11 
patients, 4 were extrapulmonary and 1 patient had both pulmona-
ry and extrapulmonary disease. Bacteriological confirmation was 
obtained in 49% of patients and histopathology in 31.3%. Regar-
ding to the evolution of tuberculosis, 50% completed treatment, 
25% were derived, lost to follow up in 12.5% and 6.3% died during 
treatment of infection .
Conclusion: The probability of association of cancer and tubercu-
losis in the same patient should be taken into account in countries 
with high prevalence of tuberculosis, The coexistence of these 
two diseases frequently poses diagnostic difficulties and delay in 
treatment of both diseases. In countries with high rates of latent TB 
the oncologist should consider the possibility of reactivation of TB 
secondary to alterations of immunity produced by tumor and che-
mo or radiation treatments.
Keyword: cancer
men and women. These findings are in accordance with the data of 
developed countries.
Keywords: Lung cancer, Epidemiology, histology, gender
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P3.22-003 EGFR GENOTYPING AND EPIDEMIOLOGY, 
CLINICAL AND PATHOLOGICAL FEATURES IN 191 PATI-
ENTS WITH METASTATIC PULMONARY ADENOCARCI-
NOMA IN SAO PAULO - BRAZIL.
Gilberto Castro Jr.1, Tiago K. Takahashi1, Rafael Caires-Lima1, Bru-
no M. Protasio1, Manuel C.D.F. Maia1, Iberê C. Soares2, Felipe S.R. 
Roitberg1, Andrea M. Marini1, Renata E. Martins1, Teresa Y. Takag-
aki3, Pedro H.X.N. Araújo4, Ricardo M. Terra4, Christina Shiang5, 
Sheila A.C. Siqueira5, Evandro S. Mello2, Venâncio A. Alves2, Paulo 
M. Hoff1
1Medical Oncology, Instituto Do Cancer Do Estado De Sao Paulo (ICE-
SP)/Brazil, 2Pathology, Instituto Do Cancer Do Estado De Sao Paulo 
(ICESP) And Lim-14 Fmusp/Brazil, 3Pneumology, Instituto Do Cancer 
Do Estado De Sao Paulo (ICESP)/Brazil, 4Thoracic Surgery, Instituto Do 
Cancer Do Estado De Sao Paulo (ICESP)/Brazil, 5Pathology, Hospital 
Das Clínicas And Lim-14 Fmusp/Brazil
Background: EGFR activating mutations in pulmonary adenocarci-
noma does confer better prognosis and are also predictive of high-
er response rates to both chemotherapy and EGFR-tyrosine kinase 
inhibitors. Therefore, EGFR genotyping in these patients (pts) is a 
very helpful biomarker for treatment selection. Here we aimed to 
report the results of consecutive EGFR genotyping in our Instituti-
on in Sao Paulo - Brazil.
Methods: It is a prospective, observational study on all consecu-
tively tested samples from pts diagnosed with pulmonary ade-
nocarcinoma and treated at ICESP. All samples were formalin-fixed 
and paraffin-embedded. Tumor areas were selected and macro-
dissected, followed by whole DNA extraction and amplification by 
PCR. EGFR genotyping was performed through DNA sequencing 
(exons 18, 19, 20 and 21) by Sanger´s methodology.
Results: 191 pts had tumor samples genotyped between Aug/2011 
and Apr/2013. Median age was 64 y (17-90), 106 (56%) female. 
According to ethnicity, 154 pts were Caucasian (81%), 26 African-
American (14%) and 11 Asian (6%). Seventy pts were classified as 
never-smokers (37%), 23 (12%) as light-smokers (≤ 10 p.y.) and 95 as 
current smokers (51%). EGFR activating mutations could be iden-
tified in 54 out of 191 samples (28%): 35 were exon 19 deletions 
(65%), 15 were L858R mutation in exon 21 (30%), and three were 
rare mutations (G719S and G719A in exon 18, and V774M in exon 
20). These mutations were found to be more frequent in females 
than in males (56% vs. 45%, p=0.035), and in never-smokers and 
light-smokers than in current smokers (77% vs. 20%, p<0.0001). It is 
noteworthy to mention that 11 mutations were detected in current 
smokers. All tumors harboring EGFR activating mutations presen-
ted TTF-1 expression by immunohistochemistry, and among those 
seven TTF-1-negative adenocarcinomas, no mutation was detected 
(p=0.0969). In a mean follow-up of 12 months, 77 pts were dead. 
Median overall survival was not reached in those pts whose tumors 
harboring EGFR-activating mutations, versus 19 months in pts with 
wild-type EGFR tumors (HR 0.40; 95%CI 0.29-0.78, p=0.003).
Conclusion: In this group of pts, the frequency of EGFR activating 
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ty=0.14, fixed-effects model). In East Asians, significant association 
was found in allele comparison model (A vs. G) (P=0.03, OR=1.13, 
95%CI [1.01–1.26], Pheterogeneity=0.39, fixed-effects model), in reces-
sive genetic model (AA vs. (AG+GG)) (P=0.005, OR=1.30, 95%CI 
[1.08–1.56], Pheterogeneity=0.58, fixed-effects model) and in the ho-
mozygote comparison (AA vs. GG) (P=0.02, OR=1.30, 95%CI[1.04–
1.63], Pheterogeneity=0.39, fixed-effects model). No evidence sugges-
ted that A23G polymorphism might associate with lung cancer risk 
in the Caucasians or African-Americans. Stratification analysis was 
performed by histologic types and indicated that AA genotype 
might represent a risk factor for squamous cell carcinoma (AA vs. 
(AG+GG)) (P=0.01, OR=1.42, 95%CI [1.08–1.86], Pheterogeneity=0.27, 
fixed-effects model); (AA vs. GG) (P=0.03, OR=1.43, 95%CI[1.04–
1.96], Pheterogeneity=0.21, fixed-effects model). No association was 
observed in adenocarcinoma subgroup. Stratification analysis 
performed by gender shown that A allele might increase the lung 
cancer risk in male (A vs. G) (P=0.02, OR=1.18, 95%CI [1.02–1.37], 
Pheterogeneity=0.48, fixed-effects model), but did not found associati-
on in female subgroup. 
Conclusion: XPA gene A23G polymorphism might associate with 
lung cancer risk in Overall and East Asians. This polymorphism 
might also associate with lung cancer risk in male and in the squa-
mous cell carcinoma subgroup.
Keywords: Lung cancer, single nucleotide polymorphism, XPA, 
Meta-analysis
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P3.22-005 XPA GENE RS1800975 SINGLE NUCLEOTIDE 
POLYMORPHISM AND LUNG CANCER RISK: A META-
ANALYSIS
Yuqing Lou, Rong Li, Xueyan Zhang, Runbo Zhong, Jun Pei, Liwen 
Xiong, Baohui Han
Pulmonary Medicine, Shanghai Chest Hospital Affiliated To Shanghai 
Jiaotong University/China
Background: No clear consensus has been reached on the XPA 
gene A23G (rs1800975) polymorphism and lung cancer risk. We 
performed a meta-analysis in an effort to systematically explore 
the possible association.
Methods: Case-control studies in English and Chinese publica-
tions performed with human subjects were identified by searching 
MEDLINE, EMBASE, Wanfang and CNKI databases prior to June 
2013. References of retrieved articles were also screened. Accor-
ding to the inclusion criteria, 10 articles (12 studies) were finally 
included. The fixed-effects model and the random-effects model 
were applied for dichotomous outcomes to combine the results of 
the individual studies.
Results: Overall, statistical association could be found between 
A23G polymorphism and lung cancer risk in recessive genetic 
model (AA vs. (AG+GG)) (P=0.001, OR=1.21, 95%CI [1.08–1.35], 
Pheterogeneity=0.11, fixed-effects model) and in the homozygote com-
parison (AA vs. GG) (P=0.03, OR=1.15, 95%CI [1.01–1.31], Pheterogenei-
Figure – Meta-analysis for the associa-
tion between XPA gene rs1800975 po-
lymorphism and lung cancer risk in the 
contrast of AA vs. (AG+GG) in overall. 
“Events” indicates the number of the 
AA genotype; “Total” indicates the total 
number of the AG+GG genotype plus 
the AA genotype.
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P3.22-007 DETERMINING COMPLETENESS OF CASE 
ASCERTAINMENT TO A LUNG CANCER REGISTRY: A 
SINGLE INSTITUTIONAL STUDY.
Robert Stirling1, Peta Mclaughlin1, Meera Senthuren1, Sue Evans1, 
Katherine Allnutt1, Lise Hales2, Annie Gilbert3, Chris Bain4, Catrio-
na Mclean5, Neil Watkins6
1Department Of Epidemiology And Preventive Medicine, Monash 
University/Australia, 2Health Information Services, Alfred Hospital/
Australia, 3Health Informatics, Alfred Hospital/Australia, 4Health Infor-
matics Department, Alfred Hospital/Australia, 5Patholgy Department, 
Alfred Hospital/Australia, 6Monash Institute Of Medical Research, 
Monash University/Australia
Background: The Victorian Lung Cancer Registry (VLCR) pilot pro-
ject was established in January 2011 and aims to recruit all newly 
diagnosed lung cancer cases across participating sites in Victoria. 
Case ascertainment for the registry is derived from institutional 
ICD-10 coding with subsequent assessment against inclusion cri-
teria. Incomplete case ascertainment threatens data validity and 
several methods have been proposed for estimating this in cancer 
registries.
Methods: A quantitative, case finding audit was employed to 
evaluate the VLCR’s case ascertainment methodology at a major 
metropolitan hospital between 01/07/2011 and 30/06/2012. ICD-
codes determined that 125 new cases were registered at the hos-
pital. Lists of patients recorded or suspected to have a diagnosis 
of lung cancer were requested from the following institutional and 
external departments: Radiotherapy, Day Procedure Unit, Onco-
logy Lung Multidisciplinary Team Meeting (MDM), Cardiothoracic 
Surgery (CTS), Victorian Cancer Registry (VCR) and Pathology. 
Comparisons were made between patients included in the registry 
and departmental lists provided. Medical records were then as-
sessed to check eligibility of outstanding patients for inclusion in 
the registry.
Results: Six patient lists were compared with the VLCR. Excluding 
duplications and exclusions a total of 10 eligible patients had not 
been recruited by the registry. Investigations indicated that the 
underreporting of these cases was largely attributed to the use of 
the ICD10 R91 Code. This code is not a primary lung malignancy 
code and is assigned by clinical coders for abnormal findings on 
diagnostic imaging of the lung where lung cancer is suspected 
but not confirmed. Of the 10 patients eligible for inclusion in the 
registry, 7 were discharged with the R91 code and pending clinical 
confirmation were later included in the registry. The remaining 3 
patients were not included in hospital data extracts as they were 
non admitted day patients and therefore not coded. A capture 
– recapture methodology is used to evaluate ascertainment com-
pleteness.
Conclusion: The completeness of cancer registry data – the extent 
to which all of the incident cancers occurring in the population 
are included in the registry database – is an extremely important 
attribute of a cancer registry. Only a high degree of completeness 
in case-finding procedures will ensure cancer incidence rates and 
survival proportions are close to their true value.[i] It was identified 
that a possible 7.5% of total lung cancer patients were not being 
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P3.22-006 INCIDENCE AND 5-YEAR SURVIVAL OF LUNG 
CANCER IN QUEENSLAND, AUSTRALIA: AN EPIDEMIO-
LOGICAL STUDY.
Elizabeth S. Ahern1, Kenneth O‘Byrne1, Dannie Zarate2, Haamid 
Jan1, Elizabeth Mccaffery1, Margaret Mcgrath1, Michelle Murphy3
1Division Of Cancer Services, Princess Alexandra Hospital/Australia, 
2QLD Cancer Control Analysis Team (QCCAT)/Australia, 3Respiratory 
And Sleep Medicine, Princess Alexandra Hospital/Australia
Background: Lung cancer is the fourth most common invasive can-
cer in Australia and was the leading cause of cancer death for both 
males and females in 2007. Five-year relative survival for lung can-
cer in Australia, which compares the risk of death for that cancer 
with age- and sex- matched population controls and overestimates 
absolute survival, is 13%. Gender based disparities have been 
noted, with men having worse outcomes. In this study, we publish 
for the first time an analysis of long-term (5 year) survival for lung 
cancer in Queensland, a northern state of Australia, where cancer 
is a notifiable disease. Differential outcomes for different tumour 
histologies, age groups, sex and estimated socio-economic status 
are compared, across 25 years spanning 1982-2006.
Methods: Cancer incidence and survival data on all Queensland 
residents diagnosed with non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC) between 1982 and 2009 were derived 
from the Oncology Analysis System, Queensland Cancer Control 
Analysis Team. Incidence and overall all-cause survival at five years 
from diagnosis were aggregated over four time periods to 2006 
and stratified by histological subtype, age, gender, and estimated 
socioeconomic status derived from postcode information. Survival 
at 5 years from diagnosis was calculated using Kaplan-Meier esti-
mates.
Results: The absolute incidence of lung cancer diagnoses in 
Queensland has increased between 1982 and 2009, from 820 ca-
ses per year (in the time period 1982-1990) to 1,632 cases per year 
(time period 2006-2009). The increased incidence of non-squa-
mous NSCLC accounts for the majority of this and has increased 
significantly from 322/year to 1,083/year. Approximately one out 
of eight cases of lung cancer are SCLC. Five year survival for those 
diagnosed 2002-06 was 14% for all lung cancer, with a significantly 
worse outcome for SCLC (6%) compared with NSCLC (15%). Survi-
val from squamous NSCLC was marginally better than non-squa-
mous histologies (17% vs 15%). Significant discrepancies are seen 
in outcome related to gender (16% for women vs 13% for men) 
(p<0.05) and based on age (17% for those aged less than 65, and 
13% for those 65 and older) (p<0.05). The outcomes are favourable 
compared with the five years 1982-86, where overall 5-year survival 
from lung cancer was 12% (4% for SCLC and 13% for NSCLC). No 
significant relationship was seen with outcome based on estimated 
socio-economic status across the entire time period, although this 
was not recorded for 34% of patients. For those classed as affluent 
or middle class, 5-year survival was 14% compared with 12% in 
disadvantaged areas.
Conclusion: Five year survival for lung cancer in Queensland, Aus-
tralia compares favourably with national and international norms, 
and has increased over the last 25 years. There is a significantly 
worse outcome for men seen across all tumour subtypes, which 
has been noted in other tumour streams. Of note, there is no signi-
ficant differential in survival based on socioeconomic status, where 
this could be estimated.
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P3.22-009 LUNG CANCER IN WOMEN: CLINICAL AND 
PATHOLOGIC FEATURES
Meltem Tor, Aysegul Tomruk, Figen Atalay
Department Of Pulmonary Medicine, Bulent Ecevit University Hospital/
Turkey
Background: There is scientific evidence of increasing lung cancer 
incidence in women. and lung cancer pattern and risk factors in 
women are not the same as with men due to genetic and hormonal 
differences
Methods: In this study we reviewed the clinical and pathologic fea-
tures in our female lung cancer patients diagnosed and followed at 
our clinic between 2005 and 2009.
Results: In this period, we followed 360 lung cancer patientsl. Of 
them, 30(8.3%) were women.Their mean age was 62.83 +/- 12.43 
(range 33-83). 93.4% (n:28) were housewives, 80% (n:24) were non-
smoker, 13.3%(n:4) were exsmoker, 6.7% (n:2) were current smo-
kers. 93.7‘% were postmenapausal women. They had no history 
of cancer, COPD, asthma, or tuberculosis. Hypertension, coronary 
arterial disease, and DM were present in 20% (n:6), 10% (n:3), and 
6.6% (n:2) of them respectively. Only one patient (3.3%) was aymp-
tomatic. Most common symptoms were cough, dyspnea, chest 
pain and hemoptysis in order. At the time of diagnosis, 63.3%(n:19) 
were ECOG 0, 23.3% (n:7) were ECOG 1, 13.3% (n:4) were ECOG 2. 
Histopathologic diagnosis were adenocarcinoma in 53.3%, squa-
mous cell carcinoma in 13.3%, NSCLC (not otherwise specified) 
in 16.7% and SCLC in 16.7%. Of NSCLC patients only 8.6% were 
early stage, remaining 91.4% were locally advanced or metastatic 
disease. 20% of SCLC patients were at limited stage, remaining 
80% had extensive disease. Most common sites of metastasis were 
lung/pleura (40%), brain (36.7%) and bone(30%). Three patients 
rejected any form of therapy. Surgery +/- adjuvant therapy were 
applied to 2 patients, chemotherapy +/- radiotherapy were given 
to 22 patients.
Conclusion: In conclusion, majority of our women lung cancer 
patients were nonsmokers, with adenocarcinoma histology, post-
menapausal and in good performance status.
Keywords: Lung cancer, women
captured by the VLCR recruitment method. The inclusion of the R 
Code in hospital ICD code extracts will increase the VLCR ascer-
tainment rate.  
[i] Parkin, D. M. and F. Bray (2009). "Evaluation of data quality in 
the cancer registry: Principles and methods Part II. Completeness.“ 
European Journal of Cancer 45(5): 756-764.
Keyword: Registry, lung cancer, completeness of case ascertain-
ment
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P3.22-008 ARE THERE DISPARITIES IN LUNG CANCER 
INCIDENCE TRENDS AMONG HISPANICS AND AFRICAN 
AMERICANS? AN ANALYSIS OF THE SURVEILLANCE EPI-
DEMIOLOGY AND END RESULTS DATABASE 1992-2010
Manali I. Patel1, Iona Cheng2, Scarlett Lin Gomez2, Kathleen Gali2, 
Robert Haile1, Heather A. Wakelee1
1Medicine, Division Of Oncology, Stanford University/United States Of 
America, 2Cancer Prevention Institute Of California/United States Of 
America
Background: Previous studies demonstrate disparities in the 
incidence of lung cancer. Specifically, in the United States, in com-
parison to non-Hispanic Whites, African Americans have a higher 
incidence rate of lung cancer while a lower incidence rate is seen 
among Hispanics. Recent studies demonstrate significant progress 
in smoking-cessation programs for non-Hispanic Whites; howe-
ver, there are still a lower number of smoking cessation programs 
directed towards African Americans and trends of increased smo-
king behavior among Hispanics. No studies have evaluated recent 
histologic-specific incidence trends of lung cancer that may reflect 
these changing smoking behavioral patterns.
Methods: Using the Surveillance, Epidemiology and End Results 
data from years 1992-2010, lung cancer incidence rates and ave-
rage annual percentage change (APC) were computed overall and 
by histology for African Americans, Hispanics, and non-Hispanic 
Whites.
Results: Incidence rates of lung cancer steadily decreased for non-
Hispanic Whites, African-Americans, and Hispanics males (APC = 
-2.0, -2.6, and -1.9, respectively) from 1992 to 2010. This was true 
for all histological subtypes. Overall incidence rates of lung cancer 
among females have been relatively stable, with evidence of recent 
declines since 2005 among African Americans and non-Hispanic 
Whites. These trends were seen for all histological subtypes 
among females, except for the notable exceptions of increases in 
adenocarcinoma among African Americans (APC = 2.9 from 2003-
2010) and Hispanics (APC = 1.2 from 1992-2010).
Conclusion: For men, overall and histologic-specific incidence 
rates of lung cancer have decreased among Non-Hispanics Whites, 
African Americans, and Hispanics. For women, in recent years, 
non-Hispanic Whites demonstrate a similar pattern of decline in 
lung cancer incidence rates. However, the overall incidence rate of 
lung cancer among African American and Hispanic women while 
decreasing or remaining slightly stable, an increased incidence of 
adenocarcinoma has been observed that warrants further explora-
tion.
Keyword: incidence, disparities, population trends, lung cancer
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P3.23-001 THE CLINICAL SIGNIFICANCE OF SMOKING 
CESSATION IN PATIENTS WITH CANCER
Ioannis Gkiozos, Ekaterini Syrigou, Fotis Psarros, Ekaterini Florou, 
Sofia Tsagkouli, Andriani Charpidou, Konstantinos N. Syrigos
Oncology Unit Gpp, Sotiria General Hospital/Greece
Background: Despite the established causal relationship between 
tobacco smoking and cancer many cancer patients continue to 
smoke after diagnosis. This partly reflects the ignorance of the be-
neficial effects of smoking cessation even after diagnosis. The aim 
of the study is to demonstrate the effect of continuing or quitting 
smoking in patients with diagnosed cancer.
Methods: This study is based on a review of medical databases 
(Pub Med CENTRAL, MEDLINE, Cochrane Library) of the last thirty 
years. All articles included in the present analysis were in English.
Results: In patients with early stage lung cancer, continued smo-
king after diagnosis is associated with an increased risk of all cause 
mortality and decreased survival. Research has demonstrated 
significant difference in actuarial overall survival favoring the 
non-smoking group among patients with lung cancer. In patients 
with oral cancer smoking cessation or reduction leads to a signi-
ficant reduction in mortality. There is also evidence that tobacco 
smoking exacerbates and prolongs radiotherapy induced compli-
cations.Of particular importance is the evidence that continued 
smoking is associated with adverse effects during anticancer 
treatment. Smoking increases tumor progression and resistance 
to chemotherapy due to nicotine-induced resistance to apoptosis 
by modulating mitochondrial signaling. Continuing smoking is 
also related with inferior outcomes during treatment with novel 
targeted therapies such as erlotinib. Continuing smoking in gas-
tric and lung cancer patients is also associated with an increased 
risk of developing second primary tumors. Quitting smoking after 
lung cancer diagnosis is associated with better performance status 
while persistent smokers have worse overall quality of life. Patients 
who continued to smoke despite being diagnosed with cancer 
report more severe pain than never smokers and a greater interfe-
rence from pain.
Conclusion: Continuing smoking after cancer diagnosis is related 
with reduced treatment efficacy and reduced survival, risk for more 
secondary malignancies and deterioration in quality of life.
Keywords: lung cancer diagnosis, tobacco smoking, adverse ef-
fects, treatment efficacy
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P3.22-010 ADVANCED NON-SMALL CELL LUNG CAN-
CER (NSCLC-AD) IN PATIENTS UNDER 50 - A NEW REA-
LITY
Ana R. Figueredo, Lígia Fernandes, Fernando Barata
Chest Oncology, Coimbra‘s University Hospital Centre/Portugal
Background: The incidence of NSCLC in young patients increases 
annually. Our objective is to characterize this specific population
Methods: Retrospective study of 61 consecutive NSCLC-AD cases 
in patients under 50 years old, diagnosed between 2001 and 2011. 
Clinical data, histology, Performance Status (PS), therapy and over-
all survival (OS) were evaluated.
Results: Of all the patients 70.5% were men, mean age 44.7 ± 4.12 
years, most of them smokers (55.7%) with a Performance Status 
(PS) of 1 (83.6%), 2 (9.8%) or 3 (6.6%). Comorbidities were found 
in 42.6% of patients. The most frequent histology was adenocar-
cinoma (55.7%) followed by squamous cell (39.4%) and large cell 
(4.9%). Metastasis in 1, 2 or 3 organs were found in 49.2%, 27.9% 
and 22.9% respectively. Excluding two patients that are still alive 
(49.5 and 65.3 months after initial diagnosis), the global OS was 
12.4 months. All patients with PS 3 were smokers with comorbidi-
ties, had more than 2 sites of metastization and underwent best 
supportive care only. Mean OS of this group was 0.7 months. 
Only 1 patient with PS 2 showed comorbidities and they were all 
submitted to 1st line chemotherapy with "platinum-based doub-
lets“. No 2nd line therapy was initiated and mean OS of this group 
was 4.7 months. In the PS 1 group (51 patients), 43.1% showed at 
least 1 comorbidity and 56.9% had >1 metastasized organ. The 
mean OS of this group was 10.8 months. All patients underwent 
1st line chemotherapy – options were "platinum-based doublets“ 
(50 patients) and Erlotinib (1 patient). Second line therapy was 
done in 60.8% (31) of these patients (Pemetrexed in 14 patients, 
Docetaxel in 11 patients and Erlotinib in 6 patients), and 3rd line in 
35.5% (11) – options were Erlotinib (9 patients), Pemetrexed and 
Carboplantin+Vinorelbine (1 patient each). Two patients started 4th 
line therapy (3.9%) with Pemetrexed. OS for different therapeutic 
lines in this group (patients that underwent only one line of thera-
py, 2 lines or 3 lines) were respectively 5.8 months, 11.45 months 
and 29.2 months.
Conclusion: In our study, young patients with NSCLC present in 
advanced stages with important comorbidities and have an overall 
prognosis similar to the literature. Stronger physical reserve may 
allow several therapeutic lines to be completed in a significant 
number of cases.
Keyword: NSCLC young patients
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P3.23-003 IMPLEMENTATION OF A TOBACCO TREAT-
MENT PROGRAM WITHIN A MULTIDISCIPLINARY THO-
RACIC ONCOLOGY SURGERY CLINIC
Matthew A. Steliga1, Claudia P. Barone2, Erna Boone3, Virginia E. 
Hullihan4, Patricia L. Franklin4
1Thoracic Surgery, University Of Arkansas/United States Of America, 
2College Of Nursing, University Of Arkansas/United States Of America, 
3College Of Health Professions, University Of Arkansas/United States 
Of America, 4Nursing- Dept Of Surgery, University Of Arkansas/United 
States Of America
Background: Many patients in a multidiscipinary thoracic onco-
logy surgery clinic smoke, and are treated for diseases related to 
smoking. While some patients may be former smokers, many are 
actively smoking and unable to quit. In the short term, periopera-
tive complications such as impaired wound healing, and increased 
respiratory complications are linked to continued tobacco use 
whereas long term survival may be impacted by smoking causing 
increased cardiovascular risk, worsening emphysema and future 
development of metachronous primary tumors. Although quitting 
smoking has proven health benefits, nicotine addiction is one of 
the most challenging to overcome leading to a nihilistic view of 
tobacco cessation in this setting by some patients and clinicians. 
Unaided cessation has a poor success rate (<5%), while a combi-
nation of physician recommendation, face to face counseling by 
certified tobacco treatment specialists (TTS), individualized phar-
macotherapy and ongoing follow up can improve quit rates and 
tobacco abstinence.
Methods: A multidisciplinary team from thoracic surgery, the 
college of nursing and the college of health professions was as-
sembled with the goal of providing multifaceted, evidence-based 
tobacco treatment as an integrated part of our thoracic oncology 
surgery clinic. Three team members obtained TTS training. After 
institutional board review approval, all clinic patients were queried 
for tobacco use, and any patient actively smoking underwent brief 
intervention by the thoracic surgeon (who is a TTS) and was refer-
red for more in depth counseling to another member of the team 
who is also a TTS. For patient convenience, and increased compli-
ance with referral to cessation services, the counseling took place 
in clinic, in a private conference room adjacent to the exam rooms. 
Demographic data, tobacco use data, other drug/alcohol use and 
medication use data were recorded prospectively in a database. 
Follow up visits were conducted in the inpatient setting, upon 
return to clinic and/or contact via phone. Exhaled breath carbon 
monoxide monitoring was used during the visits to confirm initial 
active use and also used to confirm successful cessation.
Results: Over the initial seven months, 60 patients were identified 
as active smokers. All received brief intervention by the surgeon 
and referral to the quitline and in-clinic TTS counselor. Despite 
physician recommendation, the free of charge service, and the 
convenience of the service in clinic, 23/60 patients refused to meet 
the TTS counselor. Of the patients (24/60) who agreed to meet 
with the TTS, consented to enroll in the program, and agreed to 
follow up contact, 17/24 (70.8%) quit and remained abstinent at 
last contact (between 1-6 month follow up). Some patients did 
not meet inclusion criteria yet still met with the TTS counselor for 
referral to the quitline, or to talk about continued abstinence after 
quitting.
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P3.23-002 ASSESSMENT OF SMOKING AMONG HIGH 
SCHOOL STUDENTS FROM NORTHERN PORTUGAL
Henrique C. Queiroga1, Diana Silva2, Julia A. Fernandes3, Claudia 
Dias4, Altamiro Costa-Pereira4, Caldas Afonso2, António Guerra2, 
Ana Valente3
1Pulmonology Unit, Centro Hospitalar S.joão/Portugal, 2Pediatric Ser-
vice, Centro Hospitalar S.joão/Portugal, 3Faculty Of Nutrition And Food 
Sciences/Portugal, 4Department Of Bioestatistics And Medical Informa-
tics/Portugal
Background: According to the World Health Organization, tobac-
co use is a major cause of illness and death worldwide, especially 
lung cancer. Currently in Portugal, tobacco use among young peo-
ple has increased. It has been observed that adolescents’ smokers 
have a high probability of becoming adult smokers. Objective: 
To assess tobacco use in high school students and the associated 
social and family factors.
Methods: Based on all students aged between 15 and 19 ye-
ars old, 100 adolescents were recruited from each of three high 
schools. The smoking habits of adolescents were evaluated accor-
ding to a protocol adapted from the Global Youth Survey (GYTS), 
Center of Disease Control and Prevention (2001). The question-
naire consisted of 34 questions related to tobacco use, knowledge 
and attitudes towards smoking, smoking cessation, school regula-
tion and the family role in preventing smoking. Participants were 
classified as: 1 - never having tried smoking; 2 - have just tried 
smoking (not smoked in the previous month); 3 - occasional smo-
kers (smoked at least 1 day during the previous month); 4 - current 
smokers (smoked at least 20 days in the previous month). The pro-
tocol was approved by the School Direction and statistical analysis 
was performed with SPSS ® for the entire sample and by gender.
Results: Of the total sample (n=285), 46% were males and 54% 
females whose average age was 16.6 ± 1.2 years (min:15; max:19). 
About 59.6% of adolescents have experienced smoking at least 
once, 54% of who were female. Although the average age of to-
bacco onset was between 12-15 years (64%), we found that 21% of 
subjects experienced smoking before 11 years of age. Over 90% 
admitted smoking with friends and public spaces were the place 
preferred (38%) followed by social events (21%). Regarding the 
harmful effects of tobacco on health, school revealed a reducer 
role as a trainer, since 51.6% of adolescents admitted that the issue 
of smoking was never raised during the present school year. There 
is a statistically significant association regarding the initiation of 
smoking and parents educational level (mother: p=0.001; father: 
p=0.05). The same occurred when the mother is a smoker (p = 
0.002).
Conclusion: There is an early initiation of smoking in this popu-
lation and a high percentage of adolescents do it regularly. We 
emphasize the enormous importance of an effective intervention 
strategy in relation to the harmful effects of tobacco, with strong 
involvement of the school and family, in order to reduce tobacco 
consumption and prevent its health consequences with regard to 
morbidity and mortality.
Keyword: adolescence, school, tobacco
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tobacco cessation was a waste of time. However, variables associa-
ted with an increased likelihood to discuss medications or provide 
cessation assistance included respondents who a) reported having 
had adequate training in tobacco cessation or b) who reported 
that additional training is needed for clinicians.
Conclusion: s: Most IASLC member oncologists who responded 
to the survey asked about tobacco use, but few routinely provided 
tobacco cessation assistance to their patients. Cancer patients 
need increased access to tobacco cessation support. Differences 
in the measurements of perceived barriers suggest that efforts are 
needed to increase cessation resources and clinician education in 
order to improve tobacco cessation support for cancer patients.
Keyword: Tobacco cessation, physician education
Conclusion: Integrating TTS in the multidisciplinary thoracic onco-
logy surgery clinic can be accomplished. For those that enroll and 
consent to follow up, this pilot data demonstrates excellent short-
term quit rates in this setting. Ongoing enrollment, further follow 
up, and planned expansion to involve other clinics (pulmonary and 
medical oncology) will allow better understanding of the efficacy 
of tobacco cessation services integrated into clinical settings.
Keywords: Tobacco Cessation, nursing, surgery, Clinical Care
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P3.23-004 THORACIC ONCOLOGY PROVIDERS AND 
ADDRESSING TOBACCO USE IN CANCER PATIENTS: A 
REPORT FROM AN IASLC SURVEY.
Carolyn Dresler1, James R. Marshall2, K Michael Cummings3, Ben-
jamin A. Toll4, Ellen R. Gritz5, Alan Hutson2, Seyedeh Dibaj2, Roy 
Herbst4, Graham W. Warren3
1Arkansas Dept Of Health/United States Of America, 2Roswell Park 
Cancer Institute/United States Of America, 3Medical University Of Sou-
th Carolina/United States Of America, 4Yale University/United States 
Of America, 5MD Anderson Cancer Center/United States Of America
Background: Tobacco use increases toxicity, recurrence, second 
primary cancers, and mortality in cancer patients. However, on-
cologists do not routinely provide assistance with tobacco ces-
sation and little is known about potential barriers that could be 
addressed to improve cessation practices among oncologists.
Methods: An online survey was sent to IASLC members query-
ing demographics, tobacco assessment and cessation practices, 
perceptions of tobacco use by cancer patients, and barriers to 
tobacco cessation intervention. Results are reported and multiva-
riate analyses were performed to identify likely barriers to tobacco 
assessment and cessation.
Results: A total of 1,507 IASLC members responded to the survey 
representing a 40.5% response rate. Most respondents reported 
that tobacco use affected cancer outcome (92%) and that tobacco 
cessation should be a standard part of cancer care (90%). However, 
whereas 90% indicated that they regularly asked about tobacco 
use, only about 40% regularly discussed medications or provided 
cessation assistance. A lower likelihood of assessing tobacco use 
was associated with the following demographic variables: a) loca-
tion outside of the United States (USA), b) practice non-academic 
centers, c) fewer years of service as a medical provider, d) less 
time spent on clinical activities, or e) current smoking. Variables 
associated with a decreased likelihood of giving advice to stop 
smoking were a) location outside of the USA and b) less time spent 
in clinic. A lower likelihood of providing cessation assistance was 
associated with providers outside of the USA. After adjustment for 
demographic variables, variables associated with increased likeli-
hood of assessing tobacco use were a) providers who felt cessation 
affected outcome and b) providers who reported more training 
on cessation is needed. An increased likelihood to advise patients 
to stop smoking was observed in respondents who reported that 
additional cessation training is needed whereas a lack of time was 
reported as a variable that decreased likelihood to provide patient 
advice. Variables associated with a decreased likelihood to provi-
de tobacco cessation assistance included: a) lack of time, b) lack 
of training, c) lack of available resources, and d) perception that 
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individuals and families due to the demands put on their time. But 
they can be encouraged by this study’s findings that suggest moni-
tored on-line support communities serve as a complement to, not 
a replacement for, formal health care. Monitored on-line support 
communities can help individuals overcome frustrations and fears 
by serving as an added resource that helps them to communicate 
and ask questions of others who are in similar situations that, in 
turn, foster their control as partners with physicians in making deci-
sions about their care.
Keywords: online support community, lung cancer stigma
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P3.24-002 INCIDENCE OF LUNG ENTRAPMENT IN  
MALIGNANT PLEURAL EFFUSION
Imran Bin Mohamed Noor
Respiratory And Critical Care Medicine, Changi General Hospital/Sin-
gapore
Background: Malignant pleural effusion s occur in up to 15% of 
patients with advance malignancies. However, the incidence of 
lung entrapment in patients with malignant pleural effusions has 
never been reported. This may have an impact in the management 
of patients with malignant pleural effusions, as pleurodesis is unli-
kely to suceed. A two year review of patients with malignant pleu-
ral effusions who underwent medical pleuroscopy was perform, 
looking at the incidence of lung entrapment. Medical pleuroscopy 
has been performed in our hospital since January 2011.
Methods: A review of the records of patient who underwent me-
dical pleuroscopy from 1 January 2011 to 31 December 2012 was 
performed. Patients with histology proven malignant effusions 
were included in our analysis. The incidence of lung entrapment 
was recorded based on the procedure report entered by the per-
forming physician.
Results: Over a two year period, seventy-three medical pleurosco-
pies were performed. All patients underwent pleuroscopy guided 
parietal pleura biopsies. Out of 73 cases, thirty six (49.3%) were 
confirmed malignant on histology. Of the cases with histology 
proven malignant effusion, there were twenty five cases of primary 
lung cancer (69.4%), 10 cases of primary breast cancer (27.8%) and 
one case of primary cervical cancer (2.8%). Adenocarcinoma was 
the histology in 96% of patients with metastatic lung cancer (twen-
ty four out of 25 patients) . The remaining patient patient with me-
tastatic lung cancer was found to have squamous cell carcinoma. 
The incidence of lung entrapment among patients with histology 
proven malignant pleural effusion who had undergone pleurosco-
py in our study was 94.4% (thirtyy four of 36 patients). Entrapment 
was not seen in two cases of metastatic lung adenocarcinoma.
Conclusion: Our study shows a 94.4% incidence of lung entrap-
ment in patients with malignant pleural effusion who had under-
gone medical pleuroscopy. However, more studies are needed to 
look at the incidence of lung entrapment, as not all patients are 
fit to undergo medical pleuroscopy. Furthermore, pleuroscopy is 
not readily available in most hospitals world wide. If the overall 
incidence is indeed high, the long term management of malignant 
plerual effusions will require a review, in particular, the use of talc 
in pleurodesis.
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P3.24-001 ONLINE SUPPORT: CONTENT ANALYSIS OF 
A "SAFE“ ONLINE HAVEN FOR INDIVIDUALS AFFECTED 
BY LUNG CANCER
Michelle Lobchuck1, Susan Mcclement1, Maureen Rigney2, Amy 
Copeland2, Hamideh Bayrampour3, Sara Lazar4
1Faculty Of Nursing, University Of Manitoba/Canada, 2Lung Cancer Al-
liance/United States Of America, 3Alberta Centre For Child, Family And 
Community Research, University Of Calgary/Canada, 4Human Ecology, 
University Of Manitoba/Canada
Background: Smoking-related stigma may increase psychological 
distress and result in isolation and lack of communication, compli-
cating attempts to mitigate stigma’s harmful effects felt by indivi-
duals dealing with lung cancer. However, monitored on-line com-
munities ensure anonymity, foster positive coping through mutual 
support and negate feelings of being alone, allowing stigmatized 
individuals to reach out to ‘trusted others’ without fear of reprisal. 
This study explored the content and tenor of ‘naturally’ occurring 
communication in a monitored on-line lung cancer support com-
munity in the United States, as well as who uses the on-line sup-
port community and their issues and concerns. 
Methods: This qualitative study comprised a convenience sample 
of archived on-line threaded messages posted in a monitored 
on-line lung cancer support community. A three phased content 
analysis approach was employed to analyze a sample of 688 pages 
(from a total of 4,916 pages) that contained threaded messages 
across two time periods: August to September 2008 and January 
to February 2009. Sixty-eight main posts and 586 replies in 344 
pages for period one (262 users) and 55 main posts and 697 replies 
in 344 pages for period two (307 users) were analyzed. Themes 
capturing the issues, concerns, and emotions raised by community 
users were identified.
Results: Most of the 569 users were female, half were individuals 
diagnosed with lung cancer. Information requests and replies were 
often embedded within narratives of personal experiences with 
lung cancer and emotional support. Message tenor tended to be 
respectful, carefully crafted and even caveat-laden concerning 
personal experiences. An overarching sense of solidarity was evi-
dent in reflections of feelings, goals, responsibilities and interests 
in living with lung cancer. Nine major themes were captured from 
main posts and replies: Disease-related information, Diagnostic-
related information, Treatment-related information, Symptoms and 
their meaning, Deterioration of health status, Advocacy, Experi-
ences with health care providers/health care system, Survivorship 
issues, and Psychosocial concerns and feelings.
Conclusion: Individuals living with lung cancer freely shared their 
unmet needs consistent with those dealing with other types of can-
cer who receive on-line empathic support and guidance. A num-
ber of users expressed dissatisfaction and mistrust of health care 
providers due to their disengagement in providing timely support 
and practical information about diagnosis, prognosis, treatment 
effects and their lack of positive attitudes. Health care providers 
cannot address all information and emotional needs of diagnosed 
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FCT Indicator Median Interval (days) 
Ref - FSA 7 (0-33) 
Tx FSA to Tx 18 (3-55) 
Ref - Tx 67.5 (14-118) 
 
Factors identified as barriers to achieving targets included diag-
nostic modality (bronchoscopy versus CT), number of staging in-
vestigations required and referral processes between services.
Conclusion: Performance against the 62 day target for patients 
in our region had improved but remained below the national re-
commended standard. A dedicated lung Cancer Clinic is to be 
established and referral processes between services streamlined 
to achieve acceptable performance against standards.
Keywords: Audit, Treatment Standards
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P3.24-004 LUNG ADENOCARCINOMA WITH EML4-ALK 
TRASLOCATION AND OVARIAN TERATOMA IN A 20-YE-
AR-OLD WOMAN. A CASE REPORT.
Gianpiero D. Romano1, A Cocciolo2, I Vasta2, A Gnoni1, A Licchetta1, 
C Nuzzo3, G Cairo1, V Saracino1, A Tornesello2
1Oncology Unit, Vito Fazzi Hospital/Italy, 2Paediatric Oncology/ha-
ematology Unit, Vito Fazzi Hospital/Italy, 3Radiology Unit, Vito Fazzi 
Hospital/Italy
Background: The echinoderm microtubule-associated protein-like 
4 (EML4)-anaplastic lymphoma kinase (ALK) is a recently identified 
fusion-type oncoprotein that occurs in about 4-5% of non small cell 
lung cancer (NSCLC). Important features associated with ALK-posi-
tive lung cancers include younger age, adenocarcinoma histology, 
and never or light smoking habit.
Methods: Review of medical record and of pathology slides.
Results: A 20 year old no-smoker girl presented in August 2012 
with weight loss (8 kg over 6 months), intermittent fever, cough 
and thrombosis of the popliteal and subclavian veins. A total body 
Computed Tomography (tbCT) scan showed lymphadenopathy in 
the mediastinum, in the supraclavear and laterocervical areas, a 
lung mass in the right inferior lobe with omolateral pleural effusi-
on, a nodule in the controlateral lung and an ovarian teratoma. A 
supraclavear node biopsy demonstrated a lung adenocarcinoma 
(cytokeratin (CK) 7 and thyroid transcription factor-1 (TTF-1) posi-
tive). Molecular analysis showed translocation of ALK and absence 
of mutations of the epidermal growth factor receptor (EGFR). Be-
cause of worsening of symptoms, a first line chemotherapy with 
cisplatin and docetaxel was started, while waiting for the molecu-
lar analysis. After three cycles, in Dicember 2012, the tbCT scan 
showed a substantial stable disease. By cause of the worsening of 
symptoms and of the chemotherapy toxicity (G4 neutropenia, G2 
anemia), an oral treatment with Crizotinib was started. It was well 
tolerated. After 13 weeks of treatment the CT scan showed a parti-
al response (40% according to Recist criteria); the ovarian teratoma 
and the thrombosis were stable.
Keywords: malignant pleural effusion, medical pleuroscopy, lung 
entrapment, pleural biopsy
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P3.24-003 COMPLIANCE WITH CANCER TREATMENT 
INDICATORS - RESULTS OF A 3 MONTH AUDIT OF PATI-
ENTS WITH LUNG CANCER TREATED WITH CURATIVE 
INTENT
Greg Frazer, Catherine Smith, Rachel Wiseman
Respiratory, Christchurch Hospital, Canterbury Dhb/New Zealand
Background: New Zealand’s National Lung Cancer Working Group 
(NLCWG) has established a number of standards for the manage-
ment of patients with lung cancer as part of the Standards of Ser-
vice Provision for Lung Cancer Patients in New Zealand. Standard 
One, relating to timely access to services, is that patients requiring 
active treatment should start treatment within 62 days of seconda-
ry care receiving a referral. The Ministry of Health has subsequent-
ly introduced Faster Cancer Treatment (FCT) Indicators for all can-
cer streams. • Indicator one (62 day target): time between referral 
with a high-suspicion of cancer and start of first cancer treatment 
• Indicator two (14 day target): time between referral and first 
specialist assessment (FSA) •Indicator three (31 day target): time 
between decision to treat and start of first cancer treatment Com-
pliance targets around these indicators have not yet been set. A 
retrospective comparative audit performed by the Southern Can-
cer Network showed that only 28.3% of patients from the Upper 
South Island (incorporating the Nelson-Marlborough, West Coast, 
Canterbury and South Canterbury District health Boards) referred 
for curative intent treatment in 2010 met NLCWG Standard One. 
We performed a 3 month prospective audit to 
• Determine if performance in the region around NLCWG Standard 
One had improved
• Identify barriers to compliance with the above targets
Methods: Data was collected prospectively for all patients presen-
ted at the regional lung cancer multidisciplinary meeting (MDM) 
from 1 August to 31 October 2012. Patients were included in the 
final audit if the recommendation of the decision MDM was that 
they should be offered curative intent treatment.
Results: A total of 73 patients were discussed at MDM during the 
audit period. 27 (37%) were recommended to undergo curative 
intent treatment. For these patients the median time between 
referral and FSA (Indicator 2) and between treatment FSA and start 
of definitive treatment (Indicator 3) were within target, with com-
pliance of 88% and 78% respectively. However the median time 
between referral and start of first cancer treatment at 67.5 days did 
not meet Standard 1/ Indicator 1, with only 39.1% compliance with 
the 62 day target  
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kers and patients with other unfavourable factors outlined above 
may still benefit from Lesser Resections. The theoretical advan-
tages of a Lesser Resections include preservation of pulmonary 
function,and the ability of the patient to undergo further resec-
tions in the future if a second primary lung cancer should develop. 
Although the numbers are small and longer follow up periods are 
needed it may be one of the other indications for lesser resections 
besides poor PFTs. We have shown that the presence of a positive 
synchronous and/or metachronous Cancer history has significantly 
influenced our surgical strategy for stage 1 patients that my have 
otherwise been suitable for Lobectomy.
Keyword: Lesser Resection,Stage 1 NSCLC
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P3.24-006 THE CONTRIBUTION OF HISTOPATHOLOGI-
CAL EVALUATION OF SMALL SAMPLES OBTAINED BY 
EBUS PUNCTURE FOR DIAGNOSIS OF PATHOLOGICAL 
MASSES IN MEDIASTINUM
Martina Vasakova1, Sarka Lefnerova1, Ludek Stehlik1, Radoslav 
Matej2
1Department Of Respiratory Medicine, Thomayer Hospital/Czech Re-
public, 2Deaprtment Of Pathology And Molecular Medicine, Thomayer 
Hospital/Czech Republic
Background: Endobronchial ultrasonography (EBUS) have reached 
an important position in diagnosis of tumors and enlarged lymph 
nodes involving mostly mediastinum. The puncture of pathologi-
cal mediastinal masses under EBUS control is perfomed with thin 
needle and the obtained samples are mainly evaluated by means 
of cytology, which in case of malignant tumors does not give de-
finite diagnosis including subtyping of tumor. Thus we aimed to 
evaluate the EBUS puncture samples also by means of histopatho-
logy including immunohistochemistry.
Methods: During one year we investigated 94 patients (53 males, 
41 females, mean age 52 years) with enalrged lymph nodes or 
tumor spread involving mediastinum by EBUS puncture with sam-
pling for cytology, histopathology and immunohistochemistry. 42 
patients had suspicion of sarcoidosis, 32 lung cancer with diastinal 
involvement, 7 metastates of extrapulmonary tumor to mediasti-
nal lymph nodes, 3 lymphoma and 10 pulmonary infiltrates with 
mediastinal lymphadenopathy probably of inflammatory origin. 
The investigation was performed under general anesthesy and the 
other samples from the invoved sites of lungs (aspirates, brushes, 
excisions, transbronchial biopsies (TBB), bronchoalveolar lavage 
(BAL)) were taken ad the same time.
Results: In the sarcoidosis group we obtained histopathologi-
cally evaluable samples from EBUS puncture of lymph nodes in 
19 patients (45%) and in 8 of them (19%) the sarcoid granulomas 
were described. In lung cancer group we had valid samples in 23 
patients (72%) and in 17 of them (53%) we diagnosed the carcino-
ma histopathologically including immunohistochemical analysis, 
and in 6 patients (19%) we confirmed normal lymph nodes. In the 
group of patients with extrapulmonary malignancy we defined 
histopathologically the metastases in mediastinal lymph nodes in 
2 of 7 patients and in 1 sarcoidosis. In the patients with suspect 
lymhopma histopathological evaluation of lymph nodes did not 
support the diagnosis. In the group of pulmonary infiltrates with 
mediastinal lymhadenopathy we proved by histopathology normal 
Conclusion: Patients with EML4-ALK mutant NSCLC are reportedly 
significantly younger than patients with wild-type, however, to our 
knowledge, only a younger case of our patient was until today re-
ported (14-year old1). This case confirms that Crizotinib is effective 
and well tollerated in very young patients. 1 Kim SJ, J Clin Oncol. 
2012 Jun 1;30(16):e147-50. Realized with the support of: 
"Associazione Genitori "Per un sorriso in piu‘“.
Keywords: Crizotinib, ALK translocation
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P3.24-005 THE ROLE OF LESSER RESECTION FOR 
TREATMENT OF EARLY STAGE NON-SMALL CELL LUNG 
CANCER IN MEDICALLLY COMPROMISED PATIENTS
Phillip N. Antippa, Marzi G. Mehta
Cardiothoracic Surgery, Royal Melbourne Hospital/Australia
Background: Lobectomy is the standard of Surgical care for me-
dically fit patients with primary Non-Small Cell Lung Cancer. It is a 
well known fact that those with small peripheral lesions and those 
unfit for surgery (impaired Performance Status or Poor Pulmonary 
Functional capacity) could be considered for Lesser Resections 
(Wedge Resection or Segmentectomy) albeit with increased risk 
of recurrence. We have attempted in this study to identify factors 
other than poor PFTs (FEV1/DLCO <45%) as an indication for per-
forming Lesser Resections rather than stereotactic Radiotherapy or 
best supportive care.
Methods: 70 patients underwent a Lesser Resection for primary 
Lung Cancer from 2002 to 2012. This was a retrospective study. 
Sixteen patients were excluded because the final histopathology 
was not consistent with primary lung cancer. Alternative diagnoses 
such as metastatic disease, benign disease and carcinoid tumours 
were made. Thus 54 patients were available for the final analysis of 
which only nine patients had poor PFTs. Therefore 45 patients with 
primary Lung cancer underwent a Wedge Resection or Segmen-
tectomy although they were fit for Lobectomy as per their Pulmo-
nary Function Test.
Results: Of the 54 patients who underwent a Lesser Resection, 
31 were chronic smokers with greater than 20 pack years smoking 
history. All the tumours were Stage I (88% stage Ia and 12% stage 
Ib). The majority of the patients had Adenocarcinoma (61%) and 
19% were Squamous Cell carcinomas with the remainder being 
Large Cell or Not Otherwise Specified Non-Small Cell Carcinomas. 
There were no Small Cell carcinomas in our study popultaion. The 
most important unfavourable factors other than decreased PFTs 
included Chronic Obstructive Airway Disease (53.7%), Coronary 
Artery Disease (20.3%) and other factors such as Hypertension, Di-
abetes and Obesity ranging from 7% to 11%. At least half the study 
population had three or more unfavourable medical comorbidities. 
Three patients had other advanced cancers in the past. Twenty 
one patients (39%) had metachronous primary Lung Cancers com-
pared to only 7% having synchronous lung primary tumours. Three 
patients (5%) had local recurrence and three (5%) had regional 
recurrence. Five patients (9%) had distant metastasis. The median 
survival for the entire population was 21 months as compared to 
historical controls where best supportive care has an overall survi-
val of only 13 months in stage 1 Lung Cancer.
Conclusion: From this study we conclude that chronic heavy smo-
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treatment recommendations. All new lung cancer patients dis-
cussed at the MDM between 1/12/05 – 31/12/2010 were identified. 
Details of patient demographics, tumour characteristics and treat-
ment were obtained from the MDM database and the Area Clinical 
Cancer Registry. GRT was assigned to each patient according to 
pathology, stage and ECOG performance status as per the 2004 
Australian Lung Cancer Guidelines. This was compared to actual 
treatment received to determine adherence to GRT. For those who 
did not receive GRT, the medical record was reviewed to determi-
ne the reason why. Survival was compared between patients who 
did and did not receive GRT.
Results: 808 patients were discussed at the MDM. 64% were male 
and the median age was 68 years. Pathology was NSCLC in 657 
(81%), SCLC in 119 (15%) and not confirmed in 32 (4%). 128 (16%) 
had Stage I or II NSCLC, 306 (38%) Stage III NSCLC or limited sta-
ge SCLC and 372 (46%) metastatic disease. GRT could be assigned 
in 98% of patients who had both stage and ECOG performance 
status documented. Overall 411 (51%) of patients received GRT, 
and 380 (47%) did not receive GRT. The main reasons for not recei-
ving GRT were decline in performance status (24%), large tumour 
volume precluding radical RT (17%), co-morbidities (14%) and pati-
ent preference (13%). On multivariate analysis, ECOG performance 
status, stage and age were significantly associated with receipt of 
GRT. GRT, ECOG performance status and stage were significant 
predictors of survival.
Conclusion: Despite discussion at an MDM, a significant pro-
portion of patients were unable to receive GRT due to legitimate 
reasons. This may reflect the characteristics of the underlying lung 
cancer population who are older and have coexisting comorbidi-
ties. Alternative treatment strategies are needed for patients who 
are not suitable for GRT.
Keywords: Multidisciplinary Teams, Guideline recommended 
treatment
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P3.24-008 EPITHELIAL-MYOEPITHELIAL CARCINOMA 
OF THE TRACHEA: ALTERNATIVE MANAGEMENT OF 
INOPERABLE DISEASE.
Henrietta Wilson1, Alexandra Rice2, Emma Beddow1
1Thoracic Surgery, Harefield Hospital/United Kingdom, 2Pathology, 
Harefield Hospital/United Kingdom
Background: Primary epithelial-myoepithelial carcinoma of the 
lung is a rare entity with fewer than 30 cases reported in the lite-
rature. These tumours are thought to arise from bronchial submu-
cosal glands and have histological features similar to their salivary 
gland counterparts. In view of the infrequent nature of the disease, 
biological behaviour and clinical course have yet to be fully de-
fined. Although considered a low-grade malignancy, there is a 
potential for invasion and metastasis; for this reason the majority 
of case reports have advocated complete surgical resection as the 
treatment of choice. Here we present a case of tracheal epithelial-
myoepithelial carcinoma treated with recurrent bronchoscopy and 
cryotherapy as surgical resection was not possible.
Methods: A 46 year old lady presented with acute shortness of 
breath and wheeze. Given her past history of asthma she was 
initially treated for an exacerbation with steroids, antibiotics and 
or inflammatory lymph nodes in 5 of 10 patients.
Conclusion: Histopathological evaluation including immuno-
histochemical analysis of samples from EBUS puncture of tu-
mors involving mediastinum and mediastinal lymh nodes is of 
important value mainly in lung cancer and metastatic cancer 
involvement. This approach enables the patients to avoid surgi-
cal bioptic procedures in non-resectable cases and thus helps to 
start the targetted tratment of lung cancer as early as possible. 
In case of sarcoidosis the histopathological evaluation of lymph 
node puncture samples rises the propability of stating defini-
te diagnosis in combination with other prcedures (BAL, TBB).
 
Fig.1 Small cell cancer, sample from EBUS puncture, EMA staining
Keywords: immunohistochemical evaluation, pathological masses 
in mediastinum, EBUS puncture, histopathology
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P3.24-007 DO PATIENTS DISCUSSED AT LUNG CANCER 
MULTIDISCIPLINARY TEAM MEETINGS RECEIVE GUIDE-
LINE-RECOMMENDED TREATMENT?
Miriam M. Boxer1, Kirsten J. Duggan2, Joseph Descallar1, Shalini K. 
Vinod1
1Ingham Institute For Applied Medical Research, Liverpool Hospital/
Australia, 2South West Sydney And Sydney Local Health Districts Clini-
cal Cancer Registry, Liverpool Hospital/Australia
Background: Many clinical practice guidelines recommend that 
all lung cancer patients should be discussed at a multidisciplinary 
team meeting (MDM) to determine a management plan. Previous 
studies have shown that lung cancer MDM recommendations are 
largely concordant with guidelines. There are limited data on whe-
ther these recommendations are translated into actual treatment 
received. The aim of this study was to evaluate whether patients 
discussed at a lung cancer MDM actually received guideline-
recommended treatment (GRT) and determine reasons for not 
receiving GRT.
Methods: The Liverpool/Macarthur lung cancer MDM prospec-
tively collects data on new lung cancer patients including patient 
and tumour characteristics, staging investigations, referrals and 
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P3.24-009 HISTOLOGIC AND GENOTYPIC EVOLUTION 
IN LUNG CANCER HARBORING MUTATIONS IN THE EPI-
DERMAL GROWTH FACTOR RECEPTOR (EGFR): A CLINI-
CAL CASE.
Tiziana Vavala‘, Luisella Righi, Simona Vatrano, Susanna Cappia, 
Elisa Gobbini, Simonetta G. Rapetti, Silvia Novello
Department Of Oncology, University Of Turin/Italy
Background: This is a clinical case of an EGFR-mutant Non-Small 
Cell Lung Cancer (NSCLC) with adenocarcinoma (ADC) histology: 
a subsequent diagnosis of high grade neuroendocrine small-cell 
lung cancer (SCLC) carrying an EGFR mutation was done at the first 
re-biopsy and further, a sarcomatous cancer was finally diagnosed. 
Recent publications were focused on drug-resistance mechanisms 
in patients with a specific biomolecular alteration re-biopsed after 
receiving the targeted therapy: in some cases morphologic and 
immunophenotypic changes were described. This finding suggests 
the possibility of "clonal resistance“ with a selective pressure of 
some groups of cells, even if the histopathological features of the-
se mechanisms have not yet been completely elucidated.
Methods: A 62-year-old caucasian man, with past smoking habit, 
presented with a 2-week history of cough and dyspnea. After a 
diagnosis of stage IV lung ADC, he received, on March 2010, 1st 
line treatment with cisplatin 75 mg/m2 plus pemetrexed 500 mg/
m2 on Day 1 every 21 days, for 6 cycles. He achieved a partial res-
ponse on computed tomography (CT) and a marked regression of 
his symptoms. On August 2011, a CT scan revealed a progressive 
disease (PD); he started treatment with Erlotinib plus ARQ-197/
placebo within a clinical trial. As deemed by protocol, molecular 
analyses were performed on biopsy specimen at time of diagno-
sis, evidencing exon 21 – point mutation, p.Leu858Arg at EGFR 
mutational assessment. After 4 cycles, a local progressive disease 
was described by CT scan and a fibrobronchoscopic re-biopsy was 
performed in order to define the novel biomolecular profile at that 
time of the history of the disease. The histological evaluation high-
lighted a SCLC and molecular analyses confirmed the p.Leu858Arg 
mutation. Based on new histological diagnosis, he underwent 
chemotherapy with AUC6 carboplatin on Day 1 every 21 days plus 
etoposide 100 mg/m2 on Day 1,2,3 every 21 days, for a total of 6 
cycles, until May 2012, achieving partial response at CT scan. On 
August 2012, because of radiological evidence of disease progres-
sion, he underwent chemotherapy with Cyclophosphamide 800 
mg/m2, Doxorubicine 40mg/m2 and Vincristine 1mg/m2 on Day 1 
every 21 days. After 3 cycles, he reported intense swelling in the 
supraclavicular right fossa and a fine needle aspiration of supracla-
vicular right lymphadenopathy was performed. The final pathologi-
cal diagnosis was undifferentiated sarcoma cells (CK-,TTF1-, VIM+) 
. Patient died, on January 2013, because of worsening of clinical 
conditions.
Results: Not applicable
Conclusion: Many studies hypothesize that SCLC either evolved 
from the previously diagnosed NSCLC or that both arose from a 
common precursor. Further comparative molecular analysis of the-
se histologically distinct tumors would be of value to better un-
derstand the potential role of EGFR in the evolution of lung cancer 
and the role of selection for an EGFR-mutant SCLC cell subclone as 
an unusual mechanism of acquired resistance to EGFR inhibitors in 
NSCLC.
nebulisers. The patient had no other history of note and had been 
a life-long non-smoker. Following a further deterioration leading to 
type I respiratory failure and episodes of haemoptysis she required 
intubation. CTPA demonstrated a tracheal mass. At bronchoscopy 
this well-circumscribed, vascular lesion was clearly identified 2cm 
above the carina (Figure 1). Multiple biopsies were taken confir-
ming a primary epithelial-myoepithelial carcinoma of the lung. 
Figure 1: Tracheal tumour at bronchoscopy
Results: Following multidisciplinary discussion the patient was 
admitted for surgical excision. However, at the time of surgery it 
was not possible to achieve adequate single lung ventilation and 
the procedure was therefore abandoned. As an alternative ma-
nagement option the patient has undergone regular bronchoscopy 
and cryotherapy. There has been no evidence of local recurrence 
or metastasis in the 14 months since diagnosis.
Conclusion: Histologically these tumours are characterised by vari-
able proportions of two cell types, with epithelial and myoepitheli-
al cells forming duct-like structures. In the majority of cases a poly-
poid endobronchial mass is present and patients therefore present 
with symptoms associated with airways obstruction. Although 
considered a low-grade malignancy there has been one case re-
port of extensive local and lymph node involvement. In addition, 
follow-up time has been too short to conclusively elucidate clinical 
behaviour. Here we have demonstrated the use of cryotherapy in 
the management of inoperable epithelial-myoepithelial carcinoma 
of the lung. The patient remains disease free at 14 months but will 
require on-going surveillance. We would agree that surgical excisi-
on remains the gold-standard in this patient group, but have provi-
ded a possible alternative strategy for inoperable cases.
Keywords: Cryotherapy, Case study, Tracheal neoplasm
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tion to somatic resources and relationships may increase its effec-
tiveness. Preliminary results from patients’ reports suggest that the 
MB-BAI both reduces symptoms of anxiety and depression and 
improves resources. Results will be presented after the complete 
achievement of the after-treatment assessment; we hope they will 
confirm that MBI favor positively impact on the adaptation to the 
disease, resulting in a reduction of the psychological burden and 
improving patients’ Quality of Life (QoL).
Keyword: cancer, consciousness, adaptation, balance
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P3.24-011 MULTIPLE PRIMARY TUMORS IN 65-YEAR 
OLD HEAVY SMOKER
Emilia Swietlik1, Anna Doboszynska2, Wlodzimierz Kupis3, Mal-
gorzata Szolkowska4
1Klinika Chorób Wewnętrznych I Kardiologii Szpital Dzieciątka Jezus, 
Warszawski Uniwersytet Medyczny/Poland, 2Klinika Pulmonologii, 
Samodzielny Publiczny Zespół Gruźlicy I Chorób Płuc, Uniwersytet 
Warmińsko-Mazurski/Poland, 3Klinika Chirurgii, Instytut Gruzlicy I 
Chorob Płuc/Poland, 4Zakład Patomorfologii, Instytut Gruzlicy I Chorob 
Płuc/Poland
Background: Since Billroth s report, in 1889, of a patient with mul-
tiple synchronous tumors, multiple primary malignances (MPM) 
have been recognized as a growing problem. The increase in inci-
dence of MPM has been ascribe to several factors, such as increase 
in the incidence of many forms of cancer, the increase in longevity 
and cancer survival and better cancer follow-up.
Methods: Case report
Results: Here we present 65-year old ex-smoker with history of 
recent surgery for vocal cord squamous cell cancer who was seen 
in pulmonary out-patient clinic due to nodular lesion in the left 
lung seen on chest x-ray. Subsequent chest CT scan revealed fo-
cal lesion 18 mm in diameter with spicular margins located in the 
right upper lobe, another lesion with septa and cavitation, 62 x 58 
mm in the right lower lobe and calcified nodule in the left lung, no 
enlarged lymph nodes or pleural effusion was seen. He underwent 
upper right lobe resection and sleeve resection of the lower right 
lobe. Histopathological examination revealed adenocarcinoma in 
the right upper lobe with lymph node metastasis. Tumor emboli 
in tumor lymphatic and pleural vessels were reported along with 
infiltration of visceral pleura. Examination of the right lower lobe 
showed squamous cell carcinoma with tumor emboli in tumor 
blood vessels. Subsequently, the patient was treated with adjuvant 
chemotherapy.He subsequently was treated with adiuvant chemo-
therapy (cisplatin+vinerolabine). During seven months of follow up 
he remained in good health with no signs of disease progression. 
MPM are defined as malignant tumors based on histology criteria 
with distinct location, which do not represent skip lesions, meta-
static disease or recurrence of a primary pulmonary malignancy. 
According to time category they can divided as synchronous or 
metachornous. Retrospective date show an increased risk of de-
veloping a second lung cancer following the diagnosis of a first 
lung neoplasm, in patients who survive more than three years as 
many as 10 to 25% will develop a second primary lung cancer. The 
male to female ratio of individuals developing pulmonary MPMs is 
approximately 3:1 with the median age at presentation in the sixth 
decade. Patients who present with pulmonary MPM have a greater 
Keywords: Non small cell lung cancer, small cell lung cancer, His-
tological change, Rebiopsy
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P3.24-010 THE EFFICACY OF A MINDFULNESS 
BASED INTERVENTION BODY AND AFFECTIVE 
INTERVENTION(MB-BAI) WITH CANCER PATIENTS AND 
THEIR RELATIVES
Luca Ostacoli1, Maria Vittoria Pacchiana2, Veronica Catti1, Stefa-
nia Vallone3, Simona Carnio2, Benedetta Crida2, Sara Carletto1, 
Francesco Scavelli1, Sara Demichelis2, Silvia Novello2
1Department Of Psychosomatic And Psycho-Oncology, San Luigi Hospi-
tal/Italy, 2Department Of Oncology, University Of Turin/Italy, 3Walce/
Italy
Background: Cancer has a great impact on psychological functio-
ning of patients and relatives and can be associated with various 
psychological disorders and symptoms. Mindfulness Based Inter-
vention (MBI) is a relatively brief and cost-effective program that 
has been studied in patients with several diseases. Recent analyses 
have shown the efficacy of MBI in improving psychological sym-
ptoms related with physical illnesses like cancer, chronic fatigue 
syndrome, fibromyalgia, chronic pain, arthritis, diabetes, heart 
disease, stroke, and traumatic brain injury. MBI is based on the 
assumption that a non-judgmental awareness and acceptance of 
one’s moment-to-moment experience have an effect on the dis-
tressing tendencies to escape from or to over-engage with one’s 
disturbing feelings, emotions and thoughts. MBI can positively 
impact on coping strategies and on the adaptation to the disease, 
by encouraging patients to relate differently to their physical and 
psychological symptoms, resulting in a reduction of the psycholo-
gical burden and improving patients’ Quality of Life (QoL). MB-BAI 
integrates MBI basic practices with increased attention to somatic 
resources and application of mindfulness in relationships.
Methods: We aim to evaluate whether a group-based Mindfulness 
Based Body and Affective Intervention can reduce psychological 
symptoms like anxiety, depression, perceived stress and improve 
the QoL of patients with cancer. Furthermore, our study involve 
patients’ caregivers/relatives in order to decrease the load of stress 
and difficulties related to the management of a disabling diseases 
like cancer. This project is designed as an observational study. The 
subjects currently involved in all are 36, including patients with 
advanced malignant disease (mostly lung cancer), their caregivers/
relatives and the control group. Participants were enrolled at the 
Oncology Unit of San Luigi University Hospital of Orbassano, Italy, 
in collaboration with WALCE (Women Against Lung Cancer in Eu-
rope). The experimental group underwent a 8 weekly sessions of 
3 hours each (plus an all day session) with a group based MB-BAI. 
The control group hasn’t receive any psychological intervention. 
The psychological assessment was performed at pre-intervention 
and after treatment for both groups. The evaluation encompasses 
the administration of the self-reportquestionnaires: Hospital Anxie-
ty and Depression Scale (HADS), Perceived Stress Scale (PSS), Five 
Facet Mindfulness Questionnaire (FFMQ), Posttraumatic Growth 
Inventory (PTGI) and WHOQoL-Brief, patients qualitative reports.
Results: not applicable
Conclusion: The study is currently ongoing. As far as we know this 
is the first MBI applicationinadvanced lung cancer. Specific atten-
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and sclerosis, moderately differentiated adenocarcinoma and small 
cell carcinoma. All patients continue managemnent with a multi-
diciplinary team getting support with other institutions in cancer 
management. In patients who had pleural effusions was performed 
on the basis of lung expansion chemical pleurodesis with 20ml 
yodopovidona more 10ml xylocaine 1% dilute to 100cc with saline 
was done and chest drain mainteined for 3 to 4 days. In cases of 
recurrence of pleural effusion a tunelized thoracic catheter was put 
on and in cases of persistent pneumothorax a Heimlich valve was 
colocated.
Conclusion: Pleuropulmonary tumors in patients with, sensitivity 
and specificity for the diagnosis and treatment by thoracoscopy is 
over 90% to reliably be able to obtain sufficient tissue for histopa-
thological examination or final intraoperative complete resections 
and procedures, achieving an aesthetic addition.
Keyword: lung tumors, thoracoscopy
POSTER SESSION 3 - SUPPORTIVE CARE  
WEDNESDAY, OCTOBER 30, 2013 - 09:30-16:30
P3.24-013 IMPROVING ACCESS TO TREATMENT FOR 
LUNG CANCER PATIENTS (ACCESSTLC): RESULTS OF 
A PILOT USING PATIENT INTERVIEWS TO DETERMINE 
TIME TO TREATMENT.
Regina Vidaver1, Marianna B. Shershneva2, Kurt R. Oettel3, Toby C. 
Campbell2
1National Lung Cancer Partnership/United States Of America, 2School 
Of Medicine & Public Health, University Of Wisconsin/United States Of 
America, 3Gunderson Lutheran Health System/United States Of Ame-
rica
Background: Some lung cancer patients experience unnecessary 
delays in their care in the US; these delays are not currently well-
documented outside the Veterans Administration Hospital system. 
We evaluated the accuracy of patient interviews as a method of 
documenting timeliness of care. Our results will be used to imple-
ment a larger study that will inform the development of targeted 
interventions to reduce time to treatment for lung cancer patients.
Methods: Oncologists referred 36 patients with lung cancer. The 
initial 20 patients were interviewed to collect 11 dates pertinent to 
their cancer care (Figure 1). The next 16 patients completed the in-
terview and their charts were reviewed in order to analyze the cor-
respondence of patient-reported data with chart-reported data. 
We conducted quantitative and qualitative analysis of the interview 
data to document time intervals and examine delays.  
cigarette smoke exposure than those who developed a single lung 
cancer. 50 to 70% of patients have similar tumor histology in both 
primaries and identical genetic changes are find in 77% of tumors, 
supporting monoclonal origin in majority of MPMs. Diagnosis of 
multiple synchronous primary cancers must be distinguished from 
a primary tumor with one or more pulmonary metastases and from 
an extrapulmonary primary tumor with multiple lung metastases. 
Moreover, a second synchronous primary cancer must be distin-
guished from a coexisting benign pulmonary nodule detected on 
preoperative imagining.
Conclusion: Patients with synchronous multiple primary lung mali-
gnances have significantly worse prognosis than those with single 
primary lung malignancy, although it can be considerably impro-
ved with an aggressive surgical approach.
Keyword: lung cancer, adenocarcinoma,squamous cell
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P3.24-012 USEFULNESS OF THORACOSCOPY IN THO-
RACIC TUMORS: DIAGNOSIS, STAGING AND THERA-
PEUTIC.
Peña G.P. Emmanuel1, Francina B. Morales2, Solano N. Alma Leti-
cia3, Maria Silvia L. Morales4
1Surgery, Pachuca General Hospital/Mexico, 2National Institute/Mexico, 
3Anesthesiology, IMSS/Mexico, 4Respiratory National Institute/Mexico
Background: Study in tertiary hospital in the thoracic surgery 
service by a group of surgeons, during which corroborate the 
usefulness of thoracoscopy in the diagnosis and management of 
different chest tumors that were presented in the thoracic surgery 
service for a period of one year: 2011 – 2012. 
During the procedure was used in all patients selective lung in-
tubation, was performed intraoperative intercostal block for pain 
control, postoperative management was all endopleural tube, pain 
control with morphine and radiographic control to assess each 
24hr endopleural catheter in 2 patients (15.3%) underwent incision 
of 2 and 4 cm to remove the tumor.
Methods: In one year 23 patients was admited to the Pachuca 
General Hospital with the diagnosis of lung tumors, all patients 
complete preoperative protocol wich include chest CT, lung or 
tumor biopsy, assesment by anesthesiology, internal medicine, 
pulmonomogist an medical oncology, the procedures include no 
anatomic segmentectomy with tumor free margin, exceresis tumor, 
lung and pleural biopsy, VATS lobectomy, lymph node dissection 
was performed mainly from stations 4, 5 and 7. 
Pathology reports were branchial cyst, mesothelioma sarcomatoid, 
bonchogenic cyst with ulcerated necrotic pneumonia, chondroid 
hamartoma with congestion and sclerosis, moderately differentia-
ted adenocarcinoma and small cell carcinoma. 
In patients who had pleural effusions was performed on the basis 
of lung expansion chemical pleurodesis with 20ml yodopovidona 
more 10ml xylocaine 1% dilute to 100cc with saline.
Results: Radiological and histopathological diagnosis was corr-
oborated in 95% of cases, the procedures include no anatomic 
segmentectomy, exceresis tumor, lung and pleural biopsy, VATS 
lobectomy, lymph node dissection. Pathology reports were bran-
chial cyst, mesothelioma sarcomatoid, bonchogenic cyst with ulce-
rated necrotic pneumonia, chondroid hamartoma with congestion 
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P3.24-014 MULTICENTER STUDY OF ZOLEDRONIC ACID 
IN LUNG CANCER PATIENTS WITH BONE METASTASIS. 
THORACIC ONCOLOGY RESEARCH GROUP (TORG) 
1017.
Yukio Hosomi1, Masahiko Shibuya1, Katsuhiko Naoki2, Kenzo 
Soejima2, Naoyuki Nogami3, Hiroaki Okamoto4, Seisuke Nagase5, 
Noriyuki Masuda6, Masanori Nishikawa7, Takashi Seto8, Kouichi 
Minato9, Yuichi Takiguchi10, Nobuhiko Seki11, Fumihiro Oshita12, 
Koshiro Watanabe13
1Department Of Thoracic Oncology And Respiratory Medicine, Tokyo 
Metropolitan Cancer And Infectious Diseases Center Komagome Hospital/
Japan, 2Pulmonary Medicine, Keio Univerisy School Of Medicine/Japan, 
3Department Of Thoracic Oncology, Shikoku Cancer Center/Japan, 4Yoko-
hama Municipal Citizen‘s Hospital/Japan, 5Thoracic Surgery, Tokyo Me-
dical University/Japan, 6Respiratory Medicine, Kitasato University School 
Of Medicine/Japan, 7Department Of Respiratory Medicine, Fujisawa City 
Hospital/Japan, 8National Kyushu Cancer Center/Japan, 9Pulmonary 
Medicine, Gunma Prefectural Cancer Center/Japan, 10Graduate School 
Of Medicine, Chiba University/Japan, 11Division Of Medical Oncology, 
Department Of Internal Medicine, Teikyo University School Of Medicine/
Japan, 12Kanagawa Cancer Center/Japan, 13Thoracic Oncology Research 
Group/Japan
Background: Bone is the most frequent site of metastasis for lung 
cancer, and metastatic bone disease causes pain. Furthermore, 
bone metastasis may produce skeletal-related events (SREs) that 
greatly reduce quality of life and may even lead to death. Sever-
al guidelines have recommended use of bone-modifying agents 
(BMA) such as zoledronic acid (ZA) at the first diagnosis of bone 
metastases in patients with solid tumors, continued every 3-4 weeks 
as long as the patient is able to tolerate therapy or until evidence of 
a substantial decline in performance status. However, due to the risk 
of osteonecrosis of the jaw (ONJ) and a perceived lack of evidence 
for reduced SRE in lung cancer, some physicians have hesitated to 
administer ZA in lung cancer patients with bone metastasis. There-
fore, the main objective of the present study was both to describe 
real world data of ZA and to compare SREs among previous reports.
Methods: All patients with non-small cell lung cancer (NSCLC) 
accompanied by metastatic bone disease (MBD) who were adminis-
tered ZA at least twice from 12 hospitals in the TORG in Japan bet-
ween January 2008 and December 2009 were eligible for inclusion 
in the study.
Results: A total of 198 consecutive patients (126 men, 72 women; 
median age, 64 years; range, 44-89 years) were identified. Histolo-
gical type was as follows: adenocarcinoma (n=131, 66%); squamous 
cell carcinoma (n=30, 15%); and others (n=37, 19%). About two-thirds 
of patients experienced SRE before starting anti-cancer therapy. 
Median duration of ZA administration was 106 days (range, 28-1126 
days), and median number of ZA administrations was four (range, 
2-41). Median time to first SRE in patients who experienced SRE 
after treatment was 202 days (range, 156-264 days). No ONJ was 
reported from the 198 patients.
Conclusion: We found that ZA was not used sufficiently in clinical 
practice in Japan. Our data suggest that ONJ during the treatment 
of lung cancer patients is very rare, and ZA is potentially useful in 
lung patients with bone metastasis.
Keywords: Zoledronic Acid, Lung cancer, bone-modifying agents, 
metastatic bone disease
Results: For the 16 patients whose charts were reviewed: 
• patient-reported and chart-reported median time from the first 
visit to the first treatment was the same (41.5 days)
• median time difference between patient-reported and chart-
reported dates varied from 0 to 8 days
• Lin’s correlation coefficient indicated almost perfect agreement 
(ρ >0.99) for five dates; and poor agreement (ρ <0.90) for six dates
• 2.25% of total dates were lacking from charts
For the entire cohort (36 patients), based on the interview data: 
• time to treatment varied (Table 1)
• 22 of 36 (61%) patients experienced one or more delays that 
could possibly be avoided
• 5.28% of total dates were not recalled by patients 
Conclusion: Interviewing patients has limitations but is an approp-
riate method of collecting dates regarding lung cancer care. There 
are multiple opportunities to reduce time to treatment for patients 
with lung cancer. More research is needed to understand delays in 
lung cancer care.
Keyword: treatment delay; patient-reported delay; symptom reco-
gnition; diagnosis
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P3.24-016 A CASE OF PRIMARY MYOEPITHELIAL CARCI-
NOMA OF THE LUNG
Tsunehiro Ii1, Shogo Toda1, Shinshichi Hamada2
1General Thoracic Surgery, Otsu Municipal Hospital/Japan, 2Pathology, 
Otsu Municipal Hospital/Japan
Background: Myoepithelial tumors commonly occur in the salivary 
glands, the sweat glands or the mammary glands, but extremely 
rare in the lung. We present a case of primary myoepithelial carci-
noma of the lung with reports of previous cases.
Methods: A 67-year-old man presented with a nodular lesion in 
the lower lobe of the left lung. The patient had a surgical history of 
stenosis of the small intestine, and his serum carcinoembryonic an-
tigen (CEA) level was slightly elevated. Histopathological examina-
tion revealed that the cause of intestinal stenosis was the ischemic 
enteritis. Computed tomography (CT) was carried out as screening 
for elevated CEA, and a small nodule was detected at the posteri-
or basal segment (S10) of the left lung. The pulmonary nodule deve-
loped a tendency to increase during progress observation of half a 
year. Because of the clinical suspicion of malignancy, he underwent 
a wedge resection of the left lower lobe by video-assisted thoracic 
surgery (VATS).
Results: Macroscopically, the tumor was a whitish, well-circumscri-
bed, irregular shaped, and solid mass measuring 10×8×6 mm in 
size. Microscopically, the tumor was mainly located outside the 
bronchial mucosa with focal invasion into the lamina propria of the 
mucosa, and composed of atypical cells arranged in trabecular or 
alveolar pattern and basement membrane-like eosinophilic hyali-
ne stroma. The tumor cells had ovoid pleomorphic nuclei varying 
in size and clear cytoplasm. Small necrotic foci were scattered in 
the tumor. Mitotic figures were frequently seen (> 14/10 HPF) and 
abnormal mitoses were occasionally encountered. No ductal struc-
tures were found throughout the tumor. Immunohistochemical 
staining showed the tumor cells were positive for 34βE12, P-63, 
S-100, α-SMA, but negative for CK7, TTF-1, chromogranin A, syn-
aptophysin, CD56. On the basis of the above features, the tumor 
was diagnosed as primary myoepithelial carcinoma of the lung 
(pT1aN0M0, Stage IA). The patient is doing well without recurrence 
for 22 months after the operation.
Conclusion: We present a rare case of primary myoepithelial carci-
noma of the lung. To our knowledge, only nine cases of pulmonary 
myoepithelial carcinoma have been reported in the literature so 
far. Because the clinical course of those cases was poor, further 
studies will be necessary in order to clarify their histological fea-
tures, biological behavior, effects of chemotherapy or radiothera-
py, and clinical outcome.
Keywords: myoepithelial carcinoma, Salivary grand-type carcino-
ma, Lung cancer
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P3.24-015 PULMONARY ADENOCARCINOMA IN A PATI-
ENT WITH HERMANSKY-PUDLAK SYNDROME
Ayse N. Ozcan1, Deniz Koksal1, Ali R. Buyukkutlu1, Orhan Erden2, 
Berna Akinci Ozyurek1, Cebrail Simsek1
1Chest Diseases, Ataturk Chest Disease And Chest Surgery Education 
And Research Hospital/Turkey, 2Ophtalmology, Ataturk Chest Disease 
And Chest Surgery Education And Research Hospital/Turkey
Background: Hermansky-Pudlak Syndrome (HPS) is a rarely seen 
autosomal recessive disease characterized by oculocutaneous 
albinism, bleeding tendency from platelet storage pool deficiency, 
and lysosomal occumulation of ceroid in the reticuloendothelial 
system. Ceroid occumulation in alveolary macrophages causes 
pulmonary inflammation and interstitial pneumonia. Pulmonary 
fibrosis is the most serious complication and main reason of mor-
tality. Pulmonary fibrosis is also a well known etiology for the onset 
of lung carcinoma.
Methods: N/A
Results: A 64-year-old albino patient admitted with dyspnea, back 
pain, and weakness. He had a smoking history of 40 pack-years. 
In his past medical history, he has recurrent nasal bleeding, and 
he was given inhaler bronchodilators for dyspnea on exertion 
last year. Rutin laboratory analysis was normal. There was a mild 
hypoxemia (PaO2: 63 mmHg). There was a restirictive pulmonary 
functional deficit with a reduced diffusion capacity (%56). A thorax 
CT demonstrated pulmonary fibrosis, left pleural effusion, and 
irregularly marginated collapse and consolidation areas adjacent to 
pleural effusion. On PET/CT a mass lesion 6 cm in largest diameter 
(SUVmax: 15.6) is distiguised in left lower lobe superior segment. 
There was also a nodular pleural thickening (SUVmax: 13.5) on the 
left hemitorax and multiple mediastinal lymph nodes with high 
SUVmax levels. The presence of albinism, the history of bleeding 
diathesis, and the presence of pulmonary fibrosis suggested the 
diagnosis of HPS. The patient referred to ophthalmology consulta-
tion. There were hypopigmentation on coroid layer and iris. Hema-
tology clinic comfirmed the presence of platelet dysfunction. After 
all the patient was diagnosed as HPS. After transfusion of platelets, 
a transtoracic needle biopsy was performed and the pathology 
was compatible with adenocarcinoma (Stage 4, pleural involve-
ment). The patient refused any therapy and discharged from hospi-
tal with home oxygen therapy.
Conclusion: Herein we present a rare case with pulmonary fibrosis 
diagnosed simultaneously as HPS and pulmonary adenocarcinoma.
Keywords: pulmonary fibrosis, hermansky pudlak syndrome, Lung 
cancer
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Conclusion: For non-small cell lung cancer with OMT, local ag-
gressive treatment to the primary site may improve overall survival. 
Our results suggest that the selected non-small cell lung cancer 
patients with distant metastasis may benefit from aggressive local 
therapy.
Keyword: Non-small cell lung cancer; Radiotherapy; Oligometas-
tases; Prognostic factors
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P3.24-018 CHEST WALL DESMOID TUMOR WITH RAPID 
GROWTH AFTER THE RESECTION OF LUNG CANCER
Motohiro Nishimura1, Kaori Ichise1, Junichi Shimada2
1Thoracic Surgery, Saiseikai Suita Hospital/Japan, 2Division Of Chest 
Surgery, Department Of Surgery, Kyoto Prefectural University Of Medi-
cine/Japan
Background: Desmiod tumor (aggressive fibromatosis) is an ag-
gressive fibroblastic proliferation of well-circumscribed, locally 
invasive, differentiated fibrous tissue. Chest wall desmoids account 
for approximately 20% of all desmoids tumors. The etiology of 
this tumors is unknown. Local inflammatory changes involved in 
the healing response after trauma have often been postulated as 
stimulating the development of desmiod tumors. Although distant 
spread has not been documented in long-term follow-up studies, 
these tumors have a strong propensity to recur locally after resec-
tion. Several authors have emphasized the use of external radio-
therapy as an adjunct to surgery to improve local control.
Methods: A 62-year-old male underwent left upper lobec-
tomy using an anterolateral approach. The postoperative 
diagnosis was pulmonary adenocarcinoma (pT1N0M0 sta-
ge1A). Two years after operation, a computed tomography 
showed the 65x45x25mm diameter mass on the left chest wall 
around the previous operative scar. Three months later, the 
mass rapidly enlarged 110x100x55mm in size. A desmoid tu-
mor was suspected from the specimen of an incisional biopsy.
Results: A Resection of the tumor with the chest wall (from the 
2nd rib to the 4th rib) was performed. And thoracoplasty using a 
myocutaneous flap made of latissimus dorsi muscle with the 10th 
rib and a titanium plates and Composix Mesh was performed for a 
defect in the chest wall. Histopathological examination revealed a 
desmoid tumor. The specimen showed proliferation of spindle sha-
pe cells with collagen fibers. No mitoses were present. Tumor cells 
invaded to ribs and intercostals muscles but surgical margin was 
negative. Adjuvant radiation therapy with a total dose of 50.4Gy 
was administered to prevent local recurrence.
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P3.24-017 THE IMPACT OF LOCAL RADIOTHERAPY TO 
THE PRIMARY SITE FOR PATIENTS WITH STAGE IV NON-
SMALL CELL LUNG CANCER
Yaping Xu, Qingren Lin, Yuanda Zheng, Xiaojiang Sun, Bo Li, Xi-
anghui Du, Weimin Mao
Zhejiang Cancer Hospital/China
Background: The prognosis of patients with non-small cell lung 
cancer and distant metastasis is poor. The aim of this study was to 
evaluate the value of local treatment to the primary site for pati-
ents with stage IV non-small cell lung cancer and oligometastatic 
disease at diagnosis, particularly the influence of local treatment to 
the primary site on prognosis.
Methods: From January 2004 to December 2011, 69 consecutive 
patients with stage IV non-small cell lung cancer treated with local 
palliative radiotherapy to the primary site were enrolled in this 
retrospective study. The prognosis factors including the patients’ 
general condition, disease characteristics and treatment factors 
were analysed. Patients were divided into two groups based on 
the number of distant metastases (Oligometastasis, OMT, 1-4 me-
tastases; Polymetastasis, PMT, > 5 metastases). The relationship 
between the prognosis and treatment factors was explored. Ove-
rall survival was estimated using the Kaplan-Meier method, and 
prognostic factors were identified by univariate and multivariate 
analyses.
Results: The median overall survival was 14.1 (95%CI:7.3-20.8) 
months and the 1, 3-year overall survival rates were 53.0% and 
9.0% , respectively. Gender, smoking index and performance 
status of Zubrod-ECOG-WHO were significantly associated 
with prognosis under univariate analysis. There was marginally 
significant associated with prognosis for those patients who re-
ceived chemotherapy(P = 0.054) and received a sufficient dose 
of local palliative radiation to the primary site (at least 60Gy) (P 
= 0.063). On multiplicity analysis, chemotherapy and perfor-
mance status retained significance. In the hierarchical analysis, 
patients who received at least 60 Gy of local radiotherapy to 
the primary site(P=0.048)(Fig 1.) and received chemotherapy 
(P= 0.041) achieved better overall survival in the OMT group.
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Keywords: Non small cell lung cancer, Synchronous solitary brain 
metastasis, pulmonary resection, Gamma knief stereotactic radio-
surgery
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P3.24-020 CASE STUDIES OF MUTIDISCIPLINARY TREAT-
MENT FOR LARGE CELL NEUROENDOCRINE LUNG 
CARCINOMA
Masao Naruke
Eiju General Hospital/Japan
Background: The World Health Organization (WHO) currently 
classifies Large Cell Neuroendocrine Lung Carcinoma (LCNEC) 
as a distinct subtype of pulmonary large cell carcinoma, however, 
the survival after surgical-resection of LCNEC appears to be sub-
stantially worse than for other Non-small cell carcinoma (NSCLC), 
resembling more the survival of small cell carcinoma. The question 
remains whether LCNEC is best treated the same as other NSCLC. 
The purpose of this study is to analyze the feasibility of the multi-
disciplinary treatment for LCNEC.
Methods: The records of 6 LCNEC (2.9%) out of 210 patients, who 
underwent an intended curative resection for lung cancer in our in-
stitute during a 10-year period beginning in 2002, were reviewed. 
The patients consisted of 6 male current smokers, with a median 
age of 68 years (63 – 82). The clinical stages were 2 in stage IB, 2 
in stage IIA, 1 stage IIB and 1 stage IIIA. 5 patients underwent an 
anatomical resection. The rest of them underwent tumorectomy. 
3 patients underwent not only pulmonary resection but also adju-
vant chemotherapy for primary cancer. Median follow-up time was 
37.5 months (15-81).
Results: The two patients with clinical stage IIA were upgraded 
to pathological stage IIIA after operation. Two of them, who were 
pathological stage IB and IIIA, died of pneumonia and seconda-
ry cancer without LCNEC recurrence 11 and 15 months after the 
operation. Recurrence of disease was observed in three patients 
with pathological stage IIB and IIIA. One of the patients died in 55 
postoperative months after receiving adrenalectomy, chemothe-
rapy and radiation therapy for 25 months for recurrent cancer. Two 
of the patients are still alive after receiving either surgery pus che-
motherapy or radiation therapy for 32 months and 43months since 
undergoing initial treatment.
Conclusion: Multidisciplinary treatment should be considered as 
complementary technique to surgery for LCNEC and examined in 
larger trial.
Keywords: Large Cell Neuroendocrine Lung Carcinoma, multidis-
ciplinary treatment
Conclusion: He is doing well without recurrence at 37months after 
surgery and radiation. Wide local excision with negative patholo-
gical margins is the treatment of choice for most desmoid tumors. 
Postoperative radiation may be a treatment of choice to prevent 
local recurrence because the development of local recurrence 
would result in mutilating reopreration with disfigurement or even 
amputation.
Keywords: Lung cancer, radiation, desmiod tumor
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P3.24-019 LOCAL MANAGEMENT OF NSCLC WITH OPE-
RABLE PRIMARY LESION AND SYNCHRONOUS SOLITA-
RY BRAIN METASTASIS
Kyukwang Chung, Ryu Nakajima, Ryoji Yamamoto, Makoto Taka-
hama, Takuma Tsukioka, Hirohito Tada
General Thoracic Surgery, Osaka City General Hospital/Japan
Background: The treatment for non small cell lung cancer (NSCLC) 
with operable primary lesion and solitary brain metastasis has not 
formed but the combined local therapy with surgical pulmonary 
resection of primary lesion and curative neurosurgical intervention 
of solitary brain metastatic site is becoming a standard option for 
such patients. The purpose of this study is to assess the efficacy 
and safety of the combined local therapy for NSCLC with operable 
primary lesion and solitary brain metastasis.
Methods: Within 1781 NSCLC patients underwent surgical re-
section from December 1993 to December 2010 at Osaka City 
General Hospital, 11 cases with synchronous (within 1 month of the 
primary NSCLC diagnosis) solitary brain metastasis and treated 
with curative neurosurgical intervention were identified. We retro-
spectively reviewed these cases and analyzed the treatment, pa-
thology, prognosis and prognostic characteristics. Overall survival 
was recorded from the date of lung surgery until the last follow-up 
observation.
Results: The study group consisted of 7 male and 4 female. The 
median age at the time of pulmonary resection was 57 years (ran-
ge, 39-76 years). The histological subgroup was adenocarcinoma 
in 10 cases and large cell carcinoma in 1 case. Neurological sym-
ptoms as the initial symptom were recognized in 3 cases. Type of 
pulmonary resection for primary lesion were lobectomy in 10 pa-
tients and sleeve lobectomy in 1 patient, and lymphatic extension 
was pN0 in 7 patients and N1-2 in 4 patients. All patients received 
gamma knife stereotactic radiosurgery (GKSRS) for management 
of the solitary brain metastasis and curative neurosurgical resec-
tion was performed in 1 patient before GKSRS. Both pulmonary 
resection and neurological intervention caused no serious adverse 
events. Of 11 patients, 7 patients had died of disease and 4 pati-
ents (3 with pN0 and 1 with pN1) were alive and with disease. The 
median overall survival time was 14 months and the 3-year overall 
survival rate was 36.4%.
Conclusion: The aggressive combined local therapy with pulmona-
ry resection and neurological intervention for NSCLC patients with 
operable primary lesion and synchronous solitary brain metastasis 
should be considered effective and safe for selected patients. The 
multicentre prospective randomized studies are required to clarify 
the effectiveness and optimal method of this local treatment for 
such patients.
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P3.24-022 A NOVEL WEB-BASED, MOBILE-DEVICE ENA-
BLED CLINICAL COLLABORATION PLATFORM IN LUNG 
CANCER - MULTIDISCIPLINARY PATIENT EVALUATIONS 
VIA NETWORKING TECHNOLOGY
Pierre R. Theodore1, Aenor Sawyer2, Wyatt Tellis2, Thomas Urba-
nia3
1Surgery, University Of California San Francisco Medical Center/United 
States Of America, 2Surgery, UCSF Medical Center/United States Of 
America, 3Radiology, UCSF Medical Center/United States Of America
Background: Expenditures in the United States on health care 
have reached and estimated $2.5 trillion and cost control measu-
res have become major features of the current health care reform 
debate in this country. An approach to reducing ballooning health 
care costs has been to focus on quality and uniformity of standards 
of care using health informatic technologies. We have designed 
and implemented a web- based clinician-to-clinician communica-
tion and collaboration platform that is mobile device enabled. The 
system permits asynchronous communication among clinicians in 
conjunction with robust sharing of the content of the Electronic 
Medical Record (EMR) including X-rays, digital histopathologic 
images and molecular diagnostics. Principle aims of the project 
incluided (1) documenting accurate diagnoses (2) appropriate 
consultation and input from specialty services (3) treatment plan 
optimization spanning disciplines and (4) archiving the results of 
multidisciplinary decision making in a virtual environment.
Methods: Using Extensible Markup Language (XML) based sys-
tem; a federal patient privacy regulation (HIPAA) compliant secure 
platform for communication was built according to specifications 
designated by clinicians in the Thoracic Oncology Section of UCSF 
Medical Center. The web based platform was approved by a com-
mitted on human research. The system was designed with integ-
ration of a Picture Archives Viewing System (PACS) and digitized 
pathology images to permit specific file upload, and annotation in 
a scalable manner allowing collaborations between two clinicians 
or among a group as large as 35. User group questionnaires and 
focus groups were performed to refine the computer-human in-
terface and customize user experience. Members of the Thoracic 
Oncology Program (N=35) at the University of California at San 
Francisco were invited to participate in pilot study of the efficiency 
and ease of use of a novel web-based collaborative system for the 
purposes of an asynchronous “Virtual Tumor Board”.
Results: A Trial of 50 patients had care plans coordinated via 
the virtual tumor board with input of the multi-disciplinary focus 
groups used in the development of the computer - human inter-
face. 20% of clinicians related concerns over ease of use. 10% 
related concerns regarding excessive electronic messaging as 
a disruption of work flow. 15% voiced a main concern regarding 
clinician reimbursement for web based consultation. Of the cases 
presented on the virtual tumor board platform 100% achieved 
clinician consensus opinion with 5 days (mean 2.5 days). Patient Sa-
tisfaction assays suggested patient comfort with protected health 
information transfer on a secure platform. No adverse events were 
directly referable to system use.
Conclusion: A novel web based system for collaboration among 
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P3.24-021 ADVANCING LUNG CANCER EARLY DETEC-
TION: THE ROLE OF THE PATIENT ADVOCACY CHARITY 
IN OUTREACH AND EDUCATION IN SUPPORT OF RES-
PONSIBLE SCREENING
Amy Copeland
Lung Cancer Alliance/United States Of America
Background: Since the validation of CT screening for lung can-
cer in 2010 in the United States by the National Cancer Institute’s 
National Lung Screening Trial, several well-respected professional 
societies have endorsed lung cancer screening and developed 
guidelines using low dose CT (LDCT). Despite this progress, adop-
tion of lung cancer screening has been slow to advance. In 2011, in 
recognition of the importance of screening for lung cancer in a re-
sponsible way, Lung Cancer Alliance (LCA) convened a panel to re-
view current evidence and develop a framework document to edu-
cate the public about their risk and guide healthcare professionals 
developing screening programs. This began a multi-year strategy 
to ensure responsible screening through a process of outreach, 
education and data collection with the goals of raising public awa-
reness about the risks and benefits of screening and contributing 
to the refinement of screening guidelines and risk definitions. The 
focus of this abstract is the process of outreach and education as 
development of a data collection system is still in progress.
Methods: The National Framework for Excellence in Lung Cancer 
Screening and Continuum of Care was developed to educate con-
sumers about rights, guide responsible screening center develop-
ment and lay the groundwork for a data collection strategy. A list 
of screening Centers of Excellence was developed based on com-
mitment to the National Framework guiding principles. Outreach 
to additional centers continues. A multi-pronged approach was ad-
opted. A national media campaign focused on understanding lung 
cancer risks and the value of early detection. Educational materials 
were developed to educate those at risk about various aspects of 
screening. Center coordinators received regular communication 
about educational opportunities related to screening, journal 
articles and other information of interest. A needs assessment of 
existing centers was carried out to understand implementation 
challenges and identify what role LCA can play in addressing them. 
A network of center coordinators willing to talk with other coordi-
nators about specific programmatic challenges was developed.
Results: At the time of submission, there were 90 centers on the 
LCA Screening Centers of Excellence list with an additional 50 
centers identified for outreach. Regular communication occurs 
between LCA and the coordinators. Based on needs assessment 
results, tools have been developed to help coordinators learn from 
each other. Future goals include developing webinars and other 
ways to address challenging issues faced by centers and evaluation 
of these approaches.
Conclusion: Charities can play an important role in supporting the 
development of responsible lung cancer screening, as is evidenced 
by the actions of LCA in the United States. Because charities are 
well-connected to those at risk for lung cancer and to lung cancer 
treatment programs, they are ideal parties to be involved in furthe-
ring adoption of programs and behaviors. By identifying the barri-
ers to adoption of responsible lung cancer screening and helping 
develop strategies to address them, lung cancer advocacy chari-
ties are a valuable partner in the effort to raise awareness of the 
risk for lung cancer and ensure that screening is done responsibly.
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Results: Via median sternotomy and left hemi-clamshell incisi-
on an intra-pericardic, extrapleural pneumonectomy extended 
to ribs 3-5, pericardium and thymus was performed. Pathologic 
examination, showed G3 "non-small cell“ lung cancer, TTF-1 
positive, Ki67 index 90%, involvement of pericardium and po-
sitive pericardial fluid. Subcarinal and all other 20 lymph nodes 
were negative. pT3N0M1a (pleural cytology), R1. Postoperatively, 
the patient‘s state improved quickly to extubation but she later 
required a temporary tracheostomy (day 7) because of exhaus-
tion and overall muscle weakness. She could be revalidated and 
discharged at post-operative day 74. At 9 months follow-up she 
is fully ambulatory and CT-scan shows no sign of recurrence. 
clinicians holds the promise for reducing delays in optimized treat-
ment planning and is regarded by clinicians as worthy approach to 
error reduction and reduction in delay to definitive treatment plan 
determination. Consensus opinions were rapidly obtained and ar-
chived records of discussion facilitates outcome reviews. Clinician 
concern included reimbursement patterns and efficiency but pa-
tient opinion was favorable toward this approach to collaborative 
decision making in oncology.
Keyword: Bioinformatics, Collaboration, Tumor Board
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P3.24-023 A HUGE LUNG CARCINOMA PRESENTING 
WITH MAJOR RESPIRATORY DISTRESS IS NOT NECES-
SARILY A CONTRAINDICATION FOR SURGICAL TREAT-
MENT, EVEN WHEN EXTENDED PNEUMONECTOMY IS 
REQUIRED.
Georges Decker1, Christian Frantz2, Muriel Schiltz1, Cyril Thix3
1Thoracic Surgery, Zithaklinik/Luxembourg, 2Pulmonology, Zithaklinik/
Luxembourg, 3Anesthesiology, Zithaklinik/Luxembourg
Background: Pneumonectomies are usually considered contraindi-
cated for advanced NSCLC.
Methods: A 49 year old female patient was admitted for acute se-
vere respiratory distress requiring intubation and mechanical venti-
lation shortly after admittance. The patient was cachectic (BMI 16) 
with a hetero-anamnesis of Graves disease, 30 pack-years smoking 
and progressive dyspnea over weeks for which the patient did not 
seek medical advice prior to admission. Chest X-ray on admission 
showed a "white“ left hemi-thorax and mediastinal shift to the 
right. Bronchoscopy showed tumor occlusion of the left main bron-
chus where biopsies revealed non-small cell lung cancer. CT-scan 
showed a huge tumor mass almost completely filling the left hemi-
thorax and displacing the mediastinum to the right, a >3 cm subca-
rinal adenopathy, a small left pleural effusion and a likely invasion 
of the left axillary chest wall. Cerebral CT-scan was normal. In this 
hopeless seeming situation, the next of kin expressed their wish for 
an attempt at palliative surgery, given the chance that relieve from 
compression and circulatory shunt might bring the patient to a 
possible extubation and ability to communicate with their children, 
even if only for a short time.
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P3.24-025 LUNG CANCER - A SCOTTISH EXPERIENCE
Diana Borthwick, Allsion Smith, Jacqueline Byers, Janet Devlin, 
Kirsty Docherty, Lynne Ferguson, Katherine Jones, Agnes Mackay, 
Lydia Morrison
On Behalf Of The Scottish Lung Cancer Forum For Nurses/United King-
dom
Background: NHS Scotland is committed to improving the quality 
of healthcare services and patient-centered care is at the heart 
of Better Cancer Care (2008). The importance of experiences of 
patients in the planning and delivery of cancer services is a priority 
in improving cancer services across Scotland and increasingly em-
phasis is being put on how services are being delivered at a local 
level.
Methods: A questionnaire developed by Gloucestershire Health 
Authority to elicit the views of patients with lung cancer was iden-
tified. This had been adapted by South-east Scotland Cancer Net-
work (SCAN) in 2010 to survey their patient population. Permission 
was sought and granted from NHS Gloucester and NHS Lothian 
to further adapt the questionnaire and use it in the wider Scottish 
population. All three networks were involved adjusting the ques-
tionnaire to explore areas of care at the time of diagnosis, during 
treatment and in the follow-up period. The survey has a mixture 
of qualitative and quantitative components with room for free text 
for clarification after many of the questions. All patients with lung 
cancer and Mesothelioma attending Oncology follow-up were 
asked to completed the survey. New patients, patients on surgical 
follow-up and those currently receiving chemotherapy or radio-
therapy were excluded. The questionnaire was handed out to all 
patients with lung cancer and mesothelioma attending oncology 
clinics during June 2013 in Scotland. The questionnaires were dis-
tributed by the receptionists or clinic staff to be completed prior 
to seeing their oncologist. All questionnaires were anonymous and 
once completed were collected and returned to the researchers. 
Assistance with the quantitative analysis will be obtained from the 
Clinical Effectiveness Team in NHS Lanarkshire. The questionnaires 
will be analysed using SPSS and Excel. Bar graphs will be provided 
for each question. Data will be cross tabulated against each region 
where the diagnosis of lung cancer was made. Free text will be col-
lated into themes and assistance with this analysis obtained from 
the University of Dundee.
Results: ‚Not applicable as yet, awaiting results‘
Conclusion: Not applicable as yet, awaiting results
Keyword: Experience, Lung Cancer, Scotland
Conclusion: In exceptional circumstances, palliative resections up 
to extended extrapleural pneumonectomy may be justifiable.
Keywords: huge tumor size, palliative pneumonectomy, Lung  
cancer
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P3.24-024 LYMPHANGIOMA OF THE DIAPHRAGM
Kaori Ichise1, Motohiro Nishimura1, Masanori Shimomura2, Da-
ishiro Kato2, Junichi Shimada2, Sumito Choh3, Chiho Ohbayashi4
1Thoracic Surgery, Saiseikai Suita Hospital/Japan, 2Division Of Chest 
Surgery, Department Of Surgery, Kyoto Prefectural University Of Me-
dicine/Japan, 3Respiratory Medicine, Saiseikai Suita Hospital/Japan, 
4Department Of Pathology, Nara Medical University/Japan
Background: Lymphangioma usually occurs in the head and neck 
area. We present a very rare case of cystic lymphangioma that 
originated from the diaphragm. Few cases were reported in the 
literature.
Methods: A 69-year-old woman was referred to our hospital for 
macrocytic anemia and weight loss. Pernicious anemia was dia-
gnosed by the presence of the atrophic gastritis, the decreased 
serum vitamin B12 level, and the anti-parietal cell antibodies and 
anti-intrinsic factor antibodies in blood serum. In addition, on 
chest computed tomography (CT) she was found to have a multi-
cystic mass, measuring 50 mm in diameter, which seemed located 
in the anterior mediastinum and abdominal cavity, across the 
diaphragm. The cranial part of the mass consisted of solid struc-
ture including fat components but no calcification, and the caudal 
part consisted of multicystic structure, of which septal wall was 
slightly enhanced. The mass did not appear to invade the liver but 
to compress. Fluorine-18-fluorodeoxyglucose positron emission 
tomography (PET) scan showed no abnormal uptake. The mass 
was suspected a cystic teratoma, a bronchial cyst, a lipoma, a thy-
moma, or Morgagni hernia. It was resected through right diagonal 
thoraco-laparotomy with short upper midline incision.
Results: Seen from intrathoracic side the mass did not invade the 
pericardium and seemed to have firm adhesion to the diaphragm, 
and from intraabdominal side did not perforate the peritoneum or 
invade the liver, and no hernia canal was seen. The mass was not 
able to apart from the diaphragm, and combined resection of the 
diaphragm was performed. Pathologically it was diagnosed as a 
lymphangioma.
Conclusion: Lymphangioma arising from diaphragm is a very rare 
tumor. It should be considered in the differential diagnosis of dia-
phragm tumor.
Keywords: Lymphangioma, diaphragm tumor
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Conclusion: Our experience with management of solitary fibrous 
tumor of the pleura emphasizes the variety of radiographic and 
clinical presentations for this entity. In our series, one patient had 
disease progression despite original pathology interpretation 
indicating typical morphology. Interestingly, this patient had the 
greatest number of mitotic figures in the tumor. Surgical resection 
remains the standard of care. Because these tumors have malig-
nant potential, ongoing radiographic surveillance is appropriate 
management in patients with this diagnosis.
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P3.24-027 THE EFFECTIVENESS OF AN OUTPATIENT 
INTERDISCIPLINARY TEAM IN REDUCING DISTRESS IN 
PATIENTS WITH LUNG CANCER & MESOTHELIOMA
Kellie Blyth1, Caitlin Broderick2, Monica Divine1, Catherine Hunt1, 
Dan Rigg1, Brooke Russell1, Shirley Witko1
1Sir Charles Gairdner Hospital/Australia, 2Wa Cancer & Palliative Care 
Network/Australia
Background: Lung cancer patients have been shown to have some 
of the highest level of unmet psychological, physical and daily 
living needs. Despite this, patients have limited access to the inter-
disciplinary team in the outpatient setting. Current best practice 
indicates that an interdisciplinary team can better meet the needs 
of patients through a collaborative approach to treatment, plan-
ning, supportive care and preserving current function Specifically 
at Sir Charles Gairdner Hospital, patients have limited access to 
interdisciplinary team members in an outpatient setting. This has 
resulted in the concept of the Lung INterdisciplinary Clinic (LINC) 
where patients will be routinely assessed and provided with appro-
priate interventions aimed at reducing their distress and increasing 
or maintaining their function. Health professionals included in the 
LINC clinic include a nurse, social worker, occupational therapist, 
physiotherapist & dietician.
Methods: This is a prospective cross sectional study of lung can-
cer and mesothelioma patients carried out between April 2013 
and September 2013. Participants will be recruited to the study via 
the Lung multi-disciplinary team meeting (MDT), those referred 
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P3.24-026 SOLITARY FIBROUS TUMOR OF THE PLEURA: 
PRESENTATION AND MANAGEMENT
Patsy L. Skabla1, Konstantin Shilo2, Patrick Ross1
1Division Of Thoracic Surgery, Ohio State University/United States Of 
America, 2Cancer Center, The Ohio State University/United States Of 
America
Background: Solitary fibrous tumor of the pleura (SFT) is an infre-
quent diagnosis and presents with a spectrum of radiographic and 
clinical findings. SFT can follow indolent or agressive clinical cour-
ses. This report describes clinical, radiologic and pathologic fin-
dings from four patients with this diagnosis. Surgical management 
options and the role of surveillance are reviewed.
Methods: The medical records and pathology reports of these 
patients were abstracted. The pathology slides were reviewed and 
interpreted by a single pathologist.
Results: Each patient had unique presentation and clinical course. 
Two patients did not have cardiopulmonary symptoms; two had 
progressive dyspnea, cardiac arrythmia, or pleuritic pain. Surgical 
approaches included robotic-assisted surgery (2), limited thoraco-
tomy (1), and posterolateral thoracotomy with median sternotomy 
(1). All patients did well in the short term and there were no mor-
talities. All tumors showed typical spindle cell morphology with 
hemagiopericytoma like vasculature. Two patients showed signi-
ficant necrosis. One patient developed bilateral pulmonary and 
subcutaneous metastasis one year after R0 resection; this tumor 
showed increased mitotic activity and necrosis on original patho-
logy. FIGURE 1: CT chest of a large fibrous tumor of the pleura 
FIGURE 2: CT Chest of pulmonary metastasis 
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simple method to detect these changes. Recent trend is the use 
of IHC markers for molecular sub typing. A retrospective analysis 
of 35 patients who were diagnosed to have NSCLC and received 
at least 3 cycles of chemotherapy was included in this study. The 
objectives of the study: (1) To explore IHC pattern (Ki67, EGFR, 
Her2neu & ALK) (2) To correlate the IHC pattern to clinical presen-
tation and response to chemotherapy.
Methods: Paraffin blocks of 35 cases of NSCLC were retrieved 
and analyzed. Histopathology sub-typing was done based on 
WHO classification. IHC markers (Biogenics) EGFR, Her2 neu, ALK 
& Ki67 were done & interpreted by using intensity of staining and 
percentage of positive cells. H-score was calculated for EGFR and 
allocated into low EGFR (< 200) & high (≥200-Positive). Her2neu 
analysis was graded from 0 to 3+, ALKs scoring was done using 0 
to 3+scale and Ki67 was scored low (≤10% cells) and high (> 10% of 
nuclear positivity).
Results: Out of 35 cases studied, 7 cases were <50 years. Male 26, 
Female 9. 21 cases were smokers. 7 patients had significant weight 
loss. Morphological classification revealed adenocarcinoma 26 
(76%) & squamous 8 (24%). EGFR was positive in 28 cases out of 
which 21 (80%) were adenocarcinoma and 7 (87%) squamous cell 
carcinoma. The positivity of Her2 and ALK was seen in one case 
each. High Ki67 was seen in 21 cases out of which 50% adenocar-
cinoma & 100% squamous cell carcinoma. EGFR Positivity was 
observed in 6 (85%) <50 years of age. There was no difference in 
sex distribution. Loss of weight did not correlate with high Ki67. 
Among EGFR positive cases high Ki67 was found in 17 cases (58%). 
The EGFR positivity did not differ between smokers and non 
smokers. Response (Partial Response & Stable Disease) to either 
Taxane / Gemcitabine based combination therapy was observed 
in 90% of low Ki67 group. In EGFR positive, 75% of chemotherapy 
group had good response (PR+SD) compared to upfront targeted 
therapy (Erlotinib). All the patients who received upfront targeted 
therapy were in low performance status.
Conclusion: This study has shown some interesting data. The 
EGFR status did not differ between smokers and non smokers. The 
observation of percentage positivity of ALK and Her2 was very low 
in this study. Low Ki67 patients responded well to chemotherapy. 
The response to treatment in EGFR positive NSCLC with Gemcita-
bine / Taxane with Platinum based combination chemotherapy was 
much better than those patients who received upfront EGFR targe-
ted therapy, but needs more patients for statistical significance.
Keyword: Non Small Cell Lung Cancer, IHC, Molecular markers
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P3.24-029 PROGRESSION OF RADIATION INDUCED 
ESOPHAGEAL STENOSIS IN A NON-SMALL CELL LUNG 
CANCER (NSCLC) PATIENT TREATED WITH SORAFENIB
Lizza Hendriks1, Wouter W. Mellema2, Egbert F Smit2, Esther Tro-
ost3, Anne-Marie Dingemans1
1Pulmonary Diseases, Maastricht University Medical Center+/Nether-
lands, 2Pulmonary Diseases, VU University Medical Center/Nether-
lands, 3Maastro Clinic/Netherlands
Background: Sorafenib is an orally available multikinase inhibitor 
with antiproliferative and anti-angiogenic activity. Reported oral 
adverse events of any grade are stomatitis/mucositis (11-38%, 
directly from any outpatient clinic or self-referred. Participants 
under 18, have a cognitive impairment or NESB will be exluded. 
Initial Screen: Participants will complete the Distress Thermo-
meter (DT), rating their overall distress on a scale of 0 to 10 and 
identifying items on a list that cause them distress. Referral pa-
thway and intervention delivery: Based on the problem items 
selected by the patient, a referral will be made to the appropriate 
health professional to receive intervention to address the problem. 
The timeframe for when the intervention will be provided is dic-
tated by the distress the problem causes the patient –see below
 
Evaluation of service: Following intervention by the required 
health professional(s), the patient will be contacted by phone and 
the DT will again be administered. A qualitative questionnaire will 
also be administered at this time.
Results: not available at this point
Conclusion: This project has significant benefits to the patient, the 
health service and the wider community. The study plans to pro-
vide a new and improved method of interdisciplinary service de-
livery to an underserviced population. At present there is no lite-
rature related to the significance of interventions completed in an 
outpatient setting aimed at reducing distress and concerns in lung 
cancer/mesothelioma patients. Therefore this research will aim to 
expand the current body of literature related to this population.
Keywords: allied health, interdisciplinary care, lung cancer nurse 
coordinator
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P3.24-028 IMMUNO-HISTOCHEMISTRY (IHC) TYPING OF 
MOLECULAR MARKERS, ITS CORRELATION WITH CLI-
NICAL PARAMETERS AND RESPONSE TO CHEMOTHE-
RAPY IN NON SMALL CELL LUNG CANCER (NSCLC) - A 
PILOT STUDY.
Bapsy P. Poonamalle1, Swarna Shivakumar2, Prabhu Meganathan2, 
Vaishnavi Srinarahari1, Patil C. Nagaraj1
1Medical Oncology, Apollo Hospitals/India, 2Pathology, Apollo Hospi-
tals/India
Background: Incidence of Lung cancer is on the rise, especially 
among women in India. NSCLC constitutes the vast majority and 
there is tendency of rise in adenocarcinomas especially in smokers. 
Recent advances suggest that NSCLC is not a single entity but 
a cohort of different types based on molecular markers. IHC is a 
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P3.24-030 ACTIVITY AND TOLERABILITY OF CARBOPLA-
TIN AND GEMCITABINE IN FIRST-LINE TREATMENT OF 
ELDERLY THAI PATIENTS WITH ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC).
Chaiyut -. Charoentum, Theerakorn Theerakittikul., Somcharo-
ne Saeteng, Juntima -. Euathrongchit, Nirush Lertprasertsuke, 
Witthawat Ariyawutyakorn, Busyamas Chewaskulyong, Sumitra 
Thongprasert
Medicine, Chiang Mai University/Thailand
Background: Despite the rising incidence of NSCLC in the elderly 
population in Thailand, a well defined chemotherapy regimen for 
these patients has not been reported. This study examines the to-
xicity and activity of doublet carboplatin and gemcitabine in Thai 
patients with advanced NSCLC.
Methods: Chemotherapy-naive patients with histological/cytologi-
cal proven advanced NSCLC, aged > 65 years, ECOG 0-1 and ade-
quate organs function were treated with carboplatin (AUC5) and 
gemcitabine (1000 mg/m2 in a 30-min infusion D1, 8) every 21 day 
for maximum 6 cycles. The primary endpoint was objective tumor 
response rate and tolerability to this regimen.
Results: From November 2011 to February 2013, 30 patients were 
evaluated. Median age was 73 years (range 65-83), 70% were male, 
70% were smoker and all patients had PS 0 (30%) or PS 1 (70%). 
Stage IIIb disease in 13% patients and stage IV in 87% patients. 
Non-squamous cell carcinoma in 73% patients (adenocarcinoma 
66%, large cell carcinoma 3.5%, other 3.5%) and squamous cell car-
cinoma in 27% patients. The median number of cycle was 4 (range 
2-6). Among the 29 patients with measurable disease, there were 7 
PR, 15 SD and 7 PD (response rate 24%). The most common hema-
tologic toxicity was grade 3 anemia in 20% and grade 3 leukopenia 
in 10%. Febrile neutropenia occurred in 3%. No treatment related 
death was observed. Non-hematologic toxicity was generally mild 
and grade 1 fatigue occurred in 30%. The median progression free 
survival was 4.9 months (range 2-16).
Conclusion: The doublets carboplatin and gemcitabine could be a 
valuable treatment option in elderly Thai patients. The activity and 
safety observed in this report is within the range of data reported 
for doublet chemotherapy regimen in the elderly patient with NS-
CLC.
Keywords: Non small cell lung cancer, chemotherapy, elderly, 
gemcitabine
mostly ≤ CTC-AE grade 2), oral mucosal pain and dysphagia in 
the absence of clinical lesions. Sorafenib is under investigation in 
NSCLC. We report a patient who developed symptomatic progres-
sion of an esophageal stenosis during sorafenib treatment.
Methods: not appicable
Results: Case: A 67-year old male presented at the outpatient 
clinic with dysphagia CTC-AE grade 3. He was diagnosed with 
a cT3N3M1a (oligometastatic adenocarcinoma, KRAS mutated) 
NSCLC in January 2011 for which he was treated with concurrent 
chemoradiotherapy. Treatment was complicated with grade 3 radi-
ation esophagitis (confirmed with duodenogastroscopy) for which 
he was treated with a feeding tube and proton pump inhibition. 
Because of remaining grade 1 dysphagia, duodenogastroscopies 
were performed in August 2011 and February 2012. A stable re-
lative stenosis of the upper esophagus was found, easy to pass 
with the duodenogastroscope. Because of progressive disease he 
was subsequently treated with erlotinib/ pemetrexed (September 
2011, study) and docetaxel monotherapy (August 2012). February 
2013 he progressed again with subsequent participation in a phase 
II study with sorafenib 400 mg BID and metformin 1000 mg BID. 
Within three weeks he developed dysphagia for solid foods. A 
chest computed tomography showed no external compression of 
the esophagus and no tumor progression. Duodenogastroscopy 
revealed a stenosis with ulceration in the upper part of the eso-
phagus, passing the stenosis was only possible with a baby-duo-
denogastroscope. Because of swallowing problems, sorafenib was 
temporarily stopped and placement of a percutaneous feeding 
tube was planned. However, two days after stopping sorafenib, his 
dysphagia completely resolved and food passage was normal. So, 
ten days later sorafenib was restarted with dose reduction (200 mg 
BID). After restarting sorafenib his dysphagia returned with grade 
3 within six weeks. Again, sorafenib was temporarily stopped and 
in a couple of days his dysphagia resolved. After another restart 
of sorafenib at the latter dose he again developed dysphagia, but 
this time manageable.
Conclusion: We present a patient who developed a grade 3 ste-
nosis of the esophagus during treatment with sorafenib which 
clinically resolved shortly after stopping sorafenib but reoccurred 
after rechallenge with sorafenib at a lower dose. Dysphagia re-
solved again after stopping the sorafenib with again complaints 
after restarting. No other explanation was found (e.g. progres-
sion of malignancy, external compression). 1.5 year before, after 
concurrent chemoradiotherapy, he was diagnosed with a relative 
stenosis of the upper esophagus, but this remained stable until 
sorafenib treatment was started. He scored 8/13 points on the 
Naranjo score, making sorafenib a probable cause of the stenosis. 
The underlying mechanism is unknown. A possible explanation is 
sorafenib inhibition of the VEGF and MAP-kinase pathway. These 
pathways are both involved in the process of mucosal defense and 
repair, and it could be that blocking this pathway combined with 
sensitization by previous irradiation caused progression of the 
stenosis. This case stresses the importance of being aware of un-
usual side effects of medication and taking into account possible 
interactions with previous treatments.
Keywords: NSCLC, Sorafenib, esophageal stenosis, side effects
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Conclusion: Anamorelin HCl is undergoing Phase III evaluation, 
with one of the trials nearing completion. Most enrolled patients 
with NSCLC and cachexia have Stage IV cancer and ECOG 1 per-
formance status. Efficacy and safety results are awaited.
Keywords: cancer cachexia, anamorelin HCl, ghrelin receptor ago-
nist, anorexia-cachexia
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P3.24-031 ANAMORELIN HCL FOR THE TREATMENT OF 
ANOREXIA-CACHEXIA IN NSCLC: BASELINE CHARAC-
TERISTICS OF PATIENTS IN THE PHASE III CLINICAL  
TRIAL ROMANA 2 (HT-ANAM-302)
David Currow1, Jennifer Temel2
1Flinders University/Australia, 2Massachussets General Hospital/Uni-
ted States Of America
Background: Cancer anorexia-cachexia may develop in up to 80% 
of advanced cancer patients, and is a debilitating and life-threa-
tening complication of an underlying malignancy which can cause 
decreased tolerance and response to treatment. Cancer cachexia 
has a multifactorial pathogenesis, and is defined, in part, by ac-
celerated losses of skeletal muscle and disproportionate losses 
of lean body mass (LBM). Safe and effective treatments for cancer 
anorexia-cachexia remain an unmet medical need. Anamorelin 
HCl is an orally administered ghrelin receptor agonist. In Phase II 
studies, it significantly increased LBM and body weight in cancer 
patients, and improved physical strength. Anamorelin HCl is cur-
rently being investigated as a cachexia treatment in a pair of Phase 
III trials enrolling patients with non-small cell lung cancer (NSCLC); 
baseline characteristics of study participants are presented here.
Methods: HT-ANAM-301 (NCT01387269) and HT-ANAM-302 
(NCT01387282), also known as ROMANA 1 and ROMANA 2, are 
double-blind, placebo-controlled, randomized (2:1 anamorelin HCl 
vs. placebo) Phase III trials in patients with NSCLC cachexia, with a 
target enrollment of 477 patients per study. Eligible patients must 
have unresectable Stage III or IV NSCLC and cachexia (weight loss 
of ≥5% body weight within prior 6 months or BMI <20 kg/m2). Pa-
tients receive once daily oral doses of anamorelin HCl (100 mg) or 
placebo for 12 weeks. Co-primary endpoints are the change from 
baseline in LBM as measured by DXA scan and in muscle strength 
as measured by handgrip strength (HGS). Secondary endpoints 
include change in body weight, overall survival, and quality of life. 
For HT-ANAM-301 only, blood samples are collected at Week 6 for 
population pharmacokinetics. After 12 weeks of treatment, pati-
ents may continue in a separate 12-week safety extension study 
(HT-ANAM-303 [ROMANA 3] NCT01395914).
Results: As of June 2013, 448 patients (93.9%) have been enrolled 
in ROMANA 2, and key baseline characteristics based on prelimi-
nary data available to-date are presented in the Table.
S1315Copyright © 2013  by the International Association for the Study of Lung Cancer
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P3.24-033 A CASE OF LUNG ADENOCARCINOMA HAR-
BORING BOTH A KRAS MUTATION AND AN EML4-ALK 
FUSION GENE WITH RESPONSE TO CRIZOTINIB.
Michael E. Menefee1, Thomas A. D‘Amico2
1Hematology Oncology, Mayo Clinic/United States Of America, 2General 
Thoracic Surgery, Duke University Medical Center/United States Of 
America
Background: Echinoderm microtubule-associated protein-like 
4-anaplastic lymphoma kinase (EML4-ALK) fusion genes occur in 
approximately 4-7% of patients with adenocarcinoma of the lung 
(ACL). These tend to occur in individuals with limited or no tobacco 
exposure and largely occur in exclusion of KRAS mutations. The 
presence of a KRAS mutation is associated with a worse prognosis 
and predicts lack of response to targeted therapeutics such as 
crizotinib. We believe this to be the first case reported of a con-
current KRAS mutation and EML4-ALK translocation with a subse-
quent response to crizotinib.
Methods: Not applicable
Results: A 56 yo White female smoker had a recent diagnosis of 
cirrhosis due to hepatitis B and C. Imaging for her liver revealed 
an incidental finding of bilateral lung opacities, both of which were 
suspicious for malignancy. A biopsy of the LLL lesion confirmed 
ACL. Resection of the superior segment of the LLL was performed 
and confirmed a well-differentiated ACL with BAC features (T1b, 
N0, M0). Analysis revealed a KRAS mutation (p.G13C (c.37G>T); 
EGFR and EML4-ALK analysis were not performed. The right-sided 
lesion was observed. One year later, disease progression was 
identified in the right hilum and mediastinum. EBUS confirmed 
the presence of ACL in levels 10R and 4R lymph nodes. Molecular 
analysis again confirmed the presence of a KRAS mutation, albeit 
a different mutation (p.G12A (c.35G>C) than was observed in the 
left lung. There was no ALK gene rearrangement. She was treated 
with concurrent chemoradiation with cisplatin as the radiosensitizer 
in light of her pre-existing grade 2-3 thrombocytopenia from her 
underlying liver disease. She received 38 out of a planned 60 Gy 
due to thrombocytopenia and subsequent interruptions in thera-
py. Nonetheless, she did respond to therapy, but she had a local 
recurrence less than 8 months after therapy was terminated. At the 
time of progression, the patient sought further surgical interventi-
on and a pneumonectomy was offered; however, mediastinosco-
py confirmed the presence of adenocarcinoma in a level 7 node 
and plans for further resection were aborted. Mutational analysis 
confirmed the presence of the activating KRAS mutation, (p.G12A 
(c.35G>C) and negativity for an EGFR mutation; however, an EML4-
ALk translocation was identified in 20% of cells analyzed. The 
patient was treated with crizotinib. After 8 weeks of therapy, PET/
CT demonstrated objective evidence of response to therapy with 
the maximum SUV decreasing from a baseline of 11.3 to 6.8, with 
the lesion remaining stable in size. Therapy was well-tolerated, 
although the patient had an unexpected finding of normalization 
of her platelet count while on therapy with crizotinib.
Conclusion: This unusual case of a female smoker with a co-
existing EML4-ALK translocation and activating KRAS mutation 
highlights several important points: 1. EML4-ALK translocations 
are not mutually exclusive of KRAS mutations in all patients with 
ACL. 2. Discordance in EML4-ALK translocation status can occur 
in metastatic deposits. 3. Individuals harboring both an EML4-ALK 
translocation and a KRAS mutation can respond to crizotinib. 4. 
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P3.24-032 SECOND OPINION FOR THORACIC CANCER 
AND ITS IMPACT ON DIAGNOSIS AND TREATMENT 
STRATEGY: A SINGLE INSTITUTIONAL SERIES
Thomas L.A. Malfait1, Veerle F. Surmont1, Birgitta I. Hiddinga2, 
Karim Y. Vermaelen1, Jan P. Van Meerbeeck2
1Respiratory Medicine, Ghent University Hospital/Belgium, 2Thoracic 
Oncology (MOCA), Antwerp University Hospital/Belgium
Background: Lung cancer patients increasingly seek a second 
opinion in order to make sure they are receiving an exact diagnosis 
and an optimal treatment. A second opinion is more likely to be 
comprehensive when performed in centers with high level of ex-
pertise and within a multidisciplinary team.
Methods: A dedicated second opinion outpatient clinic was star-
ted within the Thoracic Oncology Unit of Ghent University Hos-
pital, in March 2012, aiming at a quick access and evaluating its 
impact on diagnosis and treatment decisions. 
Second opinion was defined as a review of the cancer diagnosis 
and/or the treatment recommendations by another independent 
oncologist and/or multidisciplinary team. 
Patients had to be referred by either their general practitioner or 
the treating specialist. Prior to the consultation relevant investiga-
tions (medical history, pathology and imaging) had to be provided.
Results: Between March 2012 and June 2013, 79 pts were referred: 
31 women and 48 men with a median age of 64 years [17-81 yrs]. 
Of these, 17 (22%) were never smokers, 18 (23%) smokers and 40 
(51%) ex-smokers. Median interval was 3 working days [0-15 days] 
after first referral. Eighteen percent of patients were referred by 
their GP’s versus 80% by their treating specialist. Medical informa-
tion including imaging was available in all pts at the moment of the 
consultation. Diagnosis included: adenocarcinoma (n=43 - 54%), 
squamous cell carcinoma (n=8 - 10%), NSCLC, NOS (n=1 large cell 
neuroendocrine carcinoma (n=3 - 4%), small cell lung cancer (n=4 
- 5%), mesothelioma (n=6 - 8%), thymoma (n=2 - 3%), carcinoid 
tumor (n= 4 - 5%). In 4 patients no diagnosis had been establis-
hed. Eleven patients were referred for confirmation of diagnosis 
and treatment, 11 for staging and 57 for treatment advice. Median 
consultation duration was 35 minutes [15-60 min], median time of 
multidisciplinary counseling 15 minutes [5-60 min]. In 43% of the 
referrals, diagnosis and treatment was confirmed, in 21% other 
diagnostic examinations were advised and in 29% a substantial 
change in treatment was proposed. Six percent of patients entered 
into a clinical trial. Almost 50% of patients continued their treat-
ment at our center (26% on request of the referring physician, 23% 
on patient‘s request). Patient‘s satisfaction on waiting time and 
quality of the advice was high.
Conclusion: This dedicated second opinion outpatient clinic 
confirms the need for an academic second medical advice and 
provided a quick access. In 50% of cases a substantial change in 
diagnostic procedure or treatment was proposed.
Keywords: second opinion, staging, Treatment, thoracic cancer
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Background: Major goals in advanced NSCLC include accurate 
evaluation of survival and quality of life. Few trials evaluate both 
of these major endpoints well. In many studies, only a minority of 
patients have quality of life and other patient reported outcomes 
(PROs) such as symptoms systematically followed over time, which 
decreases the value of the assessment of the treatment. Prior stu-
dies have identified barriers to measuring quality of life in clinical 
trials and in practice. To overcome these barriers, we used a com-
puter-assisted version of the validated LCSS measure and tested 
this prospectively in a large study in patients with Stage IV and IIIB 
NSCLC. The eLCSS-QL requires only two minutes for completion 
of the patient version and proved to be highly acceptable in earlier 
studies (Hollen, Supp Care Cancer 2012).
Methods: This trial was conducted at 65 sites in 9 Asian countries. 
622 patients received first-line treatment with docetaxel -based 
chemotherapy. Patient demographics included: 70% male; 65% 
adenocarcinoma; median: KPS = 90; ECOG = 1 (27% ECOG 0). 
Stages: IV (72%), IIIB (28%). 84% had two or more major symptoms. 
80% received combination chemotherapy with cisplatin (52%) or 
carboplatin (28%). The eLCSS-QL was completed every 3 weeks 
at the clinic. We also surveyed 98 physicians and nurses treating 
these patients regarding their experiences concerning communica-
tion, usefulness and acceptability of the eLCSS-QL.
Results: Ninety-seven percent of patients completed the eLCSS-
QL at baseline; 90% completed follow-up evaluations. Over 90% 
found the eLCSS-QL easy to use and acceptable to complete at 
each visit. More than 80% of patients reported increased aware-
ness of symptoms and that the quality of life evaluation made it 
easier to speak with doctors and nurses. 1% refused eLCSS-QL 
completion. Of physicians and nurses, more than 90% found the 
eLCSS-QL easy to use and increased symptom awareness; 80% 
reported improved communication, enhanced satisfaction with 
the patient visit, and would recommend its use to others. Nearly 
90% of physicians reported they could identify benefit from che-
motherapy earlier; 76% would order fewer imaging tests and 80% 
said the eLCSS-QL could save time. Cross-cultural testing was 
performed in this 9 nation trial. Cronbach’s alpha scores were high 
for each country, and exceeded 0.85 overall, demonstrating good 
cross-cultural reliability. Treatment outcomes: major response rate 
37%; median survivals: 13.9 months (docetaxel + cisplatin), 12.7 
months (docetaxel + carboplatin).
Conclusion: Placing the well validated LCSS onto an electronic 
platform (eLCSS-QL) helped overcome barriers to evaluating QL 
in this large clinical trial, with 90% of patients completing base-
line and repeated QL measures. Patients, physicians, and nurses 
all found the eLCSS-QL to be highly acceptable and easy to use. 
The good cross-cultural aspects of the eLCSS-QL indicate that 
the electronic platform is particularly suitable for multinational 
trials. This large prospective trial demonstrates that improved 
compliance with quality of life and PRO evaluation is feasible and 
can easily be accomplished in large clinical trials. Additionally, the 
electronic format enhances the potential for the use of PROs in 
decision making in clinical practice.
Keywords: quality of life, PRO, LCSS, eLCSS-QL
Commonly used algorithms for molecular testing in ACL do not 
identify all patients who may benefit from molecularly targeted 
therapies.
Keywords: KRAS, Crizotinib, NSCLC, EML4-ALK
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P3.24-034 PRIMARY PULMONARY LYMPHOMA MIMI-
KING LUNG ABSCESS
Min-Woong Kang, Seung Pyung Lim
Department Of Thoracic And Cardiovascular Surgery, Chungnam Nati-
onal University School Of Medicine/Korea
Background: Primary pulmonary lymphoma (PPL) is a rare disease. 
Half of the patients are asymptomatic and other patients can pre-
sent nonspecific symptoms such as cough, mild dyspnea, chest 
pain, or hemoptysis. The diagnosis of disease is based on histolo-
gical examination and we can obtain a tissue by surgical biopsy, 
transbronchial or transthoracic biopsy. We report a case that PPL 
mimicking lung abscess was confirmed by surgical biopsy.
Methods: 68-year-old female presenting with continuous mild 
fever and cough for 2 weeks, and suspected as pneumonia or lung 
abscess at the initial evaluation. There was no clinical improvement 
after antibiotic therapy for 5 weeks. Chest computed tomography 
showed as organizing pneumonia with abscess formation right 
middle lobe RML). So, we performed right middle lobe lobectomy. 
In operative findings, there was large amount milkfish drainage 
with hard mass in RML. There was no culture positive in milkfish 
drainage. Post op 7th day, she discharge without any complication.
Results: Pathologic findings reveals the mass was malignant prima-
ry pulmonary lymphoma in (diffuse large cell type B-cell lympho-
ma).
Conclusion: PPL is a vary rare entity and the diagnosis based on 
radiological findings is limited so, we reports it.
Keyword: Primary pulmonary lymphoma
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P3.24-035 EVALUATING HEALTH RELATED QUALITY 
OF LIFE AND SYMPTOMS BY USING THE ELECTRONIC 
(EPRO) VERSION OF THE LCSS (ELCSS-QL) IN A 622 
PATIENT PROSPECTIVE MULTINATIONAL NSCLC TRIAL 
(AP-QL TRIAL) WITH GOOD CROSS-CULTURAL RELIABI-
LITY.
Sumitra Thongprasert1, Richard J. Gralla2, Patricia J. Hollen3, 
Hoon-Kyo Kim4, Te-Chun Hsia5, Yuankai Shi6, Nina Kohn7, Martin 
Lesser7
1Chiang Mai University/Thailand, 2Albert Einstein College Of Medicine, 
Jacobi Medical Center/United States Of America, 3University Of Virgi-
nia/United States Of America, 4St. Vincent‘s Hospital/Korea, 5China 
Medical University Hospital/Taiwan, 6Medical Oncology, Cancer Hos-
pital (Institute), Chinese Academy Of Medical Sciences & Peking Union 
Medical College/China, 7Feinstein Institute For Medical Research, North 
Shore Long Island Jewish Health Sytem/United States Of America
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P3.24-037 THE COST-EFFECTIVENESS OF SECOND-LINE 
CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED 
NON-SMALL CELL LUNG CANCER
Donna M. Graham1, Sandjar Djalalov2, Jaclyn Beca2, Jeffrey Hoch3, 
Ming S. Tsao4, Jc Cutz5, Natasha Leighl1
1Thoracic Oncology, Division Of Medical Oncology And Hematolo-
gy, Princess Margaret Cancer Centre/Canada, 2Pharmacoeconomics 
Research Unit, Cancer Care Ontario/Canada, 3Cancer Care Ontarior 
Pharmacoeconomics Unit/Canada, 4Department Of Pathology, Princess 
Margaret Cancer Center/Canada, 5Pathology And Molecular Medicine, 
Mcmaster University/Canada
Background: The management of non-small cell lung cancer (NS-
CLC) has changed markedly over last decade with the discovery 
of distinct molecular and genetic changes within the lung cancer 
genome and the availability of new therapeutic agents to target 
these genetic aberrations. However, the clinical benefits observed 
are not without significant financial costs. These include diagnostic 
testing to identify molecular targets and an increasing cost of 
cancer treatment. Chromosomal rearrangements of the anaplastic 
lymphoma kinase gene (ALK) are predictive for clinical response to 
crizotinib, a first-in-class oral ALK inhibitor. In a recent phase 3 trial, 
crizotinib was associated with a higher response rate, improved 
progression-free survival and improved quality of life when com-
pared with docetaxel or pemetrexed as second-line chemotherapy 
for advanced NSCLC following platinum-based chemotherapy. 
We performed an analysis to estimate the cost-effectiveness of 
ALK testing and crizotinib treatment in the second-line setting for 
patients with stage IV ALK-rearranged NSCLC in the province of 
Ontario, Canada.
Methods: We developed a Markov state-transition model to com-
pare the costs and effectiveness of ALK testing and treatment with 
crizotinib in positive cases with the current standard of care (doce-
taxel or pemetrexed chemotherapy). Patients had stage IV NSCLC 
with non-squamous histology and were previously treated with a 
platinum-based regimen. The analysis was conducted from the 
Canadian public health perspective (Ontario) and a “lifetime” time 
horizon was used. Transition probabilities, mortality rates and costs 
were calculated from the Ontario Registry, Cancer Care Ontario 
New Drug Funding Program, Ontario Case Costing Initiative, Uni-
versity Health Network and published literature, including a recent 
second-line randomized trial of crizotinib versus chemotherapy 
(Shaw et al. New Engl J Med 2013). Population-based ALK testing 
included initial immunohistochemical (IHC) staining followed by 
fluorescent in-situ hybridization (FISH) for positive cases. The out-
come of the analysis was incremental cost per quality-adjusted 
life-years (QALY). The survival impact of crizotinib in ALK-positive 
NSCLC was derived from a retrospective study (Shaw et al. J Clin 
Oncol 2012), as the second-line randomized trial of crizotinib ver-
sus chemotherapy permitted >80% crossover from the standard 
chemotherapy arm to crizotinib.
Results: The use of crizotinib compared to pemetrexed and doce-
taxel in ALK-rearranged NSCLC, based on our preliminary model, 
could yield as much as +0.309 QALY and +0.433 QALY respec-
tively, assuming no crossover from chemotherapy to crizotinib. 
Incremental costs based on the preliminary model are estimated 
at CAD $88,446 for pemetrexed and $102,764 for docetaxel, with 
incremental cost-effectiveness ratios of $286,198/QALY ($162,814/
life-year) and $237,575/QALY ($136,707/life-year) gained respec-
tively. Major drivers of cost-effectiveness included the cost of 
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P3.24-036 LUNG CANCER AWARENESS MONTHS IN 
SLOVAKIA - WHAT HAVE THEY CHANGED?
Peter Berzinec1, Beata Bellova2, Maria Cerna3, Lucia Dolakova1, 
Gabriela Chowaniecova1, Peter Kasan3, Milan Kroslak1, Marian 
Martinak3, Erik Ondrejka4, Denisa Selicka4, Matus Vancek2, Milada 
Vesela3, Erika Zimanova5
1Specialized Hospital Of St Zoerardus Zobor/Slovak Republic, 2Roche/
Slovak Republic, 3Faculty Hospital Of Comenius University/Slovak 
Republic, 4Second Breath Citizens Organization/Slovak Republic, 5Acce-
lerate/Slovak Republic
Background: The tradition of Lung Cancer Awareness Month 
(LCAM) started in Slovakia in November 2008 with the help of 
several organizations, including Slovak Oncological Society, Minis-
try of Health, Ministry of Education, Ministry of Agriculture, Roche 
Slovakia, leading lung cancer centers, and many others, including 
volunteers, with the main purpose to raise awareness about all 
aspects of lung cancer. Several interesting projects were realized 
as a part of LCAMs in 2008 – 2012. Among them were the press 
conferences with participation of patients, leading experts, well 
known persons from cultural and political life; lung function testing 
in the Parliament of the Slovak Republic; lung function testing and 
educational leaflets distribution in the largest shopping centers in 
the country; the moving exhibition of lung models colored by the 
VIPs from the Slovakian cultural and sport life, i.e. by well known 
writers, actors and actresses, and sport stars; teaching activities at 
the secondary schools; publishing of free educational materials for 
patients and their relatives. In addition, during the LCAM in 2011 
the Second Breath (Druhy Dych) Citizens Organization was estab-
lished to help patients with lung cancer, and successfully continues 
with their activities (www.druhydych.eu). We decided to assess the 
influence of LCAMs on public awareness of lung cancer.
Methods: 1. Search for the Slovak web pages containing the 
term “rakovina pluc” (“lung cancer“) was done in Google.sk for 
the time periods: 01.NOV.2007 – 31.DEC.2007, 01.NOV.2008 – 
31.DEC.2008, and 01.NOV.2012 – 31.DEC.2012. 2. Another search 
was done in a Newton Media Database, aimed at the major Slovak 
media, for the years 2007 and 2012 to find the entries with the 
term “rakovina pluc” (“lung cancer”).
Results: 1. The number of the Slovak web pages with the term 
“rakovina pluc” (“lung cancer”) in the time periods 01.NOV. 
– 31.DEC.2007, 01.NOV. – 31.DEC.2008, and O1.NOV. – 
31.DEC.2012 was 14, 58, and 130, respectively. 2. The number of 
entries with the term “rakovina pluc” (“lung cancer”) in the Newton 
Media Database was 16 in 2007, and 36 in 2012.
Conclusion: Our results confirm, that LCAMs in Slovakia attracted 
media and public attention and thus increased the awareness of 
lung cancer. We believe that this has a positive impact on lung can-
cer patients’ care, and encourages us to continue with the LCAMs 
tradition.
Keyword: Lung Cancer Awareness Month, media, public, impact
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identified as a tobacco-induced, life-threatening disease, imposing 
heavy treatment and b) the minor repertoire in which significant 
units belonged to the representation of lung cancer as an environ-
mental-induced disease. In comparison with breast cancer, lung 
cancer is characterized by a greater feeling of guilt and a more 
frequent association with the way of life.
Conclusion: We deciphered some aspects of lung cancer percep-
tion in the general population and anticipated that it may improve 
psychological adjustment in patient-doctor communication, fill in 
the knowledge gap of the perception of the disease and eventually 
help in lung cancer management.
Keywords: Treatment, Survey, lung cancer perception, Prognostic
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P3.24-039 NON SMALL CELLS LUNG CANCER STAGE IV: 
A RETROSPECTIVE STUDY OF 278 CASES
Farah Khedda
Constantine, Chu/Algeria
Background: Lung cancer is one of the most common cancers 
worldwide. It represents the first human cancer and the first cause 
of death by cancer. The mean age at diagnosis is above 60 years, 
and it is rare before age 40 years with a clear male predominance. 
There is an increase in incidence in women due to the increase use 
of tobacco, which represents the main etiologic factor of this can-
cer. Therapeutic modalities vary according to the histological type 
and the stage. 
Methods: We conducted a retrospective study for medical records 
of all patients with metastatic NSCLC admitted to our service bet-
ween 2005 and 2011.
Results: Our study included 278 patients accounting for (55%) of 
all NSCLC patients in this period. 19% of patients were recruited 
in 2011. Average age was 59 years (22-85). (93%) were male with a 
female/male ratio of 13.1. (80%) were smokers. The average time 
to diagnosis was six months (1-24). Chest pain accounted for (37%) 
of the presenting symptoms. The routine chest x-ray and CT scan 
were made in all patients, (63%) of patients were diagnosed by a 
CT scan guided biopsy. Histological type was an adenocarcinoma 
in (54%) of the cases, contralateral lung accounted for (37%) of the 
metastatic sites. (89%) of patients have received first line chemo-
therapy protocols using platinum combinations. (45%) had tolera-
ted the chemotherapy. A partial response was attained in (51%) of 
cases, (6%) of patients underwent surgery. Palliative radiotherapy 
was performed in (11%) of patients. (95%) of the patients were lost 
to follow up.
Conclusion: The metastatic NSCLC has a poor prognosis. , high-
lighting that the most effective intervention against this disease is 
primary prevention by tobacco control. Additional means include 
proper screening and early detection, and the development of 
new therapeutic agents may lead an increase in progression-free 
survival or even overall survival and cure. Establishing an infra-
structure for follow up, palliative care and home health services is 
direly needed to assure proper support and end of life care.
Keyword: tobacco, adenocarcinoma, platinum, prognosis
drug therapy and incremental survival. Data on the impact of ALK 
testing on the overall cost-effectiveness ratio will be presented at 
the 2013 WCLC meeting, as will refined cost estimates after further 
model calibration.
Conclusion: While crizotinib therapy 2nd line for advanced ALK-
rearranged NSCLC is clearly superior to chemotherapy, the cost-
effectiveness ratio is higher than traditionally accepted thresholds, 
driven largely by drug cost. Payors and manufacturers should 
collaborate to ensure that highly effective NSCLC treatments are 
available and affordable to patients with NSCLC.
Keywords: cost-effectiveness, ALK-rearrangement, Crizotinib, 
advanced non-small cell lung cancer
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P3.24-038 PERCEPTION OF LUNG CANCER AMONG 
THE GENERAL POPULATION AND COMPARISON WITH 
OTHER CANCERS.
Julien Mazieres1, Jean-Louis Pujol2, Diane Bouvry3, Elisabeth Quo-
ix4, Nathalie Targowla5, Bernard Milleron6
1Thoracic Oncology, Toulouse Universitary Hospital/France, 2Thoracic 
Oncology, Academic Hospital/France, 3Pulmonology, Hopital Avicennes/
France, 4Pulmonology, Universitary Hospital/France, 5Médecine Généra-
le/France, 6Pulmonology, Hopital Tenon/France
Background: After decades of very slow progresses, lung cancer 
management rapidly evolved in the past few years. One could 
anticipate a possible leap in perception of the disease between 
patients and physicians.
Methods: We conducted a prospective nationwide observational 
survey of 2200 healthy subjects selected within a representative 
permanent polling database according to the relevant national and 
European laws. We collected data in relation to aetiology, epide-
miology, diagnostic, therapy and prognostic by using a specific 
questionnaire as well as perception of lung cancer by using a lexi-
cal approach. Among them, 1629 returned the questionnaire and 
1469 were eligible for a full analysis.
Results: We observed that the population has an average high 
level of information regarding epidemiological changes of lung 
cancer (“same incidence” for 40%, “higher incidence” for 47%, 
“increase in women” for 75%), and main risk factors (tobacco 93%, 
occupational 81% and environmental exposure 56%). Two thirds 
(67%) are aware of the danger of passive smoking. Only 22% of the 
whole population believed to be at risk of lung cancer. Differences 
were seen according to smoking habits as 62% of current smokers, 
21% of former smokers and 6% of never-smokers believed to be 
at risk (p < 0.05) and according to the age, as 15% of responders 
above 65 years old thought to be at risk in comparison of 26% of 
responders below 34 (p < 0.05). The population overestimated 
the overall survival of lung cancer (32%) and underestimated the 
potential cure of early stage disease (52%). The participants clearly 
identified lung cancer as a severe disease (82%) with a worse pro-
gnostic than other cancers (colorectal, breast, prostate, p < 0.05). 
Most of the population was aware of the main treatments of lung 
cancer (surgery, chemotherapy and radiotherapy) but only 45% 
cited targeted therapy. By using lexical tests we observed that 
corpus can be split in two main lexical repertoires: a) the major 
repertoire in which the significant units have encoded lung cancer 
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P3.24-041 MALIGNANT PLEURAL MESOTHELIOMA: AC-
CUMULATED EXPERIENCE IN A BRAZILIAN TERTIARY 
HOSPITAL
Benoit J. Bibas1, Ricardo M. Terra1, Mauro F.L. Tamagno2, Ricardo 
Beyruti2, Paulo M. Pêgo-Fernandes2
1Instituto Do Câncer Do Estado De São Paulo (ICESP) Fmusp/Brazil, 
2Incor Hcfmusp/Brazil
Background: Malignant pleural mesothelioma (MPM) is the main 
primary malignant tumor of the pleura. It is extremely aggressive 
and associated with poor survival, despite multimodal treatment 
appropriate. Most series report the experience accumulated with 
the treatment of MPM in a few North American or European spe-
cialized centers. In literature, we found very little information on 
epidemiology and treatment of mesothelioma in Latin America. 
The aim of this study was to describe the experience with MPM in 
a tertiary university hospital in Brazil.
Methods: Retrospective study with patients diagnosed with MPM 
between December 1999 and December 2011. Diagnosis was esta-
blished by histopathological analysis of the pleura. Tumor staging 
included CT scans of the head, thorax and abdomen. Pet Scan/
PET-CT has been included since 2002. Mediastinoscopy is routi-
nely performed since 2002. All patients were initially considered 
for multimodal therapy (extrapleural pleuropneumonectomy with 
chemotherapy and radiotherapy). The chemotherapy regimens 
used were cisplatin, doxorubicin, cyclophosphamide, and recently, 
Pemetrexed. Categorical variables were presented as percentage 
and continuous variables as mean and standard deviation. Kaplan-
Meier estimate was used for survival analysis.
Results: Fifty-nine patients were included (45 M/ 14 F); mean age 
49 years (13-79). Forty-five patients had epithelioid tumors (76%); 4 
(7%) had sarcomathoid tumors; 8 had biphasic tumors (14%), and 2 
(3%) had desmoplastic tumors. 36% of the patients had confirmed 
asbestos exposure. Clincal stage was Stage I, 18 patients; Stage 
II, 8 patients; Stage III, 21 patients: and, Stage IV, 12 patients. 
Therapeutic approaches were multimodal (pleuropneumonectomy 
extrapleural plus chemotherapy-radiotherapy) in 21 patients (36%), 
chemotherapy and radiotherapy in 8 (14%), radiotherapy alone in 
4 (7%), chemotherapy alone in 25 (43%). Survival among patients 
operated was 16 + 2 months, and 15.9 + 5.7 months in the non-
operated group. There was no statistical difference in survival bet-
ween the groups operated and non-operated. Surgical mortality 
was 15%, with 40% morbidity.
Conclusion: The pattern of our demographic data is similar to 
other international series. Despite aggressive treatment, poor sur-
vival was observed in the present study.
Keywords: mesothelioma, Pleuropneumonectomy, Survival esti-
mation
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P3.24-040 IODOPOVIDONE FOR PLEURODESIS IN  
PATIENTS WITH MALIGNANT PLEURAL EFFUSION:  
A SAFE OPTION
José D.A. Neto1, Ricardo M. Terra2, Silvana Vianna1, Rodrigo Maia1, 
Alessandro W. Mariani2, Paulo M. Pêgo-Fernandes2
1Hospital Aristides Maltez/Brazil, 2Thoracic Surgery, Incor HCFMUSP/
Brazil
Background: Malignant pleural effusion (MPE) is a disabling condi-
tion in patients with metastatic disease. Pleurodesis is a well esta-
blished treatment for recurrent MPE; however, the best sclerosing 
agent is still a matter of debate. Iodopovidone is described in the 
literature as a sclerosing agent easily obtained, easy to use, and 
inexpensive; nevertheless, its safety has not been systematically 
evaluated. The objective of this study was to analyze the occur-
rence of frequent (>5%) adverse events after pleurodesis using two 
different dosages of Iodopovidone in patients with MPE.
Methods: Randomized double blind clinical trial including pati-
ents with recurrent MPE eligible for pleurodesis. All patients were 
randomized into two groups; group 1 received 1% Iodopovido-
ne and group 2 received 2% Iodopovidone. We sought adverse 
events systematically after pleurodesis through pain analog scale, 
dyspnea scale, oxygen saturation, heart frequency, arterial blood 
pressure, body temperature, visual acuity, EKG, chest x-ray and 
laboratory tests (CRP, hemogram, renal function, liver function and 
thyroid function). All adverse events were registered and classified 
according to the CTCAEV v3.0. We considered pleurodesis as 
failed when the patient underwent new pleural procedures. We 
compared groups as for adverse events, quality-of-life, and suc-
cess using, chi-square or t-test, p<0.05 was considered significant.
Results: Fifty patients underwent pleurodesis over the study pe-
riod, 45 females and 5 males with a mean age of 56,7 years. The 
etiology of MPE was breast cancer in 34 patients (68%), lung can-
cer in 6 patients (12%), and other neoplasms in 10 patients (20%). 
We found no difference in patient’s demographical data between 
groups. The most frequent adverse event was elevation of alkaline 
phosphatase, which occurred in 21 patients (42%), 6 in group 1 
and 15 in group 2 (p = 0.03). Hyponatremia was the second most 
common adverse event, it occurred in 19 patients (38%), 5 in group 
1 and 14 in group 2 (p= 0,02). In no patient did these laboratorial 
alterations require further care. The most frequent clinical adverse 
event was severe pain, it was observed in 5 patients (10%), 1 pati-
ents from group 1 and in 4 patients from group 2 (p=0.69). Hypo-
tension occurred in one patient from each group (p=1). Two pati-
ents had postoperative empyema in group 2, and none in group 1 
(p=0,35). Other adverse effects or complications commonly repor-
ted in the literature such as fever, renal or visual disorder were not 
found. Pleurodesis success rate was 92% in the Group 1 and 84% 
in Group 2 (p = 0.5).
Conclusion: Clinically relevant adverse events are not frequent 
after iodopovidone pleurodesis, being pain the most common. 
Apparently, the occurrence of laboratorial alterations is dose-
dependent
Keywords: pleural effusion, pleurodesis, Iodopovidone, adverse 
events
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rence of ALK-rearranged NSCLC patients. We reacknowledge an 
importance of molecular targeted therapy that creates dramatic 
clinical effects within a short time period. Further observation and 
accumulation of cases will be necessary to evaluate the clinical 
effectiveness of this treatment in postoperative recurrence of ALK-
rearranged NSCLC patients. 
Keywords: Lung cancer, Crizotinib, ALK, XALKORI
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P3.24-043 DONOR - DERIVED METASTATIC LUNG CAN-
CER IN A LIVER TRANSPLANT RECIPIENT
Harshita R. Paripati1, Juan F. Gallegos-Orozco2, David D. Douglas1, 
David C. Mulligan1, James W. Williams1, Helen J. Ross1
1Mayo Clinic/United States Of America, 2University Of Utah/United 
States Of America
Background: Malignancy after organ transplantation is generally 
the result of de-novo occurrence or recurrence of prior malignancy. 
Donor-related malignancy, defined as direct transmission of tumor 
from the donor organ or tumor arising from cells of donor origin 
in a recipient of a solid organ or hematopoietic stem cell trans-
plant, is less common (0.02-0.2% of solid organ transplants). When 
organs from donors with known malignancy are used, the rate of 
transmission is up to 45%, with a mortality of 33-42%. We present 
the first case of donor-transmitted lung cancer in 550 liver trans-
plants at Mayo Clinic Arizona.
Methods: Case report and literature review.
Results: A 69 year-old Caucasian male, former smoker, under-
went deceased-donor liver transplantation for alcoholic cirrhosis 
and hepatocellular carcinoma. He was seen for a routine 4 month 
follow-up visit, had no complaints and was compliant with immu-
nosuppression. Physical exam and laboratory tests were unremar-
kable. Abdominal CT revealed 3 small, solid, indeterminate liver 
masses. Follow-up MRI 6 weeks later demonstrated an increase in 
number and size of liver lesions. US-guided biopsy revealed poorly 
differentiated carcinoma most consistent with non-small cell carci-
noma of the lung, with a minor component of small cell carcinoma. 
On PET-CT, the abnormal uptake was limited solely to the liver. 
Suspicion of donor-transmitted malignancy arose. The donor was a 
50 year-old man, with history of alcohol and nicotine dependence 
(>20 pack/year), without history of malignancy. Chest x-ray, bron-
choscopy and surgical lung examination, performed as part of pro-
curement protocol, were normal. No other organ from this donor 
was transplanted. A PCR-panel of markers that recognize highly 
variable regions of DNA was used to compare donor liver tissue to 
the tumor and recipient liver tissue. Results confirmed cancer cells 
were of donor origin. Cancer was confined to the donor organ, but 
the patient could not undergo graft removal and re-transplantati-
on. Immunosuppression was reduced, and chemotherapy (etopo-
side & carboplatin) was begun with initial response. Progression of 
metastatic liver disease led to second-line therapy with erlotinib. 
Unfortunately, patient succumbed shortly thereafter.
Conclusion: Donor-derived bronchogenic carcinoma after solid 
organ transplantation is extremely rare. One series reported lung 
cancer in 9 of 3374 patients (0.3%) transplanted over a 15 year pe-
riod. Of these 9 patients, 3 patients had a kidney transplant, 3 had 
liver transplant, 2 had heart transplant and 1 had lung transplant. 
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P3.24-042 THE USE EXPERIENCE OF CRIZOTINIB (XAL-
KORI®) FOR POSTOPERATIVE RECURRENCE OF ALK-
REARRANGED NON-SMALL CELL LUNG CANCER
Daisuke Noma1, Kazuhiro Sakamoto1, Kohei Ando1, Shinya G. 
Amano1, Shigeto Sudo2, Hideto Goto2, Yasushi Yamakawa2, Moto-
fumi Tsubakihara2, Masahiro Tsuboi3, Munetaka Masuda4
1Department Of Respiratory Surgery, National Yokohama Medical Cen-
ter/Japan, 2Department Of Respiratory Medicine, National Yokohama 
Medical Center/Japan, 3Department Of Respiratory Surgery, Yokohama 
City University Medical Center/Japan, 4Department Of Surgery, Yoko-
hama City University School Of Medicine/Japan
Background: Crizotinib(Xalkori®) was developed as a medicine for 
anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung 
cancer (NSCLC). Multi institutes studies established its efficacy 
and safety for advanced lung carcinoma. After crizotinib release in 
Japan, there has been no report about usage of crizotinib for post-
operative recurrence of lung cancer. We have four patients with 
postoperative recurrence of ALK-rearranged NSCLC who were 
treated with crizotinib. We herein report the efficacy and safety of 
the treatment.
Methods: not applicable
Results: Case report ALK-rearrangements were confirmed by FISH 
examination from surgical specimen in (all four patients. Histo-
logical diagnoses were pulmonary adenocarcinoma in all cases. 
Case 1. A 62-year-old man underwent the right middle and lower 
lobectomy (pT3N2M0) followed by adjuvant chemotherapy with 
platinum doublet. He had a mediastinum lymph node relapse six 
months after the operation. Crizotinib was administered as the 2nd 
line. A long stable disease (SD, six months) was obtained in this 
patient. Case 2. A 62-year-old woman underwent the right upper 
and middle lobectomy (pT2aN2M1a) followed by adjuvant chemo-
therapy with platinum doublet. She had multiple lung metastases 
thirty-one months after the operation. Progressive disease (PD) 
was detected after four courses of platinum doublet. Crizotinib was 
administered as the 5th line and partial response (PR) was obtained 
over 5 months. Case 3. A 63-year-old man underwent preoperative 
chemotherapy followed by the right upper lobectomy (ypT3N2M0). 
He received an adjuvant chemotherapy with platinum doublet. He 
developed brain metastases five months after the operation. Crizo-
tinib was administered one month as the 4th line, and PR was obtai-
ned. Case 4. An 83-year-old woman underwent the left lower lobe 
wedge resection. (pT2aNXM1a) followed by four regimens of che-
motherapy, resulting in PD. Crizotinib was administered as the 5th 
line. The side effects with increase in body weight (+4kg, Grade1), 
leg edema (Grade 2) and liver dysfunction (Grade 1) deveroped on 
the 7th day. Her symptoms quickly disappeared after discontinue of 
crizotinib. Another regimen chemotherapy was administered be-
cause she rejected restart of the crizotinib treatment.
Conclusion: In the efficacies of the crizotinib treatment, two ca-
ses were PR, one case was SD and one case was drop out. The 
crizotinib was effective in two cases which were PD with other 
regimen treatments. Crizotinib has possibilities of giving dramatic 
clinical response in ALK-rearranged NSCLC patients. In safeties 
of the crizotinib treatment, no adverse event was occurred in 
three cases and Grade 2 adverse in one case. There have been no 
serious complications. (Crizotinib treatments in ALK-rearranged 
NSCLC patients have great possibilities of having a clinical benefit. 
Crizotinib can also be effective and safe in postoperative recur-
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Caregivers Patients HCPs
General 
Public
EXPLICIT
Negative 
Descriptive
75%, 7%, 18% 
81%, 
7%, 12% 
88%, 
5%, 7% 
74%, 8%, 
18% 
Negative 
Normative
59%, 3%, 38% 
64%, 
2%, 34% 
65%, 
3%, 
32% 
56%, 3%, 
41%
IMPLICIT ATTITUDES
Bad
D=0.43 
73%, 12%, 15% 
D=0.33 
72%, 
13%, 
15% 
D=0.33 
63%, 
17%, 
20.0% 
D=0.44 
74%, 9%, 
17% 
Despair
D=0.43 
73%, 10%, 17% 
D=0.54 
76%, 
5%, 19% 
D=0.44 
77%, 
13%, 
10% 
D=0.47 
77%, 8%, 
15% 
Shame
D=0.32 
65%, 18%, 17% 
D=0.52 
82%, 
9%, 9% 
D=0.41 
72%, 
11%, 
17% 
D=0.35 
66%, 17%, 
17% 
IMPLICIT STEREOTYPES
Smoking 
vs. Eating
D=0.69 
89%, 5%, 6% 
D=0.71 
90%, 
5%, 5% 
D=0.79 
94%, 
3%, 3% 
D=0.57 
84%, 8%, 
8% 
Smoking 
vs. Drin      
king
D=0.34 
65%, 18%, 17% 
D=0.17 
54%, 
31%, 
15% 
D=0.54 
81%, 
5%, 14% 
D=0.34 
69%, 17%, 
14% 
Drinking vs. 
Eating
D=0.10 
40%,33%,27% 
D=0.22 
54%, 
23%, 
23% 
D=0.21 
59%, 
29%, 
12% 
D=0.16 
50%, 27%, 
23% 
 
Percentage order: LC bias%, BC bias%, No bias%. D=mean IAT 
score. All D scores significantly > 0 with ps<0.001
Conclusion: Ps had greater explicit and implicit negative bias 
against LC compared to BC.
Keywords: NSCLC, Bevacizumab, elderly, pooled analysis
Treatment includes reduction/discontinuation of immunosuppres-
sion, chemotherapy and/or radiation therapy as appropriate, as 
well as removal of the transplanted organ and re-transplantation 
when feasible. In the present case we hypothesize that the donor 
had an undiagnosed lung cancer with subclinical hepatic metasta-
ses transmitted to our patient at the time of liver transplantation. 
Donor-derived lung cancer is extremely rare and can lead to sig-
nificant morbidity and mortality. Proper diagnosis of donor origin 
is critical since it has a significant impact on management of these 
patients.
Keywords: organ transplantation, non-small cell lung cancer, 
donor-derived malignancy
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P3.24-044 EXPLICIT AND IMPLICIT ASSOCIATIONS  
TOWARD LUNG CANCER (LC) RELATIVE TO BREAST 
CANCER (BC)
Joan H. Schiller1, Christopher J. Bowden2, Jennifer Mills2, Edward 
Lang2, Holli K. Dickson2, Heidi A. Hamann1, N Sriram3
1University Of Texas Southwestern Medical Center/United States Of 
America, 2Genentech/United States Of America, 3University Of Virgi-
nia/United States Of America
Background: Emerging research suggests that LC may be associ-
ated with greater levels of stigma, shame and hopelessness com-
pared to other cancers. This study measured explicit, conscious 
attitudes (EAs) and used the Implicit Association Test (IAT) to 
assess implicit, unconscious attitudes (IAs) and stereotypes (ISs) of 
LC relative to BC.
Methods: To assess EAs, participants (Ps), [people with cancer 
(n=243), caregivers (n=677), healthcare providers (HCPs, n=142), 
and the general public (n=864)] were asked to rate their agree-
ment, on a six-point scale, with statements about how people 
with LC and BC “do feel” (descriptive attitudes) or “ought to feel” 
(normative attitudes) about their disease. Implicit attitudes were 
measured with three IATs that used LC or BC images with words re-
presenting good/bad; hope/despair; or suitable/shameful. Implicit 
stereotypes used images representing smoking cigarettes, driN-
KIng alcohol and eating unhealthy foods. An IAT D score indicated 
the strength of bias against LC relative to BC: >0.65 = strong bias; 
0.35-0.65 = moderate bias; 0.15-0.35 = slight bias; -0.15 -+0.15 = 
no bias, and < -0.15 indicated bias against BC.
Results: EAs and IAs were substantially more negative towards LC. 
Most Ps provided more negative ratings for LC than BC for both 
descriptive (70%vs.8%) and normative statements (56% vs. 3%). Ps 
had strong negative IAs towards LC compared to BC (bad: 74% vs. 
10%; despair: 75% vs. 9%; shame: 67% vs. 17%). In the stereotype 
IATs, Ps were far more likely to associate LC with smoking than with 
eating unhealthy foods or driNKIng alcohol. Conversely, Ps were 
far less likely to associate BC with smoking than with eating or 
driNKIng (smoking: 86% LC vs. 7% BC; eating: 86% LC vs. 7% BC; 
driNKIng: 67% LC vs. 18%BC). These trends were consistent across 
caregivers, patients, HCPs, and the public. EAs, IAs and ISs were 
uncorrelated.  
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P3.24-046 FEASIBILITY AND SAFETY OF CHEMOTHE-
RAPY ADMINISTRATION USING TELEONCOLOGY FOR 
RURAL LUNG CANCER PATIENTS IN NORTH QUEENS-
LAND.
Abhishek Joshi, Sabe Sabesan, Suresh Varma, Zulfiquer Otty
Medical Oncology, Townsville Cancer Centre/Australia
Background: Chemotherapy is the standard treatment for most 
(stage II and beyond) lung cancer patients and treatment duration 
can be long ranging from months to years. Rural lung cancer pa-
tients often have to travel long distances for such specialist treat-
ment. Geographical isolation and remoteness is implicated as one 
of the factors leading to inferior outcomes in these patients. Since 
2007 Townsville cancer centre has been providing chemotherapy 
services to Mount Isa at a distance of 1000 km via Teleoncology ( 
using video conferencing). This model has previously been shown 
to be effective, safe, cost saving and sustainable. This study eva-
luates the feasibility and safety of chemotherapy for lung cancer 
patients treated via Teleoncology.
Methods: All patients with a diagnosis of lung cancer from Towns-
ville Teleoncology data resource (comprising all patients treated 
with chemotherapy at Mount Isa Base hospital using videoconfe-
rencing from Townsville cancer centre) between April 2007 and 
March 2012 were eligible. Patient and tumour characteristics were 
studied and feasibility was evaluated using number and type of 
cycles, dose intensity and completion rates for chemotherapy 
administration. Toxicity was graded as per common terminology 
criteria for adverse events (CTCAE) v 4.0.
Results: Out of total 170 patients treated using Teleoncology, 33 
(22%) had lung cancer. Of these 3 (9%) were small cell (SCLC) and 
remaining non small cell lung carcinomas. A total of 287 chemothe-
rapy cycles (148 in first line, 97 in second line and 42 in third line) 
were administered under distant supervision. Of these, 8 cycles 
were neoadjuvant, 15 cycles in adjuvant and 254 cycles in palliative 
setting. One patient of SCLC had emergency chemotherapy initia-
ted via Teleoncology. Carboplatin(C) and Gemcitabine(G) was the 
commonest regimen (72 cycles 25%) followed by Pemetrexate (66 
cycles 23%) and C and Paclitaxel (56 cycles 19%). Other types of 
regimen administered were Cisplatin (Cis) and G, C and Etoposide 
(Eto), Cis and Vinorelbine (Vnb), and single agent Docetaxel, Gem, 
Vnb, Eto, C and Erlotinib. Commonest toxicities were fatigue, 
neuropathy, thrombocytopenia and anaemia. Grade 3-4 toxicity 
requiring dose reduction was 4% in first line, 32% in second line 
and 58% in third line setting. Accounting for dose reductions 
based on toxicity, anticipated chemotherapy dose intensity could 
be maintained in 261 cycles (91%). There were 7 episodes of in-
patient admission at Mount Isa (3 febrile neutropenia and 2 each 
pulmonary embolism and recurrent pleural effusion), all supervised 
via Teleoncology from Townsville. 29 of these 33 patients had all 
of their chemotherapy treatment at Mount Isa without travelling to 
Townsville. Only 3 patients needed to travel to Townsville during 
palliative treatment, two for brain radiotherapy and one for VATS 
pleurodesis.
Conclusion: Teleoncology is a novel model of care for rural lung 
cancer patients. Using this model, standard chemotherapy for lung 
cancer can be safely administered with expected dose intensity. 
The feasibility and safety results from this study are comparable 
to published literature in lung cancer. Use of teleoncology has the 
potential to overcome the barrier of travel time associated with 
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P3.24-045 A FIRST ATTEMPT ON VIDEO-ASSISTED 
THORACIC SURGERY BRONCHIAL SLEEVE LOBECTOMY 
CONCOMITANT WITH PULMONARY ARTERY RECON-
STRUCTION (DOUBLE SLEEVE) FOR NON-SMALL CELL 
LUNG CANCER
Lunxu Liu, Jiandong Mei, Qiang Pu, Lin Ma, Hu Liao
Department Of Thoracic Surgery, West China Hospital, Sichuan Univer-
sity/China
Background: Bronchial sleeve lobectomy concomitant with pul-
monary artery reconstruction (double sleeve) is a reasonable alter-
native procedure for pneumonectomy in appropriately selected 
patients with non-small cell lung cancer. However, video-assisted 
thoracic surgery double sleeve lobectomy is technically more chal-
lenging than routine lobectomy, and has never been reported. We 
aimed to report the first attempt on video-assisted thoracic surge-
ry double sleeve lobectomy for non-small cell lung cancer.  
 
Methods: From May 2012 to February 2013, three patients with 
non-small cell lung cancer of the left hilum directly involving the 
pulmonary artery were selected for curative resection via the VATS 
approach. Surgical procedures were performed with four ports 
for the first patient and three ports for the next two patients. The 
bronchus and pulmonary artery were reconstructed by end-to-end 
anastomosis using running Prolene stitches. Low-molecular hepa-
rin was subcutaneously administered during the first week after 
surgery.  
 
Results: Surgical duration ranged from 350 to 490 min with blood 
loss between 30 to 200 ml. The first two patients developed pneu-
monia after surgery with no mortalities. All the patients were di-
scharged home within 9-14 days after surgery. A total of 17, 12 and 
14 lymph nodes were removed, and pathological stage of these 
three patients were T2bN1M0, T2aN0M0 
and T2bN0M0 respectively. The reconstructed bronchus and artery 
worked well during 3-12 months follow-up.
Conclusion: video-assisted thoracic surgery double sleeve lo-
bectomy is technically difficult but feasible. The operation can be 
successfully finished by skilled thoracoscopic surgeons, but the 
surgical incisions, procedures, and specific instruments still require 
further improvement.  
 
Keyword: lung neoplasms; VATS; double sleeve ; lobectomy
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P3.24-048 PREVALENCE OF UNEXPECTED PULMONARY 
EMBOLISM AT CONTRAST-ENHANCED CT SCAN PER-
FORMED FOR CANCER STAGING IN PATIENTS WITH 
ADVANCED LUNG CANCER
Lucio Crino1, Rita Chiari1, Melina Verso2, Laura Franco2, Stefano 
Mosca3, Mattias Fischer3, Chiara Bennati1, Valeria Marconi3, Luca 
Paglialunga1, Giancarlo Agnelli2
1Medical Oncology, Santa Maria Della Misericordia Hospital/Italy, 2Di-
vision Internal And Vascular Medicine - Stroke Unit, Santa Maria Della 
Misericordia Hospital/Italy, 3Radiology Department, Santa Maria Della 
Misericordia Hospital/Italy
Background: Patients with advanced lung cancer have been re-
ported to be at high risk for venous thromboembolism (VTE). In 
patients with cancer, a rate of unexpected pulmonary embolism 
(UPE) of about 1.5% has been reported.The aim of the study was 
to determine the prevalence of UPE in patients with stage IIIB or 
IV NSCLC or extensive SCLC who underwent CT scans for cancer 
staging.
Methods: We reviewed the contrast-enhanced CT scans of the 
chest performed for routine cancer staging in consecutive patients 
with advanced lung cancer (stage IIIB or IV NSCLC or extensive 
SCLC) referred to the Division of Medical Oncology at the hospital 
of Perugia between 2008 and 2012. All CT scans were reviewed 
by an ad hoc panel composed by 3 radiologists. PE was defined 
as unexpected when a filling defect in central, lobar, segmental 
or sub-segmental pulmonary arteries was observed in absence of 
clinical suspicion of PE.
Results: Overall, 223 patients were included in the analysis: 180 
patients with stage IV-NSCLC, 24 patients with stage IIIB-NSCLC, 
and 19 patients with extensive SCLC. A total of 899 CT scans were 
reviewed. The prevalence of UPE was 19.7% (44/223): 34 (77.3%) in 
patients with stage IV-NSCLC, 7 (15.9%) in patients with stage IIIB-
NSCLC, and 3 (6.8%) in patients with advanced SCLC. Patients with 
UPE were 26 males and 18 females and had a mean age of 58 years 
(range 24-78). UPE was monolateral in 30 patients and bilateral in 
14 patients. UPE involved central pulmonary arteries in 6 patients, 
lobar arteries in 16 patients and segmental arteries in 19 patients. 
3 patients had an isolated sub-segmental UPE. The mean time bet-
ween cancer diagnosis and UPE was 11.8 months. 27% of cancer 
patients with UPE had the positive CT scan at diagnosis and 50% 
within 3 months. A recurrence of UPE was observed in one patient.
Conclusion: Patients with stage IIIB or IV NSCLC or extensive SCLC 
have a high rate of UPE at CT scan performed for cancer staging. 
UPE was bilateral in about one third of patients. A minority of UPE 
involved isolated sub-segmental arteries.
Keywords: Lung cancer, pulmonary embolism
long distances and possibly improve outcome for rural lung cancer 
patients.
Keyword: Teleoncology, rural, chemotherapy, safety
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P3.24-047 PULMONARY PAPILLARY ADENOMA LOCA-
LIZED CENTRALLY
Nurettin Yiyit1, Haluk Sasmaz1, Zafer Kucukodaci2, Akin Yildiz-
han1, Fatih H. Candas1, Rauf Gorur1, Turgut Isitmangil1
1Thoracic Surgery, Gmma Haydarpasa Training Hospital/Turkey, 2Pa-
thology, Gmma Haydarpasa Training Hospital/Turkey
Background: Pulmonary papillary adenoma is an extremely rare 
tumor and considered to be benign although its malignancy po-
tentiality is not completely understood. It is usually asymptomatic 
and detected incidentally as peripheral lesions in chest radiogra-
phy. It originates from type II pneumocytes. The largest mass of 
20 cases which has been reported in English literature was 3 cm 
in diameter. The diameter of the tumor of our case was 4 cm. We 
present our postoperatively diagnosed papillary adenoma case 
due to its rarity and central location.
Methods: Twenty-one year old male patient was admitted with a 
round mass lesion with regular margins was observed on the right 
side of his chest radiography. This 4 cm diameter mass in the right 
upper lobe closed to bronchus has been observed in thorax com-
puted tomography. Any endobronchial lesion could be detected 
with bronchoscopy.
Results: Right thoracotomy was performed. The solid mass was 
enucleated and capitonnage was performed. The patient being 
discharged on the 7th postoperative day is being followed for 8 
months.
Conclusion: Our case is a centrally localized pulmonary papillary 
adenoma although most of the cases presented in the literature 
are peripheral. This case should be considered in the differential 
diagnosis of solid pulmonary masses. The recommended treat-
ment for this mass is surgically removal of the mass because of its 
malignancy potentiality.
Keywords: Pulmonary papillary adenoma, Pulmonary tumor
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A total of 529 consults were seen in the first year. 61% were seen 
in a traditional clinic model and 39% were seen in the concurrent 
model. Volume of consults have increased over time. There were 
10 consults per month in January of 2012. Currently over 100 con-
sults are seen per month.
Conclusion: Appropriate integration of PC into oncology care for 
thoracic oncology patients is still under investigation. Here we 
describe the strengths and weaknesses of three separate models 
of integration of PC with oncology care at an academic medical 
center.
Keyword: Palliative Care Integration
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P3.24-050 MULTIPLE DISTANT METASTASES IN A CASE 
OF MALIGNANT PLEURAL MESOTELIOMA
Kemal Can Tertemiz1, Aylin Ozgen Alpaydin1, Duygu Gurel2, Berna 
Degirmenci Polack3, Aytac Gulcu4, Atila Akkoclu1
1Pulmonary Diseases, Dokuz Eylul University Medical Faculty/Turkey, 
2Pathology, Dokuz Eylul University Medical Faculty/Turkey, 3Nuclear 
Medicine, Dokuz Eylul University Medical Faculty/Turkey, 4Radiology, 
Dokuz Eylul University Medical Faculty/Turkey
Background: Distant metastases of MPM to the skeletal muscle, 
endocardium and skin have not been reported previously.
Methods: A 75 year-old male admitted to our pulmonary diseases 
clinic with chest and lower limb pain. He was a heavy smoker and 
exposed to asbestos in his childhood. Respiratory system was nor-
mal in physical examination. The thigh muscles were observed to 
be thick and hard and palpation was painful. There were few nodu-
lar lesions on the scalp which he reported to appear 2 months ago 
as well as the accompanying femoral thickening.
Results: Chest X-ray showed upper mediastinal enlargement and 
a mass in left superior lobe. Thorax CT revealed a pleural mass in 
the left apical region, left hilar lymphadenopathy and pleural thi-
ckening. Pathological FDG uptakes were observed over the right 
paraspinal muscle (C6), posterior scalp, paratracheal and left hilar 
lymp nodes, left apical mass, left pleura in lower and middle zone, 
left diaphragma, anterior pericardium, interventricular septum, left 
axilla, right 4. costochondral region, liver segment 8, right para-
spinal muscle in L3 level, right abdominal oblic muscles, bilateral 
gluteal muscles and bilateral muscles in femoral region. Tru-cut 
biopsy was performed from the left apical mass and the diagnose 
was epitheloid type malignant pleural mesothelioma. A second bi-
opsy was performed from anterior thigh muscles. The morphologic 
pattern was the same with the biopsy taken from lungs
Conclusion: Metastases of a MPM are very rare. We are presenting 
this case for the skeletal muscle metastasis defined for the first 
time.
Keyword: mesothelioma, metastases
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P3.24-049 PALLIATIVE CARE AND ANTI-CANCER CARE 
INTEGRATION: DESCRIPTION OF THREE MODELS OF 
CARE DELIVERY AT A TERTIARY MEDICAL CENTER
Kavitha J. Ramchandran1, Joshua Fronk1, Sandy Trieu1, Heather A. 
Wakelee1, Millie Das2, Joel W. Neal3, Stephanie Harman1, Patricia 
Dwyer1, Jenny Bosch1, Heather Shaw1, Saba Safari1, Ryan Oden1, 
Timothy Morrison1, Doug Blayney4
1Medicine, Stanford University/United States Of America, 2Medicine- 
Oncology, Va Palo Alto Health Care System/United States Of America, 
3Medicine, Division Of Oncology, Stanford University School Of Medi-
cine/United States Of America, 4Oncology, Stanford Cancer Institute/
United States Of America
Background: The American Society of Clinical Oncology issued 
a Provisional Clinical Opinion on the integration of palliative care 
(PC) with anti-cancer care which states, “Based upon strong evi-
dence from a phase III RCT, patients with metastatic non-small-
cell lung cancer should be offered concurrent palliative care and 
standard oncologic care at time of initial diagnosis.” There is both 
a national shortage of PC providers, as well as a lack of guidelines 
on the best operational ways to integrate PC into oncologic care. 
Here we describe different models of palliative care integration 
into anti-cancer care models performed at the Stanford Cancer 
Institute.
Methods: Three methods of PC integration into oncology care at 
Stanford Hospital and Clinics, a tertiary medical center, are being 
tested. These include a low resource model using a social work 
(SW) only intervention for advance care planning and goals of care, 
as well as two high resource models using an MD, advance nurse 
practitioner, and social worker. The first high resource model is 
concurrent care with joint PC and oncology visits, and the second 
is a traditional model of separate PC and oncology visits. Obser-
vations around successes and barriers within these various models, 
as well as resources needed, will be described. Data evaluated 
include volume, referral patterns, advance care planning, symptom 
assessment, and resource utilization.
Results: The SW only intervention was run as a pilot in thoracic 
oncology. Resources required for appropriate implementation 
included information technology (IT) for appropriate cohort iden-
tification, operations support, data management support, and 
team cooperation from the physician and nursing team. Process 
outcomes measured included % of patients seen by SW within 3 
visits, documentation of advance care planning within the medical 
record, and co-signature of advance care planning documentation 
by the physician.
The joint visit model utilized a high resource team (physician, nurse 
practitioner, and social worker) which was present concurrently 
with the oncology visit for advance care planning and symptom 
management. In addition to the resources required for the SW 
only intervention, this model also included a care coordinator for 
visit coordination. Process outcomes measured included lead time 
to arrange for the joint visit and documentation of advance care 
planning. End outcomes included discharge to hospice, hospital 
utilization patterns, and effective symptom management. Other 
outcomes included volume and number of referring providers.
Our third model was a traditional clinic visit with the PC team only, 
not coordinated with the oncology team. Resources and outcomes 
were the same as for the joint visit model.
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P3.24-052 MYXOID MESENCHYMAL NEOPLASM PRE-
SENTING AS MASSIVE ARM AND CHEST WALL EDEMA 
WITH PLEURAL EFFUSION
Konstantinos Arnaoutakis1, Matthew A. Steliga2
1Medicine, University Of Arkansas For Medical Sciences/United States 
Of America, 2Thoracic Surgery, University Of Arkansas/United States 
Of America
Background: not applicable
Methods: 
This patient is a 50-year-old Hispanic woman who had been dia-
gnosed with idiopathic edema of the right upper extremity and 
chest wall which progressed gradually over the last 8 years. Over 
the last year and-a-half, she has developed dyspnea on exertion 
with occasional cough. She has occasional right chest wall discom-
fort, but no abdominal pain. She has arm and back pain from the 
massive swelling. She has no GI complaints with the exception of 
nausea after meals. She has no lower extremity edema, no fever, 
chills or sweats. During our evaluation she was found to have mas-
sive right-sided pleural effusion.
Results: 
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P3.24-051 PRIMARY THORACIC ANGIOSARCOMA: 
TREATMENT AND OUTCOMES OF 5 PATIENTS
Mariana Scaranti1, Cheng T. Yen1, Julia A. De Oliveira1, Diego A. 
Toloi1, Sheila A.C. Siqueira2, Renata E. Martins1, Veridiana P. De 
Camargo1, Olavo Feher1, Paulo M. Hoff1, Gilberto Castro Jr.1
1Medical Oncology, Instituto Do Cancer Do Estado De Sao Paulo/Brazil, 
2Pathology, Hospital Das Clínicas And Lim-14 Fmusp/Brazil
Background: Angiosarcomas (AS) are rare aggressive tumors that 
represent about 1-2% of all soft-tissue sarcomas; 9.5% of them ari-
se in the thorax. We describe five patients diagnosed with thoracic 
AS who were treated at ICESP.
Methods: It is a case series descriptive study with review of the 
medical files from five consecutively registered patients with AS 
confirmed by immunohistochemistry at our institution between 
June 2010 and March 2013.
Results: Case 1: A 49-year-old woman was admitted with pulmo-
nary AS presenting progressive dyspnea and a recent hemoptysis. 
Pneumonectomy was performed in April 2011 and she was treated 
with adjuvant doxorubicin (every 3 weeks, 4 cycles) and paclitaxel 
(12 weeks). After 7 months, she developed progressive disease 
(PD) in liver, bones and lymph nodes. Weekly paclitaxel was restar-
ted, but she had hepatic PD. Since May 2013 she has been treated 
with liposomal doxorubicin. She is alive after 26 months of diagno-
sis. Case 2: A 62-year-old woman was diagnosed with metastatic 
paracardiac AS after cardiac tamponade. She was treated with 
weekly paclitaxel and developed PD in liver and lungs. She died 3 
months after diagnosis. Case 3: A 32-year-old man, was diagnosed 
with a primary AS in the right ventricle, metastatic to lungs, was 
admitted with recurrent pericardial effusion for 6 months. The 
tumor was considered unresectable and he was treated with do-
xorubicin and ifosfamide (only one cycle), temporarily interrupted 
due to febrile neutropenia grade 4, but with a partial response. 
He is alive after 3 months of diagnosis. Case 4: A 31-year-old man 
was diagnosed with unresectable AS in the right atrium after de-
veloping a superior vena cava syndrome. Weekly paclitaxel was 
started, with initial clinical improvement, but PD was detected 
after 6 cycles (24 weeks). As a second-line treatment, doxorubicin 
and ifosfamide were administered, with PD in lungs after 5 cycles. 
He died 13 months after the beginning of chemotherapy. Case 5: 
A 58-year-old woman was diagnosed with a right infraclavicular 
unresectable AS with local pain and edema in the upper right arm 
for one year. No response was seen after two cycles of doxorubicin 
and ifosfamide. Palliative radiotherapy followed by weekly pacli-
taxel was attempted as a second-line therapy with no response. 
Best supportive care was started and she is alive 6 months after 
diagnosis.
Conclusion: We concluded that thoracic AS presents a very dismal 
prognosis, due to the primary location and the high incidence of 
metastatic disease. For those patients with resectable disease and 
curative intent, surgery must always be considered. Weekly pacli-
taxel and the combination of doxorubicin and ifosfamide are both 
active in thoracic AS, but responses usually were not long-lasting. 
Oral tyrosine kinase inhibitors with antiangiogenic properties may 
be an option to be better explored.
Keywords: angiosarcoma, thoracic tumor, Treatment
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than those who underwent radiotherapy with a 5 year survival in 
the surgical cohort of 60% (14/23) vs 7% (1/13) in the radical radio-
therapy cohort as well as lower rates of lung cancer related death 
17% (4/23) vs 46% (6/13).
Conclusion: Mortality in early stage lung cancer remains high 
in our cohort with recurrence of the lung cancer being the main 
cause of death. All patients were staged with PETCT prior to treat-
ment. Diseases strongly associated with smoking were a common 
cause of disease as may be expected. Patients with radical therapy 
presenting with pneumonia are at high risk of death.
Keywords: Cause of death, survival, NSCLC, radical treatment
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P3.24-054 ERLOTINIB IN NON-SMALL CELL LUNG CAN-
CER: ANALYSIS OF TOXICITY AND EFFICACY IN CLINI-
CAL PRACTICE
Maria Teresa A. Alexandre1, Joana Ip2, Isabel Duarte2, Teresa Alm-
odovar3, José Duro Da Costa3
1Medical Oncology, Instituto Português De Oncologia De Lisboa/Portu-
gal, 2Radiology, Instituto Português De Oncologia De Lisboa/Portugal, 
3Pneumology, Instituto Português De Oncologia De Lisboa/Portugal
Background: Lung cancer is the leading cause of cancer death 
despite the improvement of therapeutics.Most patients (pts) pre-
sent with advanced disease when first diagnosed. Erlotinib is an 
inhibitor of the epidermal growth factor receptor (EGFR) that is 
standardtreatment for non-small cell lung cancer (NSCLC) after 
failure of previous chemotherapy and 1st line in EGFR mutated pts. 
There are few data on toxicity observed in clinical practice descri-
bed in the literature.
Methods: Retrospective study of all consecutive patients with 
advanced NSCLC treated with erlotinib in our department from 
October 2005 to November 2012.Primaryendpoint was to eva-
luate thetoxicity, secondary endpoint was to evaluate time to 
progression and survival. Data were obtained from clinical files 
and namely:demographics, histology, performance status (ECOG), 
stage and toxicity according to common terminology criteria for 
adverse events (CTCAE) version 4.
Results: From the 194pts treated with erlotinib, 111 pts (57%) were 
male and 83(43%) female, with a median age of 62 years (range 
28-92); 37(19%) pts were former smokers, 87(45%) smokers and 
70(36%) non-smokers. Histology was adenocarcinoma in 146 (75%) 
pts, squamous-cell in 25 (13%) and NSCLC-NOS in 23 (12%). Mu-
tation: 21(11%) pts were EGFR mutated. Staging at the diagnosis: 
III in 71(37%) pts and IV 123(63%) pts. Before erlotinib 93(48%) pts 
had one line-chemotherapy, 79(41%) two-lines and 3 more than 
two-lines. Most commons used regimens were platin-based. Skin 
toxicity was observed in 85 pts (20 pts G2/3 toxicity) and gastro-in-
testinal toxicity in 21pts, 9 pts with G2/3 toxicity; 4 stop treatment 
due to toxicity (2 pts due to gastro-intestinal, 2 due to cutaneous). 
There were no treatment-related deaths or hospitalization. Com-
plete/partial response was observed in 19(9.8%) pts, stable disease 
in 51 pts. The median TTP and survival after erlotinib treatment 
were 2.6 months, range (0.2-61) and 5 months range (0.7-160), re-
spectively (CI 95%) with a median follow-up 6 months, (1- 61). Mu-
tated pts had a longer TTP 9,4 month (6.6-12.2) than non-mutated 
2,5 months(2,1-2,9),p< 0,001. Pts with cutaneous toxicity had a bet-
Biopsies of the pleura , soft tissues, and skin showed a myxoid 
mesenchymal neoplasm. Brain MRI showed no intracranial or me-
ningeal masses. Her pleural fluid was most consistent with exuda-
te. Cultures and cytology was negative. Glucose in the pleural fluid 
was not decreased. Triglycerides in the pleural fluid were 21 mg/
dL.
Conclusion: This is an unsual case of a soft tissue sarcoma with sig-
nificant swelling of the entire arm and ipsilateral chest with meta-
stasis to the pleura. She had previously been diagnosed with idio-
pathic lymphededma and treated for that for years. The swelling 
was likely not due to lymphatic obstruction but rather due to slow 
progressive growth of the myxoid mesenchymal neoplasm. Earlier 
definitive diagnosis could have led to potential surgical resection, 
but with the massive involvement of her entire right arm, and ispi-
lateral hemithorax, supportive care and systemic chemotherapy 
are the only treatment options.
Keywords: malignant pleural effusion, sarcoma, chest wall
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P3.24-053 CAUSE OF DEATH IN EARLY STAGE NON-
SMALL CELL LUNG CANCER TREATED WITH CURATIVE 
INTENT
Katharine See1, Cameron Hunter1, Guy Bannick2
1Respiratory, Royal Hobart Hospital/Australia, 2Palliative Care, Royal 
Hobart Hospital/Australia
Background: Lung cancer is the main cause of cancer death in 
men and women in Australia. Cure can be achieved by identifying 
patients with early (i.e. stage I and II) disease, treating them with 
surgery or radical radiotherapy. Despite this, the 5 year survival for 
stage I and II patients is reported at 60%. We looked at the cause 
of death in patients treated with curative intent over a 2 year peri-
od.
Methods: Local clinical practice information was collected in a 
prospective database. Cases presented at a multidisciplinary lung 
cancer meeting over a 24 month period (April 2006 -March 2008) 
were analysed. Patients with early stage NSCLC (stage I and stage 
II) based on the 6th edition IASLC TNM classification were identi-
fied (n=62). Treatment data was obtained for all identified cases 
(n=62/62) via hospital records. Cause of Death was determined via 
the death certificate as submitted to the Registry of Births, Deaths 
and Marriages.
Results: Five year survival was 25% (16/62) for early stage NSCLC. 
Cause of death of obtained for all but 3 patients (43/46). 74% 
(46/62) of patients received treatment with curative intent, 37% 
(23/62) surgery and 20% (13/62) radical radiotherapy. Of all pati-
ents who underwent radical treatment, lung cancer was the prima-
ry cause of death in 16% (10/46). Respiratory conditions were the 
second most common cause of death with 13% (6/46) attributed. 
The main cause was reported as pneumonia in 7 patients, COPD, 
IPF and Respiratory failure being others. The loss of lung from 
surgery or radiotherapy could be hypothesised to be a factor in 
these deaths due to reduce lung volume. Cardiac disease was the 
cause of death in 5 patients and 3 patients died due to bladder 
cancer, both diseases strongly associated with smoking. 1 patient 
died due to colonic cancer and 1 due to vascular dementia. Pati-
ents who underwent surgical resection had lower mortality rates 
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P3.25-001 INCREASING RESEARCH UTILISATION AND 
CAPACITY IN LUNG CANCER NURSING IN THE UK
Angela M. Tod1, John White2, Diana Borthwick3
1Centre For Health And Social Care Research, Sheffield Hallam Univer-
sity/United Kingdom, 2St James`s Institute Of Oncology, Leeds Teaching 
Hospitals NHS Trust/United Kingdom, 3Western General Hospital, 
Edinburgh Cancer Centre/United Kingdom
Background: The National Lung Cancer Forum for Nurses (NLCFN) 
is a UK professional organization which has a membership of 
around 280 Lung Cancer Nurse Specialists (LCNS) who primarily 
with lung cancer patients. LCNSs are the multi-disciplinary team 
members who spend the most time with patients. Therefore they 
add a unique and valued contribution to the debate regarding 
research priorities in lung cancer. The NLCFN is committed to de-
veloping the evidence base to inform the effectiveness and quality 
of their clinical care. The NLCFN recognized a need to develop 
research skills and capacity amongst its membership and facilitate 
research collaborations between academics and practitioners. To 
this aim the NLCFN established a Research Interest Group (RIG) 
in 2009. This paper summarizes a research development project 
undertaken by the NLCFN to increase research utilisation and ca-
pacity in lung cancer nursing. 
Methods: A structured approach was taken building on research 
into evidence utilisation in health. (Birdell et al, 2005, Tod et al 
2004, Palfreyman et al 2003a/b). Research development activity 
focused on four key areas, roles and responsibilities, relevance, 
relationships and partnerships, and organisational culture. 
Results: Over a four year period the NLCFN has successfully 
developed its research activity and the infrastructure to support 
subsequent growth. Roles: The RIG is chaired jointly by a Professor 
of Health Services Research and NLCFN Chair. All NLCFN mem-
bers are encouraged to have a role by contributing to the critical 
discussion regarding evidence. However, a core group of research 
active members take responsibility to lead on research. The RIG 
has provided a mechanism for the NLCFN to liaise with key nati-
onal lung cancer groups and committees regarding evidence for 
practice and new project development, for example a current na-
tional project exploring the contribution of lung nurse specialists 
to clinical trial recruitment. Research relevance is guided by an 
on-going research prioritisation exercise. Research partnerships 
have been developed through shared membership of the RIG bet-
ween clinical and academic staff. The partnership has fostered five 
applications for research funding from a range of funding organisa-
tions, two of which have been successful, one is currently in review. 
Funded projects include an evaluation of the LCNS role in treat-
ment access. Another is evaluating the use of support roles in lung 
multi-disciplinary teams. Current applications include an analysis of 
treatment and health outcomes using linked national data sources. 
In addition a new PhD studentship has been developed through a 
collaboration between the NLCFN and Sheffield Hallam University. 
Regular meetings, good communication, sharing of good practice 
and support provide a culture to allow research ideas to flourish.
ter TTP 2 months vs 4.2 months (p< 0.001) and survival 3,9months 
vs 9.4 months (p<0.001).
Conclusion: Although in our data there were no death related-
treatments, the toxicity observed was highercomparing tothe 
literature. The efficacy results were similar. Cutaneous toxicity was 
positively correlated with better outcomes namely TTP and  
survival.
Keyword: Lung cancer, Erlotinib, toxicity
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were conducted. Of the 7 participants 6 were female, average age 
68 years (range 58 - 81 years). All were currently taking Gefitinib, 
average 13 months (range 5 - 23 months). Early analysis shows com-
mon themes emerging such as pragmatic acceptance about their 
situation, feelings of isolation, experiencing the inconsistency and 
variety of chronic physical toxicities, the necessity of self-manage-
ment, the need for support and uncertainty about their future. Body 
image changes were a significant problem for females including hair 
and skin changes. It is clear from the data that there is an on-going 
and changing psychosocial and physical experience for the patient. 
The nature of this experience will be expanded upon with individual 
anonymous quotes.
Conclusion: The experience of taking TKI’s, over an indefinite pe-
riod of time, for advanced lung cancer is complex. Using the MRC 
framework we aim to evaluate the themes identified, so assessing 
not only the quantitative physical toxicities of the treatment but also 
the qualitative issues, the provision of support and the patients’ un-
derstanding of the side effects and management of their treatment.
Keyword: Molecular targeted therapies, advanced lung cancer, 
focus group
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P3.25-003 EFFECTS OF ELECTRIC STIMULATION TO 
ACUPOINTS ON GASTROINTESTINAL HORMONES AND 
MOTILITY AMONG OLD POSTOPERATIVE PATIENTS 
WITH LUNG TUMORS
Lili Hou
Nursing Department, Nursing Department Of Shanghai Pulmonary 
Hospital/China
Background: Recently, early movement on bed was encouraged 
to promote gastrointestinal function recovery. However, due to old 
ages and weak physical strength, the effects remain limited.
Methods: We selected 40 old patients with lung tumors recei-
ving surgeries between January 2009 and December 2010.The 
patient evenly randomly assigned them into regular nursing care 
group(RNC) and acupoint electric stimulation group(AES) group 
each with 20 cases. Patients in the RNC group received regular 
nursing care and patients in the AES group received regular nursing 
care plus electric stimulation on acupoints. We evaluated the serum 
concentration of gastrin(GAS), motilin(MOT), cholecystokinin(CCK) 
and electrogastrogram(EGG) on the first, third and fifth day after 
surgery. We also recorded the anal exhaust time and the number 
of cases with such gastrointestinal function disorders as abdominal 
pain, abdominal distention and diarrhea.
Results: Comparison between two groups in GAS, MOT, EGG, the 
anal exhaust time, abdominal pain, abdominal distention and di-
arrhea showed significant statistical difference(P<0.05).
Conclusion: Electric stimulation on acupoints could increase post-
operative GAS, MOT levels, promote recovery of gastrointestinal 
functions and decrease complications among senile patients with 
lung tumors.
Keywords: Senile people, gastrointestinal tumor, gastrointestinal 
hormone, Acupoint electric stimulation
Conclusion: In four years the NLCFN has made remarkable pro-
gress regarding research development and capacity building. By 
taking a structured and systematic approach the outcomes have 
been impressive. It has supported LCNSs to be a valued partner in 
research prioritisation and in generating evidence to support lung 
cancer practice at a local and National level. The foundations for 
research growth have been built and an infrastructure developed 
to enhance future nursing engagement in research at all levels 
from application to leadership.
Keyword: lung cancer nursing, research utilisation, research capci-
ty building, evidence-based practice,
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P3.25-002 THE EFFECTS OF THE MOLECULAR TARGE-
TED THERAPIES IN ADVANCED LUNG CANCER - FOCUS 
GROUP ANALYSIS
Lavinia R.A. Magee1, Tim G.Q. Eisen2, Angela M. Tod3, Karen L. 
Burnet4
1Thoracic Oncology, Papworth Hospital, Cambridge Biomedical Research 
Centre/United Kingdom, 2Cambridge Biomedical Research Centre/Uni-
ted Kingdom, 3Centre For Health And Social Care Research, Sheffield 
Hallam University/United Kingdom, 4Cambridge Biomedical Research 
Centre, Cambridge Cancer Trials Centre/United Kingdom
Background: The development of molecular targeted therapies has 
provided many cancer patients with promising treatment options. 
Tyrosine kinase inhibitors (TKIs) are a group of biological molecules 
designed to block specific molecular targets within the cell. They 
are easily taken in tablet form but can have significant systemic side 
effects causing physical and psychological discomfort. The impor-
tance of preparing the patient before treatment starts, evaluating 
the toxicities carefully using various validated tools and implemen-
ting appropriate care is well recognised. This study aimed to exa-
mine the physical side effects and psychosocial experiences of pa-
tients with advanced lung cancer taking TKIs. By using the Medical 
Research Council (MRC) framework for developing and evaluating 
complex interventions, this study forms the first stage of data gathe-
ring to inform the design of subsequent research projects. The ove-
rall aim is to develop a more specific toxicity measurement tool. A 
grant was awarded from the National Lung Cancer Forum for Nurses 
Research Interest Group.
Methods: Clinical teams at 4 hospitals within the West Anglia Can-
cer Research Network approached patients with advanced lung 
cancer taking TKI therapy for 3 to 24 months. Written informed con-
sent was taken prior to focus group meetings which were held in the 
comfort of a cancer support centre. Separate provision was made 
for carers. Conversation was captured using two digital recorders 
and transcribed verbatim. A topic guide shaped the conversation. 
Field notes were taken to describe the dynamics of the group. The 
transcripts were analysed using grounded theory techniques of 
constant comparison of the narrative, incorporating memos of the 
researchers thoughts during the recordings, and deviant case analy-
sis. Data was analysed and coded independently by two researchers 
and the findings compared and discussed. The theories generated 
were validated by checking the findings against the original data 
demonstrating a systematic research process of rigour and transpa-
rency. Analysis was aided by the use of NVivo 10 software.
Results: Two focus groups including 3 and 4 patients respectively 
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